id|nct_id|intervention_type|name|description
32970|NCT03927443|Drug|Lumigan|one drop
43634|NCT03842761|Drug|Placebo|Tablet
118577|NCT03259503|Drug|Olaparib|Given PO
118614|NCT03259230|Other|Blood Draws|
118615|NCT03259230|Other|Data Collection|
120093|NCT03247686|Drug|Placebo|Placebo
2135|NCT04179097|Diagnostic Test|Finger photoplethysmography|Bilateral finger photoplethysmogray, bilateral brachial artery Doppler, Aorta artery Doppler
2136|NCT04179084|Drug|fruquintinib|5mg qd, 2weeks on, 1week off
2137|NCT04179084|Drug|Sintilimab|200mg q3w
2138|NCT04179071|Drug|Savolitinib|Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.
2139|NCT04179071|Drug|Famotidine|Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
2140|NCT04179058|Other|Follow-up|Clinical data, radiological data and laboratory tests follow-up
2141|NCT04179045|Device|The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Subjects enrolled will be treated with Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent.
2142|NCT04179032|Combination Product|Belimumab|Belimumab 200 mg/mL will be administered as SC injection in left or right thigh and the abdomen.
2145|NCT04178993|Drug|Methamphetamine|In each arm, subjects will receive doses of methamphetamine.
2146|NCT04178993|Drug|Methylphenidate|In each arm, subjects will receive methylphenidate capsules.
2147|NCT04178993|Drug|Placebo oral capsule|In each arm, subjects will receive placebo capsules.
2148|NCT04178993|Drug|Duloxetine|Subjects will receive duloxetine capsules in the duloxetine arm.
2150|NCT04178967|Biological|Lebrikizumab|Subcutaneous injection
2151|NCT04178967|Other|Placebo|Subcutaneous Injection
2152|NCT04178954|Diagnostic Test|semen fluid analysis|semen fluid analysis
2153|NCT04178941|Behavioral|Audit and Feedback|The audit and feedback intervention includes providing each hospital's own continuous pulse oximetry use data back to them on a weekly basis for review and action.
2154|NCT04178941|Behavioral|Educational outreach|Educational outreach includes staff-targeted educational materials and outreach sessions summarizing the current evidence and guideline recommendations for continuous pulse oximetry use in bronchiolitis.
2156|NCT04178915|Diagnostic Test|Bood leukocyte subsets|Determination of blood leukocyte subpopulations, myeloid suppressor cells of various origins, type 2 congenital lymphoid cells, depleted T cells, CD45RA+ CD45RB+ CD62L-IRC, T-cell differentiation stages (naive - memory cells - effector - terminally differentiated effectors), B cells (CD5+ B1 cells, CD11c+ ABC, differentiation stages: immature - naive - isotype-unswitched memory cells - isotype-switched memory cells - plasmoblast)
2157|NCT04178915|Diagnostic Test|The cholesterol content of the cell membrane of T-cells and monocytes|The cholesterol content of the cell membrane of T-cells and monocytes with flow cytometry analysis
2158|NCT04178902|Drug|ABBV-467|Intravenous (IV) infusion
2159|NCT04178876|Procedure|ethanol sclerotherapy|Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol
2160|NCT04178876|Procedure|stripping technique|Endometrioma laparoscopic cystectomy
2161|NCT04178863|Device|CATS Tonometer|latanoprost vs. timolol
2162|NCT04178863|Drug|Latanoprost|latanoprost IOP reduction
2163|NCT04178850|Biological|GB242|GB242: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
2164|NCT04178850|Biological|Infliximab|Infliximab: Dosing of 3 mg/kg, intravenous drip, to be completed over 120 minutes, dosing at weeks 0, 2, 6, 14 and 22, a total of 5 doses; MTX:Dosage and administration at enrollment are maintained (10~15mg/week), oral administration, a total of 30 doses; Folic acid: 5-10mg/week, oral administration, a total of 30 doses
2165|NCT04178824|Behavioral|Discount Intervention|15% or 30% discount on fruits and vegetables
2166|NCT04178811|Device|Holmium Laser Enucleation of Prostate and Prostatic Uretheral Lift|Use of Holmium Laser Enucleation of Prostate and Prostatic Uretheral Lift in management of Benign Prostatic Hyperplasia
2168|NCT04178785|Drug|Remifentanil|Patients electively admitted for laparoscopic hysterectomy will be approached for requirement. After obtaining a written informed consent, patients will be randomly assigned either to the study group (Remifentanil group) or to the control group (Fentanyl group) in a 1:1 ratio.
2169|NCT04178772|Device|Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens|JJVC Marketed Contact Lens
2170|NCT04178759|Procedure|Liver resection|Laparoscopic or open approach liver resection where at least 1 segment is removed
2171|NCT04178746|Device|Artemis Neuro Evacuation Device|"The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope."
2172|NCT04178733|Drug|LY3493269 - SC|Administered SC
2173|NCT04178733|Drug|Placebo - SC|Administered SC
2174|NCT04178733|Drug|LY3493269 - IV|Administered IV
2488|NCT04176367|Drug|Nicergoline from Italy|This is the reference arm of Italy originator Nicergoline.
2175|NCT04178707|Device|OnZurf Probe, Senzime AB, Uppsala, Sweden|Probe is inserted into the fistula and measurements are made of the inner environment.
2176|NCT04178694|Device|non-invasive ventilation|non-invasive ventilation will be performed on every subjects
2177|NCT04178681|Other|100% vegetable blend|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of vegetable fat blend.
2178|NCT04178681|Other|100% AMF|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat.
2179|NCT04178681|Other|100% cream|Dietary lipid challenge test: 600 ml skimmed milk plus 95 gram of anhydrous milk fat plus milk fat globular membranes.
2180|NCT04178668|Other|Oral mucosa and saliva samples|one oral mucosa sample and one saliva sample
2181|NCT04178655|Drug|Tranexamic acid injection|1 GRAM TRANEXAMIC ACID INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
2182|NCT04178655|Drug|PLACEBO|10 MILILITERS 0.9% NORMAL SALINE INTRAVENOUS BOLUS ONCE PRIOR TO SKIN INCISION AND TOURNIQUET INFLATION
2183|NCT04178642|Drug|percutaneous destruction of the tumor + Idarubicin-Lipiodol treatment|Patients will receive the standard treatment protocol consisting of a percutaneous destruction of the tumor. In addition they will receive an adjuvant treatment by hepatic arterial chemo-infusion of Idarubicin (Zavedos®, Pfizer), which is an anthracycline antineoplastic agent, mixed with Lipiodol (Lipiodol Ultra-Fluid®, Guerbet), which is a contrast agent.
2184|NCT04178642|Procedure|Percutaneous destruction of the tumor|Patients will received the standard treatment protocol consisting of a percutaneous destruction of the tumor.
2185|NCT04178616|Diagnostic Test|olfactory testing with specific odorants (localisation and identification)|Olfactory testing : ETOC (European Test of Olfactory capabilities)
2186|NCT04178603|Other|Exercise, insulin infusion|Trial A: Acute one-legged exercise Trial B: Insulin infusion 4 hours after one-legged exercise
2187|NCT04178590|Drug|SRP + i-PRF|Scaling and root planing in conjunction with injectable platelet rich fibrin
2188|NCT04178577|Drug|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)|Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
2189|NCT04178564|Behavioral|Cognitive Stimulation|"The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 60 minutes and they will be developed according to the following structure:~Welcoming to the group (5 minutes) Reality orientation therapy (10 minutes) Main activity (35 minutes) Session evaluation (10 minutes) CS sessions will be conducted in groups. The intervention sessions will include several activities based on different non-pharmacological therapies, whose effectiveness in elderly with neurocognitive disorders has been scientifically proven. Non-pharmacological therapies used encompass therapies such as musictherapy, reminiscence therapy, validation therapy, Montessori method in geriatrics, ADL training, art therapy and the computer software Rehacom."
2190|NCT04178551|Other|Implementation Facilitation|The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
2193|NCT04178525|Device|ChitoCare gel|ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.
2194|NCT04178525|Device|Placebo gel|Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
2196|NCT04178499|Diagnostic Test|cytokine analysis|analysis of intraocular cytokines
2197|NCT04178486|Behavioral|Hypnosis with amnesia suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
2198|NCT04178486|Behavioral|Hypnosis with cognitive rehearsal suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
2199|NCT04178486|Behavioral|Hypnosis with memory substitution suggestions|Participants received hypnotic induction with hypnotic suggestions for their eating behaviors.
2200|NCT04178486|Behavioral|Hypnosis with induction only|Participants received only hypnotic induction.
2201|NCT04178473|Procedure|total abdominal hysterectomy|total abdominal hysterectomy at time of sacrocolpopexy
2202|NCT04178473|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy at time of sacrocolpopexy
2204|NCT04178447|Drug|Glepaglutide|Single dose of Glepaglutide 10 mg
2205|NCT04178434|Behavioral|Internet-based CBT intervention|A nine step intervention including internet-based feedback by psychologists
2206|NCT04178421|Other|Computerized training program|Eye-gaze fixation computer based training program
2207|NCT04178421|Other|Placebo|Pac-Man, Zookeeper, Tetris
2230|NCT04178213|Device|Implantation of ADAPT 3D ALR|The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
2231|NCT04178200|Drug|Lidocaine 2% Injectable Solution 0.75 ml|0.75 ml of Lidocaine will be added to the anesthetic solution.
2209|NCT04178395|Device|bihemispheric transcranial direct stimulation|"tDCS was applied with the anode placed over the M1 hand area of the ipsilesional motor cortex and the cathode over the same area of the contralesional motor cortex (C3/C4). For the active condition, patients received 5 consecutive daily sessions of 2 mA anodal tDCS over the AH and cathodal tDCS over the UH of 20 minutes each, with fade-in and fade-out periods of 1s. For the sham condition, the stimulation applied in the same sites and with the same parameters, was turned off after a fade-in period, 30 seconds of direct current stimulation and a fade-out period.~Repetitive peripheral nerve stimulation was performed by a peripheral nerve stimulator to the radial nerve and applied at the same time as tDCS. Radial nerve was chosen to improve wrist extension. Trains of 40 stimuli (ISI: 10 ms, duration: 1ms) were delivered every 6 seconds to the radial nerve through bipolar electrodes (5 cm diameter) at an intensity that could elicit a visible wrist extension (20-30 mA)."
2210|NCT04178382|Diagnostic Test|PCR-CRISPR／Cas12a detection|Evaluate whether the combination of PCR and CRISPR/Cas12a detection of alveolar lavage fluid changes the choice of early antibiotics in patients with pneumonia in artificial airways, and whether it changes the prognosis compared with traditional pathogenic microbial detection techniques.
2211|NCT04178369|Other|Proximal And Distal Tibiofibular Joint Manipulations|"For PTFJ, the experimental intervention will be based on previously published methods. Physiotherapist will make contact with the fibular head, extending to the popliteal fossa. The associated soft tissue will be pulled in a lateral direction until the metacarpophalangeal joint will be firmly stabilized behind the fibular head.~For DTFJ, the experimental intervention will be conducted according to previously published methods. Physiotherapist will grasp and stabilize the distal tibia with one hand and grasp the distal fibula between the finger and thenar eminence of the other hand. The fibula will be translated posteriorly until the restrictive barrier (end range) will be engaged. Then a high-velocity, low-amplitude thrust will be applied through the fibula in a posterior-superior direction."
2212|NCT04178369|Other|Bobath Treatment|All participants will be given a 6-week-long physiotherapy and rehabilitation program based on the Bobath concept for 5 days a week, 45 minutes each. The techniques will be applied by a physiotherapist who is specialized in Bobath concept. 35 different techniques will be used to improve the selective control and weight transfer of the pelvis in sitting, standing and supine/side lying positions. Moreover, soft tissue mobilization will be also used to relieve tension and loosen stiff tissues to provide biomechanical alignment and reduce pain.
2213|NCT04178356|Other|Proprioceptive Neuromuscular Facilitation Training|The Proprioceptive Neuromuscular Facilitation Training will be performed using patterns and techniques in various positions for abdominal and back muscles' facilitation and strengthening. Supine, side-lying, and sitting positions will be used. There will be a rest of about 20 sec between sets. Warm-up for 10 min, main exercises for 25 min, cool-down for 10 min (a total of 45 min), 5 times a week for 4 weeks.
2214|NCT04178356|Other|Control Group|Ultrasound, TENS, massage, and exercise will be used with each other because in most of the physical therapy clinics these modalities are used together for such problems as a conventional treatment. After massage application, hamstring and paravertebral muscles stretching and also stabilizing exercises will be prescribed, each one for ten times in each session.
2215|NCT04178343|Radiation|tomotherapy|"the prescription of tomotherapy: whole brain radiation (WBRT) with 40Gy in 20 fractions and concurrent boost of 60Gy of the leptomeningeal metastases;~WBRT of 50Gy in 25 fractions, with dose limitation of hippocampus and brain stem; c.TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles.~d. Some patients received intrathecal chemotherapy (MTX+AraC+Dex) based on the cytology of cerebrospinal fluid (CSF)."
2216|NCT04178330|Radiation|tomotherapy|Whole brain radiation (WBRT) with 38-40Gy in 20 fractions and concurrent boost of 60-70Gy of the lesions. TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles.
2217|NCT04178304|Drug|Prolotherapy with 25% Dextrose|Intra-articular injection of 6mL of 25% dextrose Extra-articular injection at tender sites with 25% dextrose
2223|NCT04178265|Other|Electroacupuncture|needles were inserted to Kunlun(BL60), Yanglingquan (GB34), Sanyinjiao(SP6), Taixi (KI 3) contralateral to the operated leg and deqi sensation elicited at acupoints.
2224|NCT04178252|Other|mask|investigators will add eye mask to standard treatment
2225|NCT04178252|Other|headset|investigators will add headset to standard treatment
2226|NCT04178252|Other|standard drug|investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes
2227|NCT04178239|Diagnostic Test|fMRI, questionnaires, pneumologic diagnostics|fMRI neuropsychological questionnaires pneumologic diagnostics: blood samples, whole body plethysmography, walking test
2228|NCT04178226|Procedure|Manual Acupuncture|The acupoints choose are (RN6) (RN4) (SP6) (PC6) (SP10) (SP4)
2229|NCT04178226|Device|Laser Acupuncture|Laser Acupuncture
2232|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 0.75 ml|0.75 ml of Bupivacaine will be added to the anesthetic solution.
2233|NCT04178200|Drug|Lidocaine 2% Injectable Solution 1.5 ml|1.5 ml of Lidocaine will be added to the anesthetic solution.
2234|NCT04178200|Drug|Bupivacaine Hcl 0.5% Inj 1.5 ml|1.5 ml of Bupivacaine will be added to the anesthetic solution.
2235|NCT04178187|Drug|Caps Lactolevure|One group will receive Caps Lactolevure x2 and the other group Caps Placebo x2.
2236|NCT04178187|Drug|Caps Placebo|Caps Placebo
2237|NCT04178174|Radiation|SABR boost and de-escalated chemoradiation|Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions
2238|NCT04178174|Radiation|Standard chemoradiation|Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
2239|NCT04178161|Device|Laser treatment|Iontophoresis of methylene blue is used to identify the sweat glands. An image guided fractional erbium laser is used to specifically target these glands for ablation.
2240|NCT04178148|Other|Amikacin dose optimization|Therapeutic drug optimization of amikacin using the BestDose software algorithm
2241|NCT04178135|Drug|rLH|rLH supplement from day 1 of stimulation
2242|NCT04178135|Drug|rLH|rLH supplement from day 6 of stimulation
2243|NCT04178122|Genetic|Result disclosure|Disclosure of clinically confirmed, medically actionable genetic testing results and post-test genetic counseling session.
2244|NCT04178109|Drug|Dexketoprofen/tramadol (27mg/75mg)|Postoperatively patients in Group A received the oral combination dexketoprofen/tramadol for the treatment of acute postoperative pain the first 72h
2245|NCT04178109|Drug|Tramadol hydrochloride|Patients in group B received IV tramadol 75mg every 8h
2246|NCT04178109|Drug|Paracetamol|Patients in group B received IV paracetamol 1g every 8h
2247|NCT04178109|Drug|Ropivacaine Hydrochloride 7.5 MG/ML|300mg ropivacaine as periarticular injection in a dilution of 100ml n/s 0,9% was done by the orthopedic surgeon in all patients
2248|NCT04178109|Drug|Levobupivacaine Hydrochloride|10-15mg levobupivacaine was done subarachnoidal for spinal anesthesia
2249|NCT04178096|Other|Quality Improvement Intervention|The investigators will assess the effectiveness of empirically determined implementation strategies that are associated with increasing cirrhosis evidence based practices and thus improving outcomes of Veterans with cirrhosis by introducing a bundle of these strategies to four new 'low-performing' hospitals every six months during and eighteen month period in this stepped wedge cluster randomized trial.
2250|NCT04178083|Diagnostic Test|medical examination|medical examination
2267|NCT04178044|Biological|GB223,7mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:7mg/kg 2 subjects receive placebo.
2268|NCT04178044|Biological|GB223,21mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:21mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
2269|NCT04178044|Biological|GB223,63mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:63mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
2270|NCT04178044|Biological|GB223,119mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:119mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
2271|NCT04178044|Biological|GB223,140mg/kg|Injection; strength of 70mg/1ml/vial; subcutaneous injection; GB223:140mg/kg 2 subjects receive placebo. The next dose group can be initiated only after the safety and tolerability are confirmed within 4 or 8 weeks after the previous dose is given.
2297|NCT04177823|Drug|Belantamab mafodotin|Belantamab mafodotin will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.
2298|NCT04177810|Drug|Cemiplimab|"Patients will receive treatment Day 1 of each cycle (21 days) for up to 2 years.~Drug: Cemiplimab (350 mg) will be administered IV on day 1 (21 day cycle)."
2489|NCT04176354|Drug|Palbociclib + an aromatase inhibitor|Palbociclib + an aromatase inhibitor therapy
2272|NCT04178031|Device|IUD insertion|"Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman."
2273|NCT04178018|Device|Photoacoustic imaging|-Emerging technique in which a short-pulsed laser beam penetrates diffusively into a tissue sample
2274|NCT04178018|Device|Ultrasound|-The ultrasound is being used in conjunction with the photoacoustic imaging
2275|NCT04178005|Drug|Cladribine|All study participants will receive treatment with cladribine 10 mg tablets at the recommended cumulative dose of 3.5 mg/kg, divided into 2 yearly treatment courses (1.75 mg/kg per treatment course). This regimen corresponds to the recommended dosage as per the USPI
2276|NCT04177992|Other|Servo control|FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
2277|NCT04177979|Behavioral|Near-assisted learning through trained peers|Students randomly allocated to this group were overseen during sessions by trained peer instructors.
2278|NCT04177966|Behavioral|pre-prepared video describing the cesarean surgery|a pre-prepared video, approximately 10 minutes in length, showing in detail the course of events around the operation - from the woman's perspective - from the time they were admitted to the department, preparation for surgery, entrance to the operating r
2279|NCT04177966|Behavioral|general information|In the control group - women will receive general information about the surgery as part of informed consent, without watching a pre-prepared film.
2280|NCT04177953|Drug|Carboplatin AUC 5|chemotherapy iv
2281|NCT04177953|Drug|Cisplatin 75 mg/m2|chemotherapy iv
2282|NCT04177953|Drug|Pemetrexed 500 mg/m2|chemotherapy iv
2283|NCT04177953|Biological|Nivolumab Injection|Human monoclonal antibody
2284|NCT04177940|Drug|DMAB Discontinuation and Switching|"We will test the hypothesis that an increase in bone turnover markers (e.g. CTX and P1NP) in patients currently taking chronic glucocorticoids will be attenuated more in those who switch from denosumab to late zoledronic acid (9 months after last denosumab dose) compared to participants randomized to early zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months after last denosumab dose"
2285|NCT04177927|Device|Capnostream 20p / Coviden|The special nasal canule is used for detection carbondioxide from breathe of patients
2286|NCT04177927|Device|Rutine monitoring|peripheric Oxygen saturation is monitored.
2287|NCT04177914|Procedure|Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)|Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.
2288|NCT04177914|Device|Ventriculoperitoneal Shunt|The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.
2289|NCT04177901|Device|Near infrared spectroscopy|It is used for detection of tissue oxygenation
2290|NCT04177888|Device|Hot Pack|It is a single-use pack filled with magnesium sulfate and water, which was squeezed between the hands to activate their warming effect. The temperature ranges between 40°C to 50°C, which is safe to use. Thus, it provided a consistent heat therapy for up to 30 minutes. They can be used directly on the skin or covered with gauze to avoid direct skin contact. Applied to the lower back area for 30 minutes, followed by 10 minutes rest between each hot pack application, then it was reapplied for another 30 minutes. This procedure was repeated till delivery.
2291|NCT04177875|Drug|Teripalimab|Teripalimab Injection 240mg/6ml fixed dose (3mg/kg for patients weighing less than 40kg) ,injection on day 1, each infusion for 30min (no less than 60 minutes for the first injection); every 3 weeks. docetaxel dose was 75mg/m2, injection on day 1;Albumin-bound Paclitaxel (no anti-allergic treatment required), 260mg/m2, injection on day 1; Cisplatin was 75mg/m2, injected on day 1.A total of two treatment cycles.
2294|NCT04177849|Procedure|ACDF|A 4-cm anterolateral transverse incision is made over the index level, on either the right or left side. Platysma is sectioned transversal to its fibers and the anterior aspect of the spinal column is bluntly exposed between the carotid sheath and the esophagus. The disk is excised, including the posterior longitudinal ligament. Disk fragments and/or osteophytes from the uncovertebral joint on the affected side are removed until the root is fully decompressed. Reconstruction is typically done with an interbody spacer, autologous bone graft and a stabilizing plate screwed to the adjacent vertebral bodies. A fusion cage with integrated screws may also be used according to the surgeon's preference.
2295|NCT04177849|Procedure|PF|A 4-cm longitudinal midline incision exposes the spinous processes of the adjacent vertebrae. The facet joint covering the index foramen is exposed through intermuscular planes. The root canal is opened as the medial third of the facet joint is removed with a high-speed diamond burr. The affected nerve root is decompressed by laterally undercutting the facet joint throughout its length.
2296|NCT04177836|Behavioral|Mindfulness intervention|Participants will either complete a mindfulness intervention or active control for 2 weeks on their smartphone
2411|NCT04176991|Biological|CTI-1601|CTI-1601 is a recombinant fusion protein and is intended to deliver human frataxin, the protein deficient in Friedreich's ataxia
2299|NCT04177810|Drug|Plerixafor|"Patients will receive treatment on the first 7 days of each cycle (21 days) for up to 2 years.~Drug: Plerixafor (80mcg/kg/hr) will be administered as a continuous IV infusion of the first 7 days of each cycle (21 days cycle)."
2300|NCT04177797|Drug|Toripalimab|Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
2301|NCT04177784|Other|Online Educational Videos|The videos were developed by the researchers based on a prior study to test if specific information about obesity and weight control influence weight bias.
2304|NCT04177745|Other|Hot application|Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
2305|NCT04177745|Other|Cold application|Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
2306|NCT04177732|Diagnostic Test|Collection of sulcular (crevicular) fluid|Sterile paper strips will be used for collecting crevicular fluid
2307|NCT04177732|Diagnostic Test|Probing depth|Williams SE manual probe will be used to measure the probing depth
2308|NCT04177732|Diagnostic Test|Bleeding on probing|Williams SE manual probe will be used to probe the sulcus a oserve the gingival reaction
2309|NCT04177732|Diagnostic Test|Gingival index|Modified Löe and Silness criteria will be used for evaluating the gingival index score
2310|NCT04177732|Diagnostic Test|Bone loss rate of alveolar bone|Using modification of criteria described by Schei et al, bone loss rate of alveolar bone will be analyzed on radiographic assessment
2311|NCT04177719|Drug|Oxytocin|oxytocin or placebo will be given intranasally. The order of administration will be counterbalanced
2312|NCT04177706|Drug|Ketamine Hydrochloride|Participants receiving the active study medication will receive 60 mg ketamine by intranasal spray twice per week for four weeks under clinical supervision.
2313|NCT04177706|Drug|Placebo|Participants receiving the placebo study medication will receive saline by intranasal spray twice per week for four weeks under clinical supervision.
2314|NCT04177693|Dietary Supplement|Epigallocatechin gallate (EGCG)|800 mg (2 capsules) of decaffeinated EGCG (green tea extract), taken orally on a daily basis for up to 2 months
2315|NCT04177693|Drug|Clomiphene Citrate|100 mg for 5 days
2316|NCT04177693|Drug|Letrozole|5 mg for 5 days
2317|NCT04177680|Drug|Omega 3 pentaenoic acid|Encapsulated omega-3 pentaenoic acid
2318|NCT04177680|Drug|icosapent ethyl|Encapsulated omega-3 acid ethyl esters
2319|NCT04177667|Dietary Supplement|Proxeed|Treatment with dietary supplement for male infertility for Proxeed Arm
2320|NCT04177667|Other|Placebo|Treatment with placebo for Placebo Arm
2321|NCT04177654|Drug|Benzimidazoles|A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
2322|NCT04177641|Diagnostic Test|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
2323|NCT04177641|Diagnostic Test|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
2324|NCT04177628|Behavioral|Shared decision making supported by an in-consultation patient decision aid|After having receiving training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
2325|NCT04177615|Procedure|Thromboectomy|Thromboectomy in Basilar Artery Occlusion patients
2326|NCT04177602|Combination Product|Trifluridine/tipiracil chemoradiation|Trifluridine/tipiracil based chemoradiation
2327|NCT04177602|Combination Product|Capecitabine based chemoradiation|Capecitabine based chemoradiation
2328|NCT04177589|Other|Incidence of Delirium in Inpatient Elderly Patients|Study design: prospective cohort study.
2329|NCT04177576|Biological|2 additional tubes of blood|2 additional tubes of blood will be collected to prepare plasma aliquots used tomeasure markers of neutrophil activation
2331|NCT04177537|Device|Low Intensity Continuous Ultrasound|3MHz, 0.132W/cm2, 1.3W for 4 hours day delivered by an acoustic device provided by Zetroz Systems LLC
2332|NCT04177524|Device|Background Mode|The LifeSaver app tracks the date, time, and global positioning system (GPS) location of each trip that the participant takes in a moving vehicle, along with a list of apps used during the trip, but does not contain any anti-distracted driving features.
2333|NCT04177524|Device|Manual Mode|"In addition to the features in the Background Mode, the LifeSaver app locks the participants' phone while they are in a moving vehicle unless they actively press an Emergency Unlock or Passenger Unlock button."
2334|NCT04177524|Device|Auto-Detect Mode|"In addition to the features in Manual Mode, the LifeSaver app's Passenger Unlock feature can only be used if the app, via the smartphone's camera, confirms that the participant is not the driver of the vehicle."
2335|NCT04177511|Device|Transcutaneous Auricular Vagus Nerve Stimulation|"Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked.~The electrode is positioned in the cymba concha of the left ear."
2336|NCT04177498|Drug|Rigosertib Sodium|given PO or 72 hour continuous infusion
2337|NCT04177498|Other|Quality-of-Life Assessment|Ancillary studies
2338|NCT04177485|Behavioral|SMS text reminders|SMS reminders (in English and the local language) for the 2nd dose of Pentavalent vaccine were sent 28, 30 and 32 days after the 1st dose. SMS reminders for the 3rd dose of Pentavalent vaccine were sent 61, 66, and 68 days after the 1st dose. SMS reminders for the measles-containing vaccine were sent 274, 279, and 281 days after the child's date of birth.
2412|NCT04176991|Biological|Placebo|Placebo Comparator
2413|NCT04176978|Drug|Rosuvastatin|Patient in this group will receive Rosuvastatin 20mg daily.
2339|NCT04177472|Behavioral|Obesity Prevention Group|Parents will be provided with responsive feeding coaching to help them recognize hunger and satiety cues and nutrition coaching that involves recommending a sequence of introducing complementary foods that corresponds with food textures and feeding styles, breast/bottle weaning, healthy snacking and hands on demonstrations for healthy food options.
2340|NCT04177459|Behavioral|Health promoting dialogue|Health promoting dialogues based on the salutogenic theory, focusing on resources within and around the individual, and on coping strategies. Seven individual dialogues for each participant, individually adapted due to the fatigue. The intervention is offered in the participants home or at the local hospital, dependent on the participants fatigue and what is preferred.
2341|NCT04177459|Other|standard treatment / treatment as usual|Follow-up from primary and secondary health care, and from schools.
2342|NCT04177446|Dietary Supplement|a production consist of various oligopeptides and the whey protein|patients will be given extra protein intake except the basic energy intake
2343|NCT04177446|Dietary Supplement|basic energy intake|supplement as basic energy intake
2344|NCT04177446|Dietary Supplement|maltodextrin|used as placebo in the control group
2345|NCT04177433|Drug|Depo-Medrol Injectable Product|Corticosteroid
2346|NCT04177433|Drug|Saline|Placebo
2347|NCT04177420|Device|FIR-C mattress|infrared-C irradiation by hot mattress with a powered heating compress
2348|NCT04177420|Device|FIR-C abdominal pad|infrared-C irradiation by hot abdominal pad with a powered heating compress
2349|NCT04177420|Device|fake FIR-C mattress|normal mattress with fake controller, custom make for placebo group
2350|NCT04177420|Device|fake FIR-C abdominal pad|normal abdominal pad with fake controller, custom make for placebo group
2351|NCT04177407|Procedure|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.|Standard laparoscopic ELAPE with pelvic peritoneal floor reconstruction using bladder peritoneum flap are to performed.
2352|NCT04177394|Device|MitraClip G4 System|Percutaneous mitral valve repair using the MitraClip G4 system.
2353|NCT04177381|Procedure|Cesarean section|"Abdominal Incision: Pfannenstiel incision Sharp dissection will be continued through the subcutaneous layer to the fascia.~The fascia will be then incised sharply at the midline~The transversalis fascia and pre peritoneal fat will be dissected carefully~The peritoneum will be then incised.~Low Transverse Cesarean Incision. Bladder flap creation effectively moves the bladder away from the planned hysterotomy site~Delivery of the Fetus and placenta.~Uterine Repair in two layers of continuous 0-or No.1 absorbable suture."
2354|NCT04177381|Procedure|subcutanous sutures|suture closure of subcutaneous tissue with interrupted 2-0 polyglactin 910 (Vicryl).the stitch interval is 1cm
2355|NCT04177381|Device|subcutanous drain|Inthedraingroup,aclosednonvacuum drain willbeinsertedin thetissueandexitefrom theskinthroughaseparateopeningandstitchto theskin
2356|NCT04177368|Dietary Supplement|Theragran 60ml|history,examination and biochemical values
2357|NCT04177355|Biological|BG505 SOSIP.664 gp140|Administered by IM injection
2358|NCT04177355|Biological|Placebo|Administered by IM injection
2359|NCT04177355|Biological|3M-052-AF|Administered by IM injection
2360|NCT04177355|Biological|CpG 1018|Administered by IM injection
2361|NCT04177355|Biological|GLA-LSQ|Administered by IM injection
2362|NCT04177355|Biological|Alum (Aluminum Hydroxide Suspension)|Administered by IM injection
2363|NCT04177342|Drug|Fentanyl|the patients use remifentanil and fentanyl as intra-operatively pain control and compare the post-operative pain condition with the oxycodone group
2364|NCT04177342|Drug|Oxycodone|the patients use oxycodone and remifentanil as intra-operatively pain control and compare the post-operative pain condition with the fentanyl group
2365|NCT04177303|Drug|Metformin|Participants will be randomized to metformin 2000 mg
2366|NCT04177303|Drug|Placebo|Participants will be randomized to placebo
2367|NCT04177290|Drug|Sintilimab (M1b)|Intravenous infusion
2368|NCT04177290|Drug|Sintilimab (approved)|Intravenous infusion
2369|NCT04177264|Procedure|Occipito-Atlantal Decompression (OA DC)|The participant lies supine in a relaxed state while the investigator cradles the patient's head with their hands, middle finger pads along the inferior aspect of inion, reaching to the occipito-atlantal joint. The investigator then applies gentle posterior and cephalad traction to the occiput, while bringing the elbows together. This results in supination of the hands and separation of the middle fingers, creating a posterior-lateral force vector to either side of the foramen magnum. The pressure is maintained until softening of the underlying structures is felt. The procedure is applied for 10 minutes.
2370|NCT04177264|Procedure|Sham Occipito-Atlantal Decompression (Sham OA DC)|The participant lies supine in a relaxed state while the investigator applies light touch to the patient's head with their hands.
2371|NCT04177264|Procedure|Splenic Lymphatic Pump Technique (SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigatory compresses and releases the spleen at a rate of 20 compressions/min for 3 min.
2372|NCT04177264|Procedure|Sham Splenic Lymphatic Pump Technique (Sham SpLPT)|With the participant supine, the investigator places a posterior hand along the left lower ribcage, and a superior hand over the left costal arch, encompassing the spleen. The investigator will maintain light touch at these positions for 3 minutes. No compressions are performed.
2373|NCT04177264|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae. Electrical stimulation (30 Hz stimulation frequency, 300 μs pulse width) is applied for 10 min. The stimulation current is determined individually for each participant by slowly increasing the stimulation current until the participants feel a mild tingling sensation at the site of the electrode. Then the current is gradually reduced until the tingling sensation disappears. This current will then be used for taVNS. A TENS 7000 or EMS 7500 device (510(k): K080661) is used.
2374|NCT04177264|Device|Sham Transcutaneous Auricular Vagus Nerve Stimulation (Sham taVNS)|A bipolar clip electrode is attached to the auricle at the location of the cymba conchae but no electrical current is applied to the electrode.
2449|NCT04176666|Device|NettOpp|NettOpp is a mobile application for adolescents aged 13-16 years who have been exposed to cyberbullying or cyberaggression.
2375|NCT04177238|Dietary Supplement|Fruit concentrate - either cherry or blueberry|Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).
2376|NCT04177225|Procedure|Trans thoracic Ultrasound Examination|Ultrasound examination of cardiac function before and after induction of general anesthesia.
2377|NCT04177225|Other|Intravenous fluid administration|Intravenous fluids will be administered as a bolus in response to standard clinical indications
2378|NCT04177199|Other|TRIAGE HF Pathway|A new care pathway (Triage-HF Plus) for the remote monitoring and management of heart failure stability in a cohort of device patients at 3 hospital sites in North West England.
2379|NCT04177186|Other|Strength training|Strength training for hamstring and gastrocnemius only, pre and post 12 weeks of intervention
2380|NCT04177186|Combination Product|Strength training with botulinum toxin|Strength training for hamstring and gastrocnemius with Ultra Sound Imaging method, pre and post 12 weeks of intervention
2381|NCT04177173|Drug|Simvastatin 20 mg|improvement of disease activity
2382|NCT04177173|Drug|Methotrexate 10 mg|improvement of disease activity
2383|NCT04177160|Behavioral|Music|Subjects sit still and listen to preferred music for 5 minutes.
2384|NCT04177160|Behavioral|White noise|Subjects sit still and listen to white noise for 5 minutes.
2385|NCT04177147|Other|Clinical decision support via alert tool|The alert tool displays the risk of hypoglycemia for outpatients with diabetes mellitus.
2386|NCT04177121|Other|qualitative analysis|Qualitative analysis of physiotherapy prescriptions
2387|NCT04177108|Drug|Atezolizumab|Atezolizumab will be administered to participants by intravenous (IV) infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28-day cycle until unacceptable toxicity.
2388|NCT04177108|Drug|Ipatasertib|Ipatasertib will be administered to participants at a starting dose of 400 mg QD PO (one tablet a day orally) for 21 days of each 28-day cycle on Days 1 - 21 unless held for management of adverse events.
2389|NCT04177108|Drug|Paclitaxel|Paclitaxel will be administered to participants at a starting dose of 80 mg/m^2 by IV infusion for 3 of 4 weeks on Days 1, 8, and 15 of each 28-day cycle unless deferred to Day 22 because of an adverse event.
2390|NCT04177108|Drug|Placebo for Atezolizumab|Placebo will be administered to participants at a fixed dose of 840 mg IV infusion for Atezolizumab on Days 1 and 15 of each 28-day cycle until unacceptable toxicity.
2391|NCT04177108|Drug|Placebo for Ipatasertib|Placebo will be administered to participants at a starting dose of 400 mg QD PO (one tablet a day orally) for Ipatasertib for 21 days of each 28-day cycle on Days 1 - 21 unless held for management of adverse events.
2392|NCT04177095|Diagnostic Test|Allosure|Monthly monitoring of dd-cfDNA levels in blood
2393|NCT04177095|Drug|Immunosuppression reduction|Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of Allosure and Trugraf results
2394|NCT04177095|Diagnostic Test|Trugraf|Monthly monitoring of Trugraf result
2395|NCT04177082|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
2396|NCT04177069|Dietary Supplement|Visucomplex Plus|capsule contains: Lutein, Zeaxanthin, alphalipoic acid MATRIX, Vitamine E, Zinc, Maquibright® (Aristotelian chilensis berry standardized, containing Anthocyanin and delphinidin extracts), Vitamin D and cupper.
2397|NCT04177056|Radiation|SBRT|30-35 Gy in 5 fractions
2398|NCT04177043|Diagnostic Test|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests|HCV antibody and hepatitis B surface antigen (HBsAg) rapid diagnostic tests
2399|NCT04177043|Drug|DAAs|Treatment with different regiments with DAAs
2400|NCT04177030|Behavioral|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
2401|NCT04177030|Behavioral|Isopesticide dietary scheme|"All participants should collect first morning urine samples on specific days during the first week and during the third week. Day indicated as 8th, represents the first day of the following week (first day of the wash-out week and first day of the fourth week which is the last day of the study). The participants are asked to consume 4 portions of fruit and 2 portions of vegetables per day during the two trial periods. Overall, dietary daily consumption of foods and fluids will be monitored with the use of a dietary diary throughout the study. Participants will also be asked to take a photograph of the ready to be consumed fruit and vegetable on actual time of consumption and share photos with research team in order to verify at a minimum whether the pre-set time-restriction criteria have been met."
2402|NCT04177017|Behavioral|Mindfulness-based intervention|"The behavioral intervention was carried out once a week during 60 minutes from May to November, and included mindfulness-based practices sought to foster self-awareness, and dyadic activities sought to awakening subtle perception of the other.~Group activities, which entailed more than two participants, were also conducted to foster empathic collaboration and prosocialness. Diverse collaborative games were carried out in which mutual help was needed for achieving shared goals in an amusing way .~Perspective-taking was encouraged within the group, by sharing each participant's experience, which included expressing how each child had felt (i.e., if neglected, ignored or cared for) and whether they had enjoyed helping their peers or no."
2403|NCT04177004|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
2404|NCT04177004|Drug|Cyclophosphamide|Given IV
2405|NCT04177004|Drug|Etoposide|Given IV
2406|NCT04177004|Radiation|Fractionated Stereotactic Radiation Therapy|Undergo FTBI
2407|NCT04177004|Drug|Goat Milk|Given human lysozyme goat milk PO
2408|NCT04177004|Biological|Palifermin|Given IV
2409|NCT04177004|Drug|Sirolimus|Given PO
2410|NCT04177004|Drug|Tacrolimus|Given IV and PO
2414|NCT04176978|Other|Treat-to-target strategy|Patient will receive treat-to-target strategy aiming at minimal disease activity (MDA). If patient cannot achieve MDA, treatment will be escalated.
2419|NCT04176939|Biological|HZ/su vaccine (GSK1437173A)|2 intramuscular (IM) doses of the HZ/su vaccine administered- first dose at month 24 and second dose at month 25
2420|NCT04176926|Diagnostic Test|Electrocardiogram|Diagnostic Test: Simultaneous assessment of heart rhythm by 12-lead ECG and wearable device characterization of heart rhythm.
2421|NCT04176913|Drug|LUCAR-20S CAR-T cells|An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
2422|NCT04176900|Other|Ingeo Biopolymer (PLA)|Biopolymer used for 3D-printing of rigid bolus
2423|NCT04176900|Other|Ecoflex 030|Polymer used for the 3D-printed flexible bolus
2424|NCT04176887|Drug|Levetiracetam Injection|The levetiracetam dose is 20- 40 mg/kg by intravenous infusion over 15 minute, a rate of 2-5 mg/kg/minute diluted in 100 ml with 0.9% sodium chloride as a single dose.
2425|NCT04176887|Drug|Phenytoin Injection|Phenytoin dose is 20-40 mg/kg/min by intravenous infusion over 30 minute, diluted with 0.9% sodium chloride to a maximum concentration of 10 mg/ml.
2426|NCT04176874|Procedure|Robotic-assisted diastasis of the rectus abdominis muscles repair|Diastasis of the rectus abdominis muscles repair using the Intuitiv SI robot
2427|NCT04176861|Device|home-based Brainwave Entrainment Technology|Smartphone app-based brainwave entrainment programme using audio stimulation via binaural beats or visual stimulation via flickering lights
2428|NCT04176848|Drug|CFI-400945|Cycle 1: CFI-400945 orally on Days 1-7 (then 7 days off) and on Days 15-21 (then 7 days off) Cycle 2 on: CFI-400945 orally once daily (28 day cycles)
2429|NCT04176848|Drug|Durvalumab|Durvalumab 1500mg IV on Day 1 (28 day cycles)
2430|NCT04176835|Drug|Oxytocin nasal spray|Single-dose oxytocin will be administered intranasally
2431|NCT04176822|Other|Educational animated movie group|Watching educational animation movie which were designed by the researcher before operation for fear and pain.
2432|NCT04176822|Other|Documentary movie group|Watching documentary movie about trees before operation for fear and pain.
2433|NCT04176809|Other|Routine Assessment of HRQoL coupled with Therapeutic Information|Participants will complete the EORTC-QLQ-C30 and EORTC-QLQ-BR23 questionnaires before their consultation via the CHES software. The scores will then be generated and provided to clinicians in a graphic form, describing scores course. Access to CHES web portal will also be open to participants outside consultation time points, to enable them to monitor HRQoL if necessary. Workshop 1, will help patients to recognize and react to the occurrence of possible adverse effects, and anticipate their occurrence through appropriate preventive means. In workshop 2, participants will have the opportunity to express their representations and experiences related to their diet and the consequences of disease and treatments on diet. In workshop 3, participants can describe their experiences of fatigue and how their life is affected by it. Moreover, they can identify possible causes and finally discuss solutions to better this symptom. Every month, a reminder letter will also be sent to participants.
2434|NCT04176796|Other|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]"
2435|NCT04176783|Drug|Opioids|narcotic pain medicine
2436|NCT04176783|Drug|Opioid-Free|non narcotoc pain medication
2440|NCT04176744|Other|Uni- and bilateral magnetic phrenic nerve stimulation|Uni- and bilateral magnetic phrenic nerve stimulation using different coils, stimulation patterns (frequency, intensity, number of pulses) and locations (neck, chest).
2442|NCT04176718|Drug|Daratumumab|predetermined dose, intravenously, at predetermined times per cycle
2443|NCT04176718|Drug|Carfilzomib|predetermined dose, intravenously, give 3 times per cycle
2444|NCT04176718|Drug|Pomalidomide|predetermined dose, orally, daily per cycle
2445|NCT04176718|Drug|Dexamethasone|predetermined dose, orally, given 8 times per cycle
2446|NCT04176705|Drug|Lidocaine Cream|Both sites will have lidocaine 4% topical anesthetic cream (Ferndale Laboratories, Ferndale MI) applied as thin layer and left for 30-45 minutes to minimize discomfort applied before laser treatment.
2447|NCT04176705|Drug|Triamcinolone Acetonide Cream|Triamcinolone acetonide cream (Bristol-Myers Squibb, Princeton, NJ) at a concentration of 20mg/ml will be applied immediately after treatment to both laser and no-laser sites - as this is often reported and there is some speculation that this may be part of the reason improvement is noted.
2448|NCT04176705|Device|Fractional Ablative Laser|Applied to only site that is randomized to laser intervention
127275|NCT03192839|Other|Placebo|Placebo
2450|NCT04176653|Drug|SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo|IMP will be provided as a solution to be injected by qualified clinical staff in patient's abdomen, upper arms or front of the thighs.
2451|NCT04176627|Device|Lung ultrasound|One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit
2454|NCT04176601|Behavioral|Engage coaching|"Participants will complete up to 8 weekly individual Social Engage psychotherapy sessions. Participants will be allotted up to 3 months to complete all sessions, a time-frame that allows for two weeks without meeting to address life stressors such as illnesses that may pop up. Phone sessions are allowed for any week except the first and last. The first and last session are longer - up to 60 minutes if needed. Middle sessions are shorter (20-45 minutes). Engage is a stepped care psychotherapy in that the simplest strategy is taught first—action planning (a derivative of problem solving therapy)—and barrier strategies are added only if needed. Action plans are designed to address loneliness and social isolation in the context of caregiving demands."
2457|NCT04176575|Other|Acupuncture|Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
2458|NCT04176562|Device|RTI Spine products|"Interbody fusion devices - intended to help facilitate fusion by providing a platform for bone growth, while maintaining height and decompression.~Supplemental fixation and/or stabilization devices - are intended to stabilize the spine to allow for fusion to occur, maintain current spinal movement, correct deformities or curvature, treat trauma, spinal stenosis, tumor and pseudarthrosis.~Bone graft substitute - is intended to aid in fusion."
2459|NCT04176549|Other|Management of Ectopic Pregnancy|Expectant, Medical or Surgical management of Ectopic Pregnancy
2460|NCT04176549|Other|Management of termination of pregnancy|Surgical termination of pregnancy
2461|NCT04176549|Other|Elective management of gynaecology patients|Elective hysterectomy and salpingo-oophorectomy
2462|NCT04176536|Drug|BI 764198|Capsules
2463|NCT04176523|Drug|Carglumic Acid|Maintenance therapy with carglumic acid
2464|NCT04176510|Behavioral|Health Coach Intervention|A structured, manualized coaching intervention by a lay Health Coach that employs a standardized positive affect/self-affirmation intervention, not tied to specific chronic diseases, to help motivate patients to learn to implement self-management by setting life goals.
2465|NCT04176497|Drug|68Ga-HBED-CC-PSMA|Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
2467|NCT04176471|Other|Therapeutic Hypothermia|Therapeutic hypothermia involves use of a servo-controlled device and blanket to lower the core body temperature by 3°C for 72 hours followed by a period of re-warming in which the temperature is increased by 0.5°C per hour for 6 hours until normothermia is achieved.
2468|NCT04176471|Other|Normothermia|Normothermia will be achieved using the same servo-controlled device and blanket to assure normothermia of the control arm. The goal temperature for normothermia is 36.5-37.3°C for 72 hours.
2469|NCT04176458|Device|Methacetin Breath Test (MBT)|The hypothesis is that MBT CPDR 20 in the Fontan patient is abnormal as a result of alterations in liver perfusion, liver cell metabolic capability and transhepatic resistance secondary to hemodynamics unique to the Fontan as well as end-organ liver damage. Due to lack of robust biomarkers or other risk stratification schemes, we aim to determine whether there is prognostic value in hepatic MBT CPDR 20 in the Fontan patient.
2470|NCT04176445|Device|Orthostatic board posture|Patients will be verticalized at at 45º, 60º and 80º using an orthostatic board. The total posture protocol will last 30 minutes
2471|NCT04176445|Other|Bedside sitting posture|Patients will be placed at the bedside, with support for the back and upper limbs. They will be kept at 90º of hip and knee flexion and feet supported. The total posture protocol will last 30 minutes.
2472|NCT04176432|Other|No intervention|Retrospective observational study with no intervention
2473|NCT04176419|Drug|Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
2474|NCT04176419|Drug|Placebo Ketamine|0.25 mg/kg IV bolus before incision, followed by 0.005 mg/kg/minute IV for the remainder of the surgical case excluding the final 30-45 minutes.
2475|NCT04176419|Drug|Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
2476|NCT04176419|Drug|Placebo Lidocaine|1.5 mg/kg IV bolus before incision, followed by infusion of 1.5 mg/kg/hour ideal body weight (max 8 hours) during the case
2477|NCT04176419|Drug|Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
2478|NCT04176419|Drug|Placebo Acetaminophen|1,000 mg orally at time of check-in to the preoperative unit
2479|NCT04176419|Drug|Gabapentin|600 mg orally at time of check in to the preoperative unit
2480|NCT04176419|Drug|Placebo Gabapentin|600 mg orally at time of check in to the preoperative unit
2481|NCT04176419|Drug|Celecoxib|200 mg orally at time of check in to the preoperative unit
2482|NCT04176419|Drug|Placebo Celecoxib|200 mg orally at time of check in to the preoperative unit
2483|NCT04176406|Device|rTMS|excitatory 5Hz rTMS will be used
2484|NCT04176406|Device|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
2485|NCT04176393|Drug|ivosidenib|subjects will receive a single dose of ivosidenib 500 mg on Day -3 (i.e., 3 days prior to the start of daily dosing) and undergo PK/PD assessments over 72 hours to evaluate drug concentrations and 2-HG levels. Following that, subjects will be treated with ivosidenib 500 mg once a day (QD) PO continuously (28-day cycles, there are no inter-cycle rest periods).
2486|NCT04176380|Biological|RAPA-201 Autologous T cells|Autologous rapamycin resistant Th1/Tc1 cells
2487|NCT04176367|Drug|Nicergoline from China|This is the test arm of China local manufactured Nicergoline
2490|NCT04176354|Drug|Palbociclib + Letrozole|Palbociclib + Letrozole therapy
2491|NCT04176354|Drug|Letrozole|Letrozole monotherapy
2492|NCT04176341|Other|a systematic proposal for non pharmacological interventions targeting the subject's empowerment among slackline, mindfulness, adapted physical activity, self-hypnosis, and Qi Gong|chronic pain patient consulting in Grenoble Alps University Hospital, and Hospital Mutualist Group who will one non pharmacological intervention between slackline, mindfulness, adapted physical activity, self-hypnosis, Qi Gong during 6 to 8 weeks.
2493|NCT04176328|Drug|Teicoplanin Sandoz 200 mg powder and solvent for solution for injection or infusion or oral solution.|Teicoplanin Sandoz administered by inhalation (aerosol).
2494|NCT04176315|Other|Conventional Home-based Rehabilitation Plan|Usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients. Participants receive inpatient care and rehabilitation for 2 weeks. At discharge, they receive a 5-exercise home-based rehabilitation plan. For the sake of homogeneity of all participants, they receive from 2 to 4 of training prior to discharge. At home, participants shall perform the exercises in the rehabilitation plan daily.
2495|NCT04176315|Device|ReHub Home-based Rehabilitation Plan|"Combination of the usual intervention at Presidio Sanitario San Camillo for post-operative rehabilitation of THA patients with ReHub, a telerehabilitation platform that serves as a guide to perform the TKA rehabilitation exercises.~Participants receive inpatient care and rehabilitation at San Camillo for 2 weeks. At discharge, a 5-exercise home-based rehabilitation plan is carried out by a site physiotherapist by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor. Participants receive from 2 to 4 sessions of ReHub prior to discharge.~At home, participants shall perform the exercises in the rehabilitation plan with ReHub daily. The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. Participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
2496|NCT04176302|Device|Parkinson Holter|The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)
2497|NCT04176302|Diagnostic Test|Motor fluctuations diary|The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).
2498|NCT04176302|Other|Traditional clinical practice|The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).
2499|NCT04176289|Diagnostic Test|PPI measurement|The pupillary dilatation reflex (PDR), induced by a standardized noxious stimulus will be measured as Pupillary Pain Index(PPI,11-point numeric scale, 0= no pain, 10= worst pain) determined with a portable pupillometer. Patients experiencing mild or more severe pain (PPI> 3) will receive intravenous opioid titration (piritramid, 3 mg bolus steps) and PPI measurement performed before and after intravenous opioid titration.
2500|NCT04176276|Other|no interventions required.|The study does not require any interventions.
2501|NCT04176263|Behavioral|SBT|The SBT group will receive a 4-week split-belt treadmill training, 3 times a week using a standardized progression protocol. The sessions, including breaks, will approximately take 1 hour each. The training will be given by a trainer experienced with PD.
2502|NCT04176263|Behavioral|TBT|The TBT group will receive a 4-week tied-belt treadmill training, 3 times a week. To make sure exposure of the two interventions is similar the sessions of the TBT group will be of similar length and progression level (approximately 1 hour each). The training will be given by a trainer experienced with PD.
2503|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
2504|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
2505|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
2506|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
2507|NCT04176250|Drug|TBA-7371|Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
2508|NCT04176250|Drug|HRZE|Participants will receive Isoniazid [H] / rifampicin [R] / pyrazinamide [Z] / ethambutol [E] (HRZE), a fixed dose combination (H: 75 mg / R: 150 mg / Z: 400 mg / E: 275 mg) tablet QD for 14 days.
2510|NCT04176224|Drug|MT-1186|Suspension
2511|NCT04176198|Drug|TP-3654|Oral PIM Inhibitor
2512|NCT04176185|Biological|Sublingual allergy immunological tablet|For daily administration (1 tablet per day)
2513|NCT04176185|Other|Placebo|For daily administration (1 tablet per day)
2514|NCT04176172|Drug|Varenicline|Participants will receive open-label varenicline for 12 weeks.
2515|NCT04176172|Drug|Nicotine patch|Participants will receive open-label nicotine patch for 12 weeks. (Participants in the NMR-tailored treatment arms will receive either varenicline OR patch; they will not receive both)
2516|NCT04176172|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks.
2517|NCT04176172|Behavioral|Standard treatment + Managed Problem Solving (MAPS) adherence intervention|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Managed Problem Solving (MAPS) is a therapeutic process that involves the systematic delineation of a participant's medication adherence problems and construction of a series of individualized solutions that therapists and participants explore together. Participants will receive up to 5 therapy sessions (2 in person, 3 over the phone) over 8 weeks. The first session will directly address potential medication adherence barriers, and therapist and participant will collaboratively brainstorm ways to overcome these barriers.
2518|NCT04176159|Other|MOTOR IMAGERY AND TASK-ORIENTED TRAINING|"The intervention will be divided into two modules. A first module will include activities of activation and relaxation of the body, prediction and sequencing of movement and motor imagery. The second module, task-oriented training, will be divided into analytical work phase (visual coordination, balance, muscular strength, fine motor skills ...), a second phase of integration into specific tasks and, at end, the inclusion of the free (and supervised) practice of a sport.~The investigators will apply 20 sessions of 40 minutes."
2519|NCT04176146|Behavioral|Peer comparison and social norms messaging|This group will receive a letter noting that their organization has not implemented at least one common care delivery practice that a majority their peers have already implemented. The letter will also note the percentage of peer organizations that have implemented the practice. This is done using peer comparison data and social norms messaging.
2520|NCT04176133|Drug|Entolimod|Single dose administration of Entolimod
2521|NCT04176133|Drug|Placebo|Single dose administration, no active ingredient
2522|NCT04176120|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).
2523|NCT04176120|Other|Standard Care|"Standard care is defined in this protocol to consist of the following:~Debridement;~Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~Appropriate use of systemic antibiotics."
2524|NCT04176107|Behavioral|Informative video|Exposure to informative video before cesarean delivery
2525|NCT04176094|Other|16h overnight duty|schedule observed by participating ICUs.
2526|NCT04176094|Other|24h overnight duty|schedule observed by participating ICUs.
2527|NCT04176094|Other|Handover training|Formal handover training for residents in both interventions. ICUs with a pre-existing standardized handover training and process will be asked to continue handover practices throughout the study. In ICUs without a pre-existing standardized handover training and process, ICU education directors will be provided with materials to include in orientation of residents to the ICU and local training to ICU staff physicians at least once per year.
2528|NCT04176081|Drug|Darolutamide|Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
2529|NCT04176081|Drug|Degarelix|Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
2530|NCT04176081|Radiation|Radiation Therapy|The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
2531|NCT04176068|Combination Product|calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)|Patients will receive IFUS to a randomly chosen side. Immediately after IFUS treatment, patients will receive the first CaHA injection. Injections will be given in the lower, anterior third of the thigh, above the knee. Only dermatology faculty will perform the filler injections. The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator. At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed. At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side. If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time. They will not receive further treatment after this visit.
2532|NCT04176055|Drug|Haloperidol|haloperidol intervention
2533|NCT04176042|Behavioral|Track 1|Intervention + Follow-up
2534|NCT04176042|Behavioral|Track 2|Wait list + Intervention
2535|NCT04176029|Device|lung ultrasound|Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
2536|NCT04176016|Drug|OTSA101-DTPA-111In|single IV injection, 185MBq/body
2537|NCT04176016|Drug|OTSA101-DTPA-90Y|IV injection (max. 3 injections per patient), 1110MBq/body
2538|NCT04176003|Other|Qualitative interview|Qualitative interview to explore experiences and perceptions of living with CPPD, and outcome measures to use in future studies
2539|NCT04176003|Other|Member checking|Participants will be sent a short report with the researchers' findings from the qualitative interview, and asked to check the accuracy of these and provide brief written feedback.
2540|NCT04175990|Drug|Dydrogesterone Pill|started from day 1 of menses till trigger day
2541|NCT04175977|Behavioral|Aliviado Dementia Care-Hospice Edition QAPI program|PWD will receive care from a care team who has received the Aliviado Dementia Care-Hospice Edition QAPI program training.
2542|NCT04175977|Behavioral|Control|PWD subjects will receive usual care as provided by their hospice agency
2543|NCT04175964|Behavioral|ketogenic diet|The ketogenic diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
2544|NCT04175964|Combination Product|caloric diet with Metformin|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet with Metformin for 8 weeks.
2609|NCT04175431|Other|LHRH agent|ADT with LHRH agent
3147|NCT04171037|Device|Optiflow THRIVE|Oxygen Administration
2545|NCT04175964|Behavioral|caloric diet|The caloric diet will be designed according to the BMI for each participant by a consultant nutritionist. All participants will be prescribed this diet for 8 weeks.
2546|NCT04175951|Device|Intraocular lens|Tecnis Eyhance is a monofocal IOL which give added intermediate vision without employing EDOF or multifocal technology and hence induces no glare and halos. Whereas monofocal IOLs such as RayOne do not give intermediate vision.
2547|NCT04175938|Device|Wearing of contact lens|All subjects will wear a contact lens for three hours. The effect of the lens on the eye (epithelial swelling) will be measured at intervals after the lens is removed.
2548|NCT04175925|Drug|BMS-986322|Specified Dose on Specified Days
2549|NCT04175925|Other|BMS-986322 Placebo|Specified Dose on Specified Days
2550|NCT04175925|Drug|famotidine|Specified Dose on Specified Days
2551|NCT04175912|Drug|Carboplatin|Given IV
2552|NCT04175912|Drug|Paclitaxel|Given IV
2553|NCT04175912|Drug|Pevonedistat|Given IV
2554|NCT04175899|Other|Pharmacist-led Oral Chemo Care Program (POCCP)|"Structured intensified pharmaceutical care program for patients ongoing oral chemotherapy treatment.~Led by oncology experienced clinical pharmacist and run alongside oncologist patient review at the clinic or daycare.~It utilizes structured educational material (for patients) and monitoring guideline or checklists (for pharmacists) during provision of service at each clinic visit such as patient education, pre-treatment review, medication reconciliation, prescription screening (dose, regime, supportive meds), adherence, adverse drug event monitoring and treatment recommendations on basis of agreed protocols.~Pharmacist scheduled additional review within 1-week interval of start of oral chemotherapy at clinic or via phone call (according to patient's preference) will also be conducted to review patients taking their oral medications at home, assess adherence and symptom experienced to provide individualized recommendations or support to patients."
2555|NCT04175886|Drug|Tofacitinib|Patients will be treated with tofacitinib
2557|NCT04175860|Behavioral|The intervention with the patient (Chronic Patient Care Group and his family.)|"Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home."
2558|NCT04175847|Drug|RC88|Participants will be allocated to one of the following dose groups: 0.1, 0.5, 1.0, 1.5, 2.0 and 2.5 mg/kg, and receive a treatment of RC88-ADC followed by 21 days of dose limited toxicity (DLT) observation period.
2559|NCT04175834|Drug|antihistamine|prophylaxis
2560|NCT04175821|Radiation|Hypofractionated radiotherapy|35Gy/ 15#/3weeks to chest wall and 40Gy/15#/3 weeks to supraclavicular fossa
2564|NCT04175795|Behavioral|My Personal Brain Health Dashboard|"The intervention of this study is grounded in the knowledge-to-action framework (Graham et al., 2006) and consists of providing feedback by sending participants their personalized health outcome profiles. As mentioned above, the context of our study is the BHN cohort. For all participants enrolled in the parent study, data on wide spectrum of health outcomes have been gathered. As part of the knowledge translation plan, a personalized profile of specific modifiable health outcomes called as My Personalized Brain Health Profile has been created for each participant (Appendix B). The profile covers information on brain health outcomes, health and quality of life ratings, and lifestyle factors."
2565|NCT04175782|Procedure|Enhanced recovery after surgery (ERAS) protocol|"Preoperative:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative:~Use of short-acting anesthetic agents Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Refraining from the use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
2566|NCT04175769|Dietary Supplement|Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)|"Subjects will be advised to orally consume two gelatin capsules (1 gram), 2 times per day with meals, totaling four capsules per day beginning the first day of treatment and continuing for the duration of their treatment.~Each capsule will contain the study product (500 mg of EPA + 200 mg of DHA)."
2567|NCT04175769|Other|Placebo|"Subjects will be advised to orally consume two gelatin capsules (1 gram), 2 times per day with meals, totaling four capsules per day beginning the first day of treatment and continuing for the duration of their treatment.~Each capsule will contain 1 g of sunflower oil."
2569|NCT04175743|Drug|CT-044 HCl|CT-044 HCl is a reactive species decomposition accelerant
2570|NCT04175730|Device|Ultrasound and MRI|A single subsequent ultrasound guided prostate biopsy with MRI fusion
2571|NCT04175730|Device|Ultrasound|A single subsequent ultrasound guided prostate biopsy
2572|NCT04175717|Other|physiotherapy-led follow-up programme|In this study arm, the participants will receive a nine weeks exercise programme and four education sessions. During the exercise programme, the patients will exercise twice per week under supervision and once by themselves. The supervised exercise sessions will consisted out of a combination of a cardiopulmonary and strength training and the unsupervised session will be an activity, which the participants like doing. Additionally, when the patient shows a reduced maximal inspiratory pressure (indication for a reduced diaphragm strength), the patient will also be ask to do an inspiratory muscle training at home. Furthermore, they will participate in education sessions, where they learn things about the intensive care unit, the post-intensive care syndrome, relaxation techniques and how to carry on with exercising.
3332|NCT04169360|Drug|Placebo oral tablet|White, oblong 300 mg tablet
2573|NCT04175704|Drug|UB-221|Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution
2574|NCT04175691|Genetic|Sequencing of circRNA/miRNA/lncRNA|Next generation sequencing of circular RNA (circRNA), micro-RNA (miRNA) and long non-coding RNA (lncRNA)
2577|NCT04175665|Drug|Semaglutide|Prescription for semaglutide as part of usual clinical practice
2578|NCT04175652|Behavioral|Laughter yoga|The laughter yoga practice was initiated through clapping and warm-up exercises: hands were clapped keeping hands in parallel with each other and ensuring that the fingertips touched each other. To increase the energy level of the group, a rhythmic beat was added to the clapping in the form of 1-2, 1-2-3. While this was being sung a rhythm was tapped out on the floor by moving the feet up and down. Eye contact was constantly maintained with the participants. In the second phase, deep breathing exercises were performed. Participants were encouraged to inhale from the diaphragm. Individuals were asked to put their hands on their belly and inhale through the nose and then slowly exhale through the mouth. After the deep breathing exercise, the participants were encouraged to laugh through playing children's games in the third phase.
2580|NCT04175626|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
2581|NCT04175613|Drug|Apremilast|Apremilast dose will be increased from 20 mg BID to 30 mg BID for those subjects that reach a weight of 50 kg or more during the study
2582|NCT04175600|Drug|Selexipag|Selexipag tablet will be administered orally.
2583|NCT04175600|Drug|Placebo|Matching placebo tablets will be administered orally.
2585|NCT04175574|Other|Music|The music has no lyrics, has a sustained melodic quality, has no strong rhythms and percussion or base, rate of 60-80 beats per minute, promotes relaxation, calming and soothing, neutral and is unbiased towards any culture or age. The volume of the music will be pre-adjusted to the patients' preference (preferable 30 dB) by the research assistant.
2586|NCT04175561|Other|Green prescription|Green prescription intervention will include horticultural activities such as planting, harvesting, learning about ecology and sustainable food growing.
2587|NCT04175548|Other|Data extraction from medical files|Data extraction from medical files
2588|NCT04175535|Procedure|Percutaneous Posterior Endoscopic Cervical Discectomy|The most common alternative in the case of soft cervical disc herniations.
2589|NCT04175535|Procedure|Anterior cervical decompression and fusion|The standard procedure for operation of cervical disc herniations.
2590|NCT04175522|Drug|Immunoglobulin G|IGIV 10%(400mg/kg) QD for 5 consecutive days administrated intravenously.
2591|NCT04175509|Drug|Rectal acetaminophen|Rectal 1300mg
2592|NCT04175509|Drug|Intravenous acetaminophen|Intravenous 1000mg
2593|NCT04175496|Other|Blueberry Cake|Blueberry cake containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
2594|NCT04175496|Other|Snacks with Cheese|Snacks with cheese containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
2595|NCT04175496|Other|Spicy Crackers|Spicy crackers containing 25 g available CHO will be served to the participants after 10-hours fasting and asked to consume it within 15 minutes, along with 250 ml of water. Taking the first bite from test food will be considered as 0 min. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min.
2596|NCT04175496|Other|Glucose Solution First Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
2597|NCT04175496|Other|Glucose Solution Second Repeat|The glucose solution will be prepared by dissolving 25 g of glucose in 250 ml of water. Participants consume the glucose solution within 15 minutes after 10-hours fasting. Blood samples will be collect at time points 0,15, 30, 45, 60, 90 and 120 min.
2598|NCT04175483|Other|assessment of subglottic diameter by ultrasonography|assessment of subglottic diameter by ultrasonography
2599|NCT04175470|Drug|Bevacizumab|10 mg/kg intravenously every three weeks
2600|NCT04175470|Dietary Supplement|Tocotrienol|Capsules, 300 mg orally three times daily
2601|NCT04175457|Other|e-cigarette|E-cigarette inhalation for 30 minutes using e-cigarette with and without nicotine
2604|NCT04175431|Diagnostic Test|fluciclovine-PET/CT scan|Undergo fluciclovine PET/CT
2605|NCT04175431|Procedure|Lymphadenectomy|Undergo lymphadenectomy
2606|NCT04175431|Radiation|Radiation Therapy|Undergo radiation therapy
2607|NCT04175431|Drug|Abiraterone Acetate|Given PO
2608|NCT04175431|Drug|Prednisone|Given PO
2610|NCT04175418|Other|Supervised Exercise Program|The exercise program in this group includes aerobic (walking) training and exercises to strengthen the upper and lower extremities and trunk muscles.
2611|NCT04175418|Other|Online Education Program|The exercise program in this group includes aerobic (walking) training and home exercises to strengthen the upper and lower extremities and trunk muscles.
2612|NCT04175405|Procedure|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser with a dose of 10J
2613|NCT04175392|Drug|Align Probiotic Supplement Capsule|Align Probiotic 1 billion units, 1 capsule once daily
2614|NCT04175392|Drug|Placebos|Placebos capsule 1 capsule Once daily
2619|NCT04175353|Dietary Supplement|Dairy snack|The effects of dairy snack are compared with orange juice.
2620|NCT04175353|Dietary Supplement|Berry snack|The effects of two berry snacks are compared with berry soup.
2621|NCT04175327|Device|CardioCel implantation|treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
2622|NCT04175314|Other|Clinical examination of gingival tissues|Measure of the periodontal recession
2623|NCT04175301|Drug|Hydrogen|Each hydrogen tablet contains 80 mg magnesium
2624|NCT04175301|Drug|Placebo oral tablet|Matching placebo tablet also contains 80 mg magnesium
2625|NCT04175288|Other|Ultrasound, manual therapy and exercise|The experimental group will receive ultrasound (US) for 3 sessions a week for 4 weeks, with continuous US (1.8 w/cm2, 1 Mega Hz 8 minutes). Manual therapy will include posterior glides to talocrural joint, subtalar lateral glide, a 1st tarsometatarsal joint dorsal glide and extension mobilization to the 1st metatarsophalangeal joint. All participants in each group will be given specific exercises by the investgators targeting intrinsic and extrinsic muscles of the foot and ankle. Specific stretches for the plantar fascia and Achilles tendon, will be performed. Home exercises will be recorded using a log.
2626|NCT04175275|Other|Interview patient|Interview patient without scoring about the reasons for the implant, the complications, the reasons for abandonment, the evaluation of the satisfaction
2627|NCT04175262|Drug|sunitinib|Patients to receive sunitinib as second line therapy for mRCC
2628|NCT04175249|Other|Pizza meal challenge|Vegetarian pizza containing 10 grams of salt
2629|NCT04175223|Dietary Supplement|Vivomixx|probiotic administration: administration of two sachets per day (one in the morning and one in the evening) during 6 months
2630|NCT04175210|Radiation|Radiation therapy - 3 weeks|Patients randomized to ARM 1 will receive whole breast radiotherapy of 4050cGY and a concomitant boost to the tumor bed of 4800cGY in 15 fractions
2631|NCT04175210|Radiation|Radiation therapy - 2 weeks|Patients randomized to ARM 2 will receive whole breast radiotherapy of 3200cGY and a concomitant boost to the tumor bed of 4200cGY in 10 fractions.
2632|NCT04175197|Device|Drug Coated Balloon|Legflow Drug Coated Balloon
2633|NCT04175184|Other|Mobilisation with Movement|"MWM is a pain-free manual therapy procedure that aims to restore full active pain-free range of motion. It consists of an accessory movement performed by the therapist followed by an active movement executed by the patient. The accessory glide might be produced by the therapist´s hands or by a belt. Minor changes in the amount of force or direction of the glide are common to produce better results.~The MWM procedures will be used pragmatically in this study. Therefore, several attempts might be needed to produce the outcome desired. In the case of the shoulder, they can be applied to the glenohumeral joint, scapulothoracic joint, acromioclavicular joint, cervical and thoracic spines and the rib cage. The decision making process in this study will be based on the outcome observed. The procedure that produced the greatest improvement in active pain-free range of motion will be the one used on that occasion."
2634|NCT04175184|Other|Sham Mobilisation with Movement|Sham MWM is a comparator procedure used in this research to control for placebo related mechanisms of action. This procedure has already been used in previous research (Delgado-Gil et al 2015). Briefly, the therapist will stand opposite to the affected shoulder, he/she will place the thenar eminence of the anterior hand on the skin in front of the humeral head, while the posterior hand will rest on the scapula. Both hands will just lightly rest on the skin, no accessory glide will be performed to the humeral head. Then, the participant will move his/her shoulder in the direction previously selected. Shall the procedure elicit pain-free full range of motion, the participant will move their shoulder ten times. Otherwise, the movement should be performed up to the onset of symptoms.
2635|NCT04175171|Drug|Herceptin|The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
2658|NCT04174963|Behavioral|Enhanced Standard of Care|Brief computerized intervention (eToke) only
3333|NCT04169347|Drug|Oxaliplatin|2 week cycles
2636|NCT04175158|Biological|GB222|Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
2637|NCT04175158|Biological|Bevacizumab|Injection; strength 100mg/4ml/bottle; intravenous drip; a total of one administration, dosage 1mg/kg; The 2.5ml syringe is used to collect required volume of the drug, and then it will be added to 250 ml of 0.9% sodium chloride solution. The infusion bag should be gently inverted to prevent air bubbles. If the required volume is > 2.5 ml, it should be collected twice, 2.5ml for the first time and the rest for the second time.
2638|NCT04175145|Other|Posterior spinal instrumentation|A fusion construct consisting of all pedicle screws except at uppermost instrumented vertebra. Contoured dual 6-mm stainless steel rods were used to connect the construct. Pedicle screw location and density was determined by the surgeon based on perceived curve stiffness and fusion length with an even distribution of fixation points along the construct. Pedicle screw instrumentation was performed by the free hand technique with biplanar fluoroscopic and direct screw EMG impedance testing for confirmation of placement. Reduction was via cantilever-segmental-translation maneuver in all cases.
2639|NCT04175132|Drug|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg
2640|NCT04175132|Drug|foliglurax|Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg
2641|NCT04175119|Device|Visual attention/perception tasks in healthy participants|The participants complete visual attention and perception tasks while fMRI, EEG, and MEG record brain signals. The tasks acquire responses with a visual saccade or button presses which are coupled to brain responses. These responses are then analyzed to identify patterns of communication between brain areas (within-subject). The flickering stimuli (experiment 1) may alter oscillations in the brain, while participants complete visual attention and perception tasks, leading to a secondary outcome measure distinct from the button presses. The procedure concerning the flickers will be the same for participants. The tACS (experiment 2, 3) delivers input in addition to gathering output while participants complete visual attention and perception tasks. A sinusoidal current at a chosen frequency interacts with the brain's natural oscillations and alters responses. Participants will have sham sessions of tACS as well (there is no group division), The sham will be compared with the stimulation
2642|NCT04175106|Other|a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value|"150 g of a non-traditional (i.e., not typically available in the supermarket) blueberry cultivar bred using natural plant breeding techniques and established as having enhanced nutritive value.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
2643|NCT04175106|Other|a standard commercially available blueberry variety (i.e., cultivar)|"150 g of a standard commercially available blueberry variety (i.e., cultivar).~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
2644|NCT04175106|Other|"a minimally processed blueberry-rich protein bar"|"A minimally processed blueberry-rich protein bar matched to the phytonutrient content of the 150 g of the non-traditional blueberry.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
2645|NCT04175106|Other|a control shake of matched-nutritive content|"The matched nutritive content of the blueberry-rich protein bar will be dissolved in rice milk.~Dietary restrictions will be observed (i.e. avoidance of food or supplements containing berry phytonutrients) for 7 days before each arm visit and throughout the study days."
2646|NCT04175093|Diagnostic Test|asymmetric dimethylarginine|measurement by ELISA of asymmetric dimethylarginine
2647|NCT04175067|Diagnostic Test|Disulphide(μmol/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
2648|NCT04175067|Diagnostic Test|Total Oxidant Capacity(μmolH2O2Equiv/L)|Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry
2649|NCT04175054|Other|Body-weight supported treadmill training in a room cooled to 16°C|Exercise will be performed on a treadmill using an overhead harness for safety in a temperature controlled-room at 16°C with 1:1 supervision. The high intensity group will maintain vigorous intensity with a target workload >60% of heart rate reserve for 30 min (plus 5min warm up and 5min cool down) while the low-intensity group will walk at mild intensity (<40% heart rate reserve) for the same duration. Heart rate, blood pressure, and rating of perceived exertion will be recorded throughout to monitor for potential adverse events and to ensure that target training zone heart rates are maintained. The intervention is 3 times per week for 12 weeks, with a 3-month run-in observational period to confirm disease stability, and 3-month follow-up to determine the sustainability of effects.
2650|NCT04175041|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
2651|NCT04175028|Device|Transcranial Direct Current Stimulation|In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
2652|NCT04175015|Other|Smartie© sweet/candy|one chocolate sweet/ chocolate candy
2653|NCT04175002|Drug|utrogestan|oral uterogeston 200mg daily to achieve window of implantation from previous study
2654|NCT04174989|Other|Plasma treated with ClearPlasma (Extra-corporeal plasma filtration device)|ClearPlasma is designed to specifically extract plasminogen, a protein that drives fibrinolysis, from up to 250 mL of plasma. ClearPlasma is a non-pyrogenic, sterile, single-use medical device that is indicated for use in conditions where massive bleeding situations exist.
2655|NCT04174989|Other|Regular fresh-frozen plasma (not treated)|Regular fresh-frozen plasma (not treated)
2656|NCT04174976|Procedure|wall hernia repair|Wall hernia repair with mesh
2657|NCT04174963|Behavioral|eToke + TPsy|Combination of brief computerized intervention (eToke) with Information-Motivation-Behavior based text messages tailored to young adults in psychiatric treatment
2747|NCT04174170|Drug|Brexpiprazole|Up to 3 mg pill
2659|NCT04174950|Other|Routine nursing care|routine perioperative nursing intervention, including intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet. NPO after the dinner one day before operation. Patients are instructed to NPO 3 days after surgery and patients should stay on the bed for 3 days. Urinary catheter is always kept for 48 hours or more.
2660|NCT04174950|Other|Perioperative Enhanced Recovery After Surgery (ERAS) Based Nursing Model|Establish ERAS nursing team and formulate ERAS nursing intervention. Nothing by mouth (NPO) 6 hours before operation and no water 4 hours before operation. Patients are given fluid food 24 hours after surgery. Urinary catheter is removed within 24 hours after surgery and encourage patient to mobile 24 hours after surgery. Give support to pain control and psychological support. Intensive observation of vital signs, preoperative education, postoperative communication and instruction on diet were also given to patients.
2661|NCT04174937|Drug|Potentiator of antibiotics (PA)|Intervention is administered to patients in this Arm
2662|NCT04174937|Other|Placebo PA|Intervention is administered to patients in this Arm
2663|NCT04174924|Procedure|Phakic intraocular lens (pIOL) explantation|"Phakic intraocular lens (pIOL) explantation is a surgical procedure to remove the pIOL which needs to be done after cataract formation.~Cataract extraction is a surgical procedure to remove a lens in the eye that has become cloudy over time, affecting vision in that eye."
2666|NCT04174898|Biological|human Mesenchymal Stem Cell (MSC) infusion therapy|Subjects will be infused with 100million human MSCs
2667|NCT04174885|Procedure|epicardial ablation|"In general anesthesia and with selective left lung ventilation, authors will practic the right thorax access by three working ports. However, a rigid video thoracoscopic camera with a direct optics will be used. Pericardium will be widely opened anterior to a phrenic nerve and transverse and oblique sinuses were dissected. An insertion of the ablation catheter will be a tricky part of the surgery with the first MW catheter, while no special introducer will be provided. Later RF devices will be equipped with a special flexible introducers, lately also with a magnetic tip and the positioning of the catheter around PVs became much safer and easier.~The correct position of catheter will be checked also by trans esophageal echocardiography before the ablation."
2668|NCT04174872|Drug|Dexmedetomidine|it has a sedative effect without significant respiratory depression , anxiolytic, analgesic, antihypertensive and sympatholytic properties. It is now being used as a neuraxial adjuvant that can be used as an effective adjuvant in epidural anaesthesia as it intensifys the motor block and prolongs the duration of postoperative analgesia.
2669|NCT04174872|Drug|Midazolam|Midazolam has been reported to have a spinally mediated analgesic effect. Clinically, single-shot epidural or spinal administration of midazolam has been shown to have an analgesic effect on perioperative pain.
2670|NCT04174859|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment dose is following the description of physicians.
2673|NCT04174820|Other|Functional Magnetic Resonance Imaging (fMRI)|list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
2674|NCT04174794|Device|Lung ultrasound|The two different lung ultrasound protocols are performed initially within 48 hours of internal medicine ward admission by a pair of expert-beginner echographers. In case of admission during non-working days, the first scan can be done within 72 hours from admission. Follow-up scans are repeated 4 to 6 days later or on the day of discharge if it occurs before de fourth day. Experts and beginners execute the lund ultrasound protocols in sequence, reciprocally blinded, without accessing to clinical data files.
2675|NCT04174781|Drug|Sintilimab Injection|Sintilimab therapy combined with standard TACE-DEB treatment
2676|NCT04174781|Drug|TACE|TACE is performed by using drug eluting beads
2677|NCT04174768|Procedure|Bariatric surgery|Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
2680|NCT04174742|Drug|pegfilgrastim|It works by increasing neutrophil migration to counteract cytotoxicity. It is commonly administered to patients receiving chemotherapy for breast cancer treatment. It has been shown to significantly reduce the incidence of neutropenic fever, although without statistically significant impact on overall survival.
2681|NCT04174729|Device|handgrip strength|First, the hand measurements of each volunteer were evaluated, followed by the measurement of handgrip strength using the Jamar® dynamometer. And later the tests were performed using the system that contains the 5 devices to quantify the hand strength.
2682|NCT04174729|Device|Door handle device|To evaluate the cylindrical grip movement, a door handle was used, which evaluated the full force in the range of motion.
2683|NCT04174729|Device|Tap device|To evaluate the spherical grip movement, a tap was used, which evaluated the full force in the range of motion.
2684|NCT04174729|Device|Door pull handle|To assess the hook grip movement, a door pull handle was used, which assessed the full force in the range of motion
2685|NCT04174729|Device|Switch device|To evaluate the pulp-pulp pinch movement, a switch was used, which evaluated the full force in the movement of the movement.
2686|NCT04174729|Device|Key device|To assess the pulp-side pinch movement, a door key was used, which evaluated the full force in the range of motion.
2687|NCT04174716|Drug|IDX-1197|Until progression or unacceptable toxicity develops
2688|NCT04174703|Other|Self-compassionate letter-writing intervention|Participants in this condition will be asked to engage in an online self-compassionate letter-writing task once per day (10-20 minutes each) for 2 weeks.
2748|NCT04174170|Drug|Sertraline|Up to 150 mg pill
2749|NCT04174170|Other|Placebo|Pill
2750|NCT04174157|Other|Prospective observational registry|This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
2689|NCT04174690|Device|Force platform|In order to volunteers to be selected for collection a recruitment test will be taken, the volunteer will have to stand on one foot for 5 seconds without additional support. So that the volunteer can go to the balance test on the force platform, he will be dressed with safety equipment (harness), and will also have the attachment of the electrodes.
2690|NCT04174677|Drug|Inebilizumab|Infusion of Inebilizumab
2691|NCT04174677|Drug|VIB4920|Infusion of VIB4920
2692|NCT04174677|Drug|Inebilzumab+VIB4920|Infusion of Inebilizumab and VIB4920
2693|NCT04174664|Diagnostic Test|1-minute sit to stand test|Childrens will complete 1-minute sit to stand test and 3 minute step test and quality of life questionnaire.
2694|NCT04174651|Behavioral|Trier Social Stress Test (TSST)|Participants randomized to receive the acute stress condition will undergo the TSST wherein the participant will be introduced to an upcoming task (i.e., job interview) and allowed to prepare (2 minutes). The participant will then be required to speak (job interview) for 4 minutes in front of 2 experimenters. After completion of the interview, participants will be asked to perform a mental arithmetic task for 4 minutes.
2695|NCT04174651|Behavioral|Landscape Video|Participants randomized to receive the control condition will be watching a landscape video for 10 minutes.
2696|NCT04174638|Other|Motivational Interview and Education Based on Watson Human Care Model|In the study, which will last for 4 months, the patients in the intervention group will receive pre-test and Motivational Interview and Education Based on Watson Human Care Model at the first interview. Patients will receive Motivational Interview Based on Watson Human Care Model at second interview after one month. Patients will receive Motivational Interview Based on Watson Human Care Model at third interview after one month. In the fourth interview and final test after one month, patients will receive Motivational Interview Based on Watson Human Care Model.
2697|NCT04174625|Dietary Supplement|Dietary Supplement: Omega3-FA|Dietary Supplement: Omega3-FA 300 mg of omega3-FA once daily for 8 weeks
2698|NCT04174612|Drug|Cytarabine|100 mg/m2/bid day 1-3 100 mg/m2/die day 4-7
2699|NCT04174612|Drug|Daunorubicin|60 mg/m2/die day 1-3
2700|NCT04174612|Drug|Midostaurin|50 mg/bid day 8-21
2701|NCT04174612|Drug|Cytarabine HD|100 mg/m2/bid day 1-3 100 mg/m2/die day 4 1.500 mg bid day 5-7
2702|NCT04174599|Biological|F-627|Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein
2703|NCT04174586|Biological|microtransplantation|HLA mismatched donor cord blood infusion
2704|NCT04174573|Other|GTO|"Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)"
2705|NCT04174573|Other|GT-tDCS|"Group therapy~Forward direction activity: Balance activity in forward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Backward direction activity: Balance activity in backward direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~Sideways direction activity: Balance activity in sideways direction on wooden balance board (5 reps X 3 sets X 2 days in a week, for 6 weeks)~tDCS Left anodal and right cathodal tDCS : Anode- F3, Cathode- Right Supra orbital area, Intensity- 2mA, Duration- 30 minutes, once in a week for 6 weeks"
2706|NCT04174560|Biological|Norovirus GII.4 Challenge Pool|Subjects will be NPO (nothing by mouth) for at least 90 minutes followed by ingestion of 60 mL of a 2% sodium bicarbonate solution by mouth. 2 minutes later, subjects will be administered Norovirus GII.4 CIN-3. Five minutes following administration of the challenge dose, subjects will be administered a 60 mL volume of a 2% sodium bicarbonate solution and then remain NPO for at least the next 90 minutes. Subjects will be observed during the 60 minutes after receipt of the challenge by a study team member to detect and treat any immediate adverse reactions.
2707|NCT04174495|Diagnostic Test|DXA and CT-scan|DXA and CT-scan are usually performed during the following of these patients before bariatric surgery
2708|NCT04174482|Procedure|morphological and functional evaluation of adult flat foot|Evaluations are realized by weight bearing computed tomography and by Gait analysis in the pre-operative phase and at a 6-months follow-up from the surgery with Grice technique
2709|NCT04174456|Drug|Olmesartan 20 Mg Oral Tablet|single pill drug of olmesartan and rosuvastatin
2710|NCT04174443|Procedure|High-voltage pulsed radiofrequency|2 Hz of pulsed radiofrequency will be administered at a voltage of 70 V, temperature of 42 °C, pulse width of 20 ms, and treatment time of 600 s.
2711|NCT04174443|Procedure|Low-temperature continuous radiofrequency|Low-temperature continuous radiofrequency will be performed at 60 °C, with a treatment time of 270 s.
2712|NCT04174430|Biological|severe bronchiolitis|Prematurity (gestational age ≤36 weeks), Low birth weight, Age less than 12 weeks,Chronic pulmonary disease, particularly bronchopulmonary dysplasia (also known as chronic lung disease), Anatomic defects of the airways, Hemodynamically significant congenital heart disease, Immunodeficiency, Neurologic disease
2713|NCT04174417|Procedure|systolic blood pressure (SBP)|"Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory"
2714|NCT04174417|Procedure|mean blood pressure (MBP)|"For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory."
2807|NCT04173715|Behavioral|Medium Physical Function Status Group|Physical activity and energy expenditure quantification
3463|NCT04168190|Biological|Pneumovax™23|Single 0.5 mL IM injection
2715|NCT04174404|Other|ICory-Circumcision|The ICory-Circumcision is specially developed for this study based on preliminary studies, other literature, and most importantly, the surgical pathway currently practiced in the study hospital. The ICory-Circumcision programme has two components: (1) the Buddy Healthcare mobile app (BuddyCare) that provides a comprehensive day-by-day perioperative guide for parents regarding their child's surgery with an interface for health care professionals to monitor parents' and their children's needs as well as communicate with them. (2) The Triumf Health mobile game app that provides emotional support and distraction to children. The ICory-Circumcision programme is designed to be a self-guided and healthcare professional-led. Participants will have access to BuddyCare for parents and Triumf Health from time of recruitment till 2 weeks after surgery while the healthcare professional would receive face-to-face training on how to use the BuddyCare dashboard.
2716|NCT04174404|Other|Routine care|The routine care consists of normal consultations with the doctor, preoperative preparation, and post-operative care. During the first consultation, the child will be assessed for the need for circumcision and the doctor explains verbally to the parents about the procedure, risks, what to expect and prepare pre-operatively.
2717|NCT04174391|Behavioral|Mediterranean diet supplemented with extra-virgin olive oil|Dietary advice on how to follow a Mediterranean diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. A total of 0.5l/week of EVOO for free will be received by participants of this group. In addition, advice on physical activity will be provided.
2718|NCT04174391|Behavioral|Low-fat diet|Dietary advice on how to follow a low-fat diet will be received by the intervention group. The intervention will be delivered mainly by phone (1 call/month), internet and written materials. Also, there will be yearly face-to-face individual interviews and biannual group sessions. Allotments of commercial foods — equivalent to the extra-virgin olive oil allotment — will be received by participants of this group for free. In addition, advice on physical activity will be provided.
2719|NCT04174378|Drug|Decapeptyl 0.2mg|IM Decapeptyl o.2 mg was given 2 days before embryo transfer
2720|NCT04174365|Drug|Brexpiprazole|Oral tablet; take once daily
2721|NCT04174365|Drug|Placebo|No Intervention
2722|NCT04174352|Drug|Tamoxifen|estrogen modulator
2723|NCT04174352|Diagnostic Test|FES PET/CT|Radiolabeled estrogen [18F]-fluoroestradiol (FES) in combination with Positron Emission Tomography / Computed Tomography is a molecular imaging technique for measuring pharmacodynamic effects of endocrine therapy. The injected dose of 18F-FES will be 6 mCi (185 MBq) ± 20% with a specific activity greater than 170 Ci/mmol at the time of injection for an activity dose of 6 mCi. Participant will receive baseline imaging and repeat imaging after 3-4 weeks to evaluate for FES blockade as assigned dose level.
2724|NCT04174339|Drug|Camrelizumab|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial，d1
2725|NCT04174339|Drug|Apatinib Mesylate|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet，TID
2726|NCT04174339|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
2727|NCT04174326|Behavioral|Immediate intervention group|Participants will be randomized to either the immediate or delayed intervention group at baseline. Participants in both groups will receive CBT for chronic pain management sequentially, once a week during the 6 week intervention period. Participants will be followed-up at 18 weeks from baseline. Two in-between sessions practice assignments will be added to each group therapy session during the the CBT program.
2728|NCT04174313|Diagnostic Test|CT scan|A CT scan will be performed on inspiration and expiration. Transpulmonary pressures will be measured and lung volumes calculated (Volume Analysis Software, Toshiba, Japan).
2729|NCT04174300|Procedure|Manual Therapy|8 sessions of manual therapy (twice weekly) of 25 minutes including pressure maneuvers of about 4,5 N
2730|NCT04174287|Drug|F-18-AV45|The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
2731|NCT04174274|Other|ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
2732|NCT04174274|Other|not ventilator-associated pneumonia-developed group followed by mechanical ventilation|compliance with ventilator-associated pneumonia prevention methods and investigating the incidence of ventilator-associated pneumonia in intensive care units
2733|NCT04174261|Drug|Ticagrelor|Preprocedural ticagrelor loading and standard dose thereafter
2734|NCT04174261|Procedure|Remote Ischemic Preconditioning|Preprocedural remote ischemic preconditioning on the non-dominant arm
2735|NCT04174261|Drug|Clopidogrel|Preprocedural clopidogrel loading and standard dose thereafter
2736|NCT04174248|Other|BCSMS App|Breast Cancer Using a Self-Management Support mHealth Application
2737|NCT04174235|Device|Ultrasound scan|A full history taking was obtained according European surveillance of congenital anomalies EURO-CAT core data. All women underwent abdominal and transvaginal US (Toshiba Xario 200 unit)
2738|NCT04174222|Other|Moderate NMB|Neuromuscular block was maintained at train of four count 1-2.
2739|NCT04174222|Other|Deep NMB|Neuromuscular block was maintained at train of four count 0 and post-tetanic count1-2.
2740|NCT04174209|Behavioral|Cylinder|Patients who receive the Jackson Cross Cylinder Method
2741|NCT04174209|Behavioral|Dial|Patients who receive the Astigmatic Dial Technique Method.
2742|NCT04174209|Behavioral|Slit|Patients who receive the Stenopeic slit Method.
2743|NCT04174196|Drug|CC-486|Participants will be treated with CC-486 and lenalidomide for 6 cycles
2744|NCT04174196|Drug|Lenalidomide|Participants will be treated with CC-486 and lenalidomide for 6 cycles
2745|NCT04174196|Radiation|Radiation Therapy|Radiation therapy will be initiated to the plasmacytoma after cycle 2
2746|NCT04174183|Device|Closed-incision Negative-pressure Therapy - Dry dressing|A Closed-incision Negative-pressure Therapy is applied on one groin incision - A dry dressing is applied on one groin incision .
2751|NCT04174144|Procedure|Single-level TLIF|Transforaminal interbody fusion approach, using polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy.
2752|NCT04174131|Device|Restylane + Lidocaine|Restylane + Lidocaine is a HA gel generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine. It is indicated for mid-to-deep dermal implantation for the correction of moderate to severe facial wrinkles and folds, such as NLFs.
2753|NCT04174131|Device|Restylane® Lyft|Restylane® Lyft is a sterile gel of HA with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation (Galderma Laboratories, 2014).
2754|NCT04174118|Drug|DCR-A1AT|DCR-A1AT will be administered subcutaneously (SC) at dose levels planned for group A. Group B dose levels to be determined upon review of data from group A.
2755|NCT04174118|Drug|Placebo|Sterile normal saline (0.9% NaCL) matching volume of DCR-A1AT doses will be administered subcutaneously (SC).
2756|NCT04174105|Genetic|AT845|AT845 is a AAV8 vector delivering a functional copy of the human GAA gene
2757|NCT04174092|Other|completing self-questionnaires|completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism
2758|NCT04174079|Drug|chemotherapy|patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
2759|NCT04174066|Other|blood sample|blood sample during planned in the follow-up of patients.
2760|NCT04174066|Other|tissue sample|tissue sample during planned in the follow-up of patients.
2761|NCT04174066|Other|excreta|urine sample during planned in the follow-up of patients.
2762|NCT04174053|Device|Enteric capsule|Enteric capsule to measure body temperature will be ingested every 24 hours during aplasia. the temperature measured with this technique will be compared with auricular temperature measurement (in current practice nurse measure temperature every 4 hours during aplasia).
2763|NCT04174040|Behavioral|Gross's Process of Emotion Regulation Model Interventions|"Interventions were based on Gross's Process Model which include the basis concepts of cognitive-behavioral therapy and carried on with five semi-structured sessions. Cognitive-behavioral theories accept the existence of a thought process (attention-perception-interpretation) that appears in the mind about the event just before the anger emerges. Therefore, anger studies with cognitive-behavioral approach generally proceed with the steps of gaining awareness about this concealed thought, identifying behavioral response and avoidance attitudes and thus regulating emotion. It consists of five 90-minute group sessions structured in this context. While being an accredited cognitive behavioral therapist, investigator have qualified to manage these approach.~The effectiveness of these semi-structured sessions were evaluated by using:~Pretest application of STAXI~Taking feedback after each intervention session~Posttest application of STAXI~Follow-up test application of STAXI"
2764|NCT04174040|Behavioral|Musical Rhythm Interventions|"This musical group rhythm intervention was continued with 90 minute long five sessions. The students participated in the practice together with a music expert and lead researcher. The lead researcher took on the role of observer in these sessions. Each session was continued with warming, improvisation and targeted semi-structured rhythm practices aiming anger regulation. The effectiveness of these semi-structured sessions were evaluated by using:~Pretest application of STAXI~Taking feedback after each intervention session~Posttest application of STAXI~Follow-up test application of STAXI"
2765|NCT04174040|Behavioral|Musical Rhythm Integrated Gross's Emotion Regulation Process Interventions|"The students participated in the practice together with a music expert and lead researcher. The lead researcher ensured the integration of rhythm applications into the Process Model through cognitive-behavioral semi-structured interventions. Five semi-structured 90-minute group sessions were performed. The effectiveness of the experiment was evaluated by using:~Pretest application of STAXI~Taking feedback after each intervention session~Posttest application of STAXI~Follow-up test application of STAXI"
2766|NCT04174014|Procedure|Recruitment manoeuvre|PEEP increment and decrement
2767|NCT04173988|Genetic|alloCART-19|"AlloCART-19 is an allogeneic CAR-T cell product targeting CD19.~For children with body weight ≤ 50 kg, dose range for dose escalation will be 0.5 - 5 × 10^6 CAR+ cells/kg~For children with body weight > 50 kg, dose range for dose escalation will be 0.25 - 2.5 × 10^8 CAR+ cells."
2768|NCT04173988|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
2769|NCT04173988|Drug|Fludarabine|Chemotherapy for lymphodepletion
2770|NCT04173975|Device|With knee exoskeleton|BELK is a wearable system that assists when and where the patient needs it intelligently through proper control of the system and optimized gait assistance techniques. Assisted-as-needed control allows to create a force field along a desired trajectory, proportionally applying torque only when patient deviates from the pre-programmed correct pattern. This force field control, by assisting only the segments that the patient need, produces a natural gait pattern, improving the rehabilitation process.
2771|NCT04173962|Drug|Ketamine|administered 1 week prior to a laboratory-induced stress
2772|NCT04173962|Drug|Midazolam|administered 1 week prior to a laboratory-induced stress
2773|NCT04173949|Drug|Ramipril 2.5 MG|3 month of treatment with daily Ramipril 2.5 MG
2774|NCT04173936|Behavioral|tai chi|12-week community-based tai chi program
2808|NCT04173715|Behavioral|High Physical Function Status Group|Physical activity and energy expenditure quantification
2809|NCT04173702|Diagnostic Test|balance analysis|Computerized balance analysis system will use to evaluate postural sway and limits of stability at four different support surfaces.
2812|NCT04173676|Drug|Indocyanine Green for Injection|The sentinel lymph nodes were observed by submucosal injection of ICG
3464|NCT04168177|Procedure|PCA|Patient controlled analgesia
2775|NCT04173923|Other|Electronic Medical Record(EMR) Data and patient survey Retrospective Data Collection|"Numeric Rating Scale(NRS), Neck Disability Index (NDI), euroqol-5 dimension(EQ-5D) scores during hospitalization~Hospitalization period and treatment details(Korean herbal medicine, Acupuncture, Chuna therapy, Physical therapy)~Question items (consistent with the case record) according to the purpose of the investigation~(1) General:~Cervical spinal surgery status after discharge~Cervical spinal surgery recommendations before hospitalization~Symptom reoccurrence experience lasting for more than a month after treatment is closed~Whether symptoms that are uncomfortable in daily life exists~Whether currently being treated for neck or upper extremity symptoms~(2) The score that patients remember at the time of the outbreak and the current score of Numeric Rating Scale(NRS), and the current score of Neck Disability Index (NDI), euroqol-5 dimension(EQ-5D), Patient Global Impression of Change (PGIC)"
2776|NCT04173910|Procedure|Ultrasound LPEC/Sellick|We will perform an ultrasound of the carotid artery and then apply a Sellick manoeuvre and a left paratracheal compression of the cervical esophagus respectively.
2777|NCT04173897|Other|LIBERATE website|The LIBERATE intervention is a self-management, symptom monitoring and signposting website tailored to the supportive needs of women living with secondary breast cancer. Components include; holistic health information specific to secondary breast cancer, symptom monitoring and self-management advice, case studies, signposting to services & support and support for family & loved ones.
2778|NCT04173884|Other|Coaching|Surgical coaching is based on a peer coaching model that has been proven to be highly effective in other disciplines and for surgeons in training. Surgical coaching can improve technical performance in one of two ways: 1) identifying new or alternative approaches to the procedure; or 2) improving surgeon technical skill, which can lead to improvements in patient outcomes. In this proposal, our primary objective is to evaluate the effectiveness of video-based collaborative learning for surgeons.
2779|NCT04173884|Other|Constructive Feedback|Constructive feedback is critical for performance improvement. It is currently unknown, however, whether asynchronous constructive feedback alone, without interactive discussions with a coach, would be as acceptable and valued as formal in-person coaching. Furthermore, the effectiveness of either approach to collaborative learning in improving surgical performance and outcomes is not known.
2780|NCT04173871|Device|Protac Myfit®|A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
2781|NCT04173858|Drug|Naloxegol|25 mg oral naloxegol once daily.
2782|NCT04173845|Drug|Tianqi Pingchan Granule|Tianqi Pingchan Granule are given twice a day
2783|NCT04173845|Drug|Tianqi Pingchan Granule Placebo|Tianqi Pingchan Granule Placebo
2784|NCT04173832|Drug|Tianqi Pingchan Granule Combined With Amantadine|Tianqi Pingchan Granule and Amantadine are given to patients simultaneously
2785|NCT04173832|Drug|Placebo Combined With Amantadine|Placebo and Amantadine are given to patients simultaneously
2786|NCT04173819|Biological|3BNC117-LS-J|300mg
2787|NCT04173819|Biological|10-1074-LS-J|300mg
2788|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J|30mg/kg of each
2789|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
2790|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
2791|NCT04173819|Biological|Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3|Total ~300 mg (< 2.5 ml) combined of 3BNC117-LS-J and 101074-LS-J - Dosage ratios chosen will be those considered worthy of further investigation based on the safety and preliminary PK observed in groups 1-2
2792|NCT04173819|Biological|Placebo|0.9% Saline
2793|NCT04173819|Biological|Placebo|Buffer Solution
2796|NCT04173793|Drug|AK102|Administered by subcutaneous injection
2797|NCT04173793|Drug|Placebo|Administered by subcutaneous injection
2798|NCT04173793|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
2799|NCT04173780|Drug|Atropine 0.01%|1 drop per day in both eyes for 1 year
2800|NCT04173780|Drug|Placebo|1 drop per day in both eyes for 1 year
2801|NCT04173767|Device|high flow nasal cannula ventilation|High-flow nasal cannula (HFNC) ventilation therapy: supply heated & humidified air up to 60 L/min of flow; effects: positive end expiratory pressure effect, humidification.
2802|NCT04173754|Procedure|Motion Style Acupuncture Treatment(MSAT)|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
2803|NCT04173741|Other|Passive leg raise|A simple bedside maneuver that involves raising a patient's legs to 45 degrees
2804|NCT04173728|Dietary Supplement|Standard meal|Consumption a standard meal consisted of 75g glucose, 60g fat and 20 protein just for once.
2805|NCT04173715|Behavioral|Older Adults Group.|Physical activity and energy expenditure quantification
2806|NCT04173715|Behavioral|Low Physical Function Status Group|Physical activity and energy expenditure quantification
2813|NCT04173663|Behavioral|ASSIST|The ASSIST program is a 12-week advocacy training to educate parents of youth with ASD about the adult service system. It is a group training, comprised of didactic instruction, family-sharing activities, case studies, and group discussions. The ASSIST program for the proposed study will be directed at each site by an experienced Program Facilitator from the community with knowledge about group processes, person-centered planning, and adult service systems, who will be coached by a member of the study team. The ASSIST program will be delivered in full partnership with the local disability community. In most sessions, the Program Facilitator will be aided by community content experts who present the specifics of each topic.
2814|NCT04173650|Drug|AGLE 103|Exosomes from MSCs
2815|NCT04173650|Other|Placebo|Vehicle control
2816|NCT04173637|Biological|AK101|an anti-IL-12/23p40 monoclonal antibody
2817|NCT04173637|Biological|Placebo|matching placebo
2818|NCT04173624|Diagnostic Test|Endosonography|Endosonography (EUS) is endoscopic method for evaluated pancreatic and biliary pathology.
2819|NCT04173624|Diagnostic Test|Magnetic Resonance Cholangiopancreatography|Magnetic Resonance Cholangiopancreatography (MRCP) is non-invasive method for evaluating pancreatic and biliary pathology
2820|NCT04173611|Drug|EXPAREL|Injection into the Intrathecal space.
2821|NCT04173611|Drug|Bupivacaine Hydrochloride|Injection into the Intrathecal space.
2822|NCT04173611|Other|Placebo|Injection into the Intrathecal space.
2823|NCT04173598|Behavioral|Cognitive Adaptation Training for Caregivers (CAT Famille)|Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
2824|NCT04173598|Behavioral|Usual Care|Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
2825|NCT04173585|Drug|Bortezomib|Bortezomib is a small molecule dipeptide binding the catalytic site of the 26 S proteasome. It acts as a potent, reversible, and specific inhibitor of proteasomes and thus impairs the degradation of ubiquitylated proteins. It has demonstrated anti-neoplastic activity in myeloma and lymphoma. It is approved and widely used in multiple myeloma both for first line treatment and relapsed patients.
2826|NCT04173585|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin is a monoclonal antibody directed against the myeloid surface antigen CD33. The antibody is linked to calicheamicin which serves as cytotoxic agent. For years, gemtuzumab ozogamicin has been tested in clinical AML trials. Though withdrawn from the US market in 2010, FDA approval was granted in September 2018, EU approval in April 2018 based on encouraging results from recent clinical trials using enhanced dosing schedules.
2827|NCT04173572|Behavioral|PACE-Life|PACE-Life Groups will occur twice per week for 30 minutes for the entire intervention without changes in frequency and duration. The intensity, however, of both group walks and home-based walks will increase throughout this intervention in a step-wise fashion to create an exercise dose response to maximize impact on CRF.
2828|NCT04173572|Behavioral|Exercise Intervention|Data from Fitbit devices will be synced and accessed through Fitbit.com. Participants will be provided account information to view data but will be asked not to change any of the settings as the investigators will be using data for tracking steps/day and minutes spent walking.
2829|NCT04173559|Behavioral|Activity Intervention|After 1 week of baseline activity is obtained, participants will be contacted with personalized activity goals that are 10% higher than their previous weeks' activity levels. Participants will also receive weekly text reminders and encouraging feedback, and will receive additional counseling in person at regularly scheduled prenatal visits until delivery.
2830|NCT04173533|Drug|Oral azacitidine|Oral azacitidine (CC-486) 200 mg tablet
2831|NCT04173533|Drug|Matched placebo|Oral azacitidine (CC-486) matched placebo tablet
2832|NCT04173520|Drug|DDA|Follow up after SVR
2833|NCT04173507|Drug|Avelumab|Given IV
2834|NCT04173507|Drug|Talazoparib|Given PO
2835|NCT04173507|Drug|Talazoparib Tosylate|Given PO
2836|NCT04173494|Drug|Momelotinib|Momelotinib tablets will be self-administered orally once daily
2837|NCT04173494|Drug|Danazol|Danazol capsules will be self-administered orally twice daily
2838|NCT04173494|Drug|Placebo to match momelotinib|Momelotinib placebo tablets will be self-administered orally once daily
2839|NCT04173494|Drug|Placebo to match danazol|Danazol placebo capsules will be self-administered orally twice daily
2840|NCT04173481|Other|Rood's Group|"ROOD'S sensory motor training~Brushing & strokings 3-5 strokings after 30sec, joint compressions and slow stretch 10 rep of 3 sets on alternative days for consecutive 6 weeks CIMT training~Writing, combing hairs and using spoon activity 1 hour training concentrated on affected limb along with restraint of non affected limb by cotton sling under supervision of therapist and 5 hours training in home plan 3 times a week on alternative days for consecutive 6 weeks along with conventional physical therapy."
2841|NCT04173481|Other|Conventional Physical Therapy Group|Conventional training Proprioceptive neuromuscular facilitations (PNF) Combination of Isotonics technique 10 rep 3 sets 10 sec hold on alternative days for consecutive 6 weeks Stretching's 10 rep 3 sets on alternative days for consecutive 6 weeks Joint approximation 10 rep of 3 sets on alternative days for 6 weeks
2842|NCT04173468|Other|Moblization with Movement|patients with group 1 will receive two techniques pertaining to MWM intervention (straight leg raised with traction and tibial Gliding) Repeat it 10 times,3 sets and 1 mint interval. .For Tibial Gliding we will asks the patient to perform 10 repetitive active knee extensions. Practice will be performed by doing 10 reps for 3 sets with 1 min interval. After this home exercises will b guided stretching of hamstrings 8 to 10 reps 20 sec hold, strengthening of Quadriceps and VMO with 10 reps and 3 sets
2843|NCT04173468|Other|Mulligan knee taping|patient with group 2 will receive Mulligan taping technique. Tape will be applied for two days then we will change it. After this home based exercise will be guided which is stretching of hamstrings 8 to 10 reps 20 sec hold , strengthening of Quadriceps and VMO with 10 reps and 3 sets.
2844|NCT04173455|Drug|HZ-A-018|"In the dose-escalation part, subjects will be assigned to five cohorts with increaing dose level to determine DLT and MTD during the first 28-day cycle.~In the expansion part, subjects will be assigned to two fixed dose corhort."
2845|NCT04173442|Drug|dupilumab|Dupilumab cohort
3148|NCT04171024|Device|Sham electrical stimulation|A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes
2846|NCT04173429|Drug|Low molecular weight heparin (LMWH), warfarin|Warfarin orally with a initial dosage of 3mg daily for 6 months(warfarin group), low molecular weight heparin subcutaneously every 12hs for 1 months followed by warfarin orally for 5 months(LMWH-warfarin group) respectively. INR(international normalized ratio ) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
2847|NCT04173416|Behavioral|Youth Opioid Recovery Support (YORS)|The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.
2848|NCT04173403|Drug|450mg AK102|AK102 Q4W
2849|NCT04173403|Drug|300mg AK102|AK102 Q4W
2850|NCT04173403|Drug|150mg AK102|AK102 Q2W
2851|NCT04173403|Drug|Statins and/or Ezetimibe|Lipid-lowering therapies
2852|NCT04173390|Drug|Pregabalin 150mg|Preemptive use of pregabalin 150 mg starting three days before surgery up to the third postoperative day
2853|NCT04173390|Drug|Placebo oral tablet|Preemptive use of Placebo oral tablet starting three days before surgery up to the third postoperative day
2854|NCT04173364|Drug|Ropivacaine 0.5% Injectable Solution|Injectable solution of ropivacaine 0.5%
2855|NCT04173364|Drug|Ropivacaine 0.1% Injectable Solution|Dilution of ropivacaine to the concentration of 0.1%
2856|NCT04173351|Behavioral|Education and Counseling|Following the pretests between the 28th and the 34th gestational weeks, nulliparous women in the intervention group received a presentation on childbirth preparation at a room of the obstetrics clinic. The education was completed in two sections in a single day. Each session took about 45 minutes there was a 15-minute break between the sessions. Following the education, the questions of the participants were responded and educational brochures on childbirth preparation were given to the participants. One of the researchers of this study telephoned the participant women in the intervention group one week after the childbirth education and provided counseling service about the demands and the points that the nulliparous women wondered.
2857|NCT04173338|Drug|Cabozantinib|start at 20mg then increase by 20mg every cycle or until there's a dose-limiting toxicity.
2858|NCT04173338|Drug|Pemetrexed|Start with 400mg/m2, then increase and maintain 500mg/m2 unless dose-limiting toxicity.
2859|NCT04173325|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|PD-1 inhibitor approved by the US FDA for treatment of patients with lung cancer.
2860|NCT04173325|Drug|Irinotecan Injection [Camptosar]|Chemotherapy drug currently FDA approved for treatment of multiple tumors, including small cell lung cancer.
2861|NCT04173312|Combination Product|Bupivacaine infusion|Local systemic Infusion of anesthetic
2862|NCT04173312|Combination Product|Saline|Local systemic infusion of saline
2863|NCT04173299|Procedure|early tips|patients with early tips
2864|NCT04173286|Procedure|antibiotherapy|< 7 days
2865|NCT04173273|Drug|Etrasimod|Dose A taken by mouth, once daily.
2866|NCT04173273|Drug|Etrasimod|Dose B taken by mouth, once daily.
2867|NCT04173273|Drug|Placebo|Etrasimod matching placebo tablet taken by mouth, once daily.
2868|NCT04173260|Drug|Deutetrabenazine 6 MG|Increasing doses of Deutetrabenazine
2869|NCT04173247|Device|KeraStat Cream|KeraStat Cream is a non-sterile, non-implantable, emollient-based wound dressing intended to act as a protective covering in the management of a variety of skin conditions.
2870|NCT04173247|Other|Routine Skin Care - Commercially Available Agents|Commercially available skin moisturizers from an approved list that do not interfere with radiation.
2871|NCT04173234|Other|Aerobic Training|Aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period to children in treatment group.
2872|NCT04173234|Other|Home exercise program|Children will be given a home program including stretching, breathing, normal joint movement, body weight and mildly resistant exercises, and children will be asked to do these for 3 to 5 days a week.
2873|NCT04173221|Other|Sublingual SDF-Measurement with communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, with communication and interpreting checklist to the treating physician
2874|NCT04173221|Other|Sublingual SDF-Measurement without communication and interpreting checklist to the treating physician|Sublingual SDF-Measurement at admission and after 24h, without communication and interpreting checklist to the treating physician
2875|NCT04173208|Other|Fecal microbial transplant|Fecal microbial transplant
2876|NCT04173208|Other|Placebo|Placebo
2877|NCT04173195|Other|Comfort Talk|A short and brief conversation based on the principles of clinical hypnosis.
2878|NCT04173182|Diagnostic Test|Probe-based confocal laser endomicroscopy evaluation|Colonoscopy with confocal laser endomicroscopy evaluation of the peridiverticular and colonic mucosa on patients with diverticular disease
2879|NCT04173169|Drug|Elagolix 200 MG|Elagolix tablet
2880|NCT04173169|Drug|Placebo|Sugar pill manufactured to mimic Elagolix 200mg
2881|NCT04173156|Device|Labrida Bioclean|The brush bristles of the test device (Labrida BioClean®, LABRIDA, Oslo, Norway) are made of the biopolymer chitosan
2882|NCT04173156|Device|Gracey Periodontal curettes|Regular commercially available area specific and medical grade steel Gracey periodontal curettes
2914|NCT04172896|Procedure|Extraperitoneal Uterosacral Ligament Suspension|Vaginal extraperitoneal uterosacral ligament suspension performed by transfixing the ligament, extraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) using a suture capturing device with two delayed absorbable 0 sutures, performed bilaterally (two sutures per side; four sutures total).
2915|NCT04172883|Other|Treatment arm|All pts are implanted with rATP enabled devices prior to the study start , the only intervention in both arms is switching on rATP and in the treatment arm programming changes done to optimize the rATP sequence delivery of therapy and prevent the patient from going into permanent or persistent AF
2883|NCT04173143|Device|Craniocervical flexion training with pressure biofeedback|Total 15 patients participated in this training group. Session was performed thrice in a week. Each session was givenfor approximately 20minutesPatients were asked to lie in supine hook lying position. After that Pressure biofeedback unit's air bag was clipped together and folded in three and positioned behind the neck just below the occiput. Patients were advised to perform Craniocervical flexion and practiced head nodding action to progressively target (reach the incremental targets) and hold the 5 pressure levels for 10 second between 22 mm Hg and 30 mmHg. A 2 minute second rest period was provided between each level. Minimum performance requirement was 26 mm Hg while ideal performance targets are 28 and 30 mm Hg... Patient will be re-assessed for all baseline variables after 4 weeks of training
2884|NCT04173143|Other|Craniocervical flexion training without pressure biofeedback|Total 15 patients participated in this control group.Session was given 3 times in a week. Each session continue forapproximately 20 minutes. The patient lies in supine crook lying position. The patientwas maximally retracted the chin and asked to maintained it while the patient lifts the head and neck until the head is relatively 2 to 5 cm (1 inch) abovethe couch. The examiner places a hand under the head of patient on the table. Patients were instructed to perform10 repetitions for a hold of 20 seconds initially, increasing it by 10 seconds progressively.The entire session had a maximum of 4 sets. Patient will be re-assessed for all baseline variables after 4 weeks of training
2885|NCT04173130|Device|Anuscope with needles|Injection of botulinum toxin into the anal sphincter with the investigational device (anuscope with needles).
2886|NCT04173117|Dietary Supplement|Low energy meal replacement plan (12 weeks)|Low energy meal replacement plan (12 weeks)
2887|NCT04173104|Diagnostic Test|PET/MR with [18F]PARPi|One PET/MR study (with up to 3 scan times) with [18F]PARPi
2888|NCT04173104|Drug|[18F]PARPi|Injection of <100ug of [18F]PARPi prior to 1 PET/MR
2889|NCT04173091|Diagnostic Test|No Intervention|No Intervention planed
2890|NCT04173078|Behavioral|Computerized Distress Intolerance Intervention|
2891|NCT04173078|Behavioral|Computerized Healthy Behaviors Intervention|
2894|NCT04173052|Device|Testis' shocker|The device gives electrical shock ranged (1-5) milliAmpere designed to fit the testis shape for the males.
2895|NCT04173039|Diagnostic Test|Serum anti-CarP antibodies detection|Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
2896|NCT04173026|Other|Provider-level intervention|Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
2897|NCT04173026|Other|Patient-level intervention|50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
2898|NCT04173013|Biological|Uromune|2 sprays of solution once daily for a total of 3 months.
2899|NCT04173000|Other|Mehealth for ADHD software with medication continuity tools|Medication continuity tools integrated within the mehealth for ADHD software will assess factors influencing medication continuity for each adolescent and recommends tools to address relevant factors. Tools include 1) a system to track outcomes and resolve uncertainty about the need for and/or benefit from medicine, 2) a module to address stigma, 3) a module to help manage side effects, and 4) reminders to take medicine and/or request refills.
2900|NCT04173000|Other|Mehealth for ADHD software with no medication continuity tools|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
2901|NCT04172987|Drug|Tirzepatide|Administered SC
2902|NCT04172987|Drug|EE/NGM|Combination oral contraceptive administered orally
2903|NCT04172974|Other|eHealth intervention|Modules developed for depression and anxiety based on cognitive behavioral therapy (CBT), acceptance and commitment therapy (ACT) and compassion-focused coping
2904|NCT04172974|Other|Usual Care|Treatment according to national clinical guideline (referral to GP)
2905|NCT04172961|Drug|nanomicellular cyclosporine 0.09%|topical ophthalmic drop prior to elective surgery for eligible patients
2906|NCT04172961|Drug|Lifitegrast|topical ophthalmic drop prior to elective surgery for eligible patients
2907|NCT04172948|Device|Oculus go headset/virtual reality headset|10 minute virtual reality tutorial on diaphragmatic breathing, a game in practicing diaphragmatic breathing, and two scenarios in which the patient can also practice diaphragmatic breathing.
2908|NCT04172948|Behavioral|Diaphragmatic breathing|10 minute tutorial on diaphragmatic breathing by a medical professional.
2909|NCT04172935|Device|Presbyopic Glasses/ Intervention Group|Immediate provision of a free pair of spherical presbyopic glasses to correct the worker's vision for optimal picking distance, astigmatism is corrected.
2910|NCT04172922|Drug|Topical Sirolimus|Open label, topical sirolimus (1%) cream will be applied to cutaneous component of complicated vascular anomalies twice daily for 4 weeks and once daily thereafter- for the duration of study.
2913|NCT04172896|Procedure|Intraperitoneal Uterosacral Ligament Suspension|Vaginal intraperitoneal uterosacral ligament suspension performed by transfixing the ligament, intraperitoneally, in the intermediate portion (at the level of or above ischial spine plane) with three delayed absorbable 0 sutures, performed bilaterally (three sutures per side; six sutures total).
2917|NCT04172857|Procedure|anterior vitrectomy combined with hyaloidotomy, zonulectomy and iridectomy|First, a 23-G incision was made at the peripheral inferior temporal sector of the cornea and connected with an anterior chamber infusion cannula. Another corneal incision was made at the superior temporal sector or superior nasal sector, and Viscoat® (Bausch & Lomb, Shandong, China) was infused though the incision to fill the anterior chamber. Iridotomy was performed through the incision using Wescott scissors and toothed forceps. Hyaloidectomy and zonulectomy were performed through a peripheral iris defect using an anterior chamber approach to set up a pathway between the anterior chamber and the vitreous cavity. We repeatedly carried out vitrectomy around the pathway to reduce the risk of postoperative re-obstruction of the tunnel created.
2918|NCT04172844|Drug|Azacitidine|75mg/m^2 Days 1-7 given IV
2919|NCT04172844|Drug|Venetoclax|100 mg on cycle 1 day 1, 200 mg daily on cycle 1 day 2, 400 mg on cycle 1 day 3 and thereafter from cycle 1. Venetoclax is given for a minimum of 21 days and a maximum of 28 days. Administered orally.
2920|NCT04172844|Drug|Pevonedistat|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
2921|NCT04172831|Drug|TNX-102 SL|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
2922|NCT04172831|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
2923|NCT04172818|Behavioral|quality of life questionnaire|Since 10 years ago, diaries are used in intensive care unit to limit these symptoms after a coma.In analogy, the diary for patients with allogenic hematopoietic stem cell transplantation could be a mean to reduce the psychological adverse impact and long term consequences. The psychological impact of a diary on patients hospitalized for allogenic hematopoetic stem cell transplantation and on their relatives will be evaluated.
2924|NCT04172805|Drug|anlotinib and toripalimab|Anlotinib 12mg orally per day, two weeks on , one week off; 240 mg of toripalimab (fixed dose) every three weeks. Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment.
2928|NCT04172779|Drug|Erlotinib Hydrochloride|Oral administration of erlotinib 25mg tablet
2929|NCT04172766|Behavioral|Advanced|"Advanced group users will receive prompts when an acutely high headphone audio level exposure (LEQ equivalent to >97 dBA for >30 minutes) occurs. Those in the WatchOS arm will be prompted when their weekly environmental sound level (7-day LEQ equivalent to >80 dBA for >40 hrs) is high. Either prompt will occur via notification, and will request that the participant review exposure data in the Research app and answer questions related to their exposure. The survey will ask for confirmation that they reviewed the exposure data and perceive it as accuracy, whether or not they used any hearing protection (e.g., ear plugs worn at a rock concert), and any intended listening behavior change resulting from their data review. To minimize notification burden for participants, exposure notification events will occur no more than twice per month. At this same frequency, they will be asked to take an abbreviated audiogram to test for temporary threshold shifts in their hearing level."
2930|NCT04172753|Radiation|Radiotherapy on the MR-Linac|Radiotherapy is performed on the 1.5 T MR Linac
2931|NCT04172753|Diagnostic Test|Imaging on the MR Linac|Only imaging performed on the MR Linac
2932|NCT04172740|Device|Radiesse (calcium hydroxylpatite)|"RADIESSE® injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principle component is synthetic calcium hydroxylapatite (CaHA) suspended in a gel carrier of sterile water for injection, glycerin and sodium carboxymethylcellulose. RADIESSE injectable implant has a CaHA particle size range of 25-45 microns. RADIESSE is available in 1.5cc and 0.8cc pre-filled syringes.~RADIESSE injectable implant is indicated for subdermal implantation for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds and it is also intended for restoration and/or correction of the signs of facial fat loss (lipoatrophy)."
2933|NCT04172727|Drug|Bupivacaine Hcl 0.25% Inj|ultrasound-guided bilateral TFP block with 20 mL of 0.25% bupivacaine
2934|NCT04172727|Drug|saline 0.9%|ultrasound-guided bilateral TFP block with 20 mL of saline 0.9%
2935|NCT04172714|Device|SIR-Spheres microspheres|SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.
2938|NCT04172688|Dietary Supplement|Prebiotic oligofructose-enriched inulin|Synergy1
2939|NCT04172688|Dietary Supplement|Placebo maltodextrin|Equicaloric dose of maltodextrin
2940|NCT04172675|Drug|Erdafitinib|Participants will receive erdafitinib orally beginning on Cycle 1 Day 1 until 2 years of treatment have been completed, disease recurrence, intolerable toxicity, withdrawal of consent, a decision by the investigator to discontinue treatment, or study termination, whichever occurs first. Each cycle is of 28 days.
2941|NCT04172675|Drug|Investigator Choice (Gemcitabine)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
2942|NCT04172675|Drug|Investigator Choice (Mitomycin C)|Investigator's Choice treatment will be given once weekly for at least 4 doses of induction followed by monthly maintenance for at least 6 months.
3128|NCT04171180|Drug|budesonide/formoterol|apply different dosage of budesonide/formoterol in two groups and evaluate the treatment effects.
3465|NCT04168177|Procedure|ESP|erector spinae plane block
2943|NCT04172662|Behavioral|Facilitated Music Listening|The patient gets a preparatory session with the music therapist one day before the invasive procedure, where individual assessment is made based on a biopsychosocial approach. Sequences of facilitated Music listening is provided during the pre-, peri and postoperative phase, and a closing dialog performed postoperatively. Patient-preferred music is chosen from a limited set of playlists provided on the app The Music Star.
2944|NCT04172649|Other|Acupuncture|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack needles (diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
2945|NCT04172649|Other|Acupressure|On the day before surgery, patients randomized to the intervention groups will receive routine postoperative analgesic care with application of 6 bilateral press tack placebos (knob without needle, diameter of 0.15mm and length of 0.6mm for P-6 and Shenmen, diameter of 0.20mm and length of 1.2mm for SP-6, Seirin New Pyonex, Seirin Corp., Shizuoka City, Japan).
2946|NCT04172636|Drug|AMR101 (VASCEPA, icosapent ethyl)|Oral administration, 4 grams per day
2947|NCT04172623|Behavioral|Real-Time Smoking Intervention|Adult smokers will use wearable technology in order to receive real-time feedback as a smoking intervention in addition to standard treatment.
2948|NCT04172623|Behavioral|Standard Treatment|Adult smokers will receive standard outpatient tobacco treatment.
2950|NCT04172584|Behavioral|correct use of the contraceptions|know the emergency contraception and how to use
2951|NCT04172571|Biological|AK105|Anti-PD-1 antibody; IV infusion, 200 mg Q3W
2952|NCT04172571|Drug|Anlotinib Hydrochloride|multi-targeted receptor TKI; oral administration; every 3 weeks as one cycle administered as 2 weeks on/1 week off
2953|NCT04172558|Biological|OnabotulinumtoxinA|a single ICI of BTX-A 100 units one day after the penile Doppler/trimix test.
2954|NCT04172558|Drug|Trimix|on demand ICI of Trimix
2955|NCT04172545|Procedure|stapling|staples are fired through the gastric wall after waiting several seconds for compression without attention to blood pressure, fluids given or intra abdominal pressure, but these might have an impact on quality of stapling. therefore the conditions during stapling will be recorded during stapling.
2956|NCT04172532|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
2957|NCT04172532|Drug|Nedisertib|Given PO
2958|NCT04172532|Other|Placebo|Given PO
2959|NCT04172519|Other|Pre- and post prostatectomy supervised PMFT|intervention before and after surgery, supervised exercises
2960|NCT04172519|Other|Unsupervised PMFT|intervention after surgery, unsupervised exercises
2961|NCT04172519|Other|Supervised PMFT|intervention after surgery and supervised exercise
2962|NCT04172506|Drug|AK105|Anti-PD-1 antibody
2963|NCT04172493|Procedure|Hyperspectral Endoscopy (HySE)|Undergo hyperspectral endoscopy
2964|NCT04172493|Device|White Light Endoscopy (WLE)|Undergo white light endoscopy
2965|NCT04172480|Other|Blood sampling|Peripheral blood sampling on EDTA
2966|NCT04172467|Other|non-interventional retrospective epidemiological observational study|non-interventional retrospective epidemiological observational study
2967|NCT04172454|Biological|AK104|AK104, 6mg/kg, Q2W
2968|NCT04172441|Drug|dasiglucagon|Glucagon analog
2969|NCT04172441|Drug|Placebo|Placebo for dasiglucagon
2970|NCT04172428|Diagnostic Test|Functional MRI (fMRI)|fMRI will be done on 3 separate MRI scanners to compare.
2971|NCT04172415|Other|Retrospective cohort|Chart Review
2972|NCT04172402|Drug|TS-1|Intervention is administered to patients in this Arm.
2973|NCT04172402|Drug|Gemcitabine|Intervention is administered to patients in this Arm.
2974|NCT04172402|Drug|Nivolumab|Intervention is administered to patients in this Arm.
2975|NCT04172389|Procedure|vesico-vaginal fistula robot assisted laparoscopic repair|realization of O'conor technique or extra-vesical technique for vaginal vesico fistula repair in robot assisted coelioscopy
2976|NCT04172376|Procedure|Minimally invasive puncture aspiration plus rt-PA|Stereotactic puncture aspiration to evacuate basal ganglion hematoma with use of thrombolytic agent
2977|NCT04172376|Drug|Conservative medical treatment|Drugs for symptomatic treatment such as hemostasis and nerve nourishing.
2978|NCT04172363|Drug|Octenisept and Serasept|Swab probes of wounds will be taken upon study inclusion and analysed for resistance on Octenisept and Serasept. If the patient indicates resistance on one of the antiseptics, he/she will receive the other antiseptic for wound dressings
2979|NCT04172350|Other|iCareBreast|The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
2980|NCT04172350|Other|Routine care|Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
2981|NCT04172337|Behavioral|Healthier Choice Symbol|The HCS is intended to improve diet quality by signaling to consumers which products are healthier options within a specific category (e.g., which are the healthier biscuits or the healthier beverages). Manufacturers must meet category-specific criteria before a product can display the HCS and an associated tagline. The labels were displayed at the bottom of the product images.
3129|NCT04171167|Drug|Fluticasone Propionate|three visits: 0, after washout, after FP usage
3130|NCT04171154|Behavioral|Expectation|writing task
3131|NCT04171154|Behavioral|Acceptance|listening
3132|NCT04171141|Drug|PF-07062119|PF-07062119
3133|NCT04171141|Drug|Anti-PD1|Anti-PD1 PF-06801591
2982|NCT04172337|Behavioral|Physical Activity Equivalent label|"For the study, we designed a simple PAE logo (Appendix Figure A1) and added a description encoded into the NUSMart user interface to ensure that participants would understand the contents of the label. Participants saw the following description whenever their cursor hovered over the PAE label: The Physical Activity Equivalent (PAE) refers to the number of minutes that a typical adult would need to jog to burn off the calories associated with one serving of the product. Previous studies have shown this labelling approach to be effective.~The labels were displayed at the bottom of the product images."
2983|NCT04172324|Device|HIBBOT|Hibbot is an assistive mechanical device, lightweight and portable. The mechanism of the Hibbot manages to control all degrees of freedom (3x rotation and 3x translation) at the level of the pelvis and lower trunk. The goal is to maximize a child's own muscle activity and postural control while giving as minimal support as needed.
2984|NCT04172324|Other|Standard Care|Standard care involves the standard physiotherapy the child would get during clinical care.
2985|NCT04172311|Other|Modified Atkins Diet|Modified Atkins diet is a type of ketogenic diet which is less restrictive
2986|NCT04172311|Drug|Levetiracetam|Levetiracetam is a second generation anti-epileptic drug which is broad spectrum and commonly used as add-on in refractory epilepsy
2987|NCT04172298|Other|sham electroacupuncture (EA) session|The stainless steels acupuncture needles inserted into the subcutaneous layer of Zusanli (cathode) and Shangjuxu acupints (anion) , and the needles connected to EA stimulator, but no electric discharge for 30 min.
2988|NCT04172298|Other|Zusanli session|The acupuncture needles inserted into Zusanli (cathode) and Shangjuxu acupoints (anion), and twisting obtain qi, and the needles then connected to EA stimulator, the frequency was 2 Hz, the duration was 30 min, and the intensity was visual slightly muscle contraction.
2989|NCT04172298|Other|Shaohai session|The methods were identical Zusanli group, but Shaohai acupoint (cathode), and 3 cm below Shaohai (anion).
2990|NCT04172285|Behavioral|Physical activity|Home-based physical activity program
2991|NCT04172285|Dietary Supplement|Physical activity and supplementation|Home-based physical activity program and amminoacid supplementation
2992|NCT04172285|Other|Control|No intervention
2993|NCT04172272|Drug|Systemic multimodal analgesia administered intravenously|"Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours. Analgesia will start immediately after surgery. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
2994|NCT04172272|Procedure|Transversus abdominis plane block (TAP block)|"The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block) of 0.25% levobupivacin in 40 ml bilaterally. If the pain persists, the patient will be given rescue analgesia: tramadol 50 mg intravenously up to a maximum dose of 400 mg / 24 h and other analgesics if needed."
2995|NCT04172272|Other|Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously|TAP block in addition to systemic, mutimodal analgesia. If such analgesia is not satisfactory, tramadol 50 mg intravenously, up to a maximum dose of 400 mg / 24h, and other analgesics will be given at the request of the patient.
2996|NCT04172259|Drug|Doxorubicin liposome|PLD
2997|NCT04172259|Drug|Cyclophosphamide|CTX
2998|NCT04172259|Drug|Trastuzumab|H
2999|NCT04172259|Drug|Docetaxel|DOC
3000|NCT04172259|Drug|Epirubicin|EPI
3002|NCT04172233|Biological|AK101|AK101 is an anti-IL-12/23p40 monoclonal antibody.
3003|NCT04172233|Biological|placebo|matching placebo
3004|NCT04172220|Drug|Midazolam|1-2 mg of Midazolam as premedication.
3005|NCT04172220|Procedure|PECS|"Loco-regional anesthesia: PEC I and serratus plane block with an echoguided technique.~For the PEC I: infiltration of 10 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of the pectoralis major muscle and the small pectoralis muscle at the height of the third rib on the anterior axillary line.~For the serratus plane block: identification of the fifth rib on the average axillary line and infusion of about 20 ml of local anesthetic (Levobupivacaine 0.25% or Ropivacaine 0.5%) between the bands of large dorsal muscle and of the anterior serratus muscle."
3006|NCT04172220|Procedure|Opioid-free general anesthesia|"Induction with Propofol 1.5-2 mg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in Target-Controlled Infusion (TCI) of 6 mcg/ml, subsequently modified to maintain a Bispectral Index (BIS) value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase >20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
3007|NCT04172220|Procedure|General anesthesia|"Induction with Propofol 1.5-2 mg/kg; Fentanyl 1μg/kg; laryngeal mask for airway management after eventual administration of Rocuronium 0.6 mg/kg. Anesthesia will be maintained with Propofol in TCI of 6 mcg/ml, subsequently modified to maintain a BIS value between 40 and 60.~Fentanyl 50ug in bolus IV, in case of mean arterial pressure or heart rate increase >20%.~In case of hypotension: 5mg ephedrine and infusion of 250 ml Lactated Ringer."
3008|NCT04172220|Procedure|Postoperative analgesia|Paracetamol 1000 mg every 8 hours for the first 24 hours, Ketorolac 30 mg in case of pain control failure (Numeric Rating Scale- NRS>4) which can be administered every 8 hours at most (max 90 mg / 24 hours), Morphine 10-20 mg IV in 24 hours as rescue analgesia.
3009|NCT04172207|Other|Sampling|After periodontal parameters measured, smear samples were obtained from the buccal mucosa and keratinized gingiva, and then a gingival biopsy was performed from the upper premolars.
3010|NCT04172181|Procedure|cord blood stem cell transplantation|Unrelated cord blood stem cell selection； Reduced intensity conditioning； GVHD prevention； Infection prevention.
3011|NCT04172168|Diagnostic Test|Heart rupture|Left ventricular free-wall ruptrue after AMI
3013|NCT04172116|Device|Continuous glucose monitoring|see arm/group descriptions
3014|NCT04172090|Other|Control|Normal physical activity and standard energy intake
3015|NCT04172090|Other|SIT+E|Reduced physical activity and standard energy intake
3016|NCT04172090|Other|SIT=E|Reduced physical activity and reduced energy intake
3017|NCT04172064|Diagnostic Test|Myocardial perfusion scintigraphy|
3018|NCT04172051|Behavioral|Tony Robbins Date with Destiny|DWD is a 6-day immersive transformational experience led by Tony Robbins. It will be held at the PALM BEACH, FLORIDA Convention Center from December 5th through December 10th. Subjects will be exposed to a variety of mind-body exercises and psychoeducational content including neural linguistic programming, designed to motivate, inspire, and improve the quality of people's lives.
3019|NCT04172038|Behavioral|Physical Therapy|Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).
3020|NCT04172038|Behavioral|Move 2 Health (M2H)|"Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~Sleep~Physical Activity~Nutrition~Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.)."
3021|NCT04172038|Behavioral|MORE Mindfulness|"Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~Mindfulness~Cognitive reappraisal~Savoring of positive experiences"
3022|NCT04172025|Diagnostic Test|Analysis of Bacterial Genome|genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
3023|NCT04172012|Biological|Labinic (R) probiotic mixture|Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
3024|NCT04172012|Other|Placebo|Placebo mixture
3025|NCT04171999|Other|Community Rx-Hunger (CRx-H)|"The CRx-H Intervention provides dosages of health content that offer assistance for food insecurity and other health-related social needs. A caregiver randomized to the intervention will receive a hard-copy print-out of their tailored list of resources to address food insecurity. A member of our research team will deliver this list and provide a brief educational component which includes: a brief, structured script about the common problem of food insecurity in households with children and co-occuring HRSNs, review of the resource list which includes nearby, vetted resources to address these needs and coaching on how to activate resources on the list. Prior to discharge, the caregiver will receive a duplicate copy of the list of resources. After discharge, the caregiver will receive text messages at a frequency based on the Critical Time Intervention (CTI) Model, from baseline to 3 months post discharge, in order to receive ongoing support by a research team member."
3026|NCT04171986|Drug|Mecapegfilgrastim|Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
3027|NCT04171973|Device|Driving an electric wheelchair in real condition|For the control group, 3 test circuits of pipes in real condition of increasing difficulty are tested. Patients perform 2 passes in this condition.
3028|NCT04171973|Device|Driving an electric wheelchair in virtual condition|For the virtual reality group, the circuits have been digitized. Patients perform 2 passes in this condition.
3029|NCT04171960|Other|Blood Draw Within 12 Hours of Injury|- Specimens collected for i-STAT testing and, if applicable, for optional collection of DNA for possible future genetic testing.
3030|NCT04171960|Other|3T MRI|- 3T Magnetic Resonance Imaging (MRI) at 2 weeks and 6 months following injury.
3031|NCT04171960|Other|In-Person Outcome Assessment at Baseline|-3 Outcome Assessments administered at Baseline.
3032|NCT04171960|Other|In-Person Outcome Assessment at Follow-Up|- Full set of Outcome Assessment at 2 weeks, 6 weeks, and 6 months following injury.
3033|NCT04171960|Other|Phone Outcome Assessment|- 6 Outcome Assessments administered at 3 months following injury by Phone.
3034|NCT04171960|Other|Blood Draw After 12 Hours of Injury|- Specimens collected at 12-24 hours, 2 weeks, and 6 month following injury then processed for storage for future use.
3035|NCT04171947|Device|Matuzalem ovule|vaginal ovule with 2 mg tea extract
3036|NCT04171947|Device|Vehicle ovule|polyethylene glycol vaginal ovule
3037|NCT04171921|Procedure|Robotic ventral hernia repair|Laparoscopic robotically assisted trans-abdominal pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
3038|NCT04171921|Procedure|Open ventral hernia repair|Standard open pre-peritoneal epigastric or umbilical hernia repair with closure of fascial defect and non-adsorbable mesh reinforcement
3039|NCT04171908|Other|Conventional therapy|Conventional Physical therapy for the upper limb
3040|NCT04171908|Other|Leap motion|Conventional Physical therapy for the upper limb plus leap motion
3041|NCT04171895|Other|Questionnaires|Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.
3042|NCT04171895|Other|Communication training|3.5 hour Communication Training
3043|NCT04171869|Other|no intervention|observational study, no intervention
3045|NCT04171843|Genetic|PBCAR269A|Allogeneic anti-BCMA CAR T-cell
3046|NCT04171843|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
3047|NCT04171843|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
3134|NCT04171141|Drug|Anti-VEGF|Anti-VEGF IV (bevacizumab)
3135|NCT04171128|Behavioral|antibiotic stewardship efforts|The local antibiotic team plan to implement procalcitonin use among the hospital physicians. the interventions are not ready yet.
3136|NCT04171115|Drug|G03-52-01|G03-52-01 administered intramuscularly
3137|NCT04171115|Drug|Placebo|Placebo administered intramuscularly
3048|NCT04171830|Other|modified Hospital One-year Mortality Risk (mHOMR)|"Every inpatient will automatically be given the intervention (an mHOMR/HOMR Now! score) upon admission to hospital and considered for secondary interventions based on their score. Baseline threshold will be set as >0.21 (59% sensitivity and 90% specificity for 12-month mortality with mHOMR).~At minimum each individual identified by the tool will receive two assessments to screen for severe symptoms and desire to engage in advance care planning (ACP):~Edmonton Symptom Assessment System Revised: scores >6 will be flagged as severe. Clinical teams will address the symptoms as appropriate for the patient.~4-item Advanced Care Planning Engagement Survey: Scores of 3-4 indicate readiness to discuss ACP. Clinical teams may choose to discuss ACP and goals of care themselves, activate a local ACP intervention, or distribute ACP documentation.~Both of these assessments will be done by a member of the treating team within 72 hours of the patient's hospital admission."
3049|NCT04171817|Drug|Chlorhexidine|The goal of this work is to assess the effect of chlorhexidine (CHX)-based interventions--specifically use of pre-session chlorhexidine shampoo for the dog and use of chlorhexidine wipes on the dog's fur--on patient exposure to hospital-associated pathogens during the sessions with the dogs
3050|NCT04171804|Device|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions on 5 consecutive days (twice a day with 3-4 hours interval). During each session, 2 milliAmpers (mA) of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
3051|NCT04171791|Drug|ABT-199 (venetoclax)|Eligible patients will be enrolled into the study and receive venetoclax daily per the US FDA package insert guidelines of venetoclax, with dose escalation up to 400 mg. To minimize the risk of tumor lysis syndrome (TLS), and following the package insert directions for dose escalation over 5 weeks, the initial dose is 20 mg daily, and may be progressively increased as tolerated to 400 mg by week 5.
3052|NCT04171778|Other|whole food, plant-based diet|The study diet is whole food, plant based defined as containing no animal products or refined grains or added oils, minimal use of any sweeteners, and, for the purposes of this study, on average containing no more than 15% calories from fat.
3053|NCT04171765|Drug|Placebo|Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
3054|NCT04171765|Drug|BFKB8488A|Participants will receive subcutaneous (SC) BFKB8488A.
3055|NCT04171752|Drug|elafibranor|elafibranor 120mg is a coated tablet for oral administration
3056|NCT04171739|Drug|Itraconazole oral solution|200 mg once daily on Days 6 to 15
3057|NCT04171739|Drug|Rifampicin Oral Capsule|600 mg once daily on Days 6 to 15
3058|NCT04171739|Drug|Olorofim|Single oral dose on Days 1 and 11
3059|NCT04171726|Drug|Edoxaban|A non-vitamin K antagonist (VKA) oral anticoagulant that selectively inhibits factor Xa.
3060|NCT04171713|Behavioral|Mindfulness-Based Health Promotion + Treatment as usual|Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
3061|NCT04171713|Behavioral|Attachment-based compassion therapy + Treatment as usual|It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.
3062|NCT04171713|Behavioral|Treatment as usual|participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
3063|NCT04171700|Drug|Rucaparib|Oral rucaparib will be administered twice daily. The starting dose will be 600 mg daily (BID).
3064|NCT04171687|Drug|Clopidogrel 75mg|Clopidogrel 75 mg tablet
3065|NCT04171687|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
3066|NCT04171687|Drug|RAPA113|RAPA113 tablet
3067|NCT04171674|Drug|Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).|High-dose ceftobiprole (500mg loading dose) will be administered to patients for 30 minutes followed by 2.5g under continuous infusion for 24 hours.
3068|NCT04171661|Other|SASS|SASS applied on chronic skin wounds as skin graft
3069|NCT04171648|Other|Roasted Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of roasted in shell peanuts a day for two weeks.
3070|NCT04171648|Other|Boiled Peanut Treatment|The subjects will consume 2 ounces or ~48 grams of boiled peanuts a day for two weeks.
3071|NCT04171635|Radiation|Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI)|Investigators will validate hepatic QSM (hQSM) using histological examination and chemical measurement of liver iron concentration (LIC). Patients will undergo clinical MRI in Aim 1. In patients with increased LIC their liver explants will undergo MRI, pathological examination, and chemical determination of the LIC.
3072|NCT04171635|Radiation|R2* Magnetic Resonance Imaging (MRI)|Investigators will be able to validate hQSM in measuring liver iron concentration (LIC) by comparing it to this traditional MRI technique
3073|NCT04171622|Drug|Lenvatinib|Given PO
3074|NCT04171622|Biological|Pembrolizumab|Given IV
3075|NCT04171609|Behavioral|Expressive writing|During this daylong expressive writing workshop intervention, the writing instructor coached participants through a series of simple writing exercises. Participation required neither any prior writing experience, nor any desire to become a writer. The practices cultivate natural abilities to express the ideas that define who you are and how you experience your life.
3138|NCT04171102|Device|ProFlor Hernia implant|Inguinal hernia repair
3139|NCT04171089|Behavioral|Child- Safety Plan Intervention|The intervention includes recognizing and knowing the individual's warning signs for a suicidal crisis, their personal coping/distraction skills, people to contact, as well as a restriction of the means to hurt oneself.
3076|NCT04171596|Behavioral|Primary care coordination|"A registered nurse currently employed at Duke Integrative Medicine, who is also trained as an integrative health coach, will serve in the PCC role. The intervention will flow as follows:~The PCC will call study participants every 2 months during the 6 months (more frequently as needed) for a semi-structured phone check-in, and will track the intervention through the REDCap database. The PCC will use guiding questions to frame the call, but will also:~Respond Ask follow-up questions Provide suggestions that are guided by the patient response and appropriateness to the individual situation and needs and scope of practice.~Prior to the call, the PCC will review the patient chart to see if any outstanding orders, medical visits due, and review the patient health goals (known as the pre-work).~The PCC will call the patient to provide intervention. If patient is not available, the PCC will leave a message, or contact via MyChart to see about scheduling a time to talk."
3077|NCT04171570|Procedure|Coronary angiography and or Percutaneous coronary Intervention|Radial access punture site
3078|NCT04171557|Behavioral|Bicycling|Total bicycling is reported in categories of: (0 - reference), (>0 to <60), (≤60 to >150), (≤150 to < 300) and (≥300) minutes/week
3079|NCT04171544|Device|Streamline Occipito-Cervico-Thoracic Spinal Fixation System|Spinal Fixation
3080|NCT04171531|Drug|Botox® injection|Botulinum toxin A will be prepared by dissolving 100 units of botulinum toxin A into 10 ml of injectable saline. Indigo carmine or methylene blue 0.1 ml will be added to each syringe of botulinum toxin A. The treating physician will inject a total of 10 ml of the Botox A® into approximately 15 to 20 different detrusor muscle sites under direct visualization.
3081|NCT04171531|Device|Mid-urethral sling|"Mid-urethral Sling Procedure includes retropubic as well as transobturator full length slings. Mini-sling and single-incision sling will not be allowed due to potential risk for higher failure rate."
3082|NCT04171518|Device|Catalys Precision Laser System|Cataract surgeons to create a precise anterior capsulotomy and/or subsequent fragmentation (phacofragmentation) of the crystalline lens using the Catalys Precision Laser System
3083|NCT04171505|Drug|HPV vaccine|". Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account."
3084|NCT04171479|Device|Epicardial mapping and/or ablation|Either catheter mapping, ablation, or mapping and ablation will be performed using an epicardial catheter approach.
3085|NCT04171466|Dietary Supplement|SH-DS01|SH-DS01 is a synbiotic developed by SEED Health Inc., which is a 24-strain live microorganism cocktail with a prebiotic.
3086|NCT04171466|Other|Ciprofloxacin + Metronidazole|Participants will be instructed to take 1 capsule of Ciprofloxacin (500mg) twice daily for 7 days and 1 capsule of Metronidazole (500mg) thrice daily for 7 days. Antibiotics should be taken at least 2 hours before or 6 hours after mineral supplements containing magnesium or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc.
3087|NCT04171466|Other|Placebo|Placebo capsules for SH-DS01 will contain rice flour.
3088|NCT04171453|Drug|Lyrica CR (Pregabalin)|Lyrica CR 82.5mg, 165mg, or 330mg OD
3089|NCT04171440|Procedure|minimally invasive pancreaticoduodenectomy|The minimally invasive pancreaticoduodenectomy is performed through small incisions using robotic-assisted technology or endoscopic techniques. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater.
3090|NCT04171440|Procedure|open pancreaticoduodenectomy|Open pancreaticoduodenectomy is considered the current standard of care. Pancreaticoduodenectomy is the operation that is necessary to remove tumors of the head and neck of the pancreas, lower portion of the bile duct, and the ampulla of Vater
3091|NCT04171427|Other|Lithium liposome|Cosmetic product
3092|NCT04171427|Other|Placebo|Cosmetic product vehicle
3093|NCT04171414|Biological|CT-P17 SC AI (adalimumab)|Subcutaneous Injection of Adalimumab 40mg once every two weeks
3094|NCT04171401|Other|In-patient stroke rehabilitation.|An in-patient multi-disciplinary stroke rehabilitation program was performed.
3095|NCT04171388|Drug|Azithromycin 500 mg|Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (<=24 weeks gestation), and follow-up ANC at least 4 weeks later
3096|NCT04171388|Dietary Supplement|Multiple Micronutrient or Fortified Balanced Energy Protein Supplement|Daily multiple micronutrient (MMN) tablet (Contract Pharmacal Corp) for women with mid-upper arm circumference (MUAC) >=23 cm, OR Daily fortified balanced energy protein (BEP) supplement (DSM South Africa; Faffa Food Products): Fortified corn-soy blend (784 kcal/day) for women with MUAC <23 cm
3097|NCT04171388|Drug|Placebo oral tablet 500 mg|Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (<24 weeks gestation), and follow up ANC at least 4 weeks later
3098|NCT04171388|Other|Enhanced Infection Management Package (EIMP)|"ENROLLMENT VISIT: Screening for bacteriuria with urine culture, and antimicrobial susceptibility testing; Screening for chlamydia and gonorrhea with Cepheid GeneXpert; Presumptive deworming with albendazole 500mg.~FOLLOWUP TREATMENT VISIT: For women with identified urinary tract infection or asymptomatic bacteriuria, treatment with antibiotics based on antimicrobial susceptibility patterns. For women with identified chlamydia or gonorrhea, treatment of woman (and partner) with appropriate antibiotics. Test of cure sample and retreatment of infection.~Second deworming with albendazole at least 4 weeks after enrollment ANC visit."
3140|NCT04171076|Procedure|Transcutaneous spinal cord stimulation|Theta burst stimulation at thoracic level (T5) over 2 minutes
3141|NCT04171063|Device|Thoracic compressor|The intervention is the use of the thoracic compressor for the conservative treatment of pectus carinatum
3142|NCT04171050|Drug|Local anaesthetic|Local anesthesia injections
3143|NCT04171050|Drug|Pudendal Nerve Block plus anesthesia|Local anesthesia injections plus a pudendal nerve block
3144|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via Optiflow THRIVE
3145|NCT04171037|Procedure|Oxygen Therapy|Receive oxygen via non-rebreather
3099|NCT04171375|Device|trans-spinal Electrical Stimulation (tsES)|The trans-spinal pulsed-current stimulation utilizes non-invasive russian stimulation using a research grade stimulator and direct-current stimulation utilizes non-invasive constant stimulation using a medical grade stimulator. Both pulsed- and direct-current stimulation will be achieved with cutaneous cathode electrodes attached to the dorsal aspect of the back overlying at and bellow thoracic vertebrae and anode electrodes placed over the iliac crests or lower abdomen. Spinal motor evoked potentials will be induced by trans-spinal pulsed-current stimulation (parameters, 1 Hz with a 1 millisecond pulse width and monophasic waveform) to determine recruitment profiles of proximal and distal motor pools with increasing stimulation intensity ranging from 10-200 milliampere. Stimulation parameters for the therapeutic stimulation will be ranged from 5-50 Hz and 20-200 milliampere. For direct-current stimulation, the stimulation current will be kept constant at 2-2.5 milliampere.
3100|NCT04171362|Other|Connective Tissue Massage|Connective tissue massage (CTM) is a manipulative technique that facilitates the diagnosis and treatment of a wide range of pathologies. Observation and subsequent manipulation of the skin and subcutaneous tissues can have a beneficial effect upon tissues remote from the area of treatment.
3101|NCT04171362|Other|Education|Education patients were informed about migraine triggers, migraine prevention and coping strategies and exercise options. The exercises were demonstrated by the physiotherapist
3102|NCT04171349|Drug|Articaine|Vial
3103|NCT04171349|Drug|Dexmedetomidine|Vial
3104|NCT04171336|Behavioral|Animal-assisted therapy|Six sessions of animal-assisted intervention for children and adolescents, group format. The sessions will focus on psycho-education on pain, mindfulness, defocusing, getting active, and resources. Additionally, the intervention includes two family visits.
3105|NCT04171323|Behavioral|Cognitive Training|Participants will be completing a total of 40 computerized sessions.
3106|NCT04171323|Behavioral|Computerized Cognitive Stimulation|Participants will be completing a total of 40 computerized cognitive stimulation sessions.
3107|NCT04171310|Drug|SAR442168|Pharmaceutical form:oral solution Route of administration: Oral
3108|NCT04171297|Procedure|Ultrasound evaluation of DE|To evaluate diagnostic accuracy of ultrasound for the presence of deep endometriosis.
3109|NCT04171284|Drug|SCT-I10|200 mg, Q3W, maximum treatment up to six cycles
3110|NCT04171284|Drug|Docetaxel|70-75mg per square meters of body surface area, Q3W, maximum treatment up to six cycles
3111|NCT04171284|Drug|Placebo|200 mg, Q3W, maximum treatment up to six cycles
3112|NCT04171271|Behavioral|Activating kinesthetic motor imagery training|Participants in the activating kinesthetic motor imagery training group will imagine high effort exercises (e.g. planking, boxing, jumping, squats, push-ups) in the sessions in home using the study audio-video motor imagery script for 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
3113|NCT04171271|Behavioral|Relaxing kinesthetic motor imagery training|Participants in the relaxing kinesthetic motor imagery training group will imagine relaxing (low effort) exercises (e.g. breathing exercises, stretching, body awareness exercises) in home using the study audio-video motor imagery script 5 times per week; 17 min per day for 2 weeks. Phone calls will be performed for support and as a reminder for the assessment (after one week).
3114|NCT04171258|Drug|Botulinum toxin type A injection|Experimental
3115|NCT04171258|Drug|Botulinum Toxin Type A Injection [Botox]|Active Comparator
3116|NCT04171245|Other|Laughie laughter prescription|Creation of a Laughie; laughing with their Laughie 3x a day
3117|NCT04171245|Device|Sleep tracking equipment|Tracking sleep using equipment
3121|NCT04171219|Biological|Pembrolizumab|Given IV
3122|NCT04171219|Drug|Talabostat|Given PO
3123|NCT04171219|Drug|Talabostat Mesylate|Given PO
3124|NCT04171206|Other|Free From Abuse|Participants in the treatment arm will watch a 15-minute talk given by an adult female survivor of IPV who tells the story of her abusive relationship. After watching the video, participants will read information on 10 signs of an unhealthy relationship. The intervention will take approximately 25 minutes to complete.
3125|NCT04171206|Other|Technology and crime|Participants in the placebo control arm will watch a 19-minute talk on technology development and crime. After watching the video, participants will read 10 facts about cyber security. The intervention will take approximately 25 minutes to complete.
3126|NCT04171193|Drug|Isoflurane|Deep anesthesia with isoflurane to achieve burst suppression pattern for more than 80% of the time for 15 minutes measured in electroencephalogram and Bi-Spectral Index
3127|NCT04171193|Drug|Sertraline Pill|Patients that did not respond to Isoflurane treatment, will star on sertraline to evaluate any enhancement in antidepressant efficacy after pre-treatment with isoflurane
3146|NCT04171037|Other|Questionnaire Administration|Ancillary studies
3149|NCT04171024|Device|Transcutaneous diaphragm electrical stimulation|A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes
3150|NCT04171011|Device|Stimulator device|The stimulator device will be used to electrically stimulate the NVB
3151|NCT04170998|Drug|Evogliptin 5mg|Participants receive Evogliptin 5mg orally once a day
3152|NCT04170998|Drug|Evogliptin Placebo|Participants receive placebo to match Evogliptin 5mg orally once a day
3153|NCT04170998|Drug|Dapagliflozin 10mg|Participants receive Dapagliflozin orally once a day
3154|NCT04170998|Drug|Metformin ≥ 1000mg|Metformin are administered at the same dose and formulation.
3155|NCT04170985|Other|clinical Whole Genome Sequencing|Participants will receive cWGS as well as standard of care testing. The clinician/site PI will be blinded to the cWGS results until Day 180.
3156|NCT04170972|Other|Acute exercise|One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
3157|NCT04170959|Drug|Metformin|Metformin 500 mg given 14 days before start until the end of radiation therapy. Once daily during the first 7 days, afterwards twice daily until the end of treatment.
3158|NCT04170959|Other|No metformin|Standard of care without metformin.
3160|NCT04170933|Procedure|Magnetic recanalization|"Establish a percutaneous transhepatic cholangio drainage (PTCD) fistula.~Perform endoscopic sphincterotomy (EST).~Place one magnet above the stricture through the PTCD fistula.~Introduce another magnet below the stricture through the common bile duct with ERCP.~Place the magnets at the appropriate point to attract each other.~The patient will be strictly followed, and the magnets will be taken out out of the mouth by the thread connected with the magnets.~A plastic stent will be placed in the bile duct for lasting support."
3161|NCT04170920|Device|LifeExtend-AI|"LifeExtend-AI (LX-AI) will be piloted by adding AI- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating to-do lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added."
3162|NCT04170907|Other|standardized vaping protocol|The following questionnaires will first be completed: Modified Minnesota Nicotine Withdrawal Scale, Tiffany Questionnaire on Smoking Urges-Brief total (global) craving score, Positive and Negative Affect Schedule. The assigned product will then be given to the participant, and one puff will be taken every 30 seconds (total of 10 puffs). Blood samples will be collected 15 minutes before vaping and 2, 5, 15, 30, 60, 120, and 180 minutes after the last puff. Heart rate and blood pressure will be measured 15 minutes before and 2, 10, 15, 30, 60, 120, and 180 minutes after the last puff. Post-use withdrawal, craving, reward, and satisfaction will be assessed 10 minutes and 1 and 3 hours after the last puff. Respiratory Symptoms will be assessed at baseline and 5 minutes after the last puff. Ten minutes post-use, the direct effects will also be assessed.
3163|NCT04170894|Other|Periods of Apnea|Periods of apnea throughout atrial fibrillation ablation.
3164|NCT04170881|Other|Exposed/non exposed - Epidemiology|visit of daycares and environmental measurement will be performed
3165|NCT04170868|Other|ADHD Psycheducation|The videos will disseminate evidence-based strategies for the management of Attention Deficit Hyperactivity Disorder (ADHD). Each video, roughly two minutes, will both introduce the viewer to a single ADHD management strategy and explain how said strategy can effectively be integrated into their life.
3166|NCT04170855|Drug|Furosemide Injection|"We will measure kidney sodium content in patient with cardiorenal syndrome. we will inject within the week of this first measurement furosemide only in patient who will be resistant to diuretics (Based on these parameters, diuretic response will be defined as:~A reduction in fractional spot urinary sodium~An increase in urinary volume~A >1 kg reduction in body weight within 24 hours from diuretic administration (extrapolation of guidance on management of acute HF) and we will do another measurement of kidney sodium content after furosemide injection."
3167|NCT04170842|Other|Music intervention|Participants will work with the music therapist to make their selections. Music therapists will provide input on how best to synchronise type, tempo and genre of music to the wound dressing procedure. As musical preference is very personal, the choice of music provided will try to strike a balance of providing what is acceptable to patients while not exposing them to music with known stimulatory effects.
3168|NCT04170829|Biological|ChAdOx1 MERS|a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.
3169|NCT04170816|Device|Dry needling|DN and KT therapy will be applied 3 sessions in 1-week intervals
3170|NCT04170803|Device|Dry Needling|The participant will undergo true or sham dry needling treatment with simultaneous monitoring using the NIRS head cap.
3171|NCT04170803|Other|Sham Dry Needling|"The participant randomized to the sham group will undergo placebo dry needling which is functionally mimicking trigger point dry needling"
3172|NCT04170790|Drug|Saxagliptin 5mg|Saxagliptin 5mg oral tablet
3173|NCT04170790|Drug|Sildenafil 50 mg|Sildenafil 50 mg Oral Tablet
3174|NCT04170751|Drug|16 mcg / cc of norepinephrine(group N)|In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
3175|NCT04170751|Drug|0.4 unit / cc of vasopressin(group V)|In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
3205|NCT04170439|Drug|Clomiphene Citrate plus N acetyle cysteine in arm number 1 and chromium in arm number 2|oral adminstration of clomiphene citrate plus N acetyl cysteine or chromium
3177|NCT04170725|Other|Patient and Healthy Volunteers training protocol|Patients and Healthy Volunteers will undergo a 14-day endurance training protocol. No study drugs will be administered. Patients and Healthy Volunteers will be instructed regarding their training protocol. Training sessions will be undertaken on days 1, 3, 5, 7, 9 and 11 after the first examination day. Patients and Healthy Volunteers will be asked to contract their TA muscle repeatedly by pulling the right foot towards the head in a standing position while the heel remains on the ground (at 5 second intervals). In order to carry out the training they will also receive a video demonstrating the exercise. On days 1 and 3 they will do the exercise for 5 minutes, on days 5 and 7 for 10 minutes and on days 9 and 11 for 15 minutes.
3178|NCT04170712|Other|Tampons|Collection of tampons, blood, cervical swabs, tissue and ascites
3179|NCT04170699|Procedure|Port-a-cath replacement|Implantation of a subcutaneous venous port-a-cath
3180|NCT04170686|Behavioral|Zemedy App for IBS|The Zemedy App for IBS is designed to be an engaging, self-help app for people with irritable bowel syndrome. It is based on empirically supported cognitive-behavioral, and GI focused hypnotherapy interventions for IBS.
3181|NCT04170660|Diagnostic Test|Diagnostic test|During a vascular check-up usually prescribed, an additional blood sample is taken to allow the determination of the sFlt1/PlGf ratio.
3182|NCT04170647|Drug|Plasminogen Activators|standard dosage of 0.9 mg/kg or reduced dosage of 0.6 mg/kg, divided into a 15% bolus and an 85% venous infusion
3183|NCT04170634|Other|Evaluation of the fracture risk using data from routine qCT (quantitative Computed Tomography) scan and numerical simulation|Assessment of the mechanical tumor bone strength by numerical simulation using qCT routine imagery of proximal femur (applying a monopodal standing load) and vertebrae (applying a uniaxial compression load).
3190|NCT04170569|Behavioral|Yoga|Yoga Practice and Program: Yoga practice consisted of 10 weeks. Yoga practice involved following stages; 5-minute breathing exercises in standing or sitting position, 40-minute postpartum period specific asanas and last 15- minute deep relaxation in lying position were made by the researcher.
3191|NCT04170556|Drug|Regorafenib|Regorafenib 160 mg/day 3 weeks on and 1 week off
3192|NCT04170556|Drug|Nivolumab|Nivolumab at the dose of 1.5-3 mg/kg every 2 weeks
3193|NCT04170543|Drug|MEDI3506|Dose 1 and Dose 2
3194|NCT04170543|Drug|Placebo|Placebo
3195|NCT04170530|Drug|mFOLFOXIRI|irinotecan* 135 mg/m² + oxaliplatin 68 mg/m² + leucovorin 400 mg/m² + 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
3196|NCT04170517|Diagnostic Test|Measurement of serum progesterone on the day of FET|Measurement of serum progesterone on the day of FET
3197|NCT04170504|Drug|Qing Re Huo Xue (QRHX)|Qing Re Huo Xue (QRHX) XXmg bid for 24 weeks
3198|NCT04170504|Drug|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
3199|NCT04170504|Drug|dummy Qing Re Huo Xue (QRHX)|dummy Qing Re Huo Xue (QRHX) XXmg bid for 24 weeks
3200|NCT04170491|Diagnostic Test|Continuous EEG|Continuous EEGs will be performed with 21 electrodes and polygraphy (ECG and EMG) placed according to the international 10-20 system. In case of extensive neurosurgical defects, a reduced montage may be applied in patients from either group. This information will be added in CRF. The reduced montage in these cases is not expected to reduce the diagnostic accuracy and the outcome, as the neurophysiological changes are generally diffuse and will be detected by adjacent electrodes.
3201|NCT04170478|Device|Echolaser X4 system|Transperineal laser ablation
3202|NCT04170465|Drug|Metformin Hydrochloride 850 mg Tablets|Oral administration of Metformin hydrochloride 850 mg tablets (1700 mg/day) daily until the completion of neoadjuvant chemotherapy cycles
3203|NCT04170465|Drug|AC-T chemotherapy regimen|AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
3204|NCT04170452|Procedure|liver biopsy|Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
3206|NCT04170426|Biological|autologous adipose derived stem cells|Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue
3207|NCT04170413|Drug|CeVUS|Contrast enhanced voiding urosonography
3208|NCT04170387|Other|Relaxometer|Day 1: signing of informed consent, medical history, physical examination, Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R), repetition of 6 minutes relaxometer pre-set programme for 3 times Day 2: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 3: repetition of 6 minutes relaxometer pre-set programme for 3 times Day 8: 6 minutes relaxometer pre-set programme once Day 10: 6 minutes relaxometer pre-set programme once, Mini-Mental State Examination Day 30: Mini-Mental State Examination (MMSE), Fibromyalgia Impairment Questionnaire revised (FIQ-R)
3209|NCT04170374|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
3210|NCT04170374|Other|Interviews with service providers|Clinicians and lay staff will be interviewed regarding the ART initiation process.
3211|NCT04170361|Other|Conventional Chest Physiotherapy|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.
3212|NCT04170361|Other|Conventional Chest Physiotherapy+Incentive Spirometer|All patients will be admitted to physiotherapy rehabilitation program including breathing exercises, modified postural drainage and percussion, lower-upper extremity mobilization exercises and posture exercises once a day during hospitalization. In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals. The program will be started within the first 24 hours and blood pressure, heart rate, oxygen saturation and respiratory frequency will be recorded before and after the sessions. The values obtained from the second session of the patients will be included in the analysis.In addition, patients in the education group will be taught the use of Triflo ® and administered at two-hour intervals.
3213|NCT04170348|Drug|Daily oral vitamin D3, 3,333 IU|Oral vitamin D3, 3,333 IU, will be administered daily.
3214|NCT04170348|Drug|Bolus oral vitamin D3, 100,000 IU|Bolus oral vitamin D3, 100,000 IU, will be administered monthly.
3215|NCT04170348|Drug|Placebo oral tablet|Participants randomized to receive once monthly oral bolus of vitamin D3, will receive placebo on all other days of the month.
3216|NCT04170335|Procedure|Bariatric surgery|Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
3217|NCT04170322|Device|thin pvc gastric tube|a thin pvc gastric tube of 40 Fr for sleeve is used to guide the surgeon
3218|NCT04170322|Device|thick silicone gastric tube|a thick silicone gastric tube 40 Fr for sleeve is used to guide the surgeon
3219|NCT04170309|Drug|Ceftobiprole medocaril|Participants in whom treatment with Ceftobiprole medocaril has been completed
3220|NCT04170296|Drug|EN3835|Collagenase Clostridium Histolyticum (CCH)
3221|NCT04170283|Drug|Zanubrutinib|Participants will receive zanubrutinib at a dose of 160 mg twice daily, or the last dosing regimen in a previous, eligible BeiGene study
3222|NCT04170270|Drug|Omeprazole|"Pre endoscopically: all patients will receive 80 mg omeprazole by 30 minute IV infusion.~After performing upper endoscopy (with initial hemostasis), the patient will be randomly allocated into two groups; group A patients will receive oral omeprazole, while group B patients are intended to receive IV omeprazole.~For patients of group A, omeprazole 40 mg will be administrated orally every 12 hours for 72 hours. Regarding group B, continuous infusion of omeprazole will be administrated at a rate of 8 mg/hour, for 72 hours."
3223|NCT04170257|Diagnostic Test|Endoscopic examination using white light, NBI and iodine staining|Participants' esophagus will be examined by three commonly used diagnostic techniques in the order of : 1. White light endoscopy (WLE); 2. Narrow Band Imaging (NBI) and 3. Iodine Staining Endoscopy (ISE) with 1.2% Lugol's iodine solution. The required observation time is no less than 1 minute for WLE and 2 minutes for NBI and ISE. Endoscopic images of each participant are routinely captured at every 5 centimeters in the esophagus, and information is recorded in detail for each focal lesion. Biopsies are taken from all visually abnormal areas found by any one of the three techniques, histopathologic diagnoses are rendered by two pathologists according to standard criteria and discrepancies are adjudicated by consultation. The recorded endoscopic images for each biopsied lesion are read by two trained researchers and the visualized feature of lesions are decomposed into several indicators (e.g. size, shape, color, and border of lesions) .
3224|NCT04170244|Other|Skin swab|Skin will be swabbed to collect samples for bacterial analysis
3225|NCT04170192|Procedure|Cord Blood Stem Cell Transplantation|Unrelated cord blood stem cell selection; Reduced intensity conditioning regime; GVHD prevention; Infection prevention.
3226|NCT04170179|Procedure|Systemic chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the peripherally inserted central catheter every 3 weeks
3227|NCT04170179|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
3228|NCT04170179|Drug|Toripalimab|240mg intravenously every 3 weeks
3229|NCT04170166|Procedure|Anterolateral subacromial steroid injection|Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
3230|NCT04170166|Procedure|Posterior subacromial steroid injection|Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
3231|NCT04170153|Drug|M1774|M1774 will be administered orally throughout the study.
3232|NCT04170140|Other|No intervention|Questionnaire
3233|NCT04170127|Procedure|Irradiation of implants with 635nm laser|Irradiation of implants with 635nm laser
3300|NCT04169633|Diagnostic Test|Cognitive Function Evaluation|Evaluation of cognitive function and evaluation of daily cognition
3573|NCT04167345|Drug|Placebo|Placebo matched to VX-814 for oral administration.
3234|NCT04170114|Other|Comprehensive Respiratory Physiotherapy|"All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control."
3235|NCT04170101|Procedure|deep NMB|0,6 mg/kg LBW Rocuronium is used to facilitate intubation, and followed by an infusion of 1 mg/kg LBW/h , further adapted to keep PTC < 3
3236|NCT04170101|Procedure|moderate NMB|0,6 mg/kg LBW rocuronium is used to facilitate intubation, not followed by an infusion or extra bolus.
3237|NCT04170088|Drug|Tranexamic Acid|Tranexamic acid intradermal injections were used for treatment of melasma
3238|NCT04170088|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal saline used at other side as placebo
3239|NCT04170075|Behavioral|Whole body vibration (WBV) plus low intensity exercise|Twice daily 10-minute WBV training sessions. Each WBV session will consist of a series of timed stands on the vibration platform (Maryodne, LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats.
3240|NCT04170062|Device|Nasal Delivery of High-Flow Air and Oxygen Therapy|They will receive high-flow air and oxygen via a dual lumen nasal cannula at rest. Participants will be administered the high-flow air and then titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for two minutes. They will then remain on this setting for 10 additional minutes with continuous monitoring of SpO2 levels.
3241|NCT04170062|Device|Nasal Delivery of Oxygen Therapy|They will receive oxygen via a dual lumen nasal cannula at rest. Participants will be titrated with oxygen from 0 L/min until they reach and maintain a SpO2 level of 95% for two minutes. They will then remain on this setting for 10 additional minutes with continuous monitoring of SpO2 levels.
3242|NCT04170049|Behavioral|Sensory Stimulative Activitiy ( proprioceptive intervention, music intervention )|Music intervention: Listening to soft music was found to be an effective method of relaxation, as indicated by a shift of the autonomic balance toward parasympathetic activity. Participants listen to preferred soft music for 30 minutes before sleeping. Proprioceptive intervention: The proprioceptive intervention can activate the parasympathetic nervous system through pathways of the central nervous system, providing calming effects that significantly reduce anxiety, hyperactivity and agitation in various populations.Participants do 10-minute joint compression exercise three times per day by themselves.
3243|NCT04170036|Dietary Supplement|protein supplement|Protein supplement usage for at least three preceding months in varied amounts
3244|NCT04170023|Drug|ACH-0145228|Oral Factor D Inhibitor
3245|NCT04169997|Drug|IMP4927|IMP4297 tablet.The starting dose from 100mg QD
3246|NCT04169997|Drug|Placebos|Placebos tablet.The starting dose from 100mg QD
3247|NCT04169984|Other|Myofunctional Therapy|Isometric, isokinetic and isotonic exercises for the upper airway muscles.
3248|NCT04169984|Other|Placebo|Exercises that do not alter the function or morphology of the upper airway.
3249|NCT04169971|Other|Music|Played through headphones during the operation under spinal anaesthesia
3250|NCT04169958|Other|safe mood|A tablet application that developed for this study. In addition, sensors are used to examine the possibility of using the system to assess the risk of suicide
3251|NCT04169945|Other|Ultrasonic instrumentation|Full mouth root surface debridement
3252|NCT04169945|Other|Air polishing with erythritol powder|Air flow PLUS
3253|NCT04169932|Biological|CD20 CAR-T|The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD20 CART cells per treatment course. The dose escalation test was designed to evaluate the four dose levels of CD20-CART (1 × 10 ^ 6 cells/kg,2 × 10 ^ 6 cells/kg,4 × 10 ^ 6 cells/kg,8 × 10 ^ 6 cells/kg).
3254|NCT04169919|Drug|Povidone-Iodine|Povidone-Iodine 5% eye wash
3255|NCT04169919|Drug|Normal Saline Flush|Normal Saline eye wash
3256|NCT04169906|Drug|Placebo|Participants will receive placebo once daily for 7 consective days
3257|NCT04169906|Drug|TS-142, 10 mg|Participants will receive 10 mg of TS-142 once daily for 7 consective days
3258|NCT04169906|Drug|TS-142, 20 mg|Participants will receive 20 mg of TS-142 once daily for 7 consective days
3259|NCT04169906|Drug|TS-142, 30 mg|Participants will receive 30 mg of TS-142 once daily for 7 consective days
3260|NCT04169893|Drug|Placebo (fasting)|Participants will receive placebo once in fasting condition
3261|NCT04169893|Drug|Placebo (feeding)|Participants will receive placebo once after meal condition
3262|NCT04169893|Drug|1 mg of TS-142|Participants will receive 1 mg of TS-142 once in fasting condition
3263|NCT04169893|Drug|3 mg of TS-142|Participants will receive 3 mg of TS-142 once in fasting condition
3264|NCT04169893|Drug|10 mg of TS-142 (fasting)|Participants will receive 10 mg of TS-142 once in fasting condition
3265|NCT04169893|Drug|10 mg of TS-142 (feeding)|Participants will receive 10 mg of TS-142 once after meal condition
3266|NCT04169893|Drug|30 mg of TS-142|Participants will receive 30 mg of TS-142 once in fasting condition
3267|NCT04169880|Device|HILT|HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.
3268|NCT04169880|Combination Product|HILT & EXERCISE|HILT&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
3269|NCT04169867|Biological|Collection of stool samples|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
3270|NCT04169854|Drug|Lidocaine 5% patch|The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
3331|NCT04169360|Drug|ANS-6637|White, oblong 300 mg tablet
3271|NCT04169854|Drug|Placebo patch|The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
3272|NCT04169841|Drug|olaparib, durvalumab, tremelimumab|"STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing."
3273|NCT04169828|Drug|Methotrexate|Children in both the intervention and control group will receive Methotrexate dose as prescribed by the rheumatologist
3274|NCT04169828|Drug|Ondansetron|"Children in the intervention group will be prescribed premedication with oral ondansetron.~Children in the control group will be prescribed ondansetron ONLY if the child reports nausea/vomiting during regular treatment care with Methotrexate"
3275|NCT04169815|Diagnostic Test|Access Immunodiagnostic Products|Access Natriuretic Peptide Assay
3276|NCT04169802|Diagnostic Test|Retinal Health Monitoring System Visual Acuity Module|Assessment of corrected near visual acuity
3277|NCT04169802|Diagnostic Test|Sloan letter, logarithmic near visual acuity chart (Reference Chart)|Assessment of corrected near visual acuity
3278|NCT04169789|Dietary Supplement|Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)|L.reuteri high or low dose with cholecalciferol compared to cholecalciferol only.
3279|NCT04169776|Device|Transcutaneous Auricular Vagus Nerve (taVNS) stimulation|Participants in this study will perform home transcutaneous auricular vagus nerve stimulation (taVNS) for 5 minutes a day for a 6-month period. The device that will be used is the commercially available Roscoe Medical TENS 7000 vagus nerve stimulator. The device will be attached to the Cymba Concha of the ear via an electrode ear clip. The intensity of the stimulation will be slowly increased and adjusted to individual tolerability for each treatment. TaVNS will be performed for 5 minutes daily for a period of 6 months.
3280|NCT04169763|Drug|Cisplatin|Given IV
3281|NCT04169763|Radiation|External Beam Radiation Therapy|Undergo EBRT
3282|NCT04169763|Drug|Nelfinavir|Given PO
3283|NCT04169750|Behavioral|Exergames|"The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the Wii Fit Plus package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only Zazen (sitting position), Table Tilt and Ski Slalom; thereafter they will add the remaining games Penguin Slide, Tightrope Walk, Balance Bubble and Soccer Heading."
3284|NCT04169750|Behavioral|Adaptive COGNI-TRAcK|"The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an operation N-back task and a dual N-back task.~The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row."
3285|NCT04169750|Behavioral|Sham COGNI-TRAcK|The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.
3286|NCT04169737|Drug|Acalabrutinib|Given PO
3287|NCT04169737|Biological|Obinutuzumab|Given IV
3288|NCT04169737|Drug|Venetoclax|Given PO
3289|NCT04169724|Behavioral|Calm Meditation|10 minutes per day of meditation via the Calm app.
3290|NCT04169711|Drug|ARO-HIF2|Multiple doses of ARO-HIF2 by intravenous infusion
3291|NCT04169698|Drug|Denosumab 60 mg/ml [Prolia]|full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand
3292|NCT04169698|Drug|Alendronate 70Mg Tab|Bisphosphonates
3293|NCT04169685|Procedure|bronchoscopy|during flexible bronchoscopy
3294|NCT04169672|Drug|Surufatinib|Surufatinib is a tablet in the form of 50mg, oral, once a day.
3295|NCT04169672|Drug|Toripalimab|Toripalimab is an injection in the form of 240mg, intravenous, once three weeks.
3296|NCT04169659|Device|Kyphoplasty with insertion of Sctructured Titanium Microspheres|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce structured titanium microspheres until the dome is full of material.
3297|NCT04169659|Device|Kyphoplasty with Polimethylmetacrilate (convetional surgery)|Under fluoroscophy, we introduce a transpeduncolar trocar inside the vertebral body where is performed a kyphoplasty with insertion of baloons. When the dome is cretated we introduce Polimethylmetacrilate until the dome is full of material.
3298|NCT04169646|Other|Multi-component intervention|Participants' workstation ergonomics will be assessed using an observation-based ergonomics assessment checklist for office-workers adapted to Swiss guidelines. Based on the initial assessment, best practice ergonomics will be applied individually using existing infrastructure. Participants will attend health promotion information group workshops for approximately one hour per week for 12 weeks. it. Participants will receive an individual progressive exercise programme aimed at conditioning the muscles of the neck and shoulder girdle. The exercises will be performed in groups (maximum of ten per group) at the workplace in a dedicated room, for approximately one hour (3x20 minutes) per week; once per week supervised by a physiotherapist, a human movement scientist, or a health scientist, and twice per week individually. Workshop session attendance will be recorded as an indication of adherence to health promotion. Adherence to neck exercises will be recorded with the Physitrack® app.
3299|NCT04169646|Other|Control|No intervention takes place during the control phase.
3301|NCT04169620|Other|aquatic Ai Chi|"The sessions took place in a pool measuring 20 m x 6 m, at a depth of 110 cm. The water temperature was 30oC (with variations of less than 0.5o) and the room temperature was 27.5oC (with variations of less than 1o). The proportions of the pool were ideally suited for collective treatment.~The sessions were designed with a gradual increase in difficulty. Initially, a recreational warm-up activity was performed, followed by 30 minutes dedicated to practicing the Ai Chi Program. At the end of the session there was a calming down activity. The exercises were performed in a specific order, until completion of the 19 possible movements."
3302|NCT04169620|Other|control|These sessions consisted of group sessions of supervised training lasting 45 minutes each. These comprised a 10-minute warm-up that included exercises for gait, trunk mobility and exercises involving the upper and lower limbs. The central part of the sessions consisted of 30-40 minutes of strength training and aerobic exercises, both individual and in groups. Each session was performed with a specific intensity goal, in order to end with a cooling down period, comprising 20 minutes of functional exercises based on activities of daily living, balance exercises, facial muscle exercises, proprioceptive exercises, muscle relaxation and stretching.
3303|NCT04169607|Procedure|Dynamic compliance guided individualized positive end-expiratory pressure titration strategy|"Chest computerized tomography（CT） one day before surgery to assess percentage of atelectasis~Bacis ventilation: Volume-controlled ventilation(VCV) mode with positive end expiratory pressure（PEEP） of 8cm H2O after induction of anesthesia，~Recruitment maneuver (RM): Pressure-controlled ventilation (PCV) mode increasing PEEP from 10 to 25cmH2O in step of 5cmH2O per 30s.~PEEP-titration maneuver:ventilation parameters reset as bacis ventilation with PEEP still 25cmH2O.Decrease PEEP to 5cmH2O in step of 2cmH2O per 10 respiratory cycles to confirm the highest dynamic lung compliance(Cdy).~After titration:A new RM will be performed and the final PEEP will be the one related to highest Cdy plus 2cm H2O.~Randomized after the second RM.Individualized PEEP arm:maintain PEEP;PEEP8 arm:reduce PEEP to 8cm H2O.~VCV with other ventilation parameters the same as basic ventilation until extubation .~After discharged from postoperative anesthesia care unit（30-60 minutes）：chest CT ."
3304|NCT04169594|Diagnostic Test|3D Gait Analysis with Statistical Parametric Mapping|A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
3305|NCT04169568|Procedure|Manuel cuff blood pressure|Blood pressure will be obtained using a sphygmomanometer. Only Registered Nurses will apply BP cuff after careful inspection of the upper extremity for bruising, swelling or tenderness.
3306|NCT04169555|Procedure|Ultrasound|"The emergency physician will perform a point of care ultrasound. If signs of expansions of the pelvicalyceal cavities are found, an early CT scan will follow"
3307|NCT04169555|Other|Standard care|Standard clinical care of patients. In regards of the clinical evolution and of biological results, a CT scan could be performed by the physician.
3308|NCT04169542|Other|Diary|Complete cost diary
3309|NCT04169542|Other|Questionnaire Administration|Complete questionnaires
3310|NCT04169529|Device|Reveal LINQ|Insertion of Reveal LINQ device to characterize collected data from patients with COPD.
3311|NCT04169516|Diagnostic Test|index of microcirculatory resistance|Physiological parameters of the culprit artery after PCI were determined with the restoration of Thrombolysis in Myocardial Infarction (TIMI) 3 flow. Aortic pressure (Pa), distal intracoronary pressure (Pd), fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) were measured using a 0.014 coronary temperature and pressure-sensing guidewire (PressureWireCertus, ST. Jude Medical, MN, USA).
3312|NCT04169503|Drug|Immune Checkpoint Modulator|identification of cases of immune-related adverse events due to immune checkpoint inhibitors. Among these cases, identification and description of those with immune checkpoint inhibitor rechallenge.
3313|NCT04169490|Other|Placebo Cream Base Emulsion Moisturizer|Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days
3314|NCT04169490|Other|FS2 Emulsion Moisturizer|Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
3315|NCT04169490|Other|Active Comparator Onion Skin Extract Gel (Mederma)|Topical onion skin extract gel (Mederma) applied b.d. for 120 days
3316|NCT04169490|Other|Active Comparator Silicone Gel (Kelo-Cote)|Topical silicone gel (Kelo-Cote) applied b.d. for 120 days
3317|NCT04169490|Other|Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer|Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
3318|NCT04169477|Device|CEFAR Primo Pro (TENS device)|"During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS.~[Cross-over] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day.~In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer."
3319|NCT04169464|Drug|Sofosbuvir Oral Product|to investigate the drug effect on renal function and insulin resistance
3321|NCT04169438|Other|Vehicle Cream Base Emulsion Moisturizer + Petrolatum|Topical vehicle white (bone) color, oil/water emulsion moisturizer.
3322|NCT04169438|Other|FS2 Emulsion Moisturizer + Petrolatum|Topical FS2 white (bone) color, oil/water emulsion moisturizer.
3323|NCT04169425|Procedure|elective diverting ileostomy|
3324|NCT04169412|Diagnostic Test|Blood Collection|Blood Gas Analysis using Stat Profile pHOx® Series (nova biomedical, Waltham, U.S.) and Enzym-linked Immunosorbent Assay (ELISA) using Bio-Rad (Bio-Rad Laboratories, California, U.S.)
3325|NCT04169399|Drug|Toripalimab|240mg intravenously every 3 weeks
3326|NCT04169399|Radiation|Stereotactic body radiotherapy|Radiotherapy dose was 36 ~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
3327|NCT04169386|Drug|AK102|AK102 single dose administered subcutaneously
3328|NCT04169386|Drug|Placebo|Placebo single dose administered subcutaneously
3334|NCT04169334|Behavioral|Prolonged planned program for the stay at the obstetric department|A five day planned and designed program delivered to the family while at the obstetric department.
3335|NCT04169321|Drug|Single Arm|[68Ga]-NOTA-hGZP is a PET imaging agent.
3336|NCT04169308|Drug|Restylane-L® Filler injection|Restylane-L® Filler injection into the soft tissue of the nose
3337|NCT04169295|Other|Gynecologists' feedback on ART-Birth rates|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo, the number of cryopreserved embryos, the quality rating of the transferred embryo's and couple's personalized IVF-prognosis (i.e. their chance on a live birth from the current IVF-cycle, including the transfer of fresh and if available cryopreserved embryos), calculated by entering eight background characteristics and five IVF-laboratory results into a prognostic model.
3338|NCT04169295|Other|Control group|At the time of their fresh embryo transfer couples will receive a document with the following feedback: a photo of their transferred embryo and the number of cryopreserved embryos
3339|NCT04169282|Device|nPEP (non-invasive positive expiratory pressure) mask|Positive end expiratory pressure (PEEP) mask
3340|NCT04169269|Drug|Enoxaparin 40 milligram/0.4 milliliter Injectable Syringe 0.4 milliliters|anticoagulant, subcutaneous injection
3341|NCT04169269|Drug|Rivaroxaban 10 milligram Oral Tablet|anticoagulant, oral
3342|NCT04169256|Drug|HYR-PB21|HYR-PB21 for injection 100mg, 200mg,or 400mg by single subcutaneous injection on the abdomen
3343|NCT04169256|Drug|Liposomal bupivacaine|Liposome Bupivacaine Suspension for injection 200mg by single subcutaneous injection on the abdomen
3344|NCT04169256|Other|Normal Saline|Normal Saline 30ml, or 40mL by single subcutaneous injection on the abdomen
3345|NCT04169243|Behavioral|New Nordic Diet|The New Nordic Diet conforms with the Nordic Nutrition Recommendations and incorporates environmental sustainability and planetary health. It includes rapeseed oil, whole grain bread, wild fish, seafood and game, potatoes, root vegetables, cabbages, Nordic fruits and berries. Women will be given advice on this diet by registered dietician. Every second wk, women are contacted through text messages to send blood glucose values and receive feedback.( All Swedish women developing gestational diabetes receive HemoCue within usual care for blood glucose monitoring.)
3346|NCT04169243|Other|Control|The control women receive diet advice according to usual care, which may be a short meeting with the regular midwife or a short meeting with a dietician.
3347|NCT04169230|Drug|Citalopram|Single dose administration of citalopram (20mg)
3348|NCT04169230|Drug|Placebo oral tablet|Single dose administration lactose placebo tablet
3349|NCT04169217|Behavioral|Prehabilitation|A combination of on off workshop and mentored prehabilitation
3350|NCT04169204|Diagnostic Test|Measurement of microcirculation|As a simple clinical test, every patient will receive the assessment capillary refill time and mottling-score. Additionally, repetitive measurements of lactate will be done. The SDF-camera (MicroVision Medical®, Amsterdam, Netherlands) will measure sublingual microcirculation at different time points (Admission and 24h).
3351|NCT04169191|Drug|Sildenafil Citrate|Cohort 1 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, and subsequent doses of 2.5mg/kg/dose q12h (= 5 mg/kg/day from dose #2) Cohort 2 of 3-6 neonates: 1st dose of 2mg/kg/dose, 2nd dose of 2.5 mg/kg/dose, 3rd dose of 3mg/kg/dose, and subsequent doses of 3mg/kg/dose q12h (= 6 mg/kg/day from dose #3) dose expansion phase in up to 5-15 asphyxiated neonates
3352|NCT04169178|Drug|HLX55|A humanized IgG2 monoclonal antibody targeting tyrosine-protein kinase MET (c-MET)
3353|NCT04169152|Procedure|Cap-assisted endoscopic sclerotherapy|Cap-assisted endoscopic sclerotherapy (CAES) is an innovation technique for having advantages in accurately controlling the injection angle, direction, depth under direct vision of flexible endoscope.
3354|NCT04169139|Device|MIST (minimally invasive surgical therapy)|REPaiR Periodontal Therapy
3355|NCT04169126|Drug|F-18 PMPBB3|The study will enroll 200 patients with prodromal AD and AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
3356|NCT04169113|Other|Group 1 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
3357|NCT04169113|Other|Group 2 - Opiate Tablets post Hip Arthroscopy|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
3358|NCT04169100|Drug|Prednisone|We propose to test whether QT prolongation is reversible with moderate doses of prednisone in patients with QT interval greater than 500 msec.
3359|NCT04169087|Other|QoR-15|The QoR-15 is the questionnaire to provide an evaluation of the postoperative quality of recovery. Patients undergoing surgery and general anesthesia are asked by the investigators to complete the QoR-15 questionnaire before and 24h after the surgery.
3360|NCT04169074|Drug|Abemaciclib|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Nivolumab will be administered on days 1 and 15 in arm 2 only. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
3361|NCT04169074|Drug|Abemaciclib plus nivolumab|Treatment will consist of a single neoadjuvant cycle of 15-21 days (+7 days). Abemaciclib will be administered from days 1-21 in both arms. Nivolumab will be administered on days 1 and 15 in arm 2 only. Abemaciclib may be continued for an additional 7 days, or up to 28 days, for delays in planned surgery.
3362|NCT04169061|Drug|Acthar|Acthar gel for subcutaneous injection
3363|NCT04169048|Behavioral|Group training for mothers with Borderline Personality Disorder|The group programme is designed to teach mothers with BPD parenting skills and to reduce dysfunctional parenting attitudes and strategies. The components are: childrens basics needs, mindfulness, stress and stress reduction, dealing with conflicts, dealing with emotions, dysfunctional attitudes, physical contact, parenting rules, self care.
3364|NCT04169035|Device|The BD Odon DeviceTM is a new device for AVB that has been designed by a team of midwives, doctors and engineers.|The BD Odon DeviceTM works by placing a cuff of air attached to a plastic sleeve, around the baby's head. The doctor then gently pulls on this sleeve and air cuff to assist the birth of the baby.
3396|NCT04168723|Drug|Moxifloxacin 400mg|Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
3574|NCT04167319|Other|QST and PRO measurements during treatment|We will observe the natural course of CIPN using multiple measurements
3365|NCT04169035|Procedure|forceps or ventouse|"The woman is unable to have an Odon assisted birth as no Odon trained practitioner is available to assist the birth.~Forceps is a metal instrument with two handles used to encircle a baby's head and assist in birth.~Ventouse is a device used to help a baby be born by putting it over the baby's head and using suction (= removing air) to pull the baby out of the mother's body."
3366|NCT04169022|Other|Sample collection|Sample collection blood and/or bone marrow
3367|NCT04169009|Biological|Zostavax|Intradermal injection of Zostavax
3368|NCT04169009|Biological|Shingrix|Given to subjects in Arm 4 who've never had a herpes zoster vaccine
3369|NCT04168996|Behavioral|Individualized discharge planning|Discharge planning is designed to ensure healthcare continuity, avoid preventable poor outcomes among at-risk populations, and promote the safe and timely transfer of patient care. The individualized discharge planning is characterized to take into account the preferences, interests and clinical profile of each patient.
3370|NCT04168983|Other|sophrology|Sophrology session provided by a nurse sophrologist in addition to the usual care during BMAB
3371|NCT04168970|Procedure|PSGB|Percutaneous stellate ganglion block: injection of 10 mL of local anaesthetic (lidocaine 2%) at the C6 level using the anatomic technique or the echo-guided technique The anaesthetic that will be used for PSGB is lidocaine.
3372|NCT04168957|Drug|Oraxol|"Oraxol (Oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets"
3373|NCT04168944|Drug|Lenvatinib|Patients in the lenvatinib group are given lenvatinib within 1-2 months after operation
3374|NCT04168944|Drug|Placebo|Sugar pill manufactured to mimic Lenvatinib 10mg tablet
3375|NCT04168944|Drug|Immunosuppressive regimen|Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus
3376|NCT04168931|Drug|Trastuzumab|The first-line standard treatment for gastric cancer is based on fluoropyrimidine and platinum-containing chemotherapy (FOLFOX). When the tumor expresses HER2 3+ on IHC or 2+ and is confirmed by FISH, trastuzumab at the standard dose of 8 mg / kg in D1 of the first cycle is added, followed by 6 mg / kg every 2 weeks for the remaining cycles until disease progression, unacceptable toxicity. (3) We will use the same doses of trastuzumab, but HER2 positivity is determined by immunocytochemical expression and FISH in CTCs for patients with negative expression in tissue biopsy.
3377|NCT04168918|Behavioral|Group psychological Intervention|There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
3378|NCT04168905|Device|AOTI Inc. TWO2 topical oxygen therapy equipment|Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
3379|NCT04168892|Drug|150 IU of HMG in patients with age ≤ 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
3380|NCT04168892|Drug|225 IU of HMG in patients with age > 35 years|The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
3381|NCT04168879|Drug|Bupivacaine 0.5% Preservative-Free Injectable Solution|1.5 ml of Bupivacaine 0.5% Preservative-Free Injectable Solution used transnasally to block the sphenopalatine ganglion
3382|NCT04168879|Drug|normal saline|1.5 ml of normal saline is delivered transnasally to the sphenopalatine ganglion
3383|NCT04168866|Procedure|Operative management|Surgery for computer tomography (CT)-proven complicated appendicitis with phlegmon or abscess.
3384|NCT04168866|Other|Drainage or antibiotics|If an abscess is present and amenable to percutaneous drainage this will be performed. If there is no abscess or it is not amenable to drainage antibiotics alone will be provided.
3385|NCT04168853|Diagnostic Test|vascular reactivity of internal thoracic arteries|"Internal thoracic arteries analysis Myography Superoxide detection and confocal microscopy Immunochemistry Quantitative real time transcription-polymerase chain reaction (RT-PCR) analysis~Blood sampling and biochemical analysis"
3387|NCT04168827|Behavioral|Questionnaire|Questionnaire completed by the parents of severe traumatized child, between 3 to 6 months after the leaving of the child out of intensive care unit
3389|NCT04168801|Dietary Supplement|early oral refeeding|Once the patient had a score of 1-3 of the analogue numerical scale (ENA), he was interrogated about symptoms such as nausea or vomiting, receives diet indicated between 16 and 24 hours after admission.
3390|NCT04168788|Other|Blood test for genetic analysis|Drawing blood to realize a genetic analysis for susceptibility to hepatic VOD.
3391|NCT04168775|Other|Home PIFR monitoring with InCheck Dial|The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
3392|NCT04168762|Other|Transcranial Ultrasound Magnetic Stimulation|Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
3393|NCT04168749|Combination Product|Numeta G13|10 days
3394|NCT04168736|Other|Feasibility and Acceptability of Genetic Counseling Materials|"To determine the feasibility and acceptability of a communication aid in sharing genetic test results with family members.~To determine the utility of a communication aid in sharing information. To determine the impact of patient focused information sheets on patient knowledge of genetic testing."
3395|NCT04168723|Drug|MD1003|Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
3397|NCT04168723|Drug|Placebo for MD1003|Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
3398|NCT04168723|Drug|Placebo for moxifloxacin|Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
3401|NCT04168697|Behavioral|Wim Hof method|8-week behavioral modification intervention instructing the participants in a combination of breathing exercises, cold exposure and meditation
3402|NCT04168684|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|Manualized intervention implemented in home with parent and child present focused on parental responsiveness
3403|NCT04168684|Behavioral|Developmental Education for Families (DEF)|Manualized intervention implemented in home with parent and child present focused on parental enhancement of child learning
3404|NCT04168671|Diagnostic Test|Continuous laryngoscopy during exercise test|Continuous laryngoscopy during exercise test
3405|NCT04168658|Combination Product|Physical activity and education intervention|"At least six staff from each nursing home that assigned to the intervention group will be invited to attend two educational workshops. Participants in the intervention group will receive the following interventions.~Face-to-face workshops: Five 1-hour educational workshops on physical activity will be delivered in months 1, 3, 5, 7 and 9 of the program held at each nursing home.~Booklet: At the first educational workshop, each participant will be provided with a pictorial booklet.~Exercise: The physical activity training consists of 50-60 min exercise sessions three times a week on non-consecutive days for 12 months.~Others (newsletters, phone calls, and reminders): The intervention group will also receive newsletters containing myth dispelling information on osteoporosis and physical activity, motivational phone calls and a total of 52 SMS via mobile phones (reminders to attend workshop sessions and physical activity motivating messages) over 12 months."
3406|NCT04168658|Behavioral|Education intervention|Participants in the control group will only receive educational materials (i.e. face-to-face workshops and booklet) and will be wait listed to receive no other interventions of this study until after the post-intervention.
3407|NCT04168645|Behavioral|Cognitive Behavioral Therapy|Up to 4 sessions of CBT (depending on length of stay) will be provided. The first session lasts 1.5 hours and subsequent sessions are 1 hour. During these sessions, the therapist will work with patients to conceptualize their suicide attempt, develop a crisis response plan, and learn coping strategies.
3408|NCT04168632|Other|OPTIMAT|The intervention was to serve a new school lunch menu plan as similar as possible to a baseline menu plan but 40% lower in greenhouse gas emissions, being nutritionally adequate and no more expensive.
3409|NCT04168619|Drug|Discontinue methotrexate|According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
3410|NCT04168619|Other|Medication depends on clinical judgement|Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
3411|NCT04168593|Procedure|Acupuncture|20 min of Acupuncture section follow by 10 min of cupping around the knee
3412|NCT04168580|Other|V02 max test/stress test|Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test.
3413|NCT04168580|Other|MRI|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method. MRI scans will be performed on a Philips 3T using axial, coronal, and sagittal slice orientations to provide anatomical reference scans in the neck and body area. Quantitative mDixon scans will be used for calculating proton density fat fraction (PDFF) maps.
3414|NCT04168580|Other|Dual Energy X-Ray Absorptiometry (DEXA)|DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric (GE) Lunar iDXA whole-body scanner.
3415|NCT04168580|Other|Handgrip strength test|All participants will perform a hand grip test that will be conducted three times with 1 minute of rest between each repetition using the dominant hand of each participant. The greatest grip strength and the average of the three tests will be recorded.
3416|NCT04168580|Other|Lower extremity performance battery|The Short Physical Performance Battery (SPPB) is a brief performance-based test that will be used to measure lower extremity performance. The SPPB consists of three tasks: five repeated timed chair stands, timed standing balance (with feet in parallel, semi-tandem, and tandem positions), and a 4-meter walk to determine usual gait speed.
3417|NCT04168580|Other|Step Test|Each participant will be asked to complete a timed step test
3418|NCT04168580|Other|Resting Metabolic Rate/Respiratory Quotient (RMR/RQ)|Indirect calorimetry will used at two times during the hyperinsulinemic-euglycemic clamp to measure the resting metabolic rate/respiratory quotient (RMR/RQ) and substrate utilization using a MAX II Metabolic cart (AEI Technologies, Pittsburgh, PA).
3419|NCT04168580|Other|Hyperinsulinemic-euglycemic clamp|After an overnight 8-hour fast, an intravenous catheter will be placed in the vein for infusion of insulin and glucose. A second catheter will be placed in the vein of the contra-lateral arm for blood withdrawal.
3420|NCT04168580|Other|Exercise Training Intervention|Older sedentary participants will undergo 8 weeks of exercise training. The exercise program will be supervised by a certified exercise physiologist and will take place at the AdventHealth Translational Research Institute (TRI) exercise training facility. Exercise compliance will be monitored for exercise training 4 days per week (32 total sessions). Aerobic training will be 30 minutes of brisk walking, jogging, cycle ergometry. Walking will be the primary mode of aerobic exercise given its widespread popularity and ease of administration across a broad segment of the older adult population. Walking will be at a moderate intensity and determined based on Heart Rate (50-70% of Maximal Heart Rate from most recent VO2max) and rating of perceived exertion using Borg's scale (ranges from 6 to 20).
3462|NCT04168190|Drug|pPCV|Single 0.5 or 1.0 mL IM injection
3421|NCT04168580|Other|Post-Intervention Testing|Following the exercise training intervention, participants in the OA group will participate in post-intervention testing.
3422|NCT04168567|Diagnostic Test|Microbiome analysis|Samples from the vagina, endometrium and anus and analyzing microbiome with NGS technique.
3423|NCT04168554|Device|Telemedicine|Patient is examined using telemedicine
3424|NCT04168541|Other|Oral Nutrition Supplement|Product intake of oral nutrition supplement provided
3425|NCT04168528|Drug|68GaNOTA-Anti-MMR-VHH2|Injection of the radiopharmaceutical and PET/CT imaging
3426|NCT04168502|Drug|Glasdegib|After randomization patients in both arms will be randomized to maintenance with glasdegib vs clinical observation
3427|NCT04168502|Drug|Gemtuzumab Ozogamicin|Both arms, before randomization, will receive induction and consolidation with Gemtuzumab ozogamicin, Daunorubicin and Cytarabine
3428|NCT04168489|Device|active rTMS|(rTMS) is received preliminary approval because of its noninvasive and safe analgesic effect.
3429|NCT04168489|Device|sham rTMS|The sham rTMS is inactive and similar to placebo effect.
3430|NCT04168476|Other|Interscapular muscle release or scapular mobilization technique as described by Travell and Simons.|"Patient is sidelying with the testing side up. The auditor stands in front of the patient, reaches over the patient's shoulder to grasp the upper portion of the vertebral border of the scapula, and the other arm reaches under the patient's humerus to grasp the lower portion of the vertebral border of the scapula.~The auditor then slowly moves the scapula into elevation/depression, internal/external rotation/abduction and adduction.~To standardize the technique and be able to reproduce it in each participant, a set of 10 repetitions for each movement was performed in the same order."
3431|NCT04168476|Other|Calcaneus abduction and adduction mobilization technique|Abduction and adduction mobilization of the calcaneus is carried out in the opposite side of the upper extremity measured.
3432|NCT04168463|Device|Two Joy for All robots (one cat and one dog)|Intervention will include the opportunity to interact with the Joy for All robot animals.
3433|NCT04168450|Other|WiSAT System, Passive Feedback|The WiSAT system is installed in the participant's wheelchair cushion and a smartphone application is installed on his/her cellphone. Participants are able to view the application as they please and they will receive no notifications from the app regarding their movement goals.
3434|NCT04168450|Other|WiSAT System, Active Feedback|The WiSAT system is installed in the participant's wheelchair cushion and smartphone application is installed on his/her cellphone. Participants receive notifications from the app to help them meet their movement goals.
3435|NCT04168437|Other|Health-Related Quality of Life Report|Two page report and interpretation guide based on SPADE cluster scores
3436|NCT04168424|Other|no intervention|Completing the questionnaire for health-related resource use in the elderly population (FIMA) by the elderly people
3437|NCT04168411|Procedure|Symptomatic Treatment|Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
3438|NCT04168398|Drug|Combination drug|Anticoagulation
3439|NCT04168385|Drug|Maralixibat|Maralixibat oral solution (up to 900 mcg/kg) orally twice daily
3440|NCT04168372|Other|High fructose, fructose labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C fructose
3441|NCT04168372|Other|High fructose, pyruvate labeled meal|Liquid meal containing high fructose (16% of energy), labeled with 2-13C pyruvate
3442|NCT04168372|Other|Low fructose, fructose labeled meal|Liquid meals containing low fructose (6% of energy), labeled with 2-13C fructose
3443|NCT04168372|Other|Low fructose, pyruvate labeled meal|Liquid meal containing low fructose (6% of energy), labeled with 2-13C pyruvate
3444|NCT04168359|Device|absorbable semi-barbed suture|Positioning the intrapulmonary nodules of patient in this group with a absorbable semi-barbed suture positioning device
3445|NCT04168346|Drug|Ferric carboxymaltose|Ferric carboxymaltose iv infusion
3446|NCT04168346|Drug|Placebos|NaCl 0.9% infusion
3447|NCT04168333|Biological|T101 Group|"Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15."
3448|NCT04168333|Biological|Placebo Group|"Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15."
3449|NCT04168320|Radiation|SBRT-PATHY (SBRT-based PArtial Tumor irradiation targeting HYpoxic segment)|Novel stereotactic high-dose partial irradiation of the hypoxic segment of bulky tumors.
3450|NCT04168307|Device|Ankle trainer device|The ankle trainer provides passive stretch in dorsal flexion of the ankle as well as active plantar flexion.
3451|NCT04168307|Other|Conventional physiotherapy|The patients were instructed in stretching exercises using a non-elastic band
3452|NCT04168294|Drug|Propofol|patients in sedation group will be intravenous injected propofol in bolus
3453|NCT04168294|Device|endoscopy|endoscopy system
3454|NCT04168281|Diagnostic Test|Magnetic resonance imaging (MRI)|instead of PCI patients will be followed-up with MRI
3455|NCT04168255|Procedure|Double tamponade|Double tamponade procedure in retinal detachment with PVR and inferior breaks
3456|NCT04168242|Device|Scalp cooling Paxman Orbis II system|The experimental arm will have scalp cooling that starts 30 minutes before the chemotherapy, continues throughout the infusion of the chemotherapy, and lasts for 20-90 minutes more depending on the type of regimen.
3457|NCT04168242|Other|Standard treatment|The control arm will not have scalp cooling before, during and after chemotherapy.
3458|NCT04168229|Device|Mermaid 9 ITE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and receiver housed in an in-the-ear hardware.
3459|NCT04168229|Device|Mermaid 9 BTE|A Hearing aid intended to amplify sounds and deliver them to the ear with a microphone and Receiver housed in a behind-the-ear hardware.
3460|NCT04168203|Drug|Apixaban 2.5 MG|apixaban 2.5 mg orally twice daily for a duration of 12 months
3461|NCT04168203|Drug|Placebo oral tablet|placebo oral tables twice daily for a duration of 12 months
3466|NCT04168164|Other|aquatic therapy|The exercises of Ai Chi were performed in a specific order, until completion of the total possible movements.
3467|NCT04168164|Other|Dry land therapy|sessions including exercises for gait, trunk mobility and exercises involving the upper and lower limbs
3468|NCT04168164|Other|Combined therapy|alternate sessions of therapy on dry land and aquatic therapy with Ai Chi
3469|NCT04168151|Other|lung recruitment protocol|lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
3470|NCT04168138|Drug|rhTPO|D: Decitabine(15mg/m2) d1-5 G: G-CSF（300ug/d） d0-9(stop using when White Blood Cell (WBC)>20*109/L) T: rhTPO(15000U/d) d3,5,7,9, d11- (Platelet>50*109/L) A: Aclarubicin(10mg/d) d3-6 C: Cytarabine(15mg Q12h) d3-9
3471|NCT04168125|Device|Tilapia skin|Application tilapia skin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
3472|NCT04168125|Device|Platelet-Rich Fibrin|Application Platelet-Rich Fibrin as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
3473|NCT04168125|Device|Hawley Retainer|Application Hawley Retainer as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
3474|NCT04168125|Device|Surgical Wound Dressing|Application surgical wound dressing as an occlusive biological dressing for palatal wound healing after free gingival graft harvesting.
3475|NCT04168112|Drug|Dextenza|Placement of intracanalicular dexamethasone insert for post-crosslinking inflammation and pain
3476|NCT04168112|Drug|Prednisolone Acetate|post-crosslinking eye drop prednisolone acetate given in a tapering schedule over 1 month
3477|NCT04168099|Drug|Cefotaxime|Cefotaxime IV
3478|NCT04168099|Drug|Gemifloxacin|Gemifloxacin oral
3479|NCT04168086|Other|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
3480|NCT04168086|Other|Sham|The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
3481|NCT04168073|Other|High-sodium diet 300 mmol sodium/day|Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
3482|NCT04168073|Other|Low-sodium diet 10 mmol sodium/day|Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
3483|NCT04168060|Procedure|Crura dissection|The diaphragmatic crura, one of two tendon structures below the diaphragm, will be removed during the laparoscopic sleeve gastrectomy.
3484|NCT04168060|Procedure|Sleeve gastrectomy|Surgical weight-loss procedure in which the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.
3485|NCT04168060|Procedure|Hiatal hernia repair|This involves tightening the opening in your diaphragm with stitches to keep your stomach from bulging upward through the opening in the muscle wall.
3486|NCT04168047|Procedure|Barostat procedure|Pressure threshold will be measured during the barostat procedure
3487|NCT04168047|Other|Anxiety and Depression Evaluation|Anxiety and Depression will be measured using HAD anxiety and depression scale
3488|NCT04168047|Other|Assessment of sleep quality|Sleep quality will be measured using Pittsburg sleep quality index
3489|NCT04168034|Behavioral|iParent2Parent Program|In addition to standard care, parents in the experimental group will receive the iParent2Parent program. The iParent2Parent program is a tailored peer mentorship program that provides modeling and reinforcement by peers (trained parents of children with JIA) to parents of children diagnosed with JIA.
3490|NCT04168034|Behavioral|Waitlist Control|The control group will receive standard care but without the iParent2Parent program
3491|NCT04168021|Behavioral|Leg ischemia|potential neuroprotection of ischemia/reperfusion of a peripheral organ or tissue against cerebral I/R injury
3492|NCT04168008|Behavioral|WISH Adherence|The educational sessions will consist of an adherence-centered curriculum.
3493|NCT04168008|Behavioral|WISH Parenting|The educational sessions will focus on parenting and baby care.
3494|NCT04167995|Drug|Probiotic Formula lacteal forte|Active Comparator: Patient with attention deficit hyperactive disorser patients (n=40) will receive probiotic preparation once daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
3495|NCT04167982|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
3496|NCT04167982|Drug|Oral conventional-dose isotretinoin|Conventional-dose isotretinoin
3497|NCT04167982|Drug|Oral low-dose isotretinoin|low-dose isotretinoin
3498|NCT04167969|Drug|(64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots|Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.
3499|NCT04167969|Diagnostic Test|PET/MRI|Imaging will be performed using the GE Signa PET/MRI.
3500|NCT04167969|Other|Blood and urine sampling|Staff will perform the IV blood draws and collect urine samples
3501|NCT04167969|Procedure|laparoscopic radical prostatectomy and bilateral pelvic LN dissection|Surgery will be performed within 24 h of the third PET/MRI scan.
3502|NCT04167956|Device|ultrasound and CT|Experimental: ultrasound combined with CT guided Active Comparator: CT guided
3504|NCT04167930|Other|electronic medical record(EMR) Data and patient survey|"Retrospective Data Collection (1) Neck Disability Index (NDI), Oswestry Low Back Disability Index(ODI), euroqol-5 dimension(EQ-5D) scores during hospitalization (2) symptom onset date, symptom onset motive, past history, accident occurrence date, accident treatmen termination agreement date, etc.~Question items (consistent with the case record) according to the purpose of the investigation (1) General: Demographic sociological characteristics (gender, age, occupation, income, etc.) (2) Matters concerning the correlation between traffic accident agreements and symptoms"
3505|NCT04167917|Drug|NTX-301|oral hypomethylating agent
3960|NCT04164459|Drug|Xalatan|One drop one times a day in study eye
3506|NCT04167891|Diagnostic Test|Calculation of early prognosis score|Early prognosis score will be calculated at intensive care unit admission for each patient based on clinical and biological values as required
3509|NCT04167865|Other|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
3510|NCT04167852|Behavioral|Daily text message|Patients will receive a daily text message stating how many days they have until or since their surgery.
3511|NCT04167852|Behavioral|Mindfulness intervention|Patients will receive a link to mindfulness meditation intervention for ten minutes.
3512|NCT04167839|Other|Sensory diet|Sensory diets are one of the interventions occupational therapists use in school-based settings to manage manifestations of sensory processing disorder. Sensory diets are composed of exercises and multisensory activities that are tailored for children and provide them sensorimotor experiences to facilitate their participation in daily activities.
3513|NCT04167813|Drug|Ondansetron 8mg or matched placebo|Participants will take 8-24mg/day of ondansetron or matched placebo. The dose will increase from a single daily 8mg tablet (AM) (weeks 1 and 2), to 16mg/day (8mg twice daily) (weeks 3 and 4), with a further increase to 24mg/day (8mg AM, 16mg PM) (weeks 5 and 6).
3514|NCT04167800|Other|Exercise|Orthosis, mobilization, strengthening, posture and segmental breathing exercises
3515|NCT04167774|Drug|Camrelizumab|Camrelizumab will be administered as a 30-minute IV infusion Q3W at a dose of 200mg (3mg/kg for underweight patients).
3516|NCT04167774|Drug|nb-Paclitaxel|nb-Paclitaxel will be administered as a 30-minute IV infusion Q3W at a dose of 260mg/m2 for 4-6 cycles.
3517|NCT04167761|Drug|Ertugliflozin|Consenting participants in the Ertugliflozen group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
3518|NCT04167761|Drug|Glipizide|Consenting participants in the Glipizide group will be supplied with 2-week course of medication prior to cardiac surgery. Participants will be educated on use and have blood glucose monitored during the medication course. The surgeon will then collect a small amount of fat near the heart during surgery.
3519|NCT04167748|Procedure|Preimplantation genetic testing for aneuploidy (PGT-A)|24-chromosome screening for aneuploidy
3520|NCT04167735|Device|Hearing Aid without Reverberation Canceller (RevC).|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is without Reverberation Canceller principle enabled.
3521|NCT04167735|Device|Hearing Aid Reverberation Canceller enabled (RevC_1)|Each participant will be fitted with the 2 different Sound Changing principles on the same hearing aid, saved to 2 manual programs (ensures exact same hearing loss compensation for each intervention). Reverberation Canceller principle is a sound processing algorithm to remove reverberation from a speech signal to improve the speech intelligibility and comfort. The experimental condition applies the Reverberation Canceller and is predicted to provide a benefit in reverberant room simulations.
3522|NCT04167722|Procedure|Robotic Radical Prostatectomy|Routine NHS Radical Prostatectomy
3523|NCT04167709|Other|Education in clinical competence in detecting signs of postpartum depression in immigrant mothers|Groupbased educational intervention aimed at nurses in the Child Health Services in strengthening clinical competence in detecting signs of postpartum depression in non-native-speaking immigrant mothers
3527|NCT04167683|Other|No intervention|No intervention
3528|NCT04167670|Drug|Vonoprazan|Over-encapsulated tablets administered orally.
3529|NCT04167670|Drug|Amoxicillin|Capsules administered orally.
3530|NCT04167670|Drug|Clarithromycin|Tablets administered orally.
3531|NCT04167670|Drug|Lansoprazole|Over-encapsulated tablets administered orally.
3532|NCT04167657|Drug|Sintilimab|"Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy/5f. Sintilimab shall be started no later than 3 weeks after radiation."
3533|NCT04167644|Diagnostic Test|Modified Rankin Scale (mRS)|Modified Rankin Scale (mRS) is a profoundly valid and reliable measure of disability and is broadly utilized for assessing stroke outcomes and degree of disability. We characterized a favorable outcome as mRS ranging from zero up to two, while unfavorable outcome ranging for 3 up to six
3534|NCT04167631|Radiation|Multi-parametric MRI|Vesical Imaging-Reporting And Data System (VI-RADS) for predicting non-muscle invasive bladder cancer (NMIBC) using multi-parametric MRI.
3535|NCT04167618|Drug|177Lu-DTPA-omburtamab|Biological, radiolabeled DPTA-omburtamab
3536|NCT04167605|Other|Bone metastasis|Collection of waste tissue samples during surgery and immediate immersion of the same in 10% Neutral buffered formalin. The samples will be send to the laboratory where they will be processed (decalcification, inclusion in paraffin, sectioning etc.) for subsequent analyzes.
3537|NCT04167605|Other|Breast cancer metastatic to bone|Patients will be assisted in the recovery of samples (slides) related to surgery on primary tumor (breast cancer responsible for metastatic disease).
3538|NCT04167592|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|Benzydamine Hydrochloride 0.15% Oral Rinse was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
3539|NCT04167592|Drug|Water|Water was used to gargle prior to Endoscopic Retrograde Cholangiopancreatography (ERCP) procedure.
3540|NCT04167579|Device|Transcutaneous Valve Therapy|Any patient who undergoes an attempted transcutaneous aortic or mitral valve therapy procedure, with an FDA approved device.
3961|NCT04164459|Drug|Taflotan-S|One drop one times a day in study eye
3541|NCT04167566|Combination Product|Artemisinin Combination Therapy ACTs|All participants will be tested using RDTs and all confirmed cases will be treated with ACTs. The ACT regimen use at each time will be the one the National Malaria Control Programme will be using at that particular moment.
3542|NCT04167553|Drug|HM15136|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 36 subjects, divided in 2 cohorts with 18 subjects (HM15136 group 9 subjects, placebo group 9 subjects) per cohort. However, Part 2 study may not be conducted after the review of the safety data in Part 1.
3543|NCT04167553|Drug|Placebo|In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 36 subjects, divided in 2 cohorts with 18 subjects (HM15136 group 9 subjects, placebo group 9 subjects) per cohort. However, Part 2 study may not be conducted after the review of the safety data in Part 1.
3545|NCT04167527|Device|Immediate mechanical thrombectomy(iMT) using EmboTrap II Revascularization Device|Treatment initiation is defined as the date and time of arterial puncture. Femoral artery puncture will occur within 45 minutes of randomization and no longer than 90 minutes after the completion of the qualifying imaging. It must occur before 8 hours since the subject was last known well.The initial procedure will be performed using only the EmboTrap II Retriever for the first two passes, and a third pass is encouraged. Date and time of arterial puncture, revascularization, and procedure end will be recorded. It is expected that the interventional procedure will be completed within two hours of arterial access.
3546|NCT04167527|Combination Product|Initial medical management (iMM)|Patients will receive standard medical therapy based on current AHA guidelines. For patients who are treated with intravenous tissue plasminogen activator (rtPA), the sites' post-rtPA protocol will be followed. Rescue mechanical thrombectomy (rMT) is allowed for patients initially assigned to iMM if they suffer major neurological worsening that clearly requires an intra-arterial intervention in the judgment of the treating team.
3547|NCT04167514|Biological|Alpha-1 antitrypsin (AAT)|AAT is a lyophilized product for intravenous administration
3548|NCT04167514|Drug|Placebo|Albumin solution administered intravenously
3549|NCT04167501|Other|biological sample analysis|HPV Prevalence analysis
3550|NCT04167488|Device|Actigraphic measurement|Physical activity assessed with actigraphic device worn during 7 days
3551|NCT04167475|Dietary Supplement|Probiotic capsule|Each probiotic capsule contains 1 x 10^9 CFU B. longum 1714™ with corn starch and magnesium stearate. The probiotic capsules will be supplied by PrecisionBiotics Ltd.
3552|NCT04167475|Dietary Supplement|Placebo capsule|Each placebo capsule contains corn starch and magnesium stearate. The placebo capsules will be supplied by PrecisionBiotics Ltd.
3553|NCT04167462|Drug|BMS-986165|Specified dose on Specified Days
3554|NCT04167462|Other|Placebo|Specified dose on Specified days
3555|NCT04167449|Dietary Supplement|HRG80 Hydroponic Red Ginseng|Powdered root preparation of Panax ginseng standardized to 31.7 mg total ginsenosides
3556|NCT04167449|Dietary Supplement|Conventional Red Ginseng|Powdered root preparation of Panax ginseng standardized to 9.8 mg total ginsenosides
3557|NCT04167449|Dietary Supplement|Placebo|Visually identical placebo capsule containing rice flour
3558|NCT04167436|Other|Prehabilitation|A minimum of four weeks of prehabilitation with exercise three times a week, protein and vitamin supplements, dietitian consultation and medical optimization prior to surgery.
3559|NCT04167410|Other|glycaemic management protocol implemented to clinic|Following the introduction of the glycaemic management protocol to the clinic, data on the patients in the intervention group was collected prospectively between June 2018 and December 2018. Data of the patients in the intervention group was collected after the patient applied to the hospital for surgery or just after the decision on surgery was taken. Patients in the intervention group whose HbA1C values exceeded 7% were referred to endocrinology specialists prior to surgery. Glycaemic management of these patients was evaluated at the department of endocrinology and medications or doses of insulin and oral antidiabetics were changed when necessary. Glycaemic management was conducted by nurses in line with the protocolConsequently, the glycaemic management of patients during the perioperative period was conducted by general surgery nurses according to the protocol.
3560|NCT04167397|Other|Collaborative learning|Participants will be allocated to either single, dyad, triad or tetrad practice during initials skills training on an ultrasound simulator. Afterwards their competencies will be assessed with an individual transfer test on another simulator.
3561|NCT04167384|Other|Product A|Usual brand (UB) filtered, combustible cigarette
3562|NCT04167384|Other|Product B|Nicorette® Mint 4 mg nicotine lozenge
3563|NCT04167384|Other|Product C|CSD1903-11, a hard nicotine lozenge, 2 mg nicotine
3564|NCT04167384|Other|Product D|CSD1903-11, a hard nicotine lozenge, 4 mg nicotine
3565|NCT04167384|Other|Product E|CSD1903-11, a hard nicotine lozenge, 8 mg nicotine
3566|NCT04167384|Other|Product F|CSD1903-12, a soft nicotine lozenge, 2 mg nicotine
3567|NCT04167384|Other|Product G|CSD1903-12, a soft nicotine lozenge, 4 mg nicotine
3568|NCT04167384|Other|Product H|CSD1903-12, a soft nicotine lozenge, 8 mg nicotine
3569|NCT04167371|Behavioral|Biofeedback|Three sessions by biofeedback will be performed during the first 3 weeks of the intervention period. In each session patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
3570|NCT04167371|Dietary Supplement|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. In each session abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
3571|NCT04167358|Drug|Linerixibat|Linerixibat will be available as tablets and administered orally. Participants will be administered with linerixibat with a dose level of 90 mg twice daily.
3572|NCT04167345|Drug|VX-814|Tablet for oral administration.
3579|NCT04167293|Radiation|stereotactic body radiotherapy|Patients will receive stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks.
3580|NCT04167293|Drug|Sintilimab|Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
3581|NCT04167280|Drug|Ipratropium Metered Dose Inhaler|MDI to deliver 20mcg per puff ipratropium bromide
3582|NCT04167280|Drug|placebo metered dose inhaler|matched MDI to deliver inactive drug
3583|NCT04167267|Drug|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
3584|NCT04167267|Drug|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
3585|NCT04167254|Behavioral|Sit Down and Play|Brief health care-based program that aims to promote key parenting behaviors that promote early childhood development
3586|NCT04167241|Diagnostic Test|Echocardiography|Before and after right pneumonectomy or bi-lobectomy patients will receive echocardiography
3587|NCT04167228|Drug|Ceftazidime-Avibactam|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated > 2 days with ceftazidime-avibactam.
3588|NCT04167228|Drug|Best Available Therapy|Patients with complicated urinary tract infections, nosocomial pneumonia (including pneumonia associated with ventilation), complicated intra-abdominal infections or bacteremia (if the focus of infection is any of the above, the patient should be included in both groups) due to CRE, treated > 2 days with the best available treatment other than ceftazidime-avibactam.
3589|NCT04167215|Procedure|superior gluteal artery flap and lumbar artery falp|Doppler ultrasound will be used to confirm location of the superior gluteal artery perforators or lumbar perforators . Flaps will be designed to allow deepithelialization and dissection . After complete sketolization of the flap it will be analyzed for viability and trimmed to achieve the desired bulk.
3590|NCT04167215|Procedure|The gluteal pocket|pocket will be created by undermining in a plane just superficial to the gluteal muscle from the lower body lift line inferiorly extending to within 5 cm of the inferior gluteal crease. should extend only over the medial half of the buttock.
3591|NCT04167215|Procedure|infragluteal dermal lifiting flap|dermal flap will be performed for lifting the ptotic buttocks with ill-defined infragluteal fold. This deepithelialized dermal flap allows for the creation of a well-defined stable infragluteal fold through an incision of the infragluteal fold and exposure of ischial tuberosity and anchor it to the ischial tuberosity.
3592|NCT04167202|Procedure|Hydrogen-rich water|Hydrogen-rich water (one hydrotherapy every 4 hours)
3593|NCT04167202|Procedure|RICE|RICE protocol
3594|NCT04167189|Drug|Lidocaine gel|Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg premeasured by compounding pharmacy and dispensed into blister pack
3595|NCT04167176|Procedure|Erector spinae plane block|Patients will be placed on their left side. The linear ultrasound (Mindray DP 9900 plus; Mindray Bio‑Medical Electronics, Shenzhen, China) probe (5-10 MHz) will be placed in a longitudinal parasagittal orientation 2.5-3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. A 21G 10‑cm needle (Stimuplex A, B Braun, Melsungen, Germany) will be inserted using an out‑of‑plane approach. The tip of the needle will be placed into the fascial plane on the deep aspect of the erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting the erector spinae muscle off the bony shadow of the transverse process on ultrasonographic imaging. A volume of 20 mL of LA mixture (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL of normal saline to make a mixture totaling 20 ml.) will be injected. The same procedure will be repeated for the opposite side.
3596|NCT04167176|Procedure|Port site infiltration|After the induction of anaesthesia, pre-incisional port-site infiltration will be performed by the same surgeon every time with 20 ml of the LA mixture. The volume will be divided equally between port sites. A total of four ports-supraumbilical, subxiphoid and two ports in the right subcostal area at mid-clavicular and anterior axillary line will be made.
3597|NCT04167176|Device|Ultrasound machine (Mindray DP 9900 plus; Mindray Bio‑Medical Electronics, Shenzhen, China)|Ultrasound will be used to identify the erector spinae muscles and to guide the LA mixture injection.
3598|NCT04167176|Drug|Bupivacaine 0.5%|Bupivacaine 0.5% will be included in the injected LA mixture.
3599|NCT04167176|Drug|Lidocaine 2%|Lidocaine 2% will be included in the injected LA mixture.
3600|NCT04167163|Drug|Abaloparatide|18 month ABL treatment
3601|NCT04167150|Dietary Supplement|tart cherry juice concentrate is a commercial product provided by King Orchards (Central Lake, MI)|Participants were instructed to reconstitute the tart cherry juice concentrate in 8 fl oz of water and consume either 1x or 2x daily for 3 months.
3602|NCT04167137|Drug|SYNB1891|Up to four 21-day cycles of escalating doses of SYNB1891 intratumoral injection on Days 1, 8 and 15 of Cycle 1 and Day 1 of cycles 2-4.
3603|NCT04167137|Drug|Atezolizumab|Administered in accordance with its recommended dose and schedule (1200 mg IV Q3W) on Day 1 of each of the 4 planned 21-day cycles.
3604|NCT04167124|Behavioral|multi-sensor lifestyle intervention|
3605|NCT04167111|Dietary Supplement|Cholecalciferol|Vitamin D
3606|NCT04167098|Other|PRP injection|0.5 ml Platelet-rich Plasma around A1 tendon sheath
3607|NCT04167098|Other|Corticosteroid injection|0.5 ml methylprednisolone around A1 tendon sheath
3608|NCT04167098|Other|Placebo injection|0.5 ml 0.9% saline around A1 tendon sheath
3609|NCT04167085|Drug|Doxycycline|Doxycycline, 100 mg twice a day for 2 months
3610|NCT04167085|Other|Placebo|Matching placebo, twice a day for 2 months
3611|NCT04167072|Procedure|Stent removal|Removal of the LAMS via endoscopy.
3644|NCT04166812|Diagnostic Test|body plethysmography|assessment of lung function using body plethysmography
3962|NCT04164446|Drug|Placebos|The placebo that will be used contains starch and glucose.
3612|NCT04167059|Behavioral|Telehealth-delivered participation strategies to increase physical activity|Therapists and primary caregivers will meet online on 6 occasions at fortnightly intervals over a 12 week period. Sessions will enable the development of strategies that will aim to increase the amount the participant stands and walks. Throughout, the therapists and primary caregivers will discuss physical activity needs, determine relevant activities, modify the program as necessary and plan additional goals.
3613|NCT04167046|Procedure|Erector spinae block|Preoperative erector spinae block.
3614|NCT04167033|Drug|Hormone replacement therapy:effect on ventricular repolarization|Hormone replacement therapy and QTc measurement
3615|NCT04167033|Diagnostic Test|ECG|QTc measurement
3616|NCT04167020|Device|High definition surface electromyography (HD-sEMG)|HD-sEMG data will be collected by Mobita 32® (TMSi) device
3617|NCT04167007|Drug|Gemcitabine|Gemcitabine at 1000 mg/m² as intravenous (IV) infusion over 30-40 minutes on days 1, 8, and 15, followed by 1 week of rest, every 28 days
3618|NCT04167007|Drug|FOLFOX|Oxaliplatin at 85 mg/m² given as a 2 hours IV infusion on days 1 and 15; Folinic acid 400 mg/m² (racemic form) or 200 mg/m² (L-form) in 250 ml glucose 5% solution given as a 2 hours IV infusion on days 1 and 15; and 5-FU 2400 mg/m² administered as continuous 46-hour IV infusion on days 1-3 and 15-17, every 28 days.
3619|NCT04166994|Behavioral|Exercise and diet|IMPACT Intervention
3620|NCT04166994|Other|No Intervention: Usual Care|No exercise or diet specialization.
3621|NCT04166981|Procedure|Instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft with supplementary pedicle screw fixation.
3622|NCT04166981|Procedure|Non-instrumented posterolateral spine fusion.|Posterolateral fusion with autologous and allogenic bone graft.
3623|NCT04166968|Device|Anodal transcranial direct current stimulation (A-tDCS)|Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
3624|NCT04166968|Device|Cathodal transcranial direct current stimulation (C-tDCS)|Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
3625|NCT04166968|Device|Sham stimulation (sham-tDCS)|placebo stimulation
3626|NCT04166968|Behavioral|Neuromotor training|conventional neuromotor treatment
3627|NCT04166955|Behavioral|Promoting Physical Activity through mobile application|Students will be randomly assigned to either the intervention or the control group. WhatsApp groups will be formed within each study group. The control participants will have the WhatsApp group only for communications. And they will keep their usual activity for 10 weeks. The intervention participants will have the intervention WhatsApp group which will be for communication and providing the intervention materials. The intervention group will receive a brief (15-minute) orientation on exercise, and benefits of keeping a healthy life pattern. They will receive 3-4 health-promotional (Physical activity) messages per week via WhatsApp for 10 weeks; group interaction is optional without adding more messages aiming to promote physical activities from any participants.
3628|NCT04166942|Drug|KD025|Single dose of 200 mg KD025 orally
3629|NCT04166929|Biological|Haplo BMT with NK cells|Patients in this arm receive haplo-BMT followed by one boost of NK cells one/two weeks after the transplant. Lymphocyte are collected by apheresis from the donor one-two weeks after BM harvest. CD3 negative/CD56 positive cells are selected by immunomagnetic columns (other lymphocytes are stored to be used as DLI)
3630|NCT04166929|Biological|Haplo BMT|Patients in this arm receive a standard haplo-BMT. All administerd therapies are the same as in other arm, except for the NK cell boost..
3631|NCT04166916|Other|Acoustic stimulation|Acoustic stimulation to modulate slow waves.
3632|NCT04166916|Other|SHAM acoustic stimulation|This is the sham-control intervention; only the biosignal will be recorded but no acoustic stimulation will be played.
3633|NCT04166890|Drug|Articaine / EPINEPHrine Cartridge|The day scheduled for the surgery, vital signs (pulse, blood pressure and oxygen saturation) will be recorded prior the administration of the anesthesia. A volume of 1.8 ml of 4% articaine and epinephrine 1: 100000 solution of either the test product or the reference product will be deposited slowly to proceed to the inferior alveolar nerve block (IANB), according to the table of allocation of treatments in each period. The vital signs will continue to be monitored during the procedure, and once the procedure has been completed. If the volunteer needs more anesthetic, this will be recorded and will be administrated according to the maximum permitted doses (7 mg / kg (up to 500 mg) 5 mg / kg in children 7), and immediately after the administration, the vital signs will be taken again.
3634|NCT04166877|Drug|Magnesium Sulfate in Parenteral Dosage Form|IV bolus followed by continuous infusion for 24 hours
3635|NCT04166877|Drug|Normal saline placebo|IV bolus followed by continuous infusion for 24 hours
3636|NCT04166864|Device|Transcranial magnetic Stimulation|Transcranial magnetic stimulation delivered at the Subject's SCC-determined frequency. Each Subject will receive 40 pulses every 26 seconds, over 75 trains.
3637|NCT04166851|Behavioral|PrEP campaign messages developed via open contest|PrEP campaign messages will be developed via an open contest in Baltimore.
3638|NCT04166851|Behavioral|PrEP campaign messages developed via social marketing approach|PrEP campaign messages developed with a traditional social marketing approach.
3639|NCT04166838|Biological|CD19 UCARTcells|This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 ^ 6 cells/kg,3 × 10 ^ 6 cells/kg,5 × 10 ^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.
3640|NCT04166825|Diagnostic Test|fibrin clot properties|Assessment of thrombin generation and efficiency of fibrinolysis.
3641|NCT04166812|Diagnostic Test|oscillometry|assessment of peripheral airway resistance using oscillometry
3642|NCT04166812|Diagnostic Test|multiple breath washout testing|assessment of ventilation heterogeneity using multiple breath washout testing
3643|NCT04166812|Diagnostic Test|spirometry|assessment of lung function using spirometry
3997|NCT04164238|Drug|5-fu|5-fu injection
3645|NCT04166812|Diagnostic Test|fractional exhaled nitric oxide|assessment of eosinophilic airway inflammation using fractional exhaled nitric oxide
3646|NCT04166812|Diagnostic Test|transfer factor|assessment of gas transfer using single breath transfer factor for carbon monoxide
3647|NCT04166812|Diagnostic Test|health status|assessment of health status using validated questionnaires (St. George's Respiratory Questionnaire [SGRQ], COPD Assessment Test [CAT])
3648|NCT04166812|Diagnostic Test|computed tomography|assessment of lung structure and function using computed tomography (only in patients with clinical indication, Heidelberg site)
3649|NCT04166812|Diagnostic Test|induced sputum|various biomarkers (subgroup of approximately 75 patients, Großhansdorf site)
3650|NCT04166799|Device|Mepitel Film|Mepitel® Film is a thin, soft and conformable transparent film dressing with Safetac®, offering protection for vulnerable skin.
3651|NCT04166786|Drug|Testosterone gel|Subjects receive a daily transdermal dose of 100 mg of testosterone (2 sachets of 5 g of gel) during 3 days.
3652|NCT04166786|Drug|Ethanol Solution|Subjects receive a daily administration of 30 g of ethanol (94 mL of Vodka Absolut® diluted in 300 mL of lemon-flavoured water Fontvella®) during 3 days.
3653|NCT04166786|Drug|Testosterone placebo (vaseline)|Subjects receive a daily transdermal dose of 5 g of pure vaseline ointment during 3 days.
3654|NCT04166786|Drug|Ethanol placebo (lemon-flavoured water)|Subjects receive a daily administration of 394 mL of lemon-flavored-water Fontvella® during 3 days.
3655|NCT04166773|Drug|Tirzepatide|Administered SC
3656|NCT04166773|Drug|Placebo|Administered SC
3657|NCT04166760|Dietary Supplement|speWHE|25 gram of a specific whey fraction (confidential)
3658|NCT04166760|Dietary Supplement|WHE|25 gram protein of a regular whey compound
3660|NCT04166734|Drug|Pembrolizumab|"Pembrolizumab will be continued dosed at 200 mg given every 3 weeks~Drug: Pembrolizumab Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks."
3661|NCT04166734|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)
3662|NCT04166721|Drug|Atezolizumab|Immunotherapy
3663|NCT04166695|Device|Monolithic / facially veneered zirconia fixed partial denture|Participant receives one monolithic / facially veneered zirconia fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
3664|NCT04166695|Device|Completely veneered CoCr fixed partial denture|Participant receives one completely veneered CoCr fixed partial denture retained by either teeth, implants or teeth and implants for the replacement of two neighbouring posterior teeth.
3665|NCT04166682|Behavioral|Home-based cardiac rehabilitation|cardiac rehabilitation done at home
3666|NCT04166682|Behavioral|Routine care|Routine care and followup
3667|NCT04166669|Drug|APX001|Cohort 1 Day 1: APX001 500 mg IV BID over a 3-hour infusion; Day 18: APX001 500 mg IV BID over a 3-hour infusion. Cohort 2 Day 1: APX001 1000 mg IV BID over a 3-hour infusion; Day 24: APX001 1000 mg IV BID over a 3-hour infusion.
3668|NCT04166669|Drug|Itraconazole|Cohort 1 Days 15-30: itraconazole 200 mg oral solution QD.
3669|NCT04166669|Drug|Rifampin|Cohort 2 Days 15-33: rifampin 600 mg oral QD.
3670|NCT04166656|Biological|Trumenba®|Trumenba® (Pfizer): Suspension for intramuscular injection in 0.5 mL single-dose prefilled.
3671|NCT04166656|Biological|Bexsero®|Bexsero® (GSK): available as a suspension for intramuscular injection in a prefilled syringe
3672|NCT04166643|Behavioral|WHHIP PLUS|Worksite health promotion and occupational health and safety (total worker health)
3673|NCT04166643|Behavioral|Education only control|Education at the start of the project
3674|NCT04166630|Device|Clinical Electrical Stimulator|Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
3675|NCT04166617|Other|Conventional therapy|conventional physcial therapy rehabilitation for the upper limb
3676|NCT04166617|Other|Leap motion plus conventional therapya|leap motion plus conventional physcial therapy rehabilitation for the upper limb
3677|NCT04166604|Drug|Trifluridine/Tipiracil|"after morning and evening meal,~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery~In case of first event of grade 3-4 neutropenia : patients will not have a dose reduction and will receive a secondary prophylaxis with G-CSF (filgrastim or lenograstim) during subsequent cycle: a starting 5 mg/kg/day dose of filgrastim or lenograstim as a single daily injection, for 5 days, from day 14 to day 18~In case of secondary event of grade 3-4 neutropenia despite G-CSF secondary prophylaxis, dose adjustment of trifluridine/tipiracil will be done according to Summary of Product Characteristics (SmPC). G-CSF secondary prophylaxis will be continuing with the reduction.~dose"
3678|NCT04166591|Behavioral|Overheard Speech|New words are introduced with the child as a bystander rather directly taught.
3679|NCT04166591|Behavioral|Addressed Speech|New words are introduced directly to the child by an experimenter.
3680|NCT04166578|Drug|lignocaine|The group of 62 patients undergoing cataract surgery received Mydrane (Mydrane group) or a combination of 1% solution of lignocaine and 0.025% solution of adrenalin (reference group) as an intraocular anesthetic
3681|NCT04166578|Procedure|Phacoemulsyfication|Phacoemulsification is a technic of cataract surgery in which the eye's internal lens is emulsified with an ultrasonic handpiece and aspirated from the eye.
3682|NCT04166578|Procedure|Intraocular lens implantation|An intraocular lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery.
3683|NCT04166578|Behavioral|Visual Analog Scale for Pain|VAS for Pain is a new tool developed to assess the pain in quantitative terms.
4183|NCT04162756|Drug|Cyclophosphamide|Administered per package insert
3684|NCT04166578|Behavioral|Brief Pain Inventory-short form|BPI short form is a tool developed to assess the pain in quantitative terms. The BPI allows patients to rate the severity of the pain and the grade to which their pain interferes with common dimensions of feeling and function.
3685|NCT04166578|Diagnostic Test|Best corrected visual acuity measurment|Measurement of the best vision correction that can be achieved, such as glasses, as measured on the standard Snellen eye chart. For example, if your uncorrected eyesight is 20/200, but you can see 20/20 with glasses, your BCVA is 20/20.
3686|NCT04166578|Diagnostic Test|Slit-lamp biomicroscopy|Slit-lamp biomicroscopy allows study of ocular structures and their relationships.
3687|NCT04166565|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered by i.v. infusion. Daratumumab will be administered weekly in Cycles 1 and 2, then every 2 weeks for Cycles 3-6, and thereafter every month up to 36 months.
3688|NCT04166565|Drug|Bortezomib|Bortezomib 1.5 mg/m2 bortezomib will be administered by a subcutaneous injection once weekly (Days 1, 8, 15 and 22) in all cycles.
3689|NCT04166565|Drug|Cyclophosphamide|"Cyclophosphamide 300 mg/m2 will be administered as a p.o. or i.v. weekly dose (Days 1, 8, 15, and 22) in every 28-day cycle (maximum weekly dose 500 mg).~Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o."
3690|NCT04166565|Drug|Dexamethasone|Dexamethasone will be administered on Days 1, 2, 8, 9, 15, 16, 22 and 23 in all cycles. On daratumumab infusion days dexamethasone may be administered i.v. or p.o. approximately 1 hour before the daratumumab infusion. On days when daratumumab is not administered, dexamethasone is to be administered p.o.
3691|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken once a day
3692|NCT04166552|Drug|Patients will be randomized to receive EHP-101 or Placebo|EHP-101 or placebo will be taken twice a day
3693|NCT04166539|Behavioral|Questionnaires|You will be asked to complete a questionnaire about your family history of neurological diseases and current and past physical thinking activities.
3694|NCT04166539|Behavioral|Interviews|Behavioral and Memory interviews will take place with the patient.
3695|NCT04166539|Other|Blood draw|Have a sample of blood drawn (4.2-5 tablespoons) for clinical and research tests.
3696|NCT04166539|Radiation|Magnetic Resonance Imaging|Each MR examination takes about 45 minutes and does not require the use of needles, medication or contrast enhancement. You will lie on your back and enter the MR scanner for the study, during which time you will hear knocking noises. People with pacemakers, aneurysm clips, cochlear implants, or metal/foreign objects in their eyes are not permitted to undergo MR studies. We will review your implants and determine your eligibility.
3697|NCT04166539|Diagnostic Test|Echocardiogram|Each echocardiogram takes about 30 minutes. This test uses sound waves to look at your heart. The person doing the test will press on your chest with a machine to obtain the pictures. The pressure may be uncomfortable. The echocardiogram will involve an image enhancement agent infusion to obtain better images.
3698|NCT04166526|Device|FDNIRS-DCS|FDNIRS-DCS measurements will be performed at the same time as all MRI scans. Participants in Group 4 will have additional measurements before, during, and after the their scheduled transfusion.
3699|NCT04166526|Device|MRI|Participants in Groups 1-3 will receive a single, hour-long MRI. Participants in Group 4 will receive two, one hour long MRI scans: one within a week prior to their transfusion and one within a week after their transfusion.
3700|NCT04166513|Device|Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion over approximately 30 seconds until reaching a strength of no more than 2mA, with a current density equal to 0.08mA/cm2. Stimulation will be maintained no longer than 20 minutes.
3701|NCT04166513|Device|Sham Transcranial Direct Current Stimulation|High-Definition-tDCS will be delivered via a battery-driven constant direct current stimulator (Soterix) using a 4x1 montage (1 central anodal electrode and 4 cathodal electrodes) arranged in a HD-cap. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the tDCS group.
3702|NCT04166513|Behavioral|Phonologic-Focused Speech Therapy|Participants are asked to generate or choose from a list phonologic information about a target picture.
3703|NCT04166513|Behavioral|Semantic-Focused Speech Therapy|Participants who have difficulty retrieving an object name are given hierarchical clues or asked questions about the objects function as a way of activating the semantic network for that object, leading to eventual retrieval of the target word.
3704|NCT04166500|Procedure|Hysteroscopy|outpatient hysteroscopy after the first menstrual cycle in the follicular phase (9-12 days).
3705|NCT04166487|Drug|Pembrolizumab|predetermined dose, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
3706|NCT04166487|Drug|PEMETREXED|administered per standard practice, once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
3707|NCT04166487|Drug|CARBOPLATIN|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
3708|NCT04166487|Drug|PACLITAXEL|administered per standard practice once per cycle via IV will be administered every 3 weeks, with 21 consecutive days defined as a treatment cycle.
3709|NCT04166487|Diagnostic Test|InVision|Plasma draw for clinical test performed at C1D1 and C2D1; plasma draw for research testing performed at other timepoints per protocol.
3710|NCT04166474|Drug|Dolutegravir|Dosed at 50 mg bd on 3 separate occasions with low, medium and high doses of rifampicin. Dosed at 50 mg od without rifampicin.
3711|NCT04166461|Other|Not application, observational study|Not application, observational study
3712|NCT04166448|Other|Fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
3713|NCT04166435|Drug|Temozolomide + Olaparib|Temozolomide (75 mg/m2 orally on days 1-7 every 3 weeks) + Olaparib (150 mg orally twice daily days 1-21) in a 21-day cycle.
3714|NCT04166422|Other|Cardiac rehabilitation program|Aerobic treatment plus strength exercises
3715|NCT04166422|Other|Experimental intervention|Aerobic treatment plus strengh exercises plus virtual reality
3716|NCT04166409|Drug|Carboplatin|Given IV
3717|NCT04166409|Other|Quality-of-Life Assessment|Ancillary studies
3718|NCT04166409|Other|Questionnaire Administration|Ancillary studies
3719|NCT04166409|Drug|Selumetinib|Given PO
3720|NCT04166409|Drug|Selumetinib Sulfate|Given PO
3721|NCT04166409|Drug|Vincristine|Given IV
3722|NCT04166409|Drug|Vincristine Sulfate|Given IV
3723|NCT04166396|Dietary Supplement|Resveratrol|500 mg resveratrol, BID
3724|NCT04166396|Dietary Supplement|NR|500 mg NR BID
3725|NCT04166396|Dietary Supplement|Placebo|Placebo
3728|NCT04166370|Other|Control|The standard of care includes nutrition and health services provided to all pregnant women and mothers of children under-2 as provided by the GoB and their supporting partners. Services that should be provided include clinic-level infant and young child feeding (IYCF) counseling, growth monitoring and promotion, immunization, iron and folic acid distribution for pregnant women, ANC, safe delivery at community and referral for complications, vitamin-A supplements for postpartum women and children, deworming and management of common childhood illness.
3729|NCT04166370|Other|Strengthened (Services and SBCC)|"Strengthening referrals to health services- Needed improvements to existing health referral networks will be assessed, identified and implemented. Peer leaders will refer PLW to nearby service delivery points.~Improving quality of health/nutrition services- Health-related service providers will be trained and supervised on nutrition best practices.~SBCC- Primarily target PLW. Delivered using traditional and digital channels. Text/voice messages will be sent to PLW twice per week. Family members (e.g. husband) will also be encouraged to sign up for these messages. Female community nutrition promoters will also be deployed; delivering SBCC during group meetings and in health facilities. Mothers' groups will be established, and will be led by peer leaders, mentored in the delivery of messages on nutrition behavior."
3730|NCT04166370|Other|Strengthened (Services and SBCC) + CCT|Will include all components of the strengthened intervention and participants will receive monthly cash transfers, which is about 25% of monthly consumption expenditure among poor rural households in Bangladesh. Cash transfers will begin when a woman enrolls (at any time during her pregnancy or until 2 months after giving birth). The monthly transfer will continue until a child is 12 months of age, thereby supporting mothers during the critical period of complementary food introduction. The transfer is contingent on having had a minimum of 4 ANC visits and monthly participation in mother's group SBCC sessions.
3731|NCT04166357|Diagnostic Test|neuromuscular ultrasound|Neuromuscular ultrasound refers to a field in medicine in which ultrasound is used to diagnosis and guide treatment for people with neuromuscular diseases. Neuromuscular ultrasound is often combined with electrodiagnosis, and particularly nerve conduction studies and EMG, to improve the accuracy of diagnosis and add anatomic information to the functional information obtained with electrodiagnosis. It has been demonstrated that neuromuscular ultrasound adds value to the diagnosis of nerve disease in over 80% of cases.
3732|NCT04166344|Behavioral|Happyair Ecosystem|"Happyair Ecosystem is a Smart Community for the integral care of patients with chronic or rare respiratory diseases such as Asthma, COPD or Alfa-1.~Our community provides online & offline training and resources in digital health and social care to patients, family, caregivers, healthcare professionals and researchers.~Using our platform, all of our members will be able to connect in order to improve the health and well-being of patients, learn to manage self-care, ensure an active lifestyle, and contribute to the development of current and future research projects."
3733|NCT04166331|Drug|Placebos|Placebo will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
3734|NCT04166331|Drug|Dobutamine|Dobutamine will initially be started at a dose of 2.5 µg/kg/min and subsequently titrated using incremental steps (predefined durations) of 2.5 µg/kg/min, up to a maximal dose of 10 µg/kg/min. Dose adaptation will be left at the discretion of attending physician.
3735|NCT04166318|Drug|Capecitabine|Given PO
3736|NCT04166318|Drug|Fluorouracil|Given IV
3737|NCT04166318|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
3738|NCT04166318|Drug|Mitomycin|Given IV
3739|NCT04166318|Other|Quality-of-Life Assessment|Ancillary studies
3740|NCT04166318|Other|Questionnaire Administration|Ancillary studies
3741|NCT04166305|Genetic|Genetic study for SCN1A c.3184 A/G and CCL2-2518G>A polymorphism:|"DNA analysis: Genomic DNA will be extracted from EDTA-anticoagulated peripheral blood (QIAamp DNA Blood mini kit,QIAGEN).~Genotyping of SCN1A c.3184 A/G(rs2298771) polymorphism"
3742|NCT04166292|Device|Stylage® XL Lidocaïne|"On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml."
3743|NCT04166279|Other|Single rehabilitative treatment|The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week).). The protocol included a first phase consist in low impact aerobics warming (15-20 minutes), then diaphragmatic breathing and postural exercises for the midline alignment. The awareness of abdominal breathing represents the preliminary phase for a complete psychophysical relaxation of the patient, an important prerequisite for the correct execution of subsequent mobility, stretching and strengthening exercises of spine, scapula and upper limb. Subsequently, isometric strengthening exercises for shoulder stabilizing muscles, first passively and, subsequently, with supervision, were performed. Specific exercises, for passive mobilization and stabilization of the scapula, cervical pumping and stretching of the pectoral muscles, have been performed.
3784|NCT04165876|Device|Primary Motor Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration
3812|NCT04165668|Other|Exposure: First on scene|To be first on scene for resuscitation at the suspected out-of hospital cardiac arrest, before EMS and first responders (fire and police services)
3744|NCT04166279|Other|Group rehabilitative treatment|Four-five patients for group. The rehabilitation treatment, performed by a physiotherapist trained in oncological rehabilitation, was carried out with a 6-week exercise program for 12 sessions (60 minutes/session, 2/week). The protocol included at first week mainly breathing techniques, then we introduced exercises gradually more active, according to the improvements of the execution. The exercises had the aim to improve the opening of the scapular chain and to increase the amplitude of the range of motion in order to stimulate better neuromuscular control during the movement of scapular retropulsion, to stretch the pectoral muscles following the rhythm of the breath and the tissues affected by post-surgical scars and fibrotic effects, finally to reinforcing, against gravity, the musculature of the shoulders and back.
3745|NCT04166253|Drug|Vitamin D|Alfacalcidol oral tablets once daily
3746|NCT04166240|Behavioral|SAFER TRACKS Intervention|SAFER Change Package delivered using a Virtual Breakthrough Series [VBTS] Collaborative supplemented with automated surveillance data on test results.
3747|NCT04166227|Procedure|Hip Arthroscopy|Patients in the Hip Arthroscopy group will undergo arthroscopy in the supine position under general anesthesia, with all procedures performed by two subspecialty-trained hip arthroscopists. An algorithmic surgical approach will be utilized to sequentially address pathology in the central and peripheral compartments of the hip based on both preoperative imaging findings and intraoperative findings. Emphasis will be placed on labral preservation and refixation, with osseous decompression under fluoroscopic guidance.
3748|NCT04166227|Procedure|Total Hip Arthroplasty|Patients randomized to the Total Hip Replacement (THR) group will undergo THR via a direct anterior approach. A slightly oblique skin incision measuring approximately 8 cm will be used, starting 3 cm distally and laterally to the anterosuperior iliac spine. The intervals between tensor fascia lata (TFL) and sartorius will be developed superficially, and between rectus femoris and gluteus minimus deeper. Capsulotomy will be performed. A double osteotomy of the femoral neck will be performed to facilitate removal of the head followed by traditional preparation of the acetabulum using an offset reamer and the acetabular component will be inserted. Next, the superior capsule will be released to elevate the femur to allow access to the femoral canal, followed by standard preparation by use of an offset broach and the stem will be implanted
3749|NCT04166214|Device|intraoral cameras|The SOPROCARE is intended for clinical practice of general dentistry, as an aid in the diagnosis of pit and fissure caries, as an aid to highlight dental plaque and gingival inflammations and as intra-oral camera to visualize anatomical details that are invisible to the naked eye or with a mirror. In CARIO mode, the camera helps the dental practitioner to highlight carious warning on pits and fissures of the occlusal side of the teeth. In DAYLIGHT mode, the camera enables you to visualize anatomical details invisible to the naked eye or with a mirror. In PERIO mode, the camera helps the dental practitioner to see the presence of dental plaque but also to highlight gingival inflammations . This mode offers to the dentist and/or hygienist a tool for an improved communication, motivation and education of his/her patients, who will then become aware of their oral health condition.
3750|NCT04166201|Procedure|double mesh hernioplasty with modified chevrel's technique|hernioplasty done by modification of the chevrel's technique , no dissection further than 1 cm of the midline laterally, the medial flaps of the anterior rectus sheath is dissected of the anterior surface of the rectus abdominis muscle and sutured together reforming the posterior rectus sheath , one polypropylene mesh was fixed over the posterior rectus sheath and the other was tailored to raw area of the rectis abdominis muscle and sutured to the lateral free edges of the anterior rectus sheath
3751|NCT04166188|Procedure|Lumbar erector spinae plane block|Injection of blue solution in the erector spinae plane in L4 ultrasound-guided and posterior dissection of the lumbar region.
3752|NCT04166175|Procedure|botox injection in intersphincteric space|injection of 80 IU of botox in the intersphincteric space in 5,7,11 and 1 O'clock position
3753|NCT04166175|Procedure|lateral internal sphincterotomy|lateral internal sphincterotomy under GA in lithotomy position
3754|NCT04166162|Behavioral|Brief Intervention Motivational Interviewing (BIMI) Intervention|BIMI is a 15-minute brief interview in person or via video chat with participating youth. The interview will be focused on discussing the impact of drinking alcohol on one's health and how to set personal goals so that alcohol use does not become a problem. A follow up phone or video call at 3 and 6 months post initial interview will also be conducted which will track on the progress of setting and keeping personal goals.
3755|NCT04166162|Behavioral|Tomando Buenas Decisiones (TBD) Intervention|The program is adapted from the Guiding Good Choices (GGC) program and will be conducted by a trained facilitator lasting for about 2 hours per session. The program discusses about the best ways to help one's child make good decisions with regards to avoiding alcohol, drugs, and other problem behaviors that may not be healthy to them as well as ways to have good communication and good connections within one's family.
3756|NCT04166162|Behavioral|Social Development Strategy (SDS) Intervention|SDS is a 2 hour broad-focused environmental intervention consisting of short presentations and workshops designed to provide skills and models for positive human interaction between employees to fellow employees, employees to their children and employees to their supervisors.
3757|NCT04166162|Behavioral|BTC Training Session|BTC training session consists of trainings, discussions and tools focused on community mobilization for the assessment and implementation of evidence-informed preventive interventions addressing community health and behavior problems. Each training session lasts about 4 hours.
3758|NCT04166149|Diagnostic Test|dd-cfDNA Blood Test|The cfDNA measurement isolated from the peripheral blood contains small amounts from the graft. The blood sample is collected in Cell-Free DNA BCT (blood collection) tubes. These are measured by their difference in SNP (single nucleotide polymorphisms) genotype to determine the ratio of donor to recipient through shotgun sequencing. Higher levels of dd-cfDNA in a patient experiencing rejection is measured as a higher percentage of the total cf-DNA.
3759|NCT04166136|Other|Transition from the Rearfoot to the Forefoot and Midfoot|Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.
3811|NCT04165681|Other|Limbix Spark|5-week, self-guided mobile + VR CBT-based program for adolescent depression
3760|NCT04166136|Other|Usual Treatment Group|This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.
3761|NCT04166136|Other|Muscle Strengthening Group|The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
3762|NCT04166110|Drug|Predetermined treatment duration|Antibiotic treatment duration left to the physician's judgement (following national guidelines, 7 to 14 days)
3763|NCT04166110|Drug|Variable treatment duration|"Treatment duration vary according to stability criteria reaching time Patients will self-monitor 2 times a day (in the morning and in the evening) using a set of connected devices, to monitor their vital signs before any treatment intake.~After at least 3 days of treatment and stability criteria obtained for the last 24 hours (i.e. 3 vital signs recording), patients will stop the antibiotic treatment."
3764|NCT04166097|Other|Heart Smart Interventional Program|6-week program consisting of weekly didactic sessions that follow the steps outlined in the book.
3765|NCT04166084|Other|Active ROM Exercises|Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
3766|NCT04166084|Other|Trunk Stabilization Exercises Training|Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
3767|NCT04166071|Drug|Naltrexone|Half of the participants will be randomly assigned to take one dose of naltrexone (50mg, capsule form) during the experimental session
3768|NCT04166071|Drug|Placebo|Half of the participants will be randomly assigned to take a placebo capsule during the experimental session
3771|NCT04166045|Device|Sham Treatment Location|The device applies transcutaneous electrical nerve stimulation to the bicep
3772|NCT04166045|Device|Verum Treatment Location|The device applies transcutaneous electrical nerve stimulation to the hand
3773|NCT04166019|Behavioral|Peer-led self-management program|The program based on completion of a self-management workbook, consisting of the main components: personal recovery goals, plans to re-establish community functioning and support networks following a crisis, identifying early warning signs and creating a relapse prevention plan, and strategies and coping resources to problem-solving and maintain well-being.
3774|NCT04166019|Behavioral|Psycho-education group|The psycho-education group program is comprised of six components: introduction and goal-setting; basic understanding of psychosis and symptom and emotion self-care; education workshop of psychosis care, treatment and community support services; learning about self-care skills; establishing social support and effective coping skills; and skills practices, review and future plan.
3775|NCT04166019|Behavioral|Usual care|Routine care services consist of monthly psychiatric consultation and treatments prescribed by psychiatrist, nursing advice on community care, brief education (1-2 hourly sessions) about mental illness/treatments by psychiatric nurses, home visits by case managers, and/or referrals to community/welfare services.
3776|NCT04166006|Biological|Autologous DC vaccine|7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
3777|NCT04166006|Drug|Interleukin-2|Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
3778|NCT04165993|Drug|KN026 combination|30 mg/kg Q3W KN026 75 mg/m2 docetaxol
3779|NCT04165993|Drug|KN026 monotherapy|30 mg/kg Q3W KN026
3780|NCT04165980|Device|transcranial direct current stimulation|Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
3781|NCT04165967|Drug|Combination of TIL Transfer with anti-PD-1 Therapy and low dose IL-2|"The study uses a personalized IMP, i.e. TIL product and in combination with IL-2 treatment and nivolumab.~Day 0: Autologous TIL: (minimum 5 x 109 and up to a maximum of 2 x 1011 lymphocytes) administered intravenously over 20 to 30 minutes.~Day 0: Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing). Actual body weight will be used in calculating the dose of interleukin-2.~Starting Day 14: Nivolumab application 240 mg i.v. over 30 minutes ever 2 weeks with a maximum to 2 years, or until disease progression or inacceptable toxicity."
3782|NCT04165941|Biological|DRI cell therapy|Drug Resistant Immunotherapy with gamma delta modified T cells to be resistance to temozolomide will be infused into the surgical cavity following the completion of standard concurrent radiation and chemotherapy with temozolomide.
3783|NCT04165902|Drug|compare the effects of steroid plus hyaluronic acid and destrose plus hyaluronic acid on knee osteroarthritis|compare the immediate effect (one week after 3 times of injections), short-term effects (one month and three months after 3 times of injections), and midterm effect (6 months after 3 times of injections).
4476|NCT04160481|Dietary Supplement|Placebo|Maltodextrin
3785|NCT04165876|Device|Dorsolateral Prefrontal Cortex Stimulation|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration
3786|NCT04165876|Device|Multimodal Stimulation (DLPFC+M1)|Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.
3787|NCT04165876|Device|Sham stimulation|Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.
3788|NCT04165863|Procedure|total knee replacement surgery|total knee replacement surgery
3789|NCT04165850|Drug|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken thrice daily, total dose 909mg/day
3790|NCT04165837|Drug|FB-101|Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study
3791|NCT04165837|Drug|Placebo|Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
3792|NCT04165824|Drug|MT-1186|"An initial treatment cycle with daily dosing for 14 days, followed by a 14-day drug free period~Subsequent treatment cycles with daily dosing for 10 days out of a 14-day period, followed by a 14 day drug free period. Treatment cycles are every 4 weeks."
3793|NCT04165811|Other|Exercise treatment|A program consisting of aerobic dance based exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
3794|NCT04165811|Other|Counselling|Only physical activity counseling will be given to the subjects in this group.
3795|NCT04165798|Diagnostic Test|Tumor Imaging|Participants will undergo tumor imaging using either a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
3796|NCT04165798|Procedure|Tumor Tissue Collection|Participants without archival tumor tissue samples will undergo tumor tissue collection for newly obtained tumor tissue.
3797|NCT04165798|Procedure|Blood Sample Collection|"Participants will have blood samples drawn for analysis of:~genetics~ribonucleic acid (RNA)~serum biomarker~plasma biomarker~circulating tumor DNA (ctDNA)"
3798|NCT04165785|Device|OPT IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
3799|NCT04165785|Device|Sham OPT IPL|Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
3800|NCT04165785|Procedure|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
3801|NCT04165772|Drug|TSR-042|Patients will be given TSR-042 at a dose of 500mg IV q 3 weeks.
3802|NCT04165772|Drug|capecitabine|capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines.
3803|NCT04165772|Radiation|Intensity Modulated Radiation Therapy (IMRT)|The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx.
3804|NCT04165746|Other|Foster Care|"Upon entry into the Child Protection System, if the child is assigned to one of the districts participating in the RCT, the court will notify the study team. Children that have been randomly assigned to Foster Care will be placed in a foster home within 48 hours of referral to the Family Court/Child Protection System.~Children and Foster Parents will receive biweekly visits from Social Workers. Children and Foster parents will also participate in the caregiving intervention described below. Children will remain in the placement until such time as the social workers, psychologists and Family Court Judge determine that one of the following outcomes is appropriate: reunification with biological family or adoption."
3805|NCT04165746|Behavioral|Caregiving Intervention|During VIPP an intervenor meets with a caregiver (foster parent or caregiver at the institution) and child in the home environment. During each session, the intervenor videotapes the caregiver and child doing play-based activities. After the meeting, the intervenor reviews the videos. At the next meeting, the intervenor reviews the videos with the caregiver and provides positive, constructive feedback to the caregiver. VIPP is aimed at increasing sensitivity in parents/caregivers in order to encourage positive interactions. The guiding principles are to create a positive environment and to convey that the caregiver is the expert on their own child. VIPP has been used as an intervention in traditional families, childcare settings, foster care, and for families with children with autism. VIPP has demonstrated its effectiveness through 12 RCTs in several different countries. This will be the first time that VIPP is being used in foster and institutional care in Brazil.
3806|NCT04165733|Diagnostic Test|Online questionnaire|Clinical psychologists in Germany currently working with patients with mental disorders
3807|NCT04165720|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
3808|NCT04165707|Device|Keyto device + app|Keyto is a self-monitoring and app-enhanced intervention to help individuals learn about and monitor their breath acetone (a measure of ketosis) levels to promote a very low carbohydrate diet and weight loss.
3809|NCT04165707|Other|Weight Watchers app|The Weight Watchers app helps people to monitor their food intake, track points and provides recipe ideas to support weight loss.
3810|NCT04165694|Procedure|Single Anastomosis Duodenal Ileal Bypass (SADI)|The purpose of the research is to study additional weight loss and resolution of comorbidities in patients who undergo revision of their sleeve gastrectomy to a Single Anastomosis Duodenal Ileal bypass (SADI). The sleeve gastrectomy which you have already undergone is now the most common bariatric procedure performed. This operation was part of a 2-stage operation known a Duodenal Switch (DS) which was a sleeve gastrectomy followed by a long bypass of the intestine that involved 2 connections. This operation has many complications such as vitamin deficiencies and potential malnutrition. The SADI procedure is a version of the DS that bypasses less of the intestine and one less connection of the small bowel.
3813|NCT04165655|Behavioral|Keep Achieving (KA)|The 10-week group based activity programme will consist of 10 sessions each lasting 50 minutes.
3814|NCT04165642|Other|Laser ballon ablation for Pulmonary vein isolation|The patients indicated to AF ablation procedure will be treated with laser balloon ablation without verification of electrical isolation of pulmonary veins using implantable loop recorder and/or Holter monitoring
3815|NCT04165629|Drug|Aspirin 300mg and Clopidogrel 300mg|Aspirin 300mg and Clopidogrel 300mg on the day of the PTA
3816|NCT04165603|Procedure|Preoperative Infusion of Indocyanine Green|preoperatively infuse indocyanine green through peripheral vein
3817|NCT04165590|Other|Plasmodium immunotherapy|The patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites.
3818|NCT04165577|Device|rTMS|1-Hz rTMS targeting frontal pole
3819|NCT04165577|Device|sham rTMS|sham rTMS targeting frontal pole
3820|NCT04165564|Other|Institutional standard of care|Institutional standard of care may involve the use of LungRADS (screening setting) or Fleischner criteria (either combined 2005, 2013 or 2017 guidelines)
3821|NCT04165564|Other|Biosamples of airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
3822|NCT04165551|Biological|Probiotic|Volunteers will take 1 capsule a day of the Probiotic during lunch without any restrictions on diet or lifestyle.
3823|NCT04165551|Biological|Placebo|Volunteers will take 1 capsule a day of the Placebo during lunch without any restrictions on diet or lifestyle.
3824|NCT04165538|Procedure|Thrombelastograph and surgical timing|Patients in the TEG group will undergo a Thrombelastograph test after admission, and the timing of operation will be determined according to the results of the test, that is, 1 day, 3 days and 5 days later respectively for patients with ADP-induced platelet-fibrin clot strength (MAADP) of > 50 mm, 30-50 mm and < 30 mm. For Non-TEG patients, the drug withdrawal time is determined by the doctor in charge according to the clinical routine, generally about one week.
3825|NCT04165525|Device|Ablation|comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
3826|NCT04165512|Combination Product|bupivacaine and triamcinolone|a mixture of 4 mL 0.5% bupivacaine (marcaine) and 1 mL 40 mg triamcinolone (kenacort-a)
3827|NCT04165499|Combination Product|Combination of Plant Extracts (BSL_EP026)|Each participant will consume 2 capsules daily, in the morning and in the evening.
3828|NCT04165499|Combination Product|Control|Each participant will consume 2 capsules daily, in the morning and in the evening.
3829|NCT04165486|Drug|BIIB101|Administered as specified in the treatment arm.
3830|NCT04165486|Drug|Placebo|Administered as specified in the treatment arm.
3831|NCT04165473|Behavioral|Training Program for Developing Social- and Personal Resources|"The training-method shows how one's own resonance can be exposed in order to live the balance between one's own needs and those of others.~Living one's own resonance means: more quality of life, work-life balance, holistic health through living feelings and talents, live equal, respectful and loving relationships, more personal responsibility, authentic decision making find new role models in private and professional areas.~The teaching and learning methods of the trainings and seminars are implemented according to the latest state of brain research and enable new perspectives with regard to new learning strategies, goals, enthusiasm and motivation.~With the Kutschera-Resonanz® method we teach and learn to consciously use this unconscious reservoir so that completely new dimensions in thinking and acting open up.~In this training program the basic tools of communication and interaction according to the Kutschera-Resonanz® method are taught and experienced by the participants."
3832|NCT04165460|Other|Psychoeducation|Delivering systematic information about cancer, oncological treatment and efficient coping strategies.
3833|NCT04165460|Other|Relaxation|Teaching the patient in diaphragmatic breathing retraining and passive relaxation with guided imagination.
3834|NCT04165460|Other|Cognitive Restructuring|Teaching the patient to identify dysfunctional cognitions about cancer and oncological treatment that trigger maladaptive emotions and behavior. Then, focus in generating alternative thoughts through contrast with empirical reality based on the Beck Model.
3835|NCT04165460|Other|Solving Problems|To generate alternative solutions to practical problems based on the model described by Nezu.
3836|NCT04165447|Behavioral|Front-of-pack labeling strategy|We designed a simple 'Lower Calorie' directive logo. We labeled the 20% of products with the lowest calories per serving within or across categories. All serving sizes used in this study were the average of the serving sizes within each category. Prior to conducting the analysis, we standardized the serving size by using the mean serving size within each subcategory. This standardization ensures that similar products are compared equally as serving sizes can be arbitrarily set by the manufacturers. The labels were displayed below the product images.
3837|NCT04165434|Other|Concurrent Training|Strength training and interval aerobic training in the same training session
3838|NCT04165421|Behavioral|Family intervention group|Education and Family conversations
3839|NCT04165408|Device|Contino|The Contino® urethral insert is a self-administered licensed medical device, is inserted into the distal portion of the male urethra inhibiting the flow of urine. The Contino is self-inserted into the adult male urethra and is removed prior to urination. Much more than just a device, Contino® is an integrated solution that includes personalised fitting and support from incontinence specialists. It is made from highly specialised medical grade polymer, which has been extensively tested for biocompatibility.
3840|NCT04165395|Device|Five-layer foam dressing|Five-layer foam dressing applied on the sacrum within 48 hours of spinal surgery
3841|NCT04165395|Device|Heelmedix boot|Heelmedix boot will be installed alternately from one foot to the other.
3842|NCT04165382|Other|Interventions in the guideline to infants receiving NIV|"Interventions in the guideline involve six components as~choice of right nasal interfaces and bonnet~use of skin protective dressing~alternate the nasal interfaces every 6 hours;~positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~supportive care with more new interventions~regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV"
3963|NCT04164446|Dietary Supplement|Oil Palm Phenolics|One capsule contains 250 mg OPP or 1 g OPP
3843|NCT04165382|Other|Usual care to infants receiving NIV|Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
3844|NCT04165356|Procedure|Mouth-rinse with 0.12% clorhexidine|mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.
3845|NCT04165356|Procedure|Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate|mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
3846|NCT04165343|Radiation|Positron Emission Tomography (PET) on EXPLORER|"Positron Emission Tomography (PET): Your blood sugar level will be checked by a finger stick before the PET scan. A small amount of radioactive tracer (approximately 0.5 teaspoons) will be injected into a vein in your arm before the imaging test. You will be asked to lay on your back on the EXPLORER scanner platform with both of your arms over the head during the duration of the test. A small amount of blood (1 tablespoon) will be collected after the test. This test will last for up to one (1) hour. This is a research test. Although the results may be available it cannot be used for clinical care. If any incidental findings are noted, it will be reported to you."
3847|NCT04165343|Diagnostic Test|Magnetic Resonance Imaging|MRI will be performed that can measure both the liver stiffness or fibrosis by a method called MR elastography (MRE) and the amount of fat deposited in the liver by MR proton density fat fraction (MR-PDFF). You will be asked to lay on your back on the scanner platform with both of your arms over the head during the duration of the test. MRE and MRI-PDFF are Food and Drugs Administration (FDA) approved tests and the results will be available to you. This test will last up to one (1) hour.
3848|NCT04165343|Diagnostic Test|Echocardiogram and Electrocardiogram|You will have baseline echocardiogram images and electrocardiogram (ECG) taken and will be asked to walk on a treadmill, which will increase in elevation and speed every 3 minutes until you can go no longer. This usually takes 9 to 12 minutes. Immediately after exercise, echocardiogram images and ECG will be taken again. The total time you will be in the stress lab including prep time and recovery is about 60 minutes. Wear comfortable or exercise clothing and walking/running shoes. You will be asked to not eat or drink (except for water) for 4 hours prior to the time of your test. Please drink water the day of the test so you are not dehydrated. This is an FDA approved test and the results will be available to you.
3849|NCT04165343|Diagnostic Test|Blood test|We will order laboratory blood tests as part of this research study and up to 3 tablespoons of blood will be collected for routine clinical and other laboratory tests relevant to the study. If you are able to become pregnant, you will have a urine pregnancy test before you begin the study.
3850|NCT04165330|Drug|AL3818|"AL3818: Part 1 - 12 mg, 10 mg, 8 mg, or 6 mg (by dosing cohort), Part 2 - RP2D (as determined from Part 1).~Administered orally once daily on Days 1-14 per 21 day Cycle."
3851|NCT04165330|Drug|Nivolumab Injection|Nivolumab 240 mg Administered by injection every 2 weeks (Odd Cycles: Days 1 and 15 and Even Cycles Day 8) per 21 day Cycle.
3852|NCT04165317|Drug|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
3853|NCT04165317|Drug|Bacillus Calmette-Guerin|Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
3854|NCT04165304|Dietary Supplement|sugar reduction|sugar reduction in the offered drinks
3855|NCT04165291|Behavioral|F4C|Fathers for Change (F4C) focuses on: 1) the fathering role to facilitate engagement, 2) RF to understand self, partner and children and emotion regulation skills to reduce IPV and child maltreatment. F4C focuses on understanding of emotional experiences, how they impact thinking and behaviors related to partners, co-parents and children. F4C clients will meet individually with their F4C therapist for 50 minutes per week over 16 weeks.
3856|NCT04165291|Behavioral|BIP|The Batterer Intervention Program (BIP) is a psychoeducational intervention that will be delivered in 50- minute individual weekly sessions over 16 weeks. The intervention focuses on the impact of violence on victims, power and control tactics, and societal influences supporting men's violence toward women. The intervention includes didactics and experiential exercises including role plays to teach anger management skills.
3857|NCT04165278|Other|hyperthermic baths|Taking hyperthermic baths
3858|NCT04165265|Device|Constant-Care|"Constant-Care (CC) (https://ibd.constant-care.com) is a web-application and contains an education and a disease monitoring package. An algorithm is established in the disease monitoring package, which consist of two variables; fecal calprotectin (FC) and a disease activity questionnaire (validated), Simple Clinical Colitis Activity index (SCCAI) for UC. The FC is obtained through CalproSmart app (it only takes 18 min) and the questionnaire is filled out in CC. Afterwards, the data are analyzed by CC and presented in a Total Inflammatory Burden Score (TIBS) as well as a visual traffic light of disease for the patients"
3859|NCT04165252|Diagnostic Test|Collection of vaginal, neonatal buccal and placental samples|Analysis of microbiome and mycobiota of vaginal, neonatal buccal and placental
3860|NCT04165239|Drug|KH176|Oral administration of 50 mg KH176 twice daily
3861|NCT04165239|Drug|KH176|Oral administration of 100 mg KH176 twice daily
3862|NCT04165239|Drug|Placebo|Oral administration of matching placebo twice daily
3863|NCT04165226|Device|Low level light therapy|Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.
3864|NCT04165226|Device|Fractional CO2|"Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2."
3865|NCT04165226|Device|Combined fractional CO2 laser and low level light therapy|Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
3866|NCT04165213|Behavioral|COPE online training|"The intervention being tested is PACE staff training in COPE - accomplished with the creation of self-paced online learning modules.~The modules will include rich multimedia content and interactive assessments to keep the learner engaged and will allow for easy packaging of the content into the latest interoperability standards for such content including the latest Shareable Content Object Reference Model (SCORM) specifications, which will allow for repurposing and sharing with other institutions and will be designed using a hyperlearning model with four dimensions. The self-paced modules will be highly interactive featuring integrated multimedia content, assessments, and learner evaluations to allow PACE staff to engage with the content at a high level and practice application in simulated scenarios. Each module will require approximately 45-60 minutes/module for the learner to complete.le for the learner to complete."
3867|NCT04165200|Diagnostic Test|Blood and feces samples|"Blood samples are going to be taken by puncturing peripheral vein extraction with 10 ml of venous blood for later biweekly to monitor in person and therefore monitor immune status with biomarkers T lymphocyte subclass CD4 and viral load. A total of four blood samples will be taken at weeks 4, 8, 12 and 24 of recruitment.~A total of four feces samples are going to be required during the study, to evaluate the changes on the microbiota of the patient. 1 week before the patients start their HAART, the same day the patients initiate their HAART, 8 weeks after they started HAART and 24 weeks after HAART."
3868|NCT04165187|Other|Body Awareness Therapy|Body scanning, stretch-release movements, centralization, contact with the ground, postural stability, movement flow and free breathing will be performed during sessions in lying, sitting and standing positions.
3869|NCT04165187|Other|Home exercise program|Home exercise program will consist of joint range of motion, stretching, strengthening and proprioceptive exercises for lower extremity.
3870|NCT04165174|Drug|Terepril monoclonal antibody; Apatinib|Terepril monoclonal antibody,240mg,ivdrip,Q3W Apatinib,250mg,po,QD
3871|NCT04165174|Radiation|SBRT|6-10Gy/F,5-8F
3872|NCT04165161|Diagnostic Test|search for a patent foramen ovale|Injection of a contrast solution A - In the upper cellar territory with controlled ventilation without positive tele-expiratory pressure; B - In the upper cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O; C - In the lower cellar territory with controlled ventilation without positive tele-expiratory pressure; D - In the lower cellar territory in controlled ventilation with a positive end-to-expiratory pressure of 10cm H2O;
3873|NCT04165148|Device|Low Impact Laparoscopy|Low Impact Laparoscopy is a minimally invasive technique that combines low pressure insufflation (with the iFS AirSeal® system) and microcoelioscopy (with specific microtrocards and laparoscopic instruments).
3874|NCT04165148|Device|conventional laparoscopy|conventional laparoscopy
3875|NCT04165148|Other|Visual Analog Scale (VAS) for Pain|"The patient evaluates her pain using an VAS scale on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with VAS scale) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an VAS."
3876|NCT04165148|Other|Saint-Antoine Pain Questionnaire (QDSA)|"The patient evaluates her pain using an QDSA questionnaire on arrival in the post-interventional surveillance room, then 30 minutes, 2 hours, 4 hours, 6 hours after leaving the operating roo, at the exit of post-interventional surveillance room and at the exit of the hospital.~The day after surgery, according to the usual practice, outpatients receive a telephone call from a Gynecologist. The assessment of their pain (with QDSA questionnaire) will be collected.~During the usual consultation at 1 month, the patient must evaluate her pain by means of an QDSA questionnaire."
3877|NCT04165148|Other|post-operative questionnaire|The patient will fill in the antalgic intake record and the patient booklet for the collection of medical consumptions from her discharge from the hospital and during the month following the surgery.
3878|NCT04165135|Drug|Standard of Care for Haemophilia A|There is no pre-determined studied medicinal product. Any treatment (including treatments started during the observational period) will be administered according to standard clinical practice, independently of participation in the current study, according to clinician's independent therapeutic decision.
3879|NCT04165122|Biological|HDIT101|i.v. Infusion
3880|NCT04165122|Drug|Valaciclovir|oral application of encapsulated Valaciclovir tablets
3881|NCT04165122|Biological|HDIT101 placebo|i.v. Infusion
3882|NCT04165122|Drug|Valaciclovir placebo|oral application of encapsulated Valaciclovir placebo tablets
3883|NCT04165096|Biological|Pembrolizumab|IV infusion
3884|NCT04165096|Biological|MK-5890|IV infusion
3885|NCT04165083|Biological|Pembrolizumab|IV infusion
3886|NCT04165083|Biological|MK-4830|IV infusion
3887|NCT04165070|Biological|Pembrolizumab|IV infusion
3888|NCT04165070|Drug|Carboplatin|IV infusion
3889|NCT04165070|Drug|Paclitaxel|IV infusion
3890|NCT04165070|Drug|Pemetrexed|IV infusion
3891|NCT04165070|Biological|MK-7684|IV infusion
3892|NCT04165057|Other|Optimal muscle tension management|including TOF monitor and reversal of neuromuscular blockade agent : sugammadex
3893|NCT04165044|Procedure|Leukocyte and Platelet Rich Fibrin plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. A double L-PRF membrane was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
3929|NCT04164771|Other|Aerobic training and Moringa Oleifera|Aerobic exercises/training refers to any type of rhythmic, continuous physical activities that use large group of muscles like walking, running, cycling, and swimming consuming additional amount of energy while Moringa Oleifera a plant from the family Moringacea, its products are used as a health supplement introduced in Africa and south Asian countries to cure many diseases and improve health status
3996|NCT04164238|Drug|Cisplatin|Cisplatin injection
3894|NCT04165044|Procedure|Connective tissue graft plus Coronally Advanced Flap|The Coronally advanced flap was made following the protocol described by Zucchelli et al. in 2007. (39). When the margin of the flap was able to passively extend until more coronal of the CEJ the coronal mobilization of the flap was considered satisfactory. Then connective tissue graft obtained from the palate was positioned at the level of CEJ, getting the stabilization with 5-0 resorbable suture. After that, the flap was coronally advanced and stabilized with interrupted sutures (5-0 resorbable) anchored to incisal contact points (mesial and distal) created with a flowable, light-curing resin material in the treated tooth. Finally, gentle pressure over the area with a moistened gauze with saline solution was performed.
3895|NCT04165031|Drug|LY3499446|Administered orally
3896|NCT04165031|Drug|Abemaciclib|Administered orally
3897|NCT04165031|Drug|Cetuximab|Administered IV
3898|NCT04165031|Drug|Erlotinib|Administered orally
3899|NCT04165031|Drug|Docetaxel|Administered IV
3900|NCT04165018|Procedure|Fine-Needle Biopsy (FNB)|Fine-needle biopsy may be used to take samples of a pancreatic neoplasm.
3901|NCT04165005|Behavioral|decentering|examined a mindfulness-based intervention focused on a decentering component, that is suitable for elders, aimed to influence on cognitive measures and psychological distress.
3902|NCT04165005|Behavioral|guided imagery|relaxing guided imagery including breathing exercises.
3903|NCT04164992|Device|EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea)|The operative needle (EUSRA—STARMED) is a novel monopolar 18 gauge radiofrequency ablation (RFA) electrode that is placed in the echoendoscope operative channel. It is 140 cm long with a sharp conical 1 cm tip for energy delivery. The needle is associated with an internal cooling system connected via a pump to an external cold saline solution source (0 °C) that prevents the charring of the tip and improves the ablation accuracy.
3904|NCT04164979|Drug|Cabozantinib|Given PO
3905|NCT04164979|Drug|Pembrolizumab|Given IV
3906|NCT04164953|Procedure|Surgical treatment|Surgical treatment of Dupuytren's disease. Average from 2 to 4 joints per hand operated on simultaneously
3907|NCT04164940|Other|Brief alcohol intervention|Brief alcohol intervention already implemented in daily routine by the individual hospitals.
3908|NCT04164927|Other|Manual Lymphatic Drainage|"Lymphatic correction method was used via the KinesioTaping® to patients group.~Standardized 30-minute Manuel Lymphatic Drainage treatment was applied to the MLD group.~Control group received only physiotherapy treatment."
3909|NCT04164927|Other|Kinesio Taping|Depending on the size of the leg two or three fan cut tapes were applied with light paper-off tension on the frontal, medial and lateral aspects of the limb. Kinesio taping was applied by certified Kinesio Tape practitioner once a week to Kinesiotaping group.
3910|NCT04164927|Other|Control|Knee-based exercises were undertaken in supine (active- assisted knee flexion using a bandage, inner range quadriceps contractions, and straight-leg raises), seated (active-assisted knee flexion using the contralateral limb and inner range quadriceps contractions), and standing (hip and knee flexion, active hamstring curls, lunges on a step, hamstring stretches) postures. These exercises were undertaken in sets of 10 repetitions, 3 times daily; the physiotherapist was present to assist, as required, on 2 occasions per day for the first 3 postoperative days and then once daily from day 4 until hospital discharge.
3911|NCT04164914|Dietary Supplement|Prebiotic|Soluble prebiotic fiber (resistant dextrin 14 g/d x 4 weeks)
3912|NCT04164901|Drug|AG-881|AG-881 oral tablets
3913|NCT04164901|Drug|Matching Placebo|Matching Placebo oral tablets
3914|NCT04164888|Drug|CIVI 007|hypercholesterolemia agent
3915|NCT04164875|Diagnostic Test|Temperature measurement|The 'intervention' is repeated rectal temperature measurements
3916|NCT04164862|Device|AccuVein AV400 Device Versus Ultrasound-guided Cannulation|Accuvein AV400 device versus Ultrasound guided cannulation
3917|NCT04164849|Drug|5-aminolevulinic acid|5-aminolevulinic acid (30 mg/ml) will be added to mononuclear cells in a dose of 3 millimolar and incubated for 1 hour
3918|NCT04164849|Procedure|Blue light photopheresis|The mononuclear cells incubated with 5-aminolevulinic acid for 1 hour will be exposed to blue light.
3919|NCT04164849|Procedure|Transfusion|The treated cells are transferred back to the patient as a standard blood transfusion
3920|NCT04164849|Procedure|Continuous Mononuclear Cell Collection (CMNC)|The mononuclear cells are collected using the Spectra Optia with the Continuous Mononuclear Cell Collection protocol. 90 ml of mononuclear cells will be collected and 100 ml of 0,9% saline will be added to dilute the cells before incubation with drug and photopheresis.
3921|NCT04164836|Diagnostic Test|rhinoscope|more suitable nose for nasotracheal intubation will be selected based on the view of rhinoscope.
3924|NCT04164810|Other|Hydrotherapy|All sessions will be done by 3 physical therapists specialized in hydrotherapy under different modalities, and a pool equipped to perform this type of intervention. The most commonly used techniques in the institution are Bad Ragaz, for motor control, and the Watsu technique for relaxation and spasticity work.
3925|NCT04164810|Other|Physical Therapy|All sessions will be done by 3 physical therapists expert in neurorehabilitation, following a physical therapy protocol, which includes stretching, aerobic excercise and muscle strengthening.
3926|NCT04164797|Drug|endostar+chemoradiotherapy|antiangiogenic drug+chemoradiotherapy
3927|NCT04164797|Other|chemoradiotherapy|chemoradiotherapy
3928|NCT04164784|Behavioral|therapeutic monitoring|According to the glucose lever recorded by FreeStyle Libre H (Flash Continuous Glucose Monitoring System) ,we give the intervention group instructions to adjust their diet and lifestyle to abtain a good glucose control.
3930|NCT04164758|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg encapsulated tablets) administered orally as a single dose once daily
3931|NCT04164758|Other|Placebo|Placebo (provided as 2 × placebo encapsulated tablets) administered orally as a single dose once daily
3932|NCT04164758|Drug|Quetiapine|Quetiapine 25 mg (provided as 1×25 mg quetiapine encapsulated tablet and 1 × placebo encapsulated tablet), OR 50 mg (provided as 2×25 mg quetiapine encapsulated tablets), OR 100 mg (provided as 2×50 mg quetiapine encapsulated tablets) administered orally as a single dose once daily
3933|NCT04164745|Drug|Anlotinib, oral capsule|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
3934|NCT04164745|Biological|Pembrolizumab|Participants receive Anlotinib 12 mg p.o, qd on Days 1-14 of each 3-week cycle until progressive disease or unacceptable toxicity plus pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).
3935|NCT04164732|Drug|LCZ696|LCZ696 at doses of 50mg, 100mg and 200mg b.i.d oral
3936|NCT04164732|Drug|Placebo|placebo
3937|NCT04164719|Drug|TNX-102 SL|Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
3938|NCT04164706|Device|HumiGard device|HumiGard is a CE marked device that delivers warmed humidified CO2 during laparoscopic surgery
3939|NCT04164706|Other|Standard care (with sham HumiGard device)|Standard methods of keeping the patient warm whilst in theatre, including warmed IV fluids, warming blankets/forced air warming devices.
3940|NCT04164693|Drug|Low molecular weight heparin|patients began to use low molecular weight heparin or warfarin sodium tablets.
3941|NCT04164693|Other|non anticoagulant therapy group|no anticoagulant was used after operation.
3942|NCT04164680|Diagnostic Test|Multimodal Neuroimaging|fludeoxyglucose (FDG-)PET/MR imaging
3943|NCT04164667|Behavioral|Directed instruction of the combined intervention of physical activity and mindfulness meditation|By using the VA's ANNIE text messaging systems, the participant's will receive detailed guidance on the exercise and mindfulness session.
3944|NCT04164667|Behavioral|Self-guided practice of the combined intervention of physical activity and mindfulness meditation|The participants will receive the same goals about exercise and mindfulness practice, but without the added text messages where explicit instruction will be provided
3945|NCT04164654|Behavioral|Loneliness Intervention|28 days of engagement with the Nod app, which consists of interactive exercises drawn from cognitive behavioral therapy (e.g behavioral activation and cognitive reframing exercises), positive psychology (e.g. acts of kindness), and mindful self-compassion programs (e.g. loving-kindness meditations)
3946|NCT04164641|Device|Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic|Physical therapy evaluation (range of motion, strength, mobility, scale). Noraxon based gait assessment on treadmill while barefoot and with instrumented inner soles. Over ground walking assessment (with wireless instrumented inner soles, observational gait analysis while climbing stairs, ramps, curbs). Noraxon gait assessment and walking on treadmill will be video recorded for assessment. Standard measure of functionality and 6 minute walk test will be conducted. Patient will be fitted with corrective orthotics, based on usual care. Physical therapy re-evaluation. Noraxon based gait assessment and foot assessment (any areas of irritation, callus formation, swelling, ulcer formation, and gait mobility irregularities will be monitored and reassessed) throughout the study.
3947|NCT04164628|Other|Quality of life assessment|Quality of life will be assessed with Nottingham Health Profile
3948|NCT04164615|Drug|GB221|"GB221:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
3949|NCT04164615|Drug|Placebo control|"Placebo control:Lyophilized powder for injection; strength 110mg/bottle; the first administration of 8 mg/kg, intravenous drip for over 90 minutes; subsequently, the administration shall be given once every 3 weeks (one cycle), the dose is 6 mg/kg, intravenous drip for 30~90 minutes; The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study.~Capecitabine:Tablets; 500mg/tablet, 12 tablets/box; Total daily dose 2000 mg/m2, orally twice daily, one dose each in the morning and evening, administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle. The administration shall be continued until disease progression or presence of intolerable toxic reactions or subject's active withdrawal from clinical study."
3950|NCT04164589|Device|SCENAR 1NT-02.2|The neuro-adaptative regulation will be carried out in vulvo-perineal and sacral area
3951|NCT04164576|Genetic|Transplant patients|Study the specific immunity against Polyomavirus
3952|NCT04164563|Device|Even-Up|Orthotic shoe lift worn on contralateral foot to increase leg length
3953|NCT04164524|Drug|Gentamycin|Gentamycin 160 mg spray applied over the mesh
3954|NCT04164511|Dietary Supplement|2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)|The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
3955|NCT04164498|Other|music|exposure to music to investigate its effects on reducing noise adverse effects
3956|NCT04164485|Biological|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with autologous adipose-derived cells will be injected into submucosa of vocal cord and paraglottic space under the surgical microscope
3957|NCT04164485|Biological|Autologous adipose cell transplantation|Autologous adipose-derived cells will be injected into the submucosa of vocal cord and paraglottic space under the surgical microscope
3958|NCT04164472|Behavioral|Friend to Friend (F2F) with Coaching|Friend to Friend (F2F) with Coaching has 16 small group sessions and 8 classroom sessions as led by school staff with coaching from the Children's Hospital of Philadelphia (CHOP) research team. The program aims to improve problem solving and prosocial behaviors, and decrease aggressive behaviors.
3959|NCT04164459|Drug|Xalost S|One drop one times a day in study eye
3964|NCT04164433|Device|Oral HIV Self-Test (OraQuick)|The oral HIV self-test is a device for taking a test which is painless. The user gently swipes the test swab along the upper gums once and the lower gums once. The swab is then inserted inside the test tube provided and results are ready in 20 minutes.
3965|NCT04164420|Behavioral|Oral neuromuscular training and orofacial sensory-vibration|Oral neuromuscular training is performed by using an oral device. The device is placed pre-dentally behind closed lips, and the participant is sitting in an up-right position. The participant is the instructed to hold the device against a gradually-increasing horizontal pulling force for 5-10 s, whilst trying to resist the force by tightening the lips and pressing the head backward against a head rest.
3966|NCT04164420|Behavioral|Orofacial sensory-vibration stimulation|All participants in the control group is given orofacial sensory-vibration stimulation by using an electrical toothbrush. Instructions is given on how to stimulate the buccinator mechanism, lips, external floor, and the tongue three times daily before a meal.
3967|NCT04164394|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
3968|NCT04164394|Dietary Supplement|I31 Probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
3969|NCT04164381|Device|Robotic assisted intervention|Robotic treatment of the upper limb (30 sessions, 5 times a week) using a set of 4 robotic devices: Motore (Humanware); Amadeo, Diego, Pablo (Tyromotion). The training will include motor-cognitive exercises specifically selected to train spatial attention, vision and working memory, praxis, executive function, and speed of processing.
3970|NCT04164368|Drug|Lenalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Lenalidomide 25mg PO QD D2-11
3971|NCT04164355|Drug|Tadalafil 20 MG|To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
3972|NCT04164342|Other|surveys|Phone interviews to pass the Brief Pain Inventory (BPI) and the Patient Health Questionnaire-2 (PHQ-2) questionnaires (this is the intervention, since questionnaires at not usually done) at 3, 6 and 12 months after ICU discharge.
3973|NCT04164329|Drug|General anesthetic|General anesthesia (propofol, fentanyl, sevorane, remifentanyl, rocuronium)
3974|NCT04164316|Device|Kinesio Tape|Kinesio TexTM Tape which is the original elastic therapeutic adhesive tape which is a latex-free, hypoallergenic, waterproof, porous.
3975|NCT04164303|Other|Physical Therapist management|Physical Therapist management included joint manipulation, mobilization with movement, strengthening exercises, and grip proprioception training.
3976|NCT04164290|Drug|Jiashen Tablets|1 tablet
3977|NCT04164290|Drug|Jiashen Tablets|2 tablets
3978|NCT04164290|Drug|Jiashen Tablets|4 tablets
3979|NCT04164290|Drug|Jiashen Tablets|6 tablets
3980|NCT04164290|Drug|Jiashen Tablets|8 tablets
3981|NCT04164290|Drug|Jiashen Tablets|9 tablets
3982|NCT04164290|Drug|Jiashen Tablets Placebo|1 tablet
3983|NCT04164290|Drug|Jiashen Tablets Placebo|2 tablets
3984|NCT04164290|Drug|Jiashen Tablets Placebo|4 tablets
3985|NCT04164290|Drug|Jiashen Tablets Placebo|6 tablets
3986|NCT04164290|Drug|Jiashen Tablets Placebo|8 tablets
3987|NCT04164290|Drug|Jiashen Tablets Placebo|9 tablets
3988|NCT04164277|Behavioral|Caregiver Component.|Facebook-based program including four new habit-formation tasks/week. Three face-to-face caregiver meetings: Meeting 1: A healthy slow cooking demonstration will be offered, and each family will receive a small bag of groceries to facilitate preparation of the demonstrated recipe at home. Each caregiver will also receive an intervention cookbook containing affordable slow-cooking recipes, quick-fix recipes, and healthy snack ideas. Meeting 2: MSU Extension health educators will demonstrate how to spend less and shop healthy and how to read nutrition fact labels to promote healthy purchasing behaviors. Meeting 3: MSU Extension health educators will present healthy eating and PA community resources (e.g., farmer's markets, community gardens, nearly parks or other free or affordable PA facilities) and provide caregivers a resource manual.
3989|NCT04164277|Behavioral|Caregiver-Preschooler Learning.|Preschoolers, using stickers, will create two letters each week regarding a food or activity presented in the center-based program that they liked or want to try at home. Letters will be sent by the PM privately to each caregiver via Facebook messenger every Wednesday and Friday. Caregivers will be asked to answer two Facebook multiple-choice questions related to the letters each week by Sunday midnight (e.g., what foods listed in the their child's letter did the participant provide? and what activities listed in the their child's letter did the participant's family try?). Caregiver responses to the questions will be summed to indicate caregiver responses to child requests. Each preschooler's letters will be kept in his/her intervention binder with other intervention materials to present to his/her caregiver at Meeting 3. Weekly preschooler activities, with pictures or videos, will be shared with caregivers via the Facebook private group every week.
3990|NCT04164277|Behavioral|Center-based Preschooler Component.|"Built on previous research, preschoolers will receive weekly, age-appropriate, participatory learning co-delivered by teachers and MSU Extension health educators. Session duration will be 20 minutes because children's normal attention span is 3-5 minutes per year of age, and 20 min/session is recommended for preschoolers. The already developed Eat & Walk My ABCs curriculum will be implemented. The curriculum includes four components: healthy eating learning, taste-testing activities, movement skill training, and fun physical activity."
3991|NCT04164264|Drug|Propofol|At T0, a propofol infusion at a rate of 1.5 mg/kg/min will be started until apnea is achieved. Loss of consciousness will be defined clinically using loss of eyelash reflex (TLOER) and tolerance of nasal cannulae (TNC), tested every 10 sec., and by a BIS <60 for 30 sec. (TBIS). Apnea will be defined as absence of end-tidal CO2 for at least 20 seconds (TAPNEA). A saliva sample with be taken under anesthesia for genome-wide association study and principal component analysis.
3992|NCT04164251|Other|Screening mammography|The purpose of the study was to evaluate the feasibility of securing inpatient breast cancer screening mammograms for non-adherent hospitalized women prior to hospital discharge.
3993|NCT04164238|Drug|Toripalimab|Toripalimab Injection
3994|NCT04164238|Drug|Paclitaxel|Paclitaxel Injection
3995|NCT04164238|Drug|Carboplatin|Carboplatin Injection
3998|NCT04164225|Behavioral|Qigong Exercise|"Participants with chronic low back pain will follow the free 5 elements Qigong healing class (estimate of 6 hours) at the Spring Forest Qigong center and then practice the 5 elements healing Qigong at home 3 times a week for 40 minutes with a freely available online video, for 12 weeks. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed."
3999|NCT04164225|Behavioral|P.Volve Exercises|P.Volve exercise focuses on low impact core strengthening, core stabilization, and stretching. The program is similar in delivery as Qigong (i.e., online videos). An introductory class (estimate of 2.5h) will be given by the P.Volve team, the principal investigator, and a physical therapist who has experience with P.Volve exercises. Participants will access online videos for individual home practice in 40min/session, 3x/week for 12 weeks. Participants will receive a P.ball for some exercises, while other exercises are done with no equipment. Tailored videos will be available for those with cLBP. A weekly group session (1 hour) will be conducted at the Brain Body Mind Lab with the principal investigator to address questions and demonstrate movements if needed.
4000|NCT04164212|Drug|Flumist Quadrivalent Nasal Product|FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer
4001|NCT04164199|Drug|Tislelizumab 200 mg, IV|Day 1 of each 21-day cycle, to be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
4002|NCT04164199|Drug|Pamiparib 20, 40, 60 mg PO BID|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
4003|NCT04164199|Drug|Pemetrexed 500 mg/m² IV|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
4004|NCT04164199|Drug|Capecitabine 1000 mg/m² PO BID|Day 1 to Day 15 of each 21 day cycle, to be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
4005|NCT04164199|Drug|Pamiparib 20 or 40 mg PO BID|To be administered until disease progression, unacceptable toxicity, the start of new anticancer therapy, withdrawal of consent, study termination by the sponsor, or death, whichever occurs first.
4006|NCT04164186|Other|Automatic detection and segmentation of NSCLC tumors|an automated deep learning detection and segmentation software for non-small cell lung cancer (NSCLC) that can automatically detect and segment tumors on CT scans and thus reduce the human variation.
4007|NCT04164173|Device|EzPAP|Patient will receive 10 min EzPAP 4 times daily
4008|NCT04164173|Device|Metaneb|Patient will receive 10 min Metaneb 4 times daily
4009|NCT04164173|Device|Intermittent Positive Pressure Breathing (IPPB)|Patient will receive 10 min IPPB 4 times daily
4010|NCT04164160|Other|integrated-care-model benefiting group|Patients will be called for the ﬁrst interview of the study by the healthcare professional. Their data will be automatically entered in the Salut + Social app, they will be asked to respond to the study questionnaires (ad hoc questionnaire for sociodemographic data, EuroQol-5D, Zarit questionnaire and Morisky-Green test) and will take part in the future actions to be planned for them. Patients will receive an appointment to attend their PCC at 6, 9, and 12 months after their incorporation into the program. In those follow-up, the same questionnaires will be provided together with the IEXPAC questionnaire, which evaluates the experience of the chronic patient with the new care model.
4011|NCT04164147|Procedure|Total knee replacement|Participant will undergo total knee replacement performed via anterior parapatellar approach with bicompartmental posterior-stabilized implants
4012|NCT04164147|Diagnostic Test|CT scan|CT scans of the affected knee joint before and after the surgical procedure
4013|NCT04164147|Diagnostic Test|Biomechanics|Participants will be asked to perform biomechanical assesment before and following surgery at baseline, 6-8 weeks and 6-months postoperatively
4014|NCT04164147|Device|either the Persona and the NexGen total knee implant|Participant are randomly allocated to receive either the Persona and the NexGen total knee implant for treatment of end-stage knee osteoarthritis.
4015|NCT04164134|Other|blood draw|"Control samples for the Rb survivor group (adult) are already available at the VUMC for the platelet study; unselected volunteers from an anti-cancer campaign. Control samples (adult) for the EV study will be collected in a blooddrive at the Essen site.~Pediatric patients. For the pediatric Rb patients, blood draw is part of standard care (3mth-4y). The control blood samples of healthy children (12) will be drawn from healthy children, where the blood draw is already part of otherwise planned care (e.g. patients which are completely healthy besides having an unrelated problem for which surgery is required). Controls will be age-matched as much as possible."
4016|NCT04164121|Drug|Phenlarmide Tablets|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
4017|NCT04164121|Drug|Placebos|Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
4019|NCT04164095|Procedure|lappg|Preservation of pylorus and vagus nerve by laparoscopy
4020|NCT04164082|Drug|Gemcitabine|Given intravesically
4021|NCT04164082|Drug|Gemcitabine Hydrochloride|Given intravesically
4022|NCT04164082|Biological|Pembrolizumab|Given IV
4023|NCT04164069|Biological|Bevacizumab|Given IV
4024|NCT04164069|Drug|Dasatinib|Given PO
4025|NCT04164069|Drug|Fluorouracil|Given IV
4026|NCT04164069|Drug|Leucovorin|Given IV
4027|NCT04164069|Drug|Leucovorin Calcium|Given IV
4028|NCT04164069|Drug|Oxaliplatin|Given IV
4029|NCT04164069|Other|Quality-of-Life Assessment|Ancillary studies
4030|NCT04164056|Device|deep brain stimulation|deep brain stimulation on the hippocampus or the anterior nucleus of the thalamus
4031|NCT04164043|Behavioral|Wellness Recovery Program|12-week community-based recreation therapy
4032|NCT04164030|Behavioral|Education and Exercise Program for Adults with Type 2 Diabetes|Eating Smart and Being Active program
4033|NCT04164030|Behavioral|Nutrition Education plus Occupational Therapy plus Yoga|multimodal interdisciplinary approach
4034|NCT04164017|Device|EUS-guided FNB with Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
4035|NCT04164017|Device|EUS-guided FNB without Syringe Suction|For each case, FNB will be performed using two punctures: one with 20mL syringe suction and another without aspiration. The order in which they will be performed will be known only by the performing physician and the nursing team at the time that FNB is proposed. This information will be concealed from the pathologist responsible for sample analysis.
4036|NCT04164004|Other|Kansas City Cardiomyopathy Questionnaire-12|Health status assessment will be completed using the well-validated Kansas City Cardiomyopathy Questionnaire-12 prior to or at the time of heart failure clinic visits.
4039|NCT04163978|Drug|Nitric Oxide|in situ 240mL nitric oxide releasing sinus irrigation solution
4040|NCT04163978|Drug|Budesonide|Saline based sinus irrigation 1mg Budesinide solution
4041|NCT04163965|Device|Capacitive ECG|Patients having a pacemaker will sit down on a seat bearing capacitive ECG electrodes during their routine heart checkup at the cardiology.
4042|NCT04163952|Biological|Panitumumab|Given IV
4043|NCT04163952|Biological|Talimogene Laherparepvec|Given IM
4044|NCT04163939|Other|Vista Therapy Collar|The patient will wear the cervical collar
4045|NCT04163939|Other|Placebo|The patient will not wear the cervical collar
4046|NCT04163926|Procedure|Intervention Group cataract follow up|Intervention group will have cataract follow up conducted by the referring optometrist 4-6 weeks after surgery
4047|NCT04163926|Procedure|Usual Care consultant follow up|Usual care group - Consultant led post op follow up
4048|NCT04163913|Other|Change in User interfaces of Cirvo compression device application.|Comparison of 2 versions of the Circo user interface
4049|NCT04163913|Other|Change in Satisfaction in use of Cirvo device|Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
4050|NCT04163900|Drug|NUC-1031|IV infusion in 500 mL of 0.9% sterile saline for injection given over 30 minutes
4051|NCT04163900|Drug|Gemcitabine|IV infusion in 250 mL of 0.9% sterile saline for injection given in accordance with the package insert
4052|NCT04163900|Drug|Cisplatin|IV in 250 mL of 0.9% saline given with appropriate hydration protocol in accordance with local institutional practice for biliary tract cancer
4053|NCT04163887|Procedure|hepatectomy|Resection colorectal liver metastases using a laparoscopic approach or an open approach.
4054|NCT04163874|Drug|Fiasp|Fiasp Insulin delivered in a basal-bolus manner.
4055|NCT04163874|Drug|Pramlintide Acetate|Pramlintide delivered in a basal-bolus manner with a fixed ratio with insulin.
4056|NCT04163874|Drug|Placebo|Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
4057|NCT04163874|Device|Artificial Pancreas|Tandem insulin pump, dexcom G5 sensor, Nexus 5 ccellphone running the iMAP algorithm.
4058|NCT04163861|Diagnostic Test|2d speckle tracking echocardiography|2d speckle tracking echocardiography
4059|NCT04163861|Diagnostic Test|serum BNP level|serum BNP level of HFpEF study subjects
4060|NCT04163848|Other|Pollution|CO2 equivalent productions related to anesthetic gases use during general anesthesia for laparoscopic surgery
4061|NCT04163835|Drug|Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 5g + Wenxin Granules placebo 5g."
4062|NCT04163835|Drug|1/2 Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 2.5g + Wenxin Granules placebo 7.5g."
4063|NCT04163835|Drug|Twice Normal-dose Wenxin Granules|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules (no sucrose) 10g."
4064|NCT04163835|Drug|Placebo|"The drugs should be taken 10 g orally each time, 3 times a day after meals, for 4 weeks.~Ingredients: Wenxin Granules placebo 10g."
4065|NCT04163822|Other|no intervention|no intervention
4066|NCT04163809|Device|Virtual Reality with Oculus Go headset|The investigator will place the Oculus Go VR headset on the patient. VR will provide distracting, pleasant visual stimulus from the beginning of the procedure (while the patient is being cleaned and draped) and removed immediately after the regional anesthesia procedure is complete for roughly 10-20 minutes. All patients receiving VR will view the same scene.
4067|NCT04163796|Device|UPnRIDE power wheelchair|The intervention will consist of approximately 3.5 hours per session, 3 times per week over 12 weeks. During each 3.5-hour session, subjects will be asked to stand at least 5 minutes during every 15 minutes or more as tolerated. One time each session, participants will be asked to perform the Activities of Daily Living course.
4068|NCT04163783|Drug|[14C]-BGB-3111|20-mg capsule containing ~200 μCi of [14C]-BGB-3111,
4069|NCT04163783|Drug|BGB-3111|Three 20-mg capsules of BGB-3111 and three 80-mg capsules of BGB-3111
4070|NCT04163770|Device|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
4071|NCT04163770|Device|caliberation of pacemaker|evaluation of ventricular impedence, ventricular sensing, ventricular capture threshold
4072|NCT04163757|Dietary Supplement|crocin|2 tablets crocin per day
4073|NCT04163757|Dietary Supplement|placebo|2 tablets placebo per day
4074|NCT04163744|Device|Double balloon catheter|Induction of labour with double balloon catheter
4075|NCT04163731|Other|DASI questionnaire|All patients who accept to participate will undergo a self-questionnaire of 10 minutes. Medical data of their cardiac stress test and risk factor will be collected.
5295|NCT04153929|Drug|Semaglutide|Injection
4076|NCT04163718|Drug|Umbralisib|800 mg Umbralisib will be self-administered on an outpatient basis. Umbralisib will be taken orally once daily within 30 minutes of a meal until removal from study. This treatment will be administered in 4 week (28-day) cycles.
4077|NCT04163705|Diagnostic Test|blood sample collection|Routine Laboratory Analysis
4078|NCT04163692|Other|Progressive relaxation exercises|"Following intructions have been given to patients:~Punch your hands and contract your forearm~Punch your hands, push your elbow towards the seat~Bend your elbows~Push your shoulders back~Press your knee down and pull your toes towards you~Pull your knees towards you and push your feet down~Tighten your hips~Push your head back~Lift your eyebrows~Make wrinkles on your nose~Tighten your teeth~Push your chin down~Close your eyes and think of good things."
4079|NCT04163679|Procedure|Vaginal Preparation|"One sponge stick will be inserted into the vagina, where it will stay during the scrubbing of thighs and genitals.~One sponge will be used to scrub the right inner thigh from mid-thigh to right labia majora. This sponge will then be discarded.~A second sponge will be used to scrub the left inner thigh from mid-thigh to left labia majora. This sponge will then be discarded.~A third sponge will be used to scrub the mons pubs, labia majora and minor, perineum and rectum in that order then will be discarded. This will be repeated with a fourth sponge.~The existing sponge stick in the vagina will be rotated in the vagina twice then removed. This will be discarded.~A second sponge stick will be inserted in the vagina, rotated twice then removed. As it is removed from the vagina, the perineum and rectum will be swabbed with the stick in that order then discarded. This will be repeated using a third sponge stick."
4080|NCT04163666|Behavioral|Mirror therapy|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for mirror therapy, while the remaining 30 minutes will be for task-oriented motor learning
4081|NCT04163666|Behavioral|Cognitive therapeutic exercise|The intervention will take place at the home of the participant for 6 weeks (30 days), during 60-minute sessions, 30 of which will be for cognoscitive therapeutic exercise, while the remaining 30 minutes will be for task-oriented motor learning
4082|NCT04163653|Diagnostic Test|Non-contrast MRI|Classification and characterization of the lymphatic vasculature using non-contrast MRI.
4083|NCT04163653|Diagnostic Test|Cardiopulmonary exercise test|Cardiopulmonary exercise test, measurement of VO2 and heart rate.
4084|NCT04163640|Other|intra-ovarian platelet rich plasma injection|patients will undergo a transvaginal intra-ovarian platelet rich plasma injection
4085|NCT04163614|Other|IBPS-Guided Ultrafiltration|Each month, the study investigator will review the average intradialytic blood pressure slope from the prior two weeks. A prespecified algorithm will be used to prescribe additional fluid removal/weight reduction based on this slope.
4086|NCT04163588|Drug|Metolazone|Study participants receive loop diuretics plus oral metolazone at a dose of 5/10 mg once daily
4087|NCT04163588|Drug|Loop Diuretics|Study participants receive a standard diuretic strategy (intravenous loop diuretics as recommended by current guidelines plus placebo)
4088|NCT04163575|Biological|:Anti-CD22-CAR|Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
4089|NCT04163562|Drug|INP20|Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.
4090|NCT04163562|Drug|Placebo|Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
4091|NCT04163549|Behavioral|Safe at Home|Discussion-based intervention
4092|NCT04163536|Drug|Methylprednisolone|In the experimental group, methylprednisolone will be administered intravenously for 5 days at a dose of 1 mg/kg/day. Methylprednisolone will be provided for reconstitution and dilution in 50 ml of NaCl 0.9% solution and administered over 15 minutes, once a day.
4093|NCT04163536|Drug|Placebos|in the control group, placebo will be administered intravenously for 5 days. Placebo will be identical (color and aspect) to experimental substance, will be provide as a 50 mL of NaCl 0.9% solution and administered intravenously over 15 minutes, once a day.
4094|NCT04163523|Drug|Zanubrutinib|
4095|NCT04163510|Behavioral|Behavioral: Parent/Child Reading Program|A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
4096|NCT04163497|Device|ICU Diaries|To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
4097|NCT04163484|Other|Iodinated contrast|Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
4098|NCT04163471|Device|Radial artery mechanical compression for hemostasis|Transradial hemostasis following arterial catheterization procedures
4103|NCT04163445|Device|MicroPort Orthopedics EVOLUTION Medial Pivot TKA|Subjects will have been implanted with the Microport Evolution Medial Pivot TKA
4104|NCT04163445|Device|Depuy Synthes ATTUNE PCR TKA|Subjects will have been implanted with the Depuy Attune PCR TKA
4105|NCT04163432|Drug|Durvalumab|Durvalumab is administered at a dose of 1500mg for patients who weigh >30 kg. If weight falls to ≤ 30 kg, weight-based dosing at 20mg/kg will be a utilized
4106|NCT04163432|Drug|Pemetrexed|Pemetrexed dosing is adjusted for kidney function. Pemetrexed is dosed at 500mg/m2 for patients with a creatinine clearance ≥ 45 mL/min (by Cockcroft-Gault formula). If creatinine clearance is < 45 mL/min, pemetrexed is dosed at 400 mg/m2.
4107|NCT04163432|Drug|Carboplatin|Carboplatin dosing is adjusted for kidney function.The total dose (in mg) of carboplatin will be calculated using the Calvert Formula utilizing a target AUC of 5 and a patient's GFR in mL/min.
4108|NCT04163419|Drug|Tanezumab|Tanezumab 10 mg SC
4109|NCT04163419|Drug|Placebo|Placebo 10 mg SC
4110|NCT04163406|Dietary Supplement|ferrous fumarate|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate
4111|NCT04163406|Dietary Supplement|ferrous fumarate + GOS|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and GOS (3g)
4112|NCT04163406|Dietary Supplement|ferrous fumarate + HMOs|Maize-based porridge fortified with iron (5mg) in form of ferrous fumarate and HMOs (2'-FL (2g) + LNnT(1g))
4113|NCT04163393|Procedure|Percutaneous Coronary Intervention|PCI with robotic assistance
4114|NCT04163393|Device|Percutaneous Coronary Intervention using R-One assistance|PCI with robotic assistance
4115|NCT04163380|Behavioral|Resistance Training|Participants will exercise at the mid-point of each menstrual cycle phase (EFP- day 4, LFP- day 11, ELP- day 18 and LLP- day 25 for a 28 day menstrual cycle). Training will consist of a warm up. Intensity will be set at 70% of 1RM, and the circuit training will include 7 strength exercises: leg press, rows, back squat, weighted crunches, deadlifts, bench press, and weighted squat jumps. The participant will perform 3 sets f 10 repetitions with 30 seconds of rest
4116|NCT04163367|Behavioral|Safer Kids|A behaviorally based parent training program with the purpose to reduce or prevent child abuse.
4117|NCT04163367|Other|Intervention as usual (IAU)|Everything that's included in the social service units' regular handling of cases; such as the formal investigation and family treatment. The units cannot offer Safer Kids as a part of IAU.
4118|NCT04163354|Procedure|5% sodium fluoride varnish (NaF)|In the NaF varnish groups, 0.25mL (one drop) of the varnish is placed in a plastic dappen dish. A disposable microbrush is used to apply the varnish onto the second primary molars included in the study and all other teeth. The child is instructed not to eat or drink after the application of varnish for at least half an hour.
4119|NCT04163354|Procedure|Glass ionomer sealant (GIS)|Glass ionomer sealants (GIS) is applied using the finger pressure technique described in the WHO manual for atraumatic restorative treatment (ART) (Frencken et al.; 1997). The primary second molars are cleaned by applying GC cavity conditioner with micro-applicator for 10-15 seconds, then clean with wet cotton pellets for several times. The surface will be dried with cotton pellets. GIS (GC Fuji VII) is mixed in standardized proportion with an amalgamator, then applied to the occlusal surface and slightly overfilled. A gloved finger with petroleum jelly will be used to push and rub the materials into the pits and fissures, and removing the excess. GIS will be covered and protected by a layer of petroleum jelly (Vaseline ®).
4120|NCT04163341|Behavioral|Adapted Common Elements Treatment Approach|The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.
4121|NCT04163328|Dietary Supplement|HydroEye®|This is an omega-3 fatty acids supplement.
4122|NCT04163315|Other|dMRI, fMRI and electrocorticography|Patients included in the study will perform the pre-operative MRI (fMRI and fMRI) with a specific High Resolution Angular Diffusion (HARDI) sequence and a functional rest sequence. The additional scan time for this specific sequence is approximately 25 minutes, with no foreseeable negative impact on the patient
4123|NCT04163302|Biological|CD19-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which has 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patients in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, the investigators select the safest dose and recruit more patients for CART test to explore its effectiveness.
4124|NCT04163289|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplantation is the process of administering stool samples derived from healthy donors, which have been processed and prepared into capsules. Capsules will be taken 7 days or more prior to the first treatment with nivolumab and ipilimumab, and 1 to 3 days prior to the next 2 treatments with nivolumab and ipilimumab.
4125|NCT04163276|Diagnostic Test|18F FDG PET exam|All patients will have had PET Imaging of 18F-FDG in nuclear médicine
4126|NCT04163263|Drug|BOS-356|topical gel
4127|NCT04163263|Drug|Vehicle|topical gel
4128|NCT04163250|Diagnostic Test|Urinary determination of TIMP-2/ IGFBP7|"Urinary determination of TIMP2-IGFBP7 in the an urine sample obtained within 12 hours prior to contrast administration. A single determination will be made, which will be sent to the laboratory. The doctor who treats the patient will not know the result of the test, and the treatment will not be influenced by the result.~According to the manufacturer, 10 ml of fresh urine should be collected in a sterile container and the laboratory should centrifuge them within the time of collection.~The result is reported as a single value calculated as the concentration of TIMP-2 (ng / mL) multiplied by the concentration of IGFBP7 (ng / mL) divided by 1000. The result is reported without units."
4129|NCT04163237|Drug|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
4130|NCT04163237|Drug|Sorafenib|Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
4184|NCT04162743|Drug|Trazodone|take trazodone 100mg before polysomnography
6160|NCT04146896|Drug|Placebo|Placebo administered orally
4131|NCT04163224|Device|RibFix Advantage|Class II device in the United States; consists of bridges (with locking posts) and locking caps for the thoracoscopic fixation and stabilization of ribs. These implants are manufactured from commercially pure titanium and titanium alloys. When fully assembled, the bridge plate is placed on the underside of the rib (pleural cortex); the threaded locking posts extend through pre-drilled holes in the rib, and the locking caps are fixed to the locking post on the anterior (cutaneous) side of the rib. The combined threaded locking post and cap provides for fixation of the bridge and stabilization of the fracture.
4132|NCT04163211|Procedure|Abdominal drain|A latex-free drain (size 20F)
4133|NCT04163198|Device|Insufflation|Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
4134|NCT04163198|Device|Exsufflation|Patients will receive different exsufflation pressures at fixed insufflation pressure.
4135|NCT04163185|Drug|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 tablet taken once upon the earliest onset of migraine pain.
4136|NCT04163185|Drug|Placebo|Placebo tablet taken once upon the earliest onset of migraine pain.
4137|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with elbow hemiarthroplasty|Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)
4138|NCT04163172|Procedure|Surgical treatment of distal humeral fracture with double plating.|Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)
4139|NCT04163146|Diagnostic Test|Measurements of PEF and FEV1|Measurements of PEF and FEV1 at home, twice a day (07:00 - 09:00 and 19:00 - 21:00) and for a period of 3 months, using portable spirometers connected to smartphone
4140|NCT04163133|Procedure|two days later trigger than regular timing|During ovarian stimulation, two days later of trigger after three follicles reach 17mm bilateral with contineous using of Gonadotrophin in antagonist protocol.
4141|NCT04163120|Other|Low calorie Mediterranean ketogenic diet with phytoextracts (KEMEPHY)|The KEMEPHY diet (24-29) is a Mediterranean low calories ketogenic protocol (about 1000/1100 Kcal/day) with the use of some phytoextracts. During this protocol subjects are allowed to eat with no limits green leafy vegetables, cruciferous, zucchini, cucumbers and eggplants. The quantity of meat, eggs and fish was limited to once a day (120g of meat or 200g of fish or 1 egg) Table 1. Moreover, subjects daily consumed four food supplements and liquid herbal extracts. Food supplements are high proteins (19g/portion) and very low carbohydrate (3.5g/portion) formulas simulating the aspect and taste of common carbohydrate rich foods added with dry phytoextracts (30). Liquid herbal extracts were used for their draining /toning activity, useful to reduce some commonly reported light side effects of ketogenic diets as constipation, headache and halitosis.
4142|NCT04163107|Drug|Hydroxychloroquine|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
4143|NCT04163107|Drug|Carfilzomib Injection|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
4144|NCT04163107|Drug|Dexamethasone|All patients start with a 14 days run-in with monotherapy with hydroxychloroquine (HCQ) at their assigned dose level. Then they continue with 6 28-day cycles of HCQ/Carfilzomib/Dexamethasone. 3 patients at each dose level.
4145|NCT04163094|Drug|W_ova1 Vaccine|Patients will be treated with a W_ova1 vaccine that includes 3 OC TAA RNA-LPX products.
4146|NCT04163081|Behavioral|Quit Card Intervention (QCI)|"The intervention is comprised of a behavioural incentive in the form of a gift card as well as tailored smoking cessation counseling. Eligible consenting smokers randomized to the QCI group will receive: a Quit Card (a gift card worth $300 that can be used to buy nicotine replacement therapies at any pharmacy); self-help information; and, enrollment in six months of telephone follow-up support tailored by treatment goal with a Nicotine Addiction Treatment Specialist."
4147|NCT04163068|Other|Interview|The interview will last approximately 45 minutes, will be audio-recorded, transcribed, and analysed
4148|NCT04163055|Device|Moleculight i:X|This device is used to visualize the bacteria in the wound. Patients do not need consume any contrast agent prior to imaging. The device does not come in contact with the wound.
4149|NCT04163042|Behavioral|12-week videoconferencing behavioural support intervention to promote physical activity behaviour|Participants in Group A will receive six real-time, 1-on-1 60-minute sessions led by a physical activity counsellor over a 12-week period. Sessions will be delivered either via videoconferencing and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
4150|NCT04163042|Behavioral|12-week in-person behavioural support intervention to promote physical activity behaviour|Participants in Group B will receive six real-time, 1-on-1 60-minute sessions in person led by a physical activity counsellor over a 12-week period. Sessions will be delivered in-person at the University of Ottawa and will aim to provide young adult cancer survivors with support as well as the knowledge, skills, and confidence to identify and overcome challenges to engaging in physical activity in order to increase physical activity behaviour and enhance patient-reported outcomes.
4151|NCT04163029|Procedure|Preoperative oral care|tooth brushing and mouthwash with chlorhexidine 0,2% five day before surgery
4152|NCT04163016|Drug|Pharmacokinetics of certolizumab pegol|"The collection of blood samples for pharmacokinetics (PK) is considered interventional. Blood samples will be drawn at enrollment, predose every 4 weeks (Q4W), postdose every 8 weeks (Q8W) and postpartum predose and postdose.~Study participants will be responsible for obtaining and administering commercially available approved dosing regimens of certolizumab pegol (CZP) as prescribed by each study participant's own physician."
4153|NCT04163003|Behavioral|Targeted Approaches for Promoting Adolescent Sleep (TAPAS)|The targeted intervention is a three part sleep program, involving a 2- minute psychoeducation video, an in-person session with a clinician focusing on sleep, and web-based goal setting related to sleep behaviors. Intervention approaches to promoting adolescent sleep and reducing insufficient sleep use a motivational interviewing style, rooted in cognitive-behavioral strategies for improving sleep.
4185|NCT04162743|Drug|Placebo oral tablet|take placebo oral tablet before polysomnography
4154|NCT04163003|Behavioral|Sleep Monitoring Only|Participants will monitor sleep with sleep diary, but they will not receive feedback or any other information on to sleep.
4155|NCT04162990|Behavioral|Lifestyle remodeling Intervention|Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.
4156|NCT04162990|Behavioral|Does Comparator: regular treatment|Participants in this group would be treated as usual, which contained the healthy education.
4157|NCT04162977|Behavioral|Personality-targeted Interventions|The Personality-targeted Interventions (i.e., Preventure programme) are selective substance use prevention programme designed to target known personality risk factors for substance misuse based on the evidence from cross-sectional and longitudinal studies which connect these personality risk factors to early initiation and escalation of substance misuse in adolescents. This selected personality-targeted approach targets four personality-specific motivational pathways to substance misuse: Hopelessness, Anxiety Sensitivity, Impulsivity, and Sensation Seeking. Each intervention will involve two 90-minute sessions, with an average of 6 personality-matched adolescents per group, and will be conducted using manuals that incorporate psycho-educational, motivational enhancement therapy (MET), and cognitive behavioural therapy (CBT) components and include real life 'scenarios' shared by high-risk local youth with similar personality profiles.
4158|NCT04162964|Behavioral|Chair Yoga|8-week dyadic chair yoga program for one hour per week. Chair yoga is an effective way to offer modified yoga postures and relaxation techniques to individuals with limited mobility and/or advanced age for whom mat-based classes may not be accessible. The weekly yoga classes will be lead by a certified instructor and will include 4-10 participants (or 2-5 patient-caregiver dyads).
4159|NCT04162951|Procedure|Ordinary approach paravertebral block|Ultrasound guided thoracic paravertebral block. At the appropriate dermatome, the needle (22-gauge, 8-10-cm, short bevelled spinal needle, or a Touhy needle if a catheter is to be placed) is inserted 2.5-3 cm lateral to the spinous process and advanced perpendicular to the skin in all planes to contact the transverse process at a variable depth (2-4 cm) depending on the build of the individual. The needle is then walked above the transverse process and gradually advanced until a loss of resistance to air or saline, or a subtle 'click' is felt as the superior costotransverse ligament is penetrated, usually within 1-1.5 cm from the superior edge of the transverse process.
4160|NCT04162951|Procedure|Retrolaminar paravertebral block|In the retrolaminar approach to TPVB or retrolaminar block (RB), local anesthetic (LA) is injected into the retrolaminar plane to achieve a truncal sensory block like that of traditional TPVB. It has been postulated that during RB, LA spreads from the injection plane to the thoracic paravertebral space (TPVS) through the superior costotransverse ligament (SCTL). Retrolaminar block will be performed under ultrasound guidance, as a single injection.
4161|NCT04162938|Other|Patient-Centered Electronic App|The coordinator will enter lab information to generate the patient's Fibrosis-4 score for liver fibrosis staging. With the information of liver fibrosis staging and survey responses, the app will generate individualized reports of the participant's comprehensive HCV disease progression, knowledge, and level of interest in receiving HCV care. The app will then deliver a streamlined, tailored, brief education message and include information regarding services and assistance for receiving HCV care.
4162|NCT04162925|Behavioral|Cancer screening education for breast, colon and oral cancers|Bedside education one-on-one by showing screening video and handouts at the end of educational session for breast, colon and oral cancer. Patient who are agreeable to oral cancer screen during hospitalization perform oral cancer screening
4163|NCT04162912|Behavioral|Motivational Interviewing tailored Advance Care Planning|The trained interventionist who is experienced in MI techniques will explore their illness experiences, emotions and beliefs about their health conditions and future care in an empathetic manner and explore their ambivalence for ACP behaviours.
4164|NCT04162899|Drug|Drug: SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK-1(known as a JAK-1 inhibitor).
4165|NCT04162886|Other|Exercise|Thrower's ten exercises will given for 8 weeks, 3 days in a week.
4166|NCT04162873|Drug|Celecoxib|Given PO or via feeding tube
4167|NCT04162873|Other|Placebo|Given PO or via feeding tube
4168|NCT04162873|Other|Quality-of-Life Assessment|Ancillary studies
4169|NCT04162873|Other|Questionnaire Administration|Ancillary studies
4170|NCT04162860|Device|Eso-SPONGE® device|Preemptive ENP therapy will be carried out with either an Eso-SPONGE® device system (Eso-SPONGE®, B. Braun Melsungen AG, Melsungen, Germany). Eso-SPONGE® consists of an open-pored polyurethane foam fitted to a gastric tube. Secretions are then continuously evacuated using a suction pump generating a negative pressure between 75 and 100 mmHg.
4171|NCT04162847|Device|SilverCloud Health Intervention|SilverCloud Health is a mobile mental health platform offering cognitive-behavioral therapy-based guided self-help programs for preventing and treating anxiety, depression, and eating disorders as appropriate Participants in this arm will receive the support of a coach to guide them through the program. Participants will be able to communicate with their coach within the program.
4172|NCT04162834|Drug|Papaverine|Immediately after the renal artery declamping, papaverine 30 mg (1 ample, 1 ml) is mixed with 5 ml of normal saline (total 6 ml) and sprinkled around the renal artery.
4173|NCT04162834|Drug|Normal saline|Immediately after the renal artery declamping, normal saline 6 ml sprinkled around the renal artery.
4174|NCT04162821|Drug|Hydronidone|Take hydroxynitone capsule
4175|NCT04162795|Drug|BAY76-2211 (Loratadine)|Chewable tablet, oral, single dose
4176|NCT04162782|Procedure|obstetric and gynaecological surgeries|surgeries for gynecologic and obstetric diseases
4177|NCT04162769|Drug|Etrasimod|"Etrasimod Dose A tablet taken by mouth, once daily up to 12 weeks during the Double-Blind Treatment Period"
4178|NCT04162769|Drug|Etrasimod|"Etrasimod Dose B tablet taken by mouth, once daily up to 12 weeks during the Double-Blind Treatment Period"
4179|NCT04162769|Drug|Etrasimod matching placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks during the Double-Blind Treatment Period
4180|NCT04162769|Drug|Etrasimod|"Etrasimod Dose B tablet taken by mouth, once daily up to 52 weeks during the Open-Label Extension Period"
4181|NCT04162756|Biological|KTE-X19|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells/kg administered intravenously.
4182|NCT04162756|Drug|Fludarabine|Administered per package insert
4186|NCT04162730|Other|Pressure pain threshold and behavioural data|Pressure pain threshold level of the knee region will be collected and behavioural data will be measured
4187|NCT04162717|Behavioral|The Effect of Telephone Symptom Triage Protocols on Symptom Management, Quality of Life and Self-Care Maintenance in Patients with Cancer Who Applied Systemic Treatment|"Symptom management, quality of life and self-maintenance were assessed by scales at the first interview and 3 months later.~Intervention group received symptom triage application with telephone, which consisted of guiding in line with symptom triage protocols. The patients who were included in the intervention were followed up by telephone on the 3rd, 7th and 10th day of after chemotherapy total of nine times during three chemotherapy cycles."
4188|NCT04162704|Device|EpiCheck|If the EpiCheck test is positive at the time of inclusion, the test is repeated prior to the fourth and sixth instillation with Mitomycin as well as prior to the subsequent two cystoscopies. If the EpiCheck test is negative at the time of inclusion, no further tests will be performed.
4189|NCT04162691|Diagnostic Test|Tissue|Four 4-5 mm tissues of the thymoma
4190|NCT04162678|Procedure|Biospecimen Collection|Undergo collection of blood via HD-SCA fluid biopsy
4191|NCT04162678|Other|Laboratory Biomarker Analysis|Correlative studies
4192|NCT04162678|Procedure|Liquid Biopsy|Undergo collection of blood via HD-SCA fluid biopsy
4193|NCT04162678|Other|Medical Chart Review|Review of medical chart
4194|NCT04162665|Radiation|MR guided radiation therapy|-Image-based treatment planning and intensity modulated radiotherapy (IMRT) is permitted.
4195|NCT04162665|Procedure|Blood for ctDNA|-Prior to start of radiation, after the completion of radiation therapy and prior to starting chemotherapy (2-4 weeks after radiation completion), at the completion of chemotherapy and prior to surgery (2-4 weeks after chemotherapy completion), and 6 months after surgery
4196|NCT04162639|Biological|Skin allograft|Participants will receive skin allograft from either 1, 2 or 3 distinct cadavers. This skin allograft will be applied in a routine fashion, with no deviation from the typical clinical course of treatment.
4197|NCT04162626|Other|Supportive home visits to new families|The new families are offered home visits by a public health nurse from 28 weeks in pregnancy until the child is two years old. The number of home visits depends on the families needs and wishes. They also get the usual follow up from the Child health center.
4198|NCT04162626|Other|Treatment as usual|Follow up at the Child health center according to national regulations
4199|NCT04162613|Other|Different measures of muscle function such as muscle strength, hop tests, postural orientation and muscle activation|"The participants will be assessed with a physical test battery at baseline including: Isokinetic knee strength, Isometric strength of trunk and lower extremity, Single-leg hop for distance, side hop, postural orientation (single leg-squat, stair descending, forward lunge, Single-leg hop for distance, side-hop), hip and ankle range of joint motion, muscular activation pattern, 3D movement analysis and proprioception test.~At follow-up (2 years), the participants will be asked to answer a survey about new ACL injuries and return to sport/previous activity level."
4200|NCT04162600|Biological|ChAdOx2 RabG|Single dose of ChAdOx2 RabG at different concentrations: 5 x 10^9 vp, 2.5 x 10^10 vp, 5 x 10^10 vp
4201|NCT04162600|Biological|Inactivated Rabies Vaccine|A complete pre-exposure prophylactic course of an existing rabies vaccine, ≥2.5 international units
4202|NCT04162587|Other|Carotid duplex+/- MRA neck|Carotid duplex and or MRA neck
4203|NCT04162587|Other|brain MRA+/-CT angio on carotid and brain|brain MRA and or CT angiography on carotid and brain
4204|NCT04162587|Other|MRI brain|MRI brain with diffusion to detect asymptomatic stroke
4205|NCT04162587|Other|DSA (digital subtraction angiography)|DSA (digital subtraction angiography) in some cases to confirm diagnosis.
4206|NCT04162574|Other|Recovery Record|Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
4207|NCT04162561|Behavioral|Patients with documented IHD|Assessment of patients' quality of life with the use of the Seattle Angina Questionnaire (SAQ), blood pressure levels (using the Korotkoff method, blood pressure is measured 3 times with 1-minute intervals on the hand with the higher blood pressure levels while sitting calm after a 5-minutes rest), laboratory methods (lipids, glycosylated hemoglobin levels), patients' adherence to treatment (original questionnaire), quality of patients' therapy taken at the time of visit, necessity of invasive coronary revascularization procedures (during all visits).
4208|NCT04162535|Drug|Lidocaine 1% Injectable Solution|"Lidocaine 1% Injectable Solution Intervention Protocol for the TIVA and Lidocaine Arm~Induction: 1.5 mg / kg i.v. bolus before induction (at the vein catch).~Maintaining anesthesia: continuous infusion with Lidocaine 2 mg / kg / h, up to a maximum of 200 mg / h during maintenance (after IOT until waking)~Infusion with 1% Lidocaine will be reduced to 1.0- 1.5 mg / kg / hour, max 100 mg / hour, for the first 48 hours postop"
4209|NCT04162535|Biological|Blood extraction|The patients will donate after consent 10 ml of blood prior and after surgery for further study
4210|NCT04162535|Drug|Sevoflurane|Patients will receive a general volatile anesthesia with Sevoflurane as anesthetic agent
4211|NCT04162535|Drug|Propofol|Patients will receive a general anesthesia with Propofol as anesthetic agent
4212|NCT04162522|Drug|Escitalopram|Participants are given escitalopram for 8 weeks. At week 8, those classified as responders will continue on escitalopram until the end of study.
4213|NCT04162522|Drug|Brexpiprazole|Participants who are classified as non-responders are given 8 weeks add-on brexpiprazole, in addition to escitalopram, for the remainder of the study.
4240|NCT04162340|Biological|CD4 CAR T cells|CD4 CAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
4241|NCT04162327|Drug|IBI315|Patients will receive IBI315 until disease progression, intolerability, informed consent withdraw, or other reasons leading to treatment discontinue.
4242|NCT04162327|Drug|IBI315|Patients will receive IBI315 RP2D until disease progression,intolerability, informed consent withdraw, or otherreasons leading to treatment discontinue.
4243|NCT04162314|Drug|Beta-1,3/1,6-D-Glucan Ganoderma lucidum|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
4244|NCT04162314|Drug|Placebos|Placebos
4214|NCT04162509|Other|AR app|Participants will be exposed to nine different AR spider scenarios with a pre-defined length of 2 minutes for each level. Each level starts with a surface scan of the environment and the placement of the AR spider model(s) by tapping on the display. Through small text pop-ups the user is instructed to perform different tasks (e.g. looking at the spider model, approaching it, holding the hand under the model). They proceed to further levels according to a predefined exposure scheme based on SUDS for fear (scale 0=no fear to 10=maximum fear) and disgust (scale 0=no disgust to 10=maximum disgust) and the assurance of the task completed (yes/no). Users will repeat each level until their SUDS are 4 or below and have completed the task. Each exposure session is limited to approx. 30 minutes (controlled by the participants) irrespective of achieved level.
4215|NCT04162496|Drug|Restylane Refyne|Injection of Restylane Refyne with a cannula on one side of the neck and a 30 guage needle on the other side.
4216|NCT04162483|Device|Neuroform Atlas Stent System|Stenting Assisted coiling procedure
4217|NCT04162470|Drug|REGN3918|Subcutaneous (SC) every week (QW) over the treatment period
4218|NCT04162457|Dietary Supplement|Stevia|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
4219|NCT04162457|Dietary Supplement|Glucose|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
4220|NCT04162457|Dietary Supplement|Maltodextrin|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
4221|NCT04162457|Dietary Supplement|Water|Participants will be administered one of the study beverages at each one of the 4 imaging sessions.
4222|NCT04162444|Diagnostic Test|Physical examination|A physical examination is a routine screening procedure used to investigate a patient's symptoms or complaints. It consists of a series of questions regarding patient medical history followed by an examination of the symptoms to determine the correct diagnosis and treatment plan.
4223|NCT04162444|Diagnostic Test|The Ross Classification for Heart Failure in Children|The assessment is performed by pediatric cardiologist according to the classic Ross scale. One of the 4 classes of chronic heart failure is registered.
4224|NCT04162444|Diagnostic Test|The Aristotle score|Surgical risks will be assessed by the ARISTOTLE score developed specially for the task. The calculation will be performed online, available from http://www.aristotleinstitute.org.
4225|NCT04162444|Other|Assessment of administered specific therapy|"The data will be registered as groups of administered medicines:~Antiplatelet agents~Loop diuretics~Potassium-sparing diuretics~Angiotensin-converting enzyme inhibitors"
4226|NCT04162444|Diagnostic Test|Multispiral computed tomography/3D echocardiography|"All patients enrolled in the study should be routinely examined with multispiral computed tomography (MS-CT) or 3D-echo before surgery and 3 years later. As a result, a 3D aortic root reconstruction will be made to assess its size and anatomy and subsequently build a 3D soft model for surgery imitation.~At the study onset, we plan to perform MS-CT, then 3D-echo. If the correlation resulting from 3D-echo and the actual sizes will be high, the isolated 3D-echo will be preferred in the future.~If none of the methods is available, the patients will not be enrolled in the study.~The following data will be registered for further analysis:~Perimeter of the aortic valve~Diameter of the aortic valve at sinuses level~Height of the aortic sinuses~Morphology of the aortic valve"
4227|NCT04162444|Diagnostic Test|Transthoracic and transesophageal echocardiography|"Transthoracic echocardiography is carried out at baseline, at discharge and then annually. It is performed in order to assess the contractile function of the heart and hemodynamic characteristics of the aortic valve and its autopericardium graft.~Transesophageal echocardiography is carried out directly after the withdrawal of the artificial circulation when performing augmentation of the aortic valve with autopericardium in order to asses hemodynamic characteristics of the aortic neo-valve."
4228|NCT04162444|Diagnostic Test|12-lead electrocardiogram|"Registering 12-lead electrocardiogram (ECG) is used as a tool for assessment of the regularity of the heart rhythm as well as screening and predictive tool for assessment of fibrosis and hypertrophy processes in the myocardium. The following data will be registered:~Heart rate~Sinus rhythm (yes/no)~Positive R wave in leads V5-6~Angle α less than 0~Presence/absence of abnormal Q wave~Presence/absence of ST-segment depression in precordial leads"
4229|NCT04162431|Diagnostic Test|spectroscopic measurement|measurement of the tissue with spectroscopy
4230|NCT04162431|Diagnostic Test|FNA biopsy|a fine needle aspiration (FNA) biopsy will be taken
4231|NCT04162431|Diagnostic Test|histopathology and cytology|Histopathology and cytology will be performed on the samples
4232|NCT04162418|Device|Temporary Spur Stent System|Treatment of qualifying infrapopliteal lesions with Temporary Spur Stent System and a commercially available, limus-base drug-coated balloon
4233|NCT04162405|Behavioral|Tinnitus Handicap Inventory Test|A prospective cohort nonrandomized study of non-masked parallel paired groups. The data will be collected from an electronic database that is filled in during diagnostic processing. During the diagnostic processing, TSI and THI questionnaires will be filled in, a tone audiogram (TA) and DPOAE will be performed.
4234|NCT04162392|Other|shared decision making|Patients can choose the intervention that they want. There are different physiotherapy interventions were the patients have to do physical activity during the hospital stay. The physiotherapist explains the advantages and disadvantages of each treatment before they choose.
4235|NCT04162392|Other|control group|Patients receive a physiotherapy intervention but they do not have the opportunity to choose the treatment
4236|NCT04162379|Drug|Oral tablet|Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mg for 3 successive dosing every 4th day then stop the drug totally).
4237|NCT04162366|Drug|Aprocitentan 25 mg|Tablet, oral use once daily
4238|NCT04162366|Drug|Placebo|Matching placebo tablet, oral use once daily
4239|NCT04162353|Biological|BCMA-CD19 cCAR T cells|BCMA-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
4283|NCT04161976|Drug|Insulin Lispro|Insulin lispro administered to participants with T1DM using CSII.
4245|NCT04162301|Drug|CS3002|CS3002 tablet will be orally administered daily for 3 weeks followed by 1 week off treatment, defining a treatment cycle of 28 days in duration.
4246|NCT04162288|Other|Online Training - Shared Decision Making in Prenatal Screening|TThe intervention consisted of an online self-study training program lasting 3 hours which aims to engage SDM in a prenatal screening context. The training was divided into four main modules: 1)SDM, 2)DS prenatal screening, 3)Decision aid and 4)Communication between healthcare professionals and patients. In each module, the targeted learning objectives and the work to be carried out (e.g. readings to be made, video to be viewed, evaluation to be carried out, etc.) are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. A simulation in the end is done to put participants in context of an actual consultation with a pregnant woman and her partner. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
4247|NCT04162288|Other|Online Training - Online Training on Prenatal Screening|The control intervention consisted of an online self-study training program lasting 3 hours which aims to provides knowledge for prenatal screening. The training has four main modules: 1)Context and history of prenatal screening(new), 2)DS prenatal screening(existing), 3)Consent in prenatal screening(new) and 4)Communication between healthcare professionals and patients(existing). In each module, the targeted learning objectives and the work to be carried out are presented. Various teaching methods and medias are used during this training: videos, interviews, narrated capsule, readings, links to scientific articles and complementary websites. Videos are done with experts on SDM, ethics of prenatal testing. For the 2 new modules, narrated capsules have replaced videos of experts. There is no simulation at the end. This training was designed to adapt to the learning pace of the user, is hosted on University Laval platform and needs an identification code to enter.
4248|NCT04162275|Drug|Finamine tablets|taken Finamine tablets orally
4249|NCT04162275|Drug|Placebo tablets|taken Placebo tablets orally
4250|NCT04162262|Other|Instrumental-assisted soft tissue mobilization (IASTM)|Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
4251|NCT04162262|Other|High-Load Strength Training|Participants will perform a heel raise exercise used by Rathleff et al (2015). The exercise will be performed twice daily. While standing with the forefoot on a step, the toes will rest on a partially folded towel, placing them in a maximally dorsiflexed position. The exercise will consist of a maximum ankle plantar flexion followed by maximal dorsiflexion. The concentric plantar flexion and eccentric lowering phases will be 3 seconds, with a 2 second isometric pause in between. The exercise will be performed unilaterally if tolerated by the subject. Otherwise, a bilateral calf raise will be performed until the subject is able to perform the unilateral version. The exercise will be performed every other day and progressed throughout the trial as described by Rathleff and colleagues.
4252|NCT04162262|Other|Plantar Flexor and Gastrocnemius Stretching|For the plantar flexor stretch (DiGiovanni et al, 2006), subjects will sit and cross the affected leg over the contralateral leg. Placing the affected side fingers on the plantar toes, distal to the metatarsophalangeal joints, they will passively dorsiflex the toes until they feel stretching in the arch of the foot. Subjects will be instructed to hold this stretch for 10 seconds and repeat it 10 times. The gastrocnemius stretch will be performed in supine with a towel placed around the distal foot and the foot actively inverted. With the knee extended, the subject will flex the hip while passively dorsiflexing the foot using the towel. This stretch will be held for 30 seconds and repeated 3 times. Subjects will be asked to perform both stretches three times each day.
4253|NCT04162249|Other|Conventional LSI/AI-guided pulmonary veins ablation.|Conventional (low-power and long-duration) radiofrequency application.
4254|NCT04162249|Other|High-power pulmonary veins ablation.|Experimental (high-power and short-duration) radiofrequency application.
4255|NCT04162249|Other|Esophageal temperature monitoring|Two probes were simultaneously used: a deflectable one and a non-deflectable one.
4256|NCT04162249|Diagnostic Test|Esophageal endoscopy|Esophageal endoscopy for acute detection of esophageal thermal lesions <72 hours after ablation.
4257|NCT04162236|Diagnostic Test|Ecocardiographyc ultrasound|"Epidemiological data: Maternal history risk factors. First trimester scan is performed on all patients.~Antropomethric measures~Systemic arterial stiffness: using applanation tonometry with pulse wave analysis and pulse wave velocity.~Carotid Intima Thickness~Echocardiography assessment: It will be performed by a cardiologist specialized in cardiac imaging according to the usual standard protocol. High resolution images will be acquired and post-processed with dedicated software for the speckle tracking analysis. 2D echocardiography parameters to be acquired, tissue Doppler and speckle tracking software~Markers in maternal blood: Angiogenic factor and cardiac function biomarkers: Blood samples will be collected without anticoagulant to obtain serum. sFLT-1, PlGF, High-sensitivity Troponin and NT-proBNP will be measured using automated electrochemiluminescence immunoassays."
4258|NCT04162223|Biological|Subcutaneous fat injection of Recombivax-HB|Subcutaneous fat injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
4259|NCT04162223|Biological|Intramuscular injection of Recombivax-HB|Intramuscular injection administration of licensed Hepatitis B Surface Antigen Vaccine (Recombivax-HB) on Days 0, 28, and 180.
4260|NCT04162210|Drug|Belantamab mafodotin|Belantamab mafodotin will be available as powder for solution for infusion which will be administered via intravenous (IV) route. Belantamab mafodotin will be reconstituted for injection 100 mg/vial with 2.0 milliliter (mL) of water for injection with dose level of 2.5 mg/kg.
4261|NCT04162210|Drug|Pom/dex (Pomalidomide plus low dose Dexamethasone)|Pomalidomide will available as capsule and Dexamethasone will be available as tablet which will be administered via oral route.
4262|NCT04162197|Device|GEO|Robot-Assisted Gait Training (RAGT) The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
4263|NCT04162197|Device|GEO and HUNOVA|Robot-Assisted Gait Training (RAGT) and Balance Training. The Balance Group (GHG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland) and a Balance training using a robotic proprioceptive platform (Hunova - Movendo Technology, Italy).
4264|NCT04162184|Behavioral|Linkage Navigator Intervention|a brief navigator-led behavioral intervention focused on identifying reproductive health needs and linking to services
4265|NCT04162171|Radiation|Stereotactic Body Radiotherapy (SBRT) ablation of VT|"Additional imaging for SBRT planning and implementation:~Planning CT (pCT) - CT simulator that utilizes a respiratory positioning monitoring (RPM) optical tracking system and SBRT immobilization setup to provide necessary data to allow for monitoring of the patient's deep inspiration breath-hold (DIGH) maneuver during treatment delivery.~SBRT treatment - 30 min procedure on a TrueBeam 1 linear accelerator using SBRT fixation. Patient alignment and DIBH maneuver from the pCT will be replicated using the on-board cone-beam CT (CBCT) guidance and RPM systems."
4266|NCT04162158|Biological|allogeneic NK cells therapy|PBMC was isolated from the peripheral blood of the donors and infused to the patient after 14 days incubation. In each cycle, patients will be infused 4.0-5.0×10`9 allogeneic NK cells. All patients in the experimental group received a total of three cycles of treatment with one month interval between each treatment.
4267|NCT04162145|Device|Active BRIDGE device placement|The active BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
4268|NCT04162145|Device|Inactive BRIDGE device placement|The inactive or sham BRIDGE device will be placed by a blinded medical provider. The severity of opioid withdrawal signs and symptoms will be assessed with the COWS, pain and cognitive functioning tests at several time points. Patients will be dosed with buprenorphine at the blinded provider's discretion. Supportive medications to help manage signs and symptoms of opioid withdrawal will NOT be allowed for one hour after the first dose of buprenorphine. Subjects will be asked to return to clinic for additional visits based on the clinic standard of care. Subjects will be reassessed using COWS, OCS and VAS at each subsequent visit, or remotely (via phone) when unrequired to return to clinic during the 5-day trial. The device will be removed at the clinic visit on Day 5 and disposed of in a sharps container. If the patient cannot come back on day 5, they will be instructed to remove the device at home and bring it back at the next clinic appointment for proper disposal.
4269|NCT04162132|Device|Smartphone app|Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.
4270|NCT04162119|Biological|BCMA-PD1-CART Cell|This study was a single-center, open-label, single-arm, non-randomized clinical trial, which was divided into 3 groups by infusion dose level. Firstly, each dose group has 3 patients. The pretreatment regimen of cyclophosphamide (25mg/m2 for 3 consecutive days) and fludarabine (10mg/kg for 3 consecutive days) was given before CART cells were reinfused. CART cells were reinfused on the third day after the pretreatment. If no serious side effects emerges in the group, then the next group uses the subsequent higher dose. If serious side effects emerges in a single patient in any dose level, 3 more patients will be enrolled to the same dose level. After 9 or more patients, we select the safest dose and recruit more patients for CART test to explore its effectiveness.
4271|NCT04162106|Device|Smoke management during laparoscopic cholecystectomy using the Ultravision™ System|The Ultravision™ System will be used during the procedure to manage smoke generated as a result of the use of diathermy.
4272|NCT04162106|Device|Smoke management during laparoscopic cholecystectomy using the Airseal® iFS|The Airseal® iFS will be used during the procedure to manage smoke generated as a result of the use of diathermy.
4273|NCT04162093|Procedure|uretero ileal anastomosis in single trough|
4274|NCT04162054|Other|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).|Observational study to evaluate acute cardiopulmonary effects of whole body vibration (WBV) on healthy individuals analysed in non-invasive cardiopulmonary exercise test (CPX).
4275|NCT04162028|Drug|Nebutlized Ketamine|The PK-BAN package will be opened and weight -based dose of ketamine will be administered to the patient via BAN. The medication will be delivered with a minimum time of 5 min and maximum time of 15 min.
4276|NCT04162015|Drug|Nivolumab|nivolumab 360 mg
4277|NCT04162015|Drug|Pemetrexed|500 mg/m^2
4278|NCT04162015|Drug|Cisplatin or Carboplatin|cisplatin 75 mg/m2 or carboplatin AUC=5
4279|NCT04162002|Drug|Restylane® Lyft|Filler Injection
4280|NCT04161989|Drug|omega-3 fatty acids|. The Omega 3 plus capsule contains 1000 mg Fish Oil (contains Eicosapentaenoic acid 13% & Docosahexaenoic acid 9%) plus 100 mg Wheat Germ Oil (Linoleic acid 52- 59%) as a natural source of Vitamin E.
4281|NCT04161989|Drug|vaginal progesterone|Prontogest 400 mg vaginal suppository contains progesterone 400 mg.
4282|NCT04161976|Drug|LY900027|LY900027 administered to participants with T1DM using CSII.
4284|NCT04161963|Device|SD-OCT|Optical Coherence Tomography of the maculy with Heidelberg Spectralis SD-OCT
4285|NCT04161963|Device|OCT-A|swept source Optical Coherence Tomography Angiography with Zeiss Plex Elite 9000 of the macula
4286|NCT04161950|Other|Assessment of the safety and validity of echoendoscope|"Ultrasonic and endoscopic image quality assessment~Device controllability assessment~System safety assessment~System stability assessment"
4287|NCT04161937|Behavioral|Behavioural Intervention|Behavior intervention will comprise of combination of intensive education session, group counseling, goal setting and monitoring based on the Diabetes Prevention Program (DPP).The curriculum includes 24 sessions: 16 core sessions weekly during the first four months of the program followed by a monthly maintenance sessions.
4288|NCT04161924|Diagnostic Test|X-ray imaging with physical grid using conventional processing|X-ray imaging with physical grid using conventional processing
4289|NCT04161924|Diagnostic Test|X-ray imaging without physical grid using conventional processing|X-ray imaging without physical grid using conventional processing
4290|NCT04161924|Diagnostic Test|X-ray imaging without physical grid using experimental SimGrid offline processing|X-ray imaging without physical grid using experimental SimGrid offline processing
4291|NCT04161898|Drug|Upadacitinib|Upadacitinib will be administered as oral tablet
4292|NCT04161898|Drug|Placebo for Upadacitinib|Placebo for upadacitinib will be administered as oral tablet
4293|NCT04161898|Drug|Prednisolone|Prednisolone will be administered as oral tablet
4294|NCT04161885|Drug|Venetoclax|Tablet; Oral
4295|NCT04161885|Drug|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
4296|NCT04161885|Other|Best Supportive Care (BSC)|BSC is the best supportive care, without AML directed therapy, determined per the investigator and institutional guidelines.
4297|NCT04161872|Drug|Uricemin|Uricemin is a nutraceutical containing quercetin, rutin, bromelain and L-carnosine
4298|NCT04161872|Drug|Placebo|Placebo
4299|NCT04161859|Dietary Supplement|Nutraceutical|Nutraceutical with action on glycemia, dsylipidemia or hypertension will be considered.
4300|NCT04161846|Behavioral|Virtual Training|The intervention will involve an 8 session/topic CHW training focused on raising awareness of diabetes prevention in the communities they serve. It will be delivered remotely using an internet based approach.
4301|NCT04161846|Behavioral|In Person Training|The intervention will involve an 8 session/topic CHW training program focused on raising awareness of diabetes prevention in the communities they serve. It will be delivered during in person sessions.
4302|NCT04161833|Dietary Supplement|OPERA|All patients were required to take an OPERA® capsule (dietary supplement where α-lipoic acid, Boswellia Serrata, methylsulfonylmethane and bromelain are combined in a single capsule) once daily,from enrollment up to sixth months.
4303|NCT04161820|Behavioral|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke|The effect of education and telephone follow ups based on the Chronic Care Model on self-management, quality of life and patient satisfaction in patients with ischemic stroke Self-management, quality of life and patient satisfaction were assessed by scales at the first interview and 3 months later. Metabolic variables of the patients were obtained from the patient clinical information system at the first interview and 3 months later.
4304|NCT04161807|Device|Nerivio|The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
4305|NCT04161794|Other|multimodal|2 g EPA/DHA as fish oil, repeated dietary counselling and twice weekly 2 x exercises
4306|NCT04161781|Drug|18F-BMS-986229 Injection|Single injection prior to scan
4307|NCT04161781|Drug|IV 18F-BMS-986229|370 MBq administered intravenously prior to scan
4308|NCT04161781|Diagnostic Test|PET/CT Scan|Whole-body PET/CT (80 mA)
4309|NCT04161768|Drug|Norfloxacin|Norfloxacin 400 mg daily
4310|NCT04161768|Drug|Itopride|Itopride 50 mg three times daily
4311|NCT04161755|Drug|Atezolizumab|Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks)
4312|NCT04161755|Biological|RO7198457|RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks)
4313|NCT04161755|Drug|mFOLFIRINOX|mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks)
4314|NCT04161742|Device|Nevisense|Nevisense measures electrical impedance of skin lesions and provides an output called the electrical impedance spectroscopy (EIS) score
4315|NCT04161729|Drug|Magnesium Sulfate|Intravenous magnesium sulfate 20 mg/kg in 100ml isotonic saline 0.9% over a 15-min period before induction of anesthesia and 20 mg/kg/h by continuous i.v. infusion until surgery completion.
4316|NCT04161729|Drug|Isotonic saline 0.9%|Isotonic saline 0.9% 100ml over a 15-min period before induction of anesthesia and thereafter continuous i.v. infusion until surgery completion in dosage identical to magnesium sulfate group.
4317|NCT04161716|Device|DETTECH recording|DETTECH is wear by patient during their urodynamic exam.
4318|NCT04161703|Procedure|focused ultrasound, diet and exercise|"Focused Ultra Sound using a device of Mabel6 DUO Ultra Cavitation Technology produced by DAEYANG MEDICAL CO., KOREA applied on the abdominal region which extending bilaterally from the line extending from mid-axilla to iliac crest, and above from center of diaphragm to the line extending between two iliac crests below.~an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity a weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction"
4319|NCT04161703|Procedure|diet and exercise|weight maintenance diet, which ranged from 1700 kcal to 2200 kcal/day, which was calculated in an individual basis for each subject according to his BMR, throughout the study period (12 weeks) to ensure that the reduction in the circumference was due to the treatment intervention rather than due to their weight reduction. All subjects in both groups (A & B) followed an aerobic exercise 3 to5 times/week for 12 weeks in the form of walking on treadmill for 30 minutes with moderate intensity (moderate intensity = 12-14 according to Borg Scale). The beginning period will be 15 mints and increased gradually until reaching 30 mints per time.
4320|NCT04161690|Drug|Dexketoprofen Trometamol|intravenous dexketoprofen 50mg or intrathecal
4321|NCT04161690|Drug|Ropivacaine Hydrochloride 7.5 MG/ML|Local Infiltration Analgesia
4322|NCT04161664|Drug|Paclitaxel and Carboplatin|6 courses of Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
4323|NCT04161651|Device|eversense|eversense CGM
4324|NCT04161638|Behavioral|Stigma Video Exposure|The participants watched a 10 minute video on a computer screen that consisted of brief clips from popular television shows that depicted women with overweight and obesity and evoked negative weight-based stereotypes (e.g., clumsy, loud, and lazy). Both the high blood pressure and normal blood pressure arms participated in this intervention.
4325|NCT04161638|Behavioral|Neutral video exposure|The participants watched a 10 minute video on a computer screen that consisted of a series of clips depicting neutral scenes (e.g., insurance commercials). Both the high blood pressure and normal blood pressure arms participated in this intervention.
4326|NCT04161625|Behavioral|Digital exercise program with support|"The Safe Step application includes an instruction movie on how to create and progress an individual exercise program. The exercises, presented in video format, are organized into 10 groups with a main focus on balance (3 groups), lower-limb strength (4 groups), and gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~Participants use the app to plan their exercises, set reminders, register their exercise, and view statistics. A virtual physiotherapist delivers motivational messages and feed-back. At the end of each month the participants receive an email asking them to report any falls during the past month in a short digital survey. These messages also contains a new video with general falls prevention information.~Technical support will be provided weekly at senior meeting sites. Try-out group exercises (step 1-3) will be provided by a local wellness association (Friskis&Svettis)"
4327|NCT04161612|Other|Demographic characteristics, duration of spinal cord injury, spinal cord injurylevel, etiology, number of intermittent bladder catheterization (IC), number of night time|Observational clinical study
4328|NCT04161599|Drug|Cefuroxime (750mg) I.V|Extra dosage
4329|NCT04161599|Procedure|Colorectal Surgery|Colorectal Surgery
4330|NCT04161599|Drug|Cefuroxime 750mg oral|Oral prophylaxis
4331|NCT04161599|Drug|MetroNIDAZOLE 250 MG Oral Tablet [Flagyl]|Oral prophylaxis
4332|NCT04161599|Drug|Metronidazole 1,5gr Intravenous|IV prophylaxis
4333|NCT04161599|Drug|Cefuroxime 1g Intravenous|IV prophylaxis
4334|NCT04161599|Drug|Sodium picosulfate, light magnesium oxide, citric acid anhydrous (15.08 g)|Laxative for bowel cleansing
4335|NCT04161586|Drug|Prilocaine Hydrochloride|Spinal Prilocaine for Ambulatory Surgery
4336|NCT04161573|Behavioral|Watching ironic stories|All the participants would be asked to watch a series of self-made stories which are figurative or literal. They have to figure out what is the real meaning of the character's statement. The whole procedure will be done with a computer.
4337|NCT04161560|Drug|Cetuximab-IRDye800|does of Cetuximab-IRDye800
4338|NCT04161547|Drug|CSPCHA115 100 mg; Matching placebo 100 mg|CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.
4339|NCT04161547|Drug|CSPCHA115 200 mg; Matching placebo 200 mg|CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.
4340|NCT04161547|Drug|CSPCHA115 400 mg; Matching placebo 400 mg|CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.
4341|NCT04161547|Drug|CSPCHA115 600 mg; Matching placebo 600 mg|CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.
4342|NCT04161534|Device|KT Tape|in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
4343|NCT04161534|Device|Arm Sling|An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
4344|NCT04161521|Procedure|Novel Technique of Placenta Accreta in Menoufia University Hospital|"Classical CS to decrease haemorrhage from placental bed.~Delievery of the fetus.~At the delivery 10 UI of oxytocin IV will be injected.~The placenta is not attempted to be delievered.~Opening of the broad ligament via round ligament division and ligation.~Gentle dissection of the urinary bladder from lateral to medial.~Bilateral uterine artery clamping at low level below the placental bed .~Gentle attempt to deliver The placenta.~If the placenta is delievered we will do bilateral uterine artery ligation at multiple levels and multiple square compression sutures(if needed) for proper hemeostasis at the placental bed. Then closure of uterine incision.~If the placenta is not delievered we will do segmental ressection of lower uterine segment including the placenta .~Intraperitoneal drain insertion."
4345|NCT04161508|Drug|Sugammadex Injection|injection of sugammadex for the reversal of neuromuscular blockade at the end of the surgery
4346|NCT04161508|Drug|Neostigmine Injection|injection of neostigmine for the reversal of neuromuscular blockade at the end of the surgery
4347|NCT04161495|Drug|BIVV001|Pharmaceutical form:solution for injection Route of administration: intravenous injection
4348|NCT04161482|Drug|Furosemide 80 mg (8 mg/mL)|Furoscix will be administered as a subcutaneous infusion.
4349|NCT04161469|Procedure|Laser closure of the anal fistula tract (FiLaC)|The FiLaC procedure was performed using a ceramic diode laser platform (12 watts, 1470-nm wavelength). The laser fiber was introduced into the fistula tract via the external orifice using the seldinger maneuver until the internal orifice was found. The fiber delivered laser energy homogenously at 3600, causing shrinkage of the fistula tract around the fiber while it was withdrawn at the speed of 1 mm/s
4350|NCT04161469|Procedure|Internal orifice closure|Closure of internal orifice with a purse-string suture using 2-0 polyglactin suture material.
4351|NCT04161456|Drug|Apremilast|Apremilast twice daily 30 mg
4352|NCT04161443|Other|physiotherapy|"Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary.~The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention)."
4353|NCT04161430|Drug|DBPR108; Placebo matching sitagliptin|"Phase A (Weeks 1-24): DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
4354|NCT04161430|Drug|Placebo matching DBPR108; Sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100mg once daily under fasted conditions for 24 weeks; Sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
4355|NCT04161430|Drug|Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108|"Phase A (Weeks 1-24): Placebo matching DBPR108 100 mg once daily under fasted conditions for 24 weeks; Placebo matching sitagliptin 100 mg once daily under fasted conditions for 24 weeks.~Phase B (Weeks 25-52): Drug: DBPR108 100 mg once daily under fasted conditions for 28 weeks."
4356|NCT04161417|Other|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling|Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study
4357|NCT04161404|Drug|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 1000mg capsules|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
4358|NCT04161404|Drug|Brand name: Andrographis paniculata (Shine Hempedu Bumi) 2000mg|Andrographis paniculata or hempedu bumi capsule is a traditional medicinal product registered under Ministry of Health Malaysia for general wealth being. It is traditionally used for anti-diabetic, anti-bacterial, anti-pyretic, anti-malarial, anti-inflammatory, antidiarrhoeal and other effects.
4359|NCT04161404|Drug|Metformin (Glucophage) 1000mg|Metformin is an oral glucose-lowering drug of the biguanides class. Drug: Period 1 Subjects
4361|NCT04161378|Diagnostic Test|Cardiac imaging|"Transthoracic echocardiography~Late gadolinium enhancement CMR"
4362|NCT04161378|Diagnostic Test|Laboratory analysis|"complete blood count~biochemistry~hs-CRP, MMPs, IL6, NT-pro-BNP"
4363|NCT04161365|Procedure|Direct visual urethrotomy|Urethral stricture is treated with urethrotomy under visual control
4364|NCT04161365|Procedure|Autologous fat grafting|Autologous fat graft is gathered and injected to stricture
4365|NCT04161339|Drug|Hydroxychloroquine|400mg/daily of hydroxychloroquine for 8 weeks
4366|NCT04161339|Drug|Placebo oral tablet|Amido pills/daily for 8 weeks
4367|NCT04161313|Other|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test.
4368|NCT04161313|Other|pulmonary function test|It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75
4369|NCT04161313|Other|Functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
4370|NCT04161313|Other|Peripheral muscle strength|Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.
4371|NCT04161313|Other|Respiratory muscle strength|Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
4372|NCT04161300|Other|Foam Rolling (FR)|FR auto-massage will place the foam roller between their ischial tuberosity and a hard surface (i.e., the floor) with their legs held in an extended position, keeping their ankles relaxed and oriented upward. For FR in the lumbar region, participants use their weight to slide the FR through the erector of the lumbar and thoracic spine. The total approximate duration will be about 10-15 minutes.
4373|NCT04161300|Other|Control Group (CG)|The CG did not receive any intervention.
4374|NCT04161300|Other|Orthopaedic Manual Physical Therapy Group (OMPT)|Based on the protocol used by Espí-López et al.: a) Unspecific and bilateral lumbar thrust (L5-S1), one of each side were performed; b) Hip joint decompression, performing 25 repetitions c) Hip rotator stretch with hip and knee flexion, 15 repetitions; d) Femorotibial decompression, 25 reps. e) Quadriceps femoral muscle compression and traction, 25 repetitions; f) Opening of the internal and external femorotibial interline, 15 repetition; g) Ankle decompression, 3 repetitions; h) Posteroanterior and anteroposterior mobilization of head and base of fibula, 25 repetitions. The total duration will be approximately 10-15 minutes.
4375|NCT04161287|Procedure|transcatheter arterial chemoembolization|The hepatocellular carcinoma patients (≤5cm）who received SBRT are devided into two groups: with TACE and SBRT alone.
4376|NCT04161274|Procedure|Traditional method: Electrosurgery|"The patient will be prepared before this technique by removing all metal objects in his possession. The area should be disinfected with a local antiseptic, leaving the area aseptic. Afterwards, perilesional infiltrated local anaesthesia (subcutaneous or intradermal) will be applied. Once the area has been anaesthetised, excision is made with scissors cutting through the most proximal part of the skin tag pendulum and the lesion is coagulated with the handle or knife of the electrocoagulator (previously regulated with the intensity in coagulation mode). The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight."
4377|NCT04161274|Procedure|Traditional method: Cryotherapy|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. for a few minutes the tip of an Adson forceps will be introduced in a container with liquid nitrogen until freezing. It will then be applied to the most proximal part of the skin tag pendulum until it is observed that the frostbite has reached the base of the lesion and the surface becomes whitish, with a halo of 1-3 mm. When this happens, it will be excise above the frost part in the pendulum. After application, it is disinfected with povidone- iodine and covered with a protective dressing of sterile occlusive gauze plaster. It will then form an eschar. Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or sunlight.
4413|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
4414|NCT04161001|Drug|Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
4378|NCT04161274|Procedure|Traditional method: Silver nitrate|"The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag cutting through the most proximal part of the skin tag pendulum, then cauterized with the tip of the silver nitrate rod, trying not to apply in the perilesional zone.~The resulting abrasion will form an eschar that will be disinfected with povidone-iodine, and a protective dressing of sterile occlusive gauze bandage will be placed.~Indications to the patient: the project participant will be instructed to dry the area with povidone-iodine antiseptic and not to expose the area to extreme humidity or solar rays."
4379|NCT04161274|Procedure|Moist healing environment method|The patient should be prepared: the area should be disinfected with a local antiseptic, leaving the area aseptic. Excision will be made with scissors of the skin tag by cutting through the most proximal part of the pendulum of the skin tag, later it will be disinfected with chlorhexidine and thin hydrocolloid dressing will be placed. Indications to the patient: the project participant will be told not to touch the dressing until the next control after 3 days with the research team. In case of incidents with the dressing (fall of the dressing), the patient will be given a replacement dressing for this purpose and be able to restore it immediately. It is recommended not to expose the area to the solar rays
4380|NCT04161261|Procedure|Electrical Stimulation|To measure the facial nerve stimulation threshold for one mid-array and one apical electrode of the implant using the pulse-train stimuli
4381|NCT04161248|Drug|Venetoclax|"Dose Level -1: Venetoclax 200 mg/day days 4-8 cycle 1, days 1-5 cycle 2 and 3, + R-GDP~Dose Level 1: Venetoclax 200 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 2: Venetoclax 400 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP~Dose Level 3: Venetoclax 800 mg/day days 4-10 cycle 1, days 1-10 cycle 2 and 3, + R-GDP"
4382|NCT04161248|Drug|RiTUXimab Injection|375 mg/m2 - Day 1, cycle 1.
4383|NCT04161248|Drug|Rituximab SC|1400 mg fixed dose - Day 1, cycle 2 and 3
4384|NCT04161248|Drug|Gemcitabine|1000 mg/m2 - Day 1 to day 8
4385|NCT04161248|Drug|Dexamethasone|40 mg daily - Day 1 to day 4
4386|NCT04161248|Drug|Cisplatin|75mg/m2 - Day 1
4387|NCT04161235|Device|The Pulmonx Zephyr Endobronchial Valve (EBV) 5.5- LP|The Zephyr Valves are implantable bronchial valves intended to control airflow in order to improve lung function in patients with hyperinflation associated with severe emphysema and/or to reduce air leaks.
4388|NCT04161222|Other|Experimental group|Experimental group will perform a typical warm-up of competitive football, added to a specific activation of gluteus medius and core.
4389|NCT04161222|Other|Control group|Control group will perform a typical warm-up of competitive football
4390|NCT04161209|Drug|Citalopram|Single dose administration of citalopram (20mg)
4391|NCT04161209|Other|Placebo|Lactose placebo tablet
4392|NCT04161196|Procedure|tonsil pillars suturing|The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
4393|NCT04161196|Procedure|tonsillectomy without tonsil pillars suturing|tonsillectomy without The technique of suturing the faucial pillars is used routinely as part of uvulopalatopharyngoplasty, after performing the tonsillectomy, with postsurgical haemorrhage occurring rarely.
4394|NCT04161183|Device|Extracoporeal shock wave therapy|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 6 weeks
4395|NCT04161183|Device|Placebo|Probe be transcutaneous applied to the region of bladder dome, right upper lateral wall, right lower lateral wall, left upper lateral wall, and left lower lateral wall with 2500 shocks, frequency of 4 pulses per second but no energy once a week for 6 weeks
4396|NCT04161170|Device|Digital integrated healthcare platform|Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring system
4397|NCT04161157|Behavioral|Pathways|Goal-setting intervention to help patients identify personal values, value-consistent goals, and ways to pursue goals and address goal obstacles. Although potential refinements may occur based on aim 1 (refining procedures and content with 6 patients), Pathways is designed to consist primarily of 2 in-person sessions (~30-60 minutes) delivered when patients are in clinic for cancer treatment, with supporting phone calls and contact in between sessions.
4398|NCT04161144|Drug|sirolimus|Rapamycin (sirolimus) is administered in three 5mg oral capsules. This administration happens once during the first visit.
4399|NCT04161144|Drug|Placebo|Placebo is administered in three 5mg oral capsules. This administration happens once during the first visit.
4400|NCT04161131|Behavioral|ONBOARD|Session 1: Overview; Overcoming Physical Barriers (experiential wear) Session 2: Managing CGM data (cognitive restructuring) Session 3: Social barriers (problem solving) Session 4: Trust in CGM (motivational interviewing, review of prior sessions)
4401|NCT04161118|Drug|Kymriah|IV Infusion
4402|NCT04161105|Procedure|Dry needling|Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
4403|NCT04161092|Procedure|Liver transplantation Ltx|Patients will be treated with Ltx at Sahlgrenska University Hospital, Göteborg, or Karolinska University Hospital, Huddinge.
4404|NCT04161092|Other|Best alternative care|All available treatments as well as other experimental treatments are tolerated, however no cross-over to other arm will be allowed.
4405|NCT04161079|Device|Medtentia Annuloplasty Ring (MAR)|Mitral valve repair using the MAR performed in clinical investigation 2010-040
4406|NCT04161066|Drug|Psilocybin-assisted psychotherapy|open-label pilot study
4407|NCT04161053|Drug|Rifaximin|Rifaximin 550 mg twice daily for 6 months
4408|NCT04161053|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily for 6 months
4409|NCT04161040|Behavioral|Performance-based incentives|Participants will earn $1 per minute of engagement in physical activity.
4410|NCT04161027|Drug|Pregabalin 75mg|Pregabalin 75 mg capsule
4411|NCT04161027|Drug|Placebos|Placebo capsule
4412|NCT04161014|Drug|Nintedanib 150 MG [Ofev]|Nintedanib 150mg twice daily for 3 years
6711|NCT04142385|Other|Questionnaire Administration|Ancillary studies
4415|NCT04161001|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg, and placebo of Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg), Olmetec Tab. 40mg(Olmesartan 40mg)
4416|NCT04160975|Behavioral|Video about safety and effectiveness of adult seasonal flu vaccination|"The investigators will show subjects videos of either black or white male actors providing scripted information on the flu vaccination. The content of the video will be the safety and effectiveness of adult seasonal flu vaccination. The videos contain one of black or white actors playing the role of either a doctor or a layperson as well as different scripts."
4417|NCT04160962|Procedure|lappg|Laparoscopic gastrectomy for pylorus preservation
4418|NCT04160949|Other|No Intervention|There is no intervention for this study.
4419|NCT04160936|Drug|Naropin Injectable Product|following PCNL under general anesthesia, patients will receive Naropin local anesthetic infiltration
4420|NCT04160910|Drug|5-Hydroxytryptophan|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
4421|NCT04160910|Drug|Placebo|Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
4422|NCT04160897|Drug|Entecavir|entecavir naive for chronic hepatitis B patients
4423|NCT04160897|Drug|Tenofovir Disoproxil|tenofovir disopropyl naive for chronic hepatitis B patients
4424|NCT04160884|Procedure|Indocyanine Green Injection through Peripheral Vein|After ligation of the segmental pulmonary artery supplying the targeted segment, indocyanine is injected intravenously at a specific concentration intraoperatively.
4425|NCT04160871|Behavioral|Family Connections|Intervention includes 12 sessions that follow a group format of 2 hours with a weekly frequency. FC program (Hoffman and Fruzzetti, 2005) is divided into six modules: 1: Updated information and research on BPD; 2: Psychoeducation on the development of BPD, available treatments and comorbidity; 3: Individual skills: self-control of emotions, mindfulness, reality acceptance skills, validation skills, etc. and skills of relationship to promote emotional well-being problem management (family skills); 4: Family skills to improve the quality of relationships in family interactions; 5: Communication skills and effective self-expression; and 6: Problem management. All modules include Practice exercises and homework. In addition, throughout the program, in order to increase social support, the FC program provides a forum where participants can stay in touch, share common problems and solutions.
4426|NCT04160871|Behavioral|Treatment As Usual|"The intervention lasts for 3 months and includes 12 sessions that follow a group format of 2 hours and with a weekly frequency. It includes the following components: Psychoeducation about personality disorders and, specifically, BPD and how these disorders evolve. Problems associated with BPD (eg, alcohol and / or drug use, eating disorders, etc.). The importance of modeling in family members: change of attitude towards difficult situations to reduce the escalation of tension and re-establish a healthy relationship between the patient and family. The handling of problems. Crisis management: Development of safe plans for when the patient is in emotional escalation."
4427|NCT04160858|Other|Exercise|Spinal Cord Injury Exercise Guidelines: Participants will begin at the Starting Level which is 20 mins of moderate to vigorous aerobic activity 2x/week & 3 sets of 10 repeats of strength training 2x/week. They will progress to Advanced Level which is 30 mins of moderate to vigorous aerobic activity 3x/week and 3 sets of 10 repetitions of strength training 2x/week. The intervention duration is 6 months.
4428|NCT04160858|Other|Control|Wait-list control
4429|NCT04160845|Procedure|cardiac surgery|cardiac surgery with hypothermic cardiopulmonary bypass
4430|NCT04160832|Genetic|Multi-Cancer Cancer Panel|Eligible patients will receive genetic testing to determine germline cancer predisposition.
4431|NCT04160819|Other|Assigned Interventions|Participants in the NI group received an iNIP according to energy and protein intake requirements in addition to dietary advice based on face-to-face interviews with their family members during hospitalization. After discharge, phone calls are adopted for prescribing iNIPs.
4432|NCT04160806|Device|Transcranial direct current stimulation|Participants will receive a total of 10 stimulation sessions. During each session, 2 milliAmpers of active or sham tDCS will be applied for 20 minutes over the dorsolateral prefrontal cortex (left anodal/right anodal).
4433|NCT04160793|Device|Genital Nerve Stimulation|Implantation the vaginal way a stimulation's electrode to the dorsal nerve of the clintoris in local anesthesia
4434|NCT04160780|Procedure|L-PRF|sinus augmentation using L-PRf as sole graft material
4435|NCT04160780|Procedure|L-PRF mixed with xenograft|sinus augmentation using L-PRF mixed with xenograft as sole graft material
4436|NCT04160780|Procedure|xenograft|sinus augmentation using xenograft as sole graft material
4437|NCT04160767|Drug|Probiotic Vivomixx|VIVOMIXX once a day for 4 months. VIVOMIXX® is a probiotic containing 8 differenct strains of bacteria: Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. bulgaricus DSM 24734). Every sachet contains 450 billions of bacteria, maltose and silicon dioxide. VIVOMIXX® will be freely given by the society MENDES S.A. - Lugano Switzerland.
4438|NCT04160767|Behavioral|Gluten free diet|Gluten free diet will be encouraged in both arms
4439|NCT04160767|Other|Placebo|Placebo with same taste than VIVOMIXX, containing maltose and silicon dioxide once a day for 4 months.
4440|NCT04160754|Behavioral|Mindfulness Based Relapse Prevention|"Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and urge surfing). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase."
4472|NCT04160507|Other|Biorepository|To collect and store biological samples (whole blood and urine), along with relevant medical information, from adult inpatients and outpatients. Buffy coats will also be received from H3Africa Kidney Disease Research Network.
4473|NCT04160494|Drug|D2C7-IT (6920 ng/mL via convection-enhanced delivery)|dual-specific mAB
5173|NCT04154865|Other|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
4441|NCT04160754|Behavioral|Control (CTL)|Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components
4442|NCT04160741|Other|Radiation and warm environment|"Exposure to hot environment (30°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
4443|NCT04160741|Other|Warm environment|"Exposure to hot environment (30°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
4444|NCT04160741|Radiation|Neutral environment with radiation|"Exposure to neutral environment (20°C WBGT) with radiation (800 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
4445|NCT04160741|Other|Neutral environment without radiation|"Exposure to neutral environment (20°C WBGT) with radiation (0 W/m2)~Exposure for 03:20:00:~rest (two hours)~work (cycling) at 100 W (one hour)~recovery (twenty minutes)"
4446|NCT04160728|Other|Work/ rest scenario|For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
4447|NCT04160728|Other|Hydration scenario|Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
4448|NCT04160728|Other|Clothing scenario|Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
4449|NCT04160728|Other|"E-carts scenario"|"Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)"
4450|NCT04160728|Other|Business as usual scenario|No interference with the usual work day of the participants
4451|NCT04160728|Other|Sham evaluation|Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
4452|NCT04160702|Behavioral|Motivate-The-Bystander (MTB)|MTB is a motivational interviewing intervention designed to increase bystander intervention behaviors. During MTB, participants will discuss their knowledge and experiences with bystander intervention. Participants will then create a plan to increase their bystander intervention behaviors in the future. The interviewer will utilize a variety of motivational interviewing techniques to help guide the conversation towards change (e.g., asking questions in an open-ended manner, reflecting participants' personal values).
4453|NCT04160689|Biological|implantology|placing of implant
4454|NCT04160676|Drug|Hydrocortisone, Ascorbic acid, Thiamine|Combination of hydrocortisone, ascorbic acid, and thiamine
4455|NCT04160676|Drug|Normal saline|Normal saline
4456|NCT04160663|Diagnostic Test|Carotid Ultrasound|Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
4457|NCT04160650|Behavioral|Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer|"This is an educational intervention which aims to answer the questions:~In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?"
4458|NCT04160637|Diagnostic Test|Immediate postoperative PTH serum sampling and cut-off value identification|The patients will undergo immediate post-thyroidectomy PTH sampling in order to establish a cut-off value for identifying patients at risk for postoperative hypocalcemia within the first 5 postoperative days.
4459|NCT04160624|Procedure|transcatheter aortic valve replacement|Use Venus-A valve or J-Valve to perform TAVR procedure. Use cardiopulmonary bypass or cardiopulmonary bypass to provide ECLS
4460|NCT04160611|Drug|Midazolam 7.5mg|The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
4461|NCT04160598|Drug|IV infusion|Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
4462|NCT04160598|Drug|intrathecal fentanyl|10‐15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
4463|NCT04160585|Other|There is no intervention.|There is no intervention.
4464|NCT04160572|Behavioral|Morning sleep schedule|sleep right after night shifts
4465|NCT04160572|Behavioral|Evening sleep schedule|sleep before night shifts
4466|NCT04160559|Other|green tea|The investigators require patients to regularly drink green tea during the trial period.
4467|NCT04160546|Drug|Ponatinib 15 MG|"Patients will receive ponatinib 15 mg/day for 104 weeks orally. Ponatinib will be self-administered by the patient on a daily schedule.~Acetyl salicylic acid (ASA) (100 mg) will be used such auxiliary medicinal product in order to prevent vascular occlusive events related with ponatinib."
4468|NCT04160546|Drug|Acetylsalicylic acid 100 MG|Patients will receive acetylsalicylic acid 100 mg/day for 104 weeks orally.
4469|NCT04160520|Drug|Pramipexole|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
4470|NCT04160520|Drug|Morphine|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
4471|NCT04160520|Drug|Placebo oral tablet|Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
4474|NCT04160494|Drug|Atezolizumab (1200 mg every three weeks)|programmed cell death ligand 1 (PD-L1) blocking antibody
4475|NCT04160481|Dietary Supplement|FruitFlow|300mg tomato extract
4477|NCT04160468|Drug|Exebacase|Participants will receive a single IV infusion of exebacase in addition to SoCA selected by the investigator. Participants with normal renal function or mild renal impairment will be administered a dose of 18 mg; participants with moderate or severe renal impairment will be administered a dose of 12 mg of exebacase; participants with end-stage renal disease, including those on hemodialysis, will be administered a dose of 8 mg of exebacase.
4478|NCT04160468|Drug|Placebo|Participants will receive a single IV infusion of placebo in addition to SoCA selected by the investigator.
4479|NCT04160455|Biological|expression of a panel|Quantify, by droplet digital PCR, the expression of a panel of 7 genes (+ GALIG) involved in autophagy2 on sub-populations (CD4+ and CD8+ lymphocytes and monocytes) after their sorting using magnetic bead cell then RNA extraction Evaluate, on a functional test (as previously described1), whether the observed expression dysregulation is associated with a deregulation of the autophagic function, whether constitutive or induced.
4480|NCT04160442|Behavioral|Carevive CarePlanning System|Subject will complete brief survey prior to seeing provider in clinic. Utilizing the CarePlanning System, the provider will review the subject's responses directing the conversation and treatment decision will be made. A treatment careplan will be developed and given to the subject.
4481|NCT04160429|Procedure|Biospecimen Collection|Undergo collection of sweat, saliva, and blood samples
4482|NCT04160429|Other|Medical Chart Review|Review of medical chart
4483|NCT04160429|Other|Questionnaire Administration|Complete questionnaire
4484|NCT04160416|Drug|Capecitabine-Oxaliplatin-Irinotecan Combination|CAP 1,600 mg/sq.m /day (p.o. day1-10) D1-10; Oxaliplatin (OX): 68 mg/sq.m (d.i.v.) D1; Irinotecan (IRI):135 mg/sq.m (d.i.v.) D1; BEV: 5mg/kg (d.i.v.) D1; CET: 500 mg/sq.m (d.i.v.) D1; Administered every 2 weeks.
4485|NCT04160403|Other|physical therapy intervention|NDT bases on neuroplasticity by which the brain change and reorganize itself and its processes according to practice and experience by a) facilitation of normal postural alignment and movement patterns; b) inhibition of the involvement during developmental and functional activities; and c) using sensory feedback (manual contact, visual integration, somatosensory reinforcement) for recovering function
4486|NCT04160390|Procedure|Biospecimen Collection|Undergo collection of blood
4487|NCT04160390|Procedure|Biospecimen Collection|Undergo collection of stool
4488|NCT04160390|Procedure|Biospecimen Collection|Undergo collection of saliva
4489|NCT04160377|Drug|Fluvoxamine|Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
4490|NCT04160364|Other|qualitative study|qualitative research via guided interview
4491|NCT04160351|Device|Theranova 400|medium cut-off dialyser
4492|NCT04160351|Device|Elisio-19H|high flux dialyser
4493|NCT04160338|Device|specular microscopy|"An informed written consent will be obtained from all patients that will be included in this study. Patients in this study will undergo specular microscopic examination of corneal endothelium before CXL procedure.~Patients will be assigned to undergo accelerated (epithelium-off ,transepithelial ) CXL .~Follow up specular microscopy will be done 3 months and 6 months after corneal collagen cross linking procedure ."
4494|NCT04160325|Dietary Supplement|postoperative 3-month exclusive enteral nutrition|postoperative 3-month exclusive enteral nutrition after surgery and alter to normal food after 3 months
4495|NCT04160325|Drug|azathioprine|azathioprine
4496|NCT04160325|Other|normal diet|normal diet
4497|NCT04160312|Dietary Supplement|Mitopure™ (Proprietary Urolithin A)|Fruit flavored sachet containing fixed dose of Mitopure™ (Proprietary Urolithin A)
4498|NCT04160312|Dietary Supplement|Pomegranate Juice|100% Pomegranate juice (approximately 1 glass equivalent)
4499|NCT04160299|Behavioral|Dance-based exergaming|Dance sessions
4500|NCT04160286|Other|Electroconvulsive therapy|"Electroconvulsive therapy is a procedure, done under general anesthesia, in which small electric currents are passed through the brain, intentionally triggering a brief seizure.~Repeated as deemed needed by the patients' doctor. Typically prescribed 10 times (3 times pr week)"
4501|NCT04160273|Diagnostic Test|patient questionnaire and telephone follow-up|PDI scale is filled in before returning home and follow-up at one month and one year thanks to a telephone call during which the patient answers the PCL-S questionnaire
4502|NCT04160260|Drug|Omadacycline|Omadacycline: PO Tablets
4503|NCT04160247|Procedure|Immediate implant placement|Implants are placed in fresh socket
4504|NCT04160247|Procedure|Angulated screw-retained crowns placement|To insert the restorations by angulated screw systems
4505|NCT04160247|Procedure|Cemented crowns placement|To cement the restorations onto the implant abutment
4507|NCT04160221|Other|12 hours interval|Time interval between treatments
4508|NCT04160221|Other|24 hours interval|Time interval between treatments
4512|NCT04160182|Behavioral|Energy Conservation Work Simplification Education|"The intervention will last approximately 45 minutes, and will be provided once/week for 6 weeks. The intervention is delivered live using web-cameras (e.g., Microsoft Zoom).~Registered and licensed occupational therapists will deliver the intervention. At beginning of the intervention, the participant and interventionist prioritize the 5 most critical fatigue-related problems that they would like to solve during the intervention. Each week, the interventionist will guide the participant through a workbook to provide knowledge and examples on how to apply the knowledge to everyday fatigue-related problems. The workbook contains: (a) information regarding fatigue in breast cancer survivors, (b) knowledge regarding fatigue management strategies, and (c) worksheets to develop skills to recognize and solve fatigue-related problems. Participants will retain the workbook after study completion."
4590|NCT04159519|Drug|Symbicort®|Participants will receive Budesonide 400 μg/formoterol fumarate 12 μg per inhalation and Budesonide 200 μg/formoterol fumarate 6 μg per inhalation.
4513|NCT04160169|Other|Counseling messages on injectable use and HIV acquisition risk|Counseling messages based on 2017 World Health Organization guidance, a review of the Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-related Risks, and the Family Planning Global Handbook were provided to clients expressing interest in injectables during regular family planning appointments.
4514|NCT04160156|Device|Long term sensor|Observational study including subjects using long term sensor according to local guidelines and patients preferences
4515|NCT04160143|Procedure|Surgical resection and stereotactic body radiation therapy (SBRT)|Surgical resection and stereotactic body radiation therapy (SBRT) are generally regarded as mutually exclusive treatment options for the local management of pulmonary malignancies. This Phase 2 prospective trial is a collaborative effort between the divisions of Thoracic Surgery and Radiation Oncology to evaluate the effects of dual treatment of pulmonary metastasis amenable to curative resection with neoadjuvant SBRT followed by surgical resection.
4516|NCT04160130|Device|Surgery|Patients will be randomized 1:1 to receive either transcatheter aortic valve replacement (TAVI) or aortic valve replacement with a commercially available surgical bioprosthetic valve.
4517|NCT04160117|Drug|Colchicine 0.6 mg|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
4518|NCT04160117|Drug|Matching placebo|p.o. twice daily for 10 days after catheter ablation for atrial fibrillation
4519|NCT04160104|Other|Questionnaire|Patients were asked to complete a questionnaire before colonoscopy. Bowel preparation was subsequently assessed by single endoscopist in each center using Boston bowel preparation quality score (BBPS). Both univariate and multivariate logistic regression models were used to identify high-risk factors associated with IBP and a predicting model with the bowel preparation score (BPS) was developed in the training cohort.
4520|NCT04160104|Other|Questionnair|Patients were asked to complete a questionnaire before colonoscopy. The predicting modle established by the training cohort will be used to assessing the preparation of validation cohort. The result will compared with endoscopists assessment of preparation.
4521|NCT04160091|Drug|FX006|Single intra-articular injection
4522|NCT04160091|Drug|Normal Saline|Single intra-articular injection
4523|NCT04160078|Behavioral|Mindfulness-based stress reduction (MBSR) Intervention|"1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~Sleep log diary: self report of sleep records~Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks"
4524|NCT04160065|Biological|IFx-Hu2.0|"Exposure Escalation:~The first 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at a single time point (28-day follow-up post last injection).~The second 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 2 time points 7 days apart (28-day follow-up post last injection).~The third 3 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection).~Exposure Expansion:~The remaining 11 subjects enrolled will receive a fixed IFx-Hu2.0 (plasmid DNA) dose of 0.1 mg injected in up to 3 lesions at 3 time points 7 days apart (28-day follow-up post last injection)."
4525|NCT04160052|Drug|Azacitidine|Given SC or IV
4526|NCT04160052|Drug|Venetoclax|Given PO
4528|NCT04160026|Drug|Monthly intermittent preventive treatment with dihydroartemisnin-piperaquine, with or without azithromycin|Feasibility study to assess adherence among health providers in antenatal clinics delivering the study interventions in a routine setting and uptake and adherence among pregnant women.
4531|NCT04160000|Device|Catheter ablation|Delivery of physical energy from external energy source via percutaneously inserted electrophysiologic catheter to destroy heart tissue in the human atrium and adjoining vasculature
4532|NCT04160000|Drug|Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation|Administration of antiarrhythmic drug to achieve either rate control or restoration of sinus rhythm for management of atrial fibrillation
4533|NCT04159987|Other|Spinraza intrathecal injection|The aim is to monitor the evolution of the Motor Function Measure-32 for SMA type II adult patients treated with SPINRAZA® (Nusinersen).
4534|NCT04159974|Drug|Durvalumab 50 MG/ML|IV Infusion
4535|NCT04159974|Drug|Tremelimumab|IV Infusion, Combination with Durvalumab
4536|NCT04159961|Drug|DWJ211|Inject the Drug into submental fat and abdominal fat via subcutaneous
4537|NCT04159948|Dietary Supplement|Carbohydrate drink|"This is a commercially available pre-op carbohydrate drink used in enhanced recovery programmes."
4538|NCT04159935|Device|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
4539|NCT04159922|Other|questionnaire|Bortner self questionnaire: 14 items Cohen PSS Perceived Stress scale: 10 items quality of life scale: 32 items depression scale: 14 items
4540|NCT04159909|Device|Transcutaneous Nerve Stimulation|510(K) number: K110390 vagus nerve for 5 minutes twice a day for 4 consecutive days
4541|NCT04159909|Device|Sham Stimulation|sham stimulation (no electrical current) for 5 minutes twice a day for 4 consecutive days
4542|NCT04159896|Drug|Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981|Given PO
4543|NCT04159896|Biological|Nivolumab|Given IV
4544|NCT04159883|Other|strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles)|Simple progressive strengthening exercise program for lower-extremity muscles (knee extensor and hip abductor muscles), the program has been evident to be significantly effective in improving self-reported knee pain and function. This program included: 1) Isometric quadriceps contraction, 2) Isotonic quadriceps contraction, 3) Isotonic hamstring contraction, 4) Isotonic quadriceps contraction with resistance band, 5), straight leg raising, 6) Side-lying hip abduction, 7) Partial Squats,
4592|NCT04159519|Drug|Ventolin®|Participants received Salbutamol sulfate 100 μg per inhalation as needed.
4545|NCT04159883|Other|"My Dear Knee smart phone application"|"The innovative app has been designed for Android and iPhone Operating System (iOS). The app provides guides with the Arabic language. It designed to be attractive for the older adult and easy to use. the exercises are demonstrated with colorful animated images to make easy to follow by the patients.~The app supports features such as alerts, monitoring system by the physical therapist and remote follow-up. The app provides automatic recording of exercise adherence, including the time and the number of sessions completed for the week in the physical therapist`s account."
4546|NCT04159870|Drug|Rifaximin|Rifaximin pills 400 mg x 3/day
4547|NCT04159870|Drug|Norfloxacin|Norlfloxacin 400 mg 1 pill/day
4548|NCT04159857|Procedure|Fetal head extraction technique during the cesarean section|see above for the description about one-hand and two-hand fetal head extraction technique
4549|NCT04159844|Device|URGOBD001|Application with 50% overlapping
4550|NCT04159844|Device|URGOBD001 associated with wading|Application with 50% overlapping in association with wading
4551|NCT04159831|Drug|LTI-01|single-chain urokinase plasminogen activator, scuPA
4552|NCT04159831|Drug|Placebo|normal saline
4553|NCT04159818|Drug|Nivolumab|240 mg flat-dose, every 2 weeks. From 20 weeks onwards, nivolumab will be administered every 4 weeks with a flat-dose of 480 mg starting from week 20 onwards
4554|NCT04159818|Drug|Cisplatin|40mg/m2, weekly for two weeks
4555|NCT04159818|Drug|Low dose doxorubicin|15mg flat dose, weekly for 8 weeks
4556|NCT04159805|Drug|TAK-079|TAK-079 subcutaneous injection
4557|NCT04159805|Drug|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection
4558|NCT04159792|Other|no intervention|No intervention
4559|NCT04159766|Drug|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
4560|NCT04159766|Drug|Placebo|normal saline
4561|NCT04159753|Device|Spinal Cord Stimulator|We will record patient's experience on the 30-Day FDA approved Burst Spinal Cord Stimulator Trial (BurstDR™, Abbott Saint Jude Medical).
4562|NCT04159740|Other|Tissue and blood collection|Tissue and swab (cells) collection for microbiome analysis. Blood collection for immune markers.
4563|NCT04159727|Other|stool and blood analysis|High throughput sequencing and quantitative PCR
4564|NCT04159714|Device|Air Optix contact lens|Contact lens will be placed on the surface of the patient's eye and is to be used as a bandage
4565|NCT04159701|Drug|LY3454738|Administered IV
4566|NCT04159701|Drug|Placebo|Administered IV
4567|NCT04159688|Drug|Alcohol|Alcohol Challenge
4568|NCT04159675|Biological|osteoblast biology study|Describe the in-vitro action of burosumab and vitamin D on human osteoblastogenesis from osteoblasts from patients with craniosynostosis due to HR
4569|NCT04159662|Behavioral|Cognitive Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
4570|NCT04159662|Behavioral|Active Control Intervention|In each of the 6 visits, participants will be completing some computerized tasks for a period of about 40 minutes. At the end of each session, there will be 10-15 minutes of bridging discussion between the research therapist and the participants. (More details about each condition will be added after study completion to protect the blinding of our participants) .
4571|NCT04159649|Drug|Letrozole 2.5Mg Tablet|Gonadotropins with or letrozol in fixed Gn RH antagonist IVF protocol
4572|NCT04159649|Drug|Gonadotropins|Gonadotropins without letrozol in fixed Gn RH antagonist IVF protocol
4573|NCT04159649|Procedure|endometrial sample in the pretreatment cycle|All participant will be exposed to mid luteal endometrial sample in the pretreatment cycle. couples will be asked to use condom in the pretreatment cycle.
4574|NCT04159636|Other|Carbohydrate beverage|The participants in this group are allowed to drink carbohydrate until 2 hours before surgery
4575|NCT04159623|Device|Belk Device|Knee exoskeleton with electrostimulation
4576|NCT04159623|Other|Standard Rehabilitative treatment|Use the standard rehabilitative treatment
4577|NCT04159610|Drug|WO3970|Application of cream to each axilla
4578|NCT04159610|Drug|Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use|Qbrexza should be applied to the clean, dry, intact skin, of your underarm areas only
4579|NCT04159597|Drug|Upadacitinib|Upadacitinib will be administered as oral tablet.
4580|NCT04159584|Other|Medical Music|Enrolled subjects will undergo 30 minutes of medical music listening
4581|NCT04159571|Device|Real cTBS to the vmPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
4582|NCT04159571|Device|Sham cTBS to the vmPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
4583|NCT04159571|Device|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
4584|NCT04159571|Device|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
4585|NCT04159558|Device|Mobile application|Experimental group will use a mobile application to help them in their self-care
4586|NCT04159545|Other|Qualitative and quantitative interviews|Qualitative semi-structured interviews and quantitative questionnaires
4587|NCT04159532|Dietary Supplement|MAG-EPA/MAG-DHA|monoglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
4588|NCT04159532|Dietary Supplement|TG-EPA/TG-DHA|Triglyceride of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
4589|NCT04159532|Dietary Supplement|EE-EPA/EE-DHA|Ethyl ester of eicosapentaenoic acid and docosahexaenoic acid in proportion of 460:200
4591|NCT04159519|Drug|Fasenra®|Participants received Benralizumab 30 mg/mL, 1 mL fill volume via Subcutaneous every 4 weeks for first 3 doses.
4593|NCT04159506|Behavioral|mindfulness, emotion didactics, interpersonal skills, experiential learning|mindfulness interventions involve body scanning, deep breathing, and muscle relaxation. Emotion didactics focus on emotion recognition and regulation. Interpersonal skill development looks at how to use emotion regulation to improve social functioning. Experiential learning means learning either through interactions with horses or via team-building activities.
4594|NCT04159493|Drug|Estriol|Vaginal Application
4595|NCT04159493|Drug|Placebo|Vaginal Application
4596|NCT04159480|Device|Experimental - Cogito Companion|Cogito Companion
4597|NCT04159480|Behavioral|Active Control|Use of MyCAP
4598|NCT04159467|Other|Pelvic Floor Muscle Training|4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
4599|NCT04159454|Device|PITA|Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate ~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
4600|NCT04159441|Other|None intervetion|None intervetion
4601|NCT04159428|Diagnostic Test|HHIE-S survey score|"First, the patient will fill in the French translation of the HHIE-S questionnaire in the observation book.~Secondly, he will perform the audiometry in silence test: for the tonal test in silence, we will test the frequencies 500, 1000, 2000 and 4000 hertz in each ear with pure tone sound. For the vocal in silence test, we will use the dissyllabic lists of words (Fournier's lists) at the intensities of 20, 30, 40, 50 and 60 decibels. This test will be in free-field conditions testing both ears.~Thirdly, he will perform the speech in noise audiometry test that consists in repeating sentences pronounced at an equal intensity (60 decibels) while the intensity of the noise is increasing. This test will be in free-field conditions testing both ears."
4602|NCT04159415|Drug|Placebo|Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
4603|NCT04159415|Drug|Low-Dose REGN4461|IV infusion loading dose or SC injection QW.
4604|NCT04159415|Drug|High-dose REGN4461|IV infusion loading dose or SC injection QW.
4605|NCT04159389|Other|Mental visualization|Instruction in mental visualization by theoretical lessons and support of practice by audio guide and session of experience sharing.
4606|NCT04159376|Diagnostic Test|PET/MR|"All patients will have a PET/CT and PET/MR study performed at the same clinical setting using a single dose of tracer administration.~The study cohort includes 150 patients 18 years or older, having metastatic skeletal involvement on baseline PET/CT prior to treatment. Baseline studies and follow up studies of the patients referred post treatment, will be reviewed.~The tracers will be FDG, labelled PSMA labelled Somatostatin and F-DOPA in order to assess skeletal lesions detection of all tumor types.~Skeletal lesions will be divided into marrow-based lesions, lytic, blastic and scleroric lesions. Tracer uptake will be measured at baseline and after treatment. Metabolic PET parameters, CT appearance and MR parameters will be assessed.~The best MR-based attenuation algorithm for detection of lesions and monitoring response will be derived."
4607|NCT04159363|Other|An interactive Colorectal Cancer self-Management enhancement smartphone-based psychosocial intervention programme (iCanManage)|The iCanManage consists of two components: (1a) Existing functions from the BuddyCare mobile application that provide a comprehensive 29 day-by-day perioperative guide for patients who will be undergoing colorectal elective surgery; (1b) a dashboard for healthcare professionals to monitor patients and their caregivers' well-being as well as allow mutual communication; and (2) Newly developed digitalised psychosocial content (e.g., mindfulness-based activities with audio cover, video materials related to positive psychology, patient ambassadors' success stories and relevant psychoeducation) tailored for colorectal cancer patients and caregivers, with the aim of providing them emotional and psychosocial support.
4608|NCT04159350|Device|Rectal Expulsion Device (RED)|"After a complete physical exam at bedside including a digital rectal exam, the patient is turned on their right side and RED is gently inserted into the rectum. The patient is then given one minute to expel RED while remaining on their right side. If the patient is unable to pass RED, the patient transfers to a commode and attempts to expel the device. If the device is not expelled, the device can be safely removed at bedside and the patient diagnosed with a biofeedback-responsive evacuation disorder.~The RED device is manufactured by Rose Medical (Grand Rapids, MI) under GMP conditions and final assembly is performed by In2Being (Saline, MI). The device contains accepted technologies that are already in use of humans, namely biomedical grade materials."
4609|NCT04159337|Other|The method of gene mutation detection|All samples were detected by large-panel, whereas some of which were also detected by WES.
4610|NCT04159324|Other|optimized cross-sectoral, structured and coordinated treatment pathway that integrates a patient-centred outcome evaluation|the optimized treatment pathway includes coordinated transitions between rehabilitation phases and institutes using individual case management and portal solutions
4611|NCT04159311|Other|Osteopathy|testing osteopathy Vs Treating osteopathy
4612|NCT04159298|Device|Top Spin 360|The TopSpin360 is a dynamic multi-planar neuromuscular training device that has been shown to improve static and dynamic multi-planar neck strength in a healthy athletic population
4613|NCT04159285|Behavioral|EffEKTiv 2.0 group CBT as continuation treatment after ECT in depressed patients|Group CBT with a maximum number of 8 participants. Group is half-open allowing a starting date right after completion of acute ECT treatment. Patients participate for 15 sessions, which are framed by 2 individual sessions before joining the group and one individual session at treatment end.
4614|NCT04159285|Other|Treatment as usual|Can include continuation ECT, psychopharmacological treatment, individual psychotherapy
4646|NCT04159012|Device|Transcranial direct current stimulation|"A Sooma transcranial direct current stimulator, using carbon electrodes, a reusable cap (to promote reproducible electrode placement), and disposable sponges that will be soaked in normal saline.~The anode will be positioned over the left dorsolateral prefrontal cortex (position F3 on the 10-20 the International EEG system), and the cathode will be positioned over the right dorsolateral prefrontal cortex (position F4)."
4647|NCT04158999|Device|milk analyzer|Human Milk Sample
4648|NCT04158999|Behavioral|Mother's nutrition values|evaluation of nutritional elements of maternal onset with Bebis Program
4673|NCT04158778|Other|Psychotherapy|Two sessions of MDMA-assisted psychotherapy will take place (session 3 & 7) within the 10 week course of psychotherapy.
4615|NCT04159272|Behavioral|Mindfulness Training|"The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (>3 years of experience). During the trial they will receive regular supervision."
4616|NCT04159259|Other|Low fiber diet|Participants will be provided with a low fiber diet in the form of packed out meals and snacks for 24 days in total (days 5-14 and days 36-49)
4617|NCT04159259|Other|Pea Fiber Bar|Participants will be provided with a low fiber diet plus 1-3 daily pea fiber bars from days 15-35
4618|NCT04159259|Other|Low fiber diet|Participants will return to the low fiber diet for days 36-49- this phase is the same as phase 1.
4619|NCT04159246|Device|Optical coherence tomography angiography|"Recent Optical coherence tomography angiography OCT-A will be performed to all patients before Treatment Administration.~Examination will be performed using Optovue AngioVue® Optovue, Inc., Fremont, CA, which uses split-spectrum amplitude-decorrelation angiography algorithm, which minimizes motion noise. This system also allows quantitative analysis, since it provides numerical data about flow area and flow density maps.~The patient will be examined before and after finishing the treatment course"
4620|NCT04159246|Drug|Sofosbuvir (Sovaldi)|Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C , here it's used with Daclatasvir for 3 months
4621|NCT04159233|Behavioral|Brief Behavioral Therapy for Insomnia (BBTI)|Participants will receive evidence-based 'Brief Behavioral Therapy for Insomnia' (BBTI), tailored to meet the needs of former football players. BBTi is a brief, efficacious treatment that focuses on modifying behaviors, rather than cognitive domains. The treatment emphasizes education, motivational tools, and specific behavioral recommendations (e.g., restricting time in bed) and will be administered through weekly phone calls with a trained sleep interventionist over 4-weeks.
4622|NCT04159220|Procedure|Clamping of the ventilator endotracheal tube|The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
4623|NCT04159194|Other|Control Diet|Players during the control trial will be instructed to maintain their normal food intake (~55% CHO) and the type and amount of ingested food will be recorded.
4624|NCT04159194|Other|Experimental Diet|The experimental diet will be administered by the investigators after M1, daily for the next 48 hours (three main meals, i.e. breakfast, lunch, and dinner, and snacks such as energy bars and raisins), and before M2 (breakfast and lunch)
4625|NCT04159181|Other|Lactulose|Oral solution lactulose (20g lactulose/200mL water).
4626|NCT04159181|Other|Picoprep|Cathartic to accomplish an evacuation of the colonic content.
4627|NCT04159181|Other|Placebo (water)|oral administration of Water (200mL).
4628|NCT04159168|Behavioral|Facial Affect Sensitivity Training (FAST)|The FAST intervention program represents a novel computerized intervention for high-risk youth that strategically targets implicated facial affect sensitivity deficits directly via a computerized real-time automated feedback and incentive system to remediate callous-unemotional tendencies associated with behavioral dysfunction.
4629|NCT04159168|Behavioral|Implicit Gaze Training task (Active control condition)|"This computerized task was developed to target implicit training of eye gaze but not facial emotion recognition per se via real-time feedback and incentives. On each trial, a fixation cross is followed by an emotional face with eyes directed either left, straight ahead, or right (balanced across expressions), followed by a response key. The child's task is to say which direction the eyes are looking (e.g., 1 or left). Stimuli are black and white standardized photographs of men and women models from the Ekman Pictures of Facial Affect each displaying the 3 gaze directions for 6 emotion expressions."
4630|NCT04159155|Drug|Cisplatin|Chemotherapy drug given by vein.
4631|NCT04159155|Radiation|External Beam Radiation|Radiation therapy given outside the patient to a particular part of the body.
4632|NCT04159155|Drug|Carboplatin|Chemotherapy drug given by vein.
4633|NCT04159155|Drug|Paclitaxel|Chemotherapy drug given by vein.
4634|NCT04159142|Drug|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles；
4635|NCT04159142|Drug|Nab-paclitaxel + Capecitabine|Nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and capecitabine given IV at 1000 mg/m^2 bid, d1-14 every 21 days x 6 cycles；
4636|NCT04159116|Other|Prophylactic suctioning when clinically indicated|Suctioned prophylactically when clinically indicated by copious secretions, coughing, choking or desaturatation
4637|NCT04159103|Biological|mRNA-3927|mRNA-3927 dispersion for intravenous (IV) infusion
4638|NCT04159090|Diagnostic Test|F18-PSMA|Patients with moderate or high risk of prostate cancer
4639|NCT04159077|Drug|Tamsulosin Hydrochloride|"Tamsulosin HCL is an alpha blocker. It relaxes the muscles in the prostate and bladder neck, making easier to urinate. The dosage used will be 0.4 mg (administered once daily)~Other names: Flomax"
4640|NCT04159077|Drug|Placebos|Half of the patients will be assigned to receive placebo tablets in the same manner as the active intervention. These tablets will have no effect.
4641|NCT04159064|Diagnostic Test|Thromboelastometry, Impedance Aggregometry|Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
4642|NCT04159051|Device|Regional Hyperthermia|Regional hyperthermia 1-2×/week to a total number of 7-10 treatments combined with salvage radiotherapy to a total dose of 70 Gy over 7 weeks
4643|NCT04159038|Other|Immediate Intervention Group|The immediate intervention group will receive training on how to properly refer and record EI/ECSE referrals.
4644|NCT04159038|Other|Delayed Intervention Group|Delayed group will receive training 6 months after the immediate intervention group does.
4645|NCT04159025|Device|CoreDx Pulmonary Mini-Forceps|Manufactured by Boston Scientific
5174|NCT04154852|Drug|Adalimumab|
4649|NCT04158986|Behavioral|Nurse-driven post-discharge intervention|"Home visits based on the concepts of Family Nursing:~The participants will receive three home visits by a nurse who is trained in the Family Nursing principles during the first 12 weeks after discharge.~The home visits will comprise of:~Filling in the Chronic Liver Disease Questionnaire.~Therapeutic conversations including drawing and review of genogram and eco-map.~Information about- and help to initiate contact to relevant municipal offers.~Evidence-based information based on the patient's current problems or symptoms, base-line knowledge and receptiveness.~Follow-up telephone calls:~• After the first 12 weeks participants will be followed-up by telephone monthly during the following 12 weeks.~Pamphlet:~• All participants will receive a pamphlet with brief information regarding preventive measures and early signs of decompensation as well as relevant contact details. The pamphlet will be handed out before discharge"
4650|NCT04158973|Other|Bleeding-risk based prophylaxis strategy during hospitalization and extended pharmacological treatment after discharge|At admission, patents undergo bleeding risk assessment and receive prophylaxis according to bleeding risk. After discharge, they will undergo an extended treatment of 5mg Rivaroxaban once daily for 15 consecutive days,
4651|NCT04158973|Other|Routine VTE prophylaxis in hospital|Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
4652|NCT04158960|Behavioral|Equine-assisted activities|Participants performed riding-related activities on and off of a horse once per week for 8 weeks
4653|NCT04158960|Behavioral|GaitWay program|Participants performed riding-related activities on and off of a horse, along with brain-building activities including balance tasks, swinging, spinning, music therapy, and sensory tasks, all once per week for 8 weeks
4654|NCT04158947|Drug|Afatinib|"Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy"
4655|NCT04158947|Drug|T-DM1|"Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
4656|NCT04158934|Biological|ADYNOVI/ADYNOVATE|Participants will receive ADYNOVI/ADYNOVATE prescribed prophylactically by physicians based on their standard clinical practice and in accordance with the national SmPC.
4657|NCT04158921|Other|Control:Diabetes mobile app|The Control:Diabetes app will encourage patients to: a) predict their blood glucose level at a particular time point in the future (e.g. the next morning); then b) enter their actual blood glucose levels when that time (the next morning) comes; and c) enter reasons for the discrepancy between prediction and reality, if the prediction was significantly (e.g. > 20%) different from the actual measurement. We hypothesize that by repeatedly encouraging disassembly of blood glucose changes into individual reasons (cognitive task analysis) while providing an incentive in the form of being able to more accurately predict blood glucose levels (operant conditioning), the app will prompt the patient to learn how various internal and environmental factors affect their blood glucose. They will then be able to adjust their behavior and medications to improve their blood glucose control.
4659|NCT04158895|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
4660|NCT04158882|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
4661|NCT04158856|Drug|Pyrotinib|400mg po every day
4662|NCT04158856|Drug|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days
4663|NCT04158843|Procedure|Radical resection|Radical resection is performed, and the cutting edge is negative.
4664|NCT04158843|Radiation|Radical radiotherapy|Radical local radiotherapy is feasible (cumulative radiotherapy dose is greater than or equal to 50Gy).
4665|NCT04158843|Other|Palliative treatment|Including palliative internal fixation, radiotherapy, systemic chemotherapy, endocrine therapy or targeted therapy
4666|NCT04158830|Drug|Aspirin 81 mg Enteric Coated Tab - 1 tablet|take one (1) 81 mg tablet each evening
4667|NCT04158830|Drug|Aspirin 81 mg Enteric Coated Tab - 2 tablets|take two (2) 81 mg tablets each evening
4668|NCT04158817|Drug|68Ga-Labeled PSMA|All participants in the study will be injected with 68Ga-THP-PSMA at a dose of 2.11 MBq/kg in a single dose injection.
4669|NCT04158817|Drug|Non-labeled PSMA|Patient will be injected with microdose (<100 ug) of THP-PSMA
4670|NCT04158804|Diagnostic Test|procalcitonin|accuracy of procalcitonin as a diagnostic marker in guiding antibiotic therapy in patients with a lower respiratory tract infection
4671|NCT04158791|Procedure|pars plana vitrectomy with epimacular membrane removal and internal limiting membrane peeling|25-gauge pars plana vitrectomy with a solution of 0.15% trypan blue, 0.025% brilliant blue G, 4% polyethylene glycol (MembraneBlue Dual) assisted ERM/ILM removal performed by a single surgeon (GV); no air-fluid exchange was performed during surgery. In phakic eyes, phacoemulsification with intraocular lens implantation was performed at the time of vitrectomy.
4672|NCT04158778|Drug|MDMA|Two sessions of MDMA-assisted psychotherapy will take place (session 3 & 7) within the 10 week course of psychotherapy. An initial dose of 125mg MDMA will be followed by an optional dose of 62.5mg 2 hours later.
4674|NCT04158765|Other|DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).|DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
4675|NCT04158752|Drug|Galcanezumab|Injection of study drug at 3 timepoints (day 30, day 60, day 90)
4676|NCT04158739|Drug|Cytarabine|Given IT
4677|NCT04158739|Biological|Flotetuzumab|Given IV
4678|NCT04158726|Behavioral|modified Geriatric Assessment (mGA)|The mGA, administered via patient self-report on a touchscreen computer, as well as the real-time use and utility by clinicians and the correlation of mGA results on treatment decision-making.
4679|NCT04158713|Drug|Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine|Monthly DP fixed dose of 3 tablets (40 mg of dihydroartemisinin and 320 mg of piperaquine) daily for three days until delivery. All participants will (continue to) receive daily cotrimoxazole (CTX) (one double-strength tablet of 160mg of sulfamethoxazole and 800mg of trimethoprim) and anti-retroviral drugs.
4680|NCT04158700|Drug|LY3200882|LY3200882 administered orally
4681|NCT04158700|Drug|Pembrolizumab|Pembrolizumab administered IV
4682|NCT04158687|Drug|CTP-692|CTP-692 taken orally
4683|NCT04158687|Drug|Placebo|Placebo taken orally
4684|NCT04158674|Drug|Levosimendan|Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
4685|NCT04158674|Drug|Cernevit|mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min
4686|NCT04158661|Procedure|thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)|preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
4687|NCT04158661|Procedure|thymectomy by means of median sternotomy (transsternal)|with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
4688|NCT04158661|Procedure|no thymectomy (control)|routine medical care
4689|NCT04158648|Drug|Emicizumab|Four loading doses of emicizumab 3 mg/kg will be administered subcutaneously once a week (QW) for 4 weeks followed by participant's preference of one of the following maintenance regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
4690|NCT04158635|Drug|Bosentan|Given PO
4691|NCT04158635|Drug|Gemcitabine|Given IV
4692|NCT04158635|Drug|Nab-paclitaxel|Given IV
4693|NCT04158635|Other|Quality-of-Life Assessment|Ancillary studies
4694|NCT04158635|Other|Questionnaire Administration|Ancillary studies
4695|NCT04158622|Procedure|PnR + laser/cryotherapy|Pneumatic retinopexy plus laser/cryotherapy
4696|NCT04158622|Procedure|PPV + laser/cryotherapy|Pars plana vitrectomy plus laser/cryotherapy
4697|NCT04158609|Diagnostic Test|Doppler flow indices assessment|Doppler flow indices, UA-PI, MCA-PI and CPR values, assessment performed prior to induction of labor
4698|NCT04158596|Device|Vibration Therapy|SDX-3101 is used for drug-free treatment of CRSsNP in adults.
4699|NCT04158583|Drug|RO7296682|RO7296682 will be administered as per the schedules specified in the respective arms.
4700|NCT04158570|Procedure|Percutaneous Nephrolithotomy|"Application of different stone scoring systems :~Guy's scoring system (GSS).~Seoul renal stone complexity scoring system (S-ReSC).~S.T.O.N.E. nephrolithometry scoring system.~CROES Nomogram. These scoring systems will be applied on each patient and correlate the predictive values with the real results to know which one of the above scoring systems better predict the outcomes."
4701|NCT04158531|Device|ECoG sensing and stimulation|Implant electrodes and a sensing+stimulation device, and use this for suppression of seizure activity
4702|NCT04158518|Radiation|Toxicities reduced treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
4703|NCT04158518|Radiation|Conventional treatment|"Drug: docetaxel and cisplatin (Induction chemotherapy) Patients receive docetaxel (75 mg/m2 d1) and cisplatin (25mg/m2 d1-3) every 3 weeks for 3 cycles before IMRT.~Concurrent cisplatin chemoradiotherapy delivered when responses to induction chemotherapy are less than 50% Partial Response(PR).~Radiation: IMRT Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor."
4704|NCT04158505|Other|non-interventional|This prospective, observational study will be conducted according to each site's routine clinical practice
4705|NCT04158492|Diagnostic Test|real-time multiplex PCR|Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
4706|NCT04158492|Diagnostic Test|Standard diagnostic procedures|Patients who will undergo only the standard microbiological diagnostic procedures: blood cultures, Gram stain and culture sputum when possible, Gram and pleural fluid culture when appropriate, urine determination of the pneumococcal and Legionella pneumophila serogroup antigens type 1. A serological study will be carried out for the etiological agents of atypical pneumonia in the acute and convalescent phases of the infection.
4707|NCT04158479|Device|ECMO|ECMO for circulatory and/or respiratory support
4708|NCT04158453|Drug|AUT00201|Oral dose of AUT00201
4709|NCT04158453|Drug|Placebo|Oral dose of placebo
4710|NCT04158440|Drug|Toripalimab + platinum-based doublet chemotherapy|Toripalimab 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m^2 by IV infusion Q3W, given on cycle day 1;Drug: Carboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m^2 by IV infusion Q3W
5175|NCT04154852|Drug|Methotrexate|
4711|NCT04158440|Drug|Placebo + platinum-based doublet chemotherapy|placebo 240 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1;Drug: Cisplatin 75 mg/m^2 by IV infusion Q3W, given on cycle day 1;Drug: Carboplatin AUC 5 by IV infusion Q3W, given on cycle day 1;Drug: Pemetrexed 500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.Drug:Paclitaxel 175 mg/m^2 by IV infusion Q3W;Drug:Docetaxel 60-75 mg/m^2 by IV infusion Q3W
4712|NCT04158427|Procedure|Faecal transplantation|Faecal transplantation from a healthy donor via colonoscopy
4713|NCT04158427|Procedure|Placebo faecal transplantation|Placebo faecal transplantation containing patient's own feces via colonoscopy
4714|NCT04158414|Diagnostic Test|PET/MR scan|500 cancer patients referred to PET-CT assessment will undergo PET/MR scan as well, and the net data will be compared. The overall data will be investigated in groups and subgroups of patients that share similar clinical characteristics and represent cancer patients in different time points during the natural history of their disease. Data analysis will be performed both visually and quantitatively using different MR and PET parameters according to the patient group. Specific populations will be detailed in the next sections per malignancy.
4715|NCT04158401|Device|Pregnolia|The Pregnolia measurement device (CE Mark for commercialization in the EU) will be used to measure the cervical stiffness (Pcl) on all subjects.
4716|NCT04158388|Other|Mediterranean-diet enriched with a higher dose of tryptophan and magnesium|That gruop eaten at both breakfast and dinner from walnuts (3-5 units), as food with high values of tryptophan and magnesium
4717|NCT04158388|Other|Isocaloric diet|That group eaten isocaloric diet plan based on Mediterranean diet.
4718|NCT04158375|Behavioral|Resistance Exercise|Resistance (RE) training will be performed 4 days per week using a combination of upper and lower body exercises at 8-12 repetitions per set. Participants will complete 2 progressing to 4 sets of 8 to 12 repetitions per exercise, with 1 minute rest between sets. Participants will warmup for 5 minutes on a treadmill, cycle ergometer or elliptical at ~50% VO2 peak then begin resistance training. Resistance will be performed 4 days per week with lower body exercise on Monday and Thursday, and upper body on Tuesday and Friday. Wednesdays are a rest day. Participants will begin at 2 sets per exercise on weeks 1 and 2, then 3 sets for week 3, and 4 sets for weeks 4 to 12.
4719|NCT04158362|Drug|Paclitaxel injection|Paclitaxel is administrated at the dose of 80 mg/m² as a 1-hour intravenous infusion every week (i.e., D1, D8 and D15) of a 3-week cycle
4720|NCT04158362|Drug|Capecitabine tablets|Capecitabine is given orally at a dose of 2000 to 2500 mg/m² daily for 14 days followed by a 7-day rest period every 3 weeks
4721|NCT04158362|Drug|Letrozole 2.5mg|Letrozole is administered orally at 2.5 mg/day continuous for patients nonsteroidal aromatase inhibitor naïve or relapsing >1 year after the end of adjuvant endocrine therapy.
4722|NCT04158362|Drug|Anastrozole 1mg|Anastrozole is administered orally at 1 mg/day continous for patients nonsteroidal aromatase inhibitor (NSAI) naïve or relapsing >1 year after the end of adjuvant endocrine therapy.
4723|NCT04158362|Drug|Fulvestrant Prefilled Syringe|Fulvestrant is administered at the dose of 500 mg intramuscular on D1-D15-D29 (as a loading dose), and then 500 mg every 28 days (as a maintenance dose) for patients relapsing on adjuvant or less than one year after completion of adjuvant NSAI.
4724|NCT04158362|Drug|Abemaciclib|Oral 150 mg BID continuous
4725|NCT04158349|Drug|Oxaliplatin|Subjects will be accrued in cohorts of 3 to 6 subjects per dose level starting at Dose Level 1 (95 mg/m2). Escalation will continue as described in the protocol until DLT stopping rules are met or the highest dose level is reached.
4726|NCT04158349|Drug|mFOLFIRI|mFOLFIRI is a standardized chemotherapy regimen utilizing 5-fluorouracil, leucovorin, and irinotecan administered on day one of a 14-day cycle. 5-Fluorouracil, leucovorin, and irinotecan should be prepared and administered per the package insert and local institutional guidelines.
4727|NCT04158336|Drug|ZN-c3|ZN-c3 is a study drug
4728|NCT04158336|Drug|Talazoparib|Talazoparib is an approved drug
4729|NCT04158336|Drug|Pembrolizumab|Pembrolizumab is an approved drug
4730|NCT04158323|Device|Airway Management in patients with a anticipated difficult airway|survey of anesthesists and intensive care physician of the perfomans with the flexible endoscope in patients with a anticipated difficult airway
4731|NCT04158297|Device|ESWL vs SOPIL|To compare the efficacy of single operator pancreatoscopy (SOP) with intracorporeal lithotripsy (SOPIL) to extracorporeal shock wave lithotripsy (ESWL) for the treatment of main pancreatic duct stones (MPDS) in patients with chronic pancreatitis.
4732|NCT04158271|Device|Prone Position|In a randomized order we evaluate techniques for securing the airway in paralyzed patients in prone position
4733|NCT04158271|Device|Laryngeal tube|In a randomized order we evaluate techniques for securing the airway in patients with a failed laryngeal tube
4734|NCT04158271|Device|Endotracheal tube Leackage|In a randomized order we evaluate techniques for securing the airway in paralyzed patients with a endotracheal tube and a cuff leackage
4735|NCT04158258|Drug|Bevacizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
4736|NCT04158258|Drug|Trastuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
4737|NCT04158258|Drug|Ado-trastuzumab emtamsine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
4738|NCT04158258|Drug|Pertuzumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
4739|NCT04158258|Drug|Atezolizumab|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
4740|NCT04158258|Drug|Capecitabine|Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
4823|NCT04157647|Device|CytoSorb|The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.
4824|NCT04157647|Device|Control|No hemadsorption filter or other treatment will be included in the CPB circuit
4741|NCT04158245|Drug|18F-fluciclovine PET Scan|The use of 18F-fluciclovine PET scanning will allow a more sensitive assessment of mCRPC patients at the initiation of systemic therapy and changes observed in 18F-fluciclovine PET will correlate better with the serologic changes in PSA, allowing superior disease monitoring, as compared to conventional imaging modalities. In addition, 18F-fluciclovine PET will detect heterogeneity in disease response and thus identify potential lesions amenable to targeted therapy.
4742|NCT04158232|Other|Method|treatment of mature teeth with apical periodontitis
4743|NCT04158219|Behavioral|Behavioral activation for health and depression (BA-HD)|Consistent with successful BA manuals, we plan to conduct up to 10 sessions of treatment over 12 weeks (the recommendation will be at least 8 sessions; scheduling of sessions will be flexible and conform to patient preference). The initial two sessions will be about 50 minutes long and later sessions will be 20-30 minutes long. Sessions can be done on site or over the phone; home visits will be offered for sessions 1-2 if a participant cannot travel. Treatment sessions will use behavioral activation techniques to assess participant values and link these values to behavior change. Goal-setting will focus on sequential, idiographic behavior change (tobacco use, medication adherence, physical activity, and diet) and be accompanied by educational materials and commercially available tools (e.g. activity trackers, pillboxes).
4744|NCT04158206|Other|Maternal voice|Recording in the intensive care unit quiet and separate consultation room. For infants in the 'maternal voice group,' mothers were asked to tape what the mother wants to say to their babies and read of a child book from the independent publish, 'Xiao Qi's yellow persimmon' which talk about the mother who has a premature infants how to take caring of their baby. After reviewing the quality of the recording, the mother's voice recordings are compiled for 13 minutes with Sound Organizer. 2 , and the volume of the sound standard according to the American Academy of Pediatrics guidelines is 60 decibels in the incubator.
4745|NCT04158193|Other|acupuncture|Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6. Needles will be remained for 30 minutes each time after DeQi sensation, one time a day，three times a week, the treatment will be lasted for 7 weeks.
4746|NCT04158193|Other|sham acupuncture|"Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6.~The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day，three times a week, the treatment will be lasted for 7 weeks."
4747|NCT04158180|Diagnostic Test|Questionnaire|A battery of questionnaires will be propose to the participants
4748|NCT04158167|Drug|oxytocin|24 International units of oxytocin or palcebo will be given intranasally. The order of administration will be counterbalanced
4749|NCT04158154|Other|Evidence-based hypertension treatment|The World Health Organization HEARTS package includes healthy lifestyle counseling, evidence-based treatment protocols, access to essential medicines and technology, team-based care, and systems for monitoring. The intervention has been adapted based on a local needs' assessment including evidence synthesis and specific exploration of health care workers' knowledge, attitudes, and behaviors related to hypertension, causes, consequences, and treatment, including fixed-dose combination and patient self-management, and patients' knowledge, attitudes, and behaviors related to hypertension, causes, consequences, and treatment. Implementation pathways have been developed with particular attention to overcoming modifiable system- and patient-level barriers to hypertension treatment and control across capability, intentional, and system domains using the Consolidated Framework for Implementation Research.
4750|NCT04158141|Drug|Carboplatin|Given IV
4751|NCT04158141|Drug|Cisplatin|Given IV
4752|NCT04158141|Procedure|Decortication|Undergo decortication
4753|NCT04158141|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
4754|NCT04158141|Drug|Pemetrexed|Given IV
4755|NCT04158141|Drug|Pemetrexed Disodium|Given IV
4756|NCT04158141|Radiation|Pencil Beam Scanning|Undergo PBS
4757|NCT04158141|Procedure|Pleurectomy|Undergo pleurectomy
4758|NCT04158141|Other|Quality-of-Life Assessment|Ancillary studies
4759|NCT04158141|Other|Questionnaire Administration|Ancillary studies
4760|NCT04158128|Other|non-intervention|non-interventional observation study
4761|NCT04158115|Other|Entire Spine Mobilization|8 sessions of Following: -Entire Spinal Mobilization of all spinal segment from C0 to C1 to L5 to S1 (10 reps × 3 sets), - Moist heat: 10 to 15 minutes, - Soft tissue Mobilization, - Exercises : (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)
4762|NCT04158115|Other|Segmental Mobilization|"8 sessions of following -Segmental Mobilization: All lumbar segment from L1 to L2 to L5 to S1 (10 reps × 3 sets) - Moist heat: (10 to 15 minutes), -Soft tissue Mobilization~- Exercises: (Knee to chest, Bridging. Hamstrings Stretching, TA stretching)"
4763|NCT04158102|Drug|Bupivacaine liposome injectable suspension|Single dose of Bupivacaine liposome injectable suspension 266 mg in 20 mL
4764|NCT04158089|Behavioral|Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)|"Participants will be randomly assigned into one of four groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to one of the three treatment groups will either receive fetal Doppler monitors to take home; receive texted attachment exercises to complete from home; or both. The intervention will take place over a 2-week period. Participants in the Doppler only group will be asked to listen to their babies' heartbeats for one minute per day over the 2-week period. Participants in the Attachment Exercises Only will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.). Participants in the Doppler and Attachment Exercises group will be asked to complete both activities."
4765|NCT04158076|Drug|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
4766|NCT04158076|Drug|Telmisartan|PO, Once daily(QD), 8weeks
4767|NCT04158076|Drug|Telmisartan/Amlodipine 80 Mg-5 Mg ORAL TABLET|PO, Once daily(QD), 8weeks
4917|NCT04156828|Drug|Gemcitabine|Given IV
4918|NCT04156828|Drug|Carboplatin|Given IV
4768|NCT04158063|Behavioral|Dual Task Training|"In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~Titrated digit span backwards~Auditory vigilance with alphabets~Subtracting by 7~Motor tasks:~Walking at self-selected speed~Walking while carrying a cup of water~Walking while stepping over obstacles~Walking crisscross"
4769|NCT04158063|Other|Single Mobility Training|standard routine training
4770|NCT04158050|Drug|IL5 Antagonist or anti-IL5R-antibody or Omalizumab|mepolizumab, reslizumab, benralizumab and omalizumab in severe asthma
4771|NCT04158037|Behavioral|mHealth App|The app uses smartphones' global positioning software (GPS) that recognizes a user's location to within 15 feet. The app will construct a customizable geofence (e.g., 3 miles) around a gambler's favored gambling venue (e.g., casino, gas station). If the individual crosses the fence boundary his or her phone will raise the alarm with a personalized motivational message.
4772|NCT04158024|Other|Erector Spinae Plane Block|The ESPB is a fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
4773|NCT04157998|Drug|normal saline|intrvenous administration of 10ml normal saline preoperative
4774|NCT04157998|Drug|Metoclopramide 10mg|intrvenous administration of 10mg metoclopramide diluted in 10ml normal saline preoperative
4775|NCT04157985|Drug|Continue PD-1/PD-L1 Inhibitors treatment|Continued treatment with PD-1/PD-L1-1 inhibitor
4776|NCT04157985|Other|Discontinue PD-1/PD-L1-1 inhibitor|Discontinued treatment with PD-1/PD-L1-1 inhibitor
4777|NCT04157972|Device|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
4778|NCT04157972|Device|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
4779|NCT04157959|Drug|SHR4640 dose1|Tablet,dose1,QD
4780|NCT04157959|Drug|Febuxostat dose2|Tablet,dose2,QD
4781|NCT04157946|Diagnostic Test|CT|"Patients with ARDS were included. We excluded patients with emphysema, asthma, pneumothorax, or serious conditions of instability: oxygen saturation ≤ 88%; severe shock, ventricular arrhythmia, or myocardial ischemia.~To allow comparison between groups, patients were ventilated in volume control under similar conditions of tidal volume (TV; 6 ml/kg-PBW), plateau pressure (PPlat 30 cmH2O), respiratory rate (18 bit/min) and constant flow. PEEP was adjusted to reach objective PPlat.~Transpulmonary pressures (TP) were measured and a chest CT scan performed during an expiratory and inspiratory pause. Global and regional volumes of lungs were measured using specific software (Volume Analysis Software,Toshiba, Japan). Three regions were identified: basal (from the diaphragm to the carina), middle (from the carina to the aortic arch) and apical (above the aortic arch)."
4782|NCT04157933|Drug|009-A1|Inhaled apomorphine via Staccato aerosol, Dose 1 (low dose) each day for first 5 days, then 3 doses Dose 1 (low dose) q 2 hr on Day 6
4783|NCT04157933|Drug|009-A2|Inhaled apomorphine via Staccato aerosol, Dose 2 (middle dose) each day for first 5 days, then 3 doses Dose 2 (middle dose) q 2 hr on Day 6
4784|NCT04157933|Drug|009-A3|Inhaled apomorphine via Staccato aerosol, Dose 3 (high dose) each day for first 5 days, then 3 doses Dose 3 (high dose) q 2 hr on Day 6
4785|NCT04157933|Drug|009-A0|Inhaled placebo via Staccato aerosol, Dose 0 (placebo) each day for first 5 days, then 3 doses Dose 0 (placebo) q 2 hr on Day 6
4786|NCT04157933|Drug|009-B1 (active --> placebo) crossover|Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 2
4787|NCT04157933|Drug|009-B2 (placebo --> active) crossover|Up to 2 doses (placebo) ; minimum of 2 hrs between doses, on Day 1, followed by Up to 2 doses (Dose 3) ; minimum of 2 hrs between doses, on Day 2
4788|NCT04157920|Device|Transcatheter Aortic Valve Implantation with ACURATE NEO/TF|Transcatheter implantation of the heart valve device ACURATE NEO/TF in patients suffering from severe aortic stenosis and are candidates for this operation
4789|NCT04157920|Device|Transcatheter Aortic Valve Implantation with Medtronic Evolut R/Pro|Transcatheter implantation of the heart valve device Medtronic Evolut R/Pro in patients suffering from severe aortic stenosis and are candidates for this operation
4790|NCT04157907|Behavioral|Mentalization based therapy|Mentalization based therapy is a specialized treatment for patients with borderline personality disorder. The treatment program combines individual and group therapy, as well as psychoeducation
4791|NCT04157894|Other|Standard long-lasting insecticidal net|Interceptor® (BASF) contains a pyrethroid insecticide
4792|NCT04157894|Other|Chlorfenapyr insecticide treated net|Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
4793|NCT04157894|Other|Piperonyl butoxide long-lasting insecticidal net|PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
4794|NCT04157881|Drug|RABEprazole 20 Mg Oral Delayed Release Tablet|Absorption of APO-Dabigatran measured with and without influence of rabeprazole
4795|NCT04157881|Drug|APO-Dabigatran 150mg|Absorption of APO-Dabigatran post single dose
4796|NCT04157868|Drug|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
4797|NCT04157868|Drug|Control|Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
4798|NCT04157855|Procedure|Abdominal Plane Block(s) with depot Steroids|APB Steroids treatment: under real time ultrasound guidance, a 100 mm needle is introduced into the specified plane (subcostal TAP for upper abdomen pain, posterior TAP for lower abdomen pain or TQL for flank and lower abdominal pain). Normal saline (10 ml) is used to open the fascial plane (saline hydrodissection). Then 40 mg of depomedrone diluted in 10 ml of 0.25% levo-bupivacaine is injected into the plane. . A total of 80 mg of depomedrone (steroid) will be used.
4799|NCT04157842|Procedure|total hip replacement with subtrochanteral osteotomy|applying subtrochanteral osteotomy during the operation to release the tension of vessels and nerve
4800|NCT04157842|Procedure|total hip replacement with no osteotomy|just total hip replacement
4801|NCT04157829|Device|Scintilling lamp|Lamp with a standardized scintilling
4802|NCT04157829|Device|Classic lamp|Lamp without a scintilling
4919|NCT04156828|Drug|Dexamethasone|Given PO
4803|NCT04157816|Other|Face-to-Face Training|This intervention is a traditional classroom-based (face-to-face) training program for non-specialist health workers offering instruction for the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The classroom instruction follows the HAP manuals and is facilitated by an experienced counselor with certification as a Master Trainer, meaning that they have significant experience delivering HAP to patients with depression in clinical settings and also training other health workers in the delivery HAP. The total duration of classroom instruction is 6 days.
4804|NCT04157816|Other|Digital Training|This 4-week digital training program for non-specialist health workers is accessed through a smart phone app and offers instruction in the delivery of the Healthy Activity Program (HAP) in primary care settings. HAP is an evidence-based brief psychological treatment for depression. The digital training covers the same content as the Face-to-Face training. The course includes 16 modules with video lectures, role-play videos, graphics, slide presentations, quizzes, and assessment questions. Participants also receive low-intensity support to enhance their learning experience and sustain engagement, including: 1) access to an automated 'Help Line' that participants can call any time with questions about the program; 2) weekly automated messages sent through the mobile app to encourage participants; and 3) automated messages and phone calls to participants who show prolonged periods of inactivity in the mobile app to offer technical support and help them complete the training program.
4805|NCT04157816|Other|Coaching Support|Individualized remote coaching is a form of high-intensity support that will be used to help sustain participant engagement in the digital training program and promote success in progressing through the course. Each week, a Coach will phone participants and offer encouragement and support related to the course. The phone call will last no more than 60 minutes. The Coach will be someone who has successfully completed the course, and therefore can offer first hand knowledge of the content. During the coaching session, the coach will review the participants' progress through the course, offer praise and encouragement, discuss any challenges or questions related to the course content, and review the participants' goals and plans for the upcoming week. Each participant will receive a maximum of 4 remote coaching sessions (1 per week over the 4-week training program).
4806|NCT04157803|Diagnostic Test|Acetic acid % spray|"If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly."
4807|NCT04157790|Other|CARE score|CARE score calculation
4808|NCT04157777|Other|Perineum massage with olive oil|"Descriptive form used for data collection included questions about women's sociodemographic features, medical and obstetric history and previous and present birthsof women participated in the study.~The Reeda Scale The scale is consisted of five parameters of healing: Redness, Edema, Ecchymosis, Discharge Approximation.~Pregnant women who came to the delivery room and met the criteria were randomly selected and assigned to experimental and control group according to age and educational status.~There was not any change in the birth process of the delivery room during data collection and the pregnant women received routine care and treatments.~REEDA scale was administered by other midwives who worked at the puerperal room where pregnant women stayed after birth and did not know their groups because those who gave vaginal birth were early discharged from the hospital as they could answer only the first three parameters of REEDA scale."
4809|NCT04157764|Device|HomeChoice Claria APD machine with SHARESOURCE|HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
4810|NCT04157751|Drug|Empagliflozin|Film-coated tablet
4811|NCT04157751|Drug|Placebo to Empagliflozin|Film-coated tablet
4812|NCT04157738|Drug|Rapid-Acting Insulin|Prior to discharge, all subjects will receive a regimen that includes a Meal-time insulin and carbohydrate regimen (number of units of insulin, number of carbohydrates, and/or ICR)
4813|NCT04157738|Drug|Long acting insulin|Prior to discharge, all subjects will receive a regimen that includes an evening dose of long-acting insulin (Glargine)
4814|NCT04157725|Drug|mild stimulation protocol: oral Clomiphene Citrate|Group A (mild stimulation protocol) will receive oral Clomiphene Citrate (Clomid®) 150 mg/day for 5 days (starting on the 2nd of menses), followed by FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting from the 6th day of the menstrual cycle. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
4815|NCT04157725|Drug|Conventional Stimulation Protocol: will receive FSH/HMG|Group B (conventional stimulation protocol) will receive FSH/HMG (human menopausal gonadotropins) at a daily dose of 150-225 IU starting on the 2nd day of menses. GnRH antagonist (Cetrotide®, Merck-Serono, Switzerland) 0.25 mg subcutaneously daily will be started once a dominant follicle becomes ≥14 mm until the day of final follicle maturation. Once 3 leading follicles reach 18mm in diameter, final follicle maturation will be triggered using HCG (Choriomon® 10,000 IU) in the presence of 14 or less pre-ovulatory follicles or GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose) in the presence of 15 or more follicles. The choice of the starting FSH/HMG daily dose will be tailored to BMI: 150 IU/d for BMI less than 25 and 225IU/d for BMI 25 and above.
4816|NCT04157712|Drug|ALZ-801 or matching placebo|
4817|NCT04157699|Drug|TDF tablet|TDF tablet 300mg QD
4818|NCT04157699|Drug|QL-007|QL-007 tablet
4819|NCT04157686|Drug|MT10109L|MT10109L will be injected into either the GL, LCL, or both the LCL and GL.
4820|NCT04157673|Behavioral|Episodic Future Thinking|This intervention involves participants engaging in episodic future thinking in order to improve their medication adherence and overall prospective thinking ability.
4821|NCT04157660|Procedure|Oxygen application|Oxygen application Supplemental oxygen via mask
4822|NCT04157660|Procedure|Sham room air|Room air will be applied via mask
4825|NCT04157634|Diagnostic Test|Prognostication model|In a prospective cohort of children hospitalized in a PICU, developement a model based on biomarkers, HRV, and a computerized classifier output, to predict long-term neurological outcome after a moderate or severe TBI in children aged 0 to 18 years.
4826|NCT04157621|Device|Active taVNS|Patients will be masked to transcutaneous stimulation of the auricular branch of the vagus nerve at the tragus
4827|NCT04157621|Device|Sham Stimulation|Sham stimulation involves identical perceptual threshold finding and stimulation parameters as active stimulation, with the exception of stimulation target. Sham stimulation will be delivered to the left earlobe, a target believed to have little to no vagal nerve innervation.
4828|NCT04157608|Device|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
4829|NCT04157608|Device|Energy-Harvesting Mesofluidic Impulse Prosthesis|e-MIP is an experimental lower limb ankle-foot prosthesis.
4830|NCT04157595|Other|Reproductive Genetic Carrier Screening|Carrier screening for approximately 1300 genes associated with severe autosomal recessive and X-linked recessive conditions affecting children will be performed on each member of the couple. A combined result will be issued indicating whether the couple has a 'low' or 'increased' risk of having a child with a genetic condition
4831|NCT04157582|Other|Pilates training|"Pilates warm-up training (5 minutes) consisted of Breathing, the Chest stretch, the Toy soldier, Upper extremity PNF patterns, and Roll down.~Pilates mat training performed in 5 different positions (30 minutes).~One leg stretch, Hundreds, the Double leg stretch, Scissors, the Shoulder bridge, Oblique preparation, and the Hip twist were performed in the supine position(Fig.7).~Clare, the Side kick, Arm openings, the Lower lift, Leg lifts, and the Side bend were performed in the side-lying position.~Swan dive, the One leg kick, Swimming, the Breast stroke preparations, the Breast stroke performed in the prone position(Fig.8).~Half roll back, Oblique roll up were performed in the sitting position.~Swimming was performed in the kneeling position.~The Pilates cool down training (5 minutes) were the Spine stretch, Saw, Chest stretch, Toy soldier. (Cruz et al .,2011)"
4832|NCT04157582|Other|Conventional physical therapy|"Gentle manual stretching exercises for (elbow flexors, wrist flexors , hamstring and calf muscle).~Strengthening Exercises for ( elbow extensors, wrist extensors and dorsiflexors)~Balance training (Wobble board training) :~Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror with hand support(with repetition 10times)~Patient will stand on squared then circled wobble board while it moves within parallel bars in front of mirror without hand support(with repetition 10times)."
4833|NCT04157556|Other|Yo-Yo Intermittent Recovery Test Level 1|"The test is a standard test battery with progressively increasing speeds. After every 40-m run (2x20 m), active rest is performed by walking or jogging at a distance of 10 m (2x5 m). for 10 seconds. Participants are trying to adjust their speed according to incoming audio signals.The test is terminated when the participants can not reach the signal twice. The test ends in 10-20 minutes depending on the level of participants.~Reference Bangsbo, J., Iaia, F. M., & Krustrup, P. (2008). The Yo-Yo intermittent recovery test. Sports medicine, 38(1), 37-51.~Krustrup, P., Mohr, M., Amstrup, T., Rysgaard, T., Johansen, J., Steensberg, A., ... & Bangsbo, J. (2003). The yo-yo intermittent recovery test: physiological response, reliability, and validity. Medicine & Science in Sports & Exercise, 35(4), 697-705."
4834|NCT04157543|Other|electroacupuncture|acupuncture with electricity
4835|NCT04157530|Device|wang-bu-liu-xing|wang-bu-liu-xing applied on the surface of Jinming and Qiuhou acupoints
4836|NCT04157530|Device|acupuncture|acupuncture applied to Qingming and Qiuhou with Der-qi
4837|NCT04157530|Device|Electroacupuncture|acupuncture, but the needles of Qinming and Qiuhou connected to the electroacupuncture machine after Der-qi, the frequencies of stimulus were 6 Hz, the intensity of stimulus was minimal visible muscle twitch
4839|NCT04157504|Other|Physical function assessment|Physical function assessment is a tool to evaluate mobility levels of patients
4840|NCT04157491|Drug|anlotinib and anti PD-1 antibody|Anti-PD-1 antibody administered by intravenous (IV) infusion on Day 1 of each 21-day cycle plus Anlotinib 12 mg administered orally (PO) once daily (QD) Day1-Day14 during each 21-day cycle.
4841|NCT04157478|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride will be given with a daily dose of 12 mg for 14 days of a 21-day cycle up to 2 cycles, initiated on the first day of radiation therapy and followed by adjuvant treatment with the same dosing schedule until patients have disease progression or intolerable toxicities.
4842|NCT04157478|Radiation|Radiation therapy|Radiation therapy will be delivered in daily fractions of 2 Gy given 5 days a week for a total of 60 Gy.
4843|NCT04157478|Drug|Temozolomide|Temozolomide will be administered at a daily dose of 75 mg/m2 until the completion of radiation therapy. Four weeks after the completion of radiation therapy, patients will be given with adjuvant chemotherapy with temozolomide at a dose of 150-200 mg/m2 for 5 days of a 28-day cycle for a total of 6 cycles.
4844|NCT04157465|Other|Treatment strategy trial|"Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~Fungal Biomarkers positivity (Beta-D Glucan>150 pg/ml, Galactomannan index>1.0)~Mycological evidence of fungal infection on fungal cultures from a non-sterile site~Radiological evidence of fungal infection~Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures."
4845|NCT04157452|Procedure|flexible ureteroscopy|flexible ureteroscopy is used to removed the stone. If a double-J stent was inserted pre-operatively, it was removed at the beginning of surgery. Rigid ureteroscopy was routinely used for ureteral dilatation before fURS. A 0.035 mm guidewire was advanced through the urethral and ureteral meatuses to the renal pelvis under direct rigid ureteroscope vision. A 14-Fr ureteral access sheath (Cook Medical, Bloomington, IN) was then passed over the wire to the ureteropelvic junction, and 7.5-Fr fURS (Flex-X2, Karl Storz, Germany) was performed through the sheath. Intrarenal pressure was stabilized by a pressure-sensitive pump (Shenda Medical, China). Holmium: yttrium-aluminum-garnet laser was used to fragment the stones. After lithotripsy, 6-Fr double-J stent was routinely inserted in all cases for 2-4 weeks.
4846|NCT04157439|Other|Control Group|"Hot fermentation was applied for 10 mints Sustain pressure on trigger point was applied with thumb for 3secs hold and 2 sec release (till pain is reduced).~Self-stretches of cervical muscles (10 reps× 1set) For home plan cervical muscles stretching and postural care was guided"
4847|NCT04157439|Other|Experimental Group|"Hot fermentation was applied for 10 mints. Integrated Neuromuscular Inhibition Technique [sustain pressure, Post Isometric Relaxation (PIR) and SCS]. Sustain pressure was applied on trigger points using thumb for 3 sec hold and 2 mints release (till pain is reduced).~Post isometric stretch (MET) was given with 4 repetitions (6-10sec hold). Strain counter strain was given in which upper trapezius shortened position was maintained by slight flexion, same side bending, opposite rotation and shoulder abduction for 90 sec and repeats this procedure till the pain is reduced to 3 out of 10.~Self-stretches for cervical muscles were done at the end of session to maintain the gained ranges (10 reps×1 set) For home plan cervical muscles stretching and postural care was guided"
4848|NCT04157426|Other|Percutaneous electrolysis|Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
4849|NCT04157426|Other|Dry needling|Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
4850|NCT04157400|Device|Intraoperative Parameter Testing|"Step 1: Recording and stimulation of spinal potentials during insertion of epidural spinal stimulator paddle~Once the epidural paddle is placed, study procedures will begin by connecting the terminals of the paddle to an electrophysiological recording device for signal amplification and filtering. Using this recording setup, motor evoked potential (MEP) and somatosensory evoked potential (SSEP) protocols will be performed to determine motor and sensory thresholds, respectively. Next, the surgical procedure will resume and after the implantable pulse generator (IPG) has been placed, study procedures will begin again and include activation of both low-frequency tonic stimulation (LFTS) and high-frequency burst stimulation (HFBS) patterns from the inserted paddle while recording EMG signals."
4851|NCT04157400|Device|Proprioception Testing During Stimulation|"Step 3: Proprioception testing~The research team will investigate the perceived change in knee joint angle and direction of movement reported by the subject in a Threshold to Detect Passive Movement (TTDPM). The TTDPM protocol will begin with the subject sitting in the Biodex testing seat, with the non-tested leg hanging freely and the tested leg strapped to the rotating arm of the dynamometer at the lower shank. The subject will be blinded as to the mode and intensity of stimulation: HFBS, LFTS, or no stim. The TTDPM will consist of at least 10 trials for each stimulation condition chosen based on SCM outcomes. The subject has control of a kill-switch that immediately halts movement of the rotating arm, which is to be activated once the subject perceives movement OR if the subject begins to feel any pain or discomfort throughout the task."
4852|NCT04157400|Device|Gait Analysis During Stimulation|"Step 4: Body weight support and treadmill (BWST) testing~Similar to step 2, LFTS and HFBS patterns will be compared by systematically testing each individual contact on the paddle while investigating for changes in stepping speed, pattern and EMG moduling complexity. Regarding EMG module analysis, muscle activity will be recorded bilaterally via surface EMG from lower extremity musculature. Furthermore, subjects will also have active LED markers placed over their clothes in order to track whole body kinematics throughout this portion of the study.~To optimize capture of steady state data on the treadmill, each subject will walk for approximately 10 sec prior to the 30 sec of data collection (40 sec per trial). This will allow capture of at least 10 consecutive steady state gait cycles (depending on cadence) per each amplitude selection for each stimulation delivery technique, which will be defined by parameters found during walking SCM."
4853|NCT04157387|Other|Cyriax inferior capsular stretching + Manual Therapy|Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching
4854|NCT04157387|Other|Manual therapy|"Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)"
4855|NCT04157374|Other|Action Observation training|They have to watch a video showing a person carrying out exercises (12 exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional). then they have to practice them. The observation of the exercises and their performance last 8 minutes (4 minutes for observation and 4 minutes for practice). They have to repeat the exercises 5 times per week for 3 weeks.
4856|NCT04157374|Other|Active Exercises|Execution of exercises: 3 of stretching, 3 of core stability, 3 of mobilization and 3 of functional activity. Patients of the control group recieve a brochure with the same exercises the patients of the experimental group received through the video. They will be asked to read the exercise 3 times and to practice it for 4 minutes. They have to repeat the exercises 5 times per week for 3 weeks.
4857|NCT04157361|Diagnostic Test|Collection of breath condensate|Breath condensate will be collected from the patients involved in study.
4858|NCT04157348|Biological|Benralizumab|30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks
4859|NCT04157348|Biological|Mepolizumab|3x100 mg vials of powder for solution for injection reconstituted into 3 separate 2mL or 3mL syringes for administration on each dosing occasion. Mepolizumab active solution will be administered subcutaneously (SC) every 4 weeks
4860|NCT04157348|Biological|Placebo to Mepolizumab|Matching placebo: 0.9% sodium chloride, solutions for injection 2mL or 3mL syringes (3 syringes will be used on each dosing occasion). Placebo to Mepolizumban will be administered subcutaneously (SC) every 4 weeks
4861|NCT04157348|Biological|Placebo to Benralizumab|Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC) every 4 weeks
4862|NCT04157335|Biological|Benralizumab 30 mg|"Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume.~Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
4920|NCT04156828|Biological|Rituximab|Given IV
4921|NCT04156828|Biological|Pegfilgrastim|Given SC
5176|NCT04154852|Drug|Placebo|Placebo to replace adalimumab
4863|NCT04157335|Biological|Matched placebo|"Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume.~Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48)."
4864|NCT04157322|Diagnostic Test|prospective single arm biomarker (plasma cell-free DNA hydroxymethylation) study|Blood draw
4865|NCT04157296|Behavioral|Cognitive behavioral therapy (CBT)|The CBT intervention will consist of 12 weekly 60 minute sessions of the manualized therapy, adapted from the Coping Cat program, for the treatment of pediatric anxiety disorders.
4866|NCT04157296|Behavioral|computerized cognitive training (CCT)|CCT intervention will consist of approximately 30 minutes of CCT games prior to each CBT session, to engage cognitive control capacity prior to receipt of CBT. The CCT games will be designed to target focused attention, response inhibition, working memory and multiple simultaneous attention to constitute a general executive function training, and activate neural systems associated with executive function/cognitive control. Difficulty of the games will be titrated individually and by session to avoid boredom and progressively activate the functional systems underlying cognitive control.
4867|NCT04157283|Diagnostic Test|MRI brain, visual evoked potential, Cerebrospinal Fluid, Sexual dysfunction measure, Depressive symptoms assessment and Multiple Sclerosis Quality of Life-54(MSQOL-54)|"Neurophysiological Evaluation:~Visual Evoked Potential (VEP).~Imaging Evaluation:~Conventional MRI.~Cerebrospinal Fluid (CSF):~Sexual dysfunction measure: through the international index of erectile function (IIEF), female sexual function questionnaire (SFQ) and the sexual Quality of life male and female version (SQoL) (American Psychiatric Association, 1994).~Depressive symptoms assessment through The BDI (The Beck Depression Inventory) which is the most common instrument measuring the severity of depression.~Fatigue symptoms were evaluated through fatigue subscale of Multiple Sclerosis Quality of Life-54(MSQOL-54)."
4868|NCT04157270|Device|Penumbra System|Penumbra System
4869|NCT04157257|Drug|TDF tablet|TDF tablet 300mg QD
4870|NCT04157257|Drug|Entecavir Tablet|Entecavir tablet 0.5mg QD
4871|NCT04157257|Drug|QL-007|QL-007 tablets 200mg BID
4872|NCT04157244|Behavioral|Tailored music listening intervention|The music intervention consists of listening to preferred soothing music at bedtime for 30 minutes every night for four weeks (28 sessions total). This theory based caregiver-assisted intervention builds on the evidence-based protocol of using individualized music to decrease agitation in nursing home residents. It also accounts for sleep-inducing properties of music.
4873|NCT04157231|Other|Acute stroke care Intervention arm|"Training and education of the site staff about the treatment protocol for the different components of the management plan will be provided on two occasions. The aim of these sessions will be to educate stroke champions and other site staff on the management protocols. Available training resources will be accessed (including online materials) and simulation training will be used. New skills such as dysphagia assessment will be emphasized based on existing knowledge and competencies. After training, staff will have another assessment (Post-test) in order to determine whether they have been adequately trained and are able to adhere to the essential acute stroke care management plan. A standardised Power Point presentation and accompanying handouts will be made available for further use in the ward.~Refresher training will be provided monthly during the intervention."
4874|NCT04157218|Device|HIFU device (Doublo, HIRONIC Co., Sungnam, Korea)|The areas treated with HIFU will include: The forehead, temples, and malar area, cheeks and submental area .
4875|NCT04157218|Device|Threads used in this study are absorbable Aptos|The threads will be inserted to the cheeks
4876|NCT04157205|Diagnostic Test|Non-invasive ECG imaging - CardioInsight test|"Consent session~Fitting of ECGi vest and CT scan of the chest~Supervised exercise test and Valsalva maneuvre~Programmed stimulation via ICD (selected participants)~Blood tests - genetics"
4877|NCT04157192|Other|Real acupuncture|The patient will be treated for migraine with real acupuncture.
4878|NCT04157192|Other|Sham acupuncture (placebo group)|Sham acupuncture is used as a control in scientific studies to test the efficacy of acupuncture in the treatment of various disorders, in this case, migraine. In this study, the subjects will not know whether they are getting true acupuncture or not. In the placebo group, the acupuncture needles will not actually be inserted into the skin. Placebo needles consisting of a sliding tube and a retractible needle are applied to the acupunture reference point (marked by a pastille stuck on the skin). The patient should not be able to feel the difference between real acupuncture and sham acupuncture.
4879|NCT04157179|Other|Carbon Dioxide|The study team will administer carbon dioxide to the participants through a special mask (RespirACT) at a level
4880|NCT04157166|Diagnostic Test|to record a whole body 3D of 25 minutes in camera VERITON-CT ™|The procedure of recording of 25 minutes in camera VERITON-CT ™ including the registration whole body 3D coupled to a scanner low dose (CT) will be added to conventional recording followed by complementary images SPECT/CT
4881|NCT04157153|Device|Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold|Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold
4882|NCT04157140|Drug|Anlotinib|12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.
4883|NCT04157140|Device|TACE+RFA|TACE first, followed by RFA within day7（+/-3days）
4884|NCT04157127|Biological|Autologous DC vaccine|Autologous DC vaccine given as 3 doses every 14 days. Dosage is cohort-dependent.
4885|NCT04157114|Drug|MAP4343|Subjects will receive daily oral doses of MAP4343 for 6 weeks in conjunction with 6 weeks of manual-guided counseling
4886|NCT04157114|Drug|Placebo|Subjects receive matched placebo for 6 weeks in conjunction with 6 weeks of manual-guided counseling
4887|NCT04157114|Behavioral|Standardized behavioral counseling|Subjects receive manually-guided counseling 1 time per week for a 6 week duration
4922|NCT04156815|Radiation|1,565nm NAFL|1,565nm M22-ResurFx NAFL can deliver additional benefits to existing acne scar and skin texture. Patients were first treated by the 1,565nm M22-ResurFx NAFL on inflammatory papules and boxcar atrophic scars using round or rectangle light spots with similar sizes of individual lesional papules or scars. The energy fluence was 60 mJ and spot density was 150 spots/cm2. A whole face pass treatment was followed using hexagon or rectangle light spots with fluences of 40-45 mJ, density of 200 spots/cm2 and no overlap on light spots. The end points of the treatment were appearance of localized erythema, edema and bruise on treated areas.
4888|NCT04157101|Behavioral|Health Coaching|The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
4889|NCT04157101|Behavioral|Supportive Psychotherapy|"Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers."
4890|NCT04157088|Drug|Darolutamide(Nubeqa, BAY1841788)|600mg, twice daily
4891|NCT04157088|Drug|Enzalutamide|160mg, once daily
4892|NCT04157075|Drug|Bupivacaine|Bupivicaine injection into uterosacral ligaments prior to colpotomy
4893|NCT04157062|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|During the rTMS session, an electromagnetic coil is placed against the subjects scalp. The electromagnet painlessly delivers a magnetic pulse that stimulates nerve cells in the region of the brain involved in memory and thinking.
4894|NCT04157036|Drug|Ibuprofen|Subject will take 800mg Ibuprofen 45 minutes prior to anesthetic delivery
4895|NCT04157036|Drug|Methylprednisolone|Subject will take 40mg Methylprednisolone 45 minutes prior to anesthetic delivery
4896|NCT04157023|Device|Simulator-based Training of Direct Ophthalmoscopy|A digital simulator is used to teach the skills of direct ophthalmoscopy
4897|NCT04157010|Drug|Tocilizumab|
4898|NCT04157010|Drug|Methotrexate|
4899|NCT04156997|Other|No intervention is involved in this study|No intervention is involved in this study
4900|NCT04156984|Drug|Golimumab Prefilled Syringe|See arm description
4901|NCT04156971|Dietary Supplement|Omega 3|
4902|NCT04156971|Behavioral|stage-based lifestyle modification intervention|
4903|NCT04156958|Drug|Fruquintinib|Fruquintinib will be administered orally at a dose of 5 mg/d, 3 weeks on, 1 week off (4 weeks as a cycle) until progression, unacceptable toxicity, or withdrawal unless toxicity not relieved after dose adjustment.
4904|NCT04156945|Behavioral|Behavioural intervention|An online tailored behavioural intervention. The intervention will be developed as part of the project and will be based on the principles of the Information-Motivation-Behavioural Skills (IBM) model for behavioural change. It will consist of four interactive text-based modules, and demonstration and modelling videos addressing information, motivation, and behavioural skills. The intervention will be offered on a website and able to be used on PCs as well as any mobile device. It will be provided to the participants after randomization at month 6 and available for a total period of 18 months.
4905|NCT04156945|Diagnostic Test|HCV RNA home-based test|An additional patient-initiated home-based HCV testing service. The service offers a maximum of 4 free-of-charge HCV-RNA tests, which involves HCV testing using self-sampled dried blood spots (DBS). The DBS obtained from a finger stick will be used for HCV-RNA testing in the laboratory. DBS test kits, along with instructions and package materials for returning the test kits with the self-collected DBS sample will be provided to the participants after randomization at month 6 and available for use for a total period of 18 months.
4906|NCT04156932|Procedure|uterine artery closure|Interruption the uterine blood flow by closing the uterine artery at its cervical-isthmic part or at its origin.
4907|NCT04156919|Behavioral|fooya!™|fooya!™ is a science/evidence-based AI-enabled neuromodulation and Cognitive Behavior Therapy (CBT) technology. fooya!™ has been shown to deliver statistically significant outcomes concerning food choices during randomized-controlled clinical trials conducted at the Baylor College of Medicine's Children's Nutrition Research in the United States of America as well as India. In the game, children make several decisions with split-second timing, such as food choices, destroying bad/unhealthy food robots using the bad foods that are thrown at the player, and saving themselves. If the children collect good/healthy foods, they are in fit-zone for a while, which shields them from bad food robots.
4908|NCT04156919|Other|WordSearch|We will have an active control group that will play a WordSearch game. The intention is to have the children play a familiar video game through the same modality (IPAD) that is unrelated to diet or lifestyle choices.
4909|NCT04156906|Biological|D+ RH genotype matched red cell units for transfusion|Chronically transfused patients with SCD and anti-D will receive D+ RH genotyped matched red cell units for transfusion in addition to standard C, E, and K antigen matching and being hemoglobin S negative, which is the Children's Hospital of Philadelphia institutional standard of care for patients with SCD. RH genotyping of donor units will be performed by the New York Blood Center (NYBC) Immunogenetics laboratory.
4910|NCT04156893|Biological|Red cell units that are genotype matched at the RHD and RHCE loci|Patients will be provided with red cell units that are C, E, and K antigen matched (standard of care for patients with SCD) and genotype matched at the RHD and RHCE loci.
4911|NCT04156880|Other|mammography|standard mammography including craniocaudal (CC) and mediolateral oblique (MLO) views
4912|NCT04156867|Device|Dynesys|discectomy with Dynesys
4913|NCT04156854|Diagnostic Test|Quantitated Blood Volume Analysis|Measurement of total blood volume, composed of red blood cell mass (RBCM) and plasma volume (PV) by administering low dose iodinated I-131 labeled albumin intravenously then taking blood samples at timed increments.
4914|NCT04156841|Diagnostic Test|mapping agent|according to different tracer methods, patients are divided into the implementation of a single mapping agent and implementation of combination of blue dye and radiotracer agent.
4915|NCT04156841|Procedure|neoadjuvant chemotherapy|Patients were divided into two groups based on whether they were receiving neoadjuvant chemotherapy.
4916|NCT04156828|Drug|Copanlisib|Given IV
4923|NCT04156815|Drug|Oral isotretinoin|Oral isotretinoin has remained the most effective medication for moderate-to-severe AV.Subjects received oral isotretinoin (Xingyi Yan'an Pharmaceutical, Shanghai, China) (1mg/kg/d for the first 2-4 weeks and 0.5mg/kg/d for the next 12-14 weeks) for a total of 16 weeks. Serum triglycerides, cholesterol and levels of liver enzymes were monitored every month during oral isotretinoin medication.
4924|NCT04156815|Other|Pricking blood therapy|Pricking blood therapy (PBT) is a modified acupuncture strategy that is adapted to treat inflammatory related diseases. It has been shown to be effective in treatment of many chronic and acute inflammatory conditions including vasomotor rhinitis, acute herpes zoster and acute gouty arthritis,suggesting a potential efficacy for AV as well. At the end point of each session of laser treatment, an acupuncture practitioner performed a PBT in the areas within 1.5 cm radius of the five facial acupoints (Yintang, Zhukong, Sun, Yingxiang, Cuanzhu) (Figure 1). These areas usually appeared intensive erythema. A facial sheet mask was used to clean the face after PBT, and the face was cooled by air cooler for 10 minutes.
4925|NCT04156802|Device|Real cTBS to the vmPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
4926|NCT04156802|Device|Sham cTBS to the vmPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
4927|NCT04156802|Device|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
4928|NCT04156802|Device|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
4929|NCT04156789|Diagnostic Test|Home sleep apnea testing|Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
4930|NCT04156776|Other|Muscle Energy Technique|Muscle energy technique was repeated 4 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session.
4931|NCT04156776|Other|Active Isolated Stretching|"The patient was asked to sit in an upright seated position and flex his/her knees 12 to 18 inches. Patient was asked to tuck the chin, exhale, and firmly contract the abdominal muscles as he/she curls their body forward. He/she was also guided not to bounce or make rapid movements at the end range of the active motion. Then, he was asked to move back to the starting position and repeat the same procedure for 8 to 10 times. Stretch on the end range was not more than 2 seconds.~This technique was repeated 10 times per session every day for 3 days a week for 4 weeks after the application of moist heating pad for 30 minutes before each session."
4932|NCT04156776|Other|Conventional Treatment|Conventional physical therapy treatment includes the application of moist heating pad for 30 minutes on lower back/ lumbar region prior to the intervention to both groups.
4933|NCT04156750|Drug|LY3556050|Administered orally.
4934|NCT04156750|Drug|Placebo|Administered orally.
4935|NCT04156750|Drug|Iohexol|Administered IV.
4936|NCT04156750|Drug|Metformin|Administered orally.
4937|NCT04156737|Device|TECNIS Symfony plus IOL Model ZHR00V|IOL replaces the natural lens removed during cataract surgery
4938|NCT04156737|Device|Trifocal Intraocular lens|IOL replaces the natural lens removed during cataract surgery
4939|NCT04156724|Device|Helmet vetilation|We will apply non-invasive positive pressure ventilation via a helmet as interface
4940|NCT04156711|Procedure|Remote Ischemic Preconditioning (RIPC)|Cycles of forearm ischemia and reperfusion by the inflation of a blood-pressure cuff over the systemic blood pressure for brief periods
4941|NCT04156698|Drug|Docetaxel|Docetaxel is a chemotherapy drug.
4942|NCT04156698|Drug|Cisplatin|Cisplatin is a chemotherapy drug.
4943|NCT04156698|Drug|Capecitabine|Capecitabine is a chemotherapy drug.
4944|NCT04156698|Drug|Camrelizumab|Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
4945|NCT04156698|Drug|Apatinib|Apatinib is a selective VEGFR2 inhibitor.
4946|NCT04156685|Drug|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
4947|NCT04156685|Drug|Part A, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fasting condition
4948|NCT04156685|Drug|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
4949|NCT04156685|Drug|Part B, Reference (D635 10/500mg, Astrazeneca)|Once a day. Under fed condition
4950|NCT04156659|Biological|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
4951|NCT04156646|Drug|Balovaptan|Balovaptan will be administered after a high-fat, high-calorie meal (Treatment A), after a 10-hour fast (Treatment B), and after a 10-hour fast with esomeprazole 40 mg (Treatment C)
4952|NCT04156646|Drug|Esomeprazole|Esomeprazole will be administered once daily for 6 days and with a single dose of balovaptan 1 hour after the fifth esomeprazole dose
4953|NCT04156633|Diagnostic Test|conventional identification method: biochemical profiling or MALDI-TOF MS|Identification of bacteria in positive blood cultures with MALDI-TOF MS from a subculture usually one day after the signal for a positive blood culture appears (from 2016 to 2018)
4954|NCT04156633|Diagnostic Test|new identification method: Biofire FilmArray© BCID panel|The Biofire FilmArray© BCID Panel is performed directly from the positive blood culture without the need of subculture to reach single bacterial colonies (from 2018 and 2019)
4955|NCT04156633|Diagnostic Test|new identification method: metagenomic WGS|shotgun metagenomic approach allows to sequence the whole genome (WGS) of pathogens and thereby potentially detect every potential pathogen and also resistance and virulence gene (from 2018 and 2019)
5082|NCT04155619|Behavioral|Timed Light Therapy|Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
4956|NCT04156620|Drug|Secukinumab|The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
4957|NCT04156620|Drug|Placebo|The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
4958|NCT04156607|Other|Kinesio taping|For the fascia technique, one part of the band which were divided by 4 fans is adhered on Achilles tendon to the heel with a 0% stretch. Then the plantar fascia was stretched by the examiner and the toes were extended (ankle dorsiflexion, toe extension) and the divided part of the band was applied toward the metatarsal heads with paper-off technique (5-15%).
4959|NCT04156607|Other|Sham taping|''I'' bant were cut from the middle point of the Achilles tendon to the metatarsal heads. The band was applied from the Achilles tendon to the metatarsal heads without any stretching of plantar fascia and band.
4960|NCT04156581|Drug|Bupivacaine|Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures.
4961|NCT04156581|Drug|Dexamethasone|Dexamethasone is a corticosteroid that reduces inflammation.
4962|NCT04156581|Other|Saline|Saline is a mixture of HCl and water that can be used as a placebo.
4963|NCT04156568|Drug|INH、RFT|6INH 10mg/kg 3INH+RFT 15mg/kg
4964|NCT04156555|Drug|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
4965|NCT04156542|Behavioral|Basic School Lunchroom Nudges|"The intervention consists of three components: 1) serving fresh fruit in attractive bowls in at least two locations on the lunch line; 2) providing descriptive names for the vegetables; and 3) increasing amount of plain milk availability by 10% and placing it in front of the chocolate milk. For the vegetable naming intervention, researchers first developed, printed, and laminated descriptive vegetable name cards (2x4). Some examples included Savory Collard Greens, and [School Mascot] Salad. Cafeteria staff affixed name cards to the serving line sneeze-guards in front of the vegetables for the day. For the fruit intervention, we purchased and delivered two ceramic bowls to the intervention school. The cafeteria staff filled the bowls and put them in different locations on the lunch line. For the milk intervention, cafeteria staff increased the amount of plain milk available by 10% and placed plain in front of chocolate milk in the coolers."
4966|NCT04156529|Behavioral|ESU position|Semi-elevated supine (ESU) position was given during tube feeding
4967|NCT04156529|Behavioral|ESRL position|Semi-elevated right lateral (ESRL) position was given during tube feeding
4968|NCT04156516|Behavioral|HEART|sexual health intervention
4969|NCT04156516|Behavioral|HealthyMinds|Growth mindsets of personality and mental health
4970|NCT04156503|Other|Palm olein vs Lard|A 5-hour postprandial feeding intervention with 2-weeks washout in between. Blood samples will be collected at hour 0 (baseline) before test meal, and hour 3, 4 and 5 after consumption of test meal.
4971|NCT04156490|Other|No intervention is planned, this will be a purely retrospective trial.|Osmotic Therapy
4972|NCT04156477|Dietary Supplement|Ketone ester|Intake of weight adjusted drink of a ketone ester
4973|NCT04156477|Dietary Supplement|Glucose|Isocaloric and - volumetric taste adjusted drink
4974|NCT04156477|Dietary Supplement|Tap water|Isovolumetric taste adjusted tap water (placebo)
4975|NCT04156464|Drug|Phenobarbital|Phenobarbital loading dose followed by a taper will be given to control acute alcohol withdrawal syndrome
4976|NCT04156464|Drug|Lorazepam|Ativan will be given according to our institutional alcohol withdrawal protocol to control acute alcohol withdrawal syndrome
4977|NCT04156451|Procedure|Fluid resuscitation and furosemide administration (bolus and continuous) with central venous pressure target 8 - 10 mmHg|Crystalloid loading or furosemide administration with the CVP target 8-10 mmHg is reached in septic shock patients
4978|NCT04156451|Procedure|Fluid deresuscitation and furosemide administration (bolus and continuous) with central venous pressure target 0 - 4 mmHg|active fluid removal with furosemide bolus and continuous or crystalloid loading until the CVP target 0-4 mmHg is reached in septic shock patients
4979|NCT04156438|Device|Low tidal volume ventilation|Conventional ventilation strategy for patient with ARDS
4980|NCT04156438|Device|Airway pressure release ventilation|Experimental ventilation protocol for patients with ARDS
4981|NCT04156425|Drug|Escitalopram+Infliximab|Escitalopram will be administered at 10-20 mg/d. Infliximab will be administered at the dose of 5mg/kg at 3 separate times (baseline, 2 weeks, and weeks).
4982|NCT04156425|Dietary Supplement|Escitalopram+Calcium Tablet|Escitalopram will be administered at 10-20 mg/d. Calcium tablet will be administered at 2000mg/d.
4983|NCT04156425|Drug|Escitalopram|Escitalopram will be administered at 10-20 mg/d.
4984|NCT04156412|Device|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
4985|NCT04156399|Other|Acupuncture|All subjects will receive a standardized 18 needle acupuncture protocol.
4986|NCT04156386|Dietary Supplement|Recovery animal (20g whey) protein supplement|Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
4987|NCT04156386|Dietary Supplement|Recover vegan (26g pea) protein supplement|Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.
4988|NCT04156386|Dietary Supplement|Placebo (32g maltodextrin)|Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
4989|NCT04156373|Behavioral|Fuerte|Fuerte is a prevention program targeting youth at risk for psychological trauma who are recent immigrants to the United States. The program is evidence-informed using cognitive-behavioral principles and the Attachment, Regulation, and Competency (ARC) model for treating psychological trauma.
4990|NCT04156347|Drug|Episcleral Topotecan|Transscleral Topotecan
4991|NCT04156334|Procedure|Extraction of teeth in general anaesthesia using either computer-controlled intraosseous anesthesia device or carpule for local anaesthesia|QuickSleeper 5 with DHT needles or carpule with periapical/nerve block needles will be used to administer local anaesthetic before teeth extraction in general anaesthesia.
5177|NCT04154852|Drug|Folic Acid|
7924|NCT04132336|Drug|Caffeine|Tablet, oral, single dose
4992|NCT04156321|Dietary Supplement|Moringa fry|"School Tiffin:~Each of the adolescent girls will receive fresh Moringa leaves (150 gram) cooked in a traditional manner as Sajna shak (stir-fried)/ bora with rice and concentrated dal once daily for 5 days during tiffin time. Sajna Stir fry and bora will be given on every alternative day. Standard questionnaire will be used to measure the compliance of food. As we are serving the food in school premises during tiffin period, it would be both unethical and socially unacceptable if few of the students from a section receive the meal. Therefore, all the students from selected section/sections will receive the daily meal. However, we will only collect information from the selected study participants who would give consent to participate in the study Each of the combination of tiffin meal will supply 411 calories in the both arm ."
4993|NCT04156308|Other|Osteopathic Manipulative Treatment (OMT) - Temp1|A total of 3 techniques selected from a list of 7 available techniques common to all centers will be applied in each session. The choice of techniques will be based on the results of the examination performed, the particularities of the patient and the clinical experience of the osteopath. In each session the techniques can change under the criteria of the osteopath. However, they will always be 3 and always within the list of available techniques.
4994|NCT04156308|Other|Combined Exercises|A home-based pattern of combined exercises based on stretching, active anti-resisted exercises and joint mobility exercises focused on the cervico-dorsal and scapulo-thoracic regions. Whose clinical effectiveness has shown significant positive changes in pain levels and cervical functionality
4995|NCT04156282|Procedure|knot burial technique|surgical suturing intervention
4996|NCT04156282|Procedure|classical closure|surgical suturing intervention
4997|NCT04156269|Biological|BCMA-CS1 cCAR T cells|BCMA-CS1 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
4998|NCT04156256|Biological|CD123-CD33 cCAR T cells|CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
4999|NCT04156243|Biological|CD19 CARvac T cells|CD19 CARvac T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy.
5000|NCT04156230|Drug|[18F]GP1 positron emission tomography/computed tomography|A radioactive dose of 250 MBq of the study drug with a total quantity of ≤ 10 µg will be administered as slow intravenous bolus injection over up to 60 seconds. PET/CT examinations will be performed at 120 ± 15 min after the administration of [18F]GP1.
5001|NCT04156217|Biological|EBV-TCR-T cells|EBV-TCR-T cells are prepared via lentiviral infection. patients with EBV emias or EBV positive PTLD will be enrolled, and donor derived EBV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 EBV-TCR-T cells. The EBV DNA copies and EBV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28).
5002|NCT04156204|Other|Medication Event Monitoring System (MEMS)|AYA kidney recipients will receive a Medication Event Monitoring System (MEMS) via medication bottle and cap system
5003|NCT04156204|Drug|Once-Daily Tacrolimus extended release|AYA kidney recipients will receive once daily tacrolimus XR 1-10mg daily
5004|NCT04156191|Drug|ARQ-151 cream 0.15%|ARQ-151 cream 0.15% applied to atopic dermatitis lesions once a day for 28 days
5005|NCT04156178|Biological|CD20-CD19 cCAR T cells|CD20-CD19 cCAR T cells administered to patients, will be either fresh or thawed CAR T cells by IV injection after receiving lymphodepleting chemotherapy
5006|NCT04156165|Dietary Supplement|VLCD-Active|Lighter life formula products supplied to subjects, four sachets pr day. Dietetic advise given regularly.
5007|NCT04156165|Other|Maintenance-Active|Weight loss maintenance diet with high protein and low glycemic index and load, high in fiber and whole grain, daily including 150 g minced beef.
5008|NCT04156165|Dietary Supplement|VLCD-Control|Lighter life VLCD products
5009|NCT04156165|Other|Maintenance-Control|Weight loss maintenance diet with moderate protein and low glycemic index and load, high in fiber and whole grain, daily including 25 g minced beef.
5010|NCT04156152|Other|DEENSIBILIZING TOOTHPASTE BASED ON NANOCRISTALS OF HYDROXIAPATITA / 5% POTASSIC NITRATE / SODIUM MONOFluORPHOSPHATE 1450 PARTS PER MILLION|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
5011|NCT04156152|Other|5% POTASSIC NITRATE / SODIUM FLUORIDE 1426 PARTS PER MILLION TOOTHPASTE|The toothpastes will be delivered by the researchers and will be applied with a manual toothbrush, with soft bristles and straight handle, by the patient.The 2nd, 3rd, 4th session (2nd, 4th, 6th week of follow-up) will be the application of tests and reinforcement of oral hygiene instruction. In the 5th session (8th week of follow-up) the pastes will be requested to verify compliance.
5012|NCT04156139|Device|HFNC|The gas flow rate was set at 45~55 L/min. The inhaled oxygen concentration will be dynamically adjusted to maintain SpO2 ≥ 92%. The temperature will be set at 37 °C.
5013|NCT04156139|Device|NPPV|The PEEP is initially set as 5 cm H2O, the inspiratory pressure is 10 cm H2O, and the target tidal volume is 6-8 ml/kg.
5014|NCT04156126|Other|Blood Collection|Blood Collection
5015|NCT04156113|Other|Yo-Yo intermittent recovery test (level 1)|The Yo-Yo intermittent recovery test (level 1) will be administered once.
5016|NCT04156100|Drug|AGEN1223|AGEN1223 is a bispecific antibody.
5017|NCT04156087|Drug|Durvalumab 50 MG/ML|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
5083|NCT04155606|Device|microsurgery; endovascular interventions|microsurgery: surgical resection of the aneurysm endovascular interventions: coiling, stenting or both
5084|NCT04155580|Drug|ASTX660|Capsule for oral administration
5085|NCT04155580|Drug|ASTX727|Tablet for oral administration
5086|NCT04155567|Drug|TAK-123|TAK-123 infusion
5018|NCT04156087|Drug|Tremelimumab|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
5019|NCT04156087|Drug|Gemcitabine|"Combination of Durvalumab (fixed dose of 1500 mg) and Tremelimumab (fixed dose of 75 mg) will be given 2 weeks before surgery.~Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab After 4 doses of Durvalumab and Tremelimumab, only Durvalumab 1500mg is provided q4w until disease progression.~Systemic gemcitabine will be started 6 weeks after MIS-MWA. Gemcitabine will be given at a dose of 1000 mg /m² body surface, once a week for 3 weeks, followed with a week of rest."
5020|NCT04156087|Procedure|Minimally Invasive Surgical Microwave Ablation (MIS-MWA)|Minimally invasive surgical microwave ablation (MIS-MWA) of the pancreatic tumor will be performed two weeks after the first dose of Durvalumab and Tremelimumab
5021|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) olive oil emulsion drink|Vitamin D enriched (20 mcg/day) olive oil emulsion drink. 30 mL drink daily
5022|NCT04156074|Dietary Supplement|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink|Vitamin D enriched (20 mcg/day) coconut oil emulsion drink 30 mL drink daily
5023|NCT04156074|Dietary Supplement|Placebo coconut oil emulsion drink|Placebo coconut oil emulsion drink 30 mL drink daily
5024|NCT04156074|Dietary Supplement|Vitamin D supplement (20 mcg/day)|Vitamin D supplement (20 mcg/day) Pill consumed daily
5025|NCT04156061|Other|Delivery of CT scan results|Method of results delivery - verbal or visual.
5026|NCT04156035|Drug|Lamotrigine|Orally; 300 mg
5027|NCT04156035|Drug|Ketamine|Intravenously; 0.12 mg/kg during the first minute followed by a continuous infusion of approximately 0.31 mg/kg/h over approx. 40 min
5028|NCT04156035|Drug|Placebo Pretreatment|Lamotrigine Placebo
5029|NCT04156035|Drug|Placebo Infusion|Ketamine Placebo
5030|NCT04156022|Other|Dystonia Coalition is an observational study.|This is not an interventional study.
5031|NCT04156009|Other|Activated Lavender Elequil aromatabs® (#372)|Activated Lavender aromatherapy tablets wrapped in tape
5032|NCT04156009|Other|Unactivated Lavender Elequil aromatabs® (#372)|Unactivated Lavender aromatherapy tablets wrapped in tape
5033|NCT04155996|Device|data collection|Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.
5034|NCT04155983|Drug|Ropivacaine|The drug will be administered in the same dosage in both arms. The location of the injection will vary by arm.
5035|NCT04155970|Other|Manual therapy|Manual therapy, which includes spinal manipulation; spinal mobilisation; light massage; and trigger point therapy.
5036|NCT04155970|Other|Evidence-informed home management booklet|The home management booklet includes advice on posture, over the counter pain medication, cold and heat packs. The booklet also includes a section on patient reassurance and where to seek help from a medical professional in an emergency.
5037|NCT04155957|Other|Rapid Recovery Rehabilitation Programme|"Usual intervention at Hospital Clínic de Barcelona for post-operative rehabilitation of TKA patients. Participants, already at home after hospital discharge, must perform 5 different exercises 4 times a day (twice in the morning, twice in the afternoon).~Participants are also encouraged to walk and stretch their legs. Domiciliary visits by a physiotherapist start at approximately 2 weeks after the surgery to help participants do the exercises."
5038|NCT04155957|Device|ReHub|"Participants use a telerehabilitation platform, ReHub, as a guide to perform the TKA rehabilitation exercises of the Rapid Recovery Rehabilitation Programme intervention.~The exercise plan in ReHub is carried out by a site physiotherapist on the first day after discharge by using ReHub to acquire the participant's movement pattern with a wearable inertial sensor that transmits data to the platform.~The wearable inertial sensor participants must wear tracks movement while they do the TKA rehabilitation exercises. Movement is analysed and feedback is given in real time. At the end of each exercise, participants can select if they have felt pain in a scale from 1 to 10. A physiotherapist monitors the participants' progress remotely."
5040|NCT04155918|Drug|Group 1: AR882 + Febuxostat (FBX)|AR882 + Febuxostat, AR882 alone, Febuxostat alone
5041|NCT04155918|Drug|Group 2: AR882 + Allopurinol (ALLO)|AR882 + Allopurinol, AR882 alone, Allopurinol alone
5042|NCT04155905|Procedure|fistulotomy and marsupialization of wound edges|after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\0 sutures
5043|NCT04155905|Procedure|fistulotomy|after defining the fistulous track it was laid open (marsupialization)
5044|NCT04155879|Drug|Colchicine Tablets|Administration of Colchicine at a dose of 0.5mg 2x a day for six months.
5045|NCT04155879|Procedure|Cardioversion|Electrical or pharmacologic restoration of sinus rhythm
5046|NCT04155866|Other|Measurement of muscle activation.|Measurement of lower-limb muscle activation during walking for healthy participants.
5047|NCT04155853|Procedure|Interposition Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be filled with a roll of fascia lata and fixed with a K-wire. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
5178|NCT04154826|Drug|Recombinant human interleukin-7|weekly intra-muscular (IM) administration
7925|NCT04132336|Drug|Placebo|Tablet, oral, single dose
5048|NCT04155853|Procedure|Hematoma and Distraction Arthroplasty|A typical Wagner incision will be used at the thenar skin one centimeter distal to the radial styloid. The interval between the abductor pollicis longus and the extensor pollicis brevis will be developed, while protecting the dorsal sensory branches of the radial nerve. A longitudinal capsulotomy will be performed and after identifying the carpometacarpal and scaphotrapeziotrapezoid joints, the trapezium will be excised. Then, the empty space will be stabilized with a K-wire without interposition of any material. The 1.4 millimeter K-wire will be introduced two centimeters distally to the metacarpal base and into the body of the trapezium. In case of scaphotrapeziotrapezoid joint arthritis, debridement and osteophyte excision of the scaphotrapezoid joint will be performed. In the end of the procedure, the capsule and the skin will be sutured, and a thumb spica will be placed to all patients.
5049|NCT04155840|Drug|Copanlisib|Given IV
5050|NCT04155840|Drug|Copanlisib Hydrochloride|Given IV
5051|NCT04155840|Biological|Rituximab|Given IV
5052|NCT04155840|Drug|Bendamustine|Given IV
5053|NCT04155840|Drug|Bendamustine Hydrochloride|Given IV
5054|NCT04155827|Other|SIT|Sprint interval training of 4*4, with 30 seconds of all out workout followed by 4 minutes of active recovery for 4 cycles.
5055|NCT04155814|Drug|Iron Sucrose Injection|USP 100 mg/5 mL (20 mg/mL), solution for IV injection, 100 mg unit dose strength
5056|NCT04155814|Drug|Venofer Injection|(Iron Sucrose 20 mg/mL), solution for IV injection, 100 mg unit dose strength
5057|NCT04155801|Dietary Supplement|Salix Probiotic Blend|Oral capsule. The probiotic strains comprise the Salix Probiotic Blend include 3 strains of Bifidobacterium lactis (Bl-04®, Bi-07®, HN019) and 2 strains of lactobacillus (Lactobacillus acidophilus [NCFM]® and Lactobacillus paracasei [Lpc-37]®).
5058|NCT04155788|Behavioral|Food Exposure|Participants will complete a meal exposure using one of their feared foods.
5059|NCT04155775|Other|Computer electronic health record alert (Best Practice Alert - BPA)|Upon ordering platelets in patients with recent platelet count >50,000, a pop-up within the electronic health system will recommend to not continue with transfuse product order and provide clinical exceptions to continue. Importantly, the alert does not trigger in operating areas, emergency medicine treatment areas, for certain specialties like neurosurgery or for massive transfusion orders.
5060|NCT04155762|Other|Pin Suspension System (a prosthetic suspension system)|Participants used the PSS for three months following fabrication and adjustment of the prosthesis, and a prosthetic training period.
5061|NCT04155762|Other|Vacuum-Assisted Suspension System (a prosthetic suspension system)|After PSS, participants employed the VASS for three months after a similar training period.
5062|NCT04155749|Drug|CART-ddBCMA|Chimeric Antigen Receptor T cells
5063|NCT04155736|Behavioral|Renew|Renew is a behavioral health self-management app/too that focuses on three core activities: 1) in vivo exposure (to help participants approach safe situations they have been avoiding that they want to feel comfortable in), 2) expressive writing (to help participants emotionally process trauma memories), and 3) Self-Care exercises (designed to promote behavioral activation, social connectedness and relaxation; includes a breathing relaxation tool). Users have access to psychoeducation via a whiteboard video and short texts as well as Motivation content (quotes, videos, images, and songs) related to confronting challenges and overcoming fears. For each exercise that is completed, the user earns points that are connected to levels and visually reinforcing images (i.e., a growing tree).
5064|NCT04155710|Biological|IOV-2001|Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
5065|NCT04155710|Drug|Low dose IL-2|6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
5066|NCT04155710|Drug|High dose IL-2|6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
5067|NCT04155710|Drug|IL-2|6 doses of IL-2 will follow the infusion of IOV-2001
5068|NCT04155697|Drug|2% Chlorohexidine Gluconate soap|Participants will wash hands for 30 seconds with 2% Chlorohexidine Gluconate soap.
5069|NCT04155697|Drug|62% ethyl alcohol-based hand sanitizer|Participants will apply 62% ethyl alcohol-based hand sanitizer for 30 seconds
5070|NCT04155671|Drug|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
5071|NCT04155671|Drug|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally paclitaxel
5072|NCT04155658|Other|Experimental Toothpaste containing 1450ppm SMFP|Experimental Toothpaste containing 1450ppm SMFP
5073|NCT04155658|Other|Toothpaste containing 1450ppm SMFP|Toothpaste containing 1450ppm SMFP
5074|NCT04155658|Other|Toothpaste with no fluoride|Toothpaste with no fluoride
5075|NCT04155645|Drug|AZD8233 subcutaneous injection|Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
5076|NCT04155645|Drug|Placebo|Randomized subjects will receive SC dose of placebo injection.
5077|NCT04155632|Drug|N-acetylcysteine|N-acetylcysteine (NAC) is a medication that is used to treat paracetamol (acetaminophen) overdose, and to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease. It has a long-established safety record in adults and children, with FDA approval since 1963. The side effects most commonly noted in people who take NAC by mouth include diarrhea, nausea, vomiting, and headache. These side effects are usually mild and go away even with continued use of NAC by mouth. There is also a risk of a skin reaction, such as flushing, itching, or rash. A meta-analysis of studies evaluating long-term oral treatment with NAC for prevention of chronic bronchitis found that NAC was well tolerated, with generally mild, most commonly gastrointestinal adverse effects that did not require treatment interruption.
5078|NCT04155632|Device|Theta-burst stimulation (TBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
5079|NCT04155619|Behavioral|No change in meal timing|Participants will eat within an ≥11-hour daily period (no change in meal timing habits).
5080|NCT04155619|Behavioral|No change in light exposure|Participants will not change their light exposure habits.
5081|NCT04155619|Behavioral|Early Time-Restricted Feeding|Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.
5179|NCT04154813|Drug|Topiramate|The initial dose of 25mg/d is rapidly increased to the target dose (100mg/d) or below the maximum tolerable dose if the patient can tolerate it.
5087|NCT04155554|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function
5088|NCT04155554|Drug|Dolutegravir/lamivudine/abacavir|Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
5089|NCT04155541|Drug|dacomitinib hydrate|The usual adult starting dosage for oral use is 45mg of dacomitinib hydrate once daily. The dose should be reduced appropriately according to the patient's condition.
5090|NCT04155528|Other|Music therapy|The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
5091|NCT04155515|Drug|TG-2349|TG-2349 400mg
5092|NCT04155515|Drug|DAG181|DAG181 200mg
5093|NCT04155515|Drug|Ribavirin|Ribavirin 1000mg/1200mg
5094|NCT04155489|Procedure|blood transfusion|In the restrictive blood transfusion group, if the hemoglobin value is less than 8 g /dL or if there are suspected symptoms of anemia such as dizziness or chest pain, headache, low on energy, blood transfusion is started. in the liberal transfusion group, If the hemoglobin value is less than 10 g /dL, blood transfusions begin.
5095|NCT04155476|Drug|Nitroglycerin Topical Product|application of NG topical to dorsals pedis and posterior tibial arteries.
5096|NCT04155463|Other|Organic Diet|Participants will receive 7 days-worth of organic food. Organic food is certified through the USDA's National Organic Program as produced without the use of synthetic pesticides, including glyphosate.
5097|NCT04155463|Other|Conventional Diet|Participants will receive 7 days-worth of conventionally grown (non-organic) food.
5098|NCT04155450|Other|Extension Biased External Limb Loading Exercises|"Begin in the quadruped position and progress the intensity by~Flexing one upper extremity~Extending one lower extremity with a leg slide~Extending one lower extremity by lifting it off the mat~Flexing one upper extremity while extending contralateral lower extremity and then alternate to opposite extremities.~Progress to prone position:~Extending one lower extremity~Extending both lower extremity"
5099|NCT04155450|Other|McKenzie Extension Exercise Protocol|"Static:~Lying Prone~Lying prone in extension~Sustained extension~Posture correction~Dynamic:~Extension in lying~Extension in lying with clinician overpressure~Extension mobilization~Extension in standing"
5100|NCT04155450|Other|Moist Heat|Moist Heating for 10 minutes at lumbar spine in prone position using moist heat packs, heated via hydro-collator.
5101|NCT04155437|Behavioral|Health Facility Level Interventions|"Intensified counseling on maternal dietary diversity and quality using job aids~Counseling on purpose of IFA supplementation, managing side effects, and importance of adherence to daily consumption~Distribution/prescription of IFA tablets at each ANC visit~Use of pill card/reminders for pregnant women and their spouses~Monthly IFA tablet stock monitoring to assure sufficient supplies~Measurement of weight gain during each ANC visit and advise on healthy weight gain~Checks for functioning scales and use of monitoring sheets~Intensified counseling on early initiation of breastfeeding and exclusive breastfeeding using job aids~Reminder on importance of early ANC attendance and 4+ visits"
5102|NCT04155437|Behavioral|Community Level Interventions|"Advocacy among community leaders (traditional and religious leaders, local associations, etc.) about ANC~Gatherings among grandmothers, husbands, and other influencers about ANC and their roles~Promotion of ANC service utilisation and the importance of early ANC visit during the first trimester.~Early identification of pregnant women~Support women's group discussions~2-3 home visits per pregnant woman by community health workers (Agent de santé a base communautaire; ASBC) which will include counseling on diet quality, breastfeeding, importance on adherence to daily IFA consumption and side effect management, etc."
5103|NCT04155437|Behavioral|Health System Level Interventions|"Training on nutrition interventions during ANC for all ANC providers and community health workers~Semi-annual supervision by the Regional Health Directorate (Direction Regionale de la Santé; DRS)~Quarterly supportive supervision of health facility staff by the health district management team~Monthly supportive supervision of ASBCs~Monthly review between health facilities and ASBCs~Training and use of data registers~Training and use of mother's cards to record up to 8 ANC visits and nutrition services~Training on data utilization to improve coverage and quality"
5104|NCT04155424|Drug|Eculizumab|Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
5105|NCT04155411|Drug|Dasatinib|70 mg of Dasatinib orally daily for 12 months
5106|NCT04155398|Procedure|EUS elastography|A forward view radial echoendoscope or a forward oblique view linear echoendoscope would be used to perform focused luminal examination of varices and EUS elastography for measurement of liver stiffness and spleen stiffness.
5107|NCT04155385|Other|Measurement|The measurement system collects information about patients' treatment progress and goals in key areas that are associated with long-term clinical outcomes (e.g., substance use, craving, coping skills, self-efficacy, life satisfaction, depression). Patients complete the measure up to once per week for up to six months.
5108|NCT04155385|Other|Feedback|The feedback system is a web-based dashboard that displays current and historical results in each of the outcome and goal domains that is measured; it is available to addiction treatment clinicians who are working with patients enrolled in the study.
5109|NCT04155372|Procedure|Different Fluid Ingestion Rate|The participants ingested sports drink in a volume equivalent to 150% of BW loss, in 30 min, 60 min, or 90min.
5110|NCT04155346|Behavioral|Exercise, nutritional optimization, and psychoeducation|Multimodal prehabilitation including exercise, nutrition, and stress-management delivered via a facility-based or home-based model
5111|NCT04155333|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that stimulates the brain through the application of a low-intensity electrical current, typically ranging from 1 to 2 milliamps (mA), via electrodes placed on an individual's scalp. During the active stimulation sessions, 2 mA of stimulation will be applied for 30 minutes. During the sham stimulation session, 2 mA of stimulation will be applied over the course of 90 sec, the electrodes will remain in place for the 30 minute duration.
5140|NCT04155125|Drug|efepoetin alfa|The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.
5441|NCT04152655|Drug|Placebo oral tablet|placebo tablets three times a day
5112|NCT04155320|Behavioral|IMPART|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell), 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together), or 3) have their partner(s) notified confidentially by a disease notifier (anonymous provider referral), who will locate partners, notify them of potential HIV exposure, and offer them HIV testing. Partners with an initial reactive HIV screening test will be referred to care and treatment services.
5113|NCT04155320|Behavioral|Standard Care|Subjects receive counseling about partner notification and are assisted in identifying all their partners and choosing a notification method for each partner. Subjects are responsible for contacting and notifying their partner(s) on their own. Subjects have the option to: 1) disclose their HIV status to their partner(s) by themselves (self-tell) or 2) disclose their HIV status to their partner(s) with a healthcare provider present (tell together). Subjects may decide which partners to notify and may choose the same or a different method for each partner.
5114|NCT04155307|Device|Anal EndoFLIP®|Anal EndoFLIP® measure to evaluate anal compliance
5115|NCT04155307|Diagnostic Test|Anal Manometry|Anal Manometry done in standard care
5116|NCT04155307|Diagnostic Test|Defecography|Defecographydone in standard care
5117|NCT04155307|Diagnostic Test|Electromyogram|Electromyogram done in standard care
5118|NCT04155281|Other|urine analysis|New Psychoactive Substances research in urine at admission in unit care
5119|NCT04155268|Behavioral|Flotation-REST + Virtual Reality|Floating in a specialized tank to attenuate sensory input. Participants will wear a waterproof virtual reality headset and watch a video from an orbiting satellite of earth from space.
5120|NCT04155268|Behavioral|Flotation-REST Only|Floating in a specialized tank to attenuate sensory input.
5121|NCT04155268|Behavioral|Virtual Reality Only|Participants will wear a virtual reality headset while laying on an air mattress and watch a video from an orbiting satellite of earth from space.
5122|NCT04155268|Behavioral|Control|Participants will lay on an air mattress in a dark room with no cell phone.
5123|NCT04155255|Other|MyBFF@school|
5124|NCT04155242|Diagnostic Test|Cytosponge test|The Cytosponge will be administered by the study nurse prior to the participant having the endoscopy, usually as part of the same visit to hospital. The capsule along with the string is swallowed by drinking a small glass of water. The participant is asked to hold the Cytosponge in situ for 5 minutes. The sponge contained within expands and is then drawn back by the research nurse up the oesophagus by the attached string, collecting cells as it moves upwards. This device received a letter of no objection by the MHRA for use in the BEST pilot trial (LRQ 0939857) but it is not CE marked. Cytosponge and research endoscopic biopsies will be couriered to the Fitzgerald laboratory, at the MRC Cancer Cell Unit on a regular basis. The specimens will be processed in conjunction with the Cambridge University Hospitals' NHS Foundation Trust tissue bank which is accredited to GLP standards.
5125|NCT04155242|Diagnostic Test|Assessment of the panel of molecular biomarkers: IM-SCORE, TFF3 protein expression, methylation panel, p53 mutation|Molecular analysis of the specimen obtained by Cytosponge or endoscopic biopsies - TFF3 protein expression, methylation panel, p53 mutation. Endoscopic biopsies will be assessed for the presence of IM (according to the IM-score).
5126|NCT04155242|Diagnostic Test|Oesophagogastroduodenoscopy|"Endoscopy will be carried out with white light and NBI with optical magnification or near focus to inspect oesophagus and GOJ.~NBI magnification will be used to assess systematically the mucosal pit pattern at the GOJ and to look for light blue crest (LBC) sign.~Targeted biopsies will be taken from either areas with LBC or irregular pit pattern on NBI, followed by random biopsies as per clinical standard. A maximum of 6 biopsies will be taken at the GOJ (maximum 4 targeted and 4 random.. During the first 2 post RFA follow up, at discretion of the endoscopists, neo-suqamous biopsies can be taken in line with local policies.~Argon plasma coagulation ablation is allowed in a single island up to 5mm or up to 3 islands <3mm within the study endoscopy as long as this does not represent an obstacle to GOJ biopsies."
5127|NCT04155229|Other|Default settings for opioid prescriptions (acetaminophen/hydrocodone, oxycodone, acetaminophen/oxycodone)|"For each of the arms, the investigators modified the default setting for the dispense quantity of study opioids on the electronic medical record settings for discharge prescriptions.~Study drugs include acetaminophen 325mg + hydrocodone 5mg, acetaminophen 325mg + hydrocodone 7.5mg, acetaminophen 325mg + hydrocodone 10mg, oxycodone 5mg, acetaminophen 325mg + oxycodone 5mg, acetaminophen 325mg + oxycodone 10mg."
5128|NCT04155216|Behavioral|Relaxation and guided imagery program|Listening to a relaxation and guided imagery program for 25 minutes during hemodialysis treatments.
5129|NCT04155203|Drug|Mupirocin Calcium|mupirocin cream
5130|NCT04155203|Drug|Mupirocin Calcium|Reference mupirocin cream
5131|NCT04155203|Drug|Vehicle|vehicle control cream
5132|NCT04155190|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
5133|NCT04155190|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
5134|NCT04155177|Procedure|FAUCS|"The participant will be first invited to consult a theoretical support and a video treating on FAUCS.~After that, he will be asked to be the first assistant, in a FAUCS with one of two surgeons assigned for the study.~In a second step, the trainee will have to to perform all the steps of the FAUCS, assisted by one of two seniors. During the surgery, Operative time will be measured, and after it, an evaluation on four stages as in the Zwisch model of supervision will be done.~Once, the two seniors agree on the highest level assessment for the resident, he will be allowed to operate alone according to FAUCS and will be evaluated by the measurement of operating times, the neonatal outcomes and the occurrence or not of complications."
5135|NCT04155164|Drug|Metformin|Participants will receive Metformin at 1000mg for 12 months.
5136|NCT04155164|Drug|Placebos|Placebo group will take Placebo at 1000mg for 12 months.
5137|NCT04155151|Other|6 minute walk test|A test of fitness that requests the participant to walk as far as they can at their own pace in 6 minutes, the distance walked in those 6 minutes is recorded.
5138|NCT04155138|Device|Naida Hearing Aid|hearing aid
5139|NCT04155138|Device|Naida Contralateral Routing of Sound Device|This is a device that routes sound to the non-cochlear implanted ear.
5172|NCT04154865|Device|Cycle ergometer|A cycle ergometer will be used to acutely increase cerebral blood flow.
8188|NCT04130009|Procedure|Tourniquet use|Use of Tourniquet in The TKA
5141|NCT04155125|Drug|Mircera|The starting dosage of Mircera arm will be 0.6 μg/kg per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.
5142|NCT04155112|Other|energy deficit|energy deficit by increased physical activity or energy deficit by diet
5143|NCT04155099|Biological|RBX7455|RBX7455 is a preparation of live intestinal microorganisms (active drug) purified from stool donations obtained from healthy, screened donors, mixed with preservative, lyophilized, and put into capsules. The capsules are taken orally (i.e., by mouth). After ingestion, these freeze-dried microorganisms can reconstitute and proliferate in the gut.
5144|NCT04155099|Biological|Placebo|Capsule with cellulose filler
5145|NCT04155086|Biological|the detection of the risk of fetal trisomy 21 by blood tests : free fetal DNA circulant analysis|The detection of the risk of fetal trisomy 21 by blood tests by 2 tests : free fetal DNA circulant analysis and first trimester serum screening
5146|NCT04155073|Behavioral|smoking cessation, early COPD detection, electronic visit|electronic visits (e-visits) for smoking cessation and early detection of chronic obstructive pulmonary disease (COPD)
5147|NCT04155073|Other|Treatment As Usual|Information about the state quitline and about the importance of quitting smoking and a recommendation to contact one's PCP to schedule a medical visit to discuss quitting smoking
5148|NCT04155047|Combination Product|Glyocopyrrolate Inhalation Solution administered by Magnair|glycopyrrolate Inhalation Solution 25mcg, single dose
5149|NCT04155047|Drug|Placebo administered by Magnair|Placebo Inhalation Solution
5150|NCT04155034|Procedure|Magnetic Resonance Imaging|Undergo MRI
5151|NCT04155034|Radiation|Prophylactic Cranial Irradiation|Undergo PCI
5152|NCT04155008|Drug|Dexamethasone|If the patient's prognosis is extremely poor (less than 12 weeks expected survival, based on discussion with the patient's treating physicians) and there is no additional disease modifying therapy planned, the patient will be prescribed 4mg dexamethasone (which is FDA approved), once daily, to be taken orally in the morning.
5153|NCT04155008|Drug|Dronabinol|If the patient has a history of marijuana use or has tried it in the past and had a positive experience with it, then the patient will be prescribed dronabinol (which is FDA approved) 2.5mg, twice daily before meals.
5154|NCT04155008|Drug|Mirtazapine|If the patient does not have any history of marijuana use, mirtazapine will be prescribed. If the patient is under the age of 70, then the patient would be prescribed 15mg of mirtazapine (which is FDA approved), once daily, to be taken orally at bedtime. For geriatric population (if the patient is over the age of 70), then the patient would be prescribed 7.5mg of mirtazapine, once daily to be taken orally at bedtime.
5155|NCT04155008|Behavioral|Nutrition Intervention|"Nutrition intervention will be in accordance with the Academy of Nutrition and Dietetics guidelines. The intervention will involve purposefully planned action(s) designed with the intent of changing a nutrition-related behavior, risk factor, environmental condition, or aspect of health status"
5156|NCT04154995|Diagnostic Test|Venipuncture|Blood testing at 3, 6 and 12 months
5157|NCT04154995|Diagnostic Test|Ultrasound Quadriceps Muscles|Ultrasound measurement of quadriceps muscle mass and health
5158|NCT04154982|Drug|Acetyl cysteine|1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.
5159|NCT04154969|Other|Physiotherapy including Vestibular rehabilitation|vestibular exercise (VOR TX1)
5160|NCT04154969|Other|conventional Physiotherapy|conventional Physiotherapy
5161|NCT04154956|Drug|SAR408701|Pharmaceutical form:Concentrate for solution for intravenous infusion Route of administration: intravenous (IV) infusion
5162|NCT04154956|Drug|docetaxel|Pharmaceutical form:Concentrate for solution for intravenous infusion Route of administration: IV infusion
5163|NCT04154943|Drug|Cemiplimab|Intravenous (IV) infusion every 3 weeks (Q3W)
5164|NCT04154930|Device|Restylane-L®|Intradermal injection
5165|NCT04154917|Other|HOME|HOME's focus is on the person's functional ability, safety and transition from hospital to home. HOME will be delivered by a community-based clinician (OT who will be involved in the hospital discharge planning) trained by the PI. Training will include two sessions covering assessment of functional ability, goal setting and home safety. The clinician will keep a record of recommendations provided, length of home visit and any adverse events during the intervention. Twice over the course of the study, the PI leader will observe the clinician conducting HOME interventions to assess adherence to the study protocol using a fidelity checklist. The HOME intervention comprises 4 phases, which are described in the arms section.
5166|NCT04154904|Other|Exercise|Subjects will be randomized to complete either aerobic, high intensity interval training, or resistance exercise videos twice weekly at home.
5167|NCT04154891|Genetic|Trio Whole Genome Sequencing|WGS trio analysis will be performed using the genome data of the index case in addition to the genome data of his parents. This analysis will follow a consensus protocol that contains 3 obligatory steps: first of all, de novo variants (SNV, CNV and others SV) will be examined in the whole genome data set; then, a SNV/CNV/other SV analysis will be performed under a AR or X linked Mendelian mode hypothesis in the whole genomic regions of a OMIM extended list (that contains all genes already involved in human genetic diseases). Finally, analysis will focus on inherited pathogenic variants under an AD mode hypothesis (analysis of variations already reported as pathogenic in clinVar or HGMD pro; CNV or truncating variation in OMIM genes, etc). When these 3 steps analysis is completed then variants of interest identified at each step will be recorded until examination by a specific multidisciplinary meeting.
5168|NCT04154891|Genetic|Simplex Whole Genome Sequencing|This analysis will be performed using only the index case following a similar strategy than the one used for the WGS trio
5169|NCT04154891|Genetic|Current French Reference strategy|Actual ANPGM recommendations defined by the following analysis: Fra-X + chromosomal microarray analysis + 44GPS
5170|NCT04154865|Other|Hypercapnia|Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
5171|NCT04154865|Device|Transcranial Doppler|A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
5180|NCT04154813|Drug|Fluoxetine|Fluoxetine was increased from 20mg/d to the target dose (60mg/d) or below the maximum tolerable dose within 2 weeks.
5181|NCT04154813|Behavioral|cognitive behavioral therapy (CBT)|CBT psychotherapy, once a week for three months.
5182|NCT04154813|Behavioral|dialectical behavior therapy (DBT)|DBT psychotherapy,once a week for three months.
5183|NCT04154800|Drug|BMS-986209|Oral administration
5184|NCT04154800|Drug|Placebo|Oral administration
5185|NCT04154787|Drug|LNP023|Investigation of low and high LNP023 dose regimens
5186|NCT04154787|Drug|Rituximab|Comparison of rituximab dose
5187|NCT04154774|Drug|Apalutamide|Apalutamide will be administered orally.
5188|NCT04154761|Procedure|Resection of inferior vena cava and reconstruction|Resection of inferior vena cava and reconstruction with primary repair, resection with autologous or prosthetic patch repair, and circumferential resection with graft replacement
5189|NCT04154748|Device|Argon Plasma Coagulation 90W power|
5190|NCT04154748|Device|Argon Plasma Coagulation 60W power|
5191|NCT04154748|Drug|Omeprazole 120 mg|
5192|NCT04154748|Drug|Omeprazole 40 mg|
5193|NCT04154735|Drug|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
5194|NCT04154735|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
5195|NCT04154735|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
5196|NCT04154735|Drug|Alemtuzumab|A protein that kills the immune cells that are thought to be causing Crohn's; it is commonly used in the treatment of leukemia and lymphoma
5197|NCT04154735|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
5198|NCT04154735|Drug|Rifaximin|An antibiotic used to treat irritable bowel syndrome and relapsing C. difficile infection; it inhibits DNA-dependent RNA polymerase
5199|NCT04154735|Drug|Tacrolimus|A medication which suppresses the immune system and inhibits T-lymphocytes; commonly used to lower the risk of organ rejection following transplant
5200|NCT04154722|Drug|Meropenem Injection|inj meropenum for 10 days
5201|NCT04154722|Drug|Azithromycin Powder|syp azithromycin for10days
5202|NCT04154709|Biological|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
5203|NCT04154696|Procedure|Liver transplantation of a graft after assessment by normothermic perfusion|Liver transplantation of a graft after assessment by normothermic perfusion
5204|NCT04154683|Device|Cellvizio®|use of the Cellvizio® optical biopsy
5205|NCT04154670|Biological|MGTA-145|MGTA-145 will be given intravenously
5206|NCT04154657|Procedure|conductance catheter measurement|biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
5207|NCT04154644|Device|CryoPop|The new CryoPop device will be tested on women with abnormal cytology. Benchmark testing occurred in the previous study and CryoPop was found to be non-inferior to standard cryotherapy device (MedGyn) in woman with normal cytology.
5208|NCT04154631|Behavioral|Standard Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C is a psychosocial treatment designed to improve sleep and circadian functioning. It is a modular, psychosocial, skills-based approach. In this study, two version of TranS-C will be tested: Standard and Adapted.
5209|NCT04154631|Behavioral|Adapted Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|The Adapted version was derived from Standard TranS-C. It was developed to improve the fit of the treatment with the CMHC context.
5210|NCT04154631|Other|Usual Care Delayed Treatment|Usual care in the partner CMHCs typically starts with a case manager who co-ordinates care and refers each client for a medication review and to various rehabilitation programs (e.g., health care, housing, nutrition, finding a job, peer monitoring).
5211|NCT04154618|Device|Continuous wireless vital sign monitoring|Infants will receive wireless vital sign monitoring throughout their birth hospitalization.
5212|NCT04154605|Device|ClariFix cryotherapy|Bilateral freeze ablation of nasal tissue using the ClariFix device.
5213|NCT04154605|Device|Sham ClariFix cryotherapy|Bilateral sham ablation procedure using the ClariFix device.
5214|NCT04154592|Other|Humeral Head Depressor Muscle Co-Activation Training- Experimental Group|In addition to the conservative treatment, humeral head depressor muscle co-activation training will be applied for 8 weeks. Participants in the coactivation group will perform the glenohumeral exercises while recruiting the pectoralis major, latissimus dorsi, and teres major muscles. To achieve this, voluntary recruitment of the pectoralis major, latissimus dorsi, and teres major will be taught prior to the demonstration of the glenohumeral exercises using visual feedback provided by EMG Biofeedback. When recruitment is correctly executed (50% of the maximum voluntary contraction signal), it should be maintained while performing the glenohumeral exercises. This will be confirmed by visualizing EMG signals during the exercise training session. During each appointment with the therapist, participants will be evaluated on their capacity to achieve the exercises while performing co-activation.
5215|NCT04154592|Other|Control Group|"The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair will be used as guideline for rehabilitation of patients (Thigpen, C. A., Shaffer, M. A., Gaunt, B. W., Leggin, B. G., Williams, G. R., & Wilcox III, R. B. (2016). The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair. Journal of shoulder and elbow surgery, 25(4), 521-535.).~Individuals in the control group will use shoulder straps for 6 weeks after arthroscopic shoulder surgery. These patients will be referred to physiotherapy clinics 6th week. Patients between 6 and 14 weeks (a total of 8 weeks) will be admitted to the rehabilitation program according to the guideline mentioned above."
5241|NCT04154397|Device|cerebellar transcranial stimulation|Feedforward-based training benefits from a dynamic postural task by application of cerebellum transcranial electrical stimulation (ctDCS) of different modes (direct current vs. noise vs. sham) were administered using a one-channel direct current stimulator (NeuroConn DC-Stimulator PlusTM) with study mode enabled for single blinding. Following the baseline trial of posture tracking, participants of three groups were seated in a chair for 20 min to receive either active or sham cerebellar tDCS prior to the posture tracking and transfer test phases.
5216|NCT04154579|Behavioral|HeRe We Arts|Art Therapy interventions to promote health, resilience & well-being will discussed; & experiences such as key chain making, collaging on journal covers, creating sculpture garden will be utilized. Music therapy interventions such as lyric discussion, singing, instrument playing, & music-assisted relaxation techniques will be utilized; & discussion of use of music to elicit positive physical & emotional responses will be held. Drums Alive (drumming & movement) will be used to promote physical activity. Art appreciation will include discussion of public art forms. Journaling will include different techniques for journaling, writing poetry, etc. Theater games such as Password, Press Conference, Props Only, & Draw What You Hear will be utilized. Chair yoga will be introduced as a form of exercise. Education will be provided on the various topics.
5217|NCT04154579|Behavioral|HeRe We Ed|Educational components and some experiential components will be utilized to educate the participants on health, resilience, well-being, nutrition, healthy eating, weight management, eating disorders, obesity, exercise, physical activity, sleep hygiene and the importance of sleep, mental health, stress management, the importance of improving life satisfaction, holistic approaches, wellness, integrative medicine, complementary and alternative medicine, chronic illness, chronic pain, methods for dealing with chronic versus acute illnesses, changing behaviors and/or maintaining healthy behaviors in order to promote health and stay out of the hospital, and navigating the healthcare system. Specific experiential components will include Chair Yoga and Stress Management Techniques.
5218|NCT04154566|Other|Aerobic Exercises|Aerobic exercise refers to exercise that involves or improves oxygen consumption by the body. It is the type of activity that uses large muscle groups. Its performance is in a continuous and rhythmic way with a main goal to make the heart and lungs work harder than they do when the person at rest
5219|NCT04154553|Diagnostic Test|Buccal swab|Pharmacogenetic panel testing is conducted by Stratipharm with the DNA of the buccal swab. TaqMan® polymerase chain reaction is proceeded to express the genetic information. Stratipharm is a product offered by Humatrix Aktiengesellschaft (AG). It consists of a laboratory analysis of approximately 100 pharmacological relevant genetic variations (polymorphisms) in over 30 different genes, which code for transport proteins, metabolizing enzymes, or drug targets.
5220|NCT04154553|Diagnostic Test|EDTA Blood sample (4.9mL)|Genetic testing of potentially relevant genetic variants using the DNA extracted from the EDTA blood sample.
5221|NCT04154553|Diagnostic Test|Serum sample (7.5mL)|blood sample to determine the actual levels of the compound in patients on medication assumed to be associated to an observed ADR (phenotype).
5222|NCT04154553|Other|communication of test results|Certified study pharmacist evaluates and communicates clinically relevant test results to the subject and to the responsible physician
5223|NCT04154553|Other|unstructured interview|One and six months after the communication of test results, the study center will make a phone call to the patient for an unstructured interview in order to gather information about potential outcomes
5224|NCT04154540|Other|Motion analysis|Gait and posture recording
5225|NCT04154527|Other|Pelvic Floor and Abdominal Exercises|two repetitions of each exercise, during exhalation phase
5226|NCT04154514|Device|A functional electrical stimulation device for post-stroke rehabilitation|Most of the FDA-approved commercial FES devices deliver therapy that targets specific kinematic impairment in the step cycle (e.g., foot drop). Our device will be unique in that it can stimulate many muscles around multiple joints for a more comprehensive and naturalistic restoration of lower-limb motor functions.
5227|NCT04154501|Drug|CNTX-6016|Oral Dose CNTX-6016
5228|NCT04154501|Other|Other: Placebo|Oral Dose Placebo
5229|NCT04154488|Drug|Mavorixafor|Mavorixafor capsules will be administered per dose and schedule specified in the arm.
5230|NCT04154475|Dietary Supplement|yogurt diet|500 g yogurt/day
5231|NCT04154475|Dietary Supplement|dairy diet|500 g non-yogurt dairy products
5232|NCT04154475|Dietary Supplement|standard diet|500 g soya-yogurt
5233|NCT04154462|Other|Scribes|Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
5234|NCT04154449|Drug|Intranasal insulin|Surgical group Received intranasal insulin, the second group surgical Received placebo and the third group is non surgical do not receive anything.
5235|NCT04154436|Other|Sodium Bicarbonate (NaHCO3) Plus Solution|Alkaline Solution
5236|NCT04154436|Other|Water (H2o)|Alkaline Solution
5237|NCT04154423|Other|Glow! Group Prenatal Care|Glow! is an enhanced group prenatal care model that offers co-located social services provided by established community programs with independent funding streams targeting low-income families. The Glow! group prenatal care model pairs a trained facilitator with a licensed prenatal care practitioner from a practice site to provide billable prenatal care to the practice's own patients. Over the course of 8-10 sessions, 10-12 women (within a 6- week gestational age range) receive prenatal medical care, risk assessments, and social support, and gain knowledge and skills related to pregnancy, birth, and parenting.
5238|NCT04154423|Other|Individual Prenatal Care with CPSP|Comprehensive Perinatal Services Program (CPSP) is a state-funded program for Medi-Cal eligible families to receive enhanced care and service coordination. Participants assigned to CPSP individual care may participate in the CPSP assessments with a Comprehensive Perinatal Health Worker at their prenatal care site, where individual prenatal care will be provided
5239|NCT04154410|Other|Analgesia Nociception Index|Non invasive finger tip monitoring before during and 5 minutes after cannulation
5240|NCT04154410|Other|algiscan|Portable videopupillometer to measure pupillary light reflex (PLR), variation coefficient of pupillary diameter (VCPD), pupillary diameter (PD) fluctuations before, during and 5 minutes after cannulation
5242|NCT04154384|Behavioral|Patient Pain Plan (PPP)|The Life Pain Specialist (LPS) will work with the patient to develop a Patient Pain Plan (PPP) focused on behavioral education, and will act as a liaison with physicians to optimize the pharmacologic component of pain management. The PPP includes education about substance misuse and provides non-pharmacological pain management options.
5690|NCT04150679|Procedure|hepaticojejunostomy without access loop|ROUX en Y hepaticojejunostomy without access loop
5243|NCT04154371|Device|Electromyography-controlled virtual and augmented reality using serious gaming|Surface electrodes and a tracking marker are placed on the subject's affected upper extremity. Electrodes are placed on active muscle sites along the affected extremity determined by palpation. Electrodes are connected to an electromyography recording device, and signal acquisition and processing software are used to record EMG signals and display feedback. Myoelectric signals are used to control a virtual limb on the screen. The intervention consists of different steps: virtual reality, augmented reality, and serious gaming, which the participant must control with their muscle activity, record by EMG, in their affected limb.
5244|NCT04154358|Diagnostic Test|HPV testing|will perform HPV testing with self-collected specimen
5245|NCT04154345|Other|Exercise therapy (exercising into pain)|The intervention consists of 12 weeks of progressive loaded exercises, three times per week. There are 9 sessions of supervised physiotherapy treatment, lasting 30 minutes, while the rest of the sessions is conducted as home exercises. There are 4 strengthening exercises, in which the pain allowed ranges between 4 and 7 on a verbal NPRS
5246|NCT04154332|Other|Sample collection|Blood, urine, and placental samples will be collected from each person enrolled in this study.
5247|NCT04154319|Behavioral|HPV Vaccination|Mothers assigned to this arm participated in educational/behavior change sessions to promote HPV vaccination among their unvaccinated 9-12 year old daughters
5248|NCT04154319|Behavioral|Healthy Eating|Mothers and daughters assigned to this arm received education on healthy eating and how to appropriately interpret nutrition labels
5249|NCT04154306|Dietary Supplement|Red clover|2 weeks of Red clover
5250|NCT04154306|Dietary Supplement|Placebo|2 weeks of Placebo
5251|NCT04154293|Drug|Isotretinoin|Topical Isotretinoin ointment
5252|NCT04154293|Other|Vehicle|Topical Vehicle Ointment
5253|NCT04154280|Diagnostic Test|PET/MR scan|"The PET will be performed with 68Ga-PSMA tracer.~The 3 tesla magnet of the MRI will be used with sequence allowing MRS acquisition, additional sequences will include T2-weighted contrast and diffusion weighted contrast.~Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV) or Ki (in case dynamic PET protocol will be applied). In addition, content relationship between metabolic entities detected will be extracted.~Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity."
5254|NCT04154267|Procedure|Percutaneous renal biopsy.|The biopsy will be performed with a 16 Gauge semi-automatic needle gun for renal biopsy under real-time ultrasound control. After the procedure will be done ultrasound control
5255|NCT04154254|Diagnostic Test|PET/MR|The PET will be performed with one of the following tracers: 18F-FDG, 18F-DOPA or 18F-flutemetamol (Vizamyl). Proper tracer will be determined by the physician according to the condition. Patients that will agree, will be asked to perform two scans each with different tracer. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, perfusion and diffusion images. Images will be analyzed visually and quantitatively. Quantitative analysis will include MR parameters such as DWI apparent diffusion coefficient (ADC) and PET quantitative metabolic data such as standard uptake values (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). Hidden image parameters will also be extracted for texture analysis purposes. Quantitative data will be correlated to clinical and pathological data to check accuracy, specificity and sensitivity.
5256|NCT04154241|Diagnostic Test|PET/MR scan|"The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity [11] [12]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results."
5257|NCT04154228|Diagnostic Test|PET/MR scan|"Patients will undergo 18F-FDG PET/CT scans before therapy initiation, interim after 2/3 treatment cycles and end of treatment after therapy completion, as part of their routine evaluation, as well as additional follow-up scans, as clinically indicated and requested by referring physicians. Given signed written informed-consent forms, patients will undergo at each time point, immediately after completion of PET/CT, a PET/MR scan, following the same single injection of 18F-FDG. Standard preparation and acquisition protocols for FDG PET imaging will be employed.~PET/MR imaging will include conventional sequences as T1, T2, diffusion weighted imaging, and advanced vascular imaging (DCE-MRI)."
5258|NCT04154215|Diagnostic Test|PET-CT FDG brain scan|"Scans will be performed in Discovery MI PET/CT scanner (by GE). Dynamic FDG PET scan start immediately after a bolus injection of 18F-FDG (0.1 mCi/kg) 5. Dynamic PET scan protocol of 30 min will be follow by a static scan protocol with a duration of 8 min combined with a low dose CT scan.~The radiation exposure of the patients is equal to the radiation exposure during the routine PET-CT FDG brain scan. The only discomfort to the patient is a longer scan duration.~After the scan is concluded the patient will be released with no restrictions. Each of the acquired PET images will undergo visual assessment. In addition, quantification of the image data using Standardized Uptake Values (SUV) and kinetic model. The correlation between the clinical information, visual assessment and quantitative parameters will be tested. Sensitivity and accuracy of the quantification methods will be calculated."
5259|NCT04154202|Other|Bone Scan|Bone Scan: three-phase planar Bone Scan and a SPECT/CT [perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan].
5260|NCT04154189|Drug|Lenvatinib|"Lenvatinib 14 milligrams per square meter (mg/m^2) capsules will be administered once daily on Days 1 to 21 of each 21-day cycle until disease progression (PD), development of unacceptable toxicity, participant request, withdrawal of consent, or discontinuation of study by the sponsor.~An extemporaneous suspension of lenvatinib capsules may be used for participants unable to swallow capsules."
5261|NCT04154189|Drug|Ifosfamide|Ifosfamide 3000 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
5262|NCT04154189|Drug|Etoposide|Etoposide 100 mg/m^2/day intravenous infusion will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
5263|NCT04154176|Other|CAM, Nu-DESC|Two trained raters, who are blinded and have no access to each other's evaluation, administer the CAM and Nu-DESC questionnaires in each shift, during the first postoperative day after the discharge from the post-anaesthesia care unit, independently. The two assessments are completed within 60 minutes of each other. If the research team set the diagnosis of POD, the appropriate treatment will be initiated, according to the Hospital's protocol
5264|NCT04154163|Diagnostic Test|Dried blood Spot (DBS)|Dried Blood Spot filter paper and sponges
5265|NCT04154163|Diagnostic Test|Venous blood sampling|Venous blood
5266|NCT04154150|Drug|Intravenous ketamine|Single subanesthetic infusion of ketamine (0.5mg/kg)
5267|NCT04154150|Behavioral|Cognitive training|8 sessions of computer-based cognitive training
5268|NCT04154150|Behavioral|Sham Training|8 sessions of computer-based sham training
5269|NCT04154137|Other|Questionnaire|Enrolled patients will fill out a modified version of a previously validated written questionnaire, including two different sections. The first comprises basic demographic information, including age, sex and ethnicity, and a screening section for symptoms consistent with irritable bowel syndrome (IBS) in accordance with the Rome III criteria, also including their past gastrointestinal, allergic and psychiatric history. The second section enquires for self-reported gluten-related symptoms. Participants will be also asked for their use of a gluten-free diet and if they had seen a healthcare professional for their symptoms. A reported diagnosis of celiac disease and wheat allergy in the population group is defined by those who had a doctor diagnosis of celiac disease and wheat allergy and are also taking a gluten-free diet.
5270|NCT04154124|Diagnostic Test|PET/MR scan|whole-body PET/CT scan and pelvic PET/MR scan (MR protocol will include three plane fast spin echo T2 weighted, DWI and dynamic contrast enhanced imaging). The ad interim assessment will use a pelvic PET/MR scan only (without PET/CT), to avoid the radiation associated with whole body CT. In the staging and post-nT assessment, the addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
5271|NCT04154111|Device|Real cTBS to the vmPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
5272|NCT04154111|Device|Sham cTBS to the vmPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
5273|NCT04154111|Device|Real iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
5274|NCT04154111|Device|Sham iTBS to the dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
5275|NCT04154098|Device|Scapula orthosis assistance|Participants are elevating their arm while their scapula is assisted by the scapula orthosis
5276|NCT04154098|Procedure|Manual scapula assistance|Participants are elevating their arm while their scapula is assisted by a trained personnel
5277|NCT04154098|Other|No assistance|Participants are elevating their arm without being assisted
5278|NCT04154098|Other|Functional Test|Participants perform a functional test once without (NO) and once with (OA) the orthosis
5279|NCT04154085|Other|Psychotherapy|Group psychotherapy
5280|NCT04154072|Drug|NLY01|exenatide and polyethylene glycol (PEG)
5281|NCT04154072|Drug|Vehicle|Saline (Sodium Chloride)
5282|NCT04154059|Other|Intervention Group|Patients will receive a physical therapy intervention for strengthening, stretching and functional training of ankle and foot.
5283|NCT04154046|Procedure|Tenotomy(cutting) of flexor tendons is performed with needle|"Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge."
5284|NCT04154033|Drug|Naltrexone|Topical naltrexone cream (1%)
5285|NCT04154033|Other|Placebo Cream|Topical placebo cream
5286|NCT04154020|Procedure|Flexor tenotomy|Tenotomy(cutting) of flexor tendons is performed with needle
5287|NCT04154007|Diagnostic Test|kidney function tests - urine output|"AKI was classified based on the worst of either creatinine or urine output criterion as follows:~Stage I 1.5-1.9 times baseline OR ≥0.3 mg/dl increase in the serum creatinine, OR urine output <0.5 ml/kg per hour for 6 to 12 hours.~Stage II 2.0-2.9 times baseline increase in the serum creatinine OR urine output <0.5 ml/kg per hour for ≥12 hours.~Stage III 3.0 times baseline increase in the serum creatinine OR increase in serum creatinine to ≥4.0 mg OR urine output of <0.3 ml/kg per hour for ≥24 hours, OR anuria for ≥12 hours OR the initiation of renal replacement therapy."
5288|NCT04153994|Procedure|Erector Spinae Plane Blockade|The ESPB is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
5289|NCT04153981|Drug|Insulin Glargine|Administered SC
5290|NCT04153968|Dietary Supplement|β-cryptoxanthin|"Phase 1:~2.0mg of [13C14]β-cryptoxanthin, 1.0mg of [13C10]β-carotene and 0.4mg [2H6]retinyl acetate are given in sunflower oil at Time 0.~Phase 2:~1.5mg of [13C14]β-cryptoxanthin, 0.75mg of [13C10]β-carotene, 0.4mg [2H6]retinyl acetate are given in sunflower oil along with 0.25mg β-carotene and 0.5mg β-cryptoxanthin from maize are given at Time 0.~Then, 0.75mg of [13C14]β-cryptoxanthin, 1.5mg of [13C10]β-carotene, and 0.4mg [2H6]retinyl acetate are given in sunflower oil along with 0.5mg β-carotene and 0.25mg β-cryptoxanthin from maize are given on day 21."
5291|NCT04153955|Behavioral|Mobilization|Any movement out of bed
5292|NCT04153942|Behavioral|Mobilization|Any movement out of bed
5293|NCT04153929|Drug|BI 456906|Injection
5294|NCT04153929|Drug|Placebo|Injection
5296|NCT04153916|Device|Neurotrigger eye blinking stimulator|"Phase 1 - The first stage is composed of a one-time participation for about three hours and involves:~Verifying compliance of the patients with the research inclusion and exclusion criteria~Completion of the study clinical report form (CRF) for this stage~Placement of the single use mini-electrodes that will be adhered to the facial skin near the non-blinking eye and coupled to the Neurotrigger stimulator to elicit eyelid closure.~In the second stage the duration of the participation is about three weeks (six days a week) and includes daily use of the device for up to 10 hours a day. During nights the patient will continue is standard pattern of either eye closure or leaving the eye open, as the patient used to do prior to the study.~This stage will involve a patient with a partner that is designated to support the patient closely during the placement and adjustment of the system."
5297|NCT04153903|Other|OCT, coronary angiography, FFR|Coronary images by OCT and angiography and FFR values will be registered.
5298|NCT04153890|Behavioral|FamPALcare|"Intervention participants will receive standard care plus five weekly coaching sessions with telephone follow-up to reinforce HF palliative home care. FamPALcare intervention will be delivered by community-based nurses. FamPALcare intervention involves coaching patients and family caregivers in advanced HF home care and supporting EOLPC discussions.~The standard care group will receive routine HF care and instruction at university hospital or at clinic appointments. All patients can be referred for supportive care and heart failure care per national HF guidelines."
5299|NCT04153877|Other|Kinesiotape|Kinesio-tape® is an elastic, hypoallergenic, cotton-fiber tape with acrylic heat-activated backing and is widely used within sports.
5300|NCT04153864|Behavioral|Brief Behavioral Activation Treatment|A manualized 6-8 session BA treatment delivered individually to each participant.
5301|NCT04153851|Procedure|neurectomy of nasopalatine nerve|Severing of nerurovascular bundle and pushing the nasopalatine canal content nasally and insertion of bone graft in the canal. Dental implant will be inserted in the central incisor location
5302|NCT04153838|Other|Cognitive test administration|Specifically chosen cognitive tests will be administered to all participants twice; with an approximate 12 month gap between initial testing and follow-up testing.
5303|NCT04153825|Device|Transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended. The device is set at pulse duration of 50 to 80 μs; pulse frequency of 50 to 100 Hz; low-intensity (paraesthesia, not painful). The patient wears TENS for a 20-minute duration for each knee.
5304|NCT04153825|Device|Interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. The device is set at carrier frequency 4000 Hz, amplitude modulated frequency (AMF) 100 Hz, scanning frequency 50 Hz, scanning mode 1: 1 s. The patient wears ICF for a 20-minute duration for each knee.
5305|NCT04153825|Other|Hydrocollator hot-pack|The hot-pack (at a surface temperature of almost 42 °C) is administered on knees while patients are in sitting position with the knees extended. Every session includes 20 minutes of hot-pack for each knee.
5306|NCT04153825|Device|Sham transcutaneous Electrical Nerve Stimulation|Electrodes are placed around painful regions determined by the patient as patients are in the sitting position with the knees extended.TENS unit in place but not turned on.The patient wears TENS for a 20-minute duration for each knee.
5307|NCT04153825|Device|Sham interferential Current|Electrodes are placed diagonally around the painful areas defined by the patient, with the patient in the sitting position with the knees extended. IFC unit in place but not turned on.The patient wears ICF for a 20-minute duration for each knee.
5308|NCT04153812|Device|vagus nerve stimulation|Vagus nerve stimulation (VNS) is a new technique for stimulating the left cervical vagus nerve through implanted lead and a programmable pulse generator.
5309|NCT04153799|Biological|CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells|The first dose group: 0.5 × 10^6/kg CAR positive T cells; The second dose group: 1.58 × 10^6 / kg CAR positive T cells; The third dose group: 5 × 10^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.
5310|NCT04153786|Other|Temporary changes in an already-implanted medical device (biventricular pacemaker)|"During the patient's routine clinic visit, investigators will adjust the patient's pacemaker to four different settings and monitor for any changes in the function of the LVAD.~The pacemaker will be set to each new setting for 2-5 minutes. After this, the pacemaker will be returned to its original / pre-existing setting, and the patient will leave the clinic with no overall changes to the settings of either the pacemaker or LVAD.~However, if investigators find that one of the four pacemaker settings results in a clear improvement in the LVAD function, the patient will be given the option of resetting their pacemaker to that new setting before leaving the clinic. In either case, the LVAD settings will not be altered at all. The adjustments will be made by the regular device staff who routinely see the patients and maintain their devices during their regular follow-up clinic visits."
5311|NCT04153773|Diagnostic Test|OCT|"The degree of physical disability was assessed by using the Expanded Disability Status Scale (EDSS). The EDSS score ranges from 0 to 10 in 0.5 unit increments that represent higher levels of disability.~Neurocognitive functions were evaluated using the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) that includes the following tests:~Symbol Digit Modalities Test (SDMT) that is used for assessment of information processing speed.~California Verbal Learning Test - 2nd edition (CVLT-II) .~Brief Visuospatial Memory Test-Revised (BVMT-R)~OCT assessment was performed by spectral domain-optical coherence tomography to assess the retinal nerve fiber layer thickness and macular volume in humans .~Each eye for every patient was assessed by measuring the thickness of RNFL and GCC, respecting presence or absence of the previous history of optic neuritis (ON)."
5312|NCT04153760|Drug|Aspirin 81 mg|Aspirin 81 mg p.o. daily
5313|NCT04153760|Drug|Placebo|Placebo p.o. daily
5314|NCT04153747|Other|High-power and short-duration radiofrequency ablatio (70 W / 9-10 s)|Pulmonary veins electrical isolation: high-power and short-duration ablation
5315|NCT04153747|Other|Low-power (25-40 W) radiofrequency ablation guided by lesion size index (LSI) and ablation index (AI) values|Pulmonary veins electrical isolation: low-power ablation.
5316|NCT04153747|Other|Esophageal endoscopy|Esophageal endoscopy to detect postablation esophageal thermal lesions.
5317|NCT04153747|Diagnostic Test|Daily 30-seconds ECG|Transtelephonic daily 30-seconds single lead electrocardiogram
5318|NCT04153734|Drug|Pembrolizumab|Pembrolizumab at 200 mg (day 1) will be administered to patients with non-squamous cell carcinoma at 3-week intervals. To those with squamous cell carcinoma, Pembrolizumab at 200 mg (day 1) will be administered at 3-week intervals until disease progression or intolerable toxicity. Pembrolizumab administration should be continued for 2 years involving induction and maintenance therapies or until the 35th course.
5319|NCT04153734|Drug|Cis Platinum|In patients with non-squamous histology, cisplatin (75 mg/m2) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
5320|NCT04153734|Drug|Carboplatin|In cisplatin-intolerable patients, carboplatin (AUC=6) will be administered every 3 weeks until 4 cycles with pemetrexed and pembrolizumab.
5321|NCT04153734|Drug|Pemetrexed|In patients with non-squamous histology, pemetrexed (500 mg/m2) will be administered every 3 weeks until progression or 2 years after initiation (35 cycles) with pembrolizumab.
5322|NCT04153734|Drug|nab paclitaxel|In patients with squamous histology, nab-paclitaxel (100 mg/m2, day 1, 8, 15, tri-weekly) will be administered until 4 cycles with pembrolizumab.
5323|NCT04153721|Behavioral|Name Digital Solution|"The digital solution offers a pre-operative program of information (pathology, treatment modalities, protocols to be followed) and training (stress management, psychological support, optional: nutritional preparation, physical exercise, reduction of alcohol and tobacco consumption).~In the post-operative phase, patients must daily assess their state of health (temperature, weight, wound, nausea / vomiting, urine / stool) and well-being (physical, moral, sleep, pain), from day 1 to day 7 after discharge, to facilitate the detection of complications by the medical team"
5324|NCT04153708|Behavioral|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by phone call.|Patients assigned to strategy 1 will be called to schedule an appointment with the hepatologist over a period of 14 days.
5325|NCT04153708|Behavioral|Retrieval patients lost to follow-up with positive HCV antibodies without RNA request or positive RNA by mail letter|Patients assigned to strategy 2 will receive an invitation letter with an appointment with the hepatologist over a period of 14 days.
5326|NCT04153695|Other|Music Therapy|to listen flamenco music during 30 minuts per day during 2 weeks
5327|NCT04153682|Diagnostic Test|Rapid Diagnostic Testing|Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples
5328|NCT04153682|Diagnostic Test|Antimicrobial stewardship|After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).
5329|NCT04153669|Behavioral|Exercise-NMES|Exercise-NMES
5330|NCT04153669|Behavioral|Exercise-No NMES|Exercise-No NMES
5331|NCT04153656|Other|Reading and studying Spiritual Flow|The Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey. Two months after the first survey, the Wellbeing Inventory will be administered to subjects and they will be compensated upon completion of the survey.
5332|NCT04153643|Procedure|Arthroscopic Partial Meniscectomy|Surgical treatment for meniscus tear
5333|NCT04153630|Biological|mesenchymal stem cells derived from bone marrow (BM-MSCs)|Procedure: Haploidentical MSCs derived from bone marrow administered by intravenous injection with a dose of 2-3x106 cells / Kg
5334|NCT04153617|Dietary Supplement|Control honey|Control honey defined as orange blossom honey. Intake daily for 3 months (40 g/day)
5335|NCT04153617|Dietary Supplement|Modified honey with soluble fiber and polyphenols|Honey modified with soluble fiber and polyphenols, with same organoleptic conditions as control honey. Intake daily for 3 months (40 g/day)
5336|NCT04153604|Drug|doxycycline|a tetracycline antibiotic that fights bacteria in the body.
5340|NCT04153552|Dietary Supplement|HLNatural, Inc. Upset Stomach Relief|Supplement to take with mild to moderate indigestion. The degree of your indigestion pre and post will be recorded
5341|NCT04153539|Behavioral|Walking along a busy road|The intervention group will walk along a busy road and be exposed to traffic-related air pollution for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
5342|NCT04153539|Behavioral|Walking in a traffic-free park|The control group will walk in a traffic-free park for 4.5 hours (from 13:00 to 17:30), while alternating 15-minute walking and 30-minute rest periods.
5343|NCT04153526|Procedure|Blood sampling|Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
5344|NCT04153526|Procedure|Surplus Tumour Tissue sample collection from surgery|In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
5345|NCT04153526|Other|Collection or archival tumour tissue (If available)|Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
5346|NCT04153513|Drug|Lanolin|Lanolin will be applied by hand in a thin layer to the nipple and areola after every breast feed (approximately every 2 to 3 hours) for a maximum of 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
5347|NCT04153513|Other|Mother's milk|After each breast feed (approximately every 2 to 3 hours), a few drops of breast milk will be applyed to the nipple and areola by hand and allow them to air dry. The treatment will last for up to 7 days or until the symptoms of pain and signs of nipple damage have ceased (if noted before 7 days).
5348|NCT04153500|Other|Anatomy class with Pelvic+ methodology|Teaching of female pelvis anatomy using a interactive training model (Pelvic+ methodology)
5349|NCT04153487|Drug|Ascorbic Acid Injectable Product|Intermittent Intravenous Infusion of Ascorbic Acid (Vitamin C) 2.5 gm / 6 hours for 96 hours
5350|NCT04153487|Drug|Placebo|Placebo saline / 6 hours for 96 hours
5351|NCT04153474|Procedure|large-bore nephrostomy tube (LBNT)|large-bore 22 french nephrostomy tube (LBNT)
5352|NCT04153474|Procedure|small-bore nephrostomy tube (SBNT)|small-bore 14 french nephrostomy tube (SBNT)
5353|NCT04153461|Procedure|MINI-PERCUTANEOUS NEPHROLITHOTOMY|MINIPERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 15 FR, LASER DUSTING OF THE STONE, NEPHROSTOMY TUBE 12 FIXATION
5354|NCT04153461|Procedure|STANDARD PERCUTANEOUS NEPHROLITHOTOMY|PERCUTANEOUS NEPHROLITHOTOMY USING NEPHROSCOPY 24 FR, ULTRASOUND OR LITHOCLAST DISINTEGRATION OF THE STONE AND FORCEPS EXTRACTION OF THE FRAGMENTS, NEPHROSTOMY TUBE 22 FIXATION
5355|NCT04153448|Other|Measurement of functional capacity|Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
5356|NCT04153435|Drug|Calcium Chloride|Calcium chloride 5 mmol
5357|NCT04153435|Drug|Sodium chloride 0.9%|Placebo
5358|NCT04153422|Drug|Gammagard IVIG|Immune Globulin Infusion 10% (Human)
5359|NCT04153422|Drug|Placebo|0.9% NaCl prepared as the calculated dose equivalent volume to IVIG.
5360|NCT04153409|Drug|LAT8881|Two 30 mg capsules of LAT8881
5361|NCT04153409|Drug|Placebo|Two capsules of placebo
5362|NCT04153396|Drug|The Treatment group|The local infiltration solution in the treatment group will consist of betamethasone and ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 0.5ml of compound betamethasone injection added to 14.5ml of saline and 15ml of 1% ropivacaine. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A 22-gauge needle will be introduced throughout the entire thickness of the planned incision site by the surgeon, at an angle of 45°, to infiltrate the prepared solution. The volume of the solution to be used will be based upon the length of the incision. It will be determined by the surgeon and recorded by the investigator.
5363|NCT04153396|Drug|The Control group|The local infiltration solution in the control group will consist of ropivacaine. For local infiltration, a total of 30 ml solution will be prepared for each group, which will include 15ml of ropivacaine added to 15 ml of saline for the Control group. The surgeon will perform wound infiltration after induction of anesthesia and before surgery. A 22-gauge needle will be introduced throughout the entire thickness of the planned incision site by the surgeon, at an angle of 45°, to infiltrate the prepared solution. The volume of the solution to be used will be based upon the length of the incision. It will be determined by the surgeon and recorded by the investigator.
5364|NCT04153383|Drug|before milrinone|Before administering IV milrinone
5365|NCT04153383|Drug|after milrinone|giving IV milrinone: 50 mcg/kg loading dose by IV push over 10 minutes, then 0.375-0.75 mcg/kg/min IV
5366|NCT04153370|Device|Airtraq|airtraq video laryngoscope was used for intubation of the infant
5367|NCT04153370|Device|glidescope|glidescope video laryngoscope was used for intubation of the infant
5368|NCT04153370|Device|c-mac|c-mac video laryngoscope was used for intubation of the infant
5369|NCT04153357|Device|airtraq|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
5370|NCT04153357|Device|glidescope|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
5371|NCT04153357|Device|c-mac|device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
5372|NCT04153344|Other|Electro-oculogram|Electrophysiological recording of changes in electrical potential across the retinal pigmentary epithelium during successive periods of dark and light adaptation, according to ISCEV standards. Results will comprise dark trough value and light/dark (Arden) ratio.
5373|NCT04153344|Other|Full-field electroretinogram|Electrophysiological recording of retinal function. Results will comprise amplitudes and latencies of each electroretinography response (dark-adapted 0.01, dark-adapted 3.0, dark-adapted 10.0, dark-adapted 3.0 oscillatory potentials, light-adapted 3.0, light-adapted 3.0 flicker).
5374|NCT04153331|Other|Nasal swab|Patient included in emergency with a nasal swab
5375|NCT04153318|Device|full-field optical coherence tomography|Pancreatic tissue sample obtained by EUS-FNB will be used for FFOCT imaging. The Images will be sent to trained pathologists for diagnosis. The same tissue sample will be sent to the pathology department for routine histological examination. Compare the diagnoses made by the 2 different methods.
5376|NCT04153279|Biological|CMV-TCR-T cells|Patients with CMV emias or CMV disease will be enrolled, and donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.1-1×106 CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
5377|NCT04153266|Other|No intervention was/is planned for this study|No intervention was/is planned for this study. The study is questionnaire-based (observational).
5378|NCT04153253|Drug|Aflibercept Injection [Eylea]|"Three monthly based intravitreal injections were given followed by PRP if the hemorrhage was sufficiently cleared.Intravitreal injection was done in sterile operating room, after sterilization and toweling with application of sterile speculum, Betadine 5% drops was instilled into the conjunctiva and kept for two minutes followed by wash with balanced salt solution. Injection of 2mg /0.05m aflibercept was given 4 mm from the limbus in phakic eyes and 3.5 mm in pseudophakic with compression by sterile cotton tip on the site of injection, Paracentesis was done in cases of very high IOP following injection. At the end of procedure check of visual acuity was done (to be at least light perception).~PRP was done if the hemorrhage is sufficiently cleared after the third injection."
5379|NCT04153253|Procedure|Vitrectomy|Was done under local peribulbar anesthesia. After sterilization and toweling, wash with diluted betadine 5% was done. Insertion of three 23 valved cannulas beginning with the lower temporal one for infusion, clearance of anterior vitreous was done followed by core vitrectomy, peripheral vitrectomy , removal of posterior hyaloid aided by triamcinolone staining , trimming and removal of any vascular epicenters followed by vitreous base shaving with 360 scleral indentation, endolaser treatment was done for all eyes followed by fluid air exchange, 20% SF6 was used only if there is active significant bleeding during surgery or if there is intraoperative retinal tears, removal of cannulas was done at the end of surgery. All eyes received combination of topical steroid and antibiotic eye drops as postoperative treatment.
5380|NCT04153240|Device|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA)|The Night Shift™ Sleep Positioner (Advanced Brain Monitoring, USA) has been developed for adult patients with positional OSA, and snorers. Worn on the back of the neck, it begins to vibrate when the patient starts to sleep in the supine position and increases in intensity until the patient changes.
5381|NCT04153227|Diagnostic Test|Bone mineral density (BMD)|Bone mineral density (BMD) measured by Dual-energy X-ray absorptiometry (DXA).
5382|NCT04153214|Behavioral|cycling|Participants will have a portable pedal machine under their desk and will use it 60minutes per day
5383|NCT04153201|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg daily for patients weighing < 60 kg, hydroxychloroquine 400 mg daily for patients weighing >= 60 kg
5384|NCT04153188|Device|The Vbeam® Prima System|3 monthly Vbeam® Prima PDL treatments with a 3-day washout of topical Oxymetazoline HCL 1% cream before each treatment.
5385|NCT04153188|Drug|Oxymetazoline HCL 1% Cream|Daily application of Oxymetazoline HCL 1% cream for the 6-month study.
5386|NCT04153175|Combination Product|ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of CT-010.
5387|NCT04153175|Combination Product|Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)|Subjects will be implanted with a drug delivery pump and catheters leading to the ICV space allowing delivery of a placebo (saline).
5388|NCT04153162|Device|Stereotactic body radiation therapy|Stereotactic body radiation therapy delivered to reduce LVOTO in patients with HCM
5391|NCT04153136|Drug|Sacubitril-Valsartan 49-51Mg Oral Tablet|By mouth twice daily
5392|NCT04153136|Drug|Placebo oral tablet|Placebo oral tablet By mouth twice daily
5393|NCT04153123|Drug|Epinephrine|
5394|NCT04153110|Device|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
5395|NCT04153110|Device|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
5396|NCT04153084|Drug|Polyethylene Glycol 4000 with electrolytes|The high volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
5397|NCT04153084|Drug|PEG-3350 with electrolytes|The low volume electrolytes PEG will be administered at a 4 mg/kg dose the day before the procedure in 4-8 hours.
5398|NCT04153084|Drug|Sodium picosulfate|"The Sodium picosulfate will be administered the day before the procedure at different doses depending on the patient´s age:~From 1 to 2 years old: ¼ sachet reconstituted in ¼ glass of water/juice in the afternoon (15:00 h) and ¼ sachet reconstituted in ¼ glass of water/juice 6 hours later (21:00 h)~From 2 to 4 years old: ½ sachet in ½ glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~From 4 to 9 years old: 1 sachet in 1 glass of water/juice in the afternoon and ½ sachet in ½ glass of water/juice at night.~Of 9 years old and older: 1 sachet in the afternoon and 1 sachet at night."
5399|NCT04153071|Device|OPUS system|Each subject will have a single cutaneous treatment of their lower abdomen, with variable treatment parameters. Punch biopsies will be obtained from each treatment section, for in-vivo histological evaluations.
5400|NCT04153058|Procedure|Robotic Assisted AEG Radical Gastrectomy|Robotic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
5401|NCT04153058|Procedure|Laparoscopic Assisted AEG Radical Gastrectomy|Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III Esophagogastric Junction Adenocarcinoma
5402|NCT04153045|Device|Radiograph interpretation for pulmonary abnormalities|"The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis."
5403|NCT04153032|Drug|Diltiazem|DTZ is a calcium channel blocker for the treatment of chronic anal fissure
5404|NCT04153032|Drug|Mebo|Moist exposed burn ointment (MEBO) is a tropical Chinese medicine composed of sesame oil and herbal plants that is clinically used for the treatment of burn wound.
5405|NCT04153019|Other|Psychoeducational and rehabilitative intervention|Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
5406|NCT04153006|Device|POC troponin analysis.|Point-of-care (POC) high sensitive troponin I (HS cTnI) analysis in whole blood, plasma and capillary whole blood with the Minicare® device.
5407|NCT04152993|Device|NeuroPace® RNS® System|All the subjects in this study will receive the experimental treatment. The treatment consists in a surgery to implant the Responsive Neurostimulation (RNS) device in the amygdala bilaterally. Subsequent programming of the RNS aims to reduce fear-related signals.
5408|NCT04152980|Drug|Pentoxifylline|The intervention consists of intravenously administered pentoxifylline. Pentoxifylline , a methylxanthine, is an off patent drug for neonates and currently registered for peripheral artery disease treatment in adults. Pentoxifylline acts as a cyclic adenosine monophosphate(cAMP)-phosphodiesterase inhibitor that suppresses tumor necrosis factor alfa (TNF-α) and modulates important parts of the inflammatory response and also reduces the production of other inflammatory cytokines, such as IL-1α, IL-6, and IL-8.
5442|NCT04152629|Drug|Methylphenidate Hydrochloride|CR Methylphenidate Hydrochloride given once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg or 100 mg)
5691|NCT04150666|Dietary Supplement|Hydration|the same with arm descriptions
5409|NCT04152967|Device|new-designed PTFE valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
5410|NCT04152967|Device|Bovine jugular vein valved conduits|In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
5411|NCT04152954|Device|Radiofrequency ablation of cervical medial branches|Radiofrequency ablation of cervical medial branches
5412|NCT04152941|Drug|Olaparib|Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
5413|NCT04152928|Diagnostic Test|PET/MR scan|The patient will be positioned in the PET/MR with the field of view of the PET including the abdomen, and IV administration of 68Ga-DOTATATE will take place, with initiation of dynamic PET simultaneous with start of IV injection. Dynamic PET imaging will consist of 22 time frames of increasing durations (6 x 10, 3 x 20, 3 x 60, 5 x 180, and 5 x 300 s). The dynamic PET examination will be followed by a whole-body PET/MR scan ranging from the proximal femur to the base of the skull (3 min per bed position) starting at 60 min after injection. MR will be used for attenuation correction of the PET images of the abdomen/pelvis and whole-body. MR protocol will include three plane fast spin echo T2 weighted, DWI, DCE and ASL. The addition of PET/MR to the standard use of PET/CT adds no radiation exposure.
5415|NCT04152902|Other|Objective outcome|The final outcome of surgical therapy was assessed according to a semi-quantitative scale graded as excellent, good, fair and poor, according to quantitative grades for dysphagia, reflux symptoms and oesophagitis
5416|NCT04152902|Other|Quality of life|SF-36 Questionnaire
5417|NCT04152889|Drug|PD-L1 inhibitor+chemotherapy|PD-L1 inhibitor 200 mg, intravenous infusion on the first day, once every 3 weeks (q3w); oxaliplatin 130 mg / m ^ 2, intravenous infusion on the first day; S-1surface area (M2) < 1.25, 40mg every time, ≥ 1.25 ~ < 1.5, 50mg every time, ≥ 1.5, 60mg every time, oral administration on the first to the 14th day every 3 weeks. Take 3 weeks as a course of treatment, a total of 6 courses, or the patient has tumor recurrence or metastasis (need to be determined by imaging as tumor recurrence or metastasis)
5418|NCT04152863|Biological|V937 IV|Administered as an IV infusion of 1 X 10^9 TCID50
5419|NCT04152863|Biological|V937 IT|Administered as an IT injection of 3 X 10^8 TCID50
5420|NCT04152863|Drug|Pembrolizumab|Administered as an IV infusion of 200 mg
5421|NCT04152850|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and Traditional Chinese Medicine
5422|NCT04152837|Drug|Lixivaptan|Oral vasopressin V2 antagonist
5423|NCT04152824|Behavioral|Resilience-Supportive Leadership Training (RESULT)|Leaders will receive a training addressing supportive supervisor behaviors and resilience
5424|NCT04152811|Behavioral|Cooking Matters for Diabetes|Each Cooking Matters course is made up of 6, 2-hour, weekly classes with 15 participants. The curricula is based on the Dietary Guidelines for Americans, MyPlate, the American Diabetes Association Standards of Medical Care in Diabetes 2017 and Medical Nutrition Therapy Evidence Based Guide for Practice/Nutrition Protocol as the foundation for basic nutrition guidelines, then builds upon these ideas using the collective groups' needs and interest to provide interactive lessons to teach cooking, food safety and food resource management with emphasis placed on blood sugar management.
5425|NCT04152811|Other|Usual Diabetes Care|Usual Diabetes Care
5426|NCT04152798|Procedure|Laparoscopic hiatal hernia repair with ProGrip™ mesh|Suturing of the right and left diaphragmatic crura using 3 to 4 interrupted nonabsorbable stitches with additional reinforcement of crura repair with ProGrip™ mesh
5427|NCT04152798|Procedure|Laparoscopic primary posterior crural repair|Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable sutures
5428|NCT04152785|Behavioral|Information regarding GHG and/or nutrition|Participants will have to select a meal from a menu.
5429|NCT04152772|Device|transcranial direct current stimulation|Active tDCS will consist of 15 minutes of 2 mA intensity once, either applied during or after extinction learning.
5430|NCT04152759|Drug|Drug: BAT2506 injection Other Names: Simponi(EU-licensed)|"Drug: BAT2506 injection Each subject will receive single subcutaneous injection of 50 mg BAT2506 Injection or Simponi(EU-licensed).~Other Names:~Simponi(EU-licensed)"
5431|NCT04152746|Other|Periostin level|The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.
5432|NCT04152733|Device|High flow nasal cannula|Oxygen is supplied via high flow nasal cannula. Heated air (2L/kg/min) is administered using Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand).
5433|NCT04152720|Device|Foley catheter|"If the subject is enrolled in this clinical trial, the test and control devices will be applied at baseline. All subjects will receive a urinary catheter at the site of the artificial bladder and the urethra after surgery, and temporary urinary replacement should be selected by the investigator at each institution in preparation for the possibility of postoperative blockage of the urinary catheter.~After surgery, urine analysis and culture are performed on the 4th and 7th day, and urine analysis and culture are performed before the urethral catheter removal on the 14th (2 weeks) and the urethral catheter is removed. At this time, the urethral catheter tip is cut about 5-8 cm and cultured."
5434|NCT04152707|Device|Splendor X|The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).
5435|NCT04152694|Other|Ceftaroline levels in CRRT|Levels of ceftaroline measured in patients receiving CRRT
5436|NCT04152681|Drug|Apatinib|Apatinib with a dosage of 250mg once daily for 4 weeks, in the absence of unacceptable toxicity or severe deterioration.
5437|NCT04152668|Procedure|Titanium curette.|Implant debridement.
5438|NCT04152668|Procedure|Ultrasonic|Implant debridement.
5439|NCT04152668|Procedure|Air-polishing|Implant debridement and polishing.
5440|NCT04152655|Drug|Idebenone|30mg tablets three times a day
5443|NCT04152629|Drug|Lisdexamfetamine Dimesylate|Lisdexamfetamine Dimesylate given once daily (10 mg, 20 mg, 30 mg, 40 mg, 50 mg or 60 mg)
5444|NCT04152616|Other|Instrumental evaluation of posture|"After a time of installation of the Optitrack® device's and two accelerometers (one placed on the subject's trunk facing the sternum fixed with a headband and the second at the level of the head also held with a headband), the subject will perform an evaluation of the balance sitting on the sensor pad; the movements of the head and trunk will be analyzed by the Optitrack® device and by the two accelerometers.~The subject will perform 4 30-second tests, two with eyes open and two with eyes closed. A rest period may be taken between each assessment depending on the subject.~During these evaluations, a physiotherapist will be present to avoid the risk of falling.~After a rest period of 30 minutes, a new assessment of the sitting posture will be carried out to assess the reproducibility of the tools (sensor pad, accelerometers, Optitrack®)."
5445|NCT04152603|Behavioral|Intervention to demonstrate respect|This intervention will be designed based on outcomes from interviews and focus groups that will identify specific actions with the potential to demonstrate respect in the recruitment and consent process. Potential interventions include but are not limited to: research staff training, messaging related to inclusivity, messaging related to voluntariness, additional ethical oversight or other autonomy protections, and guidelines for researchers about study design.
5446|NCT04152590|Device|Uincare|Interactive digital healthcare system
5447|NCT04152577|Drug|R2-combination chemotherapy|"R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
5448|NCT04152577|Drug|R-combination chemotherapy|"R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1"
5449|NCT04152564|Procedure|levo-bupivacaine infusion via Thoracic epidural catheter|The epidural catheter will be placed via a paramedian approach as close as possible to the surgical procedure via the inter-vertebral space (from T7 to T10) so that the affected dermatomes of the surgical wound would receive the benefits of bupivacaine infusion
5450|NCT04152564|Procedure|levo-bupivacaine infusion via preperitoneal catheter|At the end of surgery and after the closure of the peritoneal layer, the catheter will be allocated above the peritoneum within the musculofascial layer and secured to the skin with an occlusive dressing
5451|NCT04152551|Drug|Risedronate Oral Tablet|Oral bisphosphonate
5452|NCT04152538|Other|not intervention but investigation|possible differences in quadriceps muscular activity
5453|NCT04152525|Other|Psychoeducation|The mindfulness-based education programme that was conducted by the researcher and aimed at increasing self-efficacy in substance addicts was conducted within eight sessions, 2 days a week for 4 weeks.
5454|NCT04152512|Behavioral|Questionnaire administration|Questionnaire administration (4 different forms: pre-treatment, 3-4 months after treatment, 1 year after treatment, 2-5 years (yearly) after treatment
5455|NCT04152499|Drug|SKB264|SKB264 is an Antibody Drug Conjugate (ADC) targeting TROP2 expressing cancer cells.
5456|NCT04152486|Biological|Ad26.ZEBOV, MVA-BN-Filo vaccine|"Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV."
5457|NCT04152473|Drug|Proglumide|oral CCK receptor antagonist
5458|NCT04152460|Device|Viscalor Bulk (VOCO,Cuxhaven)|Viscalor Despenser (Preheating dispenser for composite Viscalor Bulk Caps)
5459|NCT04152460|Other|Grandioso x-tra|Nanohybrid Bulk Resin Composite
5460|NCT04152447|Device|VR device|Patients use a VR device
5461|NCT04152434|Drug|Erenumab Auto-Injector|Assess synergy of add on medication to Erenumab
5462|NCT04152421|Other|Software use|"The patient will connect to a computerized platform to access the program. The program consists of 5 modules (lessons), each lasting approximately 40 minutes. Each module or lesson includes pedagogical assessments and explanations of the problem(s) in question, illustrations, testimonies, tips, exercises and recommended activities."
5463|NCT04152408|Device|FiberSense System|FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
5464|NCT04152395|Other|EVAR|Patients undergoing EVAR
5469|NCT04152369|Procedure|Anti-microbial prophylaxis for an endourological procedure or ESWL|anti-microbial prophylaxis according to urine culture results
5470|NCT04152356|Drug|PD-1|PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti-autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
5498|NCT04152148|Biological|1000mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
5742|NCT04150276|Procedure|ZEEP during awakening|ZEEP will be established 2 min prior to the start of emergence preoxygenation and awakening.
5471|NCT04152356|Drug|Sorafenib|Sorafenib tosylate is a novel multi-target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
5472|NCT04152343|Device|RFA Physics Library -- a Planning and Guidance Platform (PGP)|Research software used to support liver RFA of HCC lesions >2cm
5473|NCT04152330|Other|Early stimulation protocol on neuropsychomotor development of children with congenital heart disease|A parent guidance booklet will be prepared. It will contain a specific program of stimulation activities for each stage of development in simple language and with illustrations. Subdivided into 4 areas: Cognition, Language, Broad Motor, and Fine Motor. The duration will be 6 months, with intervention at 30 days and 3 months. Parents will attend 2 individual meetings, where they will receive information and clarifications on the application of the booklet. Parents will be advised about the capabilities and limitations of their babies according to the congenital heart disease the child has, as well as what is expected within the typical development for that age group, and the importance of early stimulation activities in each child. one of 4 development areas. They will be informed about the need for that stimulus for the baby's development, as well as possible doubts about the stimulus.
5474|NCT04152317|Drug|Misoprostol 200mcg Tab|In the misoprostol 200mcg group there will be one tablet of 200mcg and three identical tablets in shape, size and color without pharmacological properties. These four tablets will be single dose administered via vaginal route for each participant.
5475|NCT04152317|Drug|Misoprostol 800mcg Tab|In the misoprostol 800mcg group there will be four tablets of 200mcg. These four tablets will be single dose administered via vaginal route for each participant.
5476|NCT04152304|Other|Sinex program (neuromuscular training program)|The SINEX program is a three months neuromuscular training program aiming to increase neuromuscular stability of the shoulder
5477|NCT04152291|Dietary Supplement|Ethyl-Eicosapentaenoic Acid (E-EPA)|3,9 grams of EPA is added to participants' normal diet.
5478|NCT04152278|Diagnostic Test|cervicovaginal culture and qPCR and serum qPCR|three cervicovaginal swabs were obtained: one was used for a smear test of vaginal fluid pH evaluation and direct microscopy, the second swabs, cultured for aerobic bacteria and yeasts, the third was eluted in 2-sucrose-phosphate (2SP) based transport medium. Placental samples from the study group were cultured for aerobic and anaerobic bacteria. Placenta sample and 2SP medium were stored at -80°C until their analysis by real time PCR (qPCR)
5479|NCT04152265|Procedure|colonoscopy|colonoscopy
5480|NCT04152265|Other|questionnaires|complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)
5481|NCT04152265|Other|demographic data collections|completing the demographic questionnaire
5482|NCT04152265|Other|anthropometric data collections|For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)
5483|NCT04152265|Procedure|Collecte the biological samples|blood and faeces collections
5484|NCT04152252|Other|Real time feedback|Real-time feedback on chest compression depth, chest compression rate and recoil available to EMS while performing CPR. Feedback is delivered as visual text, numeric and graphical presentations on the defibrillator with audio tones for rate.
5485|NCT04152252|Behavioral|Post-event debriefing|Structured oral post-event debriefing based on objective performance data from the resuscitation attempt. The debriefing is conducted as hot/immediate self-directed debriefing session with a maximum length of 10 minutes.
5486|NCT04152239|Procedure|Motorized spiral enteroscopy (MSE)|Endoscopic Procedures MSE is a 1.6m enteroscope equipped with a single-use short spiral overtube propelled by a user-controlled motor contained in the handle of the endoscope. The endoscopist controls the left-right and up-down movements by the usual manuvers while the forward or backward advancement of the enteroscope would be contolled by a foot pedal that activates the spiral overtube rotation. Antegrade MSE, retrograde MSE, or combined antegrade and retrograde MSE would be performed as clinically indicated for diagnostic +/- therapeutic procedures.
5487|NCT04152226|Drug|J. Lividum|Investigational Product
5488|NCT04152213|Behavioral|Low GI diet|This educational session will cover information on obesity, complications of obesity, the benefit of weight loss, the glycemic index and its associated low GI diet, a food-exchange table including high- to low-GI foods, and self-decision in food choices. The dietary advice will be based on the standard food pyramid for the conventional Chinese diet as promoted by the Hong Kong Department of Health, with an emphasis on the selection of low-GI products. Practical tips will be given such as the selection of low-GI rice and rice products, the impact of cooking methods (including cooking time, cooking conditions, and cooking liquid volume) on rice GI, intervention to reduce the GI of rice, and listing low-GI food options and meal plans.
5489|NCT04152200|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
5490|NCT04152187|Other|Inspiratory muscle training|The treatment group will receive inspiratory muscle training.
5491|NCT04152174|Procedure|Combined extracorporeal blood purification|Patients receive combined extracorporeal blood purification: CRRT in CVVHDF mode with AN 69 ST set (Baxter) and hemoadsorption with Cytosorbents Corp. CytoSorb adsorber.
5492|NCT04152174|Procedure|CRRT|Patients receive CRRT in CVVHDF mode with AN 69 ST set (Baxter)
5493|NCT04152161|Biological|BCG vaccine SSI|Participants will receive a single 0.1 milliliter (mL) volume of BCG vaccine SSI, administered intradermally in deltoid region of the upper arm.
5494|NCT04152161|Biological|Placebo|Participants will receive a single 0.1 mL volume of normal saline, administered intradermally in deltoid region of the upper arm.
5495|NCT04152148|Biological|500mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
5496|NCT04152148|Biological|750mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
5497|NCT04152148|Biological|900mg BAT4306F|Phase 1 dose titration study from BAT4306F 500mg to 1000mg, then choose a proper dose for amplification study based on DLT result
5576|NCT04151563|Drug|lucitanib|Specified dose on Specified days
5499|NCT04152135|Procedure|vena cava inferior diameter measurement|Ultrasound equipment with convex probe will be used to measure IVC diameters of the patients in supine position.The IVC sagittal section is described with the probe in the area of subxiphoid. IVC diameters at the junction point of the IVC and right atrium (2cm caudal) are standardized measurement.
5500|NCT04152122|Diagnostic Test|The dynamic stereopsis test|The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
5501|NCT04152109|Procedure|Laying on hands with Spiritual connection|Laying on hands with spiritual connection by mediators intended to heal the patient
5502|NCT04152096|Drug|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
5503|NCT04152096|Drug|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
5504|NCT04152083|Biological|Eptinezumab|Subjects will receive a single dose of 100 mg eptinezumab (IV)
5505|NCT04152083|Biological|Placebo|Participants will receive placebo matched to a single dose of 100mg of eptinezumab given IV
5506|NCT04152070|Other|No intervention|There was no intervention to be administered, only collection of data through various tests and questionnaires.
5507|NCT04152057|Drug|Pyrotinib Maleate Tablets|400mg/d,po qd,q3w, 4 cycles
5508|NCT04152057|Drug|Albumin Paclitaxel|125mg/m2,ivggt,d1,q3w,4 cycles.
5509|NCT04152057|Drug|Trastuzumab|The first week load dose 4mg / kg, followed by 2mg / kg per week, d1,ivggt,q3w,4 cycles.
5510|NCT04152044|Other|Observation of different types of obesity and liver pathology in patients undergoing and oesophagectomy|Patinets undergoing surgery
5511|NCT04152031|Other|Prompting|Participants receive medication reminders on a smartphone. The reminders are generated through machine learning algorithms that automate the process of medication prompting according to successful medication contexts that occurred in the past.
5512|NCT04152018|Drug|PF-06940434|PF-06940434 is given intravenously (IV) every 2 weeks in a 28 day cycle. Multiple dose levels will be evaluated
5513|NCT04152018|Drug|PF-06801591|PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle.
5514|NCT04152005|Other|Observation|Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease
5515|NCT04151966|Diagnostic Test|Blood sample collection|Blood sample collection for markers of myocardial injury
5516|NCT04151953|Diagnostic Test|Blood sample collection|Blood sample collection for markers of myocardial injury
5517|NCT04151940|Procedure|Positron Emission Tomography|Undergo PET/CT scan
5518|NCT04151940|Procedure|Computed Tomography|Undergo PET/CT scan
5519|NCT04151940|Drug|Chemotherapy|Receive standard of care chemotherapy
5520|NCT04151940|Biological|Immunotherapy|Receive standard of care immunotherapy
5521|NCT04151940|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
5522|NCT04151927|Device|Normobaric Hypoxia|Low oxygen exposure to mimic ~8500 feet elevation.
5523|NCT04151927|Device|Normobaric Normoxia|Normal oxygen exposure to mimic ~1000 feet elevation (sham comparator).
5524|NCT04151901|Other|Resistance Exercise Rehabilitation|Following disuse, the REHAB groups (M-REHAB, F-REHAB) will complete monitored resistance exercise rehabilitation sessions using an isokinetic dynamometer at a similar relative load at each rehab visit.
5525|NCT04151901|Other|Walking-based rehabilitation|Following disuse, the CON groups (M-CON, F-CON) will complete 30 minutes of monitored walking at a moderate intensity at each rehab visit.
5526|NCT04151888|Device|Foley catheter|Thin sterile tube will be inserted in choana
5527|NCT04151875|Device|Extraction orthodontic treatment|orthodontic treatment with teeth extraction
5528|NCT04151875|Device|Non-extraction orthodontic treatment|Non-extraction orthodontic treatment
5529|NCT04151862|Device|tight eye bandage|sterile eye pad made of 100% cotton
5530|NCT04151862|Device|Soflex Soft Contact Lens|Therapeutic contact lenses (TCL)
5531|NCT04151849|Drug|GLP-1 receptor agonist|Treatment with GLP-1 agonist for up to 1 year.
5532|NCT04151849|Drug|SGLT2 inhibitor|Treatment with SGLT2 inhibitor for up to 1 year
5533|NCT04151836|Other|walking exercise|in the experimental group,the patients needs to cooperate with the moderate-intensity walking exercise training for 3 times a week.
5534|NCT04151823|Drug|Vitamin D3|2 ml per day SMART D3 MATRIX Smartfarma S.r.l. Via San Vittore 40 - 20123 MILAN: 2 mL of product will give 1600 UI/die of VIT D3.
5535|NCT04151823|Drug|Immunofos|Postbiotics will be given at the dose of 80 mg/day. immunofos from Lactobacillus paracasei CNCM I-5220).
5536|NCT04151823|Other|Promotion of physical activity|Promotion of physical activity will be encouraged at t0, t1, t2
5537|NCT04151823|Other|Healthy food habits promotion|Promotion of healthy food habits will be encouraged at t0, t1, t2
5538|NCT04151810|Drug|CDP1|"Single-dose Phase: Cohort 1:400mg/m2;Cohort 2: 500mg/m2;Cohort 3: 750mg/m2;~Multi-dose Phase:Cohort 1 Dosing regimen is the first administration of 400mg/m2, followed by 250mg/m2/W;Cohort 2,3 Dosing regimen is the first administration of 500mg/m2, followed by 500mg/m2/2W."
5539|NCT04151797|Other|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~Data collection on comorbidities, medication and laboratory results.~A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~A detailed feedback to the geriatrician.~A written report addressed to the attending physician"
5540|NCT04151784|Other|Pulmonary Group|Data collection will be obtained on the day an individual has an appointment at the pulmonary clinic. After patients meet with their pulmonary physicians, the physicians will inform them about the study and explain that participation is voluntary. If a patient agrees, the researcher will provide copies of the questionnaires and again clarify that participation is voluntary. The workflow of the clinic will not be interrupted while the researcher conducts the study, and he will only ask participants to fill out the questionnaires if they have enough time to participate.
5932|NCT04148833|Drug|LDE-Placebo|LDE-Placebo at the dose of 175 mg/m2 IV each 21 days for 6 weeks
5541|NCT04151784|Other|Healthy Control|The second group will be recruited as a control group consisting of healthy adult participants through purposive convenience sampling at other collaborating UAB sites. The principal investigator will collect self-report responses through a questionnaire packet given to anyone willing to participate in the study
5542|NCT04151771|Other|Low-load blood flow restriction training|The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).
5543|NCT04151771|Other|Usual outpatient pulmonary rehabilitation|The control group will perform outpatient pulmonary rehabilitation as established.
5544|NCT04151758|Drug|Docosahexaenoic Acid Supplementation|Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
5545|NCT04151758|Other|Promotion of physical activity|All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
5546|NCT04151758|Other|Promotion of healthy food habits|All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
5547|NCT04151745|Procedure|external pacemaker switched off|When a hemodynamically stable state is achieved, the external pacemaker will be switched off for 30 minutes. Hemodynamic parameters will be acquired directly prior to switching off, 15 respectively 30 minutes after switching off, and 15 minutes after switching back on. To gain insight in the natural course of stunning, this routine will be repeated the next morning.
5548|NCT04151732|Behavioral|Physical activity, alcohol, tobacco|Physical activity, alcohol, tobacco - selfreported in the 1990's
5549|NCT04151732|Other|Hormonal factors|Hormonal factors - selfreported in the 1990's
5550|NCT04151732|Other|Cardiovascular disease|Cardiovascular disease - selfreported in the 1990's
5551|NCT04151732|Other|Anthropometric measures|Height, length, BMI
5552|NCT04151719|Drug|Methylnaltrexone bromide (MNTX)|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
5553|NCT04151706|Drug|CD8+ Memory T Cell Selection|Allogeneic phenotypic CD8+ memory T cells from HLA matched donors infused at the time of hematopoietic cell transplantation
5554|NCT04151706|Drug|Thio Tepa|5 mg/kg/day: IV for 2 consecutive days (days -6 to -5)
5555|NCT04151706|Drug|Fludarabine|25 mg/m2/day: IV for 5 consecutive days (days -6 to -2)
5556|NCT04151706|Radiation|Hyperfractionated TBI|Administered in 11 fractions of 125 cGy over 4 days (Total dose of 1375 cGy)
5557|NCT04151693|Behavioral|CBT-based group therapy for patients with chronic fatigue syndrome (CFS)|Goal is to relief patients anxiety and offer to learn better coping skills in situation where patients functioning in everyday life is difficult.
5558|NCT04151680|Drug|Intermittent administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive intermittent treatment with a novel oral anticoagulant drug
5559|NCT04151680|Drug|Chronic administration of dabigatran, rivaroxaban, apixaban, or edoxaban|Patients will receive chronic treatment with a novel oral anticoagulant drug
5560|NCT04151667|Drug|Daratumumab Injection|Patient will receive daratumumab (1800 mg in 15 ml) administered by manual subcutaneous injections weekly for the first 8 weeks, every other week for the next 16 weeks and every 4 weeks after.
5561|NCT04151667|Drug|Dexamethasone Oral|The dexamethasone starting dose will be 20 mg PO once a week. Commercial dexamethasone will be used. Dexamethasone is often supplied in 4 mg tablets. Accordingly, patients will take 5 (4 mg tablets) one day of the week prior to the administration of daratumumab if this corresponds to a daratumumab dosing days. In non daratumumab dosing days, dexamethasone will be taken by the patient at home, usually in the morning with breakfast.
5562|NCT04151667|Drug|Lenalidomide Pill|"Lenalidomide will be given orally on days 1-21 of a 28 days cycle. The starting dose of lenalidomide will be based on the patient creatinine clearance per the package insert.~Specifically patients with a creatinine clearance ≥ 50 ml/min will receive 25 mg of lenalidomide PO Days 1-21. Patients with a creatinine clearance ≥ 30 but less than 50 ml/min will receive 10 mg of lenalidomide.~Patients with a creatinine clearance < 30 ml/min are not eligible but patients who experience a deterioration in the renal function during screening or treatment may continue on lenalidomide therapy as long as the risk / benefit profile is deemed acceptable, that study therapy is in the best interest of the patient and after discussion with the study principal investigator / sponsor."
5563|NCT04151667|Drug|Bortezomib Injection|Bortezomib will be given weekly subcutaneously in an effort to decrease the toxicity of the therapy. Specifically patients will receive a starting dose of bortezomib of 1.3 mg/m^2 Days 1,8,15 of a 28 day cycle. Bortezomib will be administered in the cancer center per standard of care procedures.
5564|NCT04151654|Other|Footwear Assessment Score|It was assessed using the Sharpened Romberg test and Single Leg Stance test for static balance. It was assessed Berg Balance Scale for dynamic balance, and Timed Up and Go test for functional performance. Balance and performance tests were done with and without footwear in all individuals.
5565|NCT04151641|Dietary Supplement|MNGDPF|Standardized mangosteen extract in dry powder form
5566|NCT04151641|Dietary Supplement|MNGEF|Standardized mangosteen extract in encapsulated form
5567|NCT04151628|Device|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent
5568|NCT04151602|Behavioral|Smoked illicit drug use|The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones
5569|NCT04151589|Behavioral|ANGEL Intervention Package and Toolbox|The interventional measures include emergency work flow management app on smartphone, specialized training, assessment of quality improvement outcomes and feedback on a regular basis, patient-centred management frame based lean six-sigma, and other specialised approach.
5570|NCT04151576|Other|aromatherapy massage|aromatherapy massage
5571|NCT04151563|Biological|nivolumab|Specified dose on Specified days
5572|NCT04151563|Biological|ipilimumab|Specified dose on Specified days
5573|NCT04151563|Drug|cabozantinib|Specified dose on Specified days
5574|NCT04151563|Drug|docetaxel|Specified dose on Specified days
5575|NCT04151563|Biological|ramucirumab|Specified dose on Specified days
5577|NCT04151550|Device|Bilateral Laser Scleral Microporation procedure|"Device: Laser Scleral Microporation~Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern."
5578|NCT04151537|Behavioral|Personal Activity Intelligence|The intervention group is provided with a PAI monitor (wristband) with a user interface (app) to track their own PAI level and are instructed to obtain at least 100 PAI on a weekly basis.
5579|NCT04151537|Behavioral|Physical Activity Guidelines|The control group is recommended to follow national PA guidelines, meaning 150 minutes of moderate-intensity PA or 75 minutes of vigorous-intensity PA, or a combination there of. The control group is provided with a PAI monitor (wristband) without any user interface and are thus blinded to track their own PAI level.
5580|NCT04151511|Procedure|Continuous Erector Spinae Plane Block|"Continuous Thoracic Epidural Thoracic Epidural Analgesia~Continuous Erector Spinae Plane Block"
5581|NCT04151498|Behavioral|Reengagement and Assessment Mobile Program|Participants will participate in mobile clinic visit that will include an educational interview, adherence counseling, and standard blood draws for HIV reengagement. The goal of this intervention is to motivate participants to become reengaged in traditional HIV care by making an in person clinic appointment.
5582|NCT04151498|Other|Qualitative Interview|Qualitative interview about barriers and facilitators to HIV care, and experience at most recent clinic visit.
5583|NCT04151485|Behavioral|Mind/Body Program for Fertility (Domar et al., 2011)|see Arm Description
5584|NCT04151485|Behavioral|Fertility Support Program|see Arm Description
5585|NCT04151472|Drug|Placebo|Placebo oral tablet, three times a day
5586|NCT04151472|Drug|90mg Idebenone|Idebenone 30 MG Oral Tablet, three times a day
5587|NCT04151472|Drug|270mg Idebenone|Idebenone 90 MG Oral Tablet, three times a day
5588|NCT04151459|Drug|Metformin|Use Metformin for 3 months to treat PCOS
5589|NCT04151446|Device|Laser Scleral Microporation|Partial depth scleral microporations with an Er:YAG laser in a predetermined pattern.
5590|NCT04151433|Procedure|Comparison between 2 different laparoscopic techniques in conservative surgical treatment of endometriomas (both arms are existing and accepted surgical strategies).|cf. different arms
5591|NCT04151420|Other|PRO validation|"There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD.~Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies."
5592|NCT04151407|Drug|Drug 601|Drug is a kind of recombinant anti-VEGF humanized monoclonal antibody injection.
5593|NCT04151394|Procedure|Duodenojejunostomy|Resection of duodenal lesions and reconstruction by duodenojejunostomy
5594|NCT04151381|Drug|Aminophylline|"the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol."
5595|NCT04151368|Procedure|Robotic Nipple-Sparing Mastectomy (RNSM)|RNSM will be performed by previously described method using 3 cm extra-mammary axillary incision along the mid-axillary line in the axillary fossa. We will use Da Vinci Si Surgical System® (Intuitive Surgical, Sunnyvale, CA).
5596|NCT04151355|Drug|Atorvastatin 20mg|atorvastatin (20 mg once daily)
5597|NCT04151342|Drug|Cancer treatment with tyrosine kinase inhibitors (TKIs)|Observing cancer patients who have received or are currently receiving tyrosine kinase inhibitors (TKIs) for their cancer treatment.
5598|NCT04151342|Other|Patient-reported outcomes (PROs)|Prospectively enrolled participants will be provided with survey packets comprised of different PRO instruments at the initial/baseline visit, at 3 month follow up intervals and at the time when treatment/therapy is changed.
5599|NCT04151329|Biological|BAT1306 and BAT8001 2.4mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 2.4mg/kg , then choose a proper dose for amplification study based on DLT result
5600|NCT04151329|Biological|BAT1306 and BAT8001 3.6mg/kg|Phase 1 dose titration study of BAT1306 and BAT8001 3.6mg/kg , then choose a proper dose for amplification study based on DLT result
5601|NCT04151316|Procedure|crown preparation|includes tooth preparation
5602|NCT04151316|Procedure|vertical preparation|type of vertical preparation on the tooth that accepts the crown
5603|NCT04151316|Procedure|horizontal preparation|type of horizontal preparation on the tooth that accepts the crown
5604|NCT04151303|Procedure|Cervical cerclage|Cervical cerclage and cervical cerclage removal
5605|NCT04151277|Drug|FOLFOX-A|Patients will recieve nab-paclitaxel, oxaliplatin, Folinic Acid and 5-FU in a 14 day cycle
5606|NCT04151277|Drug|Gemcitabe and Abraxane|Patients will receive gemcitabine and nab-paclitaxel 3 weeks out of 4
5607|NCT04151277|Drug|G-CSF|Patients in the FOLFOX-A arm will also receive daily G-CSF as primary prophylaxis for all cycles. This will be given as per local site policy for 14 day chemotherapy regimens
5608|NCT04151264|Device|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
5609|NCT04151251|Behavioral|Patient Empowerment|Group to receive a 5 minute video about typical hospital sleep disruptions and what they can do to prevent them, as well as a brochure outlining the importance of sleep
5610|NCT04151251|Other|Sleep Kit|Patients receive a small pouch that includes an eye mask, ear plugs, and headphones, all to be used to aid in falling/staying asleep
5689|NCT04150679|Procedure|duodenojejunostomy access loop|ROUX en Y hepaticojejunostomy with duodenojejunal anastomosis as permanent access
5611|NCT04151238|Behavioral|Exercise intervention for cancer patients to increase physical activity during chemotherapy|The duration of the exercise intervention is eight (8) weeks. There will be guided endurance and muscle power training two (2) time weekly. The participants will also be provided with one training program per week for use at home.
5612|NCT04151225|Drug|GSK2330811|GSK2330811 will be available as SC injection with a unit dose strength of 150 mg/mL. GSK2330811 will be available in single-use pre-filled syringe.
5613|NCT04151225|Drug|Placebo|Placebo will be available as SC injection of 0.9 percent saline solution. It will be available as single-use pre-filled syringe.
5614|NCT04151212|Drug|BAT5906 injection|Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
5615|NCT04151199|Other|Endurance Training|Participants randomized to EE training engage in three school-based or center-based (PERC) EE training sessions each week for approximately 12 weeks; each session lasting roughly 70 min with a 45-50 minutes of a stimulus phase and the remaining time being used to warm-up and cool down.
5616|NCT04151186|Biological|TM4SF1- and EpCAM-positive chimeric antigen receptor T-cell therapy|"Specification: 30 mL-100 mL, cell density of about (1-10) x10^6 cells/ml in each bag, number of T-cells about (1-10) x10^8 cells.) 300 ml for each infusion.~Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)<71> and <85> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 5-10 min."
5617|NCT04151173|Procedure|laparoscopic aspiration/electrocoagulation|laparoscopic aspiration/electrocoagulation of ovarian endometrioma
5618|NCT04151173|Procedure|laparoscopic cystectomy|laparoscopic cystectomy of ovarian endometrioma
5619|NCT04151160|Diagnostic Test|Point of care ultrasound measurements|i. Ultrasound images will be obtained using a commercial, high frequency, linear Philips ultrasound probe attached to small, portable tablet. This tablet will have the capability of transferring the saved images to the secure MuscleSound cloud-based server.
5620|NCT04151147|Procedure|Concentrated Growth Factor (Test group)|The patients' blood was collected in 9 ml glass tubes and immediately centrifuged to prevent coagulation in special centrifuge device. The CGF program was set up as follows: accelerated for 30 seconds so as to reach 2700 rpm, rotated for 2 minutes, then reduced to 2400 rpm, then rotated again for 4 minutes and accelerated to 2700 rpm, rotated for 4 minutes, then accelerated to 3000 rpm for 3 minutes, and decelerated for 36 seconds to stop. The middle layer in the tube was separated by the ''Buffy coat'' containing the CGFs fibrin gel using forceps and scissor. Then, this fibrin gel was inserted in the extraction cavity.
5621|NCT04151147|Procedure|Non-Concentrated Growth Factor (Control group)|Third molar extraction was performed under local anesthesia. Following the extraction, the socket was sutured and natural healing process was observed. This side was considered as a control group.
5622|NCT04151134|Diagnostic Test|Step serial sectioning histological processing|Step serial sectioning histological processing
5623|NCT04151121|Behavioral|MBCT (Mindfulness Based Cognitive Therapy)|MBCT is recognized behavior therapy for patients with recurrent depression. The program will be adapted for patients with chest pain.
5624|NCT04151108|Other|Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia, cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, handgrip strength and body composition (BIA)
5625|NCT04151108|Other|Development of a risk assessment tool for loss of muscle mass and physical function based on clinical and functional measures and systemic biomarkers|Blood tests, frailty (CSHA Clinical Frailty Scale), Early Warning Score (EWS), cognitive status, sarcopenia, comorbidity (Charlson comorbidity Index), polypharmacy, physical function and body composition (BIA)
5626|NCT04151095|Other|BFR Exercise Training|Participants will complete exercise training on a recumbent bike placed on a 45 degree incline (BFR).
5627|NCT04151095|Other|CTL Exercise Training|Participants will complete exercise training on a recumbent bike placed on flat ground (CTL).
5628|NCT04151082|Drug|Methylprednisolone|Given IV
5629|NCT04151082|Drug|Prednisone|Given PO
5630|NCT04151082|Other|Quality-of-Life Assessment|Ancillary studies
5631|NCT04151082|Other|Questionnaire Administration|Ancillary studies
5632|NCT04151069|Other|Procedure A|Up-dosing nut drink at home
5633|NCT04151069|Other|Procedure B|Up-dosing nut drink at the hospital
5634|NCT04151069|Other|Control group|Strict avoidance of tree nut consumption
5635|NCT04151043|Behavioral|Suggestions|Verbal suggestions or no suggestions about treatment outcome
5636|NCT04151043|Device|Deep brain stimulation|Regulation of deep brain stimulation intensity
5637|NCT04151030|Procedure|PEG placement|Push PEG placement
5638|NCT04151017|Other|Autologous fibrin glue|Conjunctival graft fixation with autologous fibrin glue
5639|NCT04151017|Other|Suture|Graft fixation using 10.0 mononylon
5640|NCT04151004|Other|Incremental cycling test (ICT)|Incremental cycling test to volitional exhaustion
5641|NCT04151004|Other|Constant load cycling test (CET)|Constant load cycling test to volitional exhaustion.
5642|NCT04151004|Other|Incremental respiratory muscle test (IncRMET)|Incremental respiratory muscle test to volitional exhaustion.
5643|NCT04151004|Other|Incremental quadriceps muscle test (IncQMT)|Incremental quadriceps muscle test to volitional exhaustion.
5644|NCT04151004|Other|Respiratory muscle training like interventions|Three different respiratory muscle training like interventions that are usually used for respiratory muscle trainings.
5645|NCT04150991|Other|Fiber intervention|Each subject will supplement his/her normal dietary intake with 35 grams of dietary fiber daily for three consecutive weeks.
5646|NCT04150991|Other|Placebo treatment|Each subject will supplement his/her normal dietary intake with an 18.53-g maltodextrin placebo daily for three consecutive weeks.
5647|NCT04150978|Other|High Protein Polymeric Formula|Component: 22.4% protein from total calorie Preparation of Peptisol: 5 spoons of Peptisol powder diluted in 200 ml warm water to have 250 ml Peptisol (equal to 250 kcal). Given as written in the group descriptions
5648|NCT04150978|Other|Oligomeric Formula|Component: Component: 22.4% protein from total calorie Preparation: 5 spoons of Peptamen powder diluted in 165 ml warm water to have 200 ml Peptamen (equal to 200 kcal). Given as written in the group descriptions
5649|NCT04150978|Drug|5% Dextrose|500 ml of 5% Dextrose administered to a peripheral vein.
5650|NCT04150965|Drug|Elotuzumab, pomalidomide, dexamethasone|Patients with relapsed Multiple Myeloma will receive: Elotuzumab, Pomalidomide, and Dexamethasone from Cycle 1 Day 1 forward. Each cycle is 28 days long.
5651|NCT04150965|Drug|Anti-LAG-3|"Patients with relapsed Multiple Myeloma will receive: Anti -LAG-3 single agent for Cycle 1.~Cycle 2 forward patients will receive Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long."
5652|NCT04150965|Drug|Anti-LAG-3 + Pomalidimide + Dexamethasone|Patients with Relapsed & Refractory Multiple Myeloma will receive: Anti-LAG-3 single agent for Cycle 1. Cycle 2 and beyond Anti-LAG-3 in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long.
5653|NCT04150965|Drug|Anti-TIGIT|"Patients with relapsed Multiple Myeloma will receive: Anti -TIGIT single agent for Cycle 1.~cycle is 28 days long."
5654|NCT04150965|Drug|Anti-TIGIT + Pomalidimide + Dexamethasone|Cycle 2 and beyond patients will receive Anti-TIGIT in combination with pomalidomide and dexamethasone from Cycle 2 forward. Each cycle is 28 days long.
5655|NCT04150952|Other|HRV-G|Intervention based on HRV-guided training for the performance improvement of athletes. Pre-competitive HRV, subjective effort perception, anxiety and mood will also be analysed.
5656|NCT04150939|Procedure|Core Biopsy|Undergo core biospy
5657|NCT04150939|Procedure|Cryosurgery|Undergo cryoablation
5658|NCT04150939|Drug|Immunotherapeutic Agent|Receive standard of care immunotherapy
5659|NCT04150926|Other|Black currant|"The effect of black currant puree will be compared with black currant-quinoa product, quinoa base and with liquid with glucose, fructose and sucrose~Experimental: Black currant and quinoa product~Active Comparator: Quinoa base Meal study comparing the effect of black currant puree with liquid with glucose, fructose and sucrose, black currant and quinoa product and quinoa base"
5660|NCT04150926|Other|Black currant-quinoa product|The effect of black currant puree will be compared with black currant-quinoa product
5661|NCT04150926|Other|Quinoa base|The effect of black currant puree will be compared with quinoa base
5662|NCT04150913|Drug|Anakinra|Subcutaneous, dosage per protocol. Day 0 through Day 6.
5663|NCT04150913|Drug|Axicabtagene Ciloleucel|Once, intravenous infusion, dosage per protocol
5664|NCT04150900|Drug|Bavituximab|Bavituximab is a chimeric (human/mouse) monoclonal antibody (mAb) derived from murine mAb 3G4 that targets phosphatidylserine (PS) after binding to β2-glycoprotein 1 (β2-GP1).
5665|NCT04150900|Drug|Pembrolizumab|Pembrolizumab is a highly selective humanized mAb designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
5666|NCT04150887|Drug|Cusatuzumab|Cusatuzumab 20 mg/kg will be administered intravenously.
5667|NCT04150887|Drug|Azacitidine|Azacitidine will be administered 75 mg/m^2 subcutaneously or intravenously.
5668|NCT04150887|Drug|Venetoclax|Venetoclax will be administered orally and the dose will ramp-up to 400 mg.
5669|NCT04150874|Diagnostic Test|Lumason®|Hepatic artery embolization using standard of care radioembolization and assessment of tumor and hepatic parenchymal perfusion kinetics before, during and after treatment with standard of care iodinated contrast (at the time of Y90 radioembolization treatment) and standard of care follow-up with multiphase CT or MRI with the addition of study agent Lumason microbubbles for contrast-enhanced ultrasound (which will be performed concurrently with standard evaluation).
5670|NCT04150861|Drug|Follitropin Delta|Solution for Injection, subcutaneous administration
5671|NCT04150848|Behavioral|Goal-Focused Emotion Regulation Therapy (GET)|Six sessions delivered individually over 8 weeks
5672|NCT04150848|Behavioral|Individual Supportive Psychotherapy (ISP)|Six sessions delivered individually over 8 weeks
5673|NCT04150835|Drug|Xingnaojing injection|Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
5674|NCT04150835|Drug|Xingnaojing placebo injection|Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.
5675|NCT04150835|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
5676|NCT04150822|Other|Registry and Saliva sample|Non-interventional registry with saliva sample collected for DNA analysis
5677|NCT04150809|Other|No intervention|There is no intervention for this study
5678|NCT04150796|Procedure|Ventral Hernia Repair|Participants will undergo ventral hernia repair according to the assigned treatment arm.
5679|NCT04150783|Procedure|Surgical repair for nasal obstruction|Patient reported quality of life questionnaires
5680|NCT04150770|Drug|infliximab|
5681|NCT04150757|Drug|Intranasal ketamine|Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
5682|NCT04150744|Combination Product|radiofrequency ablation|take advantage of RFA to destroy hepatocellular carcinoma by high temperature
5683|NCT04150731|Radiation|16α-18F-fluor-17β-estradiol|16α-18F-fluor-17β-estradiol PET/CT scan
5684|NCT04150718|Behavioral|slow-wave disruption|A tone will be played through earplugs that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
5685|NCT04150705|Device|FDG PET/MRI|-All patients will undergo a simultaneous list mode PET and MR acquisition beginning 55-65 minutes after administration of FDG according to a standard weight-based scale.
5686|NCT04150692|Biological|Daratumumab|-Given via intravenous infusion
5687|NCT04150692|Procedure|Blood for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
5688|NCT04150692|Procedure|Bone marrow for research assessments|-Cycle 1 Day 1, Cycle 3 Day 1, and at progression or end of study (whichever is first)
5692|NCT04150653|Device|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)|Multiphase scan CT, non-invasive vascular ultrasound elastography by ultrasound (NIVE)
5693|NCT04150640|Drug|Nal-IRI|chemotherapy drug
5694|NCT04150640|Drug|Oxaliplatin|chemotherapy drug
5695|NCT04150640|Drug|5-FU|chemotherapy drug
5696|NCT04150640|Drug|Trastuzumab|chemotherapy drug
5697|NCT04150627|Other|deep breathing|Deep breathing maneuver to increase parasympathetic nerve activity
5698|NCT04150614|Drug|Granisetron Transdermal Patch|Antiemetic
5699|NCT04150614|Drug|Intravenous Dexamethasone|Antiemetic
5700|NCT04150614|Drug|Ondansetron|ondansetron
5701|NCT04150601|Device|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
5702|NCT04150601|Device|PEP|A PEP device (Pari-PEP) will be used to provoke a positive expiratory pressure while exhaling, thereby stabilizing the airways during expiration.
5703|NCT04150601|Other|Spontaneous Exhalation|A slow vital capacity maneuver will be performed according to the guidelines, from total lung capacity to residual volume
5704|NCT04150588|Drug|Efrin drops|The amount that the eyelid rise after Erin drops before surgery
5705|NCT04150575|Drug|HLX10+Albumin-Bound Paclitaxel|HLX10: 4.5 mg/kg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and HLX10 for up to 2 years.
5708|NCT04150549|Biological|Fecal Microbial Transplants|Healthy donor stool will be processed and placed into capsules.
5709|NCT04150549|Biological|Fecal Microbial Transplants|Participants stool will be processed and placed into capsules.
5710|NCT04150536|Drug|Lidocaine topical system 1.8%|
5711|NCT04150523|Other|Survey|The study will involve a 22 question online survey, administered through the online survey platform conjoint.ly. Conjoint.ly is a web-based survey tool used to conduct survey research, evaluations and other data collection activities. Participants will complete a conjoint.ly survey and choose between treatment (antibiotic vs no antibiotic) scenarios.
5712|NCT04150497|Biological|UCART22|Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen
5713|NCT04150484|Other|Mediterranean diet, physical exercise and mindfulness workshops|a group of dietary intervention, physical exercise and mindfulness and another control group, and a longitudinal follow-up was carried out for 6 months from the beginning of the intervention.
5714|NCT04150471|Other|RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis|Conventional Q-RT-PCR every 3 months
5715|NCT04150458|Drug|18F-fluorocholine PET/CT.|18F-fluorocholine positron emission tomography / computed tomography
5716|NCT04150445|Behavioral|Internet treatment for overweight and obese patients|The behavioral treatment is provided via the Internet and comprises 12 modules that the patient follows for 6 months. The treatment modules include self-monitoring, goal setting, relapse prevention, psycho-education about nutrition, eating behavior, physical activity, sleep and stress management. Each module ends with one or more exercises to be completed before the next module is activated.
5717|NCT04150432|Device|Edmon|New device for exhaled propofol concentration measurements
5718|NCT04150419|Other|Group 1|Attentional training to avoid threatening, negative or pain-related information.
5719|NCT04150419|Other|Group 2|Attention training for vigilance for positive emotional information.
5720|NCT04150419|Other|Group 3 (control group)|Neutral attentional training (control group).
5721|NCT04150406|Dietary Supplement|Flexofytol|Curcuma extract
5722|NCT04150406|Other|Placebo|placebo
5723|NCT04150393|Drug|MaaT033 capsule|Oral capsule
5724|NCT04150380|Biological|Lactobacillus rhamnosus GG (LGG; ATCC strain 53103; CRMTS #11272; PTS #3766)|See arm descriptions
5725|NCT04150380|Other|Placebo|See arm descriptions
5726|NCT04150367|Drug|Isoniazid|Solution for injections, 100 mg/ml, 5 ml. Participants will get the dosage according to the instruction for use.
5727|NCT04150367|Drug|Rifampicin|Participants will get the dosage according to the instruction for use.
5728|NCT04150367|Drug|Ethambutol|Participants will get the dosage according to the instruction for use.
5729|NCT04150367|Drug|Rifampicin|Participants will get the dosage according to the instruction for use.
5730|NCT04150367|Drug|Isoniazid|. Participants will get the dosage according to the instruction for use.
5731|NCT04150367|Drug|Ethambutol|Participants will get the dosage according to the instruction for use.
5732|NCT04150354|Behavioral|Cogito Companion|During the course of the study, the research application (Cogito Companion) will be installed on participants' mobile phone. The application on the participants' phone will be recording data about their behavior. Participants will also be asked to complete bi-weekly surveys via the app.
5733|NCT04150341|Drug|TD-8236|The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
5734|NCT04150341|Drug|Placebo|The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
5735|NCT04150315|Diagnostic Test|Proteome analysis|Evaluation of specific protein levels in tissue and plasma.
5736|NCT04150302|Other|Exploratory interviews|Exploratory interviews to generate an interview guide
5737|NCT04150302|Other|Semi-directive interviews|Semi-directive interviews to collect qualitative data that will be used for questionnaire item generation
5738|NCT04150302|Other|Delphi Process|Cotation of newly developed items pertinence on a 4 points likert scale.
5739|NCT04150302|Other|Think aloud interviews|Debriefing session for the newly developed items: final possibility to adjust the tool before validating the psychometric proprieties of the questionnaire.
5740|NCT04150302|Other|Psychometric validation|Psychometric properties study
5741|NCT04150289|Drug|Farydak|non-interventional study
5743|NCT04150276|Procedure|PEEP during awakening|PEEP will be maintained throughout emergence preoxygenation and awakening.
5744|NCT04150263|Procedure|Intraocular lens (IOL) ab externo scleral suture fixation|traditional IOL scleral suture fixation
5745|NCT04150263|Procedure|Modified IOL ab externo scleral suture fixation|Modified IOL scleral suture fixation
5746|NCT04150250|Drug|iOWH032|Anti-secretory synthetically manufactured small molecule designed to inhit the cystic fibrosis transmembrane conductance regulator chloride channel.
5747|NCT04150250|Drug|Placebo oral tablet|Oral tablets matching iOWH032 on taste, appearance, dissolution time with the same excipients but no active ingredients.
5748|NCT04150237|Other|Simulation training in gastroscopy|Simulation-based training with virtual reality simulation at a Simbionix GI-mentor II endoscopy simulator and procedure training on a phantom.
5749|NCT04150224|Drug|PBTZ169 640 mg OD|Two administrations once a day with a wash-out period: food effect
5750|NCT04150224|Drug|PBTZ169 640 mg BiD|Twice a day fasted; 1 day of administration
5751|NCT04150224|Drug|PBTZ169 960 mg SD|Once a day fasted
5752|NCT04150224|Drug|PBTZ169 1280 mg SD|Once a day fasted
5753|NCT04150224|Drug|PBTZ169 1280 mg MD|Once a day after meal, 14 doses
5754|NCT04150211|Dietary Supplement|Polyherbal Exten(d) vs Placebo|Supplementation during 4 weeks
5755|NCT04150198|Device|TEP/IRM|All participants will have a PET / MRI examination including: i) a 30-minute PET scan, 80 minutes after intravenous injection of 240 MBq of 18F-AV1451 ± 10% ii) a ZTE sequence (for attenuation correction of PET images), a 3D T1 anatomical sequence, a diffusion MRI, a functional MRI at rest (total duration: 45 minutes). These acquisitions will be made during the same exam session on a hybrid PET / MRI camera allowing simultaneous acquisitions. This visit lasts about 3 hours.
5756|NCT04150185|Procedure|Donor hepatectomy|
5757|NCT04150172|Drug|Rebamipide SR 150mg|Test drug
5758|NCT04150172|Drug|Rebamipide IR 100mg|Reference Drug
5759|NCT04150159|Dietary Supplement|FMD Arm|ProLon Fasting Mimicking Diet Plan
5760|NCT04150146|Drug|Rebamipide SR 150mg after high-fat meal|Test Drug
5761|NCT04150146|Drug|Rebamipide SR 150mg under fasting condition|Reference Drug
5762|NCT04150133|Other|Low Residue Diet|Variable cohort will eat 3 low residue meals on the day prior to their planned colonoscopy
5763|NCT04150120|Device|e-health device with application|In this project we focus on eHealth solutions for patients and/or their families in situations where they could benefit from enhanced communication options with specialist staff. In this design space we use a model where a 4G-enabled tablet computer is lent to the families for the length of the study, thus avoiding economic requirements on the families and keeping the equipment uniform. The tablets run an application that enables multiple forms of direct and bi-directional communication in real-time with specialist staff at the hospital. For the staff, the technical situation is different; here we have in earlier demonstrators used web-based solutions accessed with existing computer equipment.
5764|NCT04150107|Drug|ORMD-0801|Oral Insulin Capsules
5765|NCT04150094|Other|Pelvic floor muscle training (PFMT)|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT without stimulus, coming once a week to a session supervised by physiotherapist and will be encouraged to perform the exercises at home during the other week days.
5766|NCT04150094|Other|Pelvic floor muscle training + intravaginal vibratory stimulus|Participants will be firstly evaluated and orientated about pelvic floor muscles and pelvic floor muscle training. They will be clarified about the role of pelvic floor muscles in continence mechanisms and will be orientated to perform 8 weeks of PFMT with intravaginal vibratory stimulus. They will need to come once a week to a session supervised by physiotherapist to use the vibration device and will be encouraged to perform the exercises at home during the other week days.
5767|NCT04150081|Procedure|Surgery or Endoscopic treatment|All the patients in the cohort will receive surgery o local (endoscopic) treatment, in some cases additional surgical treatment will be performed after an endoscopic primary treatment. This decision will have been taken based on daily clinical practice and does not represent a study intervention.
5768|NCT04150068|Drug|Oral GS-6207|Tablets administered without regard to food
5769|NCT04150068|Drug|Placebo oral tablet|Tablets administered without regard to food
5770|NCT04150068|Drug|Subcutaneous GS-6207|Administered in the abdomen via subcutaneous injections
5771|NCT04150068|Drug|Failing ARV Regimen|Failing antiretroviral regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
5772|NCT04150068|Drug|Optimized Background Regimen (OBR)|Optimized background regimen as prescribed by the Investigator
5773|NCT04150055|Behavioral|Mindfulness Coach|Mindfulness Coach is an mHealth delivered mindfulness therapy.
5774|NCT04150042|Drug|Melphalan|Intravenous melphalan (to be given in conjunction with the other listed drugs).
5775|NCT04150042|Drug|BCNU|Intravenous BCNU (to be given in conjunction with the other listed drugs).
5776|NCT04150042|Drug|Vitamin B12B|Intravenous vitamin B12b (to be given in conjunction with the other listed drugs).
5777|NCT04150042|Drug|Vitamin C|Intravenous vitamin C (to be given in conjunction with the other listed drugs).
5778|NCT04150042|Drug|Ethanol|Intravenous ethanol (to be given in conjunction with the other listed drugs).
5779|NCT04150042|Device|CliniMACS-Enriched CD34+ Autologous Hematopoietic Stem Cells|After each cycle of chemotherapy, participants will receive a CD34+ enriched autologous hematopoietic stem cell infusion. The enrichment will be performed with the CliniMACS system.
5780|NCT04150029|Drug|MBG453|Solution for intravenous infusion
5781|NCT04150029|Drug|Venetoclax|Tablet for oral administration
5782|NCT04150029|Drug|Azacitidine|Solution for subcutaneous injection or intravenous infusion
5829|NCT04149652|Diagnostic Test|Lung Elastosonography|Bedside lung ultrasound integrated with lung elastosonography, performed by using the convex probe of an Esaote Mylab Seven ultrasound system (Esaote, Genova, Italy), equipped with the strain elastography module ElaXto©.
5830|NCT04149639|Dietary Supplement|NeuroQ|Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
5783|NCT04150016|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
5784|NCT04150003|Behavioral|Pulmonary Rehabilitation program|Structured rehabilitation program of directed exercises
5785|NCT04150003|Other|Usual care|Usual care for patients who had suffered a Pulmonary Embolism
5786|NCT04149990|Drug|Valsartan+ sacubitril|Treatment with Entresto(valsartan+sacubitril)
5787|NCT04149990|Drug|Placebo Oral Tablet|Matching placebo treatment
5788|NCT04149977|Behavioral|Physical Therapy with pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a cuff around the affected leg during the exercises.
5789|NCT04149977|Behavioral|Physical Therapy with placebo pressure cuff|6 weeks of physical therapy will have similar exercises to standard therapy however the patients will use a pressure cuff around the affected leg during the exercises. The pressure cuff will have 50% of the pressure that will be considered effective.
5790|NCT04149964|Drug|Acetaminophen 325 mg Oral Tablet|Standard of Care Acetaminophen 325 mg every 6 hours as needed for pain
5791|NCT04149964|Drug|Acetaminophen 650 mg Oral Tablet|Acetaminophen 650 mg scheduled every 6 hours round the clock for pain
5792|NCT04149964|Drug|OxyCODONE 5 mg Oral Tablet|Oxycodone 5 mg every 4 hours as needed for breakthrough pain
5793|NCT04149964|Drug|Acetaminophen/Hydrocodone 325 mg/7.5 mg oral tablet|Acetaminophen 325 mg/ Hydrocodone 7.5 mg oral tablet every 4 hours as needed for breakthrough pain
5794|NCT04149951|Device|Vestal Device|Vestibular nerve stimulator
5795|NCT04149951|Device|Placebo device|Sham nerve stimulator
5796|NCT04149938|Drug|Lidocaine topical system 1.8%|
5797|NCT04149938|Drug|Lidocaine patch 5%|
5798|NCT04149925|Device|AEON Endostapler|Surgery with AEON Endostapler
5799|NCT04149925|Device|Echelon Flex Powered Stapler|Surgery with Echelon Flex Powered Stapler
5800|NCT04149912|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
5801|NCT04149899|Drug|Study Treatment 1 WB007|Dosed for 14 days in both eyes
5802|NCT04149899|Drug|Study Treatment 2 WB007|Dosed for 14 days in both eyes
5803|NCT04149899|Drug|Study Treatment 3 WB007|Dosed for 14 days in both eyes
5804|NCT04149899|Drug|Timolol 0.5%|Dosed for 14 days in both eyes
5805|NCT04149886|Procedure|cardiac ganglion plexus ablation(cardioneuroablation)|Cardiac ganglion plexus ablation in the left atrium will be performed before implanting permanent pacemaker in patients with sick sinus syndrome.
5806|NCT04149886|Device|Permanent pacemaker implantation|DDD permanent pacemaker will be implanted in the paticipants.
5807|NCT04149873|Procedure|MIE|MIE
5808|NCT04149860|Drug|Lu AF87908|Lu AF87908 concentrate for solution for infusion IV, single dose
5809|NCT04149860|Drug|Placebo|concentrate for solution for infusion IV
5810|NCT04149847|Procedure|inguinal hernia repair|patients 18 years and above presenting with primary inguinal hernia
5811|NCT04149834|Procedure|Group A (Test): Patients will receive NIPSA|patients received Non- incised papilla surgical approache
5812|NCT04149834|Procedure|Group B (Control): Patients will receive M-MIST|patients received Modified Minimally Invasive Surgical Technique
5813|NCT04149821|Drug|Umbralisib|"Lead-in cycle of 28 days (Cycle -1) of umbralisib monotherapy, 800mg oral daily~Continued 800mg oral daily dosing in all subsequent cycles (combination therapy cycles 1-6, then continued monotherapy cycle 7 and beyond)"
5814|NCT04149821|Drug|Ublituximab|-Co-administered on days 1 and 2 (dose split over days 1 and 2), 8, 15 of cycle 1 then on day 1 for subsequent cycles 2-6
5815|NCT04149808|Device|Mepilex Ag (burn dressing)|Dressing for low to medium exuding burns and wounds.
5816|NCT04149808|Device|Xeroform Dressing|Standard of care dressing for low to medium exuding burns and wounds.
5817|NCT04149795|Diagnostic Test|Online questionnaire|Online questionnaire via SoSciSurvey
5818|NCT04149782|Other|Routine medical record data collection|The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
5819|NCT04149769|Device|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
5820|NCT04149756|Other|observation of weight after 6months|"This study is an observational study for 96 people who have completed the previous weight loss program.~We will check the body composition and lipid profile of the participants who voluntarily visit after 6months after the end of the study. ."
5821|NCT04149743|Diagnostic Test|Standard of Care with Hemotag|Comparison of outcomes
5822|NCT04149717|Dietary Supplement|Energy Drink Ingredients and Exercise|"Subject will ingest 500 mL of one of three test solutions:~A) sucrose (150g) B) sucrose (150g); caffeine (400 mg) C) sucrose (150g); caffeine (400 mg); taurine (4,000 mg); carnitine (400 mg) 3. 30 min later, subject will exercise on a treadmill using the Bruce Protocol maximum exercise test (https://www.aopa.org/go-fly/medical-resources/health-conditions/heart-and-circulatory-system/bru...). For one additional session, subjects will receive test solution C without exercise.~4. Each stage will last 3 minutes. Stage 1 = 1.7 mph at 2% Grade Stage 2 = 2.5 mph at 4% Grade Stage 3 = 3.4 mph at 6% Grade Stage 4 = 4.2 mph at 8% Grade Stage 5 = 5.0 mph at 10% Grade Stage 6 = 5.5 mph at 12% Grade Stage 7 = 6.0 mph at 14% Grade Stage 8 = 6.5 mph at 15% Grade Stage 9 = 7.0 mph at 15% Grade. The test will end when subjects reach exhaustion.~5. 1, 2, and 4 hrs following ingestion, HR, BP, and EKG will be recorded."
5823|NCT04149704|Behavioral|ACP video decision aid|10 minute video decision aid describing the goals-of-care options
5824|NCT04149704|Other|Usual Care-|Verbal description of the three types of care
5825|NCT04149691|Drug|CPL304110|CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
5826|NCT04149678|Drug|Ozanimod|Ozanimod
5827|NCT04149678|Drug|Cyclosporine|Cyclosporine
5828|NCT04149665|Device|simple blind observation|Device that measures continuously the angle of bed by mechanical Ventilation to assess the time the bed is above 35°.
5831|NCT04149626|Drug|Dexmedetomidine|Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)
5832|NCT04149626|Drug|Midazolam|Sedation using midazolam (initial bolus dose followed by continuous infusion)
5833|NCT04149626|Drug|Remifentanil|Sedation using remifentanil (initial bolus dose followed by continuous infusion)
5834|NCT04149600|Procedure|Patients scheduled to undergo aortic valve replacement or aortic surgery at BIDMC will be approached for participation in this study.|Adult patients undergoing aortic valve replacement (AVR) and/or aortic resection will be enrolled.
5835|NCT04149587|Drug|Brodalumab|Brodalumab will be administered per dose and schedule specified in the arm.
5836|NCT04149574|Drug|nivolumab|Specified Dose on Specific Days
5837|NCT04149574|Other|Placebo|Specified Dose on Specific Days
5838|NCT04149574|Biological|Bacillus Calmette-Guérin (BCG)|Intravesicular
5839|NCT04149561|Other|communication skill measurement with self report questionnaire|Demographic information form, Communication Function Classification System, Functional Communication Classification System, The Gross Motor Function Classification System and Manual Ability Classification System will be filled in for the patients.
5840|NCT04149548|Diagnostic Test|ultrasound|Obstetric ultrasound to pregnant women
5841|NCT04149535|Device|Sentinel® Cerebral Protection System|cerebral protection system
5842|NCT04149522|Device|Mepitel Film®|As a part of this research study, Mepitel Film® will be placed prior to a participant's first radiation treatment, and will be removed one week following the end of treatment. The Film will be placed by the physician or his/her designee to cover approximately one-half of the breast divided in the cephalo-caudal plane. The film will remain in place until one week following the completion of radiotherapy. Any loss of film applied will be replaced as needed. Application of the Film is done by research personnel clinically trained in its application procedures.
5843|NCT04149496|Combination Product|in vitro maturation of oocytes|Immature oocytes (rather than mature oocytes) are harvested as in IVF. These oocytes are allowed to mature in the laboratory before fertilization
5844|NCT04149483|Drug|Atorvastatin|One with the intervention (atorvastatin, 20mg OD), 30 patients for this arm.
5845|NCT04149483|Drug|Placebos|One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
5846|NCT04149470|Drug|Omeprazole 20mg BID|High dose PPI therapy (Omeprazole 20mg twice daily)
5847|NCT04149457|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets visual processing speed, memory, attention and alertness.
5848|NCT04149457|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
5849|NCT04149444|Drug|Trifluridine/Tipiracil|Oral medication
5850|NCT04149431|Drug|Derinat|desoxyribonucleate sodium
5851|NCT04149418|Other|Yogurt|Low-fat flavored yogurt
5852|NCT04149418|Other|Control food|Low-fat flavored soy pudding
5853|NCT04149405|Procedure|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia.
5854|NCT04149405|Drug|bisphosphonate therapy|bisphosphonate therapy refers to the use of zoledronic acid 5 mg/year (i.v.)
5855|NCT04149405|Procedure|GCF|gingival crevicular fluid collection by the same investigator.
5856|NCT04149392|Device|Continuous Glucose Monitor|Patients with diabetes hospitalized for heart failure or acute myocardial infarction will have a continuous glucose monitor (CGM) placed on the day of discharge. The participants will go home with the device and keep it for 6-14 days until they return to clinic for follow up visit. At this time the device will be removed, the information regarding glucose levels during those days will be downloaded and based on the download, a PharmD will have the option of increasing or decreasing insulin doses by a maximum of 10% to reduce hypoglycemia and/or hyperglycemia. The goal will be to adjust medications, if needed, to target blood sugars between 90-250mg/dl greater than 80% of the time.
5857|NCT04149379|Drug|Hyperbaric oxygen|20 sessions of hyperbaric therapy in a pressure chamber at 2,4 absolute atmospheres, 90 minutes per day of breathing 100% medical oxygen through an own mask. Table 14/90.
5858|NCT04149366|Device|Retainer|Orthodontic retainer
5859|NCT04149353|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
5860|NCT04149340|Drug|Cataract surgery|Patient's satisfaction and surgeon's satisfaction was assessed by four Lickert's scales, ranging from one to four. hemodynamic parameters before incision, 10 min post-incision and at the end of the surgery
5861|NCT04149327|Drug|amoxicillin 500 mg + metronidazole 500 mg|500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
5862|NCT04149327|Procedure|non-surgical periodontal and peri-implant treatment|"Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned."
5863|NCT04149314|Other|HPI based hemodynamic optimization algorithm|Interventional patients will be treated by a HPI-based hemodynamic optimization protocol including HPI, Stroke volume, cardiac index and mean arterial pressure.
5864|NCT04149301|Diagnostic Test|3D gait analysis|Children will have their walking measured in the gait laboratory to record their kinematics and kinetics along with electromyography (EMG) from key muscle groups.
5865|NCT04149301|Diagnostic Test|MRI scan|The children will have two MRI scans taken - one with the foot loaded and one with no load applied.
5866|NCT04149288|Dietary Supplement|High-polyphenol olive oil|High-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
5930|NCT04148846|Dietary Supplement|Espresso coffee|Espresso coffee 20ml, 5x / day, for 7 days
5867|NCT04149288|Dietary Supplement|Low-polyphenol olive oil|Low-polyphenol olive oil will be provided to study participants to consume at home. Participants will be asked to consume 40 mL each day for 2 weeks.
5868|NCT04149275|Drug|Cabozantinib|Treatment with oral Cabozantinib once daily
5869|NCT04149275|Drug|Ipilimumab|IV administration of Ipilimumab on 21 day cycles
5870|NCT04149275|Drug|Nivolumab|IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
5871|NCT04149262|Drug|Fiasp|Fiasp® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
5872|NCT04149262|Drug|Novorapid|Novorapid® used in a MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link transmitter
5873|NCT04149262|Device|640G pump|MiniMed 640G system equipped with SmartGuardTM technology and accompanied with EnliteTM Sensor and GuardianTM 2 Link
5874|NCT04149249|Other|Computer-Assisted Intervention Video Doctor|Complete CONNECT: participants will undergo in-person assessment questions and follow-up assessment questions. They will view and participate in the interactive Video Doctor about Smoking Cessation.
5875|NCT04149249|Other|Computer-Assisted Intervention no Video Doctor|Individuals who are randomized to the control group will undergo the same assessment questions and all follow up assessments like the intervention group. Instead of viewing and participating in the interactive Video Doctor about Smoking Cessation, they receive a handout containing smoking cessation resources.
5876|NCT04149223|Other|Evidence-based standardized Cirrhosis order set|Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
5877|NCT04149210|Drug|Fluorometholone 0.1% Oph Susp|fluorometholone 0.1% one drop twice daily for four weeks, beginning with one drop just before trachomatous trichiasis surgery on the upper lid.
5878|NCT04149210|Drug|Artificial Tears|Artificial tears (placebo) given one drop twice daily for four weeks, beginning with one drop just prior to trachomatous trichiasis surgery on the upper lid.
5879|NCT04149171|Drug|with red blood cells (RBC), Tranexamic acid (TXA) and Fibrinogen Concentrate (FC),administration of Crystalloids and TXA.|The treating physician must have evaluated the patient's eligibility and approved the patient's enrolment in the trial prior to blood samples extraction and RBC, TXA and Fibrinogen Concentrate administration. The experimental and control arms will be determined according to the medical emergency system units with RBC, TXA and Fibrinogen Concentrate administration capacity which will be the H2 helicopter unit ,fast intervention vehicle and G409 ambulance (Advanced Life Support). The medical emergency system units are activated according current protocols based on distance, severity and weather conditions.
5880|NCT04149171|Drug|conventional treatment|standard treatment based on crystalloid fluid and tranexamic acid (TXA)
5881|NCT04149158|Dietary Supplement|Placebo|
5882|NCT04149158|Dietary Supplement|Sinetrol® Xpur|
5883|NCT04149145|Drug|M4344+Niraparib|The first phase will be a 3+3 design of fixed dose Niraparib by mouth (PO) every day (QD) and M4344 will be escalated from 100-200 mg PO QD (28-day cycle). There will be a 4-week lead in with niraparib only.
5884|NCT04149145|Drug|M4344+Niraparib|In the second phase eligible patients will receive combination Niraparib + the determined dose of M4344 from the first phase.
5885|NCT04149132|Device|pulse photoplethysmography (PPG)|PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
5886|NCT04149132|Diagnostic Test|Measurements of nitric oxide (NO) and malondialdehyde (MDA)|On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
5887|NCT04149119|Device|Attractive Target Sugar Baits (ATSB)|Within the intervention area, a total of four ATSB station will be deployed (external wall). ATSB stations will be monitored by community health workers through weekly visit and all stations will be replaced 6months after deployment.
5888|NCT04149106|Drug|Sulfadoxine pyrimethamine + Amodiaquin|Monthly dose of SPAQ over three days for SMC
5889|NCT04149106|Drug|Dihydroartemisinin piperaquin|Monthly dose of DHAPQ for SMC
5890|NCT04149093|Diagnostic Test|Calretinin staining|"A paraffin-embedded hematoxylinphloxin-safran sections will be performed on tissue specimens of proximal resection margins to evaluate the presence or absence of ganglion cells.~Immunohistochemistry (IHC) will then be done on paraffin-embedded sections for calretinin staining."
5891|NCT04149080|Procedure|SIM + polypropylene membrane|After tooth extraction the socket will be filled with 1.2% simvastatin gel and covered with polypropylene membrane, which will be intentionally exposed.
5892|NCT04149080|Procedure|Placebo|After tooth extraction the socket will be filled with gel and covered with polypropylene membrane, which will be intentionally exposed.
5893|NCT04149067|Drug|Dapagliflozin|Evaluation of the effectiveness and safety of the Dapagliflozin treatment.
5894|NCT04149067|Drug|Sitagliptin|Evaluation of the effectiveness and safety of the Sitagliptin treatment.
5895|NCT04149054|Behavioral|"Mobile health app called Hola Bebe"|For the pilot, all participants received a mobile app that contained 6 interactive audio/written modules in Spanish and English on the following topics: healthy eating; physical activity; portion control; eating healthy while eating out; eating out in Chinese, Italian, Mexican restaurants; and eating out in fast food restaurants. As noted above, the mobile app was customizable to include personalized activity reminders/notifications, and tailored action plans, along with videos for easy at-home exercises and user-friendly, easy-to-follow recipes.
5896|NCT04149041|Diagnostic Test|ultrasound|POCUS is applied to adult patientsin an emergency department.
5931|NCT04148833|Drug|LDE-Paclitaxel|LDE-Paclitaxel at the dose of 175 mg/m2 IV each 21 days for 6 weeks
5898|NCT04149015|Drug|paclitaxel ,oxaliplatin,fluorouracil|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 4 cycles.
5899|NCT04149002|Behavioral|Intervention Arm Weekly 17-P text messages|Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of receiving 17-P. Subjects will also receive weekly automated text messages to encourage adherence to the need for weekly 17-P injections.
5900|NCT04149002|Other|Active Control Arm General pregnancy text messages|Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
5901|NCT04148989|Other|Code Sepsis protocol (full implementation)|Implementation of a coordinated, structured, multidisciplinary team-based protocol for initial evaluation and treatment of ED patients with suspected sepsis.
5902|NCT04148976|Dietary Supplement|Placebo|A mixture of maltodextrins and calcium caseinate divided into 30g individual packets.
5903|NCT04148976|Dietary Supplement|Dietary portfolio|A mixture of functional foods divided into 30g individual packets.
5904|NCT04148963|Drug|Inhaled loxapine|Inhaled Loxapine 9.1 mg, may repeat x 1 or 2 after 2 hours
5905|NCT04148963|Drug|Inhaled placebo|Inhaled placebo, may repeat x 1 or 2 after 2 hours
5906|NCT04148950|Other|Kinesio Tape|
5907|NCT04148950|Other|Compression Stockings|
5908|NCT04148950|Other|Exercise Program|
5909|NCT04148937|Drug|LY3475070|Administered orally
5910|NCT04148937|Drug|Pembrolizumab|Administered IV
5911|NCT04148924|Other|Questionnaire|"Patients complete a questionnaire for assess their symptoms like anxiety and depression.~These questionnaires contains:~socio-demographic characteristics : sex, age, type and stage of cancer, performans status~ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms~HADS - A : Hospital Anxiety and Depression scale includes 2 subscales which assess anxiety (HADS-A) and depression (HADS-D)~BEDS : Brief Edimburg depression Scale is s a relevant scale for assess depression in palliative care patients.~Questions on the assessment, the treatment and difficulties in management of anxious and depressive symptoms.~The evaluation will be realized in the first days of hospitalization (72 hours)."
5912|NCT04148924|Other|Medical staff questionnaire|"Questionnaire is different from caregivers. The evaluation will be realized in the first days of hospitalization (72 hours).~Physicians, nurses and caregivers complete another questionnaire. The physician questioned will be the doctor of unit having received the patient, or the doctor of the mobile team of palliative care having admitted the patient in the unit.~These questionnaires contains:~socio-demographic characteristics : sex, age, type and stage of cancer, performans status~ESAS : Edmonton Symptom Assessement Scale is a validated tool for assessment of several symptoms"
5913|NCT04148911|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 840 mg via IV infusion
5914|NCT04148911|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered at the 100 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle
5915|NCT04148911|Drug|Paclitaxel|"Paclitaxel will be administered at the 90 mg/m2 dose via IV infusion on Days 1, 8, and 15 of every 28-day cycle.~Paclitaxel will be made available as an option only after data supporting its use in combination with Atezolizumab in previously untreated mTNBC become available from the currently ongoing IMpassion131 study"
5916|NCT04148898|Drug|Osimertinib|Treatment of LM With osimertinb
5917|NCT04148898|Drug|Bevacizumab|Treatment of LM With osimertinb combined with bevacizumab
5918|NCT04148885|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
5919|NCT04148885|Drug|carboplatin|Patients secondly receive carboplatin AUC=5 (iv, 30 minutes) on days 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
5920|NCT04148872|Other|Neuromuscular Retraining Therapy (4 months)|Neuromuscular retraining is an intervention where facial therapists utilize voluntary input to access improved movement patterns in patients with synkinesis.
5921|NCT04148872|Drug|Chemodenervation (4 months)|A neurotoxin that temporarily reduces muscle activity and minimizes the effects of uncoordinated muscle.
5922|NCT04148872|Other|Neuromuscular Retraining + Chemodenervation|Participants will receive both interventions for the last 4 months of their time on study.
5923|NCT04148859|Procedure|amnioreduction|The amniotic fluid is drained via needle, which is stubbed in the abdomen wall, connected to a tube into a plastic bag. The amniotic fluid pressure will be measured by a water manometer. A T-shape connector will be connected to the tube on one side, and to a short tube on the other side. The height of the fluid within the short tube will indicate the pressure. All the fluid will be drained to the plastic bag. The pressure and the blood flow of the fetuses will be measured during the procedure, depends on the drainage rate.
5924|NCT04148846|Drug|Dypirone|Dipyrone 2g, 6 / 6h for 7 days, orally or intravenous
5925|NCT04148846|Procedure|Sphenopalatine block|The sphenopalatine block will be performed with the patient in the supine position, with neck extended. Following topical anesthesia of the nasal vestibules with one application of 10% lidocaine spray and one application of 2% lidocaine gel in each nostril, two long cotton swab applicators embedded in 2% lidocaine jelly, one in each nostril, will be introduced. They will be advanced at a 45-degree angle to the floor of the nose until resistance is encountered, indicating that the swab is in the posterior nasopharyngeal wall, superior to the middle nasal concha. It will be held in this position for 5 minutes and then removed. Thereafter, a 14 gauge, non-cutting, teflon blunt catheter will be introduced into each nostril at a 45 ° angle to the hard palate until it touches the posterior wall of the nasopharynx. For it will be applied 2ml of 0.375% Ropivacaine, on each side, slowly.
5926|NCT04148846|Drug|Ketoprofen|Ketoprofen 100 mg, 12 / 12h for 5 days, orally or intravenous
5927|NCT04148846|Drug|Gabapentin|Gabapentin 300 mg 8 / 8h for 7 days orally
5928|NCT04148846|Drug|Dexamethasone|Dexamethasone 4mg 8 / 8h for 48h orally
5929|NCT04148846|Drug|Theophylline|Theophylline 200mg, 12 / 12h, for 5 days, orally
5933|NCT04148820|Drug|Aspirin, Atorvastatin, Perindopril|Cardiovascular drugs will be administered all together every day at the same time
5934|NCT04148807|Behavioral|Gait Retraining|During retraining sessions participants will walk on a treadmill at self-selected comfortable walking speed wearing an inertial measurement unit (IMU) on the medial aspect of the distal tibia. The (vertical) peak positive acceleration (PPA) of the tibia is a measure of tibial shock. Subjects will be provided real-time audio feedback to reduce PPA by 20% of their average peak PPA. During retraining sessions, a faded feedback approach will be used. Feedback will be provided continuously during the first four sessions and will be faded over the last 4 sessions. Walking time will increase over the 8 sessions.
5935|NCT04148807|Behavioral|Control|The control walking intervention will also be performed on a treadmill where subjects will walk at a self-selected comfortable speed with the same walking times per session as the retraining group without any feedback or retraining cues.
5936|NCT04148794|Behavioral|echo-assisted advanced life support|"Integrated point-of-care ultrasound skill in to the setting of resuscitation, and critical condition patients.~Educate the participants to use these protocols and monitoring if there were improvement of patient's outcomes"
5937|NCT04148781|Drug|Fampridine SR|Fampridine-SR 10 mg twice daily for 8 weeks
5938|NCT04148768|Device|Inferential therapy|Interferential therapy(IFT) utilises two of these medium frequency currents, passed through the tissues simultaneously, where they are set up so that their paths cross & they literally interfere with each other - hence another term that has been used in the past but appears to be out of favour at the moment - Interference Current Therapy. This interaction gives rise to an interference current (or beat frequency) which has the characteristics of low-frequency stimulation.
5939|NCT04148768|Device|short wave diathermy|SWD: Technical specification of Generator frequency: 27.12 MHz, ± 0.6% Output power: continuous High-Frequency max. 400 W, pulsed High-Frequency max. 1000 W (peak) Pulse duration: ca. 400 µs Pulse repetition frequency: 15-200 Hz adjustable in 10 steps Mains supply: 230-240 V / 50 Hz Mains voltage variation: approx. ± 10% Current consumption: approx. 6 Ampere (at 230 V)
5940|NCT04148755|Procedure|Endoscopic ultrasound guided fine needle aspirate|All patients are going to have an EUS guided elastography with FNA of solid pancreatic lesions
5941|NCT04148742|Drug|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
5942|NCT04148729|Drug|ESP block|Ultrasound guided ESP block will perform with 15 ml bupivacaine+ 5 ml lidocaine at the T10 level bilaterally.
5943|NCT04148729|Drug|Control Group|In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine.
5944|NCT04148716|Procedure|additional biopsies|additional biopsies during a fibroscopy planned in the care
5945|NCT04148703|Other|Follow up post Pacemaker implantation in office|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up
5946|NCT04148703|Other|Follow up post Pacemaker implantation by home monitoring|All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
5947|NCT04148690|Other|Group antenatal care (GANC)|Group antenatal care (GANC) is a service delivery model where women with pregnancies of similar gestational age are brought together for antenatal care (ANC), incorporating information sharing and peer support.
5948|NCT04148690|Other|Standard antenatal care|Routine antenatal care as recommended by th Ministry of Health of Tanzania
5949|NCT04148677|Dietary Supplement|Protoves M1®|A combination of two alkaloid, Protopine and Nuciferine (Protoves-M1 ®)
5950|NCT04148664|Procedure|Catheter ablation with Standard RF ablation settings|"Standard RF ablation settings (n=25):~Maximum 35W for 20-40 seconds, per operator standard."
5951|NCT04148664|Procedure|Catheter ablation with High Power Short Duration RF ablation settings|"High power short duration RF (n=25):~Maximum 50 Watts for 5-15 seconds, per operator standard."
5952|NCT04148651|Device|The CO2RE® System|The CO2RE® system is a fractional CO2 laser that is FDA-cleared under a 510(k) K181523 for laser incision, excision, ablation and/or vaporization and of soft tissue in gynecology (GYN).
5953|NCT04148612|Diagnostic Test|Opti-Me|Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
5954|NCT04148599|Drug|dexmedetomidine infusion|a loading dose of 1µg/kg of dexmedetomidine (precedex) made to 50 ml using normal saline will be given over 10 minutes followed by infusion of dexmedetomidine with a dose of 0.5µg/kg/hour till the end of surgery.
5955|NCT04148599|Drug|lidocaine infusion|a loading dose of 1.5 mg/kg of lidocaine made to 50 ml using normal saline and given over 10 minutes followed by infusion of lidocaine with a dose of 1.5 mg/kg/hour till the end of surgery.
5956|NCT04148599|Drug|Placebos|50 ml of normal saline given over 10 minutes followed by saline infusion intraoperatively at a rate of 10 ml/hour till the end of surgery.
5957|NCT04148586|Other|Whole Breast Irradiation|Whole Breast Irradiation after CBS in females with DCIS and early stage breast cancer
5958|NCT04148573|Drug|NFX88 - 1|3 times a day
5959|NCT04148573|Drug|NFX88 - 2|3 times a day
5960|NCT04148573|Drug|NFX88 - 3|3 times a day
5961|NCT04148573|Drug|PLACEBO - 4|3 times a day
5962|NCT04148560|Other|Tests of the validity of the RFPM and SmartIntake app.|Participants who enroll will be trained in using the RFPM/SmartIntake app and a food record and will complete the Food Intake Assessment Preference Survey. They will also use both methods to estimate intake during a simulated lab-based meal (they will not eat during this simulated meal). They will be dosed with DLW at this visit and will use the RFPM for the subsequent 1-2 days to get accustomed to using the method, with the following three days comprising the data collection period.
5963|NCT04148547|Device|Sooma transcranial direct current stimulation device|This group received brain training through transcranial direct current for 20 minutes.
5964|NCT04148547|Device|Placebo Sooma transcranial direct current stimulation device|This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
5995|NCT04148248|Other|No intervention|There is no intervention for this study
5965|NCT04148534|Device|rocronium|compare the operating condition of two different levels of muscle relaxation on facial nerve monitoring using transcranial motor evocked potential in CPA surgery
5966|NCT04148521|Behavioral|Behavioral Health - Virtual Patient Navigation|Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
5967|NCT04148508|Behavioral|Tailored Emotional Competence Self-help|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion. Interventions are personalised to the individual based on emotional competence skills. Intervention is in addition to self-monitoring in the app. Intervention components include selection of 2 from 4 of : targeting worry and rumination; increasing emotional knowledge and perception skills; improving achievement appraisals including attribution retraining and growth mindset; improving social appraisals including positive interpretations of ambiguous social events
5968|NCT04148508|Behavioral|Cognitive-behavioural Approach|The active interventions are all entirely self-help and provide psycho-education, tips, advice and strategies for well-being promotion, based on cognitive-behavioural principles such as increased activity and challenging negative thinking. Interventions are generic and common to all participants. Intervention is in addition to self-monitoring in the app.
5969|NCT04148508|Behavioral|Self-monitoring|Self-monitoring app that involves monitoring emotions and emotional events over time within the app and being able to review emotion over time
5970|NCT04148495|Drug|placebo of acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg followed by bolus of 0.05 mg/kg every 10 minutes as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%"
5971|NCT04148495|Drug|acetaminophen IV|"Mophine IV: Initial loading dose of 0.1 mg/kg followed by bolus of 0.05 mg/kg every 10 minutes as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g"
5972|NCT04148482|Other|Dietary intervention|To investigate whether individuals with divergent genetic susceptibility have different food preferences and have differential post-prandial glycemic and metabolomics responses to a standardized or an election meal.
5973|NCT04148469|Procedure|Dry needling|Dry needlin is a manual therapy technique used for miofascuial pain syndrom treatment. The patient will be supine, in a confortable position. The therapist localizes the trapezius trigger point number 2 and then performes the needling until 2 REL are obtenined. The patient will remain supine during 15 minutes.
5974|NCT04148469|Procedure|Transcutaneous Nerve Stimulation.|Transcutaneous Nerve Stimulation (TENS) is a current used for pain treatment. The needle will be used as the negative pole and a adhesive patch 2 centimeters lateral will be the positive pole. The frecuency selected will have 2 Hz with pulses of 120 microseconds. The currente will be applied for 15 minutes.
5975|NCT04148469|Procedure|Placebo needling|No active technique is performed with the placebo needling. Patient will be supine and a placebo needle willb be performed. The patient will remain supine for 15 minutes.
5976|NCT04148456|Procedure|Covered Endovacular Reconstruction of Aortic Bifurcation|"The occlusive lesion is then passed, either subintimal or endoluminal, using crossing wires and catheters.~After gaining re-entry into the lumen of the aorta, angiography will be confirmed proper positioning for those with a subintimal passage.~A 10-12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath.~The proximal 2/3 part of the aortic stent will be flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two 8 mm V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) will be placed proximally in the distal 1/3 of the aortic stent, and then simultaneously deployed distally into the common iliac arteries creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation."
5977|NCT04148443|Other|Preoxygenation|participants will receive 3 minutes of preoxygenation before intubation
5978|NCT04148443|Other|Preoxygenation (longer)|participants will receive 5 minutes of preoxygenation before intubation
5979|NCT04148430|Drug|Anakinra|100mg subcutaneous
5980|NCT04148417|Device|Solo+ Tympanostomy Tube Device|The Solo+ Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure
5981|NCT04148404|Procedure|Normothermic group|"Normothermic group (NT group) included patients will undergo CABG under warm bypass using warm blood cardioplegia (Normothermic CBP).~Hypothermic group (HT group) included patients will undergo CABG under cold bypass using cold blood cardioplegia (Hypothermic CBP)."
5982|NCT04148391|Drug|Placebo Oral Capsule|Matching placebo capsules.
5983|NCT04148391|Drug|NYX-458|NYX-458 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
5984|NCT04148378|Other|No intervention|There is no intervention for this study.
5985|NCT04148352|Drug|Dupilumab|Dupilumab injected every 2 weeks for 18 weeks
5986|NCT04148352|Other|Placebo|Placebo injected every 2 weeks for 18 weeks
5987|NCT04148339|Other|No Intervention|There is no intervention for this study.
5988|NCT04148326|Other|No Intervention|There is no intervention for this study.
5989|NCT04148313|Other|No Intervention|There is no intervention for this study.
5990|NCT04148287|Drug|APX001|Day 1: APX001 1000 mg IV BID over a 3-hour infusion Days 2-3: APX001 600 mg IV QD over a 3-hour infusion Days 4 - 42: APX001 600 mg IV QD over a 3-hour infusion or APX001 800 mg QD oral.
5991|NCT04148274|Other|No intervention|There is no intervention for this study.
5992|NCT04148261|Drug|Hydrocortisone Acetate (CORT)|Participants will receive a single dose of hydrocortisone at a dosage of 0.65 mg/kg
5993|NCT04148261|Drug|Epinephrine Sulfate (EPI)|Participants will receive a continuous infusion of epinephrine at a dosage of 80 ng/kg/min
5994|NCT04148261|Drug|Placebo (PLB)|Participants will receive a placebo
5996|NCT04148235|Other|No Intervention|There is no intervention for this study
5997|NCT04148222|Other|No intervention|There is no intervention for this study
5998|NCT04148209|Drug|PF-07081532|Participants will receive single ascending doses PF-07081532
5999|NCT04148209|Drug|Placebo|Participants will receive placebo
6000|NCT04148196|Other|Progressive muscle relaxation exercise|The CD on relaxation exercises developed by the Turkish Psy-chological Associationwas used.In the second of CD 30-min section; relaxation exercises are explained to the accompaniment ofrunning water sounds and verbal instructions. Progressive relaxation technique includes stretching and relaxing the bigmuscle groups (hands, arms, neck, shoulders, face, chest, abdomen,hip, feet andfingers) in the human body on purpose. When steps ofProgressive Relaxation Exercises are analyzed, it is observed thatlearning how to take correct and deep breaths is the most impor-tant step towards learning relaxation. In addition, taking correct breaths is used as a part of the exercise among all relaxation exercises.Steps of Progressive Relaxation Exercise:- breathing exercises- lower extremity exercises- upper extremity exercises- exercise of respiratory muscles. Elderly individuals will receive PMR exercise twice a week under the guidance of an investigator for eight weeks.
6001|NCT04148183|Drug|Metformin group|We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks
6002|NCT04148183|Drug|Rosiglitazone group|we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks
6003|NCT04148183|Drug|Placebo oral tablet|We add Placebo, treatment was administered for 8 weeks
6004|NCT04148170|Procedure|Endodiathermy Probe and Intubation Versus Intubation|children suffer from congenital nasolacrimal duct obstruction will have probing with endodiathermy probe and then intubation with bicanlicular silicon tube
6005|NCT04148144|Other|No intervention included|No intervention included
6006|NCT04148118|Biological|BW-1010: 50 µg - sprayer - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
6007|NCT04148118|Biological|BW-1010: 50 µg - pipette - IN|"20% Nanoemulsion and 50 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
6008|NCT04148118|Biological|BW-1010: 100 µg - sprayer - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by Aptar Bidose Sprayer (400µL)~Two doses administered 4 weeks apart"
6009|NCT04148118|Biological|BW-1010: 100 µg - pipette - IN|"20% Nanoemulsion and 100 µg recombinant protective antigen administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
6010|NCT04148118|Biological|Saline (Placebo) - sprayer - IN|"Saline (negative control) administered intranasally by Aptar Bidose Sprayer (400µL).~Two doses administered 4 weeks apart."
6011|NCT04148118|Biological|Saline (Placebo) - pipette - IN|"Saline (negative control) administered intranasally by pipette (400µL).~Two doses administered 4 weeks apart."
6012|NCT04148118|Biological|BioThrax (positive control) - SC|"BioThrax licensed vaccine administered subcutaneously (500µL).~Three doses administered 2 weeks apart."
6013|NCT04148105|Drug|Cilostazol 100 MG|The addition of 100 mg cilostazol, twice daily for 14 days, to the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
6014|NCT04148105|Other|Placebo|The standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway
6015|NCT04148092|Drug|ripretinib|orally administered solid dosage form
6016|NCT04148079|Other|physical therapy|low frequency currents (galvanic or TENS), medium frequency currents (interferential) and high frequency currents (short wave diathermy), all combined with an individualized exercise program and massage therapy
6017|NCT04148066|Diagnostic Test|ctDNA blood sample|every six weeks during treatment and upon radiological progression blood will be drawn to analyse ctDNA with Avenio ctDNA (Expanded panel) to detect all known EGFR TKI resistance mechanisms.
6018|NCT04148053|Diagnostic Test|TB-antigen responsive T cell markers|A blood test including a series of T cell markers which are responsive to TB antigens
6019|NCT04148040|Procedure|G-POEM|Per-oral pyloromyotomy (POP), also named as gastric per-oral endoscopic myotomy (G-POEM), for treating infantile hypertrophic pyloric stenosis (IHPS) has the following steps: mucosal incision, creation of submucosal tunnel, full-thickness pyloromyotomy, closure of the mucosal entry.
6020|NCT04148027|Other|Treatment recommendation by emergency department physicians|Standard treatment after admission in the emergency department from a team of residents in internal medicine, neurology and general surgery.
6021|NCT04148027|Other|Treatment recommendation by telemedical geriatric co-evaluation|Treatment recommendation from a board-certified geriatrician linked for co-evaluation by means of video transmission
6022|NCT04148014|Behavioral|An Adjunctive Emotion Regulation Skills Training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 5 weeks to young adults with eating disorders together with treatment as usual
6023|NCT04147988|Other|screening and diagnostic assessment DONALD T unit list|Screening and diagnostic assessment of the group of people awaiting assessment, and thus test the feasibility of a screening and diagnosis procedure for autism in adults without intellectual disabilities
6024|NCT04147975|Diagnostic Test|RaPID/BSI Test|RaPID/BSI Test
6025|NCT04147962|Device|intense pulsed light (usual practice)|collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light
6026|NCT04147949|Drug|AV-101|Oral capsules taken twice daily for 14 days
6027|NCT04147949|Drug|Placebo|Oral capsules taken twice a day for 14 days
6028|NCT04147936|Dietary Supplement|AXA1665|Dietary supplement: AXA1665
6029|NCT04147936|Dietary Supplement|Placebo|Placebo
6030|NCT04147923|Dietary Supplement|Floradapt Mature Immune Defense + Multivitamin|The product consists of two L. plantarum strains, KABP XXXX and KABP XXXX with a combined strength of >1 x 10^9 CFU. Participants will also consume a multivitamin.
6031|NCT04147923|Other|Placebo + Multivitamin|No active ingredients + a multivitamin supplement
6032|NCT04147910|Drug|KW-6356|Single oral dose of KW-6356
6033|NCT04147897|Device|FOCUS|FOCUS is a self management mHealth application for people with serious mental illness.
6124|NCT04147234|Drug|BI 1387446|intratumoral injection
6034|NCT04147884|Device|Millipede Transcatheter Annuloplasty Ring System (Millipede System)|The Millipede Transcatheter Annuloplasty Ring System is a repair device used for treating mitral valve regurgitation (MR). The system consists of several components: a transcatheter annuloplasty ring (implant) which remains in the body and a delivery system and intracardiac echocardiography catheter (imaging device) used to deliver the implant to the mitral valve.
6035|NCT04147871|Drug|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances.
6036|NCT04147871|Drug|Placebo|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
6037|NCT04147858|Drug|NYX-2925|NYX-2925 administered orally
6038|NCT04147858|Drug|Placebo|Placebo administered orally
6039|NCT04147845|Other|Fractional Carbon Dioxide Laser|"The ablative fractional CO2 laser is delivered to the patients' scalp. The fractional ablative method is applied immediately before the topcial medication.~Laser treatment will be given to the affected area, and immediately after the treatment, the treatment solution will be dropped on the treated area and spread evenly"
6040|NCT04147845|Other|Microneedling using dermapen|"Microneedling is performed using Dermapen. This creates pin point bleeding or mild erythema which will be considered as the end point.~The treatment solution will be applied on each lesion twice, before and after performing microneedling."
6041|NCT04147845|Other|Triamcinolone Acetonide|triamcinolone solution (10 mg/ml) will be dropped on the treated area and spread evenly
6042|NCT04147845|Other|Platelet-rich plasma|The applied PRP will be spread over the whole affected area
6043|NCT04147832|Other|Alert to provider|Provider will receive an alert of sub-optimal patient attendance using 4 rules.
6044|NCT04147819|Drug|BAY2701439|Intravenous (IV) injection on Day 1 of each cycle.The duration of each cycle will be 6 weeks (42 days).
6045|NCT04147819|Drug|BAY2701438|Intravenous (IV) injection on Day 1 of each cycle and 1 hour before the start of administration of BAY2701439. The duration of each cycle will be 6 weeks (42 days).
6046|NCT04147806|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
6047|NCT04147806|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
6048|NCT04147806|Drug|Dexamethasone|4 mg by mouth on treatment days only
6049|NCT04147806|Drug|Tamsulosin|0.4 mg by mouth daily starting the day of simulation and until 2 weeks post-treatment.
6050|NCT04147780|Procedure|Sentinel node biopsy|Sentinel node biopsy, radiotracer (mandatory) and blye dye (optional). Scintigraphy.
6051|NCT04147767|Dietary Supplement|Cholesterol Reducing Strawberry Yogurt Drink (Tesco Ltd)|"Ingredients: Skimmed Milk, Strawberry Juice from Concentrate (5%), Plant Sterols Ester (3.4%)***, Sugar, Maize Starch, Flavourings, Colour (Anthocyanins), Starter Culture including Bifidobacterium (Milk), Thickener (Carob Gum), Sweetener (Sucralose), Milk Proteins.~*** Equivalent to 2% Free Plant Sterols"
6052|NCT04147767|Dietary Supplement|Low Fat Strawberry Yogurt Drinks (Morrisons Ltd)|Ingredients: Yogurt (Milk), Water, Sugar, Strawberry Purée (1%), Modified Maize Starch, Carrot Concentrate, Flavouring, Acidity Regulator (Citric Acid), Vitamin C, Colour (Paprika Extract), Sweetener (Sucralose), Vitamin D, Vitamin B6.
6053|NCT04147754|Procedure|Epidural anesthesia|Preoperative epidural anesthesia at physician discretion
6054|NCT04147754|Procedure|Intrathecal morphine|Preoperative intrathecal morphine at physician discretion
6055|NCT04147754|Procedure|Erector spinae block|Preoperative erector spinae block at physician discretion
6056|NCT04147741|Dietary Supplement|Pre-Workout Supplement|"One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin."
6057|NCT04147741|Other|Resistance Training|-Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
6058|NCT04147741|Other|Endurance Training|- Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
6061|NCT04147715|Drug|S-648414|Tablet for oral administration
6062|NCT04147715|Drug|Placebo|Tablet for oral administration
6063|NCT04147715|Drug|Midazolam|Solution for oral administration
6064|NCT04147702|Other|Balance analysis|Balance analysis is assessment method to estimate deterioration of postural control.
6125|NCT04147234|Drug|BI 754091|intravenous infusion
6126|NCT04147221|Drug|Imipenem-relebactam|After receipt of imipenem-relebactam, participants will have six blood samples collected over 6 hours for determination of imipenem and relebactam concentrations.
6127|NCT04147208|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
6128|NCT04147208|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
6065|NCT04147689|Device|DESIRIAL® PLUS|"DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue.~The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction.~One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study."
6066|NCT04147663|Other|describe the management of the adult population suffering from suspected seizure by the emergency structures|For 3 consecutive days, all patients with suspected epileptic seizures (assessed by the Emergency medical assistance service ( SAMU), paramedical team and the emergency unit) will be included in the study. With the use of questionnaries, information will be collected from patients or witnesses by the SAMU, the paramedical team or physicians of the emergency unit. A 7-day follow-up will be carried out by the principal investigator (PI) of each center.
6067|NCT04147650|Drug|0.05% Voclosporin Ophthalmic Solution (VOS)|0.05% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
6068|NCT04147650|Drug|0.10% VOS|0.10% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
6069|NCT04147650|Drug|0.20% VOS|0.20% VOS, in both eyes (OU) twice a day (BID) over 12 weeks
6070|NCT04147650|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution, in both eyes (OU) twice a day (BID) over 12 weeks
6071|NCT04147637|Combination Product|FreeStyle Libre with MiaoMiao|Use of FreeStyle Libre with MiaoMiao Bluetooth adjunct and mobile device application to enable calibration and alarms
6072|NCT04147637|Device|FreeStyle Libre alone|Use of standard FreeStyle Libre with Libre Link app and mobile phone scanning
6073|NCT04147624|Drug|Souvenaid|Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.
6074|NCT04147624|Other|Placebo|The Placebo used in this study is an oral beverage vitamin mixture containing Vitamins A, B1, B2, B3 and B5.
6075|NCT04147611|Device|BAHA|Participant's pediatric bone conduction hearing device.
6076|NCT04147611|Device|Wireless Audio Streaming Accessory|Cochlear Corporation's Mini Microphone 2+ Wireless Audio Streaming Accessory is an accessory used to transmit speech and sound. It consists of a microphone and a transmitter that transfers the signal to a receiver that's connected to a hearing device.
6077|NCT04147611|Device|Digital Adaptive RM System|Sonova's Roger Digital Adaptive RM system is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
6078|NCT04147598|Other|LFD|Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
6079|NCT04147598|Other|SAD|Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
6080|NCT04147585|Other|Intermittent Reduced Calorie Diet (IRCD)|Three cycles of a 5-day Intermittent Reduced Calorie Diet over three months.
6081|NCT04147572|Drug|Placebo Tiotropium inhalation powder type A|Placebo inhalation from inhaler A
6082|NCT04147572|Drug|Placebo Spiriva capsule|Placebo inhalation from HandiHaler
6083|NCT04147572|Drug|Placebo Tiotropium inhalation powder type B|Placebo inhalation from inhaler B
6084|NCT04147572|Device|Substudy Placebo Tiotropium Easyhaler|Substudy placebo inhalation
6085|NCT04147572|Device|Substudy Placebo Spiriva® via HandiHaler|Substudy placebo inhalation
6086|NCT04147559|Device|Total Hip Arthroplasty Implant|Single study group either newly or previously implanted with the PROFEMUR® Preserve Classic Femoral Stem combined with other Wright Medical Technology (WMT) or MicroPort Orthopedics Inc (MPO) THA components including acetabular shells, liners and femoral heads.
6087|NCT04147546|Diagnostic Test|Additional screening using ultra sensitive RDTs|At each ANC visit, study nurses will perform an HS-RDT for participants in the intervention arm
6088|NCT04147546|Drug|Dihydroartemisinin-piperaquin|All pregnant women with a positive HS-RDT will be treated with a full course of dihydroartemisinin-piperaquine (DP) over 3 days. The first dose of DP will be administered under direct observation at the antenatal care clinic (ANC) and the subsequent doses of the intervention in days 2 and 3 will be taken unsupervised at home
6089|NCT04147546|Other|Reminders|Before each scheduled ANC visit, reminders using SMS or phone call will be used. This is order to increase ANC attendance
6090|NCT04147533|Drug|Imatinib withdrawal|withdrawal of imatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of imatinib is 50% of the standard dose (200 mg daily), during the second 6 months after study entry, the dose of imatinib is 200 mg every other day; 12 months after study entry, imatinib is discontinued, the patient is followed in line with the aims of the trial
6091|NCT04147533|Drug|Dasatinib|withdrawal of dasatinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of dasatinib is 50% of the standard dose (40 mg daily; tablets containing 50 mg are not available on the market), during the second 6 months after study entry, the dose of dasatinib is 40 mg every other day; 12 months after study entry, dasatinib is discontinued, the patient is followed in line with the aims of the trial
6092|NCT04147533|Drug|Nilotinib|withdrawal of nilotinib after previous two-step dose reduction: during the first 6 months after study entry, the dose of nilotinib is 50% of the standard dose (200 mg every 12 hours), during the second 6 months after study entry, the dose of nilotinib is 400 mg every other day; 12 months after study entry, nilotinib is discontinued, the patient is followed in line with the aims of the trial
6093|NCT04147520|Behavioral|Brief Motivational Interview|Single (60 min) session discussion of alcohol use and associated experiences.
6129|NCT04147208|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
6130|NCT04147195|Drug|LYS006|Single treatment with LYS006
6131|NCT04147195|Drug|LYS006 + Tropifexor (LJN452)|Combination treatment with LYS006 + Tropifexor (LJN452)
6159|NCT04146896|Drug|NYX-2925 50 mg|NYX-2925 administered orally. At some point in the study, all subjects will receive placebo.
6094|NCT04147507|Other|Passive Music Therapy|Music group (N=15) will receive listen to music therapy passively for 20 minutes/day, 5 days/week for 4 weeks, along with lifestyle modifications. Music therapy will be provided via headphones in an isolated quiet non-disrupted room, with room temperature maintained between 20-22 degree Celsius and having medium light intensity. Participants would be instructed to listen to music with eyes closed in sitting position, back supported in comfortable position on a chair. The participants will be given 5 minutes' rest in sitting position before and after each music therapy session.
6095|NCT04147507|Behavioral|Control|Control group (N=15) would receive only lifestyle modification. Handout of lifestyle modification according to the Seventh Joint National Committee (JNC VII) report guidelines will be given to all participants. Participants would be instructed to not participate in any form of physical activity and to focus only on two components from the guideline which includes practice the DASH eating plan (diet rich in fruits and vegetables, low fat dairy or unsaturated fat) and limit the daily sodium intake (less than 100 mmol per day).
6096|NCT04147494|Drug|68GA-PSMA, 68GA-FAPi|Tracer biodistribution of 68Ga-PSMA, 68Ga-FAPi evaluated by Computer Tomography
6097|NCT04147481|Other|Group Abdominal Nerve Block with local anesthetics|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with 0.2% ropivacaine
6098|NCT04147481|Other|Group Abdominal Nerve Block with saline|surgical under general anesthesia combined with transversus abdominis plane block (TAPB) and/or rectus sheath block (RSB) with not 0.2% ropivacaine but 0.9% saline.
6099|NCT04147468|Other|Virtual Reality|For the VR intervention, we focus on using our developed VR gaming platform called Super Pop VR, a VR system that can be individualized to the movement capabilities of the participant. The research team will travel to the family to conduct the intervention to ensure the treatment adherence. The participants will be asked to move their arms to 'pop' as many virtual objects as possible.
6100|NCT04147468|Other|Functional Strength Training|For the functional strength training, participants will receive repetitive progressive resistance exercise during goal-directed functional activity with the participants focus on the activity being performed. The research team will also go to the family to conduct the FST intervention.
6101|NCT04147455|Behavioral|Adapted RealConsent|The program is a novel, theory-driven, evidence-based serial drama and educational program tailored to young men and delivered in six episodes via the web. Participants will view 6 30-minute modules designed to prevent sexual violence in young men
6102|NCT04147455|Behavioral|Health Education Control Condition|Participants will view 6 30-minute web-based serial drama modules designed to promote health.
6103|NCT04147442|Device|Hearing aid with standard program|A digital, wireless hearing aid that is programmed specifically to each subject's hearing loss and fine-tuned for their specific music playing.
6104|NCT04147442|Device|Hearing aid with fine-tuned program|A digital, wireless hearing aid that is programmed specifically to each subject's hearing loss and fine-tuned for their specific music playing.
6105|NCT04147429|Behavioral|Early Literacy Intervention|Similar to the standard Reach out and Read model, parents will be given a high-contrast board book, Cluck and Moo, and education about the importance of and how to engage with newborns in early shared reading behaviors. This will include instructive information for families about using books to stimulate newborns through pictures and spoken words.
6106|NCT04147416|Drug|HSK3486 0.1-0.2 /0.3 mg / kg group|Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
6107|NCT04147416|Drug|Propofol 0.5-1.0/1.5 mg/kg group|Administered with Propofol at a loading dose of 0.5-1.0mg/kg via intravenous pump. Then Propofol shall be administered immediately at an initial maintenance dose of 1.5 mg/kg/h respectively.
6108|NCT04147390|Drug|prescribe topical 0.03 % tacrolimus|prescribe topical 0.03 % tacrolimus 3 times a day for 12 months
6109|NCT04147390|Drug|prescribe mycophenolate mofetil(MMF)|MMF orally 1 g twice daily for the first 6 months and then 1 g daily for the next 6 months
6110|NCT04147377|Behavioral|behavioral intervention based on sensory cues|Patients will receive behavior intervention training that includes how to apply visual and auditory cues to freezing of gait in real clinical practice.
6111|NCT04147364|Other|no intervention|only retrospective reviews for medical records
6112|NCT04147351|Drug|Atezolizumab Injection; bevacizumab Injection|a PD-L1 inhibitor; anti-angiogenesis
6114|NCT04147325|Drug|Antiretroviral Therapy|ART will be administered chosen by the investigator according to country/ local standards/ guidelines/ available ARV for current treatment guidelines for rapid initiation.
6115|NCT04147312|Drug|Fufang E'Jiao Jiang|Fufang E'Jiao Jiang, 20milliliters(mL) once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
6116|NCT04147312|Drug|placebo containing low-dose fufang E'Jiao Jiang|placebo containing low-dose Fufang E'Jiao Jiang, 20mL once, 3 times a day, continuous intervention for 21 days each cycle, and use 2 cycles
6117|NCT04147286|Drug|Atorvastatin 40mg|12 weeks of 40 mg atorvastatin therapy per os
6118|NCT04147286|Drug|Placebo oral tablet|Identical placebo
6119|NCT04147273|Device|Determination of postprandial glucose response by continuous glucose measurement after consuming different carbohydrate containing foods|"One day prior to the study beginning, participants were equipped with a CGM system (FreeStyle Libre®, Abbott Diabetes Care, Alameda, CA, USA). This CGM system provides glucose recordings every 15 min over a period of 14 days. The glucose data were downloaded manually by a scan with a handheld device.~On the second day of the study, participants consumed portions of these three test products containing 50 g of available carbohydrate on 3 separate days without a washout period. The products were tested in random order at the same time of the morning after a 10 h overnight fast. Venous blood samples were collected at 0, 15, 30, 45, 60, 75, 90, 105 and 120 min postprandial by inserting an intravenous cannula into a forearm vein. Capillary blood samples were obtained through finger pricking. Blood glucose levels in these samples were measured with a high quality SMBG system (ContourXT/Contour next, Ascensia Diabetes Care, Leverkusen, Deutschland, Germany)."
6120|NCT04147260|Drug|BI 730357|Film-coated tablet
6121|NCT04147260|Drug|Placebo to match BI 730357|Film-coated tablet
6122|NCT04147260|Drug|Ciprofloxacin|Film-coated tablet
6123|NCT04147247|Drug|BI 905681|Infusion
6132|NCT04147182|Drug|Hypertonic Saline 3%|3% and 5% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, hypertonic solution for fluid and electrolyte replenishment in single dose containers for intravenous administration. The pH may have been adjusted with hydrochloric acid. It contains no antimicrobial agents.
6133|NCT04147169|Behavioral|Focused end-of-life conversations to promote connections among patients, family members and clinicians.|All eligible patients and families who were invited to participate in wish elicitation and implementation. For family interviews, criterion sampling was used. For the clinician focus groups, criterion sampling was used, based on involvement in the care of a 3WP patient. For the manager/hospital administrator interviews, purposive sampling was used, based on relevant leadership positions. Investigators employed qualitative and quantitative methods to collect and analyze data. Quantitative data include characteristics of patients, families and clinicians, questionnaire responses from families who agree to interviews, and clinicians who agree to focus groups, respectively, types of wishes elicited and implemented, and their cost. Qualitative data was obtained through individual family interviews, inter-professional clinician focus groups, project team field notes, additional ideas about the costs and benefits of the project from manager interviews, and analysis of project documents.
6134|NCT04147156|Procedure|Epley's Maneuver|Treatment with Epley's Maneuver in the ROTUNDUM-chair
6135|NCT04147156|Procedure|Semont Maneuver|Treatment with the Semont Maneuver in the ROTUNDUM-chair
6136|NCT04147156|Procedure|360 degree vertical rotation|Treatment with 360 degree vertical rotation in the ROTUNDUM-chair
6137|NCT04147143|Other|Documentation|Retrospective chart review of patients who have already completed treatment with cabozantinib after nivolumab or nivolumab plus ipilimumab before inclusion.
6138|NCT04147130|Other|MultiPAP Plus|Complex intervention incorporating previous MultiPAP intervention (based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient-centered clinical interview) And it adds a clinical-decision support system to help structured treatment-plan review.
6139|NCT04147130|Other|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
6140|NCT04147117|Device|Cervical pessary|Cervical pessary is a silicone ring with a smaller diameter to be fitted around the cervix and a larger diameter to fix the device to the pelvic floor. It modifies the direction of the cervix to the posterior vaginal wall.
6141|NCT04147104|Device|Low flow ECCO2R|"Treatment with a medical device called ECCO2R. The device consists of a drainage cannula placed in a large central vein, a membrane lung (artificial gas exchanger), and a return cannula into the venous system. Blood is pumped through the membrane lung, and CO2 is removed by diffusion. A flowing gas known as sweep gas containing little or no CO2 runs along the other side of the membrane, ensuring a diffusion gradient from blood to the other side, hence promoting CO2 removal."
6142|NCT04147104|Device|Invasive mechanical ventilation|Invasive mechanical ventilation deviceto support acute respiratory failure and facilitate exhalation via an endotracheal tube or tracheotomy.
6143|NCT04147091|Other|ApaCare & Repair|Initial cariuos lesions were treated.
6144|NCT04147078|Biological|DC vaccine subcutaneous administration|subcutaneous administration
6145|NCT04147065|Drug|Duration of eradication regimen|14 day eradication regimen
6146|NCT04147052|Behavioral|iSLEEPms|Participants randomized to iSLEEPms complete four weekly online modules through the study website. Modules are interactive and focus on typical elements of CBT-I, adapted for individuals with MS: education about sleep in MS, sleep restriction, and stimulus control; sleep hygiene and relaxation; and cognitive restructuring around sleep and coping with MS. Sleep diaries are reviewed each week by study personnel, and personalized feedback is provided to participants to guide treatment.
6147|NCT04147039|Behavioral|MINISTOP 2.0|The MINISTOP 2.0 is a behavioural change program aiming to promote healthier diet and physical activity among 2.5-year-old children. The program consists of features such as information, monitoring and feedback (dietary key variables, physical activity, screen time) and it is built around 12 themes during the 6-month period.
6148|NCT04147026|Device|SinnoTest®|"The selection of the biotherapy is carried out based on the recommendations of SinnoTest®. This test categorizes the bDMARDs based on the probability of response. It will allow to prescribe both original molecules, as well as biosimilars, in an equivalent way.~In the SinnoTest® arm, the investigator prescribes the treatment defined as the most effective by SinnoTest®, except in case of contraindication. If contraindicated, the investigator prescribes the second-choice treatment (if any) of SinnoTest® in terms of efficacy."
6149|NCT04147026|Other|Biotherapy prescription without SinnoTest® software|The rheumatologist will use the current guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient
6150|NCT04147013|Drug|Celecoxib|Patients will receive celecoxib 200 mg PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
6151|NCT04147013|Drug|Placebo|Patients will receive placebo PO BID for 7 days post endoscopic sinus surgery, starting on the evening of the day of surgery.
6152|NCT04146987|Procedure|Rotator cuff repair surgery|Patients will undergo open rotator cuff repair or arthroscopic rotator cuff repair
6153|NCT04146961|Device|Alcon PanOptix or PanOptix Toric IOL|Patients who previously underwent cataract surgery with the Alcon PanOptix or PanOptix Toric IOL in both eyes.
6154|NCT04146948|Other|no intervention|no intervention in this study
6155|NCT04146935|Drug|Burosumab Injection [Crysvita]|Burosumab/Crysvita SC injection monthly
6156|NCT04146922|Other|Step down to oral antimicrobial therapy|Step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
6157|NCT04146922|Other|IV antimicrobial therapy|No step down from intravenous to oral antimicrobial therapy to complete the intended course of treatment.
6158|NCT04146909|Diagnostic Test|Hyperinsulinemic-euglycemic clamp|After an overnight fast and an equilibration period lasting 2 hours, the 2-step euglycemic-hyperinsulinemic clamp study will be performed. A primed-continuous infusion of regular insulin will be given at 8 mU/(m2 × min) during the first 2 hours, and increased to 40 mU/(m2 × min) for the subsequent 2 hours. Plasma glucose levels will be measured every 5 min, and a variable glucose infusion will be initiated to maintain levels at ∼90 mg/dl. Plasma samples will be drawn at baseline and throughout the infusion period for measurement of isotope enrichment, insulin, NEFA, glycerol turnover, and additional hormones which may be altered with lactation. Approximately 160 mL of blood will be drawn at this visit.
6161|NCT04146883|Drug|Antibiotics|Post-procedural one-day iv cefazolin then 3-day prophylactic cephalexin
6162|NCT04146870|Other|not have|not have
6163|NCT04146857|Other|Normoxia|Nap in hypoxia chamber at 20.9% oxygen (36 m asl)
6164|NCT04146857|Other|Hypoxia 1|Nap in hypoxia chamber at 15.0% oxygen (simulates 2660 m asl)
6165|NCT04146857|Other|Hypoxia 2|Nap in hypoxia chamber at 12.8% oxygen (simulates 4000 m asl)
6166|NCT04146831|Drug|Sintilimab|Sintilimab: intravenous, 200mg, every 3 week. Course of treatment: Stop the treatment until clinical or radiographic progression occurs.
6167|NCT04146818|Behavioral|Adapted Tango Dancing|Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.
6168|NCT04146818|Behavioral|Control|Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
6169|NCT04146805|Drug|BLD-0409|For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
6170|NCT04146805|Drug|Control: Placebo|Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
6171|NCT04146792|Behavioral|body acceptance program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
6172|NCT04146792|Behavioral|writing creatively program|Complete 3 writing exercises over the course of week. Each writing exercise will take approximately 15 minutes to complete
6173|NCT04146779|Behavioral|Yoga Video|A guided practice that includes gentle stretching of the jaw, neck and shoulders. It lasts approximately 25 minutes.
6174|NCT04146779|Behavioral|Posture and Strengthening Video|The strengthening video directs patients through a sequence of isometric exercises to strengthen neck, shoulder and core muscles that are critical for good posture and musculoskeletal integrity. The patient may opt to do the strengthening exercises standing, sitting or with their back on the floor depending on their strength. The video lasts 20 minutes.
6175|NCT04146779|Behavioral|Relaxation Video|The relaxation video uses meditative techniques to quiet and calm the mind. The video lasts 15 minutes
6176|NCT04146779|Behavioral|Breath Work Video|The breath work video will guide patients through a series of abdominal and chest breathing exercises. The video lasts 15 minutes.
6177|NCT04146779|Behavioral|Satisfaction Survey|Participants will complete a questionnaire addressing satisfaction with the yoga program.
6178|NCT04146779|Behavioral|Guided Yoga Session|Instructor guided yoga session twice a week
6179|NCT04146779|Behavioral|Written Yoga Instructions|Introduction to Yoga and Yoga poses
6180|NCT04146766|Combination Product|eHealth|The study was randomized (wait-list-control), and it was estimated that 60 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the eHealth. After the first questionnaire evaluation, the experimental group was involved in the eHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the eHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month
6181|NCT04146740|Other|Structured Exercise for Experimental (Structured Exercise) Group|"Structured aerobic exercise regime of moderate intensity by using stationary cycle (3-5 MET) 10 min, brisk walk 10 min.~The combination of Stabilization exercise (10 repeatitions) and PFM training ( 20 repeatitions set).~Relaxation therapy including Mitchells physiological relaxation technique (10 repetitions) along with deep breathing exercises."
6182|NCT04146740|Behavioral|Control treatment for both groups|Medical and dietary interventions like insulin in addition of the postural education and back care from Physical Therapist.
6183|NCT04146714|Other|Substance use questionnaire|Screening questionnaire about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
6184|NCT04146714|Other|Physical activity questionnaire|Screening questionnaire about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
6185|NCT04146701|Other|Blood draw|venous blood withdraw (ca. 40ml)
6186|NCT04146688|Other|Music Balance Board|The SSM is measured with an innovative tool (Music Balance Board) developed at the University of Ghent (Belgium) and specially designed to record the movements of the elderly in a natural and comfortable position This chair is equipped with a tablet and sensors that record the movements of the hand and body during the SSM to a musical sequence. The analysis will focus on the difference between the participant's striking and the beat of the music measured using this chair.
6187|NCT04146675|Device|TRICOT JERSEY VANISE DOUBLE FACE|"Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis."
6188|NCT04146675|Device|TRICOT JERSEY SIMPLE|Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
6189|NCT04146662|Diagnostic Test|Faecal immunochemical test|Faecal immunochemical test (FIT) and urine volatile organic compounds (VOC) analysis.
6190|NCT04146649|Procedure|Arthrocentesis|Patients will receive a joint arthrocentesis to remove fluid from the joint.
6191|NCT04146636|Diagnostic Test|e-LIFT|Diagnostic procedure: elastography devices, blood tests (e-LIFT), liver biopsy if necessary (elstometry ≥ 8 kPa and < 15 kPa)
6192|NCT04146623|Biological|CodaVax-H1N1 influenza vaccine|CodaVax-H1N1, a live attenuated vaccine (LAIV) strain based on the A/California/07/2009 (H1N1) influenza virus, administered once intranasally via a sprayer at a dose of 8 x10^5 plaque forming units (PFU).
6193|NCT04146623|Biological|Normal Saline Placebo|Saline (0.9%) administered intranasally via sprayer
6194|NCT04146610|Drug|an antibody drug conjugate|Multiple dose grouping
6195|NCT04146597|Other|Neural mobilization|Neural mobilization (NM) is a physiotherapy method aimed at restoring the dynamic balance between the relative movement of neural tissues and surrounding mechanical interfaces, and different techniques are used for the treatment of various compression syndromes as well as other pain conditions, such as back and neck pain (Basson et al., 2017; Ellis and Hing, 2008). The main techniques used are neurodynamic sliders and neurodynamic tensioners, with the tensioning techniques being considered the more aggressive approach, in which the increase in nerve length occurs (Silva et al., 2014). The neurodynamic sliders techniques are gentle maneuvers as they involve nerve lengthening at one joint and simultaneous reduction in its length at an adjacent joint in order to produce sliding movements of neural structures relative to adjacent tissues (Efstathiou et al., 2015).
6196|NCT04146584|Device|Sofwave Treatments|The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.
6197|NCT04146571|Drug|Ensartinib|Oral, ALK inhibitor
6198|NCT04146558|Drug|Individualized internal ayurvedic treatment|"All possible internal preparations will be administered for a period of 12 months.~All administered preparations with its dosage and duration will be documented All preparations will be subjected to lab test for clearing heavy metal and pesticide content before the administration"
6199|NCT04146558|Other|External ayurvedic treatment|Application of warm external oil (Ayyapala kera tailam) on affected parts twice daily
6200|NCT04146545|Behavioral|Community Rx-Caregiver Resources|A tailored list of resources addressing health-related social needs (HRSN) for caregivers and access to an online community resource finder.
6201|NCT04146532|Drug|Aspirin 500 MG|Single 500mg aspirin capsule.
6202|NCT04146532|Drug|Placebo|Single 500mg placebo capsule.
6203|NCT04146519|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
6205|NCT04146493|Diagnostic Test|Blood samples for Heparin-binding protein measurement|Blood samples before and after given heparin
6206|NCT04146480|Diagnostic Test|F18-NaF PET/CT|"The scan will be performed on the Discovery 690 Nuclear Medicine Camera. On the day of the scan, the patient will be admitted to the Office of Nuclear Medicine and will be admitted to administrative. Prior to the scan, the subject will undergo a brief interview by a physician or nurse and a 22 G Prefill will be installed on him, through which a 5 millikiric (mCi) of 18 F-NaF will be injected.~4. An hour after the injection, the PET / CT scan, which will last about 10 minutes, during, the patient is required to lie down and breathe normally.~5. Upon completion of the scan, will be released without any restrictions."
6207|NCT04146467|Device|Apyx Plasma/RF Device|The Apyx Plasma/RF Handpiece is a sterile, single use electrosurgical (monopolar) device intended to be used in conjunction with compatible generators for the percutaneous delivery of radiofrequency energy and/or helium plasma for cutting, coagulation and ablation of soft tissue. Radiofrequency energy is delivered to the handpiece by the generator and used to energize the electrode. When helium gas is passed over the energized electrode, a helium plasma is generated for soft tissue cutting, coagulation or ablation. The Apyx Plasma/RF Handpiece has a non-extendable electrode to generate helium plasma.
6208|NCT04146454|Other|Smartphone-based balance exercises|A smartphone-based wearable telerehabilitation system will provide video and audio instructions on how to perform in-home dynamic weight-shifting balance exercises (i.e., physical therapists' recommended dynamic balance exercises).
6209|NCT04146441|Combination Product|SonoVue|1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
6210|NCT04146441|Drug|Chemotherapy|FOLFIRINOX Regime according to Norwegian national guidelines
6211|NCT04146428|Behavioral|clinician-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the clinician/therapist.
6212|NCT04146428|Behavioral|parent-mediated JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child. The adult referred in this condition is the parent.
6213|NCT04146415|Diagnostic Test|Spect scan with mTc99-PYP|. About forty-five minutes after the injection mTc99-PYP , flanner and SPECT-CT mappings will be performed and then the patient will move to the CZT camera and undergo another photograph.
6214|NCT04146402|Drug|SCT-I10A+chemo|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
6215|NCT04146402|Drug|Placebos+chemo|Placebo, 200 mg intravenous (IV) on Day 1 of each 3-week cycle Standard chemotherapy: Cisplatin+5-FU
6216|NCT04146376|Other|Use of a postpartum diary and additional blood draws|"A diary will be used to capture postpartum hemorrhage (PPH), Wilate and tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
6217|NCT04146376|Drug|VWF replacement therapy with Wilate|This study design uses on-label Wilate for VWF replacement therapy for delivery and the postpartum period in VWD patients whose VWF levels are <100% in the third trimester of pregnancy
6218|NCT04146376|Drug|Tranexamic acid|This study design uses tranexamic acid for prophylaxis for postpartum hemorrhage for all women with VWD
6219|NCT04146376|Other|Use of a postpartum diary and additional blood draws.|"A diary will be used to capture postpartum hemorrhage (PPH), tranexamic acid use, other drug use, bleeding episodes, and treatment schedules.~Several blood draws additional to what is expected for routine clinical care will also be taken."
6220|NCT04146363|Biological|Lebrikizumab|Subcutaneous injection
6221|NCT04146363|Other|Placebo|Subcutaneous Injection
6222|NCT04146350|Procedure|PPV+/-Cat|pars plana vitrectomy+/-cataract
6223|NCT04146350|Procedure|PPV+/-Cat+Gas|pars plana vitrectomy+/-cataract+gas tamponade
6224|NCT04146350|Procedure|PPV+ILM+/-Cat+/-Gas|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-gas tamponade
6225|NCT04146350|Procedure|PPV+ILM+/-Cat+/-Oil|pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade
6226|NCT04146350|Procedure|PSR|posterior scleral reinforcement
6227|NCT04146350|Procedure|PSR+ PPV+ILM+/-Cat+/-Oil （or Gas）|posterior scleral reinforcement+pars plana vitrectomy+internal limiting membrane peeling+/-cataract+/-silicone oil tamponade (or gas)
6228|NCT04146350|Procedure|Gas|gas tamponade alone
6229|NCT04146337|Biological|FMT|Fecal microbiota in frozen capsules
6230|NCT04146324|Drug|nivolumab|Administered as adjuvant therapy as per the market authorization in Australia
6231|NCT04146311|Drug|Hypertonic saline|A bolus injection (0.25 ml) of hypertonic saline (5%) into the left infrapatellar fat pad.
6232|NCT04146311|Drug|isotonic saline|A bolus injection (0.25 ml) of isotonic saline (5%) into the left infrapatellar fat pad.
6233|NCT04146311|Other|Motor training|All the subjects recruited need to have a short-term motor task training at home. 30 times a session, totally 2 sessions a day for 6 days
6234|NCT04146298|Drug|Cyclophosphamide|Cyclophosphamide will be administered prior to cell infusion.
6235|NCT04146298|Drug|Fludarabine|Fludarabine will be administered prior to cell infusion.
6236|NCT04146298|Biological|Mutant KRAS G12V-specific TCR transduced autologous T cells|After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.
6237|NCT04146298|Drug|Anti-PD-1 monoclonal antibody|During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
6238|NCT04146285|Drug|BAT4406F|"Open-label dose escalation starting from 20mg.~Route of administration: intravenous infusion."
6239|NCT04146272|Device|Hearing Aid Mermaid|The current hearing aid used to treat hearing loss.
6240|NCT04146272|Device|Hearing Aid Mermaid 2|The new hearing aid used to treat hearing loss with an upgraded feedback cancellation system.
6241|NCT04146272|Device|Current Power Hearing Aid|The current power hearing aid used to treat strong hearing loss.
6242|NCT04146272|Device|New Power Hearing Aid|The new power hearing aid used to treat strong hearing loss with an upgraded feedback cancellation system.
6243|NCT04146259|Drug|calcium carbonate and alphacalcidol|treatment for hypocalcemia
6244|NCT04146246|Diagnostic Test|G6PD assay|A test for G6PD deficiency.
6245|NCT04146233|Other|Point of care gastric ultrasound|Point-of-care gastric ultrasound will be performed using a low-frequency curvilinear ultrasound probe to assess stomach contents (empty vs. not empty, liquid vs. solid, gastric volume).
6246|NCT04146220|Drug|Prednisolone|Patients of the low and the high dose groups recieved prednisolone in different dose for initial 4 weeks, then tapered gradually. Both groups received pulse I/V methylprednisolone 500 mg/day daily for initial 3 days and monthly cyclophosphamide infusion 750-1000 mg/m2 body surface area.
6247|NCT04146207|Drug|SHR0302|SHR0302 po QD
6248|NCT04146207|Drug|Prednisone|Prednisone 1mg/kg/d po
6249|NCT04146194|Other|None. This is a non-interventional observational study.|None. This is a non-interventional observational study.
6250|NCT04146181|Drug|PD-1|SCT-I10A, 200 mg intravenous (IV) on Day 1 of each 3-week cycle.
6251|NCT04146168|Diagnostic Test|Ultrasound|Closure of previously treated veins (with Venaseal) will be assessed via ultrasound.
6252|NCT04146155|Drug|Liraglutide+standard-of-care treatment|"Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.~Liraglutide is added to existing standard-of-care treatment containing one or more oral anti-hyperglycemic agents or insulin or a combination of these agents with the exception of other incretin and SGLT2i therapies in accordance with local clinical practice guidelines."
6253|NCT04146155|Other|standard-of-care treatment|Standard-of-care treatment including: metformin should be given as the first line therapy as long as it is tolerated and not contraindicated; other agents, including sulfonylureas or glucosidase inhibitor or insulin, should be added to metformin .Glycemic control will be managed by the investigators in accordance with local clinical practice guidelines by the adjustment of concomitant glucose-lowering agents or the addition of new antidiabetic medications with the exception of incretin and SGLT2i therapies. This approach expect to yield similar glycemic control in the two study groups.
6254|NCT04146142|Procedure|Transperineal prostate biopsy with or without antibiotic prophylaxis|As described above.
6255|NCT04146129|Drug|CDX-0159|Single dose of one of four dosages of CDX-0159
6256|NCT04146129|Drug|Normal saline|Single infusion of normal saline
6257|NCT04146116|Drug|intranasal povidone-iodine|povidone-iodine USP, 10% w/w antiseptic
6258|NCT04146103|Drug|Novex|Novex® made of Pumpkin Seed Extract 550mg, Soy Germ Isoflavonoids 50 mg and Cranberry 50mg. The dose is 2 tablets/day taken orally.
6259|NCT04146090|Other|Low-pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 10 mmHg
6260|NCT04146090|Other|Standard pressure pneumoperitoneum|Pneumoperitoneum will be maintained in 14 mmHg
6261|NCT04146064|Other|Breathprint analysis and patient-reported outcomes|"Breathprint analysis: Patients will be providing breathprint samples into the eNose device at baseline and every 12 weeks thereafter as long as on immunotherapy treatment.~Questionnaires will be completed at the same timepoints."
6262|NCT04146051|Drug|Descartes-08|Autogolous T-cells expressing a chimeric antigen receptor directed to BCMA
6328|NCT04145440|Drug|MOR202|9 doses of MOR202 will be administered as an intravenous infusion at 16 mg/kg over 6 treatment cycles at 28-days each, weekly in C1 and every 4 weeks C2-6.
6373|NCT04145076|Drug|Tianeptine|Single oral dose of tianeptine (12.5mg) and single oral dose of placebo.
6374|NCT04145063|Other|no stent|following uretroscopy, no stent will be placed
6267|NCT04146025|Behavioral|Nature Coach Intervention|"Home visit. During the 1-hour home visit, the coach will (a) provide education about the health benefits of nature, (b) identify nearby nature targets for the participant to visit, (c) complete a pre-commitment contract based on individualized weekly nature goals, and (d) brainstorm barriers and solutions to reaching the goals.~Personalized weekly text messages. Texts will serve as reminders of goals set with the Nature Coach, as well as encouragement to meet the goals. The context of text messages with change slightly based on individual participants, the goals they set, and the barriers they identify.~Goal feedback- At the end of each week, participants will receive a progression badge via text message that shows the amount of days and time they spent in nature, and how this matched up to the goal set with the Nature Coach."
6268|NCT04146012|Device|Artegraft® Collagen Vascular Graft™ (Artegraft)|The Artegraft is intended for use distal to the aorta as a segmental arterial replacement, as an arterial bypass, as an arteriovenous shunt where more conventional methods have proven inadequate, or as an arterial patch graft.
6269|NCT04145999|Procedure|PRP application|The study participant will receive topical anesthesia with lidocaine ointment (50mg/g). After 5 minutes the face will be cleaned with 0.5% alcohol chlorhexidine solution. The newly obtained platelet-rich plasma activated with 10% calcium chloride packed in a 5mL syringe will be applied to the face using a 30G needle in the frontal, lateral periorbital, nasogenian sulcus, bilateral malar region and an infra-auricular point. 0.1ml per cm2 will be injected, totaling 43 points. Only one application of PRP will be performed at the defined points.
6270|NCT04145999|Other|Placebo PRP application|Blood collection will be performed normally, the time between collection and application of saline will be the same as the PRP protocol, but in this case, the blood will be discarded, only a sample to quantify the number of platelets will be sent for analysis.
6271|NCT04145999|Radiation|Photobiomodulation|Photobiomodulation will be applied with a Cosmedical LED face mask (São Paulo, Brazil) containing 92 red LEDs. The applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP or placebo.
6272|NCT04145999|Other|Placebo Photobiomodulation|Participants will not be aware of whether or not they have received the PBM application as they will be using eye protection and the researcher will position the equipment at the irradiation locations on all participants. The characteristic sound of the device will be triggered by recording in the placebos groups for the PBM. The placebo applications will occur in the experimental periods of 0, 3, 7, 14, 21 and 28 days after the application of PRP.
6273|NCT04145934|Behavioral|ADSTEP|ADSTEP is a training program of six weekly one-on-one sessions with a physical therapist intended to reduce falls among people who use a hand-held walking aid, such as a cane or a walker. ADSTEP focuses on training in the use of the walking aid, and includes gait evaluation, walking aid selection and fitting, and progressive task-oriented training with the walking aid.
6274|NCT04145921|Procedure|ERAS for MIS-THA|enhanced recovery after surgery (ERAS) pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
6275|NCT04145921|Procedure|conventional MIS-THA|conventional pathway for minimally-invasive surgery of total hip arthroplasty (MIS-THA)
6276|NCT04145908|Procedure|midline mesh reinforcement|augmentation of midline closure by nonabsorbsble mesh
6277|NCT04145895|Other|Postoperative activity restrictions|Recommendations for return to full activity including return to school, sports, exercise, etc.
6278|NCT04145882|Procedure|additional osteotomies|varisation osteotomy, supination osteotomy or both
6279|NCT04145869|Procedure|Cholangiography|All patients will be subjected to intraoperative fluorescent and concommitant X-ray cholangiography
6280|NCT04145856|Dietary Supplement|I31 probiotic|I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
6281|NCT04145856|Combination Product|I31 probiotic combined to Alverine/Simethicone|"I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)~Antispasmodic/antifoam drug, consisting of Alverine Citrate 60 mg and Simethicone 300 mg, thrice daily (t.i.d)"
6282|NCT04145856|Other|Placebo|Placebo treatment (maltodextrin), once daily (u.i.d)
6283|NCT04145843|Procedure|endoscopic retrograde cholangiopancreatography|ERCP is a procedure that enables the physician to examine the pancreatic and bile ducts and remove gallstones.
6284|NCT04145830|Device|Ultrasound Cyclo Plasty (UCP)|Cyclocoagulation using High Intensity Focused Ultrasound
6285|NCT04145817|Genetic|BRIDGES gene panel testing|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
6286|NCT04145817|Genetic|Breast cancer risk polygenic risk score (PRS)|"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."
6287|NCT04145817|Behavioral|Questionnaires|Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,
6288|NCT04145804|Device|Medtronic Minimed 670G insulin pump|It is an insulin pump to deliver insulin to the patient and associated with a sensor to monitor the glucose levels of the patient. The new feature in this device is the automode algorithm which regulates insulin delivery to the patient automatically to keep glucose levels within target.
6289|NCT04145791|Other|Ice|ice packs
6290|NCT04145778|Other|non interventionnal study|non interventionnal study
6291|NCT04145765|Other|correlation|the subjects completed the questionnaires
6292|NCT04145752|Procedure|Nurse-led femoral nerve block|The nurse perform a femoral nerve block in the emergency department in patients diagnosed with a hip fracture (x-ray)
6370|NCT04145089|Device|Glidescope video laryngoscopy/ C-MAC video laryngoscopy|usage of said devices according to manual
6371|NCT04145076|Drug|Placebo|Two oral doses of placebo.
6372|NCT04145076|Drug|Citalopram|Single oral dose of citalopram (20mg) and single oral dose of placebo.
6293|NCT04145739|Other|Rehabilitation protocol|The rehabilitation treatment was performer in single session, lasted 60 minutes for session, 2 times a week, carried-out a 6-week exercises program for a total of 12 sessions, by a physiotherapist trained in oncologic rehabilitation, who started with a first phase of at least 15-20 min of low-impact aerobics warm-up. The second phase consisted in diaphragmatic breathing and postural exercises for the midline alignment in a supine position. Finally the patient continued in front of the mirror with exercises for the recovery of shoulder joint, isometric reinforcement exercises for the recovery of strength of shoulder stabilizer muscles. In the presence of lymphedema an additional weekly lymph drainage session was performed for a total of 10 sessions.
6294|NCT04145713|Dietary Supplement|Probiotic mixture|The experimental intervention will consist in administrating a high-dose multi-strain probiotic (SIVOMIXXTM) for 30 days in addition to hypothermic therapy. The administration of probiotics will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
6295|NCT04145713|Other|Placebo|The comparison intervention will consist in administrating placebo for 30 days in addition to hypothermic therapy. The administration of placebo will begin during the first 24 hours of hypothermia, at the dose of 1 capsule open in 5 millilitre of water. It will be administered daily for 30 days, either via nasogastric tube or orally.
6296|NCT04145700|Drug|Ramucirumab|Ramucirumab given IV
6297|NCT04145700|Drug|Gemcitabine|Gemcitabine given IV
6298|NCT04145700|Drug|Docetaxel|Docetaxel given IV
6299|NCT04145687|Drug|Metformin|Metformin 500mg tid
6300|NCT04145674|Drug|d-Dextromethadone (REL-1017 )|Patients will take a total of 2 capsules (one capsule from each bottle of the kit), once daily at 6 pm over a period of 10 days
6301|NCT04145674|Other|Placebo|Patients will take a total of 2 capsules (one capsule from each bottle of the kit), once daily at 6 pm over a period of 10 days
6302|NCT04145661|Device|Hearing aids programmed conventionally.|All participants will wear their hearing aids programmed in this way for around six weeks.
6303|NCT04145661|Device|Hearing aids programmed with compression activated.|All participants will wear their hearing aids programmed in this way for around six weeks.
6304|NCT04145648|Device|a wearable adhesive cardiac monitoring device|A wearable adhesive cardiac monitoring device that provides continuous cardiac rhythm monitoring
6305|NCT04145635|Device|Aortix System|Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) with worsening renal function.
6306|NCT04145622|Drug|DS-7300a|A total anti-B7H3 antibody and MAAA-1181a
6307|NCT04145609|Behavioral|Multidisciplinary team (MDT) care and Acute kidney disease (AKD) clinic|Multidisciplinary team (MDT) care: NPDS care model Acute kidney disease (AKD) clinic: layered approach
6308|NCT04145596|Drug|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
6309|NCT04145583|Drug|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
6310|NCT04145583|Drug|voriconazole +HSK3486|Sequence 2: voriconazole：Day 1,400mg，BID；Day 2--Day 6,200mg，BID；200 mg of voriconazole were taken orally in the morning on an empty stomach of Day 7; followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
6311|NCT04145570|Drug|Erlotinib HCl 150 mg|"Concentrations of erlotinib were measured from the samples collected over a 72 hour interval after receiving either Erotinib generic or Tarceva original. Later, after 14 days, a crossover was took place with the same measures.~dosing in each period."
6312|NCT04145570|Drug|Tarceva®|Tarceva® 150 mg
6313|NCT04145557|Device|diode laser 980nm|Procedure: Periodontal therapy with laser Scaling, root planning, oral hygiene instruction and diode laser 980nm treatment of periodontal pockets
6314|NCT04145557|Device|scaling root planing|scaling and root planing
6315|NCT04145544|Device|Implantation of the ArtiFascia®|"Following are the general instructions for use for the ArtiFascia®:~Cut the ArtiFascia® to the required shape under aseptic conditions~Apply ArtiFascia® to the damaged area~Suture the ArtiFascia® in place~Suture bites should be taken 2-3 millimeters from the edges of the implant. Either a running suture or interrupted stitches' technique may be used, depending on clinical conditions or surgeon's decision.~Important Note: If clinically possible, do not use dural adhesive or sealants as it is an uncontrolled variable, that can influence the results."
6316|NCT04145544|Device|Implantation of other commercial dural substitute|Implantation of the commercial dural substitute will be according to clinical discretion of the physician, and in compliance with each specific device instructions for use. Detailed instructions are in the instructions for use
6317|NCT04145531|Drug|IM JZP-458|IM JZP-458 will be administered in Part A, Cohorts 1 & 2
6318|NCT04145531|Drug|IV JZP-458|IV JZP-458 will be administered in Part B
6319|NCT04145518|Drug|Naproxen Sodium|Participants will be randomized to take either a placebo pill or a single 550 mg naproxen sodium pill.
6320|NCT04145505|Procedure|COLORECTAL CANCER SURGERY|SENTINEL NODE DETECTION
6321|NCT04145492|Drug|Vitamin K2|Patients will take 90 ug of vitamin K2
6322|NCT04145492|Drug|Cholecalciferol (inactive vitamin D)|Patients will take 10 ug of vitamin inactive vitamin D
6323|NCT04145492|Drug|Vitamin K2 and Cholecalciferol|Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D
6324|NCT04145479|Behavioral|physical activity|exercise
6325|NCT04145466|Behavioral|High-fat diet|"The high-fat diet will consist of ~40% energy from fat and ~45% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
6326|NCT04145466|Behavioral|High-carbohydrate diet|"The high-carbohydrate diet will consist of ~20% of energy from fat and ~65% from carbohydrates. Protein will be 15% of energy.~All participants will be assigned an energy intake target that will result in a daily deficit of ~750 kcal, though no energy intake targets below 1,100 kcal/d (women) and 1,300 kcal/day (men) will be prescribed"
6327|NCT04145453|Behavioral|Intervention|Participants will receine general nutritional recommendations to increase fruit and vegetables consumption
6329|NCT04145427|Behavioral|Control|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
6330|NCT04145427|Behavioral|LCD|"Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management."
6331|NCT04145414|Device|MRI|Reproductiblitity test assessed with MRI for cerebrospinal fluid movements
6332|NCT04145401|Device|Revision Knee implants|Primary knee arthroplasty or a revision knee that requires a revision procedure.
6333|NCT04145388|Other|online cancer risk assessment|Electronic surveys to collect family cancer history information.
6334|NCT04145388|Other|Usual care|Family cancer history captured by provider during a clinical encounter
6335|NCT04145375|Drug|ZEN003694|Up to 120mg
6336|NCT04145375|Drug|Enzalutamide|160mg
6337|NCT04145349|Drug|Ramucirumab|Administered IV
6338|NCT04145349|Drug|Cyclophosphamide|Administered orally
6339|NCT04145349|Drug|Vinorelbine|Administered IV
6340|NCT04145336|Device|5cm 5-Fr PDS|High-risk patients receive 5cm 5-Fr PDS
6341|NCT04145336|Device|7cm 5-Fr PDS|High-risk patients receive 7cm 5-Fr PDS
6342|NCT04145336|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
6343|NCT04145323|Diagnostic Test|ICG microangiography|Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.
6344|NCT04145310|Drug|BOL-DP-o-04 + SCO|sublingual drops
6345|NCT04145310|Drug|Placebo + SCO|sublingual drops
6346|NCT04145297|Drug|Ulixertinib|"Ulixertinib will be provided as 150 mg capsules and will be self-administered twice daily by mouth at the assigned dose level.~Ulixertinib Dose Level 0 300 mg PO BID, Dose Level 1 (starting dose) 450 mg PO BID, Dose Level 2 600 mg PO BID,~Medication will be administered in 28-day cycles"
6347|NCT04145297|Drug|Hydroxychloroquine|Hydroxychloroquine will be provided as 200 mg tablets and will be self-administered by mouth twice daily. Fixed Dose 600mg POBID. Medication will be administered in 28-day cycles
6348|NCT04145271|Device|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA)|Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) is a minimally invasive damage control procedure for life-threatening abdominal and/or pelvic haemorrhage. It involves temporary occlusion of the aorta with an endovascular balloon, providing proximal control to the site of vascular injury whilst supporting cerebral and myocardial perfusion
6349|NCT04145258|Drug|Aspirin|Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
6350|NCT04145258|Drug|Placebo of aspirin|Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)
6351|NCT04145258|Drug|WHO TBM treatment|2 months of (R-H-Z-E) + 7 months of (R-H)
6352|NCT04145258|Drug|Intensified TBM treatment|2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid
6353|NCT04145245|Drug|Levocarnitine|Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks
6354|NCT04145232|Biological|Collection of biopsy (FFPE), blood (PBMC) and stool|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
6355|NCT04145219|Biological|Sublingual allergy immunotherapy tablet|For daily administration (1 tablet per day)
6356|NCT04145219|Other|Placebo|For daily administration (1 tablet per day)
6357|NCT04145206|Behavioral|Flamenco dance|evaluation of ankle injuries in the flamenco dancers
6358|NCT04145193|Drug|Standard of Care - mFOLFOX6|Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).
6359|NCT04145193|Drug|E1 - mFOLFOX and durvalumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle)"
6360|NCT04145193|Drug|E2 - mFOLFOX6, durvalumab and oleclumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Oleclumab 3,000 mg IV Q2W x5 then Q4W (Day 1 of every 14-day cycle through cycle 4 then Day 1 of every other 14-day cycle)"
6361|NCT04145193|Drug|E3 - mFOLFOX6, durvalumab and monalizumab|"Parts of mFOLFOX6 are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 400 mg/m2 IV bolus on Day 1 then 2,400 mg/m2 over 46 to 48 hours IV infusion Q2W (Day 1-2 of every 14-day cycle).~Durvalumab 1500 mg IV, Q4W (Day 1 of every other 14-day cycle) Monalizumab 750 mg IV, Q2W (Day 1 of every 14-day cycle)"
6362|NCT04145180|Other|Manual therapy|40 minutes of physiotherapy, based on manual therapy sessions over 6 weeks. Three times a week.
6363|NCT04145154|Other|Application of platelet rich plasma in chronic wounds of diabetic origin|Application of plasma rich in autologous growht factors after advanced healing
6364|NCT04145128|Drug|AG881|AG-881 tablets.
6365|NCT04145115|Biological|Ipilimumab|Given IV
6366|NCT04145115|Biological|Nivolumab|Given IV
6367|NCT04145102|Other|hesperidine|used for antibacterial and reminerlization assesment
6368|NCT04145102|Other|propolis|used for antibacterial and reminerlization assesment
6369|NCT04145102|Other|silver diamine fluoride|used for antibacterial and reminerlization assesment
6414|NCT04144673|Other|Placebo|Placebo water with no active ingredients
6375|NCT04145050|Other|Carbohydrate dosing|The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
6376|NCT04145037|Drug|AVR-RD-02|AVR-RD-02 Drug product, ( autologous CD34+ enriched hematopoietic stem cells ( HSCs) that have been genetically modified
6377|NCT04145011|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe (18g, 4mm active tip)
6378|NCT04145011|Device|Standard Radiofrequency|Delivery of energy to ablate sensory nerves via non-cooled standard radiofrequency probe (22g, curved 10mm active tip)
6379|NCT04144998|Diagnostic Test|central sensitization inventory (questionnaire)|T.G. Mayer, R. Neblett, H. Cohen, et al. The development and psychometric validation of the central sensitization inventory Pain Pract, 12 (2012), pp. 276-285
6380|NCT04144985|Other|Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.|Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
6381|NCT04144972|Device|Medtronic Summit RC+S|The investigators will perform DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. Closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion after initial, efficacy evaluation.
6382|NCT04144959|Device|Indigo Aspiration System|Indigo Aspiration System
6383|NCT04144933|Drug|Acetaminophen, Gabapentin|975 mg, 300 mg
6384|NCT04144933|Drug|Acetaminophen, Gabapentin|975 mg, 300 mg
6385|NCT04144933|Drug|Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine|1.5 mg/kg, 0.5 mcg/kg, 0.5 mg/kg
6386|NCT04144933|Drug|Dexamethasone, Ondansetron|6 mg, 4 mg
6387|NCT04144933|Drug|Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate|Dose titrated to effect, 1.5 mg/kg/hr, 0.15 mg/kg/hr, 0.3 -1 mcg/kg/hr (titrated to effect), 30 mg/kg bolus over 30 minutes
6388|NCT04144933|Drug|Lidocaine 1% Injectable Solution, Sufentanil|0.5 mg/kg, 0.25-0.5 mcg/kg (titrated to effect)
6389|NCT04144933|Drug|Sevoflurane, Sufentanil|Dose titrated to effect, As needed (dose at anesthesiologist's discretion)
6390|NCT04144920|Behavioral|CS: Continuous sitting|Participants were asked to sit continuously throughout the duration of the lab visit.
6391|NCT04144920|Behavioral|HFLD: HIgh frequency, low duration standing breaks|Participants were asked to interrupt their sitting time every 15 minutes using 2.5-minute standing breaks.
6392|NCT04144920|Behavioral|LFHD: Low frequency, high duration standing breaks|Participants were asked to interrupt their sitting time every 60 minutes using 10-minute standing breaks.
6393|NCT04144907|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein-free cookies and 4 labeled amino acid experimental meals.
6394|NCT04144894|Diagnostic Test|Shear Wave Elastography|Advanced ultrasound technique
6395|NCT04144881|Diagnostic Test|coronary computed tomography|patients randomized in this arm will perform computed coronary tomography 6 months after the index percutaneous revascularization on unprotected left main artery
6396|NCT04144868|Other|Normobaric Oxygen|
6397|NCT04144855|Drug|TQB3474 injection|This is a kind of heat shock protein (HSP90) inhibitor.
6398|NCT04144842|Biological|ATOR-1017|ATOR-1017 is a human monoclonal antibody targeting 4-1BB (CD137)
6399|NCT04144829|Procedure|HIFU|Intravaginal HIFU procedure, lengths 1.5, 3 and 4.5 mm - 200, 200 and 100 impulses respectively
6400|NCT04144829|Procedure|Fibrin|Injection of 2ml platelet-rich fibrin from centrifuged for 5 min patient's blood under the urethra
6401|NCT04144816|Other|Not applicable (no intervention)|Not applicable (no intervention)
6402|NCT04144803|Diagnostic Test|Cerebral near-infrared spectroscopy|Nonin H500 one-channel near-infrared spectroscopy monitor on forehead of the patient from before induction of anesthesia to arrival to hospital
6403|NCT04144790|Dietary Supplement|ferrous sulfate|Although established guidelines do not currently exist for iron supplementation for children, studies have demonstrated effectiveness of a 3-month treatment regimen of 5mg/kg per day of orally-administered ferrous sulfate in reducing PLMS and subjective RLS symptoms and in increasing serum ferritin levels. Ferrous sulfate 80 mg/day resulted in improvement of ADHD symptoms in iron-deficient children.
6404|NCT04144777|Dietary Supplement|Solarplast|Subjects will take one capsule of Solarplast (100mg) daily for 45 days.
6405|NCT04144764|Other|Workplace-based exercise|Participants will have to perform 10-week of workplace-based exercise programme which consist of 5 sessions of 10 minutes per week. The workplace-based exercise programme will consist of general stretching and strengthening exercise using resistance tubing for both the neck and upper limb. Specific rotator cuff and scapular muscles strengthening exercise were also included to enhance glenohumeral and scapular kinematics (Appendix). Each participant will receive a set of elastic resistance tubing that comprise red (2kg), green (3kg) and blue (4kg). The exercise programme will be taught by physiotherapist during their baseline assessment. They will be asked to train at the workplace during workdays (Monday to Friday), five times a week during the 10-week intervention. The program built on the principle of progressive overload.
6406|NCT04144764|Other|Ergonomic advice and education|Participants will receive ergonomic training and education on how to adjust their workstations to reduce the ergonomic risk factors when using computers.
6407|NCT04144751|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
6408|NCT04144738|Diagnostic Test|mt-sDNA 2.0 screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
6409|NCT04144738|Diagnostic Test|FIT test|Stool samples will be collected by the subject for the FIT test.
6410|NCT04144738|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
6411|NCT04144712|Drug|Caffeine Citrate|study rate of occurrence of Apnea of Prematurity between the 2 groups
6412|NCT04144686|Other|Physiotherapy Rehabilitation|Participants will be randomly allocated, using a random number generator, to a 12-week supervised customised exercise group incorporating VRT programme without (Group A) or with cognitive DT exercises (Group B).
6413|NCT04144673|Other|Silver Hydrosol|Silver quantity will be 7 doses per day, with 50 mcg per dose.
6415|NCT04144660|Device|Extracorporeal Membrane Oxygenation|Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
6416|NCT04144647|Other|Single testing session|"All participants that meet the inclusion criteria, will have to attend the research laboratory at Centre for Human and Applied Physiological Sciences, Shepherd's House, Guy's Campus, King's College London, SE1 1UL to be assessed in a single testing session.~The testing session will require them to complete some questionnaires regarding balance confidence, psychological state, sleep and physical function and to undertake some simple tests of cognitive function. They will also undertake a brief dynamic balance assessment and the dual-task gait test. The dual-task component involves two cognitive tasks (a numeracy and a literacy task) or auditory task. The gait test will be performed separately and then together with each of two cognitive tasks or auditory task.~On the day, after the testing, each participant will, also, be provided a physical activity monitor (accelerometer-AX3) to wear on their wrist for 24 hours a day, seven days a week without taking it off."
6417|NCT04144634|Other|Strengthening exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of progressive resistance training based around the movement of standing up/sitting down.
6418|NCT04144634|Other|Stretching exercises|The intervention group will receive 2 supervised exercise sessions a day. The exercise consists of gentle stretching of upper limbs and lower limbs.
6419|NCT04144621|Procedure|ICSI|Intracytoplasmic sperm injection of female partner oocytes with ejaculated sperm selected by density gradient centrifugation
6420|NCT04144608|Drug|treprilumab combination with platinum-containing dual-drug chemotherapy|Nab-paclitaxel/pem +cisplatin +PD-1(Nab-paclitaxel260mg/m2 D1 Cisplatin 75mg/m2 D1 or carboplatin,determined by the investigator AUC)PD-1 200mg D1
6421|NCT04144595|Diagnostic Test|2 hour 75 g Oral glucose tolerance test|In pregnant women between 24 and 34 weeks of gestational age, plasma glucose was recorded after an overnight fast. Following consumption of 75 g glucose in 200 mL water over 10 min, the equivalent 1 hour and 2 hour values was recorded
6422|NCT04144582|Drug|Sintilimab Combined With Docetaxel Monotherapy|Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
6423|NCT04144569|Drug|PD-1 Combined With Pyrotinib|PD-1 Combined With Pyrotinib
6424|NCT04144556|Other|Nintendo Wii and conventional physical therapy|"This group of patients will receive, in addition to the exercise program described below, a virtual rehabilitation program through Nintendo Wii. This program will include upper limb training and lower limb balance training. Participants will choose the games they want to perform the session with. Wii Fit (balance games) will be used for the treatment of the lower limbs, and Wii Sports (bowling, golf and tennis games) will be used for the treatment of the upper limbs."
6425|NCT04144556|Other|Conventional Physical therapy|A warm-up period using a stationary bicycle, mobility exercises in supine position, active-assisted/passive kinesiotherapy of the lower and upper limbs, strengthening exercises in sitting position, balance, stability and coordination exercises and walking re-education exercises.
6426|NCT04144543|Other|White Noise|The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. The baby was exposed to white noise for 2 minutes before the procedure.
6427|NCT04144543|Other|Facilitated Tucking|The baby's arms and legs were held in flexed positions close to the midline of the torso in sidelying position, so the baby was able to move his/her extremities. The baby was held in facilitated tucking position for one minute before the procedure.
6428|NCT04144543|Other|White Noise+Facilitated Tucking|The baby was exposed to white noise for 1 minute before the procedure. The white noise was initiated 50 cm away from the baby, with the decibel meter set to an average of 55 decibels. At the second minute, when the white noise still continued to play, facilitated tucking was performed at the same time and the baby continued to listen to the white noise for 1 minute while in facilitated tucking position.
6429|NCT04144517|Drug|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
6430|NCT04144517|Drug|Pembrolizumab|IV infusion over 30 minutes administered on Day 1 of each cycle
6431|NCT04144504|Device|Retrievable metallic stenting|Use of retrievable metallic stents for the treatment of biliary anastomotic stricture after liver transplantation
6432|NCT04144504|Device|Plastic stenting|Use of plastic stents
6433|NCT04144491|Dietary Supplement|Probiotic|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug.~100ml of yoghurt containing Lactobacillus rhamnosus yoba 2012 will be consumed 5 days per week, for 9 weeks."
6434|NCT04144491|Dietary Supplement|Placebo|100ml of custard will be consumed 5 days per week, for 9 weeks.
6435|NCT04144478|Other|Web based education|Web based education
6436|NCT04144465|Drug|NORADRENALIN|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
6437|NCT04144465|Drug|PHENYLEPHRINE|DRUG THAT IS IMPROVING TISSUE AND ORGAN PERFUSION
6438|NCT04144452|Other|Patient Education Session|The intervention of Patient Education will be designed individually according to the patient's need who have undergone lumbar microdiscectomy procedure through MIS. The basic purpose of the educational session will be to inform the participants about their pre operative and current back condition and discuss methods to care for their back. The session will be given for one hour and face to face interaction will be ensured twice a week. Initially the post operative education plan and instructions will be formulated, reviewed and finalized by the operating surgeon.
6467|NCT04144244|Other|MicroFluidic Sperm Sorting Chips|sperm selection of IUI treatment
6468|NCT04144244|Other|Gradient-Density Centrifugation|sperm selection of IUI treatment
6469|NCT04144231|Behavioral|iCBT-I|Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
6470|NCT04144231|Behavioral|GCBT-I|Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
6439|NCT04144452|Other|Therapeutic Exercise plus educational session|Therapeutic exercises include strength and endurance training and mat exercises. Strengthening exercises of the trunk extensors will be initiated first and then endurance exercises will be targeted. Mat exercises will be performed to strengthen the back and lower musculature. Treatment will be given twice a week for almost three months. Individualized educational sessions will be performed in the same way as conducted in the other group. Progression of the exercises and the rest periods will be incorporated according to the status of patient.
6440|NCT04144439|Drug|GABA|Gamma amino butyric acid
6441|NCT04144426|Behavioral|Normal diet|Participants will receive either a 2000 calorie or a 2500 calorie diet at normal meal times
6442|NCT04144426|Behavioral|Modified diet|Participants will receive either a 2000 calorie or a 2500 calorie diet with a single meal shift, breakfast is moved to an hour before bedtime.
6443|NCT04144413|Drug|Open-label Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
6444|NCT04144413|Drug|Masked Ikervis|NOVA22007, IKERVIS® is a sterile, ophthalmic cationic oil-in-water emulsion containing 1mg/ml CsA.
6445|NCT04144413|Other|Vehicle Comparator: Masked Vehicle|Vehicle of IKERVIS® - sterile, ophthalmic cationic oil-in-water emulsion containing no active substance.
6446|NCT04144400|Behavioral|Direction Check App|Direction Check is a simple, inexpensive app that builds resilience through balanced values to target the everyday personal and occupational stressors faced by military populations.
6447|NCT04144400|Behavioral|Direction Check App (Time Management Version)|Direction Check (Time Management Version) is a simple, inexpensive app that builds resilience through time management exercises to target the everyday personal and occupational stressors faced by military populations.
6448|NCT04144387|Procedure|Myelogram|Two additional myelograms will be performed comparing to standard of care.
6449|NCT04144374|Drug|Omadacycline|Omadacycline will be administered 200 mg IV once daily on day 1 followed by omadacycline 300 mg by mouth once daily for 2-4 doses.
6450|NCT04144374|Procedure|Microdialysis Catheter Insertion|A 20 kilodalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
6451|NCT04144361|Procedure|sleeve with plication|sleeve with plication
6452|NCT04144361|Procedure|sleeve without plication|sleeve without plication
6453|NCT04144348|Biological|mRNA-1653|Experimental vaccine
6454|NCT04144348|Biological|Placebo|Saline
6455|NCT04144335|Biological|N-803 and bNAbs|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle) and bNAbs will be given every 9 weeks.
6456|NCT04144335|Biological|haNK™ Cells|Treatment will consist of N-803, VRC07-523LS, PGT121, and haNK, with N-803 given for 3 cycles of 9 weeks/cycle. N-803 will be given every 3 weeks (3 doses/cycle), bNAbs will be given every 9 weeks, and haNK cells administered on the same day as each infusion of N-803.
6457|NCT04144322|Device|Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition|Placement of a short implant
6458|NCT04144322|Device|Zimmer T3 with DCD Ex Hex Parallel Walled implants|Placement of a long implant with sinus lift and bone graft
6459|NCT04144309|Procedure|Electroacupuncture (EA) and Auricular Acupressure (AA)|"EA: A semi-standardised acupuncture point prescription will be used. Ten points will be used, including six fixed points that are the frequently used points in treating insomnia and four additional points based on subjects' TCM syndrome to address the particular constitutions. The six fixed points are: GV24 (Shenting), GV20 (Baihui), EX-HN1 (Sishenchong), PC6 (Neiguan), SP6 (Sanyinjiao), KI3 (Taixi). The four acupoints will be selected from the following list: EX-HN3 (Yintang), EX-HN22 (Anmian), HT7 (Shenmen), LI4 (Hegu), CV4 (Guanyuan), ST25 (Tianshu), ST36 (Zusanli), KI6 (Zhaohai), LR3 (Taichong), BL15 (Xinshu), BL18 (Ganshu), BL20 (Pishu), BL23 (Shenshu), BL62 (Shenmai), and any other points if necessary.~AA: Vaccaria seeds will be embedded by acupuncturists on three auricular points (Shenmen, Sympathetic and Heart) and maintained between EA treatments."
6460|NCT04144309|Procedure|Sham Electroacupuncture (SE) and Sham Auricular Acupressure (SA)|"SE: The sham acupuncture treatment procedure, including the acupoint selection principle, sterilization procedure and treatment schedule, will be the same as in the acupuncture treatment group, except that sham points 1 to 2 cm exterior and inferior to the real points will be used, and no needle penetration or electric stimulation will be performed.~SA: Three sham auricular points in the helix region (HX7, HX8, HX9) will be selected. Instead of Vaccaria seeds, soft Junci Medulla (1 to 2 mm in length, dyed black) will be used to mimic real AA with no pressure."
6461|NCT04144296|Diagnostic Test|Study procedure|"Measurement of the flow rate of supplemental oxygen~Measurement of the peripheral arterial saturation (SpO2) by pulse oximetry~Taking of an ABG sample (ABG1) from the arterial line~Taking of capillary blood gas analysis from the earlobe and from the finger tip~Taking of an a second ABG (ABG2) from the arterial line"
6462|NCT04144283|Behavioral|NAP|"For experiment 1, the NAP group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') without cues.~For experiment 2 the NAP+TMR group will undergo a post-learning 2-hour diurnal sleep opportunity (i.e. 'nap') with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold using headphones during stage 2 and stage 3 of NREM sleep."
6463|NCT04144283|Behavioral|WAKE|"For experiment 1, the WAKE group will undergo a post-learning 2-hour period of quiescent wakefulness without cues.~For experiment 2 the WAKE+TMR group will undergo a post-learning 2-hour period of quiescent wakefulness with auditory TMR. The learning related sounds will be presented to participants at 140% of their minimal auditory detection threshold using headphones for a similar duration as in the NAP+TMR group."
6464|NCT04144270|Other|Evaluation of muscle mass and muscle function|Included patients have their muscle mass and muscle function evaluated before start on and after completion of oncological treatment.
6465|NCT04144257|Drug|[F-18]PBR06|PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).
6466|NCT04144257|Drug|[C-11]Methylreboxetine|PET radiopharmaceutical. Subjects will undergo [C-11]MRB-PET (norepinephrine transporter binding).
6471|NCT04144218|Drug|Lacosamide|The experimental group will be given oral lacosamide supplementation on the basis of the original antiepileptic drugs.
6472|NCT04144218|Drug|Placebo oral tablet|The control group will be given oral placebo supplementation on the basis of the original antiepileptic drugs.
6474|NCT04144192|Drug|Lidocaine patch 1.8%|
6475|NCT04144192|Drug|Lidocaine 5% patch|
6476|NCT04144192|Drug|Lidocaine 2% Injectable Solution|
6482|NCT04144166|Device|capillary refill index (CRI)|a waveform analysis method using a pulse oximeter to assess peripheral perfusion
6483|NCT04144153|Combination Product|Opioid Free Total Intravenous Anesthesia|Total intravenous anesthesia with propofol and dexmedetomidine hydrochloride and ketamine hydrochloride
6484|NCT04144153|Combination Product|Total Intravenous anesthesia with opioid|Total Intravenous anesthesia with opioid
6485|NCT04144140|Drug|E7766|E7766, solution, intratumorally
6486|NCT04144127|Behavioral|Soccer|"Soccer drills and other fitness routines (two 1-hour sessions per week)~In person education in Life's Simple 7 to help improve life through Lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure."
6487|NCT04144127|Behavioral|mHealth|It is an online platform is accessible on a smartphone application (IOS or Android) or desktop, to help patients monitor their physical activity (PA) data weekly and receive messages for behavior change support and reminders for data synchronization. The study team will send two short text messages twice weekly: one message will be focused on a weekly goal for minutes of moderate-to-vigorous PA; and the second will be based on one of the AHA's Life's Simple 7, including lifestyle messages so the participants can improve through lifestyle changes, helping to achieve ideal cardiovascular health.
6488|NCT04144114|Dietary Supplement|ProHydrolase®|Subjects received 250mg of ProHydrolase® with 25g whey protein mixed together in a drink
6489|NCT04144114|Dietary Supplement|Whey protein|Subjects received 25g of whey protein powder mixed to together in a drink
6490|NCT04144114|Dietary Supplement|Placebo|Placebo
6491|NCT04144101|Drug|Etoricoxib|Etoricoxib 60 mg QD Oral
6492|NCT04144101|Drug|Aceclofenac|Aceclofenac 100 mg BID Oral
6493|NCT04144088|Drug|Wu Ling San|assigned to Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Wu Ling San for a period of 4 weeks.
6494|NCT04144088|Drug|Yin-Chen Wu Ling San|assigned to Yin-Chen Wu Ling San (n =20) and were instructed to take 4.5 gm 2 times per day of Yin-Chen Wu Ling San for a period of 4 weeks.
6495|NCT04144088|Drug|Placebo|1/10 Wu Ling San assigned to Placebo (n =20) and were instructed to take 4.5 gm 2 times per day of Placebo for a period of 4 weeks.
6496|NCT04144075|Behavioral|Mindful Self-Compassion Program|It is a protocolized training program in mindfulness and self-compassion skills. It has a duration of 8 weekly group sessions of about two hours and 45 minutes and a silent retreat of 4 hours.
6497|NCT04144075|Behavioral|Cognitive Behaviour Therapy Group|It is a control intervention designed for the development of a control group suitable for comparison with experimental groups.
6498|NCT04144075|Other|Treatment as usual|It is variable according to the clinical and personal characteristics of the patient, the most common components will be described.
6499|NCT04144062|Other|CAD/CAM crowns|CAD/CAM crowns
6500|NCT04144049|Drug|MT921|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
6501|NCT04144049|Drug|Placebo|Subcutaneously administered, 0.2ml per injection, at most 50 injections per treatment session.
6502|NCT04144036|Drug|Neihulizumab|The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.
6506|NCT04143997|Diagnostic Test|A clinical Transthoracic echocardiogram|A previously clinically completed transthoracic echocardiogram will be utilized to assess for diastolic dysfunction in the presence of normal systolic function for patients with previously diagnosed peripartum cardiomyopathy.
6507|NCT04143984|Radiation|Carbon-ion radiotherapy|Accelerated carbon-ion beam with pencil beam scanning technique.
6508|NCT04143984|Drug|Camrelizumab|An anti-PD-1 antibody.
6509|NCT04143984|Drug|Apatinib|A tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptor-2.
6510|NCT04143971|Other|intermittent fasting diet|intermittent fasting diet
6511|NCT04143971|Other|low calorie diet|continuous low calorie diet
6512|NCT04143958|Drug|agalsidase beta (GZ419828)|Pharmaceutical form:Powder for concentrate for solution for infusion Route of administration: Intravenous (IV) infusion,
6513|NCT04143958|Drug|agalsidase alfa|Pharmaceutical form:concentrate for solution for infusion Route of administration: Intravenous (IV) infusion
6646|NCT04142918|Other|Immunostaining|Immunostaining of oral mucosa/gingiva samples
6514|NCT04143945|Drug|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
6515|NCT04143945|Drug|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
6516|NCT04143919|Diagnostic Test|NYHA assessment|The New York Heart Association (NYHA) functional classification of HF
6517|NCT04143919|Procedure|Serum NT-proBNP concentration|Subjects with NYHA score ≥ II will undergo a rapid, on site serum NT-proBNP test on the same day of the visit. Roche CARDIAC proBNP+ test, using the Cobas h 232 device, is a quantitative immunological test for the determination of NT-proBNP in heparinized venous blood.
6518|NCT04143919|Diagnostic Test|Transthoracic Ecocardiogram|Subjects with a serum NT-proBNP result of ≥ 125 pg/mL at Visit 1 will be referred to a study cardiologist for a transthoracic echocardiogram to assess LVEF and relevant structural heart disease
6519|NCT04143906|Drug|Vinorelbine|injection
6520|NCT04143906|Drug|Gemcitabine|injection
6521|NCT04143906|Drug|Carboplatin|injection
6522|NCT04143893|Device|Mechanical circulatory support|Patients with cardiogenic shock who underwent MCS
6523|NCT04143893|Drug|Optimal medical treatment|Patients with cardiogenic shock who received optimal medical treatment including vasopressor
6526|NCT04143867|Device|Nolix Device|For temporary management of SUI
6527|NCT04143854|Drug|MBA-P01(Botulinum toxin A)|Intramuscular injection; Dose varies by group
6528|NCT04143854|Drug|Placebo|Intramuscular injection; normal saline
6529|NCT04143841|Device|Viveye OMNS treatment|The Viveye OMNS treatment ( ~30 min) will be applied once, during the treatment visit only
6530|NCT04143841|Device|Viveye OMNS sham treatment|The Viveye OMNS sham treatment ( ~30 min) will be applied once, during the treatment visit only
6531|NCT04143828|Behavioral|mobile mindfulness programme|"The mobile mindfulness programme adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of six modules. Each module consists of a short movie (talking head) explaining the content and two audiofiles to guide experiential mindfulness meditation exercises. Participants can follow the different modules based on their own time-schedule.~Key objectives are: (1) to increase awareness of one's present moment experience; (2) to teach an attitude of openness and acceptance (non-judging) toward one's experience."
6532|NCT04143815|Drug|MBA-P01 (Botulinum toxin A)|Intramuscular injection, dose varies by groups
6533|NCT04143815|Drug|Placebo|Intramuscular injection
6537|NCT04143789|Drug|AP-002|Dose escalation
6538|NCT04143776|Procedure|Abdominal reconstruction|No restrictions are set on surgical procedures or anaesthetic management.
6539|NCT04143763|Other|Ecological Momentary Intervention (EMI)|Using the messaging function of mobile devices, EMI offers a framework to deliver health information to the target population, corresponding to each individual's demands in terms of type (e.g., photo, text and/or voice message), timing, duration, and frequency of the messages, which are different to the features from other interventions
6540|NCT04143750|Drug|[14C]Vicagrel|Take a suspension of 20 mg vicagrel ,containing about 120 μCi [14C]Vicagrel, in fasting within 5 minutes
6541|NCT04143737|Behavioral|Healthy lifestyle intervention|38 women participated in the intervention group which was located in a community center in Zur-Baher neighborhood. The intervention consisted of 20 weekly sessions on nutrition, physical activity, stress management skills, and self-monitoring. All taught by professional facilitators (nutritionists, exercise trainers, health coaches, and psychotherapists). Baseline data was collected
6542|NCT04143724|Drug|ACE-536|Subjects will start with luspatercept at 0.75mg/kg and the Dose review team (DRT) will evaluate all toxicities of each subject after Cycle 1 and determine whether or not to enroll the next cohort at the next planned dose level and/or next lower age group
6543|NCT04143724|Drug|ACE-536|Subjects will start with luspatercept at 1.0mg/kg and the Dose review team (DRT) will evaluate all toxicities of each subject after Cycle 1 and determine whether or not to enroll the next cohort at the next planned dose level and/or next lower age group
6544|NCT04143711|Drug|DF1001|Immunotherapy agent targeting NK cells.
6545|NCT04143711|Drug|Pembrolizumab|Anti-PD-1 immunotherapy agent
6546|NCT04143698|Device|endoscopic retrograde cholangiopancreatography|Cannulation of the desired duct will be performed in the standard fashion, with the type of accessories used left to the discretion of the individual endoscopist performing the procedure.If cannulation is considered difficult7, 8 (defined as an inability to achieve cannulation by standard ERCP techniques after 5 cannulation attempts, or within 10 minutes, or failure to access the papilla), advanced cannulation techniques can be used at the discretion of the individual endoscopist. Advance cannulation techniques include the double guidewire technique, precut technique, or cut over a pancreatic stent technique.
6547|NCT04143685|Drug|Misoprostol|Oral administration of cytotec every 4 hours until a maximum of 6 doses
6548|NCT04143685|Drug|Oxytocin|Intravenous infusion of Pitocin through an IVAC until delivery
6549|NCT04143672|Device|Electronic digital pressure algometer|"Evaluation of pain threshold using an algometer is conducted one day before surgery.~The pressure of the plunger of algometer is applied vertically to the patient's right thenar muscle belly at a speed of 10 N/sec by the tester. Then the tester removes the algometer when the patients start to feel pain and record the pressure recorded on the algometer."
6550|NCT04143672|Diagnostic Test|Pain sensitivity questionnaire|Evaluation of pain threshold using the Korean-version pain sensitivity questionnaire is conducted one day before surgery.
6551|NCT04143659|Biological|levonorgestrel butanoate (LB) injection|The study medication is LB Injectable Suspension, 40 mg/2mL (20 mg/mL). The formulation consists of a suspension of spray dried LB powder, with an approximate mean particle size of 13 micron, in an aqueous vehicle containing: super refined polysorbate 80 (Tween® 80), spray dried sorbitan monopalmitate (Span® 40), sodium carboxymethylcellulose, sodium phosphate dibasic anhydrous, sodium phosphate monobasic dihydrate, benzyl alcohol and water for injection, USP. Each vial contains 2 mL at 20mg/mL for a total of 40 mg.
6552|NCT04143646|Behavioral|Web-based prevention program|"Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk."
6553|NCT04143633|Other|Low FODMAP diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. The distribution of carbohydrates depends on the content of fodmaps on each food.
6554|NCT04143633|Other|Standard diet|The diet will be in accordance to the baseline energy expenditure calculated by Harris-Benedict whit 55% of carbohydrates, 25% of lipids and 20% of proteins, divided in five meals. Cruciferous vegetables, fruits and condiments will be eliminated and a normal content of fodmap.
6555|NCT04143620|Procedure|Procedure|Triple procedure
6556|NCT04143607|Drug|ASK120067|The initial dose of ASK120067 160 mg twice daily can be reduced to 80 mg twice daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
6557|NCT04143607|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
6558|NCT04143607|Drug|Gefitinib|Gefitinib (250 mg orally, once daily) , in accordance with the randomization schedule. Following objective disease progression according to RECIST1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label ASK120067 (crossover to active ASK120067).
6559|NCT04143607|Drug|Placebo ASK120067|The initial dose of Placebo ASK120067 160 mg once daily can be reduced to Placebo ASK120067 80 mg twice daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
6560|NCT04143594|Drug|Oral GS-6207|Tablets administered without regard to food
6561|NCT04143594|Drug|F/TAF|Tablets administered without regard to food
6562|NCT04143594|Drug|Subcutaneous GS-6207|Administered in the abdomen via subcutaneous injections
6563|NCT04143594|Drug|TAF|Tablets administered without regard to food
6564|NCT04143594|Drug|BIC|Tablets administered without regard to food
6565|NCT04143594|Drug|B/F/TAF|Tablets administered without regard to food
6566|NCT04143581|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg/die for 28 days
6567|NCT04143568|Other|Observation|Evaluation of endothelial progenitor cells level and correlation of endothelial progenitor cells level with periodontal and cardiovascular disease
6568|NCT04143555|Procedure|endoscopic submucosal injection of indocyanine green before laparoscopic gastrectomy|Indocyanine green was injected under endoscope within 24 hours before operation. Four points(0.5ml/point,1.25mg/ml) were evenly injected in four quadrants at the edge of the tumor. The injection method was direct submucosal injection and 0.5ml saline + 0.5ml indocyanine green solution + 0.5ml saline (sandwich method). The imaging effect was evaluated by indocyanine green fluorescence imaging system during the operation. The effect was divided into grade0 and Grade1. Grade1: The imaging of the tumor and the corresponding lymphatic drainage area in the injection area both were ideal. Grade 0: not up to grade 1, classified into tumor body and drainage area without imaging, only tumor body imaging, and even though tumor body and regional lymph drainage area imaging, the contrast agent in the gastric wall was too diffuse or even overflowing, which seriously interfered with the observation of lymph drainage area imaging.
6569|NCT04143542|Procedure|trunk blocks|Comparison of trunks blocks and control groups for Postoperative Analgesia in Abdominal Surgery
6570|NCT04143529|Behavioral|Personalized acceptance-based mindfulness exercise|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
6571|NCT04143529|Behavioral|Brief educational pamphlet|The control condition will be educational information on pain and stress that patients will read over within 60 seconds
6572|NCT04143516|Diagnostic Test|[18-F]- FDG - PET|Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion
6573|NCT04143516|Procedure|Thermal ablation (TA)|Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor.
6574|NCT04143516|Diagnostic Test|PET/CT Scan|Eligible patients will undergo PET/CT -guided thermal ablation. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of thermal ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.
6575|NCT04143490|Other|Exercise|60 minutes of continuous exercise at 65% VO2peak and drink ingestion
6576|NCT04143477|Drug|peficitinib|Oral
6577|NCT04143464|Behavioral|Kyphosis-specific exercise class and kyphosis-specific exercise videos|"The kyphosis-specific exercise is based on the protocol published by Katzman and team in 2016. It includes warm-up, back muscle strength training, spine mobility training, spine alignment training, and stretching. The class will last around 60 minutes.~The exercise videos have the same content as the kyphosis-specific exercise class. The participants are asked to practice everyday at home following the videos."
6578|NCT04143451|Biological|Vaxigrip tetra|quadrivalent influenza vaccine
6579|NCT04143451|Biological|Fluzone high-dose|high-dose trivalent influenza vaccine
6580|NCT04143451|Drug|Aldara 5% Topical Cream|imiquimod cream
6581|NCT04143451|Drug|Aqueous cream BP|inactive aqueous cream
6582|NCT04143438|Procedure|EOS 3D imaging protocol pre- and post-surgery|Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
6583|NCT04143425|Diagnostic Test|3-Tesla conventional magnetic resonance imaging|T1-weighted, T2-weighted, fluid-attenuated inversion recovery, and contrast-enhanced T1-weighted imaging
6644|NCT04142944|Device|Dexcom G6 without alert|Dexcom G6 CGM device without the predictive hypoglycaemia alert function
6584|NCT04143425|Diagnostic Test|Advanced imaging without contrast use|Diffusion-weighted imaging, amide proton transfer-weighted imaging, electrical properties tomography, and 2hG-magnetic resonance spectroscopy
6585|NCT04143425|Diagnostic Test|Dynamic susceptibility contrast-weighted imaging|Cerebral blood volume and vessel architectural imaging parameters
6586|NCT04143412|Drug|Tritace (Ramipril 10 mg)|Stratified randomized clinical trial
6587|NCT04143399|Procedure|holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Versa pulse 100W; Lumenis; Germany)
6588|NCT04143399|Procedure|Bipolar resection of the prostate|cystoscopic transurethral resection of the prostate using bipolar energy
6589|NCT04143373|Procedure|warm saline irrigation|The objective of this research was to compare the effect of irrigation during impacted mandibular third molar surgery, with normal saline of 25 ± 2 ° C and 37 ± 1 ° C for control and experimental sides, respectively.
6590|NCT04143360|Device|New Closed Drainage Device|For the first group, a new closed drainage device was adopted.
6591|NCT04143360|Device|Traditional closed drainage device|For group 2, conventional closed drainage device was used.
6592|NCT04143347|Other|No Intervention|
6593|NCT04143334|Diagnostic Test|Conventional survey|
6594|NCT04143321|Drug|Empagliflozin 25 MG|after washout period and EST and SAQ patients gave 25 mg Empagliflozin daily in experimental group
6595|NCT04143308|Other|Simultaneous training of walking and cognitive group|"Device:~SWATCH system (App & controller)~Wearable technology Fitness wristband & APP"
6596|NCT04143308|Other|Cognitive training group|"Device:~SWATCH system (App)~Wearable technology Fitness wristband & APP"
6597|NCT04143308|Other|Treatment as usual group|Keep treatment as usual
6598|NCT04143295|Drug|Diiodothyropropionic acid|Drug Administration
6599|NCT04143282|Drug|Metformin|determine the effect of metformin along with standard cancer treatment
6600|NCT04143269|Device|Non-invasive transcutaneous vagus nerve stimulation|Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
6601|NCT04143269|Device|Sham vagus nerve stimulation|"Bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.~The sham device produces a slight vibrating sensation, but do not provide any vagal nerve activation"
6602|NCT04143256|Other|JUUL ENDS 5% Virginia Tobacco|JUUL ENDS Virginia Tobacco 5% nicotine strength
6603|NCT04143256|Other|JUUL 3% Virginia Tobacco ENDS|JUUL ENDS Virginia Tobacco 3% nicotine strength
6604|NCT04143256|Other|JUUL 5% Mint ENDS|JUUL ENDS Mint 5% nicotine strength
6605|NCT04143256|Other|JUUL 3% Mint ENDS|JUUL ENDS Mint 3% nicotine strength
6606|NCT04143256|Other|JUUL 5% Menthol ENDS|JUUL ENDS Menthol 5% nicotine strength
6607|NCT04143256|Other|JUUL 3% Menthol ENDS|JUUL ENDS Menthol 3% nicotine strength
6608|NCT04143256|Other|JUUL 5% Mango ENDS|JUUL ENDS Mango 5% nicotine strength
6609|NCT04143256|Other|JUUL 3% Mango ENDS|JUUL ENDS Mango 3% nicotine strength
6610|NCT04143256|Other|US Cigarette, Non-menthol - Marlboro Gold King Size|US Cigarette, Non-menthol - Marlboro Gold King Size
6611|NCT04143256|Other|US Cigarette, Menthol - Newport King Size|US Cigarette, Menthol - Newport King Size
6612|NCT04143243|Behavioral|ACT on Life|1 day group workshop of ACT plus ERS
6613|NCT04143243|Behavioral|Education, Resources, and Support|1 day group workshop of Education, Resources, and Support
6614|NCT04143230|Other|Screening for PC by means of two different screening tools|Screening of chronically ill patients admitted to an Internal Medicine Unit from the Emergency Department, for palliative care need, using of both the SIAARTI/NCCN screening tool (EST), and the Simplified Screening Tool (SST), derived from the first instrument.
6615|NCT04143217|Drug|SPN-812|SPN-812 200 to 600 mg
6616|NCT04143204|Other|Oral nutritional intake|The exposure are oral nutritional intake and all nutritional intake during early life (28 days), and insulin-like growth factor 1, leptin, Ghrelin, and C-peptide in serum at corrected age 40 gestational weeks.
6617|NCT04143191|Drug|Sorafenib|Sorafenib is one of tyrosine kinase inhibitors. The initial dosage is 400mg orally, twice daily.
6618|NCT04143191|Procedure|Transarterial chemoembolization|TACE including conventional TACE (cTACE) and DEB-TACE. Treatment choices are according to the specific condition of each patient and the experience of interventional radiologists.
6619|NCT04143178|Other|Expressive Writing|The expressive writing is a form of writing therapy developed primarily by James W. Pennebaker in the late 1980s consisting of writing about stressful and traumatic experience for 15-20 min for 3 consecutive days, including one's thoughts and feelings. The expressive writing allows people to express and process emotions, feelings, and thoughts related to the life events and consequent changes and this may favor a mental reorganization of the negative events, a greater expression and regulation of the emotions related to them. This intervention could provoke social, emotional, and consequently, psychophysical changes as is showed in patients with chronic diseases and cancer. In the present study, to all participants in the writing group, 5 days after the transplant, has been asked to write for 3 consecutive days, 20 minutes each days about their deepest emotions and feelings related to the chronic failure, the transplant and their expectations after that.
6620|NCT04143178|Other|Neutral Writing|Five days after the transplant, to the control group participants has been asked to write for 3 consecutive days 20 minutes a day on an assigned neutral theme (eg. describe 1 object in the room) as objectively as possible, without mentioning their emotions or thoughts related to it.
6621|NCT04143165|Drug|Epidural block with lidocaine and triamcinilone|caudal epidural injections with 1% lidocaine hydrochloride (xylocaine AstraZeneca) 9 mL mixed with 1 mL of triamcinolone 40 milligrams (Kenacort Bristol Myers Squip)
6622|NCT04143126|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
6645|NCT04142931|Combination Product|ImmunicomAIAC|filtration through the ImmunicomAIAC followed by Nivolumab Administrated IV starting C2 on Cohort C and on Cohort D
6623|NCT04143126|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help patients learn about schizophrenia, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
6624|NCT04143113|Other|Decision Aid|Shared decision making tool
6625|NCT04143100|Other|Survey|For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
6626|NCT04143087|Drug|withdrawal TKIs or halve TKIs|Stop TKIs or treated by half TKIs
6627|NCT04143074|Behavioral|multidisciplinary behavioral intervention|behavioral intervention - 4 visits with each of the specialist team (pediatrician, dietician, psychologist, physical activity specialist), (4 visits x 4 specialists). Each specialist ap. 30 min time. Wisits in 0-3m-6m-12m time frame. Visits focused on behavioral intervention - motivation for change and basic tools (dietician, physical activity specialist, psychologist) to implement change in nutrition and physical activity based on individual reediness for change (based on Prochaska model).
6628|NCT04143061|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine|Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL
6629|NCT04143061|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine|Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL
6630|NCT04143061|Biological|Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine|Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL
6631|NCT04143048|Other|DNA extraction of tumer tissue samples and high-throughput sequencing of small panels|DNA extraction of stromal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed
6632|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood cfDNA and tissue gDNA for the gene detection of gastrointestinal stromal tumor
6633|NCT04143048|Other|DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels|DNA extraction and small panel sequencing were conducted for each patient sample. Based on the indicator results of the previous mutant spectrum for each stage of gastrointestinal stromal tumor, the clinical stage classification of patients and the benign and malignant nodules were determined by the mutant spectrum, and compared with the real clinical data of patients
6634|NCT04143035|Other|No Intervention|No Intervention
6635|NCT04143022|Device|acupuncture press needle|Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
6636|NCT04143009|Behavioral|Adapted Friendship Bench|In the AFB intervention, the existing Friendship Bench intervention protocol will be adapted to address the unique needs of HIV-infected women. This will include integrating problem solving therapy- based ART adherence support into existing counseling sessions and providing opportunities for participants to address HIV-specific concerns, such as stigma, disclosure, mother-to-child HIV transmission or other issues women identify during counseling sessions. AFB will include 4 individual prenatal counseling session and 2 group postnatal counseling sessions. No specific retention support will be provided, but participants may identify barriers to engagement in HIV care to address during their pre- or postnatal counseling sessions.
6637|NCT04143009|Behavioral|Enhanced Friendship Bench|EFB will include all elements of AFB, but will additionally integrate retention strategies to support engagement in care for HIV-infected women with PND. To provide additional social support for participants, one support session will be added to the AFB at which participants will be invited to bring a person of her choice who can be a support to her in managing both her HIV and/or depression. To assist women with receiving their medication during late pregnancy and postpartum, a trained psychosocial counselor will also conduct up to six home visits in the EFB arm. At each home visit, counselors will be able to deliver a participants' medications and conduct a counseling session.
6638|NCT04143009|Other|Enhanced Standard Care (Control)|Standard care for mental health in public facilities in Malawi includes options for basic supportive counseling by the primary provider or nurse, medication management by the primary provider, referral to the clinic psychiatric nurse or mental health clinic, or in more severe cases referral to the psychiatric units at tertiary care hospitals. For this study, standard care will be enhanced by a trained study research assistant who will provide mental health evaluation; brief supportive counseling; information, education, and support on common mental disorders; and (if indicated) facilitation of referral to the clinic's psychiatric nurse or mental health clinic. The study research assistant will have up to 3 follow-up contacts with the participant to assess whether she has followed up on recommended referrals or treatment plans and to assess whether any further outreach is indicated.
6639|NCT04142996|Device|Theta burst stimulation|Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
6640|NCT04142983|Biological|Adacel|0.5 mL, Intramuscular
6641|NCT04142970|Drug|HSK3486|HSK3486，Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.
6642|NCT04142957|Other|COPD Pal|'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
6643|NCT04142944|Device|Dexcom G6 with alert|Dexcom G6 CGM device with the predictive hypoglycaemia alert function
6647|NCT04142892|Drug|Onapristone|50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
6648|NCT04142879|Device|Viz Device Software|Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
6649|NCT04142866|Device|Anodal transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the active tDCS condition, stimulation continues for the first 20 minutes of the 60-minute treatment session, and then ramps back down to 0 milliamps (mA).
6650|NCT04142866|Device|Sham transcranial direct current stimulation|2 milliamps (mA) of stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode) is placed on the scalp over the targeted cortical region and the other (cathode) is placed on the right side of the forehead. Ramping up of the current to 2 milliamps (mA) occurs over 30 seconds to allow participants to habituate to the tingling sensation. In the sham tDCS condition, the current is only on for 30 seconds before it is ramped back down to 0 milliamps (mA), although the electrodes are still worn for 20 minutes.
6651|NCT04142866|Behavioral|Speech-Language Therapy (SLT)|Therapy provided is Verb Network Strengthening Treatment (VNeST). Therapy sessions last for 60 minutes and are provided twice weekly for 8 weeks. Active or sham tDCS is delivered during the first 20 minutes of therapy. The therapist is blinded to stimulation condition (active or sham).
6652|NCT04142853|Other|Training intervention + Dance intervention|Training intervention + Dance intervention
6653|NCT04142840|Drug|Dexmedetomidine|a selective α-2 adrenoceptor agonist which is widely used as an adjuvant to general anesthesia
6654|NCT04142840|Drug|Propofol|a short -acting medication that result in a decreased level of consciousness and lack of memory for events,widely used including the starting and maintenance of general anesthesia.
6655|NCT04142827|Device|High Flow Humidification|myAirvo2 gives at home for long therapy treatment
6656|NCT04142814|Procedure|T-PEP|"First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist."
6657|NCT04142814|Procedure|IPV|IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
6658|NCT04142801|Device|MeMo web application|The patient betwenn 2 consultation could use the application MeMo. MeMo is a web application that can thus be used on any web browser (computer or tablet). On tablet, the application can be installed on home screen to look like a native app, and used offline.
6659|NCT04142801|Other|Control group|the patient have the classical follow up at the memory center (consultation)
6660|NCT04142788|Drug|Patiromer|Patiromer (8.4g/day to 25.2g/day) and spironolactone (up to 200mg/day) or eplerenone (up to 50mg/day if spironolactone not acceptable). Treatments should be titrated to maintain serum potassium close to the target of 4.5mmol/L.
6661|NCT04142775|Other|complication versus no complication|development of ICH
6662|NCT04142762|Drug|ABI-H2158|ABI-H2158 tablets
6663|NCT04142762|Drug|Itraconazole|Itraconazole capsules
6664|NCT04142762|Drug|Rifampin|Rifampin capsules
6665|NCT04142762|Drug|Midazolam|Midazolam syrup
6666|NCT04142762|Drug|Ethinyl Estradiol / Levonorgestrel|Ethinyl Estradiol / Levonorgestrel tablets
6667|NCT04142762|Drug|Esomeprazole|Esomeprazole capsules
6668|NCT04142762|Drug|Placebo matching oral contraceptive|Placebo matching Ethinyl Estradiol / Levonorgestrel tablets
6669|NCT04142749|Drug|Oltipraz|Total 90mg, By mouth, TID
6670|NCT04142749|Drug|Placebos|Total 90mg, By mouth, TID
6671|NCT04142736|Other|Prone Position|"Patients will undergo HFNC during a 15-minute monitoring window in the supine position. HFNC will be started at 50 l/min and flow set to the patient's tolerance. FiO2 will be titrated to 92% >SpO2 <96 %. If SpO2/FiO2 <123 mmHg or RR>35 bpm, the patient will be excluded for safety reasons. Prone position will last for at least 2 hours. After the PP period, he/she will be turned to supine for 2-4 hours. The total duration of the study will be 48 hours.~Weaning success is considered if the patient remains on standard O2 > 48 hours."
6672|NCT04142723|Biological|blood withdraw|venous blood sampling
6673|NCT04142710|Device|Telemedicine: tablet and possibly tools to perform measurements|Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
6674|NCT04142697|Behavioral|Heading direction adaptation|Will adapt subject's perceived heading direction using exposure to visual environments that include rotation and situations where visual and inertial heading direction are systematically offset.
6706|NCT04142385|Other|Cytology Specimen Collection Procedure|Undergo blood, urethral swab, penile skin cell, and anal swab collection
6707|NCT04142385|Other|Laboratory Biomarker Analysis|Correlative studies
6708|NCT04142385|Procedure|Medical Examination|Undergo anal and penile clinical exam
6709|NCT04142385|Procedure|Physical Examination|Undergo targeted physical exam
6675|NCT04142671|Other|Individualised gait modification intervention|An individualised gait modification intervention to reduce knee joint loading. Knee joint loading will be presented in real-time during treadmill walking. A 10% reduction of each patients baseline knee loading will be used as a target threshold along with visualisation of the history of 5 previous steps. Patients are encouraged to determine their own gait modification strategy that is most efficient for them. Previous examples of gait modifications that mechanically reduce knee loading will be presented to them.
6676|NCT04142658|Drug|Apixaban 5 MG|"For patients that do NOT meet the following criteria~age ≥ 80 years~weight ≤ 60 kilograms~creatinine ≥ 1.5 mg/dL (133 micromol/L)"
6677|NCT04142658|Drug|Apixaban 2.5 MG|"For patients that meet at least 2 of the following criteria~age ≥ 80 years~weight ≤ 60 kilograms~creatinine ≥ 1.5 mg/dL (133 micromol/L)"
6678|NCT04142658|Drug|Warfarin|Active Control Intervention
6679|NCT04142658|Device|On-X Aortic Mechanical Valve|Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.
6680|NCT04142645|Device|OptiMEDs|"The OptiMEDs intervention is a multi-faceted intervention combining:~an ICT platform:~automatic and secure capture of individual prescribing information from the electronic medication administration records in the nursing home~a tool for structured nurse observations of side effects, derived from the existing Pharmanurse application (20) (used to list potential medication side effects, based on the individual medication chart of the nursing home residents) to support monitoring of medication safety by nurses.~an electronic decision support tool for the appraisal of potentially inappropriate medication (explicit criteria of misuse and underused of medication, based on existing lists of explicit criteria (PIMs)), use of medication with anticholinergic properties and medication inappropriate in view of the limited life expectancy.~a multidisciplinary medication review with the input of GPs, trained community-pharmacists and nurses."
6681|NCT04142632|Procedure|clinical and paraclinical examination|Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
6683|NCT04142606|Other|fetal MRI|The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus (s)
6684|NCT04142554|Drug|Parsaclisib|Parsaclisib tablets (1.0, 2.5 or 5 mg) are administered orally daily for up to 14 days
6685|NCT04142541|Device|Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)|The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
6686|NCT04142528|Device|ParkinPal|Wear and periodic recording of motion data during daily wear
6687|NCT04142515|Other|no intervention|no intervention
6688|NCT04142502|Drug|Propofol|Propofol as a sedation drug
6689|NCT04142502|Drug|Dexmedetomidin|Dexmedetomidine as a sedation drug
6690|NCT04142489|Other|solar irradiation and biopsies|the minimum erythematous dose (DEM) will be calculated using a solar irradiator on the scalp (study area) and on a forearm (control area). On D2 (D1+24h) a solar irradiation corresponding to 2 DEM will be performed on a region of the scalp (studied area), as well as on a forearm (control area). A 3mm biopsy will be performed 15mn after irradiation in these 2 regions to study DNA damage. At D4 (D2+48h) a 2nd biopsy of 3 mm will be performed to study the repair of induced DNA damage.
6691|NCT04142476|Other|interview|interviews with patient's pharmacist to motivate in the hormonotherapy's compliance.
6692|NCT04142463|Other|Care pathway|A care pathway is a complex intervention for the mutual decision-making and organisation of care processes for a well-defined group of patients during a well-defined period. Care pathways can be used to optimise care processes when problems arise on communication, coordination, standardisation and monitoring of care for a specific group of patients. A care pathway for patients treated with OACD, should therefore consist of all relevant sustainable interventions that cover the continuum of the medicines' pathway with the aim to support self-management (e.g. consultations with doctors, contact moments with nurses, telephone follow-up, ...). The role of each stakeholder in the different interventions should be well-described including communication strategies between HCPs from primary and secondary care.
6693|NCT04142450|Device|CoolSculpting® System|Each participant will undergo a single treatment session that comprises timed segments of cooling followed by 2 minutes of manual massage.
6695|NCT04142424|Drug|AZD2693|Within each cohort, 6 subjects will be randomized to receive AZD2693. Dosing for each ascending dose cohort will proceed with 2 subjects in a sentinel cohort, such that 1 subject will be randomized to receive AZD2693. The first cohort will receive SC injection of AZD2693 dose 1. The planned doses for the subsequent cohorts will be determined after review of all available safety or other pertinent data from the previous dose by the safety review committee.
6696|NCT04142424|Drug|Placebo|Within each cohort, 2 subjects randomized to receive placebo. Dosing for each ascending dose cohort will proceed with 2 subjects in a sentinel cohort, such that 1 subject will be randomized to receive placebo.
6697|NCT04142411|Drug|Insulin|Ultrasound guided perineural injection therapy (PIT)
6698|NCT04142411|Drug|Sodium Hyaluronate|Ultrasound guided perineural injection therapy (PIT)
6699|NCT04142411|Device|Ultrasound|Philips Neuromuscular Ultrasound
6700|NCT04142398|Other|Cytology Specimen Collection Procedure|Undergo penile skin cell and anal swab collection
6701|NCT04142398|Procedure|High Resolution Anoscopy with Biopsy|Undergo HRA with biopsy
6702|NCT04142398|Other|Laboratory Biomarker Analysis|Correlative studies
6703|NCT04142398|Procedure|Medical Examination|Undergo anal and penile clinical exam
6704|NCT04142398|Procedure|Physical Examination|Undergo targeted physical exam
6705|NCT04142398|Other|Questionnaire Administration|Ancillary studies
6710|NCT04142385|Procedure|Proctoscopy with Biopsy|Undergo HRA
6712|NCT04142359|Biological|BCG in Combination with N-803|BCG in Combination with N-803
6713|NCT04142346|Behavioral|Sitting + moderate intensity breaks|Participants will be followed in a randomized crossover trial undertaken at Faculty of Human Kinetics between April and August 2019. Participants will attend to the laboratory on twelve separate occasions: visit 1 (day 1), baseline assessments for body composition; visit 2 (day 2), cardiorespiratory fitness assessment; visit 3 (day 3), OGTT and the first randomized experimental protocol; visit 4 (day 4), follow-up OGTT; visit 5 (4-6 days after the first experimental protocol), OGTT and the remaining experimental protocol; visit 6 (day following the previous experimental protocol), follow-up OGTT. An additional 6 visits will be performed following the same rational, after a 2-week period of detraining, where participants will be instructed to refrain from structured exercise. The follow-up assessments for body composition and cardiorespiratory fitness will be accomplished after the protocols.
6714|NCT04142333|Genetic|GIA|Patients receive a secure GIA link from their provider and then are able to send their relatives the link to GIA through texting, email, and/or Facebook messenger. Once a relative clicks on the provided link, GIA's platform is structured as a decision tree, allowing family members to construct a personalized conversation about their family member's test results. This can be done either on a smartphone or computer. GIA provides basic genetics education and risk assessment and connects family members with local genetic counseling resources to continue this conversation and/or go forward with genetic testing. At the end of the conversation, the family member has the option of having a transcript sent to them via email for their reference. The objective of the current study is to evaluate the application of GIA for cascade testing in newly identified high risk breast and gynecologic mutation carriers.
6715|NCT04142320|Device|closed-loop rTMS|Delivers patterned magnetic stimulation in closed-loop fashion
6716|NCT04142320|Device|open-loop rTMS|Delivers patterned magnetic stimulation in open-loop fashion
6717|NCT04142320|Device|sham rTMS|Delivers placebo magnetic stimulation
6718|NCT04142307|Device|Biofeedback Training|Microperimeter biofeedback training as described provides to the patient a variable frequency sound and a luminous stimulus that vary according to the eyes position, thus guides the oculomotor control and fixation stability accordingly.
6719|NCT04142307|Device|Sham - simulated BT|The simulated biofeedback training for Group B involves the following: each session includes presentation of a C10-2 microperimetry program. The procedure involves presentation of a standard LED fixation target (FT) consisting of a small red circle of about 0.76° diameter. Initially the participant will be instructed to stare at the FT circle. Following this stage the participant will be guided to look at the FT and simultaneously to be aware of any flashing lights in the periphery of vision. As performing this task, the participant will actively control the eye movements and similar to computer games, the patient has to identify targets in the peripheral field of vision and respond by pressing a button.
6720|NCT04142294|Dietary Supplement|Histidine|ingestion of encapsulated high quality histidine for four continuous weeks followed by a washout period of 3 weeks
6721|NCT04142255|Biological|FMT|FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
6722|NCT04142242|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
6723|NCT04142242|Other|Blood sample|Blood sample for assessment of antibody persistence
6724|NCT04142229|Device|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
6725|NCT04142229|Other|Sensor-Augmented Pump|Subjects will use their home insulin pump and a Dexcom G6 continuous glucose monitoring sensor.
6726|NCT04142216|Dietary Supplement|Chewing Gum|The patients will chew one piece of regular chewing gum six times in a day and feeling of thirst for ten minutes for three months.
6727|NCT04142203|Other|23 h surgery|Patients were treated in 23 surgical unit
6728|NCT04142190|Drug|ELONVA|Elonva is a solution for injection that contains the active substance corifollitropin alfa. It is available as a pre-filled syringe (100 and 150 micrograms).Elonva is used in women who are undergoing fertility treatment to stimulate the development of more than one mature egg at a time in the ovaries.
6729|NCT04142190|Drug|PUREGON|Puregon contains the active substance follitropin beta. fertilisation). Puregon is administered to stimulate the ovaries to produce more than one egg at a time
6730|NCT04142177|Other|Pain EASE|The internet-based pain self-management program consists of open access to the Pain EASE program (Pain E-health for Activity, Skills, and Education) for the duration of participation in the trial. Pain EASE has 10 pain coping skill modules: pain education, setting personal goals, planning meaningful activities, physical activity (stretching, body mechanics, and a pedometer-based walking program), relaxation, developing healthy thinking patterns, pacing and problem-solving, improving sleep, effective communication, and future planning.
6731|NCT04142177|Procedure|Tailored exercise|Findings from the initial examination and the Keele STarT Back Screening Tool (Hill, et al., 2011) will be used by the physical therapist to guide and tailor the intervention to individual participants which will involve up to 8 treatment sessions with ongoing home exercise. For most participants, exercise and physical activity will focus on walking in addition to motor control and stabilization exercises for the low back with flexibility exercises when lumbar spine stiffness is present.
6732|NCT04142177|Other|Continued Care and Active Monitoring|CCAM will not be standardized keeping in line with the pragmatic nature of this trial. CCAM may be variable across sites and for individual participants reflecting de facto clinical practice for cLBP. Clinical practice may involve pharmacological and non-pharmacological treatments for cLBP. Current analgesics (including opioids, acetaminophen, NSAIDs, topical analgesics (capsaicin), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, skeletal muscle relaxants, and alpha-2-delta ligands (gabapentin-like drugs)) and non-pharmacological treatments may be continued by participants. CCAM participants will be encouraged to discuss pain problems with their treating physician, but not begin new treatments if possible. Patients will specifically be discouraged from starting CBT, chiropractic, or yoga. Other than this, there will be no attempt by study personnel to influence pain management.
6767|NCT04141930|Drug|Baloxavir Marboxil|Individuals willing and able, will receive a weight-based oral dose of baloxavir within 48 hours of symptom onset
6733|NCT04142177|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants randomized to CBT in Step 2 will receive face-to-face treatment with a trained therapist using the VA's CBT-chronic pain (CBT-CP) protocol involving one planning session and 9 treatment sessions (10 total) over 3 months. The VA's CBT-CP protocol consists of 11 core CBT-CP modules that can be completed in up to 10 sessions. Weekly, individual sessions of 45-50 minutes are recommended, although it is recognized that bi-weekly or other arrangements are often made to fit practical needs.
6734|NCT04142177|Procedure|Spinal Manipulation Therapy (SMT)|After examination by a qualified Doctor of Chiropractic (DC), a SMT intervention consisting of up to 10 sessions over 3 months will be designed focusing on spinal manipulation and/or mobilization of the lower thoracic, lumbar and/or sacroiliac joints. Adjunctive use of myofascial and/or stretching techniques are allowed as they are commonly used along with SMT, and can be considered a standard accompaniment to SMT.
6735|NCT04142177|Procedure|Yoga|The Yoga for Veterans with cLBP program consists of up to 10 weekly, 60-minute instructor-led sessions along with 15-20 minutes of yoga practiced at home each non-session day. The initial session is 75 minutes (15 minutes longer than the other sessions). The yoga program can be considered classical hatha yoga with influences from Iyengar and Viniyoga yoga. These styles emphasize modifications and adaptations including the use of props such as straps and blocks to minimize the risk of injury and make the poses accessible to people with health problems and limitations (Iyengar, 1979). The instructor leads participants through a series of 23 yoga poses (32 total variations) at a slow-moderate pace.
6736|NCT04142164|Other|MacInfo presentation|Presentation about intravitreal drug injection
6737|NCT04142164|Other|Placebo presentation|Placebo presentation
6738|NCT04142151|Drug|Sanchitongshu|SanchiTongshu capsule produced by Chengdu Huashen Group Co., Ltd.
6739|NCT04142151|Drug|Aspirin|Aspirin produced by Bayer Co., Ltd.
6740|NCT04142151|Drug|Clopidogrel|Clopidogrel produced by Shenzhen Salubris Co., Ltd.
6741|NCT04142151|Drug|placebo of Sanchitongshu|SanchiTongshu palcebo capsule contained dark brown muscovada sugar and the same inactive excipient (starch). Produced by Chengdu Huashen Group Co., Ltd.
6742|NCT04142138|Other|DASH|DASH diet is based on low salt, high potassium components, and is comprised of mainly fruits and vegetables. During hospitalization we will collect laboratory data of blood and urine, and follow participants clinically by measuring blood pressure.
6743|NCT04142125|Drug|Rivaroxaban 2.5 Mg Oral Tablet bid|Pts will receive rivaroxaban + aspirin
6744|NCT04142125|Drug|Acetylsalicyclic acid 81 mg tablet qd|Pts will receive ASA
6747|NCT04142099|Behavioral|skin to skin contact 60 min group|Newborns are exposed to maternal and child skin within five minutes of birth for 60 min.
6748|NCT04142099|Behavioral|skin to skin contact 20min group|Newborns are exposed to maternal and child skin within five minutes of birth for 20 min.
6749|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
6750|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
6751|NCT04142086|Biological|Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
6752|NCT04142086|Biological|Yellow fever vaccine|Pharmaceutical form: Powder and diluent for suspension for injection Route of administration: Subcutaneous
6753|NCT04142060|Drug|Enzalutamide|Patients will be dispensed with oral enzalutamide 160 mg (four 40 mg capsules) as a self-administered single oral daily dose, continuously.
6754|NCT04142034|Behavioral|the iAmHealthy Behavioral Intervention|"iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~usual care at their clinic for all issues, including overweight and obesity;~a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician"
6755|NCT04142021|Diagnostic Test|Coronary computed tomography angiography|Surgery planning done based solely on coronary computed tomography angiography.
6756|NCT04142008|Device|Walk with Me app|For 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking
6757|NCT04141995|Drug|Digoxin|Tablet, Oral: Generic: 0.125 mg, 0.25 mg
6758|NCT04141995|Drug|5Fluorouracil|5-FU will be given as a 46 hour continuous IV infusion
6759|NCT04141995|Drug|Calcium Leucovorin|IV injection over 90 minutes
6760|NCT04141995|Drug|Irinotecan|IV administration over 90 minutes
6761|NCT04141995|Drug|Oxaliplatin|IV administration
6762|NCT04141982|Diagnostic Test|T-Cell SelectTM Kit|The T-Cell Select kit is intended for the isolation of mononuclear immune cells from whole blood, using positive selection via a magnetic bead-based cell separation system, for use in the T-SPOT.TB assay.
6763|NCT04141969|Dietary Supplement|RLP|RLP nutraceutical
6764|NCT04141969|Other|Placebo|Inert brown powder
6765|NCT04141956|Other|High-Flow Nasal Cannula|Incidence of nasal High Flow Nasal Cannula (HFNC) Oxygen therapy in patients admitted to intensive care.
6766|NCT04141943|Other|Virtual reality|The patients who are allocated to the VR arm will receive information about radiotherapy via virtual reality.
6832|NCT04141371|Drug|physiological serum|daily saline infusion over 3 hours during the vasospasm period
6768|NCT04141917|Combination Product|Point-of-care molecular testing and treatment of influenza|Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged <12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving.
6769|NCT04141904|Drug|Tofacitinib 5 MG [Xeljanz]|Tofacitinib 5mg capsules twice a day for 7-10 days
6770|NCT04141904|Other|Placebo|Placebo capsules twice a day for 7-10 days
6771|NCT04141891|Behavioral|Driving Decision Aid|Healthwise DDA
6772|NCT04141891|Behavioral|Older Drivers Website|National Institute on Aging (NIA) Older Drivers Website
6773|NCT04141878|Behavioral|Aerobic Exercise|Participants will follow a structured program that includes exercise 3 times per week for about 30 minutes each time. The type of aerobic exercise may vary, but will primarily focus on walking tutorials.
6774|NCT04141878|Behavioral|Diet Skills|Participants will attend weekly classes focused on incorporating heart healthy foods into their existing diets. Calories will be restricted, and portion control will be taught with the goal of losing body weight. Hands-on skills will be taught for preparing healthy home-cooked meals by professional chefs.
6775|NCT04141865|Device|Xen|Xen microstent implantation
6776|NCT04141865|Device|Aqueous shunt|Aqueous shunt implantation
6777|NCT04141852|Device|Implantation of VasQ device|"The VasQ external support device (Laminate Medical Technologies, Israel) is a novel Nitinol implant, externally surrounding and supporting the vein and hugging the artery near the junction site, without being in contact with the blood flow."
6778|NCT04141839|Behavioral|Safer Bars|Safer Bars, a primary perpetration prevention program based on a bystander intervention model and the theory of planned behavior. Bar staff are trained to recognize and respond to sexual aggression and its precursors among patrons.
6779|NCT04141826|Dietary Supplement|Hydrolysed whey|500 mL solution of 25 gram hydrolysed whey per day during 4 weeks
6780|NCT04141826|Dietary Supplement|Intact whey|500 mL solution of 25 gram intact whey per day during 4 weeks
6781|NCT04141826|Dietary Supplement|Caseinate|500 mL solution of 25 gram casein ate per day during 4 weeks
6782|NCT04141787|Drug|Ceftriaxone|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
6783|NCT04141787|Drug|Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin)|"Participants with methicillin-sensitive deep-seated staphylococcal infections eligible for treatment on home IV will be randomly assigned to a treatment group of ceftriaxone or standard therapy/usual antibiotics with either cloxacillin, cefazolin or daptomycin. The treatment with one of the three standard therapies/usual antibiotics will be left to the discretion of the treating Infectious Disease doctor, in line with current standards of practice."
6784|NCT04141774|Device|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
6785|NCT04141774|Behavioral|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
6786|NCT04141774|Other|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
6787|NCT04141774|Other|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
6788|NCT04141761|Dietary Supplement|Visbiome|This group will receive Visbiome probiotic in powder form.
6789|NCT04141761|Other|Placebo|This group will receive a placebo in powder form.
6790|NCT04141748|Device|Symphonie Aqua SystemTM|a water filled cylinder that can be pressurized around the residual limb to support body weight
6791|NCT04141748|Procedure|Hand Casting|plaster of Paris or fiberglass bandages are wrapped around the residual limb
6792|NCT04141735|Diagnostic Test|ultrasound|no intervention
6793|NCT04141722|Behavioral|Overnight sleep|Participant sent home to sleep overnight wearing PSG.
6794|NCT04141722|Behavioral|Wake|Participant sent to go about normal daily routine, instructed not to nap, drink caffeine, or engage in strenuous exercise.
6795|NCT04141709|Radiation|local ablative radiotherapy|"Within the scope of the study, irradiation with two irradiation schemes is possible (the scheme applied is recorded in the CRF):~Scheme A 3*10 Gy (once a day, 2-3 days a week)~Scheme B 25*2 Gy (once a day, 5 days a week) The decision which irradiation scheme (3*10 Gy or 25*2 Gy) to use is made by the treating physician based on the anatomical position, the size of the metastases and the expected normal tissue load. Hypofractionated irradiation in three fractions is only possible if the limit values for the risk organs are adhered to. Radiotherapy should be performed with photons."
6798|NCT04141683|Diagnostic Test|Stress Echocardiography|Dynamic stress echocardiography using a cycle ergometer on a semi supine exercise table.
6799|NCT04141683|Diagnostic Test|Pressure volume loop analysis|Pressure volume loop analysis unsing conductance catheter measurements during right heart catheterization.
6800|NCT04141683|Procedure|Tricuspid valve repair or replacement|Tricuspid valve repair or replacement using a surgical or interventionale approach according to local heart team recommendation and patients' preference.
6801|NCT04141670|Drug|S48168|A novel oral small molecule which is designed to repair leaky RYR1 channels
6802|NCT04141657|Other|Pharmacogenetic test|Buccal swabs are a relatively non-invasive way to collect deoxyribonucleic acid (DNA) samples for testing. A buccal swab will be performed to collect DNA from the cells on the inside of a subject's cheek for phenotyping of CYP3A4.
6831|NCT04141371|Drug|Molar Sodium Lactate|daily 3-hour infusion of sodium molar lactate during the vasospasm period
6803|NCT04141644|Drug|Ipilimumab|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
6804|NCT04141644|Drug|Osimertinib|Cohort 1: Osi 40 mg or 80 mg daily; Ipi 3 mg/kg every 3 weeks Cohort 2: Osi 40 mg or 80 mg daily; Ipi 1 mg/kg every 3 weeks
6805|NCT04141631|Drug|EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)|"EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min) will be administered if~Hb < 12g/dL the day before surgery~Hb ≥ 7g/dL AND ScvO2 > 65% in postoperative ICU stay~Postoperative Transfusion will be guided by ScvO2 values :~if Hb ≤ 8 g/dL AND ScvO2 ≤ 65% or if Hb < 7g/dL independently of ScVO2 value"
6806|NCT04141605|Device|SherpaPak Cardiac Transport System|"The Paragonix SherpaPak Cardiac Transport System (SherpaPak CTS) is an ultraportable hypothermic preservation and transport system intended for use with donor hearts. The device is a legally marketed, FDA cleared medical device in the United States and CE Marked medical device in the European Union.~The SherpaPak CTS consists of multiple components: 1) outer transport shipper which contains within various non-ice based temperature controlled packaging elements, 2) an inner and outer hard shell assembly which provides a rigid barrier enclosure in which the heart is immersed and suspended in a cold storage solution cleared for use in storing and transporting donor hearts, 3) a data logger that monitors and displays the temperature of the cold storage solution in which the heart is stored during transport, and 4) four size heart connectors designed to accommodate various size aortic stem diameters by which donor hearts are attached."
6807|NCT04141592|Procedure|Bariatric Surgery|Already clinically indicated surgical procedures
6808|NCT04141579|Drug|Evolocumab 140 MG/ML [Repatha]|Evolocumab (also known as Repatha, formerly referred to as AMG 145) is a human monoclonal immunoglobulin G2 (IgG2) that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) preventing its interaction with the low-density lipoprotein receptor (LDLR). The inhibition of PCSK9 by evolocumab leads to increased LDLR expression and subsequent decreased circulating concentrations of low-density lipoprotein cholesterol (LDL-C).
6809|NCT04141566|Procedure|Perineal pseudocontinent colostomy|"The procedure is performed in 2stages: as a usual APR starting by a laparoscopic approach esnsuring a complete mesorectal excision,then a perineal approach ensuring an extended excision of the entire internal and external sphincter complex, allowing the excision of the specimen.~8to10cm of tof the colon is resected and harvested as a free graft, stripped of its meso and epiploics , then from its mucosa and placed in an antibiotic solution for 10min. This graft is wrapped snugly around the end of the colon 2-3 cm from its distal end for 1 and a half round. Absorbable 3.0 Sutures are taken to hold it in place. The end of the colon is brought out as a stoma in the perineum.~Colonic irrigations are started from the third day according to the protocol previously reported. Patients and one of their family members are daily educated and assisted while performing colonic irrigations by specialized nurses."
6810|NCT04141566|Procedure|Permanent left iliac colostomy|After a usual laparoscopic APR, the perineal wound is closed and a permanent left iliac colostomy is performed
6811|NCT04141553|Drug|Diltiazem Injection|Randomization to one of to active comparator groups
6812|NCT04141540|Genetic|Molecular analyses|Comparaison of the molecular profil between two monozygotic twins carrying a deletion 22q11.2
6813|NCT04141527|Procedure|Spinal analgesia|Spinal analgesia (SA) was provided by a resident or specialist anaesthesiologist with the patient in a sitting or a recumbent position. A pencil-point needle, primarily 27 G (0.4 mm), otherwise 25 G (0.5 mm), was used for transdermal intrathecal administration of 2.0 ml of sufentanil 5 µg/ml (Sufenta®, Janssen-Cilag AB, Solna, Sweden) at low-lumbar level. Blood pressure was recorded before, immediately after, and at five-minute intervals for 20 minutes after the block. Any decrease in blood pressure by more than 30 % from the baseline level despite infusion of crystalloid was defined to indicate maternal hypotension.
6814|NCT04141514|Other|therapeutic fasting|fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
6815|NCT04141501|Drug|Psilocybin|single dose of psilocybin (25mg). orally in form of a capsule
6816|NCT04141501|Drug|Placebo oral capsule|single dose of mannitol (100%)
6817|NCT04141488|Other|experimantal group|Control Group
6818|NCT04141475|Dietary Supplement|Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
6819|NCT04141475|Dietary Supplement|Placebo - Physiomance acide lipoïque gold|1 capsule of 300 mg in the morning outside a meal and 1 capsule of 300 mg in the evening outside a meal during 12 weeks
6820|NCT04141462|Genetic|blood sample|blood test
6821|NCT04141449|Other|Potlako intervention|Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
6822|NCT04141449|Other|Enhanced care|Provider education and limited patient counseling.
6823|NCT04141436|Behavioral|Interventions Based on Hypnofertility|Affirmation Visualization Imagination Relaxation
6824|NCT04141436|Other|Routine clinical procedure|Routine clinical procedure
6825|NCT04141423|Drug|Tregopil|Insulin Tregopil is recombinant human insulin modified by a single amphiphilic oligomer covalently linked via an amide bond to lysine at position 29 of the B-chain. This alters the physicochemical characteristics of the molecule, leading to enhanced stability and resistance to intestinal degradation following oral administration.
6826|NCT04141410|Drug|Levosimendan|Use of Levosimendan in cardiogenic shock during sepsis
6827|NCT04141410|Device|Echocardiography|Use of global longitudinal strain in cardiogenic shock during sepsis
6828|NCT04141397|Genetic|Initiation of POG-related WGTA|POG-related WGTA generally involves collecting biopsy samples, applying whole-genome and transcriptome sequencing, and using bioinformatics analysis to interpret sequence data and inform clinical decision-making.
6829|NCT04141397|Genetic|Usual care|Usual care, not involving the initiation of POG-related WGTA
6830|NCT04141384|Device|Modular Interactive Tiles System, MITS|The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
6833|NCT04141358|Diagnostic Test|Advanced ultrasound measurements|"Clinical interventions and procedures:~Consent at 0 week~Clinical data collection at 0 week~Strain for native artery at 0 week~Young's modulus for native artery at 0 week~Intimal medial thickness for native artery at 0 week~Ultrasound blood volume flow measurement at 0 week~Vessel diameter at 0 week~Blood pressure at 0 week~BMI at 0 week~Intra-operative blood volume flow measurement at AVF surgery time~Strain for native artery at 6 weeks~Young's modulus native artery at 6 weeks~Intimal medial thickness native artery arteries at 6 weeks~Ultrasound blood volume flow measurement at 6 weeks~Vessel diameter at 6 weeks~Blood pressure at 6 weeks~BMI at 6 weeks"
6834|NCT04141345|Diagnostic Test|cardiopulmonary exercise test|Patients performed an upright graded bicycle exercise using a personalized protocol or performed a motorized treadmill exercise using a modified Bruce protocol. Peak VO2 and peak respiratory exchange ratio (RER) were defined as the highest 30-second average value obtained during exercise. The anaerobic threshold (AT) was determined by V-slope method. The VE(minute ventilation)/VCO2 (carbon dioxide production) at AT was calculated as the average VE/VCO2 for 1 minute during AT and immediately after AT. If AT could not be determined, the lowest VE/VCO2 was determined by averaging the three lowest consecutive 0.5-minute data points.
6835|NCT04141332|Diagnostic Test|EEG was recorded by EEG Machines|EEG was recorded by EEG Machines
6836|NCT04141319|Drug|Ketorolac|30ml of local infiltration solution containing 60mg ropivacaine
6837|NCT04141319|Drug|Ropivacaine|30ml of local infiltration solution containing 6mg ketorolac
6838|NCT04141319|Drug|Epinephrine|30ml of local infiltration solution containing 0.1mg epinephrine
6839|NCT04141306|Other|Administrative data|Evaluation of month and year of birth, sex, referent doctor and surgeon
6840|NCT04141306|Other|Clinical data|Evaluation of diagnostic circumstances, vital status at last follow up
6841|NCT04141306|Other|Histological data|Evaluation of Pathology report of thyroid surgery
6842|NCT04141306|Other|Imaging data|Evaluation of scintigraphy, MRI, scan
6843|NCT04141306|Other|Biological data|Evaluation of thyroglobulin, antithyroglobulin antibodies
6844|NCT04141306|Other|Further treatment|Evaluation of surgery, radiotherapy, targeted therapy
6845|NCT04141293|Procedure|alveolar recruitment|Alveolar recruitment is a procedure to re-expand collapsed lung regions with the transient increment in transpulmonary pressure.
6846|NCT04141254|Other|Debriefing and educative components|The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month
6847|NCT04141254|Other|Without debriefing and educative components|Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
6848|NCT04141241|Drug|Ecklonia cava Phlorotannin|Drugs that have been administered prior to participation in this study that are not expected to affect the results of this study will be accepted at the investigator's discretion.
6849|NCT04141215|Biological|BIOBank bone paste|BIOBank bone paste (PPT322)
6850|NCT04141215|Biological|BIOBank cortico-cancellous bone powder|BIOBank cortico-cancellous bone powder (PPT6)
6851|NCT04141189|Procedure|weekly|fetal surveillance frequency
6852|NCT04141189|Procedure|bi-weekly|fetal surveillance frequency
6853|NCT04141176|Device|Spiri+|CPAP Spiri+ will be weared during one night for each included patient.The validation of the CPAP Spiri+ algorithm will be in the first 10 patients and appreciation of overall clinical efficacy on the 10 last OSAS.
6854|NCT04141163|Drug|Metformin|Metformin, 1,1 dimethylbiguanide, or systematic (IUPAC) name N,N-dimethylimidodicarbonimidic diamide, is an oral anti-diabetic medicine approved in the US by the FDA in 1994. It is marketed alone under the names metformin (generic), Glucophage XR, Riomet, Fortamet, Glumetza, Obimet, Gluformin, Dianben, Diabex, and Diaformin and in combination with other drugs under the names Actoplus Met, Metaglip, Glucovance, Janumet, Kombiglyze XR, and PrandiMet
6855|NCT04141163|Drug|Placebo oral tablet|No therapeutic effect
6856|NCT04141150|Drug|[18F]APN-1607|In this study, all patients will receive one injection of [18F]APN-1607, a PET radiopharmaceutical selective for fibrillar tau. For the injection, subjects will receive a target dose of 7 mCi IV as a bolus injection. [18F]APN-1607 injection will be followed by a 10 ml saline flush.
6857|NCT04141137|Device|TricValve® System|The TricValve® Delivery System (catheter) with already pre-mounted biological heart valve is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is released at the implantation site and positions itself as per the anatomy - self expanding frame.
6858|NCT04141124|Other|breathing exercise/HRV-biofeedback|5 min of relaxing breathing, coupled with biological feedback.
6859|NCT04141124|Other|Relaxing Breathing|5 minutes of relaxing breathing guided by a computer helping to follow inspiration and expiration.
6860|NCT04141124|Other|Control|5 minutes of reading fictitious biological medical results
6861|NCT04141111|Device|Continuous Glucose Monitoring (CGM)|"On each visit (baseline, 4, 8, and 12 months), participants received an iPro2 CGM device (MiniMed Medtronic), placed according to the manufacturer's standard procedure. The iPro2 was used each time for 7-days. During this period, patients were asked to perform 4 SMBG measurements daily for calibration (fasting, lunch, dinner, and before bed). Patients received a diary to register food intake, physical activity and medication, SMBG values, and any diabetes-related event (extra consultations, phone calls, etc) in the previous 4 months.~Each time, CGM data was interpreted by an expert clinician, and a report was delivered, within one week, to the respective healthcare team. This report was discussed together by the patient and one member of the healthcare team, either in consultation or by phone, agreeing on any necessary therapeutic changes. If necessary, extra consultations for nutrition, nursing, or education, were scheduled, to address specific needs identified during rCGM review."
6862|NCT04141098|Device|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.|All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board. Any patient meeting any of the three intraoperative exclusion criteria will receive an alternative standard of care therapy.
6863|NCT04141085|Other|Endometrial biopsy|All groups will undergo a mock frozen embryo transfer cycle with an endometrial biopsy being performed as opposed to an embryo transfer
6864|NCT04141072|Diagnostic Test|Shrunken Pore Syndrome|eGFR Cystatin C ≤ 60% of eGFR Creatinine
6865|NCT04141059|Dietary Supplement|Oligopin|Oligopin capsules composition is :100 mg Oligopin®, 150 mg Maltodextrin, 1.5 mg Mg stearate.
6866|NCT04141059|Dietary Supplement|Placebo|Placebo capsules composition is: 250 mg Maltodextrin and 1.5 mg Mg stearate
6867|NCT04141046|Device|XCSITE100 Stimulator - Individualized theta-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
6868|NCT04141046|Device|XCSITE100 Stimulator - Individualized alpha-tACS|20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
6869|NCT04141046|Device|XCSITE100 Stimulator - Active Sham|20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
6870|NCT04141033|Diagnostic Test|assessment of neopterin levels|neopterin is a macrophage biomarker used for diagnosis of active periodontitis and the response to treatment
6871|NCT04141020|Procedure|Microsurgical clipping|Standard of care microsurgical clipping of an unruptured cerebral artery aneurysm.
6872|NCT04141020|Procedure|Endovascular treatment|Standard of care endovascular treatment of an unruptured cerebral artery aneurysm.
6873|NCT04141020|Drug|Sirolimus|Daily oral Sirolimus 2 mg tablets, adjusted as necessary per treating physician.
6874|NCT04140994|Device|rTMS device|Participants will participate in 1 session of neuronavigated (TMS Navigator, Localite, Schloss Birlinghoven, D-53757, Sankt Augustin, Germany ) iTBS (patterned form of TMS) coupled with motor learning.
6875|NCT04140981|Device|ultrasounography|in preoperative period, airway ultrasounagraphy for all patients will be made
6876|NCT04140968|Drug|Utrogestan|300mg Utrogestan (1 tablet 100mg + 1 tablet 200mg) in the second and third menstrual cycle daily from cycle day 15 to 26.
6877|NCT04140955|Procedure|Tapering plan and telephone counselling|Before discharge, a tapering plan is made in collaboration between the patient and one of the investigators. The telephone counselling will include guidance of the patient and/or adjustments of the tapering plan if needed.
6878|NCT04140942|Behavioral|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout training.
6879|NCT04140942|Behavioral|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
6880|NCT04140929|Other|Oral Health Tool Box|Please see, description of the intervention group
6881|NCT04140916|Device|Midline catheter|Peripherally inserted short intravenous catheter
6882|NCT04140916|Device|PICC-line catheter|Peripherally inserted long intravenous catheter
6883|NCT04140903|Drug|Early transition to oral antibiotics|Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
6884|NCT04140903|Drug|Standard treatment of intravenous antibiotics|Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
6885|NCT04140890|Behavioral|Habit Formation|Treatment sessions consist of 12 weekly health coaching sessions at participants' home. During the intervention period, an occupational therapist will help the participant to commit to developing new simple habits (dietary habits or physical activity habits) in each 60-minute session.
6886|NCT04140890|Behavioral|Education|In the education group, participants will receive newsletters containing general healthy aging materials over 12 weeks. A trained research assistant will call participants to verify receipt of the newsletter, and answer their questions about the materials. Each phone call will last ~15 minutes.
6887|NCT04140877|Device|Visu|An experimental (test) virtual reality display
6888|NCT04140851|Dietary Supplement|Dietary fiber intervention|Dietary intervention
6889|NCT04140851|Dietary Supplement|Normal diet|Normal diet
6890|NCT04140838|Behavioral|Acceptance and Commitment Therapy (ACT)|Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.
6891|NCT04140838|Behavioral|Behavioral Activation Therapy for Depression (BATD)|"Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about."
6892|NCT04140838|Other|Treatment as Usual (TAU)|Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
6894|NCT04140812|Diagnostic Test|mass spectrometry (LC-MS/MS)|Blood collection (5 drops) during newborn-screening (36-72h after birth) or postnatal hospitalization (<36h after birth). The blood sample will then be examined using mass spectrometry (LC-MS/MS) for 125 proteins.
6895|NCT04140799|Device|vocal cord ultrasonography|assess vocal cord motion and recurrent nerve function by Transcutaneous laryngeal Ultrasonography in patients scheduled for anterior cervical spine surgeries
6896|NCT04140786|Drug|Gentamicin Sulfate, Injectable|10mg/kg prepared from commercially available stock (typically Kabi Pharmaceuticals) by licensed pharmacists.
6897|NCT04140773|Dietary Supplement|D-serine|Capsule D-serine
6898|NCT04140773|Other|Placebo|Capsule D-serine
6899|NCT04140760|Other|Symprove|A liquid probiotic
6900|NCT04140760|Other|Symprove placebo product|An inert placebo
6901|NCT04140734|Device|Spacer Graft|In this prospective, randomized clinical trial, patients who will already be undergoing lower eyelid retraction repair with a spacer graft will randomly be assigned via a randomization web-site to receive 1 of 3 spacer grafts: hard palate, autologous auricular cartilage, and porcine acellular dermal matrix (Enduragen). Both the patient and the surgeon will know which of the three possible grafts are being used.
6902|NCT04140721|Drug|Placebo oral tablet|Placebo pill identical to moxonidine administered for 4 weeks
6903|NCT04140721|Drug|Moxonidine Pill|Moxonidine pill administered for 4 weeks
6904|NCT04140708|Behavioral|Exercise--Rock Steady Boxing class|Rock Steady Boxing is a class designed specifically for those with Parkinsonism and movement difficulty using explosive and fine tuned movements as well as cognitive learning skills.
6905|NCT04140695|Drug|Tradipitant|BID
6906|NCT04140695|Drug|Placebo|BID
6907|NCT04140682|Device|PAV+ mode|PAV+ mode by using Puritan-Bennett 840 ventilator
6908|NCT04140682|Device|PSV mode|PSV mode by using Puritan-Bennett 840 ventilator
6909|NCT04140669|Device|Automated Myocardial Performance Index (MPI)|Automated Myocardial Performance Index will be performed using Samsung HERA W10 prior too fetal surgical interventions, during surgery, and following surgery.
6910|NCT04140656|Other|Plantar sensitive exercises|"Plantar sensitive exercises:~40 minutes / 3 days per week / 8 weeks Warm up exercise (5 minute) Walking on different 4 different textured floors and hot floor (15 minute) Trying to recognize small objects with the soles of the feet (5min) Seated work with barbed ball and balance pad (5min) Massage to the sole of the foot with different textured fabrics (5min) Cooling exercise (5 min)"
6911|NCT04140656|Other|Textured insole|"Textured insole group.~Plantar sensitive exercises with insole 40 minutes / 3 days per week / 8 weeks (all exercises will be done with insoles) Warm up exercise (5 minute) Walking on flat ground (15 minute) Exercise with roller under the sole of the foot (5 minute) Seated work with barbed balance pad (5 min) Dorsi flexion and plantar flexion and hip flexion exercises (5min). Cooling exercise (5 min)"
6912|NCT04140643|Device|Ozonated water delivering device effects on the oral health of pregnant women|Oral Hygiene instructions and use of an ozonated water delivering device in pregnant women for a period of 75 days.
6913|NCT04140643|Behavioral|Oral hygiene instructions|Oral Hygiene instructions
6914|NCT04140630|Other|No intervention|No intervention; 1 week observational study
6915|NCT04140617|Behavioral|Exposure to aerosol of electronic cigarette|Exposure to aerosol of electronic cigarette (30 min)
6916|NCT04140604|Other|Lactobacillus salivarius AP-32|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
6917|NCT04140604|Other|Bifidobacterium lactis CP-9|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
6918|NCT04140604|Other|Placebo|Infants will be given the content of one capsule (mixed in infant formula or breast milk) twice daily (morning and evening) for 15 weeks.
6919|NCT04140591|Drug|Proton-pump inhibitor|PPI: Pariet EC 20mg/QDAC
6920|NCT04140591|Drug|Propranolol+Proton-pump inhibitor|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure >90mmHg) PPI: Pariet EC 20mg/QDAC
6921|NCT04140578|Drug|Ertapenem|inject from iv drip before endoscopic cyanoacrylateinjection obliteration
6922|NCT04140539|Biological|OTL-101|Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo using a lentiviral vector (LV) encoding the human adenosine deaminase (ADA) gene.
6923|NCT04140526|Drug|ONC-392|ONC-392 will be given by intravenous infusion, once every 21 days (Q3W).
6924|NCT04140526|Drug|Pembrolizumab|Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).
6925|NCT04140513|Radiation|Fludeoxyglucose F-18|Given via injection
6926|NCT04140513|Procedure|Positron Emission Tomography|Undergo dPET
6927|NCT04140500|Drug|RO7247669|Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)
6928|NCT04140487|Drug|Azacitidine|Given IV
6929|NCT04140487|Drug|Gilteritinib|Given PO
6930|NCT04140487|Drug|Gilteritinib Fumarate|Given PO
6931|NCT04140487|Drug|Venetoclax|Given PO
6932|NCT04140474|Device|Archimedes procedure|All patients will initially have a scanner necessary for planning by the Archimedes system of the tunneling path. each patient will then undergo a general anesthesia as for any bronchoscopy. Then start the Archimedes procedure itself to reach the SPN
6933|NCT04140461|Drug|Amphotericin B|The trial group and the control group received AmB 0.5mg/kg for 4 weeks and 0.7mg/kg for 2 weeks respectively.
6934|NCT04140461|Drug|Flucytosine|The trial group and the control group received 100mg/kg for 4 weeks and for 2 weeks respectively.
6935|NCT04140448|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML
6936|NCT04140448|Device|Ultra-wide Fluorescein Angiography|Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
6937|NCT04140435|Device|EUS-guided through-the-needle microbiopsy forceps (Moray)|"EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through‑the‑needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology."
6938|NCT04140422|Other|Hyperosmolar eye drops|Application of one preservative-free hyperosmolar eye drop, when waking up and one eye drop 30 min later to one eye by the investigators
7022|NCT04139694|Behavioral|Food plan without cinnamon supplementation|Cardiometabolic diet only
6939|NCT04140422|Other|Placebo|Application of one preservative-free lubricating eye drop, when waking up and one eye drop 30 min later to the fellow eye by the investigators
6940|NCT04140409|Drug|Sandostatin|All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.
6941|NCT04140396|Drug|Saline infusion|Normal saline infusion at 10mL/hour
6942|NCT04140396|Drug|Lidocaine infusion|Lidocaine infusion at 1.0mg/kg/hr
6943|NCT04140383|Procedure|Cataract Surgery|Cataract surgery was performed by using phacoemulsification technique, routinely. But other techniques for instance extra or intracapsular cataract extraction (ECCE, ICCE) techniques were performed when needed. Phacoemulsification technique was performed by 2 experienced surgeon (G.A. and E.C.) under topical anesthesia, thorough limbal incision. Foldable single piece hydrophobic acrylic intraocular lens (IOL) was inserted in the bag. In the presence of complications related to anterior or posterior capsules, 3 pieces IOL was preferred. When ECCE technique was chosen, single piece polymethyl methacrylate IOL was inserted.
6944|NCT04140370|Other|There is no intervention|There is no intervention
6945|NCT04140344|Other|Text Message Group|The intervention group will receive automated text messages every day for the first week, and every other day for the second week post-operatively. The text messages will follow a series of pre-defined standardized scripts (Appendix 3) with embedded hyperlinks to a video from the providers with further advice. The patient is directed not to respond to the text messages, but to call for any questions or concerns. The text message group will receive a 30-day post-operative phone call to evaluate: number of ED visits, hospital readmissions, and to re-administer the questionnaires completed at baseline visit. Other data to be collected may include the following: number of phone calls to provider, MyChart messages to provider, pain medications, and new problems like pain and infection.
6946|NCT04140331|Device|Accelerometer|Patient will wear the accelerometer for 7 consecutive days to measure the level of physical activity.
6947|NCT04140318|Drug|sintilimab|Sintilimab 200mg, iv, 30-60min, q3w;
6948|NCT04140318|Drug|nab-paclitaxel|Nab-paclitaxel: 125 mg/m2 iv d1、d8, q3w
6949|NCT04140305|Drug|RPC-1063|Oral capsule
6950|NCT04140292|Drug|Photodynamic therapy (PDT)|"PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells~Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered."
6951|NCT04140292|Drug|Vitamin D3|D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment
6952|NCT04140279|Drug|Latanoprostene Bunod|Ophthalmic solution
6953|NCT04140279|Drug|Placebo|Ophthalmic solution, no active ingredient.
6954|NCT04140266|Drug|Dapivirine (DPV) Vaginal Ring (VR)-004|Vaginal ring containing 25 mg of DPV
6955|NCT04140266|Drug|Truvada Tablet|Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)
6956|NCT04140253|Behavioral|Pelvic floor muscle training (PFMT) with lumbopelvic stabilization|"Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.~Educating of probands about anatomy, physiology, and pelvic floor muscles functions~Training of pelvic floor muscles in different position~Training of pelvic floor muscles with lumbopelvic stabilization~Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist."
6957|NCT04140240|Behavioral|intervention group|Parallel Assignment a experimental design with pre test and post test
6958|NCT04140227|Drug|NOV03|100% Perfluorohexyloctane
6959|NCT04140214|Drug|Hypertonic saline|Nebulized hypertonic saline solution (6%)
6960|NCT04140214|Drug|Carbocysteine 750 MG|Carbocisteine tablet
6961|NCT04140201|Drug|Simvastatin 40mg|Drugs that lower lipid level
6962|NCT04140201|Drug|Fenofibrate 200mg|Drugs that lower lipid levels
6963|NCT04140201|Drug|Omega 3 fatty acid|Drugs that lower lipid levels
6964|NCT04140188|Diagnostic Test|Senti-Scint (99mTc- pertechnetate combined with human albumin)|Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.
6965|NCT04140162|Drug|Daratumumab|"Induction: 16 mg/kg actual body weight IV weekly (weeks 1-8; total of 8 doses) then every 2 weeks (weeks 9-24; total of 8 doses).~Consolidation: 16 mg/kg actual body weight IV every four weeks (weeks 25-36)~Maintenance: 16 mg/kg actual body weight IV every eight weeks (weeks 37-88)"
6966|NCT04140162|Drug|Lenalidomide|"Induction: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 1-24)~Consolidation: 25 mg PO once daily, on days 1-21 of each 28-day cycle (weeks 25-36)~Maintenance: 10 mg PO once daily, on days 1-21 of each 28-day cycle until progression or intolerance~Maintenance: 10 mg PO once daily, on days 1-21, weeks 37+ until progression"
6967|NCT04140162|Drug|Bortezomib|Consolidation: 1.5 mg/m2 SQ on day 1, 8, 15 and 22 of each 28-day cycle (weeks 25-36)
6968|NCT04140162|Drug|Dexamethasone|Induction and Consolidation: 40 mg (or reduced dose of 20 mg) PO or IV/week once daily, on day 1, 8, 15 and 22 of each 28-day cycle (weeks 1-36).
6969|NCT04140149|Behavioral|Living with Hope|12-week, CBT-based, psychoeducational skills class
6970|NCT04140136|Dietary Supplement|Tocotrienols|Tocotrienols as a potent antioxidant to modulate oxidative stress and inflammatory response
6971|NCT04140136|Dietary Supplement|Placebo|The placebo is similar in appearance, but does not contain tocotrienols and consist of palm oil
6972|NCT04140123|Drug|ZSP1601|ZSP1601 tablets be taken orally for 28 days.
6973|NCT04140123|Drug|ZSP1601 Placebo|Subjects will receive matching placebo of ZSP1601
6974|NCT04140110|Other|Intensive BP lowering|The aim is to achieve a systolic BP level of <120mmHg within 30 minutes after randomisation and to maintain this BP level for the next 72 hours (or until hospital discharge or death if this should occur earlier).
7023|NCT04139681|Drug|A. Vogels Sore Throat lozenges|5 times 1 A. Vogels sore throat lozenges daily for 4 days
7024|NCT04139668|Drug|Naltrexone 380 MG [Vivitrol]|Three 4ml intramuscular injections of naltrexone 380mg (Vivitrol) administered over 12 weeks (one injection every 4 weeks)
7058|NCT04139382|Other|Face-to-Face Consultation|A face-to-face consultation comprising clinical history, contraception planning, explanation of medical method of abortion
6975|NCT04140097|Other|Prospective monitoring of a large variety of parameters|Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
6976|NCT04140084|Device|Real-life clinical meetings|Study coordinators will identify potentially eligible parent/patient dyads and adult patients based on a chief complaint related to head trauma recorded at the time of ED registration and communication with treating clinicians in realtime. After using the decision aid with their health professional, a cognitive interview session will then be organized with the dyads of participants (parents/patients and clinicians) to address any usability issues. These interviews will be audio recorded and transcribed verbatim for content analysis and future reference. This process will allow to identify any conceptual barriers and unanticipated user needs. Written consent form will be signed by participants.
6977|NCT04140058|Drug|Ondansetron|ondansetron was administered 20 minutes prior to spinal anesthesia.
6978|NCT04140058|Drug|Normal saline|Placebo of 10 mL normal saline was administered.
6979|NCT04140045|Other|Water intake|Water intake will be manipulated in both arms to create a hypohydrated state and a euhydrated state, post-exercise
6980|NCT04140032|Behavioral|Multi-level preschool obesity control intervention|The multi-level intervention is a preschool-based program that integrates healthy nutrition and physical activity policies and practices into preschool operations via the Sesame Street Healthy Habits for Life curriculum. In addition to the curriculum, the intervention includes coaching sessions to enhance teacher lesson planning to routinely include nutrition and physical activity; as well as assist preschool site directors with implementing policy changes and parent engagement sessions.
6981|NCT04140019|Diagnostic Test|CMR|Early CMR with adenosine stress/rest perfusion before invasive coronary angiography.
6982|NCT04140006|Drug|ALN Gel|Flapped surgery for insertion of dental implant with topical application of ALN gel
6983|NCT04140006|Drug|BMP Gel|Flapped surgery for insertion of dental implant with topical application of BMP gel
6984|NCT04140006|Drug|Mixed Gel|Flapped surgery for insertion of dental implant with topical application of mixed gel of ALN and BMP
6985|NCT04140006|Drug|Control|Flapped surgery for insertion of dental implant without topical application of any gel
6986|NCT04139993|Biological|RBX7455|To evaluate intratumoral immunomodulatory effects of RBX7455 in operable breast cancer patients, tumor tissue samples from the diagnostic biopsy prior to RBX7455 and surgical specimen after RBX7455 treatment will be utilized.
6987|NCT04139980|Device|Virtual Reality (VR)|Each VR session is 30 minutes long. Participants are able to pause or discontinue at any time. Each participant will receive one VR sessions five times per week over the course of a two-week period.
6988|NCT04139967|Radiation|Short course radiation therapy|25 Gray in 5 fractions over 5-7 days
6989|NCT04139954|Other|There is no intervention in the study|There is no intervention in the study
6990|NCT04139941|Diagnostic Test|Test for HCV antibodies with an RDT|Fingerstick whole blood, plasma and serum of each participant is tested with three investigational HCV RDTs and one reference HCV RDT. Plasma is also used for testing with the composite reference standard, HCV viral load and genotyping. All participants are also tested for HIV with an HIV RDT.
6991|NCT04139928|Dietary Supplement|Picometer-ionic form of magnesium chloride|Single-dose (300 mg) of the picometer-ionic form of magnesium chloride
6992|NCT04139928|Dietary Supplement|Magnesium citrate or magnesium oxide|Single-dose (300 mg) of magnesium citrate or magnesium oxide
6993|NCT04139928|Dietary Supplement|Placebo|Placebo
6994|NCT04139915|Drug|Dactolisib|TORC1 inhibitor
6995|NCT04139915|Drug|Placebo|Placebo capsule
6996|NCT04139902|Drug|Dostarlimab (TSR-042) (singly)|"If patients are randomized to Dostarlimab (TSR-042) alone, during the Pre-operative Phase, 500mg will be administered through an IV over 30 minutes, on Cycle 1 Day 1, and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4), and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
6997|NCT04139902|Drug|Dostarlimab (TSR-042) and TSR-022 (combination)|"If patients are randomized to the combination, Dostarlimab (TSR-042) and TSR-022, during the Pre-operative Phase, Dostarlimab (TSR-042) 500mg and TSR-022 900mg will be administered through an IV over 30 minutes on Cycle 1 Day 1 and then again on Cycle 2 Day 1.~Surgery will occur 1-4 weeks after completion of the pre-operative phase.~During the Post-operative Phase, Dostarlimab (TSR-042) 500mg will be administered through an IV over 30 minutes for 4 cycles every 3 weeks (Cycles 3-4) and then 1000mg will be administered through an IV over 30 minutes every 6 weeks (Cycles 5-10) for approximately 48 weeks."
6998|NCT04139889|Diagnostic Test|Confocal Laser Endomicroscopy|"Confocal laser microendoscopy (CLE) as a new non-invasive imaging technique can be used for optical biopsy, which can perform real-time microscopic information of tissue in vivo at cellular level with resolutions up to 1μm and magnifications up to 1000 times. CLE is now being increasingly used with very promising results in gastroenterology, especially in the diagnostic investigation of Barret's esophagus, stomach cancer, colorectal cancer and various lesions of the biliary tract. With an intravenous injection of fluorescein, probe-based CLE (pCLE: GastroFlex probe with the Cellvizio laser system, Mauna Technologies, Paris, France) allows us to view the interstitial spaces, cells, and small capillaries in a window of 240 μm and to a depth of 60 μm."
7025|NCT04139668|Behavioral|Motivational Enhancement Therapy and Cognitive Behavioral Therapy|Weekly Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT), based upon the Brief Counselling for Marijuana Dependence Manual published by the Substance Abuse and Mental Health Services Administration (SAMHSA), for 12 weeks
7338|NCT04137055|Drug|ZSP0678-180mg|ZSP0678 tablets administered orally under fasted condition
6999|NCT04139876|Procedure|Open Haemorrhoidectomy|Patient operated in the lithotomy position. The external components are grasped by clamps using gentle traction. Diathermy is used for dissection and hemostasis. The skin is incised midway to one-third of the distance from the top of the pedicle, thus, minimizing the skin excision. The subdermal fascia continuing into a submucosal fascia covering the internal anal sphincter is identified as are fibers passing between the hemorrhoid (H) and this fascia. The H is dissected free from the underlying internal sphincter in this plane, leaving the sphincter unharmed. The anal mucosa is incised at the transition from anal mucosa to hemorrhoidal mucosa and only anal mucosa overlying the H is excised. Only the caudal part of the H is excised. With the H held with gentle traction it is divided at the anal orifice. There will thus be a residual part of the H intra-anally with its caudal end 1-2 cm proximal to the anal orifice.
7000|NCT04139876|Procedure|LigaSure Hemorrhoidectomy|Patient is operated in the lithotomy position. The main haemorrhoidal (H) masses are identified and delineated. The H are prolapsed out from the anal canal with Allis clamps or similar pick up forceps. Tension is applied to visualise the junction between the nodule and the mucosal wall (internal) or the perianal tissue (external). A small V-shaped anodermal seal is performed by applying the LigaSure (LS) forceps close to the edge of each pile. The seal is then transacted with scissors along the line of coagulum. Care should be taken to limit the amount of tissue removed to minimize the stricture risk. Repeated applications of the device are performed and the excision is continued into the anal canal, lifting the pile from the internal anal sphincter to the level of the vascular pedicle that is finally sealed by LS and divided.
7001|NCT04139863|Diagnostic Test|aMMP-8 chairside test|No test
7002|NCT04139850|Drug|Discontinuation of antiviral treatment in chronic hepatitis B cohort patients|For the selective patients in the cohort with long-term antiviral therapy and with conditions such as HBeAg negative or loss more than one year, antiviral therapy is able to be discontinued with an intensive inspection who agreed to the process. If there are need of this intervention, another multicenter IRB approval will be taken.
7003|NCT04139837|Behavioral|Health screening, community health talks or activities on frailty|Screening for frailty using the FRAIL scale to categorize participant's status as robust, prefrail and frail. A series of community health talks or activities on frailty will be provided to each category of participants for the prevention or management of frailty.
7004|NCT04139824|Drug|Xanthine Oxidase Inhibitor|LC350189 200mg qd
7005|NCT04139824|Drug|nonsteroidal anti-inflammatory drug|Naproxen 500mg BID
7006|NCT04139811|Other|Pars Plana Vitrectomy|vitrectomy with and without ILM peeling
7007|NCT04139798|Drug|NOV03|100% Perfluorohexyloctane
7008|NCT04139798|Drug|Placebo|Saline solution (0.6% sodium chloride solution)
7009|NCT04139785|Other|Moodbuster|"Moodbuster intervention comprises three elements: (1) a web-based interface providing the patients access to CBT therapies, (2) a web-based portal for the trial co-ordinator and researchers, where they can view participation, amend modules and send login codes, (3) a mobile phone component which enables daily EMA monitoring of mood state, cognitions, activities, social interaction, and sleep.~The mobile application will be used to capture EMA data."
7010|NCT04139772|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous (iv) infusion every 3 weeks plus oral prednisone 5 mg twice daily for a maximum of 10 cycles.
7011|NCT04139772|Drug|Abiraterone Acetate or Enzalutamide|"Patient will receive Abiraterone or Enzalutamide based on previous treatment.~Abiraterone given orally at the dose of 1000 mg daily plus oral prednisone 5 mg twice daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment.~Enzalutamide given orally at the dose of 160 mg daily until progression or unacceptable toxicity. One course of therapy corresponds to four weeks of treatment."
7012|NCT04139759|Other|hand massage|In the hand massage group (n = 28), hand massage was applied to the hand without fistula for 8 minutes, 3 times a week, for 4 weeks.
7013|NCT04139759|Other|foot massage|Foot massages were applied to both feet of the patients in the foot massage group (n = 28), 3 times a week, for 4 weeks and patting and kneading movements were repeated 3-4 times.
7014|NCT04139746|Procedure|Scleral Buckling|Limbal 360 degrees peritomy of the conjunctiva was performed and the four recti muscles were isolated with 4 silk threads 4-0. A width-2 mm silicone encircling band was placed and sutured with 5-0 mersilene on the 4 quadrants of the sclera. Anterior chamber paracentesis was performed, draining about 0.3 mL of aqueous humour, and a buckle (220, 501, 506, or 516; Mira, Waltham, MA, USA) was sutured over the break. In all cases, the drainage puncture was executed at a distance of 11 mm from the limbus, in the area of greatest amount of subretinal fluid. Soon after the drainage puncture, a balanced salt solution (BSS) injection was performed in order to compensate the escape of the subretinal fluid.
7015|NCT04139746|Procedure|Drainage-Injection-Pneumoretinopexy|According to the location of the sub-retinal fluid, a quadrant-flap of conjunctiva was opened. Indirect ophthalmoscopy evaluation was also used intraoperatively to localize the break and the subretinal fluid drainage site: in this area a vicryl 6-0 thread was passed through the sclera, about 9-10 mm posteriorly from the limbus, to facilitate the surgical maneuvers. The drainage puncture was performed 11 mm posteriorly from the limbus, having attention not to perform it directly above the site of the retinal break. In detail, a 2 mm radial sclera incision was created with a 15° disposable knife. The incision was cautiously deepened down to the choroid, which was finally perforated by a lachrymal dilator having a blunt tip. Soon after beginning the subretinal fluid drainage, an injection of BSS was performed in the opposite quadrant of the sclera (4 mm from the limbus) in order to allow an optimal spillage of the subretinal fluid and to flatten the retina.
7016|NCT04139733|Procedure|Prone positon|Prone position within 6 hours after randomization. Prone position for at least conservative hours per days during a minimum of 5 days.
7017|NCT04139733|Procedure|Supine positon|Conventional supine position ventilation, no prone position.
7018|NCT04139720|Behavioral|e-book|sexual harassment prevention via education e-book
7019|NCT04139707|Device|Caring4Dementia|A mobile application administered for 30 days, which provides people caring for a person living with dementia with a useful and intuitive tool targeting communication skills.
7020|NCT04139707|Other|White Paper|The White Paper group will receive a white paper (hard copy and electronically) on the principles of communicating efficiently with persons living with dementia.
7021|NCT04139694|Dietary Supplement|Food plan with cinnamon supplementation|cinnamon twice daily plus follow Cardiometabolic diet
10304|NCT04112160|Drug|normal saline|normal saline
7026|NCT04139655|Drug|Colchicine 0.6 mg|Oral colchicine given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
7027|NCT04139655|Drug|Placebo oral tablet|Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
7028|NCT04139642|Device|SimpleSway|"During the 9-month period each practitioner who receives the balance + weight device is asked to provide anonymous feedback via a kiosk regarding if the balance data influenced clinical decision making after every patient. The kiosk has four marked buttons indicating a 4-point Likert Scale, so the practitioner just presses one of the four buttons to indicate their agreement with the statement, The balance measurement influenced my clinical decision making with this patient. After 9 months, the devices are switched so that every practitioner who had a weight only device receives balance + weight device and vice versa. After the second 9-month period concludes all devices will be retrieved by study personnel, and participants will be asked to complete surveys regarding their experience and attend group feedback sessions regarding their experiences."
7029|NCT04139629|Diagnostic Test|antichlamydial antibody test|At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.
7030|NCT04139629|Drug|treatment of infertility with ART|COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.
7031|NCT04139603|Other|Lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
7032|NCT04139603|Other|Abdominal supported lumbopelvic kinesio taping|"Kinesio tapes applied to the lumbopelvic region and abdominal area will stay 3 days. They will be removed from the sites, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
7033|NCT04139603|Other|Placebo tapng|"Placebo tapes (just like Kinesio tapes) applied to the lumbopelvic region without any tension will stay 3 days. They will be removed from the site, and the skin will be checked and cleaned, and then reapplied for the next 3 days.~An ergonomic education program will be given after the baseline measurements, and will last for 45-60 minutes. A brochure including ergonomic principles with images will also be provided."
7034|NCT04139590|Device|Panda|
7035|NCT04139590|Device|Visual Analogue Scale - Original|
7036|NCT04139577|Biological|Fecal Microbiota Transplant|FMT- Oral Study Drug, predetermined dosage and timings, up to 2 cycles
7037|NCT04139538|Procedure|orthodontic treatment|Malocclusion will be treated with orthodontic appliances (fixed or removable)
7038|NCT04139525|Other|unfractionated heparin|i.v. heparin
7039|NCT04139525|Other|8% trisodium citrate|i.v. citrate
7040|NCT04139512|Procedure|guided surgery|placement of implant with local anesthesia using full guided surgery protocol versus free- hande one
7041|NCT04139512|Procedure|conventionnel implant placement|placement of dental implant with conventionnal freehand technic
7042|NCT04139499|Procedure|Drug-induced sleep endoscopy (DISE)|DISE involves administering anesthetic to a patient to simulate a sleep state, and then visualizing the upper airway using transnasal flexible endoscopy. Sites of obstruction at key locations including the adenoids, soft palate, lateral oropharynx, tongue base, and epiglottis can be identified.
7043|NCT04139499|Procedure|High-resolution manometry (HRM):|After the necessary clinical information has been obtained (if obstruction is occurring at those levels and, if so, to what degree), a flexible high-resolution manometry (HRM) catheter will be passes through the contralateral nostril to record pressure along the length of the pharynx at those same sites.
7044|NCT04139486|Procedure|combined EMBOTRAP II and Contact Aspiration|refer to title
7045|NCT04139486|Procedure|Contact Aspiration alone|refer to title
7046|NCT04139473|Procedure|Hepaticojejunostomy / Duct-to-duct anastomosis|
7047|NCT04139460|Device|CRT-D|After randomization, devices will be implanted as soon as possible (within 2 weeks). The ICD will be programmed with anti-tachycardia pacing and shock therapy as per common praxis.
7048|NCT04139460|Device|CRT-P|After randomization, devices will be implanted as soon as possible (within 2 weeks).
7049|NCT04139434|Drug|LP-108|Evaluate safety, tolerability, pharmacokinetics, and clinical activity of orally administered LP-108 in subjects with r/r MDS, CMML, or AML
7050|NCT04139421|Behavioral|Shinrin-Yoku|Shinrin-Yoku is a traditional Japanese practice of getting in touch with nature through walking in the forest in a relaxed way using all five senses.
7051|NCT04139408|Device|Disposable Pulmonary Surgical Marker|The subjects will undergo Marker placement procedure, within 24h before VATS.
7052|NCT04139395|Drug|68Ga-Citrate PET/MRI|Participants will be injected intravenously (IV) with 370 MBq of 68Ga Citrate. 45 -60 minutes after the radiopharmaceutical IV administration, whole body data acquisition at the PET/MRI suite will begin.
7053|NCT04139395|Drug|67Ga-Citrate SPECT|67Ga-Citrate will be used as the radiotracer for a regular medical care SPECT scan
7054|NCT04139395|Device|Positron Emission Tomography|Imaging with 68Ga-Citrate PET/MRI
7055|NCT04139395|Device|Magnetic Resonance Imaging|Imaging with 68Ga-Citrate PET/MRI
7056|NCT04139395|Device|SPECT|Imaging with 67Ga-Citrate radiotracer. SPECT scan will be conducted as part of regular medical care.
7057|NCT04139382|Other|Telephone Consultation|A telephone consultation comprising clinical history, contraception planning, explanation of medical method of abortion
7059|NCT04139356|Procedure|Deep breaths|Patients will undergo a 6 minutes protocol. Baseline: 1 minute normal breaths. Intervention: 1 minute with 10 deep breaths, 1 each 6 secs. Pulse-oxymetry will be continuously recorded.
7060|NCT04139330|Drug|NPC-06|Infuse NPC-06 intravenously
7061|NCT04139317|Drug|Capmatinib|Oral tablet
7062|NCT04139317|Biological|Pembrolizumab|IV infusion
7063|NCT04139304|Drug|Cyclophosphamide|Given IV
7064|NCT04139304|Biological|Daratumumab|Given IV
7065|NCT04139304|Drug|Doxorubicin|Given IV
7066|NCT04139304|Drug|Doxorubicin Hydrochloride|Given IV
7067|NCT04139304|Drug|Etoposide|Given IV
7068|NCT04139304|Drug|Prednisone|Given PO
7069|NCT04139304|Drug|Vincristine|Given IV
7070|NCT04139304|Drug|Vincristine Sulfate|Given IV
7071|NCT04139291|Other|Complex decongestive therapy phase 1|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
7072|NCT04139278|Other|Observational|Observational retrospective study
7073|NCT04139265|Diagnostic Test|biologic analysis (ferritinemia, transferrin saturation coefficient)|Each patient will follow a blood test in order to compare between ferritinemia and transferrin saturation coefficient in iron deficiency diagnosis
7074|NCT04139252|Other|No intervention|No intervention
7075|NCT04139239|Diagnostic Test|Coma Recovery Scale-revision|Patients were assessed by Coma Recovery Scale-revision to detect the DOC patients enrolled by clinicians.
7076|NCT04139226|Drug|CC-11050|CC-11050
7077|NCT04139213|Drug|buprenorphine/naloxone oral product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
7078|NCT04139213|Drug|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
7079|NCT04139213|Other|Pharmacy maintenance addiction care|Patients randomized to the pharmacy study arm and on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for up to three months. Patients will visit for check-ins with a pharmacist on a monthly, weekly, or more frequent basis, depending on the individual treatment plan. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it monthly by the pharmacist. All patients will visit the pharmacy at least monthly for addiction care (assessment, toxicological testing).
7080|NCT04139213|Drug|oral naltrexone|To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
7081|NCT04139200|Behavioral|Type 1 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed. B) Step counter providing direct feedback. C) A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards. D) Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data, failure to progress or change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
7082|NCT04139200|Behavioral|Type 2 physical activity tele coaching intervention|A) Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity. B) A step counter providing direct feedback. C) A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period). D) Telephone contacts triggered in the case of change in medication. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
7083|NCT04139187|Other|Combined training with power and strength exercises|"The training will be compose by power and strength exercises and divided in two days. One day with the exercises: vertical jumps, box jumps, sit-ups, back-extension and guided squat. The second with half squat jumps, high straight jumps, bounding jumps, drop jumps and sprint. Both days will be started with warm up on treadmill running lasting 5 minutes at 6.5-7.5 km/h.~The training protocol includes 20 sessions with 2 sessions per week during 10 weeks (2 weeks to adaptation and others 8 to training with progression of load after 4 weeks)."
7084|NCT04139174|Procedure|first premolar extraction and complete canine retraction.|measurements on panoramic radiograph will be done after first premolar extraction and complete canine retraction.
7116|NCT04138914|Device|Focal Cryotherapy|Ablation of the cancer focus within the prostate using cryotherapy
7117|NCT04138901|Procedure|Ultrasound guided subcostal transversus abdominis plane block (TAPB)|At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.
7118|NCT04138901|Drug|Ropivacaine 0.75% Injectable Solution|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
7119|NCT04138901|Device|21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)|0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)
7085|NCT04139161|Procedure|Q-Factor Intervention|The intervention period will consist of 12 training sessions across four consecutive weeks, with three training sessions held per week. If pain is not increased or reduced and Rating of Perceived Exertion is ≤12, the participant will progress to the next bout. If pain is increased from the pre-bout pain score, participants will repeat the bout, at the same workrate and Q-Factor settings. Following this fashion, participants will progress through three increasing Q-Factors for each given workrate; Q-Factor 1 (Q1, 192mm), Q2 (234mm), Q3 (276mm). After completing bouts of all three Q-Factors for a given workrate, workrate will be increased by 20 Watts and bouts at each Q-Factor will be repeated. For each training session, participants will complete bouts of cycling until 1) the maximum number of bouts (4 bouts) has been accomplished, 2) self-reported Rating of Perceived Exertion >12, indicating a transition to moderate physical activity, or 3) self-reported pain >5.
7086|NCT04139148|Device|Ture Transcranial Direct Current Stimulation (tDCS)|Ture 1-2 mA current of tDCS intervention in patients' binary brain DLPFC areas(20 mm).
7087|NCT04139148|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Sham tDCS intervention in patients' binary brain DLPFC areas(20 mm).
7088|NCT04139135|Drug|HLX10|neoadjuvant treatment phase：HLX10（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：HLX10（4.5mg/kg/3w IV）
7089|NCT04139135|Drug|Placebos|neoadjuvant treatment phase：placebos（4.5mg/kg/3w IV） +SOX, adjuvant treatment phase：SOX
7090|NCT04139122|Drug|SJP-0132|SJP-0132 is administered as an eye drop
7091|NCT04139122|Drug|Placebo|Placebo is administered as an eye drop
7092|NCT04139083|Procedure|LSC mesh suspension|Long mesh, a synthetic T-shaped mesh (Gynemsh, Ethicon, San Lorenzo, Puerto Rico), is delivered into the pelvic cavity. Bilateral mesh arms are extracted outside trocar wounds bilaterally to stabilize mesh position. The center piece is fixed to the cervix with 5mm ProTack screws (Covidien, New Haven, Connecticut). Fixation is strengthened with Stratafix 2-0 sutures (Ethicon, Norderstedt, Germany), followed by Tisseel fibrin sealant (Baxter, Deerfield, Illinois) for better hemostasis among surrounding tissues. An extraperitoneal tunnel is created along the left round ligament until reaching 2cm medial to the anterior superior iliac spine (ASIS). One arm of the long mesh is pulled out along the tunnel underneath round ligament and fixed with the fascia of oblique abdominis. The same procedure is repeated for the contralateral side. Bilateral round ligaments and the mesh arms are sutured continuously with Stratafix 2-0.
7093|NCT04139083|Procedure|TVM|Transvaginal mesh kit is delivered into the pelvis via vagina route.
7094|NCT04139070|Drug|Bleomycin|Electroporation in combination with systemically administered bleomycin
7095|NCT04139057|Drug|HPV E6-specific TCR-T cell with anti-PD1 auto-secreted element|Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
7096|NCT04139044|Procedure|Balance Exercise Training for Stable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
7097|NCT04139044|Procedure|Balance Exercise Training for Unstable Ankle|Balance and hop stabilization exercises were administered for 30 minutes of each exercise session.
7098|NCT04139031|Biological|Ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 6-13 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure < 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
7099|NCT04139018|Drug|Timolol Gel|Timolol nasal gel 0.1% will be prepared with a poloxamer gel (combination of poloxamer 188 and 407; pH adjusted to 4.5-6.5) and 0.5 ml applied to each nostril twice daily. The total daily dose would amount to 2 mg.
7100|NCT04139018|Drug|Placebo Gel|Placebo gel is prepared with poloxamers and no active ingredients.
7104|NCT04138992|Drug|bevacizumab|bevacizumab will be used during neoadjuvant and concurrent chemoradiotherapy
7105|NCT04138992|Drug|DDP|DDP will be used during neoadjuvant and concurrent chemoradiotherapy
7106|NCT04138992|Drug|Docetaxel|used in neoadjuvant chemotherapy
7107|NCT04138992|Radiation|radiotherapy|standard treatment includes pelvic external beam radiation and brachytherapy
7108|NCT04138979|Drug|cyclophosphamide|First use of chemotherapy after breast cancer
7109|NCT04138966|Device|Nol-Index|Multiparametric monitor that studies that establishes an index as a surrogate to nociception
7110|NCT04138966|Device|Skin Conductance|Measures skin conductance as a surrogate to nociception
7111|NCT04138966|Device|Analgesia-Nociception-Index|Analysis of the heart rates parasympathetic component via the respiratory sinus arrhythmia reflex as a surrogate to nociception
7112|NCT04138953|Device|Transcranial Magnetic Stimulation (TMS)|"Transcranial magnetic stimulation, also known as repetitive transcranial magnetic stimulation, is a noninvasive form of brain stimulation in which a changing magnetic field is used to cause electric current at a specific area of the brain through electromagnetic induction.~It will be used to create a 'virtual lesion,' disrupting neural activity in a specific brain region to identify whether it is causally involved in a specific behavioral process."
7113|NCT04138953|Other|Sham TMS|Sham Transcranial Magnetic Stimulation (TMS) over premotor cortex
7114|NCT04138940|Behavioral|Script Training|Participant uses a computer program to practice scripts with a virtual therapist.
7115|NCT04138927|Drug|Fostamatinib disodium|"Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed."
7339|NCT04137055|Drug|ZSP0678-240mg|ZSP0678 tablets administered orally under fasted condition
7120|NCT04138888|Drug|Olmesartan Medoxomil/Hydrochlorothiazide 40 Mg/25 Mg film-coated tablets for oral use|Olmesartan Medoxomil/Hydrochlorothiazide is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
7121|NCT04138888|Drug|Olmetec® Plus 40 Mg/25 Mg film-coated tablets for oral use|Olmetec® Plus is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
7122|NCT04138875|Drug|Rituximab|Rituximab is dosed at 375mg/m2 as an intravenous infusion. No adjustments are necessary for hepatic or renal impairment. Dosing will be done on baseline weight and height, however in patients who experience a >10% change in weight dosing will be readjusted.
7123|NCT04138875|Drug|Brentuximab Vedotin|Brentuximab vedotin is to be given as intravenous infusion at a dose of 1.2mg/kg during induction and 1.8mg/kg with each cycle. Dose reductions to 1.2mg/kg are allowed at investigator discretion.
7124|NCT04138875|Drug|Bendamustine|Bendamustine is to be given intravenously at a dose of 90mg/m2 on day 1 and day 2 of each high risk cycle. Dose reductions to 60mg/m2 are allowed at investigator discretion.
7125|NCT04138862|Behavioral|Product Labelling and Sensory modifications|the beverages varied in the label that was attached (no label or a 'Healthier Choice' label) and the sensory matching of the calorie reduction (sensory matched, reduced or enhanced).
7126|NCT04138849|Drug|BBT-877 single dose|Oral capsule, single dose.
7127|NCT04138849|Drug|Placebo single dose|Oral capsule, single dose.
7128|NCT04138836|Drug|BBT-877|BBT-877 oral capsule.
7129|NCT04138836|Drug|Midazolam|Midazolam oral syrup.
7130|NCT04138836|Drug|Itraconazole|Itraconazole oral capsule.
7131|NCT04138836|Drug|Esomeprazole|Esomeprazole oral capsule.
7132|NCT04138823|Drug|BI 891065|Tablets
7133|NCT04138823|Drug|BI 754091|Solution for infusion
7134|NCT04138810|Other|VCE|Videoconference conducted according to a standard script which reviews the following key aspects of post-operative care: bowel functions, voiding functions, presence of vaginal bleeding, pain control, diet status, ambulatory status and any additional concerns. Standard post-operative instructions and precautions are reviewed as well.
7135|NCT04138810|Other|Survey|Measure of satisfaction regarding post-op visit.
7136|NCT04138797|Procedure|Electrophysiological exploration|Electrophysiological exploration is performed, as part of the routine care, after the Biosemi high density ECG, the same day or maximum 4 days later. It is performed in interventional rhythmology room, under fluoroscopic control. After local anesthesia, one or more introducers are placed in the femoral vein allowing the introduction of catheters. These catheters allow recording of the HV interval
7137|NCT04138797|Device|ECG Biosemi|Non invasive ECG monitoring for HV measurement using high density Biosemi device. This device use 256 skin electrodes. At the same time and with the same system, a chest pressure sensor can record the patient's breathing movements.
7138|NCT04138784|Other|Individualized comprehensive rehabilitation program|The program general contents were pain education, joint protection techniques, general care lifestyle habits, which were complemented by a problem-based session. The program plan was designed to fit patients' goals, priorities, and lifestyles after an initial interview.
7139|NCT04138784|Other|Aquatic training|Patients received a 45 min-water exercise program which included balance and proprioception activities, isometric exercise, flexibility exercises, core stabilization exercises and aerobic/endurance exercises. All sessions were developed in groups and addressed by a qualified professional.
7140|NCT04138771|Device|An artificial intelligence system for postoperative management of cataract patients|This system can detect multiple postoperative complications of cataract patients and then provide a management strategy.
7143|NCT04138745|Other|Transverse Thoracic Plane Block|A bilateral plane block in the transverse thoracic space
7144|NCT04138732|Behavioral|Improve health behaviors of medical personel|This arm will receive the intervention treatment aimed to help improve their health behaviors, as determined by employee-based steering committee. Interventions will target nutrition, physical activity and stress reduction
7145|NCT04138719|Drug|Nab-paclitaxel + Carboplatin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and carboplatin given IV at AUC 5 on days 1 every 21 days x 6 cycles;
7146|NCT04138719|Drug|Nab-paclitaxel + Epirubicin|nab-paclitaxel given IV at 125 mg/m^2 on days 1, 8 and epirubicin given IV at 75 mg/m^2 on days 1 every 21 days x 6 cycles；
7147|NCT04138706|Drug|Vancomycin|Extension of initial vancomycin regimen for the treatment of C. diff from 14 days to 28 days (i.e. an additional 14 days of vancomycin treatment)
7148|NCT04138706|Drug|Placebos|Initial vancomycin treatment (x14 days) will be followed by 14 days of placebo.
7149|NCT04138693|Device|G-PUR® 2x 2.0 g oral suspension|Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
7150|NCT04138693|Device|G-PUR® 1x 2.0 g oral suspension|Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
7151|NCT04138693|Device|Placebo oral suspension|Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
7152|NCT04138680|Behavioral|Active Biofeedback|"The active biofeedback session will be done within the 7T MRI. It will include a pre-training run, 3 training runs, and a post-training run. Each run will be comprised of MOTIVATE and REST trials. During each MOTIVATE trial, subjects will be instructed to generate a heightened state of motivation. Participants will be encouraged to identify strategies that are personally relevant or useful and to monitor the efficacy of the strategies. Subjects will simultaneously view a progress bar on the screen during MOTIVATE trials that represents their VTA activity and they will be trained to try to increase the level of the bar by motivating themselves. For the active VTA biofeedback group, the progress bar will be updated every second to accurately convey level of VTA signal activation. During REST trials, all subjects will be instructed to count backwards. During the post-training 'test' run, subjects will be instructed to use the strategies they found to be most effective."
12918|NCT04090567|Drug|Ceralasertib|Given PO
7153|NCT04138680|Behavioral|Sham Biofeedback|The sham biofeedback session resembles the active condition, however, the thermometer seen during the MOTIVATE trials will represent yoked sham values.
7154|NCT04138667|Other|complex decongestive therapy|Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
7155|NCT04138654|Dietary Supplement|Processed meat product|300 grams per day during 2 weeks
7156|NCT04138654|Dietary Supplement|White meat wash-out|300 grams per day during 2 weeks
7157|NCT04138654|Dietary Supplement|Processed meat products enriched with natural compounds|300 grams per day during 2 weeks
7158|NCT04138654|Dietary Supplement|Drinking water containing nitrate up to acceptable daily intake level (ADI = 3.7 mg/kg bw) in combination with 300 grams of processed meat, white meat or processed meat enriched with natural compounds|3.7 mg nitrate/kg bw per day plus 300 grams of meat for 1 week
7159|NCT04138641|Drug|Cangrelor|Cangrelor intravenous
7160|NCT04138628|Drug|Atezolizumab|The study drug will be given according to current recommendations as systemic treatment every third week for 12 months or until progression. Treatment will be initiated within 28 days of detection of ctDNA.
7161|NCT04138615|Drug|Morphine|Subjects will receive Morphine while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
7162|NCT04138615|Other|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
7163|NCT04138602|Device|BTL Emsella|Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella Chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
7164|NCT04138602|Device|Sham BTL Emsella|Sham subjects will be seated on the device in the same manner as the active treatment group. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level ( < 10 % power).
7165|NCT04138537|Other|OB volume|The mean OB volume was calculated in cubic millimeters and compared between the two groups.
7166|NCT04138537|Other|CCCRC test|CCCRC test was done for olfactory function assessment and compared between the two groups.
7167|NCT04138524|Other|SAFIR©|Early Supportive intervention for families of patients with acquired brain injuries.
7168|NCT04138511|Device|ECOFISIO|The ECOFISIO application is focused on sports pathologies and contains relevant written and digital information about ultrasound imaging and managing as well as diagnosis of sport injuries.
7169|NCT04138498|Drug|Dexmethylphenidate 5 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
7170|NCT04138498|Drug|Dexmethylphenidate 6.25 mg Tablet|Experimental drug for comparative BA evaluation
7171|NCT04138498|Drug|Dexmethylphenidate 40 Mg Oral Capsule, Extended Release|Reference listed drug (RLD) for comparative BA evaluation
7172|NCT04138498|Drug|Dexmethylphenidate 50 mg Tablet|Experimental drug for comparative BA evaluation
7173|NCT04138485|Biological|IgPro10|10% liquid formulation of human immunoglobulin for IVIG
7174|NCT04138485|Biological|Placebo|0.5% human albumin solution stabilized with 250 mmol/L L-proline
7175|NCT04138472|Drug|dexmedetomidine|intravenous dexmedetomidine 0.06mg/kg in 100ml normal saline 0.9% over 10minutes.
7176|NCT04138472|Drug|fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline over 10 minutes in induction room.
7177|NCT04138472|Drug|lidocaine|intravenous lidocaine 1.5mg/kg in 100ml saline over 10 minutes in induction room.
7178|NCT04138459|Other|Not an interventional study. This is a qualitative, explorative study of recovery orientation of community mental health services|"Explore recovery orientation of mental health services in a municipality through:~Qualitative, in-depth interviews with service users and mental health professionals and~Observational fieldwork"
7179|NCT04138446|Other|Altitude exposure in climate chamber|Altitude exposure in a climate chamber will consist of hypobaric hypoxia similar to the conditions found at 3000m asl and 5000m asl.
7180|NCT04138433|Device|Real tDCS|Anodal tDCS 2 ma
7181|NCT04138433|Device|Sham tDCS|Sham tDCS 2 ma
7182|NCT04138420|Drug|Bevacizumab Injection|Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
7183|NCT04138407|Other|seated Tai Chi|Seated Tai Chi is a redesigned short form of traditional Tai Chi, can be practiced in a chair or wheelchair
7184|NCT04138407|Other|Usual rehabilitation exercise|Regular rehabilitation exercise used in participating hospital
7185|NCT04138394|Drug|Ascorbic Acid|We will conduct a double-blind, randomized controlled pilot trial of 90 patients with severe burns randomly allocated to receive 2 different dosing strategies of intravenous vitamin C (200 mg/kg/day vs 400 mg/kg/day for 96 hours) or placebo (30 per group). Ultimately, we aim to determine the optimal dose of vitamin C in severe burn injury by testing 2 different dosing strategies utilizing some features of an adaptive seamless study design, such as dose selection and sample size re-estimation at the end of the phase II component. Subsequently, if feasibility is demonstrated in the pilot, a larger phase III component will be conducted and aimed at lowering morbidity and mortality and reducing health care costs in an otherwise very devastating and disabling injury worldwide.
7186|NCT04138394|Drug|placebo|Patients will receive a similar amount of placebo (either D5W or saline) delivered in the same manner as the vitamin C.
7187|NCT04138381|Drug|Selinexor|oral selinexor given once weekly.
7188|NCT04138381|Drug|Imatinib|imatinib 400 mg, once daily
7274|NCT04137575|Behavioral|Relaxation Training|The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training.
7275|NCT04137562|Biological|ADSTEM Inj.|Two 5mL of the following study drug is pre-mixed with 320mL of 0.9% normal saline is injected intravenously twice for the duration of the study. Treatment group: ADSTEM Inj. 0.5x10^8 cells/5mL
7189|NCT04138368|Behavioral|dyadic psychotherapeutic intervention|Mothers and infants will be treated with dyadic psychotherapy focused on interactions, emphasizing eye contact, body language, empathy, and social reciprocity, using the principles of Interaction Guidance Therapy (Sameroff et al., 2004). Dyadic psychotherapy will be administered one time a week during the 8-week trial period, at the subject's home. Each session, approximately 90 minutes long, will include videotaping mother-infant interaction, watching the last session's interaction as a part of video-feedback technique, and discussing main issues in the mother-infant relationship. In addition, each session will begin and end with a- 5-minute episode of affectionate touch and gaze synchrony between the mother and her infant.
7190|NCT04138368|Behavioral|supportive intervention|Supportive therapy: mothers will receive psychoeducational knowledge regarding the infants' development. The treatment will be administered one time a week during the 8-week trial period, at the subjects' home.
7191|NCT04138355|Other|Extracorporeal shock wave therapy|ESWT was conducted using the Duolith SD-1® device (StorzMedical, Tägerwilen,Switzerland) with an electromagnetic cylindrical coil source for the focused shock wave. ESWT was performed around the primary treatment site at 100 impulses/cm2, an energy flux density(EFD) of 0.05 to 0.30 mJ/mm2, frequency of 4Hz, and 1000 to 2000 impulses were administered at 1-week intervals for 4 sessions.
7192|NCT04138342|Drug|Quantum dots coated with veldoreotide|The active group will receive Quantum dots coated with veldoreotide in different topical dosage forms as an anti-cancer drug.
7193|NCT04138342|Drug|Topical approved placebo|The placebo group will receive topical FDA approved in different dosage forms as a negative control drug.
7194|NCT04138329|Procedure|Lichtenstein Technique|In this group was used the Lichtenstein technique for inguinal repair
7195|NCT04138329|Procedure|Onstep Technique|In this group was used the Onstep technique for inguinal repair
7196|NCT04138316|Drug|Candesartan|Treatment with Candesartan
7197|NCT04138303|Other|Exercise Protocol|The exercise protocol consists of a nine-week progressive intense-conditioning program involving six consecutive days (Monday-Saturday) of one-hour exercises and one-day rest weekly for a total of 54 days of exercise. Exercises are performed in person as a group with other participating subjects and lead by certified instructors. Exercises will involve a variety of activities ranging from running, cycling, whole-body functional movements, power movements, and open-chain weight lifting with barbells and resistance bands.
7198|NCT04138303|Other|Calorie-Restrictive Low Carbohydrate Diet (CR-LC)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. CR-LC consists of caloric and macronutrient restrictions. Caloric restrictions involves a 40% deficit from calculated total daily energy expenditure. Macronutrient restriction involves a high protein, low carbohydrate diet (35% protein, 25% carbohydrate and 40% fat).
7199|NCT04138303|Other|Ancestral Diet (AD)|Consists of weekly nutrition plans, counseling and monitoring by on-site registered dietitians and nutritionists for nine weeks. AD consists of consuming only whole foods and avoiding processed foods. Emphasis will be on food quality with no caloric or macronutrient restrictions.
7200|NCT04138290|Device|Predictix Antidepressant Software tool|Predictix Antidepressant is a stand-alone software tool based on a patients' genetic panel, clinical, demographic and behavioral inputs, intended to support a clinician in choosing the most suitable antidepressant treatment/s for an individual patient diagnosed with Major Depressive Disorder.
7201|NCT04138277|Drug|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
7202|NCT04138277|Biological|ATB200|Enzyme Replacement Therapy via intravenous infusion
7203|NCT04138264|Other|Preoperative opioid counseling|preoperative counseling consists of education with a brief multi-media presentation in the preoperative area on the day of surgery using a handheld tablet. The message of the preoperative counseling consisted of: 1) Background on the opioid epidemic including basic facts and consequences, 2) Description of risk factors for opioid abuse and how to consume opioids safely, 3) Information on the specific opioid the patient was prescribed and the anticipated amount and duration of use postoperatively, 4) Encouraging the use of non-opioid therapy prior to taking the prescribed opioids or quickly transitioning to non-opioid medications postoperatively, and 5) Contact information and instructions to call if the patient experienced any adverse events and/or if additional pain medication is needed.
7204|NCT04138251|Drug|Empagliflozin|oral administration of Empagliflozin
7205|NCT04138238|Device|Supraflex Cruz Sirolimus-eluting Stent|Patient implanted with at least one Supraflex Cruz sirolimus-eluting stent as a part of planned clinical care
7208|NCT04138186|Device|2.0g G-PUR®, oral administration|tid for 12 weeks
7209|NCT04138186|Device|Placebo, oral administration|tid for 12 weeks
7210|NCT04138173|Behavioral|Tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
7211|NCT04138160|Other|5:2 Intermittent energy restriction|Substantial (70%) energy restriction for 2 non-consecutive days/week interspersed with normal energy intake (isoenergetic) on the remaining 5 days of the week.
7212|NCT04138160|Other|Continuous energy restriction|20% energy restriction each day relative to the energy requirement.
7213|NCT04138147|Procedure|Superficial cervical plexus with auriculotemporal nerve blocks|Superficial cervical plexus block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
7214|NCT04138147|Procedure|Cervical retrolaminar with auriculotemporal nerve blocks|Cervical retrolaminar block using 10 ml bupivacaine 0.5%. Auriculotemporal nerve block using 3 ml bupivacaine 0.5%.
7340|NCT04137055|Drug|ZSP0678-320mg|ZSP0678 tablets administered orally under fasted condition
7216|NCT04138108|Other|Psychoeducation|The parents of each child were educated as couples and each training session lasted 45-60 minutes for each family. Approximately the first five minutes of the training were used for warm-up, 25 minutes were used for basic ADHD knowledge and the last 15 minutes were catechetic and conducted interactively. The psychoeducation included discussion about the causes, symptoms and signs of ADHD, the course and characteristics of the disease according to age, the treatment process, the drugs used in the treatment and their side effects, correct and incorrect information about drugs, the other symptoms which can coexist with ADHD and their treatment, and what the parents can do about these issues.
7217|NCT04138095|Device|Virtual Reality|Participants will have access to an Oculus Quest Virtual Reality Headset every second day as an alternative to opioids for pain management and benzodiazepines for anxiety management
7218|NCT04138082|Other|Exposition to high-dB soundtrack|Already stated
7219|NCT04138069|Other|PLB+Aerobic Bicycling|"Combination of Breathing control and Purse lips breathing technique for 5 minutes at the start of session.~Purse lips breathing with aerobic bicycling for 8 minutes"
7220|NCT04138069|Other|Aerobic Bicycling|"Breathing control for 5 minutes at the start of session.~Aerobic bicycling for 8 minutes"
7221|NCT04138056|Biological|RSVPreF3 formulation 3|One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left arm.
7222|NCT04138056|Biological|RSVPreF3 formulation 2|One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
7223|NCT04138056|Biological|Boostrix-ex-US|One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
7224|NCT04138056|Procedure|Boostrix-US|One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
7225|NCT04138056|Drug|Placebo|One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
7226|NCT04138043|Drug|Placebo|Placebo is 0.9 percent sodium chloride solution. It will be administered as subcutaneous (SC) injection to abdomen by study personnel. Three injections will be used to match active doses.
7227|NCT04138043|Drug|GSK2330811|GSK2330811 will be administered as SC injection (150 mg per milliliter [mL]), by study personnel. Three injections will be used to provide 450 mg SC dose.
7228|NCT04138030|Procedure|Conventional Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery
7229|NCT04138030|Procedure|Cold Snare Endoscopic Mucosal Resection|Use of injected chromogelofusine solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
7230|NCT04138017|Device|ViviGen|A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.
7231|NCT04138004|Drug|polyethylene glycol in combination with lubiprostone|2-litre polyethylene glycol split-dose in combination with one 24 mcg tablet of lubiprostone
7232|NCT04138004|Drug|polyethylene glycol alone|4-litre polyethylene glycol split-dose
7233|NCT04137991|Device|Nol-Index guided analgesia|Monitor that indicates the level of nociception-antinociception balance
7234|NCT04137991|Other|Standard Analgesia|Administration of remifentanil based guided by heart rate, blood pressure, and experience
7235|NCT04137978|Drug|ADV7103|Patients receive ADV7103 twice a day at optimal dose.
7236|NCT04137978|Drug|Standard of Care|Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
7237|NCT04137952|Behavioral|size of error visual feedback|The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
7238|NCT04137939|Device|smart exercise system|The smart exercise system contains an upper extremity ergometer (UEE) and a lower extremity ergometer (LEE). The revolutions per minute (RPM) of the ergometer are instructed to maintain in 55-65. The resistance of UEE is set from level 1 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session. The resistance of LEE is set from level 2 at the first session, and adjusted by rating of perceived exertion (RPE) of each user after each end of the session.
7239|NCT04137926|Diagnostic Test|MicRNAs battery|for MCI due to AD diagnosis
7240|NCT04137913|Behavioral|Musical arts intervention|A 6-week group music class that incorporates listening, theory, performance, and creation of music.
7241|NCT04137900|Drug|TAB004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection|Intravenous infusion
7242|NCT04137887|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated) High-Dose (QIV-HD) QIV-HD|Pharmaceutical form:Suspension for injection in pre-filled syringe Route of administration: Intramuscular
7243|NCT04137887|Biological|Standard-Dose Inactivated Influenza Vaccine Quadrivalent, Northern Hemisphere strains (QIV-SD) QIV-SD|Pharmaceutical form:Suspension for injection in pre-filled syringe Route of administration: Intramuscular
7244|NCT04137874|Diagnostic Test|eSTROKE model|The eSTROKE model includes an electronic learning module, a full day course with practical teaching of National Institute of Health Stroke Scale and a mobile application which will be used for communication with in-hospital stroke physician
7245|NCT04137874|Other|Control|Conventional prehospital care
7246|NCT04137861|Other|Bioceramics|root repair material
7247|NCT04137848|Procedure|Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
7276|NCT04137562|Other|Placebo|330mL of 0.9% normal saline is injected intravenously twice for the duration of the study.
7248|NCT04137848|Procedure|Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|"SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy."
7249|NCT04137835|Device|Showmotion|Each healthy volunteers will wear sensors at the interested joint and do the measurement.
7250|NCT04137822|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline. The treatment regimen with IMM-101 is one dose given every 2 weeks for three doses followed by 4 weeks rest, then one dose is given every 2 weeks for a further three doses. Subsequent doses are given every 4 weeks.
7251|NCT04137809|Device|AMBLE|Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
7252|NCT04137783|Other|no intervention|there is no intervention in this study, only observation.
7253|NCT04137770|Other|Ice pack|Ice packs will be applied to the surgical site
7254|NCT04137757|Device|Lower Body Negative Pressure|Lower body negative pressure will be applied.
7255|NCT04137757|Device|Sham Pressure|Noise will be turned on but no pressure will be applied.
7256|NCT04137744|Procedure|AXILLARY REVERSE MAPPING|subcutaneous injection of 1to 2 ml methylene blue 15 minutes before the procedure, identification of blue LN and lymphatic vessels
7257|NCT04137731|Device|Interferential Current Therapy|IFC treatment after Total Knee Arthroplasty
7258|NCT04137718|Other|nonIntervention|nonIntervention
7259|NCT04137705|Other|Multiparametric MRI|A standardised MRI protocol that provides a number of quantitative metrics on liver and other organs relevant to type 2 Diabetes - pancreas, kidneys, spleen and aorta
7260|NCT04137692|Other|Red Blood Cell Transfusion|The procedure will be performed as an outpatient according to protocols established for sickle cell anemia patients. Two IVs are placed for the purposes of transfusion, one for draw and one for return. Patients will undergo isovolemic hemodilution-red cell exchange (IHD- RBCx) with up to 10 units of red cell antigens (Rh group, Kell, Duffy, Kidd blood group antigens) matched normal donor red cells to replace a target of 70% of the patient's red cells with donor red cells.Total time of procedure: approximately 150 minutes.
7261|NCT04137679|Radiation|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
7262|NCT04137679|Procedure|Neoadjuvant Radiochemotherapy followed by surgery|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
7263|NCT04137653|Drug|nab-Paclitaxel+carboplatin|Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
7264|NCT04137653|Drug|Paclitaxel+carboplatin|Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.
7265|NCT04137640|Drug|palbociclib combined with letrozole|Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
7266|NCT04137640|Drug|epirubicin combined with cyclophosphamide and sequential docetaxel|Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
7267|NCT04137627|Drug|Melatonin 20 MG Oral Capsule|The administration of Melatonin 20 mg in addition to neoadjuvant chemotherapy to observe the antioxidant and onco-static effect.
7268|NCT04137627|Drug|Placebo oral capsule|The administration of placebo capsule in addition to neoadjuvant chemotherapy
7269|NCT04137614|Procedure|Drug coated balloon (DCB)|Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
7270|NCT04137614|Procedure|Digital substraction angiography (DSA)|DSA was used to evaluated the stenosis of renal artery
7271|NCT04137588|Drug|Antiangiogenesis Agents|antiangiogenesis agents plus chemotherapy as first line treatment
7272|NCT04137588|Drug|Immune checkpoint inhibitor|immune checkpoint inhibitor plus chemotherapy as first line treatment
7273|NCT04137575|Behavioral|ConquerFear-Group|The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy.
7335|NCT04137055|Drug|ZSP0678-30mg|ZSP0678 tablets administered orally under fasted condition
12919|NCT04090567|Drug|Olaparib|Given PO
7277|NCT04137536|Drug|anti-EGFR-bispecific antibody armed activated T-cells|"Phase I:~First 3 participants, twice weekly infusions of 10^10 EGFR BATs infusions~If there is toxicity in 0 or 1 of 3 participants, 3 additional participants will be added to the dose level of up to 10^10.~If >/= 2 of 6 participants experience DLTs, then the dose will be reduced to 7.5 x 10^9 per infusion~If only 0 or 1 participants has toxicity in the first 6, then the study will proceed to enroll in the expansion cohort~Expansion cohort:~- 8 infusions of 7.5 x 10^9 or 10^10 EGFR BATs in 22 evaluable participants (including the 6 participants treated at the maximum tolerated dose in Phase I)"
7278|NCT04137510|Device|Percutaneous coronary intervention|It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.
7279|NCT04137497|Diagnostic Test|The Coma Recovery Scale-Revised and the Nociception Coma Scale-Revised (NCS-R)|All enrolled DOC patients were evaluated at least five times over one week by two trained professionals using the Chinese version of the CRS-R. During the evaluation of the patient's consciousness level, the NCS-R was used to evaluate the pain response of all patients in random order at least once, and the best behavioral response (i.e., the highest score) of each subscale was recorded during resting, noxious, and physiotherapy conditions, respectively, according to the NCS-R guidelines.
7281|NCT04137445|Other|Baby Foods|Commercially available baby foods
7282|NCT04137445|Other|Foods from the home|Caregiver will provide participant with usual foods from the home
7283|NCT04137432|Drug|Oxytocin nasal spray|Intranasal administration of 24 international units oxytocin.
7284|NCT04137432|Drug|Placebo|The placebo nasal sprays contains identical ingredients except for the peptide itself.
7285|NCT04137419|Dietary Supplement|Probiotic lozenges|Probiotic strains
7286|NCT04137419|Other|Placebo|Similar to ProlacSan lozenges in taste in colour
7287|NCT04137393|Combination Product|brushing|mechanical and chemical plaque removal
7288|NCT04137380|Drug|Mirikizumab - IV|Administered IV
7289|NCT04137380|Drug|Mirikizumab - SC|Administered SC
7290|NCT04137380|Drug|Placebo - IV|Administered IV
7291|NCT04137380|Drug|Placebo - SC|Administered SC
7292|NCT04137367|Behavioral|Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the active condition, the probe appears at the location of the most positive stimuli of each pair in 87 % of trials (encouraging a positive affective bias). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
7293|NCT04137367|Behavioral|Sham Affective bias modification|In the Affective bias modification (ABM) procedure, paired stimuli (e.g. a negative and a positive facial expression) are presented on a laptop screen, followed by one or two probes (dots) appearing in the spatial location of one of the stimuli. Participants are then required to press one of two buttons as quickly as possible to indicate the number of dots in the probe. Stimuli presentation time is 50% 500 ms and 50 % 1000 ms (evenly distributed throughout the task). In total, the ABM will comprise 90 trials of paired images of faces of different valences. In the sham condition, the probe appears at the location of the most positive stimuli of each pair in 50 % of trials (no contingency between facial expressions shown and the probe location). Participants will do ABM in their homes (approx. 5 min.) twice a day for two weeks (28 sessions) using laptop computers provided by us.
7294|NCT04137354|Other|Intermittent placebo iron supplement|Placebo iron supplements are also three tablets containing the same ingredients as for iron tablets and will be given to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
7295|NCT04137354|Other|Intermittent iron supplement|Three iron tablets containing 42 mg of elemental iron will be provided to the children on a weekly basis for the whole duration of the intervention (i.e. the school year of 9 months)
7296|NCT04137354|Other|Placebo Vitamin A|Children will receive in a colorful Eppendorf tube 400 micro-liter of corn oil stabilized with vitamin A twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
7297|NCT04137354|Other|High-dose Vitamin A supplement|Children will receive in a colorful Eppendorf tube 400 micro-liter of oil-based preparation of retinyl palmitate that contains the equivalent of 100,000 IU (110μmol) of vitamin A and stabilized with 20IU of vitamin E twice during the intervention period of 9 months, at baseline (after enrollment) and at mid-line (4.5 months).
7298|NCT04137341|Drug|GLPG1972 - A|Film-coated tablet, formulation A
7299|NCT04137341|Drug|GLPG1972 - B|Film-coated tablet, formulation B
7300|NCT04137341|Drug|GLPG1972 - C|Film-coated tablet, formulation C
7301|NCT04137328|Drug|Liraglutide|0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months
7302|NCT04137328|Drug|insulin|Add or adjust insulin (when basic insulin is preferred for those who do not use insulin, such as those who have already used insulin, adjust the dosage or program according to the condition, inject subcutaneously) for 3 months
7303|NCT04137315|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
7304|NCT04137302|Drug|Hydrocortisone administration|Hydrocortisone administration with collection of blood, urine and saliva samples before (1 week), during (5 days) and after (1 week) the 2 treatments
7305|NCT04137289|Drug|BI 905711|Powder for Solution for Infusion
7306|NCT04137276|Drug|vitamin C, vitamin B1|vitamin C 1,5 g/6 hours IV + thiamine 200 mg/12 hours for 3 days
7307|NCT04137276|Drug|vitamin B1|thiamine 200 mg/12 hours for 3 days
7308|NCT04137263|Other|DOSE formulation|over-the-counter topical
7336|NCT04137055|Drug|ZSP0678-60mg|ZSP0678 tablets administered orally under fasted condition
7337|NCT04137055|Drug|ZSP0678-120mg|ZSP0678 tablets administered orally under fasted condition
7309|NCT04137250|Procedure|Hamstring|The intervention will consist of make an incision on the medial side of the proximal portion of the leg approximately 3 centimeters to dissect by planes until the tendons of the hamstrings are located, which will be removed surgically with specialized instruments and the wound will be closed, for later These tendons be used as an autograft for the reconstruction of the anterior cruciate ligament
7310|NCT04137250|Procedure|Quadriceps tendon|orThe intervention consisted in making an incision in the anterior aspect of the distal portion of the thigh of approximately 3 centimeters to dissect by planes until locating the membranous portion of the quadriceps tendon, from which will be removed a portion of surgical way with specialized instruments and the Wound will be closed, for later this tendon to be used as an autograft for the reconstruction of the anterior cruciate ligament.
7311|NCT04137224|Biological|IgPro20|Human normal immunoglobulin for subcutaneous administration
7312|NCT04137224|Biological|IgPro10|Human normal immunoglobulin for intravenous administration
7313|NCT04137211|Behavioral|Prolonged sitting with social break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
7314|NCT04137211|Behavioral|Prolonged sitting with walk break|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
7315|NCT04137211|Behavioral|Prolonged sitting with simple resistance activities|Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
7316|NCT04137198|Drug|Sufentanil|intranasal administration of Sufentanil Forte 0,7mcg/kg as first dose and 0,3mcg/kg as titration doses
7317|NCT04137185|Drug|Recombinant Human Thyroid Stimulating Hormone for Injection|Each was dissolved in 1.2 mL of sterile water for injection to obtain a solution containing 0.9 mg/mL rhTSH, which was intramuscularly injected according to the dosing schedule.
7318|NCT04137172|Procedure|laparoscopic (IPOM) hernioplasty without repair|"Under general anesthesia, supine position, lateral visiport 12mm was inserted at the left anterior axillary line . Other two 5mm ports were inserted under vision. A 30-degree optics were used. Adhesiolysis was done . The contents of hernia were reduced . The borders of the defect were illuminated and outlined. The abdominal wall was marked from outside for measurement of defect size and for corners fixation of mesh with 5cm away from defect edge. Defect with axis from 9 to 12 cm is considered big defect.~Group I:~Proline (1) sutures were applied at the corners of the mesh introduced into the peritoneal cavity. Endoclose passed at the marked site from abdominal wall, sutures hanged and tied subcutaneously, completion of mesh fixation using secure strap ."
7319|NCT04137172|Procedure|aparoscopic IIPOM hernioplasty with intracorporeal repair using proline 0 versus stratifix PDS|"Group II:~Using PDS 0, a stratifix suture (STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device) versus proline 1 , used to repair and plicate the defect then mesh fixation"
7320|NCT04137172|Procedure|laparoscopic IPOM hernioplasty with transfacial closure using PDS LOOP 0|The PDS loop sutures were prepared by cutting the needles, keeping two detached ends and one blind end. A small curved supraumbilical incision was done. The endoclose passed through upper border of incision penetrating the abdominal wall above the defect, hanging the blind end of the PDS Loop to outside. It passed through the lower border of the wound crossing the defect. It hanged one detached end of the PDS Loop suture to outside, passed again through lower border of incision to catch the other detached end. The two ends were hanged not tied to avoid incision closure. The process is repeated by passing 1-2 cm lateral or medial to the previous sutures, then blind ends were divided. Lastly, all sutures are tied. Mesh was fixed as before.
7321|NCT04137159|Other|Functional Electrical Stimulation rowing exercise|Full-body aerobic exercise
7322|NCT04137146|Device|Sacral Nerve Stimulation|"Implantation of a sacral nerve neurostimulation system: A single electrode (Interstim® model 3889-28; Medtronic, Minneapolis, MN) was inserted bilaterally into the sacral foramen (S3), connected to an internal pulse generator (Medtronic Interstim~® II 3058)"
7323|NCT04137133|Diagnostic Test|collection|bronchial secretions, blood, stools, superficial skin sample, dental plaque sample and urine
7324|NCT04137120|Drug|Aflibercept (BAY86-5321, Eylea)|Intravitreal injection of aflibercept as scheduled by treating physician
7325|NCT04137107|Drug|Oxaliplatin|Given standard of care oxaliplatin
7326|NCT04137107|Drug|Duloxetine Hydrochloride|Given PO
7327|NCT04137107|Drug|Duloxetine|Given PO
7328|NCT04137107|Other|Quality-of-Life Assessment|Ancillary studies
7329|NCT04137107|Other|Questionnaire Administration|Ancillary studies
7330|NCT04137107|Other|Placebo|Given PO
7331|NCT04137094|Behavioral|Persuasive Health Communication Intervention|A persuasive health communication intervention will be performed
7332|NCT04137081|Behavioral|App-based mindfulness training|Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time.
7333|NCT04137068|Behavioral|Reduced Activity or Maintain habitual activity|Participants reduce their activity level to <5,000 steps/day and <50 % of baseline steps.
7334|NCT04137055|Drug|ZSP0678-10mg|ZSP0678 tablet administered orally under fasted condition
13192|NCT04088396|Drug|Placebo|Administered orally
7341|NCT04137055|Drug|ZSP0678|ZSP0678 tablets administered orally under fasted or fed condition
7342|NCT04137055|Drug|ZSP0678-Dose 1|ZSP0678 tablets administered orally once daily for 14 Days
7343|NCT04137055|Drug|ZSP0678-Dose 2|ZSP0678 tablets administered orally once daily for 14 Days
7344|NCT04137055|Drug|ZSP0678-Dose 3|ZSP0678 tablets administered orally once daily for 14 Days
7345|NCT04137055|Drug|ZSP0678 Placebo|Participants will receive placebo matching to ZSP0678 orally.
7346|NCT04137042|Drug|Saline|Intraoperative fluid therapy is administrated by using 0.9% saline
7347|NCT04137042|Drug|Balanced crystalloid|Intraoperative fluid therapy is administrated by using balanced crystalloid
7348|NCT04137029|Drug|Formoterol|The participants will receive inhalation of formoterol 12 micrograms
7349|NCT04137029|Drug|Tiotropium Bromide|The participants will receive inhalation of tiotropium bromide 18 mkg once
7350|NCT04137029|Diagnostic Test|metacholine test|The participants will receive inhalation of metacholine once
7351|NCT04137016|Other|Mobile application|
7352|NCT04137003|Other|Rouge et Or Program|It is a detailed, structured and precise training program. It is used from the third-month post ACL surgery to the sixth month.
7353|NCT04137003|Other|CHU intervention guide|From the third month to the sixth month, it outlines the progression to have in the training without precise information on exercises, parameter or frequency.
7354|NCT04136990|Procedure|Isolated ACL reconstruction|Isolated ACL reconstruction using the bone-patellar tendon autograft.
7355|NCT04136990|Procedure|ACL + LEAT reconstruction|ACL reconstruction using the bone-patella-tendon-bone autograft combined with LEAT using the mini Lemaire technique.
7356|NCT04136977|Device|Eustachian tube dilation|Unilateral or bilateral balloon dilation of the Eustachian tube using the FDA-cleared XprESS ENT Dilation System
7357|NCT04136964|Other|Neck COMI|Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
7358|NCT04136951|Other|PREVENT clinical decision support|PREVENT clinical decision support tool consideres five patient risk factors as significant predictors of patient's priority for the first homecare nursing visit: (a) Presence of wounds (either surgical or pressure ulcers); (b) a documented comorbid condition of depression; (c) need for assistive equipment, assistive person, or both for toileting; (d) number of medications; and (e) number of comorbid conditions. Each risk factor was assigned a specific score based on the logistic regression weights. For instance, for a wound (e.g., pressure ulcer, vascular ulcer), the patient received a score of 15 points. For each additional co‐morbid condition, one point was added to the final score. Summing the scores for the factors generated a cumulative score. The optimal cut‐off point was established based on the regression model performance statistics, indicating that patients with a score greater than 26 points are a high priority for the first nursing visit.
7359|NCT04136938|Other|Social marketing campaign|A social marketing campaign of prevention workshop sessions will be performed.
7360|NCT04136925|Other|questionnaire|questionnaire before and after race
7361|NCT04136912|Drug|Definity|Perflutren will be administered in split doses using the dosing range and administration type IV bolus) within the perflutren prescribing information. When administered as a bolus, the package insert recommends 10 uL/kg patient weight administered within 30-60 seconds, followed by a 10mL saline flush with a second dose of 10 uL/kg patient weight 30 minutes following the first dose, if needed.
7362|NCT04136912|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research ultrasound scanner as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. Imaging will be performed within the package insert guidelines for ultrasound system mechanical index (a measurement of output power) when imaging perflutren contrast agent (less than 0.8).~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
7363|NCT04136899|Other|Dukes scale|collection of questionnaires
7364|NCT04136886|Drug|Cisplatin|cisplatin is to give from the first Day of radiation therapy D1,D22 Q3W for 2 cycles Radiation: IMRT IMRT is to give 60Gy in 27 fraction
7365|NCT04136886|Radiation|IMRT|Radiation: IMRT IMRT is to give 60Gy in 27 fraction
7366|NCT04136873|Drug|CVL-231|CVL-231
7367|NCT04136873|Drug|Matching Placebo|Placebo matching CVL-231
7368|NCT04136847|Device|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
7369|NCT04136834|Biological|PT01 (Pegtomarginase)|PT01 (Pegtomarginase) breaks down arginine in the blood stream, reducing the supply of arginine and stopping the cancer cells from growing. Normal cells can continue to make their own arginine inside the cell, so PT01 targets the rapidly growing cancer cells.
7370|NCT04136821|Dietary Supplement|Oceanix|Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.
7371|NCT04136821|Other|Resistance Training|6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
7373|NCT04136782|Drug|Albumin-bound paclitaxel combined with carboplatin|Albumin-bound paclitaxel combined with carboplatin: Albumin-bound paclitaxel (Abraxis BioScience, LLC., Mclrose Park, IL, USA; certificate number: H20091059) will be intravenously administered at 125 mg/m2 for 30 minutes on days 1 and 8 of each 21-day session of treatment. There will be six 21-day sessions of treatment. At the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; National Drug Approval Number: H20020181) will be intravenously administered at AUC = 2 mg•min/mL for 120 minutes on days 1 and 8 of each 21-day session of treatment. Carboplatin must be hydrated for 3 days before use to prevent nephrotoxicity.
7374|NCT04136782|Drug|Epirubicin combined with docetaxel|Epirubicin (Pfizer Pharmaceutical (Wuxi) Co., Ltd., China; National Drug Approval Number: H20000496) will be intravenously administered at 90 mg/m2 for 120 minutes on day 1 of each 21-day session of treatment. At the same time, docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; National Drug Approval Number: J20150083) will be intravenously administered at 75 mg/m2 for 120 minutes. Drug administration will be performed once every other 3 weeks for four times.
7375|NCT04136769|Procedure|Visceral Debranching|Visceral debranching is defined as a vascular reconstruction with the aim of ensuring a sufficient arterial blood flow to the mesentery and liver after the subsequently planned tumor resection, which usually comprises ligation of the gastroduodenal artery or other relevant collateral vessels. All open vascular procedures can be employed for visceral debranching. Examples are aorto-visceral or iliaco-visceral bypasses using autologous vein or an allogeneic graft, or re-insertion of the superior mesenteric artery or celiac trunk into the aorta.
7376|NCT04136756|Drug|NKTR-255|NKTR-255 administered by intravenous infusion (IV) every 21 days to establish safety and tolerability
7377|NCT04136756|Drug|Daratumumab|Daratumumab administered by IV at a dose of 16 mg/kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter
7378|NCT04136743|Device|Lipogems|The Lipogems system (Lipogems International SpA, Milan, Italy) is designed to isolate autologous, micro-fragmented adipose tissue without enzymes or other additives. It uses mild mechanical forces to break down adipose tissue that is extracted from the patient into a form that can be injected into the tendon lesion and other degenerated tissues in a sterile and safe manner. The resulting product is rich in pericytes and mesenchymal stromal cells, retained within an intact stromal vascular niche, that is ready for use in clinical applications.
7379|NCT04136743|Drug|Dexamethasone|Triamcinolone Acetonide is a corticosteroid, which is a class of drugs that are commonly prescribed for shoulder pain. They work to reduce pain by limiting inflammation. They are typically injected into the subacromial space with or without ultrasound guidance.
7380|NCT04136730|Behavioral|Home-based|Resistance exercise carried out unsupervised at home
7381|NCT04136730|Behavioral|Gym-based|Resistance exercise carried out supervised in a gym facility
7382|NCT04136717|Other|Washout period|During this period the patients will breath spontaneously oxygen titrated using the FreeO2 device with a SpO2 target set at 90%. The period duration is 30 minutes.
7383|NCT04136717|Device|NIV - FreeO2|"During this period the patients will receive NIV using FreeO2 device for oxygen titration with a SpO2 target set at 90%. Initially, the inspiratory pressure will be set to obtain a tidal volume between 6 to 8 mL/Kg of predictive body weight and positive end-expiratory end pressure (PEEP) at 5 centimeters of water (cmH2O).~After NIV initiation, the parameters can be adjusted to improve patient comfort. The period duration is 30 minutes."
7384|NCT04136717|Device|Nasal High flow Oxygen therapy - FreeO2|During this period the patients will receive NHFOT using the FreeO2 device for oxygen titration with a SpO2 target set at 90%. The high flow device will be set at 30 lpm.The period duration is 30 minutes.
7385|NCT04136717|Other|CPAP - Oxygen constant flow|During this period, the patients will have their own CPAP with oxygen adjusted by hospital staff according to hospital protocol. The period duration is 15 minutes.
7386|NCT04136717|Other|CPAP - FreeO2|During this period, the patients will have their own CPAP with oxygen adjusted using the FreeO2 device. SpO2 target will be set at 90% The period duration is 60 minutes.
7387|NCT04136704|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy
7388|NCT04136691|Other|simulation training|Burn patient scenario was performed with the intervention group.
7389|NCT04136678|Other|walking training|15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
7390|NCT04136665|Other|Physical Activity Adapted program|6-month APA home program, supervised by videoconferencing in post-cancer for children / AYA treated for leukemia
7391|NCT04136652|Procedure|CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch|women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
7392|NCT04136639|Other|Miswak|sticks
7393|NCT04136639|Other|Grape Seed Extract Mouthwash|Mouthwash
7394|NCT04136639|Other|fluoride|mouthwash
7395|NCT04136626|Device|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and mindfulness skills.
7396|NCT04136613|Device|Copper Intra uterine contarceptive device ( Cu-T 380A)|Insertion of the Cu-T 380A during cesarean delivery immediately after placental removal.
7397|NCT04136600|Drug|EGFR antibody and Chemotherapy|"Drug: Cetuximab Cetuximab: 500 mg/m2 iv on Day 1 of cycle every 3 weeks, until disease progression.~Other Names:~Erbitux Drug: Nimotuzumab Nimotuzumab: 400mg iv on Day 1 of cycle, every week, until disease progression~Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
7398|NCT04136600|Drug|Chemotherapy|"Drug: Fluoropyrimidine 5-fluorouracil (5-FU): 2,400 mg/m2/day iv in first 46 hours of cycle, every two weeks for 12 cycles~Other Names:~5-Fu Drug: Capecitabine Capecitabine: 1000 mg/m2 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~Xeloda Drug: S-1 S-1: 60mg for BSA>1.5, 50 mg for 1.5>BSA>1.25 , 40mg for BSA<1.25 po twice daily for 14 days every 3 weeks, for 6 cycles~Other Names:~S-1 Drug: Oxaliplatin Oxaliplatin: 85 mg/m2 iv on Day 1 of cycle, every 2 week for 12 cycles with 5-Fu; Oxaplatin: 130 mg/m2 iv on Day 1 of cycle, every 3 week for 6 cycles combined with S-1 or Capecitabine;"
7399|NCT04136587|Other|Colonic fluid collection during endoscopy for analysis of the bacterial secretome|Colonic content will be collected by suction during routine colonoscopy including the residual fluid in the colon and stool contents and also suction of washing fluid (sterile physiologic H2O solution)
7400|NCT04136561|Device|Midline catheter|Midline catheter placed in patients with existing standard of care CVC
7401|NCT04136548|Drug|Fentanyl|Subjects will receive 75 ug Fentanyl while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
7402|NCT04136548|Other|Placebo|Subjects will receive saline while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.
7403|NCT04136535|Drug|Pemetrexed|Pemetrexed，500mg/m²，ivgtt ，d1，q3w
7404|NCT04136535|Drug|Carboplatin|Carboplatin，AUC 5.0，ivgtt，d1，q3w，
7405|NCT04136535|Drug|Anlotinib|Anlotinib ，12 mg，po，qd，d1-14，q3w；
7406|NCT04136522|Procedure|conventional pancreaticoduodenectomy|In this subgroup, the surgeon will perform pancreaticoduodenectomy without isolation of superior mesenteric artery and dissection of nerve plexus and lymph node around superior mesenteric artery.
7407|NCT04136522|Procedure|total mesopancreas excision including superior mesenteric artery first approach|In this subgroup, the surgeon will identify and isolate superior mesenteric artery before pancreatic transection, they dissect soft tissues including nerve plexus and node around superior mesenteric artery.
7408|NCT04136509|Procedure|sinus floor elevation|sinus floor elevation with the lateral technique
7409|NCT04136509|Procedure|bone core biopsy|After 6 month healing time reentry took place and bone core biopsy samples were collected from the augmented bone of the maxillary sinuses with a trephine drill. Biopsy samples were collected from the sites where the dental implants were to be placed.
7410|NCT04136509|Device|dental implant placement|During reentry after bone biopsy dental implants were placed.
7411|NCT04136509|Diagnostic Test|Cone Beam Computed Tomography scans (CBCT)|Preoperative CBCT scans are carried out before dental implant placement, 6 months after sinus floor elevations. Postoperative CBCT scans are taken 3 years after sinus floor augmentations.
7412|NCT04136496|Device|Black-Eye Ink|There are two proposed studies utilizing the Ink during differing timepoints.Both will identify patients with breast cancer, with a biopsied metastatic axillary lymph node(LN) with a tissue marker clip placed, as is current practice. In Study A, 0.5mL of Black Eye Ink will be placed in the metastatic LN after neoadjuvant therapy. In Study B, 0.5mL of Black Eye Ink will be placed before neoadjuvant therapy. In both studies, the LN containing the tissue marker clip will be the one to have the radioactive seed and Ink inserted. The seed will still be inserted, in the event the dye is not well-visualized. In both studies, the surgeon will attempt to find the LN by direct visualization and then confirm the appropriate LN has been removed by using the Gamma probe and intra-operative radiographs. If the seed is not within the tattooed node, the LN containing the seed will also be removed. All lymph nodes injected with Ink will be removed by the surgeon;no Ink-injected node remains in body.
7413|NCT04136483|Behavioral|CBT-I|The theoretical framework is cognitive-behavioral therapy that includes sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive interventions and relaxation. The intervention has been adapted to adolescents by reducing the amount of psychoeducational information and the interventions related to changing cognitions. It involves six weekly face-to-face individual sessions with a therapist, supported by a participant workbook that contains information, work- sheets, and at-home tasks. Clinical psychologists or graduate clinical psychologists in training delivered the intervention sessions under supervision by the first author. Parents/care-givers were given information about the components, but did not take active part of the intervention.
7414|NCT04136470|Biological|Collection of stool, blood (PBMC) and biopsy (FFPE)|Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).
7415|NCT04136457|Other|Endurance training|Subjects perform a period of endurance training
7416|NCT04136457|Other|Resistance training|Subjects perform a period of resistance training
7417|NCT04136457|Other|Sprint training|Subjects perform a period of sprint training
7418|NCT04136444|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
7419|NCT04136431|Other|Programed cryotherapy and continuous passive motion|The intervention group started to use a CPM machine and applied programed cryotherapy intermittently within one hour while returning to the ward on the day of surgery.
7420|NCT04136431|Other|Unrogramed cryotherapy and continuous passive motion|A CPM machine and cryotherapy were not applied on the day of surgery while returning to the ward
7421|NCT04136418|Device|COPDPredict mobile App|An App on a mobile device is used by the patient to track the status of their COPD and inform the patient's care team
7422|NCT04136418|Other|Usual care|Patients self-manage their COPD using prescribed medication in accordance with basic guidance information
7423|NCT04136392|Device|ABIOMED, Inc. hemodynamic support devices|ABIOMED, Inc. hemodynamic support technology are the smallest and least invasive percutaneous ventricular support blood pumps available on the market. They are routinely used in clinical practice in a variety of clinical scenarios to support patients in prophylactic or emergent settings.
7424|NCT04136379|Diagnostic Test|INR monitoring using a CoaguChek POC device|INR monitoring using a CoaguChek POC device
7425|NCT04136366|Drug|ADX-2191 (intravitreal methotrexate 0.8%)|ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy
7426|NCT04136366|Other|Standard surgical care procedure|Standard surgical care performed upon completion of pars plana vitrectomy
7427|NCT04136353|Drug|Darolutamide|2 x 300mg oral tablets twice daily for 96 weeks
7428|NCT04136353|Drug|Placebo oral tablet|2 oral tablets twice daily for 96 weeks
7429|NCT04136353|Drug|Luteinizing Hormone-Releasing Hormone Analog|All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.
7430|NCT04136353|Radiation|External Beam Radiotherapy|All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.
7431|NCT04136340|Other|In-person in clinic follow-up visit|Patient will be seen in-person in the clinic by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.
7463|NCT04136041|Device|Smartphone Application|The experimental group will watch movies using the Smartphone application for at least 10 min a day for 5 weeks.
7464|NCT04136028|Drug|Kineret|Kineret at a dose of 8 mg/kg per day subcutaneously daily, every day at the same time
7432|NCT04136340|Other|Telemedicine follow-up visit|"i. Patients will be seen by video telemedicine at home by a Supportive Care Specialist for at least 3 follow-up visits over 14 weeks.~ii. Patients will have access to a clickable link that will initiate a video telemedicine call to the clinician's office. The clinical team will be responsible for answering such calls and for ensuring the clinician and the patient connect and begin the actual visit."
7433|NCT04136327|Drug|GLPG1972 film-coated tablets|single oral dose of GLPG1972
7434|NCT04136327|Drug|[14C]-GLPG1972 solution for infusion|a 15-minute IV infusion [14C]-GLPG1972
7435|NCT04136327|Drug|[14C]-GLPG1972 oral solution|single oral dose of [14C]-GLPG1972
7436|NCT04136314|Behavioral|Decision-Framed Survey|Survey will ask all subjects for will be asked to indicate basic demographic information, such as age, sex, race, and education level. Also, subjects will indicate whether they have been diagnosed with psoriatic arthritis. Importantly, patients will complete the survey questions anonymously, and no direct patient identifiers or HIPPA-protected information will be collected. Subjects will then be asked to indicate their preference for a hypothetical injectable medication after exposure to [A] a gain-framed message or [B] a loss-framed message.
7437|NCT04136301|Other|Informative Video group|Informative Video group before labor in nulliparous women
7438|NCT04136288|Device|MoreNova|Shockwave therapy delivered to the genital area with low dose shocks
7439|NCT04136275|Biological|CAR-37 T cells|CAR-37 is an investigational treatment that uses the participant own immune cells, called T cells, to try to kill the cancerous cells
7440|NCT04136262|Drug|Tripterygium wilfordii Hook F (TwHF)|Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
7441|NCT04136262|Drug|Methotrexate|Oral methotrexate 10 mg per week for 24 weeks.
7442|NCT04136262|Other|Dummy Tripterygium wilfordii Hook F (TwHF)|Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.
7443|NCT04136249|Dietary Supplement|Over physical activity|105/5000 resistance training combined with nutritional monitoring on maximum strength of knee extensors
7444|NCT04136236|Diagnostic Test|The diagnosis of Artificial Intelligence and endoscopist|When suspected esophageal mucosal lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
7445|NCT04136197|Diagnostic Test|Manual palpation for incidence determination|The patients are positioned in a sitting and prone lying posture. Trigger points are discrete, local, hypersensitive spots located in a taut band of muscles. Palpation of the trigger point will cause elicitation pain over the affected area and radiation of pain toward a zone of reference and a local twitch response.
7446|NCT04136184|Drug|AKCEA-TTR-LRx|AKCEA-TTR-LRx by subcutaneous injection
7447|NCT04136184|Drug|Inotersen|Inotersen by subcutaneous injection
7448|NCT04136171|Drug|AKCEA-TTR-LRx|ACKEA-TTR-LRx by subcutaneous injection
7449|NCT04136171|Drug|Placebo|Matching placebo by subcutaneous injection
7450|NCT04136145|Drug|Belimumab for IV|Belimumab will be available as white to off-white lyophilized cake at a unit dose strength of 400 mg to be reconstituted and diluted in normal saline to obtain 200 mg per dose.
7451|NCT04136145|Drug|Belimumab for SC|Belimumab will be available as clear to opalescent, colorless to pale yellow sterile solution at unit dose strength of 200 mg/milliliter (mg/mL) for SC injection in a single-use, prefilled syringe contained within an auto-injector device.
7452|NCT04136132|Other|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
7453|NCT04136119|Other|questionnaire|survey exploring practice of vitamin and micronutrient supplementation
7454|NCT04136106|Drug|IL-2|IL-2 is a medicine which can use in autoimmune disease, infection or cancer with different dose. Low-dose IL-2 preferentially used in autoimmune disease, such as SLE. Our enrolled SLE patients will divided into two groups depend on whether use IL-2 or not, combined with corticosteroid and immunosuppressor.
7458|NCT04136080|Other|vasopressors|control the mean arterial pressure with vasopressors
7459|NCT04136067|Drug|NNC0268-0965|One daily dose of 1.5, 3.0 or 4.5 nmol/kg administered s.c. (subcutaneously, under the skin) for 6 days
7460|NCT04136067|Drug|insulin glargine|One daily dose of 3.0 nmol/kg administered s.c. for 6 days
7461|NCT04136054|Behavioral|Adjusted group CBT-i for Anxiety and Affective disorders|Adjusted group CBT-i for Anxiety and Affective disorders. CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. Adjustments include the relationship between sleep and the psychiatric conditions at hand and and working with motivational enhancement techniques to increase adherence to treatment.
7462|NCT04136054|Other|Care as usual wait-list control group|Usual care at the clinic. This entails managing pharmacological treatment for the psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and CBT groups for symptoms of worry and depression, and individual therapy.
7465|NCT04136015|Drug|Dasatinib 100 MG|The CML-CP patients with early(3m to 6m) molecular response failure on imatinib,Conversion dasatinib group or Imatinib group
7466|NCT04135989|Device|Percutaneous coronary intervention with implantation of amphilimus-eluting stents for coronary artery disease.|Implantation of polymer-free, amphilimus-eluting, drug-eluting stents
7467|NCT04135989|Device|Percutaneous coronary intervention with implantation of everolimus-eluting stents for coronary artery disease.|Implantation of biodegradable-polymer, everolimus-eluting, drug-eluting stents
7468|NCT04135989|Drug|Personalized DAPT duration|Duration of dual antiplatelet therapy according to DAPT score for 3- or 6- months in patients with low DAPT score (stable CAD or ACS, respectively) or for 24-months in patients with high DAPT score
7469|NCT04135989|Drug|Standard DAPT duration|Duration of dual antiplatelet therapy for 12 months.
7470|NCT04135937|Drug|Bupropion|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
7471|NCT04135937|Drug|Varenicline|Smoking cessation pharmacotherapy prescribed in accordance with package insert.
7472|NCT04135937|Behavioral|Cognitive Behavioral Therapy|Behavioral intervention; modules include identifying reasons for quitting, setting a quit date, breathing relaxation technique, identifying smoking triggers, identifying social support, and education about relapse prevention
7473|NCT04135937|Drug|Nicotine Replacement Therapy|Participants may be prescribed single-formulation NRT (i.e., nicotine patch) or dual NRT (patch + rescue method such as nicotine gum, inhaler, or lozenges).
7474|NCT04135937|Behavioral|Relapse Prevention Text Messaging|Participants will be invited to utilize SmokefreeVET, a mobile text messaging service for military Veterans trying to quit smoking. The 6- to 8-week program provides 24/7 encouragement, advice, and tips to help smokers quit smoking and stay quit.
7475|NCT04135924|Other|Rehabilitation|physical exercise and respiratory muscle training
7476|NCT04135898|Drug|SIBP-04|3mg/kg, infusion in 90 minutes
7477|NCT04135898|Drug|Bevacizumab|3mg/kg, infusion in 90 minutes
7478|NCT04135885|Drug|Folic Acid|The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
7479|NCT04135885|Drug|Placebos|Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0~20 points, and the score ≥10 points is defined as the recovery period).
7480|NCT04135872|Other|strengthened nuitritional treatment|improving nutritional status by nasal feeding for dysphagia or iv. albumin when serum albumin level lower than 35g/L
7481|NCT04135859|Behavioral|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
7482|NCT04135859|Behavioral|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
7483|NCT04135846|Drug|Doxazosin|16 mg or maximum tolerated dose (MTD)
7484|NCT04135846|Drug|Placebo|Matching placebo
7485|NCT04135833|Drug|BPI-7711|BPI-7711 60 mg
7486|NCT04135833|Drug|BPI-7711|BPI-7711 180 mg
7487|NCT04135833|Drug|Itraconazole|Itraconazole 200 mg
7488|NCT04135833|Drug|Rifampicin|Rifampicin 600 mg
7489|NCT04135820|Drug|BPI-7711|BPI-7711 180 mg
7490|NCT04135807|Combination Product|Microdevice|"Placement of 1-3 microdevices (depending on the size of the tumor) before tumor resection is started.~The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin, Lapatinib, Osimertinib, Abenaciclib, and Everolimus) released by the microdevice reservoirs. The drugs used in this study will only include drugs already used systemically for the treatment of gliomas."
7491|NCT04135781|Drug|nab paclitaxel|nab paclitaxel （120mg/m2；iv；d1，8）
7492|NCT04135781|Drug|Tegafur|S-1 （<1.25 m2, 40 mg; 1.25 to ≤1.5 m2, 50 mg; and ≥ 1.5 m2, 60 mg；po；d1-14 bid）
7493|NCT04135781|Drug|Oxaliplatin|Oxaliplatin（130mg/m2 , iv, d1）
7494|NCT04135781|Drug|Capecitabine|Capetabine（1000 mg/m2 po, d1-14 bid ）
7497|NCT04135755|Other|no drug intervention|no drug or treatment intervention
7498|NCT04135742|Device|Transcranial Alternating Current Stimulation|Transcranial alternate current stimulation (tACS) is a method of alternative current stimulation that can modulate neural activity by imposing local oscillatory activity.
7499|NCT04135742|Behavioral|Cognitive Training|Cognitive training includes memory, reasoning, processing speed and role playing, etc.
7500|NCT04135742|Behavioral|Aerobic Exercise|Aerobic exercise is based on fast walking.
7640|NCT04134650|Combination Product|Linagliptin + metformin|Linagliptin-Metformin 2.5/1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
7714|NCT04134026|Drug|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
7501|NCT04135716|Diagnostic Test|Colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
7502|NCT04135716|Diagnostic Test|Colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
7503|NCT04135703|Behavioral|SBOA + Housing|opioid and related prevention services intervention
7504|NCT04135690|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
7505|NCT04135690|Drug|Toripalimab|240mg intravenously every 3 weeks
7506|NCT04135690|Drug|Sorafenib|400mg bid po
7507|NCT04135677|Drug|Rivaroxaban|Drug: Rivaroxaban 10mg Duration of treatment: 3 months(3months for DAPT afterwards)
7508|NCT04135677|Drug|Rivaroxaban|Drug: Rivaroxaban 20mg Duration of treatment: 3 months(3months for DAPT afterwards
7509|NCT04135677|Drug|DAPT|Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:6 months
7510|NCT04135664|Procedure|esophagectomy|esophagectomy with at least two-field (thoracic-abdominal) lymphadenectomy
7511|NCT04135664|Combination Product|chemoradiation|concurrent chemotherapy and radiotherapy
7512|NCT04135664|Other|active surveillance|No further adjuvant therapy
7513|NCT04135651|Procedure|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
7514|NCT04135651|Procedure|Cricoid pressure|To apply cricoid pressure, the crocoid cartilage was compressed with a single-handed three-finger maneuvre towards the vertebral bodies.
7515|NCT04135638|Procedure|Cover Group|"Cover when the ILM flap is everted over the MH gap in a single layer"
7516|NCT04135638|Procedure|Fill Group|"Fill when the ILM is folded into multiple layers within the MH"
7517|NCT04135625|Behavioral|Integrated nutrition and agricultural (INA) trainings|Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
7518|NCT04135625|Behavioral|Ceremonial Gifting of Livestock|Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
7519|NCT04135612|Other|Smartphone based communication|Each patient will document each evening her lactation performance during the day, and the App will generate a daily report transmitted by email every evening to our computerized research database. Every evening the patient will receive via email an individualized feedback from our team regarding her lactation. This feedback could include: reassurance and positive feedback and lactation tips in attempt to optimize specific obstacles.
7520|NCT04135599|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive, safe and easy-to-operate neuro-electrophysiological technique, which becoming an emerging therapeutic option for many mental disorders.It can modulate cortical excitability of target brain region, neuron plasticity and brain connections. Previous studies suggest that tDCS could reduce cue-induced craving and improve cognition in drug addiction.
7521|NCT04135586|Other|Exercise training|Exercise program for 24 weeks (with neo-adjuvant treatment), with two sessions per week including both moderate-to-intense aerobic and resistance training. The intensity of each type of exercise will range between 65% and 100% of the maximum score in the Rated Perceived Exertion (RPE) scale.
7522|NCT04135586|Other|Control|Yoga + educational program
7523|NCT04135560|Drug|PF-07038124 and Vehicle|PF-07038124 0.06% and vehicle Ointment BID applied to 1% Body Surface Area (BSA)
7524|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment QD applied to 10% BSA
7525|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.01% or vehicle Ointment BID applied to 10% BSA
7526|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.03% or vehicle Ointment BID applied to 10% BSA
7527|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 0.06% or vehicle ointment BID applied to 10% BSA
7528|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle ointment BID applied to 20% BSA
7529|NCT04135560|Drug|PF-07038124 or vehicle|PF-07038124 safe concentration or vehicle BID applied to 10% BSA
7530|NCT04135547|Device|intra-osseous access vs. intra-venous access|EZ-IO®: The Arrow® Intraosseous Vascular Access System from Teleflex IV-catheter: form local qualified manufactures
7531|NCT04135534|Drug|group A|mutonpain 0.05 mg/kg
7532|NCT04135534|Drug|group B|mutonpain 0.1 mg/kg
7533|NCT04135534|Drug|group C|mutonpain 0.2 mg/kg
7534|NCT04135521|Drug|Intraperitoneal chemotherapy|Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
7535|NCT04135508|Drug|BAT1406|40mg/0.8ml
7536|NCT04135508|Drug|Humira|40mg/0.8ml
7537|NCT04135495|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaroyotic ribosomal selective glycoside (ERSG)
7538|NCT04135482|Other|colonic tissue biopsy|colonic tissue biospy of patients with severe crohn's disease using colonoscopy
7539|NCT04135469|Other|Referral for tax preparation services|Printed materials will be provided with contact information for tax preparation services at BMC and other sites in the city.
7540|NCT04135469|Other|Navigator assisted tax preparation services at BMC|A study navigator will assist the participant in accessing the BMC located tax preparation services.
7541|NCT04135456|Drug|Mannitol|When the neurosurgeon starts the skin incision, 20% mannitol administered through the venous catheter with fulldrip in 5-10 minutes. Neurosurgeons evaluate the degree of brain relaxation after dura opening in 4 point scale (1=bulging brain, 2=firm brain, 3=satisfactorily relaxed, 4=perfectly relaxed).
7641|NCT04134650|Drug|Metformin|Metformin 1700mg daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
7642|NCT04134637|Device|ultrasound|in the PIFB group linear ultrasound (Philips clear vue350,Philips healthcare,Andover MAO1810,USA,Machine Identification number:1385,Nile medical center,service@nilemed.net) probe will be used.
7542|NCT04135443|Behavioral|3T Tune in! Turn on! Turn up!|A sex positive multimedia interactive mobile app delivered HIV/STI intervention developed for use by YBMSM ages 14-17. The program employs a theory based approach to address essential knowledge, perceptions of risk, peer norms, attitudes and skill with two primary goals: (1) To reduce HIV/STI the program emphasizes partner reduction, avoidance of concurrent partners, condoms and HIV/STI tests; and (2) To improve sexual health and relationships.
7543|NCT04135443|Behavioral|General Health App|The control group will download a mobile app that addresses general health behaviors, specifically drinking more water.
7544|NCT04135430|Other|Survey|practice of an updated questionnaire at D0, D2 and D7
7545|NCT04135417|Biological|HAV|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
7546|NCT04135404|Other|health-related telephone surveys|The Behavioral Risk Factor Surveillance System (BRFSS) is a health-related telephone surveys that collect state data about United States residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services (Secondary-data analysis).
7547|NCT04135391|Behavioral|Aerobic exercise training|All recruited subjects underwent 36 times of moderate-intensity continuous training (MICT) at 60% of peak oxygen consumption (VO2peak) for 30 mins, and 10or had high-intensity interval training (HIIT) at alternative 80% and 40% VO2peak with the same training times and duration.
7548|NCT04135378|Drug|ascorbic acid|Study Group :- ascorbic acid ( 500 mg per day) for one week before presentation
7549|NCT04135378|Other|placebo|:- included 30 students given placebo for one week before presentation.
7550|NCT04135365|Behavioral|neurocognitive assessment|Observational study therefore there are no interventions
7551|NCT04135365|Behavioral|neuroimaging assessment|Observational study therefore there are no interventions
7552|NCT04135352|Drug|200 mg of pembrolizumab|Participants receive 200 mg of pembrolizumab intravenously on day 1 of every 21-day cycle for 35 cycles.
7553|NCT04135352|Biological|V938|Participants receive V938 intratumorally in the first 21-day cycle.
7554|NCT04135339|Other|Eccentric exercise|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure eccentric contraction.
7555|NCT04135339|Other|Concentric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure concentric contraction.
7556|NCT04135339|Other|Isometric exercise.|The exercise session will consist of 3 sets of 15 reps, 3´´ per rep, with 30'' rest between sets, of the previous treated gastrocnemius muscle (by DN). Each rep will be a pure isometric contraction.
7557|NCT04135326|Other|Quality-of-Life Assessment|Ancillary studies
7558|NCT04135326|Other|Questionnaire Administration|Ancillary studies
7559|NCT04135326|Procedure|Transcranial Direct Current Stimulation|Undergo tDCS
7560|NCT04135313|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14
7561|NCT04135313|Drug|Oxaliplatin|130 mg/m2 iv day 1
7562|NCT04135313|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
7563|NCT04135313|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 54 Gy on primary tumor in 2 Gy fractions
7564|NCT04135313|Procedure|Rectal cancer surgery|Laparoscopic or open total mesorectal excision or extralevator abdominoperineal resection
7565|NCT04135300|Genetic|Single dose intravenous injection of BBM-H901|Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10`12 vg/Kg.
7566|NCT04135287|Drug|GLP-1 receptor agonist|The main objective of the study is to determine the relationship between the increase in glucose-stimulated insulin secretion and decrease in HbA1c caused by GLP-1 RA therapy in poorly controlled T2DM patients. We also will identify a cut point of an increase in beta cell function which produces a clinically meaningful decrease in HbA1c.
7567|NCT04135274|Diagnostic Test|Neutrophil to lymphocyte ratio|Neutrophil to lymphocyte ratio
7568|NCT04135261|Drug|HBM4003|Intravenous (IV) administration on days 1, 8, 15 and 22 of a 28-day treatment cycle.
7569|NCT04135235|Drug|TAF|Propofol tenofovir fumarate
7570|NCT04135235|Drug|TDF|Dipirofurate fumarate tenofovir
7571|NCT04135222|Diagnostic Test|Measurements of gingiva thickness|Measurements were performed at upper canines and incisors in thirty periodontally healthy patients. The CBCT/CAD technology along with the PDIP software were used to measure crestal (CGT in mm ), supracrestal (SGT in mm) and free gingival thickness (FGT in mm ) as well as alveolar crest-gingival margin (AC-GM) and cemento-enamel junction (AC-CEJ) distance and the TLPAC localized 2, 4 and 8mm apically than the edge of the AC. Width of keratinized tissue (WKT) were measured using a periodontal probe. For each patient, the periodontal phenotype was evaluated on the basis of coronal width/length (CW/CL in percentages) ratio of both upper central incisors. For each tooth, the gingival phenotype was assessed on the basis of the GT measurement( in mm).
7572|NCT04135209|Diagnostic Test|Optical coherence tomography angiography OCTA|Macular scanning using regular structural OCT as well as microvasculature analysis using OCTA
7573|NCT04135196|Other|voluntary forearm loading task|voluntary task, consisting of leaning onto the palm of the hand until a target force is reached. Each loading bout consists of 100 loading cycles, which takes approximately 2 minutes to complete. The task is performed 4 times per week during the intervention period.
7574|NCT04135183|Procedure|changes of Pneumonia Severity Score|assessing effectiveness of CAP treatment by using continuous pneumonia severity score
7575|NCT04135170|Combination Product|ALBC vs plain bone cement|The patients undergoing primary total knee arthroplasty are allocated to either ALBC or plain bone cement and compare the effectiveness of ALBC use vs pain bone cement bone cement without antibiotic) with respect to revision due to deep infection one year after primary TKA surgery.
7576|NCT04135157|Procedure|Pectoralis nerve block|Pecs block will be performed 30 min. before general anesthesia.
7577|NCT04135157|Procedure|Erector spine plane block|ESP block will be performed 30 minutes before general anesthesia.
7578|NCT04135157|Other|Control|Only general anesthesia will be performed.
9781|NCT04116424|Other|neurologist accompaniement|presentation during consultation by neurologist
7579|NCT04135144|Other|Group 1 (printed materials)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
7580|NCT04135144|Other|Group 2 (video phone reminder)|Exercises were given at least 3 times a week for 10 weeks and 1 set per day for a total of 6 weeks. individuals; normal joint movement exercises; neck flexion, lateral flexion, rotation, extension and retraction movements, isometric exercises; neck flexion, extension, lateral flexion and rotation movements and stretching exercises; neck lateral flexion, neck rotation and flexion movements were given.
7581|NCT04135131|Other|pilates mat exercises and home exercises|Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
7582|NCT04135105|Other|Normal hearing group|Observational
7583|NCT04135092|Biological|Individual Patient TCR Transduced PBL|Day 0: Cells will be infused at a dose not to exceed .5e11 in 400 mL IV on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
7584|NCT04135092|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
7585|NCT04135092|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
7586|NCT04135092|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).
7587|NCT04135092|Drug|Pembrolizumab|Pembrolizumab 2 mg /kg IV over approximately 30 minutes on Day -2 and then every 3 weeks until time of disease progression.
7588|NCT04135053|Biological|Lyophilised Neisseria lactamica|Previously lyophilised Neisseria lactamica will be reconstituted and intranasally given to participants
7589|NCT04135040|Dietary Supplement|L-Amino Acid|8 different lysine intakes (L-Amino Acid and food) will be tested for 8 hours each.
7590|NCT04135027|Other|no interventions|no interventions
7591|NCT04135014|Drug|Midazolam|oral midazolam 0.5mg.kg-1 approximately 30-40 minutes before surgery using a computer-generated random number table.
7592|NCT04135014|Drug|Dexmedetomidine|intranasal dexmedetomidine 2µg.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
7593|NCT04135014|Drug|Midazolam and Dexmedetomidine|oral midazolam 0.5mg.kg-1 and intranasal dexmedetomidine 1ug.kg-1 approximately 30-40 mins before surgery using a computer-generated random number table.
7594|NCT04135001|Behavioral|HBM Training|A computer-based training to reduce hostile bias and interpersonal conflict as a mechanism to improve trust and cohesion within an operational military unit across the deployment cycle. The computer training is based on the Go/No-Go task (Fillmore et al., 2006) and Lexical Decision Task (Lepore & Brown, 2002). The training reduces HAB by affecting two cognitive mechanisms: prime seeking non-hostile concepts when presented with ambiguous cues and conditioning inhibition in response to hostile cues. Thus, the training induces a non-hostile attribution bias while simultaneously training the inhibition of hostile attribution bias and aggressive behavior in response to ambiguous cues.
7595|NCT04135001|Other|Placebo Training|Volunteers in the placebo condition will be told to complete the fragments with the first word that comes to mind. This placebo still exposes volunteers to the training stimuli and computer task, but does not train inhibition or selectively prime non-hostility, which are the hypothesized mechanisms of the training.
7596|NCT04134988|Other|Medimoov|The Medimoov game platform (created by NaturalPad©) is a physio-gaming medical device, which comes in the form of functional and postural rehabilitation software. Associating movement capture and videogames, Medimoov contributes to the older adults' motivation and engagement and offers adapted physical activities.
7597|NCT04134988|Other|Standard psychomotor therapy|Psychomotor therapists are among the professionals recommended by the French national health authority. They intervene on psychomotor dimensions of falls, namely the motor, sensory and cognitive aspects.
7598|NCT04134975|Procedure|Spine surgery|surgery with pedicle screw placement between L1 and S1
7599|NCT04134962|Diagnostic Test|3D Imaging FAO measurement|"The Cone Beam under load is used for the diagnosis and monitoring of the foot and ankle. It has a CE marking for this purpose.~The images obtained by the Cone Beam under load (Ped Cat) will be analysed using the TALAS mathematical algorithm tool to measure the FAO.~The internal software of the Cone Beam under load will also be used to obtain a radiographic image corresponding to a 2D projection on which the tibio-calcaneal angle can be measured."
7600|NCT04134949|Behavioral|Cognitive Behavior Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
7601|NCT04134949|Behavioral|Mindfulness-Based Cognitive Therapy|consists of eight weekly treatment sessions of 45 to 60 minutes.
7602|NCT04134936|Drug|Tafasitamab|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) in addition to R-CHOP
7603|NCT04134936|Drug|Tafasitamab plus Lenalidomide|Six 21-day cycles of tafasitamab (12 mg/kg intravenously, on Day 1, 8 and 15) plus lenalidomide (starting dose 25 mg orally, on Day 1-10) in addition to R-CHOP
7604|NCT04134923|Drug|[11C] Pittsburgh Compound-B (PIB)|Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer [11C] PIB. Participants will then undergo a [11C] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.
7643|NCT04134637|Drug|Bupivacaine Hydrochloride 5 MG/ML|twenty milliliters of a solution of 0.25% bupivacaine in the PIFB group
7644|NCT04134624|Other|Sepsis care bundle|Initiation of sepsis care bundle in prehospital setting, including collection of blood cultures, administration of antibiotics, and initiation of IV fluids
7831|NCT04132908|Dietary Supplement|Placebo|Subjects will consume two capsules at breakfast and dinner for ten weeks.
7605|NCT04134910|Procedure|Physical Therapy|Subjects will be prescribed a 6-week physical therapy regimen consisting of one 45 minute in office visit per week, and home exercises performed daily. The in-office visits with a physical therapy provider will consist of the application of manual therapy, particularly high-velocity, low amplitude thrust mobilization in the anterior/posterior direction of the lumbar spine. In office visits will also include supervised repeated motion of the lumbar spine into extension (McKenzie therapy, 3 sets of 10 repetitions, in prone and standing positions) Patients will be instructed to complete these repeated extension exercises at home daily for the 6 week period.
7606|NCT04134897|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
7607|NCT04134897|Drug|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
7608|NCT04134897|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
7609|NCT04134897|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
7610|NCT04134897|Procedure|Rectal cancer surgery|Laparoscopic or open total mesorectal excision
7611|NCT04134897|Radiation|Radiotherapy|Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
7612|NCT04134884|Drug|Talazoparib|Talazoparib will be given orally once daily on a continuous basis, beginning on Day 1 of Cycle 1 at a dose level of 0.5, 0.75 or 1.0 mg depending on cohort assignment)
7613|NCT04134884|Drug|ASTX727|ASTX727 will be given orally once daily on Days 1-5 of the 28 day cycle at doses of 20 mg:100 mg, 30 mg: 100 mg, and 35mg : 100 mg depending on cohort assignment
7614|NCT04134871|Behavioral|Group walk and one to one coaching|Participants will be invited to attend a group education session, weekly group walks and fortnightly coaching sessions
7615|NCT04134858|Other|The nurse-led health coaching program|The intervention was based on the customized nurse-led health-coaching program. The program consisted of an individual health-coaching nurse, health-coaching sessions and a written action plan according to each participant´s individual needs.
7616|NCT04134845|Drug|Dantrolene|muscle relaxant
7617|NCT04134806|Device|Accelerometer|Participants will wear the accelerometer during the experiments to measure the walking pattern.
7618|NCT04134806|Device|Gait Sensor|26 gait markers will be attached to participants' trunk and lower body during the experiments to measure gait patterns.
7619|NCT04134806|Device|ECG|Participants will wear an electrocardiogram during the experiments to measure heart rate variability.
7620|NCT04134806|Device|EDA|Participants will wear an electrodermal activity sensor during the experiments to measure the pattern of skin conductance.
7621|NCT04134793|Procedure|radiofrequency ablation|bipolar radiofrequency ablation by ablation forceps
7622|NCT04134767|Behavioral|Re-entry Health Linkage|Research staff will: 1) help participants set goals and reduce their health risks by helping them to reflect on personal drug use, sexual relationships, and their consequences in the context of personal values and goals; 2) help link participants to services that they need and want; 3) offer participants the option of HIV and hepatitis C testing, provide the test result, and provide post-test counseling; and 4) provided participants nasal spray naloxone (Narcan) to carry with them in case they encounter someone who has an opioid overdose or in case they have an opioid overdose and a friend can use the naloxone to respond.
7623|NCT04134767|Behavioral|Overdose Education|Participants will complete a 20-minute overdose education training (i.e.,an interactive training with animated scenarios and narration on preventing, recognizing, and responding effectively to an opioid OD).
7624|NCT04134754|Other|6% Carbon dioxide/50% oxygen/balance nitrogen mixture|In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
7625|NCT04134741|Other|Kinetic Control|"The Kinetic Control training included a functional examination of motor disorders and individual training. The KC training included active exercises, active exercises with torso muscle resistance and exercises involving lower limbs.~The duration of one training was 20-30 minutes."
7626|NCT04134728|Biological|GSK3196165|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered subcutaneously (SC).
7627|NCT04134728|Biological|Sarilumab|Sarilumab solution in pre-filled syringe (PFS) to be administered subcutaneously (SC).
7628|NCT04134728|Drug|Placebo to GSK3196165/ Sarilumab|Placebo sterile 0.9% w/v sodium chloride solution in vial/pre-filled syringe (PFS) to be administered subcutaneously (SC).
7629|NCT04134728|Drug|csDMARDs|Stable dose of csDMARD(s) as standard of care (SoC).
7630|NCT04134715|Drug|PF-06826647|100 mg tablet
7631|NCT04134715|Drug|Oral Contraceptive (OC)|OC in the form of 1 PORTIA (30 µg EE and 150 µg LN) or equivalent tablet
7632|NCT04134702|Other|Acupuncture|Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
7633|NCT04134689|Device|DOT Selfie Intervention|This comprises a smart phone, the VDOT App, a prepaid weekly internet bundle and text message medication reminders
7634|NCT04134689|Other|In-person DOT|Directly observed TB treatment by a health-worker either in a patient's home or at an agreed upon location within the community.
7635|NCT04134676|Drug|Conditioned Media|Conditioned Media represents the complete regenerative milieu of cell-sourced secretome and vesicular elements. The soluble components of the secretome may be separated from the microvesicle fraction by centrifugation, filtration, polymer precipitation-based methodologies, ion exchange chromatography and size-exclusion chromatography. Both of these components may be capable of independently triggering regeneration and repair as well as of mediating the de novo organogenesis of tissue-engineered organs ex vivo.
7636|NCT04134676|Drug|Topical Antibiotic Combinations|Topical antibiotic ointment such as Mupirocin 2%
7637|NCT04134663|Drug|vasoconstrictor and oxytocin treatment|intransal administration of vasoconstrictor and oxytocin
7638|NCT04134663|Drug|vasoconstrictor's placebo and oxytocin treatment|intransal administration of vasoconstrictor's placebo and oxytocin
7639|NCT04134663|Drug|vasoconstrictor and oxytocin's placebo treatment|intransal administration of vasoconstrictor and oxytocin's placebo
7673|NCT04134325|Biological|Pembrolizumab|Pembrolizumab administered at 200 mg every three weeks as per standard of care after treatment with CD30.CAR T cells
7645|NCT04134611|Device|Hyaluronic acid injection|Injection of Hyaluronic acid in knees of those who has degenerative changes after arthroscopic treatment of lateral patellar compression syndrome
7646|NCT04134611|Device|No injection of Hyaluronic acid|No injection of Hyaluronic acid was done
7647|NCT04134598|Radiation|Partial Breast Irradiation (PBI)|Irradiation of volume's portion of the residual breast (index quadrant).
7648|NCT04134598|Drug|Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen|Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
7649|NCT04134585|Other|semi-structured interviews|Semi-structured interviews will be performed to determine representations of physical activity, reluctance/motivation to participate in physical activity sessions and facilitators who can help them overcome these barriers.
7650|NCT04134559|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks, at predetermined dose with 21 consecutive days defined as a treatment cycle.
7651|NCT04134546|Procedure|CBD exoloration|Early versus late intervention after biliary tract injury post cholecystectomy
7652|NCT04134533|Other|Gross Motor Function Measurement|These instruments will be used for determine the gross motor functional level and quality of life of the children with cerebral palsy and anxiety, depression levels of caregivers.
7653|NCT04134520|Device|ProLung System|Non-invasive bioconductance measurements
7654|NCT04134494|Device|Ablative Fractional 2940 nm Laser|"Treatment visit 1, month 0: On the first pass, the depth of the laser will be from 300 to 500 microns, or the thickness of 3 to 5 sheets of paper; the depth will be based on the biopsy that was used to diagnosis the lichen sclerosus. On the second pass, the depth will be 50 microns deeper than the first pass and the hand piece rotated 45˚.~Treatment visit 2, month 1: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚.~Treatment visit 3, month 2: The first pass of the laser will be the same depth as the second pass from the last visit. The second pass will be 50 microns deeper and the hand piece rotated 45˚."
7655|NCT04134468|Drug|Pegvorhyaluronidase alfa|IV infusion
7656|NCT04134468|Drug|Abraxane|IV infusion
7657|NCT04134468|Drug|Gemcitabine|IV infusion
7658|NCT04134455|Procedure|Mesh reinforcement|Once the surgery is over. The closure is made with the 4: 1 rule, then an onlay mesh is placed that exceeds 3 cm on each side the wound is fixed with suture.
7659|NCT04134455|Procedure|RTL reinforcement|Once the surgery is finished, the ared is reinforced by placing a longitudinal suture parallel to the edge of the wound 0.5 cm, then the wound is closed with a 4: 1 rule but the suture enters lateral to the reinforcement suture
7660|NCT04134442|Drug|Bupivacaine Liposome Injection [Exparel]|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%"
7661|NCT04134442|Drug|Standard Therapy|"Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 10ml 0.5% bupivacaine and epinephrine 1:200,000, and 10ml of 0.9% normal saline"
7662|NCT04134429|Device|Everion|The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.
7663|NCT04134416|Drug|Donepezil|Donepezil shall be administered at the times stipulated in the study design as follows: one 5 mg tablet at night for 4 weeks and then one 10 mg tablet at night until the end of the trial (week 10).
7664|NCT04134416|Behavioral|Intensive-Language Action Therapy|All patients participating in the study will receive in weeks 9 and 10 daily three and a half hours of ILATplus therapy. This therapy consists of 30 minutes of specific repetition training (tailored and reinforced by the therapist) before starting with classic ILAT for 3 hours/day during 10 consecutive days.
7665|NCT04134416|Device|Transcranial direct current stimulation|Transcortical direct current stimulation (tDCS) will be applied using a STARSTIM neurostimulation device (Neuroelectrics, Barcelona). Each participant will receive either anodal or sham 20-minute sessions while receiving ILATplus. In the sham stimulation, the same helmet and electrode that is used in the active stimulation will be placed but, in this case, we will apply only a slight current at the beginning and end of the session with the objective of simulating the effects that are experienced with the active stimulation without producing significant cortical stimulation. The active electrode will be placed in the region of the lower right frontal rotation and the reference electrode in the extraencephalic zone (left clavicle). Combined rehabilitation sessions (ILATplus/tDCS) will be conducted, as indicated above, in weeks 9 and 10 of the trial.
7666|NCT04134403|Drug|STASIS|Hydrocortisone sodium succinate, 50 mg, every 6 hours, 7 days or until ICU discharge Thiamine, 200 mg, every 12 hours, 4 days or until ICU discharge Ascorbic acid, 1,500 mg, every 6 hours, 4 days or until ICU discharge
7667|NCT04134390|Drug|Cabozantinib|Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation
7668|NCT04134377|Other|Protein Food Snack|The intervention is 6-months using a food snack with control being three months prior to and three months after-study invention whereby serum albumin levels will be collected monthly. If patients are participating in a supplement program, they will be maintained throughout all ten months of the study so long as the criteria for the supplement program (enrollment and discontinuation) is still being met.
7669|NCT04134364|Drug|Sodium alginate|3 days oral administration of sodium alginate after gastric biopsy
7670|NCT04134351|Other|Bronchial challenge test|Bronchial challenge test with sphingosine-1-phosphate
7671|NCT04134338|Other|To evaluate the effect of wound infection on costs|the degree of costs that is required for trating wound infection
7672|NCT04134325|Biological|Nivolumab|Nivolumab administered at 240mg every two weeks or 480 mg every four weeks as per standard of care after treatment with CD30.CAR T cells
7674|NCT04134312|Biological|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
7675|NCT04134299|Dietary Supplement|AXA4010|The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
7676|NCT04134273|Drug|CLPG Topical Gel 1%|Clindamycin Phosphate Topical Gel 1% (Taro Pharmaceuticals U.S.A, Inc.)
7677|NCT04134273|Drug|Clindamycin|Clindamycin Phosphate topical gel 1%
7678|NCT04134273|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
7686|NCT04134247|Drug|PD-1 combined with chemotherapy|"PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
7687|NCT04134247|Drug|chemotherapy|"Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3"
7688|NCT04134221|Diagnostic Test|Ultrasound assessment|Ultrasound assessment of internal carotid artery blood flow
7689|NCT04134208|Procedure|Computed Tomography|Undergo PET-CT scan
7690|NCT04134208|Drug|Fluciclovine F18|Given IV
7691|NCT04134208|Procedure|Positron Emission Tomography|Undergo PET-CT scan
7692|NCT04134195|Device|Transcranial direct current stimulation|2mA stimulation for 20 minutes
7693|NCT04134182|Drug|Nivolumab|3 mg/kg intravenously every 2 weeks during 16 weeks
7694|NCT04134182|Drug|Ipilimumab|1 mg/kg intravenously every 3 weeks for four doses
7695|NCT04134169|Other|Not applicable(observational study)|Not applicable(observational study)
7696|NCT04134156|Procedure|sleeve gastrectomy|5-port sleeve gastrectomy
7697|NCT04134156|Procedure|one anastomosis gastric bypass|5-port one anastomosis gastric bypass
7698|NCT04134143|Biological|ExpressGraft-C9T1 Skin Tissue|A round patch of experimental skin tissue that the doctor applies over the ulcer
7699|NCT04134130|Drug|Degarelix 120 MG [Firmagon]|Two doses of degarelix, 240 mg, subcutaneously once, at study start.
7700|NCT04134130|Drug|Gonal F RFF Pen 900 UNT Per 1.5 ML Pen Injector|Gonal-f 300 IU subcutaneously 3 times per week for 5 weeks.
7701|NCT04134130|Drug|Testosterone Undecanoate|One dose 1000 mg testosterone once, after 3 weeks.
7702|NCT04134117|Biological|Tisagenlecleucel|One time single predetermined dose level CAR-positive T cells will be utilized based on the FDA approved product label.
7703|NCT04134104|Procedure|Surgery for Colorectal malignant diseases either LAR or APR|Patients following LAR or APR were observed for the Bowel, Bladder, and Sexual Dysfunction
7704|NCT04134091|Drug|LPCN 1144 Formulation A|Oral LPCN 1144 Formulation A capsule, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose)
7705|NCT04134091|Drug|LPCN 1144 Formulation B|Oral LPCN 1144 Formulation B capsule, total daily dose of 450 mg testosterone undecanoate administered as BID (225 mg testosterone undecanoate per dose)
7706|NCT04134091|Drug|Placebo|Oral matching placebo capsule administered as BID
7707|NCT04134078|Drug|inhaled nitric oxide|Inhaled nitric oxide at 40 ppm will be administered upto 24 hours post ROSC in patient who developed in hospital cardiac arrest
7708|NCT04134065|Drug|Vitamin D|patients with refractory Crohn disease and a serum 25(OH)D concentration <75 nmol/L were prescribed oral liquid vitamin D supplementation over 12 weeks using a specific protocol with dose adjusted 4-weekly to aim for a target level of 100e125 nmol/L.
7709|NCT04134065|Drug|Placebo oral capsule|the capsule contain nothing
7710|NCT04134052|Drug|ketamine sedation versus midazolam sedation|Sedation with ketamine 5-20 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% during surgery and the second midazolam group 5 mcg- 35 mcg / kg / hr in infusion in 100ml Na Cl solution 0.9% will be administered during surgery
7711|NCT04134039|Device|Polyurethane (PU) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
7712|NCT04134039|Device|Natural Rubber Latex (NRL) condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to couples to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 2 condom types.
7713|NCT04134026|Drug|Roxadustat|Drug will be dosed orally three times a week.
7715|NCT04134013|Dietary Supplement|Combination: Nutrition AND Chiropractic Adjustment|LBP chiropractic adjustment per protocol, nutrition counseling/ 4 Nutrient offerings (Vitamin Booster, Shake + 2 other offerings)
7716|NCT04134013|Other|Chiropractic Adjustment: Spinal Manipulation Therapy|LBP chiropractic adjustment per protocol
7717|NCT04134000|Drug|Atezolizumab|1200 mg IV q3w until recurrence of disease, disease progression (e.g., muscle−invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
7718|NCT04134000|Drug|BCG|1 or 1/2 instillation per week until recurrence of disease, disease progression (e.g., muscle−invasive or metastatic UBC), symptomatic deterioration (i.e., uncontrollable pain secondary to disease or unmanageable ascites, etc.) attributed to disease progression as determined by the investigator, Intolerable toxicity related to atezolizumab, including development of an immune-mediated adverse event determined by the investigator to be unacceptable given the individual patient's potential response to therapy and severity of the event, any medical condition that may jeopardize the patient's safety if he or she continues on study treatment, use of another non-protocol anti-cancer therapy or pregnancy.
7719|NCT04133987|Biological|Tetravalent live attenuated dengue vaccine admixture TV005|The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
7720|NCT04133987|Biological|Placebo|PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
7721|NCT04133974|Behavioral|methadone induced memory retrieval-extinction procedure|Drug memory is not invariably stable and can be induced transiently labile again by drug-related cues or drug itself, which is termed as 'reconsolidation'. Previously we and other groups have demonstrated that extinction coincided with reconsolidation weakened the drug memory and decreased drug craving and relapse. In the present study, we tried to interfere the methadone-induced heroin addiction memory reconsolidation by extinction given at different times following methadone administration.
7722|NCT04133961|Drug|Phenylephrine|Phenylephrine infusion 0.3ml/kg/hour (equivalent to 0.5mcg/kg/min, phenylephrine dilution is 100mcg/ml in 20ml syringe)
7723|NCT04133961|Drug|Normal saline|Normal saline infusion 0.3ml/kg/hour (normal saline in 20ml syringe)
7724|NCT04133948|Drug|Domatinostat|"Patients in arm B and C will receive domatinostat 200 mg BID, days 1-14 q3weeks.~Patients in arm D will start with once daily (OD) dosing scheme of domatinostat 200mg, d1-14 q3wks. Based on safety data of the first 5 patients in this arm, the next patients will be treated with either a higher dosing scheme (200mg BID, d1-14, q3wks), a lower dosing scheme (100mg OD, d1-14, q3wks) or the same dosing scheme (200mg OD, d1-14, q3wks)."
7725|NCT04133948|Drug|Nivolumab|2 courses nivolumab 240 mg q3weeks
7726|NCT04133948|Drug|Ipilimumab|2 courses ipilimumab 80 mg q3weeks
7727|NCT04133935|Procedure|Laparoscopic Obturator Urethropexy|Suspending the periurethral vaginal tissue to the obturator internus fascia bilaterally via sutures, creating a support for the bladder neck compartment.
7728|NCT04133935|Procedure|Burch Urethropexy|Suspending the periurethral vaginal tissue to Cooper's ligament bilaterally via sutures, creating a support for the bladder neck compartment
7729|NCT04133922|Drug|GLP-1|glucagon-like peptide 1
7730|NCT04133922|Drug|Insulin|we are using to replace basal insulin and to raise insulin concentrations during the insulin clamp
7731|NCT04133922|Drug|Dextrose 20 % in Water|We are using Dextrose to maintain Euglycemia during the insulin clamp
7732|NCT04133909|Drug|Placebo|Placebo is a 0.9% sodium chloride solution. It will be administered as a subcutaneous (SC) injection delivered once every 4 weeks using a pre-filled safety syringe.
7733|NCT04133909|Biological|Mepolizumab|Mepolizumab is a sterile liquid formulation. It will be administered as a SC injection (100 mg/mL) delivered once every 4 weeks using a pre-filled safety syringe.
7734|NCT04133896|Diagnostic Test|IL-6, Clusterin, Irisin Level|Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
7735|NCT04133883|Procedure|Ultrasound, Haemophilia Joint Health Score|Systematic joint examinations of ankles, knees and elbows
7736|NCT04133857|Other|aerobic exercise|aerobic exercise HIIT : High intensity interval training SSMIT : Steady state moderate intensity training
7737|NCT04133844|Biological|Blood sample|Blood sample collection from a peripheral catheter at ECMO initiation (H0), then 2h, 6h, 12h, 24h and daily from day 2 to day 7 or at ECMO discontinuation
7738|NCT04133831|Other|Total Survival|"The overall or total survival rate at each center is displayed in the table of outcome statistics.~Total survival is computed from survival rates of both transplant and waitlist patients: [(number of patients surviving after transplant at end of year + number of patients alive on waitlist at end of year)] / [number of patients alive on waitlist at start of year]."
7739|NCT04133831|Other|Stratified Transplant Survival|"The transplant survival rate in the table of outcome statistics is stratified into two groups: (i) patients who received excellent donor organs and (ii) patients who received less than optimal donor organs.~Stratified transplant survival is computed from survival rates of transplant patients who received each quality category of organ.~excellent transplant survival = [number of patients surviving after transplant with excellent organ]/[number of patients for whom excellent organ was accepted for transplant] marginal transplant survival = [number of patients surviving after transplant with marginal organ]/[number of patients for whom marginal organ was accepted for transplant]"
7740|NCT04133818|Behavioral|Multidisciplinary education and exercise therapy program|"Multidisciplinary program: one and a half day of education and exercise therapy about low back pain :~Lectures and explanations about low back pain~Physical activity~Relaxation"
7741|NCT04133805|Dietary Supplement|viscous fiber|ex. barley b-glucan, oat b-glucan, konjac glucomannan, psyllium, guar gum, and pectin
7742|NCT04133792|Drug|Simvastatin 40mg|40 mg orally daily for 5 years.
7743|NCT04133792|Drug|Placebo oral tablet|40 mg orally daily for 5 years.
9782|NCT04116411|Drug|Valganciclovir Tablets|Valganciclovir treatment of glioblastoma
7744|NCT04133779|Procedure|neurological examination, Kurtzke EDSS, Barthel scale, ecocolor-Doppler|For the subjects diagnosed with MS (group A), who did not need to be in a period of clinical relapse of the disease (at least 30 days from the last clinical relapse), the duration and the form of the disease was indicated (CIS, RR, SP or PP). The Investigator has submitted these subjects to a neurological examination which included the standard neurological examination, the Kurtzke EDSS (Kurtzke Expanded Disability Status Scale) comprising the functional systems of Kurtzke and the Barthel scale. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
7745|NCT04133779|Procedure|neurological evaluation, ecocolor-Doppler|For the subjects affected by OND and ONDi, as in the groups C and D respectively, the Investigator has performed, beside the anamnesis and the physical examination, a specific neurological evaluation which included the compilation of the Barthel scale for the disability evaluation. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for performing the ecocolor-Doppler examination which was performed in blind.
7746|NCT04133779|Procedure|medical history, vital signs, ecocolor-Doppler|For the healthy subjects (HC) of the group B, the Investigator has solely performed the medical history and a check of the vital signs, reporting the demographic and clinical data of the subjects. After completing the selection phase following the previous examinations, the subjects were directed towards the qualified practitioner for the ecocolor-Doppler examination which was performed in blind.
7747|NCT04133766|Behavioral|Community Based Nutrition Package (CNBP)|The Community-Based Nutrition Package (CBNP) is a multi-level intervention that comprises: advocacy and training for government stakeholders and employees; selection and training of master trainers who then cascade the training at provincial level; and selection and training of community-level Nutrition Mobilizing Teams. The Nutrition Mobilizing Teams then organize a 2-day community mobilization session in the catchment areas of each health post to develop a community nutrition plan, which is then implemented by community health workers and two additional volunteers under the mentorship of the Nutrition Mobilizing Teams and with the support of the community members that participated in the community mobilization session.
7748|NCT04133753|Behavioral|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
7749|NCT04133740|Drug|Oxygen|Liberal versus conservative oxygen therapy.
7750|NCT04133727|Behavioral|Use of an ageing suit|The simulation suit consists of a pair glasses which simulates narrowing of visual field; a pair of gloves ; a vest ; elbow and knee wraps and sand bags worn on the wrists and ankles
7751|NCT04133727|Other|Polypharmacy workshop|Participants will conduct a full medication review for older adults within 1 hour and develop a medication list which can be used for counselling of older adults
7752|NCT04133714|Device|multi-channel tDCS|multi-channel transcranial direct current stimulation, tDCS
7753|NCT04133714|Device|single-channel tDCS|single-channel transcranial direct current stimulation
7754|NCT04133701|Behavioral|Time-Restricted Feeding|After baseline measurements have been completed, participants will enroll in a time-restricted feeding intervention. Participants will be asked to restrict the time in which they eat each day to 10 hours, fasting for the remaining 14 hours. Participants will also be asked to finish their last meal of the day at least 2 hours prior to bedtime.
7755|NCT04133688|Device|ASC|mobile app
7756|NCT04133675|Device|BTL Emsella|The Emsella Chair is a novel high-intensity focused electromagnetic (HIFEM) technology for the treatment of SUI, in addition to other pelvic floor related disorders. HIFEM technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes. The treatment paradigm consists of 3 different phases. The phases consist of an intense stimulation of the pelvic floor muscles (PFM), which consists of stimlulation and relaxation. The repetition of the phases and focused electromagnetic energy delivery leads to pelvic floor stimulation, adaptation, and remodelation.
7757|NCT04133675|Device|Sham BTL Emsella|Sham subjects will be positioned on the device in the same manner as the active treatment group. The sham treatment will be provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below therapeutic level (<10% power).
7758|NCT04133662|Behavioral|Sleep Manipulation Protocol|A structured sleep duration intervention will be taught to patients
7759|NCT04133649|Drug|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
7760|NCT04133636|Drug|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
7761|NCT04133623|Drug|Ketorolac|Administration of ketorolac 0.5 mg/kg up to 10 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ibuprofen.
7762|NCT04133623|Drug|Ibuprofen|Administration of ibuprofen 10 mg/kg up to 600 mg, one single dose at the enrollment. This group will receive also a placebo indistinguishable from the ketorolac.
7763|NCT04133610|Diagnostic Test|Self-sampling using digene HC2 DNA Collection Device|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
7764|NCT04133610|Diagnostic Test|Self-sampling using Evalyn Brush|All women will undergo a clinician-collected cervical swab and self-collected cervicovaginal swab.
7765|NCT04133597|Device|social media stimuli (Line app)|social media stimuli (Line app) with texting messages or calls
7766|NCT04133584|Biological|EV71 +SIV|Give 2 doses of EV71 +SIV, get 2 blood samples before the first dose and 28-43 days after the last dose.
7767|NCT04133584|Biological|EV71|Give 2 doses of EV71 , get 2 blood samples before the first dose and 28-43 days after the last
7768|NCT04133584|Biological|SIV|Give 2 doses of SIV , get 2 blood samples before the first dose and 28-43 days after the last
7769|NCT04133571|Drug|0.05% Lidocaine|0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
7770|NCT04133558|Other|tracheal aspirate during routine care|tracheal aspirate during routine care
7771|NCT04133532|Drug|Metoprolol|metoprolol 50 mg daily for three months
7772|NCT04133519|Device|Arm 1 - Active behavioral Treatment Arm|The active treatment consists of 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks (SaMD). Since subjects in both the active and sham treatment arms receive a behavioral treatment and since the sham treatment is inactive the subjects are blinded to active treatment.
7773|NCT04133519|Device|Arm 2 - Sham Treatment Arm with inactive behavioral treatment|The sham treatment consists of an identical treatment, scheduling and reminder platform as the Active Treatment Arm, but in place of the active treatment there is an inactive sham treatment administered in an identical schedule: 7 unique video/audio recordings administered via a mobile application every other week for 12 weeks.
7774|NCT04133506|Drug|Aspirin 300mg|see earlier (only half of healthy volunteers receive aspirin)
7775|NCT04133493|Device|Kerecis Omega3 Wound|"The intervention group will receive, in addition, a fish skin graft (KerecisTM Omega3 Wound) secured with Steristrips, sutures or staples, covered with a nonadherent dressing (Adaptic, Systagenix, Yorkshire, UK or equivalent), the product bolstered down to the wound bed with a foam dressing (HydraFoam, DermaRite) and hydrogel as needed to retain adequate moisture balance and padded with stretch gauze and self adherent wrap as needed.~The wound will be dressed by the site investigator 1 day a week."
7776|NCT04133493|Device|Fibracol|The Standard of Care Group will receive Fibracol covered with DSD. Change three times per week
7777|NCT04133480|Drug|GWP42003-P|oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
7778|NCT04133467|Other|scalp block|intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
7779|NCT04133454|Drug|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV and IT administration
7780|NCT04133428|Drug|Sacubitril-Valsartan|"Evaluation of the Sacubitril-Valsartan treatment effectiveness.~As there are three possible doses, during the first 30 days of treatment 3 evaluations will be carried out (every 10 days) for dose titration based on safety and tolerability as well as a blood test the 30rd day of treatment.~Afterwards the patient will be evaluated after 3 and 6 months of treatment with a blood test and in the final visit (6 months) an echocardiography will be carried out and the final clinical evaluation will be made."
7781|NCT04133415|Radiation|Lattice stereotactic body radiation therapy|-As long as radiotherapy fields do not overlap, treatment of up to 4 other tumor sites are allowed
7782|NCT04133415|Procedure|Peripheral blood|-Before treatment, immediately after radiotherapy completion, 14 days after radiotherapy, and 30 days after radiotherapy
7783|NCT04133389|Other|Growth mindset of personality educational intervention|This is a brief online educational intervention that teaches growth mindset of personality. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
7784|NCT04133389|Other|Growth mindset of athletic ability educational intervention|This is a brief online educational intervention that teaches growth mindset of athletic ability. The intervention includes pictures, text, videos, and questions administered through Qualtrics survey software.
7785|NCT04133376|Other|Electronic Hookah Inhalation (+ nicotine)|Participants will be instructed to inhale a typical 30-minute session of e-hookah containing nicotine
7786|NCT04133376|Other|Electronic Hookah Inhalation (- nicotine)|Participants will be instructed to inhale a typical 30-minute session of e-hookah not containing nicotine
7787|NCT04133376|Other|Sham Inhalation|Participants will be instructed to inhale a 30-minute sham session
7788|NCT04133363|Procedure|Ridge preservation using L-PRF/FDBA layered technique|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique
7789|NCT04133363|Procedure|Ridge preservation using L-PRF/FDBA|Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
7790|NCT04133363|Procedure|Ridge preservation using L-PRF|Atraumatic tooth extraction following by socket grafting using L-PRF
7791|NCT04133350|Behavioral|Active Patient Engagement|The APE intervention will be delivered through a patient-facing application and website called myAir, which provides patients with access to their own usage data, educational tips, and coaching.
7792|NCT04133337|Drug|Apatinib|Apatinib Mesylate Tablets
7793|NCT04133337|Drug|SHR-1210|Camrelizumab for Injection
7794|NCT04133324|Diagnostic Test|C-reactive protein|C-reactive protein at postoperative days four and two.
7795|NCT04133311|Drug|DE-130A|Latanoprost 50 microg/ml eye drops emulsion, eye drops emulsion in single-dose containers
7796|NCT04133311|Drug|Xalatan®|Latanoprost 50 microg/ml eye drops solution, eye drops in 2.5 ml dropper containers
7797|NCT04133298|Procedure|Tunneling with laser de-epithelized gingival graft|After the administration of local anesthesia, the dimension of the needed graft will be marked by a #15c blade and then diode laser de-epithelization will take place. The de-epithelized area will be then harvested using a # 15c blade. The donor site will be covered by cyanoacrylate tissue adhesive dressing .
7798|NCT04133298|Procedure|Tunnelingwith subepithelial connective tissue graf|After administration of local anesthesia. A single incision will be made to the bone in a horizontal direction 3mm apical to the gingival margin of the maxillary teeth. The length of the incision will be determined by the dimensions of the graft required. A partial-thickness dissection will be then made within the single incision aiming to harvest an average thickness of two mm subepithelial connective tissue. Then, the graft will be carefully elevated from the palate with the use of the blade. Primary closure will be obtained using 4-0 polyglycolic acid
7799|NCT04133259|Drug|Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody|Treatment of CHB patient with HLX10
7800|NCT04133259|Drug|Nucleoside/nucleotide analogues|Treatment NAs for chronic hepatitis B subject to achieve adequate HBV viral suppression
7801|NCT04133246|Behavioral|Focus group|Groups of 6 to 10 patients and spouses led by the psychologist about their parenthood lasting 2 hours
7802|NCT04133246|Behavioral|Individual interview|Interview led by the psychologist about the patient's parenthood
7994|NCT04131738|Drug|Baricitinib|Baricitinib may be taken without regard to food. It should be taken at the same time every day.
7803|NCT04133233|Drug|ILT101|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
7804|NCT04133233|Drug|Placebos|Treatment administration consists in a first course of five-day treatment (induction), followed by a single injection every week for 4 weeks (maintenance; from Week 3 to Week 6)
7805|NCT04133194|Drug|Mesalazine|1600 mg Asacol [mesalazine]
7806|NCT04133194|Drug|Mesalazine|800 mg Asacol [mesalazine]
7807|NCT04133181|Device|3D guide|Use of a 3D guide in endodontic surgery
7808|NCT04133181|Device|Mock guide|Use of a mock guide in endodontic surgery
7809|NCT04133168|Device|POLARx™ Cardiac Cryoablation System|"The POLARx Cardiac Cryoablation System is intended for ablation and electrical mapping of the pulmonary veins for pulmonary vein isolation (PVI) in the ablation treatment of patients with paroxysmal atrial fibrillation (PAF).The system consists of the following devices and components:~POLARx™ Cryoablation Catheter~POLARMAP™ Catheter~POLARSHEATH™~SMARTFREEZE™ Console~Diaphragm Movement Sensor (DMS)~Related Accessories"
7810|NCT04133155|Drug|nab paclitaxel plus gemcitabine|Nab-paclitaxel 125 mg/m2 weekly for 3 weeks, every 4 weeks Gemcitabine 1000 mg/m2 weekly for 3 weeks, every 4 weeks
7811|NCT04133142|Procedure|peripheral nerve block, inter fascial nerve block|regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
7812|NCT04133129|Behavioral|Low Volume-High Intensity Interval Training|On a treadmill, a 2 minute warm-up will be followed by 2 bouts of 4 minutes at an intensity between 85% and 95% of Maximum Heart Rate (HRmax) interspersed by a 2 minutes recovery bout at 70% of heart rate max, followed by a 3 minutes Cool Down
7813|NCT04133129|Behavioral|Moderate Intensity Continuous Training|On a treadmill,a 2-minute warm-up will be followed by 45 minutes at 65%-75% of Heart Rate max followed by 3 minutes cool down.
7814|NCT04133116|Drug|LY3471851|Administered SC
7815|NCT04133116|Drug|Placebo|Administered SC
7816|NCT04133103|Procedure|first ambulation at 4 hour after operation|Two groups were conducted for first ambulation at 4 or 24 hours aftër operation
7817|NCT04133090|Procedure|Autogenous block bone graft|Vertical and horizontal osteotomies were performed by means of a 6-mm diameter separation disc under copious irrigation with saline.The harvested bone graft was immediately placed in sterile saline solution to prevent dehydration. Sharp edges around the block graft were rounded under saline irrigation using a 4-mm round bur. The screw holes were properly made on both the recipient site and the block graft using a 1.3 mm drill. The graft was firmly fixed with 1.3 mm screws and a compatible driver. The periphery of the graft and the underlying gap between the screws and the recipient site, were covered with a mixture of particulate allograft and sterile saline solution to minimize resorption and to improve the adaption of the graft. All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
7818|NCT04133090|Procedure|i-PRF enriched allograft material+ screw tent pole technique|The i-PRF preparation was performed as follows: the blood sample collected in an 8 ml, non-coated plastic tube without anticoagulant was immediately centrifuged at a protocol of 2700 rpm for 2 min. After centrifugation, the liquid autologous fibrin material which comprised the 1 mL upper layer of the tube was collected, using a disposable syringe. The screw holes were made on the recipient site using a 1.3 mm drill. 7 mm long screws were fixed 2mm or 4mm higher than on the recipient site to provide the desired augmentation distance and stabilized by a compatible driver. i-PRF was mixed with allograft material in a sterile metal box. Polymerization was done in 3 to 5 minutes, then this material was applied to the underlying gap between the screws and the recipient site.All augmentation sites were covered by L-PRF membrane and flap closure was effected with 4/0 silk suture.
7819|NCT04133077|Biological|blood samples collection|Serology and genetic analysis will be performed in patients blood samples
7820|NCT04133064|Device|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
7821|NCT04133051|Drug|Quadratus Lumborum Block Using Bupivacaine 0.2%|"Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block"
7822|NCT04133051|Drug|Epidural Analgesia Using Bupivacaine 0.25%|"With Patients placed in sitting position, puncture site will be identified at (T8-9, T9-10, or T10-11) intervertebral spaces. Using aseptic conditions, an 18G Tuohy epidural needle will be used to insert epidural catheter as appropriate.~Induction of epidural analgesia with 10-15 ml bupivacaine 0.25% preoperatively with top up doses of 5-7 ml bupivacaine 0.25% or equivalent administered judiciously till we achieve analgesic level of T4 to L1. The calculated top up doses will be administered each hour using bupivacaine 0.25% or by using a continuous infusion syringe pump for equivalent doses"
7823|NCT04133038|Other|Questionnaire|Parent(s) answering questionnaires about his child's phobic and selective eating behaviour.
7824|NCT04133025|Other|Vestibular Rehabilitation|Vestibular Exercises and Software in vestibular rehabilitation
7825|NCT04133012|Other|Samplings|"blood samples~rectal biopsies~nodes biopsies~cutaneous fat tissues biopsies~semen sample"
7826|NCT04132999|Behavioral|Family-informed intervention|Multiple face-to-face visits, telephone calls and-person visits with the PAP psychologist and team
7827|NCT04132999|Behavioral|Standard Clinical Care|Support which is given as part of the standard clinical care for patients who are currently prescribed PAP.
7828|NCT04132973|Behavioral|Compassion for Skin Conditions|Online guided self-help intervention derived from Compassion Focused Therapy (Gilbert, 2010).
7829|NCT04132960|Drug|DS-8201a|Anti-HER2-antibody drug conjugate (ADC)
7830|NCT04132908|Dietary Supplement|Dietary Supplement: nutraceutical|Subjects will consume two capsules at breakfast and dinner for ten weeks.
7832|NCT04132895|Other|observational only, no interventions are prescribed in protocol.|"Treatment will be given as per usual standard of care.~No treatments are specified by this protocol."
7833|NCT04132882|Drug|Sodium Thiosulfate (STS)|
7834|NCT04132869|Behavioral|Sports Readiness Intervention|Sixth graders will participate in a 6 month after-school program in which each daily session will last 90 minutes, 60 minutes of which will be moderate to vigorous physical activity. Two sports tracks will be offered during each 8-week season, and children will choose which they prefer. Coaches will be trained through a one day capacity building session and will receive online training throughout the program. Coaches will integrate sports readiness/physical activity programming, nutrition and healthy eating, and social emotional learning into the program with a focus on habit formation. A text-based platform will be utilized to encourage habits learned in the active portion of the program during June and July as well as on weekends during the intervention. Parents will be sent fliers weekly summarizing concepts addressed, and will be invited to cooking classes to watch students compete.
7835|NCT04132856|Other|Psychosocial Navigator|Services of psychosocial navigator
7836|NCT04132856|Other|Communication of Summary Profile|Both patient/caregiver dyad and HCPs will receive a summary of the PAT results and levels of depression and anxiety.
7837|NCT04132843|Drug|Gadobenate Dimeglumine|Given IV
7838|NCT04132843|Drug|Gadobutrol|Given IV
7839|NCT04132843|Procedure|Magnetic Resonance Imaging|Undergo MRI
7840|NCT04132817|Drug|nivolumab|specified dose on specified days
7841|NCT04132817|Drug|ipilimumab|specified dose on specified days
7842|NCT04132817|Drug|nab-paclitaxel|specified dose on specified days
7843|NCT04132804|Behavioral|Tai Chi|Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
7844|NCT04132791|Other|placebo after awakening + aspirin before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
7845|NCT04132791|Other|aspirin after awakening + placebo before bedtime|determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.
7846|NCT04132778|Device|AsthmaTuner|Conventional treatment was defined as non-digital self-management using paper individual treatment plans, which contained treatment adjustments of prescribed medications according to symptoms of controlled, partly controlled or uncontrolled asthma, along with instructions according to national guidelines.
7859|NCT04132752|Other|Motivation|Families were called via phone weekly and all questions were answered. Parents were motivated through phone.
7890|NCT04132544|Other|standardized gerontological evaluation (EGS)|Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by an IDEG (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS (Rubenstein LZ, 1984) and the assessment of risk factors for falls (HAS, INPES).
8028|NCT04131439|Diagnostic Test|Computed Tomography and Magnetic resonance imaging|Preoperative imaging for patients undergoing cochlear implants
7860|NCT04132739|Behavioral|Diet|The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.
7861|NCT04132739|Behavioral|Exercise|The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.
7862|NCT04132739|Behavioral|Diet and exercise|A combination of the diet and exercise interventions following the same procedures previously described.
7863|NCT04132726|Other|Massage therapy|Massage therapy performed by a physiotherapist
7864|NCT04132726|Other|non-effective treatment|non-effective treatment
7865|NCT04132713|Drug|Capecitabine 150Mg Oral Tablet|Advanced breast cancer patients with first-line medication
7866|NCT04132700|Device|Q-NRG Metobolic Cart Device|ICU pateints will be measured using the Q-NRG device for up to 30 mins. These measurements will take place every other day while the patients are in the ICU. Then they will occur a minimum of 3 times a week until discharge.
7867|NCT04132687|Procedure|autologous blood patch therapy|use autologous blood as blood patch therapy in persistent air leak
7868|NCT04132674|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|Taking one oral tablet of B/F/TAF once-daily for 72 weeks
7869|NCT04132661|Drug|Bisacodyl 5 milligram|one single dose
7870|NCT04132661|Drug|Placebo oral tablet|one single dose
7871|NCT04132648|Drug|Curcumin|Oral supplement one time at 2,000 mg
7872|NCT04132648|Other|Placebo|Oral supplement one time at 2,000 mg
7873|NCT04132635|Device|artificial dermis|artificial dermis will be used after fully debridement of the wound
7874|NCT04132635|Other|growth factor|growth factor
7875|NCT04132622|Drug|Levothyroxine Sodium|Levothyroxine Sodium Tablets (50 ug, calculated by Levothyroxine Sodium ), produced by Merck KGaA, Darmstadt.
7876|NCT04132622|Drug|Traditional therapy|including steroids, vitamin C, hemodialysis and blood perfusion.
7877|NCT04132609|Behavioral|Cognitive bias modification|: In CBM, the task presentation and timing is the same as attentional bias, except the probe always replaces the neutral word. It ensures that: 1) the duration of CBM and control training should not differ; 2) CBM and control participants receive equal practice on the motoric aspects of the task; and 3) CBM and control participants are exposed to the same word cues. Based on previous data, duration of CBM and control trainings will be about 10 minutes.
7878|NCT04132609|Behavioral|Standard attentional bias|"the standard attentional bias task, a drug or pain-related word is presented next to a neutral word for 500ms. Subsequently, a probe (i.e., a q or p) replaces the drug/pain word or the neutral word at an equal rate. The participant's task is to indicate the location of the probe as quickly as possible by pressing q or p. Attentional bias is calculated from the difference in reaction times (i.e., neutral cue minus drug/pain cue) to indicate the location of the probe, with higher values indicating greater attentional bias. For all tasks, opioid and pain words will be presented in separate blocks in counterbalanced order. Neutral words paired with opioid or pain words will be matched for length and frequency of use in the English language."
7879|NCT04132596|Device|Transcutaneous spinal cord stimulation|Electrical stimulation of the spinal cord via transcutaneous hydrogel electrodes
7880|NCT04132596|Other|Activity Based Therapy|Physical therapy
7881|NCT04132583|Drug|Deflox®|Participants will receive a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting condition.
7882|NCT04132583|Drug|Cataflam DD®|Participants will receive a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting condition.
7883|NCT04132570|Drug|Budesonide|Participants will self-administer 2 nasal sprays of Budesonide (64 mcg/spray) once daily up to 10 +\- 3 Days.
7884|NCT04132570|Other|Placebo|Participants will self-administer 2 nasal sprays of matching placebo once daily up to 10 +\- 3 Days.
7885|NCT04132557|Drug|Methylphenidate|Methylphenidate is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three United States (US) health care databases and one US electronic health record database.
7886|NCT04132557|Drug|Lisdexamfetamine|Lisdexamfetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from three US health care databases and one US electronic health record database.
7887|NCT04132557|Drug|Atomoxetine|Atomoxetine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
7888|NCT04132557|Drug|Amphetamine|Amphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
7889|NCT04132557|Drug|Dextroamphetamine|Dextroamphetamine is common ADHD medications in the United States. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from on three US health care databases and one US electronic health record database.
7923|NCT04132336|Drug|Naproxen sodium (Aleve)|Tablet, oral, single dose
7891|NCT04132544|Other|Proposal for a personalized intervention plan (PIP)|"A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the IDEG in the week following the CPR during the V1 visit to the patient's home."
7892|NCT04132544|Other|Follow-up|"Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the IDEG reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the IDEG at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations."
7893|NCT04132544|Other|Usual care|"The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health [series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the IDEG. The documents are sent by mail to the patient's home address."
7894|NCT04132531|Procedure|Bariatric (weight loss) surgery|Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
7896|NCT04132505|Drug|Binimetinib|Given PO
7897|NCT04132505|Drug|Hydroxychloroquine|Given PO
7898|NCT04132479|Drug|Clarithromycin 500mg|1000mg taken orally every 12 hours for 5 days
7899|NCT04132479|Drug|Amoxicillin 500mg|1000mg taken orally every 12 hours for 5 days
7900|NCT04132479|Drug|Tinidazole 500mg|500mg taken orally every 12 hours for 5 days
7901|NCT04132479|Drug|Rabeprazole 20mg|20mg taken orally every 12 hours for 5 days
7902|NCT04132479|Drug|Clarithromycin 500mg|1000mg taken orally every 12 hours for 14 days
7903|NCT04132479|Drug|Amoxicillin 500mg|1000mg taken orally every 12 hours for 14 days
7904|NCT04132479|Drug|Tinidazole 500mg|500mg taken orally every 12 hours for 14 days
7905|NCT04132479|Drug|Rabeprazole 20mg|20mg taken orally every 12 hours for 14 days
7906|NCT04132466|Device|ACE-CONVERT Study Test System|defibrillation
7907|NCT04132453|Device|Arterial catheterization kit|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
7908|NCT04132453|Device|GE Datex-Ohmeda Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
7909|NCT04132453|Device|NIBP Cuff (GE Healthcare)|A blood pressure cuff is used to measure blood pressure. The cuff has an inflatable rubber bladder that is typically fastened around the arm. A pressure meter indicates the cuff's pressure.
7910|NCT04132440|Other|Interview|Complete interview
7911|NCT04132440|Other|Questionnaire Administration|Complete questionnaire
7912|NCT04132427|Combination Product|vancomycin, magnesium citrate, microbiota|10 days of oral vancomycin, then 1 day of oral magnesium citrate, , then 4 days of high-dose oral microbiota, followed by 12 weeks of low-dose oral microbiota
7913|NCT04132427|Combination Product|placebo vancomycin, real magnsium citrate, placebo microbiota|10 days of oral placebo vancomycin, then 1 day of oral real magnesium citrate, , then 4 days of high-dose oral placebo microbiota, followed by 12 weeks of low-dose oral placebo microbiota
7914|NCT04132414|Diagnostic Test|NIRS open|Treatment according to protocol in phases of cerebral hypoxia.
7915|NCT04132401|Diagnostic Test|algorithm|The diagnostic capacity of the algorithm will be compared with that of the family medicine physicians and with retina specialists. The reference will be a blinded double reading conducted by the retina specialists
7916|NCT04132388|Other|Electronic Reporting|"The electronic reporting intervention consists of reporting the experience with the treatment (whether the treatment was taken, the efficacy of the treatment, and any issues that have come up) at weekly intervals for 6 weeks, then every 4 weeks thereafter.~Subjects will return for evaluation at 12 & 26 weeks (or end of study). At each visit the subject will be scored for disease severity and adverse events. The assessor of these measures will be blinded to treatment group assignment. At the baseline and at the end of therapy visit (26 weeks), all subjects will complete a HS self-assessment questionnaire, treatment satisfaction questionnaire and physician trust survey. Pregnancy tests will be completed on females of childbearing potential at the baseline visit."
7917|NCT04132388|Drug|Adalimumab|Subjects will be instructed to take Humira according to the labelled dosing regimen. Treatment will be for 26 weeks
7918|NCT04132375|Drug|INM004|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
7919|NCT04132375|Drug|Placebo|"The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses."
7920|NCT04132362|Behavioral|Personalised music listening|People will be sequentially recruited to discover their favourite music playlist, monitor their emotional responses to specific songs and explore the impact of listening to the music, on their behavioural and psychological symptoms. This will be done through a one hour music listening session, to discover the top 10-20 songs they respond to. It will then be followed by multiple shorter music listening sessions, initiated by the dementia resident themselves or their carer, where they listen to their favourite songs during their day, before difficult moments of care or during visits with their families.
7921|NCT04132349|Drug|Ulipristal Acetate 5 mg|Ulipristal acetate (from Cenexi manufacturer, France) at daily dose of 5mg in 3 consecutive months course
7922|NCT04132336|Drug|Naproxen sodium/Caffeine (BAY2880376)|Tablet, oral, single dose
7926|NCT04132323|Procedure|Sclerotherapy|Examination, photographing, inclusion in the study, signing of informed consent, randomization, diameter measurement, sclerotherapy according to the randomization group
7927|NCT04132310|Other|N/A This is an observational study.|This is an observational study.
7928|NCT04132297|Behavioral|Asthma Academy|The Asthma Academy is a 3-4 hour in-person training that includes providing information about asthma, asthma medications, communicating with healthcare providers and navigating healthcare resources.
7929|NCT04132297|Behavioral|Telehealth Visit|The telehealth Visit will be conduct by a trained Doctor of Nurse Practice (DNP) student via a scheduled meeting through the free MedWeb application on the participant's smart phone. The visit will last about one hour wherein participant will be asked about their asthma knowledge and will be given information about asthma.
7930|NCT04132284|Behavioral|DBT-Based Parenting Intervention|The intervention will consist of 8-10 individual parent sessions, to be completed within one week after the teen completes the IOP program. Sessions will be 1 hour in length and will be offered weekly. Therapists may see parents more than once a week if needed, as long as the total number of sessions does not exceed 10. Sessions will follow the standard agenda used for DBT skills training: 1) mindfulness practice, 2) homework review, 3) teaching of a new skill; 4) practice of the new skill; and 5) assignment of new homework (Linehan, 1993). The intervention will utilize the Middle Path module of the DBT Skills Manual for Adolescents (Rathus & Miller, 2015), which was created by the developers of DBT for adolescents and includes both instructions for therapists and handouts for clients.
7931|NCT04132284|Behavioral|Treatment as Usual|No parenting intervention provided beyond standard practices in DBT IOP program.
7932|NCT04132271|Other|Personalized diet|Modified texture and volumen diet according to the OD specifications
7933|NCT04132271|Other|Control|Nutritional Recommendations according to the OD specifications
7934|NCT04132258|Other|survey|(presence of certain antecedents, weight, height, current or past existence of inflammatory rhinitis) and a second by the specialist doctor (pathology at the origin of the start of biotherapy, year of beginning of treatment, previous biotherapies over the last 3 years).
7935|NCT04132245|Behavioral|behavioral intervention|Families were randomized to a 14-week family based obesity prevention intervention or a 14-week general health intervention
7936|NCT04132245|Behavioral|Obesity prevention intervention trial|Families were randomized to a 14-week obesity prevention intervention or a 14-week general health intervention
7937|NCT04132232|Diagnostic Test|maternal carbon monoxide level|Will use Smokerlyzer device which measures carbon monoxide levels in the maternal blood and the fetal carboxyhemoglobin levels calculated from maternal carbon monoxide blood level.
7938|NCT04132219|Behavioral|eHealth Intervention|Every week, each dyad member will receive a tailored text message that provides a new fun fact or that encourages them to log-on to the website to access findings of new research and how the results might apply to them. They will be directed to specific pages in the Web-based program and asked to select strategies from a list that they will practice during the upcoming week. Graphic displays of their progress will be provided along with SCT-based feedback. They will be directed to the website to record their behavioral goals for the upcoming week. Tips also will be provided for effective communication to enhance couple efficacy. All usage will be tracked to assess adherence.
7939|NCT04132206|Other|stool sampling|Participants will provide two stool samples: one collected the day of inclusion and a second, six months later
7940|NCT04132180|Other|Early Mobilization|Range of motion exercises of the upper extremity will be performed under the guidance of the physical therapy team starting on post-operative day 1.
7941|NCT04132180|Other|Late Mobilization|The patient's grafted upper extremity will be immobilized using an elbow flexion blocking splint until post-operative day 5.
7942|NCT04132167|Procedure|perturbation training|exercises for body stability in different positions (bridge, sitting, quadrupedal, half- kneeling, kneeling, standing, monopodalic) performed with visual biofeedback; transfers training performed in front of a mirror; ambulation training with courses drawn on the ground in a straight line and with more complex tracks with visual controlin particular using the protocols seated balance/strength training, standing bal- ance/weight-bearing training, mobility training and closed-chain training;
7943|NCT04132154|Procedure|Convective Forced-Air Active Warming|Underbody Blanket Model 585 of the 3M BairHugger Series
7944|NCT04132141|Other|Virtual Reality Headset with curated content|clinicians will wear VR immersive headset for up to 15 minutes during their break
7945|NCT04132128|Other|carbohydrate counting|taught how to count carbohydrates in their diet with their personal tool
7946|NCT04132115|Drug|Piperacillin/tazobactam|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
7947|NCT04132115|Drug|Meropenem|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
7948|NCT04132115|Drug|Daptomycin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
7949|NCT04132115|Drug|Ceftobiprole|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
7950|NCT04132115|Drug|Linezolid|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
7951|NCT04132115|Drug|Vancomycin|Therapeutic drug monitoring(TDM) of this antibiotic plasma concentration
7952|NCT04132115|Drug|Fluconazol|Therapeutic drug monitoring (TDM) of this antifungal plasma concentration
7953|NCT04132115|Drug|Acyclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
7954|NCT04132115|Drug|Gentamicins|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
7955|NCT04132115|Drug|Amikacin|Therapeutic drug monitoring (TDM) of this antibiotic plasma concentration
7956|NCT04132115|Drug|Ganciclovir|Therapeutic drug monitoring (TDM) of this antiviral plasma concentration
7957|NCT04132102|Drug|Afatinib|Afatinib is a member of the second generation TKIs, which binds irreversibly to the erbB family of receptors. Afatinib will be administrated orally with the starting dose of 40 mg tablets, once per day. If patients can't tolerate drug related AEs with 40mg, patients can receive 30mg once per day after AEs recovered to Grade 0-1.
8029|NCT04131426|Dietary Supplement|Remune|Remune is intended for the dietary management of disease related malnutrition especially in patients with precachexia or cachexia due to cancer or COPD
8030|NCT04131426|Other|EXCAP©®|EXCAP©® is a home-based low-to-moderate intensity program that employs a tailored walking prescription and total body resistance exercises
7958|NCT04132089|Behavioral|capABILITY|All participants utilized the designed capABILITy application. The application consisted of education material and persuasive messaging. There were two types of messaging components named facilitators and sparks. This created three groups consisting of: control, facilitators and sparks. Participants spent 1 month in each group (total duration of the study was three months).
7959|NCT04132063|Drug|Generic levetiracetam|Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date
7960|NCT04132050|Drug|R788|Oral administration
7961|NCT04132050|Drug|Placebo|Oral administration
7962|NCT04132037|Other|data record|At each protocol's visit, clinical and urinary data will be recorded and the answers of the questionnaires will be also reported
7963|NCT04132024|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I has a specific protocol with behavioral targets that differ significantly from standard CBT. This approach focuses on implementing sleep restriction and stimulus control interventions which are fully deployed during the first session. 5 CBT-I sessions will be delivered over the course of 8 weeks. Key recommendations include: 1) reduce time in bed; 2) get up at the same time every day; 3) do not go to bed unless sleepy; 4) do not stay in bed awake for more than 15 minutes; and 5) avoid napping. Participants are also taught relaxation strategies and cognitive therapy addresses arousal and catastrophizing.
7964|NCT04132011|Drug|Extended Release Opioid Formulation, Shortened Intervals|Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours
7965|NCT04132011|Drug|Extended Release Opioid Formulation, Standard intervals|Extended release opioid, individualized total daily dose, dosing interval is every 12 hours
7966|NCT04132011|Drug|Placebo oral tablet|Lactose pill manufactured to mimic extended release opioid formulation
7967|NCT04131985|Procedure|Erector Spina Block|After the C7 spinous protrusion is prepared as sterile as T10, the erector spina muscle is seen at the T7 level on the same side as the hernia with the convex probe and block is applied with 0.25% bupivacaine (15 cc) and 2% lidocaine (5 cc).
7968|NCT04131972|Device|REGENERA|REGENERA breast implant
7969|NCT04131959|Device|CytoSorb 300 mL device|Intra-operative CytoSorb hemoadsorption of ticagrelor during cardiopulmonary bypass
7970|NCT04131946|Other|Community-Based (Intervention Arm)|Community dispensed FIT
7971|NCT04131920|Device|handheld ultrasound: Philips Lumify integrated tele-ultrasound powered by Reacts collaborative platform|Patients receive training by the physical therapist to operate a handheld ultrasound (HHUS) including proper probe placement. Subjects will be tested on their knowledge at the HTC to demonstrate proficiency, and will then repeat the testing at home via tele-ultrasound.
7972|NCT04131907|Device|Optilume BPH Catheter System|The Optilume™ BPH, Prostatic Dilation DCB Catheter is a dilation catheter used to exert radial force to dilate the prostatic urethra resulting in a commissurotomy. The distal end of the catheter has a semi-compliant inflatable double lobe balloon that is coated with a proprietary coating containing the active pharmaceutical paclitaxel.
7973|NCT04131907|Device|Optilume Sham Device|21 Fr sheathed Optilume™ BPH Prostatic Pre-dilation Catheter (modified to prevent inflation)
7974|NCT04131894|Biological|autogenous dentin graft|
7975|NCT04131894|Biological|platelet rich fibrin (PRF)|
7976|NCT04131868|Behavioral|Typical sleep opportunity|Typical sleep opportunity with consistent sleep timing for 1 week
7977|NCT04131868|Behavioral|Extended sleep opportunity|Extended sleep opportunity by 90 min per night with consistent sleep timing for 1 week
7978|NCT04131855|Other|Pumice prophylaxis|Pumicing the teeth is the recommended prophylaxis to be used prior to the application of the self etch primer by the manufacturer - 3M Unitek Transbond Plus Self Etch Primer which will be used in the experiment.
7979|NCT04131855|Other|No pumice prophylaxis|Pumice prophylaxis will not be used as per manufacturers instructions.
7980|NCT04131842|Other|External focus of attention visual feedback|Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
7981|NCT04131842|Other|External focus of attention auditory feedback|Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
7982|NCT04131842|Other|Internal focus of attention video feedback|Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
7983|NCT04131842|Other|No feedback|Patients will receive no feedback during the impairment-based rehabilitation program.
7984|NCT04131829|Drug|Fluoxetine - immediate treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
7985|NCT04131829|Drug|Fluoxetine - delayed treatment|Following the Baseline assessment, OCD subjects will be randomized to receive either immediate fluoxetine monotherapy or delayed fluoxetine, after a 6-week placebo lead-in.
7986|NCT04131816|Behavioral|HeartHome|The HeartHome program is an expanded home-based cardiac rehabilitation program that combines nurse home visits with telephone and electronic supports for participants that allows them to engage in cardiac rehabilitation activities at home.
7987|NCT04131803|Drug|Bifico combined with chemotherapy plus targeted therapy|Bifico combined with chemotherapy plus targeted therapy
7988|NCT04131803|Drug|chemotherapy plus targeted therapy|chemotherapy plus targeted therapy
7989|NCT04131790|Behavioral|Tele-Behavioral Activation|Five 1-hour sessions of BA delivered by a trained interventionist via video-conferencing
7990|NCT04131790|Behavioral|Tele-Friendly Visiting|Five 1-hour FV sessions delivered by a trained interventionist via video-conferencing
7991|NCT04131777|Device|Radiofrequency (RF) catheter|A catheter introduced into the lung lesion via a bronchoscope, used to deliver radiofrequency (RF) energy for the purpose of ablation
7992|NCT04131764|Diagnostic Test|Reflex (Brightlamp Inc., Purdue University)|The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
7993|NCT04131751|Diagnostic Test|Next generation sequencing|we will investigate the sensitivity and specificity of next generation sequencing as a diagnostic tool in ascites infections.
7995|NCT04131725|Device|Cardiac Performance System|Device: Cardiac Performance System Participants will be asked to wear the Cardiac Performance System, a non-invasive sensor device on their upper abdomen. The Cardiac Performance System monitoring device will continuously monitor cardiac function. The device will be worn at the time when Pulmonary Artery Catheter procedures are conducted.
7996|NCT04131725|Device|Pulmonary Artery Catheter|The subject will receive standard Pulmonary Artery Catheter assessment of cardiac function metrics.
7997|NCT04131725|Device|Echocardiography|The subject will receive standard Echocardiography assessment of cardiac function metrics.
7998|NCT04131712|Other|Massage|A custom-made cyclic compressive loading (CCL) device will be used to apply a mechanical load to the left thigh of the participants. Massage application using a 35 Newton load will be applied for 15 minutes every other day over the course of 7 days for a total of four massages.
7999|NCT04131699|Device|Cardiotronic ICON continuous non-invasive cardiac output monitor.|cardiac index, cardiac output & stroke volume measured and recorded with every change in intrathoracic pressure.
8000|NCT04131660|Device|AVAPS-AE mode during NIV|NIV will be setup in AVAPS-AE mode, with a Trilogy ventilation device (Respironics, Murrysville, PA). The range of positive expiratory pressure will be set between 4 and 14 cmH2O. The range of inspiratory pressure support will be set between 14 and 24 cmH2. The target tidal volume will be set to achieve 8 to 10 mL/kg of ideal body weight (Size (m) * Size (m) * 23).
8001|NCT04131660|Device|S/T mode during NIV|"NIV will be setup in ST mode, with a Trilogy ventilation device (Respironics, Murrysville, PA).~The physician will decide the level of positive expiratory pressure and of pressure support."
8002|NCT04131647|Other|Weight Maintenance|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, and resistance band exercise
8003|NCT04131647|Other|Weight Maintenance + Intermittent Fasting|Following a 12-week weight loss and exercise program, subjects will participate in a weight maintenance program of Heart Healthy nutrition, walking, resistance band exercise and intermittent fasting (2 small meals per day) one day per week for 24 weeks.
8004|NCT04131634|Radiation|Stereotactic Ablative Radiation|A stereotactic relocalization system that relies upon stereoscopic radiographs, implanted fiducials, or near real-time CT based verification will be used.Investigators will have the discretion to choose from biologically equivalent dose levels using 1, 3 or 5 fractions. All active lesions need to be addressed by local therapy
8005|NCT04131621|Biological|Nivolumab/Ipilimumab|Immune checkpoint inhibitor combination
8006|NCT04131608|Diagnostic Test|CBC ,Serum ferritin ,HBA1C|Diabetic patients will be applied to CBC, HBA1C and serum ferritin
8010|NCT04131582|Combination Product|Linagliptin + metformin and Empagliflozin + metformin|Linagliptin-Metformin 2.5/850mg once daily, Empagliflozin-Metformin 12.5/850mg one daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
8011|NCT04131582|Drug|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
8012|NCT04131569|Diagnostic Test|ESBL-E fecal carriage screening according to routine care|ESBL-E fecal carriage screening according to routine care
8014|NCT04131543|Drug|Cabozantinib 20 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
8015|NCT04131543|Drug|Cabozantinib 40 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions (40mg 20mg) and delays to manage toxicity.
8016|NCT04131543|Drug|Cabozantinib 60 MG|Cabozantinib will be administered orally at a (starting) dose of 60 mg once daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. In all subjects, dose reductions and delays to manage toxicity. Cabozantinib should be taken in fasting condition with no food for at least 2 hours before and 1 hour after taking the tablets. A high fat meal significantly increased the median tmax to 6 hours from 4 hours (fasted). The treatment will be continued until disease progression, intolerable toxicity, patient refusal or Investigator's decision or any criterion for withdrawal from the trial or trial drug is fulfilled.
8017|NCT04131530|Diagnostic Test|The diagnosis of Artificial Intelligence and endoscopist|When the colon mucosa is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
8018|NCT04131517|Drug|Padsevonil|Study Medication: Padsevonil Dosage formulation: Oral tablets
8019|NCT04131517|Drug|Microgynon 30®|Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
8020|NCT04131504|Drug|Infliximab|No standard dosing regimen will be used and the dose will be determined by the treating physician
8021|NCT04131504|Drug|Adalimumab|No standard dosing regimen will be used and the dose will be determined by the treating physician
8022|NCT04131491|Procedure|Lumbar puncture|Lumbar puncture for AD biomarker fluid analysis
8023|NCT04131478|Genetic|Pharmacogenetic testing|Pharmacogenetic testing for TNF alfa
8024|NCT04131465|Diagnostic Test|Home HIV self-testing|Offer of 3 OraQuick HIV self-test kits
8025|NCT04131465|Diagnostic Test|Home HIV rapid testing|Offer of HIV rapid testing with Alere Determine HIV-1/2
8026|NCT04131465|Diagnostic Test|Home HIV self-testing and rapid testing|Offer of 3 OraQuick HIV self-test kits and HIV rapid testing with Alere Determine HIV-1/2
8027|NCT04131452|Other|Filling out the forms including IDAS-II, BAI, SF-36 and FSFI|Participants will fill out certain validated forms including the expanded version of the inventory of depression and anxiety symptoms (IDAS-II), Beck Anxiety inventory (BAI), Short Form Survey (SF-36) and Female Sexual Function Index (FSFI).
8031|NCT04131413|Drug|pNGVL4aCRTE6E7L2|The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
8032|NCT04131400|Diagnostic Test|Visual Acuity Testing and Retinal Imaging|All clinical and para- clinical tests including visual acuity assessment, perimetry, optical coherence tomography (OCT), enhanced depth- OCT, OCT angiography, color fundus, autofluorescence and infrared fundus photography will be performed
8033|NCT04131387|Device|LIPUS-1|After installing the disposable treatment head coat, the pelvic floor muscles, ligaments, etc. were treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Treated twice a week for 6 weeks.
8034|NCT04131387|Device|LIPUS-2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
8035|NCT04131374|Behavioral|Reminiscence Therapy|Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
8036|NCT04131361|Other|Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
8037|NCT04131348|Procedure|botulinum toxin type A|From to December 2016 to December 2018, a single-center prospective comparative study was performed in 80 patients with LMIH at our tertiary center.
8038|NCT04131335|Drug|AEONTM Repair|Lubricating eye drops
8039|NCT04131335|Other|Routine post-operative eye drops used.|Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
8040|NCT04131322|Drug|Amgevita 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
8041|NCT04131322|Drug|HUMIRA 40Mg Solution for Injection|Adalimumab 40Mg Solution for Injection
8042|NCT04131309|Drug|Daratumumab|Daratumumab will be administered as an intravenous (IV) infusion at a dose of 16 mg/kg weekly or as a subcutaneous injection 1800mg weekly for Cycles 1-2,every 2 weeks for Cycles 3-6 and every 4 weeks thereafter, until progression of disease (according to MOD-PFS criteria), unacceptable toxicity or subsequent therapy, for a maximum of 2 years in total.
8043|NCT04131309|Drug|Bortezomib Injection|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab, bortezomib at a dose of 1.3 mg/m2 weekly for a maximum of 6 cycles as a subcutaneous injection
8044|NCT04131309|Drug|Dexamethasone oral tablet|Subjects who do not achieve either a hematologic VGPR or better, OR a hematologic PR with a major organ response by Cycle 4 Day 1 may receive at Investigator's discretion, in addition to daratumumab low dose dexamethasone at a maximum total dose of 20 mg weekly.
8045|NCT04131296|Diagnostic Test|influenza screening|positive influenza screening
8046|NCT04131283|Drug|Epinephrine|Vasoconstrictor solution is applied on the surface of the attached gingiva and on the gingival sulcus.
8047|NCT04131270|Behavioral|Planning + Education|"Planning: Participants will fill in the planning forms that efer to replacing sedentary behavior with physical activity.~The following behavior change techniques are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all behavior change techniques would include references to planning."
8048|NCT04131270|Behavioral|Education|The education would include extended sedentary behavior and physical activity education, delivered face-to-face by the experimenters. The education includes: (1) the behavioral guidelines, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent, and (3) the education about ways to break sedentary behavior with active breaks.
8049|NCT04131257|Behavioral|Nurse-led Continuum of Care|This will be a nurse-led community level prevention program for individuals with diabetes and pre-diabetes, where participants in intervention group will receive nurse-led continuum of care while control group will receive usual diabetic care.
8050|NCT04131244|Procedure|In vitro activation of primordial follicles by PTEN inhibitor and AKT stimulator|After laparoscopic unilateral oophorectomy, ovarian medulla would be dissected from cortex. After fragmentation of 2 cm square ovarian cortex into smaller pieces they would be incubated PTEN inhibitor and AKT stimulator for 48 hours. Finally we will auto graft these fragments beneath to the fallopian tube peritoneal surface.
8051|NCT04131231|Drug|microparticles packaging methotrexate (MPs-MTX)|50ml, intrapleural infusion, day5,6,7,8
8052|NCT04131231|Drug|recombinant human interleukin-2(rhIL-2)|50ml, intrapleural infusion, day5,8,11
8053|NCT04131218|Drug|Sugammadex|Each patient received a single dose administration of sugammadex 2mg/kg accroding to the ideal body weight(IBW) at reappearance of the second twitch of the train-of-four(TOF).
8054|NCT04131205|Diagnostic Test|Magnetic Resonance Imaging|We will assess the role of magnetic resonance (MR) in mHE diagnosis with emphasis on multimodal imaging technique
8055|NCT04131192|Drug|Z650|250 or 300 or 200 mg/d, starting on the 2nd day, once a day, continuous administration, or about half an hour after a meal
8056|NCT04131192|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, of a 21-day cycle ，for 4-6 cycles
8057|NCT04131179|Behavioral|Youth Culturally Adapted Manual Assisted Psychological Therapy (Y-CMAP)|"Y-CMAP is a manual assisted brief psychological intervention based on the principles of Cognitive Behaviour Therapy (CBT), including 8-10 sessions delivered over three months.~This intervention includes evaluation of the self-harm attempt, psycho education, crisis skills, problem solving and simple cognitive techniques to manage emotions, negative thinking,relapse prevention strategies and training on anger management and assertiveness."
9783|NCT04116411|Drug|Temozolomide 120 mg|Chemotherapy
8058|NCT04131166|Behavioral|Mediterranean diet|A Mediterranean-type diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
8059|NCT04131166|Behavioral|Low-carbohydrate, ketogenic diet|A low-carbohydrate, ketogenic diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
8060|NCT04131166|Behavioral|Low-fat diet|A low-fat diet will be consumed for 4 to 8 weeks in the weight stable state with all meals provided.
8061|NCT04131166|Other|Annual follow-up testing for 5 years|Annual follow-up testing with no restrictions on dietary intake during periods between annual testing.
8062|NCT04131153|Procedure|"three-step radiofrequency ablation"|"After destroying the main blood supply of the tumor, extracting the blood in the tumor, reducing the blood flow in the tumor and shrinking the tumor volume, the remaining tumor was then treated with radiofrequency ablation, namely the three-step radiofrequency ablation with one block, two inhalation and three damages."
8063|NCT04131153|Procedure|radiofrequency ablation|Conventional radiofrequency ablation
8064|NCT04131127|Device|Sentinel Device|Sentinel Device used during TAVI in a Low Risk Patient
8065|NCT04131101|Behavioral|Community Organizing|The intervention will be community organizing and will consist of engaging tenants, health providers, legal service staff, social service agencies and advocacy organizations (e.g. ACORN). Each building team will identify initial priorities and then invite all building members to discuss and to finalize, as well as a plan for change. Building teams will engage in advocacy to TCHC and its representatives, and other city departments as appropriate. Engaging in advocacy will consist of a wide range of activities but essentially means presenting evidence (e.g. personal experiences, data) to policymakers and decision makers to affect change.
8066|NCT04131088|Other|Follow up of midlines|The follow-up data to be collected will be recorded on a monitoring logbook that will follow the patient (Appendix 4). The latter will be involved in the follow-up of his data insofar as he will be able to solicit the various professionals performing care on his midline in order to aim at the exhaustiveness of the filling of the book.
8067|NCT04131075|Procedure|Coronary Angiography and Multimodal Coronary Physiology Study (FFR, CFR, HMR)|Coronary Angiography according to clinical indication and Multimodal Coronary Physiology Study (FFR, CFR, HMR) for functional assessment of intermediate coronary lesions
8068|NCT04131062|Behavioral|Electronic Consent (iPad)|Participants who receive the intervention will be consented using an electronic app presented via iPad and developed according to the Sage eConsent framework.
8069|NCT04131049|Other|High GI calculated by CC (CHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
8070|NCT04131049|Other|Low GI calculated by CC (CLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
8071|NCT04131049|Other|High GI calculated by FII (FHGI)|This test meal with high GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
8072|NCT04131049|Other|Low GI calculated by FII (FLGI)|This test meal with low GI were served as a breakfast after 8-hours fasting and participants were asked to consume the meal in full, within 20 min.
8073|NCT04131036|Other|assessment of joint health and bone density|We propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
8074|NCT04131023|Behavioral|Breezing Metabolic Rate Tracking|Metabolism (indirect calorimetry) data were collected every two weeks over 13 weeks of gestation across the second trimester (weeks 13-27) and the values obtained were provided to the participant without health education.
8075|NCT04131010|Device|single operator video cholangioscopy|The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
8076|NCT04130997|Biological|Ublituximab|Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
8077|NCT04130984|Device|EZ-IO|The insertion site locates at 1 cm medial tibial tuberosity. EZ-IO (U.S. Teleflex® Corporation) will be used with an adult 15G needle. Pull out the needle when having a sense of frustration, withdraw the bone marrow with the syringe, bolus 20 mL of normal saline to open intramedullary path and begin drug resuscitation at the same time. The retention time of IO route should be less than 24 h, and venous access should be established after winning rescue time as soon as possible to continue treatment.
8078|NCT04130971|Other|No intervention, just observation|No intervention, just observation of the differences between groups and within patients.
8079|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Active)|iTBS-TMS is a noninvasive neuromodulation technique that uses a powerful magnet to induce focal electrical currents in target brain regions.
8080|NCT04130958|Device|Intermittent Theta Burst Transcranial Magnetic Stimulation (Sham)|The sham version of iTBS-TMS involves placing the magnet over the same target brain region but the device will not be turned on during the treatment. There will be two electrodes placed on the scalp that mimic the sensation of iTBS-TMS but does not induce focal electrical currents.
8081|NCT04130945|Other|erector spina plane block, cost analysis|in preopererative period, ESP block is going to utilise for postoperative analgesia for patients who undergo laparoscopic procedure and cost analysis will make after the end of 24 hour of operation
8082|NCT04130932|Other|Ergonomic flooring|Specially designed flooring system to optimize ergonomics of participants
8083|NCT04130919|Drug|GS-4875|Tablets administered orally once daily
8084|NCT04130919|Drug|Placebo|Tablets administered orally once daily
8085|NCT04130906|Device|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
8186|NCT04130048|Diagnostic Test|Ultrasound Elastography|Ultrasound elastography aims to assess the stiffness of a tissue, submitting it to an ultrasound impulse.
8086|NCT04130906|Device|Sham Intermittent Theta Burst Stimulation|Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
8087|NCT04130893|Behavioral|stimulation of G13 then G15|Study participant randomized into arm A will undergo a stimulation of point G13 at session N°2, then stimulation of point G15 at session N°3.
8088|NCT04130893|Behavioral|stimulation of G15 then G13|Study participant randomized into arm B will undergo a stimulation of point G15 at session N°2, then stimulation of point G13 at session N°3.
8089|NCT04130880|Diagnostic Test|Turkish Montreal Children's Hospital Feeding Scale|The Turkish version of the Montreal Children's Hospital Feeding Scale, and the Behavioral Pediatrics Feeding Assessment Scale will be completed.
8090|NCT04130867|Procedure|pHRM|Pharyngeal high--resolution manometry (pHRM) provides direct and objective measurement of pressure changes in the pharynx that characterize basic mechanisms of swallowing.
8091|NCT04130867|Procedure|VFSS|Videofluoroscopic Swallow Study (VFSS) enables real-time visualization of bolus flow during swallow movement.
8093|NCT04130841|Procedure|Internal Limiting Membrane Peeling|After removal of the epiretinal membrane, indocyanine green staining will be used to determine the internal limiting membrane (ILM) peeled off with the epiretinal membrane. (Group 1: spontaneous ILM peeling) If it is confirmed that the internal limiting membrane is not peeled together, the investigators determine whether the active Internal limiting membrane peeling is performed by 1:1 randomization immediately during surgery. (Group 2: Active ILM peeling, Group 3: no ILM peeling) The outcomes of the three groups will be compared.
8094|NCT04130828|Drug|Ferrous Fumarate|Ferrous fumarate 200 mg PO PC
8095|NCT04130815|Drug|Inhaled furosemide|4ml of 10mg/ml solution of furosemide nebulized with small and large droplet sizes and inhaled with different breathing patterns
8096|NCT04130802|Drug|OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL|OCS-01 eye drops
8097|NCT04130802|Drug|Placebo|Vehicle eye drops
8098|NCT04130789|Other|compare data patterns by data-driven algorithms to determine sepsis|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to reliably determine sepsis
8099|NCT04130789|Other|compare data patterns by data-driven algorithms to predict sepsis-related mortality|compare data patterns by data-driven algorithms including machine learning and multi-dimensional modelling to to predict sepsis-related mortality
8100|NCT04130776|Diagnostic Test|Measurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged|The 4Kscore Test helps clarify the biopsy decision-making process by determining a patient specific probability for finding aggressive, Gleason score 7 or higher prostate cancer upon biopsy. These are the aggressive prostate cancers that always require medical treatment or intervention. The 4Kscore Test relies on the measurement of four prostate-specific kallikreins in the blood: Total PSA, Free PSA, Intact PSA, and Human Kallikrein 2 (hK2). The blood test results are combined in an algorithm with patient age, digital rectal exam (nodules, no nodules), and prior negative biopsy (yes, no) to give physicians a personal score for each patient. The 4Kscore Test predicts the risk percent score from <1% to >95% of a man having aggressive cancer in a prospective biopsy.
8101|NCT04130763|Biological|FMT capsule|FMT capsules administration starts on the first week of enrollment. Capsules are taken every other day for 3 times on the first week. Then once a week for 2 weeks. Anti-PD1 therapy starts on week 2.
8102|NCT04130750|Combination Product|treatment of drug screening|Patients in experimental group will receive a drug screening in vitro to select sensitive chemotherapy drug. And neoadjuvant chemotherapy will be performed according the results of drug screening.
8103|NCT04130737|Device|TORUS Stent Graft System|The TORUS Stent Graft is an intravascular prosthesis intended to improve blood flow in the area in which it is implanted and the TORUS Stent Graft Delivery System is a standard pin-and-pull delivery system used to implant the SG in the desired area. Use of the TORUS Stent Graft allows for improving blood flow in the peripheral vasculature.
8104|NCT04130724|Diagnostic Test|Blood ketone testing|Ketone testing will be done using a blood beta-hydroxybutyrate (BHB) test at least five (5) times per day.
8105|NCT04130724|Diagnostic Test|Breath ketone testing|Ketone testing will be done using a breath acetone (BrAce) test at least five (5) times per day.
8106|NCT04130711|Other|Visual virtual Conditions|"The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background."
8107|NCT04130711|Other|Standard EEG|"In this phase of Test 2 in post-stroke subjects, the aim is to study the modification of the cortical excitability related to simple vibration stimulation, in subjects with supra-tentorial vascular cerebral lesions. For this step, we broaden the criteria for inclusion of post-stroke subjects.~Twenty healthy volunteers and 20 post-stroke subjects test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject (healthy and post-stroke) an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand (or deficit), or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order."
8142|NCT04130451|Drug|PYODINE AND TALC SLURRY|"pyodine Povidone-iodine is a broad spectrum antiseptic for topical application in the treatment and prevention of wound infection. It may be used in first aid for minor cuts, grazes, burns, abrasions and blisters.~TALC a white, grey, or pale green soft mineral with a greasy feel, occurring as translucent masses or laminae and consisting of hydrated magnesium silicate"
8108|NCT04130711|Other|Neurofeedback Trial|Twenty-one healthy volunteers participate in the study. The healthy subject performs a session of Neurofeedback (on the non-dominant limb) of 30 minutes, trying in a random order the 3 modalities of feedback for 10 minutes each (visual, vibratory, visual combination + vibratory). The subject evaluates by a satisfaction questionnaire immediately after the session the tolerance of each modality and its possible preference. An analysis of the recorded EEG signals will then be performed.
8109|NCT04130711|Other|Neurofeedback Training Healthy subjects|Twenty-one healthy volunteers participate in the study. The healthy subject is evaluated on the Finger Tapping test and the NHPT to assess the motor skills of his 2 upper limbs. Then he performs 6 sessions of Neurofeedback (on the non-dominant limb) lasting 45 minutes each, spread over 2 weeks, according to the feedback modality that has been drawn randomly (visual, vibratory, visual combination + vibratory). A second visit after the first session of NFB and a third visit after the last session of NFB evaluates the motor skills of the 2 upper limbs (Finger Tapping test, NHPT) and a satisfaction questionnaire is given to the subject to assess tolerance and satisfaction compared to the feedback mode assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
8110|NCT04130711|Other|Neurofeedback Training Stroke Patients|The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 15 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 5 weeks, depending on the feedback modality that has been drawn randomly (visual or vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
8111|NCT04130698|Behavioral|Distress Tolerance|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with distress tolerance intervention to quit smoking and lose weight.
8112|NCT04130698|Drug|transdermal nicotine patch|Participants will use the patch for 8 weeks as outlined by the recommended usage for steps 1-3 going from 21mg for 4 weeks, 14mg for 1 week, and 7mg for 1 week.
8113|NCT04130698|Behavioral|Active Health Control|The group-level intervention is comprised of one 2-hour weekly group sessions with overweight smokers to learn skills and strategies consistent with psychoeducation intervention to quit smoking and lose weight.
8114|NCT04130685|Diagnostic Test|Allosure Test|Venous Blood Draw
8115|NCT04130672|Procedure|Hot nasal packing with hot saline irrigation for hemostasis after adenoidectomy|After hot packing nasopharyngeal irrigation with 50 C saline
8116|NCT04130672|Procedure|Cold nasal packing with cold saline irrigation for hemostasis after adenoidectomy|After cold packing nasopharyngeal irrigation with 22 C saline
8117|NCT04130659|Device|Marial® + PPI (generic omeprazole)|Marial®: 1 stick of Marial® twice a day after meals from day 1 to 28 Omeprazole 20 mg cps: once a day from day 1 to 28
8118|NCT04130659|Other|PPI alone (generic omeprazole)|Omeprazole 20 mg cps: once a day from day 1 to 28
8121|NCT04130633|Drug|Placebo|Placebo vapor (distilled water)
8122|NCT04130633|Drug|THC|Pure THC vapor
8123|NCT04130633|Drug|Alpha-Pinene|Pure alpha-pinene vapor
8124|NCT04130620|Diagnostic Test|Applied Kinesiology|An Applied Kinesiology muscle test will be supplemented by a single blood draw for validation.
8125|NCT04130607|Other|Conceptual teaching|"The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group."
8126|NCT04130594|Biological|BVRS-GamVac|a vector vaccine for the prevention of the Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration
8127|NCT04130594|Other|placebo|placebo
8128|NCT04130581|Other|Transcranial Magnetic Stimulation (TMS)|TMS is a safe and non-invasive technique, which involves the generation of brief magnetic pulses applied to the head through a coil. The magnetic pulses pass through the scalp and skull and induce weak electric currents in the neural tissue directly underneath the coil. When TMS is applied in repetitive, patterned trains of pulses (rTMS), it can induce cortical plasticity specifically in the targeted brain region.
8129|NCT04130568|Diagnostic Test|INO survey|Garvin's Learning organisation tool
8130|NCT04130555|Device|CELLIS Rectopexy (Porcine Acellular Dermal Matrix, PADM)|Biological membrane used in Laparoscopic Ventral Rectopexy (LVR) or robotic assisted rectopexy
8131|NCT04130542|Biological|LVGN6051|IV infusion once every 3 weeks (Q3W).
8132|NCT04130529|Behavioral|Adjusted group CBT-i for Bipolar disorder|CBT-i includes sleep scheduling/sleep compression, stimulus control, relaxation, cognitive interventions and sleep hygiene advice. In addition components targeting circadian rhythm problems and problems with very high or very low levels of activity are included.
8133|NCT04130529|Other|Sleep lectures|Lectures on the topic of sleep.
8134|NCT04130516|Drug|Small molecule, orally bioavailable, selective agonist of GPER|LNS8801
8135|NCT04130503|Device|PAP|Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).
8136|NCT04130503|Behavioral|HLE|All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
8137|NCT04130477|Device|Tunnel attachments and light Nickel Titanium wire|Tunnel attachments planned virtually and light Nickel Titanium wire
8138|NCT04130477|Device|Clear Aligner therapy|Clear Aligner therapy
8139|NCT04130464|Drug|Ropivacaine Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine at 8 mL/hour for 72 hours
8140|NCT04130464|Drug|Ropivacaine + Ketorolac Infusion from ON-Q Pump|Infusion of 0.2% ropivacaine + 30 mg ketorolac at 8 mL/hour for 72 hours
8141|NCT04130464|Drug|Normal Saline Infusion from ON-Q Pump|Infusion of 0.9% normal saline at 8 mL/hour for 72 hours
8187|NCT04130022|Device|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
8143|NCT04130438|Drug|Nebivolol|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
8144|NCT04130438|Drug|Diltiazem|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
8145|NCT04130438|Other|Placebo|The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
8146|NCT04130425|Device|Hely & Weber MTC Fracture Brace|Prefabricated muenster orthosis
8147|NCT04130425|Device|Thermoplastic orthosis|Muenster orthosis fabricated out of thermoplastics and secured with Velcro
8148|NCT04130425|Device|Delta cast orthosis|Muenster orthosis fabricated out of Delta Cast and secured with Velcro
8149|NCT04130412|Procedure|open release|Open release of lateral retinaculae
8150|NCT04130399|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will receive 5 fractions of SBRT delivered over a five-day period. Treatment may be delivered over 2 weeks, provided that the patient receives at least 2 fractions per week.
8151|NCT04130399|Drug|FOLFIRINOX|Participants in this trial will receive neoadjuvant and adjuvant FOLFIRINOX chemotherapy for 6 cycles (1 cycle = 14 days) per routine guidelines
8152|NCT04130386|Behavioral|Motivational Interviewing|Participants receiving MI
8153|NCT04130386|Behavioral|e-education|Participants receiving e-education
8154|NCT04130373|Procedure|Autologous fat grafting procedure|Surgical intervention based on the injection of autologous fat grafting after radical or conservative breast surgery and breast reconstruction.
8155|NCT04130373|Procedure|Breast reconstruction|Breast reconstructive procedures after oncological radical or conservative breast surgery
8156|NCT04130360|Behavioral|Problem-solving|The steps of problem-solving are explained to the participants. Then, they are presented two conflictive situations and they are asked to apply the problem-solving steps to find a solution. Once they finish, they are asked to apply the steps in a conflictive situation they have experience in the last month. In the end, they are reminded of the steps and encouraged to practice them in their daily conflicts.
8157|NCT04130334|Procedure|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea|After mechanical trephination, horizontal meridian of donor's cornea sutured to horizontal meridian of recipient cornea
8158|NCT04130334|Procedure|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea|: After mechanical trephination, horizontal meridian of donor's cornea sutured to vertical meridian of recipient cornea
8159|NCT04130321|Dietary Supplement|Camu camu|3 capsules of camu camu powder (500 mg / capsule) daily during 12 weeks
8160|NCT04130321|Dietary Supplement|Placebo|3 capsules of placebo daily during 12 weeks
8161|NCT04130308|Other|Retrun to run protocol|Progressive return to run protocol for patients after ACL-R
8162|NCT04130295|Other|Wearable intensive nerve stimulator|The wearbale device consists of 2 leads that provide biphasic, with alternating lead phase, asymemetrical rectangular current at a pulse duration of 0.28 msec, a randomly varying pulse frequency between 60-100 Hz, with a maximum intensity of 100mA.
8163|NCT04130282|Biological|Pfs25-IMX313/Matrix-M1|3 doses of 10µg Pfs25-IMX313 in 50 µg Matrix-M1 on days 0, 28 and 56
8164|NCT04130269|Other|No intervention|Questionnaires, lab-run
8165|NCT04130256|Device|Electronic Pill Bottle|Electronic bottles that can beep and blink to send medication use reminders, record medication use data, and upload medication use data to a secure server.
8166|NCT04130243|Other|Blood test|Withdrawal of (extra) blood to measure serum biomarkers with a blood test
8167|NCT04130230|Drug|Neostigmine|Neostigmine continuous infusion plus standard therapy for sepsis and septic shock.
8168|NCT04130230|Drug|Standard therapy|Standard therapy for sepsis and septic shock
8169|NCT04130217|Procedure|addition of positive end expiratory pressure in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O.
8170|NCT04130217|Procedure|addition of positive end expiratory pressure and recruitment maneuver in ventilated patients|patients will be intraoperatively mechanically ventilated with PEEP of 5 cmH2O and intermittent four times of RM consisting of maintaining airway pressure 40 cmH2O for 40 sec.
8171|NCT04130204|Drug|DYV700|Topical Transdermal Delivery Lotion with Actives
8172|NCT04130204|Other|Placebo|Topical Transdermal Delivery Lotion without Actives
8173|NCT04130178|Drug|Nerve block|block of the digital nerves in rheumatoid arthritis patient
8174|NCT04130165|Other|Matched donor human milk|Milk from donor mothers will be sorted according to their secretor status. This milk will be provided to infants in the intervention (experimental) arm.
8175|NCT04130152|Drug|Palbociclib|Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle
8176|NCT04130152|Drug|Letrozole|Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
8177|NCT04130139|Other|oocyte pick up simulator|oocyte pick up simulation
8179|NCT04130100|Biological|Low Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
8180|NCT04130100|Biological|High Dose of Mesenchymal stem cell|Mesenchymal stem cell injection
8181|NCT04130100|Drug|Sodium Hyaluronate|Sodium Hyaluronate injection
8182|NCT04130087|Drug|Selegiline Hydrochloride 10 MG|Single 10mg tablet of Selegiline Hydrochloride
8183|NCT04130087|Drug|Placebo|Single Placebo Tablet, identical appearance to experimental tablet.
8184|NCT04130074|Device|duplex doppler ultra sound and CT|graded compression US done in different positions then take MSCT with contrast on abdomen to compare with
8185|NCT04130061|Biological|Human Amniotic Membrane|Epicardial application of human amniotic membrane during cardiac surgery
8189|NCT04129996|Drug|camrelizumab in combination with nab-paclitaxel and famitinib|camrelizumab in combination with nab-paclitaxel and famitinib for triple negative breast cancer
8190|NCT04129983|Combination Product|Drugs and Stimulation|60 cases of sudden deafness were inquired about their medical history and examined by hearing and cranial magnetic resonance. They were randomly divided into two groups and given different treatments. The hearing test was repeated every 7 days. One month and three months after the treatment, the hearing examination was reexamined.
8191|NCT04129970|Device|Intermittent Theta Burst Stimulation|iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
8192|NCT04129957|Procedure|Placement of dental implants|All the included patients underwent the placement of at least one implant in either upper jaw, or lower jaw, or both.
8193|NCT04129944|Drug|UBX0101|Investigational drug intra-articular injection
8194|NCT04129944|Other|Placebo|Placebo intra-articular injection
8195|NCT04129931|Drug|MCT|Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily
8196|NCT04129931|Drug|Clazakizumab|12.5 mg subcutaneous injection given once every 4 weeks for 16 weeks. Lab driven dose reductions will be made based on safety lab data. If criteria are met for dose reduction, the participant will be reduced to a 6.25 mg dose.
8197|NCT04129931|Drug|Broncho-Vaxom|7 mg taken orally once a day, on an empty stomach, for 16 weeks
8198|NCT04129931|Drug|Imatinib Mesylate|Two 100 mg tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. If the drug is well tolerated, participants will titrate up to four 100 mg tablets once a day with a meal and an 8 oz glass of water for 14 weeks. Safety labs will be collected at each study visit to monitor the tolerability of each participant.
8199|NCT04129931|Drug|Cavosonstat|50 mg capsule orally twice a day for 16 weeks.
8200|NCT04129931|Drug|Itacitinib|Two 100 mg tablets orally once a day for 16 weeks.
8201|NCT04129931|Other|Placebo|"MCT Matching Placebo: MCT matching placebo packets. Mix 1-2 packets, as instructed by a physician, into liquid or food three times daily~Clazakizumab Matching Placebo: 12.5 mg subcutaneous saline injection given once every 4 weeks for 16 weeks.~Broncho-Vaxom Matching Placebo: 7 mg matching placebo taken orally once a day on an empty stomach for 16 weeks~Imatinib Matching Placebo: Two 100 mg placebo tablets orally once a day with a meal and an 8 oz glass of water for 2 weeks. Then four 100 mg placebo tablets once a day with a meal and an 8 oz glass of water for 14 weeks.~Cavosonstat Matching Placebo: 50 mg matching placebo capsule orally twice a day for 16 weeks.~Itacitinib Matching Placebo: Two 100 mg matching placebo tablets orally once a day for 16 weeks."
8202|NCT04129918|Behavioral|light and sound modification (earplugs and eye masks)|In the experimental group，the patients used earplugs and eye masks during nighttime sleep.
8203|NCT04129905|Biological|BNP blood sample test|Performed during normal recommended follow-up of the HCM patients.
8204|NCT04129905|Diagnostic Test|Electrocardiogram|Performed during normal recommended follow-up of the HCM patients.
8205|NCT04129905|Diagnostic Test|Holter ECG|Performed during normal recommended follow-up of the HCM patients.
8206|NCT04129905|Diagnostic Test|Echocardiography|Performed during normal recommended follow-up of the HCM patients. Echocardiography at rest and during exercise.
8207|NCT04129905|Diagnostic Test|Air venous plethysmography|Performed specifically for the research. Non invasive, and non painful test evaluating different parameters of venous filling by inflation of an armband around the leg, upright positioning, flexion-extension of the leg. Total duration estimated at 30-45 minute.
8208|NCT04129905|Diagnostic Test|Upper member arterial Doppler echography with analysis of FMD|Performed specifically for the research. Measurement of the evolution of brachial artery diameter before and after inflation of a armband during 5 minutes. Non invasive and non painful test, duration 30 minutes.
8209|NCT04129905|Biological|Endothelial function biomarkers|Performed specifically for the research. Blood sample test, 5 minutes.
8210|NCT04129892|Behavioral|"In Favor of My Resilient Self Academic course"|Assessing the effect of an academic course on student's emotional resilience.
8211|NCT04129879|Procedure|ABC technique|The intraperitoneal use of methylene blue diluted isotonic sodium chloride solution to visualize endometriotic lesions
8212|NCT04129866|Behavioral|M-IBM|"In this paradigm, an ambiguous word or two-word phrase related to ASCC is followed by a sentence that resolves the word-sentence meaning as threatening or benign. For example, participants are presented with an ambiguous word or two-word phrase for 1 second. On half the trials the combination of the word/phrase and sentence creates a benign meaning (as in the previous example). On the other half of trials this combination creates an anxious-threat meaning Participants are required to judge the relatedness of the word/phrase and the sentence. Participants are given feedback during training such that judging the anxious-threat combinations to be unrelated and the benign combinations as being related would produce a correct response. In contrast, if participants produce an incorrect response they see incorrect."
8213|NCT04129866|Behavioral|Control-IBM|Placebo IBM where sentences are not related to anxious threat meaning of cue word.
8214|NCT04129853|Device|Cyberlegs Xleg|Sit to stand, Stair Climbing, Slope walking, L-test, Hallway walking with the current vs. cyberlegs xleg and cyberlegs vs power knee
8215|NCT04129840|Other|dual combination|Participants will be started on a dual therapy with half dose of CCB and an ARB. If needed, a) the dose of the CCB will be increased at 4 weeks, and b) the dose of the ARB at 8 weeks, if blood pressure remains uncontrolled ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
8216|NCT04129840|Other|triple combination|Participants will be started with low dose (1/4) triple combination treatment with CCB, TZD and ARB. If uncontrolled after 4 weeks, dosages of all drugs will be doubled. If after 8 weeks still uncontrolled dosage will be increased to full dose of all three drugs ((if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
8612|NCT04126421|Device|Prosthesis component (acetabular cup) Marathon cup|Semented acetabuar cup With Marathon cup
8217|NCT04129840|Other|Standard of care|Participants will be started on regular dose of CCB with a) addition of TZD at 4 weeks, if needed, b) increase of dose of TZD after 8 weeks, if needed (if target blood pressure is not achieved at this time point (target blood pressure defined as clinic BP </=130/80mmHg in patients <65years and </=140/90mmHg in patients >65years)
8218|NCT04129827|Other|Clinical, self-reported psychological and biomechanical assessments|"medical check up~active and passive Range Of Motion (ROM)~anterior drawer test~knee's alignment~modified cincinnati rating system questionnaire (mCRSQ)~tegner lysholm knee scoring scale (TLKS)~Tegner Activity Level Score (TALS)~self-reported psychological questionnaires~Tampa Scale of Kinesiophobia (TSK)~ACL Return to Sport after Injury (ACL-RSI) score~biomechanical tests~Stability test: to balance on one/two legs on a free to move disc for 30s~Jump test: i) a maximize jump with both legs; ii) a maximize jump with only one leg; three consecutive jumps; iv) jump coordination path where the patient had to perform a forward-backward-forward jump and a sideway jump on one leg~Coordination test: a square hurdle was used for the quick test, where the patient had to step in and out with both feet for a total of 15-rep as quickly as possible~fatigue test: to rise and sit from a chair for 30-rep as quickly and safely as possible"
8219|NCT04129814|Procedure|Non surgical periodontal therapy|single session full-mouth scaling and root planing
8220|NCT04129801|Other|Isokinetic Dynamometer|Participants then executed two series of four uninterrupted repetitions of Ext and Flex of both legs, first with the dominant member and subsequently with the non-dominant member, at an angular velocity of 60o/s, with a 60-second interval between series.
8221|NCT04129801|Other|Bioimpedance|Bioimpedance The BC measurements as FM (% and kg), FFM (% and kg), will be obtained by the indirect noninvasive method of electrical bioimpedance (BIA) 230, 2.0, (Biospace Seoul, Korea). Those evaluated will be standing and positioned on the platform electrodes, barefoot and with their arms extended with their hands on the two supports (electrodes).
8222|NCT04129788|Drug|Bisacodyl 5 milligram|three doses taken, one per day on three consecutive days
8223|NCT04129788|Drug|Placebo oral tablet|three doses taken, one per day on three consecutive days
8224|NCT04129775|Drug|OTO-413|Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)
8225|NCT04129775|Drug|Placebo|Single intratympanic injection of placebo
8226|NCT04129762|Other|Diet without NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will not contain products with NCS."
8227|NCT04129762|Other|Diet with NCS|"A standard diet in terms of macronutrients will be calculated.~55% Carbohydrates~20% protein~25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.~The menu will contain products with NCS."
8228|NCT04129749|Procedure|Real-Time Analysis Interactive Lab|The Real-Time Analysis Interactive Lab uses an instrumented treadmill, a motion capture system (Vicon System), an electromyographic system as well as a virtual environment is projected on a 180 ° screen. This equipment allows patients to walk spontaneously or at prescribed speeds to a standstill in a virtual and secure virtual reality environment.
8229|NCT04129736|Drug|Teriflunomide 14 MG|Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
8230|NCT04129723|Other|Stopping biological therapy|Stopping biological therapy The primary endpoint is clinical relapse at 12 months
8231|NCT04129710|Drug|Ibrutinib|Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
8232|NCT04129710|Drug|Lenalidomide|Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
8233|NCT04129710|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
8234|NCT04129710|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day 1
8235|NCT04129710|Drug|Etoposide|Etoposide 250 mg/m2 over 3 hours on day3
8236|NCT04129710|Drug|PEGylated recombinant human granulocyte colony|PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
8237|NCT04129697|Drug|Dexamethasone or Methylprednisolone|steroids
8238|NCT04129684|Other|Probiotics|subgingival delivery and lozenges
8239|NCT04129671|Genetic|No intervention was applied|No intervention was administered
8240|NCT04129658|Behavioral|Educational outreach visit|Two-four hours of discussion between a cardiologist and the primary care physicians at the PHCC encompassing evidence-based treatment guidelines and counseling upon specific patient cases and their diagnose and treatment for congestive heart failure.
8241|NCT04129645|Device|URS|"URS is a permanent ureteral stent made of nitinol and covered by a polymer, that is indicated to open strictures in the ureter.~Study patients who has strictures in the ureter, will be implanted with the URS for long term opening of the stricture."
8242|NCT04129632|Behavioral|IEPF Wellness Tool|A daily 5 minute mindfulness exercise over 28 days
8243|NCT04129619|Drug|ORP-101|Oral tablet
8244|NCT04129619|Drug|Placebo|Oral tablet
8245|NCT04129606|Diagnostic Test|Computed tomographic cystography|CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
8246|NCT04129593|Behavioral|Self Awakening - Natural Waking|subjects in this arm will be assigned to natural waking and self awaking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: natural waking, Sunday: self awakening and Saturday: self awakening, Sunday: natural waking.
8247|NCT04129593|Behavioral|Snooze - Natural waking|subjects in this arm will be assigned to snooze and natural waking conditions on Saturday and Sunday. they will be counterbalanced equally between Saturday: snooze, Sunday: natural waking and Saturday: natural waking, Sunday: snooze.
8248|NCT04129580|Device|reSET-O app|The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
8260|NCT04129541|Other|Same Day Discharge|Patients in the planned same day discharge (SDD) cohort will be discharged from the PACU once they meet standard discharge criteria.
8261|NCT04129541|Other|Overnight Hospitalization|Patients in the planned overnight hospitalization (OH) group will be discharged on post-operative day 1 once they meet standard discharge criteria.
8262|NCT04129528|Drug|CFZ533|First dose is administered via intravenous infusion, subsequent doses are administered subcutaneously.
8263|NCT04129528|Other|Placebo|Placebo for active drug
8264|NCT04129515|Device|NovoTTF-200A|•NovoTTF-200A will be applied continuously, with 21 consecutive days defined as a treatment cycle
8265|NCT04129515|Drug|Pembrolizumab|Pembrolizumab will be administered once every 3 weeks, with 21 consecutive days also defined as a treatment cycle
8266|NCT04129502|Drug|TAK-788|TAK-788 capsule
8267|NCT04129502|Drug|Pemetrexed|Pemetrexed IV infusion
8268|NCT04129502|Drug|Cisplatin|Cisplatin IV infusion
8269|NCT04129502|Drug|Carboplatin|Carboplatin IV infusion
8270|NCT04129489|Drug|Cannabidiol|Synthetic Cannabidiol, dissolved in pharmaceutical grade olive oil at a concentration of 5% will be administered orally
8271|NCT04129476|Behavioral|Cooperative Education Program based on Precede-Proceed Model|The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
8272|NCT04129463|Device|Subscleral Trabeculectomy (SST) with Iris incarceration|Subscleral Trabeculectomy with Iris Incarceration using iris forceps and scissors
8273|NCT04129463|Device|Conventional trabeculotomy|Conventional trabeculotomy in Buphthalmous using rigid Hans trabeculotome
8274|NCT04129450|Other|Group medical visits with mindfulness-based stress reduction|Eight weekly 90 minute sessions of mindfulness-based stress reduction in group medical visits
8275|NCT04129450|Other|Usual PCP care|Usual one on one PCP care for chronic lower back pain
8276|NCT04129437|Drug|Ibuprofen|Weight based ibuprofen dosing
8277|NCT04129437|Procedure|Osteopathic manipulative treatment|Low velocity osteopathic manipulative treatment
8278|NCT04129424|Device|Insulin pump (Microtech, Equil®)|Those patients of different types of diabetes mellitus were assigned to different groups, those groups were classified by the time to reach target blood glucose .
8279|NCT04129411|Device|RFA|Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.
8280|NCT04129398|Drug|Letermovir tablet|A single 240 mg tablet or two 240 mg tablets letermovir administered orally, once daily for 28 weeks
8281|NCT04129398|Drug|Letermovir IV|IV solution of 240 mg (one vial) or 480 mg (2 vials) letermovir in 250 mL infused over 60 minutes, once daily for 28 weeks
8282|NCT04129385|Procedure|20 degree Trendelenburg position|The patients in the intervention group will be placed in trendelenburg position postoperatively.
8283|NCT04129372|Behavioral|New Foods Take Time|New Foods Take Time is a series of 5 classroom lessons focused on increasing children's willingness to try fruits and vegetables.
8284|NCT04129359|Behavioral|FamilieTrivsel|FamilieTrivsel is a modular internet-based low-cost and brief psychoeducation intervention based on the Robusthed (Resilience) programme (RP). Mentalisation approaches are used to increase resilience and ability to handle the challenges of life. The programme is licence free and can be used with low or high intensity and it can be combined with any other interventions. RP provides simple explanations and tools that can be used to discover, understand and regulate one's own thoughts and feelings by activating mental and physical resources and it provides examples and exercises that may promote communication about mental states between parents and the child. The content has been developed to include video-based training sessions based on different stages of pregnancy and early childrearing. RP appears suitable for use in general practice, where the GP sees young parents regularly and thus can direct patients towards components of the programme when need appears greatest.
8285|NCT04129359|Other|enhanced care as usual|Structured assessments of maternal mental health, child neurodevelopment and parent-child interaction in routine preventive health care in general practice
8323|NCT04129086|Drug|Usual Care|Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
8324|NCT04129073|Other|Intensive care treatment|Intensive care treatment; Utilization of neuroprognostication tools
9784|NCT04116411|Radiation|Radiotherapy 60 Gy|Radiation therapy
8286|NCT04129346|Behavioral|Fit2ThriveMB App|The Fit2thriveMB app will encourage participants to increase their physical activity. Participants will be provided with educational information on physical activity and effective behavior change strategies for incorporating more physical activity into their daily lives to increase their step count. Participants will be prompted each morning to report the intensity of their symptom burden (0 to 10). Based on their symptom rating and their previous day's step counts, participants will be provided with three different options or levels of goals for that day to either increase or decrease 10-20% or remain constant.
8287|NCT04129346|Behavioral|Fitbit|The Fitbit measures PA intensity, steps, and heart rate and syncs directly with the smartphone and will automatically sync with the Fit2ThriveMB app and provide Fitbit data to the study team in real-time.
8288|NCT04129346|Behavioral|Physical Activity Coaching Calls|Participants will receive weekly coaching calls which will: a) provide feedback on the previous week's symptom burden and progress on PA goals; b) review personalized goals and strategies for increasing PA for the next week; c) provide instruction on effective behavioral change techniques
8289|NCT04129346|Behavioral|Healthy Living Coaching Calls|Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.
8290|NCT04129346|Behavioral|Cancer.net app|Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
8291|NCT04129333|Other|Hypnosis|"The hypnosis session :~Creation of the therapist-patient link~Choice of a theme and the preferred sensory channel by the patient~Collection of the theme chosen by the patient~Orientation in the here and now.~Induction~Realization of the gesture and hypnosis~At the end of the procedure, reassociation of the patient in the here and now"
8292|NCT04129333|Other|No hypnosis|No hypnosis
8293|NCT04129320|Biological|pembrolizumab|anti-PD-1 antibody
8294|NCT04129320|Biological|enoblituzumab|anti-B7-H3 antibody
8295|NCT04129320|Biological|MGA012|anti-PD-1 antibody
8296|NCT04129320|Drug|Chemotherapeutic Combinations|carboplatin or cisplatin plus 5-fluorouracil (5-FU)
8297|NCT04129307|Behavioral|Motor imagery|This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.
8298|NCT04129307|Behavioral|Double time motor imagery|This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.
8299|NCT04129307|Behavioral|Action observation|This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
8300|NCT04129294|Drug|NS-089/NCNP-02|"NS-089/NCNP-02 for Infusion is packaged as 50 mg/mL with 3 mL per vial. Study dosages will be infused over a 1 hour period at the following dose levels.~[Part 1] NS-089/NCNP-02 is administered at dose levels 1 and 3 in Cohort 1 and at dose levels 2 and 4 in Cohort 2.~Dose level 1: 1.62 mg/kg once weekly for 2 weeks; Dose level 2: 10 mg/kg once weekly for 2 weeks; Dose level 3: 40 mg/kg once weekly for 2 weeks; Dose level 4: 80 mg/kg once weekly for 2 weeks [Part 2] Based on the results from Part 1, two dosages are selected as study dosages in Part 2. Each selected dose are administered once a week for 24 weeks."
8301|NCT04129281|Procedure|Surgery|Surgery acconding to clinical practice
8302|NCT04129268|Other|Cycle ergometry exercise at 60% VO2max|Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
8303|NCT04129255|Drug|Octreotide Acetate|administration every 28 days
8304|NCT04129242|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training|A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
8305|NCT04129216|Drug|Tamoxifen Citrate|10mg administered daily. Patients take this drug for 2-6 weeks
8306|NCT04129216|Drug|Letrozole|2.5mg is administered daily. Patients take this drug for 2-6 weeks
8307|NCT04129216|Drug|Exemestane|25mg is administered daily. Patients take this drug for 2-6 weeks.
8308|NCT04129216|Diagnostic Test|Blueprint|studies the genomics of the tumor and tumor behavior
8309|NCT04129216|Diagnostic Test|Mammaprint|studies the genomics of the tumor
8310|NCT04129203|Device|Versi Retriever thrombectomy|Mechanical thrombectomy using Versi Retriever
8311|NCT04129190|Biological|Glucose|Oral Intake of Glucose
8312|NCT04129177|Other|Implementation of a bundle of surgical infection preventive measures|A bundle of six preventative measures is recommended to the VINCat hospitals. Bundle measures were: systemic and oral antibiotic prophylaxis, mechanical bowel preparation (MBP), laparoscopic surgery, maintenance of normothermia, and the use of a double-ring wound retractor.
8313|NCT04129164|Drug|VIB4920|Intravenous Dose 1.
8314|NCT04129164|Drug|Placebo|Intravenous dose matched to VIB4920.
8317|NCT04129138|Other|Survey Administration|Complete survey
8318|NCT04129125|Device|ZOOM Reperfusion Catheter|Reperfusion catheter
8319|NCT04129125|Device|Trevo® Pro (Stryker) or Solitaire™ (Medtronic) Stent Retrievers|Mechanical thrombectomy
8321|NCT04129099|Biological|GC022F|GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.
8322|NCT04129086|Drug|Ketamine plus usual care|Bolus of .35 mg/kg Infusion start @ 0.15 mg/kg/hr; titrate range is 0.1 - 0.25 mg/kg/hr for 24 to 48 hours after admission and each subsequent major surgery plus multi-modal pain therapy considered as standard of care. Standard of care medications include Acetaminophen 1000 mg po q6 hours, Naproxen 500 mg po q12 hours, Gabapentin 300 mg po q8 hours and Lidocaine patch q 12 hours.
9785|NCT04116411|Drug|Placebo oral tablet|Placebo treatment of glioblastoma
8325|NCT04129060|Drug|Cholinergic antagonist|The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
8326|NCT04129047|Drug|Omnichroma (one shade universal) composite by Tokuyama|Omnichroma is a single shade composite that is intended to have a color blending potential. It eliminates the shade matching procedures and makes it easier to avoid individual errors in shade matching in composite restorations.
8327|NCT04129047|Drug|A microhybrid composite Z250 (3 M ESPE, St. Paul, MN, USA|a multiple shade universal composite that needs prior shade selection procedure
8328|NCT04129034|Device|Neurolyser XR|Non-Invasive Thermal Ablation of the Medial Branch Nerves
8329|NCT04129021|Device|High-resolution retinal imaging through adaptive optics|The protocol consists of performing retinal imaging using full-field optical coherence tomography. The participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
8330|NCT04129021|Device|High-resolution retinal imaging through holographic systems|The protocol consists of performing retinal imaging using a laser Doppler holography. For each system, the participant is asked to put his forehead against the temple supports and his chin on a chin rest. The subject will be asked to fix a test pattern in the form of a cross. The pattern is positioned according to the desired eccentricity with respect to the fovea. The actual acquisition lasts a few seconds, possibly repeated to cover the field of the desired eye. The acquisition protocol depends on the subjects, their pathology and the system used; the area examined will be modified on a case by case basis. The total duration of each exam can be estimated at less than half an hour, with frequent breaks.
8331|NCT04129008|Drug|Indobufen and aspirin mimetic|Day 1 to 84±7: The first time: indobufen 100mg + aspirin mimetic; The second time: indobufen 100mg
8332|NCT04129008|Drug|Aspirin and indobufen mimetic|Day 1 to 84±7: The first time : aspirin 100mg+ indobufen mimetic; The second time: indobufen mimetic
8333|NCT04128995|Procedure|Bariatric Surgery|Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin
8334|NCT04128995|Drug|Advanced Medical Therapy|Use of combination medical therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin
8335|NCT04128982|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
8336|NCT04128969|Dietary Supplement|CS+|Oral carnitine supplementation
8337|NCT04128969|Dietary Supplement|CS-|Placebo
8338|NCT04128956|Drug|Aspirin 100mg|Aspirin® cardio (CH) or Aspirin® protect (DE, AT) Film coated tablets Acetylsalicylic acid 100 mg Once daily oral intake for 6 months
8339|NCT04128943|Other|symptom questionnaire|"A weekly filled in symptom questionnaire for reported symptoms of AA and/or PNH (yes/no, grade, date). Grading according to current grading systems (Common Terminology Criteria for Adverse Events,CTCAE).~Data collection and processing via the ePRO application by Kaiku Health Ltd"
8340|NCT04128943|Other|recording of vital signs|Record function for vital parameters (blood pressure, temperature and pulse); Data collection and processing via the ePRO application by Kaiku Health Ltd
8341|NCT04128943|Other|European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 questionnaire|The EORTC QLQ-C30 incorporates nine multi-item scales: five functional scales (Physical, Role, Cognitive, Emotional and Social Functioning); three symptom scales (Fatigue, Pain and Nausea/Vomiting); and a Global Health Status/QoL scale. Six single item scales are also included (Dyspnoea, Insomnia, Appetite Loss, Constipation, Diarrhoea and Financial Difficulties). All of the scales range in score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
8342|NCT04128943|Other|interview|Interview with the patients and responsible medical team by phone or during hospital visit about functional problems regarding the application (duration: 15-30 min) to avoid incorrect use of the application, at week 3 and month 3 and month 6
8343|NCT04128930|Device|PAP titration at home|Fixed CPAP or APAP titration at home
8344|NCT04128917|Drug|Tegoprazan|Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral
8345|NCT04128917|Drug|RAPAE01|RAPAE01/Clarithromycin/Amoxicillin BID peroral
8346|NCT04128904|Procedure|IVF|"Fertilisation with standard in vitro fertilisation (IVF). For details please see Project Description."
8347|NCT04128904|Procedure|ICSI|"Fertilisation with intracytoplasmic sperm injection (ICSI). For details please see Project Description."
8348|NCT04128891|Drug|Sacubitril-Valsartan|Cardiomagnetic Resonance Imaging
8349|NCT04128878|Drug|Sotalol|The primary goal of the study will be to evaluate the change in endothelial function seen after initiating anti-arrhythmic medical therapy. Testing will be performed at baseline prior to the 1st dose of anti-arrhythmic therapy and again 1-3 months later at outpatient follow-up visit. We will record the resting flow (RF), biological zero (BZ) and peak flow (PF) as perfusion units (PU). Specifically, we will assess arterial stiffness and vasodilation in response to acetylcholine iontophoresis, nitroprusside iontophoresis, local thermal hyperemia and reactive hyperemia. Laser speckle contrast imaging will be employed to evaluate the microvasculature. SphygmoCor (arterial tonometry) will be used to assess macrovasculature.
8350|NCT04128878|Drug|Dofetilide|Same as described above with sotalol.
8351|NCT04128852|Device|MagnetOs Putty|MagnetOs Putty has a CE-mark (2115660CE01) as well as FDA 510(k) clearance (K171563/K181958).
8352|NCT04128826|Other|Resistance Training|Using the cable machine, shoulders will be flexed to 180° for both (PROM & FROM) groups throughout the training; FROM would train with full elbow extension (complete elbow flexion to extension) whereas PROM will train with partial elbow extension from 60° to 110°. A total of 8 sessions, 2 sessions/week for 4 weeks will be carried out by both groups. CON group will not participate in training protocol.
8353|NCT04128813|Device|Vertical whole body vibration|A neuromuscular treatment using two types of whole body vibration platforms, a rotational and a vertical platform.
8354|NCT04128800|Drug|Apatinib S-1|apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
8355|NCT04128787|Drug|AG881 Formulation 1|AG881 uncoated tablets
8356|NCT04128787|Drug|AG881 Formulation 2|AG881 film-coated tablets
8357|NCT04128787|Drug|Omeprazole|Omeprazole capsules
8358|NCT04128774|Drug|Dexamethasone|The case group receives dexamethasone based on the clinical indication.
8359|NCT04128761|Behavioral|Scarcity Narrative|Participants are presented with a hypothetical scarcity narrative and asked to read and consider the scenario.
8360|NCT04128761|Behavioral|Neutral Narrative|Participants are presented with a hypothetical neutral narrative and asked to read and consider the scenario.
8361|NCT04128748|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
8362|NCT04128748|Drug|Quizartinib|Given PO
8363|NCT04128722|Drug|Sirolimus Oral Liquid Product 1mg/mL|0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
8364|NCT04128709|Device|Urodynamics Testing|The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
8365|NCT04128696|Drug|GSK3359609|GSK3359609 is available as an intravenous infusion.
8366|NCT04128696|Drug|Pembrolizumab|Pembrolizumab is available as an intravenous infusion.
8367|NCT04128696|Drug|Placebo|Placebo is available as an intravenous infusion.
8368|NCT04128683|Drug|amisulpride|Dopamine D2 antagonist to test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
8369|NCT04128683|Drug|bromocriptine|Dopamine D2 receptor agonist test how it affects brain response and behavior to prediction error and reversal tasks during functional magnetic resonance imaging (fMRI).
8370|NCT04128670|Device|Kinesiotape|Tape will be applied to the biceps muscle of the nondominant arm from approximately the shoulder to the elbow for up to 72 hours. For the KT group taping will be applied with a lymphatic application method according to the guidelines recommended by Kenzo Kase. This type of application is known to improve blood and lymphatic circulation which enhances the removal of metabolic products. It is recommended that the application of the tape for lymphatic correction be applied for 24-72 hours. The tape will be applied with a tension of 10-20%.
8371|NCT04128657|Diagnostic Test|MA_LARS|Validation of the MA_LARS and MA_Wexner
8372|NCT04128644|Behavioral|Thoughts & health|12 sessions of Thoughts & Health. Baseline questionaires and follow up assessments
8373|NCT04128644|Other|Treatment as Usual|Baseline questionnaires and follow up assessments, intervention as usual, Student Health
8374|NCT04128618|Device|CyMedica e-vive NMES|Neuromuscular Electrical Stimulation (NMES) therapy
8375|NCT04128605|Procedure|Suprascapular nerve block (SSNB)|"SSNB is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. Then, a mixture of 5 mls of Bupivacaine, 5 mls Lidocaine 1% and 10 mls of saline are injected at posterior shoulder towards suprascapular notch surrounding suprascapular nerve."
8376|NCT04128605|Procedure|Intraarticular shoulder steroid injection (IAS)|"IAS is performed using ultrasound guidance by skilled interventionist under ultrasound guidance.~Skin area at posterior shoulder is first infiltrated with Lidocaine 1%. IAS is performed by injecting 40 mg of Triamcenolone Acetonide along with 2 ml of Lidocaine 1% into glenohumeral articular space"
8377|NCT04128592|Device|diagnosing noisy breathing in infants and toddlers|breath sampling and nasal mucus sampling to analyze biomarkers and breath sound analysis to diagnose noisy breathing.
8378|NCT04128579|Drug|Itolizumab [Bmab 600]|EQ001
8379|NCT04128579|Drug|EQ001 Placebo|EQ001 Placebo
8380|NCT04128566|Procedure|walking stress test|walk for 30 minutes on a treadmill with either one of the three loading conditions (reduced load = 80% Bodyweight (BW), normal load = 100% BW, increased load = 120% BW). The order of experimental condition will be applied in randomized order determined by block randomization, and the same self-selected walking speed will be used for all conditions.
8381|NCT04128553|Behavioral|Intervention motivational interview group|Motivational interviewing (MI) a client-centered, goal-oriented method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. Motivational interviewing is underpinned by a series of principles that emphasise a collaborative therapeutic relationship in which the autonomy of the patient is respected and the patient's intrinsic resources for change are elicited by the therapist.
8382|NCT04128540|Drug|Fentanyl|fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
8383|NCT04128540|Procedure|Erector spinae plane block|"ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.."
8384|NCT04128527|Device|Placement of laryngeal mask|All participants are experienced in placement of laryngeal masks and placement will be performed according to standard clinical practice.
8385|NCT04128514|Device|Panoptix Toric|Cataract surgery and IOL implantation
8386|NCT04128501|Drug|Azacitidine|Given SC
8387|NCT04128501|Drug|Venetoclax|Given PO
8388|NCT04128488|Other|Abdominal MR Imaging|Imaging to visceral adipose tissue
8389|NCT04128488|Other|Cardiac MRI/MRS|Imaging to evaluate cardiac function and structure
8390|NCT04128488|Other|Oral Glucose Tolerance Testing|Blood testing to evaluate changes in glucose and insulin in response to oral glucose load
8391|NCT04128488|Other|Whole Body, Lumbar Spine, and Hip DEXA Imaging|Imaging to evaluate fat and lean body mass as well as bone mineral density
8392|NCT04128475|Other|N/A - observational study.|N/A - observational study.
8393|NCT04128462|Drug|MNK-6105|L-Ornithine Phenylacetate for IV infusion
8394|NCT04128462|Drug|Placebo|Matching placebo for IV infusion
8395|NCT04128462|Drug|Standard of Care|Lactulose ± rifaximin as SoC treatment for overt HE should be administered per the clinical judgement of the investigator and usual institutional practice.
8396|NCT04128449|Dietary Supplement|docosahexaenoic acid|5 dragees every 24 hours
8397|NCT04128449|Dietary Supplement|Placebo|5 dragees every 24 hours
8398|NCT04128436|Other|Taking blood samples for analyzing progesterone levels|As part of standard in vitro fertilization treatment, Crinone gel will be used starting the next morning following the oocyte pick-up (OPU) as a luteal phase support. On the trigger day, on the day OPU+2/3 (early luteal phase) and on the embryo transfer day (OPU+5, mid luteal phase) blood samples will be taken from patients for evaluating the progesterone levels. Blood samples will be collected at the 6th hour following the morning dose of vaginal progesterone gel. No other intervention will be done to the patients.
8399|NCT04128423|Biological|AMV564|AMV564 will be administered daily
8400|NCT04128397|Device|transcranial magnetic stimulation|before TMS treatment , do fMRI to confirm stimulation site
8401|NCT04128384|Diagnostic Test|Limited electrophysiologic study including measurements of HV- and AH-intervals pre- and post-TAVR|For the purpose of obtaining intracardiac measurements, the quadripolar diagnostic catheter used as temporary pacemaker wire (5F, Woven, Boston Scientific) during TAVR was retracted from the apex and positioned at the His bundle to measure HV- and AH-intervals.
8402|NCT04128371|Biological|Nucala (mepolizumab)|Mepolizumab is a fully humanized monoclonal antibody (IgG1, kappa mAb) supplied as 100 mg of lyophilized powder in sterile, single-dose vials. Mepolizumab 100 mg vials will be reconstituted with 1.2 ml sterile water for injection (according to the product labeling) and secondarily diluted in 100-250 ml of 0.9% normal saline (NaCl) for infusion (to a final concentration of 0.3-7.5 mg/ml).
8403|NCT04128358|Diagnostic Test|Serological assay for blood born viral hepatitis|Qualitative PCR for patients with hepatitis C antibody positive
8404|NCT04128358|Diagnostic Test|Quantitative microbiological test for HCV|Quantitative PCR in those with proven HCV infection
8405|NCT04128345|Device|Use of navigation system|Feasibility assessment of using an integrated navigation system incorporating advanced diffusion MRI, volumentric tumour representation and intraoperative ultrasound
8406|NCT04128332|Radiation|Pre-operative stereotactic ablative body radiotherapy|Stereotactic ablative body radiotherapy is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumour, while limiting the dose to the surrounding tissues.
8408|NCT04128306|Behavioral|Behavioral task|In the task, participants will see an object approaching toward them. During its movement, the object disappears, and the participants have to press a button to indicate when they estimate the object to contact with them. The motion parameters of the ball will be varied. The pre and post-surgery phases will test the participants in a long duration version of the task, approximately 30 minutes. The per surgery phase will be made of a 5 minutes version of the task, and the participants will receive a direct cortical stimulation for 4 seconds, at an intensity of 1 to 10 mA, in the premotor ventral area, or posterior parietal cortex or somesthetic associative areas.
8409|NCT04128306|Procedure|Awake surgery|"The patient is first anesthetized for opening the scalp and skull, then awake. During this waking phase, the surgeon passes a few quick and simple tests to the patient, visual (for example, line bisection), language (for example, repeating a list of words) etc. While doing this task, the neurosurgeon disrupts the functioning of certain brain regions by direct electrical stimulation of the cortex in order to identify the regions whose dysfunction will have an impact on the current task.~During the operation, the areas involved in the construction of the peri-personal space will be stimulated by direct electrical stimulation, for a duration of 4 seconds at an intensity of 1 to 10 mA. These areas are:~Ventral premotor cortex (with the exception of the primary motor cortex controlling the dominant hand, so as not to interfere with the motor response of the patient)~Posterior parietal cortex~Associative somesthetic areas"
8410|NCT04128306|Other|Neurological assessment|The Mini Mental State Evaluation, which generally assesses the cognitive state of an individual through his 6 subtests testing both working memory, episodic and semantic praxies as well as spatio-temporal orientation capacity.
8411|NCT04128306|Other|Neurological assessment|The Wechsler Adult Intelligence Scale was selected for two of its subtests: The Subtest Codes checking the processing of information, visuo-constructive abilities but also attention. The subtest Cubes evaluates the capacities of visuospatial and constructive organizations as well as the referencing of the space in relation to the subject.
8412|NCT04128306|Other|Neurological assessment|The State-Trait Anxiety Inventory, consisting of two self-administered questionnaires: Questionnaire A, measuring the state of anxiety of the person on the present moment and B measuring anxiety as a character trait of the person
8413|NCT04128306|Other|Neurological assessment|The Verbal Fluences test, in its oral version. Categorial and lexical fluences make it possible to quickly realize a possible lack of the word of the person as well as disturbances of working memory or the capacity of inhibition.
8414|NCT04128306|Other|Neurological assessment|The board of the Corsi cubes that evaluates the non-verbal visual-spatial working memory of the participants with a reminder location that tests the visuo-spatial notebook and a reminder to who tests the central administrator of the working memory.
8415|NCT04128306|Other|Neurological assessment|The neurocognitive naming test was chosen to verify correct access to both semantic memory and lexicon, as well as to test the early visual process of image processing necessary for our task.
8416|NCT04128306|Other|Neurological assessment|Benton lines are commonly used to determine possible deficits in the localization of isolated objects or judgment of line direction.
8417|NCT04128306|Other|Neurological assessment|The patient will finally pass a depression assessment test, answering Beck's questionnaire.
8418|NCT04128293|Drug|GSK3640254 Tablet|GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
8419|NCT04128293|Drug|GSK3640254 Capsule|GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
8420|NCT04128280|Procedure|TUDP|a surgery: transurethral dilation of prostate with a columnar balloon
8421|NCT04128280|Procedure|TUIB|a surgery: transurethral incision of bladder neck
8422|NCT04128267|Device|IPC-1000|Delivers pressure to thumbnail for five seconds at a time
8423|NCT04128267|Device|Magnetic resonance imaging|Scan of brain using Magnetic resonance imaging
8424|NCT04128267|Other|Correlative Studies|Administration of questionnaires via computer
8425|NCT04128254|Drug|Apixaban Oral Tablet|Apixaban is a kind of oral anticoagulant drugs used to prevent venous thromboembolism
8426|NCT04128228|Behavioral|8-week outpatient treatment|All patients will receive outpatient treatment for alcohol use disorder for 8 weeks. There will be two appointments each week for individual therapy sessions using cognitive behavioral therapy combined with stress management.
8427|NCT04128215|Behavioral|Control Period|Subjects will complete an 8-week control period of normal lifestyle, followed by the 8-week exercise period.
8428|NCT04128215|Behavioral|Exercise Period|Subjects will complete an 8-week non-weight-bearing all-extremity high intensity interval training (NWA-HIIT). NWA-HIIT will consist of 4x4-min bouts at 90% of maximal heart rate (HRmax) interspersed by 3x3-min bouts at 70% of HRmax. A 10-min warm-up and 5-minute cool-down at 70% of HRmax will be included.
8429|NCT04128202|Behavioral|Sunnyside|The Sunnyside intervention is an online intervention (an interactive website with didactic material and interactive tools) targeting skills to manage mood during and after pregnancy. The Sunnyside intervention will consist of 6weeks of online lessons during pregnancy and booster sessions at 2 weeks, 4 weeks, and 6 weeks postpartum. Each lesson takes approximately 10 minutes to complete.
8430|NCT04128202|Behavioral|Sunnyside Plus|Sunnyside Plus will build upon the Sunnyside intervention, plus include additional education and support to promote breastfeeding. Breastfeeding education and skills will be provided during the 6weeks of online lessons during pregnancy; each lesson takes approximately 10 minutes to complete. Breastfeeding support will continue through 6 weeks postpartum. This postpartum support will involve weekly online lessons(each taking approximately 10 minutes to complete), text support messages(3 sent during weeks 1 and 2, 2 sent during weeks 3 and 4, 1 sent during weeks 5 and 6), and video support calls with a Lactation Educator (LE)provided on an as-needed basis(exception: at least 1 video call is required during both week 1 postpartum and week 2 postpartum).
8431|NCT04128189|Biological|Shingrix|Both arms receive standard 2 doses of Shingrix. Transplanted subjects may receive 3rd dose.
8432|NCT04128176|Drug|Rituximab combined with Omalizumab|Rituximab 1000 mg will be administered by IV infusion 6 months after the patient's initial cycle of rituximab (received in the screening period).Omalizumab (300 mg) will be administered subcutaneously every 2 weeks starting on Day 1 until week 24 (primary endpoint) and again until week 52 (secondary endpoint).
8433|NCT04128163|Drug|QL1206|"subcutaneous injection of 60 mg（60mg:1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
8434|NCT04128163|Drug|Placebos|"subcutaneous injection of（1ml）, Q6M, twice for one year.~Dietary Supplement: Elemental Calcium Oral, at least 500 mg Dietary Supplement: Vitamin D Oral, 1000 IU"
8435|NCT04128137|Drug|Fludrocortisone|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
8436|NCT04128137|Other|Placebo|50 µg/day during one week then augmentation of 50 µg each weeks until a maximum dose of 200 µg/day. And a maintenance phase of 4 weeks at a stable dose
8437|NCT04128124|Other|processing signals of airway pressure and airway flow to calculate entropy|processing of previously recorded data from a dedicated software of airway pressure and airway flow in order to calculate entropy
8438|NCT04128098|Other|Evaluation|"Functional tests: 400-meter walking test, 200-meter brisk walking test, Sorensen test, Shirado test, measurement of maximum isometric force of extensors/back flexors.~3D analysis of locomotion and posture~Test of the flexion-relaxation phenomenon of the lumbar erector muscles"
8439|NCT04128098|Other|Questionnaires|Self-questionnaires: Oswestry, Québec, SF-12, VAS pain, HAD, pain dramatization questionnaire, physical activity questionnaires, VAS and GPE satisfaction, FABQ, GPE functional status and EPICES score.
8440|NCT04128098|Other|Rehabilitation care program|"Personalized global exercises (aerobics) on ergometers~Muscle strengthening with resistance~Balneotherapy~Learning health skills related to their condition (therapeutic education)~Personal and group motivational interviews~Nutritional advice~Relaxation session"
8441|NCT04128085|Drug|TQB3804|A kind of tyrosine kinase inhibitor.
8442|NCT04128072|Drug|Mogamulizumab|• Patients will receive mogamulizumab 1.0 mg/kg IV over at least 1 hour on Days 1, 8, 15 and 22 of the first 28 day treatment cycle (C1) and on Days 1 and 15 of subsequent 28 day cycle (C2).
8443|NCT04128072|Radiation|Total Skin Electron Beam Therapy (TSEB)|"After completion of C2, patients will be administered TSEB at a dose of 12 Gy in 8 fractions (4 fractions per week). TSEB will start 28 days (window of + 7 days) after mogamulizumab (C2 D1).~In case of toxicity from mogamulizumab, the maximum delay permitted for the start of TSEB is 2 weeks.~If recovery to at least grade 1 from toxicity exceeds the 2 weeks interval, please contact the medical monitor.~Mogamulizumab is stopped during TSEB administration."
8444|NCT04128072|Drug|Mogamulizumab (subsequent cycles post TSEB)|"• Mogamulizumab will be restarted at a dose of 1.0 mg/kg IV on Days 1, 8, 15 and 22 for cycle 3. Subsequent cycles will be administered as for C2.~Treatment with mogamulizumab will be continued until disease progression (PD) or the occurrence of another withdrawal criterion."
8445|NCT04128059|Drug|BVRS-GamVac-Combi|"BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration"
8446|NCT04128059|Other|placebo|placebo
8447|NCT04128046|Procedure|PRFM injection|Using a 27-gauge microcannula, a total of 4 mL of PRFM was injected intradermally into the mid-cheek and NLF (2 mL for each site) on one side of the face.
8481|NCT04127747|Drug|Standard dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day, 14th day of admission, and on the 6th, 12th and 18th month after that.
8448|NCT04128046|Procedure|Saline injection|Using a 27-gauge microcannula, a total of 4 mL of saline was injected intradermally into the mid-cheek and NLF (2 mL for each site) on the contralateral side of the face.
8449|NCT04128033|Other|Puncture of the RP6 point|"Puncture of RP6 San Yin Jiao point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus."
8450|NCT04128033|Other|Puncture of the placebo point|"Puncture of a placebo point outside the meridian, with no effect"
8451|NCT04128020|Drug|Nivolumab|Nivolumab
8452|NCT04128020|Drug|Azacitidine|Azacitidine
8453|NCT04128007|Drug|ARQ-154|active vs vehicle
8454|NCT04127994|Other|Comparing 3 versus 6 meals in type 2 diabetes patients|We will compare a 3 meals regimen versus a 6 meal regimen in patients with type 2 diabetes and overweight or obesity, to analyze which of the regimens have better outcomes in glycemic variability
8455|NCT04127981|Diagnostic Test|18F-FDG PET + Dexa Scan|18F-FDG PET will be compared with Dexa Scan result within and between arms.
8456|NCT04127968|Drug|Vitamin A|Children in intervention group will receive 50,000 IU vitamin A after being randomized.
8457|NCT04127968|Drug|Oil|Children in control group will receive equal volume of oil.
8458|NCT04127955|Other|Theory of Planned Behavior based Physical Activity Intervention|"Health education: The first component of intervention consisted of one session 30 minutes educational lesson relation to physical activity.~Group walking: The format of the 15-minute group walking session included 5 minutes of warm-up, 5 minute moderate intensity walking, 5 minute cool-down.~Counseling (individually tailored): The nurse received training about motivational interview technique for use in their physical activity counseling with participants. Using pedometers and step diary to set goals and monitor progress.~Pedometer: pedometer will be used objective physical activity assessment. Measurement of physical activity levels, wearing a pedometer (Omron HJ321E) on a belt over one hip, all day for 7 days, removing for bathing and sleeping. A diary is also provided to record step count. The pedometer will be used for baseline and outcome measurement of step-counts for the trial."
8459|NCT04127942|Procedure|platelet-rich plasma injection therapy of TMD|The administer injected 1cc PRP in the superior temporomandibular disk joint space by ultrasound guidance.
8460|NCT04127929|Other|Restoration of cavities using glass carbomer material (GCP Dental)|Detection of caries then restoration of cavities
8461|NCT04127929|Other|Restoration of cavities using nanocomposite resin (Tokuyama Estelite Posterior)|Detection of caries then restoration of cavities
8462|NCT04127916|Drug|Bendamustine|To investigate the efficacy and safety of bendamustine plus rituximab in patients with mantle cell lymphoma.
8463|NCT04127903|Other|the Length of Right Main Stem Bronchus|The distance between the carina and the proximal margin of the right upper lobe orifice on the coronal plane measured by computerised tomography
8464|NCT04127890|Dietary Supplement|ELO Water|oxygen-enriched water
8465|NCT04127890|Dietary Supplement|Placebo drinking water|bottled drinking water
8466|NCT04127877|Device|NICAS|Electric regional bio impedance device
8467|NCT04127864|Procedure|Colorectal cancer surgery|All participants will undergo surgery for colorectal cancer.
8468|NCT04127851|Drug|TJO-018|TJO-018 / one drop / 6 times daily in both eyes
8469|NCT04127851|Drug|Cyclosporine Ophthalmic Emulsion 0.05%|Cyclosporine / one drop / twice daily in both eyes
8470|NCT04127851|Drug|TJO-018 + Cyclosporine Ophthalmic Emulsion 0.05%|TJO-018 one drop 6 times daily & Cyclosporine one drop twice daily in both eyes
8471|NCT04127838|Behavioral|Low Vision Occupational Therapy|Occupational therapy may include methods to effectively modify environments (such as addition of task lighting), training in the use of assistive technology (such as voice activated devices), teaching new skills (such as sensory substitution) and prevention of accidents and injury (such as home safety modifications).
8472|NCT04127825|Procedure|Acute Normovolemic Hemodilution (ANH)|Acute normovolemic hemodilution (ANH) is a method of blood conservation used to reduce the amount of donor blood transfused. It involves removing blood from appropriate patients immediately after the induction of anesthesia, replacing the volume lost with colloids (e.g. 5% albumin), then storing and returning this blood to the patient at the completion of the surgical procedures.
8473|NCT04127812|Behavioral|Savor the Flavor|A series of five interactive classroom lessons focused on mindfulness in eating.
8474|NCT04127799|Other|Hospital-Community-Family-Care Management Platform Online|Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
8475|NCT04127799|Other|Subjects with AF conventional treatment|Subjects with standardized treatment according to latest guidelines via conventional visit.
8476|NCT04127786|Biological|Purified vero rabies vaccine - serum free VRVg-2|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
8477|NCT04127786|Biological|Purified inactivated rabies vaccine (Verorab)|Pharmaceutical form:Freeze-dried Route of administration: Intramuscular
8478|NCT04127786|Biological|Purified inactivated rabies vaccine (Imovax rabies)|Pharmaceutical form: Freeze-dried Route of administration: Intramuscular
8479|NCT04127773|Device|oro gastric tube|According to clinical need, an orogastric tube will be inserted at birth using the group method in VLBW infants in whom an umbilical catheter has been placed. An X-ray chest will be performed according to routine clinical practice to assess the position of the umbilical catheter. On the same X-ray the position of the gastric tube will be assessed by a radiologist blinded to the method used for orogastric tube placement.
8480|NCT04127760|Radiation|radiotherapy|Radiotherapy would start within 2 months after the operation, and 5 days of radiotherapy is performed every week. The dose of each radiotherapy is 1.8 Gy for 6 weeks, and the total dose is 54 Gy.
8574|NCT04126811|Drug|Apatinib Mesylate|Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
8482|NCT04127747|Drug|Individualized dose of rituximab|Patients in this group will accept RTX 500mg treatment on the first day of admission. Patients will be followed-up every 3 months, and will receive one RTX 500mg treatment, if CD19 B cell count > 1%, or dsDNA titer increased (dsDNA antibody positive, and increased more than 100% compared with the previous time), or complement C3 level decreased (lower than normal value, and decreased more than 50% compared with the previous time).
8483|NCT04127734|Procedure|The efficacy of various interventions for anastomotic leakage after rectal cancer resection are investigated|Investigated interventions comprise conservative, radiological, endoscopic and surgical (including stoma formation) interventions
8484|NCT04127721|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
8485|NCT04127721|Drug|Busulfan|Given IV
8486|NCT04127721|Drug|Fludarabine|Given IV
8487|NCT04127721|Drug|Itacitinib|Given PO
8488|NCT04127721|Drug|Methotrexate|Given IV
8489|NCT04127721|Drug|Tacrolimus|Given IV and PO
8490|NCT04127708|Biological|acupuncture|acupuncture group and control group
8491|NCT04127695|Drug|ABBV-0805|ABBV-0805 administered by IV infusion.
8492|NCT04127695|Drug|Placebo ABBV-0805|Placebo ABBV-0805 administered by IV infusion.
8493|NCT04127682|Behavioral|Antibiotic Prescription Audit|Baseline data about outpatient antibiotic prescriptions for ARIs will be collected then compared to guidelines. The multiple audit meetings will be conducted with recruited pediatricians to educate them about appropriate prescriptions.
8494|NCT04127669|Drug|OSU 6162|The active ingredient of OSU6162 is the S-enantiomer with the chemical name (S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride. The substance is a white powder with a melting point of 177-182°C. Solubility in water is > 2000 mg/ml. Current laboratory code used is OSU6162-HCl. In trial protocol, OSU6162-HCl is shortened to OSU6162.
8495|NCT04127669|Drug|Placebo oral tablet|Circular coated tablet (with identical appearance to active treatment tablets 15 mg).
8496|NCT04127656|Other|Amino Acid-Based Experimental Study Formula|Amino acid-based study formula; feed ad libitum
8497|NCT04127630|Procedure|mobilization of the larynx|we aim to asses with an magnetic resonance imaging the compressibility of the oesophagus with LPEC
8498|NCT04127617|Other|Osteopathic Manipulative Treatment|"Osteopathic treatment~Dural system:~L5-S1 decompression; sacred decompression among the iliacs; occipital-sphenoid approach; decongestion of occipital condyles~Fascial system:~fascial techniques in the abdominal region: right hypochondrium, epigastrium, left hypochondrium, right side, mesogastrium, left side, right iliac area, hypogastrium, left iliac area; relationship with corresponding vertebral levels (eg, hypogastrium); fibro scar adhesions treatment.~Biomechanical system:~diaphragm rebalancing with respect to anatomical insertions; passive mobilization of dysfunctional areas. Nursing education as described in Standard Treatment"
8499|NCT04127617|Other|Nursing Educational Care|"Nursing education~assessment of the best personal evacuation strategy concerning the quality of life, individual resources, and level of autonomy;~assessment of the correct execution of the identified evacuation manoeuvre (digital stimulation, manual removal, reflex stimulation, transanal irrigation, use of micro-enemas or suppositories;~identification of the best postural strategies during evacuation;~nutrition and proper hydration education;~education in completing the evacuation diary;~colonic massage training;~verification of the correct hiring of any previously prescribed laxative drugs."
8500|NCT04127604|Behavioral|Integrated Treatment Adherence Program for Veterans (ITAP-VA)|Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.
8501|NCT04127604|Behavioral|Safety Assessment and Follow-up Evaluation (SAFE)|Measurement-based care assessment and evaluation.
8502|NCT04127591|Other|exosome|Collect exosomes in peripheral blood of patients and extract miRNAs from them.
8503|NCT04127578|Biological|PR001A|Participants will receive a single dose of PR001A, administered intracisternally.
8504|NCT04127578|Other|Sham procedure|Participants will receive a one-time sham surgical procedure.
8505|NCT04127552|Procedure|Adrenalectomy|Adrenalectomy accordint to 2016 ESE guidelines
8506|NCT04127539|Behavioral|Strong & Steady exercise program|The community-based group exercise program S&S, with strengthening and balance exercise as the main components. The participants will attend a once-weekly, one hour supervised session. The exercises that will be used can be found in the S&S handbook which includes different difficulty levels. All instructors are volunteers and have completed the S&S education. Each exercise session will consist of a warm-up (5-8 min.), endurance exercises (10-15 min.), strength exercises (15 min.), balance exercises (20 min.) and a cool down/stretching (5 min.). In addition to attending the group exercises, the participants will be taught and encouraged to do home exercises twice a week from hand out leaflets that can be found at www.sterkogstodig.no.
8507|NCT04127539|Behavioral|Control|Will be given the Norwegian recommendations for physical activity: https://www.helsedirektoratet.no/faglige-rad/fysisk-aktivitet-for-barn-unge-voksne-eldre-og-gravide/fysisk-aktivitet-for-voksne-og-eldre
8508|NCT04127526|Other|Connection to Environment with Cognitive Therapy (CONNECT)|8 sessions of strategies to reduce dissociation. Flexible, toolbox approach including but not limited to grounding strategies using objects, therapy oils and naming objects in the room.
8509|NCT04127513|Drug|Ammonium Lactate|12% ammonium lactate moisturizing cream
8510|NCT04127513|Drug|Urea|10% urea moisturizing cream
8511|NCT04127500|Drug|dexmedetomidine|dexmedetomidine
8512|NCT04127461|Device|Medtronic endoscope|The endoscope is a minimally invasive tool used to remove veins from the leg traditionally used for CABG.
8513|NCT04127448|Other|Exergaming Training Group|"Training was given using X-box 360 Kinect. Dr. Kawashima's brain and body exercise game comprising of multiple cognitive games out of which 4 selected games were played by the participants. These games were Traffic control (participants have to guide the colored cars into their matching colored tunnels by using their arms), balloon buster (players pop numbered balloons in order from the lowest to the highest), pop till u drop, (match the color that appears on screen with the balloon of same color) and strike a pose (participant have to remember the poses shown and then copy them after few seconds). Games were played for 10 minutes initially then the duration was gradually increased to 30 minutes each session for 3 days/week and duration of 6 weeks. The session included 5-minute warm up, 20-minute interactive gaming, and 5-minute cool down."
8611|NCT04126421|Device|Prosthesis component (acetabular cup) E1 cup|Semented acetabuar cup With E1 cup
8514|NCT04127448|Other|Aerobic Exercise Group|Session of 30-35 minutes, 3 days a week for 6 weeks was given using treadmill (model no TMX58 220). Time and intensity was gradually increased over the duration of 6 weeks. Starting from 10 minutes in 1st week, every 5 minutes was added to aerobics phase to each week until patient reached to 35 minutes in week 6 maintaining the intensity of 40-60% of heart rate reserve (%HRR).
8515|NCT04127409|Other|Control Chicken-meat|
8516|NCT04127409|Other|Control Eggs|
8517|NCT04127409|Other|Omega-3-PUFA Enriched Chicken-meat|
8518|NCT04127409|Other|Omega-3PUFA Enriched Eggs|
8519|NCT04127396|Drug|Lenvatinib Pill|Lenvatinib capsules will be admministered orally, once daily in continuous 28-day cycles. Body weight (BW)＞60 kilograms(kg)-Lenvatinib 12 mg (taken as three 4-mg capsules); BW＜60kg-Lenvatinib 8 mg (taken as two 4-mg capsules)
8520|NCT04127396|Procedure|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of lenvatinib . TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
8521|NCT04127396|Drug|Sorafenib|Sorafenib capsules will be admministered orally, 400 mg twice daily (BID) oral dosing.
8522|NCT04127396|Procedure|Transarterial chemoembolization(TACE)|TACE will be performed one day after oral administration of Sorafenib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of center.
8523|NCT04127383|Device|Assessment of Burden of Chronic Conditions (ABCC)-tool|The tool consists of a questionnaire, a visualisation using balloons, and treatment advice. A patient will complete the questionnaire before consultation. The questionnaire measures the experienced burden of the chronic condition(s), and several risk factors. The questionnaire consists of a generic part and disease-specific parts. The generic questionnaire will be combined with any amount of disease-specific questionnaires (i.e. COPD, asthma, DM2 and heart failure), to form a single personalised scale and balloon chart for each individual patient. Outcomes of the questionnaire are visualised using balloons. The healthcare provider opens the visualisation during consultation. A balloon represents a domain, and the colour and height indicate a patient's score on that domain. If a patient and healthcare provider can select a balloon by clicking on it, treatment advice is shown by means of pop-ups. Based on the discussion following treatment advice, personal care plans can be determined.
8524|NCT04127370|Procedure|Bariatric Surgery|The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
8525|NCT04127357|Procedure|1450 ppm fluoride toothpaste brushing x Resin sealing (FluroShield, Dentsply, Brazil).|"After randomization of the children, the selected molars were allocated through a randomized sequence list in 2 groups: A. Brushing with 1450 ppm fluoride toothpaste, donated by the researcher; B. Resin Sealing (FluroShield, Dentsply, Brazil).~The teeth included in the second group (group B) underwent a second randomization: B1. With absolute isolation; B2. With relative isolation. For the group with absolute isolation, topical anesthesia and local papillary infiltration were performed for subsequent staple placement. Relative isolation was performed with cotton rollers and moisture control suction. The sealant selected was the opaque fluroshield to facilitate visualization upon visual examination during reevaluations and was applied following the manufacturer's standards. The teeth were clinically and radiographically followed at 6 and 12 months and two sessions of motivation reinforcement were performed through video and brush change at 3 and 9 months."
8526|NCT04127344|Behavioral|Music Therapy Intervention|Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
8527|NCT04127331|Device|Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
8528|NCT04127318|Behavioral|Pedaling Group|Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
8529|NCT04127305|Other|No Intervention|No Intervention
8530|NCT04127292|Behavioral|Emotional Self Awareness (ESA) Individual Feedback|Virtual Human Interaction (VHI) to train outpatient clinicians in emotional self-awareness (ESA) and receive clinician-focused, comprehensive feedback in ESA
8531|NCT04127279|Biological|Cream|"The enriched cream is self-administered and contains a blend of 4 essential oils, namely Juniperus phoenicea gum extract, Copaifera officinalis resin, Aniba rosaeodora wood oil and Juniperus virginiana oil.~The placebo cream is devoid of the essential oils"
8532|NCT04127253|Device|Sooma transcranial direct current stimulation device plus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the stimulation of the transcranial direct current.
8533|NCT04127253|Device|Placebo Sooma transcranial direct current stimulation deviceplus Brain training tools|This group will carry out an observation training of actions and motor imagery in combination with the placebo stimulation of the transcranial direct current, where it will be acrtivo during 15 seconds and then it will be turned off during the rest of the intervention.
8534|NCT04127253|Behavioral|Brain training tools in isolation|This group will act as a control, they will only carry out the training of action observation and motor imagery.
8535|NCT04127240|Other|DASH diet containing daily intakes of red meat|Each participant was randomized to consume 3 or 6 ounces of red meat as a part of the DASH dietary pattern for 12-weeks.
8536|NCT04127227|Drug|sintilimab,pegaspargase,gemcitabine,oxaliplatin|"All patients enrolled in the study will accept sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimenas their first-line therapy.~Stage IV patients with localized disease will be treated with consolidative RT. Patients with CR or PR will receive sintilimab maintenance therapy"
8537|NCT04127214|Other|ITA Integrated Treatment|The ITA Model combines outpatient intervention (mainly psychotherapy), day hospital care and hospitalization as a function of patients' characteristics. Case conceptualization of the psychological processes of patients is formulated and revised within a team including psychologists, psychotherapists, psychiatrists, nutritionists, physicians, nurses, and social workers. The major emphasis of the ITA model is on psychological interventions which include individual psychotherapy, family therapy and/or guidance, and group therapy of various formats and contents (e.g., drug abuse, mindfulness, emotion work) tailored to the needs of each patient. However, when required, drugs are prescribed adjusting type of medication and dosage to the need of the patient.
8538|NCT04127201|Behavioral|en_línea|This is an online adaptation of the LEARN program. A self-help weight control program developed by Kelly Brownell in 2004.
8539|NCT04127201|Behavioral|Group therapy|This is a traditional behavioral weight control program
8540|NCT04127175|Device|Volpara|This tool represents a physics-based model which extract pixel-wise information from the FFDM or DBT images, and combine it with metadata information from the DICOM header and appropriate linear attenuation coefficients of both adipose and glandular tissue.
8541|NCT04127149|Diagnostic Test|Ultrasound scan|The group uses an ultrasound device for the consultation.
8542|NCT04127136|Behavioral|Multi-disciplinary obesity management therapy|In the 4th module, the aim is to provide cognitive awareness and change. The most common problems in losing weight, management of the environmental factors, using the technology to aid weight loss, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture issues are examined. The aim of the 5th module is to change learning to behavior. In order to provide reinforcement, the topics of the previous modules are reviewed, and healthy nutrition, the nutrition profiles of the patients, depression and anxiety, psychological trauma, and affirmation issues are addressed in the group meetings. In the last module, patients are expected to discuss each other's experiences and opinions in group meetings. In all modules, in addition to group meetings, there are monthly individual meetings evaluating the progression.
8543|NCT04127110|Drug|Lorlatinib|Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
8544|NCT04127097|Other|cartoon group|The children in the groups were distracted by watching cartoon 2 minutes before treatment, until the process was over
8545|NCT04127084|Drug|SGLT2 Inhibition|Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
8546|NCT04127071|Procedure|Ultrasound-guided Needle Aspiration Procedure|The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.
8547|NCT04127071|Procedure|Incision and Drainage (I&D)|The current standard procedure to drain an abscess of purulent material.
8548|NCT04127058|Drug|Iloperidone|Oral Tablet
8549|NCT04127045|Procedure|IMN-Group|Most intertrochanteric fractures are managed with an intramedullary nail, which allows for impaction at the fracture site. The intramedullary nail is placed directly into the marrow canal of the bone through an opening made at the top of the greater trochanter. A lag screw is then placed through the nail and up into the neck and head of the hip. As with the compression hip screw, sliding of the lag screw and impaction of the fracture take place.
8550|NCT04127045|Procedure|HA-Group|In the older patient, the chance that the head of the femur is damaged in this way is higher. It is generally felt that for these displaced fractures, patients will do better if some of the components of the hip are replaced. In some cases, this can mean a replacement of the ball, or head of the femur (hemiarthroplasty).
8551|NCT04127032|Behavioral|PSP Wellbeing Course|A tailored ICBT intervention will be delivered to public safety personnel who report symptoms of depression, anxiety, or posttraumatic stress. Clients will choose whether they prefer weekly therapist support, twice-weekly therapist support, or as-needed therapist support. Clients will also choose the number of weeks (between 8-16) for which they would like support.
8552|NCT04127019|Drug|Paclitaxel|Paclitaxel chemotherapy (injection)
8553|NCT04127019|Drug|Docetaxel|Docetaxel chemotherapy (injection)
8554|NCT04127019|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
8555|NCT04127019|Drug|epirubicin|Epirubicin chemotherapy (injection)
8556|NCT04127019|Drug|5-fluorouracil|5-fluorouracil chemotherapy (injection)
8557|NCT04126993|Drug|Camrelizumab,|Camrelizumab+ Apatinib test group: intravenous injection once every three weeks, Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
8558|NCT04126993|Drug|Apatinib|Apatinib single drug control group: Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
8559|NCT04126980|Behavioral|Rates of readmission and reoperation|All patients were then followed-up for 180 days after the indexed surgery of lumbar fusion. All-causes of re-hospitalization and re-operations for lumbar spine fusion, were analyzed at 30, 60 and 180 days for comparison between the ED group and the comparison group.
8560|NCT04126967|Diagnostic Test|NGS patients|The next generation sequencing technique (NGS) was used to monitor the minimal residual lesions after allogeneic hematopoietic stem cell transplantation
8561|NCT04126954|Other|Serum PTH concentrations results|To compare serum PTH concentrations results in patients with primary or secondary hyperPTH resulting from phosphocalcic pathology before and three months after initiation of cinacalcet therapy.
8562|NCT04126941|Other|Serum calcium concentrations results|To compare serum calcium concentrations results in patients with hypoparathyroidism before and three months after initiation of teriparatide therapy
8563|NCT04126928|Diagnostic Test|Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.|
8564|NCT04126915|Genetic|Whole Exome Sequencing|Whole Exome Sequencing of the patient's primary tumor, metastases
8565|NCT04126902|Other|interleukin-6, presepsin and pentraxin-3|measurements and compare
8566|NCT04126889|Other|questionnaire survey|questionnaire survey
8567|NCT04126876|Drug|Tilsotolimod|Intradermal, single injection of 1 ml (8 mg) Tilsotolimod (IMO-2125) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
8568|NCT04126876|Drug|Saline (0.9% sodium chloride)|Intradermal, single injection of 1 ml plain saline (0.9% sodium chloride) at the primary melanoma excision site, one week prior to sentinel node biopsy (SNB).
8570|NCT04126824|Drug|Triamcinolone|40 mg triamcinolone administered as a Superior Hypogastric Nerve Block (SHNB)
8571|NCT04126824|Drug|Bupivacaine|0.5% bupivacaine (20 mL) administered as a Superior Hypogastric Nerve Block (SHNB).
8572|NCT04126824|Other|Iohexol contrast|The appropriate amount of contrast to enable visualization of the nerve block under fluoroscopy given as a Superior Hypogastric Nerve Block (SHNB) will be administered.
8573|NCT04126811|Drug|Apatinib Mesylate, Pirarubicin, Ifosfamide|Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
8575|NCT04126811|Drug|Pirarubicin, Ifosfamide|Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks
8576|NCT04126798|Other|Behavioural|Assessment of the 2BALANCE protocol: dual-task protocol consisting of a motor task, cognitive task, and motor-cognitive dual-tasks
8577|NCT04126785|Other|High Intensity Interval Exercise in Heated Water-Based|High intensity interval exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level of rate perceived exertion (RPE) scale, followed by 21 min of HIIE, alternating 1 min of jogging/running at 15-17 (hard-very hard) level with 2 min of walking at 9-11 (very light-fairly light) level of RPE.
8578|NCT04126785|Other|Continuous Moderate Exercise in Heated Water-Based|Continuous moderate exercise will perform at controlled heated water-base (30 e 32 ºC). Subject will be submerged at the xiphoid process level. The session will consist in 4 min walking (warm-up) at 9 level (light) of RPE, followed by 26 min of MICE, walking at 11-13 (fairly light)level of RPE.
8579|NCT04126785|Other|Control Group|CON session will perform at controlled heated water-base (30 e 32 ºC). Subject will be seated in a chair and submerged at the until xiphoid process level for 30 min.
8580|NCT04126759|Device|P0.3|Subjects will perform daily measurements on the IMD (Prototype 0.3) for 35 days.
8581|NCT04126733|Drug|Regorafenib (BAY73-4506, Stivarga)|Regorafenib administered as oral tablets given every day for 3 weeks of each 28 days treatment cycle (i.e., 3 weeks on, 1 week off)
8582|NCT04126733|Biological|Nivolumab (Opdivo)|Administered on day 1 of every treatment cycle.
8583|NCT04126720|Dietary Supplement|topical corticosteroids and vitamin E suplements|
8584|NCT04126720|Drug|Topical corticosteroid and placebo capsules|
8585|NCT04126707|Drug|[14C] HQP1351|Orally, single dose of 30mg
8586|NCT04126694|Behavioral|CBT with smartphone application SenseSupport|SenseSupport intervention system used as an augment to a 12 week in-person CBT treatment for transdiagnostic binge eating pathology
8587|NCT04126681|Drug|HQP1351|HQP1351 is a new, bioavailable inhibitor against BCRABLWT and a broad spectrum of BCR-ABL mutants including BCR-ABLT315I
8588|NCT04126681|Drug|Hydroxyurea or Interferon-based therapy|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
8589|NCT04126681|Drug|Homoharringtonine|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
8590|NCT04126681|Drug|Imatinib, Dasatinib or Nilotinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines.
8591|NCT04126668|Drug|CM082 with fed or fasting|The two groups of subjects were given an equal dose of CM082 tablet (200 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of CM082.
8592|NCT04126655|Drug|Arfolitixorin|Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate
8593|NCT04126642|Behavioral|Assessment only group|Individuals randomized to this group will receive radiation therapy as usual plus baseline, follow-up, and EMA assessments.
8594|NCT04126642|Behavioral|Intervention group|Individuals randomized to the intervention group will complete the same measures (in person and daily EMAs) as the assessment only group, but will additionally receive messaging that is tailored to patient responses on EMAs.
8595|NCT04126616|Diagnostic Test|chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent|chest MRI will be performed at rest and after moderate exercise
8596|NCT04126603|Drug|Semaglutide|0.25mg/week for week 0 - 4 , then increasing to 0.5mg/week for weeks 5 - 8, then 1 mg/week for week 9 - 24 weeks
8597|NCT04126603|Drug|Placebos|Placebo injection
8598|NCT04126590|Biological|KN044|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN044: 0.03mg/kg,0.3 mg/kg,1 mg/kg,3 mg/kg,6 mg/kg,10 mg/kg."
8599|NCT04126577|Biological|blood samples|4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
8600|NCT04126564|Behavioral|Inner Engineering Online|Inner Engineering Online (IEO) is a web based intervention administered by the Isha Foundation, a not-for-profit, global, volunteer-based organization.The Inner engineering online program is a holistic tool for promoting well-being that teaches individuals how to mindfully and effectively respond to daily stressors using yogic sciences. The program offers guided meditation and yoga practices to promote harmonizing mind-body-emotion, and energy of the individual while simultaneously promoting mindfulness, joy, and vitality. It includes seven modules of 90 minutes each, discussing meditations & yoga.
8601|NCT04126564|Behavioral|Reading a book/ journal|Reading a book regularly promotes knowledge enhancement, reduces stress and enhances memory among other benefits. For the purpose of this study, we advocate reading any book/ journal of participants choice routinely.
8602|NCT04126551|Other|Methylation status|Participants will be recruited, and muscle biopsies will be obtained for methylation analyses and measuring mitochondrial function
8603|NCT04126538|Drug|pirfenidone capsule|In the patient group, pirfenidone capsule was taken orally once for 400mg
8604|NCT04126538|Drug|pirfenidone capsule|Healthy subjects took pirfenidone capsule 400mg once orally
8605|NCT04126525|Drug|Pyrotinib|dual HER2 blockade in the neoadjuvant setting
8606|NCT04126512|Other|PDA ligation|PDA ligation was performed at bedside, if a local cardiac surgery team was available, or in the case this service was not available, infants were referred to off-site specialist paediatric cardiac surgical services, where PDA ligation was performed.
8607|NCT04126486|Other|AF Detection Intervention|Zio® XT monitor
8608|NCT04126473|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
8609|NCT04126460|Drug|Toripalimab|Toripalimab is a type of PD-1 antibody
8610|NCT04126434|Device|mask|facemask
13193|NCT04088383|Other|Amnios™ RT|Acellular human allograft
8613|NCT04126408|Device|gammaCore|The intervention consists of a transcutaneous non-invasive stimulation of the cervical branch of the vagus nerve (nVNS) using gammaCore, an FDA approved device for the treatment of migraine and cluster headache. This will be compared to the sham device, which is the same device which will not provide stimulation to the nerve. Stimulation frequency will be identical to the frequency used in previous nVNS studies for the treatment of migraine headache.
8614|NCT04126395|Diagnostic Test|Movement Assessment Battery for Children 2(M-ABC-2)|The M-ABC-2 is a motor performance test for children aged 3 trough 16 years of age. We will use Dutch-Flemish norms.
8615|NCT04126395|Diagnostic Test|Developmental Coordination Disorder - Questionnaire (DCD-Q)|The DCD-Q is a brief parent questionnaire designed to screen for the presence of DCD in children aged 5 trough 15 years of age. We will use Dutch norms.
8616|NCT04126395|Diagnostic Test|Social Responsiveness Scale 2 (SRS-2)|The SRS-2 is a parent questionnaire designed to identify social impairments associated with ASD in children 4 trough 18 years of age. We will used Dutch norms.
8617|NCT04126395|Other|Retrospective Video Analysis|Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
8618|NCT04126382|Procedure|Intubate-Surfactant-Extubate(INSURE)|Infants are given an endotracheal intubation, with manual lung inflation in order to keep the oxygen supply，and the surfactant(kelisu,China Resources Shuanghe Pharmaceutical) was slowly instilled into the airway through the tracheal tube, and the tracheal tube was removed for non-invasive NCPAP(nasal continuous positive airway pressure)-assisted breathing.
8619|NCT04126382|Procedure|less invasive surfactant administration(LISA)|Infants are spontaneously breathing with nasal CPAP(continuous positive airway pressure) support without manual lung inflation and surfactant(kelisu,China Resources Shuanghe Pharmaceutical) is administered through vocal cords via a smaller catheter.
8620|NCT04126369|Other|mindfulness intervention|The mindfulness program is conducted in a group session of up to 10 people. Each session lasts 2 hours. A total of 12 sessions will be conducted by a practitioner who is specifically trained in this type of programme.
8621|NCT04126369|Other|psycho educative programme|The psycho-educational control intervention will follow the same format and structure as the mindfulness meditation intervention in terms of group format, session duration and frequency. This is a therapeutic education programme developed for several years in the neurology department of the university hospital of Lyon and Grenoble. The program follows the repository recommended by the french league against epilepsy.
8622|NCT04126356|Procedure|mobilization of the larynx|Check the intubation conditions during laryngoscopy without external mobilization of the larynx, with Sellick manoeuvre or with low paratracheal esophagal compression.
8623|NCT04126343|Drug|Padsevonil|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period"
8624|NCT04126343|Drug|Moxifloxacin|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive moxifloxacin once during the Treatment Period"
8625|NCT04126343|Drug|Placebo|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use~Study participants will receive placebo in a pre-specified sequence during the Treatment Period to match padsevonil and maintain the blinding"
8626|NCT04126330|Dietary Supplement|Probiotic, Omega-3, Vitamin D supplement|"The first supplement we would like to assess is named VNP and is composed by Omega-3 Active and vitamin D. It contains a total of 1100 mg fish oils: 640 mg Omega-3 and with 300 mg eicosapentaenoic acid (EPA), 220 mg docosahexaenoic acid (DHA) plus 200 IU Vitamin D per daily dose (2 capsules).~The second supplement we investigate is four-strain probiotics combination based on the commercially available formulation HOWARU® by DuPont; two capsules containing 10 billion CFU total (supplied by Pfizer but manufactured by Danisco, DuPont). The probiotic specific composition, contains equal amounts of each strain per capsule (1.25 x 109 CFU each): Bifidobacterium lactis Bi-07, Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus NCFM, Bifidobacterium lactis Bl-04. One capsule contains 5 billion CFU (Swedish milliards)."
8627|NCT04126330|Dietary Supplement|Placebo|Placebo generated for probiotic and omega-3/vitamin D supplements
8628|NCT04126317|Drug|aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
8629|NCT04126317|Drug|High-Dose aflibercept|Intravitreally (IVT) administered as a liquid formulation in a vial
8630|NCT04126304|Drug|Azithromycin|If the diagnosis is common cold, acute bronchitis or post-infection cough ，treated with non-macrolides when the mycoplasma colloidal gold test is negative, treated with azithromycin when colloidal gold test is positive.
8631|NCT04126304|Drug|non-macrolides antibiotics|If the diagnosis is community-acquired pneumonia with negative mycoplasma antibody-granule agglutination, non-macrolides are used for treatment
8632|NCT04126304|Diagnostic Test|Mycoplasma detection|"common cold, acute bronchitis or post-infection cough :MPlgM colloidal gold detection;Pharyngeal swab MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection~community-acquired pneumonia:mycoplasma antigen antibody particle agglutination detection ;Sputum MP-RNA PCR, mutated gene detection at 2063 and 2064 site of macrolide-resistant 23S rRNA II region detection"
8633|NCT04126304|Other|Data collection|"Common cold:On enrollment, day 3 and day 7, scores were collected based on the Canadian acute respiratory diseases and influenza scale (CARIFS scale), success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~Acute bronchitis :on enrollment, day 3, and day 7, the Likert 7 subscale was used to score the cough severity questionnaire, collect the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate.~Post-infection cough:on the day after outpatient visit, day 3, day 7, and day 14, the cough severity questionnaire (Likert 7 subscale) was used to score the success rate of initial treatment, antimicrobial conversion rate, intravenous rehydration rate, pneumonia conversion rate, re-visit rate, and hospitalization rate."
8634|NCT04126304|Other|Data collection|Acquisition of children hospitalized time, heating time, mixed infection, drug (azithromycin, tetracycline, quinolone) dose and use time, pulmonary complication (pleural effusion, atelectasis, necrotizing pneumonia, interstitial pneumonia, occlusive bronchitis, occlusive bronchiolitis, lung, emphysema, lung abscess, bronchiectasis, transparent), pleural puncture/drainage, bronchoscope, oxygen time, into the ICU, mechanical ventilation time, surgery, and deaths and re-visit, hospitalization, surgery and death within 30 days after discharge
8635|NCT04126291|Behavioral|Evaluation of whiteboard videos|Participants will be provided an internet link via email to access the videos and questionnaires through REDCap (Research Electronic Data Capture), and responses will be tracked. Before viewing, participants will complete a pre-questionnaire to collect demographic and practice data and ratings of perceived self-efficacy/confidence and knowledge in talking about weight-related issues. This pre-questionnaire only needs to be completed once. Participants will then be asked to watch each video. Immediately after watching each video, participants will rate their perceived self-efficacy/confidence and knowledge to help elucidate outstanding educational gaps. For those who consent to do a follow up questionnaire four-six months later, they will be sent an email link to complete a satisfaction questionnaire and rate their perceived self-efficacy/confidence and change in practice to help elucidate outstanding educational gaps.
8636|NCT04126278|Drug|Barbotage|Administered as per standard of care
8637|NCT04126278|Drug|Dexamethasone|4 mg of dexamethasone
8638|NCT04126265|Device|Artificial intelligence assisted colonoscopy|The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
8639|NCT04126252|Drug|Sildenafil Citrate 50Mg Tab|The Group A received sildenafil citrate 50 mg on demand for a period of max 3 months.
8640|NCT04126252|Behavioral|Cognitive Behavioral Psychotherapy|The Group B received cognitive behavior psychotherapy for a period of max 3 months.
8641|NCT04126252|Combination Product|Combined or Integrated Therapy|The Group C received the combined therapeutic approach for a period of max 3 months.
8642|NCT04126252|Other|Placebo|The Group D received no treatment or placebo for a period of max 3 months.
8643|NCT04126239|Other|Online survey - questionnaire|Online survey - questionnaire
8644|NCT04126226|Other|Speech-language guidance|Speech-language guidance for speech enhancement and on food management in terms of consistency, volumes, utensils and temperature, beyond the care for safe and efficient swallowing.
8645|NCT04126226|Other|Speech therapy exercises for swallowing|Use of lip exercises and facial muscles, laryngeal elevation maneuver and airway protection technique, 5 repetitions 3 times a day for a month.
8646|NCT04126226|Other|Speech therapy exercises for speech|Use of over-articulation technique and glottal firmness exercise, 5 repetitions 3 times a day for a month.
8647|NCT04126213|Biological|RSVPreF3 formulation 2|One single dose of RSVPreF3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
8648|NCT04126213|Biological|RSVPreF3 formulation 3|One single dose of RSVPreF3 vaccine administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
8649|NCT04126213|Drug|Placebo|One single dose of placebo (NaCl solution) administered intramuscularly in the deltoid region of the non-dominant arm on Day 1.
8650|NCT04126200|Drug|GSK'916 (belantamab mafodotin)|GSK'916 (belantamab mafodotin) is available as powder for solution for infusion in unit dose strength of 100 mg per vial. It will be delivered as intravenous solution.
8651|NCT04126200|Drug|GSK3174998|GSK3174998 is available as powder for solution for infusion in unit dose strength of 40 mg per vial. It will be delivered as intravenous solution.
8652|NCT04126200|Drug|GSK3359609|GSK3359609 is available as aqueous solution in unit dose strength of 10 mg per milliliter (mL). It will be delivered as intravenous solution.
8653|NCT04126187|Device|Panoptix|Panoptix trifocal intraocular lens (IOL)
8654|NCT04126174|Device|femtosecond laser system arcuate corneal incision|Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
8655|NCT04126174|Other|Manual LRI|Manual LRI
8656|NCT04126161|Procedure|CT|standard of care CT prior to primary hip replacement
8657|NCT04126161|Device|Ultrasound|Ultrasound scan together with standard of care CT prior to primary hip replacement
8658|NCT04126135|Drug|Cytisine|Subjects will take a 25-day course of Cytisine tablets started during the 4 days before the quit date. They will be asked to reduce smoking during this time.
8659|NCT04126135|Drug|Nicotine Replacement Therapy (NRT)|Subjects are asked to completely stop smoking on their quit day and use a daily NRT patch for 25 days.
8660|NCT04126122|Diagnostic Test|Ultrasonography to assess fetus and mother|to assess fetal growth and maternal outcome
8661|NCT04126109|Other|questionaire|A questionaire will be offered to every parents
8662|NCT04126096|Diagnostic Test|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
8663|NCT04126083|Drug|Lofexidine Oral Tablet|Open label trial of lofexidine to facilitate opioid tapering prior to elective lumbar spine surgery.
8664|NCT04126070|Drug|Androgen Deprivation Therapy|Given per standard care for duration of study leuprolide (Lupron Depot) intramuscularly every 3 months, Goserelin acetate (Zoladex) subcutaneously every 4 weeks, or degarelix (Firmagon) subcutaneously every month per standard of care.
8665|NCT04126070|Drug|Nivolumab|Given once per every 3 weeks for cycle 1-6 intravenously and then every 4 weeks during subsequent cycles, at predetermined dosage; up to 28 cycles total.
8666|NCT04126070|Drug|Docetaxel|Given once every 3 weeks intravenously at pre determined dosage for cycle 1-6.
8667|NCT04126057|Device|SightGlass Vision DOT Spectacle Lenses|Subjects randomized to test vs control, left eyes and right eyes
8668|NCT04126044|Drug|PF-06439535 (CN)|This is the test drug Pfizer biosimilar of bevacizumab-EU.
8669|NCT04126044|Drug|bevacizumab - EU|This is the reference drug bevacizumab sourced from EU
8670|NCT04126031|Drug|Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3|Single intravenous infusion of ceftazidime-avibactam over 2 hours
8671|NCT04126031|Drug|Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3|Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
8672|NCT04126018|Diagnostic Test|MRI with strain measurement|CMR measurements of left and right ventricular systolic function strain and myocardial fibrosis
8673|NCT04126018|Diagnostic Test|Echocardiography|Doppler, PISA, VCA, volumetric method as performed during echocardiography
8701|NCT04125849|Procedure|Mediastinoscopy-assisted transhiatal esophagectomy|Mediastinoscopy-assisted transhiatal esophagectomy surgery
8702|NCT04125836|Drug|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
8674|NCT04125992|Procedure|distal radial artery access in coronary angiography and angioplasty|"The patient grasps his thumb towards the palm to bring the radial artery up to the surface. The left hand is set on the right side of the groin toward the operator, who stands on the right side, with the dorsal surface of hand upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the distal radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, Safe Guard, is used for hemostasis."
8675|NCT04125992|Procedure|Forearm radial artery access in coronary angiography and angioplasty|"The right hand is set in the anatomical position, with the anterior surface of arm face upwards.~Afterward, the access site is disinfected, lidocaine HCL is SC injected for local anesthesia. Subsequently, the forearm radial artery is palpated to find the point of the strongest pulse. Later, at a 45-degree angle, the artery is punctured with a 21-gauge needle and a 0.018 soft, flexible, metallic wire is then inserted in the needle. Through the sheath, 200 micrograms of Nitroglycerin is given. A 5000 unit of unfractionated heparin is administered through the IV line. A weight-adjusted dose of heparin is further added if PCI is needed. Then, a 0.035 wire is introduced in the sheath with other required instruments such as the intracoronary device and the catheters. After pulling out the sheath, a compression device, TR band, is used for hemostasis."
8676|NCT04125979|Other|In minimally invasive surgery，Vagus nerve preservation|In minimally invasive surgery for lung cancer, the experimental group retained the pulmonary branches of vagus nerve
8677|NCT04125979|Other|In minimally invasive surgery，Vagus nerve is not preserved|In minimally invasive surgery for lung cancer, the control group did not retain the vagus nerve.
8678|NCT04125953|Device|Andullation|Andullation is a horizontal vibration technique with stochastically modulated vibrations, build-in in a mattress.
8679|NCT04125953|Other|Placebo|Placebo Andullation
8680|NCT04125940|Dietary Supplement|Resync|The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.
8681|NCT04125940|Dietary Supplement|Resync + Collagen|17g Collagen + 2g Resync + 1g Carbohydrate
8682|NCT04125940|Other|Placebo|12oz water + food coloring
8683|NCT04125927|Drug|Mercaptamine|Patients will be treated with 1 drop in each eye 4 times a day, at the same dose and regimen than the one indicated in adults and children from 2 years of age.
8684|NCT04125914|Behavioral|Behavioral Dietary Intervention|Record food intake
8685|NCT04125914|Other|E-mail|Receive e-mails
8686|NCT04125914|Behavioral|Exercise Intervention|Undergo exercise
8687|NCT04125914|Other|Internet-Based Intervention|Join Facebook page
8688|NCT04125914|Other|Questionnaire Administration|Ancillary studies
8689|NCT04125914|Behavioral|Telephone-Based Intervention|Receive telephone coaching
8690|NCT04125914|Other|Text Message|Receive text messages
8691|NCT04125901|Other|Pain Neuroscience Education and Exercise|The experimental group will performed 8 sessions which will included pain neuroscience education. The incorporation of the exercise in this group will be gradual, in order to decrease the education component and increase the exercise component (up to 45/60 minutes).
8692|NCT04125901|Other|Exercise|The experimental group will performed 8 sessions which will included exercise.
8693|NCT04125888|Drug|Allergy immunotherapy (AIT)|Immunotherapy for different types of allergies
8694|NCT04125875|Diagnostic Test|Electrogastrogram(EGG)|Heart Rate Variability
8695|NCT04125875|Diagnostic Test|Heart Rate Variability(HRV)|Heart Rate Variability
8696|NCT04125862|Diagnostic Test|MRI-based Neuroimaging|During evoked pain fMRI, noxious pressure and heat stimuli will be applied in the two anatomical sites noted above. During fMRI data acquisition, a total of 5 pressure stimulations and 5 heat stimulations will be delivered. Both types of pain stimuli will be applied in a 36/17-sec off/on cycle. The off-condition will correspond to a baseline temperature of 35C and the on condition will match the subject-specific and site-specific 7/10 pressure and heat pain thresholds defined during QST procedures. VAS pain ratings associated with evoked pain stimulation will be collected at the end of each scan. The investigators will also explore the structural properties of the CNS by implementing high-resolution anatomical MRI (gray matter volumes) and diffusion tensor imaging (white matter pathway integrity). All CNS imaging will take approximately 50-60 minutes to complete
8697|NCT04125862|Diagnostic Test|Non-contrast MRI|Musculoskeletal imaging of the affected lower extremity. Patients will be allowed to watch a movie during data acquisition. The following MRI procedures will be completed in order to identify soft tissue lesions in active or painful regions. Fast spin echo (FSE) T2 fat saturated, T1 weighted MRI, FSE proton density MRI, Short-TI Inversion Recovery (STIR), Diffusion weighted MRI (DW-MRI) and 3D Double Echo Steady State (DESS) will be collected. All musculoskeletal MRI will take approximately 30 minutes to complete.
8698|NCT04125862|Diagnostic Test|18F-FDG-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-FDG with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
8699|NCT04125862|Diagnostic Test|18F-NaF-PET/CT|Data will be collected 30 min after the intravenous administration of 18F-NaF with an expected average dose of approximately 200 MBq. CT data will be collected at a low-dose to minimize radiation exposure. Patients will be positioned supine head-first with arms on the side. The investigators project whole body data to be collected, but in some cases, the field of view may be limited to the patient's skull to below the knees. The data acquisition period is expected to last between 15-30 minutes and total radiation dose will be ~3-4 mSv.
8700|NCT04125849|Procedure|Minimally invasive esophagectomy|Minimally invasive esophagectomy surgery
8703|NCT04125823|Behavioral|Video game-based physical activity training|"Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with a motion sensor (Microsoft) and a 52'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades and types of games will be changed.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
8704|NCT04125823|Behavioral|Conventional physiotherapy program|"A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented.~Sessions will be performed by a physiotherapist for 45 minutes once a day during the hospital stay."
8705|NCT04125810|Biological|Probiotic|Probiotic
8706|NCT04125810|Other|Placebo|Placebo
8707|NCT04125797|Other|Application of adhesive|Adhesive will be placed on the subjects skin below the bra. Placement of the adhesive will be randomized.
8708|NCT04125771|Diagnostic Test|Diclofenac + HBB with hysteroscopy|Giving Diclofenac + HBB with hysteroscopy
8709|NCT04125771|Diagnostic Test|Diclofenav + placebo|Giving Diclofenac + placebo with hysteroscopy
8710|NCT04125758|Behavioral|Mindfulness training|Brief audio recordings discussing mindfulness or guided mindfulness practices.
8711|NCT04125758|Behavioral|Tracking time spent on mobile device|Participants will record each day how much time they estimate they spent on their smart phone in the past 24 hours.
8712|NCT04125745|Drug|CXA-10|Each subject will receive oral CXA-10 at the dose of 150 mg once daily for 12 weeks
8713|NCT04125732|Biological|AdVEGFXC1|AdVEGFXC1 at one of 4 doses
8714|NCT04125719|Biological|PVSRIPO|Intralesional injection of PVSRIPO
8715|NCT04125719|Drug|Nivolumab|Nivolumab infusion
8716|NCT04125706|Drug|Minocycline Topical|Minocycline will be delivered locally in the periodontal pocket
8717|NCT04125706|Drug|Metronidazole Topical Gel|Metronidazole will be delivered locally in the periodontal pocket
8718|NCT04125693|Drug|Rogaratinib (BAY1163877)|Participants will be treated with investigational drug following the treatment schedule and dosing instructions from the feeder-study protocol.
8719|NCT04125693|Drug|Combination drug|Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
8720|NCT04125680|Behavioral|ESL Health Literacy Classes|The intervention will last 8-weeks, and the first and last classes will be devoted to survey assessments. Participants will be asked to reflect on their health knowledge and behaviors, and how they have changed since starting the program. The curriculum administered during the classes will use pedagogies for health literacy as a practice. It will focus on skills needed to learn about lead exposure in the ESL classroom: (1) vocabulary; (2) grammar; and (3) identifying risk factors, symptoms and preventive strategies. A focus on health literacy as practice will include personal engagement using language in context: (1) role-play interactions about lead exposure prevention; (2) discussing views about risk, and how to talk about it with peers and family members; (3) identifying sources of reliable health information; and (4) learning to ask for support and resources.
8721|NCT04125654|Device|mNGS for pathogen detection|This assay is a metagenomic test undertaken by BGI Genomics Co., Ltd. for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
8722|NCT04125628|Behavioral|Exercise with cooling|The exercise training session involved head cooling and neck wraps. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the condition each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed
8723|NCT04125628|Behavioral|Exercise without cooling|The exercise session performed without cooling. Participants followed a 40-minute continuous cycling where they performed an incremental sub-maximal exercise protocol beginning at 45 W, increasing 10 W every 10 min for a total of four stages on a semirecumbent cycle ergometer in a 20oC room. Before and after the completion of the session each participant performed a variety of functional ability tests. The evaluation of the core temperature and the assessment of the patient's quality of life also was performed.
8724|NCT04125615|Behavioral|Protected Time Intervention|Participants were assigned two hours of protected, non-clinical time by the chief resident of the service. Chief residents were instructed to assign this time when clinical learning opportunities were lowest. Each participant acted as their own control and was on the intervention phase of the study for the first or last 6 weeks of a quarterly rotation. Residents were concurrently assigned to the same phase of the study (intervention versus control). Participants were not specifically limited in what they could do during their non-clinical time, but they were encouraged to use this time in a way they felt would decrease their own personal burnout and increase their well-being, whether this be performing work-related administrative duties previously done on personal time or fulfilling obligations that are integral to personal health and well-being that can only be completed during normal business hours.
8725|NCT04125602|Other|High fat low carbohydrate diet|Participants will be randomized to either the HF-LCD or the LF-HCD as their starting intervention and alternate between these two conditions for six 6-day treatment periods. Participants will complete three 6-day intervention periods on each diet. There will be a wash-out period lasting for 6 days with normal diet between two interventions to eliminate previous intervention effects.
8726|NCT04125602|Other|Low fat high carbohydrate diet|Participants will be randomized to either the HF-LCD or the LF-HCD as their starting intervention and alternate between these two conditions for six 6-day treatment periods. Participants will complete three 6-day intervention periods on each diet. There will be a wash-out period lasting for 6 days with normal diet between two interventions to eliminate previous intervention effects.
8727|NCT04125589|Behavioral|Introduction Activity|"Participants will engage in a getting to know you introduction activity."
8728|NCT04125589|Behavioral|Product Evaluation Activity|Participants will engage in a product evaluation activity.
8729|NCT04125576|Diagnostic Test|magnetic resonance imaging(MRI)|magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
8825|NCT04124601|Radiation|Chemoradiotherapy|Capecitabine tablet with fractionated radiotherapy
8826|NCT04124601|Drug|Ipilimumab|Infusion
8730|NCT04125563|Drug|Capsicum Oleoresin|The soft gel capsules used in the study are easily digested in the stomach and contain standardised doses of 0,4 mg Capsicum oleoresin with the main component capsaicin (8-methyl-N-vanillyl-6-nonenamide) (from chili extract).
8731|NCT04125563|Drug|Placebos|Soft gel capsules filled with placebo - sorbitol and colorant.
8732|NCT04125550|Drug|Propofol|2-3 mg/kg propofol will be administered for anesthesia induction. 10 mg/ kg/h propofol infusion will be administered for the maintenance of anesthesia.
8733|NCT04125550|Drug|Sevoflurane|sevoflurane inhalation (2-8%) will be administered for anesthesia induction. 2% sevoflurane inhalation will be administered for the maintenance of anesthesia.
8734|NCT04125537|Behavioral|IHI Breakthrough Collaborative Model|Staff participants participate in a quality improvement/collaborative learning model that includes three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project.
8735|NCT04125524|Diagnostic Test|Terahertz metamaterials|A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
8736|NCT04125511|Drug|68Ga-FAPI|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-FAPI. Tracer doses of 68Ga-FAPI will be used to image lesions of IgG4-RD by PET/CT.
8737|NCT04125498|Other|Osteopathic treatment|Manual treatment that aims to release myofascial tensions
8738|NCT04125498|Other|Placebo treatment|Similar to OMT without pressure
8739|NCT04125498|Other|Self-massage|Women will be instructed to perform self-massage at home once a day for 5 minutes.
8740|NCT04125472|Drug|Lumasiran|Lumasiran administered as a subcutaneous (SC) injection
8741|NCT04125459|Procedure|Joint Biopsy|a synovial biopsy of a joint that has been affected by a gout attack
8742|NCT04125433|Behavioral|Peer Integrated Care Services|The project employs a two level intervention to include Peer Support Specialist (PSS) and Community Health Advocate (CHA). Contact and engagement with participating members will be through both direct intervention in the emergency department as well as in the community for prevention visits and follow up. Peers and Community Health Advocates will address Behavioral and Social Determinants of Health (SDoH) concerns through a coordinated intervention supported by a common IT Medicaid member tracking platform. This research project will determine the feasibility of deploying a single shared IT platform that will include referral, appointment completion, and intervention outcome data. Project staff will develop a relationship with the members improving member access and engagement with community-based services. The project will determine the impact on total cost of care through redirecting study participants to community resources rather than return visits to the emergency department.
8743|NCT04125407|Other|Sensorimotor foot orthoses|The interventional group will receive one customized pair of sensorimotor insoles and will be instructed for their using on a daily bases for the period of 3 months. The duration of using the insoles was established as 1 hour at the day after receiving the insoles. After that, the insoles' tolerance will be assessed based on the email correspondence and further adjustments of insole will be consulted with manufacturer if necessary. Recommended progression in time of using the insoles was established as +1 hour per each day (if possible) with no maximal limit. After 3 weeks, control examination will take place for the control of subjective effect of insoles. Consulting will be offered to the participants through the duration of research. Participants will not undergo any other supplementary treatment (physiotherapy, …) focusing on the flatfoot deformity.
8744|NCT04125394|Device|hypertonic Sodium chloride (NaCl 5%) eye drops solution in single-dose|Ophthalmic solution of hypertonic sodium chloride (NaCl 5%) without preservatives in single-dose container
8745|NCT04125381|Other|Exposure to Arsenic by drinking water|People residing in municipalities with Arsenic drinking water concentrations over legal threshold (10 µg/L), were considered as exposed.
8746|NCT04125368|Behavioral|A&T Interventions|"Intensified counselling on dietary diversity and quality during pregnancy.~Strengthened government distribution and promotion of IFA supplementation with counseling about its importance, how to manage side effects, and reminders about subsequent supplies.~Weight-gain monitoring with messaging to mothers about healthy diet and adequate rest; excess weight gain as a danger sign.~Intensified counseling on importance, benefits, and how-tos of early initiation of breastfeeding and exclusive breastfeeding."
8747|NCT04125355|Other|Reflexology|Foot reflexology massage for 3 consecutive days and 60 minutes per day.
8748|NCT04125355|Other|Placebo|Placebo for 3 consecutive days and 60 minutes per day. This intervention only include touch to the foot, it doesn't include deep stimulation.
8749|NCT04125342|Device|Preventive Conditioned NIV Therapy after planned extubation|Conditioned NIV during 48 hours following extubation.
8750|NCT04125342|Device|Preventive HFOT after planned extubation|HFOT set according to patients tolerance during 48 hours following extubation
8751|NCT04125329|Drug|Human umbilical cord mesenchymal stem cells|Human umbilical cord mesenchymal stem cells were given to each diabetic nephropathy subject once a month, peripheral intravenous injection, a total of three times
8752|NCT04125316|Other|Observation, no intervention|Observational study, no intervnetion
8753|NCT04125303|Behavioral|brief motivational psychoeducational therapy|The brief motivational psychoeducational therapy (BMPT) it lasted an average of 90 min and followed the following structure: (i) brainstorming the concepts of health, lifestyle, and substance-use prevention; (ii) analysis of a work accident at an international rock group concert, which was used to generate (iii), a debate on consumer habits (30 min); (iv) discussion of the substance types and classifications known by the participants; (v) Prochaska and DiClemente's stages of change and (vi), the consequences of drug use (50 min); and finally, (vii) a true/false quiz used to discuss myths and beliefs about drugs (10 min).
8754|NCT04125277|Other|FES-PET scan, and possibly one additional visit for an FDG-PET|One visit to either the UMCG or Amsterdam UMC-location VUMC is required for the FES-PET scan, and possibly one additional visit for an FDG-PET. A FES- or FDG-PET scan plus low dose CT will each induce an extra radiation burden of about 6.1 mSv (210 MBq injected for an average patient of 70 kilogram body weight).
8755|NCT04125264|Device|Intense Therapeutic Ultrasound|Application of 1000 pulses, until 5000 joules (5 joules per pulse), during approximately 15 minutes, with the possibility of 5 minutes rest, depending on the tolerance of the patient.
8827|NCT04124601|Drug|Nivolumab|Infusion
8756|NCT04125251|Behavioral|Life Skills Building Training|The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
8757|NCT04125238|Behavioral|Episodic Future Thinking|Participants will generate descriptions of vivid positive future events.
8758|NCT04125238|Behavioral|Control Episodic Thinking|Participants will generate descriptions of vivid positive recent past events.
8759|NCT04125199|Dietary Supplement|supplement consumption|"Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® * (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days)."
8760|NCT04125186|Diagnostic Test|Baseline EpiNP survey|The survey takes approximately 20 to 30 minutes to complete, and consists of the following: Short Form Health Survey version 2.0 (SF-12v2.0); Lower Urinary Tract Symptoms (LUTS) Tool; Patient Perception of Bladder Condition (PPBC); Self-report Medical History and Current Medication Form; Nocturia Impact Diary (NID); Disease-Specific Healthcare-Seeking Behavior and Treatment; Epworth Sleepiness Questionnaire (ESS); Patient Reported Outcome Measurement Information System Fatigue-Short Form version 1.0 (PROMIS F-SFv1.0); Patient Health Questionnaire (PHQ-8); Work Productivity and Activity Index (WPAI-SHP); Sexual health questions; lifestyle and sociodemographic questions; additionally, only men will complete the International Prostate Symptom Score (IPSS).
8761|NCT04125186|Diagnostic Test|Bladder diary|It consists of four components: measurement of waist and neck circumference, daily voiding diary (to assess voiding patterns, including frequency, volume, associated urgency, and incontinence episodes over a 24-hour period), NID (to assess nocturia impact), and assessment of morning sleepiness for 3 consecutive days and nights (including the morning of the fourth day).
8762|NCT04125186|Diagnostic Test|Testing of EpiNP baseline survey, bladder diary and a qualitative interview|This part briefly reviews the usability of the EpiNP survey and bladder diary. The feedback obtained after qualitative interview will be used to refine and finalize the instructions sent to the participants in the main part.
8763|NCT04125186|Other|No other intervention|No other intervention
8764|NCT04125173|Other|Pneumoperitoneum pressure = 15mmHg|Randomized pneumoperitoneum 1
8765|NCT04125173|Other|Pneumoperitoneum pressure = 12mm Hg|Randomized pneumoperitoneum 2
8766|NCT04125173|Other|Pneumoperitoneum pressure = 10mmHg|Randomized pneumoperitoneum 3
8767|NCT04125160|Device|Continuous glucose monitoring|Continuous glucose monitoring over 16 days
8768|NCT04125160|Diagnostic Test|Glycaemic markers|Measurement of HbA1c, glycated albumin and fructosamine.
8769|NCT04125147|Device|Experimental: Montage Bone Hemostat|Use of Montage bone hemostat on the cut surfaces of bone at the osteotomy site
8770|NCT04125134|Drug|Preservative-free Refresh Optive Advanced Lubricant Eye Drops|over the counter artificial tear
8771|NCT04125121|Drug|Sevoflurane-propofol|General anaesthesia with a maintenance phase of two hours duration with either sevoflurane or propofol.
8772|NCT04125108|Other|pulmonary rehabilitation|Pulmonary rehabilitation programs were designed to include both 30 minutes resistance and 30 minutes aerobic exercises. Eight basic resistnace exercises were used incorporating, bench press, leg press, leg curl, leg extension, toe raises, biceps curl, triceps curl, shoulder press. Additionally each exercise training session also included aerobic conditioning exercises ona treadmill or cycle ergometer. Aerobic exercise training was carried out 5 days per week, with each session lasting 30 minutes. All exercise sessions were preceded by a 5-minutes warm up period on a treadmill set.
8773|NCT04125082|Drug|Afrezza Inhalant Product|Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
8774|NCT04125069|Procedure|Coronary Artery Bypass Graft (CABG)|Mitochondrial function will be studied on cardiac tissue collected intraoperatively at the time of placement of the ECC cannulas by the surgeon. Fragments from auricle dissection of the right atrium of the patient will be requalified as sample residues, and will be used immediately by the surgeon to measure mitochondrial respiration (measurement of oxygen consumption by oxygenation and permeability test of the external mitochondrial membrane by the addition of cytochrome C in the oxygen chamber).
8775|NCT04125056|Drug|Hydronidone Capsule(Specification: 30 mg / grain）|Test group
8776|NCT04125056|Drug|Hydronidone Capsule(Specification: 15 mg / grain）|Control group
8777|NCT04125043|Diagnostic Test|Direct ophthalmoscope|Red reflex test
8778|NCT04125030|Other|Validation of questionnaires|Participants will complete i) the RAS (24 items, 5-point Likert scale), ii) the CM (23 items, 5-point Likert scale), and the iii) the RSA for consumers (32 items, 5-point Likert scale). These participants have already completed these other measures (clinical recovery): iv-Anxiety: Anxiety State-Trait Anxiety Inventory Form Y6 (STAI-Y6) (6 items); v- Depression: Depression Patient Health Questionnaire (PHQ-9) (9 items) ; vi- Alcohol Dependence: Alcohol Use Disorders Identification Test (AUDIT-10) (10 items) ; vii- Drug Dependence: Drug Abuse Screening Test (DAST-10) (10 items) ; viii- Psychosis : Psychosis Screening Questionnaire (PSQ 12 items) ; ix- Social functioning : World Health Organization Disability Assessment Schedule (WHODAS 2.0) (12 items).
8779|NCT04125017|Other|ICSI with laser pulse|Using laser pulse before ICSI
8780|NCT04125017|Other|ICSI with micro needle technique|Using micro needle technique before ICSI
8781|NCT04125004|Device|Samsung Virtual Reality Headset|Patients will pick a game or feature from the virtual reality headset to use during their procedure
8782|NCT04124991|Drug|Durvalumab|Radioembolization with Yttrium-90 Microspheres
8783|NCT04124991|Radiation|Radioembolization|Radioembolization with Yttrium-90 Microspheres
8784|NCT04124978|Device|mandibular advancement device|use of prefabricated adjustable mandibular advancement device to improve OSA
8785|NCT04124965|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in 2 different dosages (dose 1 and dose 2) in dosage regimen 1 and 2.
8786|NCT04124952|Device|Panoptix|Alcon Acrysof(R) Panoptix(R) intraocular lens (IOL)
9073|NCT04122443|Drug|Acetaminophen|Acetaminophen 650mg
9074|NCT04122443|Drug|Oxycodone|Oxycodone 10mg
8787|NCT04124939|Drug|OnabotulinumtoxinA 100 UNT|"BOTOX for injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for:~• Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication."
8790|NCT04124913|Drug|Dydrogesterone 10 MG Oral Tablet|Oral dydrogesterone 10 mg tablet three times a day for luteal phase support
8791|NCT04124913|Drug|Progesterone Vaginal Gel [Crinone]|Vaginal progesterone gel 90 mg once a day for luteal phase support
8792|NCT04124887|Drug|Sodium Fluoride|Sodium Fluoride varnish was applied to the targeted teeth at baseline, one and three months.
8793|NCT04124887|Drug|Tricalcium Phosphate|Varnish with Tricalcium Phosphate was applied to the targeted teeth at baseline, one and three months.
8794|NCT04124887|Drug|Xylitol-coated calcium and phosphate|Varnish with Xylitol-coated calcium and phosphate was applied to the targeted teeth at baseline, one and three months.
8795|NCT04124887|Drug|Casein phosphopeptide amorphous calcium phosphate|Varnish with Casein phosphopeptide amorphous calcium phosphate was applied to the targeted teeth at baseline, one and three months.
8796|NCT04124874|Other|There will be no intervention|There will be no intervention
8797|NCT04124861|Drug|Drug free, IS monotherapy and GC combined with IS|Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
8798|NCT04124835|Other|Swiss Ball|"Top narrow (DeLee Plan -5 to -1 or Hodge Plan 1-3) Retroversion, lateralization and pelvic circumference exercises with abducted hips and external rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and external rotation.~Lower Narrow (DeLee Plan +1 to +5 or Hodge Plan 3-4) Pelvic anteversion, tilt, and circumference exercises with abducted hips and internal rotation will be encouraged. Exercises according to fetal positioning: Four ball-assisted supports and / or biped stance with anterior trunk inclination with asymmetrical opening of lower limbs with the aid of the ball. The hips will be in abduction and internal rotation."
8799|NCT04124835|Other|Control Grup|Habitual Care of the Service.
8800|NCT04124822|Drug|Piroxicam 20 mg|Piroxicm is from oxicam family of anti inflammatory drug that inhibits prostaglandin synthesis and effectively lower pain threshold levels
8801|NCT04124822|Drug|prednisolone 20 mg|prednisolone is from steroid family of anti inflammatory drug that inhibit arachidonic acid and effectively lowers the pain
8802|NCT04124809|Device|laser assisted collapse|Apply 1-2 pulses of laser using the Saturn between 2 adjacent trophectoderm cells away from the inner cell mass in the blastocysts
8803|NCT04124796|Other|Semi-structured interviews|Based on an interview grid previously built, the interviews will investigate the factors governing the decision to consult and methods of intervention to reduce the time to consult.
8804|NCT04124783|Device|Cooling Bolero|A vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
8805|NCT04124770|Other|Movement|Re-positioning of neck
8806|NCT04124757|Other|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
8807|NCT04124744|Other|Health Champions intervention|Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
8808|NCT04124744|Other|Control group-treatment as usual|Participants will receive treatment as usual from their Community Mental Health Team
8809|NCT04124731|Drug|sintilimab plus anlotinib|Sintilimab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle plus anlotinib capsules 12 mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21
8810|NCT04124731|Drug|Chemotherapy|"Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total."
8811|NCT04124718|Genetic|high caries experience|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
8812|NCT04124705|Drug|Armour® Thyroid|Oral administration once daily
8813|NCT04124705|Drug|Synthetic T4|Oral administration once daily
8814|NCT04124692|Device|Sculptra Aesthetic new dilution|Treatment of cheek wrinkles
8815|NCT04124679|Other|Transcutaneous Electrical Acupoint Stimulation|patients received Transcutaneous Electrical Acupoint Stimulation for 30 mins on the acupoints
8816|NCT04124666|Biological|Granulocytes|Granulocytes cross-matched for ABO-Rh and CMV; bioactivity of anti-cancer ability meets the criteria.
8817|NCT04124653|Drug|PF-06842874|Single dose administration of PF-06842874
8818|NCT04124653|Drug|Placebo|Single dose administration of placebo
8819|NCT04124653|Drug|Relative Bioavailability|Relative bioavailability assessment of modified-release formulation
8820|NCT04124640|Other|Patients' data (baseline characteristics, clinical and outcomes) from routine care visits|Use of a standardized scale to collect clinical and patient-centered data, to assess the effectiveness of Libicare in real life in female 45-65 years old. Patients' data (baseline characteristics, clinical and outcomes) will be collected according to sites routine care.
8821|NCT04124627|Procedure|Ultrasound guidance in addition to radiographic guidance|Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
8822|NCT04124614|Drug|Brexpiprazole|Up to 3 mg pill
8823|NCT04124614|Drug|Sertraline|Up to 150 mg pill
8824|NCT04124614|Other|Placebo|Pill
8828|NCT04124588|Device|Nexpowder (Hemostatic powder)|Nexpowder generates gelation-effects when the powder comes into contact with water, forms a physical barrier to control hemorrhage, preserve ulcer sites and thereby demonstrates its effective hemostatic performance. Hydrogels, which turned into gel-formation through water contacts in the gastrointestinal tract protect the wound sites for over 24 hours, are subsequently detached from the lesion, and completely excreted from the patient body system within 3 days.
8829|NCT04124588|Device|Conventional Technique|Argon Plasma Coagulation, Coagulation including Forcep, Hemoclipping, Band Ligation, Epinephrine or Absolute Alcohol Injecction can be used as standard-of-care hemostatic treatment(s).
8830|NCT04124562|Other|Nitrous Oxide|Nitrous Oxide use ratio in Turkey's hospitals
8831|NCT04124549|Other|Usual care with sham intervention|Patients in the control group received usual care and were advised to do sham exercise such as stretch legs and arms about 15 minutes during the first 2 HD hours.
8832|NCT04124549|Other|Intradialytic Combined Exercise|Each session consisted of a 5-minute warm-up, cool-down and 30-minute cycling at a Rating of Perceived Exertion (RPE) of 12-14. The machine has two exercise types including aerobic exercise and resistance exercise. Patients were asked to perform aerobic exercise 20-min and resistance exercise 10-min in the first stage. Every four weeks is divided into a stage. And the time of aerobic exercise and resistance exercise were personally adjusted per stage to maintain the personalized target RPE. In the following stages, aerobic exercise was continued 15-min for the second stage, 10-min for the third and the forth stage, 15-min for the fifth stage and 20-min for the last stage. And the time for resistance exercise was adjusted for the total exercise time. The resistance of exercise also progressive increased in order to adapt the target RPE. It was accessible to patients of different ages, gender, cultures and ethnicities.
8833|NCT04124536|Behavioral|HIV self-testing with partner notification.|HIV self-test kits are oral swabs. Partner notification will be offered to all women in the intervention arm, regardless of HIV status.
8834|NCT04124510|Drug|Brand Name: Flutiform K-haler|Brand Name: Flutiform K-haler Generic name: Fluticasone/formoterol dosage form: oral inhalation
8835|NCT04124497|Drug|Daratumumab|"Daratumumab 16 mg/kg intravenously at following schedule:~cycle 1 and 2: days 1, 8, 15, and 22~cycle 3 through 6: days 1, and 15~from cycle 7 until disease progression: day 1."
8836|NCT04124497|Drug|Pomalidomide|4 mg once daily on days 1-21
8837|NCT04124497|Drug|Dexamethasone|Oral or intravenous dexamethasone 40 mg/day (≤ 75 years old) or 20 mg/ day (>75 years old) on days 1, 8, 15 and 22
8838|NCT04124484|Drug|DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
8839|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)|One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
8840|NCT04124484|Drug|DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
8841|NCT04124484|Drug|Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)|Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
8842|NCT04124471|Behavioral|Open-ended semi-structured interviews|Semi-structured interviews will explore such key constructs as knowledge/belief about OSAS and PAP therapy, routines and resources that promote or limit PAP use, barriers, self-efficacy, and communication and attitudes about PAP. The interviews will be performed with the parent and that they will be audio-recorded.
8843|NCT04124458|Device|Radiofrequency ablation|In radiofrequency ablation arm, sensory brunch of occipital nerve will be burn with max allowable temperature: 42 degrees Celsius, real temperature: 41 degrees Celsius, power=65 volts, two cycles of 180 second.
8844|NCT04124445|Procedure|Pulsed Radiofrequency Ablation|"Radiofrequency ablation, also called rhizotomy, is a nonsurgical, minimally invasive procedure that uses heat to reduce or stop the transmission of pain. Radiofrequency waves ablate, or burn, the nerve that is causing the pain, essentially eliminating the transmission of pain signals to the brain."
8845|NCT04124432|Drug|Cannabis|Cannabis will be smoked
8846|NCT04124432|Drug|Nicotine|Nicotine will be smoked or vaporized
8847|NCT04124419|Device|Treatment with Evolve System|EMS and RF Treatment
8848|NCT04124406|Device|Cologuard|multi-target stool Deoxyribonucleic Acid (MT-sDNA) screening test
8849|NCT04124393|Procedure|Colon Polypectomy|Polyp search and resection will be performed entirely during the withdrawal phase in both WE and CO2 groups. Insertion inspection and polypectomy will not be performed. All polyps in the proximal colon, defined as cecum, ascending colon, hepatic flexure, and transverse colon, will be removed irrespective of their size and appearance.
8850|NCT04124380|Behavioral|Imaginal Exposure|Six 50 min, twice weekly sessions will be provided based on prolonged exposure therapy for PTSD. This brief intervention includes psycho-education and focuses on imaginal exposure only based on Zoellner et al., (2016).
8851|NCT04124380|Behavioral|Alcohol Skills Training|Six 50 min, twice weekly sessions will be provided based on content from the alcohol skills training program and CBT protocols. Each session includes teaching skills and practice, focusing on mitigating rewarding aspects of alcohol, addressing cravings, and increasing other natural rewards.
8852|NCT04124380|Behavioral|Supportive Telehealth|The supportive counseling intervention, modeled after Litz et al. (2007), will ask participants to self-monitor their experience of weekly symptoms and complete weekly online writing about daily non-trauma related concerns and hassles. Participants will talk with a therapist on the telephone twice per week.
8853|NCT04124367|Drug|Cerebrolysin|30 ml once daily (+70 ml 0.9% saline)
8854|NCT04124367|Device|non-invasive brain stimulation|2 mA/35 cm² for 2x20 minutes, once daily
8855|NCT04124367|Drug|Placebo|100 ml once daily 0.9% saline
8856|NCT04124367|Device|sham intervention|0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
9075|NCT04122430|Other|Review of Health Information|
10112|NCT04113772|Drug|Nitisinone|Measure bio equivalency/efficacy of nitinosine and orfadin
8857|NCT04124354|Behavioral|Physical Activity|Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)—exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
8858|NCT04124341|Device|Epidural Prefrontal Cortical Stimulation (EpCS)|Prior to surgery, subjects will undergo a high resolution structural scan to identify anatomical landmarks for rostral anterior and lateral prefrontal cortex. Following identification of target areas, EpCS quad leads will be projected over the anterior and lateral prefrontal cortex.Subjects will be kept in the hospital for a minimum of 72 hours for observation during which the investigators will obtain a high resolution spiral CT scan without contrast to confirm lead placements post- operatively and rule out any intra-cranial bleeds. Patients will receive analgesics which they may continue as an outpatient on as needed basis. During this 2-3 weeks recovery period, the attention to pain control and mood is critical. The research team will contact patients at least twice per week to check on their status.
8859|NCT04124328|Procedure|ALINE + VoM infusion|In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.
8860|NCT04124328|Procedure|ALINE only|In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
8861|NCT04124315|Other|Accelerometry|Patients will be given accelerometers at this visit and informed on how to use them (e.g., wear on the ankle during waking hours, upright, etc).
8862|NCT04124315|Other|Daynamica app|Participants will be asked to record location/activity on the app in order to characterize activity patterns both inside and outside of the hospital SET setting.
8863|NCT04124302|Drug|Insulin Glulisine|A kind of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
8864|NCT04124302|Drug|Insulin Aspart|A kind of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
8865|NCT04124302|Drug|Insulin Lispro|A kind of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
8866|NCT04124289|Other|Pain measurement using 3 scales|Patients will assess their pain after surgery using three different pain scales.
8867|NCT04124276|Dietary Supplement|Lycium barbarum polysaccharide|Experimental groups take Lycium barbarum polysaccharide (LBP) (400mg/day) for 6 weeks
8868|NCT04124276|Dietary Supplement|Placebo|Placebo control group takes placebo (400mg/day) for 6 weeks.
8869|NCT04124263|Other|Educational short message texts|Educational messages for patient engagement
8870|NCT04124263|Other|Adherence short message texts|Reminder messages of medication use time
8871|NCT04124250|Other|Observational|Mass Drug Administration with a single co-administered dose of Ivermectin, DEC and Albendazole performed by Provincial and National Health Departments annually for two years
8872|NCT04124224|Other|Unidos|The investigators will collaborate with our community partners to implement and evaluate a Community-Clinical Linkage (CCL) model in which Community Health Workers (CHWs) connect individuals to social determinant and community health services and build sociocultural resilience through CHW-facilitated individual and group support. As a public health practice-based study that incorporates evidence-based strategies, the investigators seek to establish Unidos effectiveness in Arizona counties with the highest percentage of Latinos of Mexican origin (Yuma, Pima, Santa Cruz, and Maricopa). Unidos CHWs, based in local health departments, will use evidence-based strategies to address three elements that are important in addressing chronic disease risk: 1) health promotion resources and programs; 2) individual and group-based social support; and 3) leveraging community resources to address social determinants of health.
8873|NCT04124211|Biological|Fecal Microbiota Transplantation (FMT)|FMT will be performed through transendoscopic enteral tubing (TET) within one week during treatment period
8874|NCT04124198|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Accelerated or hyper-fractionated radiotherapy
8875|NCT04124198|Drug|Cisplatin|Concurrent weekly cisplatin 40 mg/sqm to fit patients
8876|NCT04124198|Drug|Nimorazole.|Concurrent nimorazole
8877|NCT04124198|Procedure|Transoral Robotic Surgery (TORS) with neck dissection|Robotic-assisted resection of the primary oropharyngeal tumour and ipsilateral selected neck dissection of lymph node levels II-IV. Patients with a primary base of tongue cancer or with significant involvement of tongue base or the soft palate defined as above 1 cm, will be offered a bilateral neck dissection of levels II-IV.
8878|NCT04124185|Diagnostic Test|Ocular assessments|Complete ocular examination, Axial length and corneal curvature, Optical Coherence Tomography, Visual acuity, Contrast sensitivity
8879|NCT04124172|Device|Real rTMS (Magstim)|See arm description
8880|NCT04124172|Device|Sham rTMS|See arm description
8881|NCT04124146|Radiation|MRI for some patients according functionnal tests results|Depending on the results obtained on the evaluation criteria, additional examinations could be prescribed (imaging) for subjects with an unsatisfactory functional score. There is therefore a potential change in the usual care.
8882|NCT04124133|Device|dressing with hyaluronic acid|Application of ialuset cream or gauzepad (hyaluronic acid)
8883|NCT04124120|Procedure|Procedure: Single arterial graft|"This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.~Coronary artery bypass surgery, also known as coronary artery bypass graft (open chest surgery). During CABG disease vein will be replaced through the by"
8884|NCT04124120|Procedure|Procedure: Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
9917|NCT04115462|Drug|Codeine|Codeine will be induced by epidermal punctures of 1 mg/mL with a 1 mm skin prick test (SPT) lancet.
8885|NCT04124107|Device|multiparametric MRI and 68Ga-PSMA PET/MRI|All participants will undergo multiparametric MRI examination. If mpMRI is unfavorable for prostate cancer, participants will undergo 68Ga-PSMA PET/MRI examination
8886|NCT04124107|Procedure|Prostate biopsy|Participants with unfavorable mpMRI but favorable 68Ga-PSMA PET/MRI will undergo both 68Ga-PSMA PET/MRI-ultrasound-fusion targeted biopsy and transperineal ultrasound guided 12-core systematic biopsy
8887|NCT04124094|Drug|Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)|Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
8888|NCT04124094|Drug|Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)|2 inhalations in one study period
8889|NCT04124094|Other|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
8890|NCT04124081|Drug|Hydronidone capsules& Entecavir capsules|take the Hydronidone capsule and then the entecavir capsule, and then take the last two together
8891|NCT04124068|Other|Hydrogen peroxide teeth whitening gel|Hydrogen peroxide teeth whitening gel with concentrations ranging between 6% - 30%
8892|NCT04124068|Device|GLO Brilliant Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
8893|NCT04124068|Device|GLO Lit Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
8894|NCT04124068|Device|GLO Science Professional Teeth Whitening Device|Intra-oral mouthpiece connected to a battery in order to generate light and heat to effect the whitening treatment.
8895|NCT04124055|Diagnostic Test|TDM|Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
8896|NCT04124042|Biological|XT-150|plasmid DNA
8897|NCT04124029|Device|No Intervention is used for this study but all subjects will be asked to complete EEG testing and an MRI scan.|No intervention will be used.
8898|NCT04124029|Procedure|No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.|No intervention will be used.
8899|NCT04124016|Dietary Supplement|Inulin|Powder of inulin fractions dissolved into 250 ml of water
8900|NCT04124016|Dietary Supplement|green tea extract|Powder of green tea extract dissolved into 200 ml of water
8901|NCT04124016|Dietary Supplement|grape seed|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol monomers) dissolved into 200 ml of water
8902|NCT04124016|Dietary Supplement|grape seed extract|Powder of grape seed extract (rich in di-hydroxylated flavan-3-ol oligomers) dissolved into 200 ml of water
8905|NCT04123990|Diagnostic Test|Iron status testing|Iron status testing
8906|NCT04123951|Other|Home-based Exercise|Patients in the home-based exercise arm will complete a 12 week home-based aerobic and resistance exercise training programme. There will be a 2 week period prior to this in which patients will complete up to 6 supervised sessions in order to learn about the home-based exercise training. There will be a 4 week return visit and an optional 8 week return visit in order to reassess fitness and aid the patients with any questions or queries they may have and to aid them in progressing their exercise.
8907|NCT04123938|Other|Pea Protein|Soluble pea protein
8908|NCT04123938|Other|Whey Protein|Whey protein concentrate
8909|NCT04123938|Other|Maltodextrin|Non-protein isocaloric comparator
8910|NCT04123925|Drug|Nivolumab|Locally advanced colon cancer must be documented at screening (within 21 days prior to initiation of study treatment) and re-assessed prior surgery by spiral or multidetector computed tomography (CT) scan Postoperatively, standard adjuvant chemotherapy will be administered in pathological III-stage and at investigator discretion in pathological II-stage at high risk
8911|NCT04123912|Behavioral|Kinesio Taping - Functional Movement Power Training|Subjects assigned to the Kinesio Taping - Functional Movement Power Training (KT-FMPT) group will receive FMPT concurrent with KT. The FMPT protocol was developed by the research team with reference to common physiotherapeutic exercises for children with motor disabilities.9 It comprises 5 functional movement exercises and 6 lower-limb power/resistance training exercises using weights or resistance bands.
8912|NCT04123912|Behavioral|Jogging with placebo taping|Subjects assigned to the control group will receive no FMPT or KT, but participate in a jogging intervention with placebo tape applied on their calf muscles and removed after the intervention.
8913|NCT04123899|Drug|IGAD→GSTD|"Drug: IGAD First Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)~Other: Washout period 7 days~Drug: GSTD Second Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)"
8914|NCT04123899|Drug|GSTD→IGAD|"Drug: GSTD First Period: Single oral administration of 1 tablet of Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)~Other: Washout period 7 days~Drug: IGAD Second Period: Single oral administration of 1 tablet of Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)"
8915|NCT04123886|Drug|SCB-313|SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .
8916|NCT04123873|Drug|Paracetamol|1g x 4 p.o.
8917|NCT04123873|Drug|Ibuprofen (400 mg x 4)|400mg x 4 p.o.
8918|NCT04123873|Drug|Dexamethasone|24mg IV x 1 after induction om anaesthesia
8919|NCT04123873|Drug|Placebo oral tablet (x 4)|p.o. x 4
8920|NCT04123873|Drug|Placebo IV (x 1)|IV x 1
8921|NCT04123860|Other|ultrasonic hydrodynamic maxillary sinus lift buccal pad fat|ultrasonic hydrodynamic maxillary sinus lift and buccal fat pad as grafting material followed by immediate implant
8922|NCT04123860|Other|ultrasonic hydrodynamic maxillary sinus lift platelet rich fibrin|ultrasonic hydrodynamic maxillary sinus lift and platelet rich fibrin as grafting material followed by immediate implant
8923|NCT04123847|Other|Standing and Stepping|Participants will have at least 80 sessions of stand and step training with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill.
10113|NCT04113772|Drug|Orfadin|Orfadin
8924|NCT04123847|Device|Standing, Stepping and Voluntary Movement with spinal cord Epidural Stimulation|Participants will be have at least 80 sessions of stand and step training with epidural stimulation, with the assistance of trainers over-ground, or in a harness on a body weight supported treadmill. Voluntary movement with epidural stimulation will be completed in the supine or seated position.
8925|NCT04123834|Procedure|Patella tendon & bone block autograft + press-fit femoral technique|Implantless Arthroscopic ACL reconstruction using press-fit femoral technique The investigator's study uses the press-fit graft fixation technique by Edgar Michael. A midline skin incision was made that extends from inferior pole of patella up to anterior tibial tuberosity. Patella tendon with tibial tuberosity bone block were harvested, patella bone was left intact. The tendon was fixed together with non-absorbable suture.
8926|NCT04123834|Procedure|Arthroscopic ACL reconstruction|Arthroscopic ACL reconstruction with implant (using hamstring autograft fixed with bioscrew and endo-button)
8927|NCT04123834|Device|Hamstring tendon autograft + implant fixation|Arthroscopic ACL reconstruction with implant (using hamstring tendon autograft fixed with bioscrew and endo-button)
8928|NCT04123821|Device|Nasopharyngeal airway|A disposable nasopharyngeal airway of appropriate size will be selected for patients allocated to the intervention group with 5L/min oxygen through nasal cannula
8929|NCT04123808|Device|IpsiHand Treatment|The IpsiHand system utilizes a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis donned on the affected upper extremity as participants are guided through a rehabilitation program on a tablet. Participants will complete 16-32 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 3 months post no-device use, to track progress.
8930|NCT04123795|Drug|Certolizumab pegol|"Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~Cimzia~CDP870~CZP"
8931|NCT04123795|Drug|Placebo|"Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Other Names:~-PBO"
8932|NCT04123782|Device|F-ESW Treatment|The biological principles on which is based Focused Shockwave Treatment (F-ESWT) is has been demonstrated mostly in terms of improvement of Platelet Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF), Fibroblast Growth Factor (FGF), Insulin Growth Factor-1 (IGF-1) and Transforming Growth Factor b1 (TGF-b1).
8933|NCT04123782|Device|Placebo F-ESW Treatment|Very low concentration of F-ESW.
8934|NCT04123769|Drug|Hydronidone|First take Hydronidone capsule, single-dose and then Multiple-dose
8935|NCT04123756|Behavioral|standardized exercise therapy for knee OA patients|Standardized exercise therapy for 6-8 weeks (two times per week).
8936|NCT04123743|Drug|Trigonella foenum-graceum extract topical cream|Topical cream containing Trigonella foenum-graceum extract
8937|NCT04123743|Other|Facial Wash|Wardah brand facial wash
8938|NCT04123743|Other|Sunscreen Cream|Parasol sunscreen cream SPF 33
8939|NCT04123743|Other|Placebo|Placebo topical cream
8940|NCT04123730|Other|Fixed-dose compared to variable oxygen flow supplementation during walking|"At day 1 the patients will perform Walk A and Walk B in a random order:~Walk A: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with the fixed-dose (FOT). O2matic will monitor pulse rate and saturation continuously during the test.~Walk B: The patients will perform a Endurance Shuttle Walk Tests (ESWT) with a variable oxygen flow (AOT) depending on the saturation. O2matic will monitor pulse rate and saturation continuously during the test, and adjust oxygen flow depending on the saturation.~At day 2 the patients will perform two 6 minutes walking (MWT) test in random order:~Walk C: A 6 MWT with FOT Walk D; A 6 MWT with AOT"
8941|NCT04123717|Drug|Intravenous Ibuprofen|The treatment phase consists of assignment to a study arm, either IV Ibuprofen, IV Paracetamol, IV paracetamol-Ibuprofen, or PO ibuprofen, and administration of the appropriate medication. The IV medications will be administered over a 15-minute period. The safety of infusion of IVIbuprofen in just 10 minutes has been established, and to infuse over 15 minutes to ensure that IV Paracetamol and IV Ibuprofen have equal infusion times. For IV paracetamol-Ibuprofen, the IV paracetamol-Ibuprofen will be administered as a sequential infusion of IV Ibuprofen over 15 minutes, followed by a flush of the IV line, followed immediately by IV paracetamol infusion over 15 minutes. Oral ibuprofen will be administered as a syrup or tablet based on patient weight and parental preference.
8942|NCT04123704|Drug|Sitravatinib|sitravatinib capsule
8943|NCT04123691|Device|pulse oximetry monitoring|pulse oximetry monitoring as per routine clinical practice
8944|NCT04123678|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|AI-based decision support tool
8945|NCT04123665|Drug|Stannous fluoride|In this arm, participants will apply a full ribbon of dentifrice ( 0.454% w/w stannous fluoride) to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
8946|NCT04123665|Drug|Sodium monofluorophosphate|In this arm, participants will apply a full ribbon of negative control dentifrice (1000 ppm fluoride as SMFP to the bristles of a study toothbrush and brush their teeth in their usual manner for one timed minute twice daily (morning and evening) and record on their study diary completed brushings.
8947|NCT04123652|Drug|Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992|"An intravenous will be started. • Lidocaine - initial dose of 5.0 mg/kg +/- 1.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, not to exceed 7 mg/kg or 600 mg.~• Ketamine - initial dose of 0.1 mg/kg (based on actual weight) over 45 minutes (rounded to nearest 5 mg, up to maximum 15 mg), increased by 0.1 mg/kg (rounded to nearest 5 mg) each infusion based on tolerability of side effects During the infusion patient will be monitored by another MD for BP, PR, PO2. Patients will not be allowed to drive for 24 hours."
8948|NCT04123639|Procedure|PTA|Percutaneous transluminal angioplasty
8951|NCT04123613|Drug|DM199|A pharmaceutical formulation comprised of recombinant human tissue kallikrein-1 (rhKLK-1) that is being developed as an injectable protein drug
9350|NCT04120194|Biological|NanoFlu|Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
8952|NCT04123600|Device|Origin Stem and Logical Cup|The Origin Stem is a straight, tapered, HA coated cementless femoral stem, and the Logical Cup is a porous coated acetabular cup mated with a cross-linked polyethylene liner. The components are used as part of a total joint replacement prosthesis.
8953|NCT04123587|Drug|discontinuation of Sulfonylureas|"Discontinuation of sulfonylurea, alternative drug administration.~If there is a significant increase in blood glucose, it is considered as a sulfonylurea-dependent patient. Discontinue the alternative drug and resume the sulfonylurea, and monitor for 12 weeks or until stabilization of blood glucose at short intervals.~if blood glucose levels are within optimal range after replacement of sulfonylureas with other agents, the patient is regard as non-SU-dependent"
8954|NCT04123574|Drug|Talabostat Mesylate|In this study, BXCL701 will be administered at a dose of 0.6 mg, once daily to all patients for a short period of 14 days. Patients will undergo a tumor biopsy before and again within 2 weeks after completing the 14 days of BXCL701therapy.
8955|NCT04123561|Drug|TLC599|TLC599 is a proprietary (Bioseizer) lipid formulation containing DSP (active ingredient)
8956|NCT04123561|Drug|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
8957|NCT04123561|Other|Normal Saline|0.9% normal saline
8958|NCT04123548|Biological|StrataGraft skin tissue|StrataGraft skin tissue is applied once to no more than 3 separate burn sites, totaling a maximum study treatment area of no more than approximately 1000 cm2, and using no more than 10 tissues.
8959|NCT04123535|Device|ExAblate 2000/2100 Magnetic Resonance-guided Focused Ultrasound (MRgFUS)|The ExAblate 2100 MRgFUS system (InSightec, Inc., Dallas, Texas, USA) is a noninvasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.14-16 The ExAblate combines a focused ultrasound surgery (FUS) delivery system and a conventional diagnostic 3T Magnetic Resonance (MR) scanner. The ExAblate systems provide a real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control. The ExAblate transducer device is an integrated component of the MR table
8960|NCT04123522|Procedure|anterior approach|anterior approach
8961|NCT04123522|Procedure|posterior appraoch|posteiror appraoch
8962|NCT04123496|Device|rTMS|Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
8963|NCT04123483|Drug|EnBrace HR Softgel|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
8964|NCT04123470|Genetic|delolimogene mupadenorepvec|LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
8965|NCT04123470|Biological|atezolizumab|Atezolizumab is an anti-PD-L1 antibody
8966|NCT04123444|Drug|Iloprost|Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
8967|NCT04123444|Drug|Isotonic saline|Continuously infusion for 72 hours.
8968|NCT04123431|Device|Total Hip Replacement|Primary elective total hip replacement
8969|NCT04123418|Biological|WVT078|WVT078 will be administered IV (intravenously) in a dose escalation schedule
8970|NCT04123405|Drug|acetylcysteine|600 mg tablet
8971|NCT04123405|Drug|Placebo|Placebo to acetylcysteine
8972|NCT04123392|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
8973|NCT04123392|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
8974|NCT04123392|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
8975|NCT04123379|Drug|Nivolumab|q4w, dosed twice before surgery and three times following recovery from surgery by injection
8976|NCT04123379|Drug|BMS-813160|300mg oral twice a day for 28 days
8977|NCT04123379|Drug|BMS-986253|2400mg once by injection
8980|NCT04123340|Diagnostic Test|Additional intraprocedural pre-ablation CT-scan|In 20 patients, besides de regular post-RFA scan, a pre-RFA contrast enhanced dual phase CT-scan will be acquired to investigate the feasibility of quantitative ablation assessment.
8982|NCT04123301|Device|Active Theta Burst Stimulation (TBS)|Each session will be comprised of ACTIVE TBS: first, continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
8983|NCT04123301|Device|Sham Theta Burst Stimulation (TBS)|The sham-TBS sessions will be performed using an identical coil that produces SHAM Stimulation: first, sham continuous inhibitory stimulation (cTBS) in the right dorsolateral prefrontal cortex followed by sham intermittent excitatory stimulation (iTBS) in the left dorsolateral prefrontal cortex.
8984|NCT04123288|Drug|ACT-709478|1 film-coated minitablet contains 2 mg of ACT-709478
8985|NCT04123288|Drug|ACT-709478|1 hard capsule contains 10 mg of ACT-709478.
8986|NCT04123275|Other|No intervention wil be done. Patient characteristics and the standard care before and after withdrawal of life-sustaining treatment in all potential cDCD donors, will be studied. .|
8987|NCT04123262|Drug|Tamoxifen 20 mg|Tamoxifen 20mg orally will be given once daily to participants with water
8988|NCT04123249|Drug|Propofol ； Sevoflurane|Group Sevoflurane was given sevoflurane inhalation maintenance (concentration of 2% to 3% and mixed with 50% oxygen and air) to assist sedation； Group Propofol was given propofol 4mg/kg/h intravenous pumping to assist sedation
8989|NCT04123236|Other|Age 0-18|Patients under 18 years of age
8990|NCT04123236|Other|Age 18-26|Patients over18 years of age
8991|NCT04123236|Other|Girls|Girls
8992|NCT04123236|Other|Boys|Boys
8993|NCT04123223|Behavioral|Cognitive Remediation|Cognitive remediation (CR) is a behavioral treatment designed to address neurocognitive deficits through task practice and/or strategy acquisition.
8994|NCT04123223|Behavioral|Computer Games|Sham placebo treatment
8995|NCT04123210|Dietary Supplement|Vitamin A supplement|
8996|NCT04123210|Dietary Supplement|Placebo|
8998|NCT04123171|Diagnostic Test|Neuroimaging studies|Complementary exams are not invasive and will be performed in enrolled individuals who sign a comprehensive informed consent form
8999|NCT04123158|Diagnostic Test|Ultrasound|"Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth >30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; ]"
9000|NCT04123158|Diagnostic Test|MRI|"Diagnostic Test: MRI; MRI investigating the following carachteristics:~TARGET LESION Maximum diameter; Borders; Signal intensity on T2WI; Heterogeneity on T2WI; Cystic alteration(s); Cystic alteration(s) borders; Hemorrhage; T2 dark area(s); Flow voids; Signal intensity on DWI(b-1000); ADC value; ≥ 1,23 Signal intensity on contrasted images Intensity [relative to myometrium] (Hyper- / Hypo- / Iso- intense) Heterogeneity (Homogeneous / Heterogeneous) Unenhanced area(s) Presence (Present / Absent) Location (Central / None or non-central) 1 Tumour - myometrium contrast ratio on T2WI [SItumour - SImyometrium / SImyometrium]"
9001|NCT04123145|Diagnostic Test|Iron status testing|Iron status testing
9002|NCT04123132|Other|Kinesiophobia|The presence of kinesiofobia in patients with metabolic syndrome
9003|NCT04123119|Biological|Rotavirus vaccine|An exploratory and observational cohort study following infants receiving two standard doses of live, attenuated, oral Rotarix™ administered at 6 & 10 weeks.
9004|NCT04123106|Procedure|ESP block|ESP block bilaterally performed at the level of the surgical site prior to surgery.
9005|NCT04123106|Procedure|Wound infiltration|Wound infiltration performed at the surgical site at the end of surgery.
9006|NCT04123093|Device|Noxsano Bandage (Healthy Volunteers)|Healthy volunteers will wear the study device (Noxsano Bandage) for 3 consecutive days (up to 72 hours), followed by weekly visits for 4 weeks of observation for tolerance, side effects, and/or adverse reactions.
9007|NCT04123093|Device|Noxsano Bandage (Wound Care)|Wound care subjects will have weekly study device (Noxsano Bandage) applications to a specific ulceration. For subjects that exhibit any reduction in wound surface area, this application will occur until the wound is healed, or for up to 3 months (whichever occurs first). For subjects that do not exhibit any reduction in wound size at 2 months, application will stop and standard treatment protocols will be pursued. At the conclusion of the treatment window (up to 3 months), subjects will be followed every 3 months for 12 consecutive months for observation of late side effects or adverse reactions (3 months of active treatment, 12 months of follow-up observation, 15 months total).
9008|NCT04123080|Device|Endoscopic band ligation assisted polypectomy|A conventional upper endoscope loaded with a band ligator was inserted in the colon and was advanced to the site of the pedunculated polyp. After approaching the lateral side of the stalk and grasping the mid-portion of the stalk using a tripod grasper. Then, the rubber band was released from the cap to ligate the stalk. Thereafter, we performed polypectomy of the remaining stalk just above the ligation by extending the electrosurgical snare.
9009|NCT04123067|Drug|Pioglitazone 45 mg|45mg Pioglitazone daily for three subsequent days, initiated within 12h of stroke symptom onset
9010|NCT04123067|Drug|Placebo oral tablet|placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
9011|NCT04123054|Other|MDI (multiple daily injections) with Optimization Algorithm|Multiple daily injections (MDI) (slow acting insulin and Rapid acting insulin) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
9012|NCT04123041|Other|JUUL ENDS, Combustible cigarette, comparator e-cigarette, Nicorette gum|JUUL ENDS and comparator e-cigarette will be used for 5 minutes ad libitum, one combustible cigarette will be used ad libitum, Nicorette gum will be used for 30 minutes ad libitum
9013|NCT04123028|Other|observatory|observation for 1 year period
9014|NCT04123002|Other|Miswak chewing sticks|Chewing stick are routinely used by this population
9015|NCT04122989|Other|MS-SUPPORT|MS-SUPPORT is a shared decision making tool designed to be used by patients and providers.
9016|NCT04122976|Drug|Darolutamide(Nubeqa, BAY1841788)|The decision on the dose and duration of treatment is solely at the discretion of the treating physician, based on the recommendations written in the local product information.
9017|NCT04122963|Procedure|High power CLOSE-guided PVI ablation|CLOSE-guided PVI ablation with 45 Watt and stricter stability criteria (3 mm for 3 seconds)
9018|NCT04122963|Procedure|Standard CLOSE-guided PVI ablation|Standard AF ablation according to the CLOSE-protocol
9019|NCT04122950|Behavioral|Exergaming|The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
9020|NCT04122937|Procedure|Cytoreductive surgery|Partial removal of peritoneal tissue involved by neoplastic invasion
9021|NCT04122924|Other|Abdominal muscle training|The intervention starts 6-8 months postpartum and will last for three months with weekly follow-up through an exercise app. Before commencing the home-based program, women in the intervention group will have an individual session in how to perform the program with a physiotherapist. The intervention consists of a 10 min 5 days a week exercise program, including the following exercises; headlift, crunch and twisted crunch. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum. The participants will be provided with a smartphone app (Athlete Monitoring) to be reminded to exercise and to register adherence.
9022|NCT04122911|Drug|Temozolomide|pharmacological
9076|NCT04122417|Other|The Effect Of Therapeutic Touch Training Given To Mothers With Preterm Babies On Attachment Level And The Responses The Baby|The study was carried out as randomized experiment to determine the effect of Yakson or Gentle Human Touch method practiced by mothers to preterm newborns on the maternal attachment level and the baby's responses.
9023|NCT04122898|Other|Pelvic Floor Muscle Training|The intervention will consist of a home-based PFM training program with weekly follow-up by phone by a physiotherapist. Before commencing PFM training, the gymnasts in the intervention group will have an individual session with a physiotherapist including thorough teaching on how to perform a correct PFM contraction (inward lift of the pelvic floor assessed with suprapubic 2D ultrasound) and instructions on how to perform the training program. The athletes will be offered at least one individual follow-up session with the same physiotherapist during the intervention period. The program will consist of 3 sets of 8-12 maximum contractions per day. An electronic app (Athlete monitoring) will be used to assess adherence to the program. The athletes will be asked to register their training sessions in a personal account. A reminder to adhere to the program will be sent by phone. The training period will be 3 months and the exercises will take approximately 10 minutes per day to perform.
9024|NCT04122885|Combination Product|PIPAC with oxaliplatin|Oxaliplatin 92 mg/m2 BSA, applied as an aerosol for 30 min under normothermic conditions at 12-15 mmHg pressure
9025|NCT04122885|Procedure|Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy|If complete cytoreduction possible (CC-0). Application time 60 min, T 41-43 °C
9026|NCT04122859|Device|Zip Skin Closure Device|The device is a CE-marked, single use, sterile medical device that is designed to provide closure speed superior to sutures, while resulting in a suture-like cosmetic outcome. It adheres to the skin adjacent to an incision or laceration by use of pressure-sensitive skin adhesives.
9027|NCT04122846|Behavioral|Emotional Awareness and Expression Therapy|"Very much based on Unlearn your pain by Howard Schubiner."
9028|NCT04122833|Other|Next generation sequencing|observational study
9029|NCT04122820|Diagnostic Test|Diagnostic of specific learning disabilities or of Developmental Coordination Disorder|Speech therapy assessment, or occupational therapy. In case of pathological disorder, search for a sensory disorder, and therapeutic management. If the pathological disorder persists for more than six months, elimination of a secondary etiology.
9030|NCT04122807|Procedure|Cardiac catheter ablation|Cryoablation
9031|NCT04122781|Device|Novel K-wire fixation devices|The patients received surgery using novel K-wire fixation devices
9032|NCT04122768|Behavioral|Multi-component physical activity tele coaching intervention|"A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly. The aim is to progressively increase the PA during the 12 weeks period and maintain afterwards.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed."
9033|NCT04122768|Behavioral|Light coaching intervention|"A. Education about the importance of PA. During a one-to-one interview with the investigator, patients will receive a personal goal (expressed in steps/day), based on their individual exercise capacity.~B.A step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application receives the step data of the patient and asks on a weekly basis about the patient's change in medication. The application does provide a graph showing the steps the patient took and presents a general activity plan including their personal goal (which stays the same throughout the entire intervention period)."
9034|NCT04122755|Drug|ALA-1000|Blood sample for PK analysis are collected before and post single injection of ALA-1000 (Day1) according to the schedule of procedures. Subjects remain in the residential phase through Day21 for safety assessment.
9035|NCT04122755|Drug|buprenorphine sublingual film|ALA-1000 injection after 7 days of buprenorphine sublingual film dosing. Blood sample for PK analysis are collected before and post sublingual buprenorphine dosing on Day-1
9036|NCT04122742|Procedure|skin biopsy for the primary fibroblast culture and a 15 ml blood sample (3 unnamed samples of 5ml) in each of the 4 SRT patients included.|Performed with a 3 mm diameter punch under local anesthesia. The procedure can be done in a consultation office respecting a strict asepsis.
9037|NCT04122742|Other|Generation of Induced Pluripotent Stem Cells (iPSC) from fibroblasts obtained by skin biopsy|induced Pluripotent Stem Cells (iPSC) production of patients with CREBBP mutation and differentiation into cortical neurons and pyramidal neurons
9038|NCT04122742|Other|Histone acetylation profiles of cells of SRT patients with CREBBP mutations|Study of acetylome by liquid chromatography coupled with tandem mass spectrometry (LC-MS / MS) Validation of specific acetylation targets by ChIP-Sequencing
9039|NCT04122742|Other|Functional involvement of identified epigenetic alterations|Transcriptome analysis with RNA-Seq Generation of isogenic iPSC clones by correction of CREBBP mutations in SRT patients by CrispR-Cas9.
9040|NCT04122742|Biological|Culture of lymphoblastoid line from blood sample|Achievement of a ficoll Culture of lymphoblasts and conservation Establishment of lymphoblastoid line and conservation
9041|NCT04122716|Drug|Liraglutide|"Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved. For subjects who do not tolerate the fast weekly up-titration of 0.6 mg study drug until the 3mg, the titration procedure can be prolonged with up to three weeks for each up-titration.~Subjects who do not tolerate the 3mg dose may in special circumstances stay at 2.4 mg, however the overall aim is to reach 3 mg for all study subjects.~The dosage and up-titration follow the recommendations from the summary of product characteristics."
9042|NCT04122716|Behavioral|Exercise|"150 min of moderate intensity, 75 min of vigorous intensity, or an equivalent combination of moderate and vigorous intensity exercise per week in accordance with WHO recommendations.~Exercise prescription will be performed under strict control of the scientific personnel.~There will be aerobic exercise and will include 4 sessions per week after the ramp-in period.~2 sessions per week will be performed under supervision of the staff and 2 sessions will be performed individually but monitored by the staff.~Supervised sessions include structured exercise with a duration of 45 min. Of this 30 min will comprise of interval-based spinning session and 15 min circuit training program focusing on large muscle groups.~Individual exercise includes aerobic exercise and general physical activity (e.g brisk walking and cycling to work).~Participants will use heart rate monitors during sessions."
13194|NCT04088383|Other|Saline|Sterile saline
9043|NCT04122703|Device|percutaneous tibial nerve stimulation (PTNS)|The PTNS treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
9044|NCT04122703|Device|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
9045|NCT04122690|Behavioral|PDAE|Participants with PD will dance the follower role only and will dance with new partners (individuals without PD) every 15-20 minutes, a widely practiced method considered by the dance teaching community to enhance learning. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Frequent repetition and musical stereotypes may foster implicit learning or muscle memory (i.e., motor learning, or procedural memory that involves consolidating a specific motor task into memory through repetition). Participants will not be required to memorize specific step patterns but will learn new steps in each class
9046|NCT04122690|Behavioral|WAE|The participants will receive equal contact and monitoring from study staff. WAE participants will report to the same facility and interact with the same interventionist and assistants. The participants will participate in sessions focused on at least 60 minutes of walking with breaks ad libitum, and 1/2 hour balance and stretching. The investigators have a designated, safe and non-cluttered area for walking. WAE will also take place in groups, with research volunteers and assistants to ensure that PDAE and WAE participants both receive a socially engaging intervention
9047|NCT04122677|Device|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw.
9048|NCT04122664|Device|RayOne® Hydrophobic lens 800C|Patients will receive a monofocal, aspheric, hydrophobic acrylic intraocular lens: the RayOne® Hydrophobic lens 800C
9049|NCT04122664|Device|RayOne® Hydrophilic lens 600C|Patients will receive a monofocal aspheric, hydrophilic acrylic intraocular lens: the RayOne® Hydrophilic lens 600C.
9050|NCT04122651|Procedure|'Off the shelf' toric lens|'Off the shelf' toric lens (either 2.00D or 4.00D) and combined limbal relaxing incisions and/or off-axis inttaocular lens rotation
9051|NCT04122651|Procedure|Tailored Toric lens|Fully targeted toric intraocular lens correction for corneal astigmatism
9054|NCT04122599|Drug|Melatonin|Melatonin for prevent post stroke delirium
9055|NCT04122586|Drug|Tongxieyaofang(granule)|Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
9061|NCT04122560|Drug|Fluconazole 200mg tab|PO dose of 400mg
9062|NCT04122560|Drug|Fluconazole 2 MG/ML|IV dose of 400mg
9063|NCT04122547|Drug|Roflumilast|Active drug
9064|NCT04122547|Drug|Placebo|Placebo one tablet oral od
9065|NCT04122534|Behavioral|Somatic Mindfulness Training|Educational and experiential training to reduce occupational-based secondary trauma.
9066|NCT04122521|Diagnostic Test|MRI|MRI
9067|NCT04122495|Dietary Supplement|Probiotic|Oral administration of B. lactis M8 at 10 log CFU/day for 4-weeks
9068|NCT04122495|Dietary Supplement|Placebo|Oral administration of maltodextrin daily for 4-weeks
9069|NCT04122482|Behavioral|Psychoeducation Course|The investigators are assessing the efficacy of the accommodations course. Specifically, the investigators will evaluate the impact on requesting and receiving accommodations for anxiety and/or depression, employee knowledge of accommodations, and employee self-stigmatizing attitudes. The investigators will also assess if the course helps improve comfort level of disclosing a mental health diagnosis and rates of disclosure in the workplace.
9070|NCT04122469|Radiation|Stereotactic Body Radiotherapy|A previous study found that in four of the five metastatic GI patients, SBRT increased the duration of effective systemic therapy with no significant additional toxicities. There have been small number of case reports in lung and renal cancers, which suggest the potential for improvement in progression free survival. The purpose of this study is to evaluate the safety, and efficacy of SBRT in this patient population
9071|NCT04122456|Radiation|Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory for exposure to ultraviolet B radiation. After 1-hour incubation, the biopsies will be bisected in half.
9072|NCT04122456|Other|No Ultraviolet B Radiation|One skin punch biopsy will be taken to the laboratory and will be kept as a non-irradiated control.
9077|NCT04122404|Diagnostic Test|LF-LAM|Open label multi-center stepped wedge cluster-randomized controlled trial with implementation of LF-LAM. All clusters (i.e. HIV/ART clinic attached wards) start with standard of care and are then randomized to switch to the intervention phase at predefined time points.
9078|NCT04122391|Other|sound level volume|Noise level during cardiac arrest
9079|NCT04122378|Other|acupuncture|The acupuncture will be provided by the licensed acupuncturist using standard methods.
9080|NCT04122365|Other|Chest Wall Mobilization Program|Soft tissue therapy and joints mobilization
9081|NCT04122365|Other|Control|Routine limbs exercises and education
9082|NCT04122352|Other|Ischemic compression|Ischemic compression was performed 3 times ; after the initial evaluation, after the first week evaulation and after the second week evaulations.
9083|NCT04122352|Other|Exercises (Rocabodo's 6x6 exercises and posture exercises)|Rocabodo's 6x6 exercises exercise was shown to be administered for 4 weeks. After the first week evaluation, posture exercises are added to the exercise programs of the patients.
9084|NCT04122339|Drug|MAX-10181|"Part 1: Dose escalation, MAX-10181 once or twice daily with dose modifications based on tolerability criteria.~Part 2: Dose expansion, Recommended doses from Part 1."
9085|NCT04122326|Behavioral|Workstation Modification|Participants are asked to work in a sequence of workstation setups for ten minutes each. The sequence include 1. sitting with workstation adjusted by the participant, 2. sitting with workstation adjusted to promote proper posture, 3. sitting with workstation adjusted to promote unnatural posture, 4. standing with workstation adjusted by the participant, 5. standing with workstation adjusted to promote proper posture, and 6. standing with workstation adjusted to promote unnatural posture. After the sequence of setups, the participant allowed to adjust the workstation in either sitting/standing to work in 60 minutes in their own desired position.
9086|NCT04122313|Other|Evaluation of Dupuytren's Disease Treatment|There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
9087|NCT04122300|Drug|Euphrasia Officinalis Preparation|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
9088|NCT04122300|Drug|Placebo|At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of placebo is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
9089|NCT04122287|Drug|clarithromycin|clarithromycin-tetracycline-containing quadruple regimens
9090|NCT04122287|Drug|tinidazole|tinidazole-tetracycline-containing quadruple regimens
9091|NCT04122274|Behavioral|NCAA education sheet|A fact sheet that includes information about basic signs and symptoms of a concussion as well as steps to take if an individual sustains a concussion and reinforces the need to report the injury.
9092|NCT04122274|Behavioral|Sham Intervention|An approximately 7-minute video that includes information about basic sports nutrition facts.
9093|NCT04122274|Behavioral|Decision-based interactive concussive education platform|A platform grounded in theoretical frameworks including the socioecological model and theory of planned behavior. It includes a short video to provide an overview of key lessons, a short quiz, and additional resource links that conclude the module.
9094|NCT04122261|Device|the MicroHand S endoscopic instrument control system|Using the MicroHand S endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
9095|NCT04122261|Device|the da Vinci endoscopic instrument control system|Using the da Vinci endoscopic instrument control system to treat gallstone or cholecystitis in minimal invasive surgery.
9096|NCT04122248|Other|standard radiographic imaging|standard radiographic imaging
9098|NCT04122222|Biological|Influenza vaccine|A single standard dose of inactivated trivalent influenza vaccine: Influvac® vaccines (Abbott, the Netherlands), intramuscularly.
9099|NCT04122209|Other|HIIE-First|Multiple exercise bout during the same day; HIIE first followed by continuous exercise
9100|NCT04122209|Other|Continuous-First|Multiple exercise bout during the same day; Continuous exercise first followed by HIIE
9101|NCT04122196|Drug|Pregabalin 300mg|Patient will receive a compounded version of 300mg pregabalin PO approximately one hour before surgery.
9102|NCT04122196|Drug|Placebo oral tablet|Patient will receive a compounded version of inactive placebo PO approximately one hour before surgery.
9103|NCT04122183|Other|iManage (my hearing loss)|An internet-based decision coaching guide to help an individual decide if they wish to visit an audiologist.
9104|NCT04122170|Drug|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 90 mg oral tablet; administered as 180 mg (2 × 90 mg tablet) loading dose plus 90 mg every 12 hours for 4 additional doses.
9105|NCT04122170|Drug|Aspirin (ASA) Oral Tablet - Pre-Treatment|Aspirin 81 mg oral tablet; administered daily between Day -7 to the morning before receiving study medication on Day 1, for a total of 8 tablets only.
9106|NCT04122170|Drug|PB2452 Infusion|PB2452 18 g Intravenous Infusion over a 16 hour duration
9107|NCT04122170|Drug|Placebo (0.9% Sodium chloride) infusion|0.9% Sodium chloride Intravenous Infusion over a 16 hour duration
9163|NCT04121663|Device|Total arthroscopic rotator cuff repair|The equivalence of the two devices was compared by using control and experimental instruments during the operation
9351|NCT04120194|Biological|Fluzone Quadrivalent|Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
9108|NCT04122144|Behavioral|ENHANCED -SPS intervention|a) Enhanced VL counseling: Explanation of VL & Importance of VL suppression,assessment of adherence, counseling based on VL result and schedule for next VL testing and the role of VL and the MTCT risk; b).Standardized peer mother support: includes training of peer mothers on mandatory enhanced VL counseling during the routine peer counseling and education, follow up of mothers and continued adherence counseling and disclosure support and bi-weekly phone calls to mothers to provide VL counseling and follow up
9109|NCT04122131|Diagnostic Test|Immunohistochemistry|Immunohistochemical analysis of biomarker in post-surgical sample
9110|NCT04122118|Other|Medical Chart Review|Review of medical chart
9111|NCT04122118|Other|Educational Intervention|Receive pharmacist-led education
9112|NCT04122118|Other|Survey Administration|Ancillary studies
9113|NCT04122105|Drug|Sildenafil|The intervention group will receive standard care in all capacities with the exception of sildenafil administration. The first dose (50mg) will be given 1-hour prior to the surgery. Patients will be given Sildenafil twice daily up to 3 days post-transplant.
9114|NCT04122092|Diagnostic Test|The level of plasma cfDNA CINs|The extracted cfDNA from PB will be analyzed by UCAD to determine the level of CINs
9115|NCT04122066|Drug|sofosbuvir \daclatsvir|study the effect of the new oral antihepatitis C drugs on the respiratory system
9116|NCT04122053|Behavioral|Intervention group with genotype information|Results of genotyping will be translated into personalised dietary recommendations. Subjects will be informed about their genotypes from the beginning of the study. The importance of personalised recommendations will be explained.
9117|NCT04122053|Behavioral|Control group without genotype information|Subjects will receive personalised dietary recommendations, but at the beginning they will not be informed about their genotypes and the meaning of personalisation. Information about their genotype will be given to the participants at the and of study.
9118|NCT04122040|Drug|Roxithromycin 300 MG|Roxithromycin 300 mg oral per day
9119|NCT04122040|Drug|Placebo|Placebo one table oral once dialy
9120|NCT04122027|Other|Cerebral oximeter|Near infra-red spectroscopy, NIRS
9121|NCT04122014|Other|Progressive balance training|Progressive balance training program
9122|NCT04122014|Other|Normal daily activities|Usual daily activities
9123|NCT04122001|Device|Active HD-tDCS|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (angular gyrus). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
9124|NCT04122001|Device|Sham|Current will be administered in a ramp-like fashion but after the ramping the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.
9125|NCT04122001|Other|Word List Learning Intervention (WordLLI)|Participants will receive a word list learning intervention (WordLLI) of semantically related and unrelated word lists. Word lists are presented across 10 trials, with an additional trial after a 10-minute delay to assess delayed recall. Immediately following verbal presentation of word lists during each trial, participants will be instructed to recall as many of the words from the list as possible. Participants may use the written modality as a strategy during recall. Word lists include 12 words matched based on psycholinguistics attributes (e.g., imageability, frequency). This task is designed to help participants improve memory via enhancing list learning capabilities.
9126|NCT04121988|Diagnostic Test|MRI|Deep learning based denoising MRI or conventional MRI
9127|NCT04121975|Radiation|Radiotherapy|Radiotherapy was administered in 1.8-2.0 Gy fractions 5 times weekly to a total dose of 45-50 Gy.
9128|NCT04121975|Drug|Endostar|30 mg/d was administered on days 1-5 every two weeks for 4 cycles.
9129|NCT04121975|Drug|Cisplatin|30-40 mg/m2 was administered day 1, 8, 15, 22 and 29.
9130|NCT04121962|Behavioral|Peer Mentor|Participants will be trained to be Peer Mentors and promote home-based testing to their social network
9131|NCT04121962|Behavioral|Website only|Participants will be given instructions on how to use the project website to request kits to test for HIV at home and collect specimens for lab testing.
9132|NCT04121949|Device|CADScor®System|The CADScor®System is a low cost, low resource-demanding, non-invasive, radiation-free device using highly advanced analysis of sounds originating from blood flow turbulence in the coronary circulation and myocardial motion. Heart sound recordings are obtained transcutaneously during a 3 minutes recording period with a microphone mounted at the IC4. A CAD-score on a scale from 0 to 99 is estimated immediately after the recording with a fully automated algorithm. The algorithm measures eight acoustic properties and the resulting acoustic score is combined with the clinical risk factors gender, age, and hypertension. The entire procedure lasts approximately 10 minutes.
9133|NCT04121936|Other|There will be no intervention|There will be no intervention
9134|NCT04121923|Device|Belun Ring Pulse Oximeter|Belun Ring Pulse Oximeter allows measurement and analysis of oximetry, pulse rate, photo-plethysmography (PPG), and accelerometer signals from the proximal phalanx of index finger. Total sleep time (Ring-TST) and respiratory event index (Ring-REI) are estimated
9135|NCT04121910|Drug|Savolitinib|On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
9136|NCT04121910|Drug|Itraconazole|Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
9137|NCT04121897|Other|Therapist Education and Massage for Parents of Extremely Preterm Infants|"TEMPO includes these components:~Early Parent Education Session~Weekly Parent Education Sessions~Infant Massage Parent Education Sessions~Discharge Parent Education Session~Parent Education Post-Discharge~Bi-weekly emails (or texts)~2 Month Follow-up Massage Review Session"
9164|NCT04121650|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
9352|NCT04120181|Other|There is no intervention.|There is no intervention.
13195|NCT04088370|Other|Blood Draw|Blood Draw Only
9138|NCT04121884|Behavioral|Accelerated Resolution Therapy|"The ART protocol first uses the technique of imaginal exposure to elicit physiological reactions associated with patient recall from beginning to end (verbally or non-verbally) of a traumatic/distressing experience. As physiological reactions emerge, the participant is directed to focus their attention on the specific body-centric reactions while laterally performing smooth pursuit eye movements which are achieved by tracking the clinician's hand which oscillates from left-to-right at a short distance from the participant's eyes. Then the participant is directed to imagine a positive way in which they prefer to recall their experience(s), including emphasis on replacing negative images in the brain with positive images. This technique is based on the process of memory reconsolidation, which allows for adding of positive material to the recall of negative, highly emotional past experiences."
9139|NCT04121871|Other|No intervention|Not required
9140|NCT04121858|Other|Brain Safe App|The Brain Safe app is a direct-to-consumer intervention with four main features that combine to encourage anticholinergic users to self-initiate de-prescribing of strong prescription anticholinergics, in consultation with a clinician. Intervention components are delivered electronically via mobile app, also accessible as a website via a web browser. In this study, Brain Safe will be loaded on a provided or personal smartphone device. The three features - Medication List, Risk Calculator, Multimedia Content, and Conversation Starter -
9141|NCT04121858|Other|Attention Control App|"• Medication List allows users to select their medications from a searchable database, built from RxNorm (National Library of Medicine). Users can also type in a medication. Users can enter for each medication a dosage, frequency, and reason for use. Each medication entry can be saved, edited, or deleted. Individuals can perform a medication review to update in serial order whether each medication is still being taken and at what dose and frequency. The medication review is due each month and notifications are sent to users reminding them to complete it."
9142|NCT04121845|Device|Coronary Sinus Reducer device|Coronary sinus reducer device (Neovasc, Richomnd, Canada) implantation in the coronary sinus. The procedure is performed in the cardiac catheterization laboratory through right internal jugular vein.
9143|NCT04121845|Other|Sham procedure|Puncture of the right internal jugular vein and simulation of the CSR implantation procedure.
9144|NCT04121832|Device|Biofeedback training treatment in Fibromyalgia, a pilot study|The selected sample will undergo 10 total Biofeedback Training sessions, once a week. Each session will last 45 minutes. The total duration of the treatment will be 10 weeks
9145|NCT04121832|Other|Control (treatment as usual)|The sample will be treated only with standard therapies without the use of biofeedback training for 10 weeks
9146|NCT04121819|Drug|Cytarabine|cytarabine 100mg/m2 d1-5 subcutaneous
9147|NCT04121806|Other|UC intervention diet|The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
9148|NCT04121793|Device|Kinesia 360 and Smartphone sensors|Data will be recorded from the Kinesia 360 system and smartphone sensors using the AWARE Framework.
9149|NCT04121780|Biological|Growth Hormone|"Daily self-injections by subjects:~1-year double-blind phase; 6-month open-label extension for those who received placebo during the double-blind phase"
9150|NCT04121780|Other|Placebo|"Daily self-injections by subjects:~1-year double-blind phase"
9151|NCT04121767|Drug|Edoxaban|oral edoxaban 60mg once daily for 3 months
9152|NCT04121767|Drug|Warfarin|oral warfarin once daily for 3 months according to prothrombin time
9153|NCT04121741|Other|Singing with Music Therapist|Music therapy sessions will begin with vocal and breathing warm-up exercises for about 10 minutes. The Music Therapist will play the songs (chosen from a list by the subject) to sing along to and will alter the characteristics of the music (volume, tempo, level of support) to ensure a successful experience for subjects and motivate them to put forth more effort into singing the song. The music therapist will continue to coach throughout the 30-minute session, reminding subjects of strategies practiced and how to implement those strategies while singing. Music therapy sessions will be led by Erica Flores, MT-BC, WMTR, Owner of Healing Harmonies Music Therapy, or a member of her team. Erica and her team of MTs were trained in Neurological Music Therapy.
9154|NCT04121741|Other|Singing with Guided Video|The videos will include a vocal warm-up (10 minutes long). The subject will then have the option to select and sing two songs (10 minutes each), with offerings in four music genres including Folk, Pop, Country, and a Hymn. Each piece will vary in tempo, melodic contour, and rhythm. The total duration of singing via this format will be 30 minutes.
9155|NCT04121741|Other|Control Arm|30 minute rest period, no singing will take place during this arm. During this rest period a member of the study team will assist the subject in a hearing test using headphones, a tablet, and a trumpet app. This is done to asses the current hearing level of the subject.
9156|NCT04121728|Drug|Ginkgo biloba extract|Symfona® commercial standardized Ginkgo biloba extracts are used in this study, at a rate of 2 capsules of 120 mg per day for 170 days.
9157|NCT04121728|Drug|Placebo|The placebo is presented in the form of capsules of identical mass, color and shape to those of the study product. It is composed of lactose, the excipients present in Symfona® 120 mg and colorants. The dosage is identical to that of the investigational product.
9158|NCT04121715|Device|Fastigial Nucleus Stimulation|Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation
9159|NCT04121715|Drug|Standard treatment|"Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition"
9160|NCT04121702|Procedure|Cardiac Rehabilitation|Implementation of a physical exercise program (PEP) with tele-monitoring
9161|NCT04121689|Dietary Supplement|Milk Protein Concentrate|The macronutrient composition and energy of the milk protein beverage provided to participants is 38 g protein (3.46 g leucine), 4.17 g carbohydrate, and 1.4 g fat. The milk protein met all chemical and bacteriologic specifications for human consumption. The L-[1-13C]phenylalanine and L-[1-13C]leucine enrichments in the milk protein concentrate averaged 38.3 and 10.8 mole percent excess (MPE), respectively.
9162|NCT04121676|Drug|AGEN2373|Infusion of AGEN2373
9165|NCT04121637|Other|Aerobic Exercise|"Each exercise session;~5 min warm-up = 30% of VO2 max~20 min exercise = 50-60% of VO2 max~5 minutes cooling in the form. The goal of aerobic exercise is to increase physical capacity, which is represented by maximum oxygen uptake (VO2max) and mechanical power generated during exercise. Training programs should be conducted at least 2 to 3 times per week (60-80% maximum work rate or 60% VO2max) for 30 to 60 minutes at moderate concentrations. These programs are effective in increasing aerobic capacity and power output in MS."
9166|NCT04121637|Other|Frenkel coordination exercises|Patients will be given Frenkel Coordination exercises (4 different exercises 4-5 repetitions depending on the individual's functional and motor status) 3 times a week for 6 weeks. 1 minute break between each exercise set
9167|NCT04121624|Device|novel mobile phone application for blood pressure monitoring.|Comparative blood pressure measurement with the smartphone application and the non-invasive reference method (upper arm cuff).
9168|NCT04121611|Drug|Unfractionated heparin|"Intravenous unfractionated heparin (UFH) infusion within 6 hours of EVT with target activated partial thromboplastin time (aPTT) 64-86~Anticoagulation to continue for minimum of 48 hours (can be maintained on UFH aPTT 64-86 or transitioned to low-molecular weight heparin (LMWH) Enoxaparin 1mg/kg)"
9169|NCT04121611|Drug|Acetylsalicylic Acid (ASA)|"Acetylsalicylic Acid (ASA) 325mg PO/PR/NG loading dose < 2 hours of EVT completion~ASA 81mg PO OD maintenance dose"
9170|NCT04121598|Other|Observational|Observational data will be obtained through self-report measures, parental report measures, cognitive assessments, and a semi-structured interview.
9171|NCT04121585|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ hydroxylapatite coated cement free hip stem
9172|NCT04121572|Device|Nasal cannula capnography|Capnography: a continuous wave form of the CO2 level with the digital reading of CO2 level at end of expiration
9173|NCT04121559|Behavioral|A&T Interventions|"Classroom sessions/lessons related to nutrition, dietary diversity, healthy food choices and hand washing.~School assemblies and discussions facilitated by Health Extension Workers (HEWs) related to nutrition, dietary diversity, healthy food choices and hand washing.~Kids club activities addressing nutrition, dietary diversity, healthy food choices and handwashing.~Parent-teacher association meetings, HEW-led community discussions, and other community gatherings to inform and encourage parents about adolescent nutrition, dietary diversity, importance of breakfast before school and healthy snacks, and handwashing.~Workshop on the adolescent nutrition interventions above for school principals, science teachers, HEWs, supervisors, and woreda officers.~Monthly/biweekly supportive supervision on adolescent nutrition activities for schools and HEWs by school supervisors or woreda health/education office."
9174|NCT04121546|Behavioral|Telecare Intervention|Patients will meet with a care coordinator to decide upon an opioid tapering schedule and fill out baseline measures. A 6 week positive psychology intervention will also be introduced in which patients will practice different techniques each week over 6 weeks, and will then practice incorporating a single technique into daily practice for the remaining 6 weeks. During the first 6 weeks, patients will have weekly check in meetings with a care manager to report on any withdrawal symptoms. These meetings will space to ever other week during the remaining 6 weeks. Possible treatment adjustments will be discussed between the care coordinator and primary investigator at weekly meetings. At the completion of the 12 week study, patients will complete 12 week measures.
9175|NCT04121533|Dietary Supplement|Placebo|Placebo supplement for vitamin D (cholecalciferol), glucosamine sulfate, and omega-3 fatty acids. Supplement was taken orally every day for 84-days.
9176|NCT04121533|Dietary Supplement|Vitamin D (cholecalciferol)|Vitamin D (cholecalciferol). Supplement was taken orally every day for 84-days.
9177|NCT04121533|Dietary Supplement|Glucosamine sulfate and omega-3 fatty acids|Glucosamine sulfate and omega-3 fatty acids supplement was taken orally every day for 84-days.
9178|NCT04121520|Other|Questionnaire|"Comprehensive perioperative assessment~Questionnaire administration"
9179|NCT04121507|Drug|High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)|High-dose therapy (HDT) prior to alloSCT will consist of FTC
9180|NCT04121507|Procedure|Bone marrow histology|Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved
9181|NCT04121507|Diagnostic Test|clinical and laboratory parameters|During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.
9182|NCT04121507|Diagnostic Test|PET-CT or CT|Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.
9183|NCT04121494|Biological|ChadOx1 85A - aerosol|Aerosol administration through the Omron MicroAIR NE-U22 nebuliser
9184|NCT04121494|Biological|ChadOx1 85A - IM|Intramuscular administration
9185|NCT04121481|Dietary Supplement|Clinical Investigation on Enhanced Sports Nutrition and Performance Activities by Prodovite VMP35 Supplement|Assess the Sports Nutrition efficacy of Prodovite VMP35 against the Placebo sample
9186|NCT04121481|Dietary Supplement|Broad Spectrum Safety|Benefits in Sports Nutrition
9187|NCT04121468|Drug|Metformin|Each tablet contains 500mg of metformin hydrochloride
9188|NCT04121468|Other|Placebo|Each tablet contains no active drug ingredient
9189|NCT04121455|Drug|Olaptesed pegol|Olaptesed pegol continuous administration for 26 weeks
9190|NCT04121455|Radiation|Radiotherapy|Radiotherapy in weeks 1-6; cumulative dose of 60 Gy in 2 Gy fractions
9191|NCT04121442|Biological|Isunakinra|Isunakinra is a recombinant protein that binds to the IL1R1 and potently blocks IL-1 alpha and IL-1 beta signaling
9192|NCT04121442|Biological|PD-(L)1 Inhibitor|Monoclonal antibody targeting PD-1 or PD-L1
9193|NCT04121429|Other|Observation|No intervention will be performed
9194|NCT04121416|Drug|Oxycodone 10mg|induction with 0.3mg/kg of oxycodone in general anesthesia
9195|NCT04121416|Drug|Sufentanil|induction with 0.3 µg/kg of Sufentanil in general anesthesia
9196|NCT04121403|Biological|Rituximab|Biosimilar rituximab concentrate for solution for infusion
9197|NCT04121403|Drug|Cladribine|Mavenclad oral cladribine tablets
9198|NCT04121390|Behavioral|Newborn Parenting Class|Newborn Parenting Class designed by Mount Sinai Parenting Center. The class is 1-hour long and taught be pediatric attending and residents to all families who deliver well babies at Mount Sinai.
9199|NCT04121377|Other|Resistance training|"Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected."
9200|NCT04121364|Device|Tetranite|Dental Adhesive for increased implant stability
9201|NCT04121351|Other|Singing participation|Participants will follow a 15 minute protocol consisting of the components of a Singing for Lung Health class, and a short period walking on a treadmill.
9202|NCT04121338|Procedure|Celiac ganglion block|The celiac ganglion block will be performed under CT guidance and with the patent under moderate sedation. With the patient prone the back will be prepped and draped sterility. Under CT guidance two 22 gauge needles will be placed with the tips on either side of the celiac artery. This is the location of the celiac ganglia. Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based. Then patient will be observed for 1-2 hours post procedure and then discharged to home
9203|NCT04121338|Drug|Liposomal bupivacaine|Liposomal bupivacaine will then be injected in that location. Maximum dose is 133 mg for 75 kg person. For lower weight patients, dose will be weight based.
9204|NCT04121325|Device|Enterra|To measure validated and subjective pain scores among patients with an existing GES device, and who have a trial of new settings directed at abdominal pain and compare their pain scores to each patient baseline symptoms, done with their previous GES settings.
9205|NCT04121312|Behavioral|Facilitation Intervention|"See arm description"
9206|NCT04121299|Drug|Carvedilol|participants will be randomized to carvedilol or amlodipine for the 1st or 2nd 4 week treatment period
9207|NCT04121299|Drug|Amlodipine|participants will be randomized to carvedilol or amlodipine for the 1st or 2nd 4 week treatment period
9208|NCT04121286|Drug|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
9209|NCT04121273|Biological|CAR-T cell immunotherapy|"Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows:~Dose 1: 1x10^7/m2~Dose 2: 3x10^7/m2~Dose 3: 1x10^8/m2~The cell numbers are calculated according to CAR-positive T cells."
9210|NCT04121260|Drug|Daratumumab|Participants will receive dose 1 daratumumab with 30,000 U (2000 U/mL) with rHuPH20 SC injection.
9211|NCT04121247|Other|nonpharmacological approaches to parents of children with sickle cell disease training program|use of non-pharmacological approaches in children with sickle cell disease, parent education
9212|NCT04121234|Other|"Exposure:  being admitted to HDU with a red code to OEWS"|High Dependency Unit, a set of predefined variables was assessed at hospital admission, HDU admission and at discharge from HDU with the aim to investigate epidemiology, clinical outcomes and risk factors for mortality in critically-ill parturients admitted to an obstetric HDU in a high volume, urban resource-limited maternity hospital
9213|NCT04121221|Drug|GA Depot|Long acting intramuscular injection of glatiramer acetate, once every 4 weeks
9214|NCT04121221|Other|Placebo|IM injection once every 4 weeks
9215|NCT04121208|Drug|JNJ-40346527|Active study drug
9216|NCT04121208|Other|Placebo|Non-active study drug
9217|NCT04121195|Drug|Dose escalation|The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
9218|NCT04121182|Other|On-line training|"Nursing teams randomized in the intervention group will benefit from an intervention in the form of a specific training online on the prevention of pneumonia and their management in the nursing home This training focuses on prevention, and management during the infectious period (the false food route and the management of pneumonia)."
9219|NCT04121182|Other|Usual practice|Nursing home with usual practice : The act of comparison is defined by the usual care, as they are performed in the nursing home at the time of the study. No restrictions are placed on residents or caregivers of any kind in the care of the resident.
9220|NCT04121169|Drug|IM-01|Antibodies react with C. difficile toxin, C. difficile bacteria and spores; neutralizes the toxin and inhibit the growth of spores and vegetative forms of C. difficile
9221|NCT04121156|Device|HD-tDCS treatment|2 milli Amp dose of HD-tDCS treatment for for 20 minutes, for 5 consecutive twice daily sessions
9222|NCT04121156|Device|sham (placebo) HD-tDCS|Participants will receive sham (placebo) HD-tDCS for 20 minutes, for 5 consecutive twice daily sessions
9223|NCT04121143|Biological|IL-17A Antagonist|SHR-1314 subcutaneous injection
9224|NCT04121143|Biological|Placebos|placebo subcutaneous injection to maintain consistency and to prevent blindness
9225|NCT04121130|Device|F-ESWT Group|3 F-ESWT sessions, 1 per week (0,10 mJ/mm2; 2000 impulses; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
9226|NCT04121130|Device|sham F-ESWT|3 sham F-ESWT sessions, 1 per week (0,01 mJ/mm2; 2000 SW; 5 Hz) in the most painful tender and/or trigger points of the upper trapezius muscle.
9308|NCT04120441|Behavioral|Group Mentoring/Intervention|Study participants randomized to intervention will be enrolled in a Y in Central Maryland group mentoring program that meets weekly over a three month period. Parents will participate in three parenting sessions.
10178|NCT04113200|Dietary Supplement|MerMed One|A 1 kcal per ml enteral feed containing an alginate.
9227|NCT04121117|Other|Chronic obstructive pulmonary disease screening|"To verify the tobacco withdrawal, the patients will make a cooximetry.~For the detection of a possible obstructive pattern a measurement of the ventilatory capacity will be make using the COPD-6 device and for the confirmation of COPD diagnosis and the assesment of the airflow obstruction severity a spirometry will be make.~The patients will also complete the COPD-PS questionnaire."
9228|NCT04121104|Other|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
9229|NCT04121104|Other|SCS is switched on|Spinal cord stimulator is on
9230|NCT04121091|Drug|Pramipexole Pill|Add-on pramipexole
9231|NCT04121078|Drug|TAK-906|TAK-906 capsule.
9232|NCT04121078|Drug|Rifampin|Rifampin infusion.
9233|NCT04121065|Procedure|Blood withdrawal|Blood withdrawal of maximum 60 ml performed to each enrolled patient during the study for primary and secondary endpoints evaluation.
9234|NCT04121052|Drug|JNJ-64417184|Participants will receive single dose of JNJ-64417184 as oral tablet.
9235|NCT04121039|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
9236|NCT04121039|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
9237|NCT04121026|Other|External validation of the PAANTHER TB treatment decision algorithm|"The PAANTHER algorithm will be used for a TB treatment decision by site clinicians in all children enrolled in the study. The PAANTHER algorithm and prediction score was designed as a guiding tool for empirical TB treatment decision in HIV-infected children with presumptive TB. The proposed score includes:~history of contact~suggestive TB symptoms~tachycardia~chest radiography~abdominal ultrasound~Xpert MTB/RIF Ultra. A score of >100 is highly predictive of TB. In children with a score >100, anti-TB treatment will be initiated immediately. In children with a score of <100, TB treatment will not be initiated except in those with severe/life-threatening conditions for whom TB treatment decision could be made at the discretion of the site clinician. TB could be definitely ruled out after further assessment and decision made as to what treatment the children should receive in accordance with existing national protocols, along with clinical follow-up."
9238|NCT04121013|Other|mothership|Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
9239|NCT04121000|Procedure|VIDEO ASSISTED THOTACOSOPIC SURGERY|VATS
9240|NCT04120987|Drug|Lifitegrast 5% Ophthalmic Solution|BID OU
9241|NCT04120974|Behavioral|Optimal insulin injection|subjects receive training in optimal injection technique.
9242|NCT04120961|Drug|delayed continuous use of bivalirudin|delayed continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)
9243|NCT04120961|Drug|bivalirudin use during ePCI|bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)
9244|NCT04120948|Device|Waterlase Express Laser System|10-minute treatment with the Waterlase Express (Biolase, Irvine CA). The dorso-posterior surface of the tongue is treated with the laser in 10 passes of 60 seconds each with 10 seconds of rest in between. Laser settings were 60μs pulse width, 4W, 40Hz, 10% air and 5% water irrigation. An MC12 sapphire laser tip (Biolase, Irvine CA) is held 3mm away from the tongue in a constant sweeping motion during treatment with passes overlapping passes in alternate direction, side to side motion and front to back motion with laser fluence on the tongue surface calculated at 3J/cm2. The settings were non ablative and non thermal.
9245|NCT04120948|Device|Tongue scraper|mechanical scraping of the dorso-posterior surface of the tongue
9246|NCT04120935|Other|Observation|Prospective Observation of standard clinical practice.
9247|NCT04120922|Other|calcium carbonate|See arm description
9248|NCT04120922|Other|sevelamer carbonate|See arm description
9249|NCT04120909|Device|Cardiac resynchronization therapy|Biventricular pacing according to current standards.
9250|NCT04120896|Behavioral|Karate group|Children in the karate group will receive the basic Goju Ryu Karate training that includes basic stances (dachi), punching (zuki), blocking (barai) and kicking techniques (keri), form training (kata), supervised sparring (kumite), and conditioning exercises (for warm up and cool down).
9251|NCT04120896|Behavioral|Kung fu group|Children in the Ving Tsun kung fu group will receive the basic Wong Shun Leung style Ving Tsun training that includes basic stances (ma), footwork (bu), punching (quan), kicking (jie) techniques and conditioning exercises (for warm up and cool down).
9252|NCT04120883|Drug|Hydroxychloroquine lower dose|The participants weight will be measured and converted to kilograms. The participants will receive 4 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily.
9253|NCT04120883|Drug|Hydroxychloroquine higher dose|"The start of intervention for treatment arm 2 of the study will be delayed until preliminary safety of the drug is established with the 6 patients in treatment arm 1 at the first follow-up visit (4 months).~The participants in this group will receive 5 mg/kg/day. At the first follow-up visit (4 months) weight will be re-measured and the study drug dosing will be adjusted accordingly if the dosing has changed. Participants receiving 100 mg daily will be instructed to ingest one 200 mg tablet every other day. Participants receiving 200 mg daily will be instructed to ingest one 200 mg tablet daily. Participants receiving 300 mg daily will be instructed to alternate days ingesting two 200 mg tablets and one 200 mg tablet. Participants receiving 400 mg daily will be instructed to ingest two 200 mg tablets daily."
9254|NCT04120870|Drug|Etomidate Injection 0.2 mg/kg|The induction agent of rapid sequence intubation is etomidate. 0.2 mg/kg
9255|NCT04120870|Drug|Ketamine injection 2 mg/kg|The induction agent of rapid sequence intubation is ketamine. 2 mg/kg
9256|NCT04120857|Behavioral|Gentle Stretching|60 minutes fo gentle stretching twice weekly for 8 weeks
9384|NCT04119908|Biological|blood sample|Collection of citrate tubes of 5 mL at baseline and at 36 months
10626|NCT04109417|Procedure|osteotomy filled with PRP-gel and covered with PRP-biomembrane|
9257|NCT04120844|Behavioral|Motivational interviewing (MI)-based patient empowerment program (PEP)|Motivational interviewing (MI) is a collaborative, patient-centered counseling approach that aims to elicit behavior change. Counselors use empathy and other techniques to create an atmosphere to help patients to explore the discrepancies between the goals and their current behavior. The focus of MI is to find and resolve the ambivalence, improve patients' perception of the importance of behavior change, and support them to make the change. MI provides a structural framework with guiding principles that can be easily followed by the primary care doctors. Program content was further informed by the Hospital Authority Patient Empowerment Program in Hong Kong. The education program consisted of four modules, held once a week, that each lasted approximately 1½ to 2 hours. They were grouped under the following four broad headings: Knowing Diabetes, Diabetes Self-Care, Healthy Diet and Physical Exercise.
9258|NCT04120844|Behavioral|Traditional lecture style health education|The control group received traditional lectures that consisted solely of conveying healthcare information to patients. In order to minimize intervention bias, the control group lectures were standardized and adapted into four modules, namely knowing diabetes, healthy diet, physical exercises, and how to use medication correctly, which were similar topic headings, durations and frequencies to those of the intervention group. Each lecture was 1 hour and was provided by one of four health professionals (a pharmacist, dietician, endocrinologist or nurse) who had never received any prior training in MI. We consciously avoided the inclusion of elements of self-reflection and motivation in these lectures.
9259|NCT04120831|Drug|Abatacept Injection|Drug
9260|NCT04120818|Procedure|secondary IOL implantation|reopened the fibrotic, closed capsular bag and achieve IOL placement
9261|NCT04120818|Procedure|primary IOL implantation|lensectomy and anterior vitrectomy and primary IOL implantation
9262|NCT04120805|Device|Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy with the use of hemostatic agents by a surgeon
9263|NCT04120805|Other|No Hemostatic Agent|Patients undergoing robotic-assisted laparoscopic partial nephrectomy without the use of hemostatic agents by a surgeon
9264|NCT04120792|Behavioral|Simultaneous exercise and cognitive training|Participants in this arm will engage in a 12-week intervention that combines physical exercise and cognitive tablet-based training. This intervention involves use of an exercise bicycle while engaging in cognitive tasks on a tablet computer three times per week.
9265|NCT04120792|Behavioral|Exercise training|Participants in this arm will engage in a 12-week exercise intervention that involves use of an exercise bicycle three times per week.
9266|NCT04120792|Behavioral|Cognitive Training|Participants in this arm will engage in a 12-week intervention that involves cognitive tablet-based training three times per week.
9267|NCT04120792|Behavioral|Neutral video|Participants in this arm will engage in a 12-week intervention that involves watching neutral videos on a tablet computer three times per week.
9268|NCT04120779|Device|The EMPOWER-SUSTAIN e-Health Self-Management Intervention|Multifaceted chronic disease management strategies involving web-based self-management intervention mobile apps based on chronic care model and persuasive technology theory to improve patient activation and self-management behaviours among patients with metabolic syndrome.
9269|NCT04120766|Drug|Nicorandil|20 mg po qd
9270|NCT04120766|Drug|Placebo|Matching tablet
9271|NCT04120753|Drug|OLOMAX 20/5/5mg|Tablets, Oral, QD
9272|NCT04120753|Drug|OLOMAX 20/5/10mg|Tablets, Oral, QD
9273|NCT04120753|Drug|Olmesartan 20 mg/Amlodipine 5 mg|Tablets, Oral, QD
9274|NCT04120714|Device|Active tDCS|active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions
9275|NCT04120714|Device|Placebo tDCS|inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions
9276|NCT04120714|Other|Questionnaires|"visual analogue scale (VAS)~impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~Go-No go test~HAM-D scale~SF-12 quality of life scale"
9277|NCT04120701|Drug|mFOLFOX6|Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
9278|NCT04120688|Device|3D generated tooth replica|3D generated tooth replicas are compared to conventional procedure
9279|NCT04120675|Dietary Supplement|Freshly-Pressed Extra Virgin Olive Oil|This is a Greek, randomized, double-blind, -controlled study group of Freshly-Pressed EVOO + MeDi compared to EVOO + MeDi and to Medi only. Qualifying patients will be randomly assigned to receive 50mL of freshly-pressed EVOO or extra virgin olive oil or MeDi dietary protocol on a daily basis for 24 months. Patients undergo assessments at baseline,12 and 24 months +/- 7 days after beginning treatment.
9280|NCT04120662|Procedure|Intramedullary screw fixation|A Kirschner wire was introduced in the proximal tuberosity under anteroposterior and lateral fluoroscopic control, following the bone axis and passing through the fracture line; a cannulated compressor screw in a diameter between 45 - 55 mm in the more satisfactory position to achieve the optimal fragments compression.
9281|NCT04120662|Device|Focused Shock Wave Treatment|3 weekly session, one per week, of focused shock waves, using an electrohydraulic device.
9282|NCT04120649|Procedure|hysterectomy|total hysterectomy, bilateral salpingo-oopherectomy (based on the age of the patient), pelvic and para-aortic lymphadenectomy, and peritoneal washings
9283|NCT04120636|Drug|Episcleral Celecoxib|Sustained Release Transscleral Celecoxib
9284|NCT04120623|Drug|Dapagliflozin 10 MG|Dapagliflozin 10 MG combined with Insulin Aspart infused by continuous subcutaneous insulin infusion ( CSII).
9285|NCT04120623|Drug|Insulin Aspart|Insulin Aspart is infused through continuous subcutaneous insulin infusion ( CSII)
9286|NCT04120610|Diagnostic Test|FlowMet-R|FlowMet-R is a noninvasive blood flow measurement.
9287|NCT04120610|Diagnostic Test|ABI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the ankle and arm.
9288|NCT04120610|Diagnostic Test|TBI|Ankle Brachial Index is a ratio-metric blood pressure measurement in the toe and arm.
9309|NCT04120428|Other|Aquatic exercise training program|The intervention will be performed in a pool in which the water surface line will remain in the imaginary line of the xiphoid process. Each season will last 50 minutes and will be divided in 3 phases as (1) warm-up (15 minutes), (2) main part (30 minutes) and (3) cool-down (5 minutes).
9289|NCT04120597|Drug|Zishen Qingre Lishi Huayu Granules|The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu（Anemarrhena asphodeloides Bge.）, Shengdi（Rehmannia glutinosa Libosch.）, Maidong（Ophio pogon japonicus (L.f) KerGawl.） , Bixie（Dioscorea septemloma Thunb.）, Huanglian（Coptis chinensis Franch.）, Zhuling（Polyporus umbellatus（Pers.）Fries）, Xuanshen（Scrophularia ningpoensis Hemsl.）, Zelan（Lycopus lucidus Turcz. Var. Hirtus Regel）, Danshen（Salvia miltiorrhiza Beg.）， Gancao（Glycyrrhiza uralensis Fisch.）. Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.
9290|NCT04120597|Drug|Placebo|"The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months."
9291|NCT04120584|Device|Forma Eye Applicator|"Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment."
9292|NCT04120571|Other|Sleep Audiological Intervention Device (SleepAID)|subtle sound stimulation in phase with the slow oscillations
9293|NCT04120571|Other|sham control|no noise
9294|NCT04120558|Other|Qualitative interviews and focus groups|"Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees."
9295|NCT04120558|Other|Biomechanical gait analysis and questionnaires|"Biomechanical seated balance will be assessed in non-ambulatory (wheelchair users) individuals. This will quantify seated postural control within motion capture. Kinetic and kinematic variables will be calculated.~Walking, stair climbing, obstacle crossing, seated activities and balance tests will be assessed in ambulatory (prosthetic using) individuals. Motion capture software will be used to analyse and compare kinematic and kinetic variables between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations"
9296|NCT04120545|Device|Microcurrents|"The electrodes will be placed with the help of gloves and adapted socks for 1 hour, twice a week, until 10 intervention sessions are completed. In addition, depending on the session, an adhesive electrode will be placed at the level of C7, L3 or S1.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.3 s and pause of 300 ms, voltage 3 mV and intensity 0.5 μA."
9297|NCT04120545|Device|Placebo Microcurrents|The same protocol described for the experimental group will be applied, but microcurrents device which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
9298|NCT04120532|Behavioral|Perioperative Rehabilitation|Physical therapist will be consulted one day before and after the operation (OP) day. On the day before the OP day, they focus on education, including how to get up from bed and stand up from a chair. Five rehabilitation exercises are also demonstrated: 1) ankle flexion and extension, 2) knee flexion and extension, 3) hip joint abduction and adduction, 4) hip joint flexion and extension, and 5) drawing-in maneuver. The participants will be required to repeat each component to confirm that they can do it correctly. Each exercise is suggested to be done 10 times per day following MI-TLIF, and the number will be recorded 3 days (pre-OP day, post-OP day, and post-OP day 2).
9299|NCT04120519|Drug|thalidomide combined with dexamethasone and cyclophosphamide|TCD
9300|NCT04120506|Drug|VPRIV|Safety, pharmacokinetics, and efficacy of rapid intravenous infusion of velaglucerase alfa (VPRIV) in adult patients with type 1 Gaucher disease
9301|NCT04120493|Genetic|rAAV5-miHTT|Single dose administration of rAAV5-miHTT gene therapy
9302|NCT04120493|Procedure|Imitation surgery|Bilateral partial thickness burr holes placed, no intrastriatal injections
9303|NCT04120480|Diagnostic Test|Pharmacogenomic test|The RightMed test is an end-to-end solution which includes sample collection, PGx testing services, data analysis, and clinical interpretation that helps prescribers select treatments based on evidence-driven predictions of patient drug response and tolerance. Genetic components of an individual's drug response are well established and often included on FDA medication labels. The RightMed test has incorporated existing evidence to classify the risk and likelihood of an antidepressant working for different patients. Patient results for each medication can fall into one of three categories: 1) Green - use as directed; 2) Yellow - use with caution; and 3) Red - adjust dose or choose alternative mediation.
9304|NCT04120467|Other|Dance|"One group will receive a 60-minute dance class weekly over a 6 weeks period. A physiotherapist - dance teacher will lead the classes, supported by at least one volunteer.~The class structure will consist of five components: warm up (10 minutes), technical exercises (10 minutes), improvisation (15 minutes), a short routine (15 minutes) and a cool down/feedback time (10 minutes). Dance exercises will be targeting flexibility, balance, endurance, upper and lower limbs functions, interaction between dancers, perception and memory. Using choreography or short routine, the class will include repeating the dance moves - which fosters memorization - and also the additional challenge of remembering a sequence of moves.~Given the great variability of each participant's functional ability, the complexity and the intensity of the dance exercises will progress according to each participant's capacity, in order to fulfill an appropriate challenge at moderate treatment intensity."
9305|NCT04120467|Other|Standard rehabilitation|The control group will have conventional rehabilitation as usually planned in the rehabilitation center: 45 to 60 minutes of physiotherapy per day integrating sensory stimulation, motor activation, strengthening, coordination, balance and exercise training. Patients also receive 45 to 60 minutes of occupational therapy per day.
9306|NCT04120454|Biological|Pembrolizumab|Given IV
9307|NCT04120454|Biological|Ramucirumab|Given IV
10627|NCT04109417|Procedure|osteotomy site following the surgical intervention was left empty|
9310|NCT04120415|Biological|Vaccine and vedolizumab (Entyvio)|"Vaccine and vedolizumab infusion (Entyvio):~0.5ml of MVA HIV-B (1 x 108 pfu/ml) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
9311|NCT04120415|Biological|Placebo vaccine and vedolizumab infusion (Entyvio)|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Vedolizumab infusion (Entyvio):~Vedolizumab (300mg) is administered as an intravenous infusion (255 ml) over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. After infusion, the line should be flushed with 30ml of normal saline. Participants will be observed throughout and after the infusion."
9312|NCT04120415|Biological|Placebo vaccine and placebo infusion|"Placebo Vaccine:~The placebo for MVA HIV-B to be used is a solution composed of S08 buffer (as for the MVA vaccine) that will be intramuscularly in the deltoid muscle of the non-dominant upper arm at weeks 0 and 8. Participants will be observed after the injection.~Placebo infusion (Entyvio):~255ml Sodium Chloride (NaCl) 0.9% bag administered as an intravenous infusion over 30 mins in the dominant arm at weeks 10,12,16,20,24,28 and 32. Participants will be observed throughout and after the infusion."
9313|NCT04120402|Drug|EP-104IAR 25 mg|Single 5 mL intra-articular injection
9314|NCT04120402|Drug|EP-104IAR 32 mg|Single 5 mL intra-articular injection
9315|NCT04120402|Drug|EP-104IAR 40 mg|Single 5 mL intra-articular injection
9316|NCT04120402|Drug|EP-104IAR 50 mg|Single 5 mL intra-articular injection
9317|NCT04120402|Drug|Vehicle|Single 5 mL intra-articular injection
9318|NCT04120389|Device|bandage contact lenses(PureVision; Bausch & Lomb Inc., Rochester, NY)|wear an bandage contact lenses for a week after Complicated and Combined cataract surgery.
9319|NCT04120389|Procedure|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
9320|NCT04120376|Behavioral|Contraception Counseling|Each participant will receive a 10 minute confidential contraception counseling session with an Advanced Practice Provider in the Emergency Department
9321|NCT04120363|Drug|Testosterone Undecanoate|single intramuscular injection of 750 mg testosterone undecanoate
9322|NCT04120363|Drug|Sesame Oil|single intramuscular injection of 3 ml sesame oil solution
9323|NCT04120350|Drug|Methotrexate|3.5g/m2 intravenous infusion for 4 hours in d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
9324|NCT04120350|Drug|Rituximab|375mg/m2 intravenous infusion d1, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol
9325|NCT04120350|Drug|Lenalidomide|"In phase 1b study, a 3+3 design dose- escalation will be taken. 3 levels should be tested, 15/20/25mg orally d1-14, every 21 days for 1 cycle. 6 cycles will be prescribed as protocol.~In phase II study, if the DLT was occured in all 3 levels of lenalidomide. 25mg daily is considered as an experiment dose for the induction cycles.~In both phase Ib and II study, the does of lenalidomide maintenance is fixed to 25mg orally d1-21.every 28 days for 1 cycle. The duration of maintenance is 2 years."
9326|NCT04120337|Device|RemovAid device + lidocaine patch|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine patch will be used prior to incision.
9327|NCT04120337|Procedure|Standard technique + lidocaine injection|Using scalpel, tweezers, and forceps to remove a subdermal implant. A lidocaine injection will be used prior to incision.
9328|NCT04120337|Device|RemovAid device + lidocaine injection|The RemovAid device incises the skin and grasps the implant for removal. A lidocaine injection will be used prior to incision.
9329|NCT04120324|Other|Eligible for Same Day Discharge|Preoperative Physiotherapy and Anesthesia Criteria met.
9330|NCT04120324|Procedure|Primary Single Joint Total Hip Arthroplasty|Total Hip Replacement Surgery
9331|NCT04120324|Other|Discharge Same Day|Postoperative criteria for Same Day Discharge met.
9332|NCT04120311|Drug|Episcleral Dexamethasone|Sustained Release Episcleral Dexamethasone
9333|NCT04120298|Behavioral|Supervised exercise|An individualised exercise programme supervised by a trained instructor
9334|NCT04120285|Behavioral|remote internet-based cognitive behavior therapy (eCBT)|Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
9335|NCT04120272|Procedure|Spine surgery|Eligible Surgeries: lumbar spine fusion surgery, posterior cervical spine fusion surgery, or anterior cervical spine fusion surgery
9336|NCT04120259|Drug|Metformin Oral Tablet|A biguanide drug used as a first line therapy for Diabetes MellitusType 2
9337|NCT04120259|Dietary Supplement|Vinegar|A common herbal/dietary supplement used for centuries as an anti bacterial, cleaning,cooking, anti diabetic agent, to name a few uses.
9338|NCT04120246|Drug|Alpha-tocopheryloxyacetic Acid|Given PO
9339|NCT04120246|Biological|Trastuzumab|Given IV
9340|NCT04120233|Drug|Placebo|Matched placebo administered orally
9341|NCT04120233|Drug|MW151, 10mg|10 mg MW151, 1 x 10mg capsule administered orally
9342|NCT04120233|Drug|MW151, 20mg|20 mg MW151, 1 x 20mg capsule administered orally
9343|NCT04120233|Drug|MW151, 40mg|40 mg MW151, 2 x 20mg capsule administered orally
9344|NCT04120233|Drug|MW151, 80mg|80 mg MW151, 1 x 80mg capsule administered orally
9345|NCT04120233|Drug|MW151, 160mg|160 mg MW151, 2 x 80mg capsule administered orally
9346|NCT04120220|Other|Heavy Cream|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with heavy cream.
9347|NCT04120220|Other|Soybean Oil|Participants will receive a meal in the form of a fruit-containing shake containing 30 g of fat prepared with soybean oil.
9348|NCT04120207|Behavioral|Home-based Pilates|The Home-based Pilates group will complete two Pilates classes at home, twice weekly, for a period of eight weeks.
9349|NCT04120207|Other|Delayed-start Pilates|The Delayed-start group will maintain their regular daily activities, and be provided with a copy of the Pilates DVD following the intervention, for their own use.
11052|NCT04106050|Drug|Lidocaine|Administered as specified in the treatment arm.
9353|NCT04120168|Genetic|Laboratory Tests|"Acid Alpha IgGlucosidase alpha enzyme test for Late Onset Pompe Disease and gene sequencing test from the same sample in samples with low enzyme activity~Genetic Analysis for DMD (only in boys): Detection of dystrophin gene for duplication and deletion with MLPA (Multiplex-ligation dependent probe amplification) and re-screening for other mutations by gene sequencing in patients without MLPA deletion / duplication."
9354|NCT04120155|Procedure|Dissection of the Inferior Pulmonary Ligament|Patients will be categorized into two groups: the division group ,who will receive the division of the inferior pulmonary ligament, and the preservation group, who will not.
9355|NCT04120142|Other|Pulmonary rehabilitation+IMT|The experimental group receives inspiratory muscle training and aerobic exercise.
9356|NCT04120142|Other|Pulmonary rehabilitation|The Active Comparator group received only aerobic exercise.
9357|NCT04120129|Device|TMS|Transcranial Magnetic Stimulation (TMS) is a noninvasive brain stimulation technique which produces short pulsatile magnetic fields (similar to that of an MRI) via two extracranial, figure 8-shaped electric coils which can induce a small, temporary, electric current in the brain currently approved and used for depression.
9358|NCT04120129|Device|sham TMS coil|The sham TMS does cause some stimulation to the participant so that the participants get the sensation of treatment without any cortical excitation that TMS delivers. The sensation experienced is similar to the muscle twitching or finger tapping experienced by TMS participants.
9359|NCT04120116|Drug|FX-322|Dosing occurs once weekly for four consecutive weeks. Patients will receive one, two or four doses of FX-322, followed by three, two or zero Placebo doses, respectively.
9360|NCT04120116|Drug|Placebo|Dosing occurs once weekly for four consecutive weeks. Patients will receive two, three or four doses of Placebo, preceded by two, one or zero Placebo doses, respectively.
9361|NCT04120103|Behavioral|Doll therapy|The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.
9362|NCT04120103|Other|Routine nursing care|The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
9363|NCT04120090|Drug|low dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 10 mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 5mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 2.5mg twice daily.
9364|NCT04120090|Drug|high dose ruxolitinib|The dose for adult patients(Age>=14 years) is generally 20mg twice daily. For children(Age<14 years ,weight >=25kg),the dose was generally 10mg twice daily. For children(Age<14 years, weight <25kg), the dose was generally 5mg twice daily
9365|NCT04120077|Dietary Supplement|EyePromise DVS, EyePromise DVS plus EyePromise EZTears|Placebo Comparator: American Association of Diabetes Educators (AADE) certified Diabetes Self-Management Education (DSME) with placebo nutritional supplements
9366|NCT04120064|Drug|Cholecalciferol|Large, one time dose of 300,000 IU oral cholecalciferol or daily 5,000 IU oral cholecalciferol
9367|NCT04120051|Dietary Supplement|Fermented canola-seaweed|A daily sachet with 5 gram FCS-granulate for 6 weeks
9368|NCT04120051|Other|Placebo|A daily sachet with 5 gram rye cereal for 6 weeks
9369|NCT04120038|Device|Self-Management for Amputee Rehabilitation using Technology [SMART]|Participants will complete a 10-week tablet-based education program for individuals with LLA that will provide them with self-management education.
9370|NCT04120025|Behavioral|Diaphragm Training|training on isolated abdominal breathing with proper effort and hold time to promote strengthening
9371|NCT04119999|Device|Mandibular Advancement Device|Mandibular advancement device (MAD) has been a novel method in the management of snoring and OSA. For mild to moderate sleep apnea, MADs have been a boon. A guideline published by American Academy of Sleep Medicine stated that MAD was indicated as first-line therapy for mild OSA and a second-line therapy for moderate to severe OSA
9372|NCT04119999|Device|Continuous Positive Airway Pressure|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people with OSA
9373|NCT04119986|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds.
9374|NCT04119986|Device|drug eluted stent|with regular techniques
9375|NCT04119973|Other|standard treatment|standard medical treatment
9376|NCT04119960|Device|Aided read with InferRead Lung CT.AI|Radiologists read chest CT scans with the aid of InferRead Lung CT.AI
9377|NCT04119947|Drug|SY-009|The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
9378|NCT04119934|Behavioral|Smoking Cessation Intervention Tool|A personalized smoking cessation infographic is provided to the physician alongside the patient's regular spirometry report.
9379|NCT04119921|Drug|prescription topical ketorolac in group 1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
9380|NCT04119921|Drug|prescription artificial tear in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
9381|NCT04119921|Drug|prescription topical ketorolac in group 2|artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
9382|NCT04119921|Drug|prescription artificial tear in group1|topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
9383|NCT04119908|Device|Sublingual videomicroscopy|Measurement of sublingual capillary density by video microscopy
13943|NCT04082520|Other|Questionnaire Administration|Ancillary studies
9385|NCT04119895|Other|Neuromuscular electrical stimulation and core stabilization exercise|"In NMES group, the amplitude of the electrical current will be set at the highest level subject can tolerate.~The lumbar stabilization mode of the device will be used. This mode consists of three phases; warming, contraction and recovery phases. The duration will be set to 35 minutes. In the first 2 minutes (warming phase), frequency is 6 Hz. Contraction phase includes consecutive cycles of contractile frequency of 40 Hz for 6 seconds and the rest frequency of 4 Hz for 12 seconds, lasting a total of 30 minutes. The last 3 minutes (recovery phase) frequency is 3 Hz. The ramp up time is 2 seconds and the ramp down time is 1 second"
9386|NCT04119895|Other|Sham neuromuscular electrical stimulation and core stabilization exercise|In sham NMES group, the amplitude of the electrical current will be set at a minimum level which does not stimulate any contraction.
9387|NCT04119882|Diagnostic Test|Blood collection|New biomarker test
9388|NCT04119869|Other|iaya|The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.
9389|NCT04119856|Other|Affiliation with the outgoing lung team|"The work of the outgoing lung team takes place in the patient's home and involves the following:~The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call."
9390|NCT04119843|Drug|Mangoral|800 mg manganese chloride [II] tetrahydrate, 500 mg L-alanine, and 800 IU vitamin D3
9391|NCT04119830|Biological|Pembrolizumab|Given IV
9392|NCT04119830|Other|Questionnaire Administration|Ancillary studies
9393|NCT04119830|Drug|Rintatolimod|Given IV
9394|NCT04119817|Dietary Supplement|Mucosave® capsules|400 mg/day of Mucosave® capsules for a period of 8 weeks, once a day.
9395|NCT04119817|Dietary Supplement|Placebo|400 mg/day of placebo capsules for a period of 8 weeks, once a day.
9396|NCT04119804|Diagnostic Test|cellular neural networks-genetic algorithm|Cellular neural networks-genetic algorithm applied to conventional radiographs of hip implants with a well-established diagnosis of loosening. The study is not intended to use a software without a CE mark as a medical device, or to use the software as a tool to diagnose or prevent human disease, according to Directive 93/42 / European Economic Community. The study will evaluate if the software, properly calibrated, is able to recognize with adequate accuracy infections already diagnosed with validated methods.
9397|NCT04119791|Other|wild rice|30 grams of wild rice in the form salad, snack bar and soup
9398|NCT04119778|Behavioral|Aerobic Exercise, Tai chi|They are aerobic and mind-body exercise respectively.
9399|NCT04119765|Biological|Blood sampling|blood sampling will be used to perform oxalemia and FGF23 quantitative analysis
9400|NCT04119765|Biological|Urine sampling|urine sampling will be used to measure glycolate urinary rate (glycolaturia) and to perform urinary inflammation markers quantitative analysis
9401|NCT04119765|Procedure|Pulse Wave Velocity (PWV) measurement|PWV will be measured thank to the Complior® device
9402|NCT04119765|Procedure|central pressure measurement|central pressure will be measured thank to the Complior® device
9403|NCT04119752|Dietary Supplement|Curcumin powder|10g of curcumin powder
9404|NCT04119752|Dietary Supplement|Placebo|1g of sucralose
9405|NCT04119739|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
9406|NCT04119739|Drug|Ibuprofen|Oral tablets
9407|NCT04119726|Behavioral|Usual Text Messages|Regular messages about prevention and cure of CHD will be sent to both groups four times a week. The short texts will be selected from the guidelines in China to avoid misinformation. There are also some pictures or videos that help patients change their behaviour.
9408|NCT04119726|Behavioral|Personalized reminders|Personal information, life behavior and risk factors will be registered when patients are enrolled. According to the baseline information, personalized knowledge will be sent to patients in the intervention group. Besides, patients will receive drug information and regular medication adherence reminders daily according to patients' baseline prescription drugs and modifications.
9409|NCT04119726|Behavioral|Internet-based counselling|"The internet-based counselling is the key module of social media in the intervention group. The consultation content mainly includes the feedback of coronary heart disease secondary prevention drug compliance, the feedback of risk factor level control, the feedback of life and behaviour habits, the feedback of adverse events, the feedback of health education knowledge improvement, the reminders of data upload, behaviour change, and health education learning.~When the patient has questions or discomfort during the medication, they can consult the applet and the applet will perform internet-based answers on the large database built by cardiologists. Meanwhile, social media will upload the question of consultation and report to the doctor according to individual differences in disease. If the patient is not satisfied with the auto-response, the patient can further consult his doctor and the doctor's response will be collected to improve the auto-response database"
9410|NCT04119700|Procedure|Fistuclectomy, suturing of muscular defect, mobilization of muco-muscular endorectal advancement flap, fixation of the flap with anoderma|After fistulectomy muco-muscular flap of the rectal wall will be mobilized. The muscular defect is sutured with separate interrupted sutures (Vicryl / Polysorb 2/0, 0/0, 3/0). The muco-muscular flap is fixed to the anoderm without tension by interrupted sutures (Vicryl / Polysorb 4/0). The wound of the perianal area is not sutured.
9411|NCT04119700|Procedure|Fistuclectomy, performing sphincteroplasty|Fistulectomy will be performed. The affected gland is visualized and removed. If there are secondary extensions, they are excised also. Sphincter defect with stitches (suture material Vicryl / Polysorb 2/0, 0/0, 3/0) with restoration of the anal canal profile (suturing of the anodermal-skin border). The skin is not suturing.
9778|NCT04116450|Procedure|Glaucolight illuminated microcatheter.|To study circumferential trabeculotomy for congenital glaucoma using Glaucolight illuminated microcatheter.
9412|NCT04119687|Biological|FX201|FX201, humantakinogene hadenovec, is a novel interleukin-1 receptor antagonist (IL-1Ra) gene therapy for IA administration that is being developed for the treatment of patients with OAK.
9413|NCT04119674|Biological|Anlotinib|Anlotinib With STUPP Regimen
9414|NCT04119674|Drug|Temozolomide Capsule|Anlotinib With STUPP Regimen
9415|NCT04119661|Device|Max-i-Probe|Using Max-i-Probe as endodontic needle during syringe irrigation
9416|NCT04119661|Device|NaviTip|Using NaviTip as endodontic needle during syringe irrigation
9417|NCT04119648|Behavioral|CAMS-4Kids|The Collaborative Assessment and Management of Suicidality (CAMS—Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.
9418|NCT04119622|Drug|Toripalimab|toripalimab 240 mg d1; q3w, up to two cycles.
9419|NCT04119622|Drug|oxaliplatin|oxaliplatin 130 mg/m2 QD, d1,q3w, up to two cycles
9420|NCT04119622|Drug|capecitabine|apecitabine 1000 mg/m2 BID, d1-d14 ,q3w, up to two cycles
9421|NCT04119596|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
9422|NCT04119596|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
9423|NCT04119583|Device|U-shape Automatic Electric Toothbrush|The U-shape Automatic Electric Toothbrush will be applied for 30-45 seconds on the teeth of both arches without the use of toothpaste.
9424|NCT04119583|Other|Usual home toothbrushing procedure|Usual home toothbrushing procedure either with manual or electric toothbrush without the use of toothpaste.
9425|NCT04119570|Behavioral|CKD Report Card|The CKD Report Card is a handout based on a NKDEP Educational Sheet that includes basic information about kidney disease and spaces where patient can record information about their own kidney disease
9426|NCT04119557|Drug|LY3471851|Administered SC
9427|NCT04119557|Drug|Placebo|Administered SC
9428|NCT04119544|Other|Conventional rehabilitation|upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible.
9429|NCT04119544|Device|Intensive Visual Simulation|"First week: observation, mentalization and then attempt to perform the movements on the screen.~Second and third weeks: production of analytical movements of wrist flexion/extension, pronation/supination, finger flexion/extension, thumb opposition.~From the 4th week until the end: depending on the patient's motor capacities, continuation of the work of the previous 2 weeks or introduction of more functional work with object manipulation, gripping work.~Conventional rehabilitation upper limb rehabilitation involving submaximal passive amplitude stretching movements, inhibition postures, active efforts assisted of varying difficulty, target approach exercises with or without elbow support and gripping tasks, adapted to the upper limb's paresis abilities. The patient will be encouraged to gradually dispense with the assistance provided by the therapist or any technical assistance (suspension...) and thus to carry out the exercises in free active as soon as possible."
9430|NCT04119518|Device|CSEM Pulse Watch|Comparison of CSEM Pulse Watch with a gold standard oscillometric device Spacelabs OnTrak Ambulatory Blood Pressure monitor.
9431|NCT04119492|Behavioral|CO-OP Treatment Group|"Cognitive Orientation to Occupational Performance (CO-OP) is a cognitive approach to solving functional motor problems (Polatajko et al., 2001). Therapists teach children a global problem-solving strategy (Goal-Plan-Do-Check) as means to develop specific strategies for overcoming motor problems; the strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists trained in CO-OP will see children for one hour, once weekly for 10 weeks. Parents or caregivers will be encouraged to attend treat¬ment sessions so therapists can instruct them how to facilitate strategy use between treatment sessions. Children will select 3 functional motor goals to be addressed during treatment."
9432|NCT04119466|Behavioral|Stabilizing training|The training will include the activation of the lumbar multifidus muscle (m. multifudus) and the transverse abdominal muscle (m. transversus abdominis). The performance of the individual stages of the training will be based on Richardson's methodology. One session will comprise 4 sets in which the patient will be asked to do pelvic tilts (draw-in) with simultaneous full exhalation, thus activating the aforementioned muscle groups in different positions: a) prone b) supine with lower extremities flexed c) quadruped d) standing back to the wall. The subjects will perform 3 series consisting of 10 repeats, each of which will last ca. 10 seconds.
9433|NCT04119453|Drug|Rivoceranib|Rivoceranib will be supplied as 100 mg and 200 mg film-coated tablets for oral (PO) administration
9434|NCT04119440|Biological|MVA-MERS-S_DF1 - Low Dose|Administrations of the low dose via the intramuscular route
9435|NCT04119440|Biological|MVA-MERS-S_DF1 - High Dose|Administrations of the high dose via the intramuscular route
9436|NCT04119440|Other|Placebo|Administrations of placebo via the intramuscular route
9437|NCT04119427|Device|ultrasonic therapeutic apparatus 1|After installing the disposable treatment head coat, the transplanted kidney was treated with an ultrasonic therapeutic apparatus; after the treatment, the disposable treatment head coat was removed. Patients were treated twice a week for 6 weeks.
9438|NCT04119427|Device|ultrasonic therapeutic apparatus 2|The placebo was treated with an ultrasound therapy device and used in the same manner as the test group.
9439|NCT04119414|Behavioral|Spear and Shield (S&S) Program|The S&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.
9440|NCT04119414|Behavioral|Like Father Like Son (LFLS) Program|The LFLS Program is a private 2 90-minute session conducted by a trained CHC facilitator. The sessions will be focused on exploring issues relevant to parental decision making related to voluntary medical male circumcision (VMMC) and early infant male circumcision (EIMC). Session 1 will be conducted antenatal and Session 2 will be immediately post-partum.
9684|NCT04117256|Device|Sham DCS|20 minutes of sham stimulation. Subjects will be stimulated during the first 30 seconds. After that, a ramp down of 10 seconds and then the stimulator is turned-off.
9441|NCT04119401|Procedure|doppler-guided hemorrhoidal artery ligation|"Ligation: a lubricating gel is applied to the tip of the Transanal Hemorrhoidal Dearterialization device and, with the patient in the lithotomy position, the proctoscope is introduced into the anal canal. The terminal branches of the superior rectal artery are detected by the doppler signal 2-3 cm above the dentate line. The tip of the instrument is gently tilted and the arteries are ligated with a Z-shaped stitch using 2:0 braided polyglycolic acid suture inserted using a special needle-holder through an aperture in the operating proctoscope.~Mucopexy: after the haemorrhoid artery ligation, the suture is continued with three to five sutures applied 5 mm apart, making sure that the last is at least 5 mm above the dentate line. The suture is then tied to create a hemorrhoidopexy. The procedure is repeated after all detected artery ligations."
9442|NCT04119401|Procedure|Finger-guided hemorrhoidal artery ligation|"Ligation: the exact placement of all terminal branches of the superior rectal artery are found by intraoperative palpation at anal clock 2-3cm above the anorectal junction. Then arteries are ligated with Z-shaped suture using 2:0 braided polyglycolic suture.~Mucopexy is then performed in the same technique as in comparative group"
9443|NCT04119388|Other|Adapted sports practices|Adapted sports practices for 30 minutes twice a week
9444|NCT04119375|Behavioral|Keheala Mobile Health Platform and Behavioral Interventions|"Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up."
9445|NCT04119375|Behavioral|Social and Behavior Change Communication (SBCC)|Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.
9446|NCT04119375|Behavioral|SMS Reminder|Patients receive a single daily SMS message to take their medication.
9447|NCT04119375|Other|Standard of Care|The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
9448|NCT04119362|Other|Quality of live questionnaires|EORTC-Q30 questionnaire, additonal questionnaire on worries about quality of life impairments and on physical condition every 8 weeks. No additional visits will be carried out for questionnaires. Questionnaires will be handed out to patients during routine visits.
9449|NCT04119362|Other|Optional translational project|Collection of archival tumor material for future translational projects. No biopsy will be performed in the context of this registry. Only tumor samples obtained in the context of standard of care and after explicit informed context will be used.
9450|NCT04119349|Behavioral|Extra counseling|Participants will be given an extra 15-minute prenatal counseling before their first-trimester scan. The extra counseling, which is the intervention in the experimental group, consists of an explanation of all screening techniques for chromosomal abnormalities, including the first trimester combined test, cfDNA testing, invasive testing, and no screening at all.
9451|NCT04119336|Drug|Nivolumab|Given intravenously once per cycle
9452|NCT04119336|Drug|Ixazomib|Given orally on days 1, 8, 15.
9453|NCT04119336|Drug|Dexamethasone|Given orally on days 1, 8, 15, 22
9454|NCT04119336|Drug|Cyclophosphamide|Given intravenously on days 1, 8, 15.
9455|NCT04119310|Other|Lumbar-thrust mobilization|The intervention group will receive passive spinal rotational grade V thrust-mobilization, based on Maitland's approach. The intervention will be performed with the subject in right sidelying and left sidelying. The operator's palpating hand is placed over the L2-3 intervertebral space, and the other hand bends both legs of the participant up to the range at which the L2-3 midposition is found. The participant is then asked to straighten the lower leg and hook the upper leg over it with the upper leg's knee positioned over the side of the plinth. While the lower component is kept still, the participant's trunk is rotated until the hip starts to lift off from the plinth. The bottom hand and uppermost hand rest under a pillow and the chest wall, respectively. With the starting position settled, the operator stands behind the participant, takes up the slack within the spine and then provides a grade V thrust- mobilization while stabilizing the uppermost shoulder.
9456|NCT04119310|Other|Sham thrust-mobilization|Subjects are positioned in right sidelying. The experimenter holds both knees with one arm while placing their opposite hand on the participant's lumbar spine. The experimenter performs 1 min of ﬂexion and extension passive range of motion without reaching physiological end range in either direction of movement. This is repeated with the subject in left sidelying.
9457|NCT04119297|Other|Routine care|"Routine care was applied to the periorbital area by clinical nurses.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
9458|NCT04119297|Other|Cold gel pack|"Cold application was applied to the periorbital area for 20 minutes per hour beginning 3rd hour following craniotomy, except from 10pm-7 am, and for three days using gel pack cooled to -14ºC.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
9459|NCT04119297|Drug|Heparinoids Topical Cream|"Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara & Gokalan's Scale"
9460|NCT04119284|Device|Anterior body tether (ABT)|To insert the ABT in patients to correct AIS.
9462|NCT04119258|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy including both behavioral and cognitive interventions.
10143|NCT04113525|Device|MyoRegulator™ System|Paired transcutaneous spinal and peripheral nerve stimulation
9463|NCT04119245|Device|I-gel supraglottic airway device|After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
9464|NCT04119232|Behavioral|Social incentives-based program|Individual participants will use a wearable device to monitor daily step counts, set a step goal, and receive automated daily feedback on step goal attainment. Participants will be placed on a team of 3 randomly assigned participants and receive the social incentives intervention.
9465|NCT04119219|Procedure|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
9466|NCT04119193|Device|Novel smartphone application for blood pressure measurement|Continuous blood pressure measurements will be compared between the new application and the reference method (invasive radial arterial line) during 5 minutes of recordings.
9467|NCT04119180|Drug|Ketamine 50 MG/ML|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
9468|NCT04119180|Drug|Midazolam Hcl 2Mg/Ml Syrup|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine;
9469|NCT04119180|Procedure|Protective stabilization|The legal guardian or accompanying person appointed by the legal guardian should sit in the dental chair with the child and contain leg and arm movements. A dental assistant keeps the child's head contained during care.
9470|NCT04119154|Diagnostic Test|Contrast Microhalography (CEM)|Fine needle aspirates evaluated by CEM device
9471|NCT04119141|Diagnostic Test|X ray imaging|"Acquisition:~140 kVp,~1/2 mAs/kg,~Pitch: 1.35,~Rotation time: 0.5 sec.~Reconstruction:~I70f filter, 3 iteration loops,~Cutting thickness 1 mm/0.7 mm~Fenestration: C -600/W 1600~Field of view (Size, x & y coordinates) identical on both acquisitions."
9472|NCT04119128|Device|Active Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS of up to 2mA, at 20 minutes per session, 1x per day. During active stimulation, the current will be active for the full 20 minutes.
9473|NCT04119128|Device|Sham Transcranial Direct Current Stimulation|Subjects will undergo 5 sessions of tDCS, at 20 minutes per session, 1x per day. For sham tDCS, electrodes will be placed the same way as in the intervention group, for 20 minutes. However, the stimulator will deliver 2mA of current for only 30s. The current will not be active for the rest of the 20 minutes.
9474|NCT04119115|Device|CT-V|CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.
9475|NCT04119115|Other|Metabolites|Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.
9476|NCT04119102|Drug|Duobrii|duobrii applied daily for 4 weeks followed by every other day for 4 weeks.
9477|NCT04119089|Other|Gastric ultrasound|"A first gastric ultrasound will be performed in the supine and the right lateral (RLD) decubitus position, allowing a qualitative analysis of the gastric contents (empty, liquid, solid, solid-liquid). The antral area will also be measured in both positions. The volume of gastric fluid content will be calculated according to the following formula: volume (ml) = -7,8 + (0,035 x antral area in RLD (mm²)) + 0,127 x age (month).~This examination will be immediately followed by the aspiration of gastric contents through the nasogastric tube used for enteral feeding, into 50-ml syringes, by a nurse blinded to the result of the first ultrasound examination. A second antral ultrasound examination will then be performed, by the same investigator blinded to the volume aspirated.~The occurrence of regurgitation and / or vomiting occurring within the 12 hours before and after the examination will be recorded."
9478|NCT04119076|Other|Classroom-based physical activity|
9479|NCT04119076|Other|Control Group|
9480|NCT04119063|Device|powered orthosis|Novel powered leg brace to provide assistance during walking.
9481|NCT04119050|Drug|M281|M281 injection administered as intravenous infusion
9482|NCT04119050|Drug|Placebo|Placebo administered as intravenous infusion
9483|NCT04119037|Procedure|Cordotomy|Undergo cordotomy
9484|NCT04119037|Drug|Morphine|Given via injection
9485|NCT04119037|Other|Questionnaire Administration|Ancillary studies
9486|NCT04119037|Procedure|Sham Intervention|Undergo fake cordotomy
9487|NCT04119024|Drug|Cyclophosphamide|Given IV
9488|NCT04119024|Drug|Fludarabine Phosphate|Given IV
9489|NCT04119024|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given IV
9490|NCT04119024|Drug|Recombinant Interleukin-2|Given SC
9491|NCT04119011|Biological|Probiotic|(Lactobacillus acidophilus, lactobacillus casei, lactobacillus lactis) and Bifidobacterium (Bifidobacterium bifidum, bifidobacterium longum, bifidobacterium infantis) lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
9492|NCT04119011|Other|Placebo|lactose, sugar, milk powder, oligosaccharides, ascorbic acid, citric acid, maltodextrin, and orange flavor
9493|NCT04118998|Behavioral|Abduction Loading|The intervention for the experimental group entails practicing reaching with abduction loading.
9494|NCT04118998|Behavioral|Supported Reaching|The intervention for the active comparator entails practicing reaching while supported.
9495|NCT04118985|Behavioral|Cognitive rehabilitation and health behavior change intervention|Cognitive rehabilitation and health behavior change intervention in a group-based program intervention compared to self-implementation of techniques without these interventions
9496|NCT04118985|Behavioral|Self-implementation|Self-implementation of cognitive rehabilitation and health behavior change recommendations
9497|NCT04118972|Behavioral|Mirror exposure and text prompt responses|Participants in the active interventions have three weekly mirror exposure sessions that are either guided with specific instructions as to where to look and how (only in functionality condition)
9498|NCT04118946|Biological|platelet enriched plasma|PRP is prepared via a two-step centrifugation preparation of a blood sample, which is cured with an anticoagulant. Then either with be applied through urethral catheter in one arm or via submucos injection in anther one.
9499|NCT04118933|Drug|JS001|JS001 240mg, Q3W
9500|NCT04118920|Drug|Topic insulin (4 units)|N=6: 100 U/ml; 4 units of insulin per application; 40 microliters per drop
9501|NCT04118920|Drug|Topic insulin (20 units)|N=6: 500 U/ml; 20 units of insulin per application; 40 microliters per drop
11053|NCT04106037|Other|Data extraction from medical files|Data extraction from medical files
9502|NCT04118907|Device|multiple sensory stimulation|The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
9503|NCT04118894|Device|Foot and Ankle Devices|Wright devices used in foot and ankle procedures
9504|NCT04118881|Other|Ear Acupuncture|Auricular Acupuncture (AA) is a micro-system of acupuncture and moxibustion initiated by Chinese and French doctors. All acupoints are distributed in the ear. In the treatment of perioperative patients, ear needle is far away from the surgical wound and its minimally invasive and tolerable position has obvious advantages over body needle.AA can regulate the function of corresponding organs at acupoints. The theoretical basis of TCM is holistic concept and syndrome differentiation and treatment.AA can prevent and treat perioperative nausea and vomiting. A number of randomized controlled trials and retrospective studies have confirmed that AA has obvious advantages in preventing nausea and vomiting in perioperative period compared with routine prevention, and its possible mechanism is ear-directed stimulation of the ear branch of vagus nerve, thereby enhancing gastrointestinal motility and accelerating gastric emptying.
9505|NCT04118868|Combination Product|Pembrolizumab administered using the Sofus® DoseConnect™|pembrolizumab will be administered intralymphatically using the Sofusa® DoseConnect™ device
9506|NCT04118855|Drug|Toripalimab|3mg/kg, IV (in the vein) on on day 1 of 3-week, 6-week and 9-week for a total of 3 doses prior to partial nephrectomy or radical nephrectomy
9507|NCT04118855|Drug|Axitinib|5 mg by mouth twice each day for 12 weeks prior to nephrectomy
9508|NCT04118842|Drug|Savolitinib|Patients will receive a single dose on Study Day 1 and Study Day 20. Savolitinib will be administrated after a high fat, high calorie breakfast to reduce the risk of adverse events.
9509|NCT04118842|Drug|Rifampicin|Patients will receive Rifampicin once daily on Study Day 15, 16, 17, 18, 19, 20 and 21. Rifampicin will be administered 1 hour before breakfast.
9510|NCT04118829|Drug|Perampanel|"For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (4 mg, 6 mg or 8mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day."
9511|NCT04118816|Diagnostic Test|Polysomnography|overnight polysomnography recording at least six hours
9512|NCT04118816|Diagnostic Test|Multiple sleep latency test|daytime naps at least four to five naps to evaluate daytime sleepiness and narcolepsy
9513|NCT04118816|Other|Continuous positive airway pressure|continuous positive airway pressure treatment for sleep-disordered breathing
9514|NCT04118803|Device|ICD replacement or Upgrade|Currently, it is common for patients to survive beyond their initial prophylactic ICD generator. It is unclear whether further benefit related to Inappropriate Shocks or ATP is derived from long-term device therapy, particularly if there has been a change in the patient's cardiovascular condition.
9515|NCT04118790|Other|Clinical Assessment|"Medical history and details of the vascular incident will be collected from the patient and the medical journal. (Duration: 1hr)~Neuropsychological measures collected using test measures and questionaries (duration approx 45-60 min)."
9516|NCT04118790|Procedure|MRI scan|1. MRI scan session, which includes Structural, Quantitative, Functional and Diffusion MRI sequences. (maximum duration: 90 min).
9517|NCT04118777|Drug|Ropivacaine|0.2 % Ropivacaine will be continuously administered intraperitoneally at a rate of 6 mL/hr
9518|NCT04118764|Device|Neuronavigation-guided single-element focused ultrasound transducer|Non-invasive focused ultrasound-induced blood-brain barrier opening will be attempted using a single-element transducer, guided with a neuronavigation system.
9519|NCT04118764|Drug|Definity|Definity microbubbles (10 μl/kg) will be used in conjunction with the ultrasound transducer to temporarily open the blood brain barrier.
9520|NCT04118764|Other|Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents|MRI scans will be completed at baseline and immediately after the focused ultrasound treatment to confirm BBB opening and safety. A follow-up MRI will be performed three days after treatment to confirm BBB closure, only in the case of successful BBB opening.
9521|NCT04118764|Other|Positron Emission Tomography (PET)|A follow-up PET scan will be performed three days after treatment to determine amyloid plaque load.
9522|NCT04118764|Other|Amyvid|To be used during the PET scan to determine uptake of Amyvid within the treated area.
9523|NCT04118725|Diagnostic Test|Pulmonary function test|Diaphragmatic electromyography with measurement of transdiaphragmatic pressure in cases of dyspnea and/or abnormal pulmonary function test (maximum inspiratory pressure and/or lying/seating low vital capacity ratio)
9524|NCT04118699|Drug|Rifaximin oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
9525|NCT04118699|Drug|Placebo oral tablet|Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks
9526|NCT04118686|Other|CoRe software training plus non-invasive brain stimulation techniques (anodical tDCS / rTMS)|CT program with Computerized cognitive training (CoRe) plus stimulation that modulates cortical activities by delivering strong magnetic pulses to the cortex through the scalp (rTMS) and weak electrical currents to the scalp to modulate neuronal transmembrane potential towards hyperpolarization or depolarization (tDCS).
9527|NCT04118686|Other|CoRe software training plus sham non-invasive brain stimulation (sham tDCS/ sham rTMS)|CT program with Computerized cognitive training (CoRe) plus sham stimulation
9528|NCT04118673|Behavioral|Lifestyle Prescription (LRx)|Standard care during consultations with the addition of a physical lifestyle prescription
9529|NCT04118660|Other|Tissue Banking|Blood, tissue, and fluid collection
9530|NCT04118647|Drug|Wu-Chu-Yu tang|Wu-Chu-Yu tang at a rate of 3.0 g three times per day for 28 days.
9531|NCT04118621|Device|chest ultrasound|detection of postoperative pulmonary complications after cardiothoracic surgery
9532|NCT04118608|Other|No intervention|No intervention
9533|NCT04118595|Behavioral|Educational Video|Patients will watch a 15-minute interactive video about acute pain management strategies that can be used at home. The focus is on medications (acetaminophen, NSAIDs, opioids) and behaviors (sleep, staying active, relaxation, and social support).
9534|NCT04118595|Behavioral|Telecare|A phone call from a research nurse will occur ~48-72 hours after the patient's discharge to assess their pain and make recommendations regarding pain management strategies.
9535|NCT04118595|Behavioral|Primary Care Provider Communication (PCP communication)|The research nurse will provide a summary of the ED visit and telecare call to the patient's primary care provider.
9536|NCT04118582|Other|Body composition and resting metabolic rate analisys|
9537|NCT04118569|Behavioral|Narrative Intervention|Research staff conducts an open-ended, audio-recorded interview with the patient about their illness and how this illness has affected their psycho-social-spiritual well-being. The investigators will use the interview transcription to create a meta-narrative, which is then uploaded to the electronic medical record and the patient's primary nurse is notified that it is available to read.
9538|NCT04118556|Biological|Decidua Stroma Cells (DSC)|"Placenta-derived Decidua Stroma Cells. The product consists of a viable allogeneic DSCs frozen in 5% of human serum albumin (HSA) in sodium chloride (NaCl) 0.9% and 10% dimethylsulfoxide (DMSO), that is thawed and immediately diluted in 40 mL sodium chloride (NaCl) 0.9% prior to infusion. That will give a final concentration of 2.2% HSA and 2% DMSO.~DSC will be infused when steroid-refractory acute GVHD after allogenic stem-cell transplantation has been diagnosed. Two doses, one week apart, will be given to all patients. Additional doses will be used depending on response."
9539|NCT04118556|Drug|Best available Treatment (BAT)|The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.
9540|NCT04118543|Other|Intervention Group|Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of a circuit-style programme of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
9541|NCT04118543|Other|Sham-Exercise Group|Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions which will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. this will last for 35-40mins, followed by a 5-10min cool-down.
9542|NCT04118530|Other|HSCT Patients|Prospective, observational review of incidence of AF/AFL through Carelink remote monitoring and safety of implantation of device in this population of patients through review of standard of care follow up visits post HSCT implant
9543|NCT04118517|Other|Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults|The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing >50% of the protein.
9544|NCT04118504|Device|Mobile application|Lifestyle intervention on through mobile application
9545|NCT04118491|Device|hyperbaric oxygen and sham hyperbaric oxygen|see arm descriptions
9546|NCT04118478|Behavioral|MULTICOMPONENT TRAINING PROGRAM|The program will be divided into three phases: The first phase will seek to develop muscle strength, power and endurance with appropriate means, such as elastic and suspension bands, medicine balls, dumbbells, guided machines of variable resistance and exercises with body weight, which will alternate according to the progress of the program. Phase two will be aimed at improving cardiorespiratory capacity, through static and dynamic gait exercises, with directional changes in a fractional manner, with density 1: 1 and 1: 2 as appropriate and the third phase aimed at improving of balance, flexibility and cognition, through exercises of static and dynamic equilibrium, general and specific mobility, coupled with the development of cognitive tasks in motion.
9547|NCT04118465|Procedure|external cephalic version|external cephalic version
9548|NCT04118452|Behavioral|Telephone-based early childhood developmental care coordination|The 211LA care coordinator will review developmental screening results and provide referral recommendations to the family and use 211LA's extensive resource directory and agency relationships to identify appropriate referrals. The 211LA care coordinator will provide a report to the clinical provider containing recommendations for follow-up and a care coordination plan. The report will be scanned into the EMR by clinic staff and be available for provider review. The 211LA care coordinator will also make all recommended referrals and will call the family monthly until 1) children begin receiving services, 2) families refuse services, or 3) children are deemed ineligible by service providers.
9549|NCT04118439|Other|Motor Imaginery and Action Observation|A set of tasks done with the shoulder, first with an Action Observation perspective and then asked to perform this tasks with motor imaginery
9550|NCT04118426|Radiation|Cognitive testing|"Patients will have their cognitive function tested by the use of standardized cognitive test and fill in questionnaires.~Cognitive function will be assessed by standardized cognitive tests: Hopkins verbal learning test (HVLT), Trail Making Test part A and B (TMT A and TMT B), Pased Auditory Test (PASAT), Wechsler Adult Intelligence Scale coding and digit span (WAIS-IV), Controlled Oral Word Association Test (Cowat) and STROOP colour and word test (STROOP)~Questionnaire include; Quality of life; EORTC QlQ-C30 (QlQ-C30), FACIT-Fatigue Scale (Version 4) (FACIT), Pittsburg Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS), Patient's Assessment of Own Functioning Inventory (PAOFI)."
9551|NCT04118413|Other|erector spinae plane block|Erector espine plane block will be administrated bilaterally to this group at low thoracic level (Th11).
9552|NCT04118400|Procedure|NIV-NAVA|NAVA mode during Non-invasive ventilation
9553|NCT04118400|Procedure|Nasal CPAP or NIMV mode|Nasal CPAP or NIMV mode during Non-invasive ventilation
9685|NCT04117243|Drug|Misoprostol|patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)
9554|NCT04118387|Drug|Acetazolamide + supplemental oxygen + PAP therapy|Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.
9555|NCT04118387|Drug|Zolpidem + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.
9556|NCT04118387|Drug|Buspirone + PAP therapy|The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.
9557|NCT04118374|Other|Standard Carb Diet|Approximately 50% of caloric intake will come from carbohydrate consumption.
9558|NCT04118374|Other|Low Carb Diet|Approximately 25% of caloric intake will come from carbohydrate consumption.
9559|NCT04118361|Diagnostic Test|HINTS Test|"The HINTS test is a clinical test composed of 3 oculomotor examinations:~Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging."
9560|NCT04118361|Diagnostic Test|STANDING Algorithm|The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
9561|NCT04118348|Behavioral|Best Practice Alert|An Epic screen pops up for a provider during an eligible 9-11 year-old patient's visit. A prompt requires that the provider respond, either confirming the prescription of a lipid panel or opting out with an acknowledgment/reason for declining the test.
9562|NCT04118348|Behavioral|Health Maintenance Topic|An Epic health maintenance topic appears for a provider during an eligible 9-11 year-old patient's visit. The HMT will be highlighted for enhanced visibility, until or unless action is taken.
9563|NCT04118335|Other|Black Mulberry Syrup|The individuals in the intervention group gargled with 5 ml black mulberry syrup and waited average one minute and then swallow it.
9564|NCT04118322|Other|aromatherapy (peppermint oil)|"The patients in the intervention group received routine medical treatment program and were asked to put one drop of peppermint oil upon lips following chemotherapy administration. Before peppermint oil application; the researcher theoretically and practically provided a training of 8-10 minutes about the use of peppermint oil and the patients were requested to apply this oil three times a day according to Oil Practice Guide (See Fig. 2) in the morning (09:00), at noon (15:00) and in the evening (21:00).~Aromatherapy essential oil used was a mixture of English peppermint (Mentha piperita; 3%) and sweet almond oil (30 ml)"
9565|NCT04118309|Behavioral|Exercise|
9566|NCT04118309|Other|Placebo|
9567|NCT04118296|Drug|Anti-Acne Preparations for Topical Use|Combination of anti acne cream that contain active substances such as Clindamycin 3%, Dexamethasone 0.05% and Tretinoin 0.05%
9568|NCT04118283|Behavioral|Cognitive Behavioral Therapy for Chronic Pain|Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
9569|NCT04118283|Behavioral|Health and Wellness|Health & Wellness was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health & Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
9570|NCT04118270|Device|Afib 2gether TM Mobile Application|The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
9571|NCT04118257|Dietary Supplement|Sugary beverage: Fruit juice|Participants consumed 100% fruit juice (~710mL) daily for three weeks, along with their habitual diets.
9572|NCT04118257|Dietary Supplement|Sugary beverage: Soda|Participants consumed soda (~710mL) daily for three weeks, along with their habitual diets.
9573|NCT04118257|Dietary Supplement|Control: Water|Participants consumed water (~710mL) daily for three weeks, along with their habitual diets.
9574|NCT04118244|Diagnostic Test|lung recruitment maneuver|The ventilator was switched to pressure control ventilation, inspiratory time was increased to 50%, the peak inspiratory pressure gradient (above PEEP) was set at 15cm H2O, and PEEP was progressively increased to obtain a stepwise increase of peak inspiratory to 20, 25, and 30 cm H2O every three breaths. The final recruiting pressure of 30 cm H2O was applied for six breaths.
9575|NCT04118231|Other|Dry needling|Group 1: Dry needling Group 2: static stretching Group 3: IASTM
9647|NCT04117607|Drug|Rezafungin|Rezafungin, 100 mg/mL, is a sterile liquid product supplied in single-dose vials containing 1.0 mL of extractable volume. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredient is mannitol.
9576|NCT04118218|Other|Rhizolysis pain analysis|"Definition of the subgroup of good clinical outcome after rhizolysis (called effective rhizolysis) by lumbar VAS or lower extremity pain VAS or Oswestry index decreased at 6 weeks after rhizolysis.~The efficiency criterion based on the decrease in the dolorimeter or the Oswestry index corresponds to a decrease of at least 50% [1, 2, 3, 4]."
9577|NCT04118192|Procedure|Tumour bed core biopsy|Collection of up to 8 core biopsies across 4 zones of the whole tumour bed to detect residual cancer post neo-adjuvant treatment
9578|NCT04118179|Other|Blood sample collection|A blood sample (1 tube) will be collected for the analysis of the CR signature.
9579|NCT04118166|Drug|Ipilimumab|Ipilimumab 1 mg/kg, injection
9580|NCT04118166|Procedure|Cryoablation|Cryoablation of the tumors occur between investigational agent treatment Cycles 1 and 2, and will be performed according to standard procedures
9581|NCT04118166|Drug|Nivolumab|Nivolumab 3 mg/kg, injection
9582|NCT04118153|Drug|Abatacept|Abatacept will be administered by subcutaneous injections weekly for 3 months. Dosing is according to body weight at screening visit and will be administered as follows: up to 25 kg receive 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL) per dose.
9583|NCT04118140|Other|Somatic Acupressure|Daily self-acupressure (details of the intervention protocol will be determined by three systematic reviews and the systematic reviews are in progress) plus usual care (an education booklet)
9584|NCT04118140|Other|Sham acupressure|Same dose as the true acupressure group but on the sham acupoints plus usual care (an education booklet)
9585|NCT04118140|Other|Usual care|Usual care only (an education booklet)
9586|NCT04118127|Drug|2mg conventional tablet, once-weekly tablets|In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
9587|NCT04118114|Drug|PRL3-zumab|IV administration every 2 weeks
9588|NCT04118101|Drug|ESPB block|A total of 25 ml bupivacaine 0.5% will be injected into the ESP.
9589|NCT04118101|Other|control|no ESPB will be given.
9590|NCT04118088|Biological|Darvadstrocel|Darvadstrocel suspension of human expanded adipose stem cells.
9591|NCT04118075|Drug|PT-CY-FK +/-ATG|GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.
9592|NCT04118062|Behavioral|Questionnaires|Questionnaires
9593|NCT04118062|Behavioral|Semi-structured individual interviews|Semi-structured individual interviews
9594|NCT04118062|Other|Focus Group|Focus Group
9595|NCT04118062|Other|DELPHI Consensus Method|DELPHI Consensus Method
9596|NCT04118049|Other|BiopHreshTM vaginal probiotic supplement (Good Clean Love, Inc. Eugene, OR) and RestoreTM gel.|BiopHreshTM is a vaginal probiotic supplement that is offered over the counter and contains four different lactobacilli strains (L. crispatus, L. gasseri, L. jensenii, and L. rhamnosus). RestoreTM is a moisturizing personal lubricant that has been on the market for three years. Participants will use 1 probiotic capsule with RestoreTM gel nightly three times weekly.
9597|NCT04118049|Other|Standard Care|Standard care arm is standard care for pessary use. Pessary maintenance will be performed standardly by their provider.
9598|NCT04118036|Drug|Pembrolizumab|intravenously over 30 minutes every 21 days (+/- 3 days)
9599|NCT04118036|Drug|Abemaciclib|Oral 2 times a day
9600|NCT04118023|Diagnostic Test|7 Tesla Magnetic Resonance Imaging Test|MAGNETOM Terra - 7T MRI Scanner by Siemens Healthineers. Each patient enrolled will undergo the study imaging test prior to planned diagnostic knee arthroscopy.
9601|NCT04118010|Drug|Vitamin D3|High-dose vitamin D3 50,000 IU /week for 12 weeks
9602|NCT04118010|Drug|Placebo vitamin D3|Matching to Vitamin D3 placebo capsules for 12 weeks
9603|NCT04118010|Drug|Inulin|Chicory-derived prebiotic inulin 12 g/day for 12 weeks
9604|NCT04118010|Drug|Placebo Inulin|Corn-derived maltodextrin 12g/day as the prebiotic placebo for 12 weeks
9605|NCT04117971|Other|Questionnaire|The study will involve structured questionnaire asking questions about knowledge, attitude, and practice of child abuse diagnosis and reporting among dentists.
9606|NCT04117958|Drug|AMG 199|AMG 199 is a BiTE® molecule designed to direct T cells towards MUC17-expressing cells.
9607|NCT04117945|Biological|Cetuximab|Given IV
9608|NCT04117945|Drug|Irinotecan|Given IV
9609|NCT04117945|Biological|Panitumumab|Given IV
9610|NCT04117945|Drug|Regorafenib|Given PO
9611|NCT04117932|Drug|Ustekinumab|Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
9612|NCT04117919|Drug|paper mulberry leaf|Topical steroids+paper mulberry leaf The botanical origin of paper mulberry leaf is Broussonetia papyrifera (L.) Vent.
9613|NCT04117919|Drug|Triamcinolone (Encort-A) 0.1%15g/Tube|only Topical steroids
9614|NCT04117906|Behavioral|STAGE training for anxiety|STAGE is a brief, online, self-help course designed to target anxiety through providing training in perspective broadening and self-distancing.
9615|NCT04117893|Drug|Duloxetine|Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
9616|NCT04117893|Drug|intra-articular injection of corticosteroid and hyaluronic acid|Participants will receive a 2 ml intra-articular injection of 30mg of hyaluronic acid plus 10mg of triamcinolone acetonide.
9617|NCT04117880|Drug|Ataluren|Oral
9618|NCT04117867|Behavioral|Patiens with intraoperative hypotension|In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
9619|NCT04117841|Other|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
10179|NCT04113200|Dietary Supplement|Nutricomp Soy Fibre|A 1kcal per ml enteral feed not containing alginate.
9620|NCT04117828|Dietary Supplement|Dates|Phoenix dactylifera, commonly known as date or date palm is a flowering plant species in the palm family, Arecaceae. Dates are the fruit of the date palm tree, which is grown in many tropical regions of the world. Dates provide a wide range of essential nutrients, and has certain protective effects on health of individuals.
9621|NCT04117815|Device|Paxman Scalp Cooling System|"All patients who accomplish inclusion criteria and do not exhibit any contraindication undergo scalp cooling with the following conditions:~Minimum 30 minutes pre-infusion cooling~Cooling for the duration of chemotherapy infusion~Minimum 90 minutes post-infusion cooling Scalp cooling is performed within the study group at each CT session."
9622|NCT04117815|Other|Alopecia Assessments|"Patients (study group and reference group) will be assessed at the following time Points:~Baseline~at the half-way Point of the cyles~at the last CT cycle~3 months after completion of Treatment~6-9 months after treatment completion~The assesments include the following~Photographs of the head, which are evaluated using the CTCAEv4.0~Questionnaire including the NCI- PRO-CTCAE-ITEMS, EORTC QLQ-C30, EORTC QLQ-B23, Body Image Scale, PRO-CTACAEs and Hairdex questionnaire"
9623|NCT04117802|Other|Maple syrup|Substitution of refined sugar by an equivalent quantity of maple syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with maple syrup.
9624|NCT04117802|Other|Placebo|Substitution of refined sugar by an equivalent quantity of maple-flavored sucrose syrup (5% of daily energy intake) in the participant diet. A dietitian will help study subjects to target added sugar sources in their usual diet and suggest ways to substitute it with the placebo (sucrose syrup).
9625|NCT04117789|Behavioral|Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.
9626|NCT04117789|Behavioral|Self-guided internet-delivered cognitive behavior therapy for depression in adolescents|Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.
9627|NCT04117789|Other|Treatment as usual|Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
9628|NCT04117776|Other|Skin microbiological sampling (wash with 2% Chlorhexidine Gluconate)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with 2% Chlorhexidine Gluconate : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
9629|NCT04117776|Other|Skin microbiological sampling (wash with mild soap)|3 microbiological samples, per application of agar on skin, after 24h of a first wash with mild soap : 1h before the second wash with the same washing product and then 1 to 2 h after, and 20 to 23h after this second wash.
9630|NCT04117763|Drug|Empagliflozin 25 MG|Empagliflozin once daily, for three months
9631|NCT04117750|Dietary Supplement|cholecalciferol (vit D3)|42,000 IU oral vitamin D per week and 500 mg calcium carbonate
9632|NCT04117737|Other|Virtual reality combined with anti-gravity treadmill|"The system is composed of three major parts: the treadmill, the antigravity system and the virtual reality system.~The treadmill is the base of the device. It is a rounded and concave structure that permits to walk in all direction. For simulate anti-gravity, a harness and pulley system allow to regulate the weight. Finally, the virtual reality system enables participants to simulate an experience of daily life."
9633|NCT04117724|Other|Survey|Patients will be asked to complete a 4 question survey assessing adherence. Follow up via patient's preferred method of contact will be conducted after the patient's intended antibiotic completion date and covariates for antibiotic regimens will be recorded including antibiotic type, number of doses, antibiotic duration, reason for non-adherence, pills remaining, and number of other medications.
9634|NCT04117711|Drug|AT-007|AT-007 will be administered once daily before breakfast. Up to 4 different dose cohorts in part A; up to 4 dose cohorts in part B, up to 2 dose cohorts for part C, and up to 3 dose cohorts for part D will be enrolled in the study. The starting dose in Part A will be 0.5 mg/kg as a single dose. Subsequent doses in Part A and all doses in Parts B, C, and D will be based on the results of previous cohorts and/or previous parts of the study. Part B will start after all subjects in Part A have completed the study. Cohort C1 will be conducted simultaneously with Cohort B3 and using the same dose as Cohort B2. The dose for Cohort D1 will not be higher than the dose for Cohort B2. The second and third cohorts in Part D (D2 and D3) will not start until after all subjects in Cohorts B3 and B4, respectively, have completed the study and the dose levels will not be higher than those for Cohorts B3 and B4, respectively.
9635|NCT04117711|Drug|Placebo|Matching placebo capsules will be administered once in the morning before breakfast
9636|NCT04117698|Drug|Antitubercular treatment (RIFATER ©)|"Treatment of ocular inflammation by antitubercular treatment  add-on of local corticosteroid therapy comprising:~RIFATER © (Isoniazid + Rifampicin + Pyrazinamide) + Ethambutol (13.5-20 mg / kg / day) for 2 months then RIFINAH © (Isoniazid + Rifampicin) for 4 months~associated with a treatment similar to the control group."
9637|NCT04117698|Drug|Ethambutol|Ethambutol
9638|NCT04117698|Drug|RIFINAH ©|RIFINAH ©
9639|NCT04117685|Other|Observational|All groups will undergo observational data collection. No interventions will be made to patient care.
9640|NCT04117672|Dietary Supplement|Salovum|Active egg yolk powder
9641|NCT04117672|Dietary Supplement|Placebo egg yolk powder|Normal egg yolk powder
9642|NCT04117659|Other|withdrawal of oral medication (phosphodiesterase-5 inhibitor) in pretreated patients|discontinuation of the oral medication with a phosphodiesterase-5 inhibitor
9643|NCT04117646|Other|Sinus and nasal quality of life survey questionnaire (SN-5)|Subjects respond to the translated questionnaire twice at 15 days apart.
9644|NCT04117633|Device|Laparoscopy|Laparoscopic Procedures for Rectopexy
9645|NCT04117620|Other|Pediatric Vestibular Symptom Questionnaire|Subjects respond to the translated questionnaire twice with 15 days interval
9646|NCT04117607|Other|Placebo|0.9% Sodium Chloride Injection, USP, is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg and contains no preservatives, bacteriostatic agent, antimicrobial agent, or added buffer.
11474|NCT04102618|Drug|Atezolizumab|1200 mg administered intravenously on Day 3
9648|NCT04117607|Drug|Rezafungin|Rezafungin, 200 mg/vial, is a sterile product supplied as a white to pale yellow lyophilized powder in single-dose glass vials for reconstitution with Sterile Water for Injection, United States Pharmacopeia (USP). The reconstituted product is diluted in 0.9% Sodium Chloride Injection, USP for IV infusion. The active pharmaceutical ingredient is rezafungin acetate, a water-soluble amorphous acetate salt. The inactive ingredients include excipients of mannitol, polysorbate 80, and histidine.
9649|NCT04117594|Diagnostic Test|WB-MRI|Whole body MRI with diffusion-weighted imaging (DWI)
9650|NCT04117581|Dietary Supplement|Vitamin D3|5000 IU (125 μg) vitamin D3 capsules daily over 12 weeks (84 days)
9651|NCT04117581|Other|Placebo|Inert filler capsules daily over 12 weeks (84 days)
9652|NCT04117568|Other|Blood sampling|Blood sampling at 3-5 occasions per admission
9653|NCT04117555|Diagnostic Test|Pupil response to light stimuli|Objective and accurate measurement of pupillary responses to light stimuli
9654|NCT04117542|Other|Observational|Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
9655|NCT04117529|Other|Blood sample|Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
9656|NCT04117516|Procedure|Open surgery|"Open carpal tunnel release will be performed, in the theatre, with tourniquet, under local anesthesia and sedation, through a short longitudinal volar classical approach of the hand, that allows to visualize the complete division of the ligament."
9657|NCT04117516|Procedure|Percutaneous surgery|Percutaneous carpal tunnel release will be performed, ambulatory, with a percutaneous scalpel, through a short transverse volar approach, 1-2cm proximal to the wrist, under Wide Awake Local Anesthesia with No Tourniquet.
9658|NCT04117490|Other|Epiitalis|Two capsules twice daily 30 mins before meals (breakfast & dinner).
9659|NCT04117490|Other|Placebo|Two capsules twice daily 30 mins before meals (breakfast & dinner).
9660|NCT04117477|Drug|Xylitol|Xylitol dental wipes
9661|NCT04117477|Other|Placebo|Placebo dental wipes
9662|NCT04117464|Behavioral|Behavioral activation therapy|Behavioral activation therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
9663|NCT04117464|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy administered on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
9664|NCT04117464|Behavioral|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy on a group basis (maximum 6 people) over 8 weekly sessions of 90 minutes.
9665|NCT04117464|Other|Wait List Group|No psychological intervention
9666|NCT04117451|Other|Propolis|Investigating the impact of propolis mouthwash on oral and cardiovascular health
9667|NCT04117438|Other|no intervention|There is no intervention. We are just asking breast cancer patients what their food story is.
9668|NCT04117425|Biological|biological collection|"Blood collection at each trimester of pregnancy, delivery and post partum visit or at medical interruption.~Collection of saliva at each trimester of pregnancy and post partum visit. Collection of cord blood and amniotic fluid at delivery or at medical interruption."
9669|NCT04117412|Other|Exercise|Same participants will undergo different one bout of exercise protocols
9670|NCT04117399|Other|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise group received only aerobic exercise.
9671|NCT04117386|Diagnostic Test|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong)|HPV genotyping assay using HPV GenoArray Diagnostic Kits (Hybribio Ltd., Sheung Wan, Hong Kong) for swab sample collected from pterygium and normal conjunctiva and also for urine collected in Colli-PeeTM device (Novosanis, Belgium)
9672|NCT04117386|Diagnostic Test|Bio-Plex® 200 system (Bio- Rad, Hercules, CA)|Bioplex was use for measure cytokine IL-6, IL-18 and VEGF from tears collected from Schirmer strip
9673|NCT04117360|Other|Orthognathic surgery and Orthodontics|This study is observational. All subjects identified to participate will be undergoing orthognathic jaw surgery and orthodontic treatment.
9677|NCT04117334|Other|Bracing|
9678|NCT04117308|Procedure|Classic information|The team delivers to each patient a unique and standardized information brochure including a definition of fetal active movements, and the need to consult if the patient perceives less the movements of her fetus.
9679|NCT04117308|Procedure|Information by detailed brochure on the fetal active movements account|Delayed single and standardized explanatory card on fetal movements (definition, interests of their follow-up, technique of movements on fetuses, table to fill during the follow-up noting the number of active movements physical feelings at 3 times of the day, managing the decrease in the number of active fetal movements).
9680|NCT04117295|Device|Carmat Total Artificial Heart|Heart replacement therapy
9681|NCT04117282|Other|gait training|training for improving the quality of gait through adjusting gait cycle phases time and improving the functional level and independence during gait
9682|NCT04117269|Device|External shoe lift|Height compensation will be made with cork or EVA (polyurethane + Ethylene Vinyl Acetate) depending the characteristics of the shoe. It will be made by the same orthophaedic technician. The prescription of the heigh of the lift will be made with the patient in a barefoot standing position, a calibre will be used to mark the femoro-tibial joint in both lower limbs in order to rule out the asymmetry. After this, the patient will shod the offloading device in the ulcerated feet and their conventional footwear in the other foot (with the use of their own foot orthosis). 5 millimeters splints will be added under the non affected footwear until the previous mark in both limbs been balanced. The difference in the heigh between limbs will be assessed measuring all the splints used previously
9683|NCT04117256|Device|Direct Current Stimulation|20 minutes of direct current stimulation using an intensity of 1.5mA and electrode size of 6x4cm
14080|NCT04081350|Drug|LY3471851|Administered SC
9686|NCT04117243|Drug|Tranexamic acid|patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)
9687|NCT04117243|Drug|Oxytocin|patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
9688|NCT04117217|Diagnostic Test|Labs drawn|We will collect blood samples/biomarkers at the time of enrollment.
9689|NCT04117204|Other|Fruits and Vegetables|Fruits and Vegetable delivery, once a week for 12 weeks.
9690|NCT04117191|Dietary Supplement|Doctor's Best L-Tryptophan|2g tryptophan loading once
9691|NCT04117178|Drug|Donepezil|Adjustment of treatment with donepezil according to serum level.
9692|NCT04117178|Drug|Memantine|Adjustment of treatment with memantine according to serum level.
9693|NCT04117178|Diagnostic Test|Measurement of serum level of anti-dementia drug|"Participants allocated to the intervention arm are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention group not experiencing side effects will have their treatment adjusted after 6 months based upon serum levels of the drug in question.~Participants allocated to the standard of care arm follow the usual routines of the dementia clinic but are requested to have the serum level of the prescribed drug and CYP2D6-genotype measured after 12 month."
9694|NCT04117165|Diagnostic Test|Biotherapy Prescription with SinnoTest® software|The rheumatologist will use the SinnoTest® software to give the best biotherapy to the patient according to the results of the software.
9695|NCT04117165|Drug|Patient Current Care|The rheumatologist will use the french guidelines of rheumatoid arthritis to choose the more adapted biotherapy treatment to the patient.
9696|NCT04117152|Other|Latent class mixed modeling|To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling
9697|NCT04117139|Diagnostic Test|PET/MRI|A PET/MRI of the Head and Neck region is done for all patients included in the project.
9698|NCT04117126|Behavioral|Prompted voiding|"Monitoring: This involves asking the incontinent individual, at regular intervals, if he or she needs to use the toilet. The care provider may look for behaviours that the client needs to be toileted (e.g., restlessness, agitation, disrobing), and take the client to the toilet at regular intervals specific to their schedule, rather than routinely every two hours.~Prompting: This process includes prompting the person to use the toilet at regular intervals, and encourages the maintenance of bladder control between prompted voiding sessions.~Praising: This important step is the positive reinforcement of dryness and appropriate toileting, and is the response from the care provider to the individual's success with maintaining bladder control."
9699|NCT04117100|Procedure|Polypectomy or myotomy|Advanced therapeutic endoscopy can replace surgery for treatment of benign and malign GI diseases and the aim of this registry-based study to improve quality related to advanced therapeutic endoscopy because the trial will provides a quantitative method to assess advanced therapeutic practise at the CHUM and may identify practices of low quality (possible intervention) or high quality (desired). Advanced therapeutic endoscopy procedures included for this registry-based study are EMR, ESD, Assessment of polypectomy quality for colorectal adenomas/polyps, Radio Frequency Ablation (RFA) and Argon Plasma Ablation (APC), and Per Oral endoscopic Myotomy (POEM).
9700|NCT04117087|Drug|KRAS peptide vaccine|"KRAS peptide vaccine will be administered on days 1, 8, 15 and 22. Five boost vaccinations with will be administered at 8-9 week intervals (on weeks 13, 22, 31, 40, and 49).~Drug: 1.8 mg KRAS peptide vaccine + 0.3mg Poly-ICLC"
9701|NCT04117087|Drug|Nivolumab|"Nivolumab 360 mg will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of each 21 day cycle.~Drug: 360 mg IV"
9702|NCT04117087|Drug|Ipilimumab|"Ipilimumab (1 mg/kg) will be administered as a 30 minute IV infusion (-10min/+15min) on Day 1 of Cycles 1, 3, 5, 7, 9, 11, 13, 15 and 17 of the study or every 6 weeks for a total of a year.~Drug: 1mg/kg IV"
9703|NCT04117074|Drug|Liposomal bupivacaine|Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
9704|NCT04117074|Other|Thoracic epidural analgesia (bupivacaine)|Perioperative bupivacaine based thoracic epidural placed preoperatively.
9705|NCT04117061|Procedure|Observation|Patient after primary investigation is observed for 8-12 hours, (instead of being send directly to CT scan), after observation repeated clinical evaluation, laboratory tests and ultrasound examination are done , if final diagnosis stays unclear the patient is refered to CT scan.
9706|NCT04117048|Device|LabPad® point-of-care|All at home INR measurements will be performed by the nurse using the LabPad® point-of-care
9707|NCT04117035|Procedure|Gamma Knife Radiosurgery (GKRS) personalised procedure|Personalised GKRS treatment
9708|NCT04117035|Procedure|GKRS standard care|Standard GKRS treatment
9709|NCT04117022|Dietary Supplement|DVS supplementation|Oral supplement. Each subject will be given the carotenoid supplement of DVS formula. The DVS formula consists of vitamins C, D3 and E (d-α tocopherol), zinc oxide, eicosapentaenoic acid, docosahexaenoic acid, α-lipoic acid (racemic mixture), coenzyme Q10, mixed tocotrienols/tocopherols, zeaxanthin, lutein, benfotiamine, N-acetyl cysteine, grape seed extract, resveratrol, turmeric root extract, green tea leaf, and Pycnogenol (patented French Maritime Pine Bark extract, sp Pinus pinaster, Horphag Research, Geneva, Switzerland). Supplements bottles will be labelled with a unique identification number for each subject and supplied by ZeaVision, LLC, Chesterfield, Missouri, USA. To assure that the participants do not have any issues with the vitamin supplement and to ensure adequate adherence to schedule of vitamin intake the participants will get regular phone calls from the study investigators (once every two weeks).
9737|NCT04116762|Device|Surgical Drain|A surgical drain used in superficial parotid surgery is a thin polyvinylchloride (PVC) tube, with perforations at the end, which is placed at the end of the procedure before the surgical wound is closed in the cavity created following removal of parotid tissue. The tube is connected to a closed vacuum system attached to a plastic bottle outside of the patient's body which acts to remove the fluid that collects after an operation.
9738|NCT04116749|Other|Water|Drink water freely until 2 hours before anesthesia.
9739|NCT04116736|Device|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
14081|NCT04081350|Drug|Placebo|Administered SC
9710|NCT04117009|Drug|Remifentanil 2 MG|Once the participants transferred to operating room, electrocardiography, noninvasive blood pressure, pulse oximetry, and respiratory rate will be recorded. An increase or decrease from the baseline value of 30% in mean arterial pressure will be treated with iv boluses of (5 mg) ephedrine or glyceryl trinitrate (25 micg). All the participants will undergo a baseline transthoracic echocardiographic evaluation to assess the systolic and diastolic function of the left ventricle before the infusion of the study drug. Then the patients will be given oxygen by a face mask at a rate of 5-6 L/min, and Remifentanil infusion will be started using a target controlled infusion pump to reach a target plasma concentration of 2 ng/mL. Once the target concentration is reached, second echocardiographic evaluation to assess the systolic and diastolic function will be performed. Potential side effects of Remifentanil will be monitored.
9711|NCT04117009|Diagnostic Test|Echocardiographic evaluation|Transthoracic echocardiographic examination will be performed in the spontaneously breathing patients right before the surgical procedure.
9712|NCT04116996|Device|DEEP BRAIN STIMULATION|NEUROMODULATION
9713|NCT04116983|Device|Deep Ensemble for the Recognition of Malignancy (DERM)|An AI-based diagnosis support tool
9714|NCT04116970|Procedure|Bronchoscopy|Undergo bronchoscopy with EBUS-TBNA
9715|NCT04116970|Procedure|Ultrasound-Guided Transbronchial Needle Aspiration|Undergo bronchoscopy with EBUS-TBNA
9716|NCT04116957|Other|RTLS current tag|Validate location system performance against manual observation of nursing activity
9717|NCT04116957|Other|RTLS tag revised|Test a next-generation RTLS tag for healthcare process validation
9718|NCT04116944|Behavioral|Resistance exercise training|The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
9719|NCT04116944|Other|Wait-list|Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
9720|NCT04116931|Drug|Switch ticagrelor to clopidogrel|Switch ticagrelor to clopidogrel with 600 mg loading dose (LD)/75 mg maintenance dose（MD）12/24 hours after the last MD of ticagrelor
9721|NCT04116905|Behavioral|Intensive Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision sessions and is aimed at achieving and maintaining at least a 15% decrease in weight from baseline. It is implemented during a 12-month period with the most intensive application during the first 4 months. To help participants achieve and maintain weight loss, partial diet replacement with very low calorie diet, strengthend exercise strategies. Mobile phone applications (apps) will be used to manage metabolic syndrome during weight loss program. Optional medications on metabolic syndrome will be utilized based on a preset algorithm and participant progress.
9722|NCT04116905|Behavioral|Conventional Treatment|Participants assigned to conventional treatment and education are offered metabolic syndrome management and social support every 1 month, aimed at achieving and maintaining a 5% decrease in weight in 1 year. Mobile phone applications (apps) will also be used in the weight loss program.
9723|NCT04116892|Procedure|the Cover group|The internal limiting membrane around the MH was left to cover the hole
9724|NCT04116892|Procedure|the Fill group|The internal limiting membrane around the MH was left to fill the hole
9725|NCT04116892|Procedure|the peeling group|the internal limiting membrane was discarded
9726|NCT04116853|Behavioral|ADAPTIVE Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
9727|NCT04116853|Behavioral|STATIC Extended-Care Program|Each extended-care intervention phone call will be initiated by the interventionist, and will begin with a brief check-in followed by a discussion of any barriers experienced by participants in meeting their weight maintenance goals. Each call will end with a formal goal setting session. Calls are expected to last for approximately 10-20 minutes.
9728|NCT04116840|Drug|MT1002 for injection|Study drug will be administered by an intravenous bolus dose followed by an infusion of 4 hours.
9729|NCT04116827|Drug|Tamoxifen Oral Tablet|Patients who are scheduled for application of tamoxifen and goserelin
9730|NCT04116814|Diagnostic Test|wall-to-lumen ratio measurement|wall-to-lumen ratio measurement in patients with renal insufficiency
9731|NCT04116801|Procedure|microsurgical resection|resection of cerebral metastases by microsurgery
9732|NCT04116788|Device|Artefact IRM assessment|IRM
9733|NCT04116775|Biological|Fecal microbiota transplant|A total of 100 mL of a mixture of stool and saline will be transplanted via endoscopy once.
9734|NCT04116775|Drug|Pembrolizumab|Pembrolizumab 200 mg administered as a 30 minute infusion every 3 weeks.
9735|NCT04116775|Drug|Enzalutamide|Daily oral dose.
9736|NCT04116762|Device|TissuePatchDS-P™|The therapy to be used in the intervention arm is TissuePatchDS-P™. This is a preformed, standard-sized artificial adhesive that will be used between the parotid tissue and subcutaneous tissue. It can be cut to an appropriate size for the defect. The intention of this installation is to seal and close the potential space that is created with removal of superficial parotid tissue
9740|NCT04116736|Device|Silicone Hydrogel Contact Lens|Any reusable spherical silicone hydrogel brand that is approved and marketed in the country conducting the study.
9779|NCT04116437|Drug|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered at a dose of 160 mg twice daily until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination.
9741|NCT04116723|Device|Flexible brace|Participants will be invited to undergo a fitting session of a flexible brace. After the fitting session, participants will join a two-hours wear trial of the flexible brace. Participants are required to wear the brace for two-hours and undergo assessments before and after the wear trial. The measurement outcomes of the assessment include 1) X-ray scan, 2) 3D body scan, 3) garment pressure, and 4) questionnaire.
9742|NCT04116710|Biological|HS-110 (viagenpumatucel-L)|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
9743|NCT04116710|Biological|HS-130|Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
9744|NCT04116697|Other|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body.
9745|NCT04116697|Other|Aromatherapy|Aromatherapy is a form of alternative medicine in which you will inhale aromatic plant extracts and essential oils.
9746|NCT04116684|Device|Withings Digital Blood Pressure Monitor|This is a home digital blood pressure monitor that can transmit recordings via a user's smartphone.
9747|NCT04116671|Device|Neuromechanical Gait Assist|A hybrid powered knee orthosis combined with surface muscle stimulation to assist walking.
9748|NCT04116658|Biological|Multiple dose of EO2401|Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase
9749|NCT04116645|Other|genital and rectal swab|6. Swabs for GBS culture should be obtained, ideally before digital examination or use of lubricants, from both the lower vagina (vaginal introitus) and rectum (insert swab through the anal sphincter) to achieve maximum sensitivity. Either two swabs (one for each site) or a single swab can be used; one swab is more cost saving. The swabs will be obtained by the patient herself after appropriate instruction or by the provider healthcare, as studies have shown equivalent sensitivity between the healthcare provider and the patient herself.
9750|NCT04116632|Drug|BMS-963272|Single dose with varying frequency among groups
9751|NCT04116632|Drug|Placebo|Specified dose on specified days
9752|NCT04116619|Other|Guided Imagery Laboratory Session|"On days 1, 2 and 3 of the study, subjects will come to the research testing rooms and be provided with lunch before beginning the laboratory session. After a 40-minute adaptation period, two blood samples will be drawn before imagery (BASELINE). After the second blood draw, a 5-minute baseline period will follow to assess continuous pulse rate, BP, and HRV assessments. The subject and research staff conducting the sessions will be blinded to the order and content of the imagery condition. In each recording, the subjects will listen to the scripts over headphones and will vividly imagine the described situation, 'as if' it were happening right now, for 5 minutes. The research nurse will take a blood draw immediately after the imagery (IMAGERY). After that, three recovery blood draws will be performed at 15-minute intervals (RECOVERY). We will analyze the total of six blood samples for levels of cortisol."
9753|NCT04116606|Drug|Active JNJ-54175446|JNJ-54175446 is a novel, potent, selective, and brain-penetrant antagonist of the adenosine triphosphate (ATP)-gated P2X7 channel.
9754|NCT04116606|Drug|Placebo|Matching placebo containing the same excipients
9755|NCT04116593|Behavioral|Nutrition education|Our intervention will be school based nutrition education.Nutrition education session will be delivered using audio-visual techniques (audio-visual presentation).Components of eight educational sessions will include overview of 16 food groups of individual dietary diversity score (IDDS) chart, detail description of 16 food groups presenting dietary diversity, overview of basic food components, importance of consuming diversified foods, strategies to select a diversified meal and remove monotony in food, proper timing and frequency of taking meals during 24 hours, selecting diversified meal in low expense, consequences of absence or scarcity of dietary diversity in meal.
9756|NCT04116580|Other|RAAP - for Raw Apple in connection with re-contact with the raw apple according to an Ultra-Rush protocol|
9757|NCT04116554|Drug|0.25% bupivacaine.|20 mL of 0.25% bupivacaine and the same procedure will be repeated on the other side
9758|NCT04116554|Device|0.9%saline|20 ml of 0.9%saline will be injected on each side
9759|NCT04116541|Drug|HDM201|HDM201 120mg, Every 3 weeks, Per os
9760|NCT04116541|Drug|Ribociclib|Ribociclib 200mg/day, once daily 2 weeks on/1 week off, Per os
9761|NCT04116541|Drug|Cabozantinib|Cabozantinib, 60 mg /day, continuous, Per os
9762|NCT04116528|Drug|Ketamine|0.5mg/kg
9763|NCT04116528|Drug|Buprenorphine|Buprenorphine (0.2-0.8mg/day) or Placebo orally dissolving tablet
9764|NCT04116528|Drug|Placebo oral tablet|Buprenorphine or Placebo orally dissolving tablet
9765|NCT04116515|Behavioral|Xbox / active video games|The investigators would expect children to play active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
9766|NCT04116515|Behavioral|Animated cartoon narratives|The investigators would expect the animated cartoon narratives to motivate children to play more active video games as a way to reduce their sedentary activities and increase their moderate and vigorous physical activities.
9767|NCT04116515|Behavioral|Standard clinical care|Each clinic will provide standard clinical care to the participants.
9768|NCT04116502|Drug|Ruxolitinib|10mg of ruxolitinib twice daily (bd)
9769|NCT04116502|Drug|Hydroxycarbamide|Via standard hospital mechanisms
9770|NCT04116502|Drug|Interferon-Alpha|Any formulation, via standard hospital mechanisms
9771|NCT04116489|Other|Forest walk|Participants will be provided with an educational program about the forest and take a guided forest walk.
9772|NCT04116489|Other|Wildlife rehabilitation|Participants will be provided with education on wildlife rehabilitation and assist with wildlife care such as feeding baby animals.
9773|NCT04116489|Other|Wildlife sanctuary observation|Participants will be provided an educational program on wildlife care and accompany park game keepers during animal feeding and will observe iconic wildlife.
9774|NCT04116489|Other|Bird feeding and watching|Participants will learn about bird identification and safe bird feeding. Bird feeders will be provided at the Soldier On facility for home bird feeding after study conclusion.
9775|NCT04116476|Drug|MT-7117|Single Dose of MT-7117
9776|NCT04116463|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
9777|NCT04116463|Behavioral|Financial Self-Management Program (FSMP)|
9780|NCT04116424|Other|nurse training of the patient|visit + telephone follow-up
9786|NCT04116398|Drug|Dexamethasone with 2 loading doses followed by PRN regimen.|"Loading dose with 2 systematic intravitreal injections (IVI) of ozurdex at the baseline and 12 weeks.Followed by a PRN regimen with strict retreatment criteria (already used and published in the Prediamex study, Bellocq,Kodjikian et al Ophthalmology Retina 2017)~Retreatment criteria: Reduction in VA ≥ 5 ETDRS Letters; and/or CSMT ≥ 275 microns by OCT-Cirrus® or ≥ 285 microns by OCT Spectralis®; and/or increase of CSMT > 50 microns; and/or onset of recurrent retinal cysts; and/or residual edema considered by the practitioner to be clinically significant.~Minimal time limit between two IVI : 3 months~Visits: monthly during 1 year (to check efficacy and safety) and then for the 2nd-year only at Month18 (M18) and Month 24 (M24)"
9787|NCT04116385|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
9788|NCT04116372|Behavioral|Digital Health Online Platform|"The website has 10 lessons that the participant will gain access to on a weekly basis. Lesson titles are as follows:~Lesson 1 - Benefits of Physical Activity on Chronic Disease Lesson 2 - Mental benefits of Physical Activities Lesson 3 - Increasing Self Confidence for Physical Activities Lesson 4 - Learning about your Emotions Lesson 5 - Building Social Support Lesson 6 - Building Physical Activity Opportunity Lesson 7 - Goal Setting and Planning Lesson 8 - Self Monitoring Lesson 9 - Habit Lesson 10 - Identity"
9789|NCT04116359|Drug|Cisplatin|Given IV
9790|NCT04116359|Drug|Etoposide|Given IV
9791|NCT04116359|Drug|Etoposide Phosphate|Given IV
9792|NCT04116359|Drug|Molibresib|Given PO
9793|NCT04116359|Drug|Molibresib Besylate|Given PO
9794|NCT04116346|Other|Oral intake allowed|Oral intake (food and fluids) allowed up to the time of the procedure
9795|NCT04116333|Device|Endotracheal tube introducer|Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
9796|NCT04116333|Device|Macintosh laryngoscope|Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
9797|NCT04116320|Device|Echopulse|The Echopulse device delivers focused ultrasound ablation (FUSA) therapy. FUSA is a technology that delivers continuous high-intensity focused ultrasound to ablate tissue.
9798|NCT04116320|Drug|Imiquimod|Imiquimod is a TLR7 agonist therapy.
9799|NCT04116320|Drug|Standard of Care PD-1 Therapy|PD-1 therapy FDA approved for use on a 3-week schedule will be used per standard of care.
9800|NCT04116307|Dietary Supplement|Polymethylsiloxane|
9801|NCT04116307|Dietary Supplement|Lactobacillus reuteri|
9802|NCT04116294|Other|Computer-assisted prescription|The intervention is based on a computer-assisted prescription: when a PAR will be ordered, an alert will arise and explain the recognized indications for this examination and ask a confirmation for the prescription. This is a non-blocking system: physicians will be able to prescribe PAR even if the PAR is not appropriate.
9803|NCT04116281|Other|Rehabilitation after breast cancer surgery|All participants are going to receive physical therapy intervention after breast cancer surgery at least removal drenaige. After that, will be randomized in two groups: Group 1 are going to receive a physical therapy program supervised by a physiotherapist; Group 2 are going to receive some instructions about the same program to perfomr at home without supervision. Both groups are going to receive 3 and 6 months of rehabilitation program.
9804|NCT04116255|Other|Mandibular oral occlusal splint|The panoramic open-mouth and close-mouth radiographs of the first group(splint group) were taken, and intraoral and extraoral examinations were performed by an experienced dentist that also examined the radiographs. The upper jaw of the patients was measured with an alginate impression material, to obtain a hard plaster model. Then, using these models, a vacuum plate machine made a customized mandibular oral occlusal splint suitable for each patient's teeth. The suitability of the splints was checked and confirmed by the dentist on the first and seventh days of use. The patients were asked to use these splints at night (for at least six hours) throughout the study.
9805|NCT04116255|Other|Temporomandibular joint Exercises|This program was created by combining patient training and a home exercise program. The exercise program consisted of slow passive and active mouth opening and closing exercises, isometric masseter exercises, mouth stretching exercises, and resistant mouth opening and closing exercises. Each exercise set was administered twice a day, and each movement was undertaken for 10 seconds and repeated 15 times. The training was given by an experienced physical medicine and rehabilitation expert over approximately 45 minutes. The exercise program was demonstrated for the patients in front of a mirror, and each exercise was performed by a set of patients under the supervision of a doctor. A training document including the written exercise program was to the patients in the exercises group.
9806|NCT04116242|Other|blood sampling for research purpose|blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
9807|NCT04116242|Other|clinical data collection|clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
9808|NCT04116242|Other|Health-related Questionnaires|Health-related Questionnaires (Questionnaire_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
9809|NCT04116242|Other|Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)|Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
9810|NCT04116229|Procedure|Oral glucose tolerance test|After 8 hours fasting overnight, an intravenous catheter is placed in the arm or hand for blood draws. Participants drink 75 grams of an oral glucose drink after baseline blood samples are drawn. More blood draws occur at 10, 20, 30, 60 and 120 min post-glucose drink.
9811|NCT04116229|Behavioral|Cognitive testing|For approximately 40 minutes, participants are assessed for cognitive function using computer-based tests available from the NIH Toolbox Cognitive Battery (Weintraub et al., 2013), including attention and executive functioning, episodic memory, working memory, language, processing speed, and immediate recall.
9812|NCT04116229|Procedure|Magnetic resonance imaging|Magnetic resonance imaging (MRI) scans will be performed in a 3 Tesla MRI scanner over 1.5 hours. Participants will be asked to lay down flat on their backs and to try to stay still throughout the MRI scan. The participant will wear MRI-safe headphones to block out noise due to the MRI scans. Participant comfort will be verbally checked on throughout the scan and the participant will be provided with a 'squeeze ball' to signal the MRI technician that they want to get out of the scanner immediately.
9813|NCT04116216|Combination Product|High frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
9814|NCT04116216|Combination Product|Low frequency repetitive transcranial magnetic stimulation|The sessions will be performed five times a week for two weeks. The individuals will be performed the following protocol: first the coil center will be positioned over Cz for the first 1000 pulses. Then the coil will be moved to C4 and C3, where 1000 pulses will be delivered to each hemisphere. The intensity will be set to 100% of the motor threshold. The high frequency stimulation will be delivered at 10 Hz, offered in 20 50-pulse trains, with 30-second train intervals. The low frequency will be performed at 1 Hz. After rTMS, patients will be submitted to 40 minutes of physical therapy protocol.
9815|NCT04116216|Combination Product|Sham repetitive transcranial magnetic stimulation|For sham stimulation, the stimulator positioned behind the patient will be turned off immediately after the determination of RMT, however, the coil will remain positioned over the patient's scalp (Cz, C3 and C4). A computer equipped with speakers will play an audio recording with the characteristic rTMS sound and no stimulation will be induced in the brain.
9816|NCT04116203|Drug|Metformin|Manufacturer's standard 500 mg. Submission Control No.:128147
9817|NCT04116203|Combination Product|Fish Oil and Metformin|Combo of 2 other arms
9818|NCT04116203|Dietary Supplement|Fish Oil|NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
9819|NCT04116190|Behavioral|Telerehabilitation|Short inpatient multidisciplinary rehabilitation followed by home-based telerehabilitation and a short evaluation period at the end of it.
9820|NCT04116190|Behavioral|Conventional inpatient rehabilitation|Multidisciplinary inpatient rehabilitation, no adjustments due to the study.
9821|NCT04116177|Device|Deep brain stimulation|Stimulation using VerciseTM system
9822|NCT04116164|Drug|111In-DOTA-h11B6|4-6 mCi 111In labeled to 2 mg DOTA-h11B6; 0, 8 or 18 mg additional h11B6.
9823|NCT04116151|Combination Product|Cosmetic cream (Alantel (R): aloe vera, chamomile and thime)|Application on the affected skin of the cream to be tested
9824|NCT04116151|Combination Product|Placebo|Harmless moisturizing substance
9825|NCT04116138|Dietary Supplement|Salovum|Egg yolk powder enriched for anti secretory factor
9826|NCT04116125|Procedure|Radiotherapy|Adjuvant radiotherapy on axillary region
9827|NCT04116112|Drug|Nicardipine|In the event where SBP values are above the randomly assigned target, intravenous nicardipine will be initiated at 2.5 mg/hr to lower the SBP. If SBP is still not reduced to below assigned target after 15 minutes, nicardipine dose will be increased by 2.5 mg/hr every 15 minutes until the target SBP or a maximum dose of 15 mg/hr is reached.
9828|NCT04116112|Drug|Labetalol|If SBP is above target despite maximum nicardipine infusion for 30 minutes, 10-20 mg of intravenous labetalol will be added every 15 minutes.
9829|NCT04116112|Drug|Hydralazine|If SBP remains unresponsive for 1 hr despite the use of maximum doses of nicardipine and labetalol, a Hydralazine will be added at the treating physician's discretion. Incidence of the latter scenario is anticipated to be exceedingly rare.
9830|NCT04116099|Other|Conservative care|May include graduated compression, MLD performed by a licensed therapist, self-MLD, and instruction on exercise and skin care.
9831|NCT04116099|Device|Flexitouch Plus|Flexitouch Plus treatment.
9832|NCT04116086|Diagnostic Test|Prostate Biopsy Test|see earlier information
9833|NCT04116073|Drug|INCMGA00012 (PD-1 antibody)|"Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.~Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)"
9834|NCT04116060|Dietary Supplement|Dietary Nitrate|Oral dietary nitrate supplementation with (0,12 mmol/kgBW sodium-nitrate)
9835|NCT04116060|Dietary Supplement|Control|Placebo Comparator: Dietary sodium-chloride dissolved in water (0,12 mmol sodium-chloride/kgBW/day)
9836|NCT04116047|Drug|Cisplatin|
9837|NCT04116047|Drug|Durvalumab|
9838|NCT04116047|Procedure|Radiotherapy|
9839|NCT04116047|Procedure|Dose-escalated radiotherapy|
9840|NCT04116034|Device|alfapump DSR system|Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump
9841|NCT04116021|Other|PECS block|Ultrasound-guided PECS block before surgical incision with 30 mL bupivacaine 0.5 %
9842|NCT04116021|Other|Local infiltration|Wound infiltration at the end of surgery with with 30 mL bupivacaine 0.5 %
9876|NCT04115709|Device|Beacon Caresystem device without advice activated|Beacon Caresystem device does not give ventilator settings advice
11475|NCT04102618|Drug|Trastuzumab|8mg/kg administered intravenously or 600mg subcutaneously on Day 3
9844|NCT04115995|Diagnostic Test|Dynamic infrared thermography (DIRT) and indocyanine green fluorescence angiography (ICG-FA)|DIRT and ICG FA are used intraoperatively to evaluate perfusion of the perforators and the anastomosis. Both technique are compared in their ability to visualize perfusion.
9845|NCT04115982|Drug|Cholecalciferol|One vial every 15 days during 2 months
9846|NCT04115982|Drug|Placebos|One vial every 15 days during 2 months
9847|NCT04115956|Drug|Melflufen|Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.
9848|NCT04115956|Drug|Dexamethasone|Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
9849|NCT04115943|Other|Treatment protocol for neck pain|The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
9850|NCT04115943|Other|Protocol for release of tongue muscles|. The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
9851|NCT04115930|Device|Physical Activity measurement:|7 days measurement with Active style Pro HJA-350IT device
9852|NCT04115917|Device|Schocket scleral depressor|Scleral Depression on eye with Schocket scleral depressor
9853|NCT04115917|Device|Cotton tipped applicator|Scleral Depression on eye with cotton tipped applicator
9854|NCT04115904|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 45 minutes in length to allow for acceptable time for completionof treatment and retreatment in one or two visits. Allthe clinical procedures were performed by the author.Following local anesthesia with 2% lidocaine with1:100,000 epinephrine (Septodont Saint-Maur desFossés, France) and rubber dam isolation the toothwas disinfected with 5.25% NaOCl (Ultra bleach,Bentonville, AR, USA).
9855|NCT04115891|Other|Anxiety scale|Anxiety Face Image Scale (FIS) assessment in a separate room with face to face interview.
9856|NCT04115891|Other|Pain scale - 1|Face, Legs, Activity, Cry, Consolability (FLACC), to assess objective operational pain after anesthesia injection and tooth extraction
9857|NCT04115891|Other|Pain scale - 2|Wong Baker Pain Rating scale (WBS), to assess subjective operational pain after anesthesia injection and tooth extraction
9858|NCT04115891|Behavioral|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to interventions
9859|NCT04115878|Drug|Atomoxetine and oxybutynin (ato-oxy)|Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
9861|NCT04115852|Behavioral|fmri|functional magnetic resonance imaging
9862|NCT04115839|Drug|Filgotinib|Tablets will be administered orally once daily with or without food.
9863|NCT04115839|Drug|Placebo to match filgotinib|Tablets administered orally once daily with or without food.
9864|NCT04115826|Procedure|Per-oral Pancreatoscopy-guided Lithotripsy|Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.
9865|NCT04115826|Procedure|Extracorporeal Shock-Wave Lithotripsy|ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.
9866|NCT04115813|Behavioral|Project YES! Youth Engaging for Success|Participants in the intervention were offered once a month one-on-one meetings and group meetings with their assigned youth peer mentors over approximately six months. The participant's caregiver could also attend up to 3 caregiver support groups held at the clinic (every other month). In addition, intervention participants in the children's hospital were assessed (clinical and psycho social factors) for physical transition to an adult clinic. After midline data collection, the intervention arm went into a maintenance phase, meeting with the youth peer mentor every other month (3 times). Participants in the comparison arm after midline started the Project YES! intervention as described above. Primary analysis was conducted using midline data.
9867|NCT04115800|Drug|Liposomal Sirolimus|Subconjunctival injections of liposomal sirolimus in patients with conventional treatment with moderate and severe dry deye disease
9868|NCT04115774|Drug|bisphosphonates|Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact
9869|NCT04115761|Biological|autologous dendritic cells|The total 10 doses (1 mL/dose; 2±0.5 × 107 cell/dose) of ADCV01 will be administered to patients assigned to the investigational group. The ADCV01 will be administered to the bilateral subaxillary subcutaneous regional lymph nodes (half of volume about 0.5 mL of ADCV01) once weekly for the first 4 doses, and the following 2 treatments will be administered bi-weekly. The last 4 treatments will be administered every 4 weeks.
9870|NCT04115748|Drug|Filgotinib|Tablets administered orally once daily with or without food
9871|NCT04115748|Drug|Adalimumab|Injection administered subcutaneously once every 2 weeks
9872|NCT04115748|Drug|Placebo to match filgotinib|Tablets administered orally once daily with or without food
9873|NCT04115748|Drug|Placebo to match adalimumab|Injection administered subcutaneously once every 2 weeks
9874|NCT04115722|Other|IBD ACTIVIT|Effect of IBD disease and activity of disease on coagulation parameters
9875|NCT04115709|Device|Beacon Caresystem device with advice|Beacon Caresystem device provides ventilator settings advice to Doctors
13446|NCT04086290|Radiation|SBRT|Stereotactic body radiotherapy to osseous lesions
9877|NCT04115696|Device|Percutaneous placement of biodegradable biliary stents|The bening biliary strictures stents used in this register are made of polydioxanone (PPDX) (Ella-DV biliary stent, ELLACS, Hradec Králové, Czech Republic). The stents are implanted using a percutaneous transhepatic cholangiography using the standard micropuncture technique. Before stent implantation, balloon bilioplasty may be performed.
9878|NCT04115683|Other|Dual Task Training|45 minutes of dual task training consisting of motor activities (walking, balance... etc.) with combination of cognitive activities (spelling words, image description, nomination, word generation, counting... etc.) at sime time.
9879|NCT04115683|Other|Single Task Training|45 minutes of single task training consisting of same motor activities (walking, balance... etc.)
9880|NCT04115670|Behavioral|Group of educational intervention on the neurophysiology of pain and physical exercises|"The physiotherapist of the institution will execute the intervention on the group:~3 first pedagogical sessions on the neurophysiology of pain, distributed: 1 group session, 1 individual session at home, 1 in a personal interview format. These 3 sessions will last 2 weeks to be completed.~Afterward, the protocol of physical exercise training will begin, supervised by the same physiotherapist who carried out the three initial sessions. There will be 15 sessions of specific and individualized physical exercise, in small groups of maximum 5 people. The duration of this part will be 10 weeks, so that from week 1 to 5 is 2 times per week, and from week 6 to 10 just 1 time per week."
9881|NCT04115670|Behavioral|Control group|The control group will follow its normal course of activity
9882|NCT04115657|Other|Starch 1|Consumption of milk tea with sucrose and boba pearls made from tapioca starch
9883|NCT04115657|Other|Starch 2|Consumption of milk tea with sucrose and boba pearls made from high amylose
9884|NCT04115657|Other|Starch 3|Consumption of milk tea with sucrose and boba pearls made from kithul flour
9885|NCT04115657|Other|Starch 4|Consumption of milk tea with sucrose and boba pearls made from sago flour
9886|NCT04115657|Other|Sugar 1|Consumption of milk tea with pure palatinose and boba pearls made from tapioca starch
9887|NCT04115657|Other|Sugar 2|Consumption of milk tea with blend of sucrose and palatinose and boba pearls made from tapioca starch
9888|NCT04115644|Drug|Ketorolac|Group 2 (ketorolac): will receive an injection of 3 cc 0.25% Marcaine without epinephrine and 2 cc ketorolac 30 mg/ml
9889|NCT04115644|Drug|Marcaine (placebo)|Group 1 (control): will receive an injection of 5 cc 0.25% Marcaine without epinephrine
9890|NCT04115644|Drug|Kenalog|Group 3 (kenalog): 4 cc 0.25% Marcaine without epinephrine and 1 cc triamcinolone.
9891|NCT04115631|Drug|Acalabrutinib|Given PO
9892|NCT04115631|Drug|Bendamustine|Given IV
9893|NCT04115631|Drug|Bendamustine Hydrochloride|Given IV
9894|NCT04115631|Drug|Cytarabine|Given IV
9895|NCT04115631|Biological|Rituximab|Given IV
9896|NCT04115618|Radiation|Simultaneous integrated boost intensity-modulated chemoradiotherapy|Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
9897|NCT04115605|Device|Altis Single Incision Sling|Minimally invasive system including permanently implantable synthetic suburethral sling for the surgical treatment of female Stress Urinary Incontinence
9898|NCT04115592|Other|Cocoa butter|Consumption of cocoa butter made with chocolate confectionery
9899|NCT04115592|Other|Cocoa butter oleogel|Consumption of cocoa butter oleogel made with chocolate confectionery
9900|NCT04115592|Other|Sal seed oil|Consumption of sal seed oil made with chocolate confectionery
9901|NCT04115592|Other|Sal seed oleogel|Consumption of sal seed oleogel made with chocolate confectionery
9902|NCT04115579|Other|Biscuit 1 Control|Consumption of control biscuit of a higher glycaemic index at one session during breakfast and afternoon snack
9903|NCT04115579|Other|Biscuit 2 Test|Consumption of test biscuit of a lower glycaemic index at one session during breakfast and afternoon snack
9904|NCT04115553|Diagnostic Test|MRI examination|Subjects will be placed in supine position. The systematic use of a headset will reduce the noise inherent to the machine. Standard MRI examination using a 32-channel head coil consists of angiographic, morphological and phase-contrast 2D flow sequences. The flow planes are set perpendicularly to the structure axis (blood or CSF regions). The velocity measured in the pixels inside the region of interest allow the calculation of a mean flow rate as well as the volume displaced during a cardiac cycle.
9905|NCT04115553|Diagnostic Test|ECG|A cardiac synchronization system using peripheral ECG allows the synchronization with the subject's heart rate.
9906|NCT04115540|Device|TENS penile nerve stimulation|The electrode pads of the transcutaneous electrical nerve stimulation (TENS 7000) will be placed at the base of the penis (and perineum) to stimulate the penile nerves.
9907|NCT04115527|Procedure|Extended Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 16 17a 17b lymph nodes
9908|NCT04115527|Procedure|Standard Lymphadenectomy|Lymph node dissection includes No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b lymph nodes
9909|NCT04115514|Drug|Liothyronine Sodium (T3) (modified formulation)|Liothyronine Sodium (T3), 5-10-25-50µg instilled directly into the airways in a total volume of 10 ml (T3+0.9% sodium chloride). Progressive dosing every 24 hours for total 96 hours.
9910|NCT04115501|Other|Fraction of Inspired Oxygen|Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
9911|NCT04115488|Biological|Intravenous (IV) infusions|Intravenous (IV) infusions of a dose of 300mg, every 4 weeks with a total of 12 doses
9912|NCT04115475|Device|Multispectral Optoacoustic Tomography (MSOT)|Non-invasive transcutaneous imaging of subcellular muscle components
9913|NCT04115462|Drug|Morphine|A 20 mg tablet of morphine
9914|NCT04115462|Drug|Placebo oral tablet|Matching tablet of placebo
9915|NCT04115462|Drug|Histamine|Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
9916|NCT04115462|Drug|Cowhage (Mucuna Pruriens)|25 spicules will be inserted in the centre of the predefined skin area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
9918|NCT04115462|Drug|Compound 48-80|Compound 48/80 will be dissolved in sterile phosphate buffered saline (PBS) at a concentration of 30 mg/mL and a droplet of solution will be placed on the predetermined area, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.
9919|NCT04115449|Drug|Dexmedetomidine|Injection dexmedetomidine 1 mcg /kg will be infused over a period of ten minutes
9920|NCT04115449|Drug|normal saline|Normal Saline as a placebo will be infused over a period of ten minutes
9921|NCT04115423|Drug|Tocilizumab|A humanized monoclonal antibody against the interleukin-6 receptor, which is mainly for the treatment of rheumatoid arthritis.
9922|NCT04115423|Drug|Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab)|Tumor Necrosis Factor inhibitors (TNFi) are a group of medicines that suppresses the physiologic response to TNF, a protein involved in early inflammatory events. We will include etanercept, infliximab, adalimumab, and golimumab as TNFis since these drugs are commercialized in Korea.
9923|NCT04115410|Drug|PD-1 inhibitor|PD-1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer. The investigators will include nivolumab, pembrolizumab, and atezolizumab as PD-1 inhibitors as these drugs are reimbursed by health authority of South Korea.
9924|NCT04115410|Drug|Chemotherapy Drugs, Cancer|Chemotherapy is a type of pharmacotherapy for cancer, that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. The investigators will include cytotoxic chemotherapy and tyrosine kinase inhibitors (epidermal growth cell receptor (EGFR) and anaplastic lymphoma kinase (ALK) inhibitors).
9925|NCT04115397|Drug|Zoledronic Acid|Treating seropositive individuals with musculoskeletal symptoms with one infusion zolendronic acid as compared to placebo
9926|NCT04115397|Drug|Placebo|Placebo
9927|NCT04115384|Drug|Novolin-R insulin|Insulin (Novolin-R) 20 IU/IN (0.1ml/10 units IN in each nostril), twice per day, once in the morning and again in the evening (at least 8 hours between doses) for 4 weeks.
9928|NCT04115371|Behavioral|Intervention|Geriatric assessment and care coordination provided by a multidisciplinary team in the emergency department including transitional care nurses, social workers, pharmacists, occupational therapists, and physical therapists.
9929|NCT04115358|Procedure|hyaluronic acid : gengigel teething|applying of 0,54% hyaluronic acid for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with SSC
9930|NCT04115358|Procedure|formocresol Buckley formula : Formacresol|applying of 1/5 diluted formocresol for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with SSC
9931|NCT04115358|Procedure|ferric sulfate : ViscoStat|applying of 20% ferric sulfate for one minute to the orifice of root canals of the primary molars, then sealing the chamber with zinc oxide eugenol cement and completing the restoration with SSC
9932|NCT04115345|Biological|REACT - renal autologous cell therapy|Renal Autologous Cell Therapy (REACT) is made from expanded autologous selected renal cells obtained from each individual subject's kidney biopsy. To manufacture REACT, biopsy tissue from each enrolled subject will be sent to Twin City Bio LLC, in whose facilities renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin-based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site.
9933|NCT04115332|Biological|bio-feedback training|The aim of this study was to explore the abused PW nurses who receiving bio-feedback training as an intervention improve, and change of physiological indicators before and after intervention (3 months later), which included Respiratory Rate (RR), skin conduction (SC), heart rate variability (HRV), and resilience.
9934|NCT04115319|Drug|SEP363856|SEP-363856, 50mg, 75mg, 100mg, flexibly dosed once daily capsule
9935|NCT04115319|Drug|quetiapine XR|quetiapine XR, 400, 600, 800 mg, flexibly dosed once daily capsule
9936|NCT04115306|Drug|PMD-026|Oral RSK1-4 inhibitor
9937|NCT04115293|Drug|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
9938|NCT04115293|Drug|Placebo|Daily subcutaneous (SC) injection
9939|NCT04115280|Diagnostic Test|Primary Hyperaldosteronism diagnostic|blood sample to obtain the aldosterone to renin ratio
9940|NCT04115267|Radiation|Radiotherapy|Combined modality
9941|NCT04115254|Radiation|MR-guided Linac|Radiation will be delivered on an MR-guided Linear Accelerator
9942|NCT04115241|Device|Actigraph|Actigraphs are non-invasive, wearable devices that measure activity levels using an accelerometer
9943|NCT04115241|Other|Grip strength test|The purpose of this test is to measure the maximum isometric strength of the hand and forearm muscles
9944|NCT04115228|Device|Implantation and neuromodulation therapy|The study device is an autonomous permanent implant for neuromodulation targeting the posterior tibial nerve. It does not require an external power source or charger.
9945|NCT04115215|Behavioral|Physical exercise (PE)|This arm includes 10 sessions of multi-component exercise sessions (including aerobic, resistance, flexibility, dual-tasking) of 1 hour/week of functional group exercise, directed to foster empowerment for subsequent continuation of exercise in community-dwelling older adults referred by primary care to a geriatrician and an expert physical therapist. Between sessions, the validated material by the ViviFrail EU program (either leaflets or an ad-hoc mobile application) is used to promote self-training. According to the available data, adherence is high and the impact on physical function (SPPB scale and gait speed) at 3 month is clinically and statistically significant.
9946|NCT04115215|Device|Transcranial current stimulation (tCS)|This arm includes 1 application/week for 10 weeks during PE, through an adapted commercial helmet. Transcranial current stimulation (tCS) is a neural stimulation technique based on electrical stimulation of selected parts of the brain with direct or alternated electrical current (tDCS or tACS) of very low intensity of 2 milliamps (mA), using one or more electrodes placed on the skull. tCS is non-invasive (no surgical procedures) and it is painless, as applied in the proposed protocols. Immediate cognitive performance will be assessed through a verbal fluency test.
10015|NCT04114643|Biological|Prothrombin Complex Concentrate|Octaplex will be administered when the blood bank receives an order for coagulation factor replacement
10016|NCT04114643|Biological|Frozen Plasma|Frozen Plasma will be administered when the blood bank receives an order for coagulation factor replacement
9947|NCT04115215|Other|Control|Participants of similar profile, randomized to the control group, will undergo weekly 30 minutes educational sessions on healthy aging, including relevant aspects of nutrition, self-care, physical activity, plus measurement of blood pressure, heart rate and peripheral oxygen Hb saturation. These participants will be offered to join the PE program after the 6-months follow-up (end of the study).
9948|NCT04115202|Procedure|lumbar arthrodesis|two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
9949|NCT04115189|Drug|Sunitinib|Patients to receive Sunitinib as first line therapy for mRCC
9950|NCT04115163|Drug|Gemcitabine|Given IV
9951|NCT04115163|Drug|Nab-paclitaxel|Given IV
9952|NCT04115137|Device|pelvic varicose veins plug embolization|pelvic varicose veins plug embolization
9953|NCT04115124|Behavioral|Participatory Action Research|The research will employ a Participatory Action research quasi-experimental pre-post test study design .
9954|NCT04115111|Drug|Durvalumab|Durvalumab in monotherapy as second line treatment
9955|NCT04115098|Drug|Drug order 1|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
9956|NCT04115098|Drug|Drug order 2|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
9957|NCT04115098|Drug|Drug order 3|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
9958|NCT04115098|Drug|Drug order 4|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
9959|NCT04115098|Drug|Drug order 5|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
9960|NCT04115098|Drug|Drug order 6|each participant will be randomized to a different initial drug sequence (6 possibilities: ABC, ACB, BAC, BCA, CBA, CAB) of the following three drugs: Naproxen 500 mg tablets twice daily (BID), Meloxicam 7.5 mg tablets BID and Celecoxib 200 mg capsules BID. Patients will be randomized in blocks of 6 to ensure that no drug is assigned to be the first drug tested more often than the others. Medications will be obtained by the investigation team, and then all 3 medications will be overencapsulated in identical opaque capsules.
9961|NCT04115085|Procedure|Hand therapy (18 treatments)|18 treatments (ea. 20 Min) within 9 weeks
9962|NCT04115085|Procedure|Therapeutic ultrasound (18 treatments)|18 treatments (ea. 10 Min) within 9 weeks
9963|NCT04115085|Procedure|Combined hand therapy and therapeutic ultrasound (18 treatments)|18 treatments (ea. 30 Min) within 9 weeks
9964|NCT04115072|Drug|Praziquantel 600Mg Oral Tablet x 5|Five doses of Praziquantel 40 mg/kg
9965|NCT04115072|Drug|Praziquantel 600Mg Oral Tablet x 1|Single dose of Praziquantel 40 mg/kg
9966|NCT04115059|Drug|Dasatinib|Oral, daily, dosing per protocol, once a day for cycle
9967|NCT04115046|Device|ShearWave Elastography (SWE) in Endoscopic Ultrasound (EUS)|ShearWave Measurement is a software option available on the ARIETTA 850 that uses transient pulses to generate shear waves in the body. The tissue's elasticity is directly deduced by measuring the speed of wave propagation.
9968|NCT04115046|Device|FibroScan|manufactured by Echosens
9969|NCT04115046|Device|ALOKA ARIETTA 850 -|manufactured by Hitachi Healthcare - included on the system is the ShearWave measurement software
9970|NCT04115033|Device|BRIDGE|"The planned device for both groups is the BRIDGE, a FDA-approved device similar to the Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical nerve field stimulation (PENFS) device evolved from percutaneous electrical neural stimulation (PENS), currently employed by the United States (US) military and used in the VA (contract number V797D-50453). The BRIDGE device and its sham comparator are manufactured by the same company (Innovative Health Solutions) and are identical with the exception of the delivery of electrical stimulation."
9971|NCT04115020|Drug|Naltrexone|Naltrexone 4.5 mg oral suspension
9972|NCT04115020|Drug|Placebo|Placebo oral suspension
10017|NCT04114630|Drug|erenumab 70mg/mL|Unit dose: 70 mg/mL single-dose., prefilled erenumab autoinjectors. 140 mg dose = 2 x 70 mg/mL, single dose, prefilled erenumab autoinjectors
10018|NCT04114617|Other|Starch-thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
10019|NCT04114617|Other|Xanthan-gum thickened liquids|Thickener added in amounts required to reach slightly thick, mildly thick, moderately thick and extremely thick consistencies, as defined by the International Dysphagia Diet Standardisation Initiative flow test.
14082|NCT04081337|Drug|Tirzepatide|Administered SC
9973|NCT04115007|Radiation|Stereotactic Body Radiotherapy (SBRT)|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients Long-term Androgen Deprivation Therapy (ADT) with or without intermittent treatment. Additional therapy with abiraterone acetate or docetaxel following tumor board meeting.~With the following radiotherapy modalities:~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used.~In de novo metastatic patients: Prostate and seminal vesicle external beam radiotherapy using either 74-80 Gy with conventional fractionation (in fractions of 2 Gy) or using a hypofractionated regimen delivering 60 Gy (20 fractions of 3 Gy)."
9974|NCT04115007|Drug|Standard of care|"Definition of standard of care (prior to randomization):~Radiotherapy to the prostate in de novo metastatic patients Long term ADT with or without intermittent treatment. Additional therapy with abiraterone acetate or docetaxel following tumor board meeting."
9975|NCT04114994|Diagnostic Test|Boston Cognitive Assessment (BoCA)|"The Boston Cognitive Assessment (BoCA) is a self-administered online test intended for longitudinal cognitive monitoring. BoCA uses random not-repeating tasks to minimize learning effects. BoCA was developed to evaluate the effects of treatment in longitudinal clinical trials and available gratis to individuals and professionals.~BoCA includes eight subtests in the following domains: Memory/Immediate Recall, Memory/Delayed Recall, Executive function/ Visuospatial, Executive function/ Mental rotation, Attention, Mental math, Language/Prefrontal Synthesis, and Orientation. The maximum total score is 30. Higher score indicates better cognitive performance.~After BoCA is completed, the domain scores and total score are provided immediately. Users will also receive an email with the link to the full report with progress charts."
9976|NCT04114981|Radiation|Single Fraction Stereotactic Radiosurgery|Undergo SSRS
9977|NCT04114981|Radiation|Fractionated Stereotactic Radiosurgery|Undergo FSRS
9978|NCT04114981|Procedure|Quality-of-Life Assessment|Ancillary studies
9979|NCT04114981|Other|Questionnaire Administration|Ancillary studies
9980|NCT04114968|Other|GP-based screening or HPV self-sampling|Women in the intervention group will receive an invitation for HPV-based cervical cancer screening by either 1) scheduling an appointment for a cervical cytology by the GP or 2) collect a cervico-vaginal sample themselves in their own home using a self-sampling kit.
9981|NCT04114955|Behavioral|Guerreiras|Guerreiras works at both the group- and individual-levels to increase self-care and reduce the negative health impacts of stigma, including: 1) a group-level, peer-led intervention, which first demonstrated efficacy with trans women in the US as 'Sheroes' and has been successfully adapted for Brazil, and 2) an individual-level peer navigation program.
9982|NCT04114942|Behavioral|Never Coach|20 weeks of didactic training and 10 weeks of internship, but no coaching.
9983|NCT04114942|Behavioral|Internship Only Coach|20 weeks of didactic training with no coaching and 10 weeks of internship with coaching.
9984|NCT04114942|Behavioral|Didactic Only Coach|20 weeks of didactic training with coaching and 10 weeks of internship with no coaching.
9985|NCT04114942|Behavioral|Constant Coach|20 weeks of didactic training and 10 weeks of internship, with coaching throughout.
9986|NCT04114929|Other|Threshold-based Training|Specific ventilatory markers determined from a cardiopulmonary test and the correlating heart rate will be used to determine exercise intensity
9987|NCT04114929|Other|Standard Care|Using the standard care cardiac rehabilitation guidelines exercise will be based on estimated heart rate maximum followed by the karvonan method to calculate 40-70% heart rate reserve
9988|NCT04114916|Dietary Supplement|Apigenin, luteonin, grapefruit extract and citrolive|Two capsules daily at breakfast and dinner.
9989|NCT04114916|Dietary Supplement|maltodextrina|Two capsules daily at breakfast and dinner.
9990|NCT04114890|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
9991|NCT04114877|Behavioral|Attentional retraining (AR)|Cognitive bias modification (CBM) procedures are interventions aimed at changing the impulsive (automatic) processes that underlie unhealthy behaviors such as smoking. AR is the most commonly used CBM intervention in the study of addiction-related attentional bias. The idea behind AR is to reduce attentional bias and therefore minimize exposure to drug cues, because attention to such stimuli may provoke craving and undermine cessation attempts.
9992|NCT04114877|Behavioral|Visual probe (VP)|The visual probe (VP) task can measure attentional bias for drug-related cues. In the typical VP task, a pair of pictures or words (e.g. one smoking-related and one neutral) is briefly presented simultaneously side by side on a computer screen. After the pictures disappear, a probe stimulus (e.g. a small dot) is presented in the location that had been occupied by one of the pictures (or words), and participants are required to press a key as quickly as possible in response to the probe. Attentional bias for drug-related cues is detected by a faster response to a probe that replaces a drug-related stimulus (vs. a neutral stimulus), since attention will have been preferentially allocated to that area of visual display. The traditional VP task only assesses attentional bias, and does not modify it in any way.
9993|NCT04114864|Behavioral|Psycho-educational sessions|"Participants of clusters allocated to the ME-WE intervention group will complete a programme based on seven weekly sessions of approximately 2 hours each, plus a follow-up meeting after 3 months from the end of the programme. All sessions maintain a similar structure (objectives, ice-breaker, central activity/ies, and final activity). At the end of some sessions, participants will be asked to do some exercises at home, between one meeting and the next one, in order to keep what has been done during the previous session fresh in their minds.~Contents of sessions will be as follows: (1) Getting to know each other; (2) The Advisor: dealing with annoying thoughts; (3) The Noticer: being in connection with our feelings; (4) The Discoverer: growing and thriving; (5) Values: connecting to meaning and vitality; (6) Developing a flexible self-view and self-compassion; (7) Building strong social networks."
9994|NCT04114851|Device|NoL|NoL active
9995|NCT04114825|Biological|RV001V|RV001V consists of the peptide RV001 and the adjuvant Montanide ISA 51. RV001 Vaccine 0.1 mg/mL (RV001V).
9996|NCT04114825|Other|Placebo|Placebo consist of the vaccine vehicle and the adjuvant Montanide ISA 51. Placebo
10177|NCT04113213|Behavioral|Lifestyle Prescription (LRx)|Lifestyle prescription, based on the UK WP10 medicinal prescription form. Includes advice and guidance regarding physical activity, diet, smoking and alcohol consumption.
9997|NCT04114812|Other|Blended learning|In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
9998|NCT04114812|Other|Standard course|In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
9999|NCT04114799|Procedure|Hemodynamic management based on invasive fluid responsiveness parameters|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
10000|NCT04114799|Procedure|Hemodynamic management based on noninvasive cardiac output and SVV measurement|In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
10003|NCT04114773|Other|SCARF (Survivors of Cardiac Arrest Rehabilitation focused on Fatigue)|"The intervention will be delivered by a multidisciplinary team. There will be individual testing and feedback on physical capacity and cognitive ability. Group sessions will include education on the consequences of cardiac arrest, promotion of techniques to ameliorate these consequences, for example, increasing physical activity or energy conservation. Additional sessions will cover psychological reactions; family life; work life; intimacy; and existential considerations.~Participants will have a course information book with a physical activity training diary and problem-solving therapy worksheets to use at home for 12-weeks. They will receive one phone call from the clinical team during this period. The 2-day return stay will revisit the subjects from the first 5-day stay.~Participating survivors who have a relative that wishes to attend will be included in all the group sessions and individual feedback but will not take part in the physical capacity or cognitive ability tests."
10004|NCT04114760|Device|patchy-type wireless ECG|This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
10005|NCT04114760|Device|defibrillator ECG|This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
10006|NCT04114747|Other|Starting at high or low blood pressure|Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
10007|NCT04114734|Behavioral|Park Rx|Participants will be advised to visit a specific park at a specific frequency and duration
10008|NCT04114708|Diagnostic Test|Anterior cruciate ligament Reconstruction (ACLR)|All patients will undergo an anatomic ACLR via a standardized fashion using BTB autograft.
10009|NCT04114708|Diagnostic Test|ACLR with lateral extra-articular tenodesis (LET)|All LETs will be performed in a standardized fashion using the modified Lameire technique. All patients will undergo an anatomic ACLR via a standardized fashion using BTB autogaft graft.
10010|NCT04114682|Other|Multi parametric MRI scan|There will be no intervention to the standard of care these patients receive. However, consented participants will be asked to make two study visits where a multiparametric MRI scan will be performed - these visits will be defined as visit 2 and visit 3. An optional echocardiogram may be included at Visit 2.
10011|NCT04114669|Behavioral|Control Condition|3 in-person study visits, approximately one hour each. These will take place at baseline, 6 months, and 12 months.
10012|NCT04114669|Behavioral|Regret Lottery|"Delivered by the Way to Health platform, installed on a smartphone and communicates with participants via text message.Participants are eligible to receive a potential cash reward if they are adherent with their antihypertensive medication the day before, which is monitored via electronic monitoring device (EMD) from AdhereTech. Each participant is assigned a 2-digit number for the trial, and each day the Way to Health platform randomly generates a 2-digit number. Participants will receive a prize if both digits match (1 in 100 chance) and will receive a prize of lesser value if one digit matches (18 in 100 chance). If they are not adherent with their medication, but would have won if they were adherent, they receive a text message that they would have won (regret component)."
10013|NCT04114656|Drug|Placebo|Participants will be administered 0.9% sodium chloride solution as Placebo. The appropriate volume of placebo will be infused over 1 hour.
10014|NCT04114656|Biological|GSK3858279|Participants will be administered GSK3858279 as solution for injection in unit dose strength of 50 milligram (mg) per milliliter (mL). Each vial has an extractable volume of 3 mL (150 mg per vial). The dose level to be administered is 3 mg per kilogram (kg). GSK3858279 may be diluted in normal saline and the appropriate volume will be infused over 1 hour. GSK3858279 is formulated in 0.79 mg per mL sodium acetate, 50 mg per mL Sorbitol, 0.4 mg per mL polysorbate 20, glacial acetic acid 0.28 mg per mL, water for injection, pH 5.0.
10020|NCT04114604|Other|Starch-based thickened liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
10021|NCT04114604|Other|Xanthan-gum thickened liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
10022|NCT04114591|Procedure|anterior resection|The distance from anal verge, preoperative radiotherapy and presence of stoma were analysed
10023|NCT04114578|Other|Echocardiography|Echocardiography has become routinely used in the diagnosis, management, and follow-up of patients with any suspected or known heart diseases. It is one of the most widely used diagnostic tests in cardiology. It can provide a wealth of helpful information, including the size and shape of the heart (internal chamber size quantification), pumping capacity, and the location and extent of any tissue damage. An echocardiogram can also give physicians other estimates of heart function, such as a calculation of the cardiac output, ejection fraction, and diastolic function (how well the heart relaxes). The acquisition usually takes about 30 minutes.
10024|NCT04114552|Other|questionnaires|"6 weeks after the trauma,during the call, an oral questionnaire will be proposed to collect data on patients' management since they have left the emergency department.~After the call, socio-demographic characteristics, trauma mechanism, medics management will be extracted from the patient's medical records"
10025|NCT04114539|Drug|Ecopipam|Ecopipam HCl 12.5-, 37.5-. 50-, 75- and 100-mg tablets; 2 mg/kg/day target dose; oral administration daily in evenings.
10026|NCT04114526|Other|Nicotine Replacement Therapy|"CHAs meet with all interested residents to discuss taking steps towards quitting. The CHAs follow a four step program with all participant 1) get to know the resident and their smoking, 2) Assess what the resident is ready to do to take steps towards quitting, 3) discuss using nicotine replacement therapy (NRT) in the form of patches, gum or lozenges, 4) set one goal for taking steps towards quitting. CHAs will attempt to follow up with participants after the initial encounter. There is no limit on the number of times the CHA may talk with the participants. Some follow interactions will be brief encounters in the neighborhood, while others will be at scheduled. All contacts with each participant will be tracked.~We will provide up to 6 weeks of NRT patches, gum and lozenges to participants who are interested in using NRT to help them quit."
10027|NCT04114513|Dietary Supplement|Maltodextrin|NOVAPRODUKT, white powder 5 weeks intervention
10028|NCT04114513|Dietary Supplement|Inulin|BENEO-Orafti, white powder 5 weeks intervention
10029|NCT04114513|Dietary Supplement|Pectin|BANG & BONSOMER GROUP OY, white powder 5 weeks intervention
10030|NCT04114513|Dietary Supplement|Beta-glucan|Tate & Lyle, white powder 5 weeks intervention
10031|NCT04114513|Dietary Supplement|Galactooligosaccharides|FrieslandCampina, white powder 5 weeks intervention
10032|NCT04114500|Diagnostic Test|serum estradiol and progesterone|blood sample for measuring serum estradiol and progesterone level on the same day of FET
10033|NCT04114487|Other|dual task balance training|The studies were planned to be 2 times a week for 12 weeks. The 20-minute Dual Task balance training program is planned to be composed of two sections of 10 minutes. In the first 10 min section, the individual will exercise with the multi-task mode of CogniBoard on the balance ball. . Stroop study will be performed on the balance ball in the second 10 minutes of the exercise.
10034|NCT04114474|Diagnostic Test|TRANSTHORACIC ECHOCARDIOGRAPY|TTE (Vivid I echocardiography machine General Electric Healthcare, Milwaukee, WI, USA) with a 3S-RS (1.5-3.6 MHz) transthoracic probe). was done by professional anesthesiologist following the :Hemodynamic Echocardiography Assessment in Real Time ( HEART) protocol. According to the clinical findings of TTE patients may be either free or have one or more of the following haemodynamic states normal, empty, vasodilated ,left ventricular systolic or diastolic failure, left ventricular systolic and diastolic failure, and right ventricular failure, valve stenosis or regurgitation of at least moderate severity
10035|NCT04114461|Drug|HL-TOF tab. 5mg|HL-TOF
10036|NCT04114461|Drug|Xeljanz tab. 5mg|Xeljanz
10037|NCT04114448|Other|Therapeutic exercise|Patients will perform an exercise protocol specifically designed for patients with hemophilia that will include exercises focused on improving range of movement, strength, flexibility, balance and coordination as well as diaphragmatic breathing at the start and at the beginning of each session.
10038|NCT04114448|Other|Usual physical therapy care|Patients will undergo usual physical therapy treatment for hemophiliacs, based on affected self and gentle joint mobilization and stretching of muscles involved in the affected joints.
10039|NCT04114435|Other|Echocardiography|Diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures
10040|NCT04114422|Other|Seven-day preoperative exercise training program|The preoperative exercise training program will be supervised by a physiotherapist and will comprise aerobic exercise on a treadmill as well as strengthening exercises for the upper and lower limbs. The protocol will include 7 daily sessions of 60 minutes in duration. The treadmill exercise will start with a 5-minute warm-up and will progress to 30 minutes of exercise with a speed corresponding to 70% of the maximum speed reached in the incremental shuttle walk test. It will finish with a 5-minute cool down period. Participants will also perform three strengthening exercises for the lower limbs (hip flexion, knee flexion and extension) and three for the upper limbs (shoulder flexion, elbow flexion and extension). The initial strengthening exercises intensity will be set at 60% of 1RM and will be progressively increased. Patients will perform 3 sets of 8 to 12 repetitions for each exercise.
10041|NCT04114396|Drug|Anti-IL5 Antibody|Asthma group: Anti-IL5 treatment Control group: No biologic.
10042|NCT04114396|Procedure|Bronchoscopy|Optional for both arms
10043|NCT04114383|Other|D3-Creatine|30mg D3-Creatine to measure muscle mass
10044|NCT04114383|Other|Deuterium Oxide|D2O provided to measure muscle protein synthesis
10045|NCT04114383|Other|D3-3-methylhistidine|D3-3-methylhistidine is provided to measure muscle protein breakdown
10108|NCT04113798|Behavioral|Moderate Intensity Exercise|The moderate-intensity aerobic exercise session will consist of a 5 minute warm-up of light intensity activity (40-60% maximum heart rate; MHR) on a treadmill followed by walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes on Day 3
10109|NCT04113798|Behavioral|Low Intensity Exercise|Control participants will maintain light-intensity activity (i.e., walking at ~50% of MHR) for the full duration of 30 minutes.
10046|NCT04114370|Drug|18F-fluciclovine|Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
10047|NCT04114357|Drug|Acetylated and Butyrylated High Amylose Maize Starch|Participants will be instructed to consume HAMS-AB in two divided doses at breakfast and dinner
10048|NCT04114344|Procedure|TAPP|Trans Abdominal Pre Peritoneal approach
10049|NCT04114344|Procedure|TEP|Total Extra Peritoneal approach
10050|NCT04114331|Other|Manual therapy and exercise|Manual therapy consisting of soft tissue and joint mobilization to gain mobility. Therapeutic exercise was active motion and resisted motion to gain motor control and motor coordination in the new range.
10051|NCT04114318|Other|Dual-task cognitive-cycling training|Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training
10052|NCT04114305|Behavioral|ECD Intervention|"Modeled on the Early Learning Resource Unit's Family & Community Motivator home visiting program and Philani Mentor Mothers home visiting program in South Africa. Program provided stimulation in 5 domains: cognitive, receptive and expressive language, gross and fine motor skills, also covered topics in maternal and child health, nutrition and social services.~Comprised primarily of home visits beginning during pregnancy and continuing until the child was 18 months. ECD MM taught the parent/caregiver about ages and stages of growth, helped facilitate responsive parenting and early learning opportunities for their children, demonstrated use of toys and books to stimulate the child, provided families with picture books, and taught caregivers to create toys and books for their child. Community parenting information play groups and educational talks on ECD at the clinic supplemented home visits."
10053|NCT04114292|Drug|Tauroursoursodeoxycholic acid, brand name Tudcabil|Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day
10054|NCT04114279|Procedure|Performance of laparoscopic duodenal atresia repair|completion of laparoscopic duodenal atresia repair in a surgical simulator
10055|NCT04114266|Other|Questionnaires on Urinary Incontinence-, Sex Function- and Quality of Life (ICIQ-UI-SF, ICIQ-FLUTSsex, ICIQ-LUTSqol, PGI-I)|"Artificial Urinary Sphincter Surgery (Robot-assisted, Laparoscopic, Open, or other) for Female Stress Urinary Incontinence due to intrinsic sphincter deficiency is according to standard practice. Patients scheduled for this type of surgery will be asked to participate in this Registry.~At baseline and follow-up, the patients will be required to fill in Questionnaires, i.e. ICIQ -Urinary Incontinence - Short Form (ICIQ-UI-SF), ICIQ Female Sexual Matters associated with Lower Urinary Tract Symptoms ( ICIQ-FLUTSsex), ICIQ Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol), Patient Global Impression of Improvement-I (PGI-I) which are commonly used in daily practice to assess urinary incontinence, sexual function and quality of life. During the yearly visits, patients will not be required to come for a clinical visit as the questionnaires and a Follow-up form can be completed by post, e-mail or phone call."
10056|NCT04114253|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
10057|NCT04114240|Drug|Xybilun|Erectil dysfunction, Viagra generic (sildénafil)
10058|NCT04114227|Behavioral|Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)|Subjects learn new ways to manage uncomfortable experiences and feelings and to engage in positive behaviors
10059|NCT04114227|Behavioral|Supportive Psychotherapy (Treatment as Usual Control)|Subjects talk about their experiences to date in a cohort of adult Cystic Fibrosis patients.
10060|NCT04114201|Procedure|PSI|Implantation of a Total Knee Arthroplasty patient-specific instrumentation using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
10061|NCT04114201|Procedure|Conventional|Implantation of a Total Knee Arthroplasty with conventional using Zimmer® NexGen Solutions (Zimmer Biomet, Warsaw, IN).
10062|NCT04114188|Drug|Antithymocyte Immunoglobulin (Rabbit)|1st kidney transplant recipients (low risk: PRA/cPRA < 20%, no DSA) will receive short rATG induction (2x1.5 mg/kg) given perioperatively and on first postoperative day. All patients will receive one shot Infliximab mAb at day 2. Since POD1, maintenance IS consists of Tac and tapered steroids therapy.
10063|NCT04114175|Other|Exercise BE|Basic exercises related to amputation will be applied
10064|NCT04114175|Other|Exercise BE+SS|Basic exercises related to amputation + Spinal stabilization exercises will be applied
10065|NCT04114149|Device|TENS (transcutaneous electrical nerve stimulation)|TENS as first line of treatment. If insufficient pain relief, i.e. postoperative pain intensity according to NRS (numeric rating scale) ≥ 3 after two treatment sessions à 1 minute, the patient receives conventional treatment with iv opioids.
10066|NCT04114149|Drug|iv opioid|Conventional treatment with iv opioid if postoperative pain intensity according to NRS (numeric rating scale) ≥ 3.
10067|NCT04114136|Drug|Nivolumab or Pembrolizumab (dependent upon approved indication)|Anti-PD-1 mAb (monoclonal antibody)
10068|NCT04114136|Drug|Metformin|Acts directly or indirectly on the liver to lower glucose production, and acts on the gut to increase glucose utilisation, increase GLP-1 and alter the microbiome.
10069|NCT04114136|Drug|Rosiglitazone|A member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ).
10070|NCT04114110|Other|RTLS data|data extraction from RTLS
10071|NCT04114097|Drug|Betnovate, betamethasone dipropionate ointment 0.1% and placebo|Explore the systemic effects of Betnovate
10072|NCT04114097|Drug|Protopic, tacrolimus ointment 0.1%|Compare the systemic effects of Betnovate to Protopic
10110|NCT04113798|Other|Day 4 Recall of Fear Extinction|During Day 4, recall of the fear extinction memory is tested. Visits on Day 4 occur ~24 hours following Day 3, and lasts about 30 minutes.
10111|NCT04113785|Device|Klassic Knee System|At present, all TKA available for surgeons to use are asymmetric where there is a distinct femoral and tibial component for the left knee and a distinct femoral and tibial component for the right knee. The Klassic knee system is a symmetrical knee implant, where the same femoral and same tibial component can be used for either the right or left knee
10073|NCT04114084|Procedure|Bone Marrow Aspirate and Biopsy|The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
10074|NCT04114071|Behavioral|TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women|See arm description
10075|NCT04114058|Drug|liposomal bupivicaine|local field infiltration
10076|NCT04114058|Procedure|Fascia iliaca blockade|fascia iliaca compartment blockade
10077|NCT04114045|Dietary Supplement|Experimental:Whey protein|Each participant in the protein group received 2 protein drinks immediately following exercise. The supplement was given using a relative quantity of whey protein isolate (0.3g/kg) and was chocolate flavoured.
10078|NCT04114045|Dietary Supplement|Active Comparator: Isoenergetic control - Carbohydrate|Each participant in the carbohydrate group received 2 drinks immediately following exercise. The supplement was given using a relative quantity of maltodextrin (0.3g/kg), non-caloric chocolate flavouring was added to mask the drinks contents.
10079|NCT04114045|Other|Placebo|Each participant in the water group received 2 drinks immediately following exercise. The water was provided in a similar volume using the same non-caloric chocolate flavouring as the other drinks.
10080|NCT04114019|Diagnostic Test|Vaginal tactile imager|Vaginal elasticity evaluation using a vaginal tactile imager
10081|NCT04113993|Drug|Bazedoxifene Acetate|Oral Bazedoxifene dosed at 40 mg daily for 12 weeks
10082|NCT04113993|Drug|Placebo|Identically packaged placebo capsule daily
10083|NCT04113980|Other|music group|The children in the groups were distracted by music 2 minutes before venipuncture, until the process was over
10084|NCT04113980|Other|kaleidoscope group|The children in the groups were distracted by kaleidoscope 2 minutes before venipuncture, until the process was over
10085|NCT04113980|Other|video group|The children in the groups were distracted by watching video 2 minutes before venipuncture, until the process was over
10086|NCT04113967|Other|Biodanza program|Biodanza is a form of intervention aimed at promoting health and well-being through the promotion of self-expression and self-regulation through interaction through music and dance. The music accompanied by the movement of the body induces some experiences that present the ability to modify the organism itself both at an organic level, as affective-motor and existential. This intervention constitutes a means for the correct development of human qualities, whose purpose is to integrate the potentials of bond, health and harmony, as well as to develop new alternatives for the life of each individual.
10087|NCT04113954|Drug|Mepivacaine Injection|Injection of 0.375% mepivacaine or 1.5% mepivacaine in nerve block
10088|NCT04113954|Drug|Normal saline Injection|Injection of normal saline in nerve block
10089|NCT04113941|Drug|Neuronox|intradetrusor injection
10090|NCT04113941|Drug|Placebo|intradetrusor injection
10091|NCT04113928|Dietary Supplement|Broccoli & mustard seed soup|200ml acute feed
10092|NCT04113928|Dietary Supplement|Broccoli soup|200ml acute feed
10093|NCT04113915|Drug|triple therapy|Effect of treatment on immunity to obtain infection with hepatitis B&C
10094|NCT04113915|Drug|Steroids|Oral or parenteral steroid therapy for ITP
10095|NCT04113902|Behavioral|Health Education|the adolescent girls and their mothers who participated in the intervention group were given health education twice in the first interview and in the fifth week. Follow-up continued for 12 weeks. The adolescent girls and their mothers in the control group received routine clinical practice. The effects of health education were evaluated with Human Papilloma Virus Knowledge Scale and Health Belief Model Scale for Human Papilloma Virus and its Vaccination.
10096|NCT04113889|Drug|Metformin (1000 mg daily), Pioglitazone (30 mg daily), Acetyl-L-carnitine (3 gm daily)|72 patients with PCOS receiving metformin, pioglitazone and Acetyl L-Carnitine 500 mg, 15 mg and 1.5 gm BD daily respectively.
10097|NCT04113889|Drug|Metformin, pioglitazone and placebo|72 patients with PCOS receiving metformin, pioglitazone and placebo 500 mg, 15 mg and placebo BD daily respectively.
10098|NCT04113863|Drug|all-trans retinoic acid|Vesanoid will be supplied orally at the total dosage of 45mg/m2/d (two daily administrations of 22.5 mg/m2 each). Treatment will last 28 days
10099|NCT04113863|Drug|Anastrozole 1mg|Anastrozole will be administered orally at the dosage of 1 mg/die.
10100|NCT04113850|Device|Mobile Acoustic startle Reflex monitoring System (MARS)|Acoustic startle testing
10101|NCT04113837|Dietary Supplement|food range|"The food range is comprised of:~sausages (1100 g per week) eggs (3 eggs per week), 100 g mushrooms per day, one bread per week, bread rolls, 100 ml ice cream per week, 3x 70 g pasta per week"
10102|NCT04113824|Procedure|trapezuis motion style acupuncture treatment|Motion Style Acupuncture Treatment(MSAT) is a therapeutic technique using acupuncture needle created in Jaseng Hospital. This treatment involves patients with musculoskeletal pain to move the part of their body actively during acupuncture treatment under physicians' observation
10103|NCT04113824|Procedure|other Korean medical treatment|acupuncture treatment, chuna, pharmacoacupuncture, Korean herbal medicine
10104|NCT04113811|Device|Biomedical TATO3® Microwave needle thermoablation device (Koelis, Grenoble, France)|In this study, we plan to investigate oncological outcome of fusion-guided microwave needle therapy using transperineal (TP) approach
10105|NCT04113798|Other|Day 1 Assessments|Structured clinical interview to assess trauma history and mental health diagnoses, as well as a screening EKG to assess safety to engage in exercise testing (lasts 3-4 hours)
10106|NCT04113798|Other|Day 2 Fear Learning|Participants undergo a standard fear conditioning procedure, in which they learn that one of two geometric shapes (circles or triangles) predict the occurrence of a noxious stimulus (mild electrotactile stimulation). Day 2 lasts about 1 hour.
10107|NCT04113798|Other|Day 3 Fear Extinction|Participants undergo a fear extinction procedure, in which participants learn that the geometric shapes no longer predict a noxious stimulus (i.e., safety learning). Blood samples will be drawn immediately before exercise, and immediately following.
10114|NCT04113759|Behavioral|Blood Flow Restriction Rehabilitative Therapy|"BFR cuffs placed at the proximal thigh, just inferior to the greater trochanter.~Inflation time not to exceed 20 minutes. One BFR session per treatment. BFR exercise dosage: 4 sets of the following repetitions 30, 15, 15, 15, 30 second rest between sets, 1 min rest between exercises.~Progress exercise if pain <2/10 on VAS and RPE <5 on 0-10 scale. (Heerey et al), and no break down in form."
10115|NCT04113759|Behavioral|Sham BFR Rehabilitative Therapy|The schedule, type of exercises, repetition ranges, and other physical therapy interventions will be the same as the BFR experimental group - however a non-occlusive pressure will be applied with the cuff in the control group.
10116|NCT04113746|Behavioral|Better asthma self-management and incorporation of physical activity|Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
10117|NCT04113746|Behavioral|Asthma Education|General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
10118|NCT04113733|Other|Sample Collection|Tissue biopsies will be performed at the time of colonoscopy along with blood and stool sample collection.
10119|NCT04113720|Drug|Levobupivacaine hydrochloride|levobupivacaine 0.25%
10120|NCT04113720|Drug|Levobupivacaine Hydrochloride + Dexmedetomidine|Levobupivacaine plus Dexmedetomidine
10121|NCT04113707|Behavioral|Motor lab activity|fitness, gross motor, fine motor, and motor coordination activities
10122|NCT04113694|Device|Extended Wear Infusion Set|Subjects will perform each Extended Wear Infusion Set wear for at least 174 hours.
10123|NCT04113681|Procedure|Geniculate Artery Embolization|"Conscious sedation : midazolam and fentanyl~Local anesthesia : Lidocaine 2% subcutaneous~Retrograde or anterograde common femoral artery access - 4Fr introducer~Sub-therapeutic anticoagulation (heparin 2000 IU IA)~Lower extremity arteriography~Selective and supra-selective catheterization of geniculate arteries supplying painful region of the knee~If abnormal arterial blushes are demonstrated selective and supra-selective embolization will be performed with Embozene microspheres (100 microns to 200 microns) - cold saline or ice-packs sac to be applied to overlying skin if significant cutaneous arteries are demonstrated at angiography.~Angiographic end-points: embolization of abnormal blush while preserving the parent vessel~Arteriotomy closure (manual compression or closure device)"
10126|NCT04113655|Biological|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
10127|NCT04113655|Biological|Boostagen (TdaP BioNet)|"Boostagen (TdaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TdaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202."
10128|NCT04113655|Biological|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine was presented in a single-dose prefilled syringe. Each subject was received one intramuscular injection in the non-dominant deltoid region in parent protocol TDA202"
10129|NCT04113642|Other|ultrasonographic measurement of abdominal muscle thickness at four positions|Thickness of transversus abdominis, internal oblique and external oblique muscles were evaluated using ultrasound at rest and during abdominal hollowing, bridge, and bridge with isometric arm extension.
10130|NCT04113629|Device|HCV point of care machine|Xpert HCV Assay performed on the GeneXpert point of care machine
10131|NCT04113616|Drug|KRT-232|KRT-232 is an experimental MDM2 inhibitor anti-cancer drug taken by mouth.
10132|NCT04113616|Drug|Cytarabine|Cytarabine is an anti-cancer chemotherapy drug taken via injection.
10133|NCT04113616|Drug|Decitabine|Decitabine is an anti-cancer chemotherapy drug taken via injection.
10134|NCT04113603|Diagnostic Test|Urinary malignancy|Single bolus three phase CTU
10135|NCT04113590|Procedure|Laparoscopic Assisted Transvaginal Cholecystectomy|Perform transvaginal cholecystectomy while obtaining safe access under laparoscopic visualization
10136|NCT04113577|Other|usability survey|usability survey composed of subpart: System Usability Scale, questions about global ergonomics of the app, questions about eronomics of the exerecices, question about global satisfaction.
10137|NCT04113564|Drug|Remimazolam|
10138|NCT04113551|Drug|MPH (Concerta)|MPH (Concerta) is approved for the indications of ADHD and Narcolepsy in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from Japan medical data center (JDMC) database.
10139|NCT04113551|Drug|MPH (Ritalin)|MPH (Ritalin) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
10140|NCT04113551|Drug|Atomoxetine (ATO)|Atomoxetine (ATO) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
10141|NCT04113551|Drug|Guanfacine (GFC)|Guanfacine (GFC) is approved for the indication of ADHD in Japan. This is a non-interventional study and no drug will be given as part of this study. Analysis will be performed from data taken from JDMC database.
10142|NCT04113538|Drug|Aflibercept|Intraocular injection of 2 ml (40mg/ml)
10144|NCT04113512|Other|Jalaneti|Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
10145|NCT04113499|Procedure|Direct Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~For endoscopic necrosectomy, in patients allocated to direct endoscopic necrosectomy group, endoscopic necrosectomy is performed during the same session as the index endoscopic drainage. It is performed using a therapeutic gastroscope and various accessories (see below for further details) for 90 to 120 minutes."
10146|NCT04113499|Procedure|Step-up Endoscopic Intervention|"The necrotic collection is first identified using a linear echoendoscope. A Hot AXIOS stent is utilized in all patients for EUS-guided drainage of the necrotic collection. The necrotic material is sent for gram stain and culture with sensitivities.~In patients allocated to the step-up endoscopic interventions group, endoscopic necrosectomy is not performed at the time of the index intervention, however it is performed when clinically indicated during the follow-up period (6 months from index intervention)."
10147|NCT04113486|Other|Blood test|About 4 ml of blood draw
10148|NCT04113473|Other|Yoga Therapy|"An hour of yoga therapy included loosening exercise (sukshma vyayama), yoga postures (asana), yoga breathing (pranayama), relaxation (shavasana) and meditation.~Each participant were given handouts to follow home practice sessions everyday for twice a day for at least 15 minutes."
10149|NCT04113460|Other|Yoga|Yoga@work program included physical movements, yoga posture, breathing exercise, pranayama and yoga chants. Session with trainer was conducted on worksite once a week for an hour.
10150|NCT04113447|Other|observational|observational
10151|NCT04113421|Diagnostic Test|Contrast-enhanced chest CT|A single follow-up contrast-enhanced chest CT to compare off-line with the contrast-enhanced chest CT done at baseline for the diagnosis of PE.
10152|NCT04113408|Other|FABIR sequence|The FABIR sequence with a duration of 8 minutes is added to the imaging protocol.
10153|NCT04113395|Other|sequences T1 FE|T1 TSE and T1 TFE sequences with a duration of 6 minutes are added to the imaging protocol.
10154|NCT04113382|Drug|CLENPIQ|"CLENPIQ consists of sodium picosulfate 10.0 mg + magnesium oxide 3.5 g + citric acid, anhydrous 12.0 g.~Supplied as a pre-mixed, ready-to-drink oral solution in two bottles, each containing 160 mL."
10155|NCT04113382|Drug|MIRALAX|MIRALAX powder for oral solution, supplied in a 8.3 oz multi-dose bottle containing 238 g of laxative powder (polyethylene glycol [PEG] 3350).
10156|NCT04113369|Device|TENS|30 minutes of conventional antalgic TENS to non-paretic forearm
10157|NCT04113369|Procedure|Conventional rehabilitation|40 minutes of lower limb training and 20 minutes of upper extremity training for stroke
10158|NCT04113369|Device|EMS|20 minutes of EMS to non-paretic forearm with 5 minutes of pre and post warm-up
10159|NCT04113356|Diagnostic Test|Cardiovascular Magnetic Resonance Imaging|Cardiovascular magnetic resonance imaging will be performed within the first week after ST-elevation myocardial infarction and in a defined subgroup 4 months, 12 months and 10 years thereafter.
10160|NCT04113343|Drug|Remimazolam|Remimazolam via oral administration
10161|NCT04113343|Other|Alcohol|Alcohol
10162|NCT04113317|Drug|G-CSF (Filgrastim)|Contains 0,59 mg of acetate, 0,04 mg of polysorbate 80, 0,035 mg of sodium, 50 mg of sorbitol
10163|NCT04113304|Behavioral|Parenting Young Children Check-up (PYCC)|The PYCC intends to motivate parents to learn behavioral parenting strategies to reduce child disruptive behavior.
10164|NCT04113291|Other|DASH Diet|12 Weeks of isocaloric DASH diet <2300 mg Na/day using meals (lunch, dinner, snacks) prepared by the Wake Forest Clinical Research Metabolic Kitchen under the direction of a registered dietician (RD). Participants will prepare their own breakfast from a menu.The subjects will be instructed to drink no more than three caffeinated beverages and no more than two alcoholic beverages per day.
10165|NCT04113291|Other|Usual diet|12 weeks usual diet <2300 mg Na/day
10166|NCT04113278|Genetic|FGL2 immunohisyochemistry|Correlation between FLG2 expression and progression free survival and overall surviv
10167|NCT04113265|Device|SUNEKOS ® Body|SUNEKOS ® Body is a medical device (class III). The study product was injected at level of the inner thighs, knees and arms by needle (29 G) using the interstitial fluid technique (IFT)
10168|NCT04113252|Other|Possible Incentive for Tablet Return|Subjects who return completed diary will have the possibility to receive money for returned opioid tablets.
10169|NCT04113252|Other|Incentive for Completed Diary|Subjects who return completed diary will receive a gift card.
10170|NCT04113252|Behavioral|Coaching|Subjects will receive coaching prior to starting pain medication.
10171|NCT04113239|Diagnostic Test|16S rRNA gene sequencing|Taking a stool sample for gut microbiome DNA sequencing
10172|NCT04113239|Genetic|DNA-microarray genotyping|Taking a saliva sample for genotyping
10173|NCT04113226|Drug|Rituximab|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.
10174|NCT04113226|Drug|Lenalidomide 20 MG|patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression
10175|NCT04113226|Other|Comprehensive Geriatric Assessment (CGA)|A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,…) on which treatment may impact.
10176|NCT04113226|Other|Activities of daily living (ADL) scale|Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
14083|NCT04081337|Drug|Placebo|Administered SC
10180|NCT04113187|Drug|Propranolol treatment|40 mg twice a day (morning and evening), per os, during three months
10181|NCT04113187|Drug|Placebo|per os, twice a day (morning and evening) during three months
10182|NCT04113174|Other|Decision Analytic Modelling|Prognostic models will be translated into a framework to guide clinical decision making by identifying relevant thresholds of predicted risk, above which implementation of our stated interventions is warranted.
10183|NCT04113161|Other|Standard Care|Standard care will consist of 1) community-based screening and referral conducted by HomeGrown St. Louis (HomeGrown StL) network members and supported by HomeGrown StL coordinator; and 2) monthly contacts by a case manager, who will track attendance in mental health services and provide referrals upon request.
10184|NCT04113161|Other|Child Behavioral Health Navigator (cbhN)|CbhNs will engage in a series of contacts in person and by phone/text to coordinate needed appointments at mental health care sites, as well as a range of human service support organizations (e.g. housing, food, financial, legal assistance). Over time, contact may decrease as the youth/family make ongoing connection with mental health care and other resources. However, over the course of the study (twelve months), twice per month check-ins will be routine between cbhNs and families. In addition, the cbhN will be expected to actively engage with the range of service providers and mental health resources as needed and preferred by the family. These contacts include telephone linkage calls, in-person advocacy meetings and at time, accompanying the youth and families to meetings at each organization.
10185|NCT04113148|Other|Physiological measurements from heel|Measurements of blood flow, tissue oxygen saturation, temperature, pressure
10186|NCT04113135|Other|Yoga|Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.
10187|NCT04113135|Other|Control|Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
10190|NCT04113109|Drug|LCZ 696|Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
10191|NCT04113109|Drug|Icatibant|Icatibant will be given intravenously at 100 µg/kg over one hour followed by 20 µg/kg/hr during each study day.
10192|NCT04113109|Drug|placebo|Placebo (vehicle) will be given at the same rate as icatibant.
10193|NCT04113109|Drug|Para-aminohippurate|Para-aminohippurate (PAH) will be given at a dose of 8 mg/kg loading dose followed by a 12 mg/min steady-state infusion during each study day.
10194|NCT04113109|Drug|Iohexol|Iohexol will be given as 5 mL of iohexol solution (3.235 g iohexol) intravenously on each study day.
10195|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
10196|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
10197|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
10198|NCT04113096|Drug|Dibenzyl trisulphide capsules|20 mg once daily for 6 months
10199|NCT04113096|Drug|Stage IV Breast Cancer Placebo|20 mg once daily for 6 months
10200|NCT04113096|Drug|Stage IV: Colon Cancer Placebo|20 mg once daily for 6 months
10201|NCT04113096|Drug|Cervical Cancer Stage IV Placebo|20 mg once daily for 6 months
10202|NCT04113096|Drug|Cancer of the Prostate Placebo|20 mg once daily for 6 months
10203|NCT04113083|Other|Blood sampling for cholestanol analysis|Blood sampling will be performed by Düzen Laboratories group for cholestanol
10204|NCT04113070|Device|Anthropometric measuring|To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.
10205|NCT04113070|Other|Growth environment evaluation|The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.
10206|NCT04113057|Other|Remote Coaching|In patients randomized to the remote coaching arm, study staff will provide feedback on home-based supplemental exercise based on heart rate and walking distance measurements from the LIVMOR health monitoring system.
10207|NCT04113044|Other|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.|All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics.
14084|NCT04081324|Drug|Lasmiditan|Administered orally
10208|NCT04113031|Behavioral|Flywheel squats versus free weight high load squats for explosive actions in football|Over the course of the interventions, all players in all three groups will be instructed to adhere to their two-three weekly football practices and preseason matches of their team (~one weekly match). The flywheel group performes squat resistance exercise in using a flywheel device, and the barbell free weight group performes squat resistance exercise using an Olympic barbell and weights.
10209|NCT04113018|Drug|Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab|Experimental
10210|NCT04113005|Drug|Desmopressin|To evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment. Additionally, CTCs will be collected before and after Desmopressin/Docetaxel treatment to evaluate therapeutic efficacy.
10211|NCT04112992|Procedure|Any treatment that is used for a defect of any long bone|Any treatment that is used for a defect of any long bone. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
10212|NCT04112979|Behavioral|Music|45 dB SL, normalized, high-frequency sampled W.A. Mozart Symphony n°4 in D K19 and n°5 in B-flat K22 (from Mozart Symphonies Vol. I - Adam Fisher, Dacapo Records, Frederiksberg C., Denmark, 2013)
10213|NCT04112979|Behavioral|Mother's lap|45 dB SL, normalized and filtered, high-frequency sampled heartbeat sound, 75 bpm tempo, looped
10214|NCT04112979|Behavioral|Soundproof earplugs|Disposable foam earplugs with a noise attenuation of at least 30 dB
10215|NCT04112966|Procedure|14 sessions of manual lymphatic drainage technique|Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
10216|NCT04112966|Other|the health education|The health education for lymphedema prevention.
10217|NCT04112940|Other|Starch-based Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
10218|NCT04112940|Other|Xanthan-gum Thickened Liquids|Barium will be thickened to slightly, mildly, moderately and extremely thick consistences as defined by the International Dysphagia Diet Standardisation Initiative flow test.
10219|NCT04112914|Behavioral|Post-concussion education for families|An educational resource for families will be developed based on the CDC ACE Care Guide, adapted with stakeholder feedback to meet the learning needs of low health literacy parents. An implementation toolkit will be developed, adapting the AHRQ RED Toolkit, to support communication about the educational resource and other best-practices for communication with families, including low health literacy families, in the ED post-concussion.
10220|NCT04112901|Device|Microprocessor-controlled knee joints|Any type of microprocessor-controlled knee joints will be considered; this includes those controlling stance phase only (e.g. Compact C-Leg), swing phase only (e.g. Smart IP), both swing and stance phases (e.g. Reho knee), or power generating knees (e.g. POWER knee Ossur).
10221|NCT04112901|Device|Non-microprocessor-controlled knee joints|Any non-microprocessor-controlled knee joints such as prosthesis incorporating hydraulic, polycentric, pneumatic mechanisms, friction or locked knees.
10222|NCT04112888|Combination Product|Collagen|Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.
10223|NCT04112888|Procedure|Rehabilitation sessions|Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
10224|NCT04112875|Dietary Supplement|L-arginine|Handled powdered supplement to be mixed with water, has orange flavor for oral use.
10225|NCT04112875|Dietary Supplement|Maltodextrin|hydrolysis of cornstarch or starch as a white powder to be mixed with water, has orange flavor for oral use.
10226|NCT04112862|Other|sodiumlactate|intravenous sodiumlactate 600mmol/L
10227|NCT04112849|Diagnostic Test|Measurement of S3 heart sound|S3 heart sound to be measured by Nanowear Congestive Heart Failure Management System device.
10228|NCT04112823|Drug|Dexamethasone 4mg|Dexamethasone 4mg + metoclopramide 10mg, intravenously
10229|NCT04112823|Drug|Dexamethasone 16mg|Dexamethasone 16mg + metoclopramide 10mg, intravenously
10230|NCT04112810|Drug|Tildrakizumab|100 mg will be injected subcutaneously on Day -1, Day 28 ± 3, Day 112 ± 7, Day 196 ± 14, and Day 280 ± 14.
10231|NCT04112797|Biological|Allergovac himenoptera|Treatment with allergy vaccine againts Apis mellifera, Vespula spp or Polistes dominula
10232|NCT04112771|Drug|Penehyclidine hydrochloride|Penehyclidine hydrochloride was administered before anesthesia induction.
10233|NCT04112771|Other|No penehyclidine hydrochloride|Penehyclidine hydrochloride was not administered before anesthesia induction.
10234|NCT04112758|Other|High-intensity interval training|2 times weekly for 5 weeks Circuit training with 4 stations
10235|NCT04112745|Other|Static magnet|Static magnet with 2,000 Gauss
10236|NCT04112745|Other|Placebo|Polyvinyl chloride resin material black jewelry
10237|NCT04112732|Dietary Supplement|Multivitamin|Multivitamin
10238|NCT04112732|Other|Placebo|Placebo
10239|NCT04112719|Other|supine position|The patient will be placed in a supine position. Changes in cardiac output will be measured.
10240|NCT04112719|Other|15 degrees lateral tilt|The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.
10241|NCT04112719|Other|30 degrees lateral tilt|The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
10242|NCT04112706|Drug|CPP-ACP|CPP-ACP WAS APPLIED AFTER TOOTH BLEACHING
10305|NCT04112147|Drug|Antroquinonol capsule 100mg|Patients will receive 12-week of 50mg BID Antroquinonol
10243|NCT04112693|Procedure|Esophageal biopsies during Peroral Endoscopic Myotomy (POEM)|In total, 14 biopsies are performed with a pediatric biopsy forceps belonging to the study center: 3 biopsies at 3-6 cm above cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 3 biopsies at the cardia, contralaterally from POEM, of which 2 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria (exposed during POEM) at 3-6 cm above cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; 4 biopsies of the muscularis propria at the cardia, of which 3 are placed in nitrogen and 1 in formol for histopathological analysis; The biopsies are taken by the gastroenterologist who performs the POEM and is assisted by an endoscopy-specialized nurse.
10244|NCT04112680|Behavioral|Debunking Misinformation through Audio Dramas|The audio dramas (one drama of 4 episodes per intervention group), aim to debunk misinformation about an infectious disease. The content of the two dramas differ in the two groups; in intervention group 1, the drama will state the misinformation and provide a plausible alternative, delivered through a trusted source, in line with world views. In intervention group 2, the audio drama will avoid mentioning the misinformation and instead only state the correct information about the infectious disease
10245|NCT04112680|Behavioral|Control group audio jingles|The control group will receive audio jingles about exclusive breastfeeding
10246|NCT04112667|Other|Normal Macular Health|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
10247|NCT04112667|Other|Early Macular Degeneration|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
10248|NCT04112667|Other|Young Normals|This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
10249|NCT04112654|Procedure|Conventional pressure laparoscopy|Conventional pressure laparoscopy using conventional insufflator AirSeal®
10250|NCT04112654|Procedure|Low pressure laparoscopy|Low pressure laparoscopy using pressure-controlled insufflator AirSeal®
10251|NCT04112641|Drug|Nicotinamide riboside|Daily oral ingestion of 1 g/day NIAGEN in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
10252|NCT04112641|Drug|Placebo capsules|Daily oral ingestion of placebo in capsule form for 84 days; two capsules in the a.m. and two capsules in the p.m.
10253|NCT04112615|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using a potential haemoglobin home monitoring system.
10254|NCT04112602|Other|Sputum|Sputum will be collected after a respiratory physiotherapy session, scheduled as part of routine care.
10255|NCT04112602|Other|Tracheal aspiration|Tracheal aspirations will be collected in intubated patients (intubation for surgery under general anesthesia).
10256|NCT04112589|Drug|Quizartinib|Quizartinib at different doses in the phase I (40mg-14 days; 60mg-14 days; 60mg-7days, 40mg-7days). RP2D in the phase II part.
10257|NCT04112589|Drug|Fludarabine|30 mg/m2 intravenous days 1 to 4 of the cycle
10258|NCT04112589|Drug|Cytarabine|2 g/m 2 intravenous days 1 to 4 (1 g/m2 in patients older than 59) of the cycle
10259|NCT04112589|Drug|Idarubicin|10 mg/ 2 intravenous days 1 to 3 of the cycle
10260|NCT04112589|Drug|glycosylated G-CSF|daily dose of 300 mcg/m 2 , from day -1 until day 5 of the cycle
10261|NCT04112576|Device|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
10262|NCT04112563|Procedure|exploration in white light (WLI)|Exploration of the right colon done in white light (WLI)
10263|NCT04112563|Procedure|Exploration in LCI|Exploration of the right colon in linked color imaging (LCI)
10264|NCT04112550|Drug|Methadone Hydrochloride|FDA approved medication to treat pain
10265|NCT04112550|Drug|Oxycodone-Acetaminophen|FDA approved medication to treat pain
10266|NCT04112524|Device|App|"Alleye® Test Alleye® Test is a mobile medical software application indicated for the detection and characterization of metamorphopsia. For the mean Alleye score (±standard deviation (SD) deviations of dots from an ideal line are calculated for each eye.~AMD-A Metamorphopsia Detector® Is based on the Amsler grid. The software uses the concept of a negative image: a distorted image can be straightened by moving the mouse. Degree and dimension of distorted lines or scotoma are transformed into indices."
10267|NCT04112498|Drug|relatlimab|Specified dose on Specified days
10268|NCT04112498|Drug|nivolumab|Specified dose on Specified days
10269|NCT04112498|Drug|rHuPH20|Specified dose on Specified days
10270|NCT04112485|Procedure|Microdiscectomy|
10271|NCT04112472|Device|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.
10272|NCT04112459|Other|prolonged mechanical ventilation|No intervention will be applied in this study
10273|NCT04112446|Drug|Saroglitazar magnesium|On Day 1, subjects will receive a single oral dose of [14C]-saroglitazar magnesium
10274|NCT04112433|Device|PURE EP 2|Enrolled patients receiving cardiac ablation treatment using the current standard of care with additional monitoring and intracardiac electrogram signal collection via the PURE EP 2 system.
10301|NCT04112186|Behavioral|Behavioral group therapy #2|Participants will participate in an 8-weeks of group therapy that uses psychological principles (but not including mindfulness training) and could help decrease craving for heroin and increase general well-being.
10302|NCT04112173|Behavioral|perturbation-based fall-recovery training|Participants will attempt to recover from treadmill-induced balance perturbations as they walk or stand. The size of the perturbations is progressively challenging and dependent upon participant performance.
10275|NCT04112420|Diagnostic Test|Trans-esophageal echocardiography|"The department registers an unplanned admission of a patient to the intensive care unit. The indication is verified again by the intensive care physician.~In this case, the patient is then admitted to the intensive care unit, supervised by an intensive care physician, orientated and initiated therapeutic and diagnostic measures.~As part of the planned transthoracic cardiac ultrasound examination, it is then selected whether the patient is suitable according to the patient's will and the inclusion or exclusion criteria.~After clarification, time to think and consent, the examination is then carried out according to the protocol by approved doctors of the Clinic for Anesthesia, intensive care and pain therapy. Followed by digital storage for the finding.~After the subsequent operation, the investigator determines whether knowledge of detected pathologies would have an effective influence on the anesthesiological procedure or not."
10276|NCT04112407|Device|Blue Light Phototherapy|Phototherapy in the blue light spectrum
10277|NCT04112407|Drug|Benzyl Peroxide|Benzyl peroxide wash to be used preoperatively during showering to the operative shoulder site.
10278|NCT04112407|Other|Control|Standard surgical site preparation with no P. acnes pretreatment
10279|NCT04112394|Other|local anesthetic injection|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. Local anesthetic mixture will be injected bilaterally into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
10280|NCT04112394|Other|Standard perioperative and postoperative analgesia protocol.|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive contramal 1 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
10281|NCT04112381|Device|Exablate Model 4000 Type 1.0/1.1|Exablate thalamotomy of non tremor dominant side of the brain
10282|NCT04112368|Drug|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
10283|NCT04112368|Drug|Oral Micronized Progesterone 200mg|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation (200mg total per day)
10284|NCT04112368|Drug|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
10285|NCT04112368|Drug|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
10286|NCT04112355|Other|Blood Collection|Blood draw
10287|NCT04112342|Device|India Ink measurement|The India ink we propose to use in this study consists of 20-50 μL of Carlo Erba India ink injected in subcutaneous or submucosal tissue. This ink (referred to herein as Carlo Erba ink or CE ink or India ink) is based on a paramagnetic black pigment: purified and depyrogenated charcoal manufactured by Carlo Erba that is prepared as a sterile ink using the protocol developed at the lab of Bernard Gallez. The India ink will be injected subdermally into the tumor.
10288|NCT04112342|Device|SPOTChip measurement|The SPOTChip is made in the form of a thin, circular in shape, disc/film having a diameter of 6-mm. After placing the SPOTChip on the tumor, it is covered with an oxygen barrier material secured to the skin by an FDA approved medical transfer adhesive.
10289|NCT04112329|Behavioral|Exergaming|will use the PlayPulse exergame for 45 minutes a minimum of two times per week for 8 weeks.
10290|NCT04112316|Drug|liothyronine or placebo|Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
10291|NCT04112303|Drug|SOF/VEL|400/100 mg tablets administered orally once daily
10292|NCT04112277|Drug|Cumulative morphine consumption|morphine equivalent [mg] 24 hours after the procedure
10293|NCT04112264|Procedure|Monopolar radiofrequency ablation|a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of <0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
10294|NCT04112264|Procedure|Bipolar radiofrequency ablation|Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of <0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
10295|NCT04112251|Dietary Supplement|Cocoa Flavonols Supplement|Whose total capsule content of 500 mg of cocoa flavonoids, 50 mg correspond to (-) - epicatechin per capsule, with a total dose of this compound being 100 mg/day.
10296|NCT04112225|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
10297|NCT04112212|Drug|Vedolizumab-800CW|Intraveniously administration of vedolizumab-800CW.
10298|NCT04112212|Device|Fluorescence endoscopy and spectroscopy|Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
10299|NCT04112199|Drug|BIV201 continuous infusion|BIV201 continuous infusion with terlipressin 3 mg per 24 hours for a total of 28 days
10300|NCT04112186|Behavioral|Behavioral group therapy #1|Participants will participate in an 8-weeks of group therapy that uses psychological principles including mindfulness training, and could help decrease cravings for heroin and increase general well-being.
10303|NCT04112160|Drug|Ketorolac|IM injection of either normal saline or Ketorolac
10306|NCT04112147|Drug|Antroquinonol capsule 200mg|Patients will receive 12-week of 100mg BID Antroquinonol
10307|NCT04112147|Drug|Placebo oral capsule|Patients will receive 12-week of 100mg BID Antroquinonol placebo
10308|NCT04112121|Behavioral|Meeting with a Chaplain coupled with Biblical Readings|
10309|NCT04112108|Procedure|PTMC|percutaneous mitral ballooning with Inoue balloon
10310|NCT04112095|Drug|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 24 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
10311|NCT04112082|Behavioral|Mobile Neurofeedback|Home-based neurofeedback training (downtrain theta, uptrain beta; training site: Cz) 4 times weekly for a 40 of total sessions over the ten-week training period. Session duration of 21 minutes for the first 20 sessions to 30 minutes for the last 20 sessions. Positive visual and auditory feedback when brainwaves are within the desired range.
10312|NCT04112082|Other|Treatment as Usual|Treatment plan as part of regular care at the ADHD clinic, which may include pharmacological intervention, cognitive behavioral therapy (CBT), a combination of pharmacological intervention and CBT, or no intervention. Care will often include pharmacological intervention, with the specifics (e.g., type of medication, dosage) determined by psychiatrist recommendation considering such factors as response to previous interventions, participant characteristics, and practical constraints. Most pharmacological interventions will be stimulants (e.g., methylphenidate) with various release mechanisms. Each participant will receive an individualized dose titration and follow-up plan, including clinic visits as needed (generally 1-2 visits over the 10-week intervention period); interventions may be switched in accord with clinical judgment.
10313|NCT04112069|Device|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
10314|NCT04112069|Other|Usual Care|Usual care
10315|NCT04112056|Dietary Supplement|Drink the study formula (NAN Comfort producted by Nestle Deutschland AG)|It is same as that stated in arm description.
10316|NCT04112043|Behavioral|Walking Exercise|Participants randomized to this intervention 3 days/week of supervised, center-based walking exercise.
10317|NCT04112043|Drug|Nicotinamide Riboside (NR)|Participants randomized to this intervention will receive 1,000 mg/day of NR.
10318|NCT04112030|Diagnostic Test|Digital image analysis|
10319|NCT04112017|Device|YVOIRE Y-Solution 360|Hyaluronic acid
10320|NCT04112004|Other|Collecting sodium reports and outcome measures|
10321|NCT04111991|Behavioral|Usual Care|Usual care in the NCH in the Complex Concussion Clinic involves assessment and treatment with a neurologist for medical management of concussion, weekly sessions with an athletic trainer for exercise therapy, and physical therapy sessions depending on need
10322|NCT04111991|Behavioral|C-STEP (Cognitive Behavioral Therapy)|The C-STEP intervention involves 4 primary components: psychoeducation, activity management, sleep hygiene, and relaxation training
10323|NCT04111978|Drug|Letrozole 2.5mg|Aromatase inhibitor
10324|NCT04111978|Other|Placebo|Placebo tablet of Femara
10325|NCT04111965|Drug|Nanodrop®|minimum to meet 1 drop 4 times a day, both eyes
10326|NCT04111965|Drug|Systane Balance|minimum to meet 1 drop 4 times a day, both eyes
10327|NCT04111952|Device|CO2 laser|A single session of CO2 vaginal laser treatment
10328|NCT04111952|Other|No intervention|Follow up with no further intervention
10329|NCT04111939|Other|Communities That HEAL|The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence based practices to address overdose and opioid use disorder.
10330|NCT04111939|Other|Wait-list control|Communities in the wait-list control condition will continue usual care during the first 24 months of the trial. At month 25, Wave 2 communities will begin receiving the CTH intervention.
10331|NCT04111926|Drug|Dexmedetomidine|A loading dose of dexmedetomidine (0.6 μg/kg) was administered during a 10-minute period before anaesthesia induction, followed by a continuous infusion at a rate of 0.5 μg/kg/hr till 1 hour before the end of surgery.
10332|NCT04111926|Drug|Placebo|Volume-matched normal saline was administered in the same rate for the same duration as in the intervention group.
10333|NCT04111913|Drug|Anlotinib Hydrochloride|anlotinib once daily on days 1-14 of 21days cycle.
10334|NCT04111900|Behavioral|Sleep/Circadian Friendly|This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
10335|NCT04111887|Behavioral|Group-based therapy|College students with depressive symptoms will be randomized to one of three conditions: 1) a cognitive behavioral prevention intervention, 2) a cognitive behavioral prevention intervention with counter-attitudinal elements or 3) an educational brochure control. We will test if the additional of counter attitudinal elements produces intervention effects when delivered to participants with sub threshold depressive symptoms.
10336|NCT04111874|Behavioral|Cognitive Behavioral Teletherapy LTA|Participating families will receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the four videoconferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
10337|NCT04111874|Behavioral|Cognitive Behavioral Teletherapy STA|Participating families will also receive a copy of the book 'Helping Your Anxious Child, 2nd Edition', as well as the companion parent and child workbooks, to use at home and in session with the therapist. During each of the ten videoconferencing sessions, therapists will guide the parent through the implementation of the program, including explaining materials, assisting to develop planned therapy activities with the child, and problem-solving as needed.
10338|NCT04111861|Other|Singing|To investigate whether singing can help people to manage their chronic pain the applicants, working together with people with chronic pain, have developed a singing intervention, Singing for Chronic Pain (SCP). The development of the programme has been supported by Snape Moultings, an international centre for the arts which offered the team a residency to develop the programme (https://snapemaltings.co.uk/music/residencies/). The model takes a holistic approach using voice and singing, movement, sound, mindfulness and breath work to provide opportunities to connect body, voice, breath and mind. This is important given that people often use body dissociation as a way to cope with physical pain
10339|NCT04111848|Drug|Ketamine|"Patients will be assigned into 2 groups (each of 45):~Ketamine group (group K): will receive a bolus of 0.5 mg/kg ketamine during induction of anaesthesia diluted in 100 ml normal saline, followed by ketamine infusion 0.12 mg/kg/hour continued till 24 hours after surgery. The infusion pump concentration will be 0.6mg/ml and the rate of infusion will be 0.2 ml/kg/hour."
10340|NCT04111848|Drug|ketamine and magnesium|Ketamine and magnesium group (group KM): will receive a bolus of 0.5 mg/kg ketamine added to 50mg/kg magnesium sulfate diluted in 100 ml normal saline over 30 minutes after induction of anaesthesia, followed by ketamine infusion 0.12 mg/kg/hour added to 8mg/kg/hour of magnesium sulfate continued till 24 hours after surgery. Each ml of the administered infusion will contain 0.6mg ketamine and 40mg magnesium and the rate of infusion will be 0.2 ml/kg/hour.
10341|NCT04111835|Diagnostic Test|Offering an alternative cervical cancer screening method - hrHPV molecular testing.|"Women randomized to this screening strategy group will take a hrHPV molecular test.~hrHPV-positive - reflex LBC:~Abnormal reflex LBC (ASC-US or worse) -> colposcopy~Normal reflex LBC -> repeat LBC in 6 months~Positive - colposcopy~Negative - rescreen in 3 years~HPV-negative - rescreen in 5 years"
10342|NCT04111822|Drug|red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate|Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
10343|NCT04111822|Drug|on crystalloid fluid and Tranexamic acid|Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
10344|NCT04111809|Biological|Blood and urine collection|collected 10 mL of blood and 15 mL of urine every 2 months until 12 months
10345|NCT04111796|Other|nature based solution for stress reduction|participation in nature activities: 30 min stress management in nature and group activity (walking, cycling)
10346|NCT04111783|Device|POU protocol ultrasound|The evaluation method performed a preoperative examination of the patient within 10 minutes by a heart scan and a standard scan of the face, a large vascular scan under the xiphoid, a body cavity scan, and a standard scan of the face and a lung scan. Preparation, providing anesthesia and surgeons with a fast, comprehensive and accurate preoperative judgment with important clinical and social significance.
10347|NCT04111770|Device|IVUS guided Percutaneous Coronary Intervention|Pre-procedural IVUS will be used to determine lesion characteristics and post-procedural IVUS to confirm correct implantation of stent.
10348|NCT04111770|Device|QCA guided Percutaneous Coronary Intervention|QCA will be used to determine lesion characteristics
10349|NCT04111744|Other|Preoperative Exercise Training|Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery
10350|NCT04111744|Other|Optimal medical therapy|Standard medication for stable CAD
10351|NCT04111731|Procedure|Cryoballoon pulmonary vein isolation|Catheter ablation using cryoballoon pulmonary vein isolation. Utilisation of a 'cold balloon' (Cryoenergy or cryoballoon ablation) to freeze the bases of the 4 pulmonary veins to achieve electrical isolation.
10352|NCT04111731|Procedure|Radiofrequency pulmonary vein isolation|Catheter ablation using radiofrequency energy to achieve pulmonary vein isolation. Radiofrequency energy is delivered through the tip of a catheter to make tiny burns (ablation lesions) around the outlines of the 4 pulmonary veins at their bases
10353|NCT04111731|Procedure|Repeat electrophysiological study|All participants will receive a repeat electrophysiological study 2 months after the index procedure during which radiofrequency catheter ablation guided by ultra-high density mapping will be used to identify regions of reconnection that need re-isolation; other tests will be carried out including testing for arrhythmia inducibility
10354|NCT04111731|Procedure|Left atrial posterior wall isolation|The left atrial posterior wall will be isolated in Group 2 participants (those who received radiofrequency ablation at the index procedure) during the repeat electrophysiological study in 2 months
10355|NCT04111718|Biological|Platelet-rich plasma (PRP)|Autologous platelet-rich plasma which will be derived from blood drawn from the patient.
10356|NCT04111718|Behavioral|Viewing of preparation|The patient will receive a description of the preparation process and will view the preparation in the centrifuge.
10357|NCT04111705|Drug|Lorlatinib|100 mg once daily
10358|NCT04111679|Other|Music|Participant selected music, applied using noise cancelling headphones
10359|NCT04111666|Biological|AL101|Active dose of AL101
10360|NCT04111666|Other|Placebo|Saline solution administered as a single infusion as palcebo.
10361|NCT04111653|Other|Mud therapy|Application of sludge poultice
10362|NCT04111640|Other|CoRe software|Computer-supported cognitive training (CT)
10363|NCT04111640|Other|Control Group|Paper and pencil cognitive training (paper-and-pencil CoRe version)
10364|NCT04111627|Behavioral|Aerobic exercise|Participants with symptomatic knee osteoarthritis and depressive symptoms will be enrolled in a progressive walking program designed to reduce pain and disability and improve psychosocial health.
10404|NCT04111315|Drug|Metamizole Sodium|Novalgin® Oblong tablets 0,5 g 2-2-2
10405|NCT04111315|Drug|Ibuprofen 600 mg|Ibufen-L® tablets 500 mg 2-2-2
10406|NCT04111315|Behavioral|Patient education|Leaflet and phone call
14085|NCT04081324|Drug|Placebo|Administered orally
10365|NCT04111627|Drug|Duloxetine|Duloxetine is an FDA-approved selective serotonin and norepinephrine reuptake inhibitor antidepressant approved for the treatment of neuropathic pain in symptomatic knee osteoarthritis as well as depression in adults. Participants with symptomatic knee osteoarthritis and depressive symptoms will receive duloxetine to decrease pain and depression severity to enhance their ability to engage in aerobic exercise.
10366|NCT04111614|Drug|Tofacitinib tablet|Single dose of tofacitinib 5 mg tablet
10367|NCT04111614|Drug|Tofacitinib Oral Solution|Single 5 mL dose of tofacitinib oral solution (1 mg/mL)
10368|NCT04111601|Device|Blue light imaging|Advanced virtual chromoendoscopy
10369|NCT04111588|Other|Diagnostic Amino acid PET/MRI examination|Diagnostic Amino acid PET/MRI examination
10370|NCT04111575|Behavioral|Music Therapy|Music Therapy
10371|NCT04111562|Procedure|Cranioplasty|Bone grafts
10372|NCT04111549|Other|Home-based telehealth GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI via in-home video telehealth.
10373|NCT04111549|Other|In-person GOALS|Goal Oriented Attentional Self-Regulation (GOALS) is a manualized cognitive training intervention for problems with attention and executive control that has been shown to improve cognitive, emotional, and functional outcomes in civilians and Veterans with history of TBI, including Veterans 65 and older, and healthy older adults. It will be delivered to aging Veterans with history of TBI in person.
10374|NCT04111536|Drug|liothyronine or placebo|Each treatment period of liothyronine or placebo will be approximately 8 weeks in duration, with weekly titration of study drug for four weeks, followed by a maintenance dose for 4 weeks, then 2-week washout before crossing over to receive the alternate therapy - placebo or LT3.
10375|NCT04111523|Drug|SY-007|A single dose of SY-007 or placebo injection(1mg-45mg)
10376|NCT04111510|Drug|Tumor infiltrating lymphocytes (TIL) LN-145|"The TIL autologous therapy with LN-145 is comprised of the following steps:~Tumor resection to provide the autologous tissue that serves as the source of the TIL cellular product;~LN-145 investigational product production at a central Good Manufacturing Practice (GMP) facility;~A 7-day nonmyeloablative lymphodepletion (NMA-LD) preconditioning regimen (hospitalization per institution standards);~Infusion of the autologous LN-145 product on Day 0 (during inpatient hospitalization);~Intravenous (IV) interleukin-2 (IL-2) administrations for up to six doses maximum (during inpatient hospitalization)."
10377|NCT04111497|Drug|Glasdegib|Given PO
10378|NCT04111484|Other|Adrenomedullin|Adrenomedullin is a naturally found in the human body and has strong vasoactive properties.
10379|NCT04111484|Other|Saline|Placebo
10380|NCT04111471|Drug|Prebiotics|Enrolled patients will receive 10 grams of inulin daily for 21 days
10381|NCT04111471|Drug|Placebos|Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
10382|NCT04111458|Drug|BI 1701963|Tablet
10383|NCT04111458|Drug|Trametinib|Tablet
10384|NCT04111445|Drug|ADG116|IV infustion at Day 1 of each cycle
10385|NCT04111432|Biological|Concomitant administration of EV71vaccine with EPI vaccines|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.# the MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
10386|NCT04111432|Biological|Single injection of EPI vaccine|The MMR vaccine was manufactured by Shanghai Institute of Biological Products Co.,Ltd.; the Live attenuated Japanese encephalitis vaccine was manufactured by Chengdu Institute of Biological Products Co.,Ltd.
10387|NCT04111432|Biological|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
10388|NCT04111419|Drug|Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET|amlodipine/atorvastatin (5/20mg tablet) once a day
10389|NCT04111419|Drug|Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET|amlodipine/atorvastatin (5/10mg tablet) once a day
10390|NCT04111419|Drug|Allisartan Isoproxil|allisartan (240mg/tablet) once a day
10391|NCT04111406|Drug|Current practice|Epidural insertion and epidural drug administration depend on anesthetist in charge
10392|NCT04111406|Drug|Protocol based|"Epidural insertion and epidural drug administration depend on anesthetist in research team using protocol based~insertion at mid-level of surgical insertion~insertion depth is 3-5 cm in space, not more than 5 cm~using benzoin tincture and transparent dressing to fix catheter~test dose with 2%xylocaine with adrenaline 1:200,000 3ml If not cover desired dermatome: 2% lidocaine with adr added 3 ml every 5 min (up to 2 times)~After induction and patients' hemodynamic are stable. Load 2 mg morphine with 0.0625% bupivacaine + morphine 0.02 mg/ml 3 ml then continuous infusion with rate according to initial local anesthetic requirement for incisional area coverage"
10393|NCT04111393|Procedure|transoral specimen extraction|transoral specimen extraction during laparoscopic gastric resection
10394|NCT04111380|Drug|cisplatin and nab-paclitaxel|Nab-paclitaxel, 130mg/m2, d1,d8, Cisplatin, 20mg/m2, d1-3 ,3week, 4-6 cycles.
10395|NCT04111367|Drug|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12，the other group will receive the same dose for 24 weeks.
10396|NCT04111367|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12,the other group will receive the same dose for 24 weeks.
10397|NCT04111354|Device|Pacemaker implantation|Pacemaker implantation
10398|NCT04111341|Drug|TCM (Gan-Lu-Yin)GLY|TCM Gan-Lu-Yin 6g in the morning TCM Jia-Wei-Xiao-Yao-San, Ye-Jiao-Teng, Suan-Zao-Ren 8g in the evening for 12 weeks
10399|NCT04111341|Drug|PLACEBO|TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
10400|NCT04111328|Drug|intravenous sufentanil|The PCA pumps contain sufentanil . And the pump is connected to participants intravenously .
10401|NCT04111328|Drug|subcutaneous sufentanil|The PCA pumps contain sufentanil. And the pump is connected to participants subcutaneously.
10402|NCT04111328|Drug|intravenous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants intravenously .
10403|NCT04111328|Drug|subcutaneous hydromorphone|The PCA pumps contain hydromorphone. And the pump is connected to participants subcutaneously.
10407|NCT04111302|Other|Auricular pressure|Select unrelated auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 3 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
10408|NCT04111289|Drug|-Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)|"After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~Randomization will be performed by Microsoft Excel where random order will be generated for the study population"
10409|NCT04111276|Device|Breg Osteoarthritis Brace gait fluoroscopy|Gait under fluoroscopy surveillance with brace
10410|NCT04111276|Other|Gait fluoroscopy without brace|Gait under fluoroscopy surveillance without brace
10411|NCT04111276|Diagnostic Test|JointVue ultrasound|JointVue ultrasound procedure to reconstruct 3D femoral and tibial bones
10412|NCT04111276|Diagnostic Test|Computer Tomography|Computer Tomography scan limited to the study knee and will image 6 inches distal on the tibia and 6 inches proximal on the femur
10413|NCT04111263|Dietary Supplement|FP|Fiber and polyphenol blend
10414|NCT04111263|Dietary Supplement|Placebo|Matched placebo
10415|NCT04111263|Other|High altitude|Simulated high altitude in altitude chamber using hypobaric hypoxia
10416|NCT04111263|Other|Sea level|Sea level environment in altitude chamber
10417|NCT04111250|Procedure|Maxillary sinus augmentation|Raise the sinus membrane to graft bone substitute to augment the sinus cavity allowing implants placement.
10418|NCT04111237|Behavioral|Two Finger technique|two thumb method for schest compression provuision
10419|NCT04111237|Behavioral|Two Thumb Technique|Two thumb technique
10420|NCT04111224|Diagnostic Test|pentraxin 3 marker|Assess the role of pentraxin3 (PTX3) in the early diagnosis of ventilator-associated pneumonia (VAP).
10421|NCT04111198|Radiation|Cardiac MRI|Cardiac MRI
10422|NCT04111185|Device|Receive Blood Volume Analysis Guided Treatment|The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
10423|NCT04111172|Biological|Ad5.F35-hGCC-PADRE|Given as intramuscular injection
10424|NCT04111159|Drug|HSK3486|Subjects < 65 years old:Initial dose of 0.4 mg/kg followed by 0.15 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
10425|NCT04111159|Drug|Propofol|Subjects < 65 years old:Initial dose of 2 mg/kg followed by 0.75 mg/kg if needed;Subjects ≥ 65 years old:75% of the dose for subjects < 65 years old.
10426|NCT04111133|Drug|Betablocker + ivabradine|Use of maximum tolerated dose of carvedilol and ivabradine to achieve therapeutic heart rate reduction (THR) to 55-65 beats per minute
10427|NCT04111133|Drug|Betablocker|Use of maximum tolerated dose of carvedilol to achieve targeted heart rate reduction (THR) to 55-65 beats per minute (responder) or inability to reach THR (non responder) with maximum dose of carvedilol, maintaining a minimum MAP of 70 mmHg.
10428|NCT04111120|Diagnostic Test|SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI|Coagulation assessment using heparinase treated SONOCLOT
10429|NCT04111107|Drug|Investigational Agent|Treatment will be administered on an inpatient or outpatient basis based on the type of medication selected. The investigatory will administer the drug as directed in the FDA approved label.
10430|NCT04111107|Other|Supportive Care Regimens|Supportive care regimens will vary depending on the type of drug that will be administered at the treating investigator's discretion.
10431|NCT04111107|Diagnostic Test|Next Gen Sequencing Report|1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
10432|NCT04111094|Diagnostic Test|No intervention|No intervention
10433|NCT04111081|Other|Auricular pressure|Select unrelated auricular points: Shenmen(TF4), sympathetic(AH6a), rectum(HX2), anus(HX5), stomach(CO4), subcortical(AT4). The auricle skin of the patient was disinfected 3 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
10434|NCT04111081|Other|Shame auricular pressure|Select unrelated auricular points: eye(LO5), occipital(AT3), tonsil(LO7,8,9), lower auricular root(R3), dorsum auricular kidney(P5) and dorsum auricular lung(P2). The auricle skin of the patient was disinfected 3 hours after the operation, and wanghuoxing seed will be used for stimulation. Ask patients press every two hours for one minute at each point. When the pain is severe, do pressure compressions at each point for 2 minutes once hour.
10435|NCT04111068|Device|anodal tDCS Active Stimulation|a weak electric current is applied to the head through electrodes to affect the cortical excitability of the targeted cells in the brain.
10436|NCT04111068|Device|anodal tDCS Sham/Placebo Stimulation|The tDCS machine will be used as in active stimulation, except the electrical current will not be applied.
10437|NCT04111055|Device|Closed-loop system|the CLV system will correct hypotension by automated adjustment of norepinephrine.
10438|NCT04111042|Device|stenting|stenting procedure in patients diagnosed malignant large bowel occlusion
10439|NCT04111029|Diagnostic Test|Cell Free DNA|Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy
10500|NCT04110548|Procedure|Craving Regulation Task|"Participants are instructed to complete the craving assessment after Look or Decrease the neutral or gaming pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of craving, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Second, a neutral or gaming picture is presented on the screen for 7s. Third, participants rate the intensity of their craving for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
10501|NCT04110535|Drug|Remimazolam|IV administration over 1 minute
10440|NCT04111016|Behavioral|Integrated child stimulation, nutrition, lead, arsenic, WASH intervention|The content of the intervention curriculum was developed considering the needs of the specific ages of the children attending the group, as well as the feasibility of delivering the package in the community. The pregnancy module encompasses information on significance of prenatal care for child development, physiological symptoms and solutions, maternal diet, education on kangaroo mother care (KMC), breast feeding, thinking healthy, hygiene, and lead and arsenic prevention. The curriculum for lactating mothers focuses on specialized messages for 4 age groups of children: 0-5 months, 6-11 months, 12-18 months and 19-24 months. The overall package includes information regarding WASH, psychosocial stimulation, nutrition, maternal mental health, lead and arsenic. As research evidence showed that psychosocial stimulation provided for 10 or 12 months can significantly improve child development, the psychosocial stimulation component is included in every fortnightly session.
10441|NCT04111003|Procedure|local anesthesia|administering local anesthesia in the region of the planned restorative procedure
10442|NCT04111003|Procedure|Tooth restored using SFRC filling|Restoration of an endodontivally treated molar using a shor-fiber base filling and veneering composite
10443|NCT04111003|Procedure|Tooth restored using Ceramic indirect endocrown|Restoration of an endodontically treated molar using a ceramic indirect restoration
10444|NCT04110977|Device|mobile application (reminder app)|This app will remind the patients four times a day to perform skin and mouth care. Instructions are given how to properly perform skin and mouth care. The patients may postpone each required care procedure for up to 2 hours. Finally, the patients are asked to state for each procedure whether or not they performed it. To increase the patients' motivation, they will earn points for each successfully performed care procedure.
10445|NCT04110964|Drug|AAV-hTERT|subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
10446|NCT04110951|Behavioral|Pranayama Breathing Technique|Yogic Breathing Technique
10447|NCT04110951|Behavioral|Relaxation technique|Progressive relaxation technique
10448|NCT04110925|Genetic|Genetic Mutations|DNA sequencing for mutations to be obtained by bloodwork within 6 months of diagnosis, or by accessing diagnostic bone marrow aspirate slides.
10449|NCT04110925|Other|Inflammatory and lipid markers|Bloodwork to be done for lipid profile, c-reactive protein (CRP), and multiplex chemokine/cytokine analysis.
10450|NCT04110925|Other|Computed Tomography (CT) of the heart|Sunnybrook Patients with no history of cardiovascular disease [ex: past/present coronary artery disease (CAD), peripheral vascular disease (PVD), angina, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or stents], not pregnant, and able to undergo CT will receive a CT of the heart to look for and quantify any occult coronary artery disease.
10451|NCT04110912|Other|This is a registry and no interventions are taking place.|
10452|NCT04110899|Other|Application of paratracheal force|An esophageal stethoscope is inserted into the upper esophagus under the application of different paratracheal force in anesthetized and paralyzed patients.
10453|NCT04110886|Drug|HSK21542|Single dose, injection, starting dose of 0.2ug escalating up to 20ug
10454|NCT04110886|Drug|Placebo|Single dose, injection matching placebo
10455|NCT04110873|Drug|Antroquinonol Capsule 50mg|patients will receive Antroquinonol 50mg per day (QD) on Day 1 for 12 weeks
10456|NCT04110873|Drug|Antroquinonol Capsule 100mg|patients will receive Antroquinonol 100mg per day (QD) on Day 1 for 12 weeks
10457|NCT04110873|Drug|Placebo oral capsule|patients will receive placebo per day (QD) on Day 1 for 12 weeks
10458|NCT04110860|Drug|voriconazole gel once daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
10459|NCT04110860|Drug|voriconazole gel twice daily|voriconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
10460|NCT04110860|Drug|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, voriconazole, is not added then applied twice daily in the same manner
10461|NCT04110847|Drug|JING CEIH SHERN YUAN EXTRACT PILL|Oral use, 3#BID
10462|NCT04110834|Drug|itraconazole gel once daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas once daily
10463|NCT04110834|Drug|itraconazole gel twice daily|itraconazole is incorporated into a nanoemulsion intermediate gel state then applied on the affected areas twice daily
10464|NCT04110834|Drug|placebo|the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
10465|NCT04110808|Drug|hypotensive anaesthesia using Nitroglycerine|"effect of hypotensive anaesthesia using Nitroglycerine vs Phentolamine on Event related potentials, quantitative Electroencephalograghy and cognitive function~Phentolamine group (30 patients): Patients will receive hypotensive anesthesia with phentolamine infusion via syringe pump by adding 20 mg (2ml) of Phentolamine to 48 ml of normal saline making it to final concentration of 0.4 mg/ml at the rate of 0.1-2 mg/min according to the patients desired target blood pressure.~Nitroglycerine group (30 patients): Patients will receive hypotensive anesthesia with nitroglycerine infusion via syringe pump by adding 5mg (5ml) of Nitroglycerin to 45ml of normal saline making it to final concentration of 100μg/ml at the rate of 0.5- 10 μg/kg/min according to the patients desired target blood pressure."
10466|NCT04110795|Other|No Intervention|No Intervention
10467|NCT04110782|Other|Radium223|55 kBq/ Kg
10468|NCT04110769|Diagnostic Test|next generation sequencing|the investigator will compare genetic mutation between responder and non-responder using next generation sequencing examination.
10469|NCT04110769|Diagnostic Test|following next generation sequencing|The patient will be examined next generation sequencing before changing palliative chemotherapy for non-responders.
10502|NCT04110535|Drug|Midazolam|IV administration over 1 minute
10503|NCT04110535|Other|Saline|IV administration over 1 minute
10504|NCT04110522|Other|Direct to patient PsA Screening Questionnaire|Patients randomized to an intervention group will be asked to complete and score the 5-item Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Those patients with an elevated score (PEST ≥3 out of 5) will be advised to complete a rheumatologic evaluation for PsA.
10505|NCT04110496|Drug|RTX-134|RTX-134 is a cellular therapy containing AvPAL
14875|NCT04074785|Drug|Abemaciclib|Abemaciclib 150 mg po bid
10470|NCT04110756|Behavioral|ChangeGradients|In the proposed intervention, adolescents at the UCSF clinics who endorse alcohol use on the Health e-Check screen, a 5-minute confidential risk behavior module, will be randomly assigned to either the CHANGEGRADIENTS Intervention or Comparison (no intervention). The CHANGEGRADIENTS system will generate behavior change narrative episodes that are tailored to the adolescent (e.g. level of alcohol use) while also universally addressing a core set of topics related to health behavior change. Shortly following the clinic visit, through 4 weekly, 20 minute episodes, adolescent participants will interact with the CHANGEGRADIENTS health behavior change environment outside of clinic. Adolescents will complete a brief alcohol screening—past 7-day use—at the beginning of each episode. At the end of the final episode, the system will produce an individualized adolescent report that summarizes use of the CHANGEGRADIENTS modules as well as self-reported alcohol use since clinic visit baseline.
10471|NCT04110743|Device|EXPLORER PET/CT|Intervention: PET/CT using different protocols
10472|NCT04110730|Device|3D Printed Upper-limb Prosthesis|The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
10473|NCT04110730|Behavioral|Home Intervention|An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
10474|NCT04110717|Device|Vestal Device|Vestibular nerve stimulator
10475|NCT04110717|Device|Control Device|Control Device
10476|NCT04110717|Behavioral|Hypocaloric Diet|Hypocaloric diet
10477|NCT04110704|Procedure|Insertion of transvaginal cerclage|Transvaginal cerclage is inserted in women with a high risk of preterm birth. However it is unknown whether this alongside cervical length monitoring improves the incidence of preterm birth. The cerclage is inserted under regional analgesia.
10478|NCT04110678|Drug|NeuroEPO|NeuroEPO [CIMAB S.A, Havana, Cuba]
10479|NCT04110665|Drug|Tramadol|Tramadol 100 mg tablet
10480|NCT04110665|Drug|Nefopam 20 MG/ML|120 mg for 24 hours
10481|NCT04110665|Drug|Morphine Sulfate|Tablet 10mg
10482|NCT04110665|Drug|Oxycodone 20mg|release
10483|NCT04110652|Other|pulmonary rehabilitation program|"The pulmonary rehabilitation program consisting of inspiratory muscle training, manual hyperinflation. chest wall mobilization, rib-cage compression, cough function training, postural drainage and secretion removal will be applied to patient group.~The program will be conducted by physical therapists for 30-45 minutes daily during ICU stay.~The exercise intensity will be increased gradually over the course. Each patient's performance during the exercise sessions will be recorded and reported regularly."
10484|NCT04110639|Device|Intracranial pressure (ICP) monitor|The investigators' hypothesis is that by utilizing an intracranial pressure (ICP) monitor to detect the presence or absence of waveforms in the femoral head, investigators could reliably assess the perfusion levels within the femoral head and possibly reduce the incidence of osteonecrosis.
10485|NCT04110639|Other|Standard of Care|10 patients with minimally displaced femoral neck fractures (Garden 1) which will be pinned in situ without manipulation
10486|NCT04110626|Other|Questionnaires|The questionnaires are completed at the 3 survey times (T0, T1 and T2) by all pupils involved. Collected data are quantitative
10487|NCT04110626|Other|Non-directive Interviews|The interviews are conducted with 80 pupils/year randomly selected (i.e. 2 per class and 8 per establishment/year). Collected data are qualitative
10488|NCT04110613|Dietary Supplement|noFAST group|Truncated fasting prior to procedure, early feeding after procedure
10489|NCT04110600|Other|Coffee effect on early gastric motility|this group 100ml coffee after two hours
10490|NCT04110600|Other|Efficacy pepper mint oil on motility|This group 100me pepper mint oil after 2 hours
10491|NCT04110587|Biological|Hyaluronic Acid|1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .
10492|NCT04110587|Procedure|Temporomandibular Joint Arthroscopy|Lysis and Lavage
10493|NCT04110587|Drug|Antibiotic therapy|Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).
10494|NCT04110587|Drug|corticosteroid|Dexamethasone, 4 mg I.V. (Intraoperative)
10495|NCT04110587|Drug|Antiinflammatories|Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).
10496|NCT04110587|Drug|Analgesics|Metamizol 575 mg / 8h by mouth (Post-operatively)
10497|NCT04110587|Other|Exercise program|Home exercise program
10498|NCT04110561|Device|Use of the Atalante exoskeleton|A session basically includes a stand up, walks over a distance of 10 meters, exercises, U-turns and a sitting
10499|NCT04110548|Procedure|Emotion Regulation Task|"Participants are instructed to complete the emotion assessment after Look or Decrease the neutral or negative pictures. The Decrease asks the participants to use cognitive reappraisal or mindfulness strategies to decrease the intensity of emotion, whereas the Look asks the participants to look naturally at the picture. First, the look or decrease is displayed on the computer for 2 s. Then, a neutral or negative picture is presented on the screen for 7s. Finally, participants will rate the intensity of their emotion for 4s. Then, they have 1s-3s to relax before the next trial. In the meantime, Skin conductance activities will be recorded using a constant voltage with 1-cm 3 AgAg/Cl electrodes attached to the medial phalanx surfaces of the middle and index fingers of the nondominant hand."
10527|NCT04110314|Behavioral|Portal Reminders for Influenza Vaccination: Gain-framed|Patients receive gain-framed reminder/recall messages via the patient portal to get an influenza vaccination.
10528|NCT04110314|Behavioral|Portal Reminders for Influenza Vaccination: Loss-framed|Patients receive loss-framed reminder/recall messages via the patient portal to get an influenza vaccination.
10628|NCT04109391|Biological|TX05 (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
10506|NCT04110483|Procedure|Thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a circumferential incision around the tumor is made in the visually intact bladder mucosa (approximately 10 mm from the edges of the tumor). It allows for accurate morphological evaluation of the surgical margin. After that, the incision is continued deeper into the muscular layer. Having identified the layer, the surgeon resects the base of the tumor with the muscular layer using traction and incisions of the muscle fibers. Making incisions in the muscular layer requires precision, a full bladder and adequate guidance with visualization techniques. Traction may be employed with the help of the tip of the resectoscope or working element. After complete tumor resection, local hemostasis was performed.
10507|NCT04110483|Procedure|Transurethral resection of non-muscle-invasive bladder cancer|After cystoscopy and determining tumor topography, a step-by-step resection of a tumor is done. Firstly, visible tumor is resected, then resection continues to the apparently normal mucosa on the border of the tumor, than resection of the muscle layer at the base of the tumor is performed until normal muscle fibers are visible.
10508|NCT04110470|Diagnostic Test|X-ray|Patients will receive standard radiographs post-operative day one or two in hospital, as well as radiographs in clinic at two and six weeks.
10509|NCT04110470|Diagnostic Test|No-Xray|These patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks, unless clinically indicated.
10510|NCT04110457|Procedure|spinal decompression|spinal surgery by decompression or fixation
10511|NCT04110444|Drug|Sildenafil|oral sildenafil t.d.s for high-risk pregnancies
10512|NCT04110431|Procedure|Left bundle branch pacing|Successful LBBP was defined as (1) LBBP lead is located at 1.5-2cm from His-bundle towards right ventricular apex; (2) Paced QRS morphology of right bundle branch delay(CRBBD) in lead V1; (3) Stimulus to the peak of R wave in V5 and V6 QRS wave, which represents left ventricular activation time(Stim-LVAT), is less than 100ms and constant at high and low output pacing; (4) Unipolar pacing threshold<1.5V/0.5ms; (5) Recording P potential when narrow QRS escape rhythm or CRBBB escape rhythm(not essential).
10513|NCT04110431|Procedure|Biventricular pacing|Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
10514|NCT04110418|Drug|Methylene Blue|"Methylene Blue group (Group MB):will receive IV MB initiated with a first loading dose ( 1 mg/kg over 30 minutes ) then continuous IV infusion( 0.15 mg/kg per hour for up to 24 hours)~Terlipressin Group (Group TP) Terlipressin will be initiated with a loading dose ( 2 μg/kg intravenous over 30 minutes ) followed by continuous IV infusion starting by 2 μg/kg/h escalating up every 15 minutes up to 20 μg/kg/h"
10515|NCT04110405|Behavioral|Stepped Care|This stepped care model involves three steps. Step 1 is a peer and nurse co-led 8-session group based upon BRIDGES. Step 2 is peer or nurse led 6-session individual meetings based upon Interpersonal Psychotherapy. Step 3 is primary care physician led medication treatment with Amitriptyline.
10516|NCT04110405|Behavioral|Standard of Care plus Healthy Lifestyle|Standard outpatient care supplemented with literature on healthy lifestyles will serve as an enhanced control condition. In each clinic, non-specialty mental health care is available in the form of counseling from doctors or nurses along with psychiatric medication management. Given the difficulties faced by women in Tajikistan, ethical responsibility compels us to enhance the control condition by having nurses distribute written materials on healthy eating, physical fitness, and personal hygiene, at a reading level which will be widely accessible.
10517|NCT04110392|Dietary Supplement|Chaya (Cnidoscolus chayamansa)|Chaya Water Beverage of Chaya will be prepared as follows: 40 g of Chaya leaves will be treated with a commercial brand disinfectant following the manufacturer's instructions for use, then added 1L of purified water and mixed in blender. Finally, 500 mL of it will be placed in bottles. Participants will be instructed to consume 1 bottle per day for 6 weeks. 7 bottles will be delivered at each visit, which will be consumed during the week; participants will be instructed to keep the water refrigerated until it is consumed.
10518|NCT04110379|Behavioral|Virtual Reality (VR)|All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.
10519|NCT04110379|Behavioral|Conventional Behavior Management Techniques|Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
10520|NCT04110366|Biological|Live attenuated influenza vaccine|Vaccination with live attenuated influenza vaccine (LAIV)
10521|NCT04110353|Other|Wound dressings: Conservative dressings|Conservative dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
10522|NCT04110353|Other|Wound dressings: Prevena dressings|Prevena dressing to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
10523|NCT04110353|Other|Wound dressings: ciVAC dressings|Closed incision VAC dressings to be placed on closed wounds post operatively, after open operations on the bowel. To be changed at day 7 or sooner if clinically indicated.
10524|NCT04110340|Drug|Ciprofloxacin|"Adults: Ciprofloxacin 500mg orally twice daily (or 400mg IV twice daily for those who cannot take oral medication) for 10 days;~Children:Ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 10 days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
10525|NCT04110340|Drug|Streptomycin|"Control arm adults: streptomycin 1g twice daily for three days, followed by ciprofloxacin 500mg orally twice daily (or ciprofloxacin 400mg twice daily by IV for those unable to take orally) for an additional 7 days.~Control arm children: streptomycin 15mg/kg twice daily for three days followed by ciprofloxacin 15mg/kg twice daily (max 500mg per dose) orally (or 10mg/kg IV twice daily for those who cannot take oral - maximum dose 400mg) for 7 additional days.~Patients who begin intravenous therapy may switch to oral administration once they are able to swallow or once deemed clinically appropriate by the treating physician."
10526|NCT04110327|Device|MicroStent|Treatment of arterial stenosis or occlusion with the MicroStent Perihperal Vascular Stent System
10529|NCT04110314|Behavioral|Pre-commitment prompt|Patients receive a pre-commitment prompt asking about their intention to get an influenza vaccination
10530|NCT04110301|Drug|Recombinant Humanized Monoclonal Antibody MIL62 Injection|1000mg /dose for 12 cycles(28 days) and a total of 11 doses :the first Cycle(Day1,Day15), the 2nd-8th Cycles(Day 1 every cycle);the 9th-12nd Cycles (One dose every two cycles).
10531|NCT04110301|Drug|Lenalidomide|Dose on days 2-22 every 28 days x 12 cycles: the starting dose is 10-mg ; Adjusted dose according to the tumor response or toxicity reaction
10532|NCT04110288|Drug|Paclitaxel|Paclitaxel to treat peripheral arterial disease
10533|NCT04110275|Drug|Recombinant human tissue-type plasminogen activator derivative|Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
10534|NCT04110275|Drug|Recombinant human tissue-type plasminogen activator|Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)&Co,
10535|NCT04110262|Other|High dietary sodium intake|Twenty five day feeding period of high dietary sodium (3400 mg/day)
10536|NCT04110262|Other|Low dietary sodium intake|Twenty five day feeding period of low dietary sodium (2300 mg/day)
10537|NCT04110249|Procedure|Photoacoustic Imaging|Undergo PAI
10538|NCT04110249|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
10539|NCT04110236|Behavioral|PriCARE|PriCARE is a group caregiver training program located in the primary care setting designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches techniques for giving effective commands in order to set age-appropriate limits and increase compliance to commands. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
10540|NCT04110236|Behavioral|Positive Discipline Module|The PriCARE Positive Discipline Module is a pilot group caregiver training program located in the primary care setting designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
10541|NCT04110223|Genetic|next generation sequence|targeted NGS of patients' pretreatment tumor biopsy samples using a 474-gene panel, which covers cancer- and radio-sensitivity-related mutations and SNPs.
10542|NCT04110210|Drug|Bilateral Ultrasound-Guided Erector Spinae Plane Block|Following skin sterilization and local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle is inserted in-plane to the ultrasound beam in a cranial-to-caudal direction until contact was made with the transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle is confirmed by injecting 0.5-1 ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total of 20ml bupivacaine 0.25% are then injected into the ESP. The procedure is repeated on the contralateral side.
10543|NCT04110210|Drug|Morphine Consumption|After operation, patients will be transferred to post anesthesia care unit (PACU) for complete recovery and monitoring. The pain VAS scores between the studied groups will be registered every 4 hours for 24 hours postoperatively. A standard postoperative analgesia regimen will be prescribed as paracetamol 1gm every 6 hours and ketorolac 30mg every 8 hours in the first 24 hours postoperatively. Morphine 2.5 mg will be given as a rescue analgesic dose if visual analogue score was ≥ 3 or when patient suffering from pain between the assessment intervals in both groups not exceeding 0.1 mg/kg in a period of 6 hours. Metoclopramide 0.15 mg/kg IV will be prescribed for patients complaining of nausea or vomiting.
10544|NCT04110184|Other|Systemic lupus erythematosus disease activity index (SLEDAI)|The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
10545|NCT04110145|Drug|Linaclotide|Single dose, once daily at approximately the same time each day, 30 minutes before any meal
10546|NCT04110145|Drug|Placebo|Single dose, once daily at approximately the same time each day, 30 minutes before any meal
10547|NCT04110132|Procedure|Ganglion impar block with Bupivacaine.|"Bupivacaine group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Bupivacaine 0.5% 10ml.~Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative."
10548|NCT04110132|Procedure|Ganglion impar block with normal saline|Saline group; Ganglion Impar will be blocked using G25 Quinqe spinal needle using Normal Saline 10ml Postoperative VAS will be measured each 1 for the first 6 hours then at 9 and 12 hours postoperative.
10549|NCT04110119|Drug|diclophenac sodium (75 mg, IM) and thiocolchicoside (4 mg, IM)|Single intramuscular injection of mixture of two commercial drugs (Analgesic-anti-inflammatory and myorelaxant) at the specified dosages
10550|NCT04110119|Other|Chiropractic Treatment|High speed and low amplitude spinal manipulation techniques are applied to the case group.
10551|NCT04110106|Other|no intervention|All participants were evaluated with the PDQ-39, and the severity of PD was recorded according to the H&Y scale by a neurologist.
10552|NCT04110093|Drug|Regorafenib and PD-1 inhibitor|All Colorectal cancer patients received regorafenib (80mg qd d1-d21,q4w) and PD-1 inhibitor. The patients could receive one type of PD-1 inhibitors according to oneself circumstance consideration including nivolumab (3mg/kg, ivgtt, q2w), Carelizumab (200mg, ivgtt, q3w), Sintilimab (200mg, ivgtt, q3w), Toripalimab(240mg ivgtt, q3w).
10553|NCT04110080|Procedure|multimodal pain management|Regional anesthesia techniques, specifically rectus sheath and transabdominal plane blocks, for pain management will be performed.
10554|NCT04110080|Other|goal directed fluid management|Intraoperatively fluids will be administered based on hemodynamic parameters, in addition to clinical judgement.
10555|NCT04110080|Other|preoperative carbohydrate loading|Patient's nutrition will be optimized preoperatively by administering carbohydrate drinks, and limiting fasting time.
10556|NCT04110080|Procedure|Donor nephrectomy|All patient will have laparoscopic nephrectomy procedure with transplant surgery.
10557|NCT04110080|Procedure|regional anesthesia|transabdominal plane and rectus sheath nerve block
10558|NCT04110067|Other|Small Incision Lenticule Extraction (SMILE) with Visumax (Carl Zeiss Meditec, Jena)|Creation of a corneal tissue disk called lenticule and extraction through a minimally invasive incision, utilizing only a femtosecond laser
10559|NCT04110054|Drug|S-600918|Tablets for oral administration
10560|NCT04110054|Drug|Placebo to S-600918|Tablets for oral administration
10561|NCT04110041|Behavioral|Aerobic Exercise|Thrice-weekly aerobic exercise sessions lasting ~45 minutes, for 12 consecutive weeks.
10564|NCT04110015|Device|virtual visual field|Patients with identified conditions will be invited to do a virtual visual field test with virtual reality headsets.
10565|NCT04110002|Behavioral|Injury Prevention Program|
10566|NCT04109989|Device|HominisTM Surgical System|Trans-vaginal gynecological procedures
10567|NCT04109976|Drug|Bimekizumab|Study participants will receive bimekizumab at pre-specified time points.
10568|NCT04109963|Device|Remote ischemic conditioning|Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
10569|NCT04109950|Drug|SEP-363856|SEP-363856 25mg, 50mg, 75mg, 100mg tablet flexibly dosed once daily
10570|NCT04109937|Radiation|External beam radiation therapy|The post-operative radiation will cover entire prosthesis/surgical fixation device and will consist of the dose fractionation of: 20 Gy in 5 fractions or 30 Gy in 10 fractions.
10571|NCT04109924|Drug|Irinotecan|Given IV
10572|NCT04109924|Biological|Bevacizumab|Given IV
10573|NCT04109924|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
10574|NCT04109911|Dietary Supplement|Fermented oyster extract|Fermented oyster extract 1,200 mg/day for 12 weeks
10575|NCT04109911|Dietary Supplement|Placebo|Placebo
10576|NCT04109898|Device|Supraglottic airway device (I-gel) insertion|Modified I-gel insertion technique believed to be easier and non traumatic in anaesthetised patients.
10577|NCT04109885|Drug|Paracervical injection|1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine.
10578|NCT04109885|Drug|prochlorperazine and diphenhydramine.(Standard Treatment)|Intravenous administration of prochlorperazine and diphenhydramine.
10579|NCT04109872|Drug|Lenalidomide|Lenalidomide effectiveness and tolerability data analysis, that will be retrospectively collected until the 30 of April 2018.
10580|NCT04109859|Drug|Saline|When using saline, if found mean arterial pressure <65mmHg, Cardic Output>4L/min, Sequential Vascular Response<800 (dyne×sec)/cm, starting dose of norepinephrine 0.04ug/min/kg
10581|NCT04109859|Drug|Methylene Blue|Patients in the methylene blue group were given methylene blue before anesthesia and continued intraoperative pumping
10582|NCT04109846|Other|Non-euploid embryo transfer|Other than choice of embryo for transfer, all other medical interventions will be at discretion of treating provider
10583|NCT04109846|Other|Euploid Transfer|Standard of Care Protocol
10584|NCT04109833|Drug|ABT|any antibiotic therapy in the first week of life
10585|NCT04109820|Dietary Supplement|MitoQ|Oral; 20mg once a day for 14 days
10586|NCT04109807|Device|HET tracker|The HET tracker has a heart rate sensor and an ozone sensor.
10587|NCT04109807|Other|Ozone|ozone exposure
10588|NCT04109807|Other|FA|Filtered air exposure
10589|NCT04109794|Procedure|E-CTG|Envelope connective tissue graft
10590|NCT04109781|Procedure|Microscope assisted discectomy|Microdiscectomy
10591|NCT04109768|Behavioral|nutrition and activity|16 sessions; nutrition 8; activity 8- 45 minutes to improve health and nutrition literacy
10592|NCT04109755|Drug|Pembrolizumab|5x5 Gy radiotherapy in 1 week, 4 cycles of Pembrolizumab (200 mg every three week), surgery
10593|NCT04109742|Drug|phosphatidylcholine-curcumin complex supplement|a dietary curcumin supplement given at two different doses
10594|NCT04109742|Drug|Placebo curcumin capsule|matching placebo to active curcumin capsules
10595|NCT04109729|Drug|Nivolumab|"Nivolumab 480mg IV every 4 weeks for up to 2 years~• Radium-223 55 kBq/kg IV q4 weeks for 6 cycles total"
10596|NCT04109716|Behavioral|Interpersonal Psychotherapy - Adolescent Skills Training|This is an indicated group depression prevention consisting of 2 individual pre-group sessions, 8 weekly group session, and up to 6 individual booster sessions.
10597|NCT04109716|Behavioral|Services as usual|Services as usual is expected to be brief periodic sessions with the school counselor or services in the community.
10598|NCT04109703|Device|Generation 5 device Soovu Labs Inc.|The Soovu Labs Inc. battery powered device is a one inch diameter heating pod that attaches to the user via a ring system. The device may be programmed to deliver a wide variety of treatment algorithms. Control of the devices are through a phone-based bluetooth connection. For this study the treatment algorithm used for all subjects in this arm was a ramp up speed of 5 seconds from skin temperature, a peak temperature of 45° C, a trough temperature of 40° C. for 30 seconds after which the cycle was repeated for 30 minutes.
10599|NCT04109690|Drug|CPX-351|Patients in both Phase I and II can receive a maximum of two induction and six consolidation cycles on an inpatient or outpatient basis per local hospital standard of care.
10622|NCT04109456|Drug|IN10018|100 mg or 75 mg, orally once daily continuously in 21-day cycles.
10623|NCT04109456|Drug|Binimetinib|45 mg or 30 mg, orally twice daily (approximately 12 hours apart) continuously in 21-day cycles.
10624|NCT04109443|Behavioral|Young Men & Media Program|The online sexual health media literacy website includes content about (1) male anatomy; (2) HIV/STI prevention; (3) overall sexual health; and (4) sexually explicit online media (SEOM) literacy.
10625|NCT04109443|Behavioral|Available websites on safe sex and preventing STIs|Available websites (such as by the CDC) that provide information about sexual health and preventing sexually transmitted infections (STIs) including HIV.
10600|NCT04109664|Procedure|laparoscopic sleeve gastrectomy|The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
10601|NCT04109651|Other|Nursing intervention|"Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants."
10602|NCT04109638|Device|Endonovo SofPulse|The active device emits PEMF signal whereas the placebo device does not emit a PEMF signal. The active device is on for 15 minutes at a time, every two hours, for 10 days.
10603|NCT04109625|Diagnostic Test|Démonstrateur MAGIA|test of capillary blood with the demonstrator at two time and 2 measures and 2 finger by subject.
10604|NCT04109599|Behavioral|PlaySmart|Participants will play the developed PlaySmart game over a 6-month period.
10605|NCT04109586|Behavioral|Personalized nutritional therapy|Dietitian led assessment and individual nutritional therapy during inpatient rehabilitation with follow-up the first year after injury
10606|NCT04109573|Procedure|high resolution anal manometry|functional studies before and after anal laser ablation
10607|NCT04109547|Drug|Oral semaglutide|Tablets to be taken once-daily for 26 weeks
10608|NCT04109547|Drug|Placebo|Tablets to be taken once-daily for 26 weeks
10609|NCT04109534|Diagnostic Test|Bronchial allergen provocation (BAP)|Nebulized Dermatophagoides farina administered at following doses: 10AE, 20 AE, 40 AE, 80 160 AE, etc… until the FEV1 decreases 20% below the initial FEV1-value
10610|NCT04109534|Diagnostic Test|Nasal provocation test (NPT)|Dermatophagoides farina will be administered in both nostrils
10611|NCT04109534|Diagnostic Test|Methacholine test|Nebulized metacholine will be administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg until the FEV1 decreases 20% below the initial FEV1-value
10612|NCT04109534|Diagnostic Test|Peak nasal expiratory flow (PNIF)|Comparison of peak nasal expiratory flow (PNIF) after NPT between groups
10613|NCT04109521|Other|Training, certification and marketing|The 12hr training will address the vendors (i) knowledge on hygienic handling of milk, preservation and low-cost methods for testing milk safety; (ii) business skills in record keeping, access and management of credit; (iii) milk marketing. On completion of the training and successfully passing an evaluation, vendors will be given a written certificate using a format suitable to be displayed in their premises (i.e. A4 poster, a hat or badge) indicating they have completed the training. The certification will not have legal value. Two quarterly unannounced visits will be conducted to collect a milk sample from the vendors and report back the results of microbiological quality. Vendors will have access to various milk marketing and communication items to be used in their daily operations. The materials will promote milk consumption through marketing focused on messages to consumers related to (i) good milk hygiene practices, (ii) good child nutrition practices, and (iii) household diets
10614|NCT04109508|Drug|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
10615|NCT04109495|Other|Smart phone application(NOOM)|The study population included first diagnosis of pancreatic cancer patients within 3 months of pancreatic cancer center visit, and randomly assigned to the use of Noom user group and non-use group. A total of 40 patients, 20 from each group, were used to examine nutritional status(PG-SGA), blood index analysis, and quality of life(EORTC QLQ) at 0, 4, 8, and 12 weeks. At the same time, the patients voluntarily record meals and receive feedback using Noom. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood(about 8ml) is collected for each visit.
10616|NCT04109495|Other|Non-user|The patients dose not use Noom application. A total of 40 patients, 20 from each group, were used to examine nutritional status (PG-SGA), blood index analysis, and quality of life (EORTC QLQ) at 0, 4, 8, and 12 weeks. The purpose and contents of this study are explained in detail to the subjects, and written consent is obtained. The questionnaire items included gender, age, weight, type of diagnosed digestive disease, treatment method, nutritional supplement, oral status and intake of oral supplement foods, and past medical history. To assess the nutritional status using laboratory data, blood (about 8ml) is collected for each visit. At each visit, you will be assessed nutritional status and quality of life through the PG-SGA and EORTC QLQ.
10617|NCT04109482|Biological|MB-102|"The study drug, MB-102 consists of adoptively transferred T cells that are genetically modified using a self-inactivating (SIN) lentiviral vector to express a CD123-specific, CD28-costimulatory chimeric antigen receptor (CAR) as well as a truncated human epidermal growth factor receptor (EGFRt) (CD123.CD28.CD3ζ.EGFRt+T cells) derived from autologous leukapheresis which is administered after a lymphodepletion regimen.~Single dose of MB-102 up to 600 x 10 6 CART-T+ cells (Day 0) as defined by Phase 1."
10618|NCT04109482|Drug|Decitabine|Decitabine will be administered at Visit 4 (Day -7) through Visit 8 (Day -3) at 20mg/m2 per day.
10619|NCT04109482|Drug|Fludarabine|"Fludarabine 30 mg/m2/day IV (3 days) on days -5, -4, and -3~A 20% dose reduction (24 mg/m2/day IV (3 days) on days -5, -4, and -3) is required for patients with moderately impaired renal function (creatine clearance ≤ 70 mL/min)."
10620|NCT04109482|Drug|Cyclophosphamide|Cyclophosphamide 300 - 500 mg/m2/day IV (3 days) on days -5, -4, and -3
10621|NCT04109469|Device|Shark Screw® transplant|Application of a Shark Screw® transplant for osteosynthesis or arthrodesis in hand- or foot surgery
10629|NCT04109391|Biological|Herceptin (trastuzumab)|Subjects will receive up to 13 cycles of adjuvant treatment.
10630|NCT04109378|Procedure|Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE|Removal of the specimen after segmental bowel resection can be performed by either mini-laparotomy or by the natural orifice specimen extraction (NOSE) technique . The conventional method raises concerns because this could disrupt the integrity of the abdominal wall.
10631|NCT04109365|Diagnostic Test|Electrical Epidural Stimulation Test (EST)|EST measures sensory/motor responses
10632|NCT04109339|Drug|Oxytocin|During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
10633|NCT04109326|Other|APAD|"8 PA sessions supervised at the hospital centers and 44 unsupervised home sessions, to be performed twice a week.~6 consultations for nutrition education to teach the principles of well balanced diet, to foster weigh control during treatment, and to induce appropriate feeding behaviors after treatment."
10634|NCT04109313|Drug|LOU064|selected dose of LOU064 taken orally twice a day (morning and evening) from day 1 to week 52 of the Treatment period.
10635|NCT04109300|Genetic|HLADQA1*05A>G screening|DNA will be extracted from whole blood collected from subjects in both arms using the MagNA Pure Compact instrument (Roche, Laval, Quebec, Canada). A custom TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) will be used to determine the presence of wild-type and/or variant alleles in the class II HLA gene region at rs2097432 mapped to the HLA-DQA1*05 region in infliximab-exposed IBD subjects. Genetic data will be used to determine whether or not one of methotrexate or azathioprine should be applied to the patient in the experimental arm.
10636|NCT04109300|Other|Standard of Care|The treating physician will use clinical judgement to determine need for the addition of one of methotrexate or azathioprine to infliximab therapy.
10637|NCT04109287|Device|REVITIVE® device|The REVITIVE® device applies neuromuscular electrical stimulation to the soles of the feet, causing the muscles of the leg to contract and relax, thus improving blood circulation through the legs.
10638|NCT04109274|Behavioral|Exercise|Exercise component: Aerobic exercise, using recumbent bikes, delivered within the cancer institution. Participants will take part in up to 30-minutes of moderate intensity (50-70% HRmax or 4-6/10 on Rate of Perceived Exertion scale)6 exercise for eight sessions during chemotherapy. An exercise specialist with experience in cancer rehabilitation will supervise the exercise component.
10639|NCT04109274|Behavioral|Self-Management|Eight SM modules will be delivered to participants. They will be viewed on an iPad prior to or after the exercise component. The goal of these modules is to aid participants in developing physical activity goals and action plans to continue with between sessions, with an overarching goal of helping them reach exercise guidelines for cancer survivors and the Canadian Physical Activity Guidelines
10640|NCT04109274|Behavioral|Booster Sessions|Four booster sessions will be provided to participants in this group. These will occur at 2, 4, 6, and 8 months post intervention completion. An assessor trained in behavioural counselling will provide booster sessions by phone and will discuss the individuals physical and emotional condition, current exercise level, accomplishment of previously set goals and action plans, and perceived barriers to participation in exercise. The assessor will use facilitation strategies to aid participants in devising strategies to overcome barriers and set realistic goals and action plans.
10641|NCT04109261|Drug|Palbociclib|Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
10642|NCT04109235|Other|High-Intensity Interval Training Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a High-Intensity-Interval-Training (HIIT) handout (developed based on research from Dr. Martin Gibala) detailing their PA recommendations. Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
10643|NCT04109235|Other|Population-Based Physical Activity (PA) Advice|This PA intervention will be primarily self-directed by the patients themselves. Each participant will receive a 1-page double-sided handout detailing their PA protocol. Participants in this arm will receive a CSEP handout (page 4&5 from: http://csep.ca/CMFiles/Guidelines/CSEP_PAGuidelines_0-65plus_en.pdf) detailing their PA recommendations.Participants will be instructed to follow their PA protocol, while noting down which days they completed the PA using a log booklet provided to them by Dr. Fernando (their family physician). Participants will be provided with the phone number for Justine Horne who is a lifestyle coach and co-investigator on this trial. If participants have questions about their PA protocol, Justine will respond to these over the phone.
10644|NCT04109222|Biological|Fluzone Quadrivalent vaccine, 2019-2020 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
10645|NCT04109222|Biological|Fluzone High-Dose vaccine, 2019-2020 formulation|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
10646|NCT04109209|Behavioral|Psychosocial Intervention Group|The intervention will consist of six one-on-one sessions (45 minutes each). Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks
10647|NCT04109209|Behavioral|Usual Care Group|"Caregivers randomized to the usual care arm will be referred to the brain tumor clinic social worker or other appropriate cancer center resources upon request from the caregiver, patient or clinician~•Complete 3 questionnaires: Baseline, 11 weeks, 16 weeks"
10648|NCT04109196|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based treatment for PTSD that will be delivered intensively twice per day over the course of five days.
10649|NCT04109183|Drug|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.|The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
10677|NCT04108988|Behavioral|One Night Stan|Participants will be randomly assigned to play either One Night Stan (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
10678|NCT04108988|Other|Non-Health Related Video Game|Participants will be randomly assigned to play either One Night Stan (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
10650|NCT04109157|Diagnostic Test|20-minute pad test|Our 20-minute modified pad test was described previously proposed first by Hahn and Fall and modified by Sand and Ostergard. Each patient's bladder was emptied with a transurethral catheter and filled to the SD amount of sterile water for test. The catheter was removed, and then the patient returned to a standing position with a pre-weighed perineal pad placed on the underwear. The patient was asked to cough 10 times, bear down 10 times, do 10 deep knee bends, jump up and down on the spot 10 times, wash her hands under cold water for 1 minute, walk up and down five stairs 10 times, walk in the hall for 10 minute, and then return for removal of the pad. The pad was then weighed and the net weight was calculated by subtracting from the original dry weight to achieve a measure of the total urine loss during the 20 minute exercise. The pad weight was measured in grams and the accuracy of the scale was 1 gram. The positive pad weight result was defined as more than 1 gram of leakage.
10651|NCT04109144|Biological|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin during the 2nd of 3 total paracentesis being monitored
10652|NCT04109144|Biological|Albumin|Albumin will be used during the 1st and 3rd paracentesis
10653|NCT04109144|Procedure|Large Volume Paracentesis (LVP)|All participants who have this procedure, meet eligibility criteria and who consent
10654|NCT04109131|Other|Samples collection: Plasma|"At baseline~Part A:~TNBC/ HER2+ BC: once a year~NSCLC/SCLC: every 4 months~Melanoma: every 6 months~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Every 3 months (+/- 1 month)"
10655|NCT04109131|Other|Samples collection: CSF|Part B: Mandatory CSF sampling at CNS diagnosis when clinically possible unless medically contra-indicated - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis Part C: Additional CSF sampling in case CSF sampling is performed for routine clinical practice
10656|NCT04109131|Other|Samples collection: Non-CNS Metastatic Tumour Tissue|Part B: Highly recommended non-CNS metastatic tumour tissue collection (1FFPE and 1 FT) at CNS metastases diagnosis (Part B) (NB: Bone lesions are excluded) - As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis
10657|NCT04109131|Other|Brain MRI|"Part A:~Brain MRI at inclusion is allowed within 45 days before enrolment~Brain MRI pre-CNS diagnosis (Part A) : HER2 BC/TNBC: once a year; NSCLC/SCLC: every 4 months; Melanoma: every 6 months (+/- 1 month)~Part B:~o As close as possible to the diagnosis of CNS metastases and no later than 6 weeks after diagnosis~Part C:~o Brain MRI post-CNS diagnosis (Part C): every 3 months (+/- 1 month window)"
10658|NCT04109118|Behavioral|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD)|Distress Tolerance - Benzodiazepine Discontinuation (DT-BD) is a psychosocial intervention. It is paired with a benzodiazepine taper. The aim of the psychosocial intervention is to improve individuals' ability to tolerate distress in order to assist benzodiazepine discontinuation in patients treated with OAT. There will be 3 sessions between therapist and participant prior to the start of the benzodiazepine taper. The taper for both the intervention and control conditions occurs over 9 weeks and involves weekly meetings with a benzodiazepine prescriber during which a gradual benzodiazepine dose reduction will take place. The DT-BD intervention combines elements of existing psychosocial interventions. Specifically, interoceptive exposure techniques will be paired with elements of acceptance and commitment therapy (ACT) and relapse prevention (RP).
10659|NCT04109118|Behavioral|Relaxation Therapy|Relaxation Therapy (RT), has been utilized in previous trials involving anxiety disorders and BZD discontinuation. In addition to providing non-specific support through therapist contact, it provides psychoeducation about BZD use in OAT and progressive muscle relaxation training. The relaxation training includes training and review of progressive muscle-relaxation procedures in session and at home.
10660|NCT04109118|Drug|BZD discontinuation protocol|All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 8 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
10661|NCT04109105|Other|NHS-PEG coated collagen patch|Analysis of the number and seriousness of leaks in the ileocolic anastomosis after using a NHS-PEG coated collagen patch reinforcement.
10662|NCT04109092|Drug|E7766|E7766, solution, intravesically.
10663|NCT04109079|Procedure|Axillary lymph node dissection|Participants will undergo removal of at least level I and II axillary lymph nodes.
10664|NCT04109079|Radiation|Axillary radiotherapy|Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
10665|NCT04109079|Radiation|Breast or chest wall radiotherapy|Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.
10673|NCT04109040|Device|slit lamp|diagnostice device to examine anterior segment of the eye and for fundus examination
10674|NCT04109027|Behavioral|BrainStrong-GSR|Goal-directed State Regulation Training (GSR)
10675|NCT04109027|Behavioral|BrainStrong-OPT|Optimization of Brain Functioning (OPT)
10676|NCT04109014|Other|FASTLANE II|"The intervention will consist of nine weekly hour-long individual counseling sessions. The FL II sessions utilize a combination of Cognitive Behavioral Therapy (CBT) and Motivational Interviewing (MI) to reduce sexual risk behaviors and mental health symptoms. Thus, individuals develop a toolbox for mood self-management to improve emotional self-regulation and reduce maladaptive coping mechanisms to minimize drug and sex risk behavior. Participants will be considered as completing the FASTLANE Intervention upon completion of the nine weeks of sessions."
15543|NCT04069273|Drug|Pembrolizumab Monotherapy|Pembrolizumab 200 mg IV
10679|NCT04108975|Procedure|Rectus muscle reapproximation during CS|Reapproximation by 3 interrupted simple sutures or 3 vertical mattress sutures.
10680|NCT04108975|Procedure|Rectus muscle non reapproximation during CS|During CS rectus muscle non reapproximation will be done.
10681|NCT04108962|Drug|Fasenra, 30 Mg/mL Subcutaneous Solution|Anti-IL5 receptor alpha monoclonal antibody
10682|NCT04108949|Behavioral|Tuning in to Kids|A psychosocial intervention focusing on emotion socialization and emotion coaching.
10683|NCT04108949|Behavioral|Treatment as usual|See description included in arm/Group description.
10684|NCT04108923|Device|Ligasure|the vessel sealing device ( ligasure covidien ) which seals vessels by fusing the inner layers of the vessel wall
10685|NCT04108923|Procedure|Conventional vessel ligation|Conventional vessel ligation either tying and /or clipping of blood vessels
10686|NCT04108910|Diagnostic Test|Guidance UTI|
10687|NCT04108897|Drug|Doxycycline|The investigators will administer doxycycline to rosacea patients according to the dose of patients' assigned study arm.
10688|NCT04108897|Drug|Ivermectin Topical|1% topical ivermectin.
10689|NCT04108884|Device|App measurement|App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations
10690|NCT04108884|Device|14 day Holter ECG|14 day moblie patch Holter ECG for AF confirmation
10691|NCT04108871|Procedure|Prostate Biopsy|Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
10692|NCT04108858|Drug|Copanlisib|Given IV
10693|NCT04108858|Biological|Pertuzumab|Given IV
10694|NCT04108858|Biological|Trastuzumab|Given IV
10695|NCT04108845|Biological|15-Valent Pneumococcal Conjugate Vaccine|3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
10696|NCT04108832|Drug|TCM OA2|Usage: 3g twice daily
10697|NCT04108832|Drug|PLACEBO|Usage: 3g twice daily
10698|NCT04108819|Dietary Supplement|Ketogenic Diet|Subjects will undergo ketogenic diet at a 2.5:1 (fat: carb + protein) ratio for a 2-week period.
10699|NCT04108806|Procedure|Endovascular therapy|Ballon dialtation of the diseased artery
10700|NCT04108793|Other|Physiotherapy exercises|The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
10701|NCT04108780|Device|T-tube|T shaped tube used as stent after CBD exploration
10702|NCT04108767|Behavioral|Answer to standardized questionnaires in quality of life, health, lifestyle and behaviors|"The cross-sectional study will be conducted in all students in health sciences in 3rd year enrolled at the University Claude Bernard Lyon 1 (UCBL) and participating at the required medical consultation at the college Health Department of UCBL, over a period of 9 months.~The self-questionnaires will be completed by the students during the mandatory medical preventive visit at the university health center.~All dimensions investigated by the questionnaire are usually questioned by the caregivers during the consultation as part of the usual follow-up of students."
10703|NCT04108754|Other|microangiopathic burden|to determine the value of the global microangiopathic burden on the prediction of early stroke risk in a homogeneous cohort of TIA.
10704|NCT04108741|Device|C-Mill augmented reality treadmill training|PD Patients will be randomized to treadmill AR training (C-Mill) or treadmill training (C-Mill) for 3 weeks at 5 days a week for 30 minutes.
10706|NCT04108715|Procedure|Erector spina plain block for mastectomy analgesia|After giving general anesthesia, patient is positioned in lateral decubitus with the surgical side up, An erector Spina plain block is performed with inserting block needle (Pajunk, Geisingen, Germany) in-plane under ultrasound control until needle tip hits the transverse process, a volume of 0.3 ml/kg of bupivacaine 0.25% (Marcaine, Astra Zeneca Pharmaceuticals) is injected. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia (PCA) for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10) and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to post-anesthesia care unit PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
10707|NCT04108715|Procedure|Deep serratus anterior plane block|After giving general anesthesia, the patient is positioned in lateral decubitus, with the surgical side up. The upper arm is abducted and elevated above the head level. A block needle is introduced in-plane, targeting the plane deep to the serratus anterior muscle, and a bolus of 0.3 ml/kg bupivacaine 0.25% is injected through ultrasound guidance. Pain management assessment and analgesic consumption will be provided through patient-controlled analgesia PCA for 24 hours. The PCA pump is programmed to deliver 1 mg morphine bolus per press with a lockout interval of 10 min. Pain scores will be measured using eleven points numerical rating scale NRS (0 to 10), and opioids consumption will be documented at 0, 1, 4, 8 and 24 hours. Time of admission to PACU is considered 0 hours. Any opioid equivalents given during the first 24 hours to manage breakthrough pain will be documented
10708|NCT04108702|Device|Virtual reality heart|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off SYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
10739|NCT04108442|Behavioral|Virtual|Surgeons (rather than individual subjects) will be randomized to virtual postoperative follow-up modality group. They will adhere to that form of postoperative follow-up for all of their surgical patients (subjects) for one month.
10740|NCT04108429|Behavioral|IntelliCare for College Students|Participants will receive access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
10709|NCT04108702|Device|Virtual reality control|"Patients will either sit or stand while wearing a head mounted display (HMD, Oculus Rift). A 360° video, showing a neutral body from the back in a neutral room, will be projected onto the HMD.~We will record the patients' ECG throughout the entire experiment. Raw data (ECG) are acquired with Arduino and in-house software will detect, in real time, the peak of each R-wave from the recorded ECG data and trigger an additional visual stimulus (e.g. a flashing outline surrounding the virtual body) that flashes on and off ASYNCHRONOUSLY with respect to the participant's heartbeat. The silhouette surrounding the virtual body flashes for a duration of 100ms and with a sinusoidal opacity."
10710|NCT04108702|Other|Standard therapy|Standard multimodal out-patient therapy program (psychological support, physiotherapy, ergotherapy).
10711|NCT04108689|Behavioral|I-ACT|An internet-based behavioral psychotherapy intervention to enhance athletic performance in elite ice hockey players.
10712|NCT04108676|Drug|Fluzoparib|PARP inhibitor
10713|NCT04108676|Drug|Omeprazole|proton pump inhibitor
10714|NCT04108663|Behavioral|Effect of tDCS on cognitive control task performance|Added verum or sham tDCS while working on a cognitive control task.
10715|NCT04108650|Other|Fit & Strong! group|Consistent with the original format of F&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
10716|NCT04108637|Procedure|penicillin allergy assessment pathway|"Summary of penicillin allergy assessment pathway :~Stage-1 PAAP in Primary Care - Clinical History. Screening, questionnaire and antimicrobial history will be undertaken in primary care Stage-2 Skin Test(ST) in hospital clinic (this may not be needed for all participants) Stage 3 Oral Challenge Test (OCT) in hospital clinic Testing will involve half a day in clinic and then a three-day post clinic course of oral antimicrobial therapy, without a reaction"
10717|NCT04108624|Other|Screening Phase|This will identify subjects who are MRD (minimal residual disease) negative and eligible for the discontinuation phase.
10718|NCT04108624|Device|Discontinuation Phase|Patients will undergo discontinuation of their maintenance therapy if they are MRD negative by PET/CT (Positron Emission Tomography/Computed Tomography), flow cytometry and next generation sequencing
10719|NCT04108611|Procedure|hemodiafiltration with endogenous re infusion (HFR)|hemodiafiltration with endogenous re infusion (HFR) for cases 2
10720|NCT04108598|Other|Quality of life questionnaire|No intervention will be administered, select sites will administer a quality of life questionnaire
10721|NCT04108585|Procedure|HFO therapy|HFO therapy from mechanical ventilation
10722|NCT04108585|Procedure|CPAP therapy|CPAP therapy from mechanical ventilation
10723|NCT04108572|Behavioral|Infant feeding|Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
10724|NCT04108559|Procedure|Kinesiologic Tape Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into five equal strips (approximately 0.5 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
10725|NCT04108559|Procedure|Surgical Drain Group|A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
10726|NCT04108559|Other|Control Group|Routine third molar extraction will be performed. No extra procedures will be done after surgery.
10727|NCT04108546|Device|Electroacupuncture device|The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% & low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.
10728|NCT04108546|Drug|Epidural analgesia|Ropivacaine (Naropeine) 0.2%, 5-7% ml, and Fentanyl 25mcg
10729|NCT04108533|Behavioral|Text-Based Support|Text-based breastfeeding support as described in arm/group descriptions
10730|NCT04108520|Other|Exercise|Exercise with respiratory training
10731|NCT04108507|Procedure|posterior branch block of spinal nerve|posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
10732|NCT04108494|Procedure|Type of omentectomy|Partial omentectomy with preservation of the greater omentum at >3 cm from the gastroepiploic arcade.Control group with total omentectomy.
10733|NCT04108481|Drug|Durvalumab|Immunotherapy
10734|NCT04108481|Radiation|Yttrium-90 RadioEmbolization|Microscopic radioactive particles (TheraSphere®) will be used for radioembolization to deliver the Y90 drug to the liver
10735|NCT04108468|Drug|Golimumab|Simponi
10736|NCT04108468|Drug|Methotrexate|Methotrexate
10737|NCT04108455|Other|Specimens Collected|Serum will be collected from patients at multiple times during pregnancy for later analysis.
10738|NCT04108442|Behavioral|Traditional|Surgeons (rather than individual subjects) will be randomized to traditional Postoperative follow-up modality groups. They will adhere to this form of postoperative follow-up for all of their surgical patients (subjects) for one month.
14658|NCT04076618|Behavioral|Resistance Exercise Training|Structured exercise training 3 days a week
10741|NCT04108416|Procedure|Cleft lip and palate repair|The intervention is the currently used cleft lip and palate repair technique at the University Hospital Basel and University Childrens Hospital Basel
10742|NCT04108403|Other|Pain Inducing Massage|A pain inducing massage (pain intensity = 50/100) will be applied for 60 seconds, 4 times.
10743|NCT04108403|Other|Pain Free Massage|A pain free massage (pain intensity = 0/100) will be applied for 60 seconds, 4 times.
10744|NCT04108403|Other|Positive Expectation Instructional Set|Participants will be instructed that the massage is effective for some people with neck pain.
10745|NCT04108403|Other|Negative Expectation Instructional Set|Participants will be instructed that the massage is ineffective for some people with neck pain.
10746|NCT04108390|Other|Dry needling|For this intervention, the physiotherapist will be placed a needle in the gluteus medius trigger point from 8 to 15 times.
10747|NCT04108377|Drug|Roflumilast|Roflumilast capsule
10748|NCT04108377|Drug|Placebo|Sugar pill manufactured to mimic look of Roflumilast capsule
10749|NCT04108364|Behavioral|Voice adaptive training for aphasia|Training with the VoiceAdapt tablet-based therapy app 25 hours (1 hr/day x 5 days/week x 5 weeks)
10750|NCT04108351|Other|Road-tracking test|Driving with simulator program for SDLP measurement
10751|NCT04108351|Other|Car-following test|Intervention Description: Driving with simulator program for DCV measurement
10752|NCT04108351|Other|Harsh-braking test|Driving with simulator program for BRT measurement
10753|NCT04108338|Other|Trial setting|Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
10754|NCT04108325|Drug|YY-20394|YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
10755|NCT04108312|Diagnostic Test|Anatomical MRI Scan|T1-weighted (T1w) magnetization prepared rapid gradient echo (MPRAGE) sequence (TR=8.776 milliseconds, TE=3.656 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution) and T2-weighted (T2w) CUBE sequence (TR=61.803 milliseconds, TE=3200 milliseconds, flip angle=8°, matrix=320x320, 0.8mm3 resolution)
10756|NCT04108299|Behavioral|Wait-list control group|For patient participants, they will continue to receive the standard of usual care for their T2D at the CBWCHC during the course of our study. For family/friend participants, they will continue to receive their routine care with their own doctors during the study. At the end of the study, the wait-list control group (both patient and family/friend participants) will be provided the opportunity to receive the counseling videos delivered to them via SMS links.
10757|NCT04108299|Behavioral|SMS intervention|2-3 SMS-based diabetes videos will be sent to patients each week for 12 weeks (each video within 10 minutes in duration) to both patients and their family members. Patients and their family members will receive the same intervention videos, including basic information about T2D, importance of diabetes self-management at home, behavioral techniques, and family-oriented sessions. BrainShark will be used to determine whether participants view these,videos. For participants who miss 3 consecutive videos, the study team will follow-up with a phone call to identify barriers to watching the video and remind them to review the video.
10758|NCT04108286|Device|1-DAY ACUVUE MOIST|TEST
10759|NCT04108286|Device|DAILIES AQUA COMFORT PLUS|CONTROL
10760|NCT04108273|Behavioral|Organizational Skills Training|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
10761|NCT04108273|Behavioral|Waitlist|Will undergo two magnetic resonance imaging (MRI) sessions separated by a 12 week wait period. Will then undergo OST treatment
10762|NCT04108260|Drug|Albutrepenonacog Alfa 1 UNT [IDELVION]|Clinical data will be collected from patients who suffered from hemophilia B, and switch from other FIX products to Idelvion as prophylaxis, prevention of bleeding (e.g. surgery) or treatment of bleeding.
10763|NCT04108247|Drug|Abiraterone+SHR3162|Participants will receive Abiraterone combined with SHR3162 orally
10764|NCT04108234|Drug|HR071603|HR071603 monotherapy ,nasal spray
10765|NCT04108234|Drug|placebo|placebo,nasal spray
10766|NCT04108221|Procedure|laparoscopy or laparotomy withTransversusAbdominis Plane Block|"The US-TAP is performed by the anesthetist under ultrasound control after the end of the procedure of laparoscopy or laparotomy. Under sterile conditions, the anesthetist identifies the oblique abdominal muscles externally, obliquely internally and transversely by ultrasound. A 20 ml needle of 0.5% ropivacaine is injected.~The surgical TAP (c-TAP) block is performed by the surgeon at the end of the procedure of laparoscopy or laparotomy.The needle and the product used are identical to those of the us-TAP block. The positioning of the needle is in the plane of the fascia between the internal oblique muscle and the transverse muscle, identified by a significant loss of resistance."
10767|NCT04108208|Drug|Apalutamide|Apalutamide 240 mg (4*60 mg tablets) will be administrated orally once daily.
10768|NCT04108208|Drug|Placebo|Matching placebo will be administered orally.
10769|NCT04108208|Drug|Androgen-deprivation Therapy (ADT)|Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
10770|NCT04108195|Drug|Daratumumab|Participants will receive daratumumab SC.
10771|NCT04108195|Drug|JNJ-64407564|Participants will receive JNJ-64407564 IV.
10772|NCT04108195|Drug|JNJ-64007957|Participants will receive JNJ-64007957 IV.
10773|NCT04108169|Procedure|Left atrial appendage occlusion surgery|CABG according to indications in the current guidelines on myocardial revascularization including surgical closure of left atrial appendage
10774|NCT04108156|Drug|PDS Implant Pre-Filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
10775|NCT04108156|Drug|Intravitreal Ranibizumab 0.5 mg Injection|Will be administered as per the schedule described in individual arm.
10876|NCT04107415|Other|yoga|A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
10877|NCT04107402|Other|Platelets Acetyl-CoA Carboxylase phosphorylation analysis|Blood sample Urine Sample
15544|NCT04069273|Drug|Ramucirumab|Ramucirumab 8 mg/kg IV
10776|NCT04108143|Device|MonitorMe|MonitorMe replaces the users existing telephone and for the majority of time is used as their ordinary telephone. At a known and set time of day for 4 weeks, participants will receive an automated MonitorMe telephone call. The participant answers a health and well-being automated script by pressing key pad numbers. At the same time vital signs data are collected. The responses and vital signs data, together with confidence values are then transmitted via telephone lines to an electronic patient record.
10777|NCT04108130|Other|Preoperative Education|Brochure and video about relevance of postoperative pulmonary complications, postoperative mobilization and use of incentive spirometry.
10778|NCT04108130|Procedure|Intraoperative PEEP Individualization|PEEP will be set by maximizing respiratory system compliance along a decremental PEEP titration following an incremental recruitment maneuver.
10779|NCT04108130|Other|Individualization of Neuromuscular Blockade|Administration of neuromuscular blocking agents and their reversal will be done based on established protocol.
10780|NCT04108130|Procedure|Postoperative Incentive Spirometry|Patients will be encouraged to adhere to incentive spirometry to be started 2 hours after surgery and maintained until patient freely ambulates. Supervision will be provided 3 times/day for continuous education and management of barriers to optimal performance.
10781|NCT04108130|Behavioral|Postoperative Ambulation|Patients will be encouraged to adhere to prescription of early ambulation.
10782|NCT04108117|Procedure|Robotic nipple sparing mastectomy|Robotic nipple sparing mastectomy means nipple sparing mastectomy performed using robotic surgical systems.
10783|NCT04108104|Drug|Cyproheptadine|3-month treatment
10784|NCT04108104|Drug|Alpress LP|3-month treatment
10785|NCT04108091|Drug|Treatment for TTR amyloidosis|The usual adult dose is 80 mg of Tafamidis Meglumine orally once daily. The dose may be reduced if not tolerated.
10786|NCT04108078|Behavioral|A multi-level stigma-reduction intervention|This intervention is a population-based multi-level stigma-reduction intervention. At the intrapersonal level MSM will attend a retreat and complete sessions related to intersectional stigma and HIV. At the interpersonal level MSM will receive a phone-based peer support service. At the organizational level HCF staff will receive training on intersectional stigma within HCFs.
10787|NCT04108052|Radiation|Low CT scanner without injection dose|CT scan acquisition will be performed at 140 kVp (kilovolt peak), 10 mAs(milliampere), CTDI 1.3 mGy with an irradiation dose 0.51 mSv (milliSievert). The CT image will be reconstructed and analyzed in parenchyma window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
10788|NCT04108052|Radiation|Ultra-low dose CT scanner without injection|CT acquisition will be performed at 80 kVp for patient with a body mass index<30, and 100 kVp with a body mass index>30, 10 mAs, CTDI 0.3 and 0.6 mGy with an irradiation dose 0.15-0.30 mSv. The CT images will be reconstructed and analyzed in mediastinal window. The CT images will be blinded and re-read by two independent senior radiologists 3 to 6 weeks apart between each re-reading.
10789|NCT04108039|Drug|GnRh antagonist|In the antagonist cycle, LH suppression will be accomplished by subcutaneous (SC) injections of 0.25 mg of Cetrorelix or Ganirelix starting in the presence of follicles >14mm or E2 levels >400 pg/ml and continuing until ovulation triggering to avoid LH surge in COS
10790|NCT04108039|Drug|Micronized progesterone|Micronized progesterone protocol to avoid LH surge in COS, from stimulation day 1 and continuing until ovulation triggering.
10791|NCT04108026|Drug|Durvalumab|1500 mg IV every 4 weeks
10792|NCT04108013|Drug|SHR-1210|In the experimental group, 200mg SHR-1210 was given in the first day of each cycle, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
10793|NCT04108013|Drug|Carboplatin and Paclitaxel-albumin|In the control group, Carboplatin was given in the first day of each cycle, Paclitaxel-albumin was given in the first and eighth day of each cycle, with intravenous drip.
10794|NCT04108000|Behavioral|SPIRIT-Dementia|"The interventionist will begin the SPIRIT-dementia session by assessing the patient's and surrogate's cognitive, emotional, and spiritual/religious representations of the patient's illness, prognosis, and end-of-life care. Individualized information will be provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the patient will examine their values about life-sustaining treatment at the end of life. The interventionist will help the surrogate prepare for end-of-life decision-making and for the emotional burden of decision-making. A Goals-of-Care document will be completed at the end of the session. The delivery of SPIRIT-dementia incorporates enhanced consent techniques, such as reducing information load by proceeding in manageable segments, offering repetition of material, opportunity for rehearsal, and using targeted questioning to verify adequate comprehension prior to eliciting preferences for goals of care."
10795|NCT04108000|Behavioral|Usual Care|As required by Centers for Medicare and Medicaid Services (CMS) written information on advance directives is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an advance directive.
10796|NCT04107987|Dietary Supplement|Reglicem|Reglicem is a nutraceutical containing Berberine, Curcumin, Inositol, Banaba, and Chromium Picolinate
10797|NCT04107987|Other|Placebo|Placebo
10798|NCT04107974|Device|Gastropexy.|Two T-fasteners for G-tube insertion (gastropexy).
10799|NCT04107974|Procedure|Non-Gastropexy|Insertion of G-tube in absence of T-fasteners.
10800|NCT04107961|Biological|Vaccine|Single intramuscular injection into the deltoid region
10801|NCT04107961|Other|Placebo|Single intramuscular injection into the deltoid region
10802|NCT04107948|Other|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42), Haute-Loire (43) or Ardèche (07) for 2 months."
10803|NCT04107948|Other|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
10878|NCT04107389|Behavioral|Art Psychotherapy, Art Therapy|Art Therapy is a form of psychotherapy, based upon the premise of utilising art materials as a form of expression and communication; the roots of the theoretical approach lie in a psychodynamic approach to working with the unconscious.
10879|NCT04107389|Behavioral|Wait List|Wait list control group. Participants randomised to Wait List group or Intervention group.
10804|NCT04107935|Behavioral|TREAT-ON|"TREAT-ON is a DE-driven self-management and support program that is delivered primarily through a real-time telemedicine videoconferencing platform. Like the usual care intervention, high risk patients with DM receiving care in underserved practices will be identified by a nurse practice-based manager (PCBM) and referred to a DE for self management services. Participants will complete an initial face-to-face visit with the DE to assess needs and develop a self-management treatment plan and goals. Via telemedicine videoconferencing, follow-up visits will be delivered by the DE to participants in their homes. Follow-up visits will be used to evaluate and support progress towards meeting and sustaining self-management goals and outcomes."
10805|NCT04107935|Behavioral|Usual Care|"A retrospective control group will be formed from individuals who have previously participated in a program called the Diabetes High Risk Initiative. In this program, patients receiving care in underserved practices are identified by a nurse PBCM to be at high risk for DM complications and/or unplanned care and referred to a DE for self management services delivered through primary care. Patients typically participate in one face-to-face visit with the DE to assess needs and develop self-management goals and then one to two follow-up encounters (generally conducted by telephone) with the PBCM or DE."
10806|NCT04107922|Dietary Supplement|Glicoset|Patients will take a nutraceutical containing Ilex Paraguariensis, White Mulberry and Chromium Picolinate
10807|NCT04107922|Other|Placebo|Patients will take placebo
10808|NCT04107909|Procedure|laparoscopic cholecystectomy|"Both four port and three port LC is performed With the patient in supine position, with the surgeon and assistant on the left side and the monitor on the right side. Head up and right up position is employed during surgery in both the groups. Pneumoperitoneum of 12mmHg is created using open Hassan's method through the umbilical port.~In 3 port a 5.5 mm umbilical visiport for 5 mm lens 30 degree A second 10 mm trocar is placed inferior to the sternum at the midline, while the third 5mm trocar is placed 4-5cm inferior to the right costal margin on the right midclavicular line. For the four port LC, additional 5mm port is placed in the sub costal region at the anterior axillary line. Posterior dissection and delineation of The Calot's triangle is done. Then, the cystic artery and cystic duct are identified, isolated, doubly clipped and divided. The gallbladder is removed through the umbilical port using a 10mm gallbladder extractor."
10809|NCT04107896|Drug|Silodosin|Cap silodosin
10810|NCT04107896|Drug|Tamsulosin|Cap tamsulosin
10811|NCT04107883|Biological|fresh frozen plasma|perform plasma transfusion in different phases during perioperation
10812|NCT04107883|Diagnostic Test|blood sample|get blood samples at several specific points in time during perioperation
10813|NCT04107870|Behavioral|Virtual Reality Exposure Therapy sessions|Female adolescents aged 13 to 18 are proposed virtual reality exposure therapy sessions, accompanied by a cognitive and behavioral therapy (CBT) therapist, to work on their body representations
10814|NCT04107870|Behavioral|Psychomotor therapy sessions|Psychomotor therapy sessions are proposed to female adolescents aged 13 to 18 years, ac-companied by a psychomotor therapist, to work on their body representations.
10815|NCT04107857|Behavioral|ELEVATE enhancement to electronic health record (EHR) to improve cessation counseling offer|"Brief advise to quit smoking~Referral to Missouri/Illinois Quitlines, Smokefree.TXT, or smokefree.gov"
10816|NCT04107857|Behavioral|ELEVATE enhancement to electronic health record (EHR) to improve smoking cessation medication offer|-Nicotine replacement therapy, varenicline, bupropion, or combination therapy (not provided by study)
10817|NCT04107857|Behavioral|Data Driven Feedback reports|-Feedback reports will be based on data
10818|NCT04107844|Diagnostic Test|Novel facilitating agility dual-task test combined with already known tests|We will investigate if a combination of a novel Dual-task test combined with already known tests can identify more athletes, not ready to return to play, although symptoms of concussion have stopped.
10819|NCT04107831|Other|Pulmonary rehabilitation|Pre-post test design
10820|NCT04107805|Drug|BI 1323495|Tablet
10821|NCT04107805|Drug|Placebo|Tablet
10822|NCT04107805|Drug|Midazolam|Oral administration
10823|NCT04107792|Behavioral|parental sense of competence workshop|The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.
10824|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Virginia Tobacco ENDS|JUUL 5%, ENDS for 6-days in confinement
10825|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Virginia Tobacco ENDS|JUUL 3%, ENDS for 6-days in confinement
10826|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Mint ENDS|JUUL 5%, ENDS for 6-days in confinement
10827|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Mint ENDS|JUUL 3%, ENDS for 6-days in confinement
10828|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Menthol ENDS|JUUL 5%, ENDS for 6-days in confinement
10829|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Menthol ENDS|JUUL 3%, ENDS for 6-days in confinement
10830|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 5% Mango ENDS|JUUL 5%, ENDS for 6-days in confinement
10831|NCT04107779|Other|Switch from UB of Combustible Cigarette to JUUL 3% Mango ENDS|JUUL 3%, ENDS for 6-days in confinement
10832|NCT04107779|Other|Switch to Dual-use of JUUL 5% and UB of Combustible Cigarette|Combination use of JUUL 5% (Virginia Tobacco, Mint, Menthol or Mango flavored) and usual brand combustible cigarettes for 6-days in confinement
10833|NCT04107779|Other|Tobacco/Nicotine Abstention|No smoking for 6-days in confinement.
10834|NCT04107779|Other|Usual Brand of cigarettes|Continue smoking UB for 6-days in confinement.
10835|NCT04107766|Device|Microwave Ablation|Patients who meet the eligibility criteria will undergo microwave ablation (MWA) with the NEUWAVE Microwave Ablation System with or without Ablation Confirmation of at least one soft-tissue liver lesion, in accordance with the study site's standard-of-care (SOC) practices.
10858|NCT04107597|Other|Core stabilization exercises and paced breathing training|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the CSE sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
10836|NCT04107753|Behavioral|Brief counseling based on the 5As model|"It is a structured brief counselling perfomed by nurse who takes clinical care of the patient and it is performed as follow:~ASK: every patient should be asked whether he/she is or is not a smoker;~ADVICE: the patient is advised to quit in a strong, clear and personalized way;~ASSESS: the patient is asked if he/she would like to quit and the strenght of his/her dependence is assessed.~ASSIST: The smoker interested in quitting are assisted in their attempts, for example by helping them to define a quit date, by advising them about strategies against withdrawal symptoms and by providing them information material; patients are asked whether they want to be contacted by the CTT.~ARRANGE: this step is only addressed to the patients who have started a treatment in the CTT and is expected to prevent or treat eventual relapses."
10837|NCT04107740|Drug|C-Trelin OD Tab(5mg Taltirelin Hydrate)|BID, 10mg per day, for 24 weeks
10838|NCT04107740|Drug|Placebo|BID for 24 weeks
10839|NCT04107727|Drug|Quizartinib|"Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
10840|NCT04107727|Drug|Placebo oral tablet|"Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days."
10841|NCT04107727|Drug|Cytarabine|"Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days."
10842|NCT04107727|Drug|Idarubicin|Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
10843|NCT04107714|Behavioral|STC|"The peer-led and web-based group program contains four lessons plus one booster session:~Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~Lesson 4: Telling your story: Participants learn how to tell their own story.~In a booster session, participants discuss their experiences with disclosure or non-disclosure."
10844|NCT04107688|Other|Control|Subjects will use plain water as an oral rinse twice a day for 3 days.
10845|NCT04107688|Other|CPE|Subjects will use a cranberry-derived oral rinse twice a day for 11 days.
10846|NCT04107675|Drug|Liposomal Cyclosporine A|Liposomal Cyclosporine A is administered with the PARI L-CsA eFlow Nebulizer.
10847|NCT04107675|Drug|Liposomal Placebo|Liposomal Placebo is administered with the PARI L-CsA eFlow Nebulizer.
10848|NCT04107662|Device|Tbit system|Suspected traumatic brain injury with head CT
10849|NCT04107649|Behavioral|Telephonic Active Coaching (Motivational Interviewing) + Financial Incentives|As part of TAC(MI)+FI, participants speak with a health coach at Brigham and Women's Hospital once a week via telephone for weeks 5-13 following surgery, and once every other week for weeks 14-31 after surgery. Participants in this arm can receive financial rewards for achieving weekly physical activity goals, as well as bonus rewards for achieving goals multiple weeks in a row. Over the course of this 6-month long TAC(MI)+FI intervention period, these participants are able to receive up to $680 for meeting physical activity goals, and up to $180 in bonus rewards.
10850|NCT04107649|Behavioral|Wrist based activity tracker wear|Participants who receive this intervention are eligible to receive $5/week for wearing a wrist-based activity tracker daily for 48-weeks ($240 total), beginning 6-weeks after surgery. Activity tracking data will be collected on a weekly basis.
10851|NCT04107649|Behavioral|Phone calls to provide information about general well being|From weeks 5-13 after surgery, participants receive weekly calls to provide educational information about improving general well-being. These calls occur once every other week for weeks 14-31 following surgery.
10852|NCT04107649|Other|Basic Study Activities|Basic study activities begin two-weeks before TKR and end approximately 24-months after TKR. Basic study activities include: two in-person visits at the local clinic site (2 weeks before TKR and 32-weeks after TKR), completing 6 surveys, and wearing an ActiGraph activity tracker (waist-worn) for five one-week periods throughout the study (2-weeks before-TKR, 32-weeks post-TKR, one-year post-TKR, 18-months post-TKR, two-years post-TKR). All participants will wear a wrist-worn activity tracker simultaneously with the ActiGraph 2-weeks before-TKR. All participants will be eligible to receive up to $235 for completing these activities over the course of two years.
10853|NCT04107636|Procedure|Vacuum assisted biopsy|First, the tumor will be removed under local anesthesia using the VAB system with US guidance, through a small skin incision (<0.5 cm). A localization marker will be placed in the biopsy cavity, to help determine the cavity location.
10854|NCT04107636|Procedure|conventional lumpectomy|After 3 weeks, the breast conserving surgery is performed, excising the VAB excision cavity and a ≥1 cm of surrounding tissue, as deemed appropriate by the attending breast surgeon. A sentinel node biopsy will be performed in the same procedure.
10855|NCT04107623|Diagnostic Test|Indocyanine Green|Using Q-ICG perfusion of the remaining Gastric Conduit will be compared
10856|NCT04107610|Device|I-PAS|I-PAS is a portable, head-mounted display goggle system with integrated eye tracking technology. I-PAS records eye movements in response to visual and auditory stimuli.
10857|NCT04107597|Other|Core stabilization exercises|Twelve specific exercises following a standard protocol aiming at an intersegmental stabilization of the spine and strengthening and stabilization of specific muscle groups. The exercises are performed under instruction and supervision by a physiotherapist twice per week for 45 minutes
10859|NCT04107597|Other|Myofascial trigger point release|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes
15545|NCT04069273|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV
10860|NCT04107597|Other|Myofascial trigger point release and paced breathing training|A standard protocol of 12 myofascial and trigger point release grips followed by so-called roll-down maneuvers and manual rhythmical oscillation, applied to specific muscles and muscle groups. The treatment is applied twice per week for 45 minutes. In addition, the participants practice paced breathing training (before and during the MTPR sessions as well as 15 minutes twice per day at home) which has a modulating effect on the autonomic nervous system
10861|NCT04107571|Procedure|A type of operation for coranary heart disease patients.|A type of operation for coranary heart disease patients.
10862|NCT04107558|Device|Virtual Reality|Subjects will undergo painful stimuli without HVR followed by a session with HVR. Subjects are their own control
10863|NCT04107545|Behavioral|athletes|Control of body temperature using the bodyCap temperature monitor that records body temperature for up to 48h (three times)
10864|NCT04107532|Other|Virtual Reality Therapy and Imagination Exposure Therapy|Virtual Reality Therapy and Imagination Exposure Therapy
10865|NCT04107519|Behavioral|Goal-Directed Resilience Training|This pilot study seeks to test the efficacy of a resilience skills training intervention for former football players who experience chronic pain. Between 20 to 48 eligible and consented participants from the Atlanta area will be identified (with a goal of 40 completing the study). They will undergo a pre-training test session and will then be randomized to either the Immediate GRIT (ImT) training intervention or the Delayed Training (DeT) control. The immediate (ImT) group will be trained for 4 weeks with 2 biweekly sessions. At the end of GRIT training they will be post-tested. The delayed (DeT) group wait during these 4 weeks and do not receive training. At the end of the 4-week waiting period, they will also be post-tested. At this point, they will be offered GRIT training for 4 weeks with 2 biweekly sessions. At the end of their training, they will be given a second post-testing. This process will then be repeated for two additional groups of 5-12 lmT and 5-12 DeT participants.
10866|NCT04107506|Behavioral|Filming Interactions to Nurture Development|FIND is a brief home-based video coaching intervention which involves feedback provided by the coach to the caregiver using brief film clips derived from video of caregiver-child interaction collected in the home. The coaching focuses on showing caregivers instances in which they are engaging in developmentally-supportive interactions during coaching sessions. FIND is delivered over 10 weekly home visits lasting 30-45 minutes. The process begins with an initial visit in which the coach provides an overview, records 10-15 minutes of caregiver-child interaction, then introduces the concept of serve and return. The video is edited to show brief clips in which the caregiver is engaged in the first of five specific caregiver-based components of serve and return. The next week, the FIND coach reviews the edited clips in detail with the caregiver. Sessions continue, alternating between filming and coaching sessions until all five components have been covered sequentially.
10867|NCT04107506|Behavioral|The Healthy Toddler Program|HTP, the active control intervention, consists of weekly home visits alternating between (a) coaching sessions covering one of five domains of child development (Motor, Cognitive, Language, Play, and Social-Emotional and (b) observation sessions that will include a review of the prior coaching session and an observation and discussion of the caregiver-child interaction. This intervention will consist of 10 home visits each lasting 25-30 minutes. The coach will not engage in any filming or video coaching, but will be able to discuss caregiving concerns. HTP materials are adapted from the Partners for a Healthy Baby curriculum developed by Florida State University's Center for Prevention and Early Intervention Policy.
10868|NCT04107493|Other|Six Minutes Walk Tests|"All participants entered into the study will be randomized in a 1:1 ratio to the following order of device use:~Control device (portable oxygen cylinder) first; or~Study device (Mobi™, POC) first."
10869|NCT04107480|Procedure|Endoscopic trans-sphenoidal adenoma resection|"Neurosurgical consultation consists of at least one consult with a neurosurgeon and at least one consult with an endocrinologist with relevant experience. If the multidisciplinary team (MDT) agrees the patient is a good surgical candidate, the patient is asked consent for surgery, as is a custom part of preoperative requirements. When the patient decides not to have the surgery, (s)he will receive standard medical treatment, but will continue study follow up in the intervention group.~Surgery only takes place if both the MDT and the patient agree to it and should then be planned within three months after randomization. Surgery is performed by one or two trained neurosurgeons in the hospital where the counseling took place. A standard, semi-protocolled, endoscopic trans-sphenoidal surgical resection of the prolactinoma is performed according to standard practice."
10870|NCT04107480|Drug|Dopamine Agonists|"The treating physician adheres to the treatment protocol in general, but has freedom to choose treatment to his/her ideas how to deliver best care.~Current first line treatment consists of a dopamine agonists: cabergoline (currently the most used), bromocriptine or quinagolide. All dopamine agonists are taken orally, and the dosage may be raised based on its effect. It is usually titrated to achieve a normal or suppressed prolactin level and restoration of the gonadal axis. Dopamine agonist treatment is discontinued after 2 years of treatment, unless a normal prolactin level cannot be achieved. The dopamine agonist is restarted when prolactin levels rise after the medication is discontinued.~In standard care, surgical treatment is reserved for patients who don't tolerate medication, or whose adenoma fails to show a sufficient response. Patients in the control group with an intolerance for dopamine agonists or an insufficient response may be offered surgery as part of standard care."
10871|NCT04107454|Device|Active microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Active application of laser radiation on the vulvar skin. The laser setting is: Power 24 W, exposure time 400 microsec, density 6,4 %, pulse energy 23,2 mJ, fluenz 1,18J/cm2, emission mode DP, DOZ Dwell 400, DOT spacing 1000.
10872|NCT04107454|Device|Sham microablative fractional CO2 laser designed as SmartXide Touch C60, CO2 laser system for MonaLisa Touch, DEKA, Florence|Sham application of laser radiation on the vulvar skin. Laser setting is a sham dose:power 0, 5 W, exposure time 400 microsec, DOT spacing 1000
10873|NCT04107441|Drug|AX-8|Orally disintegrating tablets (ODTs) of four strengths (5, 10, 20 and 40 mg AX-8).
10874|NCT04107428|Drug|Somatostatin|A bolus of 5cc of saline containing 500 mcg of somatostatin will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 250 mcg per hour of somatostatin (infusion rate 2.5 cc/hour) for 10 days.
10875|NCT04107428|Drug|Placebo|A bolus of 5cc of saline will be administered intravenously after graft reperfusion (after portal and arterial anastomosis) over a 2 minutes period, followed by a continuous infusion of 2.5 cc of saline/hour for 10 days.
10880|NCT04107376|Diagnostic Test|Retroviewing endoscopy|The colon is inspected with a new retroviewing endoscope
10881|NCT04107363|Procedure|Oropharyngeal aspiration before changing the position of the patient|"Patients in the experimental group underwent oropharyngeal aspiration prior to each position change in addition to routine nursing care (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).~Patients in this group underwent oropharyngeal aspiration at least 9 times in 24 hours with a pressure of 100-120 mmHg for 10 seconds prior to routine (2 hours a day, 4 hours a night) and non-routine position changes. After the oropharyngeal aspiration was completed, the patient's position was changed."
10882|NCT04107363|Other|Control group:|The patients in the control group received routine nursing care in the unit. (Endotracheal aspiration in case of indication and oropharyngeal aspiration in the follow-up; routine and non-routine position changes every 2 hours during the day and 4 hours during the night; oral care).
10883|NCT04107350|Device|whole-body vibration|10 minutes WBV exercise in standing position; amplitude 2mm,; frequency 4-10Hz; resting interval: 3 minutes rest.
10884|NCT04107337|Other|Vocal work session with straw exercises|"Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~Vocal exercises during 20 minutes : (2 minutes) Checking the posture ; (3 minutes) Control of the management of breath in the straw ; (3 minutes) Phonation in the straw ; (3 minutes) Make a siren in the straw ; (9 minutes) Vocalizations in the straw on the arpeggio of Rossini.~This working session will be preceded and followed by the same 20-minute voice assessment focusing on aerodynamic parameters."
10885|NCT04107337|Other|Vocal work session with open mouth exercises|"Voice assessment: A questionnaire on the subject's voice biography will be sent to the subject at the moment of inclusion.~Vocal exercises during 20 minutes : (2 minutes) Checking the posture ; (3 minutes) Control of the management of breath on a [f] with open mouth ; (3 minutes) Phonation on the vowel [a] with open mouth ; (3 minutes) Make a siren on the vowel [a] with open mouth ; (9 minutes) Vocalizations on the vowel [a] on the arpeggio of Rossini with open mouth.~This working session will be preceded and followed by the same 20-minute voice assessment focusing on aerodynamic parameters."
10886|NCT04107324|Procedure|ARAPS|In a previous experimental study on rats, the investigators have shown that PVE combined with radiofrequency ablation (RFA), hereafter called Associated Radiofrequency Ablation and Portal Vein Ligation for Staged Hepatectomy (ARAPS), can induce accelerated growth of the FLR
10887|NCT04107324|Procedure|PVE|Portal vein embolisation
10888|NCT04107298|Device|SUNDANCE™ Drug Coated Balloon|Angioplasty procedure with a sirolimus-coated, percutaneous transluminal angioplasty (PTA) balloon catheter
10889|NCT04107285|Behavioral|neurocognitive evaluations|The test battery consists of validated and reliable measures of attention, executive functions and memory.
10890|NCT04107285|Diagnostic Test|brain MRIs|Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).
10891|NCT04107285|Other|Blood samples|Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
10892|NCT04107272|Device|Real repetitive transcranial magnetic stimulation|"The real rTMS will be delivered over M1 (hand representation) of dual hemispheres with 10 trains of 10 Hz pulses for 10 seconds, with a total of 1,000 pulses per hemisphere. The real rTMS intensity will be set as 80% resting motor threshold and the interval between each train of pulses will be set as 50 seconds. The real rTMS will be delivered as daily session for five consecutive days, followed by two fortnightly maintenance sessions during the follow-up period after the completion of five daily sessions. The real rTMS will be delivered by designated physical therapists using figure-of-8 shaped coil."
10893|NCT04107272|Device|Sham repetitive transcranial magnetic stimulation|The sham rTMS of this study will be delivered with the same active coil angled 90-degree way from the scalp. The intensity of sham rTMS will be set at lowest stimulator output that can generate similar noise to the real rTMS. The sham rTMS will be delivered in the same manner and duration with real rTMS.
10894|NCT04107259|Diagnostic Test|Blood sample|Ten ml of venous blood was collected from all participants in the early morning after an overnight 12 hour fast by venipuncture of the antecubital vein into sterile tubes. Plasma and sera were separated immediately and were stored at -70 C until biochemical analyses.
10896|NCT04107233|Behavioral|Audit and Feedback|Charts for enrolled physicians will be audited and they will receive feedback, consisting of tailored reports and one-on-one meeting with colleague to review at baseline, 3 months and 6 months
10897|NCT04107220|Drug|Sacubitril/Valsartan|Effect of Sacubitril/Valsartan on BNP and NT-proBNP
10898|NCT04107207|Dietary Supplement|Ginger Kombucha|Craft Ginger Kombucha, a fermented black tea
10899|NCT04107207|Dietary Supplement|Ginger Water|Placebo
10900|NCT04107194|Drug|Pantoprazole 40mg|Proton pump inhibitor
10901|NCT04107194|Drug|Amoxicillin 1000 MG|Antibiotic
10902|NCT04107194|Drug|Clarithromycin 500mg|Antibiotic
10903|NCT04107194|Drug|Metronidazole|Antibiotic
10904|NCT04107194|Drug|Tetracycline 125 MG|Antibiotic
10905|NCT04107194|Drug|Bismuth Subcitrate|Antibiotic adjuvant
10906|NCT04107194|Drug|Rifabutin 150 MG|Antibiotic
10907|NCT04107194|Drug|Levofloxacin 500mg|Antibiotic
10908|NCT04107181|Device|"Introducer calla device"|The research introducer will be used after the patient consents prior to the annual pap smear.
10909|NCT04107181|Behavioral|Interviews only|Healthy volunteer interviews
10910|NCT04107168|Drug|Nivolumab|A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
10911|NCT04107168|Drug|Pembrolizumab|A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
10912|NCT04107168|Drug|Ipilimumab|A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
10913|NCT04107168|Drug|Durvalumab|A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
10914|NCT04107168|Drug|Tremelimumab|A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
10915|NCT04107168|Drug|Atezolizumab|A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
10916|NCT04107168|Drug|Bevacizumab|A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
10917|NCT04107155|Dietary Supplement|Weight Management Formulation|Saffron extract and Gynostemma extract with hesperidin
10918|NCT04107155|Dietary Supplement|Placebo|Placebo
10919|NCT04107155|Other|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
10920|NCT04107155|Other|Handout with Suggestions for Healthy Eating and Overall Health|Suggestions for Healthy Eating and Overall Health
10921|NCT04107142|Biological|Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell|Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
10922|NCT04107129|Procedure|Endometrial Biopsy|An endometrial biopsy is the removal of a small piece of tissue from the endometrium, which is the lining of the uterus. Endometrial tissue will be tested for BCL6 and SIRT1 Biomarkers
10923|NCT04107129|Other|Euploid embryo transfer|Patients undergoing IVF and Preimplantation genetic testing will undergo delayed euploid frozen embryo transfer per clinical protocol and standard of care.
10924|NCT04107116|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
10925|NCT04107116|Other|Usual Care|Usual care as provided by local oncologists
10926|NCT04107103|Drug|Combination Product: Nivolumab with Pemetrexed|Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
10927|NCT04107090|Other|lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome
10928|NCT04107090|Other|tracheal IL-6 level|tracheal IL-6 level was measured before and after recruitment maneuver
10929|NCT04107090|Other|US guided lung recruitment maneuver|Lung recruitment maneuver done for ventilated preterm neonates diagnosed with respiratory distress syndrome guided by lung ultrasound
10930|NCT04107077|Drug|Cisplatin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 200mg of Cisplatin
10931|NCT04107077|Drug|Mitomycin|Laparoscopic HIPEC will be performed at a maximum of two (2) times spaced approximately 6 weeks apart. The dosing of the drugs will be the same during each administration but adjusted if needed based on lab work. The typical dosages are 30mg of Mitomycin C.
10932|NCT04107064|Behavioral|NaW|Participants will receive assistance with finding employment, onboarding, training, and so on.
10933|NCT04107064|Behavioral|NaW-DS|Participants will receive assistance with onboarding and training 6 months after the initiation of their employment.
10934|NCT04107051|Drug|Nalmefene Hydrochloride Hydrate|Oral administration of nalmefene hydrochloride hydrate
10935|NCT04107038|Procedure|General Endotracheal Anesthesia|Participants receive general endotracheal anesthesia for the procedure, as well as analyzing the information from their transesophageal echocardiography per routine clinical care.
10936|NCT04107038|Procedure|Monitored anesthesia care|Participants receive monitored anesthesia care for their procedure.
10937|NCT04107025|Other|HELP|Individual counseling were given to each intervention group participant. They were assisted with safety, emotional and mental support and referrals for health and financial assistance. Participants were also given handout to manage anxiety and panic situations during the legal procedures.
10938|NCT04107012|Device|Orthodontic treatment with clear aligner|Included orthodontic treatment with clear aligner (eon Aligners)
10939|NCT04106999|Drug|Dexmedetomidine|Drug infusion will be delivered intra-operatively
10940|NCT04106999|Drug|Placebos|Normal Saline will be infused as a control drug
10941|NCT04106986|Combination Product|PEMF and PRE|"The pulsed electromagnetic field treatment consist of 30 minutes pulsed electromagnetic field with 50 Hz pulses~The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
10942|NCT04106986|Other|PRE|"The progressive resistance exercise training consist of 45 minutes of progressive resistance exercise protocol as the following:~The PRE session begun with warm-up exercises that included riding a stationary ergometer for 5 minutes followed by stretching exercises for the hamstrings, quadriceps and gastrocnemius muscles. After this, subjects performed non-weight bearing (open chain) and weight bearing (closed chain) quadriceps exercises.~The amount of resistance and number of repetitions for each exercise are based on a modification of the daily adjustable progressive resistance exercise (DAPRE) program that was described by Knight eta al."
10943|NCT04106960|Other|No Intevention Used|N/A as in the study does not have intervention in place. It is exploring the relationships between the social and physical features of the environment and participation through using standardized outcome measures.
10944|NCT04106947|Other|Questionnaires|Questionnaires
10972|NCT04106700|Drug|Apixaban 2.5 MG|Apixaban will be started simultaneously with anti myeloma treatment on day 1 of cycle 1 of VTD, and continues for 4 to 6 months depending on the number of induction cycles administered to the patient
10973|NCT04106687|Procedure|Ultrasound Guided Caudal Block|Postoperative pain procedure
10945|NCT04106921|Other|Universal Health Coverage Mode|"In the intervention arm, the CHW's household list will appear differently within the app in the following ways:~The CHW will be able to filter and order households by the date of the most recent home visit.~A color-coded visual icon will display the number of home visits in the past month for each household.~A red exclamation mark will be displayed for every household that has not reached 2 visits in the past month (default at the start of every month).~Text displayed below each household showing the date of last visit will turn red if more than 30 days have passed since last visit. When more than 60 days have passed since the most recent visit, the text displayed below each household showing the date of last visit will be changed to date of last visit is unknown in red.~The family profile will also contain the date of last visit, and the visits they have received in that month"
10946|NCT04106908|Biological|Eqwilate|Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
10947|NCT04106895|Drug|Fibryga|Fibryga
10948|NCT04106882|Drug|Ketones|Supplement administered mid-scan.
10949|NCT04106882|Drug|Glucose|Supplement administered mid-scan.
10950|NCT04106869|Other|Hyperventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (<35 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
10951|NCT04106869|Other|Hypoventilation|"Ventilatory settings will be the following:~6-8 ml/kg and Respiratory rate adjusted to the required ETC02 (40-45 mmHg) PEEP in order to ensure a driving pressure (P plateau- PEEP) below 15 mmHg."
10952|NCT04106856|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
10953|NCT04106856|Drug|Losartan|Given PO
10954|NCT04106856|Drug|Losartan Potassium|Given PO
10955|NCT04106856|Other|Quality-of-Life Assessment|Ancillary studies
10956|NCT04106856|Other|Questionnaire Administration|Ancillary studies
10957|NCT04106843|Drug|Lutetium Lu 177 Dotatate|Given IV
10958|NCT04106830|Drug|Intravenous steroid|This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, the 30th day and the 180th day, then 500mg per year).
10959|NCT04106817|Biological|Live, wild-type A/California/H1N1 2009 influenza virus|Live, wild type influenza A virus that was inoculated and manufactured in allantoic fluid of SPF embryonated hen eggs
10960|NCT04106804|Drug|Abatacept 125 MG/ML|Patients will receive weekly abatacept (Orencia®) s.c. Abatacept in the dose regimen given in the label for RA and PsA for six months
10961|NCT04106791|Device|closed-loop system for vasopressor administration|The closed-loop system' goal is to keep MAP within 5 mmHg of the predefined target MAP.
10962|NCT04106778|Drug|DMT310|Topical Powder
10963|NCT04106778|Drug|Placebo|Placebo Topical Powder
10964|NCT04106752|Dietary Supplement|Caffeine|Provide caffeine supplements with or without meal before exercise
10965|NCT04106739|Device|Drug Relief V(version) 2.0 Auricular Percutaneous Electrical Neural Field Stimulation (PENFS)|"This is a Small electronic circuit board with a minimal number of electronic components in it, which is powered by three zinc-air batteries. Each battery consists of 1.4v of charge. From this charge, the circuit produces a maximum voltage of 3.4V under no load condition.~The produced Voltage is driven as output by using the three stimulation wires, and the fourth insulated wire acts as a ground. The wires are Bio-compatible and do not have any impact when in contact with the human skin. The wire is attached with a needle to transfer the produced voltage into the nerves of the human ear. The sterilized needle (Titanium) is attached at the end of the wire through a snap fit ring. All the materials used are gone through necessary safety and performance testing including bio-compatibility and sterility testing, wherever necessary."
10966|NCT04106726|Drug|Soolantra® Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
10967|NCT04106726|Drug|Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
10968|NCT04106726|Drug|Placebo for Ivermectin cream 1%|Apply topically to the face once daily for 84 consecutive days.
10969|NCT04106713|Behavioral|Individual Psychotherapy|The individual therapy program will differ in orientation according to therapist and session notes will be coded according to the Comparative Psychotherapy Process Scale. Therapy sessions take place approximately once every fortnight, with 8 sessions in total, according to the agreed-upon schedule.
10970|NCT04106713|Behavioral|Internet-delivered Cognitive Behavioural Therapy (iCBT)|"The iCBT program (clinician follow-up with the therapist and 4 online modules) will be administered for 8 weeks. The four modules: 1) psychoeducation about emotions, including a functional nature of emotions; 2) alteration of antecedent cognitive misappraisals; 3) prevention of emotional avoidance; and 4) modification of emotion-driven [behaviours] (EDBs), are adapted from The Unified Protocol (UP) for transdiagnostic treatment of emotional disorders. UP is a CBT consisting of four overarching themes- increasing emotional awareness, facilitating flexibility in appraisals, identifying and preventing [behavioural] and emotional awareness, and situational and interoceptive exposure to emotion cues."
10971|NCT04106713|Behavioral|Group Cognitive Behavioural Therapy (group CBT)|The group CBT program (for e.g. PsychUp) will be conducted over 8 weeks, with weekly 2-hour sessions. Each group consists of 4-8 patients and are facilitated by two practicing clinical psychologists and one clinical psychologist in training. Sessions are structured such that each session, except the first, begins with a brief review of previous session material and a collaborative review of homework. This is followed by introduction of new material and completion of any in-session exercises, with sessions concluding with homework assignment. Specific treatment content is similarly adapted from UP. Session 1 begins by covering psychoeducation on the CBT model of pathological depression and anxiety and the role of avoidance in maintenance of symptoms. Sessions 2 to 7 covers goal-setting, cognitive reappraisal and development of adaptive emotional coping strategies through situational emotion-focused exposures. Session 8 ends with a discussion on relapse prevention.
10974|NCT04106687|Procedure|Sacral Erector Spinae Block|Postoperative pain procedure
10975|NCT04106674|Procedure|Open reduction internal stabilisation (ORIF)|Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
10976|NCT04106661|Other|Tai Chi|Physical activity requiring slow, controlled whole body movement and weight shifting.
10977|NCT04106635|Procedure|Paratracheal pressure|To apply paratracheal pressure, the thumb was placed over the left side of the trachea cephalad to the clavicle and medial to the sternocleidomastoid muscle.
10978|NCT04106635|Procedure|Cricoid pressure|To apply cricoid pressure, the cricoid cartilage is compressed by 30N force with a single-handed three finger maneuvre towards the vertebral bodies.
10979|NCT04106622|Procedure|electrophysiological study|"To assess whether the AP is of high risk or not, for all patients the AERP of the AP will be determined by one of the following ways:~The cycle length at which abrupt and complete loss of pre-excitation occurs during exercise test. If this didn't happen, the patient will be subjected to invasive electrophysiologic study..~The Antegrade refractory period of the AP is measured during EPS as the shortest cycle length with one-to-one conduction over the AP by incremental atrial stimulation after which the QRS becomes narrow or no conduction occurs due to block of the impulse in the AP.~The shortest pre-excited R-R interval during spontaneous or induced AF."
10980|NCT04106609|Other|Supervised, individualized exercise oncology program|The study intervention is a supervised, individualized exercise oncology program described in previous literature2,3,12 and provided by Maple Tree Cancer Alliance, a non-profit organization providing exercise training to individuals with cancer (https://www.mapletreecanceralliance.org/). This organization was founded in 2011 and currently operates in 9 hospitals serving Ohio and Pennsylvania, offering free exercise programs and nutritional guidance to approximately 500 patients annually to help relieve side effects related to cancer treatment.
10981|NCT04106609|Other|Current standard of care|Resource guide with various options available to cancer survivor. Within this guide are tips for healthy eating and pictures of standard exercises to improve fitness.
10983|NCT04106570|Other|fatiguability of the knee extensors|fatiguability of the knee extensors (in N.m) measured with a dynamometer.
10984|NCT04106557|Drug|Gaboxadol|OV101 versus placebo once daily at bedtime for 12 weeks
10985|NCT04106557|Drug|Placebo|Matching placebo capsules to OV101 capsules.
10986|NCT04106544|Procedure|Investigational Procedures|The investigational assessments will be performed
10987|NCT04106505|Behavioral|Biofeedback training via app on smartphone|Biofeedback training as described in biofeedback arm.
10988|NCT04106505|Behavioral|Sham-biofeedback training via app on smartphone|Sham-biofeedback training as described in sham-biofeedback arm.
10989|NCT04106492|Drug|SQ3370|SQ3370 consists of 2 components: SQL70, a prodrug-activating biomaterial and SQP33, a prodrug of Doxorubicin
10990|NCT04106479|Device|NIRS evaluation|NIRS will be used for measurement of cerebral and renal saturation.
10991|NCT04106466|Device|Medtronic Summit RC+S DBS system|Open label active Deep Brain Stimulation (DBS)
10992|NCT04106453|Procedure|navigated microwave ablation|the laparoscopic microwave ablation in the pig liver is performed with the CasOne-Spot system
10993|NCT04106453|Procedure|ultrasound guided navigation|the laparoscopic microwave ablation iin the pic liver is performed with ultrasound guidance
10994|NCT04106440|Behavioral|Application Use|Use applications after initial diagnosis to share information with study team.
10995|NCT04106427|Device|continuous theta burst stimulation (cTBS)|"cTBS stimulation of 17 mins over right inferior parietal lobe (IPL) with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 100% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
10996|NCT04106427|Device|placebo cTBS|"Placebo stimulation of 17 mins over right IPL with two 44 s stimulations separated by 15 mins, 10 sessions in total (5 per week). intensity will be 0% of resting motor threshold at 30 Hz.~administered in weeks 1 and 2 of the trial"
10997|NCT04106427|Behavioral|social cognitive remediation therapy (SCRT)|16 sessions of group SCRT will be scheduled within 8 weeks, comprising 6-8 participants per group with 2 therapists. Duration of group sessions will be 60-90 mins. The content will follow the manual of SCRT and we will add a short intervention to practice the use of co-speech gestures at each session
10998|NCT04106427|Behavioral|Sham group therapy|Group activities in closed groups of 6 participants. Schedule of two sessions per week for 8 weeks. Two therapists are guiding different leisure activities, e.g. group walks, going to museums/movies, games.
10999|NCT04106414|Drug|Nivolumab|Nivolumab 480 mg every 4 weeks.
11000|NCT04106414|Drug|BMS- 986205|BMS-986205 100 mg every 4 weeks.
11001|NCT04106401|Other|carbon-monoxide rebreathing|Inhaled carbon monoxide (CO) administrated as a bolus into a rebreathing circuit serves as a marker to tag circulating hemoglobin molecules and to calculate total hemoglobin mass (Hbmass). The change in blood CO concentration from pre- to postadministration (delta carboxyhemoglobin concentration) and the dose of administrated CO allows for Hbmass determination. The other blood compartments (total red blood cell volume, plasma volume and total blood volume) are derived from Hbmass, hematocrit and/or hemoglobin concentration.
11002|NCT04106401|Other|venous blood sampling|venous blood sampling at rest to evaluate blood viscosity, erythropoiesis and iron metabolism
11003|NCT04106401|Other|physical activity monitoring|recording of physical activity by actimetry
11004|NCT04106401|Other|apnea-hypopnea index and nocturnal oxygenation|recorded by ambulatory sleep recording device
11005|NCT04106401|Other|24-hour blood pressure|recorded by ambulatory device
11006|NCT04106388|Behavioral|Virtual Behavioral Health Integration|The virtual behavioral health integration program, implemented in primary care settings, is a structured mental illness treatment program that includes both behavioral treatment and counseling components aimed at reducing cost of care, developing and sustaining adaptive coping strategies, and improving short term acute care utilization.
11048|NCT04106063|Other|KID SSQ12 questionnaire|During a face to face interview (maximum 15 minutes), the child will complete a short questionnaire (KID SSQ12 questionnaire) to assess his auditory difficulties
11049|NCT04106050|Drug|BIIB095|Administered as specified in the treatment arm.
11050|NCT04106050|Drug|BIIB074|Administered as specified in the treatment arm.
11051|NCT04106050|Drug|Placebo|Administered as specified in the treatment arm.
11007|NCT04106375|Behavioral|Online mindfulness based cognitive therapy intervention|MBCT is based on Mindfulness-Based Stress Reduction (MBSR), combining principles of cognitive therapy (CT) with those of mindfulness meditation to prevent depression relapse. Both MBSR and MBCT use contemplative practices, including sitting meditation, body scan and walking meditation, as core methods to teach awareness of negative thoughts and emotions with the aim of disengaging from pervasive patterns of ruminative self-centered mentation. Participants will be given an initial orientation session and then complete an online 8-week MBCT program. Each week participants will take part in one 2-hour online group session and will complete homework assignments anticipated to take 15-30 minutes per day to complete. Additionally, weekly phone coaching will be offered based on the modified tele-coach manual developed by Mohr and colleagues (Duffecy et al. 2010).
11008|NCT04106362|Biological|Cetuximab|Given IV
11009|NCT04106362|Drug|Cisplatin|Given IV
11010|NCT04106362|Other|Quality-of-Life Assessment|Ancillary studies
11011|NCT04106362|Other|Questionnaire Administration|Ancillary studies
11012|NCT04106362|Radiation|Radiation Therapy|Undergo radiation therapy
11013|NCT04106336|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict
11014|NCT04106310|Device|High-flux dialyzer|a dialyzer meeting the definition of high-flux
11015|NCT04106310|Device|Theranova dialyzer|a middle cut-off dialyzer
11016|NCT04106297|Drug|GLPG3970 oral solution|GLPG3970 for oral administration
11017|NCT04106297|Drug|Placebo oral solution|Placebo for oral administration
11018|NCT04106297|Drug|GLPG3970 capsule|GLPG3970 for oral administration
11019|NCT04106271|Other|dyadic pain management program|a dyadic pain management program for older adults and their informal caregivers is developed as intervention. The program will be conducted at community activity center face-to-face combined with digital-based activities and the program will include 4 sessions, weekly 1 hours. Each session will be classified into three stages, including 10 minutes for watching videos and group discussion, 20 minutes for theoretical knowledge and coping skills and 20 minutes for exercising together. Last 10 minutes of each session is to wrap up and Q & A. There will be a brief introduction of program and self-introduction of participants at the beginning of the first session. One exercise book is given to each pair and researchers have a 4-week follow-up.
11020|NCT04106258|Drug|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin under general anesthesia. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
11021|NCT04106245|Behavioral|Behavioral Intervention|Participate in PACK Health
11022|NCT04106245|Other|Survey Administration|Complete survey
11023|NCT04106232|Other|No change in procedure except for specimen collection throughout procedure|Stool specimens will be taken before and during the HyGIeaCare procedure. Microbiome comparisons will be made across all specimens
11024|NCT04106219|Drug|LY3295668 Erbumine|Administered orally.
11025|NCT04106219|Drug|Topotecan|Administered IV.
11026|NCT04106219|Drug|Cyclophosphamide|Administered IV.
11027|NCT04106206|Drug|LY3372689|Administered orally
11028|NCT04106206|Drug|Placebo|Administered orally
11029|NCT04106193|Other|Blended Facilitation|Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.
11030|NCT04106193|Other|1-item screener|This term refers to the use of a 1-item screening tool to detect intimate partner violence among WVs treated in primary care.
11031|NCT04106193|Other|5-item screener|This term refers to the use of a 5-item screening tool to detect intimate partner violence among WVs treated in primary care.
11032|NCT04106193|Other|Implementation as usual|Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.
11033|NCT04106193|Other|Toolkit|All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
11034|NCT04106180|Drug|GM-CSF|Patients will receive GM-CSF 125μg/m2 daily for 14 consecutive days after completing SBRT treatment.
11035|NCT04106180|Drug|Sintilimab|Patients will receive Sintilimab 200 mg every 3 weeks up to 2 years after completing SBRT treatment.
11036|NCT04106180|Radiation|SBRT|Patients will receive SBRT for one previously unirradiated primary or metastatic lesion (size: 1-5cm). 24 Gy in 3 fractions (8Gy/Fx) administered once-daily for 3 consecutive days.
11037|NCT04106167|Genetic|Allogeneic natural killer (NK) cell|No study drug is administered in this study. Subjects who received an allogeneic, iPSC-derived NK cell in a previous trial will be evaluated in this trial for long-term safety and efficacy
11038|NCT04106154|Behavioral|Kinesiology Support|12 week physical activity group led by Kinesiologist. The intervention will be used to increase confidence in the participants by providing physical activity education and a variety of activities.
11039|NCT04106141|Other|6 weeks changing of archwire|changing the archwire after 6 weeks instead of 4 weeks
11040|NCT04106141|Other|4 weeks changing of archwire|changing the archwire every 4 weeks
11041|NCT04106128|Diagnostic Test|ultrasound examination|Measuring the thickening fraction by diaphragmatic ultrasound of acute diaphragmatic dysfunction in patients admitted for acute respiratory distress
11042|NCT04106115|Drug|Durvalumab|1500 mg IV infusion every 4 weeks for up to 7 doses
11043|NCT04106115|Biological|S-488210/S-488211|S-488210/S-488211 is given as a 1 mL subcutaneous (SC) injection of S-488210/Montanide emulsion and a 1 mL SC injection of S-488211/Montanide emulsion starting the day after first dose of durvalumab and continuing weekly for 6 doses and then every 2 weeks for a further 9 doses
11044|NCT04106102|Device|Transcramial Direct current stimulation|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder
11045|NCT04106102|Device|Placebo|Two sessions of 5 stimulations will be made on patient with obsessive-compulsive disorder without direct current. They xwill just wear electrodes.
11046|NCT04106089|Behavioral|Extended time between vitals check|Participants will have 6 hours protected sleep time (vitals checks moved from every 4 to every 6 hours)
11047|NCT04106076|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor
11054|NCT04106024|Drug|Anlotinib|Anlotinib 12mg.qd ,taken for 2 weeks and discontinued for 1 week, namely 3 weeks (21 days).
11055|NCT04106011|Drug|Gabapentin|Titration of gabapentin will be standardized as 300mg QHS and increased by 300mg every 3 days until taking 1200mg TID or maximum tolerable dose. Subjects will undergo cognitive evaluation prior to initiation of the medication, at 1 week (when titrated to approximately 900mg/day), 3 weeks (when titrated to approximately 2100mg/day), and at 6 weeks (when titrated to 3600mg/day or maximum tolerable dose).
11056|NCT04106011|Diagnostic Test|BTACT|Cognition measure: Brief Test of Adult Cognition by Telephone
11057|NCT04106011|Diagnostic Test|BPI|Pain severity and interference at baseline using the Brief Pain Inventory
11058|NCT04106011|Diagnostic Test|HADS|Assessment of depression and anxiety with the Hospital Anxiety and Depression Scale
11059|NCT04106011|Diagnostic Test|SLP9|Assessment of Sleep
11060|NCT04106011|Diagnostic Test|NPSI|Assessment of neuropathic components
11061|NCT04105998|Drug|Oxytocin|Oxytocin 10 IU
11062|NCT04105998|Drug|Placebo|Placebo
11063|NCT04105985|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
11064|NCT04105985|Drug|Articaine Injection|Local anesthetic
11065|NCT04105972|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
11066|NCT04105972|Drug|TEZ/IVA|FDC tablet for oral administration.
11067|NCT04105972|Drug|IVA|Mono tablet for oral administration
11068|NCT04105959|Drug|RIST4721|RIST4721 oral solution
11069|NCT04105959|Drug|Placebo|Placebo oral solution
11070|NCT04105946|Drug|Dexmedetomidine|dexmedetomidine administration intraoperatively in combination with other drugs used in OFA
11071|NCT04105946|Drug|Remifentanil|remifentanil administration intraoperatively in combination with other drugs used in TIVA
11072|NCT04105933|Other|CS-CBT|Culturally sensitive Cognitive Behavioural Therapy was delivered individually, focused on potential cultural beliefs and attitudes that might collide with core values of CBT.
11073|NCT04105933|Other|CBT|CBT was delivered at an individual level, dealing with thoughts, feelings and behaviours in the present. Thoughts are identified and then challenged, to make them more objective and rational.
11074|NCT04105920|Device|Hyaluronic acid arm|Patients included in this arm, will have, before insertion of brachytherapy seeds in the prostate, an injection of hyaluronic acid between the prostate, rectum, and pudendal arteries
11075|NCT04105907|Device|GentleWave|Subject teeth will receive a partial root canal treatment with the Sonendo GentleWave system followed by extraction of the tooth and histological evaluation of the tooth
11076|NCT04105894|Device|MSCT of nose and PNs|MSCT of nose and PNs axial, coronal and sagittal cuts without contrast to evaluate the state of the sinuses at the beginning of evaluation and after 2 months duration of medical treatment for GERD
11077|NCT04105894|Diagnostic Test|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin|Swab from nasal and oral mucous discharge to evaluate presence of HCL and pepsin at the at the beginning of evaluation and after 2 months duration of medical treatment for GERD
11078|NCT04105894|Drug|medical treatment of GERD t|medical treatment of GERD only for 2 months as described by gastroenterology department
11079|NCT04105881|Dietary Supplement|Investigation|Cross sectional intervention
11080|NCT04105868|Other|Neurofeedback|Participants will receive feedback during a computerized task that is based on their own visuocortical activity evoked by attention to negative distractors and task-relevant stimuli on the computer screen.
11081|NCT04105842|Device|Delfilcon A|Participants wear delafilcon A contact lenses on a daily disposable basis.
11082|NCT04105829|Other|Bond-a braid|Stainless steel lingual retainer application
11083|NCT04105829|Other|EverStick-Ortho|Fiber reinforced lingual retainer
11084|NCT04105829|Other|Ribbond|Fiber reinforced lingual retainer
11085|NCT04105816|Device|892.1550 Ultrasonic pulsed doppler imaging system|Use of the ultrasound to measure quadriceps volume
11086|NCT04105816|Diagnostic Test|Thigh circumference measurement|Tape measure used to measure thigh circumference of all participating patients in the study at the same visit in which they receive ultrasound measurements of thigh muscles.
11087|NCT04105790|Behavioral|Cognitive Behavioural Therapy with Mindfulness classes|The standard CBTm protocol is comprised of four 90-minute classes offered once a week for four consecutive weeks. The classes cover topics including mindfulness, cognitive therapy principles, behaviour therapy principles, managing anger, assertiveness, problem solving, goal setting, and evidence-based self-help resources. They are lecture-based but also involve experiential elements, such as mindfulness activities and practice of cognitive therapy strategies. Participants are assigned daily homework between each class to practice the strategies taught in session.
11088|NCT04105777|Device|Parenteral Nutrition Bag Eurotube|7-,8- or 9-chamber bags for individualized parenteral nutrition compounding.
11089|NCT04105777|Device|Parenteral Nutrition 2/3 chamber Bag|Premixed 2/3-chamber bags which are eventually completed with other supplements shortly before administration by infusion into the bag.
11090|NCT04105764|Drug|Rocuronium|DEEP block to PTC 1-3
11091|NCT04105764|Drug|Rocuronium bromide|MODERATE block to TOF1-2
11092|NCT04105751|Device|Novel Communication System|Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
11093|NCT04105725|Behavioral|Brief Motivational Intervention+Substance-Free Activity Session|A dialogue with the individual of their own experiences with alcohol use and related problems, as well as academic/career goals and personal interests.
11094|NCT04105725|Other|Alcohol + Nutrition Education Session|Education on alcohol, alcohol metabolism in the body, and alcohol overdose, as well as education on food groups and recommendations for a balanced diet.
11154|NCT04105244|Behavioral|Resourcefulness Training©|The intervention includes self-help and help-seeking skills.
11155|NCT04105231|Drug|Cannabidiol|Cannabidiol capsule
11156|NCT04105231|Drug|Risperidone|Risperidone tablet, encapsulated
11198|NCT04104893|Drug|Pembrolizumab|Pembrolizumab is a programmed death receptor-1 (PD 1)-blocking antibody. Pembrolizumab is a humanized monoclonal IgG4 kappa antibody with an approximate molecular weight of 149 kDa. Pembrolizumab is produced in recombinant Chinese hamster ovary (CHO) cells.
15675|NCT04068090|Other|Patient Questionnaires|FACT-Ntx, EORTC-CIPN20
11095|NCT04105712|Behavioral|Dietary Change (low in highly processed foods)|Food is provided to participant for 3 days. The University of Michigan's Nutrition Obesity Research Center (NORC)'s Metabolic Kitchen prepares the food. The low HP food diet is based on prior methods where participants are placed on an isocaloric diet composed of 5% or less of calories from added sugar and 10% or less of overall calories from total sugar. No foods that meet the criteria for a HP food based (defined by Kant and colleagues) that corresponds to: sweeteners (sugar, candy, etc); carbonated and non-carbonated beverages (fruit drinks, sweetened / diet beverages, etc. ); baked / dairy desserts (cookies, pies, ice cream, etc.); salted snacks (potato chips, etc.) and fast foods (pizza, cheeseburgers, French fries, etc.) are included in the diet portions. The overall macro nutrient composition of the diet will be approximately 20-25% of kcal from protein, 30-35% of kcal from fat, and 40-50% of kcal from carbohydrates.
11096|NCT04105699|Device|Blood sampling|Daily blood sample which will be taken for the PSP measurement using the abioSCOPE as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein [CRP] and Procalcitonin [PCT]).
11097|NCT04105686|Other|Control Infant Formula|Ready to feed infant formula, feed ad libitum
11098|NCT04105686|Other|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
11099|NCT04105673|Other|Clinical examination and survey|Children will be seen during an one consultation. A clinical examination and survey are realized.
11100|NCT04105660|Other|Training for EEG monitoring|Training for reading EEG curves during anaesthesia
11101|NCT04105660|Other|Standard monitoring|Standard monitoring including clinical parameters and BIS index
11102|NCT04105647|Behavioral|Lifestyle-integrated exercise|The experimental group will receive a face-to-face group session and a package of instant messages related to lifestyle-integrated exercise and physical activity. The lifestyle-integrated exercise is modified from Zero-time exercise. It focuses on four exercise domains that patients with lung cancer could be done at home, including breathing, balance, aerobic, strength, stretching exercises
11103|NCT04105647|Behavioral|Healthy living information|The control group will receive a face-to-face group session and a package healthy living instant messages, but not related to lifestyle-integrated exercise and physical activity.
11104|NCT04105634|Drug|FNOS|The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
11105|NCT04105634|Drug|Florbetaben|The imaging drug used for this group is called Florbetaben, it is an FDA approved radioactive PET tracer used to image amyloid plaques in the body. Although not yet FDA approved for this purpose, it has already been used clinically to image amyloid in other parts of the body. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
11106|NCT04105608|Dietary Supplement|High-fiber vegetarian meal|The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.
11107|NCT04105608|Dietary Supplement|Mediterranean-like meal|The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
11108|NCT04105595|Device|Septal defect closure|Device closure of atrial septal defect
11109|NCT04105582|Biological|Neo-antigen pulsed Dendritic cell|Patients that have already finished their conventional treatment (chemotherapy and/or surgery) will be vaccinated with dendritic cells pulsed with synthetic peptide
11110|NCT04105569|Procedure|Stent-Induced Biofilm Overgrowth|Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
11111|NCT04105556|Other|Nursing Care Based on Kolcaba's Comfort Theory|In this study, nursing care based on Kolcaba's Comfort Theory, which continues throughout the perioperative period, was applied to children and their parents.
11112|NCT04105543|Drug|CLR 131|CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height
11113|NCT04105530|Device|Anodal tDCS treatment|The Anodal intervention excites neuronal activity. For condition one, the anode will be attached to the left frontal region (Fp1) and the cathode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
11114|NCT04105530|Device|Cathodal tDCS treatment|The Cathodal intervention inhibits or reduces neuronal activity. We propose that the use of the cathodal tDCS to the superior temporal gyrus in survivors of childhood ALL may facilitate the inhibition of over connected motor-sensory and auditory neural networks. For condition two, the cathode will be attached to the left temporal region (T3) and the anode will be attached to the right neck. The intervention involves a direct current of 1 mA applied for 20 minutes.
11115|NCT04105530|Device|Sham treatment|The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramping up and no intervention is provided. Sham will be applied for 20 minutes. Stimulation will start 5 minutes before testing and continue throughout completing the NIH Toolbox Cognitive Battery at each trial.
11116|NCT04105530|Other|NIH Toolbox List Sorting Working Memory Test|List Sorting is using information processing and storage. Performance tends to peak in early adulthood and then decline across the life span. This task assesses working memory and requires the participant to sequence different visually- and orally-presented stimuli. The list scoring task takes approximately 7 minutes to administer. List Sorting is scored by summing the total number of items correctly recalled and sequenced on Lists-1 and -2, which can range from 0-26.
11117|NCT04105530|Other|NIH Toolbox Flanker Inhibitory Control and Attention Test|The Flanker tests inhibitory control and attention and the capacity for new learning and information processing novel situations. This performance also reaches a peak in early adulthood and tends to decline across the life span. A total of 40 trials require 4 minutes. Scoring is based on both accuracy and reaction time, which will we evaluate individually as well as in combination. The raw scores are converted to a scale score with a mean of 100 and SD of 15. Higher scores indicate higher executive function.
11235|NCT04104594|Other|numerical evaluation scale for olfaction|numerical rating scale from 0 (no smell) to 10 (perfect smell)
11118|NCT04105530|Other|Grooved Peg Board Test|The Grooved Peg Board test measures visual-motor coordination and motor speed. Additionally, it is cognitively challenging and has been associated with attention, perceptual speed and non-verbal reasoning. Performance is better in the dominant/preferred hand and tends to improve in childhood and decline with advancing age. The test consists of placing metal pegs with ridges along onside in matching slots as quickly as possible. The score is the time in seconds required to compete the array with each hand. Longer times reflect worse performance. Times are compared to normative data that is organized by ethnicity, age, gender and education. The test takes approximately 5 minutes to complete.
11119|NCT04105530|Other|Buschke Selective Reminding Test|This selective reminding task purports to distinguish verbal memory into short-term and long-term components. Scores are organized by short- and long-term storage and retrieval with normative scores organized by age and gender. The task requires participants to remember a list of orally-presented words and recall them with selective reminders of the words that they didn't recall. The test will last 5-10 minutes and is available in four different versions, thus reducing rehearsal effects.
11120|NCT04105504|Drug|Glutathione|Oral glutathione capsule (500 mg), were taken once daily by the subjects.
11121|NCT04105504|Drug|Placebo oral tablet|Placebo oral capsule were taken once daily by the subjects.
11122|NCT04105491|Device|IInvisalign® Aligners|Clear aligner orthodontic treatment
11123|NCT04105478|Procedure|Shoulder arthroplasty|Patients suffering from severe glenohumeral osteoarthritis are treated surgically by a total shoulder arthroplasty
11124|NCT04105465|Device|PlasmaJet|The PlasmaJet device is used following groin node dissection on the side randomised to receive it as per protocol specifications
11125|NCT04105426|Dietary Supplement|Antioxidants|one multivitamin and multimineral tablet with 500 mg grape seed extract once a day and one tablet of alpha-lipoic acid (300 mg ALA) twice a day for 3 months.
11126|NCT04105426|Dietary Supplement|Placebo|one placebo tablet three times per day for 3 months.
11127|NCT04105413|Diagnostic Test|Blood culturs|CBC, Blood culture and CRP
11128|NCT04105387|Procedure|Early Tracheostomy Change|The treatment group will have the first tracheostomy change on postoperative day 4 by an Otolaryngology physician (attending or fellow) on the study team.
11129|NCT04105374|Drug|Extended Release Flucytosine|Given PO
11130|NCT04105374|Device|NovoTTF-100A Device|Receive Optune device
11131|NCT04105374|Other|Quality-of-Life Assessment|Ancillary studies
11132|NCT04105374|Other|Questionnaire Administration|Ancillary studies
11133|NCT04105374|Radiation|Radiation Therapy|Undergo radiation
11134|NCT04105374|Drug|Temozolomide|Given PO
11135|NCT04105374|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
11136|NCT04105374|Biological|Vocimagene Amiretrorepvec|Given via intracranial injection
11137|NCT04105361|Procedure|Posterior neurectomy|Cut of posterior nasal nerve
11138|NCT04105348|Diagnostic Test|HbA1c|patients with raised investigations will be included in group 1 patients with normal investigations will be included in group 2
11139|NCT04105335|Drug|MTL-CEBPA|Intravenous administration
11140|NCT04105335|Drug|Pembrolizumab|Intravenous administration
11141|NCT04105322|Other|Kinesio Taping|The kinesio tape is adhesive and it does not contain drug substance. After the patients were randomized to the groups, kinesio tape will be applied to the relevant region.
11142|NCT04105309|Behavioral|Implementation Intentions|"Implementation intentions aid in pre-planning and habitualization of behaviors, as they serve to identify the when, where, and how of behaviors leading to goal attainment. Often taking the form of If/when situation x arises, then I will do y!, implementation intentions can be conceptualized in two parts, namely, an environmental or internal retrieval cue and a goal-directed behavioral response. Implementation intentions are effective because they 1) create a strong association between a retrieval cue and a goal-aligned behavior, increasing the likelihood that the goal-aligned behavior will be retrieved and utilized when the cue is encountered, and 2) increase attention for and cognitive accessibility of the retrieval cue, increasing opportunities for goal-aligned action ."
11143|NCT04105309|Behavioral|Fluency Training|Fluency training is a learning strategy that requires an individual to perform a skill or demonstrate knowledge repeatedly for both accuracy and response rate; the goal is to enhance automaticity of the response and promote endurance and retention of skills and knowledge over time and in the face of distractors. Participants completed 1 minute fluency training protocol 4 times throughout the study.
11144|NCT04105309|Behavioral|Text Messages|SMS reminders sent to phone of implementation intentions 16 times throughout the study.
11145|NCT04105309|Behavioral|Goal Intentions|Intentions to complete a goal that do not specify a plan about how to do so (compared to implementation intentions, that do)
11146|NCT04105296|Device|EKSO+ES|6 months of exoskeleton training with epidural stimulation.
11147|NCT04105283|Biological|Tc99m-MAA|Tc99m-MAA is a particle that is used to assess blood flow distribution and has a similar size to the particles that are utilized for arterial delivery of radiation therapy, also called radioembolization. Tc99m-MAA is currently used to estimate radiation dosimetry prior to arterial radiotherapy administration for liver malignancies.
11148|NCT04105270|Drug|A: Oral Restorative Microbiota Therapy (RMT) Capsules|Arm A: Patients with PD-L1 TC expression (≥25%) will receive sixteen doses of oral RMT capsules (weekly
11149|NCT04105270|Drug|B: Oral Restorative Microbiota Therapy (RMT) Capsules|Arm B: Patients with PD-L1 TC (<25%) will receive sixteen doses of oral RMT capsules (weekly)
11150|NCT04105270|Drug|A: Durvalumab 1500 mg IV|Arm A: Patients with PD-L1 TC expression (≥25%) receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab
11151|NCT04105270|Drug|B: Durvalumab 1500 mg IV|Arm B: Patients with PD-L1 TC (<25%) receive durvalumab 1500 mg IV every 3 weeks (Q3W) for 4 cycles followed by durvalumab maintenance 1500 mg IV Q3W until disease progression or for a maximum of two years from the 1st dose of durvalumab
11152|NCT04105270|Drug|B: Cisplatin/pemetrexed or Carboplatin/pemetrexed|Arm B: Patients with PD-L1 TC (<25%) receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W
11153|NCT04105257|Diagnostic Test|All patients|Comparison of the results of the CTP with MRI
11157|NCT04105218|Behavioral|Exercise|Participants will perform 4 study visits over 1-3 months. The 1st study visit is a screening visit, during which eligibility will be determined. During the 2nd visit, resting metabolic rate (RMR) and body composition will be measured. Participants will also perform a submaximal exercise test. Prior to each condition, habitual sleep/wake patterns will then be measured for 1 week. Participants will then perform each of the 2 study conditions (evening exercise and control) in randomized order with at least a 1-week washout period between conditions. Females will be studied during the luteal phase to control for potential confounding effects of hormonal variations across the menstrual cycle.
11158|NCT04105205|Drug|Apramycin injection|30-min infusion
11159|NCT04105205|Drug|Placebo injection|30-min infusion
11160|NCT04105192|Dietary Supplement|dietary supplement consumption|Consumption of the product under study for 84 days, plecebo or experimental product
11161|NCT04105179|Device|Zimmer NexGen LPS-Flex|Patients will be randomly assigned to 1 of 2 devices
11162|NCT04105179|Device|Smith & Nephew Journey II|Patients will be randomly assigned to 1 of 2 devices
11163|NCT04105166|Biological|RP-L301|Autologous genetically modified CD34+ hematopoietic stem cells containing the corrected PKD gene
11164|NCT04105140|Drug|Oxytocin|intranasal administration of oxytocin (24 IU)
11165|NCT04105140|Drug|Placebo|intranasal administration of placebo (24 IU)
11166|NCT04105127|Device|orthodontic - Anterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the palatal aspect of the upper central incisors. Both central incisors are customarily bonded to broadly distribute the occlusal forces. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
11167|NCT04105127|Device|orthodontic - Posterior resin builds-ups|After lower brackets placement, resin builds-ups are added on the supporting cusps of first or second upper/lower molars. Builds-ups are removed when the overbite was considered adequate to prevent lower brackets detachment.
11168|NCT04105114|Drug|Buspirone|Oral Buspirone 7.5mg - 10mg daily during the treatment phase.
11169|NCT04105114|Device|Non-invasive Spinal Cord Stimulation|A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.
11170|NCT04105114|Device|Ekso Bionics Exoskeleton|This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.
11171|NCT04105114|Device|Gravity Neutral Device|This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.
11172|NCT04105114|Device|Body Weight Supported Treadmill Training|Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.
11173|NCT04105114|Device|Rolling Walker|A standard rolling walker will be used for balance support and stability during stepping overground.
11174|NCT04105101|Device|Industrial passive shoulder exoskeleton|Both exoskeleton types are passive shoulder exoskeletons. The goal is to compare the human response to the simulated industrial tasks between the different exoskeleton conditions.
11175|NCT04105062|Drug|LS301|-LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
11176|NCT04105062|Device|Cancer Vision Goggles|-Non-significant risk device
11177|NCT04105049|Other|Observation of psychological aspects|Motivational, socioeconomic, family, stress, and other aspects are tested.
11178|NCT04105036|Other|Data Collection|Telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
11179|NCT04105023|Dietary Supplement|genistein|Administered orally once every 12 hours
11180|NCT04105023|Dietary Supplement|Placebo|Administered orally once every 12 hours
11181|NCT04105010|Drug|AZD4205|AZD4205 will be administrated orally as capsules. AZD4205 treatment will be continued until disease progression or intolerable adverse reactions
11182|NCT04104997|Drug|5% GLH8NDE|5% GLH8NDE as eye drops
11183|NCT04104997|Drug|Placebos|Placebo as eye drops
11184|NCT04104984|Device|transvaginal ultrasound|a transvaginal ultrasound is done to patient to determine cervical length
11185|NCT04104984|Drug|Progesterone Vaginal Suppository|a progesterone vaginal suppository to prevent preterm labour
11186|NCT04104984|Procedure|cervical cercalage|Mcdonald's cervical cercalage . a stitch taken around the cervix to prevent preterm labour
11187|NCT04104984|Other|digital vaginal exam|vaginal examination to detect short cervix
11188|NCT04104984|Device|abdominal ultrasound|use abdominal ultrasound to measure cervical length
11189|NCT04104984|Drug|Tocolytic Agents|a medication is given to prevent uterine contraction
11190|NCT04104971|Diagnostic Test|blood tests , abdominal US and doppler|
11191|NCT04104958|Genetic|qRTPCR (mRNA level).|RNA extraction and RT-qPCR Protein extraction and western blotting ELISA assay
11192|NCT04104945|Radiation|De-intensified chemoradiotherapy|Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
11193|NCT04104932|Procedure|Open reduction and internal fixation|Open reduction and internal fixation
11194|NCT04104919|Drug|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
11195|NCT04104919|Drug|Placebo 6 mL|Single preoperative intrathecal injection
11196|NCT04104906|Other|motor control training|The volunteers of the motor control group will initiate the exercises on a stable and rigid basis. These will be progressed with adding an unstable base as the volunteer gains motor learning (between the fourth and fifth week of the protocol). For the motor control group, two sets of 10 repetitions will be performed keeping in isometry for ten seconds each repetition.
11197|NCT04104906|Other|The exercise group|the protocol of strengthening and will have five elastic bands with different resistances available (extra-light, light, moderate, strong and extra-strong) for elbow flexion exercises progression, medial rotation and lateral rotation of the shoulder and scapular retraction.
11199|NCT04104880|Device|Continuous positive airway pressure (CPAP)|Adults previously diagnosed with obstructive sleep apnoea will receive a three-month CPAP intervention
11200|NCT04104867|Drug|Itopride|the patients are instructed to take one pill of Itopride at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
11201|NCT04104867|Drug|Domperidone|the patients are instructed to take one pill of Domperidone at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
11202|NCT04104867|Other|Placebo|the patients are instructed to take one pill of placebo at 8.00 AM, 12.00 AM, 4.30 PM respectively before the dat of colonoscopy. Lastly, they are instructed to take the fourth pill at 6.00 AM on the day of colonoscopy.
11203|NCT04104854|Device|drug coated balloon|Balloon/vessel diameter ratio 0.8-1.0, 8-12 ATM (atmosphere), lasting for >30 seconds
11204|NCT04104841|Behavioral|Behaviorally Enhancing Adolescents' Mood in Schools|8-session modified behavioral activation intervention
11205|NCT04104841|Behavioral|Usual Care|Referral to school mental health provider, social worker, or community care.
11206|NCT04104828|Biological|Allergovit|Grass/tree-allergen extract with aluminium adjuvant for treatment of allergic rhinitis
11207|NCT04104828|Biological|Polvac|Grass/tree-allergen extract with MCT adjuvant for treatment of allergic rhinitis
11208|NCT04104828|Biological|Pollinex Quattro|Grass/tree-allergen extract with MCT-MPLA adjuvant for treatment of allergic rhinitis
11209|NCT04104815|Other|Experimental Thickener|Use to thicken liquids
11210|NCT04104802|Device|MRI|"All patients included will benefit from both methods of assessing anatomical relationships between the facial nerve and the parotid tumor:~1) New medical imaging technique evaluated: 3 Tesla Parotidic MRI High Resolution with Specific Sequences and Gadolinium Injection 2) Standard Gold: Intraoperative Exam"
11211|NCT04104789|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
11212|NCT04104789|Drug|Articaine Injection|Local anesthetic
11213|NCT04104776|Drug|CPI-0209|CPI-0209 alone
11214|NCT04104776|Drug|Irinotecan|CPI-0209 in combination with irinotecan
11215|NCT04104763|Behavioral|study of osteofibrous dysplasia features|obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.
11216|NCT04104750|Other|assessment scales (BFI, QLQ, TESS)|the patient's Fatigue will be measured during the treatment period with antiblastic drugs and part of the followup period. To this end the BFI scale validated in Italian will be used (Mendoza et al 1999; Catania et al, 2013) which includes 9 items with a score for each of 0 to 10 and a consequent total score from 0 to 90. The measurement will take place in 4 times: the day of enrollment, 6 months, 12 months and 24 months after enrollment.the quality of life of patients measured by the EORTC QLQ C-30 scale (Aaronson et al, 1993) and the level of autonomy measured by the TESS scale (Davis et al, 1996) in 4 steps: the enrollment day , at 6 months, at 12 months and at 24 months from enrollment.
11217|NCT04104737|Device|Spire Medical Health Tag|"Collect data to validate the respiratory rate performance of the Medical Health Tag developed by Spire Health. The Medical Health Tag respiratory rate will be evaluated during non-motion conditions over the range a range of 5-50 breaths per minute via Reference EtCO2.~A FDA cleared, GE Healthcare S5 Multi-parameter monitoring system with End Tidal Carbon Dioxide (EtCO2) and 3- lead ECG will be used for the Respiratory and Pulse Rate References."
11218|NCT04104724|Other|Self-help|self-help materials - cognitive behavioural and compassion-focused; psychoeducation, practical help re. attending cervical cancer screening
11219|NCT04104711|Other|Home visits, health education|
11220|NCT04104698|Diagnostic Test|Quantitative EEG|"Both groups will undergo evaluation of depression severity using Beck Depression Inventory Scale-II (Arabic Version)~Both groups will be assessed for psychological & cognitive contributes respectively using:~A. Connor and Davidson Scale for resilience (Arabic Version) B. The scale of Islamic Religiosity Attitude (SIRA)~Both groups will do Quantitative EEG (qEEG) to detect electrical, functional and brain mapping changes {Using Neurovirtual BW III, Florida, USA)~The quantitative analysis of EEG will focus on the following functions:~Histogram, Topography, Spectrum Analysis, Spectral Differences, Propagation, Positional Diagram, Medium Amplitude, Ranges of Absolute Frequencies, Ranges of Relative Frequencies, CSA, Spectrum, and CSA Compressed."
11221|NCT04104685|Combination Product|FCD105|Experimental combination
11222|NCT04104685|Drug|3% Minocycline Foam|Active Comparator
11223|NCT04104685|Drug|0.3% Adapalene Foam|Active Comparator
11224|NCT04104685|Other|Vehicle Foam|Placebo
11225|NCT04104672|Drug|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor.
11226|NCT04104672|Drug|AB122|AB122 is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
11227|NCT04104659|Drug|MK 6240|"PET tracer, [18F]MK-6240 (an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.(Hostetler, Walji et al. 2016, Lohith, Bennacef et al. 2016, Walji, Hostetler et al. 2016, Lohith, Bennacef et al. 2017, Neelamegam, Yokell et al. 2017).We will evaluate this imaging agent in individuals from families with a known Autosomal Dominant Alzheimer's Disease (ADAD) mutation.~The planned dosage for [18F]MK-6240 is a single intravenous bolus injection of 185 MBq (5.0 mCi) in a large peripheral vein followed by a 10 mL normal saline (0.9% NaCl) flush."
11228|NCT04104646|Drug|CHF6563|Sublingual CHF6563 administration
11229|NCT04104646|Drug|Morphine|Oral morphine administration.
11230|NCT04104646|Drug|CHF6563 matched placebo|Sublingual CHF6563 matched placebo administration
11231|NCT04104646|Drug|Morphine matched placebo|Oral morphine matched placebo administration
11232|NCT04104633|Procedure|Blood samples|30 ml of blood collection
11233|NCT04104607|Drug|CC-1, PSMAxCD3|Infusion of CC-1 over 24 hours for 7 days with possible intra-patient dose-escalation
11234|NCT04104594|Diagnostic Test|Sniffin Stick Test|"The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.~The final score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores. Normal test values are defined as greater than the tenth percentile of the general population, so the test result is compared to reference values on a chart to determine whether the patient is normosmic, hyposmic or anosmic."
11236|NCT04104594|Other|numerical evaluation scale for nasal obstruction|numerical rating scale from 0 (no freedom of the nasal passages) to 10 (maximum nasal freedom)
11237|NCT04104594|Other|nasal outcome test|"list of symptoms and social/emotional consequences of rhino-sinusitis. 16 questions that the patient must code from no problem to serious problem over the last 15 days"
11238|NCT04104581|Other|Control Refined Grain Diet|Subjects will be fed the average American diet except it will be free of whole grains
11239|NCT04104581|Other|Low Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain oats
11240|NCT04104581|Other|High Whole Grain Oat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain oats
11241|NCT04104581|Other|Low Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a low level of whole grain wheat
11242|NCT04104581|Other|High Whole Grain Wheat Diet|Subjects will be fed the average American diet with addition of a high level of whole grain wheat
11243|NCT04104568|Behavioral|iSupport for dementia - European-Portuguese version|iSupport for dementia, European-Portuguese version consists in an online self-help training and support program developed by the World Health Organization to to provide education, skills training and support to informal caregivers of people with dementia and culturally adapted to Portugal by the Institute of Biomedical Sciences Abel Salazar and CINTESIS. Framed as a multi-component intervention, iSupport is grounded in problem-solving and cognitive behavioral therapy techniques. The program comprises 23 lessons on dementia and caregiver support distributed by 5 modules: 'Introduction to dementia'; 'Being a carer'; 'Caring for me'; 'Providing everyday care' and 'Dealing with behavior changes'. The education plan can be personalized by the caregiver and each lesson includes interactive exercises with immediate feedback; and positive messages as well as 'skills certificates' are displayed when lessons are completed.
11244|NCT04104568|Other|e-book (comparator)|The e-book contains information on relevant topics for dementia and caregiving, including basic information about dementia; practical tips on managing dementia; the changing needs of a person with dementia; dealing with care provision; caring for oneself (the caregiver) and finding emotional support; dealing with the death of the care receiver; relevant legislation (e.g. advance directives); how to get help; and how to reach the national Alzheimer's Association.
11245|NCT04104555|Other|Birthday card|Birthday card sent to participants in the post
11246|NCT04104555|Other|Birthday card plus nudge|Birthday card plus nudge sent to participants in the post
11247|NCT04104555|Device|Prefabricated orthoses|Prefabricated insole
11248|NCT04104555|Device|Custom orthoses|Custom made orthoses
11249|NCT04104555|Other|Pen|Pen included in the participant OSTRICH recruitment pack
11250|NCT04104555|Other|Signposting to multimedia|Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
11251|NCT04104555|Other|Pen and signposting to multimedia|Pen and signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.
11252|NCT04104555|Other|Usual supportive care - exercises and footwear advice (the comparator)|Active comparator
11253|NCT04104542|Behavioral|Mindfulness based stress reduction|on-line training on the website = www.palousemindfulness.com
11254|NCT04104542|Behavioral|Healthy Lifestyle|Diet and Exercise
11255|NCT04104529|Other|Biological collection|The biological collection will also include samples of blood samples collected before and during treatment.
11256|NCT04104503|Drug|Lu AF11167|Lu AF11167 - 2 mg modified release tablet (reference formulation), up to 5 prototype MR tablet formulations (test formulations)
11257|NCT04104503|Drug|[14C]-Lu AF11167|single iv microdose administered as a 15 minutes infusion
11258|NCT04104503|Drug|Lu AF11167 MR tablet prototype formulation selected from part A|Single oral dose
11259|NCT04104477|Other|Range of Motion Tasks|Participants will perform range of motion (thumb only) to evaluate fine and gross motor function.
11260|NCT04104477|Other|Strength Tasks|Participants will perform strength (pinch and grip) tests to evaluate fine and gross motor function.
11261|NCT04104477|Other|Jebsen Hand Function Test|Participants will perform the Jebsen Hand Function test to evaluate fine and gross motor function.
11262|NCT04104451|Drug|Corlicyte|expanded umbilical cord lining mesenchymal stem cells
11263|NCT04104438|Drug|Basiliximab 20 MG|Basiliximab induction followed by tacrolimus, corticosteroids and mycophenolic acid with a switch to everolimus by post operative day 30
11264|NCT04104412|Biological|human umbilical cord mesenchymal stem cell|2*10^7
11265|NCT04104399|Drug|XC101-D13H|XC101-D13H supplied as 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
11266|NCT04104399|Drug|Placebo|Placebo supplied as matching capsules
11267|NCT04104386|Other|Telomere Disclosure Impact|Participants were either provided or not provided information about their personal telomere length and how they compared to the rest of the sample.
11268|NCT04104373|Other|Observational Cohort|
11269|NCT04104360|Dietary Supplement|Galacto-oligosaccharides|During this period subjects will receive 7.2 grams of Vivinal GOS supplements three times daily for four weeks
11270|NCT04104360|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.2 grams of maltodextrin supplements three times daily for four weeks
11271|NCT04104347|Other|Metacognitive training (MCT)|Metacognitive Training (MCT) was first developed in Germany in 2007 by Steffen Moritz and Todd Woodward (Moritz & Woodward, 2007) targeting positive psychotic symptoms of patients with schizophrenia. MCT aims to change cognitive biases leading to delusional beliefs and consists of ten group sessions focused on different topics (Modules) as follows: Attributional Style (Module 1), Jumping to Conclusions (Modules 2 and 7), Changing Beliefs (Module 3), Empathy (Modules 4 and 6), Memory (Modules 5), Depression and Self-Esteem (Module 8) and two additional modules, namely Self-Esteem (Module 9) and Stigma (Module 10). Modules 8 (Self-Esteem), 9 (Self-Esteem) and 10 (Stigma) can be delivered together as one session so the intervention totals eight weekly group (3-10 participants) sessions. The MCT manual is available at: http://www.uke.de/mkt and was directly supervised by Steffen Moritz.
11308|NCT04104074|Drug|Sintilimab|Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks
11309|NCT04104061|Other|iron profile|blood test
11272|NCT04104347|Other|Support group|Controls will attend eight weekly support groups. Seven group sessions will focus on the following topics: 1) basic activities of daily living (BADL), 2) instrumental activities of daily living (IADL), 3) physical health, 4) press-based work, 5) psychoeducation on emotions, 6) psychoeducation on illness, 7) social and family relationships. One additional session will give participants some time to openly raise general issues and concerns which were not discussed during the above sessions. Controls will be encouraged to attend these group sessions from which they are likely to benefit. While not an intervention as such, this should turn into enough incentive to reach similar attendance rates in both arms of the RCT.
11273|NCT04104334|Drug|Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively|NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
11274|NCT04104334|Drug|Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices|Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
11275|NCT04104321|Drug|Aramchol|Aramchol 300 mg BID
11276|NCT04104321|Drug|Placebo|Placebo BID
11277|NCT04104295|Diagnostic Test|Ultrasound following X-ray|A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
11278|NCT04104269|Diagnostic Test|Heart rupture|Free wall rupture and Ventricular septal rupture
11279|NCT04104256|Behavioral|Nudge #1: Alert with new default tailored pre-op note template and order-set|"EHR clinical decision alert to pre-op clinic physician with a default tailored pre-op note template (that will include text referencing national guidelines making it clear that most patients do not benefit from pre-op testing) and a smart order-set with testing guidelines."
11280|NCT04104256|Behavioral|"Nudge #2: Accountable justification hard stop for orders"|EHR requirement that the preop physician ordering any non-recommended testing must write free text in the chart to justify the order.
11281|NCT04104256|Other|Usual Care|Patients will receive usual care from their physicians.
11282|NCT04104243|Other|Men-Tailored DPP (Power-Up)|Evaluating whether a diabetes prevention program (DPP) tailored for men (Power-Up) will show better or similar percent weight loss and retention than a standard mixed-gender DPP
11283|NCT04104217|Behavioral|Music therapy|Music therapy sessions may last 20-60 minutes, with length and frequency to be determined mutually (generally 1-3 times per week). Music therapy sessions are done at the patient's bedside, where the music therapist plays live music on a guitar, keyboard, harp, or percussion instrument, sometimes as accompaniment to singing.
11284|NCT04104217|Behavioral|Interviews|Each interview will be conducted in person in a private setting (with the exception of caregivers, who have the option to conduct interviews over the phone if it is not feasible to take place in the hospital). Each interview will follow a semi-structured interview guide and will ask for consent to audio record the interviews .
11285|NCT04104204|Drug|Intrathecal morphine|0.5% Iso/Hyperbaric bupivacaine 2-3 ml add morphine 0.1 mg for spinal anesthesia
11286|NCT04104204|Drug|Ultrasound guided supra-inguinal fascia iliaca block|Ultrasound guided supra-inguinal fascia iliaca block with 0.25% bupivacaine 40 ml and 0.5% Iso/Hyperbaric bupivacaine 2-3 ml without spinal morphine for spinal anesthesia
11287|NCT04104191|Device|L-1000AF System|The L-1000AF System is a wrist worn system that analyzes pulse rate data. The system identifies atrial fibrillation rhythms.
11288|NCT04104178|Drug|Clindamycin|Investigating whether a significantly higher number of MRSA throat carriers succeed in becoming MRSA free, when using Clindamycin on top of our general recommended topical treatment of Mupirocin nasal ointment + chorhexidin baths
11289|NCT04104178|Drug|Placebo|Placebo
11290|NCT04104165|Device|Foley Catheter|Foley catheter used for treatment of urinary retention
11291|NCT04104152|Other|CSD1902-11|A 2.4% nicotine ENDS product
11292|NCT04104152|Other|CSD1902-12|A 2.4% nicotine ENDS product
11293|NCT04104152|Other|CSD1902-13|A 2.4% nicotine ENDS product
11294|NCT04104152|Other|CSD1902-14|A 2.4% nicotine ENDS product
11295|NCT04104152|Other|CSD1902-21|A 5.0% nicotine ENDS product
11296|NCT04104152|Other|CSD1902-22|A 5.0% nicotine ENDS product
11297|NCT04104152|Other|CSD1902-23|A 5.0% nicotine ENDS product
11298|NCT04104152|Other|CSD1902-24|A 5.0% nicotine ENDS product
11299|NCT04104139|Drug|Trifluridine and Tipiracil Hydrochloride (TAS-102)|Given PO
11300|NCT04104139|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
11301|NCT04104139|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
11302|NCT04104126|Other|Standard of Care Physical Therapy|Will receive standard of care physical therapy
11303|NCT04104126|Other|Blood flow restriction|Blood flow restriction therapy is a blood pressure cuff placed around the desired limb with a handheld device that controls the pressure exerted by the cuff. The cuff is placed around the desired limb before a specific exercise, the physical therapist determines the appropriate pressure and time, and the patient completes the exercise as they normally would. The monitor determines the limb occlusion pressure and has an automatic timer that will deflate after the specified time has elapsed.
11304|NCT04104113|Other|Modified Xiang Bei Yangrong Tang|Modified Xiang Bei Yangrong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
11305|NCT04104113|Other|Placebo|Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
11306|NCT04104087|Procedure|tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.|enhancing papillary hight and treating gingival recession RT2 by performing tunneling technique with sub epithelial connective tissue graft or deepithelialized free gingival graft.
11307|NCT04104074|Radiation|Radiotherapy|The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy.
14878|NCT04074746|Biological|Anti-CD30/CD16A Monoclonal Antibody AFM13|Given IV
11310|NCT04104022|Behavioral|Prolonged Exposure Therapy|Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. Moreover, recent data suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
11311|NCT04104022|Behavioral|Attendance-based monetary incentives|Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
11312|NCT04104009|Other|Education|"Following the randomization process, group education of pregnant women will be conducted through four one-hour meetings.~Education program: teaching about the basics of childbirth physiology, visit to the maternity ward with the aim of reducing the fear of childbirth, applying the deep inhale and exhale exercise in the first birth stage, applying the classical music listening technique that will continue until the end of pregnancy daily (in the evenings before bedtime) (for 15 minutes), teaching and applying techniques for successful breastfeeding, maternal and infant health care after delivery. The training program will be implemented so that after 4 workshops a 5-week break will be taken. At the end of the program, the educator arranges with the respondents a weekly telephone check (for the sake of communication quality) to inform them of adherence to the agreed classical music listening.Pregnant women who do not meet expectations will be excluded from the study."
11313|NCT04104009|Other|No education|In the control group there will be no education, no breathing exercises and no listening to classical music.
11314|NCT04103996|Diagnostic Test|Ultrasound|Sonographic measurements (diaphragm, abdominal muscle, and quadriceps thickness) will be acquired when listed for lung transplantation. Sonographic measurements will be recorded on a daily basis for up to 1 week after transplantation (while the patient remains intubated).
11315|NCT04103996|Diagnostic Test|Respiratory function measurements|Maximal expiratory pressure (MEP) and maximal inspiratory pressure (MIP) will be acquired after listing for lung transplantation. After transplant, MIP will be recorded once patients are eligible for a trial of spontaneous breathing and weekly thereafter. MEP will also be recorded at ICU discharge.
11316|NCT04103983|Device|Sensory retraining device|Participants will be given a device to keep at home and will be asked to use it for 90 minutes each day, as one block, or as multiple shorter sessions of 10 minutes minimum duration. Participants will be asked to use their device on 15 of the 21 days. They will asked to spread out the use of the device over the 21 days. Participants are asked to record device use in a diary.
11317|NCT04103970|Behavioral|Graded Activity and Pain Education (GAPE)|"GAPE is based on a cognitive behavioral perspective that human behavior is affected by behavioral, cognitive and affective factors, this include the patient's perception of and response to pain. The perspective is a psycho-social perspective which amplify and interact with the individual patient's pathology.~The overall theoretical perspective in GAPE is that fear of movement and/or lack of self-efficacy for exercise can potentially lead to disuse and sedentary behavior, a perspective modified from the fear-avoidance model. In this modified version the patients´ and the physiotherapists´ former experiences, knowledge, and beliefs are factors influencing on the patients´ experience of pain and thereby their self-efficacy for exercise and fear of movement."
11318|NCT04103944|Procedure|Core Decompression|10 patients will be randomized chosen in this group
11319|NCT04103944|Procedure|Osteonecrotic Repair Device|10 patients will be randomized chosen in this group
11320|NCT04103931|Behavioral|"Treatment Choices for Aortic Stenosis Decision Aid"|"A decision aid, titled Treatment Choices for Aortic Stenosis, produced by the American College of Cardiology that contains information for patients deciding between TAVR and surgery to treat their aortic stenosis."
11321|NCT04103918|Device|Jalucomplex|Jalucomplex is an injectable intradermal gel containing sodium salts derived from hyaluronic acid.
11322|NCT04103905|Drug|Recombinant Humanized Monoclonal Antibody MIL62 Injection|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (200mg, 400mg, 800mg, 1000mg, and 1500mg, respectively) based on the sequence of inclusion. Each patient received an intravenous infusion of MIL62 on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 10 infusions. Each cycle was 21 days.
11323|NCT04103892|Drug|CLE-100|1 tablet of CLE-100 administered once daily
11324|NCT04103892|Drug|placebo|1 tablet of placebo administered once daily
11325|NCT04103879|Biological|ECT-001-CB (UM171-Expanded Cord Blood Transplant)|"Conditioning: High dose TBI (1320 cGy TBI + Fludarabine 75 mg/m2 + Cyclophosphamide 120 mg/kg) or Intermediate Intensity regimen (400 cGy TBI + Fludarabine 150 mg/m2 + Cyclophosphamide 50 mg/kg + Thiotepa 10 mg/kg).~Single UM171-Expanded CB transplant (CD34+: 2.5-50x10E5/kg, CD3+>1x10E6/kg)~Immunosuppression: Tacrolimus/MMF"
11326|NCT04103866|Device|Juvederm Voluma|Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.
11327|NCT04103853|Drug|Proxalutamide|Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
11328|NCT04103840|Other|Testing stool mycobiota|Both cohorts of SAH and their family controls will be tested for fecal mycobiota
11329|NCT04103827|Other|usability assessment|"Usability of Le Qoos will be assessed using a validated usability questionnaire"
11330|NCT04103814|Drug|Cannabidiol cream|Patients will receive cannabidiol cream for topical treatment of hallux rigidus or hallux valgus.
11331|NCT04103814|Drug|Placebo cream|Patients will receive placebo cream (neutral emollient containing no active agent) for topical treatment of hallux rigidus or hallux valgus. The ingredients of the placebo cream are as follows: Butyrospermum parkii (shea butter), caprylic/capric triglycerides medium-chain triglycerides (MCT oil), food coloring to match the CBD oil. There will be 345 grams of shea butter and 62ml MCT oil per batch.
11332|NCT04103801|Dietary Supplement|Sucrose|Participants in the intervention group were given 2 ml dose of 50% sucrose solution and participants in the placebo group were given 2 ml dose of sterile water. Both groups were administered slowly over 30 seconds sublingually via needle-less syringe immediately prior to the immunization injections.
11333|NCT04103788|Dietary Supplement|95% Curcuminoid Powder|1200 mg curcuminoids
11334|NCT04103788|Dietary Supplement|BIOCURC|400 mg curcuminoids
11335|NCT04103775|Behavioral|Cognitive Remediation|See Cognitive Remediation Arm description.
11336|NCT04103775|Behavioral|Active Control|See Active Control Arm description.
11337|NCT04103762|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
11338|NCT04103762|Diagnostic Test|systematic intraoperative cholangiography|systematic intraoperative cholangiography in both groups (use of Indocyanine Green in ICG group and Iomeron in the CPO group)
11339|NCT04103749|Device|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP or other duodenoscope-based procedure performed with the Exalt single use duodenoscope study device.
11340|NCT04103736|Dietary Supplement|Beet It Sport Shot|Source of naturally occurring dietary nitrates
11341|NCT04103736|Dietary Supplement|Nitrate-depleted placebo|Placebo
11342|NCT04103723|Procedure|Preoperative premedication|Every patient with or without a preoperative premedication with midazolam before surgery.
11343|NCT04103697|Drug|Capecitabine|2000 mg/m2, bid, per os, days 1-14, 4 cycles
11344|NCT04103697|Drug|Oxaliplatin|130 mg/m2 iv day 1, 4 cycles
11345|NCT04103697|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
11346|NCT04103697|Radiation|Radiotherapy|Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
11347|NCT04103697|Procedure|Rectal cancer surgery|Laparoscopic or open partial or total mesorectal excision (based on exact tumor location and surgeons discretion)
11348|NCT04103684|Drug|Methylprednisolone|30mg per kg per day for 5 days followed by course of oral prednisolone
11349|NCT04103684|Drug|Dexamethasone|0.6mg per kg perday for 5 days
11350|NCT04103671|Procedure|Prompt panretinal photocoagulation|Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
11351|NCT04103671|Procedure|25G Pars-plana vitrectomy|Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid. Surgery should be completed within 4 weeks after randomization.
11352|NCT04103658|Radiation|Near-infrared heating|Same as the arm/group description. The NIR heating group will have the non-melanoma skin cancer lesion excised based on the lesion borders established from application of NIR heat at a distance of 20cm for 10 minutes.
11353|NCT04103645|Drug|Vactosertib|This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
11354|NCT04103632|Diagnostic Test|EVH test|"Spirometry~Skin prick test~Peripheral blood test~FeNO measurement"
11355|NCT04103619|Device|AccuTite|Subjects will undergo treatment with AccuTite
11356|NCT04103619|Device|AccuTite + Morpheus 8|Subjects will undergo treatment with AccuTite and Morpheus 8
11357|NCT04103606|Device|GGBI: Positive Body Image (Mobile App)|Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
11358|NCT04103593|Behavioral|exercise training|12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
11359|NCT04103580|Behavioral|Photo elicitation|Caregivers are taught to use photos to illustrate various feelings and meanings
11360|NCT04103567|Other|Biological collection|Fecal samples collected at different times : during inclusion consultation with surgeon, before and after surgery.
11361|NCT04103554|Drug|Sacubitril-Valsartan|Sacubitril-Valsartan 24/26 mg BID, 49/51 mg BID, 97/103 mg BID
11362|NCT04103554|Drug|Enalapril|Enalapril 2.5 mg BID, 5 mg BID, 10 mg BID
11363|NCT04103541|Behavioral|IP-Colombia|The IP-Colombia program is a multi-component intervention carried out in the context of therapeutic camp, based on EDMR therapies and mindfulness-based interventions. Alongside the interventions, activities are done to facilitate healthy lifestyles, empathy, [and] the recognition and expression of emotions through exercise, art workshops, musical creation, dance and theater.
11364|NCT04103528|Other|morning surgery|31 patients will be operated on between 8:00 and 12:00 in the morning.
11365|NCT04103528|Other|afternoon surgery|31 patients will be operated on between 14:00 and 18:00 in the afternoon.
11366|NCT04103515|Device|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty|Zimmer-Biomet Posterior Cruciate Retaining total knee arthroplasty
11367|NCT04103515|Device|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty|Zimmer-Biomet Posterior Stabilizing total knee arthroplasty
11368|NCT04103502|Device|MicroPort Medial Pivot TKA|Subjects will have been implanted with the MicroPort Medial Pivot TKA
11369|NCT04103502|Device|DePuy Attune PCR TKA|Subjects will have been implanted with the DePuy Attune PCR TKA
11370|NCT04103489|Drug|Eculizumab|Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.
11371|NCT04103476|Combination Product|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg|Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
11372|NCT04103476|Other|Placebo|Placebo
11373|NCT04103463|Other|Interactive stepping exercise|An exercise intervention based on the principle of square stepping exercise
11374|NCT04103463|Other|Home exercise|Home exercise
11375|NCT04103450|Drug|Vibegron|oral administration
11376|NCT04103437|Diagnostic Test|Maximal incremental running test|"Maximal incremental running test with measures of metabolic, spatio-temporal parameters and video recording with camera in the frontal plane.~video recording of frontal view, metabolic and spatio-temporal measures of three (self-selected speed, + and - 20 percentage of self-selected speed) 6 minutes running test monthly (12 months) follow-up questionnaire"
11377|NCT04103437|Diagnostic Test|Metabolic and movement analysis of running|Running analysis of three six minutes running test (self-selected speed, + and - 20% of the self-selected speed) by video recording with camera in the frontal plane, and acquisition of the metabolic and spatio-temporal parameters
11378|NCT04103437|Other|Questionnaires|Monthly follow-up questionnaire (12 months) about training habits and injuries
11379|NCT04103424|Behavioral|Short-term Exercise Training|Participants will perform 2-weeks of supervised exercise training on a stationary bike.
11380|NCT04103411|Other|24h-Ambulatory Blood Pressure|Effect of High Intensity Interval Training compared to Hydrochlorothiazide on ambulatory Blood Pressure.
11381|NCT04103398|Combination Product|TACE+sorafenib|The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
11382|NCT04103398|Procedure|TACE|Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (oxaliplatin 200mg, raltitrexed 4mg, epirubicin 20mg in cTACE or 70mg in dTACE) and embolizing agents (gelatin sponge or microsphere) into blood vessels that help tumor grow.
11383|NCT04103385|Behavioral|RISE (Reconnecting to Internal Sensations and Experiences)|The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations
11384|NCT04103385|Behavioral|RISE (Reconnecting to Individual Strength and Energy)|Aims to reduce life stressors and improve physical health
11385|NCT04103372|Other|Surveillance 6 monthly|6 monthly surveillance
11386|NCT04103372|Other|Radiotherapy and surveillance|as per local policy
11387|NCT04103372|Other|surveillance 3 montly|3 monthly surveillance
11388|NCT04103359|Other|Physiological tests to measure fatigue level|Physiological tests to measure fatigue level
11389|NCT04103346|Other|air filtration with air purifier with hepa filter|long-term (4 week) air filtration with the Holmes HAP8650B-NU-1 air purifier in the residence of low-income seniors impacted by roadway pollutants.
11390|NCT04103346|Other|sham|air purifier running with air filter removed
11391|NCT04103333|Procedure|Lumbar Puncture|Administered as specified in the treatment arm.
11392|NCT04103333|Procedure|Blood Collection|Administered as specified in the treatment arm.
11393|NCT04103320|Other|Using different survey to evaluate pain|Survey will be at different time of the IVF protocol (at the first medical appointment in the medically assisted department, after stimulation, after oocytes retrieval, after embryo transfer, one month after the IVF protocol)
11394|NCT04103307|Procedure|Dialysis cooling|Cooling the blood in the CRRT circuit during delivery
11395|NCT04103294|Dietary Supplement|cowpea variety #1|two most popular varieties of cowpea currently consumed in the selected geographic area
11396|NCT04103294|Dietary Supplement|cowpea variety #2|two most popular varieties of cowpea currently consumed in the selected geographic area
11397|NCT04103281|Other|Sepsis|Sepsis patients in the ICU with a breathing tube
11398|NCT04103268|Other|sepsis|patients in the ICU with infection called sepsis
11399|NCT04103255|Other|High frequency and intensive prevention program|This study is a 4 week randomized controlled trial (RCT)
11400|NCT04103242|Other|16s rRNA gene sequencing|High-throughput sequencing of the microbial 16s rRNA subunit to define the abundance of microbial phyla and genera
11401|NCT04103229|Procedure|The use of different types and volumes of solutions to inflate the catheter balloon|In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
11402|NCT04103216|Other|Nitazoxanide with Lactobacillus Reuteri DSM 17938|Nitazoxanide with probiotics
11403|NCT04103216|Other|Nitazoxanide|Nitazoxanide with placebo
11404|NCT04103203|Diagnostic Test|PathoRobot/ Patho-Doc Test result|Test results of the new diagnostics will be available to the treating physician.
11405|NCT04103190|Device|cerebral MRI|"Patients who agree to participate in the study will perform a 3T multi-parametric MRI with advanced spectroscopic imaging techniques and standard protocol.~A neurological consultation will take place during the inclusion visit as well as a questionnaire and a control MRI at 1 year and 2 years +/- 1 month."
11406|NCT04103177|Other|Chair based exercises in the dialysis environment|"Each participant will be given an educational / information booklet. It will include when the right time to engage in Physical Activity. The Chair-based Exercise Program will be the focus of the exercise intervention with written step- by-step instructions with demonstrative image of the exercises. Further details included in this booklet will include, information regarding the benefits of exercise including walking and safety measures in undertaking the exercises.~Sports Exercise Instructor led Chair-based Exercise Programme Patients will be given Sports Exercise Instructor led training on how to perform the chair-based exercises, for 6 weeks. This will be delivered during one of the patients' dialysis sessions. The Instructor will deliver a short 10 minute session to patients and deliver safety instruction.~Motivational interviewing Motivational interviewing will consist of discussion to encourage the participant without coercion and help them develop goals."
11441|NCT04102878|Other|Facial photograph|The patient will have a photograph taken following the anaesthetic injections to document the presence or absence of bruising
11442|NCT04102878|Procedure|Eyelid surgery|Eyelid surgery will be performed as per the plan from their preoperative appointment
11476|NCT04102605|Device|Nunap Vision|Participants receive visual perceptual training using the Nunap Vision software
14879|NCT04074746|Drug|Cyclophosphamide|Given IV
11407|NCT04103164|Device|Cutera excel V™ Laser|The Cutera® excel V laser is manufactured by Cutera, Inc. This laser with 532 nm KTP and 1064 nm Nd:YAG wavelengths has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market the device for use in surgical and aesthetic applications requiring selective photothermolysis of target chromophores in soft tissue 510(k) number 022226. The 532 nm wavelength is indicated for the coagulation and hemostasis of benign vascular and cutaneous lesions in dermatology including, but not limited to, benign vascular lesions like angiomas, hemangiomas, port wine stains, venous anomalies and telangiectasia; benign pigmented lesions like nevi, lentigines, chloasma, café-au-lait; verrucae; skin tags; keratoses; plaques. The Cutera® excel V laser has also obtained the European CE Mark. The system was tested to ensure compliance with federal laser performance standards as applicable.
11408|NCT04103151|Device|Single lead ECG|Heart Rate Variability will be monitored using a single lead electrocardiogram
11409|NCT04103138|Device|Sedline EEG sensor placement|Patients will have Sedline EEG sensor placed before or immediately after induction.
11410|NCT04103138|Device|Sedline EEG monitoring|Anaesthesia depth will be guided by EEG characteristics in addition to routine clinical parameters
11411|NCT04103125|Device|Janesse® is a sterile, injectable, non-pyrogenic, re-absorbable medical product made of reticulated hyaluronic acid of non-animal origin, produced via bacterial fermentation.|The subjects will receive at baseline the first IMD by the Investigator in accordance with the CIP
11412|NCT04103112|Device|Graduated compression stocking|"Compression stockings have been used safely in the UK for about 50 years. They contain an elastic fibre designed to fit tightly around the legs. These specialist stockings are tighter around the ankle, with the level of compression gradually decreasing up the garment.~The pressure created by the stockings helps blood flow up the leg, allowing blood to flow freely to the heart and not pool in the leg which can result in pain and swelling."
11413|NCT04103099|Dietary Supplement|HLNatural Immune|Vitamin C, Echinacea, Ivy Extract, Zinc, Ginger and Turmeric in a powder form mixed with water
11414|NCT04103086|Drug|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
11415|NCT04103086|Drug|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
11416|NCT04103060|Drug|Cerdulatinib 0.37% gel|Cerdulatinib 0.37% gel applied topically twice daily for 6 weeks
11417|NCT04103060|Drug|Vehicle gel|Vehicle gel applied topically twice daily for 6 weeks
11418|NCT04103047|Other|SAD|The patients who have an SAD inserted as part of their normal Anaesthetic plan will be consented prior to their Anaesthetic and then have a questionnaire to fill out post operatively.
11419|NCT04103034|Drug|BT200|BT200 is a PEGylated synthetic RNA oligonucleotide
11420|NCT04103034|Drug|Desmopressin|Sterile solution for injection
11421|NCT04103034|Drug|Placebo|Sterile saline for injection
11422|NCT04103021|Device|Port-A-Cath|Totally implanted central venous access device
11423|NCT04103008|Diagnostic Test|Speckle tracking echocardiography|assess left ventricular function on admission and after 40 days
11424|NCT04102995|Drug|Sepranolone injection low dose|Subcutaneous (SC) administration
11425|NCT04102995|Drug|Sepranolone injection high dose|Subcutaneous (SC) administration
11426|NCT04102995|Drug|Placebo injection|Subcutaneous (SC) administration
11427|NCT04102982|Drug|Camrelizumab|Patients will be treated with camrelizumab alone.
11428|NCT04102982|Other|Camrelizumab plus microwave ablation|In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
11429|NCT04102969|Behavioral|Benson Relaxation Technique|Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.
11430|NCT04102969|Other|Nutrition Package Session|A nutrition package session will be given to the control group.
11431|NCT04102956|Drug|Kallikrein|HUK has been approved by China's State Food and Drug Administration as a state category I new drug for the treatment of stroke patients. Based on the available evidence, HUK injection ameliorates neurological deficits and improves long-term outcomes.
11432|NCT04102943|Drug|tacrolimus tablet|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
11433|NCT04102943|Drug|tacrolimus capsules|"Orally, twice a day in the morning and night~After first dose 0.1mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 7~12ng/ml for 0 to 3months and then at 5~8ng/ml for 3 to 6months of study treatment."
11434|NCT04102917|Diagnostic Test|QFR assessment|The quantitative flow ratio (QFR) is a novel angiography-based method for noninvasive functional assessment of intermediate coronary lesions.
11435|NCT04102904|Other|Observational|Patients will be asked to donate a semen sample which will be analysed and compared with their eventual diagnosis.
11436|NCT04102891|Other|Microbiota modulation diet|The Collect&Go shopping carts of the 400 participants will be adapted by replacing food products by healthier alternative ones based on the Flemish food-based dietary guidelines and the microbiota modulation diet guidelines for the control and study arm respectively. Based on these guidelines, and the habitual dietary pattern and level of food literacy of the participant, personalized dietary advice will be provided. A dietitian helpline will be available for further nutritional issues as well.
11437|NCT04102878|Drug|Topical Anesthetic|Topical anaesthetic drops (proxymetacaine 0.5% and tetracaine 1%) applied
11438|NCT04102878|Procedure|Transconjunctival anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transconjunctival route
11439|NCT04102878|Procedure|Transcutaneous anaesthetic|Local anaesthetic (50/50 mixture of bupivacaine 0.5% / lidocaine 2% with adrenaline 1:200 000) administered to the eyelid via the transcutaneous route
11440|NCT04102878|Other|Patient comfort questionnaire|The patient will be asked to rate the level of pain during each local anaesthetic injection on a 0-10 scale
11443|NCT04102865|Device|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
11444|NCT04102852|Dietary Supplement|Lactobacillus rhamnosus GG ATCC 53103|probiotic administration at two different doses for 1 month
11445|NCT04102839|Other|Interview|Qualitative Interview
11446|NCT04102826|Device|Functional electrical stimulation (FES)|Functional electrical stimulation combined with mobile arm support to restore upper limb function.
11447|NCT04102813|Behavioral|Functional Therapy|It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
11448|NCT04102800|Drug|Benralizumab|subcutaneous injection every 4 weeks
11449|NCT04102787|Other|cardiac educational program|"Love your Heart is a Heart Foundation program (2016), the Arabic version will be used as the educational program in this study. The programme has been adopted from relevant articles in the evidence- based literature. The program is a guide to support recovery and good heart health. It includes the following: anatomy and physiology of the heart, causes, symptoms and risk factors of CAD, healthy diet, physical activity, weight management, and risk factors management."
11450|NCT04102774|Device|Over-night treatment with myAIRVO2|"Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.~Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription."
11451|NCT04102761|Procedure|Intradiscal PRP & BMC Injections|The intervention to be studied is the intradiscal delivery of autologous Platelet Rich Plasma (PRP) or bone marrow concentrate (BMC) into the nucleus pulposus of the disrupted disc(s).
11452|NCT04102748|Procedure|I-incision, M-flap and conventional implant exposure techniques|Implant uncovering in the second stage using 3 different exposure techniques
11453|NCT04102735|Device|Under-the-nose facemask|Patients with acute hypercapnic respiratory failure that need noninvasive ventilation and are randomized in the experimental group will receive the AF541 facemask used with the under-the-nose cushion.
11454|NCT04102735|Device|Over-the-nose facemask|Patients with acute hypercapnic respiratory failure that need non-invasive ventilation and are randomized in the comparator group will receive the AF541 facemask used with the over-the-nose cushion.
11455|NCT04102722|Device|MUST device|Imaging with MUST device
11456|NCT04102709|Device|Health Tag|Health Monitoring Device
11457|NCT04102696|Drug|Aromatherapy|"Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal."
11458|NCT04102696|Drug|Placebo|Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy.
11459|NCT04102683|Behavioral|Therapeutic recreation activity program|The experimental recreation program, which consisted of two sessions per week and lasted approximately 1 hour each session, lasted for 8 weeks between March 2019 and May 2019 for the adolescents in the experimental group. The Therapeutic Recreation Activity Program, which consists of 16 sessions, is organized according to the self-determination and entertainment development model. This model aims to provide individual development and prosperity by creating an entertaining environment with therapeutic recreation. According to the degree of enjoyment, activity improves freedom of choice, preferences and ability to express oneself. Pleasure is a feeling that the participant feels deeply during therapeutic recreation. Provides entertainment experience. Pleasure increases individual motivation to participate, as well as making the best use of physical, social and emotional conditions.
11460|NCT04102670|Device|Ultherapy|Subjects will be treated with Ultherapy, which is a microfocused ultrasound, on the lower face, neck, and chest.
11461|NCT04102670|Device|Xeomin|Vertical neckbands, also known as platysma bands, will be injected with Xeomin to relax the bands.
11462|NCT04102670|Device|Belotero Balance|Horizontal necklace lines will be filled using Beletero Balance.
11463|NCT04102670|Device|Dilute Radiesse|The chest area will be injected with dilute Radiesse to stimulate collagen.
11464|NCT04102670|Other|Neocutis Micro Firm Face and Neck Cream|Neocutis Micro Firm Face and Neck Cream will be provided to subjects for topical use at home.
11465|NCT04102657|Other|Intermittent Fasting|Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.
11466|NCT04102657|Other|Free-Living Diet|Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.
11467|NCT04102657|Other|Left Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.
11468|NCT04102657|Other|Right Arm Exercise|Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
11469|NCT04102644|Other|Observation|Documentation of course and outcome of labor, delivery, and postpartum period
11470|NCT04102631|Diagnostic Test|colonoscopy with assistance of Endo.Angel|Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.
11471|NCT04102631|Diagnostic Test|colonoscopy without assistance of Endo.Angel|Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
11472|NCT04102618|Biological|Pelareorep|4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 & 9
11473|NCT04102618|Drug|Letrozole|Oral dose of 2.5 mg/day starting on Day 3 for 13 days
11477|NCT04102605|Device|Nunap Vision-C|Participants receive sham training using the Nunap Vision-C software
11478|NCT04102592|Other|Permethrin-treated Lesu (baby wrap)|0.5% permethrin application
11479|NCT04102592|Other|Untreated Lesu (baby wrap)|Matching untreated lesu
11480|NCT04102579|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
11481|NCT04102579|Drug|Placebo|non-active dosage form
11482|NCT04102566|Drug|Ibuprofen 600 mg|We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
11483|NCT04102566|Behavioral|Education|We'll be adding education to patient's post-operative instructions to aid in their pain control management.
11484|NCT04102553|Drug|F-18-PSMA-1007|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
11485|NCT04102553|Drug|F-18-Fluorocholine|Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.
11486|NCT04102540|Other|Infographic intervention|Information visualizations (infographics) will be used to teach participants about HIV during study visits immediately following their normal clinic visits.
11487|NCT04102527|Other|Questionnaires|"Patients have to complete the study questionnaires every 2 months :~Digestive Functional Score of Neurological Patients~Bowel Function Index~Severity score for constipation~Bristol Scale~Constipation assessment scale~Estimate scale of risk of constipation"
11488|NCT04102514|Behavioral|Real-time Group Video|Dyads in the RGV arm will be asked to complete three 45 min sessions that include aerobic, resistance, and balance/coordination exercises delivered by a trained health coach via Zoom® software on an iPad during mos. 0-6, and 1 session/wk. during mos. 7-12 to groups of 5-8 dyads in their home along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
11489|NCT04102514|Behavioral|Enhanced Usual Care|Dyads in the EUC arm, will be given a recommended exercise plan to follow on their own along with being provided written materials regarding exercise and physical activity from the National Institute on Aging and brief (15-20 min) FaceTime meetings (0-6 mos.= 2/mo.; 7-12 mos.= 1/mo.) with the heath coach to discuss progress, provide support and receive additional guidance on how to increase MPA.
11490|NCT04102501|Drug|RT001|RT001 is encapsulated 9-cis, 12-cis-11,11-D2-linoleic acid ethyl ester, which is a site specific (C11) di-deutero synthetic homologue of LA ethyl ester. Each capsule contains 960 mg of RT001.
11491|NCT04102501|Drug|Placebo|The placebo product is composed of encapsulated USP safflower oil. The placebo capsules are identical in appearance and size to RT001.
11492|NCT04102488|Procedure|Six-step hand hygiene technique with an application time of 30 seconds|Six-step hand hygiene technique with an application time of 30 seconds
11493|NCT04102488|Procedure|Six-step hand hygiene technique with an application time of 15 seconds|Six-step hand hygiene technique with an application time of 15 seconds
11494|NCT04102488|Procedure|Three-step hand hygiene technique with an application time of 30 seconds|Three-step hand hygiene technique with an application time of 30 seconds
11495|NCT04102488|Procedure|Three-step hand hygiene technique with an application time of 15 seconds|Three-step hand hygiene technique with an application time of 15 seconds
11496|NCT04102475|Other|Eatline|"After discharge from a first hospitalization:~Phone calls at 15 days, 1, 2, 4 and 9 months by a trained psychologist. The phone interview will be guided by the same standardized frame, which was developed by a group of experts and tested with a group of patients. The purpose of this intervention is to provide a therapeutic and motivational approach, with positive reinforcement and reassurance.~Added to treatment as usual (TAU): outpatient visits (at least monthly consultations) or scheduled hospitalizations~6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
11497|NCT04102475|Other|Control|"After discharge from the first hospitalization:~No specific phone calls~TAU: outpatient visits (at least monthly consultations) or scheduled hospitalizations~6- and 12-month assessments as an outpatient interview with an assessor who is blind to condition"
11498|NCT04102462|Drug|BI 764198|Capsules
11499|NCT04102462|Drug|Matching placebo|Capsules
11500|NCT04102449|Drug|Apremilast|Single arm receiving Apremilast and ultrasound examinations
11505|NCT04102410|Other|Sprints|"Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after."
11506|NCT04102410|Other|Vertical jumps|"Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after."
11507|NCT04102410|Other|Questionary Short Form-12 (SF-12)|"Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after."
11508|NCT04102410|Device|activity actigraph|"Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after."
11509|NCT04102410|Other|Program composed of two 2 training strategies|"Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed."
11579|NCT04101877|Drug|Aflibercept Injection|40 mg/ml
11510|NCT04102410|Other|Program of usual practice|Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
11511|NCT04102397|Procedure|Vojta therapy after standard therapy|Vojta Therapy ~20 minutes/session: Application of the Reflex Creeping complex, activating several stimulus points on the facial and the nuchal sides (Figure 3a), and then the activation of the Reflex Rolling complex in both the supine position and with the patient lying on his or her side, alternating between nuchal and facial stimulation and guiding from the head.
11512|NCT04102397|Procedure|Standard therapy|"~50 minutes/session:~TENS Current (20 minutes, phase duration=0.10 microseconds, frequency=50 Hz). The intensity applied depended on the patient's tolerance for the treatment (Figure 2a).~Pulsating ultrasound (5 minutes around the shoulder, frequency=1MHz, intensity=1 W/cm2) (Figure 2b).~Kinesiotherapy. In stages: at first assisted (with isometric exercises), then free, and finally, with resistance, usually with elastic bands (Figure 2c).~Cryotherapy (5 minutes)."
11513|NCT04102384|Other|e-PRO App|The e-PRO app is designed to further facilitate the delivery of PRO instruments in a convenient manner to participants. Through its computing capability, and user-friendly interface, the e-PRO app can collect data and implement complex scoring requirements, thus supporting the delivery of self-administered survey questionnaires.
11514|NCT04102371|Drug|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
11515|NCT04102371|Drug|Normal Saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
11516|NCT04102358|Procedure|Medial approach infraclavicular block with single injection|infraclavicular blocks performed with single injection
11517|NCT04102358|Procedure|Medial approach infraclavicular block with triple injection|infraclavicular blocks performed with triple injection
11518|NCT04102345|Other|Lavender Aromatherapy|Commercially available lavender essential oil and diffuser.
11519|NCT04102345|Drug|Zolpidem|Physician directed, pre-prescribed. Study team does not prescribe zolpidem.
11520|NCT04102332|Device|Safe Infusion Device|Safe infusion device is a different method than usual infusion practices (neutral solvent-purged infusers)
11521|NCT04102319|Diagnostic Test|serum hepcidin|it is a serum marker
11522|NCT04102306|Other|reliability and validity construct of the TMIQ|comparison of the TMIQ to the gold-standard questionnaire (KVIQ) and test-retest
11523|NCT04102293|Procedure|NSK Endo motor Endomate|Rotary instrumenation used in pulp therapy
11524|NCT04102293|Procedure|manual K-files|manual instrumentation used in pulp therapy
11525|NCT04102280|Device|Dialyser|Three consecutive treatment weeks and one follow-up week per patient. Each treatment week includes three hemodiafiltration HDF sessions and is assigned to one type of dialyzer: FX P600 Fresenius Medical Care, comparator Xevonta Hi 15 (B. Braun) and comparator Elisio 150H (Nipro)
11526|NCT04102267|Drug|Bupivacaine liposome injectable suspension|Liposomal bupivacaine 266 mg via injection
11527|NCT04102267|Drug|Bupivacaine HCl without epinephrine via continuous infusion|Bupivacaine HCl 300 mg via continuous infusion
11528|NCT04102254|Procedure|ANT recording and stimulation|In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
11529|NCT04102241|Drug|15mg Hemay005|Hemay005 is a small molecule PDE4 inhibitor.
11530|NCT04102241|Drug|Placebos|Placebos are the same as drugs, but contain no Hemay005.
11531|NCT04102228|Device|1Hz inhibitory rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 coil
11532|NCT04102228|Device|1Hz sham rTMS|20 minutes of 1Hz (1200 pulses) repetitive transcranial magnetic stimulation (rTMS) applied by Magstim Rapid 2 stimulator equipped with an airfilm figure-8 sham coil.
11533|NCT04102228|Behavioral|Multi-Modality Aphasia Therapy (M-MAT)|Participants receive 3.5 hours of intensive speech therapy in small groups delivered by a blinded speech language pathologist and therapy assistant. The objective of M-MAT is to improve word production through shaping of responses (ie. Gradually increasing complexity of spoken targets towards eventual mastery) and social-mediated repetitive practice. Therapists use game-based interactive tasks and rich multi-modal cueing (gestures, written words, drawing, reading words) to improve spoken production and oral communication.
11534|NCT04102215|Device|HEARO|Robotic system for otological procedures
11535|NCT04102215|Device|OTOPLAN|Otological surgical planning software
11536|NCT04102202|Drug|BOL-DP-o-05|BOL-DP-o-05
11537|NCT04102202|Drug|Placebo|Placebo
11540|NCT04102176|Other|stopping nucleos(t)ide therapy|patients taking nucleoside(t)ide therapy will stop treatment
11541|NCT04102176|Other|Continue nucleos(t)ide analogue|Continue nucleos(t)ide analogue
11542|NCT04102150|Drug|Valemetostat Tosylate|Once a day, 200 mg, oral administration
11543|NCT04102137|Biological|Pertagen (aP BioNet)|"Pertagen (aP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Pertagen (aP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
11580|NCT04101864|Procedure|Electromagnetic navigation|Acetabular component placement in total hip arthroplasty will be performed wit the help of electromagnetic image-less navigation system.
11581|NCT04101864|Procedure|Freehand|In the control group acetabular components in total hip arthroplasty will be placed with the help of the freehand technique.
14880|NCT04074746|Drug|Fludarabine|Given IV
11544|NCT04102137|Biological|Boostagen (TDaP BioNet)|"Boostagen (TDaP BioNet) was produced with a recombinant B pertussis strain that was genetically inactivated by the introduction of mutations (Arg9Lys and Glu129Gly) in the ptx operon of the S1 gene. Each 0.5 mL dose of Boostagen (TDaP BioNet) contained 5 µg PTgen, 5 µg FHA, and 0.3 mg as aluminium cation. TDaP dose additional contained at least 7.5 Lf tetanus toxoid and at least 2.0 Lf diphtheria toxoid.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
11545|NCT04102137|Biological|Adacel|"Comparator vaccine, Adacel (Sanofi-Pasteur, North York, ON, Canada) was produced chemically inactivated pertussis toxin. Each 0.5 mL dose of Adacel (as comparator vaccine) contained 2.5 µg PTchem, 5 µg FHA, 3 µg pertactin, 5 µg fimbriae types 2 and 3, 5.0 Lf tetanus toxoid, 2.0 Lf diphtheria toxoid and 0.33 mg as aluminium cation.~The study vaccine will be presented in a single-dose prefilled syringe. Each subject will be received one intramuscular injection in the non-dominant deltoid region."
11546|NCT04102124|Drug|SHR3680|Tablet. Specifications of 80mg
11547|NCT04102124|Drug|SHR3162|Tablet. Specifications of 10mg、40mg、50mg and 100mg
11548|NCT04102124|Drug|SHR3680(Placebo)|Tablet. Specifications of 80mg
11549|NCT04102124|Drug|SHR3162(Placebo)|Tablet. Specifications of 10mg、40mg、50mg and 100mg
11550|NCT04102111|Drug|JNJ-67864238|Participants will receive oral tablets of JNJ-67864238 twice daily.
11551|NCT04102111|Drug|Placebo|Participants will receive oral tablets of matching placebo twice daily.
11552|NCT04102098|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by IV infusion on Day 1 of each 21-day cycle.
11553|NCT04102098|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
11554|NCT04102085|Other|no intervention|no intervention
11555|NCT04102072|Diagnostic Test|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
11556|NCT04102072|Diagnostic Test|dobutamine stress test|Dobutamine was infused intravenously at the initial dose of 2.5 ug/kg/min. Echocardiography was performed after 5-10 minutes of continuous infusion, and hemodynamic data were recorded.
11557|NCT04102033|Drug|Eltrombopag|Thrombopietic agent approved for its efficacy in chronic immune thrombocytopenia in pediatric patients
11558|NCT04102020|Drug|Venetoclax|Tablet: Oral
11559|NCT04102020|Drug|Azacitidine|Subcutaneous (SC) or intravenous (IV) injection
11560|NCT04102020|Other|Best Supportive Care (BSC)|BSC is the best supportive care and expectant management according to institutional standards excluding AML directed therapy. BSC will be determined for each participant by the investigator.
11561|NCT04102007|Drug|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS).
11562|NCT04101994|Device|Virtual cycling training|Virtual cycling training is a convenient and easy approach for muscle strengthening.
11563|NCT04101994|Device|Repetitive transcranial magnetic stimulation|Intermittent theta burst stimulation produces short TBS trains intermittently to facilitate cortical excitability.
11564|NCT04101994|Device|Transcranial electric stimulation|TES is a constant current with low intensity delivered to the skull through surface electrodes.
11565|NCT04101981|Procedure|oocytes retrieval|The oocytes retrieval was performed after 34-36 hours from hCG administration . The collection of cumulus-oocyte complexes and FFs were performed via transvaginal ultrasound-guided aspiration with a needle of 18 gauge of diameter. The three major diameter follicles were identified by intraoperative ultrasound and FF of each follicle was collected in its own test tube.
11566|NCT04101968|Diagnostic Test|PET scan|3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
11567|NCT04101968|Diagnostic Test|neuroQWERTY|Analysis of free-text typing in a computer and/or a touch-screen device.
11568|NCT04101955|Procedure|Incisionless Threaded Carpal Tunnel|ultra-minimally invasive thread carpal tunnel release
11569|NCT04101955|Procedure|Standard Mini-Open Carpal Tunnel|open surgical carpal tunnel release
11570|NCT04101942|Behavioral|Internet-based CBT|The experimental group will go through active internet-based treatment which is delivered on a safe internet platform. Treatment is divided into four modules, each containing homework assignments. Participants in experimental group will be assigned a therapist that they can contact through a message system in the platform and expect answer within 36 hours.
11571|NCT04101929|Drug|Apatinib|Patients receive Apatinib 250mg po qd , Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
11572|NCT04101929|Drug|S-1 capsule|Patients receive S-1 capsule According to the body surface area <1.25m2 60mg/d, 1.25 ~ 1.5 m2 80 mg/d, > 1.5m2 100mg/d po bid, taking 7 days, stopping for 7 days, 28 days for 1 cycle, Treatment repeats until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
11573|NCT04101929|Drug|Irinotecan|"Patients receive Irinotecan According to the body surface area of 180 mg/m2, ivgg/90min, once every two weeks. Continuous chemotherapy until the criteria for discontinuation of the drug are met (eg, progression of the disease, intolerance of adverse reactions, or withdrawal of informed consent by the patient).~Because the toxicity of apatinib or irinotecan or tigeol in the chemotherapy regimen meets the withdrawal criteria, the drug can be discontinued alone and the exact duration of the trial treatment recorded."
11574|NCT04101916|Device|Paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 12 weeks to upper limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
11575|NCT04101916|Device|Sham paired associative stimulation|Sham transcranial magnetic stimulation and sham peripheral nerve stimulation.
11576|NCT04101903|Diagnostic Test|The 6-week Hip Checklist|Comprehensive 9-item structured guide for correct diagnosis of developmental dysplasia of the hip. Used in paper and electronic format. Seeks to improve the ability of doctors in evaluating infants hips.
11577|NCT04101890|Drug|Diaper care with Theraworx|Theraworx foam formulation to be used as a preventive and treatment agent for diaper rashes
11578|NCT04101877|Drug|Bevacizumab Injection|25 mg/ml
11582|NCT04101851|Procedure|omission of SLNB|After radiologic complete remission at the end of NAST all patients will be treated with breast-conserving surgery alone without any axillary surgery.
11583|NCT04101838|Drug|Fluzone|inactivated seasonal influenza vaccine
11584|NCT04101838|Drug|Flucelvax|inactivated seasonal influenza vaccine
11585|NCT04101838|Drug|Fluzone High-Dose|inactivated seasonal influenza vaccine
11586|NCT04101838|Drug|Fluad|inactivated seasonal influenza vaccine
11587|NCT04101825|Device|Auralya|Hyaluronic Acid-Dermal Filler
11588|NCT04101812|Drug|pegylated liposomal doxorubicin (PLD)|PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.
11589|NCT04101812|Drug|PD-1|PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.
11590|NCT04101799|Behavioral|For Our Children's Sake|Parental support with the aim to support positive parenting and promote healthy child development. Conducted in group-format with weekly 2.hour sessions conducted by trained group leaders according to a programme manual.
11591|NCT04101799|Other|Active control|Participating in everyday activities that may include parenting activities in the control prisons
11592|NCT04101786|Other|Hip adductors exercise variations|The participants will perform different exercise variations targeting hip adductors in randomized order.
11593|NCT04101773|Procedure|RBL versus sutured mucopexy versus haemorrhoidectomy.|All 3 interventions are part of Dutch usual care, and serve as each other's control.
11594|NCT04101760|Drug|Long-acting granulocyte colony stimulating factor|Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
11595|NCT04101760|Drug|Short-acting granulocyte colony stimulating factor|Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
11596|NCT04101734|Device|Double Lumen Endotracheal Tube.|Intubation was performed with Double Lumen Endotracheal Tube.
11597|NCT04101734|Device|Double Lumen Video Endotracheal Tube.|Intubation was performed with Double Lumen Video Endotracheal Tube.
11598|NCT04101721|Drug|aflibercept|Administered IVT
11599|NCT04101721|Procedure|laser photocoagulation|Transpupillary conventional laser will be administered according to standard local procedures.
11600|NCT04101708|Drug|Lansoprazole, Amoxicillin|high dose dual regimen
11601|NCT04101708|Drug|Lansoprazole, Amoxicillin,Clarithromycin and Bismuth subcitrate|half-dose clarithromycin-containing bismuth quadruple regimen
11602|NCT04101695|Device|tDCS|Ybrain tDCS System (Ybrain, Korea) is used for anodal stimulation of cerebellar hemisphere. Anode of tDCS is placed over right cerebellar hemisphere (3cm lateral from the occipital protuberance) and cathode over the on right buccinator muscle.
11603|NCT04101682|Drug|Bupivacaine|Administered by an anesthesiologist or certified nurse anesthetist, under ultrasound guidance a catheter placed overlying the nerve sheath. This catheter is then connected to a device with a reservoir that administers local anesthetic at a set rate.
11604|NCT04101669|Device|EndoBarrier Liner|The EndoBarrier System is provided as a single-use, sterile device and consists of an EndoBarrier Liner preloaded, packaged and sterilized within the EndoBarrier Delivery System. The EndoBarrier Delivery System is utilized to deliver the EndoBarrier Liner to the proximal small intestine. The EndoBarrier Liner is removed using the EndoBarrier Retrieval System. The EndoBarrier System incorporates no pharmacological, biological tissue or blood products.
11605|NCT04101669|Other|Sham|Patient receives upper endoscopy but no treatment
11606|NCT04101643|Drug|evolocumab|Eligible patients receive subcutaneous injections of evolocumab 420 mg
11607|NCT04101630|Behavioral|Activity Monitoring|Monitoring with FitBit
11608|NCT04101617|Behavioral|Oral Health education including printed educational material|Printed and online educational materials were developed and provided to pediatricians so they can share relevant information about caries control to parents of toddlers. A previous interview was performed to pediatricians as focus groups to know how they are doing their evaluations and what do they take into account during the children visits in order to identify where to focus for the training what it is necessary to change. After that pediatricians were trained to give oral health recommendations. So, to the intervention group, the pediatricians will give these recommendations to the parents and also they will give them a printed educational material previously developed for the project.
11609|NCT04101604|Other|Collection of blood samples|Collection of blood samples for DNA extraction and genetic characterization, and for identification of peripheral blood biomarkers using single-cell transcriptomics and mass cytometry.
11610|NCT04101578|Drug|Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)|Treatment regimens are determined according to the physician's judgment and preferences of the patients.
11611|NCT04101565|Behavioral|Text4Father|Receipt of twice-weekly texts that include resource links and instructions to support behavior change (e.g., videos, infographics) and start mid-pregnancy and continuing through 2 months of age.
11612|NCT04101552|Procedure|socket shield technique with xenophobic graft particulate and without the use of graft|the jumping gap between the implant and the shield is grafted by xenograft particulate and the control group is not grafted
11613|NCT04101539|Device|OPTIMA-guided catheter ablation|Patients in the experimental arm will undergo supplemental ablation of OPTIMA-identified sites hypothesized to support/perpetuate chronic atrial fibrillation.
11614|NCT04101539|Device|Standard PVI|Standard PVI for AF.
11615|NCT04101526|Behavioral|New Intervention for Cancer-Related Sleep Disturbance|Modality of this intervention will be determined in Arm 1
11616|NCT04101500|Drug|Compound Ipratropium Bromide Solution(C1) for Inhalation|The patient's condition and basic condition were the same in the experimental group and the control group.
11617|NCT04101500|Drug|Compound Sodium Chlolate and Aminophylline Tablets(C2)|Applied only to the experimental group.
11618|NCT04101500|Drug|Placebo Tablets|Applied only to the control group.
11619|NCT04101487|Other|Cash Transfer|Monthly cash transfers
11620|NCT04101487|Other|Cash Transfers and Nutrition Education|Cash transfers every month and structured nutrition education provided at household level by community health assistants based on a nutrition education handbook
14881|NCT04074746|Drug|Fludarabine Phosphate|Given IV
11621|NCT04101474|Drug|Ketamine|Ketamine is a high-affinity, noncompetitive N-methyl-D- aspartate (NMDA) glutamate receptor antagonist it has been used in anesthesiology for more than 50 years the time course of antidepressant response to ketamine is characterized by an initial reduction in depressive symptoms within 2 h
11622|NCT04101461|Drug|Iron|PharaFerro27; Devart Lab Company, Egypt
11623|NCT04101461|Diagnostic Test|Complete blood count|to assess the anemia
11624|NCT04101461|Diagnostic Test|Serum ferritin|to assess the anemia
11625|NCT04101448|Other|prevalence|percentage of bronchectasis in COPD and its effect as prognostic measure
11626|NCT04101435|Biological|AdimFlu-S (QIS)|This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
11627|NCT04101422|Behavioral|Augmented Reality 1|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) and non-smoking related stimuli (pens, notebook, eraser).
11628|NCT04101422|Behavioral|Augmented Reality 2|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of smoking related AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.). They will also be presented with real smoking (e.g., ashtray) and non-smoking (e.g., pencil) items. Their urge to smoke rating following each presentation will be compared for AR images vs. vivo items, and smoking-related vs. non-smoking related.
11629|NCT04101422|Behavioral|Augmented Reality 3|Participants will use an Augmented Reality )AR) application on smart phones in locations and situations where they typically smoke. the application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays). Participants will have a goal of using application at least 5 times per day for 7 days. Usage and rating data will be collected in real-time.
11630|NCT04101422|Behavioral|Augmented Reality 4|Participants will use an Augmented Reality (AR) application on smart phones. The AR application will create simulated examples of AR stimuli (cigarettes, lighters, ashtrays) as well as non-smoking images (pens, notebook, etc.) Their urge to smoke rating following each presentation will be compared from baseline urge to smoke. The post-test urge to smoke will be compared between control group and extinction group.
11631|NCT04101409|Other|Decision aids|Shared decision making with decision aids
11632|NCT04101396|Dietary Supplement|diabetic diet|Patients with gestational diabetes will be seen by the dietitian to be taught diet modification
11633|NCT04101383|Drug|RinGlar®|Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg
11634|NCT04101383|Drug|Lantus®|Single subcutaneous administration of Lantus® in dose 0.6 Units/kg
11635|NCT04101370|Drug|Bosentan 125 mg|Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition
11636|NCT04101370|Drug|Tracleer 125Mg Tablet|Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
11637|NCT04101357|Drug|BNT411|intravenous
11638|NCT04101357|Drug|Atezolizumab|intravenous
11639|NCT04101357|Drug|Carboplatin|intravenous
11640|NCT04101357|Drug|Etoposide|intravenous
11641|NCT04101344|Other|Two fiber-blend snack and four fiber-blend snack|All subjects will complete a 47-day, multi-phase feeding study to evaluate the effect of two snack prototypes containing two different fiber blends on gut community structure and features of host biological state (plasma proteome/ metabolome).
11642|NCT04101331|Drug|AFM13|weekly intravenous infusions of 200mg
11643|NCT04101318|Device|New Stoma Baseplat based on the Sensuro Mio product line.|New Stoma Baseplate based on the Sensuro Mio product line. New Baseplate is not named at this point, but has a new protective layer.
11644|NCT04101305|Diagnostic Test|IsoPic|Biomimetic circulating epithelial cell enrichment followed by epithelial cell detection and single cell DNA sampling and sequencing
11645|NCT04101292|Other|Characterization of tumor tissue by fluorescence|"HSI Imaging of the resected specimen, from the serum and the mucous side~FF-OCT imaging of the tumor and the healthy tissue biopsies~Local application of Bevacizumab-IRDye800CW and visualization with the Surgvision Explorer system~Standard anti-VEGF Immunohistochemistry and pathology"
11646|NCT04101279|Procedure|surgical management of stress urinary incontinence with midurethral tension free tape.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach.
11647|NCT04101279|Procedure|surgical management of stress urinary incontinence with synthetic tape with tension control mechanism.|Standard protocol for the surgical treatment of stress urinary incontinence using a transobturator approach. A absorbing gasket attached to the middle of the tape provides tension control.
11648|NCT04101266|Other|Interscalene block|30 minutes before anaesthesia induction interscalene nerve block will be applied with ultrasound guidance with %0,025 bupivacain 20 cc .
11649|NCT04101266|Other|suprascapular and infraclavicular nerve block|30 minutes before anaesthesia induction suprascapular with %0,025 bupivacain 10 cc .and infraclavicular nerve block with %0,025 bupivacain 10 cc will be applied with ultrasound guidance
11650|NCT04101253|Procedure|new screening procedure with small variations in electrode positioning|"Every ICD patient will undergo the standard screening process. Initial screening will be performed as usually performed by physician or Boston Scientific technical support. In case of one or more vector satisfying screening criteria, patient will be assigned in screening success group. In case of failure, a pre-determined electrode positioning protocol will be done with variation of para-sternal and axillary electrodes. Positioning variations will be left to the discretion of the operator cardiologist."
11651|NCT04101227|Drug|AD04 (ondansetron)|AD04 (ondansetron) 0.33 mg, orally (p.o.) twice a day (BID)
11652|NCT04101227|Drug|Matching placebo|Matching placebo to AD04 (ondansetron), orally (p.o.) twice a day (BID)
11653|NCT04101227|Device|Companion Diagnostic for Genetic Testing|Companion Diagnostic for Genetic Testing
11654|NCT04101227|Behavioral|Brief Psychological Counseling|Brief Psychological Counseling
11655|NCT04101214|Other|Dry needling|Dry needling into spastic muscle
11656|NCT04101214|Other|Sham dry Needling|Sham dry needling into spastic muscle
11657|NCT04101201|Dietary Supplement|µSmin® Plus|µSmin® Plus is a new Micronized Diosmin Formulation for oral administration. Diosmin is extremely well tolerated and safe to use. Diosmin is safe for most people when used short-term for up to 6 months. During the 8 weeks of the clinical investigation, the subject will administer 1 tablet of µSMIN® Plus (corresponding to 450 mg of micronized diosmin) or placebo per day.
11658|NCT04101201|Other|Placebo|It will be supplied by the Sponsor in an amount enough for the duration of the study. The subject will administer 1 tablet per day
11659|NCT04101188|Other|Moderate Potassium/Low Sodium Diet|Consumption of 10 days of a diet moderate in potassium and low in sodium.
11660|NCT04101188|Other|Moderate Potassium/High Sodium Diet|Consumption of 10 days of a diet moderate in potassium and high in sodium.
11661|NCT04101188|Other|High Potassium/High Sodium Diet|Consumption of 10 days of a diet high in potassium and high in sodium.
11662|NCT04101175|Procedure|Evaluation of the procedure of abortion|Observational study using questionnaires
11663|NCT04101162|Diagnostic Test|shear waves elastography; liver biopsy|Diagnostic accuracy in a new ultrasound software compared to histology for Non Alcoholic Fatty liver disease (NAFLD) and Non Alcoholic Steato Hepatitis (NASH)
11664|NCT04101149|Other|No intervention|No intervention.
11665|NCT04101136|Drug|Atorvastatin - placebo controlled clinical trial|The participants will get the medication supply every month along with the refill of antiretroviral drugs. The drug and placebo tablets will be administered to patients by a staff member who are privy to the treatment. In the end of every month, each participant should return the unused pills every month
11666|NCT04101123|Other|Non-Interventional|Non-Interventional
11667|NCT04101110|Other|Renal biopsy|Kidney biopsy will be done to understand the nature and degree of structural kidney damage
11668|NCT04101084|Other|Therapy|Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
11669|NCT04101071|Other|Modular ketogenic feed|Dietician prescribed, and consisting of Betaquik® (from Vitaflo, Nutritional company) to provide medium chain triglycerides), Renapro Shot® (protein), Maxijul® (carbohydrate) and multivitamins according to nutritional need (energy and protein requirements) based on clinical status of the participant. Ketogenic feed to be given continuously via nasogastric tube for 10 days
11670|NCT04101071|Other|Standard feed|Standard Enteral feed. Dietician prescribed based on clinical status of the participant, as per individual Trust protocols. Standard feed to be given continuously via nasogastric tube for 10 days
11672|NCT04101032|Behavioral|eBEfree|Contextual interventions based on promoting acceptance,mindfulness and self-compassion abilities
11673|NCT04101019|Drug|Lidocaine|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of 5% lidocaine will be dripped into one or two nostrils.
11674|NCT04101019|Drug|Saline Solution|Intervention will include the SPGB block which will be performed by placing the patient supine with the neck extended and 1.5 ml of saline will be dripped into one or two nostrils.
11675|NCT04100993|Other|No intervention used|No intervention used
11676|NCT04100980|Other|No Intervention|There is no intervention for this study
11677|NCT04100954|Device|Reinforced prosthesis|Implementation of a reinforced prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
11678|NCT04100954|Device|Standard prosthesis|Implementation of a standard prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
11679|NCT04100941|Diagnostic Test|standard suction|After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.
11680|NCT04100941|Diagnostic Test|slow pull|After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.
11681|NCT04100941|Diagnostic Test|wet suction|After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
11682|NCT04100928|Other|dental students|WEMWBS and a questionnaire included demographic details and social background, lifestyle behaviors was applied to the participants.
11683|NCT04100915|Other|No Intervention|There is no intervention for this study
11684|NCT04100902|Drug|ODACTRA 12 SQ-HDM Sublingual Tablet|Subjects are assigned standard scheme for administration of ODACTRA 12 SQ-HDM Sublingual Tablet.
11685|NCT04100902|Drug|Placebo oral tablet|Subjects randomized to placebo are assigned standard scheme for administration of ODACTRA 12 SQ-HDM Sublingual Tablet.
11686|NCT04100889|Other|No Intervention|There is no intervention for this study.
11687|NCT04100876|Genetic|Global DNA methylation will be quantified in the DNA samples by colorimetry|Global DNA methylation will be quantified in the DNA samples by colorimetry
11688|NCT04100863|Other|No Intervention|There is no intervention for this study.
11689|NCT04100850|Other|Aquatic Exercises|twice a week, lasting 50 minutes, for two months.
11690|NCT04100850|Other|Watsu|twice a week, lasting 50 minutes, for two months.
11691|NCT04100824|Procedure|stellate ganglion block by transcranial doppler|stellate ganglion block is a block of sympathetic ganglion
11692|NCT04100824|Drug|Nimodipine|Nimodipine 60mg every 4h
11806|NCT04099901|Drug|Placebos|Subjects will be treated with a daily dose of placebo, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
11693|NCT04100798|Procedure|Entire Papilla Preservation technique|A minimally invasive technique that allow access to the intrabony defect without affecting the interdental papilla related to it
11694|NCT04100798|Procedure|Modified Minimally invasive Surgical Technique|a minimally invasive technique that allow access to the intrabony defect area from the buccal aspect through a horizontal incision below the papilla without elevating it.
11695|NCT04100785|Behavioral|Internet-delivered Cognitive Behavioural Therapy|The iCBT programme comprised on 6 online modules. Module 1 provided an introduction to the symptoms of depression, its causes and information on CBT. Module 2 covered problem-solving strategies. Module 3 provided information on problematic thought patterns and beliefs in depression. Module 4 entailed identifying problematic thought patterns and using various techniques to counter problematic thoughts. Module 5 covered pleasurable activities scheduling to help increase activity levels.
11696|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）|0.5mL,Intramuscular other name:PCV13i
11697|NCT04100772|Biological|13-Valent Pneumococcal Polysaccharide Conjugate Vaccine|0.5mL,Intramuscular other name:Prevnar
11698|NCT04100759|Drug|Sildenafil 50 mg Oral Tablet|Sildenafil 50 mg Oral Tablet
11699|NCT04100746|Procedure|supramalleolar osteotomy|surgical intervention by using low tibial osteotomy
11700|NCT04100733|Diagnostic Test|Xpert Bladder Cancer Monitor|Xpert Bladder Cancer Monitor detects mRNA fragments from 5 genes frequently overexpressed in non-muscle invasive bladder cancer.
11701|NCT04100733|Diagnostic Test|Flexible cystoscopy (WL/NBI) and urinary cytology|Adhering to current danish guidelines for follow-up of non-muscle invasive bladder cancer.
11702|NCT04100720|Device|Cardiovalve Transfemoral Tricuspid Valve|The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation
11703|NCT04100707|Procedure|Genicular block was applied|This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions
11704|NCT04100694|Drug|MCLA-128|
11705|NCT04100681|Device|Active FlowOx™|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
11706|NCT04100681|Device|Sham FlowOx™ (Placebo)|Treatment is done by the patient at home for about 2 hours per day. Recommended to be 1 hour in the morning and 1 hour in the afternoon.
11707|NCT04100668|Device|Sensifree's Alpha sensor|RF based, wrist mounted sensor, that acquires a high fidelity signal originating at the radial artery, and constructs a pressure waveform
11708|NCT04100668|Device|Arrow® arterial catheterization kit (Teleflex)|Invasive monitoring of blood pressure via catheterization of the radial artery, displaying a continuous pressure waveform
11709|NCT04100668|Device|GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor|PPG based, fingertip mounted sensor, that measures the oxygen level (oxygen saturation) of the blood and generates a waveform
11710|NCT04100655|Drug|GM-CSF|3ml GM-CSF gel will be irrigated into the uterine cavity immediately when hysteroscopy is complete. Then same dose gel will be given every other day twice
11711|NCT04100655|Drug|17-ß estradiol|A hormone replace treatment by 17-ß estradiol (6mg per day) follows next cycle to prepare for embryo transfer
11712|NCT04100642|Drug|Hemay808|topical apply
11713|NCT04100642|Drug|Placebo|topical apply
11714|NCT04100629|Behavioral|digital support: text messages|In this study, the text messages are intended to be one-directional, from the PI to the participant. Participants are not expected to reply. If participants reply to any of the text messages, the PI will screen the content and only reply if it is a question regarding the study or a request to seek counseling. Additionally, participants will be instructed by the PI to access their Smartphones to read texts while on a break, after their shift, or when not at work; participants will be instructed to not use Smartphones to read texts while working. A series of four text messages will be sent to all study participants (experimental and control groups) by the PI every Monday, Wednesday, Friday, and Saturday (M, W, F, S) at 1pm for six weeks, for a total of 24 different texts for each group.
11715|NCT04100616|Other|No intervention|There is no intervention for this study
11716|NCT04100603|Other|No Intervention|There is no intervention for this study
11717|NCT04100590|Drug|Cannabis|Smoked active cannabis (7% THC) vs. placebo inactive cannabis (0% THC)
11718|NCT04100577|Other|Today Not Tomorrrow Pregnancy and Infant Support Program|The Today Not Tomorrow Pregnancy and Infant Support Program (TNT-PISP) is a collaborative community-based support group uniquely designed to serve black women and infants through once monthly group sessions delivered prenatally and in the immediate postpartum period.
11719|NCT04100564|Device|Supraglottic airway device|Initial advanced airway management with a supraglottic device
11720|NCT04100564|Other|Standard airway management|Initial advanced airway management with standard care method
11721|NCT04100538|Behavioral|health coach|"The health-coaching program includes (1) my file, (2) lesson, (3) self-assessment, and (4) interaction modules. My file allows participants recording their disease history. The lesson includes knowledge of fibromyalgia, stress and relaxation, emotion and positive thinking, sleep hygiene, communication skills, and exercise. The self-assessments includes symptom diary, exercise and general diary. The interaction encourages participants interacting with peers and the health coach. Participants can share practical advices, strategies, real-life examples or questions via texts or photos in share garden. Participants can connect to the health coach via contact with health coach. The coach will provide comments or responses approximately 10-30 min for each time. The coach will monitor each participant's lesson list and attendance for each lesson. The health coach will also guide the participants to create their own tailored programs according to participants' predominant symptom subtypes."
11722|NCT04100525|Behavioral|Neuropsychological testing intervention plus follow up|Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
11807|NCT04099888|Drug|Fimaporfin and Gemcitabine|PCI treatment consists of IV administration of Amphinex solution for injection (investigational product) at 0.22 mg/kg dose of fimaporfin, followed 4 days later by a standard dose of gemcitabine infusion (1000 mg/m^2) and intraluminal laser light application. Up to 2 PCI treatments will be given.
11723|NCT04100512|Device|Oscillating Positive Expiratory Pressure Device|Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously. The Aerobika® OPEP device opens weak or collapsed airways to mobilize and assist mucociliary clearance to the upper airways where it can be coughed out.
11724|NCT04100512|Device|Incentive spirometry|An incentive spirometer is a device that measures how deeply you can inhale (breathe in). It helps you take slow, deep breaths to expand and fill your lungs with air. The incentive spirometer is made up of a breathing tube, an air chamber, and an indicator.
11725|NCT04100499|Device|ESAR (Endosutured Aneurysm Repair)|EndoAnchors adjunctive therapy for EVAR and TEVAR
11726|NCT04100486|Other|Standing-Squatting-Standing Test|The participant will begin by actively standing for one minute, followed by a transition to a squat for one minute, and one last transition to one minute of standing.
11727|NCT04100486|Other|Deep Breathing Test|The participant will be asked to lay down for seven minutes and take long, controlled breaths at a rate within 4 to 10 breaths per minute.
11728|NCT04100486|Other|Cold Pressor Test|The participant will be asked to immerse their hand into ice water (1- 10°C) for up to three minutes, followed by removal of the hand from the bath and continuation for recording for a further three to five minutes. The participant will be informed that he or she can remove his or her hand at any point if there is discomfort.
11729|NCT04100486|Other|Cold Face Test|The cold stimulus will be applied with refrigerated gel-filled compresses places on the forehead and cheeks of the participant for one minute.
11730|NCT04100486|Other|Valsalva Maneuver|The participant will be asked to inhale deeply, pinch his or her nose, close his or her mouth, and forcibly exhale, while bearing down with tight chest and stomach muscles, for approximately 10 to 15 seconds. The sensors will continue recording as the participant recovers to normal breathing over the next one minute.
11731|NCT04100486|Device|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)|The participant will receive electrical stimulation applied to their ear for five minutes. The threshold for stimulation will be determined before the test begins at a level that may elicit sensation (tickling, vibrating, pricking), but no pain. There is a possibility that the participant will receive sham stimulation, or inactive stimulation, for this test.
11732|NCT04100473|Drug|Inhaled Human Insulin|Dance 501 administered using the Dance 501 Inhaler
11733|NCT04100473|Drug|Insulin Lispro (Humalog U-100)|Lispro
11734|NCT04100460|Dietary Supplement|7.25 grams of Arabinoxylan leaf fiber extract|Participants are given 7.25 grams of Arabinoxylan daily
11735|NCT04100460|Dietary Supplement|14.5 grams of Arabinoxylan leaf fiber extract|Participants are given 14.5 grams of Arabinoxylan daily
11736|NCT04100460|Dietary Supplement|Control - No Arabinoxylan|Participants are given no Arabinoxylan
11737|NCT04100447|Drug|Tranexamic Acid|A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.
11738|NCT04100434|Drug|Evolocumab|Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy.
11739|NCT04100408|Other|Biospecimen Collection|Undergo saliva or buccal mucosa collection
11740|NCT04100408|Other|Laboratory Biomarker Analysis|Correlative studies
11741|NCT04100408|Other|Questionnaire Administration|Ancillary studies
11742|NCT04100395|Device|sonoclot|Sonoclot Analyzer is best described as a microviscometer. The electronics are sensitive to any resistance to motion that the oscillating probe encounters as it moves within the test sample.
11743|NCT04100382|Device|Laser and SLA|Patients will be randomized into two groups, control group for SLA implants, and study group will receive the Laser treated implants. Implants will be placed classically in the posterior maxillary region and their stability will be measured by ISQ device at the placement. Measurements will be taken again at 2, 4, 6, 8 , 10 and 12 weeks.
11744|NCT04100369|Diagnostic Test|laboratory|Arm
11745|NCT04100356|Other|Exercise|Exercise program - indoor bicycle interval exercise, duration 60 min 3x week
11746|NCT04100356|Other|Normal Diet|Normal diet recommended by the health authorities
11747|NCT04100356|Other|LCHF Diet|LCHF Diet, a modified Atkins diet with high percentage of fat and very low percentage of karbohydrates
11748|NCT04100330|Biological|Ficlatuzumab|Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
11749|NCT04100330|Drug|Cytarabine|Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
11750|NCT04100304|Diagnostic Test|resection|CT volumetry,liver function,biopsy before resection
11751|NCT04100291|Other|Faecal microbiota transplantation|FMT by daily enema with donor faeces
11752|NCT04100291|Other|Placebo|Placebo by daily enema with placebo mixture
11753|NCT04100278|Behavioral|Shared Care diabetes management|After the inclusion visit, the patients will be randomized to Shared Care group or traditional therapy group. Compared to conventional diabetes education in the traditional therapy group, the Shared Care group provides patients with online services and continuous diabetes management and education through a mobile application. It also addresses that it is important for patients to meet regularly with diabetes multidisciplinary team for better results. The total observation period is 3 years for each patient. The visits will be done every 3 months.
11754|NCT04100265|Device|Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.
11755|NCT04100265|Device|Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)|The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.
11756|NCT04100252|Other|AFI via transabdominal ultrasonography|AFI via transabdominal ultrasonography was performed at the time of diagnosis.
15676|NCT04068090|Other|Blood Collection|biomarker analysis
11757|NCT04100239|Behavioral|Mindfulness-based stress reduction (MBSR)|MBSR is designed to complement any existing medical treatments, and focuses on the development of mindfulness meditation practice to alleviate psychological distress. MBCL is designed as a follow-up intervention to MBSR and aims to help individuals to turn towards suffering and developing a kind attitude to the self.
11758|NCT04100226|Dietary Supplement|Vitamin D3 (1.25 (OH)2 cholecalciferol)|"Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients."
11759|NCT04100213|Behavioral|Trier Social Stress Test|The TSST-G is a psychological paradigm which combines high levels of social-evaluative threat and uncontrollability in a group setting. The TSST-G will proceed in groups of three to five participants (from the same diagnostic group). The TSST-G consists of three phases: a briefing; the psychological test itself, followed by a debriefing phase. Each phase will last 40, 20 and 60 minutes, respectively. The briefing and debriefing of the TSST-G will be conducted by experienced psychotherapists. The TSST-G itself will be conducted by personal unknown to the participants.
11760|NCT04100200|Dietary Supplement|Mixed berries|Strawberry and red raspberry
11761|NCT04100200|Dietary Supplement|FOS|Fructo-oligosaccharide
11762|NCT04100200|Dietary Supplement|Control|Placebo similar in color to mixed berry supplement without any polyphenols
11763|NCT04100200|Dietary Supplement|Combination|Mixed berry composite + FOS
11764|NCT04100187|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
11765|NCT04100174|Radiation|focal brachytherapy boost to SBRT|As above
11766|NCT04100161|Dietary Supplement|Protein supplementation|Daily dose of 40 g whey protein for 3 months
11767|NCT04100161|Dietary Supplement|Carbohydrate supplementation|Daily dose of 40 g maltodextrin for 3 months
11768|NCT04100161|Procedure|Active rehabilitation|Progressive rehabilitation following a muscle strain injury for 3 months
11769|NCT04100148|Device|SyncAV programmed ON|For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.
11770|NCT04100148|Device|Fixed AV delay|For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
11771|NCT04100135|Device|Actual device PFO closure|Actual PFO closure with the GORE® CARDIOFORM Septal Occluder
11772|NCT04100135|Drug|Thienopyridine (clopidogrel or prasugrel)|Thienopyridine tablets (clopidogrel or prasugrel) administered for 6 months following device procedure
11773|NCT04100135|Device|Sham device PFO closure|Sham (simulated) device PFO closure with result of no device implantation and no PFO closure
11774|NCT04100122|Procedure|Blood drawing|Blood drawn will be done once using 15 mL of blood volume (Serum or plasma samples will be collected during the routine follow up of level of sIgE to wheat or during the oral food challenge test which intravenous insertion routinely prepared in case of the emergency reaction occurred). The specimen will be transferred to the Icahn School of Medicine at Mount Sinai, New York, USA for Laboratory processing (Luminex-based peptide assay)
11775|NCT04100109|Dietary Supplement|Polylactose|Polylactose 15 g/day
11776|NCT04100109|Other|Placebo|Cellulose 15 g/day
11777|NCT04100096|Drug|Brexpiprazole|Tablet
11778|NCT04100096|Other|Placebo|Tablet
11779|NCT04100083|Drug|Spironolactone 50 MG|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
11780|NCT04100083|Drug|Spironolactone 100mg|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
11781|NCT04100083|Drug|Spironolactone 200 mg|"Study visit timeline: initial visit [consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria."
11782|NCT04100070|Behavioral|Monitoring of the patients|"Follow-up of the patients during the 12 months study periods including :~visits with the diabetologist/pediatrician~contacts with the service provider (nurses' visits) (more in intensive group)~personalized monitoring of glycemic data transferred to the diabetologist/pediatrician for each visit (only in intensive group)"
11808|NCT04099888|Drug|Gemcitabine/Cisplatin chemotherapy|Up to 8 cycles of gemcitabine/cisplatin combination chemotherapy will be administered.
16234|NCT04063410|Procedure|MRI-Based Angiogram|Undergo pPCA
11783|NCT04100057|Behavioral|CBT-I|CBT-I improves sleep through a combination of behavioral interventions (stimulus control (SC), sleep restriction (SR)), cognitive therapy (CT) as well as additional components such as mindfulness training and sleep hygiene education. SC is an intervention that re-establishes the connection between the bed/bedroom with sleep to help develop a more consistent sleep/wake pattern. SR leads to higher quality sleep by reducing excessive time spent in bed to the actual amount of sleep, thereby creating mild sleep deprivation and increasing the homeostatic sleep drive. Like CT for other disorders, CT for insomnia targets maladaptive thoughts and cognitions that may interfere with sleep.
11784|NCT04100057|Behavioral|CCT-I|"CCT-I is a quasidesensitization treatment presented as a means of eliminating the conditioned arousal, which prolongs nocturnal awakenings. CCT-I has been validated as an active-placebo control condition. Therapists help each CCT-I recipient develop a chronological 12-item hierarchy of common activities he/she does on awakening at night (e.g., opening eyes, clock watching). Therapists also help them develop 6 imaginal scenes of themselves engaged in neutral activities (e.g., reading the newspaper). Each session, CCT-I recipients are taught to pair neutral scenes with items on the 12-item hierarchy so, by the end of the sixth session, all hierarchy items have been practiced with therapist assistance. Each session, the exercise is tape recorded and the patient is given this tape locked in a player. The patients are told to practice their exercises at home once each day, no less than 2 hours before bedtime, but to avoid using the tape or exercise during sleep periods."
11785|NCT04100044|Other|Exercise Counseling|Meet with physical therapist
11786|NCT04100044|Behavioral|Exercise Intervention|Receive personalized home exercise intervention
11787|NCT04100044|Other|Questionnaire administration|Ancillary studies
11788|NCT04100044|Other|Quality-of-Life Assessment|Ancillary studies
11789|NCT04100031|Device|bandage contact lenses|wear bandage contact lensesfor a week after cataract surgery.
11790|NCT04100031|Procedure|phacoemulsification|underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
11791|NCT04100018|Biological|nivolumab|specified dose on specified days
11792|NCT04100018|Drug|prednisone|specified dose on specified days
11793|NCT04100018|Drug|docetaxel|specified dose on specified days
11794|NCT04100005|Other|No intervention|There is no intervention for this study.
11795|NCT04099992|Behavioral|Mindfulness-based stress reduction (MBSR)|Mindfulness-based stress reduction (MBSR) is delivered in 8 weekly 2.5-hour group sessions and one day-long retreat that occurs after the 6th session. MBSR teaches to become more aware of thoughts, feelings, and sensations, and to skillfully respond to stressors. Each of the sessions includes education about mindfulness and stress; experiential mindfulness practice, and discussion of participants' experiences with mindfulness practice. Participants learn formal mindfulness practices (e.g., meditation, yoga, body scan, body scan) as well as informal such as awareness of breath, thoughts, or emotions, and mindfulness of daily activities. Participants will receive digital audio (MP3) downloads with guided MM practices, a home practice manual, and handouts with each week's assignments. Daily home practice will consist of 40-45 minutes of recorded practice. Participants will log their daily practice. If a participant misses a class, it is possible to make up the class on a different day.
11796|NCT04099992|Behavioral|Health enhancement program (HEP)|"8-week health enhancement program (HEP) is designed to provide a structurally parallel, active control intervention to MBSR with health benefits in their own right, while omitting any components of mindfulness. HEP matches MBSR in structure and content, and in parallel to MBSR, consists of music therapy, nutritional education, posture and balance movements, walking and stretching. Work with all practices with group discussion and exercises during an all-day spa day will match the all-day retreat in MBSR. HEP participants will meet with a health educator in a group setting for 8 weekly 2.5-hour sessions. Participants will receive MP3 downloads on an MP3 player with recordings of health education topics, a home listening manual, and weekly handouts with each week's listening assignments. Participants will listen to these MP3 recordings daily for 40-45 minutes and log their daily adherence."
11797|NCT04099992|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|Transcutaneous Vagus Nerve Stimulation (tVNS) is delivered using gammaCore (Electrocore), a multi-use, hand-held, rechargeable portable device consisting of a rechargeable battery, signal generating and amplifying electronics, and a button for operator control of the stimulation intensity. Conductive gel is applied to the stainless steel round discs on the device and placed vertically on the skin overlying the vagus nerve under the angle of the mandible, between the trachea and sternocleidomastoid muscle. A low-voltage electrical signal is delivered consisting of 5-kilohertz (kHz) sine wave series for 1 ms and repeated every 40 ms, with a maximum delivery of 24 V and 60 milliampere (mA) output. Stimulation amplitude is adjusted by the user and is increased until there is a vibration and slight muscle contraction in the lower face or neck. Stimulation is delivered for 2 minutes on the left side of the neck, and 2 minutes on the right side of the neck, for a total 4 minutes per one dose.
11798|NCT04099992|Device|Sham-transcutaneous Vagus Nerve Stimulation (tVNS)|Sham stimulation will be delivered using a sham device that is identical in appearance and function, but programmed to produce a lower frequency biphasic signal that can be felt by the participant without actually stimulating the vagus nerve.
11799|NCT04099979|Other|No Intervention|There is no intervention for this study
11800|NCT04099966|Drug|alpha beta depletion|donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.
11801|NCT04099953|Diagnostic Test|Hand grip, joint range of motion , functional level of the upper extremity, physical activity levels|Hand grip force with Jamar Hand Dynamometer, joint range of motion with Baseline Digital Goniometer, functional level of the upper extremity with the Shoulder-Arm and Hand Problems Questionnaire(DASH), physical activity levels with International Physical Activity Questionnaire Short Form(IPAQ-short form) and physical functions with Human Activity Profile (HAP) were evaluated.
11802|NCT04099940|Behavioral|Virtual Reality Avatar Therapy (VRAT)|The Virtual Reality Avatar Therapy (VRAT) is a Cognitive Behavioral Intervention, delivered through Virtual Reality.
11803|NCT04099940|Behavioral|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a Cognitive Behavioral Intervention, delivered as group therapy.
11804|NCT04099927|Drug|SHR0410|SHR0410 monotherapy,given intravenously
11805|NCT04099901|Drug|Anakinra|Subjects will be treated with a daily dose of 300 mg anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT).
11809|NCT04099875|Diagnostic Test|ultrasound|Ultrasound is a type of imaging. It uses high-frequency sound waves to look at organs and structures inside the body.
11810|NCT04099862|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP)
11811|NCT04099862|Procedure|EUS-BD|Endoscopic UltraSound Biliary Drainage
11812|NCT04099849|Dietary Supplement|Diet-ZnBfR: Zinc biofortified rice-based diet|Diet-ZnBfR: Zinc biofortified rice-based diet
11813|NCT04099849|Dietary Supplement|Diet- CR: Conventional rice-based diet|Diet- CR: Conventional rice-based diet
11814|NCT04099849|Dietary Supplement|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).|CR + Zn: Conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
11817|NCT04099823|Other|MRI screening form|Participants will be asked to complete a MRI screening form to check for the presence of metallic implants and materials. People with pacemakers, aneurysm clips, and cochlear implants, or metal/foreign objects in their eyes cannot have an MRI and will not be able to participate in the study.
11818|NCT04099823|Diagnostic Test|Urine pregnancy test|Pre-menopausal females will be asked if they think they may be pregnant. If yes, a urine pregnancy test will be performed.
11819|NCT04099823|Diagnostic Test|MR brain|"You will be asked to lie down on the bed of the MRI scanner. Then a MRI coil/antenna will be placed over your head. This will allow us to get clearer pictures of the tissue of interest. The MRI machine makes loud knocking sounds. Because of this you will be asked to wear earplugs. You will receive a squeeze ball alarm in case you need urgent help. We will be able to talk with you and hear you during the MRI exam. The entire MRI scan will last about 45-60 minutes. The MR exam will include standard clinical images as well as the CSF flow imaging."
11820|NCT04099810|Diagnostic Test|three-dimensional echocardiography|"A focused echocardiographic exam will be performed. In details will be acquired:~high frame rate imaging clips acquired in a static position with attention to endocardial border optimization, minimum of 3 beats recorded with 'Acquire 2', of: a. Left ventricle 2c/3c/4c; b. left ventricle SAB, SAX-M, SAX-A; c. right ventricular focused apical view.~Full volumes: a. 3d left ventricular apical acquisition; b. right ventricular apical acquisition; c. subcostal right ventricular acquisition."
11821|NCT04099797|Genetic|(C7R)-GD2.CART cells|"Dose Level 0: 1 x 10^7 GD2.CART cells single transduced without C7R with lymphodepletion chemotherapy~Dose Level 1: 1 x 10^7 C7R-GD2.CART cells with lymphodepletion chemotherapy~Dose Level 2: 3 x 10^7 C7R-GD2.CART cells with lymphodepletion chemotherapy~Dose Level 3: 1 x 10^8 C7R-GD2.CART cells with lymphodepletion chemotherapy"
11822|NCT04099797|Drug|Cyclophosphamide|Patients at all dose levels will receive lymphodepletion chemotherapy. They will receive 2 daily doses of cyclophosphamide (500mg/m2/day) finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle).
11823|NCT04099797|Drug|Fludarabine|Patients at all dose levels will receive lymphodepletion chemotherapy. They will receive 3 daily doses of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle).
11824|NCT04099784|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
11825|NCT04099784|Other|Physical development and General Health|Physical development and General health examination
11826|NCT04099784|Other|Developmental Red flags|Developmental Red flags Questionnaires
11827|NCT04099771|Drug|Ketamine|Ketamine infusion
11828|NCT04099758|Behavioral|Mindfulness of the breath meditation|A 10-minute mindfulness of the breath meditation practice
11829|NCT04099758|Behavioral|Audio-recording control|10 minute non-fiction audio-recording delivered online
11830|NCT04099745|Device|CGM|Continuous Glucose Monitoring System
11831|NCT04099745|Device|FGM|Flash glucose monitoring System
11832|NCT04099732|Drug|Rosuvastatin|Tablet
11833|NCT04099732|Drug|BI 1358894|Tablet
11834|NCT04099732|Device|Dabigatran etexilate|Capsule
11835|NCT04099706|Procedure|Autologous Fat Grafting / Fat Transplant|See arm descriptions.
11836|NCT04099680|Procedure|Partial thickness recipient bed|Flap will be separated by sharp dissection and elevated toward apical direction, leaving the periosteum covering the bone, and the elevated pedicle flap will be incised and removed.
11837|NCT04099680|Procedure|Full thickness recipient bed|Full-thickness (mucoperiosteal) flap will be raised on the recipient bed to establish a denuded bone area. Two bone screws will be placed at the most apical border of the denuded bone.
11838|NCT04099680|Device|Bone screw (FDA approved bone screw)|Two bone screws placed at the most apical border of the denuded bone after osteotomy.
11839|NCT04099680|Procedure|Periosteal sutures|Interrupted periosteal sutures placed at the 4 corners of each graft, and mesial and distal surfaces to engage the graft at an equidistance from the graft corners.
11840|NCT04099680|Procedure|Sling sutures|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and the periosteum apically.
11841|NCT04099680|Procedure|Sling sutures around screws|Crossed sling sutures placed over the graft engaging the fixed crestal/lingual KT coronally and each is apically looped around the corresponding apically positioned screw.
11844|NCT04099654|Other|Core-Stabilization Exercise|A program consisting of core stabilization exercises and physical activity counseling accompanied by physiotherapists will be applied to the study group.
11845|NCT04099654|Other|Counseling of physical activity|Only physical activity counseling will be given to the subjects in this group.
11846|NCT04099641|Drug|Bavituximab|Bavituximab IV infusion
11847|NCT04099641|Drug|Pembrolizumab Injection|Pembrolizumab IV Infusion
11921|NCT04098926|Radiation|Dose-integrated accelerated EBRT in pN0 breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy
12119|NCT04097145|Device|Edwards PASCAL System|Transcatheter tricuspid valve repair with the Edwards PASCAL System in patients on optimal medical therapy
11848|NCT04099628|Diagnostic Test|Rapid diagnostic test (RDT); Serological and molecular tests on DBS|"The population of low to zero prevalence HAT foci will be actively screened for HAT by taking a blood sample for performing 3 rapid diagnostic tests (RDT) and for preparing dried blood spots to perform 4 serological and molecular high throughput reference tests. If at least one of the RDTs, serological or molecular reference tests is positive, parasitological examination is performed twice. The combined results of parasitological examinations serve as reference standard.~Other Names:~rHAT Sero-Strip (Coris Bioconcept, Belgium) SD Bioline HAT 1.0 (Standard Diagnostics Korea) HAT Sero-K-Set (Coris Bioconcept, Belgium) Immune trypanolysis: presence of antibodies ELISA: on native LiTat 1.3 + LiTat 1.5 variant surface glycoprotein (VSG) LAMP T. brucei Detection Kit (Eiken) RT-PCR: Trypanozoon 18S, Tbg Trypanosoma gambiense specific glycoprotein (TgsGP)"
11849|NCT04099615|Procedure|Somatosensory Evoked Potentials|We stimulate both median nerves at wrist by means of surface adhesive electrodes. We apply square wave electrical pulses of 0.2 ms duration at a frequency of 5.7Hz. SEPs are recorded in a referential fashion from the C3' and C4' positions and from a reference electrode at Fpz or Cz' electrodes(international 10-20 system) with needle electrodes. The target signal is the presence of N20 response ipsilateral to the stroke site and, if present, measure amplitude and latency comparing with the contralateral if present. SEPs are registered during the whole procedure.
11850|NCT04099602|Other|Baby Massage|Received baby massage and bilirubin levels were measured twice daily by the transcutaneous bilirubin meter for 5 days
11851|NCT04099589|Drug|Toripalimab|Gemcitabine/Cisplatin plus Toripalimab
11852|NCT04099576|Other|physiotherapy and education|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program. In addition to physiotherapy, therapeutic neuroscience education were applied to experimental group. One-to-one speech sessions focusing on pain neurophysiology were organized twice a week for three weeks. Each session lasted 40 minutes. The Therapeutic neuroscience education program included nociception, ion channel neurophysiology, central and peripheral sensitization, methods to help reduce sensitization, neuroplasticity, psychosocial factors involved in the transition from acute pain to chronic pain and behavioral, cognitive responses to pain.
11853|NCT04099576|Other|Physiotherapy alone|Hot-pack, ultrasound, trancutaneus nerve electrical stimulation (TENS) and home program exercises were applied or given to the individuals within the physiotherapy program.
11854|NCT04099563|Drug|PF-04965842|"For this study, the investigational product is PF-04965842 (provided as 100 mg tablet).~PF-04965842 100 mg tablets will be provided by Pfizer. Investigational product will be presented to the participants in individual dosing containers"
11855|NCT04099550|Device|RT-CGM|The group was monitored blood glucose initial 1-week with a RT-CGM.
11856|NCT04099550|Other|SMBG|The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
11857|NCT04099537|Behavioral|Computerized cognitive training|Participants are trained to approach or avoid stimuli of skin using a joystick. Participants are to pull or push the joystick toward or away when skin stimuli are present. Thus, behaviorally, there may be an increase, decrease, or no change in approach tendencies towards skin.
11858|NCT04099524|Device|tDCS|tDCS (LPG/C3-anode, orbitofrontal cortex/Fp2-cathode) will be administered for 4 weeks (1 session per weekday for 2 weeks, and then 2 sessions per week for 2 weeks, for a total of 14 sessions). All subjects will receive anodal tDCS stimulation for 20 minutes per session, on C3 and the cathode electrode on Fp2 using 10/20 EEG system. tDCS will be applied with a pair of 35 cm2 single-use sponges soaked in approximately 4mL of saline solution on each side (~8mL per sponge) connected to the stimulator. During the 20-minute tDCS session, we will use online tDCS design (i.e., a subject will simultaneously work on the visual attention-oriented task.
11859|NCT04099511|Behavioral|Usual Care Occupational Therapy-Outpatient|The control group in the proposed study will receive usual care occupational therapy services. The dosage between the experimental group and usual care will be identical with each group receiving ten 45- minute treatment sessions. The treating therapists will be unfamiliar with the experimental group intervention to avoid contamination. Each therapist will be instructed to provide care in the same manner as they typically provide in day-to-day practice for patients with similar characteristics as those in the study. The therapists will be encouraged to provide home action plans to participants. Usual care services will be monitored through a log of number of sessions, time spent in each session, and what activities were the focus of each session. The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
11860|NCT04099511|Behavioral|Cognitive Orientation to daily Occupational Performance|The Cognitive Orientation to daily Occupational Performance (CO-OP) approach was developed within the field of occupational therapy and is a performance-based, problem-solving approach to address activity performance limitations. Subjects will be taught to use the global problem-solving strategy of Goal-Plan-Do-Check: identifying a specific goal (Goal), outlining a practical plan for reaching that goal (Plan), accurately performing the plan (Do), and analyzing whether the plan led to achievement of the goal and altering the plan accordingly (Check). The Goal-Plan-Do-Check process will be iteratively applied to each of the activity goals. Therapists will use guided discovery to allow the subject to self-identify their own potential solutions within an activity (develop the plan). The therapists will be instructed that they can address any participant goals they wish other than transfer goals identified by the participant.
11861|NCT04099498|Behavioral|Online Program: Healthy Eating Promotion with Self-regulation|Online-Intervention group
11862|NCT04099498|Behavioral|Enhanced Online Program: Healthy Eating Promotion with Self-regulation|Enhanced-online-Intervention Group
11863|NCT04099485|Other|Electronic Health Record Best Practice Advisory|The AFDST is a decision support tool that is embedded in our electronic health record system. Currently, this is a passive tool that requires the clinician to launch the tool if an analysis is desired. The experimental arm of this study will add a best practice advisory (BPA) that will trigger when a clinician is in the medical record of an AF patient who might gain substantial benefit (survival and quality of life) if treatment were changed from the current anticoagulation plan, which might be no anticoagulant therapy.
11922|NCT04098926|Radiation|Dose-integrated accelerated EBRT in pN+ breast cancer|WBI: 5 x 5.7Gy Thoracic wall: 5 x 5.7Gy R0 boost: 5 x 6.5Gy R1 boost: 5 x 6.9Gy Lymph node region: 5 x 5.4Gy
12120|NCT04097145|Drug|Optimal Medical Therapy|Optimal Medical Therapy alone in patients with tricuspid regurgitation
11864|NCT04099472|Behavioral|Delirium Education, Prevention, and Management|"Patients and families will have a choice of either watching a 6-minute video or reading an educational booklet with a competent research assistant on the signs of delirium, risk factors, and prevention and management strategies.~Caregivers will practice identifying delirium with the Sour Seven questionnaire, using previously validated case vignettes of hypothetical ICU patients. Family members will also complete a daily checklist of non-pharmacological interventions (ie. orientation, mobility, and environmental cues).~Delirium detection by family caregivers will be assessed by the Sour Seven Questionnaire and communicated to the bedside nurse."
11865|NCT04099472|Behavioral|Standard Care|Patients and families will receive standard care, which is an informational pamphlet on ICU delirium upon admission.
11866|NCT04099446|Other|Non-interventional|There is no intervention for this study
11867|NCT04099433|Dietary Supplement|Vivomixx|Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
11868|NCT04099433|Other|Placebo|Individuals in the placebo arm will undergo daily oral intake of placebo supplement
11869|NCT04099420|Behavioral|Lifestyle counseling|An in-depth analysis of the lifestyle of Italian and Spanish university students will be carried out for the first time, with assessment of the frequency of self-medication and use of drugs and supplements/nutraceuticals. The composition of the oral microbiota in relation to eating habits will be determined for the first time. The results of this study will be useful for designing promotion programs for the correct use of drugs/supplements and for healthy diets and lifestyles in university students
11870|NCT04099407|Drug|Pirfenidone|Treatment consist of 600 mg tablets of a prolonged-released formulation of Pirfenidone. Patients are instructed to take medication orally, every 12 h, after breakfast and dinner.
11871|NCT04099407|Other|Standard of care|All participants will require to adhere to a standard of care including nutritional support, quarterly medical evaluation to review lab results and adjust medications, bi-annual Fibrotest, FibroScan and liver ultrasound, and annual upper-gastrointestinal endoscopy.
11872|NCT04099394|Behavioral|Behavioral Health|Ten, group-based classes lasting one hour each that teaches symptom management and promotes physical activity.
11873|NCT04099394|Behavioral|Health Education|Ten, group-based classes lasting one hour each that teaches topics related to aging and health (e.g., blood pressure control, maintaining healthy bones, cancer screening, immunizations).
11874|NCT04099381|Biological|ASD CB-MNC infusion low level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 3 or fewer by A, B, DRB1 loci.
11875|NCT04099381|Biological|ASD CB-MNC infusion high level HLA compatibility.|CB-MNC infusion from different donors. One dose consists of 2-15х10^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of the cord blood is 4 or more by A, B, DRB1 loci.
11876|NCT04099381|Other|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
11877|NCT04099368|Behavioral|Musical pitch training|Crossover design with one group receiving musical training as rehabilitation, second group receiving visual training first as a control rehabilitation.
11878|NCT04099355|Drug|Dronabinol|PO
11879|NCT04099342|Device|FEAST|FEAST with standard electrode configuration and current flow
11880|NCT04099342|Device|FEAST RP|FEAST with standard electrode configuration and reversed current flow
11881|NCT04099342|Device|FEAST RC|FEAST with standard current flow and reversed electrode configuration
11882|NCT04099329|Behavioral|Pre-game Safety Huddles|Coaches will be trained to lead Pre-game Safety Huddles by the RA with the study using a multi-media tool we have developed. Huddles will be brief (1-2 minutes) and will primarily focused on 1) encouraging concussion reporting and 2) encouraging good sportsmanship
11883|NCT04099316|Device|Eccentric exercise|Eccentric exercise with Eccentron electronic device. Exercise intervention: The exercise intervention is performed to twice a week (Total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage),(5-8 weeks; 2nd stage).
11884|NCT04099316|Device|Conventional resistance exercise|Leg press exercise with leg press machine. Exercise intervention: The exercise intervention is performed to twice a week (total 8 weeks). Exercise intensity is gradually increased to the number of times by divided into two stages (1-4 weeks; 1st stage), (5-8 weeks; 2nd stage).
11885|NCT04099303|Biological|Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed|0.5 mL, Intramuscular Other Name: DTcP
11886|NCT04099303|Biological|Diphtheria and Tetanus Combined Vaccine, Adsorbed|2mL, Intramuscular Other Name: DT
11887|NCT04099303|Biological|Diphtheria-tetanus-acellular pertussis vaccine|0.5 mL, Intramuscular Other Name: DTaP
11888|NCT04099303|Biological|Diphtheria,tetanus,pertussis(acellular,component),poliomyelitis(inactivated) vaccine(absorbed) and Haemophilus influenzae type b conjugate vaccine|0.5 mL, Intramuscular Other Name: PENTAXIM
11889|NCT04099290|Other|Blood and tumor samples|Blood samples to be obtained at consent, post-operatively, post-adjuvant treatment, and at follow-up or recurrence. Tumor samples to be obtained at surgery and at time of recurrence or post-treatment biopsy, if applicable.
11890|NCT04099277|Drug|LY3435151|Administered IV
11891|NCT04099277|Drug|Pembrolizumab|Administered IV
11892|NCT04099264|Other|Personalized music|Patients in the intervention group will listen to personalized music from the Musicare application
11893|NCT04099264|Other|Audio Books|Patients in the active comparator group will listen to audio books
11897|NCT04099225|Diagnostic Test|Multiple breath washout (MBW) testing|Lung clearance index (LCI), acinar (Sacin) and conductive (Scond) ventilation heterogeneity were derived from triplicate SF6-MBW measurements. Global ventilation heterogeneity was calculated for the 2.5% (LCI2.5) and 5% (LCI5) stopping points.
11988|NCT04098302|Drug|Placebo Capsules|Placebo capsules with matching appearance as Dutasteride Capsules
12224|NCT04096131|Procedure|cataract surgery|phacoemulsification
11898|NCT04099199|Diagnostic Test|Click Sexual Health Test|The Click Diagnostics device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
11899|NCT04099186|Procedure|catheter directed hydro-mechanical fragmentation of pulmonary embolism|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery , then 200 ml saline will be injected via power injector to aid fragmentation of thrombus
11900|NCT04099173|Behavioral|Brief Mindfulness Based Intervention|This intervention will consist of four, 45 minute individual mindfulness training sessions (one session per day, over a range of 12 subsequent days) provided by a trained mindfulness facilitator.
11901|NCT04099160|Other|Evaluation|The Turkish version of the Revised Neurophysiology of Pain Questionnaire will be applied to patients with chronic spinal pain at the beginning of the study and a week later. The Visual Analogue Scale and the Short Form-36 (SF-36) questionnaire will be applied to patients only at the beginning of the stuy.
11902|NCT04099147|Other|This is an observational study.|This is an observational study. No intervention is planned outside of usual clinical practice.
11903|NCT04099121|Device|Ultrasound Imaging|3D ultrasound of the pelvic floor and vaginal cavity will be obtained by using a commercial ultrasound system.
11904|NCT04099108|Combination Product|Combined cycle ergometry and bolus amino acid supplementation|A 4-hour bolus amino acid supplement administered within 30 minutes after a 30-minute in-bed cycling session.
11905|NCT04099095|Behavioral|Immediate Appointment|The participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
11906|NCT04099095|Behavioral|Delayed Appointment|After a period of delay (control) the participant will meet the British Red Cross link worker and decide upon a course of action requiring the use of local services appropriate for the participant
11907|NCT04099082|Other|samples|blood sample nasal swab
11908|NCT04099069|Procedure|anesthesia|patient was insert trachial intubation or rigid bronchoscopy with ventilation under general anesthesia
11909|NCT04099056|Device|Transcranial Magnetic Stimulation (TMS)|Participants will be seated comfortably in a chair and asked to complete simple computer tasks. Either during, or just before any of the tasks, participants will receive either repetitive transcranial magnetic stimulation (rTMS) or single pulse TMS. During this, the researchers place a small plastic coil next to the participant's head. The coil will then generate a magnetic pulse, and stimulation will occur during presentation of the visual stimuli on which subjects will conduct behavioral or cognitive tasks.
11910|NCT04099043|Device|Cascade Continuous Glucose Monitoring System|Continuous Glucose Monitoring for 15 days
11911|NCT04099017|Other|Mulligan Joint mobilization|"This study ARM will received Mulligan joint mobilization and concomitant therapies in this group.~The following are the brief detail of therapy~Mulligan joint mobilization in Non-weight bearing (NWB) to weight-bearing (WB) 6 -10 Reps and 3 sets/ session.~Procedural detail:~Joint mobilization will be performed in sagittal, frontal and transverse direction, following glide will be preferred will depend on patient adherence to the joint mobilization. Mobilization will be progress from NWB to WB according to patient compliance 27~Knee strengthening Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Kinesiotaping:"
11912|NCT04099017|Other|Trunk stabilization group|"This study ARM will received Trunk stabilization exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Trunk stabilization Area: Trunk Type of exercise: Stabilization exercise Intensity: 6-8 reps Frequency: 3 sets per session and 30 second duration break between sets~Procedural detail:~i. modified supermen extension exercise ii. Back bridge: iii. Unilateral back bridge:~Iv. lateral step up:~Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Procedural detail:~i. Isometric quadriceps exercise: ii. Straight leg raising (SLR) exercise:~Kinesiotaping:"
11913|NCT04099017|Other|Knee strengthening group|"This study ARM will received Knee strengthening exercises and concomitant therapies in this group.~The following are the brief detail of therapy:~Knee strengthening Area: Knee Joint Type of exercise: Knee Isometric Strengthening exercises. Intensity: 10 reps Frequency: At 1st week one set of all knee exercise will be performed then it will be progressed to 2 sets at 3 weeks, and these exercises will be progressed to three sets until the 6 weeks~Procedural detail:~i. Isometric quadriceps exercise ii. Straight leg raising (SLR) exercise:~Kinesio-taping:~Muscle stretch method will be applied which involves one Y and two I straps: The Y-shaped tape base will be affixed over the top of patella then pulls up his/her knee to its maximum bending capacity then both end of Y strip is placed around the patella ending on the tibial tuberosity. Then reinforcing I-tape will be affixed at the origin and insertion of MCL and LCL. Tape will be change in every session."
11914|NCT04098991|Drug|Levothyroxine|All participants will be treated for their hypothyroidism according to the standard of care as reflected in recent guidelines from the American Thyroid Association.
11915|NCT04098978|Other|Pharmacist Drug Therapy Management|Patients will be seen by pharmacist for collaborative drug therapy management.
11916|NCT04098965|Other|Pysiotherapy techniques|manual therapy techniques, postural re-education and muscle strengthening
11917|NCT04098965|Other|physician treatment|hygienic-dietary recommendations, Kegel exercises and pain relievers
11918|NCT04098952|Other|Control group|The treatment techniques used will be: ischemic compression in the trigger point of the masseter and myofascial technique for the decompression of the temporals.
11919|NCT04098952|Other|Experimental group|In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
11920|NCT04098939|Diagnostic Test|Diaphragm evaluation|Ultrasound and radiographic evaluation of diaphragm function
11923|NCT04098913|Behavioral|Reduced screen-based media use|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use screen-based media for necessary contact/errands. If one of the adult participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
11924|NCT04098900|Diagnostic Test|Click Sexual Health Test|The Click Device is a single-use (disposable), fully integrated, rapid, compact, device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for accurate, qualitative detection and differentiation of deoxyribonucleic acid (DNA) for Neisseria gonorrhea (NG), Trichomonas vaginalis (TV), and Chlamydia trachomatis (CT) organisms.
11925|NCT04098887|Radiation|Lattice stereotactic body radiation therapy|For Lattice SBRT, the daily prescription dose will be 20 Gy to be delivered to the PTV_2000 with a simultaneous integrated boost of 66.7 Gy to be delivered to the PTV_6670 over 5 fractions (4 Gy and 13.2 Gy to the PTV_2000 and PTV_6670, respectively).
11926|NCT04098874|Drug|Bupropion Extended Release Oral Tablet|12 weeks postpartum of blinded study medication
11927|NCT04098874|Drug|Placebo oral tablet|12 weeks postpartum of blinded placebo
11928|NCT04098861|Drug|Latanoprost/Timolol|Latanoprost/Timolol Fixed Combination
11929|NCT04098848|Other|Cycling exercise|Intradialytic cycling exercise for 30 minutes a time
11930|NCT04098835|Behavioral|ASCEND|ASCEND is a behavioral intervention that combines computer-based cognitive exercise, strategy coaching with a neuropsychologist, and homework exercises in order to improve attention, working memory, and cognitive control after stroke.
11931|NCT04098822|Device|Virtue male sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from in-trinsic sphincter deficiency (ISD). The sling is manufactured from polypropylene and is sold for single use only. The device is a quadratic sling and consists of a knitted monofilament polypropylene mesh. The body of the device provides surface area for supporting the bulbous urethra.
11932|NCT04098809|Device|16 French urinary catheter|16 French urinary catheter
11933|NCT04098809|Device|20 French urinary catheter|20 French urinary catheter
11934|NCT04098796|Drug|Anti-PD-1 antibody|Sintilimab will be administered 200 mg intravenous drip, every 3 weeks. Anti-PD-1 antibody will be administered until the disease progresses or lasts for two years.
11935|NCT04098796|Drug|XELOX|Oxaliplatin 130 mg/m2, intravenous drip, d 1; Capecitabine 1000mg/ kg, twice a day, orally, d1-14; Every 21 days. XELOX 6-8cycles，followed by capecitabine monotherapy, the course of treatment is determined by the investigators according to clinical practice.
11936|NCT04098783|Other|Home visit, health education|
11937|NCT04098770|Biological|Allogeneic Adoptive Immune Therapy|A dose (2-3 times) of AAIT was added on conventional treatment for advanced AIDS patients
11938|NCT04098757|Dietary Supplement|Migratens|2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
11941|NCT04098718|Drug|Benralizumab|100mg sub cut once only
11942|NCT04098718|Drug|Prednisolone|30mg tablet daily for 5 days
11943|NCT04098705|Other|Introduction of the World Health Organization Triage Scale|"The intervention will comprise implementation of a new triage and patient flow system facilitated through staff training and clinical redesign.~The three-tier World Health Organization Triage Scale (WHOTS) will be used as the triage instrument. This tool, developed collaboratively by the WHO, International Committee of the Red Cross (ICRC) and Médecins Sans Frontières (MSF), incorporates features of the South African Triage Scale but has been modified for application in a wide variety of RL settings. WHOTS documents are provided in the research protocol."
11944|NCT04098692|Drug|Derazantinib capsule|300 mg derazantinib oral administration (3x100 mg capsules)
11945|NCT04098692|Drug|[14C]-Derazantinib solution for infusion|100 μg [14C]-derazantinib intravenous administration
11946|NCT04098692|Drug|[14C]-Derazantinib capsule|300 mg [14C]-derazantinib oral administration (3x100 mg capsules)
11947|NCT04098666|Drug|Placebo oral tablet|Placebo tablet identical to metformin, up to 4 tablets a day
11948|NCT04098666|Drug|extended release metformin|Metformin extended release 500 mg tablets, up to 4 tablets a day
11949|NCT04098653|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
11950|NCT04098653|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
11951|NCT04098653|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
11952|NCT04098640|Genetic|FoundationOne CDx|FoundationOne CDx will be performed using archival tumor tissue
11953|NCT04098627|Behavioral|Laughter Therapy|Once weekly 30-minute long group laughter therapy session for 8 weeks
11954|NCT04098614|Behavioral|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
11989|NCT04098289|Procedure|Hysteroscopic septum resection|Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.
12225|NCT04096105|Drug|CC-93538|a single dose CC-93538 SC
11955|NCT04098601|Behavioral|Recovery Coach Intervention|Participants randomized to the intervention arm are linked to a recovery peer coach while they are in the hospital. Recovery peer coaches are provided to the participant by Faces and Voices of Recovery (FAVOR) - Greenville. Recovery coaches are Certified Peer Support Specialists (CPSS), individuals who have firsthand experience in successful recovery and are trained in using recovery-oriented tools to help peers overcome addiction. FAVOR offers immediate access to a personal coach, a local center, and assistance to off-site intervention and recovery resources in the community. They provide twice weekly contact with participants.
11956|NCT04098588|Behavioral|BEAST|See Arm Description
11957|NCT04098588|Behavioral|Descriptive Feedback|See Arm Description
11959|NCT04098562|Drug|LL37|cream
11960|NCT04098562|Procedure|Standard Wound Care|Standard wound debridement
11961|NCT04098549|Other|Rapid lowering of plasma glucose|Rapid lowering of plasma glucose using hypoglycemic clamp technique
11962|NCT04098549|Other|Slow lowering of plasma glucose|Slow lowering of plasma glucose using hypoglycemic clamp technique
11963|NCT04098536|Behavioral|Diesel exhaust|Exposure to diesel exhaust fumes
11964|NCT04098523|Diagnostic Test|Duplex ultrasound|A one-time carotis and abdominal aorta duplex ultrasound will be performed on-site by a skilled site staff to determine the prevalence of, and risk factors associated with, CAS and AAA. A diameter measurement will be performed of the abdominal aorta as well as a determination of the carotid arteries.
11965|NCT04098510|Dietary Supplement|MitoQ|Subjects ingest 8x20 mg MitoQ capsules
11966|NCT04098497|Behavioral|Mobile intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of mania, depression, medication adherence, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
11967|NCT04098484|Other|Control Trial|Participants will abstain from exercise throughout a 3-month period
11968|NCT04098484|Other|Exercise Trial|Participants will execute a 3-month exercise training program
11969|NCT04098471|Procedure|transanal local excision following radiotherapy|transanal local excision following radiotherapy
11970|NCT04098458|Behavioral|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months)
11971|NCT04098432|Drug|Nivolumab|Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity
11972|NCT04098432|Radiation|Stereotactic radiotherapy|The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).
11973|NCT04098419|Behavioral|Science for Life|The implementation for both school years will follow the same procedures with different cohorts. Sixteen adolescents will be recruited through existing after-school programs at each location (32 total each year). College interns will facilitate food literacy lessons after school once per week with high school-aged adolescents. Beginning in January, adolescents will participate in training led by project staff and college interns to become competent cross-age teachers for garden-enhanced nutrition curricula. This training will consist of instruction in utilization of inquiry-based teaching practices and will be followed by adolescents practicing facilitating the curricula in teaching pairs. Up to 32 younger youth participants at each location (up to 64 total each year) will be recruited from local elementary schools while adolescents complete the cross-age teaching training. With mentorship from college interns, adolescents will facilitate curricula in pairs with younger youth.
11974|NCT04098406|Drug|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a nominal concentration of 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose 60 mL HDPE containers.
11975|NCT04098406|Drug|Placebo|Placebo is liquid with identical color and taste
11976|NCT04098393|Drug|Busulfan 3.2 mg/kg/day|Busulfan 3.2 mg/kg/day, with dose adjustments made according to pharmacokinetic (PK) levels.
11977|NCT04098393|Drug|Fludarabine|Fludarabine (25mg/m2/ day) administered on days -6, -5, -4, -3, and -2.
11978|NCT04098393|Drug|Melphalan|Melphalan (70mg/m2/day) administered on days -6 and -5.
11979|NCT04098393|Drug|Antithymocyte globulin (ATG)|Anti-thymocyte globulin (ATG) 2.5 mg/kg/day on days -3 and -2
11980|NCT04098393|Drug|Busulfan 0.8 mg/kg|Busulfan 0.8 mg/kg every 6 hours x 10 doses, with dose adjustments made according to PK levels.
11981|NCT04098393|Procedure|Allogeneic hematopoietic cell transplantation (Allo-HCT)|Allogeneic hematopoietic cell transplantation following the conditioning regimen.
11982|NCT04098380|Procedure|Small Bite|the bites will be applied with a bite width of 5 mm and inter-suture spacing of 5 mm
11983|NCT04098380|Procedure|Larger bite|the bites will be applied with a width of 10 mm and inter-suture spacing of 10 mm
11984|NCT04098354|Diagnostic Test|home BP telemonitoring system .|home BP telemonitoring system whereby a patient pushes a single button on a home BP monitor to initiate measurement, and data are auto-transmitted via Bluetooth to an Android smartphone and relayed to a secured web portal for review.
11985|NCT04098341|Diagnostic Test|IGRA blood test used as a tool for opt-out screening for latent Tuberculsis infection|All eligible pregnant migrants will be offered an opt-out screening IGRA blood test for latent Tuberculosis infection
11986|NCT04098315|Other|REGISTER CREATION|Build a national registry of patients with HIV-1 infection and documented resistance to the 4 classes of antiretroviral drugs.
11987|NCT04098302|Drug|Dutasteride Capsules|1 mg/day oral dutasteride (2 x 0.5 mg capsules)
11990|NCT04098289|Procedure|In vitro fertilization|Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
11991|NCT04098276|Behavioral|WeWomen Plus technology based intervention|The WeWomen Plus intervention is a technology based (online, text and phone)culturally tailored intervention designed to reduce the risk of future intimate partner violence or a homicide, improve mental health and increase empowerment of abused immigrant women.
11992|NCT04098263|Biological|LMN-101|variable heavy chain-derived binding protein designed to bind and inhibit flagellin filament protein of Campylobacter jejuni, delivered in whole spray-dried, encapsulated spirulina biomass
11993|NCT04098250|Drug|Erenumab|a CGRP receptor monoclonal antibody
11994|NCT04098250|Other|Placebo|Placebo
11995|NCT04098237|Drug|Pancrelipase|Pancrelipase delayed-release capsules
11996|NCT04098224|Device|smART+ System|Utilizing the smART+ System to provide feeding optimization to the patient
11997|NCT04098198|Diagnostic Test|Panel of genes|Disease-specific mutations will be tested via Next Generation Sequencing using a comprehensive panel with 166 genes
11998|NCT04098198|Diagnostic Test|Biomaker or Enzymatic testing|Biomarker using mass spectrometry and enzymatic testing will be done
11999|NCT04098185|Device|CT|Non-contrast Multidetector Computed Tomography will be done for all patients using 16 or 64 MDCT scanner. Standard scanning parameters of chest CT are used with slice thickness 5 mm, 120kv and automated mAs.The evaluation of pleural effusion attenuation will be done using the average measure of 3 slices with greatest amount of fluid. A region of interest (ROI) is placed for measurement of Hounsfield unit values, where pleural fluid is observed to be most intense and the density values of the pleural fluid and of the aorta are quantitatively measured in the same section with taking care not to involve adjacent ribs, lung parenchyma or areas of pleural thickening.
12000|NCT04098172|Device|Pressure Guidewire|Fractional Flow Reserve measurement
12001|NCT04098159|Device|duplex ultrasound|regular duplex follow up every three months with subsequent intervention either diagnostic venography , angioplasty or surgery according to the type of the lesion
12002|NCT04098146|Procedure|Surgical Resection and Reconstruction|"One stage reconstruction: Osseous reconstruction is performed in the same surgery of the tumor/mandibular resection. It is also known as immediate or primary reconstruction.~Second stage reconstruction: Osseous reconstruction is performed after the tumor/mandibular resection surgery as an independent surgery. After the mandibular resection a temporary alloplastic bridging might be put in place. It is also known as delayed or secondary reconstruction."
12003|NCT04098133|Other|data collection for demographic data|data collection for demographic data (age, gender, hospital admission and discharge date, length of stay, hospitalization prior to current hospital stay (acute care facilities, long-term healthcare centres, nursing homes), discharge destination, outcome, cause of death, travel history, previous exposure to antibiotics and proton pump Inhibitors)
12004|NCT04098133|Other|data collection for clinical data|data collection for clinical data (comorbidities, Charlson Comorbidity Index, immunosuppressive treatment, date of diagnosis of CPB, days between hospital admission and diagnosis of CPB, type of consecutive infection, indwelling vascular hardware, urinary catheterization, surgical therapies)
12005|NCT04098133|Other|data collection for treatment data|data collection for treatment data (antibiotic therapy, immunosuppressive therapy, concomitant medication)
12006|NCT04098133|Other|data collection for microbiological data|data collection for microbiological data (species of CPB, type of sample, date of sample, history of colonization or infection with any antibiotic resistant pathogen)
12007|NCT04098107|Device|Throwing Device|The Innovative Design Labs ( IDL) PhySens will be used to monitor the physical motions of subjects during standard sports-related actions (e.g. throwing a baseball). For this test, the PhySens Carrier will be attached via clothing rivets to a fabric sleeve or strap made of compliant materials commonly used in clothing and wearable products (e.g. nylon, spandex, neoprene).
12008|NCT04098081|Drug|galeterone|Therapeutic
12009|NCT04098081|Drug|Gemcitabine|Therapeutic
12010|NCT04098068|Drug|MK-3475 (an Antibody That Blocks Negative Signals to T Cells)|MK-3475 (an Antibody That Blocks Negative Signals to T Cells) 200 mg/kg flat dose every 21 days
12011|NCT04098055|Device|Custom-Made Foot Orthoses|The foot orthoses were custom made using phenolic foam molds of the feet. They consisted of a polypropylene layer of 2 mm from heel to just proximal to the metatarsal heads, an upper sheet of 30 Shore A polyethylene foam.
12012|NCT04098055|Device|Placebo|The insole made using phenolic foam molds of the feet. They consisted of an upper sheet of 30 Shore A polyethylene foam.
12013|NCT04098042|Device|Scaffold|implantation of a Magmaris scaffold
12014|NCT04098029|Biological|Low HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 3 or fewer by A, B, DRB1 loci.
12015|NCT04098029|Biological|High HLA group CBU infusion|CB-MNC (Cord Blood Mononuclear Cells) infusion from different donors. One dose consists of 2-15х10^7 cells per 1 kg of patient weight for each infusion. The protocol includes 2 infusions with an interval of 6-x months. HLA compatibility of CB is 4 or more by A, B, DRB1 loci.
12016|NCT04098029|Other|Standard therapy|The standard therapy can include drugs, special psychology training, etc.
12017|NCT04098016|Behavioral|Digital Intervention|Participants (N=50) will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) responsive coaching, and 4) skills training.
12018|NCT04098003|Drug|Rosuvastatin|rosuvastatin 20 mg daily or placebo for eight weeks
12019|NCT04098003|Drug|Placebo|Matched placebo control
12020|NCT04097990|Other|blood sample|a 5 cc blood sample will be taken after a 12-hour fast for separation of triglycerides from the serum and for checking fatty acid levels
12111|NCT04097236|Other|Qualitative and quantitative assessment of gastric content volume without bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
12112|NCT04097223|Drug|Long-acting beta agonist + Long-acting muscarinic antagonist|drug
12021|NCT04097977|Other|An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work) targeting young people with mental health difficulties.|"An educational support model called RENEW (Rehabilitation for Empowerment, Natural Support, Education and Work).~Intervention The RENEW-S intervention consists of two key elements: collaborative networking and a youth group.~Network meetings The RENEW-S network meetings is fundamental for this approach. First meeting between the young person and the facilitator is about what the young person can expect, and information about the principles and ideas behind RENEW-S. The RENEW-S process consists of 4 general phases: 1) a mapping process 2) the development of a team to support goal attainment 3) implementing the plans 4) preparation for exiting RENEW.~Youth group The group is structured around the same agenda each time, starting with a presentation round, followed by an activity within the topic of the day, and finishing with sharing experiences of the activity in plenum. The young people can find inspiration regarding themes and exercises in the RENEW manual."
12022|NCT04097964|Behavioral|brief intervention|1 minute or less of anticipatory guidance will be provided for adolescents reporting no use in the past year, a 3-5 minute abbreviated brief intervention including raising the subject, asking more questions, and correcting misinformation will be provided for adolescents reporting substance use once or twice in the past year, and a 5-10 minute full brief intervention will be provided, including the above steps as well as assessing readiness and negotiating change and scheduling a follow-up to potentially include a referral to treatment will be provided to adolescents reporting monthly to weekly use in the past year.
12023|NCT04097964|Behavioral|treatment as usual|standard care conducted by primary care providers during clinic visits
12024|NCT04097951|Drug|Combinations|Montelukast and Bepotastine Combination
12025|NCT04097938|Drug|GLPG3667|GLPG3667 oral suspension
12026|NCT04097938|Drug|Placebos|Placebo oral suspension
12027|NCT04097925|Drug|Doravirine|Doravirine 100 mg tablet
12028|NCT04097925|Drug|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
12029|NCT04097912|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|75-100mg
12030|NCT04097899|Other|implementation of antimicrobial stewardship comprehensive care bundle program on ventilator associated pneumonia patients|"Construction of a comprehensive care bundle educational program. This program consisted of many elements: Antimicrobial stewardship programs, VAP bundles and infection control policy implementation and the investigators studied the impact of this program on:~Antibiotics cost.~Appropriates of antibiotic use (initiation, duration & time of discontinuation).~Rate of resistance~Clinical outcome, infection rate &length of stay."
12031|NCT04097886|Other|Morning Exercise|moderate intensity exercise (70% VO2 max) each morning for 5 days
12032|NCT04097886|Other|Evening Exercise|moderate intensity exercise (70% VO2 max) each evening for 5 days
12033|NCT04097873|Other|Diaphragm ultrasonography reeducation plus inspiratory training|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
12034|NCT04097873|Other|Isolated inspiratory training|Isolated high-intensity inspiratory muscle training during 8 weeks
12035|NCT04097860|Behavioral|Text message including biomarker of breast pumping adequacy|The intervention group will be sent one message that includes general information pertinent to all mothers expressing BM for their infants and one personalized real-time biomarker based message which will include the sodium level contained in the BM since the previous message, the number of times pumped on those days and will either congratulate the participant on how well the participant is pumping BM for the infant or how many more times per day the participant needs to pump to decrease the BM sodium level and increase BM production
12036|NCT04097847|Drug|Pentoxifylline-Tocopherol-Clodronate|the aim of this retrospective study is to analyze from patient records the impact of the PENTOCLO protocol on maxillofacial osteoradionecrosis at Brest Hospital University, France.
12041|NCT04097808|Dietary Supplement|collagen peptides|Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
12042|NCT04097795|Other|Prehabilitation|According to our definition, prehabilitation consists of exercise therapy during at least 2 weeks. This is combined with optimalisation of the patients' nutritional status at least 2 weeks before surgery.
12043|NCT04097782|Behavioral|Antenat education|Antenatal education group The primiparous pregnant women assigned to the intervention group participated in education classes in groups of 8-10 people. Pregnant women were given structured antenatal education twice a week for two weeks (240 minutes). The total education time was 16 hours. Each session comprised 150 minutes presentation of theoretical knowledge, 45 minutes warm-up and stretching exercises, and 45 minutes relaxation exercises.
12044|NCT04097769|Drug|HX009|During study treatment, subjects will receive HX009 treatment via IV infusion once every 2 weeks at doses of 0.1, 0.3, 1, 2, 3, 5, and 7.5 mg/kg.
12045|NCT04097756|Drug|LX-039 tablets|orally once daily until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
12046|NCT04097743|Behavioral|Coping Statement|Daily practice of coping statement
12047|NCT04097730|Drug|Moxifloxacin Ophthalmic|Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is standard therapy for bacterial keratitis. Immediately after CXL/sham CXL and repeat culture, all participants will receive topical moxifloxacin drops every 1 hour for 2 days, and then every 2 hours while awake until resolution of the epithelial defect.
12048|NCT04097730|Drug|Difluprednate Ophthalmic|Difluprednate 0.05% is a corticosteroid used to reduce inflammation in the eye. Participants will receive one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of steroid therapy.
12113|NCT04097223|Drug|Long-acting beta agonist + Long-acting muscarinic antagonist+Inhaled corticosteriods|drug
12114|NCT04097210|Diagnostic Test|POC|
12115|NCT04097197|Behavioral|Brief educational intervention|same as before
12116|NCT04097184|Device|Neurostimulation with non-implanted electrodes|Neurostimulation with non-implanted electrodes
12226|NCT04096092|Other|No intervention|No intervention
12049|NCT04097730|Drug|Riboflavin Ophthalmic|All participants will receive a 30 minute loading dose of topical 0.1% riboflavin and 20% dextran T500 drops every 2 minutes. For participants randomized to corneal cross-linking(CXL), this will be followed by exposure to UV-A light at a wavelength of 365 nm with an irradiance of 3 mW/cm2 for 30 minutes for a total dose of 5.4 J/cm2 (UV lamp: PESCHKE Meditrade GmbH, Hueneberg, Switzerland for India; Avedro KXL System, Waltham, MA, USA for USA). During irradiation patients will continue to receive topical riboflavin at 5-minute intervals. For those randomized to sham CXL, this experience is simulated however the light will be shined adjacent to the patient, careful to avoid exposure to the cornea. The patient's cornea will be completely covered with a corneal sponge to further prevent exposure.
12050|NCT04097730|Other|Topical Placebo|Participants randomized to topical placebo will receive topical placebo on the same medication schedule as difluprednate: one drop of 0.05% difluprednate four times daily beginning 24 hours after the initiation of antibiotics for 1 week, decreased by 1 drop weekly for a total of 4 weeks of placebo therapy. Placebo will be the vehicle used in difluprednate.
12051|NCT04097717|Behavioral|"My Decision tubal sterilization decision aid"|"The My Decision tubal sterilization decision aid is a web-based decision aid designed to help women make informed decisions about tubal sterilization."
12052|NCT04097717|Other|Usual Care|Usual medical care will vary among participants.
12053|NCT04097691|Drug|GLUCOSE 10%|subcutaneous glucose 0.5 ml per site around subcutaneous nerves
12054|NCT04097678|Other|Retained Surgical Sponge|A surgical sponge will be intentionally placed in the surgical field prior to final imaging and then removed. Postoperatively, images will be assessed for the presence or absence of a retained surgical sponge.
12055|NCT04097665|Device|indocyanine green angiography|All patients treated with expanded flaps will be assessed by surgeons, and the possible area of necrosis will be marked based on clinical experience. This area will be further divided into perfusion units (1*1 square centimeter for each), and the center of each perfusion unit will be marked. Then all patients will receive ICGA after the complete transfer of flap to the recipient site. For ICGA, a 2ml bolus of indocyanine green (2.5mg/ml) was injected through the patient's intravenous line. The detector/camera of the SPY imaging system should place over the flap at approximately 30cm for fluorescence image acquisition. The fluorescence value will be recorded afterwards.
12056|NCT04097652|Biological|UMC119-06|Cohort 1: Low does of UMC119-06；Cohort 2: Medium does of UMC119- 06；Cohort 3: High does of UMC119-06
12057|NCT04097626|Other|nutrition education|The experimental group will receive nutrition education once during the study. It will occur at the beginning of the second week. This will consist of a 30-minute interactive lecture and a 15-minute question-and-answer session. The information covered will be basic nutrition principles for good health and to support regular exercise.
12058|NCT04097626|Other|no nutrition education|This group will not receive nutrition education.
12059|NCT04097613|Drug|Povidone-Iodine|Povidone Iodine solution 5% (0.5% available iodine) by 3MTM has been specially formulated as a nasal antiseptic. They have shown topical application to be clinically safe, tolerable and to be rapidly bacteriocidal against aerobic gram positive and gram- negative bacteria including methicillin resistant Staphylococcus aureus, methicillin resistant Staphylococcus epidermidis, vancomycin resistant Enterococcus faecium and Enterococcus faecalis (VRE) and yeast (3M study 05-011100,05-011017, 05-011322).
12060|NCT04097613|Drug|Budesonide|Budesonide is is provided in nebules (1mg/2cc). Patients will place two nebules of budesonide into the 250mls of saline.
12061|NCT04097600|Drug|Oral semaglutide|Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
12062|NCT04097587|Behavioral|experimental group|This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.
12063|NCT04097587|Other|control group|received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
12064|NCT04097574|Drug|NPO-13: l-menthol|20 mL/site
12066|NCT04097548|Behavioral|CenteringPregnancy|Pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
12067|NCT04097535|Other|PET/MRI|Imaging scan
12068|NCT04097522|Other|Neurofeedback|During the neurofeedback intervention, participants will be shown visual representations of their own brain activity in real-time. Over a number of sessions participants will teach themselves to increase this brain activity, in order to increase their own pain resilience levels.
12069|NCT04097509|Biological|AFG application on palatinal wound healing|9 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. In the protocol, venous blood collected in the tube was centrifuged for 2 minutes at 2700 rpm (approximately 692 g) in a special centrifuge (Medifuge, Silfradent, Italy) to obtain two layers: the lower layer of red blood cells and the upper layer of AFG. The AFG at the top of the tube was collected by means of an injector and transferred to the metal godet. It was held for 15-20 minutes for polymerization. After polymerization occurred, the polymerized AFG in the metal gum was applied to the wound surface in the donor site . No suture or tissue glue was used. Adhesive properties of AFG were utilized.
12117|NCT04097171|Other|Diet|Participants will consume each diet for 14 days in a crossover design.
12118|NCT04097158|Other|Sample Collection|We will be collecting blood, urine, and spinal fluid samples.
14882|NCT04074746|Biological|Genetically Engineered Lymphocyte Therapy|Given AFM13-NK cells IV
12070|NCT04097509|Biological|i-PRF application on palatinal wound healing|10 ml venous blood collected from the patient was transferred to the tube without any anticoagulants. Based on G force, collected venous blood were centrifuged at 2300 rpm (about 241 g) in a centrifuge (PC-O2, Process for PRF, Nice, France) for 3 minutes to obtain two layers: The two layers are the lower layer of red blood cells and the upper layer of i-PRF. The i-PRF at the top of the tube was collected with a syringe and transferred to the metal godet. It was held for 20-25 minutes for polymerization. After the polymerization, the polymerized i-PRF was applied to the wound surface in the donor site. No suture or tissue glue was used. Adhesive properties of AFG were utilized.
12071|NCT04097509|Other|control|no application
12072|NCT04097496|Behavioral|Act Out! Intervention|Data included in the description of the intervention arm.
12073|NCT04097483|Behavioral|Telephone Intervention Group|Nurse-led, telephone-based, and psychoeducational intervention centered on motivational interviewing and cognitive behavioral therapy for adherence and depression.
12074|NCT04097470|Drug|Decitabine|Decitabine dosage 20mg/m2 i.v.
12075|NCT04097470|Drug|Midostaurin|Midostaurin 50 mg b.i.d.
12076|NCT04097457|Behavioral|"Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)"|"The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers"
12077|NCT04097444|Biological|Bevacizumab|Given IV
12078|NCT04097444|Drug|5-fluorouracil|Given IV
12079|NCT04097444|Drug|Leucovorin calcium|Given IV
12080|NCT04097444|Drug|Irinotecan hydrochloride|Given IV
12081|NCT04097444|Drug|Oxaliplatin|Given IV
12082|NCT04097444|Drug|Capecitabine|Given PO
12083|NCT04097431|Behavioral|Response Blocking|Physically preventing the response (i.e., precursor) from occurring.
12084|NCT04097418|Behavioral|Aerobic training compared to conventional motor training|"Aerobic training: aerobic training by treadmill at moderate intensity. Each treatment will consists of 35 minutes of training, administered 3 times per week, for 8 weeks.~Conventional motor training: 15 minutes of passive mobilization of upper and lower limbs and spine, 5 minutes of stretching of the upper and the lower limbs and 10 minutes of balance training, administered 3 times per week, for 8 weeks."
12085|NCT04097405|Drug|D-0120|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
12086|NCT04097405|Drug|Placebo oral tablet|Randomized, Double-Blind, Placebo-Controlled, Multiple Dose and Dose Escalation of D-0120 or Placebo
12087|NCT04097392|Other|Experimental|Diaphragm biofeedback reeducation plus inspiratory training during 6 weeks
12088|NCT04097392|Other|Active comparator|Isolated high-intensity inspiratory muscle training during 8 weeks
12089|NCT04097379|Drug|LRX712|LRX712 intra-articular injections
12090|NCT04097379|Drug|Placebo|Placebo intra-articular injections
12091|NCT04097366|Diagnostic Test|ABUS|Automated whole breast ultrasound (ABUS) is undertaken with a large transducer panel placed on the breast in three positions. Resultant images are combined to make a 3D image of the breast.
12092|NCT04097366|Diagnostic Test|CESM|A high kV and a low kV image is taken in two standard views of each breast following the intravenous injection of an iodinated contrast agent.
12093|NCT04097366|Diagnostic Test|ABB-MRI|ABB-MRI is a shorter version of breast MRI. Standard T1W pre and post contrast images are acquired. A MIP and post-contrast T1 weighted image are read.
12094|NCT04097353|Behavioral|Harvesting Hope for Kids (HH4K)|Weekly meetings at university-based farm
12095|NCT04097353|Behavioral|Surviving Strong for Kids (SS4K)|Enhanced usual care
12096|NCT04097340|Device|Attentional Bias Retraining (ABR)|Participants randomized to this intervention will receive 2 weeks of ABR for opioids delivered via a mobile device.
12097|NCT04097340|Device|Control Training|Participants randomized to this intervention will receive 2 weeks of training without ABR, delivered via a mobile device.
12098|NCT04097327|Other|Ectoin Dermatitis Cream 7% (EHK02)|Application of Ectoin Dermatitis Cream in accordance with the instructions for use
12099|NCT04097314|Drug|Zibotentan|10mg OD Zibotentan
12100|NCT04097314|Drug|Placebo oral tablet|Placebo
12101|NCT04097301|Drug|MLM-CAR44.1 T-cells, cyclophosphamide and fludarabine from -5 to -3|Single intravenous infusion
12102|NCT04097288|Drug|Citalopram 40mg|Single dose
12103|NCT04097288|Drug|Reboxetine 8 mg|Single dose
12104|NCT04097288|Drug|Placebo oral tablet|Single dose
12105|NCT04097288|Drug|Placebo oral tablet|Single dose
12106|NCT04097275|Other|Skin biopsy|The biopsy will be performed by means of punch biopsy (diameter 2.5 mm) under local anesthesia on a forearm. The skin biopsy will be transferred to sterile cell culture Dulbecco's Modified Eagle Medium (DMEM) 1% Penicillin 1% Streptomycin 1% Gentamycin medium 10% FBS.
12107|NCT04097275|Other|Withdraw of blood|"Blood will be collected in:~1 x Ethylene Diamine Tetraacetic Acid (EDTA) tube (7.5 ml) - for further leucocytes extraction that are a potential backup for new iPS cell lines generation~1 x Citrate Phosphate Dextrose Adenine (CPDA) tube (8.5 ml) - for EBV-transformed lymphoblastoid cell lines generation~1 x Dried Blood Spot DBS-filtercard, called CentoCard® - for quality control confirmatory genetic testing"
12108|NCT04097262|Other|Own-Price Elasticity|The price of fruit will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
12109|NCT04097262|Other|Cross-Price Elasticity|The price of fruit will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
12110|NCT04097236|Other|Qualitative and quantitative assessment of gastric content volume with bed elevation|Ultrasound examination of the gastric antrum are performed 3 minutes after the ingestion of a volume of water (either 0, 50, 100, 150, or 200 milliliters (ml), determined by randomization). The procedure is repeated three times (three different volumes, the same volumes for each session with randomized order for each session).
12121|NCT04097132|Device|echocardiography|echocardiography for left atrial diameter, size ,Ejection Fraction Holter for detection of paroxusmal AF
12122|NCT04097119|Dietary Supplement|Dietary supplementation|Subjects receive a specific dietary supplementation designed to support HDL function daily for 12 weeks
12123|NCT04097106|Dietary Supplement|Synbiotic|Synbiotic dietary supplement in capsule form
12124|NCT04097093|Other|No intervention|No intervention
12125|NCT04097080|Drug|NBTX-001|Active drug group will receive 6 doses of NBTX-001 given three times a week.
12126|NCT04097080|Drug|Standard of Care|Placebo group will receive reconstituted air given three times a week.
12127|NCT04097067|Radiation|Radiation Therapy|Low dose radiotherapy with 20 Gy (10x2Gy)
12128|NCT04097054|Procedure|Augmented preoperative planning|The study investigates the impact of augmented preoperative planning on OR time variance in complex and rare visceral surgical procedures.
12129|NCT04097041|Procedure|Tympanomastoidectomy|Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
12130|NCT04097041|Procedure|Non-Surgery|"Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing."
12131|NCT04097028|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
12132|NCT04097028|Drug|Oxaliplatin|Given IV
12133|NCT04097015|Device|Alpha-Stim M|Alpha-Stim M with and Ocular Interface and a Spinal Interface
12134|NCT04097002|Biological|ORCA-010|The investigational new drug ORCA-010 is a novel and improved oncolytic adenovirus based on the adenovirus serotype 5 (Ad5) genome. ORCA-010 replicates specifically in cancer cells and not in normal tissue cells. Its replication has been shown in a wide variety of cancer cell types, and it is not limited to prostate cancer.
12135|NCT04096989|Other|Traditional Chinese medicine regimen-based lifestyle mobile health APP|The Experimental group receives TCM regimen-based lifestyle mobile health application intervention.
12136|NCT04096989|Other|Lifestyle mobile health APP|Sham comparator group receives mobile health application, but there is no traditional Chinese medicine information.
12137|NCT04096976|Other|logistic regression|To identify associations between factors listed in Table 1 and hospital survival, we used logistic regression
12138|NCT04096963|Device|The WATCHMAN FLX Delivery System|WATCHMAN FLX Delivery System permit device placement in the LAA via femoral venous access and crossing the inter-atrial septum into the left atrium
12139|NCT04096950|Biological|MT-3921 Low dose|MT-3921 Low dose, intravenous, single dosing
12140|NCT04096950|Biological|MT-3921 High dose|MT-3921 High dose, intravenous, single dosing
12141|NCT04096937|Other|Focus groups|Focus groups will be conducted with adult stakeholders and with youth in Appalachia. Feedback from the focus groups will guide cultural tailoring of the Journey of Hope in Appalachia intervention for use in a later phase.
12142|NCT04096924|Device|Guidewire for echo-guided interventions|Under echocardiography guided treatment of ASD with a novel interventional guidewire
12143|NCT04096924|Device|Cook lunderquist guidewire|Subjects with ASD treated with amplatzer using the Cook lunderquist guidewire.
12144|NCT04096911|Drug|Sintilimab|Sintilimab 200 mg intravenously every 3 weeks
12145|NCT04096911|Drug|quadrivalent HPV vaccine|The first dose of quadrivalent HPV vaccine intramuscularly at the day before the first dose of Sintilimab ，the second and third doses of quadrivalent HPV vaccine intramuscularly at the 60th and 180th days respectively
12146|NCT04096898|Device|Senofilcon A contact lens|Senofilcon lenses will be tested in moderate to severe dry eye patients to determine their efficacy in reducing discomfort associated with dry eye.
12147|NCT04096885|Diagnostic Test|Blood and urine samples, skin and stool swabs|Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
12148|NCT04096846|Diagnostic Test|laboratory investigation|detection of serum level of methotrexate and serum level of vitamin D
12149|NCT04096833|Other|Virtual Reality Group|Participants are from 3 to 14 years old who attend a pediatric primarey health care of the Fuensanta Health Center (Valencia) for immunization by vaccine.
12150|NCT04096820|Biological|Uromune|2 sprays of vaccine under the tongue for 90 days. Liquid is to held under tongue for 2 minutes without swallowing.
12151|NCT04096807|Other|Standard TEE exam including measurement of left upper pulmonary vein diameter and collapsibility, compared with PCWP measured continuously by a pulmonary arterial catheter|TEE takes part of the standard perioperative hemodynamic monitoring in cardiac surgery. Patients enrolled in the study are also monitored by a pulmonary arterial catheter
12152|NCT04096781|Behavioral|SDMT|The intervention involves a clear pathway centered on the use of a web-based decision tool. This tool aims to support the shared decision-making process for anticoagulation for stroke prevention in atrial fibrillation. This web-based tool will be used both by the participants as well the physician responsible for atrial fibrillation decision making.
12153|NCT04096781|Behavioral|Usual Care|The participants will receive usual care. The clinician will be provided with the checklists of best practices for discussion of stroke prevention in atrial fibrillation.
12154|NCT04096768|Drug|Dexmedetomidine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
12155|NCT04096768|Drug|Ketamine|Comparing Dexmedetomidine + Ketamine versus Dexmedetomidine + Placebo for sedation in ICU patients
12156|NCT04096755|Diagnostic Test|Procedure|serum and urine samples will be taken for analysis
12157|NCT04096742|Drug|tretinoin 0.05% lotion (Altreno)|Altreno topical lotion
12158|NCT04096742|Other|Vehicle|Lotion not containing active ingredient (tretinoin)
12159|NCT04096729|Other|compression stockings|patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
12160|NCT04096716|Drug|Tc-99m tilmanocept|Tc-99m tilmanocept is a radioactive diagnostic agent.
12161|NCT04096703|Procedure|Pneumatic dilation|The patients randomized to the pneumatic dilation cohort will undergo an initial pneumatic dilation with a 30mm Rigiflex (Boston Scientific). If the Eckardt score four weeks after initial dilation is > 4, then the patient will be scheduled for a second dilation with a 35mm Rigiflex balloon (Boston Scientific).
12162|NCT04096690|Drug|Pegaspargase|Pegaspargase 3750IU administered by intramuscular injection on Day 1 of each 21-day cycle for 6 cycles in induction treatment
12163|NCT04096690|Drug|Anti-PD-1 monoclonal antibody|Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 2 of each 21-day cycle for 6 cycles in induction treatment Anti-PD-1 antibody 200mg administered intravenously (IV) on Day 1 of each 21-day cycle for up to 28 cycles in maintenance treatment
12164|NCT04096677|Procedure|hysteroscpy|
12165|NCT04096664|Device|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
12166|NCT04096651|Other|gait recordings|gait recordings
12167|NCT04096651|Other|brain magnetic resonance imaging|brain magnetic resonance imaging
12168|NCT04096651|Other|oculomotor movement recordings|oculomotor movement recordings
12169|NCT04096638|Drug|SB 11285|SB 11285 2mg lyophilized powder for IV infusion
12170|NCT04096638|Drug|Nivolumab|40 mg/4 mL, 100 mg/10 mL, and 240 mg/24 mL solution for injection in a single dose vial.
12171|NCT04096625|Device|Active tDCS|Active tDCS will be delivered at 2mA for 20 minutes.
12172|NCT04096625|Behavioral|Assertiveness Training Program (ATP)|The Assertiveness Training Program (ATP) is a cognitive-behavioural therapy delivered in group sessions.
12173|NCT04096625|Device|Sham tDCS|Sham tDCS, after 40 seconds of stimulation (2mA), a small current pulse was delivered every 550 msec (110 muA over 15 msec).
12174|NCT04096612|Procedure|Orbital decompression combined with MPT|Orbital decompression combined with MPT
12175|NCT04096599|Other|Xylitol toothpaste|At-home preventive measures + xylitol-containing (25%) toothpaste
12176|NCT04096599|Other|Fluoride toothpaste|At-home preventive measures + fluoride (1000 ppm F) toothpaste
12177|NCT04096586|Other|Red juice|To determine the effects of red juice on satiety and gut health
12178|NCT04096586|Other|Watermelon juice|To determine the effects of watermelon juice on satiety and gut health
12179|NCT04096573|Drug|LC51-0255|LC51-0255
12180|NCT04096573|Drug|Placebo|Placebo
12181|NCT04096560|Drug|TAK-994|TAK-994 tablets
12182|NCT04096560|Drug|Placebo|TAK-994 placebo-matching tablets
12183|NCT04096547|Drug|Rivaroxaban|rivaroxaban for stroke prevention of atrial fibrillation
12184|NCT04096534|Procedure|Normotonic partial nephrectomy|partial nephrectomy performing with avoidance of hypotension: average blood pressure of at least 80 mm Hg
12185|NCT04096534|Procedure|Hypotonic partial nephrectomy|partial nephrectomy performing with using of medical hypotension; avoidance of hypertension: average blood pressure of at least 60 mmHg
12186|NCT04096508|Behavioral|Music listening|Patients sit comfortably in a chair for 20 min listening music before the procedure.
12187|NCT04096482|Device|Peregrine Drivable ENT Scope|Peregrine, developed by 3NT Medical, is a single-use disposable handheld endoscope, which is thinner and more flexible than other endoscopes. The endoscope includes a camera at its end and a working channel. The thin endoscope provides a means to visualize the nasal cavity and paranasal sinus space and to deliver irrigation to treat the sinus ostia (drainage openings) and spaces within the paranasal sinus cavities
12188|NCT04096482|Device|Standard 30° 4mm Endoscope|The Standard 30° 4mm endoscopic sinus evaluation is the standard procedure that would normally be used to evaluate the condition of each participant.
12189|NCT04096469|Behavioral|Motivational Interviewing|The motivational interviewing strengthens the motivation and commitment to achieve a specific change through the induction and exploration of the reasons for modifying behavior. All this within an atmosphere of acceptance and compassion. It is about extracting the possible solutions to the change that is faced from the individual and his environment and not from the professional. This strategy is achieved by looking for the patient to feel motivated, and to express their problem and thus create discrepancy so that they evaluate their actions and reflect on the changes they should make.
12190|NCT04096469|Behavioral|Traditional Education|Traditional education refers to the normal care given to breast cancer survivors. That is, they receive recommendations about their physical activity and diet but without any motivational approach.
12191|NCT04096443|Biological|Fecal microbial transplant (FMT)|Oral fecal microbial transplant capsules
12192|NCT04096430|Behavioral|ENGAGE approach (child-oriented goal-setting)|See description of experimental arm.
12193|NCT04096417|Drug|Pemigatinib|Given PO
12194|NCT04096417|Other|Quality-of-Life Assessment|Ancillary studies
12195|NCT04096404|Genetic|Genotype- based personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their genotype via email
12196|NCT04096404|Behavioral|Non genetic personalised advice|Following allocation to groups participants will receive appropriate dietary and physical activity advice based on their reported intake, BMI and activity via email
12197|NCT04096391|Device|Flowonix Prometra® II Programmable Infusion System|The Flowonix Prometra® II Programmable Infusion System consists of an implanted infusion pump and catheter, and external components including a clinician programmer, refill and catheter access port kits, the PTC™(a subject operated controller).
12198|NCT04096391|Drug|Pain Medicine|Injections, spinal cord stimulation, peripheral nerve stimulation, pain medication, etc.
12227|NCT04096066|Drug|Carfilzomib|"20 mg/m2 IV on day 1 of cycle 1 enhanced to 56 mg/m2 on days 8, and 15 of cycle 1;~56 mg/m2 IV on days 1, 8 and 15 in cycles 2-12;~56 mg/m2 IV on days 1 and 15 from cycle 13 and onwards."
12228|NCT04096066|Drug|Lenalidomide|- 25 mg orally on days 1-21 of each cycle.
12265|NCT04095754|Drug|Dexmedetomidine|Controlled hypotension: All patients will receive dexmedetomidine 1mcg. Kg-1 loading dose over 10 min just before induction, followed by continuous infusion of 0.4 mcg.kg-1hr-1
14920|NCT04074460|Drug|isoflurane, sevoflurane or desflurane|General Anaesthesia
12199|NCT04096378|Behavioral|EMBRace Intervention Group|The EMBRace intervention will consist of five weekly sessions (weeks 2 - 6) that will be facilitated by EMBRace-trained therapists. Throughout the 8-week intervention, families will be scheduled for 2-hour blocks with sessions being administered to each parent and adolescent for 90 minutes (individually for 30 minutes, 15-minute break, and 45-minutes session with parent and adolescent together). The sessions will cover research-based types of Racial Socialization, including cultural pride, preparation for bias, and attentiveness and balance towards societal racism. Parents and youth will also learn and practice five literacy skills to process and manage the stress of racial encounters including the ability to recognize racial discrimination, accurately appraise the stress of self and others, reduce one's stress, engage instead of avoid, and finally resolve toward healthy outcomes.
12200|NCT04096378|Behavioral|EMBRace Waitlist Group|The waitlist group will be asked to complete a pretest and posttest while the treatment group goes through the EMBRace intervention. During this time, the waitlist group will not have any additional requirements and will not be given any form of comparative treatments. Upon the completion of the treatment from the intervention group, the waitlist group will be consented for entry into the intervention arm of the study and will follow the procedures for the intervention group above.
12201|NCT04096365|Device|Subcostal Temporary Extracardiac Pacing Lead|The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.
12202|NCT04096352|Behavioral|Direct Method|Learning effective vocal skills using speech therapy exercises and virtual reality simulations.
12203|NCT04096352|Behavioral|Indirect Method|Information on voice function and voice hygiene.
12204|NCT04096339|Other|Colonoscopy followed by EGD|Colonoscopy is done first followed by EGD
12205|NCT04096339|Other|EGD followed by Colonoscopy|Esophagoduodenoscopy (EGD) is done first followed by Colonoscopy
12206|NCT04096326|Drug|AGN-151586|Participants will receive 5 injections (1 in the procerus, 2 in each of the bilateral corrugators). Up to 5 cohorts will be enrolled in this study.
12207|NCT04096326|Drug|Placebo|Participants will receive 5 injections (1 in the procerus, 2 in each of the bilateral corrugators) of placebo matched AGN-151586
12209|NCT04096287|Biological|PNT001|PNT001 diluted in 5% dextrose
12210|NCT04096287|Drug|Placebo|5% dextrose
12211|NCT04096274|Behavioral|Leadership for Organization Change and Implementation (LOCI)|LOCI is a leadership training and coaching program designed to support leaders and foster a climate that implements and sustains use of evidence based practices.
12212|NCT04096274|Behavioral|Leadership webinars|A set of 4 leadership training webinars will be provided that cover topics ranging from effective leadership, to giving effective feedback.
12213|NCT04096261|Diagnostic Test|Diagnostic Test|Diagnostic Test: Contrast agentenhanced MRI using Gadovist by using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid. And sleep quality measurement with a polysomnography.
12214|NCT04096235|Other|RAM Nasal Cannula|The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
12215|NCT04096209|Device|autograft mixed with xenograft bone|"Eligible patients will be randomized in equal proportions between control group (immediate implant placement without bone grafts in the jumping gap) and study group (immediate implant placement with a mixture of Xenograft and autogenous bone placed in the jumping gap).~All patients will be evaluated by proper history taking and thorough clinical and radio graphical examination and assessed according to the inclusion and exclusion criteria.~Patients of both groups will be subjected to Cone beam Computed tomography (CBCT).~Primary impression will be taken, a study model will then be poured and then waxing up will be performed.~Patients will be instructed to rinse with chlorhexidine 0.1% mouthwash. Articaine 4% (1:100,000) local anesthesia will be given to the patient. Atraumatic extraction of the tooth or remaining root using No. 15c lancet and periotome"
12216|NCT04096196|Behavioral|Safe City game|The game intervention uses a game-based learning approach to teach players how to recognize and remove injury hazards from different homes and sports areas. It also highlights the need to pay attention to traffic and safety facilities to prevent injuries in a real-world environment. Players will create their own avatar to assume the duties of safety inspectors in the game. Point, level and reward systems will be included to increase player motivation to engage in the game.
12217|NCT04096196|Other|Health education|All students in the health education group will receive a comprehensive package on safety information. The information package includes both printed and electronic promotional materials regarding safety and a comprehensive list of relevant website and information sources. The information from these relevant websites and information sources are similar to those used in setting the safety case scenarios for the Safe City game. As a result, both intervention arms will have comparable accessibility to safety-related information and the major contrast between the two groups will be the method of presentation (game-based learning vs traditional health promotion approach, i.e. unidirectional information package).
12218|NCT04096183|Other|Ventilation of healthy volunteers|Ventilation of healthy volunteers in different clinical situations
12219|NCT04096170|Drug|IV lidocaine|Patients randomized to the IV lidocaine group will receive a 100 mg lidocaine bolus on induction then an infusion of 1.5 mg/kg/hr prior to incision. This infusion will continue throughout operation and into the PACU for 1 hour OR until the 2gm/250 mL D5W bag has been infused, whichever occurs first.
12220|NCT04096170|Drug|Placebo|o Patients randomized to the placebo group will receive D5W solution (as this is the carrier for lidocaine) at the same volume and rate as the IV lidocaine.
12221|NCT04096157|Drug|Isavuconazonium sulfate IV|Intravenous (IV) via nasogastric (NG) tube
12222|NCT04096157|Drug|Isavuconazonium sulfate capsules|Oral
12223|NCT04096144|Drug|Neuromuscular Blocking Agents|Neuromuscular agents will be used to block muscle function for the safety and efficiency of the procedure. At the procedure's conclusion, neuromusclar agents such as Neostigmine or Sugammadex will be used to reverse the neuromuscular reversal.
12229|NCT04096066|Drug|Dexamethasone|"- 40 mg orally on days 1, 8, 15 and 22 of each cycle. Each cycle is to be repeated every 28 days. Patients that achieve at least a VGPR within the first year of study treatment and in sustained MRD negativity (MRD negative at least at 10-5 after 1 and 2 years of therapy) will stop carfilzomib administration after 2 years and will continue with lenalidomide and dexamethasone treatment until disease progression or intolerance to the therapy. Other patients will continue carfilzomib administration until disease progression or intolerance.~For patients >75 years of age, the dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each treatment cycle."
12230|NCT04096053|Other|TEACHH|See arm/group description.
12231|NCT04096040|Device|μCor|μCor consists of the following components: A) Patch B) Sensor C) Charger D) Data transmission device (Gateway) E) Server Once activated, the wearable Sensor automatically acquires ECG, RF readings, heart rate, respiration rate, activity, and posture measurements.
12232|NCT04096027|Drug|Cabergoline Pill|0.5 mg cabergoline pill taken orally
12233|NCT04096014|Dietary Supplement|Ensure Enlive|The subjects in the intervention group will receive two Ensure Enlive supplements per day for 180 days.
12234|NCT04096014|Other|Standard Of Care|The subjects in the Standard of care group will continue to receive the standard clinical therapy.
12235|NCT04096001|Device|Woebot-SUDs (W-SUDs)|Woebot-SUDs (W-SUDS), an artificially intelligence-powered conversational agent on a smartphone app, eliminates most current SUDs treatment barriers while simultaneously leveraging technology to enhance user experience and engagement. W-SUDs expands and refines existing SUDs treatments by adapting skills from cognitive behavioral therapy, motivational interviewing, and dialectical behavior therapy.
12236|NCT04095988|Procedure|Allogeneic microbiota reconstitution|gastroscopic microbiota Infusion (Verum)
12237|NCT04095988|Procedure|Placebo-Allogeneic microbiota reconstitution|gastroscopic saline Infusion (placebo)
12238|NCT04095975|Dietary Supplement|Baking Soda|Standard baking soda that can be bought from stores.
12239|NCT04095975|Dietary Supplement|LithoLyte|LithoLyte is considered a medical food and consists of: potassium citrate, magnesium citrate, sodium bicarbonate, and erythritol.
12240|NCT04095975|Drug|Urocit K|Prescription potassium citrate.
12241|NCT04095962|Other|Exercise|The intervention consists in: (1) warm-up, with a slow walk, calisthenics and stretching exercises (2) Aerobic exercises involving walking, jogging, dance, etc. (3) Main muscle groups Strength exercises perform in a circuit (4) Balance/coordination exercises (5) Cool-down with respiratory and flexibility exercises. Routine, simple, enjoyable and functional exercises will be emphasized. Besides heart rate (HR) evaluation by means of portable heart rate monitors, accelerometers and the Borg Scale will be used.
12242|NCT04095949|Dietary Supplement|Artichokes|Approximately 200 g of cooked artichokes
12243|NCT04095936|Drug|Romiplostim|Subcutaneous administration of 0 to 20ug/kg for 6 months
12244|NCT04095923|Behavioral|Social media game|Participants will engage in weekly challenges that require them to take photographs of interesting things they discover during their walks. They will post and discuss these photographs with other participants on a private social media page. They will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
12245|NCT04095923|Behavioral|Standard self-regulation|Participants will track their steps using a wearable activity monitor and receive brief standard self-regulatory counseling.
12246|NCT04095910|Behavioral|Planet Nutrition program|"- Nutrition education: It consists of 18 sessions of one hour, twice a week. Previously a nutrition manual with 26 topics was designed for these sessions. Behavior change strategies were used.The sessions were implemented by Nutrition interns.~- Physical activity sessions: There were designed and implemented by profesionals in the area. About 20 sessions of one hour, three times per week were provided.~- Parents information: Nine informational flyers with different topics of nutrition and health were sent."
12247|NCT04095897|Procedure|Pecs II Block|Peripheral nerve block - Regional anesthesia : Pectoral Nerve block type 2
12248|NCT04095884|Procedure|blood sampling|observational study and no intervention will be given. only blood samples collected and treated with iron supplements
12249|NCT04095871|Other|Observational study|No intervention, patients record the time of CISC
12250|NCT04095858|Drug|CD24Fc|IV infusion: 480 mg at Day -1, 240 mg at Day 14, 240 mg at Day 28.
12251|NCT04095858|Drug|Placebo|IV infusion, 100 ml at Day -1, Day 14, and Day 28.
12252|NCT04095858|Drug|Methotrexate|IV, 15 mg/m2/dose at Day 1, then 10 mg/m2/dose at Day 3, 6, 11.
12253|NCT04095858|Drug|Tacrolimus|Begin on day -3. IV [0.03mg/kg/day] or PO [0.045mg/kg/dose] dosing is permitted
12254|NCT04095845|Device|CO THA|Replacement of arthritic hip with artificial implant using CT-based navigation and conventional technique
12255|NCT04095845|Device|Mako THA|Replacement of arthritic hip with artificial implant using mako robotic-arm assist
12256|NCT04095832|Procedure|Epidural anesthesia|Epidural anesthesia using standardized technique
12257|NCT04095819|Procedure|Middle Meningeal Artery procedure|Seal off the blood supply to the middle meningeal artery to prevent growth of the Subdural Hematoma
12258|NCT04095819|Procedure|Traditional Surgery|Drainage of Subdural Hematoma using Craniotomy or Burr Hole
12259|NCT04095806|Other|Stroke (exposure)|stroke case definition (exposure) listed in inclusion/exclusion criteria section
12260|NCT04095793|Drug|ampreloxetine|Oral tablet, QD
12261|NCT04095780|Other|Advanced oral hygiene care programme|"Brush teeth with standardized power tooth brush twice a day.~Rinse mouth with chlorhexidine twice a day.~Oral hygiene education"
12262|NCT04095780|Other|Oral hygiene instruction|Oral hygiene education
12263|NCT04095767|Device|Neurothrombectomy|Intra-arterial recanalization therapy or mechanical thrombectomy (MT) is a therapeutic option for patients who are not candidates for t-PA or in whom t-PA has failed. MT is performed by means of various devices (Merci Revive, Penumbra, etc.). There are currently two major approaches to MT: the so-called stent retrievers (used with or without a balloon catheter), and catheters used for direct aspiration (manual with syringe or by aspiration pump via distal access catheters [DACs]). Moreover, both techniques can be combined. MT may be performed following IV t-PA, as a stand alone therapy, or in conjunction with IA thrombolysis.
12264|NCT04095754|Procedure|Head-Up Position|Anti-Trendelenburg Position
12372|NCT04095104|Drug|Placebo for Immediate Release Topiramate|Compounded tablet to mimic immediate release topiramate 25mg tablet
12266|NCT04095754|Drug|Induction and maintenance of anaesthesia|"Induction of anaesthesia: fentanyl 1 μg.Kg-1, propofol 1.5-2 mg.kg -1 titrated to loss of verbal response, atracurium 0.5 mg. Kg-1 to facilitate endotracheal intubation.~Maintenance:Anaesthesia will be maintained using isoflurane 1 % in oxygen and air mixture 1:1 and atracurium 0.1 mg. Kg-1 every 20 mim."
12267|NCT04095741|Diagnostic Test|Questionnaires|Filling in questionnaires of general functioning and symptomes of anorexia nervosa and autism spectrum disorders will demanded to children and their parents. The children all have a history of anorexia nervosa.
12268|NCT04095728|Dietary Supplement|Brain Octane Oil|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
12269|NCT04095728|Other|Placebo|Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
12270|NCT04095715|Other|Haemostasis consultation|Haemostasis consultation
12271|NCT04095715|Biological|Standard management of patients suspected of thrombopathy|Standard management of patients suspected of thrombopathy
12272|NCT04095702|Other|Weighted Pacifier|The weighted pacifier is a standard of care pacifier with a weighted, breathable star attachment to help keep the pacifier from popping out of the neonates mouth during non-nutritive suck.
12273|NCT04095702|Other|Non-Weighted Pacifier|The non-weighted pacifier is a standard of care pacifier that a neonate would receive if they were not part of this study.
12274|NCT04095689|Drug|Docetaxel|Microtubule-targeting drug (inhibits microtubule depolymerization)
12275|NCT04095689|Drug|Doxorubicin|Topoisomerase inhibitor
12276|NCT04095689|Drug|Cyclophosphamide|DNA crosslinking drug
12277|NCT04095689|Drug|Pembrolizumab|Programmed cell death-1 (PD-1) inhibitor
12278|NCT04095689|Drug|IL-12 gene therapy|Adenoviral-mediated IL-12
12279|NCT04095689|Drug|L-NMMA|pan-NOS inhibitor
12280|NCT04095676|Procedure|VATS group|VATS procedure with drainage, including rinse with NaCl
12281|NCT04095676|Procedure|Drain and intrapleural therapy group|Drainage with pigtail and Intrapleural therapy
12282|NCT04095663|Procedure|Partial Colectomy|Most partial colectomies are performed using a laparoscopic approach, when possible, and surgeons sometimes use a temporary, protective stoma if the re-connection is considered high risk.
12283|NCT04095663|Other|Medical Management|"Patients will be offered a varying combination of tools from the best medical management toolbox (diet and exercise, fiber supplementation/probiotics, and rifamycin/mesalazine) depending on what they have already tried. Based on the evidence-based best medical toolbox clinicians will be asked to consider rifamycin (dose/frequency) for those with AUD who are not responding to diet and exercise and mesalazine (dose/frequency) for those with lingering symptoms who are not responding to diet and exercise."
12284|NCT04095650|Behavioral|STEPS (Seniors using Technology to Engage in Pain Self-management)|Participants will meet with a community health worker (CHW) at a one-hour in-person study orientation session. At this session, they will be introduced to the program, learn how to use the online modules and associated materials, and schedule six weekly telephone sessions with the CHW. Participants will be given a wearable physical activity tracker to use throughout the course of the program. They can choose to report daily step counts by automatically syncing to an app or via text message. Each week during the study period, participants will engage with content on the website, have a session with the community health worker, track their daily steps, and set and work toward pain-management goals.
12285|NCT04095637|Device|Medial knee arthroplasty|Surgical intervention where the medial portion of the knee is replaced by an artificial metal and polyethylene implant
12286|NCT04095624|Behavioral|Spinal Fusion Preoperative Opioid Taper|Guided weekly opioid pain medication reduction via telephone calls prior to elective spinal fusion surgery.
12287|NCT04095624|Other|Non-taper Control|Weekly phone calls prior to elective spinal fusion surgery, without opioid pain medication reduction recommendation or guidance.
12288|NCT04095611|Procedure|SPAIRE|To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.
12289|NCT04095611|Procedure|LATERAL|surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
12290|NCT04095598|Diagnostic Test|Comparative Ankle Tomography with Stress Maneuvers|All diagnostic imaging exams and FAAM questionnaire will be applied in a standard way in both groups.
12291|NCT04095585|Genetic|chromosomal microarray analysis (CMA) and whole exome sequencing (WES)|"The investigator evaluated the following hypotheses:~i) atypically large 7q11.23 deletions including additional genes; ii) rare pathogenic variants in genes located within the deletion, in particular GTF2I iii) additional pathogenic copy number variants (CNVs) or rare intragenic pathogenic variants located in other chromosomal regions with various inheritance patterns (autosomal recessive, X-linked, de novo autosomal dominant); given the small number of patients recruited, we focused on rare exonic variants considered to be pathogenic according to the criteria of the American College of Medical Genetics and Genomics (ACMG)"
12292|NCT04095572|Device|intravesical instillation with HA-CS|intravesical instillation with HA-CS (Ialuril Prefill®, IBSA Farmaceutici Italia Srl, Lodi, Italy)
12293|NCT04095572|Device|intravesical instillation of sterile purified water|intravesical instillation of sterile purified water (packed and labelled according to Good Manufacturing Practice at IBSA Farmaceutici Italia Srl in Lodi, Italy to provide adequate blinding)
12294|NCT04095559|Diagnostic Test|multipolar mapping catheter|mapping of the left atrium will be performed in sinus rhythm using the IntellaMap Orion multipolar mapping catheter (Boston Scientific).
12295|NCT04095559|Diagnostic Test|multielectrode circular catheter|mapping of the left atrium will be performed using the multielectrode circular catheter (Lasso, spacing 2-6-2 mm, Biosense Webster)
12296|NCT04095559|Diagnostic Test|irrigated ablation catheter|mapping of the left atrium will be performed using the irrigated ablation catheter (IntellaNav Mifi OI)
12297|NCT04095546|Other|routine psychotherapy for Borderline Personality Disorder (BPD)|Routine psychotherapy as treatment for patients with Borderline Personality Disorder
12432|NCT04094675|Drug|Sirolimus|Use of sirolimus 2 mg by mouth daily for 1 year
12298|NCT04095533|Other|Tibialis anterior muscle cross-sectional area assessment by ultrasound|"Assessed using bedside ultrasound with repeat assessments every second day up to 2 weeks of ICU admission, or until discharge from ICU to yield an overall rate of muscle area decline reported as a %/day average muscle atrophy rate.~Tibialis anterior cross-sectional area assessments will be assessed by measurement ultrasound to both legs with portable bedside ultrasound. The cross sectional area will be measured in cm^2 at 5 cm distal to the lateral eminence of the tibial tuberosity along the muscle belly. Image processing will be performed at the bedside using features available on the ultrasound device. Muscle boundaries will be marked on the device and the cross-sectional area (computed from the perimetral contour of the muscle section) will be determined. This process will be repeated for two times for each leg."
12299|NCT04095533|Other|Muscle strength assessment|Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
12300|NCT04095520|Procedure|Laser Etching|Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.
12301|NCT04095520|Procedure|Phosphoric acid etching|Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
12302|NCT04095507|Diagnostic Test|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
12303|NCT04095494|Behavioral|Nitrous oxide use|In order to evaluate the perception of the Nantes health students we wish to place an anonymous survey concerning their training, their knowledge of the legislative framework governing the use of EMONO and their personal and professional experience around nitrous oxide.
12304|NCT04095481|Device|Obalon Navigation/Touch System|The NTS Compatible Obalon Balloon System does NOT require the use of radiographic verification prior to the inflation of the intragastric balloon
12305|NCT04095468|Radiation|Preoperative Radio(Chemo)Therapy|Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
12306|NCT04095455|Procedure|pectoral nerves block group|ultrasound guided block of nerve supply of surgical site
12307|NCT04095455|Drug|Ketamine plus magnesium group|Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).
12308|NCT04095455|Drug|Control group|Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
12309|NCT04095442|Drug|Cepacol|Twice-daily use of Cepacol per the manufacturer's guidelines
12310|NCT04095442|Drug|Tom's Natural Mouthwash|Twice-daily use of Tom's Natural Mouthwash per the manufacturer's guidelines
12311|NCT04095429|Behavioral|Expect Respect|Expect Respect is a 24 session curriculum designed to support middle school students to increase skills in emotion regulation, relationship skills, communication, and positive bystander intervention behaviors.
12312|NCT04095429|Behavioral|Enhanced Usual Care|Participants will be connected via a warm referral to available individual behavioral health supports and resources in their community that can support them.
12313|NCT04095416|Device|ACE compression wrap|Bilateral lower extremity ACE compression wraps
12314|NCT04095403|Other|Tarp Assisted Cooling|Body cooling utilizing a tarp and water
12315|NCT04095403|Other|passive cooling|Supine rest.
12316|NCT04095390|Drug|Pyrotinib|400 mg
12317|NCT04095390|Drug|SHR6390|125mg
12318|NCT04095390|Drug|Letrozole|2.5mg
12319|NCT04095390|Drug|Capecitabine|500mg
12320|NCT04095377|Other|No intervention, this is a retrospective study.|No intervention, this is a retrospective study.
12321|NCT04095364|Drug|Carboplatin|Given IV
12322|NCT04095364|Drug|Letrozole|Given PO
12323|NCT04095364|Drug|Paclitaxel|Given IV
12324|NCT04095351|Diagnostic Test|Pulmonary function test|Spirometry or plethysmography, measurement of diffusion capacity
12325|NCT04095351|Diagnostic Test|Imaging|Thoracic ultrasound, HRCT as scheduled within routine clinical examinations, echocardiography
12326|NCT04095351|Biological|Blood sampling|Standard laboratory test for CTDs as part of routine clinical examination
12327|NCT04095338|Other|traditional rehabilitation|Each session will include 50 minutes of traditional physical rehabilitation therapy
12328|NCT04095338|Other|virtual reality games intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Tymo system (Tyromotion, Austria), a wireless platform for the balance and the postural control training that simulates floor walking and stairs climbing. Tymo system is connected to a screen and provides virtual reality games, adaptable to the functional capacity of the patient. Through the games proposed, the physiotherapist will decide to work in a dimension (antero-posterior or medio-lateral dimension) or in two dimensions (combining the antero-posterior and medio-lateral movements).
12329|NCT04095338|Other|robotic treadmill intervention|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training by Walker view (TecnoBody, Italy), a treadmill equipped with a sensorized belt with eight load cells and a 3D camera.to detect length, speed and symmetry of the pace and load, range of the trunk, hips and knees. Patients will be asked to walk at a comfortable speed, while the physiotherapist will be able to work on different parameters such as step length, load distribution, and step height. The setting will take place taking into account the clinical conditions of each patient, customizing the intervention. The Walker View will offer visual and auditory feedback to the patient, so as to correct gait in real time.
12330|NCT04095325|Device|Ultrasound guided erector spinae block|Group 2 (n: 50): those who underwent ESP block after propofol atropine induction and maintained with only 1 mg / kg / h propofol in anesthesia maintenance
12331|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery
12332|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
12333|NCT04095312|Procedure|Revo-i robotic surgery system (Model MSR-5100)|for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
12334|NCT04095299|Radiation|50.4 Gy to the tumor and elective volume|Standard radiotherapy
12335|NCT04095299|Radiation|62 Gy to the clinical tumor volume and 50.4 Gy to the elective volume|Experimental radiotherapy
12336|NCT04095299|Drug|Capecitabine 825 mg/m2 twice daily on weekdays|Standard chemotherapy
12337|NCT04095286|Drug|AMB new formulation (1 mg)|AMB tablets will be available at a unit dose strength of 1 mg. Participants will orally administer 5 tablets of 1 mg unit dose.
12338|NCT04095286|Drug|Reference AMB (5 mg)|AMB reference tablet will be available as film-coated tablet at unit dose strength of 5 mg. Participants will orally administer 1 tablet of 5 mg unit dose
12339|NCT04095273|Drug|BAY1895344|Study drugs will be administered as scheduled
12340|NCT04095273|Drug|Pembrolizumab|Study drugs will be administered as scheduled
12341|NCT04095260|Other|Pre-season strength and conditioning program|The structured physical performance assessment will include functional movement testing, motor coordination testing, joint mobility screen, muscle strength testing, and agility performance testing. These measures will assess the effectiveness of pre-season strength and conditioning program to reduce musculoskeletal impairments and increase resistance to injury.
12342|NCT04095247|Device|Vagus nerv stimulator|pulse triggered autostimulation
12343|NCT04095234|Procedure|Acupuncture|Acupuncture, a therapy of traditional Chinese medicine (TCM), involves penetrating the skin with thin, solid, metallic needles that are manipulated by hand or electrical stimulation.
12344|NCT04095234|Procedure|Massage|Massage, which involves the manual manipulation of muscles and other soft tissue areas of the body, is one of the earliest known forms of pain relief.
12345|NCT04095221|Drug|Prexasertib|"DOSE LEVELS FOR PATIENTS > 21 YEARS OF AGE, Dose Level -1, prexasertib 105 mg/ m2 once every 14 days in 28 day cycles Dose Level 0, 60 mg/m2 prexasertib once every 21 days Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days Dose Level 2, 105 mg/m2 prexasertib once every 21 days Dose Level 3, 105 mg/m2 prexasertib once every 21 days~DOSE LEVELS FOR PATIENTS ≤ 21 YEARS OF AGE Dose Level -1, prexasertib 150 mg/ m2 once every 14 days in 28 day cycles, Dose Level 0, 60 mg/m2 prexasertib once every 21 days, Dose Level 1, (STARTING) 80 mg/m2 prexasertib once every 21 days, Dose Level 2, 150 mg/m2 prexasertib once every 21 days, Dose Level 3, 150 mg/m2 prexasertib once every 21 days"
12346|NCT04095221|Drug|Irinotecan|15 mg/m2 IV daily x 10 days in 21 day cycles
12347|NCT04095221|Drug|Temozolomide|temozolomide 100 mg/m2 orally daily x 5 days
12348|NCT04095208|Drug|Association of Nivolumab + Relatlimab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [240 mg].~Relatlimab will be administered as a 60-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [80 mg]."
12349|NCT04095208|Drug|Nivolumab|"A treatment cycle consists of 4 weeks.~Nivolumab will be administered as a 30-minutes intravenous infusion, on Days 1 and 15 of each cycle (every 2 weeks) - [240 mg]."
12350|NCT04095195|Radiation|MRCP|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
12351|NCT04095195|Procedure|Endoultrasonography|"Subjects fulfilling the radiological follow-up criteria will be submitted to MRCP or EUS according to the pancreatologist's prescription"
12352|NCT04095182|Drug|Zebinix 400mg|Zebinix 400mg group is administered with two Zebinix 200mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)
12353|NCT04095182|Drug|Placebo for Zebinix 400mg|"Placebo for Zebinix 400mg group is administered with two placebo for Zebinix 200mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
12354|NCT04095182|Drug|Zebinix 800mg|Zebinix 800mg group is administered with a Zebinix 800mg tablet per day. (Single dose: Day 1, Multiple dose: Day5~11)
12355|NCT04095182|Drug|Placebo for Zebinix 800mg|"Placebo for Zebinix 800mg group is administered with a placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
12356|NCT04095182|Drug|Zebinix 1600mg|Zebinix 1600mg group is administered with two Zebinix 800mg tablets per day. (Single dose: Day 1, Multiple dose: Day5~11)
12357|NCT04095182|Drug|Placebo for Zebinix 1600mg|"Placebo for Zebinix 1600mg group is administered with two placebo for Zebinix 800mg tablets per day.~(Single dose: Day 1, Multiple dose: Day5~11)"
12358|NCT04095169|Diagnostic Test|Complement C3d test (blood sample)|Evaluation of C3d levels in EDTA samples from participants
12359|NCT04095156|Diagnostic Test|In vitro assays.|Biochemical and flow-cytometry analysis of specimen collected.
12360|NCT04095143|Diagnostic Test|Portal vein flow|Doppler assessment performed on day 0, 3 and 7.
12361|NCT04095143|Diagnostic Test|Intra-renal flow|Doppler assessment performed on day 0, 3 and 7.
12362|NCT04095143|Diagnostic Test|Hepatic vein flow|Doppler assessment performed on day 0, 3 and 7.
12363|NCT04095143|Diagnostic Test|Pulmonary B-lines|Ultrasound assessment of performed on day 0, 3 and 7.
12364|NCT04095143|Diagnostic Test|Dimensions of the inferior vena cava|Ultrasound assessment of performed on day 0, 3 and 7.
12365|NCT04095143|Diagnostic Test|Left ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
12366|NCT04095143|Diagnostic Test|Right ventricular function|Ultrasound assessment of performed on day 0, 3 and 7.
12367|NCT04095130|Diagnostic Test|23Na Magnetic resonance imaging|Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.
12368|NCT04095117|Procedure|Epidural block|"Epidural catheter will be inserted at the L3-L4 or L4-L5 interspace in obese subjects scheduled for surgery on the lower extremities under epidural anesthesia.~The sagittal abdominal diameter, BMI and skin to epidural space distance will be recorded."
12369|NCT04095104|Drug|Phentermine|Phentermine tablet
12370|NCT04095104|Drug|Immediate Release Topiramate|Topiramate tablet
12371|NCT04095104|Drug|Placebo for Phentermine|Compounded tablet to mimic phentermine 8mg tablet
16235|NCT04063410|Other|Quality-of-Life Assessment|Ancillary studies
12373|NCT04095091|Device|4D Planar US Transducer|This 4D planar US transducer is being developed and validated to provide a novel image-guidance technique to directly track tumor motion during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition.
12374|NCT04095078|Device|SIMEOX|Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
12375|NCT04095065|Behavioral|itMatters|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking.
12376|NCT04095065|Behavioral|itMatters and itMatters Sexual Violence Prevention|Increase knowledge related to STIs, STI risk, alcohol impairment, condom use, alcohol use behavior tracking skill, testing & treatment knowledge. Correct misperceptions regarding approval (injunctive norms) and prevalence (descriptive norms) of alcohol misuse & sexual risk taking. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increased knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
12377|NCT04095065|Behavioral|itMatters Well-being and itMatters Sexual Violence Prevention|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines. Additionally, increased knowledge related to sexual violence (prevalence, key definitions, individual rights and responsibilities, laws) and increase knowledge, efficacy, and intentions to use bystander behaviors during moments of sexual violence.
12378|NCT04095065|Behavioral|itMatters Well-being|Increase knowledge related to sleep, including biological effects of sleep and sleep hygiene. Increase knowledge related to time management, including important definitions, sleep management strategies, and effective time management routines.
12379|NCT04095052|Dietary Supplement|Methyl Folate|1,000 mcg methyl folate and Microcrystalline Cellulose in a capsule
12380|NCT04095052|Dietary Supplement|Placebo|Microcrystalline Cellulose capsule
12381|NCT04095039|Procedure|Hemodialysis|Patients in both arms will undergo hemodialysis to remove phosphate from the blood; however, patients in the Hi Arm will only be titrated down to no lower than 6.5mg/dl
12382|NCT04095013|Drug|Bupivacaine, fentanyl|Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
12383|NCT04095013|Drug|Bupivacaine, dexmedetomidine|Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
12384|NCT04095000|Behavioral|FACE-TC SP|The current FACE-TC protocol consists of three weekly 60 to 90-minute sessions in a dyadic format facilitated by a trained/certified interviewer. If our community partners recommend otherwise, this structure could change. Each session is followed by a 10-minute assessment, using process measures to assess participants' ratings of the quality of communication and satisfaction.
12385|NCT04095000|Behavioral|Treatment as Usual|Treatment as Usual comparison condition will also be assessed and measures administered at the same time intervals.
12386|NCT04094987|Device|inter-fascial pressure|İn the Block procedure during will used the pressure line addition the block needle .
12387|NCT04094974|Device|ANSiscope|Heart rate variability will be assessed using ansiscope before surgery
12388|NCT04094961|Drug|Ixazomib|Oral, administered four times per cycle
12389|NCT04094961|Drug|Pomalidomide|Oral, administered 14 times per cycle
12390|NCT04094961|Drug|Dexamethasone|Oral, fixed dose administered 8 times per cycle
12391|NCT04094948|Drug|Clenbuterol|20 mcg spiropent tablets will be overencapsulated (two 20 mcg tablets per capsule)
12392|NCT04094948|Drug|Placebos|dextrose-filled capsules
12393|NCT04094922|Behavioral|Swedish PTSD Coach smartphone app|Self-help smartphone app targeted towards posttraumatic stress that includes psychoeducation, rating/monitoring of distress, lists of support and treatment resources, and strategies for coping with distress.
12394|NCT04094909|Drug|Rh-endostatin|"Squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +[nab]-paclitaxel during the treatment. Rh-endostatin+Pembrolizumab during the maintenance period.~Non-squamous NSCLC: Rh-endostatin+Pembrolizumab+carboplatin or cisplatin +pemetrexed during the treatment. Rh-endostatin+Pembrolizumab + pemetrexed during the maintenance period."
12395|NCT04094896|Drug|TCHP|Both TCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment for HER2-Positive Breast Cancer have been recommended by NCCN guideline. It is unknown which regimen is better. This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab/Pertuzumab)regimens as Neoadjuvant Treatment in HER2- Positive breast cancer. The endpoint of pathologic complete response is used as a surrogate marker for survival. Safety and tolerability assessed by number of grade 4 toxicities and hospitalizations.
12396|NCT04094883|Biological|Meningococcal Group B Vaccine|All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
12397|NCT04094870|Drug|Sertraline|daily SSRI (Sertraline 25mg)
12398|NCT04094870|Behavioral|Interpersonal therapy|11 sessions over a 24-week period
12399|NCT04094857|Drug|HBN-1|Intravenous infusion
12400|NCT04094844|Other|Wearable activity sensor|Caregivers and patients in both arms of the study will have a Fitbit wearable activity sensor to track activity and sleep.
12401|NCT04094844|Behavioral|Roadmap 2.0 information system|"Caregivers in the Roadmap 2.0 app arm download a Positive Activities app onto their mobile phone to use freely throughout inpatient and outpatient (through day 120 post-transplant). Caregiver may also use an electronic tablet provided by the study team during the patient's hospital stay."
12402|NCT04094844|Other|Survey administration|Caregivers and patients will be asked to respond to survey questions at 3 timepoints.
12433|NCT04094662|Drug|Mirogabalin|Mirogabalin tablets for oral administration
12434|NCT04094662|Drug|Placebo|Matching placebo tablets for oral administration
12435|NCT04094649|Device|Ultrasound Vagus Nerve Stimulation (DECIMA)|This is a single-site, double-blind, randomized, prospective, sham-controlled, crossover early feasibility study to determine whether ultrasound Vagus Nerve Stimulation (uVNS) inhibits postprandial hyperglycemia in humans.
12403|NCT04094831|Other|Health education|The intervention group will receive health education through CKD campaign and mHealth technology. During the half day CKD campaign, health education materials (leaflet and short textbook and recording notebook) will be provided to the study participants. A nephrologist will facilitate the campaign and contents (Annex-3) of the text book and leaflet (Annex-4) will be discussed. Important message from the text book (such as stage, risk factor, preventive measures) will be used to develop the leaflet. In addition, education through mHealth will be provided by Short Message Service (SMS) during the study period. The contents of the SMS are: 1). Reduce salt intake; 2) Do exercise and take medicine regularly; 3). Control blood pressure (if hypertensive) and blood sugar (if diabetic); and 4) Avoid painkiller and smoking will be sent to the participants using mobile phone once a week for first 2.5 months and once a 2-week for next 3 months.
12404|NCT04094818|Diagnostic Test|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
12405|NCT04094805|Drug|Rocaltrol|Rocaltrol 0.25 μg daily for 1 month; HD-DXM (orally at 40 mg daily for 4d )
12406|NCT04094805|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d )
12407|NCT04094792|Device|Happify Breather App|Subjects in the intervention group will be cued to breathe at 6 breaths per minute and will receive real time heart rate variability biofeedback. As they increase HRV, screen elements will become more visually appealing.
12408|NCT04094779|Other|Usual relation care|When a patient begins to agitate, he will be isolated from the group to establish a dual relationship where the caregiver will try through his relational approach to calm the agitation.
12409|NCT04094779|Other|"Flash activity breath of fresh air"|When a patient begins to agitate , he will be isolated from the group and the patient leave from the unit to walk outside with the caregiver.
12410|NCT04094766|Drug|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
12411|NCT04094753|Diagnostic Test|Blood Sample|A sober blood sample is taken to observe the following parameters: creatinin, ureum, sodium, potassium, osmolality, HDL cholesterol, LDL cholesterol, triglycerides)
12412|NCT04094753|Diagnostic Test|Renal Function Profile|A Renal Function Profile is a 24 hour-urine collection in which urine samples are collected at fixed time points every 3 hours, starting 3 hours after the first morning void. Daytime samples were taken at 10:00-11:30 (U1), 13:00-15:30 (U2), 16:00-17:30 (U3), 19:00-20:30 (U4), and 22:00-23:30 (U5). The nighttime samples were taken at 1:00-2:30 (U6), 4:00-5:30 (U7) and 7:00-8:30 (U8). The volume of each sample, and of each micturition in between, was noted to calculate the 24h, daytime and nighttime urine volume and diuresis rate.
12413|NCT04094753|Diagnostic Test|Frequency Volume Chart|Every patient complets a frequency volume chart during 24 of 72 hours
12414|NCT04094753|Diagnostic Test|Cystometry|This technique provide the most precise measurement of bladder and urethral sphincter behaviour during bladder filling and during voiding.
12415|NCT04094753|Diagnostic Test|Questionaires|"Patients have to fulfill the following questionaires~ICIQ-Fluts for female participants or ICIQ-Mluts for male participants~TILBURG FRAILTY INDICATOR~SF-36 Quality of Life score~N- QOL"
12416|NCT04094753|Diagnostic Test|Flow rate measurement + Observation of the post-void residual urine volume|A measurement of the urinary flow rate is observed to collect the maximum Q/s. Afterwards an observation of the PVR is done using ultrasound.
12417|NCT04094753|Diagnostic Test|Clinical Examination|Clinical examination of the genital region. For women, coeles are described using the POPQ
12418|NCT04094740|Device|Jet Injector without A Needle|Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
12419|NCT04094727|Drug|Presumptive treatment with Artemether-lumefantrine (AL)|All eligible HRPs will be presumptively treated with artemether-lumefantrine (AL) at two timepoints, separated by at least one month. All individuals who have provided informed consent, meet eligibility criteria, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages). AL is currently the first line drug used for uncomplicated malaria in Namibia, and has been used previously in northern Namibia for focal mass drug administration and has no severe adverse effects and is well-tolerated, with high adherence and acceptability in this context. AL requires two daily doses for three consecutive days, for a total of six doses. The first antimalarial dose will be delivered by directly observed therapy (DOT) and subsequent doses will be left with the subject, with instructions to self-administer them.
12420|NCT04094727|Other|Enhanced vector control|"The mop up indoor residual spraying (IRS) campaign will be targeted to farms and cattle posts/kraals in intervention areas in December 2019 to fill gaps from the routine spray campaign (September to November 2019) and utilize the same insecticides and protocols as the national campaign. The team will spray each unsprayed structure with the recommended solution of dichloro-diphenyl-trichloroethane (DDT) for traditional structures and/or Actellic for modern structures, tarps and tents.~Alternative vector control interventions, including LLINs (long-lasting insecticide treated bed nets), sprayed tents/tarps and topical repellents will be distributed to eligible HRPs between November and January 2020 during one round."
12421|NCT04094701|Other|15 oxycodone immediate release pills|"Patients in the experimental group will receive 50% less oxycodone relative to control group:~Scheduled Tylenol 1g every 8 hours, meloxicam 15mg every 12 hours~Tramadol 50mg, 20 pills~Oxycodone 5mg, 15 pills"
12422|NCT04094701|Other|30 oxycodone pills|"Patients will receive the following pain medication regimen postoperatively:~Scheduled Tylenol 1g every 8 hours, meloxicam 15mg every 12 hours~Tramadol 50mg, 20 pills~Oxycodone 5mg, 30 pills"
12423|NCT04094688|Drug|Bevacizumab|Given IV
12424|NCT04094688|Drug|Oxaliplatin|Given IV
12425|NCT04094688|Drug|Leucovorin Calcium|Given IV
12426|NCT04094688|Drug|Fluorouracil|Given IV
12427|NCT04094688|Drug|Irinotecan Hydrochloride|Given IV
12428|NCT04094688|Drug|Irinotecan|Given IV
12429|NCT04094688|Dietary Supplement|Cholecalciferol|Given PO
12430|NCT04094688|Other|Quality-of-Life Assessment|Ancillary studies
12431|NCT04094688|Other|Questionnaire Administration|Ancillary studies
12436|NCT04094636|Behavioral|In-bed cycling|Patients will daily perform 30 min of supervised in-bed cycling
12437|NCT04094636|Behavioral|Exercise booklet|Patients will daily perform 30 min of supervised physical training with exercises from the exercise booklet
12438|NCT04094623|Other|Dialectical behavior therapy|15 patients in a group are treated by 2 psychotherapist by DBT including mindfulness skills, distress tolerance skills, emotional regulation skills and interpersonal effectiveness skills.
12439|NCT04094623|Other|Social support group therapy|15 patients in a group are treated by 2 psychotherapist by SSGT.(Giving support to each other.)
12440|NCT04094610|Drug|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005)
12441|NCT04094597|Drug|Lactoferrin|lactoferrin is given orally in comparsion to placebp
12442|NCT04094597|Drug|Placebos|placebp is given in 2 ml saline
12443|NCT04094584|Drug|Vivitrol (Extended Release Naltrexone)|Monthly Injection of 380mg Extended-Release Naltrexone
12444|NCT04094571|Device|Functional Electrical Stimulation (FES) Control Protocol|To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.
12445|NCT04094571|Device|Functional Electrical Stimulation (FES) Angle Protocol|To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
12446|NCT04094558|Device|Ingestible capsule|Participants will swallow capsule and undergo X-rays to establish transit.
12447|NCT04094532|Drug|Bupivacaine|Ultrasound guided 20 ml % 0.250 bupivacaine injection to transverse thoracic muscle plane bilaterally
12448|NCT04094532|Drug|Saline|Ultrasound guided 20 ml % 0.9 saline injection to transverse thoracic muscle plane bilaterally
12453|NCT04094506|Drug|ASP1948|Intravenous
12454|NCT04094493|Drug|vit D|preoperative intra muscular vit D injection
12455|NCT04094480|Device|polymeric non absorbable clips|a method to secure appendicular stump
12456|NCT04094480|Other|endoloops|a method to secure appendicular stump
12457|NCT04094467|Drug|Cetrorelix|0.25 mg subcutaneous injection daily for 6 days
12458|NCT04094467|Drug|Leuprolide Acetate|0.1 mg subcutaneous injection daily for 12 days
12459|NCT04094454|Device|special tampon with a diameter of 28mm|patients will use a special tampon with extended vaginal dilatation (diameter 28mm) during radiotherapy
12460|NCT04094454|Device|standard tampon with a diameter of 12-13mm|patients in Arm B will use a normal commercially available tampon (diameter 12-13mm) during radiotherapy
12461|NCT04094441|Other|chest physiotherapy|chest physiotherapy
12462|NCT04094415|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
12463|NCT04094402|Other|None. It is an observational study|None. It is an observational study
12464|NCT04094389|Other|Orthotic continuous wear group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the continuous wear group will be instructed to wear their orthotic continuously around the clock as tolerated with removal for hygiene and home exercise program (HEP) performance. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
12465|NCT04094389|Other|Orthotic wear during waking hours only group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~Participants in the waking hours only group will be instructed to wear their orthotic during all waking hours as tolerated, with removal for hygiene, HEP performance, but not at night while sleeping. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated."
12466|NCT04094389|Other|Orthotic wear only while sleeping group|"Performed exclusively for research purposes, participants will be assigned at entrance to the study to either wear the orthotic continuously, only during waking hours, or only while sleeping. There will be three participants in each of the three groups.~In the night-wear group, participants will be told to wear their orthosis only at night. Consistent with standard of care for the treatment of trigger finger with an orthotic, all nine of the participants will be instructed to wear their orthotic for at least six weeks, as tolerated, with continuation of orthotic wear up to 10 weeks if their triggering has not completely abated"
12467|NCT04094376|Other|receiving operation during the day or at night|eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
12468|NCT04094363|Other|Product A|Usual Brand, filtered combustible cigarette
12469|NCT04094363|Other|Product B|CSD1902-11, an electronic nicotine delivery system
12470|NCT04094363|Other|Product C|CSD1902-21, an electronic nicotine delivery system
12471|NCT04094363|Other|Product D|4mg Nicotine gum
12495|NCT04094142|Drug|Acalabrutinib|"Acalabrutinib, lenalidomide, rituximab will be given as described in the Arms decriptions. Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, for 6 cycles.~After 6 cycles, maintenance of acalabrutinib 100mg bid will be administered up to 1 year for subjects whose best responses- to the regimen are partial response or complete remission."
12472|NCT04094350|Other|ACF with a seed-and-recruit model|The intervention will take place for 12 months. In the intervention clusters, potential seeds - TB survivors, people living with HIV, and household contacts of people with TB - will be approached by the research team. Seeds will be trained and act as recruiters in the community to refer presumptive TB cases to the attached health centers. The research team will work with staff at the health centers to facilitate screening and enrollment of recruits who are diagnosed with TB to care. New people with TB who have the potential to be a recruiter will be invited and trained to recruit their peers in the community who may have TB for TB screening. Seeds will be trained to identify people who may have TB and equipped with health promotion skills to impart knowledge and practices about TB. We will follow-up all people with TB referred by seeds for six months from the treatment initiation.
12473|NCT04094350|Other|ACF targeting household and neighborhood contacts|In this arm, community health volunteers will recruit household contacts of people with TB and TB survivors diagnosed during the preceding two years. Immediate neighbors (10 nearest households) of the index cases (people with TB) who are symptomatic will also be invited by the community health volunteers to the screening session. Next nearest households within the same village will be approached if the number of presumptive TB cases in the 10 nearest households is low. The one-off screening session will be held at the nearest health center on specific days. Presumptive TB cases will be screened for symptoms on-site, and chest x-ray (CXR) will be taken. Sputum samples from presumptive TB cases with abnormal (CXR) will be collected for GeneXpert testing. Test results will be communicated to the newly diagnosed people with TB, and they will be referred to the health centers for treatment and follow-up.
12474|NCT04094350|Other|ACF targeting the older population using mobile screening units|The outreach team will conduct training and sensitization of the target population of the activities. The schedule of a one-off screening session will be made known to the communities in the districts before the screening day. Each person who visits the screening session will be screened. Demographic information and presence of TB symptoms will be collected at registration by a trained staff. A chest x-ray will then be performed on-site for all persons exhibiting TB symptoms and all elderly aged 55 and above regardless of symptoms. When CXR findings are abnormal, sputum samples will be collected for GeneXpert testing on-site as well. Test results will be communicated to the participants on the spot or via phone calls, and people with TB will be referred for treatment and follow-up at the health center where screening is conducted or a center of their choice. Should the health center of their choice do not fall within the selected sites, follow-up will be conducted via phone calls.
12475|NCT04094350|Other|Passive case finding|Passive case finding (PCF) strategy is a default setup in the national health system. PCF relies on the self-presentation of presumptive TB cases to the health centers to be diagnosed with TB.
12476|NCT04094337|Behavioral|Internet-assisted treatment|Internet-assisted treatment
12477|NCT04094324|Behavioral|Questionnaires|4 questionnaires will be answered via iPads
12478|NCT04094311|Biological|Tisagenlecleucel|A single intravenous (i.v.) infusion of CAR-positive viable T cells.
12479|NCT04094298|Drug|FX006 Injection|One injection of extended release triamcinolone. 32 milligram injection of the extended release triamcinolone in a 75:25 ratio of polylactic-co-glycolic acid (PLGA) microspheres to drug load of 25%. The drug product is reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium chloride, carboxymethylcellulose sodium and polysorbate-80 to form a suspension prior to injection.
12480|NCT04094285|Drug|SAUERSTOFF|"SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes"
12481|NCT04094285|Drug|STICKSTOFF|"STICKSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~88% with 12% oxygen, breathing for 30 minutes"
12482|NCT04094272|Diagnostic Test|transthoracic doppler-echocardiography (TTE)|Transthoracic doppler-echocardiography (TTE) in patients with a new diagnosis of HCV before and after treatment with DAA medication.
12483|NCT04094259|Behavioral|Questionnaire.|patients will respond to a specific questionnaire regarding the use of alternative medicine
12484|NCT04094246|Procedure|Battlefield Acupuncture|Battlefield Acupuncture (BFA), an auricular acupuncture protocol developed in 2001 by Dr. Niemtzow (Ret. Colonel, USAF), is widely used among civilian and military medical providers to treat pain. Participants in the Experimental Group will receive BFA in addition to standard post-surgical rehabilitation up to four times following their shoulder surgery: 24-hours, 48-hours, 72-hours, and 1-week post-surgery.
12485|NCT04094246|Procedure|Standard post-surgical rehabilitation|Participants will receive rehabilitation and will perform a home exercise program in accordance with the standard post-operative shoulder protocol. Participants will be asked to record compliance on an exercise log.
12486|NCT04094233|Dietary Supplement|Beetroot extract|Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
12487|NCT04094233|Other|Placebo|Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
12488|NCT04094220|Procedure|Lateral lumbar interbody fusion|LLIF is an indirect decompression technique, and does not directly remove the disc or osteophyte protruding into the spinal canal. Its decompression effect is not as thorough as traditional posterior decompression surgery. Usually, posterior decompression is required for patients who have unsuccessful indirect decompression.
12489|NCT04094207|Drug|Placebo oral tablet|Placebo tablets PLUS Risperidone 2 mg tablet up to 6 mg/day
12490|NCT04094207|Drug|Pentoxifylline|Pentoxifylline tablet PLUS Risperidone 2 mg tablet up to 6 mg/day
12491|NCT04094194|Other|Nordic diet|Healthy dietary pattern that is consumed in Nordic countries
12492|NCT04094168|Drug|DEL NIDO CARDIOPLEGIA|"Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq."
12493|NCT04094168|Drug|COLD BLOOD BASED CARDIOPLEGIA|Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
12494|NCT04094155|Diagnostic Test|retinal vascular analysis|Retinal fundoscopy over a 3 week period in stationary patients after aneurysmatic subarachnoid hemorrhage
12496|NCT04094129|Dietary Supplement|Wismemo|Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-89, Lactobacillus paracasei GMNL-133 and Lactobacillus plantarum GMNL-141.
12497|NCT04094129|Dietary Supplement|Placebo|placebo
12498|NCT04094116|Procedure|ear wax syringing without pre ear oil treatment|Active Comparator: ear wax syringing with pre ear oil treatment Sham Comparator: ear wax syringing without pre ear oil treatment
12499|NCT04094103|Dietary Supplement|Active strawberry powder|Participants will drink a strawberry beverage with active ingredients once a day during the 4-week intervention period.
12500|NCT04094103|Dietary Supplement|Placebo strawberry powder|Participants will drink a strawberry placebo beverage once a day during the 4-week intervention period.
12501|NCT04094103|Dietary Supplement|Mixed strawberry powder|Participants will drink a mixed strawberry beverage with active ingredients and placebo once a day during the 4-week intervention period.
12502|NCT04094090|Combination Product|PXL-330 Platinum device for crosslinking with Peschke riboflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
12503|NCT04094077|Drug|AGuIX|2 IV injections (100 mg/Kg/injection) at day 4 and day 8 + Strereotactic Radiation from day 8 to day 15 as per standard practice.
12504|NCT04094064|Device|Continuous Glucose Monitor|Use of a continuous glucose monitor during study period.
12505|NCT04094051|Drug|Ibrutinib|In the retrospective period, clinical information of approximate 500 patients with CLL/SLL prior to the study initiation will be collected retrospectively through chart review. There will be one time follow-up to collect data on disease progression, survival status and patient-reported outcomes.
12506|NCT04094038|Drug|Olimel N12|A mixture of glucose, lipids, amino acids.
12507|NCT04094038|Drug|Glucose IV|Glucose 5%
12508|NCT04094025|Drug|dATS|d-Amphetamine Transdermal System
12509|NCT04094012|Drug|isoniazid and rifapentine|This prospective multicenter randomized control trial (RCT) will be conducted on LTBI cases (see 2. Study population) to compare the risk of SDRs under conventional 3HP regimen (Arm 1: 3HP) and a new regimen consisting of daily RPT (10 mg/kg) plus INH (5 mg/kg) for 1 month (Arm 2: 1HP)
12510|NCT04093999|Procedure|Sensory nerve coaptation|A recipient sensory nerve branch of the 11th-12th intercostal nerve was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
12511|NCT04093986|Other|Chart Review|Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.
12512|NCT04093986|Other|Survey|Women who choose to participate directly and provide information in survey format will receive a brief survey and the option to upload their medical records (if available) into Cincinnati Children's maintained REDCap database.
12513|NCT04093973|Diagnostic Test|bicycle stress echocardiography|Study subjects will perform supine bicycle exercise with echocardiography performed before, during, and after exercise. Definity (perflutren microbubble contrast agent) will be used as needed to enhance echo images.
12514|NCT04093960|Dietary Supplement|Lactobacillus plantarum PS128|10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
12515|NCT04093947|Other|Observational study|Observational and prospective study
12516|NCT04093934|Behavioral|Psychosocial stimulation|Children will receive fortnightly sessions of psychosocial stimulation and nutritional support for one year during the study period.
12517|NCT04093921|Behavioral|MET-based therapy|see previous
12518|NCT04093921|Behavioral|Standard Care|To include all recommended outpatient treatments
12519|NCT04093908|Other|Prediction of motor outcome after STN DBS based on preoperative variables|Generating individual probabilities for motor response based on preoperative variables
12520|NCT04093895|Drug|PerioSept(r)|Scaling and root planing followed by 3% PerioSept(r) administration
12521|NCT04093882|Diagnostic Test|Contrast agent enhanced MRI using Gadovist|By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.
12522|NCT04093869|Behavioral|Coping Skills Training combined with Exercise (CSTEX)|The CSTEX condition has two integrated components: the CST component will systematically train patients in the use of coping skills for stress reduction and promote key transplant-specific health behaviors. The exercise component of the intervention will progressively increase participants exercise and promote daily physical activity through motivational interviewing strategies.
12523|NCT04093869|Behavioral|Standard of Care plus Education (SOC-ED)|The SOC-ED condition provides support and enhanced post-transplant education. Participants will be given detailed educational information about post-transplant care, the importance of medication adherence, and maintenance of physical activity.
12524|NCT04093843|Device|TMS|NeuroStar TMS Therapy
12525|NCT04093830|Device|hearing aid|hearing aid can be used in their non- implanted ear with residual hearing
12526|NCT04093817|Device|cardio pulmonary bypass machine|cardio pulmonary bypass machine is a machine that work to compensate for the function of the heart and the lungs in the operation
12527|NCT04093804|Device|Glenosphere size for Reverse Shoulder Arthroplasty|Two randomized study groups will be formed with the consented patients (experimental and control). All patients will undergo reverse shoulder arthroplasty by the Principal Investigator. The experimental group patients will receive a 36mm glenosphere and the control group will receive a 32mm glenosphere. All other procedures during the surgery are identical between groups.
12528|NCT04093791|Behavioral|"Collective Intervention G"|"The steps are:~Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mothers. The operator maintains a nonjudgmental approach encouraging the women to describe the need for behavioral change.~Analysis. The situation must be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way and they will assign a grade of discomfort for each problem.~Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mothers to face problems and the reasons of the failures.~Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
12606|NCT04093245|Other|Wiki-based Knowledge tools|access to wiki-based patient-oriented KT tools
12607|NCT04093245|Other|Telemonitoring service|access to a community-based telemonitoring service
12529|NCT04093791|Behavioral|"Individual Intervention I"|"The steps are:~Listening/establishing relationship. This step is characterized by listening and understanding the critical points from the new mother. The operator maintains a nonjudgmental approach encouraging the woman to describe the need for behavioral change.~Analysis. The situation have be carefully evaluated, considering the discomfort and emotional distress. The stress situation will be described in a subjective way, and she will assign a grade of discomfort for each problem.~Assessment. The operator will carry out a multidimensional evaluation of the mothers within the dyad. The operator will evaluate the strategies implemented by the mother to face problems and the reasons of the failures.~Summary and goal of the intervention. The problems detected by the operator will be explained and summarized to the participants. The operator explores ways to implement change."
12530|NCT04093778|Other|Low dose high frequency training and Safe Delivery Phone Application|The intervention period is a 9-month period where we will facilitate a quality improvement cycle using Low Dose High Frequency training with the Safe Delivery App as an anchor point and facilitate the integration into clinical practice through our Safe Delivery Focal Points at each hospital. All staff in maternity, paediatric wards and outpatient clinics will receive training and be encouraged to use the Safe Delivery App on a weekly basis.
12531|NCT04093765|Diagnostic Test|Ultrasensitive Rapid Diagnostic Test (URDT)|"Investigation will consist in 1 URDT.~For P. falciparum URDT positive:~collection of 3x1cm dried blood spots on filter paper~administration of a supervised antimalarial treatment course to individuals for which a P. falciparum will have been detected by URDT.~Specifically in group 1, a population list will be collected in each village prior to MSAT campaign and all participants will undergo:~collection of a 200 µL-aliquot of capillary blood for each participant to the screening during the MSAT intervention.~1 URDT + collection of a 200µL-aliquot of capillary blood for each participant to the follow-up survey at M12."
12532|NCT04093765|Drug|Antimalarials|"A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary."
12533|NCT04093752|Drug|Tirzepatide|Administered SC
12534|NCT04093752|Drug|Insulin Glargine|Administered SC
12535|NCT04093739|Device|G7 Freedom Constrained Liners|Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
12536|NCT04093726|Other|lollipop|chewing lollipop for 20min
12537|NCT04093713|Procedure|A novel technique to block the inferior alveolar nerve block using Mepivecaine with Levonordefrin|blocking the inferior alveolar nerve using extroral landmarks
12538|NCT04093700|Device|SureLock All-Suture Anchor|Subjects that have been implanted with the SureLock All-Suture Anchor to repair the glenoid labrum
12539|NCT04093687|Other|Endoscopist's training|"The training session will be divided into two parts: theoretical and practical. Trainees will be blinded to the criterion of being chosen due to their performance status.~During the first, theoretical part, the body of research on the phenomenon of colonoscopy pain will be presented. Aspects on how to deliver a painless colonoscopy (patient characteristics, insertion technique, endoscope characteristics, non-technical skills, additional manoeuvres) will be discussed. This part will be based on the findings from Phase I.~The second, practical part of the training, will consist of a one-day session of 7 colonoscopies. Participants will be matched with each other. Each participant, will perform one colonoscopy with an oversight of a matched partner, then in turn oversee the colonoscopy of another participant. The rest of the participants will observe a live transmission of each colonoscopy in a separate room, with a commentary from study coordinator."
12540|NCT04093674|Procedure|de-epithelized (DE) SCTG|subepithelial connective tissue grafts
12541|NCT04093648|Genetic|TEGAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:DL1: 1x10^7/m2 DL2: 3x10^7/m2 DL3: 1x10^8/m2 DL4: 3x10^8/m2 DL5: 1x10^9/m2 If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10^6/m2 dose.~The first patient on each dose level has to be 28 days post-CAR T cell infusion before the second patient can be enrolled. The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
12542|NCT04093648|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
12543|NCT04093648|Drug|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
12544|NCT04093635|Device|Negative Pressure Wound Therapy|VAC was applied by placing sterile pads in two layers with a 16Fr Ryle's tube placed between the two layers and then the wound was sealed by a sterile transparent polyurethane sheet. The tube was connected to a wall-mounted suction device and the pressure will be set at −125 mmHg Mode of NPWT. This dressing will be changed every 72 hrs
12545|NCT04093622|Genetic|Genetically engineered NK cells|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered NK Cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
12546|NCT04093609|Genetic|XIST gene deletion|detection of XIST gene deletion by fluorescence in situ hybridization
12551|NCT04093583|Procedure|Exodontia|Atraumatic exodontia followed by simple suture
12552|NCT04093583|Drug|Alveolar ridge preservation with a PRP (PRGF-Endoret)|Filling of the alveolus with PRGF clot and fibrin plug.
12553|NCT04093583|Device|Preparation of PRGF using Endoret technology|Preparation of PRGF using Endoret technology following manufacturer instructions
12554|NCT04093570|Drug|ASTX727|Form: Tablet Route of Administration: Oral
16443|NCT04061772|Drug|Cyclophosphamide|Cyclophosphamide injection
12555|NCT04093557|Other|Orton Score|Significant a priori predictors of poor prep included: male gender, COPD, diabetes with end-organ damage, severe neurologic disease, constipation medication use, and tricyclic antidepressant use. Proprietary web-based weighted scoring model allows screening clinician to predict which bowel prep would be best for patient depending on which risk factors patients have.
12556|NCT04093557|Other|Typical Standard of Care|Clinician usual practice of prescribing bowel preps to patient
12557|NCT04093544|Device|Deep brain stimulation|Steered stimulation using directional leads
12558|NCT04093531|Drug|Ustekinumab|Up to 15 subjects will receive an infusion loading dose of 6 mg/kg of ustekinumab at baseline, and 90 mg of ustekinumab subcutaneously at week 4, week 12 and week 20. Subjects will be followed for 24 weeks.
12559|NCT04093518|Drug|Estradiol|2 transdermal patches to be changed twice a week for the duration of 16 weeks
12560|NCT04093518|Drug|Placebo|2 transdermal patches to be changed twice a week for the duration of 16 weeks
12561|NCT04093505|Drug|Gemtuzumab Ozogamicin 147|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on days 1,4 and 7
12562|NCT04093505|Drug|Gemtuzumab Ozogamicin 1|Induction therapy: Gemtuzumab Ozogamicin 3mg/m² on day 1
12563|NCT04093505|Drug|Glasdegib|Consolidation & Maintenance therapy Glasdegib 100mg on days 4 to 27
12564|NCT04093505|Drug|Placebo Oral Tablet|Consolidation & Maintenance therapy Placebo 100mg on days 4 to 27
12565|NCT04093492|Other|Preemie Prep for Parents (P3) Outpatient Mobile Intervention|The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
12566|NCT04093492|Other|ACOG links|Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
12567|NCT04093479|Other|blood samples|blood samples will be taken repeatedly
12568|NCT04093466|Drug|CX1003|Oral dose A 4-day single dose period, followed by a period of daily-dose in continuous 28-day treatment cycle (the 1st cycle) or 21-day treatment cycles (the 2nd cycle and beyond) Dosage range: 25 mg, 50mg, 75mg, 100mg
12569|NCT04093453|Other|Placebo (Sodium Chloride)|Participant receive Placebo (Sodium Chloride)
12570|NCT04093453|Other|Exercise|1 hour exercise
12571|NCT04093453|Dietary Supplement|Sodium Propionate|Participant receive Sodium Propionate
12572|NCT04093440|Other|lifestyle modification|nutrition counselling, diet and physical exercise monitoring, smoking cessation, and medication optimization
12573|NCT04093427|Other|softSTOPP|Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end
12574|NCT04093414|Device|Select Secure pacing lead|A Select Secure pacing lead is placed in the bundle of His or left bundle branch, based upon randomization
12575|NCT04093401|Other|individualized risk assessment|Individualized risk assessment of developing a second basal cell carcinoma
12576|NCT04093388|Diagnostic Test|Self-PAP|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
12577|NCT04093388|Diagnostic Test|Traditional Pap smear|A single cohort of 250 patients will be recruited from among those who need a Papanicolaou (Pap) smear for routine cervical cancer screening, to perform a self-administered Pap smear immediately prior to the traditional Pap smear. Blinded assessment of both tests will be then conducted.
12578|NCT04093375|Procedure|Radical Prostatectomy|Radical prostatectomy with or without androgen deprivation therapy
12579|NCT04093375|Other|Radical Radiotherapy|Radical Radiotherapy with adjuvant androgen deprivation therapy
12580|NCT04093362|Drug|TAS-120|TAS-120 is an oral FGFR inhibitor
12581|NCT04093362|Drug|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine is currently 1st line standard of care
12582|NCT04093349|Genetic|SPK-3006|adeno-associated viral (AAV) vector
12583|NCT04093336|Biological|human umbilical cord mesenchymal stem cells|The MSCs was intravenous transplanted to acute cerebral infarction patients as a single dose.
12584|NCT04093336|Biological|Placebo|Placebo
12585|NCT04093336|Other|standardized treatment|standardized treatment
12586|NCT04093323|Biological|Alpha-type-1 Polarized Dendritic Cells|Given ID
12587|NCT04093323|Drug|Celecoxib|Given PO
12588|NCT04093323|Drug|PD-1 Ligand Inhibitor|Given IV
12589|NCT04093323|Drug|PD1 Inhibitor|Given IV
12590|NCT04093323|Biological|Recombinant Interferon Alfa-2b|Given IV
12591|NCT04093323|Drug|Rintatolimod|Given IV
12592|NCT04093310|Device|Word Catheter|Use of the Word catheter to remove the Bartholin's abscess
12593|NCT04093310|Procedure|Incision-drainage|Incision-drainage to remove the Bartholin's abscess
12594|NCT04093297|Procedure|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
12595|NCT04093284|Device|The needle-free jet injector|Continuous insulin therapy for 9 days
12596|NCT04093271|Dietary Supplement|Rest-ZZZ|A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm
12597|NCT04093271|Drug|Active Comparator - Diphenhydramine HCl|DIN 02229960 encapsulated for blinding purposes
12598|NCT04093271|Other|Placebo|No active ingredients
12599|NCT04093258|Device|Dailies Total 1® Multifocal Contact Lenses|TEST
12600|NCT04093258|Device|Air Optix® Multifocal Contact Lenses Plus HydraGlyde®|CONTROL
12601|NCT04093245|Behavioral|GEM nurse|hospital-based geriatric emergency nurse (GEM nurse) specialist to support patients during the post-discharge transition period
12602|NCT04093245|Behavioral|pre- and post-hospitalization medication list reconciliation|pre- and post-hospitalization medication list reconciliation for elderly
12603|NCT04093245|Behavioral|systematic discharge summaries|systematic discharge summaries given to patients and/or caregiver, and sent to their family physician
12604|NCT04093245|Behavioral|medical follow-up appointment|a planned follow-up appointment with their family physician
12605|NCT04093245|Behavioral|follow-up phone call|a systematic follow-up phone call for discharged patients
12608|NCT04093232|Drug|Hymovis|All subjects will receive 2 ultrasound guided Hymovis injections and the goal of the study is to correlate responsiveness to subjects unique SF biomarker panel results before the first Hymovis injection and identify potential mechanism of action of those OA patients who receive the greatest benefit.
12609|NCT04093219|Drug|IV acetaminophen|use of IV tylenol for pain
12610|NCT04093219|Other|Placebo|Volume of the placebo (saline) will match that of IV acetaminophen at 100ml 0.9% NaCl
12611|NCT04093206|Dietary Supplement|EpiCor and Vitamin C|One daily dose
12612|NCT04093206|Dietary Supplement|Vitamin C|One daily dose
12613|NCT04093193|Procedure|Debridement|Debridement or cleaning of the sinuses post-operatively has been described as a regular post-surgery procedure .
12614|NCT04093180|Procedure|Intensive Neurophysiological Rehabilitation System|Intensive Neurophysiological Rehabilitation System (INRS) is a multicomponent approach that consists of different treatment modalities.
12615|NCT04093180|Procedure|Activity and care as usual|Control group continues usual activity and care while staying in the waiting list.
12617|NCT04093154|Device|wearing the virtual headset|watching the application by wearing virtual glasses to the child/adolescent
12618|NCT04093141|Procedure|IRE|in situ irreversible electroporation
12619|NCT04093128|Other|herbal tea intervention|herbal tea intervention for 7 weeks
12620|NCT04093115|Drug|CX1106|administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
12621|NCT04093102|Diagnostic Test|biomarkers|bio-markers testing will be made to all suspected OSA patients(CRP, Hba1C,uric acid, ESR, plasma fibrinogen, pentraxin3), and to control cases.
12622|NCT04093089|Device|Bionode IOP Lowering System|Patients wearing Bionode spectacles and customized contact lens and will receive stimulation at 50 Hz, 100 µs, up to 150 µA for 2 hours.
12623|NCT04093089|Device|Bionode IOP Lowering System|Control: No stimulation
12624|NCT04093076|Drug|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
12625|NCT04093076|Device|CELLECTRA™ 2000|EP using the CELLECTRA™ 2000 device will be administered following ID drug administration.
12626|NCT04093076|Drug|Placebo|Placebo will be administered ID on Day 0 and Week 4.
12627|NCT04093063|Other|Micro-stellated Icosahedron|A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
12628|NCT04093050|Drug|Vasostrict Injectable Product|Vasostrict® (vasopressin injection, USP)
12629|NCT04093037|Diagnostic Test|Time #1: Non Invasive Break-Up Time (NIBUT)|"A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed."
12630|NCT04093037|Diagnostic Test|Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score|"The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity)."
12631|NCT04093037|Diagnostic Test|Time #3: Standard Break-Up Time (SBUT)|The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
12632|NCT04093037|Diagnostic Test|Time #4: Schirmer test|The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
12633|NCT04093037|Diagnostic Test|Satisfaction questionnaire to the patient|A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
12636|NCT04093011|Procedure|Congenital Heart Disease Surgery|Patients with congenital heart disease will undergo congenital heart disease surgery.
12637|NCT04092998|Procedure|Thermocautery circumcision|Histopathological changes from thermocautery circumcision
12638|NCT04092985|Device|iECG recording|iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smartwatch (Apple Watch Series 4) with the ECG application
12639|NCT04092972|Other|Atherectomy|Straub Rotarex S atherectomy and drug-coated balloon DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
12640|NCT04092972|Other|POBA and DCB|Standard predilation (POBA) and DCB. Predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA).
12641|NCT04092959|Behavioral|Walking|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β- blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
12642|NCT04092959|Behavioral|Chinese square dancing group|Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study. Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13.
12643|NCT04092959|Behavioral|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
12644|NCT04092946|Device|Digital intervention|Patients will perform a tailored rehabilitation program consisting of therapeutic exercise to be performed independently at home, through the use of the medical device SWORD Phoenix, under remote monitoring from a physical therapist.
12645|NCT04092920|Device|laser and SLA|"ligible patients will be randomized to 2 groups control group will receive SLA surface treated implant to replace badly broken tooth immediately after extraction and a study group will receive laser surface treated implant to replace badly broken tooth immediately after extraction.~atraumatic extraction will be performed and socket will be examined for presence of bone dehesince or fenestration if no, implant will be placed immediately and a implant primary stability will be measured using an ISQ unit and recorded as base Line reading .~gingival former will be attached to the implant and removed at 2 ,4,8,12 week intervals to record ISQ readings."
12646|NCT04092907|Drug|HBM9036 0.25% Ophthalmic Solution|Ophthalmic Solution
12647|NCT04092907|Drug|placebo|Ophthalmic Solution
12648|NCT04092894|Drug|Suvorexant 20 mg|Administration of oral Suvorexant 20 mg
12649|NCT04092894|Drug|Placebo oral tablet|Administration of oral placebo (same non-identifiable form as active comparator)
12650|NCT04092881|Device|Laser|Application of four laser sessions one month apart using short pulsed mode of 1064 nm Nd-YAG laser (Fotona XP® - Accelera mode) using parameters (fluence 20-40 J/Cm2, pulse duration= 0.25 ms and spot size 3-5 mm) for one side.
12651|NCT04092881|Device|Laser|Application of four laser sessions one month apart (in the same day after Nd-YAG session) using 10600 nm ablative fractional CO2 laser (Deka SmartXide DOT®) using -parameters (fluence 17-20 J/Cm2, pulse duration 700-1000 µs, spacing 600-700 µm and stacking 1-2) on the other. Sessions are separated by one month interval plus three months for clinical follow up.
12652|NCT04092868|Other|Blood samples PK/ PD protamine|PK/ PD protamine
12653|NCT04092842|Device|Silicone prosthesis|Silicone prosthesis
12654|NCT04092842|Procedure|Usual practice|Usual surgery
12655|NCT04092829|Procedure|FROZEN EMBRYO TRANSFER IN SUBSTITUTED CYCLE|The intervention group will be prepared with hormone replacement therapy with estrogens according to usual clinical practice. Frozen embryos will be transferred after ten doses of exogenous progesterone.
12656|NCT04092816|Behavioral|FAMILY Intervention|The FAMILY intervention involves 2-3 study visits with a specially-trained intervention facilitator. Study visits are manualized and complemented by patient education materials.
12657|NCT04092803|Other|Virtual Reality|The system includes a VR headset with VR software already loaded in to it.
12658|NCT04092790|Device|Virtual Gate Device (VGD)|A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
12659|NCT04092777|Behavioral|Strong Minds|The proposed intervention integrates cognitive behavioral therapy techniques combined with mindfulness exercises and promotion of behavioral activation through pleasant activities and developing supportive relationships. The intervention is led by CHWs and organized into 10 sessions, tailored to the participant using a collaborative approach, to improve mood symptoms, augment self-reported functioning, and increase self-reported quality of care among participants with moderate to severe symptoms of depression and/or anxiety. It is complemented by a care manager that links participant to services for needs related to social determinants of health (i.e. education, housing). The intervention has been tailored for delivery by CHWs in Spanish, Mandarin, Cantonese, and English.
12660|NCT04092777|Other|Enhanced Usual Care|Participants in this arm will receive a booklet about anxiety and depression in Spanish, English, or Mandarin/Cantonese. The Care Manager will call the participant 4 times over the course of 6 months to administer the PROMIS depression (8 item) and anxiety (7 item) short forms, a suicide questionnaire, and a question about medication side effects to mimic the administration schedule in the intervention group. With patient's permission, the care manager will inform the PCP about screening and other assessments and determine if participants should be referred to mental health or substance services and removed from control group given symptom severity.
12661|NCT04092764|Device|Electroacupuncture|Participants will receive electroacupuncture for 30 minutes once per week for a total of 3 weeks. The acupoints will be stimulated by the electroacupuncture machine with alternating frequencies in order to induce endorphins at different points in the nervous system. Frequencies between 2 Hz and 100 Hz will be utilized. Sterile single-use needles will be placed at Ba Feng, four points on the dorsum of each foot between the digits. KI2 (Rang Gu), a point located at the soles of the feet and SP-4 (Gongsun) will also be needled per recommendation of our acupuncturist. A total of 12 needles will be used per participant.
12662|NCT04092764|Device|NeuroMetrix|The NeuroMetrix is a point-of-care conduction device that will be used to measure peripheral neuropathy
12663|NCT04092764|Device|Rydel-Seiffer tuning fork|The level of periphal neuropathy will be measured by vibration detection using a Rydel-Seiffer graduated tuning fork placed on the dorsum of the right great toe between the nail and the distal interphalangeal joint. The two arms of the 128 Hz tuning fork are fitted with calibrated weights at the ends, and as the amplitude decreases, the intersection of the triangles moves upward on the weight. This test will be performed three times and a mean of the scores calculated. Vibration sensation is lost sooner in CIPN, which means that lower scores are associated with increased CIPN
12664|NCT04092751|Drug|PRA|Single oral 20-mg dose of PRA on Day 1 AM
12665|NCT04092751|Drug|SCY-078 plus PRA|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later
12666|NCT04092738|Behavioral|Walk@WorkApp-Diab|The intervention (Walk@WorkApp-Diab), based on an mHealth program, consists on replacing sedentary job tasks for active ones, during 13 weeks. The intervention group will download the mHealth program into their personal cellphones
12667|NCT04092725|Drug|DAB|Single oral 150-mg dose of DAB on Day 1 AM.
16444|NCT04061772|Drug|Pharmorubicin|Pharmorubicin injection
12668|NCT04092725|Drug|SCY-078 plus DAB|Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and single oral AM doses of SCY-078 750 mg on Day 3 and Day 4. On Day 3 a single 150-mg dose of DAB will be administered one hour after the AM dose of SCY-078.
12669|NCT04092712|Drug|[14C]-CTP-543|Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
12670|NCT04092699|Device|semiautomatic software|semiautomatic segmentation is as accurate as the direct volume of maxillary sinus and as well as the manual segmentation.
12671|NCT04092686|Drug|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
12672|NCT04092686|Drug|SEP-363856 100mg|SEP-363856 100mg tablet dosed once daily
12673|NCT04092686|Drug|Placebo|Placebo tablet dosed once daily
12674|NCT04092673|Drug|eFT226|eFT226 is a novel small-molecule, investigational drug being developed by eFFECTOR Therapeutics as an anticancer therapy. eFT226 is a potent and selective inhibitor of eIF4A1-mediated translation and selectively regulates the translation of a subset of mRNAs based on sequence specific recognition motifs in their 5'-UTR. eIF4A1 inhibition by eFT226 downregulates expression of receptor tyrosine kinases and KRAS, leading to decreased signaling through the PI3K/AKT and MAPK pathways. Preclinical efficacy testing of eFT226 demonstrates activity across models of solid tumor cancers with amplifications in HER2, FGFR1/2 and mutations in KRAS (including breast, NSCLC and CRC).
12675|NCT04092660|Behavioral|Behaviour change Intervention Based on Health Action Process Approach Model|"The Behaviour change intervention based on the Health Action Process Approach model entails delivering interventions in a staged manner. Following are the intervention that will be delivered along with the time point of the delivery.~Health Pamphlet at the initial screening~Sleep Apnoea video highlighting the negative consequences at the day of the fitting of the appliance~Counseling involving motivational interviewing for both the participant and the participant's partner at the day of fitting of the appliance and follow up visits.~Booster phone calls in between the follow-up visits"
12676|NCT04092660|Device|Mandibular Advancement Appliance (MAA) or Anti-snoring mouth guard|"Patients with mild-to-moderate sleep apnoea are treated with Mandibular Advancement Appliances [MAA] also known as Anti-snoring mouth guards or Oral appliances. These are best made to fit and use the teeth to hold them in place during sleep. They work by moving (in a gradual fashion) the bottom jaw forward, opening the airway at the back of the throat.~Both the arms- Intervention arm and Standardized arm will be given the anti-snoring mouth guard. The usage of the device will be measured subjectively by providing a sleep diary to the participants to record the hour of the usage and objectively by downloading the data from a micro sensor chip embedded in the device."
12677|NCT04092647|Drug|Ashwagandha|Ashwagandha 500 mg po BID
12678|NCT04092647|Drug|Placebo|Placebo 500 mg po BID
12679|NCT04092634|Device|Dual mobility implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
12680|NCT04092634|Device|Traditional, Single-bearing hip implant|Patients that are eligible and consent to the study will be randomized to receive either a dual mobility implant or a traditional single-bearing hip implant. This group is for the dual mobility implant
12681|NCT04092621|Drug|Amiodarone in Parenteral Dosage Form|Amiodarone IV
12682|NCT04092621|Drug|Amiodarone Pill|Amiodarone tablet
12683|NCT04092621|Procedure|Direct Current Cardioversion (DCC)|Convert arrhythmia back to sinus rhythm
12684|NCT04092621|Drug|Rate-control therapy|one or combination of the following: Amiodarone, beta blockers or non-dihydropyridine calcium channel blockers, digoxin
12685|NCT04092608|Procedure|GDFT|The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable < 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.
12686|NCT04092608|Procedure|LOW CVP|Goal = CVP < 7mmHg
12687|NCT04092595|Drug|PF-06651600|PF-06651600: 200 mg dose provided as four 50 mg oral tablets
12688|NCT04092595|Drug|Rosuvastatin|10 mg oral tablet
12689|NCT04092582|Drug|MTPS9579A|MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
12690|NCT04092582|Drug|Placebo|Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
12691|NCT04092569|Behavioral|Pre-medical consultation structured diabetes self-care education programme|"The findings of integrative review revealed positive effects of DSME in improving glycemic control and promoting self-care among people with type 2 diabetes.~An evidence-based protocol is developed based on these findings to generate a DSME program for newly referred patients to SOPCs and before their first medical consultation to improve glycemic control and enhance self-care of people with type 2 diabetes in Hong Kong. The investigator will ensure that this study is conducted in compliance with ICH-GCP and in compliance with the Declaration of Helsinki."
12692|NCT04092556|Device|transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability.
12693|NCT04092530|Behavioral|LINCC intervention - enable co-schedule feature|Clinics will offer postpartum contraception appointments earlier and the opportunity to co-schedule these appointments with their infant's next well-baby visit
12694|NCT04092517|Other|Control Corn Soya Diet|Ingredients (% by weight): Maize (78.30); Whole soya beans (20.00); Vitamin/Mineral FBF-V-13 (0.20); Dicalcium Phosphate anhydrous (1.23); Potassium chloride (0.27)
12695|NCT04092517|Other|Test Corn Moringa Diet|Ingredients (% by weight): Maize (78.30); Moringa (20.0)
12696|NCT04092504|Other|gero-erat|"The intervention is a standardize Care Plan which will be developed based on the evidence of caring for eldery patients in a trauma setting. The Care Plan will have its base in, the concept of ERAS and CGA. Also, patient experience will be taken in consideration and complement the care pathway.~Patients admitted to the trauma unit will be given the care and asked to be a part of the study witch include to fill out surveys at baseline, six months and 1 year."
12697|NCT04092491|Other|blood sample|"1 blood sample during a consultation carried out as part of a medical follow-up:~2 PAXgene RNA tubes of 2 ml each~1 dry tube for creatinine and IgA assay~1 tube of NFs (5ml)"
12698|NCT04092478|Other|Spinal Anesthesia Position|The patient positions during the spinal anesthesia
12699|NCT04092465|Procedure|Pulmonary parenchyma resection, lobectomy, pneumonectomy, sleeve lobectomy, extended lobectomy/pneumonectomy|Resection of the downstaged locally advanced NSCLC through formal thoracotomy
12700|NCT04092452|Drug|PF-06650833|400 mg QD
12701|NCT04092452|Drug|PF-06700841|45 mg QD
12702|NCT04092452|Drug|PF-06826647|400 mg QD
12703|NCT04092452|Drug|Placebo|placebo
12704|NCT04092439|Dietary Supplement|Watermelon Juice|100% Watermelon Juice
12705|NCT04092426|Other|opthalmologic examination|opthalmologic examination : Refraction Best corrected visual acuity Intraocular pressure Slit lamp examination
12706|NCT04092413|Device|Dermoscope|It is a non invasive tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic dermatopathology .
12707|NCT04092400|Device|Micro-invasive Glaucoma Surgical Devices|Safety and efficacy of Micro-invasive Glaucoma Surgical Devices
12708|NCT04092387|Other|Cigarettes with varying nicotine content|1) Altering the nicotine content of the tobacco research cigarettes
12709|NCT04092387|Other|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig conditions
12710|NCT04092374|Procedure|Locking compression plates|Fixation of sternal fracture using locking compression mechanism
12711|NCT04092361|Device|optical coherence tomography|It generates cross sectional images by analyzing the time delay and magnitude change of low coherence light as it is backscattered by ocular tissues. An infrared scanning beam is split into a sample arm and a reference arm. As the sample beam returns to the instrument it is correlated with the reference arm in order to determine distance and signal change via photodetector measurement. The resulting change in signal amplitude allows tissue differentiation by analysis of the reflective properties, which are matched to a false color scale. As the scanning beam moves across tissue, the sequential longitudinal signals, or A-scans, can be reassembled into a transverse scan yielding cross-sectional images, or B-scans, of the subject. The scans can then be analyzed in a variety of ways providing both empirical measurements (e.g. RNFL or retinal thickness/volume) and qualitative morphological information.
12712|NCT04092348|Other|complete blood count|"total RNA is isolated from fresh blood samples~RNA is converted into complementary DNA c.DNA~cDNA is then analysed by quantitatine Real Time PCR(qRT-PCR) to evaluate the relative expression levels of FoxO3a, PU.1 genes and TATA-binding protein (TBP) ,as an endogenous control gene."
12713|NCT04092322|Device|Actical accelerometers (Philips Respironics)|patients with stroke will be evaluated by using PASE scale and accelerometer results (accelerometer will be held from Monday to Friday
12714|NCT04092322|Other|PASE|Physical Activity Scale for Elderly
12715|NCT04092309|Drug|ACE inhibitor, Sacubitril-Valsartan|Search for Protective effect after chemotherapy and bone marrow transplantation
12716|NCT04092296|Other|resin infiltration|using infiltrant resin intervene proximal caries
12717|NCT04092296|Other|remineralization|using fluoride to remineralize proximal caries
12718|NCT04092296|Other|sham|replace resin with water
12719|NCT04092283|Drug|Carboplatin|Given IV
12720|NCT04092283|Drug|Cisplatin|Given IV
12721|NCT04092283|Biological|Durvalumab|Given IV
12722|NCT04092283|Drug|Etoposide|Given IV
12723|NCT04092283|Drug|Paclitaxel|Given IV
12724|NCT04092283|Drug|Pemetrexed|Given IV
12725|NCT04092283|Drug|Pemetrexed Disodium|Given IV
12726|NCT04092270|Drug|Nedisertib|Given PO
12727|NCT04092270|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
12728|NCT04092257|Procedure|VIA and thermocoagulation|Participants will self-collect a vaginal brush for hr-HPV testing. HPV-positive women and every 10th consecutive HPV-negative woman will complete same-day VIA with colposcopically-directed cervical biopsy and ECC (if lesion seen), and thermocoagulation if ablation-eligible by colposcopy. If no lesion is seen on colposcopy, the woman will have a cervical pap smear and ECC collected, and no thermocoagulation will be performed. Finally, women who are suspicious for cancer at VIA will undergo colposcopically-directed cervical biopsies.
12729|NCT04092244|Diagnostic Test|CTHRC1 biomarker|its a biomarker detected in the serum of the patients
12730|NCT04092231|Behavioral|Early speech perception test|The early speech test is one of the closed-set response speech discrimination tests,using object identification technique.It was carefully designed for estimation of speech perception abilities in very young children who have extremely low verbal abilities
12731|NCT04092218|Other|Questionnaire|"Data will be obtained through a written questionnaire to determine the type of parenting style of parents or caregivers.~The collected data will be saved and tabulated on computer and finally statistically analysed."
12732|NCT04092205|Drug|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
12733|NCT04092192|Device|IVC filter removal|"In the clinic, it will be explained to patient that they are asked to participate in a study that would randomize them to one of two established techniques for IVC filter removal. It will be explained these are both techniques that are used by interventional radiologists normally used for IVC filter retrieval.~One technique would be the utilization of an endovascular snare (like a lasso) device that is designed to catch the hook of the filter and allow it to be captured.~The other technique described will be the usage of a rigid forceps device that will be used to engage the filter apex directly and allow for the filter to be capture/removed."
12734|NCT04092179|Drug|Enasidenib|Enasidenib is a drug that blocks a protein called isocitrate dehydrogenase (IDH) 2 from working. The family of IDH proteins have been indicated in the development of leukemia. By blocking IDH2, enasidenib may help stop cancer cells from growing. It is believed that the drug may be more useful in patients with a change (mutation) in their IDH 2 protein. The IDH2 gene (substances in the body that contain instructions for the proper development and function of cells) makes IDH2 proteins. As such, only patients with IDH 2 mutated gene are eligible for this study. Enasidenib is currently approved for the treatment of IDH2 mutated AML.
12735|NCT04092179|Drug|Venetoclax|Venetoclax is a drug that blocks a protein called B-cell lymphoma (BCL2) protein from working. BCL2 is a protein that helps control whether a cell lives or dies and is thought to help cancer cells to live. Blocking BCL2 is believed to help kill cancer cells. Venetoclax is currently approved for the treatment of type of blood cancer called chronic lymphocytic leukemia (CLL) who have received prior treatment.
16445|NCT04061772|Drug|Prednisone|Prednisone tablet
12736|NCT04092166|Other|Stationary Bike|Participants will use a stationary bike machine that also engages the arms and use . This will be performed for 6 minutes, 3 times a week for a total of 8 weeks).
12737|NCT04092153|Device|Total knee arthroplasy|Surgical implantation of prosthetic knee using robotic-arm assist
12738|NCT04092140|Device|ultrasound|easy new non invasive tool
12739|NCT04092127|Other|Video Record|Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
12740|NCT04092114|Other|Control|Standard of care (SOC) HIV prevention services in line with the South African DoH (Department of Health) PrEP (Pre-exposure Prophylaxis) rollout program that include daily oral TDF/FTC (tenofovir disoproxil fumarate/emtricitabine). In addition, risk reduction counseling, IPV (Intimate Partner Violence) screening using the VAWS (WHO Violence Against Women Survey) with referrals for counseling, medical care, or shelter assistance, among other care options, if needed and an informational packet regarding HIV prevention services for themselves and male partners will be offered
12741|NCT04092114|Behavioral|CHARISMA Intervention|"SOC (Standard of Care) per control arm plus provider-administration of HEART and provider-administration of CHARISMA counseling modules, as applicable:~Module A: General Partner Communication and Relationship Skills~Module B: Partner Disclosure and Communication around PrEP Use~Module C: Responding to Intimate Partner Violence and Safety Planning"
12742|NCT04092101|Other|Cigarettes with varying nicotine content|1) Altering the nicotine content of the tobacco research cigarette
12743|NCT04092101|Other|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
12744|NCT04092088|Device|tDCS-r|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned on for 20 minutes).
12745|NCT04092088|Device|TENS-r|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned on for 20 minutes)..
12746|NCT04092088|Device|tDCS-s|The transcranial stimulation will be applied by a constant current device (tdcs) with an intensity of 2 mA for 20 minutes (the set will be turned off after 30 seconds).
12747|NCT04092088|Device|TENS-s|Conventional TENS will be applied for 20 minutes. The cathode will be placed on the carpal ligament, and the anode electrodes on the palmar area of the hand, with a layer of conductive gel applied to the area (the set will be turned off after 30 seconds).
12748|NCT04092075|Device|RF-utilizing powered toothbrush|RF-utilizing Powered toothbrush
12749|NCT04092075|Device|Control placebo with no RF|Placebo control, toothbrush with no RF
12750|NCT04092062|Device|ToothWave|RF-utilizing powered toothbrush for teeth whitening
12751|NCT04092062|Device|powered toothbrush|regular powered toothbrush with no RF
12752|NCT04092049|Other|lollipop|chewing lollipop for 10 minutes
12753|NCT04092036|Device|Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound|"ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye)."
12754|NCT04092023|Other|nursing education|Participants will be recruited to attend 2 group sessions; each group will have 10-12 participants and each session will be lasted for 120 minutes. Two subsequent phones follow up to participants will be arranged.
12755|NCT04092010|Behavioral|Problem-solving education (PSE)|PSE will be offered to mothers with low baseline depressive symptoms (the first, preventive step of the SCI). PSE participants will have their symptoms assessed at each session and will convert to Engagement Sessions if they meet pre-specified 'step up' criteria.
12756|NCT04092010|Behavioral|Engagement sessions|Engagement sessions will be offered to mothers with greater depressive symptoms to link them to formal mental health services (the second, referral step of the SCI)
12757|NCT04092010|Behavioral|Usual care|Normal services provided children and their mothers in Head Start
12758|NCT04091997|Diagnostic Test|serum Eliza assay|laparoscopy and biopsy of lesions in endometriotic patients and seum ELIZA assay of microphage migration inhibitory factor
12759|NCT04091984|Diagnostic Test|Prospera|No Interventions, this is an observational study.
12760|NCT04091971|Drug|Ketamine|See arm description.
12761|NCT04091958|Procedure|Pectoralis myo-glandular flap reconstruction.|Tumorectomy with surgical margin will be evaluated with frozen-section examination. Reconstruction starts with mobilization of skin flaps. The sternal head of the pectoralis major muscle will be disconnected from its insertion at the humerus. The muscle fibers will be mobilized off the chest wall. The pectoralis major receives dual blood supply. The pectoral branches of the thoraco-acromial artery enter the superior part of the muscle and the perforator branches of the internal mammary artery enter the medial part of the muscle. According to the location of the defect in the breast, the muscle will be mobilized based on one vascular pedicle. The muscle flap may consist of all or some segmental fibres of the sternal head of the pectoralis major muscle. In all cases, the muscle flap connection to the overlying breast parenchyma is kept intact and the clavicular head of the pectoralis major muscle is undisturbed. Closure of the cavity in layers over suction drain will follow.
12762|NCT04091945|Drug|LT3001 Drug Product|Active comparator
12763|NCT04091945|Drug|Placebo|Placebo comparator
12764|NCT04091932|Drug|Pembrolizumab|Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
12765|NCT04091919|Diagnostic Test|2D- Transthoracic Echocardiography (TTE)|2D- Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain imaging
12766|NCT04091906|Device|Peripheral blood mononuclear cell apheresis|Peripheral blood mononuclear cell donation for tumor immunotherapy study of UCAR-T cells
12767|NCT04091893|Behavioral|Usual care/wait list|Individuals in this group can continue with their usual care (but receive no museum-based intervention)
12768|NCT04091893|Behavioral|Art Rx|Individuals in this group participate in a specialized tour of an art museum
12769|NCT04091893|Behavioral|Artful Meditation|Individuals in this group participate in a meditation and art appreciation program at an art museum
12770|NCT04091880|Biological|EV71 vaccine and influenza vaccine|simultaneously administrated with EV71 vaccine and influenza vaccine
12771|NCT04091880|Biological|EV71 vaccine|administrated with EV71 vaccine only
12772|NCT04091880|Biological|influenza vaccine|administrated with influenza vaccine only
12773|NCT04091867|Drug|sEphB4-HSA with cetuximab and radiation|sEphB4-HSA is a fusion protein combining the soluble extracellular EphB4 domain with albumin that targets the ephrin B2 receptor, which is thought to mediate resistance to EGFR-targeted therapy, and acts as a radiosensitizer by enhancing DNA damage and promoting apoptosis.
12774|NCT04091854|Drug|HMS5552|To observe the progress of diabetes mellitus after 52 or 28 weeks of HMS5552 treatment for type 2 diabetes mellitus
12775|NCT04091841|Drug|protein supplement|Three sachet of protein supplement to be mixed in with water used daily.
12776|NCT04091841|Other|Maltodextrine|Three sachet of Maltodextrine supplement to be mixed in with water used daily.
12777|NCT04091815|Other|Type of anaesthesia|Two different types of anesthesia general vs combined (spinal and general)
12778|NCT04091802|Procedure|interdental papilla reconstruction with L-PRF|interdental papilla reconstruction with single layer of L-PRF versus multiple layers of L-PRF
12779|NCT04091789|Drug|Pure Femme Tablets|A sublingual tablet containing 30 mg of cannabidiol (CBD), 1 mg tetrahydrocannabinol (THC), 97 mg palmitoylethanolamide (PEA), and a 0.2 mg combination of myrcene, beta-caryophyllene, humulene, linalool, and limonene and peppermint oil.
12780|NCT04091776|Radiation|CT scan|"Quantitative CT scan to measure localized osteoporosis and detection of cortices comminution.~Blinded surgeon decision as regard to replace or to fix using DHS or PFN (depending on x-rays data only).~Pathological assessment of osteoporosis in retrieved bone in patients whom hip replacement was decided.~Assessment of fixation failure in fixed fractures if occurred.~Fixation failure is defined as:~5.1. Lag cut through 5.2. Lag cutout 5.3. Z-effect (lag penetration) 5.4. Non-union (within 6 months) 5.5. Loss of reduction with progressive varus deformity 5.6. Femoral fracture 5.7. Intra-operative fracture of lateral wall or anterior cortex"
12781|NCT04091763|Drug|Polidocanol Injectable Foam|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
12782|NCT04091763|Device|Rubber band ligation|"Two distinct periods were considered: intervention and follow-up. During the intervention period patients were observed at 3-week intervals (minimum of 3 weeks and maximum of 9 weeks depending on the number of instrumental treatments performed). The required number of sessions of any of the office-based treatments (maximum of 3 sessions) was determined by clinical and anoscopy response (if after the treatment the participant scored zero points in the Sodergren scale or the anoscopy did not reveal significant hemorrhoidal disease, there was no place for additional instrumental therapy and the patient started the follow-up period.~If there was therapeutic failure at the end of the third session or if there was a significant complication (moderate or severe) the patient's participation in the study ended and he was referred for treatment with other type of office-based procedure or surgery."
12783|NCT04091750|Drug|Nivolumab|"Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks"
12784|NCT04091750|Drug|Ipilimumab|Induction: 1mg/kg IV every 3 weeks x 4 cycles
12785|NCT04091750|Drug|Cabozantinib|Induction and Maintenance: 40mg PO daily
12786|NCT04091737|Biological|Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734|"Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~Single dose melphalan before administration of CSL200"
12787|NCT04091711|Device|ReX-C system|Oral oncolytic medications are dispensed to patients via ReX-C system
12788|NCT04091698|Drug|Co-Enzyme Q10 mucoadhesive tablets|will receive topical co enzyme q10 in the form of mucoadhesive tablets 3 times daily for 3months.
12789|NCT04091685|Device|Gamma camera imaging|Use gamma camera in detection of renal cortical defects
12792|NCT04091659|Other|Virtual Reality Education|Virtual Reality Education (Intervention): The experimental group of libraries will receive the virtual reality simulation, which is guided by the NLN Jeffries Simulation Theory, and lasts 9 minutes. The virtual reality education is based on scenes and dialogue conducted during the hybrid high-fidelity simulation, from a script developed using the existing hybrid simulation on opioid overdose intervention. This virtual reality education is an educational intervention.
12793|NCT04091659|Other|Standard Education|Standard Educational (Control): The public health department's training includes printed handouts on how to administer naloxone and youtube videos on how to spot signs and symptoms of overdose and administer naloxone. Additionally, staff are on hand to provide one on one verbal educational trainings to local community members voluntarily seeking education.
12794|NCT04091646|Drug|ARQ-154 foam 0.3%|experimental
12823|NCT04091360|Drug|Ensifentrine 100mcg|"Single doses of RPL554 inhaled via pressurised metered dose inhaler:~Doses are - 100mcg"
12824|NCT04091360|Drug|Ensifentrine 300mcg|"Single doses of RPL554 inhaled via pressurised metered dose inhaler:~Doses are - 300mcg"
12825|NCT04091360|Drug|Ensifentrine 1000mcg|single doses of RPL554 inhaled via pressurised metered dose inhaler: Doses are - 1000mcg
12826|NCT04091360|Drug|Ensifentrine 3000mcg|"Single doses of RPL554 inhaled via pressurised metered dose inhaler:~Doses are - 3000mcg"
12795|NCT04091633|Behavioral|WHO School Mental Health Program|World Health Organization (WHO) School Mental Health Program (SMHP) is a manual based multi-component, multi-tiered and evidence-informed intervention for common mental health problems in school going children. SMHP is designed to be introduced into the normal classroom and school setting by trained teachers. The intervention has a universal component which takes a whole school approach that aims to promote mental health among all school children. It includes basic counseling skills for teachers, core values of mental health promoting schools and other health promoting efforts that impact upon mental health and can be administered to all students in school and classroom settings. The manual also contains targeted intervention strategies on anxiety, separation anxiety/ school refusal, post-trauma, depression, suicide, ADHD, autism, psychosis, conduct problems and substance use problems that can be implemented by teachers in classroom settings.
12796|NCT04091633|Behavioral|Enhanced School Mental Health Program (eSMHP)|Informed by the results of pilot implementation, a number of content and delivery adaptations have been made to the School Mental Health Program (SMHP) to address the implementation challenges to scale-up of program in Pakistan. The adapted version of the intervention is called Enhanced School Mental Health Program (eSMHP). Enhancements to conventional SMHP have occurred at two levels: A) Content enhancements, such as a collaborative care model for engaging parents/primary caregivers, strategies for teacher's well-being, and adaptation and operationalization of particular clinical intervention strategies and B) Technological enhancements which include adaptation of the training manual for delivery using an online training platform, and a 'Chat-bot' to aid the implementation of intervention strategies in classroom settings.
12797|NCT04091620|Procedure|Transanal Total Mesorectal Excision|As above
12798|NCT04091620|Procedure|Robotic Total Mesorectal Excision|As above
12800|NCT04091594|Device|Flexible orthotic|Participants will receive the SIAFO to wear
12801|NCT04091594|Device|Standard orthotic|Participants will received the standard AFO to wear
12802|NCT04091581|Drug|Systane Complete|Systane Complete will be instilled and rate of evaporation assessed before and after.
12803|NCT04091555|Dietary Supplement|HLNatural Tension|Understand the impact of the supplement on Tension Headaches
12804|NCT04091542|Device|Optiflow/Ventilator|Participants will have 2 days with optiflow, 2 days with ventilator.
12805|NCT04091529|Device|RADIOFREQUENCY ABLATION OF UTERINE MYOMAS|The ablation device consisted of an radiofrequency (RF) energy generator (STARmed, RF generator VRS01) and an electric pump for the continuous cooling of the electrode tip. The RF generator to which the electrode (STARmed Gyeonggi-Do, Korea) is connected displays simultaneously the temperature of the electrode tip, the tissue impedance characteristics, the power and the ablation time. A 35 cm long 18Gauge internally cooled electrode with an exposed tip of 10 mm or a variable exposed tip was used
12806|NCT04091516|Behavioral|Low-fat plant-based diet|Participants will follow a diet that consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products and added oils will be excluded. Except for light refreshments and tastings at the group sessions, no meals will be provided. Participants will handle their own food preparation and purchases, with guidance from the education team, with no restriction on energy intake.
12807|NCT04091503|Drug|Intranasal Modified Temozolomide|"Intranasally Modified Temozolomide is administered to patients at a dose of 75/150/200 mg / M2 for five days continuously. After the 5-day course, patients do not take treatment for two days, and they will be examined on an outpatient basis (blood tests, kidney and liver tests, visually mucous membranes of the mouth, nasal cavity, olfactory rapid tests, including the University of Pennsylvania test, etc.).~After 30 days after the first intranasal administration of Modified Temozolomide (IM-TMZ), all patients undergo an MRI of the brain with perfusion and ultrasound of the abdominal cavity as an outpatient, after which the results are evaluated"
12808|NCT04091490|Drug|Nivolumab|Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
12809|NCT04091464|Behavioral|Backward Walking Training|Training will consist of BW training on both a treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline BW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes BW, backward stepping, and functional exercises that incorporate BW movements.
12810|NCT04091464|Behavioral|Forward Walking Training|Training will consist of FW training on both treadmill and overground. All participants will receive 1x/week training with a trained member of the research team, who will progress the participant week-to-week and ensure safety. Treadmill speed will be determined by baseline FW walking speed and incrementally increased with each training week to subject tolerance. Participants will follow a home exercise program for the remainder of the week that includes FW, forward stepping, and functional exercises that incorporate FW movements.
12811|NCT04091451|Biological|Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A)|2 doses of the HZ/su vaccine in a 0,2 Months schedule, administered intramuscularly
12812|NCT04091451|Drug|Placebo|2 doses of the placebo in a 0,2 Months schedule, administered intramuscularly
12813|NCT04091438|Drug|TAK-925|TAK-925 IV infusion
12814|NCT04091438|Drug|TAK-925 Placebo|TAK-925 placebo-matching IV infusion
12815|NCT04091425|Drug|TAK-925|TAK-925 IV infusion
12816|NCT04091425|Drug|Placebo|TAK-925 placebo-matching IV infusion
12817|NCT04091412|Drug|Butylphthalide Soft Capsules|The first class national new drug for the Treatment of Mild to Moderate Acute Ischemic Stroke; Long-term application can improve collateral circulation.
12818|NCT04091399|Drug|Stamatological tamponade Contipro|The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
12819|NCT04091386|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|Intervention is given as part of routine medical practice
12820|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the upper arm
12821|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the lower abdomen
12822|NCT04091373|Combination Product|cotadutide multidose pen injection|SC injection in the thigh
12827|NCT04091360|Drug|Ensifentrine 6000mcg|"Single doses of RPL554 inhaled via pressurised metered dose inhaler:~Doses are - 6000mcg"
12828|NCT04091360|Drug|Placebos|"Single doses of Placebo inhaled via pressurised metered dose inhaler:~Doses are - Placebo"
12829|NCT04091347|Behavioral|DAPPER|The DAPPER program is person directed and will consist of 8 nurse visits during which the nurse assesses each participant for pain, depression and frailty and then implements a manualized individually tailored intervention. Participants will be randomized into either the intervention or the wait list control group. Once the intervention group has completed the intervention group's visits, the wait list control group will begin the waitlist control group's visits. All participants will all be offered the same information and format of nurse visits. The nurses will systematically tailor the content of the visits to the participants' risk profile and goals based on protocols. All participants will be assessed at the start of the study, at 12 weeks and 24 weeks.
12830|NCT04091334|Device|Focused ultrasound of the lungs (FLUS) and focused cardiac ultrasound (FoCUS)|"FLUS: Scanning 8 zones of the front and lateral of the thorax. Record number of B-lines, consolidations, pneumothorax, pleural effusions.~FoCUS: Scan the heart in different views and record the ejection fraction, size of the right side of the heart, pericardial effusion, tricuspid annular plane systolic excursion (TAPSE), inferior vena cava (IVC) diameter, and IVC collapsibility Index (IVC-CI)."
12831|NCT04091334|Other|Standard care|Standard care and evaluation and monitoring
12832|NCT04091308|Other|Usual Care|Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.
12833|NCT04091308|Other|Usual Care with Protein Supplementation|The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.
12834|NCT04091308|Other|Individualized Physical Exercise Training with Protein Supplementation|Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.
12835|NCT04091295|Drug|DeltaRex-G|Intravenous infusions of DeltaRex-G for treatment of advanced solid tumors, B cell lymphoma, and multiple myeloma that have failed standard therapies
12836|NCT04091282|Other|No intervention|No intervention
12838|NCT04091256|Other|Single arm clinical study|Participants will be treated with desensitizing toothpaste containing zinc-carbonate hydroxyapatite nanocrystals (Zn-CHA) for 8 weeks.
12839|NCT04091243|Drug|Romosozumab|Experimental drug for the treatment of glucocorticoid induced osteoporosis
12840|NCT04091230|Device|TRUSbx|Trans Rectal UltraSound guided Prostate Biopsy
12843|NCT04091204|Drug|Olaparib tablets|Olaparib is given orally at the dose of 300 mg bid continually as maintenance therapy after a platinum based chemotherapy
12844|NCT04091191|Dietary Supplement|Meta19.01|A specialized nutraceutical containing plant extracts, vitamins and fish oil
12845|NCT04091178|Dietary Supplement|VITAMIN D|ORAL SOLUTION (2 ml) at 100.000 UI
12846|NCT04091165|Other|My Plate Calorie Tracker|"My Plate Calorie Tracker is a user-friendly weight management, calorie record application, available for smart phone devices. Users have the option to input items manually (i.e., calories, carbohydrates, fats, and proteins), select from a list of popular food items, or scan barcodes on the food packaging. In addition to food entries, users can also enter daily water intake and physical activities. Once an account is created, data entered into the mobile application can be sync'd to the My Plate Calorie Tracker website."
12847|NCT04091152|Other|usability assessment|"Usability of ardoiz will be assesse using a validated usability questionnary"
12848|NCT04091139|Behavioral|Unified protocol for adolescents (UP-A)|"The Unified Protocol (UP) is an emotion-focused, cognitive-behavioural intervention that is developed to target core temperamental characteristics underlying anxiety and depressive disorders. The goal of the UP is to help patients to cultivate a greater willingness to experience uncomfortable emotions and to reduce maladaptive emotion response tendencies, so as to lessen the intensity and frequency of uncomfortable emotions. Ehrenreich and colleagues modified from the original UP and developed the UP for adolescents (UP-A).~A Chinese treatment protocol would be developed based on the UP-A. Contents of the treatment includes motivational enhancement, psychoeducation of emotion, avoidance and emotion driven behaviours, interoceptive exposure, cognitive reappraisal, emotion awareness training and emotion exposure. It consists of 10 to 12 individual sessions for the adolescents, and 4 to 6 sessions for parents or guardians."
12849|NCT04091139|Behavioral|Treatment as usual (TAU)|TAU participants will receive usual clinical psychological service provided in the clinic (i.e. treatment as usual) in the first 12 weeks, before they start receiving same individual treatment program based on UP-A.
12850|NCT04091126|Drug|Belantamab mafodotin|Selected doses of belantamab mafodotin, will be administered as infusion during Part 1 and Part 2, in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone.
12851|NCT04091126|Drug|Bortezomib|Bortezomib will be administered subcutaneously or intravenously 1 hour after the belantamab mafodotin infusion.
12852|NCT04091126|Drug|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
12853|NCT04091126|Drug|Dexamethasone|Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
12854|NCT04091113|Diagnostic Test|Withdraw of blood|"A blood sample will be taken on seven subsequent visits with 3 month intervals in the first 12 months (visit 1-5) and 6 month intervals thereafter (visit 6-7) and the cHMWK biomarker and other metabolite levels will be biochemically assessed.~DBS based biochemical measurements of C4 complement and C1-INH levels will be tested for HAE type 1 and type 2 via liquid chromatography multiple reaction-monitoring mass spectrometry, and the cHMWK biomarker and other metabolite levels will be biochemically assessed.~Additionally, every patient will be asked to pay attention for occurring HAE attacks: at the beginning, 3 hours, 6 hours, 12 hours and 24 hours after the beginning of the attack."
12855|NCT04091100|Procedure|Electroacupuncture|An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
12856|NCT04091100|Procedure|Myofascial Release|longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
12857|NCT04091087|Drug|crisaborole ointment|crisaborole ointment
12858|NCT04091087|Other|vehicle ointment|vehicle ointment
12859|NCT04091074|Drug|Ticagrelor|Half of patients undergoing carotid stenting take ticagrelor+aspirin
12860|NCT04091074|Drug|Clopidogrel|Other half ofpatients undergoing carotid stenting take clopidogrel+aspirin
12861|NCT04091074|Procedure|Carotid stenting|Patients with carotid stenosis will undergo carotid stenting
12862|NCT04091061|Drug|PF-06865571 100 mg|PF-06865571 in 100 mg oral tablet will be administered on Day 1
12863|NCT04091048|Device|Evolut™ PRO System|Aortic valve replacement
12864|NCT04091035|Other|To describe the incidence of disease and evaluate risk factors|Se above
12865|NCT04091022|Drug|Solaraze and Vaniqa|Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for one year
12866|NCT04091009|Drug|Buprenorphine|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine or to have their buprenorphine reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
12867|NCT04091009|Drug|Buprenorphine/naloxone|"Participants will be randomly assigned to be maintained on their daily dose of buprenorphine/naloxone or to have their buprenorphine/naloxone reduced to 16mg on the day before surgery.~Participants in the reduced group will then be prescribed 8mg buprenorphine daily from the day of surgery until transitioned back to their regular dose of buprenorphine when postoperative surgical pain has subsided"
12868|NCT04090996|Diagnostic Test|Dual TAsk|"Motor assessment includes:~posturographic examination in Single-task (ST) and Double-task (DT)~an analysis of ST and DT walking;~Timed Up and Go (TUG) performances in real (rTUG) and imagined (iTUG) versions;"
12869|NCT04090983|Behavioral|Cognitive-behavioral therapy (Hesslinger protocol)|Cognitive-behavioral therapy in a group format focusing on improving symptoms of ADHD, specifically by using skills in counteracting hyperactivity and impulsiveness, and promoting mindful awareness.
12870|NCT04090983|Behavioral|Cognitive-behavioral therapy (CADDI protocol)|Cognitive-behavioral therapy in a group format focusing on improving inattentive symptoms of ADHD, specifically by using skills in organizing, executing, and completing activity, and promoting mindful awareness.
12871|NCT04090970|Device|Briagen|Natural complex carbohydrate wound dressing for skin wounds
12872|NCT04090957|Drug|Estetrol oral tablet|Estetrol oral tablet will be administered orally once daily.
12873|NCT04090957|Drug|Placebo oral tablet|Placebo oral tablet will be administered orally once daily.
12874|NCT04090944|Procedure|the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) for confirmation of LMA position|-The position of LMA will be assessed by another anesthetist (blinded assessor) using the fiberoptic laryngoscope (KARL STORZ 11301BN1, Germany) per the grading licensed by Aoyama et al.
12875|NCT04090931|Procedure|Orthodontic treatment|leveling and aligning stage in orthodontics
12876|NCT04090918|Diagnostic Test|Cardiac examination programme 3 months after abdominal surgery|Blood- and urine sampling, electrocardiogram, wavECG (Myovista), transthoracic echocardiography, Finapres, cardiac magnetic resonance imaging
12877|NCT04090905|Diagnostic Test|Holter monitoring|Cardiac rhythm monitoring before, during and at least 72 hours after abdominal surgery
12878|NCT04090892|Procedure|selective percutaneous muscle release|Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
12879|NCT04090879|Other|Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)|1) Altering the nicotine content of the tobacco research cigarette
12880|NCT04090879|Other|E-Cigarettes|1) Altering the availability of e-cigarettes; 2) Altering option to personalize the e-liquid in the e-cig condition
12881|NCT04090866|Other|PET/MRI|Positron Emission Tomograph/Magnetic Resonance Imaging - participants will undergo PET/MRI prior to initiation of pulmonary vasodilator therapy and again 4-6 months after initiation of therapy
12882|NCT04090853|Device|Venus Bliss|The investigational device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1064 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
12883|NCT04090840|Behavioral|Intermittent Fasting|Time restricted eating for 8 hours per day, with 16 hour fast. During the daily fast, patients are encouraged to drink water, black coffee, or green tea without sugar, cream, milk, or sweeteners.
12884|NCT04090827|Other|Nurse-led transition intervention and access to the iHeartChange website|"Elements of the transition interventions include: (i) introduction to transition and its importance, (ii) creation of a MyHealth Passport, (iii) review diagram of participant's cardiac anatomy, (iv) discussion of 3 potential future cardiac complications (v) iHeartChange website (vi) discussion of the concept of self-management (vii) discussion and promotion of communication skills by the adolescent with their healthcare team via the GLADD technique (Give, Listen, Ask, Decide, Do) (viii) a 3-sentence summary about their CHD (ix) ongoing text/email support from RN"
12885|NCT04090814|Device|HeatTens (HV-F311-E)|(1) 2~108 Hertz (modulation program inside); (2) 100 microseconds (pulse duration)
12886|NCT04090801|Drug|Topical minoxidil 5% in 90% ethanol and 5% propylene glycol|
12887|NCT04090801|Drug|Topical minoxidil 5% in pure ethanol alone|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
12888|NCT04090801|Other|Placebo (Ethanol)|The treatment will be continued twice daily.for six months with regular visits at 3 months intervals.
12889|NCT04090788|Dietary Supplement|dried bitter-gourd supplements|intervention with 2.4g/d dried bitter-gourd supplements
12890|NCT04090788|Dietary Supplement|dried cucumber supplements|reference intervention with 2.4g/d dried cucumber supplements
12891|NCT04090775|Drug|Opdivo Injectable Product|"Opdivo (nivolumab): PD-1 inhibitor antibody~Injectable 10mg/mL, only 1 mL injected."
12892|NCT04090775|Drug|Yervoy Injectable Product|"Yervoy (ipilimumab): Anti-CTLA-4 antibody~Injectable 5mg/mL, only 1 mL injected."
12893|NCT04090775|Drug|Cytoxan|"Cytoxan (cyclophosphamide): Chemotherapy agent~Both Injectable and Oral low dose:~Injectable 250mg/m2, only 1 mL injected. Oral low dose cyclophosphamide: option of either 50mg once daily pill or 25mg twice daily pill for two weeks on, then two weeks off, then two weeks on again."
12894|NCT04090775|Procedure|Cryosurgical freezing (cryosurgery)|Cryosurgery, also known as cryoablation, for prostate cancer works by freezing the cancer cells inside the prostate gland. Cryoablation will release intact antigens to prime the immune system.
12895|NCT04090762|Behavioral|Conditional cash transfer|Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
12896|NCT04090762|Behavioral|Risk information provision|Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
12897|NCT04090749|Behavioral|Caregiver-Support|intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
12900|NCT04090723|Behavioral|CBI-CC with peer navigation|Computer delivered brief alcohol intervention enhanced with information of HIV infection, HIV risk, and comorbid mental health disorders
12901|NCT04090723|Behavioral|Usual Care|Usual care provided by clinical site
12902|NCT04090710|Drug|Ipilimumab/ Nivolumab|induction ipilimumab 1 mg/kg combined with nivolumab 3 mg/kg (I/N) every 3 weeks for cycles 1-4 followed by maintenance treatment with nivolumab 240mg every 2 weeks or 480mg every 4 weeks until disease progression
12903|NCT04090710|Radiation|SBRT + Ipilimumab/Nivolumab|SBRT to the primary disease in-situ, prior to cycle 2-4 of I/N. Patients randomized to SBRT will undergo radiation planning during the first cycle of I/N to their primary kidney mass, and then the radiation will be delivered between cycles 1 and 2 to a dose of 30-40 Gy in 5 fractions every other day over 1.5 weeks.
12904|NCT04090697|Drug|Oxandrolone|Oxandrolone 2.5mg tabs will be suspended in multi-chain triglyceride (MCT) oil and administered buccally.
12905|NCT04090684|Drug|Fixed dose combination Ciprofloxacin/Celecoxib|Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
12906|NCT04090671|Diagnostic Test|Multidimensional Dyspne Profile|The Multidimensional Dyspnea Profile measures the intensity of dyspneic breathing discomforts. It tests five sensory qualities that describe the patient's dyspnea in its respective intensity. Additionally it includes five potential reactions. The MDP is designed to refer to a specific event of time.
12907|NCT04090658|Biological|RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the non-dominant arm preferably.
12908|NCT04090658|Drug|Placebo|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the non-dominant arm preferably.
12909|NCT04090645|Device|TheraSphere|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with a relatively limited concurrent injury to surrounding normal tissue.
12910|NCT04090632|Diagnostic Test|Closed Kinetic Chain Upper Extremity Stability Test|Each patient receive the same intervention, the CKCUEST. The CKCUEST is a functional test which assess shoulder's stability. Patient is in push-up position, with 91 cm between his hands. His body is straight and his foots are squeeze. patient has to touch his hand with his other one and returns in the initial position. Then, patient repeats this movement with his other hand, etc, during 15 secondes. The CKCUEST score is the movement's number performed.
12911|NCT04090619|Other|Questionnaire Administration|Complete questionnaires
12912|NCT04090606|Other|FTC Method Smoking Regimen|cigarettes are smoked by drawing 35 mL puff volumes over 2 s, with 60 s interval between puffs and no blocking of filter ventilation holes
12913|NCT04090606|Other|Massachusetts Method Smoking Regimen|45-mL puffs drawn over 2 s, with 30 s interval between puffs and 50% blocking of filter ventilation holes
12914|NCT04090606|Other|Health Canada Intense Smoking Regimen|55-mL puff volumes of 2-s duration, with 30 s interval between puffs and 100% blocking of filter ventilation holes
12915|NCT04090593|Other|Patient Education 101: Mobile Health Education Tool|Intervention is interactive, mobile (tablet-or-smart-phone delivered), educational module that patients engage with during hospital admission.
12916|NCT04090580|Diagnostic Test|Continuous glucose monitoring|"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
12917|NCT04090567|Drug|Cediranib|Given PO
12920|NCT04090554|Device|Cytosponge™|The device consists of a spherical mesh enclosed in a gelatine capsule and attached to a string. The capsule is swallowed and allowed to reach the stomach . In the stomach the capsule is left for up to 5 minutes where it dissolves allowing the sponge to expand to its full size. It is then withdrawn using the suture, and as it does so collects cells from the lining of the oesophagus.
12921|NCT04090541|Other|Rigid Tape|Non-Elastic Tape
12922|NCT04090541|Other|Kinesiology Tape|Tape can be elongate only one direction
12923|NCT04090541|Other|Biomechanical Tape|Tape can be elongate only two direction
12924|NCT04090528|Biological|pTVG-HP|pTVG-HP is a plasmid DNA, produced in E. coli, that encodes the complementary deoxyribonucleic acid (cDNA) for human prostatic acid phosphatase (PAP).
12925|NCT04090528|Biological|pTVG-AR|pTVG-AR is a plasmid DNA
12926|NCT04090528|Drug|Pembrolizumab|Pembrolizumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
12927|NCT04090528|Drug|rhGM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
12928|NCT04090515|Behavioral|Project Health|This intervention involves a one-hour group meeting for six consecutive weeks.
12929|NCT04090515|Other|Educational Video Control|This intervention involves a one-hour educational video control viewing for six consecutive weeks.
12930|NCT04090502|Other|Dry needling in hamstring muscle trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied to this area.
12931|NCT04090502|Other|Dry needling in hamstring muscle not trigger points|Participants with nonspecific mechanical low back pain will be assessed for the hamstring muscle. Subsequently, the most sensitive areas associated with the shortening of the muscle will be located and the technique will be applied out of this area.
12932|NCT04090476|Other|Exercise|Enrolled subjects will participate in a 8-week series of peer group exercise sessions. Each class will last one hour and will be facilitated by a physical therapist and physical therapy students. During each session, the daily exercises as part of the LSVT Big program will be performed and modified to the participant's ability level, along with performance of functional tasks stations (i.e. putting on a jacket, putting on a sock, etc.) which will rotate weekly to monthly, and gait tasks (i.e. forward, backwards, stepping over obstacles).
12933|NCT04090463|Radiation|Intraoperative radiotherapy|"IORT will be delivered as follows:~Radical resection --> delivery of 10-15 Gy to the tumor bed~Non radical resection --> delivery of 15-20 Gy to the tumor in situ"
12934|NCT04090450|Radiation|chemo-radiotherapy|The study will not have a direct intervention. It will recruit patients who have had chemo-radiation as part of their standard of care treatment for rectal cancer.
12935|NCT04090437|Procedure|Catheter ablation procedure|Catheter ablation procedure using Acutus mapping system
12936|NCT04090424|Device|NovoSorb BTM|NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
12937|NCT04090424|Procedure|Standard of Care|Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.
12938|NCT04090411|Drug|50 mg|PF-06480605
12939|NCT04090411|Drug|450 mg|PF-06480605
12940|NCT04090411|Drug|150 mg|PF-06480605
12941|NCT04090411|Other|0 mg|0 mg Placebo
12942|NCT04090398|Drug|Paclitaxel|Given IV
12943|NCT04090398|Radiation|Radium Ra 223 Dichloride|Given IV
12944|NCT04090385|Device|Transcranial Direct Current Stimulation|Participants will receive 16 sessions of Transcranial Direct Current Stimulation (tDCS) for 20 minutes each at 2 mA intensity, on alternate days (3 times a week). The current will be delivered via saline-embedded sponge surface electrodes using a battery-powered neurostimulator (TCT-Research, Trans Cranial Technologies, Hong Kong). A small active specific electrode (5x5 cm) will be used to prevent coverage of adjacent areas, resulting in a current density of 0.08 mA / cm². These parameters are within the safe limits established in previous human studies.
12945|NCT04090372|Device|evaluation of pre-op planning using Traumacad|The study will be compare pre-op planning with standard condition or with TraumaCad
12946|NCT04090359|Device|Dual Mobility Implant|Patients in this intervention will receive a dual mobility implant
12947|NCT04090359|Device|Conventional, single-bearing implant|Patients in this intervention will receive a conventional, single-bearing implant
12948|NCT04090346|Procedure|Fecal Microbiota Transplant|Fecal Microbiota Transplant (FMT) is a procedure to replace beneficial bacteria which has been killed or suppressed in the colon.
12949|NCT04090333|Other|Standard withdrawal therapy|All painkillers are abruptly stopped for a 2 months period.
12950|NCT04090320|Device|CATERPILLAR™ Arterial Embolization Device|Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
12952|NCT04090294|Drug|Roflumilast|"Roflumilast is a phosphodiesterase (PDE) type 4 inhibitor will be prescribed for three month for the study group. the patients will then be assessed for improvement regarding exacerbation frequency , performance and pulmonary function test.~patients will receive Roflumilast 500 Mcg. Tablet once daily for three months"
12953|NCT04090281|Genetic|CYP2C19 genotyping|Upon hospital discharge, patients will undergo CYP2C19 genotyping to guide initial P2Y12 inhibitor selection. At 14 days, post discharge, patients will undergo on treatment platelet reactivity phenotyping to further guide deescalation of P2Y12 inhibitor therapy
12954|NCT04090268|Other|Sport Therapy|Children and adolescent with malignant hemopathies will attend a 3 days/weekly combined training
12955|NCT04090255|Procedure|Renal puncture|The use of a needle for entering pelvicalyceal system of the kidney and put a guide wire for further pcnl or only pcn
12956|NCT04090242|Device|BD Diabetes Care Application (for mobile devices) PLUS use of BD Nano Pen Needle|Subjects in the Intervention Group will be instructed to use the DC-App and switch from their current pen needle to the BD Nano 2nd Gen Pen needle during their participation in the study. The app is intended to be used as a patient education tool and data logger to augment the diabetes care team.
12957|NCT04090229|Drug|ASLAN004|Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
12958|NCT04090229|Drug|ASLAN004 Placebo|Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
12959|NCT04090216|Device|Primary Percutaneous Coronary Intervention|Primary PCI will be done for patients with STEMI in both groups of patients
12960|NCT04090203|Drug|Boiled Peanut Powder|Oral Immunotherapy will be administered utilizing a powder derived from boiled peanuts. Treatment will begin with an initial escalation day in which dosing is begun at 0.1 mg peanut protein and escalated to a final dose of 6 mg peanut protein. Doses are ingested orally. The subjects will continue daily oral ingestion of doses at home and return for updosing every 2 weeks to a final maintenance dose of 300 mg peanut protein. The subjects will continue daily oral ingestion of the peanut product for a minimum duration of 28 days before undergoing exit DBPCFC. At the conclusion of the study, patients will be offered continued maintenance therapy off study in line with current specialty standards.
12961|NCT04090190|Drug|Oxybutynin, Solifenacin, Tolterodine, Sanctura or Toviaz|Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
12962|NCT04090177|Behavioral|TEAM Wheels|A 1-month, peer-led, eHealth training program (TEAM Wheels) for individuals transitioning to manual wheelchair use to improve satisfaction with activity participation and related rehabilitation outcomes.
12963|NCT04090138|Dietary Supplement|Setria performance blend|Oral capsules
12964|NCT04090138|Dietary Supplement|Placebo|Oral capsules
12965|NCT04090125|Behavioral|PAS Intervention|The PAS program will be initiated during the final usual care PT visits. The PAS content will be included within the last two routine PT visits (Sessions 1 and 2). Session 1 will emphasize the importance of PA in TKA recovery, work with participants to establish SMART goals regarding overall PA and provide community-based and other resources to support overall PA. Session 2 will include balance exercise content to improve joint loading symmetry and home exercises will be assigned. Then, PAS participants will receive a follow-up phone call after 4 weeks (to assist with activity progression and problem-solving) and an additional in-person visit after 8 weeks (to visually monitor exercise performance and re-assess proportional weight-bearing ability).
12966|NCT04090125|Behavioral|Attention Control|This will include usual in-person post TKA PT followed by 2 additional contacts (Session 1 and 2) with the physical therapist. Session 1 (phone) will review recovery benchmarks, assessment of participants' daily activities and reminders about symptoms that should trigger contacting a medical professional. Session 2 (in-person) will involve physical performance tests and comparison to appropriate normative values.
12967|NCT04090112|Drug|10% lidocaine sprayed|four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet
12968|NCT04090112|Drug|2% lidocaine intravenous|15 mg/kg of 2% lidocaine intravenous injection prior to extubation
12969|NCT04090099|Other|Erector spina plane block|While the patient is in the sitting position, an area containing 2 cm lateral of the T5 spinous process will be cleaned with povidone iodine. A high frequency ultrasound linear probe covered with a sterile sheath will be placed 2 cm to the side of the T5 spinous process, first to the right or left. After demonstrating the T5 transverse process and the erector spinae muscle on top, the 22-gauge, 80 mm insulated Quincke-type needle will be inserted into the skin at an angle of about 30 degrees from the cranial to the caudal, using an in-plane technique. When the transverse process is touched, the needle is withdrawn and after a negative aspiration test with 0.5 mL of normal saline and after a hypo-echogenic display and hydrodissection, a local anesthetic solution will be applied to the fascia under the erector spinae muscle.
12970|NCT04090086|Drug|JNJ-53718678|JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
12971|NCT04090086|Drug|JNJ-64417184|JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.
12972|NCT04090073|Procedure|Electroacupuncture|As above
12973|NCT04090073|Other|Fast-track Perioperative program|As above
12974|NCT04090060|Behavioral|Practice Self-/Companion Exams|300 men and 50 couples will be randomized and encouraged to practice anal exams every four months (four and eight months following Visit 1). Practice results will be elicited by staff. They will return for Visit 2 (12 months after Visit 1). At Visit 2, they will complete a pre- and post-visit computer assisted self-interview. They will receive written instructions. After completing an anal self-exam or anal companion exam, they will record the results. They will have a digital anal Rectal exam by a clinician who will give the subject his results.
12975|NCT04090060|Behavioral|Control Arm|300 individuals and 50 couples will be randomized to this arm. Following Visit 1, they will neither be encouraged nor discouraged from practicing self- or companion exam. They will return for Visit 2 (12 months after Visit 1). They will receive written anal exam instructions. They will then complete the self- or companion exam, record results and receive a clinician DARE. Clinicians will give DARE results. Persons will take a post-exam computer-assisted self-interview. Persons in this arm (control) will be asked if they have performed exams between visits.
12976|NCT04090047|Drug|PF-06700841|PF-06700841 oral tablets in 5mg and 25mg provided for a 30mg dose
12977|NCT04090047|Drug|Itraconazole|200 mg oral solution administered as 20 milliliters(mL) (10 mg/mL)
13676|NCT04084431|Radiation|Radiation|WBRT will be applied in 10 fractions with single doses of 2 Gy (Arm 1) to the whole brain
12978|NCT04090034|Procedure|Peptide Receptor Radionuclide Therapy|a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs
12979|NCT04090021|Drug|Esomeprazole 40mg|Use in a drug combination for H. pylori eradication
12980|NCT04090021|Drug|Clarithromycin 500mg|Use in a drug combination for H. pylori eradication
12981|NCT04090021|Drug|Metronidazole 500 mg|Use in a drug combination for H. pylori eradication
12982|NCT04090021|Drug|Amoxicillin 1000 MG|Use in a drug combination for H. pylori eradication
12983|NCT04090021|Drug|Levofloxacin 500mg|Use in a drug combination for H. pylori eradication
12984|NCT04090021|Drug|Rifabutin 150 MG|Use in a drug combination for H. pylori eradication
12985|NCT04090008|Drug|PRP gel|The PRP gel is applied on the ulcer twice per week
12986|NCT04090008|Drug|Saline dressing|Normal saline is used for dressing of the ulcer twice a week
12987|NCT04089995|Other|data collection|No intervention
12988|NCT04089982|Drug|Varenicline|Chantix
12989|NCT04089982|Drug|Placebo oral tablet|Placebo
12990|NCT04089969|Diagnostic Test|CTA/FFRct|Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.
12991|NCT04089969|Diagnostic Test|SOC cardiovascular evaluation|Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
12993|NCT04089943|Procedure|Revascularization operation|Participants will be randomized into an endovascular or open bypass procedure.
12994|NCT04089943|Other|Control group|Healthy non-PAD participants will be recruited for the study.
12995|NCT04089930|Diagnostic Test|Immunogenicity|anti-VZV IgG titer and cell-mediated immunity (VZV-stimulated T cell spots)
12996|NCT04089917|Device|Q Aspiration Catheter|The Q Aspiration Catheter is indicated for use in the removal of fresh, soft emboli and thrombi in the neurovascular system.
12997|NCT04089904|Drug|Pembrolizumab Injection|Patients will receive 3 cycles of pembrolizumab at 200mg intravenously on day 1 of a 3 week cycle. After 3 cycles the patients will undergo surgery
12998|NCT04089878|Procedure|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration|Plug assisted retrograde transvenous obliteration/Balloon-occluded retrograde transvenous obliteration
12999|NCT04089878|Other|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
13000|NCT04089865|Drug|Tranexamic Acid|Tranexamic acid (TXA) is an antifibrinolytic medication used to reduce bleeding in a variety of medical settings. Patients will be randomized to receive either oral or intravenous tranexamic acid.
13001|NCT04089852|Drug|Nitrous oxide gas for inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. Environmental safety will be maintained with an N2O scavenger system and Porter Miniature Vacuum System. The treatment group will receive inhaled N2O/O2. The N2O will be gradually up-titrated to a goal ratio of 70/30 N2O/O2 and will be administered as outlined in the treatment arm description.
13002|NCT04089852|Drug|Oxygen Gas for Inhalation|All inhaled gases will be administered via nasal mask using a portable nitrous oxide/oxygen (N2O/O2) machine. The control group will receive inhaled O2 alone. Control group participants will receive 100% O2 for two minutes prior to speculum placement. Inhaled oxygen will be administered continuously throughout the procedure as outlined in the control arm description.
13003|NCT04089839|Other|Non-Interventional|Non-Interventional
13004|NCT04089813|Drug|Metformin|Patients use metformin to control blood sugar
13005|NCT04089800|Other|Mobile phone based multimedia application|The investigators shall develop a multimedia mobile health application using Java programming language, while the database that hosts multimedia messages shall be developed using SQlite. It shall be an offline (stand-alone) application following user-centered design approaches that involve incorporating input from pregnant women as prospective users. Pregnant women shall be provided with solar chargers to supplement electricity charging. The application has three major functionalities, appointment reminder function, calling function and the multimedia (Video and audio) function.
13006|NCT04089787|Other|Intervention|Shortened antibiotic treatment of 5 days
13007|NCT04089787|Other|Control|Antibiotic treatment of 7 days or longer at the discretion of the treating physician
13008|NCT04089774|Behavioral|Adapted Physical Activity (APA)|Supported by an Adapted Physical Activity (APA), at the rate of 3 sessions per week supervised by the association SCO STE MARGUERITE, spread over 12 months
13009|NCT04089761|Device|Nerivio|Nerivio™ is an FDA-authorized remote electrical neuromodulation (REN) device for the acute treatment of migraine with or without aura in patients 18 years old or above who do not have chronic migraine. The device delivers transcutaneous electrical stimulation to the upper arm to induce conditioned pain modulation (CPM) that activates a descending endogenous analgesic mechanism. The treatment is self-administered and controlled by a smartphone application.
13010|NCT04089748|Combination Product|neoadjuvant chemotherapy with cisplatine|Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine
13011|NCT04089735|Drug|APP13007, 0.05%|APP13007 eye drop, 0.05%
13012|NCT04089735|Drug|APP13007, 0.1%|APP13007 eye drop, 0.1%
13013|NCT04089735|Drug|APP13007 Placebo, 0.05%|APP13007 eye drop, placebo 0.05%
13014|NCT04089735|Drug|APP13007 Placebo, 0.1%|APP13007 eye drop, placebo 0.1%
13015|NCT04089722|Drug|Deoxycholic Acid|The active ingredient in KYBELLA® is synthetic deoxycholic acid. Deoxycholic acid is a naturally occurring molecule in the body that aids in the breakdown and absorption of dietary fat.
13016|NCT04089709|Behavioral|Well-arm Exercise|Patients randomized to the treatment arm will perform these exercises on the contralateral arm once daily for 3 months: wrist flexion and extension, ball or sock squeeze, wrist curls and biceps curls. Participants allocated to this study arm will be provided a print out of the exercises with detailed explanations and pictures of each exercise.
13017|NCT04089696|Device|ExSprion|The primary objective is the validation of the ExSpiron© non-invasive monitor in patients diagnosed with ALS.
13018|NCT04089683|Other|Swab stick|Swab sticks collected from Web Spaces, Scrub, Anterior Nares
13677|NCT04084431|Other|OSC|optimal supportive Care (OSC) alone
13019|NCT04089670|Behavioral|Online Acceptance and Commitment Therapy Intervention|"The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week."
13020|NCT04089657|Drug|Apatinib Mesylate|Apatinib 500mg qd, oral, taken half an hour after a meal
13021|NCT04089657|Drug|Sintilimab|Sintilimab 200mg intravenously on day 1
13022|NCT04089644|Device|closed-loop system|"Hypotension will be corrected by an automated system for vasopressor administration.~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
13023|NCT04089644|Device|Manual adjustment|"Vasopressor agents will be manually adjusted (standard practice).~Fluids will be given using a goal directed strategy (EV1000 Monitor, Edwards Lifesciences, Irvine, CA, USA)"
13024|NCT04089631|Drug|Capecitabine|6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
13025|NCT04089618|Behavioral|MBLM|Complex 8 week Mind-Body program.
13026|NCT04089605|Drug|dexamethasone implant|intravitreal dexamethasone implant injections in vitrectomized patients with DME
13027|NCT04089605|Drug|Ranibizumab|intravitreal ranibizumab injections in vitrectomized patients with DME
13028|NCT04089592|Drug|Dexmedetomidine|intravenous dexmedetomidine 0.6mcg/kg in 100ml normal saline 0.9%
13029|NCT04089592|Drug|Fentanyl|intravenous fentanyl at 2mcg/kg in 100ml saline
13030|NCT04089579|Biological|Cord Tissue Mesenchymal Stromal Cells|Human Umbilical Cord Tissue Derived Mesenchymal Stromal Cells (hCT-MSC), isolated and expanded from umbilical cord tissue from allogeneic unrelated donors. One dose of 6x10e6 cells/kg administered intravenously.
13031|NCT04089579|Other|Placebo Infusion|Placebo comparative infusion
13032|NCT04089566|Drug|Nusinersen|Administered as specified in the treatment arm
13033|NCT04089553|Drug|AZD4635|Capsule
13034|NCT04089553|Drug|Oleclumab|Oleclumab is supplied as a solution for infusion after dilution. After dilution the solution contains 50 mg/mL oleclumab (MEDI9447) in 25 mM histidine/histidine HCl, 240 mM sucrose, 0.03% (w/v) polysorbate 80;
13035|NCT04089553|Drug|Durvalumab|Durvalumab will be supplied as a solution for infusion after dilution. After dilution the solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine HCl, 275 mM trehalose dihydrate, and 0.02%(w/v) polysorbate 80.
13036|NCT04089540|Procedure|New intubation method|
13037|NCT04089540|Procedure|Conventional intubation method|
13038|NCT04089527|Drug|CC-95775|CC-95775
13039|NCT04089514|Drug|Adalimumab|Administered as specified in the treatment arm
13040|NCT04089501|Diagnostic Test|Stool collection|Stool will be collected from subjects who have been diagnosed with IBD or whom small intestinal, colonic or ileocolonic and have signed consent for the control group. Stool will be self-collected or through routine colonoscopy procedure.
13041|NCT04089501|Diagnostic Test|Biopsy collection|3 additional biopsies (for research purposes) will be taken from patients who undergo colonoscopy as per standard of care
13042|NCT04089488|Other|Medical Chart Review|Correlative studies
13043|NCT04089488|Other|Survey Administration|Respond to surveys
13044|NCT04089475|Device|Dermoscope|Dermoscopy is a noninvasive diagnostic tool that permits the visualization of morphological features that are not visible to the naked eye thus representing a link between macroscopic clinical dermatology and microscopic dermatopathology.
13045|NCT04089462|Behavioral|"Five sessions per period - Two sessions per period"|"Period 1: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)~Period 2: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)"
13046|NCT04089462|Behavioral|"Two sessions per period - Five sessions per period"|"Period 1: 2 exercise sessions within a 5-day period (10 min anaerobic exercise and 75 min aerobic exercise per session)~Period 2: 5 exercise sessions on 5 consecutive days (4 min anaerobic exercise and 30 min aerobic exercise per session)"
13047|NCT04089449|Drug|PRT811|PRT811 will be administered orally
13048|NCT04089436|Diagnostic Test|CSF sampling|CSF sampling by lumbar puncture
13049|NCT04089436|Diagnostic Test|Blood sampling|Blood sampling by blood test
13050|NCT04089436|Diagnostic Test|Nasopharyngeal and rectal sampling|Nasopharyngeal and rectal sample by swabbing
13051|NCT04089423|Device|Fujifilm SILVAMP TB LAM|Fujifilm SILVAMP TB LAM detects the presence of lipoarabinomannan (LAM) in urine with a visually read lateral flow test that uses silver amplification.
13052|NCT04089410|Device|Hyperthermic Fitness Treatment (HFT)|The Hyperthermic Fitness Treatment uses Alfa Basic capsule, an ergonomic camera in which a participant may take a lying position and undergo hyperthermia procedures (infrared heating with intracapsule temperature increase up to 80 degrees C◦), the head being outside the camera blown by cool air with a built-in ventilator. HFT is comparable to dry sauna bathing. Core body temperatures will be raised to 37.5-38.5°C◦. Recommended duration of one HFT session is 40 min. All the HFT group participants while undergoing sessions in the Cocoon will be dressed in bathing suits.
13053|NCT04089410|Device|Placebo Hyperthermic Fitness Treatment|Attenuated heating with less heat set (20-30 degrees C◦). This results in no increase of core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual HFT, and will be in the capsule for the same period of time.
13078|NCT04089254|Behavioral|Outpatient Crisis Intervention Clinic|Outpatient psychiatric clinic that provides crisis intervention to treat and stabilize suicidal thoughts and behavior.
13079|NCT04089241|Other|Contrast 3D Ultrasound|an ultrasound examination which will include a 3D reconstruction and thereafter CEUS will be performed using SONOVIEW contrast agent
13080|NCT04089228|Other|Kinesiotaping|Total of 4 sessions on upper trapezius trigger points on alternate days.
13054|NCT04089410|Other|Physical Examination|"Resting hearth rate (HR), Systolic and Diastolic blood pressure (SBP and DBP) values are measured twice in supine position using an automatic tonometer after 5 min of rest.~Body mass (BM) and height are measured to calculate Body Mass Index. Body composition is assessed with the use of portable body-impedance-meter for the whole body impedance-analysis.~Body core temperature, Blood pressure (BP) and Heart rate (HR) are measured before and right after each session. Arterial oxygen saturation (SpO2) and HR is monitored continuously by the use of a pulse oximeter, attached to the index fingertip of non dominant hand."
13055|NCT04089410|Other|Assessment of Cardiorespiratory Fitness|An assessment of exercise tolerance and cardiorespiratory fitness (ET, CRF) is carried out with the use of Cardiopulmonary Exercise Test - CPET). Testing is carried out using a gas analyzer and an Intertrack treadmill. Evaluation of gas exchange parameters conducted according to a given program - Cardiopulmonary load testing.
13056|NCT04089410|Other|Autonomic Balance, Orthostatic and Hypoxic tolerance|"Evaluation of Autonomic balance is assesed using Heart Rate Variability (HRV) analysis. The HRV test relies on a 5-min RR interval (time in milliseconds between two R waves of the electrocardiogram complex) recorded at rest for 5 min supine (SU) followed of 5 min resting time. Measurement of the interval duration between two R waves of the cardiac electrical activity are performed with a HR monitor.~Orthostatic tolerance is assessed after ANS balance assessment by HRV analysis to continue RR intervals registration for 3 min after participant was asked to stand up taking a vertical position near the couch.~The individual sensitivity to hypoxia is determined by conducting a 10-minute hypoxic test (HT) - breathing through a facial mask by a gas mixture with 11% of O2, with minute-by-minute monitoring of HR and hemoglobin saturation by oxygen (SaO2). Arterial blood pressure is recorded before and after HT."
13057|NCT04089410|Other|Psychological Testing|"Medical Outcomes Study Short-Form 36-Item Health Survey (SF-36), which is a self-completed quantity of health-related QoL.~Participants are asked to complete the Pittsburgh Sleep Quality Index (PSQI), a retrospective self-report measure assessing their quality of sleep during the last three weeks preceding the study.~Anxiety level is estimated by using State and Trait Anxiety Scales (SA and TA) developed by Ch. Spielberger~Subjective Ratings of Thermosensation and Pain.Participants rate their comfort, thermosensation, and pain by fixing results in visual-analogous scale (VAS) while passing each of HFT treatment."
13058|NCT04089410|Other|Measurement of Blood Markers|Periferal venous blood (10 ml) sumples of the fastest (overnight fast) study subjects are withdrawn by a qualified laboratory technician via aseptic technique from the antecubital vein in the sitting position, using sterile needles and are collected. Serum BDNF, HGH, HSPs (60, 70, 90) concentrations are determined.
13059|NCT04089397|Device|Light Therapy|Five weeks of light therapy, with 3 weekly sessions of 30 minutes, to be performed between 8:00 to 10:00, the days of dialysis
13060|NCT04089384|Other|Control Group|Will receive individualized dietary plan - alimentary reeducation and micropore containing a point made with a black gel pen that will be placed in the ear
13061|NCT04089384|Other|Auriculotherapy Group|Will receive individualized diet plan - diet reeducation and auricular therapy method with strategic points for obesity
13062|NCT04089384|Other|Placebo group|Will receive individualized diet plan - diet reeducation and sham points, points not indicative for the proposed treatment).
13063|NCT04089371|Device|ReUnion Total Shoulder Arthroplasty (TSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
13064|NCT04089371|Device|ReUnion Reverse Shoulder Arthroplasty (RSA)|The ReUnion RFX System includes a Reversible Fracture Stem (RFX Stem) that can utilize either the ReUnion Total Shoulder Arthroplasty (TSA) or ReUnion Reverse Shoulder Arthroplasty (RSA) humeral and glenoid components and is indicated for use as a hemi, total or reverse shoulder replacement. The ReUnion RFX stem is intended for cemented use only.
13065|NCT04089358|Behavioral|PA Tracker|Participants will engage in a physical activity program.
13066|NCT04089358|Behavioral|Social Media|Participants will receive enhanced support in the physical activity program using social media.
13067|NCT04089345|Drug|Ustekinumab|All patients will receive intravenously (IV) ustekinumab ~6mg/kg at baseline and subcutaneously (SC) ustekinumab 90mg every 8 weeks thereafter until Week 48.
13068|NCT04089332|Other|Oral Glucose Tolerance Test|Eligible subjects will undergo MRI scanning before and after oral glucose tolerance test.
13069|NCT04089332|Device|3 Tesla MRI|A 3 Tesla MRI will be used to assess brain structure, quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits.
13070|NCT04089332|Device|Intravenous Catheter|A blood sampling IV catheter will be used to draw blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin.
13071|NCT04089332|Other|Cognitive Tests|A battery of cognitive tests will be completed by the subject.
13072|NCT04089319|Other|Music recording|Participants will listen to music for 45 minutes while they rest with acupuncture needles in place.
13073|NCT04089319|Other|Mindfulness recording|Participants will listen to a recording of mindfulness for 15 minutes and then listen to music for 30 minutes while they rest with acupuncture needles in place.
13074|NCT04089280|Dietary Supplement|Sanprobi Barrier-multispecies probiotic|"Multi-strain probiotic Sanprobi Barrier (Bifidobacterium lactis W52, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus lactis W19, Lactobacillus lactis W58, Lactobacillus acidophilus W37, Bifidobacterium bifidum W23, Lactobacillus salivarius W24) or placebo. Patients will be randomized to one of the two products (A or B) each containing probiotic/placebo and administered for 12 weeks. After 12 weeks of supplementation, the probiotic/placebo product A or B will be discontinued and reintroduced again after next 4 weeks - patients will be switched to the other A or B group of probiotic/placebo arm. Patients will be administered with 4 capsules per day for 24 weeks (12 weeks for group A probiotic/placebo and 12 weeks for group B probiotic/placebo allowing 4 weeks washout between the group assignment)."
13075|NCT04089280|Other|Placebo Comparator|Carrier material of Sanprobi Barrier-multispecies probiotic product, not containing bacterial strains,similar appearance as the probiotic
13076|NCT04089267|Drug|TPO|
13077|NCT04089254|Behavioral|Inpatient Psychiatry|Inpatient hospitalization to treat and stabilize suicidal thoughts and behavior.
13081|NCT04089228|Other|Integrated Neuromuscular Inhibition Technique|Sustain Pressure. Strain Counter-strain (for 90 sec) Passive Isometric Relaxation (PIR) (6-10 sec hold, 4 reps)
13082|NCT04089215|Biological|CD19-targeted Chimeric Antigen Receptor (CAR) T Cells|JWCAR029 be administered at dose level: 1 x 10^8 CAR+T cells and 1.5 x 10^8 CAR+T cells
13083|NCT04089202|Other|eConsult|Completion of electronic consult utilizing data collected from flash glucose monitoring
13084|NCT04089202|Other|Standard of care|Care by the Endocrinologist is provided as would typically be done, taking into account patient factors and preferences.
13085|NCT04089189|Drug|IMP4297|IMP4297 100mg PO QD
13086|NCT04089176|Drug|Carbetocin|carbetocin 100 mcg + RLS solution 10 ml injected directly into the vein over 2 min
13087|NCT04089176|Drug|oxytocin|oxytocin 20 IU diluted in 1000 ml of RLS solution administered intravenously at rate 120 ml/hr x 8 hr
13088|NCT04089163|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal drug, flucytosine (5-fluorocytosine; 5-FC) to the anticancer drug 5-fluorouracil (5-FU) in cancer cells that have been infected by the Toca 511 vector.
13089|NCT04089163|Drug|Toca FC (extended-release formulation of flucytosine)|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
13090|NCT04089150|Radiation|Stereotactic Radiotherapy (SBRT)|40 Gray (Gy) in 5 fractions, 2-3 fractions per week over two weeks, 8 Gy per fraction
13091|NCT04089150|Drug|mFOLFIRINOX|"Day 1: oxaliplatin 85mg/m2 + irinotecan 150mg/m2 + leucovorin 50mg~5-FU 2400mg/m2 continuous IV infusion, 46 hour continuous infusion~14-day cycle, 6 cycles"
13092|NCT04089150|Drug|Gemcitabine + Nab-paclitaxel|"Day 1, Day 8 and Day 15 gemcitabine 1000mg/m2 + nab-paclitaxel 125mg/m2~28-day cycle, 3 cycles"
13093|NCT04089150|Drug|Gemcitabine + Capecitabine|"Week 1, 2 and 3, qw: 1000 mg/m2 gemcitabine~21 days continuous: 830 mg/m2 oral capecitabine + 7 days rest~28-day cycle, 3 cycles"
13094|NCT04089150|Procedure|Pancreatoduodenectomy (Whipple procedure)|R0 resection. When the tumour is within the head of the pancreas, a standard Whipple's procedure and level 2/3 dissection with modification to obtain margin clearance will be offered. For lesions in the tail, a standard modular resection will be offered.
13095|NCT04089137|Behavioral|ASAP (Alcohol and Sexual Assault Prevention)|This is an integrated social norms-based personalized feedback intervention for college students targeting alcohol misuse and sexual assault.
13096|NCT04089124|Procedure|surgery of zone 2 cut flexor repair|we will repair tendon of FDP. use 6 strand technique using PDS 4/0 core suture - vicryl 5/0 running suture
13097|NCT04089111|Other|Minute volume target of 100%|Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
13098|NCT04089111|Other|Minute volume target to reach PaCO2 less than 45% (high tidal volume)|Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
13099|NCT04089098|Diagnostic Test|passive leg raising versus mini volume challenge|Blood samples will be collected and ultrasound evaluation of renal perfusion conducted in study participants immediately before conducting passive leg raising (PLR). PLR will then be carried out on study participants, followed by MVC. PLR- and/or MVC-responsive patients will receive a further 700 ml fluid immediately after the MVC. Renal perfusion will be further assessed 1 and 24 hours after the MVC.
13100|NCT04089085|Behavioral|STRONGer Together|STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
13101|NCT04089072|Drug|Methylene Blue|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin), they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of >65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
13102|NCT04089072|Drug|Phenylephrine|"Prior to the initiation of the randomized treatment, the subject will have received 2 vasopressors ( norepinephrine and vasopressin) already , they will be initiated on IV hydrocortisone . Once the patient is unable to maintain a mean arterial pressure of >65mmHg and the hydrocortisone has been administered there will be an addition of a third-line vasopressor.~Patients enrolled in the intervention group will receive ProvayBlue® and Patients enrolled in the control group will receive Phenylephrine infusion as a third line vasopressor in the treatment of septic shock."
13103|NCT04089059|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor~Cordella Delivery System~myCordella Patient Reader~Reader Dock~Cordella Calibration Equipment (CalEQ)~myCordella Hub~Cordella Data Analysis Platform (CDAP)"
13104|NCT04089059|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System (CorPASS) is intended to measure, record, and transmit pulmonary artery pressure (PAP) data from NYHA Class III heart failure patients at home to clinicians for assessment and patient-centered heart failure management and comprises of seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor~Cordella Delivery System~myCordella Patient Reader~Reader Dock~Cordella Calibration Equipment (CalEQ)~myCordella Hub~Cordella Data Analysis Platform (CDAP)"
13105|NCT04089046|Behavioral|TEAM-UP for Teens|TEAM-UP for Teens pairs school-based directly observed therapy (DOT) of daily preventive asthma medications with specialist care and ongoing self-management support using live, real-time telemedicine through school.
13129|NCT04088851|Drug|Metformin|Type 2 Diabetics with prescribed Metformin therapy (1 g / day) will pause the medication for 2 weeks and then continue the anti-diabetic treatment again. Aim is to measure the gluconeogenic precursor fluxes with and without metformin therapy.
13707|NCT04084210|Other|Placebo Patch|Placebo patch containing no nicotine.
13106|NCT04089046|Behavioral|Enhanced Care (EC)|Teens in the EC group will receive a symptom assessment and asthma education materials at baseline, and their PCPs will be contacted by facsimile or email to recommend DOT of preventive asthma medication through school as well as referral to an asthma specialist. Systematic reminders will be sent to the family and PCPs to schedule recommended healthcare visits and consider specialist referral at the same intervals as the TEAM-UP group's virtual visits.
13107|NCT04089033|Procedure|Pneumatic Retinopexy|The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.
13108|NCT04089033|Procedure|Pars Plana Vitrectomy|For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
13109|NCT04089020|Behavioral|Support for walking to school|5 modules that address psychosocial skills, with ongoing text messaging.
13110|NCT04089007|Device|SOmNI app|In addition to allowing users to track sleep behaviours across the four-week intervention period, the SOmNI app will also provide messaging via alerts and tips to outline the importance of sleep to health, suggest optimal sleep timing/duration, and suggest sleep promotion strategies. Daily review questions in the app will help the participants link changes in sleep behaviours to changes in health outcomes. As well, when goals related to sleep extension are met, the SOmNI rewards program awards points to the participant and these points can then be redeemed in $5 increments to a maximum of $40 for gift certificates.
13111|NCT04089007|Other|Control group|The research assistant will advise the participant to increase the amount of nighttime sleep achieved but will not give any sleep hygiene advice or instructions for moving their bedtime earlier.
13112|NCT04088994|Other|AOT Pathological Model Experimental Group|The children will participate in a rehabilitation intervention based on the observation of unimanual and bimanual actions performed by a model with the same degree of motor impairment, but an improvement on the participant's current abilities.
13113|NCT04088994|Other|AOT Healthy Model Control Group|The children assigned to the healthy group will participate in a rehabilitative protocol based on the AOT observing unimanual and bimanual actions performed by a healthy model
13114|NCT04088981|Behavioral|Dietary intervention|low-fat vegan diet and a portion controlled diet.
13115|NCT04088968|Behavioral|Prehabilitation|Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
13116|NCT04088955|Other|DigiMeds|Digitized Capecitabine
13117|NCT04088942|Other|High-intensity smoking cessation intervention|"Varenicline for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.~Group-sessions in 6 months:~Preparation phase: 5 sessions Day 1-14: 5 sessions Day 15-30: 5 sessions Day 31-60: 5 sessions Day 61-90: 5 sessions Day 90-180: 5 sessions c) Hotline and scheduled phone consultations:~A hotline is established which the high-intensity group can call.~Weekly calls to all patients in the project for 26 weeks. Call for 5-10 min. If the patient has not had relapse, there will be called week 34 and week 42. If the patient has had relapse, calls continue until relapse-free for 10 weeks, then week 34 and week 42.~d) Buddy-arrangement: i. Patients who have completed the program and have become smoke-free, are matched with new ones in the program. A meeting frequency of approx. every 7-14 days. The first patients are matched with patients from pulmonary medical outpatient clinic who have ceased smoking."
13118|NCT04088942|Drug|Low-intensity smoking cessation intervention|Varenicline prescribed for 12 weeks - Day 1-3: 0.5 mg daily. Dag 4-7: 0.5 mg two times daily. Thereafter 1 mg 2 times daily.
13119|NCT04088929|Drug|CBD|A water-soluble sublingual tablet containing 20 mg of cannabidiol (CBD) and 0.1 mg of a proprietary blend of terpenes.
13120|NCT04088903|Drug|Daratumumab|>Daratumumab 16 mg/kg intravenous weekly for 8 weeks and then every other week for 2 doses.
13121|NCT04088890|Drug|Fludarabine|Fludarabine 30 mg/m2
13122|NCT04088890|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2
13123|NCT04088890|Drug|CD22 CAR|Autologous T cells transduced with lentiviral vector (CD22.BB.Z) Chimeric Antigen Receptor (CD22 CAR)
13124|NCT04088877|Behavioral|Exercise|The participants will attend the exercise facility at Wellspring two times a week. Sessions are completed under the supervision of an exercise physiologist and the duration of each session ranges from 1.0 - 1.5 hours. Each session includes a warm up on an aerobic exercise machine, a full body progressive RET program followed by balance and stretching exercises.
13125|NCT04088877|Behavioral|Art Sculpting Class|The sculpting program will take place once a week for 2 hours over an 8-week period. Sessions will be themed around body image and facilitated by an artist and registered psychologist who will lead the group in art techniques and self-reflection, respectively. Each group session will focus on a theme related to body image, and the participants will have the opportunity to reflect through their art and social interactions with one another.
13126|NCT04088864|Drug|Fludarabine|Fludarabine is a purine antagonist antimetabolite
13127|NCT04088864|Drug|Cyclophosphamide|Cyclophosphamide is a nitrogen mustard derivative alkylating agent
13128|NCT04088864|Drug|Autologous CD22 CAR T|Autologous T cells transduced with lentiviral vector (m971BBZ) Chimeric Antigen Receptor (CD22 CAR)
13130|NCT04088838|Other|Pain tracking app|In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
13131|NCT04088825|Other|CONUT screening system|"CONUT has been working from june of 2010 and it has detected risk of malnutrition in 32% of the evaluated patients. The method collects information from databases of Admission Service (affiliation, age, date) and Laboratory (albumin, cholesterol, total lymphocytes) and generates, in the report of analytical results, alert information about each patient's nutritional risk and also nutritional recommendations based on the risk identified."
13132|NCT04088812|Other|Placebo meat derivative + Placebo satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound placebo diluted in water
13133|NCT04088812|Other|Placebo meat derivative + Satiating compound|Subjects will consume 60 g of meat derivative placebo in a brunch type meal with 25 g of the satiating compound diluted in water
13134|NCT04088812|Other|Experimental meat derivative + Placebo satiating control|Subjects will consume 60 g of the experimental meat derivative in a brunch type meal with 25 g of satiating compound placebo diluted in water
13135|NCT04088799|Other|No intervention|No intervention
13136|NCT04088786|Drug|nanoliposomal irinotecan|The starting dose of nal-IRI will be 70 mg/m2 (cohort level 1) applied for 30 min using a closed HIPEC technique following completion of cytoreductive surgery. If there is dose limiting toxicity (DLT) in cohort level 1, then the dose will be reduced the dosage of the next cohort to 50 mg/m2 (cohort level 0). If there is no DLT, the dose of nal-IRI will be increased to 140 mg/m2, 210 mg/m2 and 280 mg/m2 . If one of the patients experiences DLT, then the cohort will expand to 6 patients and accrual to the current dose level and dose escalation will stop if 2 or more patients experience a DLT at a given dose level.
13137|NCT04088773|Diagnostic Test|blood biomarkers|biomarkers to distinguish fibrotic vs non-fibrotic CD lesions
13138|NCT04088773|Diagnostic Test|stool biomarkers|fecal biomarkers of inflammation, mucosal inflammation
13139|NCT04088773|Diagnostic Test|MRI imaging|MRI imaging to detect bowel wall fibrosis and to detect inflamed, non-fibrotic from inflamed, fibrotic bowel
13140|NCT04088760|Drug|TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT)|The majority of TCRαβ+ T cells and CD19+ B cells will be removed from the allogeneic graft utilizing the CliniMACS® immunomagnetic selection device (Miltenyi Biotec). The depletion process involves two phases; cell labeling (phase 1) and the automated immunomagnetic depletion process (phase 2). The CD34+ dose may be adjusted by the need to not exceed the TCRαβ+CD3+ dose threshold.
13141|NCT04088747|Diagnostic Test|Ultrasound Imaging|B-mode ultrasound pictures of the upper Trapezius were collected from both left and right sides.
13142|NCT04088734|Drug|ABO-102|Single dose of ABO-102 (scAAV9.U1a.hSGSH) administered by intravenous injection through a peripheral limb vein at a dose of 3 X 10^13 vg/kg
13143|NCT04088721|Biological|AD17002|LTh(αK) as immunomodulator
13144|NCT04088721|Other|Formulation Buffer|Formulation buffer
13145|NCT04088708|Other|Aerobic Exercise Training|Each session will last 20 to 60 minutes depending on the stage of progression (shorter duration in the first few weeks). Sessions will occur on nonconsecutive days of the week. Moderate-intensity, continuous aerobic exercise will be used to target large muscle groups (e.g., legs) with the principal goal of increasing cardiorespiratory fitness. Exercise intensity will be gradually increased. To mitigate stagnation and support continued improvement of cardiorespiratory fitness, high-intensity interval exercise will be added in later weeks of the intervention.
13146|NCT04088708|Other|Attention Control|The flexibility/toning control condition will be delivered using the same frequency as the aerobic condition (i.e., 3 times per week) and use light resistance bands of least difficulty. The flexibility/toning sessions will last about 40 minutes, be led by trained exercise specialists. Flexibility/toning activities will target the head/neck, shoulder, elbow/forearm, hand/wrist, trunk/hip, and ankle/foot. The progression of activities over the 10-week period will involve performing additional exercises and sets along with using progressively thicker elastic resistance bands (i.e., Thera-bands) that provide minimal resistance.
13147|NCT04088695|Other|Video through a web page|Participants will see a video about blood donation.
13148|NCT04088695|Other|Informative text|Participants will see a brief text about blood donation.
13149|NCT04088682|Behavioral|Quality improvement strategies and tools|Quality improvement strategies and tools
13150|NCT04088669|Other|Home-based Pulmonary Rehabilitation|Patients will admit a home-based pulmonary rehabilitation program for 8 weeks, with a minimum of 3 days per week and one session of this is under the supervision of a physiotherapist. The pulmonary rehabilitation program includes stretching exercises, strengthening exercises for upper and lower extremities, breathing exercises and aerobic exercises (walking). All of these exercises will be equipped with equipment that the patients can easily provide at home. In addition, patients will be provided with a pedometer and exercise diary.
13151|NCT04088669|Other|Education and Recommendations|The control group will be given a training session on the course of the disease and the correct inhaler use and will be given booklets on breathing exercises, aerobic exercises (walking) and physical activity recommendations for a minimum of 2-3 days per week for 8 weeks. Patients will be given a pedometer and exercise diary.
13152|NCT04088656|Other|Systems Analysis and Improvement Approach for Hypertension Screening and Treatment Optimization|The Systems Analysis and Improvement Approach to Optimize the Hypertension Care Cascade for People Living with HIV (SAIA-HTN) is a five-step systems analysis and iterative improvement cycle intervention which will be implemented by study nurses and district managers in intervention facilities. Components of the intervention include joint care cascade analysis, patient flow mapping and continuous quality improvement, aimed to incrementally improve hypertension screening, diagnosis, treatment and care in the HIV+ population at intervention health facilities.
13153|NCT04088643|Device|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with 4Hz frequency and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
13191|NCT04088396|Drug|Baricitinib|Administered orally
13154|NCT04088643|Device|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
13155|NCT04088630|Drug|Fingolimod 0.5 mg|A single dose of 0.5 mg oral fingolimod within 24 hours of symptom onset
13156|NCT04088630|Drug|Placebo|A single oral placebo pill within 24 hours of symptom onset
13157|NCT04088630|Other|Standard of care|Standard of care protocol for the treatment of spontaneous ICH
13158|NCT04088617|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour high carbohydrate mixed meal tolerance test.
13159|NCT04088617|Dietary Supplement|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour high carbohydrate mixed meal tolerance test.
13160|NCT04088604|Drug|LY01610 ( Irinotecan hydrochloride liposome injection )|Part1-Dose Escalation and Part1-Dose Extension : subjects take LY01610;
13161|NCT04088604|Drug|LY01610 ( Irinotecan hydrochloride liposome injection ) with 5-Fu（Fluorouracil Injection）|Part2-Dose Escalation and Part2-Dose Extension : subjects take LY01610 with 5-Fu;
13162|NCT04088604|Drug|Irinotecan Hydrochloride Injection（CAMPTO®）|Irinotecan Hydrochloride Injection（CAMPTO®） pharmacokinetics comparative study
13163|NCT04088591|Drug|Ascorbic Acid 500Mg/Ml Inj|Ascorbic acid 200mg/kg/day administered upon suspicion or confirmation of sepsis every 6 hours for a total duration of 96 hours
13164|NCT04088591|Drug|Dextrose in Water|50 ml of 5% dextrose in water every 6 hours for a total duration of 96 hours
13165|NCT04088578|Other|Training|Controlling movement of an object on computer screen by adjusting muscle activity.
13166|NCT04088578|Other|Vagus Nerve Stimulation|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
13167|NCT04088578|Other|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
13168|NCT04088565|Other|Paired-Associative Stimulation (PAS)|Simultaneous activation of connections in motor cortex via stimulation to the nerves and brain.
13169|NCT04088565|Other|Vagus Nerve Stimulation (VNS)|Recruits the auricular branch of the vagus nerve which activates brain structures that release chemicals mediating cortical plasticity.
13170|NCT04088565|Other|Sham Stimulation|Sub-threshold stimulation that does not activate neural structures.
13171|NCT04088552|Other|"Go4Life-Physical Activity/Exercise Program Workout to Go 5"|"The Go4Life-Physical Activity/Exercise Program Workout to Go 5 Program is an exercise regimen provided to participants. Participants will be provided a booklet with exercise routines that requires minimal equipment and can be performed anywhere for approximately 30 minutes per session. Recommendation on staying active by increasing daily steps through walking will also be recommended as part of the regimen."
13172|NCT04088552|Behavioral|ActuaYa Educational Sessions|The ActuaYa Educational Sessions will be delivered by a facilitator in 3 separate sessions with each session lasting 2.5 hours for a total of 7.5 hours administered for the study duration. Each session will be conducted in separate groups of 6-10 participants. Session 1 will discuss the impact of chronic disease in the older Hispanic community. Session 2 will discuss the communication and negotiation with the family and partner. Session 3 will discuss saying goodbye and having a plan for a healthy lifestyle.
13173|NCT04088539|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date)
13174|NCT04088539|Behavioral|Video-based health education|Educational videos on smoking and health will be developed to improve the knowledge of CSD smokers. Smoking cessation counselor from the School of Nursing will conduct health talks. CSD will provide venue for viewing the video and health promotion talks. Health talks (n=4) will be provided by small group format. This health talk aims to raise their awareness on these important health topics and acquire effective cessation methods. The effectiveness of the educational videos will be evaluated by pre- and post-tests through a self-administered survey that assess the changes in knowledge related to smoking hazards, benefits of quitting, and methods to quit smoking.
13175|NCT04088526|Combination Product|intervention group|Through effective intervention combined with drugs and dietary guidance within 3 to 6 months, all the observation markers including blood pressure and laboratory results will reach the target target value.
13176|NCT04088513|Drug|Aspirin|This group will receive a 100 mg/day aspirin plus clopidogrel placebo for 90 days.
13177|NCT04088513|Drug|Clopidogrel|This group will receive a 75 mg/day clopidogrel plus aspirin placebo for 90 days.
13178|NCT04088500|Biological|Nivolumab|Specific dose on specific days
13179|NCT04088500|Biological|Ipilimumab|Specific dose on specific days
13180|NCT04088487|Behavioral|New in Town—Interner Intervention for Migrants|New in Town is an internet intervention for migrants that aims at increasing social self-efficacy. Exercises in the intervention are based on the principles of Cognitive Behavioral Therapy and relate to four sources of self-efficacy beliefs—mastery experiences, vicarious experiences, verbal persuasions, and emotional and physiological states (Bandura, 1997).
13181|NCT04088474|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules (5 billion CFU/day)
13182|NCT04088474|Dietary Supplement|Placebo|Maltodextrin was used as a placebo
13183|NCT04088461|Drug|Linagliptin / Metformin Oral Tablet|Linagliptin 2.5 mg + Metformin 850 mg twice daily plus a lifestyle modifications program
13184|NCT04088461|Drug|Metformin|Metformin 850 mg twice daily plus lifestyle modifications program
13185|NCT04088448|Drug|Placebo oral tablet|Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
13186|NCT04088448|Drug|Metformin|Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
13187|NCT04088435|Radiation|Intraoperative radiotherapy|The IORT component of this treatment is being delivered as per standard clinical practice. 20 Gy in one fraction will be delivered at the time of lumpectomy.
13188|NCT04088422|Procedure|peripheral blood collection|peripheral blood collection at treatment start, interm PET/CT, end of treatment PET/CT, one-year and two-year follow-up and or progression or relapse
13196|NCT04088357|Drug|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.
13197|NCT04088344|Dietary Supplement|isocaloric diet|a 7-day isocaloric diet
13198|NCT04088344|Dietary Supplement|Hypercaloric diet|A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).
13199|NCT04088344|Other|Liquid meal|
13200|NCT04088344|Radiation|PET imaging|
13201|NCT04088344|Other|perfusions of stable tracers|
13202|NCT04088344|Device|Indirect calorimetry|
13203|NCT04088331|Device|AMS 800 Artificial Urinary Sphincter|The AMS 800 Artificial Urinary Sphincter (AUS) is an implantable, fluid filled, solid silicone elastomer device used to treat stress urinary incontinence due to reduced urethral/bladder outlet resistance (intrinsic sphincter deficiency). It is designed to restore the natural process of urinary control. The device simulates normal sphincter function by opening and closing the urethra under the control of the patient.
13204|NCT04088318|Drug|OQL011|OQL011 is an ointment containing active ingredient.
13205|NCT04088318|Drug|Vehicle Ointment|Vehicle ointment is an ointment containing no active ingredient.
13206|NCT04088305|Drug|Dose|Dosage of Vancocin decided by a serum trough concentration, instead of decided by attending physician
13207|NCT04088292|Drug|Alteplase 20 Mg Powder for Solution for Injection Vial|Low dose alteplase delivered IV or bu Ultrasound Assisted Thrombolysis device
13208|NCT04088292|Device|Ultrasound assisted Thrombolysis|Ultrasound assisted thrombolysis (USAT)
13209|NCT04088279|Diagnostic Test|MRI|Oxygen enhanced and fourier decomposition MRI
13210|NCT04088266|Combination Product|16 mg buprenorphine with 4 mg naloxone sublingual film|CASSIPA®
13211|NCT04088253|Procedure|umbilical herneal repair|reduction of the herneal content an repair of the defect with IPOM
13212|NCT04088240|Dietary Supplement|DPA enriched n-3|4 g/d DPA enriched n-3 concentrate (~980 mg DPA, 380 mg EPA, 1720 mg DHA)
13213|NCT04088240|Dietary Supplement|n-3 control|4 g/d n-3 control (~980 oleic acid, 380 mg EPA, 1720 mg DHA)
13214|NCT04088240|Dietary Supplement|Placebo|"4 g/d placebo control (light olive oil)"
13215|NCT04088227|Drug|Experimental Group|Patients will receive platelet rich plasma injection two times prior to surgery.
13216|NCT04088227|Other|Control Group|Patients will have their knee aspirated at their initial physician visit and at the time of surgery.
13217|NCT04088214|Procedure|Arthroscopic lateral soft tissue release|The arthroscopic lateral soft tissue release is performed using an inside-out approach via the 1MTPJ arthroscopy.
13218|NCT04088201|Device|Glucose measurements|We will not conduct an intervention, but will obtain measurements from a continuous, non-invasive glucose sensor, and compare with those from a glucometer.
13219|NCT04088188|Drug|Cisplatin|Given IV
13220|NCT04088188|Drug|Gemcitabine|Given IV
13221|NCT04088188|Drug|Gemcitabine Hydrochloride|Given IV
13222|NCT04088188|Drug|Ivosidenib|Given PO
13223|NCT04088188|Drug|Pemigatinib|Given PO
13224|NCT04088175|Other|JUUL ENDS - Virginia Tobacco 5% nicotine strength|JUUL ENDS - Virginia Tobacco 5% nicotine strength
13225|NCT04088175|Other|JUUL ENDS - Virginia Tobacco 3% nicotine strength|JUUL ENDS - Virginia Tobacco 3% nicotine strength
13226|NCT04088175|Other|JUUL ENDS - Menthol 5% nicotine strength|JUUL ENDS - Menthol 5% nicotine strength
13227|NCT04088175|Other|JUUL ENDS - Menthol 3% nicotine strength|JUUL ENDS - Menthol 3% nicotine strength
13228|NCT04088175|Other|JUUL ENDS - Mint 5% nicotine strength|JUUL ENDS - Mint 5% nicotine strength
13229|NCT04088175|Other|JUUL ENDS - Mint 3% nicotine strength|JUUL ENDS - Mint 3% nicotine strength
13230|NCT04088175|Other|JUUL ENDS - Mango 5% nicotine strength|JUUL ENDS - Mango 5% nicotine strength
13231|NCT04088175|Other|JUUL ENDS - Mango 3% nicotine strength|JUUL ENDS - Mango 3% nicotine strength
13232|NCT04088162|Device|Postoperative Negative Pressure Wound Therapy KCI NANOVA|
13233|NCT04088149|Drug|GXNPC1|Autologous ADSCs
13234|NCT04088136|Behavioral|Everyday Metacognitive Memory Intervention|Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.
13235|NCT04088136|Behavioral|Memory Strategy Control Intervention|Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
13236|NCT04088123|Drug|Ticagrelor Oral Tablet [Brilinta]|A single loading dose of ticagrelor (180 mg) will be administered to each participant in this study.
13237|NCT04088110|Drug|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
13238|NCT04088110|Drug|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
13239|NCT04088110|Drug|Aromatase Inhibitors|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
13240|NCT04088097|Behavioral|Cognitive-Behavioral Therapy for Adolescent Binge/Loss-of-Control Eating|Cognitive-behavioral therapy (CBT) developed for adolescents with binge eating or loss-of-control eating.
13241|NCT04088097|Other|Control Condition|Educational and informational materials on adolescent health and nutrition.
13242|NCT04088084|Dietary Supplement|palmitoylethanolamide (PEA) 600 mg|PEA 600 mg was added to topical therapy
13243|NCT04088071|Device|Catheter ablation with novel radiofrequency technologies|PAF ablation RF technologies (e.g., THERMOCOOL SMARTTOUCH®, THERMOCOOL SMARTTOUCH® SF).
13244|NCT04088058|Drug|GXHPC1|autologous ADSCs
13245|NCT04088045|Device|Autologous platelet rich plasma and 5% dextrose solution injections.|"One group of patients will receive autologous platelet rich plasma injection into the knee joint and pes anserinus complex. The other group will receive both PRP injections into the knee joint and pes anserinus complex, and prolotherapy of 5% dextrose solution to the genicular nerves.~Dextrose solutions are injected to the genicular nerves."
13246|NCT04088032|Drug|Abemaciclib, durvalumab and aromatase inhibitor|Subjects will receive standard therapy with an aromatase inhibitor (exemestane, anastrozole, or letrozole), combined with the experimental treatment of abemaciclib and durvalumab
13247|NCT04088019|Drug|Fixed drug combination (FDC) of ATT and Oral steroid|"In the first two week, patients receive FDC of ATT only. Oral steroid start to be given in week three.~The ATT regiment is continued for up to 6 months or more, in accordance with WHO guidelines. In the first two months the antibiotic combination given consisted of isoniazid (INH), rifampicin, pyrazinamide, and ethambutol. The next four months or continuation phases, the ATT given is rifampicin and isoniazid.~The following dosage and administration of oral steroids will be given to patients, according to guidelines from the American Journal of Ophthalmologists (Douglas A. Jabs et al, 2000):~Initial dose: 1mg/kg/day, with maximum adult oral dose 60-80 mg/kg and maintenance dose less than or equal to 10 mg/day. The tapering schedule: Over 40 mg/day, decrease by 10 mg/day every 1-2 weeks, 40-20 mg/day, decrease by 5 mg/day every 1-2 weeks, 20-10 mg/day, decrease by 2.5 mg/day every 1-2 weeks, 10-0 mg/day, decrease by 1 to 2.5 mg/day every 1-4 weeks."
13248|NCT04088006|Device|Injection of STYLAGE® HydroMax|"STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject."
13249|NCT04087993|Drug|Polyglucoferron|intravenous administration
13250|NCT04087993|Drug|Ferric carboxymaltose|intravenous administration
13251|NCT04087993|Drug|Ferrous Sulfate|oral administration
13252|NCT04087980|Device|Poseidon System|Multicenter Pilot Study of the Poseidon System for the Ablation of Prostate Tissue in Patients with Intermediate Risk Localized Prostate Cancer
13253|NCT04087967|Drug|Decitabine plus HAAG regimen|"Decitabine:20mg/m2/d,d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~16,intravenous infusion; Aclarubicin:10mg/d, d3~d10, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-16, subcutaneous injection;~Granulocyte colony-stimulating factor (G-CSF):~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
13254|NCT04087967|Drug|Idarubicine plus Cytarabine regimen|Idarubicine :12mg/m2, d1-3, intravenous infusion; Cytarabine :100mg/m2, d1-7, 24-hours continuous intravenous infusion
13255|NCT04087954|Behavioral|Stigma reduction program|"Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community."
13256|NCT04087941|Biological|VM-202|VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.
13257|NCT04087928|Device|FMV_flex|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to flexor muscles of the upper limb (brachial biceps and carpal flexors).
13258|NCT04087928|Device|FMV_ext|Fisiocomputer EVM (Endomedica, Italy) for application of FMV to extensors muscles of the upper limb (triceps brachial and carpus extensors).
13259|NCT04087915|Drug|Evolocumab|Participants received evolocumab 140 mg Q2W or 420 mg QM subcutaneous injections according to their own preference
13260|NCT04087889|Drug|Hope Biosciences Allogeneic, First Blood Relative Adipose-Derived Mesenchymal Stem Cells|Culture-expanded, adipose-derived mesenchymal stem cells donated by first blood relative
13261|NCT04087876|Drug|derazantinib|derazantinib will be administered orally
13262|NCT04087863|Other|Not applicable(observational study)|Not applicable(observational study)
13263|NCT04087850|Behavioral|Making Socially Accepting Inclusive Classrooms|Using a consultation model, study staff members met with teachers approximately twice per month and observed them an additional two times per month. The goal was to help teachers implement practices that create a socially accepting classroom climate for children.
13264|NCT04087837|Device|bougie|The endotracheal tube is used in the bougie mode under the direct view of the electronic imaging laryngoscope.
13265|NCT04087837|Device|Nasogastric(NG) tube|The endotracheal tube is used in the NG tube mode under the direct view of the electronic imaging laryngoscope.
13266|NCT04087824|Device|AI assisted recognition of colonic segments|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. The whole withdrawal process is monitored by AI associated recognition system. Key colonic segments include ileocecal valve, ascending colon, transverse colon, descending colon, sigmoid colon and rectum. When typical anatomic sites are detected, the AI device will automatically captured relevant images and report the name of each segment on the screen. The operating endoscopy expert will give the final answer and judge the performance of AI, which is set as a golden standard. Then all the AI captured images will be reviewed by human group, which consists of three to five experienced endoscopic physicians.
13267|NCT04087811|Device|Superion® Indirect Decompression System (IDS)|Superion® Indirect Decompression System (IDS) (Superion® implant)
13293|NCT04087577|Other|conventional physical therapy|includes electrical stimulation for denervated muscles, and soft tissue massage, joint range of motion exercises to maintain the flexibility of the affected joint, muscle or connected tissues
13294|NCT04087577|Other|mirror therapy|mirror therapy
13447|NCT04086290|Drug|ADT|six month of neo-adjuvant/concomitant medical castration therapy using a gonadotropin-releasing hormone antagonist or agonist.
13708|NCT04084197|Drug|HIP1402|Tamsulosin (HanmiTams Capsule) 0.4mg
13270|NCT04087772|Behavioral|Mental Health Enhanced Positive Behavioral Interventions and Supports (PBIS-MH)|Mental health-enhanced Positive Behavioral Interventions and Supports (PBIS-MH) integrates mental health into the three core elements of PBIS. 1) School-based mental health clinicians are included on leadership teams. 2) Data from teacher and student perceived school climate, as well as universal screening for aggression and mental health difficulties, are used to inform intervention decision-making. 3) Evidence-based mental health prevention and intervention practices are layered into PBIS' three-tiered continuum.
13271|NCT04087772|Behavioral|Racial/Ethnic Discrimination Interventions (RED)|Racial/Ethnic Discrimination Interventions are a set of components to address multiple forms of school-based racial and ethnic discrimination. 1) Unintentional bias training for school personnel, involving teaching participants to conceptualize prejudice as well as strategies to reduce bias. 2) Unintentional bias training for students that is delivered in a classroom in a developmentally appropriate lesson format. 3) Vulnerable Decision Point process: Leadership teams are trained to reduce disparities in school discipline by a) using disaggregated student discipline data to identify particular settings or practices that are drivers for racial/ethnic disproportionality in a school and b) using iterative problem-solving to address these drivers. 4) Teacher stress reduction training where they are provided with strategies to reduce stress.
13272|NCT04087759|Drug|Bedaquiline (Test formulation)|Participants will receive bedaquiline orally.
13273|NCT04087759|Drug|Bedaquiline (Reference formulation)|Participants will receive bedaquiline orally.
13274|NCT04087746|Drug|Aflibercept|Intra-vitreal injection of AVEGF AFLIBERCEPT in group I
13275|NCT04087746|Drug|Ranibizumab|Intra-vitreal injection of AVEGF Ranibizumab in group 2
13276|NCT04087733|Drug|OZODROP|3 days before the cataract surgery (T0), two conjunctival swabs will be taken from the patients enrolled in the study, one in the eye to be operated and one in the control eye, who will be kept at a controlled temperature (+ 2 / + 7 ° C) and sent to the laboratory within 24 hours. Than, starting on the day of collection, the patients will instill the OZODROP® eye drops in the eye to be used (2 drops 4 times a day, 1 drop every 4 hours: 9:00 am, 1:00 pm, 5:00 pm: 00, h21: 00), while the untreated contralateral eye will serve as a control.Immediately before the cataract surgery (T3), the patients enrolled in the study will again receive two conjunctival swabs, one in the eye to be operated and one in the control eye. The last OZODROP® instillation will be carried out 10 minutes before the withdrawal. For the microbiological evaluation, the conjunctival swabs taken at T0 and T3 will be sent to the Microbiology laboratory
13277|NCT04087720|Biological|Pegloticase|Participants will receive 8 mg pegloticase by IV infusion every 2 weeks from Day 1 through Week 22
13278|NCT04087707|Drug|Step 1: TS-142|Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
13279|NCT04087707|Drug|Step 2: TS-142|Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
13280|NCT04087707|Drug|Step 2: Placebo|Elderly participants will receive placebo once daily for 7 consective days
13281|NCT04087694|Procedure|Microdecompression|comparative surgical treatment
13282|NCT04087668|Procedure|Monitored Anesthesia Care|MAC was induced and maintained via the continuous infusion of propofol AND remifentanil using a target-controlled infusion (TCI) pump. The appropriate level of sedation was 65 to 80 points on BIS. The adjunctive sedatives (eg, fentanyl, midazolam) was at the discretion of the anesthesia team.
13283|NCT04087668|Procedure|General Anesthesia|Induction was done with propofol (2 mg/kg) , cis-atracurium (0.15 mg/kg) , and fentanyl (5μg/kg). After orotracheal intubation, general anesthesia was maintained with sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min) and repetitive doses of 0.1mg atracurium per kilogram were administered. After the procedure was completed, neostigmine mixed with atropine was used as a reversal agent for the neuromuscular blockade, and the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
13284|NCT04087668|Procedure|Induction Without Neuromuscular Blockade|Anaesthesia was induced with propofol (2 mg/kg), remifentanil(3 ug/kg) and 2% lidocaine (1 mg/kg). Nasotracheal intubation was performed 60 s after the administration. After intubation, general anesthesia was sevoflurane (1-1.3MAC) , propofol (3mg/kg/h), remifentanil (0.05-0.2 ug/kg/min). After the procedure was completed, the patient was extubated when the recovery from anesthesia was confirmed.The BIS was 45 to 60 points .
13285|NCT04087655|Behavioral|Exercise|Eight weeks of interval exercise training
13286|NCT04087642|Diagnostic Test|Intraoperative Crede manoeuver|In this group, both tests will be performed but the intraoperative Crede manoeuver will determine if a mid-urethral sling is placed concomitantly. If the test is positive, a sling will be placed. If the test is negative, no sling will be placed.
13287|NCT04087642|Diagnostic Test|Preoperative prolapse reduction cough stress test|In this group, both tests will be performed but the preoperative prolapse reduction cough stress test will determine if a mid-urethral sling is placed concomitantly. If the test is positive, a sling will be placed. If the test is negative, no sling will be placed.
13288|NCT04087629|Device|StrataXRT gel|Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis
13289|NCT04087616|Behavioral|ICBIT|The intervention consists of 9 modules delivered over 9 weeks comprise of age-appropriate texts and descriptive diagrams, animations, films of clinicians demonstrating techniques such as competing response exercising.
13290|NCT04087616|Behavioral|waiting list|Participants initially assigned to the wait list received no psychosocial intervention for 9 weeks. Following post-WL assessment, all participants chose to receive ICBIT.
13291|NCT04087603|Behavioral|Weekend Morning Bright Light & Early Bedtime|
13292|NCT04087590|Drug|Formoterol-glycopyrronium co suspension (PT003)|Formoterol-glycopyrronium co suspension (PT003) in a Metered Dose Inhaler, 2 puffs twice daily
13295|NCT04087564|Other|music intervention|"The music intervention (Unwind), developed by the investigators collaborators at the Sync Project, is a machine learning protocol that generates specific sounds and phrases of music that are stitched into a music track in response to user-reported pain, anxiety and catastrophizing scales. Unwind is delivered via a web application on a smart phone.~Participants will also listen to white noise and their favorite music throughout the study session"
13296|NCT04087551|Other|Developing the list of items for BRFES|The finalized list of items will be discussed by two researchers who will combine similar items generated by the two focus groups to complete the Balance Recovery Falls-Efficacy Scale. The list of items has been developed by a group of community-dwelling older adults who had demonstrated an understanding of near-falls and will be able to articulate the use of balance recovery strategies used in near-fall experiences.
13297|NCT04087538|Diagnostic Test|Troponin T and I|Does the use of troponin T or I increase the number of patients referred to coronary angiography
13298|NCT04087525|Drug|HIP1701|Vildagliptin
13299|NCT04087525|Drug|HGP1809|Vildagliptin
13300|NCT04087512|Other|Training on perturbation treadmill|Perturbations into different directions are induced during static and dynamic tasks on a treadmill. Perturbations include announced and unannounced perturbations. Intensity and number of perturbations increases over the course of the intervention based on judgement of participant. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 30 minutes.
13301|NCT04087512|Other|Exercises of dynamic stability under unstable conditions|The mechanisms of dynamic stability recovery are trained under unstable conditions. Different unstable undergrounds are used to stand on, perform lunges or jumps. Additionally, balance is challenged by different restrictions (e.g. decreased base of support, closed eyes) or therapist-applied perturbations. Intervention duration: 6 weeks, 3 sessions a week, each session approx. 45 minutes.
13302|NCT04087499|Device|Acupuncture|acupuncture treatment on selected acupoint
13303|NCT04087486|Diagnostic Test|Implementation of a behavioural test for patients with TBI|"The following data will be collected: (1) sociodemographic variables (2); clinical and psychological data; (3) functional tests (neuropsychological testing, TEM version CRR and TEM-PRO).~On day one, patients will undergo standard neuropsychological tests and questionnaires listed hereafter, which are commonly used in the clinical practice at the CRR.~The Patient Competency Rating Scale (PCRS)~TEM (Multiple errands test)~GREFEX~5 POINTS TEST~TAP 2.3~Behavioral Assessment of the Dysexecutives Syndrome (BADS)~On day two, the patients will perform the TEM-PRO test ambulatory in our vocation rehabilitation unit.~Predictors variables will be collected before testing: Sociodemographic: age, sex, education, marital status, mother language, time since TBI, severity of the TBI (moderate or severe), type of lesion (contusion, diffuse axonal injury grade 1-3, ischemic or other complications), history of TBI, stroke or meningitis."
13304|NCT04087460|Biological|Protein based pneumococcal vaccine(Low dose)|0.2mL,Intramuscular other name:PBPV
13305|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(Low dose)|0.2mL,Intramuscular other name:PBPV placebo
13306|NCT04087460|Biological|Protein based pneumococcal vaccine(Middle dose)|0.5mL,Intramuscular other name:PBPV
13307|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(Middle dose)|0.5mL,Intramuscular other name:PBPV placebo
13308|NCT04087460|Biological|Protein based pneumococcal vaccine(High dose)|1.0mL,Intramuscular other name:PBPV
13309|NCT04087460|Biological|Protein based pneumococcal vaccine placebo(High dose)|1.0mL,Intramuscular other name:PBPV placebo
13310|NCT04087447|Procedure|Thyroidectomy|Thyroidectomy
13311|NCT04087434|Device|Brain Gauge Prospective and Healthy Control|The Brain Gauge is a brain health assessment system that takes advantage of the well-documented relationship between the sensory nerves in the fingers and the projection of those nerves to corresponding regions in the brain. The system is composed of a test device (the Brain Gauge) that uses novel fingertip vibration patterns to probe cortical complexity and utilize that complexity to gain more sensitive and specific detection of compromised neural function.
13312|NCT04087421|Device|Qufora Irrisedo Cone System|The system works by connecting a tube from a water bag to a cone. The cone is placed into the rectum and the prescribed water volume is pumped into the rectum. When the water has been installed the valve is closed and the cone removed. Residual water and stool will then flow into the toilet.
13313|NCT04087421|Drug|"Glycerol OBA"|Rectal suppository. Stimulates the rectum and softens and loosens stool.
13314|NCT04087408|Drug|Effect of adding gonadotropins releasing hormone agonist to progesterone for luteal phase support in assisted reproductive technique )antagonist cycles(: a randomized controlled trial|"Ovarian stimulation will be initiated from the day 2 of the menstrual cycle using gonadotropins 150-300 IU~doses will be adjusted according to ovarian response. Once the leading follicle will reach a size of 14 mm, co-treatment with a GnRH antagonist will initiated and continued up until at least three follicles reached a size of 17-18 mm.~Trigger will be done using HCG 10000 IU followed by OPU 36 h later.~Retrieved oocytes will be fertilized by ICSI.~LPS, using micronized P (400 mg/day) vaginally beginning on the day of oocyte retrieval.~GnRH agonist 0.1 mg will be given 6 days after OPU for the study group.~Blood sampling will be performed for progesterone within 24 h following the GnRH agonist 0.1 mg~Quantative BHCG will be performed 14 days after OPU."
13315|NCT04087382|Device|thrombectomy|Transfemoral a microcatheter with its distal end was positioned a few millimeters beyond the distal aspect of the clot, the guide wire was exchanged by Solitaire stent device. The device was held in place when 3 mm was out of the microcatheter. The microcatheter was slowly pulled back to deploy the TR or ST device over the clot.
13316|NCT04087382|Other|non intervention group|medical treatment (Asprin, statin, nootropic drug)
13317|NCT04087369|Other|Bundled NCD WHO PEN Intervention|In the intervention includes the planned roll-out of the World Health Organization's Package of essential noncommunicable disease interventions (WHO PEN) for primary care in low resource settings by the Government of Nepal, Ministry of Health and Population. In addition, this intervention will include three evidence-based components: 1) non-communicable disease (NCD) care integration using mid-level practitioners (MLPs) and community healthcare workers (CHWs); 2) clinical decision support (CDS) tools to ensure quality care in accordance with best practices; and 3) training and supervision of MLPs to provide motivational interviewing (MI) techniques for modifiable risk factor optimization, with a specific focus on tobacco and alcohol use.
13318|NCT04087356|Genetic|Blood draw|Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.
13319|NCT04087343|Behavioral|Meals plus exercise|Patients will receive 12 weeks of meals on wheels meal delivery consisting of 3 meals per day during the weekdays with 6 frozen meals to cover the weekends.They will also receive an exercise kit on the first visit by the meal delivery driver with 2 tennis balls,2 1-pound hand weights, and one towel.Every week,the driver will give them 3 exercises from the National Institute on Aging's Go4Life Workout-to-Go book,1 exercise from each of 3 categories:strength/endurance, balance, and flexibility. They will be asked to do the 3 exercises every day.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
13320|NCT04087343|Behavioral|Meals only|Patients will receive 12 weeks of an enhanced meals on wheels (MOW) in-person meal delivery consisting of 3 meals per day (1 shelf-stable, 1 hot, and 1 frozen) during the weekdays (Monday through Friday) with 6 frozen meals at the end of the week to cover the weekends.The meal delivery drivers will ask daily questions about physical activity and any potential injuries and the participants will be asked to track their own weekly exercise and physical activity as well as their monthly progress on a standardized log. All participants will also be asked to wear a fitness activity tracker which will monitor heart rate, activity level, and sleep habits for the duration of the study.
13321|NCT04087330|Other|Group 1 Experimental group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars.~Whole body vibration."
13322|NCT04087330|Other|Group 2 Control group|"Stretching exercises for Achilles tendon, hamstrings, hip flexors and adductors of lower limbs, upper abdominal and pectoralis muscles.~Facilitation of postural reactions, including: facilitation of righting, equilibrium and protective reactions from sitting on ball.~Facilitation of standing and weight shift. Facilitation of standing balance by tilting the child from standing to different directions (forward, back-ward and side-way) using a balance board.~Gait training: by forward, backward, and side-way walking between parallel bars."
13323|NCT04087317|Drug|Paracetamol 500 Mg Oral Tablet|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
13324|NCT04087317|Drug|Ibuprofen 400Mg Tab|The drug will be administrated when the woman arrive to the maternity unit, and every 6 hours thereafter, for first 24 hours following delivery.
13325|NCT04087317|Drug|Paracetamol 500 Mg Oral Tablet|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
13326|NCT04087317|Drug|Ibuprofen 400 mg|The drug will be administrated after a maternal request, by at least 6 hours apart between dosages.
13327|NCT04087304|Behavioral|Risk Status Optimization|Assessment of risk factors putting surgical candidates of total hip and knee arthroplasty at higher risk of complication, and promoting risk factor optimization, thereby decreasing associated risk.
13328|NCT04087291|Other|Chiropractic Care|"Chiropractic interventions:~Patient education.~Passive interventions, such as spinal manipulation and myofascial therapies which include thrust type (high velocity-low amplitude) spinal manipulation for the low back, non-thrust manipulation (joint mobilization), and use of manually held instruments, such as an Activator. Myofascial therapies are also commonly used, such as myofascial release and trigger point therapy.~Transitional interventions, such as therapeutic exercise.~Recommendations for active interventions, such as general exercise and mind-body therapies.~Self-management advice, which refers to advice given to build the capacity of a person to self-monitor, control, and/or reduce the impact of a condition over time."
13329|NCT04087278|Dietary Supplement|Red Raspberry Ellagitannin Extract|Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)
13330|NCT04087278|Dietary Supplement|Matching Placebo|Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
13331|NCT04087265|Diagnostic Test|Transabdominal ultrasound|Transabdominal ultrasound will be performed 30 minutes before colonoscopy
13332|NCT04087252|Biological|tumor neoantigen|tumor neoantigens
13333|NCT04087239|Other|HIV|
13334|NCT04087226|Device|PTFE Retraction Cord|Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal presssure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
13335|NCT04087213|Device|HemoCare™ Hemodialysis System|The HemoCare™ Hemodialysis System is intended for hemodialysis treatment, including short daily and nocturnal hemodialysis, of renal failure patients. The HemoCare™ Hemodialysis System is intended for use in chronic dialysis facilities, self‐care dialysis facilities, or the home setting. All treatments must be prescribed by a physician and administered by a trained operator. Treatments must be performed under the supervision or assistance of a medical professional or a care partner who has been trained and deemed competent in the use of the device by the prescribing physician.
13336|NCT04087187|Drug|Treatment A|Subject will be given AZD5718 Dose A tablet once daily
13337|NCT04087187|Drug|Treatment B|Subjects will be given AZD5718 Dose B tablet once daily
13338|NCT04087187|Drug|Treatment C|Subjects will be given AZD5718 Dose C tablet once daily
13342|NCT04087161|Other|Nephrocheck bed side testing of AKI|Usage of Nephrocheck system to assess AKI after open TAAA repair
13343|NCT04087135|Other|direct laryngoscopy|Participants will intubate the hemoptysis cadaver model in simulation with direct laryngoscopy MacIntosh blade.
13344|NCT04087135|Other|videolaryngoscopy McGrath|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade)
13404|NCT04086602|Drug|IZD334|Active Drug
13405|NCT04086602|Drug|Placebos|Placebo to Match
13345|NCT04087135|Other|videolaryngoscopy McGrath with suction|Participants will intubate the hemoptysis cadaver model in simulation with videolaryngoscopy using McGrath and the short curved blade (XBlade) and a suction they will advanced directly before the optic of the camera.
13346|NCT04087122|Device|Esophageal warming device (Attune Medical, Chicago, IL|Prospective, single center pilot stud
13347|NCT04087109|Other|Electronic decision support for deprescribing (MedSafer tool)|During the intervention phase, MedSafer will provide users with individualized and prioritized deprescribing opportunities: a) identifying the medication, b) explaining why that medication is potentially inappropriate and c) providing instructions on how to safely stop/taper the medication. The user will review these opportunities and appropriate candidate medications for deprescribing can then be tapered or stopped directly in the EMR. Patients or proxy will also receive educational medications brochures (EMPOWER) from the research assistant or staff at the nursing home, as applicable to the medications they are taking (PPI, sedative-hypnotic, antipsychotic, antihistamine, sulfonylurea, NSAID, opioid/narcotic).
13348|NCT04087096|Drug|Denosumab|Denosumab will be administered at postoperative months 1, 7, and 13
13349|NCT04087096|Drug|Placebo|Placebo will be administered at postoperative months 1, 7, and 13
13350|NCT04087083|Other|Technological intervention arm|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic training (G-EO system, Reha Technology, Switzerland), an end-effector technology that simulates floor walking and stairs climbing (up and down)
13351|NCT04087083|Other|Control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
13352|NCT04087070|Device|Biosignal measurements|"Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~PAT(time between R peak of ECG and beginning of the pulse of PPG)~PEP(time between R peak of ECG and peak of accelerometer signal)~PTT(PAT-PEP)"
13353|NCT04087057|Other|Interview|Participate in interview
13354|NCT04087057|Other|Medical Chart Review|Patients' medical records are reviewed
13355|NCT04087057|Behavioral|Questionnaire|Complete questionnaires
13356|NCT04087044|Device|Computerized Rotational Head Impulse Test ( crHIT)-Vertical|"Oculo-Motility and Positional Testing,~Caloric Testing"
13357|NCT04087031|Other|control arm|Each session will include 50 minutes of traditional physical rehabilitation therapy
13358|NCT04087031|Other|virtual reality games|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Tymo system (Tyromotion, Austria), a wireless static and dynamic platform, for evaluating and rehabilitating posture.
13359|NCT04087031|Other|robotic treadmill|Each session will include 30 minutes of traditional physical rehabilitation therapy followed by 20 minutes of robotic Walker View (TecnoBody, Italy) a treadmill equipped with a sensorized belt with eight load cells and a 3D camera
13360|NCT04087018|Drug|AB122|AB122 is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1. Participants in each cohort will receive AB122 intravenously Q3W. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for which investigational product discontinuation occurs.
13361|NCT04087005|Other|hominis placental pharmacopuncture|Hominis placental pharmacopuncture is human placental extract, which has been used in traditional Korean medicine to treat chronic diseases, including frailty, cough, anorexia, and fatigue, by enhancing the body's resistance.
13362|NCT04086992|Other|Remote monitoring|Caregivers will be able to monitor blood pressure and blood glucose from home and upload in a cloud-based application on a hand-held tablet. In addition, this technology will administer surveys to the caregiver to assess for therapy side effects and adherence. Nurse-led telemedicine visits will also be utilized. The healthcare team will be able to monitor these parameters remotely.
13363|NCT04086979|Behavioral|Parental Friendship Coaching|In this condition, therapists instructed parents in ways to coach their children to display better friendship behaviors using skills teaching, role play, active practice, and homework. This is a 10 week group intervention.
13364|NCT04086979|Behavioral|Coping with ADHD through Relationships and Education|In this condition, the therapist provided parents with psychoeducation about ADHD and friendship difficulties, and encouraged them to apply this information to their child and to support one another with tips about how to address these problems. This is a 10 week group intervention.
13365|NCT04086966|Diagnostic Test|[68Ga]PSMA-PET/MRI or PET/CT|[68Ga]PSMA-PET/MRI or PET/CT
13366|NCT04086953|Diagnostic Test|6-minute walk test|This test is carried out in a 30-meter long walking corridor with two cones placed at the ends of the course and representing the turning zones
13367|NCT04086953|Diagnostic Test|Walk-Time Limit Tes|Endurance test where the patient must walk at the same speed during the whole test (time limit). The test is carried out in a corridor 10 meter long.
13368|NCT04086953|Diagnostic Test|Incremental shuttle walk test|Incremental walking test suitable for patients with chronic respiratory diseases. To perform this test, it is necessary to have a 10-meter walking corridor. The walking speed is dictated by a sound signal previously recorded. Every minute, the time between each beep is decreased and therefore the walking speed increased. The increment is 0.17m / sec every minute. Shifting to a higher speed is indicated by a triple beep. At most, the ISWT includes 12 speed levels.
13369|NCT04086953|Diagnostic Test|Endurance shuttle walk test|"Constant load endurance running test performed on the same 10 meter run as the ISWT.~The patient is walking at a constant speed imposed by the audio beeps as for the ISWT. The objective of this test is to maintain the imposed walking speed as long as possible. The speed is calculated from the ISWT."
13370|NCT04086953|Diagnostic Test|Respiratory Functional Assessment|Forced vital capacity, total lung capacity, forced expiratory volume measured during the first second of forced expiration, and carbon monoxide diffusion capacity will be measured by plethysmographic examination and spirometry.
13371|NCT04086940|Drug|Esmolol|preventive
13372|NCT04086927|Device|Unna Boot|The unna boot is a zinc coated compression dressing
13373|NCT04086914|Procedure|Nerve Block|This group will receive a nerve block consisting of 20mL of 5mg/mL ropivicanine and 0.1mL of 10mg'mL dexamethasone.
13406|NCT04086589|Other|Observational study without intervention|Observational study without intervention
13709|NCT04084197|Drug|HIP1801|Tamsulosin 0.4mg
13374|NCT04086901|Radiation|Radiotherapy dose escalation|Flour-Deoxy-Glucose /Positron Emissions Tomografi (FDG-PET) scans will be used to identify and delineate the tumour sub-volumes with the highest tracer uptake to guide the dose-escalation. The dose to the Gross tumor volume (GTV) will be escalated to a high dose while clinical target volume (CTV) and planning target volume (PTV) will be treated with standard dose.
13375|NCT04086875|Behavioral|Focus Group|Participate in focus group
13376|NCT04086875|Other|Text Message|Receive text messages
13377|NCT04086875|Other|Best Practice|Receive usual care
13378|NCT04086875|Other|Questionnaire Administration|Ancillary studies
13379|NCT04086862|Procedure|Therapeutic ultrasound|A commercially available ultrasound machine will provide 5 minutes of ultrasound at 0.4 watt/cm^2 and 100% duty cycle sequentially to each masseter muscle.
13380|NCT04086849|Diagnostic Test|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
13381|NCT04086836|Device|TAVR|Patient recieving a TAVR
13382|NCT04086823|Drug|RZL-012|Subcutaneous injection to the submental fat area
13383|NCT04086823|Drug|Placebo|Placebo
13384|NCT04086810|Drug|DCCR|Once daily oral administration
13385|NCT04086797|Dietary Supplement|IQP-AE-103|1980 mg
13386|NCT04086797|Dietary Supplement|Placebo|Placebo
13387|NCT04086771|Behavioral|Navigation|Weekly phone-calls, personal messages, and American Cancer Society Pap test and mammography test reminder post card
13388|NCT04086771|Other|Information only|American Cancer Society breast and cervical cancer screening information and Pap test and mammography test reminder post card
13389|NCT04086758|Drug|zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion
13390|NCT04086745|Drug|Baricitinib|Administered orally.
13391|NCT04086745|Drug|TNF Inhibitor|Administered SC
13392|NCT04086732|Procedure|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be milliampere. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
13395|NCT04086706|Procedure|Retroflexion in the Right Colon|Prospective evaluation of an every day technique (retroflexion) used in our department for many years. The protocol of ascending colon examination encompassed 2 phases: A first phase (1) divided in Forward view (1a) videlicet insertion from the right flexure to the caecum followed by a second forward view (1b) namely withdrawal till the right flexure and reinsertion to the caecum maintaining the endoscope straight and a second phase (2, Retroflexion) with U-turn of the colonoscope in the caecum till the right flexure and then redressing to the forward view and reinsertion to the caecum.
13396|NCT04086693|Device|Standard IV dressing|Polyurethane and clear tape dressing used to secure peripheral IV
13397|NCT04086693|Device|Standard IV dressing plus a tissue adhesive peripheral IV securement device|Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
13398|NCT04086667|Other|Spinal manipulation|Spinal manipulation: The patient is placed in the side-position and a standard manipulation lumbar-roll technique will be applied at the indicated segment dependent on the subgroup indication.
13399|NCT04086654|Diagnostic Test|International Trauma Interview (ITI) for ICD-11 PTSD and Complex PTSD - German version|The ITI consists of 18 items and for each symptom, standardized questions as well as probes are presented. A trained professional rates both symptom frequency and intensity, which are converted into an overall index of symptom severity. A diagnosis of PTSD/CPTSD is established by applying the ICD-11 diagnostic rules. It takes approximately 30-60 minutes to administer.
13400|NCT04086641|Device|Crossover foot|A prosthetic foot that features an extended strut (keel) that attaches to the posterior proximal aspect of the prosthetic socket.
13401|NCT04086641|Device|Energy Storing Foot|A prosthetic foot that features a short strut (keel) that attaches to the distal aspect of the prosthetic socket.
13407|NCT04086576|Device|Smartphone-paired mobile breathalyzer|All subjects will first be given a priming dose of alcohol containing vodka designed to raise the blood alcohol content based on weight and gender. Blood alcohol content will first be measured with three commercial smartphone-paired breathalyzers: Drivesafe Evoc, Alcohoot, and BacTrack Pro which will be tested in a randomized order and recorded. Participants' blood alcohol content will also be measured using the Intoxilyzer 240, a police grade breathalyzer device. After the tertiary dose of alcohol, a nurse will perform a blood draw on the participants, which will be used to determine blood alcohol content.
13408|NCT04086563|Other|Action observation|look at a clip of a hand doing neurodynamic exercises.
13409|NCT04086563|Other|Mirror therapy|With a mirror glasses on, do the neurodynamic exercises with the non-dominant hand while the patient is looking at the dominant hand
13410|NCT04086563|Other|Neurodynamic exercises|active movement of the dominant hand. Do neurodynamic exercises.
13411|NCT04086563|Other|Strength|Execute a short strength training for the dominant hand
13412|NCT04086550|Device|LIQOSEAL|Adjunctive bioresorbable patch
13413|NCT04086550|Device|DuraSeal, Adherus|synthetic absorbable sealants
13414|NCT04086537|Diagnostic Test|hepcidin levels and BMPR2 expression|Samples will be collected in the three groups. Hepcidin levels will be measured in serum using ELISA and BMPR2 expression will be assessed as previously described using real time-qPCR
13415|NCT04086524|Other|Binocular cartoon treatment at home|see arm description.
13416|NCT04086524|Other|Patching|see arm description
13417|NCT04086524|Other|Binocular cartoon treatment in office|see arm description.
13418|NCT04086498|Other|Mediterranean diet|The group received a plan for a isocaloric Mediterranean Diet
13419|NCT04086498|Other|KEMEPHY|The group received a plan for a ketogenic mediterranean with herbal extracts diet
13420|NCT04086498|Other|KD|The group received a plan for a low carbohydrate ketogenic diet
13425|NCT04086472|Biological|MK-1654|Single dose of MK-1654 administered via IV infusion.
13426|NCT04086472|Other|Placebo|Placebo (0.9% sodium chloride, USP sterile saline) administered via IV infusion.
13427|NCT04086472|Biological|RSV-A Memphis 37b|Approximately 4Log10 plaque-forming units (PFU)/mL RSV-A virus inoculation strain Memphis 37b administered via intranasal inoculation.
13428|NCT04086459|Device|Repetitive transcranial magnetic stimulation|Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)
13429|NCT04086446|Device|high-definition transcranial direct current stimulation|The tDCS device will deliver a direct current of 1.5mA during 20 minutes. Cathode electrode will be localized in front of the right OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8)
13430|NCT04086446|Device|Sham tDCS|The same procedure will be applied except that the tDCS device will only deliver a current stimulation for the first and last 15 seconds.
13431|NCT04086433|Device|gastric tissue resection|human stomach specimens will be resected with the surgical staplers for pressure testing and staple malformation assessment
13432|NCT04086420|Behavioral|Mindfulness|Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
13433|NCT04086420|Behavioral|Heart-Rate|Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
13434|NCT04086407|Device|Dual-axis inclinometer attached to the subject's forehead with tape|This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
13435|NCT04086394|Procedure|Pectoral Nerve Block|Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block
13436|NCT04086394|Procedure|Surgery without Nerve Block|Patient's underwent indicated procedure without regional pectoralis nerve block
13437|NCT04086381|Dietary Supplement|Creatine monohydrate|5 grams of creatine monohydrate, four times daily, for 9 consecutive days.
13438|NCT04086368|Device|Adolescent Lateral Entry Femoral Nail|The use of an less invasive implant that has the same accuracy.
13439|NCT04086368|Device|Pediatric LCP Hip Plate System|Open approach to the femur where the osteotomy and osteofixation with plate and screws are preformed
13440|NCT04086355|Other|oromotor exercises and neuromuscular electrical stimulations|treatment study group with occupational exercises and electrical stimulation
13441|NCT04086342|Drug|CHI-902|A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
13442|NCT04086342|Drug|Placebo|Placebo is a vehicle oil that will match CHI-902.
13443|NCT04086329|Device|Nanosensor|"The purpose of the study is to test a device called a nanosensor, which measures oxygen levels (a proxy of mitochondrial function) in muscle. The nanosensor has not been tested in humans nor has it been approved by the FDA.~The study nanosensor measures 1.8 mm width x 6 mm length x 0.3 mm depth. Placement of the sterilized nanosensor involves a small incision for manual placement of the nanosensor in muscle forearm tissue."
13444|NCT04086303|Other|LSST test|LSST test: Scapular mobility testing Upper Extremity test: Upper extremity agility and endurance testing Y Balance test: Balance and Coordination testing Sit and Reach Test: Assessment of flexibility
13445|NCT04086290|Procedure|RARP|Radical prostatectomy + extended pelvic lymph node dissection
13448|NCT04086277|Procedure|Continuous Intrapartum Support|Received the usual obstetric care plus continuous intrapartum support that was provided by a Bachelor of Nursing and Obstetrics who received prior training by a professional doula.
13449|NCT04086264|Drug|Azacitidine|IMGN632 in combination with azacitidine
13450|NCT04086264|Drug|IMGN632|IMGN632 in combination with azacitidine
13451|NCT04086264|Drug|Venetoclax|IMGN632 in combination with venetoclax
13452|NCT04086251|Other|Gaido|Patients will participate for up to 21 days. Over the course of the study, 25-100 patients will be enrolled.
13453|NCT04086238|Drug|Decitabine|Capsules containing a combination of decitabine and THU
13454|NCT04086212|Drug|Icodextrin, xylitol and carnitine solution for peritoneal dialysis|Patients will receive a long dwell exchange for three days.
13455|NCT04086212|Drug|EXTRANEAL 7.5G/100Ml Peritoneal Dialysis Solution|Patients will receive a long dwell exchange for three days.
13456|NCT04086199|Procedure|Lumbar discectomy|Lumbar discectomy either by an anterior extraperitoneal approach or by a posterior midline approach.
13457|NCT04086186|Procedure|Liposomal Bupivacaine Peri-articular Injection|A 20mL solution of 266mg of liposomal bupivacaine (Exparel) was mixed with 40mL of normal saline, which was then infiltrated consistently in the posterior capsule, medial and lateral side of the arthrotomy, patella tendon, quadriceps tendon, quadriceps musculature, and subcutaneous soft tissue.
13458|NCT04086186|Procedure|Adductor canal block|Anesthesiologist performs preoperative adductor canal block using 15mL of 0.5% Bupivacaine HCl
13459|NCT04086173|Dietary Supplement|Probiotics|Probiotics will be administered at night and will consist of 4 capsules
13460|NCT04086173|Other|Placebo|Placebo
13461|NCT04086160|Device|Transcranial direct current stimulation device (Soterix Medical, New York, NY)|Transcranial direct current stimulation (tDCS) is a non-invasive intervention, which applies low-amplitude direct electric currents to the brain through scalp electrodes. The real (2mA) or sham tDCS intervention will be given for a total of eight sessions in four weeks with 20 minutes per session.
13462|NCT04086147|Drug|Low dose tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
13463|NCT04086147|Drug|High dose tenecteplase|Intravenous (IV) tenecteplase 0.32 mg/kg (single bolus; maximum dose 32 mg)
13464|NCT04086134|Other|Fruit Products|Fruit Products with the potential to improve constipation-related outcomes
13466|NCT04086108|Dietary Supplement|Tomato|A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
13467|NCT04086108|Dietary Supplement|GABA supplement|1 gram of GABA dissolved in water.
13468|NCT04086108|Dietary Supplement|Glutamate supplement|A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
13469|NCT04086095|Device|Neofact application aid|The Neofact application aid is a specifically for the LISA procedure designed guide of a soft catheter and replaces the Magill forceps. Catheter (3.5 Fr.) and guide are already combined and packed together sterile. The catheter tip is marked in black (1cm).
13470|NCT04086082|Device|Markerless Image Guidance|Single arm trial using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging
13471|NCT04086069|Device|Sit-to-stand trainer|The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
13472|NCT04086056|Other|NIRS monitoring|Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
13473|NCT04086043|Device|Endovascular Denervation|multi-electrode catheter-based endovascular denervation
13474|NCT04086030|Other|Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program including blood flow restriction training. Exercises will be performed with BFR at 80% LOP.
13475|NCT04086030|Other|Sham Blood Flow Restriction Training|Patients will undergo standardized postoperative rehabilitation program where exercises will be performed with sham BFR pressure of 20 mmHG.
13476|NCT04086017|Other|Reiki therapy|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the caregivers how to perform a simple 10-minute Reiki and self-Reiki session.
13477|NCT04086004|Other|Group I Experimental Motor Imagery|The experimental group will receive dual task balance training for 30 minutes/day with additional mental imagery for 10 minutes/day, three days/week, for a period of eight weeks
13478|NCT04086004|Other|Dual task training|group will receive dual task balance training for 40 minutes for three days/ week for eight weeks
13479|NCT04085991|Drug|131I-PSMA-1095 Radioligand Therapy (RLT)|Intravenous injection of 100 mCi of 131I-PSMA-1095, Q8 weeks up to a maximum of 4 doses.
13480|NCT04085965|Behavioral|Boys and Girls Club summer day camp|Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
13481|NCT04085952|Procedure|dermal graft (ARCUS repliform) for anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with dermal graft augmentation
13482|NCT04085952|Procedure|suture based anterior colporrhaphy|At the time of surgery patients were randomized to anterior colporrhaphy with a suture based repair
13483|NCT04085939|Other|Online survey|Anonymous survey using the online survey tool, JotForm
13484|NCT04085926|Device|Sealed therapeutic shoe|Off-the-shelf therapeutic shoe and custom-made insole
13485|NCT04085926|Device|Total contact cast|Custom-made total contact cast
13486|NCT04085913|Drug|Lidocaine Epinephrine|Preincision injection, as is current practice
13487|NCT04085913|Drug|Bupivacaine Hydrochloride-EPINEPHrine|Preincision injection
13637|NCT04084691|Other|Physical exercice - high intensity|standardized physical activity (high intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
13488|NCT04085913|Drug|Lidocaine Epinephrine, Bupivacaine Hydrochloride-EPINEPHrine|Preincison injection of lidocaine and epinephrine and a postincision injection of Exparel
13489|NCT04085887|Drug|Panitumumab-IRDye800|Panitumumab-IRDye800 is an imaging agent prepared as a drug-dye compound from panitumumab (Vectibix), a fully-humanized IgG2 monoclonal anti-epidermal growth factor receptor (EGFR) antibody, and IRDye800CW dye. Panitumumab-IRDye800 delivered intravenous (IV).
13490|NCT04085887|Device|Pinpoint-IR9000 endoscopic/handheld device|"Novadaq intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
13491|NCT04085887|Device|Explorer Air camera|"Surgvision intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
13492|NCT04085887|Device|PDE-NEO-II|"Hamamatsu Photonics KK intraoperative camera. Imaging will be performed on subjects during both during surgery (in vivo) and/or on the resected tissues while at the back table in the surgery suite (ex-vivo)."
13493|NCT04085874|Behavioral|Promotion of Food-based recommendations|Prolonged contact through weekly home visits and monthly group meeting for 12 weeks
13494|NCT04085874|Behavioral|Nutrition counseling from standard health services care|once nutrition counselling from health services
13495|NCT04085861|Behavioral|Mental health literacy in dancers|Receive a designed informative intervention (3 workshops of 90min each) aimed at improving their knowledge and skills on proper recovery, performance nutrition, and mental health literacy.
13496|NCT04085861|Behavioral|Mental health literacy in dance teachers|Receive a designed informative intervention (3 workshops of 60min each) aimed at improving their knowledge and skills on how to identify and deal with mental health- and nutritional issues in dancers.
13497|NCT04085848|Other|music therapy|4 music therapy sessions during a period of time of 48 hours. Each session lasts 30 minutes.
13498|NCT04085822|Device|SMA-001|Intra-dermal injection of SMA-001 and control device.
13499|NCT04085809|Other|AmLactin® Rapid Relief|AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
13500|NCT04085796|Other|ICCI|Intentional Compassionate Communication Intervention
13501|NCT04085783|Procedure|PRP|Platelet Rich Plasma
13502|NCT04085770|Drug|Alfacalcidol 1 MCG Oral Capsule|2 mcg of oral Bone Care© soft gelatin capsules once daily with food starting from the day of admission till the end of hospital stay
13503|NCT04085757|Drug|long interval dinoprostone|A small envelope including two labeled plastic bags (A & B) (each bag containing either 1 dinoprostone tablet(3mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In long interval dinoprostone group, bag (A) contains dinoprostone tablet and bag (B) contains placebo tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 10 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
13504|NCT04085757|Drug|short interval dinoprostone|A small envelope including two labeled plastic bags (A& B) (each bag containing either 1 dinoprostone tablet(3 mg) or 1 identically appearing placebo tablet) will be packaged in sequentially numbered sealed envelopes. In short interval dinoprostone group, bag (A) contains placebo tablet and bag (B) contains dinoprostone tablet. After signing the informed consent, the sequentially numbered sealed envelopes will be opened (according to the sequence of attendance of the patient) by the study nurse. Tablets in bag (A) will be inserted 10 hours before office hysteroscopy and tablets in bag (B) will be inserted 3 hours before office hysteroscopy.
13505|NCT04085744|Drug|Lidocaine 10% Spray|lidocaine will be apply on the cuff
13506|NCT04085744|Drug|Mometasone nasal spray|mometasone spray will be applied on the cuff
13507|NCT04085731|Procedure|Catheter ablation|Driver-guided catheter ablation of persistent atrial fibrillation
13508|NCT04085705|Diagnostic Test|PATCH test|The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
13509|NCT04085692|Behavioral|Low-Dose, High-Frequency Simulation-Based Training|"Twelve weeks of LDHF training~The simulation-based training sessions take place at the EMDC, at extra workstations set-up as ordinary EMD workstations in an out-of-the-way area. Before each session, the EMD is informed about the simulation call and receives instructions concerning technical differences from a regular call. The instructor acts as a standardised caller, guided by a computer program. This program, the Danish version of Resuscitation Quality Improvement for Telecommunicators (Laerdal Medical AS, Stavanger, Norway), is a training program for DA-CPR based on the simulation platform Laerdal Learning Application. This modified version of the RQI-T program has, one test scenario, one data collection scenario and six different cardiac arrests scenarios as well as a feedback checklist based on the Danish dispatcher protocol Danish Index for Emergency Care.~Each simulation session takes approximately 20 minutes, including introduction and feedback"
13510|NCT04085679|Other|Multidisciplinary Mobile Unit (MMU)|MMU is called in case of urgent clinical situations involving patients residing in nursing home
13511|NCT04085666|Drug|CDX 6114|CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.
13512|NCT04085666|Other|Matching Placebo|The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
13513|NCT04085653|Drug|alpelisib|"Alpelisib will be provided as 50 mg and 200 mg film coated tablets as individual patient supply and will be dosed on a flat scale of mg/day.~In Adult patients, alpelisib will be administered at a starting dose of 250 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this treatment plan.~In Pediatric patients, alpelisib will be administered at a starting dose of 50 mg orally once daily on a continuous dosing schedule and can be interrupted for toxicity per the recommendations in this treatment plan; no dose reductions are allowed."
13638|NCT04084691|Other|Physical exercice - workout|standardized physical activity (bodybuilding) lasting 30 minutes and having a warm-up portion of 5 minutes
13514|NCT04085640|Other|Obturator nerve block with ropivacaine 0.2%.|20 milliliters of ropivacaine 2 mg/mL will be injected in the interfacial plane between the pectineus and external obturator muscles.
13515|NCT04085640|Other|Obturator nerve block with isotonic saline|20 milliliters of isotonic saline will be injected in the interfacial plane between the pectineus and external obturator muscles.
13516|NCT04085627|Drug|Valsartan and Amlodipine Tablets|1 tablet contains Valsartan 80mg& Amlodipine 5mg
13517|NCT04085614|Device|PCI with Dynamic Coronary Roadmap|Standard of care PCI with Dynamic Coronary Roadmap
13518|NCT04085614|Device|PCI without Dynamic Coronary Roadmap|Standard of care PCI without Dynamic Coronary Roadmap
13519|NCT04085601|Drug|APL-2|Complement (C3) Inhibitor
13520|NCT04085575|Drug|Acide Tranexamique|Recruited patients were randomly before the operation by generating random numbers with Microsoft Excel 2007. They were assigned in two groups: 1 g of intra-articular tranexamic acid (TXA) and 2 g of intra-articular tranexamic acid.
13521|NCT04085562|Drug|Bisoprolol Fumarate 5-10 mg|Bisoprolol as antihypertensive drug in patients on hemodialysis
13522|NCT04085562|Drug|Amlodipine 5-10 mg|Amlodipine as antihypertensive drug in patients on hemodialysis
13523|NCT04085549|Device|Berry Oil Cream|Cream containing berry and plant oils and humectants; a medical device product in development
13524|NCT04085549|Other|Reference Cream|Commercial refence cream not containing berry and plant oils.
13525|NCT04085536|Procedure|Dental and medical treatment|If the dental cause of sinusitis is objective, if necessary, dental treatment combined with medical treatment will be carried out.
13526|NCT04085523|Drug|TransCon CNP|TransCon CNP drug product is a lyophilized powder in a single-use vial containing either TransCon CNP 3.9 mg CNP-38/vial or TransCon CNP 0.80 mg CNP-38/vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
13527|NCT04085523|Drug|Placebo for TransCon CNP|The placebo for TransCon CNP contains the same excipients as TransCon CNP drug product but does not contain TransCon CNP. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
13528|NCT04085510|Device|Contrast-enhanced mammogram|Contrast-enhanced mammography (CEM) is a new FDA-approved exam that is similar to magnetic resonance imaging (MRI) in depicting breast cancers due to increased and leaky blood vessels. Contrast-enhanced mammography is used as an adjunct following mammography and/or ultrasound examinations to localize a known or suspected lesion.
13529|NCT04085497|Other|Treatment|KT application: KT application includes 2 stages. The banding in the first step is directed to the patellar tendon in order to absorb the load of the knee. The second step is directed directly on the medial plica to benefit from its analgesic effect. For the first step, an I-band is measured from the top of the patella to the tuberositas tibia. I-band is 6 cm wide and 5 mm thick. This I-band is cut into Y-band. First, the part of the band above the patella is pasted with 10% tension. Then the patient's knee is flexed to maximum flexion and the tails of the band are pasted around the patella with 0% tension. The tails of the band are combined together on the tuberositas and completed. For the second step, 4 I-bands 8 cm long and 1.5 cm wide are prepared. The middle of the I-bands is attached to the medial plica with a 0% tension, giving a star shape.
13530|NCT04085484|Dietary Supplement|More concentrated parenteral nutrition solution|This study is a single-center retrospective observational study comparing two cohorts of very low birth weight (VLBW, birth weight < 1500 grams) infants who received parenteral nutrition (PN) either before or after a concentrated PN regime was implemented into clinical use. Both PN regimes were based on standardized PN solutions.
13531|NCT04085471|Diagnostic Test|CTHRC1 biomarker level in rheumatoid arthritis|measurment of levels of CTHRC1 in patients diagnosed as RA
13532|NCT04085458|Drug|Damoctocog alfa pegol (Jivi, BAY94-9027)|The recommended starting dose is every 5 days treatment (45 IU/kg)- An assessment of response to treatment will be performed at the next scheduled visit after 10-15 ED (8-10 weeks). Participants may be assigned to different dosing regimens (every 7 days or 2x/week) or continue with every 5 days regimen, according to individual bleeding tendency and needs at investigator's discretion.
13533|NCT04085445|Device|AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter|To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
13534|NCT04085432|Other|Self administered questionnaire and Clinical evaluation|Self administered questionnaire and clinical evaluation
13535|NCT04085419|Drug|Denosumab 60 MG/ML Prefilled Syringe [Prolia]|denosumab 60 mg subcutaneously every 6 months
13536|NCT04085419|Drug|Zoledronic Acid|zoledronic acid 5 mg intravenously once a year
13537|NCT04085406|Device|Deep Brain Stimulation of the Subgenus Cingulate Cortex|The Abbott Infinity DBS device will be surgically implanted in the bilateral subgenual cingulate cortex to provide electrical stimulation to this region.
13538|NCT04085393|Drug|GRANISETRON EXTENDED RELEASE INJECTION (GERSC)|GERSC is a new, subcutaneously (SC) administered polymeric formulation of granisetron that was developed to provide slow, controlled, and sustained release of granisetron to prevent both acute and delayed CINV associated with MEC and HEC. Due to the prolonged efficacy, GERSC may potentially improve CINV in the acute and delayed periods and the single dose regimen may improve patient adherence to antiemetic therapy
13539|NCT04085367|Drug|MAL 16.8% cream|Two treatments of DL-PDT
13540|NCT04085354|Drug|Multi-Vitamin Tablets|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse.
13541|NCT04085354|Drug|Dapoxetine|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 2 was given on-demand 30 mg dapoxetine 1-2 h before intercourse.
13542|NCT04085354|Drug|Dapoxetine and folic acid.|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 3 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg folic acid.
13576|NCT04085133|Diagnostic Test|Gene Xpert Chest x ray and MSCT chest|Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis
13543|NCT04085354|Drug|Dapoxetine and vitamin B12|The distribution of the patients among the four groups was based on randomized coded cards, so the patients were unaware of the type of the drugs used. Group 1 was given placebo in form oral multivitamin tablet 1 h before intercourse. Group 4 was given on-demand 30 mg dapoxetine 1-2 h before intercourse and daily oral supplementation of 0.5 mg vitamin B12
13544|NCT04085341|Drug|GB-102|Intravitreal injection of GB-102
13545|NCT04085315|Drug|Osimertinib|Osimertinib is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Patients will be receiving full dose osimertinib (80 mg PO daily) as part of the patient's current standard of care.
13546|NCT04085315|Drug|Alisertib|Alisertib is an orally available selective aurora A kinase inhibitor. Alisertib will be administered to eligible patients in combination with osimertinib at doses ranging from 20 mg to 50 mg PO twice daily on days 1-3, 8-10, and 15-17 of a 28-day cycle. The starting alisertib dose for Cohort 1 will be 30 mg twice daily (dose level 1).
13547|NCT04085302|Behavioral|Digital Behaviour Change Intervention|14 days
13550|NCT04085276|Drug|JS001|JS001 240mg, i.v., q3w; Other name: Toripalimab
13551|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
13552|NCT04085276|Drug|Placebo|Placebo, i.v., q3w;
13553|NCT04085276|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m2, i.v., d1, d8, q3w
13554|NCT04085263|Procedure|Control group|The patients in this group will receive sham rhomboid intercostal and subserratus plane.
13555|NCT04085263|Procedure|Rhomboid intercostal and subserratus plane block group|The patients in this group will be receive real ultrasound-guided rhomboid intercostal and subserratus plane.
13556|NCT04085250|Other|Neoadjuvant therapy|The neoadjuvant therapy before radiotherapy comprised of Docetaxel 75 mg/m2 for 1 hour + Cisplatin 75 mg/m2+Nivolumab 360 mg, once every 3 weeks (Q3W), for a total of 2 cycles.
13557|NCT04085250|Other|Chemotherapy concurrent with radiotherapy|Docetaxel 25 mg/m2for 1 hour +Cisplatin 25 mg/m2, once a week (QW), for a total of 4 weeks.
13558|NCT04085250|Radiation|Radiotherapy|Simultaneousintegrated boost intensity-modulated radiation therapy(SIB-IMRT) technique was used to deliver a definitive radiation dose
13559|NCT04085250|Drug|Nivolumab|Nivolumab consolidation (480 mg) via iv infusion once every 4 weeks (Q4W)±3 days after the neoadjuvant therapy and concurrent chemo-radiotherapy. Administration of nivolumab will commence on Day 1 following randomisation to Nivolumab after confirmation of eligibility and will continue on a Q4W schedule for a maximum duration of 12 months.
13560|NCT04085250|Other|Observation|Observation after the neoadjuvant therapy and concurrent chemo-radiotherapy.
13561|NCT04085237|Drug|Ropivacaine injection|30ml of 0.375% ropivacaine with 5mcg/ml of epinephrine will be injected into the fascial plane on the anterior spinae muscle.
13562|NCT04085237|Other|Sham|Saline will be used at the same amounts as the ropivacaine arm.
13563|NCT04085224|Drug|Somatropin|LG Somatropin
13564|NCT04085198|Procedure|Light physics enhanced 'no-touch' hysteroscopy|The light source used in hysteroscopy provides an illumined environment during the imagination with these techniques. During hysteroscopy, the light reflecting from the adjacent tissue appears bright, however, this reflection is weaker in farther tissue and these structures appear dark. This information will be used in determining the route from the vaginal introitus to the uterine cavity during the hysteroscopy.
13565|NCT04085198|Procedure|Standard hysteroscopy|Anatomical structures as illumined by the light source of the camera will be used to find the route from the vaginal introitus to the uterine cavity
13566|NCT04085185|Drug|IBI110|Several dose levels will be evaluated for IBI110 administered as a single agent and in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent IBI110 may receive combination treatment with IBI110 plus Sintilimab. Combination treatment may continue until disease progression or loss of clinical benefit.
13567|NCT04085185|Drug|IBI110|IBI110 will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.
13568|NCT04085185|Drug|IBI110+ Sintilimab|"IBI110: Several dose levels will be evaluated for IBI110 in combination with Sintilimab. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
13569|NCT04085185|Drug|IBI110+ Sintilimab|"IBI110: IBI110 in combination with Sintilimab will be given with RP2D. IBI110 will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit.~Sintilimab: Sintilimab will be given as 200 mg via IV infusion on Day 1 of each 21-day cycle in combination with IBI110. Combination treatment may continue until disease progression or loss of clinical benefit."
13570|NCT04085172|Drug|Guanfacine hydrochloride (SPD503)|In both Part A and Part B of the study participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg SPD503 oral tablets once daily for 52 weeks.
13571|NCT04085172|Drug|Atomoxetine hydrochloride|Participants in Part A of the study will receive Atomoxetine hydrochloride oral capsule once daily for 52 weeks.
13572|NCT04085172|Other|Placebo|In Part A participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to SPD503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks.
13573|NCT04085159|Biological|Antigen-specific T cells CART/CTL and DCvac|Antigen-specific T cells CART/CTL and DCvac cells to treat cancer
13574|NCT04085146|Procedure|Individualized optimal positive end-expiratory pressure|Optimal PEEP will be determined by the automated procedure of step-wised decrease in the amount of PEEP of the anesthesia ventilator Aisys Care Station (GE Healthcare, Madison, Wisconsin, USA).
13575|NCT04085146|Procedure|Conventional positive end-expiratory pressure|A same amount of PEEP of 7 centimeter hydrogen dioxide will be provided during the laparoscopic period of surgery.
13675|NCT04084444|Drug|Placebo|Blank control.
13577|NCT04085120|Procedure|0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Distal glossopharyngeal nerve in the neck will be blocked by using 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection
13578|NCT04085120|Procedure|10% lignocaine injection|Distal glossopharyngeal nerve in the neck will be blocked by using 10% lignocaine injection
13579|NCT04085107|Behavioral|Face-to-face interviews|243 PwMCI will receive two face-to-face interviews to complete two sets of questionnaires, of which 30 participants will be recruited attend a 1-hour semi-structured interview.
13580|NCT04085094|Dietary Supplement|high-salt diet (V1) and low salt diet (V2)|Before the first visit, the participant will follow a five-day high salt diet (addition of 6g/day of salt to their regular diet followed at home). Before the second visit (V2), the participant will follow for five days a low-salt diet, according to dietary instructions followed provided during the screening visit.
13581|NCT04085094|Diagnostic Test|Contrast-enhanced ultrasound (CEUS)|Renal ultrasound with use of a contrast product (SonoVue®), perfusion rate 0.015ml/kg/min. Four destruction-reperfusion sequences are performed in order to measure the Perfusion Index (PI) of the renal cortex.
13582|NCT04085094|Diagnostic Test|functional MRI|Measurement of renal oxygenation with the Blood Oxygenation Level Dependant-MRI technique (BOLD-MRI) on Siemens Prisma 3T scanner before and 15minutes after 0.03mg/kg of IV furosemide. Assessment of the amount of salt stored in the skin and muscles with the 23Na MRI technique.
13583|NCT04085094|Other|Pilocarpine test|Assessment of sweat salt and potassium concentrations in healthy volunteers according to slat intake. Two electrodes are placed on the forearm. The electric current between the two electrodes will induce perspiration which will be collected with the Macroduct system.
13584|NCT04085081|Other|E-mail|Receive brief motivational text or email messages
13585|NCT04085081|Behavioral|Exercise Intervention|Receive personalized walking program plus strength exercises
13586|NCT04085081|Other|Quality-of-Life Assessment|Ancillary studies
13587|NCT04085081|Other|Questionnaire Administration|Ancillary studies
13588|NCT04085081|Behavioral|Telephone-Based Intervention|Receive intervention coaching sessions via telephone
13589|NCT04085081|Other|Text Message|Receive brief motivational text or email messages
13590|NCT04085068|Other|cranioscaral treatment|dural release
13591|NCT04085055|Diagnostic Test|Solid pancreatic mass lesion biopsy|The needle will be used to puncture the lesion and remove a piece of tissue from the mass for histological diagnosis.
13592|NCT04085042|Device|PIVC pack|The PIVC pack is a sterile container that includes inside all the need devices to perform peripheral catheterization. The pack is color-coded to inform healthcare professionals about the catheter caliber inside.
13593|NCT04085016|Device|Keratograph 5M, Oculus, Wetzlar, Germany|
13594|NCT04085003|Procedure|Endovascular repair or Open surgery|The outcomes of different types of repair will be obtained for intact and ruptured abdominal aortic aneurysm
13595|NCT04084990|Device|S9 VPAP Adapt|Auto-titrated positive airway pressure
13596|NCT04084977|Diagnostic Test|Antibody detection|detecting anti bodies against D1, D2 receptor, tubolin Lysoganglioside
13597|NCT04084964|Other|Home-hospitalisation platform for heart failure|The primary objective of the INTERREG NWE-Chance project is the development of an integrated home-hospitalisation platform and the assessment of the feasibility of a home hospitalisation strategy for heart failure patients.
13598|NCT04084951|Biological|SQZ-PBMC-HPV|antigen presenting cell therapy; therapeutic vaccine consisting of autologous peripheral blood mononuclear cells (PBMCs) presenting immunogenic epitopes of the E6 and E7 proteins of HPV16
13599|NCT04084951|Drug|Atezolizumab|programmed cell death ligand 1 (PD-L1) blocking antibody
13600|NCT04084938|Procedure|Prostate operation or prostate artery embolization|As described above.
13601|NCT04084912|Drug|Dexamethasone Sodium Phosphate|intravenous injection of one ampoule dexamethasone Sodium phosphate 2 ml 8 mg
13602|NCT04084912|Drug|Saline Solution|intravenous injection of one ampoule saline
13603|NCT04084899|Device|Continuous Positive Airway Pressure therapy|Standard treatment with continuous positive airway pressure
13604|NCT04084873|Behavioral|PBrE|PbRE is a word reading task implementing through an App developed for smartphones. The patient will choose emotional positive and negative words related to personal and clinical characteristics.
13605|NCT04084873|Behavioral|PBrE-Control|Participants are exposed to several neutral words. These words do not have any emotional content and there are no reasons to think that they have any effect over the emotional regulation.
13606|NCT04084873|Behavioral|Control|Participants do not receive the intervention.
13607|NCT04084860|Drug|CI-581a|CI-581a during weeks 1 and 6 at 0.71 mg/kg
13608|NCT04084860|Drug|CI-581b|CI-581b during weeks 1 and 6 at 0.0125 mg/kg
13609|NCT04084860|Behavioral|MBRP|MBRP will help with maintaining use reduction/abstinence.In this trial, 3 sessions will occur in the first 2 weeks following the second infusion (weeks 6 and 7), while one session a week will be administered in the latter 5 weeks (weeks 8 through 12).
13610|NCT04084860|Behavioral|MET|MET may help with goal setting and enhancing engagement with MBRP. In this trial, a standard 5-week MET platform will be provided to individuals randomized to receive behavioral treatment, with an additional session after each infusion (7 sessions total).
13611|NCT04084847|Dietary Supplement|berberis vulgaris=barberry|10 grams of barberry powder will be consumed daily for 8 weeks.
13612|NCT04084847|Dietary Supplement|Placebo|Placebo powder
13613|NCT04084834|Other|Exercise|Participants will be offered to take part in a 5-hour Learning and Mastery-course at Diakonhjemmet Hospital, receiving information about the osteoarthritis disease, symptoms and the importance of exercise and physical activity. Participants will then be given a weekly web-based exercise program (12 weeks) consisting of three aerobic exercise sessions per week. The exercise program consists of five levels, and the participants will each week be guided to the most appropriate level based on their measured physical fitness level and the weekly exercise diary. The participants will at initial assessment at Diakonhjemmet Hospital be instructed to use Borgs scale to adjust exercise level. Based on the weekly exercise diary the participants will also get motivational messages by email.
13614|NCT04084821|Other|none - observation only|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
13710|NCT04084184|Drug|HGP1812|Dapagliflozin (Forxiga) 10mg
13615|NCT04084808|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 1 liter of the experimental solution, spread over the 45 minutes of exercise. A first ingestion of 167 mL of solution will be made at rest, right before starting warmup, and another dose (167 mL) after it. Four additional doses of 167 mL will be ingested immediately after the first four 3-minute bouts at 95% of Maximal Aerobic Power. A final dose (167 mL) will be ingested after the last effort.
13616|NCT04084808|Behavioral|Cognitive flexibility|"Subjects will be required to undergo the Stroop task. They will have to answer as quickly as possible, with push buttons, to a colour stimulus, following specific rules, and get the highest possible number of right answers. The flexibility block will show a pre-signal on a screen in front of the subject (a square or a cross will be shown). The form presented will indicate if the subject must use the colour of the writing, or the word written. Each block will consist of 50 trials, 25% of which switching the condition of answer. During this test, reaction time in milliseconds (ms) as well as the number of right answers will be measured.~This test will be measured before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise."
13617|NCT04084808|Procedure|Brain oxygenation|"Optic imagery (Near-infrared spectroscopy, or NIRS) is a non-invasive technique allowing a fine investigation of the inner workings of the brain. It allows discrimination of oxygenated hemoglobin from deoxygenated hemoglobin, which informs on the coupling between blood flow and oxygen consumption inside the brain. To measure brain oxygenation with NIRS, optodes will be installed on the subject's skin without glue or transmission gel.~[ Time Frame: During Stroop's task (i.e.before the exercise protocol, during the 3-minutes exercise bouts, and every 15 minutes during the 45 minutes following exercise). ] Measured with near-infrared spectroscopy (NIRS)."
13618|NCT04084808|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
13619|NCT04084808|Procedure|Blood glucose|Blood glucose will be measured with a puncture on the tip of a finger to get a droplet of blood.
13620|NCT04084808|Behavioral|Perceived exertion|Perceived exertion will be assessed using 3 scales : Borg (RPE), and DP-15 scale for mental effort (Delignières, Brisswalter, & Legros, 1994). These scales will be administrated at the end of each 3 minute high intensity bout.
13621|NCT04084808|Behavioral|High Intensity Interval Training bouts|6 3-minute bouts at 95% of maximal aerobic power will be done on a bike. Each bout will be separated by 3 minutes of passive recovery. The last bout will be followed by 45 minutes of rest.
13622|NCT04084795|Behavioral|Eye Movement Desensitization and Reprocessing therapy|"EMDR is a psychotherapeutic approach using a standardized 8-phase protocol to alleviate the distress associated with traumatic memories, facilitating the access to and processing of traumatic memories. Patients will receive 20 individual EMDR sessions of 60 minutes each using the standard protocol, as well as a specific pain protocol and the fibromyalgia protocol. EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history. Patient preparation. Patient assessment. Memory desensitization. Installing the positive cognition. Body scan. Closure. Reevaluation."
13623|NCT04084795|Other|Transcranial Direct Current Stimulation|tDCS represents a promising intervention option, given its capacity to modulate cerebral excitability in a simple, safe manner. We will use a multifocal transcranial direct current stimulation (MtDCS) montage (AF3 anodal, Fp1, AF7, F5, F3, F1, AFz return), intended to target the right dlPFC. Half of the patients will receive active stimulation and the other half sham stimulation. Active stimulation will consist of 1mA MtDCS for 20 minutes applied immediately before EMDR sessions. The same protocol and montage will be used for sham stimulation.
13624|NCT04084782|Device|Fungal Nail Treatment Kit|The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
13625|NCT04084769|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
13626|NCT04084769|Biological|Meningococcal Group B Vaccine (Trumenba®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
13627|NCT04084769|Biological|Meningococcal group B Vaccine (Bexsero®)|Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: Intramuscular
13628|NCT04084756|Behavioral|Couples Crisis Response Plan|The CCRP is a single session therapist-facilitated suicide prevention intervention conducted with a dyad
13629|NCT04084756|Behavioral|Mental Health Education|The Mental Health Education session is a single session therapist-facilitated mental health psychoeducation session conducted with a dyad
13630|NCT04084743|Other|Virtual reality intervention|Virtual reality intervention includes: Maze game software
13631|NCT04084743|Other|Dual task intervention|The intervention combined both motor and cognitive training which includes, walking 10 meter (1) Free walking (2) Walking carrying an emptying tray (3) Walking carrying a tray with 4 empty glasses (4) Digit calculations (Counting forward and backward, addition, subtraction, multiplication and division) during walking.
13632|NCT04084743|Other|Conventional physiotherapy|"Gait training in parallel bar~Balance activities which includes, a. Forward direction activity b. Backward direction activity c. Sideways direction activity"
13633|NCT04084730|Radiation|Accelerated Partial Breast Irradiation|Treatment will consist of APBI delivered using external beam RT techniques to a dose of 24 Gy in 3 fractions of 8.0 Gy delivered on consecutive weekdays
13634|NCT04084717|Drug|Crizotinib|"Crizotinib is an orally administered, chemotherapy drug that works by blocking ALK, MET and ROS1 receptor tyrosine kinases from working.~Participants will receive crizotinib, orally (by mouth), at a dose of 250 mg, twice per day, every day of each 28 day cycle."
13635|NCT04084704|Device|Cingal|Cingal will be administered by fellowship-trained physicians through ultrasound-guided injection using a 22-gauge needle into the joint space of the hip under sterile conditions. The needle track will be anesthetized with local anesthetic.
13636|NCT04084691|Other|Physical exercice - moderate intensity|standardized physical activity (moderate intensity) lasting 30 minutes and having a warm-up portion of 5 minutes
13711|NCT04084184|Drug|HGP1602|Dapagliflozin 10mg
13639|NCT04084691|Other|Normal meal|- Hyperlipidic meal Energy supply: 800 kcal Distribution of macronutrients: proteins: 15% +/- 5; carbohydrates: 40% +/- 5; lipids: 45 +/- 5 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market The same meal will be taken before the 3 sessions concerned.
13640|NCT04084691|Other|Normalized meal|"- Hyperglucidic meal Energy supply: 800 kcal Macronutrient distribution: protein 15% +/- 5; carbohydrates 60% +/- 5; lipids 25 +/- 2 Choice of foods determined with the dietician taking into account the patient's tastes and products available on the market.~The same meal will be taken before the 3 sessions concerned."
13641|NCT04084691|Other|Fasting|non meal in the hour before exercise
13642|NCT04084678|Drug|Ralinepag|Oral ralinepag
13643|NCT04084678|Drug|Placebo|Matching oral tablets
13644|NCT04084665|Drug|Guselkumab|Guselkumab
13645|NCT04084652|Dietary Supplement|Mycoprotein ingestion|The ingestion of mycoprotein
13646|NCT04084639|Dietary Supplement|Mycoprotein Ingestion|Ingestion of various doses of mycoprotein compared to placebo control
13647|NCT04084626|Drug|PD1 antibody|2mg/kg ivgtt on day 1
13648|NCT04084626|Drug|lenalidomide|5mg orally twice a day（age<18years) ,day 1-14; 10mg orally twice a day(age>=18years), day 1-14.
13649|NCT04084600|Other|Kinesiotherapy Protocol|Kinesiotherapy Protocol is an specific exercise based treatment designed to strengthening, gaining range of motion and stretching the muscles.
13650|NCT04084600|Other|Manual Therapy Protocol|Manual therapy protocol: is a manual treatment intended to the release of fascias and soft tissues.
13651|NCT04084600|Other|Traditional Massage|Traditional Massage is a gentle and superficial massage.
13652|NCT04084587|Device|Retimax Vision Trainer|The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
13653|NCT04084574|Behavioral|DASH diet counseling|Culturally-appropriate, disease-sensitive counseling intervention to enhance DASH diet adherence in Blacks with CKD compared to standard of care condition
13654|NCT04084561|Behavioral|HRHA|participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (~90%).
13655|NCT04084561|Behavioral|LRLA|participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (~10%).
13656|NCT04084561|Behavioral|HRLA|"participants will receive High Risk, Low Ancestry (HRLA) hypothetical"
13657|NCT04084561|Behavioral|LRHA|"participants will receive Low Risk, High Ancestry (HRLA) hypothetical"
13658|NCT04084548|Drug|Lidocaine and ketamine|Perioperative lidocaine and ketamine infusion (see below for dosages and timings)
13659|NCT04084548|Drug|Lidocaine|Perioperative lidocaine infusion (1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
13660|NCT04084548|Drug|Ketamine|Perioperative ketamine infusion (0.5 mg/kg bolus followed by an infusion of 0.3 mg/kg/hour based on actual body weight; the bolus and infusion will be started after anesthesia induction and before surgical incision, and continued until 1 hour after transfer from the operating room to the PACU)
13661|NCT04084548|Drug|Placebo|Perioperative placebo infusion (normal saline)
13662|NCT04084535|Other|High intensity interval training|Participants will perform 3 HIIT sessions per week, involving 10 min of intense exercise within a time commitment of 30 min per session, including warm-up, recovery between intervals and cool down.
13663|NCT04084535|Other|Inspiratory muscle training|Participants will perform 3 inspiratory resistance training sessions per week, involving 30 min per session, including warm-up, recovery between intervals
13664|NCT04084522|Dietary Supplement|Saturated Fat- Desi Ghee (Clarified Butter)|Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.
13665|NCT04084522|Dietary Supplement|Soyabean Oil|Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
13666|NCT04084496|Drug|Folfirinox|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
13667|NCT04084483|Drug|K-161|K-161 alternate dosage
13668|NCT04084483|Other|Placebo (Vehicle)|Placebo solution
13669|NCT04084470|Dietary Supplement|Different types of bread|Three-arm randomized cross-over study. All subjects start with a run-in period of 3 days, thereafter they will receive two different types of bread in a randomized order for 3 consecutive days, with a wash-out period of 11 days in between. After each period, biological samples will be collected.
13670|NCT04084457|Dietary Supplement|Wild Blueberry powder|Powdered extract obtained from wild blueberries. A daily administration of 27g wild blueberry powder will be administered.
13671|NCT04084457|Dietary Supplement|Placebo|Identical formulation as the treatment matched for fibre and vitamin C
13672|NCT04084444|Drug|T8 tablet 0.25mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
13673|NCT04084444|Drug|T8 tablet 0.5mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
13674|NCT04084444|Drug|T8 tablet 1mg|Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
13678|NCT04084418|Other|Control Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Control diet, the diet will provide 50% of energy from CHO, 15% from protein, and 35% from lipids. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
13679|NCT04084418|Other|VLCHF Diet|Participants will be provided with a two-week menu to be consumed 3 times for each intervention, for a total of 6 weeks per intervention. For the Experimental diet, the diet will provide 10% of energy from CHO, 15% from protein, and 75% from lipids. During the Experimental diet, participants will be provided with a multivitamin to reduce risk of deficiencies due to restrictions on fruits and grain products. Menu will be adapted to the participant's food preferences and usual caloric intake by a dietitian. Participants will be asked to limit their alcohol intake in both interventions. During this phase, participants will also have to wear a pedometer and use the Pezio: Achieve the Guidelines! mobile application to help the research assistant track their daily steps remotely.
13680|NCT04084405|Other|Pulmonary rehabilitation|The experimental group receives inspiratory muscle training and aerobic exercise. The Active Comparator group received only aerobic exercise.
13685|NCT04084353|Other|Intrapartum fetal monitoring training and quality improvement project|Intrapartum fetal monitoring training
13686|NCT04084340|Procedure|Real transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Real transcranial direct current stimulation associated with therapeutic exercises for urinary incontinence~tDCS: 20 minutes, 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
13687|NCT04084340|Procedure|Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence|"Sham transcranial direct current stimulation + therapeutic exercises for urinary incontinence~tDCS: 20 minutes (30 seconds ON), 2mA, motor supplementary area anode and supraorbital cathode (ipsilateral to the dominant lower limb).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
13688|NCT04084327|Other|stastical analysis|1-Clinical examination data-Complete Blood Count (CBC).Bone Marrow Aspiration (BMA)-Bone Marrow Biopsy (BMB). (if available)-Immunophenotyping results (IPT).Cytogenetic results
13689|NCT04084314|Biological|Erenumab|pre-filled pen (auto-injector)
13690|NCT04084301|Procedure|High CPB flow|Target CPB flow 2.9 L/min/m2 throughout the CPB period
13691|NCT04084288|Device|Acupuncture|Ipsilateral Auricular Trauma Protocol (ATP) acupuncture at eight ear points (Hypothalamus, Amygdala, Hippocampus, Prefrontal Cortex, Point Zero, Shen Men, Insula, Vagus) with 30Hz electrostimulation at two of those points (Shen Men and Hypothalamus). Acupuncture needles will be left in place and stimulated for 60 min and then removed
13692|NCT04084275|Behavioral|breastfeeding education|
13693|NCT04084275|Behavioral|personal hygiene education|In this training, the puerpera was informed about personal hygiene to prevent infection.
13694|NCT04084275|Behavioral|nutrition education|In this training, the amount of nutrients that breastfeeding women should take daily was explained.
13695|NCT04084275|Behavioral|fatigue education|In this training, suggestions were made to prevent the negative effects of fatigue
13696|NCT04084275|Behavioral|sleep education|In this training, suggestions were offered the puerperants for better sleep. Strategies to improve sleep quality were explained.
13697|NCT04084275|Behavioral|pilates exercises education|In this study, pilates exercises exclusively for postpartum women were selected from two reference books, Fitness Professional's Handbook and Guide Women's and Fitness Health, which include 13 movements: Bridging, Hundred, Roll Up, One Leg Circle (both ways), Rocker with close legs,Single Straight Leg Stretch, Double Leg Stretch, Spine Stretch Forward, Single Leg Kick, Side Kick up and down, Side Kick circles, Rest position (stretch and relaxation) and Curling. The trainings were provided by the investigator during home visits to the puerpera in the intervention group and the pilates exercises by the investigator who was also a pilates trainer. An appropriate setting was prepared at the homes of puerpera so that they could do the pilates exercises easily.
13698|NCT04084262|Device|Intramedullary Nail|Subjects undergo a Lapidus Arthrodesis procedure combined with a supinating reduction technique to create a multi-plane correction of hallux valgus
13699|NCT04084249|Diagnostic Test|ctDNA-analysis|Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
13700|NCT04084249|Other|Intensified Follow-up Schedule|PET/CT-scans every 3. month
13701|NCT04084236|Device|electrical stimulation|electrical stimulation
13702|NCT04084236|Device|Sham|no stimulation
13703|NCT04084223|Other|Ultrasound|"An Ultrasound exam (not performed in routine care) will be performed at Baseline, 1, 3 and 6 months for protocol.~All patients will also have CRP dosage (for DAS28 assessment), RAPID-3 and PROs (performed in routine care but analyzed for the study)."
13704|NCT04084210|Device|JUUL Electronic cigarette|The JUUL e-cigarette pods contain 0.7 ml nicotine by volume / 5% nicotine by weight.
13705|NCT04084210|Other|Very Low Nicotine Cigarettes|These very low nicotine cigarettes (VLNCs) consist of reduced nicotine cigarettes containing 0.03 mg of nicotine; these VLNCs were obtained from NIDA's Drug Supply Program (NOT-DA-14-004).
13706|NCT04084210|Drug|Active Nicotine Patch|Active nicotine patches, with dosing based on the package insert (>10 cigs/day = 21 mg patch and <11 cigs/day = 14 mg patches).
13712|NCT04084158|Drug|Triprizumab|Triprizumab (JS001) is a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks the interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies.
13713|NCT04084158|Drug|Paclitaxel, Albumin-Bound|Paclitaxel
13714|NCT04084158|Radiation|Radiotherapy|PTV 50.4Gy/28 fractions, PGTV 61.6Gy/28 fractions, once a day, 5 days a week.
13715|NCT04084158|Drug|Platinum-Based Drug|carboplatin
13716|NCT04084132|Procedure|Pulmonary valve replacement|Surgical implantation of an adult-sized (≥ 18 mm) homograft or Contegra graft as right ventricle-to-pulmonary artery conduit under cardiopulmonary bypass through a sternotomy.
13717|NCT04084119|Other|hypopressive abdominal exercise|Participants will perform an hypopressive abdominal exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
13718|NCT04084119|Other|general strengthening exercise|Participants will perform a general strengthening exercise program consisting of 18 sessions (6 weeks), 3 times a week, 30 minutes each session.
13719|NCT04084106|Drug|Phenoxymethylpenicillin|Oral administration
13720|NCT04084106|Drug|Amoxicillin|Oral administration
13721|NCT04084106|Drug|Amoxicillin-clavulanic acid|Oral administration
13722|NCT04084093|Device|Surfactant Gel|This device is helps in the creation of an optimal moist wound healing environment that aids in protecting healthy tissues and provides an environment conductive to autolytic debridement. The device is 100% water-soluble, biocompatible, and non-ionic. The dressing is a surfactant based gel.
13723|NCT04084080|Biological|Red Blood Cell|Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of <20% and a pre-transfusion hemoglobin S of <30%.
13724|NCT04084080|Other|Standard of care|NHLBI Expert Panel-recommended guidelines for sickle cell disease
13725|NCT04084067|Drug|Indocyanine Green|IV
13726|NCT04084054|Diagnostic Test|Ultrasound|Ultrasonic measurement of the optic nerve sheath diameter
13727|NCT04084041|Device|Simeox|Airway clearance device
13728|NCT04084041|Other|CCPT|Conventional chest physiotherapy
13729|NCT04084028|Behavioral|Active Cooking + Meal Kits + Recipes|6 cooking classes will be held every week for 6 consecutive weeks. The lessons are patterned after Dr. Amy Trubek's cooking pedagogy and will be tailored for those cooking for themselves for the first time. Classes begin with a brief lecture on the day's topic. Students will work in teams of 2 in the foods lab to actively practice skills and cook a meal. Students receive recipes and information sheets that cover pantry supplies, grocery lists, knife skills and cooking equipment. All students attend a 2 hour kitchen intensive demonstration as an orientation. After 6 weeks students receive 6 weeks of meal kits followed by 6 weeks of recipes.
13730|NCT04084028|Behavioral|Active cooking|Students receive the same cooking intervention and kitchen intensive orientation as described in the Active cooking + meal kits + recipes. However, once the 6 weeks of the cooking class have ended, there is no further intervention.
13731|NCT04084028|Behavioral|Demonstration class + Meal Kits + Recipes|"Students receive the Kitchen Intensive orientation as described previously. The demonstration condition will serve as an attention only control. Previous research suggests that demonstrations of cooking have little to no impact on cooking behavior, therefore, cooking demonstrations can be used to even out the time and attention devoted to the active cooking participants without introducing bias into the study design. Subjects in the demonstration condition will also begin with a brief lecture on the day's lesson followed by a cooking demonstration that covers the same topics as the active intervention group. All students will receive the same printed information and also have an opportunity to sample the prepared food at the end of class. The demonstrations will be led by the same chef as the active intervention group.~Following 6 weeks of demonstration classes, students will receive meal kits, then recipes as describe in the Active Cooking + meal kits + recipes arm."
13732|NCT04084028|Behavioral|Demonstration Classes|"The demonstration condition is the same as described in the demonstration class + meal kits + recipes, except that there will be no further intervention after the 6 weekly classes of cooking demonstrations.~Kitchen Intensive. As part of the orientation process, participants will attend a 2-hour kitchen intensive demonstration. This demonstration will introduce participants to the kitchen lab space and cover basic kitchen skills including food safety, sanitation, equipment overview, and the basic principles of food agency. The Kitchen Intensive is the same for all arms."
13733|NCT04084015|Device|Axillary Impella®|All enrolled patients will undergo surgical placement of Impella® via axillary artery within 48 hours after peripheral VA ECMO initiation and be managed with early extubation and ambulation strategy
13734|NCT04084002|Other|physical activity measurement|Physical activity will be measured via accelerometer and self reported questionnaire (Physical activity scale for elderly)
13735|NCT04083989|Other|Integrative medicine-based multimodal treatment|Multimodal inpatient treatment program based on anthroposophic medicine, including individual and group psychotherapy, family therapy, art therapies and specific nursing applications such as embrocations, rhythmical massage and oil dispersion baths.
13736|NCT04083976|Drug|Erdafitinib|Participants will receive erdafitinib oral tablets.
13737|NCT04083963|Drug|Carboplatin|Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
13738|NCT04083963|Drug|Paclitaxel|Paclitaxel will be given weekly along with carboplatin for 12 weeks.
13739|NCT04083963|Drug|Doxorubicin|Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.
13740|NCT04083963|Drug|Cyclophosphamide|Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
13741|NCT04083950|Biological|Vivotif Typhoid Oral Vaccine|One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.
13742|NCT04083950|Drug|Aspirin (Positive Control)|Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.
13743|NCT04083937|Radiation|Hypofractionated radiotherapy with photons|hypofractionated radiotherapy with photons (total dose 57.0 Gray in 19 fractions)
13744|NCT04083937|Radiation|Hypofractionated radiotherapy with protons|hypofractionated radiotherapy with protons (total dose 57.0 Gray relative biological effectiveness (RBE) in 19 fractions)
13745|NCT04083937|Radiation|Normofractionated radiotherapy with photons|normofractionated radiotherapy with photons (total dose 70.0 Gray in 35 fractions)
13746|NCT04083924|Other|Basic cardiac ultrasound training with Butterfly iQ handheld ultrasound|Pre-training online module of the American society of Echocardiography and hands-on training of basic cardiac ultrasound with Butterfly iQ handheld ultrasound.
13747|NCT04083911|Drug|Decitabine, Homoharringtonine, Aclarubicin, Cytarabine and G-CSF|"Decitabine:20mg/m2/d, d1~5, intravenous infusion; Homoharringtonine:1mg/d,d3~9,intravenous infusion; Aclarubicin:10mg/d, d3~d6, intravenous infusion; Cytarabine:10mg/m2,q12h,d3-9, subcutaneous injection;~Granulocyte colony-stimulating factor:~50-300μg/d (when WBC counts are less than 20×10^9/L ),subcutaneous injection;"
13748|NCT04083898|Biological|Isatuximab|Isatuximab will be administered on a 28-day cycle
13749|NCT04083898|Drug|Bendamustine|Bendamustine will be administered on a 28-day cycle as follows
13750|NCT04083898|Drug|Prednisone|Prednisone will be administered on a 28-day cycle as follows
13751|NCT04083885|Other|Virtual Reality|Participants will be provided with a virtual reality training program, personalized with respect to their abilities, endurance, needs and treatment goals. They will be trained to use the program and it will be installed in their home or provided at their long-term care facility. Participants will be suggested to perform VR 3-5 times a week. Sessions will be 20-30 minutes long, depending on tolerance.
13752|NCT04083872|Drug|Reference drug|D744 Cap. 1 Cap., single oral administration under fasting condition
13753|NCT04083872|Drug|Test drug|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fasting condition
13754|NCT04083859|Other|mPATH-Lung|A web-based program that determines patients eligibility for lung cancer screening (LCS), informs them of LCS, presents them with personalized risk-benefit information, helps them make a screening decision, and helps them schedule a LCS clinic appointment.
13755|NCT04083859|Other|Lung health video|Web-based video about guideline recommended exercise for lung health
13756|NCT04083846|Drug|Reference drug|D744 Cap. 1 Cap., single oral administration under fed condition
13757|NCT04083846|Drug|Test drug 1|CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
13758|NCT04083846|Drug|Test drug 2|CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
13759|NCT04083833|Drug|Tetrodotoxin|A single TTX dose in a dose ascending study
13760|NCT04083833|Drug|Placebos|matching placebo comparator
13761|NCT04083820|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
13762|NCT04083807|Biological|TISSEEL Lyo|The dose to be applied is governed by variables including the type of surgical intervention, the size of the affected area and the mode of intended application, and the number of applications.. The guideline for sealing surfaces is one package of Tisseel Lyo 2 ml (i.e. 1 ml sealer protein solution plus 1 ml thrombin solution) is sufficient for a surface of at least 10 cm2.
13763|NCT04083807|Procedure|Manual compression with surgical gauze pads|Surgical 4x4 inches gauze pads
13764|NCT04083794|Other|Laboratory based assessments|physical maneuvers to assess physiological responses in bone blood flow
13766|NCT04083768|Device|15° and 30° wedge sponges|After the spinal anesthesia is completed, the wedge sponge is placed between the patient's pelvis and ribs and the wedge is removed before the skin is cut.
13767|NCT04083755|Drug|Ferric Carboxymaltose Injection [Injectafer]|1000mg intravenous
13768|NCT04083755|Other|no treatment or oral iron supplementation|No treatment or treatment oral with iron supplementation if iron-deficiency anemia
13769|NCT04083729|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
13772|NCT04083703|Procedure|Interbody cage insertion in lumbar disc prolapse|Discectomy alone versus interbody cage insertion in treatment of lumbar disc proapse
13773|NCT04083690|Device|Reprogramming of CRT Device Settings to Optimal Electrical Synchrony|Reprogramming of CRT device to maximize the benefit based on the ECG CRT optimization information.
13774|NCT04083677|Device|SONAR|A curved low- frequency (2-5 MHZ) probe and (simens ACUSON x 300) ultrasound system will be used. All patient will be first scanned in the supine position, followed by the right lateral decubitus (RLD) position. The gastric antrum was identified in a sagittal scanning plane in the epigastrium immediately inferior to xiphoid and superior to umbilicus. The liver anteriorly and the aorta, inferior vena cava and pancreas posteriorly were used as anatomical reference points.
13775|NCT04083664|Diagnostic Test|NGAL and Hepcidin|Both NGAL and hepcidin are elevated inchronic kidney disease,not only through iron metabolism, but both are also associated with inflammationand may be related to anemia
13776|NCT04083651|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide will be administered per dose and schedule specified in the respective arm.
13777|NCT04083651|Drug|Placebo|Placebo matching to methylnaltrexone bromide will be administered as mentioned in the respective arm.
13778|NCT04083638|Diagnostic Test|IFAB|Intestinal Fatty Acid Binding Protein will be taken from all participants before the tx and after the tx
13779|NCT04083625|Drug|carbetocin 100 mcg|a 10 cm syringe containing 100 mcg carbetocin given IV 30 min prior to myomectomy
13780|NCT04083625|Drug|placebo|a 10 cm syringe normal saline IV given 30 min before myomectomy
13781|NCT04083612|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of ixekizumab
13782|NCT04083612|Other|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L questionnaires at each study visit.
16973|NCT04057456|Drug|High CBD Capsules|See arms description
13783|NCT04083599|Biological|GEN1042|GEN1042 will be administered intravenously every 21 days. The dose level will be determined by the starting dose and escalation steps in the trial.
13784|NCT04083586|Other|All investigations; laboratory and radiological, needed for diagnosis|mri brain, ct brain, drug screening
13785|NCT04083573|Other|application of medical augmented reality glasses|Endoscopic images from medical monitor and medical augmented reality glasses will be collected and reviewed. Outcomes from both series of images will be compared
13786|NCT04083560|Drug|Vit B12|Vitamin B12 250mcg
13787|NCT04083547|Diagnostic Test|iCellate|New method of circulating tumour cell detection and capture.
13788|NCT04083534|Drug|REGN5459|Administered by intravenous (IV) infusion
13789|NCT04083521|Dietary Supplement|Bacillus subtilis DE111®|Subjects were administered a dose of Bacillus subtilis at levels of 1x10^9 CFU once a day for 90-days.
13790|NCT04083508|Other|Mosquito bites|Successful feeding of 5 infected P. vivax mosquitoes
13791|NCT04083495|Biological|ATLCAR.CD30 T cells|Autologous T Lymphocyte Chimeric Antigen Receptor cells targeted against the CD30 antigen
13792|NCT04083482|Procedure|continous venovenous hemofiltraion|CVVH
13793|NCT04083469|Behavioral|Peer-Led Peer-Elected Intervention|The intervention will be given to students by a peer opinion leader that the students in the audience elected. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
13794|NCT04083469|Behavioral|Adult-Led Intervention|The intervention will be given to students by an adult. The intervention is a version of CATCH My Breath curriculum that has been modified to match the Peer-Led Intervention curriculum but is able to be administered by an adult.
13795|NCT04083469|Behavioral|Peer-Led Non-Elected Intervention|The intervention will be given to students by a peer opinion leader that was elected by other students. The intervention is a version of CATCH My Breath curriculum that has been modified to facilitate peer leadership.
13796|NCT04083456|Behavioral|Walking Biobehavioral Intervention|Each walking biobehavioral training session includes self-monitoring, tailored feedback, identification of barriers and facilitators, problem solving, action planning and encouragement. Self-monitoring of walking behavior will occur with participant use of the FitBit sensor and software, reviewed with the interventionist at each session. Tailored feedback from the FitBit sensor, as well as feedback from the interventionist, will detail progress over time and be compared to baseline data. Barriers and facilitators of reaching activity goals will be discussed with emphasis on problem solving to take advantage of facilitators and minimize/remove participant-specific barriers. Action planning will be based on weekly step goals set collaboratively by the interventionist and participant, based the FitBit data. Finally, encouragement will be provided by the interventionist by putting progress or lack of progress in perspective of the efforts made by the participant.
13797|NCT04083456|Other|Attention Control|Attention control sessions will include a brief review of the conventional home-exercises, a summary of all healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use). Outpatient therapists will provide home-based exercises to ensure that the participant receives adequate training and demonstrates safe performance prior to home use. The CTL interventionist will assess and discuss the safe performance of each home-based exercise with CTL group participants. Exercises in the CTL group will only be progressed by the outpatient physical therapist and not during the telehealth sessions.
13798|NCT04083443|Other|Additional blood sampling|Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
13799|NCT04083430|Drug|Yellow Fever Vaccine|"STAMARIL, powder and solvent for suspension for injection in pre-filled syringe.~After reconstitution, 1 dose (0.5 ml) contains: Yellow fever virus1 17D-204 strain (live, attenuated) not less than 1000 IU.~Powder and solvent for suspension for injection.~Before reconstitution, the powder is homogeneous, beige to orange beige, and the solvent is a limpid solution."
13800|NCT04083417|Drug|Phenoxymethylpenicillin|tablet PcV 1000 mg x 3 for 10 days
13801|NCT04083417|Other|No antibiotic treatment|No prescription of antibiotics
13802|NCT04083378|Procedure|Ablation Therapy|Undergo standard of care ablation
13803|NCT04083378|Procedure|Image-Guided Therapy|Undergo software-aided imaging (Morfeus)
13804|NCT04083378|Other|Quality-of-Life Assessment|Ancillary studies
13805|NCT04083378|Other|Questionnaire Administration|Ancillary studies
13806|NCT04083365|Drug|Capecitabine|chemoradiation therapy with 825 mg/m2 twice daily capecitabine every day for 5 weeks
13807|NCT04083365|Drug|Radiotherapy|5040 cGy radiotherapy for 5 days per week for 5 weeks
13808|NCT04083365|Drug|Durvalumab|One week after the end of CT/RT patients will be treated with 1500 mg IV Q4W durvalumab for 3 administrations
13809|NCT04083352|Dietary Supplement|Pruvit Ketomax Ketone Salt|6-week supplementation with ketone salts
13810|NCT04083352|Dietary Supplement|Placebo|Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
13811|NCT04083339|Drug|AT-001|"AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner.~At present AT001 is the sole name for the active substance. No INN/genetic name is available to date"
13812|NCT04083339|Drug|Placebo|Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
13813|NCT04083326|Device|Digital Patient Journey Solution|Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
13849|NCT04083144|Device|Deep Repetitive Transcranial Magnetic Stimulation (Active)|Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
13814|NCT04083313|Device|Technique used for closing the appendiceal stump|In all patients, laparoscopic appendectomy is performed, only difference is the way of managing appendiceal stump
13815|NCT04083287|Other|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
13816|NCT04083287|Other|Interscalen brachial plexus block (Group I)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
13817|NCT04083274|Other|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
13818|NCT04083274|Other|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded"
13819|NCT04083261|Other|DNA Genotek Oragene 600|Saliva-based DNA sample collection kit
13820|NCT04083248|Behavioral|Feasibility group|Same as arm description
13821|NCT04083235|Drug|Irinotecan Liposomal Injection|Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
13822|NCT04083235|Drug|Oxaliplatin|Generic formulation used to be confirmed
13823|NCT04083235|Drug|5Fluorouracil|Generic formulation used to be confirmed
13824|NCT04083235|Drug|Leucovorin|Generic formulation used to be confirmed
13825|NCT04083235|Drug|Nab-paclitaxel|Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
13826|NCT04083235|Drug|Gemcitabine|Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
13827|NCT04083222|Drug|IONIS-AGT-LRx|IONIS-AGT-LRx administered subcutaneously
13828|NCT04083222|Drug|Placebo|Placebo matching IONIS-AGT-LRx solution administered subcutaneously
13829|NCT04083209|Behavioral|Opioid counseling|The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
13830|NCT04083196|Biological|11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)|Injection vaccine produced by ChinaVaccineSerum ,containing HPV antigen protein, 270μg/1ml/bottle
13831|NCT04083196|Biological|Placebo|Placebo
13832|NCT04083183|Biological|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given IV
13833|NCT04083183|Drug|Fludarabine|Given IV
13834|NCT04083183|Drug|Cyclophosphamide|Given IV
13835|NCT04083183|Biological|Lapine T-Lymphocyte Immune Globulin|Given IV
13836|NCT04083183|Radiation|Total-Body Irradiation|Undergo TBI
13837|NCT04083183|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
13838|NCT04083183|Drug|Mycophenolate Mofetil|Given PO or IV
13839|NCT04083183|Drug|Sirolimus|Given PO
13840|NCT04083170|Drug|Fludarabine|Given IV
13841|NCT04083170|Drug|Fludarabine Phosphate|Given IV
13842|NCT04083170|Drug|Cyclophosphamide|Given IV
13843|NCT04083170|Drug|Thiotepa|Given IV
13844|NCT04083170|Radiation|Total-Body Irradiation|Undergo TBI
13845|NCT04083170|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
13846|NCT04083170|Other|Cellular Therapy|Given OTS IV
13847|NCT04083157|Biological|Intradermal hepatitis B vaccine with imiquimod|Intradermal hepatitis B vaccine with topical imiquimod pretreatment
13848|NCT04083157|Biological|Intramuscular hepatitis B vaccine with aqueous cream|Intramuscular hepatitis B vaccine with topical aqueous cream pretreatment
13850|NCT04083144|Device|Deep Repetitive Transcranial Magnetic Stimulation (Sham)|Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
13851|NCT04083144|Drug|Varenicline|12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
13852|NCT04083118|Diagnostic Test|clinical evaluation, blood markers, pulse wave analysis, 18F sodium fluoride PET/CT and PET/MRI|Patients will receive a structured clinic history, examination, blood sampling, pulse wave analysis, pulse wave velocity, 18F-sodium fluoride PET/CT, 18F-sodium fluoride PET/MRI with detailed cardiac magnetic resonance imaging and magnetic resonance imaging of the aorta
13853|NCT04083118|Diagnostic Test|Repeat 18F sodium fluoride PET/MRI|as per first study visit but without the PET/CT
13854|NCT04083105|Drug|Nitrous Oxide|Nitrous oxide will be given prior to determine if it reduces pain from intranasal midazolam administration. Nitrous oxide is a minimal sedation drug used as an inhaled gas to reduce anxiety and produce anxiolysis and analgesia during dental procedures.
13855|NCT04083105|Drug|Midazolam|Intranasal midazolam will be given after nitrous oxide administration.
13856|NCT04083079|Drug|PEG-rhG-CSF|Patients will be given PEG-rhG-CSF for primary/secondary prevention each cycle.
13857|NCT04083079|Drug|rhG-CSF|Patients will be given rhG-CSF for either primary/secondary prevention or treatment once any neutropenia each cycle.
13858|NCT04083066|Drug|rituximab in combination with methotrexate, cytarabine and dexamethasone|"Rituximab 375mg/m2D0 is soluble in 0.9% NS concentration 1mg/ml, micro pump is pumped in 4h HD-methotrexate 3.5g/m2 D1 dissolved in 0.9% NS intravenous drip HD-cytarabine 1g/m2 Q12H D2-3 Dissolved in 250ml 5% GS intravenously~Dexamethasone 40mg D1-5 is dissolved in 100ml 5% GS intravenous drip (21 days is a cycle)"
13859|NCT04083053|Procedure|Perianal Exam|Perianal Exam is part of anal cancer screening. The perianal skin is also examined under magnification and, less commonly, perianal biopsies are obtained.
13860|NCT04083053|Procedure|high-resolution anoscopy (HRA) with biopsy|The HRA exam involves insertion of a plastic anoscope 4-6 cm into the anal canal, with use of 5% acetic acid and Lugol's iodine to highlight abnormal lesions for biopsy. The entire squamocolumnar junction is visualized during the exam, which lasts between 5 and 20 minutes.
13861|NCT04083040|Procedure|transcatheter aortic valve implantation|"Tilt angle.~Depth of implantation of the valve.~Type of the valve.(Medtronic core valve self expandable valve ,Edwards sapient balloon expandable valve"
13862|NCT04083027|Device|MRI|Breast MRI
13863|NCT04083014|Drug|combination of a single dose anti-CD20 antibody and bortezomib|Relapsed and refractory warm AIHA patients receive treatment of combination of a single dose anti-CD20 antibody and bortezomib twice during three months interval.
13864|NCT04083001|Device|OTR4132MD|"According to Regulation (EU) 2017/745(MDR), OTR4132-MD is an implantable medical device, for short term use which is specifically intended for use in direct contact with systemic circulation system.~OTR4132-MD is by definition intended to come into contact with the patient when being injected. It is administered through intra-arterial injection, in an one-shot dose and the majority of the product is eliminated within 24 hours."
13865|NCT04082988|Diagnostic Test|18F-FDG PET-CT|18F-FDG PET-CT scan
13870|NCT04082962|Drug|Dexamethasone intravitreal implant|Ozurdex™ is an intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR® solid polymer drug delivery system (NOVADUR™ system contains poly (D,L-lactide-co-glycolide) PLGA intravitreal polymer matrix, which slowly degrades to lactic acid and glycolic acid.). Ozurdex™ is preservative-free. It is supplied in a foil pouch with a single-use plastic applicator.
13871|NCT04082949|Biological|autologous fibrin glue application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|The purpose of this study was to investigate effects of autologous fibrin glue (AFG) which was an injectable platelet concentration, on clinical parameters in the nonsurgical treatment of chronic periodontitis.Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The test group was administered AFG using a blunt dental injector in the subgingival region, as an adjunct to SRP Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
13872|NCT04082949|Other|placebo application as an adjunct to nonsurgical periodontal treatment of chronic periodontitis|Seventy-two quadrants from 18 patients included in the study and divided into 2 random split-mouth groups. Control group included 631 sites (SRP+Placebo) and AFG group included 682 sites (SRP+AFG). Both groups divided into two subgroups according to initial pocket depth (PD:5-6mm and PD≥7mm).The control group was administered placebo as an adjunct to SRP.Clinical periodontal parameters including PD, clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI) and plaque index (PI) were collected at the 1st, 3rd, and 6th months.
13873|NCT04082936|Drug|IGM-2323|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
13874|NCT04082936|Drug|IGM-2323|Subjects with r/r B-cell NHL will receive IGM-2323 via IV infusion.
13875|NCT04082923|Other|Liquid meal|Four-hour liquid mixed meal test
13876|NCT04082923|Other|Solid meal|Four-hour solid mixed meal test
13877|NCT04082910|Drug|Metoprolol|Metoprolol for patients undergoing CRS after CAR T cells infusion.
13878|NCT04082910|Drug|anti-TNFα antibody|Metoprolol plus anti-TNFα antibody for patients in prophylactic group.
13879|NCT04082897|Drug|Obinutuzumab 25 MG/ML [Gazyva]|Obinutuzumab will be administered from C1 to C8
13880|NCT04082897|Drug|Atezolizumab 60 MG/ML [Tecentriq]|Atezolizumab will be administered iv from C1 to C18
13881|NCT04082897|Drug|Venetoclax Oral Tablet|Venetoclax will be administered from day 15 cycle 1) until day 21 of cycle 35
13882|NCT04082884|Behavioral|VLCD|A very low carbohydrate diet (VLCD), is defined as limiting carbohydrate intake to 50 grams per day or less.
13939|NCT04082520|Drug|Lutetium Lu 177 Dotatate|Given IV
13883|NCT04082871|Other|Medication management review|The researcher screened each completed an MMR template and verified that all information in each patient template was complete. A classification system was then used to identify the TRPs which either actually or potentially interfered with the clinical outcomes for each patient.[19] This system was explained in detail and applied successfully in many previous studies.[10, 14, 20] The researcher then identified TRPs for each patient in both groups using evidence-based medicine. The TRPs including unneeded drug treatment, untreated condition/s, efficacy/effectiveness issues, safety issues, inadequate knowledge, inappropriate adherence to pharmacological therapy, inappropriate adherence to self-care activities and miscellaneous problems.
13884|NCT04082858|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in twice-weekly infusions
13885|NCT04082858|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in twice-weekly infusions
13886|NCT04082845|Other|Education|Web-based patient education
13887|NCT04082832|Drug|Cu(II)ATSM|oral suspension
13888|NCT04082832|Drug|Placebos|oral suspension
13889|NCT04082819|Device|Contec CMS50EW|Participants' blood pressure will be measured 3 times with the wearable finger pulse oximeter at their study visit.
13890|NCT04082819|Device|Sphygmomanometer|Participants' blood pressure will be measured 4 times manually with a blood pressure cuff at their study visit.
13891|NCT04082806|Drug|GHB|50 mg/kg GHB at one experimental night
13892|NCT04082806|Drug|Trazodone|1.5 mg/kg trazodone at one experimental night
13893|NCT04082806|Drug|Placebos|placebo oral solution (placebo for GHB) and placebo pills (placebo for trazodon)
13894|NCT04082793|Combination Product|Photobiomodulation therapy with mandibular exercises|Low-level laser therapy (BMI 1005 Laser 2200) Wavelength: 658 nm Power: 100 MW Energy density: 4J/cm2 Dose administered: 4J Mode: Pulsed Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions/week on alternating days for 12 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement of the jaw Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetitions X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day
13895|NCT04082793|Combination Product|Sonophoresis with mandibular exercises|"Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel Frequency: 1.0 MHz Mode: Continuous Intensity: 0.8 to 1.5 W/cm2~Site of application: Over bilateral Temporomandibular joint Number of sessions: 3 sessions per week on alternating days for 8 minutes each, for 4 weeks Mandibular mobilization exercises Side to side movement Forward jaw movement Tongue up Goldfish exercise (Partial opening) Goldfish exercise (Full opening) Exercise duration: 6 repetition X 2 sets X 4 times a day Mandibular Stabilization exercises Exercise duration: 5 repetitions X 3 sec. Hold X 4 times a day"
13896|NCT04082780|Drug|Rifamycin SV MMX|Intervention arm
13897|NCT04082780|Other|Placebo|Placebo arm
13898|NCT04082767|Drug|Precedex|Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team
13899|NCT04082767|Drug|Midazolam|Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team
13900|NCT04082754|Biological|Human beta common receptor antagonist monoclonal antibody|Human beta common receptor antagonist monoclonal antibody administered intravenously
13901|NCT04082754|Drug|Placebo|0.9% sodium chloride, same volume and same duration as CSL311, administered intravenously
13902|NCT04082741|Drug|BMS-986318|Specified dose on specified days
13903|NCT04082741|Other|Placebo|Placebo Matching BMS-986318
13904|NCT04082728|Drug|Metamizole|Patients in the experimental group will be instructed to take metamizole 1000 mg orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
13905|NCT04082728|Drug|Placebo oral tablet|Patients in the placebo group will be instructed to take a placebo orally three times a day for four days. All patients will be instructed to take ibuprofen 600 mg orally three times a day for four days and 1000 mg paracetamol orally four times a day during the entire study period.
13906|NCT04082715|Drug|carbidopa/levodopa and celecoxib|Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
13907|NCT04082715|Drug|placebo1 and celecoxib|Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
13908|NCT04082715|Drug|placebo1 and placebo2|Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
13940|NCT04082520|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
13941|NCT04082520|Procedure|Positron Emission Tomography|Undergo PET/MRI
13942|NCT04082520|Other|Quality-of-Life Assessment|Ancillary studies
13909|NCT04082702|Behavioral|Faith-enhanced diabetes prevention program|The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
13910|NCT04082702|Behavioral|Standard diabetes prevention program|The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
13911|NCT04082689|Behavioral|Infant Toilet Training|"The parents learn to sensitively respond to the child's routines and signals of elimination needs.The child's ability to convey the need for bowel and bladder evacuation is enhanced through responsive interaction so that a kind of assisted dryness is developed. The baby is held squatting over a potty or basin, while bigger children are sitting on the potty."
13912|NCT04082676|Drug|Hyperbaric bupivacaine spinal|In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
13913|NCT04082676|Drug|Hyperbaric bupivacaine spinal|In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
13914|NCT04082663|Device|Dental Mouthpiece|Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
13915|NCT04082650|Drug|vitamin D|4000IU per day
13916|NCT04082650|Other|Placebo|The same doses with vitamin D
13917|NCT04082637|Behavioral|Mindful Awareness in Body-oriented Therapy|A mind-body intervention designed to teach interoceptive awareness skills for emotion regulation and self-care. Delivered individually in 75 minute sessions once a week for 8 weeks.
13918|NCT04082624|Behavioral|Nutrition condition|Received nutritional information in in-person PowerPoint presentations.
13919|NCT04082624|Behavioral|Affective condition|Received information about affective benefits of less sitting in the workplace in in-person PowerPoint presentations.
13920|NCT04082624|Behavioral|Instrumental condition|Received information about instrumental benefits of less sitting in the workplace in in-person PowerPoint presentations.
13921|NCT04082624|Behavioral|Self-regulation condition|Learned how to self-regulate behavior to sit less in the workplace in in-person PowerPoint presentations.
13922|NCT04082611|Behavioral|Data-Driven Clinical Recommendations|Data-driven clinical recommendations. Participants will receive routine care with data-driven, personalized, multi-modal clinical recommendations by a study physician based on study assessments and clinical lab values and be monitored and re-assessed for a period of 12 months.
13923|NCT04082611|Behavioral|Coached Data-Driven Clinical Recommendations|Data-driven multi-modal lifestyle intervention with coaching. Participants will receive coached routine care with data-driven, personalized, multimodal recommendations. MMIC participants will receive an intensive multi-modal intervention with health coaching, support and resources to carry out these recommendations. This additional intervention services include: 13 personal, data-driven brain health coaching sessions (with an RDN), 7 personal dietary counseling sessions (with an RDN), 33 group-based cognitive and physical exercise classes (CogFit) with a certified personal trainer and a computer-based neurocognitive program at home and be monitored and re-assessed for a period of 12 months.
13924|NCT04082598|Drug|Amoxicillin Clavulanate|tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
13925|NCT04082598|Dietary Supplement|Bifidobacterium longum and Lactoferrin|
13926|NCT04082585|Behavioral|Total Health Improvement Program|The Total Health Improvement program is a 13 week community based nutrition program designed to assist participants in improving their physical and emotional well being. The program focuses on a plant based diet and increased physical activity.
13927|NCT04082572|Biological|Pembrolizumab|Given IV
13928|NCT04082559|Other|Arm 1- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
13929|NCT04082559|Other|Arm 2- Antibiotics treatment|Patients with active disease will be randomized and will receive a prescription antibiotic regimens
13930|NCT04082559|Other|Arm 1- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
13931|NCT04082559|Other|Arm 2- Combination therapy (Antibiotics + diet)|Patients with active disease receiving a prescription for the antibiotic regimen defined as favorable in the antibiotics according to aim 1 , and randomized into one of two dietary interventions: Mediterranean diet (MED) or the specific carbohydrate diet (SCD).
13932|NCT04082559|Other|Arm 1- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
13933|NCT04082559|Other|Arm 2- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
13934|NCT04082559|Other|Arm 3- Nutritional prevention|Patients in clinical remission will be recruited to a dietary prevention study
13935|NCT04082546|Procedure|Surgical unroofing of muscle-briged coronary artery|Medical therapy with beta-blockers or calcium-channels blockers
13936|NCT04082533|Drug|Hydrocortisone|Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
13937|NCT04082533|Drug|Dextrose 5% in water (D5W)|Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
13938|NCT04082520|Radiation|Gallium Ga 68-DOTATATE|Given IV
13944|NCT04082507|Diagnostic Test|Serum alpha-fetoproteine|Midtrimesteric serum alpha-fetoprotein mesurment with 2D US and 3D power Doppler with MS US scan .
13945|NCT04082494|Device|Music via internet and noise canceling headphones|Optional music via internet and noise canceling headphones will be offered.
13946|NCT04082494|Other|Beverages|Beverages will be optionally offered (with and without sugar, warm or cold).
13947|NCT04082481|Drug|TAK-988|TAK-988 tablets.
13948|NCT04082481|Drug|TAK-988 Placebo|TAK-988 placebo-matching tablets.
13949|NCT04082468|Diagnostic Test|Blood sample collection for coagulation profile|Factor VIII Activity Level, Factor VIII Antigen Level, Interleukin 6, vWF Antigen Level, Thrombin Activity, Protein C Activity, Protein C Antigen Level, CRP, PT/PTT/INR ,T & B lymphocyte panel at above time points
13950|NCT04082455|Radiation|carbon ion radiotherapy|carbon ion radiotherapy
13951|NCT04082442|Drug|Evolocumab|420 mg evolocumab.
13952|NCT04082442|Drug|Placebos|Matching placebo.
13954|NCT04082416|Biological|Placebo plus standard therapy|"Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )"
13955|NCT04082416|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
13956|NCT04082403|Procedure|Training on Suction Assisted Laryngoscopy and Airway Decontamination|Education on Suction Assisted Laryngoscopy and Airway Decontamination, via 30 minute teaching session, followed by practical demonstration of techniques.
13957|NCT04082403|Procedure|No Training on Suction Assisted Laryngoscopy and Airway Decontamination Provided|No Training on Suction Assisted Laryngoscopy and Airway Decontamination provided to trainees
13958|NCT04082390|Dietary Supplement|RELEASE|Dietary supplement
13959|NCT04082390|Dietary Supplement|Placebo|Placebo
13960|NCT04082377|Procedure|Recruitment maneuver with tidal volume (RM TV)|"The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, inspiratory-to-expiratory (I:E) ratio at 1:2, and respiratory rate (RR) set to normocapnia (end-tidal CO2 partial pressure between 35 and 40mmHg, TV 6 mL/kg PBW and 5 cmH2O PEEP.~RMs were conducted under volume controlled ventilation with initial settings of a limit of peak inspiratory pressure at 40cmH2O, TV at 6 mL/kg PBW (PBW = 50.0+0.905*((height in cm)-152.4) for men, and = 45.5+0.905*((height in cm)-152.4) for women) Brower, et al. 1999, RR at 7 breaths/min, PEEP at5 cmH2O, and I:E ratio at1:1. The TV was then increased by steps of 4 mL/kg PBW until plateau airway pressure (Pplt) was 40 cmH2O, after which 3 breaths were allowed. Finally, the limit of peak inspiratory pressure, TV, RR, and I:E ratio were reset at values equal to those preceding the RM."
13961|NCT04082377|Procedure|Recruitment maneuver by PEEP (RM PEEP)|The ventilation protocol consisted of volume controlled mechanical ventilation, FiO2 0.4, in RMs was conducted under pressure controlled ventilation so ventilation technique will be changed, pressure-control mode will be started and inspiratory time is increased to 50% (inspiratory: expiratory ratio will be set to 1:1). Peak airway inspiratory pressure (Ppeak) will be initially set to 20 cmH2O for three breaths, and then PEEP will be increased in steps from 5 to10 cmH2O for five breaths, from 10 to 15 cmH2O for seven breaths, from 15 to 20 cmH2O for ten breaths while Ppeak increased to 40 cmH2O and will be maintained for three more breaths. Following ARM, volume control will be re-established using Vt 6 mL/kg and step-wise reductions in PEEP from 20 to 15 cmH2O for three breaths,and then to 5 cmH2O until the end of recruitment maneuver
13962|NCT04082364|Combination Product|margetuximab plus INCMGA00012|"margetuximab: Fc-modified anti-HER2 monoclonal antibody:~• 15 mg/kg IV Day1 of each 3 week cycle~INCMGA00012: anti-PD-1 checkpoint inhibitor:~• 375 mg IV Day 1 of each 3 week cycle"
13963|NCT04082364|Combination Product|Margetuximab plus INCMGA00012 plus chemo|"margetuximab: Fc-modified anti-HER2 monoclonal antibody~• 15 mg/kg IV Day1 of each 3 week cycle~INCMGA00012: anti-PD-1 checkpoint inhibitor~• 375 mg IV Day 1 of each 3 week cycle~Chemotherapy~Drug Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, administered as part of XELOX chemotherapy~Drug Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion, administered as part of XELOX chemotherapy~Drug Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, as part of mFOLFOX-6~Drug Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy"
13964|NCT04082364|Combination Product|Margetuximab plus MGD013 plus chemo|"margetuximab: Fc-modified anti-HER2 monoclonal antibody~• 15 mg/kg IV Day1 of each 3 week cycle~MGD013: Anti-PD-1, anti-LAG-3 dual checkpoint inhibitor DART molecule~• Dosing regimen located in the protocol~Chemotherapy~Drug Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, administered as part of XELOX chemotherapy~Drug Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion, administered as part of XELOX chemotherapy~Drug Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, as part of mFOLFOX-6~Drug Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy"
13965|NCT04082364|Combination Product|Margetuximab plus chemo|"margetuximab: Fc-modified anti-HER2 monoclonal antibody~• 15 mg/kg IV Day1 of each 3 week cycle~Chemotherapy~Drug Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, administered as part of XELOX chemotherapy~Drug Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion, administered as part of XELOX chemotherapy~Drug Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, as part of mFOLFOX-6~Drug Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy"
13966|NCT04082364|Combination Product|Trastuzumab plus chemo|"Anti-HER2 monoclonal antibody~• 8 mg/kg loading dose and then 6 mg/kg administered IV on Day 1 of each 3 week cycle~Chemotherapy~Drug Capecitabine: 1000 mg/m2 as oral capsules twice a day Days 1-14 of each cycle, administered as part of XELOX chemotherapy~Drug Oxaliplatin: 130 mg/m2 of Day 1 of each 3-week cycle as IV infusion, administered as part of XELOX chemotherapy~Drug Leucovorin: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU bolus: 400 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy~Drug 5-FU continuous infusion: 2400 mg/m2 every 2 weeks as a 46 hr infusion, as part of mFOLFOX-6~Drug Oxaliplatin: 85 mg/m2 every 2 weeks as IV infusion, administered as part of mFOLFOX-6 chemotherapy"
13967|NCT04082351|Dietary Supplement|Nanotechnology structured water ( Magnalife)|Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .
13968|NCT04082351|Dietary Supplement|ordinary water|Ordinary bottled water
13969|NCT04082338|Behavioral|VPN|"The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period."
13970|NCT04082338|Behavioral|TM|Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
13971|NCT04082325|Drug|Lu AF88434|Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
13972|NCT04082325|Drug|Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
13973|NCT04082325|Drug|Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)|Oral solution
13974|NCT04082325|Drug|Placebo|Placebo to Lu AF88434 oral solution, single dose
13975|NCT04082312|Other|No intervention|No intervention
13976|NCT04082286|Other|Yttrium-90 labelled monoclonal antibody against CD66|
13977|NCT04082273|Device|Femtosecond Laser for Cataract Surgery|Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment
13978|NCT04082273|Other|Conventional Cataract Surgery|Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
13979|NCT04082260|Drug|Alemtuzumab Injection [Lemtrada]|"Administration of 2 courses of alemtuzumab at an interval of 1 year. Course 1: Intravenous infusion of 12 mg alemtuzumab per day on 5 consecutive days.~Course 2: Intravenous infusion of 12 mg alemtuzumab per day on 3 consecutive days."
13980|NCT04082247|Behavioral|The education and training of early childhood educators and their intervention on children|"A 24-week cluster randomized trial will be developed, with the childcare being the randomization unit. Training sessions will be conducted for all early childhood educators in the intervention group. The control group will receive the Portuguese standard education and at the end of the intervention this group will also receive the initial training given to the intervention group, so that they can later also implement the intervention. At the end of the intervention, all early childhood educators and parents/guardians will have access to the intervention outcomes."
13981|NCT04082234|Behavioral|Partnering to Achieve School Success (PASS)|Individualized parent training program delivered at child's primary care provider office. Providers use engagement and motivation strategies during each session to reinforce help-seeking behavior and family empowerment, and encourage family adherence to recommended strategies. Also includes regular communication between pass provider and PCP and development of a problem-solving partnership between parents and teachers to address school problems. Families are supported in between sessions by a Community Health Partner who contacts families to promote attendance and implementation of strategies and assist in resolving barriers to treatment. The intervention is 9 to 12 sessions over the course of 16 weeks depending on caregiver goals.
13982|NCT04082234|Other|Treatment as Usual (TAU) plus Family Education|Caregivers will work with their primary care physician to address their child's ADHD. Primary care physicians have been trained in and informed of American Academy of Pediatrics guidelines for treating ADHD. Treatment may include strategies to educate families about ADHD and evidence-based treatments, refer families to community mental health agencies that deliver evidence-based behavioral programming (other than PASS), engage families in shared decision making, titrate medication, and monitor treatment effects. In addition, TAU is enhanced by offering two group psychoeducation sessions to families to provide them opportunities to learn about ADHD and ADHD treatment. Behavioral parent training strategies are not included in Family Education sessions.
13983|NCT04082221|Other|no intervention|no intervention
13984|NCT04082208|Device|High Flow nasal cannula|Administration of high flow nasal cannula during ERCP procedure
13985|NCT04082208|Device|Low Flow nasal cannula|Administration of low flow nasal cannula during ERCP procedure: standard care
13986|NCT04082195|Other|Fooya mobile game|An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.
13987|NCT04082195|Other|Uno board game|A popular board game which is not a mobile app.
13988|NCT04082182|Biological|Dendritic cell immunotherapy|Intravenous infusions of MIDRIX4-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
13989|NCT04082182|Biological|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIX4-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
14086|NCT04081311|Device|comparing interdental floss to water flosser around dental implants|to determine the effectiveness in reducing the bleeding on probing (BOP) index around dental implants
13990|NCT04082182|Biological|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
13991|NCT04082156|Device|electrical stimulation|electrical stimulation
13992|NCT04082156|Device|Sham|no stimulation
13993|NCT04082143|Device|Allograft mucosal enhancement with dental implant|implant placement with allograft mucosal enhancement
13994|NCT04082143|Device|No allograft mucosal enhancement at time of dental implant placement|implant placement without allograft mucosal enhancement
13995|NCT04082130|Procedure|(XCM)+(CAF)|The description of this intervention has been already given before.
13996|NCT04082130|Procedure|(SCTG)+(CAF)|The description of this intervention has been already given before.
13997|NCT04082117|Behavioral|Educational video|Educational genetic counseling video
13998|NCT04082104|Diagnostic Test|Stuttering Severity Instument version 3|Riley's Stuttering Severity Instrument is used for the objective assessment of severity and in other examinations of stuttered speech. Current versions of the instrument measures three parameters: 1) stuttering frequency; 2) duration of selected stutters; 3) observed physical concomitants.
13999|NCT04082091|Behavioral|SELECT mHealth Program|"Individuals will be screened via the telephone, using a mobile-based algorithm that prompts questions about hypertension, risk of Diabetes Mellitus, use of smokeless tobacco and smoking, level of physical activity, and main nutritional choices. These questions are based on tools that have been validated in studies undertaken in this population and will be directly administered by trained research staff of Aga Khan University. Screening will prompt triage into three categories: high‟ - referred to the conveniently located integrated medical center for a medical teleconsultation and fasting glucose test; medium‟ - receive fasting glucose test and BP measurement; and low‟ risk. All subjects in each category will be enrolled in an e_Prescription intervention for lifestyle change tailored to their individual risk profile."
14000|NCT04082065|Other|conventional physical therapy|hot pack for 15 minutes Myofacial release (10 minutes) and Stretching of hamstrings and Piriformis (5 reps each with 2 second hold)
14001|NCT04082065|Other|cyriax lumber manipulation group|Hot Pack, Myofacial Release, stretching of hamstrings and Piriformis (five reps each with 2 seconds hold) and Cyriax Lumbar Manipulation Techniques
14002|NCT04082052|Behavioral|Single Session Interventions|A single session intervention either active (for self-dislike) or placebo (feelings disclosure)
14003|NCT04082039|Other|convetional PCA method unsing only 1-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg, ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline); Ch-2 (flow 2ml/h): 100ml normal saline only (for blinding)
14004|NCT04082039|Other|utilizing 2-channel|Ch-1 (flow 2 ml/hr with bolus 2ml/30min lock-out): fentanyl 16 µg/kg (total volume 100 ml with normal saline; Ch-2 (flow 2ml/h fixed): ketorolac 2 mg/kg, ondansetron 12 mg (total volume 100 ml with normal saline)
14005|NCT04082026|Behavioral|Early Adolescent Skills for Emotions EASE)|"EASE is conducted in 7 weekly group sessions with adolescents. EASE sessions help adolescents:~Identify their feelings and body reactions~Practice breathing exercises~Get active: Make a plan to positively change their actions~Manage their problems"
14006|NCT04082013|Other|Hamstring Flexibility|"The active knee extension test has been proposed as the gold standard for assessment of hamstring flexibility, as it utilizes readily available equipment and offers a quick, reliable, and low-cost alternative for measurement of hamstring flexibility (Connor et al; 2015).~The subject will be instructed to maintain 90° hip flexion in the supine position.~Then asked to actively extend the knee joint.~The degree of achieving active knee extension will be measured using a universal goniometer.~The average of three active knee extension measurements will be used as the hamstring muscle length for the data analysis (Dong-Kyu Lee, et al; 2018).~the procedures will be done with opposite-leg flexed, then repeated with opposite-leg extended."
14007|NCT04082000|Drug|BOL-DP-o-04|BOL-DP-o-04
14008|NCT04082000|Drug|Placebo|Placebo
14009|NCT04081987|Device|non-invasive monitoring|Comparing blood pressure (diastolic & systolic), heart and respiration rates, blood oxygen level and body temperature measurement using the BiPS non-invasive monitor to an arterial line.
14010|NCT04081974|Other|Distal leg perfusion|On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.
14011|NCT04081961|Device|Anamed OEM device; Air Next mobile spirometry device|Anamed OEM (Original Equipment Manufacturer) device - physical activity and vital signs monitoring; Air Next mobile spirometry device
14012|NCT04081948|Other|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
14087|NCT04081298|Behavioral|Health Education|Attend nutrition and PA classes, cooking sessions, and field trips
14088|NCT04081298|Other|Physical Activity|Participate in physical activities
14089|NCT04081298|Other|Text Message|Receive motivational text messages
14090|NCT04081298|Other|Web Site|Given access to nutrition website
14091|NCT04081298|Device|FitBit|Wear a FitBit
14092|NCT04081298|Device|Actigraph|Wear an actigraph
14093|NCT04081298|Other|Quality-of-Life Assessment|Ancillary studies
14094|NCT04081298|Other|Questionnaire Administration|Ancillary studies
14013|NCT04081948|Other|Sham block group (Group S)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
14014|NCT04081935|Device|Virtual Reality|virtual reality (VR) as a distracting intervention could reduce pain and fear during an IV placement for school-age children in the emergent department.
14015|NCT04081922|Procedure|Erector spinae plane block|Using ultrasound, place the needle in the erector spinae fascia plane at T7-8 level. Then, 0.25% ropivacaine 0.5 ml is injected to confirm the needle location. After checking the location, 0.25% ropivacaine 0.5 ml/kg is administered. This procedure is repeated at contralateral side.
14016|NCT04081909|Drug|Fentanyl，Remifentanil|Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
14017|NCT04081909|Drug|Ketamine,Dexmedetomidine|Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
14018|NCT04081896|Other|Exercise|"Exercise prescribed to participants includes personalized spine-specific strengthening exercises targeting the core musculature (i.e. Multifidus, Erector Spinae, Transversus Abdominus, Obliques, and Rectus Abdominus). The in-clinic exercise program recommends a minimum of 20 visits at 2 visits/week, with a goal of 24 total visits over a 12-week period. Exercise is progressed by 5-10% of their exercise load once they are able to do >20 repetitions. If they are able to reach >10 repetitions but <20 repetitions their exercise load remains the same. If they are unable to reach 10 repetitions their exercise load is decreased 5-10% at their next visit. For each visit, pain and medication usage will be documented, and the strengthening protocol will be progressed as described above.~The online exercise program includes non-machine based home exercises targeting the same muscles of interest, and are personalized to each participant based on their home resources and comfort level."
14019|NCT04081883|Other|Biosensor algorithm|The biosensor DIABLO responses will be compared to the measurements of standard CGMS, using blood glucose measures every 10 minutes by taking interstitial fluid from Diabetes Type 1 (DT1) patients with an internal or external insulin pump.
14020|NCT04081870|Diagnostic Test|3D power doppler US|Three D power Doppler US was done for every woman at the day after HCG administration. Ovum pick up was done after 35 hours following HCG administration.
14021|NCT04081857|Drug|HGP1810|HGP1810: Vildagliptin/Metformin
14022|NCT04081857|Drug|HCP1704|HCP1704: Vildagliptin/Metformin
14023|NCT04081844|Drug|HCP1306|Ezetimibe 10mg / Rosuvastatin 20mg (Rosuzet)
14024|NCT04081844|Drug|HGP0904|Amlodipine 5mg(Norvasc)
14025|NCT04081844|Drug|HGP0608|Losartan 100mg(Cozaar)
14026|NCT04081831|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Follow clinical administration
14027|NCT04081818|Other|Nutritious Mushrooms|The Intervention group will consume antioxidant rich and Vitamin D2-enhanced mushrooms as a snack daily for 3 months.
14028|NCT04081805|Procedure|LASER|The patient will use intravaginal estriol, daily for 2 weeks and them twice a week for 3 months . Each 30 days, the patients will have an appointment when will be checked the weight of the estriol tube to verify the correct use.vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
14029|NCT04081805|Procedure|Micro Ablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured
14030|NCT04081805|Drug|Promestriene|The patient will perform self application of this vaginal promestriene daily for 2 weeks and after that the applications will occur twice a week.
14031|NCT04081792|Procedure|Antibiotic therapy|Postoperative randomizations regarding the duration of systemic antibiotics
14032|NCT04081779|Other|Survivorship Care Plan|Receive patient-generated SCP
14033|NCT04081779|Other|Educational Intervention|Receive telephone-based educational counseling session
14034|NCT04081779|Other|Questionnaire Administration|Ancillary studies
14035|NCT04081766|Behavioral|SUGAR Handshake|"An interactive patient counselling session delivered by a clinical pharmacist that focuses on hypoglycemia recognition, causes, medication-related instructions, and recommendations for treatment. The intervention package is individualised according to shared decision making and each participant's lifestyle, health status, and antidiabetic medications.~The oral session will be accompanied by a pictogram that contains the main recommendations for easy recall by the participant. Moreover, it will be reinforced by a phone call in the middle of the follow-up duration."
14036|NCT04081753|Device|Remote monitoring of temperature|The patient will be set up with a remote monitoring device for temperature recording and the temperature will monitored remotely
14037|NCT04081714|Drug|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered USP water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers.
14095|NCT04081272|Drug|Sodium Chromate Cr51|Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
14171|NCT04080661|Other|Patient questionnaires|The study participants will complete the Dermatology Quality of Life (DLQI) and EQ-5D-5L questionnaire at each study visit.
14038|NCT04081701|Diagnostic Test|Ga68-DOTATATE-PET/MRI|"In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI."
14039|NCT04081688|Drug|Atezolizumab 1200 MG in 20 ML Injection|Given IV every 3 weeks on day 2 of each cycle (cycle is 21 days)
14040|NCT04081688|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT between cycle 1 and cycle 2 (each cycle is 21 days)
14041|NCT04081688|Drug|Varlilumab 3 mg/kg|Given IV every 3 weeks on day 1 of each cycle (cycle is 21 days)
14042|NCT04081675|Device|Ankle Foot Orthosis (AFO)|Thermoplastic orthotic device spanning the calf, ankle and foot.
14043|NCT04081662|Behavioral|compACT Intervention|"The mobile intervention in this study consists of two components: 1) self-monitoring and 2) an ACT-based microintervention.~Self-monitoring: twice daily, participants will complete self-reports of distress, depressive symptoms, and activity through the mobile app Lorevimo.~Microintervention: The microintervention will consist of one of 84 prompts that aim to target one of 6 processes targeted in ACT (contacting the present moment, defusion, acceptance, self-as-context, values, and committed action). At each time-point, participants have a 50% chance of receiving a microintervention question along with the daily self-monitoring assessments."
14044|NCT04081636|Procedure|Transrectal biopsy (TR-Bx)|through the rectum
14045|NCT04081636|Procedure|Transperineal biopsy (TP-Bx)|Through the skin
14046|NCT04081623|Device|Raydiant Oximetry Sensing System|The investigational device is used to record fetal pulse signals.
14047|NCT04081610|Drug|lagricel ofteno multidose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
14048|NCT04081610|Drug|lagricel ofteno single dose|"Dosage: 1 drop 4 times a day per 7 days, both eyes~Route of administration: Ophthalmic"
14051|NCT04081584|Device|ISS Device|The ISS Device (commercial and prototype) is used to measure tissue light scattering.
14052|NCT04081558|Device|Electronic patient reported outcomes tool|Electronic patient reported outcomes
14053|NCT04081545|Drug|Opioid Anesthetics|see arm/group description
14054|NCT04081545|Drug|Non Opioid Analgesics|see arm/group description
14055|NCT04081532|Procedure|surgical removal of superficial peritoneal endometriosis|In the active comparator group patients will have endometriosis lesions removed by ablation or excision. Patients randomised to no surgical treatment arm will not have lesions removed and will only be given diagnosis on whether endometriosis was found or not.
14056|NCT04081519|Device|active rTMS over DLPFC|15 sessions of active rTMS over DLPFC
14057|NCT04081519|Device|Add-on active rTMS over DLPFC|15 additional sessions of active rTMS over DLPFC
14058|NCT04081519|Device|Add-on active rTMS over LPC|15 additional sessions of active rTMS over LPC
14059|NCT04081519|Device|Add-on sham rTMS|15 additional sessions of sham rTMS over DLPFC or LPC
14060|NCT04081506|Other|Individualized perfusion targets|Targeting +/-5mmHg of the optimal mean arterial pressure
14061|NCT04081493|Other|Low-load blood flow restricted exercise|"Leg press and knee extension exercise 3 times per week for 8 weeks. Repetition scheme: 30-15-15-until exhaustion interspaced by 30 sec rest. 5 min free-flow rest between exercises"
14062|NCT04081480|Drug|Valacyclovir|PK curve collection to determine acyclovir exposure after administration of valacyclovir oral solution
14063|NCT04081467|Other|Bed rest|10-day of complete bed rest
14064|NCT04081454|Behavioral|Workshop|one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
14065|NCT04081454|Behavioral|Education|The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
14066|NCT04081441|Device|Inyenyeri clean cookstove and fuel system|The Inyenyeri cooking systems includes a tier 4 clean cooking system with biomass pellets that are purchased through the unconditional cash transfer program in the refugee camp
14067|NCT04081441|Behavioral|I-ACT (Individual, Agency-Centered Training) workshop|The I-ACT (Individual, Agency-Centered Training) empowerment workshop consists of behavioral exercises drawn primarily from positive psychology, that provide the tools to foster a growth mindset by allowing participants to understand the link between their thoughts, beliefs, and past actions to their future actions. Conducted in a workshop setting, this locally adapted version of the I-ACT curriculum consists of two days for women and a 1 day workshop for their male partners (as applicable)
14068|NCT04081428|Radiation|Stereotactic Body Radiotherapy|Daily collection of breath and blood before and after each of the 5 radiotherapy treatment sessions. Before and after daily cone beam CT image collection
14069|NCT04081402|Biological|HU-014|Hutox Inj(Clostridium botulinum type A)
14070|NCT04081402|Biological|Botox Inj|Botox Inj(Clostridium botulinum type A)
14071|NCT04081389|Drug|Celecoxib|Given PO
14072|NCT04081389|Drug|Cyclophosphamide|Given IV
14073|NCT04081389|Drug|Doxorubicin|Given IV
14074|NCT04081389|Drug|Doxorubicin Hydrochloride|Given IV
14075|NCT04081389|Drug|Paclitaxel|Given IV
14076|NCT04081389|Biological|Recombinant Interferon Alfa-2b|Given IV
14077|NCT04081389|Drug|Rintatolimod|Given IV
14078|NCT04081376|Drug|Hydromorphone Hydrochloride|4 mg of hydromorphone hydrochloride (equivalent to 3.56 mg of hydromorphone) administered orally in a single dose.
14079|NCT04081363|Drug|Centanafadine|Extended-release capsule
14096|NCT04081259|Drug|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor that is being developed as a treatment for patients with advanced cancer. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
14097|NCT04081246|Device|Bipolar transurethral modified en bloc resection of bladder tumour|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
14098|NCT04081233|Procedure|surgical stabilization|Surgical procedure utilizing any commercially available internal rib fixation system
14099|NCT04081233|Procedure|Usual care|Usual care typically consists of breathing exercises and pain control,often including opioids
14100|NCT04081220|Drug|IMG-7289|Single starting dose with individualized dose titrations throughout
14101|NCT04081207|Behavioral|AAC for Language Recovery (AAC-LaRc)|iPads will be programmed with a personalized communication application (app) and a structured 4-step intervention will be employed to instruct patients how to cue themselves during anomic events via pictures, text, or speak buttons.
14102|NCT04081181|Procedure|Microwave ablation|CT_guided Microwave ablation is a minimally invasive technique that kill the insitu lung cancer cells, produce large volumes of cellular necrosis with reduced procedure time .According to the preoperative CT image of the patient , we will determine the focal position of the lesion ,it's size and it's relationship with adjacent organs to choose the optimal puncture point , puncture path and proper microwave antenna and to set the power and time of ablation.Then under the guidance of CT , the tip of antenna will be sent into the focus by puncture with ablation power of 60_80 W .according to tumor size , the ablation time will be determined.Needle track coagulation will be done to prevent seeding of malignant cells. After ablation a CT scan will be done immediately to observe the size ,shape and relation to nearby organ of the lesion and to determine if there is pneumothorax
14103|NCT04081168|Device|Stereotactic Body Radiotherapy|Patients will undergo Stereotactic Body Radiotherapy (SBRT)
14104|NCT04081168|Device|Microwave Ablation|Patients will undergo Microwave Ablation (MWA)
14105|NCT04081116|Other|Symmetric settings (high pressures/fast rate)|Describes settings on the MI-E device
14106|NCT04081116|Other|Asymmetric settings (Pi<Pe/Ti>Te)|Lower insufflation pressures at longer times
14107|NCT04081116|Other|Preinclusion settings|Settings in use at start of study
14108|NCT04081103|Drug|NEXAGON High Dose Concentration|Applied under a bandage contact lens and to the fornices of the eye.
14109|NCT04081103|Drug|NEXAGON Low Dose Concentration|Applied under a bandage contact lens and to the fornices of the eye.
14110|NCT04081103|Drug|NEXAGON Vehicle|Applied under a bandage contact lens and to the fornices of the eye.
14111|NCT04081090|Behavioral|Brain HQ Cognitive Modules|Online personalized cognitive therapy modules to address and improve neuroplasticity.
14112|NCT04081077|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
14113|NCT04081077|Drug|Pretomanid|Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
14114|NCT04081077|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
14115|NCT04081077|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
14116|NCT04081077|Drug|Clofazimine|Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
14117|NCT04081064|Behavioral|10-week exercise programme based on aerobic interval and resistance training|The intervention will take place over 10 weeks. Participants will complete three sessions per week; each sessions will be scheduled at least 24 hours apart. Two sessions per week will consist of aerobic interval exercise and resistance training, and one session per week will consist of aerobic interval exercise only.
14118|NCT04081051|Other|diagnostic algorithm+Point of care rapid diagnostic tests+ Behavior change ( assessed together as a single package of interventions)|Diagnostic algorithm utilizing pathogen specific and non-pathogen specific point of care, rapid diagnostic tests, behavioral change intervention for healthcare workers
14119|NCT04081038|Diagnostic Test|Brush biopsy|Brush biopsy will be performed by dentists and dental hygienists
14120|NCT04081025|Other|EpiWux|A cross-sectional and longitudinal study including a questionnaire and a clinical examination
14121|NCT04081012|Drug|N-acetyl cysteine|Patients will receive a 4-dose schedule of 600 mg diluted in 50 ml of 0.9% saline intravenously every 12 hours starting 24 hours before pulmonary endarterectomy or balloon pulmonary angioplasty.
14122|NCT04081012|Drug|Placebo|The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
14123|NCT04080999|Device|r-TMS|The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.
14124|NCT04080999|Device|SHAM|Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
14125|NCT04080986|Procedure|Double Sequential Defibrillation|Defibrillation using pad placement in anterior-posterior position
15244|NCT04071743|Device|gammaCore Sapphire|non-invasive vagus nerve stimulator
14126|NCT04080986|Procedure|Vector Change Defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position and the other with pad placement in anterior-anterior position delivering two rapid sequential shocks.
14127|NCT04080973|Diagnostic Test|CT scan|non contrast spiral CT of the urinary tract including the bony structures of the spine and pelvis
14128|NCT04080973|Diagnostic Test|24 hour urine collection|24 hours collection of urine and measurement of the concentration of calcium, phosphorous, uric acid, oxalate and citrate
14129|NCT04080960|Behavioral|Lifestyle modification education|Lifestyle modification education and goal setting
14130|NCT04080947|Drug|Control group|patients received matching-image placebo once daily at bedtime for 24 weeks.
14131|NCT04080947|Drug|Montelukast group|patients received montelukast (10-mg chewable tablet) once daily at bedtime for 24 weeks.
14132|NCT04080934|Behavioral|Swimming|Patients will participate in 8 weeks of the swimming program, which involves three weekly swimming sessions of 30 minutes minimum.
14133|NCT04080921|Combination Product|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
14134|NCT04080908|Drug|Ferumoxytol injection|Two doses of ferumoxytol injection will be administered intravenously 3-8 days apart.
14135|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
14136|NCT04080895|Drug|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
14137|NCT04080895|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
14138|NCT04080895|Drug|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
14139|NCT04080882|Biological|AbobotulinumtoxinA dose 1|Treatment of platysmal bands
14140|NCT04080882|Other|Placebo|Treatment of platysmal bands
14141|NCT04080882|Biological|AbobotulinumtoxinA dose 2|Treatment of platysmal bands
14142|NCT04080869|Drug|retinyl palmitate|topical retinyl palmitate loaded ethosomes
14143|NCT04080869|Drug|Tretinoin|topical tretinoin
14144|NCT04080843|Drug|Anlotinib Hydrochloride|Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
14145|NCT04080843|Drug|Capecitabine|Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
14146|NCT04080843|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2,D1
14147|NCT04080817|Device|Neolexon|Application (Neolexon) on Tablet. Same frequency & intensity as in the other interventions
14148|NCT04080817|Other|Speech therapy|standard logopedic speech therapy. Same frequency & intensity as in the other interventions
14149|NCT04080817|Other|Self training|Same frequency & intensity as in the other interventions
14150|NCT04080804|Drug|Nivolumab|A fully human anti-programmed death 1 (PD-1) monoclonal antibody checkpoint inhibitor, that blocks a signal that prevents activated T cells from attacking the cancer cells.
14151|NCT04080804|Drug|Relatlimab|A monoclonal antibody with anti-Lymphocyte-activation gene 3 (LAG-3) (immune checkpoint receptor protein found on the cell surface) activity.
14152|NCT04080804|Drug|Ipilimumab|A monoclonal anitibody that targets CTLA-4, a protein receptor, that down regulates the immune system.
14153|NCT04080791|Device|Virtual Reality (VR) System|The participants will undergo daily 30-minute sessions for 8 days of Virtual Reality (VR) with a VR system using commercially available default programs in addition to traditional intensive therapy regimen provided during inpatient rehab.
14154|NCT04080791|Procedure|Standard of care|Control group participants will receive the traditional daily 30-minute intensive therapy regimen provided during acute inpatient rehabilitation stroke treatment protocol.
14155|NCT04080778|Device|MST|MST will be performed with the MagPro XP (120 V) device under anesthesia 2-3 times a week up to 15 sessions.Treatment is performed by magnetic stimulation of both hemispheres inducing a focal stimulation above vertex, using a serial of pulse trains with a frequency of at least 25 Hz but up to 100 Hz for 4-6 s (up to 10 s), which is sufficient to induce a tonic clonic seizure.
14156|NCT04080778|Device|ECT|ECT will be performed with MECTA 5000Q, 4th generation ECT devices provided by MECTA Corporation under anesthesia 2-3 times a week up to 15 sessions.For initial procedure Seizure Threshold (ST) will be estimated by empiric titration in the first session of each participant. ST will be then determined as by the manufacturer of ECT Device by the titration schedule for the initial titration session.The subsequent treatment sessions were dosed at 6 times the charge of the seizure threshold.
14157|NCT04080765|Behavioral|HIV-ASSIST|HIV-ASSIST is an online interactive patient-based tool that allows for individualized HIV treatment recommendations through the synthesis of patient-specific factors with existing guidelines and evidence.
14158|NCT04080765|Behavioral|DHHS guidelines|This is the Department of Health and Human Services HIV/AIDS Treatment Guidelines.
14159|NCT04080752|Drug|JNJ-61393215|JNJ-61393215 will be administrated orally.
14160|NCT04080752|Drug|Placebo|Matching placebo will be administered orally.
14161|NCT04080739|Drug|ropivicaine 0.2%|2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.
14162|NCT04080726|Drug|HIP1601|Oral esomeprazole
14163|NCT04080726|Drug|HGP1705|Oral Nexium Tab
14164|NCT04080726|Drug|HIP1601 Placebo|Oral Placebo
14165|NCT04080726|Drug|HGP1705 Placebo|Oral Placebo
14166|NCT04080713|Drug|Budesonide|Budesonide 9 mg prolonged release tablet
14167|NCT04080700|Procedure|Distal radial approach|Operator puncture the distal radial artery with open needle or venipuncture catheter needle for coronary angiography and percutaneous coronary intervention.
14168|NCT04080687|Device|Ankle-foot orthosis|Ankle-foot orthosis of any type (unilateral or bilateral, standard or carbon fiber, for support or correction)
14169|NCT04080674|Other|Feed-back controlled deep brain stimulation|Feed-back controlled deep brain stimulation
14170|NCT04080661|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of secukinumab.
14172|NCT04080648|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of guselkumab.
14173|NCT04080648|Other|Patient questionnaires|The study participant will complete the dermatology quality of life index (DLQI) and EQ-5D-5L questionnaire at each study visit
14174|NCT04080635|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab
14175|NCT04080635|Other|Patient questionnaires|The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L
14176|NCT04080622|Drug|Selenium|Selenium 300 µg/day (IV infusion)
14177|NCT04080622|Drug|Placebos|NaCl 0,9% (IV infusion)
14178|NCT04080609|Drug|Dorzagliatin|GKA currently under clinical development
14179|NCT04080596|Drug|Dorzagliatin|GKA for T2DM currently under clinical development
14180|NCT04080570|Other|Remote Visit|After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
14181|NCT04080557|Other|Surgery|All patients treated electively for an abdominal aortic aneurysm (AAA) by open repair and patients undergoing emergency treatment for a ruptured AAA between 2013 and 2018.
14182|NCT04080544|Drug|[18F]AV-1451|The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of [18F]AV-1451.
14183|NCT04080544|Procedure|Positron Emission Tomography|Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
14184|NCT04080531|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
14185|NCT04080531|Biological|Trivalent Influenza Vaccine|Given IM
14186|NCT04080518|Drug|Dapagliflozin 10 MG [Farxiga]|24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis
14187|NCT04080505|Drug|SSKI- Potassium Iodide|1g/mL, 2 drops orally 3 times a day for 7 days before surgery
14188|NCT04080492|Other|QOL Survey|The Cardiac Quality of Life (QOL) survey measures health status in five domains: global, physical, emotional, social, and spiritual health. It also includes questions that assess self-efficacy and resilience. The global section asks about your overall quality of life and satisfaction with health. The physical section asks about symptoms and difficulty performing day-to-day tasks. The emotional section asks about depression, anxiety, and stress. The social section asks about social support and relationships. The spiritual section asks about the spiritual outlook on the burden of heart disease. Responses on a 5-level scale.
14189|NCT04080479|Diagnostic Test|Quadriceps Muscle Layer Fitness|The QMLF examination will be performed in all study subjects, with both bolus and continuous enteral feeding.
14190|NCT04080479|Diagnostic Test|Muscle Strength|All study subjects, with both bolus and continuous enteral feeding, will undergo measurement of the muscle strength using dynamometer.
14191|NCT04080479|Diagnostic Test|Acute Physiology and Chronic Health Evaluation|All study subjects, with both bolus and continuous enteral feeding, will undergo the APACHE evaluation.
14192|NCT04080479|Diagnostic Test|Sequential Organ Failure Assessment|All study subjects, with both bolus and continuous enteral feeding, will undergo the SOFA assessment.
14193|NCT04080479|Diagnostic Test|Nutritional Risk Screening|All study subjects, with both bolus and continuous enteral feeding, will undergo the NSR screening.
14194|NCT04080479|Diagnostic Test|Energy and Protein Intake|The amount of energy and protein supplied to the study subjects will be observed daily in all study subjects, with both bolus and continuous enteral feeding, the percentage of the planned daily intake will be analyzed.
14195|NCT04080466|Radiation|Low-dose CT Scan|"Low dose computed tomography, also known as qCT, is sensitive to the mineral content within bone tissue, and can assess bone mineral density, a strong predictor of bone strength and stiffness, which can influence the health of the cartilage. Participants will undergo a low dose CT scan of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
14196|NCT04080466|Other|Blood Collection|"Collection of blood allows researchers to look for a biomarker in the blood that might help to predict the evolution of disease/hip osteoarthritis. Identifying a marker in the blood that could be used for early detection of individuals with cam deformity that are at-risk of hip degeneration could greatly improve patient care.~Participants in the Cam Group will undergo the blood collection twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo a blood collection once as part of the study."
14197|NCT04080466|Other|Patient Reported Questionnaires|"The purpose of the questionnaires is to assess how much trouble the participant is having with their hip and how it affects their quality of life.~Participants in the Cam Group will complete the questionnaires twice; once before surgery and once 2-years post-operative. Participants in the Control Group will complete the questionnaires once as part of the study."
14198|NCT04080466|Radiation|EOS Scan|"The EOS® uses a new imaging technique that allows precise measurement of the hip and pelvis geometry and structure. This innovative x-ray technique exposes participants to 2-10 times less radiation than a routine x-ray and can capture multiple images at once.~Participants in the Cam Group will undergo the EOS scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
14199|NCT04080466|Radiation|PET-MRI|"Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that allows physicians to examine bone and cartilage at the molecular level.~Participants in the Cam Group will undergo the scan twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the scan once as part of the study."
14200|NCT04080466|Other|Motion Analysis|"Motion analysis is the study of how joints move and which muscles fire during specific movements. In the lab, participants will be asked to perform movements that they might do during a typical day or when exercising.~Participants in the Cam Group will undergo the Motion Analysis session twice; once before surgery and once 2-years post-operative. Participants in the Control Group will undergo the Motion Analysis session once as part of the study."
14201|NCT04080466|Radiation|3T MRI|"Participants will undergo a 3-Tesla (3T) Magnetic Resonance Imaging (MRI) of both hips.~Participants in the Cam Group will undergo this scan once as part of their standard of care. Participants in the Control Group will undergo this scan once as part of the study."
14231|NCT04080245|Biological|Treatment Group Live Attenuated Flu Vaccine (LAIV)|We will administer LAIV once as a vaccine prime and IIV once as a vaccine boost with serial weekly blood draws for a month to validate a biomarker of LAIV efficacy.
14202|NCT04080453|Other|Septic shock|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
14203|NCT04080453|Other|Systemic Inflammatory Response Syndrome|Plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha, HMGB-1, monocyte Dnases signal, circulating free DNA and DNase1 and DNase1L3 activities will be studied and compared at inclusion (Day 0), Day 1 and Day 5.
14204|NCT04080440|Procedure|Extubation readiness clinical score|"After treatment of the acute neurological condition, elligibility for a spontaneous breathing trial will be assessed 2 times a day.~In the intervention group, after a successful spontaneous breathing trial in unconscious patients, the score will be evaluated.~If the score is >9, extubation has to be completed"
14205|NCT04080440|Procedure|Standard of care|"After treatment of the acute neurological condition, elligibility for a spontaneous breathing trial will be assessed 2 times a day.~In the control group, after a successful spontaneous breathing trial in unconscious patients, the extubation will be achieved according to the standard of care"
14206|NCT04080427|Drug|Placebo capsule|Placebo is administered just prior to weekly exposure sessions by the oral route and contains only dextrose in opaque capsules.
14207|NCT04080427|Drug|Dronabinol 7.5 milligram oral capsule|Dronabinol (7.5mg) is administered just prior to weekly exposure sessions by the oral route and is placed in an opaque capsule with dextrose filler.
14208|NCT04080414|Behavioral|Home-based high-intensity interval training|Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
14209|NCT04080414|Behavioral|Home-based moderate-intensity continuous exercise|Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
14210|NCT04080401|Device|Game-based rehabilitation exercise|4 games (exercises) on operated limb, for 3 sessions daily, until outpatient physiotherapy review visit.
14211|NCT04080401|Other|Conventional brochures of rehabilitation exercise|4 exercises on operated limb, 30 reps each, for 3 sessions daily, until outpatient physiotherapy review visit.
14212|NCT04080388|Diagnostic Test|Lung Impedance Device|The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.
14213|NCT04080388|Drug|Anti-congestive treatment|Continuation of in-hospital anti-congestive treatment
14214|NCT04080375|Drug|Dinoprostone 3 mg|the patient will take one vaginal tablet of 3 mg dinoprostone 1 hour before surgery
14215|NCT04080375|Drug|placebo|the patient will take one vaginal tablet of placebo 1 hour before surgery
14216|NCT04080362|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial neochordae or ege-to-ege repair using MitralStitch System
14217|NCT04080349|Drug|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
14218|NCT04080349|Drug|Misoprostol 200Mcg Tab|1 vaginal tablet of misoprostol (200 mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
14219|NCT04080349|Drug|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion
14220|NCT04080336|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3hours before IUD insertion.
14221|NCT04080336|Drug|Misoprostol|1 vaginal tablet of misoprostol (200mcg) (Misotac®; Sigma Pharma, SAE, Egypt) inserted by the study nurse 3 hours before IUD insertion.
14222|NCT04080336|Drug|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
14223|NCT04080323|Drug|Dinoprostone 3 mg|1 vaginal tablet of 3mg dinoprostone 60 minutes before surgery
14224|NCT04080323|Drug|placebo|1 vaginal tablet of placebo 60 minutes before surgery
14225|NCT04080310|Drug|Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin|"This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.~After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily."
14226|NCT04080297|Drug|oral capsule of Q-122|
14227|NCT04080284|Drug|Niraparib|Study treatment will be administered orally Q day continuously. Up to three capsules of 100mg strength will be taken at each dose administration. Initiation dose will be defined per current FDA guidelines for Niraparib treatment in ovarian cancer. Dose interruption (no longer than 28 days) will be allowed. Dose reduction will be allowed based on treatment side effects. Dose reductions to 2 capsules daily (200mg) and subsequently to 1 capsule daily (100mg) will be allowed. No further dose reductions will be allowed. The timing of efficacy or safety evaluations should not be affected by dose interruptions or reductions.
14228|NCT04080271|Device|18F-FDG PET/CT|18F-fludeoxyglucose positron emission tomography/computed tomography
14229|NCT04080258|Other|Osteopathic manipulative therapy (OMTh)|"The Osteopathic Manipulative Therapy includes both evaluation and treatment. The evaluation is semi-structured, two osteopaths will assess the presence of somatic dysfunctions which have to include the hyoid-pharyngeal, laryngeal, temporo-mandibular and lingual areas.~The therapy is based on the treatment of somatic dysfunctions with different approaches that include: the balanced ligamentous tension technique, the myofascial release, the visceral manipulation, and the balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 of evaluation and 30 of treatment."
14230|NCT04080258|Other|Light Touch Therapy (LTT)|The Light Touch Therapy is a sham treatment consistent with the OMTh one during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body by moving the hands every few seconds and by flattening and softening the surface of the hands in order to minimize focal areas of force.
15245|NCT04071743|Device|sham gammaCore Sapphire|sham gammaCore Sapphire
14232|NCT04080232|Device|lung MRI|lung MRI (1.5T Siemens Aera) using the following sequences: 3D Fast gradient-echo pulse sequences with ultra-short echo time (UTE), acquisitions at end-inspiration breath hold, end-expiration breath hold, and free-breathing using an echonavigator positioned on the diaphragm, acquisitions using routine pulse sequences (SSFP, T2FSE) and the administration of oxygen during the MRI: O2 will be administered at 15L/min during 6 minutes.
14233|NCT04080206|Drug|188-0551 Spray|Applied topically twice daily for two weeks
14234|NCT04080206|Drug|RLD|Applied topically twice daily for two weeks
14235|NCT04080193|Behavioral|Smartphone-based interventional trial|According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
14236|NCT04080180|Behavioral|Contingency Management|Contingency management (CM) is a behavioral method that employs external rewards for target behavior. For this study, participants will receive vouchers for adhering to Medication-Assisted Treatment.
14237|NCT04080180|Behavioral|Brief Motivational Intervention plus Substance Free Activities Session|Brief Motivational Intervention plus Substance Free Activities Session (BMI+SFAS) is an intervention that uses Motivational Interviewing and Behavioral Economics strategies to increase the salience of delayed rewards by eliciting personal goals, developing opioid-free activities, and engaging in reward bundling and episodic future thinking.
14238|NCT04080167|Behavioral|InCharge Health mobile application|"The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a health partner; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a health partner, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been <4 hours since not documenting the use of hydroxyurea. The app healthy partner will be encouraged to message the participant to remind him/her to take the medication."
14239|NCT04080167|Behavioral|HU Toolbox mobile application|The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.
14240|NCT04080154|Drug|Anlotinib|12mg orally (p.o.) every day (qd) for 2 weeks of every 3 week cycle (i.e. 2 weeks on, 1 week off)
14241|NCT04080141|Diagnostic Test|Multiple psychometric questionnaire|At the time of first contact (T0) only women were subjected to Hamilton's rating scale for depression (HRSD or HAM-D), Hamilton's rating scale for anxiety (HRSA or HAM-A), Beck Depression Inventory (BDI-II). At the follow up after 1 year from the first examination (T1) they were subjected to a questionnaire with multiple psychometric tests for mother and her partner. The female version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Beck Depression Inventory (BDI-II), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF). The male version included Post-traumatic stress disorder checklist (PCL-5), Iowa Personality Disorder Screen (IPDS), Connor-Davidson Resilience Scale 10 (CD-RISC 10) and Short-Form Questionnaire on childhood trauma (CTQ-SF).
14242|NCT04080141|Procedure|Clinical psychiatric examination|At the time of first contact (T0) only women were subjected to psychiatric clinical examination
14243|NCT04080128|Device|Contact lenses|Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
14244|NCT04080115|Behavioral|Attention Training Technique|ATT will be administered through a customized Expimetrics smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The ATT sessions are comprised of three phases. The first is a 5-minute phase during which the participant is instructed to attend to specific sounds in the recording and disregard other sounds. The subsequent 5-minute phase includes instructions to rapidly switch their attention between sounds in the recording. The final phase is a dual attention task lasting 2 minutes wherein the participant is instructed to pay attention to multiple sounds in the recording at once. In total, each session of ATT lasts 12 minutes.
14245|NCT04080115|Behavioral|Progressive Muscle Relaxation|PMR will be administered through a customized Expimetrics smartphone application that will be downloaded onto participants' cell phones at the first laboratory session (T2). For the purposes of the proposed study, participants need to complete the intervention once a day, for the six days between their lab sessions; signals will begin the day after their T2 session and they will be notified up to a maximum of five times per day to complete their daily session. The PMR group will complete a 12-minute audio-led exercise wherein the participant is asked to sit comfortably in a chair and progressively tense and relax muscles in their body according to the instructions in the recording.
14246|NCT04080102|Other|High Intensity Interval Training|Exercise
14247|NCT04080102|Dietary Supplement|Essential Amino Acid|Oral ingestion of a powdered dietary supplement
14248|NCT04080102|Other|High intensity interval training and essential amino acid supplement|Exercise and dietary supplement
14281|NCT04079790|Drug|Gepotidacin|Tablets containing gepotidacin mesylate with a unit dose of 750 mg will be administered orally with 240 milliliter (mL) of water.
14249|NCT04080089|Combination Product|Surgical treatment, drug therapy, remote cognitive training|"Surgical treatment：Children with OSAHS who had surgical indications and informed consent from the parents underwent tonsillectomy and adenoidectomy.~drug therapy：For children whose parents only agree to receive medical treatment, montelukast sodium tablets are given for 6 months to reduce the inflammatory response of adenoids, tonsils, etc.~remote cognitive training:For children whose parents did not agree to undergo surgery or medication, the cognitive function was evaluated at the time of enrollment, and cognitive training was performed. Individualized training programs were developed according to the cognitive assessment system, and cognitive function was evaluated again after one course of treatment."
14250|NCT04080076|Drug|Acthar 80 UNT/ML Injectable Solution|ACTHar 80 Units SQ 2 x Week
14251|NCT04080076|Drug|Tacrolimus capsule|Tacrolimus 1.0mg PO BID
14252|NCT04080063|Other|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
14253|NCT04080050|Drug|Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy|No investigational product will be administered in this study. All participants have previously received a one-time intravenous infusion of RGX-501 in a separate clinical trial
14254|NCT04080037|Other|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, with a specific focus on the CDC opioid guidelines.~Cases will cover typical primary care patients presenting with acute and chronic pain, who may or may not be already taking opioid medication."
14255|NCT04080024|Drug|SN132D|Novel manganese-based macromolecular MRI contrast agent
14256|NCT04080011|Device|NP-PWD|Application of NP-PWD device.
14257|NCT04079998|Device|Procellera®|Application of Procellera® dressing.
14258|NCT04079998|Other|Standard of Care|Application of standard of care dressings as prescribed.
14259|NCT04079985|Other|Animal-assisted therapy|The sessions were held in the primary care centre, and had specific objectives agreed in advance by the research team. The sessions had the following schedule: Session 1, lower extremities in sitting position; Session 2, upper extremities in sitting position; Session 3, cervical spine in sitting position; Session 4, dorsal spine in sitting position; Session 5, lumbar spine in sitting position; Session 6, Static Standing and Upper Extremities; Session 7, Static Standing; Sessions 8, 9, 10 and 11, Dynamic Standing; and Session 12, Safety Reinforcement.
14260|NCT04079972|Behavioral|personalized lifestyle intervention|Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.
14261|NCT04079972|Behavioral|general lifestyle intervention|Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
14262|NCT04079959|Procedure|endometrial biopsy|. Endometrial samples are obtained using a biopsy catheter as follows: the Pipette is inserted through the cervical os and advanced gently until resistance is felt. The inner piton of the device is then withdrawn to create suction, and the endometrial sample is obtained by moving the pipette up and down approximately 2-3 cm within the uterine cavity. The device is rotated 360° to ensure adequate coverage of the area.
14263|NCT04079946|Procedure|Total Mesocolic Excision with Central Vessel Ligation|sharp dissection of the anatomical layers and the dissection of the visceral plane from the parietal one . In addition a central division of the feeding arteries at their origins is performed at the level of superior mesenteric artery for tumors of the right colon and at the level of inferior mesenteric artery or the aorta for tumors of the left colon .this allows for removal of the maximum number of lymph nodes possible.
14264|NCT04079946|Procedure|conventional surgery of cancer colon|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
14265|NCT04079933|Other|Oral tobacco-derived nicotine product (OTDN)|
14266|NCT04079907|Dietary Supplement|Ketone|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
14267|NCT04079907|Dietary Supplement|Placebo|This intervention will take their respective supplement for 14 days, then will be followed for up to 1 year during routine clinic visits.
14268|NCT04079894|Other|Standard Movement Protocol|Participant walking, cycling and sitting according to a pre-specified protocol.
14269|NCT04079894|Device|Accerelerometer Monitoring|7 days of accelerometer monitoring in participants home-environment.
14270|NCT04079881|Drug|Insulin|to give pre-prandial and post-prandial insulin (will use patient insulin dose patient use at home) to patients with T1D and evaluate the response of post-prandial glucagon and post-prandial hyperglycemia.
14271|NCT04079868|Behavioral|Bone Health Service Model|Patients in PACTs randomized to the BHS model will have osteoporosis screening, education, and follow-up handled centrally by the bone health team.
14272|NCT04079868|Behavioral|PACT Practice Management Model|This model represents a robust practice management support model, with multiple tools and processes to facilitate osteoporosis care. In addition, it adds an adherence support component.
14273|NCT04079855|Other|Diet composition 1|A diet with a specified macronutrient composition different from arms 2, 3, and 4.
14274|NCT04079855|Other|Diet composition 2|A diet with a specified macronutrient composition different from arms 1, 3, and 4.
14275|NCT04079855|Other|Diet composition 3|A diet with a specified macronutrient composition different from arms 1, 2, and 4.
14276|NCT04079855|Other|Diet composition 4|A diet with a specified macronutrient composition different from arms 1, 2, and 3 based on the current information about the US macronutrient composition.
14277|NCT04079829|Other|Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data|No interventions
14278|NCT04079803|Drug|Placebo oral tablet|Oral placebo tablet
14279|NCT04079803|Drug|PTI-125 50 mg tablet|PTI-125 50 mg oral tablet
14280|NCT04079803|Drug|PTI-125 100 mg oral tablet|PTI-125 100 mg oral tablet
14282|NCT04079790|Drug|Placebo|Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
14283|NCT04079777|Drug|Clinical treatment|Liquid Resuscitation, Anti-infection
14284|NCT04079751|Procedure|Neutral Mechanical Alignment|Hip-knee-ankle angle of 180° ± 3°.
14285|NCT04079751|Procedure|Anatomical Alignment|Restoring a patient's pre-diseased limb alignment
14286|NCT04079738|Drug|TAK-659|TAK-659
14287|NCT04079738|Drug|Ixazomib|Ixazomib
14288|NCT04079725|Procedure|Combined trabeculotomy-trabeculectomy with mitomycin c|Combined trabeculotomy-trabeculectomy with mitomycin C Will be done in all cases then histopathological examination of iris tissue to detect the nature of the disease
14289|NCT04079712|Drug|Cabozantinib|Given PO
14290|NCT04079712|Drug|Cabozantinib S-malate|Given PO
14291|NCT04079712|Biological|Ipilimumab|Given IV
14292|NCT04079712|Biological|Nivolumab|Given IV
14293|NCT04079699|Diagnostic Test|Liquid Biopsy|Measuring biomarkers in blood and urine samples
14294|NCT04079699|Diagnostic Test|Standard biopsy|Histological examination of tissue biopsies
14295|NCT04079686|Drug|Cephazolin|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and postoperatively every 6 hours, for 24 hours.
14296|NCT04079686|Other|Sterile saline|Patients undergoing reduction mammaplasty will receive 1g of cephazolin intravenously anesthetic induction and intravenous sterile saline postoperatively, every 6 hours, for 24 hours.
14297|NCT04079673|Procedure|Patient controlled epidural analgesia|Patient controlled epidural analgesia with marcaine 0.66mg/ml +fentanyl 1.75mcg/ml for postoperative pain control
14298|NCT04079673|Drug|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
14299|NCT04079660|Diagnostic Test|Capillary blood glucose blood draw|Capillary blood glucose (CBG), HbA1c, fructosamine, albumin, BUN, and creatinine values will be obtained from a blood draw as a standard of care
14300|NCT04079647|Drug|Immunotherapy|Patients receive immunotherapy for cancer treatment
14301|NCT04079634|Device|Esophageal warming|Use of EnsoETM for esophageal warming to limit injury during atrial fibrillation ablation procedure
14302|NCT04079634|Device|Control|Standard temperature probe monitoring
14303|NCT04079621|Drug|primaquine|Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)
14304|NCT04079608|Behavioral|FLASH curriculum|High School FLASH is a 15-session comprehensive sexual health curriculum designed for classroom settings in grades 9 to 12. The basis of High School FLASH is a public health approach to behavior change. The primary strategy used in the FLASH curriculum for preventing teen pregnancy, sexually transmitted diseases (STDs), and sexual violence is to address student behaviors and attitudes. To this end, FLASH uses a harm reduction and behavior change framework, implements best practices as outlined in the research on effective programs, addresses risk and protective factors for program goals, and rests on the theory of planned behavior. The instructional approach of High School FLASH employs key concepts in every lesson, which enables teachers to hone in on the risk and protective factors outlined in the curriculum logic model.
14305|NCT04079608|Behavioral|Sexual Health Education for Adolescents|Sexual Health Education for Adolescents is a five-session knowledge-based sexual health curriculum designed for classroom settings. The lessons cover the reproductive system, pregnancy, birth control, abstinence, human immunodeficiency virus (HIV) and other sexually transmitted diseases (STDs), and healthy relationships. The goal of the curriculum is to increase student knowledge in all content areas. The primary strategy employed by Sexual Health Education for Adolescents is to address the cognitive learning domain. The curriculum aligns to national health education standards and is intended to be implemented by classroom teachers. The lessons can be delivered according to the schedule that works best for schools (e.g., twice a week, once a week, every days) within a school semester.
14306|NCT04079595|Device|Head immobilization mask|Immobilization
14307|NCT04079582|Other|Higher dialysate magnesium formulation|Dialysis centres randomized to the intervention arm will provide a dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L).
14308|NCT04079569|Behavioral|Tobacco|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
14309|NCT04079569|Behavioral|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
14310|NCT04079556|Behavioral|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
14311|NCT04079543|Other|NPO past midnight|NPO after midnight (solids and liquids), except for a sip of water with medication.
14312|NCT04079543|Other|NPO|No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
14313|NCT04079530|Drug|K-877 IR 0.2 mg/day|K-877 IR 0.1 mg tablet
14314|NCT04079530|Drug|K-877 CR 0.4 mg/day|K-877 CR 0.4 mg tablet
14315|NCT04079530|Drug|K-877 CR 0.8 mg/day|Two K-877 CR 0.4 mg tablet
14316|NCT04079517|Drug|Tamoxifen|A registered SERM drug, Tamoxifen.
14317|NCT04079504|Procedure|Ligation of indirect hernia sac|Indirect inguinal hernia sac will be separated from the spermatic cord and contents of the sac will be reduced before ligating it at the deep inguinal ring.
14318|NCT04079504|Procedure|Non-ligation of Indirect Inguinal hernia sac|the indirect inguinal hernia sac will be separated from the spermatic cord and reduced/inverted in to the peritoneal cavity through the deep inguinal ring along with its contents.
14319|NCT04079491|Other|questionnaire survey|A web-based questionnaire will be send by the trade union for dental hygienists
14320|NCT04079478|Other|AI|Artificial intellignece colonoscopy
14321|NCT04079465|Device|O2matic|O2matic controls oxygen supply with a closed-loop feedback from a pulse oximeter. The aim is to maintain SpO2 within a predefined target interval according to guidelines for the specific condition causing hypoxemia, with the lowest possible supplementation of oxygen.
14322|NCT04079452|Drug|Doravirine|Doravirine 100 mg tablet
14323|NCT04079452|Drug|Descovy|Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet
14324|NCT04079439|Behavioral|Physical activity with tailored e-health support|The planned e-health intervention will contain several elements: A motivating smartphone app registers indoor- and outdoor activity as well as activity from the use of an ergometer-bike. For recording of outdoor activity commercial wrist-born accelerometers will be used. The app-solution will be motivating and result in a reward after a predefined level of activity.
14325|NCT04079426|Other|Sampling of Blood and bronchoalveolar lavage|Multiplex assays for pro- and anti-inflammatory markers and incubation of immune cells isolated from serum and bronchoalveolar lavage fluid of patients with ARDS.
14326|NCT04079413|Drug|GP40071|GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
14327|NCT04079413|Drug|NovoRapid® Penfill®|NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
14328|NCT04079387|Device|ENDOTRACHEAL TUBE + STYLET|"The experimental group consists in intubating the trachea with an endotracheal tube + stylet with a straight-to-cuff shape and a bend angle of 25° to 35°"
14329|NCT04079387|Device|ENDOTRACHEAL TUBE ALONE|intubating the trachea with an endotracheal tube alone
14330|NCT04079374|Drug|Etanercept|Subcutaneous injections
14331|NCT04079374|Drug|Enbrel|Subcutaneous injections
14332|NCT04079361|Diagnostic Test|Blood samples|Bood samples during prenatal and postnatal visits
14333|NCT04079348|Device|Oasis ECM|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Oasis Extracellular Matrix to their donor site wound.
14334|NCT04079348|Device|Aquacel AG|The patient will undergo harvesting of a split-thickness skin graft using a dermatome set at standard depth with the subsequent application of Aquacel AG dressing to their donor site wound.
14335|NCT04079322|Other|Meal|Participants will consume a meal containing a stable iron isotope following exercise or rest.
14336|NCT04079309|Behavioral|Lavender/Orange|A diffuser containing 120 ml water and 0.3 ml lavender oil / 0.3 ml orange oil will be set into the parents' perioperative waiting rooms to mist at least 1 hour before the parent arrive.
14337|NCT04079296|Biological|ASP7517|Intravenous (IV)
14338|NCT04079283|Diagnostic Test|Clinical|Clinical: A diagnostic model incorporating clinical variables (Age, Pathological diagnosis, level of serum tumor biomarkers etc.)
14339|NCT04079283|Diagnostic Test|Agnostic|Agnostic: A diagnostic model incorporating agnostic radiological features (shape, location, border, density etc.)
14340|NCT04079283|Diagnostic Test|Radiomic|Radiomic: A diagnostic model incorporating quantitative radiomic features (histogram, texture, morphology etc.)
14341|NCT04079270|Other|Nutrition intervention|The diet recommendations will be provided by a certified dietitian. Participants will be asked to document their food intake and daily activities including exercise and sleep using a dedicated smartphone app throughout the intervention period.
14342|NCT04079257|Other|Blood collection for measurement of eculizumab peak concentrations|collection of blood
14343|NCT04079244|Behavioral|Video game|"Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children."
14344|NCT04079244|Behavioral|Animated cartoon|"Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children."
14345|NCT04079231|Drug|Brolucizumab|Intravitreal Injection
14346|NCT04079231|Drug|Aflibercept|Intravitreal injection
14347|NCT04079218|Drug|Estradiol Vaginal Insert|Using a pre-loaded single-use plastic applicator, participants will insert one 10 microgram estradiol tablet intravaginally daily for 2 weeks and then one tablet twice weekly for the remainder of the study for a total of 12 weeks.
14348|NCT04079205|Device|Wearable Device(exoRehab)|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction using Wearable Device (exoRehab)
14349|NCT04079205|Behavioral|Home rehabilitation program|rehabilitation program for patients after Anterior Cruciate Ligament Reconstruction
14350|NCT04079192|Device|Biolimus A9 Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
14351|NCT04079192|Device|SeQuent Please Paclitaxel Drug Coated Balloon|A non-surgical procedure that uses a catheter to place a semi-compliant angioplasty drug coated balloon to open up coronary arteries that have been narrowed by atherosclerosis. The balloon is inflated to treat the stenosis and transfer the drug to arterial wall, and then is deflated and withdrawn.
14352|NCT04079179|Drug|Cobimetinib|All groups will receive the same intervention. Cobimetinib will be given orally at a maximal dose of 60mg daily for 21 days on, then 7 days off, in a 28-day treatment cycle for a total of 12 cycles (approximately 12 months).
14407|NCT04078737|Drug|Clopidogrel and Aspirin|"Day of randomization:~Day 1: Clopidogrel 300mg; placebo of ticagrelor 180mg; aspirin 75-300mg (open label) Day2-21st: Clopidogrel 75mg/day; placebo of ticagrelor 90mg bid/day; aspirin 75mg (open label) Day 22nd-3 months:Clopidogrel 75mg; placebo of ticagrelor 90mg bid/day"
14408|NCT04078724|Dietary Supplement|5-HTP|5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.
14409|NCT04078724|Other|Without 5-HTP|Subject will not take 5-HTP
14410|NCT04078711|Drug|Losartan 100Mg Tab|100Mg Tab, qd, po, 6 months
14411|NCT04078711|Drug|Qianyangyuyin 20g Granule|20g, Granule, bid, po, 6 months
14412|NCT04078711|Drug|placebo|Similar granule manufactured to mimic qianyangyuyin granule, 20g, Granule, bid, po, 6 months
14353|NCT04079166|Biological|SCIB1 administered with a small, hand-held electroporation device (TDS-IM v2.0).|"SCIB1 to be given for up to 2 years, The plan for this research study is for SCIB1 to be given for up to 2 years, in combination with pembrolizumab according to the current label.~After the initial dose of SCIB1, the patient will then receive SCIB1 3 times, 3 weeks apart, then once 6 weeks later, and after that once every 12 weeks until the treatment is stopped.~Pembrolizumab will be given by an infusion into the patient's vein once every 3 weeks. This normally takes about 30 minutes to complete.~Every time the patient has a SCIB1 infusion, they will also receive pembrolizumab. Additionally, there will also be some days when the patient will receive pembrolizumab alone.~On each occasion, SCIB1 will be given by two injections into a muscle in a different limb, e.g. one into the upper arm and the other into the thigh. Instead of a normal needle and syringe, a small, hand-held electroporation device (TDS-IM v2.0) will be used to inject SCIB1 into the muscles."
14354|NCT04079166|Device|Electroporation device (TDS-IM v 2.0).|The small, hand-held electroporation device (TDS-IM v2.0) will be used to administer SCIB for up to 2 years.
14355|NCT04079153|Device|Mandibular advancement Appliance|Advances the mandible at desired range at a fixed vertical dimension
14356|NCT04079140|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 3 hours before IUD insertion.
14357|NCT04079140|Drug|placebo|one tablet of placebo inserted by the study nurse 3 hours before IUD insertion.
14358|NCT04079127|Device|Patients who met the inclusion/exclusion criteria to receive the Avenir Müller stem.|Consecutive cohort of patients enrolled at every site who received the Avenir Müller stem.
14359|NCT04079114|Device|Patients who received the Stafit Acetabular System|Patients, suffering from severe hip pain and disability, requiring primary total hip arthroplasty with high risk of dislocation, who meet the inclusion/exclusion criteria.
14360|NCT04079101|Drug|BIIB104|Administered as specified in the treatment arm.
14361|NCT04079101|Drug|Placebo|Administered as specified in the treatment arm.
14362|NCT04079088|Drug|Placebo|Administered as specified in the treatment arm.
14363|NCT04079088|Drug|BIIB061|Administered as specified in the treatment arm.
14364|NCT04079088|Biological|Interferon-beta1|Stable dose as prescribed by the physician.
14365|NCT04079075|Other|Cognitive training|"This comprises training using using the cogweb software, both in person and remotely:~i) in person training: 30-minute sessions, supervised by a trained nurse, twice weekly .~ii) remote training: unsupervised 30-minute sessions, to be performed at home at the participants will."
14366|NCT04079075|Behavioral|Physical activity|This is based on 60-minute sessions including aerobic, resistance, agility/balance and flexibility exercises, directed by a physical education teacher and supervised by a nurse, twice weekly.
14367|NCT04079075|Behavioral|Nutrition education|"This is based on monthly 180-minute sessions, directed by a nutritionist, comprising:~i) Presentation and discussion of healthy and easy to cook recipes by the nutritionist; ii) Preparation of healthy meals by the participants, followed by a period of social interaction between the participants while consuming the meals prepared."
14368|NCT04079075|Behavioral|Adaption to memory loss|This is based on monthly 30-minute sessions, directed by a psychologist or a nurse, who will provide strategies that participants may use in their daily life to cope with memory loss.
14369|NCT04079075|Diagnostic Test|Diagnosis of hearing impairment|Before implementing the sessions of cognitive training, physical activity, nutrition education and adaption to memory loss, an audiologist will perform an audiogram to all participants. Those with auditive performance inferior to the reference values will be referred for a medical appointment with an otolaryngologist.
14370|NCT04079062|Biological|ONO-4685|Single ascending dose of ONO-4685 will be administered by intravenous continuous infusion at the designated speed.
14371|NCT04079062|Biological|Placebo|Placebo will be administered by intravenous continuous infusion at the designated speed.
14372|NCT04079062|Biological|KLH|KLH 1 mg per dose will be subcutaneously administered. In addition, all subjects will be administered placebo after KLH administration.
14373|NCT04079062|Biological|KLH, ONO-4685|Part C will be conducted in a study design that ONO-4685 will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose regimens selected according to the investigation result in Part B.
14374|NCT04079062|Biological|KLH, placebo|Part C will be conducted in a study design that placebo will be administered within the dose range, for which the safety has been confirmed in Part A, after administering KLH in the dose resimens selected according to the investigation result in Part B.
14375|NCT04079049|Procedure|Surgical intervention|Surgical intervention by liver resection, ablation or stereotactic body radiotherapy as complement to oncological treatment
14376|NCT04079049|Drug|Control|Oncological treatment in control group
14377|NCT04079023|Procedure|Sleeve Gastrectomy|Subtotal vertical gastrectomy
14378|NCT04079010|Procedure|BFR|Blood flow restriction (BFR) training is a non-invasive technique that uses wraps, bands, or inflated blood pressure cuffs to change blood flow within targeted muscles. Occlusion pressure of the femoral artery will be determine before each training session using the Delfi Personalize Tourniquet System for Blood Flow Restriction (2.0) which has embedded ultrasound technology to continually measure the blood flow and with auto-adjust the pressure. The target percent of occlusion is 50% of total blood flow while completed a prescribed resistance training regimen 4 times per week.
14379|NCT04079010|Dietary Supplement|Arginine|"The BFR+Arg group will consume Arginine supplement daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg L-Arginine (ARG; Kyowa). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
14413|NCT04078698|Device|Immunoadsorbers GLOBAFFIN®, LIGASORB® and IgEnio®|Documentation of the treatment with one of the immunoadsorbers GLOBAFFIN®, LIGASORB® or IgEnio® depending on the patient's underlying disease
14380|NCT04079010|Dietary Supplement|Placebo Pill|"The CON and BFR groups will consume placebo pill daily throughout the course of the study. Supplements were manufactured by Kyowa, a US-based cGMP-compliant contract manufacturing facility independently audited and pre-qualified by the quality compliance firm, Obvium*Q, LLC (Dallas, TX). Manufacturing batch records for production of each of the supplements were maintained by the manufacturer and finished supplements were independently assayed for identity, purity, potency, and composition using appropriate USP, AOAC, or BAM methods at the independent, analytical laboratory, Dyad Labs (Salt Lake City, UT), prior to approval for release and consumption of the supplements by participants.~Each serving of the supplements were formulated to contain 3,000 mg Maltodextrin placebo (PLA; MALTRIN-M100; Grain Processing Corporation; Muscantine, IA). Each supplement also contained the inert and non-insulinotropic excipient ingredients, microcystalline cellulose and silicon dioxide."
14381|NCT04078997|Other|nasopharyngeal swab|A nasopharyngeal swab will be collected from consenting individuals by inserting a commercially-available dacron swab to the nasopharynx, gently rotating before removing.
14382|NCT04078984|Other|Experimental|"Daily measures of End Inspiratory Pressure with respiratory synchronisation optimised by use of EAdi~Daily spontaneous breathing trial using low levels of pressure support~Pplat, Respiratory System Compliance, Driving Pressure, PEEP, Tidal Volume will be monitored daily as well as clinical and other routine ventilatory data. Data concerning initial severity of ARDS, and duration of ARDS, controlled mechanical ventilation, sedation and neuromuscular blockade and date of first spontaneous breathing trial will be collected. A weaning test will be conducted daily."
14383|NCT04078971|Other|Western diet|Subjects in this intervention will follow a normal western diet
14384|NCT04078971|Other|ketogenic diet|Subjects in this group will follow a low carbohydrate ketogenic diet
14385|NCT04078958|Dietary Supplement|Salmon fishmeal|Salmon fishmeal with high protein content
14386|NCT04078958|Dietary Supplement|Whey|Whey with high protein content
14387|NCT04078932|Behavioral|Violence Prevention Conversation Script to Discuss Safely Navigating Police Encounters|A conversation script to facilitate conversations on safely navigating police encounters as anticipatory guidance and violence prevention strategy. The conversation script will be created using expert recommendations from existing resources and using recommendations (determined from focus groups) from black male youth and their caregivers. The script will be patient-centered.
14388|NCT04078919|Dietary Supplement|Nut consumption|daily consumption of 20 percent of daily calories intake from nuts (pistachio, almond and peanuts)
14389|NCT04078919|Other|Low calorie diet|Low calorie diet
14390|NCT04078906|Other|n3-LCPUFA enriched Intravenous Lipid Emulsion|To start from D0 at 1g/kg/day and increase by 1 g/kg daily till reaching 3 g/kg/day.
14391|NCT04078893|Other|telephone recruitment|using telephone to recruit inactive donors on two different methods
14392|NCT04078880|Dietary Supplement|Sucrosomial iron plus ascorbic acid|A number of 41 subjects are supplemented with 30 mg of iron plus 70 mg of ascorbic acid daily for 30+/-5 days before orthopedic surgery.
14393|NCT04078867|Procedure|tricuspid valve repair|Tricuspid valve repair during mitral valve replacement for rheumatic heart disease using suture (DeVega) repair or ring annuloplasty
14394|NCT04078854|Behavioral|Diabetes education|Both presentations are identical in educating patients how to control diabetes and the risk of future amputations in diabetes, but the experimental arm presentation will also include information regarding sexual dysfunction in diabetes.
14395|NCT04078841|Dietary Supplement|ReaLife+ (RLP)|RLP is a dietary supplement containing Acetogenins, vitamin, mineral and amino acids.
14396|NCT04078841|Other|Inert Brown powder|Brown powder Inert brown powder to look similar to RLP
14397|NCT04078828|Procedure|Pelvic floor Reconstruction|Pelvic floor Reconstruction after laparoscopic anterior resection and double-stapling technique anastomosis were finished.
14398|NCT04078802|Procedure|VNOTES/VH|same as above
14399|NCT04078776|Other|No intervention|There is no intervention in this study
14400|NCT04078763|Behavioral|Rehabilitation protocol with visual-auditory feedback|The rehabilitation protocol with visual-auditory feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will always have a visual-auditory feedback
14401|NCT04078763|Behavioral|Rehabilitation protocol with visual feedback|The rehabilitation protocol with visual feedback is based on 8 sessions, over a period of 1 month, with 2 sessions per week. Each session lasts 45 minutes. During a session, the participant has to localize a sound around him, at hand. For this, he has to direct his head (which acts as a pointer) to the place where he seems to get the sound. Then, he validates his answer using the joystick placed in his hand. Regardless of the answer given (exact or incorrect), the subject will only have a visual feedback.
14402|NCT04078763|Behavioral|SPHERE protocol|"Data from spatial sound perception will be recorded in three dimensional space (azimuth, elevation, and depth). First, the pointing error will be computed separately for azimuth, elevation, and depth, in terms of constant error (absolute and signed) and variable error. Then, these separate errors will be combined into a cumulative error 3d-D, hence summarizing all three space dimensions, and taking into account absolute and variable error in one measure. This lasts 10 minutes and the result is expressed by the 3d-D value"
14403|NCT04078763|Behavioral|French Matrix Test|This test assesses the intelligibility threshold defined as the noise level (in decibels) for which the subject can repeat 50% of the words heard (in dichotic listening), resulting in an Speech Recognition Threshold (SRT) value. This test lasts 10 minutes.
14404|NCT04078763|Behavioral|Speech Spatial and Qualities of Hearing Scale (SSQ15) questionnaire|15 items questionnaire (each answer to questions is quoted between 0 and 10) resulting in a global SSQ 15 score. It takes 10 minutes to fill the questionnaire.
14405|NCT04078750|Behavioral|Tailored medication adherence plan|Comparison of mean daily medication adherence between intervention and control groups over 3 months, as measured by MEMS caps.
14406|NCT04078737|Drug|Ticagrelor and Aspirin|"Day of randomization:~Day1:Ticagrelor 180mg; placebo of clopidogrel 300mg; aspirin 75-300mg (open label) Day2-21st: Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg; aspirin 75mg (open label) Day 22nd-3 months:Ticagrelor 90mg bid/day; placebo of clopidogrel 75mg"
14414|NCT04078685|Procedure|Standard catheter ablation|Radiofrequency catheter ablation using a standard ablation catheters: not equipped with contact-force sensing
14415|NCT04078685|Procedure|Contact Force-sensing-based catheter ablation|Radiofrequency catheter ablation using a Contact-Force-sensing ablation catheter
14416|NCT04078672|Procedure|NOTAL-OCT V3.0|AMD and DR patients
14417|NCT04078659|Drug|Propofol infusion|Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
14418|NCT04078659|Drug|Magnesium Sulfate infusion|Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
14419|NCT04078659|Drug|Lidocaine|Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
14420|NCT04078659|Drug|Fentanyl|Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
14421|NCT04078659|Drug|Propofol|Patients will receive propofol in a dose of 1-2 mg /kg
14422|NCT04078659|Drug|Atracurium|Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
14423|NCT04078659|Procedure|Mechanical Ventilation|Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
14424|NCT04078646|Other|Intervention with soy protein isolate|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added soy protein, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
14425|NCT04078646|Other|Intervention with whey protein|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), with 30 g added whey protein isolate, plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
14426|NCT04078646|Other|Intervention without protein addition|"Test meals will be served to the subjects, containing soy protein isolate:~350 mL carrot/tomato juice (50:50, v/v), plus 5 ml peanut oil~as morning test meal, served together with 40 g toasted bread and 20 g of cream-cheese plus 10 g margarine."
14427|NCT04078633|Behavioral|Hand hygiene interventions|Interventions are commonly used physical props for handwashing and commonly used hygiene promotion activities.
14428|NCT04078620|Diagnostic Test|Survey for drug drug interactions on medscape and lexicomp applications|Survey for drug drug interactions on Medscape and Lexicomp interaction checker applications
14429|NCT04078607|Behavioral|Rapid Visual Information Processing task|A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.
14430|NCT04078607|Behavioral|None or Control condition|Participant were instructed to eat at will during a 15-minute duration.
14431|NCT04078594|Other|sepsis e-alert|At 2-each month interval, the e-alert will be activated in five new randomly selected wards, until all wards eventually will have active alert
14432|NCT04078581|Other|Questionnaire and fecal sample collection|Questionnaire and fecal sample collection in order to select donors for FMT.
14433|NCT04078568|Drug|IVIG|IVIG at a single dose of 2 g/kg
14434|NCT04078568|Drug|Aspirin|Asprin 30 mg/kg in oral per day
14435|NCT04078568|Drug|Prednisolone|Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses), then changed to oral prednisolone when fever subsides for 3 days and CRP is ≤8 mg/L. The oral dose will be reduced every 3 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 9 days). Then prednisolone will be discontinued.
14436|NCT04078555|Drug|ENERGI-F703 GEL|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
14437|NCT04078555|Drug|ENERGI-F703 GEL matched vehicle|"The study medication will be applied twice daily until the end of 84 days or up to the visit confirmation of complete ulcer closure, whichever comes first.~The estimated amount of study medication applied to the ulcer area is 0.25 cm (about 0.11 g) in length per cm2 of ulcer size."
14438|NCT04078529|Other|5 day falls prevention training|Intensive training on balance, gait re-education, functional activities, backwards chaining and postural control, completed at 0 and 12 weeks.
14439|NCT04078529|Other|Home exercise programme|A modified version of the Falls Management Exercise programme (FaME) provided in written or audio format and completed over 12 weeks.
14440|NCT04078529|Other|Environmental Assessment|Use of the Homefast assessment tool to reduce risk of falls at home.
14441|NCT04078516|Diagnostic Test|Perception Threshold Tracking (PTT)|low-current electrical stimulation of both large- and small nerve fibers.
14442|NCT04078516|Diagnostic Test|Axon-flair mediated respons|Laser-doppler examination of small blood vessels in the peripheral skin.
14443|NCT04078516|Diagnostic Test|Heart rate variability|4 measurements of heart rate.
14444|NCT04078516|Diagnostic Test|Quantitative Sensory Testing (QST)|Seven tests measuring 13 parameters including heat- and cold-detection and pain thresholds, mechanical pain treshold, mechanical detection threshold, pressure pain treshold and vibration threshold.
14445|NCT04078516|Diagnostic Test|Peripheral blood pressure and transcutaneous oxygen tension|Ankle/brachial index, toe/brachial index, TcpO2.
14446|NCT04078516|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI-scans of peripheral nerves and the central nervous system. Blood oxygen level dependent (BOLD) MRI.
14447|NCT04078516|Diagnostic Test|Questionnaires|Questionnaires for detecting painful neuropathy
14448|NCT04078516|Diagnostic Test|Corneal Confocal Microscopy /CCM)|Confocal microscopy of the cornea measuring NBD, NFD, NFL
14449|NCT04078477|Other|Body positioning|Comparison lateral tilt bed to standard patient´s body positioning in the bed.
14450|NCT04078464|Other|Mindfulness Training Alone|Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.
14451|NCT04078464|Other|Acute Physical Activity Alone|Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
14452|NCT04078464|Other|Acute Physical Activity and Mindfulness Training Together|Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
14453|NCT04078451|Procedure|preserve the main cystic artery|The experimental group preserve the main cystic artery, and the control group cut off the main cystic artery
14454|NCT04078438|Device|neurofeedback augmentation|"Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study."
14455|NCT04078438|Drug|treatment as usual|The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.
14456|NCT04078438|Other|psychotherapy placebo sessions|To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
14457|NCT04078425|Drug|Aldosterone Antagonists|aldosterone antagonist will be applied to patients of heart failure with preserved ejection fraction, level of the drug will be sampled before administration of the drug and follow up will be sampled after one month
14458|NCT04078399|Drug|Azacitidine combined with interferon preemptive treatment|Azacitidine combined with interferon preemptive therapy for prevention and treatment of recurrence of allogeneic transplantation of myeloid tumors (AML/MDS/MPN) in the blood system
14459|NCT04078386|Biological|Placebo|Patients received the test group Placebo weekly administered subcutaneously for 24 times.
14460|NCT04078386|Biological|RC18 240 mg|Arm Description:Patients received the test group RC18 240mg weekly administered subcutaneously for 24 times.
14461|NCT04078386|Biological|RC18 160 mg|Patients received the test group RC18 160mg weekly administered subcutaneously for 24 times.
14462|NCT04078373|Behavioral|Immediate urination|Patients with decreased cognitive ability will be taught to immediately go to the toilet upon feeling the urge to urinate and to be independent in urinating.
14463|NCT04078373|Behavioral|Bladder diary|Patients with normal cognitive abilities will be instructed to go to the toilet every 2-3 hours regardless of the urge to urinate
14464|NCT04078360|Behavioral|AMBIT (Alcohol use disorders- mobile based Brief Intervention treatment) intervention|"The intervention will consist of participants receiving messages and/IVR calls not more than twice or thrice a week on their mobile phone for a duration of 8 weeks. Messages/IVR calls will be sent through VIAMO's technology platform. Each week messages will be focussed on specific content areas derived from the formative research of the study. Some of the components of the intervention include:~Self awareness messages~Self reflection messages~Motivational messages~Messages on safe drinking, alcohol reduction, drinking management, risk management, craving management and drinking alternatives.~Health education messages~Personalized feedback and information~Help-seeking resources~Goal setting messages"
14465|NCT04078360|Behavioral|Face to face Brief Intervention|The intervention will consist of the participants receiving the BI based on the WHO Mental Health Gap Action Programme (mhGAP) intervention from a trained researcher. The BI will be conducted over a single session (5-10 mins).
14466|NCT04078360|Behavioral|BI leaflet intervention|The intervention will consist of an educational BI leaflet consisting of health information on alcohol consumption, and tips to manage and reduce drinking.
14467|NCT04078334|Other|Per hospitalization patient PA program|In the first days of hospitalization , the physiotherapist determines the score determining the patient's mobility profile using of a decision tree measuring the balance, the cardio-muscle, 4 meter test, comfortable walking speed and cognitive status. The PA program has 5 levels depending on the score obtained in the decisional tree: red, yellow, orange, green and blue. Each level of the PA program has 2 or 3 exercises to be done with or without supervision 3 times per week. day. The level of supervision required depends on the outcome of the MMSE and the presence or absence of a caregiver. These daily exercises are prescribed by the doctor and taught by the physiotherapist. A flyer explaining the instructions, a banner at the bedside of the patient's bed and a follow-up sheet are provided to facilitate the involvement of the entire heath team and the caregivers to encourage the patient to do his physical exercises with him according to his type of supervision.
14468|NCT04078334|Other|Post-hospital PA program:|In the days prior to discharge, the physiotherapist determines the patient's mobility profile using the decision tree made up of the same tests as mentioned above (balance, cardio-muscular, walking speed and status cognitive) but whose calculation of scores generates 27 mobility profiles to which are connected 27 PA programs prescribed for 12 weeks. Each program includes 3 or 4 exercises that can be completed in 12 to 20 continuous minutes, per day and a walk. The program is taught by the physiotherapist in 2 sessions and he gives the patient a plastic sheet of reminder to affix on the fridge and a logbook detailing the exercises and including the scales to be completed. Patient adherence to the PA program for 12 weeks is monitored by the Home Care Program (DAS) or by a research assistant as needed.
14523|NCT04077918|Dietary Supplement|protein diet|100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
14524|NCT04077905|Drug|Pegylated liposomal doxorubicin|35mg/m² ivgtt on day 1
14525|NCT04077905|Drug|Etoposide|100mg/m² ivgtt on day 1
14469|NCT04078321|Other|Mollii ®|The garment claims to have a 48 hours lasting effect of an hour of treatment. The garment should be worn for at least 1 hour every other day. All participants receive individually tailored garments and individually tailored appropriate training towards specific goals set in connection to study start. The garment is used in the home environment and the family is responsible for documentation of use in a diary. Measurements is performed following an ABAB design for four weeks. Measurement performed at 12 occasions during the four weeks are; spasticity, physical function, pain, sleep and adherence. Standardized protocols for the intervention are provided to involved physical therapists.
14470|NCT04078308|Biological|Intravenous Injection of autologous mesenchymal stem cells|Intravenous injection 1 millions of bone-marrow derived autologous Mesenchymal Stem Cells (MSCs) per kg of patient's body weight in each dose, weeks 0 & 3
14471|NCT04078308|Other|Intravenous injection of placebo|Intravenous injection of normal saline (sodium chloride 0.9%)
14472|NCT04078295|Drug|E7389-LF|E7389-LF Intravenous infusion.
14473|NCT04078295|Drug|Nivolumab|Nivolumab Intravenous infusion.
14474|NCT04078282|Behavioral|Intervention group|see above
14475|NCT04078269|Biological|Dendritic cell immunotherapy|Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks, using an intra-patient dose escalation scheme progressing along the following range: 10 x10E6 DCs (minimal dose), 20 x 10E6 DCs, 40 x 10E6 DCs, 80 x 10E6 DCs, 100 x 10E6 DCs (maximal dose), until exhaustion of the batch or occurrence of grade ≥3 toxicity event
14476|NCT04078269|Biological|Antigen-specific DTH|Intradermal injection of 1 x 10E6 MIDRIXNEO-LUNG DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of induction of antigen-specific immune responses as part of in vivo immunomonitoring (delayed-type hypersensitivity cutaneous reaction as test read-out)
14477|NCT04078269|Biological|Control DTH|Intradermal injection of 1 x 10E6 MIDRIX-CTRL DCs at baseline and after completion of all i.v. DC vaccination rounds. This is used for assessment of background (i.e. non-antigen-specific) reactivity (delayed-type hypersensitivity cutaneous reaction as test read-out)
14478|NCT04078256|Other|Proprioceptive exercise program|Group A will carry out two sessions of proprioceptive training per week, in a total of 8 weeks, during the pre-season period (September-October). Each session will last approximately 30 minutes and will include 6 exercises. The execution of the exercises will be supervised by a physiotherapist and a national trainer of athletics.
14479|NCT04078256|Other|Usual training routine|The subjects of the control group (group B) will be informed so that they do not include any change in their usual training routine.
14480|NCT04078243|Device|CardioMEMS HF System|The CardioMEMS HF System is the first and only FDA-approved wireless heart failure monitor. The system is a safe, reliable way to help your patients manage their heart failure.
14481|NCT04078230|Procedure|Extend LymphAdenectomy|Expanded lymph node dissection for right liver tumors included stations 12, 8, and 13, and stations 12, 1, 3, 7, and 8 for left liver tumors
14482|NCT04078217|Device|Jintronix|Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.
14483|NCT04078217|Other|Booklet|Home-based exercise program using a paper booklet (not the technology).
14484|NCT04078204|Drug|Butylphthalide Soft Capsules|The experimental group will receive the Butylphthalide Soft Capsules during the 24-month intervention period. After the 24-month intervention,The experimental group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
14485|NCT04078204|Drug|placebo Soft Capsules|The placebo group will receive the Placebo Soft Capsules during the 24-month intervention period. After the 24-month intervention,The placebo group will receive Butylphthalide Soft Capsules for the 6-month open treatment period.
14486|NCT04078191|Drug|Tc 99m tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
14487|NCT04078178|Dietary Supplement|Niagen|Vitamin B3
14488|NCT04078165|Device|Zero-Gravity|Free-floating, suspended personal radiation protection
14489|NCT04078165|Device|Conventional radiation protection|Standard lead shields and aprons
14490|NCT04078152|Drug|Durvalumab|IV infusion q4w with 1500mg durvalumab until progressive disease
14491|NCT04078139|Drug|The MP/RP group|Miscible liquid of methylprednisolone and ropivacaine in this study will be peri-incisional scalp infiltration with 40mg methylprednisolone, 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
14492|NCT04078139|Drug|The RP group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10 ml 1% ropivacaine and 10 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
14493|NCT04078126|Combination Product|BFF|Treatment with budesonide and formoterol furmate MDI (metered-dose inhaler)
14494|NCT04078126|Combination Product|Symbicort Turbuhaler|Treatment with budesonide and formoterol furmate DPI (dry-powder inhaler)
14495|NCT04078113|Other|Pupillometer|Measurements of pupillary dilatation with pupillometer to administer or not analgesia
14496|NCT04078100|Procedure|Transseptal approach.|surgical approach to the mitral valve through the Fossa Ovalis by way of the right atrium.
14497|NCT04078087|Drug|Non obese|After standard anesthesia monitoring, Administration of oxygen was performed for 3 minutes with 10 L/min fresh gas flow of 100% oxygen. After oxygen administration, 25% of (2 mg/kg) total propofol dose was injected over 3-5 seconds (Propofol Lipuro 1%, B. Braun Melsungen AG, Germany). The patients were observed and asked immediately whether they had pain in the arm, its VAS score, type of pain (burning, parathesia or other) and its onset was documented (to differentiate early or late type of pain).
14526|NCT04077905|Drug|Methylprednisolone|2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
14876|NCT04074785|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles
14498|NCT04078074|Device|Maxillary OSS|Maxillary OSS will be a night guard for the top teeth. Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo cone beam computed tomography (CBCT) airway imaging with and without splint.
14499|NCT04078074|Device|Mandibular OSS|Mandibular OSS will be a night guard for the bottom teeth.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep.This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
14500|NCT04078074|Device|Modified farrar splint|Modified farrar splint will be a night guard for the top teeth that positions and maintains the lower jaw in a more forward position.Digital impressions will be taken at the first appointment. After delivery appointment the patient will take home a sleep test monitor and bruxism monitor to record respiration and muscle activity during sleep. This will be a 2 night sleep study (Night A will be without splint and Night B will be with splint). Therefore, the patient will sleep with the mouth guard one night and the monitoring device two nights. Subjects will also undergo CBCT airway imaging with and without splint.
14501|NCT04078061|Behavioral|MABA|Adaptive, modular, behavioral intervention.
14502|NCT04078061|Behavioral|EIBI|Early Intensive Behavioral Intervention
14503|NCT04078048|Dietary Supplement|Antioxidants (Vitamin C, E )|For eight weeks, Vitamin C group was intervened with tablet vitamin c 500 mg once a day ,vitamin E group was intervened with Tablet vitamin E 600 I U twice a day.
14504|NCT04078035|Behavioral|Socio-evaluative speech task, then Control|First session: 5-minute speech task designed to induce physiological arousal in a laboratory setting. Second Sessions: 5-minute rest period.
14505|NCT04078035|Behavioral|Control, then Socio-evaluative speech task|First session: 5-minute rest period. Second session: 5-minute speech task designed to induce physiological arousal in a laboratory setting
14506|NCT04078022|Biological|SF2a-TT15 Shigella Vaccine|0.5 mL of the vaccine is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
14507|NCT04078022|Other|Placebo|0.5 mL of normal saline is administered via an intramuscular injection into the deltoid muscle on Study Day 1 and Study Day 29.
14508|NCT04078022|Biological|S. flexneri 2a strain 2457T Challenge Agent|Each participant will drink 120 mL of sodium bicarbonate buffer solution. Approximately 1 to 2 minutes later, the participant will ingest approximately 1500 cfu of S. flexneri 2a strain 2457T suspended in 30 mL of the bicarbonate buffer solution.
14509|NCT04078009|Diagnostic Test|Aquagen|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
14510|NCT04078009|Diagnostic Test|Grazax|To compare the clinical allergic response after direct installation of an aqueous solution of Aquagen Timothy Grass pollen extract via nasal allergen challenge with the clinical allergic response after direct installation of an aqueous solution of Grazax Timothy Grass lyophilisate tablets via nasal allergen challenge in grass pollen allergic individuals.
14511|NCT04077996|Device|Peritonitis treatment placed in APD|Antibiotic treatment of peritontiis placed in bags of Automated peritoneal dialysis.
14512|NCT04077996|Device|Peritonitis treatment with one exchange in CAPD|Antibiotic treatment of peritontiis placed in one bag of Continuos ambulatory peritoneal dialysis per 6 hours each day.
14513|NCT04077983|Drug|combined therapy using nab-paclitaxel and gemcitabine chemotherapy|"Day1 nab-paclitaxel 125mg/m2, Day8 nab-paclitaxel 125mg/m2~Day1 gemcitabine 1000mg/m2, Day8 gemcitabine 1000mg/m2~Three weeks is a course of treatment with a total of 4 courses."
14514|NCT04077970|Biological|Intrauterine flushing of follicular fluid with granulosa cells|All patients in case and control groups will receive GnRH agonist protocol. Ovarian stimulation will be carried out when pituitary desensitization is achieved and is continued until the day of hCG administration. COCs aspiration will be performed 34-36h after hCG injection. Clear Follicular Fluids (without blood cells) which contain COCs will be used. After explaining the procedure and taking informed consent from the patients: Endometrial flushing after oocyte retrieval with 2 ml of clear FF plus granulose cells will be performed by an IUI catheter. The control group included 70 women who would not have FF endometrial flushing. In both groups, embryo transfer will be carried out 2-3 days later. Luteal phase support will be started the day after ovum pick up by the vaginal administration of progesterone daily for 16 days and will continued for up to12 weeks if pregnancy occurred. Pregnancy was diagnosed by measurement of β-hCG level and later was confirmed by Transvaginal sonography.
14515|NCT04077957|Drug|Methotrexate|Methotrexate 10mg per week will be the background therapy in participants in Group 1. Experimental.
14516|NCT04077957|Drug|Sulfasalazine|Sulfasalazine 2.25g per day will be the background therapy in participants in Group 1. Experimental.
14517|NCT04077957|Drug|Hydroxychloroquine|Hydroxychloroquine 0.2g per day will be the background therapy in participants in Group 1. Experimental.
14518|NCT04077957|Drug|Etanercept (50mg per week, for 4 weeks)|Participants in Group 1. Experimental who satisfied the criteria for high disease activity (ASDAS≥2.1) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 4 weeks.
14519|NCT04077957|Drug|Etanercept (50mg per week, for 2 weeks)|Participants in Group 1. Experimental who satisfied the criteria for low disease activity (2.1>ASDAS≥1.3) at every follow-up point will receive etanercept (50mg per week, for 4 weeks) in the next 2 weeks.
14520|NCT04077957|Drug|Etanercept (50mg per week)|Participants in Group 2. Positive Control will receive etanercept (50mg per week, for 12 weeks) for 48 weeks.
14521|NCT04077944|Diagnostic Test|maternal serum concentration of trace elements and heavy metals levels|The maternal serum levels of trace elements and heavy metals in both groups were measured using an inductively coupled plasma-mass spectrometry (ICP-MS)
14522|NCT04077931|Other|exercises|Walking on treadmill with fixed 0% grade inclination
14877|NCT04074759|Drug|FPT155|A soluble CD80 fusion protein
14527|NCT04077892|Drug|budesonide|SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
14528|NCT04077879|Drug|ASP1617|Oral
14529|NCT04077879|Drug|Placebo|Oral
14530|NCT04077866|Drug|Temozolomide|Temozolomide is an FDA-approved drug that is given to patients
14531|NCT04077866|Biological|B7-H3 CAR-T|B7-H3-targeting CAR-T cells derived from patient own peripheral blood mononuclear cells will be given to patients via intracerebral injection though an Ommaya catheter
14532|NCT04077866|Other|Placebo|Placebo is 2% human serum albumin in pharmaceutical preservative-free normal saline and will be given to patients via intracerebral injection though an Ommaya catheter
14533|NCT04077853|Drug|17 Hydroxyprogesterone Capronate|Intramuscular injection 250 mg
14534|NCT04077827|Drug|Propofol|Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
14535|NCT04077814|Device|Foot Drop Stimulatio - Neuro Orthosis|Walkaide is the Foot drop stimulator (FDS) on the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.
14536|NCT04077814|Device|Transcranial direct brain stimulation|Transcranial direct brain stimulation on motor cortex
14537|NCT04077801|Diagnostic Test|diagnostic test|diagnostic test
14538|NCT04077788|Other|muscle energy technique|"Muscle energy technique:~Application of MET for bone of pelvis:~I) Pubis:~Cranial Os pubis.~Caudal os pubis.~II) ileum:~Anterior ileum.~Posterior ileum.~External Rotation (In flare) Lesion.~Internal Rotation (Out flare) Lesion.~III) sacrum:~Forward torsion of sacrum.~Backward torsion of sacrum.~Muscle energy technique for specific muscles of pelvis and spine:~Stretch of the Psoas Major.~Stretch of the paravertebral muscle.~Stretch of the piriforms."
14539|NCT04077775|Diagnostic Test|assesment|assesment
14540|NCT04077762|Procedure|Radial Access|Radial Access
14541|NCT04077762|Procedure|State-of-the-art femoral access with 18 gauge needle|State-of-the-art femoral access with 18 gauge needle
14542|NCT04077762|Procedure|State-of-the-art femoral access with 21 gauge needle|State-of-the-art femoral access with 21 gauge needle. For patients randomized to micropuncture (21G) the micropuncture wire must be advanced under fluoroscopy to avoid inadvertent wiring of side-branches.
14543|NCT04077749|Biological|Femdophilus probiotic|Lactobacillus rhamnosus (GR-1®) and reuteri (RC-14®) species, which is offered as an over the counter probiotic capsule sold under the brand name of Femdophilus dissolved in 50 mL normal saline at room temperature.
14544|NCT04077749|Other|Normal Saline|50 mL normal saline at room temperature
14545|NCT04077736|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 million IU five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82). Then all patients were followed up for 3 months
14546|NCT04077723|Drug|RO7227166|RO7227166 will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of CD20-TCB (Part II and Part III).
14547|NCT04077723|Drug|Obinutuzumab|A fixed dose of obinutuzumab will be administered seven days prior to first does of RO7227166 and CD20-TBC (Part I and Part II) and then Q3W in combination with RO7227166 in Part I
14548|NCT04077723|Drug|RO7082859|A fixed dose of CD20-TBC will be administered Q3W in combination with RO7227166 in Part II and Part III
14549|NCT04077710|Radiation|Radioactive Iodine-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring. 3D-printing template includes information on the path of the implantation needle, characteristics of the surface of the therapy area of the patient, and positioning and orientation effects which can make the operation more accurate.
14550|NCT04077697|Diagnostic Test|RT-PCR for influenza|influenza real time polymerase chain reaction (RT-PCR) from a nasopharyngeal swab or bronchoalveolar lavage (BAL) fluid.
14551|NCT04077684|Drug|Interleukin-2|IL2 (0.2 MIU, 0.5 MIU or 1 MIU) : placebo = 1:1:1:1
14552|NCT04077671|Biological|CHF6467 active|CHF6467, is mutated form of the human Nerve Growth Factor (NGF).
14553|NCT04077658|Behavioral|HeartMath|HeartMath is a program where individuals learn heart rate variability biofeedback. Essentially, they learn breathing exercises that reduce their heart rate. The HeartMath program will be administered via an application on the smartphone and ear monitor.
14554|NCT04077658|Behavioral|Waitlist Control|Standard of Care Migraine Treatment
14555|NCT04077645|Behavioral|Sun salutations|This group will be asked to participate in 25 minutes of low-to-moderate intensity Yoga. This acute session will include engaging in sun salutations, breathing exercises and relaxation. Sun salutations involves performing 10 postures in a particular sequence, and then repeating that sequence. Some of the positions include bending over and touching one's toes, and lying belly-down on the ground and pushing up from ground while arching backwards. The activity will begin as a low intensity activity for the first 5 minutes, and the intensity will be gradually increased. Participants' heart rate will be measured before and after the intervention. The intervention will be delivered by a video displayed on a tablet device. An orientation session in the beginning will familiarize participants with the activity.
14556|NCT04077645|Behavioral|Aerobic exercise|This group will be asked to walk on the treadmill for the same amount of time (i.e. 25 minutes) at a moderate intensity (50-70% of their maximum heart rate). Participants will receive an initial 5-minute orientation and then begin at a self-selected speed for the first 5 minutes. Heart rate will be measured and monitored by an undergraduate research assistant. Speed will be increased after 5 minutes if participants have not reached the moderate zone. If participants still have not reached the target heart rate zone by the 10-min mark, the incline of the treadmill will be increased by a 5% grade until the zone is reached.
14557|NCT04077645|Behavioral|Seated rest|This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
14604|NCT04077203|Behavioral|Biofeedback / No biofeedback|Biofeedback / No biofeedback
14605|NCT04077190|Device|Adipose-derived stem cells|5cc adipose derived stem cells.
14558|NCT04077632|Device|Transcranial direct current stimulation|tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
14559|NCT04077619|Behavioral|Modern pain neuroscience approach|Modern pain neuroscience approach. The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
14560|NCT04077619|Behavioral|Usual care physiotherapy|Usual care evidence-based physiotherapy The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
14561|NCT04077606|Other|ceramo-metallic crown prepartion|tooth will be prepared to receive ceramo-metallic crowns
14562|NCT04077606|Other|full anatomical monolithic zirconia crown|tooth will be prepared to receive monolithic zirconia crowns
14563|NCT04077593|Device|RRate Mobile app|Test respiratory rate with RRate application
14564|NCT04077580|Drug|Methenamine Hippurate 1000 MG|Methenamine and placebo is taken 1 tablet morning and evening for 180 days
14565|NCT04077567|Drug|TS-152|30mg,80mg
14566|NCT04077554|Genetic|gene expression|determination of VEGF gene expression, VEGF gene polymorphism and serum leptin concentration
14567|NCT04077541|Behavioral|internet platform|The trauma care bundles combined with the internet platform.
14568|NCT04077515|Drug|Sirolimus(0.8mg/m2)|The initial use of sirolimus is 0.8mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
14569|NCT04077515|Drug|Sirolimus(0.7mg/m2)|The initial use of sirolimus is 0.7mg/m2 administered twice daily.After two weeks of taking the drug, blood concentrations are measured and adjusted appropriately to maintain the targeted blood concentration.
14570|NCT04077502|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
14571|NCT04077489|Procedure|cataract surgery|To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
14572|NCT04077476|Behavioral|Online Yoga + Facebook|Each week, the research team will post a prompt for discussion to encourage participation. Prompts will be developed in the beginning stages of the project based on data from the current R34 study and with guidance from consultant Waibel. Participants will be encouraged to post about their experiences with the intervention and stillbirth (emotional support), share resources, (informational support), and offer feedback and advice (appraisal support). Participants will not be required to adhere to certain criteria for engagement (e.g., number of posts, etc.), other than their weekly log in. This is to account for different types of engagement when using social networking as a means of support (e.g., posting, just reading); the benefits of each type of engagement are person-specific. The page will be moderated by members of the research team, who will post prompts and ensure content is updated and appropriate. No members can be added to the group without approval from the research team.
14573|NCT04077476|Behavioral|Online Yoga|Participants will complete a series of videos covering basic poses and safety techniques, tracked using the Wistia plugin software. Once complete, they will be able to access the library of pre-selected classes (range in time from 10-90 minutes). Participants will be asked to complete at least 60 minutes of yoga per week; participants may choose any classes to yield 60 minutes. Preliminary data from the current R34 study suggests 60 minutes is a feasible amount of time for yoga participation. There is no upper limit to the number of minutes participants can complete.
14574|NCT04077463|Drug|Lazertinib|Lazertinib will be administered orally.
14575|NCT04077463|Drug|JNJ-61186372|JNJ-61186372 will be administered as an intravenous infusion.
14576|NCT04077450|Behavioral|Online Heart-Focused Breathing Intervention|Participants will receive an online standardized HeartMath© heart-focused breathing intervention.
14577|NCT04077437|Behavioral|Behavioral: Psychotherapy|Standardized non-directive psychotherapy performed by therapist team
14578|NCT04077437|Drug|MDMA|Administration of 80 to 120 mg MDMA during three sessions of MDMAassisted psychotherapy followed by a supplemental dose of 40 or 60 mg MDMA offered 1.5/2 hrs after the initial dose, respectively.
14579|NCT04077437|Drug|Placebo|Administration of placebo during three sessions of MDMA-assisted psychotherapy
14580|NCT04077411|Other|Observational|This is an observational study with no interventions.
14581|NCT04077398|Drug|Ropivacaine 0.5% Injectable Solution|There will be two groups, in order to compare two different sets of volumes with the same amount of drug. we will try to identify if it is better one volume over the other in terms of pain control and consume of opioids, as well the presence or absence of motor weakness.
14582|NCT04077385|Behavioral|Retrieval-extinction (R-E) Training|The retrieval-extinction (R-E) training intervention will occur on two consecutive days and consist of (a) retrieval of high calorie food cue-reward associative memories and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 high calorie food images (e.g., cakes, cookies, muffins, hamburgers, french fries, potato chips, pizza). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion (i.e., one piece) of high calorie snack foods such as a single M&M or potato chip.
14606|NCT04077190|Device|cortisone injection|cortisone injection
14655|NCT04076657|Behavioral|Standard of Care|patient engages in normal behavior to manage vision issues, such as breaks with reading and screen use
14656|NCT04076644|Device|TMS treatment|TMS using either a standard 10hz 20min or 3 min theta burst protocol
14583|NCT04077385|Behavioral|Extinction Training|The extinction control group will engage in two consecutive days of intervention consisting of (a) retrieval of memories not associated with high calorie foods and (b) 60-min extinction training for high calorie foods. During the 5-min of retrieval, participants will observe 30 non-food-related neutral images (e.g., office supplies, tools). Images will be presented in E-Prime for 8-s each (2-s delay between images). After the 5-min of retrieval and a 10-min rest period, participants will engage in 60-min of extinction training for high calorie foods consisting of 12, 5-min high calorie food cue sequences: 6 image sequences and 6 real food sequences. The real foods will consist of a small portion (i.e., one piece) of high calorie snack foods such as a single M&M or potato chip. The 60-min extinction training is the same as the extinction training received by participants in the R-E training intervention.
14584|NCT04077372|Behavioral|Serious Illness Conversation Guide (SICG)|The Serious Illness Conversation Guide (SICG) is a structured communication template designed to provide effective tool in initiating advanced care planning discussion with patients.
14585|NCT04077372|Behavioral|Quality of Life (QOL) survey|Quality of life survey by questionnaire (FACT-G) given every three months
14586|NCT04077359|Diagnostic Test|CT|the CT consist of four phases; non-enhanced, corticomedullary, nephrographic and excretory phase.
14587|NCT04077346|Device|Biostim-5 transcutaneous spinal stimulator|"Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions"
14588|NCT04077346|Other|Activity Based Locomotor Training|Activity-based locomotor training (AB-LT): The AB-LT sessions will occur daily (5x/week) for 60 sessions and consist of a minimum of 55-60 min on the treadmill (TM) for facilitated standing/stepping followed by 30 min of activities off the TM (over ground) in sitting, standing, or stepping.
14589|NCT04077346|Other|Transcutaneous Spinal Stimulator + Activity Based Locomotor Training|Participants will receive a combination of AB-LT+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
14590|NCT04077333|Procedure|Minimal Invasive surfactant administration|Participants enrolled spontaneously breathing preterm infants born between 26.1 and 31.9 weeks' gestational age with signs of respiratory distress syndrome. Preterm infants of the MISA (Minimal invasive surfactant administration) group were assigned to receive surfactant (Calf pulmonary surfactant, Double-Crane Pharmaceutical Co., China) via a 5Fr nasogastric tube with an ophthalmic surgery straight forceps during CPAP/NIPPV-assisted spontaneous breathing.
14591|NCT04077320|Behavioral|Memory Self-Efficacy Training|The intervention will consist of a six-week cognitive behavioral intervention integrating the four pillars of self-efficacy, Mastery, Social Modeling, Coaching, and Physiological Responses (West et al. 2008). Each week will comprise of a 1.5 hour session which focuses on an educational component, discussions and active learning practice activities to apply lesson material. Additionally, participants will be given take home exercises to practice outside a classroom setting. The sessions will be conducted in small groups of 4-6 people.
14592|NCT04077320|Behavioral|General Education|The active control intervention will be a general education class consisting of real world knowledge and factual information on various topics unrelated to memory. This intervention will follow the same format as the memory self-efficacy training arm. One 1.5 hours session every week for 6 weeks, in small groups.
14593|NCT04077307|Drug|Karonudib|Dose escalation of administration with oral solution of Karonudib.
14594|NCT04077294|Other|Cardiac risk stratification using preoperative BNP measurement, followed by postoperative cardiac monitoring|Patients undergoing non-cardiac surgery risk stratified using BNP measurements according to CCS guidelines.
14595|NCT04077294|Other|Use of traditional perioperative cardiac risk stratification only|Patients undergoing non-cardiac surgery risk stratified using tools other than BNP measurement such as revised cardiac risk index (RCRI).
14596|NCT04077281|Other|Medication Coordinated care|"Clinical Pharmacology & Toxicology consult~CPT team completes detailed circle of care communication~Telemedicine followup by CPT team (approximately 48 hrs post-discharge & 1 week to1 month post-discharge)"
14597|NCT04077268|Other|GOS-E|Call at 7 days, patients add a brain trauma to know their sequeals
14598|NCT04077255|Drug|Anti-EGFR antibody in combination with weekly paclitaxel|Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy
14599|NCT04077255|Drug|FGFR inhibitor in combination with weekly paclitaxel|Oral rogaratinib in combination with weekly paclitaxel for metastatic cancer cancer with FGFR activation as a second-line therapy
14600|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Parryscope technique"|A small amount of air is introduced into the iv tubing by inverting the drip chamber to create air bubbles. When air enters the uterine cavity, a single large air bubble or stream of air bubbles traversing the ostia is considered indicative of tubal patency. At least 10 seconds of intracavitary evaluation is typically performed before air bubble entry to allow pressure equilibration if a hydrosalpinx is present [10]. At least 30 seconds of observation per ostia is performed if patency is not observed.
14601|NCT04077242|Diagnostic Test|"Hysteroscopic Fallopian tube assessment using the Tubal flow technique"|"a positive flow is defined as the observation of saline directly traversing the ostia, endometrial structures floating toward the ostia, or air bubbles traversing the ostia."
14602|NCT04077229|Behavioral|Intervention arm: Text Message Intervention|Participants will receive a combination of messages promoting both psychological well-being and education /support around health behavior adherence, such as physical activity or diet. In the first part of the study, participants will receive 28 fixed text messages that alternate between physical activity and PP (Positive Psychology) messages. In the second part of the study, participants will first receive a set of 14 pre-selected daily messages that contain a broad range of attributes to allow sufficient participant feedback to clearly identify preferences. After the first 14 messages, new messages will be selected based on the prior preferences of participants.
14603|NCT04077216|Dietary Supplement|Extra Virgin Olive Oil (EVOO)|This study used the FDA approved Doña Elena Extra virgin olive oil, which is readily available in local supermarkets. Its free acidity expressed as oleic acid was found to be 0.26%, comparable with the International food standards.15
14607|NCT04077177|Behavioral|Male Athlete Body Project|Participants who meet eligibility criteria and consent to the study will be randomized to one of two conditions: intervention condition (i.e., Male Athlete Body Project) or an assessment only control condition. The intervention groups will take place at IIT. Participants who accept randomization to condition will complete baseline questionnaires after randomization (immediately prior to Session 1 in the intervention condition and after being randomized to the assessment only control condition). Questionnaires will be repeated immediately post-intervention (intervention condition)/after a 3-week interval (control). All participants will be asked to complete the questionnaires again, 4 weeks after the previous round of questionnaires. The 3, 80-minute group sessions will be separated by 1 week.
14608|NCT04077164|Other|No intervention, observational only.|No intervention, this study will use self-report information regarding health, social, and behavioral factors for each member of the couple.
14609|NCT04077151|Behavioral|PrEP Demonstration Project|In phase 2, a culturally, developmentally, and gender-affirmative intervention to increase uptake of and adherence to PrEP among TW and TM youth will be developed by incorporates the PK data from phase 1 and data gathered from focus groups and in-depth interviews with young transgender women and transgender men. During phase 3, this intervention will be given to the experimental arm and tested versus a standard-of-care control group.
14610|NCT04077125|Drug|Rifaximin|to investigate changes in cerebral, splanchnic hemodynamics and endothelial function in cirrhotic patients with MHE after 15 days of rifaximin therapy (1200 mg/d)
14611|NCT04077112|Behavioral|Parent Child Interaction Therapy|Behavioral parent training program targeting parent-child relationship
14612|NCT04077099|Drug|REGN5093|Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
14613|NCT04077086|Device|Spectacles|Intervention group children in middle school Years 1 and 2 will receive spectacles at the beginning of the academic year (September 2019). Assuming that the relevant effects of treatment (glasses wear) on the main study outcome are complete once examinations determining high school attendance are finished at the end of Middle School Year 3, Intervention participants will have undergone either 22 months (September 2019 to July 2021 for those recruited in Year 2) or 34 months (September 2019 to July 2022 for those recruited in Year 1) of treatment by the endpoint of the trial.
14614|NCT04077073|Device|ReIn-Hand|ReIn-Hand assists the hand opening
14615|NCT04077073|Device|Robot|Robot supports the shoulder load
14616|NCT04077060|Diagnostic Test|NIPT|"Women randomized in the intervention group will be offered cfDNA screening, along with an early detailed anatomy scan, including nuchal measurement, at 11-13 weeks of gestation. cfDNA analysis will include a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. NIPT will be performed at the time of randomization or after if gestational age at randomization < 9 6/7 weeks of gestation.~Women in both groups will be given oral counseling by obstetricians and will be counseled about test procedures, reporting time, test sensitivity and specificity, and the necessity to confirm abnormal screening results with invasive testing."
14617|NCT04077060|Diagnostic Test|combined screening|Control group includes the standard of care. In our department, first-trimester risk assessment is performed routinely at 11-13 weeks of gestation by FTCS as per standard of care. FTCS includes crown-rump length, NT measurements, and a detailed ultrasound examination based on ISUOG guidelines. All operators who perform this examination are certified by the UK Fetal Medicine Foundation (FMF). A specific risk for aneuploidy is not calculated if NT measurement is >3.5 mm or if fetal anomaly is identified. These cases are deemed to be at a very high risk for chromosomal abnormalities and are offered invasive testing.
14618|NCT04077047|Other|iEngage (tentative title)|The intervention is a network-based, social support intervention to improve ALWH retention in HIV care and ART adherence. The specific intervention will be developed during Aim 2 of the study and uses qualitative findings, along with data from Aim 1, to develop an interventions that integrates participant feedback and borrows components from two existing interventions: Masivukeni and LIFECommunity.
14619|NCT04077034|Dietary Supplement|Probiotic Formula Bacillus subtilis DE111®|Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
14620|NCT04077034|Dietary Supplement|Placebo comparator|Placebo comparator, once a day for 8 weeks
14621|NCT04077021|Drug|CCW702|Investigational immunotherapy for prostate cancer
14622|NCT04077008|Procedure|unilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
14623|NCT04077008|Procedure|bilateral drainage of Bilaterally Obstructed Kidneys|drainage of obsructed kidneys by PCN or jj
14624|NCT04076995|Other|Water Intake|Increased water intake during the 11 h protocol
14625|NCT04076982|Dietary Supplement|mung bean protein|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
14626|NCT04076982|Other|control biscuit|Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
14627|NCT04076969|Behavioral|Integrated educational session|The educational session aimed to correct the pregnant women diatery habits and enhance the degree of compliance to the iron treatment and follow up instruction.
14628|NCT04076956|Device|Anterior Cruciate Ligament Reconstruction|Reconstruction of the Anterior Cruciate Ligament using an interference screw
14629|NCT04076943|Drug|Roxadustat (FG-4592)|Roxadustat will be dosed orally three times a week.
14630|NCT04076930|Drug|angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)|The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
14631|NCT04076904|Diagnostic Test|transvaginal us|transvaginal us is made to all women
14632|NCT04076891|Drug|RZL-012|The dosing regimen will be a single dose treatment injection of RZL-012 in multiple sites.
14653|NCT04076670|Other|Psychological intervention for family caregivers of patients at the end of life|The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
14654|NCT04076657|Behavioral|Brock String Therapy|Oculomotor exercise to improve binocular vision function
14633|NCT04076878|Device|Mollii|The Mollii method is provided in a tight fitting, whole body suit with multiple electrodes that can be set individually. The Mollii method uses low frequencies and low intensities that evokes sensory input but does not directly elicit muscle contractions. The theoretical background of this treatment method primarily refers to the concept of reciprocal inhibition, i.e. that sensory input from a muscle may inhibit the activation of an antagonistic muscle through the activation of the disynaptic reciprocal Ia inhibitory pathway.
14634|NCT04076865|Drug|EMLA (lidocaine) +Itch (Histamine and cowhage)|"Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).~Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.~Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain."
14635|NCT04076852|Other|Administration of questionnaires|"According to clinical practice, the following questionnaires are administered:~Y-GTSS~Y-BOCS or cY-BOCS"
14636|NCT04076839|Behavioral|Goal Management Training|Goal Management Therapy is a structured, short-term, present-oriented cognitive remediation program with emphasis on mindfulness and practice in planning and completion of goal-oriented behaviors. The primary objective of GMT is to train patients to interrupt ongoing behavior through the resumption of executive control in order to define goal hierarchies and monitor performance in achieving goals. Sessions include instructional material, interactive tasks, discussion of patients' real-life deficits, and homework assignments.
14637|NCT04076826|Drug|Dexmedetomidine|Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
14638|NCT04076826|Drug|Propofol or Midazolam|Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.
14639|NCT04076826|Diagnostic Test|Blood sampling|In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.
14640|NCT04076800|Procedure|Acupuncture|Acupuncture treatment will include use of somatic points (SP6; ST36; KI3; CV4; CV12; TE5; LI4; LI11; YinTang; ST28; BL23; BL22; BL20; BL13) and auricular points (most tender point on palpation with pressure feelers of 400 gr on Stomach, Endocrine, Spleen, Kidney, Hungry, Shen man and Pancreas auricular points).
14641|NCT04076787|Drug|Sunitinib|patients who received sunitinib as first line therapy for mRCC
14642|NCT04076774|Device|Wondaleaf Female Condom|Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
14643|NCT04076774|Device|FC2 Female Condom|FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
14644|NCT04076761|Drug|Trifluridine/Tipiracil|FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
14645|NCT04076748|Drug|Sufentanil|The intervention is intranasal Sufentanil adminstration, then IV morphine as soon as possible.
14646|NCT04076748|Drug|EMONO|In the control group, patients will receive EMONO then IV morphine as soon as possible.
14647|NCT04076735|Procedure|Distal femoral replacement|The distal portion of the femur (up to two thirds) is excised and replaced by a endoprosthesis incorporating a hinged total knee replacement.
14648|NCT04076735|Procedure|Surgical Fixation (ORIF)|A trained orthopaedic surgeon uses open or minimally invasive reduction techniques and achieves stable fixation with internal fixation devices (plates/screws or intramedullary nail) to restore structural integrity and alignment of the distal femur
14649|NCT04076722|Behavioral|Brief Acceptance-Based Treatment for Weight Loss|8-week treatment protocol utilizing acceptance-based principles for behavioral weight loss.
14650|NCT04076709|Procedure|goal directed anaesthesia|Deep neuromuscular blockade (PTC 1-2) Nociception level index (NOL) target 10-25
14651|NCT04076696|Device|Scatter corrected s-DCT|All patients will have a breath held s-DCT scan in an anterior-posterior direction
14652|NCT04076683|Device|Algodrep|Algorithm computing the volume of blood to be transfused and the interval between apheresis which are necessary to maintain an individual objective of HbS percentage.
14657|NCT04076618|Device|Vest|Weighted Vest worn > or = 6 hours per day
14659|NCT04076618|Behavioral|weight loss program|a 24-week intensive phase (with weekly dietary classes) followed by a 27-week transition phase (with biweekly dietary classes)
14660|NCT04076579|Drug|Olaparib|Olaparib taken by mouth twice daily
14661|NCT04076579|Drug|Trabectedin|Trabectedin administered intravenously (IV) every 21 days
14662|NCT04076566|Device|alfapump system|active implantable device for treatment of malignant ascites
14663|NCT04076553|Behavioral|CBT|Participants will complete 12 sessions of CBT
14664|NCT04076553|Behavioral|ICT|"Participants will complete 4 weeks of daily inhibitory control trainings and booster ICT trainings following CBT treatment in weeks 5-12"
14665|NCT04076540|Drug|AZD4041|Administration by Oral syringe
14666|NCT04076540|Drug|Placebo|Administration by Oral syringe
14667|NCT04076527|Drug|UDCA|Routine data is collected for UDCA therapy.
14668|NCT04076527|Drug|Ocaliva|Routine data is collected for OCA therapy.
14669|NCT04076514|Procedure|central neck dissection|dissection of central cervical lymph node grope in low grade papillary thyroid cancer
14670|NCT04076501|Procedure|Oxygen application|Oxygen application Supplemental oxygen via mask
14671|NCT04076501|Procedure|Sham room air|Room air applied via mask
14672|NCT04076488|Other|Dividat Fit|tablet based, remote assisted home-training
14673|NCT04076475|Device|neuromuscular electrical stimulation|Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
14674|NCT04076462|Drug|CAM2029 (octreotide subcutaneous depot)|Octreotide subcutaneous depot for monthly injections in acromegaly patients
14675|NCT04076462|Drug|Matching placebo|Matching placebo for CAM2029
14676|NCT04076436|Other|Drug: Intravenous fosfomycin|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 2, 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visit on day 2: Blood collection to fosfomycin levels calculation.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
14677|NCT04076436|Other|Drug: Intravenous quinolone or beta-lactam|"Patients will be visited on days 1 (Day of the urine and blood culture taking), 5, 7, 14, on the test of cure and on day 30.~Visit on day 1: First day of treatment. Basal data collection.~Visits on days 5, 7, 14, on the test of cure (day 21): Clinical evolution data, Urocultures and Adverse effects.~Visit on day 30: Assess mortality"
14678|NCT04076423|Drug|Dual Therapy|DTG + 3TC
14679|NCT04076423|Drug|Triple therapy|BIC / FTC / TAF
14680|NCT04076410|Device|Z1|CE marked device
14681|NCT04076410|Device|B1|CE marked device
14682|NCT04076410|Device|B1+G1|CE marked device
14683|NCT04076410|Device|B1+G2|CE marked device
14684|NCT04076410|Device|B1+G3|CE marked device
14685|NCT04076397|Procedure|autologous transplant reinjection|The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
14686|NCT04076397|Other|desensitization|Patients will have to stimulate the pulp of your finger on a daily basis
14687|NCT04076384|Behavioral|Guided Self-Determination|Structured team-based consultations
14688|NCT04076384|Behavioral|Standard care|Standard consultations
14689|NCT04076371|Drug|olanzapine-sertraline combination|the patient was prescribed low-dose olanzapine (7.5-10mg/day) combined with low-dose sertraline (50-100mg/day)
14690|NCT04076371|Drug|only olanzapine|the patient was prescribed moderate to severity dose of olanzapine (12.5-20mg/day)
14691|NCT04076371|Drug|risperidone-sertraline combination|the patient was prescribed low-dose risperidone (2-3.5mg/day) combined with low-dose sertraline (50-100mg/day)
14692|NCT04076371|Drug|only risperidone|the patient was prescribed moderate to severity dose of risperidone (4-6mg/day)
14693|NCT04076371|Drug|paliperidone-sertraline combination|the patient was prescribed low-dose paliperidone (3-4.5mg/day) combined with low-dose sertraline (50-100mg/day)
14694|NCT04076371|Drug|only paliperidone|the patient was prescribed moderate to severity dose of paliperidone (6-9mg/day)
14695|NCT04076371|Drug|ziprasidone-sertraline combination|the patient was prescribed low-dose ziprasidone (60-100mg/day) combined with low-dose sertraline (50-100mg/day)
14696|NCT04076371|Drug|only ziprasidone|the patient was prescribed moderate to severity dose of ziprasidone (120-160mg/day)
14697|NCT04076358|Behavioral|Tab-CBI|Participants receive a tablet preloaded with Tab-CBI application and an accelerometer.
14698|NCT04076345|Diagnostic Test|Prespesin assay on PATHFAST analyser|"Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence."
14699|NCT04076332|Other|Decision aid|Decision aid is a tool that helps patients become involved in decision making on choosing treatment plans. Decision aid provides information about the options and outcomes, and by clarifying personal values.
14719|NCT04076150|Device|Transcatheter Aortic Valve (TAV) Implantation With The Optimum TAV System|Treating patients with severe symptomatic aortic stenosis via transcatheter aortic valve implantation by implanting the Optimum TAV inside the native diseased valve via a the Precision Catheter. The Optimum TAV and Precision Catheter together are the Optimum TAV System.
14720|NCT04076137|Other|Targeted T-cell armed with bispecific antibody (Decitabine)|In this study, 10 patients eligible for the study were clinically screened for intravenous infusion of targeted activated T cells,every participant has a unique identification number and emergency letter which have the information of group.
14700|NCT04076319|Behavioral|CAPABLE: Community Aging in Place—Advancing Better Living for Elders|"CAPABLE is a client-directed home-based intervention that consists of time-limited services from an occupational therapist, a nurse, and a handyman working collaboratively with the older adult client. In most cases, the OT makes 6 visits, the RN makes 4 visits, and a handyman makes 1 to 2 visits to make any modifications to a person's home during a 6-month period. The first visits for the OT and RN are usually 90 minutes each and the later ones are usually an hour each. Visits are spaced to enable older adults to practice new strategies learned in the previous visit. There should be a clear conclusion/graduation, with the older adult understanding how to use their new skills and apply them to future situations."
14701|NCT04076306|Other|iSTEP exercise testing|iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
14702|NCT04076293|Drug|HM15912 or Placebo|"The study will be conducted in approximately 5 sequential dosing cohorts, enrolling 8 subjects per cohort. Subjects will be randomized to HM15912 or placebo in a ratio of 6:2 (6 active, 2 placebo). When necessary, one dosing cohort may be added or removed.~In this first-in-human (FiH) study, each cohort will be divided in 2 blocks in order to implement the sentinel dosing approach. Within each cohort, the first block will consist of 2 sentinel subjects"
14703|NCT04076280|Behavioral|Sodium Watcher Program-Hypertension|The Sodium Watcher Program -Hypertension intervention consists of 14 weeks of education [4 weekly education sessions (45 minutes)followed by 5 bi-weekly sessions 5-20 minutes] that will be held at the dyads' preferred time delivered to their homes using a video conferencing program through an iPad.
14704|NCT04076280|Behavioral|Usual Care|Participants in the usual care group receive their routine medical and nursing care for hypertension that consists of a recommendation to follow a sodium restricted diet and take medications as ordered. Usual care consists of recommendations to follow a sodium restricted diet, but without explicit skills training including instructions on gradual adaptation to sodium restricted diet, follow-up of progress or provision of monitoring.
14705|NCT04076267|Other|Tool assessing symptoms validation|Comparison between 2 tools evaluating the symptoms of patients with advanced cancer: the ESAS12-F and the EORTC QLQ C30 to assess if the ESAS12-F well evaluates the symptoms and if it is easy to complete. The objective is to validate the ESAS12-F, which is easier and shorter than the well validated EORTC QLQ C30
14706|NCT04076254|Drug|Albumins|albumin 5%
14707|NCT04076254|Drug|Fluid|Ringer Lactate
14708|NCT04076241|Other|Osteopathic Manipulative Treatment|The investigators applied six different OMT techniques including rib raising, abdominal diaphragm release, suboccipital decompression, mobilisation of 1st rib, mobilisation of mediastinum and plevrovertebral ligament release. Rib raising is used to increase the mobility of the rib cage and to reduce vasoconstriction by regulating sympathetic tone. Abdominal diaphragm release is used to increase diaphragm movement. Suboccipital decompression involves traction of the base of the skull. We aim to improve respiration with mobilisation of the 1st rib which is associated with sternum, sympathetic truncus and important vascular structures. One of the supporting ligaments of Sibson's fascia which resists intrathoracic pressure changes during respiration is pleurovertebral ligament. Finally, the goal of mobilisation of mediastinum is to increase the mobility of the rib cage by providing relaxation in the tension of the facial tissues.
14709|NCT04076241|Other|Pranayama|Nadi Shodhana Pranayama (Alternate Nostril Breathing), Ujjayi Pranayama and Bhramari Pranayama were used for the study. Nadi Shodhana is one of the most common yoga breathing exercises and involves breathing through one nostril while closing the other one. The patients performed 2 sets of 7 breathing cycles with a resting time of 1 minute between the sets. Ujjayi Pranayama involves soft contraction of laryngeal muscles and the partial closure of the glottis. The patients performed 1 set of 10 breathing cycles per session with an inspiration:expiration phase as 1:2. Bhramari Pranayama includes a nasal humming sound during exhalation to create slight vibrations on the laryngeal walls, and the inner walls of the nostrils. The patients applied 1 set of 10 breathing cycles per session with a respiration rate of 3-4/min.
14710|NCT04076228|Drug|Pembrolizumab|pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
14711|NCT04076215|Behavioral|Stressogenic stimulus|Participants will be exposed to an anxiety-provoking stimulus for 15-20 minutes, in a controlled setting
14712|NCT04076215|Device|Biobeat smart watch and adhesive biosensor patches.|Physiological and biochemical measures will be obtained using the Biobeat smart watch and adhesive biosensor patches.
14713|NCT04076202|Device|Cementless Vanguard DD RP|Patients treated with the Cementless Vanguard DD RP knee implant
14714|NCT04076189|Procedure|Endotracheal suctioning|Procedure includes: Endotracheal intubation-Suctioning-Endotracheal intubation again and initiation of positive pressure ventilation
14715|NCT04076189|Procedure|No endotracheal suctioning|Procedure includes: immediate initiation of positive pressure ventilation without intubation and tracheal suctioning
14716|NCT04076176|Dietary Supplement|CGMP protein substitute|PKU sphere is a powdered, low phenylalanine protein substitute, containing a balanced mix of casein glycomacropeptide (CGMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals, trace elements and the omega-3 long chain polyunsaturated fatty acid (LCP); docosahexaenoic acid.
14717|NCT04076176|Dietary Supplement|L-amino acid protein substitute|Patient may choose from a list of products, specified in the protocol, that are nutritionally comparable to PKU Sphere.
14718|NCT04076163|Other|serious game|a serious game was performed by the investigators in order to enhance the critical appraisal practice of students
14796|NCT04075474|Device|silver diamine fluoride|38% SDF on primary upper anterior teeth
14797|NCT04075474|Device|sodium fluoride|5% NaF on primary upper anterior teeth
14721|NCT04076124|Device|Active rTMS-DLPFC|Participants in the rTMS active stimulation group will receive 4-week 10 Hz 120% of RMT to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
14722|NCT04076124|Device|Active iTBS-DLPFC|Participants in the intermittent TBS(iTBS) active stimulation group will receive 4-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to left DLPFC. Left side DLPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the L-DLPFC using a Magstim stimulator.
14723|NCT04076124|Device|Sham TBS-DLPFC or Sham rTMS-DLPFC|Half of the patients in the sham group received 4-week the same iTBS parameter stimulation (sham-iTBS), and the other half received the same rTMS parameter stimulation using a sham coil (sham-rTMS), which also improved the blinding process.
14724|NCT04076098|Drug|Minocycline Hydrochloride|Administration of Periocline gel into the periodontal pockets will be carried out until it overflows the pockets
14725|NCT04076085|Other|exercise|Stretching exercise for warmup, All arm exercise with and without weights as tolerated by the patients. Similarly lower limb exercise in different positions like lying standing as tolerated by the patients
14726|NCT04076072|Device|Utravit High-Speed 10000 cpm Beveled Probe|This is a prospective, randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
14727|NCT04076072|Device|standard vitrector probe- Alcon (non-beveled) Ultravit 7500 cpm|This is a prospective, randomized controlled trial comparing the Ultravit High-Speed Beveled Probe with the current Alcon vitrector probe in a cohort of patients undergoing routine vitrectomy surgery.
14728|NCT04076059|Drug|Enzalutamide|Oral
14729|NCT04076059|Drug|Placebo|Oral
14730|NCT04076059|Drug|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or having a history of bilateral orchiectomy.
14731|NCT04076033|Other|functional compressive bandage|"The functional compressive bandage is being performed with the volunteer sitting with the upper limb homolateral to the surgery supported by a support. After hydration of the limb, a cotton mesh is being used to prevent friction of the 1 cm density foam band being wrapped around the limb. No therapeutic procedure is being performed prior to functional compressive bandage.~The bandage of the limb is being performed with 5 cm, 10 cm, 15 cm elastic cotton bandages from the fingers to the axillary region in four layers."
14734|NCT04076007|Dietary Supplement|Beetroot juice|
14735|NCT04076007|Dietary Supplement|Nitrate depleted beetroot juice|
14736|NCT04075994|Behavioral|Relational Agent and heart rate and rhythm monitor|Use of the Relational Agent and heart rate and rhythm monitor daily for 120 days.
14737|NCT04075994|Behavioral|Usual Care|Use of the WebMD app and heart rate and rhythm monitor daily for 120 days.
14738|NCT04075981|Drug|Botulinum Toxin Type A Injection [Xeomin]|Before the main stage of the surgery, botulinum toxin will be injected into the entire visible area of the 4 major epicardial fat pads, during extra corporal circulation and before aortic cross clamping in order to reduce the time of ischemia.
14739|NCT04075981|Other|Drug placebo|All patients from the control group will receive placebo. Before the main stage of the surgery, during extra corporal circulation and before aortic cross clamping, the placebo will be injected into the entire visible area of the 4 major epicardial fat pads as follows (1 mL at each fat pad).
14740|NCT04075968|Other|Cognitive exercise|Cognitive exercise will be applied
14741|NCT04075968|Other|Home exercise|Home exercise will be applied
14742|NCT04075955|Drug|Zyprexa® (OLANZapine 5MG)|"Olanzapine 5mg orally at bedtime for 4 days (starting the day before the chemotherapy)~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally twice a day for 6 doses (starting on the morning of day 2)"
14743|NCT04075955|Drug|Emend® (Aprepitant)|"Aprepitant 125mg orally pre-chemotherapy on day 1, then 80mg orally once daily on days 2 and 3~Ondansetron 16mg orally pre-chemotherapy on day 1~Dexamethasone 12mg orally pre-chemotherapy on day 1~Dexamethasone 8mg orally once daily for 3 doses (starting on the morning of day 2)"
14744|NCT04075942|Procedure|Atrophic Anterior Maxillary Ridges|Use of modified cortical shell technique grafted with customized Xenograft bone shell
14745|NCT04075929|Other|Training effects on aerobic output|The cyclists were allowed to perform ad libitum low intensity (LIT) in addition to high intensity (HIT) sessions that were determined to each group. The cyclists completed 12 supervised HIT sessions during the intervention period, three HIT sessions per week with at least 48 hours between each HIT-session. All HIT sessions were performed as supervised group training sessions. Each HIT session started with an individual 30 minutes' warm up at low intensity (55-70% HRmax) interspersed by freely chosen progressive sprints. For all groups the power output during the recovery periods was 50 % of the power output used during work intervals. The cyclists in all groups were instructed to perform each interval session at their maximal sustainable intensity. Each session ended with 15-20 minutes' cool down (55-70% HRmax). All HIT sessions were supervised and performed in groups on the University of Agder's (UiA) premises at Spicheren fitness center in Kristiansand.
14746|NCT04075916|Drug|Epclusa|All patients will receive 12 weeks of sofosbuvir/velpatasvir as per the FDA label.
14747|NCT04075903|Behavioral|Storytelling|"A health literacy-appropriate and culturally-adapted intervention delivered on a tablet computer containing storytelling to improve patient gout knowledge and approaches to prevent flares, destigmatize gout, and enhance readiness to adopt available long-term treatments for gout including medications, diet, and exercise, or ii) usual gout care (control state)."
14748|NCT04075890|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation method by which constant low direct current can be delivered to the sculpt for changing the excitability of neuronal structure adjunct to the stimulating electrode.
14749|NCT04075877|Behavioral|FOCUS|See prior section.
14750|NCT04075864|Behavioral|Behavioral Counseling and Exercise|exercise program combined with behavioral counseling for patients who are hospitalized with a cystic fibrosis exacerbation
14751|NCT04075838|Other|Recovery group|The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the PTR (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
14753|NCT04075812|Device|Neuromuscular Stimulator|
14754|NCT04075799|Other|high-intensity interval training|The HIIT protocol consists of 8 weeks using stair climbing three times per week. The warm-up will consist of 2 minutes of ascending and descending the stairs at a comfortable pace. The high-intensity intermittent exercise will comprise 6-12 x 30-seconds bouts of ascending at an all-effort. A 30- seconds walking recovery will occur between the exercise bouts. Post-exercise the subject will walk during a 2-minute cool down. Every session will last between 10 to 15 minutes. The number of bouts (6-12) will be increased progressively over the weeks. The first (week 1) and final week (week 8) of the exercise program will be monitored by a trained exercise physiologist. During supervised visits, heart rate and rating of perceived exertion (OMNI scale) will be measured at the end of each bout and after active recovery. Subjects will have the option to request further monitoring if desired.
14755|NCT04075786|Other|Survey|Each participant will be shown 40 (forty) 3D ultrasound images of uterus of normal women without infertility and 40 (forty) infertile women with uterus with narrowing in the middle third diagnosed by hysteroscopy + 3D ultrasound and associated infertility (T, Y or I shaped).
14756|NCT04075773|Behavioral|Expressive Writing|The participants are asked to write for a period of time about specific concepts so that they think carefully and cognitively process the information they are generating.
14757|NCT04075760|Procedure|Coils + Cyanoacrylate Group + beta-blocker|"EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group."
14758|NCT04075760|Drug|beta blocker therapy|A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure < 90 mm Hg or pulse rate < 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
14759|NCT04075747|Drug|CPX-351|Up to 2 induction and 2 consolidation courses will be offered
14760|NCT04075747|Drug|Venetoclax|Will be administered over specified duration during induction and consolidation courses
14761|NCT04075747|Drug|Midostaurin|Will be administered over specified duration during induction and consolidation courses
14762|NCT04075747|Drug|Enasidenib|Will be administered over specified duration during induction and consolidation courses
14763|NCT04075734|Behavioral|Managing Your Health: Self-Management + Peer Mentoring|"The online educational component consists of 5 self-management educational modules:~(1) Understanding Your Survivorship Care Plan; (2) Managing Your Healthcare; (3) Family and Significant Other Involvement in Your Healthcare; (4) Emotions about Your Health and Follow-Up Care; (5) Staying Healthy.~Participants will be matched with a peer mentor and complete a total of six calls. The first call is to build a rapport and identify the participant's self-management strengths, weaknesses, and goals. The next five calls align with the topic of each module, which the mentee is expected to complete prior to their scheduled call."
14764|NCT04075721|Drug|M3258|Participants will receive M3258 in a protocol-defined dose escalation scheme in Part A and M3258 at a dose defined and considered to be safe by safety monitoring committee (SMC) in Part B until disease progression.
14765|NCT04075721|Drug|Dexamethasone|Participants will receive 20 milligrams per day of dexamethasone on 2 consecutive days in a weekly regimen along with M3258 in Part A and Part B until disease progression.
14766|NCT04075682|Other|Inserts with efficacy messages|Four rotating inserts (i.e., small, printed messages) with messages about cessation benefits (i.e., response efficacy) and tips to quit (i.e., self-efficacy messages) will be placed inside cigarette packs.
14767|NCT04075682|Other|Pictorial warnings on packs|Four rotating pictorial warnings illustrating the harms of smoking will be printed on labels that will placed on and cover approximately 50% of the cigarette packs.
14768|NCT04075669|Diagnostic Test|Multiplex Strip PCR|Corneal scraping from patients will have its DNA extracted and eluted in the buffer. The DNA than mixed with the primer strips tube and be analyzed in Real-Time PCR machine. According to the record information from the hospital, the pathogen that usually found from endophthalmitis, keratitis, corneal ulcer diseases in our hospital is Pseudomonas sp., Staphylococcus aureus, Staphylococcus epidermidis, Acinetobacter sp., Pseudomonas aeruginosa, Acanthamoeba sp., Aspergillus fumigatus, Aspergillus flavus, Fusarium sp., and Candida albicans. And based on the report from Zhao et al (2014) Herpes Simplex Virus may be detected from patients with keratitis. Therefore in this study, we are trying to detect all of the pathogens simultaneously using the real-time PCR assay from patients corneal scraping who experience eye infections as mention above.
14769|NCT04075656|Behavioral|Standard of Care|Participants will be provided a folder of educational material on NS, including general information on symptoms, treatments, and possible complications; healthy diet for children taking corticosteroids; and low sodium diet. Site research staff will demonstrate how to check urine for protein with test strips, and educate patients on the definitions of disease relapse and remission. Urine test strips and urine protein logs will be provided to ensure that each participant can check their urine daily for protein. Participants will be instructed to check their urine daily for protein and call their provider within 1 business day for relapses and remissions.
14798|NCT04075461|Procedure|Arthroplasty|Arthroplasty is commonly used for a displaced femoral neck fracture.
14799|NCT04075461|Procedure|Internal fixation|Internal fixation is commonly used for undisplaced femoral neck fracture
14800|NCT04075448|Other|Control|100 grams breakfast cereal
14801|NCT04075448|Other|50 g Walnut|50 grams walnuts mixed with 50 gram breakfast cereal.
16974|NCT04057456|Other|Placebo capsules|no active ingredient capsule
14770|NCT04075656|Behavioral|UrApp|Caregivers/parents will download UrApp at the baseline visit. UrApp contains instructional videos to guide users. The telephone number of the patient's provider will be entered into UrApp and participants will be able to call their providers directly through UrApp. The email address of the Emory study staff will also be entered. UrApp will automatically e-mail test results to the research staff when elected by the users. Participants will be asked by study staff, and reminded by the app, to call their providers and send urine testing results to the study staff whenever there is a relapse or remission. When the study staff receives alerts of a relapse/remission via UrApp, the information will be communicated to the treating physician within 1 business day.
14771|NCT04075643|Drug|Reference drug|D935 Cap. 1 Cap., single oral administration under fasting condition
14772|NCT04075643|Drug|Test drug|CKD-385 Tab. 1 Tab., single oral administration under fasting condition
14773|NCT04075617|Device|electronic habit reminder|Habit reminder in the form of wrist watch with music that display as reminder is one of recent innovations for cessation of the habit in short time and the child accepts it and it's comfortable
14774|NCT04075617|Other|palatal crib|Fixed palatal crib is commonly used and recommended for treating thumb/finger sucking habit.
14775|NCT04075604|Biological|Nivolumab|Specified Dose on Specified Days
14776|NCT04075604|Drug|Abemaciclib|Specified Dose on Specified Days
14777|NCT04075604|Drug|Anastrozole|Specified Dose on Specified Days
14778|NCT04075604|Drug|Palbociclib|Specified Dose on Specified Days
14779|NCT04075591|Device|iDesign Refractive Studio with STAR S4 IR® Excimer laser System|Surgeons will perform wavefront-guided monovision LASIK for the treatment of myopic subjects with presbyopia based upon measurements obtained with an iDesign Refractive Studio.
14780|NCT04075578|Drug|OnabotulinumtoxinA / Botox®, Allergan Ltd, Irvine, CA, United-States|Botox® intradetrusor injections, with a rigid cystoscope, under local anaesthesia performed by Lidocaïne 2% diluted in 30ml of bicarbonate 14‰. 20 injections of 0,5ml each will be heterogeneously administrated into the bladder wall, sparing the trigone
14781|NCT04075565|Behavioral|Terrestrial altitude|Terrestrial altitude: The volunteers are in an SAC hut at an altitude of 3000 m. By means of this exposure the psychophysiological effect under hypobaric and hypoxic conditions is determined. The subjects spend the night in this SAC hut and the measurements are repeated the next day.
14782|NCT04075565|Behavioral|Cloud 9|"Cloud 9 is a solid, certified product that complies with European Directives on Electromagnetic Compatibility, Machine Directive, Air Pressure Equipment and Low Voltage Equipment (89/336 / EEC, 91/368 / CEE, 93/68 / CEE, 97/23 / EC, EN61010-1 All directives are in writing in the Supplements to this Ethics Application.~Simulated height: The subjects are in the laboratory of our institution and are connected to the Cloud 9 by means of a mask. Subjects are exposed to a simulated altitude of 3530m under normobaric conditions. By means of this intervention the psychophysiological effect under normobaric and hypoxic conditions is determined."
14783|NCT04075552|Behavioral|Pre Meal Presentation|Pre-Meal Presentation. In the Pre-Meal Presentation (PMP) condition, school staff delivered the plate of vegetable pieces prior to students regularly scheduled lunchtime (about 5 min). Like baseline, no programmed consequences were provided for student interaction or consumption of the vegetables.
14784|NCT04075552|Behavioral|Pre Meal Presentation + Modeling|"Similar to the prior condition, each participant will be offered a plate containing target foods for 4 min. Once the plate has been delivered to each participant, a staff person will model eating the food. The model will have an identical plate of food. Within six feet of students oriented towards the model (i.e., the students will be facing the model), the model will pick up one piece of food, say Yum, this looks good in a loud and excited tone, eat it, and then deliver a soft prompt to the participants to try it (e.g., You should try this!). Staff will avoid giving a firm/hard demand (e.g., Eat the food). Repeat this for four pieces of food, alternating between the two target foods, with about 10-20 sec between each bite. Repeat the model as necessary based on the room arrangement, such that each students contacts the model within six feet while oriented towards the model."
14785|NCT04075552|Behavioral|Pre Meal Presentation + Token Economy|Similar to prior condition, expect each participant can earn tokens for eating food items. Tokens can be exchanged for small prizes (e.g., pencil or sticker) at the end of a session.
14786|NCT04075539|Other|Home-based cycling program|"Usual care (i.e. standardized prescription of 6 sessions of outpatient physiotherapy), and~1 supervised session of cycling aimed at explaining how to use the connected ergometric bicycle and at designing a personalized home-based cycling program~a 12-month home-based cycling program using connected ergometric bicycles which intensity and dose are self-determined~3 phone or email contacts with a care provider to deliver positive feedbacks and encouragements"
14787|NCT04075539|Other|usual care|A prescription of 6 sessions of outpatient physiotherapy
14788|NCT04075526|Drug|Povidone iodine|To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.
14789|NCT04075526|Drug|Vancomycin powder|2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia
14790|NCT04075526|Other|Conventional|No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort
14791|NCT04075513|Drug|Insulin glargine, 300 U/ml|"Pharmaceutical form:solution for injection in a prefilled pen~Route of administration: subcutaneous injection"
14792|NCT04075513|Drug|Insulin degludec, 100U/ml|"Pharmaceutical form:solution for injection in a prefilled pen~Route of administration: subcutaneous injection"
14793|NCT04075513|Drug|Background therapy: Rapid acting insulin analogs|Route of administration: subcutaneous injection
14794|NCT04075500|Device|24-h Holter monitoring|Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).
14795|NCT04075487|Other|Web-module for patient education and planning|Our goal is a mobile web-based application (App) that provides immediate feedback to Veterans seeking to develop their own pain self-management plan
14802|NCT04075435|Drug|high CBD/low THC sublingual solution|Coconut oil based solution of 20mg/ml CBD and 0.58mg/ml THC to be administered sublingually.
14803|NCT04075422|Drug|Bezlotoxumab Injection [Zinplava]|Treatment with bezlotoxumad according to the routine clinical practices
14804|NCT04075409|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
14805|NCT04075396|Drug|YH25448|Participants will receive YH25448 tablets once daily.
14806|NCT04075383|Procedure|immediate dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone in the same session of tooth extraction.
14807|NCT04075383|Procedure|immediate-delayed dental implant|Replacement of a lost tooth with a titanium screw retained in the alveolar bone 8 weeks after tooth extraction.
14808|NCT04075370|Other|Neuropsychological Testing|Measure cognition function and cognitive reserve in patients before, during and after radiation therapy using cumulative scores of Hollingshead Index, North American Adult Reading Test, HVLT-R, TMT A&B and COWA over time.
14809|NCT04075357|Other|Amniotic membrane transplantation|Amniotic membrane was located over median nerve during surgery of CTS, prior of closing.
14810|NCT04075344|Other|Multimodal Infection control programme|12 weekse educational programme with 6 sessions, 45 minutes per session will be provided to experimental group RCHEs staff
14811|NCT04075331|Drug|Mepolizumab|Mepolizumab 100mg subcutaneous injection
14812|NCT04075331|Drug|Placebo|Saline solution for subcutaneous injection
14813|NCT04075318|Biological|UB-312|A synthetic peptide-based vaccine
14814|NCT04075318|Biological|Placebo|Matching placebo
14815|NCT04075305|Radiation|Radiation therapy|Radiation therapy on the CE marked and FDA approved MR-Linac
14816|NCT04075292|Drug|Acalabrutinib|acalabrutinib 100 mg twice daily orally
14817|NCT04075292|Drug|Rituximab|Rituximab: 375 mg/m2 IV infusion on Day 1 of Cycle 1. 500 mg/m2 IV infusion on Day 1 for each of subsequent cycles (Cycles 2-6)
14818|NCT04075292|Drug|Chlorambucil|Chlorambucil: 0.5 mg/kg body weight orally on Day 1 and Day 15 of Cycles 1-6
14819|NCT04075266|Drug|Ocrelizumab|"Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks.~Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg"
14820|NCT04075253|Behavioral|VO2 peak testing|Exercise on treadmill starts with ~4km/h at 0% inclination before inclination is increased to 4% and speed kept unchanged. Inclination will then be increased with two percent approximately after each minute until exhaustion.
14821|NCT04075240|Drug|Rivaroxaban 10 MG and acetylsalicylic acid 81 mg|Starting post op, rivaroxaban (5 days) followed by aspirin (9 days for TKA; 30 days for THA)
14822|NCT04075240|Drug|acetylsalicylic acid 81 mg|Starting post op, aspirin for 9 days for TKA and 30 days for THA
14823|NCT04075227|Drug|0.2% loteprednol etabonate|Use topical 0.2% loteprednol etabonate eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
14824|NCT04075227|Drug|0.1% dexamethasone|Use topical 0.1% dexamethasone eyedrop every 4-6 hours for 4 weeks. After that, the regimen was gradually decreased until cessation at 3 months.
14825|NCT04075201|Biological|One dose of investigational vaccine|One dose of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research & Development Co., Ltd.
14826|NCT04075201|Biological|One dose of control vaccine|One dose of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
14827|NCT04075201|Biological|Three doses of investigational vaccine|Three doses of investigational hepatitis B vaccine (10μg/0.5ml) developed by Sinovac Research & Development Co., Ltd. on the schedule of month 0,1,2
14828|NCT04075201|Biological|Three doses of control vaccine|Three doses of control hepatitis B vaccine (10μg/0.5ml) manufactured by Dalian Hissen Bio-pharmInc.
14829|NCT04075188|Drug|Aflibercept Injection|Patients will be treated with combined therapy to determine the synergy of this treatment, causing anti- Vascular Endothelial Growth Factor (anti-VEGF) to block neovascular exudation and photodynamic therapy to close aneurismal vessel and reduce choroidal vascular congestion.
14830|NCT04075175|Drug|S315|Human monoclonal antibody against Diphtheria Toxin
14831|NCT04075175|Drug|0.9% Sodium Chloride (NaCl)|Placebo 0.9% Sodium Chloride (NaCl)
14832|NCT04075149|Drug|Spironolactone|Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if > 60 kg, 100 mg twice daily.
14833|NCT04075136|Drug|Ranibizumab|Intravitreal injection 0.5 MG Per 0.05 ML Injection.
14834|NCT04075136|Device|Photodynamic laser treatment (PDT)|PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.
14835|NCT04075136|Drug|Triamcinolone Acetonide|Intravitreal injection of 0.5ml-2mg
14836|NCT04075136|Drug|verteporfin|Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
14837|NCT04075123|Other|CPAP|The two NRS strategies being compared will be initiated at the time of first extubation (NRS support practices prior to initial intubation will be as per local unit guidelines and practices) and all subsequent extubations (if applicable) until 32 weeks PMA. For instance, a unit adopting post-extubation NCPAP strategy will initiate this mode following the initial and all subsequent extubations until 32 weeks PMA whereas centres adopting post-extubation NIPPV will initiate NIPPV following initial and all subsequent extubations until 32 weeks PMA.
14838|NCT04075110|Drug|Montelukast 10mg|Montelukast is an orally dosed drug (available as a chewable tablet) which is FDA-approved for the treatment of chronic asthma and prophylaxis and the prevention of exercise-induced bronchoconstriction. It is also approved for the relief of symptoms of both seasonal and perennial allergic rhinitis.
14839|NCT04075097|Behavioral|Aerobic exercise|1 session
14840|NCT04075097|Behavioral|Iyengar yoga|1 session
14841|NCT04075071|Behavioral|Teacher-Child Interaction Training - Universal|Teacher-Child Interaction Training - Universal (TCIT-U) is an empirically-supported classroom-based intervention designed to strengthen teacher-child relationships, reduce and prevent child behavior problems, and promote social-emotional skills. TCIT-U is based in behavioral and attachment principles and was developed as a modification of Parent-Child Interaction Therapy (PCIT), an evidence-based treatment with well-established support for decreasing disruptive child behaviors and parental stress with children ages two to seven years old. In TCIT-U, teachers of children, preschool through second grade, are taught and coached in skills to manage challenging classroom behaviors and improve the quality of relationships. TCIT-U is delivered to teachers through group didactic training and live individualized coaching.
14842|NCT04075058|Radiation|Hypofractionated Radiation therapy|
14843|NCT04075045|Behavioral|Wellth Smartphone App|Patients will receive the app that provides reminders to adhere to their self-care regimen and ability to track their daily adherence via photos of the self-care related items (medications, blood pressure cuff, meals).
14844|NCT04075045|Behavioral|Targeted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at pharmacies.
14845|NCT04075045|Behavioral|Non-Restricted Incentives|Participants may earn up financial rewards tied to their adherence. The rewards are only usable at most stores, except for prohibited purchases such as alcohol, tobacco, or firearms, and is not redeemable for cash.
14846|NCT04075032|Dietary Supplement|Pomegranate extract|Pomegranate extract consumption (900 mg/day) for 4 weeks
14847|NCT04075032|Other|Placebo|Placebo (microcrystalline cellulose) consumption (900 mg/day) for 4 weeks
14848|NCT04075019|Behavioral|The Raising Healthy Children intervention, including teacher training, child skill development, and parent training|
14849|NCT04075006|Drug|Ketamine|standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
14850|NCT04074993|Drug|Brigatinib|Subject will be treated with Brigatinib 90mg/day for 1 week and then 180mg/day PO daily. A Cycle will be defined as 28-days. Treatment will be continued until disease progression or unacceptable toxicity.
14851|NCT04074980|Diagnostic Test|Venous and Fingerstick blood draws|Fingerstick sampling to collect blood from subjects Venepuncture to collect blood samples from subjects
14852|NCT04074980|Diagnostic Test|Venous blood draw|Venepuncture to collect blood samples from subjects
14853|NCT04074967|Drug|Phase Ib ARRY-614 + nivolumab|Participants with advanced solid tumors will take ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
14854|NCT04074967|Drug|Phase Ib ARRY-614 + ipilimumab|Participants with melanoma will take ARRY-614 continuously in 4-week cycles (± 3 days). Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
14855|NCT04074967|Drug|Phase II ARRY-614 + ipilimumab|Subjects with melanoma will receive the recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days). Ipilimumab will be dosed according to FDA-approved dosing schedule.
14856|NCT04074967|Drug|Phase II ARRY-614 + nivolumab (melanoma)|Subjects with melanoma will receive the recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
14857|NCT04074967|Drug|Phase II ARRY-614 + nivolumab (RCC)|Subjects with RCC will receive the recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
14858|NCT04074954|Procedure|Cataract surgery|Patients will receive cataract surgery
14859|NCT04074941|Other|Dietary intervention|Intervention include low sodium or usual sodium diet
14860|NCT04074928|Biological|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains.
14861|NCT04074928|Biological|Comparator QIV|Comparator Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains.
14862|NCT04074915|Other|Placebo mouth rinse|Normal saline
14863|NCT04074915|Drug|Chlorhexidine mouth rinse|Chlorhexidine gluconate
14864|NCT04074915|Drug|Test group|Chamomile mouth rinse
14865|NCT04074902|Device|Ultrasonography|Mindray dp1100 plus.
14866|NCT04074889|Dietary Supplement|(Microbial cell preparation) Probiotics|Lactobacillus acidophilus (107mg), Lactobacillus casei subsp (107mg), Lactobacillus lactis (107mg), Bifidobacterium bifidum (107mg), Bifidobacterium infantis (107mg) and Bifidobacterium longum (107mg)
14867|NCT04074889|Other|Placebo|Placebo sachet with no microbial cell preparation
14868|NCT04074876|Device|Pulmonary echography|"Pulmonary echography during preoperative evaluation for patients undergoing urgency orthopedic surgery for femur fracture.~Pulmonary ultrasound will evaluate the presence of one of four patterns defined by Lung Ultrasound Score in the 6 fields for each hemithorax of the patient (2 anterior, 2 lateral and 2 posterior). Each region is defined by axillary lines (anterior and posterior) and then is divided into 2 subregions (superior and inferior), thus defining the 6 fields. For a comprehensive exam, all intercostal spaces in the setting of each field will have to be examined by sliding the probe along them . A score will be used for each field that will have this definition:~0: normal pattern (A-lines)~1: multiple B lines (at least 3 for field), well defined.~2: B lines coalescent~3: consolidation of any dimension"
14869|NCT04074863|Procedure|Darrach|Surgical treatment of painful DRU osteoarthritis with resection of distal ulna
14870|NCT04074863|Procedure|Prosthesis|Surgical treatment of painful DRU osteoarthritis with distal ulna replacement with Herbert implant
14871|NCT04074837|Drug|NNI-362|NNI-362 small molecule in liquid suspension.
14872|NCT04074837|Drug|Placebo|Placebo liquid suspension
14873|NCT04074811|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The investigators will use the Figure of 8 coil, which affects ~10cm2 of cortical surface. The active condition will deliver stimulation at 110% of resting motor threshold (RMT). To determine RMT, the protocol will be: 10 trials of single-pulse TMS on the scalp position of the abductor pollicis brevis muscle (which controls thumb flexion); RMT is the lowest TMS power setting yielding visible motor contraction on >50% of trials.
14874|NCT04074798|Behavioral|assessment of hyperventilation, postural control and psychological behavior|assessment of hyperventilation, postural control and psychological behavior
14883|NCT04074733|Diagnostic Test|Patient undergoes a ULD scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
14884|NCT04074733|Diagnostic Test|Patient undergoes a standard X-ray|"The following doses will be applied:~For the pelvis : front view and profile for the hip. For the dorsal spine : front and profile. For the lumbar spine : front and profile For the extremities : front and profile"
14885|NCT04074733|Diagnostic Test|Patient undergoes a classic-dose scan|"The following doses will be applied:~6 mGy.cm for the extremities 50 mGy.cm for the dorsal spine 130 mGy.cm for the lumbar spine 130 mGy.cm for the pelvis"
14886|NCT04074720|Procedure|Tissue Sample collection|Tissue sample collected following standard of care procedure patient was already scheduled to have
14887|NCT04074720|Other|Blood Sample Collection|A one time sample of blood will be collected on day of standard of care procedure
14888|NCT04074720|Other|Rectal Swab|optional rectal swab may be collected on day of standard of care procedure
14889|NCT04074707|Dietary Supplement|Labeled iron solution (60mg and 120mg Ferrous Sulfate)|3 doses of 60mg iron as FeSO4 are given on 3 consecutive days (e.g., days 1-3); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one alternate day (e.g., days 20, 21, 23); 3 doses of 120mg iron as FeSO4 are given on one consecutive and one 3rd day (e.g., days 37, 38, 41). Iron doses are labeled with 4mg of a stable isotope in 100ml deionized water (57Fe, 58Fe or 54Fe). Participants will be randomly assigned to start with daily, alternate-day or every-third day dosing.
14890|NCT04074694|Procedure|Sialoendoscopy|Sialoendoscopy
14891|NCT04074681|Behavioral|Gambling Internet-based Protocol|Gambling Internet-based protocol is a multimedia interactive and self-help program for risk, problem and pathological gamblers, which will allow individuals to learn and practice adaptive ways to cope with this problem. The main therapeutic modules included in this program are: 1) Motivational for change; 2) Psychoeducation; 3) Stimulus control (e.g. self-prohibition and blocking of usual gambling websites with therapist confirmation) and responsible return of debts; 4) Cognitive restructuring; 5) Emotion regulation; 6) Planning of significant activities; 7) Coping skills and exposure with response prevention; 8) Relapse prevention.
14892|NCT04074668|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
14893|NCT04074668|Drug|Iohexol Inj 300 milligrams/milliliter (mg/ml)|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
14894|NCT04074668|Radiation|PET/CT Scan|Imaging used to visualize the kidneys and quantify renal metabolic activity
14895|NCT04074655|Device|Driving Simulator in a Virtual Reality Environment|Driving simulator in virtual reality environment is a game with the several level of difficulty and the goal of improving the cognition level of participants in general and their spatial cognition in particular. Moreover this game, will have a positive effect on its users' mood as well.
14896|NCT04074642|Procedure|Neurosurgery|adenoma removal
14897|NCT04074629|Diagnostic Test|Diagnosis, skin volatile organic compounds (VOCs)|"The skin related VOCs will be collected by off-line method using Polydimethylsiloxane (PDMS) patches from different body locations for sensor system and\or GC-MS analysis"
14898|NCT04074616|Device|High Dose|Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks,with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used.
14899|NCT04074616|Device|Low dose|Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes
14900|NCT04074603|Device|The needle-free jet injector|Continuous insulin therapy for 2 weeks
14901|NCT04074603|Device|Conventional insulin pen|Continuous insulin therapy for 2 weeks
14902|NCT04074590|Drug|LYS006|capsule for oral use
14903|NCT04074590|Drug|Placebo|capsule for oral use
14904|NCT04074577|Diagnostic Test|Standard technique First|colonoscopy without automated polyp detection software
14905|NCT04074577|Diagnostic Test|combination technique First|automated polyp detection software
14906|NCT04074564|Combination Product|MASCT-I,PD1 Antibody,Apatinib|"Multi-antigen autoimmune cell injection (MASCT-I) is an adoptive cellular immunotherapeutic product being developed by Heng Ruiyuan.~PD1 antibody is a blocking antibody of human programmed death receptor-1 (PD-1). It can bind to PD-1 receptor, block its interaction with PD-L 1 and PD-L2, release PD-1 pathway mediated inhibition of immune response, including anti-tumor immune response.~Apatinib is a small molecule targeted anti-angiogenesis drug. It can highly selectively compete for ATP binding sites of endothelial growth factor R-2, block downstream signal transduction and inhibit neovascularization in tumor tissues."
14907|NCT04074551|Drug|HCP1701|HCP1701
14908|NCT04074551|Drug|Losartan|Losartan
14909|NCT04074551|Drug|Amlodipine|Amlodipine
14910|NCT04074551|Drug|Rosuvastatin and Ezetimibe|Rosuvastatin and Ezetimibe
14911|NCT04074512|Drug|Copper Histidinate|Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.
14912|NCT04074499|Other|No intervention|There is no intervention.
14913|NCT04074486|Device|BrainScope Ahead 300iP-O|BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.
14914|NCT04074486|Diagnostic Test|SCAT5|Sports Concussion Assessment Tool 5
14915|NCT04074486|Diagnostic Test|Near Point Convergence|Manual ocular function measurement conducted only if electronic version on device fails
14916|NCT04074473|Drug|propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
14917|NCT04074473|Procedure|Esophageal varice ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
14918|NCT04074473|Other|DC propranolol|Patients randomized to banding ligation group discontinue propranolol after eradication of esophageal varices.
14919|NCT04074460|Drug|Propofol|General Anaesthesia
14921|NCT04074434|Device|Study Watch|Study Watch is a miniaturized physiological data monitoring and data collection device for continuous recording of physiological and environmental data
14922|NCT04074421|Drug|Rifaximin|A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.
14923|NCT04074421|Drug|Probiotic Formula|A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
14924|NCT04074421|Drug|Placebo oral tablet|Placebo oral tablet that has no therapeutic effect
14925|NCT04074408|Procedure|stereotactic surgery|stereotactic aspiration surgery
14926|NCT04074408|Biological|hUMSCs|single intracavitary infusion 1 day after stereotactic aspiration surgery
14927|NCT04074408|Biological|placebo|single intracavitary infusion 1 day after stereotactic aspiration surgery
14928|NCT04074382|Other|Online Questionnaires|We will use online questionnaires to complete research into functional outcomes after trauma
14929|NCT04074382|Other|Qualitative Interviews|We will undertake qualitative interviews (remote or face to face) to shed more light on reasons for functional outcomes after trauma
14930|NCT04074369|Diagnostic Test|CRISPR-based Test|CRISPR-based Test performed on sputum or BALF in TB suspects.
14931|NCT04074356|Other|Clinical measure questionnaires|Collection of patient reported symptoms and perception of health
14932|NCT04074356|Diagnostic Test|EESG|Use of silver-silver chloride cutaneous electrogastrogram (EGG) electrodes to get myoelectrical readings
14933|NCT04074356|Diagnostic Test|MESG|MESG measures spatiotemporal properties of magnetic fields from the esophageal slow wave and allows characterization of the propagation of the slow wave in addition to evaluation of its frequency and power distribution
14934|NCT04074356|Diagnostic Test|High resolution manometry (HRM)|Dysphagia subjects will have undergone standard of care HRM to determine placement in the achalasia or hypercontractile/spastic disorder arms
14935|NCT04074343|Drug|TAS-102|Given PO
14936|NCT04074343|Drug|Irinotecan|Given IV
14937|NCT04074330|Drug|TAK-981|TAK-981 intravenous infusion.
14938|NCT04074330|Drug|Rituximab|Rituximab intravenous infusion.
14939|NCT04074317|Drug|PRAM9|SC injection
14940|NCT04074317|Drug|Regular Insulin + Pramlintide|Separate SC injections
14941|NCT04074317|Drug|Regular Insulin|SC injection
14942|NCT04074304|Other|I-HoME|A multi-component technology-based care intervention.
14943|NCT04074265|Drug|Ropivacaine injection|Injection containing a mix of the above medications will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
14944|NCT04074265|Drug|normal saline|Injection containing normal saline will be performed while the patient is still under general anesthesia, following wound closure, and will be injected evenly between the deep and superficial tissues in an extra-articular pattern (no injection of the synovium or capsule).
14945|NCT04074252|Device|Lofstrand Crutches|Device: Set of Lofstrand Crutches
14946|NCT04074252|Device|Axillary Crutches|Device: Set of Axillary Crutches
14947|NCT04074239|Other|Video triage|The operator at the Medical Helpline will offer the parent who's calling regarding the sick child to assess the child on video, as compared to the routine way; on the telephone.
14948|NCT04074226|Procedure|Erector Spinae Plane block|The Erector Spinae Plane (ESP) block is a new block first described in 2016 which blocks terminal branches of the lower thoracic and lumbar nerve roots. It is performed by injection of local anesthetic in the fascial plane below the erector spinae muscle group.
14949|NCT04074226|Procedure|Quadratus Lumborum Block|Ultrasound-guided QL block has been reported to provide effective analgesia in patients undergoing lower abdominal surgical procedures, including in patients undergoing abdominal hysterectomy. Ultrasound guidance offers a number of advantages, including the ability to visualize the anatomy, perform real-time navigation, and direct observation of local anesthetic spread. The QL block is performed via ultrasound-guided injection of local anesthetic in the fascial planes above or below the QL muscle
14950|NCT04074213|Drug|Clozapine|Clozapine treatment
14951|NCT04074200|Procedure|Open Inguinal Hernia Repair|With the patient under anesthesia, a single incision is made in the groin area. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific open approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
14952|NCT04074200|Procedure|Laparoscopic Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope (a lighted scope used to visualize the hernia) are inserted to complete the repair. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific laparoscopic approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
14953|NCT04074200|Device|Robotic-Assisted Inguinal Hernia Repair|With the patient under general anesthesia, several small incisions are made in the groin area. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the procedure. The hernia defect may be closed, as per the operating surgeon's standard of care (SOC). Mesh may be used to repair the hernia, as per SOC. The specific robotic-assisted approach may vary due to surgeon preference and patient characteristics. After the repair, the patient will be prescribed a 5 day supply of pain medication, as per SOC.
14954|NCT04074187|Drug|Caplacizumab (ALX-0081)|Pharmaceutical form:Lyophilized powder for solution for injection Route of administration: IV (first dose), SC (all subsequent doses)
14955|NCT04074187|Drug|Plasma exchange (PE)|Pharmaceutical form:Plasma (e.g. fresh frozen plasma) Route of administration: Plasma exchange
14956|NCT04074187|Drug|Corticosteroid treatment (Methylprednisolone or prednisolone)|Pharmaceutical form:Solution for injection or Tablet Route of administration: IV or Oral
14957|NCT04074187|Drug|Immunosuppressive treatment (eg, rituximab)|Pharmaceutical form:Solution for injection (depending on product) Route of administration: IV (depending on product)
15288|NCT04071366|Drug|Itacitinib|Itacitinib 200 mg once daily for 30 days.
14958|NCT04074174|Drug|NNC0174-0833|NNC0174-0833 administered s.c. (subcutaneously, under the skin) once weekly for 12 weeks
14959|NCT04074174|Drug|Oral contraceptive (OC) tablets|1 tablet daily on days 1-8 and days 79-86
14960|NCT04074174|Drug|Acetaminophen|Single dose of acetaminophen as part of a standardised meal on day 1 and day 79
14961|NCT04074161|Drug|Semaglutide|Dose gradually increased to 2.4 mg administered once weekly for 68 weeks
14962|NCT04074161|Drug|Placebo (semaglutide)|Administered once weekly for 68 weeks
14963|NCT04074161|Drug|Liraglutide|Dose gradually increased to 3.0 mg administered once daily for 68 weeks
14964|NCT04074161|Drug|Placebo (liraglutide)|Administered once daily for 68 weeks
14965|NCT04074148|Behavioral|Diabetes Prevention Education Program|An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
14966|NCT04074148|Behavioral|Diabetes Prevention Education brochure|An educational lifestyle modification brochure
14967|NCT04074122|Diagnostic Test|Adenosine and epinephrine, isoprenaline provocation|High-resolution electromechanical mapping at baseline and after provocative measures.
14968|NCT04074109|Combination Product|Teleyoga|the yoga protocol will be delivered via a tablet computer to groups of participants
14969|NCT04074109|Behavioral|In-person yoga|the yoga protocol will be delivered by a yoga instructor in the room to group of participants
14970|NCT04074096|Radiation|Stereotaxic radiosurgery (SRS)|"Upfront SRS of all lesions ≥5 mm in diameter (or ≥3 mm if other cerebral metastases >5 mm); followed by encorafenib 450 mg PO QD + binimetinib 45 mg PO BID. The treatment should be started more than 2 days and less than 8 days (excluded) after the SRS.~The binimetinib and encorafenib combination will be administered according to a 28-day cycle."
14971|NCT04074096|Drug|Binimetinib Oral Tablet|"encorafenib 450 mg PO QD + binimetinib 45 mg PO BID.~The binimetinib and encorafenib combination will be administered according to a 28-day cycle."
14972|NCT04074096|Drug|Encorafenib Oral Capsule|encorafenib 450 mg PO QD + binimetinib 45 mg PO BID. he binimetinib and encorafenib combination will be administered according to a 28-day cycle.
14973|NCT04074083|Behavioral|electronic IMCI|Participants will be trained to use an electronic version of the Integrated Management of Childhood Illness (IMCI) guidelines
14974|NCT04074083|Behavioral|paper IMCI|Participants will be trained to use routine paper version of Integrated Management of Childhood Illness (IMCI) guidelines
14975|NCT04074070|Other|Ultrasound examination|Ultrasound examination of joints, tendons and entheses.
14976|NCT04074057|Other|Conventional Cardiac Rehab Classes|conventional weekly CR programme lasting 8-12 sessions.
14977|NCT04074057|Device|Heart Track|"Key components of Heart-Track are a heart rate sensor, a mobile app and a remote monitoring portal. The Heart-Track mobile app is synchronized/ connected to Polar heart rate sensor through bluetooth in order to provide continous heart rate monitoring when subjects are exercising. This is to ensure safety and exercise effectiveness."
14978|NCT04074044|Behavioral|BHmApp|Use of BHmApp for bladder education and training in pregnancy
14979|NCT04074031|Device|Transcranial Ultrasound Therapy (Exablate® 4000 Type 1.1)|The Exablate® 4000 Type 1.1 model designed for noninvasive ablation of brain tissue is an MRI-guided transcranial ultrasound system (MRgFUS). The goal of the Exablate Neuro system is to precisely guide the focus of the ultrasound energy on the target region. The focused ultrasound energy is then repeatedly transmitted to the target until the desired result is achieved. Targeting is performed using MRI acquired during treatment. The treatment process is constantly monitored by closed-loop thermal feedback in real time, under the supervision of the treating physician. Once targeting is complete, the treatment outcome is confirmed by MRI sequences immediately after treatment. The Exablate Neuro is compatible with Siemens 3 Tesla MRI.
14980|NCT04074018|Other|Self-rehabilitation program|facial self-rehabilitation for a duration of 6 months
14981|NCT04074018|Other|Conventional rehabilitation program|Conventional facial rehabilitation for a duration of 6 months
14982|NCT04073992|Behavioral|cognitive behavioral treatment of insomnia|A behavioral modification program consisting of 8 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
14983|NCT04073979|Device|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
14984|NCT04073953|Drug|RPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
14985|NCT04073953|Drug|SPQ|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
14986|NCT04073953|Drug|Placebo|The study will compare the individual enantiomers of Primaquine -R-(-)-PQ, S-(+)-PQ, and Placebo.
14987|NCT04073940|Behavioral|Targeted Ballet Program|All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
14988|NCT04073927|Dietary Supplement|Sodium butyrate|"Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).~The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane."
14989|NCT04073914|Behavioral|Type 1 Teamwork Program|Psychoeducational web program
14990|NCT04073901|Other|Endocrowns|Adhesive monoblock restoration for pulpotomized primary molars
14991|NCT04073888|Procedure|Semen collection|Semen collection for seminogram and spermocytogram
14992|NCT04073875|Diagnostic Test|18F-GP1|18F-GP1 PET-CT scan
14993|NCT04073862|Other|Stepped-Care TF-CBT|SC-TF-CBT will be administered to children meeting the inclusion criteria of the study. The treatment aims to improve daily function for trauma-exposed children and their families by way of stress-mastery exercises, coping skills and gradual exposure.
14994|NCT04073849|Drug|EPOGEN® (epoetin alfa)|Active drug
14995|NCT04073849|Other|Normal Saline|Placebo
17686|NCT04051463|Drug|Placebo|Placebo eye drops instilled once daily
14996|NCT04073810|Diagnostic Test|PET imaging|Coronary 68Ga-DOTATATE PET-MRI or PET-CT at baseline and 3 months
14997|NCT04073810|Diagnostic Test|Coronary CT angiography|CTCA at baseline and 2 years
14998|NCT04073797|Drug|PCSK9 inhibitor|PCSK9 inhibitor
14999|NCT04073797|Diagnostic Test|68Ga-DOTATATE PET-MRI|68Ga-DOTATATE PET-MRI at baseline and 12 weeks
15000|NCT04073784|Drug|Gemcitabine combined with Aptinib and Toripalimab|"Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance."
15001|NCT04073771|Device|Continuous renal replacement therapy with oXiris|Continuous renal replacement therapy with oXiris in patient with septic shock
15002|NCT04073758|Drug|Dexmedetomidine|Comparing effects of remifentanil versus dexmedetomidine
15003|NCT04073745|Other|Quality-of-Life Assessment|Ancillary studies
15004|NCT04073745|Other|Questionnaire Administration|Ancillary studies
15005|NCT04073745|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
15006|NCT04073719|Dietary Supplement|Apple Cider Vinegar|Will drinking apple cider vinegar increase urinary citrate levels to a greater degree than other beverages and which beverages produce the most significant effects compared against one another.
15007|NCT04073719|Dietary Supplement|Other Beverage|To what degree do other high citrate beverages impact urinary citrate output.
15008|NCT04073706|Procedure|TH BSO with SNB|"Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the sentinel node. These one or two nodes are thought to be first involved with cancer spread."
15009|NCT04073706|Procedure|TH BSO without retroperitoneal node dissection|Removal of uterus, tubes and ovaries without retroperitoneal node dissection
15010|NCT04073693|Dietary Supplement|Branched chain amino acids (BRCA)|They were with BRCA during the day apart of following the standard recommendations
15011|NCT04073680|Drug|Serabelisib|Subjects will be dosed with Serabelisib on 3 consecutive days a week in a 28 day cycle until tumor progression. in combination with Canagliflozin 300mg, both are oral medications
15012|NCT04073680|Drug|Canagliflozin 300mg|All subjects will be dosed with 300 mg canagliflozin in combination with serabelisib
15013|NCT04073667|Behavioral|Exercise|"Specific Exercises:~a. Exercises for cervical flexors: Objectives are summarized below:~To increase the endurance and strength of cervical flexors. b. Exercises for cervical extensors:~Training of craniocervical extensors and rotators with the cervical spine in the neutral position, c. Axiocapular muscles;~Teaching the correct scapular position, D. Postural correction exercises;~Teaching the neutral spine position from the first treatment session, 2) Sensorimotor Exercises:~a. Joint position sense:~Participants are trained to point their heads in different directions with the help of an illuminated band that is attached to the head with the eyes open at the beginning.~b. The sense of cervical movement, c. Oculomotor control exercises, 3) Balance and coordination exercises;~a. Balance training starts with static balance exercises and continues with dynamic balance exercises and walking exercises with different difficulty."
15014|NCT04073654|Procedure|Placement of dental implants (surgical procedure)|The two study implants have to be placed in the same surgical session according to similar procedures. Implants will be placed in the planned anatomic sites by using a flapless or a miniflap approach. Implants sites will be prepared based on the bone density, and according to the manufacturers's instruction by using the 122 Taper kit (Osstem Implant).
15015|NCT04073641|Other|No intervention|No intervention
15016|NCT04073628|Device|Lighting Intervention|Lighting Intervention consisting of a cool or warm light source.
15017|NCT04073615|Drug|Rivoceranib|Rivoceranib will be supplied as 100 mg and 200 mg film-coated tablets for oral administration.
15018|NCT04073615|Drug|Trifluridine/Tipiracil|Trifluridine/tipiracil will be supplied as 15 mg trifluridine/6.14 mg tipiracil and 20 mg trifluridine/8.19 mg tipiracil tablets for PO administration.
15019|NCT04073602|Drug|RC48-ADC|The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
15020|NCT04073589|Biological|ARGX-113 with rHuPH20|subcutaneous administration of efgartigimod with recombinant human hyaluronidase PH20 (rHuPH20)
15021|NCT04073576|Device|AHCL|Closed loop algorithm contained in the MiniMed™ 670G 4.0 pump to be used in the study; includes a modified proportional integrative derivative (PID) model, with insulin feedback, an auto correction bolus feature and additional safety features.
15022|NCT04073576|Device|SAP+PLGM|Sensor Augmented Pump (SAP) Therapy Mode with Predictive Low Glucose Management (PLGM), contained in the the MiniMed™ 670G 4.0 pump to be used in the study.
15023|NCT04073563|Device|Infuse™ Bone Graft (Infuse™)|(Recombinant human bone morphogenetic protein-2 (rhBMP-2)/absorbable collagen sponge (ACS))
15024|NCT04073563|Device|Capstone™ Spinal System and Medtronic posterior Fixation Systems|Capstone™ Spinal System and Medtronic posterior fixation systems
15025|NCT04073550|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
15026|NCT04073550|Drug|Placebos|Anlotinib blank analog capsule.
15027|NCT04073550|Drug|Topotecan|A topoisomerase I inhibitor.
15028|NCT04073537|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor.
15029|NCT04073537|Drug|Placebos|Anlotinib blank analog capsule.
15030|NCT04073537|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV on Day 1 of each 21-day cycle.
15031|NCT04073537|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 5 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
15032|NCT04073524|Other|Nature-Body-Mind-Community|The Nature-Body-Mind-Community (NBMC) approach has been developed in a pilot project over 2014-2018. The 'Wild man Programme' consists of the following main elements: 1. Nature environments and nature experiences, 2. Mind relaxation and meditation, 3. Body awareness and 4. Fire talks, storytelling and community spirit.
15033|NCT04073524|Other|Treatment as usual|Treatment as usual consist of the rehabilitation offered by the hospital or municipality for the specific condition e.i. cancer, diabetes, COPD, anxiety, depression and stress
15034|NCT04073511|Drug|Eungyosan|This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.
15035|NCT04073511|Drug|Samsoeum|This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
15036|NCT04073511|Drug|Placebo|It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
15037|NCT04073498|Drug|SerpinPC|Administered as IV infusion (over 30 minutes) or SC injection (abdomen) according to cohort dosing instructions.
15038|NCT04073498|Drug|Placebo|Matching placebo administered by SC injection according to cohort dosing instructions.
15039|NCT04073485|Procedure|Microwave ablation|Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
15040|NCT04073472|Drug|mesenchymal stem cells (MSCs)|Allogeneic bone marrow derived mesenchymal stem cells (MSCs) direct injection to an ileal pouch fistula in the setting of Crohn's disease of the pouch
15041|NCT04073459|Biological|DTwP-HepB-Sabin IPV-Hib|Intramuscular injection into the anterolateral area of the thigh
15042|NCT04073459|Biological|Pentavalent vaccine and Salk IPV|Intramuscular injection into anterolateral area of the thigh
15043|NCT04073446|Device|Spinal Cord Stimulation|Patients eligible for SCS
15044|NCT04073433|Drug|MDMA|120 mg MDMA
15045|NCT04073433|Behavioral|Psychotherapy|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
15046|NCT04073420|Device|Surgical Heart Valve Repair Products|Surgical heart valve repair products.
15047|NCT04073420|Device|Surgical Heart Valve Replacement Products|Surgical heart valve replacement products.
15048|NCT04073407|Dietary Supplement|AXA1957|Amino acids, food study
15049|NCT04073407|Dietary Supplement|Placebo|placebo
15050|NCT04073394|Behavioral|Diet Intervention|Mayo Clinic Diet
15051|NCT04073381|Combination Product|Prehabilitation Program|This is a 4 week prehabilitation program which uses both exercise and nutrition. Exercise will be prescribed at least 6 days a week. Three days a week , for 45 mins, participants will be asked to perform body, leg and arm exercises against light resistance while wearing pneumatic blood flow restriction arm and leg bands. minutes. On the alternate days participants will walk approximately 15 minutes while wearing the leg bands that restrict blood flow. Additionally, a nutrition supplement cocktail will be provided and should be taken every day within 1 hour after completing each exercise session. The 4 Week Nutrition (Sports Drink) Supplement Cocktail: will include whey protein (25 g/day), creatine monohydrate (8 g/day), and L-citrulline (5 g/day). The supplement mixture will be provided in daily packages by the investigators (nutrition supplements are not regulated by the FDA)
15052|NCT04073368|Dietary Supplement|AXA1957|Amino acids, food study
15053|NCT04073368|Dietary Supplement|AXA1125|Amino acids, food study
15054|NCT04073368|Dietary Supplement|Placebo|Amino acids, food study
15055|NCT04073355|Behavioral|Physical Activity|Smartphone-delivered physical activity intervention
15056|NCT04073342|Genetic|Gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).|Ileal tissue from both group will be tested for gene expression of inflammatory mediator (Interleukin 8) and recognition receptor of Toll like receptor (TLR4).
15057|NCT04073329|Other|post operative measure of reduction|measurement was used to grade quality of reduction according to Matta's system . In accordance with prior studies, adequate (or anatomic) reductions with 0-1 mm of displacement were compared to inadequate (imperfect or poor) reductions with > 1 mm displacement . For the CT-based method, postoperative pre-digital (prior to 2000) and digital CT images were independently assessed in the axial, sagittal, and coronal planes, and residual gap and step displacement were measured along the articular surface at the level of the weight-bearing dome. Adequate reductions on postoperative CT were defined as < 1 mm step and < 5 mm gap displacement and inadequate reductions as ≥ 1 mm step and/or ≥ 5 mm gap displacement.
15058|NCT04073316|Drug|Rivaroxaban 20 MG|Rivaroxaban intake, 20mg/day
15059|NCT04073316|Drug|Warfarin|Warfarin intake, with target INR range between 2 and 3
15060|NCT04073303|Biological|Botulinum Toxin Type A|Day 1 Administration of bilateral intramuscular injections into the masseter
15061|NCT04073303|Other|Placebo|Day 1 Administration of bilateral intramuscular injections of placebo (normal saline) into the masseter
15062|NCT04073290|Drug|Rifaximin 550 MG Oral Tablet [XIFAXAN]|Rifaximin 550mg b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
15063|NCT04073290|Drug|Placebo oral tablet|Placebo b.i.d. 72 hours before TIPS placement till 3 months post-TIPS
15064|NCT04073290|Drug|Lactulose 667 MG/ML Oral Solution|Lactulose based on soft stool frequency, 72 hours before TIPS placement till 3 months post-TIPS
15065|NCT04073277|Device|SCF-N-treated needles|The SCF-N-treated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the experimental groups..
15066|NCT04073277|Device|Untreated needles|he untreated needles were used for acupuncture at LI 4 (Hegu) and LI 11 (Quchi) acupoints in the control groups.
15067|NCT04073264|Procedure|monofilament|In the intervention group,monofilament absorbable suture,will be used.
15068|NCT04073251|Dietary Supplement|KalobaTuss children|Syrup, dosage: 5 ml for 4 times a day for 8 days.
15069|NCT04073251|Dietary Supplement|Placebo|Syrup, dosage: 5 ml for 4 times a day for 8 days.
15070|NCT04073238|Device|Low-level Red-light Therapy|In addition to wearing single vision spectacle lens with power for correcting distance refraction, low-level red-light therapy is performed twice per school day at home with an interval of at least 4 hours, each treatment lasting 3 minutes.
15160|NCT04072471|Drug|Zurampic®|non-interventional study where patients are exposed to Zurampic® plus a xanthine oxidase inhibitor (allopurinol or febuxostat) during the normal course of clinical practice
15071|NCT04073225|Device|MindPod Dolphin|"The immersive video game being tested in this study is called Bandit the Dolphin, developed by neurologist Dr. John Krakauer, and engineers in the Brain, Learning, Animation, and Movement Lab at Johns Hopkins. Bandit the Dolphin provides an oceanic environment in which the individual's arm movements control a simulated dolphin. The neuromotor effects of this game have been designed to be used in the clinical setting to rehabilitate arm and hand function following stroke. The game has further been modified to a Microsoft Kinect-based system and piloted for play in non-laboratory settings among community-dwelling adults. The game offers a unique combination of skilled arm movements plus varying levels of cognitive challenge. In this way, the individual's arms are challenged the same way the legs would be when walking in a complex, outdoor environment. Importantly, the participant plays while standing, thus engaging the whole body in this novel multi-sensorial experience."
15072|NCT04073225|Device|Hand Bike|The control intervention in this study is a hand bike, a single-component upper-arm aerobic exercise device. This arm is innovative in its own right, by evaluating the benefits of upper arm aerobic activity on cognitive and physical health given that the vast majority of physical interventions focus on lower-extremity walking and biking exercise.
15073|NCT04073212|Other|Dry Needling|Dry needling directly to the long head of the biceps tendon. The DN will be performed with disposable stainless-steel needles (.3 X 40mm; Seirin; Weymouth, MA) inserted into the skin over the most painful and/or thickened areas of the tendon, confirmed with palpation. Prior to insertion of the needle the overlying skin will be cleaned with alcohol. The needle will be inserted into the tendon. The technique will be a fast-in and fast-out technique described by Chiavaras et al.26 for 20-30 repetitions per session in up to 3 areas. An eccentric-concentric exercise program of the biceps muscle/tendon will follow each DN session and will be performed daily for the course of treatment and will be performed as described by McDevitt et al.
15074|NCT04073212|Other|Eccentric and Concentric Exercise|Eccentric exercise protocols have been found to be an effective treatment for tendinopathies of the upper and lower extremities and recent evidence supports heavy slow resistance training (including the addition of a concentric phase) as having better outcomes over eccentric exercise alone. Patients will use 1-5 pound weights to perform slow and controlled concentric and eccentric exercise to biceps muscle.
15075|NCT04073212|Other|Rotator cuff and scapular stabilization exercise program|Both groups will be treated with a stretching and strengthening program. The rotator cuff and scapular stabilization strengthening and flexibility program used in this study has 3 phases and patients progress in phases based on their ability to perform a number of exercises using theraband or body weight resistance.
15076|NCT04073212|Other|Soft tissue mobilization|Both groups will receive soft tissue mobilization to the anterior shoulder.
15077|NCT04073199|Procedure|Long Lever Group|"the physiotherapist wears the limb passively towards flexion, external rotation and abduction until the physiotherapist has perception of stretch of the tissues (sensation terminal elastic firm according to the concept of Orthopaedic Manual Therapy for the soft tissue treatment) The patient's own weight stabilizes the proximal segment, in case that the scapula is not stable, the physiotherapist fixes with his free hand the scapula.~The technique will be performed two days a week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)."
15078|NCT04073199|Procedure|Short Lever Group|"It consists of a stretch made by the physiotherapist, with the patient in supine position, with the extremity to be treated in a submaximal position of flexion and external rotation (fixed by the arm and body of the physiotherapist) and realizing the stretch a through the scapula in the medial and caudal dorsal direction.~The technique will be performed two days per week, at intervals of 20 seconds of technique and 20 rest periods for ten reps (estimated time per session is 7 minutes approximate)"
15079|NCT04073186|Device|ACUVUE® OASYS with Transitions™|JJVC Marketed Contact Lens
15080|NCT04073173|Procedure|INSURE|Patients will be intubated by endotracheal tube, exogenous surfactant (Poractant alfa) will be administered and then they will be extubated.
15081|NCT04073173|Procedure|LISA|Surfactant (Poractant alfa) will be directly delivered into the lungs via a fine bore catheter inserted into the trachea and then patients will be extubated.
15082|NCT04073173|Drug|Analgesic, Opioid|Remifentanil (0.5-2 micrograms/kg/dose)
15083|NCT04073160|Drug|Tremelimumab|Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Tremelimumab will be administered intravenously at a dose of 75 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.
15084|NCT04073160|Drug|Durvalumab|"Tremelimumab and durvalumab will be administered in combination during cycles 1 and 2. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 1 day 1 and cycle 2 day 1. Cycles are 4 weeks long.~Eligible subjects may go on to receive a combination of durvalumab and bladder radiation during cycles 3 and 4. Durvalumab will be administered intravenously at a dose of 1500 mg on cycle 3 day 1 and cycle 4 day 1.~At the completion of radiation, eligible subjects may continue to receive durvalumab for a maximum of one year from the date of their initial dose. Durvalumab will be administered intravenously at a dose of 1500 mg on the first day of each cycle."
15085|NCT04073160|Radiation|Bladder radiation|During the durvalumab cycles 3 and 4, eligible subjects will receive 6.5 weeks of radiation to the bladder. Radiation will be administered at a dose of 64 Gy in daily 2 Gy fractions.
15086|NCT04073160|Drug|Intravesicular Therapy|Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
15087|NCT04073147|Drug|Venetoclax|Venetoclax per os
15088|NCT04073147|Drug|Obinutuzumab|ObintuzumabIV
15089|NCT04073134|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
15090|NCT04073134|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
15091|NCT04073121|Device|Luminor DCB and Angiolite DES|Patient to undergo angioplasty with Luminor DCB and Angiolite DES
15092|NCT04073108|Diagnostic Test|tuberculin test|tuberclin test used to diagnose tuberculosis as cause of fever of unknown origin
15161|NCT04072471|Drug|Control group: xanthine oxidase inhibitor monotherapy|non-interventional study where patients are exposed to xanthine oxidase inhibitor monotherapy (allopurinol or febuxostat) during the normal course of clinical practice
16045|NCT04065074|Drug|FX006 32 mg|Extended-release 32 mg FX006 IA injection
15093|NCT04073095|Other|Erector spinae plane block (Group E)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
15094|NCT04073095|Other|modified-thoracolumbar interfascial plane block (Group T)|"Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period.A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16 and 24 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded."
15095|NCT04073069|Drug|The DR group|Miscible liquid of diprospan and ropivacaine in this study will be peri-incisional scalp infiltration with 0.5 ml diprospan, 15 ml 1% ropivacaine and 14.5 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
15096|NCT04073069|Drug|The R group|Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 15 ml 1% ropivacaine and 15 ml normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
15097|NCT04073056|Drug|Bupivacaine|Bupivacaine Hcl 0.25% Inj
15098|NCT04073043|Behavioral|Telephone Coaching|Access to Telephone Coaching for a period of 12 weeks
15099|NCT04073017|Dietary Supplement|Enterade®|Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks
15100|NCT04073017|Other|Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)|Ancillary studies
15101|NCT04073004|Behavioral|Rapid Resolution Therapy|psychotherapy that includes trance states
15102|NCT04072991|Other|dietary therapy|participants will undertake a four week diet as part of their IBS treatment
15103|NCT04072978|Device|Intraocular lens implantation|Implantation of an intraocular lens using either an anterior chamber IOL or a scleral fixated IOL using the modified Yamane technique.
15104|NCT04072965|Other|balance training|Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
15105|NCT04072952|Drug|ARV-471|Dosages are predetermined by Cohort Review Committee after the initial starting dose cohort after the first 28 days of treatment
15106|NCT04072939|Other|Patients having had a lens surgery|Dilated fundus exam
15107|NCT04072926|Drug|BioRoot|Influence of biomaterial BioRoot on periapical healing
15108|NCT04072913|Other|Vaginal samples (biopsies + vaginal smear)|Two types of samples are envisaged: tissue (large biopsies, coin of conization or hysterectomy) to affirm the diagnosis and detect the matrix metalloproteinases and their tissue inhibitors by immunohistochemistry; cell sample (monolayer smear type) to evaluate the expression of oncogenic Human papillomavirus.
15109|NCT04072900|Drug|Peptide|4 x 3 mg all the peptides given on days 84，87，91，98，105，133，and 161
15110|NCT04072900|Drug|Anti-PD-1|3mg/kg, ivgtt, Q2w
15111|NCT04072900|Drug|rhGM-CSF|3μg/kg given on Days 81，82，83，95，96，97，102，103，104，130，131，132，158，159，and 160
15112|NCT04072900|Drug|Imiquimod 5% Topical Cream|topical application on the injection site 6 hours before each NeoAntigen peptides injection
15113|NCT04072887|Drug|QBW251|QBW251 b.i.d
15114|NCT04072887|Drug|Placebo|Placebo b.i.d
15115|NCT04072874|Drug|Experimental topical (Curaleish Topical)|Curaleish is a formulation in lotion and cream. Curaleish lotion and Curaleish cream will be applied topically by each participant in all lesion until day 28 or 42, depending on the regimen to be evaluated. Study staff will be closely observing the safety assessment. The application until Day 28 or 42 will continue, even if the lesion has shown 100% re-epithelization before day 28 or day 42.
15116|NCT04072861|Drug|SnPP Protoporphyrin|Escalating doses of SnPP Protoporphyrin
15118|NCT04072822|Drug|Anakinra and Zinc|Anakinra is indicated for reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis. It has been previously studied in AH. Zinc is a nutritional supplement. Zinc supplementation reverses the clinical signs of zinc deficiency in participants with alcoholic liver disease.
15287|NCT04071379|Biological|Hep B + Pentabio (registered)|1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
15119|NCT04072822|Drug|Granulocyte-colony factor|G-CSF is used to stimulate the production, maturation, and activation of neutrophils to increase both their migration and cytotoxicity. It is commonly used to treat neutropenia resulting from myelosuppressive chemotherapy or radiation, bone marrow transplantation, and for severe chronic neutropenia to reduce the risk and duration of neutropenia related infections.
15120|NCT04072822|Drug|Prednisone|Prednisone is indicated for numerous conditions including inflammatory disease. Corticosteroids, such as prednisolone, are considered standard of care in alcoholic liver disease.
15121|NCT04072822|Drug|Placebos|Matching placebo
15122|NCT04072809|Other|No intervention|This study does not involve any interventions.
15123|NCT04072796|Behavioral|Questionnaires|Short Form-36 (SF-36), Barthel Index (BI), Functional Ambulation Category (FAC), Mini-Mental Test (MMT) and Beck Depression Inventory (BDI) questionnaires
15124|NCT04072783|Diagnostic Test|MRI,DTI, functional MRI|"Patients will undergo testing with Pre- and and post-surgical MRI. The protocol will be Sagittal T1, Axial inversion recovery, T2, fluid-attenuated inversion recovery, susceptibility weighted image, diffusion weighted images, diffusion tensor imaging, resting state fMRI, sagittal 3D GRE / FFE or 3D T1 VIBE and tractography.~Once patients are identified, surgery is planned.The standard of care procedures fall into two categories based on age of presentation, clinician judgement and family preference all other things being equal. Both the endoscopic-assisted craniectomy and open CVR are standard of care procedures. Patients self-select into these groups. None of the surgery nor any aspect of it is experimental.~Patients are routinely examined for neurodevelopment pre- and post-operatively as part of American Cleft Palate Craniofacial Association guidelines.The Vineland Adaptive Behavior Scales are used up to and including age 4."
15125|NCT04072770|Dietary Supplement|Pea|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
15126|NCT04072770|Dietary Supplement|Casein|Proteins are intrinsically enriched with 15N and 2H. There are incorporated into mashed potatoes and the test meal is formulated to supply 30 g of pea protein per volunteer.
15127|NCT04072757|Behavioral|Intervention Group|"Session One: Loving Food That Loves You Back - Food as Fuel~connection nutrition and health Session Two: Myth busting: Fruits and Vegetables - delicious and affordable~seasonal fruits & vegetables in the diet Session Three: No Time to Cook! Making nutritious meals that are fast and easy~quickly make delicious/nutritious meals using minimal ingredients Session Four: Don't Eat Food You Can't Pronounce Except Quinoa; Eat Quinoa~choose healthier foods Session Five: Taste Bud Rehab~reduce foods high in sugar and salt.Mind-body connection Session Six: Batch & One Ingredient Cooking~making large quantities to freeze; one ingredient cooking Session Seven: Sweet Tooth? Healthy Desserts~prepare healthier desserts Session Eight: Family Meal Practices~healthy eating habits in children Session Nine: Snacks as Mini Meals~make nutritious snacks to keep energy up all day Session Ten: Revamp Your Favorite Recipe~healthy up favorite recipes"
15128|NCT04072757|Behavioral|Control Group|"The control group will not receive vouchers or nutrition education/skill building but will be exposed to any standard Griffin Hospital worksite offerings. A mini program (2 -4 hours) workshop will be offered to participants in the control group, and all intervention materials will be provided."
15129|NCT04072744|Device|Heartfelt measurements|"The measurements taken using the Heartfelt device do not require contact with the participant. For the measurements to take place, the participant will simply walk in the field of view of the device. As the device(s) will have been installed at a location allowing the best view of where the participant goes in an out of bed, the participant is not expected to change anything to their routine.~The device can also take measurements in the dark, so if the participant walks in front of the device in the dark, this information will also be captured.~The Heartfelt device is a CE (European Conformity) marked product. Neither the participant, or the medical team will be able to see the data collected by the Heartfelt device during the study. They will be blinded to the data until each participant has completed the study. At that point they can choose to review the data from participant individually or wait until all the data from all participants is available."
15130|NCT04072744|Device|Connected weighing scales|"The participant will be instructed to use those scales for the period of the study, as often as directed by their healthcare professional. The weighing scales display weight so that the participants can record the weight in their own heart failure records.~The participant will be able to see the weight readings on the weighing scales during the study.~The scales will communicate with the Personal Computer (PC) contained in the Heartfelt device and the data will be sent to the Heartfelt server through an encrypted link."
15131|NCT04072731|Other|pathologic|All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.
15132|NCT04072718|Radiation|Radiotherapy|34 Gy/10#/2wk to the PTV and 40Gy/10#/2 Wk to the PTV SIB with IGRT using Rapid arc technique.
15133|NCT04072705|Drug|General principles of care and judgement of researcher|Because our study will be performed by observational design, there will be no intervention for our study. Because it is a registry-based study, overall decision making for medications will be performed according to the general principles of care and judgement of researcher.
15134|NCT04072692|Other|Hybrid rehabilitation training|Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
15135|NCT04072692|Other|Traditional rehabilitation training|Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
15136|NCT04072692|Other|Wearable anti-bowstringing orthosis (WABO)|WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
15137|NCT04072679|Drug|Sintilimab+IBI305|It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
15162|NCT04072458|Drug|L-Bcl-2 antisense oligonucleotide|There will be 2 planned dose levels, 20, and 40 mg/m^2. Successive cohorts of eligible patients with will be treated with BP1002. BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle. Cycles may be repeated every 4 weeks.
15163|NCT04072445|Drug|Irinotecan|Given IV
15164|NCT04072445|Drug|Irinotecan Hydrochloride|Given IV
15165|NCT04072445|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
15166|NCT04072432|Drug|Iron sucrose|single FeS infusion
15138|NCT04072666|Behavioral|Attempted Suicide Short Intervention Program (ASSIP)|The first session is based on a narrative interview with the consumer relating the personal story of how the point of attempting suicide was reached, videorecorded with consent. The second session involves the therapist and consumer watching the session together to reactivate the consumer's mental state during the crisis in a safe environment. Automatic thoughts, emotions, psychological pain and stress, and contingent behaviour are discussed. A psycho-educative handout is given to consumers. The third session involves discussing the handout. A credit card size leaflet is provided, with long term goals, individual warning signs and safety strategies listed, in addition to a card with crisis phone numbers. The sessions are followed by letters sent over 24 months (Michel, Valach & Gysin-Maillart, 2017).
15139|NCT04072666|Behavioral|Cognitive Behavioural Therapy (CBT)|The intervention incorporates skills development and emphasises internal self-management. Therapy focuses on the identification of internal, external and/or thematic triggers for suicidal thinking and behaviours, as well as factors that maintain the desire to suicide, using thought records and/or chain analyses. Therapy aims to challenge distortions and misconceptions, including core beliefs that interfere with the motivation to initiate the process of problem solving and distress tolerance, by working on acceptance of emotional and/or physical pain. The final phase of treatment focuses on relapse prevention. CBT can challenge maladaptive beliefs, improve problem solving skills and social competence.
15140|NCT04072666|Behavioral|Suicide Prevention Pathway (SPP)|The standardised care approach involves a Suicide Prevention Pathway (SPP) modelled on the Zero Suicide Framework, utilising comprehensive chronological assessment of suicide events (CASE) (Shea, 2009) to elicit suicidal intent, the prevention orientated risk formulation (Pisani, Murrie, & Silverman, 2016), brief interventions conducted with the consumer during their initial assessment prior to the treatment setting (Stanley et al., 2016), Safety Planning Intervention, Counselling on Access to Lethal Means (CALM), brief patient/carer information, rapid, structured follow up, safe transitions of care and caring contacts (Fleischmann et al., 2008). The SPP is supported by a blended learning course with online and face-to-face training for staff.
15141|NCT04072653|Procedure|SLNB is spared|SLNB is spared in patients with negative preoperative axillary assessment(including MAMMI BB PET and other imaging examinations)
15142|NCT04072640|Drug|Voriconazole 200mg|Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;
15143|NCT04072640|Drug|amphotericin B deoxycholate (0.4-0.5mg/kg/d)|Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days
15144|NCT04072640|Drug|Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)|Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days
15145|NCT04072601|Drug|Placebo oral tablet|Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
15146|NCT04072601|Drug|Atorvastatin 10mg|Tablet, can be adjusted to 2 tablets if tolerated
15147|NCT04072588|Procedure|vaginal cuff prolapse surgery|Different surgical methods for the treatment of vaginal cuff prolapse in patients who have previously undergone hysterectomy for benign causes
15148|NCT04072575|Drug|PP6M injection Dose 1|Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.
15149|NCT04072575|Drug|PP6M injection Dose 2|Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
15150|NCT04072562|Drug|AZD7594|"Treatment A: The study drug is a nebulizer suspension with strength 2.8 mg/mL using 2 mL in the device. The study drug is administered via oral inhalation.~Treatment B: The study drug is a nebulizer suspension with strength 6.3 mg/mL using 2 mL in the device. The study drug was administered via oral inhalation.~Treatment C: The study drug is an inhalation powder. The study drug was administered via oral inhalation."
15151|NCT04072549|Behavioral|Free Summer Programming|The summer day camps are not singularly focused, such as sport camps or academic only camps. Rather, the camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. To standardize programming, the schools operate their camps on the same daily schedules which are developed by the same district-level personnel, with identical programmatic content delivered across all schools. The schools also provide the same meals to all children enrolled. The meals adhere to the Summer Food Service Program nutrition guidelines and are reimbursed through existing federal food programs.
15152|NCT04072536|Device|Electric wheelchair with activated assistance module|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with activated assistance
15153|NCT04072536|Device|Electric wheelchair with assistance module not activated|This evaluation will be carried out in 3 standardized test circuits of increasing difficulty, one week apart. At each session, the patient will perform the circuit 6 times, including 3 with no activated assistance
15154|NCT04072510|Behavioral|Self-esteem group|"The intervention will comprise of 6 sessions of group self-esteem therapy which uses a cognitive behavioural approach. The therapy has been manualised into a 76 page treatment protocol and will be administered by Assistant Psychologists employed at Newbridge House receiving weekly supervision from a Clinical Psychologist. The self-esteem group is based on Melanie Fennel's cognitive behavioural model of low self-esteem addressing thoughts, feeling and behaviours. The group aims to improve self-esteem and build positivity.~The sessions are structured and laid out in the following overview:~Week 1, Session 1: What is self-esteem and an introduction to CBT Week 2, Session 2: How might low self-esteem develop? Week 3, Session 3: Negative automatic thoughts Week 4, Session 4: Challenging negative automatic thoughts Week 5, Session 5: Creating new coping strategies Week 6, Session 6: Building positivity"
15155|NCT04072510|Behavioral|Treatment as Usual|Treatment as usual refers to the standard inpatient treatment programme at Newbridge House which includes: individual therapy, occupational therapy, drama therapy, family therapy, dietetic support, nursing support, yoga and medication prescribed by a consultant psychiatrist.
15156|NCT04072497|Biological|One shot of the zoster vaccine|One shot of the zoster vaccine (with live virus >=4.3 LgPFU per dose)
15157|NCT04072497|Biological|One shot of the varicella vaccine|One shot of the varicella vaccine (with live virus >=3.3 LgPFU per dose)
15158|NCT04072497|Biological|one shot of placebo|one shot of placebo with no live virus
15159|NCT04072484|Other|Mild hypoxia|The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
15167|NCT04072406|Other|Mindfulness meditation|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
15168|NCT04072406|Other|Usual care packet|Participants assigned to either condition who do not have a personal electronic device for listening to meditations or completing survey will receive a loaned device from the study team.
15170|NCT04072380|Drug|SUVN-G3031|SUVN-G3031 Tablets
15171|NCT04072380|Drug|Placebo|Placebo Tablets
15172|NCT04072367|Device|NeVa Stent Retrievers|thrombus removal
15173|NCT04072367|Device|Solitaire Stent Retrievers|thrombus removal
15177|NCT04072341|Drug|Propolis Period (Green Propolis 250mg/day)|Randomized, cross-over, open-label. Patients will go through two 4 week periods with 1 week washout between them. During the intervention period will use 250mg of green Propolis per day. In the control period they will only follow standard treatment for their comorbidities.
15178|NCT04072341|Other|Control Period|In the control period they will only follow standard treatment for their comorbidities.
15179|NCT04072328|Drug|Propofol|Propofol will be given 0.5 mg/kg bolus initially, and can be administered additionally after a least 30 secs if necessary.
15180|NCT04072328|Drug|Midazolam|midazolam with propofol
15181|NCT04072315|Drug|PLN-74809|PLN-74809
15182|NCT04072315|Drug|Placebo|Placebo
15183|NCT04072315|Radiation|Knottin tracer|Radiotracer
15184|NCT04072302|Drug|KAF156|100 mg tablet, 20 mg tablet, 50 mg tablet
15185|NCT04072302|Drug|Placebo|100 mg tablet, 20 mg tablet, 50 mg tablet
15186|NCT04072289|Device|Visumax spherocylindrical treatment|treatment of low cylinder (<0.75D)
15187|NCT04072276|Biological|EV71 vaccine|EV71 vaccine with Adjuvant AlPO4 and the placebo (Adjuvant AlPO4 only) were randomly administrated to subject in CT-EV-21 study
15188|NCT04072263|Biological|Tumor Infiltrating Lymphocytes (TIL)|Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
15189|NCT04072263|Drug|Interferon Alfa 2A|Interferon alpha (IFNα) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
15190|NCT04072263|Drug|Carboplatin|chemotherapy i.v.
15191|NCT04072263|Drug|Paclitaxel|Chemotherapy i.v.
15192|NCT04072250|Procedure|hepatectomy|Hepatectomy for patients with recurrent intrahepatic cholanigocarcinoma
15193|NCT04072237|Biological|Coagulation Factor VIIa variant|Single intravenous dose and ascending doses of subcutaneous injection of MarzAA
15195|NCT04072198|Drug|Nivolumab|240 mg every 2 weeks for 8 cycles followed by maintenance
15196|NCT04072198|Drug|Bevacizumab|5 mg/kg every 2 weeks for 8 cycles followed by maintenance
15197|NCT04072198|Drug|Irinotecan|165 mg/m2 every 2 weeks for 8 cycles
15198|NCT04072198|Drug|Oxaliplatin|85 mg/m2 every 2 weeks for 8 cycles
15199|NCT04072198|Drug|Leucovorin|200 mg/m2 every 2 weeks for 8 cycles
15200|NCT04072198|Drug|fluoruracil|3200mg/m2 every 2 weeks for 8 cycles
15201|NCT04072185|Other|Physical activity|TThe intervention group will participate in a group physical activity program for 4 months. It will consist of 60 minutes of walking sessions 2 days a week. The sessions will be directed by two referents of each primary care center. Also once a month, coinciding with the walk, you will visit some sociocultural municipal equipment to promote a community connection.
15202|NCT04072172|Device|Mole Freckle Pen|Insulated micro steel needle use current: 5V / 1A of 5-speed free adjustment.5
15203|NCT04072159|Behavioral|Community Pharmacists Vaccinating Against Cancer|Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
15204|NCT04072146|Drug|OC-01|Cross over bioavailability study
15205|NCT04072146|Drug|Chantix|Cross over bioavailability study
15206|NCT04072133|Behavioral|Meditative Movement|Intervention will be taught by a certified Tai Chi Easy (TCE) group practice leader. The TCE movements will be repeated in differing sequences and time-frames during the course of the study. The variety and combination of the exercises will begin easy and progress to more advanced movements and/or intensities as the study progresses and participants become more experienced and comfortable with the routine. Participants spend one hour in class each week for a total of eight weeks.
15207|NCT04072107|Drug|sintilimab|Investigate whether capecitabine would be able to improve prognosis in patients at high risk groups
15208|NCT04072107|Drug|Capecitabine|Investigate whether capecitabine would be able to improve prognosis in patients at intermediate risk groups
15209|NCT04072094|Procedure|Minimally Invasive Locking Plate Fixation|Patients randomized to the Minimally Invasive Locking Plate Fixation arm will be treated with plate fixation. The plate may be applied in a percutaneous fashion. Any combination of locked and/or non-locked screws may be used.
15243|NCT04071756|Other|Placebo|A substance that has no therapeutic effect, used as a control in testing new drugs
15210|NCT04072094|Procedure|Intramedullary Nail Fixation|Patients randomized to the Intramedullary Nail Fixation arm will be receive a standard locked intramedullary nail fixation. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with a reamed technique.
15211|NCT04072081|Device|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
15212|NCT04072081|Device|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
15213|NCT04072068|Drug|Edoxaban|Every patient will receive every day edoxaban orally once a day. Edoxaban therapy will start after at least 5 days of lead-in with low-molecular-weight heparin, as per clinical practice. Edoxaban will be administered at dosage of 60 mg/day. In case of patients with body weight ≤60kg or with renal failure (creatinine clearance between 15 and 50 ml/min) or that are treated with P-gp inhibitors (cyclosporine, dronedarone, erythomycin, ketoconazole), dosage will be 30 mg/day. Patients will be treated for 6 up to 12 months with edoxaban, as per medical decision.
15214|NCT04072055|Device|MOTO Medial|MOTO medial unicompartmental knee system
15215|NCT04072042|Drug|Apatinib monotherapy|patients will receive Apatinib 250mg tablet by mouth, bid.
15216|NCT04072029|Procedure|Phacoemulsification with intraocular lens implantation|Phacoemulsification (2.2mm coaxial, viscoelastic shield, experienced surgeon) with intraocular lens implantation (acrylic hidrophobic)
15217|NCT04072016|Device|Beacon Aqueous Microshunt|The Beacon Aqueous Microshunt (BAM) is an implantable device intended to reduce intraocular pressure (IOP) in patients with refractory glaucoma by shunting aqueous humor from the anterior chamber to the surface of the eye.
15218|NCT04072003|Device|intravascular ultrasound (IVUS)|use IVUS in the procedure
15219|NCT04072003|Other|coronary angiography|Coronary angiography is required for all PCI procedure.
15220|NCT04071990|Behavioral|FB-CBGT|CBGT for OCD patients, with Involvement of family members (partner, parent, sibling, ...)
15221|NCT04071990|Behavioral|CBGT|CBGT for OCD patients, without involvement of family members
15222|NCT04071977|Drug|Combined antioxidant therapy|It consists of a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1 mg), vitamin C (L-ascorbic acid 180 mg), vitamin E (DL-alpha tocopherol 30 mg), zinc (zinc oxide 20 mg), copper (copper sulfate 1 mg), taken once a day for 12 months
15223|NCT04071977|Other|Placebo|It consists in a capsule with 100 mg of magnesium oxide
15224|NCT04071951|Behavioral|Pharmacist-led Hospital Discharge Care Intervention|"Pharmacists will address medication reconciliation, medication adherence, and polypharmacy issues as appropriate. Pharmacists will rely most on their prior training, but study investigators will also encourage the use of documentation templates with reminders, Beers list, deprescribing, motivational interviewing, the Medication Adherence and Literacy tool, and post-discharge phone calls.~Pharmacists will assess patient needs and customize accordingly. All patients will receive one discharge counseling visit and one post-discharge phone call, but pharmacists will find that some patients need further phone calls, interventions, referrals, or other interactions."
15225|NCT04071938|Other|Teaching to GPs|Educational modules on bladder, bowel and skin-care, and pain management will be provided to participating GPs by Spinal Cord Injury specialists
15226|NCT04071938|Other|Site visits to GP practices|Visits by specialized nurses to the participating GPs at their practices to support the establishment of specialized care on-site
15227|NCT04071925|Procedure|Urethroplasty|Open reconstructive surgery to restore urethral patency in case of urethral stricture disease.
15228|NCT04071899|Other|Scale vaidation|It's just filling a scale in order to validate it in French
15229|NCT04071886|Behavioral|Mindfulness-Based Training|Mindfulness-Based Training comprises of mindful walking, body scanning and raisin meditation exercise. Participants will receive a guided session of mindfulness meditation, and will be asked to finish at least 30 minutes of Mindfulness-Based Training every day as homework as well as keep a diary describing their experiences and reflections. An expert in mindfulness practice will offer feedback and answer any questions online.
15230|NCT04071886|Behavioral|Relaxation Training|Participants will listen to a 15-minute Relaxation Training tape twice a day.
15231|NCT04071873|Diagnostic Test|Point-of-care HIV testing|Participants will undergo an HIV 1/2 antibody point of care test (Oraquick) and receive pre- and post-test counselling.Participants with positive tests will be referred to the HIV clinic for Western Blot confirmation, and linkage to care.
15232|NCT04071873|Behavioral|HIV testing education|Participants will be provided with education on community based HIV resources.
15233|NCT04071847|Device|Deep Brain Stimulation (DBS)|Deep brain stimulation therapy involves the delivery of electrical pulses to specific structures in the brain and has been used to improve motor symptoms associated with Parkinson's disease, disabling tremor including essential tremor, and dystonia.
15234|NCT04071834|Diagnostic Test|ELISA|Detection of blood orphanin and norepinephrine in patients
15235|NCT04071821|Drug|cetirizine HCl Gummy|cetirizine HCl 10mg in a gummy formulation
15236|NCT04071821|Drug|Zyrtec tablet 10mg|cetirizine HCl 10mg tablet
15237|NCT04071808|Diagnostic Test|ELISA Test|The levels of orphanin and norepinephrine in blood of diabetic patients with painless myocardial ischemia requiring interventional therapy and diabetic patients without interventional therapy were measured.
15238|NCT04071795|Behavioral|Opt-Out Reminder|half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
15239|NCT04071795|Behavioral|Opt-In Reminder|Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
15240|NCT04071782|Device|Drug Coated Balloon|SELUTION DCB will be used during lower limb angioplasty for treatment of lesions that are TASC C and D, in patients with Critical Limb Ischemia
15242|NCT04071756|Drug|Topical Tazarotene|This medicine works by making the skin less inflamed and reducing the thickness and pain from lesions of the skin
18065|NCT04048616|Other|maltodextrin powder|isocaloric placebo powder
15246|NCT04071730|Dietary Supplement|Immulina Dietary Supplementation|Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
15247|NCT04071717|Behavioral|NIRS neurofeedback|Neurofeedback as a treatment for people which can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
15248|NCT04071717|Behavioral|Sham NIRS neurofeedback|Sham NIRS neurofeedback
15249|NCT04071691|Diagnostic Test|PET-MRI|SST2 PET-MRI scan
15250|NCT04071678|Behavioral|Careful examination during endoscopic procedures to identify lesions|When the AI model alarms, check carefully to confirm the lesion
15251|NCT04071665|Procedure|Modified lateral lumbar interbody fusion|Modified lateral lumbar interbody fusion
15252|NCT04071652|Device|Mistral implantation|Mistral implant is implanted in the Tricuspid valve
15253|NCT04071639|Drug|Haloperidol|Haloperidol take 0.5mg~2mg three time a day.
15254|NCT04071639|Drug|Risperidone|Risperidone take 1mg once at night.
15255|NCT04071639|Drug|Zoloft|Zoloft take 5mg once in the morning.
15256|NCT04071639|Drug|Coenzyme Q10|Coenzyme Q10 take 10mg three times a day.
15257|NCT04071626|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg once a day for 12 weeks
15258|NCT04071626|Drug|Placebo oral tablet|Placebo oral tablet once a day for 12 weeks
15259|NCT04071613|Drug|Tenecteplase|Route: IV bolus injection Frequency: once only, within 4.5 hours of stroke onset
15260|NCT04071613|Drug|Intravenous tissue plasminogen activator (tPA)|Route: Intravenous (IV) infusion (10% as bolus and the remainder over 60 minutes) Frequency: once only, within 4.5 hours of stroke onset
15261|NCT04071600|Drug|Neuropeptide Y|Intranasal
15262|NCT04071600|Other|Placebo|intranasal
15263|NCT04071587|Device|Brain Computer Interface training|Training with RecoveriX system.
15264|NCT04071587|Behavioral|Control|Standard physiotherapy and occupational therapy according to clinical routines.
15265|NCT04071574|Drug|Human Chorionic Gonadotropin (hCG)|Administration of hCG (10.000IU) for ovulation triggering
15266|NCT04071574|Drug|Gonadotropins|Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day)
15267|NCT04071574|Drug|GNRH-A Triptorelin|Administration of Triptorelin (0.1mg/day)
15268|NCT04071574|Drug|GnRH antagonist|Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day)
15269|NCT04071561|Other|Posterior retroperitoneal adrenalectomy (PRA)|Minimally invasive adrenalectomy procedure
15270|NCT04071561|Other|Lateral transperitoneal adrenalectomy (LTA)|During posterior retroperitoneal adrenalectomy, the failure to progress or the difficulty of creating or maintaining a pneumoperitoneum are reasons why conversion occurs.
15271|NCT04071548|Other|HIIT Exercise|"HIIT exercise bike protocol~3 minute warm up~Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~10x60 second Recovery period~5 minute cool-down"
15272|NCT04071535|Device|sudoscan、nerve conduction tests|To evaluate sudomotor nerve and macrofibropathy.
15273|NCT04071522|Other|no intervention|no intervention
15274|NCT04071509|Device|Percutaneous Lung Biopsy|Patients will undergo the usual biopsy procedure with a fine needle inserted through a larger guide needle, under CT guidance; at the end of the biopsy, the MIPP-Kit will be introduced through the same guide needle. The guide needle and the MIPP Kit will be retracted together slowly, whilst injecting BioGlue in appropriate amounts along the whole track, from the lesion to the skin.
15275|NCT04071496|Other|Blood samples|1 dry tube of 5 ml, 3 citrated tubes of 5 ml, 1 tube citrate dextrose acid of 7 ml
15276|NCT04071483|Procedure|Cervical transforaminal epidural steroid injection|Cervical transforaminal epidural steroid injection is a useful option in the diagnosis and treatment of cervical radicular pain.
15277|NCT04071470|Behavioral|Storytelling|Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
15278|NCT04071470|Drug|PrEP|Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
15279|NCT04071457|Drug|Lenalidomide|Commercially available intervention
15280|NCT04071457|Drug|Daratumumab/rHuPH20|SWOG-Held IND
15281|NCT04071444|Other|Baduanjin program|The entire program continued for 6 months (December, 2018 to July, 2019), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
15282|NCT04071431|Other|Result masking|"The quality control system randomly shows the RFQ result to the endoscopists and keep 50% of the RFQ results are not known (deliberately showing N/A) by the endoscopists before and during the endoscopy."
15283|NCT04071418|Radiation|3D-printing Template-assisted CT-guided I-125 Seeds Implantation|(1) positioning and preoperative plan design;(2) 3D printing template design and production;(3) reset and seeds implantation;(4) intraoperative optimization;Postoperative dose verification.Dosimetric parameters include: dose D90 and D100 reaching a certain percentage target volume; Target volume V100, V150 and V200 reaching a certain percentage of prescribed dose;And the dose of organs at risk: Dmean, D2cc, d0.5cc, d0.1cc. Regular follow-up was conducted after treatment.
15284|NCT04071405|Other|Non-intervention|Non-intervention observational study
15285|NCT04071392|Procedure|Hysterosalpingogram (HSG)|An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.
15286|NCT04071379|Biological|Recombinant Hepatitis B + DTP-HB-Hib|1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib
15289|NCT04071366|Drug|Immune effector cell therapy|Tisagenlecleucel or axicabtagene ciloleucel administered per prescribing label on Day 0.
15290|NCT04071353|Drug|Interferon|Interferon combined with ribavirin antiviral therapy
15291|NCT04071353|Drug|ribavirin|Interferon combined with ribavirin antiviral therapy
15292|NCT04071353|Drug|DAAs|DAAs antiviral treatment
15293|NCT04071340|Device|non-contrast MSCT|non-contrast multi-slice computed tomography
15294|NCT04071340|Device|Abdominal ultrasonography|Abdominal ultrasonography
15295|NCT04071340|Diagnostic Test|Urine analysis|Urine analysis
15296|NCT04071340|Diagnostic Test|Urine culture|Urine culture
15297|NCT04071301|Device|TENA SmartCare Urine Sensor and Gateway|"Each participating subject will be provided with Urine Sensor and absorbent products for the duration of the investigation. Nine types of absorbent products will be used to collect real-life measurement data in order to assess the mathematical algorithms involved in the TENA SmartCare Change Indicator. Each participating subject will be allocated to the type(s) that are considered most suitable.~Gateways will be placed in the resident's rooms as well as in common areas, this to enable full measurement registration."
15298|NCT04071288|Procedure|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes|total laparoscopic hysterectomy and simultaneous incontinence surgery with benign causes; Burch colposuspension and mid-urethral sling operations for stress urinary incontinence
15299|NCT04071275|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive technique that allow the administration of low currents directly to the scalp. The currents affect the cortex, and result in changes to the membrane potential of neurons in the stimulated area. This in turn affects the tendency of those neurons to generate action potentials.
15300|NCT04071275|Other|Mirror therapy|Mirror therapy is a behavioral technique that proven useful for the treatment of phantom pain, yet the analgesic effects are unfortunately moderate and not long lasting. The assumed underlying mechanism of mirror therapy treatment is the induction of neuronal plasticity in the opposite direction than the abnormal reorganization of the cortex (due to the amputation), and by that relive pain.
15301|NCT04071262|Drug|Abemaciclib|Administered orally
15302|NCT04071262|Drug|Abiraterone Acetate|Administered orally
15303|NCT04071262|Drug|Prednisolone|Administered orally
15304|NCT04071249|Drug|Approved and registered symptomatic medication|The treatment follows normal medical practice in accordance with national medical guidelines. The physicians are free to prescribe any approved and registered medication at their choice.
15305|NCT04071236|Drug|Avelumab|Given IV
15306|NCT04071236|Drug|Nedisertib|Given PO
15307|NCT04071236|Other|Quality-of-Life Assessment|Ancillary studies
15308|NCT04071236|Other|Questionnaire Administration|Ancillary studies
15309|NCT04071236|Radiation|Radium Ra 223 Dichloride|Given IV
15310|NCT04071223|Drug|Cabozantinib|Given PO
15311|NCT04071223|Drug|Cabozantinib S-malate|Given PO
15312|NCT04071223|Other|Quality-of-Life Assessment|Ancillary studies
15313|NCT04071223|Other|Questionnaire Administration|Ancillary studies
15314|NCT04071223|Radiation|Radium Ra 223 Dichloride|Given IV
15315|NCT04071210|Dietary Supplement|Probiotic tablet|Probiotic tablet twice a day for 12 weeks
15316|NCT04071210|Dietary Supplement|Placebo tablet|Placebo tablet twice a day for 12 weeks
15317|NCT04071197|Device|Gastostomy-biliary tube|gastrostomy followed by ERCP with nasobiliary stent placement in the CBD with its distal end been exit from the previously performed gastrostomy instead of the nostril
15318|NCT04071197|Device|External biliary diversion, internal biliary diversion and nasobiliary tube|All biliary diversion modalities other than gastrobiliary tube
15319|NCT04071184|Drug|Alofanib|Five dose cohorts and expanded cohort will be included
15320|NCT04071171|Drug|CVVH with Phoxilium® in the first 48h after randomization|After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
15321|NCT04071171|Drug|CVVH with Biphozyl® in the first 48h after randomization|After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
15322|NCT04071171|Drug|CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)|48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
15323|NCT04071171|Drug|CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)|48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
15327|NCT04071119|Drug|Oxytocin nasal spray|Participants administer the oxytocin (40 IU) twice a day for 5 - 7 days
15328|NCT04071119|Drug|Placebo|Participants administer the placebo (40 IU) twice a day for 5 - 7 days
15329|NCT04071106|Drug|Turmeric Extract|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
15330|NCT04071106|Drug|Turmeric Extract in Olive oil|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
18701|NCT04043494|Drug|Doxorubicin|Part of standard chemotherapy
15331|NCT04071106|Drug|Petrolatum|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
15332|NCT04071106|Device|NB-UVB|Patients will receive 2 sessions of NB-UVB phototherapy and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
15333|NCT04071106|Drug|calcipotriol/ Betamethasone|Patient will apply the treatment twice daily for 12 weeks and will be assessed clinically and by dermoscope weekly and by histopathology every 4 weeks
15334|NCT04071093|Other|Home Telemonitoring System (HTS)|The HTS consists of an App that daily collects measurements of weight, blood pressure, heart rate and symptoms (checklist of symptoms questions). The HTS processes the data and generates and sends an alert to the physicians if a risk situation occurs (measurements are outside of normal ranges). The App has also an educational functionality that allows learning about lifestyle, self-care and healthy habits for HF patients. For this purpose, the application: a) has a section that answers frequent questions, b) has a question and answer game about HF, and c) sends educational messages to the patients every day.
15335|NCT04071080|Drug|fluorescein sodium|Fluorescein sodium in 500mL Gatorade
15336|NCT04071080|Drug|Placebo|500mL Gatorade
15337|NCT04071054|Diagnostic Test|Carnation Ambulatory Monitor (CAM)|7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
15338|NCT04071041|Drug|Albumin Human|Administration of albumin 20%, 20g in 100ml (Albutein Instituto Grifols, S.A. Can Guasch 2, Parets del Vallès, 08015 Barcelona, Spain) intravenously every 12 hours for 4 days or until death, discharge or clinical stability if occurring before.
15339|NCT04071028|Procedure|warm-water footbath|"All the participants in the intervention group were arranged to stay in an air-conditioned, quiet room from 5:30 to 6:30 p.m. on their menstruation days 1 and 2. After sitting quietly for 20 minutes, the participants in the footbath group received legs soaking from the heel to the Sanyinjiao (SP6) acupoint (above the ankle) 24 in 42 ℃ water with air bubbles and vibration given to the soles for 20 minutes, whereas the participants in the control group kept on sitting quietly without legs soaking during the additional 20-minute period."
15340|NCT04071015|Device|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line.
15341|NCT04071002|Other|12 weeks physical therapy programme|The programme include contrast bath, bandage, massage, active exercises, resistive exercises.
15342|NCT04070989|Device|THA|Pinnacle Acetabular Shell (Sector, Gription, no screws), AltrX Polyethylene Liner and Corail Femoral Stem
15343|NCT04070976|Radiation|Hypofractionated therapy|All patients will be treated with an external beam of 37.5 Gray in 15 fractions (2.5 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using the anterior/posterior field and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
15344|NCT04070976|Radiation|Standard therapy|All patients will be treated with external beam radiotherapy with 50 Gray in 25 fractions (1.8-2 Gray / fraction). They will be treated once a day, 5 days a week. If photon energy 6 MV or 10 MV is used, the patient should be treated with a 4-field technique using anterior/posterior fields and 2 lateral fields. The specification of the dose is in terms of a dose to a point at or near the center of the target volume. For all field dispositions, the dose specification point is the common isocenter of all beams.
15345|NCT04070963|Other|HbA1C|To take additional blood test of HbA1C once patient consented to the study
15346|NCT04070950|Other|Questionnaires|Two self-questionnaires
15347|NCT04070937|Diagnostic Test|vestibular test 1|videonystagmography
15348|NCT04070937|Diagnostic Test|vestibular test 2|video head impulse test
15349|NCT04070937|Diagnostic Test|vestibular evoked myogenic potentials|vestibular evoked myogenic potentials to measure the function of otolith organs
15350|NCT04070937|Diagnostic Test|audiometry|tonal liminar audiometric thresholds
15351|NCT04070937|Diagnostic Test|CT and MR imaging of temporal bone|Ct and MR imaging of temporal bone
15352|NCT04070937|Genetic|p.P51S mutation|analysis of presence of p.P51S mutation in COCH
15353|NCT04070924|Other|Bandaid|Bandaid dressing
15354|NCT04070924|Other|Conventional bulky soft tissue dressing|Conventional bulky soft tissue dressing
15355|NCT04070911|Other|WATER|ORAL WATER
15356|NCT04070911|Other|ICE APPLICATION|ICE APPLICATION
15357|NCT04070898|Procedure|Remove urinary catheter after surgery|Remove bladder catheter after surgery
15358|NCT04070885|Procedure|Blood sample|A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
15359|NCT04070885|Procedure|Urine sample|The urine will be taken from three 15 ml tubes.
15360|NCT04070872|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
15361|NCT04070872|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
15362|NCT04070859|Procedure|Internal Fixation of Glenoid Fractures|Internal Fixation via (Paltes & Screws, Tension bands. etc)
15363|NCT04070846|Drug|[14C] LC350189|Carbon-14 labelded LC350189
15364|NCT04070833|Dietary Supplement|Vitamin D|Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU Other Name: cholecalciferol
15365|NCT04070833|Drug|Fish oil|Drug: Omega-3 fatty acids (fish oil) Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
15366|NCT04070833|Dietary Supplement|Vitamin D placebo|Vitamin D placebo
15367|NCT04070833|Drug|Fish oil placebo|Fish oil placebo
15368|NCT04070794|Drug|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)|Fasting conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water after an overnight fasting for at least 8 hours.
15412|NCT04070339|Other|transfontanelle ultrasound|cerebral blood flow investigation using transfontanelle ultrasound
15547|NCT04069247|Behavioral|ECBT-I|The eCBT-I will be delivered through a mobile application (eSleep) with a personal password.
15369|NCT04070794|Drug|Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)|Fed conditions: Each subject will receive a single dose of fixed dose combination Zemimet® SR Tab. 50/1000 mg with 240±2 mL of 20% glucose solution in drinking water at 30 minutes after the start of standardized HFHC breakfast.
15370|NCT04070781|Drug|Itacitinib|"Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product.~Itacitinib 200 mg daily in 28-day long cycles"
15371|NCT04070781|Drug|Tocilizumab|"Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation.~Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles"
15372|NCT04070768|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 3mg/m^2, Days 1,4,7
15373|NCT04070768|Drug|Venetoclax|Venetoclax, 100,200,400, or 600mg Daily Dose
15374|NCT04070755|Drug|FMX-101|
15375|NCT04070742|Drug|FMX101|
15376|NCT04070729|Other|Placebo gel|Localized subgingival application
15377|NCT04070729|Drug|Hyaluronic acid gel|Localized subgingival application
15378|NCT04070729|Biological|Platelet rich fibrin|Localized subgingival application
15379|NCT04070716|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
15380|NCT04070716|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
15381|NCT04070703|Behavioral|The Go for Exercise & Healthy Aging Project|Exercise and Cognition
15382|NCT04070690|Procedure|Concentration of dialysate bicarbonate|Adjust the dialysate bicarbonate concentration
15383|NCT04070677|Combination Product|Ziverel|Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
15384|NCT04070625|Other|Communication book group|Communication book
15385|NCT04070625|Other|Control group|Simple speech therapy
15386|NCT04070612|Other|Blood sample|A blood sample of 2 times 2 to 5 ml additional maximum
15387|NCT04070599|Biological|Collection of biological samples|A collection of biological samples will be carried out, with the remainders of the immunological samples taken on dry tube: the serum of the patients, taken at the initial diagnosis, will be kept frozen at -20 ° C.
15388|NCT04070586|Device|4DCBCT images|Images are acquired and assessed offline
15389|NCT04070573|Drug|acetylsalicylic acid|High risk pregnant women will be treated with daily aspirin during pregnancy.
15390|NCT04070560|Procedure|Intact cord (≥ 180 seconds) resuscitation|Resuscitation performed in near proximity to the mother with umbilical cord uncut
15391|NCT04070560|Procedure|Early (≤ 60 seconds) cord clamping|Resuscitation performed at a designated area after umbilical cord is cut
15392|NCT04070547|Device|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device 4hours a day at 25Hz, 250 μs pulse width placed on tragus.
15393|NCT04070547|Device|Sham stimulation|Sham stimulation will be performed using electrodes 4 hours a day placed on earlobe.
15394|NCT04070534|Other|PALS|patient activated learning system
15395|NCT04070521|Other|Observational EEG Monitoring|Subjects will be monitored with electroencephalogram (EEG) after arriving to the Emergency Department with suspected overdose
15399|NCT04070482|Other|Tenofovir exposure in utero and during breastfeeding|Exposed in utero and during breastfeeding to Tenofovir-containing antiretroviral drugs
15400|NCT04070469|Drug|Amoxicillin|dosage of plasma concentration of amoxicillin
15402|NCT04070443|Drug|Ponatinib|30mg/day; 6 months. Dose adaptation procedures are planned in case of toxicity.
15403|NCT04070443|Drug|Imatinib|400 mg/day; at least 30 months (M7 to M36), then depending of MR4.5 . Dose adaptation procedures are planned in case of toxicity.
15404|NCT04070430|Other|2 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
15405|NCT04070430|Other|4 weeks of partial weight bearing on crutches|Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
15406|NCT04070417|Behavioral|Lifestyle Medicine|Lifestyle intervention with components including physical activity, diet, relaxation/mindfulness, sleep and socialisation
15407|NCT04070391|Dietary Supplement|vitamin B6|oral administration
15408|NCT04070391|Other|control|oral administration
15409|NCT04070378|Drug|Daratumumab Injection|Daratumumab SC 1800 mg (daratumumab 1800 mg with rHuPH20 30,000 units) subcutaneous infusion
15410|NCT04070365|Device|FLEX Vessel Prep System followed by angioplasty|Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
15411|NCT04070352|Drug|Fidaxomicin|patients who are receiving fidaxomicin are enrolled into the study, blood is obtained for analysis, EMR and outcome data collected regarding their CDI
19287|NCT04038619|Drug|Loperamide|Given PO
15413|NCT04070326|Drug|Lanadelumab|Participants will receive 150 mg dose of lanadelumab every 2 or 4 weeks, depending on the participants age, over the 52-week treatment period.
15414|NCT04070313|Drug|S-1|Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
15415|NCT04070300|Behavioral|Interval exercise|Aerobic interval training during 12 weeks 3 times a week: 4 x 4 minutes intervals at an intensity of 90-95% of VO2 peak and active breaks of 3 minutes between intervals.
15416|NCT04070287|Combination Product|SMART Pack|The SMART pack is a re-branded and repackaged box for HIV self-testing kits. The intervention aims to promote distribution of HIVST kits through in institutions, vocational centers, and social media platforms. The intervention would also include a referral systems, where participants provided with the HIV self-testing kits are provided with information with youth-friendly health facilities for uptake of testing for sexually transmitted infections. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the SMART pack and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Yaba local government area in Lagos state.
15417|NCT04070287|Combination Product|Luv Box|"The Luv box is packaged in two colors: blue and pink. The LUVBox would be made available in supermarkets, on-line stores, mini-marts, pharmacies, neighborhood stores and markets, for easy accessibility in hard to reach areas. The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the Luv Box and the location where the pack can be obtained for individuals who are interested.For this pilot study, the intervention will be implemented in Yaba in Lagos state."
15418|NCT04070287|Combination Product|Bili Vibes|The HIV self-testing kits will be available for interested individuals at the community youth events. These events and information the HIV self-testing kits will be on flyers that would be promoted at community centers and schools. For this pilot study, the intervention will be implemented in Ngenevu/Bunker communities in Enugu state.
15419|NCT04070287|Combination Product|BeterDoc|"The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the BeterDoc Safety Kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Ibadan, Dugbe and Agbowo in Oyo state."
15420|NCT04070287|Combination Product|IUNGO|The intervention would be promoted using flyers at community events and schools. The flyers will provide information on the HIV self-testing kits and the location where the pack can be obtained for individuals who are interested. For this pilot study, the intervention will be implemented in Akure South, Orita-Obele, Ipinsa, Ilara Mokin and Ijare in Ondo state.
15421|NCT04070274|Procedure|different types of surgery platforms|58 patients with lateral calcaneus surgeries are divided into the control group of 29 patients and the experimental group with 29 patients. The traditional lateral method and calcaneus lateral surgery platforms are separately applied in the groups.
15422|NCT04070261|Other|iOS application usability test|user tasks, questionnaires, semi-structured interviews
15423|NCT04070248|Other|No intervention|No intervention
15424|NCT04070235|Drug|SH229 tablets|SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。
15425|NCT04070235|Drug|Daclatasvir dihydrochloride|Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
15426|NCT04070222|Other|Hysteroscopy|"Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~ART will be carried out with standard protocol and the clinical outcome will be recorded;~The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate."
15427|NCT04070209|Drug|Darolutamide (BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
15428|NCT04070209|Radiation|SBRT|SBRT will consist of 2-5 fractions of highly targeted radiation therapy delivered every other day. The radiation component will be completed in 4-10 days.
15429|NCT04070196|Diagnostic Test|Periplex|Periplex test strip will be used to examine the PD effluent for peritonitis, in addition to the routine leucocyte testing of PD effluent
15430|NCT04070183|Behavioral|POST Facilitation|Advanced steps is initiated as a component of quality end-of-life care for frail elders and those whose death in the next 12 months would not be unexpected. The AS planning conversation is focused on goals of care to make timely, proactive, and specific end-of-life decisions. Ideally, these decisions are converted into medical orders that can be followed throughout the continuum of care. The Physician Orders for Life-Sustaining Treatment (POLST) program is the nationally recognized model for this stage of planning.
15431|NCT04070183|Behavioral|Home Safety Evaluation|Nurse evaluation and education on how to improve safety at home for community dwelling older adults (examples of education and evaluation includes fall risks, fire and CO detectors, transferring safety (e.g. in and out of the tub, bed, etc.) and others.
15432|NCT04070170|Device|Low-level Laser Therapy|Low-level laser therapy was applied on premolars that were going to be extracted for treatment plan reasons
15433|NCT04070170|Procedure|Orthodontic force|Mechanical loading was applied on premolars that were going to be extracted for treatment plan reasons and in canines for tooth movement
15434|NCT04070157|Drug|Lofexidine|Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
15435|NCT04070157|Drug|Placebo|Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
15436|NCT04070144|Device|IQ-Tip(tm) system|Physician performs therapeutic or diagnostic lumbar puncture using Injeq IQ-Tip(tm) system
15437|NCT04070131|Other|Horse-Assisted Rehabilitation|One hour weelky session of hippotherapy.
15438|NCT04070118|Procedure|Measure niche thickness with ultrasound|in patients with previous cesarean section who applied to the emergency department with pain and underwent surgery; Measure niche thickness before operation
15439|NCT04070105|Device|Compliant Adaptive Energy Storage and Return Foot|The primary concept of the CAESAR foot is to capture the energy at heel strike and then store it to be released at a later time when it can provide additional propulsive forces during walking. Each transtibial amputee will wear the CAESAR foot and perform various tasks in the lab.
15440|NCT04070105|Device|Conventional Prosthetic Foot|This is a commercial prosthetic foot that has been prescribed to the individual
15441|NCT04070079|Drug|Tenofovir Alafenamide|TAF 25mg once daily orally, for 48 weeks
15442|NCT04070066|Other|Digital didactic environment|Students assigned to this group will receive access to a digital didactic environment where they will have at their disposal the exchange transfusion guide and a complete video explaining the indications, the preparation of supplies and the newborn for the procedure, the management of medical devices required and a step-by-step description of the exchange transfusion technique. Finally, the student will see an integrated clinical case. This video will be developed by the neonatology and paediatric medical education teaching team in the simulation laboratory of the university using neonatal high-fidelity simulators, a simulated mother and the necessary medical equipment and supplies.
15443|NCT04070066|Other|• Simulated scenario|The educational intervention will be developed with the students, led by the neonatology teacher, in the simulation laboratory. For the training, neonatal high-fidelity simulators, clinical history and paraclinical exams, necessary supplies for the procedure, a simulated mother, a professional nurse and a nursing assistant will be available. Training will take place in individual skill stations (identification of indications, communication, management of medical devices and procedures) and in integrated clinical scenarios.
15444|NCT04070053|Other|TheraPPP Pathway|"TheraPPP Steps:~Step 1. All mechanically ventilated patients will have a height measured and documented. Step 2. Screening for HRF. Step 3. Initiate Lung Protective Ventilation (LPV). Step 4. Paralysis. Step 5. Prone Positioning."
15445|NCT04070040|Drug|Camrelizumab|Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
15446|NCT04070027|Procedure|Total Hip Arthroplasty|Total hip arthroplasty following standard procedures.
15447|NCT04070027|Other|Progressive Resistance Training|"Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power."
15448|NCT04070001|Drug|400 Mg Ibuprofen|1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
15449|NCT04070001|Device|laser application|A single irradiation of laser after elastomeric separator placement
15450|NCT04070001|Other|placebo tablets|Placebo lactose tablets 1-hour before elastomeric separator placement
15451|NCT04069988|Behavioral|Baduanjin program|This exercise program aimed to increase patient participation and control their metabolic parameters and body mass index through Baduanjin program. The entire program continued for 6 months (March to October 2016), and the intervention was performed for 60 min 3 times for 12-weeks; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warmup, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
15452|NCT04069975|Other|Sedation|The group of patients who did endoscopies with or without sedation. (This is a choice of themselves)
15453|NCT04069962|Behavioral|CGA coordination by geriatric team including intensive patient coaching and follow-up|In the intervention group, the CGA including geriatric recommendations for interventions will be coordinated by the geriatric team and will be complemented with patient coaching. This intervention aims to support patient empowerment by improving self-efficacy and supporting self-management of existing age-related problems before systemic therapy or occurring during systemic therapy, and includes an individual counselling session at start of systemic therapy to discuss the recommendations with the patient and to determine their priorities.
15454|NCT04069949|Drug|sorafenib; toripalimab|Stage I: cohort A: sorafenib 400 mg qd+ toripalimab 240 mg d1; q3w cohort B: sorafenib 400 mg bid, toripalimab 240 mg d1; q3w Stage II: According to the expansion dose based on stage I, subjects are enlarged to 39.
15455|NCT04069936|Biological|MILs™ - NSCLC|To evaluate the safety of MILs™ - NSCLC alone in subjects with advanced unresectable or metastatic NSCLC
15456|NCT04069936|Biological|pembrolizumab|To evaluate the efficacy of MILs™ - NSCLC in combination with pembrolizumab in subjects with advanced unresectable or metastatic NSCLC
15457|NCT04069923|Other|Magnesium-based Bone Void Filler|Given intraoperatively
15458|NCT04069910|Other|Quality-of-Life Assessment|Ancillary studies
15459|NCT04069910|Other|Questionnaire Administration|Ancillary studies
15460|NCT04069910|Radiation|Stereotactic Radiosurgery|Undergo SRS/SRT
15461|NCT04069910|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
15462|NCT04069897|Drug|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
15463|NCT04069897|Drug|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. Two injections, one in each side of the face, and targeting the sphenopalatine ganglion.
15464|NCT04069884|Radiation|regional nodal irradiation|external-beam radiotherapy (XRT)
15465|NCT04069884|Radiation|WBI|Whole Breast Irradiation
15466|NCT04069884|Radiation|chestwall XRT|chestwall irradiation
15467|NCT04069871|Device|trans-cutaneous electrical nerve stimulation.|• Patients assigned to the EMS group received daily EMS sessions of both lower extremities starting from the second day for 5days.
15468|NCT04069871|Device|Sham TENS|Patients in the control group will receive sham TENS.
15469|NCT04069858|Drug|Switching to Generic Entecavir (Baracle®)|switching to Baracle® 1 mg (generic drug) in chronic hepatitis B patients taking Baraclude® 1 mg (brand drug)
15470|NCT04069845|Drug|liposomal doxorubicin|intravenous liposomal doxorubicin
15499|NCT04069624|Other|Services as Usual|Medications to treat opioid use disorder (MOUD) pre-treatment.
15546|NCT04069260|Drug|ELX-02|ELX-02 is a small molecule, new chemical entity being developed for the treatment of genetic diseases caused by nonsense mutations. ELX-02 is a eukaryotic ribosomal selective glycoside (ERSG).
15471|NCT04069832|Behavioral|Single-Session Consultation|A single, goal-directed consultation session based on Solution-Focused Brief Therapy (SFBT). SFBT is an evidence-based therapy approach that is primarily focused on the client's present problems and their immediate future. When using SFBT in a single-session the aim of the intervention becomes empowering the client to take the smallest possible steps towards their desired future.
15472|NCT04069819|Drug|Cilostazol 100 MG Oral Tablet|Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.
15473|NCT04069819|Drug|Escitalopram|Escitalopram 20 mg tablet once daily for 12 week
15474|NCT04069819|Drug|Placebo|placebo
15475|NCT04069806|Dietary Supplement|preoperative oral carbohydrate, preOp|Patients in the experimental arm will receive oral carbohydrate preparation at 2 hours prior to planned caesarian section.
15476|NCT04069793|Device|Commercially available device|A commercially available and registered with the FDA prosthesis equipped with a powered single-degree of freedom wrist and powered hand.
15477|NCT04069793|Device|Non FDA registered device|An experimental, non FDA registered prosthesis equipped with a multi function wrist and a powered hand.
15478|NCT04069780|Procedure|Intravitreal injection (4mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Intravitreal injection (4mg/0.1ml) of triamicinolone acetonide will be done using a 30-31 gauge needle at a distance of 3.5 mm from the limbus in aphakic or pseudophakic patients, and 4 mm in phakic patients. The needle will be then removed with application of cotton tipped applicator over the entry site.~-IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups."
15479|NCT04069780|Procedure|Superachoroidal injection (4 mg/0.1ml)|"Injection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (4mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
15480|NCT04069780|Procedure|Suprachoroidal injection (2mg/0.1ml)|"njection will be performed in the operating room under complete sterile conditions Under topical anaesthesia. Suprachoroidal injection (2mg/0.1ml) of triamcinolone acetonide will be done using a custom-made 30-31 gauge needle with a sleeve to prevent further penetration of the needle into the vitreous cavity. Injection will be done at approximately 4 mm from the limbus.~IOP monitoring will be done at 15, 30 and 60 minutes following injection in all groups.~UBM assessment will be done 24 hours following injection to confirm targeting of the suprachoroidal space."
15481|NCT04069767|Procedure|ICoreDIST|"The intervention consists of exercises that demand enhancement of dynamic trunk stability and functional movements, combined with the following:~Optimised alignment and adaptation to the base of support and often using an unstable reference point for the trunk (therapeutic ball) or the distal body parts.~Enhanced somatosensory integration of hands, feet and face, including reduced influence of vision to enhance somatosensory integration.~Proximal stability prior to selective task-oriented movement of limbs, head, eyes.~Inclusion of dual tasks (motor/motor and motor/cognitive) in exercises and activities such as walking indoors, out-doors and climbing stairs.~Specific hands-on interactions or other adaptations to optimise alignment and neuromuscular recruitment.~Exercises combining core activation and moderate increase in heart rate: in lying, sitting, standing and walking."
15482|NCT04069767|Procedure|Standard Care|According to national guidelines for stroke care, every patient in Norway will receive in-patient rehabilitation, home-based and out-patient based physiotherapy.
15483|NCT04069754|Behavioral|Adapted Passport to Freedom|5 weekly, 90 minute group sessions that cover topics such as mindfulness, health, healthy relationships, family matters, and reflections.
15484|NCT04069741|Other|Decision Aid|A website that contains information about de Quervain's tenosynovitis and the options for treatment
15485|NCT04069741|Behavioral|Toolkit for de Quervain's|A website that offers 4 sessions of mind-body skills to help manage pain from de Quervain's tenosynovitis
15486|NCT04069728|Other|Explanation with 3D printed fistula model|Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.
15487|NCT04069728|Other|Standard explanation|Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
15488|NCT04069715|Dietary Supplement|Farlong NotoGinseng™ (Farlong Ginseng Plus®)|A product made of highly concentrated pharmaceutical grade notoginseng root extract, and containing high potency bioactive components, notoginsenoside, ginsenoside Rb1, Rg1, Rd, Re and Rb2.
15489|NCT04069715|Other|Placebo|Turmeric 0.4%, Rice Flour 76.6%, Magnesium stearate 23%, capsule shell (gelatin) 61 mg
15490|NCT04069702|Behavioral|VR Blue|VR Blue provides patients with an immersive computer-generated environment that can reduce pain, tension and distress.
15491|NCT04069689|Drug|EPX-100 (Clemizole Hydrochloride)|EPX-100 (Clemizole Hydrochloride)
15492|NCT04069689|Drug|Placebos|Placebo to match EPX-100
15493|NCT04069676|Other|EEG|EEG, ECG and EDR record during a behavioral task
15494|NCT04069663|Other|No interventional study|Retrospective data analysis
15495|NCT04069650|Procedure|Free flap|Free flap reconstruction of the oral cavity
15496|NCT04069637|Combination Product|Growth-sparing instrumentation and titanium levels|Patients with growth-sparing instrumentation as treatment for early onset scoliosis, will have their titanium (serum and urine) levels tested, to evaluated if they have elevated titanium levels compared to a control group.
15497|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth
15498|NCT04069624|Behavioral|MOUD Pre-Treatment Telehealth and Peer Navigator|Opioid use disorder (OUD) assessment, medical evaluation, and medications to treat opioid use disorder (MOUD) education with a MOUD provider during incarceration via telehealth. Additionally, participants will be connected with a Peer Navigator who will meet with them via telehealth prior to release and provide ongoing support by telephone post-release.
15500|NCT04069611|Other|Probiotic|Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
15501|NCT04069611|Other|Placebo|Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.
15502|NCT04069611|Procedure|Scaling and root planing|Mechanical debridement with US and curettes of hard and soft plaque deposits
15503|NCT04069598|Diagnostic Test|Statin intolerance test|Statin intolerance test
15504|NCT04069572|Device|Vibrotactile Stimulation|Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
15505|NCT04069572|Device|Sham Stimulation|Low-frequency sham of VCR stimulation
15506|NCT04069559|Other|To develop nursing students' attitudes towards refugees program which based on contact hypothesis.|In the first three weeks, education were given to the intervention group about refugees. Students watched a film on the theme of migration. After than the students contacted refugees in three different centers ( an immigrant health center, a school and a civil Society Organization) each of them for a total of nine weeks and two days a week.
15507|NCT04069546|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric device with cuffs placed on the unilateral arm and inflated to 180 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times.
15508|NCT04069533|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene
15509|NCT04069520|Other|Augmented biofeedback|augmented biofeedback received during training sessions
15510|NCT04069520|Other|Sham comparator|sham feedback received during training sessions
15511|NCT04069494|Other|questionnaires|Two questionnaires in patients and another two questionnaires in carer.
15512|NCT04069481|Other|Dance|One-hour class, twice a week. Classes include dance warm up exercises, various dance movements and choreography that include coordinated whole body movements through space synchronized to music.
15513|NCT04069481|Other|Mindfulness meditation and Exercise|One hour class, twice a week. Classes include upper and lower extremity stretching and resistance exercises and mindfulness meditation, that includes body scan technique and breathing exercises.
15514|NCT04069468|Device|TheraSphere|Participants will receive treatment with TheraSphere in accordance with Instructions for Use
15515|NCT04069455|Other|Electronic Patients Reported Outcomes|ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
15516|NCT04069442|Other|This is a non-interventional study|This is a non-interventional study
15517|NCT04069429|Radiation|Computerized Tomography scan|imaging scan from a person's eyes to their thighs
15518|NCT04069429|Radiation|Single Photon Emission Computed Tomography scans|imaging scan taken during, and after, the administration of the radioactive agent
15519|NCT04069429|Drug|Technetium Tc 99M|subjects are administered radioactive heparin as part of study participation.
15520|NCT04069429|Radiation|Planar Images|2 dimensional imaging - whole body planar scans
15521|NCT04069429|Procedure|Esophagogastroduodenoscopy|esophagogastroduodenoscopy with tissue biopsies
15522|NCT04069416|Procedure|living donor liver transplantation|liver graft from a living donor
15523|NCT04069403|Other|Automated Reports on prescription patterns for their patients|de-identified aggregate reports
15524|NCT04069390|Device|CARDIOSKIN - Short record|A short record (max 2H15) is performed with Cardioskin
15525|NCT04069390|Device|Cardioskin - long record|A long record (max 8H) is performed with Cardioskin
15526|NCT04069390|Device|Neuronaute - long record|A long record (max 8H) is performed with Neuronaute
15527|NCT04069390|Device|Neuronaute -short record|A short record (max 2H15) is performed with Neuronaute
15528|NCT04069377|Device|LUCAS™ 2 Chest Compression System|LUCAS is a portable device designed to rule out the problems encountered during manual chest compression, capable of performing standard and continuous chest compressions at a depth of 4-5 cm and at least 100 times per minute.
15529|NCT04069377|Other|Manuel chest compressions by human efforts|In this way chest compressions will be handled by humans themselves.
15530|NCT04069364|Behavioral|TinnitusTipps|Self-helf tips for managing chronic tinnitus will be given via smartphones.
15531|NCT04069351|Dietary Supplement|High-calorie mass gainer supplement|A high-calorie mass gainer supplement will be provided to all participants to promote weight gain.
15532|NCT04069351|Other|Resistance Training|All participants will complete a 6-week supervised resistance training program.
15533|NCT04069338|Procedure|Lithotripter|Patients receive standard of care treatment for their urolithiasis using one of two lithotripter machines
15534|NCT04069325|Drug|simiaowan|pills, 6g twice daily (BID), oral, 12 weeks
15535|NCT04069325|Drug|placebo|pills, 6g twice daily (BID), oral, 12 weeks
15536|NCT04069325|Drug|febuxostat|tablets, 40 mg once daily (QD), oral, 12 weeks
15537|NCT04069312|Drug|Roflumilast|Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 36 months
15538|NCT04069312|Drug|Azithromycin|Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 36 months
15539|NCT04069299|Drug|68Ga-DOTATATE|The NETspot kit is 2 vials, Vial 1 contains 40 mcg dotatate, 5 mcg 1,10phenanthroline; 6mcg gentisic acid and 20 mg mannitol. Vial 2 contains 60 mg formic acid, 56.5 mg sodium hydroxide and water for injection
15540|NCT04069299|Diagnostic Test|Positron Emission Tomography (PET) Scan|PET scan is an imaging test using radioactive tracers.
15541|NCT04069286|Drug|Oral Aroeira/ Amoxicillin/ Claritromycin|Oral Aroeira (Schinus terebinthifolius Raddi, 640mg/tablet) 1 tablet, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
15542|NCT04069286|Drug|Omeprazole/ Amoxicillin/ Claritromycin|Omeprazole 1 tablet of 20mg, twice day, 12/12 hours + Amoxicillin 2 tablets of 500mg, twice day, 12/12 hours, + Claritromycin, 1 tablet of 500mg, twice day, 12/12 hours, for 14 days.
15548|NCT04069247|Behavioral|HE|The HE will be delivered in control though a mobile application (eSleep) with a personal password.
15549|NCT04069234|Drug|Ticagrelor|ticagrelor 60 mg BID for 30 days
15550|NCT04069234|Drug|Clopidogrel|clopidogrel 75mg OD for 30 Days
15551|NCT04069221|Drug|Single oral dose of 800 mg OZ439|Single oral dose of 800 mg OZ439
15552|NCT04069221|Drug|Single oral dose of 400 mg OZ439|Single oral dose of 400 mg OZ439
15553|NCT04069221|Drug|Single oral dose of cobicistat|Single oral dose of 150 mg cobicistat
15554|NCT04069221|Drug|iv infusion of [14C]-OZ439|15-minute 10-mL iv infusion of 100 μg [14C]-OZ439
15555|NCT04069208|Drug|Idarubicin and cytarabine induction|Idarubicin 14mg/m2 for 3 days cytarabine 100mg/m2 every 12 hour for 7 days
15556|NCT04069195|Dietary Supplement|DHA supplement|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through delivery of their infant
15557|NCT04069195|Dietary Supplement|Corn Oil: Soybean Oil|Patient's will be randomized to recieve either DHA or 50:50 corn oil/soybean oil supplement as a once daily supplement to be taken from enrollment through
15558|NCT04069182|Behavioral|Behavioral Activation Therapy|Behavioral Activation Therapy (BAT) has its origins in Cognitive Behavioral Therapy. In BAT, the patient monitors his emotions and daily activities, as a behavioral element. It seeks to increase the number of pleasant activities and increase interactions with the environment. The BAT considers positive reinforcement as the main intervention strategy. The treatment focuses on helping patients to systematically increase contact with their life's reward sources and solve their problems through procedures that focus on activation and on processes that inhibit it such as escape, avoidance behaviors and ruminant thoughts. It is a brief treatment consisting of 10 to 12 sessions spaced weekly (one hour per session), the first sessions are an explanation of the treatment and depression. Subsequent sessions are based on a collaborative work where the therapist and the patient work together to find activities that are according to the needs of the patient.
15559|NCT04069169|Drug|Lidocaine|Intervention group (A) will receive P-IVLT in addition to the standard multimodal analgesia. P-IVLT will consist of 1 mg/kg bolus at start of anesthesia (T0), followed by 2 mg·kg-1·hr-1 infusion for 8 hours (T1), then continued at 1 mg·kg-1·hr-1 infusion thereafter and postoperatively until T0 + 48 hours (T2).
15560|NCT04069169|Drug|Saline Solution|Control group (B) will receive a placebo (0.9% sodium chloride also known as normal saline), made to mimic the intervention protocol described above, in addition to the standard multimodal analgesia.
15561|NCT04069156|Device|LVAD Implant|Subjects will undergo Heartmate 3 LVAD implant prior to randomization
15562|NCT04069156|Drug|Aspirin 100mg|Subjects will be randomized to either Placebo or Aspirin post implant.
15563|NCT04069156|Drug|Placebo oral tablet|Subjects will be randomized to either Placebo or Aspirin post implant
15564|NCT04069143|Diagnostic Test|18F-BMS-986327|Imaging Agent
15565|NCT04069130|Drug|400 mg of BIA 5-1058|1 x 400 mg capsule Oral, Fasted
15566|NCT04069117|Drug|letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)|letrozole /antagonist protocol
15567|NCT04069104|Behavioral|ABCD Information|The intervention condition includes exposure to a message emphasizing the ABCD strategy to identify malignant melanoma.
15568|NCT04069104|Behavioral|UDS information|The intervention condition includes exposure to a message emphasizing the UDS strategy to identify malignant melanoma.
15569|NCT04069104|Behavioral|Standard (clinical) feedback|Feedback on mole identification task provided by a dermatologist.
15570|NCT04069104|Behavioral|Motivational feedback|Feedback on mole identification task provided by a dermatologist plus exposure to a motivational fear appeal message designed to increase skin self exam intentions.
15571|NCT04069091|Behavioral|'Enjoy your Bump' online self-help intervention|"The intervention employs elements of cognitive behavioral therapy: empathic, clear and sensitive communication with women and their families, problem self-formulation of solutions to problems, behavioral activation, identification and changing negative automated negative thoughts, addressing low confidence, and promoting problem- solving and relapse prevention.~The Enjoy your Bump intervention will be adapted to the Finnish culture and healthcare setting."
15572|NCT04069078|Drug|Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule|Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
15573|NCT04069078|Other|Normal saline|Patients will receive 1 ml of IV normal saline as a placebo one minute after spinal anesthesia
15574|NCT04069065|Drug|Conversion to Once-daily Tacrolimus|"Orally, once-daily in the morning~The first dose is converted to approximately 100% of the existing daily dose, taking into account the subject's blood concentration, after which the investigator check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 3~10ng/ml."
15575|NCT04069052|Drug|Nitric Oxide|Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.
15576|NCT04069052|Drug|Placebo|Room air (placebo) flowed into a mask and breathed in.
15577|NCT04069026|Drug|BAY2416964|Oral application of study drug daily in a predefined dose escalation scheme.
15578|NCT04069026|Drug|BAY2416964|Oral application of study drug daily at the dose defined in the dose escalation scheme to determine the recommended phase 2 dose (RP2D).
15579|NCT04069013|Procedure|PCNL|Patients receive standard of care treatment for their urolithiasis using one of two surgical procedures, either standard PCNL or Mini-PCNL
15580|NCT04069000|Behavioral|Mindfulness-based social-emotional learning program|Grade 3 teachers implement MindUP in their classrooms over the academic year. MindUP is a manualized program informed by cognitive-developmental neuroscience, contemplative science, positive psychology, and social-emotional learning. The curriculum consists of 15 sequential lessons taught in 10-15 minute chunks and cross-curricular extension activities. There are four lesson units: Getting Focused (introduction to brain structure and function, the core practice, and how focused awareness affects brains and feelings), Sharpening Your Senses (focus on internal experiences such as mindful smelling and tasting), It's All About Attitude (focus on cognitive experiences such as positive mindset, perspective-taking, and practicing gratitude), and Taking Action Mindfully (performing acts of kindness to others and building positive relationships). An essential component is the core practice, a focused breathing exercise and mindfulness practice that is implemented three times daily.
15581|NCT04069000|Behavioral|Regular grade 3 program|Grade 3 teachers are expected to implement activities to achieve a number of pre-specified social-emotional learning outcomes that are identified by the Ministry of Education. Educators have leeway over how they achieve these curriculum expectations and they will report on a weekly basis regarding their implementation of social-emotional learning activities.
15582|NCT04068987|Diagnostic Test|MRI parametric mapping|Magnetic resonance (MR) sequences (T1 mapping, T2 mapping, T2* mapping, ECV mapping) to determine the MR signal characteristics of the body
15583|NCT04068974|Drug|Camrelizumab (SHR-1210)|Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 [PD-1]). Monoclonal antibodies like SHR-1210 that can block this pathway.
15584|NCT04068974|Drug|Apatinib|Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
15585|NCT04068961|Other|Genetic analyzes|Analysis by CGH array, homozygotic cartography and candidate gene sequencing
15586|NCT04068948|Drug|Meperidine|This intervention assesses a child's behavioral outcome for dental procedural sedation in combination with midazolam and hydroxyzine. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
15587|NCT04068948|Drug|Hydroxyzine|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
15588|NCT04068948|Drug|Midazolam|This intervention is given to children for a sedative effect. Children participating in the study will randomly be assigned to receive either a drug regimen of midazolam+hydroxyzine, or midazolam+hydroxyzine+meperidine.
15589|NCT04068935|Procedure|fracture immobilization after reduction of displaced finger fractures|After closed reduction of a displaced finger fracture, fracture immobilization with either Buddy taping or Splint immobilization
15590|NCT04068922|Behavioral|Resilience Intervention|Resilience skills training including: pleasant activities, hope/goal-setting, pain acceptance, positive events/reappraisals, and self-efficacy.
15591|NCT04068896|Biological|NGM120|NGM120 Dose 1
15592|NCT04068896|Biological|NGM120|NGM120 Dose 2
15593|NCT04068896|Biological|NGM120|NGM120 Dose 3
15594|NCT04068896|Biological|NGM120|NGM120 Dose 4
15595|NCT04068896|Biological|NGM120|NGM120 Dose 5
15596|NCT04068896|Biological|NGM120|NGM120 Dose 6
15597|NCT04068896|Other|Placebo|Placebo
15598|NCT04068883|Other|Q collar|An externally-worn medical device that applies mild jugular compression
15599|NCT04068870|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
15600|NCT04068857|Device|rTMS|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that received FDA clearance for use in treatment resistant major depressive disorder in 2008 and has become commonly used in clinical practice. rTMS utilizes the application of a repetitively pulsed magnetic field over the scalp to induce an electric field within a discrete area of the cerebral cortex. This electric field results in altered ion flow across the neuronal cellular membrane and ultimately changes in neuronal polarization. rTMS enables investigators to manipulate brain activity in a targeted cortical region as well as downstream connectivity within an associated neuronal circuit. High frequency (HF) rTMS leads to facilitatory effects on brain excitability. Previous studies have demonstrated that administration of as little as a single train or a small number of trains are able to produce an immediate increase in cortical excitability.
15601|NCT04068844|Behavioral|Exercise training|Exercise training, either whole body or isolated single leg
15602|NCT04068831|Drug|Talazoparib|1 mg talazoparib daily
15603|NCT04068831|Drug|Avelumab|800 mg avelumab every 2 weeks
15604|NCT04068805|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
15605|NCT04068792|Other|RSV Mobile Application|Participants will not receive any intervention in observational phase of this study. Participant's respiratory symptoms will be captured by RSV mobile application installed in participant's caregiver/parent mobile phone.
15606|NCT04068792|Drug|Placebo|Participants in each Age Group (1,2,3) will receive matching placebo (volume placebo to match the calculated volume of the JNJ-53718678 dose) orally once daily on Day 1 to Day 7.
15607|NCT04068792|Drug|JNJ-53718678 5 mg/kg|JNJ-53718678 will be administered to Age Group 1 once daily for 7 days.
15608|NCT04068792|Drug|JNJ-53718678 6 mg/kg|JNJ-53718678 will be administered to Age Group 2 once daily for 7 days.
15609|NCT04068792|Drug|JNJ-53718678 9 mg/kg|JNJ-53718678 will be administered to Age Group 3 once daily for 7 days.
15610|NCT04068766|Device|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
15611|NCT04068766|Drug|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
15612|NCT04068766|Drug|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
15613|NCT04068753|Drug|Niraparib|Niraparib: 200 mg, oral, once daily, days 1-21
15614|NCT04068753|Drug|TSR-042|TSR-042: 500 mg IV, every three weeks for 4 cycles followed by 1000 mg every six weeks
15615|NCT04068740|Procedure|Surgical treatment of valvular heart disease|Valve replacement or repair
15616|NCT04068740|Diagnostic Test|Virtual treatment|Virtual valve replacement or repair surgery
15643|NCT04068467|Other|Smartphone App|The application consists of content areas focused on mental health.
15644|NCT04068467|Other|Waitlist Control|Waitlist control
16046|NCT04065061|Dietary Supplement|Erinacine A-enriched Hericium Erinaceus Mycelia|
15617|NCT04068727|Behavioral|Clinical Pharmacist Intervention|The Intervention Clinical Pharmacist(s) will provide the components of the intervention to all intervention study subjects, including: conducting initial consultations, providing patient education, conducting follow-up phone consultation, fielding safety net access line inquiries, and corresponding with the patient's clinical care team.
15618|NCT04068714|Procedure|Type of aneurysm repair|In open surgery repair group, aneurysm repair was performed by open surgery including aortobifemoral bypass, aorto-bi-iliac bypass and tubular aortic bypass. In endovascular repair (EVAR group), aneurysm correction was performed by percutaneous approach, femoral cutdowns and aorto-uni-iliac EVARs with femorofemoral bypass.
15619|NCT04068701|Other|MaNMT Biofeedback|neuromuscular training intervention that incorporates biofeedback training
15620|NCT04068688|Behavioral|Early Start Denver Model (ESDM)|"Twelve one hour sessions, skill is introduced by Help is in your hands Community ESDM videos. Session skills include specific strategies caregivers can use to increase their child's attention to people and their child's communication; strategies to identify, create and use joint activity routines to engage with and teach their child; in addition to ways to use the ABCs of learning to teach their child new behaviors. Help is in your hands Community ESDM materials also provide video examples of other caregivers using the session skill with their child. The early childhood development practitioner then coaches the caregiver in the session skill, in at least two activities. The goal of coaching was to provide enough support for the caregiver to experience success in implementing the new skill with their child. Coaching is followed by caregiver reflection and a discussion of generalization of the new skill across various daily activities, using a daily activities visual aid."
15621|NCT04068675|Behavioral|Group pre-operative counseling|Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
15622|NCT04068662|Behavioral|Pregnant Moms' Empowerment Program|The Pregnant Moms' Empowerment Program is a five session group therapy program designed for pregnant women with a recent history of exposure to intimate partner violence. One session is administered each week with a duration of 2 hours each, for a total of ten contact hours across the course of the intervention. Intervention topics includes safety planning, social support, resilience, psychoeducation about intimate partner violence, cognitive and behavioral strategies for remediating distress, infant sleep and breastfeeding, responsive parenting, and co-parenting.
15623|NCT04068662|Behavioral|Nondirective Support Group|Participants in the non-directive support group condition participate in groups of the same size and with the same total contact time as women in Intervention 1. In contrast to the structured, manualized content delivered as a part of the Pregnant Moms' Empowerment Program, however, group leaders in this condition facilitate open conversation on topics that women identify together as a group.
15624|NCT04068649|Radiation|Palliative Radiation Therapy|Undergo palliative RT
15625|NCT04068649|Other|Quality-of-Life Assessment|Ancillary studies
15626|NCT04068649|Other|Questionnaire Administration|Ancillary studies
15627|NCT04068649|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
15628|NCT04068636|Procedure|Radioactive tracer injection via flexible endoscopy and SPECT scan for visualization of lymph nodes.|Flexible endoscopy will be performed by one of two experienced head and neck surgeons. Inspection of larynx and pharynx will be performed to determine the extensions of the tumor in all directions. After local anesthesia, 2-4 peritumoral injections of Tc-99m-nanocolloïd will be given. Ten minutes after injection of Tc-99m-nanocolloïd a SPECT scan will be performed.
15629|NCT04068623|Other|Blood sample|Blood samples will be collected at 12 months after radiation therapy and at the time of first metastatic recurrence
15630|NCT04068610|Drug|Standard of Care|"Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only.~Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle)"
15631|NCT04068610|Drug|Experimental|Parts of FOLFOX are: Oxaliplatin 85 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Folinic acid (leucovorin) 400 mg/m2 IV infusion Q2W (Day 1 of every 14-day cycle), Fluorouracil (5-FU) 2400 mg/m2 administered by continuous IV infusion over 46 to 48 hours Q2W (Day 1-2 of every 14-day cycle). Note: 5-FU will be administered as infusion only. Bevacizumab 5 mg/kg IV infusion Q2W (Day 1 of every 14-day cycle) Durvalumab 1500 mg IV Q4W Oleclumab 3000mg IV Q2W x 4 then Q4W
15632|NCT04068597|Drug|CCS1477|Oral
15633|NCT04068584|Other|Smart Angel|Patient issued with a tablet with the Smart Angel application to monitor clinical signs and symptoms
15634|NCT04068571|Behavioral|I-PUSH|Innovative partnership for universal and sustainable healthcare
15635|NCT04068558|Device|VNI-NAVA/sNIPPV|Ventilation of the child in NIV-NAVA for 2 hours then ventilation of the child in sNIPPV for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
15636|NCT04068558|Device|sNIPPV/VNI-NAVA|Ventilation of the child in sNIPPV for 2 hours then ventilation of the child in NIV-NAVA for two hours. The ventilation periods consist of one hour of wash-out and one hour of data collection
15637|NCT04068545|Device|Device: Thoraguard Surgical Drainage System|Fluid drainage following thoracic surgery
15638|NCT04068532|Drug|Placebo|Administered as specified in the treatment arm.
15639|NCT04068532|Drug|BIIB104|Administered as specified in the treatment arm.
15640|NCT04068519|Drug|BGB-A317|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
15641|NCT04068506|Drug|Gabapentin 600 mg Tab|Gabapentin 600 mg Tab is a drug of choice for treating postoperative pain.
15642|NCT04068493|Behavioral|Enhanced Project Health|A dissonance-based obesity intervention consisting of eight weekly groups sessions (1.5 hours).
15645|NCT04068454|Device|Virtual reality device|Functional exercises will be done by virtual reality group
15646|NCT04068454|Other|EBM rehabilitation exercises|scapular exercises will be done
15647|NCT04068441|Other|no intervention|No intervention
15648|NCT04068415|Other|Constipation risk assessment scale|questionnaires
15649|NCT04068402|Device|Vivio System|The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
15650|NCT04068389|Procedure|Pulmonary Tissue Collection|Pulmonary Tissue Collection
15651|NCT04068376|Other|"Mind and Movement for Cognitive Health in the Older Adult"|"Each session will be for 60 minutes, 3 days a week, for 24 weeks. The make-up of each session is: 1) 5 minutes of warm-up; 2) 30 minutes of moderate-to-strong intensity aerobic exercise, 3) 5 minutes of aerobic cool-down, 4) 20 minutes of double-task exercise (mat); and 5) 5 minutes of cool-down stretching (this times does not count as activity).~Description of the patterns of the squared mat: Each person will have a goal, based on age and academic level. To progress to the next level, the older adult must reach 80% success in execution, individually and by class, with the trainer tracking progress, considering advances from the previous session. The person will always begin with the last pattern from the previous session. To facilitate progress, the instructor will first perform and repeat the pattern together with the participants. For advanced participants, there are mechanisms by which difficulty can be increased within the current pattern (such as increasing step speed)."
15652|NCT04068363|Other|non interventional|non interventional study
15653|NCT04068350|Other|Pain questionnaire|Pain questionnaire, 3 months after surgery
15654|NCT04068337|Procedure|Aortic root replacement with Freestyle biological prosthesis with and without hemiarch replacement|Aortic root replacement with Freestyle biological prosthesis. Some patients receive additional hemiarch replacement performing an open anastomosis to the aortic arch under antegrade cerebral perfusion through axillary artery. Comparison with patients, who were cannulated and perfused systemically
15655|NCT04068324|Dietary Supplement|New Care No Nil Per Os|"The product name NoNPO is from South Korean company Well life. It contains carbohydrate and is frequently used in preoperative fasting patients in order to alleviate patients' discomfort resulting from empty stomach and thirst. It is also known to decrease insulin resistant."
15656|NCT04068311|Other|Geriatric Screening tools|Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
15657|NCT04068285|Other|Aerobic Exercise|Participants will be making aerobic exercise
15658|NCT04068272|Drug|Bosentan|Eyedrop
15659|NCT04068272|Drug|Placebo|Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
15660|NCT04068259|Drug|PBI-4547|PBI-4547 tablet
15661|NCT04068259|Other|Placebo|Placebo tablet
15662|NCT04068246|Drug|Metformin|850 mg of Metformin table taken orally twice daily
15663|NCT04068233|Other|Pacemaker stimulation mode|Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
15664|NCT04068220|Other|intraoperative FVEPs monitoring|During the surgery, a pair of goggles (similar to the swimming goggles) will be placed on patient's closed eyes. The goggles equipped with red LEDs will apply no pressure or minimal pressure on patient's closed eyes. Patient's left eye then right eye will be stimulated with flashing red light emitted by the goggles. Two subdermal needle electrodes will be placed under the skin behind patient's ears, and one subdermal needle electrode will be placed under the skin above the bridge of patient's nose. The two electrodes placed behind patient's ears, will record intraoperative flash visual evoked potentials (FVEPs) resulted from red light stimulation of patient's visual pathway through the eyes and the electrode above the bridge of the nose will record, at the same time, the activity of each eye's retina.
15665|NCT04068207|Drug|Minocycline|Tab. Minocycline 100mg po per day for 24 weeks
15666|NCT04068194|Drug|Avelumab|Given IV
15667|NCT04068194|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
15668|NCT04068194|Drug|Nedisertib|Given PO
15669|NCT04068181|Drug|Talimogene laherparepvec|"On day 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL by intralesional injection into injectable cutaneous, subcutaneous, and nodal lesions with or without image ultrasound guidance. The second dose of up to 4.0 mL of 10^8 PFU/mL talimogene laherparepvec will be administered 21 days after the initial dose.~Subsequent doses of up to 4.0 mL of 10^8 PFU/mL talimogene laherparepvec will be given every 3 weeks."
15670|NCT04068181|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously at a fixed dose of 200 mg every 3 weeks.
15671|NCT04068155|Device|DaRT- Diffusing Alpha-emitters Radiation Therapy|Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
15672|NCT04068142|Other|Peer Supporter Safety Planning|The rationale for testing a peer-delivered intervention in the ED relies on the following evidence: a) a peer is an individual with lived experience who is now supporting other mental health patients in crisis; b) the experience of a mental health patient in the ED often shapes the perception of the health system, and may influence willingness to seek future care; c) peers may provide more empathetic care than providers without lived experience, which may positively impact patients; d) peer-based programs for patients with serious mental illness that do not involve safety planning are at least as good as non-peer based programs at preventing hospitalizations and promoting engagement in care, with the most promising interventions involving self-management or peer-navigator roles; and e) existing evidence from high-quality studies is scarce, but in moderate-low quality studies has indicated that peers are no less effective than mental health workers
15673|NCT04068129|Device|photoscreen|Determine amblyopia risk factors
15674|NCT04068116|Procedure|Primary per-cutaneous coronary intervention|Patients presenting with ST-elevation myocardial infarction will undergo primary per-cutaneous coronary intervention including balloon angioplasty & coronary stent deployment as needed +/- post-conditioning (for post-conditioning arm) making 4 cycles of repeated occlusion & reperfusion 30-second each by inflation/deflation of an appropriately sized PTCA (percutaneous transluminal coronary angioplasty) balloon
15677|NCT04068077|Device|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
15678|NCT04068064|Procedure|EABM training|"The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every day."
15679|NCT04068064|Procedure|sham training|In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
15680|NCT04068051|Drug|AXS-07|AXS-07 (MoSEIC meloxicam and rizatriptan) taken by mouth for the acute treatment of migraine.
15681|NCT04068025|Other|Assigned Interventions|"Information: In the information step of the bladder training program given through the IMB model, training was given about pelvic floor muscle exercises, bladder program formation, and lifestyle change. The training was conducted face-to-face by the nurse researcher for about 15-20 min, and the training booklet was given to the patients.~Motivation: The patients in the intervention group were interviewed by the nurse researcher by phone or face-to-face in the 1st, 3rd, and 6th months after the training. The patients were motivated by providing information and counseling on the necessary issues. This process was carried out using motivational interviewing principles. Patients were given positive behavioral feedback and encouraged to control urinary incontinence.~Behavioral Skills: Behavioral skills related to urinary incontinence were evaluated 6 months after the training,together with their effects on urinary incontinence symptom score and quality of life."
15682|NCT04068012|Other|Ventilator protocol|open loop ventilator management by a computer based protocol
15683|NCT04067999|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.The decision to initiate treatment with semaglutide is at the treating physician's discretion, and clearly separated from the decision to include the patient in the study.
15684|NCT04067986|Drug|Camrelizumab|Drug:Camrelizumab One course will last 28 days. Oral administration at a dose of 200 mg, q2w Drug:Apatinib One course will last 28 days. Oral administration at a dose of 250 mg/d
15685|NCT04067960|Procedure|Biospecimen Collection|Undergo collection of saliva
15686|NCT04067960|Other|Genetic Testing|Undergo pharmacogenomics testing
15687|NCT04067960|Other|Quality-of-Life Assessment|Ancillary studies
15688|NCT04067960|Other|Questionnaire Administration|Ancillary studies
15689|NCT04067947|Drug|XG005|XG005 Tablet
15690|NCT04067947|Drug|Placebos|Placebo Tablet
15691|NCT04067934|Behavioral|Jumping Exercise programme|Four weeks of three jumping-based exercise sessions per week. These sessions will involve basic jumping movements, with approximately 50-100 jumps per session; incorporating 20-30 minutes of exercise.
15692|NCT04067908|Other|2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling|The samples taken during this study are taken at the same time as those taken in routine during the diagnosis of threat of premature labor. There are added 2 tubes of 5ml during the blood collection and 2 swabs during vaginal sampling.
15693|NCT04067895|Procedure|epiphysiodesis|All patients undergo surgical treatment of leg lengths discrepancies or primordial gigantism. Human bone graft screws will be used to stop the distraction of the growth plate.
15694|NCT04067882|Other|Genetic signature|The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.
15695|NCT04067869|Procedure|Blood samples|Blood sample containing 3 ethylene-diamine-tetra-acetic acid tubes (7ml), 3 dry tubes (7ml) and 5 citrated tubes, ie 9 tubes
15696|NCT04067856|Drug|Bevacizumab Injection|Intravitreal injection
15697|NCT04067843|Procedure|Photodynamic treatment|Photosensitiser application, followed by fluorescence photography Photodynamic therapy (PHT) (1x) over 15 minutes
15698|NCT04067830|Other|Best Practice|Receive usual care
15699|NCT04067830|Procedure|Laparoscopic Surgery|Undergo laparoscopic surgery
15700|NCT04067830|Other|Quality-of-Life Assessment|Ancillary studies
15701|NCT04067830|Other|Questionnaire Administration|Ancillary studies
15702|NCT04067830|Device|Respiratory Muscle Training Device|Use power lung device to complete RMT
15703|NCT04067830|Procedure|Video-Assisted Thoracic Surgery|Undergo video-assisted thoracic surgery
15704|NCT04067817|Drug|norepinephrine|patient who was received the treatment of norepinephrine
15705|NCT04067817|Drug|Phenylephrine|patient who was received the treatment of phenylephrine
15706|NCT04067804|Behavioral|Dynamic Adaptation Process|The Dynamic Adaptation Process draws from implementation science frameworks and methods, including the Exploration, Preparation, Implementation, and Sustainment model, to organize planning and implementation activities. The Dynamic Adaptation Process is a structured methodology designed to integrate new interventions within complex systems, such as schools.
15707|NCT04067791|Dietary Supplement|Prolonged-Release Melatonin|4.47 mg melatonin in a bi-layer prolonged-release capsule
15708|NCT04067791|Dietary Supplement|Immediate-Release Melatonin|4.47 mg melatonin in a standard release bi-layer capsule
15709|NCT04067778|Diagnostic Test|Intervention Group|Standard colonoscopy with targeted biopsies only
15710|NCT04067778|Diagnostic Test|Control Group|Standard colonoscopy with random AND targeted biopsies
15711|NCT04067765|Behavioral|Alcohol vs Neutral Cue|Participants will undergo a validated in-scanner alcohol cue exposure protocol involving passive viewing of images of alcohol beverages (beer, wine, liquor) and neutral beverages (water, soft drinks, juice).
15712|NCT04067765|Behavioral|Responsibility vs No Responsibility|Participants will be presented with two hypothetical scenarios, involving either a significant responsibility the next day (i.e., an important work or academic-related obligation) or no responsibility (i.e., drinking on a typical occasion with no explicit obligations the next day)
15713|NCT04067752|Other|high dialysate sodium concentration (138 mEq/L)|high dialysate sodium concentration (138 mEq/L)
15714|NCT04067752|Other|Low dialysate sodium concentration|low dialysate sodium concentration (132 mEq/L)
15715|NCT04067739|Other|non interventional study|non interventional study
15716|NCT04067726|Drug|Denosumab|Denosumab is commercially available and will be provided at no cost to participants.
15717|NCT04067726|Drug|Placebo|Placebo will be made available as 1 mL sterile, non-pyrogenic water solution in a single-use prefilled syringe.
15718|NCT04067726|Drug|Calcium|-Participants will be instructed to take calcium (600 mg) daily for 12 months between baseline examination and 12- month mammographic breast density examination.
15719|NCT04067726|Drug|Vitamin D3|Participants will be instructed to take vitamin D3 (800 IU) supplements daily for 12 months between baseline examination and 12- month mammographic breast density examination.
15720|NCT04067726|Procedure|Core needle biopsy|Baseline and 12 months
15721|NCT04067726|Procedure|Blood draw|Baseline and 12 months
15722|NCT04067700|Procedure|Invasive coronary treatment|Coronary artery bypass surgery or percutaneous coronary intervention.
15723|NCT04067687|Other|Palliative home visit|a 3-month home visit, providing two-way communication between a trained health worker and patients with or without their parents were conducted as the intervention (report by proxy or self-report). Interventions were given in 6 sessions (1 session every 2 weeks) focusing on problems solving education, symptoms management, self-care, communication, decision making, and long-term care plan assistance.
15724|NCT04067674|Biological|Blood sampling|Blood sampling for biomarker measurement
15727|NCT04067648|Drug|Sufentanil Injection|three doses of sufentanil was intravenously given during anesthesia induction
15728|NCT04067622|Device|Exersides|A novel arm restraint which permits arm mobility but prohibits hands from reaching oral/nasal endotracheal and feeding tubes or intravenous lines.
15729|NCT04067609|Drug|Dexamethasone|subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
15730|NCT04067609|Other|placebo|100mL of normal saline (placebo)
15731|NCT04067596|Procedure|epiphysiodesis|"The procedure consists of sterilizing the growth cartilage of the various localizations (distal femur and proximal tibia).~Under general anesthesia under scopic control, the growth cartilage will be approached from both sides in order to curse the growth zone.~This procedure is monitored throughout the procedure with iterative X-rays, to ensure complete curettage of the growth cartilage. The average duration of the intervention is 1 hour and a half.~At the end of the procedure, there will be on each limb, 2 operative scars on each side of the knee, 8 scars in all.~Closing will be done with resorbable stitches A simple dressing will be applied to each scar and a Zimmer splint in extension will be installed postoperatively to limit the painful mobilizations in acute phase."
15732|NCT04067583|Other|Physician questionnaire|This is a one-time cross-sectional survey of physicians, conducted electronically; there are no in person visits
15733|NCT04067570|Radiation|SBRT|Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
15734|NCT04067557|Diagnostic Test|molecuar test of BV|diagnosis of BV
15735|NCT04067544|Device|Acupuncture|"The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion."
15736|NCT04067531|Drug|treatment of BV with first Deqularum and then direkt after with vaginal clindamycin|All patients will get the same treatment
15737|NCT04067518|Biological|Pegaspargase|Pegaspargase : powder for solution for injection, IV (administered by 1 to 2 hours of drip infusion), dose determination : if BSA ≥0.6 m2: 2500 IU/m2 every 14 days if BSA <0.6 m2: 82.5 IU/kg every 14 days
15738|NCT04067505|Drug|Rivaroxaban|Dose: 20mg Duration: 6 months Frequency: once daily Application: oral
15739|NCT04067505|Drug|Warfarin|Dose: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until 6 months Duration: 6 months Frequency: once daily Application: oral
15740|NCT04067505|Drug|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
15741|NCT04067492|Drug|RPH - 104|solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
15742|NCT04067492|Drug|Voltaren®|Enteric-coated tablets, 25 mg and 50 mg
15743|NCT04067479|Dietary Supplement|Amino Acids|Oral bolus of essential amino acids
15744|NCT04067466|Dietary Supplement|Fiber product|Fiber product with inulin, maltodextrin, gum guar and plum powder.
15745|NCT04067466|Dietary Supplement|Control product|Placebo product with maltodextrin and plum powder
15747|NCT04067440|Diagnostic Test|Microbial Swab|Swabs will be taken from peritoneum and jejunum (intraoperatively), rectum, and stool
15748|NCT04067427|Other|Mental training|App-based mental training
16041|NCT04065113|Procedure|Drainage of Subdural Hematoma|Drainage of subdural hematoma via burrhole or craniotomy
15749|NCT04067414|Biological|BZ019|"Subjects will be enrolled in three dose-groups:~Dose 1: 1×10^6/kg CAR+ cells; Dose 2: 3×10^6/kg CAR+ cells; Dose 3: 6×10^6/kg CAR+ cells."
15750|NCT04067401|Behavioral|Wingman Connect|Wingman-Connect combines group and individual skill training. Group exercises build cohesion, belonging and shared purpose, and promote value of healthy unit, giving and receiving support. Individual skills promote the ability to thrive during transitions, manage stressors and meet career goals, and decrease barriers to utilizing organizational resources (family, health). The training has a total of 22 modules comprised of specific learning objectives and activities. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
15751|NCT04067401|Behavioral|Stress Management|Stress management training reviews the basics of the hypothalamic-pituitary-adrenal axis stress-response system; common experiences of stress (physiological, cognitive, emotional); the impact of chronic stress on the brain and other domains of health; how exercise reduces harmful effects of stress; and relaxation techniques that have been shown to reduce stress and adverse effects of stress on health. Additional modules review the physiological stress response and effects of stress on health; introduces how cognition influences stress responses; common cognitive distortions/attributions are reviewed that affect stress including strategies to strengthen protective cognitive responses. Six months of text messages (1-2 per week) to reinforce and extend program concepts and skills.
15752|NCT04067388|Other|Rapid Evaporative Ionisation Mass Spectrometry (REIMS)|Use of iKnife instrument during standard operative practice
15753|NCT04067375|Other|Clinical data collection.|The following clinical data will be collected; maternal baseline characteristics, delivery related data, neonatal outcome, neonatal bleeding signs.
15754|NCT04067362|Other|food containing dietary fiber|commercially available chicory root flour and chicory root fiber
15755|NCT04067349|Other|Ergometry|"Patients underwent a preoperative ergometry to assess their physical fitness prior to their planned liver resection.~Bicycle stress testing was performed preoperatively and 1 and 6 months postoperatively."
15756|NCT04067336|Drug|KO-539|Oral administration
15757|NCT04067323|Dietary Supplement|Soya bean oil|Participants will consume soya bean oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
15758|NCT04067323|Dietary Supplement|MCT oil|Participants will consume MCT oil together with yogurt in lunch daily meals and be monitored side effects and diarrhea. Then they will be evaluated anthropometric index, body compositions and blood lipid profile after 2 months (T1) and 4 months (T2) intervention. This product is composed of 12% total energy intake of participants.
15759|NCT04067310|Other|Spray skin protector|Patients will use spray skin protector treatment from the randomization day until the last day of radiotherapy.
15760|NCT04067310|Other|moisturizer containing in its composition calendula officinalis|Patients will use conventional preventive treatment from the randomization day until the last day of radiotherapy.
15761|NCT04067297|Other|Lipid management toolbox|The intervention toolbox will include: 1) community-level report cards on lipid management (developed using an updated version of the 2016 CANHEART 'big data' registry of ~10.9 million adults created through linkage of 19+ population health databases) to distribute to family physicians, 2) printed and electronic patient education materials on cholesterol screening and management, 3) a new online clinical decision aid to facilitate shared decision-making between patients and their family physicians regarding statin utilization, 3) patient educational videos, and 4) physician educational videos and material.
15762|NCT04067284|Behavioral|Nutrition education|"Nutrition Education on~Continued breastfeeding until two years of age~Food groups~Balanced diet~Introduction to locally available nutritious and low-cost foods~Amount and frequency of complementary feeding~Safe water, and~Handwashing with soap before feeding"
15763|NCT04067284|Dietary Supplement|Nutrition education+Homemade yogurt supplementation|"Nutrition Education on~Continued breastfeeding until two years of age~Food groups~Balanced diet~Introduction to locally available nutritious and low-cost foods~Amount and frequency of complementary feeding~Safe water, and~Handwashing with soap before feeding~The homemade yogurt supplementation will start a week after beginning of 6 months of age once the child is introduced to solid foods of the mother's choice. The yogurt will be supplied to the mothers every day at time of feeding."
15764|NCT04067284|Other|Usual care|No intervention/ control group
15765|NCT04067271|Other|Analyze changes in intestinal microbiome|Descriptive Analysis
15766|NCT04067258|Diagnostic Test|EDI-OCT|"EDI-OCT (enhanced depth imaging spectral domain optical coherence tomography) wiil be performed in all study participants.~Three sets of measurements in the macular (horizontal and vertical) and peripapillary area will be averaged."
15767|NCT04067245|Device|Tetrasodium EDTA catheter lock solution|Home parenteral nutrition patients who meets inclusion criteria is to receive tetrasodium edta catheter lock solution. Patient will receive standard catheter lock solution of heparin/saline for 1 month, followed by tetrasodium EDTA catheter lock solution using withdrawal method for 1 month and followed by tetrasodium EDTA catheter lock solution using flush method for 1 month. In total, patient will stay in the study for 3 months. A phone call will be conducted before the start of the study to give instruction to patient regarding the use of catheter lock solution. Time taken to connect and disconnect TPN will be recorded by patients, twice a month on first and last mondays of the month for 3 months. A survey regarding the ease of use of catheter lock solution will be conducted at the end of each month via phone by nurse coodinator.
15768|NCT04067232|Diagnostic Test|4D-CT-scan|Both forearms of the subjects with posttraumatic forearm impairment are scanned with a 4D-CT scanning technique, during forearm rotation.
15769|NCT04067219|Procedure|DXA (dual-energy x-ray absorptiometric) measurement|DXA, evaluation of muscular function and muscle strength; neurocognitive tests; non invasive analysis of mechanical skin properties; food frequency questionnaire; laboratory assessment (25 hydroxy vitamin D, calcium/phosphate metabolism, bone remodelling markers, T cell activation).
15770|NCT04067206|Other|RECORDED MOTHER'S VOICE|The mothers of the babies were given voice recorders and asked to record their voice in a comfortable room saying whatever they wanted to their baby. Each mother recorded her voice for 3-5 minutes. The voice recorder was placed at the baby's foot five minutes before the procedure and then played to the baby during the procedure.The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups.
15771|NCT04067206|Other|White Noise|"The white noise was started five minutes before the heel lance and was played to the baby during the procedure. Dr. Harvery Karp's The Happiest Baby, which consists of only intrauterine sounds, was used. The speakers were placed at a distance of about 30 cm from the foot of the neonate. The American Academy of Pediatrics (AAP) recommends that the sound level for newborns and premature babies should be 45-50 decibels and emphasizes it should not exceed 65 decibels. The sound level was adjusted to 50 decibels using the Benetech Digital Sound Level Meter for the mother's voice and white noise groups."
15772|NCT04067206|Other|MiniMuff|MiniMuffs placed on their ears five minutes before the procedure to reduce the environmental noise. Latus MiniMuffs - Neonatal Noise Attenuators have been developed for newborns and premature babies. MiniMuffs protect the sensitive ears of the premature and provide a safe environment for healthy development. MiniMuffs reduce sound levels by at least 7 decibels (dB), and allow the sound pressure level to decrease by more than 50%. MiniMuffs comply with the Safe Noise Levels regulations in Newborn Units from the American Academy of Pediatrics.
15773|NCT04067193|Other|usability survey|usability survey composed of subpart: System Usability Scale, questions about ergonomic, questions about design, question about global satisfaction.
15774|NCT04067180|Other|allogeneic stem cell transplantation with a haplo-identical family donor graft|"The graft should preferably be bone marrow, but peripheral stem cells are also acceptable.~Pre-conditioning: thiotepa 5 mg/kg/day for two days (day -6, -5), busulfan at 3,2 mg/kg/day (i.v.) and fludarabine at 50 mg/m2 (i.v.) for three consecutive days (day -4, -3, -2). Intravenous busulfan can be replaced by orally administered busulfan at a dose of 4 mg/kg/day on 3 consecutive days (day -4, -3, -2).~GVHD prophylaxis: cyclophosphamide 50 mg/kg day +3 and +5, cyclosporin A and mycophenolate mofetil."
15775|NCT04067180|Other|allogeneic stem cell transplantation with a matched unrelated donor graft|"Patients are treated according to the standard conditioning protocols developed for URD SCT at each participating center, with a recommendation to use Flu+Bu (fludarabine + busulfan, with a total Bu dose of 8-16 mg/kg body weight orally, or 6,4-12,8 mg/kg i.v.) or Bu+Cy (busulfan + cyclophosphamide, with a dose of Cy not exceeding 50 mg/kg x 2).~The standard GVHD prophylaxis at the center should be applied."
15776|NCT04067167|Other|WB-EMS (Sham-intervention)|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS with low-threshold stimulation during a study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
15777|NCT04067167|Other|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
15778|NCT04067167|Other|Free WB-EMS|"Whole-Body Electromyostimulation (WB-EMS) using a mobile system:~WB-EMS during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~WB-EMS stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec;~patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
15779|NCT04067167|Other|Flexi band resistance training|"Flexi band resistance Training:~Training during study period of 12 weeks combined with standard nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted Protein intake/day: 1.2 - 1.5 g per kg bodyweight)~patients perform resistance exercises using flexi bands~flexi band exercises are conceptualized to activate similar muscle groups as EMS exercise~time-effort per session: ~20 min~2 training sessions per week"
15780|NCT04067154|Diagnostic Test|ALPE|Measurement of CT scan at PEEP of 5, 20 and 45 cm H2O Measurement of gas exchange by model-based method and FiO2 titration at PEEP of 5 and 20 cm H2O
15781|NCT04067141|Device|somofilcon A|Contact Lens
15782|NCT04067141|Device|nelfilcon A|Contact Lens
15783|NCT04067128|Behavioral|Health coaching|Brief telephonic intervention consisting of up to three phone calls
15784|NCT04067115|Drug|Trabectedin 1 MG [Yondelis]|Patients attempted in two steps.administered starting at 25 mg/m2/dose with a limited dose escalation.will start at dose level 1 = trabectedin 0.8 mg/m2/dose; dose level 2 = trabectedin 1.0 mg/m2/dose and the maximum dose level 3 = trabectedin 1.1 mg/m2/dose (the MTD of single agent trabectedin given as a 1-hour infusion in adults) with irinotecan. Patients will receive trabectedin on D1 and irinotecan on D2 and D4 of each cycle until the recommended dose is established. Cycles are 21 days.
15785|NCT04067115|Drug|Irinotecan|Patients will start at dose level 1 = irinotecan 25 mg/m2/dose until the recommended dose of trabectedin is established. Then a dose escalation of irinotecan to 35 mg/m2/dose will be attempted in 2 steps. Patients will receive trabectedin on D1 and irinotecan on D2 and D4 of each cycle until the recommended dose is established. Cycles are 21 days.
15786|NCT04067115|Diagnostic Test|tumor biopsy|Tumor tissue samples will be collected to confirm the presence of the EWS-FLI1 or EWS-ERG transcription factor using a gene sequencing assay designed to detect biomarkers for targeted therapy in pediatric cancers, including sarcomas, on the basis of the genomic alterations specific to the tumor before the patient is enrolled on the study. A second tumor biopsy will be taken after the first administration of Trabectedin to evaluate the effect on the tumor cells
15787|NCT04067115|Other|3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging|On Cycle 1 D1 patients will receive an 18F-FLT scans performed at the National Cancer Institute. Patients will also receive a second 18F-FLT scan with biopsy 18-24 hours after trabectedin administration on cycle 1, day 2-5. This radiopharmaceutical for intravenous infusion is intended for use as an in vivo diagnostic for imaging active cellular proliferation of malignant tumors. Patients will start at dose level 1 = 0.8 mg/kg/dose
15788|NCT04067102|Drug|Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel for injection (albumin binding)260mg/m2，I.v., d1；carboplatin AUC=5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment
15789|NCT04067102|Drug|paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|Paclitaxel 175mg/m2, I.v., d1； Carboplatin injection AUC 5, I.v., d1； 21 days in one cycle, 4 cycles in total.Continue the protocol when evaluated as CR/PR/SD at the second cycle, Terminate the protocol paclitaxel (albumin binding) combined with carboplatin when evaluated as PD at the second cycle，and use the EC protocol in advance or decide the next treatment protocol by the researcher
15790|NCT04067089|Procedure|TAVR - Transcatheter aortic valve replacement|TAVR - Transcatheter aortic valve replacement with Acurate Neo bioprosthesis (Boston Scientific) using minimalist approach
15791|NCT04067089|Procedure|Surgical aortic valve replacement|Surgical aortic valve replacement
15792|NCT04067076|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
15793|NCT04067063|Other|Self-administered evaluation questionnaire|Smartphone app with MeMind questionnaires
15794|NCT04067050|Device|comfilcon A asphere|Contact Lens
15795|NCT04067050|Device|Spectacles|Habitual spectacles
15796|NCT04067037|Drug|Camrelizumab|30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
15797|NCT04067037|Drug|Epirubicin|35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
15798|NCT04067037|Drug|Vincristine|1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
15799|NCT04067037|Drug|Dacarbazine|375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
15800|NCT04067024|Procedure|Local anesthesia made by surgeon|infiltration with local anesthetics
15801|NCT04067024|Procedure|Regional anesthesia group|Pecs block I and Supraclavicular nerf block
15802|NCT04067011|Drug|Ciprofloxacin 500Mg Tablet|Ciprofloxacin 500mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 4-9, 22-24 and 31-37.
15803|NCT04067011|Drug|Doxycycline 100Mg Tablet|Doxycycline 100mg administered by mouth every 12 hours. The antibiotic will be administered orally on Study Days 2-9, 22-24 and 32-38.
15804|NCT04067011|Biological|AV7909|0.5mL AVA and 0.25mg CPG 7909 per 0.5mL dose.The vaccine will be administered intramuscularly on Study Days 8 and 23.
15805|NCT04066998|Other|Tears sampling|Tears sampling
15806|NCT04066998|Other|Lashes sampling|Lashes sampling
15807|NCT04066985|Behavioral|Growth Mindset Online Single-Session Program|30minute self-administered program for youths
15808|NCT04066985|Behavioral|Self-Kindness Online Single-Session Program|30minute self-administered program for youths
15809|NCT04066985|Behavioral|Supportive Therapy Online Single-Session Program (Control)|30minute self-administered active comparator program for youths
15810|NCT04066972|Other|Body-weight supported treadmill training in a room cooled to 16°C|A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods [1 to 5 minutes] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
15811|NCT04066959|Behavioral|Motivational Enhancement System (MES)|MES is a brief eHealth intervention delivered via an internet-based software application. MES is grounded in the Motivational Interviewing framework and the Information-Motivation-Behavioral Skills model of health behavior change. The goal of MES is to increase motivation to complete daily diabetes care tasks. MES consists of two 20-minute sessions that integrate psychoeducation with motivation-enhancing therapeutic exercises and behavioral goal setting.
15812|NCT04066959|Behavioral|Question Prompt List (QPL)|A QPL is a list of questions related to the physical and psychosocial aspects of diabetes and treatment that youth may want to ask their physicians during a clinic visit. The theoretical foundation for the QPL resides in social-cognitive theory which posits that behavioral performance is a function of self-efficacy and behavioral expectations. Thus, the goal of a QPL is to increase self-efficacy and active participation in clinical care. QPL is completed within 14-days of a diabetes clinic visit and results in a personalized set of questions for youth to bring to their clinic visit.
15813|NCT04066959|Behavioral|Text Message Reminders (TXT)|TXT is a behavioral support strategy composed of one-way text message reminders to promote daily diabetes care task completion. TXT is supported by social cognitive theory which suggests that consistent task completion leads to perceptions of control and supports goal attainment. TXT may also foster a stronger relationship with diabetes care providers through greater communication and satisfaction. Youth will receive daily reminders to complete key diabetes care tasks.
15814|NCT04066946|Device|Microcurrent therapy|Micro current therapy is a therapy to treat humans / animals using electric current with amperages flowing in the μA range. The device offers 2 treatment methods: manual treatment, which requires manual input corresponding to the mentioned parameters, and automatic treatment which, depending on the clinical picture and the currently measured resistance between the electrodes, allows the device to automatically change the mentioned parameters. For this study the investigators use an automatic treatment with predefined settings. This automatic programme consists of a variation of 20 different frequency settings during 17 minutes. This programme is repeated one time which leads to a total treatment time of 34 minutes. The intensity setting for the treatment is between 200 and 350 µA. The treatment is applied 5x per week in the first 6 weeks. The treatment is stopped after six weeks.
15815|NCT04066946|Other|Standard of care|"Standard of Care consists of:~During the first two weeks:~Histoacryl glue to close the surgical incisions.~Suture strips to keep the wound closed.~Isobetadine Dermicum as anti-septic treatment~Dry wound dressings during the first 2 weeks.~Tubigrip~From two weeks until three months:~• Hydration with hydrating crème 2x per day (not within 4 hours before microcurrent treatment.~From three months onwards:~• Silicone gel sheet."
16042|NCT04065100|Diagnostic Test|Sebum test|Measuring sebum in newborn
15816|NCT04066933|Combination Product|A2M enriched plasma|Plasma enriched for alpha2macroglobulin (A2M-PPP) was produced by a centrifugation and filtration process developed by Cytonics Corporation. Initially, 7 milliliters of Anticoagulant Citrate Dextrose Solution A, ubiquitous surface protein (USP) was drawn into a 60 cc syringe and then an additional 38 cc of autologous blood was drawn up through an antecubital vein. Two syringes were prepared in this manner and then centrifuged at 4000 rpm (1280G) for 4 minutes. The supernatant plasma fraction was then transferred to a roller pump system that circulates the fluid through a proprietary filter having a high molecular weight cutoff designed to trap larger molecules including alpha 2 macroglobulin (720 kDa).
15817|NCT04066920|Drug|IBER salvage chemotherapy followed by ibrutinib maintenance therapy|Induction therapy with IBER (up to 6 cycles) [ Ibrutinib 560 mg/d on D1-21 + Rituximab 375 mg/m2 on D1 (on D1/8/15 in C1) + Ifosfamide 3.75 g/m2 on D2 + Etoposide 100 mg/m2 on D2-4 ], followed by ibrutinib 560 mg/d maintenance therapy for up to 6 months
15818|NCT04066907|Other|Integrated Disease Management|Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
15819|NCT04066894|Procedure|Explantation|Undergo lead removal
15820|NCT04066894|Other|Quality-of-Life Assessment|Ancillary studies
15821|NCT04066894|Other|Questionnaire Administration|Ancillary studies
15822|NCT04066894|Device|Sacral Nerve Stimulator|Undergo sacral nerve stimulator implantation
15823|NCT04066894|Device|Sacral Nerve Stimulator Battery|Undergo sacral nerve stimulator battery implantation
15824|NCT04066894|Procedure|Therapeutic Conventional Surgery|Undergo sacral nerve stimulator implantation
15825|NCT04066881|Biological|Vaccine Group A: DNA-HIV-PT123 and AIDSVAX® B/E (weeks 0,4,24,48)|"DNA-HIV-PT123 HIV vaccine includes three DNA plasmids that encode clade C ZM96 Gag, clade C ZM96 Env, and CN54 Pol-Nef.~AIDSVAX® B/E is a bivalent HIV gp120 glycoprotein encompassing both subtype B (MN) and subtype E (A244) proteins that are adsorbed onto 600mcg of aluminum hydroxide gel suspension as adjuvant."
15826|NCT04066881|Biological|Vaccine Group B: DNA-HIV-PT123 and CN54gp140+MPLA-L (weeks 0,4), then MVA and CN54gp140+MPLA-L (weeks 24,48)|"DNA-HIV-PT123 (see above)~CN54gp140+MPLA-L. Recombinant CN54gp140 is a HIV-1 envelope protein from the clade C strain 97/CN/54 isolate, which comprises a sequence of 634 amino acids. MPLA is a non-toxic version of LipoPolySaccharide (LPS), which is isolated from the LPS lipid A region of Salmonella Minnesota R595 and retains the immune-stimulatory properties of LPS, but exhibits low toxicity.~MVA-CMDR (Modified Vaccinia Ankara-Chiang Mai Double Recombinant) is a non-replicating, highly attenuated strain of Vaccina virus that has been genetically engineered to express the HIV-1 genes envgp160 CM235 Subtype E and gag and pol CM240 Subtype A (integrase-deleted and reverse transcriptase non-functional)."
15827|NCT04066881|Biological|Vaccine Group C: Saline placebo (weeks 0,4,24,48)|Sodium Chloride (NaCl) for injection, 0.9%
15828|NCT04066881|Drug|Control PrEP:TDF/FTC once daily (weeks 0-26)|Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
15829|NCT04066881|Drug|Experimental PrEP:TAF/FTC once daily (weeks 0-26)|Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
15830|NCT04066868|Other|Patient-reported outcomes assessment|Patient-reported outcomes are electronically assessed using EORTC QOL measures
15831|NCT04066868|Other|CTCAE rating|CTCAE Ratings are conducted by clinicians
15832|NCT04066868|Other|PRO data is displayed|PRO data is displayed right next to the CTCAE rating
15833|NCT04066842|Other|Observation|Evaluation of Vitamin D levels and correlation of Vitamin D levels level with periodontal and cardiovascular disease
15834|NCT04066829|Behavioral|Default setting intervention|All patients in the treatment group (patients undergoing tonsillectomy at Mott by pediatric otolaryngology attendings) will have clinicians who are exposed to the new default settings.
15835|NCT04066816|Other|Walnuts|Participants will consume 2 ounces of walnuts for 21 days
15836|NCT04066803|Drug|MTX|MTX group would be intervened by incremental MTX and folic acid，while the control group would be intervened by incremental original DMARDs they already used（including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony)
15837|NCT04066803|Drug|Folic Acid|MTX group would be intervened by folic acid，while the control group would be not intervened by folic acid
15838|NCT04066803|Drug|DMARDs|including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony
15839|NCT04066790|Drug|Pyrotinib|Pyrotinib 400 mg taken orally everyday, every 3 weeks, for 4 cycles.
15840|NCT04066790|Drug|nab-Paclitaxel|Nab-paclitaxel 100mg/m2 by intravenous (IV) infusion on day1, day8 and day15, every 3 weeks, for 4 cycles.
15841|NCT04066790|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 9, followed by 6 mg/kg for remaining cycles till completion of 1 year trastuzumab
15842|NCT04066790|Drug|EC chemotherapy|epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 by intravenous (IV) infusion every 3 weeks 4 cycles (Cycles 5-8)
15843|NCT04066790|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
15844|NCT04066777|Procedure|alcohol septal ablation|injection of 1-4 mL of 96% ethanol into a septal perforator of the left anterior coronary artery to produce a myocardial infarction
15845|NCT04066764|Drug|Rivaroxaban|15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
15846|NCT04066764|Drug|Warfarin|3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
15847|NCT04066764|Drug|Nadroparin|Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
15848|NCT04066751|Drug|Ivacaftor|Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
15849|NCT04066738|Diagnostic Test|Cardiac MRI with gadolinium contrast|Imaging of left ventricular scar and coronary sinus venous system
16043|NCT04065087|Biological|GX-I7|Investigational drug
16044|NCT04065087|Other|Placebo|Placebo drug
15850|NCT04066738|Diagnostic Test|3D reconstruction and location of coronary sinus venous system relative to myocardial scar|Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar
15851|NCT04066738|Diagnostic Test|Acute haemodynamic measurements during CRT implant|Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
15852|NCT04066725|Drug|Aspirin 81 mg|Participants will be given ASA 81 mg orally once daily for a total of 60 days
15853|NCT04066725|Drug|Aspirin 325mg|Participants will be given ASA 325 mg orally once daily for a total of 60 days
15854|NCT04066725|Drug|Placebo oral tablet|Participants will be given placebo orally once daily for a total of 60 days
15856|NCT04066699|Procedure|Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools.|Transthoracic localization of suspicious lung lesion(s) in preparation for subsequent resection.
15857|NCT04066673|Diagnostic Test|Stanford-Binet Intelligence Scale, 5th Edition|The SB5 is a descendent of the very first intelligence measure ever created. It tests general intellectual ability, and the Fifth Edition affords the ability to report Full Scale, Abbreviated, Nonverbal, and Verbal IQ scores
15858|NCT04066660|Dietary Supplement|Oligo Fucoidan|4.4 g oligo fucoidan powder, oral, BID
15859|NCT04066660|Dietary Supplement|Placebo|4.4 g placebo powder, oral, BID
15860|NCT04066647|Drug|Dexamethasone 4mg|1 mg IV dexamethasone will be pushed and miRNA levels will be checked at baseline just before injection and then at 15, 30, 45, and 60 minutes after injection.
15861|NCT04066634|Device|Vivio System|The Vivio Analysis Software is an analysis software that assists in identifying suspected systolic murmurs associated with aortic stenosis. The Vivio Analysis Software is used with the Vivio System, a non-invasive device used for the detection and amplification of sounds from the heart and arteries.
15862|NCT04066621|Drug|Ceftriaxone Sodium and Sulbactam Sodium for Injection|daily dose was 75 mg/kg by weight, 1-2 times ivgtt per day, 4 to 14 days
15863|NCT04066595|Drug|Cabozantinib|60 mg cabozantinib oral daily. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
15864|NCT04066582|Device|ApolloVue™ S100 image system, Viper1-S003|The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
15865|NCT04066569|Other|Performed 3 diagnostic tests (2 OGTT tests with 75 g of Glucose and 1 placebo test with 375 mg of Aspartam|"After inclusion, the study will include the sequential realization of 3 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water) and a placebo test (oral administration of 375 mg of aspartame in 100 mL of water). The order of the three tests (2 OGTT and 1 placebo) in acromegalic patients will be randomized.~The tests will be performed under the same conditions"
15866|NCT04066569|Other|Performed 2 diagnostic tests (2 OGTT tests with 75g of Glucose)|"After inclusion, the study will include the sequential realization of 2 dynamic GH secretion tests, separated by a period of 24 hours to 30 days. Each subject will have two OGTT tests (oral administration of 75 g of glucose in 100 mL of water).~The tests will be performed under the same conditions (fasting, semi-recumbent position, start of the test at 9 am) and will include a measurement of blood glucose, GH, insulinemia at -15, 0, 30, 60, 90, 120 min after ingestion of glucose or placebo."
15867|NCT04066556|Other|Brain CT imaging|"The investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. The investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.~Cut-off values in thrombus volume and Hounsfield unit according to non-contrast CT images~Cut-off values in areas of irreversible changes according to non-contrast CT images~Cut-off values in occlusion sites and collateral scores according to CT angiographies~Cut-off values of consolidated CT imaging index including clot, core, and collateral score~Cut-off values of comorbidity index~Medical care expenses according to comorbidity index in patients who received intravenous thrombolytic treatment and/or endovascular recanalization treatments."
15868|NCT04066543|Device|TACE|The modified Seldinger puncture was used to puncture the cutaneous-femoral artery, insert the catheter and perform hepatic artery angiography. The location, morphology and blood supply of liver tissue lesions were comprehensively understood. The use of chemotherapeutic drugs and the dosage of iodized oil as the embolic agent were determined according to the general situation. The catheter was injected into the supply vessel of the tumor, and 5-FU and adriamycin were injected according to the situation. The embolic agent was injected with iodized oil as carrier, mixed with chemotherapeutic drugs at the same time, and then assisted with gelatin sponge for embolization. Antiemetic drugs were given before treatment and hepatoprotective drugs were given after operation. Until the disease progresses.
15869|NCT04066543|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule, according to the recommended dose, po, qd, continuous oral 2 weeks stop for 1 week, 3 weeks for a cycle.
15870|NCT04066530|Drug|AD-203|AD-203 administered two times daily for two weeks
15871|NCT04066530|Drug|Mucosta tab.|Mucosta tab. administered three times daily for two weeks
15872|NCT04066517|Procedure|SBRT|Multimodal-imaging guided SBRT for VT ablation.
15873|NCT04066504|Drug|sonidegib|Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
15874|NCT04066491|Drug|M7824|Participants after the first onset of Complete Response (CR) will receive M7824 intravenously at a dose of 2400 milligram (mg) once every 3 weeks (Q3W) until confirmed disease progression, death, unacceptable toxicity, study withdrawal, or up to 2 years.
15875|NCT04066491|Drug|Placebo|Participants after the first onset of CR will receive M7824 matched Placebo intravenously once every 3 weeks (Q3W) until confirmed disease progression, death, unacceptable toxicity, study withdrawal, or up to 2 year
15876|NCT04066491|Drug|Gemcitabine|Gemcitabine will be received intravenously at a dose of 1000 milligram per meter square (mg/m^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).
15877|NCT04066491|Drug|Cisplatin|Cisplatin will be received intravenously at a dose of 25 mg/m^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).
15878|NCT04066478|Drug|Dehydroepiandrosterone|75mg Dehydroepiandrosterone daily
15879|NCT04066478|Drug|Placebo|Placebo
15880|NCT04066452|Diagnostic Test|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).|Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
15881|NCT04066452|Diagnostic Test|Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine|Analysis to rule out the presence of monoclonal protein in blood and urine.
15882|NCT04066439|Other|specimen|Immunohistochemistry analysis
15883|NCT04066426|Drug|naproxen sodium+codeine phosphate, naproxen sodium+dexamethasone, naproxen sodium, paracetamol|NSAID, steroid, opioid, paracetamol and combinations of this drugs can be used in temporomandibular disorders.
15884|NCT04066413|Other|Standard infant formula|Standard infant formula
15885|NCT04066413|Other|Infant formula supplemented with HMO|Infant formula supplemented with HMO
15886|NCT04066400|Other|Nutritional Intervention|Dietary Counselling
15887|NCT04066374|Device|Peripheral Nerve Stimulation|Medtronic Intellis Spinal Cord Stimulation Device to be implanted in thoracic cavity to treat postoperative acute pain.
15888|NCT04066361|Other|Chatbot|Interactive text chat designed to mirror the educational components of a traditional genetic counseling visit
15889|NCT04066361|Other|Video Education|Brief video designed to mirror the educational components of a traditional genetic counseling visit
15890|NCT04066361|Other|In Person Genetic Counseling|Meeting with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
15891|NCT04066348|Biological|Etanercept|To treat blast or noise induced tinnitus
15892|NCT04066322|Procedure|system treatment and surgery|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to receive Synchronous resection of primary tumor and metastasis. after surgery, the investigator decide further treatments.
15893|NCT04066322|Other|system treatment|to patients with PR/SD after system treatment, investigator assess the tumor is resectable, and participants decide to continue take system treatment.
15894|NCT04066309|Device|Neodent GM Helix Implant|4.0x10 mm Neodent GM Helix Implants will be placed 2mm subcrestally (in relation to the buccal bone plate) in the posterior region of the maxilla, under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer, using the guided surgery technique.
15895|NCT04066309|Device|GM Customizable Healing Abutment|Customizable healing abutments will be placed at the time of implant placement.
15896|NCT04066309|Device|GM Pro PEEK Abutment|Placement of temporary single prostheses (early loading), over temporary abutments.
15897|NCT04066309|Device|GM Exact Titanium Base|Insertion of the final abutment (Titanium Base and Zirconia Coping), following the digital workflow.
15898|NCT04066296|Drug|Liposomal bupivacaine|Injection of either liposomal bupivicaine or standard local anesthetic during surgical procedure.
15899|NCT04066270|Diagnostic Test|video nystagmografy|routine test battery applied to all cochlear implant candidates
15900|NCT04066257|Drug|Tegoprazan|Tegoprazan 50 mg tablet
15901|NCT04066257|Drug|Metronidazole|Metronidazole 250 mg tablet
15902|NCT04066257|Drug|Tetracycline|Tetracycline hydrochloride 250 mg capsule
15903|NCT04066257|Drug|Bismuth|Tripotassium bismuth dicitrate 300 mg tablet
15904|NCT04066244|Drug|BLZ945|Investigational drug
15905|NCT04066231|Device|VIPUN GMS|Motility is measured for 4 hours with the VIPUN Gastric Monitoring System (GMS).
15906|NCT04066231|Drug|Erythromycin Lactobionate|"Test model: Erythromycin has gastroprokinetic properties. The primary aim of this investigation is to validate the ability of the VIPUN GMS to discriminate between normal and pharmacologically-enhanced fasting gastric motility in healthy adults.~Erythromycin Lactobionate infusion: 200 mg i.v. infusion over a period of 20 minutes. Note: Erythromycin is not labeled as a gastroprokinetic agent in Belgium."
15907|NCT04066218|Other|Interviews|"Participation will serve as verbal consent.~Qualitative PRA will call participant to schedule either phone or in person interview. If via phone, the study PRA performing the interview, will remind them to find a private space to speak.~REDCap link will be sent for PROMIS SexFS Brief.~PRA will perform semistructured interview and guide Think-Aloud to complete the PROMIS SexFS Brief.~Participants will not submit responses to PROMIS SexFS Brief responses after completing the tool."
15908|NCT04066205|Behavioral|SLEEPSAMRT|SLEEPSMART will be designed to improve sleep by providing guidance and structure to assist JIA children and their parent in adhering to the intervention protocol. The intervention will be interactive and personalized; users will interface with three primary components:1) monitoring: daily records of sleep and symptoms; 2) skill building modules: sleep education, sleep skills training, relaxation techniques, positive coping skills, and reward systems for activity participation for reducing sleep deficiency; and 3) assignment review and personalized feedback via behavioral assignments for skill implementation and tailored feedback. Modules will take an estimated 30 minutes each week to complete and will include multimedia elements to enhance learning.
15909|NCT04066192|Drug|Brexpiprazole|Brexpiprazole will be used in .5mg, 1mg, 2mg, and 4mg doses as described in the study arms.
15910|NCT04066192|Drug|Placebo|A medically inert placebo medication will be used as described in the study arms.
15911|NCT04066179|Drug|Gcsf|Granulocytes-Colony Stimulating Factor 300 mcg for 7 days followed by 300 mcg every 3 days
15912|NCT04066179|Drug|Prednisolone|Prednisolone 40 mg for initial 7 days
15913|NCT04066166|Diagnostic Test|Palpation|All healthy subjects palpated
15914|NCT04066140|Other|No intervention|No Intervention. Observational Study.
15915|NCT04066127|Device|Non-ischemic heart preservation (NIHP)|The device is a miniaturized and fully automated heart-lung machine, housed in a portable device (weight 32 kg), that enables transportation between hospitals. The reservoir is filled with 2.5 liters of the perfusion solution plus approximately 500 mL compatible washed and leucocyte-filtered red blood cells from the hospital blood bank. The NIHP system software is adjusted to maintain a mean blood pressure of 20-25 mmHg in the aortic root, giving a coronary flow between 150 mL/min and 250 mL/min.
20510|NCT04028765|Drug|Misoprostol|As above
15916|NCT04066127|Device|Standard ischemic cold static storage (SCS)|The device is a cool box that enables transportation between hospitals. The heart is stored on ice slush in the box at a temperature of approximately 4-8 °C.
15917|NCT04066114|Biological|lulizumab pegol|25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)
15918|NCT04066114|Biological|antithymocyte globulin (rabbit)|1.5 mg/kg intravenously (IV) on Day 0 (day of transplantation) and the day following (Day 1)
15919|NCT04066114|Drug|methylprednisolone|500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2
15920|NCT04066114|Biological|tocilizumab|8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)
15921|NCT04066114|Drug|Prednisone|"Beginning on Day 3 post transplantation, taken orally: 60 mg daily~Days 4 through 10: 30 mg daily~Days 11 through 17: 20 mg daily~Days 18 through 24: 10 mg daily~After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol"
15922|NCT04066114|Drug|everolimus|Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.
15923|NCT04066114|Biological|belatacept|5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)
15924|NCT04066114|Drug|mycophenolate mofetil|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolate mofetil 1000 mg administered orally twice daily or~mycophenolic acid"
15925|NCT04066114|Drug|mycophenolic acid|"An option for participants who do not tolerate everolimus: to be switched to either~mycophenolic acid 720 mg taken orally twice daily or~mycophenolate mofetil"
15926|NCT04066101|Genetic|high caries risk|DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit Genotyping for a variant was carried out on a Roche Applied Science LightCycler® 480 (Roche Diagnostics GmbH, Mannheim, Germany) with real-time polymerase reaction of Taqman
15927|NCT04066101|Diagnostic Test|saliva parameters|saliva secretion rate measurement after paraffin stimulated 1.1 min/mL high 0.5 min/mL low Buffering capacity pH 6: high 4.5-5.5 medium pH: 4 low
15928|NCT04066088|Other|Placebo|Placebo will be administered same times as GXR
15929|NCT04066088|Drug|Guanfacine extended release (GXR)|The starting dose for all subjects will be 1 mg per day. If the medication is well-tolerated, the dose can be raised to 2 mg until day 28 and increased to 3mg for the remaining 4 weeks in the trial. The dose schedule will not be fixed; the treating clinician can delay a planned increase or lower the dose to manage adverse effects. At week 8, the study will be unblinded and subjects will continue treatment for 8 more weeks.
15930|NCT04066075|Behavioral|Low Vision Rehabilitation|Low Vision Rehabilitation for use of magnification devices for near reading tasks
15931|NCT04066049|Behavioral|EMT en Español|EMT en Español utilizes intervention strategies adapted from Enhanced Milieu Teaching (Kaiser & Hampton, 2016), an evidence-based naturalistic communication intervention, to promote home language and improve children's language use across the day in home routines, play, and book sharing in individual sessions with a therapist and in caregiver training sessions.
15932|NCT04066036|Other|This is an observational study only.|This is an observational study only.
15933|NCT04066023|Drug|C213 Microneedle System|The C213 System is a proprietary disposable patch and a reusable applicator. The zolmitriptan-coated titanium microneedle array (3 cm^2 array) is attached to a 5 cm^2 adhesive patch.
15934|NCT04066023|Drug|Placebo|The C213 System is a proprietary disposable patch and a reusable applicator. The placebo patch is a single use, 3 cm^2 Placebo (intracutaneous microneedle) system that contains no active ingredients.
15935|NCT04066010|Other|Mobile application (BP-n-Me)|"The mobile app consisted of a series of features including (1) calendar reminders of when to take medications and the patient's antihypertensive medication regimen (2) a Call your Pharmacist button specific to patient's pharmacy, (3) a BP log in which the patient could enter blood pressure values that were automatically compared to goal values, (4) counseling points for lifestyle and adherence factors individually tailored to each patient and (5) lifestyle and medication adherence surveys."
15936|NCT04065997|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
15937|NCT04065984|Device|Microstim 2v2 Stimulator|Neuro-muscular electrical stimulator portable device (9v battery) connected to the skin participant over the muscle body of choice using self adhesive electro-gel pads. Treatment devices and placebo devices.
15938|NCT04065971|Drug|2LHERP®|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
15939|NCT04065971|Drug|Placebo|The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
15940|NCT04065958|Behavioral|Yoga-mindfulness|Body-mind therapy
15941|NCT04065958|Behavioral|Patient education and physiotherapy|Lectures and physiotherapy
15942|NCT04065945|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
15943|NCT04065932|Drug|BMS-986165-01|Participants will receive BMS- 986165 -01 in prototype formulation
15944|NCT04065932|Drug|BMS-986165 Tablet|Participants will receive BMS-986165 in tablet form.
15945|NCT04065932|Drug|Famotidine|Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine
15946|NCT04065919|Drug|Liposomal bupivacaine|20mL EXPAREL+40mL bupivacaine 0.25% infiltrated into 5th intercostal space
15947|NCT04065919|Drug|0.25% Bupivacaine with epinephrine|0.25% Bupivacaine with epinephrine at 1cc/kg total dose infiltrated into 5th intercostal space
15948|NCT04065906|Behavioral|NIRS neurofeedback|Neurofeedback as a treatment for ADHD can be interpreted as a way to increase behavioral inhibition. A method to assess brain activity is functional near-infrared spectroscopy (NIRS), measuring hemodynamic correlates of neural activity.
15949|NCT04065906|Drug|Methylphenidate or Tomoxetine|Methylphenidate is the first line drug of ADHD Tomoxetine is the second line drug of ADHD
15950|NCT04065893|Procedure|Catheter ablation of ventricular arrhythmia|PVC or VT ablation
15951|NCT04065893|Drug|Intensified medical therapy|Dosage increase / new onset of Betablocker / medical antiarrhythmic medication according to guideline and clinical practice
15952|NCT04065880|Other|TachoSil®|topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.
15953|NCT04065880|Other|Neoveil®|bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.
15954|NCT04065867|Behavioral|ICT activities|Family interventions using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
15955|NCT04065854|Behavioral|Intervention|Assessment, tailored strength and balance exercise programme, activity analysis and risk enablement advice, and assessment for environmental hazards. Tailored adherence support and supervision.
15956|NCT04065841|Drug|Tropifexor|Tropifexor is a highly potent, specific and orally available non-bile acid agonist of the bile acid receptor FXR.
15957|NCT04065841|Drug|Licogliflozin|Licogliflozin is a selective and potent inhibitor of the sodium glucose co-transporters (SGLTs) 1 and 2
15958|NCT04065815|Other|Resistance Training|"Conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a resistance training program consisting of five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~2 training sessions per week"
15959|NCT04065815|Other|WB-EMS|"Whole-Body Electromyostimulation (WB-EMS):~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with WB-EMS training:~Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; patients perform simple exercises during the stimulation period following a video tutorial~time-effort per session: ~20 min~2 training sessions per week"
15960|NCT04065815|Other|High-intensity interval training (HIIT)|"HIIT:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with high-intensity interval training (HIIT):~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~2 training sessions per week"
15961|NCT04065815|Other|Combined HIIT and Resistance Training (Combi)|"HIIT combined with conventional Resistance Training:~Nutritional therapy (individualized, protein-rich nutritional therapy and counseling; targeted protein intake/day: 1.2 - 1.5 g per kg bodyweight) during a study period of 12 weeks combined with a combined HIIT and resistance training program:~HIIT:~supervised cycle-ergometer training at at 80-95% HRmax~time-effort per session: ~15 min~1 training session per week~Resistance Training:~five exercises: exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~1 training session per week"
15962|NCT04065802|Radiation|Stereotactic Radioablation|External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
15963|NCT04065789|Drug|Carfilzomib|Carfilzomib on Days 1, 8, 15, of cycle numbers 1-9 and Days 1 and 15 only of cycle numbers 10-18, at a dose of 20 mg/m2 on day 1 of cycle 1; at dose of 56 mg/m2 on all subsequent once weekly dosing days. The quadruple regimen treatment will be administered for 18 cycles.
15964|NCT04065789|Drug|Daratumumab|Daratumumab : 16 mg/Kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and then every 4 weeks thereafter. The quadruple regimen treatment will be administered for 18 cycles.
15965|NCT04065789|Drug|Lenalidomide|Lenalidomide (25 mg), administered on days 1-21 of 28-day cycle.In frail patients, Lenalidomide dose will be reduced according to 15 mg . The quadruple regimen treatment will be administered for 18 cycles.
15966|NCT04065789|Drug|Dexamethasone|Patients will be treated with IV or oral dexamethasone (20 mg for fit and INT-FIT, 10 mg for frail), administered on Days 1-2, 8-9, 15-16, and 22-23 of each 28-day cycle for cycles 1-2 followed by weekly 20 mg dexamethasone on subsequent cycles; In frail patients, dexamethasone will be reduced to 10 mg . The quadruple regimen treatment will be administered for 18 cycles.
15967|NCT04065776|Radiation|Hippocampal-avoidance proton therapy|Hippocampal-avoidance proton therapy
15968|NCT04065763|Other|Ultrasound assessment of dural sac dimension|Dural sac dimension is assessed using ultrasonography in the lateral decubitus position for spinal anesthesia.
15969|NCT04065737|Drug|Sintilimab|"Sintilimab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.~other name: IBI308"
15970|NCT04065724|Other|Physical training as resistance and aerobic training.|
15971|NCT04065711|Device|Soliton's Rapid Acoustic Pulse (RAP)|Treatment for the temporary improvement in the appearance of cellulite.
15972|NCT04065698|Drug|RV521|Single doses of RV521 administered as the drug in capsule formulation when fed and as the dry powder blend formulation dispersed in water when fed and whilst fasting, each on a separate dosing day.
15973|NCT04065685|Other|serious game named Go Wish|"The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences."
20511|NCT04028765|Drug|Oxytocin|As above
15974|NCT04065685|Other|usual care|Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
15975|NCT04065672|Drug|Low-dose IL-2|One million units of rhIL-2 was administered subcutaneously five days every week for 4 weeks and then once a week for 8 weeks. All patients were followed up for 3 months after treatment.
15976|NCT04065646|Other|Mobile|
15977|NCT04065633|Drug|P3-Fast|200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
15978|NCT04065633|Drug|Comm-Fast|200 mg PF-04965842 commercial tablet formulation under fasted conditions
15979|NCT04065633|Drug|Vari-Fast|200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
15980|NCT04065633|Drug|Comm-Fed|200 mg PF-04965842 commercial tablet formulation under fed conditions
15981|NCT04065620|Diagnostic Test|ambulatory blood pressure measurement|24-hour ABPM will be made using validated devices, following ABPM device should be programmed to take measurements every 30 minutes . Patients will be instructed in their use. Periods of activity and rest will be pre-determined in short windows: for Asian and European Countries daytime period will be defined between 10:00 and 8:00 pm; and night-time period between 00:00 am and 6:00 am. For Latin American Countries daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 00:00 am and 6:00 am. For Africa daytime period will be defined between 08:00 and 06:00 pm; and night-time period between 11 PM and 5 AM In addition, the duration of ABPM (hours), the percentage of valid readings, and the mean SBP/DBP values during periods of activity, rest and in 24 hours will be recorded. Records with a duration <24 hours, those without one good reading per hour and those with <70% of satisfactory readings will be excluded
15982|NCT04065607|Procedure|Reopen the abdomen to check missed pathology or abdominal washouts|Re opening of the abdomen once the patient is stabilized after 24-48 hours to check the missed injury after damaged control surgery in trauma and to control the sepsis in fecal peritonitis due to abdominal tuberculosis or typhoid perforation
15983|NCT04065594|Procedure|PRP dressing|PRP dressing gel dressings for treatment of chronic ulcer
15984|NCT04065594|Procedure|conventional ordinary dressing|conventional ordinary dressing for treatment of chronic ulcer
15985|NCT04065581|Drug|Acarbose/Metformin FDC(BAY81-9783)|Single dose: 50 mg acarbose/500 mg metformin tablet, oral
15986|NCT04065581|Drug|Glucobay|Single dose: 50 mg tablet, oral
15987|NCT04065581|Drug|Glucophage|Single dose: 500 mg tablet, oral
15988|NCT04065568|Device|DISKO-tool|The training program will be based on the initial assessments of functioning and disability and the patients' performance of the test exercises. Type and number of exercises per session, level of difficulty and number of repetitions (including proportion of repetitions to the right and left side of the body) will be set. The set training program is thereafter introduced and evaluated during the first follow-up by video communication with the patients.
15989|NCT04065555|Drug|TAK-981|Intratumoral microdose injection by the CIVO device.
15990|NCT04065555|Biological|Cetuximab|Intratumoral microdose injection by the CIVO device.
15991|NCT04065555|Biological|Avelumab|Intratumoral microdose injection by the CIVO device.
15992|NCT04065555|Combination Product|TAK-981 + Cetuximab|Intratumoral microdose injection by the CIVO device.
15993|NCT04065555|Combination Product|TAK-981 + Avelumab|Intratumoral microdose injection by the CIVO device.
15994|NCT04065529|Combination Product|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation|Gelatin tannate (GT) + oral rehydration solution (ORS) + Zinc supplementation
15995|NCT04065529|Combination Product|placebo + ORS + Zinc supplementation|placebo + ORS + Zinc supplementation
15996|NCT04065516|Procedure|ARAT technique|After an initial endoscopic evaluation, ARAT technique will be performed with marking, submucosal elevation at esophagogastric junction and then ablation with 100-120w of 270-300 degrees at esophagogastric junction, once the application of the therapy is performed mucosal lavage and immersion technique will be made to corroborate integrity and continuity of the gastrointestinal tract and rule out immediate complications.
15997|NCT04065503|Biological|Probiotic Strains|A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
15998|NCT04065490|Device|Valeda PBM treatment|The Valeda Light Delivery System
15999|NCT04065490|Device|Valeda Sham treatment|The sham mode of the Valeda Light Delivery System.
16000|NCT04065477|Behavioral|computer-based cognitive rehabilitation (CBCR)|Program designed to improve strategic cognitive domains (e.g., complex attention, working memory)
16001|NCT04065464|Device|Ava Fertility Tracker|All women aged 18 to 40 years using Ava Fertility Tracker to track their cycles.
16002|NCT04065451|Drug|Epinephrine|Epinephrine in the submucosal injection fluid
16003|NCT04065438|Device|LIPOSORBER® LA-15|"LIPOSORBER® LA-15 is a blood purification therapy; selectively removes apoprotein B-containing lipoproteins such as LDL from circulating blood and rapidly reduces the plasma cholesterol level. It was originally developed for prevention of coronary atherosclerosis progression in patients with serious hyperlipidemia such as familial hypercholesterolemia.~In the late 1980's, LDL-A was used to improve dyslipidemia in Nephrotic Syndrome, initially to prevent organ damage. LDL-A was found to improve both the dyslipidemic condition and clinical symptoms (proteinuria and hypoproteinemia)."
16004|NCT04065412|Procedure|Conventional laryngeal handshake technique|The conventional laryngeal handshake technique is performed with the non-dominant hand, identifying the hyoid bone and thyroid laminae, stabilizing the larynx between thumb and middle finger, and moving down the neck to palpate the cricothyroid membrane with the index finger.
16005|NCT04065412|Procedure|Modified laryngeal handshake technique|The modified laryngeal handshake is performed with the non-dominant hand, stabilizing the trachea between thumb and middle finger from the suprasternal notch and moving up the neck to palate the cricoid cartilage and cricothyroid membrane with the index finger.
16006|NCT04065399|Drug|SNDX-5613|SNDX-5613 capsules orally
16007|NCT04065386|Device|Active taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS), at the cymba conchea, ipsilaterally to the most injured cerebral hemisphere, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA, width: 200-300 μsec.
16008|NCT04065386|Device|sham taVNS|Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS), at the ear lobe, ipsilaterally to the most injured cerebral hemisphere, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA, width: 200-300 μsec.
16009|NCT04065373|Device|ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored tissue at common IV sites over a 24 hour period.
16010|NCT04065360|Behavioral|Cognitive behavioural family intervention (CBFI)|4-week, 6-session CBT-based family intervention programme
16011|NCT04065360|Behavioral|Usual group psychoeducation|Treatment as usual in the institution studied
16012|NCT04065347|Device|Digital Pill|Digital Pill over encapsulating tenofovir alafenamide ART
16015|NCT04065321|Procedure|PET-CT examination|All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
16016|NCT04065321|Procedure|Peripheral blood detection|All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
16017|NCT04065308|Drug|Drug Combinations|"Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response <CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~dexamethasone :40mg/day D1-4, intravenous~cyclophosphamide: 400mg/m2 D1-4, intravenous~etoposide: 40mg/m2 D1-4, intravenous~cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle"
16018|NCT04065295|Drug|BI 1356225|Oral Dose
16019|NCT04065295|Drug|Placebo|Oral dose
16020|NCT04065282|Drug|Sintilimab|3 cycles before radical surgery
16021|NCT04065282|Drug|Oxaliplatin|85mg/m2 Q3W, 3 cycles perioperation
16022|NCT04065282|Drug|Capecitabine|1000mg/m2 bid po D1~14 Q3W, 3 cycles perioperation
16025|NCT04065256|Other|Personalized music|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player.
16026|NCT04065256|Other|Personalized music plus earplug|Personalized music intervention will be conducted by research nurse independently. Firstly, the music preference will be confirmed by using predesigned music list. After confirming the music preference, participants will receive a music session for forty minutes through headphone and MP3 player. In addition, participants will be worn earplug during night time sleep for decreasing the noise until next morning.
16027|NCT04065243|Other|Overfeeding diet|Two weeks of overfeeding
16028|NCT04065243|Other|Isocaloric diet|Two weeks of isocaloric weight maintenance
16029|NCT04065230|Drug|Tenofovir Alafenamide Fumarate tablets|Eligible hepatitis B pregnant women are given TAF antiviral therapy (25mg, oral, 1/day) at 24-28 weeks of gestation until one month after delivery.
16030|NCT04065217|Procedure|Diode laser 980-nm|Before starting the laser session, cosmetics or makeup were removed and the skin was cleaned. The area was anesthetized by the application of as EMLA lotion (lidocaine 2.5% + prilocaine 2.5%) [ONLY MEDICAL; CAT No. R331/72394/P001] 20 minutes before the session. During the procedure, the laser probe was held perpendicular to the lesion and a guide beam was used to direct the application. The patient wore protective eye goggles [CE; DIR 8001100L4]. After the session, cool air was applied to the whole region. Each patient received a maximum of six sessions, delivered at two-week intervals. Patients reported itchiness and erythema during the session.
16031|NCT04065191|Other|High-intensity interval training|Heart rate based high-intensity interval training
16032|NCT04065178|Behavioral|Level of activity|"Inpatients will be asked if they are willing to wear a heart rate tracking fitness watch during their stay. They will be asked quality of life questions on a questionnaire that will take approximately 30 minutes to answer at admission and discharge. At the end of the study they will return the Fitbit Charge 2 to the study coordinator or their nurse.~Your rehabilitation plan of care will not change in any other way."
16033|NCT04065165|Drug|Telotristat Ethyl|250 mg TID orally
16034|NCT04065165|Drug|Lanreotide|120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
16035|NCT04065152|Drug|Talimogene laherparepvec|Talimogene laherparepvec
16036|NCT04065139|Drug|Pressurized intraperitoneal aerosol chemotherapy (PIPAC)|After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
16037|NCT04065139|Drug|Standard chemotherapy|Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.
16038|NCT04065126|Behavioral|Physical activity intervention|Ten sessions (two hours each) with physical activity and psycho-educational components.
16039|NCT04065126|Behavioral|Brief psycho-education|Two brief lectures with psycho-educational components, soon after baseline assessment and in connection to follow-up assessment.
16040|NCT04065113|Procedure|Middle Meningeal Artery Embolization with polyvinyl alcohol particles (PVA)|Seal off blood supply to the middle meningeal artery to prevent growth of subdural hematoma
16047|NCT04065061|Dietary Supplement|Placebo|Placebo supplement was given to the participants.
16048|NCT04065048|Other|Soy based diet|The diet will be based on the detailed descriptions according to the American Heart Association, US Food and Drug Administration (FDA), and the Soyfoods Association of North America Website, which all promote soy products as having beneficial nutrient profiles with a daily consumption of 25 grams or more of soy protein (average serving = 6.25 grams), upper limit of 50g.
16049|NCT04065035|Other|Topical Body Firming Moisturizer|Moisturizer composed of a patent-pending blend of botanical extracts, bioavailable peptides, antioxidants, and a prebiotic innovation
16050|NCT04065035|Other|Body Cleanser|Body cleanser to be used by study participants
16051|NCT04065035|Other|Sunscreen|Sunscreen to be applied after application of moisturizer
16052|NCT04065035|Other|Placebo Moisturizer|Placebo moisturizer is the vehicle control of the topical body firming moisturizer
16053|NCT04065022|Device|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
16054|NCT04065009|Drug|Ropivacaine|Experimental drug will be administered intraperitoneally
16055|NCT04065009|Drug|Saline Solution|Placebo will be administered intraperitoneally
16056|NCT04064996|Other|Routine rehabilitation program patient education|"Patient education~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS), hand-held dynamometer, range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test, circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
16057|NCT04064996|Other|Routine rehabilitation program + foot exercise training|"In addition to the patient education , foot exercise training will be performed. Patients will be applied exercise training consisted of aerobic, strengthening, sensory training and stretching exercises for 3 days/week, 8 weeks.~All the patients were assessed with Wagner Classification, Diabetic Neuropathy Symptom (DNS) score, Diabetic Neuropathy Examination (DNE) score, Visual Analogue Scale (VAS), Leeds assessment of neuropathic symptoms and signs (LANSS) ,hand-held dynamometer,range of motion measurements, Semmes-Weinstein monofilament, two point discrimination test,circumference measurements, Foot and Ankle Ability Measure(FAAM), 6-minute walk test (6MWT) before and after the treatment."
16058|NCT04064983|Drug|HB-adMSC|Hope Biosciences autologous adipose-derived mesenchymal stem cells
16059|NCT04064970|Behavioral|patient acceptable symptom state (PASS)|The Severity Index for Urinary Incontinence, which documents incontinence frequency and severity, pelvic floor distress, patient global impression of severity and improvement, physical function, depression, sleep disturbance, anxiety, global health and ability to participate in social roles and activities.
16060|NCT04064957|Drug|HB-adMSCs|
16061|NCT04064944|Device|blood purification equipment|The subjects enrolled in this study will undergo blood purification treatment, and will be randomized into either immunoadsorption group or plasma exchange group, and the following indicators will be evaluated: (1) changes in EDSS scores and visual acuity before and after treatment; (2) changes in AQP4-IgG levels; (3) the safety of immunoadsorption treatment.
16062|NCT04064931|Diagnostic Test|Detection of niacin and other vitamins in plasma|Detection of niacin and other vitamins in plasma
16063|NCT04064918|Other|Netarsudil 0.02% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
16064|NCT04064918|Other|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: netarsudil 0.02% QD and timolol maleate 0.5% BID.
16065|NCT04064905|Biological|mRNA-1893|Zika vaccine
16066|NCT04064905|Other|Placebo|0.9% sodium chloride
16067|NCT04064892|Behavioral|Exercise Intervention|The intervention will use peer mentors, motivational interviewing, and technology (Fitbit, Fitbit Coach App, & Fitbit message board) to support behavior change. All participants will receive phone or video calls from their peer mentors every other week, and interact with their peer mentor and other participants through a private Fitbit message board at least weekly. Peer mentors will use Fitbit data to identify participants who need additional support to increase their activity.
16068|NCT04064879|Other|AD-SVF|Intravenous, intra-articular, and soft tissue injection delivery of SVF. Target regions include forehead, temporal, and suboccipital regions.
16069|NCT04064866|Device|High yield pure PRP|"The investigational product is hemocyte autograft derived from the subject's own blood. Subjects with a clinical diagnosis of discogenic pain had a discogram with ¼ cc to ½ cc of contrast injected by hand (leaving up to ½ cc contrast in the needle lumen and connecting tube); any concordant pain will be noted. Subjects received the injectant delineated by coordinator-provided randomization. Subjects were awake for the entirety of study treatment procedure.~All subjects had blood drawn (50 cc) from any access site and double-centrifuged using the EmCyte Hemocyte Autograft system; the first spin separated the buffy coat, the second spin and subsequent siphoning separated a purified platelet sample."
16070|NCT04064866|Other|Placebo|Placebo injections will have saline placed in centrifuges and run for the duration required for PRP preparation. 3cc of saline will be placed in 3 cc syringes with opaque tape around the barrel to cover the fluid chamber. 1-2 cc of saline will be injected into the nucleus pulposus of each treatment level disc under fluoroscopy for lumbar; 0.5-1 cc for thoracic and 0.5-1 cc for cervical.
16071|NCT04064866|Device|ProPlaz PPC|Trademarked name of an FDA-cleared product
16072|NCT04064840|Drug|IVF: Decapeptyl and hCG|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
16073|NCT04064840|Drug|FET: Decapeptyl|On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
16074|NCT04064840|Drug|IVF: hCG and normal saline|When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
16075|NCT04064840|Drug|FET: Normal Saline|On the day of FET, normal saline will be injected subcutaneously.
16076|NCT04064827|Drug|Paricalcitol|Paricalcitol oral solution (2.5 mcg/mL) will be administered with an oral dispenser
16077|NCT04064814|Drug|Flunarizine 5mg|Flunarizine 5mg once daily,orally for 12 weeks
16078|NCT04064814|Drug|Alpha lipoic acid 300mg|Alpha lipoic acid 300mg ,once daily ,orally for 12 weeks
16079|NCT04064788|Other|Modified Constraint Induced Movement Therapy|Consecutive mCIMT group will receive 6 hours per day mCIMT sessions for consecutive 10 days.1 hour of 6 hours will be accompanied by therapist and 5 hours will be within the framework of the treatment program determined by the therapist with his family.
16080|NCT04064788|Other|Traditional physiotherapy|Traditional physiotherapy within a specific program
16081|NCT04064788|Other|Modified Constraint Induced Movement Therapy|Intermittent mCIMT group will receive mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). 1 hour of 6 hours will be accompanied by therapist and 5 hours will be within the framework of the treatment program determined by the therapist with his family.
16082|NCT04064775|Behavioral|Smart snacking intervention|The smart snacking intervention aimed to examine whether peer-led nudging on social media influenced adolescents to reduce their self-reported ideal portion sizes for a variety of HED snacks and SSBs. In intervention 2, participants were randomly allocated to the intervention or control condition, and their ideal portion sizes were assessed through a survey at baseline and intervention end.
16083|NCT04064762|Device|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with Prolonged Exposure Therapy.
16084|NCT04064749|Behavioral|Text messages|The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
16085|NCT04064723|Device|Randomization between prosthetic components|Patients are randomized between two types of stem components and two types of cup components in total hip arthroplasty. Thus randomized between 4 different groups.
16086|NCT04064710|Device|Biological Allograft Chain Tissue Implant|Used as bone void filler in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.
16087|NCT04064697|Drug|Valganciclovir|The experimental intervention consists of taking the treatment Valganciclovir 900 mg morning and evening for 3 weeks
16088|NCT04064684|Drug|Budesonide|Enrolled patients will be treated with Pulmicort Repsules®, Budesonide inhalation suspension [57], at a dose of 0.5 mg, nebulized twice daily through the mechanical ventilator.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
16089|NCT04064684|Drug|Placebo|Enrolled patients will be treated with normal saline.The medication will be administered to the patient by the respiratory therapist with the single-patient-use medication nebulizer attached to the mechanical ventilator circuit. The maximum length of treatment will be 10 days.
16090|NCT04064671|Other|Implantation of the Zephyr ZSI 475 FTM erectile implant|Until recently, all penile implants were manufactured for erectile dysfunction in biological males and thus presumed the presence of two corpora cavernosa. In 2016 however, the Swiss company, Zephyr Surgical Implants (ZSI), created a 3-piece inflatable erectile device specifically for female-to-male transsexuals: the Zephyr ZSI 475 FTM. This prosthesis has a realistic gland shape, only one cylinder, and a specific anchorage device made of titanium and silicone to anchor the system to the pubic bone of the patient. These specific features could potentially address the aforementioned issues with implanting erectile devices in the neophallus and hopefully lead to better surgical outcomes in these particular patients.
16091|NCT04064658|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
16092|NCT04064658|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
16093|NCT04064658|Procedure|Encephaloduroarteriosynangiosis|Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
16094|NCT04064645|Device|Measurement of respiratory rate with DUT and comparison with reference|"The subject will follow the paced breathing app, once a stable Respiration Rate at the natural rate (without the breathing app) is captured. The breathing pattern on the app will be set to begin near the normal Respiration Rate of the subject and continue to go down by five intervals until reaching the Respiration Rate of 5 bpm. After that, we will pick back up at the rate above the subject's normal Respiration Rate and continue upwards until reaching 50 bpm or as high as the subject can tolerate up to 50 bpm.~The respiratory rate will be monitored simultaneously with an EtCo2 (Reference) and the BORA BAND™ wristband monitoring system, Device Under Test. These data will be continuously recorded electronically. Additional study notes that describe conditions of the test as well as deviations, device issues and any adverse events will be recorded in written documentation."
16095|NCT04064632|Drug|Rilpivirine + darunavir/cobicistat|Switch to a dual ART
16096|NCT04064619|Drug|Solifenacin Succinate 5 MG|gradual weaning of drug vs. stopping
16097|NCT04064593|Diagnostic Test|Polygraphy|"The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management."
16098|NCT04064580|Other|diagnostic test|performing a capnography examination
16099|NCT04064567|Behavioral|PrEP-LINK|CHW will assist with healthcare and social service navigation and will utilize adherence counseling techniques. As per the model our intervention is based upon (the national Transitions Clinic Network [TCN]), our CHW has a history of incarceration. Participants randomized to the intervention group, the CHW will assist individuals with employment, housing (if needed), referrals to mental health or substance use treatment, keeping track of medical appointments and medication adherence.
16100|NCT04064567|Other|Enhanced Standard of Care|Participants will receive education about PrEP and referral to a community PrEP provider which exceeds the standards of care these individuals would otherwise receive.
16101|NCT04064554|Device|BCG vaccination with MicronJet600|BCG vaccination with MicronJet600
16102|NCT04064554|Device|BCG vaccination with conventional needle|BCG vaccination with conventional needle
16103|NCT04064541|Other|Virtual Visit|Virtual Visit
16104|NCT04064528|Dietary Supplement|Amino Acids|10 g bolus of essential amino acids
16105|NCT04064515|Diagnostic Test|Blood Assayed for CTCs|All study participants will have 15 mL of blood drawn for the purpose of the study.
16106|NCT04064502|Diagnostic Test|CHRONIC ANKLE INSTABILITY AND ASSOCIATED FACTORS:|Questionnaire including sociodemographic information, general medical condition, history of orthopedic surgery, pain intensity, and the number of painful areas of the foot.
16107|NCT04064489|Other|TRIPscore|TRIPcast score calculation
16108|NCT04064476|Drug|Paliperidone Palmitate|This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.
16109|NCT04064463|Behavioral|Standard care|standard treatment for substance use disorders, along with sample monitoring
16110|NCT04064463|Behavioral|Contingency management|Participants can earn reinforcement for attending group and abstinence from alcohol
16111|NCT04064437|Diagnostic Test|Clinical tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, and height, weight and waist circumference measurement in every participant.
16112|NCT04064437|Diagnostic Test|Clinical tests|The investigators perform the following clinical tests: height, weight and waist circumference measurement in every participant.
16113|NCT04064437|Diagnostic Test|Biochemical tests|The investigators perform blood and urine tests in every participant.
16114|NCT04064437|Diagnostic Test|DXA scan|The investigators perform a dual energy x-ray absorptiometry (DXA scan or osteodensitometry) in every participant.
16115|NCT04064437|Diagnostic Test|AGE Reader|The investigators perform a skin AGE (advanced glycation end products) measurement with the AGE Reader machine in every participant.
16116|NCT04064424|Other|Prevention video advertisement|Skin Cancer Prevention videos
16117|NCT04064424|Other|Prevention images for advertisement|Skin Cancer Prevention images
16118|NCT04064424|Other|No Advertisement|No skin cancer prevention videos or images were advertised.
16119|NCT04064411|Combination Product|abaloparatide solid microstructured transdermal system|abaloparatide 300 μg applied to the thigh for 5 minutes once daily for 12 months
16120|NCT04064411|Combination Product|abaloparatide-SC|abaloparatide 80 μg injected into the abdomen once daily for 12 months
16121|NCT04064398|Procedure|Aspiration of gastric residuals|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
16122|NCT04064385|Device|FES Cycling|Stimulation parameters will be 450μs, 40Hz, and up to 140mA, these values will be changed if needed based on individual response. For example, stimulation to the gluteal muscles often may to be decreased to prevent autonomic dysreflexia. To receive correct stimulation parameters, stimulation intensity will be chosen to ensure a palpable muscle contraction and sensor tolerance. Each session will include a 2-minute warm-up and 2-minute cool-down of passive cycling. The unit automatically delivers enough stimulation to maintain a speed of 30 rotations per minute (rpm). Where this is not achieved, the leg cycle will assist the stimulated movement to maintain a speed of 30 rpm.
16123|NCT04064372|Behavioral|Mindful response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of mindfulness, equanimity, and non-judgment, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
16124|NCT04064372|Behavioral|Strengths-based response to adversity brief training|Participants will attend a group training session, led by a professional instructor, about responding to adversity with an approach of strengths-based, narrative self-analysis, which will include a description of the skills, a writing and sharing activity focused on the proposed approach, and a practice session. Following the training, participants will be instructed to practice the skills that they just learned during a group version of a standard stress-induction task called the Trier Social Stress Task (the TSST-G).
16125|NCT04064359|Drug|OBT076, a CD205-directed antibody-drug conjugate|Intravenous (IV) infusion of OBT076 every 3 weeks.
16126|NCT04064346|Drug|Lixivaptan|Oral vasopressin 2 receptor antagonist
16127|NCT04064346|Drug|Placebo|Matching placebo
16128|NCT04064333|Device|Slow-Stream Expiratory Muscle Strength Training|All participants will receive an initial visit for training on the therapy protocol, use of a weekly therapy log to track breaths, and use and maintenance of the EMST device. This will constitute the first EMST session and will be included in the therapy log as Week 1, Day 1. Each participant will have a minimum of seven weekly check-in visits from the research assistant and/or a member of the research team, where the EMST150 resistance will be recorded and adjusted to maintain training at 75% of their maximum load, as measured using the EMST150 device instruction manual. During these check-in visits, participants will provide their completed weekly therapy log and receive a new log.
16129|NCT04064320|Behavioral|Lullaby recital|Listening to lullabies of hospitalized women with high-risk pregnancy
16130|NCT04064294|Drug|Intravenous Infusion|Intravenous levodopa given 1.0 to 1.5 mg/kg/hr from 0930 - 1130 on a single visit day.
16131|NCT04064281|Other|the healthy Cantonese diet|After a 1-week run-in period, the intervention group will eat the healthy Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
16166|NCT04064008|Device|PROFEMUR® Z Revision Femoral Stem|Total Hip Total Hip Arthroscopy
16132|NCT04064281|Other|the typical Cantonese diet|After a 1-week run-in period, the control group will still eat the typical Cantonese diet for 4 consecutive weeks. Free meals will be provided 3 times a day (breakfast, lunch, dinner). The actually intake of every meal for all subjects will be recorded to estimate their nutrients intake. All subjects will be advised to avoid eating other food, but they should inform researchers of what they eat if they eat food that we will not provide.
16133|NCT04064268|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
16134|NCT04064268|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
16135|NCT04064255|Other|Practical Body Image (session 1 - 7)|Practical body image therapy
16136|NCT04064255|Other|Practical Body Image (session 8 - 14)|Twice weekly mirror exposure plus ending session
16137|NCT04064242|Drug|CMK389|single i.v. dose every 4 weeks
16138|NCT04064242|Drug|Placebo|single i.v. dose every 4 weeks
16139|NCT04064229|Device|The ivWatch Model 400 with SmartTouch and fiber optic sensor|The ivWatch Model 400 with SmartTouch or fiber optic sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
16140|NCT04064216|Procedure|Laparoscopic surgery|Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
16141|NCT04064203|Other|Oral glucose tolerance test|50 grams OGTT
16142|NCT04064203|Other|Clamp experiment|insulin-induced hypoglycaemic clamp followed by an 50 grams OGTT
16143|NCT04064190|Drug|Vactosertib(TEW-7197)/ Durvalumab|Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks
16144|NCT04064177|Device|NICAS cardiac output monitor|Non-invasive continuous cardiac output monitoring device using total body bioimpedance.
16145|NCT04064164|Behavioral|Speeko for Elderspeak|Speeko for Elderspeak is a communication feedback IOS application.
16146|NCT04064151|Behavioral|My Guide|12-week long health promotion Smartphone application
16147|NCT04064138|Procedure|Peritoneal block|At the beginning of surgery, immediately after insertion of the first port 2 mg/kg lidocaine and 25mg/kg magnesium sulfate and 1/200 000 epinephrine in a total volume 50 ml (completed with saline .9%) will be given intra-peritoneal 10 min before the surgeon proceeds . At the end of the surgery another similar lidocaine-magnesium-epinephrine injection will be instillated before removal of the last port and the drain will be kept closed for 30 min.
16148|NCT04064138|Procedure|Ultrasound guided erector spinae plane block|Before general anesthesia, ESPB will be performed under ultrasound guidance. The linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T9 spinous process. The erector spinae muscles will be identified superficial to the tip of the T9 transverse process. The patient's skin will be anesthetized with 3 mL of 2% lidocaine. A 21 gauge 10cm needle will be inserted using an in plane superior to inferior. The tip of the needle will be placed into the facial plane on the deep aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process on ultrasonographical imaging. The calculated dose of lidocaine (2mg/kg) with 150 mg MgSo4 and 1/200 000 epinephrine will be injected on each side.
16149|NCT04064138|Other|General anesthesia|General anesthesia
16150|NCT04064125|Drug|FMX-101|
16151|NCT04064112|Procedure|S-BLR|Surery of slanted bilateral LR recession for CI-IXT patients
16152|NCT04064112|Procedure|C-BLR|Surery of conventional bilateral lateral rectus recession for CI-IXT patients
16153|NCT04064099|Device|Custom-fitted sports mouthguard|Pressure dual laminated technique will be used to fabricate the mouthguards. Ethylene-vinyl acetate (EVA) thermoplastic sheets of 3 mm in thickness with 125 mm diameter (Dentsply International Raintree Essix, Court East Sarasota, USA) will be used. Two 3 mm sheets pressure-laminated together should form an even thickness of 4 mm mouthguard. The design of the mouthguards takes into consideration of the following limits: (i) the labial borders of the mouthguard were extended to within 2 mm of the vestibular reflection, (ii) the palatal margins were trimmed to the cervical area of the palatal surface of the upper teeth, (iii) enclosing the maxillary teeth to the distal surface of the first molars.
16154|NCT04064086|Other|Comprehensive Pre-ESRD Patient Education (CPE)|Structured education session/s
16155|NCT04064086|Other|Provision of the freely available resources for Kidney Disease Education|freely available resources
16156|NCT04064073|Drug|DWP16001|Tablets, Oral, once daily single dose
16157|NCT04064073|Drug|Metformin IR|Metformin IR 1000mg, Tablets, Oral, BID for 7 days
16158|NCT04064073|Drug|DWP16001+Metformin IR|Tablets, Oral, once daily single dose DWP16001 Metformin IR 1000mg
16159|NCT04064060|Drug|Luspatercept|Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the human immunoglobin G 1 (IgG1) Fc domain. ActRIIB receptor and its ligands are members of the transforming growth factor-β (TGF-β) superfamily. Members of the TGF-β superfamily ligands, through their binding to activin receptors, are involved in modulating the differentiation of late-stage erythrocyte precursors (normoblasts) in the bone marrow. Luspatercept for injection is formulated as a sterile, preservative-free, lyophilized cake/powder. Luspatercept for injection is available in 25 mg and 75 mg vials and when reconstituted with water for injection, each consists of 50 mg/mL luspatercept in a 10 mM citrate buffer-based solution
16160|NCT04064047|Procedure|Trans rectal ultrasound guided prostate biopsy|The investigators checked visual analogue scale of pain at different time periods: prior to probe insertion, during probe insertion. during probe manipulation in the rectum, during performance of periprostatic nerve block, during actual biopsy collection and at termination of procedure.
16161|NCT04064047|Device|Trans rectal ultrasound|Performing a prostate biopsy using a transrectal ultrasound probe - the BK pro focus 2202 transrectal ultrasound and the 8808 bi-plane transrectal probe
16162|NCT04064047|Device|Prostate biopsy|Prostate biopsy guided by a transrectal ultrasound with an 18 gauge needle
16163|NCT04064047|Device|Periprostatic nerve block|Performing a bilateral peri-prostatic nerve block with 10 mL of 1% lidocaine (5 mL on each side)
16164|NCT04064034|Other|Lateral Flow Assay (LFA)|Test to detect the Quiescin Sulfhydryl Oxidase 1 (QSOX1) protein
16165|NCT04064021|Procedure|Acupunture|Patient will receive 12 acupuncture treatments over 6 weeks (2x per week)
16167|NCT04063995|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders, including stroke-related motor impairment.
16168|NCT04063982|Other|none, only assessment at different time points|assessment at different time points
16169|NCT04063969|Other|Assessment of radiation safety climate|"The rating tool contains 28 statements which cover 5 dimensions (Leadership, communication, commitment, resources, risk awareness) of the radiation safety climate. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety climate score is calculated by adding ratings on all items.~Minimum scale score 28 - Maximum scale score 140"
16170|NCT04063969|Other|Assessment of radiation safety behavior|The rating tool contains 2 statements which cover 2 dimensions of the radiation safety behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement. A composite radiation safety behavior score is calculated by adding ratings on both items Minimum scale score 2 - Maximum scale score 10
16171|NCT04063969|Other|Assessment of radiation safety knowledge and motivation|"The rating tool contains 2 statements which cover the radiation safety knowledge and behavior. Participants are asked to indicate on a scale of 1 (completely disagree) - 3 (neutral) - 5 (completely agree) whether they agree with each statement.~Minimum item score 1 - maximum item score 5"
16172|NCT04063969|Other|Data collection|Collection of patient-related data points Demographic information: ASA-classification, BMI Procedure related information: Procedural time, approach, contrast usage case difficulty Radiation safety parameters: Air Kerma, DAP, fluoroscopy time
16173|NCT04063956|Behavioral|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. Within each task, high accuracy (80%) is required to upgrade to the next difficulty level.
16174|NCT04063956|Behavioral|active-control program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
16175|NCT04063943|Device|Sidus Stem-Free Shoulder|Device: Sidus Stem-Free Total Shoulder Arthroplasty System
16176|NCT04063930|Drug|LOKELMA 5 GM Powder for Oral Suspension|Sodium zirconium cyclosilicate (a hyperkalemia treatment)
16177|NCT04063930|Drug|Placebos|Matching placebo
16178|NCT04063917|Device|ZENS|ZENS transcutaneous nerve stimulator (ZENS Device)
16179|NCT04063904|Drug|Mifepristone|One 200 mg pill (oral)
16180|NCT04063904|Drug|Misoprostol|Two 400 mcg pills (sublingual)
16181|NCT04063891|Device|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
16182|NCT04063891|Device|Low-magnitude high-frequency vibration (LMHFV)|Placebo group will have sham treatment by standing on the LMHFV platform for 20 minutes/day
16183|NCT04063878|Device|Conometric Abutment and Conometric Final Cap|Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
16184|NCT04063865|Drug|Tacrolimus|Tacrolimus (FK / Prograf) titrated to a goal trough of 6 - 8 ng/ml
16185|NCT04063865|Drug|Everolimus|Everolimus monotherapy - target trough levels 4 - 8 ng/ml as maintenance immunosuppression
16186|NCT04063839|Drug|Elbasvir / Grazoprevir Oral Tablet|HCV treatment according to Norwegian guidelines
16187|NCT04063826|Device|PET MRI|All participants will have a liver scan
16188|NCT04063813|Behavioral|Experimental: 40 minute up trial|
16189|NCT04063813|Behavioral|Experimental: 40 minute down trial|
16190|NCT04063813|Behavioral|Experimental: Two 20 minute up trials|
16191|NCT04063813|Behavioral|Experimental: Two 20 min down trials|
16192|NCT04063813|Behavioral|Active Comparator: Sedentary trial|
16193|NCT04063787|Device|Fist Assist|"The Fist Assist device works by applying pressure to the subject's arm in the area where their arteriovenous fistula will eventually be created. The device is mobile and battery powered.~The Fist Assist device will be assigned to each enrolled subject by randomization code. All subjects will be asked to use their assigned device twice daily, for two 2-hour sessions, once in the morning and once in the evening. Patients will apply the device to the non-dominant arm above the level of the elbow, and to keep a written log to record use, complications and any problems. They will be asked to do this for 3 months, and will come in to be evaluated via study visits at Months 3, 6, 9 and 12."
16194|NCT04063774|Diagnostic Test|Dengue calculator|Clinical diagnostic algorithms of dengue generated by discrete and continuos Bayes formulas installed in a mobile device
16195|NCT04063761|Device|esophageal cooling device (Attune Medical, Chicago, IL)|Prospective, single center pilot study
16196|NCT04063748|Behavioral|Audiological rehabilitation|Experimental: tablet-based take-home auditory-cognitive training, which consists of phoneme tasks, words in quiet and in different types of noise
16197|NCT04063748|Behavioral|Placebo Rehabilitation|Placebo: tablet-based take-home psychophysical tasks, reading (non auditory)
16198|NCT04063735|Dietary Supplement|Cordyceps Cicadae Mycelia|Cordyceps Cicadae Mycelia supplement for 3 months
16199|NCT04063735|Dietary Supplement|Placebo|Placebo was given to participants.
16200|NCT04063722|Procedure|modified Benelli procedure|use of modified Benelli procedure for surgical treatment of gynecomastia
16201|NCT04063709|Diagnostic Test|Acoustic Radiation Force Impulse (ARFI) ultrasound|ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
16202|NCT04063683|Drug|Anlotinib Hydrochloride, Paclitaxel, cisplatin|"anlotinib: 1 capsule (10mg) once a day, d1-d14 per cycle, 3 weeks for a treatment cycle.~Paclitaxel: intravenously infused at 135mg/ m2, administered d1 per cycle, 3 weeks for a treatment cycle.~Cisplatin: administered after paclitaxel, intravenously infused at 60-75 mg/m2, divided into d1-d3 medications per cycle; 3 weeks for one treatment cycle."
16233|NCT04063410|Procedure|Angiography|Undergo standard of care CTA
16203|NCT04063670|Other|Video Intervention|Peri-operative video series focusing on expanded education and coping skills before and after scoliosis surgery for adolescent idiopathic scoliosis
16204|NCT04063670|Other|Control|Routine, Standard-of-Care
16205|NCT04063657|Procedure|External fixator|Patients will be placed in an external fixator followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
16206|NCT04063657|Procedure|Splinting|Patients will be placed in a short leg splint followed by open versus closed surgical stabilization of their calcaneus fracture when their soft tissue is appropriate for surgery.
16207|NCT04063644|Device|Vis Glyc Neo|1 drop in each eye, three times a day.
16208|NCT04063644|Device|Physiological saline solution|1 drop in each eye, three times a day.
16209|NCT04063618|Procedure|Osteopathic Manipulative Therapy|The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles, joints, and tissues are moved using techniques that include stretching, gentle pressure, and resistance.
16210|NCT04063618|Procedure|Standard of Care Concussion Treatment|Standard of care for concussion management is cognitive rest, meaning no stimulation (or as little as possible). This mean no TV/phones/music/school/homework generally for 24 hours. After that a return to academic work is typically started. Once patient is symptom free for 24 hours, then the return to play protocol is initiated (this takes 7 total days to complete at a minimum).
16211|NCT04063605|Other|Clinical Pilates|This exercise model focus on the awareness of the neutral position of the spine and strengthen the deep postural muscles of the spine. Training of trunk muscles is emphasized and trunk stabilization is achieved and more difficult activities are initiated and thus, body awareness is improved. There are general principles to be followed during exercises. These; The principle of concentration is respiration, central focus, control, stability and isolation. These principles are achieved by simultaneous muscle activation of muscles responsible for trunk stabilization (multifidus, diaphragm, transversus abdominis and pelvic floor muscles). In order for an exercise to become a clinical pilates exercise, trunk stabilization must be ensured and breath control should be established in each exercise.
16212|NCT04063605|Other|Classic Physiotherapy|This exercise program will include strengthening, stretching, posture exercises, balance and gait exercises. Aim is to improve muscle strength and prevent shortness of muscles. Also, balance and gait exercise aim to improve walking capacity.
16213|NCT04063592|Procedure|Residual limb revision|Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
16214|NCT04063579|Diagnostic Test|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP), cardiac catheterization|Imaging, blood tests, LV pressure measurement
16215|NCT04063579|Diagnostic Test|Cardiac Magnetic Resonance, Echocardiogram, Blood investigation (NT-proBNP)|Imaging and Blood tests
16216|NCT04063566|Procedure|Magnetic Resonance Imaging (MRI)|Prostate cancer screening MRI
16217|NCT04063566|Procedure|Prostate-specific antigen (PSA) test|Blood test for PSA levels
16218|NCT04063553|Other|Volunteers Service|"Subjects in the intervention group will receive standard physiotherapy care and an additional volunteers session once a day for at least 3 times during their stay in the hospital. The volunteer will set up the TKR exercise video for the subjects, then supervise or guide the subjects with the exercises.~All volunteers are recruited from TTSH volunteers pool managed by Center of Health Activation (CHA). TKR volunteers are trained by the study team, including a formal classroom session and a practical and role play session. After the training, volunteers need to pass 3 assessment by the physiotherapists in order to attend to patients independently by themselves. Volunteers who are bilingual will attend to the subject alone, or else those who can only converse in Chinese/ English will pair up with another volunteer who knows another language to make sure there is no communication barrier between volunteers and patients."
16219|NCT04063553|Other|Exercise brochure|. The control group subjects will receive only standard physiotherapy care and they will be instructed to perform 1 set of exercises daily following a brochure given. The exercises in the brochure and exercises taught by the volunteers are the same. The video and brochure are available in both English and Chinese version.
16220|NCT04063540|Drug|Amiloride|Treatment by Amiloride vs placebo in crossover
16221|NCT04063540|Drug|Placebos|Treatment by Amiloride vs placebo in crossover
16222|NCT04063527|Drug|adjuvant chemotherapy|combination of paclitaxel and carboplatin
16223|NCT04063514|Other|Focused Ultrasound and Microbubble Infusion|With focused ultrasound, there is an expected accentuation of local perfusion and potential temporary opening of the blood brain barrier with the aim is to provide better delivery of therapeutic agents including medication, particulates and cellular elements for treatment of neoplastic, inflammatory and degenerative brain diseases. The present study seeks to investigate differences in perfusion between areas treated and untreated by this modality in order to further explore its use in clinical application for the treatment of brain disease.
16224|NCT04063501|Other|Bronchoscopy|The patient will then return within a week for a research bronchoscopy to sample the upper and lower airways
16225|NCT04063501|Other|Research Procedures|electrocardiogram, blood work (CBC, chemistry, coagulation profile and liver function tests, pregnancy test if applicable), X-ray and pulmonary function (spirometry) testing, and provide the patient with a stool collection kit.
16226|NCT04063488|Drug|Metreleptin|This is an observational study in which the subjects will serve as their own controls. Study testing will be conducted at baseline (pre-treatment) and for 2 years, post-treatment with metreleptin.
16227|NCT04063475|Drug|cyanoacrylate tissue adhesive beside sutures|using cyanoacrylate tissue adhesive for FGG fixation
16228|NCT04063462|Drug|Pyrotinib|pyrotinib, single agent, 400mg p.o once daily until disease progressed
16229|NCT04063449|Drug|endostar/PD-1 inhibitor|Antiangiogenic therapy plus immunotherapy and chemotherapy
16230|NCT04063449|Drug|endostar|Antiangiogenic therapy plus chemotherapy
16231|NCT04063436|Device|New nasal pillows mask with PAP therapy|Participants will be placed in the experimental arm for 14±5 days, during which they will be using the new nasal pillows mask for PAP therapy.
16232|NCT04063423|Procedure|blood sample|Blood sample at start and at the end of the dialysis session; membrane scoring after dialysis; total cell volume measurement of dialyzer after dialysis; micro-CT of dialyzer after dialysis.
16236|NCT04063397|Diagnostic Test|Echocardiogram|Serial echocardiograms will be done on all patients pre-delivery, and at 3 months, 6 months and 1 year postpartum
16237|NCT04063397|Diagnostic Test|Blood draw|Serial blood draws at same time points as echocardiograms for biomarker levels
16238|NCT04063384|Other|alcohol beverage|Participants will be provided alcohol during study visits and changes in behavior/neural activity after consuming alcohol will be examined.
16239|NCT04063384|Other|Placebo beverage|placebo beverage conditions.
16240|NCT04063371|Other|Self-Administered Gerocognitive Examination (SAGE) or Electronic Self-Administered Gerocognitive Examination (eSAGE)|The Self-Administered Gerocognitive Examination (SAGE) is a reliable and valid assessment that is used to detect MCI and early dementia. It is a pen and paper assessment that has 4 interchangeable versions. The digital version of SAGE (eSAGE; commercially known as BrainTest®) is made for tablet use, consists of the identical test questions as SAGE, and is strongly associated with the validated SAGE.
16241|NCT04063371|Other|Informant Conversation|If possible, the provider will have a conversation with an individual who knows the patient will to ascertain if a significant change (based on primary care provider opinion) occurred in the patient's cognitive skills over the previous year.
16242|NCT04063358|Drug|Lucentis|Lucentis 0.5 MG Per 0.05 ML Injection
16243|NCT04063345|Procedure|IVUS-guided PCI|Performing intravascular ultrasound before or/and after percutaneous intervention
16244|NCT04063345|Procedure|Angiography-guided PCI|Performing percutaneous intervention without intravascular ultrasound guidance
16245|NCT04063319|Other|High-fidelity simulation|The set up in the high-fidelity simulation intervention is a deteriorating patient scenario.
16246|NCT04063306|Other|none of intervention was given|this is an observational survey and no intervention is given
16247|NCT04063293|Biological|Platelet Rich Plasma|PRP injection into tha anal canal in patients underwent low anterior resection for rectal cancer
16248|NCT04063280|Procedure|Snare Tip Soft Coagulation (STSC)|Patients who have provided informed consented and are scheduled to undergo endoscopic mucosal resection (EMR) of lesions 15mm and larger will be randomized to STSC (80 W, Effect 5)
16249|NCT04063280|Procedure|Argon Plasma Coagulation (APC)|APC (preferred settings) of the perimeter of the EMR site
16250|NCT04063267|Device|E cigarettes|Participants will be encouraged to substitute e-cigarettes for combustible cigarettes in order to reduce nicotine withdrawal symptoms
16251|NCT04063267|Other|Nicotine Replacement Therapy|Nicotine patches and gum to last them the first week based on their baseline recorded smoking. Participants will be advised to use both a 21 mg nicotine patch and 4 mg nicotine for cravings.
16252|NCT04063254|Radiation|Stereotactic Radiotherapy|"High Dose (Arm A): Stereotactic radiotherapy with 12 or 16 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).~Standard-dose (Arm B): Stereotactic radiotherapy with 8 or 10 Gy in single fraction using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc)."
16253|NCT04063241|Other|Parent Surveys|"Parent perception of written discharge materials~Parent report of physician/nurse use of advanced counseling strategies (teach-back, show back, demonstration, or pictures/drawings)~parent perceptions of discharge education process (amount of time spent, language used, clarity)~parent self-reported execution of discharge instructions~parent ability to properly dose liquid medications.~Starting at 30 days post-hospital discharge, phone surveys+ to parents will assess: parent execution of discharge instructions and post-hospitalization morbidity (readmissions, ED visits, doctor visits)."
16254|NCT04063228|Other|Simple Skill Group|will practice the following skills as needed: bed mobility, transfer, walking, and stairs.
16255|NCT04063228|Other|Complex Skill Group|The program will consist of interventions at the impairments level with an emphasis on core strengthening, functional lower extremity strengthening, balance and endurance training, and at the skill acquisition level. Participants will learn pre-running skills (walking, stairs with handrail, walking backward, walking over obstacles, walking on toes, stairs without handrail, bounding), running skills (force generation in vertical plane: hopping, alternate hopping, running in place in gravity minimized position and against gravity; force generation in horizontal plane: bounding, alternate bounding, open chain movement for swing phase, running) and post running skills (running forward, backward, sideways, skipping, hopping).
16256|NCT04063215|Drug|HB-adMSC|autologous adipose-derived mesenchymal stem cells
16257|NCT04063202|Other|Observation|The anonymous structured questionnaire will be self-administered by the participating students in the absence of their teachers in class-room settings.
16258|NCT04063189|Drug|Clarithromycin Lenalidomide Dexamethasone (BiRd) Regimen|Clarithromycin 500mg，po，bid，d1-21; Lenalidomide 25mg，po，daily，d1-21 (dose according to creatinine clearance rate); Dexamethasone 20mg，po，daily，d1-2, 8-9,15-16, 22-23
16259|NCT04063163|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
16260|NCT04063163|Drug|carboplatin and etoposide|chemotherapeutics
16261|NCT04063163|Drug|placebo|placebo
16262|NCT04063150|Biological|fIPV (0.1 mL) ID|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal (ID) injection in lieu of the full 0.5 mL dose.
16263|NCT04063150|Biological|fIPV (0.1mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
16264|NCT04063150|Biological|fIPV (0.2mL) IM|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.2 milliliter (mL) dose (fractional) by intramuscular (IM) injection in lieu of the full 0.5 mL dose.
16265|NCT04063150|Biological|IPV|Full dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.5 milliliter (mL) dose by intramuscular (IM) injection.
16266|NCT04063137|Dietary Supplement|Anthocyanin fortified bread with beef patty (35% fat)|Bread is fortified at a 4% level using 25% (w/w) anthocyanin black rice extract. It is served with a beef patty (35% fat) to simulate a high-fat diet.
16267|NCT04063124|Drug|Dasatinib + Quercetin|Intermittent D+Q administered for 2 days on/14 days off for 12 weeks (6 cycles)
17480|NCT04053140|Drug|Penicillin G_1200mg|Benzylpenicillin IV 1200mg administered every 4 hours.
16268|NCT04063111|Device|vacuum assistant closure|Expose the open wound bed to negative pressure. This pressure removes edema or hemorrhage, mechanically pulls on the wound edges, decreases in wound surface area, improves circulation, and enhances proliferation of granulation tissue that filled the soft tissue defect.
16269|NCT04063111|Device|CONVENTIONAL DRESSING|CONVENTIONAL DRESSING for wound of open fracture of tibia grade III B
16270|NCT04063098|Other|Oral glucose tolerance test|Oral glucose tolerance test (OGTT) after a 72-hours standardized diet. OGTT will be performed 1 month prior to as well as 1, 3, 6, and 12 months after endoscopic sleeve gastroplasty
16271|NCT04063085|Device|PROTAHERE Absorbable Adhesion Barrier|40 mg/ml (4%) cross-linked hyaluronan
16272|NCT04063085|Device|Hyalobarrier Gel|Laparotomy: 40 mg/ml (4%) cross-linked hyaluronan Endoscopy: 30 mg/ml (3%) cross-linked hyaluronan
16273|NCT04063085|Other|No treatment|No anti-adhesion agent applied
16274|NCT04063085|Device|Seprafilm Adhesion Barrier|a hyaluronate carboxymethylcellulose-based bioresorbable membrane
16275|NCT04063085|Device|Gynecare Interceed (TC7) Absorbable Adhesion Barrier|an oxidized regenerated cellulose absorbable membrane
16276|NCT04063072|Procedure|ERAS protocol|In gynecological surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting, the omission of intestinal preparation, the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
16277|NCT04063059|Behavioral|PRIDE counseling intervention|Step-by-Step program to create positive lifestyle change geared toward wellness and long term healthy living through group sessions and telephone counseling.
16278|NCT04063046|Drug|General anesthesia|General anesthesia is induced with propofol (0.5-2mg / kg), remifentanil (4-8㎍ / kg / hr) and rocuronium (0.4 ~ 0.6 mg / kg) involving laryngeal mask(supraglottic airway device) insertion or endotracheal intubation. Anesthesia is maintained with 1.0-2.5% sevoflurane and remifentanil.
16279|NCT04063046|Drug|Peripheral nerve block|ultrasound-guided popliteal sciatic nerve block is performed
16280|NCT04063033|Drug|IV iron - Sodium Ferric Gluconate Complex|IV Iron will be administered 125 mg each day, to 3-5 days during hospitalisation.
16281|NCT04063020|Behavioral|Psychological monitoring|"Discussions with the psychologist PhD student before and after every surgery times : 3 discussions.~Before the first surgery (about 1 month before) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)~Before the second surgery (3 months later the first surgery) Clinical interview Drawing a person~After the second surgery (15 months later the first surgery) Clinical interview Rorschach and TAT (Thematic Apperception Test) Drawing a person test Self Questionnaires : KIDSCREEN-27 and CDI Children's Depression Inventory- de Kovacs et Beck (1977)"
16282|NCT04063007|Other|Ketogenic diet|The patients follow the ordinary treatment protocol for ketogenic diet
16283|NCT04062994|Behavioral|Nudge to reduce intraoperative hypotension|Providers will be alerted if their patients are at high risk of hypotension or at increased risk of sequelae from hypotension. Intraoperatively, if patients have more than 10 minutes of hypotension an alert will be displayed on the screen.
16284|NCT04062981|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
16285|NCT04062968|Other|Video education|"Prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetic-testing-videos ."
16286|NCT04062955|Dietary Supplement|Dietary Intervention|Receive dietary counseling
16287|NCT04062955|Procedure|Dual X-ray Absorptiometry|Undergo DXA scan
16288|NCT04062929|Behavioral|4-day physical activity program with behavioral intervention|Each program included 8-12 patients. During the four days, the participants had 4 collective sessions of educational information on PA and heart disease and 2 one-to-one sessions for promoting personal advice and experience on PA behavior. The participants had 6 sessions of PA and 2 food-counseling sessions.
16289|NCT04062916|Other|BSGE pelvic pain questionnaire and VAS scores|Patients were evaluated using the BSGE pelvic pain questionnaire in terms of pre-operative and post-operative pain assessment in order to determine the effects of endometriosis surgery on the quality of life. The patients were asked to indicate their levels of dyspareunia, dysmenorrhea, and chronic pelvic pain on a VAS on the pelvic pain questionnaire.
16290|NCT04062903|Behavioral|Immediate Appointment|The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
16291|NCT04062903|Behavioral|Delayed appointment|After a period of delay (Control) The participant will meet with the MIND Cymru link worker and decide upon a course of action requiring the use of local services appropriate for the participant.
16292|NCT04062890|Drug|Vigabatrin Pill|Oral Vigabatrin Pill
16293|NCT04062890|Drug|Placebo oral tablet|Oral Placebo Pill
16294|NCT04062864|Device|Pupil size|Measures the diameter of pupil before and after painful stimuli
16295|NCT04062851|Other|No Gastric residual volume monitoring|Gastric residual volumes will not be monitored
16296|NCT04062838|Drug|Dextrose 50|As above
16297|NCT04062838|Drug|Methylprednisolone Acetate|Subacromial injection
16298|NCT04062799|Other|no intervention|It is an observationa study. There is no intervention.
16299|NCT04062786|Other|Pmsf-PVC gradient measurement|implementation of standard standard hemodynamic monitorin
16300|NCT04062773|Behavioral|TRF|time restricted feeding group
16301|NCT04062773|Behavioral|Normal timing of food intake|no time restricted feeding
16302|NCT04062760|Drug|Standard diuretic therapy|The patients in this arm will be randomized to receiving oral furosemide in 2 daily divided doses at twice the intravenous dose administered during the past 24 hours. Unless serum potassium value is higher than 5 mmol/L, oral spironolactone or potassium canrenoate will be added; dose will be established based on serum creatinine value.
16303|NCT04062760|Drug|Early sequential nephron blockade|"After 24-72 hours of an algorithm-based treatment with high-dose intravenous furosemide started at the time of hospital admission, the patients in this arm will be randomized to receiving:~oral furosemide in 2 daily divided doses at a dose equivalent to that administered intravenously during the past 24 hours~metolazone at a dose based on serum creatinine value~acetazolamide at a dose based on serum creatinine value~spironolactone or potassium canrenoate (unless serum potassium value is higher than 5 mmol/L); dose will be established based on serum creatinine value"
16304|NCT04062747|Device|I-gel|After standard anesthesia i-Gel was placed into the patient
16305|NCT04062747|Device|Ambu aura i|After standard anesthesia ambu aura was placed into the patient
16306|NCT04062721|Drug|Chemotherapy|Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
16307|NCT04062721|Procedure|Radiofrequency ablation (RFA)|Complete macroscopic ablation by RFA.
16308|NCT04062721|Drug|In situ immunotherapy|Hydrogel combining TLR agonist and GM-CSF will be injected in 2 distinct lesions after RFA.
16309|NCT04062708|Drug|Durvalumab|"Preoperative Treatment:~Non-squamous NSCLC: durvalumab 1125 mg, followed by pemetrexed 500 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Squamous NSCLC: durvalumab 1125 mg, followed by docetaxel 75 mg/m2 IV with cisplatin 75 mg/m2 IV, every 3 weeks, for 4 cycles~Adjuvant Therapy:~• 1-6 weeks after completion of radiotherapy, durvalumab 1500 mg IV every 4 weeks will be administered for 13 cycles."
16310|NCT04062708|Procedure|Surgery|Patients will be re-evaluated following preoperative treatment to assess if patient is still medically fit to withstand surgery. Eligible patients will then undergo lobectomy, bilobectomy, sleeve lobectomy or other extended resection, or a pneumonectomy will be performed at the discretion of the attending thoracic surgeon.
16311|NCT04062708|Radiation|Radiotherapy|4-10 weeks after surgery, patients will receive 54 Gy of radiotherapy with single daily fractions.
16312|NCT04062695|Drug|Tofacitinib 5 MG Oral Tablet [Xeljanz]|verum tablets
16313|NCT04062695|Drug|Placebo oral tablet|tablets containing placebo
16314|NCT04062682|Behavioral|Healthy Diet + Physical Activity|Receive counseling to meet guidelines for healthy dietary patterns and physical activity level
16315|NCT04062682|Behavioral|Healthy Diet|Receive counseling to meet guidelines for healthy dietary patterns
16316|NCT04062669|Biological|Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the low dose (Ld-) RG SAM (CNE) group will receive 3 doses of RG SAM (CNE) low dose formulation, administered intramuscularly, according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181).
16317|NCT04062669|Biological|Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the medium dose (Md-) RG SAM (CNE) group will receive 3 doses of RG SAM (CNE) medium dose formulation, administered intramuscularly, according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181).
16318|NCT04062669|Biological|High dose formulation of RG SAM (CNE) vaccine (GSK3903133A)|Subjects in the High dose (Hd-) RG SAM (CNE) group will receive 3 doses of RG SAM (CNE) high dose formulation, administered intramuscularly, according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181).
16319|NCT04062669|Drug|Saline Placebo|Subjects in the Saline Placebo group will receive 3 doses of saline Placebo, administered intramuscularly, according to a 0, 2, 6-month schedule (i.e. at Days 1, 61 and 181).
16320|NCT04062669|Biological|RabAvert|Subjects in the RabAvert Group will receive 3 doses of RabAvert vaccine, administered intramuscularly, according to a 0, 2, 6-month schedule (i.e. at Day 1, 61 and 181).
16321|NCT04062656|Drug|Nivolumab|Nivolumab 240mg administered IV over 30 minutes Nivolumab 480mg should be administered IV over 60 minutes
16322|NCT04062656|Drug|Ipilimumab|Ipilimumab 1 mg/kg administered IV over 30 minutes
16323|NCT04062656|Drug|relatlimab|relatlimab (80mg flat dose) administered IV over 60 min
16324|NCT04062656|Drug|Oxaliplatin|Oxaliplatin 85mg/m² IV over 1 h
16325|NCT04062656|Drug|Docetaxel|Docetaxel 50mg/m² IV over 1 h
16326|NCT04062656|Drug|5-Fluorouracil (5-FU)|5-fluorouracil 2600mg/m² IV over 24h
16327|NCT04062656|Drug|Folic acid (FA)|Folic acid 200mg/m² IV over 30 min
16328|NCT04062643|Diagnostic Test|Obesity assessment|Body mass index (BMI (kg/m2) was calculated from measurements of weight to the nearest kg and height
16329|NCT04062630|Device|iFuse 3-D in Bedrock Configuration|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed, additionally iFuse 3-D implants are placed in a trajectory parallel to the S2AI screws.
16330|NCT04062630|Procedure|Multilevel Lumbar Fusion surgery|Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
16331|NCT04062604|Other|surgery|surgical treatment of femur fracture, hip and knee alloplasty, knee arthroscopy
16332|NCT04062591|Drug|Piroxicam group|patients will receive 0.4 mg/kg piroxicam IM
16333|NCT04062591|Drug|Placebo|saline IM in the same dose of piroxicam
16334|NCT04062578|Behavioral|Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature|The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
16335|NCT04062565|Drug|Treprostinil Injectable Product|Injection
16336|NCT04062565|Drug|Riociguat Pill|Tablet
16337|NCT04062552|Other|Behavioral, Psychological or Informational Intervention|Receive ENABLE palliative care information
16338|NCT04062552|Other|Educational Intervention|Participate in VLC group-based learning sessions
16339|NCT04062552|Other|Educational Intervention|Participate in consultation with ENABLE/TA expert
16340|NCT04062552|Procedure|Medical Examination|Undergo palliative care assessment
16341|NCT04062552|Other|Quality-of-Life Assessment|Ancillary studies
16342|NCT04062552|Other|Survey Administration|Complete surveys
16343|NCT04062552|Behavioral|Telephone-Based Intervention|Receive monthly phone calls
16344|NCT04062539|Device|Sentinel and Spider|Dual filter and single filter
16345|NCT04062526|Drug|[18F]NOS|[18F]NOS is an investigational radiotracer which each subject will have one [18F]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
16346|NCT04062513|Other|Olfactive stimulation intervention with familiarization|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick. For the familiarization stage, infants were familiarized with the odor of their mothers' milk for 9 hours before heel prick.
16347|NCT04062513|Other|Olfactive stimulation intervention|The intervention consists of placing a pad immersed with breast milk near the preterm infant's nose during heel prick.
16348|NCT04062513|Other|Standard care|Preterm infants will receive sucrose during heel prick.
16349|NCT04062500|Other|Mortality and Rehospitalization rate|Mortality and Re-hospitalization of acute decompensated heart failure
16350|NCT04062487|Device|Mixed Reality technology|combine image with real body
16351|NCT04062474|Procedure|Epidural Intervention with TNF-α inhibitor|Epidural administration with TNF-α inhibitor
16352|NCT04062461|Other|Multifaceted strategy based on sending text messages(SMS)|"multifaceted strategy based on sending text messages(SMS) to patients with heart failure.~Press educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity).~The text messages are about how the patient should take your drugs (evem diuretics), measure blood pressure and weight in Kg, and about signals and symptoms (shorthbreathness during the night), and about how important is practice physical exercises and don't drink alcohol."
16353|NCT04062461|Other|Usual outpatient care|Educational content on heart failure for the patient (symptoms of the disease, healthy habits for HF, warning signs for severity)
16356|NCT04062435|Drug|Drop application in the inferior fornix|See Arms
16357|NCT04062435|Drug|Drop application on the cornea|See Arms
16358|NCT04062396|Device|Eurosets REMOWELL 2 oxygenator|The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
16359|NCT04062396|Device|LivaNova INSPIRE oxygenator|INSPIRE oxygenator has no filtration system for extracavitary inlet
16360|NCT04062383|Behavioral|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
16361|NCT04062370|Drug|Ranibizumab|Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
16362|NCT04062370|Device|laser photocoagulation|After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
16363|NCT04062357|Drug|Lidocaine 5% spray|Group 1 (n₌75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1-2 ml) of lidocaine 5% sprays; contain 5 -10 mg of lidocaine, in a metered dose aerosol-delivery system).
16364|NCT04062357|Other|Placebo|Group 2 (n₌75); was given placebo in form on demand alcohol spray for 8 weeks.
16365|NCT04062344|Other|Swab|Rectal swab before and after the drug provocation testing
16366|NCT04062331|Device|Transcranial Magnetic Stimulation (TMS)|"By means of the magnetic stimulator we induce a cerebral electric current that is able to obtain a motor potential in the first dorsal interosseous bone of the left hand.~The intervention procedure consists of two steps: First step: Obtaining the Motor Evoked Threshold at Rest: Each patient, regardless of to the group to which they belong will have his/her threshold evoked motor calculated at rest, by stimulation of the right motor cortex, evoking electromyographic responses in the contralateral muscles. Second step: Administration of TMS: To calculate the motive threshold as the percentage of the same to which the treatment will have to be applied, a device equipped with a coil. The treatment will be administered for 5 consecutive days, with 3 weeks of rest, between each stimulation. To complete a treatment period of 14 months. The stimulation with TMS will be carried out every day in the same time slot for 5 consecutive days every 4 weeks, during a period of 14 months."
16367|NCT04062331|Drug|Placebos|Administration of Transcranial Magnetic Stimulation at 0 Hz (the patient will be only under drug standar therapy)
16368|NCT04062318|Device|Online active TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task, at less than or equal to 80% active motor threshold."
16369|NCT04062318|Device|Online sham TMS|"One single pulse or triple pulse train (3 pulses, 20ms inter-pulse interval) of sham TMS will be delivered per trial (at least 5 seconds apart) online, or during the tactile detection task. A sham TMS coil will be used that looks, feels and sounds like experimental TMS, but is incapable of of delivering TMS pulses."
16370|NCT04062305|Behavioral|Hand Function Test|Complete tasks that test grip strength, pinch strength, and ability to use and feel with hands
16371|NCT04062305|Procedure|Navigated Transcranial Magnetic Stimulation|Undergo nTMS
16372|NCT04062305|Other|Quality-of-Life Assessment|Ancillary studies
16373|NCT04062305|Other|Questionnaire Administration|Ancillary studies
16374|NCT04062279|Diagnostic Test|serum alpha synuclein autoantibodies, motor and non motor scales|measuring serum alpha synuclein autoantibodies by ELIZA at baseline assessment
16375|NCT04062266|Drug|Azacitidine|Given SC or IV
16376|NCT04062266|Drug|Venetoclax|Given PO
16377|NCT04062253|Diagnostic Test|HCV rapid test|Individuals who test positive for either HIV or HCV are offered PCR (polymerase chain reaction) testing with the xpert technology. Patients with a confirmed active infection are offered delivery and are taken into hospital.
16378|NCT04062240|Device|BIS sensor|BIS sensors will be labeled L and R. The degree of variability between the concurrent use of the sensors will be assessed .
16379|NCT04062214|Behavioral|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
16380|NCT04062201|Drug|Bedaquiline Oral Tablet|Days 1-14: 400mg once daily for two weeks and then 200mg three times per week for weeks 3-24
16381|NCT04062201|Drug|Linezolid Oral Tablet|Weight Group 30-33kg: 300mg daily for 24 weeks; Weight Group 33kg or more: 600mg daily for 24 weeks. Dose reduction, interruption or permanent discontinuation of this drug is allowed per protocol.
16382|NCT04062201|Drug|Delamanid in Oral Dosage Form|100mg twice daily for 8 weeks and then 200mg daily for 16 weeks
16383|NCT04062201|Drug|Clofazimine Oral Product|100mg daily (duration dependent on fluoroquinolone sensitivity results) duration may be up to 24 weeks
16384|NCT04062201|Drug|Levofloxacin Oral Tablet|Weight Group 30-33kg: 15mg/kg daily; Weight Group 33-50kg: 750mg daily; Weight Group more than 50kg: 1000mg daily. Duration dependent on fluoroquinolone sensitivity results- duration may be up to 24 weeks
16385|NCT04062201|Drug|Isoniazid Oral Product|At 10 mg/kg to a maximum dose of 600mg for 16 weeks. Weight Group 30-33kg: 300mg daily for 16 weeks; Weight Group 33-50kg: 400mg daily for 16 weeks; Weight Group more than 50kg: 600mg daily for 16 weeks If the smear is positive at week 16, Isoniazid must be extended to 24 weeks
16386|NCT04062201|Drug|Ethambutol Oral Product|Weight Group 30-33kg: 800mg daily for 40 weeks; Weight Group 33-50kg: 800mg daily for 40 weeks; Weight Group more than 50kg: 1200mg daily for 40 weeks
16387|NCT04062201|Drug|Pyrazinamide Oral Product|Weight Group 30-33kg: 1000mg daily for 40 weeks; Weight Group 33-50kg: 1500mg daily for 40 weeks; Weight Group more than 50kg: 2000mg daily for 40 weeks
16388|NCT04062201|Drug|Linezolid Oral Tablet|Weight Group 30-33kg: 300mg daily for 8 weeks; Weight Group more than 33kg: 600mg daily for 8 weeks;
16389|NCT04062201|Drug|Clofazimine Oral Product|100mg for 40 weeks
16390|NCT04062201|Drug|Levofloxacin Oral Tablet|Weight Group 30-33kg: 15mg/kg daily for 40 weeks; Weight Group 33-50kg: 750mg daily for 40 weeks; Weight Group more than 50kg: 1000mg daily for 40 weeks
16391|NCT04062188|Diagnostic Test|Telephone Interview Form|Telephone Interview Form is an original simple questionnaire which consists of Barthel Index and modified Rankin Scale.
16392|NCT04062175|Drug|cephalosporin|72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision
16393|NCT04062175|Drug|Azithromycin Tablets|72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision
16394|NCT04062162|Behavioral|Walking football training|Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
16395|NCT04062149|Other|single leg stance treatment|SLS treatment following the neurodevelopmental treatment (NDT). SLS is the ability of one limb to support the body's weight in a standing position. In gait it is the foot being in contact with the ground whilst the body passes over it and this stance phase of gait accounts for 60% of the gait cycle. The treatment approach of NDT has been chosen as this is the most common physiotherapy treatment option in the UK and is the most common option in the studies above. NDT is a problem-solving approach to the assessment and treatment of individuals with disturbances of function, movement and postural control due to a lesion of the central nervous system and provides an outline of the treatment required to achieve SLS which will form the basis of the intervention of this study.
16396|NCT04062149|Other|Usual physiotherapy|Individualised physiotherapy treatment approach, as per standard protocol, but it will not work specifically on SLS. Will be based on the neuro-developmental technique.
16397|NCT04062136|Combination Product|stem cell transplantation|Transplantation of umbilical cord mesenchymal stem cells
16398|NCT04062123|Drug|Dexmedetomidine|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.15 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
16399|NCT04062123|Drug|Propofol|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.7 mcg/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
16400|NCT04062123|Drug|Fentanyl|Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, & weight.
16401|NCT04062123|Device|Peripheral Nerve Stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the experimental cues.
16402|NCT04062123|Drug|Placebo|Crystalloid IV solution will be infused, with no active drug.
16403|NCT04062110|Device|plaster cast|Closed Reduction of Fracture and Application of Plaster Cast
16404|NCT04062097|Drug|Dabigatran Etexilate Oral Capsule [Pradaxa]|Dabigatran is the most frequently used direct thrombin inhibitor in secondary stroke prevention in patients with atrial fibrillation.
16405|NCT04062097|Drug|Idarucizumab 2.5 GM/50 ML Intravenous Solution [PRAXBIND]|Idarucizumab is the current standard therapy in patients with intracranial bleeding under anticoagulation with dabigatran.
16406|NCT04062097|Drug|Vitamin K antagonist|This drug group includes the active substances phenprocoumon and warfarin.
16407|NCT04062084|Device|Multifunctional Cataract-assisted Retractor|Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
16408|NCT04062071|Other|no intervention|no intervention
16409|NCT04062058|Radiation|SIB-IMRT|45Gy in 25 fractions using intensity-modulated radiotherapy to the radiation target
17606|NCT04052204|Drug|talazoparib|poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor
16410|NCT04062058|Drug|S-1|40-60mg/m2(according to patient's body surface area), orally twice daily every weekday concurrently with radiotherapy treatment
16411|NCT04062058|Drug|SOX|SOX (S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
16412|NCT04062058|Procedure|Surgery|Surgery, preferred D2 lymphadenectomy
16413|NCT04062045|Drug|Ropivacaine Hcl 0.2% Inj Vil 10Ml|Group A will receive the medicine through the erector spinae catheter.
16414|NCT04062045|Drug|Saline 0.9%|Group B will receive Saline 0,9% through the erector spinae catheter.
16415|NCT04062032|Drug|Aspirin 81 mg|ASA 81mg taken daily
16416|NCT04062032|Drug|Aspirin 325mg|ASA 325mg taken daily
16417|NCT04062019|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 once every other day, for 3 months.
16418|NCT04062006|Drug|Interleukin-2|low dose interleukin-2 injected subcutaneously, at a dose of 1 x 10~6 IU/m2 five days per week for 4 weeks (day1-5, 8-12, 15-19, 22-26) and then once a week for 8 weeks (day33, 40, 47, 54, 61, 68, 75, 82).
16419|NCT04061993|Procedure|Strength and Sensory-Motor Training|Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).
16420|NCT04061993|Procedure|Current Standard Physiotherapy|Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
16421|NCT04061980|Drug|Binimetinib|Given PO
16422|NCT04061980|Drug|Encorafenib|Given PO
16423|NCT04061980|Biological|Nivolumab|Given IV
16424|NCT04061967|Other|Sending of screening summon.|A Cobas PCR Female swab sample packet will be sent. Response rates will be measured.
16425|NCT04061954|Behavioral|Comprehensive family intervention including individual sessions of FORNET|"Families in the intervention group received:~Parents participate in a group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug and alcohol abuse, anger management, family planning, parenting skills, communication skills, and dealing with couples conflicts~Family visits to address topics as family cohesion, intra-familial communication and psychological basic need of children~Trauma-focused therapies (FORNET), which aim also at reducing violent behaviour~Parents receive training regarding agriculture and micro credit projects, and financial assistance~One child per family receives a social skill training group preparing them for returning to school~Access to schools and school material~If needed medical assistance is provided~If needed legal assistance is provided"
16426|NCT04061941|Behavioral|Cognitive Assessment|Assessment on cognitive dysfunction using standardised cognitive tests
16427|NCT04061928|Drug|PD-1|2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
16428|NCT04061915|Behavioral|Infographic Intervention|A HIV self-testing infographic that utilizes a simplicity model collaboratively designed by a leadership group of HIV community members
16429|NCT04061915|Behavioral|Paper-based HIV self-testing information|The online control arm will consist of paper-based, HIV self-testing information that the emerging adults will read.
16430|NCT04061902|Other|Participation with enhanced patient perioperative information|Improved information and dialogue about the care goals in the fast track protocol.
16431|NCT04061889|Other|intervention name is not applicable|Another intervention is not applicable either, due to the observational study design
16432|NCT04061876|Drug|Ruxolitinib|Participants began oral administration of ruxolitinib at 5 mg QD; if stable after the first 7 days of treatment, the dose could be increased to 5 mg BID. if stable after the first 14 days of treatment, the dose could be increased to 10 mg BID.
16433|NCT04061876|Drug|Corticosteroid|Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response. 1mg/kg/d , iv or iv gtt for at least 5 days, then taper according to the clinical response.
16434|NCT04061863|Drug|Nivolumab|Nivolumab 360mg on D1 every 3 weeks Eribulin 1.4mg/m2 on D1, 8 every 3 weeks
16435|NCT04061837|Device|MitralStitch|With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
16436|NCT04061824|Drug|Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))|In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.
16437|NCT04061824|Drug|Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)|In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).
16438|NCT04061811|Diagnostic Test|Diagnostic biomarker study|Comparing circulating concentrations of NT-proBNP, GDF15, and neprilysin (NEP) along with NEP activity in patients with and without HF, as diagnosed by clinical parameters and post-dialysis echocardiography.
16439|NCT04061798|Drug|ACT guided heparinization|"If the ACT is <180 sec., an additional dose of heparin of 60 IU/kg is administered. If the ACT is 180-200 sec., 30 IU/kg.~If the ACT is >200 sec., no extra heparin is given. 5 min. after every administration of heparin the ACT is measured. If the ACT is >200 sec, the next ACT measurement is performed every 30 min., until the end of the procedure or until new heparin administration is required. After each new dose of heparin, an ACT measurement is performed after 5 min. and the above- described protocol of ACT measurements will be repeated. After re-establishing blood flow and removing all clamps, the ACT is measured.~If the ACT at closure is 200-250 sec., 25 mg protamine should be administered. If >250 sec., 50 mg protamine. If 180-200 sec., 10 mg protamine. 5 min. after the administration of protamine, the ACT is measured. The ACT should preferably be below 180 sec. If the ACT is still more than 200 sec., protamine should be administered again."
16440|NCT04061785|Other|Judo4Balance - 16 week judo inspired exercise program|16 weeks x 45 minute judo inspired exercise in lead by instructor in a group setting.
16441|NCT04061772|Drug|Bortezomib|Bortezomib injection
16442|NCT04061772|Drug|Etoposide|Etoposide injection
16446|NCT04061759|Other|Effectiveness of four physical therapy approaches (soft tissue manual therapy, Kinesio® Taping techniques, stabilization exercises and reflex therapy) for treating lumbar disc pathologies.|Visual analog scale (VAS) scores for pain intensity, goniometric measurements for the range of motion and hamstring flexibility, the sit and reach test for flexibility, an isokinetic evaluation for strength at 60°/sec, and a side-plank position test for trunk stabilization were measured. The functional status was evaluated with the Oswestry Disability Index. All groups were assessed at the beginning, after a four-week treatment and four weeks of follow-up.
16447|NCT04061746|Biological|Mesenchymal Stem Cells (MSCs)|Patients in Group A will receive a single MSCs infusion
16448|NCT04061746|Other|Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)|Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
16449|NCT04061733|Device|Hydrogel injection|Hydrogel injection
16450|NCT04061720|Behavioral|Enhanced Chronic Care|Enhanced Chronic Care involves four chronic care calls per year. Enhanced Chronic Care is designed to help participants explore their goals and concerns with regard to smoking, engage in a nondirective, supportive, motivational interventions, and provide information about evidence-based smoking treatment available to them and ways to initiate treatment (i.e., warm hand-off from a clinical provider).
16451|NCT04061720|Behavioral|Standard Care|Standard Care involves one call per year. During the Standard Care call, participants will be encouraged to quit smoking, reminded of the cessation treatment available to them, and provided with a number to call should they become interested in treatment.
16452|NCT04061694|Procedure|Immediate loading, fully guided surgery and 3D printed restoration|Fully guided surgery installation of single dental implants. 3D printed restorations that were immediate loaded.
16453|NCT04061694|Procedure|Immediate loading|Only subjected to immediate loading. Conventional procedure.
16454|NCT04061681|Behavioral|Behavioral Intervention (BIPAMS)|This 16-week behavioral intervention teaches people the skills, techniques, and strategies based on Social Cognitive Theory of behavior change for modifying and self-regulating health behaviors, including physical activity. The behavioral intervention consists of two primary components, namely a dedicated Internet website and one-on-one video chats with a behavioral coach via SkypeTM.
16455|NCT04061668|Other|single needle path PECS I and II block group|The probe is placed inferior to the clavicle . The US probe is placed below outer third of the clavicle showing pectoralis major and minor muscles and the thoraco- acromial artery then moved infero-laterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised . The probe is moved toward anterior axillary line till pectoralis minor and serratus anterior muscles ise identified at 4th rib at the level of thoraco-acromial artery , the needle is inserted in plane with the probe from caudal to cranial using an inclined manner, 15mL of bupivacaine is put into the potential space between pectoralis minor muscle and serratus muscle (PECS II) then it is withdrawn to inject another 15 ml of bupivacaine in the plane between pectoralis muscles . The block will be performed with needle introduced in-plane with the ultrasound probe, and the local anesthetic injection is visualised.
16456|NCT04061668|Other|double needle path PECS I and II block group|The US probe will be initially placed below outer third of the clavicle after skin sterilization showing pectoralis major and minor muscles and the thoraco- acromial artery then moved inferolaterally to locate fourth rib where pectoralis major and pectoralis minor muscles will be visualised, then the needle will be inserted in plane with the probe and 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis muscles. In the second puncture , the US probe will be moved toward anterior axillary line till pectoralis minor and serratus anterior muscles will be identified at 4th rib at the level of thoraco-acromial artery then the needle will be inserted in plane with the probe from caudal to cranial in an inclined way, 15mL of bupivacaine 0.25% after negative aspiration will be put into the potential space between pectoralis minor muscle and serratus muscle (PECS II).
16457|NCT04061655|Drug|Iron Isomaltoside 1000|Apatients (n= 40) received single dose intravenous infusions of iron isomaltoside 1000 mg over 15 min with a maximum single dose of 20 mg/kg.
16458|NCT04061655|Other|placebo|Patients in the placebo group (n=40)received as a single-dose of saline (Natriumklorid 9 mg/ml; Fresenius Kabi, Copenhagen, Denmark) 100 ml infused over 15 min.
16459|NCT04061642|Device|Clinical Decision Aid|The Clinical Decision Aid is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of all possible treatments, with each treatment associated with a predicted efficacy (likelihood to achieve response and likelihood to achieve remission, each expressed as a percentage). The treatments, which may include any approved treatment for depression, will be ordered by efficacy and presented to the physician. Lifestyle interventions, such as exercise or mindfulness, which have an evidence base, but do not require formal regulatory approval, will also be outputted. The system will additionally produce a side effect profile for each pharmacological treatment recommended, including known side effects, modified by a prediction about which side effects may be more likely for a given individual based on their individual characteristics.
16460|NCT04061629|Device|Cuffed ETT|Cuffed endotracheal tube.
16461|NCT04061616|Behavioral|PASIPD-Fr|Fill-out the PASIPD-Fr self questionaire twice (2 completions at a 2-week interval)
16462|NCT04061603|Device|Adagio AF Cryoablation System (iCLAS™)|Endovascular ablation of the left and right atrium
16463|NCT04061590|Drug|Cisplatin|Given IV
16464|NCT04061590|Biological|Pembrolizumab|Given IV
16465|NCT04061590|Drug|Pemetrexed|Given IV
16466|NCT04061590|Drug|Pemetrexed Disodium|Given IV
16467|NCT04061590|Procedure|Therapeutic Conventional Surgery|Undergo surgery
16468|NCT04061577|Device|Transcranial Direct Current Stimulation (tDCS)|20 minutes of Cathodal tDCS before +/- after endovascular thrombectomy (EVT)
16469|NCT04061564|Device|Vagal nerve stimulation|The participant will be administered electrical stimulation at a level specifically set to their comfort. This will be performed using a TENS machine device.
16499|NCT04061278|Drug|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy|3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy, instead of definitive radiotherapy
16500|NCT04061265|Drug|Articaine 4%/Epi 1:200000 Inj Cart 1.7Ml|Local anesthetic agent
16501|NCT04061252|Drug|KHK4827|brodalumab 210mg Q2W, SC
16502|NCT04061252|Drug|Placebo|Q2W, SC
16470|NCT04061551|Other|EC clinic support - whole of practice interventions delivery through nurse-led model|"The primary interventions will be delivered through a team of nurses, an evaluation team and practice support team that will be working with each of the services to improved Hepatitis C service delivery.~The EC project team will predominantly be involved in working with providers and staff at EC sites to implement key interventions that have been collated into a Primary Care Practice Toolkit, which cover three domains; patient support, provider support and practice Support. The toolkit is designed to be an educational and implementation resource that the nursing team will support services to deliver.~Patient support to reduce the impact of hepatitis C and other blood borne viruses~Provider support to reduce the impact of hepatitis C and other blood borne viruses~Practice support to reduce the impact of hepatitis C and other blood borne viruses"
16471|NCT04061538|Dietary Supplement|zinc sulfate|zinc 20mg tablets
16472|NCT04061538|Dietary Supplement|Placebo|Sugar pill manufactured to mimic zinc 20mg tablet
16473|NCT04061525|Procedure|Percutaneous coronary intervention with FFR measurement and intracoronary ECG registration|Measurement of fractional flow reserve (FFR), registration of intracoronary ECG and radioscopic registration of wire tip movement in the main and in the side branch in the beginning, at the end and during every step of coronary bifurcation percutaneous intervention.
16474|NCT04061512|Drug|Dexamethasone, cyclophosphamide, rituximab|DRC Arm (chemotherapy) consists of dexamethasone, cyclophosphamide and rituximab treatment
16475|NCT04061512|Drug|Rituximab, ibrutinib|RI Arm (chemotherapy free) consists of rituximab and ibrutinib treatment
16476|NCT04061473|Drug|Sitagliptin 100mg|"2 tablets of sitagliptin 100 mg.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
16477|NCT04061473|Drug|Empagliflozin 25 MG|2 tablets of empagliflozin 25 mg.
16478|NCT04061473|Other|Placebo tablet|"2 placebo tablets.~Standardized liquid meal Standardized liquid meal (200 ml) containing: 1,650 KJ, (394 kcal), carbohydrate 50%, protein 15%, fat 35% consisting of glucose (47.2 g + 2.8 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol."
16479|NCT04061460|Procedure|mechanical plaque control|supra and sub gingival debridment ( plaque control)
16480|NCT04061447|Drug|susceptibility-guided therapy|rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
16481|NCT04061447|Drug|empirical clarithromycin-based triple therapy|The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
16482|NCT04061421|Drug|INCB053914|Taken by mouth twice daily during each 28-day cycle
16483|NCT04061421|Drug|ASTX727|Taken by mouth daily during days 1-5 of every 28-day cycle.
16484|NCT04061421|Drug|Itacitinib|Taken by mouth daily during each 28-day cycle
16485|NCT04061421|Drug|INCB059872|Taken by mouth daily during each 28-day cycle
16486|NCT04061408|Radiation|Fractionated stereotactic radiotherapy(FSRT)|3 to 5 fractions and 8Gy per fraction will be used for breast cancer patients with 1-10 brain metastases based on the lesion number and volume.
16487|NCT04061395|Biological|Guselkumab|See study arm description.
16488|NCT04061382|Procedure|venepuncture|This is a pilot study to assess the feasibility of establishing a national seroepidemiological survey in England in individuals aged 0-24 years, focusing initially on Diphtheria and Group C invasive Meningococcal disease. The investigators are aiming to recruit 2300 individuals and the investigators are aiming to ensure that sample is broadly representative of the region according to IMD (Index of Multiple Deprivation scores). The PHE generated a list of all postcodes in recruiting regions and determining the quintiles of IMD within that region. Participants interested in taking part in the study will contact sites to arrange a visits. Basic demographic characteristics will be collected by questionnaire and/ or case report form (CRF) and will include: DOB, gender, GP details, Ethnic group, association with communities of special interest, household income and vaccination history. One study visit will be conducted by research study staff and blood sampling will be carried out.
16489|NCT04061369|Other|Low fat meal|Meal consisting of conventional foods that is low (20% of energy) in fat calories.
16490|NCT04061369|Other|Moderate fat meal|Meal consisting of conventional foods that is moderate (40% of energy) in fat calories.
16491|NCT04061369|Other|High fat meal|Meal consisting of conventional foods that is high (60% of energy) in fat calories.
16492|NCT04061369|Other|High fat liquid meal|Liquid meal that is high (60% of energy) in fat calories.
16493|NCT04061330|Drug|Ketamine|Initial bolus of ketamine 0.3 mg/kg IV (maximum 30 mg) followed by ketamine infusion of 0.25mg/kg/hr (maximum 25mg/kg/hr) for 6 hours or until patient leaves the emergency department (ED),whichever occurs first.
16494|NCT04061330|Drug|Morphine|Bolus doses of morphine 0.1 mg/kg (maximum 8 mg) intravenously every 2 hours for 6 hours or until patient leaves the ED, whichever occurs first.
16495|NCT04061317|Other|Frailty Assessment|"We will use validated measures to determine existence of frailty prior to interventional cardiac procedures (PRISMA-7, Edmonton and FRIED Frailty Index). We will repeat the measures at 6 weeks and 6 months post procedure. We will also collect clinical data to assess any links between frailty and clinical outcomes.~We are also keen to understand the effects of health-related quality of life on frailty and will be collecting generic data via the SF-36 and EQ5-D."
16496|NCT04061304|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
16497|NCT04061304|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
16498|NCT04061278|Drug|4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy|4 Cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, instead of Concurrent Chemoradiotherapy
16503|NCT04061239|Drug|CPX-351|CPX-351 is a liposomal formulation with a fixed 5:1 molar ratio of cytarabine and daunorubicin. It will be administered as a 90-minute intravenous infusion.
16504|NCT04061239|Drug|Daunorubicin|Daunorubicin is commercially available as a powder for reconstitution in 20 mg vials. In this trial, daunorubicin should be administered as an IV infusion over 60 min.
16505|NCT04061239|Drug|Cytarabine|Cytarabine is commercially available as vials/bottles for preparation of diluted infusion solution. Cytarabine will be administrated intravenously. In this trial, cytarabine is administered as a continuous infusion.
16506|NCT04061239|Drug|Azacitidine|Azacitidine at 75mg/m² for 7 days. Patients should receive a minimum of 2 and up to 6 cycles.
16507|NCT04061226|Device|Overnight polysomnography|Overnight polysomnography will be performed in a sleep laboratory (EEG, EOG, EMG, ECG, respiratory movements of the chest and abdomen, oro-nasal airflow, and O2 saturation will be examined
16508|NCT04061213|Diagnostic Test|Tc-99m-DPD scintigraphy|Myocardial scintigraphy
16509|NCT04061200|Drug|Semaglutide, 1.34 mg/mL|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks. Participants will be randomized and up titrated to semaglutide 1.34 mg/ml or matching placebo once weekly during the following 26 weeks in a 1:1 ratio.
16510|NCT04061200|Other|Placebo, 1,34 mg/mL|Participants will be randomised to either semaglutide or placebo as an add on treatment after 26 weeks of intervention with empagliflozin 25 mg.
16511|NCT04061200|Drug|Empagliflozin 25 MG|After informed consent, subjects will be initiated on open-label empagliflozin 25 mg or maximal tolerated dosis once daily during a run-in period of 26 weeks.
16512|NCT04061174|Other|Shoulder stabilization exercises|When participants are able to do the exercise 15 repetitions without difficulty, the exercise will be advanced by modifying or adding the weight.The exercises include chin tulk exercise, shoulder closed chain weight transfer, prone and iso-abdominal exercises, push-up exercise, lower trapezius muscle strengthening exercise, dead bug exercise, ball rolling on the wall, bench press with dumbbell and internal/external rotation (IR / ER) strengthening exercises
16513|NCT04061174|Other|Office exercises training|Information will be given in a brochure that includes the appropriate chair height and work table, sitting position, distance between eyes and monitor, and table chair dimensions.approved and standardized office-based stretching and strengthening exercises will be given for workplaces
16514|NCT04061161|Drug|Tiotropium Bromide|Participants will be double-blind randomized for Tiotropium or Placebo treatment for 6 weeks
16515|NCT04061148|Device|NIRSIT|NIRSIT is a device that utilizes Near Infrared Spectroscopy to provide a non-invasive measurement of frontal lobe blood oxygenation over time.
16516|NCT04061135|Procedure|Response Inhibition and Deep Brain Stimulation in Parkinson's disease|After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
16517|NCT04061122|Diagnostic Test|airway epithelial smear test|all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture
16518|NCT04061109|Drug|Recombinant Human Coagulation FVIII|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
16519|NCT04061096|Diagnostic Test|Evaluation of cold test|Cold test evaluation to describe the sensitivity level of teeth due to induce the hydrodynamic forces in dentine tubules.
16520|NCT04061096|Diagnostic Test|Evaluation of electrical pulp test|Electrical pulp test evaluation to describe the sensitivity level of teeth due to induce the nerve fibers in pulp tissue.
16521|NCT04061096|Diagnostic Test|Evaluation of pain during the treatment|Describe the sensitivity level due to induce the hydrodynamic forces during treatment procedure.
16522|NCT04061083|Device|Smart Cuff Manager|Participant will be attached to the smart cuff manager within 4 hours after intubation. They will remain attached during the first 48 hours of intubation in the intensive care unit
16523|NCT04061083|Device|Manometer|Participant will be attached to the manometer within 4 hours after intubation. They will assess 3 times per day during the first 48 hours of intubation in the intensive care unit
16524|NCT04061070|Other|Supplementation with mix of threalose plus polyphenols|The patients will be treated with a mix of trehalose plus polyphenols for 60 days
16525|NCT04061070|Other|No Supplementation with mix of threalose plus polyphenols|The patients will not be treated with a mix trehalose plus polyphenols for 60 days
16526|NCT04061057|Drug|Lidocaine|"Drug: 1. Lidocaine Intravenous lidocaine bolus of 1.5mg/kg immediately after anesthesia induction followed by infusion at 2.0mg/kg/hr up to 1 hr after end of surgery.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
16527|NCT04061057|Drug|Normal saline|"Drug: 1. Normal saline Intravenous normal saline bolus of immediately after anesthesia induction followed by infusion up to 1 hr after end of surgery. Volume of normal saline is equal to lidocaine.~2. Fentanyl IV infusion via PCA (patient controlled analgesia) machine of fentanyl 10 μg/ml, ramosetron 0.3 mg, normal saline, total 100 ml, infusion rate 1 ml/hr, 1 ml bolus and lockout time 7 min."
16528|NCT04061044|Drug|Ophthalmic Insert|Travoprost, 0.32 mg
16529|NCT04061031|Behavioral|Parent-Child Interaction Therapy (PCIT)|A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
16530|NCT04061031|Behavioral|Child-Centered Therapy with Parent Education|A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
16531|NCT04061005|Procedure|Cold snare polypectomy|CSP, which does not include electrocautery to do a polypectomy with a snare.
16532|NCT04061005|Procedure|Hot snare polypectomy|HSP, which uses the electrocautery to do a polypectomy with a snare.
16533|NCT04061005|Procedure|Endoscopic margin observation method|Endoscopic margin observation method, After rinsing the polyp specimen with physiological saline, fully natural extension, fixing it to the foam board with a needle, and observing the margin with a colonoscope or a magnifying colonoscope near-focus mode to determine whether there is residual polyp tissue.
16534|NCT04060992|Drug|Elagolix 200 MG Oral Tablet [Orilissa]|oral tablet given twice daily
16535|NCT04060979|Drug|Nitric Oxide|Nitric Oxide given intermittently via inhalation
16536|NCT04060979|Other|Standard Supportive treatment|Standard Supportive treatment (including oxygen)
16537|NCT04060966|Behavioral|Cold Pressor Task|The acute stress induction is called 'Cold Pressor Task' which consists of participants submerging their dominant forear, in ice-water (0-4°C) for 3 minutes (no-stress group uses warm water,~30°C).
16538|NCT04060953|Other|Health-Related Quality of Life Report|Subject report and interpretation guide based on SPADE cluster scores
16539|NCT04060940|Behavioral|Emotion Regulation Therapy: 8-session version|Emotion Regulation Therapy will be administered over 8 individual sessions on a weekly basis, resulting in a total required time commitment of 9 hours over the course of 8 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
16540|NCT04060940|Behavioral|Emotion Regulation Therapy: 16-session version|Emotion Regulation Therapy will be administered over 16 individual sessions on a weekly basis, resulting in a total required time commitment of 18 hours over the course of 16 weeks. The initial stage of treatment focuses on psychoeducation about anxiety and depression, individual patterns of these behaviors, emotions in recent situations, and self-monitoring of worry, anxiety, and depression. The sessions focus on the development of skills that help regulate one's emotional experience (i.e., recognizing emotions when they are happening, identifying the meaning of a given emotion experience, and soothing oneself in the context of negative emotional experiences). Following the development of these skills, sessions focus on the application of somatic awareness and emotion regulation skills while imagining emotionally evocative themes. The remaining sessions focus on terminating therapy, relapse prevention, and future goals.
16541|NCT04060927|Device|SGRT|Surface Guided Radiation Therapy
16542|NCT04060914|Drug|Ticagrelor 90mg|Ticagrelor 90 mg plus aspirin for 12 months
16543|NCT04060914|Drug|Ticagrelor 90mg/60mg|1 month after treatment with ticagrelor 90 mg plus aspirin, followed by treatment with ticagrelor 60 mg plus aspirin for 11 months
16544|NCT04060914|Drug|Clopidogrel 75mg|Clopidogrel 75mg plus aspirin for 12 months
16545|NCT04060901|Behavioral|CCSH Intervention for Teams|"CCSH Interventions for Teams will be a six session intervention. The groups meet once per week for 60 minutes for 4 weeks, coupled with 2 booster sessions over the following 2 months. Participants will receive the CCSH interventional approach, adapted for a group setting, which follows four stages: 1) Preparing the care responder; 2) Attuning to the Relationship; 3) Accessing Compassion, and 4) Entrusting the Careseeker.~The CCSH approach will be used to assess group dynamics, individual member sources of distress, as well as existing resources for resilience and compassion. Through the intervention, resources will then be identified and accessed in order to respond to team (and individual) sources of distress with greater resilience and increased compassion toward self and others. CCSH clinicians will utilize group process skills to encourage team communication about work-related challenges, enhance team cohesion, and enable interpersonal support among members of the team."
16549|NCT04060875|Device|Karuna Labs Virtual Reality Software|The subjects will engage in the three therapeutic modules: laterality, motor imagery, and 'mirroring.' The decision of which module to employ will be based on the subject's readiness and comfort on a case-by-case basis. A subject visit can be expected to last 40 minutes, with enough time to complete PHQ-9, and to accustom to the virtual reality setup by playing in a non-therapeutic virtual environment should they choose to do so. Time in the virtual reality is expected to last approximately 20 minutes per session.
16550|NCT04060862|Drug|Ipatasertib|Phase 1b: Ipatasertib, 300 mg starting dose administered orally once daily (PO QD) during an initial 5-7 day run-in period, then continued on Days 1-21 during the first cycle. Starting with Cycle 2, Day 1 ipatasertib will be taken orally once daily on Days 1-21 of each 28-day cycle. Phase 3: Ipatasertib, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
16551|NCT04060862|Drug|Placebo|Phase 3: Matching placebo, administered PO QD on Days 1-21 of each 28-day cycle at the dose confirmed in the Phase Ib portion.
16552|NCT04060862|Drug|Palbociclib|Palbociclib, administered PO QD on Days 1-21 of each 28-day cycle.
16553|NCT04060862|Drug|Fulvestrant|Fulvestrant, 500 mg administered as two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15 and Day 1 of each subsequent 28-day cycle.
16554|NCT04060849|Drug|Nozin|Given via nasal single-use popswabs or single-use cotton tipped applicators
16555|NCT04060849|Other|Best Practice|Receive standard of care
16556|NCT04060836|Drug|Xyntha|Recombinant Coagulation Factor VIII Injection produced by Pfizer Inc.
16557|NCT04060836|Drug|Recombinant Coagulation Factor VIII Injection|A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
16591|NCT04060511|Drug|HS-10342|HS-10342 either 25mg, 50mg, 100mg, 150mg, 200mg given orally, QD or 50mg, 100mg, 150mg, 200mg, 250mg, 275mg given orally, BID
16664|NCT04059900|Drug|STW5 (Iberogast®, BAY98-7411)|The medication was applied daily per os (orally, p.o.) from day 0 to day 28. The dosage was 20 drops three times daily before the meals.
16558|NCT04060823|Other|Easy Breathing program|Easy Breathing is a longstanding, nationally recognized program that translates asthma management guidelines into a standardized and usable format for healthcare providers. As part of the program primary healthcare providers and school health personnel (e.g., nurses, health aides) identify children at-risk for adverse asthma outcomes and provide care coordination services. Patients receive a tailored, comprehensive Asthma Treatment Plan with information regarding daily medication use and management of acute symptoms based on asthma severity.
16559|NCT04060810|Other|MR CSF flowmetry|MR flowmetry in grey zone hydro cephalic patients followed by ventriculoperitoneal shunt
16560|NCT04060797|Device|endovascular denervation|multi-electrode catheter-based endovascular denervation
16561|NCT04060784|Device|Immediate implant placement and provisionalization|Failing tooth will be extracted and immediate placed endosseous implant
16562|NCT04060771|Drug|Palonosetron|prophylaxis of postoperative nausea and vomiting
16563|NCT04060771|Drug|Dexamethasone|prophylaxis of postoperative nausea and vomiting
16564|NCT04060758|Drug|PA5108 Latanoprost FA SR Ocular Implant|Ocular Implant
16565|NCT04060745|Other|cooling using a water-perfused vest|"BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed"
16566|NCT04060745|Other|thermoneutrality|In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
16567|NCT04060732|Device|Flash Glucose Monitoring-FGM|"The Flash Glucose Monitoring-FGM is a real-time glycemic monitoring system called hybrid will be assigned to the enrolled patients at baseline until the end of follow-up after 12 months."
16568|NCT04060719|Drug|BI 894416|tablet
16569|NCT04060719|Drug|Rifampicin|tablet
16570|NCT04060706|Radiation|Radical Image-Guided Radiotherapy|Questionnaires administered will monitor the clinical toxicity experienced by each patient up to 5 years post radiotherapy
16571|NCT04060693|Device|P0.5|Investigational Medical Device collecting spectral raman data from tissue.
16573|NCT04060667|Combination Product|Wireless physiologic monitoring|The intervention in this study is the use of a wireless monitor to perform physiologic monitoring of women undergoing emergency cesarean delivery for the first 24 hours after completion of the cesarean and send alerts to responding clinicians should vital signs fall out of a pre-specified range.
16574|NCT04060654|Drug|Sublocade|SUBLOCADE to be administered approximately every 4 weeks per local standard of care
16575|NCT04060641|Genetic|Geneticure for RDN Genetic Panel|This retrospective trial will include the collection of DNA using buccal swabs and the assessment of 22 genotypes for scoring to assess response to renal denervation
16576|NCT04060628|Drug|NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension|
16577|NCT04060615|Procedure|percutaneous coronary intervention|PCI of the chronic total occlusion of the coronary artery
16578|NCT04060602|Behavioral|Personalized Feedback|A report comparing the participant's cannabis use to peer usage, and summarizing problems experienced and risk associated with future use.
16579|NCT04060602|Behavioral|Education|Canada's Lower-Risk Cannabis Use Guidelines prepared by the Centre for Addiction and Mental Health which outlines methods to help reduce health risks associated with cannabis use.
16580|NCT04060589|Other|Tissue donation|Biopsies will be performed as part of standard of care, additional cores will be performed for research. Access to standard of care prostate biopsy tissue will also be requested after standard of care reporting is complete.
16581|NCT04060589|Other|Blood Donation|Phlebotomy will be performed prior to tissue collection following trust standard operating procedures or drawn when cannula already in situ in preparation for the prostate biopsy.
16582|NCT04060589|Other|Urine Donation|Urine will be collected prior to prostate biopsy
16583|NCT04060589|Other|Healthcare data linkage|Men will consent to healthcare data linkage via national databases.
16584|NCT04060576|Procedure|Dry needling treatment with a thinner needle|We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.
16585|NCT04060576|Procedure|Dry needling treatment with a medium-sized needle|We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.
16586|NCT04060576|Procedure|Dry needling treatment with a thickest needle|We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
16587|NCT04060563|Device|INSPIRSTAR IS02 MICROCURRENT STIMULATOR|"Investigators will use the Inspirstar microcurrent stimulator TENS device. It is an FDA 510k approved portable hand-held device used for the symptomatic relief of chronic pain. It generates low current intensity pulses in the ranges of 20μA to 400μA.~For this study, investigators will use a treatment range of 100-300μA. Frequency specific microcurrent therapy (100-300μA microccurrent amps) with Diastasis Recti Repair protocol (8), times 2 treatments for a consistent total of 11 hours 32 minutes."
16588|NCT04060550|Biological|Xolair|This is in vitro mechanistic study. No drug will be given in vivo to patients.
16589|NCT04060537|Other|Laboratory analysis of samples|RNA sequencing, immunohistochemistry, immunofluorescence, and cytometry of tumour tissues
16590|NCT04060537|Other|Application of machine learning|Using machine learning to interrogate data generated from analysis of Renal Cell Cancer tumours using RNA sequencing, immunohistochemistry, immunofluorescence, cytometry, and MRI imaging of tumours.
16662|NCT04059926|Other|insert apossing lumen metal stent|insert apossing lumen metal stent
16592|NCT04060498|Behavioral|Mindfulness intervention|MBI-p focuses on simplicity, for both facilitators and patients; and use acceptance and embracing attitude for fear and sadness. The ultimate aims are to help patients achieve a greater sense of peace and calmness, and facilitate participants in handling everyday stress and conflicts.
16593|NCT04060498|Behavioral|Psychoeducation intervention|Psychoeducation focuses on disseminating information about common mental disorders, psychosis (its causes, risk factors and trajectory), and methods of treatment for psychosis.
16594|NCT04060472|Drug|albumin-bound paclitaxel + oxaliplatin|Using albumin-bound paclitaxel (125 mg/m2, d1, 8, 15, ivgtt) + oxaliplatin (80 mg/m2, d1, 8, ivgtt) with or without other chemotherapeutic drugs, 28 days /cycle, until the disease progresses or patients can not tolerate toxicity. The investigators decide the follow-up treatment plan.
16595|NCT04060459|Drug|Paclitaxel-binding albumin|Paclitaxel-binding albumin 260 mg/m2，d1，ivgtt；cisplatin 75 mg/m2，d1，ivgtt
16596|NCT04060446|Device|Medical Device|Smoke cigarettes with CReSSMicro topography measurement device and BioRadio device
16597|NCT04060446|Other|Questionnaire Administration|Ancillary studies
16598|NCT04060446|Behavioral|Tobacco Smoking|Smoke cigarettes
16599|NCT04060433|Behavioral|Family Therapy|Swedish version of the evidence based manualized Family Therapy
16600|NCT04060420|Other|Comprehensive sexual and reproductive health services|The intervention includes community-based and peer-led delivery of comprehensive sexual and reproductive health services and a Yathu Yathu prevention points card, which is a card that adolescents and young people can use to gain points for accessing services and use these points to redeem rewards.
16601|NCT04060407|Drug|CD24Fc|CD24Fc will be administrated as IV infusion in a dose of 480 mg, q3w x 4, then q4w for up to 1 year.
16602|NCT04060407|Drug|Ipilimumab|Ipilimumab will be administrated as IV infusion, q3w x 4. For metastatic melanoma, the dose will be 3mg/kg, q3w x4. For renal cell carcinoma and colon cancer, the dose will be 1mg/kg, q3w x 4.
16603|NCT04060407|Drug|Nivolumab|"Nivolumab will be administrated as IV infusion. For metastatic melanoma, the dose will be 1mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year.~For renal cell carcinoma or colon cancer, the dose will be 3mg/kg, q3w x 4, then 480 mg, q4w for up to 1 year."
16604|NCT04060394|Drug|Phase I and Phase II: LAE001/prednisone + afuresertib|In the Phase I portion of the study we will identify the RPD2 of the combined therapy. In the Phase II portion of the study we will evaluate safety and efficacy of the combined therapy and afuresertib monotherapy.
16605|NCT04060381|Drug|Blood transfusion, Ibuprofen, or epinephrine, norepinephrine or dopamine|Treatment/ intervention given according to standard protocols at the Neonatal Intensive Care Unit
16606|NCT04060368|Procedure|Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications|Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
16607|NCT04060368|Procedure|Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications|Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
16608|NCT04060355|Behavioral|Savvy program|Caregiver program (Savvy) is an evidence-based dementia family caregiver psychoeducation program. Provided to groups of 8-12 (typically) individuals caring for family members living with Alzheimer's disease or related dementias (PLWD), Savvy employs a mechanism of action based in Social Cognitive theory to promote caregivers' solution-focused coping behaviors through the acquisition of appropriate knowledge, skills, and outlook and the enhancement of caregiving mastery.
16609|NCT04060355|Behavioral|Semi-structured video interviews|Semi-structured video interviews will assess the preliminary efficacy of programs led by system-trained interventionists in producing anticipated outcomes in caregiver participants - reduced depression and burden and enhanced caregiving mastery. It will also focus on sense of the completeness and adequacy of the training program, including the training methods, videos, and materials
16610|NCT04060342|Drug|GB1275|Oral
16611|NCT04060342|Drug|nab-paclitaxel and gemcitabine|IV infusion
16612|NCT04060342|Drug|pembrolizumab|IV infusion
16613|NCT04060329|Behavioral|coopeRATE Prompt|The coopeRATE Prompt intervention is a set of two questions delivered to patients immediately before the clinical encounter that elicit their concerns and goals.
16614|NCT04060316|Drug|Quinine|Quinine is given as a nasal spray using an atomizer
16615|NCT04060316|Drug|Placebo|Placebo is given as a nasal spray using an atomizer
16616|NCT04060303|Procedure|Perioperative surgical care|The ENRICH-US Protocol includes perioperative counseling and education, maintaining euvolumia through limited perioperative fasting and limited intraoperative fluid resuscitation, early enteral intake and mobilization, limited use of opioids, and non-routine use of surgical drains and tubes. Elements span the pre-, intra-, and post-operative experience for patients and involve care coordination among surgery, anesthesia, and nursing providers. Though individually simple, the concomitant implementation of the combined elements results in a markedly improved patient care experience that mitigates the physiologic stress of surgery and hastens recovery.
16617|NCT04060290|Other|Observational study|Observational study of this study, no interventions involved
16618|NCT04060277|Drug|Letermovir|Given as SOC
16619|NCT04060277|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
16620|NCT04060277|Other|Placebo|Given IM
16621|NCT04060264|Biological|BCD-148|"Active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period).~QW - once weekly"
16622|NCT04060264|Biological|Soliris|"Active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5.~Cycle 1 (induction therapy): 600 mg of eculizumab QW for the first four weeks; Cycle 2 (maintenance therapy): 900 mg of eculizumab at Week 5 and 900 mg of eculizumab every 14±2 days until Week 27 (inclusive) afterwards (dosing regimen for the main study period)."
16663|NCT04059913|Drug|FG-4592|Roxadustat will be dosed orally
16623|NCT04060251|Device|CyMedica e-vive™ System; CY-1000|"All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical."
16624|NCT04060251|Other|iGetBetter telemedicine physical therapy|Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
16625|NCT04060238|Diagnostic Test|Anomaloscope (colour vision test)|"The Heidelberg Multi Colour (HMC) Anolmaloscope (Oculus Inc., Dutenhofen/FRG) is used to differentiate between normal controls (normal trichromatopsia) and test subjects with protanopia (inherited red colour blindness)"
16626|NCT04060225|Other|Coffee|Starbuck's brand blonde roast coffee, 20 ounces
16627|NCT04060212|Other|Tuna fish|Six meals of tunafish (~200gms) will be consumed. Three meals will be consumed in a period of 14 days, and a subsequent 3 meals will be consumed within a 14 day period six month after the first 3 meals.
16628|NCT04060212|Dietary Supplement|prebiotic|Prebiotin brand prebiotic will be consumed at 8grms/day for a period of 75 days. The prebiotic administration will begin with the second grouping of 3 fish meals.
16631|NCT04060186|Procedure|Balloninflation|Patient will inflate into a ballon made by a handglove 2-3times/h from 8:00-20:00 after evacuation of chronic subdural hematoma.
16632|NCT04060173|Drug|ABP-671|ABP-671 is an investigational drug
16633|NCT04060173|Other|Placebo|Matching placebo
16634|NCT04060160|Other|Self- learning software that can detect acne lesions|Self- learning software that can detect acne lesions from patients who take a picture of their face every single day for 3 months with a secure mobile phone.
16635|NCT04060160|Other|Patient reported outcomes|Collection of patient reported outcomes and clinical data via a mobile electronic case report form
16637|NCT04060134|Other|InteguPly FD|InteguPly is to be used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
16638|NCT04060134|Other|SimpliDerm|SimpliDerm is to be used for the repair or replacement of damaged or inadequate integumental tissue or for other homologous uses of human integument.
16639|NCT04060108|Drug|MDMA|.75mg/kg, 1.5 mg/kg, Placebo
16640|NCT04060095|Procedure|standardized noxious stimulus under general anesthesia.|"50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.~At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.~At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient."
16641|NCT04060082|Other|Telephone Interview|Participants will be asked to answer questions about their experiences with FTD.
16642|NCT04060069|Other|Ringer Lactate|Fluids
16643|NCT04060043|Drug|Goserelin Acetate|The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
16644|NCT04060030|Drug|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
16645|NCT04060030|Other|Placebo|Placebo
16646|NCT04060017|Drug|Levoleucovorin Calcium|Liquid leucovorin calcium dosed by weight
16647|NCT04060017|Other|Placebo|Placebo
16648|NCT04060004|Other|Dry needling|Dry needling is a technique used by physiotherapists.
16649|NCT04060004|Other|Sham dry needling|Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.
16650|NCT04060004|Other|Electrotherapy + therapeutic exercise|Standard care of neck pain.
16651|NCT04059991|Biological|Influenza Vaccination|Only subjects vaccinated against influenza will be enrolled. The study itself is observational
16652|NCT04059978|Drug|CBD|800mg cannabidiol, single oral dose (8 ml oily solution)
16653|NCT04059978|Drug|Placebo|Placebo p.o, single oral dose (8 ml oily solution)
16654|NCT04059978|Drug|Remifentanil|Remifentanil 0.1 µg/kg/min i.v. for 30 min
16655|NCT04059965|Other|Panel Management for Anticoagulation Therapy|Patients in the intervention arm will receive notifications reminding them of upcoming labs and appointments. We hypothesize this will improve adherence and therapeutic control and reduce risk for bleeds and/or strokes
16656|NCT04059965|Other|Usual Care|Patients will receive standard, protocolized care in their respective anticoagulation clinics
16657|NCT04059952|Procedure|Electroconvulsive Therapy|Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
16658|NCT04059939|Other|Reading|Small group reading instruction
16659|NCT04059939|Behavioral|Anxiety Management|small group anxiety management skills instruction
16660|NCT04059939|Other|Classroom Business as Usual|Classroom Business as Usual
16661|NCT04059939|Other|Attention Control (math practice)|Attention Control (math practice)
16665|NCT04059900|Drug|Placebo|The medication was applied daily p.o. from day 0 to day 28. The dosage was 20 drops three times daily before the meals
16666|NCT04059887|Drug|Atezolizumab Injection [Tecentriq]|Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden
16667|NCT04059874|Drug|donafenib tablets|donafenib tablets 100mg qd dose group and donafenib tablets 100mg bid dose group
16668|NCT04059861|Diagnostic Test|Ultrasound|enrolled patients will be investigated by ultrasound two times, awake in the clinic and in narcosis before the surgery. For those with tongue cancer ultrasound will be used during the surgery to visualise the deep margin of the tumour.
16669|NCT04059848|Combination Product|tDCS(Intelect Mobile Stimulation and Combination, DJO, France)|
16670|NCT04059848|Combination Product|NMES(Enraf Nonius, Endomed-182, Netherlands)|
16671|NCT04059835|Other|OptiBra study|compare two different bra after breast cancer surgery
16672|NCT04059822|Other|Slow and deep breathing|Please see arm description
16673|NCT04059809|Device|Photobiomodulation|Photobiomodulation will be with the Cicatrillux (Cosmedical®) LED that contains 36 red light emitters in a 10x12 cm neoprene plate with 650 nm LED wave length whose optical spot diameter is 5 mm and with an average wave length of 2 ~ 5 mw for 10 minutes that will be placed over the area that will be irradiated for 10 minutes;
16674|NCT04059796|Device|Omega Gemini III Rev 2 Device|Eyes randomized to receive the Gemini III Rev 2 device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
16675|NCT04059796|Device|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
16676|NCT04059783|Drug|STW5 (Iberogast®, BAY98-7411)|The medication was applied 3 x 20 drops per day orally, before or at meals with some liquid, ideally three weeks
16677|NCT04059770|Drug|single dose of L-AmB|(i) single IV dose of 10 mg/kg of L-AmB on day 1;
16678|NCT04059770|Drug|2 doses of L-AmB|(ii) IV dose of 10 mg/kg of L-AmB on day 1, followed by 5 mg/kg of L-AmB on day 3;
16679|NCT04059770|Drug|2 weeks of L-AmB|(iii) IV dose of 3 mg/kg of L-AmB for 2 weeks.
16680|NCT04059757|Biological|Fecal Microbiota Transplantation (FMT)|1 dose = 30 capsules on day 1 of Fecal Microbiota Transplantation
16681|NCT04059744|Device|Fun-Knee|"Portable and low cost sensors are used in the Smart Knee Sleeve. The sensor system is composed of two inclinometers and one Bluetooth transmitter.~Fun Knee™ contains total knee replacement exercises that are gamified and supported on mobile device running on Android or iOS platforms. The mobile apps is able to capture the angle a and position data from the two inclinometers on smart knee sleeve.The free-sized knee sleeve prototypes are purchased and assembled by our collaborating vendor."
16682|NCT04059731|Dietary Supplement|Nutrition supplement|Administration twice a day of Survimed OPD or Impact/Atempero depending on arm assigned during 5 postoperative days
16683|NCT04059718|Behavioral|SCI Thrive Peer-Led Online Self-Management Program|6 week online course in self-management for individuals with spinal cord injuries. This was developed by a team using principles of cognitive behavioral techniques.
16684|NCT04059705|Behavioral|Dual-Task Training|The ThinkFIT intervention will involve two days per week participation in simultaneous cognitive and motor training activities, facilitated by the SMARTFit Multisensory FItness System.
16685|NCT04059692|Other|Cervical manipulation intervention|Cervical manipulative technique
16686|NCT04059692|Other|Placebo intervention|Sham intervention
16687|NCT04059679|Drug|Rivaroxaban 2.5 Mg Oral Tablet|EC aspirin (81mg qd) plus rivaroxaban (2.5 mg bid)
16688|NCT04059679|Drug|Aspirin 81 mg|EC aspirin 81 mg qd
16689|NCT04059666|Other|Investigational|Cow's milk-based Infant Formula with whey protein-lipid concentrate
16690|NCT04059666|Other|Control|Cow's milk-based Infant Formula
16691|NCT04059653|Device|Electrical stimulation|Electrical stimulation device
16692|NCT04059653|Other|Treatment as usual|GP treatment as usual
16693|NCT04059640|Device|LiquiBand FIX8 Open Hernia Mesh Fixation Device|"Subjects will undergo hernia mesh fixation and topical wound closure using the LiquiBand FIX8® OHMF device.~Subjects will be evaluated intra-operatively, post-operatively, at discharge, and at 6 weeks, 3, 6, and 12 months post-operatively. The Liquiband surgical study device is considered a permanent implant."
16694|NCT04059627|Device|Heart Track|"Description of the device: Wearable heart rate sensors are used in Heart-track, and a receiver on a smartphone app. Real-time wireless heart rate data is sent to paired mobile device with a wireless distance of up to 10m. The sensor is able to monitor a heart rate range of 30 to 240 beats per minute.~Another component of Heart-track is a Heart-track mobile app which captures and reflect real-time heart rate from the heart rate sensor. The mobile app also includes warm-up and cool down exercises that are gamified and supported on a smart-phone running on Android or iOS platforms.~The HR sensor will be purchased by our collaborator, Immersive Play Pte Ltd."
16695|NCT04059614|Procedure|HFNC; COT|"HFNC: high-flow nasal cannula therapy COT: conventional oxygen therapy"
16696|NCT04059601|Diagnostic Test|Magnetic resonance cholangiography|preoperative MRCP in acute cholecystitis before cholecystectomy
16697|NCT04059601|Diagnostic Test|Intraoperative cholangiography|Intraoperative cholangiography in acute cholecystitis during cholecystectomy
16698|NCT04059588|Drug|2141 V-11|intratumoral injection of 2141-V11
16699|NCT04059575|Other|Kinesio Taping (Performance Plus)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
16700|NCT04059575|Other|Kinesio taping (Gold Tex)|PP and GT taping applications were done by using kinesio taping muscle facilitation techniques to Quadriceps and Gastrosoleus muscles. I tape with a tension of 10-35% was used for muscle facilitation. All patients were assessed by an experienced physiotherapist, and the tapings were done by another experienced physiotherapist in order to provide a single blind structure of the study.
16734|NCT04059341|Device|Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT)|Five sessions of penile Low Intensity Extracorporeal Shockwave Therapy initiated three weeks after radical prostatectomy.
16735|NCT04059328|Procedure|Surgical training|This was a gyn laparoscopy training and simulation course
16701|NCT04059562|Combination Product|Combination of Lonsurf® and Campto®|"Trifluridine/Tipiracil (Lonsurf®) and Irinotecan (Campto®)~Trifluridine/Tipiracil will be administered at a dose of 25 mg/m2 / dose twice daily on days 1-5 followed by a 9-days recovery period from day 6 trough day 14 of each 14-days treatment cycle.~Irinotecan will be administered at the same time as Trifluridine/Tipiracil (Lonsurf®) on day 1 of each cycle at a dose of 180 mg/m2 / dose."
16702|NCT04059549|Behavioral|PartnerCHESS|"Patients randomized to the PartnerCHESS group will receive all A-CHESS services plus the following services from ABCT:~Urge discussion. Daily EMAs will track preconditions for relapse (urges), review urge reduction options on PartnerCHESS, and encourage discussions between partners on the causes of and ways to reduce urges.~Homework checklist. Tracks which interventions the couple is using/practicing, along with resources to help.~Relapse plan. Monitoring and reminders of steps planned for relapse prevention. Reminders. Reminders to notice something positive in partner, of reasons to stay sober, to take meds, etc.~Trigger identification and removal. During set-up, patient and partner enter triggers. PartnerCHESS will quiz couples on upcoming trigger events and remind them of ways to address each."
16703|NCT04059549|Behavioral|A-CHESS|A-CHESS control group
16704|NCT04059536|Device|Roxwood Anchoring Catheters|Anchoring catheters
16705|NCT04059536|Drug|Acetylsalicylic Acid|Oral Tablet
16706|NCT04059536|Drug|Heparin|Intravenous Injection
16707|NCT04059523|Drug|S6G5T-3|once daily
16708|NCT04059523|Drug|Retin-A® 0.1% Cream|once daily
16709|NCT04059510|Procedure|rectovaginal swab|Self taken rectal and vaginal swab
16710|NCT04059510|Procedure|pregnancy test|Urine pregnancy test
16711|NCT04059510|Procedure|Menstrual cup|Menstrual cup vaginal fluid collection
16712|NCT04059510|Procedure|Blood test|Venous blood sample
16713|NCT04059510|Other|Focus group|Focus group responses will be audio-recorded, transcribed, and analysed by developing a coding framework and identifying emerging themes
16714|NCT04059497|Behavioral|Exercise condition|Each participant in the intervention group can freely choose a handgrip of strength from 10 to 25kg which can be gripped with adequate grip strength. The PI will play the short video (5 minutes, www.youtube.com/watch?v=mZex2Wwy3fU) about the 10s-E for the participant, including (1) rapid grip-and-release the handgrip for at least 30 times in 10seconds in each hand, and (2) short-bout hand pushing and pulling exercises without handgrip. During the video, participants are asked to follow the 10s-E demonstrated by the medical professor. After the video, the PI will guide the participant to repeat the 10s-E for 5 times within the next 5 minutes. If participants feel pain in their hands, they can slow down the exercise. Between each exercise set, rest time for 10-20 seconds will be allowed. After practicing all these exercises, participants are asked to complete a post-intervention questionnaire
16715|NCT04059497|Behavioral|Healthy diet condition|The control group will watch two videos on healthy diet (https://www.youtube.com/watch?v=w_u4BYV2Okc). Similar to the 10s-E condition, they will complete a post-intervention questionnaire after the two videos.
16716|NCT04059484|Drug|SAR439859|Pharmaceutical form:Capsule Route of administration: Oral
16717|NCT04059484|Drug|Endocrine monotherapy as per physician choice|"Pharmaceutical form:~Route of administration:"
16718|NCT04059471|Biological|Yellow fever vaccine, Institut Pasteur|Full dose and de-escalating fractional doses
16719|NCT04059458|Device|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Device: Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + collagen membrane.
16720|NCT04059458|Drug|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Drug: Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain) Following open flap debridement of mandibular grade II furcation defects, regenerative therapy is performed with biphasic calcium phosphate + enamel matrix proteins.
16721|NCT04059445|Device|Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)|Regenerative therapy with biphasic calcium phosphate + collagen membrane.
16722|NCT04059445|Drug|Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)|Regenerative therapy with biphasic calcium phosphate + enamel matrix proteins.
16723|NCT04059432|Diagnostic Test|Tooth Wear and Musculoskeletal Disorders evaluation|"Evaluation of dental wear by BEWE (Basic Erosive Wear Examination: score 0-3) examination and Musculoskeletal disorders are listed by the NORDIC questionnaire developed by Kuorinka et al. (2001)"
16724|NCT04059419|Behavioral|PARQVE Program|Two days of lectures about knee OA, come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved, participate in a group therapy session with the psychologists and sessions with the physical educators.
16725|NCT04059419|Behavioral|Geriatric Care|Remain under geriatric care as usual
16726|NCT04059406|Drug|IONIS TMPRSS6-LRx|IONIS TMPRSS6-LRx administered subcutaneously
16727|NCT04059393|Other|Internet-Based Intervention|Complete web-based legacy intervention
16728|NCT04059393|Other|Best Practice|Receive standard of care
16729|NCT04059393|Other|Quality-of-Life Assessment|Ancillary studies
16730|NCT04059393|Other|Questionnaire Administration|Ancillary studies
16731|NCT04059367|Drug|NNC9204-1177|Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
16732|NCT04059367|Drug|Cocktail of 5 already approved drugs|5 medicines as tablets, capsules or syrup to be taken with water on Day 1 and Day 78 of the study
16733|NCT04059354|Behavioral|Speech therapy addressing phonology and motor learning|Determine the efficacy of a newly devised intensive speech treatment plan (DS-DxTx) focusing on vowels that combines efficacious treatment approaches to use with individuals with Down syndrome. The phonological speech intervention, Phonological Cycles approach, is designed for use with children with highly unintelligible speech and the speech motor learning intervention, Script training is a functional treatment to promote phrase level productions. Both approaches are documented to be efficacious with other speech disorders. The proposed approach takes into account the multiple deficits commonly present in individuals with DS, and based on the acoustic and perceptual finding on vowels from our VTLab. Acoustic and perceptual measures will be used to assess treatment efficacy.
16736|NCT04059315|Other|surgical treatment of facial bone fracture|oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
16737|NCT04059302|Behavioral|Internet-delivered Cognitive Behavioral Therapy for Insomnia|The therapy consists of 6 modules or 'cores' that are introduced on a weekly basis. The cores are designed to decrease sleep-inhibiting cognitions and behaviors, and to alter sleep-wake schedules.
16738|NCT04059289|Other|Posterior chamber intraocular lens (IOL)|This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
16739|NCT04059276|Diagnostic Test|MRI|We will examine chronic (>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
16740|NCT04059276|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
16741|NCT04059250|Device|Nobio composite|Nobio has developed a bactericidal composite, which does not leak out the bactericidal nano fillers
16742|NCT04059250|Device|traditional composite|traditional composite which has no bactericidal activities
16743|NCT04059237|Behavioral|Web based decision aid intervention|Decision aid tool (website) to assist young adult female cancer survivors in making decisions and preparing for family-building after cancer.
16744|NCT04059224|Drug|Trametinib|Trametinib 2 mg once a day by mouth.
16745|NCT04059224|Drug|Dabrafenib|Dabrafenib 50 mg twice a day by mouth. Dabrafenib can be uptitrated to 150 mg twice a day in case of dose-limiting trametinib-associated skin toxicity.
16746|NCT04059211|Diagnostic Test|Urinary dipstick|Sensitivity and specificity of urinary dipstick for proteinuria in emergency departments
16747|NCT04059198|Drug|Inarigivir soproxil|Inarigivir soproxil 400 mg tablets
16748|NCT04059198|Drug|Tenofovir alafenamide fumarate (TAF)|Tenofovir alafenamide fumarate 25 mg tablet
16749|NCT04059185|Other|Triple P-Level 2|Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.
16750|NCT04059185|Other|Play Nicely|"Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes."
16751|NCT04059185|Other|Usual care|"Our usual care control group participants receive a resource and referral list for local social services"
16752|NCT04059172|Drug|Ibuprofen 200 mg and acetaminphen 650 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
16753|NCT04059172|Drug|Ibuprofen 200 mg|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
16754|NCT04059172|Drug|Placebo oral tablet|"For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively."
16755|NCT04059159|Device|Connected Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
16821|NCT04058678|Other|Without intervention|Women with normal ovarian reserve will not be treated in anyway, thus, randomization will not be necessary.
16822|NCT04058665|Device|Floseal|Hemostatic agent
16756|NCT04059146|Other|Pain Education and Exercise|Participants will be randomly assigned to a pain education group, following biopsychosocial model, or standard of care education, following biomedical model. The goals of the pain education intervention are for patients to 1) address fear of movement and pain catastrophizing specific to AT, 2) learn about the neurophysiology of pain, 3) develop coping skills, and 4) promote exercise participation through pacing. This program enables patients to have a conceptual change in their understanding of what causes pain, gain greater control over the psychological aspects of pain, and reduce the perceived threat of chronic pain. Participants will be given weekly online exercises to promote engagement with the material, give individual feedback to participants, and assess understanding. In person sessions with the physical therapist will reinforce self-learning and application to a home exercise program.
16757|NCT04059146|Other|Standard Education and Exercise|The comparison group will be given education based on standard of care resources that primarily utilize a biomedical model, which assumes that AT pain is primarily caused by tissue damage. The videos, handouts, and exercises will be equivalent to the pain education group in terms of time and learning requirements.
16758|NCT04059133|Device|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-Sham arm|Sham treatment (shock wave probe w/o energy)
16759|NCT04059133|Device|DUOLITH SD1-TOP focused shock wave system (STORZ MEDICAL EvoTronTM, GA)-LiESWT arm|Low intensity extracorporeal low energy shock wave treatment (shock wave probe w/ energy)
16760|NCT04059120|Other|Experimental group whit specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining
16761|NCT04059120|Other|Control group whit out specific stretching|The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
16762|NCT04059107|Device|3D Printed Myoelectric Prosthetic Device|3D Printed Myoelectric Prosthetic Device
16765|NCT04059081|Drug|Obinutuzumab|"Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles."
16766|NCT04059042|Behavioral|Music Listening|Participants will have pain threshold testing while listening to silence, music, or nature sounds.
16767|NCT04059029|Procedure|Bariatric surgery|During bariatric surgery, all patients would undergo a wedge liver biopsy under laparoscopic guidance.
16768|NCT04059016|Other|MBC4OUD|This computer software program consists of patient-completed self reports for screening and diagnosis of opioid use disorder among primary care patients and provides web-based clinical decision support to primary care providers for provision of pharmacotherapy for opioid use disorder.
16769|NCT04059003|Drug|Taxanes or/and anthracycline-based therapy|Taxanes or/and anthracycline-based therapy will be used in this group. That is, intravenous injection of 90 mg/m2 epirubicin (trade name: Pharmorubicin, Pfizer, Shanghai, China; drug approval number: H20100155) + 135 mg/m2 paclitaxel liposome (trade name: Taxotere, Sanofi (Hangzhou) Pharmaceutical Co., Ltd., Hangzhou, China; drug approval number: J20090104), every 3 weeks as a course of treatment. The efficacy will be evaluated every 2 courses. After the 6th course, mastectomy will be performed according to the patient's conditions.
16770|NCT04058990|Device|Device: Paclitaxel-Coated PTCA Balloon Catheter|Percutaneous Transluminal Coronary Angioplasty
16771|NCT04058990|Device|SeQuent Please Drug Eluting Balloon Catheter with Paclitaxel|Percutaneous Transluminal Coronary Angioplasty
16772|NCT04058977|Other|Power training|Progressive exercise protocol with focus on velocity of movement
16773|NCT04058964|Biological|Pegylated Recombinant Human Hyaluronidase PH20|Given SC
16774|NCT04058964|Biological|Pembrolizumab|Given IV
16775|NCT04058951|Other|High Animal Protein Diet (HAPD)|A diet containing 2,0 g protein per kilo body weight per day from primarily animal origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on beef isolate.
16776|NCT04058951|Other|High Plant Protein Diet (HPPD)|A diet containing 2,0 g protein per kilo body weight per day exclusively from plant origin. To accommodate the high protein intake, the diet is supplemented with protein powder based on soy isolate.
16777|NCT04058938|Behavioral|Educational handout instrument|The handout was single-paged (front and back), and was titled Pain After Surgery: What to Expect. The handout starts with information on rating pain and expectations for control of pain, not complete absence of pain, after surgery. Mutli-modal approach to pain control is then discussed, including pharmacologic and non-pharmacologic methods that may be used for pain control by the perioperative team and postoperatively.
16778|NCT04058938|Behavioral|Control|Standard patient counseling
16779|NCT04058925|Device|NIRS device|Application of NIRS electrode to forehead and thenar eminence.
16780|NCT04058912|Genetic|PTEN-AKT-FOXO3 Gene Expression|In the patient and patient control groups, 0.5 mm tissue strip will be removed for pathology from the cyst wall removed during surgery. and tissue samples will be stored in phosphate buffered saline at -80 C and PTEN-AKT-FOXO3 gene expression level will be evaluated by RT-PCR analysis.
16781|NCT04058899|Drug|Dexmedetomidine|sedative and might be analgesic drug
16782|NCT04058899|Drug|Nalbuphine|agonist antagonist narcotic
16783|NCT04058899|Device|infusion pump|infusion pump for titration of fluid containing drug infusion
16823|NCT04058652|Device|transcutaneous electrical nerve stimulation (TENS) unit|The transcutaneous electrical nerve stimulation (TENS) unit is a noninvasive, inexpensive, battery-operated device that was originally designed to provide modulation of the afferent nervous system to relieve pain. By providing alternating current through cutaneous electrodes, TENS activates large-diameter afferent fibers of the nervous system (A-delta, A-beta, C fibers), whose ascending signals are subsequently relayed to the central nervous system.
16824|NCT04058639|Procedure|"custom felt relief"|Felt is adjusted to the wound by cutting it in different ways and layers once every week
17607|NCT04052204|Drug|enzalutamide|androgen receptor inhibitor
16784|NCT04058886|Behavioral|Telephone-delivered Mindfulness|The telephone-delivered mindfulness training intervention that will incorporate the following elements: 1) training for primary caregivers (CG) and their caregiving partner (CP) in a telephone-based mindfulness training intervention; 2) groups of up to eight participants (four CG-CP pairs) plus an instructor, on a shared telephone line; and 3) training in a 8-week, modified MBSR program, which places additional emphasis on training in the following: a) mindful experiencing, including mindfulness of feelings and body sensations; b) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking; and c) mindful compassion for self and others. Additionally, homework assignments will involve listening to exercises on a dial-in telephone line; and assignments for CG-CP dyads (e.g. mindful listening and communication practices) as well as CG mindfulness practices in the presence of care recipients (e.g. mindful eating, and mindful listening).
16785|NCT04058873|Drug|Levonorgestrel 1.5mg|Levonorgestrel 1.5mg for pericoital use
16786|NCT04058860|Device|NIRS monitoring|Cerebral and somatic near-infrared spectroscopy (rScO2) measurements
16787|NCT04058860|Device|Cox monitoring|Cerebral autoregulation monitoring
16788|NCT04058860|Device|Sublingual microscopy|Sublingual mucosal microcirculation measurements during surgery using side dark field (SDF) imaging
16789|NCT04058847|Other|Your Heart Forecast|1 year follow up with Your Heart Forecast and a follow-up email every 2 weeks.
16790|NCT04058834|Drug|NNC0385-0434|Healthy volunteers and patients will receive one injection s.c. (subcutaneously, under the skin)
16791|NCT04058834|Drug|Placebo (NNC0385-0434)|Healthy volunteers will receive one injection s.c.
16792|NCT04058821|Diagnostic Test|Novel MRI scan - 7 days post injury|"A turbo spin-echo localiser (20 seconds)~Single-shot echo planar diffusion tensor imaging (7 minutes)~3D constructive interference in steady state (CISS, 6 minutes)~Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
16793|NCT04058821|Diagnostic Test|Novel MRI scan - 14 days post injury|"A turbo spin-echo localiser (20 seconds)~Single-shot echo planar diffusion tensor imaging (7 minutes)~3D constructive interference in steady state (CISS, 6 minutes)~Phase-sensitive inversion-recovery gradient echo with cardiac gating (4 minutes)"
16794|NCT04058821|Diagnostic Test|Functional MRI scan - 6 months post brachial plexus exploration|"Continuous whole brain echo-planar imaging~High-resolution T1-weighted imaging of the brain~Bilateral magnetic resonance spectroscopy (12 minutes)"
16795|NCT04058821|Diagnostic Test|Functional MRI scan - 12 months post brachial plexus exploration|"Continuous whole brain echo-planar imaging~High-resolution T1-weighted imaging of the brain~Bilateral magnetic resonance spectroscopy (12 minutes)"
16796|NCT04058808|Other|Weight Watchers|online or in a weekly wellbeing workshop, there is a fee of £12.95 per month, this is a healthy lifestyle programme based on food items having a point attached to them depending on the calorie, fat and sugar content. Each member has a specific number of points per day to use on their meals. The healthier foods have fewer points therefore you can eat more of them.
16797|NCT04058808|Other|Slimming world|online or in a weekly class, there is a fee of £5 per week. Free foods can be consumed freely are low fat healthy options, healthy extras (bread/milk/pulses) can be consumed in moderation. Higher fat, higher calorific foods have a number of SYNS attached, each person has a set number of SYNS (sins) per week to use as they wish.
16798|NCT04058808|Other|Leeds 'One You'|a free weekly 1 hour class (run in various places across Leeds), a variety of topics are covered, from food labels to the Eat well guide. This eating plan is based on calorie counting.
16799|NCT04058808|Other|NHS Choices|a free on line programme that is based on restricting calories using the Eat well guide and encouraging physical activity.
16800|NCT04058808|Other|5:2 diet|5 days of eating normal calories (2000 Female, 2500 Male) and 2 days eating restricted 500 calories (this may be amended depending on the patient).
16801|NCT04058808|Other|Individuals own personal plan|the participant will explain in detail their own designed plan and this will be documented on the paper records.
16802|NCT04058795|Behavioral|Cancer Distress Coach (CaDC) App|an app that provides participants with tools to manage their stress in the moment they experience it.
16803|NCT04058795|Behavioral|CaDC + mCoaching|The CaDC app plus weekly clinician support which provides support in navigating the app, encouraging adherence to the use of the CaDC, and providing guidance in choosing treatment strategies.
16804|NCT04058795|Behavioral|mCBT|10- sessions with a therapist via FaceTime or Skype
16805|NCT04058782|Other|Imaging evaluation for vascular assessment|At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
16806|NCT04058769|Device|Premedication Guide|Software with guidelines recommendations for preoperative assessment
16807|NCT04058756|Drug|PDR001|PDR001
16808|NCT04058743|Device|TKA with nickel free components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
16809|NCT04058743|Device|TKA with standard cobalt chromium components|Patients will be randomized to receive either the standard cobalt chromium components or nickel free components
16810|NCT04058730|Procedure|Laparoscopic Roux en Y Gastric by pass surgery|
16811|NCT04058730|Procedure|Laparoscopic Sleeve Surgery|
16812|NCT04058730|Other|Standard Medical Management|
16813|NCT04058717|Other|Normal Nicotine Content research cigarettes|Research cigarettes with 11.6 mg nicotine/cigarette.
16814|NCT04058717|Other|High Nicotine e-cigarette|E-cigarette containing high nicotine e-liquid
16815|NCT04058717|Other|Very Low Nicotine Content research cigarettes|Research cigarettes with 0.2 mg nicotine/cigarette.
16816|NCT04058717|Other|Zero Nicotine e-cigarette|E-cigarette containing zero nicotine e-liquid
16817|NCT04058704|Drug|Icotinib|125mg Tid/375mg per day
16818|NCT04058704|Radiation|SRS/WBRT/HA-WBRT/SMART|＞3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
16819|NCT04058691|Device|Surgical repair|Open surgery
16820|NCT04058678|Drug|Danazol/Placebo|This group will be randomized 1:1 for either inactive substance or Danazol, according to a computer-generated randomization list prepared. Women will be treated with Danazol/Placebo oral way for 3 months.
17608|NCT04052191|Biological|MCRcI® stem cells|Intra-Coronary Administration of MCRcI® stem cells
16825|NCT04058639|Procedure|standard relief treatment|Felt in the shape of a letter U is put around the wound once every week.
16826|NCT04058626|Diagnostic Test|Transcutaneous pressure of oxygen (TcPO2)|Measurements will be taken from the dorsum of the foot using an automated machine equipped with Clark electrodes.
16827|NCT04058626|Diagnostic Test|Toe Brachial Pressure Index (TBPI)|TBPI will be measured using the photoplethysmography (PPG) method, employing an infrared sensor placed on the hallux and index finger.
16828|NCT04058626|Diagnostic Test|Podiatry Ankle Duplex scan (PAD-scan)|Podiatry ankle duplex scan (PAD-scan) involves using an ultrasound machine to visualise the anterior and posterior tibial arteries at the ankle.
16829|NCT04058626|Diagnostic Test|Duplex Assist|Continuous Doppler device which gives visual display of arterial spectral waveform at the ankle.
16830|NCT04058626|Diagnostic Test|Ankle Brachial Pressure Index (ABPI)|A sphygmomanometer-cuff placed at the ankle and a handheld continuous wave Doppler device will be used to measure the systolic pressure of the DPA and PTA.
16831|NCT04058613|Drug|ALB Protein, Human|Albumin infusions will be given at a dose of 40 g twice weekly till a steady albumin level of 4.0g/dl is reached followed by 100ml of 20% albumin at least once in two weeks to maintain a steady albumin level of 4.0g/dl along with the standard medical therapy
16832|NCT04058613|Other|placebo|placebo
16833|NCT04058600|Behavioral|Virtual Reality Software|Patients will be exposed to a virtual reality software that simulates the hospitalary enviroment, from admission to the operating room and the recovery room.
16834|NCT04058587|Drug|Simmitinib|"The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration.~The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage.~The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days)."
16835|NCT04058574|Device|Proprioception measurement on isokinetic dynamometer|Proprioception measurement on isokinetic dynamometer using joint position sense (JPS) and the threshold to detection of passive motion (TTDPM)
16837|NCT04058548|Diagnostic Test|Sit to stand test|Participants will complete a sit to stand test in addition to a 6 minute walk test
16838|NCT04058535|Biological|Eylea|Aflibercept
16839|NCT04058535|Biological|ALT-L9|Aflibercept biosimilar
16840|NCT04058522|Other|Rotator cuff rehabilitation classes|
16841|NCT04058522|Other|Individual Physiotherapy|
16842|NCT04058522|Drug|Triamcinolone Injection|Subacromial Injection 40mg/1ml
16843|NCT04058509|Combination Product|Focused shockwave therapy|3 session of shockwave therapy. The wave is focused through a standoff and transmitted into the tissue. Enhanced Energy: 0.01 - 0.55mJ/mm2. Broad Frequency Range: 1 - 8Hz. 12.5 cm penetration with pinpoint focus. The patient will be treated in the lateral decubitus position. The shock wave will focus on the area of maximal tenderness, which will be treated in a circumferential pattern.
16844|NCT04058496|Other|Blood sampling|Five Timepoints: baseline (pre-operative), ICU admission, 4 hours after ICU admission, 8 hours after ICU admission, 48 hours after ICU admission
16845|NCT04058483|Other|Hypnotizability testing|Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
16846|NCT04058470|Drug|Toripalimab|Toripalimab will be administered every 3 weeks in combination with R-CHOP for 6 cycles.
16847|NCT04058470|Drug|R-CHOP Protocol|R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP for 6 cycles.
16848|NCT04058457|Device|DBS|Patients are tested pre-operatively and the post-operatively with their implanted neurostimulators ON and OFF. DBS implantation itself is part of routine care, and not part of the study.
16849|NCT04058444|Combination Product|ERAS protocol|No routine bowel preparation Antibiotics prophylaxis PONV (Postoperative Nausea and Vomiting) prophylaxis Spinal anesthesia Post- Cesarean analgesia (Acetaminophen 1g IV q6h, Tramadol 50mg IV q6h, Quadratus lumborum Block Oral pain relief medication Pain scores every day (VAS) Hospital length of stay Patient satisfaction
16850|NCT04058431|Other|Osteopathic Manipulative Treatment|Osteopathic manipulative treatment (OMT) is defined as the therapeutic application of manually guided forces by an osteopathic physician to improve physiologic function and/or support homeostasis that has been altered by somatic dysfunction. Somatic (body framework) dysfunction or altered function of related components is observed in the skeletal, arthrodial and myofascial structures, and their related vascular, lymphatic, and neural elements. Techniques can use a direct method where the restrictive barrier is engaged and a final activating force is applied to correct the somatic dysfunction, or an indirect method where the restrictive barrier is disengaged and the dysfunctional body part is moved away from the restrictive barrier until tissue tension is equal in one or all planes and directions
16851|NCT04058431|Other|Control- No Intervention|This group will refrain from getting OMT while in the study.
16852|NCT04058418|Other|Survey Administration|Completion of a short survey.
16853|NCT04058405|Behavioral|Observational|Cross-sectional observations
16854|NCT04058392|Biological|Camu Camu Capsules|Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
16855|NCT04058379|Radiation|CT scan|3 ct scans : D0, D1 and D3
16856|NCT04058366|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration.
16857|NCT04058366|Drug|IVA|150-mg tablet for oral administration.
16858|NCT04058353|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
16859|NCT04058353|Drug|IVA|150-mg tablet for oral administration
16860|NCT04058353|Drug|TEZ/IVA|FDC tablet for oral administration
16908|NCT04058041|Procedure|Surgery and neural mobilization|following the surgery patients will be treat with neural mobilization exercises.
16861|NCT04058340|Dietary Supplement|lactizole nebulization|Lactizole is generally recognized as safe: GRAS Flavor and Extract Manufacturers Association ( numer: 3773 ) Lactizole solution for nebulization was calculated based on dose-response curves; 150ppm was chosen as minimal effective (decreased sweet taste perception) and safety ( lack of FEV1 changes after nebulization)
16862|NCT04058340|Other|Placebo|0.9% NaCl solution in nebulization
16863|NCT04058327|Diagnostic Test|blood ammonia test, neurophysiological/psychological tests, blood markers.|Let the patients do neuropsychological/psychological tests and use blood test for ammonia and blood markers.
16864|NCT04058327|Drug|HE drug treatments in clinical real world|record the HE drug treatments in clinical real world if doctors use them
16865|NCT04058314|Device|Gemini IV|Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
16866|NCT04058314|Device|Control Eye|Control eyes will receive an approved monofocal or toric IOL post cataract extraction
16867|NCT04058301|Other|Text message information|Geographically proximate resources delivered by text message
16868|NCT04058288|Device|High-definition Transcranial Direct Current Stimulation|Stimulation sessions will be conducted on 2 different visits separated by 2-week gap. In a crossover design, Anodal HD-tDCS will be delivered either in Active/Sham mode (during the first visit) and Sham/Active during the second visit in a 4x1 ring configuration (center electrode being Anode and the surrounding 4 electrodes being cathodes) over the affected motor area.
16869|NCT04058275|Other|Draw blood (phlebotomy, 83 ml)|Draw 83 ml of blood
16870|NCT04058262|Other|Meditation presential|Facilitator-guided meditation in groups or individually, in 45-minute sessions twice a week for 2 weeks, in a quiet room with controlled light and temperature, and comfortable cushions and chairs.
16871|NCT04058262|Other|Reiki|Reiki will be performed in 45-minute sessions twice a week for 2 weeks then in a quiet room with controlled brightness and temperature.
16872|NCT04058262|Other|Meditation (app)|Mindfulness meditation guided through 10-15 minute audio using app, to be practiced daily at home.
16873|NCT04058262|Other|round of conversation|The Round of Conversation will take place twice a week, lasting 45 minutes, for two weeks thereafter, at the same clinic, where women will talk about their lives, their needs, how they handle reported situations and how also your skills and preferences.
16874|NCT04058249|Device|Accelerated intermittent theta-burst stimulation over right DLPFC|"All participants will receive accelerated intermittent theta-burst stimulation to the right DLPFC. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to right-DLPFC using the Brainsway stimulator."
16875|NCT04058236|Other|human albumin 5%|Human Albumin 5% will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
16876|NCT04058236|Other|gelofusine.|Gelofusine will be given as fluid management for this group in accordance to goal directed therapy and guided by stroke volume variation of approximately 12-15%. This percentage of SVV has been validated as a threshold above which fluid administration increases stroke volume with an area under the receiver operating characteristics curve reported at 0.87. If the SVV remains more than 15% for more than 2 minutes, 250ml of fluid replacement according to patient group will be given. These boluses are given in aliquots over 30 min to avoid effects of rapid volume expansion. and the same fluid and technique will be carried out within 24 hours intra and post operatively in the Intensive Care Unit (ICU). All clinical parameters and fluids including blood that will be given will be recorded.
16877|NCT04058223|Device|Hemorrhoidopexy|stapled hemorrhoidopexy
16878|NCT04058210|Drug|ELX/TEZ/IVA|Fixed-dose combination tablet for oral administration.
16879|NCT04058210|Drug|IVA|150-mg tablet for oral administration.
16880|NCT04058197|Drug|Deferoxamine Product|Deferoxamine Intradermal Delivery Patch
16881|NCT04058197|Other|Placebo|Placebo Patch
16882|NCT04058171|Diagnostic Test|Treadmill walking test|Participants will be invited to walk on a treadmill at a speed of 1,2 mph for at most five minutes for both conditions (straight walking posture and inclined walking posture). Each walking posture condition will be followed by a rest time of five minutes in sitting position. Conditions were randomized in each group using a computer-generated sequence.
16883|NCT04058158|Drug|SB12 (proposed eculizumab biosimilar)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
16884|NCT04058158|Drug|Soliris (eculizumab)|600 mg IV every week for first 4 weeks and 900 mg for the fifth week, followed by 900 mg every 2 weeks thereafter
16885|NCT04058145|Drug|AMD3100|AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
16886|NCT04058145|Drug|Pembrolizumab|"Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor."
16887|NCT04058132|Drug|Sildenafil Citrate 50Mg Tab|sildenafil citrate (Viagra®, Pfizer. Inc., NY, NY). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo[4,3-d]pyrimidin-5-yl)-4- ethoxyphenyl]sulfonyl]-4-methylpiperazine citrate. Sildenafil citrate is a white to off-white crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7. For this study, we will use 50 mg tablets for the single dose studies.
16911|NCT04058015|Other|Stress-induced hyperglycemia|Stress-induced hyperglycemia (SIH)was defined as a serum glucose ≥ 200 mg/dL in the patients without Diabetes mellitus.
16888|NCT04058132|Device|functional Near-infrared Spectroscopy (fNIRS)|Functional Near-Infrared Spectroscopy (fNIRS): Functional near-infrared spectroscopy (fNIRS) a noninvasive technique that can measure cerebrovascular reactivity (CVR) will be used to measure regional cerebral blood flow and cerebrovascular reactivity in the brain. The device (fNRIS100, fNIR Device LLC), uses laser emission diodes (730nm and 850nm)which in a headband that is worn on the front of the scalp and forehead. Surrounding detectors a few centimeters away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes. fNIRS will be performed twice at each study visit, once before and once about 45 minutes after single dose administration of sildenafil 50 mg.
16889|NCT04058132|Other|Carbon Dioxide (CO2) 5%|"Carbon Dioxide (CO2) 5% mixed with room air. Both the fNIRS procedure and one Magnetic Resonance Imaging (MRI) session at visits that include imaging will be done with a hypercapnia challenge for comparison.~CO2 (hypercapnia) challenge is similar to holding one's breath. Participant will wear a nose clip and a mouth breathing apparatus while in the MRI scanner or sitting in a chair during the fNIRS procedure.~During the 7-minute hypercapnia procedure, participants will breathe room air and then switch to room air mixed with 5% CO2, from one to the other for one minute each."
16890|NCT04058132|Other|Neuropsychological Assessments|TBI Neuropsychological Assessments: Study participants will be administered a set of Neuropsychological Tests designed by the NINDS Common Data Elements (CDEs) initiative for TBI, in order to provide a comprehensive and broad assessment of deficits commonly found after TBI. We anticipate that the neuropsychological battery will require approximately 1 hour to complete. The measures (pencil and paper exercises, questionnaires, and interview by the examiner) to be administered are: Glasgow Outcome Scale-Extended (GOS-E). Learning trials portion of the California Verbal Learning Test (CVLT-II): The Trail Making Tests A and B (TMT): Subsets of the Wechsler Adult Intelligence Scale (WAIS-IV) (Digit Symbol and Symbol Search): Behavioral Symptoms Inventory-18: Satisfaction with Life Scale (SWLS): Word Reading subtest of Wide Range Achievement Test (WRAT)-4: Rivermead Post-Concussion Symptom Questionnaire.
16891|NCT04058132|Drug|Gadolinium contrast infusion|Gadolinium contrast infusion: Brain MRI with gadolinium contrast: Dynamic contrast-enhanced (DCE) MRI with intravenous gadolinium-based contrast agents (GBCAs) to measure their transfer rate between intravascular and extravascular compartments as a marker of blood-brain barrier (BBB) permeability. For the DCE sequence, the participant is injected with the contrast agent through a heplock/iv in the scanner and the sequence takes about 15 min. Half-life of gadolinium is about 1 ½ hours and 90-98% clearance from the body in 24 hours in people with normal kidney function.
16892|NCT04058132|Procedure|Blood sample collection for research purposes|Serum and plasma (5 ml each) will be collected at at each study visit 10 m or 2 tsp. per visit or up to 40 ml or 8 tsp. over the 180 day course of the study). Samples will be collected by study personnel.
16893|NCT04058132|Other|Structural brain Magnetic Resonance Imaging (MRI|"Structural brain Magnetic Resonance Imaging (MRI): The scanner used is a 3.0 Tesla MR (Model 750, General Electric Healthcare), which is equipped with a high-performance gradient subsystem and a 32-channel head coil (General Electric Healthcare). These scans involve lying still in a scanner for several minutes at a time which is tube shaped, using magnetism to take images of the brain. There is no radiation in MRI. The participants will have up to 3 research brain MRIs. Healthy controls will have 1 MRI session.~Common TBI MRI techniques will be performed. Block-design BOLD fMRI during which there will be a 7 minute hypercapnia challenge will be done to assess brain blood flow and measure cerebral vascular reactivity (CVR)."
16894|NCT04058119|Behavioral|Mind-body therapies|Sessions of body-mind therapies (yoga, qigong and pilates), oriented by certified instructors. Every sessions will be 60-minutes long, biweekly, with a total duration of 6 months.
16895|NCT04058106|Procedure|A patient who need the cerebral artery aneurysm clipping surgery|A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
16896|NCT04058093|Behavioral|Functional Training Program|"Functional training program (FTP) include:~Functional training sessions will be oriented by graduates or masters in sport with the supervision of a sports medicine doctor;~Group nutrition counseling, in the form of healthy cooking classes direct by nutritionists with the support of culinary students."
16897|NCT04058080|Other|Bikram Yoga|Participants in the Bikram yoga group were asked to attend two classes per week for 8 weeks (16 classes in total) at a local affiliated Bikram yoga studio. Certified Bikram yoga teachers instructed all classes using a scripted instructional dialogue. Each 90-min class was held in a temperature-controlled room (40.6C, 40% humidity). The yoga studio regularly offered 22 class times per week, all of which were accessible to participants.
16898|NCT04058080|Other|Aerobic Exercise|Participants in the aerobic exercise group were asked to attend two group aerobic exercise classes per week for 8 weeks (16 classes in total) at the Kingston Family YMCA. They were provided with a modified schedule of the YMCA group classes, which included only classes with a strong aerobic component and excluded those involving yoga, pilates, or cycling. Classes involving the following components were available to participants: choreography-based cardio, aerobics, light muscular conditioning, and stretching; cardio, plyometric, and strength training exercises; high intensity aerobic exercise with intermittent rest periods; circuit-based cardio and strength training exercises; stepper-based exercises; and Latin-inspired dance/fitness. Classes were 50-60 minutes in duration. Participants were able to attend any of the offered classes each week. Participants had approximately 18-22 classes in total to choose from each week.
16899|NCT04058067|Drug|Brolucizumab|5 x every 6 weeks loading then every 12 weeks or every 8 weeks maintenance
16900|NCT04058067|Drug|Aflibercept|5 x every 4 weeks loading then every 8 weeks maintenance
16901|NCT04058054|Device|KeraStat® Cream|Administered 0.025 gm of KeraStat Cream per subject on day 1 of the study.
16902|NCT04058054|Device|KeraStat Gel|Administered 0.025 gm of KeraStat Gel per subject on day 1 of the study.
16903|NCT04058054|Device|Biafine|Administered 0.025 gm of Biafine per subject on day 1 of the study.
16904|NCT04058054|Drug|Histamine|Administered 1 drop of Histamine Dihydrocl (6 mg/mL) per subject on day 1 of the study.
16905|NCT04058054|Drug|Saline (0.9% NaCl)|Administered 1 drop of saline per subject on day 1 of the study.
16906|NCT04058041|Procedure|Neural Mobilization|neural exercise Will be performed in the patients
16907|NCT04058041|Procedure|Surgery|open or endoscopic surgery will be permed in the patients with tunnel carpal syndrome
16912|NCT04058015|Other|Diabetic hyperglycemia|Diabetic hyperglycemia (DH) which indicated a serum glucose ≥ 200 mg/dL in patients with Diabetes mellitus.
16913|NCT04058015|Other|Diabetic normoglycemia|Diabetic normoglycemia (DN), which was defined when there was a serum glucose < 200 mg/dL in the patients with Diabetes mellitus.
16914|NCT04058015|Other|Non-diabetic normoglycemia|Non-diabetic normoglycemia (NDN) indicating a serum glucose < 200 mg/dL in patients who were absent of Diabetes mellitus.
16915|NCT04058002|Other|Multiprofessional treatment and Educational Program Associated (EPA+C+BCAA) with supplementation of creatine and BCAA.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of BCAA (1,200 milligrams of leucine, 600 milligrams of isoleucine and 600 milligrams of valine per dose)
16916|NCT04058002|Other|Multiprofessional treatment and Educational Program Associated (EPA+C) with supplementation of creatine only.|17 patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times). Patients will be supplemented with creatine 5 grams and maltodextrin 100g, 30 minutes before training. At breakfast they will also ingest 5 grams of placebo.
16917|NCT04057989|Drug|ketamine|
16918|NCT04057976|Diagnostic Test|Probabilistic diffusion tensor tractography|Patients enrolled in this study will undergo probabilistic diffusion tensor tractography (additional MRI sequence) preoperatively in order to determine whether this it is possible to determine the course of the facial nerve.
16919|NCT04057963|Other|Conventional plus Functional Inspiratory Muscle Training Group|functional inspiratory muscle training is an exercise program that practises gradual training of the diaphragm muscle.
16920|NCT04057963|Other|Conventional Physiotherapy Program|conventional physiotherapy is a treatment program consisting of evidence based modalities as mobilization and specific exercises.
16921|NCT04057950|Other|cosmetic product|Disulfure de sélénium versus placebo formula
16922|NCT04057937|Drug|Apremilast|Apremilast
16923|NCT04057937|Drug|Placebo|Placebo
16924|NCT04057924|Other|abstention from CIN2 treatment and surveillance for at least 2 years|Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
16925|NCT04057911|Device|Active NIBS|Cathodal noninvasive brain stimulation will be given for 20 mins.
16926|NCT04057911|Device|Sham NIBS|The electrode placement will be same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation
16927|NCT04057898|Drug|MN-166|Subjects will take MN-166 with a stable dose of riluzole for 12 months followed by a 6-month open-label extension phase.
16928|NCT04057898|Drug|placebo|Subjects will take matching placebo with a stable dose of riluzole for 12 months followed by a 6-month open-label extension phase.
16929|NCT04057885|Device|Orthosensor™ VERASENSE™ Knee System|A group of patients will receive a total knee arthroplasty using the Orthosensor device
16930|NCT04057872|Device|Therapeutic plasma exchange|The removed plasma is 'exchanged or replaced' with either IV fluids, albumin, and/or Fresh frozen plasma
16931|NCT04057846|Device|EUS guided transgastric drainage|Whenever possible, randomisation and intervention shall be postponed until 4 weeks after onset of pancreatitis in line with international guidelines. All procedures in this study shall be performed by three experienced endoscopists (PNS, EFH, SN), who all have an extensive experience in endoscopic ultrasound (EUS-) guided drainage of pancreatic collections and the use of self-expanding stents. They have together performed more than 300 endoscopic, transmural drainage and debridement procedures in patients with WON since 2005. Endosonography-guided, transgastric drainage of the WONs shall be performed using a curve-linear echoendoscope (endoscope: Olympus GF-UCT180; ultrasound scanner: Hitachi Arietta 850 or Olympus EU-ME2). All collections shall be treated by single tract transmural cystogastrostomy (single-gate technique). T
16932|NCT04057833|Drug|E-CEL UVEC|Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
16933|NCT04057820|Other|Finnegan Neonatal Abstinence Scoring Tool|The FNAST is a scoring system used in neonatal units to initiate and guide therapy in infants of opiate-dependent mothers.
16934|NCT04057820|Other|Eat, Sleep, Console (ESC) care tool|The ESC care approach emphasizes parental involvement, simplifies the assessment of infants with NOWS and focuses interventions on non-pharmacologic therapies.
16935|NCT04057807|Drug|LPS|LPS (0.4 ng/kg)
16936|NCT04057794|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by an in-person visit by site clinician/physician
16937|NCT04057794|Device|Lab Assay for seven genetic variants for Parkinson's Disease|Counseling provided to participant by telephone from Genetic Specialists from Indiana University
16938|NCT04057781|Procedure|Dry Needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and the subject will lie on a treatment table without moving arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
16939|NCT04057781|Procedure|Dry needling with Intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the trigger point(s) of the muscle. The needles will be repositioned a few times to make the muscle twitch (local twitch response). After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject lies on a treatment table without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
16940|NCT04057768|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.
16941|NCT04057755|Drug|botulinum toxin A|
16942|NCT04057755|Drug|NaCl|
16943|NCT04057742|Diagnostic Test|AlloSure ddcfDNA assay|2.5 mL collection for Donor Derived Cell Free DNA at transplant, 3 weeks, 6 weeks, 6 months, 12 months, 24 months post-transplant for Group A, at transplant for Group B, and transplant ans 3 months for Group C
16944|NCT04057742|Diagnostic Test|AlloMap assay|10 mL collection PAXgene blood sample at transplant, 3 weeks, 6 weeks, 6 months, 12 months, 24 months post-transplant for Group A, at transplant for Group B, and transplant ans 3 months for Group C
16945|NCT04057742|Diagnostic Test|Inflammatory Cytokines|10 mL collection at transplant, 3 weeks, 6 weeks, 6 months, 12 months, 24 months post-transplant for Group A
16946|NCT04057729|Drug|IMP4297|10mg/capsule.
16947|NCT04057716|Behavioral|Sleep Restriction|Participants will be asked to restrict their sleep by 1.5 hours for one week, and extend their sleep by 1.5 hours for one week.
16948|NCT04057677|Other|Bed Rest Intervention|The participant will remain in bed rest for 10 days. The metabolically balanced study diet will be individually formulated for each participant based on their energy needs and food preferences. Participants will maintain strict bedrest and remain flat as much as possible during bed rest; however, participants can have the head elevated to 30 degrees (by study staff) for meals. This is an intervention that has been shown by our group to produce robust reductions in lean mass in older adults
16949|NCT04057677|Other|Resistance Exercise Program|Strength training will consist of upper and lower body exercises. Participants will participate in strength training 3 days per week (12 total sessions). Each resistance exercise will be performed with a resistance that will allow 8-10 repetitions (approximately 70-80% of 1 RM). Three sets of 8-12 repetitions of each exercise will be performed to target the major upper and lower body muscle groups after appropriate rests.
16950|NCT04057664|Behavioral|Learning of Coping Strategies|Group sessions with psychotherapy and physiotherapy
16951|NCT04057638|Procedure|Combined Craniomaxillofacial and Upper Extremity Allotransplantation|Combined Craniomaxillofacial and Upper Extremity Allotransplantation
16952|NCT04057625|Device|transthoracic ultrasound|using transthoracic ultrasound in the diagnosis and follow up of vap,measuring the largest area of consolidation according to intercostal space and the direction of the probe.
16953|NCT04057612|Other|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
16954|NCT04057612|Other|Carotid artery temperature monitoring|Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
16955|NCT04057586|Procedure|Nonintubated|During surgery, patient is deeply sedated and respiration is maintained by spontaneous breath under the nasal high flow oxygen support.
16956|NCT04057586|Procedure|Intubated|During surgery, patient received standard general anesthesia and respiration is maintained by using mechanical ventilation.
16957|NCT04057573|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
16958|NCT04057573|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
16959|NCT04057547|Drug|Modified Gegen Qinlian Decoction|Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
16960|NCT04057534|Behavioral|Standard therapy for AUD plus Chess-based cognitive treatment|"Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting.~Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy. Additional, the experimental group receives chess based cognitive remediation treatment (CB-CRT) for 1,5 hours three times a week. The tasks of the treatment were created by our cooperation partner, the psychologist Juan Antonio Montero. He is currently successfully applying this battery as an add-on therapy before. The training battery is designed to strengthen cognitive functioning in specific domains such as short-term memory, focal attention, selective attention, pattern recognition, visuospatial abilities and also inhibition."
16961|NCT04057534|Behavioral|Standard therapy for AUD|Behavioral: standard AUD Cognitive Behavioral Therapy (CBT) in Clinical setting. Patients who voluntarily submit to enter a qualified detoxification treatment program will be examined, either in-patient, out-patient, or in a day-clinic setting at the Department of Addictive Behaviour and Addiction Medicine. They receive a six-week standard therapy.
16962|NCT04057521|Other|Care Coordination|Comprehensive care coordination.
16963|NCT04057508|Other|Modulation of muscle sympathetic nerve activity|Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
16964|NCT04057495|Other|further fasting|2 hours of fasting
16965|NCT04057495|Other|white bread consumption|113 grams of white bread consumption
16966|NCT04057495|Other|mango consumption|330 grams of mango consumption
16967|NCT04057482|Drug|D|treatment of BV with dequalinium chloride vaginal tablets
16968|NCT04057469|Drug|Tulobuterol Hydrochloride|Participants received tulobuterol patch 7 to 8 hours before the anesthetic induction
16969|NCT04057469|Drug|Placebo transdermal patch|Participants received placebo patch 7 to 8 hours before the anesthetic induction
16970|NCT04057456|Other|Placebo diet|"The dietitian will assist in developing a diet that is isocaloric to the anti-inflammatory diet and healthy (for the sake of the participants' well-being, and to blind participants), while allowing many foods that are (counterintuitively) pro-inflammatory (e.g. whole wheat bread, white beans, oats, soy, eggplant, raspberries, pumpkin seeds, popcorn, etc). Occasional cheat foods are built into the placebo diet but with more pro-inflammatory options (e.g. two glasses of wine per week)."
16971|NCT04057456|Other|Anti-inflammatory diet|"Participants will also be given a list of foods that they are allowed on the anti-inflammatory diet, and a list of foods to avoid so that they can make informed substitutions to the meals and ingredients that they are given. The study participants will be given a one-week meal plan with accompanying recipes. Occasional cheat foods are built into the anti-inflammatory diet (e.g. two bottles of beer per week)"
16972|NCT04057456|Drug|TCH/CBD Capsules|See arms description
16975|NCT04057443|Other|Nutritional support|Nutritional support will be given to all patients according with their nutritional body composition parameters (Nutritional assessment and sarcopenia evaluation). It could be diet counselling, oral supplemented nutrition, enteral nutrition o parenteral nutrition.
16976|NCT04057443|Other|Physical exercise|The exercise program, designed, applied and monitored by research staff of the Physiology Unit, will have duration of 24 weeks (6 months). The program will have a mixed structure, the participants in an individual way fulfill their training and attend group sessions (8 subjects). In addition, 3 days a week should conduct sessions that will focus on the work of balance and general strength.
16977|NCT04057443|Drug|Hematologic Drug|The patients of the control group will follow the standard treatment and follow-up according to the clinical protocol of the institution.
16978|NCT04057430|Device|GumChucks|GumChucks® is an innovative flossing system resembling mini nunchucks. The two-handle design eliminates the need to wrap the floss around fingers, and a proper flossing technique is facilitated by the nature of its curved shaped.
16979|NCT04057430|Device|String floss|Traditional string floss used in this study was Oral-B Glide® Pro-Health Original Floss
16980|NCT04057417|Other|Urban Trail|A newly built urban trail that was part of a large policy/infrastructure investment from the city/province to enhance the built environment for active transport and recreational physical activity in the city of Winnipeg, Manitoba Canada between 2010 and 2012.
16981|NCT04057404|Device|Alivecor Heart Monitor|
16982|NCT04057391|Diagnostic Test|QT Scanner|Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
16983|NCT04057378|Device|Electroconvulsive therapy|Electrically induced convulsion under anesthesia
16984|NCT04057365|Drug|Nivolumab|Nivolumab is believed to work by attaching to and inhibiting a specific protein in the cancer that controls parts of the immune system (the system in the body that fights off infections and diseases) by shutting down certain immune responses. The investigators believe that nivolumab will inhibit the protein, thus allowing the immune cells to recognize and destroy cancer cells.
16985|NCT04057365|Drug|DKN-01|DKN-01 is believed to work by attaching to and inhibiting (stopping) a specific pathway in the cells that is responsible for processes such as cell growth
16986|NCT04057352|Device|Citadel Embolization Device|The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
16987|NCT04057339|Behavioral|Time Restricted Feeding + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietitian.
16988|NCT04057339|Behavioral|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
16989|NCT04057326|Drug|Oryz-Aspergillus Enzyme and Pancreatin Tablet|2 tablets/time, 3 times daily,Oral Administration.
16990|NCT04057326|Drug|Placebo|2 tablets/time, 3 times daily,Oral Administration.
16991|NCT04057313|Dietary Supplement|Coffee|Coffee used will be the boiled unfiltered Arabica coffee
16992|NCT04057300|Drug|Ticagrelor 90mg|Ticagrelor tablet
16993|NCT04057300|Drug|Clopidogrel 75mg|Clopidogrel tablet
16994|NCT04057300|Drug|acetylsalicylic acid (ASA) 81mg|acetylsalicylic acid tablet
16995|NCT04057287|Other|No intervention|No intervention
16996|NCT04057274|Other|Exercise assessment|The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.
16997|NCT04057261|Drug|Liraglutide Pen Injector [Victoza]|Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen
16998|NCT04057261|Drug|Placebo|Matching Placebo once daily, subcutaneous injection via pre-filled pen.
16999|NCT04057248|Device|Dario Blood Glucose Monitoring System|Dario Blood Glucose Monitoring System (BGMS) with Dario App and Dario digital platform
17000|NCT04057248|Behavioral|CDE|Certified Diabetes Educator Sessions
17001|NCT04057235|Device|FlareHawk Interbody Fusion System|Expandable lumbar intervertebral body fusion device
17003|NCT04057209|Radiation|Single Vocal Cord Irradiation (SVCI)|The following planning aim will be pursued: full coverage of the PTV with at least 95% of the prescribed dose and a maximum (0.03 cc) PTV dose of <107%: 16 x 3.63 = 58.08 Gy in 5 fractions per week using 5 to 9 static IMRT or VMAT.
17004|NCT04057209|Procedure|Arm A: Transoral CO2-Laser Microsurgical Cordectomy (TLM)|"The TLM has to be performed using a CO2 laser, coupled to an operative microscope, at 4-8W in ultrapulse mode. The type of cordectomy performed must be mentioned using the following classification according the classification of the European Laryngological Society.~The type of resection chosen should provide complete removal of the primary lesion with negative margins.~Surgery will generally be performed within 3 weeks after randomization and not more than 6 weeks after panendoscopy.~The extent of the cordectomy must include a complete anterior, posterior, inferior and supero-lateral mucosal and deep soft tissue margin."
17005|NCT04057196|Behavioral|Self-System Therapy for Older Adults with Advanced Lung Cancer (SST-LC)|The SST-LC is a brief structured intervention deliverable by video conference. The new SST-LC protocol will incorporate behavioral strategies designed to meet the needs of older adults with lung cancer, including examining individual and shared expectations for lung cancer care, identifying discrepancies between expectations and realistic possibilities, and modifying stress-exacerbating behaviors.
17006|NCT04057183|Diagnostic Test|Carotid Stenotic Scan|Noninvasive determination of presence or absence of carotid artery stenosis
17007|NCT04057170|Other|accelerated protocol and mulligan method|manual therapy technic
17008|NCT04057157|Device|Biodesign Dural or Duraplasty Repair Grafts|Patients will receive the Biodesign Dural or Duraplasty Repair Grafts according to the Instruction for Use.
17009|NCT04057144|Behavioral|ACT|Acceptance and commitment therapy (ACT) sessions, lead by 2 qualified therapists, using a manual based on Steven Hayes et al 1999 that was adapted to group therapy and includes all the dynamic processes of ACT.
17010|NCT04057144|Behavioral|mindfulness exercises and audio recordings|mindfulness exercises introduced in the ACT sessions. In addition daily home meditation exercises based on the program developed by Kabat-Zinn 2005 and with help of audio recordings.
17011|NCT04057144|Behavioral|Education program|"Self-management education program. Information given by a qualified health professional on pain and symptom management, stress, sleep, eating habits, mental health problems. Group discussions about thoughts and experiences.~communication skills and physical activity"
17012|NCT04057131|Drug|Firazyr|Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.
17013|NCT04057118|Drug|SKI-O-703|Oral administration, twice per day
17014|NCT04057118|Drug|Placebo|Oral administration, twice per day
17015|NCT04057092|Dietary Supplement|Dietary Supplement INergy-FLD|INergy-FLD® is an immune modulating formula containing various ingredients including L-Arginine, whey protein isolate, and omega-6 fatty acid, aimed to attenuate excessive inflammatory responses without being immunosuppressive and to replenish nutrients that are depleted in a state of surgical stress, thereby enhancing the recovery process and decreasing the risk of infection. The volume of the beverage is 250mL per serving and patients will be asked to consume 3 servings periodically per day for 5 days prior to surgery and 5 days following surgery.
17016|NCT04057079|Combination Product|Anugel, Hydrogel sponge|A calibrated sponge impregnated with hydrogel is inserted to the rectum post hemoroidectomy.
17017|NCT04057079|Combination Product|Gelatine Sponge|A gelatine sponge is inserted in to the rectum pos hemoroidectomy.
17018|NCT04057066|Behavioral|Physical activity counseling|Physical activity counseling consists of two phone or video calls with a therapists, two group video calls with a therapist and a complementary e-learning course.
17019|NCT04057066|Behavioral|Exercise|Participants will agree with their therapist on an exercise plan (endurance and resistance training) that will be made available through the studies mobile app. Frequency and duration of endurance and strength training shall be prescribed in accordance with exercise guidelines for pwMS. However, they can be adjusted according to participants prior physical activity level and their available time slots for exercise during the week.
17020|NCT04057053|Drug|Netarsudil 0.02% Ophthalmic Solution|Use of Netarsudil 0.02% ophthalmic solution daily after surgery
17021|NCT04057040|Drug|PTG-300|Active
17022|NCT04057040|Drug|Placebo|Placebo
17023|NCT04057027|Procedure|Delayed umbilical cord clamping|During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.
17024|NCT04057027|Procedure|Cord Milking|Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
17025|NCT04057014|Drug|Amoxicillin|Antibiotic given at different dosages and durations.
17026|NCT04057014|Procedure|Tooth extraction|Removal of infected tooth on first day of study, this approach does not require an antibiotic drug.
17027|NCT04056988|Drug|Perflutren Lipid Microsphere|Perflutren lipid microsphere preparation is an ultrasound contrast agent. Ultrasound contrast agents are used to help provide a clear picture during ultrasound.
17028|NCT04056975|Biological|Recombinant Anti-CD19m-CD3 Antibody Injection|Intravenous Infusion
17029|NCT04056962|Drug|Tacrolimus ointment|topical application of tacrolimus for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
17030|NCT04056949|Drug|Paclitaxel/Albumin-Bound Paclitaxel|Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
17031|NCT04056949|Drug|IBI308|IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
17032|NCT04056936|Procedure|Frenotomy|To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
17033|NCT04056923|Procedure|3D-printing guided|3D printed navigational template guided
17034|NCT04056923|Procedure|CT-guided|CT-guided
17035|NCT04056923|Drug|Indocyanine Green|The results are shown by comparison of different colors.
17036|NCT04056923|Drug|Methylene blue|The results are shown by comparison of different colors.
17037|NCT04056923|Procedure|Preoperative|Preoperative localization.
17038|NCT04056923|Procedure|Intraoperative|Intraoperative localization.
17039|NCT04056910|Drug|ivosidenib and nivolumab|"Ivosidenib will be administered orally at a dose of 500 mg (provided as 250 mg strength tablets) daily. The dose may be reduced to 250 mg for patients experiencing more than one event of Grade 2 nausea or vomiting (related or unrelated), or Grade 3 or Grade 4 adverse events.~Nivolumab will be administered at 480 mg IV every 28 days."
17040|NCT04056897|Biological|BCD-132, 125 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
17041|NCT04056897|Drug|Teriflunomide|14 mg teriflunomide tablet. Per os. Daily in combination with IV placebo. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of placebo IV therapy in combination with daily administration of teriflunomide)
17042|NCT04056897|Drug|Placebo|intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
17043|NCT04056897|Biological|BCD-132, 500 mg|IV infusion every 24 weeks in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks (a total of 5 cycles of therapy BCD-132 in combination with a daily placebo)
17044|NCT04056884|Behavioral|SIBS intervention|SIBS is a manual-based group intervention for siblings and parents of children with chronic illness
17045|NCT04056871|Diagnostic Test|Frailty Screening Tools|This is an observational and prospective study of patients who are going for elective surgery, thus no intervention will be given.
17046|NCT04056845|Device|Valgus knee brace (Medex K39-OA Corrector)|Valgus knee brace given to patients as part of the conservative management for knee osteoarthritis.
17047|NCT04056845|Other|Physiotherapy and oral analgesic (diclofenac and panadol)|Physiotherapy and oral analgesic (diclofenac and panadol)
17048|NCT04056832|Procedure|Single Strip Pericardium|The anterior pericardium is taken in accordance with the measurements made using an aortic annulus sizer or Ismail sizer. The diameter of the annulus valve is converted to circumference of the aortic valve according as a measure of the length of the pericardium. Measurement of aortic commissure height is done by measuring the distance between the lowest point of the valve attachment to the highest point on the commissure as a measure of pericardium width. The pericardium is immersed in 0.6% glutaraldehyde solution for 10 minutes, then rinsed and soaked with saline solution 3 times for 6 minutes each. After the pericardium becomes firm it is cut to be a single strip according to the length and width in the previous measurement. It is then sutured to the aortic valve annulus.
17049|NCT04056832|Procedure|Mechanical Prosthetic Valve|Median incision is performed at the surgical site. Sternal retractor is placed at the sternum after median sternotomy being performed. Aortic valve is measured using aortic annulus sizer. Pledgeted suture is performed for the mattress. Sutures are performed to attach the mechanical prosthetic to the aortic annulus.
17050|NCT04056819|Biological|Allogeneic umbilical cord mesenchymal stem cells|UMSC01 cells will be one single IC infusion followed by one single IV infusion with 12 months of follow up after treatment.
17051|NCT04056806|Drug|Terlipressin 1Mg Powder for Conventional Release Solution for Injection Vial|efficacy comparison between 2 days and 5 days
17052|NCT04056793|Other|Optimized birthing position|The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
17053|NCT04056780|Other|Sample collection study|Sample collection and collection of laboratory values
17054|NCT04056754|Drug|Abiraterone Acetate|Subjects administered 4 tablets abiraterone acetate twice daily in 28-day cycle.
17055|NCT04056754|Drug|Placebo|Subjects administered 4 tablets abiraterone acetate blank analog tablet twice daily in 28-day cycle.
17056|NCT04056754|Drug|Prednisone|Subjects administered 5mg prednisone twice daily in 28-day cycle.
17057|NCT04056741|Combination Product|surfactant airway device|Infants who meet eligibility criteria and have a signed consent form by their parent or guardian will be enrolled in the study. Once enrolled, the surfactant airway device placement and surfactant administration will occur as detailed in the protocol. The infant will be monitored. If the infant meets instillation failure criteria, the procedure will be repeated shortly after the initial procedure. A maximum of two (2) doses will be given during the initial procedure. If the infant meets re-dosing criteria, (s)he may receive up to two (2) additional doses through the surfactant airway device (initial procedure with 1-2 doses and up to two additional doses). If at any time the infant reaches treatment failure criteria, the infant would be intubated and receive a site-specific surfactant through an endotracheal tube. Study outcome data will be followed until discharge from the NICU.
17058|NCT04056728|Biological|Eupenta Inj.|fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [recombinant-deoxyribonucleic acid])-Haemophilus influenzae type b conjugate vaccine single dose 0.5 mL/vial The vaccine is given at 6, 10 and 14 weeks of age in infants.
17059|NCT04056715|Device|Zio XT|ambulatory cardiac monitoring device
17060|NCT04056702|Drug|Elexacaftor-tezacaftor-ivacaftor exposure|Once a clinical decision has been made to prescribed a patient triple combination therapy, people with CF are eligible to participate in this study.
17064|NCT04056676|Procedure|Thoracic paravertebral block under ultrasound guidance|Ultrasound-guided thoracic paravertebral blocks in T2, T4 level
17065|NCT04056676|Procedure|Intraoperative modified PEC block|Pectoral nerve block by surgeon under direct vision after total mastectomy
17066|NCT04056676|Procedure|GA with ETT|General anesthesia with endotracheal intubation
17067|NCT04056663|Behavioral|Health-Circuit mobile application|Health-Circuit as a collaborative tool between professionals and patient and professionals
17068|NCT04056650|Drug|L-theanine|up to 250 mg
17069|NCT04056650|Dietary Supplement|Caffeine supplement|50-400mg
17070|NCT04056650|Device|N1 app|N1 App on mobile device
17071|NCT04056637|Other|Choice of follow-up option|Participant will be given the opportunity to choose from 3 follow-up options.
17072|NCT04056637|Device|Multi-level pregnancy test|The Multi-level pregnancy test (MLPT) strategy involves the use of the MLPT to estimate a pregnant person's baseline hCG range prior to beginning their abortion (i.e. prior to mifepristone administration). A follow-up test is then administered one week later to again estimate the woman's hCG range. A decline in hCG range reliably signifies absence of an ongoing pregnancy. Among clients ≤63 days' LMP at initiation of treatment, this strategy has shown to be highly effective: 100% of clients (n=1487/1487) with a decline in hCG range did not have an ongoing pregnancy and 100% of clients (n=21/21) with an ongoing pregnancy showed steady or increase in hCG range on their follow-up MLPT.
17073|NCT04056624|Dietary Supplement|High carotenoid juice|Juice with high carotenoids
17074|NCT04056624|Dietary Supplement|Placebo control - Apple juice|Juice with negligible carotenoids
17075|NCT04056611|Drug|JNJ-53718678|JNJ-53718678 500 mg will be administered orally.
17076|NCT04056611|Drug|Placebo|Matching placebo will be administered orally.
17077|NCT04056598|Diagnostic Test|Study of humoral immunity|Analysis: Surface antigen ELISA, recognition of living P. acnes bacteria via FACS, 16SRNA study of microbiome, SLST typing of P. acnes bacteria
17078|NCT04056585|Procedure|Ultrasound guided axillary plexus block|Ultrasound guided axillary plexus block with 1.5% mepivacaine 30 ml
17079|NCT04056585|Procedure|Intermittent pneumatic compression maneuver|Following ultrasound guided axillary plexus block, the pneumatic compression maneuver of upper arm is composed of 6 repeated inflation-deflation periods; inflation with a pressure of 200 mmHg for 30 seconds and deflation for 10 seconds each.
17080|NCT04056572|Drug|TQ-B3139|TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
17183|NCT04055636|Diagnostic Test|48-hour ECG monitoring.|Ambulatory 48-hour electrocardiography monitoring.
17081|NCT04056559|Device|Adaptable mouthguards|Validate a prototype of Adaptable Intra-Oral Protections patented by Bordeaux University and Bordeaux University Hospital according to 3 levels (ventilation, comfort, cervical muscle activity).
17082|NCT04056533|Biological|CMV CTLs|The donor derived cytomegalovirus specific T lymphocytes (CMV-CTL) will be transfused to the patients. The patients will receive CMV-CTL cells when their donors are sero-positive for CMV-DNA 21 days after transplant. The CMV-DNA levels will be monitored weekly for at least 100 days after the HAPLO. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then they may be eligible to receive a CMV specific antiviral drug.
17083|NCT04056520|Device|Medtronic Infinity Occipitocervical-Upper Thoracic System using the O-arm Imaging System and StealthStation Navigation system|"The INFINITY™ OCT System is intended to provide immobilization and stabilization of spinal segments as an adjunct to fusion for the following acute and chronic instabilities of the craniocervical junction, the cervical spine (C1 to C7), and the thoracic spine from T1-T3:~Traumatic spinal fractures and/or traumatic dislocations.~Instability or deformity.~Failed previous fusions (e.g. pseudarthrosis).~Tumors involving the cervical spine.~Degenerative disease, including intractable radiculopathy and/or myelopathy, neck and/ or arm pain of discogenic origin as confirmed by radiographic studies, and degenerative disease of the facets with instability."
17084|NCT04056507|Procedure|Immunolabeling|Immunolabeling of abnormalities observed by the cell study in flow cytometry.
17085|NCT04056481|Drug|Givosiran|givosiran (ALN-AS1) administered as a subcutaneous (SC) injection
17086|NCT04056468|Drug|TAK-788|TAK-788 capsule.
17087|NCT04056455|Drug|TAK-788|TAK-788 capsule.
17088|NCT04056442|Drug|Cannabidiol , synthetic form|Cannabidiol ( synthetic form)
17089|NCT04056442|Drug|Placebo|Olive Oil Solution, 5%
17090|NCT04056429|Combination Product|BHA|BHA active ingredients include beta-tricalcium phosphate and a blood-derived component. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
17091|NCT04056416|Device|MedBIKE|A MedBIKE will be installed into a participants home and connected to clinicians via telehealth for monitoring during exercise sessions. Sessions will be based on standardized guidelines for aerobic exercise. Heart rate, ECG, oxygen saturation and rating of perceived exertion will be monitored throughout the session.
17092|NCT04056390|Procedure|Catheter ablation using irrigated radiofrequency current ablation or cryothermal energy|Substrate ablation in terms of voltage abatement versus electrical left atrial appendage isolation.
17093|NCT04056364|Biological|sputum cytology|Sputum cytology refers to the examination of sputum (mucus) under a microscope to look for abnormal or cancerous cells. Sputum, or phlegm, is the fluid that is secreted by cells in the lower respiratory tract such as the bronchi and the trachea. It differs from saliva, in that it contains cells that line the respiratory passages.
17094|NCT04056351|Diagnostic Test|Post-Operative (OP) Computer Tomography (CT)|Post-OP CT of the treated shoulder
17095|NCT04056351|Other|Questionnaires on patient activity and comorbidities|"Shoulder activity scale (Marx)~Parker Mobility Scale~Barthel index~Charlson Comorbidity Score"
17096|NCT04056351|Other|Grip strength measurement|Grip strength will be measured using a CE marked hydraulic hand dynamometer device.
17097|NCT04056351|Other|Non-invasive shoulder activity tracking usinig wearable sensors|Post-OP activity will be assessed via wearable CE-marked accelerometer sensors.
17098|NCT04056338|Other|No intervention|No intervention.
17099|NCT04056325|Drug|Moxidectin|Monotherapy, oral administration, single dose, fixed dose
17100|NCT04056325|Drug|Ivermectin|Monotherapy, oral administration, single dose, weight dependent
17101|NCT04056325|Drug|Placebo oral tablet|Monotherapy, oral administration, single dose, matching number of tablets
17102|NCT04056312|Behavioral|Group Memory retraining exercises|Experimental group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
17103|NCT04056312|Behavioral|Placebo controlled group memory exercise training|Placebo group will be receiving memory retraining exercises via lap top twice a week for 5 weeks. Four people in a group.
17104|NCT04056299|Biological|AR201 Powder|AR201 powder provided in capsules (Hen Egg allergen formulation)
17105|NCT04056299|Biological|Placebo powder|Placebo powder provided in capsules
17106|NCT04056286|Dietary Supplement|Whey|45 g whey protein + 20 g maltodextrin
17107|NCT04056286|Dietary Supplement|3-OHB/whey|50 g 3-OHB + 45 g whey protein + 20 g maltodextrin
17108|NCT04056273|Other|Guide sheath group|After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.
17109|NCT04056273|Other|Conventional group|After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.
17110|NCT04056260|Procedure|ICG-NIR guided surgery|ICG 0.5mg/ml x 0.5ml x 4 sites injection through intra-operative endoscopy
17111|NCT04056247|Other|Plasma sample collection|Collect two plasma samples
17112|NCT04056234|Procedure|Joint puncture|Patient requiring joint puncture for diagnostic or therapeutic reasons.
17113|NCT04056221|Other|Acupuncture|Acupuncture stimulation was done manually, using single-use acupuncture needles that will be inserted on the selected acupoints (R6, E6, E2, Ig4, VC24, TA23, B2) once a week,for 8 weeks, 20 minutes sessions with 12 weeks of follow up.
17114|NCT04056221|Other|Sham acupuncture|The sham acupuncture consists of needles that achieves no skin penetration and are holden on the points by an adhesive pad.
17115|NCT04056208|Drug|Pistachio|Unsalted pistachios
17116|NCT04056208|Other|Usual care|Advice and resources will be provided
17117|NCT04056195|Drug|SKI-O-703|The SKI-O-703 capsules will contain 100 mg of drug substance.
17118|NCT04056195|Drug|Placebo oral tablet|Placebo capsules are filled with microcrystalline cellulose.
17119|NCT04056182|Drug|Lofexidine 0.18 MG|Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
17120|NCT04056169|Drug|high-dose rosuvastatin|rosuvastatin 20 mg once a day for 6 months
17121|NCT04056169|Drug|low-dose rosuvastatin plus ezetimibe|ezetimibe/rosuvastatin 10/5 mg once a day for 6 months
17122|NCT04056156|Behavioral|HIV-screening advice|To increase GP's HIV-testing behavior a targeted HIV-testing advice is spread to participants through an electronic mail
17123|NCT04056156|Behavioral|HIV-testing advice plus group-level training|To increase specific HIV-testing behavior among GPs a targeted HIV-testing advice is spread to participants through an electronic mail and an additional face-to-face group-level training is provided.
17124|NCT04056143|Other|Pharmacogenomics|Subjects enrolled in this study are providing blood samples for completing a set of laboratory testing and pharmacogenomic analyses. They are requested to comply a Pharmacist interview and complete of assisted questionnaires.
17125|NCT04056130|Drug|KBL697|"Part A: 1 day 460mg/day of KBL697 or placebo~Route of Administration: Oral"
17126|NCT04056130|Drug|KBL697|"Part A: 1 day 4,600mg/day of KBL697~Route of Administration: Oral"
17127|NCT04056130|Drug|KBL697|"Part B: 14 days~Cohort MAD1:~460mg/day of KBL697~Route of Administration: Oral"
17128|NCT04056130|Drug|KBL697|"Part B: 14 days~Cohort MAD2:~4,600mg/day of KBL697~Route of Administration: Oral"
17129|NCT04056117|Biological|Shigella 4V|Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
17130|NCT04056117|Biological|MenACWY|Control vaccine administrated to adults and infants
17131|NCT04056117|Biological|Rabies|Control vaccine administrated to children
17132|NCT04056117|Biological|Diphtheria, Tetanus and Pertussis (DTaP)|Control vaccine administrated to infants
17133|NCT04056117|Biological|Placebo|Control administrated to adults
17134|NCT04056104|Diagnostic Test|SpO2 and PIx Measurement|Right upper and any lower extremity oxygen saturation (SpO2) and perfusion index (PIx) will be measured
17135|NCT04056091|Procedure|Back rub stimulation|Immediately after birth, all infants with an expected birthweight >1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (back rubs). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
17136|NCT04056091|Procedure|Foot flicks stimulation|Immediately after birth, all infants with an expected birthweight >1500 g who have been dried and remain apneic (not crying) will receive physical stimulation (foot flicks). Stimulation can be repeated at maximum two or three times for about 3-5 seconds.
17137|NCT04056065|Drug|Normal Saline|In addition to standard of care normal saline to be used as vehicle in the phase-II study to assess efficacy of PMZ-2010 as a resuscitative agent for hypovolemic shock
17138|NCT04056065|Drug|Centhaquine|In addition to standard of care PMZ-2010 to be used as an experimental drug in the phase-II study to assess its efficacy as a resuscitative agent for hypovolemic shock
17139|NCT04056052|Behavioral|Mind the Gap: Home Activity Only|The primary focus of the home activity program was based on collaborative parent-child cooking activities which the families undertook themselves at home. There were two key tasks: the first was to add one extra vegetable to the evening meal each day, the second was to select, prepare and cook one recipe from the cook book each week.
17140|NCT04056052|Behavioral|Mind the Gap: Home Activity + cooking Workshop|The main purpose of these workshops was to provide hands-on successful food preparation and cooking experiences for the families and several opportunities to taste new vegetable-based recipes as well as promoting knowledge of cost and healthy eating. Children and their parents were then encouraged to take whatever was learned and apply it at home.
17141|NCT04056039|Drug|Atorvastatin|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
17142|NCT04056039|Drug|Colchicine|Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
17143|NCT04056026|Biological|Fecal Microbiota Transplant|Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
17144|NCT04056013|Device|Vicryl Rapide absorbable suture|"In general, most laceration repair has been done with sutures on the surface of the skin that do not break down and fall off on their own, so after enough days have passed for the laceration to heal properly, the patient needs to return to the ED to have the sutures removed by cutting them off. These sutures are called nonabsorbable. Some newer sutures have been designed to slowly dissolve on their own and fall out over several days. These are called absorbable sutures. You do not normally need to return to the ED for removal as these should slowly dissolve and fall out on their own."
17145|NCT04056000|Dietary Supplement|Caffeine|200 mg of caffeine, 60 minutes before exercise
17146|NCT04056000|Dietary Supplement|High-carbohdyrate breakfast|Ingestion of a high-carbohydrate breakfast 60 minutes before exercise
17147|NCT04056000|Behavioral|60-minutes of steady state exercise|See intervention name
17148|NCT04055987|Behavioral|Visual biofeedback, auditory feedback and models|The EPG software program allows the speech clinician to model and comment upon the visual patterns during tongue/palate contact and to replay the participant's production for additional correction or reinforcement productions. Auditory feedback will be used to facilitate participant's perception of differences in production.
17149|NCT04055974|Behavioral|Be a Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention targeting postpartum women. It consists of 5 weekly modules, each targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
17150|NCT04055961|Device|Atrial Fibrillation Ablation|A procedure used to treat an irregular heart rhythm (arrhythmia)
17151|NCT04055948|Behavioral|One-on-one teaching sessions|One-on-one teaching sessions with the caregiver during radiation treatments.
17152|NCT04055948|Behavioral|Telephone booster contact|Telephone booster contact 2 weeks post-treatment.
17184|NCT04055636|Diagnostic Test|Blood samples analysis.|Analysis of blood samples for biochemistry, biomarkers of myocardial damage, fibrosis and inflammation.
17185|NCT04055623|Biological|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the first 6-months of the study: T-regulatory cells taken from a patient, increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient + 3 times per week subcutaneous Interleukin-2 injections
17153|NCT04055935|Procedure|elevation of full thickness mucoperiosteal flap|A free gingival sulcular incision was done from the distal surface of maxillary second premolar to the mesial side of the maxillary canine. A releasing oblique incision was done including the interdental papilla between maxillary canine and lateral incisor extending to the mucogingival junction just beyond the attached mucosa. The flap reflection extended beyond the canine root apex. A FTMPF reflection was done with mucoperiosteal elevator. Free sulcus incision was done to allow elevation of palatal mucosa by tunneling technique on the palatal gingiva of maxillary canine.
17154|NCT04055935|Device|low level laser therapy|LLLT was done using a diode soft laser (Epic X, BioLase, USA). It is a semiconductor diode soft laser. Active medium is In-Ga-As with 940nm wave length. LLLT protocol was using active laser tip (bleaching tip)
17155|NCT04055909|Drug|nangibotide low dose|nangibotide 0.3 mg/kg/h
17156|NCT04055909|Drug|nangibotide high dose|nangibotide 1.0 mg/kg/h
17157|NCT04055909|Drug|placebo|matching placebo
17158|NCT04055896|Other|Medication Reduction|Systematic approach to reduction in polypharmacy
17159|NCT04055883|Drug|DA-1229|All participants are administered one tablet per day for 96 weeks
17160|NCT04055870|Procedure|EUS-guided liver biopsy at MDMC|Endoscopic ultrasound (EUS) guided liver biopsy sampling is emerging as an alternative to the aforementioned approaches that offers several advantages, including decreased sampling variability and procedure-related complications.
17161|NCT04055844|Drug|Decitabine|10 days of decitabine 20 mg/m2 IV daily; or, alternatively, per institution, physician, or patient preference on a 5-2-5 schedule with no weekend infusion. If a CR is achieved after 2 cycles using the 10-day schedule, subsequent cycles will change to a 5-day schedule.
17162|NCT04055844|Drug|Ruxolitinib|Starting with day 1 of cycle 1 and continuing for up to 6 months after the end of the last cycle, patients will receive ruxolitinib 5 mg twice daily orally. Dose may be increased to 10 mg twice daily in cycles 2 through 4 if platelets improve to >100 x 10^9/L.
17163|NCT04055844|Drug|Donor Lymphocyte Infusion (DLI)|DLI from the original donor will be infused within 10 days after the last dose of decitabine in each cycle.
17164|NCT04055818|Drug|Nicotinamide|Oral nicotinamide (Vitamin B3) alone compared to THU Decitabine combination
17165|NCT04055805|Behavioral|Observational Analysis|Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
17166|NCT04055792|Drug|Sintilimab|Sintilimab 200mg intravenously on day 1 of each 3-week cycle
17167|NCT04055792|Drug|Anlotinib|Anlotinib 12mg per os on day 1-14 of each 3-week cycle
17168|NCT04055779|Other|estimation method for arterial occlusion pressure|The patients will receive induced hypotensive anaesthesia and the tourniquet pressure will be based on the AOP.the tourniquet pressure will be determined based on the AOP which will be determined by the estimation formula (AOP=[SBP+10]/KTP) . The calculation is based on using initial SBP and tissue padding coefficient values , according to limb circumferences of the patient.After calculation of AOP, tourniquet pressures will be determined by adding a safety margin of 20 mmHg to AOP values(tourniquet pressure=AOP+20 mmHg).
17169|NCT04055779|Other|the limb occlusion pressure|: using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP.using the ultrasound Doppler technique and the tourniquet will be inflated until the arterial pulsations disappear at the side of the operation. This pressure will be recorded as LOP .the tourniquet cuff will be inflated to the pressure according to theguidelines of the Association of Perioperative Registered Nurses(AORN) which recommends that a safety margin of 40 mmHg should be added for AOP below 130 mmHg, 60 mmHg for AOP between 131 mmHg and 190 mmHg, and 80 mmHg for AOP above 190 mmHg for adult patients
17170|NCT04055766|Device|DeepDoc AI-based Decision Support System|Patients are diagnosed by the DeepDoc within 24 hours of admission.
17171|NCT04055753|Drug|Doxil|Doxil 50 mg/m2, as per institutional standard
17172|NCT04055753|Drug|Doxorubicin|Doxorubicin 75 mg/m2, IV over 5-15 min OR Continuous infusion over 48-72 hours
17173|NCT04055740|Device|IVUS Imaging|IVUS or radial-ICE (intracardiac echocardiography) is a visualization tool used in many cardiac procedures including electrophysiology procedures (catheter ablation). Its utility in identifying ILA will be assessed in this study.
17174|NCT04055714|Device|Balloon dilation of the Eustachian tubes|Use the Aera Balloon through the nose to dilate the Eustachian tubes
17175|NCT04055701|Other|assesment of thymus volume|assesment of thymus volume
17176|NCT04055688|Device|Orbeye surgical videomicroscope|The ORBEYE surgical microscope is an FDA-cleared apparatus designed to facilitate operating procedures that involve fine nerves, blood vessels, and other small anatomic features by providing an enlarged stereoscopic visual field of the surgical site. The 4K 3D digital images of the ORBEYE microscope provide high-resolution stereoscopic images of the fine structures of tissue and blood vessels. As the surgical procedures are displayed on a large 55-inch monitor, the device is expected to reduce fatigue of the operator by eliminating the need for extensive viewing via microscope eyepieces for an extended period of time. The technology adopted in the ORBEYE was developed by Sony Olympus Medical Solutions, and its product design was handled by Olympus Medical Systems Corp. The ORBEYE is marketed by the Olympus Corporation.
17177|NCT04055688|Drug|5-Aminolevulinic Acid|5- aminolevulinic acid (5-ALA) is a European Medicines Agency- and Food and Drug Administration- (FDA-) approved drug that is administered to patients 2 to 4 hours before surgery and converted preferentially by tumor cells to protoporphyrrin IX (PPIX). PPIX fluoresces red when exposed to blue light. Use of 5-ALA has previously been shown to permit surgeons to obtain a more complete tumor resection, and its use has also been associated with an increased rate of progression-free survival.(3) There are currently 2 surgical microscope systems available on the market that are equipped with a 5-ALA visualization system. These visualization systems are currently classified by the FDA as Class I-exempt accessories to Class I-cleared surgical microscopes.
17178|NCT04055675|Diagnostic Test|Urine dipstick test|A sample of urine will be tested using a Mission Urinalysis Reagent Strip.
17179|NCT04055649|Drug|Akt/ERK Inhibitor ONC201|Given orally (PO)
17180|NCT04055649|Drug|Paclitaxel|Given IV
17181|NCT04055649|Other|Questionnaire Administration|Ancillary studies
17182|NCT04055636|Diagnostic Test|Echocardiography with speckle tracking analysis.|Transthoracic echocardiography with speckle tracking analysis.
20854|NCT04025879|Drug|Cisplatin|Specified dose on specified days.
17186|NCT04055623|Other|Monthly placebo infusions + 3 times per week placebo injections|For first 6-months of study: monthly placebo infusions + 3 times per week subcutaneous placebo injections
17187|NCT04055623|Biological|Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections|For the second 6-months of the study: all participants will receive T-regulatory cells taken from the patient, that have been increased in number in a lab, and returned through monthly intravenous (IV) infusions back to same patient (Treg cell owner) + 3 times per week subcutaneous Interleukin-2 injections.
17188|NCT04055610|Device|Gait training using H-MEX exoskeleton|Participants will train 3 times a week for 10 weeks using H-MEX powered exoskeleton.
17189|NCT04055597|Other|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
17190|NCT04055597|Other|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
17191|NCT04055584|Diagnostic Test|Sputum|DNA extraction and perform a diversity of molecular diagnostic tests
17192|NCT04055545|Other|HIIT|"5 min. warm up~10 × 60 seconds burst~60 seconds recovery after each burst~Burst phase: HRR >90%~Recovery phase: HRR btw. 30-39%~5 min. cool down"
17193|NCT04055545|Other|MICT|"5 min. warm up~20 min. continuous cycling: HRR btw. 40% - 59%~5 min. cool down"
17194|NCT04055532|Other|Neuraceq|Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
17195|NCT04055506|Drug|BMS-986165|Dose 1
17196|NCT04055506|Drug|Ritonavir|100 mg
17197|NCT04055493|Drug|Ribociclib 200Mg Oral Tablet|3 x 200 MG per os
17198|NCT04055480|Device|Closed-loop using standard rapid-acting insulin|Closed-loop using standard rapid-acting insulin
17199|NCT04055480|Device|Closed-loop using faster insulin aspart|Closed-loop using faster insulin aspart
17202|NCT04055454|Biological|MV-LASV|The MV-LASV vaccine candidate is a recombinant live attenuated viral vectored vaccine, based on the backbone of the measles Schwarz virus strain for prophylaxis of Lassa infection and will be administered in two different dose levels by intra muscular (i.m.) injection.
17203|NCT04055454|Other|Placebo|A sterile physiological saline solution will be used as placebo to ensure blinding of the treatment with low dose MV-LASV and placebo within treatment group A. Additionally, the Placebo will be used as a control arm to enable comparison of treatment reactions within treatment groups B and C.
17204|NCT04055428|Drug|Sacubitril, Valsartan 97-103 mg Oral Tablet|The subject will be randomized, in a double-blind manner to sacubitril/valsartan 97/103 mg twice daily for a period of 12 weeks.
17205|NCT04055428|Drug|Valsartan 160 mg|The subject will be randomized, in a double-blind manner to valsartan 160 mg twice daily for a period of 12 weeks.
17206|NCT04055428|Other|Intravenous Glucose Tolerance Test|An assessment of the insulin sensitivity will be done using the IVGTT, at baseline and after 12 weeks of pharmacological interventions.
17207|NCT04055428|Dietary Supplement|Standardized Meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
17208|NCT04055428|Other|Exercise capacity VO2 maximum determination|Each participant's maximal oxygen capacity will be determined using modified Bruce treadmill protocol.
17209|NCT04055415|Biological|adipose derived mesenchymal stem cells|The MSCs of 1×10*6/kg will be given in Central venous catheterization for injection at a total 100 ml (2) the experimental group was treated with conventional drug and adipose mesenchymal stem cell injection, and adipose MSCs were treated with central venous catheterization. The injection cycle was once every week of two times.Injection dose: 1×106 /kg.
17210|NCT04055415|Drug|Conventional drug therapy（expectorant，bronchodilator）|Conventional drug therapy（expectorant，bronchodilator）
17211|NCT04055402|Other|Ecological momentary assessments|The staff will help the participants in the EMA group to install and set up the EMA App. The briefing will also emphasise the role of EMA participants that they should perform their normal activities as usual instead of finding out the alcohol advertisements and PADC intentionally. Within 2 weeks after completing the baseline survey, participants in EMA group will complete 5 EMAs prompted regularly every day for 14 consecutive days. The participants will then be contacted for a follow-up survey 2 weeks after the completion of EMA.
17212|NCT04055402|Other|Control|Completion of a baseline questionnaire and a 1-month follow-up survey.
17213|NCT04055389|Drug|Antithrombin III|"Patients with reversal of flow or sluggish flow in the main portal vein (<15 cm/s by Doppler ultrasound exam) will be enrolled and randomized to either weekly infusions of AT-III (half-life ~4 days) at a weight-based dosage according to the following formula:~[Desired level of AT (100%) - Subject level of AT (%)] * subject weight (kg) 1.4~or placebo for 24 weeks of therapy."
17214|NCT04055389|Other|Placebo|No study drug
17215|NCT04055376|Device|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 60 minutes daily over 6 months. After 6 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 months.
17216|NCT04055376|Device|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 60 minutes daily over 6 months. After 6 months, each participant will be given an option to continue the daily usage of the GENUS device configured to active settings for additional 6 months.
17217|NCT04055363|Other|HMO-supplemented infant formula|Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
17238|NCT04055181|Device|rTMS in major depressive disorders controls|"all procedures were identical to rTMS in major depressive disorders patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
17239|NCT04055181|Device|rTMS in major depressive disorders patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
17771|NCT04050800|Drug|Carbon 11 Butanol|Two sequential administrations of a PET tracer
17218|NCT04055337|Procedure|Flap sliding|"All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated."
17219|NCT04055311|Behavioral|CRIS - Cancer, resource, information, support|Intervention support is patient initiated and accessed as needed
17220|NCT04055311|Behavioral|Usual Care Enhanced|Usual care is provided by nursing staff
17221|NCT04055298|Device|SMASS-Triage|SMASS-Triage is a web-based symptom checker developed by In4medicine Ltd. SMASS-Triage is based on a computerized transparent neural network, which was trained with the evidence of more than 1200 studies and the expertise of various panels of specialists in the field of preclinical medical triage. SMASS-Triage provides digitalized questionnaires of 87 frequent reasons of encounters (e.g. fever, cough, abdominal pain) and their associated red flags. The triage-result of SMASS-Triage encompasses the appropriate time-to-treat (T2T) and the adequate point-of-care (PoC).
17222|NCT04055285|Procedure|Sympathetic Renal Denervation|Catheter-based sympathetic renal denervation (RDN) using radiofrequency, ultrasound, or perivascular injection of neurotoxic agents such as alcohol has been introduced as a minimally invasive alternative treatment option for patients with resistant hypertension. RDN consists of endovascular catalysis of the kidney sympathetic nerves running in the wall of the renal arteries.
17223|NCT04055285|Device|Implantable Loop Recorder|Implantable Loop Recorders (ILRs) are small, subcutaneously implanted devices that are able to detect and store atrial fibrillation episodes lasting longer than 2 minutes with high sensitivity (96.1-100%) and good specificity (67-85.4%) for a period of up to three years.
17224|NCT04055272|Behavioral|Mobile text messaging intervention|Participants in the intervention arm will receive text messages to their mobile phones designed to communicate the risks of indoor tanning and motivate cessation. The intervention exposure lasts for 4 weeks with messages sent 2 days each week. It is an interactive intervention that engages participants by asking them to respond to prompts, and sending indoor tanning message content in return on message days.
17225|NCT04055259|Behavioral|mobile Health and Wellness Coaching|Participants in the mobile health and wellness coaching (mHWC) group received text-based mHWC messages and did not return to the clinic until the end of the 6 month intervention. Messages were sent at least weekly and focused on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. Participants could respond via text at any time. The Nudge platform was used for all messaging.
17226|NCT04055259|Behavioral|Usual Care|Participants in the usual care (UC) group met in-person once a month with either a pharmacist or dietician for the duration of the 6-month intervention. The focus of these sessions was on facilitating the adoption and maintenance of health behaviors related to diet, physical activity and sleep to promote weight loss. These participants were set up on the Nudge app, but they did not use the mHWC (texting) feature.
17227|NCT04055246|Dietary Supplement|Inulin|9 grams of food grade inulin added to custom made fiber bars.
17228|NCT04055246|Dietary Supplement|Placebo (maltodextrin)|9 grams of food grade maltodextrin - replaces inulin in fiber bars.
17229|NCT04055233|Drug|Polihexanide; Serasept|"Experimental arm: irrigation of subcutaneous tissue after fascia closure with polihexanide (ten minutes).~A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
17230|NCT04055233|Drug|NaCl; saline|"Control arm: irrigation of subcutaneous tissue after fascia closure with NaCl (one minute) A single dose of perioperative antibiotics (cefuroxim alone or cefuroxim and metrodidazole in bowel surgeries) was given 30 minutes before skin incision.~Hair removal was done with electronic clippers and preoperative skin antisepsis was performed with propanol and povidone-iodine.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin.~Before closure of fascia, instruments and gloves were changed. No subcutaneous suture was used. Skin was closed either with skin staples, continuous intracutaneous suture or interrupted suture.~All surgeries were done according to the Standard Operating Procedures of the Department for General, Visceral and Vascular Surgery, Charité Campus Benjamin Franklin."
17231|NCT04055220|Drug|Treatment by Regorafenib|Treatment for 13 cycles (12 months) maximum. During each cycle, patient will take 3 tablets, once a day, corresponding to a total of 120 mg Regorafenib, during 21 days, followed by 7 days without treatment.
17232|NCT04055220|Drug|Treatment by Placebo|Treatment for 13 cycles (12 months) maximum. During each cycle, patient will take 3 placebo tablets, once a day, during 21 days, followed by 7 days without placebo treatment.
17233|NCT04055207|Other|VVC|Telehealth treatment is delivered via VA-approved technology to a patient's computer or mobile device.
17234|NCT04055194|Drug|Tranexamic acid tablets|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive tranexamic acid tablets (500mg four times daily) till delivery.
17235|NCT04055194|Drug|Placebo oral tablet|Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
17236|NCT04055181|Device|rTMS in schizophrenia Controls|"all procedures were identical to rTMS in schizophrenia patients group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated."
17237|NCT04055181|Device|rTMS in schizophrenia patients|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s intertrain interval. 20 minutes were administered each day (Monday-Friday) for 4 consecutive weeks
17894|NCT04049799|Other|Medically-supervised withdrawal|6-8 day withdrawal with buprenorphine/naloxone
17242|NCT04055142|Procedure|electrocoagulation|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and electrocoagulation will be performed in 2-3 sessions (session every 2 weeks)
17243|NCT04055142|Drug|cidofovir 1% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with cidofovir 1% ointment (3 times per week during 8 weeks)
17244|NCT04055142|Drug|sinecatechins 10% topical ointment|HIV homosexuals males with High-grade anal intraepithelial neoplasia will be randomized and they will be treated with sinecatechins 10% ointment (3 times per week during 8 weeks)
17245|NCT04055129|Other|No interventions|Observational. Data will be gathered and analyzed on ligament laxity, EMG, kinetics and kinematics during a landing and jumping activity
17246|NCT04055116|Drug|Buffered Lidocaine|Investigator will prepare 1:10 dilution of sodium bicarbonate to 2% lidocaine with 1:100,000 epinephrine on one occasion. 8.4% Sodium Bicarbonate will be used.
17247|NCT04055103|Other|Monthly feedback, education and linking hospitals|- Give monthly feedback from LROI-data (revision rate & patient reported outcome measures) as well as other outcomes from the participating hospital (length-of-stay, readmission and complications), combined with education on how to use this information for improvement. This will be send monthly by email to the intervention group. Further, hospitals with worse performance for a certain outcome will be linked to hospitals with good performance for this outcome.
17248|NCT04055090|Genetic|Long-Term Follow-Up of Patients who Received VM202|No study drug is administered in this study. Patients who received VM202 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
17249|NCT04055090|Drug|Long-Term Follow-Up of Patients who Received Placebo|No study drug is administered in this study. Patients who received Placebo in a previous trial will be evaluated in this trial for long-term safety and efficacy.
17250|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA I|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
17251|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA II|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
17252|NCT04055077|Device|Low-flow nasal oxygenation (LFNO) ASA III|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
17253|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASA I|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
17254|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASAII|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
17255|NCT04055077|Device|High-flow nasal oxygenation (HFNO) ASA III|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
17256|NCT04055064|Dietary Supplement|glucose control nutritional shake, nutrition education|Participants in the treatment group were educated about improving their diet by consuming more low-fat high-quality protein sources, vegetables, complex carbohydrates and less simple carbohydrates. They were also instructed to consume two servings (474 ml) of a commercially produced Glucose Control Nutritional Shake between meals throughout the day for 12 weeks or until complete healing. The supplements provided a total of 500 kilocalories, 28 grams of high-quality protein and essential vitamins and minerals.
17257|NCT04055038|Drug|Platinum-Based Drug|Reintroduction of platinum-based chemotherapy
17258|NCT04055038|Drug|Conventional chemotherapy|Conventional chemotherapy
17259|NCT04055025|Other|Placebo|Four-hour liquid solid meal tests and a subsequent ad libitum meal during saline infusion.
17260|NCT04055025|Other|Ghrelin|Four-hour liquid solid meal tests and a subsequent ad libitum meal during acyl-ghrelin infusion.
17261|NCT04055012|Drug|Metformin|500mg tabs of Metformin Extended Release
17262|NCT04055012|Drug|Placebo|Placebo Tabs
17263|NCT04054999|Drug|Hydroxocobalamin|Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes
17264|NCT04054999|Drug|Methylene Blue|Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
17265|NCT04054986|Diagnostic Test|F-Var3 PET/CT|Participants will undergo up to 5 serial F-Var3 PET/CT scans.
17266|NCT04054973|Drug|L-arginine|6000mg of L-arginine daily for 14 days
17267|NCT04054973|Drug|Sapropterin Dihydrochloride|800mg of Kuvan daily for 14 days
17268|NCT04054960|Device|Active tPCS|Active anodal tPCS will be given for 20 mins to motor cortex (M1) or supplementary motor area (SMA), based on our quantitative EEG findings.
17269|NCT04054960|Device|Sham tPCS|For the sham condition, the electrode placement will be the same, but the electric current will be ramped down 5 seconds after the beginning of the stimulation.
17270|NCT04054960|Drug|Levodopa tablet|We will give 3 tablets of Levodopa-Carbidopa (100/25).
17271|NCT04054947|Behavioral|Suicide Prevention Program|Structured care management to improve adherence to discharge planning.
17272|NCT04054934|Behavioral|Reversed Circadian Rhythm|Revered day/ night sleep cycle
17273|NCT04054934|Behavioral|Normal Circadian Rhythm|Normal day/ night sleep cycle
17274|NCT04054921|Drug|PTG-300|PTG-300 is ahepcidin Mimetic
17275|NCT04054895|Device|Lead placed in the His bundle in order to achieve QRS shortening.|The lead that provides resynchronization is positioned in the His bundle to achieve QRS shortening via His bundle capture. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).
17276|NCT04054895|Device|Lead is placed in a tributary of the coronary sinus.|Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
17277|NCT04054882|Biological|Sabin-IPV and DTaP|simultaneously administration of Sabin-IPV and DTaP
17278|NCT04054882|Biological|Sabin-IPV|administration of Sabin-IPV only
17279|NCT04054882|Biological|DTaP|administration of DTaP only
17895|NCT04049799|Other|Opioid agonist treatment|Induction and maintenance with buprenorphine/naloxone
17282|NCT04054856|Device|Body Sensor Network|"The Integrated Posture and Activity NEtwork by Medit Aachen (IPANEMA) Body Sensor Network (BSN) is a wireless sensor network with several sensor nodes. A sensor node consists of a base unit equipped with different sensor modalities: Acceleration sensor, Rotation rate sensor, Air pressure sensor, Photoplethysmography (PPG, optional), Galvanic Skin Response (GSR, optional) measurement. The sensor data is transmitted via a wireless 433/868 MHz ISM band radio link to the central radio node. From there, the data is transferred via a Bluetooth connection to a laptop or PC for processing. Three sensors are attached 1) to the wrist with a flexible Velcro strap, 2) hung around the neck on a specially designed collar and 3) worn loosely in the trouser pocket without further fixation or at the belt. The respective sensors are located in a closed, ergonomically shaped housing (size 70x40x20mm^3, approx. 35g) and have no electrically conductive contact to the skin surface of the test person."
17283|NCT04054843|Diagnostic Test|Afamin|Plasma maternal afamin levels
17284|NCT04054830|Drug|Voltaren Ophtha 1 mg/ml, GSK|Voltaren Ophtha 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
17285|NCT04054830|Drug|Monopex 1 mg/ml, Théa|Monopex 1 mg/ml, eye drops used 6 times daily for the 2 first weeks, tapering to 4 drops per day for the next 4 weeks. Depending on the clinical condition of the eye, the topical anti-inflammatory treatment will be reduced with 1 daily drop per week.
17286|NCT04054817|Device|Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix|Lamellar keratoplasty was done by removing stromal layer, ABCcolla® Collagen Ophthalmic Matrix was sutured to the defective part of the cornea.
17287|NCT04054804|Diagnostic Test|D-Foot|A digital foot check i assessed by using the software D-Foot.
17288|NCT04054778|Behavioral|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
17289|NCT04054778|Behavioral|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
17290|NCT04054765|Device|videogame|smokeSCREEN VR videogame
17291|NCT04054765|Device|VR videogame|attention/control non-health-related VR videogame
17295|NCT04054739|Device|Robot-assisted gait training|intervention with robot-assisted gait training
17296|NCT04054739|Device|Treadmill gait training|intervention with treadmill gait training
17297|NCT04054726|Device|Active Transcranial pulsed current stimulation (tPCS)|Active tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. Stimulation will be given for 20 mins.
17298|NCT04054726|Device|Sham Transcranial pulsed current stimulation (tPCS)|Sham tPCS will be delivered through a pair of saline-soaked (0.9% NaCl) surface sponge electrodes (7 × 5 cm2, for the anodal cerebellar electrode; 8 × 6 cm2 for the cathodal spinal electrode). Anode will be placed on the scalp over the cerebellum area (2 cm under the inion). Cathode will be placed over the dorsal cord. The electric current will be ramped down 5 seconds after the beginning of the stimulation to make this condition indistinguishable from the experimental active stimulation.
17299|NCT04054713|Diagnostic Test|Acetic acid chromoendoscopy|Acetic acid is prepared at a concentration of 2.5% in a 20ml syringe, it will be applied with a 7 french spray catheter compatible with a working channel 2.8mm onwards, starting the proximal application When distally performing a uniform application on the area of intestinal metaplasia and the timed time for mucous visualization in search of areas of loss of acetowhitening begins, in case of finding such area will be registered the time in which there was loss of acetowhitening, the distance at which it is located from the upper dental arch in addition to the face on which the area is located, subsequently evaluation of the glandular pattern is performed only by classifying as normal or abnormal, once this evaluation has been carried out, biopsies are directed to these areas to be sent to the pathology service.
17300|NCT04054713|Diagnostic Test|Seattle protocol|Take random biopsies by quadrants every 2 centimeters. Biopsy of the intestinal metaplasia areas 1cm above the esophagogastric junction will be initiated, taking tissue every 2cm from the four quadrants, separating the biopsies in different bottles based on the length in which they were taken, to later be sent to the pathology service.
17301|NCT04054700|Device|distal upper rehabilitation robot|Intervention with distal upper rehabilitation robot
17302|NCT04054700|Device|proximal upper rehabilitation robot|Intervention with proximal upper rehabilitation robot
17338|NCT04054362|Drug|Cisplatin|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
20855|NCT04025879|Drug|Paclitaxel|Specified dose on specified days.
17303|NCT04054687|Drug|Tranexamic Acid|Enrolled patients will be placed in one of two groups: either the group receiving a cotton pledget soaked in (0.9%) saline or (100mg/1mL) TXA. Patients will initially be asked to gently blow their nose to remove any clots. Group 1 will receive the saline soaked pledget. After fifteen minutes the pledget will be removed. If patient continues to bleed within a reevaluation period of fifteen minutes, this will be deemed a 'failure' and the examiner will pack the nose with the method of his or her choice. Group 2 will receive the TXA soaked pledget and the procedure will continue like Group 1.
17304|NCT04054687|Other|Placebo|This group will receive pledget soaked in saline. Protocol will continue as with TXA group.
17305|NCT04054674|Procedure|Abutments with flat occlusal scheme preparation restored by lithium disilicate crowns|Clinical trials lacks information about flat occlusal preparation design in case of endodontically treated teeth. Therefore, this is tested during preparation when compared to planer occlusal preparation while the final restoration in both arms is lithium disilicate (e.max) crowns.
17306|NCT04054661|Diagnostic Test|STANDARD G6PD test|"The STANDARD G6PD Analyzer is designed to measure the quantitative determination of total Hb concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product. System components shall be labeled in accordance with regulatory requirements, including the following statement, For Investigational Use Only. The performance characteristics of this product have not been established."
17307|NCT04054648|Other|Bedtime administration of the participant's pre-existing antihypertensive medications|Changing the administration time of once daily blood pressure lowering medications, one at a time as tolerated, from morning to bedtime.
17308|NCT04054635|Device|silver diamine fluoride|Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
17309|NCT04054609|Diagnostic Test|FAZA PET/MRI scan|PET/MRI scan using radio tracer named 18F-Fluoroazomycin Arabinoside (FAZA) pre and post standard of care endovascular treatment for critical limb ischemia patients
17310|NCT04054596|Behavioral|SME|The treatment group (TX) will complete 8 sessions of SME (2 sessions per week for 4 weeks), de-signed to teach the concepts of SG, SL and RP and the application of these techniques in daily life. Sessions are approximately 30-45 minutes long.
17311|NCT04054583|Other|Renovation of long-term residential care living spaces|Living spaces of the long term care facility will be renovated.
17312|NCT04054570|Other|No intervention|No Intervention
17313|NCT04054557|Other|Telemedicine|Participate in virtual visits with oncologist
17314|NCT04054557|Other|Best Practice|Receive 4 in-office visits with oncologist
17315|NCT04054557|Other|Questionnaire Administration|Correlative studies
17316|NCT04054557|Other|Quality-of-Life Assessment|Ancillary studies
17317|NCT04054544|Dietary Supplement|Gluten powder 4g|Gluten powder 4g oral BID
17318|NCT04054531|Biological|KN046|IV infusion
17319|NCT04054531|Drug|Paclitaxel|IV infusion
17320|NCT04054531|Drug|Pemetrexed|IV infusion
17321|NCT04054531|Drug|Carboplatin|IV infusion
17322|NCT04054518|Drug|Durvalumab|Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.
17323|NCT04054505|Dietary Supplement|EZPAK|One packet with breakfast for three months
17324|NCT04054492|Biological|Sabin-IPV+bOPV+bOPV|202 subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively
17325|NCT04054492|Biological|Sabin-IPV+Sabin-IPV+bOPV|197 subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively
17326|NCT04054492|Biological|Sabin-IPV+Sabin-IPV+Sabin-IPV|205 subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively
17327|NCT04054479|Drug|Penehyclidine|Patients receive penehyclidine 10μg/kg(up to 0.5mg, diluted with normal saline to 0.1mg/ml) after anesthesia intubation.
17328|NCT04054479|Drug|normal saline|Patients receive 0.1ml/kg normal saline(up to 5ml) after anesthesia intubation.
17329|NCT04054466|Behavioral|Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART|"It is a health intervention, performed by the nurse with the purpose of providing support or support to the patient's health care. The main objective of counseling is to improve adherence to treatment in patients who receive HAART but also consume alcoholic beverages.~The components of the differentiated counseling according to the levels of consumption are consolidated according to the recommendations given by the World Health Organization (WHO) after the application of the AUDIT:~Social consumption (sometime in life, in the last year or in the last month) = mainly education about consumer risks, its application will be bi-monthly."
17330|NCT04054466|Behavioral|Habitual Counseling|Regular counseling provided to patients receiving HAART, based on education and guidance to comply with antiretroviral treatment
17331|NCT04054453|Combination Product|Intra-partum care bundle invoking 4 elements|Care bundle involving all the 4 elements
17332|NCT04054427|Device|IOL implantation experimental|Implantation of trifocal IOL POD L GF consisting of hydrophobic material
17333|NCT04054414|Drug|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
17334|NCT04054414|Drug|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
17335|NCT04054388|Behavioral|LINE re-education|
17336|NCT04054375|Drug|Prednisone|Subjects will be asked to take weekly GC oral prednisone dosed based on weight (1mg/kg for patients who weigh less than or equal to 70 kg and 0.75 mg/kg for patients who weigh more than 70 kg). Subjects will also be instructed to take their weekly prednisone on Mondays after their last meal between 7 and 9 PM
17337|NCT04054362|Drug|Paclitaxel protein bound|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
17339|NCT04054362|Drug|Gemcitabine|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
17340|NCT04054362|Drug|Paricalcitol|paclitaxel protein bound and gemcitabine with or without cisplatin until stable or progressive disease at which point paricalcitol will be introduced
17341|NCT04054349|Other|Low FODMAP diet|The low FODMAP diet group reduced the intake of FODMAP(fermentable oligosaccharides, disaccharides, monosaccharides, and polyols)
17342|NCT04054336|Behavioral|Inhibit AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
17343|NCT04054336|Behavioral|classical AAT|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
17344|NCT04054336|Behavioral|Control Group|Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
17345|NCT04054323|Behavioral|Physical Activity Intervention|The physical activity intervention will include basic skill training during which the participant will be instructed on the use of (1) the activPAL physical activity device for the tracking of time spent sitting, standing, and walking, (2) tools to monitor exercise intensity, including ratings of perceived exertion, (3) an exercise calendar for setting a specific schedule for the completion of the home exercise program using the exercise videos posted on our website, (4) use of the exercise equipment that will be used in the home program (Therabands), and (5) strategies for reduction of sedentary behavior that target prolonged sitting and encourages frequent activity breaks. Duration of intervention is 6 months.
17346|NCT04054310|Diagnostic Test|Liver Multi Scan|MRI to create cT1, T2* and PDFF images of patients liver.
17347|NCT04054297|Behavioral|High GI/SFA diet|Subject will adhere to a 2 week high GI/SFA diet.
17348|NCT04054297|Behavioral|Low GI/SFA diet|Subject will adhere to a 2 week low GI/SFA diet.
17349|NCT04054284|Dietary Supplement|Antidiabetic Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
17350|NCT04054284|Dietary Supplement|Herbal Tea|Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks. The first tea needs to be taken in the morning prior any meal. The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
17351|NCT04054258|Device|App support Programme (ASP) group|All subjects will continue their usual care with prescribed medical treatments, ED nursing advice, and follow-ups as indicated. In addition to the above usual care, bi-weekly 20 minutes telephone follow ups will be provided by a trained research nurse (B) up to 3 months. Patients can ask related health problems if any. The nurse will address their problem by providing advices or refer them to the ED follow up clinic if the problems cannot be solved by the nurse.
17352|NCT04054245|Drug|LOXL2 Inhibitor PAT-1251|Given PO
17353|NCT04054245|Other|Quality-of-Life Assessment|Ancillary studies
17354|NCT04054245|Other|Questionnaire Administration|Ancillary studies
17355|NCT04054232|Other|High PAD risk Alert|"In this message sent via the electronic health record, a participant's primary care physician will receive a message that details the following:~Participant flagged as having a high risk of peripheral artery disease based on their electronic health record data~What peripheral artery disease is and why diagnosis may be important~Recommendation to refer to a vascular medicine specialist or order ankle brachial index for definitive diagnosis~The option to opt out if the potential participant is not deemed a candidate for inclusion in the study with a short explanation of why the potential participant should not be included."
17356|NCT04054219|Device|Bone graft substitute|Evaluation of a device made of deproteinized bovine bone material as bone graft substitute in different indications requiring bone grafting procedures before implant placement
17357|NCT04054206|Drug|MN-166|MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.
17358|NCT04054193|Drug|Fosaprepitant|Intravenous (IV) infusion
17359|NCT04054193|Drug|5-HT3 antagonist|Administered according to the product label or local standard of care
17360|NCT04054193|Drug|Dexamethasone|Administered according to the product label or local standard of care.
17361|NCT04054180|Other|CPAP associated with connected devices: blood pressure monitor , scales and activity monitor|CPAP associated with connected devices: blood pressure monitor , PROMs and activity monitor Patients will use their connected devices for one year. Data from the connected devices will be transmitted to their smartphone application Sefam Access. At the beginning of the study, patients will have a dietary assessment and start a support program for nutrition counselling and physical activity. At each study visit the dietician and physical exercise coach will give the patient advices on diet and for adjusting physical activity.
17362|NCT04054167|Drug|Low Dose Radiation Therapy|Undergo ultra low dose radiation
17363|NCT04054154|Device|Shear Wave Elastography|Undergo shear wave elastography
17364|NCT04054154|Procedure|Tumor Interstitial Fluid Pressure Measurement|Undergo tumor pressure measurement
17365|NCT04054141|Device|Mag Stim|rTMS
17366|NCT04054128|Drug|Sodium Bicarbonate 7.5% Injection|Sodium bicarbonate solution for catheter lock; 7.5% sodium bicarbonate solution will be used for catheter lock in both catheter lumens, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
17367|NCT04054128|Drug|Heparin Sodium, 1000 Units/mL Injectable Solution 1|Heparin for catheter lock: 1000 u/mL heparin solution will be used for catheter lock in both catheter lumens as standard treatment, 1.9 mL in each catheter lumen will be infused after hemodialysis treatment during 3 months.
17368|NCT04054115|Drug|Alprostadil 5 MCG Injection|During the MRI, Alprostadil infusion will be started and titrated to the target dose, ensuring there is a less than 20% drop in blood pressure from baseline. Repeat pressure and MRI flow measurements once Alprostadil reaches 0.1mcg/kg/min.
17406|NCT04053803|Drug|IMR-687|Oral administration of once daily IMR-687
17369|NCT04054102|Other|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
17370|NCT04054102|Other|Robot and sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
17371|NCT04054089|Drug|Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy]|Biktarvy OD
17372|NCT04054089|Drug|dolutegravir 50 mg / lamivudine 300 mg|DTG +3TC (Dovato OD)
17373|NCT04054076|Device|Prefabricated insoles|The participants received prefabricated insoles
17374|NCT04054076|Device|Soft custom-made insoles|The participants received soft custom-made insoles
17375|NCT04054076|Device|Hard custom-made insoles|The participants received hard custom-made insoles
17376|NCT04054063|Drug|HSK3486+ etomidate|
17377|NCT04054050|Other|Light therapy|Bright light (10,000 lux) therapy will be administered via a light box.
17378|NCT04054037|Other|No intervention|This is an observation study, no intervention will be indicated during diagnosis and treatment.
17379|NCT04054024|Drug|Erenumab|140 mg Erenumab
17380|NCT04054024|Drug|Placebos|Saline
17381|NCT04054011|Drug|Deoxycholic Acid|Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous
17382|NCT04053998|Procedure|Pancreaticoduodenectomy with portal vein resection|Pancreatic surgery with vein resection to achieve disease clearance.
17383|NCT04053985|Combination Product|TAI combine lenvatinib|TAI combine lenvatinib
17384|NCT04053985|Drug|Lenvatinib|lenvatinib only
17385|NCT04053972|Drug|Lenvatinib|oral lenvatinib after hepatectomy
17386|NCT04053959|Drug|AI assisted insulin system|The patients receive the insulin regime set by AI assisted insulin titration system
17387|NCT04053959|Drug|Physician based insulin regime|Patients receive the insulin regime recommended by physicians
17388|NCT04053946|Device|Next Science Wounds Gels|SurgX will be applied once at closure while BlastX will be applied everyday until day 28 with each dressing change.
17389|NCT04053920|Behavioral|Low Load Resistance exercise|leg extension, leg press, leg curl and calf press
17390|NCT04053920|Behavioral|High Load Resistance exercise|leg extension, leg press, leg curl and calf press
17391|NCT04053907|Other|Community Case Management|Community Case Management (CCM), consisting of community health workers able to diagnose malaria by standard RDTs and treating positive individuals with artemether-lumefantrine (AL), according to national guidelines.
17392|NCT04053907|Other|Weekly fever screening and treatment|Consists of weekly visits by trained VHW who will screen for fever by taking the axillary temperature. If the body temperature is ≥37.5°C, a standard RDT will be performed and, if positive, the individual will be treated with AL, according to national guidelines.
17393|NCT04053907|Other|Monthly malaria screening|CCM plus monthly screening of the whole population with high sensitive RDT (HS-RDT); positive individuals will be treated with AL regardless of symptoms (MSAT).
17394|NCT04053907|Other|MDA|CCM plus 3 monthly rounds of MDA with dihydroartemisinin-piperaquine (DP) starting during the dry season, before the malaria transmission season starts.
17395|NCT04053881|Drug|Certolizumab pegol|Active Substance: Certolizumab Pegol Pharmaceutical Form: Prefilled syringe Concentration: 200 mg/ml Route of Administration: Subcutaneous injection
17396|NCT04053868|Other|JUUL|Electronic Cigarette
17397|NCT04053868|Other|Tobacco|Tobacco Cigarette
17398|NCT04053855|Biological|Urinary sample|Urinary sample (100 ml) will be collected in the urology department to analysis urinary exosomes.
17399|NCT04053842|Diagnostic Test|PET Scan|PET imaging uses small amounts of a radioactive substance called a tracer to look for disease in the body. The radioactive substance used in this study is [F-18]-DCFPyL.
17400|NCT04053842|Drug|[F-18]-DCFPyL Injection|[F-18]-DCFPyL is given by intravenous (IV) injection into the arm. It travels through the blood stream where it is rapidly taken up by prostate cancer cells and emits tiny, positively charged particles (called positrons) that produce signals into the body. These signals are detected by the PET component of the PET/MRI scanner.
17401|NCT04053842|Diagnostic Test|Sodium MRI|Sodium MRI uses magnetic waves and a specially-designed rectal probe to measure the sodium concentration (amount of salt) in the prostate. Previous research has shown that higher sodium concentrations in the prostate might be a sign of more aggressive cancer.
17402|NCT04053842|Diagnostic Test|Multiparametric MRI|MRI is a common medical diagnostic tool that uses magnetic waves and a contrast agent (dye) called Gadovist to take pictures of body tissue.
17403|NCT04053829|Device|HOLOBalance|"The HOLOBalance tele-rehabilitation system will be used to deliver an evidence based, multi-sensory balance rehabilitation programme to participants, and will deliver a series of exercises prescribed by an expert balance physiotherapist following an initial balance assessment.~The HOLOBalance system will use a head mounted augmented reality display to deliver exercises and games to participants and will record task performance via a combination of body worn sensors and a depth camera. The HOLOBalance tele-rehabilitation system will provide feedback to the supervising clinical team regarding task performance, participant usage and user feedback. The system will have daily presence in the users' home with users expected to complete their prescribed rehabilitation on a daily basis, which mirrors the prescribed exercise routines often provided by balance physiotherapists."
17404|NCT04053829|Other|OTAGO Home Exercise Programme|The OTAGO is a systematic, progressive strength and balance training programme and is supported by a comprehensive workbook that provides written and pictorial instructions for each exercise. It is well-established and widely used in clinical practice in the UK, and has been shown to reduce falls rate in older adults by 35-40%. It is well tolerated in older adults in community settings with good adherence rates.The OTAGO has also been used as the standard intervention in previous investigations of MSR interventions in older adults. To match intervention and control interventions, participants in the OTAGO group will be asked to complete the OTAGO programme every day for the duration of the 10 week programme.
17405|NCT04053816|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
17407|NCT04053790|Drug|lactobacillus LB|administration of different doses of Lactobacillus LB according to the treatment groups described previously
17408|NCT04053790|Other|placebo|a tablet of placebo every 12 hours given by mouth
17409|NCT04053777|Device|non-invasive ventilation|Noninvasive positive pressure ventilation used assist/control mode to treat chronic respiratory disease.
17410|NCT04053764|Drug|Crizanlizuamb|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
17411|NCT04053764|Drug|Standard of Care|HU/HC (hydroxyurea/hydroxycarbamide), ACE (angiotensin-converting enzyme)inhibitors, and ARBs (angiotensin-receptor blocker)
17412|NCT04053751|Procedure|closed suctioning system|a randomized allocated patient will be monitored for two days. Closed suctioning system will evaluate as experimental group. open suctioning system will evaluate as control group.
17413|NCT04053738|Device|Anti-snoring bed|The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
17414|NCT04053712|Drug|Glucagon|GlucaGen(R), Novo Nordisk, DK
17415|NCT04053712|Device|Closed-loop system|Closed-loop system comprise of two DANA RS (R) insulin pumps (FiAsp-GlucaGen vs FiAsp-saline), one DexCom G6 sensor, and a smartphone for the control algorithm.
17416|NCT04053699|Drug|VWF-containing products|Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
17417|NCT04053686|Behavioral|Breaks|3-min breaks every half hour at work
17418|NCT04053673|Drug|RBN-2397|an oral PARP7 Inhibitor
17419|NCT04053660|Procedure|Non-surgical periodontal treatment|Mechanical non-surgical treatment were performed
17420|NCT04053647|Other|Non-interventional study|Non-interventional study
17421|NCT04053634|Biological|Benralizumab|Benralizumab solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
17422|NCT04053634|Biological|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks until the end of treatment.
17423|NCT04053621|Dietary Supplement|Thiamine pyrophosphate|12 weeks of weekly dose of 1 gram of thiamine pyrophosphate administered in an intravenous manner with saline solution
17424|NCT04053621|Other|Placebo|12 weeks of weekly dose of 275 ml of saline solution administered in an intravenous manner
17425|NCT04053621|Drug|Metformin|All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
17426|NCT04053595|Diagnostic Test|Dynamic parameters of fluid responsiveness protocol|Dynamic parameter of fluid responsiveness (pulse pressure variation/stroke volume variation) are used to optimize hemodynamics intraoperatively and during the first 6 hours postoperatively when appropriate. A cutoff of 12% is used to predict an increase of stroke volume >10% after fluid administration.
17427|NCT04053595|Diagnostic Test|Estimated oxygen extraction protocol|Oxygen extraction is estimated by the difference of arterial oxygen saturation and central venous oxygen saturation divided by arterial oxygen saturation. A cutoff of 27% is used as a marker of inadequate tissue perfusion requiring hemodynamic optimization.
17428|NCT04053582|Behavioral|AMT|The session will be done on an individual basis. AMT group will receive neurofeedback training from the PCC while focusing on the physical sensations of the breath. The session will last one hour, including 4 neurofeedback runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath with neurofeedback (70s).
17429|NCT04053582|Behavioral|MT|The session will be done on an individual basis. MT group will focus on the physical sensations of the breath while undergoing scanning. The session will last one hour, including 4 runs during which subjects will undergo three conditions across three consecutive blocks: Rest (30s), Describe (view an adjective and decide whether the word describes them; 20s), and Focus on the Breath without neurofeedback (70s).
17430|NCT04053569|Dietary Supplement|Table Grape supplement|5g/Kg of table grape for four weeks with dietary recommendations along with a strict restriction of fruits and limitation of other foods containing polyphenols.
17431|NCT04053543|Drug|CXA-10|(10-nitro-9(E)-octadec-9enoic acid)
17432|NCT04053530|Other|restorative materials|glass ionomer and bulk fill flowable composite
17433|NCT04053517|Other|Medical Chart Review|Medical chart is reviewed
17434|NCT04053517|Other|Quality-of-Life Assessment|Ancillary studies
17435|NCT04053517|Other|Questionnaire Administration|Ancillary studies
17436|NCT04053504|Behavioral|Family Teamwork-Peer Delivery|Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
17437|NCT04053491|Procedure|Hand surgery under regional anesthesia|In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
17441|NCT04053465|Other|Heat acclimation|14 days of aerobic exercise in a hot environment
17442|NCT04053465|Other|Exercise in a cool environment|14 days of aerobic exercise in a cool environment
17443|NCT04053452|Diagnostic Test|Peripheral nerve ultrasound|Ultrasound of the bilateral ulnar nerves, median nerves, vagus nerves, and C6 and C7 nerve roots will be performed.
20856|NCT04025879|Drug|Pemetrexed|Specified dose on specified days.
17444|NCT04053452|Diagnostic Test|Measurement of strength|Strength will be assessed by physical examination and recorded using Medical Research Council (MRC) scale, and a hand dynamometer will be used to measure grip strength.
17445|NCT04053439|Other|Blood test for determination of CHIP|Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.
17446|NCT04053426|Other|Implementation of agitation care algorithm|Following the agitation care algorithm care professional adapt their behavior regarding agitation
17447|NCT04053413|Other|Decision Aid|The decision aid is a series of web pages that includes videos, questions, and evidence-based information. The decision aid is designed to help women think about what matters to them and what questions they may have for their doctor or midwife. At the end, they receive a summary of which way they are leaning and what matters most to them.
17448|NCT04053400|Drug|Ketamine|
17449|NCT04053387|Drug|DMVT-505 (tapinarof cream, 1%)|Tapinarof cream, 1%, applied once daily
17450|NCT04053374|Other|Blood sampling|Blood sampling +/- CSF sampling
17451|NCT04053361|Procedure|Catheter ablation|Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.
17452|NCT04053348|Procedure|Home-based rehabilitation program using mobile app|Home-based rehabilitation program
17453|NCT04053335|Behavioral|Multicomponent Physician Performance Peer-Comparison Feedback Intervention|"The intervention will consist of 5 components delivered simultaneously~Clinical Leadership Team: Each site will develop a Clinical Leadership Team (CLT), typically consisting of quality officers, clinician champions, etc. to implement and monitor the intervention~Speaker Series: VCHI will offer the CLTs access to national experts via a CME-approved speaker series and office hours to support the intervention.~Education Materials: The CLTs will distribute clinician and consumer education throughout the health systems calling to avoid 7 low-value services.~Clinician Report Cards: VCHI will distribute quarterly customized clinician performance report cards to the CLTs teams using the Milliman Health Waste Calculator and Virginia APCD~Quality improvement training: The intervention will provide the CLTs with in-person quality improvement and clinician performance feedback training, using principles of self-determination theory, and will include monthly check-in calls"
17454|NCT04053322|Drug|Durvalumab|Durvalumab will start 4 weeks after the first dose of olaparib (Cycle 2, Day 1) at 1500 mg intravenous (IV) every 4 weeks.
17455|NCT04053322|Drug|Olaparib|2 x 150 mg tablets taken in the morning and in the evening orally (2 X 300 mg daily)
17456|NCT04053322|Drug|Fulvestrant|Two intramuscular injections of 250 mg each on Cycle 1 Days 1 and 15, and then Day 1 of each subsequent 28-day cycle.
17457|NCT04053296|Other|Observational study|We follow up the results of patients.
17460|NCT04053270|Drug|Afamelanotide|16mg subcutaneous implant
17461|NCT04053270|Drug|Placebo|Placebo subcutaneous implant
17462|NCT04053257|Other|Hand hygiene compliance observation with video camera surveillance system and performance feedback of the HH rates to HCWs|"Intervention:~We will report baseline HH compliance rates and HAI rates to HCWs during a meeting where all HCWs are present. During this meeting we will remind major infection control measures, give examples of common mistakes they made without violating personal privacy rights of HCWs and patients."
17463|NCT04053244|Behavioral|internet-based cognitive behavioural therapy|Designed for general clinical use (but not specifically cardiac patients), it consists of 5 online modules outlining cognitive-behavioural skills for depression, completed over 7-8 weeks. The participants will be guided step-wise through the modules by the therapist. Participants can work more or less at their own pace, but are expected to proceed to the next module within 1-2 weeks. Because the content is identical for each participant, fidelity to the web-based component of the intervention is ensured.
17464|NCT04053231|Other|liver resection|all type of liver surgical procedures
17465|NCT04053218|Combination Product|Exercise plus omega-3 supplement|Supervised aerobic exercise and omega-3 supplement
17466|NCT04053218|Dietary Supplement|Placebo|Olive oil placebo
17467|NCT04053205|Drug|Gentuximab|Administered intravenously (IV)
17468|NCT04053205|Drug|Paclitaxel|Administered intravenously (IV)
17469|NCT04053192|Procedure|BAV|BAV
17470|NCT04053192|Procedure|BAV + TAVR|BAV + TAVR
17471|NCT04053179|Device|Patch validation|Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
17472|NCT04053166|Device|individualized home-based physical activity|Subjects will have to reach a daily goal in number of steps, based on the initial evaluation, during 6 months . They will wear connected wrists, and will be contacted twice a month by phone call by an adapted physical activity to revaluate these goals.
17473|NCT04053166|Other|MRI|An MRI will be performed for each patient at the end of the study to identify IPH and other features of histological vulnerability (lipid core, fibrous cap integrity and calcifications).
17474|NCT04053166|Biological|blood sampling|Blood will be collected, to analyse monocyte phenotype by flow cytometry, blood rheology by ektacytometry, coagulation by rotational thromboelastometry (ROTEM). Plasma will be extracted from blood to assess inflammation, oxidative stress and antioxidant markers.
17475|NCT04053166|Other|Questionnaires|sedentary, physical activity, nutrition and quality of life questionnaire will be performed fo each patient.
17476|NCT04053166|Other|6-minute walk test|The 6-minute walk test is a simple, individualized test that measures how fast a patient walks on a flat, hard surface for 6 minutes.
17477|NCT04053153|Device|Exercise equipment (a musical instrument that is based on the Medical Didgeridoo)|exercise equipment (a musical instrument that is based on the Medical Didgeridoo)
17478|NCT04053140|Device|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
17479|NCT04053140|Device|Microneedle array and closed-loop control of penicillin delivery|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed. Microneedle data will be used to titrate benzylpenicillin dosage according to PK-PD target.
17481|NCT04053140|Drug|Penicillin G_2400mg|Benzylpenicillin IV administered in intermittent dosing schedule. Dosage to be determined by closed-loop algorithm. Limits set to 2400mg every 4 hours.
17482|NCT04053140|Drug|Penicillin G_600mg/hr|Benzylpenicillin IV administered in continuous dosing schedule. Dosage to be determined by closed-loop algorithm. Initial loading dose, and limits set to 600mg/hr.
17483|NCT04053127|Device|RAVANS|Electrical stimulation of somatosensory vagal afferent receptors in the ear modulated by respiration.
17484|NCT04053114|Other|DNA and RNA extraction from FFPE or frozen tissue sample|Next generation sequencing (NGS)
17485|NCT04053101|Device|PET CT|Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).
17486|NCT04053088|Device|INSPIRIS RESILIA Aortic Valve™|Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
17487|NCT04053075|Other|Routine cluster detection|Hospitals will use routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
17488|NCT04053075|Other|Enhanced cluster detection|Hospitals will use an automated statistical cluster detection tool in addition to routine practices for cluster detection with a structured cluster response protocol when a cluster is detected.
17489|NCT04053062|Biological|PSMA-CART cells|PSMA-CART cells will be given IV on day 0 over 20-30 mins
17490|NCT04053049|Other|Diet|Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
17491|NCT04053036|Drug|MDMA|Participants will be given 1.5mg/kg of MDMA
17492|NCT04053036|Drug|Placebo oral tablet|Participants will be given a placebo capsule that will only contain lactose.
17493|NCT04053023|Drug|GSK2330672 (linerixibat)|GSK2330672 is available as a tablet with unit dose strength of 45 mg.
17494|NCT04053023|Drug|Obeticholic acid|Obeticholic acid is available as a tablet with a unit dose strength of 10 mg (or 5 mg dependent on evaluation of Part A).
17495|NCT04053010|Biological|Sabin-IPV and DTaP|Sabin-IPV +DTaP at the age of 3/4/5 months old respectively
17496|NCT04053010|Biological|Sabin-IPV|Sabin-IPV only at the age of 3/4/5 months old respectively
17497|NCT04053010|Biological|DTaP|DTaP only at the age of 3/4/5 months old respectively
17499|NCT04052984|Procedure|Delayed umbilical clamping and immediate skin-to-skin contact after birth by caesarean section|Mother: Placement of the insulating surgical arch was on the skin, between the abdomen and the thorax, electrocautery plate on the back, the gown superimposed, non-invasive blood pressure monitoring in legs and ear oximetry. The newborn was placed immediately on the mother's chest, passing it under the insulating arch and removing the mother's gown. Non-invasive monitoring was initiated with preductal pulse oximetry. The obstetrician cut the umbilical cord by not feeling the beats of the cord, or until 5 minutes. The newborn was reanimated without separating the baby from his mother. The temperature was taken with an infrared thermometer. Pulse oximetry was recorded. The newborn was colocated to the mother's breast as soon as possible, even if the mother was still in surgery. The mother's transfer to her room was with her baby skin to skin. The support staff was instructed not to separate the newborn until breast feeding occur for the first time or the mother required it.
17500|NCT04052971|Drug|ABN401- Escalation Phase|Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 0.9 mg/kg to 54.0 mg/kg QD daily for 21 days.
17501|NCT04052971|Drug|ABN401- Expansion Phase|Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of patients representing various c-Met-amplification or mutant tumor types of interest.
17502|NCT04052958|Device|IMT - inspiratory muscle training|respiratory strength or indurance training with respiratory therapy device
17503|NCT04052945|Procedure|SPA acupuncture|"For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations .~The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
17504|NCT04052945|Procedure|sham acupuncture|"For patients in the SA group, the needle was inserted at the same acupuncture point as for patients in the AA group, but to a depth of only 2-3cm and the procedure of rotating, twirling and thrusting the needle was repeated. During the acupuncture process, the acupuncturist sat on the side of the participant, where the patient could neither see the acupuncturist's face nor the length of the needle.~The patients in the SA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4)."
17505|NCT04052932|Drug|SHR4640 dose1|tablets，dose1，QD
17506|NCT04052932|Drug|SHR4640 dose2|tablets，dose2，QD
17507|NCT04052932|Drug|Placebo oral tablet|tablets，QD
17508|NCT04052932|Drug|Allopurinol 300 MG|tablets，300mg，QD
17509|NCT04052919|Other|Cardiac dysfunction in adolescents with type 1 diabetes|"to identify specific parameters related to glucoregulation which correlate with cardiac function and structure in adolescent with T1DM.~In T1DM, exercise training to have beneficial effects on HbA1c levels, cardiovascular risk profile.~To evaluate the association between cardiac function/structure and cardiopulmonary exercise capacity in adolescent T1DM patients (in the perspective of their physical activity behavior). This study thus may provide greater insights in the etiology and consequences of a disturbed cardiac function/structure in adolescents with T1DM."
17510|NCT04052906|Other|Training|Planned Inhaler Medication Trainning
17535|NCT04052737|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients. In this arm normal saline along with standard treatment will be given for active comparison.
18927|NCT04041674|Biological|MVA/HIV62B Vaccine|Administered by IM injection into the vastus lateralis
17511|NCT04052893|Procedure|Expanded Mckissock surgery|Expanded Mckissock surgery: (1) According to patient's preoperative imaging results and subjective expectations of their own breast morphology, the incision design and breast surface marking will be performed under the standing position. (2) After general anesthesia, the upper limbs will be abducted, and the upper body will be tilted by 15°-20° to dermatize the labeled skin around and below the areola. (3) The medial and lateral flaps will be dissociated to remove the total gland with nipple and areola preserved. (4) The cutting-edge of nipple-areola complex will be sent for cancer screening. The axillary lymph node biopsy or cleaning will be performed along the outer edge of the pectoralis major muscle. (5) The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
17512|NCT04052893|Procedure|Modified radical mastectomy|The patients will be placed in the supine position. After intravenous anesthesia, the tumor boundary will be marked and the breast will be removed. The vertical subcutaneous pedicle flaps will be W-folded, and the flaps on both sides will be pulled to the vertical pedicle to reshape the breast. During this process, the breast and armpit drainage tubes will be indwelled.
17513|NCT04052880|Drug|Daratumumab|Daratumumab 1800 mg will be delivered by subcutaneous injection given through a syringe and needle by a manual push over approximately 3 to 5 minutes. Doses will be administered at alternating locations on the abdomen. Daratumumab will be administered weekly during treatment in Cycles 1 to 2, every 2 weeks during cycles 3-6, and every 4 weeks thereafter.
17514|NCT04052880|Drug|Bortezomib|Subjects will receive 1.3 mg/m2 bortezomib as a subcutaneous infusion on Days 1, 8, and 15 during the 28-day cycles.
17515|NCT04052880|Drug|Lenalidomide|"In Cycles 1 through 12, lenalidomide will be self-administered at a dose of 15 mg orally each day on Days 1 through 21 of each 28-day cycle.~For subjects with CrCl 30-60mL/min, lenalidomide will be reduced to 10mg daily, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5mg daily.~In maintenance phase: lenalidomide will be administered at one dose level below Cycles 1-12 dosing ie 10 mg orally daily.~In maintenance, for subjects with CrCl 30-60 mL/min, lenalidomide will be reduced to 5 mg daily during maintenance treatment, and for subjects with CrCl 15-30 mL/min, lenalidomide will be reduced to 5 mg every other day during maintenance treatment."
17516|NCT04052880|Drug|Dexamethasone|"Dexamethasone will be self-administered orally at a total dose of 20 mg weekly during cycles.~However, the dexamethasone 20 mg oral or IV (only if oral is not available) dose administered as a preinfusion medication on daratumumab infusion days replaces the oral dexamethasone dose for that day. Dexamethasone will be administered until the subject experiences disease progression or unacceptable toxicity.~In the maintenance phase, dexamethasone/steroid premedications may be tapered or discontinued in the absence of daratumumab related infusion reactions/based on patient tolerance. In the event of persistent daratumumab related infusion reactions, the least amount of steroid premedications needed to prevent the same may be used."
17517|NCT04052880|Drug|Ixazomib|During maintenance treatment, if choice of maintenance therapy includes ixazomib, ixazomib will be administered at 3 mg orally daily on Days 1,8, and 15 of each cycle. For subjects with CrCl 15-30 mL/min, ixazomib will be reduced to 2.3 mg once per week during maintenance treatment.
17518|NCT04052867|Drug|Lignocaine|Slow bolus of lignocaine is given over 15 min before the start of surgery, followed by infusion of lignocaine
17519|NCT04052867|Drug|Normal saline|An equivalent volume of normal saline is given
17521|NCT04052841|Procedure|Thermal pulsation|Lipiflow (TearScience®, Inc. Morrisville, USA): the lipiflow thermal pulsation system consists of a console and a single-use sterile device, known as the Activator, and has a drug-free mechanism of action. Eye care professionals use the Lipiflow System to treat MGD patients in-office with confidence and efficiency.
17522|NCT04052841|Procedure|Intense pulsed light therapy|Intense pulsed light (IPL) devices employ high intensity pulses of polychromatic lights with a broad range of wavelength (515-1200 nm). IPL treatment has been utilized for years in the field of dermatology, and then its use was applied to ophthalmology for the treatment of MGD.
17523|NCT04052841|Procedure|Manual meibomian gland expression|Using an eyelid massaging devices -Eyepeace (Eye Comfort Ltd, Belfast, UK)) for lid massage. The Eyepeace was placed on closed eyelids and gently squeeze and release between 5-10 times daily.
17524|NCT04052828|Device|FETO with Goldballoon Detachable Balloon (GOLDBAL2) along with the Delivery Microcatheter (BALTACCI-BDPE100)|This will take place between gestation of 27w0d - 29w6d. The balloon will be removed at approximately 34 weeks gestation.
17525|NCT04052815|Behavioral|Diabetes prevention program culturally tailored|Diabetes prevention Program (DPP) as specified by the CDC, physical activity prior to DPP sessions, motivational interviewing individual and in group. Culturally tailored nutrition tips and recipes.
17526|NCT04052802|Other|Fissure sealing|The materials will be applied to the demineralized fissures as stated in manufacturer's instructions
17527|NCT04052789|Other|BioHPP PEEK copings veneered with composite resin|In the first visit, a Face-to-Face adherence session will be held in which the patient should be informed about the study steps and how to maintain oral hygiene measures. Further sessions will occur at the follow-up visits . Participant patients will be asked about any problems they are having. Patients will be recalled every two months for one year for follow up visits.
17528|NCT04052776|Drug|Buspirone|40mg
17529|NCT04052776|Drug|Levodopa-Carbidopa|400mg/100mg
17530|NCT04052776|Drug|Buspirone + Levodopa-Carbidopa|40mg + 400mg/100mg
17531|NCT04052776|Drug|Placebo oral tablet|Non-active metabolite
17532|NCT04052763|Diagnostic Test|FFR-CT|FFR-CT is a non invasive method using coronary CT images and 3 dimensional modelling to reconstruct coronary arteries and their stenoses, with subsequent calculation of fractional flow reserve (FFR) based on a mathematical algorithm.
17533|NCT04052763|Diagnostic Test|FFRangio™|Angiography-derived FFR (FFRangio™) uses coronary angiography images and a mathematical algorithm to reconstruct a 3 dimensional model of coronary arteries with calculation of FFR without the use of a pressure guide.
17534|NCT04052750|Behavioral|SMS follow-up|In addition to conventional treatment, the experimental group received SMS reminding every day until the end of the treatment.
17572|NCT04052438|Diagnostic Test|HLA-C and KIR determination for patients, couples, oocyte or semen donors, abortive tissue and newborn.|
20857|NCT04025879|Drug|Placebo|Specified dose on specified days
17536|NCT04052737|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in Alzheimer's disease patients.
17537|NCT04052724|Behavioral|Intervention group LINGI|Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
17538|NCT04052711|Drug|FMX-101|
17539|NCT04052698|Drug|Wilate|"Produced from the plasma of human donors, Wilate is presented as a powder or solvent for intravenous injection containing normally 500 IU or 1000 IU human VWF and human FVIII per vial. The ratio between VWF ristocetin co-factor activity (VWF:RCo) and FVIII:C is 1:1. The product contains approximately 100 IU/ml human VWF when reconstituted with 5ml/10mL water for injection with 0.1% polysorbate 80.~The specific activity of Wilate is ≥67 IU VWF:RCo/mg protein. The injection or infusion rate should not exceed 2-3mL per minute."
17540|NCT04052685|Procedure|Selective removal to soft dentin (SRSD)|In order to prevent pulp exposure in deep caries lesions radiographically extending at least 3/4 of dentin, periphery of the cavity prepared to hard dentin while reasonable amount of soft carious tissue over the pulp is left. This caries removal strategy is termed selective removal to soft dentine.
17541|NCT04052685|Procedure|Selective removal to firm dentine (SRFD)|Carious tissue is totally removed until hard dentin dry in appearance and hard on probing. This carious removal strategy is strongly recommended for shallow or moderately deep carious lesions.
17542|NCT04052672|Other|Exercise and Nutritional Supplement|The intervention consists of exercise (a combination of supervised and in home) as well as a nutritional supplement (a combination of whey protein and creatine).
17543|NCT04052659|Drug|Sintilimab|200 mg IV，every 3 weeks
17544|NCT04052646|Other|Medical condition: Subarachnoid hemorrhage|We identify patients with the condition of interest and retrospectively collect data on them.
17545|NCT04052633|Radiation|intraoperative cholangiography|success or failure of cholangiography
17546|NCT04052620|Drug|Diclofenac diethylamine 2.32% gel|Participants will apply DDEA 2.32% gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 two times daily for 7 days.
17547|NCT04052620|Drug|Diclofenac diethylamine 1.16% gel|Participants will apply DDEA 1.16 % gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 four times daily for 7 days.
17548|NCT04052620|Other|Placebo|Participants will apply Placebo gel topically with the finger tips (for approximately 1 minute) on both sides of affected ankle 5 cm on 200 cm^2 two times daily for 7 days.
17549|NCT04052607|Drug|LH Suppression|Stimulation protocols
17550|NCT04052594|Drug|LY3475766 - IV|Administered IV
17551|NCT04052594|Drug|LY3475766 - SC|Administered SC
17552|NCT04052594|Drug|Placebo - IV|Administered IV
17553|NCT04052594|Drug|Placebo - SC|Administered SC
17554|NCT04052581|Procedure|POEM-TIF|Transoral Incisionless Fundoplication (TIF) following Per oral Endoscopic Myotomy (POEM) in the same session
17555|NCT04052568|Drug|Psilocybin|Participants will undergo two moderate to high dose psilocybin sessions. Dosing at the first session will be the lesser of 20 mg or 0.6 mg/kg. For the second session participants will either remain at participants' initial dose, or increase to the lesser of 25 mg or 0.6 mg/kg at the discretion of the study team.
17556|NCT04052555|Drug|ATR Kinase Inhibitor M6620|Given IV
17557|NCT04052555|Other|Quality-of-Life Assessment|Ancillary studies
17558|NCT04052555|Other|Questionnaire Administration|Ancillary studies
17559|NCT04052555|Radiation|Radiation Therapy|Undergo RT
17560|NCT04052542|Behavioral|Traditional online continuing education|30-minute, online, interactive, educational video describing the benefits of preventive post-extubation NIV, the indications and contraindications for preventive post-extubation NIV, and the value of working together as an interprofessional ICU team when implementing preventive post-extubation NIV
17561|NCT04052542|Behavioral|Interprofessional education|One-time, 90-120-minute, in-person, interprofessional educational workshop consisting of a 30-minute didactic session and a 60-90-minute small group session
17562|NCT04052542|Behavioral|Just-in-time education|"Just-in-time, point-of-care education provided by trained advanced practice providers who will be on-hand in the study ICU, where they will deliver the education at the bedside during rounds when a patient meets criteria for preventive post-extubation NIV"
17563|NCT04052529|Other|Dietary self-monitoring|Participants use a popular smartphone application to track their food and drink intake for one month.
17566|NCT04052503|Behavioral|Knowledge Broker|Tailored knowledge translation intervention that included barrier assessment and intervention mapping using the theoretical domains framework and participant engagement either fully or partially supported by the knowledge broker.
17567|NCT04052490|Other|Abutment with flat occlusal reduction with feather edge finish|Non vital teeth require a full coverage restoration to withstand the functional stresses and prevent any further destruction of tooth/crown complex. The zirconia all-ceramic crowns yield a high flexure strength and are used as an esthetic alternative to ceramo-metallic crowns. Several studies linked the effect of preparation designs to the survival of the restoration. Others, studied the effect of the finish line geometries as deep chamfer and shoulder on the marginal integrity of restorations. The feather edge finish line is used with zirconia crowns with limited data regarding its success. However, there is no presented research dealing with the effect of finishing line designs in combination with different occlusal reduction schemes on the marginal fit of full contour zirconia crowns.
17568|NCT04052464|Other|endometrium biopsy|All patients will have endometrium biopsy.
17569|NCT04052464|Other|endometrium lavage|In some selected cases biopsy is preceded by endometrium lavage.
17570|NCT04052464|Other|repeated endometrium lavage|Endometrium lavage is repeated during the same cycle.
17571|NCT04052451|Biological|MET-2|Subjects will take study medication once daily for the duration of the study
17605|NCT04052204|Drug|Bempegaldesleukin|Investigational CD122-biased cytokine agonist
17573|NCT04052425|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
17574|NCT04052425|Drug|Vehicle|Vehicle cream is a topical formulation applied as a thin film to affected areas.
17575|NCT04052412|Drug|18F-AraG|All arms of the study will receive an injection of 18F-AraG while on the PET imaging system. Following a 6 minute scan over the heart to acquire input function data, the patient will undergo a 1 hour multi-pass whole-body dynamic PET/CT acquisition to gather whole-body biodistribution data.
17576|NCT04052399|Device|anodal transcranial direct current stimulation|"Anodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
17577|NCT04052399|Device|cathodal transcranial direct current stimulation|"Cathodal tDCS of the lateral hypothalamus-cognitive or medial hypothalamus-cognitive network.~The total injected current will never go beyond 4 milliamp, which will be split among the different stimulation electrodes."
17578|NCT04052399|Device|transcranial direct current stimulation|Single blind sham stimulation (ramp-up ramp-down stimulation will be applied for 30 seconds)
17579|NCT04052386|Behavioral|BASICCS|Participants randomized to the BASICCS condition received a personalized feedback intervention conducted through a web-conferencing platform. The personalized feedback intervention included tailored feedback on drinking quantity and frequency of alcohol, BAC, alcohol-related consequences, normative perceptions of peer drinking, alcohol outcome expectancies, family history of risk, and financial costs of alcohol. They also received up to 24 text messages with protective behavioral strategies for drinking during the following month.
17580|NCT04052373|Procedure|Implantoplasty|Implantoplasty is the mechanical smoothening of rough titanium implants as part of the surgical treatment of peri-implantitis. Treatment is thought to facilitate self-performed oral hygiene.
17581|NCT04052373|Procedure|Open flap debridement alone|Open flap debridement alone
17582|NCT04052360|Drug|Cenerimod|A single oral dose of 4 mg cenerimod will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
17583|NCT04052360|Drug|Matching Placebo|A single oral dose of matching placebo will be administered as a film-coated tablet in the morning of Day 1 under fasted conditions.
17584|NCT04052347|Behavioral|Shared decision-making with a Decision-aid|A tablet computer-based decision-aid was developed by the study investigators based on the standards of the International Patient Decision Aid Standards Collaboration9
17585|NCT04052347|Behavioral|routine shared decision-making|control group
17586|NCT04052334|Drug|TIL|Participants will receive an infusion of Tumor-infiltrating lymphocytes (TIL) after tumor resection and TIL product is generated.
17587|NCT04052334|Drug|Interleukin-2|Participants will receive Interleukin-2 (IL-2) 600 000 IU/kg intravenously (IV) bolus (about 15 minutes) every 8 to 16 hours for up to 15 doses, beginning approximately 12 to 16 hours after T-cell infusion.
17588|NCT04052334|Drug|Fludarabine|Participants will receive an intravenously (IV) infusion of Fludarabine 25 mg/m2 for approximately 30 minutes for 5 days, prior to T-Cell infusion
17589|NCT04052334|Drug|Cyclophosphamide|Participants will receive Cyclophosphamide 60 mg/kg/day intravenously (IV) in 250 mL normal saline (NS) over approximately 2 hours, 7 days prior to T-Cell infusion
17590|NCT04052321|Other|3D optical surface scan|A 3D optical surface scan is acquired utilizing a handheld 3D scanner. Such a scanner is comparable to an ordinary photo camera, however, it also records depth.
17591|NCT04052308|Behavioral|ABPM|Ambulatory Blood Pressure Monitoring at Baseline and at the end of the study
17592|NCT04052308|Behavioral|The arterial stiffness and endothelial reactivity|The arterial stiffness and endothelial reactivity will be assessed at baseline and at the end of the study
17593|NCT04052308|Behavioral|Euroqol EQ-5D-5L|Answer Euroqol EQ-5D-5L at baseline and at the end of the study
17594|NCT04052308|Behavioral|Lectures about knee OA|Patients will participate in two days of lectures two-months apart on the subject of knee OA, but will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits to be improved; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy team followed by 7 sessions with the physical educators team (once a week/4 weeks and once every two weeks, three times).
17595|NCT04052308|Behavioral|Continuous intensity exercise|40 min of treadmill physical exercise (40 min on treadmill at 60% of reserve heart rate.)
17596|NCT04052308|Behavioral|Exercises with varying intensity and interval|40 min of treadmill physical exercise ( 40 min on treadmill with alternating intensity between 50% (2 min) and 80% (1 min) of HR, resulting in an average load of 60% ((50% 2) + 80% / 3)), 20 min of sub-maximal strength training and 10 min of cooling exercises.
17597|NCT04052295|Procedure|surgical diaphragmatic plication|The plication was done by the same surgeon either via a 7-8 cm long lateral thoracotomy and entrance to the pleural cavity through the eighth intercostals space on the affected side or using VATS (video-assisted thoracoscopic surgery) procedure. It was performed under single lumen intubation general anaesthesia. The diaphragm with the abdominal content was pushed caudally till the normal position of the copula achieved. At this position a fold of about 5 cm is made using traction forceps of the reluctant diaphragm. Polypropylene sutures (zero or 1) were used to perform the plication of the diaphragm. in making a fold on itself. The plication was performed using interrupted polypropylene U-stitches; usually, it started from posterior part to the anterior part of the diaphragm. We merged every two rows with continuous polypropylene sutures. The diaphragm became tough and firm and returned to its normal position. An intercostal tube was inserted, and the thoracotomy was closed in layers.
17598|NCT04052282|Device|Mobile Health App|There is no intervention
17599|NCT04052269|Drug|Sildenafil 100mg|study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
17600|NCT04052256|Diagnostic Test|Coronary computed tomography angiography|Computational fluid dynamic model information derived from CT
17601|NCT04052243|Diagnostic Test|Invasive exercise testing|Invasive hemodynamic exercise testing
17602|NCT04052230|Other|ultrasound mesure|Admission to the intensive care unit, and setting up an ECMO Daily monitoring from D1 to D7, follow up at D60
17603|NCT04052217|Device|Penile Ring|Penile Ring at base of penis
17604|NCT04052204|Drug|avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
24426|NCT03996772|Drug|Apixaban Oral Tablet|Factor Xa Inhibitor
17609|NCT04052178|Device|rTMS active and sham|Repetitive transcranial magnetic stimulation of the pharyngeal sensory cortex.
17610|NCT04052178|Device|PES active and sham|Intrapharyngeal electrical stimulation with a catheter delivering electrical pulses.
17611|NCT04052178|Dietary Supplement|Capsaicin active and placebo|Capsaicin solution (TRPV1 agonist) at a concentration of 10-5M or placebo solution.
17612|NCT04052165|Procedure|Glaucoma Implant|
17613|NCT04052152|Drug|Anlotinib and Sintilimab injection|Patients will be treated with Anlotinib and Sintilimab injection
17614|NCT04052139|Drug|Low-dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks. Participants in this group will also receive two matching placebo capsules to be taken twice daily with the active medication in weeks 1-3 and 8. In weeks 3-7, participants will take take 2 capsules three times per day (5 placebos, 1 active study medication) to match the the dosing regimen of the gabapentin arm. In week 7, participants will take two matching placebo capsules to be taken twice daily with the active medication (three capsules per day).
17615|NCT04052139|Drug|Gabapentin|Dose will begin at 900 mg daily (300 mg tid), in week 2 the dose will be titrated up to 1800 mg daily (600 mg tid). In week 3, the dose will be titrated to 2700 mg daily (600 mg+300 mg tid) until week 7, and then tapered back down to 900 mg daily (days 1-3: 600 mg tid, days 4-7: 300 mg tid). Gabapentin will only be titrated up as tolerated by the participant.
17616|NCT04052139|Drug|Placebo|Capsule taken three times a day for 8 weeks in weeks 1-3 and 8. In week 3, dosing will change to 2 capsules three times per day until week 7. In week 7, participants will take three placebo capsules per day.
17617|NCT04052126|Other|Individualized physical activity program|"Participants who agreed to participate in the study will participate in an individualized 6-month physical activity (PA) program, consisting of 3 periods: initiation (1st month), transition (2nd-3rd months) and autonomy (4th-6th months). It is based on 4 PA modalities:~The supervised PA session in a sterile room or at home once a week during the initiation and transition phases (20-45 min, low-to-moderate intensity, walking, muscle strengthening, balance and flexibility exercises).~The unsupervised PA session in a sterile room or at home once a week during the transition phase and twice a week during the autonomy phase (same as supervised session).~Follow-up by telephone once a month during the autonomy phase (30 min, support to PA).~Continuously wearing an activity tracker throughout the entire program (promotion of walking).~Activities are planned over a period of 6 months to achieve an intervention that meets the key principles of progression, specificity and empowerment."
17618|NCT04052100|Other|Usual care|The standard preoperative measures will consist of a recommendation for physical activity and advice on tobacco smoking cessation and reduction of alcohol intake. In addition, patients who suffer from iron deficient anemia will receive intravenous iron and those at risk of malnutrition (Malnutrition Universal Screening Tool ≥2 (www.bapen.org.uk/pdfs/must/must_full.pdf)) or that require weight control for obesity (IMC≥30) will perform a nutrition intervention by a nutritionist.
17619|NCT04052100|Other|Multimodal prehabilitation|"The experimental group will also carry out a prehabilitation program consisting in:~A. A motivational interview to reinforce the patient's motivation and generate a commitment in relation to the objectives of the program.~B. A physical activity promotion program to increase the number of daily steps of patients, measured by a wristband and a mobile App.~C. A supervised high-intensity exercise training program. D. An individualized nutritional optimization plan with dietary advice and protein supplementation (if necessary). Educational material and motivational messages will be sent through a mobile App.~F. Psychological support through weekly Mindfulness sessions (1.5 hours duration). Educational material and motivational messages will be sent through a mobile App.~E. A smoking cessation program consisting psycho-cognitive therapy combined with pharmacological treatment. Educational material and motivational messages will be sent through a mobile App."
17620|NCT04052074|Other|Music Therapy|We are aiming to use music therapy, with pre-recorded favoured music, as a complementary treatment in oncological patients in palliative care, as well as on the carer. It will be performed using mp3 players or mobile phones.
17621|NCT04052074|Other|simulation with therapeutic education|Basic therapeutic education repetition performed to all caregivers and oncological patients in palliative care, through earphones
17622|NCT04052061|Biological|CD19 t-haNK|CD19 t-haNK Suspension for Infusion
17623|NCT04052048|Diagnostic Test|Subtraction Normalized Expression of Phagocytes Blood Test|Non-invasive blood based immunogenomic assay that targets RNA sequencing to identify disease and disease aggressiveness
17624|NCT04052035|Procedure|measuring the size of the follicle at time of follicle aspiration|While for an OPU out of the study the follicles are aspirated without measuring their sizes, now the follicles will be measured before they are aspirated. The measurement of the follicles is a non- invasive measurement: as the OPU is always performed under vaginal echo-guidance, the follicles are visible on the screen connected to the vaginal echo probe. By measuring two dimensions of the follicle, an average follicle diameter is registered for that follicle
17625|NCT04052009|Other|Conventional gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
17626|NCT04052009|Other|End-effector based gait training|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
17627|NCT04052009|Other|combined training (conventional and end-effector-based)|Duration and Intensity: 10 sessions of 45 minutes 3-4 times per week Each intervention is conducted by a local physiotherapist For further details please see the description of arms
17628|NCT04051996|Drug|Glasdegib|Glasdegib will be administered at the starting dose of 100 mg orally once daily.
17629|NCT04051996|Drug|Decitabine|Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
17660|NCT04051671|Device|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) during the first 20 mins of conventional physical therapy. Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 2 weeks. The two experiments will be performed in random order for each subject.
17858|NCT04050046|Behavioral|Computer-based cognitive therapy (CBCT)|Repetitive, drill-like training usually presented in the form of a game that targets a specific cognitive construct.
17630|NCT04051970|Drug|Antiretroviral|"Antiretroviral treatments (ART) will be allocated through central randomization (1:1:) according to the following two strategies:~Tritherapy-Bitherapy (TRI-BI) strategy:~TRI between D0 and W16: 3-drug combination (3-DR) including 2 NRTI (either TDF or TAF+XTC) and a once daily integrase inhibitor (Stribild® or Genvoya® or Biktarvy®) or TDF/XTC Gé + Tivicay® or TDF/XTC Gé + Isentress® QD 1200 mg when available) during 16 weeks BI between W16 and W96: if pVL viral load <500 cp/mL at W4 and <50 cp/mL at W12, participants will start the 2-DR regimen TDF or TAF / XTC (TDF/XTC Gé or Descovy®) at W16, until W96.~(Descovy® : provided that it is available in France), (XTC = FTC or 3TC)~Immediate Bitherapy (BI) strategy Dolutegravir (DTG, Tivicay® 50 mg QD) plus lamivudine (3TC, 300 mg QD) between D0 and W96.~Antiretroviral drugs will be prescribed in the context of standard of care."
17631|NCT04051957|Drug|Isosorbide Mononitrate|The starting dose will be Isosorbide Mononitrate 60 mg ER daily and after 4 weeks, if tolerated but response is not achieved, the dose will be escalated to Isosorbide Mononitrate 120 mg ER daily (2 tabs of 60 mg ER tablets).
17632|NCT04051957|Drug|Placebo oral tablet|Placebo will be given daily and will be doubled after 4 weeks of start of therapy.
17633|NCT04051944|Drug|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
17634|NCT04051918|Behavioral|Piano Training|Cognitive training via music learning
17635|NCT04051892|Device|FixNip™ NRI|The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
17636|NCT04051866|Procedure|Non-surgical periodontal treatment: Scaling and root planing (SRP)|Removal of dental plaque and dental calculus from the surface of a tooth, from the surface of a tooth apical to the gingival margin accumulated in periodontal pockets, or from the surface coronal to the gingival margin.
17637|NCT04051866|Other|Oral hygiene instructions|Education for individual health regarding peridontal disease and its association with diabetes, as well as oral hygiene instructions that include the modified Bass technique, use of interproximal brushes and dental floss
17638|NCT04051853|Drug|Sorafenib|Patients will receive sorafenib at a starting dose of 200 mg twice daily. In the absence of toxicity dosage will be gradually escalated up to 400 mg BID.
17639|NCT04051853|Other|Midazolam clearance test|Before start of treatment patients receive a single oral dose of midazolam to phenotype CYP3A4 activity. Blood samples will be taken at several time points to measure sorafenib and midazolam concentrations.
17640|NCT04051853|Other|CYP cocktail clearance test|In a subgroup of 15 patients (in the Academic Medical Center Amsterdam), this test will be replaced by an oral cocktail of subclinical doses of caffeine, midazolam, omeprazole, warfarin and metoprolol and will be repeated after 4 weeks of treatment to assess the influence of sorafenib on cytochrome P450 (CYP) 1A2, 3A4, 2C19, 2C9 and 2D6 activity, respectively.
17641|NCT04051840|Drug|ClinOleic (Baxter Healthcare, Deerfield, IL, USA)|ClinOleic group: Patients using ClinOleic or Structolipid-based lipid parenteral nutrition regimen. From day 0 to day 5, the goal of treatment is to deliver 25kcal/kg/day, 1.05g/kg/day amino acids, and 1.1g/kg/day lipid.
17642|NCT04051827|Drug|Midazolam|Midazolam Oral Solution and Midazolam Intravenous Infusion.
17643|NCT04051827|Drug|TAK-788|TAK-788 Oral Capsules.
17644|NCT04051814|Other|Micra Transcatheter Pacemaker System|A miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart
17645|NCT04051801|Drug|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
17646|NCT04051801|Drug|Dose Escalation of Placebo|dose levels of the cohorts will be increased step wise
17647|NCT04051788|Other|Step Aerobics|Alternating step knee-lift sequences; alternating leg up, up, down, down patterns; and step kicks, 120 to 126 foot strikes per minute, 20 to 30 minutes per session s, 3 sessions per week up to 6 weeks,The target intensity for all sessions will set at 50-70% heart rate (HR) reserve.
17648|NCT04051788|Other|Aerobic exercise (Lower limb Cycling)|Lower Limb Aerobic cycling, 20 to 30 minutes per session, 3 sessions per week up to 6 weeks, The target intensity for all sessions will set at 50-70% heart rate (HR) reserve
17649|NCT04051762|Device|High flow nasal cannula vs. Nasal continuous positive airway pressure|High flow nasal cannula
17650|NCT04051749|Procedure|Noncardiac Vascular Surgery|Noncardiac Vascular Surgery
17651|NCT04051736|Biological|Inactivated Polio Vaccine|Inactivated Polio Vaccine at age of 2,3,4 months old, respectively
17652|NCT04051723|Drug|The dexamethasone plus ropivacaine|The local infiltration solution containing 0.25mg Dexamethasone and 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
17653|NCT04051723|Drug|The ropivacaine|The local infiltration solution containing 2mg ropivacaine per milliliter. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
17654|NCT04051710|Drug|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
17655|NCT04051710|Drug|Reference Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
17656|NCT04051710|Drug|Placebo|Placebo Product
17657|NCT04051697|Behavioral|SEA CHANGE intervention|The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
17658|NCT04051684|Procedure|Transverse abdominal plane block|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
17659|NCT04051684|Drug|Ropivacaine|Regional anesthesia team will perform a single shot TAP block with 0.5% ropivacaine 15-20 ml / side under ultrasound guided technique with blunt tipped, 21 gauge needle.
17661|NCT04051658|Device|Transcranial direct current stimulation|Dual/Cathodal/Anodal/Sham tDCS will be applied in 1.5 mA, 20 mins before conventional physical therapy for 5 days. All experiments will be performed in random order for each subject.
17662|NCT04051645|Device|Breathing through a system with adjustable flow resistance|"The proband will breathe through the adjustable flow resistance within the experiment, to which a standard D-lite Flow sensor will be connected, and the airway pressure, flow, minute consumption, oxygen and carbon dioxide, tidal volume, oxygen saturation of peripheral blood and oxygen and carbon dioxide concentrations in both inspired and expired air will be recorded using the Datex-Ohmeda S/5 Patient Monitor vital signs monitor.~The proband will breathe through the flow resistors in a randomized order, and pre-defined three-minute pauses will be maintained between measurements with different flow resistance values. Each measurement will take approximately two minutes and will be measured on ten different flow resistances."
17663|NCT04051632|Device|Medtronic 670G insulin pump|"percent of patients who continue to use Medtronic 670G over time~impact of 670G on glycemic control: hemoglobin A1c, time in range"
17664|NCT04051619|Drug|intranasal oxytocin, 40 IU, twice a day for 7 days|Adjunct therapy
17665|NCT04051606|Drug|Regorafenib|Regorafenib is a monotherapy during the study, oral administration at 160 mg once daily will be administered for 3 weeks on /1 week off.
17666|NCT04051593|Other|Cervical stabilization exercise|The participants followed instructional videos and performed the cervical stabilization exercise program at home for 20 minutes/day, 3 days/week, for 6 weeks.
17667|NCT04051580|Drug|Lactated Ringer|Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
17668|NCT04051567|Drug|Aspirin 100mg|In LDA group, patients were asked for taking 100mg aspirin per night;
17669|NCT04051554|Other|Neuromuscular and Proprioceptive Training|Myklebust's training program (floor exercises, mat exercises, and wobble board exercises for 5 weeks)
17670|NCT04051554|Other|Conventional Training|Running, Sprinting, Agility training and Dynamic stretching for five weeks
17671|NCT04051541|Other|Agitated saline push|Push of agitated saline to simulate adenosine used for supraventricular tachycardia
17672|NCT04051528|Procedure|aerobic exercise training|The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
17673|NCT04051528|Procedure|computerized cognitive training|The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
17674|NCT04051528|Procedure|guiding training|At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
17675|NCT04051515|Other|Intradialysis exercise training|Combined exercise, aerobic and resistance training, implemented by nursing staff
17676|NCT04051515|Other|Home-based exercise training|Combined exercise, aerobic and resistance training, implemented independently home
17677|NCT04051502|Drug|Method 1: Indocyanine green dye|Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located
17678|NCT04051502|Drug|Method 2: Indocyanine green dye|"1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~Dorsal side of the IP ligament~Ventral side of the IP ligament~Dorsal side of the utero-ovarian ligament~Ventral side of the utero-ovarian ligament"
17679|NCT04051502|Drug|Method 3: Indocyanine green dye|Injection of 4mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
17680|NCT04051489|Other|Mobile health App - Test|"Beta Testing 1: The Beta test 1 will be performed with participants inside the Research Center. The purpose of this phase is to increase usability, acceptability and reliability of the mHealth App in participants with knee osteoarthritis (KOA).~Beta Testing 2: The Beta test 2 will be performed with patients outside the Research Center, at their houses. The purpose is to focus on the mHealth App remote usability, acceptability, and data collection."
17681|NCT04051476|Other|3-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g ginger flour (3 g per l), followed by a ten-minute post-intervention rest period.
17682|NCT04051476|Other|6-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g ginger flour (6 g per l), followed by a ten-minute post-intervention rest period.
17683|NCT04051476|Other|12-g footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g ginger flour (12 g per l), followed by a ten-minute post-intervention rest period.
17684|NCT04051476|Other|Warm water footbath|A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
17685|NCT04051463|Drug|Netarsudil Ophthalmic Solution|Netarsudil eye drops instilled once daily
17687|NCT04051437|Procedure|Plasma exchange|During each plasma exchange session 3-4lt (1.2-1.3 times of plasma volume) of plasma will be exchanged with fresh frozen plasma and 5% albumin. Plasma exchange session will be done on an alternate day to a maximum of 5 procedures. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session No improvement in clinical condition Intolerant to PLEX procedure
17688|NCT04051437|Drug|Standard medical treatment|The consented patients will receive standard medical treatment which includes adequate nutrition (35-45 Kcal/Kg with 1.5gm/Kg protein) diuretics, anti HE measures, appropriate antibiotics for infections,tablet entecavir 0.5 mg once daily for hepatitis B, and steroids for autoimmune hepatitis.
17689|NCT04051424|Device|ConMed bite block|Investigator will fit ConMed bite block in patient's mouth and bronchoscopist will try to visualize the vocal cords.
17690|NCT04051424|Device|McKay airway|Investigator will fit McKay airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
17691|NCT04051424|Device|Williams Airway|Investigator will fit Williams Airway in patient's mouth and bronchoscopist will try to visualize the vocal cords.
17692|NCT04051398|Other|transcutaneous nerve electrostimulation (TENS) of acupuncture points|TENS application session over the acupuncture points: Feishu, Zhongfu, Taiyuan and Dingchuan using a frequency of 200Hz and a pulse time of 80 seconds of sufficient intensity to cause a slight sensation of local numbness without muscle fasciculations. The TENS application time will be 30 minutes.
17693|NCT04051385|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
17694|NCT04051385|Other|Gingival crevicular fluid and serum collection|GCF with filter paper using the intracrevicular method and serum collection
17695|NCT04051372|Diagnostic Test|Bronchoscopic Alveolar Lavage|"The diagnostic yield of different diagnostic methods for lung infection and non-infectious diseases under allo-HSCT patients.~Classic microbiological cultures designed for bacteria, fungi, and mycobacteria.~Detection of human cytomegalovirus (CMV) and EB virus in serum and BAL was tested using a Real-time PCR kit.~Detection of aspergillus galactomannan antigen 1,3-beta-D-glucan in serum and BAL was performed using an enzyme immunoassay method.~Cytological and pathogenic microscopic evaluation in BALF~Flow cytological analysis of T lymphocyte subsets in BALF and serum~Cytokine detection in BALF and serum~Microbiology detection in BALF by mNGS"
17696|NCT04051359|Other|Low carbohydrate (130 g) diet|Isocaloric moderately reduced carbohydrate diet (RCD, reduced carbohydrate diet) (~130 grams of carbohydrates)
17697|NCT04051346|Dietary Supplement|Low Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them
17698|NCT04051346|Dietary Supplement|High Oxalate Diet|Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, to exercise strenuously, or to consume food or drink that is not provided to them.
17699|NCT04051333|Device|ALS Nutrition App (MyDataHelps platform)|We have designed a mobile health app to provide nutritional counseling and to measure disease outcomes both through self-reported questionnaires and through passive data collection.
17700|NCT04051320|Drug|Leuprolide Acetate 3.75 MG/ML|3.75 mg/month leuprolide acetate intramuscular injection
17701|NCT04051320|Drug|Estradiol 2 Mg tablet|2 mg estradiol tablet
17702|NCT04051320|Drug|Micronized progesterone|200 mg micronized progesterone tablets
17703|NCT04051307|Drug|PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|Peptide vaccination
17704|NCT04051307|Drug|Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL|Peptide vaccination
17705|NCT04051294|Dietary Supplement|Commercial kombucha tea|Commercially-available kombucha tea.
17706|NCT04051294|Dietary Supplement|Brewed kombucha tea|Kombucha tea brewed
17707|NCT04051294|Other|Control: Tea|Tea brewed in our lab.
17708|NCT04051294|Other|Control: Water|Tap water
17709|NCT04051281|Behavioral|Letter|Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)
17710|NCT04051268|Biological|Vi-DT Typhoid Conjugate Vaccine|1 dose of Investigational Product
17711|NCT04051268|Biological|PQed Typhoid Conjugate Vaccine|1 dose of Active Comparator
17712|NCT04051268|Biological|Vi Polysaccharide Vaccine|1 dose of Active Comparator
17713|NCT04051255|Drug|full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg|The patients were treated by a single-session of periodontal debridement under local anaesthesia during 45 minutes, using an ultrasonic instrument#, using subgengival tips* and irrigation with sterile saline solution, by the same operator (MGC, Paulista University, São Paulo, Brazil). After the debridement, all patients was prescribed with Amoxicillin 500 mg and Metronidazole 400 mg, every 8 hours, for 10 days (Casarin et al., 2012). Subjects were extensively informed about the intake of the prescribed medication. Subjects were clinically and microbiologically monitored at baseline (before therapy) and at 3 and 6 months post-therapy. During the monitored sessions, oral hygiene was evaluated and home care instructions were re-emphasized. Additionally, all subjects were recalled monthly for oral hygiene instructions.
17714|NCT04051242|Device|XenMatrix™ AB Surgical Graft|Graft implantation, radiographic, functional, and electrophysotherapy outcomes will be measured at various time points up to 24-28 weeks post-operatively. A CT scan or MRI will be collected at screening and pre-operative visits to evaluate tissue volume, then again at post-operative Visit 1 and Visit 6. Physical therapy training will be performed as a research procedure following Graft implantation for a maximum of 30 weeks. Additionally, Physical Therapy evaluations will be conducted at screening, pre-op visit 1, post-op, and at post-op Visits 3, and 4. A small core needle biopsy 1-5 grams will be collected at three time points to conduct histomorphological assessment of the tissue prior to Graft implantation (Operative visit, Visit 2 and at Visit 4).
17715|NCT04051229|Behavioral|6-week exercise training program|Participants will walk at 50% Heart Rate Reserve (HRR) 3 to 5 days per week for 6 weeks at the Department of Health and Exercise Science Clinical Research Center under the supervision of study staff.
17716|NCT04051229|Behavioral|Standardized isoenergetic high fat diet|Prior to the submaximal exercise testing visits, all participants will be provided with 3 days of a standardized isoenergetic high fat diet (20% of kcals from carbohydrate, 65% fat; 15% protein) to promote lipid oxidation. The meals will be prepared and provided by the Clinical Research Unit of Wake Forest Baptist Health. Participants will pick up 3 days' worth of food and snacks 4 days prior the testing visit. For the 3 days leading up to the visit, participants will eat the provided foods and complete a compliance assessment.
17717|NCT04051216|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention
17718|NCT04051216|Other|Activity monitor|Participants will receive at least 1 of 4 activity monitoring devices
17719|NCT04051216|Other|Interview|Participants will be interviewed about their experience using the device(s)
17720|NCT04051216|Other|Survey Administration|Participants will receive surveys
17721|NCT04051216|Other|Laboratory Biomarker Analysis|Correlative studies
17722|NCT04051203|Biological|Autologous Platelet Rich Plasma Injection|60mL of blood will be drawn from the antecubital vein and processed via centrifugation. Samples will be centrifuged as per manufacturer instructions, yielding 5mL of PRP. For quality testing, 1mL of PRP will be sent to the lab for analysis of platelet and leukocyte count, as compared to the patients' whole blood.
17723|NCT04051203|Drug|Depo-Medrol and lidocaine|Steroid injections will be prepared to include 20mg Depo-Medrol and 2mL 2% lidocaine.
17724|NCT04051203|Other|Normal Saline|2mL normal saline.
17725|NCT04051190|Dietary Supplement|VLED group|10-week weight loss period with total meal replacement, consisting of 750 kcal/day followed by 2 week weight stabilization prior to surgery. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy).
17726|NCT04051190|Procedure|Sleeve Gastrectomy group|Standard clinical practice with 2-week diet consisting of 750 kcal/day prior to surgery. The pre- and post-surgical diet of this group will be matched with the VLED group in macro- and micronutrient composition. Measurements will be taken at baseline (before diet start), 10 weeks after intervention start (Wk11), and 1 year after surgery (sleeve gastrectomy)
17727|NCT04051177|Behavioral|"Interactive Communication with Openness, Passion, and Empowerment ICOPE"|"The parent curriculum consists of five interactive training sessions (120 minutes each session for 10 hours total) with three specific focuses: understanding the stages of childhood cognitive development in the context of parental illness (Session #1 Child's readiness for disclosure); improving the parents' cognitive and behavioral skills related to parental HIV disclosure (Session #2 Benefits and risks of disclosure, Session #3 How to tell and what to tell, and Session #4 Disclosure is an ongoing process); and improving parental psychosocial well-being in adapting to living with HIV/AIDS (Session #5 Cope with my infection/illness). The curriculum addresses the issues of child and family strengths and community support across sessions."
17728|NCT04051177|Behavioral|Nutrition Curriculum|"The modified curriculum consists of five 2-hour interactive training sessions with aims to increase parents' knowledge of nutrition (Session #1: Food variety; Session #2: Food for growing child), healthy diets and cooking practice (Session 3: Fat, salt and sugar; Session 4: Fruits, vegetables and minerals), and food safety (Session #5 Food safety)"
17729|NCT04051164|Other|Progressive Muscle Relaxation Technique|"PMRT begins by assuming a comfortable position of lying down, sitting or leaning back.~Patient is asked to take a breathe in and intentionally contract muscle and hold muscle and after that release all tension and focus on sensation of relaxation. Each muscle group is tensed for 5-7 seconds and relaxed for 20-30 seconds. PMRT is given twice a day for one week."
17730|NCT04051164|Other|Conventional treatment|Strengthening exercises of residual limb: After amputation strengthening exercises of residual limb is necessary to prevent shortening of muscles and tightening of joints, moreover it is necessary to make residual limb strong and flexible in order to use a prosthesis. This include Hip abduction, prone hip extension and Prone position. Gait training: This include standing exercises in the parallel bars with or without the prosthesis. Initial walking exercises in which the patient is taught to raise each knee alternately and to try to take weight on his limb as much as possible. Deep Breathing exercise: Deep breathing 10-15 repetitions twice a day.
17731|NCT04051151|Behavioral|Gameficiation|Participants and partners that have randomized to the gamification group will receive instructions and help in setting up a game platform via Way to Health. This game will include wearing a Fit Bit device, setting a daily step goal, and point deductions for failure to meet this step goal throughout the following 4 weeks. Participants will move up or down specified levels each week depending on how many days they met their step goal.
17732|NCT04051138|Other|Voxx socks and sleeves|participants will be tested with a true device as well as with a placebo device
17733|NCT04051112|Drug|SCB-313|10mg group: Intraperitoneal injection single dose on Day 0, safety observation for 7 days, then 3 continuous doses on Day7, Day8, Day9, 21 days for 1 cycle
17734|NCT04051099|Procedure|Bilateral superficial cervical plexus block with 0.25% bupivacaine 8 ml each (total 16 ml)|bilateral superficial cervical plexus
17735|NCT04051099|Drug|Dexmedetomidine plus propofol infusion|Dexmedetomidine 0.5 ug/kg infusion in 10 min then 0.5 ug/kg/h, Propofol infusion
17736|NCT04051099|Procedure|Local infiltraion analgesia|local infiltration analgesia with 2%lidocaine with adrenaline 5 ug/ml 10 ml
17737|NCT04051099|Procedure|General anesthesia with endotracheal tube|Induction with Propofol and intubation with cisatracurium
17738|NCT04051086|Biological|Physical examination and Urine and blood samples|"Only one visit for each participant : A large majority of visits will be part of patients' usual care~Medical examination : birth, weight, gender, blood pressure, medical history~Urine and blood samples"
17739|NCT04051086|Biological|Urine and blood samples|"Only one visit for each participant~Medical history~Urine and blood samples"
17740|NCT04051073|Device|Continuous non-invasive blood pressure monitoring|Continuous non-invasive blood pressure monitoring using CNAP
17827|NCT04050254|Device|Sham tDCS|Sham current (STARSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days. Sham tDCS will be applied for the same time than real tDCS.
17743|NCT04051034|Dietary Supplement|Omega 3|"Active: 1.25 g capsules/420 35-count bottles [1.25 g capsule contains min. 750 mg EPA + 250 mg DHA] and heat therapy, increase internal body temperature 1.2 C above baseline.~Placebo: 14,700 1.25 g capsules/420 35-count bottles [1.25-gram high oleic safflower oil capsule]"
17744|NCT04051034|Other|Placebo|Active: 1.25 g capsules [1.25-gram high oleic safflower oil capsule] and heat therapy, increase internal body temperature 1.2 C above baseline.
17745|NCT04051021|Behavioral|Comfort Coach|A trained comfort coach will provide emotional and psychological interventions at six time points: preoperative clinic, day of surgery, extubation, chest tube removal, discharge, 30-day clinic follow-up, and 90-day post-discharge. Patients will also complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
17746|NCT04051021|Other|Usual Care|Patients will complete surveys at specific time points (preoperative clinic, hospital discharge, 30-day clinic follow-up, and 90-day post-discharge).
17747|NCT04051008|Behavioral|Online - use of online grocery shopping platform|The Online intervention will utilize online grocery shopping (shopping at a local grocery store via online platform).
17748|NCT04051008|Behavioral|Default - use of online grocery shopping platform with default shopping carts|The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
17749|NCT04050982|Device|AF CARE|Patients will receive personalized messages twice weekly that will include behavior recommendations for CVRF reduction and AF education based on the initially entered psychographic profile and data entered.
17750|NCT04050982|Behavioral|Usual Care|Participants will be given recommendations for CVRF reduction based on their initial LS7 assessment and will be provided educational materials and a wireless scale.
17751|NCT04050969|Procedure|Bariatric surgery|Participants will undergo either a laparoscopic sleeve gastrectomy or laparoscopic Roux-en-Y gastric bypass.
17752|NCT04050969|Procedure|Atrial Fibrillation (AF) Catheter Ablation|Participants will undergo catheter ablation using either radiofrequency or cryoablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extrapulmonary sites at the physician's discretion.
17753|NCT04050943|Other|observational cohort|Recording the clinical, pathophysiology, and psychological parameters, to observe and predict the clinical outcomes of these patients.
17754|NCT04050930|Other|Mastication|Simultaneous recordings of postprandial thermogenesis (gas exchange), cardiac activity (ECG), masticatory muscle contraction (EMG), and blood collection, during alternating periods of no-mastication or mastication of natural foods or chewing gums of different hardness
17755|NCT04050917|Device|real stimulation|The smartwatch generates imperceptible vibratory stimulation.
17756|NCT04050917|Device|no stimulation|The smartwatch generates no stimulation.
17757|NCT04050904|Device|ExpHeart|ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.
17758|NCT04050891|Device|combined supraclavicular and interscalene block|"Supraclavicular block An in plane approach, a 22G needle 75mm was advanced from lateral to medial to the corner pocket where the lower trunk commonly lies at this area between the subclavian artery medially, first rib inferiorly and the plexus superiorly then 10ml of the mixture local anesthetic was injected, the remaining volume was injected just above and lateral to the subclavian artery.~Interscalene block After local anesthetic infiltration of the skin, a 22G needle 75mm was inserted in plane approach from lateral to medial toward the inter-scalene groove between the anterior and middle scalene muscles. The anesthetic mixture 15 ml was injected toward C5, C6 cervical nerve roots aiming to block nerves escaped from supraclavicular nerve block."
17759|NCT04050878|Device|Facial scanner (Bellus3D) to assess perioral alterations|Use of a facial scanner (Bellus3D) to analyse the modifications induced by the use of implant supported dental prostheses in the lip support
17760|NCT04050865|Drug|Dexamethasone, 0.4mg|Ophthalmic Insert
17761|NCT04050865|Device|Placebo plug with no drug|Ophthalmic Insert
17762|NCT04050852|Drug|Nusinersen Treatments|Antisense oligonucleotide, which targets the SMN2 pre-mRNA, particularly exon 7.
17763|NCT04050839|Other|Pain neuroscience education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
17764|NCT04050839|Drug|Medical treatment|The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians.
17765|NCT04050826|Drug|Lidocaine 2.5% and Prilocaine 2.5% cream, USP (Actavis Pharma incorporated, USA)|Topical application
17766|NCT04050826|Drug|Lidocaine 2.5% and Prilocaine 2.5% cream (E. Fougera & Co. a division of Fougera Pharmaceuticals Inc., USA)|Topical application
17767|NCT04050826|Drug|Oraqix Parodontal-Gel (Dentsply Detrey GmbH, Germany)|Topical application
17768|NCT04050826|Device|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~16 dOFM probes will be implanted per participant (8 test-sites; 2 dOFM probes per test-site).~From each dOFM probe 13 samples will be taken (1 pre-dose, 12 post-dose)."
17769|NCT04050826|Procedure|Blood sampling|1 sample will be taken pre-dose and 12 samples post-dose.
17770|NCT04050813|Behavioral|Exercises program for hamstring architecture and function|To assess the effectiveness of the inertial flywheel resistance program in the architecture and function of the hamstrings post structural hamstring injury
17772|NCT04050787|Procedure|D2 Lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
17773|NCT04050787|Procedure|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
17774|NCT04050774|Device|Balance boards|The unstable surface will be created with a balance board consisting of a wooden board mounted on a section of a cylinder, creating an unstable support in the sagittal plane or in the frontal plane. The participants will stand on three balance boards, varying the height of the surface of the board above the point of contact (15, 17 and 19 cm respectively). The radius of the cylinder will kept constant at 24 cm. The standing surface will be 48cm x 48 cm
17775|NCT04050761|Biological|Nivolumab|Specified dose on Specific Days
17776|NCT04050748|Procedure|Achilles tendon repair|Patients will be undergoing achilles tendon repair
17777|NCT04050735|Other|Alcohol, ethyl, moderate dose|Moderate oral dose of ethyl alcohol
17778|NCT04050735|Other|Placebo|Placebo beverage
17779|NCT04050722|Drug|Sensodyne Repair and Protect|Participants will brush their teeth with Sensodyne Repair and Protect (containing 0.454% stannous fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
17780|NCT04050722|Drug|Colgate Cavity Protection|Participants will brush their teeth with Colgate Cavity Protection repair and protect (containing sodium fluoride) for 1 timed minute twice a day (morning and evening), for 3 weeks.
17781|NCT04050709|Biological|PD-L1 t-haNK|PD-L1 t-haNK Suspension for Infusion
17782|NCT04050696|Device|BQ 1.2|BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
17783|NCT04050683|Procedure|Study - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Prior to and 24-72 hours after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). Subjects with abnormal heart pressures during TIPS will have a right heart catheterization (RHC) to monitor heart function, blood flow, and pressures in and around the heart. The subject will be admitted to the Cardiovascular Intensive Care Unit for a minimum of 24 hours and have a TTE all of which are standard of care. Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; TTEs; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. Diagnostic RHC will be done as needed per standard of care.
17784|NCT04050683|Procedure|Control - Transjugular Intrahepatic Portosystemic Shunt (TIPS)|"Subject's with normal heart pressures who are having elective (planned in advance and not due to an emergency) TIPS due to refractory ascites (fluid build up in the belly that does not go away or comes back shortly after being removed). Prior to and 24-72 hours after the TIPS procedure, the following blood tests are done for research purposes: Brain Natriuretic Peptide (BNP); Endothelin-1; Tumor Necrosis Factor-alpha (TNF-a); Endothelial Nitric Oxide Synthase (eNOS). The subject will be admitted to the hospital after TIPS for standard of care 24 hour monitoring.~Routine follow-up visits will occur in IR Clinic at 2 Weeks (± 3 days), 4-6 weeks and 4-6 months. Visits will include: blood draws for research related blood tests as listed above; standard of care ultrasound of the abdomen; and for at least one year, routine lab testing, imaging, medications, and subject overall condition will be assessed for long term outcomes. A research related TTE will be done at the 4-6 week visit."
17785|NCT04050670|Drug|Tirzepatide|Tirzepatide administered SC
17786|NCT04050657|Other|appointment interval|To change the appointment interval for one group and keep the standard interval for the other group by measuring alignment duration, measured as days needed to align the teeth using full-arch fixed appliances
17787|NCT04050644|Drug|Preservative Free drop treatment|Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
17788|NCT04050644|Drug|Preserved drop treatment|Patients will use the preserved dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third week and once daily in the fourth week and diclofenac 0.1% eye drops 3 times daily for 1 day preoperatively and every 15 minutes in the hour before surgery and then 3 times a day for four weeks.
17789|NCT04050631|Behavioral|maternal arrest simulation on L&D floor|AFE on L&D
17790|NCT04050618|Device|fanfilcon A test lens|Silicone hydrogel contact lens
17791|NCT04050618|Device|ocufilcon D control lens|hydrogel contact lens
17792|NCT04050618|Device|etafilcon A control lens|hydrogel contact lens
17793|NCT04050605|Device|somofilcon A toric contact lens|Contact Lens
17794|NCT04050605|Device|fanfilcon A toric contact lens|Contact Lens
17795|NCT04050592|Drug|Estradiol|Active intervention is estradiol. Hormone therapy (HT) of all 150 participants will be standardized to 2.0 mg of oral estradiol (E2) without progestogen for six weeks prior to randomization. After that participants will be randomized into three groups (A, B, C) of equal size.
17796|NCT04050592|Other|Placebo|Those in groups A and B will switch from estradiol to placebo at the beginning of the 10th week after abrupt or tapered discontinuation of HT.
17828|NCT04050254|Device|Therapeutic exercise|The therapeutic exercise program will include aerobic exercise and muscle strengthening for five sessions on alternate days. The program will include exercises and will last 30-45 minutes.
17829|NCT04050241|Device|Glidescope intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Glidescope videolaryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
17797|NCT04050579|Device|on-pump intracardiac echocardiography|Subjects will be patients with hypertrophic cardiomyopathy with interventricular septae less than 2.0cm who are undergoing septal myectomy. The patients will have already had a number of preoperative transthoracic echocardiographs as part of their normal hypertrophic cardiomyopathy care. Before cardiopulmonary bypass, the basal anterior septal thickness will be measured by transesophageal echocardiograph as is performed in all septal myectomy procedures. The Principal Investigator will then use the OPIE probe to measure the anterior basilar septal thickness. Myectomy will be performed and OPIE will be repeated. The post-myectomy anterior basilar septal thickness will again be measured by transesophageal echocardiography.
17798|NCT04050553|Drug|Tirzepatide|Administered SC
17799|NCT04050553|Drug|Placebo|Administered SC
17800|NCT04050540|Drug|Doxycycline|200 mg of doxycycline to be taken orally within 24 hours and up to 72 hours after each condomless sex act
17801|NCT04050514|Device|H-MAD with a hinge system according to Herbst|"The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD"
17802|NCT04050501|Device|non-invasive Vagus Nerve Stimulator|Two stimulations of two minutes each will be applied in the neck every 15 minutes in the first 3 hours. Thereafter two stimulations will be applied every 8 hours over the next 5 days or until discharge, whichever occurs first. The stimulation side in the neck will be the radiological side of the stroke.
17803|NCT04050488|Drug|Zinc Sulfate|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
17804|NCT04050488|Drug|Placebos|At the age of 3 days or priming> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.
17805|NCT04050475|Dietary Supplement|Fasting Mimicking Diet|The Fasting Mimicking Diet is a low-calorie, five-day eating program meant to promote weight loss and provide the same benefits as more traditional fasting methods.
17806|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + Cabiralizumab 4 mg/kg IV every 2 weeks|Nivolumab 240 mg IV plus Cabiralizumab 4 mg/kg IV every 2 weeks combination therapy
17807|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks + BMS-986253 1200 mg IV every 2 weeks|Nivolumab 240 mg IV plus BMS-986253 1200mg IV every 2 weeks
17808|NCT04050462|Drug|Nivolumab 240 mg IV every 2 weeks|Arm 1 (control) Nivolumab 240mg IV every 2 weeks monotherapy
17809|NCT04050436|Drug|Cemiplimab|Cemiplimab administered intravenously
17810|NCT04050436|Biological|RP1|RP1 administered intratumorally
17811|NCT04050410|Drug|Moxonidine|active drug given as 1 dose
17812|NCT04050410|Drug|Placebo|placebo pill given as 1 dose
17813|NCT04050397|Other|Progressive supervised weight training|12 weeks of progressive weight training twice a week supervised by a qualified physiotherapist.
17814|NCT04050397|Other|Lecture|Urologist informs participants on adverse effects of castration treatments and benefits of regular exercise. Physiotherapist gives an exercise program to follow at home, and nutritionist informs patients on correct nutrition to assist physical exercise.
17815|NCT04050384|Device|Baby GentleStick|The Baby GentleStick is a handheld device that fits and provides vibration to an Owen Mumford Unistik3 Dual lancet. The gentle vibration occurs at 178 Hertz with a free-hanging 0.24 mm range of motion. The device may provide vibration alone and also allow for simultaneous vibration and deployment of the lancet.
17816|NCT04050371|Drug|200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate|daily observed therapy
17817|NCT04050358|Dietary Supplement|NRPT|Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
17818|NCT04050358|Dietary Supplement|Placebo oral capsule|Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
17819|NCT04050332|Behavioral|Stair Walking|Walking up and down stairs for four minutes at a comfortable pace
17820|NCT04050319|Diagnostic Test|Screening and diagnosis if injured|physical therapy
17821|NCT04050293|Drug|SPN-538|Patients will receive SPN-538
17822|NCT04050293|Drug|Placebo|Patients will receive Placebo
17823|NCT04050280|Drug|Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)|"Induction:~G-CSF 300 mcg subcutaneously daily on days 0-5.~Cladribine 5 mg/m2 in normal saline given intravenously over 2 hours daily on days 1-5.~Cytarabine 2000 mg/m2 in normal saline given intravenously over 4 hours daily on days 1-5.~Gemtuzumab ozogamicin 3 mg/m2 intravenously over 2 hours on days 1 and 4, prior to cladribine and cytarabine.~Consolidation:~If CRMRD-, CR or CRi is confirmed by bone marrow biopsy and aspirate after induction chemotherapy, patients may receive one cycle of consolidation chemotherapy (at the discretion of the investigator) with the same CLAG-GO regimen at the same doses given for induction. In addition, the investigator has the option of giving CLAG alone without GO if there is concern for increased risk of sinusoidal obstruction syndrome.~Patients who remain in CRMRD-, CR or CRi after consolidation chemotherapy may receive up to eight infusions of GO 2 mg/m2 approximately every 28 days."
17824|NCT04050267|Drug|Nitrous Oxide|Breathing nitrous oxide, concentrations 5, 7, 10, 12, 15, 20 % in air with 21 % oxygen, in random order.
17825|NCT04050267|Other|Placebo - air|Breathing air with 21 % oxygen, no nitrous oxide.
17826|NCT04050254|Device|Real tDCS|Real tDCS (STARTSTIM® 8 stimulator, Neuroelectric Barcelona, Spain) for five sessions on alternate days.tDCS is a galvanic current applied by a cap for 20 minutes at an intensity of 2 milliamps.
17859|NCT04050033|Device|Evoke Device|Subjects will undergo treatment with Evoke Device
17830|NCT04050241|Device|Mcintosh intubation|Anesthetists will perform intubation in patients undergoing elective neurosurgery with the Mcintosh laryngoscope, while completing a secondary auditory task. Response times to the secondary task will be recorded, and operators will complete the NASA Task Load Index questionnaire at the end of each procedure.
17831|NCT04050228|Other|Imaging|Patient in the control arm will receive standard neoadjuvant chemotherapy and clinical monitoring as per standard of care. Patients will be imaged but no modifications to treatment will occur in this trial arm depending on response by quantitative ultrasound. Patients in the experimental arm will receive adaptive neoadjuvant chemotherapy based on quantitative ultrasound monitoring. Non-responders to neoadjuvant chemotherapy based on quantitative ultrasound will be switched to different chemotherapy or other treatments reflecting current clinical practice. The treatment option will be left to the discretion of the treating medical oncologist and the care team.
17832|NCT04050215|Procedure|Computed Tomography|Undergo PET/CT
17833|NCT04050215|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
17834|NCT04050215|Procedure|Positron Emission Tomography|Undergo PET/CT
17835|NCT04050215|Other|Questionnaire Administration|Ancillary studies
17836|NCT04050202|Behavioral|Attachment and Biobehavioral Catch-up (ABC) Intervention|ABC is a 10 session, home-based, dyadic therapy that is delivered by a trained professional. The sessions focus on improving the parent-child relationship and children's biological and behavioral responses to stress.
17837|NCT04050189|Biological|Natural products: Probiotics|Probiotics intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
17838|NCT04050189|Other|Placebo|Placebo intake every day (1.5 gram) from 34 weeks of gestation to delivery OR from delivery to 10 days postpartum
17839|NCT04050176|Behavioral|Hypnotic Medication Open-Label Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.
17840|NCT04050176|Behavioral|Hypnotic Medication Blinded Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.
17841|NCT04050163|Biological|MiSaver®|Intravenous administration of MiSaver® Stem Cell via peripheral vein access.
17842|NCT04050150|Behavioral|Arm training in standing|Arm training will be provided in one hour sessions, 3 time per week for 8 weeks. In each session, you will practice functional tasks with your weaker arm and hand in standing or during walking. Practice will be scaled to match your current level of function and progressed over time as able.
17843|NCT04050137|Other|Therapeutic Exercise|"Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL."
17844|NCT04050124|Drug|Promogran Prisma|Promogran+SOC; composite collagen, silver-oxidized regenerated cellulose matrix
17845|NCT04050124|Other|Standard of care (SOC) dressings|standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
17846|NCT04050111|Biological|Stromal-vascular fraction|Concentrate of stromal-vascular fraction of cells derived from autologous adipose tissue
17847|NCT04050098|Drug|gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release|"Zemiglo Tablet 50 mg: Each tablet contains gemigliptin tartrate sesquihydrate, equivalent to 50 mg gemigliptin.~Glucophage XR 1000 mg: Each tablet contains metformin hydrochloride 1000 mg (equivalent to 780 mg of metformin base)."
17848|NCT04050098|Drug|Gemigliptin tartrate sesquihydrate and metformin|Each tablet contains gemigliptin tartrate sesquihydrate 68.9 mg (equivalent to gemigliptin pure free base 50 mg) and metformin hydrochloride 1000.0 mg.
17849|NCT04050085|Biological|Nivolumab|Given IV
17850|NCT04050085|Radiation|Radiation Therapy|Undergo radiation therapy
17851|NCT04050085|Drug|TLR9 Agonist SD-101|Given intratumorally
17852|NCT04050072|Other|Childhood Cancer Survivors (CCSS)|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in adult survivors of childhood cancer vs. non-cancer controls, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
17853|NCT04050072|Other|SJLIFE|To use the current PRO-CTCAE to conduct a symptom content creation process for the PRO-CTCAE-SCC by identifying clinically meaningful symptomatic AEs for adult survivors of childhood cancer, to create symptomatic AE items not included in the current PRO-CTCAE, and to perform comprehensive medical evaluation, physical performance evaluation, and neurocognitive evaluation to clinically validate the PRO-CTCAE-SCC.
17854|NCT04050072|Other|Community non-cancer control|To use the PRO-CTCAE-SCC (beta version) to identify symptomatic adverse event (AEs) that are prevalent and clinically meaningful in non-cancer controls vs. adult survivors of childhood cancer, and to create symptomatic AE items that are not included in the current PRO-CTCAE for adult survivors of childhood cancer.
17855|NCT04050059|Drug|EMLA cream|EMLA cream (5g tube Aspen pharma trading limited) will be applied topically in dose of 2.5 grams (half tube of cream) and area will be covered with tegaderm dressing. Application of EMLA will at least stay for 30 minutes before spinal needle insertion
17856|NCT04050059|Drug|2% lidocaine|In 2% lidocaine group infiltration (Xylocaine 2% Barrett Hodgson Pakistan Pvt limited), skin and subcutaneous tissue will be infiltrated with 3 ml of 2% lidocaine (dose of 60 mg) before spinal needle insertion
17857|NCT04050046|Device|Transcranial Direct Current Stimulation|tDCS is a neuromodulatory technique that delivers a small electric current (about the equivalent of a 9V battery) to the head. A fixed current between 1 and 2 mA is typically applied. tDCS works by applying a positive (anodal) or negative (cathodal) current via electrodes to an area, facilitating the depolarization or hyperpolarization of neurons, respectively.
17891|NCT04049812|Device|Hot pack|
17892|NCT04049812|Device|TENS|
17893|NCT04049812|Device|Sham PEMF|
17860|NCT04050020|Biological|Platelet-Rich Plasma (PRP)|All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
17861|NCT04050020|Biological|Normal saline injection|All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
17862|NCT04050007|Other|Preventive initiation of fluid removal|"Preventive initiation of fluid removal will be started right after the randomization with intravenous diuretics according to a predefined algorithm based on the urine output every three hours.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
17863|NCT04050007|Other|Curative initiation of fluid removal|"The initiation of fluid removal will be considered by the attending physician only in case of failure to the spontaneous breathing trial with a clinical suspicion of weaning induced pulmonary edema.~The weaning process and post extubation preventive strategy will be protocolized based on the last international guidelines"
17864|NCT04049994|Drug|Uro-Vaxom|Uro-Vaxom® (OM Pharma SA, Meyrin, Switzerland) is a lyophilized lysate of 18 E. coli strains.
17865|NCT04049994|Drug|Placebo oral tablet|Placebo oral tablet
17866|NCT04049981|Device|Superpower Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents.
17867|NCT04049968|Device|Mobile health application (APP)|The mobile health application (APP) was applied to patients with oral cancer.
17868|NCT04049968|Other|Routine health care and instruction|Traditional routine health care and instruction was applied to patients with oral cancer.
17869|NCT04049955|Procedure|endoscopy|In the case of a well-organized abscessed collection responsible for sepsis instability, or poorly organized collection, an external drainage is carried out, by a radiological or a surgical way. The endoscopy is performed 7 days later. If there is no hemodynamic instability and in presence of a well-organized abscessed collection, a first-line endoscopy is carried out. After laying 2 double pig tail stents, the external drainage is removed 2 to 7 days later.
17870|NCT04049942|Other|Multimodal prehabilitation group|Multimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization(whey protein supplement), and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence). Patients are advised to record daily exercises and adherence to nutritional, psychological and other recommendations. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
17871|NCT04049942|Behavioral|Aerobic training group|Aerobic training strategy includes the same guided individualized moderate aerobic exercise as the multimodal prehabilitation group, as well as the conventional guidance. Patients are advised to record daily exercises. Short message interviews are sent to patients twice a week to optimize adherence and promote feedback.
17872|NCT04049929|Drug|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
17873|NCT04049916|Drug|Pyronaridine Tetraphosphate/Artesunate|Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
17874|NCT04049916|Drug|Dihydroartemisinin/Piperaquine|Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
17875|NCT04049916|Drug|Primaquine Diphosphate|Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
17876|NCT04049903|Drug|MP0310|MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
17877|NCT04049890|Other|FAI-O|"Administration of Family Adjustment Inventory in the version Only-child"
17878|NCT04049890|Other|FAI-S|"Administration of Family Adjustment Inventory in the version Sibling"
17879|NCT04049890|Other|Personal Data Questionnaire|This form requires informations about child, respondent and partner (if any), and evaluates the presence of any distressful event happened during the last year
17880|NCT04049877|Other|None - Observational study|None - Observational study
17881|NCT04049864|Biological|DNA vaccine|conjugate of plasmid DNA with linear polyethylenimine 20 kDa (PEI) One dose includes 400 µg of DNA and 500 µg of PEI.
17882|NCT04049864|Biological|Salmonella oral vaccine|suspension 10^10 CFU of an attenuated Salmonella enterica serovar typhimurium strain (SS2017) containing the plasmid of the corresponding DNA vaccine.
17883|NCT04049864|Drug|Lenalidomide|Lenalidomide is prescribed in a dose of 25 mg / day in a course of three weeks starting 7 days before the first vaccination course and ending on the day of the last vaccination course.
17884|NCT04049851|Drug|Moxidectin 2 MG Oral Tablet|One Moxidectin 2 mg tablet will be blinded and will be administrated with 3 tablets of placebo.
17885|NCT04049851|Drug|Ivermectin 3Mg Tab|3 ivermectin tablets (or 4 according to the weight) will be blinded and will be administrated with 1 (or 0 according to the weight) tablet of placebo.
17886|NCT04049851|Drug|Placebo oral tablet|Placebo will be administrated with Moxidectin or ivermectin. Each participant will have 4 tablets in total.
17887|NCT04049838|Procedure|postoperative analgesia for lower abdominal surgery in children|compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
17888|NCT04049825|Drug|OPB-111077|OPB-111077+bendamustine
17889|NCT04049825|Drug|OPB-111077|OPB-111077+rituximab+bendamustine
17890|NCT04049812|Device|PEMF|
17896|NCT04049799|Behavioral|Comprehensive clinical care|Obstetrical visits, counseling, case management, psychiatry services, and urine drug screening
17897|NCT04049786|Procedure|Roux-en-Y gastric bypass bariatric surgery|Patients with body mass index equal or higher 35 mgkg/mˆ2 and with indication for RYGB bariatric surgery are being recruited for the present investigation.
17898|NCT04049786|Procedure|Intestinal biopsy|All patients with indication for RYGB bariatric surgery undergo to endoscopy before and after the surgery as standard protocol. Intestinal biopsy are being performed during the surgery, pre- and post-endoscopies.
17899|NCT04049786|Drug|Carvedilol 25mg|Single-dose of carvedilol 25 mg are being administrated orally.
17900|NCT04049786|Procedure|Serial blood sampling for carvedilol|Serial blood samples are being collected at times 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after carvedilol administration.
17901|NCT04049786|Drug|Metoprolol 100 mg|Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
17902|NCT04049786|Procedure|Urine sampling|Urine sample is being collected until 8 hours after metoprolol 100 mg administration.
17903|NCT04049786|Procedure|Serial blood sampling for simvastatin|Serial blood samples are being collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours after simvastatin administration.
17904|NCT04049786|Drug|Simvastatin 40mg|Single-dose of simvastatin 40 mg are being administrated orally.
17905|NCT04049786|Drug|Midazolam 2 mg|Midazolam is being used as probe drug to evaluate CYP3A4 activity. Single-dose of midazolam 2 mg are being administrated intravenous.
17906|NCT04049786|Procedure|Blood Sampling|Blood sample is being collected 4 hours after midazolam administration.
17907|NCT04049786|Procedure|DNA extraction|Blood sample is being collected for DNA extraction. DNA are being extracted from the whole blood of all patients.
17908|NCT04049786|Other|CYP2C9 genotyping|Patients are being genotyped for CYP2C9 432C>T (rs1799853) and 1075A>C (rs1057910) polymorphisms.
17909|NCT04049786|Other|ABCB1 genotyping|Patients are being genotyped for ABCB1 1236C>T (rs1128503), 2677nonG (rs2032582), and 3435C>T (rs1045642) polymorphisms.
17910|NCT04049786|Other|SLCO1B1 genotyping|Patients are being genotyped for SLCO1B1 521C>T (rs4149056) polymorphism.
17911|NCT04049773|Procedure|haemodialysis|haemodialysis, thrice weekly in-center
17912|NCT04049760|Drug|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
17913|NCT04049747|Procedure|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]|Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]
17914|NCT04049747|Procedure|Focal therapy|Focal therapy (high intensity focused ultrasound or cryotherapy)
17915|NCT04049747|Procedure|Focal therapy after Finasteride 5Mg tablets for 12 weeks|finasteride 5mg tablets 12 weeks prior to focal therapy
17916|NCT04049747|Procedure|Focal therapy after Bicalutamide 50Mg tablets for 12 weeks|Bicalutamide 50mg per day - 12 weeks prior to focal therapy
17917|NCT04049734|Drug|oral losatan|50 mg of oral losartan one hour before the ERCP once
17918|NCT04049721|Procedure|HBO|2.5 atmospheres absolute (ATA) with 90 minutes of hyperbaric oxygen will be given over the course of two weeks.
17919|NCT04049721|Other|Standard of Care|20 patients will be included in the retrospective review arm. The retrospective chart review will be performed to determine the outcomes of patients with crush injuries treated at NYU Winthrop Hospital without HBO from 1/1/2012-12/31/2018.
17920|NCT04049708|Other|Reliability of physical function|Test-retest reliability of physical function in hemodialysis patients
17921|NCT04049695|Behavioral|Exercise|This intervention is based on Control Theory and Social Cognitive Theory and includes: 1) weekly emails with tips and tools to set personalized exercise goals and to increase exercise; 2) Health coaching phone sessions; 3) wrist worn monitor such as a Fitbit to track activity
17922|NCT04049695|Behavioral|Control|This intervention includes: 1) weekly emails with tips and tools to support health and wellness such as brain health, stress management, nutrition; 2) Health coaching phone sessions
17923|NCT04049682|Behavioral|Delayed School Start Time|Francis Parker High School implemented 45-minute later school start time.
17924|NCT04049669|Drug|Indoximod|Indoximod will be taken by mouth twice daily during radiation and until the first cycle of Core Regimen therapy.
17925|NCT04049669|Radiation|Partial Radiation|Palliative low-dose or partial-field radiation plan (low-dose radiation or not all disease sites included).
17926|NCT04049669|Radiation|Full-dose Radiation|Palliative full-dose radiation plan to all known sites of disease (>50 Gy to brain, >45 Gy to spine).
17927|NCT04049669|Drug|Indoximod|Indoximod will be taken by mouth twice daily, throughout each chemo-immunotherapy treatment cycle.
17928|NCT04049669|Drug|Temozolomide|Temozolomide will be taken by mouth once daily, on days 1-5 of each treatment cycle.
17929|NCT04049669|Drug|Cyclophosphamide|Cyclophosphamide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
17930|NCT04049669|Drug|Etoposide|Etoposide will be taken by mouth once daily, on days 1-21 of each treatment cycle.
17931|NCT04049669|Drug|Lomustine|Lomustine will be taken by mouth once daily, on day 1 of each treatment cycle.
17932|NCT04049656|Device|HFVI|Subjects in the HFVI intervention group will be monitored in the same manner as the control group, but the HFVI monitor display will also be available to the anesthesia provider in real time. Bolus doses of 25ug or 50 ug of fentanyl will be recommended to be administered when the HFVI values begin to decrease below 50, and as needed based on the judgment of the clinician responsible for the case. All anesthetic medications that are given, patient events, and vital sign recordings will be included in the anesthetic record and data collection forms.
17933|NCT04049643|Device|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
17934|NCT04049643|Device|Service-only Fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. In this intervention group, audiological services plus hearing aids that provide minimum amplification will be provided. Specifically, patient participants in this group will receive audiological services (e.g., counselling and education), except that the hearing aids will be set to provide no amplification other than what is needed to overcome any sounds that are dampened by the earpieces.
24427|NCT03996772|Drug|Dabigatran|Direct Thrombin Inhibitor
17935|NCT04049643|Device|Device-only fitting|This intervention group is designed to explore the contribution of amplification devices in hearing aid intervention, which consists of devices and services. The patient participants in this intervention group will have minimum services regarding the pre-fitting, selection, and orientation of the hearing aids. The participants will have a hearing evaluation, including pure-tone audiometry. The audiologist will select the amplification characteristics and non-custom ear piece based on the audiogram. The audiologist will then briefly orient the participant on how to use the hearing aids and counsel on how to optimize their performance.
17936|NCT04049630|Drug|LEV 1 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
17937|NCT04049630|Drug|LEV 1,5 mg/kg|A combinaison of LEV 10 mg, 50 mg, and placebo will be adapted to the weight ; all the tablets will be blinded, and each participant will receive 5 tablets.
17938|NCT04049630|Drug|Placebo|5 tablets of placebo will be administrated to the participants.
17939|NCT04049617|Drug|GS-4224|Tablets administered orally once daily
17940|NCT04049591|Drug|Higher Dose UFH|Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
17941|NCT04049591|Drug|Lower Dose UFH|Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
17943|NCT04049565|Diagnostic Test|Procalcitonin biomarker and CRP biomarker|collecting blood samples to measure serum CRP and Procalcitonin
17944|NCT04049552|Drug|Rapamycin 8% Ointment|A compounded ointment containing 8% rapamycin
17945|NCT04049552|Drug|Placebo|Petrolatum ointment placebo
17946|NCT04049539|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
17947|NCT04049526|Behavioral|The influence of different music genres on Heart Rate Variability (HRV) in preterm infants|Neonates undergo a daily randomized music listening program (25 minutes, every day, for 3 days) based on different music genres listening (soft pop-rap, pop-rock and classical music). Music programs is followed by 1 day of no music monitoring (25 minutes). An electrocardiogram is performed to evaluate HRV parameters in each neonate with and without music exposure
17948|NCT04049513|Biological|WZTL002-1 (1928T2z CAR-T cells)|WZTL-002 comprises autologous third-generation anti-CD19 chimeric antigen receptor T-cells (termed 1928T2z). The chimeric antigen receptor in WZTL-002 incorporates the FMC63 anti-CD19 soluble chain variable fragment extracellularly, and portions of both CD28 and the Toll/interleukin-1 receptor (TIR) domain of Toll Like Receptor 2 (TLR2) as intracellular co-stimulatory domains, alongside CD3ζ. WZTL-002 (autologous 1928T2z CAR T-cells) will be administered on D0 as a single IV infusion, following lymphodepleting chemotherapy.
17949|NCT04049513|Drug|Cyclophosphamide and Fludarabine lymphodepleting chemotherapy|Cyclophosphamide 500 mg/m^2 IV on days -5 to -3, inclusive. Fludarabine 30 mg/m^2 IV on days -5 to -3, inclusive
17950|NCT04049500|Other|Digital Diabetes Prevention Program (dDPP)|dDPP tool suite to integrate with the EHR and clinical workflows
17951|NCT04049487|Other|Exercise|Both groups will participate in group exercise as previously described
17952|NCT04049474|Device|ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)|See BCI description.
17953|NCT04049461|Diagnostic Test|Bone alkaline phosphatase|Hematologic indicators reflecting ossification.
17954|NCT04049461|Radiation|Abdominal CT scan|Observe whether HOAI occurs.
17955|NCT04049448|Drug|ABX464|All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 12 months (52 weeks).
17956|NCT04049435|Device|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla|Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
17957|NCT04049409|Drug|CMAB809|CMAB809 will be administered by IV infusion at a single dose of 6mg/kg.
17958|NCT04049409|Drug|Trastuzumab|Trastuzumab will be administered by IV infusion at a single dose of 6mg/kg.
17959|NCT04049396|Other|Berberine|24 Patient consumed 6,25 g/day Berberine for 6 weeks
17960|NCT04049383|Biological|CAR-20/19-T cells|"The investigational agent in this protocol is the CAR-20/19-T cells.CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection. Patients will receive one of four dose levels of CAR-20/19-T cells based on our dose escalation design (Section 6). Cell dose will be maxed at 80 kg.~Dose Level -1: 1 x 10*5 CAR-20/19-T cells/kg Dose Level 0: 2.5 x10*5 CAR-20/19-T cells/kg (starting dose level) Dose Level 1: 7.5 x10*5 CAR-20/19-T cells/kg Dose Level 2: 2.5 x10*6 CAR-20/19-T cells/kg (goal cell dose)"
17961|NCT04049370|Other|No intervention|"Assessment of the actual state prior to implementation of the SOP as clinical decision tool into the electronic database of the chest pain unit."
17962|NCT04049357|Device|Camera Capsule Endoscopy/ PillCam|Camera Capsule Endoscopy in screening
17963|NCT04049344|Drug|Decitabine; Oxaliplatin|Patients receive Decitabine 10 mg/day for 5 consecutive days (d1-5) plus Oxaliplatin 75mg/m2 2-week-cycle (d6, d20) within 4 weeks. One cycle is defined as 4 weeks of treatment and total of 6 cycles are designed for patients.
17964|NCT04049331|Drug|Testosterone cypionate 125 mg/week|weekly intra-muscular injections of Testosterone cypionate
17965|NCT04049331|Other|placebo|weekly intra-muscular injections of clinical grade 0.9% sodium chloride
17966|NCT04049318|Other|Education+ exercise (delivered digitally)|The intervention consisted of a digital, structured and individualized treatment program for people with hip or knee OA (Joint Academy®; www.jointacademy.com). The program consists of neuromuscular exercises appropriately adjusted to each patient in regard to degrees of complexity and difficulty, continuous access to and dialogue with a physiotherapist through a chat function, and/or telephone , and information in the form of text or video lessons (with quizzes on the material after each episode) on subjects related to OA, OA symptoms and its management.
18027|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.
24428|NCT03996772|Drug|Edoxaban Tablets|Factor Xa Inhibitor
17967|NCT04049305|Device|Robotic assisted nipple sparing mastectomy (R-NSM)|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
17968|NCT04049305|Procedure|conventional nipple sparing mastectomy (C-NSM)|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
17969|NCT04049305|Procedure|Endoscopic assisted nipple sparing mastectomy (E-NSM)|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
17970|NCT04049292|Other|Better and safer return to sport (BEAST)|The RTS assessment includes a Lachman test, modified stroke test, side hop test, triple hop test, and quadriceps muscle power test. The sport-specific progression plans have 6 participation levels in practice and 6 participation levels in match play. A minimum of 2 weeks and 4 training sessions without pain or effusion must be completed before the athlete progresses to the next level. Criteria for full, unrestricted participation in practice: (1)at least 9 months from ACLR, (2)modified stroke test grade 0, (3)completed previous levels in the sport-specific progression plan, (4)negative Lachman test, (5)side hop test limb symmetry at least 90%, (6)triple hop test limb symmetry at least 90%, (7)quadriceps power symmetry at least 90%. The strength training and knee control exercise protocols each have 3-4 different exercises of 3-4 sets that are performed 3 days per week.
17971|NCT04049292|Other|Usual care|Usual care is determined by the treating health care professional
17972|NCT04049279|Procedure|BiMobile standard cement|BiMobile dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
17973|NCT04049279|Procedure|BiMobile larger cement|BiMobile dual mobility cup, in one size smaller than standard after optimal reaming, resulting in a cement mantle of approximately 4mm.
17974|NCT04049279|Procedure|Avantage standard cement|Avantage dual mobility cup, in a standard size after optimal reaming, resulting in a cement mantle of approximately 2mm.
17975|NCT04049266|Drug|KSI-301|Intravitreal Injection
17976|NCT04049266|Drug|Aflibercept|Intravitreal Injection
17977|NCT04049266|Other|Sham Procedure|The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
17978|NCT04049253|Drug|Phosphate Buffer Solution|Phosphate-buffered saline (abbreviated PBS) is a buffer solution commonly used in biological research. It is a water-based salt solution containing disodium hydrogen phosphate, sodium dihydrogen phosphate. The buffer helps to maintain a constant pH. The osmolarity and ion concentrations of the solutions match those of the human body (isotonic).
17979|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 18<BMI<30 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
17980|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) 30≤BMI<35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
17981|NCT04049240|Device|Device: low-flow nasal oxygenation (LFNO) BMI≥35 kg/m2|Active comparator LFNO: O2 flow 5 L/min, FiO2 40%
17982|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 18<BMI<30 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
17983|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) 30≤BMI<35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
17984|NCT04049240|Device|Device: High-flow nasal oxygenation (HFNO) BMI≥35 kg/m2|Experimental HFNO: O2 flow 40 L/min, FiO2 40%
17985|NCT04049227|Drug|Abemaciclib|Given PO
17986|NCT04049227|Drug|Letrozole|Given PO
17987|NCT04049227|Procedure|Therapeutic Conventional Surgery|Undergo standard of care hysterectomy
17988|NCT04049214|Other|Meditation|Two guided meditations will be provided to participants. They will be asked to meditate twice daily, once in the morning once before bed, for a total time of 12 minutes per day. Surgical treatment and postoperative care will be provided by surgeon preference and usual practice, including post-operative pain medications. For 12 weeks patients will maintain a daily meditation log, medication log and complete daily pain assessment questionnaire.
17989|NCT04049201|Procedure|elective surgery|investigators will compare the effect of interactive tablet on preoperative anxiety in children to the effect ofMidazolam in elective surgery
17990|NCT04049201|Drug|Midazolam|Oral Midazolam
17991|NCT04049201|Device|Interactive Tablet|interactive Tablet containing many cartoon's videos
17992|NCT04049188|Radiation|Single-Fraction Palliative Radiation Therapy|All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.
17993|NCT04049175|Drug|Treatment A|Tablet of CHF 6532
17994|NCT04049175|Drug|Treatment B|Tablet of CHF 6532
17995|NCT04049175|Drug|Treatment C|Tablet of CHF 6532
17996|NCT04049175|Drug|Treatment D|Tablet of CHF 6532 placebo
17997|NCT04049162|Dietary Supplement|Blueberry Plus Exercise (BB-EX)|Pre-packaged blueberry powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
18028|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
17998|NCT04049162|Dietary Supplement|Blueberry Placebo Plus Exercise (P-EX)|Pre-packaged placebo powders are from U.S. Highbush Blueberry Council and are packaged in sealed single-serving packets (18 g/packet) to prevent exposure to light and moisture. All supplement packets are stored under refrigeration until distribution to study participants. Participants will be asked to increase physical activity through a weekly supervised exercise class and increasing baseline daily step counts gradually over the course of the intervention.
17999|NCT04049149|Other|Biogenetic explanation and endocrinologist intensive managment|"JADE report and JADE APP~Biogenetic explanation~First-year intensive management by endocrinologists~Follow up by their usual care doctors for continue treatment regimen maintenance.~Yearly DM nurses follow up for blood taking and questionnaires"
18000|NCT04049149|Other|Usual care management|"JADE report and JADE APP~Attend their usual care clinic for ongoing treatment~Yearly DM nurses follow up for blood taking and questionnaires"
18001|NCT04049136|Diagnostic Test|NT-proBNP|Measure levels of NT-proBNP in healthy pregnancy women across BMI categories.
18002|NCT04049123|Drug|LY900014|Administered SC
18003|NCT04049123|Drug|Insulin Lispro (Humalog)|Administered SC
18004|NCT04049110|Drug|Forxiga 10mg|Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days
18005|NCT04049110|Drug|Placebo|Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
18006|NCT04049097|Drug|Arimoclomol|1200 mg/day arimoclomol citrate (400 mg t.i.d.)
18007|NCT04049084|Biological|autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)|ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV)
18008|NCT04049045|Drug|Empagliflozin 25 mg|Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
18009|NCT04049045|Drug|Placebo|matching Placebo, film-coated tablets, for oral use, matching to investigational product Jardiance® administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
18010|NCT04049032|Behavioral|In-Person Perinatal OUD Treatment|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care.
18011|NCT04049032|Behavioral|Perinatal OUD Treatment via Telemedicine|Participants were seen weekly for four weeks, every two weeks for four weeks and monthly thereafter and provided relapse-prevention therapy and buprenorphine as part of standard of care..
18012|NCT04049019|Diagnostic Test|Urine collection through a collecting device (Uridom®) for maximum 1 week|"The child will collect:~Urine at bedtime on a wet and a dry night.~Urine during a wet night through a collecting device.~First morning voided volume following both a wet and a dry night."
18013|NCT04049006|Other|complex treatment|The complex treatment will be based on health education, aerobic physical exercise and cognitive-behavioral therapy, during 12 weeks in sessions of 2 hours/week. The sessions will be conducted in the primary health care by trained professionals.
18014|NCT04048993|Other|Biobank development and integrative physiological analysis|Collection of biological samples (blood, urine, interstitial fluid, adipose tissue and muscle) from subjects enrolled in the Section registry, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
18015|NCT04048980|Behavioral|CARExDEM|CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
18016|NCT04048967|Behavioral|Professional development|professional development of preschool staff
18017|NCT04048954|Device|SMOKECHECK|Smartphone application in screening on tabagism complications
18018|NCT04048941|Procedure|One Needle Hand Acupuncture with Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
18019|NCT04048941|Procedure|One Needle Hand Acupuncture without Movement|One needle is inserted along the radial aspect of the 2nd metacarpal which relieves pain at a distant site. Then, the subject is asked to lay quietly on the examination table.
18020|NCT04048941|Procedure|Control Acupuncture with Movement|Control acupuncture at acupoint LI4 is performed, which should not have a large affect on pain at a distant site. Then, the subject is asked to perform a series of movements that were previously painful.
18021|NCT04048928|Behavioral|maximal strength training|The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
18022|NCT04048915|Behavioral|Long live drama|"The interactive live 90-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
18023|NCT04048915|Behavioral|Short live drama|"The interactive live 60-minute drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
18024|NCT04048902|Device|Pilates and Shortwave placebo|Pilates exercises and application of the device without produce thermal effects
18025|NCT04048902|Device|Pilates and Shortwave active|Pilates exercises and application of the device producing thermal effects
18026|NCT04048889|Drug|Ropivacaine 0.5% Injectable Solution|Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca
18029|NCT04048876|Drug|CC-90001|oral
18030|NCT04048876|Drug|Placebo|oral
18031|NCT04048863|Device|B. Braun Peripheral Advantage (PA) Program|B. Braun PA includes: Christie VeinViewer® Vision2 , Introcan Safety® IV Catheters, STEADYCare™ Smallbore Extension Set, and the PA Education
18032|NCT04048863|Device|Hospital Standard of Care|Standard of Care for PIVC access per hospital protocol
18033|NCT04048850|Drug|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Daily medication
18034|NCT04048824|Behavioral|Inhibitory Learning-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on maximizing the mismatch between participant's feared outcome and what actually occurred (i.e., expectancy violation). This condition includes techniques that incorporate associative learning principles such as exposure to multiple feared stimuli (i.e., deepened extinction), exposure variability in contexts and stimuli, occasional reinforcement, and mental reinstatement of inhibitory learning.
18035|NCT04048824|Behavioral|Habituation-Based Exposure|9 weekly treatment sessions conducted individually with a therapist. Exposure is focused on fear reduction from initial fear ratings. This condition includes theoretically-consistent techniques such as staying in the situation until fear declines, repetition of exposures until fear has declined, and a gradual approach to feared stimuli using an exposure hierarchy.
18036|NCT04048811|Drug|HSK3486|The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
18037|NCT04048811|Drug|Propofol|The induction dose is 2.0mg/mg. The initial maintenance dose of the first 2 subject is 5 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 2 subjects, so as to explore the optimal initial maintenance dose. The adjustment range of the initial maintenance dose is 5 (± 2.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 2.5 mg/kg/h, and the maximum should not be more than 7.5 mg/kg/h.
18038|NCT04048811|Drug|Propofol HSK3486|The induction dose of Propofol is 2.0mg/mgThe initial maintenance dose of HSK3486 is fixed at 1 mg/kg/h, without adjustment.
18039|NCT04048798|Other|Oxygen therapy via HFNC|Oxygen treatment will be applied to the patients via HFNC before and after surgery
18040|NCT04048798|Other|Oxygen therapy via face mask|Oxygen treatment will be applied to the patients via face mask before and after surgery
18041|NCT04048785|Other|infant behavioral sleep intervention|The intervention consists of an infant behavioral sleep protocol. In the standard intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings and so on
18042|NCT04048772|Behavioral|CALM IVF|The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.
18043|NCT04048772|Other|Standard of Care|Patients will receive the standard of care IVF treatment at the University of Iowa.
18044|NCT04048759|Behavioral|Remote Low|Participants will attend 40 min remotely delivered group MVPA sessions once a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
18045|NCT04048759|Behavioral|Remote High|Participants will attend 40 min remotely delivered group MVPA sessions 3x a week, receive a step counter, access to resources for increasing MVPA, and one 20-min remotely delivered individual support/education session/wk.
18046|NCT04048759|Behavioral|Personal Coach|Participants will receive a step counter, access to resources for increasing MVPA, and monthly remote individual support/education.
18047|NCT04048733|Device|patchy-type wireless 12-lead ECG|Perform 12-lead ECG using patchy-type wireless 12-lead ECG. This device automatically record 12-lead ECG in every 15 minutes by its algorithm.
18048|NCT04048720|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
18049|NCT04048707|Drug|Angiotensin II|Intravenous
18050|NCT04048707|Drug|Midodrine|Pill
18051|NCT04048707|Drug|Octreotide|Subcutaneous
18052|NCT04048707|Drug|Albumin solution|Intravenous suspension
18053|NCT04048681|Behavioral|diet soda|12 oz can of artificially sweetened cola beverage (Diet Coke planned to be used but similar to Diet Pepsi or other Diet Colas)
18054|NCT04048681|Behavioral|Regular soda|12oz can of regular cola beverage (Coke planned but similar to Pepsi or other regular cola sodas)
18055|NCT04048681|Behavioral|Carbonated Water|12oz can of carbonated water (sparking water, selzter water) unflavored
18056|NCT04048668|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
18057|NCT04048655|Drug|Neostigmine, Combinations|All patients have neostigmine induced recovery of neuromuscular block.
18058|NCT04048642|Behavioral|DASH|7 days of a DASH diet
18059|NCT04048642|Behavioral|Whole-Food, Plant-Based|7 days of a WFPB diet
18060|NCT04048629|Device|Point-of-care (POC) viral load (VL) testing plus refresher training|VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
18061|NCT04048629|Other|Standard of care central laboratory VL testing plus refresher training|VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
18062|NCT04048616|Dietary Supplement|whey protein isolate|one 15-25 gm (based on body weight) protein packet three times a day with each meal
18063|NCT04048616|Dietary Supplement|potassium bicarbonate (KHCO3)|two 13.5 mmol capsules three times a day with each meal
18064|NCT04048616|Other|microcrystalline cellulose|identical placebo capsule
18066|NCT04048590|Other|Skilled Nursing Facility at Home|We plan to deploy an innovative and tailored set of rehabilitation services delivered in a patient's home that would allow for discharge from the hospital directly to home, despite the need for more intensive rehabilitative care not currently found in the home setting. We plan to combine a high-touch and high-tech approach that combines novel uses of personnel practicing at the very top of their license with novel uses of technology.
18067|NCT04048577|Drug|Dosing Interruption of Natalizumab|Planned 12 week dosing interruption of natalizumab
18068|NCT04048551|Behavioral|Modified Health Policy Project (HPP) HIV-Stigma and Discrimination Reduction Training Curriculum|The Health Policy Project (HPP) training curriculum provides participatory training modules that address three key actionable drivers of HIV-stigma. The HPP curriculum was adapted through participatory workshops with key stakeholders representing clinics, study staff, and adolescent girls and young women (AGYW) and other formative activities. The training is a whole-site training to address barriers to accessing clinical services by AGYW. Consequently, staff at all levels (clinical and nonclinical) will be trained on stigma and discrimination as it relates to AGYW in order to reduce stigma-related barriers to healthcare and increase uptake of PrEP and sexual and reproductive health services among AGYW.
18069|NCT04048551|Behavioral|Women's Health CoOp (WHC)|In this study, researchers adapted the Women's Health CoOp (WHC) evidence-based empowerment intervention that addresses issues of gender-based violence (GBV), substance use, and sexual risk to include information about PrEP (Pre-exposure prophylaxis) and sexual and reproductive health. AGYWs will be provided with comprehensive information and will engage in activities that seek to reduce HIV risk factors and increase PrEP readiness, uptake and adherence.
18070|NCT04048538|Other|Precare|an innovative patient education platform using animated videos created by using up-to-date evidence-based informaiton
18071|NCT04048538|Other|usual standard of care|individuals will receive treatment as per the usual standard of care
18072|NCT04048525|Procedure|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
18073|NCT04048525|Procedure|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter infusion to maintain a theoretical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
18074|NCT04048512|Procedure|Resection with intraoperative use of ECMO/CPB|Patients are operated with the use of intraoperative ECMO/CPB
18075|NCT04048512|Procedure|Resection without intraoperative use of ECMO/CPB|Patients are operated without the use of intraoperative ECMO/CPB
18076|NCT04048499|Device|the Colour Assessment and Diagnosis (CAD) test|The CAD test (City Occupational Ltd, London, UK) measures the severity of red-green and yellow-blue colour vision loss according to red-green and yellow-blue thresholds which are expressed in CAD units and diagnoses accurately the subject's class of colour vision
18077|NCT04048486|Other|Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3|Ages & Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
18078|NCT04048486|Other|Physical development and General Health|Physical development and General health examination
18079|NCT04048486|Other|Developmental Red flags|Developmental Red flags Questionnaires
18080|NCT04048460|Device|Delivery of hearing healthcare through eAudiology application|Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
18081|NCT04048434|Device|Cytosorb|extracorporeal cytokine adsorption
18082|NCT04048421|Procedure|hvNOTES radical colectomy|With the patient under general anesthesia, pneumoperitoneum is achieved. Three trocars are inserted, one 12 mm or 5 mm in the umbilicus and two 5 mm in the right and/or left flanks. Mobilization of the splenic flexure or the hepatic flexure is performed with an initial traditional laparoscopic approach. A single-port is inserted into the abdominal cavity transvaginally through the colpotomy. Then most of the procedures are performed transvaginally with conventional rigid laparoscopic instruments. The corresponding arteries and veins are divided. The mesocolon is mobilized. The small intestine/colon/rectum are then divided with stapler. The specimen is removed transvaginally. Intracorporeal anastomosis is performed as per the surgeon's standard of care. For sigmoidectomy, the colon is then exteriorized and the anvil is fixed in the colon. An end-to-end anastomosis is performed using a circular stapler. Drainage tubes may be used.
18083|NCT04048382|Behavioral|Patient Navigation|Spanish-English bilingual peer lay navigators hired by Family Health Centers of San Diego will provide the PN intervention during the study, trained using manuals developed in formative research and via the Patient Navigation Research Program training approach. Services will generally focus on: 1) overcoming community, health system, interpersonal, and individual barriers to accessing PrEP-related healthcare; 2) increasing each patient's knowledge, attitudes, and self-efficacy for initiating and adhering to PrEP; 3) improving communication between the patient and healthcare team through appointment scheduling and reminders; and 4) sexual risk reduction counseling.
18110|NCT04048161|Drug|Mycophenolate Mofetil|"The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20~30mg/kg/day，BID. The concentration for MPA-AUC is 30~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
18111|NCT04048148|Device|Novel designed myopia control spectacle lenses|A novel designed myopia control spectacle lenses (test lenses) will be given to both arms to wear for 6 months.
18084|NCT04048382|Other|Usual Care|The booklet given is a 2-page booklet including the following information: 1) overview of PrEP; 2) eligibility for PrEP; 3) efficacy of PrEP; 4) safety of PrEP; and 5) obtaining, initiating, and adhering to PrEP. Participants will also be provided with both verbal and written information regarding available sexual health and HIV prevention services, including PrEP, at Family Health Centers of San Diego (FHCSD). Comprehensive HIV-prevention healthcare, including PrEP, is available to study participants at FHCSD at no or minimal cost. If a UC participant is diagnosed with a sexually transmitted infection, including HIV, treatment and follow-up will be coordinated by FHCSD staff as per usual care procedures.
18085|NCT04048369|Diagnostic Test|Rapid diagnosis of influenza in the emergency medical service|Comparison at the University Hospital of Clermont-Ferrand of a test performed in the Adult Emergencies Department by the nursing staff (point-of-care testing) to a test carried out in the core laboratory (classical testing).
18086|NCT04048356|Drug|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.|Vaginal scrub, to be applied vaginally and perineally immediately prior to surgery.
18087|NCT04048343|Drug|Biological: Experimental: Tezepelumab|Tezepelumab subcutaneous injection every 4 weeks
18088|NCT04048317|Drug|HepaSphere Microspheres/Doxorubicin Hydrochloride|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours."
18089|NCT04048317|Drug|Lipiodol|"evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.~Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration"
18090|NCT04048304|Drug|duration of standard antibiotic therapy|antibiotic therapy for spine infections. 3 vs 6 weeks if no implant left in place. 6 vs 12 weeks if implant left in place. The antibiotic agents used are officially indicated for orthopedic infections, including spine infections and available in Switzerland since decades. Standard dosing will be applied and only modified according to the patient's co-morbidities, intolerances and weight.
18091|NCT04048291|Behavioral|Brisk walking and balance training|6 months of combined brisk walking and balance training
18092|NCT04048291|Behavioral|Upper limb exercise|6 month of hand dexterity training
18093|NCT04048278|Drug|Lidocaine Hydrochloride|IV Lidocaine a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
18094|NCT04048278|Drug|Saline Solution for Injection|IV Saline a 1.0 - 1.5 mg/kg loading infusion for perioperative pain control
18095|NCT04048265|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
18096|NCT04048252|Other|Focus group creation|Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention
18097|NCT04048252|Other|Workshop|Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition
18098|NCT04048239|Procedure|cochlear implantation|cochlear implantation is a system developed to restore hearing in people with profound sensorineural hearing loss, whose classical hearing aids are ineffective. Surgery is necessary to insert the internal part into the cochlea and requires milling the mastoid to access the round window. This approach is technically difficult, and is performed under a microscope by an experienced surgeon.
18099|NCT04048239|Other|computerized tomography (CT) scan|computerized tomography (CT) scan of the facial nerve
18100|NCT04048239|Other|electromyograph|electromyographic verification of the facial nerve
18101|NCT04048226|Drug|Placebos|The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
18102|NCT04048226|Drug|Dexmedetomidine +Ketamine|The patients in this group will be connected to the syringe pump that contain mixture of dexmedetomidine and ketamine with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery. The solution will contain 2 ug dexmedetomidine/ml and 1 mg ketamine/ml.
18103|NCT04048213|Other|questionnaire|questionnaire send to the parents
18104|NCT04048200|Drug|Fentanyl|Anesthesia will be induced by fentanyl, propofol, and rocuronium with maintenance of anesthesia using sevoflurane.
18105|NCT04048200|Drug|Dexmedetomidine Ketamine|No opioid will be used in induction of anesthesia. A combination of dexmedetomidine and ketamine will be infused. Sevoflurane will be used for maintenance of anesthesia.
18106|NCT04048187|Device|Phone Application|Phone application is developed to adjust hearing aids. It incorporates functionalities like volume control and program change.
18107|NCT04048174|Other|Topical probiotic treatment with Lactococcus lactis W136|Nasal and sinus irrigation with reconstituted live probiotic bacteria
18108|NCT04048174|Other|Saline irrigation|Nasal and sinus irrigation with saline solution
18109|NCT04048161|Drug|Tacrolimus|"The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is < 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day."
18112|NCT04048135|Drug|BIO89-100|Subcutaneous injection
18113|NCT04048135|Other|Placebo|Subcutaneous injection
24429|NCT03996772|Drug|Rivaroxaban|Factor Xa Inhibitor
18114|NCT04048122|Behavioral|MultiContext for PD Strategy Training|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions. Graded task practice with OT feedback on performance accuracy is used to produce neurocognitive improvement (or possibly independent strategy development). The OT assigns practice of specific cognitively challenging everyday life activities for homework (but without action plans).
18115|NCT04048122|Behavioral|Standard of Care|This treatment is task-oriented training, a widely-used approach in neurorehabilitation, that parallels the cognitive process training used in PD to-date but with simulated functional tasks (vs. computer or paper & pencil tasks). It has the same basic protocol as MC4PD, but it is therapist-directed, and the OT does not address strategies, metacognition, generalization, or use mediation or action plans. Therefore, this is a standard-of-care approach that includes all but the proposed critical elements of MC4PD. The OT reviews pre-treatment cognitive test scores with the client but without discussion to build awareness. The OT selects treatment activities based on the client's cognitive profile and goals from a published set of activities designed for use in cognitive interventions.
18116|NCT04048096|Dietary Supplement|Krill Oil|Aker Biomarine Superba Krill Oil
18117|NCT04048096|Dietary Supplement|Placebo|Mixed vegetable oil
18118|NCT04048083|Behavioral|Mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement. During each training session they will perform 3 practice trials by following the instructions, after practicing 3 trials, the instructions will be discontinued, and subjects will perform 30 mental movements by following auditory cues.
18119|NCT04048083|Behavioral|Computer-aided trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of visual feedback of reaching-to-grasp movement. During each training session they will be sitting on a chair, in front of a computer screen observing simple tasks of reaching and precision fine grasping of a small object with 4 fingers of virtual upper extremity using the visualization software that will be coded specifically for the purpose of this experiment.
18120|NCT04048083|Behavioral|Computer-aided and mental trainings|Patients will receive 36 trainings (12 weeks with 3 trainings a week) of mental, kinesthetic reaching-to-grasp movement that will be supplemented by visual feedback of this task by the visualization software that will be coded specifically for the purpose of this experiment (they will receive trainings that link the features of the two mentioned above types of training (MT and CAT).
18121|NCT04048083|Other|No trainings|Healthy controls without any kind of training
18122|NCT04048070|Drug|Flurbiprofen Axetil|One kind of NSAIDs, 200mg for 48 hours after surgery.
18123|NCT04048070|Drug|Sufentanil|One kind of opioid drugs, 1.5μg/kg, and recorded the drug consumption after surgery
18124|NCT04048070|Behavioral|Extended perioperative counseling|The extended perioperative counseling contained additional information, including surgery procedures, importance of medicine treatment and medical help to relieve depression and anxiety about disease during peri-operation period.
18125|NCT04048070|Behavioral|Shorter fasting food and water time before surgery|The patients in ERAS group were required to fast food for 6 to 8 hours and provided 12.6% maltodextrin carbohydrate supplement beverage for 2 hours before surgery
18126|NCT04048070|Behavioral|Conventional perioperative counseling|THe conventional perioperative counseling included the risk of surgery and prognosis of disease and other things patients need to know.
18127|NCT04048070|Behavioral|Regular fasting food and water time before surgery|The stricter control of preoperative fasting requirements, prohibiting solids and liquids from previous midnight to operation time.
18128|NCT04048057|Other|Exercise|"Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power."
18129|NCT04048044|Device|Exposure to GHz electromagnetic energy (RejuvaMatrix)|75 decibels of 54 to 78 GHz daily for 60 minutes
18130|NCT04048031|Dietary Supplement|Nutrafol Supplement Capsules|NUTRAFOL's Synergen Complex Plus® is a formulation based on a patent-pending Synergen Complex®, a combination of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant, DHT-inhibiting and hormone-rebalancing properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some key ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, gelatinized Maca, Astaxanthin, Bioperine (piperine), and Capsimax (capsaicin), all of which are bio-optimized and clinically tested. The Nutafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
18131|NCT04048031|Other|Placebo Capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial amount of food.
18132|NCT04048018|Diagnostic Test|Blood draw and IGRA test|One to two blood samples will be obtained from participants in all arms in order to conduct testing.
18133|NCT04048005|Diagnostic Test|Fractional flow reserve|
18134|NCT04047992|Device|Indego™ Exoskeleton|The Indego® is a powered exoskeleton that can be used as a mode of therapy in an institutional setting. Proper walking in this device requires the user to manipulate their center of gravity and balance by postural trunk excursions in order for the legs to take steps.
18135|NCT04047979|Biological|Shingrix®|A zoster vaccine recombinant, adjuvanted, recently approved by the FDA for prevention of herpes zoster (shingles) in adults aged 50 years and older. It is given in two doses (0.5 mL each): at 0 and 2 to 6 months.
18175|NCT04047680|Drug|Elbasvir / Grazoprevir Oral Tablet|Elbasvir/grazoprevir for 12 weeks
18176|NCT04047680|Drug|Glecaprevir and Pibrentasvir|Glecaprevir/pibrentasvir for 12 weeks
18136|NCT04047953|Drug|Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1|Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40~60mg，bid, d1-14( BSA<1.25m2，40mg；1.25m2≤BSA≤1.5m2，50mg；BSA>1.5m2，60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\PR\SD and decided by the investigator to continue the treatment for two cycles or directly.
18137|NCT04047940|Drug|LY900020|Administered orally
18138|NCT04047940|Drug|Metformin XR|Administered orally
18139|NCT04047940|Drug|Atorvastatin|Administered orally
18140|NCT04047940|Drug|Valsartan|Administered orally
18141|NCT04047927|Device|EpiFinder|The EpiFinder is a sensing device intended to assist physicians performing placement of epidural needle analgesic and/or anesthesia injection in a safely and accurately manner. The device is a single use sterile device consisting of a probe (Stylet), an actuator (micro DC motor), IR sensor and Controller. The device is integrated to a standard LOR Syringe and an 18G Tuohy needle and enables to simultaneously work with the standard LOR technique.
18142|NCT04047914|Device|pdt Photodynamic therapy|"Application of 0.01% methylene blue with enough sterile swab to cover the inner nostril extension with a 1 minute pre-irradiation time~• Irradiations will be performed with a red laser diode (wavelength = 660 nm), 240 seconds and 4-point nostril application"
18143|NCT04047901|Other|exercise training|Patients undergo 16 weeks of physical training
18144|NCT04047888|Other|Nutrition-based education on infant feeding and practices as well as Non nutrition-based educational message|60 minute educational message at each visit
18145|NCT04047888|Other|Non nutrition-based educational message|No nutrition-based education on infant feeding and practices
18146|NCT04047875|Drug|Norethisterone 10mg/day|NET-only pill (Norethisterone, Primolut-Nor®), 10 mg/day, 1 pill per day until 2 consecutive days without bleeding/spotting
18147|NCT04047875|Drug|Placebo|Identically appearing placebo to Primolut-Nor®, 1 pill per day until 2 consecutive days without bleeding/spotting
18148|NCT04047862|Drug|BGB-A1217|Dose escalation of BGB-A1217 in combination with tislelizumab in patients with advanced solid tumors
18149|NCT04047862|Drug|Tislelizumab|Dose escalation of BGB-A1217 in combination with tislelizumab in patients with advanced solid tumors
18150|NCT04047849|Drug|Antibiotics, oral Azithromycin and oral Amoxicillin|Azithromycin (500mg day one followed by 250mg per day for 4 more days) and amoxicillin (500mg orally three times daily for 7 days) for a total course of seven days of antibiotic therapy
18151|NCT04047836|Other|Low Nicotine E-Liquid|Participants will vape e-liquid with nicotine concentration of 3 mg/ml.
18152|NCT04047836|Other|Medium or High Nicotine E-Liquid|Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.
18153|NCT04047823|Device|a digital Infrared thermography (FLIR E5 Serial No.63985976）|Measurements were taken during radiation and additionally two weeks after radiotherapy weekly. Temperature change was measured by thermal infrared imager (FLIR) for 4 test areas within the supraclavicular radiation field and on an opposite non-irradiated area, which was outlined using a specific software package (FLIR Systems 6.3.17227.1001).
18154|NCT04047810|Biological|Mesenchymal Stem Cells|0.5- 2 million cells/kg, intravenously once
18155|NCT04047797|Drug|Ixazomib|Given by mouth
18156|NCT04047797|Drug|Ixazomib Citrate|Given by mouth
18157|NCT04047797|Biological|Rituximab|Given Intravenous
18158|NCT04047784|Device|Endobronchial ultrasound (EBUS)|"An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and 30-degree oblique forward-viewing optics. A 12 MHz linear ultrasound transducer with a maximum penetration of 50 mm will be linked to a processor (Olympus EU-ME2) that allows an integrated power Doppler mode to visualize the vascular blood flow.~Bronchoscopy will be introduced through the adaptor connected to the endotracheal tube, in patients who are already under general anesthesia and on mechanical ventilation. The bronchoscope will be advanced into the airways and endobronchial ultrasound of the main pulmonary artery (PA) and lobar branches will be performed in a standardized fashion. At the completion of the imaging the EBUS bronchoscope will be withdrawn."
18159|NCT04047771|Drug|SCB-313|Intraperitoneal injection, 3 doses on D1,D4,D7，21 days for 1 cycle
18160|NCT04047758|Drug|Palbociclib + Letrozole|(1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment [3 weeks on (days 1-21) and 1 week off (days 22-28)], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
18161|NCT04047758|Drug|Letrozole|Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
18162|NCT04047745|Drug|Liposomal bupivacaine|interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
18163|NCT04047745|Drug|Ropivacaine injection|interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
18164|NCT04047732|Biological|KB105|KB105, a replication-incompetent, non-integrating HSV-1 vector expressing human transglutaminase 1 (TGM1) formulated as a topical gel
18165|NCT04047719|Diagnostic Test|Karius Test|Karius Test for detection of microbial cell free DNA (mcfDNA) in plasma
18166|NCT04047706|Biological|IDO1 Inhibitor BMS-986205|Given PO
18167|NCT04047706|Biological|Nivolumab|Given IV
18168|NCT04047706|Radiation|Radiation Therapy|Undergo radiation therapy
18169|NCT04047706|Drug|Temozolomide|Given PO
18170|NCT04047693|Drug|dose dense MVAC with pegylated GCSF|Methotrexate, 30 mg/m2 IV bolus, Day 1 Vinblastine, 3 mg/m2 IV bolus, Day2 Doxorubicin, 30 mg/m2 IV bolus, Day2 Cisplatin, 70 mg/m2 IV over 1hr, Day2 Pegylated G-CSF, 6mg SC, Day 3 every 2 weeks
18171|NCT04047680|Drug|Sofosbuvir / Velpatasvir Oral Tablet|Sofosbuvir/velpatasvir for 12 weeks
18172|NCT04047680|Drug|Sofosbuvir and Ledipasvir|Sofosbuvir and ledipasvir for 12 weeks
18173|NCT04047680|Drug|Sofosbuvir Tablets|Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks
18174|NCT04047680|Drug|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir for 12 weeks
18177|NCT04047667|Procedure|cone beam CT guided transbronchial cryobiopsy|CBCT images are acquried and reviewed in axial, coronal and sagittal planes to most accurately assess the cryoprobe position within the lung parenchyma and relative to other thoracic structures. The minimum probe-to-pleura distance will be measured. If the position of cryoprobe is proper, TBCB will be perfomed.
18178|NCT04047654|Drug|Non vitamin K oral anticoagulants|Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
18179|NCT04047641|Drug|Cladribine|Given Intravenous
18180|NCT04047641|Drug|Cytarabine|Given Intravenous
18181|NCT04047641|Drug|Idarubicin|Given Intravenous
18182|NCT04047641|Drug|Quizartinib|Given by mouth
18183|NCT04047628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|"PBSC mobilization & collection regimen per protocol/ institutional standards includes: intravenous cyclophosphamide (Cytoxan®), 4 grams/m^2); intravenous mesna (Mesnex®),a total delivery of 4 grams/m^2); oral dexamethasone, 10 mg dose, four times daily); subcutaneous filgrastim,10 mcg/kg/day until leukapheresis goal is completed; and CD34+ peripheral blood stem cells collection by leukapheresis.~Conditioning per protocol& institutional standards:~6-day BEAM (e.g. Carmustine (BCNU), Etoposide (VP-16), Cytarbine (Ara-C), and Melphalan) chemotherapy protocol and,~rabbit anti-thymocyte globulin (rATG) 2.5 mg/kg/day x2~Autologous cryopreserved graft infusion: The target Cluster of Differentiation (CD)34+ cell dose for infusion is 5 x 10^6 CD34+ cells/kg (minimum 4 x 10^6 CD34+ cells/kg; maximum 7.5 x 10^6 CD34+ cells/kg).~For 1&2 above: Ideal body weight (IBW) versus Actual Body Weight (ABW) are applicable."
18184|NCT04047628|Biological|Best Available Therapy (BAT)|"Disease-modifying therapy (DMT) selected by the Site Investigator from the below:~natalizumab~alemtuzumab~ocrelizumab, or~rituximab"
18185|NCT04047615|Other|Exercise|An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
18186|NCT04047602|Radiation|Reduced Dose SRS|Subjects will receive SRS treatment at a reduced dose based on the brain tumor size
18187|NCT04047589|Behavioral|Survey regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.|Survey created at Indiana University to gain information regarding exercise habits, barriers to exercise, and experience with exercise services from the cancer center.
18188|NCT04047589|Behavioral|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations|Survey regarding personal exercise habits and beliefs, barriers to making exercise recommendations, and potential resources the cancer center might provide to help make effective exercise recommendations in the future
18189|NCT04047576|Drug|Sirolimus|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
18190|NCT04047576|Drug|Corticosteroid|The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be switched to experimental group.
18191|NCT04047563|Drug|Normal Saline along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. In this arm normal saline along with standard treatment will be given for active comparison.
18192|NCT04047563|Drug|PMZ-1620 (sovateltide) along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
18193|NCT04047550|Diagnostic Test|Ventilatory chemosensitivity|Using this technique, the patient first voluntarily hyperventilates to a PETCO2 value of 20-25 mmHg, then undergoes a rebreathing test allowing the PCO2 to rise to 55-60 mmHg while PETO2 is maintained at 150 mmHg. The procedure is then repeated with PETO2 clamped at 50 mmHg. Parameters derived from this method include slopes of the ventilatory response during hyperoxia and hypoxia.
18194|NCT04047537|Other|Medical Food Formulation 1|WBF-0011
18195|NCT04047537|Other|Medical Food Formulation 2|WBF-0011 (0.2X concentration)
18196|NCT04047537|Other|Placebo|Placebo Capsules identical to those containing Formulation 1 and 2
18197|NCT04047524|Other|Monitoring using a FitBit|Each participant will receive a Fitbit. The Prehabilitaiton Group will receive a Fitbit Charge 2 and they will be able to review their progress on this and be required to increase their exercise activity and input information and data about the exercise they have completed each day during their participation in the study. The Control group will receive a Fitbit Flex and will not be required to review any of their activity or input any data and will be encouraged to continue with their daily activity rates i.e. not to change.
18198|NCT04047511|Device|VRTierOne|"As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VRTierOne Stolgraf® provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the lector (therapist) tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient influences the course of this story, becomes an active participant of the therapeutic process and sees the effects his work."
18199|NCT04047511|Behavioral|Group general fitness training|A single session of general fitness training will be composed of low-intensity, general-fitness exercises. Most of the exercises will be carried out in a sitting position and standing positon. The session will contain aerobic (general warm-up), musculo-articular (strengthening muscles and joints range of motion) and stabilizing exercises (improve spatio-visual coordination). Conducted by a physiotherapist in group form.
18235|NCT04047186|Drug|Nivolumab Injection|Nivolumab 3mg/kg on day-28 and day-14 prior to planned surgical resection
18200|NCT04047511|Behavioral|Group Psychoeducation|This section will contain mini-lectures about mental well-being and psychohygiene, conduced by a psychotherapist in group form.
18201|NCT04047498|Device|Alternating DBS|Constant DBS will be changed to DBS that is up- and downmodulated alternating between the left and right stimulation side.
18202|NCT04047485|Diagnostic Test|Visual Acuity|During T0, T2 and T3, every subject has been evaluated with a Snellen Chart, to measure visual acuity in number of letters (BVCA)
18203|NCT04047485|Diagnostic Test|CAM (Confusion Assesment Method)|"During the first 48 hours of post-op follow-up, any episode of post-operative Delirium is checked and evaluated."
18204|NCT04047485|Diagnostic Test|CATQUEST 9-SF|The questionnaire contains questions evaluating the benefits of cataract surgery. The questionnaire has been used during T0, T2 and T3
18205|NCT04047485|Diagnostic Test|OCT|Using the RNFL and the Macular Topography protocol, the macula and optical nerve are measured during the T2 phase of each patient the risk of Irvine Gas's syndrome or any other retinal complication.
18206|NCT04047485|Diagnostic Test|6CIT|This Cognitive Impairment test doesn't require Visual function to be executed. Cognitive function is evaluated at T0, T1 and the post-operative trend at T2 and T3.
18207|NCT04047485|Diagnostic Test|Barthel Index|To evaluate the everyday independence of the subject and it's trend durin the follow-up
18208|NCT04047485|Diagnostic Test|Endothelial Microscopy - Cornea|Endothelial cell density is evaluated before surgery (T0) and during the follow-up (T2 and T3). The reason of the choice of this test is to evaluate the trend of these instrumental parameters in the elderly population.
18209|NCT04047472|Drug|Brolucizumab 6mg|Subjects will receive Brolucizumab 3 x q4w up to Week 8 followed by q12w / q8w up to Week 40 or Week 44, depending on disease activity status.
18210|NCT04047472|Drug|Aflibercept 2 mg|Subjects will receive Aflibercept 3 x q4w up to Week 8 followed by q8w up to Week 40.
18211|NCT04047459|Other|Tissue samples collection and cells isolation|During surgery, leftover samples of bone (femoral head/ trabecular bone tissue) and muscle will be collected. Then they will be sent to the laboratory where isolation of cells will be performed.
18212|NCT04047446|Drug|Exparel 133 MG Per 10 ML Injection|10mL of 133mg liposomal bupivacaine with 5mL of 0.5% bupivacaine (15mL total)
18213|NCT04047446|Drug|Dexamethasone|15mL of 0.5% bupivacaine with 4mg of preservative-free dexamethasone will be injected
18214|NCT04047433|Genetic|screening for single nucleotide polymorphism|samples will be tested for a set of single nucleotide polymorphism
18215|NCT04047433|Genetic|whole exome sequencing|samples will be tested for identifying specific genetic mutation
18216|NCT04047420|Drug|TAF/EVG Insert|TAF/EVG Insert (20/16 mg) administered rectally by study staff
18217|NCT04047407|Device|Suprathreshold pain stimulation|"Suprathreshold pain stimulation will be applied in the infraspinatus muscle (point equidistant between the midpoint of the spine of the scapula, the inferior angle of the scapula and the midpoint of the medial border of the scapula) with a pressure algometer (Force Ten ™, Wagner Instruments, USA). Four suprathreshold pressure stimulations (pressure pain threshold + 20%, +30%, +40% and +50%) will be made for 60 seconds, with a minimum rest of 5 minutes between each stimulation.~The sequence of stimulation (ascending or descending) will be randomized."
18218|NCT04047394|Drug|PEGylated recombinant candida urate oxidase|PEGylated recombinant candida urate oxidase is a combination of 20kDa linear polyethylene glycol (PEG) linked to Candida utilis recombinant uricase by succinimide succinate
18219|NCT04047381|Other|Measurement of Quality of Life|Quality of life will be measured using Atrial Fibrillation Impact Questionnaire, Short Form-36 and Pittsburgh Sleep Quality Index
18220|NCT04047368|Procedure|Rotablation|Percutaneous Coronary Intervention using Rotablation
18221|NCT04047368|Procedure|Coronary Lithoplasty|Percutaneous Coronary Intervention using Lithoplasty
18222|NCT04047355|Drug|Propranolol|Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
18223|NCT04047342|Behavioral|Welcome email|Email
18224|NCT04047342|Behavioral|Loss frame|Email
18225|NCT04047329|Other|general anesthesia or neuraxial anesthesia|
18226|NCT04047316|Device|Digital dermoscopy|Acquire skin images with a new digital dermatoscope
18227|NCT04047303|Drug|CC-90010|CC-90010
18228|NCT04047290|Drug|AK112|AK112 is a PD1/VEGF bispecific antibody.
18229|NCT04047277|Behavioral|Cognitive Behavioral Therapy|The manualized CBT protocol is five sessions that teach sleep hygiene, relaxation strategies, and addresses nightmares therapeutically through exposure and rescripting.
18230|NCT04047264|Device|Intraoperative cerebral microdialysis using M dialysis 107 pump and 71 High cut-off brain microdialysis catheter|Each microdialysis catheter will be connected to a M dialysis 107 pump, with flow rates between 0.5 and 1.5 µL per minute. Prior to tumor removal, catheters will be placed within appropriate regions of tumor core or adjacent tissue with assistance of neuronavigation. Any awake or asleep neurophysiological mapping and/or additional localization-guided tissue sampling procedures will be performed while microdialysis is in progress, including cortical or subcortical language or motor mapping. Microdialysis will end when the region being sampled is removed as part of the planned tumor resection. The tissue region sampled by each catheter will be harvested separately for correlative analyses.
18231|NCT04047251|Drug|FF-10850 Topotecan Liposome Injection|FF-10850 to be diluted and infused over 60 minutes.
18232|NCT04047238|Other|Reminiscence Therapy|"Intervention group will receive two Reminiscence Therapy sessions per week for 3 months. Reminiscence therapy sessions will last approximately 50 minutes and will be developed according to the following structure:~Welcome to the patient and reality orientation therapy (7 minutes)~Conducting the main activity of reminiscence (40 minutes)~Closure, thank you for the participation and farewell until the next session (3 minutes) Reminiscence therapy sessions will have an individual format and will be conducted by a therapist previously trained in the protocol and the principles of Reminiscence Therapy. The Reminiscence activities of each session will be carried out following the protocol proposed in the Book of Past and Present."
18233|NCT04047225|Device|THE ANALGESIA NOCICEPTIVE INDEX (ANI)|Utilisation of the ANI during the operation
18234|NCT04047212|Other|metagenomic testing of the subgingival plaque samples|16S rRNA metagenomic testing (sampling, extraction and sequencing of the oral microbiome in the samples)
18236|NCT04047173|Radiation|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 33-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
18237|NCT04047173|Procedure|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 2 times.
18238|NCT04047160|Drug|OP-724|Twice a week for 4 hours continuous intravenous administration of OP-724
18239|NCT04047147|Other|Enrollment in the Million Hearts CVD Risk Reduction Model|"The intervention is at a provider organization level and all eligible beneficiaries enrolled by participants will be considered exposed. Intervention organizations receive payments to:~Risk stratify eligible Medicare FFS beneficiaries~Provide CVD care management to high-risk beneficiaries~Collect and report clinical data to CMS via the Million Hearts Data Registry and participate in learning system activities~Participating organizations receive payments for each eligible beneficiary they risk stratify. In model year 1, the organizations receive a fixed payment per beneficiary per month to provide cardiovascular management. In model years 2-5, the organizations receive a risk reduction payment that is scaled based on reductions in 10-year predicted risk scores among their cohort of high-risk beneficiaries."
18240|NCT04047147|Other|Enrollment in control provider organizations|Control organizations receive payments to collect and report clinical data on their eligible Medicare FFS beneficiaries, but are not asked to calculate CVD risk scores or otherwise change their clinical care.
18241|NCT04047134|Other|Action Observation Treatrment|Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.
18242|NCT04047134|Other|Observation of videos with Non Motor contents|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
18243|NCT04047095|Dietary Supplement|Immunonutrients + normal daily meal|"Glutamine Plus by Fresenius Kabi (one sachet composition: glutamine 10 g, carbohydrate 10 g, β-carotene 1.7 mg, vitamin E 83 mg, vitamin C 250 mg, zinc 3.4 mg, selenium 50 μg, and fibre 1.2 g)."
18244|NCT04047095|Dietary Supplement|Normal daily meal|Normal daily meal (75-80 g protein)
18245|NCT04047082|Diagnostic Test|Quantitative aortogram (videodensitometry)|Patients that performed TAVR will have their aortogram analysed in the cath-lab by videodensitometry (quantitative aortogram)
18246|NCT04047069|Behavioral|Awareness Training and Person-Centered Occupational Therapy Intervention|Exp. identifying the activities the person wants to do, suggestions to facilitate the activity, arranging the activity according to the needs of the person, arranging the environment so that the environment can be a facilitating factor in the activities the person wants to do.
18247|NCT04047069|Behavioral|Awareness Training|"Exp.~General information about HD~Approaches to Coping with HD Symptoms~Self care skills (eg hygiene)"
18248|NCT04047056|Other|Labor Kinesiotherapy|"The intervention group will perform 5 minutes of warm-up with free active exercises, 10 minutes of specific resistance exercises for the cervical and upper limbs and 5 minutes of stretching and muscle relaxation.The initial free active exercises will be performed in 3 sets of 15 repetitions; Resistance exercises will be performed in 3 sets of 10 repetitions and stretching will be performed in 3 sets of 30 seconds.~Regarding the intervals between exercises, active recovery will be adopted to counteract the effects of muscle fatigue."
18249|NCT04047043|Diagnostic Test|serum taurine|blood sample for serum taurine level
18250|NCT04047030|Other|None- Observational Study|No Intervention
18251|NCT04047017|Drug|Apatinib|250mg, po, qd
18252|NCT04047017|Drug|Camrelizumab|200mg, q2w
18253|NCT04047004|Drug|Doxorubicin|Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
18254|NCT04047004|Drug|Cisplatin|Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.
18255|NCT04046991|Device|high-definition transcranial direct current stimulation|High definition transcranial direct current stimulation (HD-tDCS) involves the application of low-intensity current through electrodes placed on the scalp. It is believed to elicit brain effects by producing incremental shifts in the resting membrane potential of large numbers of neurons, which alters neuronal firing rates and thus modulates patterns of brain activity in potentially behaviorally-relevant ways. HD-tDCS differs from conventional transcranial direct current stimulation (tDCS) because it employed smaller electrodes configured in such a way as to deliver more focal stimulation of the brain.
18283|NCT04046809|Other|Placebo|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
18284|NCT04046796|Genetic|NGS Diagnostic|Blood take for genetic diagnostic.
18256|NCT04046991|Behavioral|modified constraint-induced language therapy|Modified constraint-induced language therapy (mCILT) is a behavioral language therapy that invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures, as a substitute for spoken output. Other key elements of CILT include massed practice of goal-directed speech and shaping of desired responses by increasing response demands as participants improve. MCILT differs from traditional constraint-induced language therapy (CILT) in three ways: 1) it will be done as an individual therapy with the examiner in the role of a communication partner; 2) treatment will be delivered in short sessions (1 hour rather than a more typical 3-4 hour session); 3) targeting nouns + semantically related verbs to generate noun + verb phrases in treatment, a modification that may be better suited to addressing syntactic structure.
18257|NCT04046978|Other|ConM SOSIP 50 ug and ConS UFO 50 ug|Intramuscular injection of synthetic viral immunogens ConM SOSIP and ConS UFO
18258|NCT04046978|Other|Mos3.1 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.1
18259|NCT04046978|Other|Mos3.2 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.2
18260|NCT04046978|Other|Mos3.3 100 ug|Intramuscular injection of synthetic viral immunogen Mos3.3
18261|NCT04046978|Other|Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug|Intramuscular injection of synthetic viral immunogens Mos3.1, Mos3.2 and Mos3.3
18262|NCT04046952|Device|Statseal with TR Band|Patients will have a Statseal Advance RAD (SS) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SS disc with the center of the balloon (the green dot) over the center of the SS disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 40 minutes (60 minutes after procedure), the TR band will be completely deflated.
18263|NCT04046952|Device|TR band only|Patients will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 60 minutes following the procedure for all patients (regardless of diagnostic or PCI procedure), after which full deflation attempts will commence.
18264|NCT04046939|Drug|low-dose dexpramipexole|dexpramipexole low-dose BID
18265|NCT04046939|Drug|mid-dose dexpramipexole|dexpramipexole mid-dose BID
18266|NCT04046939|Drug|high-dose dexpramipexole|dexpramipexole high-dose BID
18267|NCT04046939|Drug|placebo oral tablet|placebo BID
18268|NCT04046913|Behavioral|Dietary education|Intervention: Low food additive diet. Control: Habitual food additive diet
18269|NCT04046900|Biological|Vaginal microbiome transplant|Vaginal fluid from healthy donors
18270|NCT04046900|Drug|Oral Metronidazole|500mg oral metronidazole twice daily for 7 days
18271|NCT04046900|Other|Sterile saline|700 uL of sterile saline placed in the vagina as a placebo intervention.
18272|NCT04046887|Drug|Lonsurf|Lonsurf will be administered orally twice a day on days 2-6 and 16-20 of every 28-day cycle at a dose of 25 mg/m2, 20 mg/m2 or 30 mg/m2 depending on cohort assignment.
18273|NCT04046887|Drug|Gemcitabine|Gemcitabine will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 800 mg/m2, 600 mg/m2 or 1000 mg/m2 depending on cohort assignment.
18274|NCT04046887|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be intravenously administered on Days 1 and 15 of every 28-day cycle at a dose of 100 mg/m2, 75 mg/m2 or 125 mg/m2 depending on cohort assignment.
18275|NCT04046874|Drug|Usual Care|Pain Medication, imaging, referrals to other health services, other health care appointments
18276|NCT04046874|Other|SPLIT Stratified Model of Care|Physiotherapy targeted treatment system of increasing complexity for each subgroup (low, medium or high) of risk of chronicity. Includes patient education, manual therapy and exercise
18277|NCT04046861|Dietary Supplement|ascorbic acid,|The vitamin C group will get high dose of intravenous vitamin C (ascorbic acid) before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
18278|NCT04046861|Other|Placebo (saline)|The placebo group will get saline before starting cardiopulmonary bypass, before removing aortic clamp and every 8 hours thereafter for additionaly 24 hours
18279|NCT04046848|Drug|OCTA101|OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
18280|NCT04046822|Drug|Liraglutide 6 MG/ML [Saxenda]|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
18281|NCT04046822|Drug|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
18282|NCT04046809|Other|Food for special medical purposes: Neurotidine®|"Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning."
18285|NCT04046783|Device|patch|an overnight application of a patch containing a standardized quantity of Allium Cepa extract and allantoin on C-section scars over 4 weeks.
18286|NCT04046770|Device|Drug administration and Flushing procedure using Double-Chamber Syringe|The new device will allow the professional to conduct all the procedure (assure the patency/enables the pre-flushing), drugs administration and flushing, using only one device.
18287|NCT04046770|Device|Drug administration and Flushing procedure using Classic Syringe|To fully complete the intravenous drug administration with rigor, nurses should flush the catheter pre, post and inbetween drug administration. This implies the use of two or three syringes.
18288|NCT04046757|Other|Mechanical thrombectomy|Neuroradiological endovascular treatment
18289|NCT04046744|Procedure|Axillary brachial plexus block with a long-acting local anesthetic|axillary block with 20-30 ml Ropivacaine 0,5%.
18290|NCT04046744|Procedure|Axillary brachial plexus block with a short-acting local anesthetic + Analgesic block at the elbow with a long-acting local anesthetic|axillary block with 20-30 ml Lidocaine 1,5% + radial and medial nerve block at the elbow with 5-7 ml Ropivacaine 0,5%.
18291|NCT04046744|Drug|Ropivacaine|axillary block with 20-30 ml Ropivacaine 0,5%
18292|NCT04046744|Drug|Ropivacaine|radial and medial nerve block at the elbow with 5-7 ml Ropivacaine 0,5%
18293|NCT04046744|Drug|Lidocaine|axillary block with 20-30 ml Lidocaine 1,5%
18294|NCT04046731|Diagnostic Test|Skin Testing|Percutaneous skin prick followed by Intradermal Injections of NMBAs at increasing concentrations compared with an established positive and negative control.
18295|NCT04046718|Device|electro-acupuncture stimulation|stimulation of acupoints of the liver meridian of lv3 lv14
18296|NCT04046705|Procedure|Allogeneic matched related haematopoietic stem cell transplantation|Allogeneic matched related haematopoietic stem cell transplantation after a reduced intensity conditioning regimen
18297|NCT04046705|Other|Standard arm|In the standard arm, patients who will not be transplanted, will receive the best standard care according to their situation and their previous treatment: initiation of hydroxyurea, continuation or optimization of the dose of hydroxyurea, initiation or continuation of transfusion program, initiation of a new drug proved to improve SCD and having authorization to use in France
18298|NCT04046692|Other|Hospital School Experience, point of view of the children|Operators of the PANAS-C, PH-C and VAS ask the children to answer the questionnaire before/after the school lesson; then they ask the children to make 2 paintings about hospital and not hospital school experience.
18299|NCT04046692|Other|Hospital School Experience, point of view of the hospital teachers|operators interview hospital teachers and make them complete a questionnaire (CEESQ)
18300|NCT04046692|Other|Hospital School Experience, point of view of the non hospital teachers|operators interview the teachers and make them complete a questionnaire (CEESQ)
18301|NCT04046692|Other|Hospital School Experience, point of view of parents|Operators interview parents
18302|NCT04046679|Drug|Bleomycin|Skin bleomycin infusion through tattoo machine
18303|NCT04046679|Other|Saline Solution|Saline solution infusion through tattoo machine
18304|NCT04046666|Device|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
18305|NCT04046653|Dietary Supplement|Allin|Dietary supplement
18306|NCT04046653|Dietary Supplement|Sulforaphane|Dietary supplement
18307|NCT04046653|Dietary Supplement|Placebo|Dietary supplement
18308|NCT04046640|Device|Infrared thermal imaging|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a NEC InfRec R450 infrared thermal imaging camera~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
18309|NCT04046614|Drug|nintedanib-nivolumab combination therapy|"Safety run-in - Dose finding stage The safety-run in phase will be designed as a standard 3+3 design for dose escalation/de-escalation and 3 to 6 patients will be enrolled in each cohort sequentially, depending on occurrence of dose limiting toxicities. The recommended phase 2 dose (RP2D) will be the highest dose in which the frequency of DLTs is less than 33% if no other safety or feasibility considerations prevail.~Expansion phase: Nintedanib RP2D + nivolumab 240 mg Q2W until progression of disease."
18310|NCT04046601|Device|impedance|After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
18311|NCT04046588|Device|Infrared thermography|"Infrared thermal imaging will be adopted to assess the heat transport characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a NEC InfRec R450 infrared thermal imaging camera~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. The height and angle of the infrared thermal imaging camera is adjusted so that the measurement sites of the participant's arm is located in the center of the camera screen. The infrared thermal imaging and acupoint temperature will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
18312|NCT04046575|Radiation|Intensity Modulated Radiation Therapy|-15 fractions of treatment
18313|NCT04046575|Drug|FOLFOX regimen|"-Includes:~5-FU bolus 400 mg/m2 over 5-15 minutes then 5-FU infusion 800 mg/m2/day x 2 days (1600 mg/m2 over 46 hrs)~Oxaliplatin 85 mg/m2 intravenous over 2 hours~Leucovorin 400 mg/m2 intravenous bolus over 2 hours"
18702|NCT04043494|Drug|Ifosfamide|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
24967|NCT03992287|Dietary Supplement|Placebo|Placebo for 12 weeks
18314|NCT04046575|Other|MD Anderson Symptom Inventory (MDASI)-Plus module|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
18315|NCT04046575|Other|EuroQol (EQ-5D)|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
18316|NCT04046575|Other|SF-12|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
18317|NCT04046575|Other|MOS Social Support Measure|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
18318|NCT04046575|Other|CES-D|The QOL questionnaires will be answered by the patients prior to the start of chemoradiation, on the last week of RT, and at 6-8 week follow-up, 3, 6, 9, and 12 months post completion of RT
18319|NCT04046575|Procedure|Blood for ctDNA|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
18320|NCT04046575|Procedure|Urine for ctDNA|-Collected at pre-treatment, every 2 weeks during chemoradiation, every 2-3 weeks during consolidation chemotherapy, completion of therapy, 6-8 week follow-up, 3 month follow-up, 6 month follow-up, and 12 month follow-up
18321|NCT04046575|Procedure|Blood for SCCA|-Collected at pre-treatment, completion of therapy, and 6 month follow-up
18322|NCT04046562|Behavioral|PAW|Pain and Weight Treatment plus standard of care
18323|NCT04046562|Behavioral|Pain Education|Pain Education plus standard of care
18324|NCT04046549|Drug|Belatacept|Belatacept Dose 1 will be administered intravenously on post-op Day 1, repeated on post-op Day 3 or 4, and at the end of Weeks 2, 4, 8 and 12; then Dose 2 every four weeks from Week 16 to Week 48.
18325|NCT04046549|Drug|VIB4920|VIB4920 Dose 1 will be administered intravenously on post-op Days 1, and 14, and at the end of Weeks 4, 6, 8 and 10; then will continue every four weeks from Week 12 to Week 48.
18326|NCT04046536|Device|Transcranial Magnetic Stimulation|A non-invasive treatment that emits magnetic pulses to stimulate the brain.
18327|NCT04046536|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
18328|NCT04046523|Device|Video ophthalmoscope|Use of a custom video ophthalmoscope with either a CCD or CMOS camera lens. The healthy controls group (first 20 subjects) will provide data to help determine which lens might be best for measuring ICP patients (Groups A and B) in the second phase of the study.
18329|NCT04046510|Drug|Ocytocin|Administration of lower doses of Ocytocin in bolus and continuous infusion
18330|NCT04046497|Other|Smartphone App|artificial intelligence (AI) smartphone app to provide support for medication adherence
18331|NCT04046497|Other|Ususal Care|Usual Care provided by CSC clinic
18332|NCT04046484|Drug|Normal Saline along with standard treatment|The arm is for active comparison for PMZ-1620 (sovateltide), an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients. Normal saline (vehicle) with standard treatment will be provided.
18333|NCT04046484|Drug|PMZ-1620 along with standard treatment|PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
18334|NCT04046471|Dietary Supplement|enhanced Stop Light Diet|Stop light diet enhanced with portion-controlled meals
18335|NCT04046471|Behavioral|Group Remote|Participants will receive remotely delivered weight loss in a group setting.
18336|NCT04046471|Behavioral|Individual In-Person|Participants will receive a weight loss intervention during individual, at-home visits.
18337|NCT04046458|Behavioral|Nighttime Vital Sign EHR Alert|A pop-up window in the EHR will notify a physician that their patient has been judged by a predictive algorithm to be safe for reduced overnight vital sign checks.
18338|NCT04046458|Other|No EHR alert|No change to EHR function; no alert visible to providers
18339|NCT04046445|Drug|ATP128|6 injections of ATP128
18340|NCT04046445|Drug|BI 754091|≥ 7 infusions of BI 754091
18341|NCT04046432|Dietary Supplement|Vigiis 101-LAB|examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)
18342|NCT04046432|Dietary Supplement|Placebo|Maltodextrin was used as a placebo.
18343|NCT04046419|Other|Turkish validity and reliability|"Explanation of the Turkish version of the scale.~Translating the Turkish version of the scale into English to ensure consistency with the original scale.~First application of scales to participants.~Second application of the scales to the participants.~Statistical analysis and scaling"
18344|NCT04046406|Device|MR neurography-guided cryoanalgesia|Treatment will be performed using a FDA-approved Galil Medical cryoablation system and FDA-approved Galil Medical cryoablation needles.
18345|NCT04046393|Device|"Taiwan Scientific noninvasive blood pressure meter TS-0411"|measure autonomic nerve
18346|NCT04046393|Device|Meridian Energy Analysis Device(MEAD)|measure meridian energy
18347|NCT04046393|Procedure|bacteria culture|use culture swab to culture nasal discharge
18348|NCT04046393|Procedure|nasopharyngoscopic examination|use nasopharyngoscopy to determine the modified Lund-Kennedy endoscopic scoring system
18349|NCT04046393|Combination Product|TCM nasal irrigation|Chinese herbal medicine (licorice) extract solution with buffered salt packet and water in rinse bottle
18350|NCT04046380|Diagnostic Test|work of breath measurement and calculation|The ventilator-imposed power at various tidal volume (6, 8, 10 ml/Kg) and positive end-expiratory pressure (5, 10 cmH 2 O) will be calculated by the formula.
18351|NCT04046367|Behavioral|Prehabilitation|Prehabilitation: The intervention of a physiotherapist will be added to the components of the control group. Patients will receive practical instructions on aerobic and resistance physical activity, as well as training of their inspiratory muscles.
18352|NCT04046367|Behavioral|Control|Standard group intervention. Educational program and cognitive-behavioral intervention. The patient receives training in nutrition and cognitive-behavioral therapy, as well as standard instructions to increase physical activity.
18353|NCT04046354|Device|Ultrasound-guided Percutaneous Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
18354|NCT04046354|Device|Ultrasound-guided Percutaneous Radiofrequency Ablation|Ultrasound-guided Percutaneous Radiofrequency Ablation
18355|NCT04046341|Behavioral|Sleep Well!|The intervention comprehensively addresses poor sleep health behaviors (e.g., use of electronics at bedtime; inconsistent and variable sleep schedules; lack of a bedtime routine) as well as insomnia (difficulty falling and staying asleep; the need for caregiver presence at bedtime) and insufficient sleep in toddlers and preschoolers who are living in disadvantaged contexts. Interventionists will use strategies to engage with and empower families, such as motivational interviewing and collaborative problem-solving. In-person session content will be reinforced via phone calls from interventionists. Families will receive intervention session appointment reminders and information about intervention content (e.g., reminders to follow a bedtime routine), using Twilio, which is integrated with Epic.
18356|NCT04046328|Drug|Enteric-Coated Cholestyramine (ECC) Capsule|Enteric-Coated Delayed Release Cholestyramine Capsules
18357|NCT04046328|Drug|Placebo|Enteric-Coated Delayed Release Placebo Capsules
18358|NCT04046315|Diagnostic Test|CMR|GLS measurement with CMR
18359|NCT04046302|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
18360|NCT04046302|Drug|placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
18361|NCT04046289|Dietary Supplement|Low Calcium Milk|50 mg calcium/day
18362|NCT04046289|Dietary Supplement|Regular Calcium Milk|400 mg/day
18363|NCT04046289|Dietary Supplement|Probiotic 1|regular calcium milk + probiotic
18364|NCT04046289|Dietary Supplement|Probiotic 2|regular calcium milk + probiotic
18365|NCT04046276|Behavioral|High Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
18366|NCT04046276|Other|Conventional Physical Therapy|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
18367|NCT04046276|Behavioral|Medium Intensity Aerobic program|Three sessions a week of hospital-based exercise on a stationary bicycle, all in presence and with the guidance of a physical education teacher, for nine months
18368|NCT04046263|Drug|Sucroferric Oxyhydroxide Chewable Tablet|Patients will be started on 1 tablet three times daily with meals and the dose will be titrated monthly in increments of 500mg (1 tablet) per day until serum phosphate is at goal
18369|NCT04046250|Drug|TK-112690|TK112690 treatment pre-methotrexate treatment
18370|NCT04046250|Drug|Placebo TK-112690|Placebo
18371|NCT04046237|Other|Periodontal treatment|"Periodontal treatment can last up to 6 months depending on the periodontal state, followed by a follow-up period of at least 6 months including a visit to M9.~Briefly, the intervention group includes initial therapy in 48 hours maximum which includes information on oral hygiene techniques (verbal + brochure), scaling and surfacing of dental roots with antiseptic irrigation and non-tooth extraction. retainable. This initial therapy is followed by a resumption of periodontal clinical measures after 6 weeks. Depending on the degree of improvement of the measurements, the treatment is either completed, or continues with further scaling-surfacing and / or performing one or more periodontal surgeries. Periodontal monitoring period often called maintenance includes repeated sessions of simple scaling whose rate does not exceed 4 per year."
18372|NCT04046224|Biological|ST-920|Single dose of investigational product ST-920
18373|NCT04046211|Drug|Hydrogen|Gas exposure for 24, 48 or 72 hours via high flow nasal cannula.
18374|NCT04046198|Other|Educational program|The Professional Values Education Program was developed in accordance with the Professional Values Model. For nurses in the intervention group program continued for three months. Group training was given before. Then, three individual interviews were conducted. After the post test was applied to the control group, group training was performed.
18375|NCT04046185|Drug|PD-1 inhibitor combined progesterone|Toripalimab combine with progesterone
18376|NCT04046185|Drug|progesterone|progesterone
18377|NCT04046172|Procedure|supra/sub gingival root surface debridement|The test group will undergo Intensive periodontal treatment (IPT)
18378|NCT04046172|Procedure|supra-gingival scaling and polishing|Control group will receive the Control periodontal treatment (CPT).
18379|NCT04046159|Drug|Low-dose tamoxifen|Low-dose tamoxifen is not inferior than radiotherapy in decreasing ipsilateral breast tumor recurrence and side effect
18380|NCT04046159|Radiation|Whole breast radiotherapy|Ipsilateral breast tumor recurrence and side effect
18381|NCT04046146|Drug|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
18382|NCT04046146|Device|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
18383|NCT04046133|Drug|Pembrolizumab|Pembrolizumab, an immune checkpoint inhibitor, concomitantly with standard CRT in patients with locally advanced T3/4 anal cancer.
18384|NCT04046120|Other|Heel-free bandage|The bandage is made by leaving the heel uncovered.
18385|NCT04046107|Biological|Cemiplimab|Administered as an intravenous (IV) infusion
18386|NCT04046094|Drug|Ascorbic Acid|Ascorbic Acid Intravenous
18387|NCT04046081|Drug|Dichloroacetate|6.25 mg/kg BD for 6 weeks increasing to 12.5 mg/kg BD for 6 weeks
18411|NCT04045899|Device|Air-Q LMA|Air-Q LMA has a self-pressurizing cuff which inflates to adequate pressure during positive pressure ventilation thus eliminating the adverse effects of cuff over inflation associated with the use of Supraglottic airway device with an inflatable cuff.
18412|NCT04045899|Device|Ambu AuraGain LMA|The AmbuAuraGain™ is a disposable, preformed second generation SAD, anatomically curved with integrated gastric access and intubation capability, taking patient safety and airway management efficiency to a new level.
18388|NCT04046068|Procedure|ComfortSafe Care|In most cases, sevoflurane, an inhalation anesthetic, will be used in higher-than-traditional concentrations to replace opioids and provide safe control of vital signs along with amnesia and analgesia. Intravenous (IV) propofol, esmolol, and other beta-blockers can also be administered to prevent increases in BP and HR during surgery. At the time of wound closure, the ComfortSafe Pyramid derived Preemergence Analgesic Checklist guides the anesthesia and surgical teams through collaborative decisions for implementation of a multimodal analgesic plan. Local anesthetics, including liposomal bupivacaine, can then be injected and IV non-opioid analgesics administered allowing the patient to awaken comfortably from anesthesia. Standardized kits for liposomal bupivacaine administration will be utilized. If the patient does have pain, IV opioids can be administered to provide immediate relief without hesitation since the non-opioid analgesics have already been given.
18389|NCT04046055|Device|Transcranial direct current stimulation at 2 mA|Uses weak electrical current (2 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
18390|NCT04046055|Device|Transcranial direct current stimulation at 4 mA|Uses weak electrical current (4 mA intensity) to either increase or decrease brain excitability and improve functional or cognitive outcomes.
18391|NCT04046055|Device|Sham transcranial direct current stimulation|Uses weak electrical current (2 mA intensity) at the beginning and the end of a given stimulation period to control for potential placebo-like effects or participant expectation bias.
18392|NCT04046042|Other|Conventional exercise|Virtual reality exercise performed during the first two hours of the hemodialysis session
18393|NCT04046042|Other|Exercise during the last two hours of the hemodialysis session|Virtual reality exercise performed during the last two hours of the hemodialysis session
18394|NCT04046029|Drug|Bivalirudin|Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
18395|NCT04046029|Drug|Heparin|Heparin will be administered at a dose of 70 to 100 units per kilogram in patients not receiving glycoprotein IIb/IIIa inhibitors and at a dose of 50 to 70 units per kilogram in patients receiving glycoprotein IIb/IIIa inhibitors. Subsequent adjustment of the heparin dose on the basis of the activated clotting time will be left to the discretion of the treating physicians.
18396|NCT04046016|Drug|Paclitaxel|Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
18397|NCT04046003|Behavioral|Tai chi exercise|24-form Yang style Tai Chi (60 min/session, 3 sessions/week) for 8 weeks
18398|NCT04045990|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS is a method to focally and reversibly stimulate a pre-specified cortical target. rTMS works through the principle of electromagnetic induction.
18399|NCT04045977|Behavioral|Cardiac rehabilitation|Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
18400|NCT04045977|Device|Virtual therapeutic support|"8 sessions of VR therapy (each of them 20 minutes long).~As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation. By performing tasks in the virtual garden, the patient becomes an active participant of the therapeutic process and sees the effects his/her work."
18401|NCT04045977|Behavioral|Standard therapeutic support|8 sessions of Schultz Autogenic Training (each of them 20 minutes long).
18402|NCT04045964|Drug|nicotine replacement therapy (NRT)|Participants were provided with either 2 weeks of 14-mg or 21-mg transdermal nicotine patches for every smoker in the home
18403|NCT04045964|Behavioral|motivational advice|Received two in-hospital motivational advice sessions by a research associate (RA). The RA adapted session content from a previous tobacco-smoke exposure protocol
18404|NCT04045964|Behavioral|Quitline referral|Quitline participants received information about tobacco-smoke exposure reduction and a referral to a tobacco Quitline.
18405|NCT04045951|Other|Myopia prediction algorithm|Candidate predictors included age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
18406|NCT04045938|Other|Low Glycemic Index or Glycemic Load|Dietary pattern focused on low glycemic index foods or on a low glycemic load
18407|NCT04045925|Other|Taïso|Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
18408|NCT04045912|Other|AGYW-Friendly Services|"Drug shops will offer a loyalty program (the Queen Club) through which AGYW can earn mystery prizes and discretely request free SRH products. Drug shops will also have an SRH product display and a tablet with SRH videos for interested customers, and drug shop employees will receive training on contraceptive counseling for AGYW."
18409|NCT04045912|Other|HIVST|Drug shops will provide HIVST kits to AGYW for free. Employees will receive training on HIVST and will institute an HIV care referral plan for customers who require linkage to confirmatory testing or treatment.
18410|NCT04045899|Device|Proseal LMA|The Proseal Laryngeal Mask Airway (p-LMA) has a dual cuff modified to provide better sealing, and a drainage tube for gastric tube insertion. These features attribute in increasing the safety of the p-LMA when used with positive pressure ventilation.
18413|NCT04045886|Behavioral|Online Educational Modules (Videos)|5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
18414|NCT04045873|Device|extracorporeal membrane oxygenation|The VA-ECMO procedure will be performed by femoral artery access, and the IABP will then be implanted in the contralateral femoral artery.
18415|NCT04045860|Procedure|Complete Decongestive Therapy|A combination of manual lymph drainage , compression bandaging, physical exercise and a skin care regimen
18416|NCT04045860|Other|Observation|Standard of care is currently observation
18417|NCT04045847|Biological|CD147-CART|Three doses of CD147-CART cells were injection to intracavity by Ommaya Reservoir.
18418|NCT04045834|Device|68Ga-DOTA-TATE PET/MR and PET/CT imaging|Intravenous access is established in advance, intravenous bolus injection, 68Ga-DOTA-TATE dose is about 2 MBq/kg body weight (0.054 mCi/kg) up to 200 MBq (5.4 mCi), 18F-FDG dose is about 3.7-5.4 MBq/kg (0.1 -0.15 mCi/kg), rinsed with 0.9% saline, and hydrated after drinking more water.
18419|NCT04045821|Drug|AMD3100|Subjects in this arm will have AMD3100 administered per the standard dosing regimen of 0.24 mg/kg actual body weight subcutaneous x1 dose
18420|NCT04045821|Drug|Normal saline|Subjects in this arm will have a placebo of normal saline administered subcutaneously x1 dose
18421|NCT04045821|Procedure|dilation and curettage|all participants will undergo routine D&C procedure
18422|NCT04045808|Other|radiographic evaluations were done|For radiographic analysis, periapical radiographs were taken from teeth with ≥ 4mm PPD using a hand held intra-oral x-ray system operating at 60kVp, 1.5 mA . The alveolar bone loss was measured by a personal computer with the Microsoft Windows XP operating system with original software.
18423|NCT04045795|Drug|isatuximab SAR650984|Pharmaceutical form: solution Route of administration: intravenous
18424|NCT04045795|Drug|pomalidomide|Pharmaceutical form: tablet Route of administration: oral
18425|NCT04045795|Drug|dexamethasone|Pharmaceutical form: tablet Route of administration: oral
18426|NCT04045782|Drug|single arm|switch from originator (Humira) to biosimilar (Imraldi)
18427|NCT04045769|Drug|Saroglitazar magnesium 4mg|1 tablet of 4 mg Saroglitazar magnesium; 4 tablets of placebo to be administered orally
18428|NCT04045769|Drug|Placebos|5 tablets of placebo to be administered orally
18429|NCT04045769|Drug|Moxifloxacin 400mg|1 tablet of 400 mg Moxifloxacin to be administered orally
18430|NCT04045769|Drug|Saroglitazar magnesium 20 mg|5 tablets of 4 mg Saroglitazar magnesium to be administered orally
18431|NCT04045756|Device|Procedure/Surgery: Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates 1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bollous of i.v. corticosteriods () is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Cirpofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
18432|NCT04045743|Drug|MABp1 (Bermekimab) OR Placebo|Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks
18433|NCT04045743|Drug|MABp1 (Bermekimab)|Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks
18434|NCT04045730|Drug|Gemcitabine|All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
18435|NCT04045717|Radiation|Hypo-FLAME 2.0 study|SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).
18436|NCT04045704|Procedure|Cataract Surgery|Patients with bilateral Advanced Age-related macular degeneration and concurrent cataracts will be receiving bilateral cataract surgery
18437|NCT04045691|Drug|Encorafenib|Observation of real-life treatment with encorafenib and binimetinib
18438|NCT04045691|Drug|Binimetinib|Observation of real-life treatment with encorafenib and binimetinib
18439|NCT04045678|Drug|LY03003 ( Rotigotine, extended-release microspheres)|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
18440|NCT04045678|Drug|Placebo, extended-release microspheres|"Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks."
18441|NCT04045665|Drug|Antiplatelet-only strategy|Aspirin 75-100 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
18442|NCT04045665|Drug|Oral Anticoagulant plus background antiplatelet therapy|OAC with vitamin K antagonist (VKA) with international normalized ratio (INR) target 2-3 or any approved direct oral anticoagulant OR apixaban, rivaroxaban, edoxaban or dabigatran) in addition to background antiplatelet therapy with aspirin 75-100 mg once-daily or a P2Y12-inhibitor (clopidogrel or ticagrelor)
18443|NCT04045626|Procedure|corneal cross-linking|Riboflavin is instilled over cornea followed by Ultraviolet-A irradiation
18444|NCT04045613|Drug|Derazantinib|"Substudy 1: Derazantinib will be administered orally at a dose of 300mg once per day~Substudy 2: Derazantinib will be administered orally at various dose levels~Substudy 3 and 4: Derazantinib will be administered orally at the dose of 300mg once per day as single agent or at the identified RP2D for derazantinib-atezolizumab"
18445|NCT04045613|Drug|Atezolizumab (drug supplied by Hoffmann-La Roche)|Atezolizumab will be intravenously administered every 3 weeks at a dose of 1200mg.
18546|NCT04044690|Drug|human immunoglobulin G|human immunoglobulin G administered subcutaneously
18446|NCT04045600|Behavioral|Trad FCT|Traditional FCT (trad FCT) thins reinforcement by incorporating unsignaled delays to reinforcement. In this study, trad FCT will be a variable-interval 15-s reinforcement schedule in which communication responses are reinforced every 15 s, on average.
18447|NCT04045600|Behavioral|Mult FCT|FCT with multiple schedules (mult FCT) thins reinforcement by incorporating treatment signals (e.g., black and white cards signaling reinforcement and extinction, respectively). In this study, mult FCT will involve 30-s reinforcement components and 15-s extinction components for the communication response (i.e., the extinction component is equivalent to the delay period during trad FCT).
18448|NCT04045600|Behavioral|Mult FCT + Stimulus Fading|This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
18449|NCT04045574|Procedure|The 1T1T concept versus conventional implant loading protocol|Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
18450|NCT04045548|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
18451|NCT04045548|Drug|Placebo|one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
18452|NCT04045535|Other|Physical Activity Program|Usual Care and a nurse-led physical activity program once a week for 8 weeks. Each session last for 60 minutes, 15 for warming-up and 45 for different exercises.
18453|NCT04045535|Other|Usual care|Usual clinical care based on current clinical practice guidelines.
18454|NCT04045522|Drug|Zoledronic Acid|Based on routine treatment, 4 mg zoledronic acid (Novartis Pharma Stein AG, Switzerland, registration No. H20140218) was intravenously administered, once every 3-4 weeks, for 1-2 years.
18455|NCT04045509|Device|Liquid Jet Esthesiometer Prototype|Balanced salt solution with a pH value similar to the tear film uesd as a liquid jet stimulus for corneal sensation threshold measurement
18456|NCT04045509|Device|Tactile Esthesiometer Prototype|A round plastic nozzle (1.8mm diameter) used as a stimulus for corneal sensation threshold measurement
18457|NCT04045509|Device|Cochet Bonnet esthesiometer|A nylon thread (0.12mm diameter) used as a stimulus for corneal sensation threshold measurement
18458|NCT04045496|Drug|JAB-3312|JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
18459|NCT04045483|Other|Virtual reality based cognitive training|The VR-based cognitive training consists of a three-dimensional simulation of home, a mart, bus stop, and street. It provides an integrative cognitive training experience where participants are required to accomplish some common ADL's in three frequently visited places: home, a supermarket, and bus stop.
18460|NCT04045470|Device|Microdevices|The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.
18461|NCT04045470|Other|Standard of care therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
18462|NCT04045470|Other|Standard of care systemic therapy|Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
18463|NCT04045457|Procedure|dry needling|insertion of needle into active myofascial trigger point
18464|NCT04045444|Other|walking|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be walking at 3 km/h, walking while doing the cognitive task, walking at the preferred speed, walking at the preferred speed while doing the cognitive task.
18465|NCT04045444|Other|cognitive task|Every participants will performed a set of tasks of 2 min. Each task will be separated by a 2 min resting period. The tasks will be a cognitive task, a control cognitive task.
18466|NCT04045431|Device|PAAG-OA|Intra-articular injection of 6ml PAAG-OA in the target knee
18467|NCT04045431|Device|Synvisc-One|Intra-articular injection of 6ml Synvisc-One in the target knee
18468|NCT04045418|Device|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated [Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)]. The acupoint microcirculation will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
18469|NCT04045405|Drug|CDR132L|i.v. administration
18470|NCT04045392|Behavioral|Mediterranean diet|Two meals (breakfast and dinner) a day, five times a week, are delivered to participants' homes without charge. The meals are prepared, under the supervision of an expert nutritionist, by a chef trained on the principles of the Mediterranean diet.
18471|NCT04045379|Procedure|LASER|Use of the SmartXide Touch V²LR, Co2 Laser System to perform ambulatory intravaginal and vulvar application of LASER, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the LASER will be applied, according to the protocol of the manufactured.
18472|NCT04045379|Procedure|Microablative Radiofrequency|Use of Linly™ equipment to perform ambulatory intravaginal and vulvar application of fractionated microablative radiofrequency, to postmenopausal genitourinary syndrome. The patient will be in gynecological position, after remove of vaginal secretion, with gauze and under topic anesthesia, the radiofrequency will be applied, according to the protocol of the manufactured.
18473|NCT04045379|Drug|Estriol|The patient will perform self application of this vaginal estriol daily for 2 weeks and after that the applications will occur twice a week.
18474|NCT04045366|Other|Sample collection|Plasma and BAL sample collection
18475|NCT04045353|Behavioral|Low carbohydrate diet education|A 200 page informational document that connects with an online application will be provided to subjects.
18476|NCT04045353|Behavioral|Low carbohydrate diet education with behavioral component|A 12 week course taught be a certified instructor will teach subjects about a low carbohydrate document. Subjects will also be given a 200 page informational document that connects with an online application.
18477|NCT04045340|Device|Philips QLAB Ultrasound Quantification Software|Offline processing of intraoperative transesophageal echocardiography would be performed with Global Longitudinal Strain on apical 4 chamber, apical 2 chamber and long axis views in order to analyze left ventricle and left atrium contractility and right ventricle free wall motion
18478|NCT04045327|Drug|Normal saline + Standard Treatment|Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
18479|NCT04045327|Drug|Centhaquine + Standard Treatment|Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock
18480|NCT04045314|Other|Topical moisturizer|The investigational product is an intensive emollient cream that is applied topically on the skin and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at soothing and conditioning the skin as well as improving hydration. The moisturizer also contains 1% hemp oil rich in essential fatty acids and antioxidants as well as 0.5% of CBD with regulatory and conditioning effect on the skin
18481|NCT04045301|Biological|Omalizumab 16mg/kg|Participants will receive omalizumab 16 mg/kg monthly doses for 12 weeks, followed by omalizumab 8 mg/kg monthly for 4 weeks and then omalizumab 4 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
18482|NCT04045301|Biological|Omalizumab 8mg/kg|Participants will receive omalizumab 8 mg/kg monthly doses for 12 weeks, followed by omalizumab 4 mg/kg monthly for 4 weeks and then omalizumab 2 mg/kg monthly for 4 weeks, for a total of 20 weeks including a taper period.
18483|NCT04045301|Biological|Placebo|Participants will receive placebo for 8 weeks prior to the initiation of oral immunotherapy and 12 weeks after for a total of 20 weeks including a taper period.
18484|NCT04045301|Other|Multi-food oral immunotherapy (OIT)|Multi-food oral immunotherapy will be conducted to a mix of three foods. It will be started 8 weeks after study drug with an initial food escalation. Participants will undergo biweekly increase until they tolerate a maintenance dose of 1500 mg (500 mg per food) of food protein.
18485|NCT04045288|Behavioral|Standard Implementation|Schools in the Standard implementation model received web-based training, access to on online education / tracking system and programming resources (modules, posters, trinkets) to facilitate wellness programming in their school. They completed audit tools at the beginning to facilitate goal setting and received weekly emails during the 12-week implementation process.
18486|NCT04045288|Behavioral|Enhanced Implementation|Schools in the Enhanced implementation model received the same training, web-access, and programming resources as those in the Standard implementation, but also received enhanced monthly support during implementation from the project team. The supplemental web calls (completed jointly by Extension leaders and SWITCH staff) utilized motivational interviewing to help schools build capacity and to enhance motivation for wellness programming.
18487|NCT04045275|Behavioral|Calm|"Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice."
18488|NCT04045249|Dietary Supplement|Home based food|Home based food is compare able to RUTF
18489|NCT04045236|Other|Registry|Data collection
18490|NCT04045223|Other|Blood samples|Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
18491|NCT04045210|Other|Psychological Support Based on Positive Suggestions|Eligible patients will be randomized at the earliest possible time after meeting inclusion criteria. Patients will be randomized 1:1:1 to intervention by either doulas or a psychiatrist or a non-intervention arms stratified by ICU location. Both intervention and controls will receive standard medical care at the discretion of the ICU team. The intervention arm will receive PSBPS as soon as feasible and continue on a daily basis. Doulas/psychiatrist will also liaise with family, the team, and with the nursing staff. Both intervention and standard of care arms will complete follow-up questionnaires measuring symptoms of anxiety, depression, acute stress and cognitive function after ICU discharge and at 6 months follow up by phone. All the patients randomized to the intervention arm will receive the same intervention.
18492|NCT04045197|Behavioral|Relaxation Focused Nursing Care|"Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors."
18493|NCT04045184|Other|Food assistance|This is an observational study of an existing community program. No intervention is provided beyond food assistance in the community program.
18494|NCT04045171|Drug|Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months
18495|NCT04045145|Drug|NBI-74788|NBI-74788 administered orally for 14 consecutive days.
18496|NCT04045132|Behavioral|Social Media-Based Parenting Program|Participants in the intervention group will be enrolled in Facebook secret user groups, administered by a trained facilitator, in order to permit participants to view and comment on posted materials. Content and user identity are restricted to invited participants to maintain privacy. For each topic, we organize educational materials into video vignettes, narrated PowerPoint presentations, and written materials. The facilitator reviews and comments on postings daily, provides feedback to participants, and removes inappropriate postings if they occur. Facebook analytics for the secret groups are available to group administrators and will provide information on any sessions viewed (engagement) and counts of sessions viewed and comments posted (dosage). Women in the intervention group will also be enrolled in the online depression treatment program, MoodGym.
18497|NCT04045132|Behavioral|MoodGym|Participants in the control group will be enrolled in MoodGym, an evidence-based online CBT program for depression. Through the MoodGym program, participants will have access to interactive exercises, workbooks, anxiety and depression quizzes, and downloadable relaxation audio files. We will supplement Moodgym with a facilitator contact by texting or email to check-in and encourage completion of intervention. MoodGym will provide information on the number of sessions completed by participants (engagement and dosage).
18498|NCT04045119|Other|Topical Moisturizer|The investigational product is a moisturizing facial cream for skin with imperfections that is applied topically and is manufactured by Avicanna Inc. This preparation contains widely used ingredients from mineral and botanical origin aimed at improving skin hydration and characteristics associated acne-prone skin. The moisturizer also contains 0.1% of hemp oil rich in essential fatty acids and antioxidants and 0.5% of cannabidiol with regulatory effect on the skin.
18499|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation Patterns|The participants were asked to sit on a chair, the therapist performed the pattern of movement himself then passively applied the pattern on the participant then asked the participant to perform the pattern, and the therapist observed and corrected the movement if it was done improperly.Then participants were told that the therapist will resist their movement, they were also told to keep breathing normally and to report any discomfort and/or pain.After mastering the pattern,the therapist placed one hand on the participant's mandibular and the other hand approximately between parietal and occipital bones to apply resistance through out the ROM, each pattern performed for 3 sets of 10 repetitions with 1-2-minute rest between sets.
18500|NCT04045106|Other|Proprioceptive Neuromuscular Facilitation stretching|was done for 6 repetitions with hold for 6 seconds in position of stretch and sub maximal isometric contraction for 6 seconds, 1-2-minute rest was given before changing the target muscle group
18501|NCT04045106|Other|Passive range of motion|ineffective passive ROM for 10 repetitions for flexion, extension, right and left side bending and right and left rotation, it was done from neutral position to the limit of motion without causing any stretch to the muscle.
18502|NCT04045093|Drug|Dabigatran etexilate|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
18503|NCT04045093|Drug|Warfarin|Subjects will be randomized into 2 groups in a 1:1 ratio, to receive either Dabigatran or Warfarin for stroke prevention, in a open-label design.
18504|NCT04045080|Device|AMADEO|"AMADEO® is an end-effector system enables intensive training with frequently repeated gripping movements. It offers the possibility to select from between passive, assistive and active modes using exercise of finger strength, finger movement, movement control and a selective activation of the fingers.~Moreover, even without muscular strength, active work can be done using EMG-based training. The Continuous Passive Motion (CPM Plus) therapy facilitates the implementation of automatic movement sequences even when the patient is unable to complete the entire range of motion on their own. It may be used in all phases of finger-hand rehabilitation and can be adapted to the needs of every patient.~In patients with PD, it will be useful in improving bradykinesia and potentially distal hypostenia."
18505|NCT04045080|Other|Training|training
18506|NCT04045080|Other|OT Training|training
18507|NCT04045067|Procedure|Isolation of pulmonary veins|Low voltage areas are identified and treated by radiofrequency. Atrial fibrillation is treated by heat produced by an electric current: radio frequency. This is an intervention that consists of blocking abnormal electrical activity, especially in the pulmonary veins.
18508|NCT04045067|Procedure|Ablation by radiofrequency of low-voltage areas|The defragmentation is guided by a map of fragmented potentials, made through a topography catheter, to locate the most abnormal areas that are the target of ablation.
18509|NCT04045054|Behavioral|Link Team|A VA home care Link Team (clinical pharmacist, social worker, physical activity trainer) provides the intervention based on a conceptual model of home care as a bridge between hospital and home, in which three interconnected domains determine short-term and long-term outcomes: medical complexity (e.g., medication management), social complexity (e.g., caregiving, environment), and functional impairment (e.g., mobility, physical activity). The Link Team provides support and assessment for each domain, and will use tablet technology and wearable sensors in the home to gather patient data and facilitate communication. At the end of formal home care services, the Link Team provides patient-centered care in: 1) support for the the Veteran and caregiver in the event of changes in medical condition or medications and social or caregiver stressors; and 2) coaching to the Veteran and the caregiver during this transition period to optimize functional mobility and physical activity.
18510|NCT04045041|Behavioral|Acceptance and commitment therapy|An acceptance based intervention with focus on exposure.
18511|NCT04045028|Drug|Tiragolumab|Administered by IV infusion at a fixed dose of 600 mg on Day 1 of each 21-day cycle (Q3W)
18512|NCT04045028|Drug|Daratumumab|Administered by IV infusion at a dose of 16 mg/kg actual body weight weekly for a total of 9 doses, then every 3 weeks for a total of 5 doses, then every 4 weeks from Week 25 onward until disease progression
18513|NCT04045028|Drug|Rituximab|Administered by IV infusion at a dose of 375 mg/m2 weekly (QW) for 8 doses
18514|NCT04045015|Dietary Supplement|Liqourice|Liqourice corresponding to 1.5, 3.0 or 6.0 mg glycyrrhizic acid per kg body weight is taken in the evening during 7 days.
18515|NCT04045002|Other|'MyPinkMom' educational intervention|"The intervention will be carried out for 2 weeks. There will be three sessions of 'MyPinkMom' that will be delivered to respondents per week. In each session, a respective 'MyPinkMom' video with audio explanation will be delivered to respondents in intervention group through WhatsApp application. It will be delivered every alternate day per week and each video will take about 3 minutes duration. Each session has its own objective and different content.~Each of the respondent in the intervention group will be given 'MyPinkMom' diary in which they are required to document time of iron tablet intake daily as well as time of reading of 'MyPinkMom' material in each session. At the end of the intervention, a meeting with all the respondents from the intervention group will be held for question and answer session."
18516|NCT04044989|Device|Laser|Diode laser device was used for photobiomodulation
18517|NCT04044989|Device|light-emitting diode (LED)|LED device was used for photobiomodulation
18518|NCT04044989|Device|Placebo|Diode laser device was used for placebo effect
18519|NCT04044976|Drug|Caffeine Citrate|Infants will receive 20 mg/kg of caffeine citrate intravenously, via the umbilical vein, or enterally, through an orogastric tube, within 10 min of birth.
18547|NCT04044690|Drug|Placebo|contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
18548|NCT04044677|Device|tDSC-active|10 sessions of active Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of sham Transcranial Direct Current Stimulation
18970|NCT04041310|Biological|GAd-209-FSP high dose|GAd20-209-FSP IM vaccine, high dose
18520|NCT04044963|Behavioral|Exercise and Prehabilitation|"All participants who are allocated to the exercise group will be asked to complete 4-5 days per week of mixed modality exercise incorporating aerobic, resistance, and flexibility training. The aerobic component can include any modality the patient is capable of doing, including walking, swimming or biking. By the end of the prehabilitation period the target will be 30 minutes of aerobic exercise three times a week at an intensity of 3-5 RPE. The resistance component will include 5-6 exercises using body weight and resistance bands. The target will be 12 repetitions and 3 sets, two times a week. The flexibility component will include 5 exercises that can be completed at the end of each session.~Participants will self-report their participation in the prehabilitation program based on an electronic survey."
18522|NCT04044937|Drug|F-18 Fluoroethyltyrosine (FET)|Patients given a one-time injected dose of 4 to 7 millicurie (mCi) of FET. The radiopharmaceutical will be administered while the patient is in the PET scanner
18523|NCT04044937|Procedure|Positron Emission Tomography (PET)|Patient receives single PET imaging lasting for 40 minutes
18524|NCT04044911|Behavioral|Task model (CogWatch)|
18525|NCT04044898|Drug|ALA Topical Powder|Use a moisturizing gel to prepare the drug in a 5% solution, apply topically to the affected area, single dose
18526|NCT04044898|Drug|ALA Topical Powder|Use a moisturizing gel to prepare the drug in a 10% solution, apply topically to the affected area, single dose
18527|NCT04044885|Behavioral|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
18529|NCT04044859|Genetic|Autologous genetically modified ADP-A2M4CD8 cells|Infusion of autologous genetically modified ADP-A2M4CD8 on Day 1
18530|NCT04044846|Behavioral|Physical activity program for homebound older adults faciliated by Personal Support Workers|The intervention is an evidence- informed, theory-driven mobility intervention for community-dwelling OAs who are moderately and severely frail according to the clinical frailty scale (Rockwood et al., 2005). The intervention, entitled Promoting Movement in OAs (ProMO), will be implementable with frail OAs in partnership with any care provider in the home. Investigators will focus the study on the two main providers of care- personal support workers (PSWs) and family caregivers. OAs, PSWs, and caregivers will co-create ProMO with us. ProMO will be distinct from existing home-based exercise programs (Johnson et al., 2003) (Giangregorio et al., 2018) because it will optimize natural opportunities for mobilization during care (e.g., bathing and dressing) and will be embedded in facilitated activities of daily living.
18531|NCT04044833|Behavioral|Health life style behaviour ,|Training: applying Personal Information Form, HLBS-II, and MSQ to the intervention and control groups determined randomly and distributing the Student Follow-up Schedules; c) Providing trainings to the intervention group; d) Monitoring the weights, BMIs, and menstrual symptoms of intervention and control groups; and e) After the Training: Applying HLBS-II and MSQ scales to intervention and control groups, collecting the follow-up schedules, and providing training to the control group and all other students. Trainings: First stage: 120 minutes basic training per week for four weeks (40 minutes on diet, 40 minutes on physical activity, and 40 minutes on menstrual symptoms)
18532|NCT04044820|Drug|Standardized Prescription|"Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~0-5 pills for simple surgeries such as a trigger finger release~10 pills for carpal tunnel or Dupuytren's contracture releases~15 pills for a ganglion cyst excision or simple tendon transfer~20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion."
18533|NCT04044807|Diagnostic Test|Modified National Institutes of Health Stroke Scale|Clinical tool used in the diagnosis of acute stroke developed by the National Institutes of Health, and modified for simplicity.
18534|NCT04044794|Behavioral|Standard Care|Standard care includes standardized educational materials to promote self-management of body weight along with provision of $60 for participants to purchase supplies or equipment to facilitate weight management.
18535|NCT04044794|Behavioral|Daily Self-Weighing|Participants will receive a wireless digital scale and will be asked to keep the scale in their home, weigh daily at the same time, and view their weight trajectory on the scale's digital display.
18536|NCT04044781|Drug|BPN14770, T2310|Subjects will be administered radio ligand T2310 and BPN14770 to determine brain occupancy of BPN14770.
18537|NCT04044768|Genetic|ADP-A2M4|Autologous genetically modified ADP-A2M4 Dose: 1.0 x109 to 10x109 transduced by a single intravenous infusion
18538|NCT04044755|Other|Myopia prediction algorithm|Candidate predictors mainly includes age at examination, SER, and annual progression rate. Using these predictors, the algorithm will be used to predict SER at 3 years.
18539|NCT04044742|Drug|Resiniferatoxin|Receiving Resiniferatoxin injection
18540|NCT04044742|Drug|Placebo|Receiving Placebo injection
18541|NCT04044729|Drug|Cannabidiol|500mg dose, suspended in medical grade olive oil and then mixed into chocolate pudding
18542|NCT04044729|Drug|Placebo|Placebo
18543|NCT04044716|Device|Auricular acupressure|Trained nurses in auricular acupressure will place acupressure beads on 4 acupoints on each ear (1-Shen Men, 2- Lung, 3- Thalamus, and 4- Hip or Knee depending on location of surgery). The nurse will do the initial activation of the acupressure site by applying pressure for 30 seconds to each point until the participant reports tingling or moderate degree of pressure. Participant will be given instructions to do this three times a day for a total of 8 days. Acupoints were selected based on recommendation of faculty acupuncturist.
18544|NCT04044716|Other|Standard of care pain management|The participant post-operative pain will be managed following the standard protocol by the treating physician.
18545|NCT04044703|Drug|Vancomycin - model-based dosing regimen|A dosing calculator based on a population pharmacokinetic model for vancomycin will be used to generate a participant's intermittent vancomycin dosing regimen. The participant's post-menstrual age, weight, creatinine and the target trough vancomycin level will be entered into the dosing calculator and the dose will be generated (intermittent infusion, dosing frequency will be from 1 to 4 times per day according to the corrected gestational age).
18549|NCT04044677|Device|tDCS-sham|10 sessions of sham Transcranial Direct Current Stimulation combined to Virtual Reality therapy followed by a one-month washout and 10 sessions of active Transcranial Direct Current Stimulation
18550|NCT04044664|Drug|Placebo oral capsule|Matching placebo capsules.
18551|NCT04044664|Drug|NYX-783|NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
18552|NCT04044651|Drug|Lenvatinib|lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
18553|NCT04044651|Drug|Nivolumab|nivolumab 480 mg IV infusions for 30 minutes q4w
18554|NCT04044638|Other|Resistance trainining|Resistance training sessions were held 3 times a week, in which each session lasted 60 minutes and was performed for a period of 8 weeks. Each session consisted of 10-minute warm-up, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up to measure BP using a G * Tech-branded automatic digital device (MASTER model).
18555|NCT04044625|Device|High-intensity NPPV|In the high-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) at a higher IPAP level. IPAP is initially set at 10 cmH2O and continuously adjusted by increments and decrements of 1-2 cmH2O (typically ranging between 20 and 30 cmH2O), according to patients' tolerance, to obtain a tidal volume (VT) of 10-15 mL/kg. IPAP should be increased as much as possible to decrease PaCO2 to a normal level. However, if PaCO2 decreases to less than 35 mmHg, IPAP should be decreased to achieve normocapnia.
18556|NCT04044625|Device|Low-intensity NPPV|In the low-intensity NPPV group, patients will undergo pressure-limited NPPV (eg, NPPV in spontaneous/timed mode) with a conventional IPAP level. IPAP is initially set to 10 cmH2O and is continuously adjusted by increments and decrements of 1-2 cmH2O (up to 20 cmH2O), according to patients' tolerance, to obtain a VT of 6-10 mL/kg.
18557|NCT04044612|Other|Medial Unloader Brace|medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
18558|NCT04044599|Drug|Gynoflor|VAGİNAL GYNOFLOR
18559|NCT04044573|Procedure|Transperineal Focal Laser Ablation (TPLA)|The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
18560|NCT04044560|Biological|blinatumomab|Continuous intravenous infusion
18561|NCT04044547|Drug|Rotigotine, extended-release microspheres|"Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
18562|NCT04044547|Drug|Placebo, extended-release microspheres|"Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks."
18563|NCT04044534|Drug|Intranasal insulin|Subjects in this arm will receive intranasal insulin (80 IU per day).
18564|NCT04044534|Drug|Placebo|Subjects in this arm will receive placebo.
18565|NCT04044521|Other|Systems consultation|"Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 18 months.~AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit & feedback report on their prescribing.~PF: clinics will be randomized to receive practice facilitation. Facilitators will travel to each clinics. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly.~PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing."
18566|NCT04044508|Dietary Supplement|Ketocal 4:1 liquid Nutricia (intervention)|Modified ketogenic diet
18567|NCT04044508|Dietary Supplement|Fortini multifibre Nutrica (placebo)|Placebo diet
18568|NCT04044495|Other|Multimodal brain imaging (MRI)|Multimodal brain imaging (MRI)
18569|NCT04044495|Other|Actimetry|7 days actimetry
18570|NCT04044495|Other|Sleep Diary|7 days Record of sleep and wake cycle
18971|NCT04041310|Biological|MVA-209-FSP high dose|MVA-209-FSP IM vaccine, high dose
18571|NCT04044469|Behavioral|Immunization-enhancement|This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.
18572|NCT04044469|Behavioral|Immunization-inhibition|This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.
18573|NCT04044469|Behavioral|Control group|This group receives no further information after watching the videotaped doctor's report.
18574|NCT04044456|Behavioral|Goal Management Training|"GMT: is a 10-session intervention to improve planning and problem solving. Interactive Power Point modules are administered by a cognitive therapist. Each session builds on the steps of a five-stage planning and problem-solving strategy. Veterans will be taught to generate and verbalize the following five-steps: stop-what am I doing?, define the goal, list the steps, learn the steps; then, check-am I doing what I planned? The five-stage strategy is then incorporated into a variety of activities in the laboratory and in-home assignments."
18575|NCT04044456|Behavioral|Attention Training|"Attention Process Training (APT-III) will be administered for a second weekly session in addition to the GMT session. Each session will be 2 hours/ week for 10 weeks. Veterans will also engage in BrainHQTM attention training at home for one-hour, five days/ week comprised of selected components of BrainHQ from Posit Science Corporation. This web-based computerized CRT modality of cognitive training is a restorative or bottom-up approach that targets basic cognitive skills such as arousal and vigilance processes, attention and information processing, and directly engages fundamental attention-control skills through repetitive graded exercises."
18576|NCT04044456|Behavioral|Brain Health Workshop|. BHW was developed specifically for consistency with GMT session length and contact with the facilitator49. BHW is an education presentation on brain function and cognitive principles of learning with homework and quizzes on information covered. To match time and contact of attention training, control participants will meet with the therapist for a separate two-hour session from BHW
18577|NCT04044456|Behavioral|National geographic movies|participants will select movies to watch and answer a few questions about to equate the time and therapist interaction to attention training in arm 1.
18578|NCT04044443|Device|IMPEDE or IMPEDE-FX|Peripheral vascular embolization
18579|NCT04044430|Drug|Binimetinib|Given PO
18580|NCT04044430|Drug|Encorafenib|Given PO
18581|NCT04044430|Biological|Nivolumab|Given IV
18582|NCT04044430|Other|Questionnaire Administration|Ancillary studies
18583|NCT04044417|Procedure|currettage|open flap debridement
18584|NCT04044417|Drug|curcumin simvastatin paste|Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
18585|NCT04044417|Drug|EDTA root conditioning|EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
18586|NCT04044404|Diagnostic Test|Ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography)|Compare the ultrasound Integrated Precision Diagnosis Technology(ultrasound elastography) with the diagnostic gold standard of kidney disease---kidney biopsy
18587|NCT04044391|Diagnostic Test|CardioFlux Magnetocardiograph|CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
18588|NCT04044378|Drug|famitinib and camrelizumab|famitinib with RP2D orally daily plus camrelizumab 200mg Q2W
18589|NCT04044352|Biological|Influenza A/Bethesda/MM2/H1N1 Challenge|Reverse-genetics derived live A/California/04/2009/H1N1-like influenza virus passaged six times in Vero cells.
18590|NCT04044339|Drug|TD-5202|Study Drug to be administered orally
18591|NCT04044339|Drug|Placebo|Placebo to be administered orally
18592|NCT04044326|Procedure|The Solero Microwave Ablation|The Solero Microwave Ablation system (Angiodynamics Ltd, USA) with a single microwave applicator operating at a 2.45 GHz will be used to perform MWA
18593|NCT04044313|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
18594|NCT04044313|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
18595|NCT04044313|Drug|Toripalimab|240mg intravenously every 3 weeks
18596|NCT04044300|Procedure|Single screw fixation|A single trans-iliac, trans-sacral screw will be inserted at the sacral one or sacral two level based upon fracture location.
18597|NCT04044300|Other|Conservative|Continued pain management and physical therapy.
18598|NCT04044287|Drug|200 micrograms of misoprostol|200 micrograms of powdered misoprostol applied sublingually together with standard parenteral oxytocic therapy
18599|NCT04044287|Drug|Placebo Oral Tablet|200 micrograms of powdered placebo applied sublingually together with standard parenteral oxytocic therapy
18600|NCT04044274|Device|IOPstim|IOPstim (IMEDOS, Jena, Germany) is a device exerting defined pressure to the sclera and hence increasing IOP.
18601|NCT04044261|Procedure|Emotion induction using video|Emotions are induced in the test subjects using videos in Hindi and English. Each subject is shown three video clips for each of the emotions.
18602|NCT04044248|Device|TIPS-obliteration|Transjugular intrahepatic portosystemic shunt (TIPS) decompression of portal hypertension coupled with transvenous obliteration of gastric varices (GVs).
18603|NCT04044235|Behavioral|PrEP Cohort|AGYW who are eligible for PrEP will be educated about the risk and benefits. For AGYW (aged 18-24 years) who consent to PrEP, an ART provider (nurse or clinician) certified by the MOH will provide PrEP (package of disoproxil fumarate/emtricitabine (Truvada)) on the same day that the client is determined eligible. Peer navigators will ensure linkage to facilities for follow-up care. The initial follow-up visit will occur one month from PrEP initiation to ensure that the client is tolerating the regimen and to answer any questions, with three-month follow-up visits thereafter.
18604|NCT04044222|Biological|Sintilimab|Given IV
18605|NCT04044222|Drug|Carboplatin|Given IV
18606|NCT04044222|Drug|Etoposide|Given IV
18607|NCT04044222|Drug|Ifosfamide|Given IV
18608|NCT04044222|Drug|Placebo|Given IV
18609|NCT04044222|Drug|Carboplatin|Given IV
18610|NCT04044222|Drug|Etoposide|Given IV
18611|NCT04044222|Drug|Ifosfamide|Given IV
19025|NCT04040855|Other|Medication review|Multi-professional medication review
18612|NCT04044209|Drug|AG-120|The IDH1 inhibitor ivosidenib (AG-120) that will be administered orally on a continuous basis at the dose of 500 mg/day starting at day 1 of each cycle. A cycle will be defined as a 28-day period.
18613|NCT04044209|Drug|Nivolumab|On Cycle 2 day 1 the patient will receive nivolumab 480mg once. This will be repeated on Day 1 of every subsequent cycle.
18614|NCT04044196|Procedure|Rotator cuff repair|Rotator cuff repair performed arthroscopically
18615|NCT04044183|Behavioral|Active Brains|The Active Brains program is a mind body physical activity program for older adults with chronic pain and subjective cognitive impairments.
18616|NCT04044183|Behavioral|Active Brains with Fitbit|Active Brains with Fitbit is identical to Active Brains with the addition of a FitBit for reinforcing physical activity.
18617|NCT04044170|Drug|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
18618|NCT04044157|Other|non-invasive measurement of cardiac output|cardiac output will be non-invasivaly measured by means of electrical cardiometry
18619|NCT04044144|Dietary Supplement|Probiotic Dietary Supplement|Dietary supplement containing a combination of 8 probiotic strains
18620|NCT04044131|Drug|Metabolic Cofactor Supplementation|Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
18621|NCT04044131|Drug|Sorbitol|As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
18622|NCT04044118|Behavioral|Low Calorie Diet|Low Calorie Diet consisted of ~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
18623|NCT04044105|Other|Pamphlet education|Patients receive an educational intervention explaining proper opioid disposal
18624|NCT04044105|Other|Pamphlet education + texts|Patients receive an educational intervention and text message explaining proper opioid disposal
18625|NCT04044092|Other|Conservative physical therapy|Moist hot packs, TENS, Cervical Traction, Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
18626|NCT04044092|Other|ELDOA stretching exercise|Experimental group was given ELDOA stretching exercise protocol along with the moist hot packs, TENS, Cervical Traction, and Neural Mobilization on alternate days Cervical Spine strengthening exercises 10 repetitions×1 set, 4 days/week. Total of 4 sessions were given each consisting of 40 mins.
18627|NCT04044079|Drug|Dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
18628|NCT04044079|Drug|Misoprostol|Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy.
18629|NCT04044079|Drug|Placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
18630|NCT04044066|Biological|Plasma biomarker|New emerging plasma biomarkers carrying prognositic information
18635|NCT04044040|Behavioral|Symptom screening with Targeted Early Palliative care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
18636|NCT04044027|Behavioral|S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring|S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
18637|NCT04044014|Device|Gellan sheet|Gellan sheet.
18638|NCT04044014|Device|Gellan fluid gel|Gellan fluid gel.
18639|NCT04044014|Device|Mepitel One|Control dressing-- Mepitel One.
18640|NCT04044001|Drug|BTZ-043|BTZ-043 (250mg per tablet)
18641|NCT04044001|Drug|Rifafour e-275®|Rifafour e-275® (150mg rifampicin, 75mg isoniazid, 400mg pyrazinamide, 275 mg ethambutol per tablet)
18642|NCT04044001|Drug|Probe Drug Cocktail|"A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~Caffeine: 1 tablet à 150mg~Tolbutamide: 1/4 tablet à 500mg~Dextromethorphan: 10 ml syrup à 15mg/5ml~Midazolam:2 ml solution à 5mg/5ml~Digoxin: 2 tablets à 0.25mg"
18643|NCT04044001|Drug|Dolutegravir 50mg Tab|1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
18644|NCT04043962|Behavioral|Web-based CBT (Web-MAP)|see arm description
18645|NCT04043936|Behavioral|Cognitive Bias Modification Intervention for Help-Seeking Stigma|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
18699|NCT04043494|Drug|Dexamethasone|Part of the experimental therapy in Randomization R1 (Protocol Ia-Dexamethasone) and in Randomization R2 (Intensified Protocol M)
18739|NCT04043247|Device|TEAS without electrical stimulation|Bilateral Neiguan and Zusanli acupuncture points, with no electrical stimulation
18646|NCT04043936|Behavioral|Placebo Cognitive Bias Modification (CBM-Placebo)|Cognitive bias modification (CBM) is an intervention designed to target stigma-related cognitions among individuals at elevated suicide risk not currently engaged in behavioral health treatment. It involves the completion of brief, web-based tasks in which participants are presented with a series of stimuli (e.g., words, sentences) and trained to respond to those stimuli in a manner that is positive or neutral, rather than negative and unhelpful. Consistent with the theoretical rationale for Cognitive Behavioral Therapy, CBM interventions function by reshaping negative cognitions. Repeated reinforcement of adaptive cognitions enhances functioning and reduces distress.
18647|NCT04043936|Behavioral|Self-Directed Psychoeducation|Material presented with information on mental health literacy, mental health stigma, & treatment options. This is based on the idea that increasing knowledge about psychiatric symptoms and treatment options encourages help-seeking behavior and engagement.
18648|NCT04043923|Drug|Norketotifen|Oral capsule
18649|NCT04043923|Drug|Placebo|Oral capsule
18650|NCT04043910|Device|fNIRS|The auditory cortical imaging will be performed by fNIRS measures. This non-invasive functional imaging technique relies on the use of a sensor-bearing cap, measuring cortical activity through scalp, during auditory stimulation. As head movement does not alter measurement that much, fNIRS is well adapted to children.
18651|NCT04043910|Other|Speech intelligibility|Speech intelligibility will be evaluated with French sentences comprehension in noise, from the Common Test or Adaptive Auditive Speech Test before 6 years, from the Common Test or Hearing in Noise Test for Children (Hint-C) from 7 to 11 years, and from the Hint-C or Marginal Benefit of Acoustic Amplification after 11 years, both with a Signal over Noise Ratio of +10 decibel at 65 decibel
18652|NCT04043910|Other|Sound localisation|Sound localisation will be evaluated with a left-right discrimination test before 7 years and a 12 loudspeakers sound localisation test after 7 years.
18653|NCT04043910|Other|Speech assessments|Speech assessments will be performed by dedicated speech therapists, with child age specific tests, and 2 global speech scores: the Category of Auditory Performances scale - second edition, and the Speech Intelligibility Rating scale.
18654|NCT04043910|Other|Quality of Life|Quality of Life (QoL) evaluation will be based on the generic QoL scale, and the Speech Spatial and Qualities of hearing (SSQ) deafness specific scale. Each scale exists in age specific modalities.
18655|NCT04043897|Drug|Rifaximin 550mg|Rifaximin 550mg
18656|NCT04043884|Other|sEmg biofeedback training|Volunteers will perform scapular strengthening and stabilization exercises added to sEMG biofeedback in the upper trapezius (TS), Trapezius (TM), Lower Trapezius (TI), and Serratil Anterior (AS) muscles in real time displayed in a Computer screen.
18657|NCT04043884|Other|Strength training|The volunteers will perform a strengthening protocol with elbow flexion exercises, medial and lateral shoulder rotation, scapular retraction and push up plus.
18658|NCT04043871|Diagnostic Test|Systolic blood pressure|Systolic blood pressure measured by Foot-to-Apex Systolic Interval, conventional oscillometric measurement, and the auscultatory method
18659|NCT04043858|Drug|Midodrine 2.5 mg tab|Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
18660|NCT04043845|Drug|Ibrutinib|Ibrutinib inhibits the function of Bruton's tyrosine kinase (BTK). Ibrutinib blocks signals that stimulate malignant B cells to grow and divide uncontrollably.
18661|NCT04043845|Drug|LY3214996|LY3214996 is an extracellular signal-regulated kinase (ERK) inhibitor. ERK inhibitors stop the signal that a cancer cell receives telling it to grow.
18662|NCT04043832|Diagnostic Test|quantitative ultrasonic technique|Collection of all quantitative ultrasonic data was performed by one ultrasound physician
18663|NCT04043819|Drug|PSC-01|PSC-01 is a form of autologous cellular therapy resulting from the enzymatic processing of lipoaspirate to yield adipose-derived stromal vascular fraction cells.
18664|NCT04043806|Drug|ELX/TEZ/IVA|Fixed-dose combination (FDC) tablet for oral administration
18665|NCT04043806|Drug|IVA|150-mg tablet for oral administration
18666|NCT04043780|Device|Decompression prototype splint for carpal tunnel syndrome|This group will wear during 6 weeks a decompression prototype splint. They we be informed to wear it as long as possible during the 6 weeks.
18667|NCT04043780|Device|Standard splint for carpal tunnel syndrome|This group will wear during 6 weeks a standard splint. They we be informed to wear it as long as possible during the 6 weeks.
18668|NCT04043767|Procedure|Measurements of thyromental distances, hyomental distances and neck circumferences|thyromental distances, hyomental distances and neck circumferences using measurement tape by two independent investigators.
18669|NCT04043754|Procedure|Procedure/Surgery: Periodontal surgery with Membrane|Patients will be treated by periodontal surgical flaps with the addition of Membrane+ bone graft
18670|NCT04043754|Procedure|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
18671|NCT04043741|Other|Dry Needling|stretching exercises :single knee to chest (15 reps x 3 sets) double knee to chest(15 reps x 3 sets) strengthening exercises: extension exercises (15 reps x 3 sets)
18672|NCT04043741|Other|Sustain Pressure|"Sustain Pressure (Number of repetition and hold according to trigger point chronic level)~+ Hot pack 10 to 15 minutes + Active muscle stretching exercise (10 repetition twice daily)"
18673|NCT04043728|Behavioral|Unified Protocol adapted for smoking cessation|Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
18674|NCT04043715|Device|Transcutaneous spinal stimulation|Physical therapy to improve standing and walking
18675|NCT04043715|Device|Epidural spinal stimulation|Physical therapy to improve standing and walking
18676|NCT04043702|Drug|The intervention being studied|Intervention Other Names have not been specified
18700|NCT04043494|Drug|Daunorubicin|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
18677|NCT04043689|Device|tACS (transcranial Alternate Current Stimulation)|"This is a single-centric comparative randomized controlled blind and cross-over study.~The order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control"
18678|NCT04043676|Drug|Ponatinib|All patient will take 15 mg/day ponatinib oral during 48 weeks.
18679|NCT04043663|Device|Virtual Reality glasses|Children are encouraged to watch the virtual reality program at least 24 hours before surgery.
18680|NCT04043663|Procedure|standard perioperative care without virtual reality program|standard perioperative care without virtual reality program
18681|NCT04043650|Behavioral|HeartSteps|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
18682|NCT04043624|Drug|Lidocaine|regimen of lidocaine administration of 1.5 mg/kg, IV bolus, followed by continuous infusion at 2 mg/kg/h
18683|NCT04043624|Drug|Saline|IV bolus of saline, followed by continuous infusion of saline
18684|NCT04043611|Other|Conservative physical therapy management|Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I & II for pain, Grade III & IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises
18685|NCT04043611|Other|ELDOA|ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I & II for pain, Grade III & IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
18686|NCT04043598|Drug|0.9% Sodium-chloride|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer`s for fluid therapy in patients with subarachnoid hemorrhage.
18687|NCT04043598|Drug|Ringer's Lactate|We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer`s for fluid therapy in patients with subarachnoid hemorrhage.
18688|NCT04043559|Other|MRI scanner|MRI was performed with a 1.5T magnet (Ingenia, Philips, The Netherlands; diffusion-weighted imaging b-values = 0 and 1,000 s/mm2, TR 4,280 ms, and TE 97 ms). In case of technical problems with the 1.5T MRI scanner, a 3T magnet (Skyra, Siemens, Erlangen, Germany) was used. MRI was analyzed by an experienced rater (DR), blinded to clinical data and MRI sequences other than diffusion-weighted imaging.
18689|NCT04043559|Other|Contrast transoesophageal echocardiography|Contrast transoesophageal echocardiography (including Valsalva manoeuvre)
18690|NCT04043546|Behavioral|aerobic+resistance exercise training program|Personalized exercise program based on the inclusion testing and patient screening will be provided to the patient. The program will consist of a gradual walking program as well as a gradual resistance training program using therabands.
18691|NCT04043533|Behavioral|Exercises|The women in the experimental group were given information about the benefits of exercises done in the postpartum period, the time to start these exercises, and the exercises to be conducted in three different phases (mild, medium, severe). The first physical exercise practice was done in the FHC together. In line with the recommendations by ACOG (2015), the women were told to do mild and medium level exercises in the first two weeks, at least five days in a week and at least half an hour daily (ACOG, 2015). They were also told that they should do medium and severe level exercises in the following two weeks. They were asked to mark on the form what time, how long, and at what level they did the exercises every day. The education booklet that included this information and the visuals of the exercises were given to the women in the experimental group. In addition, the women were called once a week in order to check whether the training was applied.
18692|NCT04043520|Drug|GnRH antagonist|GnRH antagonist will be given once for premenopausal women (12-week intervention) and twice for postmenopausal women (24-week intervention)
18693|NCT04043520|Drug|Estrogen Product|Estrogen patches will be worn by those randomized to the Estradiol arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
18694|NCT04043520|Drug|Placebo estradiol|Placebo patches will be worn by those randomized to the placebo arms in both premenopausal and postmenopausal groups. Patches will be applied weekly and will be worn for the for entirety of the intervention (12 or 24 weeks).
18695|NCT04043520|Drug|Placebo GnRH antagonist|Postmenopausal women randomized to the placebo injection arm will receive two placebo drug injections of normal saline (24-week intervention)
18696|NCT04043507|Other|Sample Collection|Blood and urine samples will be collected for research purposes along with the routinely collected blood and urine samples that are collected as part of the standard of care.
18697|NCT04043494|Drug|Cyclophosphamide|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
18698|NCT04043494|Drug|Cytarabine|"No involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2).~Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)"
18703|NCT04043494|Drug|6-Mercaptopurine|Part of standard chemotherapy and included in the experimental treatment phase protocol Ib* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
18704|NCT04043494|Drug|Methotrexate|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
18705|NCT04043494|Drug|PEG asparaginase|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Protocol Ib* (Randomization R2)
18706|NCT04043494|Drug|Prednisone|Part of standard chemotherapy
18707|NCT04043494|Drug|Prednisolone|No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
18708|NCT04043494|Drug|Thioguanine|Part of standard chemotherapy
18709|NCT04043494|Drug|Vincristine|Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
18710|NCT04043494|Drug|Vindesine|Part of the experimental therapy in Randomization R2 (Intensified Protocol M)
18711|NCT04043468|Other|Audit and feedback|Audit and feedback (A&F) is an intervention that aims to improve professionals practices by providing professionals with a summary of their performance over a period of time.
18712|NCT04043455|Drug|Olorinab|Olorinab Dose 1 capsule by mouth, 3 times a day up to 12 weeks
18713|NCT04043455|Drug|Olorinab|Olorinab Dose 2 capsule by mouth, 3 times a day up to 12 weeks
18714|NCT04043455|Drug|Olorinab|Olorinab Dose 3 capsule by mouth, 3 times a day up to 12 weeks
18715|NCT04043455|Drug|Placebo|Olorinab matching placebo capsule by mouth, 3 times a day up to 12 weeks
18716|NCT04043442|Device|Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P|rTMS device
18717|NCT04043429|Behavioral|Vision Restoration Training (VRT)|
18718|NCT04043429|Behavioral|Vision Exploration Training (VET)|
18719|NCT04043416|Other|Motivating reminiscence technology|The jDome BikeAround uses Google Street View, a stationary bike and a domed screen. Residents are seated in front of the screen; their destination is typed into the computer and when loaded the image appears on the screen. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
18720|NCT04043403|Device|Open Loop DBS (Summit RC+S)|Standard DBS therapy at a constant frequency and voltage
18721|NCT04043403|Device|Adaptive (Closed Loop) DBS (Summit RC+S)|DBS that responds to neural or kinematic features of patient's current state
18722|NCT04043403|Device|Intermittent Open Loop DBS (Summit RC+S)|Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
18723|NCT04043390|Diagnostic Test|CRP and Molbio Truenat MTB|A molecular assay to detect M tuberculosis DNA Truenat is currently undergoing the process of endorsement by the WHO.
18724|NCT04043390|Diagnostic Test|CRP and Xpert ULTRA MTB/RIF|A molecular assay to detect M tuberculosis DNA ULTRA is already endorsed by the WHO. However the tests are still considered experimental in Nigeria and Ethiopia.
18725|NCT04043390|Diagnostic Test|standard test Xpert|The investigators will use Xpert to compare its agreement with scheme 1 (CRP plus Truenat MTB) and scheme 2 (CRP plus ULTRA).
18726|NCT04043390|Diagnostic Test|Culture as reference standard|The investigators will use culture to assess the sensitivity of schemes 1 and 2
18727|NCT04043377|Drug|injection of 68Ga-DOTATATE|PET after injection of 68Ga-DOTATATE 2 MBq/kg (Max. 200 MBq); intra-venous; single injection, at M0 followed by a coronary CTA to localize the signal in coronary arteries Consultation and low-dose cardiac CT for coronary calcium scoring performed at M12 and M24 after inclusion.
18728|NCT04043364|Behavioral|LIVE|Learning, Innovation, Volunteers and Empowerment
18729|NCT04043338|Drug|XC130-A10H|XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules
18730|NCT04043338|Drug|Placebo|Placebo supplied as matching capsules
18731|NCT04043325|Diagnostic Test|Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay|Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
18732|NCT04043312|Device|Magstim SuperRapid|Transcutaneous magnetic stimulation targeting the left stellate ganglion.
18733|NCT04043312|Device|Magstim SuperRapid|Sham transcutaneous magnetic stimulation.
18734|NCT04043299|Drug|100% Oxygen|High flow cylinder oxygen will be administered to women with fetal distress during labour
18735|NCT04043286|Device|Definitive abutment|With two height options available, On1 Base are selected depending on the thickness of the soft tissue. It remains in position from implant placement to finalization, which leaves the soft tissue undisturbed for optimized healing, moved the restorative platform of Nobel Biocare conical connection implants from bone level to tissue level, thereby simplifying the restorative procedures
18736|NCT04043273|Behavioral|Characterization of patients expectations and preferences regarding their treatment|Patients will be clustered before and after a principal components analysis (PCA) on PNQ. Observations will be clustered by the Ward method. The number of clusters will be chosen using the Kolinski criteria. Characteristics of patients will be described by cluster.
18737|NCT04043260|Device|Advisor Pro|The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient‐specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
18738|NCT04043247|Device|TEAS|Bilateral Neiguan and Zusanli acupuncture points, 2/10Hz Dense wave , 6-9mA,30min
18799|NCT04042753|Drug|Nivolumab|Nivolumab 1 mg/kg every 3 weeks for 4 cycles
18740|NCT04043208|Behavioral|Biofeedback|Three sessions of biofeedback will be performed during the first 3 weeks of the intervention period. Biofeedback sessions will be performed 30 min after ingestion of the offending meal: patients will be taught to control abdominal and thoracic muscular activity by providing a visual display of the abdominal and thoracic perimeter; specifically, they will be instructed to reduce the abdominal perimeter (girth). Patients will be instructed to perform the same exercises before and after breakfast, lunch and dinner during the 4-week intervention period.
18741|NCT04043208|Dietary Supplement|Placebo|Three sessions will be performed during the first 3 weeks of the intervention period. Each session will be performed 30 min after ingestion of the offending meal: abdominal and thoracic perimeter will be recorded but not shown to the patient; patients will take a pill of placebo containing 0.5 g glucose and no specific instructions will be provided. Patients will be instructed to take a pill of placebo before breakfast, lunch and dinner during the 4-week intervention period.
18742|NCT04043195|Drug|Nivolumab|240 mg every 2 weeks. Nivolumab will continue for up to 2 years.
18743|NCT04043195|Drug|Oxaliplatin|65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.
18744|NCT04043195|Drug|Ipilimumab|1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles
18745|NCT04043182|Procedure|ultrassound|The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
18746|NCT04043169|Diagnostic Test|Clearblue pregnancy test|Urine pregnancy test
18747|NCT04043156|Radiation|High-precision RT|18 x 2.33 Gy of high-precision RT in 3.5 weeks
18748|NCT04043143|Other|Arm 1 Prescription As Usual|At the time of writing the discharge prescription for a patient the provider will receive a best practice alert (BPA) to consider prescribing the usual medications for pain management after discharge.
18749|NCT04043143|Other|Arm 2 Prescription Tool Intervention|The best practice alert (BPA) Prescription Tool will only make a suggestion to the provider if the patient may be considered for a lower post-discharge opioid dose. Providers may still choose to prescribe a higher dose as clinically indicated.
18750|NCT04043130|Behavioral|Pulse|The intervention provides participants access to Pulse, a web-based mobile health app designed for Black and Latinx women ages 18-20. Participants can access the app autonomously and on their own schedule. The app for the experimental arm, the Pulse treatment app, provides information on birth control, healthy relationships, sexual health and physiology, pregnancy, and utilization of clinical services. The app for the comparator arm, the Pulse control app, provides information on general health topics, such as the importance of sleep, healthy eating, and friendships. Participants receive MMS messages that reinforce app content and remind them to visit the app.
18751|NCT04043117|Other|Body Image evaluation|"Evaluation of body image perception requires three assessment tools administered at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~Italian Body Image Concern Inventory: 19-items self-report instrument rated on a 5-points Likert scale (1 = never; 5 = always). It consists of two sub-scales to evaluate body image-related dissatisfaction and concern respectively.~Body Uneasiness Test: 71-item self-report questionnaire on a 6-points Likert scale (0 = never; 5 = always) that consists of two subscales: BUT-A (measuring weight phobia, body image concerns, avoidance, compulsive self-monitoring, detachment and body depersonalization) and BUT-B (measuring worries about specific body parts or functions).~Human Figure Drawing: qualitative measure of adolescent's body perception; participants are asked a free draw, representing themselves."
18752|NCT04043117|Other|Self esteem evaluation|"Evaluation of body image perception is achieved administering TMA test at four different times:~T0: During the first week of admission T1: Three months from the first admission T2: Six months from the first admission T3: One year from the end of the treatment~TMA (Multidimensional Self-Esteem Test): a 150-items self-report questionnaire for children and adolescents from 9 to 19 years old. It's made up of six subscales: interpersonal relationships, environmental control competence, emotionality, scholastic success, family life, body perception. Participants have to express their agreement with each item according to the following response options: absolutely true, true, false, absolutely false."
18753|NCT04043104|Drug|intra-parotid administration of AAV2hAQP1|"Open-label, non-randomized, dose escalation trial of AAV2hAQP1 administered via Stensen's duct to a single parotid gland in subjects with radiation-induced xerostomia. Dose levels:~1 x 1011 vg/mL*~3 x 1011 vg/mL~1 x 1012 vg/mL~3 x 1012 vg/mL~6 x 1012 vg/mL~If 2 subjects experience a dose-limiting toxicity at the 1 x 1011 vg/mL dose level (Dose Group 1), then a lower dose of 3 x 1010 vg/mL may be studied. The total volume to be administered is subject specific, based on the subject's parotid gland volume."
18754|NCT04043091|Procedure|percutaneous coronary intervention (stenting)|percutaneous stent implantation in coronary artery
18755|NCT04043078|Other|Exercise|The exercise regime will include daily upper limb aerobic (hand bike) and inspiratory muscle training (POWERbreathe) and upper body strength training every second day until discharge.
18756|NCT04043065|Biological|Liver-enriched antimicrobial peptide 2|Infusion of LEAP-2 during a 180 min grated glucose infusion.
18757|NCT04043065|Other|Placebo|Saline
18758|NCT04043052|Other|Psychological evaluation|Psychological evaluation including: MINI (current diagnosis) ; HDRS ; MDQ ; GAD-7 ; PC-PTSD-5 ; Quality of Sleep (item 6 of the Pittsburgh Sleep Quality Index) ; CES-D ; BAI ; RRS-short form ; IES-R ; mYFAS2.0;
18759|NCT04043052|Other|Functional evaluation|Functional evaluation including : EQ5-D ; MFI ; LUNS ; MMAS-6 ; SSQ ; Physical activity (IPAQ)
18760|NCT04043052|Biological|Biological assessment|Biological assessment : White and red blood cells count ; platelets count ; Haemoglobin ; CRPus ; Glycaemia ; Plasmatic HbA1c ; Plasmatic LDLc ; HDLc and triglyceride ; Creatinin clearance, Transaminases.
18761|NCT04043052|Other|Ecological Momentary Assessment|During 3 months after inclusion, a 3 to 5 minutes daily interview will administer questions concerning mood symptoms, activities, stress experience, substance use, social relationships and medication intake, activities, social interaction, environmental conditions, experience of depressed mood, anhedonia, changes in weight, appetite, sleep, fatigue, feelings of worthlessness or inappropriate guilt, concentration or decision-making difficulty
18928|NCT04041674|Biological|B63521^11 gp120|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
18762|NCT04043039|Procedure|Palatal wound bandage with PRF|palatal wound will be protected by a quadruple layer of Platelet Rich Fibrin obtained by folding on itself 2 Platelet Rich Fibrin membranes
18763|NCT04043039|Procedure|Palatal wound bandage with Gelatine Sponge|palatal wound will be protected by gelatine sponge
18764|NCT04043026|Drug|Warfarin|INR-dependent dosage
18765|NCT04043026|Drug|Statin|Any statin therapy acceptable
18766|NCT04043013|Device|Mini-Taurus® (Rocky Mountain©) Brackets|
18767|NCT04043013|Device|Smart Clip® SL3 High Torque (3M Unitek©)|
18768|NCT04043013|Device|Tip-Edge Plus® (TP Orthodontics©)|
18769|NCT04043013|Device|Victory® (3M Unitek©)|
18770|NCT04043000|Dietary Supplement|Super 13 Pro & Prebiotics|"Super 13 Pro & Prebiotics was given three times a day for four weeks."
18771|NCT04042974|Drug|vaginal dinoprostone|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
18772|NCT04042974|Drug|placebo|one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
18773|NCT04042961|Other|Reactive balance training|A variety of tasks will be included to induce external or internal perturbations. External perturbations will be caused by forces outside participants' control (e.g. a push or pull from the physiotherapist). Internal perturbations are when the participant fails to control the centre of mass-base of support relationship during voluntary movement; e.g., 'agility' tasks such as kicking a soccer ball. Each session will include a five-minute warm-up, at least 60 perturbations, and a five-minute cool-down. The difficulty of the task will be set such that participants will 'fail' to recover balance ~50% of the time; 'failure' is defined as use of an upper extremity response, use of external assistance (i.e. from the overhead harness or physiotherapist), or taking more than 2 steps to regain stability. Training tasks will progressed by increasing the perturbation magnitude, including cognitive or movement tasks, or imposing sensory or environmental challenges (e.g. eyes closed, obstacles).
18774|NCT04042961|Other|Aerobic and strength training (AST)|"AST sessions will consist of 30 minutes of aerobic and 30 minutes of strength training.~Aerobic training: Aerobic training will be done using treadmill walking or combination of modalities (e.g. cycling or recumbent stepping) for those unable to maintain the target heart rate with walking. The heart rate that occurred at the ventilatory threshold (V̇O2VT) during the cardiopulmonary exercise test will be used to prescribe intensity. In the absence of a discernible V̇O2VT a combination of the following will be used: 60-80% of heart rate reserve, peak oxygen uptake, and rating of perceived exertion of 11-16 (Borg 6-20 scale). Prescriptions will be initially progressed by increasing duration to ≥20 minutes and then increasing intensity to target heart rate.~Resistance training: Participants will be prescribed 1-2 sets of 8 exercises per session (squat, heel raise, ankle dorsiflexion, knee extension and flexion, abdominal curl-up, wall push up, bicep curl), at 70% of 1 repetition maximum."
18775|NCT04042948|Drug|Tylenol|when we decide to remove the drainage tube, we ask the patient to take a pill of tylenol, and another pill in 12h later
18776|NCT04042935|Drug|Alpha Lipoic Acid|Stage II-IVB HNSCC patients receiving concurrent systemic therapy and radiation in the definitive, adjuvant, or palliative setting will receive ALA according to their prescribed dose level. ALA will be taken orally or per feeding tube. It will start 1 week prior to the start of CRT, continue on through CRT, and then continue for 2 weeks after the completion of CRT. Patients will be given dosing diaries to document date and time of each drug administration as well as any missed doses. They will also have weekly visits to report AEs and concurrent medications, have a history and physical exam, report VAS pain scores and OMAS scores, and fill FACT-HN surveys.
18777|NCT04042922|Device|GENUS device (Active Settings)|Participants in the experimental group will use the GENUS device configured to active settings for 30 - 60 minutes.
18778|NCT04042922|Device|GENUS device (Sham Settings)|Participants in the control group will use the GENUS device configured to sham settings for 30 - 60 minutes.
18779|NCT04042909|Behavioral|Counter Attitudinal Advocacy|same as Counter Attitudinal Advocacy arm
18780|NCT04042909|Behavioral|Personalized Normative Feedback|same as Personalized Normative Feedback arm
18781|NCT04042896|Behavioral|exergame|Exergame is 'exercise + game'.
18782|NCT04042896|Behavioral|treadmill exercise|traditional aerobic exercise
18783|NCT04042883|Procedure|Acute normovolemic hemodilution|500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
18784|NCT04042870|Behavioral|Joint Loosening Yoga|Sukshma Vyayama Joint Loosening Yoga was practiced Monday - Friday for four weeks. Each session included twelve joint loosening exercises performed in a chair, each performed 10 times with mindful awareness of physical movements and breath synchronization. Sessions lasted 15 minutes.
18785|NCT04042857|Device|Next Science Treatment Gel|Next Science Treatment Gel will be applied after nail surface nail-filing and/or debridement.
18786|NCT04042844|Biological|BRTX-100|Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
18787|NCT04042844|Drug|Saline|Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
18788|NCT04042831|Drug|Olaparib|Given PO
18789|NCT04042818|Diagnostic Test|Rehabilitative Ultrasound|Ultrasound imagining
18790|NCT04042805|Biological|Sintilimab|200mg intravenously every 3 weeks
18791|NCT04042805|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
18792|NCT04042792|Other|pharmacokinetics (PK) measurement|two ADA-PK samples will be collected during routine rheumatology visits in case of medical indicated blood draw (1 trough PK sample and 1 random PK sample per subject)
18793|NCT04042779|Other|model-based WM training|model-based WM training program: four sessions a week, 45 minutes each; lasting for three weeks
18794|NCT04042779|Other|single-task WM training|single-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
18795|NCT04042779|Other|multiple-task WM training|multiple-task WM training program: four sessions a week, 45 minutes each; lasting for three weeks
18796|NCT04042779|Other|sham intervention|motor training program: four sessions a week, 45 minutes each; lasting for three weeks
18797|NCT04042766|Procedure|laser vaginal treatment|Er:YAG laser
18798|NCT04042753|Drug|Ipilimumab|Ipilimumab 3 mg/kg every 3 weeks,
28609|NCT03962738|Drug|Placebo|Administered orally
18800|NCT04042753|Drug|Nivolumab|Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
18803|NCT04042727|Drug|Dexmedetomidine Hydrochloride|Six vials of Dexmedetomidine hydrochloride 100mcg/ml (2ml per vial) will be added to a 250mL bag of normal saline by the investigational pharmacy to prepare for infusion by patient's bedside nurse. Infusion rate will be 1mcg/kg/hr.
18804|NCT04042727|Other|Normal Saline|0.5% sodium chloride (NaCl). The investigational pharmacy will prepare the normal saline placebo 250mL bag for infusion by patient's bedside nurse. Infusion will be 1mcg/kg/hr.
18805|NCT04042714|Drug|All patients- TAS-102|Patients will receive TAS-102, Orally, BID for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest treatment cycle. Treatment may continue until disease progresses, intolerable toxicity is developed, or if the patient becomes pregnant or dies.
18806|NCT04042701|Drug|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin. All participants will receive DS-8201a at the RDE in combination with pembrolizumab."
18807|NCT04042701|Drug|Trastuzumab deruxtecan (DS-8201a)|"Part 1: Two dose levels of DS-8201a (3.2 mg/kg Q3W and 5.4 mg/kg Q3W via intravenous (IV) infusion will be administered for the dose escalation part of the study in combination with pembrolizumab.~Part 2: Once Part 1 of the study is complete and a RDE for DS-8201a has been established, Part 2 will begin."
18808|NCT04042701|Drug|Pembrolizumab|All participants will receive pembrolizumab (200 mg Q3W) via intravenous (IV) infusion prior to DS-8201a in Parts 1 and 2 of the study.
18809|NCT04042688|Drug|intraarticular administration of tranexamic acid|Intraarticular administration with concentration of 30mg/mL was selected. The operation room nurses prepared 3g tranexamic acid in 100 mL of saline solution during operation. After finishing surgical wound suture and orthopaedic surgeons related to this study left operation room, the orthopaedic residents who were not involved in the postoperative evaluation administered tranexamic acid solution through suprapatellar pouch before tourniquet release in patients in the treatment group. The control group did not receive any solution. intraarticular drain was not inserted in all patients.
18810|NCT04042675|Diagnostic Test|observational study|There will be two groups in this study. One of the groups will consist of 30 parkinson's patients aged between 40-75 years and 1-3 according to Hoehn-Yahr stage. The other group will consist of 30 healthy individuals between the ages of 40-75 and without any neurological disorders. Participants' respiratory muscle strength, exercise capasity, fatigue and physical activity levels will be assessed. All asessements will done for only one time.
18811|NCT04042662|Other|no intervention|no intervention
18812|NCT04042649|Behavioral|environmental intervention|provide environmental intervention (help sleep cycle, provide comfortable environment)
18813|NCT04042623|Drug|AVB-S6-500|AVB-S6-500 is experimental drug
18814|NCT04042610|Behavioral|Electronic Prompt for Interrupting Sitting Time|An electronic prompt via the IOS application Stand-Up will be given through the Amazfit BIP device to interrupt sitting time every hour during the office workers workday. The office worker will engage in 2 minutes of physical activity with each prompt.
18815|NCT04042597|Drug|Anlotinib Hydrochloride|anlotinib was given at a fixed dose of 12mg D1-14 every 21 days
18816|NCT04042584|Procedure|Visio conference device evaluation (DVCM)|Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.
18817|NCT04042571|Device|Cerebral oxymetry monitoring (NIRS)|Near-InfraRed Spectroscopy (NIRS) is a non-invasive method measuring tissue oxygenation by regional saturation of capillary-oxygenated hemoglobin (rSO2). Starting on day 4 after aneurismal rupture NIRS electrods will be placed and maintained until day 12 permanently and blindly recording rSO2. Patients will be monitored following daily practice recommandations inclunding vasospasm detection and treatment.
18818|NCT04042558|Drug|Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab|4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
18819|NCT04042558|Drug|Carboplatin + Pemetrexed + Atezolizumab|Carboplatin + Pemetrexed + Atezolizumab
18820|NCT04042545|Drug|PPP001|1 pellet inhaled 3 times a day with a vaporizer device
18821|NCT04042545|Drug|Placebo|1 pellet inhaled 3 times a day with a vaporizer device
18822|NCT04042532|Device|Theta-burst stimulation (TBS)|We will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, we will give two sessions of iTBS separated by 15 min.
18823|NCT04042519|Diagnostic Test|Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.|This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.
18824|NCT04042519|Diagnostic Test|Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.|We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.
18825|NCT04042519|Diagnostic Test|Routine blood test|Blood routine test results include CRP, PCT, white blood cell count, red blood cell count, neutrophil percentage, eosinophil, basophil, et al.
18828|NCT04042493|Behavioral|Connect for Health|The program includes (1) electronic health record (EHR)‐based clinical decision support tools to guide pediatric providers in child weight management; (2) clinician and medical staff training in obesity management best practices, (3) family educational materials focused on evidence‐based behavioral targets; and (4) social‐ and community‐informed text messages for parents to support behavior change.
18830|NCT04042467|Behavioral|Greenlight Plus|Families randomized to the Greenlight Plus arm will receive a HIT intervention starting at the newborn clinic visit. During the newborn visit, these families will receive basic instructions on how to access the Greenlight technology platform, which includes the iOTA text‐messaging application and a website (usable on desktop or mobile platform). Families will receive text messages and goal-setting over the first 2 years of the child's life.
18831|NCT04042467|Behavioral|Greenlight|All residents and families seen in the participating clinics will receive the basic Greenlight materials.
18832|NCT04042454|Other|milk based anti-regurgitation infant formula|Cow's milk-based infant formula containing the thickener locust bean gum containing prebiotic oligosaccharides and postbiotics
18833|NCT04042454|Other|Milk based infant formula|Cow's milk-based infant formula containing prebiotic oligosaccharides and postbiotics
18835|NCT04042428|Drug|Somatropin injection|Subjects receive a daily subcutaneous dose of 0.2 IU/kg (0.067 mg/kg) of recombinant somatropin (rhGH) during 14 days.
18836|NCT04042415|Other|Caloric restriction|Patients will be treated with a diet regimen of mild caloric restriction (15-20% caloric restriction)
18837|NCT04042415|Other|Caloric restriction without cow's milk and gluten|Patients will be treated with mild caloric restriction (15-20% caloric restriction) plus excluding from diet cow's milk, its derivatives and gluten.
18838|NCT04042402|Drug|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
18839|NCT04042389|Behavioral|WhatsApp reminder|"The WhatsApp group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
18840|NCT04042389|Behavioral|Email reminder|"The Email group received oral health messages once a week for four weeks (totaling 4 messages) as a reminder to practice good oral hygiene~The reminder included an image reminding them to maintain their oral hygiene."
18841|NCT04042389|Behavioral|Control|No messages sent.
18842|NCT04042376|Drug|Ibrutinib|Ibrutinib will be administered orally, once daily, at a dose of 420 mg (140 mg*3 capsules taken together at one time).
18843|NCT04042363|Device|Transorbital electrical stimulation (Eyetronic Next Wave 1.1)|"Calibration phase: The patient will use a response button to indicate the threshold from which he feels a luminous sensation (phosphene). In a second step, he will use the same answer button to indicate the stimulation frequency from which the phosphenes become continuous.~Stimulation phase: From these 2 parameters (amplitude and frequency), the stimulation session will begin for a duration of approximately 40 to 50 minutes, the settings being dependent of the individual thresholds."
18844|NCT04042363|Device|Transorbital electrical stimulation (Eyetronic Next Wave 1.1) - Sham stimulation|The calibration phase is identical to the active stimulation. During the stimulation phase, the operator will manually interrupt the stimulation 60 seconds after the start of the session.
18845|NCT04042350|Other|Non-interventional|Exploring clinical risk factors associated with the risk for cardiovascular events and mortality, rather than to evaluate specific drugs.
18846|NCT04042337|Behavioral|Pivotal Response Treatment|PRT will target functional communication abilities
18847|NCT04042324|Drug|Triferic|Triferic (ferric pyrophosphate citrate, FPC), an iron-replacement product, is an iron complex in which iron(III) is bound to pyrophosphate and citrate.
18848|NCT04042324|Drug|Heparin|Unfractionated heparin (UFH): a common anticoagulant used during hemodialysis treatments.
18849|NCT04042311|Other|High-intensity interval training|a high-intensity interval training programme completed 3 times a week for 6 weeks using a stationary Wattbike.
18850|NCT04042298|Other|Arterial blood pressure|Measured using an automated non-invasive finger cuff that obtains beat-by-beat blood pressure measurements via finger photoplesmography. Briefly, changes in artery diameter are detected through infrared light in the finger cuff. (Finometer Pro, FMS, The Netherlands).
18851|NCT04042298|Other|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine and norepinepherine or phenylepherine via iontophoresis.
18852|NCT04042298|Other|Brachial artery blood flow|A GE Ultrasound System will be used to non-invasively assess brachial artery blood flow prior to and following a standard flow mediated dilation protocol.
18853|NCT04042298|Other|Venous blood draw|A venous blood sample from the antecubital vein or a vein in the back of the hand will be taken via venipuncure by a nurse or a certified phlebotomist at the beginning of the experimental visit. These blood samples will be analyzed for the presence of reactive oxygen species and inflammatory markers.
18854|NCT04042285|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy will be given at 120 pulses/cm2, penetration 5mm at a dose of 0.1mJ/mm2 at 5 pulses/second. Participants will receive 3 sessions of shockwave therapy in a 7-day period.
18855|NCT04042285|Other|Standard Wound Care|dressing changes, negative pressure wound therapy, offloading footwear, debridement, glycaemic control and antibiotics as necessary
18887|NCT04042025|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
18888|NCT04042012|Other|Eccentric exercise|soleus eccentric exercise
18889|NCT04042012|Other|PNE|the application of galvanic current
18856|NCT04042272|Diagnostic Test|S100β, Neuron specific enolase (NSE) and Glial fibrillary acidic protein (GFAP)|S100β is 10.4 kDa protein. Synthesized with end-feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium-binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction. Glial fibrillary acidic protein (GFAP) is the intermediate filament cell skeleton protein found in astrocytes. It originates from the same root structure as S100β.
18857|NCT04042259|Device|Abthera|Negative Pressure Wound Therapy Device
18858|NCT04042259|Procedure|Open adbdomen for post-laparotomy without NPWT device|Historic cohort treatment of open abdomen for dirty wounds without use of negative pressure therapy device
18859|NCT04042246|Behavioral|Information Provision|Provide the information on the importance of the vaccination and tailored vaccination schedule
18860|NCT04042233|Drug|Experimental Intraosseous vancomycin 500mg in 250 mL NS|500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
18861|NCT04042233|Drug|Standard IV administration of vancomycin|IV antibiotics (cefepime & vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
18862|NCT04042220|Drug|Glucocorticoids|Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
18863|NCT04042207|Device|External Insulin Pump|Insulin delivery
18864|NCT04042207|Device|Continuous Glucose Monitoring|Collection of glucose data
18865|NCT04042207|Device|DBLHU System|DBLHU system embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
18866|NCT04042207|Device|predictive low glucose management technology|This technology allows for the automatic suspension of insulin delivery using a predictive low glucose management algorithm.
18867|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with T-PRF|A total of 40 ml blood sample was collected from the antecubital vein of the patients' right or left arms with 10 ml injectors. 40 ml blood was transferred to a grade-IV titanium tube for the T-PRF group. The titanium tubes containing the blood samples were instantly centrifuged in a tabletop centrifuge at room temperature. The blood samples of the T-PRF group were centrifuged clockwise at 2700 RPM for 20 minutes. Subsequent to the centrifugation process, the clots of the T-PRF group were removed from the tubes with sterile tweezers, separated from the RBC base with scissors, and left for over 20 minutes on sterile woven gauze to release the serum slowly from the collected clots. The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with T-PRF.
18868|NCT04042194|Procedure|Placement of Implants and Thickening Peri-Implant Mucosa with CTG|The implants were placed in thin tissues, and the thickness of the thin tissues was simultaneously increased with CTG. Autogenous connective tissue graft was harvested according to a single incision technique.
18869|NCT04042181|Dietary Supplement|Placebo|standard food grade excipients
18870|NCT04042181|Dietary Supplement|Bifidobacterium longum|Target dose of 1x10^10 CFU/day, plus standard food grade excipients
18871|NCT04042168|Diagnostic Test|In Check Dial test|In Check Dial test will test the ability to actuate the inhaler.
18872|NCT04042155|Drug|dabigatran, rivaroxaban, apixaban or edoxaban|Record of all serious complications associated with any of the drugs and the clinical changes that occurred during prospective follow-up.
18873|NCT04042142|Other|glucagon|Infusion of low dose glucagon and high dose glucagon during simultaneous somatostatin infusion and replacement doses of insulin and growth hormone. Infusion of palmitate, VLDL-triglyceride and glucose tracers.
18874|NCT04042129|Other|gynecologic operations with urological complications|
18875|NCT04042116|Drug|Lucitanib|Oral lucitanib will be administered once daily. The starting dose will be 6mg daily (QD).
18876|NCT04042116|Drug|Nivolumab|IV nivolumab 480mg will be administered once every 4 weeks.
18877|NCT04042103|Drug|Tapinarof cream, 1%|Tapinarof cream, 1% applied topically once daily
18878|NCT04042090|Device|Reducept, virtual reality (Oculus Go)|The VR serious game Reducept is a novel psychological VR intervention for treating chronic pain. It incorporates several psychological therapies into one application: hypnotherapy, mindfulness, ACT and EMDR. Reducept has been made in co-creation with patients, researchers, psychologists and developers and can be installed and played on the VR goggles Oculus Go. It consists of an education module and three games.
18879|NCT04042077|Drug|Delafloxacin|Powder for solution for infusion 300 mg or tablet 450 mg, BID, for 5 to 14 days
18880|NCT04042077|Drug|Vancomycin|Powder for solution for infusion 15mg/kg, BID, for 5 to 14 days
18881|NCT04042077|Drug|Linezolid|Solution for infusion or tablet, 600 mg BID, for 5 to 14 days
18882|NCT04042077|Drug|Piperacillin/Tazobactam|Powder for solution for infusion 4/0.5 g, TID, for 5 to 14 days
18883|NCT04042077|Drug|Tigecycline|Powder for solution for infusion 50 mg, TID, for 5 to 14 days
18884|NCT04042051|Drug|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1 (and 8 and 15 [according to the dose escalation scheme]) of each 21-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab emtansine.
18885|NCT04042051|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6mg/kg IV infusion on Day 1 of each 21-day treatment cycle.
18886|NCT04042038|Behavioral|Cognitive-behavior therapy (psychological treatment)|Participants will receive up to 20 hours of manualized and structured CBT based on exposure and response prevention by experienced clinicians
18890|NCT04042012|Other|Combined|soleus eccentric exercise and PNE
18891|NCT04041999|Behavioral|Daily Cognition Training Program|"Tasks are carried out in which the subject has to exercise different cognitive functions (praxies, attention, language, memory orientation, gnosias and executive functions; mainly working memory decision making, planning, reasoning and temporal estimation) during the development of AIVD For this, similar materials are used to those that the elderly could find in daily tasks or when solving day-to-day problems.~Specifically we focus on tasks related to taking medication and adherence to treatment. Some examples of tasks are: the management of a medical prescription, expiration of a medication, understanding of the prescriptions made by the doctor, guidelines for taking medication (doses, schedules ...) and indications and contraindications, filling pill boxes, recall of controls doctors, medication control, prospective memory of medical management, etc."
18892|NCT04041986|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that uses constant, low (1-2mA), direct current delivered via electrodes on the head.
18893|NCT04041973|Drug|Artemether-lumefantrine|"One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
18894|NCT04041973|Dietary Supplement|Multivitamin|"One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest."
18895|NCT04041960|Other|Transcranial magnetic stimulation (TMS)|The TMS protocol to be used, excitatory intermittent theta burst stimulation (iTBS), has been shown to have minimal risk in children as young as 6 (Hong et al., 2015), as well as adults (Huang et al., 2005). This stimulation paradigm uses a series of theta burst stimulation (TBS) units. Each unit consists of 3 pulses of stimulation given at 50 Hz (Huang et al., 2005). Excitatory iTBS consists of 20 sets of 10 TBS units (2 second duration) repeated every 10 seconds for a total of 190 seconds. One session of excitatory stimulation delivers a total of 600 pulses.
18896|NCT04041934|Dietary Supplement|tryptophan|Each experimental session will be carried out over a week. Adolescents will take part randomly in three sessions. In order to limit inter-individual differences, the diet of the first 3 days will be fixed to the RDA followed by 3 days where dietary intake will be supplemented with different protein (PROT REF : ratio = 0,04 PROT1 : ratio = 0,07, session PROT2 : ratio = 0,11). Tryptophan (Trp) / Large neutral amino acids (Lnaa) ratio of proteins taken varies-double-blind between sessions. All proteins had the same dose and packages. Neither the researcher nor the participants were aware of the quality of the protein.
18897|NCT04041921|Procedure|Percutaneous coronary intervention|
18898|NCT04041921|Procedure|Coronary Artery Bypass Grafting|
18899|NCT04041921|Drug|Medical treatment|
18900|NCT04041908|Other|Experimental Product|2 sachets per day
18901|NCT04041895|Other|Audio speech recording|Audio recording of speech sample from subject description of Cookie-Theft image.
18902|NCT04041882|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-DOTATATE. Tracer doses of 68Ga-DOTATATE will be used to image lesions of NET PET/CT scan.
18903|NCT04041869|Behavioral|MapTrek|Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.
18904|NCT04041856|Drug|Povidone Ophthalmic|Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
18905|NCT04041843|Drug|Apixaban|Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg
18906|NCT04041830|Behavioral|Visit 1|the participants will fill in the LFPQ questionnaire before and after a lunch test meal
18907|NCT04041830|Behavioral|Visit 2|this is a replication of Visit 1, testing the reproducibility of the LFPQ and of its response to a meal.
18908|NCT04041817|Other|Trigger setting of pressure support ventilation|Trigger variations will be performed following increasing steps of 3 L/min every 15 minutes, from 0.2 to 15 L/min (0.2 - 3 - 6 - 9 - 12 - 15).
18909|NCT04041804|Procedure|Rapid Palatal expansion|A Banded Hyrax is going to be used in order to provide an increase in the maxillary transverse dimension
18910|NCT04041791|Drug|Benzyl penicillin|Benzyl penicillin is a penicillin antibiotic.
18911|NCT04041791|Drug|Gentamicin Sulfate|Gentamicin is an aminoglycoside antibiotic.
18912|NCT04041791|Drug|Ceftriaxone|Ceftriaxone is a third generation cephalosporin antibiotic active against a wide range of gram negative and positive bacteria.
18913|NCT04041791|Drug|Amoxicillin Clavulanate|Amoxicillin Clavulanate is a combination of amoxicillin, a β-lactam antibiotic, and potassium clavulanate, a β-lactamase inhibitor.
18914|NCT04041791|Other|Intravenous fluid|Maintenance fluids administered for at least 24 hours.
18915|NCT04041791|Other|Nasogastric feeds|Feeds given via nasogastric tube. Feeds may include cow's milk, breast milk, porridge, formula among others.
18916|NCT04041791|Drug|Ampicillin|Ampicillin is a penicillin-type antibiotic.
18917|NCT04041778|Other|Catheter ablation|Substrate ablation. Pulmonary vein isolation.
18918|NCT04041765|Drug|IgM-enriched IVIG|Contains human plasma protein 50mg/ml. With composition of Immunoglobulin M (IgM) 6mg, Immunoglobulin A (IgA) 6mg, Immunoglobulin G (IgG) 38mg (IgG subcl. approx. 63 % IgG1, 26 % IgG2, 4 % IgG3 and 7 % IgG4), Glucose monohydrate, sodium chloride, water for injections
18919|NCT04041752|Behavioral|SOLID|condition with a classical meal served using solid food items
18920|NCT04041752|Behavioral|LIQUID_P|condition with a liquid meal served using a powder solution
18921|NCT04041752|Behavioral|LIQUID_L|condition with a pre-prepared meal served using a liquid solution.
18922|NCT04041739|Diagnostic Test|fungal osteomyelitis culture and sensitivity|swabs from ulcer tissue and bone biopsy for culture and sensitivity test and blood sampling
18923|NCT04041713|Drug|Rett-T|antioxidant cocktail
18924|NCT04041713|Other|Placebo|Placebo
18925|NCT04041700|Device|Osia 2 system|System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
18926|NCT04041674|Biological|GEO-D02 DNA|Administered by IM injection into the vastus lateralis
18929|NCT04041674|Biological|IHV01 Protein|Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
18930|NCT04041674|Biological|Protein Placebo|"Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose"
18931|NCT04041661|Other|Active tDCS plus gait training|Participants in experimental group will accept Active tDCS which combined with treadmill
18932|NCT04041661|Other|Sham tDCS plus gait training|Participants in control group will accept Sham tDCS which combined with treadmill
18933|NCT04041648|Drug|L606 (Liposomal Treprostinil) Inhalation Solution 51ug|Single ascending dose
18934|NCT04041648|Device|L606 Inhalation System|Single ascending dose
18935|NCT04041648|Other|Placebo Solution|Single ascending dose
18936|NCT04041635|Procedure|Stimuli reduction|Phototherapy goggles and earmuffs will be placed 3 minutes before the venipuncture (leaving the patient in resting state after the manipulation) and will be maintained during the procedure. Monitor alarms and devices will be silenced and will remain silenced and noise in the unit will be minimized during the procedure.
18937|NCT04041635|Procedure|Usual care|Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
18938|NCT04041622|Diagnostic Test|Endoscopy and biopsy|Participants with a positive celiac serology are assessed by endoscopy and duodenal biopsy
18939|NCT04041609|Drug|LYR-210|Management of Chronic Sinusitis in Adult Patients with nasal polyps (CSwNP) and without nasal polyps (CSsNP)
18940|NCT04041609|Other|Sham comparator|Sham comparator
18941|NCT04041596|Device|Advanced Bionics' Acoustic Earhook|designed to deliver acoustic amplification through the modular attachment of the Naída CI Q90 AcoustiEarhook, while also delivering electrical stimulation along the full range of the implanted Advanced Bionics electrode.
18942|NCT04041583|Device|Cervical Interfacet Spacers|The use of Cervical Interfacet Spacers is a relatively novel technique shown to be useful for posterior fusion to address symptomatic pseudoarthrosis (fusion failure) after anterior cervical arthrodesis [2]. CIS have a relatively large osteoconductive surface area and are placed under tension in the interfacet space, which together favorably influence bony fusion [2].
18943|NCT04041570|Biological|cAd3-EBO S vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Ebola vaccine, VRC-EBOADC086-00-VP (cAd3-EBO S) is composed of a cAd3 vector that expresses Ebola Sudan wild type glycoprotein (WT GP).
18944|NCT04041544|Drug|SN1011|SN1011 will be supplied to the Pharmacy as 25 mg and 100 mg capsules.
18945|NCT04041544|Drug|SN1011 placebo|The placebo to be used in this study will be identical to SN1011, minus the active ingredient.
18946|NCT04041531|Other|blood sampling|venous blood sampling for oxygen affinity in-vitro test
18947|NCT04041518|Procedure|Autotransplantation|Autotransplantation of tooth with an almost fully or completely developed root with intraoperative extraoral apicoectomy.
18948|NCT04041505|Behavioral|(feeding modality)|The intervention is a change in feeding modality: in both arms, infant's will consume mother's milk. The difference in arms is the modality in which human milk is consumed: either directly from the breast, or from a bottle.
18949|NCT04041492|Dietary Supplement|Supplementation with Vitamin D3 y K2|Supplementation at a dose of 1 capsule every 24 hours x 3 months
18950|NCT04041479|Device|Repetitive Transcranial Magnetic Stimulation|10 Hz rTMS targeting the DMPFC or left DLPFC
18951|NCT04041479|Device|Repetitive Transcranial Magnetic Stimulation|10 Hz rTMS targeting the left DLPFC
18952|NCT04041466|Diagnostic Test|AF detection by ECG|Single-lead ECG with Withings watch HWA08 and reference 12-lead ECG
18953|NCT04041453|Drug|Ivermectin|Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
18954|NCT04041453|Drug|Albendazole|Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
18955|NCT04041440|Behavioral|clEAR auditory training|Children play auditory brain training computer games
18956|NCT04041427|Drug|Albendazole Pill|Albendazole 400mg po
18957|NCT04041427|Other|High fat content diet|High fat content diet
18958|NCT04041427|Other|Moderate fat content die|Moderate fat content die
18959|NCT04041414|Other|Proud & Empowered!|Proud & Empowered! is a school-based intervention to decrease sexual minority stress and improve coping among LGBTQ students. It is administered by school counselors and trained social workers.
18960|NCT04041401|Other|PICU storybook|Narrative and developmentally appropriate intervention
18961|NCT04041388|Other|Conebeam CT|medical imaging technique consisting of X-ray computed tomography where the X-rays are divergent, forming a cone
18962|NCT04041375|Behavioral|iNSPiRED|The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.
18963|NCT04041375|Other|Usual Care|Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
18964|NCT04041362|Biological|UB-421|Monoclonal antibody by IV infusion plus standard ART
18965|NCT04041362|Other|Antiretroviral Therapy (ART)|Standard ART
18966|NCT04041349|Drug|mouse nerve growth factor|mouse nerve growth factor of 20 UG (9000 U)/day for 14 consecutive days by intramuscular injection
18967|NCT04041336|Diagnostic Test|Optical coherence tomography|Non-invasive method of acquiring cross sectional imaging of tissues using the coherent property of light
18968|NCT04041310|Biological|GAd-209-FSP low dose|GAd20-209-FSP IM vaccine, low dose
18969|NCT04041310|Biological|MVA-209-FSP low dose|MVA-209-FSP IM vaccine, low dose
18972|NCT04041297|Other|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
18973|NCT04041284|Drug|Fremanezumab|Monthly 225 mg subcutaneous
18974|NCT04041284|Drug|Placebo|Matching Placebo
18975|NCT04041271|Other|Cervical range of motion (CROM)|Subjects will perform full-range cervical flexion, extension, side-bending and rotation actively in sitting position. In supine position, cervical flexion-rotation will be performed passively by the assessor.
18976|NCT04041271|Other|Pressure pain threshold (PPT)|A digital algometer with rubber head will be used to apply pressure on the muscles of subjects. When the subjects start to feel pain, the algometer will be removed immediately.
18977|NCT04041271|Other|Cranial-cervical angle (CCA)|Subjects will stand in a relaxed position with colour markers on the earlobe and C7 spinous process. A photo of the head posture will be taken to calculate the included angle between the markers and the horizontal line.
18978|NCT04041271|Other|Jaw kinematics|Jaw kinematics is measured by Ultrasonic Jaw Motion Analyzer (Zebris). The subjects will perform jaw opening, closing, lateral left, lateral right and protrusion for three times.
18979|NCT04041271|Other|Muscle activation|Surface electromyography is used to assess the activities of bilateral masseter, anterior temporalis, sternocleidomastoid muscle and upper trapezius. Subjects will perform jaw resting and clenching.
18980|NCT04041258|Procedure|pseudoarthrosis of clavicle|Pseudoarthrosis represents a complication following a fracture, resulting in persistent symptoms and functional limitation, which prolongs the recovery time for the patient and necessitates new surgery. The purpose of surgery for pseudoarthrosis is to re-establish the length and alignment of the clavicle in an environment favorable to the union of bone fragments.
18981|NCT04041245|Device|Near infrared spectroscopy|"Near infrared spectroscopy will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: a four-channel INVOS 5100C Oximeter (Somanetics Corp., Troy, USA)~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination.~They are asked to keep silent, breathe normally and avoid movement of limbs during the whole measuring period. After ripping the transparent adhesive tape on the probe, the probes will be left at 4 measuring sites. Regional oxygen saturation (rSO2) will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian."
18982|NCT04041232|Drug|PBA|Glycerol phenylbutyrate (PBA) is a triglyceride that consists of three molecules of phenylbutrate linked to a glycerol backbone. It is a nitrogen-binding agent that has been approved by the Food and Drug Administration (FDA) for the treatment of urea cycle disorders. Oral supplementation of PBA demonstrated no severe side effects, and are found to be therapeutically effective in reducing ER stress. Patients will be instructed to take three doses of PBA per day at equally divided time intervals and rounded up to the nearest 0.5 mL. The total dose of PBA will be 4.5 to 11.2 mL/m2/day (5 to 12.4 g/m2/day) and will not exceed 17.5 mL/day (19 g/day).
18983|NCT04041219|Drug|Tacrolimus|Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually.
18984|NCT04041206|Device|Laser doppler|"Laser doppler will be adopted to assess the microcirculatory characteristics of meridian phenomenon for participants in the two groups.~Experimental device: Four-channel laser doppler flowmetry (PeriFlux System 5000, Sweden).~Experimental process: The participants will be allowed to stabilize for 15 minutes in a supine position in the experimental room before formal examination. They are asked to keep silent and normal breath and avoid limb movement during the whole measuring period. The probes will be left at 4 measuring sites. Blood flow curve will be recorded constantly using Perisoft software (PeriFlux, Sweden). Microcirculatory flux in the measuring sites will be calculated [Perfusion units (PU) =concentration of moving blood cells (CMBC)×velocity (V)]. The acupoint microcirculation will be recorded for 5 minutes.~Measurement sites: Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan(LU9) and Chize (LU5) of the Lung meridian"
18985|NCT04041193|Behavioral|SIDERA^B|The group will receive a kit home-based (a tablet home, access to a daily individualized training program). Five sessions for a week (3 components: monitoring, motor rehabilitation acitivities, motivational support)
18986|NCT04041193|Behavioral|Usual Care Program|Usual Care program activities (paper and pencil at home)
18987|NCT04041167|Drug|alpha lipoic acid|alpha lipoic acid treatment
18988|NCT04041167|Drug|Saline|No alpha lipoic acid treatment
18989|NCT04041154|Behavioral|Cognitive Fatigue|Participants will perform a cognitively demanding task (spatial attention task), repeatedly, to induce cognitive fatigue.
18990|NCT04041154|Behavioral|Physical Fatigue|Participants will perform a physically demanding task (grip force exertion task), repeatedly, to induce cognitive fatigue.
18991|NCT04041154|Behavioral|Rewarding Stimuli|Reward-associated stimuli will be used to study how reward-induced changes in motivational state influence effort choices.
18992|NCT04041141|Diagnostic Test|CT Scan|An additional cone beam CT will be repeated at midcourse of therapy (3rd week) and during the end of therapy (5th week)
18993|NCT04041141|Device|Experimental Oral Stent Device|Patients undergoing standard of care planning for head and neck tongue cancer will have a radiation plan of the body imaged via CT scan construction with the experimental oral stent device in place
18994|NCT04041128|Drug|Lynparza|Lynparza taken orally at a dose of 300mg twice daily for 7 days
18995|NCT04041115|Dietary Supplement|Non-alcoholic beer|Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
30961|NCT03943940|Other|Control|Standard medicine
18996|NCT04041115|Other|control|Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
18997|NCT04041089|Behavioral|Recognition of objects|"Name of shapes / colors / images / objects~Classification of shapes / colors / images / objects"
18998|NCT04041089|Behavioral|Location of objects|"Search for frequent/rarse targets among distractors sharing one or more characteristics with the target~Hit/catch a stationary/mobile target as quickly as possible"
18999|NCT04041089|Behavioral|Manipulation of objects|"Storage of shapes/objects~Use of everyday objects (pen, cutlery, etc.)"
19000|NCT04041076|Procedure|Major surgical operation|Surgical operation with magnitude defined as major or ultra-major
19001|NCT04041063|Device|Upper limb robotic training|"Subjects will remain seated in their own wheelchair in front of the InMotion Hand™ Robot (Interactive Motion Technologies, Massachusetts, MA, Figure 6) facing a video screen.~The arm of the participants will be abducted, forearm supported, and hand grasping a cone shaped handle. Velcro straps will lightly hold the forearm and fingers secure. The InMotion Hand™ robot attaches to the InMotion Arm™ robots to provide 'assisted-as-needed'™ gross grasp and release motion and support for functional reach. In each session, patients perform a total of 1024 movement repetitions (Cortes et al., 2013). Patients will receive a total of 18 sessions (3x/week, 6 weeks) comprising one hour of interactive hand robotic training. The interactive robotic features involve visuomotor task, moving the robotic manipulandum according to targets on a computer screen mounted at eye level."
19002|NCT04041063|Procedure|Nerve transfer surgery|C5 injury; Teres minor branch of axillary nerve transferred to long head of triceps branch of radial nerve (RN); Brachialis branch of musculocutaneous nerve to anterior interosseous nerve (AIN); Supinator branch of RN to posterior interosseous nerve (PIN). C6 injury; Teres minor branch of axillary nerve to long head of triceps branch of RN; Extensor carpi radialis brevis (ECRB) branch of RN to AIN; Supinator branch of RN to PIN. C7 injury with preserved triceps, loss of grasp/release; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN; Supinator branch of RN transferred to PIN. C7 injury with preserved triceps/finger extension, loss of grasp; Pronator teres branch of median nerve to AIN; Terminal branch of ECRB branch of RN to flexor pollicis longus branch of AIN.
19003|NCT04041050|Drug|Navitoclax|tablet; oral
19004|NCT04041050|Drug|Ruxolitinib|tablet; oral
19005|NCT04041037|Device|Wound Sheet Matrix 2-Layer and Powder Urinary Bladder Matrix|Porcine-derived extracellular matrix will be used in powder and 2-Layer wound sheet form in masses up to 1000 mg. Each product is intended for a one-time use only.
19006|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
19007|NCT04041024|Other|tasks and questionnaires|"Each of the 4 experiments is built of a main task. The first task involves a first phase of subjective valuation of food items.~The second phase requires from the participant to make a choice between two out of three food items selected by the computer."
19008|NCT04041011|Drug|1.Experimental: A (Part 1): Fluzoparib and SHR -1316|1．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
19009|NCT04041011|Drug|2.Experimental: B (Part 1): Fluzoparib and SHR -1316|2．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
19010|NCT04041011|Drug|3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion|3．Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).
19011|NCT04040998|Behavioral|Compensatory Cognitive Training|Teach the participants compensatory cognitive skills and strategies
19012|NCT04040985|Procedure|Total Knee Arthroplasty using Legion Total Knee System|Primary Total Knee Arthroscopy using Legion Total Knee System
19013|NCT04040972|Other|Compassion Focussed Therapy|Group compassion focussed therapy. One session every week for 10 weeks. Each session lasts 2.5 hours with two breaks during this time.
19014|NCT04040959|Drug|Nicotinamide riboside|Nicotinamide riboside is a naturally occurring vitamin B3 derivative found in yeast, bacteria, and mammalian tissues, and also has been detected in cows' milk.
19015|NCT04040946|Diagnostic Test|MIBI scintigraphy|Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET
19016|NCT04040946|Diagnostic Test|F18-choline PET|Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
19017|NCT04040920|Device|Ozone|One minute of pretreatment with ozone by using the OzoneDTA device
19018|NCT04040920|Other|Pits and fissure sealants|cleansing of the occlusal surfaces with a nylon brush and polishing toothpaste; surface etching with 36% orthophosphoric acid for 30'', surface cleaning and drying for 30 '', application of the sealing material, polymerization for 60'';
19019|NCT04040907|Drug|XNW3009|XNW3009 is a small molecule hURAT1 inhibitor
19020|NCT04040907|Drug|Placebo|Placebo and active drug will have the same appearance
19021|NCT04040894|Biological|Teprotumumab|Treatment with 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
19022|NCT04040881|Behavioral|Remote monitoring using smartphone accelerometer|"Patients will be instructed to carry the smartphone around their hips during waking hours, regardless of whether they are at home or outside (a nylon hip holster will be provided) and to keep it turned on at all times.~Daily steps will be recorded for at least seven days before the start of chemotherapy, and the median baseline number of daily steps will be calculated for each patient.~On the first day of chemotherapy, patients will receive side effect education as per standard of care. Patients will be instructed to continue carrying the smartphone daily as indicated for the entire duration of the first three chemotherapy cycles.~At the end of the follow-up period (or sooner in cases of early interruption of chemotherapy due to toxicity or disease progression; a change in chemotherapy regimen; or hospitalizations lasting ≥3 days), patients will rate their satisfaction with the intervention using a Likert-scale questionnaire and open-ended questions."
19023|NCT04040868|Device|the TiRobot system|The TiRobot system (TINAVI Medical Technologies Co. Ltd.) is a multi-indication orthopedic surgical robot that can be used in spinal, pelvic, and limb surgeries performed via an open or a minimally invasive approach
19024|NCT04040868|Device|Freehand|conventional fluoroscopy-assisted
19026|NCT04040842|Diagnostic Test|Patients undergoing low anterior resection|Patients before the surgery and one year after the surgery will be assessed with questionnaire.
19027|NCT04040829|Behavioral|Cognitive remediation therapy (CR)|Cognitive remediation therapy is a behavioral intervention that aims to improve cognition. This intervention has the goal to produce long-term improvements in cognition as well as to generalize these improvements in daily functioning.
19028|NCT04040829|Behavioral|Supported education (SE)|Supported education (SE) is a behavioral intervention that aims to help people return to school and/or succeed in school. SE offers a wide range of services that are personalized to the needs of each patients.
19029|NCT04040829|Other|Treatment as usual (TAU)|Treatment as usual (TAU) consists of medication and routine contact with the clinical team.
19030|NCT04040816|Drug|SAP-001|SAP-001 or placebo treatment in a 4:1 randomization ratio
19031|NCT04040803|Device|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS)|Transcranial alternating current stimulation (tACS) and transcranial random noise stimulation (tRNS) are two (CE marked medical devices) new, non-invasive (over the scalp) brain stimulation (NIBS) techniques. Both tACS and tRNS deliver a weak current continuously across the brain using pads placed over the scalp, which has been shown safe and well-tolerated by healthy adults and patients. These two techniques are able to softly alter physiological function within the brain. tACS can influence the brainwaves which have been demonstrated to play important roles in movement, sensation, and thinking functions. tACS and tRNS have been investigated for several years and have been shown to be safe, well tolerated and produce beneficial results in hand movement, hearing, and working memory.
19032|NCT04040790|Device|Scleral contact lens without a passive artificial iris|Participants wear a scleral contact lens without a passive artificial iris (Design A) on the dominant eye to perform the baseline visual performance assessment
19033|NCT04040790|Device|Scleral contact lens with a passive artificial iris with low contrast (<1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
19034|NCT04040790|Device|Scleral contact lens with a passive artificial iris with high contrast (>1:5)|Participants wear a scleral contact lens with a low contrast (<1:5) passive artificial iris (Design B) on the dominant eye to perform the baseline visual performance assessment
19035|NCT04040790|Drug|Tropicamide and phenylephrine|Participants receive pupil dilation eye drops on the dominant eye, after baseline measurement and before wearing the scleral contact lenses (Designs A, B and C)
19036|NCT04040764|Procedure|Tritanium uncemented Total Knee Replacement|This will be an internal pilot study in which patients will be blinded and randomly assigned to 1 of 2 arms with 30 patients in each arm. The first arm will receive a Triathlon knee replacement device which is cemented into place. The second arm will receive an uncemented Triathlon Tritanium TKR.
19037|NCT04040751|Behavioral|CARE -CITE|The primary CARE-CITE components will be education via web platform. CP completes 6 online CARE-CITE modules (15-30-minute sessions each). Modules include demonstration videos and instructive content covering following areas: principles of functional task practice (i.e., activities of daily living such as eating, grooming, or leisure/vocational activities), adaptation of tasks, and importance of progression of challenging tasks to drive neuroplasticity (i.e., increasing numbers of practice repetitions or weight of objects lifted). Underpinning the content is the concept of autonomy support, with examples of fostering empathy, problem solving, instruction in the use of non-controlling language with role playing situations and the importance of creating choice in activities.
19038|NCT04040751|Behavioral|Standard of care|The CP will receive a CP support brochure with general caregiving information including website resources to mimic web interaction of intervention group (e.g., stroke caregiver resource site).
19039|NCT04040738|Procedure|Upper extremity surgery under general anaesthesia|Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance
19040|NCT04040738|Procedure|Upper extremity surgery under regional anaesthesia|Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
19041|NCT04040725|Drug|Rogaratinib|Rogaratinib is an oral drug that inhibits FGFR. Mutations in FGFR help bladder cancer grow.
19042|NCT04040712|Other|Donor FMT|Fecal microbiota transplantation using stools from healthy donors
19043|NCT04040712|Other|Sham FMT|Sham fecal microbiota transplantation
19044|NCT04040699|Biological|KN026 combined with KN046|KN026 and KN046 are given at 20mg/Kg and 3mg/Kg intravenously on day 1of each 2 weeks cycle at the beginning respectively.The dosage will be escalated if adverse events are tolerated according to the scheme.
19045|NCT04040686|Drug|99m-Tc-NM-02 Injection|Patient will be injected with microdose (<100ug) of 99m-Tc-NM-02 radiotracer
19046|NCT04040673|Procedure|thyroid lobectomy|routine surgical removal of thyroid for biopsy
19047|NCT04040673|Device|Raman spectroscopy probe measurement|The measurement of Raman spectra from the excised tissue
19048|NCT04040660|Drug|NexoBrid|NexoBrid is presented as lyophilized powder and gel vehicle for preparation of a gel for cutaneous use. The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)
19049|NCT04040647|Behavioral|mobilization and ambulation|6-min walk test (6-MWT)
19050|NCT04040634|Drug|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP <120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged.
19051|NCT04040634|Drug|Standard control of Systolic Blood Pressure (SBP)|The same medications used in the Intensive BP arm will be used for the Standard BP arm.
19052|NCT04040621|Drug|Ceftazidime-avibactam|Single intravenous infusion of ceftazidime-avibactam over 2 hours. Dosage will vary depending upon age, weight and renal function.
19078|NCT04040374|Diagnostic Test|AI-based diagnosis|AI-based diagnosis will be performed based on analysis of endoscopic images (Olympus Optical, Tokyo, Japan). The investigators will use the Single Shot MultiBox Detector (SSD), a deep neural network architecture (https://arxiv.org/abs/1512.02325), and an optimal diagnostic cutoff from a prior report2. The AI system reviewed endoscopy images and reported those in which gastric cancer was detected, together with the coordinates (X, Y) of the lesions.
31434|NCT03940066|Other|No Intervention|No intervention
19053|NCT04040608|Other|Influence of screen sizes on responses to visual analog scales of stress|"An open questionnaire will be created by the Clinical Research Direction. The questionnaire will be opened by the examinator who will fulfill the anonymized identification of participants and the type of screens. In a dedicated room at the LaPSCo, the participants will answer the same VAS on four different sizes/types of screens (24-inch screen, laptop, tablet, smartphone) and on paper. Saliva will be collected after answering questionnaires. Heart rate variability and skin conductance will be measured with the use of a wrist watch during 15 minutes, from the entrance in the room to the completion of questionnaires.~The participant will undergo the same examination within a week (15 minutes)."
19054|NCT04040595|Procedure|Abdominal fat biopsy|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
19056|NCT04040556|Other|Simulation class|Pediatric anesthesia simulation class for anesthesia residences
19057|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing adherence markers|The supplement will be provided once daily for 10 days
19058|NCT04040543|Dietary Supplement|lipid-based nutrient supplement containing or not containing adherence markers|The product containing adherence markers will be provided once daily every other day (5 days total); the product not containing adherence markers will be provided on the intervening days for a total of 10 days.
19059|NCT04040543|Dietary Supplement|lipid-based nutrient supplement not containing adherence markers|The supplement will be provided once daily for 10 days
19060|NCT04040530|Procedure|CT-guided cryoablation|Percutaneous computed tomography guided cryoablation with the patient in sedation or general anaesthesia.
19061|NCT04040530|Procedure|Partial nephrectomy|Surgical removal of the renal cancer, leaving the healthy renal tissue. Surgery is either done laparoscopically, robot-assisted laparoscopically or as an open surgery. The patient is under general anaesthesia.
19062|NCT04040517|Diagnostic Test|Evoked potential audiometer|The ASSR [ steady state response] test stimuli are modulated pure tones with insert earphone..
19063|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)|ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
19064|NCT04040504|Device|ERCP procedure with Pentax ED-34i10T Duodenoscope|ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
19065|NCT04040491|Drug|PD-1 blocking antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
19066|NCT04040478|Device|Transcutaneous monitoring|"Transcutaneous monitoring of oxygen and carbon dioxide by using Radiometer TCM5 flex monitor with 3 electrodes on the patient.~Abdominal patients are monitored for 4 hours during surgery and for 2 hours in the Post-Anesthesia Care Unit. Arterial blood gasses are drawn from the arterial line 4 times during surgery and 4 times after surgery.~Patients undergoing vascular surgery are monitored for up to 4 hours during surgery."
19067|NCT04040465|Drug|Aspirin|Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
19068|NCT04040452|Drug|Continuous ketorolac|Patients randomized for the treatment arm of the study group will receive a continuous infusion of ketorolac plus an intermittent dose of placebo (plasmalyte) for 48 hours.
19069|NCT04040439|Drug|Dexmedetomidine Hydrochloride|"[Sedation during and after mechanical ventilation in the intensive care setting] For pediatric patients ages of 6 years and over, dexmedetomidine is usually administrated by continuous intravenous (IV) infusion of at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.0 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition.~For pediatric patients with corrected gestational ages (gestational age + postnatal age) of 45 weeks to under 6 years, dexmedetomidine is usually administrated by continuous IV infusion at a rate of 0.2 μg/kg/hr, following by continuous infusion at a range of 0.2 to 1.4 μg/kg/hr adjusted to achieve the optimal level of sedation depending on the patient's condition. The dosing rate could be decreased according to the patient's condition as appropriate."
19070|NCT04040426|Other|Human split thickness skin allograft|Application of a fenestrated human skin graft
19071|NCT04040426|Other|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
19072|NCT04040426|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
19073|NCT04040426|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
19074|NCT04040413|Procedure|bariatric surgery|All bariatric procedures
19075|NCT04040400|Device|intraoperative radiotherapy (IORT)|intraoperative radiotherapy (IORT) during brain tumor resection
19076|NCT04040387|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
19077|NCT04040387|Device|Sham NightWare|NightWare device not providing interventions
19079|NCT04040374|Diagnostic Test|The expert endoscopists-based diagnosis|The expert endoscopists are two physicians with experience of more than 20,000 endoscopies. The expert endoscopists will review the endoscopy images of each patient for 5 min. They will then report endoscopy images in which gastric cancer was detected and manually annotate the lesions in those images.
32660|NCT03929965|Drug|Anlotinib|Anlotinib
19080|NCT04040361|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200mg as a 30-minutes IV infusion, Q3W
19081|NCT04040361|Drug|Ramucirumab|Ramucirumab will be administered as a dose of 10mg/kg as a 60-minutes IV infusion, Q3W
19082|NCT04040361|Procedure|Surgery|Surgery to be performed is lobectomy or more extensive lung resection and lymph node dissection
19083|NCT04040348|Biological|100 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of 100 million cells per infusion.
19084|NCT04040348|Biological|200 million cells allogeneic hMSC|Umbilical cord-derived, allogeneic hMSC administered intravenously at a dose of 200 million cells per infusion.
19085|NCT04040335|Behavioral|Tailor Made|Each small group session will last approximately 45 minutes and include provision of health education materials and activities that promote positive behavior change for a healthier lifestyle including information about activities that promote physical activity and healthy eating.
19086|NCT04040335|Behavioral|Control|Participants will receive educational materials on health promotion topics and will be asked to review on their own.
19087|NCT04040322|Drug|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
19088|NCT04040322|Drug|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
19089|NCT04040309|Biological|PRGF injection|Plasma rich in growth factors will be prepared following the protocol described by E. Anitua. 9 ml of patients venous blood will be taken into one tube with 3,8% sodium citrate used as an anticoagulant. The blood then will be centrifuged (PRGF Centrifuge System, Biotechnology Institute, Vitoria, Spain) at room temperature for 8 min at 1800 rpm. After centrifugation 1 ml of 2nd plasma fraction will be collected by using a pipet. To activate plasma 10% calcium chloride will be used immediately before injecting plasma into the trigger point in the masseter muscle.
19090|NCT04040309|Drug|Lidocaine injection|1 ml 2 % Lidocaine will be injected into the trigger point in the patient's masseter muscle.
19091|NCT04040296|Other|Kidney Action Team Recommendations|Upon review of the patient's medical information, the Kidney Action Team will create personalized recommendations that will be delivered to the patient's primary care team via a specialized note in the electronic medical record system within 30 minutes of AKI development. The attending of record will be identified as a cosigner to ensure that a member of the care team is made aware of the note's presence.
19092|NCT04040283|Procedure|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a technique in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
19093|NCT04040270|Behavioral|Live drama+DVD+Worksheets|"Interactive live drama was proposed to enhance memories of the audience of health promotion programmes.~The interactive live drama and DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
19094|NCT04040270|Behavioral|DVD+Worksheets|"The DVD conveyed educational information on healthy living habits (including physical activity and healthy eating) as well as the importance and suggested methods to enhance family well-being. Students were encouraged to share the information on healthy living habits and watched the DVD with their parents.~Worksheets were given to all students and encouraged to finish the worksheets with their parents."
19095|NCT04040257|Behavioral|Team-based approach|Team-based participation in the The Perinatal Quality Foundation Fetal Monitoring Credentialing (PQF/FMC) exam.
19096|NCT04040244|Other|Exhaled Breath Collection|Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
19097|NCT04040244|Other|Blood sample|Blood samples collected simultaneously with routine standard of care blood draws.
19098|NCT04040231|Biological|Galinpepimut-S|Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.
19099|NCT04040231|Drug|Nivolumab|Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.
19100|NCT04040231|Biological|Sargramostim|All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle
19101|NCT04040218|Procedure|Dry Needling|Dry needling is utilized by multiple practitioners to address impairments in neuromusculoskeletal function, often related to pain and loss of mobility. Dry needling, according the American Physical Therapy Association (APTA), is defined as a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments
19102|NCT04040205|Drug|Abemaciclib|Abemaciclib 200 mg will be taken by mouth twice daily..
19103|NCT04040192|Drug|Crisaborole 2%|Crisaborole ointment 2%
19104|NCT04040192|Drug|Vehicle|Vehicle ointment
19105|NCT04040166|Diagnostic Test|PET/MRI of carotid arteries with 68Ga DOTATATE|PET/MRI of carotid arteries with 68Ga DOTATATE in patients post head and neck radiation therapy
19106|NCT04040153|Behavioral|Guiding Good Choices|Guiding Good Choices is a 5-session group-based prevention program for parents of early adolescents. Weekly 2.5 hour sessions will be held at participants' primary care clinics and led by two trained interventionists. Through didactic material, video segments, interactive activities, and home practice, the curriculum teaches parents to understand the progression from individual and environmental risk and protective factors to substance use and problem behavior, enhances parenting behaviors and skills, teaches effective family management skills, strengthens parent-adolescent interactions and bonding, broadens opportunities for family involvement, teaches conflict reduction and anger management skills, and teaches adolescents skills to resist peer influences to engage in risky behavior. Parents who opt not to attend groups will be offered a self-guided intervention manual containing the same core content and video access, plus supportive coaching to motivate use and address questions.
19107|NCT04040140|Other|APA Treatment|Light touch using vaccaria seeds on corresponding ear points related to patient's pain.
19108|NCT04040127|Biological|Cord blood stem cells|Umbilical cords are collected from eligible donors at the time of delivery and transported to the processing facility on ice (2-8℃) in Dulbecco's Modified Eagle Media (DMEM). Cords are processed immediately under aseptic conditions and MSCs are collected for culture. Culture is maintained this way until the target number of cells has been reached, at which point passaged cells are suspended in Stem Cellbanker (Amsbio, Cambridge, MA) and frozen at -80℃.
19109|NCT04040127|Other|Saline solution|saline solution used to rinse the canal.
19110|NCT04040114|Device|Molemap Skin Cancer Triage Artificial Intelligence Device|This device/software incorporates artificial intelligence to provide a diagnostic aide for clinicians of patients with potentially malignant skin lesions. The software is supported by the use of cameras for acquisition of images.
19111|NCT04040101|Device|smartphone-based balance training system|use smartphone application to training balance
19112|NCT04040088|Procedure|Computed Tomography|Undergo PET/CT
19113|NCT04040088|Drug|Gallium Ga 68-DOTATATE|Given IV
19114|NCT04040088|Procedure|Positron Emission Tomography|Undergo PET/CT
19115|NCT04040075|Drug|Biktarvy Tab|Antiretroviral drug
19116|NCT04040062|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression. Using pulsed magnetic fields, transcranial magnetic stimulation therapy stimulates the part of the brain thought to be involved with mood regulation. These magnetic fields do not directly affect the whole brain; they only reach about 2-3 centimeters into the brain directly beneath the treatment coil.As these magnetic fields move into the brain, they produce very small electrical currents. These electrical currents activate cells within the brain, causing them to rewire, a process called neuroplasticity.
19117|NCT04040049|Genetic|FLT190|Gene Therapy product.
19118|NCT04040036|Behavioral|Children watch applications by wearing the virtual headset during the blood draw.|wearing the virtual headset
19119|NCT04040023|Drug|Iron Deficiency Correction Program|"Preoperative:~For patient with iron deficiency: Intravenous iron supplementation~For patient with iron deficiency and anemia: Intravenous iron supplementation and erythropoietin injections~Postoperative:~Systematic iron supplementation"
19120|NCT04040023|Other|PBMi: Training program to improve transfusion practices|Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
19121|NCT04040010|Dietary Supplement|Colostrum supplementation for bone loss|Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.
19122|NCT04039997|Device|CPRMeter|teaching resuscitation with application of cpr feedback device
19123|NCT04039997|Other|Manual chest compression|Manual chest compression
19124|NCT04039984|Device|Prime Cup|Patients in this group will have the Prime cementless acetabular cup used during surgery.
19125|NCT04039971|Procedure|ACL Reconstruction|Surgical techniques
19126|NCT04039958|Drug|Soviredia|Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
19127|NCT04039958|Drug|Harvoni (first dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
19128|NCT04039958|Drug|Harvoni (Second dose)|Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
19129|NCT04039932|Behavioral|FLAME|The FLAME intervention trains pairs of faith leaders and community health workers and deploys them to conduct behavior change outreach in their communities.
19130|NCT04039919|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
19131|NCT04039919|Drug|Placebo (PSL)|Placebo will be provided matching Padsevonil to maintain the blinding.
19132|NCT04039906|Device|Removal of needle with using ANDYs|"ANDY will be provided to medical staffs to be use in removal needles from syringes during 7 days~Record the time required for the needle removal procedure by photographing the needle removal procedure during 24 hours/7 days.~Identify the number of syringes processed by ANDY.~After 3rd week, do survey and interview 15 people selected by the convenient sample method. By interviewing, collect information of overall experience after using automated needle processing system, how long their hospital working experience is, and other information or systems the interviewees felt those are necessary."
19133|NCT04039893|Diagnostic Test|Systematic axillary ultrasound imaging|Before surgery, all patients will be explored with a pre-defined systematic and reproducible axillary ultrasound imaging workflow intending to establish the number of neoplastic lymph nodes.
19134|NCT04039893|Diagnostic Test|Sentinel node|Sentinel nodes will be identified with a radioisotope tracer and blue dye or fluorescein.
19135|NCT04039893|Procedure|Excision of suspicious lymph nodes|Nodes suspected to be infiltrated both by physical exploration and/or ultrasound will be excised and evaluated separately.
19136|NCT04039893|Procedure|Two steps axillary node clearance|Axillary node clearance will be performed in two steps comprising inferior and superior clearance. The second intercostobraquial nerve will be considered the limit defining the border between superior and inferior axilla.
19137|NCT04039880|Drug|Olorofim|single oral dose (120 mg, 3.7 MBq)
19138|NCT04039867|Drug|Oxaliplatin with Gemcitabine|Oxaliplatin will be given as an intravenous infusion over 60 minutes on Days 1 and 14 at a dose of 100 mg/m2 for each cycle. Gemcitabine (1000 mg/m2) will be given on days 1 and 14 as an intravenous infusion over 30 minutes immediately prior to Oxaliplatin.
19165|NCT04039646|Combination Product|ERAS treatment|The ERAS group had an enhanced postoperative recovery protocol. The gastric content was aspirated via the nasogastric tube by the anesthesiologist at the end of the procedure, and the nasogastric tube was withdrawn in the operating room immediately after the patient had recovered from anesthesia. and also early feeding and move.
19291|NCT04038580|Device|Laminated Socket|This is the currently prescribed socket the participant normally wears.
19139|NCT04039854|Drug|Isoflurane, Sevoflurane or Desflurane|"The volatile anaesthetic agent will be administered via inhalation, i.e. ventilation through alveolar membrane in lungs) during the maintenance of anaesthesia. During CPB the volatile anaesthetic agent will be administered through the oxygenator oxygen inflow of the CPB machine.~The maintenance dose of the volatile anaesthetic agent will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia and blood pressure.~The administration of the volatile anaesthetic agent will be started after induction of anaesthesia and it will be ended at the end of surgery, before the patient is transferred to the CCU."
19140|NCT04039854|Drug|Propofol|Patients will receive propofol only during the surgical procedure. The maintenance dose of the propofol infusion will be titrated to doses deemed necessary in order to provide sufficient depth of anaesthesia (titrated to a depth of anaesthesia with BIS 30-60) and mean arterial pressure (MAP) of 50-80mmHg by the treating anaesthetist.
19141|NCT04039841|Diagnostic Test|Motor Imagery Test|"Imagined Timed Up and Go (iTUG) is the imagined version of the actual Timed Up and Go (rTUG) described above). It is possible to calculate the absolute value of the difference between the time of execution of the TUG imagined and actually executed. This difference is called isochrony index. The alteration of this isochrony index is correlated with the decrease in walking speed during the double task. This test is performed during the osteoporosis screening consultation.~For patients who agree to participate in the FallMI study, the name and contact information of the attending physician will be collected during the same consultation.~Standardised email will be sent to the attending physicians to collect the presence of falls and its consequences. They will be classified as fatal, severe, moderate and inconsequential."
19142|NCT04039828|Drug|Zinc Sulfate Dispersible Tablet 20 mg (Elemental Zinc 20 mg as Zinc Sulfate Monohydrate / Tablet)|Half of the tablet (10 mg) for 3 to 6 months old children and one tablet (20 mg) daily for > 6 to 59 months old children. The tablet will be dissolved in a teaspoon of safe water or breast milk and administered once daily for 10 days.
19143|NCT04039815|Drug|Ascorbic acid-Vitamin B1-Hydrocortisone|intravenous Thiamine (200mg in 50 mL of 0.9% normal saline and was administered as a 30-min infusion every 12 hours for 4 days or until ICU discharge), plus Vitamin C (1.5g mixed in a 100-mL solution of normal saline and was administered as an infusion over 30 to 60 min every 6 hours for four days or until ICU discharge) as well as hydrocortisone 50mg every 6 hours (or other equivalent products) for 7 days
19144|NCT04039815|Drug|Placebo|patients would receive 50mL 0.9% normal saline, 100 mL 0.9% normal saline with the same infusion rate and hydrocortisone dependent on the discretion of the attending physician
19145|NCT04039802|Procedure|Single-stage surgery|In the test group, patients will be scheduled for bone-anchored hearing implant surgery using the single-stage procedure. The implant and abutment will be placed in one surgery.
19146|NCT04039802|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
19147|NCT04039789|Behavioral|Project active legs|Home program of exercises of lower extremities includes the performance of 4 exercises of lower extremities of progressive difficulty that must be carried out at home 5 days a week, twice a day and walking progressively until reaching the marked goal (150 min / week (30 minutes for 5 days a week)).
19148|NCT04039789|Procedure|Usual care|Evaluation, cleaning, debridement, topical treatment (moist healing) and compressive therapy according to the recommendations for the treatment of chronic cutaneous ulcers of the Community of Madrid.
19149|NCT04039776|Diagnostic Test|"Cone Beam Computed Tomography (CBCT)"|"Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism."
19150|NCT04039763|Device|Dexcom G6|Realtime Continous Glucose Monitoring
19151|NCT04039763|Device|Self monitoring of blood glucose|Finger prick self monitoring of blood glucose
19152|NCT04039750|Drug|antibiotic rinse with suction|antibiotic rinse with suction
19153|NCT04039750|Procedure|suction only|no irrigation, suction only
19154|NCT04039737|Drug|Qingpeng Ointment|Take Qingpeng ointment (produced by Tibet Qizheng Tibetan Medicine Co., Ltd.) and apply it evenly on the shoulder joints, wrist joints and palms of the upper limbs. Press for 20 minutes and have rehabilitation training afer 10 minutes.
19155|NCT04039724|Drug|HCP0605 + HGP0816|
19156|NCT04039724|Drug|HCP1305|
19157|NCT04039711|Procedure|Vaginal self-sampling|The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.
19158|NCT04039698|Other|Telemedicine|Telemedicine monitoring and teleconsultation by video calls
19159|NCT04039698|Drug|Velpatasvir/Sofosbuvir|Velpatasvir 100mg / Sofosbuvir 400mg once a day for twelve weeks
19160|NCT04039685|Other|Effects of an eight weeks aerobic exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks aerobic exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
19161|NCT04039685|Other|Effects of an eight weeks resistance exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks resistance exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
19162|NCT04039685|Other|Effects of an eight weeks combined (aerobic+resistance) exercise followed by an eight weeks de-training period on UCP1 gene of human white adipose tissue|The investigators evaluated the effects of an eight weeks combined (aerobic+resistance) exercise program and a following of eight weeks of a de-training period on UCP1 gene in previously non-regular exercisers healthy adult men
19163|NCT04039672|Procedure|Skin biopsy|5mm skin metastasis or primary melanoma biopsy
19164|NCT04039659|Device|Negative-pressure wound therapy (PICO)|After the selection of patients and the signing of the consent, patients will be randomized and the device will be placed to those who belong to the PICO group in the operating room.
19166|NCT04039633|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
19167|NCT04039633|Procedure|Sham spinal cord stimulation|A pulse generator is implanted, but no spinal cord stimulation is provided
19168|NCT04039620|Other|Observational study, no interventions expected|No interventions are planned
19173|NCT04039594|Device|VA ECMO|VA ECMO for cardiopulmonary support
19174|NCT04039581|Other|Kinesio Taping|Kinesio Taping
19175|NCT04039581|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|TENS
19176|NCT04039568|Behavioral|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
19177|NCT04039568|Behavioral|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
19178|NCT04039555|Device|CO2 intimate|Two sessions with CO2 intimate laser for vaginal symptoms treatment
19179|NCT04039555|Device|Erbium-yag|Two sessions with Erbium-yag laser for vaginal symptoms treatment
19180|NCT04039555|Device|CO2 intimate or Erbium-yag|Two sessions of one of the two lasers with no therapeuthical energy
19181|NCT04039542|Other|Compassion focused therapy (CFT)|Compassion focused therapy (CFT) sessions (developed from cognitive behavioural therapies) to target underlying shame and self-criticism - 10 x 90 minute sessions
19182|NCT04039529|Device|SCENERGY-guided Biopsy|Use of SCENERGY during a lung, liver or kidney biopsy
19183|NCT04039516|Drug|Lutathera|A total of 4 infusions of Lutathera to be administered every 8 weeks.
19184|NCT04039503|Drug|Tirzepatide|Administered SC as add-on to the pre-trial background medication.
19185|NCT04039503|Drug|Placebo|Administered SC as add-on to the pre-trial background medication.
19186|NCT04039490|Device|SCENERGY|Use of the SCENERGY guidance device in conjunction with ultrasound to guide needles for pediatric vessel cannulations
19187|NCT04039477|Drug|KZR-616|Patients will receive KZR-616 SC once weekly. Patients assigned to Arm A will receive 30 mg for 13 weeks and patients assigned to Arm B will receive 30 mg for 2 weeks then 45 mg for 11 weeks
19188|NCT04039464|Drug|Mono-Therapy with Sildenafil|The subjects will be randomized to receive sildenafil alone and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
19189|NCT04039464|Drug|Duo-Therapy with Sildenafil + Bosentan|The subjects will be randomized to receive combination up-front therapy sildenafil and bosentan and will undergo study procedures as outlined in section 1.3. There will not be a placebo group.
19190|NCT04039438|Other|No intervention|No intervention will be provided during the study nor participants will be receiving any intervention anywhere else.
19191|NCT04039425|Procedure|Hair cut|Use only head hair. Cut samples of hair from back of head (see illustration). Cut hair as close to the scalp as possible. As each piece of hair is cut from the head, save only 3.7 square inches of hair closest to the scalp. According to the Doctors Data Lab, this amount is about enough hair to fill a tablespoon. Cut off and discard the rest. Place the saved hair on the scale. Keep cutting and adding hair to the scale until it tips. Hair collection will be about the weight of one to two paper clips (about 3800 strands). Remove the hair on the scale and put it in the plastic bag. Label the plastic bag with the patient's unique random identification and the date collected. Put the hair into the plastic bag, seal, and send to The Doctor's Data Lab.
19192|NCT04039412|Drug|Hybrid regimen|two-step (dual-quadruple) treatment
19193|NCT04039412|Drug|Reverse hybrid regimen|one-step two-phase (quadruple-dual) treatment
19194|NCT04039412|Drug|Levofloxacin quadruple regimen|non-Clarithromycin non-Bismuth quadruple therapy
19195|NCT04039399|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants will receive one session of the intervention (45 minutes total).
19196|NCT04039399|Procedure|Sham Ischemic Conditioning|There will also be an IC Sham group which is identical to the IC intervention, except the cuff is only inflated to 10 mmHg, which is a high enough pressure to perceive cuff tightness but not high enough to have any physiological effects.
19197|NCT04039386|Device|Cell Phone Based Cognitive Based Therapy (Pacifica App)|Cell phone application that provides support for individuals with psychosocial conditions.
19198|NCT04039386|Other|Control|Subjects in the control group will receive standard care.
19201|NCT04039360|Combination Product|self-expanding metallic stent placement followed by neoadjuvant chemotherapy|Neoadjuvant chemotherapy was administered 1 week after successful SEMS placement and decompression for patient with obstructing left-sided colonic cancer. Patients received either three cycles of mFOLFOX6 repeated every 2 weeks or two cycles of CAPOX repeated every 3 weeks. Elective surgery was performed 2 weeks after completion of chemotherapy by experienced colorectal surgeons.
19202|NCT04039347|Drug|Liposomal Cyclosporine A 5 mg|delivered via the PARI eFlow® device
19203|NCT04039347|Drug|Liposomal Cyclosporine A 10 mg|delivered via the PARI eFlow® device
19204|NCT04039334|Other|Conventional Chest Physiotherapy|Conventional chest physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), teaching of respiratory control, relaxing and coughing techniques.
19205|NCT04039334|Other|Creative Dance Based Exercise Training|Creative dance based exercise training will be given under the supervision of a physiotherapist who takes creative dance instructor training 2 days and 60 minutes per week.
19206|NCT04039321|Drug|ESPB group|USG probe will be placed in a longitudinal parasagittal orientation 3 cm lateral to T7 spinous process. The erector spinae muscles will be identified hyperechoic transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 21-gauge 10-cm needle was inserted using an in-plane superior-to-inferior approach or an outplane approach. Following confirmation of the correct position of the needle with 5 ml normal saline, a dose of 20 ml %0.25 bupivacaine will be administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine). Standard pain follow up and monitorization will be performed.
19207|NCT04039321|Drug|Control group|The patients in this group will be performed no block. Standard pain follow up and monitorization will be performed.
19208|NCT04039295|Procedure|ultrasound guided caudal epidural block|dynamic ultrasound imaging of the spread of local anesthetics
19209|NCT04039282|Device|myfood24|online website for dietary analysis
19210|NCT04039269|Other|Preoperative video information|
19211|NCT04039256|Device|percutaneous ventricular restoration using heartech® device|Patients who are confirmed suitability by imaging analysis, receive heartech® left ventricular partitioning device implantation.
19212|NCT04039243|Behavioral|Being Brave|Up to 12 weekly sessions
19213|NCT04039243|Other|Parent Education|Parents receive educational materials about helping children overcome shyness and fear
19214|NCT04039230|Drug|Talazoparib|Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
19215|NCT04039230|Drug|Sacituzumab Govitecan|Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
19216|NCT04039217|Drug|Biktarvy|Participants will be given 2 doses of the oral fixed dose combination anti-HIV medication Biktarvy (TAF/FTC/BIC) separated by 24 hours
19217|NCT04039204|Drug|Elagolix|This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET
19218|NCT04039191|Behavioral|SMS education|Patients will receive additional educational SMS messages post-operatively
19219|NCT04039191|Behavioral|SMS survey|Patients will receive survey questions about post-operative pain and opioid use but no education
19220|NCT04039178|Device|BQ|The BQ device (BrainQ Technologies Ltd., Israel), a Brain Computer Interface based stimulation device, uses machine learning tools to identify high resolution spectral patterns associated with motor functions in EEG measurements of healthy/non healthy subjects. These patterns are then translated into a tailored frequency dependent low intensity, non-invasive electro-magnetic treatment protocol.
19221|NCT04039178|Device|Sham|Sham BQ device
19222|NCT04039165|Behavioral|PP-MI Intervention|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
19223|NCT04039152|Other|Clinical pharmacists recommendations to optimize antibiotics use|Optimal dosing, drug bug mismatch
19224|NCT04039139|Behavioral|Mind Body Intervention 1|Mind body techniques for Intervention 1 will be taught in lectures and group discussion sessions.
19225|NCT04039139|Behavioral|Mind Body Intervention 2|Mind body techniques for Intervention 2 will be taught in lectures and group and/or individual sessions.
19226|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE-TETRACYCLINE COMBINATION|Pleurodesis is the obliteration of the pleural cavity by inducing adhesions of the visceral and parietal pleural layers, mostly used in patients with pleural effusions, pneumothorax (18). The use of pleurodesis to induce pleural symphysis between the pleural layers dates backs to the beginning of the 20th century by Benthune(19) and has continued to evolve with different Thoracic surgeons and researchers still looking for the ideal pleurodesis agent.
19227|NCT04039126|Drug|CHEMICAL PLEURODESIS WITH POVIDONE-IODINE ALONE|20mls of 10% povidone-iodine (Wosan Solution Povidone-Iodine Usp 10%, Jawa International Limited) is mixed with 10mls of 1% xylocaine and 30mls of water for injection added to the mixture, making also a total volume of 60mls of the the single pleurodesis agents alone, which will be instilled into the pleural space via the closed thoracotomy tube.
19228|NCT04039113|Biological|Tezepelumab|Tezepelumab subcutaneous injection
19229|NCT04039113|Other|Placebo|Placebo subcutaneous injection
19230|NCT04039100|Other|Family Caregiver Ambassador Support|Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
19231|NCT04039087|Drug|Sildenafil 40mg oral capsule|40 mg, sildenafil capsule taken by mouth thrice daily
19232|NCT04039087|Drug|Placebo Oral capsule|Placebo capsule taken by mouth thrice daily
19233|NCT04039074|Behavioral|Integrative Yoga|"A 12-week Integrative Yoga intervention which has meditative and psycho-educational components corresponding to traditional yoga practice."
19234|NCT04039074|Behavioral|Iyengar Yoga|A 12-week established, predominantly body-oriented yoga intervention (Iyengar yoga).
19235|NCT04039074|Behavioral|Education with progressive muscle relaxation|A 12-week conventional psycho-education involving progressive muscle relaxation.
19236|NCT04039048|Device|cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
19237|NCT04039048|Device|Sham cerebellar transcranial direct current stimulation|Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
19238|NCT04039048|Other|Balance training|Balance training will be performed through the Biodex Balance System for 20 minutes.
19239|NCT04039022|Drug|AXS-05|Oral tablets, taken twice daily for up to 12 months.
19288|NCT04038606|Other|Determination of acceptance and / or rejection of mastectomy|Blood exams,Participants completed a questionnaire translated in French language : Rosenberg,SF-36, QLQC30, Big Five Inventory,BPI-SF.:-)
19240|NCT04039009|Diagnostic Test|Pelvic Organ Prolapse Quantification system|The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
19241|NCT04038970|Biological|KN019, 5mg/kg|Solution, intravenous, 5 mg/kg
19242|NCT04038970|Biological|KN019, 10 mg/kg|Solution, intravenous, 10 mg/kg
19243|NCT04038970|Biological|Placebo|Solution, intravenous, Placebo
19244|NCT04038970|Combination Product|Methotrexate|Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition
19245|NCT04038957|Drug|SEP-363856|SEP-363856 50mg, 75mg flexable dosing, dosed once daily capsule
19246|NCT04038931|Other|Liver biopsy collection|Liver biopsy collection to Confirm suitability of T1DM, total or partial pancreatectomy patient's liver cells to be used as future personalized cell replacement therapy.
19247|NCT04038918|Other|progressive muscle relaxation exercise|In addition to standard postoperative rehabilitation, intervention group will receive PMR exercises focusing on reduce overall body tension, anxiety. The intervention group will perform the PMR exercise in accompanying with a qualified physiotherapist for postoperative 3 days (2 times/day; along 30 minutes for one session).
19248|NCT04038918|Other|standard postoperative physiotherapy program|After surgery, patients will receive standard postoperative rehabilitation program including active-assistive and active range of motion exercises, isometric and isotonic strengthening exercises, gait training and transfer training.
19249|NCT04038892|Other|Conventional Chest Physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
19250|NCT04038892|Other|Nintendo Wii Fit Based Exercise Training|Nintendo Wii Fit based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (yoga games; deep breathing and half moon etc.), aerobic exercises for 30 minutes (aerobic games; Twisting and Squat, Step Plus, Jogging Plus and Hula Hoop etc.) and cooling exercises in 5 minutes (yoga games; deep breathing and half moon etc.).
19251|NCT04038892|Other|BreathingLabs Breathing Games Based Exercise Training|BreathingLabs Breathing Games based exercise training will be given under the supervision of a physiotherapist. The one session will be included: warm-up exercises for 5 minutes (respiratory control exerice and coughing techniques), breathing games exercises for 30 minutes (breathing games; Kite, Balloon, Pluto, Butterflies and Plane etc.) and cooling exercises in 5 minutes (respiratory control exerice and coughing techniques).
19252|NCT04038879|Diagnostic Test|MRI|MRI of the heart
19253|NCT04038866|Other|rehabilitation gait with dual task|
19254|NCT04038866|Other|rehabilitation gait without dual task|
19255|NCT04038853|Drug|1,25-Dihydroxyvitamin D|1,25-dihydroxy-vitamin D3 1000 IU orally daily for 12 months
19256|NCT04038853|Drug|Placebo|Placebo identical to the study intervention drug
19257|NCT04038840|Drug|[11C]UCB-J radiotracer|I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
19258|NCT04038840|Device|PET-MR|Positron emission tomography and magnetic resonance imaging, with a scan duration of up to 120 minutes
19259|NCT04038827|Diagnostic Test|D-CEC counting|By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted
19260|NCT04038814|Procedure|Routine prevention of VAP|Enhanced hand hygiene protocol, tube cuff pressure monitoring ( set on 25-30 mm Hg) every 12 hours and every time when we suspected under or over distention, fast withdrawal of sedation, moderate supportive mechanical ventilation ( tidal volume (VT) 5-8 ml/kg ideal body weight (IBW), positive end expiratory pressure (PEEP) 3-5 cmH2O, Plateau pressure (Ppl) < 25 cm H2O, normocapnia ), Proton Pump Inhibitors (PPIs) reduction, Selective oral decontamination (SOD) every 8 hours - 0,2% chlorhexidine digluconate mouthwash, Closed Tracheal Suction System (CTSS) - changed every 7 day, 30-45% lifting of the thorax
19261|NCT04038814|Procedure|Modified prevention of VAP|"3 modifications of the routine bundle in the prevention of VAP:~Endotracheal tube ( Shiley Evac Endotracheal tube with TaperGuard Cuff) and tracheostomy tubes (Tracheostomy Tube Cuffed Seal Guard) instead of regular tubes,~Automatic, continuous tube cuff pressure monitoring ( Covidien Shiley M Pressure Control Automatic Cuff Controller ( 25-30 mmHg),~Automatic continuous subglottic secretion drainage"
19262|NCT04038801|Procedure|Quadrant-wise scaling and root planning (Q-SRP)|Quadrant-wise scaling and root planing were performed by assortment of manuel periodontal curettes over four visits at 1-weekly intervals.
19263|NCT04038801|Procedure|Full-mouth ultrasonic debridement (FMUD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts in two visits of the same day.
19264|NCT04038801|Procedure|Full-mouth disinfection (FMD)|Subgingival debridement were performed by a piezoceramic ultrasonic inserts and an intensive regime of chlorhexidine in two visits of the same day.
19265|NCT04038788|Device|HD hf-tRNS|See detail in arm/group descriptions regarding the intervention.
19266|NCT04038775|Behavioral|Volunteering|Subjects recommended volunteer by their provider.
19267|NCT04038762|Procedure|cuff deflation-inflation -deflation method|Nasotracheal intubation placed with video-laryngoscopy assistance, via the tracheal tube cuff inflation-deflation method with or without the aid of Magill forceps
19268|NCT04038749|Drug|Bromocriptine|Bromocriptine - on the first day of treatment (1,25 mg) with morning and evening meal and then 2,5 mg dose twice a day for two weeks (14 days)
19269|NCT04038749|Drug|Cabergoline|Cabergoline - one dose (1 mg) on the first day after childbirth or 0.25 mg dose every 12 hours for 2 days
19270|NCT04038749|Other|Natural methods|milk expression, cold compress, cabbage leaf compresses, mild painkiller- e.g. ibuprofen, supportive bra, sage tea.
19284|NCT04038645|Other|Control group (Placebo)|Patients will receive the LED at the same points recommended for the experimental group, but will be off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of the application of the laser. The questionnaire to assess the impact of treatment on quality of life will be applied at baseline and after 8 days as well as the evaluation of serum CRP.
19289|NCT04038593|Other|Youtube© relaxation music|Use of non standardized relaxation music with Youtube© during cares
19290|NCT04038593|Device|MUSIC CARE© intervention|Use of MUSIC CARE© during cares
19271|NCT04038736|Device|C-Scan System|During C-Scan procedure the subject swallows the C-Scan cap. The capsule travels painlessly through the gastrointestinal tract, seeking polyps, the precursors of colorectal cancer. It is essential to increase the stool's contrast by ingesting radio-opaque material. During the passage of the capsule in the gastrointestinal tract, it transmits information to a recorder attached to the back. In order to collect data about the instantaneous localization of the capsule traveling in the colon additional sensors are embedded in the recorder on the back side. After the capsule is expelled, the data from the recorder is downloaded to an acquisition workstation. Later, the data is transferred to a processing workstation where dedicated software visualizes and analyses the data.
19272|NCT04038723|Behavioral|High-intensity interval training|Cardiac patients have completed 36 times of exercise training with the exercise frequency of 2-3 times per week. Subjects performed five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak after the warm-up period. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak.
19273|NCT04038710|Drug|Triple combination therapy|Triple combination is compromised of the drugs ivacaftor, tezacaftor and Vertex's next generation modulator.
19274|NCT04038697|Procedure|Ischemic Conditioning|Ischemic conditioning is a well-defined, non-invasive procedure which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 225 mmHg to occlude blood flow to the limb for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. In our study, participants assigned to the IC Only and IC + Treadmill Training groups will undergo twelve sessions of ischemic conditioning over a four-week period.
19275|NCT04038697|Procedure|Ischemic Conditioning Sham|Ischemic conditioning sham consists of the same setup as ischemic conditioning, which consists of inflating a blood pressure cuff around a limb (in our study, the paretic leg), inflating the cuff to 10 mmHg for 5 minutes, releasing the cuff for 5 minutes, and repeating 5 times. 10 mmHg is a sufficient inflation pressure for study participants to perceive some cuff tightness, but is not high enough to occlude blood flow. In our study, participants assigned to the IC Sham + Treadmill Training groups will undergo twelve sessions of ischemic conditioning sham over a four-week period.
19276|NCT04038697|Procedure|Treadmill Training|Participants will perform 3 treadmill training sessions/week for a 4 week period (12 sessions total). Treadmill training will immediately follow IC or IC Sham. Personnel performing the treadmill training will be blinded to the IC treatment group. Subjects will walk on a treadmill for six, 5-minute intervals. Walking speed will be continuously adjusted to maintain heart rate between 50% and 60% of age-adjusted heart rate reserve to minimize the confounder of intensity. If individuals cannot walk at 80% of their overground self-selected walking speed, for 5 minutes, they will be assisted into a body weight support harness. Body weight support will be adjusted (up to 50%) such that individuals can walk at 80% of their over ground walking speed for five minutes and adjusted accordingly throughout the session. Participants assigned to the Treadmill + IC and Treadmill + IC Sham groups will receive Treadmill Training.
19277|NCT04038684|Behavioral|Mindfulness-Based Weight Control (MBWC)|Mindfulness-Based Weight Control will be administered over 16 group-based sessions with weekly home practice (mindfulness exercises, dietary self-monitoring, physical activity). Sessions will include Standard Behavioral Weight Control (SBWC) and mindfulness components. SBWC components include: 1) a dietary plan based on a balanced, reduced caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g. self-monitoring, goal setting, stimulus control); and 4) minimal parent involvement (i.e., 3 parent sessions). Participants will be taught core mindfulness exercises (e.g. breath-awareness, body scan, mindful eating) while focusing attention on the present moment and non-judgmentally acknowledging thoughts, emotions, or sensations. Participants will learn informal mindful strategies for daily living, which are designed to increase awareness of pleasant and unpleasant emotions and the relation to habitual behaviors (e.g. emotional eating).
19278|NCT04038684|Behavioral|Standard Behavioral Weight Control (SBWC)|Standard Behavioral Weight Control will be administered over 16 group-based sessions with weekly home activities (dietary self-monitoring, physical activity). Group sessions will include SBWC component, including: 1) a balanced, reduced caloric deficit diet; 2) incrementally increasing physical activity; 3) behavioral components (e.g., self-monitoring, goal setting, stimulus control, motivation, problem-solving, etc.); and 4) minimal parent involvement (i.e., 3 parent sessions).
19279|NCT04038671|Device|Activated Carbon Cloth Dressing|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
19280|NCT04038671|Device|Knitted Cellulose Acetate Mesh|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
19281|NCT04038671|Device|Antimicrobial Alginate Dressing with Silver|Patients will return for weekly follow-up evaluations the first four weeks following surgery and then will return for a final evaluation eight weeks postoperatively. Incision dressings will be changed by the investigator or the investigator's nursing staff at each weekly visit to assess for incision closure and post-surgical wound complications.
19282|NCT04038658|Behavioral|Move-It|
19283|NCT04038645|Other|Experimental group (laser)|"The patients will receive infrared LEDs in 6 points using a mask developed for the research . The irradiations will be performed with red LED ( wavelength = 660 nm) with output power of 100 milliwatt. During application of the LED both patient and operator will wear goggles.~The red diode laser will be used. The power of the device is 100 mW and the wavelength used was 660nm (± 10nm). The diameter of the fiber optic of the apparatus has 600 μm, therefore a spot (area) of 0.002826cm2. The energy delivered per point is 1 Joule. 10 seconds of application is required. As 6 points are irradiated, the total energy delivered is 6 Joules. The energy density is 354 J / cm2 and the power density would be 35.4 W / cm2. The points will be determined by the same operator, obeying the protocol."
19285|NCT04038632|Other|Decentralization of Childhood TB Diagnosis|The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels
19286|NCT04038619|Procedure|Fecal Microbiota Transplantation|Undergo FMT via colonoscopy
19292|NCT04038580|Device|Socket-less Socket|The Socket-less Socket (MartinBionics) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
19293|NCT04038580|Device|Infinite Socket|The Infinite Socket (LiM Innovations) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
19294|NCT04038580|Device|CJ Socket|The CJ Socket (CJ Socket Technologies) is one of three commercially available adjustable sockets used in this study that will be fit by a certified prosthetist.
19295|NCT04038567|Behavioral|Mobile mindfulness-based training|The intervention core is a mobile app-based mindfulness training program designed to be used over a 1-month period. All 8 factorial groups will use the app, though the delivery of the app and response to psychological distress symptoms over time will differ by group.
19296|NCT04038554|Diagnostic Test|Feces and saliva analysis|Qualitative and quantitative analysis of the microbiota in the feces and saliva by mRNA sequencing.
19297|NCT04038541|Dietary Supplement|Prebiotics (Prebiotin Prebiotic Fiber Stick Pac)|"Commercially available Prebiotin Prebiotic.~2 packets (Inulin 4000 mg), Twice Daily (Total of 16 g Daily)"
19298|NCT04038541|Dietary Supplement|Probiotics (Visbiome®)|"Commercially available Probiotics Visbiome extra strength, which is a combination of live lactic acid bacteria probiotics that have been cultivated, freeze-dried and mixed in very high concentrations.~2 packets (450 billion CFU), Twice Daily (Total of 3,600 billion Daily)"
19299|NCT04038528|Behavioral|telemonitoring of T2DM|"Baseline record of:~Weight~Height~BMI~Abdominal circumference~Winsor Index~ECG~Retinography~Blood level of (fasting values): total cholesterol, HDL cholesterol, LDL cholesterol, blood sugar, triglycerides, glycated hemoglobin These parameters will be checked again at 3, 6 and 18 months in the two groups.~Telemedicine group (intervention):~Blood sugar (two measurements per week).~Body weight (weekly)~Blood pressure (weekly) Use of devices that allow the automatic upload of data via wi-fi or web is allowed~Control group (control):~Routine appointments scheduled by their GPs and specialists in outpatient clinics to record blood sugar levels as per standard GP or specialist physician's indications.~Blood sugar level is measured in mg/dl in a drop of capillary blood with the use of standard glucose meter"
19300|NCT04038515|Drug|Nicotine 0 mg/mL|E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
19301|NCT04038515|Drug|Nicotine 6 mg/mL|E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
19302|NCT04038515|Drug|Nicotine 12 mg/mL|E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
19303|NCT04038515|Drug|Nicotine 24 mg/mL|E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).
19304|NCT04038515|Other|'Menthol' flavor|E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
19305|NCT04038515|Other|'Menthol/Mint' flavor|E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
19306|NCT04038515|Other|'Green Apple' flavor|E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
19307|NCT04038515|Other|'Watermelon' flavor|E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
19308|NCT04038515|Other|'Unflavored'|E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).
19309|NCT04038502|Drug|Carboplatin|Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.
19310|NCT04038502|Drug|Docetaxel|Chemotherapy FDA approved drug used to treat many types of cancer including: breast, prostate, stomach, head and neck and non-small cell lung cancer.
19311|NCT04038489|Drug|Aspirin|325 mg aspirin daily during AC-T chemotherapy
19312|NCT04038489|Drug|Tamoxifen Pill|Tamoxifen (either 20 mg daily or 10 mg twice a day) during AC-T chemotherapy
19313|NCT04038489|Drug|Doxorubicin|Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
19314|NCT04038489|Drug|Cyclophosphamide|Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
19315|NCT04038489|Drug|Paclitaxel|Paclitaxel 80 mg/m2 or 175 mg/m2 based on provider preference. Given by IV after completion of doxorubicin/cyclophosphamide therapy
19316|NCT04038476|Diagnostic Test|Standard monitoring + transcutaneous CO2 monitoring|The transcutaneous CO2 Monitoring measures the CO2 partial pressure of the skin and in condition of good circulation these values approximate the arterial/venous CO2 partial pressure. The sensor is placed on the forehead. The physician adapts the sedation Management according to the transcutaneous CO2 monitoring.
19317|NCT04038476|Diagnostic Test|Standard monitoring|The transcutaneous CO2-sensor is also positioned on the patients' forehead, but the transcutaneous CO2-monitoring is not available for the physician to adapt the sedative management.
19318|NCT04038463|Behavioral|EFP|This intervention will take place on day 4 of the participants' menstrual cycle. This will correspond to the mid-point of the early follicular phase (EFP).
19319|NCT04038463|Behavioral|LFP|The intervention will take place on day 8 of the participants' menstrual cycle. This will correspond to the mid-point of the late follicular phase (LFP).
19320|NCT04038463|Behavioral|ELP|The intervention will take place on day 18 of the participants' menstrual cycle. This will correspond to the mid-point of the early luteal phase (ELP).
19321|NCT04038463|Behavioral|LLP|The intervention will take place on day 25 of the participants' menstrual cycle. This will correspond to the mid-point of the late luteal phase (LLP).
19322|NCT04038450|Other|No intervention|No interventions separated the groups. Each group reviewed pictures and wrote down their estimated ROM of the joint pictured.
19323|NCT04038437|Drug|CPX-351|CPX-351 will be administered on Days 1 and 3 of each cycle
19324|NCT04038437|Drug|Venetoclax|Venetoclax will be adminstered on Days 2 to 21 of each cycle
19325|NCT04038424|Other|Art therapy|Art therapy including coloring, painting and listening to music
19326|NCT04038411|Drug|PD-1 Antibody, chidamide, lenalidomide and etoposide|PD-1 blocking antibody inhibits PD-1. Chidamide is an histone deacetylase inhibitor. Lenalidomide is a potent inhibitor of TNF-α. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA.
19327|NCT04038398|Procedure|Non-invasive ventilation with different FiO2 settings|CPAP therapy applied with different order of FiO2 settings.
19328|NCT04038385|Behavioral|Multilevel Behavioral Intervention|Behaviorally-focused intervention grounded in the Social Ecological Model and Social Cognitive Theory to promote vegetable intake and the redemption of seasonal Farmers' Market Nutrition Program vouchers and monthly Cash Value Vouchers provided to WIC participants to purchase fruits and vegetables.
19329|NCT04038359|Drug|Duvelisib|PI3K Inhibitor
19330|NCT04038346|Drug|Naproxen|Patients will be randomized to an NSAID (naproxen)
19331|NCT04038346|Drug|Acetaminophen|Patients will be randomized to acetaminophen
19332|NCT04038333|Other|No intervention|This is an observational study without any interventions.
19333|NCT04038320|Drug|Sofosbuvir/ledipasvir (SOF/LDV)|"SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients <75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients."
19334|NCT04038307|Drug|paracetamol|1gm
19335|NCT04038307|Drug|Saline Solution|100ml
19336|NCT04038294|Dietary Supplement|ISOlution protein supplement|EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.
19337|NCT04038294|Dietary Supplement|Placebo Supplement|PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
19338|NCT04038281|Other|Sensory tests|Fat, bitter taste sensitivity and food preference measurement
19339|NCT04038255|Drug|Nicoderm C-Q Transdermal Product|6 weeks of nicotine replacement therapy patches
19340|NCT04038255|Behavioral|Orientation session|This session will occur 2 weeks before quit date. It will be moderated by a certified instructor in MT, and will last approximately 90 min. During the session, participants will learn the purpose, format, and procedures of the study, provide written informed consent, and complete the baseline assessment.
19341|NCT04038255|Behavioral|Craving-to-Quit app|The app is comprised of 22 modules for 22 days, 5-15 minutes each, designed to teach MT using audio, video, and animation. The app also includes other features such as social support (quit friend sign-ups, the tip of the week), activity feed (to track interaction with the app), and my morning stats (to track smoking).
19342|NCT04038255|Behavioral|Two brief follow-up phone calls|The first phone call will occur one day before the quit date to remind participants about their quit date and provide support. The second will occur at the end of treatment (around day 60 after quit date) to review progress, provide support, and schedule the 3-month follow-up visit. Each phone call will last approximately 15 minutes.
19343|NCT04038255|Behavioral|Group MT sessions|Total of eight group sessions (twice a week) during 4 weeks. The overarching theme of momentary awareness and acceptance of cravings and affect (e.g., stress, anxiety etc.) will be introduced and reinforced in complementary ways throughout the training. Each session will last 45-60 minutes.
19344|NCT04038255|Behavioral|Brief advice on quitting smoking|Standard advice on how to quit smoking.
19345|NCT04038255|Behavioral|Self-help smoking cessation materials|Written materials on how to quit smoking including contact info for state tobacco quitline.
19346|NCT04038242|Other|Resilience promotion program|Resilience Promotion Program consists of eight sessions. Except the first orientation session and the last review session, other six sessions focus on cultivating the five internal resiliency factors (physical, behavioral, cognitive, emotional and spiritual). There are two sessions for behavioral factor, including one special to deal with the relationships between parents and children.
19347|NCT04038229|Other|Enhanced recovery pathway|The applied protocol include psychological screening for yellow flags, preoperative gabapentin, peroperative multimodal preemptive management and postoperative holistic evaluation short -and long term
19348|NCT04038216|Procedure|Single-stage surgery|the bone-anchored hearing implant will be inserted in one surgery
19349|NCT04038216|Other|Two-stage surgery|Two-stage surgery has already been performed, data will therefore be retrospectively collected
19350|NCT04038203|Device|Resonance Raman Spectroscopy (RPS)|RRS is a technology that utilizes vibrational spectroscopy, rather than absorbance spectroscopy, to determine the oxyhemoglobin concentration in tissues. Raman measurements for the UAC neonates will be obtained simultaneously on the right AND left lower extremity for 15 minutes daily in the first week of life.
19351|NCT04038190|Behavioral|behavioral activation|Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
19352|NCT04038177|Behavioral|Superset strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by superset strength training two days per week for 12-weeks. Superset 1 are bench-press and seated rows, and superset 2 are leg-press and lateral pulldown. Each superset is performed three times.
19353|NCT04038177|Behavioral|Traditional strength training|Three weeks of familiarization (two times per week) to the exercises leg-press, bench press, lateral pulldown and seated rows, followed by strength training two days per week for 12-weeks. Each exercise is performed for three sets with rest intervals between each set.
19354|NCT04038164|Behavioral|Dog-Assisted Therapy and pharmacological treatment|The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
19453|NCT04037527|Procedure|Surgical Resection|Upon completing neoadjuvant chemotherapy plus radiation therapy, surgical resection will occur.
19355|NCT04038151|Device|Hybrid Leg|The Hybrid Knee uses an actively variable transmission in combination of a passive spring/damper system. This allows the motor torque output to be adapted to the requirements of active dynamic tasks - changing the effective transmission ration from zero (fully passive) for level ground walking to a maximum value (fully active) for sit-to-stand transfers. This provides physiological knee torque and speed with a small motor and primary transmission system while also maximizing electrical efficiency, which minimized battery weight. The knee prototype weights 1.7kg. The Semi-active ankle can actively reposition during non-weight bearing phases of gait and uses a non back driveable transmission to maintain its set point during weight bearing activities.
19356|NCT04038151|Device|Prescribed Passive Prosthesis|Participants will participate in training sessions of community skills and advanced ambulation training for their home, prescribed passive prosthesis.
19357|NCT04038138|Diagnostic Test|Validation of FSHD in French as COA|FSHD Genetically confirmed FSHD1 or clinical diagnosis of FSHD with characteristic findings on clinical examination and an affected parent or offspring
19358|NCT04038125|Drug|Ozurdex Drug Implant Product|Intravitreal Ozurdex injection
19359|NCT04038112|Other|psychological therapy Method of Levels (MOL)|Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
19360|NCT04038099|Drug|Water-Based Vaginal Lubricant|5cc water based jelly applied intraurethral
19361|NCT04038099|Drug|lidocaine topical|5cc 2% lidocaine jelly applied intraurethral
19362|NCT04038086|Diagnostic Test|oral glucose tolerance test|Participants will undergo an 75 gram oral glucose tolerance test. Blood and CSF will be collected in the fasting state before the test and every 30 minutes throughout the test which lasts for 2 hours.
19363|NCT04038086|Other|circadian rhythm|Blood and CSF will be collected five times throughout the day.
19364|NCT04038086|Drug|effect of insulin on peptide transport|Blood and CSF will be collected in the fasting state and 15, 30, 60, 120 und 240 min after administration of 160 U of human insulin as nasal spray.
19365|NCT04038073|Diagnostic Test|Antistreptolysin O Test|Test for the evaluation of any histories of streptococcal infections
19366|NCT04038073|Diagnostic Test|Anti-Deoxyribonuclease B|Test for the evaluation of any histories of streptococcal infections
19367|NCT04038073|Diagnostic Test|TLR, MyD88, IRAK-4 polymorphism|For the evaluation of the frequency and types of genetic alterations of innate immunity
19368|NCT04038060|Behavioral|WhatsApp Group|Participants will receive peer adherence support through WhatsApp groups
19369|NCT04038060|Behavioral|2-way SMS|Participants will receive healthcare worker adherence support through 2-way SMS
19370|NCT04038060|Behavioral|Drug level feedback|Participants will receive adherence counseling based on tenofovir drug levels
19371|NCT04038060|Behavioral|Monthly counseling sessions|Participants will receive monthly counseling on a variety of issues that may be impacting their PrEP adherence
19372|NCT04038034|Dietary Supplement|CoQ10- MINIACTIVES|COQUN oral formulation 100 mg BID
19373|NCT04038034|Dietary Supplement|Placebo|Placebo
19374|NCT04038021|Behavioral|Phosphatidylethanol-based Contingency Management|In CM, tangible reinforcers are provided after individuals demonstrate biochemically verified abstinence of various substances. CM is associated with increased abstinence from illicit drugs, nicotine, and alcohol and is the most powerful psychosocial treatment for initiating abstinence of these substances. When participants submit a negative result for alcohol (via blood phosphatidylethanol biomarkers), the subject will receive rewards (gift cards). In contrast, they will not receive rewards when their samples test positive for alcohol.
19375|NCT04038021|Behavioral|Non-Contingent Control|In the non-contingent control intervention, participants will receive rewards (gift cards) regardless of the alcohol biomarker results in their samples. Once the samples have been received, the subjects will receive reinforcers that is consistent with the average from the CM group's earnings.
19376|NCT04038008|Drug|Fluconazole|Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
19377|NCT04038008|Drug|Diflucan®|Diflucan® is manufactured by Fareva Amboise, France (MAH: PFIZER PHARMA PFE GmbH, Germany). Each hard capsule contains 200 mg of fluconazole.
19378|NCT04037995|Other|No intervation|No intervation
19379|NCT04037982|Procedure|laparoscopic pancreaticoduodenectomy|During laparoscopic surgery, the surgeon makes several smaller incisions in your abdomen and inserts special instruments, including a camera that transmits video to a monitor in the operating room. The surgeon watches the monitor to guide the surgical tools in performing the Whipple procedure. Laparoscopic surgery is a type of minimally invasive surgery.
19380|NCT04037982|Procedure|Open pancreaticoduodenectomy|During an open procedure, your surgeon makes an incision in your abdomen in order to access your pancreas. This is the most common approach and the most studied.
19381|NCT04037969|Device|Nesofilcon A|Hydrogel contact lens for daily wear
19382|NCT04037969|Device|Delefilcon A|Silicone hydrogel contact lens for daily wear
19383|NCT04037956|Procedure|Tubeless NOSES|The whole procedures undergo by total laparoscopic surgery with no specimen extraction incision in the abdominal wall. The specimen then will be removed through natural orifice such (anal).
19384|NCT04037956|Procedure|traditional laparoscopic radical resection|The traditional laparoscopic operation undergo and then a small incision(5-8cm) is made in the middle of the lower abdominal wall to remove the specimen.
19385|NCT04037943|Dietary Supplement|Walnuts 30 grams|Roasted walnuts without salt or sugar.
19386|NCT04037943|Dietary Supplement|Walnuts 60 grams|Roasted walnuts without salt or sugar.
19387|NCT04037930|Behavioral|multiple implant surgery|Patients older than 30 years who will undergo elective dental implant surgery.
19388|NCT04037917|Device|CorNeat EverPatch|Addressing Ophthalmic Tissue Gaps and Weaknesses and for Covering Ophthalmic Implants
19389|NCT04037891|Drug|rVA576|"19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial."
19390|NCT04037891|Other|Placebo|Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
33301|NCT03924921|Other|autogenic training|autogenic training
19391|NCT04037878|Procedure|Transversus Abdominis Plane Block(TAP Block)|Under ultrasound guidance, a 22 gauge stimuplex needle will be used to approach the transversus abdominis plane and 20ml of 0.25% Bupivicaine will be infiltrated into the TAP space. This procedure will be performed on either sides once anesthesia is induced.
19392|NCT04037878|Procedure|Intra-peritoneal infiltration|Before skin closure, the surgeon will infiltrate the peritoneal cavity using a mixture of bupivicaine and epinephrine
19393|NCT04037878|Drug|PCIA Tramadol|All patients will be given patient controlled intravenous analgesia using Tramadol as the drug
19394|NCT04037865|Drug|PF-06651600|PF-06651600 50 mg oral tablets will be administered on Days 1 to 10
19395|NCT04037852|Device|robotic assisted nipple sparing mastectomy|R-NSM, which introduce da Vinci surgical platform through a small extra-mammary axillary or lateral chest wound to perform NSM, had been applied in the surgical treatment of early breast cancer or risk reducing mastectomy. R-NSM, which incorporated 3-dimensional (3D) imaging system and flexibility of robotic arm and instruments, was reported to have the potential to overcome the technique difficulty of E-NSM.
19396|NCT04037852|Procedure|Endoscopic assisted nipple sparing mastectomy|E-NSM, which is performed through small axillary and/or peri-areolar incisions, was reported to be associated with small inconspicuous incision and good cosmetic outcome. Conventional E-NSM was performed with two separate incisions over axilla and peri-areolar regions. E-NSM with areolar incision, just like NSM with areolar related incision (NAC ischemia/necrosis rate: range 7%-81.8%), was associated with increased NAC ischemia/necrosis (reported ranged: 9.1-19%). New technique modifications of E-NSM were emerging focusing on single axillary incision NSM, which spare the peri-areolar incision and thereby decrease the compromise of bloody supply from mastectomy skin flap, was reported to have low NAC necrosis rate (0%).
19397|NCT04037852|Procedure|Conventional nipple sparing mastectomy|Nipple-sparing mastectomy (NSM), which preserved the nipple areolar complex (NAC) and skin flap during mastectomy, was increasingly performed in breast cancer patients due to better cosmetic outcome, higher patient satisfaction, and maintained oncologic safety.
19398|NCT04037839|Other|Questionnaire|"Medical records of children aged 0-18 years who were prescribed a HFNC device at Schneider Children's between 2014-2018 for use in the home setting will be reviewed retrospectively. As part of the telephone consent process, parents will be offered to opt out at the beginning of the interview."
19399|NCT04037826|Dietary Supplement|L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475|L. reuteri Gastrus (L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475) at dose of 2x108 Colony Forming Units (CFU) per tablet. One chewable tablet is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
19400|NCT04037826|Dietary Supplement|Placebo|Placebo
19401|NCT04037813|Procedure|Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx|"For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut."
19402|NCT04037800|Procedure|SFUR-RARP|Robotic-assisted radical prostatectomy with sustainable functional urethral reconstruction (SFUR)
19403|NCT04037800|Procedure|Standard RARP|Robotic-assisted radical prostatectomy without sustainable functional urethral reconstruction (SFUR)
19404|NCT04037787|Procedure|ERAS protocol|In colorectal cancer surgery, the ERAS protocol involves an accurate interview with the patient in the preoperative phase aimed at smoking and alcohol cessation, the reduction of preoperative fasting with administration of oral carbohydrates before surgery, use of intestinal preparation for selected cases only (rectal surgery), the prophylaxis of thromboembolism, a correct antibiotic prophylaxis, the prevention of intraoperative hypothermia, prevention of volume overload, preference for minimally invasive surgery, prevention of postoperative nausea and vomiting, very limited use of the nasogastric tube, early removal of the urinary catheter, multimodal analgesia to minimize opiate consumption, early postoperative mobilization and early post-operative feeding, to promote rapid recovery of gastro-intestinal functions.
19405|NCT04037774|Drug|Dexmedetomidine|comparision of different doses of dexmedetomidine used intrathecally
19406|NCT04037774|Other|placebo|addition of placebo with local anesthetic to create a control group
19407|NCT04037748|Drug|Puran T4®|Participants will receive single oral dose of Puran T4® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2.
19408|NCT04037748|Drug|Eutirox®|Participants will receive single oral dose of Eutirox® 600 mcg tablets (3 tablets of 200 mcg Levothyroxine sodium) in either Treatment Period 1 or 2.
19409|NCT04037735|Device|ATTUNE S+ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE S+ Knee Prosthesis by DePuy
19410|NCT04037735|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
19411|NCT04037722|Dietary Supplement|Whey|45 g whey + 20 g maltodextrin
19412|NCT04037722|Dietary Supplement|3-OHB + Whey|50 g ketone + 45 g whey + 20 g maltodextrin
19413|NCT04037709|Procedure|scaling and root planing (SRP) + PDT placebo|Patientes will receive periodontal treatment (scaling and root planing - SRP) with universal curettes and ultrasound depending on their needs. The SRP will be done in one session. The PDT placebo wil be done using an agent with the same vehicle as that of the methylene blue to mimic irrigation with the photosensitizer; the laser will be switched off at the time of application.
19414|NCT04037709|Procedure|scaling and root planing (SRP) + PDT|patients will receive the same scaling and root planing treatment that placebo group.However the PDT will be done using methylene blue 0.005% .The red laser diode (λ = 660 nm) will be applied with an output power of 100mW . The laser head will be positioned in direct contact with the pseudo periodontal pockets.
19451|NCT04037527|Drug|Docetaxel|Docetaxel will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity (10 mg/m² to 25 mg/m²).
19452|NCT04037527|Radiation|Radiation|Radiation is to be done with standard preop dose of 50 Gy but at lower doses per fraction. Thus 50.4 Gy in 28 FX. Radiation will be given for 5 days (Monday - Friday) every week for approx. 6 weeks.
19652|NCT04035876|Drug|Camrelizumab plus apatinib|Camrelizumab 200mg q2w iv and apatinib 250mg qd po.
19415|NCT04037696|Behavioral|General Health Promotion Approach|"The trained Research assistants will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
19416|NCT04037696|Behavioral|Control|The subjects will be given general brief advice and a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention.
19417|NCT04037683|Drug|Misoprostol Oral Tablet|Misoprostol 25mcg orally given 2-hourly
19418|NCT04037683|Drug|Oxytocin|Oxytocin infusion
19419|NCT04037670|Procedure|SASI bypass|Sleeve gastrectomy with single loop anastomosis between gastric antrum and ileum, 3 meters away from ileocecal junction
19420|NCT04037657|Drug|HSK3486|HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).
19421|NCT04037657|Drug|Propofol|Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.
19422|NCT04037644|Procedure|Fluid loading with Albumin|Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
19423|NCT04037644|Procedure|Fluid loading with Ringer Lactate|Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
19424|NCT04037631|Device|AT LISA tri 839MP|Implantation of AT LISA tri 839MP intraocular lens in one eye
19425|NCT04037618|Drug|[14C]-EYP001a|Oral drinking suspension
19426|NCT04037605|Drug|Ketoconazole Pill (also known as nizoral)|Ketoconazole pill is taken 4 times per inpatient visit
19427|NCT04037605|Drug|Ganirelix|Ganirelix subcutaneous injection is administered twice per inpatient visit
19428|NCT04037605|Drug|Dexamethasone Pill|Dexamethasone pills is taken twice per inpatient visit
19429|NCT04037605|Drug|Dexamethasone injection|Dexamethasone IV injection is given twice per inpatient visit
19430|NCT04037605|Drug|Cosyntropin Injectable Product|Cosyntropin injection is given twice per inpatient visit
19431|NCT04037605|Drug|Recombinant Human Luteinizing Hormone (also known as luveris)|Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit
19432|NCT04037605|Drug|Hydrocortisone Injection (also known as solu-cortef)|Hydrocortisone IV push is given twice per inpatient visit
19433|NCT04037605|Drug|Gonadorelin (also known as Lutrepulse)|Gonadorelin IV injection is given twice per inpatient visit
19434|NCT04037605|Drug|Corticorelin (also known as Acthrel)|Corticorelin IV injection is given twice per inpatient visit
19435|NCT04037605|Drug|Placebo oral tablet|Placebo for Ketoconazole are given 4 times per inpatient visit
19436|NCT04037605|Drug|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
19437|NCT04037605|Drug|Saline solution for injection|Saline Solution (placebo) for ganirelix subcutaneous injection
19438|NCT04037592|Device|Active standardized iTBS-DMPFC|Participants in the standardized dosage(600 pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
19439|NCT04037592|Device|Active high-dosage iTBS-DMPFC|Participants in the standardized dosage(1800pulse) of intermittent TBS(iTBS) active stimulation group will receive 3-week three-pulse 50-Hz bursts administered every 200 milliseconds (at 5 Hz) at an intensity of 80% active motor threshold (MT) to bilateral DMPF, twice a day. Bilateral side DMPFC will be targeted by MRI-neuronavigation system. Stimulation will be delivered to the DMPFC using a Magstim stimulator.
19440|NCT04037592|Device|Sham standardized iTBS-DMPFC or high-dosage iTBS-DMPFC|Half of the patients in the sham group received 3-week the same standardized iTBS parameter stimulation (standardized sham-iTBS), and the other half received the same high dosage iTBS parameter stimulation using a sham coil (high dosage sham-rTMS), which also improved the blinding process
19441|NCT04037579|Other|Survey|Non-randomised survey
19442|NCT04037566|Genetic|XYF19 CAR-T cell|Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1 administered by IV injection.
19443|NCT04037566|Drug|Cyclophosphamide|A cytotoxic chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
19444|NCT04037566|Drug|Fludarabine|A chemotherapy agent used for lymphodepletion prior to XYF19 CAR-T cells.
19445|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
19446|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
19447|NCT04037553|Other|Intracuff pressure measurement|Intracuff pressure values were monitorized and noted before and after head and neck positions and during the surgeries at 15th, 30th, 60th and 90th minutes at related positions and just before extubation at neutral position.
19448|NCT04037540|Procedure|Operational approach|Operational approach was used to treat the Jones fracture in patients randomized into the respective study arm.
19449|NCT04037540|Procedure|Conservative approach|Conservative approach was used to treat the Jones fracture in patients randomized into the respective study arm.
19450|NCT04037527|Drug|Gemcitabine|Gemcitabine will be administered on day 1 of each one-week cycle for 6 cycles concurrently with radiation to the extremity on a 3+3 escalating dose (100 mg/m² to 300 mg/m²)
19454|NCT04037527|Other|Blood draws|Before treatment, blood (about 2 tubes of 10 mls each) to better understand some aspects of participants' immune system before chemotherapy.
19455|NCT04037514|Drug|Paracetamol|Intravenous paracetamol 15 mg/kg/6h
19456|NCT04037514|Drug|Ibuprofen|Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
19457|NCT04037501|Other|Care Management|A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
19458|NCT04037488|Diagnostic Test|Inbody 320|Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
19459|NCT04037475|Device|photodynamic therapy herpes labialis|Patients will receive Photodynamic Therapy (PDT), irradiations will be performed with the Laser Duo® red laser diode (MMOptics, São Carlos, SP, Brazil) with a wavelength of 660 nm, with a power of 100 mW, the energy density of 300 J / cm², with energy of 3 J in the center of the lesion for 30 seconds. The laser will be positioned in direct contact with the lesion, perpendicular, applied centrally to each isolated lesion that presents with fixed energy per point of 3J. Wash in abundance with saline solution until the removal of the photosensitizer is complete. All treatment proposed in group 1 (simulation of PDT + delivery of aciclovir cream) in each patient will be concluded in a single session. Treatment for group 2 (PDT + placebo cream) will also be completed in a single session. All possible adverse effects will be noted and qualified during the treatment protocol and maintenance period (3/3 months) using the questionnaire developed for this protocol.
19460|NCT04037462|Drug|Dexamthasone|escalating doses of pretreatment dexamethasone in patients who have failed initial immunotherapy to 1. assess changes in FLT PET uptake 2. assess overall response rates of pretreatment dexamethasone (dose from 1) on subsequent immunotherapy re-challenge
19461|NCT04037449|Procedure|TAP block|With the patient placed in the supine position, after asepsis of the skin with chlorhexidine, bilateral TAP blockage will be carried out under ultrasound control. We will use a high frequency linear transducer (12-15 MHz) on one side of the abdominal wall, at the level of the mid-axillary line, between the costal margin and the iliac crest. At this level we can identify three muscle layers, from superficial to deep: external oblique muscle, internal oblique muscle and transverse muscle of the abdomen. We will move the transducer more laterally to locate the most posterior border of the internal oblique and transverse muscles. It is at this level that we perform the posterior TAP blockade: we administer 10 ml of 2% Mepivacaine plus 10 ml of 0.5% Bupivacaine between the fasciae of the internal oblique muscle and the transverse muscle of the abdomen and observe an appropriate diffusion pattern of local anesthetics
19462|NCT04037449|Other|Conventional analgesia|"Intravenous dexketoprofen 50 mg / 8 hours, alternate with intravenous paracetamol 1g / 8 hours. If allergy to Nonsteroidal anti-inflammatory drugs (NSAIDs) or in case of renal failure: Intravenous metamizol 2g / 8 hours alternate with intravenous paracetamol 1g / 8 hours.~Rescue Analgesia: intravenous morphine (2 mg every 15 minutes until VAS less or equal to 3)"
19463|NCT04037436|Other|Strength and Balance Training & Nutrition Education|Exercise:A kinesiologist-led twice-weekly program. Prior to attending the program, each attendee gets a 1:1 session with the kinesiologist to decide exercise starting levels. Group exercises start with a warm-up stepping game. Participants then perform 2 sets of 8 repetitions of each exercise, gradually progressing to an intensity of 3-8 repetitions maximum. Exercises include one each of a push, pull, squat, reach/press, lunge/step-up, lift and carry movement. After, there is a 10-minute group discussion to prompt making exercise routine at home. Nutrition:Two dietitian-led interactive group seminars to promote strategies to increase protein intake and sampling of protein-rich snacks and protein supplements. Seminar topics consider the cost to prepare high protein foods, the ability of retirement home residents to alter diet, how and why to spread protein intake through the day, how much protein is in their usual choices, and easy-to-consume protein-rich snacks.
19464|NCT04037436|Other|Usual Care|During periods when a site is not involved in the MoveSTroNg program, participants will continue with their usual care routine. Usual care routines should not involve strength and balance exercises.
19465|NCT04037397|Drug|Anti Arrhythmics|Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
19466|NCT04037397|Procedure|Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation|Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
19467|NCT04037384|Behavioral|Eye yoga|Eye yoga exercises at home given by a trained instructor
19468|NCT04037384|Behavioral|Passive Reading|Passive reading at home
19469|NCT04037371|Other|Cold exposure|Participants were tested for white fat thermogenic activity against their environmental temperature exposure
19470|NCT04037358|Drug|Radium-223|Radium-223 plus SABR will be within two weeks.
19471|NCT04037358|Radiation|stereotactic ablative radiotherapy (SABR)|SABR 1-5 fractions
19472|NCT04037345|Biological|SMUP-IA-01(low-dose)|A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10^6 cells/2mL)
19473|NCT04037345|Biological|SMUP-IA-01(mid-dose)|A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10^7 cells/2mL)
19474|NCT04037345|Biological|SMUP-IA-01(high-dose)|A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10^7 cells/2mL)
19475|NCT04037332|Other|Blood sample (combined with malaria RDT) followed by gentoyping analysis|Finger-prick blood samples collected from children with signs of severe febrile illness and a positive mRDT presenting to community-based providers and referral facilities ; analysis for mutations in portions of a P. falciparum gene encoding kelch (K13)-propeller domain
19476|NCT04037319|Diagnostic Test|24 Hour Holter Monitor|24 hour holter monitor to be performed pre-operatively, and at day 30 and 90 post-operatively.
19477|NCT04037306|Behavioral|Butyrate Feedback|Measure concentrations of stool butyrate by gas chromatography, returned to participants in summary report.
19478|NCT04037306|Behavioral|Fiber Feedback|Estimated fiber consumption from menu records of weight loss facility.
19479|NCT04037293|Diagnostic Test|CIMT and baPWV measurement|All patients will receive carotid intima media thickness (CIMT) and brachial-ankle pulse wave velocity (baPWV) measurement at baseline and 5-year follow-up.
19480|NCT04037280|Other|Exercise|Four type of exercises will be delivered to patients. These exercises differ for posology and typology.
19481|NCT04037267|Procedure|endoscopic intraventricular evacuation surgery|According to the discussion between the patient and the doctor, the patient signed the consent form and voluntarily enrolled and subsequently the patient was included in the endoscopic intraventricular evacuation surgery group.
19482|NCT04037254|Biological|Gonadotrophin Releasing Hormone|Receive standard of care GnRH agonist androgen suppression therapy
19483|NCT04037254|Radiation|Intensity-Modulated Radiation Therapy|Undergo standard of care IMRT
19484|NCT04037254|Drug|Niraparib|Given PO
19485|NCT04037241|Biological|Anti-CEA CAR-T cells|Doses will be delivered by hepatic arterial infusions using a pressure enabled drug delivery (PEDD) device
19486|NCT04037241|Drug|gemcitabine/nab paclitaxel|systemic chemotherapy regimen
19487|NCT04037241|Drug|NLIR+FU/FA|systemic chemotherapy regimen
19488|NCT04037241|Drug|Capecitabine|systemic chemotherapy regimen
19489|NCT04037228|Device|KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California)|The KneeAlign 2 system (OrthAlign Inc, Aliso Viejo, California) is an accelerometer-based, portable navigation device for TKA that attempts to combine the alignment accuracy of large-console CAS systems, with the ease of use and convenience of conventional alignment methods. It is used to perform the proximal tibial and distal femoral resections in TKA. It consists of a disposable display console (2 × 4 × 2 inches in size) and a reference sensor, both of which are used for the tibial and femoral resections The display console and reference sensor each contains triaxial accelerometers that communicate wirelessly with one another. Briefly, the tibial jig has 2 primary components (a fixed component and a mobile component) connected by a proximal articulation .The fixed component, with the attached reference sensor, is first pinned to the tibia. The purpose of the fixed component is to account for the movement of the tibia during cutting block alignment.
19491|NCT04037202|Other|Foot massage|Foot massage includes classical massage techniques such as effleurage, petrissage and friction techniques. Effleurage is the movement of stroking and lubricating superficial tissues. Therefore, it is performed at the beginning and ending of the massage. Petrissage is the slow and rhythmic movement to apply direct pressure to the soft tissue underlying the skin with the balls of the fingers and thumbs. Friction is the application of pressure through small circular movements only in small areas, using hand or fingers. While muscle tissue is compressed and relaxed, blood and lymph circulation increases. Thus, lactic acid in the muscle fibers is diminished and fatigue and stress are decreased.
19492|NCT04037176|Drug|Omalizumab|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
19493|NCT04037176|Other|Placebo|Subcutaneous administration every 2. week or every 4. week. Dose is depending of the patients weight and IgE
19494|NCT04037163|Diagnostic Test|Fractional flow reserve, Coronary CT angiography|Coronary CT angiography was performed as part of routine clinical practice for patients with suspected coronary artery disease and the decision to perform coronary CT angiography before invasive angiography was at the judgment of the physicians in charge.
19495|NCT04037150|Diagnostic Test|Circulating tumor DNA|Circulating tumor DNA
19496|NCT04037137|Other|Questionnaire|Caregiver Difficulties Scale, Impact on Family Scale, WHOQOL-BREF Quality of Life Assessment, Nottingham Health Profile, Fatigue Severity Scale, Beck Depression Scale
19497|NCT04037124|Procedure|Cervical procedure|simple hysterectomy, radical hysterectomy or fertility sparing surgery
19498|NCT04037111|Device|Transcutaneous electrical vagus nerve stimulation|The patient received active VNS and escitalopram oxalate tablets for 2 months.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
19499|NCT04037111|Device|Sham vagus nerve stimulation|The patient received sham VNS.When the VNS was stimulated, the two electrodes were vertically attached to the left carotid sinus at 2cm, or the auricular clip electrode was applied to the tragus.
19500|NCT04037111|Drug|drug treatment|Escitalopram oxalate tablets should be taken orally once every morning for 2 months, each time 10-20mg
19501|NCT04037098|Dietary Supplement|Magnesium lactate.|2 tablets orally every 12 hours (equivalent to 360 mg of elemental magnesium) for 3 months
19502|NCT04037098|Dietary Supplement|Placebo|2 tablets orally every 12 hours of on inert placebo for three months
19503|NCT04037085|Drug|Ketamine|Subjects in the intervention arm will receive bolus and infusion dosing as noted in arm/group descriptions at the time of cord clamping. Duration of infusion will be 12 hours. Breastmilk, maternal serum and urine, side effects, adverse events, and efficacy endpoints will be measured over the 12 hour infusion and over 15 hours after infusion discontinuation.
19504|NCT04037072|Drug|Mitomycin C|Topical application of Mytomycin C (MMC)
19505|NCT04037072|Other|Control|Topical application of Normal Saline
19506|NCT04037046|Behavioral|Screening HCV attached onto CCR screening|Patients assigned to this strategy will receive an invitation letter for HCV screening with DBS and CCR screening with FOT at the primary care center to be performed by the general practitioner
19507|NCT04037046|Behavioral|Screening HCV attached onto CCR screening by self-testing|Patients assigned to this strategy will receive an invitation letter for self-testing for HCV screening with DBS, and CCR screening with FOT
19508|NCT04037046|Behavioral|Screening HCV at primary care center|DBS for HCV screening at primary care center
19534|NCT04036825|Dietary Supplement|Liquid Nutritional Supplement from Hospital Product|Liquid Nutritional Supplement from Hospital Product is given 2 times daily for 14 days
19679|NCT04035616|Dietary Supplement|microbial cell preparation [MCP]|active microbial cell preparation
19509|NCT04037033|Behavioral|Everyday Meaningful Activities (EMA) intervention|"The EMA intervention will include 6 intervention sessions. At session 1, the interventionist and participant will identify 2 meaningful active lifestyle behavior goals using COPM. Last, an action plan will be created for behavior 1. Participants will be asked to implement the action plan everyday.~At session 2, the interventionist and participants will review the daily activity log and the action plan.~At session 3, the interventionist and the participants will review the daily activity log and the action plan.~At session 4, an action plan will be created for behavior 2. Participants will be asked to implement the action plan for behavior 2 everyday.~At session 5, the participants and interventionists will discuss the participant's daily activity log and action plan.~At session 6, the participants and interventionists will discuss the participant's daily activity log and action plan."
19510|NCT04037020|Other|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (extreme dark (90%), dark (70%), milk (38%), and white (0%)).
19511|NCT04037007|Procedure|Fistulotomy - High experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
19512|NCT04037007|Procedure|Fistulotomy - Low experienced.|We will perform a duodenoscopy, once located next to the papilla, we will perform precut fistulotomy on the papillary infundibulum with a needle knife with EBRE, EndoCut I, Effect 2, until biliary fluid exit is seen or the biliary duct is noted, then we will access to the biliary tree to complete de procedure.
19513|NCT04037007|Procedure|Conventional (guidewire) cannulation- High experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
19514|NCT04037007|Procedure|Conventional (guidewire) cannulation - Low experienced|We will perform a duodenoscopy, once located next to the papilla, we will perform cannulation with sphincterotome and hydrophilic tipped guidewire aided by fluoroscopy, once the guidewire reaches de common bile duct (seen on fluoroscopy) we will continue with the procedure according to the patient's indication.
19515|NCT04036994|Device|Photobiomodulation therapy|All patients will undergo photobiomodulation therapy sessions twice-weekly for the total duration of 12 weeks starting at their last CT administration.
19516|NCT04036994|Device|Sham photobiomodulation therapy|All patients will undergo placebo photobiomodulation therapy sessions twice-weekly for the total duration of 12 weeks starting at their last CT administration.
19517|NCT04036981|Drug|Botulinum toxin type A|Injection of botulinum toxin A into the spastic elbow flexor muscle or muscles
19518|NCT04036968|Drug|Within-subject test of blinded study medications|This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (sugar pill). This study will use a within-subject design, and all participants will serve as participants' own control. Study medication administration will be randomized within each participant.
19519|NCT04036955|Other|INFOSA-DEM|Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
19520|NCT04036942|Procedure|Ablation of the gastroesophageal junction with hybrid argon plasma|In the management group with argon plasma hybrid after marking 270 degrees of the esophagogastric junction, submucosal elevation and argon plasma burn of the marked and elevated area is performed.
19521|NCT04036942|Procedure|mucosectomy with band of the gastroesophageal junction|In the management group with mucosectomy after marking 270 degrees of the esophagogastric junction, a submucosal elevation of the marked area is performed to subsequently perform ligation and resection with a hot snare below the ligation area.
19522|NCT04036929|Drug|Estrogen-bazedoxifene|Conjugated estrogens 0.45 mg-bazedoxifene acetate 20 mg.
19523|NCT04036929|Drug|Placebo oral tablet|Placebo oral tablet
19524|NCT04036916|Other|Virtual Reality Sensorimotor Training|Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
19525|NCT04036903|Radiation|computed tomography|thoracic CT examinations for diagnosis, and/or follow-up.
19526|NCT04036890|Drug|2% minocycline hydrochloride controlled-delivery system (MHS)|The test product is a highly viscous gel for local subgingival placement composing of an ointment containing micro-capsule type particles for sustained release and the active ingredient 2% minocycline gel (10mg in each syringe of 0.5g) (Periocline, SUNSTAR, Osaka, Japan). The other ingredients include magnesium chloride, hydroxyl-ethylcellulose, aminoalkylmethacrylaye copolymer, triacetin and concentrated glycerine, giving the preparation a sustained-released property. It will be applied to experimental teeth and the adjacent teeth by gently inserting the tip of a specially designed applicator until the paste flows over the gingival margin.
19527|NCT04036890|Drug|Placebos|It is the same gel as MHS but without active ingredient minocycline hydrochloride.
19528|NCT04036877|Other|Mood Disorder Assessment|Assess depression, anxiety, HRQOL, and financial toxicity in both bladder cancer patients and their caregivers via telephone survey
19529|NCT04036851|Behavioral|Peer support intervention|Peer support groups will meet monthly for the duration of follow-up, with separate groups for pregnant and postpartum women. Groups will be facilitated by women who are living with HIV and have experience of PMTCT services in this setting. Group sessions will include brief information and a structured discussion about a relevant topic, followed by opportunities for unstructured discussion.
19530|NCT04036838|Combination Product|PyloPlus UBT System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of enriched carbon 13 urea.
19531|NCT04036838|Diagnostic Test|Histology|Biopsy specimen fixed with 10% buffered formalin were cut into 4mm sections, stained with Giemsa stain, and examined by experienced pathologist
19532|NCT04036838|Diagnostic Test|Rapid Urease Test|Biopsy specimen obtained and placed onto Rapid Urease Test
19533|NCT04036838|Diagnostic Test|H.pylori Culture|Biopsy specimen obtained and sent to lab for culture analysis
19535|NCT04036825|Dietary Supplement|Placebo|Standard nutritional supplement is given 2 times daily as placebo for 14 days
19536|NCT04036812|Procedure|Superficial cervical plexus block|superficial cervical plexus nerve block will be performed under the guidance of ultrasound
19537|NCT04036812|Other|Control group|ultrasound guidance will be used to determine the location of superficial cervical plexus nerve. The puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed without infusion.
19538|NCT04036786|Behavioral|study group|We prepared a preeclampsia education booklet in accordance with the literature,The content of the booklet was guided by the opinion of experts. It was written in easily understandable language and contained attractive and colorful illustrations. This booklet contents were definition and risk factors for the development of preeclampsia, maternal and fetal damages, recommendations for preventing its development (diet, rest, study, exercise, coping with stress techniques), follow-up of symptoms at home (blood pressure, weight and edema follow-up, counting fetal movements), danger signs, drug use, follow up in hospital, risk of developing in subsequent pregnancies, and its results. Pregnant women in the study group were given education and counseling at four times in addition to standard care, using the preeclampsia education booklet, in a special place. The participants' questions were answered, and each received a copy of the booklet.
19539|NCT04036786|Behavioral|standard care|standard pregnancy follow up
19540|NCT04036773|Dietary Supplement|Fruit and vegetable deliveries|Weekly home deliveries of approximately 15 pounds of fresh fruits & vegetables
19541|NCT04036760|Behavioral|Research transitional care coordination|Though care coordination was offered to all HCV positive inmates who are approached,the care coordination will still constitute a research intervention that requires informed consent, rather than a new uniform standard of care, to allow maximum autonomy for this incarcerated population.
19542|NCT04036734|Diagnostic Test|Longitudinal|Longitudinal orientation of ultrasound to long axis of vein to guide access needle
19543|NCT04036734|Diagnostic Test|Transverse|Transverse orientation of ultrasound to long axis of vein to guide access needle
19544|NCT04036721|Drug|Prolonged glucocorticosteroid (prednisone) regimen|Prolongation of maintenance therapy with prednisone of patients with pneumonitis inducted by anyi-PD-1/anti-PD-L1 antibodies.
19545|NCT04036721|Drug|Short glucocorticosteroid (prednisone) regimen|Prednison regimen based upon American Society of Clinical Oncology and European Society for Medical Oncology Clinical Practice Guidelines on pneumonitis treatment in patients receiving immunotherapy agents
19546|NCT04036708|Behavioral|Wetting method (WTM)|The wetting method is an evidence-based, simple process to remove cyanogens from cassava flour. It involves teaching women to add water to cassava flour and allow it to stand for 2 h in the sun or 5 h in the shade for the hydrogen cyanide gas to escape. Colorfully illustrated and durable laminated posters depicting the WTM will be distributed to participating households. Women will receive this training bi-weekly for 12 months
19547|NCT04036708|Behavioral|Mediational Intervention for Sensitizing Caregivers (MISC)|The study team will use MISC to train DRC mothers in practical day-to-day activities with their children to enhance 5 key mediational processes: 1) focusing (getting the child's attention and engaging directing them to learning experiences); 2) exciting (communicating excitement, appreciation, and affection with the learning experience); 3) expanding (making the child aware of how the learning experience transcends the present situation and can include past and future issues beyond the immediate need of the moment); 4) encouraging (emotional support to foster the child's sense of security and competence); and 5) regulating (helping to direct the child's behavior in constructive ways with a goal towards self-regulation).
19548|NCT04036695|Device|Reveal LINQ device|a small implantable cardiac monitor (Reveal LINQ device) will be inserted under local anaesthetic in an outpatient procedure. The Reveal LINQ device is composed of two electrodes and is used to continuously monitor electric activity temporally. It can detect arrhythmic episode and record up to 27 minutes of electrocardiographic (ECG) activity. This device is capable of continuous monitoring of patient's ECG activity for up to three years and will be utilized in this study to obtain initial information on the timing and nature of the arrhythmia suffered by hemodialysis patients leading to SCD.
19549|NCT04036682|Drug|CLN-081|CLN-081 tablets
19550|NCT04036656|Drug|SYHA136 0.5 mg|oral tablet
19551|NCT04036656|Drug|SYHA136 1 mg|oral tablet
19552|NCT04036656|Drug|SYHA136 2.5 mg|oral tablet
19553|NCT04036656|Drug|SYHA136 5 mg|oral tablet
19554|NCT04036656|Drug|SYHA136 10 mg|oral tablet
19555|NCT04036656|Drug|SYHA136 20 mg|oral tablet
19556|NCT04036656|Drug|SYHA136 35 mg|oral tablet
19557|NCT04036656|Drug|SYHA136 50 mg|oral tablet
19558|NCT04036656|Drug|Placebo matching SYHA136 0.5 mg|oral tablet
19559|NCT04036656|Drug|Placebo matching SYHA136 1 mg|oral tablet
19560|NCT04036656|Drug|Placebo matching SYHA136 2.5 mg|oral tablet
19561|NCT04036656|Drug|Placebo matching SYHA136 5 mg|oral tablet
19562|NCT04036656|Drug|Placebo matching SYHA136 10 mg|oral tablet
19563|NCT04036656|Drug|Placebo matching SYHA136 20 mg|oral tablet
19564|NCT04036656|Drug|Placebo matching SYHA136 35 mg|oral tablet
19565|NCT04036656|Drug|Placebo matching SYHA136 50 mg|oral tablet
19566|NCT04036643|Radiation|PET-MRI|Hybrid PET / MRI machine for simultaneous acquisition of functional and molecular information of different natures coupled with the high anatomical resolution of MRI.
19567|NCT04036630|Device|Transcranial alternating current stimulation (tACS)|"The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.~The aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.~TACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)~The arm will be compared to the tACS sham stimulation condition."
19629|NCT04036097|Other|infection diary (MS-AWIS diary)|MS patients prospectively fill out monthly infection diaries for 24 months. Infection diaries will either be sent back (with pre-franked envelopes) or handed back to the InRIMS-study team during regular clinical visits (usually every 6 or 12 months).
19680|NCT04035616|Other|placebo|inactive ingredient
34667|NCT03913559|Drug|Cytarabine|Intrathecal (IT) therapy
19568|NCT04036630|Device|Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)|"TMS is a technique where a transient magnetic field (or pulse) is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.~MEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple."
19569|NCT04036617|Drug|NaQuinate|SAD cohorts will receive 1 dose between 10-150 mg. MAD cohorts will receive 7 days dosing between 70-150mg
19570|NCT04036617|Drug|Placebo|SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
19571|NCT04036604|Other|Exercise|"Pelvic floor exercise programme include repetition of pelvic floor muscle contraction during twice a week for 8 weeks performed by an expert pelvic health physiotherapist.~Pelvic floor education programme include pelvic floor anatomy, information about pelvic floor dysfunction and behavioral changes."
19572|NCT04036591|Diagnostic Test|Acute Bronchiolitis Severity Scale (ABSS)|All infants will be assessed using the Acute Bronchiolitis Severity Scale (ABSS) before and after being treated by experienced physiotherapists using the prolonged slow expiration technique and provoqued cough. Before the application of these techniques a retrograde rhinopharyngeal unclogging will be performed in order to clean the nasopharynx.
19573|NCT04036578|Device|A 12-week PFMT bio-assisted surface electromyographic program|
19574|NCT04036565|Behavioral|sunlight therapy|Exposed to sunlight for at least 30 minutes per day, at least 14 days of exposure duration of 4 weeks.
19575|NCT04036539|Procedure|Placement of the mini-implant and verticalization|an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
19576|NCT04036526|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
19577|NCT04036526|Other|Placebo|Placebo
19578|NCT04036513|Procedure|MINST|"For reducing the need of surgical treatment in patients with chronic periodontal disease, we will use specifically designed Hu-Friedy curettes mini five, micro mini five and after five together with piezoelectric device with thin and delicate tips that produce less periodontal trauma than usual Gracey curettes."
19579|NCT04036513|Procedure|Conventional SRP|Scaling and root planing with conventional instruments.
19580|NCT04036500|Drug|Estradiol Tablets|Patients will be given estradiol: 1 mg oral or 1 mg sublingual.
19581|NCT04036487|Drug|Desflurane|Anesthesia is maintained by desflurane in an oxygen air mixture of 60/40%. If inadequate depth of anesthesia is observed, the end-expiratory concentration of desflurane would be increased.
19582|NCT04036487|Drug|Propofol|Anesthesia is maintained by propofol 100-200 μg/kg/min. If inadequate depth of anesthesia is observed, the rate of propofol infusion would be increased.
19583|NCT04036474|Other|Smoking Prevention Education Program|"The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness."
19584|NCT04036461|Drug|CC-99712|CC-99712
19585|NCT04036448|Drug|REVLIMID®|REVLIMID®
19586|NCT04036435|Drug|BMS-986165|Participants will receive BMS-986165 in tablet form
19587|NCT04036422|Device|Rejoyce (Rehabilitation Joystick for Computerized Exercise)|Rejoyce (Rehabilitation Joystick for Computerized Exercise), is a computer game based task specific exercise system developed by Rehabtronics Inc. for use as part of the treatment of stroke and spinal cord injury patients. Rejoyce aims to improve upper extremity and hand function by encouraging neuroplasticity through repeated task specific games.
19588|NCT04036422|Other|Conventional physical therapy|A physical therapy session customised to the patient's needs overseen by a physical medicine and rehabilitation specialist and conducted by a physiotherapist which includes range of motion, neurophysiological and strengthening exercises, balance and coordination training and walking exercises.
19589|NCT04036422|Other|Occupational therapy|Task based exercises overseen by a physical medicine and rehabilitation specialist and conducted by an occupational therapist aimed at improving upper arm dexterity, coordination and strength.
19590|NCT04036409|Drug|Intensive Control of Systolic Blood Pressure (SBP)|Participants in the Intensive arm have a goal of SBP <120 mm Hg. Use of angiotensin converting enzyme (ACE)-inhibitors/Angiotension receptor blockers (ARBs), Thiazide-type diuretics, calcium channel blockers (CCB), Sustained-release calcium channel blockers (CCBs) will be encouraged.
19591|NCT04036409|Drug|Standard control of Systolic Blood Pressure (SBP)|he same medications used in the Intensive BP arm will be used for the Standard BP arm.
19592|NCT04036396|Behavioral|Mobile Enhanced Prevention Support|Access to the newly developed GeoPassport App, incentives for accessing identified services, and a trained Peer Mentor.
19593|NCT04036396|Behavioral|Substance Treatment And Re-entry Transition program|Client-centered needs assessment and prioritization, customized referrals, and substance abuse focused transitional case management.
19594|NCT04036383|Other|vestibular exercise training|The home exercise program consists of vestibulookular reflex stimulating exercises, lower extremity somatosensory system training, static and dynamic balance exercises
19595|NCT04036383|Other|Balance training with computerized balance system|Thanks to the receivers under the Neurocom balance master platform, the data of the center of gravity is transferred to the system and visual feedback is provided. Qualitative information reflects progression during static and dynamic postural exercises of the patient. To correct the load distribution, it is necessary to move the cursor to the specified targets in the exercises. The degree of difficulty of training can be increased by increasing the distance between the targets, reducing the time required to reach the targets, changing foot positions or adding upper extremity activity.
19596|NCT04036383|Other|square step exercises|Elderly individuals in the square step exercise group will perform step exercises on 2.5x1.0 m thin cushions divided into 40 equal parts. Square step exercises include exercises that include anterior, posterior, lateral and diagonal directions of increasing difficulty. The order of the training program is at four different levels and is organized according to small, basic, regular and advanced levels.
19597|NCT04036370|Procedure|PECS group|Pecs block performed using ultrasound guidance. Standard pain follow up and monitorization will be performed.
19598|NCT04036370|Other|Control group|Standard pain follow up and monitorization will be performed.
19599|NCT04036344|Behavioral|Peer Mentorship Program|Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
19600|NCT04036331|Behavioral|Brenner FIT Standard|After referral, families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and physical activity specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, physical activity, and parenting. Specialized visits with the physical activity specialist or dietician are scheduled as pertinent issues arise. Clinic visits include individualized goal setting (for behaviors family/clinician have agreed to address), healthy eating and physical activity education, and behavioral counseling to implement changes at home.
19601|NCT04036331|Behavioral|By Design Essentials|A dietitian provides each participant with a detailed program manual that describes the prescribed diet. The dietitian utilizes standard behavioral techniques to promote lifestyle behavior changes that enable participants to implement and maintain behaviors necessary to adhere to the dietary prescription. Participants also receive a standard exercise program designed to promote exercise energy expenditure of approximately 600 kilocalories*/week. The exercise prescription includes resistance training for 2 days per week and aerobic training for 3 days per week, to meet a 600 kilocalories*/week expenditure goal. Behaviorists meet with participants to provide individual and group-based counseling to learn the skills necessary to adopt the prescribed dietary pattern and exercise plans. Group sessions will be delivered consecutively over 6 months (20 total; 1.5 hours each).
19602|NCT04036331|Behavioral|Dyad Plus|"This will include all components of the standard Brenner FIT program and By Design Essentials.~In addition, group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. Dyads will attend 6 meetings that will last approximately 1 hour each."
19603|NCT04036305|Drug|0.9% Sodium Chloride Injection|All participants will be injected subcutaneously with a single 0.5ml dose
19604|NCT04036305|Drug|Lidocaine Injection 2%|All participants will be injected subcutaneously with a single 0.5ml dose
19605|NCT04036305|Drug|Bupivacaine Injection 0.5%|All participants will be injected subcutaneously with a single 0.5ml dose
19606|NCT04036292|Drug|OC-01|OC-01
19607|NCT04036292|Drug|Placebos|Placebo
19608|NCT04036279|Procedure|Total Hip Arthroplasty|
19609|NCT04036266|Procedure|medial open wedge high tibial osteotomy|opening of medial aspects of the proximal tibial metaphysis and change the coronal alignment of the tibia in order to shift the center of force passing axially through the knee from the arthritic region of the knee towards the unaffected side then fixation with a plate (the standard plate is the T-locked plate )
19610|NCT04036253|Biological|Erythropoietin alfa|Prefilled syringes of erythropoietin
19611|NCT04036240|Other|Finger feeding|After discharge, subjects will be given HMF supplementation by finger feeding method using finger feeder
19612|NCT04036227|Drug|GS-248|GS-248 oral solution
19613|NCT04036227|Drug|Placebo|Placebo oral solution with the same composition to match active drug
19614|NCT04036214|Device|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty Laser
19615|NCT04036201|Drug|Bupivacaine|peribulbar block
19616|NCT04036188|Drug|Triamcinolone|Triamcinolone 0.1% daily
19617|NCT04036188|Dietary Supplement|Vitamin D3|40,000 IU Vitamin D3 daily
19618|NCT04036188|Drug|Placebo|Placebo daily
19619|NCT04036175|Device|High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen|Device High Flow Nasal Oxygen: gas flow of 50L:Min and FiO2 adjusted to obtain SpO2>= 92% Device NIV: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cmH2O and FiO2 adjusted for SpO2>= 92%
19620|NCT04036162|Behavioral|Cognitive tasks|MagnetoEncephaloGraphy (MEG) records
19621|NCT04036149|Device|Intraocular lens|Implantation as part of cataract surgery
19622|NCT04036136|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
19623|NCT04036136|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
19624|NCT04036123|Other|Urodynamic investigation|Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
19625|NCT04036110|Dietary Supplement|Vitamin C 500 mg|500 mg tablet taken orally with one meal daily
19626|NCT04036110|Dietary Supplement|Vitamin C 1000 mg|1000 mg tablet taken orally with one meal daily
19627|NCT04036110|Other|Placebo|1 tablet taken orally with one meal daily
19628|NCT04036097|Other|MS-adapted AWIS questionnaire (MS-AWIS)|The predefined questionnaire-based infection score of the Airway Infection Susceptibility (AWIS) study is predictive for the occurrence of respiratory tract infections (RTI). In addition several MS-specific items (e.g. bladder dysfunction and urinary tract infections) are included into the AWIS questionnaire (MS-AWIS).
19630|NCT04036084|Diagnostic Test|Cerebral Magnetic resonance imaging (MRI)|Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Inclusion Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Month 1 Cerebral Magnetic resonance imaging (MRI) 3 Tesla at Year 1
19631|NCT04036071|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using the SL-PLUS™ MIA cement free hip stem
19632|NCT04036058|Other|Universal gloving|The intervention will consist of all healthcare workers (nurses, providers, respiratory therapists, radiology and laboratory technicians, etc) utilizing universal gloving (non-sterile gloves) for all patient contacts in the units that are randomized to receive the intervention. If a patient in the intervention unit is known to have CDI or a multidrug-resistant organisms, both gowns and gloves will be used as is currently recommended. Signage denoting what type of precautions are needed will be utilized.
19633|NCT04036045|Other|Cardiac MRI|Patients will have a cardiac MRI at four time points during the study
19634|NCT04036045|Other|Echocardiogram|Patients will have an echocardiogram at four time points during the study
19635|NCT04036045|Other|Blood Draw|Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.
19636|NCT04036032|Other|Exercise program|Encourage to work out 4 to 5 times a week for 3 months. Patient chooses what exercise they would like to do. At YMCA visit for fitness assessments they provide exercise support
19637|NCT04036019|Biological|CD20-directed CAR-T cells|Autologous 2nd generation CD20-directed CAR-T cells, single infusion intravenously
19638|NCT04036006|Behavioral|Group-Based Program|The Group-based Program uses an ecologically valid setting in which participants exercise, prepare foods, and eat together to facilitate the emergence of old habits and replace them with healthy alternatives. The intervention team consists of a health psychologist, registered dietitian, and health coach. They co-facilitate group meetings for 15 participants that are held weekly for 3 months, bi-weekly for 3 months, and then monthly in participant-led maintenance meetings. Each session includes: weigh-in and physical activity (20 min), cooking demonstration (20 min), and a shared vegetable dish with discussion (50 min). The maintenance phase (months 7 to 24 post randomization) consists of support and health-related topics of the participants' own choosing. Progress reports with lab results are sent to participants and primary care physicians.
19639|NCT04036006|Behavioral|Self-Directed Program|The Self-Directed lifestyle program represents enhanced usual care based upon what is currently offered in primary care in the United States for lifestyle treatments for adults with metabolic syndrome. Usual care is enhanced by: 1) lifestyle education for management of metabolic syndrome provided in evidence-based tip sheets from nationally recognized organizations; 2) provision of a Fitbit for self-monitoring physical activity; 3) access to a website containing all education materials; and 4) progress report letters with lab results sent to participants and primary care physicians after completion of each assessment.
19640|NCT04035993|Other|Controlled hypoglycaemic state while driving with a driving simulator|"Patients will arrive in the morning after an overnight fast. During the controlled hypoglycaemic state, participants will drive on a designated circuit using a driving simulator. Initially, euglycemic state (5.0 mmol/L) will be kept stable and then blood glucose will be declined progressively targeting at a level of 2.5mmol/L by administering an insulin bolus. Glucose will be kept stable at 2.5 mmol/L for 30 minutes. Thereafter, glucose will be raised again and kept stable for another 30 minutes at the starting level of 5.0mmol/L. During the procedure, the investigators will analyse counterregulatory hormones. Heart rate, skin conductance, CGM values, eye movement and facial expression, will be recorded by a smart-watch, a CGM device, An eye-tracker and an onboard camera, respectively.~Participants will be blinded to the glucose values during the procedure. They will have to rate their symptoms and their performance on a 0-6 scale every 15 minutes."
19641|NCT04035980|Behavioral|Telemedicine based healthcare programme|Two-way videoconference to evaluate the need of screening with DBS, disease stage evaluation and treatment of HCV RNA positive patients at drug addiction centers
19642|NCT04035967|Other|Questionnaire|Impact on Family Scale (IPFAM), WeeFIM Pediatric Functional Independence Measurement, Nottingham Health Profile. State-Trait Anxiety Inven¬tory (STAI-I and STAI-II), PEDI (Pediatric Evaulation of Disability Inventory)
19643|NCT04035954|Other|exercise|The control group will continue the routine NDT: Neurodevelopmental Therapy-based physiotherapy program twice a week. The treatment group will participate in clinical pilates exercises for 2 hours / day for 1 hour / 8 weeks. They will also continue their weekly routine physiotherapy programs.
19644|NCT04035941|Behavioral|Cycle Nation Multicomponent Intervention|"This intervention group will receive 4 elements:~Practical skills programme: a workplace-based programme covering basic cycling skills, delivered by trained 'cycle champions' - HSBC staff members.~Cycle provision scheme: participants will have the opportunity to have their own bicycles serviced or obtain a loaned bike or e-bike from local bike shops before the start of the programme.~Cycle-friendly workplace culture: all offices taking part will have a minimum of secure bike parking facilities as part of an ongoing roll-out of cycle infrastructure across HSBC UK offices.~Our Cycle Hub app: an adapted version of an existing HSBC app including route planning, goal setting and practical skills videos, as well as supportive social interaction among participants."
19645|NCT04035928|Device|3D digital scanning for maxillofacial prosthetics|The non-invasive Artec Space Spider 3D scanner will be used to image the indicated areas of the patients head and face. In the case of an intraoral defect, the noninvasive TRIOS intraoral 3D scanner will be used. The study may also use nasometry or nasal endoscopy to measure the amount of airflow through the patient's fistula to help guide the design. The software that will be used will create a 3D image of the prosthesis during the patient's clinic appointment. Once a model of the prosthesis is fully designed and manufactured, the patient will return to clinic for a second appointment which may involve fitting and coloring. A subsequent appointment will involve delivery of a successfully fitted and colored prosthesis that the patient will take home.
19646|NCT04035915|Procedure|Limited driving pressure|Keep driving pressure <15 cmH2O
19647|NCT04035915|Procedure|Conventional mechanical ventilation strategies|Keep tidalvolume </= 8
19648|NCT04035902|Drug|Ferric carboxymaltose|Ferric carboxymaltose is administered during surgery
19649|NCT04035902|Drug|control|Ferric carboxymaltose is not administered
19650|NCT04035889|Dietary Supplement|Melatonin|Participants will start with 0.5 mg tablets of melatonin with the option of switching to an 'escalation dose' of 3 mg if no relief after 3 days.
19651|NCT04035889|Dietary Supplement|Placebo|Placebo
19653|NCT04035863|Device|Low level laser therapy|"For the PBM protocol, articles of interest were identified through analyses of titles and abstracts. Articles addressing PBM in experimental models or clinical trials of spinal cord injuries were included and articles not pertinent to the proposed study were excluded. Next, the selected articles were analyzed and used for the creation of an initial protocol (Table 1).~For irradiation, the individuals will be positioned comfortably in lateral decubitus on the examining table. Three points will be irradiated above the lesion level, which will be located using an imaging exam brought by the guardian on the day of the evaluation. After determining the lesion level, palpation of the transverse processes of the vertebrae will be performed. The same laser device (Laser DMC Therapy EC) will be used for both groups. For the placebo group, the device will emit sound but not light."
19654|NCT04035850|Drug|Vortioxetine Tablets|Strength 5-20 mg
19655|NCT04035837|Drug|pegylated interferon-alfa|All the patients in this study will receive pegylated interferon for all course.
19656|NCT04035824|Drug|Gastrodia and Uncaria granule|Patients allocated to the intervention group take 10g of Gastrodia and Uncaria granule each time, twice per day, and for two months.
19657|NCT04035824|Drug|Placebo of Gastrodia and Uncaria granule|Patients allocated to the control group take 10g of placebo of Gastrodia and Uncaria granule each time, twice per day, and for two months. The placebo has similar appearance and smell to genuine drug but has no effective anti-hypertensive agents.
19658|NCT04035798|Drug|Memantine or placebo|BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
19659|NCT04035785|Drug|Kangfu Anti-inflammatory Suppository|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
19660|NCT04035772|Other|Wiki101 and WikiTrauma|Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
19661|NCT04035759|Behavioral|APPEAL|Three-session, individually administered program, with sessions spaced monthly. Optional weekly contacts with participants to support engagement in program exercises/activities.
19662|NCT04035746|Other|Observation of microcirculation and plasticity of the brain|Assessment of microcirculation, brain plasticity and clinical function
19663|NCT04035733|Biological|rVA576|BP subjects will be treated with 30 mg once daily rVA576 regime for 6 weeks.
19664|NCT04035720|Other|Quantitative risk|Participants will be able to see a square box that represent the estimated risk of disease progression. They will have to elect making a therapeutic decision based on the description of the case-scenario or based on the estimated prediction as represented in the square box.
19665|NCT04035707|Drug|Rocuronium|using rocuronium as a relaxants during general anaesthesia
19666|NCT04035707|Drug|general volatile anaesthesia|method of anaesthesia
19667|NCT04035694|Other|Media Aware Sexual Health - High School|Media Aware is an online media literacy and sexual health education program developed for high school students that addresses the influence of media on sexual behaviors explicitly using established message processing theory. The program consists of 4 self-paced modules each with two to three lessons. Broadly, the modules cover healthy and unhealthy relationships, sexually transmitted infections, consent, substance use, pregnancy, protection and contraception, and communication between adolescents and their partners, parents, or health providers. Users also learn media literacy skills including message deconstruction to help examine the truth behind media messages.
19668|NCT04035681|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.
19669|NCT04035681|Other|Stroke-Related Health Education|The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
19670|NCT04035668|Drug|LOU064|10mg hard gelatin capsules 25mg hard gelatin capsules 50mg hard gelatin capsules
19671|NCT04035668|Drug|Placebo|0mg hard gelatin capsule
19672|NCT04035655|Behavioral|Coma Recovery Scale - revised|"Assessment of the level of consciousness by the dedicated Coma Recovery Scale - Revised, current gold-standard in consciousness level assessment.~Assessment before and after the tDCS session (immediately before and after the electrophysiological assessment, see below)."
19673|NCT04035655|Diagnostic Test|Electrophysiological recordings|"The electrophysiological assessment consisted of:~a 5 minutes resting state high-density EEG recording~a approximately 6 minutes auditory oddball paradigm These two procedures were administered immediately before and after the tDCS session"
19674|NCT04035642|Radiation|IGRT 24 Gy Single dose|Previously untreated patients with prostate cancer will be treated with 24Gy in in one session.
19675|NCT04035642|Procedure|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
19676|NCT04035642|Device|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
19677|NCT04035642|Device|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
19678|NCT04035629|Combination Product|MagniXene, hyperpolarized 129Xe MRI|"All subjects will undergo hyperpolarized 129-Xenon MR imaging (HP MRI) and conventional proton MR imaging of lung. Hyperpolarized 129Xe gas is prepared in a process termed spin-exchange optical pumping.~Xenon is highly lipophilic and therefore soluble in blood and tissue, making it an excellent tool for imaging the gas in both the air spaces (gas-phase imaging) and dissolved in the lung parenchyma (dissolved-phase imaging). This solubility in combination with xenon's chemical shift properties, results in the possibility of quantifying pulmonary gas exchange and gas transport within the parenchyma.~Additionally, previous images and lung function tests will be reviewed to compare findings and evaluate if there is a correlation between the obtained results."
34668|NCT03913559|Drug|Diphenhydramine|1 mg/kg (max 50 mg) IV
19681|NCT04035603|Drug|D-Cycloserine|50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
19682|NCT04035603|Drug|Placebo oral tablet|matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
19683|NCT04035603|Behavioral|Open Phase CBT that preceeds the randomization phase|Four sessions of weekly individual cognitive-behavior therapy (CBT: a form of psychotherapy that treats problems by helping people modify thoughts, behaviors, and emotions; in this case, for the goal of smoking cessation). Session topics include educational (e.g., health risks of smoking, effectiveness of different treatment approaches), motivational enhancement (e.g., identifying personally relevant benefits of quitting, and costs of continuing to smoke), and cognitive-behavioral elements (e.g., identifying smoking triggers, developing coping strategies for these triggers, planning for high risk situations, relapse prevention).
19684|NCT04035603|Drug|Open phase smoking cessation pharmacotherapy that proceeds the randomization phase|Initiating 2 weeks prior to quit date and continuing for 8 weeks after quit date, choice of one of three pharmacological smoking cessation aids: Nicotine Replacement Therapy (nicotine patch), Varenicline, or Bupropion.
19685|NCT04035590|Procedure|No drain|Mastectomy with flap fixation without low vacuum drainage
19686|NCT04035590|Procedure|With drain|Mastectomy with flap fixation with low vacuum drainage
19687|NCT04035577|Behavioral|Mobile self-help intervention|During the trial, participants will use Intellicare apps for up to 8 weeks and will be invited to provide feedback about their experience at two follow-up time points: weeks 4 and 8. All participants will first undergo initial assessments that will include a series of online questionnaires about their mood. Eligible participants will receive up to 8 weeks of access to the IntelliCare system, which consists of apps with a variety of resources, including lessons and tools designed to teach skills for mood management. It is suggested that participants utilize the mobile phone tools every day
19688|NCT04035564|Drug|Sodium < 1mEq/kg/day|Sodium administration enteral and/or parenteral less than 1mEq/kg/day started on day of life 1
19689|NCT04035564|Drug|Sodium 5mEq/kg/day|Sodium administration enteral and/or parenteral 5mEq/kg/day started on day of life 1
19690|NCT04035538|Drug|CKD-320, D012|R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
19691|NCT04035525|Dietary Supplement|MaxSimil® fish oil + CoQ10|"The intervention is a randomized double bold cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
19692|NCT04035525|Dietary Supplement|Rice bran oil + CoQ10|"The intervention is a randomized double bold cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
19693|NCT04035525|Dietary Supplement|CoQ10 as powder form|"The intervention is a randomized double bold cross over design testing the pharmacokinetics of 1) CoQ10 combined with MaxSimil fish oil as a carrier, 2) CoQ10 combined with rice bran oil as a carrier, and 3) CoQ10 as a powder form.~Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants."
19694|NCT04035512|Other|Expressive writing|"The procedure for the writing group will be as follow:~on day 1 the researcher will call the participant at designed time and will provide a brief introduction to the writing task. Participant will be asked to go in a quiet place in their house where they would have no interruptions but can still be close to the phone. Next, participants were given standardized instructions. Then participants will ask to start writing immediately after hanging up the phone and to write for 20 minutes. The researcher will call the participants after 20 minutes. The procedure for the second and third writing days will be identical.~The above method was previously tested by Zakowski et al., 2004."
19695|NCT04035499|Behavioral|GO-EXCAP Mobile App|A mobile app delivery platform and the EXCAP©® exercise program
19696|NCT04035486|Drug|Osimertinib|"Drug: Osimertinib (Oral)~Other Names:~AZD9291"
19697|NCT04035486|Drug|Pemetrexed/Carboplatin|Drug: Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
19698|NCT04035486|Drug|Pemetrexed/Cisplatin|Drug: Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
19699|NCT04035473|Drug|Oraxol|"HM30181 methanesulfonate monohydrate~Oral paclitaxel capsules"
19700|NCT04035460|Device|Helmet|The helmet encloses the head and neck of the patient, has a rigid ring and is secured by 2 armpit braces. A soft collar adheres to the neck and ensures a sealed connection once the helmet is inflated.
19701|NCT04035460|Device|High Flow Nasal Oxygen|Large-bore nasal prongs through which oxygen is delivered at high flow rates
19702|NCT04035447|Behavioral|Behavioral Symptom Management for Young Adult Cancer Survivors|The hybrid intervention will include in-person group sessions along with an integrated mobile application to provide participants with instruction in cognitive and behavioral strategies for managing symptoms (i.e., pain, fatigue, distress). Investigators anticipate that the developed intervention will include 8 face-to-face group sessions (10 therapy hours). Sessions will be delivered using a faded contact approach (i.e., sessions 1-6: weekly, sessions 7-8: biweekly). Participants will receive secure access to a study-specific mobile application that will include: 1) audio and video files and brief text-based educational content reviewing strategies discussed during the groups; 2) the ability to self-monitor symptom severity; 3) the ability to connect with group members via a social networking platform; and 4) activity tracking synchronization.
34669|NCT03913559|Drug|Acetaminophen|10 mg/kg (max 650 mg) PO x 1
19703|NCT04035434|Biological|CTX110|CTX110 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
19704|NCT04035408|Other|Skin health assessment|Assess and measure the natural history of facial skin changes in pre and perimenopausal women undergoing chemotherapy and/or endocrine therapy for breast cancer
19705|NCT04035395|Other|Peer-led Support Group|The Viviendo Saludable pláticas (or talks) connected Salud y Vida participants living with diabetes together. These talks served as a forum for Salud y Vida participants to share their knowledge and experiences, including some that many health workers, friends, or family do not have. Viviendo Saludable helped participants develop better strategies for managing their diabetes in their daily life. The Viviendo Saludable pláticas complement and enhance the other services by helping participants create a network of emotional, social, and practical support needed to manage diabetes and stay healthy over the long term. Classes met once a week for one hour at locations central to participants' homes.
19706|NCT04035395|Other|Behavioral Health Consult|In a Behavioral Health consult, a participant meets with a counselor for one or more thorough meetings to talk about things that influence their health and well-being. A participant receiving a Behavioral Health consult receives support and is empowered with health coping skills that will allow for improved medication adherence and motivation to control their diabetes.
19707|NCT04035395|Other|Medication Therapy Management Consult|Medication Therapy Management helps participants and their doctors make sure that their medications are working to improve their health. In a Medication Therapy Management (MTM) consult, a pharmacist gives participants a comprehensive review of all their medications and speaks with them about 1) how well their medications are working, 2) whether their medications have side effects, 3) if there might be interactions between the drugs their taking, 4) whether costs can be lowered and 5) other problems participants are having. The participant will get a written summary of this discussion, including an action plan that recommends what can be done to make the best use of their medications.
19708|NCT04035395|Other|La Cocina Alegre/ The Happy Kitchen|The Happy Kitchen is a program where people come together to learn skills and self-sufficiency in preparing healthy, economical meals, laugh, cook, and enjoy food together. The cooking and nutrition program is an interactive 6-week series of classes, where the essential skills for healthy eating is taught and emphasis is placed on the selection and preparation of fresh, seasonal foods that are nutritious, economical, and delicious. Classes meet once a week for 1 ½ hours to cook, discuss, and learn together. All participants leave each class with recipes and groceries to practice new cooking skills.
19709|NCT04035395|Other|Mind, Exercise, Nutrition, Do it!|MEND is a diet and exercise education program that helps families support their kids, ages 6-13, to reach a healthy weight. The program teaches adults and their children how to maintain energy and confidence throughout the day while learning how to cook healthy meals. Each program lasts 10 weeks and classes are 2 times per week. An adult must attend with the child.
19710|NCT04035382|Procedure|Labor induction|The study intervention is labor induction from 39 0/7 to 39 6/7 weeks. The individual labor induction process will be at the discretion of the physician or midwife managing the subject's care. Methods of induction that may be used include misoprostol, intracervical Foley catheter, oxytocin, and/or amniotomy. Participating clinicians will be encouraged to use only one course of cervical ripening followed by oxytocin infusion and amniotomy.
19711|NCT04035369|Procedure|Tap and Inject (TAI)|"Patients randomized to the TAI group will have a 0.2 mL vitreous specimen collected and a 0.1 mL anterior chamber paracentesis performed to be sent for standard cultures, Gram stain, and sensitivities.~Intravitreal injection of the following antibiotics: Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL (amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy) and an intravitreal injection of dexamethasone 400 mcg/0.1 mL"
19712|NCT04035369|Procedure|Pars Plana Vitrectomy (PPV)|Patients randomized to the PPV group will undergo a three-port PPV. The patient should be added to the OR list as an A-case (maximum 6 hours wait) and no intravitreal injection should be performed prior to the surgery. A 0.1 mL aqueous humor simple immediately before the surgery. A 0.2 mL vitreous specimen will be obtained after the sclerotomies are placed. The PPV procedure should be limited to core vitrectomy, air fluid exchange and intravitreal injections (antibiotics and dexamethasone - Vancomycin 1.0 mg/0.1 mL, ceftazidime 2.25 mg/0.1 mL or amikacin 400 mcg/0.1 mL instead of Ceftazidime if severe penicillin allergy and an intravitreal injection of dexamethasone 400 mcg/0.1 mL). Other tamponades such as silicone oil should be avoided if possible. The PPV will then be completed by the surgeon and the vitreous specimen will be sent for standard cultures, Gram stain, and sensitivities.
19713|NCT04035356|Device|Aortic valve repair|Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
19714|NCT04035343|Behavioral|Face down positioning|See description of the face down positioning group
19715|NCT04035343|Behavioral|Supine positioning|See description of the supine positioning group
19716|NCT04035330|Combination Product|etidronate in sodium hypochlorite|using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
19717|NCT04035330|Combination Product|sodium hypochlorite|irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
19718|NCT04035317|Drug|Aesculus Hippocastanum / Horse Chestnut|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
19719|NCT04035317|Drug|Placebo|Treatment for 4 months, washout of 4 weeks, then crossover for another 4 months.
19720|NCT04035304|Other|Mindfulness Coach|"Mindfulness Coach provides 4 primary treatment components: 1) psychoeducation about PTSD and Mindfulness (e.g., What is Mindfulness?, Why Practice Mindfulness?, Mindfulness for Veterans, Benefits of Mindfulness for PTSD, Practice Challenges with PTSD, and PTSD Symptoms During Practice), 2) self-monitoring tools for tracking mindfulness practice, 3) 9 audio- guided mindfulness exercises (e.g., Mindful Breathing, Body Scan, Clouds in the Sky, etc.), and 4) reminders to regularly practice mindfulness exercises."
19721|NCT04035291|Other|exercise|exercises,play therapy models and positioning, handling and holding principles for babies, daily routins
19722|NCT04035278|Biological|Dengusiil|Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
19755|NCT04035031|Drug|Forxiga 10mg|Forxiga™ 10mg, dapagliflozin 10mg, oral, once daily for 7 days (70 mg total)
19756|NCT04035031|Drug|Placebo|Placebo tablets, starch, oral, once daily for 7 days (7 tablets total)
19723|NCT04035278|Biological|Placebo|Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
19724|NCT04035265|Procedure|Blood test|Carpus and fingers of non-dominating hand MRI with gadolinium contrast
19725|NCT04035252|Diagnostic Test|Carotid artery reactivity test (CAR-test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved. During this test as well the carotid artery as the abdominal aorta will be visualized using ultrasound.
19726|NCT04035239|Device|BGS goggles|BGS goggles use for 3-6 weeks
19727|NCT04035226|Other|No intervention|No intervention will be administered as a part of this study.
19728|NCT04035213|Behavioral|Behavior of Sleep Course|The current study will evaluate whether a semester-long course focused on sleep improves college students' sleep patterns over one semester compared to students completing a similar-level course in the same department (Psychology) at the same university.
19729|NCT04035200|Drug|V117957 tablets|V117957 tablets taken orally at bedtime
19730|NCT04035200|Drug|Placebo|Tablets to match V117957
19731|NCT04035187|Drug|fast itraconazole tablet|100mg dose
19732|NCT04035187|Drug|medium itraconazole tablet|100mg dose
19733|NCT04035187|Drug|slow itraconazole tablet|100mg dose
19734|NCT04035187|Drug|oral itraconazole solution|100mg dose
19735|NCT04035174|Diagnostic Test|LTS-2 DEC patch|After 24 hours, the patch will be removed, and then the reaction of the skin under the device will be assessed : no reaction, weak reaction (< 50% skin surface under the patch), medium reaction (> 50% skin surface under the patch), and important reaction (reaction on all the surface of the skin under the patch).
19736|NCT04035174|Diagnostic Test|Skin snips|Regarding skin snips, a reading will be done at 24 hours after incubation of the skin in saline serum during 24 hours.
19737|NCT04035148|Diagnostic Test|Cardiopulmonary exercise test|we prepared incremental treadmill exercise protocol in which the work rate increased at one-minute intervals.Transthoracic Echocardiography(TTE) : The first step non-invasive method to diagnose PHT.
19738|NCT04035135|Drug|ANX005|investigational drug
19739|NCT04035135|Drug|Intravenous immunoglobulin|investigational drug
19740|NCT04035122|Other|Robotic Treatment|The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.
19741|NCT04035122|Other|Conventional Treatment|The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.
19742|NCT04035109|Drug|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered after nasal allergen challenge.
19743|NCT04035109|Drug|Preservative-free 0.9% sodium chloride (Placebo)|A single subcutaneous injection of sodium chloride (placebo) will be administered after nasal allergen challenge.
19744|NCT04035109|Biological|House dust mite allergen|Standardized house dust mite (Dermatophagoides farinae) allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to house dust mite (determined by skin prick testing) will undergo intranasal challenge with house dust mite allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
19745|NCT04035109|Biological|Cat hair allergen|Standardized cat hair allergen extract (provided by Greer Laboratories, Lenoir, NC). Participants who are sensitized to cat hair (determined by skin prick testing) will undergo intranasal challenge with cat hair allergen extract. All participants will undergo allergen challenge with a single allergen (house dust mite or cat hair).
19746|NCT04035096|Drug|Ascorbic Acid|"Start with IVC (intravenous ascorbic acid) 25 g biweekly, 50 g biweekly, and 75 g biweekly. If the target blood level is below 350mg/dl, the dose will titrate up to 100 g/dose or maximal dose of 1.5g/kg/dose to achieve the target level.~The final dose will be kept for 12 weeks.~Maintenance dose: 75-100g every 2 week will be maintained for additional 12 weeks"
19747|NCT04035096|Other|Control group|"Selection of control group: stage IV colon cancer patients match for sex, age and chemotherapy /target therapy drugs~Usual care"
19748|NCT04035083|Device|Laser activated irrigation|Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
19749|NCT04035083|Device|Passive ultrasonic irrigation|ultrasonic activation inside the canal for 1 min
19750|NCT04035070|Combination Product|co-amoxiclav-clindamycin solution|antibiotic-containing solution will be prepared by mixing equal quantities of 1.2gm Co-amoxiclav solution and 600mg Clindamycin solution at a ratio of 1:1 by volume to be used as a root canal irrigating solution
19751|NCT04035070|Combination Product|MTAD|mixture of 3% doxycycline hyclate, 4.25% citric acid and detergent (Tween 80) to be used as a root canal irrigating solution
19752|NCT04035070|Combination Product|2.5% sodium hypochlorite|It will be prepared by adding 10mL of sterile distilled water to 10mL of 5.25% sodium hypochlorite solution to be used as a root canal irrigating solution
19753|NCT04035057|Other|Behaviorally Enhanced Training|Therapists in the Behaviorally Enhanced Training will receive the same didactic instruction as those in the Standard Didactic Training arm during the first full day of training. In the second half-day training, those in the Behaviorally Enhanced Training arm will focus on behavioral strategies (i.e., exposure to exposure) that provide direct experience with the process of treatment delivery.
19754|NCT04035057|Other|Standard Didactic Training|Therapists in the Standard Didactic Training arm will complete training as usual, consisting of PowerPoint and video training tasks instructing the delivery of exposure therapy for anxious youth.
19757|NCT04035018|Procedure|pharmacopuncture therapy|The participants in the treatment group will be receive one or more pharmacopuncture therapy according to the physician's decision.
19758|NCT04035018|Procedure|Physical therapy|The participants in the control group will be receive one or more physical therapy according to the physician's decision.
19759|NCT04035005|Drug|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, ocrelizumab will be administered as a single 600 mg infusion every 24 weeks, with a minimum interval of 22 weeks between each dose of ocrelizumab.
19760|NCT04035005|Drug|Placebo|The first dose of placebo will be administered as two 300 mg IV infusions given 14 days apart. For the subsequent doses, placebo will be administered as a single 600 mg infusion every 24 weeks, with a minimum interval of 22 weeks between each dose of placebo.
19761|NCT04034979|Behavioral|decision aid|One hour online training about shared-decision making about goals-of-care and best practices regarding goals-of-care discussions and decision-making. One hour debriefing in presence.
19762|NCT04034966|Device|Claria telemedicine device|Use of Claria telemedicine module, which stores patient information in the cloud.
19763|NCT04034953|Diagnostic Test|Faecal Immunochemical Test|Faecal Immunochemical Test detects if there is any hemoglobin presents in stools, so even tiny amount of blood in stool can be found.
19764|NCT04034953|Diagnostic Test|Prostate-Specific Antigen Test|PSA blood test is used to measure the level of PSA in blood. When the PSA level is higher than normal, it may represent prostate cancer or benign prostate hyperplasia. Patient who have high PSA level should receive additional tests.
19765|NCT04034953|Diagnostic Test|Mammogram|Each sides of breast will be taken imaging in 2 different views.The breast will be pressed between 2 plastic plates to flatten and spread the breast tissue for clear imaging.
19766|NCT04034940|Other|Dosing Oxidative stress biomarkers & hFABP in STEMI pPCI patients|Dosing oxidative stress biomarkers and hFABP in STEMI pPCI
19767|NCT04034927|Drug|Olaparib|Given PO
19768|NCT04034927|Biological|Tremelimumab|Given IV
19769|NCT04034914|Other|Questionnaire administration|Ancillary studies
19770|NCT04034901|Device|Monitoring of cardiorespiratory parameters with BORA Band|"The subjects will continuously wear a connected wrist-worn pulse oximeter which will remotely collect the following measurements :~Activity~Step count~Heart rate~Respiratory rate~Skin temperature~SpO2"
19771|NCT04034888|Behavioral|HEX|HEX is a customized exercise program with components including: 1) controlled flexibility movements; 2) progressive ADL training focusing on bed mobility, bed to chair transfers, and indoor walking; 3) task-specific seated resistance training to improve ability to get out of bed and; 4) and balance exercises. Participants will be expected to perform their HEX program at least 2 times/week in their home and all individualized exercise sessions will be supervised by an Exercise Physiologist. Each exercise has four levels of difficulty, which will be progressed as tolerated throughout the 12-weeks. Seated resistance exercises were designed to target all the major muscle groups and will include the following: arm curls, shoulder raises (lateral/front), overhead arm raise, wrist curls, leg extensions, hip flexion, hip ab/adduction, sit-to-stands, torso rotation, and marching.
19772|NCT04034875|Other|Questionnaire|questionnaire
19773|NCT04034862|Drug|Treatment simplification (dolutegravir lamivudine)|Switch from 3 drug regimen (DTG/ABC/3TC) to 2 drug regimen
19774|NCT04034849|Radiation|Photobiomodulation|Photobiomodulation whit Low-Level Laser Therapy
19775|NCT04034849|Radiation|Placebo|Device turned off
19776|NCT04034836|Drug|Scalp blocks with ropivacaine plus parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
19777|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous parecoxib|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) together with 10 mg parecoxib (diluted in 2 mL NS) intravenously. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
19778|NCT04034836|Drug|Scalp blocks with ropivacaine and intravenous saline|Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus saline 2ml with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml. An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
19779|NCT04034823|Biological|KN035|KN035 5 mg/kg s.c. Q3W
19780|NCT04034823|Biological|Trastuzumab|8 mg/kg IV loading followed by 6 mg/kg Q3W IV
19781|NCT04034823|Drug|Docetaxel|100 mg/m2 Q3W IV
20234|NCT04031027|Drug|Apremilast|Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.
19782|NCT04034810|Device|Intracranial aneurysm treated with Silk vista baby|Patients with intracranial aneurysm(s) intended to be treated with the silk vista baby according to standard of care.
19783|NCT04034797|Other|Photography teletransmission|A photography of the trauma is teletransmitted to SAMU's physician
19784|NCT04034797|Other|No photo|Usual management without photography teletransmission
19785|NCT04034784|Device|Discrete(TM)|Following laparoscopic surgery a designated volume of Discrete(TM) (according to cohort) is applied
19786|NCT04034784|Other|Control Lactated Ringer's Solution (Control LRS)|Following laparoscopic surgery a designated volume of LRS (according to cohort and equivalent to volume of Discrete(TM)) is applied
19787|NCT04034771|Drug|Melatonin 10 MG Oral Tablet|Melatonin tablets
19788|NCT04034771|Drug|Propofol|propofol amp
19789|NCT04034771|Drug|Placebo oral tablet|sugar pill manufactured to mimic melatonin tablets
19790|NCT04034758|Procedure|Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)|heterologous fecal microbiota transplantation (FMT) by Standardized Quantitative multi-donor Intestinal Microbiota Capsule (SQIMC-md)
19791|NCT04034758|Procedure|placebo capsule|Oral administration of 30 placebo capsule containing edible pigmented starch
19792|NCT04034745|Drug|telotristat ethyl|250 mg tablets of Xermelo (telotristat ethyl) is administered orally 3x daily in combination with somatostatin analogs (SSAs) for approximately 84 days as per standard of care
19793|NCT04034732|Behavioral|Mindfulness-based Relapses Prevention (MBRP)|"Manualized MBRP program is used with a central theme in each session, with meditation practices and relapse prevention exercises and discussions. Themes include the concept of automatic pilot and its relationship to addiction relapse, recognizing thoughts and emotions in relation to triggers of relapse, integrating mindfulness practices into daily activities, practicing mindfulness in high risk situations and the role of thoughts and emotions in relapse. Include daily homework exercises that consist of awareness exercises directed at increasing non-judgmental awareness of bodily sensations, thoughts and feelings, together with exercises designed to integrate awareness skills into daily life. Include training in mindfulness through body scan, sitting meditation, and mindful stretching exercises, to cultivate awareness during simple stretching movement."
19794|NCT04034732|Behavioral|Usual Care Control|Participants in the UCCG condition will remain in their standard outpatient aftercare provided by the treatment agency with an aim to maintain their abstinence with the help from social workers or other healthcare professionals through different activities, such as topics on life training skills such as rational thinking skills, grief and loss, assertiveness, self esteem, goal setting, effects of drugs on interpersonal relationships and experience. Frequency of their visits to / contacts with healthcare professionals will be recorded.
19795|NCT04034719|Other|portage scarf|Parents will be carried their newborn with the portage scarf provided by the department.
19796|NCT04034719|Other|usual practice|Parents will be carried their newborn as their usual practice.
19797|NCT04034706|Other|DEXA|DEXA Scans will be performed to measure body fat and estimate muscle mass using a General Electric Lunar iDXA whole-body scanner.
19798|NCT04034706|Other|Magnetic Resonance (MR) Assessment of the Abdomen|Include measures to assess liver lipid content and stiffness and perform volumetric fat quantitation.
19799|NCT04034706|Other|MR assessment of Whole Body Fat|Volumetric measurement of fat, muscle and bone
19800|NCT04034706|Procedure|Adipose tissue biopsy|0.5 cm incision of the upper-outer right vastus lateralis, and either a 3-4mm Mercedes Liposuction needle, or a 4-6 mm Bergstrom needle will be inserted to aspirate approximately 7 grams of adipose tissue.
19801|NCT04034706|Other|Oral glucose tolerance test|Glucose tolerance will be assessed with a 75 g oral glucose tolerance test (OGTT). Subjects will be studied after an overnight fast.
19802|NCT04034693|Device|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
19803|NCT04034680|Other|TIME|The intervention of the TIME model includes two hours of lectures about dementia and NPS and three hours of training and roleplay in using TIME. The staff of the home care service will receive the TIME manual and access to the TIME website with access to additional educational materials. From each municipality, three staff members called TIME administrators, will receive additional three hours of lectures and roleplay in TIME, and will thereafter have the responsibility for performing the intervention.
19804|NCT04034680|Other|Education-only intervention|Staff in the home care service in municipalities in the control group will receive thesame two hours lectures about dementia and NPS as the intervention grorp. After the cluster RCT pilot study is ended, municipalities in the control group will receive the same three-hour lessons in the TIME as the intervention group of municipalities.
19805|NCT04034667|Other|No intervention|No intervention
19806|NCT04034654|Other|Questionaire|Child behavior checklist is a questionaire, designed to evaluate 1.5-5 years old child's behavior. The checklist is filled out by parents/caregivers.
19807|NCT04034641|Drug|Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
19836|NCT04034407|Procedure|Damage control surgery|"All patients with clinical and radiological suspicion of colonic perforation and generalized Peritonitis with indication for emergency surgery were included in the study.~Randomisation was performed intraoperatively in all patients after the performing surgeon confirmed a colonic perforation with generalized peritonitis."
19916|NCT04033796|Dietary Supplement|25,000 IU|Vitamin-D3 supplementation providing 25,000 IU administered orally every two months (equivalent to ~400 IU/d);
34670|NCT03913559|Drug|Methylprednisolone|1 mg/kg IV x 1
19808|NCT04034641|Drug|Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy|On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.
19809|NCT04034628|Device|Peritoneal Catheter Insertion - Laparoscopic|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
19810|NCT04034628|Device|Peritoneal Catheter Insertion - Percutaneous|Insertion of a Peritoneal Catheter into the abdomen for the purposes of treating kidney failure
19811|NCT04034615|Biological|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
19812|NCT04034615|Biological|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
19813|NCT04034615|Biological|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
19814|NCT04034602|Other|vibration group|plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 5 minutes.
19815|NCT04034602|Other|placebo group|the placebo group, both sides will be held in the supine position under the soles of the foot for 5 minutes each so that the device is in contact with the foot without vibration.
19816|NCT04034589|Drug|Pyrotinib combined with fulvestrant|Pyrotinib 400 mg once daily; Fulvestrant 500 mg administered on days 0, 14 (plus or minus 3 days), 28 (plus or minus 3 days), and every 28 (plus or minus 3 days) days
19817|NCT04034576|Behavioral|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 24 sessions, while on average every fourth is supervized by an CBT expert therapist.
19818|NCT04034563|Procedure|1) Risk of metachronous advanced neoplasia at 3-year, beyond 3 years surveillance colonoscopy|"3-year group: High-risk subjects who have baseline colonoscopy done in 2014, 2015 and 2016 and will be eligible for 3-year surveillance colonoscopy in 2017-2019.~Beyond 3 years group: High-risk subjects who had screening colonoscopy prior 3 years, but not received or scheduled for a surveillance colonoscopy- either due to non-adherence or limited access to surveillance colonoscopy will be eligible for surveillance colonoscopy in 2017-2019.~For the surveillance interval beyond 3 years group, recruitment will be prioritizing to subjects who had the screening colonoscopy at the earliest date. This will in part ensure that subjects in this group will consist those with the longest surveillance interval, leading to an applicable estimation of the risk of metachronous advanced neoplasia beyond 3 years surveillance interval."
19819|NCT04034550|Other|Blood and urine sampling and blood banking|In routine management, blood and urine will be sampled for each patients and specific analyses carried out. Only blood samples will be banked.
19820|NCT04034537|Diagnostic Test|cPSTA|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal. All enrolled patients will perform cPSTA signal recording.
19821|NCT04034524|Drug|GLP-1 receptor agonist|any GLP-1 receptor agonist (other than Saxenda or liraglutide 3.0mg)
19822|NCT04034524|Drug|Insulin|glargine, detemir, neutral protamine Hagedorn (NPH), degludec
19823|NCT04034511|Other|Medically-tailored meal delivery and medical nutrition therapy|Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months
19824|NCT04034485|Drug|LIB003|PCSK9 inhibitor
19825|NCT04034485|Drug|evolocumab|PCSK9 inhibitor
19826|NCT04034472|Other|Interdisciplinary intervention in obesity|Interdisciplinary weight loss intervention associate to the use of digital technology to treat obesity and related disorders
19827|NCT04034459|Drug|Bevacizumab|Bevacizumab 5 mg/kg BW iv over 30 to 90* min day 1
19828|NCT04034459|Drug|Irinotecan|Irinotecan 150 mg/m² iv, 30 - 90 min. day 1
19829|NCT04034459|Drug|Folinic acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1
19830|NCT04034459|Drug|Oxaliplatin|Oxaliplatin 85mg/m² day 1
19831|NCT04034459|Drug|5-FU|5-FU 3000 mg/m² iv over 48 h days 1-2
19832|NCT04034459|Drug|Cetuximab|Cetuximab initially 400 mg/m² with infusion rate of ≤5 mg/min., subsequently 250 mg/m² iv with infusion rate of ≤10 mg/min. days 1+8
19833|NCT04034446|Biological|CD19-CD22 CAR-T cells|0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.
19834|NCT04034433|Procedure|Handgrip exercise program|Handgrip exercise with a rubber ball 4 weeks before the surgery until 4 weeks after the surgery 20 contractions per minute for a total of 20 minutes each day.
19835|NCT04034420|Other|Online training platform|Self-paced training and learning materials in relation to family services
19837|NCT04034394|Other|Electromoxibustion|Electromoxibustion is a electric device that mimic the burning or moxa. Subjects in this group will receive electromoxibustion using a knee-brace-like device which produces thermal stimulation with a moxa pad inside. The treatment will be delivered 3 times per week for 4 weeks.
19838|NCT04034394|Other|Knee health education|Subjects in this group will attend 2 lessons (120 minutes each) of health education related to knee OA symptom management in a small group of 5-7 subject. The course content is developed from the course materials from the websites of Elderly Health Service, Department of Health, Hong Kong SAR.
19839|NCT04034381|Other|No intervention (descriptive survey only)|No intervention
19840|NCT04034368|Drug|Tenofovir Alafenamide (TAF)|Tenofovir alafenamide (TAF) 25 mg QD, oral administration, 48 weeks；
19841|NCT04034355|Drug|Calmangafodipir (5 µmol/kg)|PledOx will be given to patients as an i.v. infusion, on top of mFOLFOX6 chemotherapy. PledOx is a bright yellow clear solution in 20 mL colorless, single dose, glass vials.
19842|NCT04034355|Other|Placebo|Placebo will be administered via the same route as PledOx (i.v. infusion). Placebo is a bright yellow clear solution in 20 mL colorless, single dose, glass vials.
19843|NCT04034342|Other|RaceRunning|RaceRunning (www.racerunning.org) is a growing disability sport that provides an opportunity for people with moderate-to-severe CP to participate in exercise in the community. It allows those who are unable to walk independently, to propel themselves using a RaceRunning bike, which has a breastplate for support but no pedals. Participants sit on the saddle and use their legs to propel themselves forward.
19844|NCT04034329|Procedure|ASVAL|Ambulatory Selective Varices Ablation under Local Anesthesia
19845|NCT04034329|Procedure|EVLA|Endovenous Laser Ablation
19846|NCT04034316|Other|Cord-blood mesenchymal stromal cells|The product is packaged in bags suitable for the cryopreservation of cell products. Before administration the cells must be thawed and diluted in an appropriate vol:vol solution: made by saline 78%, human albumin 10%, Acyl-CoA dehydrogenase-A (ACD-A) 12%.
19847|NCT04034303|Genetic|analysis of genetic and epigenetic risk factors|analysis of gene, methylation and expression, microbiome
19848|NCT04034290|Biological|GamFluVac|The drug is a vaccine that induces high-level immunity against influenza A viruses
19849|NCT04034290|Other|Placebo|Placebo
19850|NCT04034277|Other|Lee Silverman Voice Therapy|LSVT LOUD® comprises maximum effort non-speech and speech drills. The non-speech drills include the production of 15 sustained 'ah' phonation at high volume and pitch glides (5 repetitions moving from modal pitch to high pitch and 15 repetitions moving from modal pitch and going down on production of sustained 'ah'). The speech drills utilize a hierarchy of speech tasks moving from single words through phrases and onto conversational speech to generalize
19851|NCT04034277|Other|Conventional Treatment|"speech rehabilitation protocol comprehend:~Respiratory and phonatory exercises: exercises to increase diaphragmatic and respiratory functions, exercises to increase expiration time using natural expiration or sibilant, exercise to increase phonation time by pronouncing the vocal /a/, exercise to reduce oral stiffness.~Articulation and prosody exercises: repetition or reading lists of possibly long and complex words that start with or contain consonants groups. Read aloud texts, sentences or words, making sure to articulate and pronounce the words well without diminishing or increasing the rhythm of speech, with the correct punctuation and intonation. If necessary, ask patients to hyperarticulate, accelerate or slow down, or exaggerate intonation."
19855|NCT04034238|Drug|LMB-100|Arms 1 and 2: Administered IV as an approximate 30-minute infusion of each 21 day cycle on days 4, 6 and 8 until disease progression, intolerance or withdrawal from study.
19856|NCT04034238|Drug|Tofacitinib|Arms 1 and 2: Administered orally twice daily on days 1-10 of each cycle until disease progression, intolerance or withdrawal from study.
19857|NCT04034238|Device|Mesothelin Expression|Test for mesothelin expression in tumor tissues for study eligibility
19858|NCT04034225|Drug|SNS-301|SNS-301 (1x1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
19859|NCT04034225|Drug|Pembrolizumab|Pembrolizumab (200 mg dose) IV infusion will be administered over 30 minutes every 3 weeks up to 24 months.
19860|NCT04034212|Other|Singing for Lung Health group attendance|Singing for Lung Health is a group singing intervention designed for people with chronic lung diseases. Participants would attend weekly sessions lasting 1 hour.
19861|NCT04034199|Drug|Denosumab|Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
19862|NCT04034199|Drug|Zoledronic Acid|Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
19863|NCT04034173|Drug|Panitumumab|"Panitumumab 6 mg/kg BW as 60-min i.v. infusion* D1~*If the 1st infusion is well tolerated, all subsequent infusions can be applied over 30-60 minutes."
19864|NCT04034173|Drug|Irinotecan|Irinotecan 180 mg/m² BSA i.v., 30 - 90 min D1
19865|NCT04034173|Drug|Folinic acid|Folinic acid (racemic) 400 mg/m²BSA i.v., 120 min D1
19866|NCT04034173|Drug|5-FU|5-FU 400 mg/m² BSA, bolus, D1 5-FU 2400 mg/m² BSA i.v. infusion over a period of 46 h D1-2
19867|NCT04034160|Other|vegetarian burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 1 will be given vegetarian burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
19868|NCT04034160|Other|beef burger|"A finger prick test will be used to determine baseline levels measurements for serum lipids, glucose, and hs-CRP levels. Group 2 will be given beef burgers to consume. Participants will need to remain in the room for 2 hours, postprandial (they may study, watch a movie, etc). They will not be allowed to consume anything except for water during this time. After consumption of burger, at 30 min, 60 min, 120 min, finger prick tests will be used to obtain blood. Participants will also be asked to try and identify the burger they consumed and rate the taste of the burger. Visit 2 will take approximately 3 hours.~Participants will be directed to fast for 8 hours prior to Visit 3 (the following week).~Visit 3: We will repeat the same procedure as Visit 2. However, this time the burgers will be switched."
19869|NCT04034134|Drug|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 150mg qd dose group and Jaktinib hydrochloride tablets 200mg qd dose group
19870|NCT04034121|Device|DESolve Cx drug eluting coronary scaffold system|percutaneous coronary intervention
19871|NCT04034108|Procedure|Surgical intervention combined with weight-supported ambulation training|"Surgeries were performed between 12 hours to 30 days after trauma. Internal fixation was implemented once instability of the injured spinal column was confirmed by radiology and exploration during operation. At 15 days after surgery, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers, the patients were encouraged to start weight-supported ambulation training under careful protection by the trainers. The training program was named Kunming Locomotor Training Program (KLTP)formulated by actively walking for a duration of 6 hours per day, 6 days per week for a minimum of 6 months."
19872|NCT04034095|Drug|Androgen-deprivation Therapy (ADT)|Participants enrolled in this study will continue to receive ADT (example- Leuprorelin, Goserelin and Degarelix) alone or in combination with other therapies in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study
19873|NCT04034095|Drug|Bicalutamide|Participants enrolled in this study will continue to receive bicalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
19874|NCT04034095|Drug|Abiraterone|Participants enrolled in this study will continue to receive abiraterone in combination with prednisolone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
19875|NCT04034095|Drug|Prednisolone|Participants enrolled in this study will continue to receive prednisolone in combination with abiraterone along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
19876|NCT04034095|Drug|Docetaxel|Participants enrolled in this study will continue to receive docetaxel along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
19877|NCT04034095|Drug|Enzalutamide|Participants enrolled in this study will continue to receive enzalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
19878|NCT04034095|Drug|Apalutamide|Participants enrolled in this study will continue to receive apalutamide along with ADT in routine clinical practice as directed by their treating physician. No intervention will be administered as a part of this study.
19879|NCT04034082|Device|Intermittent hypoxia therapy|Intermittent Hypoxic Therapy (further referred to as IHT). A typical IHT session consists of repeated short-term moderate hypoxia (down to 10 vol.% O2), interrupted by brief periods of reoxygenation. These periods of recovery could be either normoxic (21 vol.% O2, Hypoxia-Normoxia mode) or hyperoxic (30-35 vol.% O2, Hypoxia-Hyperoxia mode, further referred to as IHHT). The gas mixtures are supplied to a patient via facial mask.
19880|NCT04034082|Other|Conventional phase 2 cardiac rehabilitation programme|The core components of a Phase 2 in-hospital cardiac rehabilitation program include: 1) patient assessment with medical control to promote clinical stabilization and optimization of pharmacologic treatment; 2) physical activity counselling; 3) prescription of an individualized exercise training; 4) diet/nutritional counselling; 5) weight control management; 6) Lipid management; 7) blood pressure monitoring and management; 8) smoking cessation; 9) vocational support; 10) psychosocial management..
19881|NCT04034069|Device|Theta burst stimulation (TBS)|Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
19882|NCT04034069|Behavioral|Robot-assisted training|Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
19915|NCT04033809|Dietary Supplement|Multigrain powder (S)|A twice daily high fiber multigrain powder supplementation for 12 weeks
19883|NCT04034056|Drug|Obinutuzumab|Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).
19884|NCT04034043|Device|ceramic-on-ceramic total hip arthroplasty|ceramic-on-ceramic, cementless total hip arthroplasty for post-traumatic hip osteoarthritis.
19885|NCT04034030|Device|Transcranial Magnetic Stimulation|"Each patient will receive a 10 minute treatment of one time stimulation of the Epileptogenic Cortical Area (ECA). The TRPMS cap will be worn over the previously fixed scalp EEG electrodes. The procedure during this treatment session will consist of positioning a device microstimulator component centered on an area of focal epileptiform discharges (identified with EEG electrode placement) with the patient relaxing in a chair.~The stimulus parameters used will be 120 stimulus trains of 100 ms in duration, each train delivered every 5 s for total session duration of 10 min. . The investigators will measure the subject for adequate placement of the device prior to stimulation. Once the placement of the device is confirmed, the study technician administrating the treatment will turn on the device using the app downloaded on an electronic device connected by Bluetooth to the device."
19886|NCT04034017|Other|no intervention|descriptive study, no intervention
19887|NCT04034004|Behavioral|Mindfulness|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
19888|NCT04034004|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
19889|NCT04034004|Other|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion will cease till the end of the experiment.
19890|NCT04034004|Behavioral|Meditation|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] is used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
19891|NCT04033991|Drug|Sunitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
19892|NCT04033991|Drug|Axitinib|Tyrosine kinase inhibitor, licensed for use in treatment of renal cell carcinoma.
19893|NCT04033978|Behavioral|Cognitive remediation|10 sessions dealing with emotion recognition, jumping to conclusion, attributional style.program lasts 10 weeks
19894|NCT04033978|Behavioral|psychosocial rehabilitation|10 sessions dealing psychosocial rehabilitation, neuropsychological evaluation, stigmatization, recovery process and severe mental disorders in general.
19895|NCT04033965|Genetic|Corellation of Mutations, TILs and Age in Breast Cancer|
19896|NCT04033952|Behavioral|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
19897|NCT04033939|Drug|HSK3486|
19898|NCT04033939|Drug|Propofol|
19899|NCT04033939|Drug|Placebo|
19900|NCT04033926|Drug|KZR-616|Subcutaneous 30 mg weekly for 2 weeks, then 45 mg weekly for 14 weeks
19901|NCT04033926|Drug|Placebo|Subcutaneous injection for 16 weeks
19903|NCT04033900|Device|Forced air warming devices|"In the treatment group, heating will be started with a pre-surgical forced-air blanket Outpatient Warming Blanket model 11101 Bair Hugger from 3M and a forced-air heating unit Bair Hugger Warming Unit Model 775 from 3M at 38-43º C which will be maintain during the stay in the pre-surgery room until the transfer to the operating room"
19904|NCT04033887|Diagnostic Test|13 Rapid Diagnostic Tests and reference tests|"Rapid diagnostic tests:~HCV antibody test (under development); bioLytical Laboratories~DPP® HCV (under development); Chembio Diagnostic Systems~HCV-Ab Rapid Test; Beijing Wantai Biological Pharmacy Enterprise~Rapid Anti-HCV Test; InTec~First Response HCV Card Test; Premire Medical Corporation~Signal HCV Ver 3.0; Arkray healthcare~TRI DOT HCV; J. Mitra & Co~Triplex HIV, HCV, HBsAg; Biosynex SA~Standard Q HCV Ab; SD Biosensor~HCV Hepatitis Virus Antibody Test; Artron Laboratories~SD Bioline HCV; Abbott Diagnostics~OraQuick HCV; OraSure~Care Start HCV Rapid Test (under development); Access Bio~Reference tests:~Enzyme Immunoassays (EIAs): Murex Anti-HCV EIA version 4.0; Fujirebio Innotest HCV Ab IV~Line Immunoassay (LIA): MP Diagnostics HCV blot 3.0"
19905|NCT04033874|Other|kangaroo care|kangaroo care
19906|NCT04033874|Other|holding on the mother's lap|holding on the mother's lap
19907|NCT04033874|Other|white noise listening|white noise listening
19908|NCT04033874|Other|ambient sound listening|ambient sound listening
19909|NCT04033861|Drug|rhBNP|rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
19910|NCT04033861|Drug|Control|saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
19911|NCT04033848|Procedure|Arthroscopic assisted ankle fracture treatment|Any complex ankle fracture, as discriped above, will be treated arthroscopically and will be prospectively followed-up using well validated PROMs
19912|NCT04033835|Other|Mentalization Based Treatment-Introductory|Mentalization Based Treatment-Introductory
19913|NCT04033835|Other|Treatment as usual|Treatment as usual
19914|NCT04033822|Procedure|cholecystectomy|If patients are randomized to the intervention arm of the study; said patient will undergo corrective cholecystectomy surgery to correct cholecystitis as soon as possible with a goal of surgery within 6 hours of diagnosis.
35645|NCT03905577|Behavioral|Motor imagery|Motor imagery protocol
19917|NCT04033796|Dietary Supplement|50,000 IU|Vitamin-D3 supplementation providing 50,000 IU administered orally every two months (equivalent to ~800 IU/d);
19918|NCT04033796|Dietary Supplement|Placebo|A placebo (administered orally every two months) supplementation control group.
19919|NCT04033783|Other|6MWT - accompanied|Assessor walks behind the patient
19920|NCT04033783|Other|6MWT - not accompanied|Assessor does not walk behind the patient
19921|NCT04033770|Other|Urodynamic investigation|Urodynamic investigation using an air-charged measurement system
19922|NCT04033770|Other|Urodynamic investigation|Urodynamic investigation using a water-perfused measurement system
19923|NCT04033744|Procedure|extraction of mandibular third molar|After loco-regional anesthesia was administered, a full-thickness mucoperiosteal flap was raised. The flap incision was extended from the vestibular side of the retromolar trigon to the second molar, corresponding to its distolingual cusp. The incision continued intrasulcular at the second molar and proceeded with a release incision distally to the papilla between the first and second molars, on a 45° angle. An osteotomy using a Lindemann burr under constant irrigation, followed by an odontotomy using a diamond burr was performed, if necessary
19924|NCT04033731|Behavioral|Attention Network Task|The Attention Network Test (ANT) is a computerized cognitive task designed to efficiently probe three independent but interactive attentional networks (alerting, orienting, executive control) in a single task paradigm.
19925|NCT04033718|Diagnostic Test|Inpatient testing package|The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure
19926|NCT04033705|Device|Freestyle Libre Pro glucose sensor|Participants will wear a Freestyle Libre Pro glucose sensor for approximately 2 weeks prior to elective surgery and then for 2 weeks following surgery.
19927|NCT04033692|Device|JuggerKnot Mini Soft Anchor|Patient who have been implanted with one or more JuggerKnot Mini Soft Anchor(s) who have undergone repair, repositioning or reattachment of soft tissues, ligament and tendons to the mandible is require for surgical stabilization of the TMJ articular disc.
19928|NCT04033679|Other|Active TDCS|Participants will receive active TDCS stimulation.
19929|NCT04033679|Other|Sham TDCS|Participants will receive sham TDCS stimulation.
19930|NCT04033666|Other|High Flow Nasal cannula|The HFNC will be instituted therapy with high-flow nasal cannula with dosage and cannula calculated according to the child's weight, ranging from 2 l / min to 30 l / min. The therapy will begin with diaphragmatic exercises 3x10 breaths and after high-flow therapy with nasal cannula for 45 minutes, after which will be performed the vital signs evaluations and Peak Flow, HRV, FEV1.
19931|NCT04033666|Other|NIV Noninvasive Ventilation|The Therapy consisted of 3x10 diaphragmatic re-education exercises after a Bipap device was coupled in bipedal mode with parameters Ipap 12 cm H2O and Epap 8 cm H2O, for 45 minutes, according to the patient's tolerance, with Full face facial mask. After therapy evaluated vital signs and measures of Peak Flow, HRV, FEV1.
19932|NCT04033640|Diagnostic Test|STANDARD G6PD Test|The STANDARD G6PD Analyzer is designed to measure the quantitative determination of total-hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimen based on reflectometry assays. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in Brazil and is considered an investigational product. PATH has conducted some initial laboratory evaluations which suggest that the test aligns to performance specifications outlined in the target product profile. The test has CE mark and is registered for use in South Korea, India, and Thailand.
19933|NCT04033627|Procedure|In Vitro T cells depletion using CliniMCAS system|Use the CliniMACS TCRα/β and CD45 Systems to deplete TCRα/β+ and CD45RA+ cells from the mobilized peripheral blood stem cells of a haploidentical donor in patients with leukemia.
19934|NCT04033614|Device|Fasciotens-Abdomen|The basic principle of Fasciotens Abdomen is the ventrally directed pulling force on the two fascial edges via an external device with support on the thorax and pelvis. A commercially available resorbable surgical mesh is sewn into the fascia margin. Commercial surgical sutures attached to this net are then attached to a height-adjustable suspension, which is connected to an external support on the thorax and pelvis. This ensures continuous traction to the two fascial edges. The remaining wound surface can then be treated with conventional dressing material.
19935|NCT04033601|Behavioral|Non-pharmacological intervention|The non-pharmacological intervention will comprise sleep hygiene education, exercise training and relevant modules of cognitive behavioral therapy.
19936|NCT04033588|Device|Freedom® Total Knee System|To evaluate the survivorship, safety and performance of the Freedom® Total Knee System in the treatment of subjects who in the surgeon's opinion require a primary total knee replacement due to severe knee joint pain and loss of mobility due to osteoarthritis, rheumatoid arthritis or post-traumatic arthritis.
19937|NCT04033575|Drug|Colgate Total SF|1100 ppm F Colgate Total Clean Mint White Paste Toothpaste is a test treatment
19938|NCT04033575|Drug|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
19939|NCT04033562|Drug|LidoPatch, 3.6%-1.25% Topical Film|Lidopatch will be applied at time of Cesarean delivery for post-operative pain control.
19940|NCT04033562|Device|Ambu ACTion pump, 0.125% bupivacaine at 8cc/hr|Infusion pump will be placed at time of Cesarean delivery for post-operative pain control.
19941|NCT04033536|Radiation|Involved Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Involved Target using IMRT/VMAT/RapidArc
19942|NCT04033536|Radiation|Elective Target Stereotacic Spine Radiosurgery|Image guidance spine stereotactic radiosurgery/ablative radiotherapy 1600 cGy in single fraction to Elective Target using IMRT/VMAT/RapidArc
19943|NCT04033523|Behavioral|HIIT|The HF group performed HIIT (3-min intervals at 40% and 80%VO2peak) on a bicycle ergometer for 30 min/day, 3 days/week for 12 weeks
19944|NCT04033510|Other|Standard of Care Interventions to convert patient from atrial fibrillation to normal rhythm|Direct current cardioversion, PVAI-atrial fibrillation ablation, Minimally Invasive Surgical Maze procedure, Medications
19945|NCT04033497|Device|MRI|Magnetic Resonance Imaging will generate imaging of the brain to identify recurrence of tumor.
20047|NCT04032678|Device|Schiller Defigard Touch 7 - DGT7, Schiller Medical, France|Cardioversion with a pulsed biphasic waveform
36584|NCT03898180|Drug|Placebo for lenvatinib|oral capsule
19946|NCT04033484|Procedure|Negative Pressure Wound Therapy|The perineal wound was reconstructed with biologic mesh after ELAPE. The subcutaneous adipose layer was closed with 2/0 vicryl sutures, and a suction drain was left in the deep layer. The subcuticular layer and skin were closed with 3/0 vicryl mattress sutures and the negative pressure system applied at 80 mmHg
19947|NCT04033471|Drug|midazolam|epidural needle in the L1-2 or L2-3 space , and using loss of resistance technique udder strict aseptic condition 10 ml of the prepared drug will be given
19948|NCT04033458|Drug|JNJ-64140284|Participants will receive JNJ-64140284 orally.
19949|NCT04033445|Drug|Guselkumab|Participants will receive guselkumab IV or SC.
19950|NCT04033445|Drug|Placebo|Participants will receive matching placebo IV or SC.
19951|NCT04033432|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
19952|NCT04033419|Drug|Memantine|"Week 1: 5 mg dose once daily~Week 2: 5 mg dose twice daily~Week 3: 5 mg each morning/10 mg each evening~Week 4 through end of Chemotherapy: 10 mg dose twice daily~Total duration: 12 - 26 weeks (depending on chemotherapy regimen)"
19953|NCT04033406|Drug|VIR-2482|VIR-2482 given by intramuscular injection
19954|NCT04033406|Drug|Placebo|Sterile normal saline (0.9% NaCl) given by intramuscular injection
19955|NCT04033393|Other|Game based dual-task training|Participants in the experimental group will receive game based dual-task training with a treadmill
19956|NCT04033393|Other|Treadmill training|Participants in the control group will receive treadmill training
19957|NCT04033380|Device|Resin blocs (Grandio Blocs, VOCO)|composite-base bloc (Grandio Blocs, VOCO)
19958|NCT04033380|Device|Ceramic (Suprinity, VITA)|glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
19959|NCT04033367|Drug|DUPILUMAB|Pharmaceutical form:solution for injection Route of administration: subcutaneous
19960|NCT04033367|Drug|PLACEBO|Pharmaceutical form: solution for injection Route of administration: subcutaneous
19961|NCT04033354|Drug|HLX10|HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
19962|NCT04033354|Drug|carboplatin and nab paclitaxel|chemotherapeutics
19963|NCT04033354|Drug|Placebo|Placebo
19964|NCT04033341|Drug|LY3214996|Administered orally
19965|NCT04033341|Drug|[14C]-LY3214996|Administered orally
19966|NCT04033328|Drug|ORIC-101|ORIC-101 once daily in each 28-day cycle
19967|NCT04033328|Drug|enzalutamide 40 MG oral capsule [Xtandi]|160 mg once daily in each 28-day cycle
19968|NCT04033302|Biological|CD7-specific CAR gene-engineered T cells|Infusion of CD7-specific CAR-T cells
19969|NCT04033289|Device|Hip protection orthosis|Experimental group would wear hip protection orthosis over 12 hours a day for 1 year.
19970|NCT04033276|Drug|Rituximab|IV rituximab
19971|NCT04033276|Drug|intravenous immune globulin|iv intravenous immune globulin
19972|NCT04033263|Other|Mouth rinse 1|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19973|NCT04033263|Other|Mouth rinse 2|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19974|NCT04033263|Other|Mouth rinse 3|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19975|NCT04033263|Other|Mouth rinse 4|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19976|NCT04033263|Other|Mouth rinse 5|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19977|NCT04033263|Other|Mouth rinse 6|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19978|NCT04033263|Other|Mouth rinse 7|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19979|NCT04033263|Other|Mouth rinse 8|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19980|NCT04033263|Other|Mouth rinse 9|Participants will use 10mL of the respective mouth rinse, swish in the mouth for 30 seconds and spit it out. This will be made twice a day, for a total of 5 days.
19981|NCT04033250|Drug|Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure|Bowel preparation
19982|NCT04033237|Other|Very low nicotine content cigarettes|Cigarettes containing 0.4 mg nicotine/g tobacco
19983|NCT04033224|Device|Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT)|Every center will prescribe EBPT with commercial membranes in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
19984|NCT04033211|Device|Novosyn® CHD for fascia and skin closure|Experimental
19985|NCT04033211|Device|Novosyn® for fascia and skin closure|Comparator
19986|NCT04033198|Procedure|Appendectomy|patients diagnosed as acute appendicitis , appendectomy done
19987|NCT04033185|Other|virtual reality, robot assisted gait training|study group: 15 sessions virtual reality, robot assisted gait training
19988|NCT04033185|Other|conventional treatment|study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
19989|NCT04033172|Drug|Pyrotinib Plus Fulvestrant|Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.
19990|NCT04033159|Drug|DYN101|DYN101, is a constrained ethyl gapmer ASO directed against human DNM2 RNA
20048|NCT04032678|Device|LIFEPAK 15, Physio-Control Inc., Redmond, WA, USA|Cardioversion with a biphasic truncated exponential waveform
20369|NCT04029935|Behavioral|Control|time-matched task (sitting on the bike without pedalling)
19991|NCT04033146|Device|Altering muscle contractions|The investigators will use biofeedback, shoes, and ankle-exoskeletons to systematically alter the behavior of participant muscle contractions. For example, we will have participants walk in shoes that have midsoles that likely elicit slower calf muscle contractions than conventional shoes.
19992|NCT04033133|Device|tDCS|Subjects will get tDCS at intensities of 0, 1, 2, 3, and 4 mA.
19993|NCT04033107|Drug|Vitamin C|Participants will receive intravenous Vitamin C injection (dose: 1.5g/kg, D1-3, every 2 weeks), treatment termination when the disease progress is confirmed.
19994|NCT04033107|Drug|Metformin|Participants will orally take metformin 4g daily.
19995|NCT04033094|Other|This was a retrospective, non-interventional study.|Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
19996|NCT04033094|Other|This was a retrospective, non-interventional study.|Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
19997|NCT04033081|Device|CivaSheet|Implanting CivaSheet radiation therapy device at the time of surgery to irradiate surgical margin potentially preventing local recurrence
19998|NCT04033068|Biological|Two MV-ZIKA-RSP vaccinations (high dose)|"In this arm of the study, 14 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~V2= day 28; dose vaccination with MV-ZIKA-RSP (high dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (high dose)"
19999|NCT04033068|Biological|Two MV-ZIKA-RSP vaccination (low dose)|"In this arm of the study, 14 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (low dose).~V2= day 28; dose vaccination with MV-ZIKA-RSP (low dose).~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (low dose) Visit 2: Participants will receive their second vaccination with MV-ZIKA-RSP (low dose)"
20000|NCT04033068|Biological|One MV-ZIKA-RSP vaccination (high dose) and one placebo|"In this arm of the study, 12 participants will receive:~V1= day 0; dose vaccination with MV-ZIKA-RSP (high dose).~V2= day 28; treatment with placebo~Description:~Visit 1: Participants will receive their first vaccination with MV-ZIKA-RSP (high dose) Visit 2: Participants will receive their second treatment with placebo"
20001|NCT04033068|Other|Two placebo injection|"In this arm of the study, 8 participants will receive:~V1= day 0; placebo treatment~V2= day 28; placebo treatment~Description:~Visit 1: Participants will receive their first treatment with placebo Visit 2: Participants will receive their second treatment with placebo"
20002|NCT04033055|Procedure|Inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride 10mg/mL|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in ropivacaine hydrochloride 10mg/mL) is positioned once the surgery for the inguinal hernia repair has been performed."
20003|NCT04033055|Procedure|Inguinal hernia repair with CycloMesh™ soaked in saline solution NaCl 9°/°°|"The surgical technique for the inguinal hernia repair is the surgeon's usual technique: open surgery (Lichtenstein technique).~CycloMesh™ device (soaked in saline solution) is positioned once the surgery for the inguinal hernia repair has been performed."
20004|NCT04033042|Device|Prototype 0.5|Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
20005|NCT04033029|Device|Continuous venovenous hemodiafiltration with high adsorption membrane (oXiris®)|CRRT initiation will be determined by the treating physician on charge, according with the current recommendations of clinical practice and prescriptions of CRRT and local management protocols. The CVVHDF mode will be performed by using PrismafleX eXeed™ system and high adsorbent polyethyleneimide membrane (oXiris®). Filtration parameters will be determined following the local protocol (dose of 25-30 ml/kg/h).
20006|NCT04033029|Drug|Antibiotics|Antibiotic concentration-time data will be collected and analyzed.
20007|NCT04033016|Behavioral|motivational interviewing|Motivational interviewing (MI) is a contemporary form of advisory support, which is often used for behavioral change. During the motivational interviewing educated health professional leads the counseling session by asking questions on lifestyle, attitude towards the behavioral change, and factors pro and against the change. During the MI the focus is on the patient/ client, his/her own perception of their health, understanding the reasons for current behavioral patterns, and encouragement to assess these patterns.
20008|NCT04033016|Behavioral|online social media intervention|Facebook group was specially designed for purposes of intervention and was administered by the research team. It was used to motivate the participants to be more physically active. The intervention used hybrid approach, with health promotion campaign with motivational messages and pictures, journal articles, questions with the aim to spark a discussion on barriers or possibilities for physical activity and participatory approach (all members were allowed to post motivational messages or questions for their peers).
20009|NCT04033003|Behavioral|Group ANC|Intervention groups of up to 14 women of similar gestation age (10 to 20 weeks) for nine meetings. The first meeting is an individual meeting with the midwife and the standard history and physical exam as well as lab tests are completed. Group meetings are held once a month until 28 weeks of pregnancy, then every 2 weeks until 34 weeks of pregnancy, and the remaining group meetings are once a week. Prior to the start of each group, blood pressure, weight, and a urinalysis are measured for each woman.
20010|NCT04032990|Device|Biostim-5 transcutaneous spinal stimulator|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
20011|NCT04032964|Drug|L19TNF|L19TNF 13 µg/kg i.v. will be administered on day 1, 3 and 5 of each 21-day cycle
20012|NCT04032964|Drug|DOXORUBICIN|Doxorubicin 75 mg/m2 will be administered on day 1 of each 21-day cycle
20013|NCT04032951|Other|Fine Needle Tissue Acquisition|diagnostic
20014|NCT04032938|Procedure|extracorporeal circulation during cardiac surgery|We will observe the cardiopulmonary bypass status and time of patients undergoing cardiac surgery and extracorporeal circulation due to their medical needs.
20084|NCT04032275|Other|Chronic hepatitis B infection|Chronic hepatitis B infection patients
20085|NCT04032262|Diagnostic Test|Gastrointestinal and Parkinson's Disease|Subjects with Parkinson's disease will come for visits that will contain questionnaires about their PD, their bowel movements, and do further tests using anal rectal probes to understand further their constipation, and other tests to gather data on their digestion.
20015|NCT04032925|Device|PICSO|"PICSO therapy is delivered through the PICSO Impulse System, which consists of the PICSO Impulse console and PICSO impulse catheter. The PICSO therapy is delivered in each patient for a minimum of 20 minutes to a maximum of 45 minutes.~The PICSO Impulse catheter is automatically activated by the PICSO Impulse console. It is inserted in the coronary sinus via femoral vein access. The PICSO Impulse Console cyclically inflates and deflates the balloon at the tip of the PICSO Impulse catheter, generating transient increase in coronary sinus pressure."
20016|NCT04032912|Diagnostic Test|iScan|this instrument provides extra confidence for in vivo diagnosis through improved vessel and mucosal pattern characterization.
20017|NCT04032899|Dietary Supplement|Lactobacillus fermentum CECT5716|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
20018|NCT04032899|Dietary Supplement|Placebo|Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits.
20019|NCT04032886|Other|kinesio tape|This is a taping method used for correction of rounded shoulders.
20020|NCT04032886|Other|exercise|Exercises include basic postural exercises.
20021|NCT04032873|Other|Monetary Cost of Immobilization Treatments|Information regarding the monetary cost of casting and splinting patient's buckle fracture to be presented to adult subject/payer.
20022|NCT04032873|Other|Physician|The monetary cost information is relayed by the patient's physician
20023|NCT04032873|Other|Study Team|The monetary cost information is relayed by a member of the study team
20024|NCT04032873|Other|Before Initial Treatment Decision|Monetary cost information is relayed during the initial consult, before the treatment decision is made.
20025|NCT04032873|Other|After Initial Treatment Decision|Monetary cost information is relayed after the initial consult with the treating physician, after the treatment decision is made.
20026|NCT04032860|Drug|Tenofovir Disoproxil|patients with HBV-HCC would take TDF as antiviral therapy before curative treatment to see the prognosis after surgery
20027|NCT04032860|Drug|Entecavir|patients with HBV-HCC would take ETV as antiviral therapy before curative treatment to see the prognosis after surgery
20028|NCT04032847|Biological|ATL001|ATL001 infusion
20029|NCT04032834|Combination Product|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a mouthpiece and dose-specific VR647 Smart Cards designed specifically for this trial.
20030|NCT04032834|Combination Product|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask|The VR647 Inhalation System consists of the AKITA JET control unit that has an inspiration flow rate of 12 L/min, an AKITA JET nebulizer handset, a facemask and dose-specific VR647 Smart Cards designed specifically for this trial.
20031|NCT04032834|Combination Product|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
20032|NCT04032834|Combination Product|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
20033|NCT04032834|Combination Product|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece operated to sputtering.
20034|NCT04032834|Combination Product|0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask|Commercial Pulmicort Respules (budesonide inhalation suspension 0.5 mg/2 mL) will be delivered by a conventional jet nebulizer (PARI VIOS) with facemask operated to sputtering.
20035|NCT04032821|Drug|Alkotinib（300mg)|"Alkotinib（300mg)~1. First empty stomach, after the meal.2. After eating first, after fasting."
20036|NCT04032795|Dietary Supplement|Lycium barbarum polysaccharide|Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (400mg/day)for 6 weeks
20037|NCT04032795|Dietary Supplement|Placebo|Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
20038|NCT04032782|Drug|HM15136|10 mg/mL as protein in prefilled syringes
20039|NCT04032782|Drug|Placebo of HM15136|Placebo in prefilled syringes
20040|NCT04032769|Other|MODS (MOdified Diagnostic Strategy)|"Modified diagnostic strategy (MODS):~All included patients will be tested with quantitative D-dimer. The MODS work-up strategy will be based on YEARS rule, that included three criteria (hemoptysis, signs of DVT, PE is the most likely diagnosis)~- If all YEARS criteria are absent, the threshold of D-Dimer for ordering a CTPA will be raised at 1000 ng/ml.~If at least one criterion of YEARS is present, then the D-dimer threshold for ordering a CTPA will be as usual (500 ng/ml, or agex10 for patients aged 50 and over)"
20041|NCT04032743|Other|ICU treatment|any treatment available by ICU
20042|NCT04032730|Device|Wisepill device|"Participants will receive a Wisepill device for TB and ART medications. Participants will receive an exit counselling session prior to being discharged.~Participants will select the content of a text message to be sent when missing a dose as measured by Wisepill non-opening during medication dose-window.~Participants will receive a post-discharge phone call by study staff for the purpose of identifying any early challenges or obstacles. All participants may receive a titrated Wisepill intervention (TWI) consisting of a text message, phone call, and/or study home visit triggered by medication non-adherence as detected by Wisepill non-opening.~All participants will receive a monthly counselling intervention (MCI). Adherence support groups (ASG) will be conducted on a monthly basis."
20043|NCT04032717|Drug|Q-Griffithsin (Q-GRFT) enema|Investigational enema composed of 4.2mL Q-Griffithsin (Q-GRFT) 9.6mg/mL combined with approximately 120.8mL of 0.9% sodium chloride solution to yield an active enema study product that will contain and deliver a dose of approximately 40mg of Q-GRFT
20044|NCT04032717|Other|Placebo enema|Approximately 125mL of 0.9% sodium chloride solution
20045|NCT04032704|Drug|ladiratuzumab vedotin|IV infusion every 21 days
20046|NCT04032691|Drug|Clonidine Pill|0.1 mg by mouth daily at bedtime for one week
20049|NCT04032665|Diagnostic Test|Rivaroxaban|In stable CAD/PAD patients with previous PCI and DES-implantation treated with DAPT (ASA+clopidogrel) platelet rich plasma (PRP) and washed platelets as well as serum/plasma/urinary samples will be collected between 2 and 4 weeks before switching from DAPT to ASA + rivaroxaban (2,5 mg b.i.d.), between 2 and 4 weeks under monotherapy with ASA 100mg o.d., and between 2 and 4 weeks under therapy with ASA 100mg o.d. + rivaroxaban (2,5 mg b.i.d.) and treated ex vivo with rivaroxaban to asses platelet activation and function, platelet-triggered thrombin generation and platelet-dependent vascular inflammation.
20050|NCT04032652|Procedure|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
20051|NCT04032652|Drug|Rectal dialysis|Rectal dialysis done after 1 week on either 1200/2400 mg Asacol dose to test rectal mucosal 5-ASA levels
20054|NCT04032613|Other|Vascular Access Navigation and Education Quality Improvement Program|A Vascular Access Navigation and Education Quality Improvement Program implemented in the Geisinger Danville, PA chronic kidney disease clinic. Participants complete questionnaires to assess their vascular access care knowledge and confidence before and after the implementation of the quality improvement program.
20055|NCT04032600|Procedure|Paracentesis|Full versus partial paracentesis (3 liters)
20056|NCT04032587|Behavioral|Modified training version of the Approach / Avoidance Task (AAT, see Wiers et al., 2011)|First, a modified training version of the Approach Avoidance Task, (see Wiers et al. 2011) with arbitrary Pavlovian cues will be developed and the effectiveness of this manipulation will be assessed. In detail, positive as well as negative Pavlovian cues (derived from a Pavlovian-to-Instrumental transfer Task, see Garbusow et al. 2014, Garbusow et al. 2016) will be modified according to their approach/ avoidance propensities by 1) approaching negative stimuli (pulling joystick), 2) approaching positive stimuli (pulling joystick), 3) avoiding negative stimuli (pushing joystick) and 4) avoiding positive stimuli (pushing joystick). Thus, we aim at reversing the PIT effect (pushing positive cues/ pulling negative cues) or enhancing the PIT effect (pulling positive cues/ pushing negative cues).
20057|NCT04032587|Behavioral|Mindfulness-based interventions (e.g. body scan)|Acute stress reduction will be applied in a standardized way using audio files with an anticipated duration of 20-30 minutes.
20058|NCT04032574|Combination Product|Herbal Medicinal Product|
20059|NCT04032574|Other|Placebo|
20060|NCT04032548|Drug|Placebo mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
20061|NCT04032548|Drug|Propolis mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
20062|NCT04032548|Drug|Chlorhexidine mouthwash|After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
20063|NCT04032535|Drug|CHF6523|CHF6523 is a PI3K inhibitor (phosphoinositide3-kinase)
20064|NCT04032522|Other|point-of care (PoC) neonatal HIV early infant diagnosis (EID)|clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)
20065|NCT04032509|Other|2 x 5 mL blood sample|2 x 5 mL blood sample to determine the performance of the automated VIDAS BTI platform in assessing serum concentrations of GFAP and UCH-L1 to rule out the need for a CT-scan after mTBI.
20066|NCT04032496|Behavioral|Contemplative-Based Intervention for People Living with SLE|Intervention sessions will follow a 6-week format consisting of weekly in-person sessions as well as guided homework to encourage practice at home. Some mindfulness practices that will be included are meditation, group exercise (yoga), group discussions, and deep breathing. Both participants diagnosed with SLE as well as caregivers will participate in the intervention sessions. 5 sessions will be approximately 2 hours long, while the final session will be approximately 4 hours long. Each intervention group will include approximately 4 participants with SLE and 4 caregivers.
20067|NCT04032496|Behavioral|Health Enhancement Program (HEP)|The HEP was designed to create an active control for mindfulness-based stress reduction (MBSR) interventions. The structure of this intervention will mirror that of the other arm of this study, but will lack the mindfulness component. The HEP includes topics such as physical activity, functional movement, music therapy, and nutrition education.
20068|NCT04032470|Device|Deep Brain Stimulation Systems (DBS)|Subjects receiving DBS implant for treatment of Essential Tremor
20069|NCT04032457|Device|Phase A - olifilcon B with Tangible Coatings|Daily disposable silicone hydrogel contact lens
20070|NCT04032457|Device|Phase B - etafilcon A with Tangible Coatings|Daily disposable hydrogel contact lens
20071|NCT04032431|Behavioral|Telerehab VR intervention|Training with VR system using software specifically designed to reproduce activities of daily living
20072|NCT04032418|Biological|Pembrolizumab|Given IV
20073|NCT04032405|Procedure|CAF+CTG+i-prf|combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)
20074|NCT04032392|Biological|autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
20075|NCT04032379|Other|Standard treatment|No intervention, some patients have additional neuro-psychological testing.
20076|NCT04032366|Drug|inhaled nitric oxide|using of inhaled nitric oxide
20077|NCT04032366|Device|PEEP|increasing PEEP
20078|NCT04032353|Other|Medical Consortium|subjects received intensive follow-up by coordinators according to the predifined protocol of MCSC
20079|NCT04032340|Other|dog presence|This project seeks to assess positive impacts of companion dog presence in elderly living at home ; to assess loneliness and isolement between eldlery with a companion dog and without, at home
20080|NCT04032327|Drug|Exparel plus plain bupivacaine|10 mL of extended release liposomal bupivacaine (Exparel) plus 10 mL of 0.25% plain bupivacaine mixed to be injected vaginally prior to the start of posterior colporrhaphy
20081|NCT04032327|Drug|Bupivacaine|20 mL of 0.25% plain bupivacaine to be injected vaginally prior to the start of posterior colporrhaphy
20082|NCT04032301|Drug|Ketamine|Six infusions of intravenous 0.5 mg/kg ketamine hydrochloride solution over 3 weeks.
20083|NCT04032301|Other|Normal Saline|Six infusions of intravenous normal saline solution over 3 weeks.
37712|NCT03888833|Device|ECMO|ECMO installation
20086|NCT04032249|Behavioral|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
20087|NCT04032249|Behavioral|Intervention Group (IG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
20088|NCT04032236|Other|caffeine|At room temperature (18-25 ° C) the same place and standard environment will be done. All involved cases will undergo a dental examination and within 30 minutes three samples of saliva will be taken, including first sample, after coffee drink and after drinking water. The pH of samples will be measured and the smoking cessation rate of the smoking cigarette smoker with simultaneous VAS (VISUAL ANALOG SCALA) will be measured. This data will be compared in-house and non-smoking control group
20089|NCT04032223|Procedure|Implant placemet in the mandibular canine regions|Implant placemet in the mandibular canine regions retained by cast metal copings or 3D printed metal copings to deliver Implant Supported telescopic overdenture in the mandible
20090|NCT04032210|Other|dual Zinc plus Arginine based toothpaste (Colgate total)|Regimen using dual Zinc plus Arginine based toothpaste (Colgate total)
20091|NCT04032210|Other|Zinc based toothpaste (Crest complete)|Regimen using Zinc based toothpaste (Crest complete)
20092|NCT04032210|Other|Fluoride based toothpaste (Signal)|Fluoride based toothpaste (Signal)
20093|NCT04032197|Drug|Semaglutide|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
20094|NCT04032197|Drug|Placebo (semaglutide)|Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
20095|NCT04032184|Other|Fluoride toothpaste|regimen using fluoride toothpaste
20096|NCT04032184|Other|fluoride toothpaste and chlorhexidine mouthwash|regimen using fluoride toothpaste and chlorhexidine mouthwash
20097|NCT04032184|Other|fluoride toothpaste, chlorhexidine mouthwash, MI varnish|regimen using fluoride toothpaste, chlorhexidine mouthwash, MI varnish
20098|NCT04032171|Drug|Evobrutinib|Evobrutinib twice daily (BID) in double-blind treatment period.
20099|NCT04032171|Drug|Evobrutinib|Evobrutinib BID in Open-Label Extension Period.
20100|NCT04032171|Drug|Avonex®|Avonex® once a week in double-blind treatment period.
20101|NCT04032171|Drug|Placebo|Placebo match to Avonex® once a week in double-blind treatment period
20102|NCT04032171|Drug|Placebo|Placebo match to Evobrutinib BID in double-blind treatment period.
20103|NCT04032158|Drug|Evobrutinib|Evobrutinib twice daily (BID) in double-blind treatment period.
20104|NCT04032158|Drug|Avonex®|Avonex® once a week in double-blind treatment period.
20105|NCT04032158|Drug|Evobrutinib|Evobrutinib BID in Open-Label Extension Period.
20106|NCT04032158|Drug|Placebo|Placebo match to Avonex® once a week in double-blind treatment period.
20107|NCT04032158|Drug|Placebo|Placebo match to Evobrutinib BID in double-blind treatment period.
20108|NCT04032132|Drug|curcumin paste|curcumin is a herb used for medical purpose
20109|NCT04032132|Procedure|curettage|open flab debridement surgery
20112|NCT04032106|Other|Best Practice|Receive standard information about HPV and HPV vaccine
20113|NCT04032106|Other|Informational Intervention|Receive Outsmart HPV intervention
20114|NCT04032106|Other|Questionnaire Administration|Ancillary studies
20115|NCT04032106|Behavioral|Text Message-Based Intervention|Receive unidirectional text message vaccine reminders
20116|NCT04032106|Behavioral|Text Message-Based Intervention|Receive interactive text message vaccine reminders
20117|NCT04032093|Biological|RSV vaccine|RSV vaccine
20118|NCT04032093|Biological|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
20119|NCT04032080|Drug|Drug 1: LY3023414; Drug 2: Prexasertib|"Patients will then be treated with 200 mg single-agent LY3023414, PO BID until disease progression. Patients will then discontinue LY3023414. At disease progression from LY3023414, a second core needle biopsy of the same metastatic lesion (or different metastases if the initial metastasis has regressed) will be performed for RPPA and other molecular analyses. If a research biopsy from a patient's metastatic disease cannot be safely obtained, a skin biopsy is permitted.~Patients will be treated with prexasertib 105 mg/m2 IV administered every 2 weeks until disease progression or unacceptable toxicity. Prexasertib will be discontinued in patients who achieve a confirmed clinical complete response, and these patients will be followed to document the durability of the complete responses. For patients achieving a CR or PR on prexasertib, a third additional core needle biopsy of metastatic disease may be obtained, if possible, for RPPA and other molecular analyses."
20120|NCT04032067|Drug|GV1001 placebo|0.9 % Normal Saline
20121|NCT04032067|Drug|Proscar placebo|PO
20122|NCT04032054|Device|mono-axial and poly-axial screws|types of pedicular screws for thoracolumbar fractures fixation
20123|NCT04032041|Device|Structure Sensor|A 3D representation of each participant's lower limb geometry will be obtained using a Structure Core scanner (Occipital, Inc.) which uses an infrared structured light projector to construct a 3D image of an object. The scanner is connected to an iPad; to operate the user rotates the iPad camera around the desired object. In seconds, the entire geometry is digitally reconstructed.
20124|NCT04032015|Device|TMS|Device used to administer electromagnetic fields to the brain to alter connectivity patterns
20125|NCT04032002|Other|Explorations|On Day 1 vascular fonctions explorations performed
20126|NCT04032002|Other|Blood samples|On Day 1 35ml taken
20127|NCT04031950|Device|Novel wearable paediatric device|The patient will wear the novel wearable paediatric device at the same time as polysmnography
20167|NCT04031677|Drug|Preoperative chemotherapy|"- High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~Note: the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimum threshold must be 7.5 g/m2 per cycle.~- LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks"
20128|NCT04031937|Other|Psychomotor assessment|the intervention include a depression scale, an anxiety scale, a sensory profile scale, a body image questionnaire, a self-esteem questionnaire, a psychomotor retardation scale and a standardized assessment of : muscle tone (dangling and extensibility); gross motor skills (walks, jump, static balance, dynamic balance); manual performance; manual praxis; adaptation of rhythm; manual gnosis; executive function
20129|NCT04031924|Other|Assessment of: 1. Functional Capacity 2. Physical Fitness 3. Physical Activity Level 4. Balance 5. Kinesiophobia 6. Psychological Status 7. Fatigue Severity|All liver transplantation patients who underwent transplant at least one year ago and healthy subjects were evaluated the first day they came.
20130|NCT04031911|Device|Hydroposturotherapy|"Hydroposturotherapy combines:~posturotherapy (patient placed upside down with water jets sent to the kidneys)~lumbar percussion~hyperdiuresis: prescribed quantities of water to be absorbed by the patient"
20131|NCT04031911|Device|Standard support in urology|Dispensing of AFU plugs Dietary advice
20133|NCT04031885|Drug|Abemaciclib|Administered orally
20134|NCT04031885|Drug|Fulvestrant|Administered IM
20135|NCT04031885|Drug|Standard Chemotherapy|Standard chemotherapy of physician's choice administered according to product label
20136|NCT04031872|Drug|LY3200882|Combination treatment with LY3200882 and capecitabine
20137|NCT04031859|Drug|acetylsalicylic acid|It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
20138|NCT04031846|Drug|Rotarix™|Single 1.5 mL oral dose at 2 and 4 months of age (Study Day 1 and Month 2)
20139|NCT04031846|Drug|Infantrix™ hexa|Single 0.5 mL intramuscular injection at 2, 3, 4, and 11-13 months of age (Study Day 1, Month 1, Month 2, and Month 9-13)
20140|NCT04031846|Drug|V114|15-valent pneumococcal conjugate vaccine (PCV) containing 13 serotypes present in Prevnar 13™ (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration,
20141|NCT04031846|Drug|Prevnar 13™|13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL intramuscular administration.
20142|NCT04031833|Drug|MAT2203|Encochleated amphotericin B
20143|NCT04031833|Drug|Amphotericin B|Intravenous amphotericin B
20144|NCT04031820|Procedure|Unipolar cup|Cemented unipolar acetabulum cup for primary THA
20145|NCT04031820|Procedure|Dual mobility cup|Cemented dual mobility acetabulum cup for primary THA
20146|NCT04031807|Procedure|Single-Incision Sling|The women with stress urinary incontinence underwent single-incision sling procedure.
20147|NCT04031794|Device|Extra Corporeal Membrane Oxygenator (ECMO)|Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.
20148|NCT04031781|Device|repetitive transcranial magnetic stimulation (rTMS) 100% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
20149|NCT04031781|Device|repetitive transcranial magnetic stimulation (rTMS) 50% motor threshold|Each rTMS session consisted of a single train of 900 total pulses over 3 minutes duration.
20150|NCT04031768|Other|Timing of rest prior to blood pressure measurement|Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which they rest prior to each set of measurements.
20151|NCT04031755|Drug|Minocycline|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
20152|NCT04031755|Drug|Placebos|Minocycline 100 mg capsules or matching placebo will be prepared by the central investigational pharmacy at Cincinnati Children's Hospital Medical Center. Drug identity will be masked by over encapsulation of the study drug.
20153|NCT04031742|Biological|IBI306|Administered by subcutaneous injection
20154|NCT04031742|Biological|IBI306|Administered by subcutaneous injection
20155|NCT04031729|Drug|Aspirin 81 mg|Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
20156|NCT04031729|Drug|Placebo oral tablet|Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.
20157|NCT04031716|Behavioral|Meditation|Participants assigned to the Meditation intervention will receive focused attention meditation training preoperatively, and encouraged to meditate for 20 minutes per day before surgery. In the postoperative inpatient period, the participants will be offered standard holistic health care, reinforcement of meditation training, and encouragement to practice at least 20 minutes of guided focused-attention meditation with breath as their focus, utilizing the MUSETM headband for bio-feedback, every day during their hospital stay. They will be asked to continue using the MUSETM neurofeedback-assisted meditation after hospital discharge, until their visit to repeat pain testing, at which time they will return the MUSETM headband.
20158|NCT04031703|Drug|Paclitaxel|Paclitaxel chemotherapy (injection)
20159|NCT04031703|Drug|Carboplatin|Carboplatin chemotherapy (injection)
20160|NCT04031703|Drug|Epirubicin|Epirubicin chemotherapy (injection)
20161|NCT04031703|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
20162|NCT04031703|Drug|5-fluorouracil|5-fluorouracil chemotherapy (injection)
20163|NCT04031703|Drug|Docetaxel|Docetaxel chemotherapy (injection)
20164|NCT04031690|Other|Caregiver Quality of Life Questionnaires|Measurement of quality of life at D0, M6 and M12 via SF-36, CarGOQoL and the one-dimensional Zarit score
20165|NCT04031690|Other|Patient Quality of Life Questionnaires|Quality of life measurement at D0, M6 and M12 via the SF-36
20166|NCT04031677|Procedure|Surgery|Large en-bloc curative-intent surgery
38287|NCT03884062|Drug|DAAs|lab, U/S, Fibroscan & CT if needed
20168|NCT04031664|Drug|Qianjin Capsule of Gynaecology|To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Qianjin Capsule of Gynaecology in reducing the use of antibiotics, reducing the risk of clinical use of drugs.
20169|NCT04031651|Drug|Pudilan Xiaoyan Oral Liquid|In the respiratory and emergency departments of the hospitals under surveillance, the medication of Pudilan Xiaoyan Oral Liquid is observed for those aged 18-80 years who strictly follow the prescription of the instructions.
20170|NCT04031638|Other|Radioactive Iodine treatment|Patients with a thyroid tumor who received radioactive Iodine treatment.
20171|NCT04031625|Other|Metastatic Colorectal Cancer Database|Metastatic Colorectal Cancer Database
20172|NCT04031612|Drug|Neoadjuvant therapy|Neoadjuvant therapy
20173|NCT04031599|Device|Single-hormone closed-loop system|Every 10 minutes, the glucose levels as measured by the sensor will be transferred automatically to a LG Google Nexus Smartphone that the algorithm is running on, which will calculate the recommended doses and will send them wirelessly to the infusion pump.
20174|NCT04031599|Device|Insulin pump|Tandem Diabetes Care
20175|NCT04031599|Device|Continuous glucose monitoring system|Dexcom G5 Platinum
20176|NCT04031599|Drug|Aspart|Aspart will be infused with the infusion pump
20177|NCT04031599|Drug|Fiasp|Fiasp will be infused with the infusion pump
20178|NCT04031599|Other|Carbohydrate counting|Participants will be required to enter an estimate of the carbohydrate content of their meal into the phone. Insulin boluses will be calculated based on grams of carbohydrates and participant's insulin-to-carbohydrate ratio. Carbohydrate-matching full prandial bolus will be given 5 to 10 minutes before the meal.
20179|NCT04031599|Other|Simplified qualitative meal-size estimation strategy|A pre-meal partial prandial bolus will be given 5-10 minutes before the meal. The partial bolus will be based on the estimated meal size (small, regular, large and extra-large). The closed-loop system will give the remaining insulin needed based on the sensor readings. For this strategy, meal size will be defined as: small as any meal less than 30g, regular meal as any meal between 30g and 60g CHO, large meal as any meal between 60g and 90g CHO, extra-large meal for anything above 90g CHO.
20180|NCT04031599|Other|2-week intervention|Glucose levels will be regulated by the single-hormone closed-loop system for 2 consecutive weeks.
20181|NCT04031573|Drug|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 2.5 to 5 mg to achieve a target heart rate between 80 and 94 bpm
20182|NCT04031573|Drug|Ivabradine|Ivabradine will be administered via the enteral route, every 12 hours, at doses ranging from 5 to 7.5 mg to achieve a target heart rate between 80 and 94
20183|NCT04031573|Drug|Placebo|Placebo will be administered via the enteral route, every 12 hours.
20184|NCT04031560|Behavioral|Integrative treatment|The experimental group (62 patients) will take part on the integrative group program consisting of 12-sessions, 90 minutes each, once a week (4 focused on psychoeducation, 1 directed to the family relatives, 3 on mindfulness and 4 on functional remediation)
20185|NCT04031547|Device|Transcranial Electrical Stimulation (tES)|In tES, a mild electrical current is passed between two or more electrodes placed on the scalp.
20186|NCT04031534|Drug|F-Miso PET scan coupled with MRI|Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
20187|NCT04031521|Diagnostic Test|Near infrared spectroscopy|NIRS is an emerging technology for measuring tissue oxygenation and endothelial function. NIRS light can penetrate through biological tissues, including skin, bone, and muscle. Similar to other optical methods, light is applied to the region of interest and undergoes scattering and absorption before being detected by a photosensor. This technique is commonly used to assess oxygen availability and consumption in living tissues. Using different wavelengths, NIRS can differentiate between oxygenated and deoxygenated hemoglobin in blood and can measure changes in total hemoglobin concentration, using the sum of oxygenated and deoxygenated hemoglobin.
20188|NCT04031508|Dietary Supplement|Parenteral emulsion|TPN will start at 2.0 g/kg/d of the lipid emulsion, increasing 1.0 g/kg/d until a maximum of 4.0 g/kg/d for at least 14 days.
20189|NCT04031495|Device|central vein cannulation|central vein cannulation
20190|NCT04031482|Other|No intervention, only standard care|"The aim of this registry is to expand on previous findings in the field of diagnostic and therapeutic pathways for patients with Crohn's disease, ulcerative colitis and indeterminate colitis undergoing routine administration of a targeted therapy (biologics or another targeted therapy such as Janus kinase therapy) and various different treatment approaches. A data pool is to be generated for this purpose, in order to~analyse disease progression~systematize findings about treatment processes~identify potential influencing factors~review any new diagnostic procedures~identify potential test subjects for further study~evaluate the safety of various treatment concepts"
20191|NCT04031469|Other|There is no intervention in this study|There is no intervention in this study
20192|NCT04031456|Biological|Autologous Platelet Rich Plasma|Autologous PRP will be injected into the ovaries.
20193|NCT04031456|Other|Placebo|Placebo injected into the ovaries.
20194|NCT04031430|Device|Telemonitoring|women who receive TM, will receive a connected blood pressure monitor and activity tracker. They have to measure their blood pressure twice a day, fill in their weight once a week in the App and wear an activity tracker day and night. These data are automatically transmitted via Bluetooth and Wi-Fi to the hospital.
20195|NCT04031417|Other|Hypoxia|
20196|NCT04031417|Other|Low Humidity|
20197|NCT04031404|Device|Single-pulse TMS|Single-pulse transcranial magnetic stimulation (TMS) on the motor cortex will lead to a twitch in the target muscle and evoke a motor-evoked potential (MEP) measured by electromyography (EMG).
20198|NCT04031391|Other|Physical activity|"The intervention group: engaged in a therapeutic physical activity program involving low-intensity exercise, strength and balance work for 2 days a week over a 12-week period, with each session lasting 90 minutes. Both the intervention group and the control group separately completed the various baseline surveys which were part of the study. Once the intervention was over, they answered them again, also separately.~The classes were led by an experienced physiotherapist who followed the physical exercise guidelines established by the American College of Sports Medicine (ACSM), although the intensity of the exercises was adapted to the participants' tolerance levels"
38731|NCT03880422|Other|Quality-of-Life Assessment|Ancillary studies
20199|NCT04031378|Radiation|Single Dose Radiotherapy (24 Gy) to all detectable lesions, followed by observation|SBRT to a single dose of 24 Gy to up to 3 sites
20200|NCT04031378|Drug|Single Dose Radiotherapy (24 Gy) to all detectable lesions followed by adjuvant systemic therapy for 6 months|SBRT 24 Gy to up to 3 nsites, followed by by systemic therapy based on phenotype.
20201|NCT04031365|Procedure|Acupuncture|Use of sterile, disposable needles in acupuncture
20202|NCT04031365|Behavioral|Cognitive Behavioral Therapy|psychotherapy
20203|NCT04031352|Other|implementation of CATCH scale|subject completed the CATCH scale
20204|NCT04031339|Procedure|Standard treatment|e.g., surgery, radioiodine therapy, systemic treatments (multikinase inhibitors), surveillance
20205|NCT04031326|Behavioral|LENA Home|LENA Home is a 13-week curriculum designed to add an early-language focus to existing home visiting or parent education programs for children ages birth to three. It employs LENA wearable audio recorder technology and targeted content to help parents and other caregivers increase interactive talk. There are 13 weekly one-on-one sessions, including modules on parent-child reading and increasing verbal interaction during typical home activities. Sessions include videos, practical techniques, and feedback from LENA recordings via intuitive reports to help parents talk more with their children. LENA Home reports provide data on adult words spoken to the child (AWC) and conversational turns (CTC). LENA Home has been shown to increase interactive talk and child language ability and informs parents how much they are talking with their children in an objective way.
20206|NCT04031300|Device|Prototype 0.5|Investigational Medical Device collecting spectral Raman data non-invasively from tissue
20207|NCT04031274|Device|TAVI|Trascatheter aortic valve implantation
20208|NCT04031274|Device|TMVR/r|Transcatheter mitral valve replacement/repair
20209|NCT04031248|Device|Whole body vibration|In this study an axial vibratory platform will be used: POWER-PLATE pro 5 AIRdaptive TM HP®. This device is reviewed annually by the technical unit of the company itself and complies with the international regulations that regulate the Medical Devices [Devices Directive (MDD) 93/42 / EEC (ISO 2631. 2011, Powerplate.com, 2013)]. The vibration will be administered with 2 mm of amplitude and 40 Hz of frequency.
20210|NCT04031248|Other|EXERCISE group|The program will consist of a routine of 18 exercises that will be executed where the greatest neuromuscular recruitment is sought. Most exercises are dynamic and isotonic. It is structured following the scheduled phases (ACSM, 2013) of warm-up, development and return to calm or stretching. The total duration of the program is 22 minutes, keeping the general lines of high-intensity aerobic interval training, which establishes a rest period at least equal to that of work. The treatment protocol will consist of 11 sessions applied in 4 weeks under an intervention regime of weeks 3 sessions, with a duration per session of 22 minutes, which will be supervised by a physiotherapist with more than 15 years of clinical experience.
20211|NCT04031235|Behavioral|Sleep Baby, Safe and Snug|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommended safe sleep practices. AAP safe sleep recommendations listed on the back cover.
20212|NCT04031235|Behavioral|Read Baby, Every Day|Specially designed children's book, 14 pages, rhyming, illustrated in color, written at a Kindergarten reading level. Each page spread highlights AAP-recommendations regarding the importance of reading and talking to infants. Recommendations and benefits of reading with infants are listed on the back cover as well.
20213|NCT04031209|Device|G7 Acetabular System|All patients will receive G7 Acetabular System
20214|NCT04031196|Procedure|QLB|QLB type 2 approach
20215|NCT04031196|Procedure|TAP block|classic TAP block approach
20216|NCT04031170|Behavioral|Incredible Years® School Age Basic Parent Training Program|The Incredible Years® School Age Basic Parent Training Program targets many of the proposed mechanisms and risk factors for internalizing distress in early childhood: harsh and unpredictable or critical parenting behaviors. Parents also learn cognitive strategies for themselves; such as self-praise, coping thoughts, how to challenge negative thoughts, and how to get support that they are encouraged to model for and teach their children. Finally, they learn how to be more positive and nurturing through academic, social and emotional coaching.
20217|NCT04031170|Other|American Academy of Pediatrics, Bright Futures Handouts|Written materials that include age-group specific tips on how parents can support their child's development and social and academic success.
20218|NCT04031157|Device|Predictix Antidepressant|Predictix Antidepressant guided treatment
20219|NCT04031144|Procedure|Ultrafiltration|At the end of CPB procedure, free water is partly removed by ultrafiltration to increase relative mass of red blood cell and plasma components
20222|NCT04031118|Device|Apioc Contact Lens|Measurement of corneal oxygen uptake with contact lens wear.
20223|NCT04031105|Device|Theta-burst stimulation (TBS)|intermittent (iTBS) and continuous (cTBS) will be applied at an intensity of 70% resting motor threshold (RMT) on the dorsolateral prefrontal cortex, position F3 (EEG 10-20 international system)
20224|NCT04031092|Device|Wearable tech with feedback|An armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone.
20225|NCT04031092|Device|Wearable tech without feedback|An armwrist device measuring physical activity level, no reporting back to the user.
20226|NCT04031092|Behavioral|Rehabilitation program|traditional inpatient rehabilitation program.
20227|NCT04031079|Device|Wearable tech with feedback|an armwrist device measuring physical activity level. The user will receive information about their physical activity level through their smartphone
20228|NCT04031079|Device|Wearable tech without feedback|an armwrist device measuring physical activity level, no reporting back to the user
20229|NCT04031079|Behavioral|Rehabilitation program|traditional inpatient rehabilitation program for overweight and obesity (lifestyle change program)
20230|NCT04031066|Drug|Velmanase Alfa|infusion i.v. treatment
20231|NCT04031066|Drug|Placebo|infusion i.v. treatment
20232|NCT04031053|Other|Pharmacokinetic study|The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose
20233|NCT04031040|Device|Genio(TM) system therapy|Hypoglossal nerve stimulation system
38732|NCT03880422|Other|Survey Administration|Ancillary studies
20235|NCT04031014|Device|BTL EMSELLA Active treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 100% for active treatment
20236|NCT04031014|Device|BTL EMSELLA Sham Treatment|BTL EMSELLA delivers high intensity focused electromagnetic technology to induce pelvic floor muscle contractions up to maximum intensity of 5% for sham treatment
20237|NCT04031001|Device|No-React Non-valved Conduit|Operative replacement of infected graft or implantation in infected area.
20238|NCT04030988|Drug|Oral dexamethasone minipulse|50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
20239|NCT04030988|Drug|Placebo oral tablet|50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments
20240|NCT04030962|Drug|AGN-242428|Ophthalmic solution administered as a topical eye drop
20241|NCT04030962|Drug|AGN-231868|Ophthalmic solution administered as a topical eye drop
20242|NCT04030962|Other|AGN-242428 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
20243|NCT04030962|Other|AGN-231868 Vehicle|Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop
20244|NCT04030949|Other|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants|No new interventions will be applied. MLST and MLVA even vPCR are tests already existing, tested and without any known adverse effects for the participants
20245|NCT04030923|Device|repetitive transcranial magnetic stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for the left DLPFC (coil placed tangential over the optimal position of 7 cm anterior to hand motor hotspot area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
20246|NCT04030910|Other|"LIFEView"|An audiovisual technology in development by Motitech AS.
20250|NCT04030884|Dietary Supplement|Honey and water mixture|"60 gr of organic Turkish BlackSea Region Chestnut Honey and 100 ml Spring water mixture both mixed in room temperature and ingested up to two hours before the surgery by participants who were nill by mouth from midnight prior to the operation day."
20251|NCT04030871|Device|Capsule Dome G-Tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
20252|NCT04030871|Device|Balloon Bolus feeding tube|Feeding replacement tubes with two different FDA approved devices in forty subjects
20253|NCT04030858|Behavioral|Plant-based diet + nutrition education|The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
20254|NCT04030845|Procedure|breast reconstruction|The breast reconstruction mainly included autologous tissue flaps (latissimus dorsi myocutaneous flaps, pedicled tansverse rectus abdominis myocutaneous flaps, free transverse rectus abdominis musculocutaneous flaps, deep inferior epigastric artery perforator flaps, etc.), implant based breast reconstruction, autologous flaps combined with implant reconstruction, fat graft, etc.
20255|NCT04030845|Procedure|oncoplastic breast-conserving surgery|The oncoplastic breast-conserving surgery were mainly those surgeries using volume displacement or volume replacement techniques.
20256|NCT04030819|Behavioral|schema therapy|The intervention is the schema therapy focuses on the management of anxiety and is based on self-efficacy, self-management . It consists of 20 once-weekly sessions of 90 minutes (with a 15 Min break), with homework activities between the sessions
20257|NCT04030806|Other|Mirror therapy intervention and control intervention|"The exercise protocol will be composed of bimanual activities, performed by both the hands of the patient (paretic and healthy). The same protocol will be applied for both groups (intervention group and control group).~Initially, the desensitization of the limbs will be accomplished by brushing the skin with objects of different textures (sponge, brush, cloths). Afterwards, isolated exercises of fingers (flexion-extension, opposition), wrists (flexo-extension), forearms (prono-supination) and elbows (flexo-extension) and functional exercises such as cleaning a table with a cloth, tightening sponges, roll balls. Each exercise will be performed slowly and repeated for 15 times, totaling three series of each exercise. The protocol used will be based on the proposal of Rothgangel and Braun (2013). The intervention will be carried out by the author of the project and by students of scientific initiation."
20258|NCT04030793|Device|Individualized transcranial direct current stimulation|Based on tDCS stimulation, individualized stimulation during 30 minutes with sitting position.
20259|NCT04030793|Device|Conventional transcranial direct current stimulation|Conventional tDCS stimulation during 30 minutes with sitting position.
20260|NCT04030780|Dietary Supplement|spore-forming probiotic|spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks
20261|NCT04030780|Other|Placebo|similar capsules administered twice daily
20262|NCT04030767|Drug|Botox Injectable Product|Botulinum toxin produces partial chemical denervation of the muscle resulting in localized reduction in muscle activity
20263|NCT04030754|Combination Product|amniotic membrane|amniotic membrane is a biological dressing
20264|NCT04030754|Combination Product|duoderm dressing|duoderm dressing is a synthetic dressing
20265|NCT04030741|Drug|Meronem and flagyl|meronem and flagy
20266|NCT04030741|Procedure|Appendectomy|Appendectomy as treatment for acute appendicitis
20267|NCT04030715|Drug|bismuth-containing quadral therapy based on antibiotic susceptibility|the different mucosal pathology graded by New Sydney System
20268|NCT04030689|Other|data collected from patient file|socio-demographics, previous HIV testing history, history of HIV contamination, clinics HIV related data will be collected for each patient who notified his non-objection to participate to this non interventional study.
20269|NCT04030676|Procedure|Biopsies|Two more biopsies in inflammatory zone will be collected.
20270|NCT04030676|Biological|Blood samples|Blood samples will be performed necessary at QuantiFERON-CMV (QF-CMV) test.
20271|NCT04030663|Drug|papaverine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
20272|NCT04030663|Drug|nitroglycerine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
20273|NCT04030663|Drug|xlyocaine|periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
20274|NCT04030650|Other|Functional analyses|2-minute walking test 200-metre walking test
20275|NCT04030650|Other|3D analysis of walking and balance|Walking analysis Balance analysis Analysis of the strength of the flexor and extensor muscles of the trunk and lower limb
20276|NCT04030650|Other|Functional analyses|400-metre walking test 200-metre walking test
20277|NCT04030624|Device|Remote Electronic Patient Monitoring|The Remote Patient Monitoring intervention is a remote monitoring system intended for use by healthcare professionals for the collection of physiological data in home and healthcare settings. Patient information is displayed on a computer located at the medical institution. Throughout the day, patient data from the remote monitoring system are presented on the clinician user interface (e.g., temperature, blood pressure, heart rate, respiration rate). Data are transmitted from sensors to the patient's smart phone.
20278|NCT04030611|Diagnostic Test|tongue diagnosis system|This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
20279|NCT04030598|Drug|IONIS PKK-LRx|IONIS PKK-LRx administered SC
20280|NCT04030598|Drug|Placebo|Placebo matching solution administered SC
20281|NCT04030585|Device|Robot|Patients with upper limb amputation using myoelectric prosthesis will done robot-assisted exercise program
20282|NCT04030585|Other|Home exercise|Patients with upper limb amputation using myoelectric prosthesis will done home exercise program
20283|NCT04030572|Drug|Clonidine Pill|0.1 mg tabs, one by mouth daily at bedtime for one week
20284|NCT04030559|Drug|Niraparib|Given PO
20285|NCT04030559|Drug|Niraparib Tosylate Monohydrate|Given PO
20286|NCT04030559|Procedure|Radical Prostatectomy|Undergo standard of care surgery
20287|NCT04030546|Drug|Ivabradine|Ivabradine capsule
20293|NCT04030520|Behavioral|POPPi behavioral intervention|behavioral intervention with offer of HIV self test
20294|NCT04030520|Behavioral|POPPi behavioral intervention|behavioral intervention
20295|NCT04030507|Device|MRI|MRI (which stands for magnetic resonance imaging) provide imaging of the brain which help look for brain metastases (spread of the breast cancer to the brain).
20296|NCT04030494|Diagnostic Test|BP measurement|sequential BP measurement with Withings WPM04 and sphygmomanometer with dual observer auscultation
20297|NCT04030494|Diagnostic Test|AF detection|single lead ECG with Withings WPM04 and 12 lead ECG
20298|NCT04030494|Diagnostic Test|VHD detection|phonocardiogram with digital stethoscope of Withings WPM04 and Doppler echocardiography
20299|NCT04030481|Other|inhalation anesthesia|sevoflurane was used to maintain anesthesia
20300|NCT04030481|Other|Total intravenous anesthesia|propofol was used to maintain anesthesia
20301|NCT04030468|Other|Educational intervention addressed to general practitioners|"feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~Continuous Medical Education (CME) course"
20302|NCT04030468|Other|Informative intervention addressed to patients|• leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
20303|NCT04030455|Drug|Carboplatin|Given IV
20304|NCT04030455|Drug|Cisplatin|Given IV
20305|NCT04030455|Drug|Docetaxel|Given IV
20306|NCT04030455|Biological|Pembrolizumab|Given IV
20307|NCT04030442|Drug|Immediate-release Oral Morphine Sulfate Tablets|0 mg Immediate release oral morphine; 15 mg Immediate release oral morphine; 30 mg Immediate release oral morphine; Randomized between sessions
20308|NCT04030442|Other|Thermal and Pressure Nociceptive Sensitivity|Primary outcome measures of pain threshold and tolerance.
20309|NCT04030429|Drug|Crizotinib 250 MG|bid orally
20310|NCT04030390|Behavioral|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
20311|NCT04030390|Behavioral|Control|time-matched task (sitting on the bike without pedalling)
20370|NCT04029922|Drug|MT-5111 (experimental study drug)|Experimental treatment with MT-5111
40137|NCT03869541|Other|Mobilization|Physical rehabilitation
20312|NCT04030364|Behavioral|CrossFit group exercise classes|"The group classes will occur at a local CrossFit gym facility. Participants will be free to attend up to 6 regularly-scheduled, free, 1-hr group classes per week at the local exercise facility for a period of 3-months. The recommendation will be to aim to attend at least three classes/week but there will no prescribed minimum. Classes will be supervised by experienced trainers.~Trainers will work collaboratively with participants to adapt the skill and workout of the day within each group class to the individual participant's physical limitations and needs. As such, each participant may complete a slightly different movement or workout on any given day based on their functional status at that time. However, all participants will be actively included in the community of the group class and will experience a relative stimulus that is moderately challenging for them."
20313|NCT04030351|Other|food - dried fruit|raisins, apricots, figs, and pineapple
20314|NCT04030338|Drug|18F-DCFPyL-iPSMA|Participants will be injected intravenously with a bolus of 7-10 mCi of 18F-DCFPyL.
20315|NCT04030338|Drug|68Ga-HBED-iPSMA|Participants will be injected intravenously with a bolus of 3-8 mCi of 68Ga-HBED-iPSMA
20316|NCT04030338|Diagnostic Test|PET/CT scan|The baseline PSMA PET scan may be performed externally or at MSKCC, but all follow-up imaging must be performed at MSKCC. Approximately 60-90 minutes after intravenous injection of radiotracer, patients will be scanned from the mid-skull to the mid-thigh. Imaging will start with a low-dose CT for attenuation correction, followed by a PET scan.
20317|NCT04030325|Behavioral|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
20318|NCT04030325|Behavioral|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
20319|NCT04030325|Behavioral|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking events
20320|NCT04030312|Dietary Supplement|Bottle Supplementation--Commercially-Sterilized Donor Human Milk|Supplementation by bottle with 20-calorie-per-ounce commercially-sterilized donor human milk (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
20321|NCT04030312|Dietary Supplement|Bottle Supplementation--Standard Infant Formula|Supplementation by bottle with 20-calorie-per-ounce standard infant formula (up to 15 ml, up to two times) for infants meeting hypoglycemia criteria and randomized to this treatment arm.
20322|NCT04030299|Device|Over-the-counter fitting|In this group, pre-configured hearing aids, which simulate over-the-counter hearing aids, will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
20323|NCT04030286|Other|Observation|Evaluation of Malondialdehyde level and correlation of Malondialdehyde level with periodontal and cardiovascular disease
20324|NCT04030273|Diagnostic Test|Diagnostic hysteroscopy|"Diagnostic hysteroscopy performed in outpatient setting, using no touch vaginoscopy technique with a 2.9 mm 30-degree rigid hysteroscope with a single inflow sheet using normal saline as distention media."
20325|NCT04030260|Drug|Regorafenib and Nivolumab in Combination with Radiotherapy|Regorafenib will be given 3 weeks on/1 week off (80 mg od po.) and Nivolumab administered IV at a dose of 3mg/kg every 2 weeks with or without irinotecan administered IV at a fixed dose of 80-100mg every 2 weeks
20326|NCT04030260|Radiation|Radiation therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
20327|NCT04030247|Drug|Plant Sterol|Patients will receive a plant sterol supplement to take twice daily in addition to the standard of care from their cardiologist/dietician in management of their moderate risk of cardiovascular disease.
20328|NCT04030234|Drug|Intensive BP treatment group|"Participants in the Intensive BP treatment group have a goal of SBP <120 mmHg. It is recommended to provide long-acting antihypertensive medications, that is once daily, unless other medication delivery frequency is needed. The local investigator may select among the available study antihypertensive medications. Other drugs not supplied by the trial may also be used as the investigator determines appropriate.~One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors; Angiotension receptor blockers (ARBs); Thiazide-type diuretics; Loop diuretics; Potassium-sparing diuretics; Beta-blockers; Calcium channel blockers (CCBs); Direct vasodilators; Alpha1-receptor blockers; Sympatholytics"
20329|NCT04030234|Drug|Standard BP treatment group|Participants in the Standard BP treatment group have a goal of SBP <140 mmHg. The same medications used in the Intensive BP treatment group will be used for the Standard BP treatment group.
20330|NCT04030221|Other|fluid infusion|250 ml of liquid will be given within 10 minutes for each patients, and the hemodynamic parameters before and after fluid infusion will be recorded. Then the experiment is completed.
20331|NCT04030208|Device|Umbulizer|Umbulizer is a reliable, user-friendly, and portable system that provides consistent air to the patient by quantitatively delivering a pre-determined tidal volume, inhale/exhale (I/E) ratio, peak pressure, and breathing rate (BPM). It can be configured to deliver either controlled ventilation or assist-controlled ventilation.
20332|NCT04030208|Device|Traditional Mechanical Ventilator|A medical device designed to artificially perform breathing functions for patients who are unable to adequately perform these functions on their own.
20333|NCT04030195|Genetic|PBCAR20A|"Single dose of Allogeneic Anti-CD20 CAR T cells will be infused, and a classic 3+3 dose escalation will be applied."
20334|NCT04030195|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
20335|NCT04030195|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
20336|NCT04030182|Diagnostic Test|Level of Vitamin D|3 ml of venous blood will be taken to determine the level of vitamin D
20337|NCT04030169|Drug|MDMA|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
20338|NCT04030156|Procedure|tonsillectomy|Tonsillectomy was performed under general anesthesia using cold dissection method.
20339|NCT04030143|Drug|Aripiprazole|Aripiprazole long acting injection.
20340|NCT04030143|Drug|Aripiprazole|Aripiprazole depot injection
20371|NCT04029909|Drug|Gimatecan 0.6mg/m2/d|0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
20372|NCT04029909|Drug|0.8mg/m2/d|0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
20373|NCT04029909|Drug|0.4mg/m2/d|0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
40847|NCT03864042|Drug|bupropion immediate release (IR)|taken orally
20341|NCT04030130|Behavioral|NDURE|NDURE is a theory-based, multi-level Patient Navigation (PN) intervention consisting of three in-person, clinic-based sessions of manualized PN with multiple intervention components that target system- (care coordination), interpersonal- (social support), and individual- (Health Belief Model; perceived susceptibility, severity, barriers, self-efficacy) level health behavior theoretical constructs to reduce barriers to care, improve cancer care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months).
20342|NCT04030117|Procedure|ACTIVA Bioactive restoration|Removal of Class II decay in second primary molars and placement of ACTIVA restoration.
20343|NCT04030117|Procedure|Compomer restoration|Removal of Class II decay in second primary molars and placement of Compomer restoration.
20344|NCT04030104|Device|Reader Study - Imagio Ultrasound|Imagio ultrasound images to be reviewed as part of Reader study
20345|NCT04030104|Device|Reader Study Imagio Ultrasound + Optoacoustic Imaging|Imagio Ultrasound + Optoacoustic images to be reviewed as part of Reader study
20346|NCT04030091|Drug|3 hours humulin R 100 IU/mL PIT|PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.
20347|NCT04030091|Drug|2 hours humulin R 100 IU/mL PIT|"As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less."
20348|NCT04030078|Other|Survey|Questionnaire-based survey
20349|NCT04030065|Drug|Omega 3 fatty acid|10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
20350|NCT04030052|Drug|Nuwiq (low dose protocol)|After receiving Emicizumab for 3-6 months, Nuwiq will be given as part of a low (25 units/kg) dose biweekly factor exposure program and for on demand use for acute bleeding episodes/procedures. Nuwiq will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
20351|NCT04030052|Drug|Emicizumab|Weekly subcutaneous (SQ) injections of Emicizumab include 4 weekly loading 3 mg/kg doses followed by weekly maintenance doses of 1.5 mg/kg.
20352|NCT04030052|Drug|Nuwiq (Atlanta protocol)|After completing Emicizumab loading, participants will receive intravenous (IV) infusions of Nuwiq 100 units/kg/dose 3 times a week for 12 months per the Atlanta protocol. Infusions will be given at least 36 hours from the previous Nuwiq injection.
20353|NCT04030039|Drug|Interferon|chronic hepatitis B patients with interferon therapy
20354|NCT04030039|Drug|nucleoside analogues|chronic hepatitis B patients with interferon therapy
20355|NCT04030026|Drug|Nalbuphine ER|Subjects on NAL ER will have the dose titrated from 27 mg once daily (QD) to 54 mg BID over a 5-day period and then maintained at 54 mg BID for approximately 4 days. Doses will be subsequently escalated and maintained at 108 mg BID over 1 week and then to 162 mg BID over 6 days.
20356|NCT04030026|Drug|Placebo oral tablet|Placebo Comparative will be given in Arm 1b and again in Arm 2a
20357|NCT04030013|Other|group education|All patients of group 1 and 2 will receive intensive education for 3-4 months, then refreshment session every 3 months for 2 years. Initially, patient data will be collected through 3 types of forms: patient identification form, metabolic control parameters form and diabetes self-care scale questionnaire; then every 6 months metabolic parameters and diabetes self-care scale questionnaire will be reassessed.
20358|NCT04030000|Drug|Paclitaxel/Carboplatin|IV paclitaxel in combination with IP carboplatin
20359|NCT04030000|Radiation|Pelvic radiation therapy|EBRT and vaginal brachytherapy
20360|NCT04029987|Procedure|Bilateral Ultrasound-Guided Transmuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from the posterior (medial) end of the probe and directed for the fascial plane between the Quadratus Lumborum and the Psoa Major muscles through the Quadratus Lumborum muscle. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
20361|NCT04029987|Procedure|Bilateral Ultrasound-Guided intra smuscular Quadratus Lumborum Block.|A 22 G echogenic needle will be inserted in plane from ventral (lateral) edge of the probe and advanced until penetration of QL muscle fascia is observed. Once the needle is confirmed in correct location, 1 mL of saline will be injected after negative aspiration. Then 0.5 mL/Kg of bupivacaine 0.25% will be injected. The spread of the injectate should be observed to distribute within this plane. This technique will be repeated to the other side.
20362|NCT04029987|Procedure|Control|Conventional analgesia
20363|NCT04029974|Device|ErigoPro|Robotic tilt-stepper lower extremity movements at the cadence of 0, 40, and 80 steps/minute.
20364|NCT04029961|Other|Video Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of a video.
20365|NCT04029961|Other|VR-based Education|Prior to their CT simulation, participants will receive education on radiation therapy in the form of an immersive VR program delivered through a head-mounted display (HMD).
20366|NCT04029948|Procedure|Laser En Bloc Resection Of bladder Tumor|Using laser beam starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
20367|NCT04029948|Procedure|Electro-surgical En Bloc Resection Of bladder Tumor|Using electro-surgical loop starting the procedure with circumferential incision few millimetres around the tumour then lifting the tumour and dissection underneath its muscle base
20368|NCT04029935|Behavioral|Physical Fatigue|Maximal cycling effort for 30s (Wingate modified)
40848|NCT03864042|Drug|encorafenib|taken orally
20374|NCT04029896|Drug|HB-adMSC|intravenous infusion of Hope Biosciences autologous adipose-derived stem cells
20375|NCT04029883|Other|Remote BP Monitoring|Remote BP monitor linked to patient's electronic health record. This is a process of care study assessing remote BP monitoring.
20376|NCT04029857|Dietary Supplement|Nutritional Supplement Drink|Given standard of care nutritional supplementation
20377|NCT04029857|Dietary Supplement|Nutritional Supplementation|Given Impact Advanced Recovery PO or via feeding tube
20378|NCT04029844|Device|Colibri TAVI System|Implantation of Colibri heart valve
20379|NCT04029831|Drug|Propofol and Ketamine Mixture (Ketofol)|Each group was given Ketofol, but group K61 received mixture of propofol and ketamine in a ratio of 6:1 while K41 received 4:1
20380|NCT04029818|Biological|Bifidobacterium BSL_PS404|Each participant will consume 1 capsule daily at lunch for 8 weeks.
20381|NCT04029818|Biological|Placebo|Each participant will consume 1 capsule daily at lunch for 8 weeks.
20382|NCT04029805|Combination Product|Combination of a plant extract (BSL_EP044) and Lactobacillus BSL_PS6|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
20383|NCT04029805|Combination Product|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
20384|NCT04029792|Combination Product|Combination of plant extracts (BSL_EP028)|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
20385|NCT04029792|Combination Product|Placebo|Each participant will consume 2 capsules daily, in the morning and at night without any restriction in the diet nor in their habits of life.
20386|NCT04029779|Biological|I-PRF|Local anaesthesia was administered and mucoperiosteal flap was reflected. Atraumatic tooth extraction was performed. Socket was curetted to remove the granulation tissue present in the socket with the help of curettes. The socket was well irrigated with saline. Implant osteotomies wasl performed with sequential drilling with standardized drills.I-PRF was freshly prepared 600rpm for 7 min(50g). 1ml of the i-PRF was applied in to the osteotomy site and the implant surface will be thoroughly coated followed by placing of the implant. The surgical site was thoroughly irrigated and debrided. Flap closure was achieved using 3-0 silk sutures to protect the implant site.
20387|NCT04029766|Drug|HSK3486|
20388|NCT04029753|Behavioral|Walk out from operating room|After the surgery of laparoscopic radical gastrectomy, patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb.
20389|NCT04029740|Behavioral|CBT- both internet and face to face|There are a few common psychotherapies for treating PD, with Cognitive Behavioral Therapy (CBT) as the most common. The most known type of CBT for treating PD consists of two major strategies: cognitive restructuring, and interoceptive and structured exposure to bodily sensations that have become associated with panic attacks (D H Barlow, 1997). The ICBT therapy is based on Barlow and Craske's (2007) protocol for treating PD with elaborations (Huppert & Baker-Morissette, 2003). It includes six modules containing psychoeducation, cognitive restructuring, exposures, acceptance, and consolidation of gains and relapse prevention. The online modules include reading passages, worksheets, videos, and homework assignments. After completing each module, participants practice related skills and complete homework assignments. The treatment is up to 16 weeks long; participants are encouraged to complete the treatment within this time period, and reminders are sent to monitor their progress.
20390|NCT04029740|Other|No intervention|Healthy controls will not receive any intervention.
20391|NCT04029727|Dietary Supplement|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
20392|NCT04029727|Dietary Supplement|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
20393|NCT04029714|Procedure|Active Surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
20394|NCT04029701|Drug|Ruyizhenbao Pill|Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
20395|NCT04029701|Drug|Placebo of Ruyizhenbao Pill|Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
20396|NCT04029688|Drug|Idasanutlin|Idasanutlin will be administered as an oral medication once daily on Days 1-5 of a 28-day cycle.
20397|NCT04029688|Drug|Venetoclax|Venetoclax will be administered orally at the adult dose equivalent (adjusted by body weight) of 400 milligrams (mg) in participants with neuroblastoma and the adult dose equivalent of 600 mg in participants with leukemia.
20398|NCT04029688|Drug|Cyclophosphamide|Cyclophosphamide will be administered once daily on Days 1-5 of each 28-day cycle at 250 milligrams per meter squared of body surface area (mg/m^2) as an intravenous (IV) infusion.
20399|NCT04029688|Drug|Topotecan|Topotecan will be administered once daily on Days 1-5 of each 28-day cycle at 0.75 mg/m^2 as an IV infusion.
20400|NCT04029688|Drug|Fludarabine|Fludarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 30 mg/m^2 as an IV infusion.
20401|NCT04029688|Drug|Cytarabine|Cytarabine will be administered once daily on Days 1-5 of each 28-day treatment cycle at 2000 mg/m^2 as an IV infusion.
20402|NCT04029688|Drug|Intrathecal Chemotherapy|All participants with leukemia, irrespective of arm, will receive intrathecal chemotherapy on Day 1 of each 28-day treatment cycle. Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate age-based dosing as specified in the protocol.
20403|NCT04029675|Dietary Supplement|Vitamin C|Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
20404|NCT04029662|Behavioral|Valsalva Maneuver|Performing Valsalva maneuver will reduce the pain intensity during spinal needle insertion.
20405|NCT04029649|Drug|Beta-1,3/1,6-D-Glucan|Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days
20406|NCT04029649|Drug|Placebo|Placebo capsule three times daily for 90 days
40849|NCT03864042|Drug|binimetinib|taken orally
20407|NCT04029636|Other|Inhaled Hyperpolarized Xenon-129|How hyperpolarized 129Xe MRI measurements of lung structure and function change over time in a population at high risk for LONIPC related to their transplant
20408|NCT04029623|Other|Partnered Rhythmic Rehabilitation (PRR)|Partnered Rhythmic Rehabilitation (PRR) is moderate intensity, cognitively-engaging social dance that targets postural control systems. PRR involves learning complex stepping patterns and fosters tactile communication of motor goals between partners, enhancing social interaction's effect on cognition. Class sizes will consist of 10 or fewer pairs of participants with pAD and partners to maximize safety. Participants will engage in partnering exercises on how to interpret motor goals through touch, exercises to develop understanding of temporal relationship of movement to music, novel step introduction, connecting previously learned and novel step elements. Classes include practicing previously-learned steps, a 20-minute standing warm-up, and partnering and rhythmic enhancement exercises.
20409|NCT04029623|Other|Group walking (WALK)|WALK sessions consist of 10 minutes of warm-up, and evaluation/tips for practicing safe walking form mechanics (i.e., head up, shoulders relaxed, abdominals engaged, heel strike, roll and toe off; keep natural stride length, and speed up cadence if increased speed is desired), 55 minutes of walking with breaks, and 20 minutes of balance and stretching. WALK will take place in small groups with research assistants and trained family members and/or caregivers to control for social effects/contact of intervention. Participants of similar walking abilities will be 'buddied' with research assistants and trained physical therapy students who will act as group backmarkers, although participants will lead the pace. WALK participants will keep walking logs documenting their progress. WALK is expected to expend 3 metabolic equivalents (METs), like that of PRR.
20410|NCT04029610|Procedure|Local anesthesia with lidocaine and adrenalin.|Local anesthesia with lidocaine and adrenalin.
20411|NCT04029610|Drug|lidocaine and adrenalin|lidocaine and adrenalin
20412|NCT04029610|Drug|lidocaine and arterial blockage|lidocaine and arterial blockage
20413|NCT04029597|Behavioral|Remote Patient Monitoring|Families participating in the study will receive standard medical care as well as the RPMS. The RPMS was developed in collaboration with the University of Mississippi Medical Center (UMMC) Center of Telehealth. Patients enrolled in this open trial of the RPMS will interact with the RPMS system on a daily basis and with UMMC's Center for Telehealth nurse care coordinators and research and clinical staff on an as needed basis. The RPMS will provide patients with include an electronic tablet (i.e., iPad) and the ability to receive data from the patient's weight scale and pedometer. Patients will be asked to wear the pedometer daily to track engagement in physical activity and weigh themselves weekly to track weight during the 3 month period. Educational information specific to pediatric obesity and healthy eating and engagement in physical activity will be presented daily through brief presentations and video clips.
20414|NCT04029584|Drug|Intravenous Rifampin|A 30-min intravenous infusion of rifampin 600mg in 10ml Normal Saline will be used to inhibit hepatic OATP1B1 transporters.
20415|NCT04029571|Drug|TCM-FMD|"Apply fastening-mimicking diet combined with a dispelling dampness meal replacement. For the convenience of implementation, a cycle of 4 weeks. The first 5 days of each cycle is the calorie restriction stage (daily calorie about 800kcal). The traditional Chinese medicine with dampness effect is used as the main source of calories in this stage. The normal diet is carried out under the guidance of a professional dietitian for the next 23 days. Study for 12 weeks."
20416|NCT04029571|Other|FMD|"A grain package is used to replace the dispelling dampness meal replacement, and the other thing is the same as the proposal in TCM-FMD."
20417|NCT04029558|Dietary Supplement|Combination of Plant Extracts (BSL_EP025)|Each participant will consume 2 capsules daily at lunch for 8 weeks.
20418|NCT04029558|Dietary Supplement|Placebo|Each participant will consume 2 capsules daily at lunch for 8 weeks.
20419|NCT04029545|Device|PN40082|1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
20420|NCT04029532|Device|Respiratory exchange ratio|Ask participants to supine on bed, using a ventilator hood cover upon their head. Measure respiratory exchange ratio for 15 minutes.
20421|NCT04029532|Device|Heart rate variability|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist. Measure heart rate variability for 5 minutes.
20422|NCT04029532|Device|Body composition|Ask participants to supine on bed for 10 minutes, connect electrodes on their right wrist and right foot. Measure body composition.
20423|NCT04029532|Behavioral|Eating behavior|Fill in questionnaire (Three-Factor Eating Questionnaire, revised 18-item, TFEQ-18).
20424|NCT04029532|Behavioral|Physical activity recall|Fill in questionnaire (Seven-days Physical Activity Recall, 7-d PAR).
20425|NCT04029532|Behavioral|Depression|Fill in questionnaire (Mongomery-Asberg Depression Rating Scale, MADRS).
20426|NCT04029532|Behavioral|Body image|Fill in questionnaire (multi-directional self-body relationship questionnaire (MBSRQ), figure rating scale (FRS)).
20427|NCT04029519|Device|PN40082|PN40082 (manufactured by Prollenium Medical Technologies) is a clear, colorless gel in 1.0 mL pre-filled syringes with 25 mg/mL of stabilized hyaluronic acid and lidocaine 0.3% w/w.
20428|NCT04029480|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg, oral, 1 tablet QD
20429|NCT04029480|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg, oral, 1 tablet QD
20430|NCT04029480|Drug|Placebo|Placebo to ertugliflozin 15 mg, oral, 1 tablet QD
20431|NCT04029480|Drug|Placebo|Placebo to ertugliflozin 5 mg, oral, 1 tablet QD
20432|NCT04029480|Biological|Insulin|The initiation and titration of insulin will be at the discretion of the investigator, based on local/regional/country guidelines.
20433|NCT04029480|Drug|Metformin|Participants will receive stable dose of background metformin.
20434|NCT04029467|Drug|Dexmedetomidine|addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
20435|NCT04029454|Biological|birth dose vaccination against hepatitis B strategy|"Complex intervention targeting healthcare workers and involving:~training on hepatitis B awareness and management~training on EPI vaccination and cold chain~training on the modalities for the birth dose administration~the use of a monovalent unidose vaccine against Hepatitis B"
20436|NCT04029441|Other|the eradication Hp|the eradication of Hp based on antimicrobial susceptibility test
20474|NCT04029103|Other|knowledge, behaviour, self efficacy|Knowledge, behavior and self-efficacy of both groups were measured before and after the study.
20437|NCT04029428|Drug|90Y-DOTATATE|Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
20438|NCT04029428|Drug|(177Lu-DOTAOTyr3)Octreotate|Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
20439|NCT04029428|Drug|90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)|Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
20440|NCT04029402|Other|RNA sequencing|Transcriptomic analysis of kidney biopsy tissue, and linking with slope of eGFR decline
20441|NCT04029389|Device|Injection|Local corticosteroid injection
20442|NCT04029389|Device|Tibial nerve block|Tibial nerve block
20443|NCT04029389|Other|Conservational therapy|Only exercise and foot insoles
20444|NCT04029376|Drug|Iberogast®|The medication was applied 3 times 20 drops per day before or at meals with some liquid, ideally to one week insofar.
20445|NCT04029363|Device|HighLife Transcatheter Mitral Valve Replacement|Transcatheter Mitral Valve Replacement
20446|NCT04029350|Drug|Anlotinib Combined With Osimertinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Osimertinib：80 mg/tablet， per os (p.o.) daily. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
20447|NCT04029337|Device|HighLife Transcatheter Mitral Valve Replacment|Transcatheter mitral valve replacement
20448|NCT04029324|Procedure|tooth extraction|Under local anesthesia, tooth will be extracted atraumatically.
20449|NCT04029324|Procedure|Implant placement|Dental implants will be placed according to the instructions in fresh sockets or alveolar ridge.
20450|NCT04029324|Procedure|Bone augmentation|Bone substitute will be used to augment or maintain the bone contour.
20451|NCT04029324|Procedure|Coronally repositioned flap|After periosteal releasing incision, mucoperiosteal flap will be sutured at a more coronally position
20452|NCT04029311|Device|Nuance Pro|Study compares Nuance Pro plus autoPAP vs TAP PAP plus autoPAP
20453|NCT04029311|Device|autoPAP|autoPAP
20454|NCT04029311|Device|TAP PAP|TAP PAP
20455|NCT04029298|Behavioral|Lifestyle Interventions|Educational based intervention to enhance lifestyle modifications such as diet, exercise, patient activation, and medication adherence
20456|NCT04029285|Other|Exergaming|The exergaming group played six IREX® exergames. Those in the TGB group performed exercises that were matched to the IREX® exergames for: movement patterns required, physiological demands, sequence, duration and mode of exercise by adopting open and closed kinetic chain movements, in the same range and loading, across both groups. Each IREX® exergame was played for two minutes and was repeated three times within a session. TGB exercise was conducted in sets of two minutes duration, repeated three times within a session. In both groups participants were given rest periods of 10 to 30 seconds, or longer, if required, between exergames or TGB exercise sets.
20457|NCT04029272|Drug|Metformin|500 mg tid for 12 weeks
20458|NCT04029272|Drug|Exenatide 2 MG|Exenatide injection once weekly for 12 weeks
20459|NCT04029259|Diagnostic Test|Brain MRI|Brain MRI diagnoses tromboembolic lesions or bleeding to the cerebrum and is part of preoperative diagnostic tests before carotid surgery. After surgery brain MRI may present New lesions related to surgery, clinically significant or insignificant. Our goal is to evaluate the relevance of this modality in carotid surgery..
20460|NCT04029246|Behavioral|Follow up phone call|Telephone call to ask if patient has received letter and whether they would like an appointment
20461|NCT04029246|Behavioral|Incentive|Offer of a shopping voucher if patient attends for appointment
20462|NCT04029233|Device|Occlutech PFO Occluder|The Occlutech PFO Occluder is a medical device for transcatheter closure of PFO.
20463|NCT04029220|Behavioral|Parent Peer Navigation|Parent Peer Navigation (PPN) is implemented by trained providers with lived experience, who are supported by training and coaching protocols. The role of PPN provider is to engage caregivers in necessary treatment for their children and prepare them to independently navigate the child serving system, community-based resources, and ongoing opportunities for support. PPN providers will support families who are just entering he child-serving systems for 6 months on a weekly basis during which they will: help link families with formal and informal supports; instill confidence and coping skills; assist in the development of goals and crisis plans; and serve as an advocate for resolution of issues. Also, the PPN provider helps the family to learn to navigate systems and advocate for their needs, prepares families for meetings and treatment sessions, helps identify ways for parents to practice self-care; and promotes family choice and shared decision making.
20464|NCT04029207|Procedure|Cesarean section|Abdominal, operative delivery of the fetus
20465|NCT04029194|Behavioral|Assistance with old age pension application|The intervention will offer elderly assistance in applying for the old age pension.
20466|NCT04029181|Other|Anti-CD8 PET imaging agent|An imaging agent radiolabelled with 89Zr developed for in human PET imaging of CD8
20467|NCT04029168|Procedure|pelvic floor surgery|midurethral slings and pelvic organ prolapse surgical procedures
20468|NCT04029155|Device|Lung biopsy|Transbronchial Needle Aspiration performed via a ultra thin bronchoscope
20469|NCT04029142|Diagnostic Test|Review of routine lab data|Review of routine lab data from pregnant women (first trimester)
20470|NCT04029129|Other|Air filtration and building envelop modifications|Air filters and closing and sealing of windows and doors was used to reduce infiltration of air pollution from outdoors in rooms next to major highways at rush hour.
20471|NCT04029116|Drug|Fluconazole Tablet|150 mg every 72 hours for 3 doses
20472|NCT04029116|Drug|IBREXAFUNGERP|300 mg BID (one day) every 4 weeks for a total of 6 dosing days
20473|NCT04029116|Drug|Placebo oral tablet|BID (one day) every 4 weeks for a total of 6 dosing days
20475|NCT04029090|Drug|MCI-186|A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.
20476|NCT04029090|Drug|MCI-186|A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.
20477|NCT04029090|Drug|Placebo|A single dose of 0.9% w/v saline over 60 min will be intravenously administered.
20478|NCT04029077|Other|NA: intervention is not part of the study|NA: it is not an interventional study
20479|NCT04029051|Other|Focus thoracic ultrasound for dyspnea diagnosis|Focus thoracic ultrasound is composed by an advanced cardiac ultrasound with Doppler measures and a lung ultrasound.
20480|NCT04029038|Biological|Autologous CD19/CD22 Chimeric Antigen Receptor T-cells|Given IV
20481|NCT04029038|Drug|Cyclophosphamide|Given IV
20482|NCT04029038|Drug|Fludarabine|Given IV
20483|NCT04029025|Procedure|Workflow A|Dentalwings DWOS Intraoral Scan (IOS A) + Dentalwings DWOS Implant Prosthetics Lab-Software (CAD A)
20484|NCT04029025|Procedure|Workflow B|3Shape TRIOS Pod Intraoral Scan (IOS B) + Straumann CARES Lab-Software (CAD B)
20485|NCT04029025|Procedure|Workflow C|Conventional Impression + conventional porcelain-fused-to metal iFDP (LabS C/CAD C)
20486|NCT04029012|Drug|Methoxyflurane|Methoxyflurane inhaler before Rezum procedure
20487|NCT04028999|Device|Evaluate the effects of the EO31 shoulder sling in adults post-stoke|Investigator want to evaluate the efficient of the EO31 shoulder sling in adults post-stroke. The EO31 shoulder sling is made-to-measure shoulder pads for upper limb after cerebrovascular accident
20488|NCT04028986|Drug|Ulipristal Acetate 5 MG Oral Tablet|use of ulipristalacetate OR surgery before fertility treatment
20491|NCT04028960|Drug|Regular insulin (Humulin-R), intranasal route|Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
20492|NCT04028960|Device|SipNose intranasal device|The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
20493|NCT04028947|Procedure|Prophylactic Infrapatellar Saphenous Neurectomy in Primary Total Knee Arthroplasty|Prophylactic infrapatellar saphenous nerve neurectomy will be performed at the same time as the TKA.
20494|NCT04028921|Other|No intervention|This is a cross-sectional study; no intervention
20495|NCT04028908|Diagnostic Test|radiographs in two views of the tibia|The anterior tilt angle of the tibia will be measured by two specialized radiologists according to a specific radiological angle measurement tool (PACS Sectra IDS7TM, Linköping, Sweden).
20496|NCT04028895|Diagnostic Test|Dosage of IRAP during OGTT|Visit 1: oral glucose tolerance test. visit 2: hyperinsulinemic euglycemic clamp
20497|NCT04028882|Other|Signaling, metabolomic and transcriptomic analysis|Signaling, metabolomic and transcriptomic analysis
20498|NCT04028869|Drug|Glycyrrhizic acid preparation|To analyze the clinical effect of glycyrrhizic acid preparation for autoimmune liver disease for 144 weeks and the safety during treatment
20499|NCT04028856|Drug|interferon|Chronic hepatitis B patients were treated with interferon for 48 weeks
20500|NCT04028843|Behavioral|Healthy Beginnings|The program includes a 24 week intensive behavior modification program that targets healthy gestational weight gain through self-monitoring of weight and activity data, automated prescriptive feedback from the smartphone application, personalized feedback from counselors and, evidence-based behavioral intervention delivered throughout pregnancy.
20501|NCT04028830|Other|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC|Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
20502|NCT04028817|Device|photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
20503|NCT04028817|Device|placebo photobiomodulation|the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied a placebo sublingual laser for 360 s.
20504|NCT04028804|Procedure|FDG PET|Each patient will receive a single intravenous injection of FDG (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FDG are being drawn up or radioactive decay has reduced the amount of available.
20505|NCT04028804|Procedure|FLT PET|The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.
20506|NCT04028791|Other|Exercise on ergocycle|The exercise includes 15 minutes of warm up, then participants will be asked to pedal as fast as possible for 6 seconds. The test of 6 seconds will be repeated twice or more with recovery each time
20507|NCT04028778|Drug|Gefitinib|Gefitinib 250mg, p.o., qd, D1-D21; 3 weeks one cycle.
20508|NCT04028778|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
20509|NCT04028778|Other|Placebo|Placebo simulating anlotinib hydrochloride capsule 12mg, p.o., qd, D1-D14; 3 weeks one cycle.
20512|NCT04028752|Biological|Blood collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in the arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
20513|NCT04028739|Dietary Supplement|curmin|curcumin 90mg/day cross-over
20514|NCT04028726|Other|Back-squat exercise|Participants begin with a 5 min dynamic warm-up. Then, they will perform two sets of five repetitions at 40-60% of predetermined 1-repetition maximum (1-RM). The clustered bout will be 4 sets of 2 clusters of 5 repetitions with a 30-second intra-set rest between clusters, and 90-second inter-set rest at a load 70% of 1-RM. The traditional bout will be 4 sets of 10 repetitions with a 120-second inter-set rest at a load 70% of 1-RM.
20515|NCT04028713|Procedure|Venapuncture|Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of adalimumab.
20516|NCT04028713|Procedure|Dried blood spot|A subset of patients will sample additionally by using the dried blood sampling technique.
20517|NCT04028713|Drug|Dose reduction|Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.
20518|NCT04028700|Biological|Red Blood Cell Transfusion|Patients will receive a red blood cell transfusion. The last 50mL of the transfusion will be labeled with chromium to allow investigators to study the lifespan of the red blood cells transfused into each patient.
20519|NCT04028687|Device|Taperloc Complete Stem|Patients that have been implanted with a Taperloc Complete Stem to improve hip malfunction/disease.
20520|NCT04028674|Device|Laryngeal Pacing Device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
20521|NCT04028674|Drug|Botulinum toxin type A|Repeated Botox injections
20522|NCT04028661|Device|3D printed Modified Twin Block Appliance|It is a functional appliance for mandibular advancement designed digitally on virtual models.
20523|NCT04028635|Behavioral|Cognitive-behavioral therapy plus VR-based body exposure|Combine usual cognitive-behavioral treatment (CBT) sessions with additional five VR-based body-exposure therapy sessions.
20524|NCT04028635|Behavioral|Cognitive behavioral therapy|Usual CBT
20525|NCT04028622|Other|TCAD (telemedicine anesthesia consultation)|Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
20526|NCT04028609|Behavioral|Healthy at Home|In addition to receiving medical services as usual, subjects receive services from Community Healthy Workers during the transition from the hospital to their community residence.
20527|NCT04028609|Other|Services as Usual|Routine medical services
20528|NCT04028596|Drug|Paracetamol|once, 1000mg, 2 h before ECT session
20529|NCT04028596|Drug|Nimotop|once, 60mg, 2 h before ECT session
20530|NCT04028583|Other|PIM-Check|In the PIM-Check group, a medication review will be conducted using PIM-Check within 72 hours of patient's admittance to the unit. The physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
20531|NCT04028583|Other|STOPP/START|In the STOPP/START group, medication lists will be analyzed within 72 hours of patient's admittance and optimized according to STOPP/START criteria. The second physician will decide whether to accept these recommendations or not and implement prescribing changes if agreed.
20532|NCT04028570|Radiation|Varying Doses of Background and Boost RT|3+3 radiation dose escalation model to see the maximum tolerated dose for background and boost radiation therapy.
20533|NCT04028557|Other|Decision Support Systems, Clinical|Active computerized clinical decision support alert within the electronic health record that recommends initiation of an evidence-based beta blocker for heart failure and reduced ejection fraction.
20534|NCT04028544|Drug|Qishenyiqi dropping pills|on the basis of standard treatment, adding QSYQ dropping pills 1 bag each time, 3 times a day
20535|NCT04028544|Drug|Placebo|on the basis of standard treatment, adding placebo 1 bag each time, 3 times a day
20536|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The high-dose group (18 mg + 18 mg) was divided into two intravenous injections. the first intravenous bolus injection of 18mg,after 30mins, the second intravenous bolus injection of 18 mg, Push slowly for more than 2mins each time."
20537|NCT04028518|Drug|r-PA|"Drug: r-PA Dose: stick 18 mg;~Mode of admin:~The low-dose group (12 mg + 12 mg) was divided into two intravenous injections, the first intravenous bolus injection of 12 mg, after 30mins, the second intravenous bolus injection of 12 mg, Push slowly for more than 2mins each time."
20538|NCT04028518|Drug|Alteplase for Injection|"Drug: Alteplase for Injection Dose:50mg; 20mg~Mode of admin:~0.9 mg/kg (maximum dose of 90 mg) intravenous, 10% of which was injected intravenously within the first 1min, and the rest continued intravenous infusion for 1 h."
20539|NCT04028505|Drug|Terlipressin Injectable Product|"Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH."
20540|NCT04028492|Drug|Tradipitant|BID
20541|NCT04028492|Drug|Placebo|BID
20542|NCT04028479|Diagnostic Test|Testing: Genome|Patients who receive genomic testing of their tumor as part of standard of care. This is an observational arm.
20543|NCT04028479|Diagnostic Test|Testing: Transcriptome|Patients who receive transcriptomic testing of their tumor as part of standard of care. This an observational arm.
20544|NCT04028479|Diagnostic Test|Testing: Proteome|Patients who receive proteomic testing of their tumor as part of standard of care. This is an observational arm.
20545|NCT04028479|Drug|Treatment: CAR-T|Patients who receive CAR-T therapy as part of standard of care. This is an observational arm. Patients may have also received any diagnostic testing of their tumor such as genomic or transcriptomic testing.
20546|NCT04028466|Drug|Vonoprazan|Patients will be randomized to receiving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
20547|NCT04028466|Drug|Omeprazole|Patients will be randomized to receving vonoprazan 20mg tablet or omeprazole 40mg capsule, either of which will be taken 30 minutes before the first meal of the day for 14 days
20548|NCT04028453|Other|Survey|There will be a first part with a retrospective study in order to collect pregnancy data to answer to the primary endpoint. Then, there will be a prospective part where mothers and their children will have to answer an evaluation survey.
20549|NCT04028440|Biological|Autologous γδT cells|Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
20550|NCT04028427|Behavioral|Values-plus-goals intervention|The VGI is a four-week intervention, adapted from an existing online value-affirmation and goals intervention (Kingston & Ellett, 2014) and an existing 'Living Well with Physical Health Conditions' programme handbook. Participants are first introduced to the concept of values as understood in Acceptance and Commitment Therapy. They are then asked to complete a card-sort task, which involves organising ten life domains according to their perceived level of importance. Participants will be asked to choose one values that is the most important and meaningful to them and to write for up to 10 minutes about it, thinking about why it is meaningful to them. Following this, participants will be given information on how to set value-based 'SMART' goals and asked to choose one to focus on over the next month. Participants will be sent a reminder e-mail every week over the 4 weeks, asking them to review their progress towards the SMART goal they set themselves.
20551|NCT04028427|Behavioral|Mindfulness-based intervention|The MBI is a four-week intervention, where participants are introduced to the concept of mindfulness and acceptance as understood in ACT (Hayes et al., 1999). They will be asked to complete a 10-minute health-focused mindfulness meditation exercise by listening to a recording of a script focusing on cultivating mindful awareness of internal experiences, particularly in relation to diabetes, and practising making room for any difficult internal experiences. This will be followed by some prompts to promote reflections related to their diabetes following the exercise. They will be asked to practise this exercise 3-4 times a week over a four-week period. As a manipulation check, participants will be sent a reminder e-mail every week over the four weeks to record how many times they practised the exercise over the past week.
20552|NCT04028414|Other|Early Weight Bearing|Patients will be instruction to weight bear as tolerated while in a boot.
20553|NCT04028401|Drug|5% benzoyl peroxide|Application of 5% benzoyl peroxide during 5 days before the procedure
20554|NCT04028388|Drug|Docetaxel in Parenteral Dosage Form|Treatment with IV docetaxel at 75 mg/m2 given as a one-hour infusion on day 1 every 21 days plus 5 mg oral prednisone twice daily
20555|NCT04028388|Drug|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
20556|NCT04028375|Other|No intervention|No intervention
20557|NCT04028362|Drug|Neuromuscular Blocking Agents|Patient who will receive neuromuscular blockade will be follow during their ICU lenght stay.
20558|NCT04028349|Drug|Ad26.ZEBOV/MVA-BN-Filo|Candidate Ebola Vaccine
20559|NCT04028336|Other|TITRATION|PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
20560|NCT04028323|Drug|Terlipressin|Terlipressin should be administrated intravenously while monitoring heart rate and blood pressure daily.
20561|NCT04028323|Drug|Octreotide|Octreotide should be continuously intravenously administrated while monitoring heart rate and blood pressure daily.
20562|NCT04028310|Other|Phonological|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
20563|NCT04028310|Other|Visual-attention|"Phase 1: intervention without targeted daily training (30 minutes/ week, for 8 weeks)~Phase 2: intervention with targeted daily training~Visuo-attentional training (15 minutes/ day, 5 days/week, for 8 weeks)~Phonological training (15 minutes/ day, 5 days/week, for 8 weeks)~Cross-modal training (15 minutes/ day, 5 days/week, for 8 weeks)~Phase 3: stopping training sessions for 8 weeks"
20564|NCT04028297|Other|Focus cardiac ultrasound (FoCUS)|
20565|NCT04028284|Device|HoloLens-guided epidural|To determine whether using the HoloLens tool increases the success of epidural insertion.
20566|NCT04028284|Other|US-guided epidural|traditional thoracic epidural procedure
20567|NCT04028271|Device|Comfort-in injection system|local anesthesia during dental treatment
20568|NCT04028271|Other|conventional injection with dental needle|for local anesthesia during dental treatment
20569|NCT04028258|Dietary Supplement|Mixture of fibers + Placebo|Study product: mixture of plant-based food fibers (3 weeks) + wash out (2 weeks) + placebo control : plum flakes + maltodextrin (3 weeks)
20570|NCT04028258|Dietary Supplement|Placebo + Mixture of fibers|Placebo control: plum flakes + maltodextrin (3 weeks) + wash out (2 weeks) + study product: mixture of plant-based food fibers (3 weeks)
20571|NCT04028245|Drug|Spartalizumab|Spartalizumab at 400 mg weeks x 2 doses prior to radical nephrectomy Infusion
20572|NCT04028245|Drug|Canakinumab|Canakinumab 300 mg IV Q4 weeks x 2 doses prior to radical nephrectomy Infusion
20573|NCT04028219|Diagnostic Test|Online surveys|Psychometric measures within 14 online surveys, which is one at each assessment point (before and 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after hormonal therapy).
20574|NCT04028206|Dietary Supplement|Hydroxymethylglutarate|Hydroxymethylglutarate supplementation at 3.0 g/day with dietary advice.
20575|NCT04028206|Device|Low-magnitude High Frequency Vibration (LMHFV)|Low-magnitude High Frequency Vibration is a non-invasive biophysical intervention which provides mechanical stimulation with no reported adverse effects. Our previous studies on bone show that LMHFV can help boost the patients' bone mineral density (BMD) and muscle health.
20576|NCT04028206|Behavioral|Elastic-band Exercise|"Subjects enrolled in the elastic-band exercise group will be instructed with 1 session of group training (at baseline) and 1 follow-up home visit (at 4 weeks) including instructions on 5-10 min warm-up and cool-down routines, 30 min chair-based resistance exercises using Thera-Bands as previously reported with training to both upper and lower body muscle groups including both hand and knee extensor muscles. The subjects will be instructed to perform the instructed routines 3 times per week, for 12 weeks. The elastic band strengths will be progressively increased from 1.3 kg to 2.1 kg (yellow to green) of tensional force as instructed by qualified coach in our project team based on each subject's multiple repetition maximum, where multiple repetition maximum is defined by reaching fatigue by 8 repetitions of stretching."
20577|NCT04028193|Dietary Supplement|Calogen|Polyunsaturated liquid fat supplement
20578|NCT04028193|Dietary Supplement|Resource Energy|Carbohydrate Supplement
20579|NCT04028180|Other|p-Menthane,3-8-diol (PMD) Topical Repellent|"p-Menthane,3-8-diol (PMD) is a recommended active ingredient, which has been evaluated for safe use by the U.S. Environmental Protection Agency (USEPA)1. According to the USEPA laboratory exposure of animals to the active ingredient, PMD, this resulted in no adverse effects except eye irritation. The eye irritation potential of the finished product formulation has not been studied; therefore as a precaution, the products will be handled in the same way as the active ingredient. The researcher and participant must wear eye protection during application of the product and the potential for eye irritation is described in the Participant Information Sheet. . Participants will be excluded if they have a known allergy to any of the product ingredients, or any skin condition, which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
20580|NCT04028180|Other|Picaridin Topical Repellent|"Icaridin (trade names include Picaridin) is a known mosquito and midge repellent active ingredient. The active ingredient, Picaridin, has been classified as potentially mildly irritating/uncomfortable to the eyes - participants and researcher will wear safety glasses during handling of the products and the participants will be warned about the potential for irritation during the Informed Consent Procedure. Participants will also be excluded if they have a known allergy to any of the product ingredients, or any skin condition which may affect their reaction to the product.~There isn't a relevant intervention type hence why other is specified. It is to deter mosquitoes landing on the skin of a human."
20581|NCT04028167|Drug|Sequential FLOT followed by chemoradiation|Chemotherapy with Docetaxel, Oxaliplatin, and 5-Fluorouracil/ Leucovorin
20582|NCT04028154|Procedure|Erector Spinae Plane (ESP) Block|ESP Block: Bilateral ESP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
20583|NCT04028154|Procedure|Thoracolumbar interfacial plane (TLIP) Block|TLIP Block: BilateralTLIP block and with ultrasound guidance will be applied A total 40 ml, 20 ml bupivacaine 0.5%, 20 ml saline.
20584|NCT04028141|Drug|Procedural sedation with ketofol in a 1 on 4 ratio|"The participant was brought to a zone where advanced life support could be optimally administered and where all necessary drugs and materials for treatment of complications are present. Oxygen saturation, continuous electrocardiogram, intermittent blood pressure measurement (every 2 minutes) and capnography were applied. A 20 gauge intravenous line was inserted. The participant was placed in semi-recumbent position and was given oxygen for at least 3 minutes through a non-rebreather mask unless contra-indications applied.~Ketofol 1 on 4 was prepared by mixing 1ml of ketamine (50mg) and 20ml of propofol (200mg) in a single syringe. It was administrated as a loading dose of 1ml/10kg, corresponding to 0,952mg/kg propofol and 0,238mg/kg ketamine, and followed by titration in aliquots of 0,5ml/10kg every 1 to 2 minutes until desired depth of sedation was achieved, and then every 3-5 minutes to retain the desired depth of sedation. The loading dose was halved if above 65 years."
20585|NCT04028128|Dietary Supplement|Cocoa group|Athletes performed a training program and consumed 5 g of cocoa (425 mg of flavonoids) mixed with semi-skimmed fat milk, daily for 10 weeks.
20586|NCT04028128|Dietary Supplement|Placebo group|The athletes performed the same training program of the cocoa group and they took for 10 weeks 5 g of maltodextrin mixed with semi-skimmed fat milk.
20587|NCT04028115|Drug|Ixazomib|Scheduled visits: Patients included in the trial will be treated with Ixazomib 4 mg on day 1, 8, and 15 in a 28-day cycle for up to 24 cycles. Patients will be evaluated every 4th week by a medical doctor, prior to initiation of a new cycle of Ixazomib.
20588|NCT04028089|Behavioral|Diet Modification Group|The diet modification group will receive diet counselling by an experienced dietician at least every four weeks throughout pregnancy starting in the first trimester. The dietary counselling will be guided by the individual glucose profiles obtained through flash glucose monitoring.
20589|NCT04028089|Other|Regular Diet Group|"Participants of the standard diet will receive general diet counselling on one occasion at the onset of the study."
20590|NCT04028076|Behavioral|Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence|An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
20591|NCT04028063|Drug|doxorubicin with AGEN1884 and AGEN2034|The first cycle of treatment will consist of AGEN2034 and AGEN1884 alone. Beginning with Cycle 2, doxorubicin will be administered every 21 days for a maximum of 6 cycles (Cycles 2-7) with appropriate premedications and pegfilgrastim growth factor support. Doxorubicin will be administered as bolus infusion on day 1 with dexrazoxane cardioprotection. Patients must have central line access for this protocol, including pheresis or trifusion catheter, PICC line, or port. AGEN2034 will be administered every cycle (every 21 days) up to two years. AGEN1884 will be administered every other cycle (Cycle 1, 3, 5, and 7) with maximum of 4 infusions.
20592|NCT04028050|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator. After the induction phase, participants will begin maintenance therapy with atezolizumab every 3 weeks.
20593|NCT04028050|Drug|Carboplatin|Carboplatin will be administered after completion of atezolizumab by IV infusion over 30-60 minutes to achieve an initial target AUC of 5 mg/mL/min (Calvert formula dosing) with standard anti-emetics per local practice guidelines.
20594|NCT04028050|Drug|Etoposide|Etoposide will be administered by IV infusion over 60 minutes following carboplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
20621|NCT04027777|Device|Aktiia.product-P0|The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
20595|NCT04028037|Procedure|FTPGT|A primary full thickness incision was given at 90 degrees to the long axis of the tooth and directly to the bone, A secondary split thickness incision was performed at 90 degrees to the long axis of the tooth but not directly to the bone, to circumscribe an area that has the same size of the gingival recession you want to cover .in a part of the first incision in order to preserve the area of tissue between them. A partial thickness flap is raised. Then two vertical incisions to the bone on the mesial and distal ends of the graft and one horizontal medial incision is made (under the partial thickness flap), to release it from the surrounding tissue incision were made, inserting the blade as much as possible parallel to the long axis of the teeth, the connective tissue was elevated from the underlying bone with a periosteal elevator.
20596|NCT04028037|Procedure|SCTG|A primary full thickness incision was given at 90 degrees to the long axis of the tooth and directly to the bone, a falp was elevated, three inner incision eas performed and the connective tissue graft was harvested
20597|NCT04028024|Drug|Ulinastatin|Ulinastatin 5000U/Kg in 20 ml NS i.v. before occlusion of aorta
20598|NCT04028011|Diagnostic Test|Novel Wearable device|patient will wear novel wearable device overnight along with normal standard of care
20599|NCT04027998|Diagnostic Test|strain and applied pressure measurement|Measurement of median nerve strain and applied pressure at proximal carpal tunnel level
20600|NCT04027985|Other|Kinesiotaping|inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
20601|NCT04027985|Other|Hand rehabilitation program|In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
20602|NCT04027985|Other|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
20603|NCT04027972|Drug|Combination of Neostigmine and Glycopyrrolate|Intravenous or transdermal
20604|NCT04027972|Device|I-Box by Dynatronics|Electric field conducting drugs through the skin without compromising its integrity
20605|NCT04027959|Dietary Supplement|Vitamin B12|Diffusion of Vitamin B12 through the skin over 20 minutes under the effect of low amount of direct electric current
20606|NCT04027946|Drug|LMB-100|Patients will receive LMB-100 on days 1, 3 and 5 of a 21 day cycle for up to 2 cycles.
20607|NCT04027946|Drug|pembrolizumab|Patients will receive pembrolizumab on day 1 of each subsequent 21 day cycle.
20608|NCT04027946|Diagnostic Test|Mesothelin Expression|Testing for mesothelin expression performed at screening
20609|NCT04027933|Behavioral|Education Based on Standard Patient Simulation|"In the first phase of the study, a theoretical education was provided to the students.~In the second phase, the students in the experimental and control groups who completed their theoretical education were given data collection forms. In the third phase, after the scales were implemented, there was no intervention with the control group. There was a standard patient implementation to the experimental group. In the fourth phase of the study, after completing the simulation practice, all scales were re-applied both to the experimental and control groups. The scales were applied after the simulation training was completed and students were sent to the clinical practice after three weeks. In the fourth phase of the study, right before the students practiced their trainings and at the end of the initial rotations of the clinical practice, which turned out to be about four weeks later on average, all scales were re-applied both to the experimental and control groups."
20610|NCT04027920|Drug|Shenghua Decoction|Three days' shenghua decoction treatment
20611|NCT04027907|Other|Flowcytometry|detect platelet activity in T2DM by surface expression of platelet receptors determined by flowcytometry using different monoclonal antibodies (CD62 and CD63).
20612|NCT04027894|Drug|Rifamycin SV MMX|200 mg Rifamycin SV-MMX® (CB-01-11)
20613|NCT04027894|Drug|Placebo to Rifamycin SV-MMX|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
20614|NCT04027881|Behavioral|Sit Together and REad|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
20615|NCT04027855|Procedure|collection of peripheral blood mononuclear cells from healthy volunteers|"Screening period: All volunteers are required to sign a written informed consent form for the study; after the signing of informed consent form, the demographic data and medical history of the volunteers will be collected, and physical examinations and local laboratory tests will be performed to assess the eligibility of the volunteers. Volunteers who meet all the inclusion criteria and do not meet any exclusion criteria (except for the basic biological indicators of UCAR-T product preparation) will receive peripheral venous whole blood sampling, and the volunteers receiving apheresis based on the assessment results will be enrolled.~Apheresis period: 5 volunteers who meet the inclusion criteria will undergo collection of peripheral blood mononuclear cells (PBMC) by means of apheresis."
20616|NCT04027842|Device|Prewarming|In the operating theater, participants allocated in Prewarming group received 10 min-prewarming, which is cutaneous warming before induction of anesthesia. For prewarming, forced air warming system (WarmTouch WT 6000 Warming Unit, Medtronic, Minneapolis, MN, USA) was used and the warming temperature of the device was set to 45°C.
20617|NCT04027829|Drug|Dexmedetomidine Hydrochloride|Intravenous infusion of dexmedetomidine at the rate of 0.5mcg/kg for 10 min, then 0.5mcg/kg/hr for 50 min.
20618|NCT04027803|Biological|BCD-148|active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5
20619|NCT04027803|Biological|Soliris|active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5
20620|NCT04027790|Diagnostic Test|Epi proColon|Analysis of DNA methylation status for Septin9 and additional biomarkers
20622|NCT04027764|Drug|Toripalimab Combined With S1 and Albumin Paclitaxel|Toripalimab 240 mg ，every 2-3 weeks S1：80-120mg，bid；oral，d1-14； Albumin Paclitaxel：120mg/m2，D 1 \8
20623|NCT04027751|Drug|Tropisetron|Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
20624|NCT04027751|Drug|Placebos|Investigators administrated intravenously 0.9% saline solution as a placebo
20625|NCT04027738|Other|PRP|The patients received a single 3-ml injection of PRP. Approximately 10-mL of venous blood was drawn from each patient and centrifuged using an Arthrex autologous conditioned plasma (ACP) kit (a low-leukocyte ACP system), spun at a speed of 1500 rpm for 5 minutes. The platelet concentration obtained was approximately 2-3 times greater than the baseline platelet concentration.
20626|NCT04027725|Behavioral|Neurofeedback|Neurofeedback experiment will consist of 20 sessions of neurofeedback training, twice or three times a week during seven weeks. Each session will last for 40 minutes. The experimental group will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-trianing (T1) and 1 month follow-up (T2). Electroencephalography will be recorded by a technician in EEG for each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T1 and T2.
20627|NCT04027699|Procedure|Mini-bolus|"First injection of 2ml/kg (saline solution)~Second injection of 18ml/kg (saline solution)"
20628|NCT04027686|Device|Laser Therapy|Adjunctive application of laser therapy in the periodontal pocket
20629|NCT04027686|Procedure|Non-surgical Scaling and Root Planing|Scaling to remove calculus deposits and root planing to smooth root surfaces
20630|NCT04027673|Behavioral|TMW ECE Curriculum|The TMW-ECE program will constitute the treatment arm of the study (Cohort A) which will complete the multi-media online professional development course beginning Summer 2019.
20631|NCT04027660|Device|Immediate Zirconia Dental Implant|"For the Exposed Group the Intervention will be the following~The Surgical procedure will envolve :~Administration of Articain 1:200.000~No flap procedure~Place a Zirconia Implant on the alveolar post extraction socket~Place xenograft biomaterial in the jumping gap~Place a provisional crown/individualized healing abutment~The Prosthodontic procedure will evolve:~Final Impression with a IOS~Placement of the Final Crown~3 month post crown post op~3 IOS will be made for volumetric evaluation :~before tooth extraction~3 month of Osseointegration for final impression~3 month after final crown is placed~Final STL evaluation will be performed on a specialized software for volumetric measurements"
20632|NCT04027647|Drug|Dacomitinib|30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.
20633|NCT04027634|Other|Baduanjin program|This exercise program aimed to increase patient participation and control their BW through Baduanjin program. The entire program continued for 3 months (mid-September to mid-December 2014), and the intervention was performed for 60 min 3 times per week; particular attention was paid to the disease characteristics of the patients with chronic schizophrenia and to preventing excessive fatigue. Every session began with a 20-min warm-up, followed by 20 min of Baduanjin program, and ended with a cool-down session. The participants were instructed, with the assistance of a video, to practice Baduanjin program in a group by two authors who are experienced in the psychiatric nurses and had been trained in this program.
20634|NCT04027621|Device|remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 200 mm Hg.
20635|NCT04027621|Device|sham remote ischemic conditioning|Sham remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min re-perfusion. Limb ischemia was induced by inflation of a blood pressure cuff to 60 mm Hg.
20636|NCT04027608|Other|Reinforcing value of HED and LED foods in response to snack food monotony|Each child will be asked to eat two different snack foods over the course of two weeks each. The RRV of that food (vs alternative reinforcer) will be tested and baseline and post exposure. Increases in RRv for food after monotony will be considered sensitization to that food. All children will be followed to observe weight change over time for 2 years each.
20637|NCT04027595|Procedure|Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) Laser Capsulotomy|A Nd: YAG laser will be used to open the cloudy posterior capsule of the lens to improve central visual acuity.
20638|NCT04027582|Other|didactic teaching and simulator practice|the trainee will undergo didactic teaching on fiber-optic intubation followed by hands on practice on their assigned simulator
20639|NCT04027569|Other|Patient Specific Functional Scale|A validated patient reported outcome measure that asks patients to write down activities and score them 0 to 10.
20640|NCT04027569|Other|PROMIS PF|A computer adaptive, validated patient reported outcome measure that measures physical function on a 1 to 100.
20641|NCT04027556|Other|low dose CT contrast media - lean body weight|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 450mgI/kg based on lean body weight.
20642|NCT04027556|Other|Standard dose CT contrast media|CT contrast media (iobitridol 350mgI/kg) is administrated at a dose of 560mgI/kg based on total body weight.
20643|NCT04027543|Combination Product|Neoadjuvant chemoradiotherapy|Radiotherapy began within the first day of the first cycle of chemotherapy and continued to a total dose of 40.0 to 50.4 Gy.In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
20644|NCT04027543|Procedure|Oesophagectomy|Various surgical oesophagectomy methods were used, such as Ivor Lewis, transthoracic, three-hole, transhiatal, and left transthoracic,and the appropriate surgical approach for each patient was chosen according to the tumour location, size, and depth.
20645|NCT04027543|Drug|Neoadjuvant chemotherapy|In most patients, the chemotherapy regimens before surgery were consisted of cisplatin combined with either fluorouracil or taxanes.
20646|NCT04027530|Drug|Ertugliflozin 15 mg|Once daily treatment with oral ertugliflozin 15mg for 4 consecutive weeks
20647|NCT04027517|Drug|JTZ-951|"Oral tablet~Dose adjustments as maintenance dose is allowed according to the result of Hb level."
20648|NCT04027517|Drug|Darbepoetin Alfa|"Intravenous administration~Dose adjustments as maintenance dose is allowed according to the result of Hb level."
20649|NCT04027504|Dietary Supplement|Fitabisc|Biscuits containing antioxidants
20787|NCT04026399|Other|peripheral vibration stimulation|wearing a wristband that delivers imperceptible vibratory stimulation.
20650|NCT04027491|Behavioral|Virtual Reality|"The selected commercial games are aimed mostly to improve upper limb functions. The games will be randomly administered during each session. Each game will be played for approximately 10 minutes, with 5 minutes break between each game session.~The intervention treatment consists of 12 sessions in 4-week period."
20651|NCT04027478|Dietary Supplement|FMD|fasting mimicking diet
20652|NCT04027465|Dietary Supplement|Egg allergy oral desensitization|Subjects in the treatment will begin treatment by undergoing an egg oral challenge. This will confirm that the subject is still allergic to egg and establish the dose of egg the subject can tolerate. The last dose of egg tolerated during the challenge will serve as the first desensitization dose Subjects will then come to the research center every two weeks to receive their dose increases until they reach the maintenance dose of 300 mg. Subjects will then enter the maintenance phase for one year. During this period they will undergo another oral food challenge one month after attaining the maintenance dose
20653|NCT04027452|Behavioral|Traumatic memory reactivation|"125 word long exposure scripts of their traumatic memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
20654|NCT04027452|Behavioral|Neutral memory reactivation|"125 word long exposure scripts of a neutral (non-traumatic) memory recorded in a neutral tone. All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient. The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds. When the participant enters the treatment room, they will be handed an MP3 player with the audio recording. The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted. The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course."
20655|NCT04027439|Drug|Part A: RPL554|1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
20656|NCT04027439|Drug|Part B: RPL554|Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
20657|NCT04027439|Drug|Placebos|"Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler.~Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A."
20660|NCT04027413|Dietary Supplement|fortisip compact protein|(24% protein; 41% carbohydrate; 35% fat)
20661|NCT04027413|Dietary Supplement|preOp|(100% carbohydrate).
20662|NCT04027400|Behavioral|computer-assisted rehabilitation|Participant is presented with 10 exercises a day, 3 minutes each. When participant achieves 100% accuracy of the exercise, he/she gets a higher level of exercise. Levels of range from 1-9. Exercises are changed every week by researcher.
20663|NCT04027387|Biological|TMB-365|An IgG1 monoclonal antibody targeting domain 2 of the CD4 receptor for treatment of HIV-1 infection
20664|NCT04027374|Procedure|Fetal surgery for MMC repair|Fetal surgery for MMC repair
20665|NCT04027361|Drug|Amphetamine Extended Release (ER) Tablet 20 mg|A single 20 mg dose of amphetamine ER Tablet, orally administered
20666|NCT04027348|Drug|Dexamethasone|Given IV
20667|NCT04027348|Drug|Metoclopramide|Given IV
20668|NCT04027348|Drug|Octreotide|Given IV
20669|NCT04027335|Device|leva|Vaginal device used for pelvic floor muscle exercises
20670|NCT04027322|Drug|Budesonide 0.25 MG/ML Inhalant Solution|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
20671|NCT04027322|Drug|Dexamethasone|"Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8)."
20672|NCT04027322|Drug|Normal saline|Placebo for the control group.
20673|NCT04027309|Drug|Gilteritinib|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
20788|NCT04026399|Behavioral|therapy|practice of daily living tasks
20791|NCT04026373|Behavioral|Treatment as usual|May include consult to health psychology and any follow-up deemed appropriate
20674|NCT04027309|Drug|Midostaurin|Patients with a FLT3 mutation w ill be randomized to receive either the investigational drug gilteritinib or midostaurin given sequentially to standard induction and consolidation chemotherapy. After completing induction and consolidation treatment, patients who achieve CR/CRi/MLFS will receive maintenance therapy with gilteritinib or midostaurin
20675|NCT04027283|Dietary Supplement|Erythritol|50g erythritol dissolved in 300mL tap water
20676|NCT04027283|Dietary Supplement|Erythritol + lactisole|50g erythritol + lactisole (450ppm) dissolved in 300mL tap water
20677|NCT04027283|Dietary Supplement|D-allulose|25g D-allulose dissolved in 300mL tap water
20678|NCT04027283|Dietary Supplement|D-allulose + lactisole|25g D-allulose + lactisole (450ppm) dissolved in 300mL tap water
20679|NCT04027283|Dietary Supplement|Tap water|300mL tap water
20680|NCT04027283|Dietary Supplement|Tap water + lactisole|300mL tap water + lactisole (450ppm)
20681|NCT04027270|Other|Physical Therapy|Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
20682|NCT04027257|Behavioral|Sit Together and Read (STAR)|STAR is an evidence-based home-based shared book reading intervention designed to improve the foundational reading skills of preschoolers who are at risk for reading disabilities.
20683|NCT04027231|Other|analysis of the synovial fluid|Electrochemical cell analysing the patients' synovial fluid whenever an invasive intervention is medically prescribed
20684|NCT04027218|Device|Dry heat|The application is made with two sacks of carob seeds during 7 minutes. The sacks are placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power.
20685|NCT04027218|Device|High pressure|It will be carried out with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand (QUIRUMED) with European Conformity (CE) marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse.
20686|NCT04027218|Device|Combination of dry heat and high pressure|"The application is made with two sacks of carob seeds during 7 minutes. The sacks may be placed on antebrachial anatomical zone, together, and previously heated in the microwave for 0.30 seconds at 850 W of power; according to instructions for use.~After 7 minutes, the pressure is applied with the use of the manual aneroid sphygmomanometer fixed at 100 millimeters of mercury. Brand QUIRUMED with CE Marking 0197. A pressure lower than the systolic blood pressure, and in each subject will be monitored the radial pulse."
20689|NCT04027192|Drug|BAY2328065 LSF|20 mg/mL LSF (liquid service formulation), orally
20690|NCT04027192|Drug|BAY2328065 tablet|50 mg tablet, orally
20691|NCT04027192|Drug|Placebo LSF|Matching Placebo LSF, orally
20692|NCT04027192|Drug|Placebo tablet|Matching Placebo tablet, orally
20693|NCT04027192|Drug|Midazolam|1 mg per day, orally
20694|NCT04027179|Drug|0.12% chlorhexidine digluconate mouthwash|0.12% chlorhexidine digluconate mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
20695|NCT04027179|Procedure|Periodontal instrumentation|Full-mouth scaling and root planing with manual curettes within 24 hours in two sections 1 hour each.
20696|NCT04027179|Drug|Placebo mouthwash|placebo mouthwash (20mL/60 seconds/ 2 times a day/ 3 weeks).
20697|NCT04027166|Drug|Methadone|Methadone will be administered before study procedures
20698|NCT04027166|Drug|Methadone|Methadone will be delayed (4 hours) until the end of the procedures
20699|NCT04027153|Other|Fee based delivery|Testing willingness to pay for services to simplify delivery is innovative as the strategy could increase funds for HIV care making home delivery cost neutral.
20700|NCT04027140|Device|M/L Taper with Kinectiv Technology Stems and Necks|Patients that have been implanted with a M/L Taper with Kinectiv Technology Stem and/or neck to repair hip malfunction/disease.
20701|NCT04027127|Other|netrin-1 value on admission to hospital|
20702|NCT04027114|Behavioral|Individualized behavioural physical activity intervention|• The intervention involves a tailored physiotherapy (PT) intake that will serve as the foundation for the individualized approach. Participants' individual attributes and physical activity needs, including a general PT assessment will occur initially. Over the next 12 months, participants will receive individualized PT coaching and a physical activity plan plus access to educational literature that outlines methods and benefits of exercise. An estimated 15 hours of PT contact hours per participant is anticipated and the specifics of each encounter will be documented.
20703|NCT04027101|Drug|Baricitinib|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
20704|NCT04027101|Drug|Placebos|patient will take a tablet of 4 mg/d during 12 weeks and then 2 mg/d during 12 weeks if the patient achieves PMR-AS≤ 10 at week 12
20705|NCT04027088|Dietary Supplement|Immunonutrition|It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
20706|NCT04027088|Dietary Supplement|Standard|It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
20707|NCT04027075|Behavioral|Rewire app users|Use of the Rewire app involves completing 12 modules and 12 practice sessions over 30 days.
20708|NCT04027062|Behavioral|Diabetes Continuing Education Intervention|"The program will follow the International Curriculum for Diabetes Health Professional Education, which developed by the International Diabetes Federation (IFD) The key components of the proposed program content are Diabetes presentation and complications, Lifestyle, Nutrition, and Fitness.~the intervention will be carried out by group of Diabetes educators from a different discipline, such as an Endocrinologist, Family physician, the dietitian will teach the attended physicians."
20709|NCT04027049|Device|Supine cycle ergometry of the lower extremities|The cycle ergometer allows for movement of the lower extremities by a motor if a patient is experiencing a disorder of consciousness or is otherwise unable to move one or both legs. If a patient is able to cycle actively the device allows the patient to move patient's legs without support of the motor.
20792|NCT04026360|Other|no intervention|
20793|NCT04026347|Device|Vesair Balloon|Indwelling, intravesical balloon
20710|NCT04027036|Biological|Inactivated poliovirus vaccine in reduced doses|"contains the following excipients: 2-phenoxyethanol (2.5 mg), water for injection and diluent solution and phosphate buffer having the following composition: sodium phosphate, sodium chloride, potassium chloride, magnesium sulfate, phenol red and calcium chloride.~dosage:0,1ml duration: first dose: month 2 of age; second dose: month 4 of age"
20711|NCT04027023|Drug|Diabetes mellitus Type 2 De-escalation treatment (DET)|"All employed drugs are approved in the US for treatment of type 2 diabetes and are used within their label. There will be defined individual treatment drug combinations at an earlier stage of diabetes as in standard treatment. The DET combination will be composed out of one each or more of the drugs and interventions listed below.~A. Relieve for the insulin-producing ß-cells insulin glargine (6 to 20 U at bedtime) insulin degludec (5 to 15 U at bedtime) B. Reduction of hormonal visceral lipid tissue activity/chronic inflammation Weight loss liraglutide (0.6 mg/day) exenatide (15 µg/day) C. Treatment of metabolic and vascular insulin resistance Pioglitazone (30 mg) D. Treatment of glucose toxicity Empagliflozin (SGLT-II inhibitor; 10 mg) Dapagliflozin (SGLTII-Inhibitor, 10 mg) Canagliflozin (SGLT-II inhibitor, 100 mg) Metformin (inhibition of hepatic glucose production, 500 mg)~To avoid hypos, all drugs are initially given in the lowest possible dose."
20712|NCT04027010|Other|"Healthy U tablet application"|"There are seven modules in Healthy U: Puberty, Birth Control, Teen Pregnancy, HIV, STDs, Healthy Relationships, and Condom Negotiation. Each module has six sections: Introduction and Review, Narrative Teen Portrait, Information Film, Activity/Game, Dramatic Film, and Imagination Challenge. The Introduction and Review has videos lasting 1-2 minutes where the Healthy U host introduces each module. In the Narrative Teen Portrait for each module, a different teen discusses their experience with the topic for 1-3 minutes. The Information Film lasts 5-18 minutes per module and provides factual information. For each module, the Activity/Game includes multiple choice, true/false, or other games. The Dramatic Film lasts 5-17 minutes for each module and shows a fictional account of a teen experiencing the topic. Finally, the Imagination Challenge asks the youth to imagine a scenario, such as going to a health clinic to obtain free condoms."
20713|NCT04026997|Drug|CIN-102 Dose 1|CIN-102 Dose 1
20714|NCT04026997|Drug|CIN-102 Dose 2|CIN-102 Dose 2
20715|NCT04026997|Drug|CIN-102 Dose 3|CIN-102 Dose 3
20716|NCT04026997|Drug|Placebo|Placebo
20717|NCT04026984|Drug|Placebo|Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
20718|NCT04026984|Drug|Rifamycin SV-MMX|2 Rifamycin SV-MMX® 50 mg tablets b.i.d. plus ORT
20719|NCT04026971|Procedure|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.|This study is a randomized controlled study aiming to evaluate the effect of phone application supported nutrition education on weight loss according to standard education.
20720|NCT04026958|Drug|Clarithromycin|Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
20721|NCT04026958|Drug|Placebo|A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
20722|NCT04026945|Drug|Lidocaine|Sustained-release lidocaine injection
20723|NCT04026932|Other|Listening to unmodified music|Listening to unmodified music for at least 2 hours a day
20724|NCT04026932|Other|Listening to modified tinnitus relieving sound|Listening to modified tinnitus relieving sound for at least 2 hours a day
20725|NCT04026919|Other|OK EN CASA-ZAINDOO|Intervention based on cognitive- behavioural techniques offered in an online format.
20726|NCT04026906|Device|Cyanoacrylate glue|One drop of cyanoacrylate glue will be applied to the intravenous (IV) insertion site and another drop under the hub of the IV catheter
20727|NCT04026906|Other|Transparent polyurethane dressing|The IV will be secured in the usual manner with tape and a transparent dressing.
20728|NCT04026893|Procedure|Uterine Transplant from Deceased Donor|The recipient will be started on anti-rejection medications (as is routine for transplant recipients) prior to the OR. Standard of care anesthesia and line placement will take place. The recipient will be appropriately identified as an organ recipient and the donor organ identified per required transplant protocols already in place. The recipient team will then connect the vasculature and appropriate supporting structures for the uterus transplant. Once the organ has been re-perfused, the remainder of the operation will take place and the patient will be moved to the Intensive Care Unit and later to the transplant patient floor for standard monitoring.
20729|NCT04026880|Drug|Testosterone Enanthate|25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
20730|NCT04026880|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks
20731|NCT04026867|Other|Linkage Navigation|The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
20732|NCT04026867|Other|Clinician Referral|"The Clinician Referral arm will serve as an active control and baseline standard of care."
20733|NCT04026854|Behavioral|Quality of live at work|The judging criteria will be collected using two questionnaires: a questionnaire sent to the local referent of each center and a questionnaire for each nurse. Because the study is longitudinal (two collections of data), the questionnaires will be completed twice to twelve months apart by the same nurses.
20734|NCT04026841|Drug|PD-1 antibody Sintilimab|Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
20735|NCT04026828|Genetic|Periodontitis Group|Periodontitis group consists of both chronic and aggressive periodontitis patients
20736|NCT04026815|Other|medical history, blood and urine tests|The study protocol consists of questionnaires (medical, socio-economic, dietary), comprehensive geriatric assessment, physical examination, anthropometric and blood pressure measurements and laboratory tests.
20737|NCT04026802|Other|In-Bed Resistance Training Device|Physical Therapy using the in bed training device
20738|NCT04026802|Other|Standard of Care|Does not include early implementation of physical therapy
20739|NCT04026789|Other|Same-day-start|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to same-day start will have their medication abortion initiated on the day that they present for services while simultaneously ruling out ectopic pregnancy with serial hcg testing
20740|NCT04026789|Other|Delay-for-diagnosis|Patients seeking medication abortion who are shown to have an asymptomatic, low-risk pregnancy of unknown location who are randomized to delay-for-diagnosis will first have ectopic pregnancy ruled out with serial hcg and ultrasounds prior to initiating medication abortion
20741|NCT04026776|Drug|Allopurinol|At Visit 3 preterm birth subjects will start the standard-Na+ diet for 7 weeks and after 1 week will start allopurinol 200 mg daily PO for 8 weeks.
20742|NCT04026776|Other|Dietary Intervention|High-Na+ (250 mmol/d) and low-Na+ (50 mmol/d) standard isocaloric K+ diets (75 mmol/1000 kcal/d) for 1 week each as 3 meals and 1 snack a day provided by the CRU Metabolic Kitchen.Self-provided intake phase: Subjects will be counseled by the RD (Registered Dietitian) to consume a standard-Na+, isocaloric diet (150 mmol Na+ and 40 mmol/1000 kcal K+ daily) for 7 weeks.
20743|NCT04026763|Procedure|prostate biopsy|standard of care
20744|NCT04026763|Procedure|MR US Fusion Guided Prostate Biopsy|Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy, Transperineal Ultrasound guided fusion prostate biopsy
20745|NCT04026763|Device|MR/TRUS Fusion Guided Prostate Biopsy|TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
20746|NCT04026750|Drug|Pitolisant|Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
20747|NCT04026724|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
20748|NCT04026711|Drug|Mitoquinol|Mitoquinol (MitoQ) 40 mg per day for 12 weeks
20749|NCT04026711|Drug|Placebo oral tablet|Placebo daily for 12 weeks
20750|NCT04026698|Behavioral|Resident and Family Engagement Intervention|"The leadership coaching component targets managers, administrators/ directors of care in long-term care settings. These sessions involve selecting a subset of relevant performance outcomes from the quality improvement plan that align with leadership vision and priorities for staff performance which leaders can monitor, reinforce and encourage.~The education component involves a one-day in-person training session for staff and managers on communication strategies and ways to engage family and residents in care planning, and includes follow-up visits.~The huddle component involves a series of resident and family led huddles (brief, 15 minute meetings) to discuss something important with staff to foster proactive communication and information sharing. Resident-family dyads will participate in the huddles, along with the staff and management team who received the training. The huddles will be scheduled for 15 minutes once/month for 6 months."
20751|NCT04026685|Drug|Phenylephrine infusion|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure
20752|NCT04026685|Drug|Phenylephrine infusion and Ringer-Acetate bolus|continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
20753|NCT04026659|Other|Multi-modal exercise|A combination of aerobic, resistance, balance and flexibility exercises will be included. Aerobic exercise will consist of 20 to 30 min of moderate intensity exercise using a variety of modalities. Heart rate will be monitored using Polar hear rate monitors (target intensity 40-70% heart rate reserve) and the BORG Rating of Perceived Exertion (12-15). Resistance exercise will target the large muscle groups of the upper and lower extremities, be performed at 40% to 70% of the one repetition maximum (1-RM) and consist of two sets of 10-15 repetitions. Flexibility and balance exercise will also be included in the twice weekly programme. A home exercise programme will encourage participants to be moderately physically active for at least 30 minutes, three times per week in addition to the supervised programme.
20754|NCT04026646|Procedure|Proprioceptive Neuromuscular Facilitation stretching exercise|Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
20755|NCT04026646|Procedure|Static stretching exercise|Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
20756|NCT04026633|Behavioral|CAA|Participants will write about the use of PBS and alcohol use.
20757|NCT04026633|Behavioral|Control|Participants will write about eating and exercise.
20758|NCT04026620|Behavioral|Informational Pamphlet|The control group will be provided with two (2) informational pamphlets (and have it read to those who are of lower literacy). Pamphlets contain information about the harmful effects of drinking alcohol during pregnancy and the harmful effects of alcohol on the unborn baby.
20759|NCT04026620|Behavioral|Brief Motivational Enhancement Therapy (MET) Session|The case control trial/efficacy study will provide a one-session MET session in Afrikaans (the predominant language of the region). The face-to-face session will provide information to help people and pregnant women who want to change their drinking behavior, become 'dry' and stay motivated to change their drinking behaviors. Sessions will be approximately one (1) hour and 30 minutes.
20760|NCT04026607|Dietary Supplement|Protein Supplementation|Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
20761|NCT04026594|Other|Mindfulness Based Stress Reduction|"MBSR teaches mindfulness meditation and mindful yoga exercises to develop non-judgmental awareness of moment-to-moment experience. The intervention duration is 8 weeks, with weekly two and half hours sessions. It will be delivered according to the fundamental concepts and specific techniques provided in the MBSR manualized protocol by Kabat-Zinn. The program also includes 30-min daily homework exercises.~MBSR teaches four main mindfulness practices: (1) body scan, a process of moving attention through the body; (2) mindful movement, consisting of gentle yoga stretches to develop awareness of body in movement; (3) sitting meditation; and (4) walking meditation. Inquiry and didactic teaching is also a part of MBSR and allows for some detailed exploration of participants' experiences."
20762|NCT04026594|Other|Relaxation group|control group
20789|NCT04026386|Behavioral|Center Based Early Intervention Program|This is a 12-week early intervention program that will include 12 weekly hours of treatment in an intensive center-based preschool environment to treat social communication deficits in children with developmental disorders.
20790|NCT04026373|Behavioral|modified Prolonged Exposure|
20763|NCT04026581|Behavioral|Speech generating device (SGD) evaluation including BCI access|At the initial evaluation the participants will review the full range of AAC options and speech generating devices (SGDs) and complete a speech and language evaluation. The second evaluation date will involve a trial of SGDs matched to the participant's assessment results. The third visit is the trial of an AAC system with BCI access. Should the dry electrode headgear for BCI access prove ineffective, then the gel electrode cap will be offered to the participant for trial. At the end of the third visit, the evaluation results will be discussed with participant and family, and they will be asked to select the preferred SGD.
20764|NCT04026581|Behavioral|Training and treatment|Participants receive training on the selected SGD followed by monthly treatment sessions from the SLP who monitors performance. In some cases the participants' SGD will be an AAC system with BCI access. In this case training will also include an identified system support person. Use of the SGD is monitored on a monthly basis through home visits and/or tele-practice sessions, when requested. Technical support for the SGD is provided on an as needed basis or when requested by the participant or support person.
20765|NCT04026568|Drug|4-Aminopyridine|Single drug test for nerve continuity
20766|NCT04026568|Drug|Placebo oral tablet|Placebo arm
20767|NCT04026555|Other|MEWS++ Monitoring|Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).
20768|NCT04026555|Other|Predictor Score|A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
20769|NCT04026529|Other|walking on incline or walking at increasing speed|"Subjects will be prepared for data collection by wearing a form-fitting suit (i.e., wrestling singlet) and obtaining height and body weight. Retro-reflective markers will be placed bilaterally on anatomical locations of the feet, legs, and hips,in addition to 89 markers on the thorax and abdomen.Subjects will~be outfitted with the portable metabolic cart and oximeter as in the previous visit. One of two treadmill trials will be performed: 1) at the speed and 2) at the slope +speed determined in the previous visit. Trial order will be randomized among subjects and across visits 3 & 4. For each trial, subjects will be asked to walk on a treadmill for up to 6 minutes. Speed or slope will be increased every 30 seconds and they will be asked to walk for one minute at that speed or"
20770|NCT04026516|Device|CAVA Device|The CAVA device will be worn continuously for thirty days, during which time it will record eye and head movements
20771|NCT04026503|Other|Live Long Walk Strong rehabilitation program|Live Long Walk Strong is a rehabilitation program that focuses on impairments known to contribute to mobility decline that are not considered standard of care in rehab and addresses behavioral change within the context of rehabilitation.
20772|NCT04026490|Behavioral|Immediate Intervention|The Interventionist will use motivational interviewing skills, assess ethnic and racial microaggressions, and provide support, screen for posttraumatic stress, and, if appropriate, link student to advanced care. The student may meet with the Interventionist several times during the remainder of the school year. These meetings will be approximately 10-30 minutes in length and occur during the school day in a private location determined by the Interventionist. The student may be referred to additional resources as a result of the meetings. The meetings will be documented by the Interventionist using a case management system (in RedCap).
20773|NCT04026490|Behavioral|Waitlist Intervention|In order to compare outcomes contemporaneously, students from waitlisted schools will be asked to complete baseline and follow-up surveys, which will be collected at approximately the same time as in the immediate intervention schools. The data will be captured for analysis at the end of the study. Students will complete intervention following the waitlist period.
20774|NCT04026477|Behavioral|Immediate Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop
20775|NCT04026477|Behavioral|Waitlisted Universal Trauma-Informed Care and Cultural Humility Training|Instructional video and workshop following waitlist period
20776|NCT04026464|Drug|Intravenous Ibuprofen|The control monotherapy group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently.
20777|NCT04026464|Drug|Intravenous Ibuprofen + Oral Acetaminophen|The combined treatment group will receive 10 mg/kg intravenous ibuprofen followed by 5 mg/kg 24 and 48 hours subsequently and will in addition receive 15 mg/kg oral acetaminophen [160 mg/5ml concentration] every 6 hours for a total of 12 doses.
20782|NCT04026438|Drug|Potassium Phosphate Injection|One ml of the preparation contains 3 mmol of phosphorous which when equated with RDA 10ml ie 30 mmol of preparation will be supplemented. The preparation is given slowly, intravenously over 4 hours diluted in 500 ml normal saline
20783|NCT04026425|Other|Two-day cardiopulmonary exercise test|A series of two cardiopulmonary exercise tests (CPETs) performed over two days. Participants will perform a CPET and then will return approximately 24 hours later to perform the second CPET. The CPET begins with 3 minutes of seated rest followed by cycling during incremental workloads which increases 15 watts throughout each minute of exercise. The participant will cycle until volitional exhaustion and/or the participant and/or test administrator determines to stop the test. Actual exercise time usually varies between 8-10 minutes.
20794|NCT04026347|Other|Sham balloon placement|Sham balloon placement procedure
20795|NCT04026334|Device|V.A.C. VERAFLO CLEANSE CHOICE™ dressing with Normal Saline|-125mmHg, 10 minute soak time, 3.5 hours of negative pressure therapy
20796|NCT04026321|Drug|SQ001 125mL/day|SQ001 125mL/day will be administered by intravenous route at a rate of 3 mL/minute
20797|NCT04026321|Drug|SQ001 250mL/day|SQ001 250mL/day will be administered by intravenous route at a rate of 3 mL/minute
20798|NCT04026321|Drug|SQ001 500mL/day|SQ001 500mL/day will be administered by intravenous route at a rate of 3 mL/minute
20799|NCT04026321|Drug|SQ001 625mL/day|SQ001 625mL/day will be administered by intravenous route at a rate of 3 mL/minute
20800|NCT04026321|Drug|Saline 0.9%|Saline 0.9% will be administered by intravenous route at a rate of 3 mL/minute
20801|NCT04026308|Other|My3 App|The My3 app is an electronic version of a safety plan, and is available for download at: http://my3app.org/. This app is owned by Link2HealthSolutions, Inc, which is the administrator for the National Suicide Prevention Lifeline. It was created in partnership with the California Mental Health Services Act. Unlike the paper version, the My3 app allows participants to email a copy of their safety plan to whomever they wish. It also allows patients to dial 911 or the National Suicide Prevention Lifeline from the app.
20802|NCT04026295|Behavioral|Short Burst Interval Treadmill Training (SBLTT)|SBLTT will consist of short-bursts (30 seconds) of high speed walking alternating with 30 seconds of low/moderate speed walking. Total duration of walking per session will be up to 30 minutes of the 30 second alternating intervals (30sec high / 30sec low/moderate) with rests as needed. Both groups will receive 40 sessions delivered 5x/week for 8 weeks. Initial speeds for high speed walking will be 75-80% of each participant's over ground baseline fast walking speed, and low/moderate speed will be 75-80% of self-selected speed calculated from the 10-Meter Walk Test.
20803|NCT04026295|Behavioral|Traditional Locomotor Treadmill Training (TLTT)|TLTT group will receive the same number of sessions (40) delivered 5x/week for 8 weeks with a total duration of walking per session up to 30 minutes with rests as needed. TLTT will consist of walking at steady-state speeds. Initial treadmill speed will be 75-80% of over ground self-selected walking speed. The overall goal will be to achieve 30 minutes of walking at a steady-state walking speed within each session. Speed will be increased on the next session by .1 to .4mph when the subject can walk for 30 minutes on the treadmill at the current speed with an OMNI score of < 6/10.
20804|NCT04026282|Procedure|GnRH-ant protocol|Recombinant FSH (Gonal-f®) will be administrated as routinely practiced by investigators. FSH doses will be adjusted according to the clinical experiences of investigators.The GnRH-ant (Cetrotide®) will be initiated in a fixed protocol on stimulation days 5 or 6 per the investigator's ART protocol.
20805|NCT04026282|Procedure|GnRH-a long protocol|The GnRH-a (Diphereline® or Decapetyl®) 0.1mg will be administered for about14 to 20 days for down-regulation. Gonal-f® will be administrated as routinely practiced by investigators. GnRH-a types, GnRH-a and FSH doses will be adjusted according to the clinical experiences of investigators in each site.
20806|NCT04026269|Drug|MOAP|the new chemotherapy regimen for r/r cHL
20807|NCT04026256|Drug|Teriparatide|teriparatide daily subcutaneous injection
20808|NCT04026256|Drug|Denosumab|denosumab subcutaneous injection
20809|NCT04026243|Procedure|QL block|U/S guided Transmuscular Quadratus Lumborum Block
20810|NCT04026243|Procedure|TF block|U/S guided Transversalis Fascia Plane Block
20811|NCT04026230|Drug|Atorvastatin 80mg|Capsules including 80 mg of atorvastatin
20812|NCT04026230|Drug|Placebo oral capsule|Similar capsules as in the atorvastatin arm, but without the active ingredient
20813|NCT04026191|Device|OrthoVisc®-T (OVT)|Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
20814|NCT04026178|Drug|Metreleptin|Subjects will receive prescribed dosage of metreleptin as indicated in the USPI
20815|NCT04026165|Drug|SEL|Tablet administered orally once daily
20816|NCT04026165|Drug|Placebo|Tablet administered orally once daily
20817|NCT04026152|Behavioral|Resistance training|Following randomization, all participants assigned to receive the resistance training intervention will receive a comprehensive exercise program. The exercise program participants will be using is similar to past research using resistance training programs with people with anxiety-related disorders and has been developed and reviewed by a team of certified personal trainers, including the primary investigator. All participants assigned receive this resistance training intervention will complete a total of six sessions with a personal trainer and six session independently over four weeks to allow for a gradual, rather than abrupt, transition to fully independently completed exercise by the 4th week. After this time participants will be encouraged to exercise independently.
20818|NCT04026152|Behavioral|Unified Protocol|This intervention consists four weekly sessions adapted from the Unified Protocol. The first module is Psychoeducation and Motivational Interviewing. During this module, participants will develop an understanding of their own pattern of emotional responding to exercise as well as increasing participants' readiness and motivation for behaviour change.The second module is Cognitive Flexibility, during which participants will learn about how automatic negative interpretations can influence their emotional reactions and prevent them from considering alternative explanations. The third module is Countering Emotion-Driven Behaviours during which participants will identify and counter behaviours used to dampen strong emotions, particularly those associated with exercise. Lastly, module four will use Exposure to external and internal emotional triggers to increase participants' tolerance to the emotions that arise in exercise environments.
20819|NCT04026139|Other|Elastic Band Resistance Exercise|Patients in the experimental and control group were instructed by clinical staff to perform home-based exercises and followed up through phone calls. The experimental group performed exercises using an elastic resistance band with 10 repetitions/set × 5 sets/day × 3 days/week.
20820|NCT04026139|Other|active joint range-of-motion exercises and isometric contraction exercises|The control group underwent active joint range-of-motion exercises and isometric contraction exercises. The intervention regimens lasted 12 weeks.
20851|NCT04025892|Behavioral|Daily weighing|Participants will be asked to use the scale to track their body weight daily at home for six weeks. They will receive a weekly email contact with weight change feedback and either a nutrition or physical activity tip for the week. The study procedures represent minimal risks, and participants will be reminded and encouraged to maintain their regular prenatal care contacts with their provider.
20821|NCT04026126|Behavioral|Heat Therapy Treatment|Subjects will undergo 10 hot water immersions of 40.5 degrees Celsius for approximately 45 minutes per session over 14 days. Subjects will be immersed up to the shoulder until rectal temperature reacher 38.5 degrees Celsius (approximately 15-20 minutes). Subjects will then remain in the water bath submerged at waist level to maintain between 38.5 to 39.0 degrees Celsius for another 30 minutes. Following hot water immersion, subjects will be monitored for 10 minutes, or until temperature falls below 38.5 degrees Celsius.
20822|NCT04026113|Drug|Linaclotide 72 μg|Oral capsule (For participants who do not wish to take the dose as a capsule, a sprinkled dose may be prepared)
20823|NCT04026113|Drug|Placebo|Matching placebo
20824|NCT04026100|Biological|CTA101|Universal CD19-directed CAR-T cells by a single infusion intravenously will be given in escalating doses. Subjects will been distributed into low dose (0.2×10^6), medium dose (2×10^6), and high dose (3×10^6).
20825|NCT04026074|Drug|Fentanyl|Weight adapted drug application
20826|NCT04026074|Drug|Remifentanil|Weight adapted drug application
20827|NCT04026074|Drug|Clonidine|Weight adapted drug application
20828|NCT04026074|Drug|EMLA Cream|Salve application on the body part where the regional anaesthesia will be administered
20829|NCT04026074|Drug|Placebo iv|i.v. administration of 0,9% NaCl
20830|NCT04026074|Drug|Placebo salve|Skin protection salve (placebo salve) application on the body part where the regional anaesthesia will be administered
20831|NCT04026061|Behavioral|FMA group|A person-centred, tailored tablet intervention, called FindMyApps (FMA). The intervention consists of the FMA training to use the tablet and the FMA selection tool to help users find apps for self-management and meaningful activities that fit their needs, wishes and abilities
20832|NCT04026061|Behavioral|Control group|Receiving an introductory tablet training and some links to websites that recommend usable apps for people with dementia in general
20833|NCT04026048|Behavioral|Cognitive Behaviour Therapy for Insomnia (CBT-I)|CBT-I is a manualized multi-component intervention that includes sleep restriction, stimulus control, cognitive restructuring, relaxation training, and sleep hygiene.
20834|NCT04026022|Drug|Fentanyl Transdermal System|Patients will be treated perioperatively with a new pain management, that has been modified to integrate the 2017 ESA guidelines on prevention/treatment of postoperative delirium. Moreover patients will be administered a 12µg/h Fentanyl TTS in the ER or PACU. The ER TTS will only be administered if the patients still has mild to intense pain after initial intravenous (i.v.) treatment as well as reposition of the fractured hip. Further aspects of the modified management are: avoiding benzodiazepines, allowing oral fluids up to 2 hours before surgery, intraoperative monitoring of anaesthesia depth and at least 1,8 ltr crystalloid infusion per day.
20835|NCT04026022|Drug|Placebo|Placebo plaster in the ER or PACU
20836|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)|"Subjects in CDIFF Ag 18 - 45 Years and CDIFF Ag 50 - 70 Years Groups will receive 2 doses (0.5 mL each) of CDIFF Ag vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval."
20837|NCT04026009|Biological|C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B|"Subjects in CDIFF Ag + AS01B 50 - 70 Years Group will receive 2 doses (0.5 mL each) of CDIFF Ag + AS01B vaccine.~The vaccine will be administered intramuscularly in the deltoid, at a 0, 1-month dose interval."
20838|NCT04026009|Drug|Placebo|Subjects will receive 2 doses (0.5 mL each) of Placebo, administered intramuscularly in the deltoid, at a 0, 1-month dose interval.
20839|NCT04025996|Diagnostic Test|Cardiac Assessments and Eye Assessments|"Cardiac Assessments, include the following:~transthoracic echocardiography~computed tomography of coronary arteries~position emission tomography computed tomography or single photon emission tomography computed tomography~Eye examinations, include the following:~pupil dilation~retinal photography~dynamic vessel analyser~IOL master"
20840|NCT04025983|Dietary Supplement|GastimunHp Plus|Each sachet contains 6mg of IgY and 50 mg of heat-killed Lactobacillus johnsonii No. 1088.
20841|NCT04025983|Other|Placebo|The placebo contains neither IgY nor L. johnsonii.
20842|NCT04025970|Genetic|Circulating tumor cell and circulating tumor DNA test|Patient stratification based on presence or absence of suspicious findings of cells and DNA
20843|NCT04025957|Drug|SHR-1501|Administered subcutaneously
20844|NCT04025931|Drug|chidamide and toripalimab|"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
20845|NCT04025918|Device|Vasopressor automated delivery system|"Novel closed-loop system incorporating:~Continuous non-invasive arterial pressure (CNAP) monitor that measured and recorded hemodynamic data in real time.~Controller algorithm loaded onto a laptop computer that monitored the hemodynamic data from CNAP and determined if vasopressors should be administered.~Two syringe pumps loaded with phenylephrine and ephedrine that was activated by the controller algorithm."
20846|NCT04025918|Drug|Phenylephrine|Phenylephrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of at least 60bpm.
20847|NCT04025918|Drug|Ephedrine|Ephedrine is a vasopressor drug that was administered when the participant's systolic blood pressure fell below 90% of baseline systolic blood pressure, with heart rate of less than 60bpm.
20848|NCT04025918|Device|Manual vasopressor delivery system|"Manual dosing system consisting:~Non-invasive intermittent blood pressure monitor that measured and recorded blood pressure at 1-minute intervals.~Attending anesthesiologist that noted the blood pressure readings and manually administered phenylephrine or ephedrine according to the algorithm."
20849|NCT04025905|Behavioral|Social Cognition Training|Evaluate the impact of the social cognition training on employment maintaining in transitional Workforce Assistance Facilities and Services.
20850|NCT04025905|Behavioral|Informations|informations about work environment, social environment, stress management, sleep management, treatments
20852|NCT04025879|Biological|Nivolumab|Specified dose on specified days.
20853|NCT04025879|Drug|Carboplatin|Specified dose on specified days.
20858|NCT04025866|Other|Conventional rehabilitation|1h/day for 5 days/week of conventional rehabilitation for femur fracture
20859|NCT04025866|Other|Aerobic exercise|30 min/day of aerobic exercise with arm cycle ergometer added to 1h/day for 5 days/week of conventional rehabilitation for femur fracture
20860|NCT04025840|Other|Epidural block|Epidural block (with 0.375% ropivacaine) is performed during surgery. Patient-controlled epidural analgesia (with a mixture of 0.12% ropivacaine and 0.5 microgram/ml sufentanyl) is provided after surgery.
20861|NCT04025840|Drug|Dexamethasone|Dexamethasone (10 mg) is administered intravenously before anesthesia induction.
20862|NCT04025827|Other|Dietary intake|We will collect detailed data on dietary intake and weight for healthy newborns in four low income countries.
20863|NCT04025814|Behavioral|CaregiverAssist|CaregiverAssist is a proposed dHealth tool to promote parent adherence and sustained strategy use of evidence-based parenting strategies.
20864|NCT04025788|Device|Magmaris Resorbable Magnesium Scaffold (RMS)|Subjects will undergo a percutaneous coronary intervention for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of two single de novo lesions in two separate major epicardial vessels are allowed.
20865|NCT04025775|Device|CamAPS HX Closed-loop|"The CamAPS HX closed-loop system comprises~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS HX Application with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump~Glooko/Diasend cloud upload system to monitor CGM/insulin data."
20866|NCT04025775|Other|Multiple Daily Insulin Injections (Control)|Multiple Daily Insulin Injections with masked Dexcom G6 CGM sensor (Dexcom, Northridge, CA, USA)
20867|NCT04025762|Device|Hybrid closed-loop system (CamAPS FX)|Hybrid closed-loop system
20868|NCT04025762|Device|Sensor augmented pump therapy|Sensor augmented pump therapy
20869|NCT04025749|Behavioral|Computerized Executive Functions training|Home-based executive function training with adaptive difficulty, through NeuronUp (https://www.neuronup.com) over 12 weeks (30 min/day, 5 days per week, 30h in total).
20870|NCT04025749|Other|Care as usual|Care as usual
20871|NCT04025736|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Tranexamic acid (TXA) is a synthetic analog of the amino acid lysine which acts by competitively blocking the plasminogen lysine-binding site and inhibiting fibrinolysis. Several studies showed that TXA could reduce both blood loss and the amount of blood transfusion after shoulder arthroplasty surgeries.
20872|NCT04025736|Drug|0.9% Sodium Chloride Injection|Normal saline is a mixture of sodium chloride in water and has a number of uses in medicine. We use the same volume of normal saline as placebo.
20873|NCT04025723|Other|Downhill running|60 minutes downhill running in 10% grade, in an effort of 65% of VO2max.
20874|NCT04025710|Device|BIOMONITOR III|"Insertion of BIOMONITOR III~three scheduled in-office follow-ups~48-hour Holter ECG"
20875|NCT04025697|Other|Complete Denture|A conventional CD will be constructed
20876|NCT04025697|Other|Rapid prototyped denture|A 3d printed complete denture will be constructed
20877|NCT04025684|Other|Oral B Indicator 123|Manual toothbrush (medium bristle stiffness; compact head, UK market).
20878|NCT04025684|Other|Dr Best Original|Manual toothbrush (medium bristle stiffness; regular head, German market)
20879|NCT04025684|Other|Dr Best Multi Expert|Manual toothbrush (medium bristle stiffness; compact head, German market)
20880|NCT04025684|Other|parodontax Interdental|Manual toothbrush (soft bristle stiffness; compact head, German market)
20881|NCT04025671|Device|Nasal Spray Naloxone|Nasal spray naloxone device.
20882|NCT04025671|Device|Intramuscular Naloxone|A vial of simulated naloxone and syringe with attached needle.
20883|NCT04025671|Device|Improvised Nasal Atomizer|A naloxone bristoject dose and nasal atomizer device.
20884|NCT04025658|Drug|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
20885|NCT04025645|Diagnostic Test|MEASUREMENT OF COMMON BILE DUCT PRESSURES|THE PRESSURES OF THE COMMON BILE DUCT WERE MEASURED
20886|NCT04025632|Drug|zilucoplan|Daily subcutaneous (SC) inection
20887|NCT04025632|Other|Placebo|Daily subcutaneous (SC) inection
20888|NCT04025619|Device|tape|Sports tape
20889|NCT04025606|Drug|Thoracic epidural|Standard thoracic epidural (needle inserted into the space between the covering of spinal cord and the cord itself) preoperatively. Standard thoracic epidural analgesia mixture (2 mg/ ml bupivacaine, 2 µg/ ml fentanyl and 2 µg/ ml adrenalin) with an infusion of 6-10 ml/hour until day 2 postoperatively. Thereafter reduction by 30 % every four hours.
20890|NCT04025606|Drug|Paravertebral block|Paravertebral block containing 5 ml bupivacaine 5 mg/ ml (optionally 10 ml bupivacaine 2,5 mg/ ml). In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.
20891|NCT04025593|Drug|Cyclophosphamide|750mg/m2 day 1
20892|NCT04025593|Drug|Rituximab|375mg/m2 day 0
20893|NCT04025593|Drug|Doxorubicin|50mg/m2 day 1
20894|NCT04025593|Drug|Vincristine|1.4mg/m2, max 2mg day 1
20895|NCT04025593|Drug|Prednisone|60mg/m2, max 100mg day 1-5
20896|NCT04025593|Drug|Ibrutinib|560mg/day qd
20897|NCT04025593|Drug|Lenalidomide|25mg day1-10
20898|NCT04025593|Drug|chidamide|20mg day 1,4,8,11
20899|NCT04025593|Drug|decitabine|decitabine 10mg/m2 day-5 to day-1
20900|NCT04025580|Biological|Flucelvax|Seasonal influenza vaccine
20901|NCT04025580|Biological|Fluvirin|Seasonal influenza vaccine
20902|NCT04025580|Biological|Fluzone High Dose|Seasonal influenza vaccine for adults ages 65 and older
20905|NCT04025541|Biological|Blood sampling|blood sampling time : cycle 1 day 15 and cycle 2 day 15 : one sample (6ml) by time
20906|NCT04025528|Procedure|Bariatric Surgery|Weight loss surgery with either gastric sleeve or gastric bypass surgery
20958|NCT04025138|Other|Neuromuscular fatigue assessment test|Neuromuscular fatigue assessment test in dynamic mode will be assessed by the Force/Velocity Profile (FVP) measure: 2 sprints of 8 seconds on a cycle ergometer.
20907|NCT04025502|Device|Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System|The testing protocol consists of an auditory oddball Event-Related Potential (ERP) paradigm, 40Hz ASSR, and the collection of 6 minutes of resting electroencephalogram (EEG). During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 6 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 60-75 minutes.
20908|NCT04025489|Dietary Supplement|Randomized control trial of vitamin D supplementation|This open-label randomized placebo-controlled prospective trial will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. Anthropometry, body composition, levels of vitamin D, blood glucose (including oral glucose tolerance test) and dietary assessments will be assessed periodically (every 3 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. Diet and exercise will be recommended as per the regular norms for overweight and obese subjects. Clinical and dietary profile, sunlight exposure, glycemic and lipid profile other metabolic parameters, body composition, hand grip strength, leukocyte telomerase length and telomerase activity will be assessed at enrolment time and one-year intervention. As mentioned above, genes related to ageing will be evaluated. Effects on polymorphisms of pro-ageing genes will be assessed.
20909|NCT04025476|Drug|Steroids|IV and oral steroids
20910|NCT04025463|Behavioral|HHMB|Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
20911|NCT04025450|Drug|Chidamide+VRD|Chidamide:30mg d0,d3,d7,d10/Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
20912|NCT04025450|Drug|VRD|Velcade:1.3mg/m2 d1,d4,d8,d11/ Dexamethasone: 10mg BID d1,d2,d4,d5,d8,d9,d10,d11/Lenalidomide: 25mg d1-d14
20913|NCT04025437|Procedure|Hepatectomy alone|Patients in this group will receive hepatectomy alone.
20914|NCT04025437|Radiation|Neoadjuvant radiotherapy|Radiotherapy for type I PVTT will be perfomed before hepatectomy. Hepatic resection will be performed in about 4 weeks after radiotherapy.
20915|NCT04025424|Genetic|Genetic tests of the available tumor and plasma samples|Only available samples or samples obtainted for other reasons will be used for molecular testing. No special intervention is preplanned
20916|NCT04025411|Device|Intensive Visual Simulation 3 (IVS3) device|"Visual motor simulation with the Intensive Visual Simulation 3 (IVS3) device will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).~The patient looks on a screen in front of him, mirroring the movements made by his healthy hand, while attempting to perform the same movement with his paretic hand."
20917|NCT04025411|Device|traditional Mirror Therapy (TM)|Simulation with the traditional Mirror Therapy (TM) will be realized and consist of 5 sessions per week for 4 weeks (20 minutes).
20918|NCT04025398|Behavioral|Cognitive remediation program|Comparison between a cognitive remediation program (REHABILITUS) (group 1) and a training group of manual activities (group 2)
20919|NCT04025398|Behavioral|Control group|"Comparison between a cognitive remediation program (Réhabilitus) (group 1) and a training group of manual activities (group 2)"
20920|NCT04025385|Other|High Intensity Interval Training|Training for 25 min with four 1 minute intervals when participants exercise up to 80% of their individual limits.
20921|NCT04025372|Drug|Bicalutamide|Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
20922|NCT04025372|Drug|GnRH Agonist|In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
20923|NCT04025372|Radiation|Radiation Therapy|Radiation Therapy is a cancer treatment that uses high doses of radiation to kill cancer cells and shrink tumors.
20924|NCT04025372|Drug|Darolutamide|Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
20925|NCT04025359|Drug|Dronabinol|Dronabinol 10Mg
20926|NCT04025359|Drug|Dronabinol|dronabinol 20Mg
20927|NCT04025359|Drug|Placebos|sugar pill
20928|NCT04025346|Other|Capsimax|1 capsule to be taken before breakfast.
20929|NCT04025346|Other|Micro Crystalline Cellulose|1 capsule to be taken before breakfast.
20930|NCT04025320|Other|Intraneural Facilitation|Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
20931|NCT04025320|Other|Sham|A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
20956|NCT04025138|Other|Neuromuscular tests in isometric mode|"Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~Voluntary maximum forces plantar flexors and knee extensors~Electrically evoked forces~ElectroMyoGraphic activity (EMG)~Three-Modality Evoked Potentials (TMEPs)"
20982|NCT04024917|Other|Standard care|Standard care
20932|NCT04025307|Drug|bacTRL-IL-12|bacTRL-IL-12 is a live, genetically modified Bifidobacterium longum (B longum), for administration via IV infusion. The probiotic bacteria selectively colonize solid tumour tissues and are engineered to deliver genetic material encoding the pro-inflammatory transgene Interleukin-12 (IL-12). Plasmid DNA encoding the IL-12 transgene is delivered to the patient's cells within the tumor microenvironment, whereupon IL-12 is expressed to stimulate local and systemic anti-tumour immune responses.
20933|NCT04025294|Device|videogame|A videogame intervention that is interactive and engaging that teaches adolescents how to restructure negative automatic thoughts through an adapted thought record (a technique used in cognitive behavioral therapy to improve moods) by modeling how to do so and then empower them through real-life activities to improve their school climate. The videogame intervention is comprised of five mini-games, each containing a short narrative that models how to restructure negative automatic thoughts and navigate through challenging situations that often take place in school settings. The topics of each mini-game are informed by the constructs of school climate according to the National School Climate Center. Students using the videogame intervention will be prompted to think deeply and reflect on the narratives presented in each mini-game.
20934|NCT04025294|Behavioral|School Climate Assessment Survey|A school climate assessment survey will include items adapted from questions developed by the National School Climate Center. Items will assess various dimensions of school climate including safety, social media, relationships, support for learning, and environment.
20935|NCT04025281|Other|Extra Virgin Olive Oil|Participants will consume a meal prepared with 50 mL extra virgin olive oil. The meals will be prepared and provided to the study participants in the cafeteria of Griffin Hospital, where the Prevention Research Center is located. With the exception of the type of olive oil used in the meals, the meal plan will be comparable in all the intervention phases for the same individual.
20936|NCT04025281|Other|Refined Olive Oil|Participants will consume a meal prepared with 50 mL refined olive oil in the cafeteria of Griffin Hospital. With the exception of the olive oil used, the meal plan will be comparable in each the intervention phases for the same individual.
20937|NCT04025268|Behavioral|Group Prenatal Care (GPNC)|GPNC participants will attend 11 group sessions total: 10 during pregnancy and one postpartum. Each session will be 90-100 minutes long. Groups will collectively identify the preferred time of day for these sessions. Groups of 10 women will be led by a locally trained, Samoan nurse-midwife with the study Project Director as a co-facilitator. At each of the visits participants will engage in self-assessments of weight and blood pressure, including learning to take their blood pressure with a digital cuff, calculating BMI, and plotting their weight gain on a graph), receive short individual clinical examinations from a midwife, and participate in group discussions about prenatal care, childbirth preparation, and their postpartum care. The session at 6-weeks postpartum will allow women to introduce their babies to the group and share childbirth stories.
20938|NCT04025268|Behavioral|Standard of Care|Standard of prenatal care
20939|NCT04025255|Dietary Supplement|Braini|A novel, neuro-protective and neuro-restorative dietary supplement composed of a combination of active ingredients which have been commercially-available since at least 2015 or have achieved FDA new dietary ingredient notification (NDIN) status in 2018
20940|NCT04025255|Dietary Supplement|Placebo|Matched placebo
20941|NCT04025229|Behavioral|HIIT exercise|High intensity interval training (4 to 6 sessions) prior to surgery
20942|NCT04025216|Biological|CART-TnMUC1|Single intravenous administration of genetically modified autologous T cells engineered to express a TnMUC1-Targeted Genetically-Modified Chimeric Antigen (CAR)
20943|NCT04025216|Drug|Cyclophosphamide|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
20944|NCT04025216|Drug|Fludarabine|Patients will receive cyclophosphamide and fludarabine lymphodepletion chemotherapy followed by the investigational product, CART-TnMUC1
20945|NCT04025203|Other|Median nerve neural mobilization|Manual therapy maneuver performed in the upper limb.
20946|NCT04025203|Drug|Ibuprofen Arginine|Oral tablets
20947|NCT04025203|Drug|Gabapentin|oral capsules
20948|NCT04025177|Drug|Indomethacin Injection|The dose of indomethacin will be 0.1 mg/kg/dose, based on birth weight, intravenously every 24 hours for a total of 3 doses. Doses 2 and 3 may be administered between 23.5 and 24.5 hours after the previous dose. Doses will be rounded to two significant figures.
20949|NCT04025164|Radiation|Hypofractionated Radiotherapy|daily fractions, 2.66 Gy/3.2 Gy per fraction to whole breast/tumor bed, five fractions per week
20950|NCT04025164|Radiation|Conventional fractionated Radiotherapy|daily fractions, 2 Gy per fraction, five fractions per week
20951|NCT04025151|Behavioral|Alcohol brief intervention|At baseline, subjects will receive face-to-face alcohol brief intervention developed based on the guideline by the World Health Organisation in 5-10 minutes
20952|NCT04025151|Behavioral|12-page health warning leaflet|Nurses will provide information about the consequences of drinking using a 12-page health warning booklet. Benefits of reducing and quit drinking will be emphasized by focusing on improving their perception towards the impacts on health, social problems, risky behaviors, academic performance and financial issues.
20953|NCT04025151|Behavioral|Regular messages through Instant Messaging (IM)|A total of 26 e-messages will be scheduled: once daily for the first week, 3 time/week for subsequent 4 weeks and 1 time/week for the remaining 7 weeks. The frequency will be adjusted according to IM Apps conversation and subject's requests.
20954|NCT04025151|Behavioral|Real-time chat-based support through IM Apps|The chat-based IM support is the extension of baseline ABI and regular e-messages, which aims to provide real-time behavioral and psychosocial support to reduce or quit drinking. It will be personalized according to the subjects' characteristics (gender, drinking pattern and alcoholic drinks preferences), intention to drink and specific questions regarding drinking. Through real-time chatting (text and/or voice), drinkers can acquire information on consequences of drinking and gain social support immediately to reduce intention to drink and alcohol consumption.
20955|NCT04025151|Behavioral|General health through IM Apps|After baseline, they will receive regular e-message through IM Apps with similar frequency to Intervention group with content on general health and the reminding the importance of participating in the follow-up surveys.
20957|NCT04025138|Device|Transcranial Magnetic Stimulation (TMS)|Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
20959|NCT04025138|Other|treadmill|2 sessions of treadmill will be realized: 8 and 10 km.h-1 for level running and 7 km.h-1 with 10% slope for graded running.
20960|NCT04025138|Biological|Blood sample|Blood sample will be realized to measure hemorrheologic and hematologic parameters.
20961|NCT04025138|Biological|Urinary sample|Urinary sample will be realized to measure hemorrheologic and hematologic parameters.
20962|NCT04025112|Device|Armeo®Power|Randomized patients will be offered rehabilitation robotic using Armeo®Power from Hocoma, the first robotic arm exoskeleton for integrated arm and hand therapy, during one month, three times a week, totalizing 12 sessions of 45 minutes.
20963|NCT04025112|Other|Conventional rehabilitation protocol|Randomized patients will be offered the conventional rehabilitation protocol from Barretos Cancer Hospital during one month, three times a week, totalizing 12 sessions of 45 minutes.
20964|NCT04025099|Other|Internal Cues|"The intuitive eating curriculum that was pilot tested and adapted has been modified for use for the Internal Cues group with college-aged females for delivery over a 10-week time period.~The classes will be delivered by two Registered Dietitians and Certified Intuitive Eating Counselors from the University of Delaware, Julia Katcher and Maryann Eastep.~During the Internal Cues group's intuitive eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn the intuitive eating principles taught in class.~The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Jones, RYT."
20965|NCT04025099|Other|External Cues|"The 10-week traditional healthy weight program for the External Cues group was created by a Graduate Assistant based on MyPlate principles.~The External Cues classes will be delivered by two Registered Dietitians from the University of Delaware, Julia Katcher and Maryann Eastep.~During the External Cues group's healthy eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn how to properly portion their meals to meet their caloric needs, in line with traditional education about weight control.~Students randomized to the External Cues group will receive a UD fitness pass and will be able to choose from select cardio-based fitness classes in order to meet public health recommendations for physical activity."
20966|NCT04025073|Other|Dietary Approaches to Stop Hypertension|The DASH diet will have a reduced caloric intake by 400 kcal/day, when compared to the standard hospital diet. The DASH diet will be planned according to the following: total daily energy intake 1,900 kcal; total daily fat intake 27%; daily intake of saturated fatty acids 6%; total daily protein intake 18%; total daily carbohydrates intake 55%; cholesterol 150 mg/day; sodium 2,300 mg/day; potassium 4,700 mg/day; calcium 1,250 mg/day; magnesium 500 mg/day; and fiber 30 g/day.
20967|NCT04025073|Other|Nutrition education program|The nutrition education program will consist of four lectures intended to improve the overall participants' dietary habits. The lectures will be interactive and will be organized in smaller groups (up to 10 participants) covering the following themes: My Plate dietary guidelines; Principles of a balanced diet; Reading and understanding food nutrition labels; Dietary recommendations for elevated blood pressure, dyslipidemia, and diabetes mellitus.
20968|NCT04025060|Behavioral|Commercially-available caffeine-free soda|Subjects are asked to consume caffeine-free soda daily for two weeks
20969|NCT04025060|Behavioral|Carbonated water|Subjects are asked to consume unsweetened, carbonated water daily for two weeks
20970|NCT04025060|Behavioral|Regular soda|Subjects are asked to consume regular soda daily for two weeks
20971|NCT04025034|Procedure|Orbital decompression with ultrasonic bone removal|Deep lateral wall partial rim-sparing decompression for thyroid-related orbitopathy using SONOPET® appears to be safe and effective, reducing the complications associated and damage to neurovascular structures.
20972|NCT04025021|Dietary Supplement|Targeted Fortification|The TPN and SMOF lipids will be optimized to provide a goal of 4 g/kg/day of protein, and 100-130kcal/kg/day. At 100 ml/kg/day of enteral feeds additional liquid protein and/or microlipids will be added to the breast milk to provide goal of 4 g/kg/day of protein and 100-130 kcal/kg/day. This will be determined by analysis of the milk and reported composition. They will continue targeted fortification for 4 weeks after achieving full feeds of 150 ml/kg/day.
20973|NCT04025021|Device|The Miris Human Milk Analyzer|The Miris human milk analyzer is a mid infrared that reports the amount of energy absorbed at each wavelength. The amount of fat (grams), lactose (grams), total protein (grams), true protein (grams), and energy (kcal) per 100 ml will be reported.
20974|NCT04025008|Device|MicroStent or percutaneous transluminal angioplasty (PTA)|Intravascular treatment
20975|NCT04024982|Other|Sequence of teaching (Lecture first followed by Simulation)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
20976|NCT04024982|Other|Sequence of teaching (Simulation first followed by Lecture)|Sequence of teaching (whether lecture or simulation session first) can help to achieve the maximum skill acquisition in TEE.
20977|NCT04024969|Diagnostic Test|T2* MRI|Research T2* weighted MRI sequence
20978|NCT04024969|Diagnostic Test|Lumbar puncture to test for presence of unmatched oligoclonal bands|Current clinical standard practice
20979|NCT04024956|Device|Sealing Device|The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.
20980|NCT04024943|Device|Quadripolar LV Lead|The Attain Stability Quad MRI SureScan LV Lead (Model 4798) is an active fixation quadripolar LV lead based on the Attain Performa lead family models (4298, 4398, and 4598). The lead incorporates an active fixation helix similar to the OUS commercialized Attain Stability bipolar LV lead (Model 20066/4796) which is designed to allow an implanter more options in lead location.
20981|NCT04024917|Other|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-12 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 12 days preceding the operation.~The anaesthetic induction will be done with a session of cardiac coherence.~The program cardiac coherence will be performed during 90 days after the surgery"
20983|NCT04024904|Device|OncomfortTM device|The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
20984|NCT04024891|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|1% phentolamine mesylate ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
20985|NCT04024891|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
20986|NCT04024878|Drug|Nivolumab|Nivolumab (Opdivo®) is an antibody. An antibody is a common type of protein produced by the body that the immune system uses to find and destroy foreign molecules.
20987|NCT04024878|Biological|NeoVax|"The vaccine will consist of up to 20 peptides as well as a drug that activates the immune system called Poly-ICLC. Poly-ICLC (also called Hiltonol) is an experimental viral mimic and an activator of immunity"
20988|NCT04024878|Procedure|Core Needle Biopsy|Surgical procedure
20989|NCT04024865|Drug|Domperidone|Women who received a prescription for domperidone (ATC A03FA03) during the six months following delivery.
20990|NCT04024852|Other|Intervention group|When Air Quality Health Index is below level 5, the intervention group did daily mild exercise (walking) outdoors for 30 minutes. When Air Quality Health Index is equal to or above level 5, the group is advised to do mild exercise indoors for 30 minutes.
20991|NCT04024839|Other|Active Isolated Stretch|In supine position, participant was asked to lock the knee and slowly lift leg using the quadriceps muscles. gentle assistance was given by the rope at the end of the movement, as the quadriceps muscles continue to move the leg. strech was applied for 2 sec and then release to starting position. two sets of 10 repetitions were performed.
20992|NCT04024839|Other|Post Isometric Relaxation|In supine line, participant was asked to do SLR until resistance was met in hamstring muscles and then was asked to do isometric contraction (10-20% of maximum) for 5 - 10 sec and inhale. After this, patient was asked to exhale while doing so gentle stretch was applied till the new barrier. Starting from this new barrier, the procedure was repeated 2 - 3 times.
20993|NCT04024826|Behavioral|EFP|This group will perform the Resistance training intervention on day 4 of the menstrual cycle, which corresponds to the mid of early follicular phase.
20994|NCT04024826|Behavioral|LFP|This group will perform the Resistance training intervention on day 11 of the menstrual cycle, which corresponds to the mid of late follicular phase.
20995|NCT04024826|Behavioral|ELP|This group will perform the Resistance training intervention on the day 18 of the menstrual cycle, which corresponds to the mid of early luteal phase
20996|NCT04024826|Behavioral|LLP|This group will perform the Resistance training intervention on day 21 of the menstrual cycle, which corresponds to the mid of late luteal phase
20997|NCT04024813|Drug|Seladelpar|Capsule(s) administered orally once daily
20998|NCT04024813|Drug|Placebo to match Seladelpar|Capsule(s) administered orally once daily
20999|NCT04024800|Biological|AE37 Peptide vaccine|"Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in > 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level −1)."
21000|NCT04024800|Biological|Pembrolizumab|Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
21001|NCT04024787|Behavioral|Cognitive-Behavioural therapy for insomnia (CBT-I)|"Participants with chronic primary insomnia are randomized into 2 groups with a 1:1 allocation ratio, after the completion of the pre-treatment assessment. Post-treatment and post-waitlist assessment occur after the 3-month treatment or waiting period.~One group will receive the intervention immediately after the pre-treatment assessment and the other group will receive the intervention after a waiting period of 3 months. The intervention consists of manualized cognitive-behavioural therapy for insomnia. This treatment includes psychoeducation about sleep and circadian rhythms, stimulus control, sleep restriction, relaxation, and cognitive therapy. The therapy is administered individually. Participants meet for 8 sessions of 50 minutes spread over 12 weeks."
21002|NCT04024774|Biological|Biological samples|blood samples, urine samples, tissue samples
21003|NCT04024774|Genetic|Genetic test|anamnesis and NGS sequencing
21007|NCT04024748|Device|PET/CT imaging|Subjects will be have a PET/CT scan with PCD-1000A following their scheduled routine PET/CT scan. There will be no additional administration of radiopharmaceutical for the study.
21008|NCT04024735|Diagnostic Test|Spirometry, Forced Oscillation Technique, Step-counter, sputum and blood samples|We will be collecting demographic and clinical information including daily physical activity level, lung function, blood and sputum samples. These measurements will be collected at patient admission, discharge and at follow-up of 30 and 90 days.
21009|NCT04024722|Procedure|In Vitro Fertilization|Patients suitable for research with poor ovarian response will receive treatment including laparoscopic surgery, resection, and transplantation of ovarian tissue in the same operation to improve the chances of success of in vitro fertilization and pregnancy. Participants will be assessed for surgical incisions and fertility assessment up to two weeks after treatment, including general physical examination, US pelvic examination, and blood tests for a hormonal profile to determine the initiation of ovarian stimulation and IVF. Patients will be monitored from 2 weeks to 1 year after treatment (once a week in the first two months and one month for one year after surgery), which will include a general physical examination, a US test, and blood tests for the hormonal profile at the IVF clinic.
21010|NCT04024709|Procedure|Gastric Peroral Endoscopic Myotomy|Creation by submucosal dissection of a tunnel in the gastric wall at the level of the antrum, then of a pyloric and antral myotomy, before closing the mucosal access by clips.
21011|NCT04024696|Drug|Abexinostat|Abexinostat Tosylate Tablets
21083|NCT04024137|Drug|Placebo|1 tablet taken orally
21012|NCT04024683|Procedure|Serratus block with ropivacaine 2mg/ml|The serratus block was made using a 50 mm needle with ultrasound guidance. It was performed supine, the ultrasound probe identifying the 3, 4 or 5th intercostal space and then the needle was introduced under ultrasound control
21013|NCT04024670|Other|Arts Intervention|If selected for the arts activity, an artist in residence will visit you 3 times a week for a total of 3 weeks during your hospital stay. Two visits will focus on the arts activity and one visit will be the administration of the questionnaire. Each visit will be approximately 25 minutes at a time.
21014|NCT04024631|Other|75g glucose beverage (Glucola, Trutol, or similar brand)|Subjects will present fasting to the study day and ingest the glucose beverage during the oral glucose tolerance test.
21015|NCT04024631|Other|DXA, whole body|Subjects will undergo a whole body DXA scan for assessment of adiposity index and body fat distribution.
21016|NCT04024618|Procedure|Parenteral Nutrition/Enteral Nutrition|Patients randomized to the parenteral nutrition arm will receive nutrition by IV and patients randomized to the enteral nutrition arm will receive nutrition by NG tube.
21017|NCT04024605|Dietary Supplement|Sunflower|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
21018|NCT04024605|Dietary Supplement|Rapeseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
21019|NCT04024605|Dietary Supplement|Flaxseed|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
21020|NCT04024605|Dietary Supplement|Lupin|Plant proteins are intrinsically enriched with 15N and 2H. There are incorporated into biscuits. The biscuits are formulated to supply 20 g of plant protein per volunteer.
21021|NCT04024592|Device|Biodex System 4|Reliability and validity of isokinetic strength measurement of the knee, hip and ankle in typically developing children.
21022|NCT04024566|Device|Vivio System|Optical/sensor tonometer applied to the neck over the carotid pulse (bilateral)
21023|NCT04024540|Dietary Supplement|isocaloric dietary restriction|Very low caloric diet
21024|NCT04024540|Procedure|Bariatric surgery|Laparoscopic vertical sleeve gastrectomy
21025|NCT04024527|Drug|Esomeprazole|Proton pump inhibitor
21026|NCT04024527|Drug|Amoxicillin|Antibiotic for H. pylori eradication
21027|NCT04024527|Drug|Metronidazole|Antibiotic for H. pylori eradication
21028|NCT04024514|Other|low dose CT contrast media|CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group
21029|NCT04024514|Other|Standard dose CT contrast media|CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.
21030|NCT04024501|Drug|Verinurad ER8 capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
21031|NCT04024501|Drug|Verinurad A-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
21032|NCT04024501|Drug|Verinurad A-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
21033|NCT04024501|Drug|Verinurad B-capsule formulation (fasted)|Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
21034|NCT04024501|Drug|Verinurad B-capsule formulation (fed)|Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
21035|NCT04024488|Behavioral|TI-CBT Intervention Arm|"TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial."
21036|NCT04024488|Behavioral|Discussion Control Arm|Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
21037|NCT04024475|Other|Observation|
21038|NCT04024462|Drug|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based loading dose of 840-milligrams (mg) IV and then a 420-mg IV maintenance dose Q3W.
21039|NCT04024462|Drug|Trastuzumab IV|Trastuzumab will be administered as an 8-milligram per kilogram of body weight (mg/kg) IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
21040|NCT04024462|Drug|FDC of Pertuzumab and Trastuzumab SC|The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
21041|NCT04024462|Drug|Doxorubicin|Doxorubicin 60 milligrams per meter squared of body surface area (mg/m^2) will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
21042|NCT04024462|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m^2 will be administered IV on Day 1 of each cycle of treatment (as part of AC Q3W) for Cycles 1-4.
21043|NCT04024462|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered IV on Day 1 of Cycle 5. At the investigator's discretion the dose may be escalated to 100 mg/m^2 IV for Cycles 6-8 (Q3W) provided no dose-limiting toxicity occurs.
21084|NCT04024137|Drug|ZSP1273-600 mg|3 X 200-mg tablet taken orally
21085|NCT04024137|Drug|Placebo|3 tablets taken orally
21044|NCT04024462|Procedure|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
21045|NCT04024462|Radiation|Post-Operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
21046|NCT04024462|Drug|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
21047|NCT04024449|Other|Group A|ovarian function test in control group
21048|NCT04024436|Drug|TAS-120|TAS-120 is an oral FGFR inhibitor
21049|NCT04024436|Drug|Fulvestrant|Fulvestrant is used for the treatment of hormone receptor positive metastatic breast cancer
21050|NCT04024423|Other|Epidemiologic investigation|Identification of overlaps in source(s) of care between participants with NTM isolates in a Cystic Fibrosis Care Center.
21051|NCT04024410|Other|Evaluation of PEEP in prone position|Assessment of optimal Positive End-Expiratory Pressure (PEEP) in patients undergoing scheduled spine surgery in prone position.
21052|NCT04024384|Drug|Daratumumab|Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
21053|NCT04024371|Behavioral|Self-rating Questionnaires|"Snaith-Hamilton Pleasure Scale (SHAPS; Snaith et al. 1995)~Quick Inventory of Depressive Symptomatology (QIDS; 16 items)~Behavioral avoidance/inhibition Scales (BIS/BAS)"
21054|NCT04024371|Behavioral|Measures of Reward processing/reinforcement learning|"Grip Strength Effort Task (Reddy et al. 2015; in combination with EEG)~Doors (Gambling) task (Foti and Hajcak 2009; in combination with EEG)~Reinforcement Learning/Working Memory task (Collins et al. 2017; no EEG)"
21055|NCT04024371|Behavioral|Additional Schizophrenia-specific Questionnaires and Interviews|"Positive and Negative Syndrome Scale (PANSS: Kay et al. 1987)~Brief Negative Symptom Scale (BNSS; Kirkpatrick et al. 2011)"
21056|NCT04024345|Diagnostic Test|Barratt Simplified Measure of Social Status (BSMSS)|Questionnaire that evaluates cultural identity, educational level and occupation of the subject and the subject's parents and spouse (if any)
21057|NCT04024345|Diagnostic Test|Global Assessment of Functioning scale (GAF)|Used to measure overall levels of functionality of an individual
21058|NCT04024345|Diagnostic Test|General Self-Efficacy Scale (GSES)|Psychometric scale that is designed to assess optimistic self-beliefs to cope with a variety of difficult demands in life
21059|NCT04024345|Diagnostic Test|Perceived Stress Scale (PSS)|To assess the perceived stress
21060|NCT04024345|Diagnostic Test|Coping Orientation to Problems Experienced (Brief COPE),|It evaluates the subject's coping style through investigation of problem-solving abilities and emotional fluctuation, as a response to stressful situations
21061|NCT04024345|Diagnostic Test|Multidimensional Scale of Perceived Social Support (MSPSS)|to explore the subject's social support system
21062|NCT04024332|Drug|ACT-541468|ACT-541468 25 mg; administered orally
21063|NCT04024319|Procedure|Genicular Nerve Block|4 ml of local anesthetic were administered in 5 genicular nerves. A total volume of 20 ml were administered in GNB group.
21064|NCT04024306|Device|Ultrafiltration|Using ultrafiltration to extract the fluid overload from the body of the patients
21065|NCT04024293|Device|Goldfish (GF)|The GF lens (SCL) will be place on participant's eye for a 24h IOP recording session
21066|NCT04024280|Other|Physical exercise program|Frequency: 3 weekly sessions. Intensity of aerobic training: reporting 12-17 in the Borg scale. Time of aerobic training: 10 minutes in the first and second weeks and then 2 added minutes at each 2 weeks. Type of aerobic training: walking and stepping. Intensity of resistance training: without load in the first week and, then, 15 submaximal repetitions. Time of resistance training: 30 minutes. Type of resistance training: using free weights; the lower body exercises will be squat, leg extension, leg curl and calf raise; the upper body exercises will be frontal and lateral arm raise, chest press, seated row and bicep curl.
21067|NCT04024267|Other|Eurythmy therapy|Mind-body therapy
21068|NCT04024267|Other|CoordiFit|Fitness training
21069|NCT04024254|Drug|Folic Acid Tablet|Folic Acid 1 mg by mouth daily
21070|NCT04024241|Device|Flow Cytometer|high dose
21071|NCT04024241|Drug|Mitoxantrone|high dose
21072|NCT04024241|Drug|Cytarabine|high dose
21073|NCT04024228|Biological|Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains QIV-SD|Pharmaceutical form:Suspension for injection in pre-filled syringe Route of administration: Intramuscular
21074|NCT04024228|Biological|High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation QIV-HD|Pharmaceutical form:Suspension for injection in pre-filled syringe Route of administration: Intramuscular
21075|NCT04024215|Device|intravascular ultrasound|IVUS creates axial images perpendicular to the long axis of the catheter by transmitting sound waves covering 360 degrees around the tip of the catheter, which is delivered into the lumen of the vessel over a guidewire.
21076|NCT04024189|Other|Survey|Patients were given a questionnaire/survey to complete in respect of their satisfaction of the consent process for their surgical procedure
21077|NCT04024176|Other|Gait analysis|The duration of participation of each subject is equal to the duration of the examination, i.e. approximately 30 minutes for the gait analysis and 30 minutes for the clinical examination (including 10 minutes for completing the questionnaire). The experiments will be carried out in a single measurement session, including several steps.
21078|NCT04024163|Drug|Benznidazole|Drug: Benznidazole Tablets 100 mg (functionally scored) or Tablets 12.5 mg
21079|NCT04024150|Biological|Blood test|Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup
21080|NCT04024137|Drug|ZSP1273 200 mg|1 X 200-mg tablet taken orally
21081|NCT04024137|Drug|Placebo|2 tablets taken orally
21082|NCT04024137|Drug|ZSP1273-400 mg|2 X 200-mg tablet taken orally
21086|NCT04024137|Drug|Placebo|Subjects will receive matching placebo of ZSP1273
21087|NCT04024111|Behavioral|KONTAKT(c)|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainer
21088|NCT04024085|Other|completion of the test created Time to be Ready to Void|completion of the test created (Time to be Ready to Void) The participants have to stand up from a chair with armrests, walk 6 meters to the toilet, open the door and turn on the light, close the door, undress and position themselves to urinate
21089|NCT04024072|Drug|Brinzolamide 1% ophthalmic suspension|Test product
21090|NCT04024072|Drug|Azopt 1% Ophthalmic Suspension|Reference product
21091|NCT04024059|Behavioral|Contingency Management for adherence|Incentives contingent on buprenorphine adherence
21092|NCT04024059|Behavioral|Contingency Management for abstinence|Incentives contingent on opiate abstinence
21093|NCT04024046|Dietary Supplement|Uqora|Participants will receive 1 Placebo Drink-Mix and 2 Placebo Capsules Daily
21094|NCT04024046|Dietary Supplement|Group1|Participants will receive 1 Uqora Drink-Mix and 2 Placebo Capsules Daily
21095|NCT04024046|Dietary Supplement|Group 2|Participants will receive 1 Uqora Drink-Mix and 2 Uqora Capsules Daily
21096|NCT04024033|Dietary Supplement|pine cone extract|pine cone extract capsule
21097|NCT04024033|Other|placebo|placebo capsule
21098|NCT04024020|Other|lumbar puncture|Subjects will have a lumbar puncture to collect cerebrospinal fluid collection
21099|NCT04024007|Diagnostic Test|Citrate dosage|Patients are dialysed according to the standard of care. Biological variables are measured in pre-filter, post-filter and dialysate 30 minutes after the dialysis is initiated.
21100|NCT04023994|Drug|RO7126209|Participants will be administered a single-ascending intravenous doses of RO7126209 with at least 2 weeks between each dose level. After the starting dose, the subsequent doses will be selected in an adaptive design. Sentinel dosing will be employed.
21101|NCT04023994|Drug|Placebo|Participants will be administered a single intravenous dose of matching placebo.
21102|NCT04023981|Device|Parafricta bootees|Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
21103|NCT04023968|Behavioral|YESplus workshop|"See description in Arms section."
21104|NCT04023968|Behavioral|WOW! workshop|"See description in Arms section."
21105|NCT04023955|Behavioral|Twitter|Participants received a daily tweet over a period of one-month with educational messages about HPV vaccine and cervical cancer
21106|NCT04023942|Behavioral|Weight maintenance intervention|Weight maintenance intervention (52 weeks): After randomization, participants will follow either a low carb or a low fat diet and get nutritional assistance either by an app or a newsletter, based on the group they got randomized to (low carb/app, low carb/newsletter, low fat/app, low fat/newsletter).
21107|NCT04023929|Procedure|Cord blood sampling|A cord blood sample will be obtained after the baby has been delivered and the cord has been clamped and cut.
21108|NCT04023916|Drug|Sintilimab-R-CHOP|"Drug:Sintilimab:~Sintilimab:200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 200 mg IV on Day 1 of Cycles 9-14.~Drug: Rituximab Rituximab:Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.~Drug: Cyclophosphamide Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Doxorubicin Hydrochloride Liposome Injection Doxorubicin Hydrochloride Liposome Injection will be administered at a dose of 35 mg/m^2 IV on Day 2-3 of Cycle 1-6, during induction treatment.~Drug: Vincristine Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 2 of Cycle 1-6, during induction treatment.~Drug: Prednisone Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6, during induction treatment. Prednisolone may be given if prednisone is unavailable."
21109|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
21110|NCT04023903|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
21111|NCT04023877|Drug|E2027|E2027 oral capsule.
21112|NCT04023864|Dietary Supplement|Platycodon Grandiflorus Extract(GCWB107)|Once-daily, once a tablet, after meals, for 12 week
21113|NCT04023864|Dietary Supplement|Placebo|Placebo for 12 week
21114|NCT04023851|Device|Mobile application Brain4U|Brain4U application provides participants to record seizures, medications, side effects, and combined psychiatric problems. It also reminds participants when to take antiepileptic drugs.
21115|NCT04023838|Procedure|artery puncture and coronary angiography|We will perform coronary angiography through a Judkins 5 French diagnostic catheter and will take a basic view. At the end of the examination, the radial sheath is removed and the right conventional radial approach is performed for about 4 hours and the left snuffbox approach for about 2 hours using the compressive bandage method. The hemostatic device will use ez ClotRadial® (SOYEON medical Co., Ltd., Wonju, Korea).
21116|NCT04023825|Drug|suprazygomatic maxillary nerve block|in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
21117|NCT04023786|Procedure|PEEP-TEST|The PEEP test will consist of lowering the PEEP level to 5 cmH2O for a maximum of 2 minutes and a minimum of 1 minute. Patients will be included if the physicians who care for them have decided to set a baseline PEEP level ≥10 cmH2O.
21118|NCT04023773|Device|Liver Machine Perfusion (MP) device|Donor livers will have ex vivo continuous perfusion on the institutional-developed Liver MP device. The temperature of liver grafts will be controlled during perfusion.
21119|NCT04023760|Drug|Apixaban|Study subjects given a single-dose of apixaban 10 mg.
21154|NCT04023513|Other|Low protein intake|6 weeks of low protein intake (1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
21231|NCT04022954|Device|Catheter ablation|Inquiry AFocusII Double Loop and Advisor HD Grid, Sensor Enabled
21120|NCT04023734|Behavioral|Reminders, habit-based strategies and/or involvement of family member|"Strategies to cope with forgetfulness include reminders, habit-based strategies and/or involvement of family members. The use of a reminder tool and pill boxes will be encouraged and a reminder app can be implemented if patients own a mobile phone. The habit-based strategy will be delivered through a printed worksheet which is tailored to patient's daily routine. Patients will be asked to identify the appropriate place and time to take their medication, and an action they conduct every day that could serve as a prompt or cue to take their medication. Patients will be asked to write coping plans to formulate their own if-then plans for all daily doses of their antihypertensive drug(s). Moreover, patients will be asked to choose a family member to become their treatment supporter. This individual will be asked to support patients to take the antihypertensive drugs. Pharmacists will remind patients to take his/her completed worksheet to the next visit."
21121|NCT04023734|Behavioral|Counselling to increase knowledge|The content of the counselling to cope with lack of knowledge will focus on educating patients about the purpose of the medication, when and how to take the medication, the need for long-term use, the importance of medication adherence, and how to deal with possible side effects. To explore which education is needed, the patient will be asked whether they know why and how to take their medication. The teach-back method will be used, where the patient is asked to explain the pharmacist what he/she has understood after receiving the education.
21122|NCT04023734|Behavioral|Counselling to increase motivation|The content of the counselling to cope with lack of motivation will focus on exploring and discussing their concerns and necessity beliefs. This method is called motivational interviewing. This is done by asking a first question about whether the medication bothers the patient. Follow-up on this question can focus on any concerns or low necessity beliefs (e.g., when patients are bothered by the medication because they think the medication is not needed or are afraid of side-effects).
21123|NCT04023734|Behavioral|Explore/address other drug related problems|The content of the counselling to address other drug related problems will focus on exploring these other problems underlying the non-adherence, for example experiencing side effects, costs, polypharmacy, difficulty to refill antihypertensive drugs in time, or medication intake problems, and offering solutions/alternatives when possible.
21124|NCT04023734|Behavioral|Usual care based on the Indonesian guideline|Patients in five CHCs randomized to the control group will receive pharmacist counselling based on the Indonesian guideline of pharmacy practice. At each visit, they will receive information about the quantity and dose of the dispensed drugs, when and how to use and store the drugs, side effects and how to deal with them, the importance of medication adherence, and confirming if the patient understands how to take medications correctly.
21125|NCT04023721|Drug|Inarigivir soproxil|Inarigivir soproxil 200 mg tablets
21126|NCT04023721|Drug|Nucleoside/nucleotide (NUC) analogue inhibitors|Continuation of prestudy NUC therapy
21127|NCT04023708|Drug|CYD-TDV Dengue Vaccine|Pharmaceutical form:Solution Route of administration: Intramuscular
21128|NCT04023695|Drug|Corticosteroid with lidocaine with epinephrine|Trigger finger injection
21129|NCT04023695|Drug|Corticosteroid with normal saline|Trigger finger injection
21130|NCT04023682|Drug|Provodine Hand Sanitizer|Intervention with Provodine
21131|NCT04023669|Drug|Prexasertib|IV
21132|NCT04023669|Drug|Cyclophosphamide|IV
21133|NCT04023669|Drug|Gemcitabine|IV
21134|NCT04023669|Biological|filgrastim|Given subcutaneously (SQ). Alternatively, pegfilgrastim may be given.
21135|NCT04023669|Biological|peg-filgrastim|Given subcutaneously (SQ). Alternatively, filgrastim may be given.
21136|NCT04023643|Other|Ventilation Weaning|Use of different weaning strategies
21137|NCT04023630|Drug|Rivaroxaban 15 MG Oral Tablet|One 15 mg tablet once daily for up to twelve months
21138|NCT04023630|Drug|Clopidogrel 75 Mg Oral Tablet|One 75 mg tablet once daily for up to twelve months
21139|NCT04023630|Drug|Ticagrelor 90 MG Oral Tablet|One 90 mg tablet twice daily for up to twelve months
21140|NCT04023617|Drug|Nivolumab|Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
21141|NCT04023604|Other|Controlled diet with beef raised without antibiotics|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised without antibiotics.
21142|NCT04023604|Other|Controlled diet with beef produced in conventional systems|The controlled diet with beef raised without antibiotics will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern. Beef included in this diet were raised with antibiotics.
21143|NCT04023591|Procedure|Surgery/Occupational Therapy|Surgery based on function and injury/ Occupational therapy for 48 months post-surgery
21144|NCT04023578|Device|RHEO KNEE XC|Microprocessor controlled knee using Magneto-Rheologic techonology.
21145|NCT04023565|Drug|perindopril + moxonidine|"After 14 days of wash-out period perindopril 10 mg + moxonidine 0.4 mg a day will be prescribed.~If target BP is achieved after 4 weeks, the dosage will remain unchanged (perindopril 10 mg + moxonidine 0.4 mg a day (given as two divided doses).~If target BP is not achieved after 4 weeks, the dosage will increase up to perindopril 10 mg + moxonidine 0.6 mg a day (given as two divided doses)."
21146|NCT04023552|Drug|TQJ230|TQJ230 80 mg injected monthly administered subcutaneously
21147|NCT04023552|Drug|Placebo|Placebo to match TQJ230 prefilled syringe to be injected subcutaneously
21148|NCT04023539|Dietary Supplement|Cinnamomum zeylanicum|Capsules of 2 g cinnamomum zeylanicum orally
21149|NCT04023539|Other|Placebo|Placebo capsules
21150|NCT04023526|Drug|Azacitidine|Azacitidine SC or IV will be administered at a standard dose of 75 mg/m^2 on days 1-7 of each cycle.
21151|NCT04023526|Drug|Cusatuzumab|Cusatuzumab IV will be administered as 10 mg/kg or 20 mg/kg.
21152|NCT04023513|Other|High protein intake|6 weeks of high protein intake mainly via food (additional 1g/kg bw/d) followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains.
21153|NCT04023513|Other|Control, no intervention|No Intervention, control
21190|NCT04023201|Other|Nocturnal symptoms|Parkinson's disease patients with or without nocturnal symptoms
21155|NCT04023513|Other|Strength training|6 weeks of different protein intake followed by a 8 weeks resistance training (Progressive strength training in a fitness center is applied; the intensity is adjusted continuously in order to obtain a sufficient training stimulus). During the training period the protein intake remains
21156|NCT04023500|Behavioral|Motivational interview vs. prevailing education|"In intervention group dental hygienists are trained to focus on patients view of their oral health, self-care skills and need for oral-health related behaviour change. They are supposed to use open-ended questions, reflective listening and reinforcing with patients.~In control croup dental hygienist defined patients educational needs and gave direct instructions how to change behaviour and self-care."
21157|NCT04023487|Behavioral|Resilient, Empowered, Active Living-Telehealth (REAL-T)|REAL-T is an individually-tailored occupational therapy intervention that focuses on incorporating diabetes self-care into participants' daily habits and routines. Participants receive approximately 12 hours of intervention, delivered via telehealth over 6 months by a licensed occupational therapist with training in diabetes education, motivational interviewing, and the REAL Diabetes intervention protocol.
21158|NCT04023474|Procedure|Platelet Rich Fibrin (PRF) Application|Platelet Rich Fibrin application to flap defect.
21159|NCT04023461|Device|PVAC GOLD catheter ablation|Isolation of pulmonary veins using PVAC GOLD catheter.
21160|NCT04023448|Procedure|transverse coloplasty pouch|a transverse coloplasty pouch was performed before end to end colon-rectum (or anal canal) anastomosis
21161|NCT04023435|Other|PNE edcuation|The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
21162|NCT04023422|Behavioral|Clinical intervention|The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
21163|NCT04023422|Behavioral|Feedback|The community health navigator will give the clinician real-time feedback on guideline-related health.
21164|NCT04023409|Other|NA: no intervention|NA: no intervention
21165|NCT04023396|Drug|ABX464|"ABX464~All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 48 weeks."
21166|NCT04023383|Drug|40 cc HyaRegen NCH gel|After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
21167|NCT04023383|Drug|40 cc sterile saline solution|After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
21168|NCT04023370|Device|Treatment of primary iliac artery stenosis and/or occlusive lesions|Stent implantation
21169|NCT04023357|Other|PEEK|New polyetheretherketones material
21170|NCT04023357|Other|Emax|standard etchable glass ceramic used for Endocrowns
21171|NCT04023344|Drug|Humalog Mix25|Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
21172|NCT04023344|Drug|Insulin Lispro Biphasic 25|"Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses"
21173|NCT04023331|Drug|67Cu-SARTATE|67Cu-labelled MeCOSar-Tyr3-octreotate
21174|NCT04023331|Drug|64Cu-SARTATE|64Cu-labelled MeCOSar-Tyr3-octreotate
21175|NCT04023318|Behavioral|Integrated Lifestyle Intervention|This program is grounded in data demonstrating the dysregulation across multiple domains and considerable life stressors experienced by this population. The central hypothesis is that by simultaneously ameliorating psychological dysregulation and directly targeting proinflammatory behaviors, ILI operates on multiple proposed mediators of poor treatment outcomes in this population, thereby enhancing treatment outcomes. As such, the overall framework emphasizes integration of self-regulation as it applies to both psychological functioning and weight control. Content will highlight the interconnectedness of mood, stress, eating and exercise behaviors, and risk for inflammation and disease. Each treatment session will present a combination of behavioral and psychological content, representing a truly integrated approach. Participants will meet for 75-minute group sessions weekly for months 1-2, followed by bi-weekly groups in months 3-4, for a total of 12 groups.
21176|NCT04023305|Drug|Deep sedation by Sevoflurane on the Morphotype of ARDS in ICU patieNts|Pharmacokinetic of inhaled sevoflurane used for sedation
21177|NCT04023292|Drug|Endocrine therapy|Use before surgery for 2 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
21178|NCT04023292|Drug|Endocrine therapy|Use before surgery for 4 weeks. Choice of endocrine therapy is according to guidelines and centre policy.
21179|NCT04023279|Other|TENS|100 Hz and 100 usec for 20 minutes
21180|NCT04023279|Other|Myofascial therapy|Seven to fifteen transverse sliding repetitions and three repetitions of longitudinal sliding of myofascial release therapy
21181|NCT04023266|Drug|Intravenous N-Acetylcysteine|Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
21182|NCT04023253|Drug|Mirabegron|Mirabegron 25 mg
21183|NCT04023253|Drug|Solifenacin|Solifenacin 5 mg
21184|NCT04023240|Drug|68Ga-FAPI|"68Ga-FAPI is quinoline based PET radiopharmaceutical.~68Ga-FAPI is administered intravenously (IV)"
21185|NCT04023240|Procedure|Computed Tomography (CT) scan|Participants will have a CT scan for attenuation correction and anatomic localization of PET data.
21186|NCT04023240|Procedure|Positron Emission Tomography (PET) scan|PET images will be acquired.
21187|NCT04023227|Drug|Sacubitril/valsartan|50 (24/26) mg, 100 (49/51) mg and 200 (97/103) mg will be available for dose adjustments.
21188|NCT04023227|Drug|Enalapril|5 mg and 10 mg will be available for dose adjustments.
21189|NCT04023214|Diagnostic Test|Peripheral (digital) arterial tonometry|This will be measured using the EndoPAT system (Itamar Medical)
21191|NCT04023175|Other|Telemedicine preoperative counseling|The telemedicine visit will be completed using an Atrium Health approved virtual visit platform.
21192|NCT04023175|Other|In office preoperative counseling|This includes our standard preoperative counseling located at the Women's Center for Pelvic Health
21193|NCT04023162|Behavioral|Operant conditioning|Active participation of respondents, Overcoming and eliminating negative behaviors, Encouraging positive behavior in pain, Overcoming the fear of the movement, Motivation to implementation pre-set specific goals.
21194|NCT04023162|Behavioral|Therapy Exercises in Group|Aerobic exercises, Stretching exercises and flexibility, Range of motion, Balance and coordination, Breathing exercises Stabilization exercises Muscle strength training exercises
21195|NCT04023162|Behavioral|Back School|Basic information on low back pain - anatomy, physiology, causes, treatment. Correct postures - standing, sitting, driving, sleeping, Correct body movements - lifting, pushing, walking.
21196|NCT04023149|Drug|recombinant human interleukin-2 (rhIL-2)|Drug: rhIL-2; Pharmaceutical form: solution; Route of administration: oral gargle.
21197|NCT04023149|Drug|placebo|Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
21198|NCT04023136|Procedure|partial hepatectomy by laparotomy on healthy or pathologic parenchyma.|Preoperative flow and MRI + intraoperative measures of flow and pressures
21199|NCT04023123|Other|Ophthalmic imaging|Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
21200|NCT04023110|Drug|Carvedilol|Individually dosed carvedilol
21201|NCT04023097|Device|Toothwave toothbrush|Subjects get the device's box with the user manual and the device. However, they don't use the device, but only read the user manual and fill questionnaires.
21202|NCT04023084|Drug|Crisaborole|Crisaborole 2% topical ointment applied twice daily to affected area(s) for 28 days
21203|NCT04023071|Drug|FT516|Experimental Interventional Therapy
21204|NCT04023071|Drug|Rituximab|Monoclonal Antibody
21205|NCT04023071|Drug|Obinutuzumab|Monoclonal Antibody
21206|NCT04023071|Drug|Cyclophosphamide|Lympho-conditioning agent
21207|NCT04023071|Drug|Fludarabine|Lympho-conditioning agent
21208|NCT04023071|Drug|IL-2|Biologic response modifier
21209|NCT04023058|Procedure|Mitral surgery|Guidelines approved mitral surgery
21210|NCT04023045|Device|Assist-Knee|Assist-Knee is an experimental lower limb knee prosthesis.
21211|NCT04023045|Device|Habitual Prosthesis|Habitual baseline prosthesis prescribed by participant's clinician.
21212|NCT04023032|Behavioral|multicomponent cognitive intervention|"The intervention takes place in groups of 6-10 participants and is leaded by one occupational therapist. It includes 16 sessions, 90 minutes each.~The first part of each session starts with a 15-minute review of previous homework or relaxation. The second part, which lasts 35 minutes, involves structured training with activity-sheets, board games, role-playing and computerized games. The third part, which lasts 30 minutes, is the lifestyle interventions. The instructor explains the generalization of the previous activities toward daily life, and introduces healthy lifestyles. Through group discussions, the therapist guides participants to develop solutions and strategies for their memory or cognition-related problems and application to daily life. The last 10 minutes are used to suggest homework."
21213|NCT04023019|Biological|Nuwiq|Nuwiq is a recombinant FVIII concentrate from a human cell line. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
21214|NCT04023019|Biological|Octanate|Octanate is a high-purity human Factor VIII / von Willebrand Factor (VWF) concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
21215|NCT04023019|Biological|Wilate|Wilate is a high-purity human von Willebrand Factor (VWF)/Factor VIII concentrate. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
21216|NCT04023019|Biological|Emicizumab|Emicizumab is a therapeutic antibody which brings activated factor IX and factor X together It is administered via subcutaneous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
21217|NCT04023019|Biological|Recombinant factor VIIa (rFVIIa)|Recombinant factor VIIa (rFVIIa) is a blood factor VII manufactured using recombinant technology. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
21218|NCT04023019|Biological|Activated prothrombin complex concentrate (aPCC)|Activated prothrombin complex concentrate (aPCC) is an anti-inhibitor coagulant complex acting on multiple pathways to facilitate coagulation. It is administered via intravenous injection at a dosage determined by the investigator's discretion, in consideration of the participants' clinical condition and prescribing information.
21219|NCT04023006|Device|Removable prostheses|Full dentures created by Additive manufacturing (Carbon Printers)
21220|NCT04022993|Drug|Lantus Solostar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
21221|NCT04022993|Drug|Insulin RinGlar, 100 Units/mL Subcutaneous Solution|4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
21222|NCT04022980|Drug|Nivolumab|R-MPV induction followed by Nivolumab consolidation.
21223|NCT04022980|Drug|Rituximab|R-MPV induction followed by Nivolumab consolidation.
21224|NCT04022980|Drug|Methotrexate|R-MPV induction followed by Nivolumab consolidation.
21225|NCT04022980|Drug|Vincristine|R-MPV induction followed by Nivolumab consolidation.
21226|NCT04022980|Drug|Procarbazine|R-MPV induction followed by Nivolumab consolidation.
21227|NCT04022967|Drug|dolutegravir|One daily tablet (50mg) during 96 weeks
21228|NCT04022967|Drug|atazanavir boosted with ritonavir|One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
21229|NCT04022967|Drug|tenofovir + lamivudine +efavirenz|One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks
21230|NCT04022967|Drug|Lamivudine|One daily tablet (300mg) during 96 weeks
40850|NCT03864042|Drug|modafinil|taken orally
21232|NCT04022941|Drug|Sodium Benzoate|Group A will receive drug packets containing 2.5 gm sodium benzoate and 5 gm powdered table sugar for 5 days.
21233|NCT04022941|Other|Powdered table sugar as palcebo|Group B will receive 7.5 gm packets of powdered table sugar for 5 days as placebo which is similar in appearance and taste as sodium benzoate.
21234|NCT04022928|Other|PRP|, For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
21235|NCT04022915|Drug|64Cu-FBP8|Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.
21236|NCT04022915|Diagnostic Test|PET-CT imaging|All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
21237|NCT04022902|Other|No intervention|This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
21238|NCT04022889|Device|INTERCEPT Treated Platelets|Apheresis platelet components in 100% plasma collected using the Trima separator, prepared with the INTERCEPT Blood System for Platelets (Test Platelets) and stored for 7, 6 or 5 days at 20°C-24°C with continuous agitation. Samples from the Test component will be processed with either the BEST or the Variant 1 procedure prior to radiolabeling. The radiolabeled autologous Test and Control platelets will be simultaneously administered intravenously into the subject.
21239|NCT04022876|Drug|ALRN-6924|ALRN-6924 will be administered IV on days 0-4 of every 21-day treatment cycle
21240|NCT04022876|Drug|Topotecan|Topotecan will be administered IV on days 1-5 of every 21-day treatment cycle
21241|NCT04022863|Diagnostic Test|TEP|Tumor Educated Platelets
21242|NCT04022863|Diagnostic Test|ctDNA|circulating tumor DNA
21243|NCT04022850|Behavioral|Intuitive de-implementation|A set of de-implementation strategies targeting automatic cognition to alter the clinical decision making of physicians regarding the CVD primary prevention practice to be performed with hypercholesterolemic patients aged 40-75 years old without ischemic heart disease or diagnosed cardiovascular disease and with low CVD risk (<5%)
21244|NCT04022850|Behavioral|Reflexive de-implementation|A set of de-implementation strategies targeting reflexive cognition to alter the clinical decision making of physicians regarding the CVD primary prevention practice to be performed with hypercholesterolemic patients aged 40-75 years old without ischemic heart disease or diagnosed cardiovascular disease and with low CVD risk (<5%)
21245|NCT04022850|Behavioral|Passive dissemination|Usual procedures of dissemination of clinical practice guidelines, focused in the distribution of materials, support tools and training in the reference group.
21246|NCT04022837|Drug|Pantoprazole 40mg|effect of this drug on renal function
21247|NCT04022824|Other|OSA|Patients with OSA (apnea hypopnea index ≥15) based on sleep study
21248|NCT04022824|Other|Non-OSA|Patients without OSA (apnea hypopnea index ＜15) based on sleep study
21249|NCT04022811|Drug|0.1% bromfenac|the patients received the use of the Ponacore 3 days before and 7 days after the operation. Local eye drops, 2 times a day.
21250|NCT04022798|Other|Exercise, manual therapy|"Participants were randomly assigned into treatment (n=15) or control group (n=15). Participants in each group received 12 treatment sessions of 45 minutes each, 2 days a week for 6 consecutive weeks.~For each group, a menu of a lumbar stabilization program was designed. This program included 8 levels of exercise ( single leg knee to chest stretch, double leg knee to chest, supine piriformis stretch, supine hamstring stretch, lower trunk rotation stretch, lumbar rotation stretch, pelvic tilt, pelivic tilt with alternative legs). Exercises were tailored for each individual ability and, if possible, progressed at each session which would last approximately 30 minutes. Each single exercise was repeated many times based on the patient's clinical condition. All sessions were provided by physiotherapists."
21251|NCT04022785|Drug|Azacitidine|Given IV or SC
21252|NCT04022785|Drug|BRD4 Inhibitor PLX51107|Given PO
21253|NCT04022772|Other|Best Practice|Receive standard of care
21254|NCT04022772|Other|Medical Chart Review|Ancillary studies
21255|NCT04022772|Other|Quality-of-Life Assessment|Ancillary studies
21256|NCT04022772|Other|Questionnaire Administration|Ancillary studies
21257|NCT04022772|Procedure|Supportive Care|Participate in PACK Health program
21258|NCT04022759|Behavioral|Treatment as Usual with Security Prime|"In addition to their treatment as usual (low-intensity guided self-help behavioural activation for depression), participants will complete an initial attachment security priming task during the first session with their allocated clinician. Participants will be prompted in their intervention workbook with a caption regarding what a secure attachment relationship represents. They will be asked to think of a person/ people with whom they feel they have this relationship, and list them. Following this, they are asked to plot these individuals on a diagram of concentric circles in relation to how close they feel this person is to them. The closer to the middle of the diagram the individual places each person, the closer they feel their relationship to that person is.~Prior to each session with their clinician, they will be prompted to complete a repeated security priming task in order to increase feelings of security prior to therapy sessions."
21259|NCT04022759|Behavioral|Treatment as Usual (Behavioural Activation)|Clients will engage in treatment as usual. This involves low-intensity guided self-help behavioural activation for depression.
21260|NCT04022746|Procedure|Magnetic Resonance Elastography|Undergo multiparametric MRI/MRE
21261|NCT04022746|Procedure|Magnetic Resonance Imaging|Undergo multiparametric MRI/MRE
21262|NCT04022733|Drug|Moderate neuromuscular block|maintaining of moderate neuromuscular block (train-of-four count 1-2) during surgery, reversal using neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg
21263|NCT04022733|Drug|Deep neuromuscular block|maintaining of deep neuromuscular block (posttetanic count 1-2) during surgery, reversal using sugammadex 4 mg/kg based on actual body weight
21264|NCT04022720|Procedure|Platelet Rich Fibrin Application|Platelet Rich Fibrin application at first post-op visit.
21265|NCT04022707|Other|High-speed circuit resistance training|The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
21266|NCT04022707|Other|Educational control|Lectures on health and fitness
21297|NCT04022408|Diagnostic Test|Liquid based cytology|Liquid based cytology
21298|NCT04022408|Diagnostic Test|Conventional cytology|Conventional cytology
21267|NCT04022694|Behavioral|Exposure to beverage health information|Red stop sign and avoidance message for sugar-sweetened beverages and green check mark and promotion message for non-sugar-sweetened beverage nutrition information
21268|NCT04022694|Behavioral|Exposure to beverage calorie information|Calories for sugar-sweetened and non-sugar-sweetened beverages
21269|NCT04022681|Other|BALLETS|Cohort were not exposed to any intervention. There information will be analysed from database searches.
21270|NCT04022668|Radiation|Coronary angiogram|Routine coronary angiogram, if indicated
21271|NCT04022655|Other|ICU Care|No intervention
21272|NCT04022642|Other|High-Intensity Interval Training|"The program will be applied in the first 10-15 minutes of each PE class, twice a week, including a brief warm-up, ranged from 14 to 20 intervals, adopting a 2:1 work to rest ratio (ie, 30-s work, followed by 30-s rest)~A cut-point of >=90% of maximal heart rate was used as our criterion for satisfactory compliance to high-intensity exercise~In order to estimate effort, fatigue and training load, a subjective effort scale will be used throughout each session. The heart rate will be monitored throughout the session in real time through Bluetooth technology.~Actigraph accelerometers (wGT3X-BT), randomly distributed by the students in each session, will be used to characterize the intensity of the sessions."
21273|NCT04022629|Procedure|Arthroscopic Washout Only|To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.
21274|NCT04022629|Procedure|Arthroscopic Bankart Repair|To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
21275|NCT04022616|Other|Specimen collection|Specimens are obtained from patients who are being treated for breast malignancies.
21276|NCT04022603|Device|Cyclometer Ergometer|The measurements are carried out on a max effort of 12 minutes on a cyclometer ergometer with a constant load (Motomed viva2 light). A first effort is made with a Venturi type mask whose Inspired Fraction in Oxygen (FiO2) is set for a pulsated oxygen saturation (SpO2) greater than or equal to 85%, and then a second at 2h interval with high-throughput googles (Optiflow) with the corresponding FiO2.
21277|NCT04022590|Device|E-clothes|The E-clothes could prove heart rate or heart rate variability(HRV) information to the participants' smart phone by blue tooth. Then the smart phone will calculate and provide the suitable aerobic training intensity by the microphone when the participants do aerobic training.
21278|NCT04022590|Behavioral|Healthy consultation|Healthy consultation will educate the participants do aerobic training three times a week for 3 months. And the each training period is at least 30 minutes.
21279|NCT04022577|Behavioral|Adherence Therapy|Motivational interviewing-based AT in this study was based on Gray et al.'s eight-session AT using the motivational interviewing technique (and principles of cognitive behavioral therapy).
21280|NCT04022577|Behavioral|control group|The control group received routine care
21281|NCT04022538|Procedure|Anterior maxillary vertical segmental sandwich osteotomy with simultaneous implant placement|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~The first implant osteotomy will be prepared and placed while a chisel is placed between the down fractured segment and the basal bone, and then the second implant will be installed.~The gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
21282|NCT04022538|Procedure|Anterior maxillary vertical segmental sandwich osteotomy using micro-plates fixation|"Following the Sandwich Osteotomy procedure described in the study description, the following steps will be done:~The created gap between the transported segment and the basal bone will be filled with xenograft particulate bone substitute.~The mobilized segment is to be fixed to the basal bone using micro-plates and micro-screws.~Finally, periosteal scoring will be done to allow tension-free interrupted closure using 3-0 vicryl suturing material."
21283|NCT04022525|Drug|Leflunomide 20Mg Tab|blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
21284|NCT04022512|Radiation|computed tomography|thoracic CT examinations for pre-treatment staging and/or subsequent post-treatment follow-up.
21285|NCT04022499|Behavioral|Presessions|"The Pre-NDPP arm includes a pre-session with three components: 1) education about diabetes risks, 2) motivational interviewing (MI) to encourage participation in the NDPP and, 3) problem-solving of barriers to engagement."
21286|NCT04022499|Behavioral|National Diabetes Prevention Program|The Diabetes Prevention Program was a successful clinical trial demonstrating that intensive lifestyle support for weight loss reduced diabetes incidence by 58%. The intervention was translated into the National Diabetes Prevention Program (NDPP) and disseminated by the Centers for Disease Control and Prevention as a yearlong group-based program since 2012.
21287|NCT04022486|Other|Incidence, management and risk factors of seizure|Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
21288|NCT04022473|Drug|Bafiertam|Over-encapsulated capsule to mask treatment
21289|NCT04022473|Drug|Tecfidera|Over-encapsulated capsule to mask treatment
21290|NCT04022460|Diagnostic Test|Video clip assessment|Parents will take short video clips of their child sleeping at night. They will be asked to review the video clips and rate whether they think their child has obstructive sleep apnea (OSA), and if so, how severe it is. Two clinicians will review the video clips on a separate night.
21291|NCT04022460|Diagnostic Test|Polysomnography (sleep study)|Children will undergo a polysomnography as the gold standard test to assess for OSA.
21292|NCT04022460|Other|Educational webinar|After evaluating the video clips of their child sleeping, parents will watch an educational webinar on OSA in children with Down syndrome and how to recognize symptoms.
21293|NCT04022447|Drug|Dupilumab|retrospective data collection
21294|NCT04022434|Dietary Supplement|Placedo|Subjects will mix the placebo in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
21295|NCT04022434|Dietary Supplement|Alanine|Subjects will mix the alanine in the beverage of their choice and consume this approximately 20 minutes before meals or snacks, in according with the dosing guidelines set for them by the dietitian.
21296|NCT04022421|Drug|Hydroxychloroquine|the drug will be taken by one group of the patients daily at a dose of 400mg
21299|NCT04022395|Diagnostic Test|stress cardiac MRI|pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia
21300|NCT04022382|Device|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL.
21301|NCT04022369|Behavioral|Exercise Group|The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
21302|NCT04022356|Device|Feetme Connected Soles|"Walk for 10 meters (and 30meters):~By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphone- collection of data by smartphone~By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers).~If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely."
21303|NCT04022343|Drug|Cabozantinib|Given PO
21304|NCT04022330|Other|Blood sampling|The blood sampling will be done just before surgery
21305|NCT04022317|Biological|Biocon Insulin R|Biocon Insulin R is a short-acting human insulin, produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing Pichia pastoris (yeast).
21306|NCT04022317|Biological|Humulin®R|Humulin® R is a polypeptide hormone structurally identical to human insulin synthesised through recombinant deoxyribonucleic acid (rDNA) technology in a non-pathogenic laboratory strain of Escherichia coli bacteria.
21307|NCT04022304|Biological|Biocon Insulin N|Biocon Insulin N is an intermediate-acting isophane suspension of human insulin produced by recombinant deoxyribonucleic acid(rDNA) technology utilizing Pichia pastoris (yeast).
21308|NCT04022304|Biological|Humulin® N|Humulin® N (human insulin [recombinant deoxyribonucleic acid origin] isophane suspension) is an intermediate-acting human isophane insulin. Humulin® N is a suspension of crystals produced from combining human insulin and protamine sulphate.
21309|NCT04022291|Biological|Humulin ®70/30|"Humulin® 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Human insulin is produced by recombinant deoxyribonucleic acid (rDNA), technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
21310|NCT04022291|Biological|Biocon Insulin 70/30|"Biocon Insulin 70/30 is a premixed suspension of human insulin of recombinant deoxyribonucleic acid (rDNA)origin, which contains 30% short-acting human soluble insulin and 70% intermediate-acting isophane insulin.~Biocon insulin is produced by recombinant deoxyribonucleic acid (rDNA) technology utilizing a non-pathogenic laboratory strain of Escherichia coli."
21311|NCT04022265|Device|implant placement|Full-thickness muco-periosteal flaps will be elevated, and the alveolar bone exposed to prepare the bed for the implant installation
21312|NCT04022252|Device|Cheese dental laser|810 nm GaAlAs diode laser device
21313|NCT04022252|Device|OrthoPulse|850 nm LED (light emitting diode)
21314|NCT04022252|Other|Placebo|810 nm GaAlAs diode laser device
21315|NCT04022239|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
21316|NCT04022239|Drug|Bendamustine|Given IV
21317|NCT04022239|Drug|Bendamustine Hydrochloride|Given IV
21318|NCT04022239|Drug|Cyclophosphamide|Given IV
21319|NCT04022239|Biological|Filgrastim-sndz|Given SC
21320|NCT04022239|Drug|Fludarabine|Given IV
21321|NCT04022239|Drug|Fludarabine Phosphate|Given IV
21322|NCT04022239|Drug|Melphalan|Given IV
21323|NCT04022239|Drug|Mycophenolate Mofetil|Given PO
21324|NCT04022239|Biological|Rituximab|Given IV
21325|NCT04022239|Drug|Tacrolimus|Given IV and PO
21326|NCT04022239|Radiation|Total-Body Irradiation|Undergo TBI
21327|NCT04022226|Drug|Ketamine|Induction agent that suppresses infra-slow waves
21328|NCT04022226|Drug|Methohexital|Induction agent that does not suppress infra-slow waves
21329|NCT04022213|Drug|131 I-omburtamab|Single dose of IP RIT administered through an IP catheter with 131 I-omburtamab at 80mCi/m2
21330|NCT04022213|Radiation|WA-IMRT|Group A participants will receive WA-IMRT 2-4 weeks after completing IP RIT. A dose of 30 Gy will be delivered in 20 fractions of 1.5 Gy given once daily, 5 days per week over the course of approximately 4 weeks
21331|NCT04022200|Device|Paclitaxel DCB|The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
21332|NCT04022187|Other|Observational study : no intervention|Observational study : no intervention, only exporting data
21333|NCT04022174|Behavioral|Moderate dosage training of action Observation and Motor imagery|Motor imagery and action observation of orofacial exercises with moderate dosage
21334|NCT04022174|Behavioral|Intensive dosage training of action observation and motor imagery|Motor imagery and action observation of the orofacial exercises with intensive dosage
21335|NCT04022174|Biological|Intensive dosage orofacial exercises|Orofacial exercises with high intensity
21336|NCT04022174|Behavioral|Moderate dosage orofacial exercises|Orofacial exercises with moderate intensity
21337|NCT04022161|Drug|Nitrogen Gas for Inhalation|See arm description
21338|NCT04022161|Other|Blood withdrawal|Blood samples will be collected over four time-points: (I) baseline (before surgery) (II) end of the surgery, (III) end of 24 hours of gas delivery and (IV) 24 hours from the gas suspension.
21339|NCT04022161|Drug|Nitric Oxide|See arm description
21340|NCT04022148|Biological|Gardasil|Experimental arm: Vaccine group VS Control arm: Non-Vaccine group
21341|NCT04022135|Dietary Supplement|Folic acid|Participants will supplement with 0.6mg/day for 16 weeks.
21342|NCT04022135|Dietary Supplement|(6S)-5-methyltetrahydrofolic acid|Participants will supplement with 0.625mg/day for 16 weeks.
21343|NCT04022122|Procedure|Usual Care follow-up in a heart failure program.|Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
21344|NCT04022109|Device|Breath sampling for VOC detection|Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy
21345|NCT04022109|Procedure|Surgery material collection for VOC headspace analysis|Only for gastric cancer patients undergoing surgery (Group 1)
21346|NCT04022109|Diagnostic Test|Upper endoscopy|Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)
21347|NCT04022109|Diagnostic Test|Microbiota testing|Faecal and gastric contents and biopsy samples for microbiota testing
21348|NCT04022096|Drug|Tegoprazan 25mg QD|Tegoprazan 25mg tablets will be orally administered, once daily, for up to 6 months.
21349|NCT04022096|Drug|Lansoprazole 15mg QD|Lansoprazole 15mg capsules will be orally administered, once daily, for up to 6 months.
21350|NCT04022070|Other|Dynamic Tape® (Tape)|To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
21351|NCT04022057|Drug|Ropivacaine injection|Local anesthetic injection
21352|NCT04022057|Drug|Dextrose 5|Sham Injection
21353|NCT04022044|Behavioral|Observational group|
21354|NCT04022031|Drug|Chinese patent medicine|Shexiang Baoxin Pill, Tongxinluo Capsule, Tongmai Yangxin Pill, Xuefu Zhuyu Capsule, Qishen Yiqi Dropping Pill.
21355|NCT04022018|Radiation|Adaptive radiotherapy|CT repositioning will be performed after 15fractions of external radiotherapy, then new target volume will be contoured and new radiotherapy plan will be formulated with the assistance of artificial intelligence program. New radiotherapy plan will be performed from the 17th fraction external radiotherapy.
21356|NCT04022018|Radiation|no adaptive radiotherapy|Concurrent external volumetric rotational intensity modulated radiotherapy and chemotherapy followed by image-guided adaptive brachytherapy is the treatment strategies of control group patients
21357|NCT04022005|Drug|Chidamide, Rituximab, Gemcitabine,Oxaliplatin|"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."
21358|NCT04021992|Drug|gemcitabine, vinorelbine and doxorubicin liposome, with or without rituximab|All patients enrolled in the study will accept gemcitabine, oral vinorelbine and doxorubicin liposome, with or without rituximab as their salvage chemotherapy.
21359|NCT04021979|Dietary Supplement|Enteral Nutrition Powder Ensure|Enteral Nutrition Powder Ensure for each meal.The duration of study is one day before colonoscopy.
21360|NCT04021979|Drug|1.5L PEG|Low volume PEG
21361|NCT04021979|Other|Self-controlled diet|Self-controlled low residue diet.
21362|NCT04021979|Drug|2L PEG|Normal volume of PEG
21363|NCT04021966|Procedure|Vaginal laser application|"One laser treatment cycle consists of 3 vaginal laser applications with a 4-weeks interval. Each application lasts around 5 minutes.~The vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators.~A vaginal probe will be gently inserted and manually rotated to provide a 360° treatment of the vaginal mucosa."
21364|NCT04021953|Behavioral|People Like Us Online Video Series Intervention|"People Like Us miniseries incorporates key sexual health messages to:~Increase viewers' knowledge and perceptions of HIV and other STI risk;~Address homophobia and sexual orientation disclosure;~Increase safer-sex negotiation self-efficacy;~Promote positive attitudes towards condom use and other safe sex behaviors;~Build skills and self-efficacy for practicing safer sex;~Provide information on HIV and other STI testing and its benefits;~Provide information on resources for HIV/STI testing and other mental health services;~Model appropriate behaviors around practicing safer sex.~Each video in the six-part series ends with an educational video segment featuring the managers of Action for AIDS and Gayhealth.sg, who provide a brief synopsis of the episode and cover key points relevant to mental and sexual health for GBQ men."
21365|NCT04021953|Behavioral|Sexual Health Pamphlet (Standard of Care)|The control group will be provided with an e-pamphlet on sexual wellness catered to GBMSM. This e-pamphlet has been developed by the National Skin Centre and Department of Sexually Transmitted Infections Clinic specifically for information on sexual wellness among GBMSM. It comprises segments on HIV/STI symptoms, etiology, information on how to seek help for HIV/STI, behavioral and biomedical methods of HIV prevention.
21366|NCT04021940|Procedure|ULOD|ULOD
21367|NCT04021927|Device|Ring Phototherapy|The product will be an open-faced ring device with an angular reflective surface that redirects unused light sideways onto the neonate's body illuminating previously unexposed regions where treatable bilirubin exists while protecting the baby from head roll with an inner transparent corral. This device is superior to current PT devices because it converts existing waste light into treatment efficacy while integrating into existing single overhead lamp systems avoiding the purchase of secondary devices that are expensive and create hospital system complexity and inefficiency issues.
21448|NCT04021225|Device|Tears Again® eye spray|A one-time application of 1-2 drops in the more affected eye will be investigated.
21449|NCT04021199|Genetic|Mody test|"Subjects will be screened using a MODY gene-sequencing test, which includes GCK, HNF1A, HNF4A, HNF1B, KCNJ11, ABCC8, and INS gene sequencing.~More comprehensive genetic tests will be conducted in patients without anomalies found after the MODY gene-sequencing test."
41548|NCT03858972|Drug|Capecitabine|Reduced dose of capecitabine
21368|NCT04021914|Device|EnChroma glasses|Each participant will be provided EnChroma products to use indoors over the course of two weeks in the emergency department, educational settings, and in their personal life. They will be encouraged to wear the glasses for at least 10 hours over 1-2 weeks prior to wearing them in a clinical setting to adjust to their use, and for 10 minutes before beginning patient care as per manufacturer instructions. They will be encouraged to take specific note of clinical scenarios that require the use of color vision (e.g., - rashes, tympanic membrane erythema, stool guaiac testing, etc.).
21369|NCT04021901|Device|balloon dilatation|"The balloon catheter (BD U30) was placed through narrow ureter along the guide wire, and the balloon was pressurized to 25 atm until the bee waist sign disappeared on the balloon or the narrow section was seen under the endoscope. Dilation, expansion for 10 min, and then through the endoscope to observe the stenosis of the stenosis (stenosis of the stenosis of the visible adipose tissue)"
21370|NCT04021888|Other|Exercise|Education of patients and their caregivers, deep breathing exercise, aerobic exercise and resistance training with elastic bands
21371|NCT04021862|Drug|Bermekimab Monoclonal Antibody|Bermekimab 2 mL (200 mg/mL) pre-filled syringe
21372|NCT04021862|Drug|Placebo|Placebo 2 mL pre-filled syringe
21373|NCT04021849|Other|Face-to-face Class|The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation
21374|NCT04021849|Other|Asynchronous Virtual Class|Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
21375|NCT04021836|Other|3d evaluation of nasolabial change|Evaluation of With vs without ala cinch suture after lefort 1 osteotomy
21376|NCT04021810|Device|Continuous Positive Airway Pressure (CPAP) and patient education|Mask connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airways. Plus patient education.
21377|NCT04021810|Device|Mandibular Advancement Device|Adjustable oral prosthesis which retains the lower mandible in an anterior position, thus limiting sleep apneas
21378|NCT04021797|Device|transcutaneous vagal nerve stimulation|The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.
21379|NCT04021784|Device|SDS|The patient gets a SDS implanted.
21380|NCT04021784|Device|NEMOST|The patient gets a NEMOST implanted.
21381|NCT04021771|Other|Educational Curriculum Intervention|The intervention includes: 1) Online web-based education module created with the Rise 360 platform that has ten lessons, providing the learner with an introduction, background, and a map of how to navigate a discharge conversation for patients with diagnostic uncertainty. Core content are presented with multiple interactive components such as flip-cards, multiple-choice, drag-and-drop, sketch videos, and narrated clips. 2) Mobile application game designed to facilitate practice of the content learned in the online curriculum 3) Deliberate practice sessions allow trainees to practice communication techniques presented within the online module and to receive feedback on their performance. These sessions will be conducted with standardized patients via a video platform, during a scheduled appointment.
21382|NCT04021758|Behavioral|Peer to peer program intervention|Peer to peer suicide prevention program aimed at reducing suicide in a military population.
21383|NCT04021745|Behavioral|App-based mindful eating|This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
21384|NCT04021719|Other|Stakeholder feedback|Stakeholders, including OnTrackNY participants, past participants, family members, clinicians, administrators, payors and state leadership, will participate in a variety of activities to provide continuous quality improvement to the OnTrackNY program, including a Stakeholder Workgroup, interviews and focus groups
21385|NCT04021719|Other|Data infrastructure|Data will be systematically collected as part of CQI activities, within a state-of-the-art data infrastructure that allows for client-level feedback to clients, providers and sites to improve quality of care.
21386|NCT04021706|Drug|Anamorelin Hydrochloride|Ghrelin receptor agonist
21387|NCT04021706|Drug|Placebo|placebo is a inert substance
21388|NCT04021693|Other|Handheld Ultrasound Devices|Interns in the handheld ultrasound device arm shall carry a personal handheld ultrasound device to be used for self-directed learning
21389|NCT04021680|Other|pre-eclampsia screening program|This screening program included the use of ultrasound, biomarkers and maternal factors in calculating the risk of developing preeclampsia.
21390|NCT04021667|Other|educational intervention|İndividual and Group Breastfeeding Education:It was taken into consideration that mothers and fathers who do not have breastfeeding experience in the antenatal period feel better in terms of their perception of the education given, and education is provided with adult education principles.Breastfeeding training slides, cloth nipple model, dummy dolls were used during the training and lecture, demonstration and application and breastfeeding training were provided.At the end of the training, they were given time to ask questions and their feedback was received.Control Group:Routine procedures in the clinic were performed for the mother and father candidates.The data of the mother and father who came to the hospital for antenatal follow-up and control were collected in four stages.
21391|NCT04021654|Procedure|Data collection|Data collection of growth, neuromotor, sensorial, behavioral, and cognitive development.
21392|NCT04021641|Diagnostic Test|Speech recognition in noise|Measurement of speech recognition performance in noise
21393|NCT04021628|Other|No intervention- not applicable|No intervention - not applicable
21450|NCT04021186|Other|Prevention of hyperglycemia|Bigger focus on postoperative blood-glucose levels in order to reduce incidents of hyperglycemia and other surgical complications.
21451|NCT04021173|Drug|Anfibatide|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
21452|NCT04021173|Drug|Placebos|5 IU/60kg intravenous infusion follow by 0.002 IU/kg/h continuous intravenous infusion
21453|NCT04021160|Device|High frequency repetitive transcranial magnetic stimulation (rTMS)|10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
21394|NCT04021615|Other|Comprehensive physical therapy rehabilitation program combined with inspiratory muscle training|A threshold inspiratory muscle trainer will be connected to the artificial airway with 15 mm and 22 mm adaptors. Training bouts consist of three to five sets of six repetitions breathing through the trainer. Training will be conducted with the patient in bed with an approximately 30° head-up tilt and with intensity about 40 %- 50 % of maximal inspiratory pressure. Patients will be returned to mechanical ventilation for rest between training sets as needed. Three to five sets of six training breaths will be completed for a total of 18 to 30 training breaths per session. Following each training set, the patient indicated a rating of perceived inspiratory exertion on modified Borg scale . The study group will also receive comprehensive rehabilitation program consist of upper-extremity exercises, lower extremity exercises, pedaling exercises, trunk control exercises and bedside functional training
21395|NCT04021615|Other|Traditional chest physical therapy rehabilitation program combined with inspiratory muscle training|The same inspiratory muscle training for the study group combined with the traditional physical therapy program consist of positioning , modified postural drainage , percussion , vibration.
21396|NCT04021602|Behavioral|Diabetes Prevention Program|Phase 1 (core curriculum) of the Diabetes Prevention Program consists of 16 sessions and will take place during Week 18 of pregnancy through Week 33. Participants will receive the DPP curriculum via virtual pre-recorded sessions to which participants will have access. A research coordinator will follow up with each study participant by phone once weekly. If participants do not make adequate progress, the coordinator will assess how much extra time the participant will need to complete each session and will work with the participant if needed. Phase 2 (post-core curriculum) consists of 15 sessions and will be completed after delivery, between Week 6 and Week 20 postpartum. Participants will re-engage into the DPP with an orientation session at Week 6 postpartum. The same session completion format and procedure for inadequate progress will be followed as during pregnancy.
21397|NCT04021602|Behavioral|Breastfeeding Education|Participants will receive a 2-hour session on breastfeeding and participate in a professional peer support group. The breastfeeding session is between Week 20 and Week 36 of pregnancy and will be taught by an International Board Certified Lactation Consultant (IBCLC). Participants will be provided with a breastfeeding assessment at Days 3 and 10; Week 3 and 6; and Months 2, 3, and 6 postpartum.
21398|NCT04021602|Behavioral|Usual Care|Participants will receive regular prenatal care provided by their physician. At delivery, all participants will receive some type of lactation support in the hospital.
21399|NCT04021589|Drug|Weileshu|a probiotics products which help to rebuild homeostasis of gut microbiome
21400|NCT04021589|Drug|Chemotherapy|chemotherapy
21401|NCT04021576|Other|preventative training program|complementary training of leg-, hip- and core-strength/stability
21402|NCT04021563|Drug|SR419|Ascending single and multiple doses of SR419 orally
21403|NCT04021563|Drug|Placebo|Ascending single and multiple doses of placebo orally
21404|NCT04021550|Device|Continuous Positive Airway Pressure CPAP|All subjects will be advised to use their continuous positive airway pressure (CPAP) in accordance to their physician's guidelines.
21405|NCT04021550|Drug|Telmisartan 80mg|Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
21406|NCT04021550|Dietary Supplement|Alpha-Lipoic Acid 600mg|Subjects in this group will receive 600mg/day of Alpha-Lipoic Acid (an antioxidant). Treatments will be administered in pre-packaged blister packages. Subjects will take Alpha-Lipoic Acid once per day for 6 weeks.
21407|NCT04021550|Other|Microcrystalline Cellulose|Subjects in this group will receive two capsules of Microcrystalline Cellulose (placebo). Treatments will be administered in pre-packaged blister packages. Subjects will take placebo pills once per day for 6 weeks.
21408|NCT04021537|Device|non-invasive nerve stimulation|Electrical stimulation will be provided via a TENS unit.
21409|NCT04021524|Drug|Benzoyl Peroxide 10% Bar|Patients will wash with Benzoyl Peroxide 10% Bar
21410|NCT04021524|Drug|Chlorhexidine Gluconate|Patients will wash with Chlorhexidine Gluconate
21411|NCT04021511|Other|OAR application by a nurse|As per protocol, in the Phase B, nurses will be allowed to apply OAR which can lead to an early radiography prescription.
21412|NCT04021498|Drug|Simvastatin 40mg|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
21413|NCT04021498|Other|Placebo|phase III, triple-blind randomised placebo-controlled trial comparing simvastatin 40 mg/day versus placebo (lactose). One hundred and fifty eight patients with recurrent AP (at least 2 episodes) will be included (79 per arm of treatment). Treatment and follow-up will last for 12 months.
21414|NCT04021485|Other|neurodevelopmental assessment|"As part of the usual follow-up of premature children, a follow-up consultation is planned around the age of 3 years. During this visit, a neurodevelopmental assessment will be carried out for the Betanino study. The duration of this evaluation is evaluated around 3h in total.~Interventions will include:~Standardized neurological exam~Morphometric measurements including height, weight, head circumference~Blood pressure measurement~Multiple aspects of cognition using ancillary indexes of WPPSI-IV subtests, NEPSY subtests and KABC-II (Kaufman Assessment Battery for Children II) subtests,~Autism spectrum disorders assessed using M-CHAT (Modified Checklist for Autism in Toddlers) questionnaire,~Social Relativeness, using Social Relativeness Scale parental questionnaire,~Parental stress using PSI questionnaire"
21415|NCT04021472|Behavioral|Text message|Two months of daily text messages to support meeting a health goal
21416|NCT04021472|Behavioral|Veteran peer health coaching|Two telephone calls from a Veteran peer health coach to support meeting a health goal
21417|NCT04021459|Procedure|blood samples|"3 samples: One before surgery on the arm vein (peripheral)~Two during the surgery, on two different venipuncture site :~One on the arm vein (peripheral)~One on ovarian vein (close to the tumor) All samples will be tested by the CellSearch method."
21418|NCT04021446|Other|Exercise|personalized exercise prescription
21419|NCT04021433|Drug|Ketamine|Repeated doses of IM/SC ketamine up to 3 times a week
21533|NCT04020549|Behavioral|Study Skills Control|Reading and writing activities designed to teach evidence-based study strategies.
42616|NCT03850509|Drug|OPS-2071 150 mg|150 mg BID Oral for 12 weeks,
21420|NCT04021420|Device|SONOCLOUD|"The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.~The SonoCloud System consists of :~an implantable ultrasound transducer,~a needle connection device,~an external radiofrequency generator, and~an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa)."
21421|NCT04021420|Drug|Nivolumab Injection|Nivolumab (flat dose: 240mg, 30 minutes infusion)
21422|NCT04021407|Device|LMA group|patients were ventilated with LMA
21423|NCT04021407|Device|AirQ group|patients were ventilated with AirQ airway
21424|NCT04021394|Diagnostic Test|CellSearch CTC platform|epithelial-based marker approach for immunomagnetic enrichment, isolation, and quantitative immunofluorescence of CTCs
21425|NCT04021394|Diagnostic Test|Parsortix CTC platform|EMT-independent platform
21426|NCT04021381|Dietary Supplement|Potassium and magnesium citrate|Patients are treated with potassium and magnesium citrate 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
21427|NCT04021381|Dietary Supplement|Placebo|Patient are treated with placebo 5.2 grams daily during 3 months, following flexible ureterorenoscopy for inferior calyx urolithiasis.
21428|NCT04021368|Drug|SEL120|SEL120 will be administered as a single oral dose every other day (q.a.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
21429|NCT04021355|Other|Oral sodium supplementation|Participants will receive dietary sodium supplementation in the form of tablets to be taken either with breakfast or dinner.
21430|NCT04021342|Dietary Supplement|Montmorency tart cherry concentrate|Based on previous analysis done by our laboratory each 60 ml of Montmorency tart cherry concentrate contains approximately 73.5 mg of anthocyanins (cyanidin-3-glucoside equivalents) and 178.8 mg of total phenolics (mean gallic acid equivalents)
21431|NCT04021342|Dietary Supplement|Placebo|Placebo beverage matched for calorie content and visual properties of the cherry concentrate
21432|NCT04021329|Behavioral|CBT Therapy|information added previously
21433|NCT04021316|Other|dCELL® Human Dermis (decellularised dermal skin allograft - DCD)|DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
21434|NCT04021316|Other|Compression bandaging therapy|Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.
21435|NCT04021303|Dietary Supplement|Experimental cereal|Cereal containing probiotics, prebiotic fiber and low carbohydrates
21436|NCT04021303|Dietary Supplement|Conventional cereal|Gluten free conventional cereal (from 4 to 6 months old) and conventional cereal with gluten (from 7 to 12 months old)
21437|NCT04021290|Drug|DTG/3TC FDC|DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Subjects will take DTG/3TC once daily via oral route.
21438|NCT04021290|Drug|CAR|Subjects who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
21439|NCT04021277|Combination Product|PS101 and Ultra Sound for escalation|Part 1 - dose escalation: PS101 given 3 times in a day + 1 US insonation for PK assessment and then PS101 +US insonation given 3 times on each chemotherapy administration day over a period of 8 weeks
21440|NCT04021277|Combination Product|PS101 and Ultra Sound for expansion|Part 2: PS101 and US insonation given 3 times on each chemotherapy administration day over a period of 8 weeks
21441|NCT04021264|Drug|Ropivacaine-Sufentanil|Local anesthetic injection
21442|NCT04021264|Drug|Dextrose 5|Sham injection
21443|NCT04021251|Device|P0.2|Investigational Medical Device collecting spectral raman data from tissue.
21444|NCT04021238|Drug|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
21445|NCT04021238|Drug|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
21446|NCT04021225|Device|Ectoin® Allergy Eye Drops 2%|A one-time application of 1-2 drops in the more affected eye will be investigated.
21447|NCT04021225|Device|Ectoin® Eye Spray Colloidal|A one-time application of 1-2 drops in the more affected eye will be investigated.
42617|NCT03850509|Drug|OPS-2071 300 mg|300 mg BID Oral for 12 weeks
21454|NCT04021160|Device|Sham stimulation|A sham coil will be used that is shielded so that it produces sounds and sensations similar to the active coil but does not produce therapeutic effects. 10hz, 20 seconds intertrain interval, 40 pulses per train with a total of 1000 pulse per session given at 100% of motor threshold. A total of 16 sessions will be given to each patient.
21455|NCT04021147|Behavioral|Exercise plus action observation|Orofacial exercise plus action observation (video) of the same exercise
21456|NCT04021147|Behavioral|Exercise plus motor imagery|Orofacial exercise plus motor imagery of the same exercise
21457|NCT04021147|Behavioral|Exercise plus visual mirror feedback|Exercise plus visual mirror feedback
21458|NCT04021147|Behavioral|Exercise|Orofacial exercises
21459|NCT04021121|Drug|LZD|LZD 1200 mg daily
21460|NCT04021121|Drug|High dose RIF|RIF 35 mg/kg/day
21461|NCT04021121|Drug|Standard dose RIF|RIF 10 mg/kg/day
21462|NCT04021108|Drug|Nivolumab 240 MG|Nivolumab (OpdivoTM) is a potent and highly selective humanized monoclonal antibody (mAB) designed to block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. Cancer cells are able to send a signal to the PD-1 via the PD-L1 molecule, tricking the T-cell into recognizing the cancer cell as normal. Nivolumab is designed to disrupt that signal and expose the cancer cell to the immune system. Nivolumab is given intravenously over a 60-minute period, usually every two weeks.
21463|NCT04021095|Device|Head protection prototype device|The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
21464|NCT04021082|Drug|Cerdulatinib|Small molecule SYK/JAK kinase inhibitor in development for treatment of hematological malignancies
21465|NCT04021069|Diagnostic Test|Radiomic, pathomic, and clinical markers|This is a non-interventional study.
21466|NCT04021056|Other|No intervention|
21467|NCT04021043|Drug|Anti-GITR Agonistic Monoclonal Antibody BMS-986156|Given IV
21468|NCT04021043|Biological|Ipilimumab|Given IV
21469|NCT04021043|Biological|Nivolumab|Given IV
21470|NCT04021043|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
21471|NCT04021030|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both chronic pain and substance use.
21472|NCT04021017|Drug|Estradiol Hemihydrate Transdermal System|Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 0.025 mg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
21473|NCT04021004|Other|Survey Questionnaire|Survey Questionnaire
21474|NCT04020991|Diagnostic Test|Sleep Study|Participants who noted to have Oxygen Desaturation Index more than 10 (moderate to severe OSA) will be referred to do formal sleep study and referral to Sleep Medicine Clinic
21475|NCT04020978|Diagnostic Test|Parametric PET/CT|Each patient will undergo a dynamic F18-FDG PET/CT scan at baseline and 2-week post therapy.
21476|NCT04020965|Behavioral|Water Treatment|"Hardware: Chlorine dispensers provided for free at communal water sources, available to households in intervention arm who were and who were not enrolled in the WASH Benefits Kenya study.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the treatment of drinking water for all children living in the household. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits. After the completion of the WASH Benefits Kenya study, the NGO Evidence Action conducted educational campaigns to promote the use of dispensers."
21477|NCT04020965|Behavioral|Sanitation|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each household enrolled in the WASH Benefits Kenya study. Upgrades included structural improvements, plastic slabs, and superstructure improvements. Households in intervention villages not enrolled in the original trial did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on handwashing with soap at critical times around food preparation, defecation, and contact with feces. Compounds in intervention villages that were not enrolled in the original trial did not receive such visits."
21478|NCT04020965|Behavioral|Handwashing|"Only households enrolled in the original WASH Benefits study and assigned to the combined WASH and combined WASH + nutrition arms received this intervention.~Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water, for each compound. Handwashing stations were stocked with soap for the duration of the WASH Benefits Kenya study. Compounds in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any hardware.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver behavior change messages that focused on the use of latrines for defecation and the removal of human and animal feces from the compound. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
21503|NCT04020744|Other|real-time fMRI based neurofeedback from another brain area|In rt-fMRI based neurofeedback, participants are trained to voluntarily 'control' brain activity from another brain area. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
21504|NCT04020731|Behavioral|Hypnosis|several blocks of hypnosis including entry into a hypnotic state (= induction), the hypnotic trance and the exit from hypnosis (= reassociation).
21716|NCT04019041|Drug|bermekimab|bermekimab 2 mL (200 mg/mL) pre-filled syringe
21479|NCT04020965|Dietary Supplement|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months, among children enrolled in the WASH Benefits Kenya study and for the duration of that study. Children in intervention villages who were not enrolled in the WASH Benefits Kenya study did not receive any supplements.~Promotion: Local promoters visited compounds enrolled in the WASH Benefits Kenya study at least monthly during the first year and bi-monthly during the second (and last) year to deliver the following behavior change messages: (1) practice exclusive breastfeeding from birth to 6 months of age; (2) continue breast feeding with the introduction of LNS; (3) provide your child micronutrient-rich foods and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old. Compounds in intervention villages that were not enrolled in the WASH Benefits Kenya study did not receive such visits."
21480|NCT04020952|Other|"st.st 0.019×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
21481|NCT04020952|Other|"st.st 0.016×0.022 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
21482|NCT04020952|Other|"st.st 0.017×0.025 wire"|rectangular stainless steel wire that will be used during canine retraction after first premolars extraction
21483|NCT04020939|Device|SPY imaging|Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
21484|NCT04020939|Drug|Indocyanine Green|Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
21485|NCT04020913|Drug|Somatropin injection|"Boys with short stature will be studied for measures of:~skeletal muscle strength, power, and endurance~muscle agility~lean body mass accrual~bone mineral density and resting energy expenditure before and after 6 months and 12 months of GH administration"
21486|NCT04020900|Other|Respiratory management|Data on respiratory management were collected at different time: data regarding the induction period, ventilatory parameters set and measured during a stable period, ventilatory change made during anaesthesia, use of recruitment manoeuvres, data regarding weaning and extubation
21487|NCT04020887|Device|Alertwatch - Interaction|Decision-support software, customized for the PACU environment, Interaction between the telemedicine center and the PACU
21488|NCT04020874|Behavioral|HuTT-2x|tackling and blocking training twice/week
21489|NCT04020874|Behavioral|HuTT-4x|tackling and blocking training four times/week
21490|NCT04020861|Device|Active PBM|To active photobiomodulation therapy (PBMT) the patient will be oriented to lie preferably in prone. The treatment area will be defined according to painful area. In the active group will be used the followings parameters: low-level laser therapy, 808 nm, 4 infrared diodes, 180 mW, 9 J. In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
21491|NCT04020861|Device|Active TENS|To active transcutaneous electrical nerve stimulation (TENS) the patient will be oriented to lie preferably in prone. Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. It will be used the following parameters: frequency of 100 Hz, pulse duration of 125 µs (positive phase), 30 minutes of current stimulation and the pulse amplitude will be increased until the patient reports a strong but comfortable paresthesia (including motor level stimulation but no painful TENS). The amplitude will be adjusted (if necessary) each 5 minutes to keep a strong but comfortable paresthesia.
21492|NCT04020861|Device|Placebo PBM|In the placebo PBMT will be performed a simulation of laser application. The cluster probe will be positioned on painful area during the same time of active PBMT, the equipment will be turned on and set, however the trigger will be not actived and no beam will be applied.
21493|NCT04020861|Device|Placebo TENS|To placebo transcutaneous electrical nerve stimulation (TENS) Two or four electrodes standard square self-adhesive electrodes (5 × 5 cm2) will be positioned according to the painful area related by patient. This device was customized to deliver a current for 30 seconds (both channels) and then ramp off over the next 15 seconds so that it will be active for a total of 45 seconds. This will permit the patient to fell the TENS sensation while applying the settings.
21494|NCT04020848|Other|Review of past medical history, clinical exam, and VINELAND II adaptive behavior scales scoring|Review of past medical history; review of paroxysmal events; identification of the presence of seizures and epilepsy and epilepsy classification; characterization of the non-paroxysmal features; degree of paroxysmal and non-paroxysmal disability indices; Vineland II adaptive behavior scales scoring; behavioral evaluation; presence of a genetic mutation; pharmacological treatments already used; AHC paroxysmal events assessement during the time of the study; patient calendar for the follow up of AHC paroxysmal events; patient calendar for the follow up of epileptic seizures; whether, or not, there was occurrence of a serious or potentially life-threatening event (status epilepticus, apnea requiring intervention, or death) during the time of the study; growth and somatic complaints; further information concerning family history and comorbidities; past instrumental and biochemical investigations (ECG, cardiac ultrasound results if done in the past as part of patient's follow-up)
21495|NCT04020822|Device|Guardian Sensor (3)|Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
21496|NCT04020809|Drug|Atezolizumab|Anti-PD-L1 monoclonal antibody
21497|NCT04020796|Dietary Supplement|Beetroot juice|Thirty-seven hypertension, with age 40-70 years were randomized to receive a 500ml volume of beetroot juice contains 11.5 mmol of inorganic nitrate or mineral water in a single moment.
21498|NCT04020783|Other|NO Intervention|NO Intervention
21499|NCT04020770|Other|Vibrating ball|Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
21500|NCT04020757|Device|variation in dialysis bicarbonate|35 mEq/L dialysate bicarbonate for one week, followed by 30 mEq/L for one week, followed by 35mEq/L for one week with nutritional supplement during dialysis
21501|NCT04020757|Dietary Supplement|Zone Perfect bar|16g protein supplement given during first 30 mins of dialysis on last testing day
21502|NCT04020744|Other|real-time fMRI based neurofeedback from the hippocampus|In rt-fMRI based neurofeedback, participants are trained to voluntarily 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
21717|NCT04019041|Drug|placebo|placebo 2 mL pre-filled syringe
21505|NCT04020718|Behavioral|Brief telephone advice plus tailored text messages|All patients are offered brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training and a text message program tailored to readiness to quit and quit date. Content is personalized with user's name and Massachusetts General Hospital resources.
21506|NCT04020718|Drug|Mailed nicotine replacement therapy|Patients who report continued smoking at Early or Late assessment (depending on random assignment) will be offered a 4 week supply of patches and/or lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette).
21507|NCT04020718|Behavioral|Proactive telephone coaching|Patients who report continued smoking at Early (4-week) or Late (8-week) assessment of response will be randomized to receive proactive telephone coaching or not. Proactive coaching will consist of an attempt to reach the patient by telephone in order to review quit activities, provide information about locally available pharmacologic and behavioral treatment options and information sharing with patient's primary care provider. The coach is trained in core Tobacco Treatment Specialist activities.
21508|NCT04020705|Device|Citicoline eye drops (OMK1)|(OMK1) will be prescribed in the dosage of 1 drop 3 times a day
21509|NCT04020705|Other|Placebo Comparator: hypromellose based ocular lubricant|will be prescribed in the dosage of 1 drop 3 times a day
21510|NCT04020692|Behavioral|EOPC Intervention|"The issue of drug continuity after hospital discharge has become a major issue in recent years. When patients return home, the drugs taken do not correspond to the treatments prescribed at the end of the hospitalization. This is due to appropriate or inappropriate initiatives of the patients (or their relatives) and/or the physicians accompanying them. Prescribed medications, on the other hand, are almost always dispensed by community pharmacists.~The scope chosen in this project is that the intervention of an operational clinical pharmacy team (EOPC), targeting both patient and health care professionals (inpatient and outpatient), will maintain, in outpatient care, the drugs treatments that have been optimized during hospitalization."
21511|NCT04020679|Behavioral|Goals of Care Initiative|Can-GUIDE will provide videos on a number of SDM topics including interviews with patients and clinicians discussing patient involvement in SDM and how goal conversations can inform the decision making process. Furthermore, there will be instructional videos on how to complete the Goal conversations sheet. Accompanying the videos will be interactive elements which will help users consider the types of questions that they wish to ask their clinical teams. The goal conversation sheet allows patients to list their goals and priorities that they wish to bring up in the consultation with their clinical teams. The Goals of Care (GOC) tool is a communication aid for clinicians to summarise goals of care discussions such as those facilitated by the goals conversation sheet. The completed tool will then be logged onto the Electronic Patient Record (EPR) and is then disseminated to other HCPs involved in the patients care.
21512|NCT04020666|Drug|Urinary Kallidinogenase|
21513|NCT04020653|Drug|5-aminolevulinic acid hydrochloride (5-ALA HCl) 600 mg QD|5-ALA HCl 150 mg capsules will be given to the patients as 600 mg QD
21514|NCT04020653|Drug|Sodium ferrous citrate (SFC) 472 mg QD|SFC 118 mg capsules will be given to the patients as 472 mg QD
21515|NCT04020653|Drug|Artemisinin-based combination (ACT)|Tablets of ACT will be administered following Dosage and Administration in the package insert of ACT. ACT will be supplied as a combination tablet.
21516|NCT04020653|Drug|Placebo|Matching placebo capsules to 5-ALA HCl and SFC will be administered to the patients
21517|NCT04020653|Drug|5-aminolevulinic acid hydrochloride (5-ALA HCl) 300 mg BID|5-ALA HCl 150 mg capsules will be given to the patients as 300 mg BID
21518|NCT04020653|Drug|Sodium ferrous citrate (SFC) 236 mg BID|SFC 118 mg capsules will be given to the patients as 236 mg BID
21519|NCT04020640|Other|no intervention|Measure human intake using stable isotope technique
21520|NCT04020627|Other|BiPAP Group|"BIPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device"
21521|NCT04020627|Other|CPAP Group|"CPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device"
21522|NCT04020614|Other|Survey|A survey with 13 questions will be applied to the patients
21523|NCT04020601|Drug|Ropivacaine|Local anesthetic injection
21524|NCT04020601|Drug|Dextrose|Sham injection
21525|NCT04020588|Drug|Celecoxib 200mg|Will be administered for 6 weeks
21526|NCT04020588|Drug|Placebo oral capsule|Will be administered for 6 weeks
21527|NCT04020588|Drug|Minocycline 100mg|Will be administered for 6 weeks
21528|NCT04020575|Biological|huMNC2-CAR44 CAR T cells|huMNC2-CAR44 T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head).
21529|NCT04020575|Biological|huMNC2-CAR44 CAR T cells @ RP2D|huMNC2-CAR44 T cells are an autologous T cell product transduced with a proprietary lentiviral vector backbone coding for humanized MNC2-scFv (the targeting head) @ RP2D
21530|NCT04020562|Other|Mild Resistive Expiratory Technique|"Mild Resistive Expiratory Technique (EMST150- five-week training protocol):~The EMST requires the participant to forcibly blow into the device for 5 seconds with sufficient pressure to open the one-way valve. Each blow is one repetition. The device will be set at a resistance of 30 cmH2O. Participants will be instructed to complete five sets of five repetitions (total of 25 times and approximately 20 minutes per day), any five days per week, for five weeks. Whole exercise will be done in sitting position. Rest between repetitions will be given according to comfort level of patient."
21531|NCT04020562|Other|Conventional Training|"Breathing exercise: Deep breathing 10-15 repetitions twice a day. Assistive Coughing: 5-6 repetitions twice a day. ROM Exercises: Both active and passive limb ROM exercises 10-15 repetitions twice a day.~Sustained stretching: Both upper and lower limbs, 10 repetitions, held for 5 seconds, twice a day.~Splinting: According to patient's injury level Bracing: According to patient's injury level Functional Mobility: Mobilizing patient according to injury level Tilt table standing: 10-15 minutes once a day"
21532|NCT04020549|Behavioral|Growth, Gratitude, & Positive Activities|Reading and writing activities based on growth (designed to instill the belief that people can change), gratitude (noticing and appreciating good things in life), and behavioral activation (identifying and scheduling positive activities).
21534|NCT04020536|Drug|Antibiotics|Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
21535|NCT04020523|Other|MRI sequence|The MR sequences added to the protocol are dedicated sequences for perfusion and diffusion imaging of breast lesion.
21536|NCT04020510|Drug|onaBoNT-A|Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
21537|NCT04020497|Behavioral|Ensemble programme|Ensemble is a individualized programme to address informal caregiver's specific unmet needs, emotions and social resources, in order to offer a targeted support in five sessions.
21538|NCT04020497|Other|SAU|"Informal caregivers have often to manage the situation in usual different ways. Support as usual (SAU) alone consists of an informal support by patient's clinical team. Specific psychoeducational programs depending on patient's illnes (like Profamille for schizophrenia) or peer-support depending to the voluntary work of families' associations. Some general professional services focused on informal caregivers or relatives in order to inform and orient them if they are avaible in the study area. No attempts have been made to standardize this treatement as SAU depend to informal caregiver's need and knowledge of the health system, also her/his capacity or possibility to be in contact with patient's clinical team."
21539|NCT04020484|Behavioral|Making Mindfulness Matter (M3)|Making Mindfulness Matter (M3) is a community-based, concurrent parent and child program that incorporates mindful awareness, social-emotional learning skills, neuroscience, and positive psychology. This program was modelled after the school-based MindUP™ program for use in the community and augmented to integrate a parent component. M3 is a facilitator-led program that integrates attitudes, skills, and behaviours related to mindfulness and social-emotional learning (SEL). During the 8-week concurrent parent and child manualized program, parents learn the same core principles as children: how our brains work, stress and the brain, mindful breathing, mindful sensing, mindful movement, perspective taking, optimism, and gratitude/acts of kindness.
21540|NCT04020458|Procedure|dental intervention|"Dental intervention plan for Group 1 and 3 subjects with periodontitis only, i) Full mouth intraoral X-rays (FMX)~ii. Full periodontal exam, diagnosis, Oral hygiene instructions (OHI)~iii. RX: 7 days of p.o. metronidazole (250mg)/amoxicillin (500mg) T.I.D., combined with local chlorhexidine rinses (not for subjects with Kidney transplant).~iv. Single visit intensive scaling and root planning (SRP) (full mouth)~v. Re-evaluation after 4-6 weeks (referral for definitive treatment)~vi. Extraction of teeth deemed hopeless based on periodontal, endodontic or restorative considerations~vii. Caries control, sedative dressing (palliative), referral to endodontic dentist for root canal treatment (RCT)"
21541|NCT04020445|Other|de-escalation of complex insulin regimens|complex insulin regimens are switched to fix ratio combinations consisting of of a basal insulin and a GLP-1 (glucagon-like peptide-1) receptor agonist
21542|NCT04020432|Behavioral|questionary|"A quantitative questionnaire has been created under primary and secondary assumptions. Questionnaires are going to be distributed to women who are agree to participate to this study. The questionnaires are going to be delivered by the investigators.~Women can answer the questionnaire in the waiting room of consultation's services. The questionnaire will be anonymous and the return of questionnaires will be made personally."
21543|NCT04020419|Drug|PediaBerry|PediaBerry or placebo will be mixed with a cream vehicle for topical administration or with water for oral administration
21544|NCT04020406|Biological|Antibacterial Activity|Antibacterial Activity of Urea Solution against Ocular Bacterial Isolates
21545|NCT04020393|Procedure|SPGB|SPGB was performed by the operating surgeon using a transnasal endoscopic approach before septorhinoplasty in the Block group. The prepared solution (4 cc % 4 lidocaine and 1 cc 8 mg dexamethasone) was delivered by a Mucosal Atomization device (LMA MADgic™ Laryngo-Tracheal Mucosal Atomization Device, US). 2,5 cc of the prepared solution was given to each side of the nose.
21546|NCT04020380|Drug|Azithromycin 250Mg Capsule|250 mg OD
21547|NCT04020367|Procedure|biopsy of mucosa's olfactory|intervention under general or local anesthesia
21548|NCT04020354|Behavioral|HABIT-ILE|Early Hand and arm bimanual intensive therapy including lower extremities
21549|NCT04020354|Behavioral|Usual Care|Usual customary care
21550|NCT04020341|Drug|Gepotidacin|Gepotidacin will be available as tablets containing 750 mg gepotidacin. Each dose should be taken with water after consumption of food.
21551|NCT04020341|Drug|Placebo matching nitrofurantoin|Placebo matching nitrofurantoin will be available as over-encapsulated unit-dose capsules. Each dose should be taken with water after consumption of food.
21552|NCT04020341|Drug|Nitrofurantoin|Nitrofurantoin will be available as over-encapsulated capsules containing 25 mg nitrofurantoin macrocrystals and 75 mg nitrofurantoin. Each dose should be taken with water after consumption of food.
21553|NCT04020341|Drug|Placebo matching gepotidacin|Placebo matching gepotidacin will be available as unit-dose gepotidacin placebo-to-match tablet. Each dose should be taken with water after consumption of food.
21554|NCT04020328|Drug|Leflunomide 20 mg+prednisone 0.5mg/kg/d|Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR<50ml/min
21555|NCT04020315|Procedure|Non-surgically performed scaling and root planing|Non-surgically performed scaling and root planing
21556|NCT04020302|Behavioral|Self-monitoring shopping intervention|Intervention will occur once per week for a duration of 8 weeks. The intervention format will alternate between individual and group sessions, so that the first week of intervention will be provided in a group format, the second week will be provided in an individual format, and so forth. Sessions will be 90 minutes in duration. Data will be collected during individual sessions, which will occur every other week. During individual sessions, each participant will meet at the facility for the first 15 minutes, will travel to a local grocery store for 45 minutes, and then reconvene at the facility for the final 30 minutes. Group sessions will follow the same structure; however, all ten participants will be present. Each of the 8 sessions will consist of the following: awareness training; facilitation of strategy generation; facilitation of error detection; reinforcement of self-monitoring techniques; and opportunity for participants to practice self-monitoring techniques.
21557|NCT04020289|Behavioral|"Psychoeducational Program BalancingMySwing"|"Patients in the intervention arm will receive a nurse-lid 8-session psychoeducational 'BalancingMySwing group psychotherapy"
21585|NCT04020029|Other|Reflection activities|Reflection activity include exercises to internalize the message
23183|NCT04006847|Drug|Eicosapentaenoic Acid|Eicosapentaenoic Acid once per day orally
21558|NCT04020276|Radiation|SBRT|Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
21559|NCT04020263|Drug|Levosimendan 2.5 MG/ML Injectable Solution|Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
21560|NCT04020263|Drug|Placebo|Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.
21561|NCT04020250|Device|Echocardiography|"Echocardiographic parameters:~Tricuspid annulus plane systolic excursion (TAPSE) Tricuspid regurgitation peak gradient (TRPG)"
21562|NCT04020237|Behavioral|Education about particulate matter practice score|"For the intervention group, specific guidance is given to the patient who might be exposure in environment with higher particulate matter concentration.~1) Start air purifier~2) Do not go out and make it to the minimum when absolutely necessary~3) It is recommended to wear a mask when going out.~4) The investigators recommend a lot of water, fresh fruit and vegetables.~5) Prepare an inhaler and use it when symptoms get worse."
21563|NCT04020224|Device|Amustaline/GSH pathogen reduction technology|Whole blood treated with pathogen reduction technology
21564|NCT04020224|Device|Standard of Care|Red Blood Cell Component or whole blood
21565|NCT04020211|Device|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
21566|NCT04020198|Other|Biomarker assay|Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder and controls.
21567|NCT04020185|Drug|IMSA101|IMSA101 administered by intra-tumoral (IT) injection on Day 1 of Weeks 1, 2, and 3 for Cycle 1 and on Day 1 of Weeks 1 and 3 for all subsequent cycles.
21568|NCT04020185|Drug|Immune checkpoint inhibitor (ICI)|Administered according to product label
21569|NCT04020185|Drug|Immuno-oncology (IO) therapy|Administered according to product label
21570|NCT04020172|Drug|Dobutamine|intraoperative fluid administration will be guided by cardiac output monitoring
21571|NCT04020159|Other|Patient Registry|No intervention/treatment
21572|NCT04020146|Other|Gingival biopsies|Gingival biopsies were obtained from all participants and biopsy samples underwent histological tissue processing.
21573|NCT04020133|Procedure|saphenous nerve block|"The skin is disinfected and the saphenous nerve is located via Ultrasound . the transducer is placed anteromedially, approximately at mid-thigh level a high-frequency linear probe 5Y12 MHz prepared in a sterile fashion (Phillips HD11) .~The block needle (Stimuplex; Braun Medical, Bethlehem, Pa), is inserted in plane in a lateral-to-medial orientation and advanced toward the femoral artery .Once the needle tip is visualized anterior to the artery and after careful aspiration, 1-2 mL of local anesthetic is injected to confirm the proper injection site . When injection of local anesthetic does not appear to result in its spread around the femoral artery, additional needle repositions and injections may be necessary."
21574|NCT04020133|Procedure|popliteal plexus block|After doing saphenous nerve block , we will move distally with the artery in the adductor canal until it moves away from the sartorius muscle to enter adductor hiatus . here , we will inject L.A above artery and so , popliteal plexus block will be accomplished
21575|NCT04020133|Drug|Plain bupivacaine|15ml of plain bupivacaine 0.5% will be given in both blocks
21576|NCT04020133|Drug|0.05 mg epinephrine|0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
21577|NCT04020120|Other|questionnaires|answer questionnaires
21578|NCT04020107|Other|Compressive garment and Somatosensori Remediation|Each patient will benefit successively: from a classic care, over a period of 2 to 4 months, then will be treated with compressive or low compressive garments associated with specific proprioceptive physiotherapy program during the next 4 months. Finally, the 4 last months, patient will made adapted physical activity with both dance sessions strengthening the body diagram and stretching sessions
21579|NCT04020094|Combination Product|MVA-BN-Brachyury|"Cycle= 21 days. Neoadjuvant Therapy: Treatment will be given for 2 neoadjuvant cycles. MVA-BN-Brachyury will be administered as intratumoral injection on Day 1 of each of 2 neoadjuvant cycles. PROSTVAC-V will be administered as a subq injection on Day 1 of Cycle 1 (the first neoadjuvant cycle) and PROSTVAC-F will be administered as a subq injection on Day 1 of Cycle 2 (the second neoadjuvant cycle). Atezolizumab will be given as an infusion on Day 1 of each 2 neoadjuvant cycles.~MVA-BN-Brachyury will be injected intratumorally into the prostate. Injections will target PI-RADS 4 and 5 lesions.~Surgery: Patients will undergo SOC radical prostatectomy Adjuvant Therapy: Systemic treatment with atezolizumab and PROSTVAC-F will be reinitiated between 3 to 8 weeks after surgery and will continue for an additional 6 cycles. PROSTVAC-F will be given as a subq injection on Day 1 of each cycle. Atezolizumab will be given as an infusion on Day 1 of each cycle."
21580|NCT04020081|Other|Yoga breathing exercises and Meditation|"8 Breathing exercises.The first set of 6 exercises is of the Upper Lobe breathing (Upper and Middle Lobe of the Lungs) while 7th exercise is abdominal breathing,8th exercise is yogic breathing.~6-steps Nirmal Dhyan (meditation).Step 1: Breath awareness,Step 2: Body awareness,Step 3: Thought awareness,Step 4: Refreshing awareness,Step 5: Gap awareness,Step 6: Expanding awareness."
21581|NCT04020055|Drug|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
21582|NCT04020042|Other|Ultrasound image guidance|Epidural landmarks will be determined with using ultrasound image
21583|NCT04020042|Other|Landmark palpation|Epidural landmarks will be determined with palpation
21584|NCT04020029|Other|Mindset|Mindset Intervention will include watching three brief ~10-25 minute films
24026|NCT04000035|Other|Health and work environment information and processes|see arm/group description
21586|NCT04020016|Drug|Nalbuphine ER|"Part 1:~Cohort 1: 6-8 subjects will receive 1 dose of 27mg and observed for 4 days. Cohort 2: 6-7 subjects will receive 1 dose of 54 mg and observed for 4 days. Cohort 3: 6-7 subjects will receive 1 dose of 108 mg and observed for 4 days. Cohort 4: 6-8 subjects will receive 1 dose of 162 mg and observed for 4 days. Cohort 5: 6-8 healthy subjects will receive dosing of NAL ER and observed for 4 days."
21587|NCT04020016|Drug|Nalbuphine ER|"Part 2:~Cohort 6: • 6-8 subjects with mild hepatic impairment and 6-8 subjects with moderate hepatic impairment. Doses will be subsequently escalated for each subject starting at 27 mg on Day 1 to twice daily, 12 hours apart, 27 mg, 54 mg, 108 mg, and 162 mg over 13 days."
21588|NCT04020003|Drug|Levosimendan|General treatment group: control the infection, remove or control the original disease, mechanical ventilation, small tidal volume, high PEEP mechanical ventilation strategy, strictly control the capacity, strengthen the airway management, timely nutrition support and intensive rehabilitation treatment. Levosimendan group: on the basis of routine group treatment, 12.5 mg of levosimendan 5% GS 50ml was given on the same day, and the micro-pump was continuously pumped for 24 hours. The initial dose was 0.5 ml/ h, and if the blood pressure was not significantly decreased, the blood pressure was gradually increased to 2.4 ml/ h at the maximum dose, until the pump was over. The above treatment is repeated every 7 days until the offline success or the patient leaves the ICU.
21589|NCT04019990|Other|The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players|Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
21590|NCT04019977|Other|Nurse Home Visiting Program|Brief nurse home visiting program
21591|NCT04019964|Drug|Nivolumab|Nivolumab 480mg intravenously every 4 weeks
21592|NCT04019951|Dietary Supplement|Ca-propionate 1 g|1 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
21593|NCT04019951|Dietary Supplement|Ca-propionate 3 g|3 g of Ca-propionate will be mixed in 203 mL of a standardized liquid breakfast
21594|NCT04019951|Dietary Supplement|Placebo|2.6 g of cellulose will be mixed in 203 mL of a standardized liquid breakfast
21595|NCT04019938|Radiation|Dual-energy X-ray absorptiometry|Cystatin C is measured as a part of routine investigation at the time of admission.
21596|NCT04019925|Device|ADM/MDM hip|Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
21597|NCT04019912|Other|Gait Training plus music|GaitTrainer3 is a platform that integrates gait training via a treadmill and RAS. The device is indeed equipped with an instrumented deck that issues acoustic cues to determine the exact tempo and rhythm during gait training and visual real-time biofeedback to prompt patients to follow their gait pattern. In fact, the device provides online feedback, including step length, speed, and symmetry, to encourage patient progress and monitor patient performance. Patient footfalls were compared in real-time to the desired footfalls step by step and documented in a histogram.
21598|NCT04019912|Other|Traditional Gait Training|The traditional training will be provided by a conventional treadmill.
21599|NCT04019899|Dietary Supplement|control group|"2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration. If pregnancy occurs, until the 12th week of gestation."
21600|NCT04019899|Dietary Supplement|study group|"2 g Myo-Inositol, 50 mg Alpha-Lactalbumin and 200 µg folic acid (1 sachet/day in the morning): from the first day of the menstrual cycle until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation.~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin (1 soft capsule/day in the evening): from the first day of the menstrual cycle until hCG administration;~600 mg Myo-Inositol, 200 µg folic acid, 1 mg melatonin, 50 µg vitamin D3 as cholecalciferol (1 soft capsule/day in the evening) substitutes the previous treatment at hCG administration and lasted until 14 days after embryo transfer. If pregnancy occurs, until the 12th week of gestation."
21601|NCT04019886|Other|Neurophysiological Facilitation of Respiration|Six neuro-facilitation techniques will be given to experimental group. Each technique will be given for 5 seconds hold with 5 repetitions and two sets.
21602|NCT04019873|Drug|Dolutegravir (DTG)|DTG is a 2nd generation integrase strand transfer inhibitor. Subjects receiving DTG as a part of 2DR treatment will be included in the study.
21603|NCT04019873|Drug|Lamivudine (3TC)|3TC is a nucleoside reverse transcriptase inhibitor. Subjects receiving 3TC as a part of 2DR treatment will be included in the study.
21604|NCT04019873|Drug|Rilpivirine (RPV)|RPV is a non-nucleoside reverse transcriptase inhibitor. Subjects receiving RPV as part of 2DR treatment will be included in the study.
21605|NCT04019860|Behavioral|High Intensity Interval Training|Three weekly, supervised exercise sessions with high intensity. Each session will last for 30-45 minutes. Intervention period will be seven weeks.
21606|NCT04019860|Behavioral|Time-Restricted Eating|Restricted daily window of caloric intake to maximum 10 hours. Intervention period will be seven weeks.
21607|NCT04019847|Device|STAK Tool|Medical stretching device
21608|NCT04019847|Other|Standard treatment|Physiotherapists tailor treatment of arthrofibrosis to meet their patients' individual needs. Treatment may comprise the following: education, advice and a range of stretching exercises/techniques to change the length and density of the adhesions and shortened tissue. These include active range of movement (AROM), passive range of movement (PROM), strengthening exercises, hands-on high intensity passive physiological stretches, joint mobilisations and a home exercise programme involving full weight bearing exercises with the aim of enabling the patient to regain AROM and function
21641|NCT04019639|Device|application of EasyFoam|Prior to applying EasyFoam, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. Marginal resection is performed until the necrotic tissue is removed sufficiently and pin point bleeding is seen on the wound. After that, hemostasis is done with an electrocoagulator and EasyFoam is applied to the affected area.
42618|NCT03850509|Drug|OPS-2071 600 mg|600 mg BID Oral for 12 weeks
21609|NCT04019834|Drug|PECs block with local anesthesia of bupivacaine with steroid|Patient will receive titrated sedation with a combination of fentanyl and versed prior to the start of the block. An ultrasound will be used to identify the fascial planes of both the PECs I and PECs II blocks. A block needle will be passed into the fascial plane and 5 cc of injectate will be deposited for the PEC I block and 20 cc of injectate will be deposited into the PECs II block. The injectate in the active arm will contain a combination of bupivacaine, epinephrine and dexamethasone.
21610|NCT04019834|Other|Placebo PECs block with normal saline|Patients who are randomized to placebo will undergo the same procedure with the exception of injection of 10cc of normal saline into the subcutaneous tissue within the axilla.
21611|NCT04019821|Drug|Insulin Glulisine|A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
21612|NCT04019821|Drug|Insulin Aspart|A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
21613|NCT04019821|Drug|Insulin Lispro|A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
21614|NCT04019795|Device|REVIAN 101|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light."
21615|NCT04019795|Device|REVIAN 102|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light."
21616|NCT04019795|Device|REVIAN 103|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light."
21617|NCT04019795|Device|REVIAN 100|"The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy"
21618|NCT04019782|Drug|Collagen-PVP|Infiltrations of 1.5 ml collagen-polyvinyl pyrrolidone (collagen-PVP) plus 1 mL of 2% xylocaine without epinephrine, administered by intraarticular injections (three doses, one each 7 days)
21619|NCT04019782|Device|Hylan G-F 20|Infiltrations of 2 mL 0.8% Hylan G-F 20 (16 mg) solution, administered by intraarticular injections (three doses, one each 7 days)
21620|NCT04019769|Drug|L-glutamine|product will be obtained by Endari and administered by NIH pharmacy. Patient will take supplement as prescribed
21621|NCT04019743|Drug|CKD-330 16/10mg Tab. 1T and D086 Tab. 1T|single oral administration under fasting condition
21622|NCT04019743|Drug|CKD-333 16/10/40mg formulation 1 Tab. 1T|single oral administration under fasting condition
21623|NCT04019743|Drug|CKD-333 16/10/40mg formulation 2 Tab. 1T|single oral administration under fasting condition
21624|NCT04019730|Other|diet|low carbohydrate diet (< 10 EN% carbs) vs high carbohydrate diet (>50 EN% carbs)
21625|NCT04019717|Drug|AT-527|Nucleotide prodrug inhibitor of HCV nonstructural protein 5B (NS5B) polymerase
21626|NCT04019717|Drug|Daclatasvir|Inhibitor of HCV nonstructural protein 5A (NS5A)
21627|NCT04019704|Drug|AXS-05|Oral AXS-05 tablets, taken daily for 6 weeks.
21628|NCT04019704|Drug|Placebo|Placebo to match oral AXS-05 tablets, taken daily for 6 weeks.
21629|NCT04019691|Device|Mix-and-Match|Phacoemulsification and implantation of Tecnis ZKB00 multifocal IOL with +2.75 D add power (Abbott Medical Optic Inc., Santa Ana, CA) in the dominant eye, and a Tecnis ZLB00 multifocal IOL with +3.25 D add power (Abbott Medical Optics Inc.) in the non-dominant eye.
21630|NCT04019691|Device|EDOF|Phacoemulsification and implantation of Tecnis Symfony ZXR00 trifocal IOLs (Abbot Medical Optics Inc.) in both eyes.
21631|NCT04019691|Device|Trifocal|Phacoemulsification and implantation of FineVision PodFT IOLs (PhysIOL SA) in both eyes.
21632|NCT04019678|Procedure|Omission of Axillary dissection|In Group 1 and 2: Axillary dissection won't be performed
21633|NCT04019678|Procedure|Axillary dissection|In Group 3: Axillary dissection will be performed
21634|NCT04019665|Other|MMSE (mini mental state examination)|mini mental state examination takes place during the consultation. The consultation is a general or post-emergency geriatric consultation.
21635|NCT04019665|Other|SAGE (Self-Administered Gerocognitive Exam)|SAGE test contains a series of questions that assess the cognitive functioning. Sage was developed by the Ohio State University Wexner Medical Center. it's an online, at-home, self-screening dementia tool that has been scientifically evaluated, and it's demonstrated good results in accurately identifying cognitive deficits.
21636|NCT04019652|Drug|CS-3150|Single, oral administration; 10-mg or 40-mg dose
21637|NCT04019652|Drug|Moxifloxacin|Single, oral administration; 400 mg-tablet
21638|NCT04019652|Drug|Placebo matching moxifloxacin tablet|Placebo tablets matching moxifloxacin tablets
21639|NCT04019652|Drug|Placebo matching CS-3150|Placebo tablets matching CS-3150 tablets
21640|NCT04019639|Device|application of CG Paste+EasyFoam|Prior to application of CG paste, sharp debridement can be performed first in the operating room under local anesthesia or general anesthesia. After this, hemostasis is performed by an electrocoagulator and the medical device is applied to the affected area. During the procedure, remove the packaging material and remove the syringe to remove the protective cap in front of the syringe. Slowly push the syringe plunger and apply the contents to the area where you want to use. Depending on the location and size of the wound area, an injection cap can be used. Apply CG paste and apply Easyfoam to finish the dressing.
21642|NCT04019626|Other|Continue-smoking|Ad-libitum use of subjects' usual brand combustible cigarette
21643|NCT04019626|Other|myblu Tobacco Chill 2.5%|Ad-libitum use of myblu e-cigarette with Tobacco Chill flavor 2.5% nicotine
21644|NCT04019626|Other|myblu Tobacco Chill 4.0%|Ad-libitum use of myblu e-cigarette with Tobacco Chill flavor 4.0% nicotine
21645|NCT04019626|Other|myblu Honeymoon 2.5%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 2.5% nicotine
21646|NCT04019626|Other|myblu Honeymoon 4.0%|Ad-libitum use of myblu e-cigarette with Honeymoon flavor 4.0% nicotine
21647|NCT04019613|Diagnostic Test|Lung ultrasound|Lung ultrasound will be performed at baseline (resting), prior to exercise with passive leg elevation, after 1.5 minutes of 20 Watts exercise, during each subsequent stage, at peak workload and at 1 minute recovery. Pulmonary thermodilution will be performed at rest, peak stress and at 1 minute recovery.
21648|NCT04019600|Other|Echocardiography|Demographic data and health risk factors will be collected on day of screening, together with the above tests. Right heart catheterization will be separately arranged in patients with a high echocardiographic probability of PAH. For those with a low-intermediate echocardiographic probability, screening will be repeated within 1 year to ensure true negativity of the original scan.
21649|NCT04019587|Diagnostic Test|Fear of Falling Avoidance Behavior Questionnaire administration|The Questionnaire includes 14 items dealing with avoidance behavior. All items will be asked by face to face technique.
21650|NCT04019574|Drug|CR845 0.5 mcg/kg IV|0.5 mcg/kg IV CR845
21651|NCT04019574|Drug|CR845 3 mcg/kg IV|3 mcg/kg IV CR845
21652|NCT04019574|Drug|Moxifloxacin 400 mg Oral Tablet|400 mg Oral Moxifloxacin
21653|NCT04019574|Other|Placebo|IV Placebo as a bolus injection
21654|NCT04019561|Drug|MEDI0382 high dose|MEDI0382 high dose administered subcutaneously
21655|NCT04019561|Drug|Placebo for MEDI0382 high dose|Placebo for MEDI0382 high dose administered subcutaneously
21656|NCT04019561|Drug|MEDI0382 low dose|MEDI0382 low dose administered subcutaneously
21657|NCT04019561|Drug|Placebo for MEDI0382 low dose|Placebo for MEDI0382 low dose administered subcutaneously
21658|NCT04019548|Device|Percutaneous Endoscopic Gastrotomy tube placement|placement of the PEG tube depends on arm
21659|NCT04019548|Drug|Cisplatin injection|"Two therapeutic regimen allowed:~Days 1 and 22 : cisplatin 100mg/m2 IV~Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV"
21660|NCT04019548|Radiation|Radiotherapy|Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.
21661|NCT04019535|Device|physiological assessment with Volcano Verrata pressure wire (iFR)|physiological assessment of the coronary lesion will be made with both iFR and dFR. all clinical decisions will be made based on the results of iFR
21662|NCT04019522|Other|Acute Intermittent Hypoxia (AIH)|An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered to the subject. Inspired fraction of oxygen (FiO2) of the gas mixture will be individually adjusted using the valve settings to reach the targeted SpO2. The gas mixtures administered during the four sessions will be 21% O2 (target SpO2 = 95%), 17% O2 (target SpO2 = 92%), 13% O2 (target SpO2 = 87%) and 9% O2 (target SpO2 = 82%).
21663|NCT04019509|Diagnostic Test|blood test|blood test for thyroid antibodies and thyroid function (TSH, FT4)
21664|NCT04019509|Other|follow up treatment outcome|questionnaire for treatment outcome: pregnancy, no pregnancy, miscarriage, delivery
21665|NCT04019496|Drug|antibodies against calcitonin-gene related peptide or its receptor|the study is observational and does not interfere with clinical routine. In lin with this notion, the intervention is chosen by the treating physician in a shared decision making process involving the patient
21666|NCT04019457|Other|Dietary intervention|Dietary intervention: Participants receive dietary fibers for a defined number of days.
21667|NCT04019444|Biological|ChAd155-RG|The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
21668|NCT04019444|Other|Placebo|0.9% Sodium Chloride, USP injection.
21669|NCT04019444|Biological|Rabies Vaccine|The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
21670|NCT04019431|Dietary Supplement|Whey protein, vegetable protein or animal protein|meal replacements or animal protein
21671|NCT04019418|Dietary Supplement|Maltodextrin (carbohydrate)|A drink containing 300ml of water and 75g of maltodextrin
21672|NCT04019418|Other|Exercise|30 minutes on a cycle ergometer working at 75% VO2 max
21673|NCT04019418|Other|Rest|30 minutes laying on a bed
21674|NCT04019418|Other|Water|A drink containing 300ml of water
21675|NCT04019392|Device|Game Ready® device|The half leg boot sleeve of the Game Ready® device (CoolSystems, Inc., Alamda, CA) will be applied to each participants' lower leg and ankle for 30 minutes set on the medium pressure setting (5-50 mmHG).
21676|NCT04019392|Other|Wetted Ice Bag with Elastic Wrap|A standard ice bag filled with 2000 mL of cubed ice and 300 mL of 5˚C water will be applied using an elastic wrap to each participants' lower leg for 30 minutes. An elastic wrap applied at approximately 75% percent tension starting distal to the treatment area and moving proximally overlapping by half will be applied over the wetted ice bag.
21677|NCT04019379|Other|Low Calcium/High Phosphorus Diet|Controlled research diet of low calcium/high phosphorus
21678|NCT04019379|Other|High Calcium/Low Phosphorus Diet|Controlled research diet of high calcium/low phosphorus
21679|NCT04019366|Other|Balance Training|Experimental group received balance training on Biodex stability System along with traditional exercise program. During balance training on Biodex, patients were instructed to stand on the platform with bare feet with open eyes and both legs supported. Patients were looking forward to screen having hands hang by the sides. The patients were instructed not to change their feet position and balance the body. The handles were accessible for safety point. But touching the handles cancelled the trail. Total time of training was 10 minutes each set is of 3 minutes with 20 sec rest intervals.
21680|NCT04019366|Other|Conventional Training|Control group has received traditional exercises i.e Quadriceps strength exercises, Hamstrings flexibility exercises and Balance exercises.
21681|NCT04019353|Genetic|cf-DNA Collection|"For all consenting recipients undergoing kidney biopsy between 1 and 12 months post-transplant, a single tube of blood will be drawn (at the time of other blood draws so that there is no additional needle stick) to measure cf-DNA. The tube will be shipped to the California lab for determination of donor cf-DNA. For recipients whose biopsy shows AR, a tube of blood will be drawn at 2, 4, 6, and 8 weeks after initiation of anti-rejection treatment and similarly will be shipped to the California lab for determination of cf-DNA.~Recipients whose exit biopsy shows ongoing inflammation and receiving additional anti-rejection therapy will have an additional exit biopsy additional cf-DNA determinations."
21682|NCT04019340|Other|Education|Usual care as described for the CG will also be provided to the IG. Wound size measurement, wound care, and questionnaires will be provided by the institute's nurses. Usual care will be enhanced by a pluridisciplinary educational program
21683|NCT04019327|Drug|Talazoparib|"Phase I maximum tolerated dose portion:~Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6"
21684|NCT04019327|Drug|Temozolomide|"Phase I maximum tolerated dose portion:~Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 & 4 - 100 mg/m2 QD Days 2-8 Level 5 & 6 - 125 mg/m2 QD Days 2-8"
21685|NCT04019314|Procedure|Blood Collection|Samples for proEnkephalin PENK will be obtained daily and aliquots of these samples will be stored for later batch assays.
21686|NCT04019314|Procedure|Blood Volume Analysis|A small amount of a radioactive isotope or tracer is injected and blood samples are taken at 6 time points during the test and analyzed.
21687|NCT04019301|Other|Baduanjin Qigong, Community-based|The Community-based Qigong group, will attend one 75 minute long Qigong class per week for 12 weeks. Additionally, participants practice Qigong at home for 20 minutes a day, 3 days a week. Printed materials will be provided to guide home practice.
21688|NCT04019301|Other|Baduanjin Qigong, Internet-based|The Internet-guided Qigong group will be given a computer tablet to access online Qigong classes. All participants assigned to this group will be provided with a tutorial to use the Qigong program by the research coordinator. Participants will be asked to follow a 40 minute long Qigong class twice a week for 12 weeks, and to practice an additional 20 minutes a day, 3 days a week. All sessions will be completed at home.
21689|NCT04019288|Drug|Anti-AXL Fusion Protein AVB-S6-500|Given IV
21690|NCT04019288|Biological|Durvalumab|Given IV
21691|NCT04019275|Behavioral|ENGAGE|ENGAGE blends social learning, guided discovery and skill training focused on community participation
21692|NCT04019262|Radiation|Radiation Therapy|Radiation
21693|NCT04019262|Drug|Temozolomide Oral Product|Oral Temozolomide (150mg/m^2 or 75 mg/m^2)
21694|NCT04019249|Behavioral|Healthy Weight Coaching|Healthy Weight Coaching is a 52 week long web-based weight loss program consisting of weekly modules, exercises, peer support, and one-on-one coaching. It encompasses themes such as diet, physical activity, coping with stress, sleep, and general health.
21695|NCT04019236|Other|visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care|Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
21696|NCT04019223|Diagnostic Test|anti-tissue transglutaminase group|Determination of anti-tissue transglutaminase IgA antibodies serum level.
21697|NCT04019223|Diagnostic Test|biopsy group|Intestinal biopsy for histopathology study the jejunal histopathological
21698|NCT04019210|Procedure|MODIFIED TRABECULECTOMY|Rectangular scleral flap
21699|NCT04019197|Drug|Semaglutide Injectable Product|semaglutide subcutaneous injection
21700|NCT04019197|Drug|Placebo|placebo injection
21701|NCT04019184|Drug|L-Alanyl/L-Glutamine|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the investigational drug
21702|NCT04019184|Drug|Placebo|Immediately after randomization (not longer than 30 min after fulfilling eligibility criteria), patients will receive intravenous infusions with the placebo
21703|NCT04019171|Behavioral|exercise training|6 weeks of physical exercise training. 3 sessions per week. Session duration : 40 minutes. Self-regulated exercise intensity using Borg's ratings of perceived exertion (RPE)
21704|NCT04019158|Device|Virtual reality headset|All participants will walk in the three conditions described earlier in this form
21705|NCT04019145|Drug|EverX Posterior|fiber reinforced bulk fill resin composite
21706|NCT04019145|Drug|Resins, Composite|incremental packing of Nanohybrid Resin composite
21707|NCT04019132|Diagnostic Test|Muscle function test|Body measurements, power and strength tests of the knee extensor muscle, handgrip strength, functional capacity tests, objective measurement of physical activity (subgroup of older adults, n=50)
21708|NCT04019119|Behavioral|Digital intervention|The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
21709|NCT04019106|Drug|Budesonide in bovine lipid extract surfactant (BLES)|Budesonide in bovine lipid extract surfactant
21710|NCT04019093|Drug|Ethanol|A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
21711|NCT04019093|Other|Placebo|A beverage that does not meaningfully increase breath alcohol concentration.
21712|NCT04019080|Other|Anti-fibrostic drugs|The real-Life use of anti-fibrotic drugs in patients with idiopathic pulmonary fibrosis in Sweden
21713|NCT04019067|Diagnostic Test|MCE first|"Patients randomized to the MCE first group will have a MCE deployed as soon as possible once confirmed to fast for at least 8 hours."
21714|NCT04019054|Device|Intermittent Theta Burst Stimulation (iTBS), Ventromedial Prefrontal Cortex (vmPFC)|iTBS delivered to vmPFC for active treatment of spider phobia.
21715|NCT04019054|Device|Intermittent Theta Burst Stimulation (iTBS), vertex|iTBS delivered to vertex for placebo treatment of spider phobia.
42906|NCT03848208|Drug|cytisine|cytisine film-coated oral tablet
21718|NCT04019028|Device|low frequency rTMS + Navigation System|1Hz low-frequency rTMS stimulation over primary motor area using navigation system
21719|NCT04019028|Device|only low frequency rTMS|1Hz low-frequency rTMS stimulation over primary motor area
21720|NCT04019028|Device|Sham low frequency rTMS + Navigation System|1Hz low-frequency sham rTMS stimulation over primary motor area using navigation system
21721|NCT04019015|Drug|Prothrombin Complex Concentrate, Human|Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors
21722|NCT04019015|Drug|Placebo|Normal saline solution
21723|NCT04019002|Drug|Hyperpolarized 13C Pyruvate|"Dosage: Given at 0.43 milliliters/kilogram body weight of a 250 millimolar (mM) solution.~Dosage Form: Intravenous injection over a period of about 1 minute~Frequency: Once prior to each research magnetic resonance imaging procedure"
21724|NCT04018976|Device|AVACEN 100|The AVACEN 100 pulls a -30mmHg vacuum around the hand from the wrist down and applies heat (108 Fahrenheit) to the palm
21725|NCT04018976|Device|AVACEN 100 heat only|The AVACEN 100 applies heat (108 Fahrenheit) to the palm
21726|NCT04018976|Device|AVACEN 100 sham|The AVACEN 100 does not provide heat or vacuum
21727|NCT04018963|Procedure|Single nostril approach endoscopic transsphenoidal pituitary surgery|Single nostril approach endoscopic transsphenoidal pituitary surgery
21728|NCT04018963|Procedure|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery|Bilateral nostril approach endoscopic transsphenoidal pituitary surgery
21729|NCT04018950|Drug|ETX2514|intravenous infusion
21730|NCT04018950|Drug|14C-ETX2514|intravenous infusion
21731|NCT04018937|Drug|Fludarabine|Fludarabine will be administered at 30 mg/m^2 IV daily for five days (Days -7 to -3).
21732|NCT04018937|Drug|Alemtuzumab|A test dose of alemtuzumab, 3 mg, will be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses will begin within 24 hours. The three treatment doses will be administered on consecutive days. On the first day, 10 mg/m2 will be given, 15 mg/m^2 the second and 20 mg/m^2 the third. Alemtuzumab will be started between Days -22 and -20, but all doses (test dose and three treatment doses) should be completed by Day -18.
21733|NCT04018937|Drug|Melphalan|Melphalan will be administered at 140 mg/m^2 IV on Day -3 following fludarabine administration.
21734|NCT04018924|Device|Illumination with blue light (400-430nm) for 60 seconds with a power density of 120mW/sqcm (EmoLED device)|Debridement and Dressing or compressive dressing if needed
21735|NCT04018911|Device|Hearing Aid with standard Noise Reduction (NR_1)|Hearing Aid with standard Noise Reduction (NR) Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs (ensures exact same hearing loss compensation for each intervention). Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The active comparator condition is the state of the art Noise Reduction principle.
21736|NCT04018911|Device|Hearing Aid with NR_2|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
21737|NCT04018911|Device|Hearing Aid with NR_3|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions (novel NR principle) vary in their parametrization to result in different degrees of noise suppression and good speech quality.
21738|NCT04018911|Drug|Hearing Aid with NR_4|Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. This experimental condition combines standard NR and novel NR principle to result in different degrees of noise suppression and good speech quality.
21739|NCT04018885|Drug|ALA 2.5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
21740|NCT04018885|Drug|ALA 5%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
21741|NCT04018885|Drug|ALA 10%|Topical treatment for photodynamic therapy, after drug incubation subsequent illumination with red light (72 J/cm2). 4 treatments at an interval of 10 (± 4) days.
21742|NCT04018872|Drug|Itraconazole|Oral administration of itraconazole twice daily from completion of neoadjuvant chemoradiation until esophagectomy.
21743|NCT04018859|Device|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to the eyebrows
21744|NCT04018859|Drug|Saline|intradermal injections to the eyebrows
21745|NCT04018846|Procedure|Revascularization using a BIOPROTEC Graft|It is about a routine care study not changing the usual follow-up of patients: postoperative visits after a Doppler ultrasonography made by a vascular Doctor in 1 month, 6 months, 12 months, 18 months and 2 years.
21746|NCT04018833|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]|
21747|NCT04018833|Drug|Aflibercept 40 MG/ML Intraocular Solution [EYLEA]|
21748|NCT04018820|Other|Training program|12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises were performed between 6 and 8 maximal repetitions.
21749|NCT04018807|Other|Resource pamphlet|The pamphlet will list violence prevention, mental health, and substance abuse services.
21750|NCT04018807|Behavioral|Remote Therapy|Remote therapy sessions will include mindfulness exercises and motivational interviewing techniques.
21751|NCT04018794|Device|Behavioral/organizational skills intervention augmented with digital health application|Behavioral/organizational skills intervention with digital health application augmentation
21845|NCT04017988|Dietary Supplement|Ethanol Extracts of Porphyra Tenera(PTE10)|2 times a day, 2 capsules for 1 time, after breakfast/dinner meal, for 8 week
21846|NCT04017988|Dietary Supplement|Placebo|Placebo for 8 week
21752|NCT04018781|Other|medication reconciliation|"During hospitalization, the hospital pharmacist will carry out a pharmaceutical analysis for all patients included in the study, each time the prescription is changed and within a maximum of 24 hours (working days).~If necessary, in consultation with the doctor in charge of the patient, the pharmacist may also propose a pharmaceutical interview to the patient at any time during his hospitalisation (e.g. proposal for the de-prescription of benzodiazepines, Proton Pump Inhibitors, etc., according to the recommendations in force)."
21753|NCT04018768|Other|ibuprofen 600 mg|MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
21754|NCT04018768|Other|Oxycodone/acetaminophen (Percocet) 5 mg/325|MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
21755|NCT04018755|Biological|anakinra|anakinra single-use prefilled glass syringes
21756|NCT04018742|Other|Surgical puncture|Investigators propose to collect 20 abscesses. A collection of abscesses is performed systematically during the diagnostic for bacteriological analysis. There will be no further examination.
21757|NCT04018729|Device|Zephyr Endobronchial Valve|Endoscopic lung volume reduction therapy.
21758|NCT04018729|Biological|Marrow-derived mesenchymal stromal cell|Mesenchymal stem cells have anti-inflammatory, anti-fibrotic, microbicide and repair potential.
21759|NCT04018716|Device|MTA|Indirect capping with MTA
21760|NCT04018716|Device|Dycal|Indirect capping with Dycal
21761|NCT04018703|Drug|Dexmedetomidine|loading dose 0.5-2.5ug/kg followed by continuous infusion 0.2-0.5ug/kg/h
21762|NCT04018703|Drug|Midazolam|loading dose 30-50ug/kg followed by continuous infusion 10-30ug/kg/h
21763|NCT04018690|Behavioral|Patients will be submitted to needle lavage, followed by the injection of 3mL of hylan and 1 mL of ropivacaine|"Patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 3mL of hylan, 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
21764|NCT04018690|Behavioral|Patients will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine,|"Patients with K&L 2 and 3 hip OA will be submitted to needle lavage, followed by the injection of 0,5mL triamcinolone (10mg) and 1 mL of ropivacaine.~Answer: WOMAC, Lequesne, VAS, EQ-5D-5L at inclusion, one week prior to surgery, 1st, 3rd, 6th and 12th months postoperatively.~Submitted to evaluaton in the isokinetic dynamometer (Cybex 6000, Ronkokoma Lumex Inc.) where de amplitudes of movement of hip flexion, extension, abduction and adduction will be measures. Hip flexion, extension, abduction and adduction force will be assessed isokinetically at 60 degrees/second.~Costs will be evaluated for cost-effectiveness and cost-utility analysis."
21765|NCT04018677|Device|TOGETHER|TOGETHER is a mobile application software by Medable Inc.
21766|NCT04018664|Drug|Nalbuphine 162 Mg ER|Treatment G
21767|NCT04018664|Drug|Nalbuphine HCl solution|Treatment Arm D: given at a low dose Treatment Arm E; given at an intermediate dose Treatment Arm F: given at a high dosing
21768|NCT04018664|Drug|Hydromorphone HCl 8 mg|Treatment Arm B: 8 mg Solution
21769|NCT04018664|Drug|Hydromorphone HCl 16 Mg|Treatment Arm C: 16 Mg solution
21770|NCT04018664|Drug|Placebo Tablet|Treatment Arm A
21771|NCT04018651|Behavioral|PrEP Master Adherence Intervention|"The PrEP Master Adherence Intervention consists of 4 face to face individual education sessions and a series of telephone contacts to identify barriers and facilitators to optimal PrEP adherence over a six-month period. Each PrEP Master education session includes a review of an individualized plan to reduce risk, review of information about PrEP, and different discussion points. Key messages include:~Importance of daily adherence;~Three week delay for full effectiveness describing PrEP like taking the birth control pill;~Condom use for other sexually transmitted infection (STI) prevention;~Pregnancy prevention plans;~Plans for follow up calls~Referral to other treatment services if necessary"
21772|NCT04018638|Other|B-FREE|Blood flow-restriction exercise enhancement (B-FREE) will be performed at home 3x/wk for 10 weeks. A blood pressure cuff will be inflated to partially occlude blood to the limb during light weight exercises involving knee extension, body weight squats, and walking.
21773|NCT04018625|Behavioral|SMART Pregnancy|SMART Pregnancy is an 8-session online stress management program offered in a group format. SMART Pregnancy is an adaptation of the Stress Management and Resiliency Training Program (Park et al., 2012).
21774|NCT04018625|Behavioral|Treatment as usual|Participant provided with list referrals to community mental health resources and support groups. No active intervention provided by study team.
21775|NCT04018612|Drug|Ofirmev Injectable Product (Acetaminophen)|Ofirmev Injectable Product (Acetaminophen)
21776|NCT04018612|Other|Placebo|IV Saline
21777|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using an auto-injector.
21778|NCT04018599|Drug|40 mg MSB11022|Single dose, as a solution, administered subcutaneously, using a pre-filled syringe.
21779|NCT04018586|Device|AVACEN 100|AVACEN 100 pulls a -30mmHg vacuum around hand from wrist down and applies heat (108 farenheit) to the palm and will be applied for 30 minutes
21780|NCT04018586|Device|AVACEN 100 Heat Only|AVACEN 100 applies heat (108 Fahrenheit) to the palm and will be applied for 30 minutes
21781|NCT04018586|Device|AVACEN Sham|AVACEN 100 neither heats nor pulls a vacuum to hand
21801|NCT04018391|Behavioral|Stepped care for nonadherence and depression|"Problem Solving for Depression and Adherence: A 6-session adherence and depression intervention based on a culturally adapted LifeSteps and Problem Solving Therapy for Depression.~Stepped Care Assessment for Antidepressant Treatment: If a participant's depression score remains above threshold in Session 6, the study interventionist will refer the participant to a Research Mental Health Nurse for a psychopharmacological assessment to prescribe an antidepressant to augment Problem Solving for Depression and Adherence."
21960|NCT04017169|Other|No intervention as observational study|
42907|NCT03848208|Drug|placebo|matching placebo oral tablet
21782|NCT04018573|Behavioral|PATHS Sexual Communication Toolkit|The PATHS Sexual Communication Toolkit is a self-guided, online intervention. The toolkit is comprised of 6 modules, covering a range of topics relevant to increasing parents' motivation, self-efficacy, and intention for communicating about sex. Material is presented in a variety of modalities (e.g., text, videos of experts, videos of other parents describing their experiences). Parents set personalized goals for themselves regarding activities and conversations they want to have with their sons, selecting from a menu of options provided by the intervention. A 1-month booster module queries parents about whether they have achieved their goals, and provides customized content to support the behaviors parents have yet to enact.
21783|NCT04018573|Behavioral|Parent Support Film|"Lead with Love is a 35-minute education entertainment film created to provide support, information, and behavioral guidance to parents of lesbian, gay, or bisexual (LGB) children. Drawing from stage-based models of behavior change, and social cognitive theory, it aims to help parents progress through the process of coming to accept their child's sexual orientation, recognizing the importance of their behaviors and reactions to their child's health, and accepting their child's sexual orientation, and engaging in behaviors that are more supportive and less rejecting. This is achieved by telling the true stories of four families and how they responded to the news that their child was LGB, and by having experts (psychologists, teachers, clergy) provide information and guidance."
21784|NCT04018560|Behavioral|Al-Anon Intensive Referral (AIR)|AIR is intended to facilitate Al-Anon participation.
21785|NCT04018547|Device|Patient wears a wrist sensor oximeter device for one to two nights.|Patients will be asked to complete a study questionnaires of STOPBANG, SCI-8 (Sleep Condition Indicator-8 questionnaire for insomnia), Epworth questionnaires and medical history. The clinician will record blood pressure, pulse rate and regularity, body mass index and neck circumference. Subjects will be required to wear the wrist sensor pulse oximeter for 1-2 nights. The Oxitone 1000M device measures pulse rate, blood oxygen saturation and movement. The oxygen desaturation events from the wrist sensor device will be statistically compared with the diagnosis assessed using the conventional PPG oximetry, Peripheral Arterial Tonometry and clinical assessment. (clinicians will be masked when analysing the data from the wrist sensor pulse device).
21786|NCT04018534|Behavioral|Standard Verbal/Written Education|This patients as control group received a standard printed educational material assisted with verbal information in accordance with British Orthodontics Society (BOS) educational goals.
21787|NCT04018534|Behavioral|Video Assisted Education|The video training consisted of two separate sessions, each one lasting 5 minutes, one about the treatment materials and the other about the oral hygiene successively and in compliance with the British Orthodontics Society (BOS) educational obligations. All of the candidates were allowed to rewind and watch the video presentation until they reach all of the educational goals. The accomplishment of the educational goals was documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics.
21788|NCT04018534|Behavioral|Hands-on Training|The hands-on training consisting of two separate sessions was performed by one of the authors (E.A). The first is about the treatment materials and the second one is about the oral hygiene successively. They are in accordance with the British Orthodontics Society (BOS) educational obligations. All of the patients were allowed to ask questions freely until they reach all of the educational goals. The accomplishments of the educational goals were documented through a written examination form filled in by the candidates themselves. All of the candidates have rated fullscore in the written examinations on both topics. The time requirements for all three different educational interventions were recorded separately.
21789|NCT04018521|Behavioral|PPN|Delivery of Coordinated Specialty Care (CSC) for Y/YA in New York's state program for FEP, called OnTrackNY (OTNY).
21790|NCT04018521|Behavioral|CSC Usual Care|standard of care provided to youth following first episode of psychosis
21791|NCT04018508|Other|Massage|Massage intervention including effleurage, petrissage and energy work/Reiki at a pressure of 2 or less (Walton Pressure Scale)
21792|NCT04018495|Device|Fitbit Tracker|Fitbit tracker; is an activity tracking product that is wireless-enabled wearable technology device that measures data such as the number of steps walked, heart rate, quality of sleep, steps climbed, and other personal metrics involved in fitness
21793|NCT04018482|Other|Povidone Iodine|FDA-approved disinfectant for intravitreal injections
21794|NCT04018482|Other|Hypochlorous Acid|FDA-approved disinfectant for intravitreal injections
21795|NCT04018469|Other|No Interventions|No Interventions
21796|NCT04018456|Other|Biodentine|Biodentine is calcium silicate based cement which is bioactive and inductive material. Biodentine will be applied as coronal plug material.
21797|NCT04018456|Other|White MTA|MTA is calcium silicate based cement which is bioactive and inductive material. MTA is used in most cases of regenerative endodontics and it will be applied as coronal plug material.
21798|NCT04018443|Diagnostic Test|common carotid artery diameter measurement|measurement of common carotid artery diameter will be carried out two times: the initial measurement (pre-infusion) which is followed by infusion of crystalloid solution (Ringer lactate) 30 ml/min till reaching a total infusion volume of 7 ml/kg body weight then another ultrasound measurement will be taken (prost-infusion). Between these sequential measurements, the patient position will not be changed. The percentage increase in CCA diameter will be calculated using the formula: [(dia-mpost/dia-mpre) × 100] − 100 [11].
21799|NCT04018417|Drug|Amphotericin B|Drug concentration: 0.255 μg/mL
21800|NCT04018404|Other|FRI CLINICAL PROGRAM|University Le Bonheur Pediatric Specialists and Le Bonheur Community Health and Well-Being, Maternal Child Department, have started the Family Resilience Initiative (FRI) in the ULPS General Pediatrics Clinic. This clinical program screens children 9 months to less than five years of age for ACES and SDH at the time of presentation for well child checks. There are two outreach coordinators who screen and enroll children attending clinic for a well-child check during morning clinics 3 to 4 days per week. Children with positive screens for ACES and/or SDH, and their adult caregivers, receive community resource referrals with warm handoffs to vetted organizations. In addition, if indicated, psychological services are offered for children based upon the presence of one or more of ACEs and current health and behavioral problems.
21844|NCT04018014|Other|CT angiography|CT angiography in detection of pulmonary embolism
21802|NCT04018391|Other|Enhanced Usual Care|Enhanced Usual Care: A combination of 1) clinic-provided adherence counseling, 2) access to providers trained in the World Health Organization Mental Health Gap Intervention Guide (mhGAP), 3) a letter to the participant's medical provider detailing the depression diagnosis, 4) access to the treatment components of the TENDAI intervention at no cost, after the participant has completed their 12-month follow-up assessment.
21803|NCT04018378|Drug|varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
21804|NCT04018378|Drug|varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR|varenicline tartrate 1mg (HGP1604) was used as a reference drug and varenicline oxalate 1mg (HIP1502) was used as a test drug.
21805|NCT04018365|Drug|Empagliflozin Tablets|The administration is oral administration with water before or after breakfast.
21806|NCT04018339|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
21807|NCT04018339|Drug|Placebo|Capsules containing an inert placebo
21808|NCT04018313|Biological|CT-P39|150 mg/mL, Solution for injection in PFS
21809|NCT04018313|Biological|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
21810|NCT04018313|Biological|CT-P39|150 mg/mL, Solution for injection in PFS
21811|NCT04018313|Biological|EU-approved Xolair|150 mg/mL, Solution for injection in PFS
21812|NCT04018313|Biological|US-licensed Xolair|150 mg/mL, Solution for injection in PFS
21813|NCT04018300|Dietary Supplement|Ferrous sulfate|65 mg Fe as ferrous sulfate
21814|NCT04018300|Dietary Supplement|Aspiron|65 mg Fe as iron-enriched koji culture, called AspironTM
21815|NCT04018300|Other|Placebo|Contains maltodextrin.
21816|NCT04018287|Other|HR-pQCT scans, BMD measurements, bone specific circulating microRNAs (miRNAs)|"HR-pQCT scans (XtremeCT, SCANCO Medical, Brütisellen, Switzerland) will be performed in all patients with HPP and all CTRL at the ultradistal radius and the distal tibia, using the manufacturer's standard protocol.~Volumetric bone Mineral density (vBMD) will be carried out. The peripheral trabecular density adjacent to the cortex and the central medullary trabecular density will be automatically evaluated. Bone microstructure including trabecular bone volume fraction, trabecular number, trabecular thickness inhomogeneity of the network, cortical thickness and cortical porosity will be analyzed.~Measurements will be carried out by two well-trained physicians and performed with the latest available software (software version 6.0). Daily crosscalibrations with standardized control phantoms (Moehrendorf, Germany) will be conducted for validation."
21817|NCT04018274|Drug|PF-06651600|50 mg by mouth (PO) once daily (QD)
21818|NCT04018274|Drug|Ethinyl estradiol (EE) and levonorgestrel(LN)|Oral tablet containing 30 ug EE and 150 ug of LN
21819|NCT04018261|Drug|Activated T-Lymphocytes|Activated T-Lymphocytes will be infused intravenously in a single-dose
21820|NCT04018248|Drug|BR101801 (Phase Ia)|Phase Ia (dose escalation):25 mg capsules and 100 mg capsules Planned doses are 50, 100, 200, 325, and 450 mg.
21821|NCT04018248|Drug|BR101801 (Phase Ib)|Phase Ib (dose expansion):25 and 100 mg capsules Doses administered will be determined from Phase Ia data.
21822|NCT04018196|Other|motor imagery as training manual task|They will have a motor imagery as training manual task for 30 minutes. They will have 3 tests for performing manual task before training (pretest) and after training (post-test).
21823|NCT04018196|Other|motor imagery as training motor task|"They will have a motor imagery as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
21824|NCT04018196|Other|emotionally neutral film as training of manual task|"They will have to watch an emotionally neutral as training manual task for 30 minutes before performing this task.~They will have 3 tests for performing manual task before training (pretest) and after training (post-test)."
21825|NCT04018196|Other|emotionally neutral film as training of motor task|"They will have to watch an emotionally neutral as training motor task for 30 minutes before performing this task.~They will have 3 tests for performing motor task before training (pretest) and after training (post-test)."
21826|NCT04018170|Drug|Study drug|oral administration, once daily. The doses will be ascending per cohort from 10 mg to 600 mg
21827|NCT04018170|Drug|Placebo|oral administration, once daily. The matching placebo doses will be ascending per cohort from 1 to 4 tablets
21829|NCT04018144|Diagnostic Test|Gingiva Biopsy Sampling|Gingival samples of healthy individuals were collected by gingivectomy or crown lengthening procedure in the routine treatment protocol or before orthodontically indicated tooth extraction. Gingival samples of periodontitis patients were obtained during the scaling and root planning procedure. Posterior maxillary teeth (#4, #5, #6, and #7) were chosen for gingival sampling.
21830|NCT04018131|Drug|Cimetidine|Antihistamine 2 antagonist
21831|NCT04018131|Drug|Placebos|Placebo drug
21832|NCT04018118|Biological|Biological sample|Additional blood samples for biobanking
21833|NCT04018105|Other|Oral glucose tolerance test (OGTT) with or without metformin|Each participant will have 3 OGTT, one without metformin, one with metformin30 minutes before the test, one with metformin 60 minutes before the test. The order for each test will be randomized.
21834|NCT04018092|Device|Active NIR-PBM|See Experimental arm for description.
21835|NCT04018092|Device|Sham NIR-PBM|See Sham Comparator arm for description.
21836|NCT04018066|Dietary Supplement|GP-SPI|grape polyphenol-soy protein isolate complex (GP-SPI)
21837|NCT04018053|Drug|18F-fluciclovine|18F-fluciclovine is a new radiotracer. This radiotracer targets amino-acid transporters, which are overexpressed in multiple cancers.
21838|NCT04018053|Device|PET/CT|Positron emission tomography/computed tomography (PET/CT) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions.
21839|NCT04018040|Other|Lacto-ovo vegetarian diet|Lacto-ovo vegetarian diet inclusive of dairy and eggs
21847|NCT04017975|Drug|Fluorescite|1 mL of Fluorescite will be diluted into 1L of saline. Up to 5mLs of the 1:1000 diluted solution will be applied topically to the cardiac tissue prior to imaging.
21848|NCT04017975|Device|Cellvizio 100 Series System with Confocal Miniprobes|The microscopy system will image cardiac tissue.
21849|NCT04017962|Drug|Letermovir Pill|Patients enrolled on the study will receive oral LTV 480 mg daily (240 mg daily for patients receiving cyclosporine A). The maximum duration of LTV administration will be 14 weeks.
21850|NCT04017949|Drug|Corticosteroid injection|1 cc (40 mg) of a corticosteroid (kenalog) is given
21851|NCT04017936|Drug|Anakinra|Active Treatment
21852|NCT04017936|Drug|Placebos|Placebo
21853|NCT04017923|Diagnostic Test|measurement of nasal tip support in different age groups.|Nasal tip resistances , were measured in all age groups with a digital Newton meter.
21854|NCT04017910|Device|Implantation of ultrasonic fiduciary|Implantation of a small ultrasonic apparent device at the time of arteriovenous fistula creation.
21855|NCT04017897|Drug|The combination of radiotherapy with anti-PD1 (pembrolizumab or nivolumab)|Subjects with treatment naïve, surgically unresectable metastatic melanoma stages IIIB to IVM1c will be treated with combination of anti-PD1 (pembrolizumab or nivolumab) and radiotherapy.
21856|NCT04017884|Combination Product|Remin Pro Forte|a combination of chemicals with natural products cream .
21857|NCT04017884|Combination Product|Remin Pro|a combination of chemicals
21858|NCT04017871|Other|MRI|MRI at baseline and J90
21859|NCT04017871|Other|Electro-Encephalography-High Density (children with unilateral PC only)|Electro-Encephalography-High Density (children with unilateral PC only) at baseline and J90
21860|NCT04017871|Other|3D and EMG analysis|3D and EMG analysis at baseline and J90
21861|NCT04017871|Other|care and classic activities|physiotherapy and psychomotility. As needed weekly sessions of speech therapist or orthoptist and daily activities of the child.
21862|NCT04017871|Device|Accelerometers|During 5 days a sensor at each wrist to quantify their movement.
21863|NCT04017858|Behavioral|Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).|"Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis"
21864|NCT04017858|Behavioral|Patients will be submitted to total knee replacement.|"Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively"
21865|NCT04017845|Diagnostic Test|FIT|Screenees were supplied with two fecal collection devices and asked to collect two specimens from two consecutive Different Bowel Movement Samples (DBMS) or, in case of infrequent bowel movements, from the Same Bowel Movement Sample (SBMS).Instruction stressed that after collection the device must be stored in refrigerator and transported in an iced pack within no more than 48h from sampling. After checking for sampling appropriateness, the received samples were analyzed by the FOB Gold/SENTiFOB method (Sentinel Diagnostics SpA, Milan, Italy), according to the previously validated procedural platform
21866|NCT04017845|Procedure|Precolonoscopy cleansing regimen|Laxative stimulant two days prior to the cleansing regimen involves the intake of one 10 mg tablet of bisacodyl (Dulcolax, Sanofi,UK) at 18:00 for two consecutive nights.The evening before colonoscopy cleansing started with 2 doses (at 16:00 and 20:00) of one sachet Sodium picosulphate preparations (PICOPREP, Ferring Pharmaceutical Co., Ltd., Zhongshan, China), dissolved in150 mL of cold water, followed with five 240 mL portions of clear liquids within 3 h. The third dose is taken in the morning about 5 h prior to colonoscopy, followed with at least three 240 mL portions of clear liquids no later than 2 h before colonoscopy.
21867|NCT04017845|Procedure|Conventional Colonoscopy|With the colonoscopists completely blinded regarding the FIT results, conventional colonoscopy examinations were conducted in the Endoscopy Unit of Al-Kindy Polyclinic. According to the five levels of competency proposed by the European guidelines, this unit is assigned as level 2, with the possibility of removing polypoid and sessile lesions <25 mm, providing there is good access. For flat lesions, larger sessile and polypoid lesions, and smaller lesions with more difficult access, the lesions were documented appropriately with the patients referred to higher competent units in order to be safely and expertly removed.
21868|NCT04017845|Diagnostic Test|Histopathological examinations of screen-detected lesions|Adenomas were classified according to the modified revised Vienna classification for the European Guidelines. Advanced adenoma was defined as the presence of one of the following features: >10 mm diameter, tubulovillous or villous structure, and high-grade neoplasia. Polypoid adenocarcinomas were reported according to the TNM classification, while colorectal cancer associated with flat and/or depressed lesions were reported as non-polypoid lesions, and further classified by the Paris classification. Pathologic results of hyperplastic polyps, sessile serrated lesions or post inflammatory polyps were considered normal findings.
21869|NCT04017845|Drug|Tribenoside 400 mg + lidocaine 40 mg suppositories|Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
21870|NCT04017845|Drug|Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment|Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
21871|NCT04017832|Drug|Oral semaglutide|Oral semaglutide to be taken every morning in a fasting state, to be followed by sitagliptin placebo after 30 minutes. Only then participants can have their first meal of the day and their pre-study metformin tablets
21872|NCT04017832|Drug|Sitagliptin|Sitagliptin to be taken every morning, 30 minutes after taking the oral semaglutide placebo tablet. Then participants can have their first meal of the day and their pre-study metformin tablets
21873|NCT04017832|Drug|Placebo (oral semaglutide)|Placebo tablet to be taken first thing in the morning
21874|NCT04017832|Drug|Placebo (sitagliptin)|Placebo tablet to be taken 30 minutes after oral semaglutide
21875|NCT04017819|Drug|18F-C-SNAT4|Radiotracer- Dose 10 mCi
21876|NCT04017819|Procedure|Positron emission tomography (PET)/Computed tomography (CT) Scan|Positron emission tomography (PET)/Computed tomography (CT) Scan
21877|NCT04017793|Behavioral|Mindfulness Based Stress Reduction|Structured 8-week training program teaching about increased mindfulness strategies and gentle stretching.
21878|NCT04017793|Behavioral|Relaxation Group|8-weekly group discussion meetings reviewing relaxation techniques and other stress reduction strategies with an emphasis on social support.
21884|NCT04017754|Other|Investigate the association of MBL plasma levels with RPL and perinatal outcome before and after RPL.|A single blood sample at first hospital meeting in the Centre for Recurrent Pregnancy Loss of Western Denmark and a follow up in hospital records for secondary outcome.
21885|NCT04017741|Drug|Combined Depo-Medrone and Lidocaine|"Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.~Patients who no longer receive any benefit will be crossed over to the placebo arm."
21886|NCT04017741|Drug|Sodium Chloride 0.9% Inj|Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
21887|NCT04017728|Device|Conventional Percutaneous Vertebroplasty|The cement is injected into the bone metastases directly.
21888|NCT04017728|Device|Percutaneous Vertebroplasty with Rotary Cutter|The rotary cutter is applied before the cement injection. Then, the cement is injected with lower pressure.
21889|NCT04017715|Other|Experimental: warm up|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
21890|NCT04017715|Other|Experimental: cool down|"Phase 1 is dynamic stretching and running exercises which includes, A jogging ,B walking lunge and sweeps, C hip in and out running : jog 3 steps stop and do hip in/hip out for Phase 2 is strength and agility which includes A- squat, B- push-ups: wide palmer push-ups. C vertical jumps. D- lateral jump. E- nordic hamstrings,. F (a)- shoulder external rotations, F(b)- modified inverted rows, Phase 3 is balance and core strength which includes A- modified ankle discs, B - planks: standard forward planks 2 repetitions for 30secs. C- side planks: standard side planks on both sides 1 repetition for 20 secs. Da- bird-dog,Db- modified back extensions, Phase 4 is run sprint which includes A- run sprint: 100% speed running between running (20m) with 1 repetition"
21891|NCT04017715|Other|No intervention: control|sprint exercise and general stretching as conventional protocol as follows in star club
21892|NCT04017702|Device|Expiron respirator|Respiratory volume monitor (RVM) (ExSpiron, is a non-invasive FDA approved device that monitors minute ventilation (MV) and provides an early indication of respiratory status in non-intubated patients. The system consists of a lightweight monitor, a patient cable, and a disposable electrode PadSet, which detects changes in breathing.
21893|NCT04017676|Other|Supervision assissted by measures|In the weeks 10 and 13, about 72 hours after the meeting scheduled for that week, and before the next therapeutic session, there will be a structured training session (based on the recommendations of Krägeloh et al., 2015), based on information in the literature about the various questionnaires
21894|NCT04017663|Other|Application of questionnaires|Application of questionnaires to identify characteristics and main barriers of patients
21895|NCT04017650|Biological|Cetuximab|Given IV
21896|NCT04017650|Drug|Encorafenib|Given PO
21897|NCT04017650|Biological|Nivolumab|Given IV
21898|NCT04017637|Behavioral|Resistance Training|Static resistance training including two arm and two leg movements will be performed twice per week for 12 weeks.
21899|NCT04017624|Other|Fresh Truck with stipend|"Linkage to Community Partner Organization~Investigators will partner with a community organization, Fresh Truck, that deploys mobile fresh produce trucks throughout Boston neighborhoods. Participants randomized to the intervention arm will receive a monthly stipend of $80 to purchase fresh produce available at any Fresh Truck mobile market location."
21900|NCT04017624|Other|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
21901|NCT04017598|Dietary Supplement|Ferrous sulfate|60 mg elemental iron as ferrous sulfate
21902|NCT04017598|Dietary Supplement|Ferrous Bisglycinate|18 mg elemental iron as ferrous bisglycinate
21903|NCT04017598|Dietary Supplement|Placebo of microcrystalline cellulose|placebo
21904|NCT04017585|Dietary Supplement|diet containing gluten|placebo or gluten will be added for 7 days to the low FODMAP/gluten free diet diet. After 1 week of wash-out, patients will switch (cross-over) to gluten or placebo for another 7 days
21905|NCT04017585|Dietary Supplement|Placebo|Placebo
21906|NCT04017572|Procedure|Automated peritoneal dialysis (APD)|Automated peritoneal dialysis (APD) using the Baxter HomeChoice Pro Cycler.
21907|NCT04017559|Behavioral|Motivational Interviewing|A pharmacist trained in MI delivered three recorded MI sessions over 2 months, with follow up at 3, 4 and 6 months.
21908|NCT04017546|Drug|CYC065|intravenous infusion
21909|NCT04017546|Drug|Venetoclax|oral capsule
21910|NCT04017533|Procedure|GMK Sphere TKR|Se earlier
21911|NCT04017507|Device|Oscillating-rotating electric toothbrush|Oscillating-rotating electric toothbrush used twice daily
21912|NCT04017507|Device|Side-to-side electric toothbrush|Side-to-side electric toothbrush used twice daily
21913|NCT04017507|Device|Manual toothbrush|Manual toothbrush used twice daily
21914|NCT04017494|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
21915|NCT04017494|Diagnostic Test|Blood draw for hematocrit and heart failure biomarkers|Approximately 10 ml of blood will be drawn before administration of contrast medium.
21916|NCT04017494|Diagnostic Test|Cardiopulmonary exercise test|In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
21917|NCT04017494|Diagnostic Test|Exhalomics|Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
21918|NCT04017494|Diagnostic Test|Quality of life questionnaire|Questionnaire to be filled out by the Patient regarding quality of life perception
21919|NCT04017481|Other|Repetitive transcranial magnetic stimulation (rTMS)|The intervention intends to change the cortical plasticity in specific cortical areas. rTMS is a non-invasive exogenous neuromodulation technique that uses repetitive magnetic pulses administered in a specific area of the head in order to influence the connectivity of the underlying brain area.
21920|NCT04017481|Other|EEG guided Neurofeedback (NFB)|The intervention intends to change the cortical plasticity in specific cortical areas. The NFB is a non-invasive endogenous technique that seeks the self-regulation of cortical activity through the information represented in a videogame which is used to interact with the subject.
21921|NCT04017468|Drug|Vancomycin|Patients randomized into the treatment arm will receive 1-2 g of vancomycin powder (Vancocin® i.v.) which will be administered above the closed muscle fascia (suprafascially) before closing the subcutaneous tissue and skin. The dose of the drug will depend on the length of the skin incision: 1 g for incisions ≤ 20 cm, 2 g for incisions ≥ 20 cm.
21922|NCT04017455|Drug|Atezolizumab|3 cycles of atezolizumab 840 mg
21923|NCT04017455|Drug|Bevacizumab|3 cycles of bevacizumab 5mg/kg
21924|NCT04017442|Drug|Preservative Free Morphine|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
21925|NCT04017442|Drug|Saline|After delivery of the baby patients will receive via the epidural catheter prior to its removal.
21926|NCT04017429|Procedure|Open flap debridement with osteoplasty|Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the tooth.
21927|NCT04017429|Procedure|Open flap debridement without osteoplasty|Treatment of furcation grade III defect with open flap debridement only.
21928|NCT04017416|Behavioral|I-PLAN|The I-PLAN is a behaviour change intervention that consists of; information on consequences of hearing aid use/non-use, reminder prompt and behavioural plan to promote hearing aid use.
21929|NCT04017403|Drug|Bifidobacterium triple live capsule|Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
21930|NCT04017403|Drug|Placebos|Placebos were administrated as same as the bifidobacterium live capsule
21931|NCT04017390|Drug|Theraworx Foam|Apply Theraworx Foam alone
21932|NCT04017390|Drug|Placebo Foam|Apply placebo foam alone
21933|NCT04017390|Other|Theraworx Foam and night splint|Apply Theraworx Foam and night time splint
21934|NCT04017390|Other|Placebo Foam and night time splint|Apply placebo foam and night time splint
21935|NCT04017377|Drug|Drug: Cisplatin; nab-paclitaxel|Drug: Paclitaxel for Injection（Albumin Bound). Other Name: Ke ai li, ZhusheyongZishanchun(Baidanbai Jiehexing)
21936|NCT04017364|Device|PCB PTCA|Predilatation of coronary de-novo stenosis followed by a PCB
21937|NCT04017364|Device|SCB PTCA|Predilatation of coronary de-novo stenosis followed by a SCB
21938|NCT04017351|Other|Artificial Intelligence Virtual Assistant|Virtual assistance application for subjects to ask questions and get information regarding planned surgery
44009|NCT03839771|Drug|AG-120|250mg tablets
21939|NCT04017338|Drug|Glecaprevir 300 MG / Pibrentasvir 120 MG Oral Tablet|A potent and effective antiviral medication that has recently been approved for use in Canada with over 99% cure rates.
21940|NCT04017338|Drug|Ezetimibe 10Mg Oral Tablet|A cholesterol-lowering medication that also blocks entry of HCV into liver cells.
21941|NCT04017338|Device|Ex Vivo Lung Perfusion|A technology that allows for the assessment and treatment of lungs prior to transplant.
21942|NCT04017325|Other|no intervention (post study follow up)|No intervention (post study follow up)
21943|NCT04017312|Device|High Frequency Chest Wall Oscillation|High frequency chest wall oscillation (HFCWO) therapy (also known as high-frequency chest-wall compression or HFCWC) is commonly prescribed to provide routine airway clearance in patients with bronchiectasis as well as other patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow. This airflow is thought to mobilize secretions by the sheer force created, effecting changes in rheology and moving mucus in a cephalad direction during the oscillation. The Vest® Airway Clearance System, a commonly used device, generates HFCWO using an air pulse generator and an inflatable garment that delivers pressure pulses to the thorax. These pressure pulses within the garment create HFCWO.
21944|NCT04017312|Device|Oscillating Positive Expiratory Pressure (OPEP)|Oscillating PEP is an airway clearance technique, where the person blows all the way out many times through a device. These types of oscillating PEP devices work in two ways. Firstly, they use resistance to make it more difficult during the breath out, like non-oscillating PEP devices. Oscillating PEP devices also create vibrations when breathing out. The vibrations move mucus from the surface of the airways. After blowing through the device several times, the person will huff and cough to clear the mucus from the lungs.
21945|NCT04017299|Other|CHOISIR|Every patient will evaluate each device after 15 minutes of distraction once or twice a day according to the patient's wishes.
21946|NCT04017260|Procedure|open and closed approach|"The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.~Group A:The wound was closed with 0 polypropylene u-shaped sutures ."
21947|NCT04017260|Procedure|Rhomboid flap technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Rhomboid flap technique: involve closure of the defect after excision of all sinuses with Rhomboid flap of skin and subcutaneous tissue
21948|NCT04017260|Procedure|Karydakis technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.the long axis of the ellipse is parallel to the midline and 2cm from it.undercutting incision is made along the whole length 1cm below the skin surface then unrolling the flap over the midline.
21949|NCT04017260|Procedure|open technique|The patients were hospitalized, and the site of the operation was shaved on the day of the surgery. All Patients were operated on under spinal anesthesia. Antibiotic was administered to all patients as prophylaxis 60 minutes prior to the surgery. An adhesive tape was used to part the buttocks. The patients were placed in the jack-knife position. (Fig. 1). Methylene blue was injected without pressure through the external opening to delineate the sinus. The operation site was cleaned with 10% povidone-iodine. All sinus tracts were resected en bloc via elliptical incision down to presacral fascia with meticulous hemostasis.Open procedure involved a wide excision of the pilonidal sinus tract and healing by secondary intention.
21950|NCT04017247|Drug|Oxytocin|Intermittent oxytocin Infusion
21951|NCT04017247|Drug|Oxytocin|Continous oxytocin Infusion
21952|NCT04017234|Other|frequency following response, eye exercise, and transcutaneous|frequency following response, eye exercise, and TENS for 3 times per week during 4 weeks
21953|NCT04017221|Drug|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Current exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor (canagliflozin, dapagliflozin, empagliflozin) alone or in combination with other antidiabetic drugs, excluding DPP-4 inhibitors and insulin.
21954|NCT04017221|Drug|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Current exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with other antidiabetic drugs, excluding SGLT2 inhibitors and insulin.
21955|NCT04017221|Drug|Other treatment combinations|Current exposure to other treatment combinations will be defined as a prescription of other antidiabetic drugs (metformin, sulfonylureas, thiazolidinediones, GLP-1 receptor agonists, alpha-glucosidase inhibitors, meglitinides, insulin, or combinations of these drugs), current use of insulin (alone or combination with other antidiabetic drugs), and non-current use of antidiabetic drugs.
21956|NCT04017208|Drug|ASP2713|Administered intravenously
21957|NCT04017208|Drug|placebo|Administered intravenously
21958|NCT04017195|Drug|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
21959|NCT04017195|Drug|High molecular weight polyisobutylene (HMW PIB) patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch will be applied to the buttock (right or left) of participants on Day 1 of each Treatment period and is removed 7 days after patch application, that is, on Day 8.
21961|NCT04017156|Procedure|implant installation|All site preparations will be performed deeper compared to the length of the implant so that the implant apex cannot reach the bottom of the osteotomy.
21962|NCT04017143|Behavioral|HPV app intervention|Participants assigned to this group will receive an HPV app that targets a dyad of parent and a teen boy or girl.
21963|NCT04017130|Drug|TAK-169|TAK-169 intravenous infusion.
21964|NCT04017117|Procedure|under local anasthesia,Ridge Augmention of posterior atrophic mandible by using mix of autogenous bone graft and bone substitutes is used under PEEK mesh|comparing between PEEK mesh and Titanium mesh for augmentation of posterior atrophic mandible using mix of autogenous bone graft and bone substitute.
21965|NCT04017104|Diagnostic Test|18F-FDG PET/CT|"For 18F-FDG as fasting period of 6 hours is required before the scan. Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.The participant will rest in a comfortable chair for 20 minutes. The participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. The participant will then be taken to the PET/CT scanner.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
21966|NCT04017104|Diagnostic Test|68Ga-DOTATOC PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for up to 90 minutes. There are no dietary restrictions. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. A CT topogram will be acquired followed by very low dose whole body CT for attenuation correction and localization of PET emission data. The participant will receive a bolus intravenous dose of the radiotracer 68Ga-DOTATOC from an approved study supplier site. Simultaneously a 6 minute dynamic acquisition of the heart will be started, then followed by several whole body static acquisitions. After the DWB scan, participants may go to the washroom again and their vital signs will be recorded. After this, a new PET/CT acquisition, as specified in the 68Ga-DOTATOC PET/CT protocol, will immediately follow.
21967|NCT04017104|Diagnostic Test|18F-DCFPyL PET/CT|Participants will not be encouraged to drink additional water due to the requirement to stay on the scanner for 90 minutes of the DWB acquisition. They will be unable to use the washroom during this time. As with the main study, participants will be instructed to fast for 4 hours prior to their appointment. Each study subject will have an intravenous catheter inserted. The participants will then be taken to a designated washroom and asked to void, and will then be taken to the PET/CT scanner. The participant will receive a bolus intravenous dose of 18F-DCFPyL from an approved supplier. This will then be followed by several whole body static acquisitions for a total scan time that will not be longer than 90 minutes. After the scan is finished, the participant will be allowed to rest in a comfortable chair or bed for 30 minutes. The participants will return to the scanner room and undergo the planned PET/CT imaging described in the main study.
21968|NCT04017091|Diagnostic Test|Virtual Reality Cognitive Training|Bimodal VR-Stroop (ClinicaVR: Apartment Stroop) Patient find themselves seated with a virtual apartment, where they see a living room, in front of a flat-screen TV set, a kitchen and a window. This intervention consisted of two Stroop conditions across all 8 sessions. In Condition 1 (Inhibition), Patients indicated when the color named (audio stimulus) matched the color shown (visual stimulus). Participants were to withhold their response in mismatched trials. In Condition 2 (Interference), Participants clicked the mouse when the color heard was the same as the ink color; not the word printed.
21969|NCT04017078|Other|diagnosis of carotid artery calcification on digital panoramic radiograph|Suspected carotid arty calcifications findings were defined as one or more radiopaque mass adjacent to the cervical vertebrae at or below the intervertebral space between C3 and C4 on the DPR.
21970|NCT04017065|Device|DePuy Synthes MAXFRAMETM system|Patients treated with the MAXFRAMETM system will be followed up from before the surgery until the removal of the device. All treatments are based on individual clinician's judgement and the patient characteristics. The registry does not dictate any specific treatment.
21971|NCT04017052|Drug|FSME-IMMUN Vaccine|Booster with TBE vaccine (i.m.) FSME Immun
21972|NCT04017039|Other|Targeted Sleep Intervention|
21973|NCT04017026|Device|Implantation|Implantation of 6 mm short implants
21974|NCT04017013|Procedure|Epidural Analgesia|"The epidural infusion will be as follows:~Isobaric Bupivacaine 0.5% 40 cc~Morphine 4 mg (1 ampoule up to 10 cc and 4 cc of the mixture will be applied)~Saline solution 0.9% 156 cc.~Total Volume: 200 cc.~This mixture will be prepared by a nurse outside the research group outside the operating room once indicated.~The infusion will be scheduled at 7 cc / hour per continuous infusion set and will be connected to the epidural catheter after its placement."
21975|NCT04017013|Drug|Lidocaine Infusion|2% Lidocaine IV without epinephrine: 1 mg/kg/ hour for up to 24 hours, started immediately after anesthetic induction.
21976|NCT04017000|Diagnostic Test|Bladder Shape Test|Capturing images of bladder under natural filling conditions images are analysed at a later date for shape change.
21977|NCT04017000|Other|Calibration images|Capturing images of bladder under artificial filling conditions during Urodynamic assessment images are analysed at a later date to inform shape change technology.
21978|NCT04016987|Behavioral|Automated structured education intervention based on an app and artificial intelligence|In the 24-week intervention period, the experimental group receives automated push notifications supported by artificial intelligent algorithm.
21979|NCT04016974|Drug|Oral semaglutide|Semaglutide tablets once daily as follows: 3 mg for the first treatment period (day 1-28), followed by 7 mg in the second treatment period (day 29-56), followed by 14 mg in the third treatment period (day 57-84)
21980|NCT04016974|Drug|Placebo|Placebo tablets once daily throughout the treatment period (day 1 to 84)
21981|NCT04016961|Other|AAT - Dog|therapy dog added to inpatient PT and OT session
21982|NCT04016961|Other|TAU - No Dog|PT and OT as usual without the addition of therapy dog
21983|NCT04016948|Device|Probe-based confocal laser endomicroscopy optical biopsy|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
44010|NCT03839771|Drug|Placebo for AG-120|250mg tablets
21984|NCT04016948|Device|Intra-operative frozen section|In the pCLE group, after intravenous injection of fluorescein, the optical biopsy will be performed, using a confocal miniprobe, to exam the rectal mucosa when the rectum transection is ready. The raters will analyse the CLE images to determine whether the distal margin is positive. In the IFS group, intra-operative frozen section will be performed at the site of distal margin after the rectum transection.
21985|NCT04016922|Other|Oral ferrous fumerate for Group A, Parenteral iron sucrose for Group B, Compatible blood transfusion for Group C|"Consent, history. US: fetal heart activity, placental site, fetal biometry, AFI, anomalies, Doppler: umbilical artery, MCA, fetal renal artery, C\U ratio.~* Maternal Hb,US at time of first visit, 10 days later after initiation of treatment, at EDD .~As part of routine medical care of these patients, they are managed as:~A: give oral iron in the form of ferrous fumerate with the possible side effects. if Hb returns to normal, continue iron for 3 mon.~B: admit to receive IV iron sucrose according to product literature allergic reaction may happen; antiallergic measures. C: give blood transfusion in the form of packed RBC. allergic and pyrogenic reaction and infection may occur. At delivery will be subjected to: examination, investigations, US."
21986|NCT04016909|Procedure|aerobic exercise plus calorie restriction|both a 6-month aerobic exercise program (moderate intensity) and caloric restriction (12.5% energy deficit)
21987|NCT04016896|Behavioral|WIdowed Elders' LIfestyle after Loss (WELL)|Digital monitoring; motivational health coaching; personalized feedback
21988|NCT04016896|Other|Enhanced Usual Care|psychoeducation plus study assessments controlling for time and attention
21989|NCT04016883|Other|Problem Solving Therapy offered through a web platform|Problem Solving Therapy offered through a web platform. There will be four sessions, during the first four weeks of treatment, and subsequent sessions are dedicated to refining problem-solving skills. Participants set treatment goals; different ways to reach goals are discussed and evaluated; action plans are created, and its effectiveness is evaluated to achieve the objectives. Participants are expected to implement plans and apply the problem-solving model to additional problems between sessions. In the last two sessions, participants create a relapse prevention plan using the problem-solving therapy model
21990|NCT04016883|Other|Conventional web platform|The conventional web platform, which will contain the general content on stress coping techniques.
21991|NCT04016870|Device|Reconditioned Pacemaker|Devices from the three manufacturers below will be used.
21992|NCT04016870|Device|New Pacemaker|Devices from the four manufacturers below will be used.
21993|NCT04016857|Procedure|RIPC|4 cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of arm cuff
21994|NCT04016857|Procedure|Control|deflated cuff placed on the left arm for 40 min
21995|NCT04016844|Device|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
21996|NCT04016844|Device|SHAM|In the sham condition, the participants will receive the initial 30 seconds of stimulation, after which the current will be set to 0. The same tDCS device (Soterix) will be used.
21997|NCT04016831|Behavioral|Mapping Enhanced Counseling (MEC)|a motivational enhancement clinical intervention derived from cognitive-behavioral models that addresses problem recognition, treatment motivation, thoughtful and objective decision making, and therapeutic engagement
21998|NCT04016831|Other|Mapping Approaches to Prepare for Implementation Transfer (MAP-IT)|an implementation intervention to explore and address agency preparation needs in order to promote implementation success
21999|NCT04016818|Drug|18F-FDG|Participant will be injected IV (intravenously) with 10 ± 2 mCi of 18F-FDG.
22000|NCT04016818|Device|Breast-dedicated PET camera|Breast-dedicated PET camera designed by Stanford satellite radiochemistry facility
22001|NCT04016805|Drug|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody~administered as an IV infusion"
22002|NCT04016805|Drug|Umbralisib|"Phosphoinositide-3-kinase (PI3K) delta inhibitor~Tablet form, to taken orally on a daily basis"
22003|NCT04016805|Drug|Ibrutinib|"Bruton Tyrosine Kinase (BTK) inhibitor~Tablet form, to taken orally on a daily basis"
22004|NCT04016805|Drug|Venetoclax|"BCL-2 inhibitor~Tablet form, to be taken orally"
22005|NCT04016792|Drug|Placebo|Placebo will be administered once daily
22006|NCT04016792|Drug|200 mg SPN-812|200 mg SPN-812 will be administered once daily and compared to Placebo
22007|NCT04016779|Drug|Placebo|Placebo will be administered once daily
22008|NCT04016779|Drug|200-600 mg SPN-812|200-600 mg SPN-812 will be administered once daily and compared to Placebo
22009|NCT04016766|Behavioral|Mobile app prepartying intervention|The intervention is comprised of a theoretically-informed and empirically-supported, brief, accessible, and personalized intervention to address prepartying drinking. the prepartying intervention app will be tailored toward an individual's personal goals, beliefs (perceptions, expectancies, self-efficacy), and behavior (protective strategies), and focus on the core components of brief interventions that have been cited as constructs that mediate the effects of multiple component intervention programs (e.g., correcting perceived norms, use of protective behavioral strategies, increased self-efficacy, challenging expectancies, feedback on blood alcohol level).
22010|NCT04016753|Drug|BMS-986256|30 mg(6ml)
22011|NCT04016753|Drug|Loestrin|1.5 mg Norethindrone and 30ug ethinyl estradiol
22012|NCT04016740|Drug|Ropivacaine|Intraoperative bilateral PIFB block with 20 mL of 0.25% Ropivicaine on either side of the sternum after anesthetic induction but before surgical incision
22013|NCT04016740|Drug|Ketamine|Intraoperative infusion
22014|NCT04016740|Drug|Remifentanil|Intraoperative infusion
22015|NCT04016740|Drug|Dexmedetomidine|Intraoperative infusion
22016|NCT04016740|Drug|Rocuronium|Intraoperative intermittent bolus
22017|NCT04016740|Drug|Propofol|Intraoperative infusion
22018|NCT04016740|Drug|Sevoflurane|Intraoperative inhaled as needed
22019|NCT04016740|Drug|Dexmedetomidine|Post-operative infusion
22020|NCT04016740|Drug|Propofol|Post-operative infusion
22021|NCT04016740|Device|EEG monitoring|Perioperative monitoring
22175|NCT04015414|Drug|Cytisine|190 patients will receive cytisine for 25 days and regular phone calls with brief counseling
22022|NCT04016727|Biological|platelet rich plasma|Platelet rich plasma was prepared using patients own blood. 60 units of PRP was injected on one side of the arch using insulin syringe. Each patient served as his/her own control (the side with PRP injected) and experimental group (the side without PRP injected). Whether the right or left side served as control or experimental was determined by lottery method. Patients were recalled after 4 weeks and the measurements were repeated again between lateral incisors and canines at mid, cervical and incisal of the teeth and their mean was recorded.
22023|NCT04016714|Drug|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, serotype 6B and aluminum phosphate adjuvant in each 0.5 mL dose.
22024|NCT04016714|Drug|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
22025|NCT04016714|Drug|Vaxelis™|Intramuscular 0.5 mL single dose
22026|NCT04016714|Drug|M-M-R®II|Subcutaneous 0.5 mL single dose
22027|NCT04016714|Drug|Varivax®|Subcutaneous 0.5 mL single dose
22028|NCT04016701|Device|Floreo Joint Attention Module|Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long
22029|NCT04016701|Behavioral|Regularly Scheduled Therapy|therapy as regularly scheduled at therapy center
22030|NCT04016688|Procedure|ESPB and TAP block|"bilateral TAP block: while the patient in the supine position, a linear ultrasound (US) transducer (Phillips Saronno Italy) is placed transversally on the anterolateral abdominal wall in the midaxillary line between the iliac crest and the costal margin identifying external oblique, internal oblique and transversus abdominis muscles. The TAP is between internal oblique and transversus abdominis.~A 22-G needle (spinocan, B.Braun, melsungen AG, Germany) is introduced anteriorly to the transducer and advanced to reach the TAP between internal oblique muscle and transversus abdominis muscle. After careful aspiration to exclude vascular puncture, 20 ml 0.5 % bupivacaine is injected causing an elliptical separation of the two muscles. The same procedure is done on the other side."
22031|NCT04016675|Other|Neoadjuvant Radiotherapy/Chemoradiotherapy Followed by Surgery|After assigned into the study group, subjects will be conducted with incisional biopsy. Based on the tumor type and tumor stage, subjects will be conducted with neoadjuvant radiotherapy/chemoradiotherapy followed by radical surgery and simultaneous orbital reconstruction. After surgery, adjuvant chemotherapy will be determined based on the tumor histology, local tumor invasiveness, proximity of the surgical margins from the tumor, and pronouncement of tumor margins on permanent section tissue review.
22032|NCT04016675|Other|Surgery Followed by Adjuvant Radiotherapy/Chemoradiotherapy|After assignment into the control group, subjects will receive radical surgery without simultaneous orbital reconstruction. Adjuvant radiotherapy / chemoradiotherapy will initiate within two weeks after surgery. Both the radiotherapy and chemoradiotherapy should be comparable between the study group and the control group when tumor characteristics in these two groups are identical.
22033|NCT04016662|Device|Dexcom G6 CGM|"The system components include the t:slim X2 with Control-IQ Technology and the Dexcom CGM G6. The modular control algorithm has a safety supervision module that limits insulin delivery to prevent hypoglycemia at all times. The algorithm gradually decreases hyperglycemia from bedtime to reach a target of 120 mg/dL by waking time. During awake hours, the control algorithm attempts to maintain glucose within a target range (112.5 to 160 mg/dL) with meal time insulin boluses delivered based on usual bolus procedures undertaken by patients on an insulin pump (Hybrid closed loop).~The system components include the t:slim X2 with with Basal-IQ Technology and the Dexcom CGM G6. The PLGS System is able to stop and resume basal insulin delivery automatically in response to predicted or low sensor glucose values, thereby reducing the incidence and duration of hypoglycemic episodes. The pump includes the hypoglycemia minimization strategy that will issue insulin delivery commands."
22034|NCT04016636|Other|Standard of Care|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
22035|NCT04016623|Device|1-day toric test contact lens|somofilcon A 1-day toric test contact lens
22036|NCT04016623|Device|1-day toric control contact lens|somofilcon A 1-day toric control contact lens
22037|NCT04016610|Device|Soliton's Acoustic Scar Reduction (SAR)|Treatment of keloid scars for the temporary improvement in appearance.
22038|NCT04016597|Device|Jaeger Masterscreen TM|Single-breath nitric oxide lung diffusing capacity
22039|NCT04016597|Device|HypAir Medisoft|Single-breath nitric oxide lung diffusing capacity
22040|NCT04016584|Behavioral|Diabetes Pueblo|These adults will receive diabetes education, the Diabetes Pueblo Program, and will complete Curriculum (A), Diabetes Fundamentals, and Curriculum (B), Insulin Success.
22041|NCT04016558|Behavioral|StreamLine|"StreamLine is an education/disease management program that focuses on systematic methods to identify and resolve specific blood glucose problems, primarily through changes in carbohydrate consumption, and use of basal and bolus insulin. Participants will attend a brief, four-hour meeting with a Certified Diabetes Educator (CDE) and, using standardized blood glucose data, will learn how to employ a five-point blood glucose management system to identify and resolve blood glucose problems (e.g., excursions, lows) that have the greatest HbA1c or hypoglycemic impacts.~Participants will then meet individually (30 minutes) with their CDE to review their blood glucose data, identify a specific blood glucose problem, and use the five-point program to create a plan to address the problem. Four additional individual meetings (30 minutes) will occur at approximately two to three-week intervals to best support individualized and participant-tailored management-change efforts."
22042|NCT04016558|Behavioral|TunedIn|"TunedIn utilizes emotion regulation-based strategies to help participants observe that how they feel affects what they do regarding diabetes management. Participants will attend two highly interactive group workshops (6 hours followed by 2 hours) facilitated by a psychologist or social worker experienced in diabetes. Each will identify and discuss common emotional responses related to blood glucose management (e.g., over-reacting, avoiding, and lack of mindfulness).~Between the two workshops (two weeks), participants will complete a feeling log to document feelings, situation/context, and resolution around specific management events. Two individual meetings with the interventionist (30 minutes) will allow participants to identify and address a specific diabetes distress-related problem. Four web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
22043|NCT04016558|Behavioral|FixIt|"FixIt combines components of StreamLine and TunedIn to allow participants to explore feelings and expectations alongside the identification of problematic blood glucose patterns. StreamLine will be co-facilitated by a psychologist/social worker experienced in diabetes and a CDE. Participants will attend two group workshops (six hours followed by four hours), separated by two weeks.~Between the two workshops, participants will record their blood glucose data and keep a parallel feeling log to provide context. Four individual meetings with an interventionist (30 minutes) will allow participants to identify and address a specific blood glucose problem and create a plan to address it. Full discussion of diabetes distress-related aspects of the plan will take place to enhance mindfulness and identify typical emotion regulation strategies to ease problem resolution. Three web-based video group meetings (60 minutes, monthly) will continue to support participants over time."
22044|NCT04016545|Device|Low profile endoprothesis (Navion Medtronic, NBS Low Profile Bolton Terumo)|Aortic aneurysm exclusion through endovascular procedure
22045|NCT04016532|Dietary Supplement|Personalized dietary management at home|"Personalized dietary management at home to improve nutritional status.~Four (J7, J30, J60 and J90 for non-undernutrition patients) or five Home visits (J7, J15, J30 and J90 for undernutrition patients or at risk of undernutrition) by professional dietitians from Saveurs & Vie over a period of 3 months after discharge from the hospital: personalized dietary advice and recipe sheet.~There will be no change in medical prescriptions"
22046|NCT04016519|Other|Gastrostomie|"Gastrostomy involves creating an opening between the skin and the stomach. It allows the administration of nutrition solutes or food directly into the stomach without passing through the mouth and esophagus. It is a method widely used since the 1980s for enteral nutrition.~In the field of pediatrics, gastrostomy is considered in chronic diseases when enteral nutrition is necessary in the long term."
22047|NCT04016506|Other|nutritional questionnaire|nutritional questionnaire is given to the patient after the injury
22048|NCT04016493|Procedure|Connective tissue graft|The patient received 600 mg of ibuprofen (paracetamol 1 g in case of allergy) prior to surgery, and chlorhexidine mouthwash 0.2% was provided for 2 min. Patients received local anaesthesia at the donor and recession sites (articaine hydrochloride 7200 mg/1.8 ml, adrenalin 1800 mcg/1.8 ml). CTG harvesting was performed prior to the preparation of the reception site to avoid any bias. The graft dimension was calculated according to the recession dimensions; a minimum of 3 mm of the graft was submerged mesially, distally and apically. The CTG was harvested from the palate with single edge incision and sutured with 4.0 silk. The patient was subsequently assigned randomly to the control (CAF+CTG) or the test group (TUN+CTG).
22049|NCT04016480|Device|High Flow Nasal Cannula|High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%
22050|NCT04016480|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy will be administered through nasal cannula with a oxygen flow set to achieve a peripheral oxygen saturation equal or greater than 94%
22051|NCT04016467|Other|Thoracic manipulation|High velocity, small amplitude thrust treatment to spine that elicits a neurophysiologic response.
22052|NCT04016467|Other|Sham thoracic treatment|Hand placement on thorax without thrust.
22053|NCT04016454|Procedure|Intervention|There will be one complete handover
22054|NCT04016441|Other|Survey|Participants will complete a survey online
22055|NCT04016428|Behavioral|OPTIMISM|Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.
22056|NCT04016428|Behavioral|Sleep Education|Six-week online program that provides education on sleep during pregnancy.
22057|NCT04016415|Behavioral|Mindfulness Based Stress Reduction|Subjects randomized to Mindfulness-Based Stress Reduction (MBSR) will receive the 8-week University of Massachusetts Authorized MBSR curriculum followed by monthly mindfulness boosters in Months 3 to 6. The University of Massachusetts MBSR curriculum was selected for the intervention, as it is the most standardized and researched mindfulness program that has been shown to reduce psychological distress in various patient populations.
22058|NCT04016415|Behavioral|Stress Management Education|Subjects randomized to Stress Management Education (SME) will receive health education on nutrition (adapted for the type 2 diabetes population), exercise as gentle stretching to match yoga in MBSR, and other general health topics that may be relevant to the type 2 diabetes population such as sleep, time management, etc. Stress Management Education does not have any mindfulness in it. Stress Management Education was specifically created as a control condition for MBSR studies so it matches MBSR for time, social support, homework, etc.
22059|NCT04016402|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Clinical transcranial magnetic stimulation administered as part of usual care for the study population
22060|NCT04016389|Drug|Cisplatin|Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
22061|NCT04016389|Drug|Carboplatin|Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.
22062|NCT04016389|Drug|Paclitaxel|Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.
22063|NCT04016389|Procedure|Trachelectomy|Surgery to remove the cervix but keep the uterus intact.
22064|NCT04016376|Drug|PVB Protocol|Patient will be placed in the prone, lateral, or sitting position. With an ultrasound probe placed in the parasagittal or transverse position, the paravertebral space will be identified. Injections will be done in an in-plane manner relative to the ultrasound probe. Local anesthesia will be injected to cover T1-T6 dermatomes.
22065|NCT04016376|Drug|PECS-1|For PECS-1, the patient will be placed in the supine position with an ultrasound probe placed inferolaterally starting at the mid-clavicular level the pectoralis major and minor will be identified. Injection of local anesthesia will be performed between the pectoralis major and minor
22066|NCT04016376|Drug|Serratus|For the serratus block, the patient will be placed in the supine or lateral decubitus position and with an ultrasound probe, in the parasagittal plane, the serratus muscles will be identified. Injections will be done in-plane below the serratus anterior.
22067|NCT04016363|Other|ProbeFix|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
22068|NCT04016363|Other|Manual hold|ProbeFix vs. manual hold of the ultrasound probe during pharmacological stress-echocardiography examinations
22218|NCT04015024|Drug|SKLB1028 300mg qd|300mg oral administration once a day
22069|NCT04016350|Behavioral|Exercise training with Inulin Propionate Ester|Supervised moderate intensity exercise training combined with Inulin Propionate Ester supplementation conducted for 4 weeks.
22070|NCT04016350|Behavioral|Exercise training with placebo|Supervised moderate intensity exercise training combined with placebo conducted for 4 weeks
22071|NCT04016337|Dietary Supplement|Beverages|The beverages were all made with lemon and maqui extracts, and different sweeteners
22072|NCT04016324|Device|InterStim Basic Evaluation lead and foramen needle|Commercial devices within their intended use as described in approved Instructions for Use.
22073|NCT04016311|Behavioral|Mindful Drinking/Eating Intervention|Participants will be individually guided during their dialysis session through: 1) a mindful drinking exercise, a meditation focused on the sensory experience of 3 sips of fluid, along with a discussion of the experience; and 2) a mindful eating exercise with select foods that are recommended for controlling thirst (i.e., hard candy, frozen fruits). Participants will be given directions for mindful drinking/eating and asked to practice mindful drinking/eating as often as possible but least once each day.
22074|NCT04016285|Device|Aquamantys|The Aquamantys bipolar sealer is a device used during surgery to help reduce bleeding in the joint. The system uses radiofrequency energy and sterile saline (salt water) to close small blood vessels in the knee to help reduce bleeding.
22075|NCT04016285|Device|Tourniquet|Standard of care for reducing bleeding during the total knee arthroplasty
22076|NCT04016272|Device|Active tDCS|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY) with headgear and saline-soaked surface sponge electrodes.
22077|NCT04016272|Device|Sham tDCS|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
22078|NCT04016259|Device|Cranial Electrical Stimulation (CES)|CES will be applied for 60 minutes per session daily for 2 weeks (Monday to Friday) via the Alpha-Stim M Electromedical Products International, Inc., Mineral Wells, TX).
22079|NCT04016259|Device|Sham-CES|For sham CES, the electrodes will be identical look and be placed in the same positions as for active stimulation, but the stimulator will not deliver electrical current.
22080|NCT04016246|Drug|Propofol-Lipuro|sedation of babies < 32wGA with propofol / placebo before a LISA Procedure
22081|NCT04016246|Drug|Placebos|injected to babies < 32wGA with propofol / placebo before a LISA Procedure
22082|NCT04016233|Drug|Tenofovir douche|660 mg TFV in 125 mL hypo-osmolar solution
22083|NCT04016220|Drug|Budesonide|first nebulization of 0.5 mg of budesonide in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 0.5 mg of budesonide at 20, 40, 60 and 120 min.
22084|NCT04016220|Drug|normal saline|first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
22085|NCT04016207|Drug|Guanfacine|regular treatment
22086|NCT04016194|Diagnostic Test|Lung function testing|Multiple-breath washout (MBW) is a safe, easy and sensitive lung function test using inert gases such as Nitrogen (N2) to assess efficiency of ventilation distribution. The latter can be estimated by the lung clearance index (LCI), an established study end-point in patients with CF
22087|NCT04016168|Biological|Blood sample collection|Three additional blood tubes (3 x 8mL) will be collected for this study. They will be added to the traditional diagnostic assessment carried out for their IPF, during their consultation at the competence centre for rare lung diseases. These samples will be taken by a registered nurse in the presence and under the responsibility of the investigator.
22088|NCT04016155|Device|Abbott FreeStyle Libre|Flash CGMS
22089|NCT04016155|Device|Patient Own SMBG|Market SMBG
22090|NCT04016142|Drug|Carboplatin-Paclitaxel adjuvant chemotherapy|"Patients will receive a first part of treatment corresponding to a standard of care (standard concomitant radio-chemotherapy, Part 1 of the study).~Then, they will be included in the second part of the study for the second part of treatment (experimental adjuvant chemotherapy, Part 2 of the study), providing they fulfill eligibility criteria at this stage.~The second part consists in 4 cycles of Carboplatin-Paclitaxel adjuvant chemotherapy (one cycle = 3 weeks of treatment and 1 free-week)"
22091|NCT04016129|Biological|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR|4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR Patients who have relapsed after CD19 CART immunotherapy or have CD19 negative B cell malignancies
22092|NCT04016116|Drug|Pembrolizumab|Pembrolizumab IV every 3 weeks
22093|NCT04016116|Drug|Ruxolitinib|Ruxolitinib po days 1-21
22094|NCT04016103|Device|MY01 - Continuous Compartmental Pressure Monitor|Insertion of the MY01 device for up to 24 hours for continuous monitoring of compartment pressure
22095|NCT04016090|Dietary Supplement|Folic Acid|Folic acid (5 mg)
22096|NCT04016090|Other|Placebo|Placebo capsule
22098|NCT04016064|Procedure|Er:YAG LASER, Nd:YAG laser, elctrosurgery, conventional surgery|"Er: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) 200 mj, 10 Hz, 2 Watt and VLP (long pulse, 1000 μs); 1.3 mm diameter, 8 mm long cylindrical, a sapphire tip was used with air cooling and water irrigation.~Nd: YAG laser (Fotana AT Fidelis III, Ljubljana, Slovenia) was applied at 4 watts, 50 Hz, 300 μm microfiber tip and SP (short pulse: 180 μs) settings.~Electrosurgical (Servotome Classic System, High Frequency Surgical Equipment, Satelec, France).~Conventional surgical method was applied with hand instruments and gingivectomy knives."
22099|NCT04016051|Drug|Clarithromycin DST (125 mg)|Clarithromycin DST (125.0 mg clarithromycin / straw).
22100|NCT04016051|Drug|Clarithromycin DST (187.5 mg)|Clarithromycin DST (187.5 mg clarithromycin / straw).
22101|NCT04016051|Drug|Clarithromycin DST (250 mg)|Clarithromycin DST (250.0 mg clarithromycin / straw).
22102|NCT04016051|Drug|Clarithromycin Syrup (125 mg)|Clarithromycin Syrup 2.5 ml (125 mg).
22103|NCT04016051|Drug|Clarithromycin Syrup (187.5 mg)|Clarithromycin Syrup 3.75 ml (187.5 mg).
22104|NCT04016051|Drug|Clarithromycin Syrup (250 mg)|Clarithromycin Syrup 5 ml (250 mg).
22428|NCT04013256|Other|Clean Air and Clean Clothing/Sham exposure|"Clean air, created by HEPA and charcoal filtration and temperature and humidity control.~Clean cotton clothing."
22105|NCT04016038|Other|a psycho-social investigation|The design of this project is based partly on the UNBIASED international study and is based on an in-depth case study in a prospective and retrospective dimension of deceased cancer patients for whom sedation has been established, and this, during a given period in different care settings: home, care center, hospital and palliative care unit.
22106|NCT04016025|Behavioral|Adherence to topical standard therapy assessed|Adherence defined as percentage of patients applying at least aimed daily dose
22107|NCT04016012|Dietary Supplement|Local Zambian Foods|Each week, participants in the intervention group will collect a pack of foodstuffs to last a week from the research site. The packs will be adjusted according to the weight of the participant and daily recommended allowances. Packaging of foodstuffs will be done in the food service lab at the Mukuba University. Instructions on how to prepare and use the food will be given to the participants. All food Items will be labelled diabetic food to avoid intra-household sharing.
22108|NCT04015999|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|MDCF2 with four complementary food ingredients (rationale: lead with evidence from Pre-POC clinical trials to optimize lead microbiota-directed complementary food prototypes for their ability to repair microbiota immaturity and positive effects on growth)
22109|NCT04015999|Dietary Supplement|Ready to Use Supplementary Food (RUSF)|Rice-lentil based RUSF (rationale: reference standard of care for MAM; based on knowledge of its effects on the gut microbiota or microbiota immaturity)
22110|NCT04015986|Dietary Supplement|Microbiota Directed Complementary Food-2|MDCF prototype with four complimentary food ingredients without powdered milk (rationale: lead with evidence from the recently completed pre-POC clinical trial of promoting growth promoting microbiota and positive effects on growth
22111|NCT04015986|Dietary Supplement|Ready to Use Supplementary Food|Rice-lentil based RUSF (rationale: reference standard of care for post-SAM, MAM; based on knowledge of its effects on child growth and the gut microbiota)
22112|NCT04015973|Dietary Supplement|High energy diet|An overfeeding regime of 135% required energy intake per day, set from baseline energy requirements consisting of high (saturated) fat snacks, added to the usual diet, supervised by a dietitian.
22113|NCT04015960|Other|no intervention|qualitative research and patient reported outcome measure (PROm) development
22114|NCT04015947|Device|CelluTome® Epidermal Harvesting System|split-thickness skin grafts from a matched bone marrow donor using the CelluTome® Epidermal Harvesting System
22115|NCT04015921|Other|No intervention|There is no intervention. Participants will be asked to complete a questionnaire and computer-based tasks.
22116|NCT04015908|Drug|Celecoxib|Celecoxib 100mg
22117|NCT04015908|Drug|Acetaminophen|Acetaminophen 325mg
22118|NCT04015908|Drug|Pregabalin|Pregabalin 50 mg
22119|NCT04015908|Drug|Oxycodone|oxycodone 5-10 mg
22120|NCT04015908|Drug|Percocet|Percocet (oxycodone 5mg/acetaminophen 325 mg)
22121|NCT04015895|Other|DEFCO tool|The Detection of social frailties and coordination of the path of patients in cancer: a new approach by an expert computer system DEFCO tool is questionnaire to identify their social vulnerabilities. A neural network instantly identifies the patient's fragility and sends the result by email to the professionals identified in the organization of each center. These professionals then relay to the social workers in order to take care of the patient's fragility.
22122|NCT04015882|Other|Exercise therapy|The exercise therapy group will make by physiotherapist supervision.
22123|NCT04015869|Drug|Allopregnanolone|neurosteroid
22124|NCT04015869|Drug|Placebos|placebo
22125|NCT04015856|Behavioral|Full TP intervention|CARE's Tipping Point initiative focuses on addressing the root causes of child, early, and forced marriage (CEFM) and promoting the rights of adolescent girls through community-level programming and evidence generation in Nepal and Bangladesh, as well as multi-level advocacy and cross-learning efforts across the globe. Tipping Point's approach focuses on synchronized engagement with different participant groups—including adolescent girls, adolescent boys, parents/community members, community leaders—around key programmatic pillars, and creates public spaces for all community members to engage in the dialogue. Tipping Point's approach relies on challenging social expectations and repressive gender norms and promoting girl-centric and girl-led activism to enable adolescent girls to identify and move into social spaces where they can challenge inequality.
22126|NCT04015856|Behavioral|Light TP intervention|The Tipping Point project also has designed a social norms light package, which includes a subset of the social norms and activism components of the full package.
22127|NCT04015830|Other|electroencephalography (EEG) and event related potentials (ERP)|This is an exploratory study of EEG/ERP measures in older African American and Whites with HIV
22128|NCT04015817|Other|paramedical and non-pharmacological services|Paramedical and non-pharmacological services (work on positions, ventilatory education, use of a fan, pulmonary rehabilitation, stress management, mindfulness meditation, psychosocial services, possible support from the mobile palliative care team)
22129|NCT04015804|Other|Clinical database|Creation of an ambispective (retrospective and prospective), multicentric and European clinical database for surgery with robotic assistance in rectal cancers with implementation in France and then in Europe
22130|NCT04015791|Other|NOCISCAN-LS Disc MR Spectroscopy|The investigational Nociscan Suite is a software suite that works with existing high field MR systems and MRS pulse sequence via and optimized protocol to conduct MRS exam of lumbar discs. The software suite post-processes the NOCISCAN-LS disc MRS exam data to calculate ratios of spectroscopic signals at regions along the MRS frequency spectrum associated with certain chemicals that change with degeneration and pain
22131|NCT04015778|Biological|Nivolumab|240mg Q2W or 360mg Q3W
22132|NCT04015778|Drug|carboplatin|AUC 5, d1 every three weeks
22133|NCT04015778|Drug|nab-paclitaxel|135 mg/m2, d1, 8
22134|NCT04015765|Procedure|Hybrid Argon Plasma Coagulation and EMR procedure|Hybrid Argon Plasma Coagulation (h-APC) combines an ablation technique (APC) with the option for submucosal saline injection using a high-pressure water jet. The technique allows to lift dysplastic epithelium thus creating a safety cushion under the mucosa is lifted with a saline injection and then to ablate larger areas more thoroughly and with a higher energy setting, with a low risk for side effects or complications
22174|NCT04015414|Drug|Varenicline|190 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 190 patients will receive cytisine for 25 days and regular phone calls with brief counseling
22135|NCT04015752|Diagnostic Test|culture from infected site|ESR ,CRP,CBC, Renal and Liver function will be done on admission and follow up Culture: On admission Urine and blood as well as sputum culture acc. To the cause of infection. Culture from suspected site of infection in catheter related infections.
22136|NCT04015739|Drug|Bevacizumab (FKB238), Olaparib and Durvalumab (MEDI 4736) combination|"Patients will receive a combination of these 3 drugs :~Bevacizumab (FKB238) 15mg/kg q3w IV, Olaparib 300mg BD Per Os; and Durvalumab (MEDI 4736) 1.12g IV q3w"
22137|NCT04015700|Biological|Personalized neoantigen DNA vaccine supplied by Geneos Therapeutics|-The neoantigen DNA vaccines are also known as DNA plasmid vector expressing tumor-specific antigens.
22138|NCT04015700|Device|CELLECTRA®2000 EP Device supplied by Geneos Therapeutics|CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
22139|NCT04015700|Drug|Plasmid encoded IL-12|The INO-9012 vials will be supplied by Geneos Therapeutics
22140|NCT04015687|Drug|AG-881|Supplied as uncoated tablets.
22141|NCT04015687|Drug|Lamotrigine|Supplied as tablets of LAMICTAL® or generic equivalent.
22142|NCT04015674|Other|Exercise group|Aerobic exercise on a stationary bicycle
22143|NCT04015674|Other|Control group|In a rest
22144|NCT04015661|Drug|Nab-paclitaxel|induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
22145|NCT04015648|Biological|ChAdOx1 Zika|Single dose of ChAdOx1 Zika at different concentrations: 5 x 10^9 vp, 2.5 x 10^10 vp, 5 x 10^10 vp, 1 x 10^11 vp
22146|NCT04015648|Biological|ChAdOx1 Zika, ChAdOx1 Chik|Co-administration of ChAdOx1 Zika and ChAdOx1 Chik at different concentrations: 5 x 10^9 vp, 1.25 x 10^10 vp, 2.5 x 10^10 vp, 5 x 10^10 vp
22147|NCT04015635|Other|None involved|NO intervention
22148|NCT04015622|Drug|Enzalutamide|Enzalutamide 160 mg PO OD
22149|NCT04015622|Drug|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks
22150|NCT04015609|Behavioral|Meaning Centered Psychotherapy for Latinos|MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span ot 7-14 weeks.
22151|NCT04015609|Behavioral|Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale|Determines the degree of spiritual well-being
22152|NCT04015609|Behavioral|Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients|Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
22153|NCT04015596|Drug|Naproxen Sodium|Dosed by weight (10mg/kg), twice daily, for 8 weeks
22154|NCT04015596|Other|Placebo|Participants take placebo pills twice daily, for 8 weeks.
22155|NCT04015583|Behavioral|exergaming group|Exergame is 'exercise + game'. Treadmill exercise is traiditional aerobic exercise
22156|NCT04015570|Biological|High Volume Plasma Exchange|PLASMA EXCHANGE is therapeutic procedure in which blood of the patient is passed through a medical device which separates plasma from other components of blood. The plasma is removed and replaced with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution.Plasma exchange leads to removal of abnormal circulating plasma factor or a physiologic factor produced in excess (IG, NH3,protein bond toxins )and also exert a immunomodulatory activity
22157|NCT04015570|Other|Standard Medical Treatment|Standard Medical Treatment (Albumin+High caloric diet)
22158|NCT04015557|Drug|Acetaminophen|Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
22159|NCT04015557|Drug|N-acetylcysteine|Patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive again a normal dose of acetaminophen (1.5g) orally and one hour later oral N-acetylcysteine (70 mg per kilogram of body weight). Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
22160|NCT04015544|Dietary Supplement|Watermelon|Pureed whole (100%) watermelon
22161|NCT04015531|Radiation|Conventional radiotherapy|50 Gy / 25 fractions / 5-6 weeks / Sequential boost of 10 Gy in 5 fractions, in case of conservative surgery.
22162|NCT04015531|Radiation|Hypofractionated radiotherapy|40 Gy / 15 fractions / 3 weeks / Concomitant boost with total dose of 48 Gy in 15 fractions, in case of conservative surgery.
22163|NCT04015518|Drug|Spesolimab|BI 655130
22164|NCT04015518|Drug|Placebo|Placebo
22165|NCT04015505|Behavioral|Cognitive Behavioural Therapy for older adults: wisdom enhancement 'timeline technique'|The intervention is comprised of five one-hour sessions of structured talking therapy, where participants create a timeline of their life with significant events included. Through dialogue with the therapist and structured worksheets, participants are encouraged to reflect on events in their life to recognise and develop qualities of resilience and self-compassion. They are then asked to use 'the wisdom of their years' to develop strategies to manage difficulties they are currently facing. Participants will also be asked to complete worksheets and try out new strategies between sessions.
22166|NCT04015492|Biological|Damoctocog-alfa-pegol (BAY94-9027, Jivi)|Single dose, 50 IU/kg BAY94-9027 (IU: international Units)
22167|NCT04015492|Biological|Rurioctocog alfa pegol (Adynovi)|Single dose, 50 IU/kg Adynovi
22168|NCT04015479|Dietary Supplement|Peanut Protein Powder|Peanut protein powder will be provided to participants who will be instructed to consume 72g daily, mixed with water
22169|NCT04015479|Behavioral|Full body resistance training|Participants will undergo supervised resistance training two times per week (5 exercises, 3 sets of 8-12 repetitions per set)
22170|NCT04015453|Procedure|Mohs micrographic surgery|All participants will have received Mohs micrographic surgical treatment for a facial skin cancer.
22171|NCT04015440|Behavioral|HBMT|Individual is presented with words with some letters missing and told to complete the word.
22172|NCT04015440|Behavioral|Other Training|Alternative to HBMT training
22173|NCT04015427|Device|implant crown|After the second 16 week period the screw-retained crowns will be (re-) inserted in all patients, single tooth x-rays taken and clinical baseline values obtained. Additionally, a soft tissue biopsy will be harvested at the time of insertion of the final screw-retained crown. Patients will be followed up for another 16-week period.
22176|NCT04015388|Device|iPro Continuous Glucose Monitoring|iPro device is a continuous glucose monitoring (CGM) FDA approved device. This CGM device consists of a small recorder which reports glucose values every five minutes. This recorder is connected directly to a glucose sensor. The glucose-oxidase based sensor measures extracellular fluid in the subcutaneous tissue. The tiny and flexible sensors are typically inserted just beneath the skin, usually in the abdominal area, but can also be placed in the buttock, or anterior or lateral thigh.
22177|NCT04015375|Drug|Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
22178|NCT04015375|Drug|ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)|Topical gel
22179|NCT04015375|Other|Placebo for Dapsone gel 7.5% (Torrent Pharmaceuticals Ltd)|Topical gel
22180|NCT04015362|Procedure|Sub-threshold intermittent pulsed magnetic stimulation|Application of sub-threshold intermittent pulsed magnetic stimulation to spinal cord
22181|NCT04015362|Procedure|Sham|Application of sham magnetic stimulation to spinal cord
22182|NCT04015349|Diagnostic Test|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
22183|NCT04015336|Biological|E7 TCR|The dose of E7 TCR T cells will be 3 x 1010 TCR+ T cells (unless fewer cells are generated) administered once.
22184|NCT04015323|Device|Interferential current|An electrotherapy current with different carrier frequencies
22185|NCT04015310|Device|Quantitative Multi parametric MRI and enhanced MRCP|Patients will have quantitative MRI and enhanced MRCP on addition to their standard of care
22186|NCT04015297|Diagnostic Test|raman analysis|negative or pozitive
22187|NCT04015284|Procedure|Suprascapular Nerve Block + Posterior Cord Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the proximal suprascapular nerve is visualized before it turns toward the suprascapular notch. It is blocked using 5mL of ropivicaine 0.5%. The posterior cord is readily visualized when performing an infraclavicular brachial plexus block. It is blocked using 10mL of ropivicaine 0.5%.
22188|NCT04015284|Procedure|Interscalene Brachial Plexus Block|The patient lies supine with the head turned to the contralateral side to the block. Using a linear high-frequency ultrasound probe, the interscalene groove is visualized along with the roots of the brachial plexus. The block is performed with 15mL of ropivacaine 0.5%.
22189|NCT04015271|Behavioral|Action Observation + Repetitive Task Practice|Observing a video of another person performing a functional task and physically repetitively performing the same task for upper extremity hemiparesis
22190|NCT04015271|Behavioral|Placebo Video + Repetitive Task Practice|Observing a video of static images and physically repetitively performing functional task for upper extremity hemiparesis
22191|NCT04015258|Dietary Supplement|Blueberries|fresh spanish blueberries
22192|NCT04015258|Dietary Supplement|Blueberry powder|freeze-dried blueberry powder
22193|NCT04015258|Dietary Supplement|Blueberry components capsules|encapsulated blueberry components (microcrystalline cellulose powder in actual)
22194|NCT04015245|Drug|Stronger Neo-Minophagen C|intravenous injection after TACE
22195|NCT04015232|Combination Product|INTP5|INTP5, a pegfilgrastim biosimilar to US Neulasta.
22196|NCT04015232|Combination Product|US Neulasta|US Neulasta: FDA approved pegfilgrastim innovator product.
22197|NCT04015219|Device|Self retained cryopreserved amniotic membrane|PROKERA SLIM
22198|NCT04015219|Other|lifitegrast ophthalmic solution|Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
22199|NCT04015206|Other|Group Interpersonal Psychotherapy|Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
22200|NCT04015193|Procedure|Single-port thoracoscopic sympathicotomy (patient care)|Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
22201|NCT04015180|Drug|Eylea (Aflibercept, BAY86-5321)|Treatment administered in 20090. Solution in a sterile glass vial, Dose A, IVT injection.
22202|NCT04015180|Procedure|Laser photocoagulation|Treatment administered in 20090. Transpupillary conventional laser ablative therapy
22203|NCT04015167|Device|T2 Alpha Tibia Nailing System|The T2 Alpha Tibia Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
22204|NCT04015154|Device|Femoral Nail PF of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
22205|NCT04015141|Drug|Perampanel Oral Suspension|Perampanel oral suspension
22206|NCT04015141|Drug|Perampanel Tablet|Perampanel tablet.
22207|NCT04015128|Device|Femoral Nail GT of the T2 Alpha Femur Antegrade GT/PF Nailing System|The T2 Alpha Femur Antegrade GT / PF Nailing System is intended for temporary stabilization of bone segments or fragments until bone consolidation has been achieved.
22208|NCT04015115|Behavioral|Youth Opioid Recovery Support service model|see arm 1 description
22209|NCT04015089|Dietary Supplement|Partially hydrolyzed formula (pHF)|Infant formula with partially hydrolyzed protein
22210|NCT04015089|Dietary Supplement|Standard formula (SF)|Infant formula with intact protein
22211|NCT04015076|Drug|Inzomelid|Active Drug
22212|NCT04015076|Drug|Placebo|Placebo to Match
22213|NCT04015063|Other|Anti-Aging Skin Care product|Primary Subjects will use P29429-01 as an anti-aging skin care product on full face twice a day for 12-week.
22214|NCT04015050|Other|milk based infant formula|Cows milk ased infant formula
22215|NCT04015037|Combination Product|placebo or drug|Group A and B (medicated or placebo)
22216|NCT04015024|Drug|SKLB1028 150mg bid|150mg oral administration twice a day
22217|NCT04015024|Drug|SKLB1028 200mg bid|200mg oral administration twice a day
44011|NCT03839771|Drug|AG-221|100mg tablets
22219|NCT04015011|Combination Product|LCD Intervention|composed of approximately 1,080 kcal/day, which includes 3 New Direction Meal Replacements containing 200 kcal (27g protein, 12g carbhydrate, 2g fiber), 1 protein bar containing 160 kcal (5 g protein, 18g carbohydrate, 5g fiber, 2g sugar alcohol), and a 350-calorie controlled meal of protein and vegetables that the patient will make on his/ her own.
22220|NCT04014998|Other|Virtual Reality|Virtual reality group will have virtual reality for 20 minutes in addition to stabilization exercises for 20 minutes. Virtual reality will apply using Oculus Go. On the other hand control group will have only exercise for 40 minutes. Exercises will include same exercises in both groups, but exercise group will perform exercises twice compared to virtual reality group.
22221|NCT04014985|Other|An extensive biological assessment|To study the morphology of red blood cells, the markers of oxidative stress and the signaling pathway of IFGF1.
22222|NCT04014959|Combination Product|TMS/ fMRI Stimulation|"The study uses a modified repetitive TMS stimulation protocol. Participants receive active TMS on five separate days: a baseline TMS/ fMRI scan, three mini TMS sessions, and a final TMS/ fMRI scan.~Again, this level of stimulation is considered to be sub-threshold for that of a TMS treatment protocol."
22223|NCT04014946|Device|ICD implantation|implantation of the Lumax 540 single/dual chamber ICD or successor
22224|NCT04014933|Diagnostic Test|LASER SPECKLE FLOWGRAPHY|Non-invasive, real-time imaging and measurement of ocular blood flow of the optic disc and peripapillary region
22225|NCT04014920|Device|Oxygen group|The control group will receive oxygen (first randomization), HFNO oxygen or standard oxygen (second randomization)
22226|NCT04014920|Device|NIV Group|The experimental group will receive NIV (first randomization) alternated with HFNO or standard oxygen (second randomization)
22227|NCT04014907|Procedure|Frozen Elephant Trunk Technique|Endovascular technique forTAA repair
22228|NCT04014894|Biological|ET019003-T Cells|there are three different dose groups in leukemia and lymphoma. If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.The maximum dose could be extended.
22229|NCT04014881|Biological|Third-generation anti-CD123 CAR-T cells|From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
22232|NCT04014855|Drug|Iron Supplement|in iron deficiency anemia
22233|NCT04014842|Device|RapidShock|Use of the Reconfirmation Analysis Mode algorithm
22234|NCT04014829|Diagnostic Test|Pain-Pressure Threshold|Performed on bilateral trapezius muscles. Pressure will be applied at 90 degrees downward with an algometer, with the speed of pressure increase approximately 1kgf/s. Upon the sensation of pain, the patient will vocalize or raise her hand to terminate the test, and the highest reading will be recorded (up to maximum 6kgf). If two values are recorded within 0.2kgf of each other, the mean value will be recorded. If two values are greater than 0.2kgf of each other, a third test will be performed and the mean obtained.
22235|NCT04014829|Diagnostic Test|Mechanical Temporal Summation|"Pinprick hyperalgesia will be evoked using a Von Frey filament, applied to the volar aspect of the dominant forearm. Participants will report using the numerical rating scale the intensity of pain from the first stimulus. Subsequently, ten repetitive stimuli one second apart will be applied with the same filament within an area of 1cm diameter of the same forearm. Subjects will report the rate the pain intensity of the tenth stimulus. The magnitude of MTS is calculated as the difference between the last to the first pain scores. The investigators will classify the participants according to evoked MTS if the last stimulus is rated higher than the first, or no MTS if the last stimulus is rated equal or lower than the first. The research team administering the test will follow a set script."
22236|NCT04014829|Diagnostic Test|Hospital Anxiety and Depression Scale|Standardized questionnaire to determine the level of anxiety and depression.
22237|NCT04014829|Diagnostic Test|Pain Catastrophizing Scale|Standardized questionnaire to determine the level of pain catastrophizing.
22238|NCT04014829|Diagnostic Test|Central Sensitization Inventory|Standardized questionnaire to determine the level of central sensitization.
22239|NCT04014829|Diagnostic Test|Fear-Avoidance Component Score|Standardized questionnaire to determine the level of fear and avoidance.
22240|NCT04014829|Diagnostic Test|EQ-5D|Standardized questionnaire to assess generic health-related quality of life.
22241|NCT04014816|Other|MDR bacteria positivity|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
22242|NCT04014816|Other|negative fluid balance|A total of 137 patients who received nasogastric tube feeding in an ICU of a tertiary hospital were enrolled.
22243|NCT04014803|Drug|Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin|"Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~Prasugrel plus Aspirin arm~Clopidogrel plus Aspirin arm"
22244|NCT04014790|Drug|RGI-2001|Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT
22245|NCT04014790|Drug|Standard of Care|Standard of care prophylaxis regimen will be administered according to institutional guidelines
22246|NCT04014777|Biological|NGM621|NGM621 Dose 1
22247|NCT04014777|Biological|NGM621|NGM621 Dose 2
22248|NCT04014777|Biological|NGM621|NGM621 Dose 3
22249|NCT04014777|Biological|NGM621|NGM621 Dose 4
22250|NCT04014764|Other|This is a non-interventional study|N/A. This is a non-interventional study. Following consent, the subject will have biospecimen samples taken during routine standard of care procedures, and provided to Sponsor for analysis. Optional research blood draws may occur at treating physician's discretion to obtain additional tissue samples.
22282|NCT04014452|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
22368|NCT04013750|Other|Modified Constraint Induced Movement Therapy|constraint-induced movement therapy (CIMT) is characterized by the restraint of the less effected upper limb accompanied by the shaping and repetitive task-oriented training of more affected upper extremity.
22251|NCT04014751|Other|Symptom Monitoring Intervention|This study involves a cancer care delivery process improvement component where all cohort participants, at specified timepoints, are assessed for psychological distress, pain, fatigue, physical function, practical and supportive needs, and dietary and nutritional needs. Patients with severe elevations in psychological distress, physical symptoms or those who endorse supportive care and/or dietary needs are triaged in real time to appropriate providers within the health system (i.e., social work, nursing pool, nutrition services) to address elevated scores and/or stated needs. As such, within the context of this process improvement care delivery project, real time referrals function as interventional processes within the health system to route patients to relevant points of care based on their needs.
22252|NCT04014725|Device|Myopia Intelligent Diagnostic System|An artificial intelligence to make diagnosis of myopia using ocular appearance images
22253|NCT04014712|Drug|Tetrahydrobiopterin|Oral, Single dose
22254|NCT04014712|Drug|Placebo oral tablet|Single dose
22255|NCT04014699|Procedure|modified 2.2mm microincision|enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification
22256|NCT04014699|Procedure|conventional 2.2mm microincision|conventional 2.2mm coaxial microincision phacoemulsification
22257|NCT04014686|Other|No exercise intervention group|no exercise intervention
22258|NCT04014686|Behavioral|Resistance band exercise intervention group|Resistance band exercise training intervention (12 weeks, 3x per week, for 60 minutes per day)
22259|NCT04014673|Behavioral|Behavioral : Characterization|Behavioral scales and neuropsychological tests; MRI, SPECT/PET
22260|NCT04014660|Dietary Supplement|Probiotic|The probiotic product consists of two different bacterial strains, L.plantarum Heal 9 and L.paracasei 8700:2
22261|NCT04014660|Dietary Supplement|Placebo|The placebo supplement consists of corn starch only.
22262|NCT04014634|Drug|Methylprednisolone|Single GON injection with methylprednisolone
22263|NCT04014634|Other|Placebo|Single GON-injection with NaCl
22264|NCT04014621|Device|SPG stimulation|The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
22265|NCT04014608|Other|Standard Practice to Prevent Hospital Onset CDI|Bleach cleaning of rooms, use of required soap/water hand hygiene for CDI patients, hand hygiene monitoring, portable ultraviolet (UV) light room disinfection, and monitoring of room cleaning.
22266|NCT04014595|Procedure|Rotational atherectomy in combination with cutting balloon|Treatment of severely calcified coronary lesion using rotational atherectomy followed by balloon angioplasty using a cutting balloon and Implantation of the hybrid sirolimus-eluting stent.
22267|NCT04014582|Behavioral|Communal Coping Intervention|This intervention aims to foster a shared appraisal and collaboration through: the discussion of past joint coping, education about communal coping (e.g. what it is and why it is beneficial), and discussions to foster the perception of diabetes as shared. Participants in the intervention group will also create collaborative action plans to increase collaboration. Couples in the intervention group will also receive two daily text messages—one a general reminder to engage in communal coping and the other one of the collaborative intentions they created during the in-person session. These couples will also receive a brief diabetes education.
22268|NCT04014582|Behavioral|Diabetes Education|Couples in the diabetes education group will receive a brief diabetes education and complete individual implementation intentions. Patients will create implementation intentions related to diabetes and partners will create implementation intentions that are not related to health.
22269|NCT04014569|Device|MPSA Algorithm|Insulin dosing will be adjusted using the MPSA Algorithm
22270|NCT04014556|Device|micropulse laser|"Micropulse session details:~Mainster focal grid contact lens (×1.05 laser magnification) was used to perform laser. The 577-nm yellow laser (OcuLight SLx, Iridex Corp., Mountain View, California, USA) was used. Fixed treatment parameters were used in all cases: 200-μm spot size, 200-ms exposure duration, 400-mW power, and a 5% duty cycle. Confluent applications with no spacing were administered using 5x5 grid pattern over the entire edematous area including the fovea."
22271|NCT04014556|Drug|Aflibercept|Aflibercept
22272|NCT04014543|Other|gastronomy|"to study the quality of life of caregivers and children with generic questionnaires (13-16), validated and used in other pathologies and chronic diseases of the child.~This will allow reproducibility and comparisons to other populations, general or other chronic diseases (acute leukemias ...) This is to conduct a pilot study, preliminary to the construction of a larger study, longitudinal with several evaluation times."
22273|NCT04014530|Drug|Ataluren + Pembrolizumab|Ataluren and Pembrolizumab combination therapy
22276|NCT04014504|Diagnostic Test|Neonatal Hearing Screening Test|neonatal hearing screening test results will be evaluated.
22277|NCT04014491|Procedure|Scapula control exercise|To perform arm elevation in the scapular plane, subjects will be first asked to correct scapular resting posture in sitting with EMG biofeedback. Then the subjects will be instructed to do elevation in the scapular plane, side lying external rotation and dynamic hug plus with control of the scapula by EMG feedback and verbal cues
22278|NCT04014491|Procedure|scapular strengthening exercise|The subjects in the scapular strengthening group will be asked to perform these three exercises the same as scapula control group and with the same number of trials but without any EMG biofeedback and oral cues of movement or posture correction.
22279|NCT04014491|Other|No intervention|No intervention
22280|NCT04014478|Device|Endovascular Denervation|A radiofrequency ablation catheter will be placed in abdominal aorta. At least 6 sites will be ablated with settings of temerature at 60 degree centigrade and time at 120 seconds.
22281|NCT04014452|Procedure|Microwave ablation|Use of microwave energy to ablate tissue surrounding fetal umbilical cord. All the procedures are performed percutaneously under ultrasound guidance.
22283|NCT04014439|Diagnostic Test|Ratio of Neutrophil to Lymphocyte|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
22284|NCT04014439|Diagnostic Test|Level of Prealbumin Serum|Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
22285|NCT04014426|Other|Blood sample|"Exposed group:~15 to 30 minutes before the start of the procedure: 1 EDTA tube of 6 ml for blood (T0)~2hours after the end of the procedure: 1 EDTA tube of 6 ml (T1)~Non-exposed group:~- During the morning (8 to 10 a.m): 1 EDTA tube of 6 ml (T0)"
22286|NCT04014426|Other|Urinary sample|"Exposed group:~15 to 30 min before the PIPAC procedure (T0)~2hours after the end of the procedure (T1)~The next morning after the procedure (T2)~Non-exposed group:~- During the morning (8 to 10 a.m) (T0)"
22287|NCT04014413|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
22288|NCT04014400|Other|Suprathel or Xeroform donor site application|The surgical procedure for recovery of a skin graft will be the same for all patients as follows. Once the patient is taken to the operating room, the selected donor site will be prepared and harvested with a Zimmer Dermatome set at 0.007 to 0.009 thousands of an inch for pediatric patients and 0.12 to 0.14 thousands for adult patients. After the harvesting procedure, the donor site will be covered with Telfa saturated with 1:10,000 epinephrine in normal saline until hemostasis is achieved. The Telfa will be irrigated off the donor site with the epinephrine saline solution. The surgeon will don a new pair of sterile gloves to handle the donor site dressing. The randomized dressing will be applied over the hemostatic donor site with an approximate 1-2cm border. Next, the wound will be dressed with 4x4 cotton gauze pads (fluffs), rolled gauze (Kerlix) and either Coban or BandNet.
22289|NCT04014387|Drug|Suvorexant|Suvorexant (Belsomra) is an FDA approved, dual orexin receptor antagonist. It is prescribed for insomnia, reducing time to sleep onset, and to maintain nighttime sleep.
22290|NCT04014387|Drug|Zolpidem|Zolpidem (Ambien) is an FDA approved, Benzodiazepine Receptor agonist that has been extensively studied for the treatment of insomnia in older adults. It acts as a sedative and is typically prescribed to treat insomnia, reducing time to sleep onset, but may not alter the ability to maintain sleep.
22291|NCT04014387|Drug|Placebo oral capsule|Placebo (microcrystalline cellulose) capsules will be used.
22292|NCT04014361|Drug|LY3154885 - Capsule|Administered orally.
22293|NCT04014361|Drug|Placebo - Capsule|Administered orally.
22294|NCT04014361|Drug|Itraconazole|Administered orally.
22295|NCT04014361|Drug|LY3154885 - Tablet|Administered orally.
22296|NCT04014335|Drug|IONIS-FB-LRx|Participants will receive IONIS-FB-LRx, by subcutaneous injection (SC) at Weeks 1, 3, 5, and every 4 weeks through Week 25.
22297|NCT04014322|Other|E-cigarette|All participants will be provided with 6 weeks of e-cigarettes at no cost based on self-report of regular cigarette use. All participants will be instructed to use e-cigarettes as much as they like (no instruction on how much they smoke combustible [regular] cigarettes) for the first 2 weeks. Then, they will be instructed to switch completely from combustible cigarettes to e-cigarettes for the next 4 weeks.
22300|NCT04014296|Behavioral|High Protein Diet|16 week weight loss program with high protein diet and supervised flexibility and balance training. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
22301|NCT04014296|Behavioral|Resistance Training|16 week weight loss program with normal protein diet and supervised resistance training. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
22302|NCT04014283|Dietary Supplement|Selenium supplementation or placebo treatment|Patients from this group will receive selenium supplement to achieve optimal selenium level
22303|NCT04014283|Other|Diet modification|Patients from this group will have modified diet over the course of the study. Diet modification is aimed to lower selenium concentration in blood.
22304|NCT04014283|Other|Selenium supplementation or placebo treatment and diet modification|In this group patients will receive supplement, placebo or diet modification. The goal is to raise selenium concentration in blood
22305|NCT04014270|Device|Self-modulated functional electrical stimulation (SM-FES)|"The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks."
22306|NCT04014270|Other|Standard Care|"The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks."
22307|NCT04014257|Drug|NOV1601(CHC2014)|a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)
22308|NCT04014244|Drug|Corticosteroid vs. Dextrose|US guided injection of corticosteroid in one hand and 5% glucose in the other will be performed in accordance with randomization. In a syringe both substances will be diluted using 0.9% NaCl to a total injection volume of 6 ml. In-plane ulnar approach will be used to visualize the median nerve at the level of the pisiform bone. A standard 23 gauge needle will be inserted in the carpal tunnel with the needle tip positioned between retinaculum and median nerve.
22342|NCT04014010|Other|End-tidal Carbon dioxide (EtCO2)|"Longest single episode (minutes) a) below 30, and b) above 45mmHg~Cumulative duration (minutes) a) below 30, and b) above 45mmHg"
22369|NCT04013737|Device|EPIC IMPOC|Clinical Decision Support System for antibiotic prescribing.
22309|NCT04014244|Procedure|Corticosteroid or Dextrose vs. Surgery|Injection will be performed unilaterally, after randomization of sides, by the same examiner as in the first part of the study. In all patients included in the second part of the study surgical release will be performed by the same plastic surgeon. The procedure will be performed under local anesthesia, following the same standard protocol. Both treatments will be performed maximally 2 months after diagnosis, with maximum period between them of 1 week.
22310|NCT04014231|Procedure|Diagnostic Imaging|Undergo placement of single wave application
22311|NCT04014231|Other|Laboratory Biomarker Analysis|Correlative studies
22312|NCT04014218|Drug|Inhalation Sedation|Inhalation Sedation by Administration of Sevoflurane
22313|NCT04014218|Drug|Intravenous Sedation|Intravenous Sedation by Administration of Propofol
22314|NCT04014205|Drug|ICP-022|ICP-002 The drug product is a white, round, uncoated tablet
22315|NCT04014192|Drug|Dapagliflozin|Treated with dapagliflozin 10mg/d for one week.
22316|NCT04014192|Drug|Empagliflozin|Treated with empagliflozin 10mg/d for one week.
22317|NCT04014192|Drug|Canagliflozin|Treated with canagliflozin 100mg/d for one week.
22318|NCT04014179|Diagnostic Test|GeneXpert HCV Viral Load Assay|A whole-blood sample will be collected from participants via a finger-stick and collected into a 100 μL minivette collection tube. Immediately after collection, 100 μL of capillary whole blood will be placed directly into the Xpert® HCV Viral Load Fingerstick cartridge (Cepheid, USA; lower limit of quantification of 10 IU/mL) for on-site HCV RNA testing.
22319|NCT04014179|Diagnostic Test|Laboratory HCV viral load assay from dried blood spots|Dried blood spots will be collected form participants and HCV RNA measured through in-house and commercial assays.
22320|NCT04014166|Other|Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)|This is a single-arm study to evaluate the safety and efficacy of hUC-MSCs to treat refractory immune thrombocytopenia. The dose of hUC-MSCs will be successively divided into three increasing dose(group A: hUC-MSCs 0.5×10^6/kg, weekly for 4 weeks, 3 patients; group B: hUC-MSCs 1.0×10^6/kg, weekly for 4 weeks, 3 patients; hUC-MSCs 2.0×10^6/kg, weekly for 4 weeks, 3 patients) with 3 patients in each group according to the dose. The principle of increasing dose will be carried out successively from low dose to high dose group. According to the results of the safety and efficacy data from these 9 patients, the investigator will determine one of the doses and expand the sample size to 6 cases.
22321|NCT04014153|Procedure|Iodinated contrast media|Percutaneous coronary intervention with iodinated contest media
22322|NCT04014140|Procedure|Coronary artery bypass grafting surgery (CABG)|Patients with MVCAD will undergo CABG as per standard of care.
22323|NCT04014127|Diagnostic Test|Coronary flow reserve assessment|Coronary flow reserve will be assessed using Doppler transthoracic echocardiograpy and myocardial contrast echocardiography.
22324|NCT04014127|Diagnostic Test|Sphygmocor|Pulse wave analysis and pulse wave velocity will be assessed using the Sphygmocor device
22325|NCT04014127|Diagnostic Test|Electrocardiogram|An electrocardiogram will be performed prior to administration of adenosine to ensure no resting conduction disease
22326|NCT04014127|Other|Blood test|Blood tests will be performed for markers of renal function, bone mineral metabolism and myocardial stretch and injury
22327|NCT04014127|Other|Urinary albumin/creatinine ratio|Urine will be analysed for albumin/creatinine ratio
22328|NCT04014114|Other|Digital Genetic Assistant|An end-to-end digital solution to the carrier screening process from participant registration to receipt of the test results and their interpretations. These steps are provided using personalized animated videos.
22329|NCT04014101|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
22330|NCT04014101|Drug|apatinib|Apatinib is a selective VEGFR2 inhibitor.
22331|NCT04014088|Device|hCPAP vs fCPAP|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or facemask CPAP.
22332|NCT04014075|Drug|Trastuzumab deruxtecan|Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion
22333|NCT04014062|Combination Product|INTP5|INTP5: A proposed pegfilgrastim biosimilar to US Neulasta.
22334|NCT04014062|Combination Product|US Neulasta|US Neulasta: FDA-approved pegfilgrastim innovator product.
22335|NCT04014036|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
22336|NCT04014023|Drug|DWP16001|DWP16001 tablets
22337|NCT04014023|Drug|Placebo|DWP16001 placebo-matching tablets
22338|NCT04014010|Other|Blood pressure|"Systolic Blood Pressure (SBP)~Maximum change from preoperative SBP, in a) absolute change (mmHg), and b) relative change (%)(emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative SBP~Longest single episode (minutes) below a) 80, b) 90, and c)100 mmHg~Cumulative duration (minutes) below a) 80, b) 90, and c)100 mmHg~Mean Arterial Pressure (MAP)~Maximum change from preoperative MAP, in a) absolute change (mmHg), and b) relative change (%) (emergency and elective cases analyzed separately)~Cumulative duration (minutes) >=20% below preoperative MAP~Longest single episode (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg~Cumulative duration (minutes) below a) 60, b) 65, c) 70, and d) 80mmHg"
22339|NCT04014010|Other|Heart rate|"Maximum change (beats per minute, BPM) from preoperative heart rate (positive and negative)~Relative change (%) from preoperative heart rate (positive and negative)~Maximum pulse variation (maximum heart rate minus minimum heart rate)~Longest single episode (minutes) a) below 60, and b) above 100BPM~Cumulative duration (minutes) a) below 60, and b) above 100BPM"
22340|NCT04014010|Other|Use of hemodynamic medications (i.e. special medications for blood pressure)|"Vasopressor/inotrope use (yes vs. no): phenylephrine, norepinephrine, epinephrine, vasopressin, dobutamine, or milrinone~Infusion of any vasopressor/inotropes above (yes vs. no) (identified by unit of weight over time)~Phenylephrine/ephedrine bolus (yes vs. no) (identified by unit of weight only)~Vasodilator use (yes vs. no): labetalol, esmolol, nitroglycerin, nitroprusside~Infusion of any vasodilator above (yes vs. no) (identified by unit of weight over time)"
22341|NCT04014010|Other|Oxygen saturation by pulse oximetry (SpO2)|"Longest single episode (minutes) below a) 88, and b) 90%~Cumulative duration (minutes) below a) 88, and b) 90%"
22367|NCT04013763|Other|wheat containing skin care products|stop or continue using wheat containing skin care products
22343|NCT04013997|Device|EksoGT|The intervention group received a minimum of 15 hours of standard of care, including physical and occupational therapy, for acute inpatient rehabilitation per week. After enrolling into the study, participants received locomotor training with the exoskeleton as part of their acute inpatient rehabilitation using the Ekso. Standing and walking with the Ekso started as soon as the clinical team determined it was safe for participants to begin standing, and continued until the participant was discharged from inpatient rehabilitation.
22344|NCT04013984|Other|Accupuncture|In experimental groups (A), acupuncture will be applied for 30 minutes in each session and will be started from the month prior to onset of ovarian stimulation (two sessions of a weekly), and during the ovarian stimulation cycle (two sessions of a weekly), totally 7 acupuncture sessions will be carried out. Acupuncture will be performed using sterile needle on specific points (CV 3 (Zhongji), CV 4 (Guanyuan), ST 25 (Tianshu), ST 28 (Shuidao), ST 29 (Guilai), and LR 3 (Taichong), BL 23 (Shenshu), BL 32 (Ciliao), GV 20 (Baihui), GV 24 (Shenting), GB 13 (Benshen), ST 36 (Zusanli), SP 6 Sanyinjiao), SP 8, SP 10 and KI 3 (Taixi)). The needles were inserted to a depth of 15-30 mm, depending on the region of the body. No sham acupuncture is considered in the control group for ethical and practical reasons
22345|NCT04013971|Other|Game without AR|During the AGRF biofeedback game without augmented reality (AR) participants will walk on a split-belt treadmill with a projector-display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game without AR for 6 minutes.
22346|NCT04013971|Other|Game with AR|During the AGRF biofeedback game with augmented reality (AR) participants will walk on a split-belt treadmill with a head-mounted AR display. Participants will be receiving real-time information or feedback about ongoing gait performance parameters while they are walking. The participants will be exposed to the AGRF biofeedback game with AR for 6 minutes.
22347|NCT04013971|Other|Traditional Biofeedback Interface|"For the traditional non-game biofeedback, the visual display comprises a horizontal line graph with a moveable cursor that represents the current measured value of antero-posterior ground reaction force for the targeted leg. The auditory feedback comprises an audible beep produced every time the cursor entered the target range. Participants will be exposed to the traditional biofeedback interface for 6 minutes."
22348|NCT04013958|Drug|IV Ketamine|IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
22349|NCT04013958|Drug|IM Ketamine|IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
22350|NCT04013945|Dietary Supplement|Superba Boost (Active)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Superba Boost.
22351|NCT04013945|Dietary Supplement|Vegetable oil (Placebo)|To assess changes in Trans-epidermal water loss (TEWL), measured at baseline and after 12 weeks of daily consumption with Placebo.
22352|NCT04013932|Behavioral|KUPAA Intervention Group (Culturally Tailored Family Psychoeducation)|"KUPAA is composed of 3 key components:~1-2 Joining sessions [~30 to 45 minutes each] give the facilitator and participants a chance to get to know each other before KUPAA groups begin and allows time for questions.~Educational Workshop is an interactive, one day workshop offering information about biological, psychological and social aspects of mental illness; the nature, effects and side effects of psychiatric treatments; what families can do to help recovery and prevent relapse; and guidelines for managing mental illnesses.~12 Family psychoeducation group sessions [~1.5 hours each session] occur weekly in multi-family groups. These sessions follow an empirically tested format and focus on solving problems that interfere with treatment, illness, and symptoms management and that support coping skills and personal care. Case management may also be provided."
22353|NCT04013919|Drug|Multiple Daily Injections of Insulin|Basal/ Bolus insulin injections
22354|NCT04013919|Drug|Single insulin injections|Basal insulin injections only
22355|NCT04013906|Diagnostic Test|Rotational atherectomy|Rotational atherectomy
22356|NCT04013880|Drug|CDA Inhibitor E7727/Decitabine Combination Agent ASTX727|Given by mouth
22357|NCT04013880|Drug|IDH-1 Inhibitor FT-2102|Given by mouth
22358|NCT04013854|Drug|nivolumab|All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.
22359|NCT04013854|Drug|Ipilimumab|Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
22360|NCT04013841|Other|Oral-agents/Enema|"Oral-agents for mechanical bowel preparation prior to left-side colorectal resection~Enema for mechanical bowel preparation prior to left-side colorectal resection"
22361|NCT04013815|Procedure|erector spinae plane block with ropivacaine|The block is performed immediately before surgery. by an ultrasound guide, with the probe positioned longitudinally, the spinous process of T5 is identified. A peripheral block needle is inserted in the cephalo-caudal direction (caliber 21G and length 10 cm) and 3 ml of physiological solution are injected to confirm the injection site: fascial plane between the erector spinae muscle and the large rhomboid, near the tip of the transverse process of T5. Once the correct position of the needle tip has been confirmed, ropivacaine 0.75% 20 ml is injected.
22362|NCT04013815|Procedure|Intercostal nerve block with ropivacaine|The intercostal nerve block will be performed by the surgeon at the time of thoracotomy from the 4th to the 8th intercostal space, by injecting 20 ml of 0.75% ropivacaine (4 ml for each space). The injection is performed at about 2-3 cm from the spine.
22363|NCT04013802|Biological|HLA-matched VSTs|"An alternative approach that bypasses the need to grow VSTs for individual patients is to bank closely HLA-matched allogeneic VSTs that could be available as an off the shelf product.~The HLA-matched VST product is to produce immune activity to CMV, Adv, BK virus and EBV in all recipients.~Most recently our group extended this off the shelf approach to five viruses using the T cell product manufactured in 10 days. The VSTs were administered to 38 patients with 45 infections in a phase II clinical trial. A single infusion produced a cumulative complete or partial response rate of 92% overall and the following rates by virus: 100% for BKV (n = 16), 94% for CMV (n = 17), 71% for AdV (n = 7), 100% for EBV (n = 2), and 67% for HHV-6 (human herpesvirus) (n = 3)."
22364|NCT04013789|Device|DACP FreshTech contact lenses|Nelfilcon A soft contact lenses with a modified lens design
22365|NCT04013789|Device|DACP contact lenses|Nelfilcon A soft contact lenses
22366|NCT04013776|Dietary Supplement|Phosphate supplemented diet|Participants will be asked to follow a 5 day menu of 750 mg of phosphorus daily along with a daily sodium phosphorus supplement of 500 mg
22370|NCT04013724|Behavioral|Group tobacco cessation interventions|"Group Session Week 1 Participants were introduced to the specific components of the group behavioral intervention. Participants shared their expectations and experiences in their goal of tobacco cessation.~Group Sessions Weeks 2-11 Participants set their anticipated quit date on the 2nd week. During weeks 2 through 11, before the start of the session, feelings of participants were explored, the previous week's self-reported tobacco consumption or cessation attempt was recorded. The topic of each week was explored first by lecture to explain the topic, and then group members took turns sharing their experiences on the topic.~Group Sessions Weeks 14-26 Behavioral group sessions weeks 14-26 were conducted once a month. Each session began with a round of discussion on how participants were feeling about their cessation attempts, including any challenges they had experienced. The self-reported amount of tobacco used and quit attempts were documented."
22371|NCT04013711|Diagnostic Test|Thermography|Thermograms will be acquired of both treated and non-treated breasts for comparison.
22372|NCT04013698|Other|PEEP level 5 cmH2O|PEEP level set for 45 minutes
22373|NCT04013698|Other|PEEP level 15 cmH2O|PEEP level set for 45 minutes
22374|NCT04013685|Biological|TregGraft|engineered donor allograft
22375|NCT04013672|Drug|Pembrolizumab|200 mg IV every 3 weeks
22376|NCT04013672|Drug|SurVaxM|500 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
22377|NCT04013672|Drug|Sargramostim|100 mcg per dose, dosed every two weeks for 4 doses and then every 3 months
22378|NCT04013672|Drug|Montanide ISA 51|1 ml per dose dosed every two weeks for 4 doses and then every 3 months
22379|NCT04013659|Other|Dental Bleaching with 35% hydrogen peroxide gel + Violet LED Irradiation|After gum protection, the bleaching gel (35% hydrogen peroxide) was applied to the surface of the tooth and irradiated with VIOLET LED
22380|NCT04013646|Drug|Umbilical cord blood infusion|The umbilical cord blood is donated umbilical cord blood which is stored in the cord blood bank donated by Cha Hospital. The total number of nuclear cells should be at least 2 x 10 7 / kg, and at least three out of six of the six human leukocyte antigens (HLA-A, B, DR) should be selected. The cord blood that matches ABO and Rh blood type is preferentially used. Umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
22381|NCT04013646|Drug|Erythropoietin injection|Recombinant human erythropoietin is used and is administered intravenously at a maximum of 5 times at a rate of 500 IU / kg 2 times/week after cord blood peripheral blood infusion, calculated as the dose per body weight. Or subcutaneous administration if intravenous administration is not possible. Store in a sealed container at 2-8 °C in the refrigerator before dosing. Erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
22382|NCT04013646|Drug|Placebo umbilical cord blood infusion|Placebo umbilical cord blood infusion is administered intravenously and is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
22383|NCT04013646|Drug|Placebo erythropoietin injection|Placebo erythropoietin injection is performed at the stem cell clinical trial center. The procedure is performed by the doctor who is enrolled in this study. Monitor pulse and oxygen saturation during the procedure.
22384|NCT04013646|Procedure|Active rehabilitation|Physical therapy and occupational therapy are performed daily.
22385|NCT04013633|Other|Lifesaver virtual reality training|CPR training using the Lifesaver virtual reality application
22386|NCT04013633|Other|Face-to-face training|Short face-to-face CPR training
22387|NCT04013620|Drug|Belatacept 250 Milligram Intravenous Powder for Solution|"Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)"
22388|NCT04013607|Dietary Supplement|fructo- and galacto-oligosaccharides|A NDC drink rich in fructo- and galacto-oligosaccharides
22389|NCT04013594|Dietary Supplement|carbohydrate group|Randomly selected patients of the carbohydrate group are given oral carbohydrate (400ml) 2-3 hours before surgery.
22390|NCT04013581|Drug|TZD group|Pioglitazone 15mg (Acpio®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM(type 2 diabetes mellitus) patients who had inadequate glycemic control (7% <HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of pioglitazone : from 15mg to 30mg
22391|NCT04013581|Drug|SGLT-2 group|Empagliflozin 10mg (Jardiance®, once daily, regardless of meal time, for 24 weeks) will be added for T2DM patients who had inadequate glycemic control (7% <HbA1c ≤ 10%) with triple therapy (metformin, DPP-4 inhibitors, sulfonylurea). At visit 3 (after 12 week-treatment), patients whose HbA1c level is more than 7.0% will be prescribed increased dosage of empagliflozin : from 10mg to 25mg
22392|NCT04013568|Other|Exercise|"12-week exercise program, 3 days/week, 90min exercise sessions at the Rehabilitation Hospital of the Pacific.~Private or semi-private (1:1 or 2:1 ratio participant to instructor) sessions, led by Kinesiology students"
22393|NCT04013555|Drug|N-acetylcysteine (NAC)|Flavored effervescent formulation
22394|NCT04013555|Drug|Placebo|Flavored effervescent formulation designed to mimic NAC
22395|NCT04013555|Drug|Tryptophan|Oral slurry form
22396|NCT04013542|Biological|Ipilimumab|Given IV
22397|NCT04013542|Biological|Nivolumab|Given IV
22398|NCT04013542|Radiation|Radiation Therapy|Undergo radiation therapy
22399|NCT04013529|Behavioral|Regret lottery|Subjects who achieve step goals are entered into a lottery in which they can win a financial incentive of $30 or $100.
22400|NCT04013529|Behavioral|Way to Health technology enhanced care|Subjects receive text reminders to reach activity goals.
22401|NCT04013516|Behavioral|Cash Incentive|During the phone call, New Incentives' team member promised a greater cash payment from New Incentives' staff members at primary health care facilities when infants enrolled in the program and received their measles vaccination.
22427|NCT04013256|Other|Cigarette Smoke|Cigarette smoke, generated by a smoking machine and aged is used to reproduce exposure to secondhand and thirdhand cigarette smoke.
22402|NCT04013516|Behavioral|Call|A New Incentives' team member reminded caregivers of their child's measles immunization date and the total amount of incentive they would receive once their child was vaccinated. If the caregiver could not be reached on the first attempt, the team made additional attempts at different times of the day on five different days across two weeks (up to 10 attempts were made per caregiver).
22403|NCT04013490|Dietary Supplement|Cassava dietary fiber capsule|Cassava dietary fiber capsule or placebo will be consumed once daily at the recommended doses of each group.
22404|NCT04013477|Drug|DA-5207|DA-5207 Transdermal Delivery System
22405|NCT04013477|Drug|Donepezil Hydrochloride|donepezil HCl 10mg QD
22406|NCT04013464|Drug|Escitalopram|Escitalopram 10-20mg/d
22407|NCT04013451|Behavioral|Acts of kindness|Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
22408|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. Control group receive 6 mg oral estrogen and 100 mg intramuscularly progesterone until 12 week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
22409|NCT04013438|Drug|Strogen|The OCP-LD begins in 2 to 3 days of the last menstrual cycle and then 500 μgr/d GnRH-a will received on day 17 for fourteen days. Then in 2-3 days of the next menstrual cycle, GnRH-a reduced to 200 μgr/d dose. the patients will receive 6 mg oral that will be continued for 14 days and during this time endometrium thickness evaluated by vaginal ultrasonography. If endometrial thickness is estimated ≥7mm, intramuscularly progesterone 100 mg/d will be started. After the onset of progesterone (days 17 to 18 cycles) frozen embryos transferred. In patients 35 days after embryo transfer and observation of gestational sac with heart beat (6 weeks of pregnancy) by ultrasound, exogenous estrogen will discontinued while progesterone will remain daily use until twelfth week of pregnancy. The levels of maternal estrogen and progesterone was measured at the time of the starting day of progesterone (day 15), the day of embryo transfer, 6 and 12 weeks of pregnancy.
22410|NCT04013425|Procedure|Ice Cream Cone Technique|Guided bone regeneration
22411|NCT04013412|Dietary Supplement|Protein-Calorie Restriction|Four day dietary intervention immediately before surgery of ScandiShake [any of 4 flavors] mixed with almond milk, calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on body weight and activity level.
22412|NCT04013399|Device|Continuous Positive Airway Pressure|The device is an auto-adjusting pressure device with an integrated humidifier. Pressure is adjusted based on airway resistance.
22413|NCT04013386|Drug|Aprepitant and Dexamethasone|Aprepitant capsule 80 mg and Dexamethasone 8 mg IVI
22414|NCT04013386|Drug|Mirtazapine and Dexamethasone|Mirtazapine tablet 30 mg and Dexamethasone 8 mg IVI
22415|NCT04013386|Drug|Dexamethasone|Dexamethasone 8 mg IVI
22416|NCT04013373|Device|SOZO Bioimpedance Spectroscopy Device|Bioimpedance spectroscopy measurements for assessment of fluid status
22417|NCT04013360|Other|Breath Stacking|The patients will perform the maneuver through successive inspiratory efforts for 20 s. Subsequently, the expiratory branch will be unobstructed to allow expiration. This maneuver will be repeated 5 times in each series, with intervals of 30 seconds between them. The technique will be performed with the trunk inclined 30º in relation to the horizontal plane, in 3 series, with interval of 2 min completing 15 min of therapy.
22418|NCT04013360|Other|Expiratory Positive Airway Pressure|Patients will perform exhalation of air through a facial mask containing an extrinsic positive expiratory pressure valve with a defined load of 10 cmH2O for 5 min. During the application of the technique the patients will have a trunk inclined 30º and will be stimulated to breathe normally, without effort or deep and fast breaths.
22419|NCT04013347|Procedure|Rectal Resection|Low Anterior Resection and Abdominoperineal Resection
22420|NCT04013334|Drug|MTG201|MTG201, 3 x 10E12 vp delivered by intratumoral injection on days 1, 8, 22 and 50
22421|NCT04013334|Drug|Nivolumab Injection [Opdivo]|Nivolumab 480 mg by IV infusion every 4 weeks
22422|NCT04013321|Device|SleepScore Max coaching feature|The SleepScore max is a non-contact sleep tracking device. The app has an integrated feedback coaching feature to improve sleep.
22423|NCT04013321|Behavioral|Online CBTi|Online Cognitive Behavioral Therapy for insomnia is a user guided program to track sleep, receive sleep coaching, and initiate behavioral techniques such as tailored sleep scheduling and sleep hygiene to help improve sleep.
22424|NCT04013308|Procedure|Iontophoresis with 2% potassium iodide|10 iontophoresis treatments with 2% potassium iodide on the area of thyroid gland; electrodes with tin foil (Amperage:2mA, duration: 30min)
22425|NCT04013295|Other|Prize-linked savings|"Participants will be eligible for prizes based on the amount by which their account balance goes up in each period (e.g. for every 100 Ksh by which savings increases, participants get an entry into a lottery for monetary rewards where they have a small probability of winning a larger amount, or a larger probability of winning a smaller amount of money). This type of prize-linked savings intervention has been shown to promote savings in other settings.~Other intervention components may include education materials to explain how the prize-linked savings incentives work and that emphasize the potential benefits of saving money. Participants in the intervention group will be encouraged to have more consideration for their future health and economic status, as this may motivate them to save more money. They will also be encouraged to consider the opportunity and health cost of their expenditures on alcohol and transactional sex and not miss the opportunity to win prizes by saving money."
22426|NCT04013269|Device|CytoSorb-Therapy|Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy
44012|NCT03839771|Drug|Placebo for AG-221|100mg tablets
22429|NCT04013243|Drug|Magnesium Sulfate|magnesium sulphate 50mg/kg in normal saline 50ml infusion for 10minutes for loading dose followed by 15mg/kg/hr for continuous infusion
22430|NCT04013243|Drug|Placebo|Normal Saline 50ml infusion for loading dose followed by continuous infusion for same dose of magnesium.
22431|NCT04013230|Behavioral|Usual care|Visit doctor and nurse at the clinic.
22432|NCT04013230|Behavioral|Web-COP|Usual care plus group sessions and a web-based treatment program for 12 weeks for the child and parents.
22433|NCT04013217|Combination Product|Eribulin ORA|Oral eribulin mesylate will be supplied as an aqueous solution and HM30181A-UK
22434|NCT04013204|Other|Endothelial function guided therapy|To evaluate the effect of integration of non invasive endothelial function test (EFT) as a routine test in increasing appropriate treatment to reduce cardiovascular risk including prescription of lipid, blood pressure and glucose lowering medications by physicians at the clinic for patients with non-obstructive coronary artery disease (NOCAD) and the effect of introducing EFT as a routine test in reducing clinical endpoint (major adverse cardiovascular events) among patients with non-obstructive coronary artery disease(NOCAD).
22435|NCT04013191|Drug|Padsevonil|Padsevonil will be administered in predefined dosages.
22436|NCT04013178|Behavioral|Accentuated eccentric loading + electromyostimulation|An innovative training intervention to optimize muscle strength and muscle mass
22437|NCT04013178|Behavioral|Conventional resistance training|A conventional approach to resistance training
22438|NCT04013165|Behavioral|Active control|Control group received usual care of the Community Mental Health Service, consisted of case management for high-risk older adults and referral to psychiatric services.
22439|NCT04013165|Behavioral|Village-based intervention|"Individual-based case management was conducted both by healthy community dwellers (local committee) and Community Mental Health Service (CMHS) team based on risk-stratification for depression in older adults. Local committee-guided care was performed after matching a healthy dweller with 4-5 older neighbors included in risk groups. They visited the matched older individuals as often as possible at least once a week using a mood sticker. The CMHS team also conducted a separate case management for older adults with risk-stratified protocols; the higher the risk of suicide, the more intensive was the management, which could include frequent face-to-face visits. High-risk individuals were also referred to the psychiatric service, if deemed necessary.~Group-based program was comprised of weekly eight sessions, which were mainly consisted of programs enhancing interpersonal network and group cohesion, and were open to all community-dwelling older adults."
22440|NCT04013152|Other|Clinical database|Constitution of a prospective, multicenter clinical database of surgery with robotic assistance in colorectal pathologies
22441|NCT04013139|Diagnostic Test|CPET|CPET
22442|NCT04013126|Diagnostic Test|• Endothelial function using ENDOPAT system|All of the participants will follow an non-invasive test for endothelial function using ENDOPAT 2000 device before surgery. A consecutive assessment will be held 6 weeks and 2 years post-surgery, using the same method.
22443|NCT04013113|Drug|Haemoperfusion|"Three sessions of Hemoperfusion, 1 plasma volume/session will be done to the selected patients.~Hemoperfusion will be done through bile acids and ammonia filters to adsorb bile acids and ammonia respectively.~Group specific fresh frozen plasma will be transfused to the patient through a peripheral vein catheter to prevent hypotension if required."
22444|NCT04013113|Drug|Standard Medical Treatment|Standard medical therapy only included as per requirement.nutritional therapy ( high calorie intake- 2400 Kcal/ day) Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
22445|NCT04013113|Other|Plasma Exchange|"Fresh frozen plasma will be used as replacement fluid.TPE treatment shall be given on first day and continued on an a dailybasis/alternate day till the desired clinical or biochemical response is achieved.~The procedures of TPE and hemoperfusion will be stopped if any major side effects occur (described below), the patient expires or the patient is transplanted within 30 days (whichever is earlier)."
22446|NCT04013100|Diagnostic Test|3D-VNE (virtual neck exploration)|The 3D-VNE model is obtained with VP Planning software (Visible Patient, Strasbourg, France), using DICOM (Digital Imaging and Communications in Medicine) images of contrasted Computed Tomography scan of the neck in operative positioning.
22447|NCT04013087|Dietary Supplement|Oral feeding of Feihe Stage 1 infant formula|Oral feeding of Feihe Stage 1 infant formula for 16 weeks
22448|NCT04013087|Dietary Supplement|Oral feeding of control Stage 1 formula|Oral feeding of control Stage 1 formula for 16 weeks (A commercially available product with comparable composition but does not contain sn-2 palmitate enriched vegetable oil as an ingredient (regular vegetable oil is used))
22449|NCT04013087|Dietary Supplement|Breast feeding|Breast feeding of human milk for 16 weeks
22450|NCT04013074|Procedure|Transjugular Intrahepatic Portosystemic Shunt|Transjugular Intrahepatic Portosystemic Shunt
22451|NCT04013074|Other|Standard Medical Treatment|Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
22452|NCT04013061|Other|Pluridisciplinary consultation|Pharmacist-anesthesiologist team will be present during the anesthetic consultation
22453|NCT04013048|Drug|[14C]-Fluzoparib|Patients will receive single dose of orally [14C]- Fluzoparib on Day 1.
22454|NCT04013035|Procedure|cervical length measurement|cervical length measurement at second trimester pregnancy termination in nulliparous pregnant women.
22455|NCT04013022|Behavioral|Exercise History|The groups will be divided based on their exercise history
22456|NCT04012996|Device|prodisc C SK and/or Vivo|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
22457|NCT04012996|Device|Mobi-C Cervical Disc|Subjects will be randomized in a 2:1 ratio either to the two-level prodisc C SK or prodisc C Vivo device (investigational group) or to the two-level Mobi-C device (control group).
22458|NCT04012983|Diagnostic Test|gingival crevicular fluid level|gingival crevicular fluid collection
22460|NCT04012957|Drug|Desidustat Oral Tablet|Desidustat tablet
22461|NCT04012957|Drug|Darbepoetin Alfa|Darbepoetin injection
22602|NCT04011787|Radiation|Chest X-ray|A chest X-ray will be performed on patients receiving study interventions on day 7 to confirm/exclude pneumonia
22462|NCT04012944|Device|Cordella™ Pulmonary Artery Sensor System|"The Cordella PA Sensor System comprises seven subsystems that operate together to take daily Pulmonary Artery Pressure (PAP) readings at a patient's home and transmit the results to a care provider for evaluation.~Cordella Sensor~Cordella Delivery System~myCordella Patient Reader~Reader Dock~Cordella Calibration Equipment (CalEQ)~myCordella Hub~Cordella Data Analysis Platform (CDAP)."
22465|NCT04012918|Drug|Capecitabine plus aromatase inhibitor|Capecitabine 625 mg/m2 bid PO for 14 days to be repeated every 21 days until progression in combination with aromatase inhibitor if postmenopausal, addition of LHRH agonist will be added if premenopausal.
22466|NCT04012918|Drug|A.I.|aromatase inhibitors ( letrozole 2.5 mg PO per day or Anastrozole 1 mg PO per day or aromasin 25 mg PO per day) if post-menopausal, if premenopausal leutnising hormone releasing hormone (LHRH) agonist will be added to the aromatase inhibitor
22467|NCT04012905|Drug|Corticosteroids for Systemic Use|"Corticosteroids tapering over 28 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,5 mg/kg S6 = 0,4 mg/kg S8 = 0,3 mg/kg S10 = 0,25 mg/kg S12 = 0,2 mg/kg S14 = 0,15 mg/kg S16 = 0,15 mg/kg S20 = 0,1 mg/kg S24 = 0,05 mg/kg S28 = 0 mg/kg~Corticosteroids tapering over 52 weeks:~J0 = 0,7 mg/kg S2 = 0,6 mg/kg S4 = 0,6 mg/kg S6 = 0,5 mg/kg S8 = 0,4 mg/kg S10 = 0,3 mg/kg S12 = 0,25 mg/kg S14 = 0,2 mg/kg S16 = 0,175 mg/kg S20 = 0,15 mg/kg S24 = 0,125 mg/kg S28 = 0,01 mg/kg S32 to S52: - 1mg per month"
22468|NCT04012892|Combination Product|CD19 CART|CD19 CART
22469|NCT04012879|Combination Product|CD19 CART|CD19 CART
22470|NCT04012866|Behavioral|Aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
22471|NCT04012866|Behavioral|Computerized cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
22472|NCT04012866|Behavioral|Control training|The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
22473|NCT04012853|Device|transcranial direct current stimulation|Treatment group will receive 20 minutes of tDCS stimulation at 2.0 mA administered daily for five days per week and a total of 4 weeks. During the 20minute treatment session, both treatment and sham groups will complete mindfulness meditation via VA health system approved program (Mindfulness Coach).
22474|NCT04012827|Drug|Apatinib Mesylate, doxorubicin, ifosfamide|Doxorubicin 50mg/m2 d1 , Ifosfamide 2.5g/m2 d1-3 , Apatinib mesylate 375mg qd
22475|NCT04012814|Device|Venus Bliss|The FDA cleared device (Venus Bliss™) is a non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060 nm diode laser applicators (60 mm x 60 mm). A belt is included to allow the operator to secure the laser applicators on the lipolysis treatment area, allowing hands free operation. The device uses vacuum assisted radiofrequency (RF) and PEMF (pulsed electromagnetic field) technology which has been shown in clinical studies to be safe and effective in body circumferential reduction and skin tightening.
22476|NCT04012801|Diagnostic Test|C13 breath test|C13 breath test for patients of acute myocardial infarction who need dual- antiplatelet after PCI.
22477|NCT04012788|Dietary Supplement|Synbiotic mixture|A synbiotic mixture consisting of four probiotic strains and inulin (a prebiotic)
22478|NCT04012788|Other|Placebo comparator|Placebo powder
22479|NCT04012775|Biological|Insulin Humulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
22480|NCT04012775|Biological|Insulin Rinsulin® NPH|4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
22481|NCT04012762|Device|Whole body vibration training|Intermittent whole-body vibration exposure is a training method providing physical stimulation effect on skeletal muscles by increasing gravitational acceleration on the vibration platform.
22482|NCT04012749|Behavioral|Advance directive|Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.
22483|NCT04012749|Behavioral|Prepare|Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.
22484|NCT04012749|Behavioral|Facilitator|Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
22485|NCT04012723|Device|MY01 Continuous Compartmental Pressure Monitor|The MY01 Continuous Compartmental Pressure Monitor is intended for real-time and continuous measurement of compartmental pressures.
22486|NCT04012710|Procedure|Laparoscopy|Conventional abdominal laparoscopy
22487|NCT04012710|Procedure|vNOTES|Transvaginal natural orifice transluminal endoscopic surgery for salpingo-oophorectomy
22515|NCT04012437|Device|Sphincter Control Training (SCT)|The SCT consists of four different exercises and an educational session into a app using a masturbation electronic aid device
22551|NCT04012164|Other|Participatory activity and contact investigation|30 human subjects will self-report daily activities and contacts with selected wild and domesticated animals for five months.
22603|NCT04011774|Other|PLANI-REV|Cognitive remediation program.
22604|NCT04011774|Other|RELAXATION|Stimulation with no cognitive remediation.
24027|NCT04000022|Device|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
22488|NCT04012697|Behavioral|Peer Support|Participants randomized to the intervention group will be seen by the peer support worker during their stay in the emergency department. The goal of the peer support worker's practice is to address the participant's wellness from a holistic point of view that includes their relationships, connections to the community, general well-being, and sense of empowerment, with an overall focus on quality-of-life goals (Sunderland et al., 2013). The peer support worker will provide a multi-faceted intervention, which aims to foster a peer-to-peer relationship encompassing elements of empathic communication, brief supportive counseling, advocacy for non-medical needs in hospital, liaising and collaborating with medical and nursing staff, motivational interviewing, and connection with programs in the community.
22489|NCT04012684|Device|Transcranial magnetic stimulation|For one-session rTMS, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz, 100% resting motor threshold TMS pulses. The inter-train interval is 26 seconds.
22490|NCT04012684|Device|Sham|For one-session sham stimulation, 50 trains of stimulation are given. Each train is consisted of 4-second 10 Hz sham pulses. The inter-train interval is 26 seconds.
22491|NCT04012658|Other|No intervention|No intervention
22492|NCT04012645|Procedure|application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME and colon-rectum or colon-anal anastomosis. near infrared-indocyanine green imaging system was used to evaluate the anastomotic flood perfusion during the operation; The operator may decide whether to change the surgical programme based on the outcome of the evaluation.
22493|NCT04012645|Procedure|Non-application of near infrared-indocyanine green imaging system|Underwent laparoscopic TME operation, and the operator judged anastomotic blood supply with naked eyes and performed the surgical intervention based on the experience
22494|NCT04012632|Other|this study was an observational study and no interventions were given to the participants|the participants were recruited and the data as well as blood sample were collected.
22495|NCT04012619|Drug|Anlotinib Hydrochloride|Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.
22496|NCT04012606|Drug|TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo|TORIPALIMAB INJECTION(JS001 ) or Placebo combined with chemotherapy, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
22497|NCT04012593|Behavioral|Diary|
22498|NCT04012580|Behavioral|Therapist-assisted ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students will provide support by email once a week.
22499|NCT04012567|Device|Investigational device: Biosure Regenesorb Interference Screw|The Biosure Regenesorb Interference Screw, an absorbable screw designed with an open structure and made of biocomposite material made of PLGA, β-TCP and calcium sulfate, is used to fix ligaments, tendons, soft tissues or bone-tendon-bone grafts in knee surgery. Its open structural design enables rapid bone ingrowth to make the screw integrated with bone tissues so as to promote healing.
22500|NCT04012567|Device|Control device: BIOSURE HA Interference Screw|BIOSURE HA Interference Screws and Drivers are designed for durability and reduced screw breakage. Both the screws and driver have been enhanced to allow screws to fully seat on the driver all the way to the tip of the screw, helping stress distribution and force transfer. The screw design also incorporates a consistent wall thickness throughout the length of the screw for added durability and features a tapered body for ideal ease of insertion.
22501|NCT04012554|Procedure|avoid chest drainage tube placement after video-assisted thoracoscopic wedge resection of lung|Avoiding chest drainage tube placement after VATS of the lung in the experiment group.
22502|NCT04012554|Procedure|Indewlling chest drainage tube after video-assisted thoracoscopic wedge resection of lung|Indewlling chest drainage tube after VATS of lung in the control group.
22503|NCT04012541|Procedure|active dental procedure|scaling and root planing
22504|NCT04012541|Drug|post-myocardial infarction management|aspirin, clopidogrel, ticagrelor
22505|NCT04012541|Radiation|basic periodontal examinations|panorama radiograph : full mouth periapical radiograph
22506|NCT04012528|Other|ERAS program|ERAS program
22507|NCT04012515|Device|Electrode Pads|Participants wear six electrode pads in total; three different types of pad, worn in the same positions on both sides of the face. The pads on the left-hand side of the face are replaced daily, and those on the right-hand side are replaced every other day. The pads do not administer a medical treatment or perform any other active function. The purpose of the intervention is to determine which combination of pad and replacement regime maximises the tolerability of wear over a 30-day period.
22508|NCT04012502|Other|Toxicities reduced treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by reducing radiation dose(60Gy/30Fx) and omitting concurrent cisplatin chemotherapy when responses to induction chemotherapy are ≥ 50% Partial Response(PR)
22509|NCT04012502|Other|conventional treatment|Two cycles docetaxel+cisplatin (TP) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy with standard radiation dose (70Gy/35Fx) when responses to induction chemotherapy are less than 50% Partial Response(PR)
22510|NCT04012489|Procedure|Breath Stacking|Patients were connected to a unidirectional valve coupled to artificial airway (tracheostomy), with bacteriological filter. The ventilator was coupled to the unidirectional valve to measure inspiratory volume mobilized in each cycle and a connection to adapt a manometer. The patient performed successive inspirations for a maximum period of 30 seconds or until unidirectional valve opening or volume increase was observed for 2 consecutive efforts. Ten cycles of the technique were performed, with an interval of 30 seconds.
22511|NCT04012489|Procedure|Air Stacking|The same system of monitoring and adaptation of the ventilometer and manometer was carried out. A manual resuscitator coupled to a unidirectional valve was used, both connected to the tracheostomy, with a filter interface. Slow and successive inspirations were performed through slow compression of the resuscitator until the maximum inspiratory pressure reached 40 cmH2O. Ten cycles of the technique were performed, with an interval of 30 seconds.
22512|NCT04012476|Drug|Indocyanine Green|Administration of 5 mg of intravenous indocyanine green after total thyroidectomy for measurement of parathyroid fluorescence under infrared light
22513|NCT04012450|Procedure|Epidural anesthesia|Performing an epidural anesthesia
22514|NCT04012450|Procedure|spina-epidural anesthesia|Performing a spina-epidural anesthesia
44656|NCT03834493|Drug|Placebo|IV infusion
22516|NCT04012424|Drug|curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf|"effect of taking 400mg curcumin one hour before endodontic ttt on post endodontic pain immediatelly and after 8,12,24,48 hours after endodontic treatment.Curcumin is an ancient coloring spice of Asia which is powerful antioxidant , it has hepatoprotective effect and traditionally used for many remedies . Interestingly, it has various pharmacological activities including analgesic, anti-inflammatory , It is even reported to have antimicrobial effect .~Medical clinical trials reported on the analgesic effect of curcuminoids in reducing postsurgical pain osteoarthritis and rheumatoid arthritis .~other name : curcum, tumeric"
22517|NCT04012424|Dietary Supplement|400mg starch|patints taking(400mg) starch in tabelts in same shape and color of control group before endodontic treatment by one hour and post endodontic pain immediately and after 8,12,24,48 hours after treatment completion
22518|NCT04012411|Procedure|Brain MRI|Multimodal brain MRI: volumetry, diffusion tensor, functional rest MRI
22519|NCT04012411|Procedure|Lumbar Punction|Analysis of BDNF, Tau, NFL and TrkB in cerebrospinal fluid
22520|NCT04012411|Genetic|Blood sample|Analysis of BDNF, Tau, NFL, and Val66Met polymorphism
22521|NCT04012411|Other|Cognitive evaluation|Symbol Digit Modality Test (SDMT), Stroop test, Trail Making Test, Empan
22522|NCT04012398|Diagnostic Test|Amsterdam IADL Questionnaire short, German version|Questionnaire to assess impairments in instrumental activities of daily living
22523|NCT04012385|Behavioral|lifestyle counseling|Nutritional plan and Physical activity goals
22524|NCT04012372|Other|ROSA Water|Ad libitum hydration with ROSA oligomineral water
22525|NCT04012372|Other|Control water|Ad libitum hydration with other waters
22526|NCT04012359|Diagnostic Test|Lung ultrasound|Non-invasive external ultrasonography of the chest wall
22527|NCT04012359|Diagnostic Test|Chest radiography|Chest radiography to search for visible pleural edge, synonym with persistent pneumothorax
22528|NCT04012359|Diagnostic Test|Pulmonary function tests|Pulmonary function evaluation as part of routine care for emphysematous patients
22529|NCT04012359|Other|Clinical examination|Standard clinical examination performed by investigating physician
22530|NCT04012346|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation device will be used. Short protocol iTBS will be applied.
22531|NCT04012333|Drug|OLIMEL 7,6%E / PeriOLIMEL 2,5%E|OLIMEL 7,6%E will be administered via a central access whereas PeriOLIMEL 2,5%E will be administered peripherally.
22532|NCT04012320|Other|No intervention, observational study|No intervention, observational study
22533|NCT04012307|Drug|Candesartan Cilexetil 32mg|Candesartan Cilexetil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 32 mg of candesartan cilexetil.
22534|NCT04012307|Drug|Atacand® PROTECT|Atacand® PROTECT is manufactured by AstraZeneca GmbH, Germany. Each tablet contains 32 mg of candesartan cilexetil.
22535|NCT04012294|Drug|Allopurinol Pill|"Individuals who meet the inclusion criteria and also have morphostructural changes suggestive of MSU crystal deposits in their MSUS will start treatment with allopurinol at a dosage of 150 mg to be taken daily, orally for a month and then to be increased to 300 mg. The rest of the individuals' medication is not to be altered. If a participant presents hypersensitivity to allopurinol, they are to stop the medication and will be excluded from the investigation.~Three months after starting treatment, the participants will have a physical exam, confirm the continuation of the treatment (adjust dosage if needed) and take a blood sample for laboratory tests. Six months after treatment is started, the participants will be reevaluated by MSUS and have another blood sample taken, Once the study is finished, continuing or ending treatment with allopurinol will be decided by the medical judgment of the physician of each participant."
22536|NCT04012281|Device|Percutaneous coronary intervention|PCI was performed using 2nd generation DES
22537|NCT04012268|Device|RIC|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
22538|NCT04012268|Device|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
22539|NCT04012255|Drug|Semaglutide (administered by DV3396 pen)|Increasing doses of semaglutide given subcutaneously (sc, under the skin) in the stomach for 21 weeks
22540|NCT04012255|Drug|Semaglutide (administered by PDS290 pen)|Increasing doses of semaglutide given sc in the stomach for 21 weeks
22541|NCT04012242|Diagnostic Test|Ultrasound application|Shear wave elastography, shear wave dispersion, attenuation imaging, and intensity analysis
22542|NCT04012229|Genetic|BRCA mutation|The genetic testing was performed according interregional consensus (Manchester score > or = 16) on blood sample using classical chain-termination (Sanger sequencing) and multiplex ligation-dependant probe amplification to search large rearrangements.
22543|NCT04012216|Device|Measure of mandibular movement using a mid-sagittal magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium)|A mid-sagittal MM magnetic sensor (Brizzy, Jawac©) Nomics, Liege, Belgium) measures the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and on the chin. Measurements last one night.
22544|NCT04012216|Device|Gold standard: polysomnography|Polysomnography will be performed according to the American Academy of Sleep Medicine Recommendations 2018
22545|NCT04012177|Dietary Supplement|LNS PLW|Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
22546|NCT04012177|Drug|Azithromycin Tablets|Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.
22547|NCT04012177|Drug|Choline Bitartrate|Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome
22548|NCT04012177|Drug|Nicotinamide|Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
22549|NCT04012164|Biological|blood sampling|5ml blood sampling
22550|NCT04012164|Biological|stool collection|self stool collection (2g)
22600|NCT04011787|Diagnostic Test|Continuous Glucose Monitoring|Both participant groups will have continuous glucose monitoring performed for 5 days while in the study
22552|NCT04012164|Other|Anthropological and historical interviews|Oral interviews on current and past practices and engagements with wild and domesticated animals will be conducted with the 30 human subjects who are recruited to self-report their activities (Participatory activity and contact investigation) and to provide blood and stool samples. Another 30 human subjects will be recruited only to participate in the same type of interviews, addressing past and present activities and relations with wild and domesticated animals.
22553|NCT04012151|Other|Physical measurement|Parturients of gestational week >= 32 weeks will have their arms and fingers measured to generate the conicity index.
22554|NCT04012151|Other|Cuff size fitting|Fit on arm cuff and finger cuff as selected by investigators based on the measurement.
22555|NCT04012138|Drug|Salbutamol|10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
22556|NCT04012138|Drug|Insulin Aspart|"Patients in the experimental group will receive either:~10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute); OR~10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol."
22557|NCT04012125|Device|flexible thoracolumbar brace|Subjects would wear the flexible thoracolumbar brace over 18 hours a day
22558|NCT04012112|Device|thoracolumbar brace (Flexpine brace)|Patient's would wear the FLEXpine brace over 18 hours a day for the 6 month
22559|NCT04012099|Drug|BMT101|Intradermal injection to each of 3 dose-groups.
22560|NCT04012086|Other|Physical therapy|Our physical therapy program included a variety of different exercise modalities (aerobic exercises, treadmill training and exercise intervention program) performed under the supervision of a physiotherapist
22561|NCT04012073|Device|Invasive Mechanical ventilation|"Volume-control ventilation with tidal volume will be set at 6 mL/Kg of predicted body weight, respiratory rate to maintain pH>7.30 and PaCO2<50 mmHg and FiO2 will be set to achieve a SpO2>88-95%.~In case of hypercapnia with Ph<7.30 despite a respiratory rate=30-35, an increase in tidal volume up to 8 ml/kg will be allowed.~In both groups, the assigned ventilation protocol will be followed for a minimum of 72 hours from randomization and any time fully controlled ventilation is deemed necessary by the attending physician up to 14 days from randomization. After 14 days from randomization, PEEP will be set according to the clinical practice of each institution.~After 72 hours from the study protocol, the PEEP setting protocol according to the assigned treatment will be resumed at any time within 14 days from enrolment if fully controlled ventilation is established, according to the decision of the attending physician in charge."
22562|NCT04012073|Drug|Neuromuscular Blocking Agents|All patients will receive NMBA for 48 hours after the enrolment. The decision to stop NMBA administration after 48 hours will be left to the attending physician, but muscle paralysis will be strongly encouraged if PaO2/FiO2 ratio remains lower than 80-100 mmHg. NMBA administration will be resumed anytime deemed necessary by the attending physician.
22563|NCT04012073|Procedure|Prone positioning|Prone positioning will be used in all enrolled patients as a standard of care: the decision about the timing and the duration of prone position sessions will be left to the attending physician and the time spent by the patient in the prone and in the supine position will be recorded: PEEP will be re-set according to the protocol of the allocated treatment anytime patient's position is changed.
22564|NCT04012073|Procedure|Resume of spontaneous breathing|"Assist/control and assist ventilation will be allowed after 72 hours from the enrolment if deemed appropriate by the attending physician.~During spontaneous breathing, PEEP will be set according to the decision of the attending physician and the practice of each institution: however, in order to standardize the treatments, moderate PEEP (10-15 cmH2O) will be encouraged in case of moderate hypoxemia (PaO2/FiO2<150 mmHg) in control group, while PEEP close to the value set during controlled ventilation according to the treatment protocol but <15 cmH2O will be suggested in the intervention group.~During assist/control and assisted ventilation, PEEP will never be higher than the last PEEP set according to the assigned protocol during controlled ventilation.~Fully controlled mechanical ventilation will be resumed any time during the study period if the patient meets the criteria described above or any time deemed necessary by the physicians in charge"
22565|NCT04012073|Procedure|Rescue treatments|Recruitment maneuvers, extracorporeal membrane oxygenation (ECMO), extracorporeal CO2 removal (ECCO2-R) after randomization will be allowed in both groups as rescue therapies and according to the decision of attending physicians: any of these procedures will be accurately recorded on the case report form.
22566|NCT04012073|Procedure|Weaning from PEEP|"In order not to delay weaning from mechanical ventilation, when a patient is managed with assist/control or assist ventilation with PEEP higher than 8 cmH2O, a daily PEEP weaning trial will be performed whether PaO2/FIO2 ratio>150 mm Hg and FIO2<0.5: PEEP will be decreased to 8-5 cm H2O and arterial blood gas will be sampled after 20 -0 minutes. Previous ventilatory settings will be resumed if during the procedure transcutaneous oxyhemoglobin saturation decreases below 88%, PaO2/FIO2 falls below 150 mm Hg or if the patient experiences abnormal changes in respiratory rate or other clinical signs suggestive of respiratory distress.~When PaO2/FIO2 is no lower than 200 mm Hg at PEEP≤8 cmH2O, the patient will be considered to have acceptable gas exchange on 8-5 cmH2O of PEEP and will be deemed capable to tolerate this setting"
22567|NCT04012073|Procedure|Weaning from mechanical ventilation|"A 30-120-minute spontaneous breathing trial will be initiated as the following criteria are met and whether the patient tolerates fully assist ventilation with PEEP≤8 cmH2O for at least 4 hours without experiencing hypoxemia (SpO2<88% or PaO2/FiO2<150mmHg):~improvement or resolution of the underlying cause of acute respiratory failure~normal sensorium~correction of arterial hypoxemia (PaO2 ≥ 60 mmHg at a FiO2 ≤ 0.4 with PEEP ≤ 8 cmH2O);~absence of fever (≥ 38 °C) or sepsis;~blood hemoglobin concentration of 7 g/dL or more;~hemodynamic stability~For the purpose of the study, success of the spontaneous breathing trial will be defined as presence of the following criteria:~respiratory rate < 35/min,~arterial oxygen saturation ≥ 90%,~heart rate < 120/min,~systolic blood pressure > 90 and < 160 mmHg~adequate cough. If the spontaneous breathing trial is successful, the patient will be extubated."
22601|NCT04011787|Diagnostic Test|Metabolic Profile|Bloods will be taken to assess all patients metabolic profile
24030|NCT03999996|Biological|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
22568|NCT04012073|Procedure|Extubation|"Each extubated patient will undergo oxygen therapy via high flow nasal cannula (maximum flows tolerated and FiO2 titrated to obtain 96%>SpO2>92%). Pre-emptive noninvasive ventilation (NIV) after extubation will be allowed in prolonged to wean patients (i.e. more than 3 SBT failure or more than 7 days from the first spontaneous breathing trial to being extubated) if deemed necessary by the physician in charge.~In case of respiratory failure during oxygen therapy via high flow nasal cannula after extubation and, a rescue NIV trial will be allowed before intubation in both groups at the discretion of the attending physician."
22569|NCT04012060|Procedure|Limited access aortic valve replacement.|Limited access aortic valve replacement through partial upper hemisternotomy
22570|NCT04012060|Procedure|Conventional aortic valve replacement|Aortic valve replacement through full median sternotomy
22571|NCT04012047|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
22572|NCT04012047|Drug|Saline|To investigate the role of levcromakalim compared with placebo in migraine with aura patients
22573|NCT04012034|Device|Radiofrequency A|Application of radiofrequency for 30 minutes per week during 8 weeks
22574|NCT04012034|Device|Radiofrequency B|Application of radiofrequency without energy for 30 minutes per week during 8 weeks
22575|NCT04012021|Diagnostic Test|7T Magnetic Resonance Imaging|"T1-weighted and T2-weighted sequences~quantitative magnetic resonance imaging approach~proton spectrum analyses"
22576|NCT04012008|Other|Comprehensive care|"Regular follow-up by nephrologists every 1-3 month~Multidisciplinary team consisting pharmacists, nurses, and dieticians"
22577|NCT04012008|Other|Standard care|"Regular follow-up by internists every 3 month~May consult nephrologists case-by-case"
22578|NCT04011995|Behavioral|Intermittent caloric restriction|"The intervention is based on the 5:2 diet, which involves caloric restriction for 2 days (consecutive or nonconsecutive, 600kcal/d for male and 500kcal/d for female) per week and unrestricted eating during the other 5 days of the week.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
22579|NCT04011995|Behavioral|Low carbohydrate diet|"During the 14-day intervention period, the subjects receive 7 days (consecutive or nonconsecutive) of low carbohydrate diet intervention. Carbohydrate intake of low-carbohydrate diet should be controlled as ≤ 50g per day.~Total trial duration is one month consisting of a 14-day intervention phase and a 14-day self-maintenance phase. During the maintenance phase, two follow-up electronic questionnaires were conducted."
22580|NCT04011995|Behavioral|Health education on reducing the cardiometabolic risk|Health education is conducted once a week during 14-day dietary intervention for all subjects. Health education including the understanding of cardiovascular disease, how to determine the cardiometabolic risk level, and the lifestyle intervention as caloric restriction and increased physical activity to promote health.
22581|NCT04011969|Diagnostic Test|Score assessment|Asia Pacific Colorectal Screening (APCS) is a validated tool to predict the risk of colorectal cancer in asymptomatic Asian population. The scoring system comprises of three categories: low risk (score 0-1), moderate risk (score 2-3) and high risk (score 4-7). Patients with moderate and high risk will undergo further examinations.
22582|NCT04011969|Diagnostic Test|Blood sampling|"Blood samples will be taken before colonoscopy procedure to evaluate the level of serum CEA by ELISA method and to evaluate the presence of NF-ҡB by immunohistochemical method.~Carcinoembryonic antigen (CEA) is a well-known marker for colorectal cancer. A pre-treatment serum CEA level of ≥ 5 ng/mL is associated with poor prognosis in colorectal cancer patients.~NF-ҡB is a chronic inflammation marker found in colorectal cancer patients."
22583|NCT04011969|Diagnostic Test|Fecal sampling|"Fecal samples will be taken before colonoscopy procedure to be tested for FIT and to evaluate the gut microbiome.~Fecal immunochemical test (FIT) is a recommended screening method for colorectal cancer. Detection of hemoglobin over a certain level in fecal samples indicated a positive FIT. Patients with positive FIT will undergo further examinations.~Gut microbiome examination will be conducted with next generation sequencing (NGS) method."
22584|NCT04011943|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
22585|NCT04011930|Drug|cholecalciferol|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
22586|NCT04011930|Drug|Placebo oral capsule|80,000 IU(2 capsules)/week for 13 weeks and then according to the serum calcium and serum D level 40,000 IU/2 to 3 weeks for next 13 weeks
22587|NCT04011917|Behavioral|Standard care|Treatment by an extended scope physiotherapist following Standard Operating Procedures.
22588|NCT04011904|Other|Cross-over study|Traditional Inuit Diet vs Westernized Diet
22589|NCT04011891|Procedure|Robotic Partial Nephrectomy|Robotic partial nephrectomy using da Vinci robot.
22590|NCT04011891|Procedure|Open Partial Nephrectomy|Standard open partial nephrectomy
22591|NCT04011878|Procedure|Combined trabeculotomy trabeculectomy with mitomycin C|Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
22592|NCT04011865|Procedure|Radical prostatectomy|The patients diagnosed with prostate cancer (local or locally advanced stages) will be allocated to the study for performing radical prostatectomy surgery.
22593|NCT04011852|Device|Electrical Impedance tomography|Monitoring with Electrical impedance tomography during spontaneous breathing trials on T-piece in children
22594|NCT04011839|Drug|Levobupivacaïne|Use of Levobupivacaïne instead ropivacaïne
22595|NCT04011813|Other|Hypotaurine : antioxidant and osmoregulator|"Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing"
22596|NCT04011800|Procedure|Catheter ablation|Pulmonary vein isolation, or additional left or righ atrial lession.
22597|NCT04011800|Combination Product|Risk Factor Modification|dietary restriction, physical exercise, reduced alcohol intake
22598|NCT04011787|Dietary Supplement|bolus NGT feeding|Participants randomised to bolus NGT feeding will receive this for 7 days at mealtimes
22599|NCT04011787|Dietary Supplement|Continuous NGT feeding|Participants randomised to bolus NGT feeding will receive this continuously for 7 days as per hospital protocol
22605|NCT04011761|Other|expert arbitration over discordant diagnoses made by AI diagnostic system and human doctors, respectively|Each participant receives two diagnoses: one from the AI diagnostic system and the other from pediatricians, and the two diagnoses are discordant. Participants in the experimental arm will be referred to an expert arbitrator for differential and decisive diagnosis and will receive treatment prescribed by the expert arbitrator.
22606|NCT04011748|Combination Product|Stem Cell Educator therapy combined with minoxidil|AA subjects will be recruited and initially primed with oral minoxidil for 30 days, and followed by the treatment with SCE therapy.
22608|NCT04011722|Device|Portico™ NG Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the new generation Portico NG valve and second-generation FlexNav Delivery system via a transfemoral or alternative access approach according to the site's anesthesia protocol for TAVR procedures.
22609|NCT04011709|Combination Product|VR647 Inhalation System + VR647 Smart Card 3 Secs|3 attempts of 19 inhalations, 3 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
22610|NCT04011709|Combination Product|VR647 Inhalation System + VR647 Smart Card 2 Secs|3 attempts of 28 inhalations, 2 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
22611|NCT04011709|Combination Product|VR647 Inhalation System + VR647 Smart Card 4 Secs|3 attempts of 14 inhalations, 4 second per breath. Attempts 1 and 2 will be made with air only. Attempt 3 will be made with isotonic saline (0.9% NaCl)
22614|NCT04011657|Other|Compulsory CDSS|Compulsory CDSS use with prospective review feedback in patients prescribed with piperacillin tazobactam or carbapenems
22615|NCT04011644|Behavioral|A-CHESS self-monitored|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
22616|NCT04011644|Behavioral|A-CHESS peer-supported|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
22617|NCT04011644|Behavioral|A-CHESS clinically-integrated|Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
22618|NCT04011631|Procedure|Internal defibrillation during cardiac surgery, using the iD-system|When ventricular fibrillation of ventricular tachycardia occurs during surgery, the iD-Paddle will be applied directly to the heart. A maximum of 4 shocks are delivered to the heart to restore normal sinus rhythm. If 4 shocks are not successful standard operating procedure will be enable conform hospital protocol.
22619|NCT04011618|Drug|Ellagic Acid / Pomegranate Extract|Phenolic acid, ellagitannin, found in a wide variety of fruits and nuts; in this particular case, pomegranate extract with ellagic acid 90% 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
22620|NCT04011618|Drug|Placebo oral capsule|Calcinated magnesia in 500mg capsules. Homologated to the other intervention. Dosage twice a day orally every 12 hours during 12 weeks
22621|NCT04011605|Procedure|Biological Sample of Carious Dentin|Dental patient volunteers will have either areas of decayed tooth structure or recurrent caries defective fillings removed using conventional, routine procedures, which will include: local anesthesia; tooth isolation using rubber dam; removal of superficial decay, weakened tooth structure or defective filling materials with rotary tooth cutting instruments; and then removal of softened dentin using sterile sharp spoon excavators, by hand. The limit of dentin removal will be determined by the clinician's estimate of tooth hardness, that is, using present conventional and ethical practice.
22622|NCT04011592|Drug|Ketamine 0.5 mg/kg|single intravenous infusion of Ketamine (0.5 mg/kg)
22623|NCT04011592|Drug|Ketamine 0.2 mg/kg|single intravenous infusion of Ketamine (0.2 mg/kg)
22624|NCT04011579|Other|MSFIT|MSFIT, by using the Microsoft Kinect Motion Controller Xbox to deliver adapted physical activity, offers the possibility to transform the Pilates exercises into a virtual reality game. Each exercise is implemented with different levels of difficulty in order to allow the adaptation to the capacities of the user.
22625|NCT04011566|Diagnostic Test|ShuntCheck|The intervention is an FDA-cleared device utilizing a transcutaneous thermal convection to analyze shunt flow.
22626|NCT04011553|Other|Virtual Reality based Rehabilitation Program|"Virtual reality-based rehabilitation was implemented via MarVAJED system. At first the sensors of MarVAJED® were placed under and above the knee joint and then it was calibrated. The content of the game programs included in the MarVAJED system and how to perform these games with the exercises were explained to the participants. We used games called Crazy Wings and Blasting Ball included in the MarVAJED®.There was a bird figure in Crazy Wings game and represented knee joint of participants. Although the bird figure moved upwards during knee flexion, it moved downward in knee extension, there were some obstacles on the way of the bird went. The subjects were asked to follow the bird figure visually and to pass through the obstacles by flexing or extending their knees when they encountered obstacles."
22627|NCT04011540|Behavioral|Digital data|0
22628|NCT04011527|Procedure|Rotational Atherectomy in Coronary Lesion/s|
22716|NCT04010747|Behavioral|Motivational Interviewing for Loved Ones (MILO)|4 sessions of behavioral coaching in motivational interviewing communication techniques
22629|NCT04011514|Behavioral|Dedicated stroke nurse care in ED|A specialized SU nursing team partner with ED nursing staff for timely fulfillment of stroke quality care indicators while awationg admission to a dedicated stroke unit
22630|NCT04011501|Procedure|Continuous Erector spinae block|Erector spine block and catheter placement will be performed for continuous analgesia prior to the surgical procedure.A initial bolus of 20 ml of Levobupivacaine 0.25% will be administered. Subsequently a 22G catheter will be introduced. At the end of the surgery, an elastomeric pump will be installed at a flow rate of 7 ml / hr with a 1.3% Ropivacaine solution.
22631|NCT04011488|Other|Shared Decision Making Tool|"We've used the framework from this model and adapted it to the patient perspective to create a Patient Shared Decision Making Tool. The model is interactive so it can be customized to a specific patient. It has adjustments built in for gender, race/ethnicity, age, and select comorbidities (obesity, hypertension and diabetes).~The strongest, underlying message is that any treatment choice is better than not seeking treatment. To illustrate this, a Do Nothing pathway is included for comparison purposes."
22632|NCT04011475|Drug|Tiotropium + Olodaterol|Spiolto®
22633|NCT04011475|Drug|Other LABA/LAMA|tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium
22634|NCT04011475|Drug|LAMA|aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
22635|NCT04011462|Device|prewarming 20 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 20 minutes.
22636|NCT04011462|Device|prewarming 30 minutes|prewarming with a forced air warming system, using a blanket covering the whole body, regulated to the temperature of 38 °C for 30 minutes.
22637|NCT04011449|Device|Medtronic RC+S DBS system|Implantation of the Medtronic RC+S Deep Brain Stimulation (DBS) system
22638|NCT04011436|Other|Strengthening program|"Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises"
22639|NCT04011423|Other|Unstable shoes plus Whole-body vibration|Wearing unstable shoes during the whole-body vibration training
22640|NCT04011423|Other|Stable shoes plus Whole-body vibration|Wearing stable shoes during the whole-body vibration training
22641|NCT04011410|Drug|Hydroxychloroquine Sulfate 200Mg Tab|Twice daily for 90-days, administered two weeks prior to radiation/surgery of oligometastatic lesions
22642|NCT04011397|Other|Exercise intervention|Exercise intervention (reduced-exertion, high-intensity interval training) delivered within an NHS setting. Consisted 10 min of cycle ergometry (inclusive of warm-up and cool down) including very brief maximal cycle sprints.
22643|NCT04011397|Behavioral|Usual care|Members of a multi-disciplinary team including a consultant, diabetes specialist nurse, clinical psychologist, physiotherapist, and dietician worked together to promote patient self-management. Care was tailored to the specific circumstances of each patient after initial assessment and focussed on weight management, dietary education, behavioural therapy, and supported pharmacotherapy initiation as appropriate.
22644|NCT04011384|Behavioral|Behavioral economic intervention of online purchasing at a food pantry|This intervention includes multiple behavioral economic interventions, healthy food shopping cart defaults, healthy placement choice architecture, traffic light nutrition labels, social norms messaging, and healthy swaps.
22645|NCT04011371|Procedure|Cyanoacrylate closure|Cyanoacrylate glue embolization targeting venous insufficiency
22646|NCT04011358|Other|Sleeping Monitor|to evaluate obstructive sleep apnea
22647|NCT04011345|Dietary Supplement|Folic Acid Supplement|1 milligram folic acid
22648|NCT04011345|Dietary Supplement|Placebo|Placebo
22649|NCT04011332|Other|Integrated Care Model|The patients who are hospitalised due to a COPD exacerbation will be aligned to a nurse-led integrated care model for three months. The model constitutes a bundle of interventions that are commonly known as key elements in COPD management. In addition, the ANP-Team (Advanced Nursing Practice-Team) will coordinate the different health professionals within the hospital and across transitions within the three months.
22650|NCT04011319|Behavioral|group culture|Four embryos were cultured in the same droplet by a special dish.
22651|NCT04011293|Biological|CNCT19|0.5 to 4 x 10^6 autologous CNCT19 transduced cells per kg body weight, with a maximum dose of 4 x 10^8 autologous CNCT19 transduced cells via intravenous infusion.
22652|NCT04011280|Drug|Varenicline|The ten 30-minute sessions will target core processes in ACT such as acceptance and being present.
22653|NCT04011267|Other|Physical therapy by foot-ankle segmental and functional exercises|The physiotherapeutic foot-ankle exercise protocol is based on previous clinical trials. It was designed following three criteria established in a supervised, face-to-face intervention: muscle stretching; strengthening of the intrinsic muscles; and strengthening of the extrinsic foot-ankle muscles and functional exercises, such as balance and gait training. To avoid monotony, game principles were inserted to reward the exercise execution and enhance motivation. The exercises change from session to session, and the maximum duration is no longer than 20 minutes. The exercises should only be done 3 times/week; no more than eight exercises each day; and the individual difficulty is regulated by the effort scale to manage the customized progression. In total, 39 different exercises were chosen, and when including their sublevels of progression, a total of 104 different exercises can be completed.
22654|NCT04011254|Procedure|haemodialysis|Routine haemodialysis session
22655|NCT04011241|Drug|BI 1323495|Tablet
22656|NCT04011241|Drug|Itraconazole|Oral solution
22657|NCT04011228|Diagnostic Test|Blood sampling|After a fasting period over night blood samples will be taken.
22658|NCT04011228|Diagnostic Test|Saliva and blood samples|After a fasting period over night blood and saliva samples will be taken for the investigation of epigenetics based modifications.
22659|NCT04011228|Diagnostic Test|Magnet Resonance Spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle will be measured using 1H-magnetic resonance spectroscopy.
22660|NCT04011215|Other|wool clothing|superfine merino wool ensembles for baby/child wear
22691|NCT04010968|Drug|FCR|"All patients will receive 6 cycles of FCR administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6.~6 cycles of FCR will be administered at 4 weeks intervals (D1 = D29) from Month 1 to Month 6."
22661|NCT04011215|Other|standard clothing|Standard clothing refers to the clothing normally worn by the infant/child. This will not be superfine merino wool as superfine merino is not generally available for baby wear. The exact nature of the standard clothing will be recorded by investigators. From previous data we expect it to be primarily cotton.
22662|NCT04011202|Behavioral|Virtual reality gaming program (VR-gaming program)|Participants in the VR-gaming program will receive three 20-30 minutes sessions of VR-gaming per week for three weeks. Participants will select VR games/program in categories of: Relaxation; Leisure sport and activities; or Action/adventure. The VR-gaming program will be implemented one-on-one, face-to-face by a clinician using the commercially-available Oculus Go system.
22663|NCT04011189|Procedure|Videotaping|Before the videotaping, patients will be asked on their baseline pain scores. Their face and body pose from a frontal view will be videotaped via a mobile phone with no internet access. The collected videos will be further processed to extract keypoints (70 points to capture key facial landmark locations and 25 points to capture joint locations), which will be the primary input for modeling algorithms and will further ensure anonymity of the patients in the video sequences.
22664|NCT04011189|Other|Questionnaires|Patients will be asked to fill in two questionnaires before surgery (Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L). After surgery, patients will be again asked to fill in HADS questionnaire daily post-operatively.
22665|NCT04011176|Procedure|Standard treatment + placebo|Placebo microcurrent
22666|NCT04011176|Procedure|Standard treatment + Microcurrent Therapy|Actual microcurrent
22667|NCT04011163|Device|VPIA pump|The pump is a specially designed and manufactured infusion syringe pump for intravenous analgesia. It incorporates the VPIA study regimen to meet the specific requirements of the clinical trial. It is intended to be used only for delivering drugs intravenously.
22668|NCT04011163|Drug|Morphine|Intravenous medication used is morphine diluted in normal saline to a concentration of 1mg/ml. This is a standard dilution and are routine drugs used as standard of care.
22669|NCT04011150|Device|Epidural infusion pump|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
22670|NCT04011150|Drug|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
22671|NCT04011150|Drug|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
22672|NCT04011137|Other|Exercise|Arm-cranking exercise
22673|NCT04011124|Drug|Fluzoparib|single dose on Day 1 and Day 12
22674|NCT04011124|Drug|Rifampicin|QD on Day 5-14 for 10 days
22675|NCT04011111|Procedure|Intubation tube and voice analysis|After the ıntubation tube application, done voice analysis early postoperative period
22676|NCT04011098|Drug|Epidural Fentanyl Bolus|Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
22677|NCT04011098|Drug|Standard Epidural Group|The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
22678|NCT04011072|Radiation|Far infrared radiation|The treatment group will receive FIR for 40 minutes on the skin above the fistula during each dialysis session for one year.
22679|NCT04011059|Biological|Wharton's jelly-derived mesenchymal cells|Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
22680|NCT04011046|Device|Stent|
22681|NCT04011033|Biological|iNKT cells|5×10^8-10^9/m2 iNKT cells will be infused to patients at 1st, 3rd, 5th, 7th, 8th and 12th week.
22682|NCT04011033|Drug|Cyclophosphamide|CTX will be administered intravenously at a dose of 750mg/m2 2 days before the first iNKT cells infusion.
22683|NCT04011033|Drug|Human recombinated Interleukin-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days after iNKT cells infusion.
22684|NCT04011033|Procedure|TACE|TACE will be conducted to all patients at 0th week and 4th week.
22685|NCT04011020|Combination Product|Stem Cell Educator therapy|Patients with T1D will be evaluated by the study principal investigator or co-investigators. Informed consent will be obtained at the initial screening visit. The initial screening visit will occur within 30 days of initiation of SCE therapy. The second screening visit will occur within 7 days of therapy. Subjects who meet all criteria will be scheduled for treatment. All enrolled subjects will receive treatment with the SCE system consisting of a single session of mononuclear cells (MNC) collection by apheresis where 10 L of blood will be processed on day -1. The MNC product will then be exposed over to the SCE and on day 0 the product will be infused intravenously back to the patient.
22686|NCT04011007|Procedure|vitrectomy with or without inverted ILM flap technique|vitrectomy without ILM peeling versus vitrectomy with inverted ILM flap technique in cases of macular hole retinal detachment in high myopic eyes.
22687|NCT04010994|Procedure|Transorbital electrical stimulation|Transorbital ACS using 8-12 Hz with 0,5-1,5 mA Intensity, during the first two weeks 1/day, after 2/week for 10 weeks, as a home treatment
22688|NCT04010981|Other|study group|The treatment protocol will consist of Nintendo wii fit virtual reality exercises (yoga,aerobic exercises,muscle strengthening exercises)
22689|NCT04010981|Other|control group|The treatment protocol will consist of home based video exercises ;yoga,aerobic exercises,muscle strengthening exercises
22690|NCT04010968|Drug|venetoclax and ibrutinib (I+VEN)|"The treatment will start with ibrutinib alone for 3 months (lead-in phase) from Month 1 to Month 3 and then venetoclax will be added from Month 4 with an initial ramp-up period.~The total duration of treatment with (I+VEN) will depend on the response achieved at Month 9:~if BM MRD at M9 < 0.01%, the treatment with (I+VEN) will be continued for 6 additional months until Month 15 and stopped then. MRD will be assessed at Month 15 (PB), Month 21 (PB) and Month 27 (PB and BM)~if BM MRD at M9 ≥ 0.01%, the treatment with (I+VEN) will be continued for 18 additional months until Month 27 and stopped then, whatever the results of MRD assessments that will be performed at the same time points as above."
22692|NCT04010955|Drug|Edoxaban Monotherapy|when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.
22693|NCT04010942|Drug|Vit D|Injection
22694|NCT04010942|Drug|Metformin|tablets
22695|NCT04010942|Drug|Clomiphene|Tablet
22696|NCT04010929|Procedure|Partial pulpotomy with laser+MTA|After removing caries, laser+MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
22697|NCT04010929|Procedure|Partial pulpotomy with MTA|After removing caries, MTA was applied to the exposed area on the pulp following bleeding control with 5.25% NaOCl.
22698|NCT04010916|Other|Group Preoperatively Adductor Canal Block|The ACB will be performed preoperatively before inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
22699|NCT04010916|Other|Group Preoperatively Tourniquet Adductor Canal Block|The ACB will be performed preoperatively after inflation of the tourniquet. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
22700|NCT04010916|Other|Group Postoperatively Adductor Canal Block|The ACB will be performed postoperatively. After identifing the adductor canal, by using the in-plane technique, the probe will be placed at the mid-thigh, half the distance between the inguinal crease and the patella, for block location. The superficial femoral artery will be visualized dorsal to the sartorius muscle. Then, the probe will be remowed to distally. At this level, the hyperechoic view of the saphenous nerve will be visualized lateral and anterior to the artery in the subsartorial region. 5 mL of saline will be injected to confirm the proper injection site, and then a dose of 0.25% bupivacaine 30 mL will be injected here.
22701|NCT04010903|Diagnostic Test|assessment of biomarkers of insulin resistance|blood and urine sample collection for assays of BCAAs
22702|NCT04010890|Behavioral|Culturally adapted CBT|Culturally adapted CBT for South Asian Canadians
22703|NCT04010877|Biological|CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells|Infusion of CLL-1, CD33 and/or CD123-specific CAR-T cells
22704|NCT04010864|Other|routine clinical treatment|Participants will be informed that this is not a treatment study and it involves naturalistic follow-up without any extra intervention. They will otherwise follow the routine clinical treatment procedure.
22705|NCT04010851|Behavioral|Peer co-led educational group|The intervention is delivered in a group format, which takes the form of a full day's training, focusing on ADHD diagnosis, its treatment, how to cope with the challenges related to living with ADHD, as well as coping with challenges of parenting a child with chronic health conditions. After this one day-intervention, the participants can continue in self-help groups, which meet once a week for a 2-hour evening session. User representatives lead these weekly self-help groups, which do not require user-fees and aim to offer practical tools, support and information to increase the parent's skills, knowledge and confidence. Participants are encouraged to adopt an active role in order to achieve a positive parent/provider partnership.
22706|NCT04010851|Behavioral|Comparator treatment as usual|Control group will receive treatment as usual, including different treatment options that can help alleviate the symptoms of ADHD and arm families with the tools needed to better handle problem behaviors when they arise. These interventions include: medication, psychotherapy, or a combination of these two approaches.
22707|NCT04010838|Procedure|spinal cord stimulation|The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.
22709|NCT04010812|Other|Questionnaire|RHDS- Readiness For Hospital Discharge Scale, Patient Self-Assessment Form
22710|NCT04010799|Drug|CHF 6333|CHF 6333 - Part I - SAD CHF 6333 - Part II - MD
22711|NCT04010799|Drug|Placebo|Placebo - Part I - SAD Placebo Part II - MAD
22712|NCT04010786|Drug|NNC0247-0829|Participants will receive either single or multiple doses given subcutaneously (s.c., under the skin) in a lifted fold of the stomach skin. Dose level and number of doses will depend on the cohort.
22713|NCT04010786|Drug|Placebo (NNC0247-0829)|Participants will receive either single or multiple doses of placebo given s.c. in a lifted fold of the stomach skin.
22714|NCT04010773|Other|collective and psycho-social intervention|The intervention duration is 1 year. It combine (1) In each unit, working groups aimed at improving QWL, (2) counseling and training of directors and frontline managers, and (3) in each unit, concertation meeting between workers, front-line managers and directors.
22715|NCT04010760|Diagnostic Test|Test of biomarkers for PE in EBC|"New method for diagnosis of pulmonary embolism (PE) in order to validate/consolidate 151 putative identified biomarkers for PE in the exhaled breath condensate (EBC).~The EBC will be collected by use of the RTube(R) system which has been used in previous studies of EBC. As the patient breathes through a mouth piece, the exhaled breath is led through a cooling chamber where the vaporous part of the exhaled breath condenses.~We aim at collecting a total minimum of 3.0 mL EBC per study subject in order to have a sufficient amount of protein for the subsequent analysis. We aim at collecting exhaled breath condensate for 2*15 minutes with the possibility to stop the collection after less than 15 minutes if the volume is sufficient."
22825|NCT04009824|Biological|Saline Placebo|Administered by subcutaneous injection
22717|NCT04010747|Behavioral|Mental Health Services Consultation|1 session of individualized consultation on relevant mental health services for the IP and participating PCSO, with assistance offered in making a specific referral.
22718|NCT04010734|Procedure|Peroral Cholangioscopy and Endoscopic retrograde cholangiopancreatography|"The peroral cholangioscopy (DSOC), one of a newer method of endocanal exploration via ERCP- commonly known as the SpyGlass - helps to provide the visual diagnostics of the strictures based on morphological and vascular patterns and to provide directed intraductal biopsy (SpyBite) from the lesions. The combination of both should increase the diagnostic yield in the evaluation of indeterminate biliary stricture by DSOC.~ERCP is the most widely used diagnostic procedure in patients with biliary obstruction. It enables to identify the biliary stricture, to determinate its location and help providing tissue sampling from the stricture for cytological evaluation. Different methods were used to take samples from the site of the stenosis. Brushing and endocanal forceps biopsies were the most used techniques. The samples from these two techniques will be additionaly examinated using Fluorescence in Situ Hybridization (FISH)."
22719|NCT04010721|Device|Experiment 1|Stimulation of one electrode at a time
22720|NCT04010721|Device|Experiment 2:|Stimulation in groups of 4, 8 and 12 electrodes
22721|NCT04010721|Device|Experiment 3|Stimulation total duration from 10 to 600 ms
22722|NCT04010708|Diagnostic Test|Urinary Iodine Concentration Measurement|UIC
22723|NCT04010695|Diagnostic Test|STANDARD G6PD|"The STANDARD G6PD Analyzer is designed to measure the quantitative determination of total Hb concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product. System components shall be labeled in accordance with regulatory requirements, including the following statement, For Investigational Use Only. The performance characteristics of this product have not been established."
22724|NCT04010682|Other|urine sample collection|no drug/devise intervention. sample collection study only
22725|NCT04010669|Drug|Somatostatin|2 amp of somatostatin at 1000ml normal saline solution in continuous 24-hour infusion for 5 days
22726|NCT04010669|Drug|Placebo|24 hours infusion of 1000ml Normal Saline solution 0.9%
22727|NCT04010656|Procedure|PVR-based self-catheterization|Home self-catheterization based on standard of care
22728|NCT04010643|Behavioral|online cognitive behavioural therapy|oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey & O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
22729|NCT04010643|Behavioral|online neurocognitive remediation therapy|NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
22730|NCT04010630|Drug|Sodium bicarbonate infusion|"Patients randomly assigned to bicarbonate group will receive intravenous 4.2% sodium bicarbonate titrated from 125ml to 250ml in 30min at physician's discretion to target a pH equal or above 7.30. Bicarbonate infusion will be repeated up to 1000ml per 24h. Arterial blood gases will be repeated from 3 to 6 times during the first 24h at physician's discretion.~Bicarbonate infusion recommendations will be as follow: a central line is recommended, infusion will be slow (125-250ml in 30 min, no intravenous push), careful surveillance of metabolic alkalosis, cardiogenic pulmonary edema, kalemia, natremia and calcemia. Repeated arterial blood gases will be suggested to monitor these critically ill patients and physicians will be reinformed of the potential side effects of sodium bicarbonate infusion."
22731|NCT04010617|Device|Pharyngeal Electrical Stimulation (PES)|PES will be delivered by a commercial device (Phagenyx, Phagenesis Ltd, Manchester, UK), which comprises a nasogastric feeding catheter that houses stimulation ring-electrodes and a computerised base station that delivers stimulation in the range 1-50 mA at 5 Hz.
22732|NCT04010591|Device|impedance measurement during urodynamic study|Impedance information is measured through the belt in the abdomen of the subject. The urodynamic test is performed from the state in which the urine of the bladder is completely emptied to the state of the bladder until the state becomes full, so the impedance measurement is measured from the state where the urine of the bladder is completely emptied to the state of the bladder until the state becomes full.
22733|NCT04010578|Dietary Supplement|Menaquinone-7|Patients will receive 360 micro-grams of Menaquinone-7 per day.
22734|NCT04010578|Other|Placebo|Patients will receive a placebo each day.
22735|NCT04010565|Dietary Supplement|Aged black garlic extract|"Participants will intake a tablet with 250 mg of a aged black garlic extract with higher concentration of bioactive compounds S-allyl cysteine and alliin, and minor unwanted compounds such as simple sugars and furfural derivatives.~In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias."
22736|NCT04010565|Dietary Supplement|Placebo|Participants will intake a tablet with 250 mg of microcrystalline cellulose. In addition, during the course of the study, participants will be urged to follow dietary guidelines according to a heart-healthy diet established by nutritionists and that they will adhere to European guidelines for the treatment of dyslipidemias.
22737|NCT04010552|Drug|NALRINOX combination|NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin
22738|NCT04010539|Drug|Gepotidacin|Gepotidacin will be administered as 3000 milligram (mg) oral dose (4 X 750 mg tablets) at the study site followed by 3000 mg oral dose (4 X 750 mg tablets) as an outpatient. Each dose should be taken after food consumption and with water.
22739|NCT04010539|Drug|Ceftriaxone|Ceftriaxone is available as sterile powder for reconstitution. It will be administered as one 500-mg IM dose at the study site.
22740|NCT04010539|Drug|Azithromycin|Azithromycin will be administered as 1000 mg oral dose (2 X 500 mg tablets) at the study site. Dose should be taken after food consumption and with water.
22741|NCT04010526|Combination Product|local co-administration of autologous ADIpose|local co-administration of autologous ADIpose derived stromal vascular fraction and microfat for refractory perianal CROHN's fistulas Each batch of the final product is composed of one 5 mL syringes containing 25,9 +/- 10,7 millions viable cells. Each syringe will be obstructed with a sterile stopper and packaged in an external packaging.
22742|NCT04010526|Other|placebo|local co-administration of placebo The study placebo will consist of a saline solution for intralesional administration and will follow the same administration schema described for the SFV
22743|NCT04010513|Behavioral|Hypnosis|Women in the hypnosis group will undergo treatment with three in-person hypnosis sessions and will be given access to hypnosis web-app for at home practice.
22744|NCT04010513|Other|Standard of Care|Women in the usual care group will continue their usual care for BPS/IC as dictated by their physicians.
22745|NCT04010500|Device|no mouthguard|Control (not using mouthguard)
22746|NCT04010500|Device|'boil and bite' mouthguard|KHZ058 Bicolor Mouth Guard (Shenzhen Kanghao Industrial Co. Ltd, China) will be immersed in a bowl of hot water (about 80 °C). After 50 seconds, the softened sheet will be fitted on the maxillary arch of the participant. The participant will then bite down to ensure the mouthguard stay firmly on the maxilla. After that, the mouthguard will be removed and immersed in cold water to retain its shape.
22747|NCT04010500|Device|custom-fitted mouthguard|The custom-fitted mouthguards will be constructed using the dual laminated technique with two layers of ethylene vinyl acetate (EVA) thermoplastic sheets (Dentsply International Raintree Essix, Court East Sarasota, USA).
22748|NCT04010487|Genetic|whole exome sequencing and RNA-sequencing|The specimens from adenomyosis, endometrial cancer, and eutopic endometrium will be tested by whole exome sequencing and RNA-sequencing
22749|NCT04010474|Procedure|Modified Surgical APGAR Score|"Four intraoperative factors~Lowest heart rate (HR),~Lowest mean arterial pressure (MAP)~Estimated blood loss~Operation time"
22750|NCT04010461|Device|TMS|Intermittent theta burst stimulation TMS applied to the cortex to excite cerebral cortex
22751|NCT04010461|Behavioral|n-back working memory task|Subjects perform an executive function task, in which they view the serial presentation of letters and decide whether or not a letter matches a letter presented 'n' letters back (3 letters or 1 letter)
22752|NCT04010448|Biological|TV P2-VP8|90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57
22753|NCT04010448|Biological|Rotarix|Rotarix® PO plus IM placebo administered on study days 1, 29 and 57
22754|NCT04010435|Device|repetitive transcranial magnetic stimulation|high frequency (10 HZ) rTMS pulses are applied to the dorsolateral prefrontal cortex of the dominant hemisphere.
22755|NCT04010435|Device|Galvanic stimulation|galvanic stimulation of the vestibular apparatus
22756|NCT04010422|Diagnostic Test|no intervention|no intervention
22757|NCT04010409|Other|no intervention|no intervention
22758|NCT04010396|Other|Blood sampling|Blood sampling: 1 EDTA and 1 Serum vial
22759|NCT04010383|Diagnostic Test|virtual reality perimeter|Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
22760|NCT04010370|Diagnostic Test|Oral glucose tolerance test (OGTT)|The patient will be cited at 8:00 AM with a minimum of 8 hours of fasting. The weight, height, waist circumference and blood pressure will be taken. Afterwards, a catheter will be placed for the venous blood sample and the biochemical determination of fasting glucose, total cholesterol, HDL, LDL, VLDL, triglycerides and assessment of A1C will be carried out. You will be tested for oral glucose tolerance and insulin sensitivity, for which you will be given a 75-g dose of glucose in water by orally. After the ingestion of the glucose solution, the venous blood sample will be at times 0, 30, 60, 90, 120, 150 and 180 minutes.
22761|NCT04010357|Drug|Abemaciclib,|Abemaciclib (CDK4/6 inhibitors) is an investigational drug that works by interrupting the rapid and uncontrolled growth of cancer cells. Some cancer cells develop because their cells overrun the molecular brakes that normally permit cell to divide only when they are needed to replace old ones. These brakes are regulated by a group of enzymes known as cyclin-dependent kinases (CDKs). Alterations causing over-activity of two of these enzymes, CDK4 andCDK6, are found in a variety of cancers, including small cell lung cancer with retinoblastoma (Rb) protein.The drugs work by selectively turning off the overactive CDK4 and CDK6. As a result, the cancer cells' division cycle is halted, preventing them from proliferating.
22762|NCT04010344|Behavioral|Enhanced Usual Care Group|"Medtronic® Labs' Akoma pa app, a culturally-tested and locally attuned mobile health platform, will be used in the intervention arm of the study to improve communication between the Community Health Officer (CHO) and the participant. This platform will be used to enhance shared decision making, clinical decision support, participatory communication, knowledge, treatment adherence (medication and lifestyle modification), and self-monitoring of hypertension. We will test the feasibility of the Akoma pa app in addressing patient-level and provider-level barriers to hypertension control.~The app will consist of the following components:~Reminders~Participant to CHO messaging~Home BP tracking~Educational materials on cardiovascular disease (CVD) and Stroke- Participants will have access to education modules on reducing the risk of CVD and stroke tailored to their knowledge level.~CHO provider portal- The provider portal will include decision support tools."
22763|NCT04010344|Other|Usual Care Group|Regular/usual appointments or visits to patients' healthcare provider for management of study outcomes
22764|NCT04010331|Dietary Supplement|Nokyong Mixture Extract(CME-PI)|2 times a day, 2 capsule for 1 time, after breakfast/dinner meal, for 8 week
22765|NCT04010331|Dietary Supplement|Placebo|Placebo for 8 week
22766|NCT04010318|Procedure|Spinal Anesthesia|The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
22767|NCT04010305|Drug|Sublingual film containing BXCL501 (Dexmedetomidine)|Sublingual film containing BXCL501 (Dexmedetomidine) for the treatment of agitation associated with Schizophrenia
22768|NCT04010305|Drug|Placebo film|Placebo film for BXCL501
22769|NCT04010292|Behavioral|Patient education card|Patient who are randomized to receive a patient card at the end of the counseling visit will be able to take an index-card sized card with them which will highlight their anticipated surgery.
22770|NCT04010279|Procedure|preoxygenation with 100% O2, fresh gas flow rate 12 L/minute|volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
22771|NCT04010253|Device|SIMEOX|Instrumental airway clearance by the medical device SIMEOX
22772|NCT04010253|Other|Autogenic drainage|Manual aiway clearance by autogenic drainage
22773|NCT04010240|Other|Retrospective cohort|Tumor material tested positive will be analyzed by next-generation sequencing to identify NTRK1, NTRK2 or NTRK3 gene fusions.
22774|NCT04010227|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers will practice various mindfulness exercises, clarify their values, and set specific goals in alignment with their values. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to unwanted internal experiences (e.g., fatigue, distress). Participants will receive handouts on session topics and a CD that we developed to guide mindfulness practices.
22775|NCT04010227|Behavioral|Education/Support|Across six weekly 50-minute sessions, advanced GI cancer patients and caregivers will be directed to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center and treatment team, education regarding common quality-of-life concerns experienced by cancer patients and caregivers, and an overview of medical center and community resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts summarizing session topics and will be asked to review them as homework.
22776|NCT04010214|Other|No intervention|No intervention
22777|NCT04010175|Behavioral|Control - Cognitive training in a practitioner's office one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office during 4 months (16 weeks of training = 16 hours of training). This training will include 10 short tasks of increasing difficulty. Performance of these tasks involve cognitive functions such as: executive functions, reasoning, auditive, visual and visuo-spatial memory, speed of processing, short-term memory and working memory. Thus the training aims to exercise all these cognitive functions.
22778|NCT04010175|Behavioral|Experimental group 1 - Cognitive training in a practitioner's office one time per week and cognitive distance training one time per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and one time per week cognitive distance training in her/his place of residence, during 4 months (16 weeks of training = 32 hours of training).
22779|NCT04010175|Behavioral|Experimental group 2 - Cognitive training in a practitioner's office one time per week and cognitive distance training four times per week|Participant will perform 1-hour cognitive computer based training one time per week in a practitioner's office and four times per week cognitive distance training in her/his place of residence during 4 months (16 weeks of training = 80 hours of training).
22780|NCT04010162|Other|Mesh debate awareness survey|"A web-based questionnaire with questions about recent discussions of mesh in urogynecology.~10 questions. Average survey completion time: 1 minute"
22781|NCT04010149|Device|Active tDCS|For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
22782|NCT04010149|Device|SHAM tDCS|For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
22783|NCT04010136|Other|Palliative care training|Intervention will consist on providing different types of palliative care training to identify the most accurate on improving GPs' identification of palliative care patients skills
22784|NCT04010123|Device|Atherectomy/Thrombectomy|Percutaneous transluminal removal of thrombotic, thromboembolic and atherothrombotic material from fresh, subacute and chronic occlusions of blood vessels in native blood vessels or vessels fitted with stents, stent grafts or native or artificial bypasses.
22785|NCT04010110|Diagnostic Test|visual field testing (10-2), spectral domain ocular coherence tomography and Fundus auto-fluorescence|The diagnosis of toxic retinopathy was based on the positivity of at least two objective tests to confirm the subjective findings. The presence or absence of toxicity was recorded.
22786|NCT04010097|Other|chewing gum|The test involves chewing a chewing gum for 4 minutes
22787|NCT04010084|Radiation|Low level laser therapy|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
22788|NCT04010084|Procedure|Placebo group|"The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested."
22789|NCT04010071|Drug|axitinib plus toripalimab|"Axitinib 5mg, twice a day, orally, 4 weeks a cycle. Dose reduction from 5mg twice a day to 3mg twice a day should be considered according to adverse events.~Toripalimab 240mg, every 3 weeks, intravenous infused, 6 weeks a cycle. Number of cycle: until disease progression or unacceptable toxicity events."
22970|NCT04008693|Dietary Supplement|Aged Garlic Extract|2.400 mg (four capsules) of a nutritional supplement of aged garlic extract (Kyolic® Hi-Po Formula - Kyolic)
22790|NCT04010058|Device|LIDCO CNAP device|The LiDCO CNAP device (referred to as CNAP in this document) provides continuous cardiac output non-invasively, without the requirement for an arterial catheter. It uses a dual finger cuff in addition to a standard arm cuff (familiar to everyone who's had their blood pressure checked) and it transforms infrared plethysmographic signals into continuous blood pressure information. It uses an algorithm to derive cardiac output-related parameters. In recognition of the potential difference between the derived values and any measured values, it refers to some of its values as 'nominal' values. It has been evaluated in a range of surgical populations8-11 a post-operative cohort12, and a haemodynamically unstable critical care population13. In a population of patients undergoing endoscopy there was increased detection of episodes of hypotension compared with standard measures.
22791|NCT04010045|Device|Endovascular Treatment of PAD|PAD endovascular treatment using the DABRA Laser System + other FDA cleared/ approved devices for the treatment of PAD.
22792|NCT04010032|Device|Programmed intermittent epidural bolus|bolus administration of 0.15 ml of ropivacaine 0.15 ml / kg into epidural space every hour(intermittent bolus injection) using PCA device
22793|NCT04010032|Device|Continuous epidural infusion|Continuous infusion of 0.15% ropivacaine 0.15 ml / kg / h into the epidural space using PCA device using PCA device
22794|NCT04010019|Behavioral|Enhanced Facebook Condition|The intervention (enhanced Facebook condition) will consist of several training components that were selected based on pain research and platform affordances. The first component will be psychoeducation on pain neurobiology. Emotional validation training will follow. The third component will consist of facilitating patients' emotional disclosure about their pain journeys and lives. The fourth and final intervention component will include prompts to engage participants in activities that they have been avoiding because of their pain.
22795|NCT04010019|Behavioral|Control Facebook Condition|The control condition will instruct participants to offer mutual support and will not offer psychosocial intervention.
22796|NCT04010006|Procedure|4K Laparoscopic Surgery|4K Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
22797|NCT04010006|Procedure|HD Laparoscopic Surgery|HD Laparoscopic Surgery will be performed for the treatment of patients assigned to this group.
22798|NCT04009993|Device|A-BIRTHPERFORM digital tool|use of A-BIRTHPERFORM digital tool
22799|NCT04009980|Other|OMK2 group|topical administration of OMk2 ophthalmic solution for 36 months three times/day
22800|NCT04009980|Other|Placebo group|topical administration of ophthalmic placebo solution for 36 months three times/day
22801|NCT04009967|Drug|Pembrolizumab|Pembrolizumab 200 mg every three weeks for 3 cycles only
22802|NCT04009954|Other|Fecal and blood samples collection for analysis|"Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs)."
22803|NCT04009941|Drug|PEG-rhG-CSF|4.5mg per cycle, 24 hours after chemotherapy
22804|NCT04009928|Device|Active stimulation of the medial forebrain bundle or subcallosal cingulate|Deep brain stimulation of the medial forebrain bundle or subcallosal cingulate
22805|NCT04009928|Device|Sham stimulation|Sham stimulation for 2 weeks (Cross-over design)
22806|NCT04009915|Procedure|VATS|Patients undergo a standard VATS operation for stage II-III lung cancer called a lobectomy.
22807|NCT04009915|Procedure|Open surgery|Patients undergo a standard open operation for stage II-III lung cancer called a lobectomy.
22808|NCT04009902|Behavioral|Beck Depression Scale and Pittsburgh Sleep Quality Index|postoperative depression and sleep disorders in patients with endometriosis will be evaluated
22809|NCT04009889|Dietary Supplement|capsule containing a probiotic blend of 5 different Lactobacilli|n=81 women (verum) starts befor end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
22810|NCT04009889|Other|capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.|n=81 women (placebo) starts befor end of pregnancy week 14 with consumption of 1 capsule daily until delivery.
22811|NCT04009876|Drug|nal-IRI|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
22812|NCT04009876|Procedure|Surgical resection|Surgical resection of the tumour
22813|NCT04009876|Other|Watch-and-wait|No surgery approach
22814|NCT04009876|Drug|5-FU/LV|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
22815|NCT04009876|Drug|Oxaliplatin|Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
22816|NCT04009863|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
22817|NCT04009863|Radiation|Radioactive iodine (Radioidine i131)|Radioactive iodine (RAI) is a radioactive form of iodine that for ablation in thyroid disease (i.e. Graves' disease or few thyroid cancer)
22818|NCT04009850|Other|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
22819|NCT04009850|Other|E-cigarette Flavor|Adult smokers will be provided with either menthol or tobacco flavored e-cigarettes in addition to the non-menthol cigarettes
22820|NCT04009837|Behavioral|Hip-focused rehabilitation intervention|The hip-focused intervention (HIP+) includes a blend of hip-focused rehabilitative techniques and some basic lumbar spine-directed techniques. HIP+ includes tailored manual therapy, progressive strengthening exercises, and flexibility exercises for the hip, as well as spinal flexibility and trunk muscle training exercises. HIP+ will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 12 weeks.
22821|NCT04009837|Behavioral|Spine-focused rehabilitation intervention|The spine focused rehabilitation (SFR) intervention is a direct and comprehensive lumbar spine rehabilitative program, but it does not include hip treatment. SFR includes spinal manual therapy, spinal flexibility exercises, and trunk muscle training exercises. SFR will be delivered by licensed physical therapists in one-hour sessions, twice per week, for 12 weeks.
22822|NCT04009824|Biological|AGS-v PLUS Vaccine|Administered by subcutaneous injection
22823|NCT04009824|Biological|Montanide ISA-51 Adjuvant|Administered by subcutaneous injection
22824|NCT04009824|Biological|Alhydrogel® Adjuvant|Administered by subcutaneous injection
22826|NCT04009811|Device|Suersen and membraneous obturators evaluation|"The patient will wear one month each obturator prothesis (Suersen and membraneous obturators). The order of evaluation will be randomized in two arms.~Half of patient will first wear one month the membranous obturator then one month the Suersen, the other half of patient will first wear one month the Suersen obturator and one month the membranous obturator."
22827|NCT04009772|Drug|Cefepime|Antibiotic prophylaxis
22828|NCT04009772|Drug|Cefuroxime plus Metronidazole|Antibiotic prophylaxis
22829|NCT04009759|Drug|Morphine|Adult patients with an out-of-hospital cardiac arrest will be evaluated by skilled paramedics or prehospital trained anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
22830|NCT04009759|Drug|Ketamine Injectable Solution|Adult patients with an out-of-hospital cardiac arrest will be evaluated by skilled paramedics or prehospital trained anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
22831|NCT04009759|Drug|Saline 0.9%|Adult patients with an out-of-hospital cardiac arrest will be evaluated by skilled paramedics or prehospital trained anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.
22832|NCT04009746|Procedure|Retrograde Perantoscopic Pancreatography (ERCP) with Spyglass|Retrograde Perantoscopic Pancreatography (ERCP) with Spyglass
22833|NCT04009733|Biological|Blood sample|A study specific blood sample will be collected.
22834|NCT04009733|Biological|Blood sample|Pre-collected serum of cohort OFELY and MODAM for women, STRAMBO for men will be used for the study.
22835|NCT04009720|Device|Lotus Edge Device|The LOTUS Edge Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] <1.0 cm2 or AVA index <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
22836|NCT04009707|Other|MoCA (Montreal Cognitive Assessment) test|the MoCA questionnaire is used to assess cognitive disorders
22837|NCT04009707|Other|BEARNI (Brief Evaluation of Alcohol Related Neuropsychological Impairment) Test|This questionnaire is used to assess cognitive disorders
22838|NCT04009694|Other|Pelvic Floor Muscle training|Sixteen weeks of supervised pelvic floor muscle training with a specialist physiotherapist
22839|NCT04009681|Drug|THOR-707|THOR-707 will be administered as specified under Arm description.
22840|NCT04009681|Drug|Checkpoint inhibitor|Checkpoint inhibitor will be administered as specified under Arm description.
22841|NCT04009668|Drug|adalimumab|Adalimumab will be dosed based on weight
22842|NCT04009655|Other|music|music selected by musician
22843|NCT04009642|Other|Surely observational based on disease state|Metabolism in T2DM vs non diabetic
22844|NCT04009629|Behavioral|Moderate Intensity Aerobic Exercise|Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
22845|NCT04009616|Drug|Aloe Vera mouthwash|rinsing with aloe vera mouthwash for 5 days.
22846|NCT04009616|Drug|Chlorhexidine mouthwash|rinsing with chlorhexidine mouthwash for 5 days.
22847|NCT04009616|Drug|Placebo mouthwash|rinsing with placebo mouthwash for 5 days.
22848|NCT04009603|Drug|Probiotic Agent|"Probiotics are live microorganisms, which when administered in adequate amounts confer a health benefit effects on the host.~Many clinical trials have been done on probiotic which show its use as a single or as an adjuvant drug therapy for various diseases with no or rare side effects. It is now frequently used agent for various diseases.~Apart from this many studies have been published related to effects of probiotics on PCOS, which shows effectiveness of probiotics when used for 8 to 12 weeks with no adverse effects observed by these micro-organisms but none of the study have compare it with standarad drug"
22849|NCT04009603|Drug|Metformin|"Metformin, an insulin sensitizer, is an oral biguanide that is most commonly prescribed for the management of type II diabetes mellitus and various symptoms of PCOS. It is derived from the extract of Galega officinalis.~It remediates hyperglycemia through activation of AMPK which stimulates glucose uptake and its consumption; promote fatty acid oxidation along with suppression of hepatic glucose production. It is also involved in increase GLUT4 translocation in the muscle and fat leading to decrease hepatic lipid synthesis. Moreover, It is also reported that it decreases gut absorption of glucose by increasing the glucagon-like peptide-1 (GLP-1) in this way, it reduces the insulin requirement too.All of these actions of metformin decrease insulin resistance and thus improve the state of hyperinsulinemia associated with diabetes and PCOS"
22850|NCT04009590|Other|Educational Intervention|Read educational booklet
22851|NCT04009590|Other|Questionnaire Administration|Ancillary studies
22852|NCT04009590|Behavioral|Smoking Cessation Intervention|Utilize Quit4Health
22853|NCT04009577|Drug|LEM 5 mg|LEM tablet.
22854|NCT04009577|Drug|LEM 10 mg|LEM tablet.
22855|NCT04009564|Dietary Supplement|Date coffee|45 g of date seeds coffee in 280 ml of water
22856|NCT04009564|Dietary Supplement|Normal coffee|6 g of normal coffee in 280ml of water
22857|NCT04009564|Dietary Supplement|Placebo|water, food colouring and coffee flavouring
22858|NCT04009538|Other|Rehabilitation program|exercise program twice a week
22859|NCT04009525|Drug|Busulfan|Busulfan（4 mg/kg/day,4 days）
22860|NCT04009525|Drug|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
22861|NCT04009525|Drug|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
22862|NCT04009525|Drug|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
22863|NCT04009525|Drug|cyclosporine A|cyclosporine A
22864|NCT04009525|Drug|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
22865|NCT04009525|Drug|Tacrolimus|Tacrolimus
22866|NCT04009525|Drug|Methotrexate|Methotrexate
22867|NCT04009525|Drug|Basiliximab|Basiliximab
22868|NCT04009525|Drug|Ruxolitinib|Ruxolitinib
22971|NCT04008693|Other|Placebo|800 mg of maltodextrin (four capsules)
22869|NCT04009512|Device|Valiant Thoracoabdominal Stent Graft System|This system of devices works to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments in patients with thoracoabdominal aneurysms.
22870|NCT04009499|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
22871|NCT04009486|Device|Whole Body Vibration|"Subjects will undergo whole body vibration (standing on a power plate device 3 times a week, for 30 minute sessions, for 6 weeks)"
22872|NCT04009473|Combination Product|SEGOVA procedure|SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
22873|NCT04009460|Drug|ES101|ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.
22874|NCT04009447|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|6-week CBT-I therapy to help improve sleep quality
22875|NCT04009434|Device|Mitral Valve Clipping|Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.
22876|NCT04009434|Device|TAVI|Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
22877|NCT04009421|Diagnostic Test|Coronary artery plaque assessment by CT coronary angiography QAngio CT RE|Assessment of segmental plaque volume and composition
22878|NCT04009408|Device|Expiratory muscle strength therapy (EMST150, Aspire LLC)|Active therapy calibrated to the participant's maximum expiratory pressure
22879|NCT04009395|Other|Pregnant Women qualitative interviewing|one-on-one in depth interviewing of pregnant African migrant women living in the UK on the barriers and facilitators to healthy eating in pregnancy.
22880|NCT04009395|Other|Midwives qualitative interviewing|one-on-one interviewing/focus group discussions with midwives on their perspectives regarding the provision of healthy eating advice to pregnant African migrant women living in the UK.
22881|NCT04009382|Other|Baduanjin Exercise|Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
22882|NCT04009382|Other|Cognitive Fitness Program|Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
22883|NCT04009369|Other|Direct access to a PT|Direct access to a PT in the ED immediately after triage and prior to physician assessment.
22884|NCT04009356|Procedure|bariatric surgical procedures|gastric bypass, sleeve, banding,biliopancreatic diversion
22885|NCT04009343|Drug|Artemether-lumefantrine|Children will receive artemether-lumefantrine (20/120 mg) dosed according to weight (5 to <15 kg: 1 tablet, 15 to <25 kg: 2 tablets) at 0, 8, 24, 36, 48 and 60 hours. Medications will be administered according to the manufacturer's instructions.
22886|NCT04009343|Drug|Dihydroartemisinin-piperaquine|Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to <8 kg: 1/2 tablet, 8 to <11 kg: 3/4 tablet, 11 to <17 kg: 1 tablet, 17 to <25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
22887|NCT04009330|Diagnostic Test|POC Assay|"Interventions:~Blood Baseline - up to 40ml Day 3 - up to 40ml~Urine Baseline - 10ml Day 3 - 10ml~Study population:~Adults (18 plus) in ICU units diagnosed with ARDS."
22888|NCT04009317|Drug|TQ-B3139|a multi-target protein kinase inhibitor.
22889|NCT04009317|Drug|Crizotinib|a multi-target protein kinase inhibitor.
22890|NCT04009304|Behavioral|OSNAP|Afterschool practice and policy change to support healthy eating and physical activity
22893|NCT04009278|Other|Self compression arm|The optimal compression level up will be under the supervision of the radiographer who will interpose the compression when a level is reached beyond which there is no further reduction in thickness (15 daN). If the woman stops at a compression of less than 10 daN and that the radiographer considers not adequate to perform a quality mammogram, the radiographer will perform the compression in conventional mode and record the passage of compression mode.
22894|NCT04009265|Combination Product|adjuvant treatment|adjuvant treatments include chemotherapy or chemoradiotherapy
22895|NCT04009252|Behavioral|3D Model Education|A 3D model of the patients ankle fracture will be printed and used as a teaching tool to discuss long-term outcomes and potential complications.
22896|NCT04009239|Behavioral|Time Restricted Feeding|Consuming energy during a short interval during the day
22897|NCT04009226|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
22898|NCT04009213|Device|LiquiBand FIX8®|An n-butyl-2-cyanoacrylate adhesive monomer and D&C Violet #2 dye
22899|NCT04009213|Device|AbsorbaTack™|An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D&C Violet No. 2.
22900|NCT04009187|Behavioral|In-person wheelchair propulsion training program|The wheelchair propulsion (WP) intervention is based on our previous pilot work and the best available evidence on WP training. The CPGs recommend minimizing the force and frequency of pushes while using long strokes during propulsion. Each training session will include massed practice with repetitions overground. Each session is organized to limit the number of variables (i.e., long push strokes and dropping the hands down below axle) presented to the participant at one time. Propulsion Set A will focus on using longer push strokes. Propulsion Set B will focus on dropping the hand down toward the axle. Propulsion Set C will focus on both A and B.
22901|NCT04009187|Behavioral|30-minute education session|Both groups will receive a 30-minute education session regarding the CPGs. This education session will follow the instructions provided in Rice and colleagues. (L. A. Rice et al., 2014). It consists of the importance of practicing biomechanical efficient propulsion. The material lists out the consequences and the impact of upper limb pain and injury. It provides a detailed step by step on how to propel properly. They will view the video that shows the biomechanics of efficient and inefficient propulsion.
22940|NCT04008940|Device|Distal femur plates|By assessing the rate and mode of mechanical failures we aim to identify risk factors for mechanical failures among the analysed plate types. This, finally, is depending on the overall number of cases and number of failure cases.
22902|NCT04009174|Other|Imaging Panel|"Initial Protocol (REB approval date 08-Sept-2011)~Pre-operative Imaging Panel~[18F]-FCH PET + Dynamic CT~MRI of the pelvis with endorectal coil (T1, T2, DW, DCE, MRS)~3D-Transrectal ultrasound~Optional PET/MRI (added with Protocol Amend 1, REB approval date 22-Aug-2012)~Optional Sodium (23Na) MRI (added with Protocol Amend 2, REB approval date 25-Feb-2013)~Protocol Amendment #3, REB approval date 20-Oct-2015:~Pre-operative Imaging Panel~[18-F]-DCFPyL PET+Dynamic CT~PET/MRI with endorectal coil~3D-Transrectal Ultrasound~Optional Sodium (23Na) MRI"
22903|NCT04009161|Procedure|Tooth extraction|Tooth extraction before the beginning of radiotherapy in patients irradiated for Head and Neck cancer
22904|NCT04009148|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
22905|NCT04009135|Behavioral|internet delivered cognitive behavioural therapy (iCBT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) thoughts and feelings; 3) understanding stress and relaxation; 4) unhealthy and healthy thoughts; 5) layers of thinking; 6) core beliefs; and 7) relationship, lifestyle, problem solving, and relapse prevention. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
22906|NCT04009135|Behavioral|online delivered acceptance and commitment therapy (iACT)|The intervention comprises 7 weekly online modules available through Therapist Assisted Online (TAO), including: 1) psychoeducation about chronic pain and depression; 2) introduction to ACT; 3) cognitive fusion and defusion; 4) thinking mind versus observing mind & acceptance; 5) mindfulness; 6) values; and 7) taking action. Online content is supplemented with weekly coaching sessions performed via video-conference with doctoral students of Clinical Psychology.
22907|NCT04009135|Other|Attention Control (AC)|1-module of psychoeducation about chronic pain and major depression. Weekly contact to complete measures of symptomatology and well-being.
22908|NCT04009122|Dietary Supplement|IGEN0206|Group A
22909|NCT04009122|Other|Placebo|Group B
22910|NCT04009109|Drug|Lenalidomide|Induction and Maintenance
22911|NCT04009109|Drug|Ixazomib|Induction and Only Maintenance Arm B
22912|NCT04009109|Drug|Daratumumab Injection|Induction and Only Maintenance Arm B
22913|NCT04009109|Drug|Dexamethasone|Induction and Only Maintenance Arm B
22914|NCT04009096|Biological|ChAd63 PvDBP and MVA PvDBP|one dose of 5 x 10^10 vp ChAd63 PvDBP and one dose of 2 x 10^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
22915|NCT04009083|Device|Standard of Care MRI|Prostate MRI, serum Prostate Specific Antigen (PSA), in field and random systemic prostate biopsies
22916|NCT04009083|Other|Fluciclovine PET scan added to MRI|18F-Fluciclovine (Axumin) is a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment
22917|NCT04009070|Device|Acupuncture Pres Needle: 0.22x1.5 mm needle|Acupunctur group; Acupunctur preoperatively 24 hours before bilateral PC6 (approximately two cm above the midline of the wrist line) and ST 36 (approximately 1-2 cm laterally from the tuberocyte tibia). The tape (Needle Press) will remain for 24 hours after surgery.
22918|NCT04009057|Other|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
22919|NCT04009044|Drug|Afimoxifene|Apply topically
22920|NCT04009044|Procedure|Core Biopsy|Undergo core needle biopsy
22921|NCT04009044|Other|Questionnaire Administration|Ancillary studies
22922|NCT04009031|Device|Bootle Blast|During the baseline assessment, an occupational therapist will calibrate the video game to the child's therapy needs and functional abilities. Within a week of the first assessment, the research team will set up the video game in the participant's home where it will remain for 12 weeks. Training on how to play the game and a user manual will be provided. The researcher will work with each family to establish a play objective (minutes/day and days/week) that considers the family's schedule. Five-minute telephone check-in calls will be done weekly.
22923|NCT04009018|Other|Perioperative Satisfaction Scale in Regional Anesthesia|This study is methodological research. Perioperative Satisfaction Scale in Regional Anesthesia will be used to collect data.
22924|NCT04009005|Behavioral|Therapeutic diet and lifestyle|Educational videos, 4 individual support calls and monthly support group meetings conducted via the Zoom video conference platform. Patients will be trained on a low lectin modified paleolithic diet; breathing meditation practice, and body weight strengthening
22925|NCT04008992|Drug|BMS-986259|Single and Multiple ascending dose from Dose 1 to Dose 5
22926|NCT04008992|Other|Placebo|Placebo matching BMS-986259
22927|NCT04008992|Diagnostic Test|P-Aminohippurate|Diagnostic Agent
22928|NCT04008992|Diagnostic Test|Iohexol|Diagnostic Agent
22929|NCT04008979|Drug|Aspirin|Aspirin - lipid complex
22930|NCT04008966|Drug|combined oral contaraceptive pills|1 tablet daily between days 5 and 25 of the cycle before stimulation
22931|NCT04008966|Drug|recombinant FSH|300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
22932|NCT04008966|Drug|Urinaru gonadotropin|150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
22933|NCT04008966|Drug|GnRH antagonist|0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
22934|NCT04008966|Drug|Human chorionic gonadotropin|10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
22935|NCT04008966|Drug|GnRH agonist|0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
22936|NCT04008966|Procedure|Ovum pick up|34 hours after triggering under the guidance of transvaginal ultrasound
22937|NCT04008966|Procedure|Embryo transfer|Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
22938|NCT04008966|Drug|natural Progesterone|400 mg twice daily per vagina
22939|NCT04008953|Device|ultrasonography|Intravascular volume assessment using ultrasonography, CVP and echocardiography
24282|NCT03997955|Other|Sham myofascial induction|Sham myofascial induction in plantar fascia
22941|NCT04008927|Diagnostic Test|HCV screening|All patients will have HCV screening using rapid tests. HIV and HBV testing will also be conducted and patients will be appropriately referred to appropriate health services.
22942|NCT04008927|Diagnostic Test|Diagnosis of hepatitis C|HCV-RNA assay (GeneXpert, Cepheid) will be performed for all participants with positive HCV serology to determine if patients have chronic hepatitis C (defined by HCV-RNA>10 UI/mL). In addition a measure of the liver stiffness will be performed.
22943|NCT04008927|Drug|HCV treatment|Direct-Acting Antiviral drugs will be prescribed for 8 or 12 weeks according to liver assessment.
22944|NCT04008914|Other|retrospective observation|Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.
22945|NCT04008901|Drug|BST-104 (Lonicera Flos Extract)|175 mg of Lonicera Flos extract in 1 tablet (300 mg)
22946|NCT04008901|Drug|Placebo oral tablet|0 mg of Lonicera Flos extract in 1 tablet (300 mg)
22947|NCT04008888|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Stem Cell Transplant: Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients.
22948|NCT04008888|Procedure|Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2|Autologous hematopoietic stem cell transplantation :Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day followed collecting CD34+ peripheral blood stem cells . Day 0 Infusion of autologous stem cells. Patients during 3-6 months after the 1st SCT will undergo a 2nd SCT. Patients who had not enough PBSC will undergo a 1st SCT.
22949|NCT04008888|Drug|Melphalan Given IV|conditioning regimen: autologous ARM: Day -2 Melphalan 200 mg/m^2/day IV over 30 minutes. allogeneic ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes
22950|NCT04008888|Drug|Fludarabine Injection|conditioning regimen:Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
22951|NCT04008888|Drug|PI and dexamethasone as maintenance therapy|Bortezomib and dexamethasone(VD),Ixazomib and dexamethasone(ID)
22952|NCT04008888|Drug|PI+IMids+Dexamethasone as Consolidated Chemotherapy|Oral lenalidomide at the starting dose of 25mg on days 1-21 every 28 days or days 1-14 every 21 days. Dexamethasone at 20mg twice weekly on days 1,2,4,5,8,9,11&12 of each 21-day.
22953|NCT04008862|Behavioral|Partnership-based nursing practice|Provided by clinical nurse specialists (n=2) and specialized nurses (n=3): i) Partnership-based theoretical nursing practice framework: Family involvement, living with symptoms and access to healthcare —primary goal of enhancement of the health experience. Key question: What are your main concerns about the health of the person with the lung disease? Followed by conversations: a) Existence of lung disease and symptoms that the patient has. b) Nature of disease, its management, quitting smoking, use of inhaler medications, utilization of health care, negative feelings and issues. Skills and motivation to undertake activities to maintain and improve well-being, skills in communication with family, relatives and health professionals. ii) Empirical knowledge about the nature of COPD, symptom management and palliative care and the GOLD clinical guidelines. iii) Patients are seen over an undefined time period in the out-patient clinic or at home depending on needs and capabilities.
22954|NCT04008849|Other|Safety and efficacy assessments|Long term safety and clinical outcomes
22955|NCT04008823|Other|Retrospective and observational epidemiological study, by review of clinical histories,|Retrospective and observational epidemiological study, by review of clinical histories,
22956|NCT04008797|Drug|E7386|E7386, tablets, orally.
22957|NCT04008797|Drug|Lenvatinib|Lenvatinib, capsules, orally.
22958|NCT04008784|Drug|Crisaborole 2% Topical Application Ointment [EUCRISA]|Ointment
22959|NCT04008784|Drug|Triamcinolone Acetonide 0.1% Ointment|Topical Corticosteroid
22960|NCT04008771|Device|SeeQ CdSe 655 ALT|SeeQ CdSe 655 Alt is a sterile colloidal solution of coated CdSe nanoparticles in a borate buffer suitable for intraocular injection.
22961|NCT04008758|Diagnostic Test|Ultrasound|Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
22962|NCT04008745|Other|Educational and home-based physical therapy by foot-related exercises|The booklet is divided in 2: educational and exercise protocol. The aim of the first part is to guide the individual for a change in his/her health behavior, and comprises info about diabetic neuropathy, foot care, shoes, and benefits of exercising. The second part is the foot protocol, composed by 6 exercises. The maximum duration of a session is 20min and should be performed 3 times/week. The subject should warm-up the foot-ankle and then start exercising in the order suggested by the booklet, filling a table with the effort perceived (effort likert scale). The foot exercises progresses from one set with 30 repetitions in a sitting position, to exercising standing, then performing the exercise on one foot only. Other progression criterion is to increase the number of sets performed. The effort scale regulates the individual effort for his/her progression, which is also registered by the participant in the monthly table at the booklet.
22963|NCT04008732|Drug|MED2005|(Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
22964|NCT04008732|Drug|Nitrostat 0.6Mg Sublingual Tablet|Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
22965|NCT04008732|Drug|Nitro Pohl|to be dosed intravenously in Part 2 of the study
22966|NCT04008719|Other|Thymic history|This interview concerns mainly the nature of the previous psychiatric and psychological care
22967|NCT04008719|Other|Evaluation of the psychiatric disorders|Mini International Neuropsychiatric Interview for the positive diagnosis of depression - under the MINI score of depression.
22968|NCT04008719|Other|Cognitive evaluation|They will be held consecutively to the patient's bedside interview on the same day. Some tests will be computerized, others will be in paper form.
22969|NCT04008706|Drug|Acalabrutinib|Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
22972|NCT04008680|Other|36 item short form survey Internal consistency|how internal consistency for the 36 item short form survey (SF-36) varies if the questionnaire is placed in a different position from a list of 7 questionnaires given
22973|NCT04008667|Other|Acupoint application|Acupoint application: The patients start using the acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
22974|NCT04008667|Other|Fake acupoint application|Fake acupoint application: The patients start using the fake acupoint application on the umbilical Shenque point in 2 hours after surgery, 1 or 2 times a day, lasting 5 days.
22975|NCT04008654|Behavioral|ERAS Protocol|"Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results"
22976|NCT04008654|Behavioral|Conventional care|This group of patients will not receive the specific ERAS protocol but will receive conventional care.
22977|NCT04008641|Other|Pediatric consultation's survey|Realization of a pediatric consultation. At the end, evaluation of comprehension and psychological impact with a survey (completed by parents).
22978|NCT04008628|Drug|Nitrous Oxide|Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
22979|NCT04008615|Other|2 times : 6-minute stepper test with cardiorespiratory parameters and gaz exchange monitoring (with a rest of 20min between each test).|"For the 6-minute stepper test, please refer to NCT02842463 and NCT04004689. Gaz exchange analyzer will be calibrate before every test. Data will be recorded breath by breath.~Heart rate will be monitored using a 12-lead electrocardiogram. Transcutaneous oxygen saturation will be assessed using a pulse oxymetry system at the earlobe."
22980|NCT04008602|Device|Quick icing|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
22981|NCT04008602|Device|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the decreased nerve conduction velocity.
22982|NCT04008589|Device|repetitive transorbital AC Stimulation|Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day
22983|NCT04008589|Device|combination of transcranial direct current stimulaton and rtACS|Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
22984|NCT04008576|Behavioral|Group Blended Transdiagnostic treatment|The treatment combines group face-to-face and Internet-delivered psychotherapy: 7 group sessions delivered every 3 weeks plus the use of an online treatment platform between sessions. Its goal is to learn and practice adaptive regulation strategies from a mechanistically transdiagnostic approach, with a focus on both negative and positive affectivity. Each group session will focus on one of the following core components: the first group session will focus on CBT traditional strategies such as motivation for change and psychoeducation about emotions; sessions 2 to 5 will focus on strategies to down-regulate negative affect: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, and interoceptive and situation-based emotion exposure; session 6 will focus on strategies to regulate positive affect; the final session will teach relapse prevention techniques. All the treatment components are delivered in 16 online treatment modules.
22985|NCT04008563|Procedure|Bariatric Surgery|Patients who are randomized to the intervention group will receive a progestin intrauterine device and be referred for bariatric service to undergo bariatric surgery within 3 months of their study consent.
22986|NCT04008550|Procedure|Right Heart Catheterization|A right heart catheterization will be done in patients with PAH before TAVI (3 months after TAVI)
22987|NCT04008537|Device|Ring gantry kV-CBCT combined with linear accelerator|Each imaging session will be less than one hour, and is expected to take no more than 15 minutes.
22988|NCT04008524|Biological|CAR-T cells|Chimeric Antigen Receptor-T cells
22989|NCT04008511|Drug|Regorafenib|Phase Ib Group A: Regorafenib 120mg + XELOX; Group B: Regorafenib 160mg + XELOX; Group C: Regorafenib 80mg + XELOX.
22990|NCT04008511|Drug|Regorafenib|Phase II: Regorafenib MAD qd po for 14 days, every 3 weeks.
22991|NCT04008511|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid po for 14 days.
22992|NCT04008511|Drug|Oxaliplatin|Oxaliplatin 130mg/m2, day 1, every 3 weeks
22993|NCT04008498|Diagnostic Test|AEEG brain monitoring|"Babies will be recorded continuously for the entire duration of their time on the intensive care unit.~Once the child is receiving high dependency or special care, we will record aEEG for 4 hours once a week until the baby is discharged home. If a participant is moved back to intensive care, the aEEG will be started again if the aEEG monitor is not being used on another baby."
22994|NCT04008485|Device|Magnetic Electric Impedance Spectroscopy Device to predict PTB|During this phase, we will measure MIS in 100 women at high risk of PTB (Group 1) and 100 women with symptoms of PTB to confirm its predictive potential for PTB. To determine whether MIS assessment could prove a platform technique for other tests and treatments within existing antenatal care pathways for PTB, we will also assess vaginal swabs for fFN and measure cervical length (CL) by ultrasound.
22995|NCT04008472|Other|Telemedecine|Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
22996|NCT04008459|Other|Therapeutic exercise class|Physiotherapy exercise class includes education, stretching, strengthening, posture and balance interventions.
22997|NCT04008433|Drug|Lidocaine|Advanced intravenous injection of lidocaine before the propofol injection
23184|NCT04006847|Drug|Tyrosine kinase inhibitor|Tyrosine kinase inhibitor to be administered at subjects' pre-study dose
22998|NCT04008420|Other|monitoring of the oxygen reserve index|The investigators will enroll adult patients who will undergo robotic esophagectomy under general anesthesia. The oxygen reserve index will be monitored continuously during anesthesia. The postoperative complications will be recorded after surgery.
22999|NCT04008407|Procedure|Endoscopic Submucosal Dissection|Endoscopic Submucosal Dissection (ESD) results in en-bloc resection of LSL, regardless of lesion size. This allows for accurate histopathological assessment of SMIC, R0/R1 resection and depth of invasion. ESD is considered a potentially curative for superficial cancers (T1a).
23000|NCT04008407|Procedure|Endoscopic Mucosal Resection|EMR is the current standard for treating colonic LSL and has been validated to be safe and efficacious. LSLs => 20mm are frequently resected piecemeal. Recent research show that resection margin soft coagulation reduces recurrence rates to those similar to en-bloc resections.
23001|NCT04008394|Genetic|Anti-CD30 CAR T cells|Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.
23002|NCT04008381|Biological|Ex-vivo Expanded γδ T Lymphocytes|Patients receive ex-vivo expanded γδ T Lymphocytes (Dose escalation, 2*10^6, 4*10^6, 8*10^6 of cells per kg of body weight).
23003|NCT04008368|Device|CliniMACS CD34 Reagent|Haploidentical recipients will receive CD34-selected cells using Miltenyi CliniMACS CD34+ cell selection kits. The target CD34+ cell dose is at least 10 x 106/kg, and the minimum CD34+ cell dose is 5 x 106/kg. All of the cells collected during the apheresis procedure will be given. The cells will be cryopreserved and stored until the day of transplant.
23004|NCT04008355|Drug|AZP2006 oral solution|Once daily intake in the morning
23005|NCT04008355|Drug|Placebo oral solution|Once daily intake in the morning
23006|NCT04008342|Other|Multisensory intervention|The intervention group (IG) was submitted to 16 individual multisensory stimulation sessions that followed the protocol. In each session, at least two senses are stimulated in a safe, quiet and confidential environment. The sessions lasted 30 minutes and were conducted twice a week, on the same day and time whenever possible. Nonetheless, the session could be interrupted when the participant wished or if the therapist observed that the patient was uncomfortable. A nondirective approach and one-to-one intervention were adopted.
23007|NCT04008316|Drug|Colchicine|colchicine 1mg/day
23008|NCT04008303|Procedure|Migraine surgery|Surgical decompression of neuromuscular structures causing migraine headaches.
23009|NCT04008290|Drug|0.6 mg Liraglutide|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
23010|NCT04008290|Drug|Placebo|For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
23011|NCT04008264|Drug|Scopolamine Patch (Transderm V)|During the observational phase, patients will be given a prescription for an 18 day supply of scopolamine, and patients will record the same data as prior to the intervention.
23012|NCT04008251|Genetic|Second generation humanized CAR-T cells|Patients receive humanized CD19 CAR-T cells transduced with a lentiviral vector on days 0/1/2 in the absence of disease progression or unacceptable toxicity.
23013|NCT04008238|Drug|Trabectedin|- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
23014|NCT04008225|Procedure|Bronchoalveolar lavage|
23015|NCT04008212|Other|Fusion imaging|Fusion imaging during aortic endovascular procedures with a mobile C-arm through the use of the EndoNaut® angio-navigation station
23016|NCT04008199|Other|Super Abbu|The investigators have developed, piloted, and propose to expand and to experimentally evaluate a speech-based service that connects expectant fathers to doctors and to each other over a simple phone call. This service is dubbed Super Abbu (Super Dad in English).
23017|NCT04008186|Drug|Omaveloxolone|50 mg capsules
23018|NCT04008186|Drug|Midazolam oral solution|2 mg/mL oral solution
23019|NCT04008186|Drug|Repaglinide 1 MG|1 mg tablet
23020|NCT04008186|Drug|MetFORMIN 500 Mg Oral Tablet|500 mg tablet
23021|NCT04008186|Drug|Rosuvastatin|10 mg tablet
23022|NCT04008186|Drug|Digoxin tablet|0.25 mg tablet
23023|NCT04008186|Drug|Gemfibrozil Tablets|600 mg tablet
23024|NCT04008186|Drug|Itraconazole capsule|100 mg capsule
23025|NCT04008186|Drug|Verapamil Pill|120 mg tablet
23026|NCT04008173|Other|Non-interventional patient registry|Non-interventional patient registry
23027|NCT04008160|Device|ProTex|Non invasive measurement of pressure, temperature, humidity, perfusion, and oxygenation
23028|NCT04008147|Drug|100mg iron sulfate|100mg iron sulfate b.i.d. for 4 consecutive days
23029|NCT04008134|Behavioral|CHoBI7 health facility program|The CHoBI7 health facility program focuses on promoting handwashing with soap and water treatment to diarrhea patients and their household members during the one-week period after the patient is admitted to the health facility, when their household is at highest risk for diarrheal diseases. The CHoBI7 program includes: (1) a WASH pictorial module delivered by a health worker bedside to diarrhea patient and their household members in a health facility on handwashing with soap, water treatment, and safe water storage; and (2) a diarrhea prevention package containing chlorine tablets for water treatment, a soapy water bottle (water and detergent powder), a handwashing station, and a water vessel with a lid and tap for safe drinking water storage. Households are instructed to boil their water once their supply of chlorine tablets is completed.
23089|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to assess the relevance of MRI to diagnose specific pancreatic lesions in obese patients
23090|NCT04007614|Other|Questionnaire|Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
23091|NCT04007601|Device|Active tDCS|Participants will receive active 1mA direct current stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
23185|NCT04006834|Other|No intervention involved|No intervention involved
23030|NCT04008134|Behavioral|CHoBI7 mHealth program|The CHoBI7 mHealth (mobile health) program targets five key behaviors: (1) preparing soapy water using water and detergent powder; (2) handwashing with soap at food and stool related events; (3) treating household drinking water using chlorine tablets during the one week high risk period after the diarrhea patient in the household was admitted to the health facility; (4) safe drinking water storage in a water vessel with a lid and tap; and (5) heating of household drinking water until it reaches a rolling boil after the one week high risk period. Participant households receive bi-weekly voice and text messages from the CHoBI7 mHealth program over a 12-month period. These mobile messages are sent using the VIAMO platform (www.viamo.io).
23031|NCT04008134|Behavioral|CHoBI7 home visit program|The CHoBI7 home visit program involves two, 30-minute home visits conducted during the week after the index diarrhea patient was recruited at the health facility. A health worker reinforces the content of the CHoBI7 health facility program in the participant's home.
23032|NCT04008121|Combination Product|Fluorescein sodium and Zeiss FF450 fundus camera|Fluorescein sodium administered as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
23033|NCT04008121|Combination Product|MB-102 and Zeiss FF450 fundus camera|MB-102 administered 3 days after fluorescein sodium as a bolus intravenous injection; Zeiss FF450 fundus camera used for imaging of the eye of all participants
23034|NCT04008121|Combination Product|Fluorescein sodium and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
23035|NCT04008121|Combination Product|MB-102 and commercially available optical angiography imaging system|Following Zeiss FF450 imaging, one of two systems (Heidelberg Spectralis or Optos California or 200Tx) will be used for imaging of the eye in a subset of participants
23036|NCT04008108|Other|Activity sensor|Activity sensor worn on the wrist during 7 days, 24h/24 to evaluate physical activity of patient (measured by the number of step per day) before and after Artificial Urinary Sphincter Implantation.
23037|NCT04008082|Drug|Lenvatinib|Lenvatinib capsule.
23038|NCT04008069|Drug|Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1|Sarilumab vs Placebo
23039|NCT04008069|Drug|Placebos|Placebo
23040|NCT04008056|Other|Patient Reported Outcome questionnaire|34 question form to assess patient symptoms
23041|NCT04008043|Drug|Vicodin|In addition to taking one tablet of vicodin for pain every 4-6 hours up to 8 tablets, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
23042|NCT04008043|Drug|Dexamethasone|In addition to taking one tablet of dexamethasone for pain beginning the day before surgery and on the day of surgery, pain scores will be recorded the evening of the surgery, the day after the surgery and one week after the surgery.
23051|NCT04008017|Diagnostic Test|Eosinophilic Cationic Protein biomarker|3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
23052|NCT04008004|Drug|EDP-514|Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD) or once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD).
23053|NCT04008004|Drug|Placebo|Placebo to match EDP-514
23054|NCT04007991|Drug|Ecopipam|Ecopipam tablets administered PO to establish 2 mg/kg/day; Matching Placebo
23055|NCT04007978|Genetic|Third generation CAR-T cells|Patients receive CD22 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity.
23056|NCT04007965|Procedure|Pneumatic Posterior Capsulorhexis|Pneumatic Posterior Capsulorhexis using air dose 0.1 ml and Healon dose 0.5 -1.0 ml.
23057|NCT04007952|Procedure|Anterior Gastropexy|Two permanent sutures will be introduced into the abdomen and placed along the lesser curvature of the stomach. A suture passer will be used to grasp the ends of the sutures to externalize them at separate fascial punctures. At time of abdominal desufflation, the sutures will be tied and the incision closed per individual surgeon practice.
23058|NCT04007926|Behavioral|Aerobic exercise programme|Participants will start with 3 x 20 minute exercise sessions in the first week, building up to 5 x 60 minutes of exercise by weeks 9-12 of the intervention, at an intensity of 65-80% of predicted maximum heart rate.
23059|NCT04007926|Behavioral|Resistance exercise programme|Participants will undertake two supervised sessions per week. The exercises performed during each session will consist of leg press, calf press, leg extension, leg curl, chest press, shoulder press, lateral pull down and seated row. Exercises will be performed at 60-80% 1RM. In weeks 1-2 participants will perform, during each session, a single set of 5-10 repetitions of each exercise (tiring but comfortably achievable) to ensure they are comfortable with the exercises and are performing these in the correct form. In weeks 3-4 participants will perform, during each session, two sets of each exercise to voluntary muscular failure - defined as not being able to perform single another repetition. In weeks 5-12 this will progress to 3 sets of each exercise to voluntary muscular failure, in each session.
23060|NCT04007913|Behavioral|teleCBIT|Eight sessions of individual behavior therapy
23092|NCT04007601|Device|Sham tDCS|Participants will receive sham (no direct current) stimulation over the left dorsolateral prefrontal cortex for 20 minutes. Cognitive training: Participants will complete 20 minutes of online cognitive training via Lumosity two days per week for a 6-month intervention period.
23093|NCT04007588|Drug|Nivolumab|Nivolumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Nivolumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
23186|NCT04006821|Drug|PD-1 antibody|Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
23061|NCT04007900|Behavioral|Positive Affect Treatment|PAT was designed as a 15-week intervention delivered in 3 modules. Module 1 (Pleasant Events Scheduling) uses behavioral activation methods to enhance positive experiencing before, during, and after rewarding events. Module 2 (Attending to the Positive) applies cognitive training techniques to promote shifting attention towards rewarding aspects of daily situations and to learn behavior mood associations. Module 3 (Cultivating the Positive) uses mindfulness approaches to foster reward experiencing. Treatment length has been expanded to 20 sessions to enhance the suitability of the intervention for AN and target the reward mechanisms that characterize AN. Additional adaptations include: 1) An emphasis on a mindful balance between reward and inhibition; 2) Additional module on shifting attention away from AN-specific rewards; 3) Addition of exercises to work towards long-term life goals and enhance healthy experiences; and 4) Further focus on navigating social rewards.
23062|NCT04007887|Other|Adult education program|A 10-hour program embodying major adult education principles, designed to achieve cognitive involvement of patients in their treatment
23063|NCT04007874|Drug|Ethinylestradiol/levonorgestrel|Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
23064|NCT04007874|Drug|Vitamin E|Vitamin E 400 IU oral capsules once daily for 3 months
23065|NCT04007848|Drug|Cobimetinib|Cobimetinib will be given at the dose of 40 milligrams once a day (21 days/28). Cobimetinib is available as 20 milligrams film-coated tablets
23066|NCT04007848|Drug|Placebo oral tablet|Placebo will be given at the dose of 40 milligrams once a day (21 days/28). Placebo is available as 20 milligrams film-coated tablets
23067|NCT04007835|Drug|Anlotinib Hydrochloride|anlotinib (12 mg orally daily for 14 days every 21 days cycle) combined with one of EGFR-TKIs
23068|NCT04007822|Behavioral|Pain Navigator Tool|The Pain Navigator Tool (PNT) was developed recently with the aim to empower patients through helping them to discuss their main concerns about pain, and to help therapists to prioritise addressing these concerns (Blomkvist et al., 2018). The initial pilot study with this tool improved the content of the consultations and patient engagement, and led to better patient-therapist interaction in a small population of healthcare providers and patients (Blomkvist et al., 2018). As it endeavours to facilitate the implementation of self-management in patients with chronic pain, the PNT aligns with the Scottish Intercollegiate Guidelines Network (SIGN) guideline for chronic pain and the Scottish Government's strategic vision (Scottish Government, 2011; SIGN, 2013).
23069|NCT04007809|Other|Glucagon|Every patients will undergo stimulated C peptide test. Glucagon will be administered using intravenous route (0,03 mg/kg, max 1mg).
23070|NCT04007796|Behavioral|Apnea and Insomnia Relief (AIR)|This treatment will be offered over six sessions. The first two appointments will be offered in-person and will last 60 minutes. The subsequent four appointments will be conducted via telehealth and will last 60 minutes. The main components of the AIR protocol are (a) psychoeducation, (b) motivational interviewing, (c) PAP adherence strategies, and (d) cognitive behavioral therapy for insomnia.
23071|NCT04007796|Behavioral|Sleep Education (SE)|The treatment will be offered over six sessions. The first two appointments will be offered in-person and will last 60 minutes. The subsequent four appointments will be conducted via telehealth and will last 60 minutes. Topics covered include the sleep cycle, sleep across the lifespan, sleep and the mind, evening activities and the sleep environment, and daytime activities and sleep.
23072|NCT04007770|Other|Acupuncture|10 treatments of acupuncture over the course of 8 weeks
23073|NCT04007770|Other|Sham Acupuncture|10 treatments of sham acupuncture over the course of 8 weeks
23074|NCT04007770|Other|8 week waiting period + optional Acupuncture|Optional real acupuncture after 8 week waiting period
23075|NCT04007744|Biological|Pembrolizumab|Given IV
23076|NCT04007744|Drug|Sonidegib|Given PO
23077|NCT04007731|Dietary Supplement|DrRip - high protein, high fibre and creatine load|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
23078|NCT04007731|Dietary Supplement|Voltage energy bar|A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
23079|NCT04007718|Behavioral|Interpretation bias training|Active: 50% positive endings to scenarios, 50% generation of positive endings to ambiguous scenarios Control: 100% ambiguous endings to scenarios with no instructions to imagine positive endings
23080|NCT04007705|Behavioral|Anti-inflammatory and low FODMAPs diet|Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
23081|NCT04007705|Behavioral|General healthy eating|Healthy eating counseling according to the World Health Organization
23082|NCT04007679|Other|Pain neuroscience education|Pain neuroscience education (PNE) was conducted in physical conditions similar to the university classrooms where the study was performed. The sessions were conducted as 70-minute didactic group lessons with the same content held in separate sessions for students in each class. PowerPoint (Microsoft Corp., Redmond, WA, USA) presentations prepared by the instructor were used in all sessions. Metaphors, anecdotes, graphics, and pictures were used in an attempt to convey the information and messages about pain physiology and theory more permanently and effectively. In the PNE sessions, it was explained that the nervous system can be overprotective and that in addition to the sensitivity of the central nervous system, nociceptive transmission can be affected by an individual's thoughts, beliefs, and surroundings. At the end of the session, the students were given time to ask questions, but group discussion was limited to 15 minutes due to time restrictions.
23083|NCT04007666|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD that combines education about trauma with strategies to challenge the trauma-related cognitions that are theorized to maintain PTSD symptoms.
23084|NCT04007666|Behavioral|Control Group|Coping-focused treatment drawn from material already offered in selected facilities.
23085|NCT04007653|Other|Observation|No intervention
23086|NCT04007640|Radiation|MRI with additional sequences|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
23087|NCT04007640|Radiation|MRI|MRI with 15 min additional sequences to validate and assess pancreatic MRI sequences
23088|NCT04007640|Procedure|Left pancreatectomy or pancreaticoduodenectomy|Histological analysis :
23094|NCT04007588|Drug|BMS-986205|BMS-986205 is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. BMS-986205 work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
23095|NCT04007588|Drug|Ipilimumab|Ipilimumab is a types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack the cancer cells. Ipilimumab work by stopping various molecules on cancer cells and body cells from working against the immune system's natural fight against cancer
23096|NCT04007575|Diagnostic Test|Magnetic Resonance CholangioPancreatography|The imaging data will be collected from the hospital records and image archiving system of the radiology departments of the University Hospitals
23097|NCT04007562|Drug|Hydroxychloroquine Sulfate|"The dosage and the route of administration of Hydroxychloroquine Sulfate was the same than in Lupus disease:~Oral administration: administered in soluble form in patients under the age of 6 years old and administered in tablets in patients other the age of 6 years old with Lipin-1 deficiency.~The soluble form was prepared at the Necker Hospital Pharmacy. Dose: 6.5 mg/kg/day (max 400 mg/day). The plasma concentration of the drug during follow-up was made, in order to follow a possible overdose."
23098|NCT04007549|Behavioral|Brief motivational interview on tobacco/alcohol risk reduction|"The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention."
23099|NCT04007536|Other|No Intervention|No Intervention
23100|NCT04007523|Behavioral|Family Support System|Family members and/or caregivers of patients will receive pagers, and alerts will provide recommendations for daily delirium screening and therapeutic activities. Protocols with associated activities will be provided to family members.
23101|NCT04007523|Behavioral|HELP Support System|A postoperative page will be sent, on behalf of participants, to the on-call HELP staff. The page will request early evaluation and enhanced therapeutic protocols for delirium prevention.
23102|NCT04007510|Combination Product|EPI-CAL data network|This mobile, app-based platform was designed to: 1) enable outcomes data collection from clients and family members/support person who are receiving care at an early psychosis program, 2) summarize the data visually for clients and providers on a secure web-based dashboard, and 3) allow download of de-identified data for program or research analysis.
23103|NCT04007510|Diagnostic Test|Community DUP Assessment Tool|A tool will be developed to enable measurement of the duration of untreated psychosis (DUP) for FEP individuals based on 1) data other assessments that are typically completed during the intake process (e.g. SIPS, SCID) or 2) specific questions, prompts, a rating scale, and anchor points to enable rating of the DUP. Participants would have their DUP rated on the new tool and also complete a second assessment of DUP by research evaluators using the Symptom Onset in Schizophrenia Inventory (SOS) to determine reliability and validity of the new tool.
23104|NCT04007484|Device|Hemoperfusion|Hemoperfusion is achieved by blood filtration with a hemoperfusion device. Specifically, the hemoperfusion device composed of multiple parallel resin cartridges is connected in parallel to the oxygenator and blood reservoir and perfused at a rate of 200-250ml/min. The purpose of hemoperfusion is to decrease inflammatory mediators produced during cardiopulmonary bypass through resin cartridges adsorption, such as cytokines, free hemoglobin and other toxins. The ultimate goal of hemoperfusion is to decrease postoperative complications, improve postoperative recovery, and eventually shorten the length of hospital stay.
23105|NCT04007471|Other|Anonymous survey|Anonymous questionnaire to determine the prevalence of dysmenorrhea of adolescent girls, to assess the severity of dysmenorrhea, how girls experience their menses, the consequences on daily living activities or at school, and how they manage their pain.
23106|NCT04007458|Behavioral|Letter|MaineGeneral Radiology will generate a reminder letter about their need for an annual low dose CT scan to the subjects in this arm.
23107|NCT04007458|Behavioral|Community Health Worker Phone Call|Patients will receive a phone call from community health worker, offering to help them overcome barriers to repeat annual screening and offering to help them schedule their screening.
23108|NCT04007445|Behavioral|Formally Directed Group (Exercise Group)|This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
23109|NCT04007445|Other|Self-Directed Group (Control Group)|This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
23110|NCT04007432|Other|pulse oxymeter|Nocturnal oxymetry data will be continuously collected during nighttime by a pulse oxymeter, covering for 1 to 3 nights.
23140|NCT04007198|Drug|EQ001|Itolizumab [Bmab 600]
23141|NCT04007198|Drug|EQ001 Placebo|EQ001 Placebo
23142|NCT04007185|Procedure|Maximal, safe resection of brain tumour|Standard surgical resection as part of routine care
23111|NCT04007419|Behavioral|Health Promoters and Organ Donation|Promotoras de Donación is a highly engaging and interactive online learning experience, that accommodates multiple learning styles by incorporating a variety of pedagogic approaches. The module consists of two components: a didactic educational component and a skills-based communication component. The didactic component provides basic information about organ donation and transplantation and the need for donors in the Hispanic community, and addresses concerns about donation commonly held by older Latina. The skills-based component provides instruction on the key communication skills needed to effectively engage small groups in discussions about organ donation. This component is intended to build communication self-efficacy or confidence opening the discussion about donation, addressing concerns raised by mature and older women participating in the small group sessions, and promoting the act of donor registration using persuasive, but non-coercive language.
23112|NCT04007406|Drug|DP13|DP13 systemic administration
23116|NCT04007380|Other|Continuous positive airway pressure (CPAP) therapy|The participants will undergo CPAP therapy for 4 consecutive months in the management of moderate-to-severe SRBDs
23117|NCT04007367|Drug|SAGE-217|SAGE-217
23118|NCT04007367|Drug|Placebo|Placebo
23119|NCT04007354|Other|Ventilation method|Depending on the group assignment, mechanical ventilation or spontaneous breathing was performed.
23120|NCT04007341|Drug|Dexmedetomidine|The study drug for each group was administered from the time immediately after induction of anesthesia until the end of the surgery.
23121|NCT04007328|Drug|Methylprednisolone Sodium Succinate|methylprednisolone vial
23122|NCT04007328|Drug|Placebo|Normal saline manufactured to mimic methylprednisolone vial
23123|NCT04007315|Device|SaeboGlove therapy|An individualised self-management training programme involving repetitive grasping and releasing movements over 6 weeks.
23124|NCT04007315|Behavioral|Usual care|6-weeks of usual NHS care
23125|NCT04007302|Other|measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)|measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method
23126|NCT04007302|Other|completion of questionnaires|igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
23127|NCT04007302|Other|completion of questionnaires for pain|analogical visual and numerical scale and Borg scale
23128|NCT04007289|Drug|Apixaban|Administration of Apixaban ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography, Biological samples collections to identify predictors of thrombosis and liver related events
23129|NCT04007289|Drug|Placebo|Administration of placebo ; 2 clinical examinations; blood tests, 3 liver and spleen stiffness measurements, 2 contrast enhanced echocardiographies, 1 hepatic ultrasonography,
23130|NCT04007276|Drug|brimonidine tartrate ophthalmic solution 0.025%|Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
23131|NCT04007276|Other|sterile balanced saline solution|Single dose of sterile balanced saline solution applied as an eye drop to the eye surface.
23132|NCT04007263|Drug|Placebo|Placebo via 30 minute infusion once daily for 5 days
23133|NCT04007263|Drug|NP10679|NP10679 25 mg via 30 minute infusion once daily for 5 days
23134|NCT04007250|Device|FENIX™ Continence Restoration System|"The FENIX™ Continence Restoration System is indicated for use for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative therapy. The FENIX™ System Implant is placed around the external anal sphincter to augment a weak anal sphincter and restore continence.~The FENIX™ System is comprised of the following components:~FENIX™ System Implant~FENIX™ System Anal Sphincter Sizing Tool The FENIX™ System Implant consists of a series of titanium beads with magnetic cores that are connected with independent titanium wires to form an annular shape. The attractive force of the magnetic beads is designed to provide additional strength to keep a weak anal sphincter closed."
23135|NCT04007237|Drug|shampoo with different composition|To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
23136|NCT04007224|Drug|Intranasal oxytocin|daily administration of oxytocin, 10 UI intrnasal, 5 UI bid, and if needed curcumin orally 250 mg bid, and/or lecithin 500 mg bid, and/or pironoquinolinquinone, 20 mg qd
23137|NCT04007224|Biological|Autologous umbilical cord blood|patients aged between 3 and 7 years will receive one-time intravenously the processed umbilical cord blood collected at the respective child's birth
23138|NCT04007211|Device|ABT13107|Dose: 3mL, maximum 10mL
23139|NCT04007211|Device|Hyalobarrier|Dose: 10mL
23143|NCT04007172|Procedure|neural therapy|Intracutaneous quaddle injections were performed using 1% lidocaine preparation as a local anesthetic for local application to painful points with palpation on the back and shoulders and for the segmental application, 2 cm lateral to the midline of the C1-T5 vertebrae and on spinous processes.
23144|NCT04007172|Device|Physical Therapy|Physical therapy program was consist of transcutaneous electrical nerve stimulation- TENS (30-40 Hz, 20 minutes), hotpack (20 minutes) and continuous ultrasound (1mHz, 1.5w / cm2, 10 minutes) on painful points with palpation on the back and shoulders.
23145|NCT04007159|Other|Serum|Participants will be topically applied serum to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of serum in an individual cell of patch)
23146|NCT04007159|Other|Lotion|Participants will be topically applied lotion to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of lotion in an individual cell of patch)
23147|NCT04007159|Other|Cream|Participants will be topically applied cream to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of cream in an individual cell of patch)
23148|NCT04007159|Other|Normal Saline|Participants will be topically applied normal saline to the dorsum, under a semi-occlusive patch (0.02mL/cm^2 of normal saline in an individual cell of patch)
23149|NCT04007146|Diagnostic Test|Transcutaneous oxymetry measurement|Transcutaneous oxymetry measurement with transient hyperoxia period (2 periods of 30seconds at 60% of oxygen)
23150|NCT04007133|Other|Girerd test|This is a simple and quick questionnaire, composed of 6 questions with a binary yes/no answer. It allows to assess the degree of compliance with the prescribed treatment to better identify the constraints related to the treatment.
23151|NCT04007120|Drug|RVT-1601|Inhaled RVT-1601 administered once daily over two days
23152|NCT04007107|Drug|Semaglutide (administered by DV3396 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
23153|NCT04007107|Drug|Semaglutide (administered by PDS290 pen)|Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
23154|NCT04007094|Drug|ViviGen Cellular Bone Matrix|Study participants will receive local autograft milled bone on one side of the fusion and an equal amount of Depuy Synthes ViviGen on the opposite side of the fusion
23155|NCT04007081|Procedure|Bone Marrow Aspiration|collection of approximately 40 mL of bone marrow aspirate
23156|NCT04007081|Diagnostic Test|Ultrasound Imaging of Salivary Glands|Salivary gland size will be measured by ultrasound.
23157|NCT04007081|Other|Salivary Assay|Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions
23158|NCT04007081|Other|Quality of Life Instruments|Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.
23159|NCT04007068|Diagnostic Test|FDG PET/CT|FDG PET/CT baseline, month 1, month 4, month 10, than every 6 months
23160|NCT04007055|Diagnostic Test|Point of care screening for HPR|HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
23161|NCT04007055|Drug|Ticagrelor 90mg|Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
23162|NCT04007029|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given Autologous anti-CD19/anti-CD20 CAR-expressing naive/memory T cells IV
23163|NCT04007029|Drug|Cyclophosphamide|Given IV
23164|NCT04007029|Drug|Fludarabine Phosphate|Given IV
23165|NCT04007029|Biological|Tocilizumab|Given IV
23166|NCT04007016|Procedure|"a new osteotomy from the inner L shaped iliac osteotomy"|"There were two ostectomies were used in the osteotomy. The first was was a cured and 5mm width and the second one was straight 1.5cm width. All the directions was started from the inner to outer just a bove the triradiate cartilage and its shape likeL"
23167|NCT04007003|Behavioral|training in optimal insulin injection technique|the training will be delivered in person as well as through online training modules via the BD and Me(TM) platform
23168|NCT04006990|Behavioral|Provision of recliner chairs and encouragement to get out of bed|Provision of recliner chairs and encouragement to get out of bed
23169|NCT04006977|Dietary Supplement|a multistrain probiotic product (DSF)|In Arm 2, participants will receive standard medical therapy plus the multistrain probiotics (DSF), 4 sachets per day.
23170|NCT04006977|Dietary Supplement|Placebo|In Arm 1, participants will receive standard medical therapy plus the placebo.
23171|NCT04006964|Device|Resmon PRO FULL v2|Measurement of lung impedance by the Forced Oscillation Technique
23172|NCT04006951|Other|Biological collection|"Blood samples are collected at different times :~Before any treatment~After pre-operative radiochemotherapy and before surgery (if applicable)"
23173|NCT04006938|Behavioral|Single Bout ('S')|Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast
23174|NCT04006938|Behavioral|Multiple Bout ('M')|Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
23175|NCT04006925|Drug|Sodium Oxybate|"Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose)."
23176|NCT04006925|Other|Placebo|Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
23177|NCT04006912|Procedure|phacoemulsification and Toric intraocular lens implantation|A clear corneal incision is made in a different position
23178|NCT04006899|Device|Bioelectrical Impedance Monitor|Subjects had been under the test of three commercially available devices and the device that the investigators had developed.
23179|NCT04006886|Dietary Supplement|Gluten-free diet|After run-in phase with normal diet under Observation, patients will be on a gluten-free diet for two months.
23180|NCT04006873|Drug|Tezacaftor/Ivacaftor + Ivacaftor|As per description in arms.
23181|NCT04006873|Drug|Placebo oral tablet|As per description in arms
23182|NCT04006860|Drug|SHC014748M Capsules|SHC014748M Capsules: 200mg
23187|NCT04006821|Drug|Apatinib mesylate|Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
23188|NCT04006808|Biological|PED-HZ/su|GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
23189|NCT04006795|Other|Serum|Participants will be topically applied adhesive patch containing developmental serum
23190|NCT04006795|Other|Lotion|Participants will be topically applied adhesive patch containing developmental lotion
23191|NCT04006795|Other|Cream|Participants will be topically applied adhesive patch containing developmental cream
23192|NCT04006795|Other|Normal Saline|Participants will be topically applied adhesive patch containing normal saline
23193|NCT04006782|Device|Narrow dental implants|Insertion of narrow dental implants in multiple fixed prosthesis
23194|NCT04006769|Drug|Entacapone|Entacapone tablet
23195|NCT04006769|Drug|Imatinib Mesylate|Imatinib Mesylate tablet
23196|NCT04006756|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
23197|NCT04006756|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
23198|NCT04006743|Behavioral|The swaddling group|The newborns were placed in a supine position on a 90 cm2 soft fabric for swaddling procedure. The upper side of the bandage was aligned with the shoulder of the newborn. Newborns' arms were put in a flexion position. The top of the body was completely covered with a bandage. The infant's head can move freely. The swaddling procedure took about one minute. In the study, swaddling process was applied 10 minutes before the painful procedure. The swaddled newborns remained in the swaddling during the procedure and for 5 minutes after the procedure.
23199|NCT04006743|Behavioral|The expressed breast milk group|In terms of the reliability of the study results, nothing was orally given to the preterm infant at least 30 minutes before the procedure. As recommended in the studies, 2 ml oral breast milk was given to preterm infants before the procedure. In the study, breast milk was given slowly to the upper part of the tongue of each preterm infant from his/her own mother as a single dose before OGT insertion. As a result, preterm was ensured to take all of 2 ml breast milk by reducing the aspiration risk of breastmilk. The breast milk was given without touching the tip of the injector to the newborn's mouth. The preterm infants were not allowed to suck the tip of the injector.
23200|NCT04006743|Behavioral|The facilitated tucking group|Facilitated tucking was given in supine position by holding the arm and legs of the preterm infant to the body by the researcher. In line with the literature, facilitated tucking was initiated 3 minutes before OGT insertion in order for the newborn to feel the fetal position and to cope with the painful procedure. The preterm was kept in fetal position during the procedure and for 5 minutes after the procedure.
23201|NCT04006743|Behavioral|The swaddling and expressed breast milk group|Swaddling procedure was conducted by the researcher to the preterm infant 10 minutes before the OGT insertion procedure. 2 ml breast milk was administered by the researcher to preterm using a sterile injector as a single dose for 2 minutes before OGT insertion procedure. The preterm was remained in swaddling during the OGT insertion procedure and for 5 minutes after the process.
23202|NCT04006743|Behavioral|The facilitated tucking and expressed breast milk group|Facilitated tucking method was applied right after giving 2 ml breast milk by the researcher to the preterm 3 minutes before OGT insertion procedure. Preterm newborn remained in facilitated tucking during the procedure and for 5 minutes after the procedure.
23203|NCT04006717|Device|Low Level Laser therapy|Diode laser (EPIC™ BIOLASE) with wavelength 940nm
23204|NCT04006717|Procedure|Intra canal Cryotherapy|Irrigation with cold saline 2-4 C
23205|NCT04006704|Drug|D/C/F/TAF FDC placebo|Participants will receive matching placebo tablet (whole and split) of D/C/F/TAF 675/150/200/10 mg FDC on Day 1 as intake period 1 and intake period 2.
23206|NCT04006691|Drug|UGN-101 instillations|Treatment with UGN-101 once weekly for a total of 3-6 times; in a retrograde fashion.
23207|NCT04006678|Procedure|computer guided sandwich osteotomy|segmental sandwich osteotomy will be done for vertically deficient ridges in anterior area of the maxilla. Either using surgical guides (Computer guide segmental sandwich osteotomy technique) for study group and conventional segmental sandwich osteotomy technique for control group.
23208|NCT04006665|Diagnostic Test|Lung Ultrasonography (Baseline)|Lung Ultrasonography will be performed prior to docking Robotic arms in basal three lung zones on both sides.
23209|NCT04006665|Diagnostic Test|Lung Ultrasonography ( At the end of surgery)|Lung Ultrasonography will be performed after removal of Robotic arms and before extubation in basal three lung zones on both sides to assess degree of atelectasis.
23210|NCT04006652|Drug|ApoGraft|ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
23211|NCT04006639|Procedure|Analgesic Technique|Patients undergoing tracheostomy procedure must be administered with analgesics, such Lidocaine 20% or Bupivacaine 0.5%
23212|NCT04006613|Other|Circuit Training|20 minutes of High Intensity Aerobic Training (HI) on treadmill: 2 minutes warm up + 4x 4 minutes HI+ 2 minutes of active recovery; 10 minutes of dynamic balance training; 10 minutes of functional strength training.
23213|NCT04006613|Other|Usual Care|Exercises aimed at improving mobility and balance
23214|NCT04006600|Procedure|proctectomia|"After rectal resection, when colorectal anastomosis is subperitoneal, it is currently recommended to perform a protective stoma to reduce the potential consequences of a fistula. This stoma, which is intended to be temporary, appears to be permanent in 6 to 32% of cases in the literature.~The objective of the study is therefore to look for a statistical link between the persistence of a permanent stoma and the intraoperative difficulty represented by pelvic anatomical stress."
23215|NCT04006587|Device|incentive spirometer|patients were instructed how to use the IS in a seated or semi-seated position, and to maintain sustained maximal inspiration for 3-5 seconds before exhalation, ten times per hour, and for at least eight hours a day.
23216|NCT04006574|Other|Exercises|Core stabilization
23256|NCT04006223|Diagnostic Test|11C-PIB or 18F-florbetapir PET/MR after treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
23257|NCT04006210|Combination Product|ND0612 Solution for SC infusion|Levodopa Carbidopa solution administered SC via infusion pump
23217|NCT04006561|Radiation|A treatment protocol of combined chemoradiation delivered in the manner of hyperfractionated conformal whole-brain radiation therapy|Each freshly-diagnosed patient with primary CNS lymphoma will be treated with combined chemoradiation in a sandwiched way, in which 2 cycles of induction chemotherapy with intravenous methotrexate (MTX in a conventional dose of 1g/m2) and intrathecal MTX are followed by a complete course of hyperfractionated WBRT and then high-dose cytarabine for 2 cycles.
23218|NCT04006535|Genetic|genetic analysis|Saliva sample collection for genetic analysis
23219|NCT04006522|Drug|89Zr-DFO-Atezolizumab|89Zr-DFO-Atezolizumab infusion
23220|NCT04006522|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan 7 days (± 1 day) after infusion of 89Zr-DFO-Atezolizumab.
23221|NCT04006509|Behavioral|Prenatally Delivered Lactation Educational Program|The support person (SP) of mothers at risk for preterm birth will be educated on how to use a breast pump and instructions regarding breast milk expression and have a pump in their hospital room
23222|NCT04006496|Behavioral|Expressive Writing Coaching|For the intervention group, a trained expressive writing expert/coach will introduce the expressive writing concept to consented patients during the first visit, followed by an introduction of the first expressive writing exercise and prompt. The expert/coach will introduce new writing prompts at each subsequent visit. A script containing each visit's writing prompt and instructions will also be left with the patients for future use and/or reference. The trained clinician will collect, read, and analyze the writing sample using a health coaching technique by: 1) summarizing what the patient wrote, 2) evoking double-sided reflection by reading back the writing sample to the patient, and 3) developing a metaphor and review with the patient. Patients will also have the opportunity to ask the trained clinician questions and receive guidance.
23223|NCT04006483|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
23224|NCT04006483|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
23225|NCT04006483|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
23226|NCT04006470|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
23227|NCT04006470|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
23228|NCT04006470|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
23231|NCT04006405|Diagnostic Test|GAG score|blood and urine samples to determine GAG scores
23232|NCT04006392|Device|Erchonia FX-635|The Erchonia FX-635 has three independent 17 milliWatts (mW) 635 nanometer (nm) red laser diodes mounted in scanner devices.
23233|NCT04006392|Device|Placebo Laser|Non-therapeutic output.
23234|NCT04006366|Behavioral|Time restricted feeding|We propose a pilot and feasibility trial of a 10 hour time restricted eating intervention among post-bariatric surgery patients.
23235|NCT04006353|Drug|ABT|320 mg, Intravenous infusion
23236|NCT04006353|Drug|RIF|600mg q.d.
23237|NCT04006340|Combination Product|triple therapy|esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days
23238|NCT04006340|Combination Product|quadruple therapy|esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 days
23239|NCT04006340|Diagnostic Test|dual-priming oligonucleotide-based multiplex (DPO)-PCR test|Resistance of clarithromycin 23S rRNA point mutation
23240|NCT04006327|Other|No intervention will be provided as this study is a cross-sectional observational study.|This item is not applicable because this study is a cross-sectional observational study and no intervention will be provided to participants.
23241|NCT04006314|Other|Autologous platelet rich plasma and dextrose solution.|"Autologous platelet rich plasma are injected into the knee joint and pes anserinus complex.~Dextrose solutions are injected to the genicular nerves."
23242|NCT04006301|Drug|JNJ-74699157|Participants will receive JNJ-74699157 orally.
23243|NCT04006288|Drug|Clopidogrel|Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban
23244|NCT04006288|Drug|Prasugrel|Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban
23245|NCT04006288|Drug|ticagrelor|Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban
23246|NCT04006288|Drug|aspirin|all patients will remain on aspirin
23247|NCT04006288|Drug|rivaroxaban|Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
23248|NCT04006275|Drug|Sonovue and Sonazoid|"Subjects were randomized to receive SonoVue firstly and Sonazid secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
23249|NCT04006275|Drug|Sonazoid and Sonovue|"Subjects were randomized to receive Sonazoid firstly and SonoVue secondly after wash out period. Between the wash out period(at least 30min) and after whole trial, the patients was carefully observed at our department for at least 30min.~contast agent dose: Sonazoid (0.12 μL/kg of perflubutane microbubbles) or SonoVue (2.4 mL) in a 1:1 ratio."
23250|NCT04006262|Drug|Nivolumab 10 MG/ML|"Neo-adjuvant treatment : 240 mg intravenous (I.V.) in 30 minutes - every 2 weeks - 6 cycles~Adjuvant treatment : 480mg I.V. in 30 minutes - every 4 weeks - 9 cycles"
23251|NCT04006262|Drug|Ipilimumab 200 MG in 40 ML Injection|Neo-adjuvant treatment : 1mg/kg over 30 minutes every 6 cycles - 2 cycles
23252|NCT04006249|Diagnostic Test|dental probes|Measurement of the depth of the periodontal pockets and clinical loss
23253|NCT04006236|Other|Experimental Infant Formula|Feed Ad Libitum
23254|NCT04006236|Other|Control Infant Formula|Feed Ad Libitum
23255|NCT04006223|Diagnostic Test|11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment|10-20 mCi 11C-PIB or 5-10 mCi 18F-florbetapir will be injected intravenously prior to imaging.
23258|NCT04006210|Combination Product|Placebo for SC infusion|Placebo solution administered SC via infusion pump
23259|NCT04006210|Drug|Carbidopa and Levodopa 25mg/100mg|Encapsulated Carbidopa and Levodopa USP 25mg/100mg
23260|NCT04006210|Drug|Placebo for Carbidopa and Levodopa 25mg/100mg|Encapsulated Placebo for Carbidopa and Levodopa USP 25mg/100mg
23261|NCT04006197|Other|laryngostroboscopy and histoh-pathology|videolaryngoscopy and laryngostroboscoby will be performed .the latter will be pathological in case of highly reduced or abolished amplitudes of vocal fold vibration and if there is reduction of mucosal wave propagation.also direct microlaryngoscopy under general anathesia will be done and excesional biobsy will be taken followed by histopatholpgical examination .the histological finding will be catagorized into the following categories according to (WHO): squamous cell hyperplasia with non dysplasia,mild dysplasia,moderate dysplasia,sever dysplasia,carcinoma in situ and squamous cell carcinoma.
23262|NCT04006184|Other|Chart review|Retrospective review of medical records at a single site with six physicians
23263|NCT04006171|Diagnostic Test|C type natriuretic peptide|Serum level of CNP in PCOS and healthy women
23264|NCT04006158|Device|LED bed|Low risk FDA cleared full body LED bed
23265|NCT04006145|Drug|Elobixibat|Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).
23266|NCT04006145|Drug|Placebo oral tablet|Placebo identical in appearance to active drug
23267|NCT04006132|Device|Fitting of Ponto 3 SuperPower|Bone-anchored hearing systems (BAHS) use the body's natural ability to transfer sound through bone conduction. The sound processor picks up sound and converts it into vibrations that are transferred through the skull bone to the inner ear (cochlea). Thus, for patients with conductive or mixed hearing losses, patients with lasting hearing loss following a middle ear disease or malformations (such as microtia), the vibrations are bypassing the conductive problem in the ear canal or middle ear. The intervention in this study is audiologically fitting two bone-anchored sound processors (Ponto 3 SuperPower) to patients that are already bilaterally implanted with abutments.
23268|NCT04006119|Biological|Ad-RTS-hIL-12|"intratumoral injection of Ad-RTS-hIL-12~2.0 x 10^11 viral particles (vp) per injection"
23269|NCT04006119|Drug|Veledimex|20mg/day 15 oral daily doses of veledimex
23270|NCT04006119|Drug|Cemiplimab-Rwlc|Infusion every 3 weeks (350mg)
23271|NCT04006093|Drug|Apixaban Oral|one Tablet 5mg
23272|NCT04006080|Biological|Vedolizumab|Intravenously administered selective leukocyte adhesion molecule inhibitor
23273|NCT04006067|Other|changing surgical gloves|All the surgical team including surgeons, surgical assists and scrub technicians replaced their outer surgical gloves with a new pair of sterile gloves just prior to abdominal closure.
23274|NCT04006054|Drug|Dexmedetomidine|When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .
23275|NCT04006054|Drug|Midazolam|When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .
23276|NCT04006041|Drug|Toripalimab|Patients received toripalimab 240 mg IVDRIP on days 1 and 22 during neoadjuvant radiotherapy.
23277|NCT04006041|Drug|Paclitaxel/cisplatin|Patients received 4 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22 during neoadjuvant radiotherapy.
23278|NCT04006041|Radiation|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 40 Gy in 20 fractions over 4 weeks.
23279|NCT04006041|Procedure|Esophagectomy|A transthoracic (Ivor-Lewis) esophagectomy is performed 6-8 weeks after CRT completion.
23280|NCT04006015|Other|No intervention being delivered.|No interventions are being delivered.
23281|NCT04006002|Other|Metabolic and Hormonal profile|To assess changes in metabolic profiles and body metrics such as weight and BMI in these patients after an endoscopic or surgical bariatric intervention
23282|NCT04005989|Biological|Stromal Cells Injection|Adipose stromal cell
23283|NCT04005963|Diagnostic Test|13N-NH3 PET cardiac blood flow perfusion rest and load imaging|"Immediately after the bedside injection of 13N-NH3 370 MBq, dynamic 2D collection of heart images 10 min, scanning 1 bed; , a total of 6 min), 3min bedside injection 13N?NH3 370-540 MBq immediately after the dynamic 2D collection of heart image 10 min. Both rest and load imaging are corrected for CT attenuation.~Image reconstruction is carried out by the method of maximum expectation of an ordered subset, the dynamic image is divided into the early phase of the first 2 min and the late phase of the last 8 min, the captured image is replayed (VIP replay) of the volume image protocol and the gated data is reconstructed."
23284|NCT04005950|Device|Scalpel Bougie technique|ScalpelCric Set
23285|NCT04005950|Device|modified Scalpel Bougie technique|ScalpelCric Set plus speculum
23286|NCT04005937|Diagnostic Test|H-reflex|Electrical stimulation of Group Ia afferent of muscle spindle
23287|NCT04005924|Other|arabinogalactan|Arabinogalactan will be mixed into sugar-free blackberry jam and consumed with the provided bread.
23288|NCT04005911|Device|Themography|Using a FLIR camera, a thermographic recording will be taken of the patient while breathing. Simultaneously, the research investigator will record the thoracic impedance-based respiratory rate as well as manually count respirations in one minute.
23289|NCT04005898|Device|Near-infrared fluorescence cholangiography|Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
23290|NCT04005885|Device|comfilcon A|Contact Lens
23291|NCT04005885|Device|somofilcon A|daily disposable contact lens
23292|NCT04005885|Device|stenfilcon A|daily disposable contact lens
23293|NCT04005872|Drug|Nano Silver Fluoride|Nano silver fluoride (NSF) is a new material consisting of nano silver particles, chitosan and sodium fluoride. It is a bacteriostatic and bactericidal compound.
23294|NCT04005872|Drug|Calcium hydroxide|Calcium hydroxide is a gold standard for indirect pulp capping which induces hard tissue.
23333|NCT04005547|Behavioral|Promoting Awareness through Live Movement and Sound for youth with Autism Spectrum Disorder|Session 1 - Let's Talk About Relationships Session 2 - Let's Talk About Intimate Relationships Session 3 - Let's Talk About Sex Session 4 - Let's Talk About Protection Session 5 - Let's Talk About Communication *Bring your Trusted Adult* Session 6 - Let's Talk About Growing Up
29155|NCT03958617|Device|Bilateral Deep brain stimulation of the thalamus, Medtronic Device|
23295|NCT04005859|Drug|Exparel|"2. Liposomal bupivacaine TAP block (experimental arm) n= 35~Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.~A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.~The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.~Adhesive tapes will be applied at the level of the TAP block puncture sites."
23296|NCT04005859|Drug|IV Lidocaine|"1. Intravenous Lidocaine infusion (control arm, current standard of care) n= 35~100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.~1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.~Adhesive tapes will be applied at the presumed level of TAP block puncture sites."
23297|NCT04005846|Device|Transcranial Direct Current Stimulation (tDCS)|The active session of tDCS will consist in applying two anodes over M1 bilaterally (C3 and C4 according to the 10-20 international EEG placement) and the cathodes over the occipital areas (O1 and O2), and to inject 2 mA for 20 minutes through sponge electrodes (35 cm²) placed on the scalp using the Startsim 8 (Neuroelectrics, Barcelona). The sham tDCS will use the same montage and device but direct current will only be injected for 30 seconds, with a ramp-up and ramp-down 15 seconds period, to mimic the somatosensory effects of active tDCS.
23298|NCT04005833|Diagnostic Test|spirometry|The lung function (FEV1) will be assessed at follow-up visits at 2 months, 12 months and 36 months after inclusion.
23299|NCT04005820|Other|Radiologic Centralized Review|The patient's imaging will be examined in one of the examination centers
23300|NCT04005820|Other|Tissue sample (tumor, sung, urine)|all the samples will be made during the patients care
23301|NCT04005807|Drug|BPN-14967|BPN-14967 oral capsules
23302|NCT04005807|Drug|Placebo|Oral capsules
23303|NCT04005794|Behavioral|VR social skills training|Social skills game that we developed in the R21 phase will be used across 10 sessions of training in the lab. Each session is about 1 hour long. Participants come to the lab twice a week for 5 weeks.
23304|NCT04005794|Behavioral|Cognitive training|Commercially available brain fitness training program will be used to control for the time spent in the lab and associated social interactions as well as the total exposure to computerized games.
23305|NCT04005781|Drug|Hydroxychloroquine sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
23306|NCT04005781|Drug|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
23307|NCT04005768|Drug|Hydroxychloroquine Sulphate|After a stabilization period of 20 min and 10 min after the first blood collection, Plaquenil (Hydroxychloroquine sulfate) will be administered per os (total dose of 400 mg) in a randomized, double-blinded fashion.
23308|NCT04005768|Drug|Placebo|After a stabilization period of 20 min and 10 min after the first blood collection, Placebo will be administered per os (2 tablets) in a randomized, double-blinded fashion.
23309|NCT04005755|Drug|Maxigesic® IV|acetaminophen 1000 mg + ibuprofen 300 mg, 100 ml solution for infusion
23310|NCT04005729|Drug|Cangrelor 50 MG|30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
23311|NCT04005716|Drug|Tislelizumab, Carboplatin /Cisplatin, Etoposide|Tislelizumab (200 mg IV Q3W) in combination with chemotherapy consisting of etoposide (100 mg/m² IV Days 1-3 of each 21-day cycle) and platinum (cisplatin 75 mg/m² IV Q3W or carboplatin AUC 5 IV Q3W) for 4 cycles. Then maintenance consists of Tislelizumab Q3W and will continue until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent.
23312|NCT04005716|Drug|Carboplatin / Cisplatin, Etoposide|Placebo Q3W in combination with chemotherapy consisting of etoposide (100 mg/m² IV Days 1-3 of each 21-day cycle) and platinum (cisplatin 75 mg/m² IV Q3W or carboplatin AUC 5 IV Q3W) for 4 cycles. Then maintenance consists of Placebo Q3W and will continue until disease progression, loss of clinical benefit, unacceptable toxicity, or withdrawal of informed consent.
23313|NCT04005690|Drug|Cobimetinib|Given PO
23314|NCT04005690|Drug|Olaparib|Given PO
23315|NCT04005677|Diagnostic Test|The serum and urine from people enrolled are used to analyze the DNA, RNA, protein, metabolites, immune status|The serum and urine from people enrolled are used to analyze the DNA, RNA, protein, metabolites, immune status
23316|NCT04005664|Drug|Phenylephrine|Prophylactic phenylephrine infusion as part of fluid coload
23317|NCT04005651|Device|POD L GF IOL|Cataractous lens will be removed in the study eyes and the POD L GF IOL will be implanted in the capsular bag
23318|NCT04005651|Device|Symfony® IOL|Cataractous lens will be removed in the study eyes and the Symfony® IOL will be implanted in the capsular bag
23319|NCT04005651|Device|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag
23320|NCT04005638|Biological|blood sample|45 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
23321|NCT04005638|Biological|urine sample|12 ml
23322|NCT04005612|Dietary Supplement|vitamin D3|50,000 IU VD3 / week for 8 weeks
23323|NCT04005612|Dietary Supplement|omega-3 fatty acid|300 mg of omega 3-FA once daily for 8 weeks
23324|NCT04005612|Dietary Supplement|vitamin D3 and omega-3 fatty acid|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
23325|NCT04005612|Other|control|no intervention
23326|NCT04005599|Drug|Remifentanil group|Venous general anesthesia with propofol and remifentanil.
23327|NCT04005599|Drug|Magnesium sulfate group|Venous general anesthesia with propofol and magnesium sulfate
23328|NCT04005573|Dietary Supplement|VD3|VD3 50000 IU/ week for 8 weeks
23329|NCT04005573|Dietary Supplement|omega 3- FA|Omega 3 FA group 300 mg once daily for 8 weeks
23330|NCT04005573|Dietary Supplement|VD3 and omega- 3FA|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
23331|NCT04005573|Other|no intervention|no intervention is given
23332|NCT04005560|Other|no interventional study|no interventional study
23334|NCT04005534|Drug|Regular group|Ultrasound examination of the brachial plexus 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
23335|NCT04005534|Drug|Preemptive group|Ultrasound guided brachial plexus blockade 2 days before the surgery. Ultrasound guided brachial plexus blockade and sedation on the day of surgery.
23336|NCT04005521|Behavioral|Preventive intervention|Preventive, structured exercise protocol
23337|NCT04005508|Diagnostic Test|Overnight sleep study|The patients will undergo an overnight sleep study using Watch-PAT sleep study device
23338|NCT04005495|Behavioral|Teaching kitchen program|The teaching kitchen program will include five 4-hour Saturday classes every other weekend over the course of 10 weeks (5 sessions totaling 20 hours of instruction). It will be taught by subject matter experts from the Emory University faculty and staff as well as potentially from the community. The classes will include the scientific rationale, practical applications, and recommendations for implementing self-care components into participants' daily lives. Experiential learning will include hands-on cooking demonstrations, mindfulness-based lunches, a yoga session, and a group exercise session. Rather than being prescriptive, the lectures and demonstrations are geared to inspire self-designed and personalized alterations in dietary patterns and behaviors that will match participants' culture, preferences, and health conditions. Biometrics and survey instruments will be assessed at 4 times: at baseline, after the 10-week program, and at 6 and 12 months after the program.
23339|NCT04005482|Other|Rate control|Rate control according to the Atrial fibrillation - ESC Guidelines 2016
23340|NCT04005469|Drug|Treprostinil|Treprostinil (Remodulin) will be administered IV by a standard 3 + 3 dose-escalation approach. This dosing model will be followed until a target dose of 15 mg/kg/min is achieved or if it is medically determined that side effects prevent dose escalation. IV infusion will commence approximately 2-3 hours before transplantation of the kidney graft and will continue for approximately 48 hours after completion of surgery, unless hemodynamic changes or tolerability require discontinuation of treprostinil.
23341|NCT04005456|Dietary Supplement|Supplements and/or medical foods|Personalized dietary supplementation (e.g., multivitamins/minerals, probiotics, specialized pro-resolving mediators, marine oil, vitamin D, hormone support, methylation support, protein drink, phytochemicals, neurocognitive support, targeted ingredients)
23342|NCT04005456|Behavioral|Behavioral change support program|Program to implement lifestyle and behavioral change according to individuals' need.
23343|NCT04005456|Other|Food plan|Personalized food plan (e.g., basic wellness food plan, cardiometabolic food plan, high protein high phytonutrient food plan, ketogenic food plan, detoxification food plan, anti-inflammatory food plan, neuro food plan)
23344|NCT04005443|Other|radiopharmaceutical|his study will consist of a monthly intra-ocular injection of antiangiogenic and a follow-up ophthalmological consultation with OCT and visual acuity score
23345|NCT04005430|Drug|Episcleral Dexamethasone|Sequestered Transscleral, Controlled-Release Dexamethasone
23346|NCT04005417|Drug|Stannous fluoride dentifrice|Stannous fluoride (0.454%) dentifrice
23347|NCT04005417|Drug|Positive control dentifrice|Positive control dentifrice containing potassium nitrate or arginine.
23348|NCT04005417|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
23349|NCT04005404|Drug|Ropivacaine (sciatic nerve block)|injection of 20 ml ropivacaine 0.375%
23350|NCT04005404|Drug|Ropivacaine (lumbar plexus block L2-L4)|injection of 20 ml ropivacaine 0.375%
23351|NCT04005404|Drug|Ropivacaine (lumbar plexus block Th12-L1)|injection of 20 ml ropivacaine 0.375%
23352|NCT04005391|Other|Offer of Participant's Choice of Contraception Method|Women will be offered a range of contraceptive options (condoms, contraceptive pills, medroxyprogesterone acetate injection, levonorgestrel implant) to choose from; they can decline to start a contraceptive method
23353|NCT04005378|Other|CSC Step-down intervention|Web-based telemedicine and a smartphone app, to decrease disengagement likelihood
23354|NCT04005378|Other|Usual Care|Usual Care provided by CSC center
23355|NCT04005365|Drug|Propranolol|add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
23356|NCT04005352|Biological|Brolucizumab 6 mg|3 x 4-week injections and one 8-week injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62.
23357|NCT04005352|Biological|Aflibercept 2 mg|3 x 4-week injections and one 8-week injection, followed by Treat-to- Control treatment from Week 16 up to Week 60/62
23358|NCT04005339|Drug|Nanoliposomal Irinotecan|Nanoliposomal irinotecan 70 mg/ IV over 90 minutes, every 14 days
23359|NCT04005339|Drug|Leucovorin|Leucovorin 400 mg/ IV over 30 minutes, every 14 days.
23360|NCT04005339|Drug|Fluorouracil|Fluorouracil 2,400 mg/m IV over 46 hours.
23361|NCT04005326|Procedure|quadratus lumborum block; (Anterior QLB or QLB III)|The patient will be in the lateral position. A low frequency convex probe will be vertically attached above the iliac crest and a needle will be inserted in plane from the posterior edge of the convex probe through the quadratus lumborum in an anteromedial direction. The needle tip will be placed between the psoas major muscle and the quadratus lumborum muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected into the fascial plane incrementally, aspirating every 5 ml.
23362|NCT04005326|Procedure|suprainguinal fascia iliaca block|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest & iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
23363|NCT04005326|Procedure|Subarachnoid block|"Patients will receive SAB using 25g spinal needle in the lateral position. Fifteen milligrams of hyperbaric bupivacaine will be administered at L3-L4 or at L4-L5 interspace in addition to 25 mcg fentanyl with rapid crystalloid co-load.~Spinal anesthesia will be considered successful when a bilateral block to T12, as assessed by loss of cold (cold ice) and pain (a 23-gauge needle) sensations, will be established 10 -minutes after the intrathecal injection. If spinal anesthesia failed, such patients will be administered general anesthesia and will be excluded from this study."
29216|NCT03958123|Drug|400 mg Moxifloxacin|Encapsulated 400 mg moxifloxacin tablet.
23364|NCT04005313|Device|vibroacoustic device|the participants will receive the vibroacustic device or music therapy
23365|NCT04005300|Dietary Supplement|standard enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 500-750kcal/d
23366|NCT04005300|Dietary Supplement|restricted enteral nutrition|Enteral nutrition was treated within 48 hours after ICU and the calories were 10-20kcal/kg/d for 3 days
23367|NCT04005287|Drug|WST-057 (4% pirenzepine) Lose Dose 2mL|Topical Solution
23368|NCT04005261|Diagnostic Test|C-peptide concentrations|The patients will be grouped by their C-peptide concentrations
23369|NCT04005248|Diagnostic Test|HCV IgG test|An HCV IgG test (performed on blood already collected for regular STI tests), combined with a questionnaire on sexual risk behavior. If client is HCV IgG positive, a HCV RNA test will be performed.
23370|NCT04005235|Device|Thorasys Tremoflo C-100 Airwave Oscillometry System (FOT)|Ultrasonography will be used to confirm hemidiaphragm dysfunction after brachial plexus nerve block. In subjects with U/S confirmed hemidiaphragm dysfunction, FOT measurements will be taken before and after nerve block and post-operatively after upper extremity surgery.
23371|NCT04005222|Drug|SELENIUM|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by selenium supplementation.
23372|NCT04005222|Drug|MELATONIN|Increased lipid peroxidation associated with ischemia of the anterior segment has been prevented by melatonin supplementation.
23373|NCT04005209|Drug|Ketamine|The experimental group will receive a ketamine intravenous infusion, initiated at 0.2 mg/kg/hr within the first 12 to 24 hours on an inpatient admission for sickle cell pain crisis, and titrated per hospital policy by the inpatient pain service.
23374|NCT04005209|Other|Pain management|Pain management
23375|NCT04005196|Diagnostic Test|EEG|Data recording will continue up until a maximum of 120 hours after emergence from sedation or at CVICU discharge. This study period is informed by baseline data from our institution where the median duration of delirium following emergence from coma was 2 days, allowing sufficient time to capture transitions from coma to wakefulness with and without delirium. EEG recordings will be divided in to epochs corresponding to coma, wakefulness, and delirium if present.
23376|NCT04005170|Drug|Toripalimab|Patients received toripalimab 240 mg on days 1 and 22 during radiotherapy followed by a maintenance phase of toripalimab IV 240 mg every 3 weeks for up to 1 year.
23377|NCT04005170|Drug|Paclitaxel/Cisplatin|Patients received 5 cycles of paclitaxel/cisplatin (paclitaxel 50mg/m2 and cisplatin 25 mg/m2) on days 1, 8, 15, 22, 29 during radiotherapy.
23378|NCT04005170|Radiation|Intensity-modulated radiotherapy|All patients received external-beam radiation using intensity-modulated radiotherapy. The prescribed dose is 50.4 Gy in 28 fractions over 5-6 weeks.
23379|NCT04005157|Procedure|MWA|Patients diagnosed with early-stage NSCLC and signing the informed consent will undergo MWA with the guidance of ENB.
23380|NCT04005157|Device|ENB|ENB (LungCare Medical Technologies Ltd., Inc, Suzhou, China)will be used to guide bronchoscope into the accurate location of the lesion during MWA.
23381|NCT04005144|Drug|Binimetinib|Given PO
23382|NCT04005144|Drug|Brigatinib|Given PO
23383|NCT04005131|Device|Robot and tDCS on-line|Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 10 weeks
23384|NCT04005131|Device|Robot and tDCS on-line after sham tDCS|Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 5 weeks, followed by combined tDCS on-line and upper extremity rehabilitation robot for 5 times a week for 5 weeks
23386|NCT04005092|Device|hCPAP versus HFNC|The patient presented with Acute Cardiogenic Pulmonary Edema will be randomized into either helmet CPAP or HFNC.
23387|NCT04005079|Drug|Pilocarpine|2% pilocarpine in the postoperative period in addition to standard postoperative drops (Prednisolone acetate and Ofloxacin)
23388|NCT04005079|Drug|Ofloxacin|Standard of care
23389|NCT04005079|Drug|Prednisolone|Standard of Care
23390|NCT04005066|Drug|Elunate®|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
23391|NCT04005053|Drug|N-acetyl cysteine|3600 or 5400 mg/day N-acetyl cysteine
23392|NCT04005053|Drug|Placebo oral tablet|Placebo
23393|NCT04005040|Procedure|Mobile X-ray|Evaluating the effect of mobile x-ray compared to x-ray at the Hospital
23394|NCT04005027|Other|Intermittent graded exercise test|Participants will run on a treadmill until volitional exhaustion. The speed of the treadmill belt will increase incrementally every 3 minutes. Within each 3 minute stage the speed will vary between the target speed and a complete pause (e.g target speed = 8 km/hr)
23395|NCT04005014|Other|Myopia prediction algorithm|Candidate predictors included age at examination, SE, and annual progression rate. Using these predictors, the algorithm will be used to predict SE and whether patients will progress to high myopia in the subsequent 10 years.
23396|NCT04005001|Diagnostic Test|HindSight|Clinical decision support (CDS) system for sepsis detection, optimized by encoder
23397|NCT04005001|Diagnostic Test|InSight|Clinical decision support (CDS) system for sepsis detection
23398|NCT04004988|Drug|Tirzepatide|Administered SC
23399|NCT04004988|Device|Prefilled syringe (PFS)|PFS used to administer tirzepatide
23400|NCT04004988|Device|Auto-injector (AI)|AI used to administer tirzepatide
23401|NCT04004975|Drug|Anlotinib|Anlotinib is a multitarget receptor tyrosine kinase inhibitor which inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, fibroblast growth factor receptor (FGFR) 1-4, platelet-derived growth factor receptors (PDGFR) α/β, c-Kit, and Met.
23402|NCT04004962|Device|Infrared spectroscopy|Infrared spectroscopy
23403|NCT04004949|Other|scapular dyskinesia measurement|The patients were diagnosed with the Lateral scapular slide test using Palpation meter (PALM) device, Fugl-Meyer upper extremity (FMUE) Scale scores & scapular balance angle test (SBA).
23431|NCT04004715|Dietary Supplement|Military Ration Entree|chili and beans entree; current meal component of the meals ready to eat rations
23432|NCT04004702|Drug|Levetiracetam|Levetiracetam 500mg twice a day
23404|NCT04004936|Other|EQUIPPED with Active Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The active feedback group will receive one-to-one (1:1) in-person academic detailing from a professional colleague that includes in-person audit, feedback, and peer benchmarking and provide on-site expertise.
23405|NCT04004936|Other|EQUIPPED with Passive Feedback|Enhancing Quality of Prescribing Practices for Older Adults Discharged from the Emergency Department (EQUIPPED is a multi-component program to reduce the prescribing of potentially inappropriate medications (PIMs) to older adults upon discharge from the Emergency Department (ED). It has three core components: 1) provider education, 2) Electronic Health Record (EHR)-based clinical decision support (CDS) including pharmacy quick order sets to facilitate provider order entry, and 3) provider audit and feedback with peer benchmarking. The passive feedback group will receive monthly provider feedback via an electronic dashboard with audit, feedback and peer benchmarking.
23406|NCT04004923|Procedure|Monopolar hysteroscopy|Unipolar resectoscopes are used in this group and the distention fluid is mannitol
23407|NCT04004923|Procedure|Bipolar hysteroscopy|Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
23408|NCT04004910|Other|Plasma soluble TNF receptor pulldown|"Immunoadsorption affinity column, the LW-02 device, uses a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy enhancing its cytotoxic effect."
23409|NCT04004910|Other|Plasma soluble TNF receptor pulldown + chemotherapy|"The LW02 device comprises an immunoadsorption affinity column, employing a proprietary human recombinant protein, single chain TNF-α ligand, covalently linked to a bead resin, that both enhances the capture efficiency of sTNF-Rs while avoiding complications from column leaching. Reduced sTNF-R plasma levels may lead to objective tumor responses.~In combined treatment arm the immunopheresis procedure is combined with low dose chemotherapy to potentially enhancing its cytotoxic effect."
23410|NCT04004910|Drug|Chemotherapy Drugs, Cancer|IV chemotherapy with paclitaxel and carboplatin in low doses on a weekly basis.
23411|NCT04004897|Diagnostic Test|Optic nerve sheath diameter measurement|Optic nerve sheath diameter measurement is performed with a linear ultrasound probe placed over the eyelid.
23412|NCT04004884|Drug|Ulipristal Acetate|Assess the variations of liver blood test parameters during UPA treatment for symptomatic uterine fibroids
23413|NCT04004871|Drug|Nab-paclitaxel, Cisplatin and Fluorouracil|Patients receive Nab-paclitaxel (200mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before concurrent chemoradiotherapy.
23414|NCT04004871|Radiation|concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
23415|NCT04004858|Radiation|External beam radiation therapy|Patient will receive 60Gy in 20 fractions as per standard practice
23416|NCT04004845|Drug|Cytotec|Misoprostol 25mcg vaginal
23417|NCT04004845|Drug|oxytocin|Oxytocin 10 IU/ml Solution for infusion
23418|NCT04004845|Device|Cervical Foley Balloon|Cervical Foley will be inflated to 80cc
23419|NCT04004832|Diagnostic Test|there is not any intervention procedure|there is not any intervention procedure
23420|NCT04004819|Drug|Rituximab|A lower dosage of rituximab for multiple system atrophy
23421|NCT04004806|Device|Hill Rom tracking device|Location tracking devices from Hill Rom company.
23422|NCT04004793|Behavioral|Intensive lifestyle intervention|Participants were will be asked to follow a weight management programme, in accordance with the American Diabetes Association guidelines. Weight loss will be induced with a diet replacement phase using an energy restriction diet (energy deficit by 500~750 kcal/day) for 3 months, with <35% as fat, >15% as protein. The minimum energy intake is 1200kcal/day for men and 1000kcal/day for women.. Additionally, participants were encouraged to increase physical exercise (≥150 minutes of brisk walking every week or ≥10000 steps per day).
23423|NCT04004793|Drug|Dapagliflozin 10 MG|The treatment of Dapagliflozin (Forxiga®) will be initiated and maintained at 10mg every morning until the completion of the study.
23424|NCT04004793|Drug|Placebo oral tablet|The treatment of placebo will be initiated and maintained at 10mg every morning until the completion of the study.
23425|NCT04004754|Drug|Miltefosine (administration is not part of study procedures)|Patients who receive miltefosine in the routine setting will be asked to participate in the study to document their outcomes
23426|NCT04004741|Procedure|Osteopathic Manipulative Treatment|"The purpose of this research is to investigate the effect of osteopathic manipulative treatment (OMT) focused on somatic dysfunctions commonly associated with arrhythmias on the amount of quantifiable arrhythmias as recorded on a diagnostic device.~It is known that OMT has a stabilizing effect on the autonomic nervous system, which plays a key role in regulating heart rate and blood pressure. This increases parasympathetic tone and decreases sympathetic tone, which generally stabilizes the heart with an antiarrhythmic effect.~Previous work has been done showing that osteopathic treatment is a beneficial adjunctive therapy for paroxysmal atrial fibrillation and decreased symptoms, though has not been proven to be helpful for patients with heart failure.~While the effect of OMT on the neurology has been studied, we would like to further research the effect OMT specifically has on arrhythmias using more quantifiable data from implanted devices."
23427|NCT04004741|Procedure|Light Touch Therapy|The physician will contact various areas of the body for 120 seconds each to expose the subject to a similar environment as the interventional group, without stimulating the autonomic nervous system.
23428|NCT04004728|Procedure|1064 Nd:YAG laser|1064 laser - 135J 25ms spot 3mm GLicose - 75% - 3 ml
23429|NCT04004715|Dietary Supplement|Essential Amino Acid Enriched Whey Protein|protein powder formulation that includes whey and free-form essential amino acids
23430|NCT04004715|Dietary Supplement|Whey Protein|commercially available whey protein isolate
23567|NCT04003467|Drug|EBP05|tablets
23433|NCT04004689|Other|2 times : 6-minute stepper test with a rest of 20min between each test.|"Patients will perform two 6-minute stepper tests separated by a rest period of at least 20 minutes. The second test will begin when the heart rate and the transcutaneous oxygen saturation values will be returned to baseline values. Standardization of the instructions for the test will be based on the actual guidelines for the 6-minute walk test.~The test will be performed in an isolated room in order to avoid noise or external stimuli which can affect performance. The stepper will be placed near a door and the patient was allowed to put a hand on it if out of balance or exhausted. The height of the step will be fixed to 20 cm. A step was defined as the rise and lowering of one foot. The patient was informed of the time each minute. No other encouragement was given. Heart rate and transcutaneous oxygen saturation will be continuously recorded by a pulse oximetry."
23434|NCT04004676|Behavioral|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on performance time
23435|NCT04004676|Behavioral|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
23436|NCT04004663|Drug|PF-06651600|PF-06651600 100 milligrams (mg) will be provided in 4 different oral formulations (Treatment A,B,C,D). Participants will receive each formulation in one of 4 periods
23437|NCT04004650|Procedure|Gluteal turnover flap|Link to procedure: https://www.youtube.com/watch?v=u7_vH2_1ZZc
23438|NCT04004637|Drug|CD7 CAR-T cells infusion|"Biological: CD7 CAR-T cells infusion. Pretreatment: patients enrolled in this study will receive cyclophosphamide or fludarabine plus cyclophosphamide. CD7 CAR-T cells infusion are allowed within 2 weeks after treatment.~CD7 CAR-T cells infusion: 30-60 minutes before infusion, H1 anti-histamine agents are applied (acetaminophen 30mg,po.; promethazine 25mg,i.v. ; diphenhydramine 0.5-1mg/kg, no more than 50mg.). Non-physiological doses of corticosteroids are not applied for patients during treatment or recovery unless a life-threatening emergency occurs. CD7 CAR-T cells are infused into patients for one time, the number of infused CD7 CAR-T cells are 1.5-5×10^6/kg."
23439|NCT04004624|Device|Ablation|Cardiac Ablation
23440|NCT04004611|Drug|Mirikizumab|Administered IV and SC
23441|NCT04004598|Behavioral|golf training|12 weeks of training by Professional Golf Association professional
23442|NCT04004585|Behavioral|Get Up For Your Health|"The intervention is a 4-week behaviour change intervention underpinned by the Theoretical Domains Framework (TDF) that aims to reduce sedentary behaviour. The intervention consists of one individualized face-to-face session and 3 subsequent weekly points of contact (face-to-face meetings or phone calls).~Behaviour change techniques will be provided including education, verbal persuasion, environmental restructuring and goal-setting."
23443|NCT04004572|Drug|LEAP regimen|Patients will be given LEAP regimen every 3 weeks for 8 cycles.
23444|NCT04004559|Other|No interventions|As this is a patient registry, there are no interventions.
23445|NCT04004546|Behavioral|Health literacy-based intervention|Participants in the intervention group will receive a: i) 30-min video about medication adherence, ii) medication adherence booklet, and iii) 2-week telephone call by a nurse.
23446|NCT04004533|Procedure|endoscopy|Duodenoscope assessment
23447|NCT04004520|Behavioral|Virtual Reality with Meditation|The Guided Meditation Virtual Reality is a mindfulness meditation app provided on a virtual reality platform that includes a 10 minute audio meditation for relaxation along with a 3D visualization of natural settings (e.g. forest, beach, mountain).
23448|NCT04004520|Behavioral|Audio Control|The UCLA Mindful App is an audio only mindfulness meditation for relaxation called Breath, Sound, Body Meditation that is 12 minutes in length.
23449|NCT04004520|Behavioral|Virtual reality Control|The Looking Glass Virtual Reality is a stereographic 3D photo viewer provided on a virtual reality platform featuring photos from around the world dating back to approximately a century ago that participants will view for 10 minutes.
23450|NCT04004507|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
23451|NCT04004507|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
23452|NCT04004494|Other|3D reconstruction|3-dimensional computed tomography reconstruction guided VATS segmentectomy
23453|NCT04004481|Drug|Postoperative analgesia using tramadol|Tramadol 100 mg will be given to the patients in the postoperative period.
23454|NCT04004468|Behavioral|Resistance Training|Standard barbell resistance training programs
23455|NCT04004442|Drug|Avelumab|Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
23456|NCT04004442|Drug|AVB-S6-500|AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
23457|NCT04004429|Drug|50 mg AP1189|50 mg AP1189 powder in bottle
23458|NCT04004429|Drug|AP1189|100 mg AP1189 powder in bottle
23459|NCT04004429|Drug|Placebo|Placebo powder in bottle
23460|NCT04004416|Other|Placebo and fMRI|A dose of Placebo will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
23461|NCT04004416|Drug|Lorazepam and fMRI|A dose of Lorazepam (assigned to one of two dose levels between subjects: 0.01 mg/kg or 0.02 mg/kg) will be given 90 minutes prior to entering the fMRI scanner. At each visit volunteers will complete assessments (blood draw, vitals, qols) prior to having an fMRI. There will be two fMRIs done approximately 1 week apart and after the assessment visit. Females may need to have this scheduled to coincide with a certain phase of their menstrual cycle. During the fMRI participants will be asked to view pleasant/unpleasant pictures and rate them while you are inside the scanner.
23568|NCT04003467|Drug|Placebo of EBP05|tablets
23462|NCT04004403|Other|Alternate day fasting|"The diet involves consuming 25% of their baseline energy needs on the fast day and eat ad libitum at home on alternating feed days."
23463|NCT04004403|Other|Exercise|The exercise intervention involves supervised aerobic exercise program 5 times per week, 40-60 min per session.
23464|NCT04004377|Other|Scale of quality life|"The PANQOL scale (Penn Acoustic Neuroma Quality-of-Life) is a specific questionnaire containing 26 items Interviewing 7 areas: hearing, balance, facial expression, anxiety, vitality, pain, and 'general health. The score is encrypted from 0 to 100, and the highest score is a reflection of the best possible quality of life. This score has been translated from French into English and validated according to the reverse translation rules by usual Oddon et al.~Three questions for this score were added, evaluating quality of life parameters that seem particularly interesting: the first regarding the difficulties in driving, the second questioning the recovery of a normal life, and the third assessing difficulties in working life."
23465|NCT04004364|Other|Coordinated Specialty Care (CSC)|CSC is an integrated and team-based treatment model for first episode psychosis elements include psychotherapy, supported employment and education, family education and support, and pharmacotherapy.
23466|NCT04004338|Drug|Kyprolis|Patients receiving kyprolis (carfilzomib)
23467|NCT04004325|Drug|FT-4101|FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.
23468|NCT04004325|Drug|FT-4101 placebo|FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.
23469|NCT04004325|Other|Deuterated Water|Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).
23470|NCT04004312|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Shorter radiation therapy means that a higher dose will be offered. To limit side effects of exposure to a high dose, a medical device protecting the rectum will be used. The medical device to be used is called SpaceOAR hydrogel (device). The SpaceOAR hydrogel creates space between the rectum and the prostate, making it much less likely that the rectum is exposed to radiation. It is injected into place prior to the start of radiation treatment using a needle. Patients may be awake or asleep under local anesthesia for the procedure. SpaceOAR hydrogel is not painful, it remains stable during radiation therapy and then is gradually absorbed by the body over the course of approximately six months, once radiation therapy has been completed.
23471|NCT04004299|Diagnostic Test|HCV RNA self-test|Self-test set including instruction manual (video available as well), finger prick device, tube and envelope to safely transport biological material. Patient takes capillary blood sample, collects it in the tube and sends the sample to the lab by regular post mail.
23472|NCT04004273|Behavioral|Exercise|24 moderate-intensity exercise training sessions over six weeks (four times per week; ~50 min per session)
23473|NCT04004260|Behavioral|Internet-based Cognitive Behavior Therapy|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.
23474|NCT04004247|Device|High Flow Nasal generator (AirVO2)|High Flow Nasal Oxygenation
23475|NCT04004234|Drug|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
23476|NCT04004234|Drug|nab-paclitaxel|Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
23477|NCT04004234|Drug|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
23478|NCT04004234|Drug|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
23479|NCT04004221|Drug|BGB-A317|BGB-A317 200mg intravenously (IV) every 3 weeks(Q3W)
23480|NCT04004208|Drug|Eylea (Aflibercept, BAY86-5321)|Solution in a sterile glass vial, Dose A, IVT injection.
23481|NCT04004208|Procedure|Laser photocoagulation|Transpupillary conventional laser ablative therapy
23482|NCT04004195|Drug|BAY2327949|A single oral dose of 30 mg BAY2327949 given as one 30 mg IR tablet (dose might be reduced to 15 mg for group 4 according to safety assessment team decision)
23483|NCT04004182|Dietary Supplement|Fruit bar with addition of polyphenols|Fruit bar with addition of 600mg bilberry anthocyanins and 1200mg apple polyphenols
23484|NCT04004169|Device|Stimulation-ON|Active neurostimulation from the NeuroPace RNS® System
23485|NCT04004169|Device|Stimulation-OFF|No neurostimulation from the NeuroPace RNS® System
23486|NCT04004156|Device|PerQdisc® Nucleus Replacement Device.|All patients that meet the inclusion/exclusion criteria will receive the PerQdisc® Nucleus Replacement Device.
23487|NCT04004143|Other|No intervention|No intervention.
23488|NCT04004130|Other|Ultrasound imaging|Ultrasound imaging of the lumbar spine/subarachnoidal space
23489|NCT04004117|Drug|Fentanyl citrate solution sublingual|Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
23490|NCT04004117|Drug|Placebo oral liquid|Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
23491|NCT04004104|Diagnostic Test|Upright Exercise|Exercise is generally performed in the upright position.
23492|NCT04004104|Diagnostic Test|Supine Exercise|Since HPS patients with orthodeoxia experience an improvement in their symptoms and oxygen levels when supine, the intervention will involve them performing exercise in the supine position.
23493|NCT04004091|Biological|Spermine|Spermine is a polyamine. It is an organic molecule that is involved in cellular metabolism and development.
23494|NCT04004078|Device|other antifungal agents,breathing machine|If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
23495|NCT04004065|Drug|SRP-5051|SRP-5051 IV infusion
23496|NCT04004052|Other|Ultrasound guided injection|
23497|NCT04004052|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|
23498|NCT04004052|Other|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
23499|NCT04004026|Other|Assesment|3-m backwards walk test, timed up and go test, 12-item MS Walking Scale, 2-min walk test, timed 25-foot walk test, 4-square step test.
23500|NCT04004013|Dietary Supplement|Lifenol®|"Lifenol®, powdered extract obtained from female hops flowers (Humulus lupulus L.) standardized in 8-PN content (100 µg /day) + maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
23501|NCT04004013|Dietary Supplement|Placebo|"Maltodextrin = 500 mg/capsule~+ 1000 mg of calcium and 800 IU of vitamin D per day"
23502|NCT04004000|Drug|Losmapimod|This study includes up to a 52 week treatment period. Patients will receive 15 mg of losmapimod twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.
23503|NCT04003987|Other|ESP Block|placed by ultrasound using 266mg Exparel (20ml) and 60ml of 0.125% bupivacaine. 40ml on each side. 20ml injected at T8 and 20ml injected at T12
23504|NCT04003987|Other|TAP Block|placed by ultrasound using 266mg Exparel (20ml) and 60ml of 0.125% bupivacaine. 40ml on each side. 20ml injected for subcostal TAP and 20ml injected for posterior TAP.
23507|NCT04003961|Other|STOP- BANG Questionnaire and Epworth sleepiness scale|STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
23508|NCT04003948|Drug|Ibogaine Hydrochloride|Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
23509|NCT04003935|Other|Juice Plus+ Complete|Plant-based smoothie; maintaining habitual diet.
23510|NCT04003935|Dietary Supplement|Juice Plus+ Premium|Fruit and vegetable juice concentrate; maintaining habitual diet.
23511|NCT04003922|Other|Adalimumab treatment|Retrospective observational study initially and then prospective with inclusion of all the patients carrying an ER treated by Adalimumab in France. Follow-up will continue for one year if adalimumab is discontinued.
23512|NCT04003909|Procedure|ultrasound-guided Erector spinae plane block|The patients will be in lateral position. A curvilinear array ultrasound probe will be placed in a transverse orientation at L4 level to identify the tip of the L4 transverse process. Local anesthetic infiltration of the superficial tissues, an echogenic 22-G block needle will be inserted inplane to the ultrasound beam in a cranial-to-caudal direction until contact made with the L4 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1ml saline and seeing the fluid lifting the erector spinae muscle off the transverse process while not distending the muscle. A total volume of 20ml bupivicaine 0.25% and 20 ml xylocaine 1% will be injected into the ESP on the affected side.
23513|NCT04003909|Procedure|subarachonoid block|Local anesthesia 2ml of lidocaine 2% will be applied intradermally to the needle entrance point. A 22-G block needle will be inserted, free cerebrospinal fluid flow will be observed and 20mg of hyperbaric bupivacaine 0.5% and 10μg of fentanyl will be injected for 30 seconds.
23514|NCT04003896|Drug|Abemaciclib|"Participant will take 200 mg capsules or tablets orally twice daily. The participant will be instructed to swallow abemaciclib as a whole tablet and not to chew, crush or split capsules or tablets before swallowing. Participants should not ingest abemaciclib tablets if broken, cracked, or otherwise not intact. Doses should be taken at a approximately the same time every day, twice daily. Capsules or tablets can be taken orally with or without food. If the participant vomits or misses a dose of abemaciclib, the participant will be instructed to take the next dose at its scheduled time.~Participants will also be provided with a diary and instructed to keep a twice daily record of the times they have taken their medications and any other events such as vomiting, diarrhea, etc."
23515|NCT04003883|Device|Holter ECG|A Holter ECG will be recorderd during shifts
23516|NCT04003870|Device|CASO|Customized arch support orthoses (CASO)
23517|NCT04003870|Device|HL|Orthotic Heel Lift (HL)
23518|NCT04003857|Biological|PNEUMOSTEM®|A single intratracheal administration of PNEUMOSTEM® (1.0 x 10^7 cells/kg)
23519|NCT04003857|Biological|normal saline|A single intratracheal administration of normal saline
23520|NCT04003844|Drug|Immunoglobulin G|single dose of IGIV 10% (2 g/kg) administered intravenously for at least 12 hours
23521|NCT04003844|Drug|Acetylsalicylic acid|Coadministration
23522|NCT04003818|Drug|TEICOPLANIN|Pharmaceutical form:solution for oral administration Route of administration: oral
23523|NCT04003805|Drug|Standardized Research E-cigarette (SREC)|The device operates at a single output voltage (3.30 ± 0.05 V) and uses sealed disposable 3-mL cartridges with tobacco-flavored e-liquid (~350 puffs/cartridge). The concentration of nicotine in e-liquid is 15 mg/mL, and the vehicle composition is 50:50 propylene glycol and glycerin. The device uses a battery that can be recharged via a micro USB port. A single charge is designed to sustain more than 400 puffs, which is more than the capacity of an e-liquid cartridge. The e-liquid and the aerosol are well-characterized in terms of chemical impurities and by-products (such as aldehydes), which are minimal. Additional information, including the results of pharmacokinetics study is available via NIDA website: https://www.drugabuse.gov/funding/supplemental-information-nida-e-cig
23524|NCT04003805|Drug|Nicotine Mini-Lozenge|We will use commercially available nicotine mini-lozenges containing 2 or 4 mg nicotine/lozenge (Nicorette, manufactured by GlaxoSmithKline). Dose will be determined per instructions on the package (e.g, if smoking within 30 minutes upon awakening, then 4 mg dose will be prescribed).
23525|NCT04003792|Drug|oxaliplatin|intra-arterial oxaliplatin administration
23526|NCT04003792|Drug|FOLFIRI Protocol|systemic FOLFIRI chemotherapy
23527|NCT04003792|Drug|Bevacizumab|systemic bevacuzimab therapy
23528|NCT04003779|Other|Room configuration|Adjust distance, handrails, degrees of turn for participant
23680|NCT04002531|Other|General and Neurological examination|Information about your general health, neurological symptoms and current medications with be collected
23529|NCT04003766|Diagnostic Test|biopsy|Liver biopsy (LB) is essential for the diagnosis and evaluation of a variety of hepatic conditions, such as grading/staging of chronic liver disease secondary to alcohol, non-alcoholic steatohepatitis, viral hepatitis, hemochromatosis, Wilson's disease, cholestatic liver disease, as well as in elucidating the etiology of elevation in liver tests.
23530|NCT04003753|Other|VR App|Participants will be exposed in three different virtual height scenarios (rural mountain, urban town, cloudy weather). At the beginning of each exposure session participants will be standing on a virtual platform at ground level (level 0). From level 0 they will proceed to further levels according to a predefined exposure scheme based on SUDS ratings (scale 0=no fear to 10=extreme fear). Participants will have to stay at each level until their SUDS are 3 or below for two times consecutively (assessment via gaze selection). In each scenario there will be 15 different height levels available (corresponding to a range of heights between 1-75m). Each exposure session will be terminated by a time limit of 20 minutes (study phase 1) or 30 minutes (study phase 2) irrespective of achieved level.
23531|NCT04003740|Device|Home-based transcranial direct current stimulation|The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
23532|NCT04003727|Device|Mcgrath Mac Videolaryngoscope|Patient's laryngoscopy will be done using McGrath Mac video laryngoscope
23533|NCT04003714|Device|Repetitive Transcranial Magnetic Stimulation|Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).
23534|NCT04003714|Device|Sham Repetitive transcranial Magnetic Stimulation|Control group received sham r-TMS.
23535|NCT04003701|Behavioral|Usual care|Control group: minimal distraction
23536|NCT04003701|Behavioral|Robot-assisted puncture procedure|Experimental group: distraction with robot
23537|NCT04003688|Drug|Magnesium sulfate through real weight group|Magnesium sulfate dose 40 mg/kg of actual patient's weight
23538|NCT04003688|Drug|Placebo group|Saline solution (instead of magnesium sulfate, as in the other groups)
23539|NCT04003688|Drug|Magnesium sulfate through ideal corrected weight group|Magnesium sulfate dose 40 mg/kg of ideal corrected patient's weight
23540|NCT04003662|Device|Vital Signs Measurement|Vital signs are measured twice with standard of care equipment while recording digital video data at the same time.
23541|NCT04003649|Biological|IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells|Given ITV/ITC
23542|NCT04003649|Biological|Ipilimumab|Given IV
23543|NCT04003649|Biological|Nivolumab|Given IV
23544|NCT04003649|Other|Quality-of-Life Assessment|Ancillary studies
23545|NCT04003649|Other|Questionnaire Administration|Ancillary studies
23546|NCT04003636|Drug|Pembrolizumab|Pembrolizumab by intravenous (IV) infusion
23547|NCT04003636|Drug|Gemcitabine|Gemcitabine by IV infusion
23548|NCT04003636|Drug|Cisplatin|Cisplatin by IV infusion
23549|NCT04003636|Drug|Placebo|Placebo to pembrolizumab
23550|NCT04003623|Drug|Pemigatinib|Pemigatinib administered orally once daily.
23551|NCT04003610|Drug|Pemigatinib|Pemigatinib at the protocol-specified dose administered orally.
23552|NCT04003610|Drug|Pembrolizumab|Pembrolizumab at the protocol-specified dose administered intravenously.
23553|NCT04003610|Drug|Gemcitabine|Gemcitabine at the protocol-specified dose administered intravenously with carboplatin.
23554|NCT04003610|Drug|Carboplatin|Carboplatin at the protocol-specified dose administered intravenously with gemcitabine.
23555|NCT04003597|Other|Usual-salt diet|Subjects followed their usual-salt diet but were asked to consume an equivalent in-house produced brown or white sliced pan bread equivalent in composition to the low-salt version but with its more typical salt content (1.2 g/100 g).
23556|NCT04003597|Other|Reduced-salt diet|Subjects randomized to start on the reduced-salt diet were asked to restrict their consumption of dietary salt using a combination of pragmatic dietary advice as well as the replacement of bread and a limited number of other foods with equivalent foods which had lower salt content; these were provided to the participants. At the beginning of the salt restriction period, a research nutritionist provided the subjects with a list of the common salt-containing food (salted and naturally salty) and were asked to limit the consumption of such, as feasible. The subjects received in-house prepared 'low-salt (<0.3 g/100 g)' brown or white sliced pan bread as well as no-salt margarine/butter, and were given luncheon meats with no added salt if desired (optional).
23557|NCT04003584|Procedure|Coronary bypass surgery|Reviewed postoperative coronary bypass patients and compared postoperative pain levels
23558|NCT04003571|Behavioral|Augmented Reality with Functional Electrical Stimulation group|Experimental group contains 30 minutes augmented reality combined with functional electrical stimulation training, and 30 minutes traditional physiotherapy. Augmented reality includes treadmill and balance exercise. Functional electrical stimulation applies on tibialis anterior muscle. Traditional physiotherapy includes rolling, sitting, standing, overground walking, facilitation of the paretic limbs, and so on.
23559|NCT04003571|Behavioral|Traditional physiotherapy|Traditional physiotherapy includes treadmill and balance training for 30 minutes as well as rolling, sitting, standing, overground walking, facilitation of the paretic limbs for another 30 minutes .
23560|NCT04003558|Other|No interventions|As this is a patient registry, there are no interventions.
23561|NCT04003545|Radiation|LED Photobiomodulation|A total of twelve laser applications (3 sessions per week) will be provided to the patients as treatment. A LED board with wavelengths of 660nm and 850nm at 5mW of power will be used for 30 minutes, resulting in a total energy of 3J per point in each session. The application site will be the lumbar region, in contact with the skin. The LED cluster (light-emitting diodes) has 72 LEDs.
23562|NCT04003545|Other|Placebo LED Photobiomodulation|For the placebo group, the procedures will be the same, however the LED equipment will remain off.
23563|NCT04003506|Drug|Liposomal bupivacaine|LIA with ACB will be given using 10ml of 1.33% liposomal bupivacaine
23564|NCT04003506|Drug|Saline|LIA with ACB will be given using saline
23565|NCT04003493|Other|Nutrition and oral health intervention|The interventions included individualised nutrition and oral health care.
23566|NCT04003480|Device|FRAME|External support for vein grafts in peripheral bypass surgery
23569|NCT04003454|Other|HCV Screening|The investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 HCV screening methods while minimizing threats to internal validity. Patients will be screened for HCV infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing EHRs for each ED.
23570|NCT04003441|Drug|DWP14012 tablet A|Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
23571|NCT04003441|Drug|DWP14012 tablet B|Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
23572|NCT04003428|Device|High Intensity Focused Ultrasound|HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
23573|NCT04003415|Device|Investigational Device: Contactless heart rate and respiratory rate monitor|Participant will be seated next to the investigational device. The device is contactless, and will measure the patient's heart rate and respiratory rate through use of radio-waves.
23574|NCT04003415|Diagnostic Test|Heart Rate (EKG) Monitor|Participant will undergo 3-lead EKG testing to measure heart rate during testing.
23575|NCT04003415|Diagnostic Test|Respiratory rate Monitor|Participant will have an elastic band around their chest for monitoring respiratory rate during testing.
23576|NCT04003415|Diagnostic Test|Pulse Oximetry|Participants will wear a finger pulse oximeter during the testing for monitoring of heart rate, respiratory rate, and pulse oximetry.
23577|NCT04003402|Drug|ASP8062|oral
23578|NCT04003402|Drug|Alcohol|oral
23579|NCT04003402|Drug|ASP8062 Placebo|oral
23580|NCT04003402|Drug|Alcohol Placebo|oral
23583|NCT04003376|Device|fractional carbon dioxide laser alone|six sessions of fractional carbon dioxide laser will be done for alopecia areata lesions
23584|NCT04003376|Drug|Triamcinolone Acetonide 10mg/mL|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of triamcinolone acetonide
23585|NCT04003376|Biological|platelet rich plasma|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of autologous platelet rich plasma
23586|NCT04003376|Drug|vitamin D solution|six sessions of fractional carbon dioxide laser will be done for 10 patients with alopecia areata followed immediately by topical application of vitamin D solution
23587|NCT04003363|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
23588|NCT04003350|Drug|Oxycodone|Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
23589|NCT04003350|Drug|Tramadol|Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
23590|NCT04003350|Drug|Tylenol|Tylenol 1000 mg: take as needed every 8 hours
23591|NCT04003350|Drug|Meloxicam|Meloxicam 15 mg as need once per day
23592|NCT04003350|Drug|Gabapentin|•Gabapentin 200 mg with morning and evening Tylenol dose
23593|NCT04003350|Drug|Metaxalone|Metaxalone 800mg TID
23594|NCT04003350|Drug|Esomeprazole 20mg|Esomeprazole 20mg daily
23595|NCT04003337|Other|Morpho-kinetics selection with time-lapse (Embryoscope) evaluation|Embryos in group B will be selected in blastocyst stage according to morpho-kinetics criteria before the embryo transfer
23596|NCT04003324|Behavioral|Op is Top - using feedback from the Activator to reduce sedentary behavior in older adults|Participants will receive a self-monitoring tool (i.e. the Activator) aimed at the reduction of sedentary behavior. Participants will be able to use the self-monitoring tool for four weeks. Apart from that, participants will receive general sedentary behavior information and an explanation on how to use the self-monitoring tool.
23597|NCT04003311|Device|Comprehensive Primary Micro Stem|Patient that have been implanted with the comprehensive primary micro stem to repair shoulder malfunction/disease
23598|NCT04003298|Device|Electric toothbrush|Electric toothbrush and power interdental device
23599|NCT04003298|Device|Control|Oscillating-rotating
23600|NCT04003285|Drug|Placebo|ALLO 0 nM (placebo: loading dose, 4-hour infusion, taper)
23601|NCT04003285|Drug|Allopregnanolone|ALLO 50 nM (lower dose ALLO: loading dose, 4 hour infusion, taper)
23602|NCT04003285|Drug|Allopregnanolone|ALLO 150 nM (higher dose ALLO: loading dose, 4 hour infusion, taper)
23603|NCT04003272|Device|Comprehensive Reverse Versa-Dial Titanium Glenosphere|Implant used for patients with allergy to typical device material metals to repair shoulder malfunction/disease.
23604|NCT04003259|Behavioral|Lifestyle management programme|The programme consisted of 1) the initiation phase (1-3 months), 2) the establishment phase (3-6 months), and 3) the maintenance phase (7-12 months). Guidance was given altogether on 25 separate occasions with special emphasis on the motivation and education. The goal for weight loss was 5-10 %. The programme included four visits by medical doctor, an educational lecture by medical doctor and personal trainer, five sessions by registered dietician, two cooking classes by professional chef, two group discussions, and exercise as follows: personalized exercise program tailored by personal trainer, one-year gym access with four guided group sessions, and two guided group Nordic walking sessions, and three individual exercise sessions by personal trainer.
23605|NCT04003246|Radiation|Thoracic RT and Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV], first dose within 3 days of RT initiation
23606|NCT04003246|Drug|Consolidative Durvalumab|1500mg every 4 weeks [Q4W] intravenous [IV] up to one year
23607|NCT04003233|Device|SDS|The SDS will be added to a traditional growing rod (TGR) of 4.5 or 5.5mm.
23608|NCT04003233|Device|MID-C|The MID-C system consists of a unilateral one-way ratchet rod that is connected to the spine with polyaxial connectors
23609|NCT04003220|Procedure|blood sample|The extra samples will be taken Blood sampling
23610|NCT04003220|Procedure|Bone marrow sample|This bone marrow sampling will be performed for 10 patients with ICTUS, and 10 controls
23681|NCT04002531|Other|Vital signs|Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
23611|NCT04003207|Drug|Recombinant human Growth hormone|Subcutaneous growth hormone injections given once daily at a dose between 0.15mg/kg/week to 0.47 mg/kg/week titrated based on IGF-1 levels in serum for a duration of 12 weeks.
23612|NCT04003194|Other|Pinto Beans|The intervention was 1/2 cup of pinto beans each day.
23613|NCT04003194|Other|Green Beans - control|The control was 1/2 cup of green beans each day.
23614|NCT04003181|Drug|Antibiotics|Ciprofloxacin or Rifaximin for 10 days.
23615|NCT04003181|Drug|Bile Acid Binder|Cholestyramine or Colesevelam lifelong.
23616|NCT04003168|Drug|Human BCMA targeted T Cells Injection|Autologous genetically modified anti-BCMA CAR transduced T cells
23621|NCT04003129|Other|questionnaire|"Data will be obtained through a written questionnaire for assessing knowledge, practice and attitude of paediatricians regarding early childhood caries.~Data collected will be saved and tabulated on computer and finally statistically analysed."
23622|NCT04003116|Drug|Oxygen gas|Supplementary oxygen during the first 48 hours added to conventional anticoagulant treatment. Patients will receive anticoagulant treatment according to updated guidelines.
23623|NCT04003103|Drug|Islatravir|Islatravir administered orally in capsule form once monthly for 24 weeks
23624|NCT04003103|Drug|Placebo|Placebo for islatravir administered orally in capsule form once monthly for 24 weeks
23625|NCT04003090|Drug|Citicoline|After treatment with a solution containing citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride patients underwent a 23G standard 3-port pars plana vitrectomy. The vitreous sample was taken at the beginning of the surgery and then analyzed.
23626|NCT04003077|Device|laser meridian massage|The participants will undergo 12 sessions of laser meridian massage, thrice a week, for 4 weeks, using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.5cm^2; power density, 300mW/cm^2; pulsed wave; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser treatment will be applied to the back including Bladder meridian (BL11-25) and Governor vessel (GV3-14) for 15 minutes, to deliver a total treatment dose of 67.5J/cm^2.
23627|NCT04003064|Diagnostic Test|Blood|3ml blood
23628|NCT04003051|Other|Internet-Based Intervention|Use Project Prepare website
23629|NCT04003051|Other|Quality-of-Life Assessment|Ancillary studies
23630|NCT04003051|Other|Questionnaire Administration|Ancillary studies
23631|NCT04003038|Procedure|Negative Pressure Wound Therapy|Receive wound care with NPWT
23632|NCT04003038|Procedure|Wound Care Management|Receive wound care with a standard dressing (bandage)
23633|NCT04003012|Drug|EMLA|EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
23634|NCT04003012|Drug|Lidocaine|lidocaine 1%
23635|NCT04002999|Device|3D printed ceramic bracket and tray|The 3D ceramic bracket being investigated is the only available customized ceramic bracket. This will be a first for the orthodontic speciality. This will also be the first and only customized bracket system that includes customization of the bracket base. This helps in the control of first order orthodontic movements and allows brackets to be bonded on any labial surface of the tooth while maintaining an ideal prescription. As 3D printing is not limited by the mold-ejection in CIM, [24] the bracket system being tested here has the potential to achieve a more accurate slot dimension.
23636|NCT04002999|Device|Stock ceramic bracket + 3D printed tray|Traditionally, indirect bonding, starts with creating a mold of all the teeth as an exact replica of the mouth of the patient. From there, in the lab, the orthodontist positions each bracket precisely where it should go on each tooth and then creates a custom tray that allows transfer of the brackets from the lab model to the patient's teeth. By taking the time to place the brackets in a proper position on the lab model, orthodontists eliminate the inaccurate process of placing orthodontic brackets directly on the teeth. It theoretically also takes less chairside time and is more comfortable for the patient. It is however more technique sensitive. In this study, indirect bonding setup will be done virtually using commonly-available orthodontic software. The trays/jigs will then be 3-D printed
23637|NCT04002999|Device|Stock bracket, no tray|Direct bonding is the traditional way of placing orthodontic brackets, in which orthodontists clinically eyeball the tooth and place the bracket where they deem most appropriate
23638|NCT04002986|Genetic|Genetic Testing|A blood draw or saliva kit will be provided to collect subject cells
23639|NCT04002947|Drug|DA-EPOCH|Vincristine 1.4 mg /m2 (2 mg cap) IV on Day 1, Doxorubicin 10 mg/m2/day CIVI on Days 1-4, Etoposide 50 mg/m2 /day CIVI on Days 1-4, Cyclophosphamide 750 mg/m2 IV on Day 5. Prednisone 60 mg/m2 PO BID is administered daily on Days 1-5 of each cycle. Each cycle is 21 days and drugs will be given for 6 cycles.
23640|NCT04002947|Biological|Rituximab|Rituximab 375 mg /m2 IV on Day 1 of each 21-day cycle for 6 cycles.
23641|NCT04002947|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, Doxorubicin 50 mg /m2 IV, Vincristine 1.4 mg/m2 (2 mg cap) IV are administered on Day 1 of each 21-day cycle for 6 cycles. Prednisone 40 mg/m2 PO is administered daily on Days 1-5 of each cycle.
23642|NCT04002947|Drug|Acalabrutinib|Acalabrutinib is administered orally at 100 mg twice a day for 14 days during the window period. During combination therapy, acalabrutinib is administered 100 mg twice daily for thefirst 10 days for 6 cycles.
23643|NCT04002934|Drug|Bazedoxifene Acetate|40 mg Bazedoxifene delivered orally in the form of 2x 20 mg blinded capsules
23644|NCT04002895|Drug|Foliglurax|Single oral dose of 80 mg [14C]-foliglurax(93µCi/3.44 MBq), 1mg/mL oral solution (prepared from [14C]-foliglurax powder for oral solution)
23645|NCT04002869|Diagnostic Test|Immunologic, molecular, metabolomic and radiolologic diagnostic|Evaluation and development of new technologies
23646|NCT04002856|Device|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride
23682|NCT04002531|Procedure|12 lead electrocardiogram|A non-invasive test that measures the electrical activity of the heart
23683|NCT04002531|Procedure|Echocardiogram|A non-invasive sonogram of the heart
23684|NCT04002531|Procedure|Blood draw|Blood will be drawn to evaluate general health and renal function (kidney health)
23647|NCT04002843|Other|paraclinical evaluation of single fibre|ENMG 5 channel Digital EMG, NCS and EP System, Neurosoft, Skybox. Amplification of the EMG signal BF 500 Hz, HF 3kHz, mains filter at 50 Hz. Acquisition at 2 ms at 100 µv, parameters can be modified. The single-use needle electrode (Neuroline Concentric, Neurology Needle Electrode; 25x0.30 mm(1''x30G)) of reference inserted into the biceps muscle of the brachial muscle on the parietal side with location of the ground reference. The paroetic arm will be supported by the evaluator in order to generate a minimal tone, necessary for the occurrence of potential actions of two muscle fibres present within the same motor unit.
23648|NCT04002830|Drug|Elelyso|Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
23649|NCT04002804|Biological|Dendritic Cells Vaccine|"Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient."
23650|NCT04002791|Device|VasoBand|Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
23651|NCT04002778|Diagnostic Test|Fine needle aspiration|
23652|NCT04002778|Diagnostic Test|Rapid on-site evaluation|
23653|NCT04002765|Diagnostic Test|pulmonary function tests|"Lung function tests (standard of care)~Dynamic and static volumes (FVC, FEV1, TPC, RV)~Lung diffusion capacity for CO (DLCO)~Chest Xrays~High resolution CT scanner (HRCT)"
23654|NCT04002752|Drug|JNJ-73763989|Participants will receive JNJ-73763989 as single subcutaneous injection.
23655|NCT04002752|Drug|Placebo|Participants will receive placebo matching to JNJ-73763989 as single subcutaneous injection.
23656|NCT04002739|Diagnostic Test|Polygraphy|Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
23657|NCT04002726|Other|Inter-grader agreement (IGA) app|A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
23658|NCT04002713|Other|ALT flap reconstruction|Patients who underwent ALT free flap reconstruction after head and neck cancer surgery.
23659|NCT04002713|Other|AMT flap reconstruction|Patients who underwent AMT free flap reconstruction after head and neck cancer surgery.
23660|NCT04002700|Drug|Haloperidol|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of haloperidol. No drug will be administered as part of this study.
23661|NCT04002700|Drug|Typical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of typical antipsychotics which includes Haloperidol, Loxapine, Thioridazine, Molindone, Thiothixene, Fluphenazine, Trifluoperazine, Perphenazine, Chlorpromazine. No drug will be administered as part of this study.
23662|NCT04002700|Drug|Atypical Antipsychotics|Stroke rates among participants from 01 January, 2002 through 31 December 2017 will be estimated among new users of atypical antipsychotics which includes Aripriprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Paliperidone, Ziprasidone, Risperidone, Quetiapine, Olanzapine. No drug will be administered as part of this study.
23663|NCT04002687|Drug|ATV-PG 1000-400 mg + AQ 612 mg|The dosing will be carried out by an unblinded member of the investigator's staff. Dosing will take place behind a curtain and during IMP administration the subjects will be blindfolded. ATV-PG (or placebo) will always be given first, then AQ (or placebo).
23664|NCT04002674|Drug|Placebo oral capsule|"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."
23665|NCT04002674|Drug|Nilotinib Oral Capsule|Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).
23666|NCT04002661|Drug|Flibanserin|Flibanserin tablet
23667|NCT04002661|Drug|Placebo|Oral Tablet
23668|NCT04002648|Procedure|Right minithoracotomy|Incision of the right chest between 3rd and 4th or 4th and 5th intercostal space
23669|NCT04002648|Procedure|Sternotomy|Longitudinal resection of the sternum
23670|NCT04002635|Drug|Letrozole|Letrozole ovulation induction
23671|NCT04002635|Drug|estradiol valerate|hormonal replacement therapy
23672|NCT04002622|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
23673|NCT04002609|Other|oxygen|oxygen supplementation during brronchoscopy
23674|NCT04002596|Device|ExAblate Neuro Thalamotomy Treatment|Non-invasive Focused Ultrasound Ablation of Thalamus Vim nucleus using ExAblate MRgFUS system for treatment Tremor Dominant Parkinson Disease
23675|NCT04002583|Diagnostic Test|Computer assisted ambulatory electroencephalogram|A portable 16 channel CAA-EEG is used to detect epileptiform abnormalities in a 48 hour ambulatory electroencephalogram (EEG)
23676|NCT04002570|Other|blood samples collection|blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.
23677|NCT04002557|Other|No intervention|Interviews contain no intervention, purely observational.
23678|NCT04002544|Drug|NTG patch|A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
23679|NCT04002544|Other|gauze cover|A gauze will be applied near the radial artery pulsation to ensure blinding
23685|NCT04002531|Procedure|Urine collection|Urine will be collection to evaluate renal function (kidney health)
23686|NCT04002531|Procedure|2-hour Holter Monitor|A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
23687|NCT04002531|Other|Brief Pain Inventory questionnaire|A questionnaire about daily pain
23688|NCT04002531|Other|Quality of Life questionnaire|A questionnaire about the impact of disease on their activities of daily living and quality of life
23689|NCT04002518|Device|Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.|Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
23690|NCT04002505|Other|Concussion and Brain Bleed App (CBB)|Tablet based decision aid that encourages shared decision making with the goal of educating patients to reduce unnecessary CT scans
23691|NCT04002492|Behavioral|Bodyweight training|Video guided and physical therapist guided bodyweight training sessions will be performed twice a week for 6 (to 8) weeks. These sessions include the following five workouts at 3 sets of 10 repetitions: step ups, calf raises, wall push ups, chair squats, and chair dips.
23692|NCT04002479|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
23693|NCT04002466|Other|Risk factors for anemia|Diet, iron, vitamin B12, folate, inflammation, soil transmitted helminth infection, malaria, other morbidities and other health/nutrition/sociodemographic factors
23694|NCT04002453|Procedure|Outpatient Parenteral Antibiotic Therapy|Application of outpatient parenteral antibiotic therapy in patients with infectious diseases to allow them to get discharged from hospital.
23695|NCT04002440|Combination Product|AMIA with SHARESOURCE Connectivity Platform|The investigators will conduct a randomized, cross-over study in peritoneal dialysis patients in which patients are randomized to either Home Choice Pro (which remains the most widely used Baxter cycler) versus treatment with the Baxter AMIA automated peritoneal dialysis system with SHARESOURCE connectivity.
23696|NCT04002440|Device|HomeChoice PRO|Usual care
23697|NCT04002427|Drug|Intravenous Infusion|30 µg [14C]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion.
23698|NCT04002427|Drug|Inhaled dose|A single inhalation on one occasion.
23699|NCT04002414|Behavioral|Sufficient physical activity|Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
23700|NCT04002414|Behavioral|Insufficient physical activity|Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
23701|NCT04002401|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
23702|NCT04002401|Drug|Rituximab|Administered intravenously
23703|NCT04002401|Drug|Lenalidomide|Capsule(s) administered orally with or without food
23704|NCT04002401|Drug|Fludarabine|Administered according to package insert
23705|NCT04002401|Drug|Cyclophosphamide|Administered according to package insert
23706|NCT04002388|Behavioral|activity monitor group|will receive a FitBit and will be asked to wear this for one year
23707|NCT04002388|Behavioral|usual care group|will NOT receive a FitBit
23708|NCT04002375|Other|pectouteropexy|The surgical procedure was initiated after adhesiolysis had been performed by opening the peritoneal layer along the round ligament toward the pelvic side wall. Preparation started at the right external iliac vein and was performed in the medial and caudal direction. A segment of area approximately 3- 4 cm2 of the right lateral part of the iliopectineal ligament (Cooper ligament) adjacent to the insertion of the iliopsoas muscle was exposed.The peritoneum of the bladder was dissected, and the anterior parts of the distal uterus were prepared for mesh fixation. The uterus was elevated to the intended tension-free position using the transvaginal probe (POP-Q level 0-1). The mesh was fixed anteriorly to the cervix using four polyester permanent sutures (Ethibond Excel®; Ethicon). Finally, the mesh was covered with peritoneum using a continuous monofilament absorbable suture (Maxon™; Medtronic).
23709|NCT04002362|Drug|Triamcinolone Acetonide|An intramuscular injection of triamcinolone acetonide (1 mg/kg, up to 40 mg maximum) will be administered deep in the gluteal muscle by a trained registered nurse.
23710|NCT04002349|Drug|Budesonide Nasal Spray (Rhinocort, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
23711|NCT04002349|Drug|Levocabastine Nasal Spray (Livostine, Shanghai Johnson & Johnson Pharmaceuticals, Ltd.)|Detailed in arm descriptions
23712|NCT04002349|Drug|0.9% natural saline|Detailed in arm descriptions
23713|NCT04002336|Behavioral|Traditional Voice therapy|Traditional method of voice therapy
23714|NCT04002336|Behavioral|Voice Therapy App|Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
23715|NCT04002323|Drug|Dolutegravir 50mg Tab|The subjects starts their ART with this drugs, once a day
23716|NCT04002323|Drug|Lamivudine 300 mg|The subjects starts their ART with this drugs, once a day
23717|NCT04002310|Drug|BI 754132|One single injection
23718|NCT04002297|Drug|zanubrutinib|BGB-3111 will be administered as two 80-mg capsules by mouth twice a day
23719|NCT04002297|Drug|bendamustine|Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
23720|NCT04002297|Drug|rituximab|Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
23721|NCT04002284|Drug|Anlotinib Hydrochloride|Anlotinib 12mg p.o. d1-14, 21days/cycle
23722|NCT04002271|Drug|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be titrated to produce a BIS value of between 40-60. For induction, remifentanil 1mcg/kg and rocuronium 0.6-1mg/kg will be given intravenously prior to intubation. Sevoflurane will not be given. Air and oxygen will be given, and FiO2 will be kept at between 35-50%. Similarly to the GAS group, remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min and titrated according to the haemodynamic parameters stated for the GAS group. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. TCI propofol and remifentanil will be switched off at the end of the procedure. Reversal of muscle relaxation will be achieved as for the GAS group.
23723|NCT04002271|Drug|Sevoflurane|Patients receiving inhalational general anaesthesia will be induced with intravenous bolus propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6mg/kg for induction of general anaesthesia and intubation of the patient. General anesthesia monitoring will be used. Maintenance of general anesthesia would be provided using sevoflurane, together with air and oxygen. FiO2 will be maintained between 35-50%. Bispectral (BIS) monitoring will be applied and level of anaesthesia will be maintained at a BIS value of between 40-60. Remifentanil infusion will be given at between 0.1-0.2mcg/kg/min. This will be titrated to maintain mean arterial blood pressure within 20% of baseline (blood pressure in the ward before surgery will be taken as baseline) and heart rate between 45 to 100 beats per minute. Morphine sulphate will be given at a dose of 0.1mg/kg before skin incision. Sevoflurane and remifentanil infusion will be switched off at the end of the procedure.
23724|NCT04002271|Procedure|Spinal anaesthesia|Patients in the SA group will receive intrathecal (L4-5, or L3-4 if failed at L4-5) administration of 2.4ml 0.5% heavy bupivicaine using a 25G Whitacare needle. No intrathecal opioid will be given during the procedure. Light sedation will be given during surgery with target-controlled infusion of propofol using the Marsh effect site model (0.3 -1 mcg/ml). Supplemental oxygen 2L/min will be given via the nasal cannula.
23725|NCT04002258|Drug|Antipsychotic|any antipsychotic medicine that would have the effect on prolactin level, such as amisulpride, risperidone, olanzapine and so on.
23726|NCT04002245|Procedure|antiseptic application|The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
23727|NCT04002232|Device|CPP-ACP-NaF varnish|calcium phosphate containing fluoride releasing varnish to prevent caries
23728|NCT04002219|Dietary Supplement|beverage containing mushroom-extracts|Subjects recruited from both arms will receive treatment and be followed up clinically for 8 weeks.
23729|NCT04002206|Other|Muscle Energy Technique|In experimental group, post-isometric relaxation technique has given to the athletes. The position of athlete was prone and the involved group of muscle was quadriceps. Firstly end range of the quadriceps muscle group assess and guide the athlete to put 20% of their maximum voluntary contraction and physiotherapist resist the athlete and isometric contraction of quadriceps remain for 6-10 seconds
23730|NCT04002206|Other|Static Stretch|Control group has treated with static stretching after the pre-assessment that includes three repetitions with duration of fifteen seconds with twenty second rest intervals on lower extremities
23731|NCT04002193|Other|volume expansion|To assess fluid responsiveness
23732|NCT04002180|Drug|Vedolizumab (Genetical Recombination)|Vedolizumab IV infusion
23733|NCT04002167|Behavioral|Neurofeedback|The Neurofeedback group will receive the proposed intervention which integrates computerized working memory training with neuromonitoring and neurofeedback.
23734|NCT04002167|Behavioral|Cognitive training|The Cognitive training group will receive computerized working memory training with performance feedback.
23735|NCT04002154|Device|Papilocare vaginal gel|Papilocare is a gel vaginally administered by a single-dose cannula. Vaginal gel formulation is effective as a local treatment with controlled systemic absorption and rapid and efficient distribution
23736|NCT04002141|Drug|Placebo oral tablet|1 tablet oral daily
23737|NCT04002141|Drug|Letrozole|5mg oral daily
23738|NCT04002128|Other|Tracheal aspirates and nasal smears were taken in all the patients. Laparotomies were performed in all patients.|Nitrous oxyde and sevoflurane anesthesia may alter mucus transport in the early postoperative period. In colonized patients it may result in more respiratory complications.
23739|NCT04002115|Drug|Clofarabine|"Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total."
23740|NCT04002115|Drug|Fludarabine|Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.
23741|NCT04002115|Drug|Busulfan|Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.
23742|NCT04002115|Procedure|Total Body Irradiation (TBI)|TBI will be administered at a dose of 200cGys on Day -1 prior to transplant
23743|NCT04002115|Drug|Cyclophosphamide|Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
23744|NCT04002115|Drug|Granulocyte Colony-Stimulating Factor|G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated
23745|NCT04002115|Drug|Tacrolimus|Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated
23746|NCT04002115|Drug|Cellcept|Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
23747|NCT04002102|Other|Treatment Group|Receive two open-label placebo pills twice a day after randomization. Will receive for 21 days and then stop.
23748|NCT04002102|Other|No Treatment Group|Remain in standard care after randomization.
23749|NCT04002089|Drug|Exparel Injectable Product|bupivacaine liposome injectable suspension
23750|NCT04002089|Drug|Bupivacaine|1.3%, 13.3 mg/mL
23751|NCT04002076|Behavioral|Robot-assisted hand combined with occupational therapy|Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
23752|NCT04002076|Behavioral|Traditional occupational therapy|Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
23753|NCT04002063|Behavioral|CBT MobileWork-V plus CBT|a smartphone app to assist with CBT homework skills practice plus CBT
23754|NCT04002063|Behavioral|CBT alone|CBT therapy individual
23755|NCT04002050|Behavioral|Cognitive Behavioural Therapy with Mindfulness Course|The Cognitive Behaviour Therapy with Mindfulness (CBTm) Course for Public Safety Personnel is a brief psychoeducational course consisting of 5 classes (90 minutes each) occurring on a weekly basis. The CBTm course addresses the fundamentals of CBT and provides participants with practical strategies for managing stress (such as relaxation strategies, cognitive restructuring, goal setting, behavioural activation, and exposure therapy).
23779|NCT04001907|Dietary Supplement|placebo|
23756|NCT04002037|Drug|Triamcinolone Acetonide 40mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
23757|NCT04002037|Drug|Triamcinolone Acetonide 10mg/mL|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
23758|NCT04002037|Drug|Dexamethasone 4 mg/ml|Corticosteroid injection will occur up to two times if trigger finger symptoms are not resolved.
23759|NCT04002024|Drug|Eucerin ProACNE®|Eucerin ProACNE®: 1 fingertip unit to cover one side of the face twice a day
23760|NCT04002024|Drug|Placebo|Placebo: 1 fingertip unit to cover one side of the face twice a day
23761|NCT04002011|Drug|Warfarin|It will be started on postoperative day 1 or later when oral anticoagulation is secondary indicated. Daily dose will be adapted to obtain an international normalized ratio of [2.0-3.0]. Other anticoagulants will be not administrated.
23762|NCT04002011|Drug|Dabigatran|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
23763|NCT04002011|Drug|Rivaroxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
23764|NCT04002011|Drug|Apixaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
23765|NCT04002011|Drug|Edoxaban|It will be started when patients will be discharged from our center. Our pharmacist referent will validated the drug and its daily dose. Other anticoagulants will be not administrated.
23766|NCT04001998|Drug|BLD-2660|Randomized to active product
23767|NCT04001985|Other|No clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function the NG tube will be removed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger.
23768|NCT04001985|Other|Clamp trial|Once the NG tube output is less than 500 mL over a 24 hour period with at least two other signs of return of bowel function, a 4 hour clamp trial will be performed. Other signs of bowel function include flatus, bowel movement, change of NG tube output from bilious to more clear/frothy character, and hunger. The NG tube will be taken off of suction and clamped. The NG tube is then reconnected to suction at the end of the four hour clamp trial and removed if less 125 mL drains or kept in place if greater than 125 mL drains. The same initial criteria are used again to determine if a clamp trial will be performed after 24 hours.
23769|NCT04001972|Behavioral|Brief advice (AWARD model)|"Ask: smoking habit, quit intention and attempt, smoking reduction intention, previous quitting experience including NRT and SC use.~Warn: smokers will be orally warned about the harms of smoking and receive a A5-sized leaflet, which includes some shocking pictures of smoking-related diseases, and SC services information.~Advise: smokers will be advised to quit as soon as possible and use NRT or SC services.~Refer: smokers will be encouraged to seek SC services for free NRT or other SC services. Those who agreed will be actively referred to their preferred SC services. The collected contact information with consent will be sent to the SC services providers for a quick appointment and follow-up.~Do-it-again: Relapsed smokers (identified during follow-ups and IM conversation) will receive the Advise and Refer intervention."
23770|NCT04001972|Drug|NRT-S|One-week free NRT (gum or patch) will be provided with dosage based on time to first cigarette smoking after waking up in the morning and previous NRT use (standard practice and according to specific NRT product instructions). Subjects who have first cigarette <30 minutes in the morning or have previously used NRT, will receive 4mg nicotine gum or 21mg nicotine patch. Those who have first cigarette >30 minutes after waking up and have not previously used NRT will receive 2mg nicotine gum or 14mg nicotine patch. NRT use and potential side effects will be briefly explained orally based on standardized script according to the product instructions. An NRT use card containing reminders of NRT use and potential side effects will be given.
23771|NCT04001972|Behavioral|IM Apps and Chatbot|Twelve-week personalized behavioral support will be delivered using interactive communication technologies using (1) regular tailored messages on abstinence, and (2) synchronous IM Apps conversation with trained SC advisors, and (3) a Chatbot: A Chatbot will be built using open source NLP and machine intelligence platforms. The unstructured text data from our previous study (ClinicalTrials.gov ID: NCT03182790) will be used to train the proposed Chatbot. We will draft responses for each identified question. The final version will be incorporated with Application Programming Interface (API) integration into user-friendly apps (iOS/Android/web app) with a backend server support and continuous data collection for potential bigdata analysis.
23772|NCT04001972|Behavioral|Regular SMS message|Regular SMS messages focus on general health and remind the importance of participating in the follow-up surveys and biochemical validation for quitting
23773|NCT04001959|Procedure|Silver Diamine Fluoride with Potassium Iodide|Dry the tooth for 30 seconds with air jet and apply one drop of Diamino 30% Silver Fluoride with a disposable applicator brush for 3 minutes and one drop of potassium iodide solution immediately on the treated surface, then wash.
23774|NCT04001946|Device|Button Huggie|low profile, external securement device for G-buttons
23775|NCT04001933|Other|CPOP Intervention|The intervention consists of two 15-minute interactive modules (maternal and infant OH), integrated into 2 group prenatal care sessions. Led by trained prenatal care providers (facilitators), the maternal module includes discussion of common OH problems during pregnancy, importance of OH, importance and safety of OH care during pregnancy, hands-on skills-building activities of learning and practicing proper tooth brushing and self-assessment of gum health, and presentation of illustrated flossing and OH promotion guides. The infant module includes discussion of infant oral hygiene, avoiding saliva sharing, proper nutrition, and importance of a dental visit by the first birthday. Activities in both modules utilize separate tool kits including tooth brushes, fluoride toothpaste, and other supplies.
23776|NCT04001920|Other|Training program|12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).
23777|NCT04001907|Behavioral|Resistance exercise|effect of exercise and an anabolic agent on body composition, muscle strength, phenylalanine and protein oxidation.
23778|NCT04001907|Dietary Supplement|β-hydroxy-β-methylbutyrate|
23780|NCT04001894|Drug|Ticagrelor 90mg|Ticagrelor (90.0 mg twice daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of clopidogrel (75mg once daily).
23781|NCT04001894|Drug|Clopidogrel 75mg|Clopidogrel (75mg once daily) for 2 weeks, followed by a 2-week washout period then 2 weeks crossover phase of ticagrelor (90.0 mg twice daily).
23782|NCT04001881|Other|Transthoracic echocardiography|A standard TTE protocol is used in all patients and included the following views: subcostal 4-chamber (SUBC), apical 4-chamber (4CH), apical 2-chamber (2CH), apical 3-chamber (3CH), parasternal long (LAX) and short axis (SAX).
23783|NCT04001881|Drug|Spinal anesthesia|Spinal anesthesia is introduced with a single intrathecal injection of 15 mg plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
23784|NCT04001868|Procedure|Suboccipital inhibition|With the patient in the supine position and the therapist sitting at the head of the bed with the elbows resting on its surface. The therapist palpates the cervical spinous processes and slides the fingers upwards until contacting the posterior projection of the posterior arch of the atlas. Then, flexing the metacarpophalangeal at 90 degrees slowly raises the skull. The therapist's hands should remain together and the base of the skull should rest on his palms pressing with the index, middle and ring fingers of each hand in a sustained manner, but without causing pain. This pressure must be maintained during 4 minutes.
23785|NCT04001868|Procedure|Placebo technique|A superficial contact in the same area as the intervention, to rule out the exteroceptive effect associated with the therapist's contact.
23786|NCT04001855|Other|Dilute vinegar (acetic acid)|Dilute vinegar baths or gauze soaks
23787|NCT04001855|Other|Dilute bleach|Dilute bleach baths or gauze soaks
23788|NCT04001842|Other|Surgical reconstruction of the mandible using an axially vascularized bone construct|Surgically reconstructing defects of the mandible using reconstruction plate and Titanium mesh filled with an artificial bone substitute to form a bone construct. This construct will be vascularized at the same operation using a vein graft from the forearm. The vein graft will be microsurgically connected to an artery and vein within the facial/neck region to provide a vascular supply to the construct (arterio venous loop)
23789|NCT04001829|Drug|Docetaxel|Given IV
23790|NCT04001829|Drug|Paclitaxel|Given IV
23791|NCT04001829|Other|Quality-of-Life Assessment|Ancillary studies
23792|NCT04001829|Other|Questionnaire Administration|Ancillary studies
23793|NCT04001816|Other|Orthodontic Brackets|Self ligating and Conventional brackets
23794|NCT04001803|Drug|CAB LA+RPV LA|Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
23795|NCT04001790|Behavioral|Project Search plus ASD Supports|Nine month job training program embedded on Fort Eustis military base.
23796|NCT04001777|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, weekly for 3 weeks of a cycle with 21days.
23797|NCT04001777|Drug|Osimertinib Mesylate Tablets|Osimertinib Mesylate Tablets 40mg/80 mg, one time a day until disease progression
23798|NCT04001764|Procedure|The radial artery cannulation over 2 cm of the wrist|The radial artery catheterization performed as short axis out-of-plane with USG over 2 cm of the wrist.
23799|NCT04001764|Procedure|The radial artery cannulation in the distal 3/4 area of the forearm|The radial artery catheterization will be performed in the distal 3/4 area of the forearm with ultrasound-guided short axis out of plane intervention.
23800|NCT04001764|Procedure|The radial artery cannulation in the distal 1/2 area of the forearm|The radial artery catheterization will be performed in the distal 1/2 area of the forearm with ultrasound-guided short axis out of plane intervention.
23801|NCT04001751|Behavioral|educational yoga program|"Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yoga."
23802|NCT04001738|Other|Direct Transfer to Angio Suite|Patient will be direct transferred to angiography suite where EVT team will be waiting for it.
23803|NCT04001725|Drug|Dexamethasone|A minimum daily dosage of 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day.
23804|NCT04001725|Drug|Metformin|A minimum daily dosage of Dexamethasone 8 mg through the oral, intramuscular or intravenous administration route, once or twice a day and 2550 mg daily (maximum dose), oral administration (OS) of Metformin; starting dose will be 850 mg/day, to be progressively increased to 1700 mg/day on day 4 and 2550 mg/day on day 7, if well tolerated.
23805|NCT04001712|Drug|Caffeine Citrate|caffeine citrate is given early to preterm neonates in need of respiratory support
23806|NCT04001699|Other|Preoperative geriatric assessment|In addition to the usual care, patients randomized to the intervention group receive preoperative assessment conducted by an interprofessional team including geriatrician, registered nurse, physiotherapist and pharmacist. Based on the assessment, a preoperative optimization plan is constructed focusing on the treatment of the patient's chronic conditions, nutritional status, medication and physical activity.
23807|NCT04001686|Other|incidence aplastic anemia|Ambispective chart review
23808|NCT04001673|Behavioral|Pharmacist's intervention|Information about bDMARDs management.
23809|NCT04001660|Procedure|Subbrow Blepharoplasty Combined with Double Eyelid Surgery|An upper incision is made along the inferior margin of the eyebrow. A lower incision is determined according to necessary amount of skin excision. Then the skin and subcutaneous tissue were excised. The orbicularis oculi muscle (OOM) was separated and an OOM flap dissection was extended to the width of 15mm. A dissected OOM flap was lifted up and three transverse 3-0 nylon sutures were placed to fix it to the periosteum and then covered by the upper myocutaneous flap of the supraorbital rim. Through eyelid-crease approach the supratarsal upper eyelid skin and orbital fat was excised, adjusted and reshaped double-fold eyelids at the same time.
23810|NCT04001647|Drug|Acetylcholine|Endothelium-dependent vasodilation will be determined via graded intra-arterial infusions of acetylcholine (ACh). Doses of 1, 4, 8, and 16 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
23882|NCT04001101|Drug|Anti-PD-1|anti-PD-1 therapy alone
23883|NCT04001088|Dietary Supplement|Probiotic|Dosing regimen of one capsule daily for a maximum of 48 weeks.
23811|NCT04001647|Drug|Sodium Nitroprusside|Endothelium-independent vasodilation will be determined via graded intra-arterial infusions of sodium nitroprusside (SNP). Doses of 0.25, 0.5, 1, and 2 μg/100ml forearm volume/min will be infused in the brachial artery for 3 minutes each.
23812|NCT04001647|Drug|Ascorbic Acid|The influence of oxidative stress on arterial stiffness and vasodilation will be assessed by using intravenous ascorbic acid (AA). A single supra-physiological dose of 0.06 g/kg fat-free mass (FFM) will be infused over 20 min followed by a drip infusion of 0.02 g/kg FFM administered over 60 min.
23813|NCT04001621|Drug|Pyrotinib combined with capecitabine|pyrotinib 400 mg once daily; Capecitabine 1000 mg/m2 per day on day 1 through 14, every 21 days.
23814|NCT04001608|Drug|Seraprevir|Subjects will receive oral tablets of Seraprevir 100 mg, twice a day from Day 1 up to Week 12
23815|NCT04001608|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12
23816|NCT04001595|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
23817|NCT04001582|Other|Patient Registry|Participants who have volunteered to participate will complete various questionnaires relating to their condition.
23818|NCT04001569|Drug|AZD8186 in combination with paclitaxel|"Phase 1b is planned for a 4-stage dose level and the traditional 3+3 design is applied. The RP2D will be determined based on the MTD and toxicity profiles.~In phase 2 part, RP2D from the phase 1b part will be applied.~AZD8186 ( )mg po bid, 5 days on, 2 days off~Paclitaxel ( )mg/m² on D1,8,15 every 4 weeks"
23819|NCT04001556|Diagnostic Test|Minor Salivary gland Biopsy|Minor salivary gland biopsy with injection of lidocain
23820|NCT04001556|Diagnostic Test|ARFI|Acoustic Radiation Force Impulse on Major Salivary Glands
23821|NCT04001556|Diagnostic Test|MSG US|Ultrasonography of Major Salivary Glands
23822|NCT04001543|Dietary Supplement|Immunomodulating oral supplementation|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
23823|NCT04001543|Dietary Supplement|Sip feed control|Per os administration, 3 times / day, 5 days before each cycle of chemotherapy.
23824|NCT04001530|Drug|Half Normal Saline 0.45% Infusion Solution Bag|Randomization to half normal saline
23825|NCT04001530|Drug|Normal Saline 0.9% Infusion Solution Bag|Randomization to normal saline
23826|NCT04001517|Drug|Neflamapimod|Double-Blind, Placebo-Controlled
23827|NCT04001504|Biological|Double Dose Quadrivalent Influenza Vaccine|Double Dose QIV (30µg Hemagglutinin)
23828|NCT04001504|Biological|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose QIV (15µg Hemagglutinin)
23829|NCT04001478|Diagnostic Test|Breath test|Patients will provide a breath test prior to gastroscopy or resection of Barrett's HGD lesion or oesophageal cancer.
23830|NCT04001465|Procedure|Volumetric methacholine challenge unmodified|Bronchoprovocation challenge performed per volumetric method
23831|NCT04001465|Procedure|Modified volumetric methacholine challenge|Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
23832|NCT04001439|Drug|Experimental drug|All patients will recive 30 microbiota capsules intake preceded by bowel lavage by 4 liters macrogol solution. the capsules are developed by the services of JC Lagier.
23833|NCT04001426|Device|The FemPulse System|Non-invasive monitoring during activation of the FemPulse System
23834|NCT04001413|Drug|MEDI0457|MEDI0457 is an investigational drug that will be administered with the Cellectra Device in this study
23835|NCT04001413|Drug|Durvalumab|Durvalumab is an investigational drug in this study.
23836|NCT04001400|Drug|Rabeprazole 20mg bid|Rabeprazole 20mg tablet b.i.d.
23837|NCT04001400|Drug|Rabeprazole 20mg qd|Rabeprazole 20mg tablet q.d.
23838|NCT04001387|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the lateral position with the hip and knees flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance using dynamic needle tip positioning to administer the spinal anesthetic.
23839|NCT04001374|Drug|Ticagrelor|90mg tablet bid for 12 months
23840|NCT04001374|Drug|ASA|enteric coated aspirin 81mg-100mg daily p.o. for 12 months
23841|NCT04001361|Procedure|Laser Cell Therapy|Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
23842|NCT04001348|Device|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23843|NCT04001348|Device|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23844|NCT04001348|Device|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23845|NCT04001348|Device|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23846|NCT04001348|Device|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23847|NCT04001348|Device|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23848|NCT04001348|Device|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23849|NCT04001348|Device|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23850|NCT04001348|Device|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23851|NCT04001348|Device|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23852|NCT04001348|Device|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23853|NCT04001348|Device|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23854|NCT04001348|Device|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23855|NCT04001348|Device|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23856|NCT04001348|Device|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23857|NCT04001348|Device|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler. Perceived pain was assessed on the visual analog scale (VAS, numeric scale). VAS scale was assessed 5 minutes after the lancing procedure."
23858|NCT04001335|Diagnostic Test|Dental Broach|Dental broach, RDT and PCR
23859|NCT04001322|Other|Community engagement|The government will conduct a cascade of sensitization meetings with traditional leaders at all levels to promote newborn line listing (birth registration), reconciliation of child's vaccination status and defaulter tracking (home-based follow up of children who have missed their vaccination doses) by health providers and community leaders
23860|NCT04001322|Other|IRISS advert for opt-in|A module to advertise and demonstrate how individuals can opt-in to IRISS to receive the messages will be included in the community engagement sensitization meetings.
23861|NCT04001322|Other|One-time SMS broadcast on immunization|General broadcast of SMS messages on the importance of immunization to all active mobile phone subscribers in the intervention LGAs
23862|NCT04001322|Other|Scheduled weekly SMS reminder of health facility RI schedule to community leaders|"Traditional and religious leaders who have a phone or access to a phone and have been registered on IRISS will receive SMS messages on the immunization session schedule of the health facilities in their communities, so they can disseminated the information through their town announcers to inform parents and caregivers. For example, Ribah clinic is holding a vaccination session tomorrow from 8am to 2pm. Please take your child there to vaccinate them and encourage your neighbors to vaccinate their children."
23884|NCT04001088|Other|Placebo|Dosing regimen of one capsule daily for a maximum of 48 weeks.
23885|NCT04001075|Drug|TJ107|Patients enrolled in dose escalation part will be given 2 doses (28 days/dose) during the main-treatment period
23886|NCT04001062|Procedure|Surgical Fixation|For both scissoring and non-scissoring injuries surgical fixation by either pinning, dorsal plate, or lag screws will be considered. This will be determined by surgeon expertise at the time of surgical fixation. Postoperative, a volar short arm splint and immediate AROM at full range with buddy taping to adjacent digit will be indicated. Transition to removable short arm splint at week 2 after suture removal. No strengthening until clinical union.
24028|NCT04000009|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
23863|NCT04001322|Other|Scheduled bi weekly RI messages to community leaders|"Traditional and religious leaders who own or have access to a phone and have been registered on IRISS will receive SMS messages on immunization, to share same with community members. The message categories are: 1) Educational messages that provide facts and increase knowledge, e.g. Have you heard of Penta vaccine? It protects against 5 diseases: they are diphtheria, whooping cough, tetanus, HiB and Hepatitis B. 2) Informative messages that dispel myths about immunization, e.g. Getting more than one vaccine at the same time does not harm a child. It is very important to completely receive all vaccine doses for full protection. 3) Normative messages to promote positive norms, e.g. Our religious leaders have immunized their children, what are we waiting for? 4) Motivational messages to inspire action, e.g. Each visit to the health center for vaccination will reap many health benefits. Say YES to good health, be on time and complete your child's vaccination."
23864|NCT04001322|Other|Responsive individualized child vaccination schedule reminder to caregivers who opt-in|"Parents and caregivers who voluntarily registered their child's information into IRISS will receive a reminder, a day before, about their child's due vaccines and the schedule of vaccination sessions in the health facilities within their locality (wards), e.g. Greetings! Amina is due for Penta 1 tomorrow, kindly visit Ribah clinic. They vaccinate on Mondays and Thursdays."
23865|NCT04001322|Other|Responsive one-time SMS message on hand washing to those that erroneously register on IRISS|"If individuals from control LGAs encounter IRISS adverts inadvertently and erroneously register into IRISS expecting a message, to avoid a loss in trust if no message is sent, they will receive a one-time general message about the importance of hand-washing, e.g. Wash your hand with soap and water every time you finish from to the toilet, to maintain clean hands and avoid germs that make you sick."
23866|NCT04001309|Other|Implementation of prospective audit and feedback stewardship interventions to reduce unnecessary use of antimicrobials and improve quality of prescriptions|Prospective audit and feedback of antimicrobial therapy at hospital wards, by interventions performed by infectious diseases specialists alone or using a team-based approach.
23867|NCT04001296|Behavioral|21 day Brush Day and Night school programme|Children participating in the 21 day Brush Day and Night school programme are provided with toothpaste and a toothbrush each and enjoy brushing instruction, supervised brushing, and the singing of songs to facilitate learn the importance of brushing day and night, and stickers and calendars to track progress. A celebration is held at the end of the programme with certificates and rewards. The programme is supported by colourful and attractive materials with bespoke cartoon characters. Parents are provided with educational leaflets.
23868|NCT04001283|Drug|Sodium Nitrite|Intravenous drug infusion
23869|NCT04001283|Drug|0.9% Sodium-chloride|Matched placebo
23870|NCT04001231|Drug|Exenatide Once-Weekly Suspension|A single dose will be administered as 2.0-mg dose of exenatide onceweekly suspension via subcutaneous (SC) injection followed by blood samples be drawn for up to 168 hours after the first dose on Day 1 to assess single-dose PK for exenatide once-weekly suspension. Subsequently Patients will receive the second dose of the investigational product (IP) at Visit 6 (Day 8). Thereafter, patients will receive weekly (±1 day) doses of IP up to Visit 18 (Week 14).
23871|NCT04001218|Drug|Injection of hypertonic saline|Painful condition: Participants will be injected in a neck muscle with 0.5ml of hypertonic saline (5.8%)
23872|NCT04001218|Drug|Injection of Isotonic saline|Control condition: Participants will be injected in a neck muscle with 0.5ml isotonic saline (0.9%)
23873|NCT04001205|Drug|Anticoagulation Therapy|Long term oral anticoagulation with VKA (vitamin K antagonist) or NOAC (non-vitamin K oral anticoagulant)
23874|NCT04001192|Behavioral|aerobic exercise program|The intervention is exercise at home, 5-6 days per week during 12 weeks, guided by a schedule that the physiotherapist will design after initial treadmill testing. Exercise intensity is 80-90 % of the heart rate threshold that was identified by the treadmill test. During the 12 weeks program, intensity will be increased according to feedback from the participant.
23875|NCT04001179|Other|Pulmonary embolism diagnosis by nuclear medicine imaging|nuclear medicine imaging
23876|NCT04001166|Other|Non-interventional study|This is a non-interventional study. Patients will be treated with any treatment deemed appropriate by the patient's physician.
23877|NCT04001153|Other|Dental impressions|"Children will be included in this study if they already are treatment planned to receive a Hall Technique preformed metal crown (HTPMC) to manage carious lesions in primary molars. They will have a dental impression taken before and after the HTPMC placement to find out what happens with their bite after the treatment.~The dental impressions will be cast up into stone study models so that we can track the changes that happens in children's bites after placing the HTPMC (as it increases the height of children's bite when placed) and let them know what to expect after this procedure and as part of this study, additional follow-ups will be required 2, 4, 6 and 8 weeks after the HTPMC placement to allow us to track the changes in the bite at regular intervals to see when the child's bite returns to its pre-treatment state."
23878|NCT04001140|Behavioral|Enhancement of emotion regulation skills|Regarding the intervention, 7 sessions will be carried out. The main purpose is to help adolescents to enhance their emotion regulation, with the ultimate goal to decrease their risk of developing addictions and other psychopathology.
23879|NCT04001127|Other|High Intensity Functional Training|"The exercise intervention for this study will be HIFT, defined as a style of training that incorporates functional, multimodal movements, performed at relatively high intensity, and designed to improve parameters of general physical fitness and performance. The program design and template will be based on the principles of the HIFT program called CrossFit®. CrossFit is described as a strength and conditioning program that focuses on constantly varying functional movements, performed at a relatively high intensity. CrossFit training includes a variety of elements from gymnastics (e.g., floor, bar and ring exercises), weightlifting exercises (e.g., squats, cleans, snatches and presses with a barbell, dumbbell or kettlebell), and cardiovascular activities (e.g., running or rowing)."
23880|NCT04001114|Combination Product|Sampling Research Cigarettes|Participants sample two research cigarettes, which differ in typical tobacco smoke constituents such as tar, nicotine, carbon monoxide, etc. In the Cigarette Discrimination Session, participants sample both types of cigarettes repeatedly, guess their identity (A or B) with regard to reference cigarettes, and rate their subjective effects. In the Ad Libitum Smoking Session, participants can smoke one of these cigarette types as much or as little as they like for eight hours.
23881|NCT04001101|Combination Product|RT and Anti-PD-1|limited metastatic site radiation
23887|NCT04001062|Other|Non-Operative Management|"For non-scissoring injuries: Placement of short-arm cast; immediate AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of <2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union.~For scissoring injuries: Closed reduction in clinic/ER and placement of short-arm cast; immediate full range AROM with buddy taping to adjacent digit. Focus on achieving pulp-to palm distance of <2cm at first visit. Transition to removable short arm splint at week 2 (discontinue at 6 weeks or when non-tender). Strengthening after clinical union"
23888|NCT04001036|Drug|1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One bag for nocturnal (long-dwell) exchange.
23889|NCT04001036|Drug|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
23890|NCT04001023|Device|Imaging with 18F-EF5 PET/CT|Both 18F-FDG PET/CT and 18F-EF5 PET/CT imaging are performed in 1) preoperative work-up to clarify the disease distribution, 2) before IDS to evaluate treatment response to NACT (IDS arm); targeted samples from hypoxic and non-hypoxic tumors are collected during surgery
23891|NCT04001010|Drug|PPP011|1 capsule inhaled 3 times a day with a vaporizer device
23892|NCT04001010|Drug|Placebo|1 capsule inhaled 3 times a day with a vaporizer device
23893|NCT04000984|Behavioral|Mindfulness Based Training (MBT) Program|Participants in the MBT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. Mindfulness, defined as caring moment-to-moment awareness, will be cultivated through the teaching and formal practice of sitting and walking meditation, body scan, and mindful movement (e.g. yoga). Participants will also be taught how to practice mindfulness informally when eating, engaging in pleasurable activities and through interactions with others. Participants will be encouraged to practice approximately 30 minutes a day, and will be provided handouts as well as guided audio recordings of formal practices taught in session to aid their practice at home.
23894|NCT04000984|Behavioral|Cognitive Rehabilitation Training|Participants in the CRT program will meet weekly for 8 weeks. Each session will last one-and-a-half hours. The 8 week-program will consist of the following components: (i) identifying and working on at least one personal rehabilitation goal related to everyday life that is associated with cognitive difficulties; (ii) reviewing and building on the use of practical memory strategies, and or introducing and teaching the use of a new strategy or memory aid; (iii) introducing techniques for learning new information and associations, identifying the preferred strategy, and encouraging the application of this strategy in daily life; (iv) providing practice in maintaining attention and concentration; and (v) exploring current ways of coping with stress and anxiety as well as providing relaxation techniques to help aid with coping (Clare, 2007). Participants will be provided with instructional hand-outs as well as logs to record, monitor and evaluate their progress.
23895|NCT04000971|Other|Integrated Stroke Practice Unit|Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3,6,and 12 months and by phone at 24 months.
23896|NCT04000971|Other|Comprehensive or Primary Stroke Center|Primary and secondary outcomes will be assessed at 3,6,and 12 months and by phone at 24 months.
23897|NCT04000958|Drug|PIRF measured by InCheck DIAL|Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/− 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
23898|NCT04000958|Drug|Regular treament|The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
23899|NCT04000945|Device|BTL-899|Treatment with BTL-899 device, 3 therapies
23900|NCT04000945|Device|Sham|Sham treatment with BTL-899 device, 3 visits
23901|NCT04000932|Drug|Local platelet rich plasma (PRP) injection-T-Lab PRP kit|Platelet rich plasma (PRP) will be obtained by centrifugation of autologous anticoagulated whole blood. 1 ml PRP extract will be injected into the carpel tunnel (of the side with a diagnosis of carpel tunnel syndrome) via the distal wrist line using 23 gauge needle.
23902|NCT04000932|Drug|Local steroid injection-Diprospan ®, Schering Plough|The local steroid injection ((1 ml Diprospan ®, Schering Plough containing 6.43 mg of betamethasone dipropionate and 2.63 mg of betamethasone sodium phosphate) will be performed once into the carpal tunnel.1 ml Diprospan ®, Schering Plough extract will be injected by using 23 gauge needle from the distal wrist line through the carpal tunnel only once.
23903|NCT04000919|Drug|5HTP|5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
23904|NCT04000919|Drug|L-DOPA|L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)
23905|NCT04000919|Drug|Placebo oral tablet|Placebo
23906|NCT04000919|Drug|Carbidopa|Carbidopa (50mg)
23907|NCT04000906|Drug|NAB paclitaxel|Intraperitoneal (IP) administration by PIPAC of Nab-paclitaxel
23908|NCT04000906|Drug|Cisplatin|Intraperitoneal (IP) administration by PIPAC of Cisplatin
23909|NCT04000893|Other|Resistance exercise session|Acute isometric exercise session performed with handgrip Jamar about 20 minutes monitored.
23910|NCT04000880|Behavioral|Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health|AMPLIFI will provide participants with a secure website where they receive and participate in educational sessions tailored to their assigned topics for the intervention arm. The website will provide a resource library for static documents, tips of the day, tracking of health behaviors, and goal-setting.
23911|NCT04000880|Other|Diet-Exercise|Diet-Exercise
23912|NCT04000880|Other|Exercise-Diet|Exercise-Diet
23913|NCT04000880|Other|Wait-list Control- Combined Diet and Exercise|Wait-list Control- Combined Diet and Exercise
23936|NCT04000711|Other|Inpatient intravenous treatment.|Participants allocated in the intravenous inpatient group continued receiving Cefepime 150 mg/kg/day every 8 hours (max dose 2 grams per dose or 6 grams per day) according to local standard of care guidelines. Intravenous antibiotic treatment was given until documented ANC > 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
23914|NCT04000867|Device|Transcutaneous Magnetic Stimulation (TCMS)|The study will evaluate whether an experimental medical device that emits a series of brief, intense magnetic pulse called TCMS will relieve foot pain from Diabetic Neuropathy (DN) when compared to the same device giving a sham treatment without magnetic pulses. Participants will be blindly randomized into either the TCMS treatment group or the sham treatment group according to the number 1-20 that they draw. This is necessary to further investigate this TCMS treatment and to determine how to obtain statistically significant data as to whether this therapy reduces the foot pain caused by diabetic neuropathy.
23915|NCT04000854|Drug|Calcium hydroxide (Calacept)|Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
23916|NCT04000841|Behavioral|Mindful You mobile app|"The CRSR intervention consists of a native mobile application for Android and iOS devices. The mobile app includes:~Guided meditations of varying length designed to connect the user to the present moment and a place of calm through culturally aligned exercises grounded in spirituality, orality, self-empowerment, and resilience.~User-customized notifications prompting users to reflect and engage with the app, such as providing African American proverbs and quotes and asking simple questions like What are you grateful for today?~Scheduled messages on the importance mindfulness as a way increase control over physical and psychological health~User-customized reminders to do specific meditations and display personally selected images or messages."
23917|NCT04000828|Device|Placement of Sensimed Triggerfish|Sensimed Triggerfish is placed on the corneal surface
23918|NCT04000815|Diagnostic Test|C Type Natriüretic Peptide|C Type Natriuretic Peptide will be measured with elisa method
23919|NCT04000802|Behavioral|response to questionnary|No intervention. Observational study
23920|NCT04000789|Drug|Sodium Hyaluronate, Vitamin A, Vitamin E|Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
23921|NCT04000776|Diagnostic Test|FDG Positron emission tomography (PET) scan|"Patients will undergo 18F-FDG and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).~The patient will be measured and weighed before the exam in order to calculate a personalized dose. An intravenous catheter will be put in place in peripheral vein to allow injection of the tracer."
23922|NCT04000776|Diagnostic Test|PSMA Positron emission tomography (PET) scan|Patients will sequentially undergo 68Ga-PSMA and whole-body PET/CT (vertex to thighs, or to feet if known lower-limb metastases).
23923|NCT04000776|Diagnostic Test|OCTREOTATE Positron emission tomography (PET) scan|"In the case a patient would present at least one PSMA-negative/FDG-positive lesion, he will be referred to undertake a whole-body 68Ga-OCTREOTATE PET/CT within 10 days of the first PET/CT. The delay between this third PET scan and the last one should be minimal (not least than 18 hours, not more than 10 days).~Images and data will be reviewed centrally within 4 days by the Imaging Corelab, which will produce a final report confirming patient's eligibility to Radioligand therapy (RLT)."
23924|NCT04000776|Other|Optional Bone or soft-tissue biopsies|Patients presenting FDG-positive/PSMA-negative or Octreotate-positive lesions on imaging will be asked to undergo a biopsy of these lesions (optional) for research purposes. Bone or soft-tissue biopsies will be collected by an interventional radiologist according to site's standard-of-care procedure and sent to the local pathology department for preparation (formalin-fixed and paraffin-embedded); the blocks being sent to the Pathology Corelab.
23925|NCT04000763|Device|superficial peroneal nerve stimulation|A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.
23926|NCT04000750|Other|Time Restricted Eating|Diet will be tracked and reported every day to a qualified dietitian.
23927|NCT04000750|Other|Normal Feeding|Diet will be tracked and reported every day to a qualified dietitian.
23928|NCT04000750|Other|Resistance Training|8 weeks of supervised and programmed whole body resistance training, performed 4x per week
23929|NCT04000750|Dietary Supplement|Whey Protein|Consumed on all exercise days.
23930|NCT04000737|Drug|YIV-906+Sorafenib|Patients will be treated orally for two 28-day courses with YIV-906 (600 mg (3 capsules) BID) + sorafenib (400 mg BID) according to the following schedule: sorafenib BID daily treatment for 28 days, and YIV-906 BID 4 days on and 3 days off weekly in each course.
23931|NCT04000737|Drug|Placebo+Sorafenib|Patients will be given sorafenib (400 mg BID) daily for two 28-day course with placebo (3 capsules, BID) 4 days on and 3 days off weekly in each course.
23932|NCT04000724|Behavioral|Text Messaging (Text+Step)|Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
23933|NCT04000724|Behavioral|WebApp (App+Step)|Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.
23934|NCT04000724|Behavioral|Information/No Step|Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
23935|NCT04000711|Other|Outpatient oral treatment.|Participants allocated in oral outpatient group were discharged home with oral antibiotic to continue management. Participants were given Cefixime oral suspension (100 mg/5 mL). Antibiotic was given to the caretakers with written instructions about dosage and time of administration. Dosage indicated was 8 mg/kg/day to be given orally as a single dose (max dose 400 mg/day). Oral antibiotic treatment was given until documented ANC > 500, failure to treatment (restart of fever) or when 14 days of antibiotic were completed (whichever occurred first).
23937|NCT04000698|Drug|Preparative regimen|"Preparative chemotherapy before allogeneic HSCT~Fludarabin~Cytarabine~Venetoclax~Daratumomab~Vecanoid Condition~treosulfan~fludarabine~thiophosphomide~Venetoclax~Plerixafor GVHD prophylaxis~abatacept~tocilizumab~rituximab~HSCT from the haploidentical donor, ex vivo depleted of alpha/beta T lymphocytes"
23938|NCT04000685|Other|Yoga exercise program|Yoga exercise program will be applied two sessions per week, totally eight week.
23939|NCT04000685|Other|Spinal stabilization exercise program|Spinal stabilization exercise program will be applied two sessions per week, totally eight week.
23940|NCT04000685|Other|Aerobic walking program|Aerobic walking program will be applied two sessions per week, totally eight week.
23941|NCT04000672|Procedure|3D printed patient specific metal jigs (PSI jig)|PSI jig is created based on the pre-operative CT image. Standard medial open wedge osteotomy described previously is performed. Incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Then the PSI jig is positioned onto the tibia. Due to the jig patient specific design (individually based on each patient's CT image), it can fit closely to the proximal tibia. The slot opening on the PSI jig corresponds to 4 cm below the medial joint line and the slot design allow the sawblade cut direction toward the safe zone of the lateral cortex under fluoroscopy. The PSI Jig is removed after the bone cut completed and would not retain in patient's body.
23942|NCT04000672|Procedure|HTO with navigation|In brief, an incision is made in the midway between posteromedial border of the tibia and medial aspect of the tibial tuberosity. Sartorius fascia is cut and retracted medially to expose the medial collateral ligament (MCL). Two to three K-wires are placed 4 cm below the medial joint line toward the safe zone (an area between the tip of the fibular head and the remnant of fibular head epiphysis line) of the lateral cortex under fluoroscopy and osteotomy is done below and parallel to the k-wires using an oscillating saw leaving the lateral 10 mm intact.
23943|NCT04000659|Device|Episealer Knee System|The Episealer Knee System is comprised of individualized endoprosthetic resurfacing implants and implantation tools (Episealer Toolkit). The implants are designed to replace the articulating surface which has been damaged due to femoral knee chondral and osteochondral defects.
23944|NCT04000659|Procedure|Microfracture|Microfracture is a minimally invasive surgical technique developed to repair defects in articular cartilage and reduce pain in the knee joint. Microfracture techniques are described in the orthopedic literature and are performed arthroscopically.
23945|NCT04000646|Other|standard care|standard care non-pharmacologic interventions during anesthesia induction
23946|NCT04000646|Other|breath-controlled app|breath-controlled app and custom-designed tablet (equipped with a breathing sensor)
23947|NCT04000633|Drug|Lidocaine 2%|the patients of this group will recieve nebulization of 5 ml of 2% lidocaine prior to induction of general anesthesia
23948|NCT04000633|Drug|Normal saline|Normal saline
23949|NCT04000620|Procedure|surgery|treatment intent surgery
23950|NCT04000620|Procedure|punture|diagnostic punture
23951|NCT04000594|Drug|RO7234292 (RG6042)|RO7234292 (RG6042) will be administered in two IT doses of the same dose level at an interval of 28 days during the treatment period (Day 1 and Day 29). Each dose of RO7234292 (RG6042) will be administered as a single IT bolus injection.
23952|NCT04000581|Other|Best Practice|Receive standard of care
23953|NCT04000581|Other|Physical Activity|Walk for minimum 30 minutes per day
23954|NCT04000568|Other|Respiratory support: NAVA -NIV and PC-NIV|The infants enrolled will receive respiratory assistance by NAVA-NIV and PC-NIV in a randomized order
23955|NCT04000555|Drug|Oral Vancomycin|Oral vancomycin 125mg twice a day prescribed for the duration of antibiotics
23956|NCT04000555|Other|Placebo|Matched placebo twice a day prescribed for the duration of antibiotics
23957|NCT04000542|Other|Pharmacist Intervention|The pharmacist will record a 30 second rhythm strip from patients using the KardiaMobile device and calculate the QTc interval using the Bazett calculation formula. The pharmacist will discuss the result with the patient and if necessary, will contact the prescriber to effect a medication change. If the QTc interval is greater than the 99th percentile, (470 ms for males, 480 ms for females) the pharmacist must contact the prescriber. The pharmacist will record any prescription changes which resulted from the intervention and the prescriber response. The pharmacist will email the rhythm strip (with study participation number) to a secure email at the Northeast Iowa Family Practice Center (NEIFPC). Rhythm strips will be archived for future potential research evaluation in a secure, electronic file.
23958|NCT04000529|Drug|TNO155|Capsule
23959|NCT04000529|Drug|Spartalizumab|Concentrate for solution for infusion
23960|NCT04000529|Drug|Ribociclib|Capsule and tablet
23961|NCT04000516|Behavioral|Time restricted feeding|Restricting the eating window to about 8 hours a day, during waking hours.
23962|NCT04000503|Behavioral|Self-collected HPV testing for cervical cancer screening|Self-collection cervical cancer screening, STI screening, and education on HIV by a community health worker. Women who test positive for high-risk HPV types will be referred to a designated health centre for VIA follow-up and treatment if indicated.
23963|NCT04000490|Other|SCARE Score|Predictive Score of acute coronary syndrome during the medical assessment of chest pain
23964|NCT04000477|Device|Cytobrush|the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total
23965|NCT04000477|Device|Kevorkian curette|the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
23966|NCT04000451|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
23967|NCT04000451|Device|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is seven days
24029|NCT03999996|Biological|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
23968|NCT04000451|Drug|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in seven days before the study
23969|NCT04000438|Drug|DF01|The subject receives sc injections of tafoxiparin solution once daily for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
23970|NCT04000438|Drug|PL1|The subject receives sc injections once daily of placebo solution for up to 7 days until labor induction or spontaneous onset of labor. Induction is done according to clinical practice; 1st balloon, 2nd PGE1
23971|NCT04000425|Combination Product|AVENIO ctDNA surveillance kit|AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
23972|NCT04000412|Device|CardioZ multifrequency impedance recording system|Patients will be submitted to mapping of both voltage and tissue impedance. The accuracy of the two maps identifying the extent and transmurality of the infarction will be assesssed by gadolinium imaging.
23973|NCT04000399|Behavioral|BRITEPath|BRITEPath will guide co-located mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.
23974|NCT04000399|Behavioral|Treatment As Usual|Participants in this group will receive usual care from their mental health clinician at their primary care office which may include a paper safety plan.
23975|NCT04000386|Other|zinc oxide nanoparticles coated socks|zinc oxide nanoparticles coated socks were given to subjects for 2 weeks
23976|NCT04000386|Other|placebo socks|placebo socks were given to subjects for 2 weeks
23977|NCT04000373|Device|Ekso GT™ exoskeleton|The rehabilitation treatment will consist of 3 sessions per week for 8 weeks, for a total of 24 sessions. Missed sessions will be made up if possible. Each session will be scheduled for 60 minutes, and will consist of stretching, overground gait training, and gait training with the study device. Rest periods will be provided as necessary during the training visits.
23978|NCT04000360|Other|High-Intensity Aerobic Exercise|The home-based exercise group will receive a Peloton indoor cycle delivered to their home and a heart rate monitor strap. Participants will be asked to cycle 3x/week for 12 months on their bike with their heart rate monitor at an aerobic intensity between 60-80% of heart rate reserve with a target cadence between 80-90 revolutions per minute (RPMs). Additionally, participants (both groups) will receive activity monitors to monitor their daily activity levels.
23979|NCT04000347|Drug|2.5% benzoyl peroxide gel|2.5% benzoyl peroxide gel was given to patients for 2 weeks
23980|NCT04000347|Drug|5% benzoyl peroxide gel|5% benzoyl peroxide gel was given to patients for 2 weeks
23981|NCT04000334|Other|MAP increased to optimize cerebral blood flow|MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
23982|NCT04000334|Other|MAP between 65 and 85 mmHg|MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.
23983|NCT04000321|Other|Windmill at 30 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
23984|NCT04000321|Other|Windmill at 45 Minutes|The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
23985|NCT04000308|Drug|Quadratus Lumborum Block type 2|The obstetrician (multiple, experienced clinicians) will infiltrate the wound (Pfannenstiel incision) subcutaneously at the end of surgery with 20 ml normal saline. Subsequently, a US-guided QLB using a linear/convex transducer will be performed by the anesthesiologist using 30 ml levobupivacaine 0.18% (20 ml 0.25% levobupivacaine + 10 ml normal saline) bilaterally (60 ml in total).
23986|NCT04000308|Drug|Wound Infiltration|Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
23987|NCT04000295|Drug|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 375 mg/d
23988|NCT04000295|Drug|Etoposide|Subjects receive Etoposide capsule orally, d1-14, q3w, Dosage form: capsule, Strength: 50 mg/d
23989|NCT04000295|Drug|Paclitaxel|Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, q3w, Dosage form: injectable, Strength: 80 mg/m2
23990|NCT04000282|Drug|SAR442085|Pharmaceutical form:Sterile lyophilized powder for reconstitution for infusion Route of administration: intravenous
23991|NCT04000269|Device|Soterix MxN Neuromodulation device|Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
23992|NCT04000269|Device|Sham Stimulation|Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
23993|NCT04000256|Behavioral|Activity based rehabilitation|Activity based rehabilitation for the upper extremity involves various gross and fine movements, reach and object transportation, and object manipulation. The rehabilitation equipment used during training will include gaming and instrumented training equipment, conventional table-top tasks, and exercise aids.
23994|NCT04000243|Diagnostic Test|Endoscopic diagnosis of Hp|Detection of a regular arrangement of collecting venules (RAC) pattern in the lesser gastric curvature
24025|NCT04000048|Genetic|sequencing of the complete exome|Once the pathological diagnosis is confirmed (WHO 2016), a tumor fragment will be selected and frozen for each lobe. DNA extraction will be performed for each fragment. The samples (4 different DNAs per GDBG corresponding to the DNA extracted from each of the 3 lobes and the blood DNA) will be sent to the Montpellier Genomix platform for sequencing of the complete exome.
23995|NCT04000230|Behavioral|TCIT|"TCIT consists of the following:~CDI Teach Session: Teachers will participate in two training workshops in Child-Directed Interaction (CDI) skills. Specifically, teachers will learn to use positive attention skills and active ignoring.~CDI Coaching: Teachers will receive 90 minutes of CDI coaching in the classroom once or twice weekly for 6 total coaching sessions over a period of 4-6 weeks. The coach will observe the class and coach the teacher live using a microphone and bug-in-the-ear device.~TDI Teach Session: Teachers will complete two training workshops in Teacher Directed Interaction (TDI) skills, which focus on increasing compliance and reducing disruptive behavior. Teachers will learn to present developmentally appropriate, direct, and clear instructions and consistent positive and negative consequences.~TDI Coaching: Teachers will receive six 90-minute TDI coaching sessions once or twice weekly for 4-6 weeks."
23996|NCT04000230|Behavioral|Booster|Teachers in the Intervention group will receive additional booster sessions during the second half of the school year. Booster sessions consist of coaching teachers in CDI and TDI skills. Teachers receive 4-8 booster sessions.
23997|NCT04000217|Behavioral|Written Exposure Therapy|In this study, written exposure therapy is delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
23998|NCT04000217|Behavioral|Imaginal Exposure Therapy|Delivery of imaginal exposure in this study will mirror the procedures used in WET. It will be delivered in an online format with coaching from trained peer support specialists. Participants will complete 4-8 sessions, depending on their level of symptom reduction (i.e., allow for early termination when low symptom levels are achieved).
23999|NCT04000204|Device|HYAJOINT Plus|60 mg / 3 ml cross-linked hyaluronan, SciVision Biotech Inc.
24000|NCT04000204|Device|Durolane|60 mg / 3 ml cross-linked hyaluronan, Bioventus LLC.
24001|NCT04000191|Procedure|MAC|Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
24002|NCT04000191|Other|Perianal ice application|Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
24003|NCT04000178|Device|polyurethane stent|patients were prospectively enrolled in the study and stratified (non-randomly) into either group A - polyurethane - control group or group B - silicone - experimental group
24004|NCT04000178|Device|silicone stent|silicone stent
24005|NCT04000165|Drug|AG-348|All subjects will receive an initial dose of 5 mg BID of AG-348 for 2 weeks followed by 2 dose increases, from 5 to 20 mg BID and from 20 to 50 mg BID,depending on safety and tolerability. Specifically, the treating clinician will assess the safety and tolerability of the current dose level before a decision is taken to escalate the dose to the next level.
24006|NCT04000152|Diagnostic Test|niPGT-A|Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of transfer or freezing. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
24007|NCT04000152|Other|Morphology criteria|Embryo selection performed according to morphology following the regular protocols of each IVF center
24008|NCT04000139|Drug|Standardized anthocyanin-rich extract|3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
24009|NCT04000139|Drug|Placebo|3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
24010|NCT04000126|Device|Pupil reflex dilation measurement (PRD)|Pupillary Reflex Dilation (PRD) measured for 60 s during orotracheal intubation using a video pupillometer
24011|NCT04000126|Device|PPI (Pupillary Pain Index)|Pupillary Reflex Dilation (PRD) measured using a video pupillometer 5 min after orotracheal intubation
24012|NCT04000126|Drug|lidocaine|1.5 mg/kg lidocaine/ 100ml 0,9% NaCl iv 10min before intubation
24013|NCT04000126|Drug|Placebo|100ml 0,9% NaCl iv 10min before intubation
24014|NCT04000126|Device|Bispectral Index (BIS)|Bispectral Index will be monitored to assess the depth of anaesthesia
24015|NCT04000126|Device|HR|HR in beats/min will be measured by the electrocardiogram monitor
24016|NCT04000126|Device|BP|BP will be measured automatically by an occluding upper arm cuff
24017|NCT04000113|Device|laser acupuncture|low level laser emission on specific acupuncture points
24018|NCT04000113|Device|Sham laser|Sham laser
24019|NCT04000100|Procedure|ultrasound- guided supraclavicular brachial plexus block|"Patient lie down supine with head turned 45 degrees to the contralateral side and ipsilateral arm adducted gently by the assistant and the shoulder kept down with flexed elbow.~After sterile preparation of the skin and the ultrasound probe (12 MHz probe) were used, the brachial plexus was visualized by placing the transducer in the sagittal plane in the supraclavicular fossa behind the middle-third of the clavicle. Two distinct appearances of the brachial plexus was seen at the supraclavicular region, it either appeared as 3 hypoechoic circles with hyperechoic outer rings or as a grape like cluster of 5 to 6 hypoechoic circles, located lateral and superior to the subclavian artery between the anterior and middle scalene muscles at the lower cervical region figure"
24020|NCT04000087|Other|AI-enabled ECG-based Screening Tool|A novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.
24021|NCT04000074|Behavioral|Telephonic Services|Provides linkage services to local programs that address the social determinants of health remotely via phone, email and/or fax
24022|NCT04000074|Behavioral|In-Person Services|Provides linkage services to local programs that address the social determinants of health directly to the client during face-to-face visits as well as remotely via phone, email, etc.
24023|NCT04000061|Other|medical chart review|data generated by medical review include Medical history, Medications at presentation, during hospitalization and at discharge, New York Heart Association (NYHA) class, Killip class, Electrocardiographic (ECG) data, echocardiographic data, Interventions (Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Graft (CABG), Implantable Cardioverter Defibrillator (ICD) implantation, Cardiac Resynchronization Therapy (CRT) Implantation), Outcome Information: all-cause death, HF hospitalizations
24024|NCT04000061|Other|data generated by direct IT export|data generated by direct IT export include Anthropometric data (age, sex, height, weight), Vital signs, Laboratory data
24031|NCT03999983|Other|Observational Prospective Registry|This is a prospective registry looking at patients admitted for stroke with evidence of Vertebral Artery Origin Stenosis. Patients clinical outcomes will be collected at 30 days and 1-year post-treatment and angiographic outcomes at 1-year post-treatment
24032|NCT03999970|Other|Sand fly bite|Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
24033|NCT03999957|Other|Telehealth web conferencing|Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
24034|NCT03999918|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
24035|NCT03999918|Drug|Placebo|Placebo (2×placebo tablets [size- and color-matched to pimavanserin]) administered orally as a single dose once daily
24036|NCT03999905|Behavioral|Counseling training|Online training using Moodle.
24037|NCT03999892|Behavioral|ACHIEVE|The investigators will test two modules of the adapted video-assisted curriculum format of 45 to 60-minute multipurpose classes, which will include a segment on group weight management (~20-30 minutes) and group exercise (~20-30 minutes). Within each module, the group weight management topic varies by week, and within each week the content of the three weight management groups builds gradually and is purposely repeated. Within each module, the group exercise classes will focus on mild to moderate intensity aerobic exercise using an exercise video. In this pilot study, a trained study interventionist will deliver the ACHIEVE-D curriculum.
24038|NCT03999879|Diagnostic Test|Measure of OxPhos upregulation|OxPhos upregulation [i.e., lower phosphocreatine (PCr)-to-ATP ratio levels] in the PET AG mask. PIB+ NL subjects will show OxPhos downregulation (i.e. increased PCr/ATP ratio that indicate the presence of metabolically inert PCr that cannot be used as ATP) when compared to PIB- NL subjects in the PETAG mask
24039|NCT03999879|Diagnostic Test|lactate (measured with 1H-MRSI)|PIB+ NL subjects will show increased levels of lactate (measured with 1H-MRSI) when compared to PIB- NL subjects in the PETAG mask.
24040|NCT03999866|Device|airtraq|airtraq videolaryngoscope
24041|NCT03999866|Device|mcgrath mac x-blade|mcgarth mac videolaryngoscope
24042|NCT03999866|Device|storz c-mac|storz c-mac videolaryngoscope
24043|NCT03999866|Device|storz d-blade|storz d-blade video laryngoscope
24044|NCT03999853|Dietary Supplement|BKR-017|500 mg butyrate tablets
24045|NCT03999840|Drug|cemdisiran|Cemdisiran has been designed to reduce the level of C5 mRNA in the liver, thereby reducing levels of circulating C5 protein, inhibiting terminal complement pathway activity, and preventing formation and deposition of the MAC (C5-b9) on endothelial cells in the kidney.
24046|NCT03999840|Drug|Placebos|The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration). Placebo will be prepared and labelled identically to cemdisiran.
24047|NCT03999827|Other|Low Glycaemic Index Diet|Adherence to a diet which limits carbohydrate intake to 40-60 g/day, but carbohydrates must have a glycaemic index of less than 50. Fat and protein intake is encouraged, with approximately 60% of calorie intake as fat.
24048|NCT03999801|Drug|RGX-314|anti-VEGF fab
24049|NCT03999788|Procedure|lumbar puncture and blood withdrawal|lumbar puncture performed to detect OCB for diagnostic purposes and blood withdrawal for SNP screening
24050|NCT03999788|Procedure|Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity|iTBS will be delivered over the scalp site corresponding to the leg area of primary motor cortex contralateral to the affected limb. The active motor threshold (AMT) will be defined as the minimum stimulation intensity required to evoke a liminal motor potential from the Soleus muscle during voluntary contraction. The stimulation intensity will be about 80% of AMT. The iTBS stimulation protocol consists of 10 bursts, each burst composed of three stimuli at 50 Hz, repeated at a theta frequency of 5 Hz every 10 s for a total of 600 stimuli (200 s). If no MEP will be detectable from the contralateral leg, the site of stimulation will be determined as symmetrical to the motor hot spot. If no MEP will be detectable even from the contralateral leg the coil will be held tangentially to the scalp with its centre placed 1 cm ahead and 1 cm lateral from CZ (10-20 EEG system). In these cases, stimulation intensity will be set to 50% of the maximum stimulator output.
24051|NCT03999775|Dietary Supplement|Calcium, vitamin D and bioactive collagen peptides supplement|
24052|NCT03999775|Dietary Supplement|Calcium and vitamin D supplement|
24053|NCT03999762|Device|sample prep|Effectiveness of a sample preparation protocol
24054|NCT03999749|Drug|Ipilimumab|4 induction doses (during the 2 treatment cycles) at a dose of 1 mg/kg intravenously (IV) every 3 weeks, 4 times during the 12-week induction period, concurrent with nivolumab at 3 mg/kg administered at the same interval
24055|NCT03999749|Drug|Nivolumab|administered first at a dose of 3 mg/kg;
24056|NCT03999749|Drug|Tocilizumab|Administered intravenously for each 42-day induction treatment cycle.
24057|NCT03999736|Device|transcranial direct current stimulation using a Soterix mini-CT device|TDCS is used to non-invasively stimulate the brain through the application of electrical currents to a small region of the scalp using a battery-powered stimulator (Soterix Medical 2018) with rubber electrodes and conductive material (saline-soaked sponges). Both electrodes are attached to the scalp with a band. The stimulation points will be located using the 10-20 system of electroencephalogram (EEG) electrode location (localization carried out using a bespoke head strap). The electrode size of the stimulator used in this study is large (25 cm2) and the current strength used is low (2 mA) resulting in very low current density (0.08 mA/cm2). This protocol applies no more than 30 minutes of stimulation in a single session, which is typical for experimental studies (Brunoni et al. 2015; Loo et al. 2017). TDCS is an investigational device and has proceeded with a non-significant risk designation in many past trials and not required an investigational device exemption from the FDA.
24058|NCT03999723|Dietary Supplement|Vitamin C|Oral vitamin C (ascorbic acid) 1000 mg daily will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS as combination treatment.
24059|NCT03999723|Dietary Supplement|Placebo|Placebo capsules (two capsules once daily) will be administered from day 1 in the 1st AZA cycle (D1/C1) and continued until discontinuation of AZA or EOS.
24060|NCT03999710|Radiation|Radiation Therapy|Treatment will consist of 60 Gy in 30 fractions to fields encompassing gross tumor and lymph nodes.
24678|NCT03994692|Procedure|autogenous onlay grafting eminoplasty|making obstacle at eminence using chin graft
24061|NCT03999710|Drug|Durvalumab|A dose of 1500mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v) saline or 5% (w/v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg/mL, and delivered through an IV administration set with a 0.2- or 0.22- μm filter.
24062|NCT03999697|Drug|Autologous chimeric antigen receptor T cell transfusing agent targeting CD22|The enrolled patients will receive autologous-derived CD22-targeted CAR-T cells in 1 day with 100% of the total expected dosage after receiving lymphodepleting chemotherapy
24063|NCT03999684|Drug|Tretinoin|ATRA control normal cell growth, cell differentiation (the normal process of making cell different from each other), and cell death during embryonic development and in certain tissues later in life. Retinoids effects on the cells are controlled by receptors on the nucleus of each cell (nuclear receptors)
24064|NCT03999671|Other|Educational|Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.
24065|NCT03999671|Other|Maneuver control|Verify that the control and intervention group developed the assigned activities in each case.
24066|NCT03999658|Biological|STI-3031|anti-PD-L1 antibody
24067|NCT03999645|Procedure|Early laparoscopic cholecystectomy|within 72h from symptom onset
24068|NCT03999645|Procedure|Late laparoscopic cholecystectomy|after 72h up to seven days from symptom onset
24069|NCT03999632|Other|Dietary modification with introduction of Mankai|Substituting the standard high protein, low carbohydrate preoperative shake during the preoperative liquid diet with Wolffia Globosa (Mankai) shake consisting of 16 oz of skim milk + 1 frozen cube of Wolffia Globosa (Mankai) +/- sugar substitute.
24070|NCT03999619|Behavioral|Move 2 Learn|10-week (1 hour/week) program designed to target fundamental movement and pre-literacy skills with active parent involvement.
24071|NCT03999606|Behavioral|Music Training - Choir participation|"Sixty participants, ages 50-65, will be recruited to partake in this study and will be randomly assigned to two groups:~participants in the experimental group will join a weekly choir, for fifteen weeks, directed by a professionally trained conductor from USC Department of Choral Music. The group practice will be accompanied by individual singing lessons (online or CDs) for home practice. Participants in the control group will be provided with weekly playlists to passively listen to. The playlists will be curated by a music therapist to reflect the music that older participants can connect to and would enjoy listening to."
24072|NCT03999593|Procedure|Resection of perihilar cholangiocarcinoma|Resection of perihilar cholangiocarcinoma
24073|NCT03999580|Drug|vitamin D3|"3000 or 4000 UI/ day:~Weight at inclusion < 40 kg : 1 ml per day of the selected concentration at induction and 1ml per day of the selected concentration at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration at induction and 1 ml per day of the selected concentration at maintenance~600 UI/ day:~Weight at inclusion < 40 kg :1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance.~Weight at inclusion ≥ 40 kg : 1 ml per day of the selected concentration (600 IU) at induction and 1 ml per day of the selected concentration (600 IU) at maintenance"
24074|NCT03999567|Other|Pen and Paper Digit Symbol Substitution Test (DSST)|The DSST is a paper-and-pencil cognitive test presented on a single sheet of paper that requires a subject to match symbols to numbers according to a key located on the top of the page. The subject copies the symbol into spaces below a row of numbers. The number of correct symbols within the allowed time, usually 90 to 120 seconds, constitutes the score.
24075|NCT03999567|Other|Electronic Digit Symbol Substitution Test (DSST)- (a.k.a. Codebreaker)|Code breaker is the mobile/electronic version of the pen and paper DSST which is capable of identifying deficits in the domains of executive function, processing speed and attention/concentration, and takes 2 minutes to complete. Six symbols are numbered consecutively. Users are presented with a series of numbers that they must then match with the correct corresponding symbol as quickly as possible. Users are scored on speed and accuracy.
24076|NCT03999554|Biological|LD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
24077|NCT03999554|Biological|MD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a medium dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
24078|NCT03999554|Biological|HD Sing2016 M2SR H3N2 influenza vaccine|This group will receive a high dose of the Sing2016 M2SR H3N2 monovalent influenza vaccine administered intranasally.
24079|NCT03999554|Biological|LD Bris10 M2SR H3N2 influenza vaccine|This group will receive a low dose of the Bris10 M2SR H3N2 monovalent influenza vaccine administered intranasally.
24080|NCT03999554|Other|Placebo|This group will receive saline placebo administered intranasally.
24081|NCT03999541|Other|Freeze-all policy|A policy of freezing all the embryos followed by subsequent thawed frozen embryo transfer
24082|NCT03999528|Diagnostic Test|14-3-3η Protein assay|blood sampling for assessment of serum 14-3-3η Protein
24083|NCT03999515|Drug|Abiraterone Acetate|Given PO
24084|NCT03999515|Drug|Abiraterone|Given PO
24085|NCT03999515|Drug|Enzalutamide|Given PO
24086|NCT03999515|Drug|Erdafitinib|Given PO
24087|NCT03999502|Device|Endomina|The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
24088|NCT03999476|Device|ambu ascope2|nasal route intubation by the device in fixed cancer tongue patients
24089|NCT03999476|Device|fibreroptic bronchoscope|nasal route intubation by the device in fixed cancer tongue patients
24090|NCT03999450|Behavioral|brief motivational intervention (BMI)|The intervention typically takes 45 minutes to administer and is designed to enhance motivation to change and includes the following components: establishing rapport, asking permission to discuss substance use and providing feedback regarding the substance use assessment, exploring personal consequences of drug use, eliciting the gap between real and desired quality of life, and discussing readiness to change. The therapist then negotiates a written action plan, during which the subject is supported with empathy and verbal reinforcement.
24679|NCT03994666|Biological|allogeneic umbilical cord-derived mesenchymal stem cells|Injection of mesenchymal stem cells
24091|NCT03999450|Behavioral|cognitive behavioral therapy|This evidence-based, online, Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT) program covers six lessons: 1) changing patterns of use, 2) coping with craving, 3) refusing drugs, 4) problem-solving skills, 5) changing drug-related thoughts, and 6) improving decision-making. The program is designed to be user-friendly and includes videotaped instructions and examples, interactive assessments, and practice exercises.
24092|NCT03999437|Drug|TERBINAFINE HYDROCHLORIDE (1%)|Topical liquid solution
24093|NCT03999437|Drug|BUTENAFINE HYDROCHLORIDE (1%)|Topical liquid solution
24094|NCT03999437|Drug|Vehicle Control|Topical liquid solution
24095|NCT03999424|Biological|autologous human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix
24096|NCT03999411|Drug|Nicoderm C-Q Transdermal Product|6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
24097|NCT03999411|Behavioral|Adherence to Antiretroviral Therapy Counseling|Brief counseling on adhering to antiretroviral therapy with self-help materials.
24098|NCT03999411|Behavioral|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and 2 follow-up phone calls.
24099|NCT03999411|Behavioral|"Crave-to-Quit app"|"Evidence-based mindfulness smoking cessation smartphone app (Crave-to-Quit) adapted from an in-person mindfulness training relapse prevention smoking cessation intervention."
24100|NCT03999411|Behavioral|"vDOT emocha app"|"Video Directly Observed Therapy (vDOT) smartphone app (emocha) that allows participants to take a video of themselves taking medication to ensure adherence."
24101|NCT03999398|Procedure|Percutaneous coronary intervention (PCI)|Participants are treated with a PCI and stent implantation in a venous graft (previously implanted during the CABG operation)
24102|NCT03999385|Behavioral|Mindful Self-Compassion (MSC)|The MSC program was developed by Christopher K. Germer, PhD and Kristin Neff, PhD.
24103|NCT03999372|Biological|Hyaluronan binding system|Hyaluronan binding system for sperm selection for ICSI procedures (PICSI)
24104|NCT03999372|Other|ICSI|Normal ICSI procedure
24105|NCT03999359|Other|Home-based Metacognitive Therapy|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
24106|NCT03999346|Other|retrospective analysis of the Swiss Trauma Registry data|retrospective analysis of protectively documented registry data based on data completeness, patient outcomes, patient characteristics
24107|NCT03999333|Device|Virtual Reality (Oculus Go)|Participants will self-administer virtual reality intervention, in addition to standard of care treatment for pain. There will be 6 weeks of weeks of monitoring period (2 weeks before, 4 weeks during, and 2 weeks after the virtual reality intervention).
24108|NCT03999320|Other|Sophrology sessions|8 sophrology sessions, approximately 60 minutes each, spread over 12 months
24109|NCT03999320|Other|usual care|usual care
24110|NCT03999307|Radiation|Low-Level Laser Therapy (LLLT)|LLLT will be applied in this group
24111|NCT03999307|Procedure|Flapless Corticopunture|Small holes in the cortical bone will be achieved using 1-mm diameter round surgical Tungsten bur
24112|NCT03999307|Other|Control|Typical orthodontic treatment with no LLLT or flapless corticopuncture
24113|NCT03999294|Other|BMGIM Music Therapy Method|The BMGIM method is today one of the models recognized by the international music therapy community, deserving this distinction those approaches that develop a solid theoretical and practical body, with specific training programs as training for new therapists, and that also promote the scientific research as a way to develop the method and Music Therapy.
24114|NCT03999281|Other|Human Allograft (Theraskin)|Biologically active cryopreserved human skin allograft (Theraskin) was used on both cohorts, both diabetic foot ulcer and venous leg ulcer.
24115|NCT03999268|Behavioral|I-START|Designed as a supplementary educational tool for patients on insulin therapy, I-START includes an injection plan to reinforce the knowledge and behaviors that users have been taught by their health care provider. This is done through eight modules created for the benefit of new and experienced insulin users, and those using pens or vial/syringes. The modules address a variety of topics pertinent to insulin therapy, including overcoming psychosocial barriers, injection techniques and best practices, managing hypo- and hyperglycemic events, monitoring blood glucose and troubleshooting and problem solving. At the end of each module, users can self-evaluate their confidence in mastering the information presented. This gives them the ability to move forward into the next module, repeat material already presented and/or save features of the modules that they would like to revisit at another time.
24116|NCT03999268|Behavioral|Standard Insulin Administration Education|Standard best practices for training patients to administer insulin therapy include 1) a thorough patient assessment prior to therapy initiation to address barriers, including evaluation for diminished cognitive capacity or other problem that may impair safe insulin self-administration, and assessment of health literacy and numeracy skills; 2) observation of a patient's injection practice, with re-education provided as needed; 3) use of appropriate language is necessary when teaching injection technique; 4) dose preparation, which includes inspecting the insulin dose for accuracy (following manufacturer instructions); and 5) review of signs, symptoms and treatment of hypoglycemia must be included as a critical component of the training.
24117|NCT03999255|Procedure|combined respiratory support (CRS)|combined respiratory support (CRS) which consisted of reduction of tidal volume to 250-300 ml and respiratory rate to 4-5 per minute with transcatheter high-frequency jet ventilation (HFJV) through an endotracheal tube with a respiratory cycle frequency (RCF) of 300 per minute and maintained during RIRS.
24118|NCT03999229|Drug|SNO|S-nitrosylating agent (SNO) Inhalation
24119|NCT03999229|Drug|Normal Saline|Normal Saline transfusion
24120|NCT03999229|Drug|Red Blood Cell|Blood transfusion (RBCs)
24250|NCT03998189|Other|Breath Collection|Pre-surgery, two 500 ml of exhaled breath volatiles (EBV) in each of 4 collection tubes will be collected in 5-7 min of breathing
24680|NCT03994666|Biological|Placebo (NaCl)|Placebo injection
24121|NCT03999216|Drug|Loop Diuretics vs. loop + thiazide diuretics|Participants will receive the diuretic type as determined by the randomized group assignment starting within the first 24 hours of hospital admission and continuing for up to 72 hours. All other treatments are left to the discretion of the treatment team, as this is a pragmatic randomized trial.
24122|NCT03999203|Drug|Citric acid|Citric Acid cough challenge to be administered to assess the cough reflex sensitivity in patients
24123|NCT03999203|Device|Leicester Cough monitor|Ambulatory cough monitor to assess cough frequency over a 24 hour period
24124|NCT03999203|Other|fractional exhaled nitric oxide testing (FeNO)|Measurement of exhaled nitric oxide to give an indication of airway inflammation
24125|NCT03999203|Other|Patient reported outcome measures|A number a patient reported outcome measures will be administered including: Asthma control questionnaire (ACQ-5), mini Asthma Quality of Life Questionnaire (mini AQLQ), Leicester Cough Questionnaire (LCQ), Cough Quality of Life Questionnaire (CQLQ), Cough Hypersensitivity Questionnaire (CHQ) and visual analogue scales for severity og cough (VASc) and Urge to Cough (VASu)
24126|NCT03999190|Drug|NPA radiotracer|"[11C]NPA radiotracer, 2 injection per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
24127|NCT03999190|Drug|Raclopride radiotracer|"[11C]raclopride radiotracer, 2 injections per subject~Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC)."
24128|NCT03999190|Drug|Dextroamphetamine|Dextroamphetamine, one oral administration of 0.5 mg/kg per subject Antagonist ([11C]raclopride) and agonist ([11C]NPA) radiotracer will be used sequentially to measure binding potential (BPND) under baseline conditions and 3-hours following oral administration of 0.5 mg/kg amphetamine in the same 30 medication free subjects with schizophrenia (MF-S) and 30 healthy control subjects (HC).
24129|NCT03999177|Behavioral|Kinect-TOLF Training System|This system will teach patients to perform the lymphatic exercises correctly. Like playing the video games, patients follow the avatar model in the video to perform the lymphatic exercises. The Kinect system can automatically detect whether a user is performing the set of lymphatic exercises correctly in real time and provide instantaneous feedback to the user, thus enhancing patients' self-efficacy to perform the lymphatic exercises correctly. Patients will be asked to conduct two types of usability testing: heuristic evaluation and end-user testing.
24130|NCT03999164|Drug|[18F]DPA-714 Positron Emission Tomography Scan|All patients will undergo a [18F]DPA-714 PET scan of the brain 2 weeks and 2 months following moderate to severe traumatic brain injury to quantify neuroinflammation.
24131|NCT03999151|Behavioral|Exercise and Diet|This Phase 2, open-label, four-arm randomized controlled trial (RCT) will investigate the effects of a 2-year behavioral program providing access to educational materials + clinical texting program (Arm A) + participant portal, text messaging, and coaching (Arms B-D) in 200 men with histologically confirmed low-risk prostate adenocarcinoma who choose radical prostatectomy as treatment.
24132|NCT03999138|Diagnostic Test|MRI|MRI studies (non-contrast) will consist of a free-breathing localizer (~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of < 3 minutes.
24133|NCT03999125|Drug|Aflibercept,|Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.
24134|NCT03999125|Drug|Ranibizumab Injection|Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.
24135|NCT03999125|Drug|Ozurdex Drug Implant Product|Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser
24136|NCT03999112|Other|Metacognitive Reflection and Insight Therapy (MERIT)|A psychological therapy aiming to increase the ability of individuals to synthesise perceptions about themselves and others; to then form complex narratives which recognise the occurrence of these within particular social contexts; and to use these to form responses to psychological problems.
24137|NCT03999099|Drug|Suvorexant 20 mg|Suvorexant at a high dose (20 mg)
24138|NCT03999099|Drug|Suvorexant 10 mg|Suvorexant at a low dose (10 mg)
24139|NCT03999099|Drug|Placebo oral tablet|Placebo
24140|NCT03999086|Procedure|Intervention|We will utilize thromboelastography to discern when to transfuse blood products in the setting of multi-level spinal fusion
24141|NCT03999086|Other|Control Group|Laboratory analysis to guide transfusion
24142|NCT03999073|Other|Ultrasound measurement|Ultrasound measurement
24143|NCT03999060|Device|Electric Current Stimulation|Electric stimulation with a Digitimer DS7AH HV Current Stimulator delivered with 4 shielded electrodes mounted on the participants head
24144|NCT03999047|Diagnostic Test|PRISMA score|Screening for frailty using PRISMA-7
24145|NCT03999034|Diagnostic Test|questionnaire completion|Every patient (140) and healthy control (400) will fill in all the tests and questionnaires, except FSS, in a random order during a single appointment. The FSS will be fill in by patients only. All 400 healthy controls will be divided in 20 groups of 20 people, according to gender, age (5 classes: 18-33, 34-43, 44-54, 55-64, and more than 65 years old), and level of education (graduated or not). 60 of them will pass the XO test at the beginning and again at the end of the consult to investigate the test-retest effect.
24146|NCT03999021|Drug|NAC effervescent tablets|After completing the pretreatment visits, all patients will enter into the treatment phase where patients will receive 1800 mg of NAC effervescent tablets twice a day. The patients will be followed up every 3 months for 2 years. Therefore, there will be a total of 9 treatment visits (baseline, months 3, 6, 9, 12, 15, 18, 21 and 24).
24251|NCT03998189|Other|Saliva Collection|Pre-surgery, 2 ml minimum of saliva will be collected into SalivaBio Passive Drool collection tubes
24252|NCT03998189|Other|Blood Collection|Pre-surgery, an optional 5 ml blood sample in each redtop and purple top vacutainer blood collection tube
24253|NCT03998189|Other|Urine Collection|Pre-surgery, 25 ml minimum of urine will be collected in sterile specimen containers
24147|NCT03999008|Drug|Budesonide Oral|"The subjects will be included at time of the first dilation for an anastomotic stricture.~Basal physical exam and clinical evaluation (weight and height, dysphagia score, gastroesophageal reflux, feeding problems, respiratory symptoms, other symptoms).~Randomization will be conducted by centre. Because long gap esophageal atresia, high tension anastomosis and history of anastomotic leak are reported as risk factors for occurrence of anastomotic strictures, a stratification at randomization will be performed according to these criteria in each centre.~OVB or placebo will be given by the parents and started the day of the dilation at the first meal after recovering of the dilation and anesthesia.~Parents will be asked to bring the empty caps which will be counted for assessment of compliance."
24148|NCT03999008|Drug|Placebos|Apple Sauce 5 mL+ 1 mL saline
24149|NCT03998995|Device|Immersive Virtual Reality|"An Oculus Rift VR Headset and a set of Oculus Touch Controllers was used as interactivity device. Two scenarios of IVR rehabilitation game were offered to the patients: 1) Archery based on behind-the-neck overhead press, using a quiver on the user back to encourage bending their arm and firing the arrow to help with stretching exercises and 2) Climbing based on an overhead arm raise exercise.~Each child will took part in a single IVR trial during their rehabilitation care with the physiotherapist, supported by IP, the games expert/researcher. Timing of participation was approximately 15 minutes of trial with each scenario of game. A short interview was conducted with each child and their parent (together) after each trial, and a focus group was conducted with the clinical staff."
24150|NCT03998982|Drug|Glycyrrhetinic Acid|Compound glycyrrhizin tablets 75 mg three times per day, 1 month
24151|NCT03998982|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
24152|NCT03998969|Drug|Pantoprazole|Pantoprazole 40mg tablet
24153|NCT03998969|Drug|DA-5204|DA-5204 tablet
24154|NCT03998969|Drug|Placebo|Film-coated tablet manufactured to mimic DA-5204
24155|NCT03998956|Procedure|CPVI|Circumferential PV isolation only
24156|NCT03998956|Procedure|CPVI+BOX|Circumferential PV and BOX isolation
24157|NCT03998956|Procedure|CPVI+BOX+SUB|Atrial substrate ablation apart from circumferential PV and BOX isolation
24158|NCT03998930|Other|Clinical evaluation of consciousness by the Coma Recovery Scale Revised (CRS-R)|Paraclinical evaluation of consciousness by the brain-machine interface by measuring evoked potentials P300 auditory and vibrotactile and recording the EEG signal during a motor imaging task
24159|NCT03998917|Diagnostic Test|Discrimination of neuromuscular alterations protocol|Patients will perform a hand grip fatigability test with their dominant hand, followed by a Timed Up and Go Test (TUG-Test), a Five-repetition sit-to-stand-test (5STS-Test) and a10 meters gait speed test.
24160|NCT03998904|Procedure|Muscle preservation|Muscle preservation during graft preparation of hamstring graft
24161|NCT03998904|Procedure|No muscle preservation|No muscle preservation during graft preparation of hamstring graft
24162|NCT03998891|Other|restricted dietary salt intake|These patients after CRTd will receive a restricted dietary salt intake. To date, the salt intake will be 1500 grams daily.
24163|NCT03998878|Behavioral|Low-Carbohydrate Diet|Participants will be instructed to follow a low-carbohydrate diet.
24164|NCT03998878|Behavioral|Intermittent Energy Restriction|Participants will be instructed to follow intermittent energy restriction.
24165|NCT03998878|Behavioral|Hunger Training|Participants will be instructed to follow Hunger Training.
24166|NCT03998865|Device|Provisional abutment material|The effect of the provisional abutment material on the characteristics of the bacterial microbiota will be assessed by using PEEK (experimental) or Titanium (active comparator) provisional abutments.
24167|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FDOPA|Positron Emission Tomography (PET) with [18F]-FDOPA
24168|NCT03998852|Drug|Positron Emission Tomography (PET) with [18F]-FEOBV|Positron Emission Tomography (PET) with [18F]-FEOBV
24169|NCT03998852|Device|Magnetic Resonnance Imaging (MRI)|MRI protocol will be performed on the same day that the [18F]-FEOBV PET imaging, using a 3T scanner (Philips Medical System). Different types of images will be acquired.
24170|NCT03998852|Other|Neuropsychological evaluation|Neuropsychological evaluation will be performed, consisting in an assessment of apathy by actigraphy (social or physical activities will be recorded during seven days) and a complementary assessment of apathy using the Lille Apathy Rating Scale (LARS)
24171|NCT03998839|Other|Community distribution of Sulfadoxine-pyrimethamine (SP)|Community health workers will distribute SP to pregnant women, targeting at least three times during pregnancy.
24172|NCT03998826|Drug|Piroxicam|20mg piroxicam
24173|NCT03998826|Drug|Placebo|placebo
24174|NCT03998813|Drug|Ropivacaine|Locoregional analgesia by femoral triangle catheterization
24175|NCT03998813|Drug|Ropivacaine|Tissue infiltration
24176|NCT03998800|Dietary Supplement|Dietary Supplement|Dietary Supplement: L-arginine and L-citrulline supplement, L-arginine supplement, or placebo supplement (corn-starch) Subjects will complete 3 individual 10 day supplementation periods, separated by washout periods of approximately 2 weeks.
24177|NCT03998800|Behavioral|Endurance exercise on a cycle ergometer|On day 10 of each supplementation period, subjects will complete a performance test on a cycle ergometer to investigate their endurance performance.
24178|NCT03998787|Other|Neurophysiological assessment|Kinematic analysis of movement and transcranial magnetic stimulation
24179|NCT03998774|Behavioral|Evaluate the anxiolytic effect during dental care with MEOPA in children|"Primary Purpose: The main objective of this study is to evaluate the anxiolytic effect of EMONO in children during dental care.~Enrollment: 30"
24180|NCT03998761|Drug|Micronized Progesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone until 7 weeks of gestation.
24254|NCT03998189|Other|Tumor Collection|During surgical tumor removal, a tumor tissue sample will be collected
29540|NCT03955562|Other|Comparison villages|Villages that do not receive a footbridge.
24181|NCT03998761|Drug|Micronized progesterone plus dydrogesterone|Progesterone will be started when endometrial thickness reached 8 mm or more. Patients will receive micronized progesterone (Cyclogest® 400mg; Actavis) at the dose of 400mg twice daily (morning and evening) plus dydrogesterone (Duphaston® 10mg, Abbott) at the dose of 10mg twice daily (morning and evening). A maximum of 2 embryos will be thawed on the day of embryo transfer, which is four days or six days after the start of progesterone depending on day-3 or day-5 embryo transfer. After thawing, surviving embryos will be transferred into the uterus under ultrasound guidance. Estradiol and progesterone will be continued until the day of pregnancy test. If the pregnancy test is positive, the patients will continue to use 800 mg micronized progesterone plus 20 mg dydrogestetrone until 7 weeks of gestation.
24182|NCT03998748|Other|Sham Genetic Feedback|Participants will be told either that they have or do not have a genetic predisposition to developing depression.
24183|NCT03998735|Drug|Herbal Snuff (Smokeless Tobacco)|4 levels of [D4]nornicotine in herbal snuff
24184|NCT03998722|Device|Vagivital|Vagivital once Daily for 12 weeks
24185|NCT03998709|Drug|Somatostatin|Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study
24186|NCT03998709|Other|Dextrose|intravenous glucose will be used to raise fasting glucose in people with NFG / NGT
24187|NCT03998709|Drug|Insulin|insulin will be used to lower fasting FFA and glucose in people with IFG / IGT
24188|NCT03998709|Other|Intralipid|intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT
24189|NCT03998696|Drug|Cisplatin 40 mg/m2|Cisplatin 40 mg/m2, weekly, concurrent with Radiotherapy
24190|NCT03998696|Drug|Cisplatin 100 mg/m2|Cisplatin 100 mg/m2, three weekly, concurrent with Radiotherapy
24193|NCT03998670|Device|Prism Glasses|Spectacles with refractive correction and base-in relieving prism (40% of the greater of the exodeviation by PACT at distance or near) equally divided between the 2 lenses
24194|NCT03998670|Device|Non-Prism Glasses|Spectacles with refractive correction (or plano spectacles if no significant refractive error) and no prism
24195|NCT03998631|Procedure|Carbon Dioxide and Saline Flush|The TEVAR or TAVI device will be flushed with approximately 1.2L of medical grade carbon dioxide using a 60mL syringe and connecting tubing. The reservoir will then be flushed with at least 60mL of standard saline prior to deployment to minimize bubbles in the saline.
24196|NCT03998631|Procedure|Standard Saline Flush|Standard of care flushing of the TEVAR or TAVI device with normal saline.
24197|NCT03998618|Behavioral|Acceptance and Commitment Therapy|Across six weekly 50-minute sessions, patients in the Acceptance and Commitment Therapy condition will practice various mindfulness exercises, clarify their values, and set specific goals consistent with their values. Sessions will incorporate discussion of patients' cancer experiences. Through in-session and home practice of skills, participants will learn new and more adaptive ways to respond to fatigue. Participants will receive handouts on session topics and a CD that we developed to guide mindfulness practices.
24198|NCT03998618|Behavioral|Education/Support|Across six weekly 50-minute sessions, patients in the education/support condition will discuss their concerns, including symptoms and other cancer-related stressors, with a therapist providing psychological support. The therapist will direct patients to resources for practical and health information and contact information for psychosocial services. Sessions will include an orientation to the patient's medical center, education regarding common cancer-related symptoms and quality-of-life concerns, and an overview of resources for addressing these concerns. The therapist will also describe resources for addressing financial concerns and methods of evaluating health information available via the Internet and other modalities. Participants will receive handouts on session topics and will be asked to review them as homework.
24199|NCT03998605|Behavioral|Abuse Prevention Program|The abuse prevention program will be comprised of nine shared learning modules for the individual with Intellectual Disabilities (ID) and a care provider. Each shared module will contain an action step in the Individual Response Plan and will include video, guided practice and workbook activities to equip persons with ID with a range of judgment, decision-making skills and the efficacy needed for identifying, rejecting, and reporting abuse.
24200|NCT03998605|Behavioral|Control Condition|The control group will receive worksheets from the ESCAPE-NOW curriculum.
24201|NCT03998592|Biological|Streptococcus pyogenes vaccine (50 µg)|Vaccine containing 50 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
24202|NCT03998592|Biological|Streptococcus pyogenes vaccine (100 µg)|Vaccine containing 100 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
24203|NCT03998592|Biological|Streptococcus pyogenes vaccine (200 µg)|Vaccine containing 200 µg of StreptInCor synthetic peptide and Aluminium Hydroxide as adjuvant
24204|NCT03998592|Other|Placebo|Placebo without active component
24205|NCT03998579|Other|The CanMoRe programme|An exercise intervention in Primary Health Care
24206|NCT03998579|Other|Home exercise|An active control group
24207|NCT03998566|Device|TraceIT Tissue Spacer implantation|The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
24208|NCT03998553|Procedure|IN VITRO MATURATION AND OOCYTE ACTIVATION|This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.
24209|NCT03998540|Diagnostic Test|Western blot|Western-blot analysis of a giant protein, with specific antibodies directed against C-ter and N-Ter of the protein
24210|NCT03998540|Other|Protein interaction studies|Analyses of several interacting proteins by specific Western-blot and in-vitro tests.
24255|NCT03998189|Other|Medical History Data Collection|Medical history will be obtained from the patients charts to identify demographics (age, race, ethnicity, zip code), oncologic history (date of diagnosis and cancer type), and medical history of disease.
24256|NCT03998176|Drug|Bictegravir/emtricitabine/tenofovir alafenamide|B/F/TAF single tablet formulation
24257|NCT03998163|Drug|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
24211|NCT03998527|Device|Transcutaneous Electrical Spinal Cord Stimulation (TcESCS)|TcESCS is a non-invasive DC battery powered device. Investigators and/or research team members will continually assess the appropriate stimulation parameters including configurations, current, voltage and frequency delivered by up to five active electrodes applied on skin of the back from cervical to lumbar levels. Stimulation parameters used during experimental assessments and interventions will be closely monitored by the research team. Every research participant will be slowly acclimated to stimulation. Blood pressure, heart rate, respiratory rate, and electromyography will be closely monitored while we are determining the correct stimulation parameters in the lab. During the stimulation training sessions, we will monitor blood pressure regularly throughout the session.
24212|NCT03998514|Drug|CB4211 Dose 1|Administered by subcutaneous injection
24213|NCT03998514|Drug|CB4211 Dose 2|Administered by subcutaneous injection
24214|NCT03998514|Drug|CB4211 Dose 3|Administered by subcutaneous injection
24215|NCT03998514|Drug|CB4211 Dose 4|Administered by subcutaneous injection
24216|NCT03998514|Drug|CB4211 Dose 5|Administered by subcutaneous injection
24217|NCT03998514|Drug|CB4211 Dose 6|Administered by subcutaneous injection
24218|NCT03998514|Drug|CB4211 Dose TBD|Administered by subcutaneous injection
24219|NCT03998514|Drug|Placebo|Administered by subcutaneous injection
24220|NCT03998501|Behavioral|Cognitive Behavioral Therapy with Mindfulness Class|The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
24221|NCT03998488|Drug|Fecal Microbiota Transplantation|"The proposed intervention will deliver 250 milliliters of FMT by colonoscopy to the investigational FMT treatment groups at week 0. The placebo treatment group will instead receive the placebo FMT by colonoscopy at week 0 and then the investigational FMT by flexible sigmoidoscopy at week 8.~Investigational FMT is biologically active human fecal material that is pre-screened, tested, quarantined, stored, packaged, and labeled by OpenBiome. Placebo FMP250 is a control unit made of glycerol, saline, and food dye that is stored, packaged, and labeled identically to the investigational FMT, to ensure blinding during delivery."
24222|NCT03998488|Dietary Supplement|Psyllium Husk Powder|"All subjects assigned to the fiber treatment arms will be required to take 1 teaspoon of psyllium husk powder twice per day for 4 weeks, beginning 3 days prior to week 0 screening colonoscopy.~Psyllium husk powder is the dried and powdered form of a psyllium seed coat."
24223|NCT03998475|Behavioral|Transition preparation intervention|Young adult participants and parents will complete transition preparation sessions that include meeting with a health behavior coach for in-person sessions and review of materials sent electronically between study visits.
24224|NCT03998462|Behavioral|Mindfulness Based Stress Reduction|MBSR consists of 6-8 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
24225|NCT03998462|Radiation|Psychoeducational/supportive care|Psychoeducational/Supportive Care consists of 6-8 individuals with PD and led by a trained instructor who is not involved in the clinical care or assessment of these participants.
24226|NCT03998449|Biological|Vaccination against cholera|Participants will receive two doses of an oral cholera vaccine with an interval of 2-4 weeks.
24227|NCT03998436|Drug|Esmolol Hydrochloride|Galnobax-14% gel application along with Standard of Care
24228|NCT03998436|Other|Only Standard of Care|Only Standard of Care treatment
24229|NCT03998436|Other|Vehicle Gel|Vehicle gel application along with Standard of Care
24230|NCT03998423|Biological|Fecal Microbiota Transplant|Double-encapsulated Fecal Microbiota Transplant Capsules
24231|NCT03998410|Device|Lung Doppler Signals|Recording Doppler ultrasound on the right chest wall
24232|NCT03998397|Biological|blood alcohol concentration withdrawal|The blood alcohol concentration is systematically performed in all intoxicated patients admitted in Emergency Department
24233|NCT03998384|Procedure|retrobulbar injection of autoserum|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, local autoserum is injected into the retrobulbar space for the neurotrophic purpose.
24234|NCT03998384|Procedure|retrobulbar injection of placebo|Retrobulbar block is usually a type of regional anesthetic nerve block used in intraocular surgery. In this technique, normal saline (NS) is injected into the retrobulbar space as a comparison
24235|NCT03998371|Diagnostic Test|Low-coverage whole-genome sequencing of urine exfoliated cells|The level of CIN The extracted DNA from morning urine will be analyzed by UCAD to determine the level of CIN.
24236|NCT03998345|Drug|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
24237|NCT03998319|Drug|Tenecteplase|50mg reconstituted to 20mL for intracoronary infusion at 1/3 weight based dose.
24238|NCT03998319|Other|Sterile water|Placebo comparative arm.
24239|NCT03998306|Dietary Supplement|Experimental: Probiotics|"the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions"
24240|NCT03998306|Other|No intervention|No intervention
24241|NCT03998293|Drug|Somatostatin|infused to block endogenous insulin secretion over a 4 hour period
24242|NCT03998280|Device|Assessment|Neck proprioception and postural stability
24243|NCT03998267|Device|Droobi|A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.
24244|NCT03998267|Other|Standard of care|Standard of care including physicians, dietetics and diabetes educators support
24245|NCT03998254|Drug|V503|9vHPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
24246|NCT03998254|Drug|Gardasil|qHPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
24247|NCT03998241|Other|No intervention was provided|No intervention given
24248|NCT03998228|Diagnostic Test|Dual X-ray absorptiometry (DMO) densitometry.|"Simple clinical examination with forearm inspection and palpation;~Radiological examination of BMD;~Calculation of the FRAX® score;~Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis"
24249|NCT03998215|Biological|Diphtheria booster vaccination|Participants received intramuscularly in the deltoid muscle one dose of the trivalent vaccine against diphtheria, tetanus and acellular pertussis
46705|NCT03818919|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
24258|NCT03998150|Procedure|Holmium laser enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using Holmium laser (Asclepion MultiPulse HoPlus 110W and Lumenis pulse 100W and 120W)
24259|NCT03998150|Procedure|Bipolar plasma kinetic enucleation of the prostate|cystoscopic transurethral enucleation of the prostate using bipolar plasma kinetic energy (KLS Martin Maxium or Covidien Force Triad)
24260|NCT03998137|Device|AUGMENT® Injectable Bone Graft|AUGMENT® Injectable Bone Graft
24261|NCT03998137|Procedure|Standard of Care|Autologous Bone Graft
24262|NCT03998124|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
24263|NCT03998124|Other|Usual care|Staff-led social activity
24264|NCT03998111|Diagnostic Test|Oral glucose tolerance test|Participants will ingest 75 g anhydrous glucose dissolved in water and the blood responses will be measured over the following 2-hours using a venous cannula.
24265|NCT03998098|Diagnostic Test|Oxygen Saturation (Oximetry)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
24266|NCT03998098|Diagnostic Test|Heart Rate (Pulse)|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
24267|NCT03998098|Diagnostic Test|Respiratory Rate|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers"
24268|NCT03998098|Diagnostic Test|Blood Pressure|"Participants enter a chamber with a modifiable atmosphere and sit on a bench associated with an exercise bicycle. The subject breathes hypoxic air to achieve various SpO2 readings throughout the range of 80-97%.~The participants undertake recumbent cycling for up to 10 minutes at various intervals and differing oxygen/nitrogen balances to induce changes in their vital signs.~Measurements of the Vital Signs are taken at various time points using Lifelight First and the reference device using 2 observers For participants only participating in the Blood Pressure Arm of the trial, they will not be required to enter the normobaric chamber but will have their blood pressure readings taken in the ambient environment including lying supine in order to generate hypotensive readings."
24269|NCT03998085|Drug|Anlotinib Hydrochloride|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
24270|NCT03998072|Other|Five session cognitive analytic therapy (CAT) consultancy|Five session consultancy with patients and care coordinators using cognitive analytic therapy
24271|NCT03998059|Procedure|splenectomy|These patients should fail to have sustained response to multiple first- and second-line treatments of ITP and agree to have splenectomy.Before splenectomy, these patients will be reassessed and still diagnosed with ITP.Their platelet level will be raised to a safe state before surgery, and the laparoscopic splenectomy will be performed in Tianjin People's Hospital.
24272|NCT03998046|Behavioral|Outreach Support for Weight Loss Goal Setting and Self-Weighing|Patients will receive a MyChart activation message assessing weight loss interest that invites them to complete a MyChart Survey encouraging a weight loss goal using principles adapted from Brief Action Planning. Patients will then receive a cellular network-enabled electronic body weight scale, and weighing data transmitted by the scale will be received and integrated into the electronic health record for access by the patient's primary care team.
24273|NCT03998046|Behavioral|Outreach Decision Support to Encourage Linkages to Intensive Community Lifestyle Interventions|"Patients will receive via MyChart information and decision support designed to encourage linkages to and participation in intensive lifestyle programs available in the community. Patients who request information or clinical referrals will also receive them. Refreshes of community linkage information will be sent by MyChart every 1 to 4 weeks."
24274|NCT03998046|Behavioral|Adaptive Tailoring of Information Delivery and Intensity of Primary Care Outreach Support|Data received into the electronic health record from the cellular network-enabled electronic scale will categorize each patient based on their daily self-weighing behaviors and rate of progress towards their weight loss goal. Patients who are not engaged in daily self-weighing or are not making progress towards their goal will receive more intensive outreach support in the form of automated weekly MyChart problem solving messages, more frequent encouragement to access a broader array of community resources, and telephonic support from a nurse care coordinator who is an existing member of the primary care team. Support from this nurse care coordinator will be facilitated by the incorporation of each patient's self-weighing data into an EpicCare patient dashboard accessible to the nurse coordinator and other members of the care team
24275|NCT03998033|Biological|ET140202 autologous T cell product|Autologous T cells transduced with lentivirus encoding an ET140202 expression construct
24276|NCT03998020|Other|scale of severity|assessment of the severity of the sleep disorders by scale
24277|NCT03998020|Genetic|blood sample|Genetical study, serum and sample
24278|NCT03998007|Device|IRIS System|A QEEG based pain biomarker that scales with the patient reported NRS
24279|NCT03997994|Device|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter coated with a proprietary coating containing the drug and carriers.
24280|NCT03997968|Drug|CYT-0851|All patients will receive CYT-0851 as a single agent
24281|NCT03997955|Other|Myofascial induction|Myofascial induction in plantar fascia
24283|NCT03997942|Other|Effect of exercise|Once the data are available, we hope to have information about which of the exercise practices included in the rehabilitation program of acute upper extremity burn patients is more effective.
24284|NCT03997929|Diagnostic Test|1.3 BETA D GLUCAN|dosage of 1.3 BETA D GLUCAN in the peritoneal fluid obtained during surgery with the FUNGITELL test (Associate of CAPE COD)
24285|NCT03997916|Device|Belun Ring|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
24286|NCT03997916|Diagnostic Test|PSG|All patients scheduled for attended overnight in-lab polysomnography (PSG) in our 2 sleep labs will undergo PSG testing. On the same night of the PSG testing, these same patients will also wear the Belun Ring device. After the study, we will compare results of the Belun Ring device vis-à-vis with the results of the PSG on the same patient.
24287|NCT03997903|Drug|Imatinib Mesylate|"The starting dose for subjects will be 340 mg/m2/day with a maximum dose of 600 mg daily.~Patients will receive Imatinib orally once daily for 6 months."
24288|NCT03997890|Procedure|Cataract surgery with binocular implantation of either Symfony (ZXR00) or Symfony toric (ZXT) IOLs|After creating an initial side port incision with a 15-degree blade, 3-step clear corneal incisions were made using a 2.5 mm disposable metal blade. Sodium hyaluronate 1.0% (Healon; Abbott Medical Optics) was then injected into the anterior chamber. A continuous curvilinear capsulorrhexis, measuring 5.5 mm in diameter, was generated using a 26 gauge bent needle. After hydrodissection, phacoemulsification was done to remove nuclear fragments and aspiration of residual cortex. In all eyes, a Symfony or Symfony toric IOL was implanted in the capsular bag using a disposable implantation system. Irrigation and aspiration were performed to minimize ophthalmic viscoelastic surgical device retention at the end of surgery. The main incision and side port were sealed with stromal hydration using a balanced salt solution.
24289|NCT03997877|Other|Physical activity|Increase physical activity Balanced diet
24290|NCT03997864|Drug|Prazosin|"Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved, max dose is reached, or side effects are problematic.~Tapering Decrease prazosin 1 mg every 3 days or 3 mgs per week until off completely. Tapering will take approximately 2-3 weeks."
24291|NCT03997864|Drug|Placebos|Starting dose: 2mg at HS. Maximum dose: 15 mg at HS. Dosage will be increased 1 mg every 3 days until sleep is improved max dose is reached, or side effects are problematic.
24292|NCT03997851|Drug|Acetaminophen|Topical acetaminophen gel
24293|NCT03997851|Drug|Carbomer 980|Topical vehicle gel
24294|NCT03997838|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
24295|NCT03997838|Drug|Placebo|IV infusion of 0 mg of VVZ-149
24296|NCT03997825|Other|Observational only. No intervention.|Observational only. No intervention.
24297|NCT03997812|Drug|VVZ-149 Injections|IV infusion of 1000 mg of VVZ-149
24298|NCT03997812|Drug|Placebo|IV infusion of 0 mg of VVZ-149
24299|NCT03997799|Procedure|uniportal lobectomy with complete lymphadenectomy|uniportal lobectomy with complete lymphadenectomy
24300|NCT03997786|Drug|Tildrakizumab|"Part A: Pediatric subjects with a body weight in the highest category will be treated with the same dose as adult subjects (e.g. 100 mg for patients weighing >40 kg). Lower doses will be selected with the aim to achieve tildrakizumab plasma exposures in the clinically relevant range across all body weight(BW) categories (e.g. subjects weighing 15 -40 kg, will be given 2.5 mg/kg BW).~Part B: Subcutaneous injection of tildrakizumab will be administered at Weeks 0 and 4"
24301|NCT03997786|Drug|Placebo - tildrakizumab|Subcutaneous injection of placebo will be administered at Weeks 0 and 4
24302|NCT03997786|Drug|Etanercept|Etanercept will be administered at 0.8mg/kg (for subjects <63kg) and 50 mg (for subjects weighing >63kg body weight) weekly for 12 weeks
24303|NCT03997773|Behavioral|Face-it Intervention|The Face-it intervention is a health promotion intervention consisting of 3 major components: 1) active involvement of health visitors, 2) digital health technology and coaching, and 3) a structured cross-sectoral communication system in the healthcare system. The intervention will begin at time approx. 3 months (after the baseline data collection, i.e. 10-14 weeks postpartum), and continues until 12 months
24304|NCT03997760|Drug|SHP655|Participants in both part A and part B of the study will receive SHP655 as a single IV infusion at one of the 3 dose levels of 40 IU/kg, 80 IU/kg, or 160 IU/kg for 12 days.
24305|NCT03997760|Other|Placebo|Participants will receive placebo matched to SHP655 of the 3 dose levels of 40 IU/kg, 80 IU/kg, and 160 IU/kg as single IV infusion in both part A and part B for 12 days.
24306|NCT03997760|Other|Standard of Care (SoC)|Participants will receive standard of care (SoC) treatment for acute VOC (part B) and either SHP655 or placebo as a single IV infusion of SHP655 or placebo at 3 dose levels of 40, 80, or 160 IU/kg for 12 days.
24307|NCT03997747|Other|cytology specimen|Biopsy and Genetic: DNA analysis;Genetic: RNA analysis;Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymorphism analysis
24308|NCT03997734|Drug|AB001|single and repeated dosing
24309|NCT03997734|Drug|oral capsule|single dose
24310|NCT03997734|Drug|positive comparative patch|single and repeated dosing
24311|NCT03997734|Drug|Placebos|single and repeated dosing
24312|NCT03997708|Other|Low FODMAP diet|All participants of this group will initially be informed of the LFD core principles, then they will receive the traditional Low FODMAP Diet, elimination phase (2 weeks). After the 2-week restrictive phase, patients will gradually reintroduce foods rich in FODMAPs (4-6 weeks), and test their tolerance. At the maintenance phase, after the reintroduction of FODMAPs, patients will follow an individualized diet based on their personal tolerance (combination of high and low FODMAPs).
24313|NCT03997708|Other|Low FODMAP diet adjusted in the Mediterranean Diet|All participants of this group will initially follow the Low FODMAP Diet adjusted in the Mediterranean Diet, elimination phase (2 weeks). After the 2-week restrictive phase, patients will gradually reintroduce foods rich in FODMAPs (4-6 weeks), and test their tolerance. At the maintenance phase, after the reintroduction of FODMAPs, patients will follow an individualized diet based on their personal tolerance (combination of high and low FODMAPs).
24711|NCT03994367|Other|High plant protein isolate|Increased dietary protein content from plant protein isolates
24314|NCT03997708|Other|Nutritional Guidelines of the British National Institute for Health and Care Excellence (NICE) Managing IBS|All participants of this group will initially be informed of the nutritional guidelines of the British National Institute for Health and Care Excellence (NICE) for Managing IBS. Then they will follow a diet based on the given guidelines for 8 weeks.
24315|NCT03997695|Other|Core stabilization exercise group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
24316|NCT03997695|Other|Core stabilization exercise plus kinesio taping group|The CSE program was carried out 2 days a week for 6 weeks (12 sessions) by supervisor physiotherapist. The CSE program aimed to perform neutral spine and activation of core muscles. Prior to the CSE program, participants were informed about core musculature and their function.The 6-weeks CSE program was performed in stages with gradual progression according to the stages of motor learning and sensory motor integration as static, dynamic, and functional.
24317|NCT03997682|Other|Hands-Up Program|In addition to the usual care, being allocated to the intervention group would require the participant to attend an exercise and education program once their cast has been removed and they've restored some strength and function in their hand and wrist. The exercise portion of the intervention will focus on strength and balance training, with aspects of managing our distal radius fracture healing as well. The education will focus on learning about risk factors for a distal radius fracture, osteoporosis, exercise for adults, nutrition for adults and falls prevention strategies.
24318|NCT03997669|Other|Collection of pleural effusion|Detection of pleural effusion
24319|NCT03997656|Behavioral|MyDiPP (Malaysia Diabetes Prevention Program)|The participants will go through 16-weekly core lessons that need to be completed within the first 24 weeks after randomisation focusing on changing dietary habits, increase physical activity and relapse prevention and 6-monthly post-core lessons focusing on maintenance of lifestyle habits and weight loss achieved during the core program.
24320|NCT03997656|Other|usual care|standard health education from primary care providers in the clinic
24321|NCT03997643|Radiation|Radiotherapy to all dissected areas|Post operative radiation therapy +/- chemotherapy based on historic treatment volumes (including the primary site, dissected areas +/- elective areas
24322|NCT03997643|Radiation|Omit radiation to pN0 neck|post operation radiation therapy +/- chemotherapy that avoids targeting the dissected pN0 neck
24323|NCT03997630|Device|High flow Oxygenation|Interventional group: All patients included in this group will receive a continuous heated and humidified high-flow (30 to 60 l/min) oxygenation with a nasal cannula for 48 hours. Initially, flow rate will be started at 50 l/min with a FiO2 at 50%. According to the protocol, flow rate and FiO2 will be titrated on SpO2 and respiratory tolerance. Weaning and failure of high-flow oxygenation are described in detail in the study protocol.
24324|NCT03997630|Device|Standard oxygen|Control group: All patients included in this group will receive a low flow oxygenation (flow rate < 15 l/min) with nasal cannula (flow rate ≤ 6 l/min) or non-rebreathing mask (flow rate ≥ 7 l/min).
24325|NCT03997617|Diagnostic Test|Personalized Functional Profiling|During this pilot study, the overall goal of the project is to establish an effective workflow between the patient, the PFP platform, the clinician and return to the patient. This includes collection of the biopsy or surgery piece and standardized processing, dissociation, drug profiling and issuing treatment recommendation to the clinician. In case the clinician follows this treatment recommendation, patient management and follow up will be performed according to standard of care.
24326|NCT03997604|Device|Full Dentures created by additive manufacturing|Full dentures created by Additive manufacturing (Carbon Printers)
24327|NCT03997591|Other|Ready2E.A.T. PROGRAM|"Training tasks based on:~reaching activities during attention tasks, memory tasks, sequential tasks This group was assessed at T0 and then after 6 weeks of conventional therapy."
24328|NCT03997578|Procedure|NIPSA (Non-incised papilla surgical approach)|To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.
24329|NCT03997578|Procedure|NIPSA plus connective tissue graft|In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
24330|NCT03997565|Procedure|TKR|No intervention provided, but investigation of the ability to modulate motor performance during specific and functional tasks in subjects undergoing TKR compared with healthy subjects.
24331|NCT03997552|Procedure|Non-incised papillae surgical approach (NIPSA)|Periodontal reconstructive surgery
24332|NCT03997552|Procedure|marginal approach by palatal incision|Periodontal reconstructive surgery
24333|NCT03997552|Procedure|Minimally invasive surgical technique (MIST)|Periodontal reconstructive surgery
24334|NCT03997539|Drug|Pyrotinib|Pyrotinib Maleate combine with vinorelbine as the second-line treatment to HER2-positive Metastatic Breast Cancer
24421|NCT03996824|Other|Peroperative collect of inner ear cells|"After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach.~The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture."
24712|NCT03994367|Other|High plant protein whole food|Increased dietary protein content from animal protein whole food
24335|NCT03997539|Drug|Treatment of physician's choice|The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for second-line HER2-positive metastatic breast cancer treatment after receipt of trastuzumab-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and single-agent HER2-directed therapy.
24336|NCT03997539|Drug|vinorelbine|vinorelbine
24337|NCT03997526|Device|3C Patch|A platelet-rich plasma gel patch comprised of distinct fibrin, platelet, and leukocyte substantially parallel layers, prepared without the use of any added reagents through a two-step centrifugation process
24338|NCT03997513|Behavioral|Pulmonary Telerehabilitation|The intervention will consist of an eight-week, three sessions per week, home-based pulmonary telerehabilitation program that will incorporate both lower extremity endurance exercise and upper and lower extremity resistance training. Subjects randomized to the study intervention will also participate in a one hour, twice-monthly support group via group video conferencing consisting of an educational topic (i.e. inhaler use, understanding COPD) and group discussion.
24339|NCT03997500|Drug|normal saline|a bolus of normal saline was given followed by normal saline infusion
24340|NCT03997500|Drug|Norepinephrine|a bolus of norepinephrine was given followed by norepinephrine infusion
24341|NCT03997487|Other|TOFTEE|Smartphone app for taking quality images of conjunctivae
24342|NCT03997474|Biological|ATL001|ATL001 infusion
24343|NCT03997461|Device|BPro|BPro and Oscar 2 comparison for 24 hours
24344|NCT03997448|Drug|Pembrolizumab|Pembrolizumab 200mg IV
24345|NCT03997448|Drug|Abemaciclib|Abemiciclib 150mg PO
24346|NCT03997435|Drug|Control arm|neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.
24347|NCT03997435|Drug|Experimental arm|Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.
24348|NCT03997422|Procedure|Vertical Sleeve Gastrectomy (VSG)|Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
24349|NCT03997409|Other|Dietary Intervention|The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine with varying macronutrient content in each group.
24350|NCT03997383|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of patisiran doses will be administered intravenously.
24351|NCT03997383|Drug|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
24355|NCT03997344|Behavioral|Group nature hikes|Six group nature hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
24356|NCT03997344|Behavioral|Group urban hikes|Six group urban hikes will be offered once every other week. Total duration of intervention is 12 weeks. Hikes will be co-lead by two experienced hike leaders.
24357|NCT03997331|Other|CRx Self-Management Solution|The CRx Self-Management Solution comprises connected devices (InsulCheck, a Bluetooth-enabled pill bottle cap, and a Bluetooth-enabled glucometer), and a mobile smartphone app (CRx App).
24358|NCT03997331|Other|CRx Remote Care Solution|The CRx Remote Care Solution comprises an automated support system (Intervention Engine), and a remote care application (Care Module).
24359|NCT03997318|Biological|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
24360|NCT03997318|Other|Placebo|Placebo control is the vehicle solution used for the study product.
24361|NCT03997305|Device|AltaValve|Transcatheter Mitral Valve Replacement
24362|NCT03997292|Drug|Alteplase|According to 0.6-0.9mg / kg alteplase (maximum can not exceed 90mg), of which 10% intravenous injection, the remaining 60 minutes intravenous infusion.
24363|NCT03997292|Drug|Urokinase|1.2-1.5 million U dissolved in 100ml sodium chloride injection, 30 minutes intravenously.
24364|NCT03997279|Drug|Saccharomyces boulardii|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Saccharomyces boulardi 500 mg 1x1, for 3 week
24365|NCT03997279|Drug|Placebo|Rabeprazole 20 mg 2x1, for 14 days, followed by 1x1 for 14 days, Amoxicillin 1000 mg 2x1, for 14 days, Clarithromycin 500 mg 2x1, for 14 days, Metronidazole 500 mg 2x1, for 14 days, Placebo 1x1, for 3 week
24366|NCT03997266|Drug|Ampicillin|Intravenous ampicillin
24367|NCT03997266|Drug|Gentamycin|Intravenous gentamycin
24368|NCT03997266|Drug|Normal saline|Intravenous normal saline
24369|NCT03997253|Other|blood and urine samples|various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12.
24370|NCT03997240|Procedure|Chiropractic Applied Clinical Neuroscience|Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.
24422|NCT03996811|Other|Exercise education|weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
24423|NCT03996798|Other|Disability Case Manager|The DCM will act as key figure between the patient, the multidisciplinary team of the revalidation centre, the employers and other back-to-work services in order to increase vocational reintegration after an incident which caused a handicap or chronic disease.
24424|NCT03996785|Behavioral|Walking in Urban setting|Walking for 60 minutes as described above
24371|NCT03997227|Procedure|Erector spinae Block|After anesthesia and surgical procedures, a bilateral ESP block with ultrasound guidance will be applied from the T10 level at the middle line 3 cm lateral. Prior to the block, with povidone iodine, the T10 transverse protrusion will be determined by using linear ultrasound probe. The local anesthetic will be applied between the transverse projection and the erector spina muscle with the help of an isolated needle designed for peripheral block operations. Without local anesthesia, the location of the needle with saline will be confirmed by hydrodissection. After confirming the location of the needle, 20 ml of LA and saline mixture will be applied and the same procedure will be repeated in the control. A total of 40 ml of LA, 20 ml of bupivacaine 0.5%, 10 ml of lidocaine 2%, 10 ml of saline will be composed of saline.
24372|NCT03997214|Device|inspiratory muscle strength training|The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
24373|NCT03997201|Procedure|Ripple Mapping guided ischaemic VT ablation|"Endocardial mapping of the ventricle performed with Ripple Mapping (CARTO3v6, Biosense Webster Inc). Ablation (SmarTouch Thermocool Catheter, Biosense Webster Inc) delivered to areas of abnormal late electrical activity within ventricular scar tissue."
24374|NCT03997188|Device|Hepilor|ZLC oral suspension and placebo were both started on Day 1 of RT-HeT and ended when RT was completed or at the onset of dysphagia.
24375|NCT03997175|Other|Biodiversity powder|Biodiversity sand contained biodiversity powder that contains a highly diverse and rich microbial community but no known pathogens.
24376|NCT03997175|Other|Placebo|Sand that looks like intervention sand but does not have high biodiversity
24377|NCT03997162|Other|Best Practice|Complete standard of care enhanced recovery after surgery protocol
24378|NCT03997162|Other|Quality-of-Life Assessment|Ancillary studies
24379|NCT03997162|Other|Questionnaire Administration|Ancillary studies
24380|NCT03997149|Behavioral|Acute Laboratory Stressor|The TSST was 20 minutes long and consisted of a five-minute instructional period where participants listened to a pre-recorded tape; a five-minute speech preparation period; a five-minute challenging serial subtraction task; and a five-minute videotaped public speaking task in front of a panel of three evaluative, non-affirming judges dressed in white coats.
24381|NCT03997149|Behavioral|Low affect video|The 20-minute TSST was replaced with a 20-minute low-affect educational film screening.
24382|NCT03997136|Procedure|Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas
24383|NCT03997123|Drug|Capivasertib|400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
24384|NCT03997123|Drug|Paclitaxel|80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
24385|NCT03997123|Drug|Placebo|Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
24386|NCT03997110|Radiation|Short course palliative radiation.|Week 1: Patients in the experimental arm will be treated with short course radiotherapy (25Gy/5#). The dose fractionation of 25 Gy in 5# over a week will be used. Week 4: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#. The patients who will be found unsuitable for brachytherapy will be kept under observation. Week 12: After treatment completion, response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/no • Vaginal discharge- yes/ no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity. Follow up: Patients follow up will be utilizing standard of care imaging and lab investigations used for the patients. Patients will be evaluated every 3 months for the study duration.
24387|NCT03997110|Radiation|Long course palliative treatment.|Week1: All the patients will receive external sitting of radiation treatment, first fraction of 10 Gy. Week4: All the patients will receive external sitting of radiation treatment, second fraction of 10 Gy. Week7: Patients who have almost complete clinical response will be evaluated for brachytherapy will receive the appropriate brachytherapy procedure depending on the tumor response to a dose of 6-8Gy x 2-3#.The patients who will be found unsuitable for brachytherapy will receive another sitting of external radiation, third fraction of 10 Gy. Week 12: After treatment completion response assessment will be done using following parameters: • Pain assessment using numerical pain rating scale on 0-10 • Vaginal bleeding- yes/ no • Vaginal discharge- yes/no • Analgesic use- WHO ladder and dosing • QOL QC30, QLQC15 Pall, QLQC Cervix 24 • Disease response • Acute toxicity
24388|NCT03997097|Drug|Sildenafil|Patients randomised in the group 1 will receive sildenafil in 3 oral doses of 20 mg per day
24389|NCT03997097|Drug|Placebos|Patients randomised in the group placebo in 3 oral doses of per day
24390|NCT03997084|Other|phone interviews|phone interviews
24391|NCT03997071|Other|functional outcome measurement|functional outcome measured in terms of joint position sense analysis, isokinetic muscle strength measurements, gait analysis, drop jump and single leg hop tests, and balance tests
24420|NCT03996837|Other|Intra uterine infusion of platelet rich plasma|Platelet Rich Plasma (PRP) is a blood product with a high platelet and a normal plasma fibrinogen level. Given the effective factors of RPR in repairing damaged tissues, its application in the field of regenerative medicine has widely been interested over the last three decades. According to the literature, PRP is an effective and safe treatment in the fields of orthopaedics, dermatology, ophthalmology, and repair of neurological, vascular, and connective tissue damage, but its application in the field of infertility is limited to a few pilot studies in which the effects of PRP on endometrium and recurrent implantation failure (RIF) were investigated.
24392|NCT03997058|Other|Auricular point pressure therapy|Use a hard and smooth pill to adhere to the center of the 0.7×0.7cm tape. Hold the puncture clip on the part of the ear which is selected, and give appropriate pressure (揉) to make the patient have heat, hemp, Swelling and painful feeling; patients with sputum press 3-5 times a day, each time 1-2 minutes per hole, and must be pressed once every 15-30 minutes before going to bed every night. Press the point pressure method (press the ear point with a fingertip and press it loosely, each interval is 0.5 seconds. It is better for the patient to feel the swelling and slightly heavy tingling, and the force should not be too heavy. Generally, each time the hole can be pressed 27 times. Each time one side of the ear is selected, the two ear points are used alternately, staying in the summer for 1-3 days, and staying in the winter for 3-7 days.It is not appropriate to have local inflammation of the auricle, frostbite or surface skin ulceration.
24393|NCT03997058|Drug|Oral estazolam medication|The first dose was started from 0.5mg, qn, and taken at 30min-1h before going to bed. If the dose is not effective, gradually increase the amount to 2mg, qn. If the patient has drug-induced liver damage and respiratory depression, it is necessary to stop the drug immediately. Hemorrhoids avoid drinking alcohol during medication.
24394|NCT03997045|Behavioral|Supervised physical exercise program|Supervised physical conditioning program of two 60-minutes sessions per week during pregnancy, developed from gestational week 20 to 38. Each session consists of 25-30 minutes of cardiovascular exercise,15 minutes of strengthening exercises, 5 minutes of coordination and balance exercises and 10 minutes of pelvic floor muscles training.
24395|NCT03997032|Dietary Supplement|Ocufolin|Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
24396|NCT03997019|Procedure|opioid analgesia|opioid analgesia will be used with general anaesthesia
24397|NCT03997019|Procedure|ESP block|ultrasound guided ESP Block before anaesthesia induction
24398|NCT03997006|Drug|Oral Theophylline Anhydrous Tablet|Oral theophylline anhydrous tablet (150 mg/12h)
24399|NCT03997006|Drug|IV Neostigmine Methylsulfate + Atropine Sulphate|IV Neostigmine/Atropine mixture (20 μg/kg Neostigmine + 10 μg/kg Atropine)/12h
24400|NCT03996993|Drug|Casodex, Axumin|Patients will receive hormone therapy if Axumin positive area appears.
24401|NCT03996993|Radiation|Salvage Radiation, Axumin|Patients will receive salvage radiation therapy if Axumin positive area appears.
24402|NCT03996980|Device|Custom-made foot orthoses Versus a flat insole|Compare the use of plantar orthoses (experimental group) with the use of a flat insoles (control group)
24403|NCT03996954|Device|Alivecor recording|Alivecor recording and ECG recording from the same patient in very close temporal proximity
24404|NCT03996941|Behavioral|Harm reduction of informal PrEP use|"Users attending the study center interested in PrEP use , as well as those who could benefit from it are invited to attend an information session in which issues are touched like the effectiveness and safety of PrEP, and the characteristics of the SeguiPrEP program. This program consists of periodic clinical controls (five during the first year and four in the following period) that include: physical examination, HIV and other STI screening, control of renal functions, estimation and promotion of PrEP adherence, monitoring of adverse events associated with PrEP and counseling.~Those who decide to use PrEP or who are already using PrEP are asked to schedule an initiation visit."
24405|NCT03996941|Other|PrEP follow up based on point of care testing|The study center has a point-of-care technology based laboratory, which allows obtaining immediate results in order to reduce the loss of follow-up.
24406|NCT03996928|Other|Exercise|
24407|NCT03996915|Device|Pdt Photodynamic Therapy|device irradiation with low intensity laser (wave length = 660 nm) 9 J (Joules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated.
24408|NCT03996915|Other|tongue scrapper|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
24409|NCT03996902|Behavioral|Tailored intervention|Brief motivational smoking intervention tailored to address smoking in the context of pain. Included a novel pain-smoking psycho education component, personalized feedback component, and elicitation of participant's pain-related goals to develop discrepancy between continued smoking and desired pain outcomes.
24410|NCT03996902|Behavioral|Ask-Advise-Refer|The Ask-Advise-Refer intervention is commonly used in standard clinical practice.
24411|NCT03996889|Device|Endovascular treatment of aneurysms of the popliteal artery by GORE VIABAHN® stent in elective surgery|"The intervention can be performed under local anesthesia (LA), regional locus (ALR) or general anesthesia (AG) (data collected) by first approach: percutaneous or conventional.~The data collected are:~Number of GORE VIABAHN® stent used (length and diameter of each)~Embolization of collaterals and other related actions~Operative complications~Intraoperative fibrinolysis~Collar cover> 2 cm~Lack of overlap in the overlap zone (nb: between 4 and 8 cm above the joint spacing)~Arteriography in profile, kink"
24412|NCT03996876|Device|Threat ABM Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iPhone Operating System (iOS) compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user."
24413|NCT03996876|Device|Neutral Attention Training|This app will be a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
24414|NCT03996863|Device|Otoband|Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
24415|NCT03996863|Device|Placebo device|Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
24416|NCT03996850|Procedure|Computed Tomography|Undergo SPECT/CT
24417|NCT03996850|Other|Questionnaire Administration|Ancillary studies
24418|NCT03996850|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
24419|NCT03996850|Radiation|Technetium Tc-99m Sestamibi|Given IV
24425|NCT03996785|Behavioral|Walking in nature setting|Walking for 60 minutes as described above
24430|NCT03996759|Diagnostic Test|Laboratory diagnostic medicine|Metabolomic profiling and laboratory diagnosis including blood routine examination, liver function, renal function, myocardial enzyme, coagulation, arterial blood gas analysis, C-reactive protein, procalcitonin, B-type natriuretic peptide, myoglobin, lipopolysaccharide, cytokines (TNF-α, IL-1β, IL-6, etc.), immune cell markers (CD3+, CD4+, CD8+, etc.), and stool routine as well as intestinal microecology analysis.
24431|NCT03996746|Diagnostic Test|No intervention|No intervention
24432|NCT03996733|Other|Lecture|Principal investigator of the study will lecture about the ultrasound guided jugular central venous catheterization according to latest guidelines.
24433|NCT03996733|Other|Demo Video|Investigators of the study prepared a detailed demo-video showing insertion of a jugular central venous catheter with USG guidance. Principal investigator will vocalize the video in real-time.
24434|NCT03996733|Other|UltrasoundImaging|Participants will exercise the proper visualisation of the right jugular vein at T6 level with USG guidance on a human subject.
24435|NCT03996733|Other|ModelTraining|"Participants will exercise the proper punction of juguler vein with USG guidance on the homemade jugular venous catheterization training model.~Training model will include carotid artery, trachea and plaure in accordance with the real anatomy."
24436|NCT03996707|Other|Weight Bearing|Immediate protected weight bearing in a CAM walking boot following foot & ankle surgery
24437|NCT03996707|Other|Strict non-weight bearing|Strict non weight bearing for 6 weeks following foot & ankle surgery
24438|NCT03996694|Drug|Belbuca 300 µg|Belbuca 300 µg buccal film
24439|NCT03996694|Drug|Belbuca 600 µg|Belbuca 600 µg buccal film
24440|NCT03996694|Drug|Belbuca 900 µg|Belbuca 900 µg buccal film
24441|NCT03996694|Drug|Oxycodone 30 mg|Oxycodone 30 mg capsule
24442|NCT03996694|Drug|Oxycodone 60 mg|Oxycodone 60 mg capsule
24443|NCT03996694|Drug|Placebo|placebo buccal film and oral placebo
24444|NCT03996681|Drug|methylcantharidimide tablets|"Drug: methylcantharidimide tablets~Methylcantharidimide is a single molecule drug used for the treatment of primary liver cancer.~Procedure: TACE~Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor."
24445|NCT03996668|Other|Thigh High Compression Stockings|Thigh high compression stockings will be placed after induction of anesthesia and intubation.
24446|NCT03996655|Drug|Sugammadex Injection [Bridion]|Reversal of neuromuscular blockers
24447|NCT03996655|Drug|Neostigmine|Reversal of neuromuscular blockers
24448|NCT03996642|Behavioral|Avatar Life Review|VoicingHan will screen-capture patient's storytelling performances as video files. Immediately before the first intervention, patients will complete an array of self-reported questionnaires to assess physical, spiritual, and psychological well-being and elicit relevant demographic and medical information. The assessments include the ESAS, FACIT-Sp subscale, and EORTC PAL 15. Subsequent administration of these questionnaires spaced 2-4 weeks apart will occur before each avatar session (pre-intervention). This will determine if intensity of the patient's symptoms have changed over the course of the intervention. Following completion of the Avatar session, a member of the research team will conduct a semi-structured, open-ended interview to assess patients' perception of intervention components and identify possible factors influencing intervention feasibility and any technical barriers.
24449|NCT03996629|Other|Patient education and compliance|When the patient is enrolled in the intervention group, pharmacists provide medical education about the pathophysiology, medications, lifestyle, how to prevent, recognize and take care of bleeding events, etc. Establish a medical record for every follow-up examination and remind follow-ups by message, phone every month.
24450|NCT03996616|Device|Assigned Intervention|"Patients will be treated with manual standard CPR ASAP upon arrival of EMS first responders, transferred to Elegard device as soon as possible, and then treated with HUP and ACD+ITD CPR using the LUCAS AD and ResQPOD-16.~Rescuers will perform CPR as continuously as possible during the placement of the Elegard, with a <10 second pause in chest compressions during the placement of this device. This is similar to the manner in which the LUCAS compressor and back plate are placed at the present time. After performing LUCAS AD + ITD CPR for 2 minutes with the head in the 'flat' position, the Elegard device will be turned on and the head will begin to rise as long as the patient is being treated with the ResQPOD-16 and the LUCAS AD. The head will be elevated to approximately 22 cm from the ground to the back of the occiput."
24451|NCT03996603|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 8 weeks
24452|NCT03996577|Drug|Lidocaine|the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
24453|NCT03996577|Drug|placebo|the control group will be given the same volume of saline.
24454|NCT03996564|Device|Battlefield Acupuncture|1-10 needles inserted in systematic nature as described by Battlefield acupuncture protocol.
24455|NCT03996564|Drug|Acetaminophen|Acetaminophen 500mg-1000mg,
24456|NCT03996564|Drug|Diclofenac|Diclofenac 50mg-75 mg orally
24457|NCT03996564|Drug|Diazepam|Diazepam 5mg-10 mg intravenous or oral
24458|NCT03996564|Drug|Hydrocodone|Hydrocodone 5mg/325mg-10mg/650mg mg
24459|NCT03996564|Drug|Ketorolac|oral, or intramuscular Ketorolac 30mg-60 mg
24460|NCT03996551|Behavioral|ExeRTiOn online resource|This is a 12-week online resource, specifically designed for new kidney transplant recipients. It includes dietary advice, physical activity advice, and recognized behavior change techniques. The participant will be monitored by a specialist physiotherapist and will receive messages of encouragement a 6 weeks and 12 weeks.
24461|NCT03996538|Drug|Metformin Hydrochloride Extended-Release Tablets|Subjects will ingest 1500mg/day of metformin hydrochloride extended release. Immune responses will be examined prior to treatment, prior to flu vaccination, and after flu vaccination.
24462|NCT03996538|Biological|Influenza Vaccine|All subjects will be vaccinated with high-dose influenza vaccine at the appropriate time of the year per current CDC and FDA recommendations
24463|NCT03996525|Device|Electrical Stimulation|"Two-Stage Facial Reanimation (Standard Practice) with electrical stimulation for one hour at 20Hz (Experimental Procedure).~Cross-Facial Nerve Graft (CFNG) immediately followed by electrical nerve stimulation proximal to the coaptation site on the donor facial nerve.~Nine-to-Twelve Months later, Free Muscle Transfer (FMT) followed by electrical nerve stimulation proximal to the coaptation site in the intraoral incision."
24464|NCT03996525|Device|Sham Treatment|"Two-Stage Facial Reanimation (Standard Practice) with sham electrical stimulation for one hour (Placebo).~Cross-Facial Nerve Graft (CFNG) followed by placement of unelectrified electrodes proximal to the coaptation site on the donor facial nerve.~Free Muscle Transfer (FMT) followed by placement of unelectrified electrodes proximal to the coaptation site in the intraoral incision."
24465|NCT03996512|Other|Early Active Controlled Motion (EACM)|Early active controlled wrist motion rehab protocol using that will allow midcarpal row motion.
24466|NCT03996499|Diagnostic Test|Stress echocardiography|"The course of the examination corresponds to the welcome of the patient, the search for contraindications and the performance of the stress ultrasound. During this stress ultrasound, the 3 indices (segmental kinetics, coronary reserve and myocardial perfusion) will be analyzed. The duration of the ultrasound is not lengthened (examination time: 20 minutes).~The evaluation of the myocardial perfusion is carried out thanks to the use of the flash, modality not being part of the usual care.~Indeed, during the examination, the power of the probe will be increased to evaluate the myocardial perfusion. The bubbles of the contrast medium are destroyed by applying a flash, that is to say a transient increase in the power of the ultrasonic beam. Systole after systole, on a recorded loop, the filling rate of the myocardium, which depends on the myocardial blood flow, is analyzed. The evaluation of the infusion is visual and qualitative."
24467|NCT03996486|Drug|BAY1093884|Drug administered via subcutaneous injections once weekly for 6 weeks (= 6 doses)
24468|NCT03996473|Drug|Radium-223 dichloride (Xofigo, BAY 88-8223)|Intravenous (IV) injection, every 6 weeks for up to 6 administrations
24469|NCT03996473|Drug|Pembrolizumab|IV infusion, every 3 weeks for a maximum of up to 35 administrations
24470|NCT03996460|Drug|Placebo oral capsule|"Fifteen (15) patients in group 1 will receive the matching placebo (sugar pill) eight (8) capsule orally daily for 12 weeks (90 days) without food."
24471|NCT03996460|Drug|96 mg of K0706|Fifteen (15) patients in group 2 will receive the 96 mg of K0706 (4 x 24 mg of K0706) orally and four placebo capsules daily for 12 weeks (90 days) without food.
24472|NCT03996460|Drug|192 mg K0706|Fifteen (15) patients in group 3 will receive the 192 mg of K0706 (8 x 24 mg of K0706) orally daily for 12 weeks (90 days) without food.
24473|NCT03996447|Drug|gadopiclenol|single intravenous (IV) bolus injection at a rate of 2ml/second
24474|NCT03996447|Drug|Gadobutrol 1Mmol/mL Solution for Injection Vial|single intravenous (IV) bolus injection at a rate of 2ml/second
24475|NCT03996434|Drug|Gonadotropin|withholding gonadotropin administration for at least 24 hours
24476|NCT03996434|Drug|Antagonist|Cetrorelix acetate 0.25 mg
24477|NCT03996421|Dietary Supplement|nutritional iron (14 mg) supplement in form of ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
24478|NCT03996421|Dietary Supplement|ferrous fumarate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
24479|NCT03996408|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
24480|NCT03996408|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
24481|NCT03996382|Diagnostic Test|DPD Scintigraphy|Confirms/Refutes diagnosis of cardiac amyloidosis.
24482|NCT03996369|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period
24483|NCT03996369|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period
24484|NCT03996356|Other|No study intervention - observational study|This is an observational study where the comparative groups will be determined by the genetic variants (SNPs) of subjects and not an intervention, per se.
24485|NCT03996343|Device|Endotracheal intubation|COMPLETE
24486|NCT03996343|Device|Laryngeal mask airway|COMPLETE
24487|NCT03996330|Diagnostic Test|taqman array card|The array card contains multiple PCR reactions for microbial pathogens, extracted microbial nuclear material from lavage or blood is run on the card to detect pathogen specific sequences by polymerase chain reaction.
24488|NCT03996317|Other|Room air|Avoidance of hyperoxygenation
24489|NCT03996291|Drug|SAR442168|Pharmaceutical form: Film coated tablet Route of administration: Oral
24490|NCT03996278|Other|Grafalon|None interventional study but there are two groups
24491|NCT03996265|Drug|Bupropion Hydrochloride Controlled-release|Given PO
24492|NCT03996265|Other|Placebo|Given PO
24493|NCT03996265|Other|Quality-of-Life Assessment|Ancillary studies
24494|NCT03996265|Other|Questionnaire Administration|Ancillary studies
24495|NCT03996252|Drug|Calcipotriene 0.005% Foam|Application of calcipotriene foam in conjunction with generic efudex cream to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
24496|NCT03996252|Drug|Efudex 5% Topical Cream|Application of generic efudex cream in conjunction with calcipotriene foam to the scalp for four consecutive nights for the treatment of scalp actinic keratoses
24497|NCT03996239|Behavioral|exercise (walking)|Exercise treatment will consist of individualized walking delivered up to 5 times weekly. This trial will evaluate one dose of exercise (i.e., ~300 mins/wk following a non-linear dosing schedule) in both cohorts. Patients will have the option to receive exercise treatment at MSK or at their residence. Home-based exercise will be implemented and monitored using a telemedicine approach (i.e.,TeleEx) established in the Exercise-Oncology (ExOnc) Service
24498|NCT03996239|Other|plasma samples|Plasma samples will be obtained at baseline.
24499|NCT03996239|Other|blood draw|fasting blood
24500|NCT03996226|Drug|E7386|E7386 oral tablets.
24501|NCT03996213|Other|head down position|Head-down position will be achieved by 30 degrees tilting of the whole operating table 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
24502|NCT03996213|Other|leg elevation position|Leg elevation position will be achieved by raising the patient legs for 30 cm using two standard pillows positioned under the heels 1-minute before induction of anesthesia. The position will be maintained for 15 minutes after induction of anesthesia
24764|NCT03993951|Device|ICT System|Update the Information and Communications Technology System in Family Service Agencies
24503|NCT03996200|Device|MINIject CS627 implant|"MINI SO627 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant (CS627) and a single operator delivery tool.~The delivery tool is a single-use tool, designed for inserting the CS627 implant into the suprachoroidal space in the eye."
24504|NCT03996174|Other|Interview|Interview bases on the use of an interview guide, during one hour maximum
24505|NCT03996161|Other|patient position|After the induction of anesthesia, mask ventilation is performed in the supine and semi-sitting position in a cross-over, randomized order.
24506|NCT03996148|Drug|Remifentanil, Propofol, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Propofol - titratable; initial starting dose 75 mcg/kg/min Desflurane 0.5 MAC
24507|NCT03996148|Drug|Remifentanil, Dexmedetomidine, and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Dexmedetomidine - titratable; initial starting dose 0.5 mcg/kg/hr Desflurane 0.5 MAC
24508|NCT03996148|Drug|Remifentanil and Desflurane|Remifentanil - titratable; initial starting dose 0.05 mcg/kg/min Desflurane - titratable
24509|NCT03996135|Device|Cannulation with AccuVein AV400|Cannulation using AccuVein AV400 device
24510|NCT03996122|Other|fMRI|3 fMRI (TO, Month 2 and Month 6) 3 BDNF samples (TO, Month 2 and Month 6)
24511|NCT03996109|Behavioral|Aim2Be smartphone app system|Youth-parent dyads will receive the LiGHT program (addressing healthy eating, physical activity, screen time and sleep) via the Aim2Be smartphone app for 1 year. It provides personalization beginning with creation of an avatar and identifying user motivations, offers progressive goal-setting considering readiness, sub-tasks, milestones, self-monitoring tools with feedback and positive reinforcement. It applies behaviour change techniques, provides a knowledge centre, simulation narratives to enable decision making, and separate social exchange platforms for parents and youth to share ideas and challenges with peers. A Virtual Coach has been programmed using motivational interviewing theory. Gamification includes elements of choice, challenge, uncertainty, discovery, and kudos for achieving outcomes in the process of developing motivations, skills and mastery.
24512|NCT03996109|Behavioral|BnLt smartphone app|Youth-parent dyads will receive a simple app called BnLt for 1 year. It provides web-links to external websites that provide information and tips on healthy eating and activity, including the Canada Food Guide, Canadian Society of Exercise Physiology recommendations for physical activity, screen time and sleep for youth, and other resources.
24513|NCT03996083|Other|Multicomponent exercise intervention|"Strength exercises were focused on lower limb strengthening. Individual bilateral intensities were calculated to estimate one repetition maximum (1-RM) for the leg and arm. This test was performed on the 2nd and 7th weeks of the intervention. A gradual and progressive intensity starting at 40% 1-RM and up 70% 1-RM was used. No external loads were applied to the rest of the exercises due to their complex execution technique and subsequent risk of adverse events. In these cases, training progression was achieved through volume (number of repetitions) and execution velocity increments.~Balance exercises included standing with their feet together, semi-tandem, tandem and one-legged stand positions and moving on to dynamic exercises (circuits, stepping and so on). Difficulty was increased by reducing arm and base support and by varying the type and complexity of exercises. An individualized progression was applied to each participant based on their progress throughout the intervention."
24514|NCT03996083|Other|Walking intervention|"To comply with the walking goals, walking distance was calculated based on each participant´s performance on the 6-minute walking test and using a rule of thumb. Therefore, every participant had an itinerary to follow to comply with the minimum walking time each week. Distance rather than time was used with participants for practical reasons and the inability of most of them to measure time. Moreover, time and distance were individually adapted according to each participant´s performance on the previous week.~To ensure that participants complied with the walking goals, each of them (if they were cognitively able) was given a record sheet in which they had to write down their everyday walking routines. In addition, the caregivers were also informed about the walking routines and ensured that those participants who needed close supervision had someone to walk with and filled the sheet of those that were unable to do so."
24515|NCT03996070|Procedure|Laser therapy|Erbium YAG laser
24516|NCT03996057|Drug|Methenamine Hippurate 1000 MG|Discussed in arm/group description
24517|NCT03996057|Drug|Vaginal estrogen|Any form of low dose vaginal estrogen, whether ring, cream, tablet, or capsule. Depends on what patient is already using.
24518|NCT03996057|Dietary Supplement|D-mannose|Powder or tablet, depending on what patient is already using.
24519|NCT03996044|Other|Teeth brushing and flossing|All participants will be instructed to brush with dentifrice containing amine fluoride in their composition (Elmex®) and floss with dental flossing, 3 times a day after meals for 30 days.
24520|NCT03996044|Other|Tongue scraping|Tongue scraping will be performed by the same operator on all participants. Posterior-anterior movements will be performed with the scraper over the tongue dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
24521|NCT03996044|Radiation|Antimicrobial Photodynamic Therapy (aPDT)|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
24522|NCT03996044|Biological|Probiotics|Pharmacy-manipulated capsules containing strains of Lactobacillus salivarius WB21 (6.7 x 108 CFU) and xylitol (280mg) will be used. Forty-two capsules will be delivered for each patient, who should take 1 capsule 3 times a day after meals for 14 days.
24523|NCT03996031|Device|Plan to Thrive smartphone application|All participants in this single-arm pilot study will receive access to Plan to Thrive. This mobile care management program is comprised of modules including educational interventions, health behavior trackers containing built-in reminders, symptom monitoring, and navigator services (see attached content). Access to intervention modules and individualized navigator services according to patients' needs as captured by 1) their patient-reported outcome (PRO) assessments via Plan to Thrive's symptom monitoring feature, and 2) patient requests.
24524|NCT03996018|Other|T-cell lymphocyte responses|T-cell lymphocyte responses to human immunodeficiency virus (HIV) with and without concomitant herpesvirus infections (specifically, the persistence of HIV-specific human CD8 T-cells in the context of antiretroviral therapy (ART).
24525|NCT03996005|Procedure|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue|Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue
24526|NCT03995992|Behavioral|sport|10 days of sport (diving or multisport), once training per day
24527|NCT03995979|Other|4 Day Protein Restricted Diet|Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
24528|NCT03995966|Behavioral|Noncontingent Reinforcement (NCR)|This treatment for ASIB is based on reinforcer competition. Noncontingent Reinforcement (NCR) will consist of first conducting a competing stimulus assessment (CSA) to identify stimuli (toys, massagers, etc.) associated with reductions in ASIB and high levels of engagement. Treatment then involves NCR in which alternative sources of reinforcement are made freely available to compete with reinforcement maintaining ASIB. Providing additional sources of reinforcement is thought to decrease ASIB by producing a shift in the allocation of responding toward accessing the newly available reinforcement. Additional, more restrictive components may be added if the competing stimuli (CS) are ineffective in reducing ASIB. These additional components are applied in accordance to the least-restrictive treatment model and include response blocking, response reduction procedures, protective equipment, or mechanical restraint.
24529|NCT03995966|Behavioral|Combination Treatment|Combination Treatment is based on the same principles as NCR, but differs in three ways: 1) It includes three pre-treatment assessments that seek to establish competing stimuli, tasks, and self-control equipment through prompting and reinforcement; ; 2) Intensive training in each of these components is conducted to strengthen skills needed to fully access available reinforcement to compete with ASIB; and 3) Combination treatment is assessed, which includes the noncontingent delivery of competing stimuli and differential reinforcement of alternative behavior to reinforce engagement with competing tasks, and use of alternative self-control equipment. This will increase the amount and vary the sources of alternative reinforcement to more effectively reduce ASIB and self-restraint. Restrictive components may be applied as described for the NCR treatment.
24530|NCT03995953|Behavioral|SHIELD intervention (Support for HIV Integrated Education, Linkages to care, and Destigmatization)|The SHIELD intervention includes a three-session, six-module program for AGYW that increases knowledge, skills, and self-efficacy to engage along the HIV prevention and care continuum, and a two-session, four-module program for family members to increase social support. In addition, the SHIELD intervention includes youth clubs to foster peer support.
24531|NCT03995953|Other|Integrated wellness care (IWC) clinics|IWC clinics will be created within health facilities where AGYWs can receive sexual and reproductive health services, including HIV testing and treatment, family planning, sexually transmitted disease screening and treatment, and HPV vaccination in a youth-friendly environment.
24532|NCT03995927|Other|Data collection and analysis|Only radiation oncology patients data from medical records regarding treatment, demographics and follow-up visits will be collected and logged by investigators.
24533|NCT03995927|Other|Quality of Life Questionnaire|Participants will be asked to complete a set of short forms at first visit and post-treatment visits. If participant has a routine visit about 3 months after treatment, participant will be asked to complete a final form that is optional.
24535|NCT03995888|Drug|rhPSMA-7.3 (18F) Injection|Radioligand for PET CT scanning
24536|NCT03995862|Other|Questionnaire|A questionnaire should be completed by the patient the day of inclusion. Health data will be collected in patients medical file from inclusion to the date of the end of study (i.e. no follow-up for the last patient included and a maximum of three years of follow-up for the first patient included).
24537|NCT03995849|Diagnostic Test|Cone Beam CT Scan|In this study, children will receive one CBCT scan before starting RT as part of standard approach. Then after RT, another CBCT scan will be used to measure movement between the beginning and end of RT.
24538|NCT03995836|Device|CPAP|Decision of CPAP treatment is according to clinical guidelines
24539|NCT03995836|Procedure|Bariatric Surgery|All patients.
24540|NCT03995810|Dietary Supplement|Carnosine, capsulle, 2 g/day, 8 weeks|We will administer supplemental carnosine (2 grams per day) for 8 weeks
24541|NCT03995797|Procedure|Laser therapy|Erbium YAG laser
24544|NCT03995771|Other|Questionnaire delivery|A questionnaire including questions regarding prognostic factors for knee pain will be delivered to children and adolescents (8-19 years old) presenting to general practice with knee pain
24545|NCT03995758|Device|MOSES|software based modulation of the laser energy delivered from the homium laser source. The software changes the pulsed laser to have two peaks of energy - one to displace water in front of the stone and a second to deliver the laser energy to the stone
24546|NCT03995745|Behavioral|Medication adherence and financial incentives|Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.
24547|NCT03995732|Drug|PC-SOD|PC-SOD will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
24548|NCT03995732|Drug|placebo|Placebo will be dissolved in 10 mL of 5% glucose injection and intravenously administrated before recanalization.
24549|NCT03995719|Other|Preoperative education|65 patients were instructed to a preoperative stoma-education program
24550|NCT03995719|Other|Postoperative education|73 patients, receiving the same information in postoperative period.
47319|NCT03814135|Other|Hipnos 3 Placebo|1 tablet, oral, once a day.
24551|NCT03995706|Drug|Sacituzumab Govitecan|All 20 subjects will receive study drug Sacituzumab Govitecan preoperatively. Intraoperative tissue collection will follow with contemporaneous CSF (depending on tumor location) and whole blood (serum) sampling. Samples will be tested for total SN-38and free SN-38, as well as SN-38G. Following recovery from surgery, patients will resume treatment
24552|NCT03995693|Dietary Supplement|Solution ingestion|Two ingestion modalities will be attributed (participant is blinded) in random order: a placebo and a glucose solution. The placebo contains water and a non-caloric sweetener (stevia) in order to reproduce the taste of the glucose solution. The glucose solution contains 6% glucose per volume, labelled with 13C. Both solutions will be administered in 8 doses: a bolus (333 mL) at rest, 30 minutes before the start of exercise, 167 mL immediately before exercise, 167 mL every 15 minutes during arm cranking, 125 mL immediately before concentric or eccentric pedalling and at 15 and 25 minutes of this last exercise period. In total, 1250 mL of solution will be administered during the experimental protocol.
24553|NCT03995693|Behavioral|Constant load arm cranking|The participants will perform 45 minutes of arm cranking on a specialized ergometer at a power output corresponding to 30% of their concentric cycling VO2max, previously measured.
24554|NCT03995693|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution.
24555|NCT03995693|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution.
24556|NCT03995693|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain vein open. 10 mL of blood will be collected immediately before ingesting the solution for a total of 80 mL.
24557|NCT03995693|Behavioral|Measure of maximal voluntary contraction force production|Maximal voluntary bilateral knee extensions (3 trials of 3-4 seconds each) will be performed on a chair equipped with force sensors to measure peak force production. These measurements will be done before the first ingestion, immediately before exercise, during the transition between arm cranking and concentric or eccentric cycling, and at the end of the exercise protocol.
24558|NCT03995693|Diagnostic Test|Measure of muscle electrical activity (EMG)|Surface electrodes will be placed on the biceps and quadriceps to measure EMG throughout the exercise protocol.
24559|NCT03995693|Diagnostic Test|Measure of central and cutaneous temperatures|Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
24560|NCT03995693|Diagnostic Test|Measure of perceived exertion, pain perception and affective response|"100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale."
24561|NCT03995693|Procedure|Measure of sweat and urine production|Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
24562|NCT03995680|Drug|Mebendazole|Treatment with one of the two formulations of mebendazole. The only difference between both arms is the type of formulation of the drug: chewable versus swallowable tablet.
24563|NCT03995667|Device|Optune®-Tumor Treating Fields (TTFields)|Transducer arrays affixed to scalp, worn continuously.
24564|NCT03995641|Drug|marcaine and kenalog|Trigger point injection (consisting of 9 cc 0.5% Marcaine and 1 cc kenalog) may be given at time of surgery if patient is randomized to receive the injection
24565|NCT03995628|Drug|Dexamethasone|One dose of dexamethasone (0.5 mg/kg) on post-operative day 3 after tonsillectomy
24566|NCT03995615|Procedure|scaling and root planing|"After initial clinical evaluation, supra gingival calculus removal will be done. GCF samples will be collected from the control and test groups (Baseline samples) using paper strips (ORAFLOW). ® Group III patients will undergo a through oral hygiene instructions, full mouth supra-gingival and sub- gingival scaling and root planing clinical parameters will be re-recorded 6 weeks later and a 2nd GCF samples will be collected from selected test site from each patients following periodontal intervention.~All the samples will be placed in eppendorf vials containing the buffer solution and samples will be stored at -800 c until the time of analysis by Enzyme -linked immune sorbent assay kit (ELISA) (GENX BIO) TM"
24567|NCT03995602|Dietary Supplement|Dragon fruit juice drink|Dragon fruit drink containing 24 g of freeze-dried dragon fruit powder dissolved in low nitrate water.
24568|NCT03995602|Dietary Supplement|Placebo|Drink with macro- and micro-nutrient matched against the intervention drink.
24569|NCT03995589|Other|Walking|Technology-guided semi-supervised walking therapy
24570|NCT03995589|Other|Control|Go Home and Walk advice
24571|NCT03995576|Other|thoracic sympathetic ganglion block|thoracic sympathetic ganglion block which needle reaches posterolateral vertebral body
24572|NCT03995563|Drug|Dexamethasone|"Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~."
24573|NCT03995563|Drug|Ropivacaine|Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
24574|NCT03995550|Drug|LEO 142397|A compound in development by LEO Pharma A/S
24575|NCT03995550|Drug|Placebo|Placebo
24576|NCT03995537|Biological|blood sample|"Samples will be collected at the inclusion and repeated if necessary before LT, including one 4 mL EDTA sample and one 9 mL EDTA sample, allowing the HLA-DR assay to be performed with also plasma aliquots and messenger RNAs.~Same samples will also be collected :~between inclusion and LT in case of major clinical change~at day 1 after LT~2 times a week after the LT for a maximum of 1 month~Biological data will be collected at those different times."
30202|NCT03950154|Drug|Bevacizumab Injection [Avastin]|Bevacizumab injection
24577|NCT03995511|Procedure|Bilateral Sagittal Split Osteotomy|Surgical correction of lower jaw deformity by performing bilateral intraoral sagittal osteotomy of the mandible under general anesthesia.
24578|NCT03995498|Other|Physical activity|Participants will engage in team sports exercise twice a day: from 9h:30 to 10h:30 and from 11h:00 to 12h:00.
24579|NCT03995498|Other|FreeStyle Libre|Glucose levels will be measured by the FreeStyle Libre
24580|NCT03995498|Other|SenseWear Armband|Energy expenditure during physical activity sessions will be measured with the SenseWear Armband.
24581|NCT03995485|Drug|KW-136 capsule|KW-136 60 mg was provided in a single capsule of 60 mg.
24582|NCT03995485|Drug|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
24583|NCT03995472|Drug|SHR-1501|Administered subcutaneously
24584|NCT03995472|Drug|SHR-1316|Administered intravenously
24585|NCT03995446|Device|low-level laser|low level laser emission on specific acupuncture points
24586|NCT03995446|Device|Sham laser|Sham laser
24587|NCT03995420|Behavioral|Virtual Reality Therapy (V-NeST)|V-NeST is a 12-session therapy using psychological intervention principles based on Cognitive Remediation and CBT partly based in Virtual Reality.
24588|NCT03995420|Other|Treatment as Usual|multi-modal treatment consisting of different therapies defined by the treating team. These will include regular contact with a care coordinator and medication management by a psychiatrist.
24589|NCT03995407|Dietary Supplement|Peptamen®|Participants in the intervention arm will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements. Those who are not currently taking oral nutritional supplement will be started on Peptamen® while those who are currently on oral nutritional supplements will have to convert to Peptamen® solely. The dietician will determine the amount of Peptamen® required per day based on the recommendations of the product information. Should the participant's daily protein requirement not be met be Peptamen® alone, the dietician will recommend additional whey protein to be added in the form of Beneprotein® Instant Protein Powder. Beneprotein® is a concentrated source of high-quality whey protein that can be added to most foods, liquids or enteral formulas.
24590|NCT03995407|Other|Usual Care|"Participants receive usual care. They will be categorised into those who are not currently taking oral nutritional supplement and those who are currently on oral nutritional supplements (non-100% whey i.e. not on Peptamen® or Beneprotein®). They will consume their regular diet in accordance with the dietician's recommendations."
24591|NCT03995394|Other|Positive Reinforcement Text Message|"A text message comprising the words, Great job! We're so proud of you! Keep up the good work!"
24592|NCT03995381|Other|Decision aids|Shared decision making with decision aids
24593|NCT03995368|Other|Electroencephalography|The investigators will use EEG combined with measures of cognition and clinical interviews to explore connections between these measures and electrical activity in the brain in Veterans with a diagnosis of schizophrenia or TBI, and healthy controls.
24594|NCT03995342|Dietary Supplement|Inulin|Inulin 15 grams after dissolution by mouth， every morning for three months.
24595|NCT03995342|Dietary Supplement|Maltodextrin|Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution
24596|NCT03995329|Other|IQOS|Acute effects of IQOS on pulmonary function, oxygen saturation, exhaled CO, heart rate and arterial blood pressure.
24597|NCT03995316|Behavioral|Treatment As Usual + MMB 2.0|Women assigned to use MMB 2.0, along with NorthShore's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
24598|NCT03995316|Behavioral|Treatment As Usual Only|NorthShore's treatment as usual, or usual care, has been in place since 2003. Screen positive women randomized to this condition will receive social work assessment by phone, followed by community mental health referral as indicated. Referrals will vary by need and may include psychotherapy, support groups, or psychiatry. Referrals will include consideration of geographic proximity, insurance, and acuity. Consistent with routine practice, NorthShore staff will document time spent during evaluation and in making specific referrals.
24599|NCT03995303|Other|NCP and home-delivered meals|The dietitian (Ph.D. student) will perform an individual nutritional assessment focusing on dietary intake, activity level and weight of each participant, as a basis for developing an individualized nutrition care plan consistent with estimated nutritional requirements and nutritional rehabilitation goals. Total fluid, energy- and protein requirements will be estimated for each patient. Giving the group free food to fulfill protein-and energy needs.
24600|NCT03995290|Other|3D Hip Model from Pre-operative CT scan|A printed 3D model will be created based off of the patient's standard of care preoperative CT scan.
24601|NCT03995277|Dietary Supplement|Biotin|Daily intake of 10 mg
24602|NCT03995264|Procedure|Ultrasound -guided cannulation|radial artery cannulation using the ultrasound
24603|NCT03995264|Procedure|Palpation -guided cannulation|radial artery cannulation using the palpation
24604|NCT03995251|Drug|Testosterone Supplementation|Intramuscular Testosterone Undecanoate 1000 Mg (4 ml volume in oily base) will be injected into the upper, outer quadrant of the buttock at 0, 6, 12,16,20, 24 weeks according to manufacturer recommendations
24605|NCT03995251|Drug|Standard Medical Treatment|Standard Medical Treatment
24606|NCT03995251|Other|Exercise|Exercise
24607|NCT03995238|Behavioral|Error-augmentation gait training|Split-belt treadmill training to enhance between-limb asymmetry during treadmill walking, which is intended to force compensation and correction of step asymmetry during treadmill walking. The error-augmentation gait training program is delivered in 8 sessions over 4 weeks.
24767|NCT03993912|Drug|Lenalidomide PO (25mg)|Lenalidomide PO (25mg): days 1 through 21 of each 28-day cycle, until progression
24608|NCT03995238|Behavioral|Error-correction gait training|Metronome will be set to cue participants to overcorrect between-limb step asymmetry during treadmill walking, through use of asymmetrical metronome tones in a 2:1 ratio. The error-correction gait training program is delivered in 8 sessions over 4 weeks.
24609|NCT03995238|Behavioral|Supervised walking|An active comparator intervention, in which a supervised treadmill walking program is delivered without attempt to correct step asymmetry. The supervised walking program is delivered in 8 sessions over 4 weeks.
24610|NCT03995225|Behavioral|Smartband automatic smoking detection and brief mindfulness interventions|Smartband/smartphone based automatic smoking monitoring, notification and real-time brief mindfulness interventions
24613|NCT03995186|Behavioral|Behavioural activation|4-week programme based on the behavioural activation treatment provided in the NHS IAPT services. The programme includes psychoeducation on the relationship between activity and depression, examining the depressed person's level of activity, helping them identify activities they would like to increase and supporting them in the planning and conduct of those activities.
24614|NCT03995186|Behavioral|Activity monitoring|4-week programme where participants simply monitor their general daily activities in a diary.
24615|NCT03995173|Device|repetitive transcranial magnetic stimulation|rTMS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P). The Magventure C-B60 coil will be used to deliver single TMS pulses for motor threshold determination.
24616|NCT03995160|Procedure|Use of closed suction drainage following total knee arthroplasty|Use of closed suction drainage following total knee arthroplasty
24617|NCT03995160|Procedure|Abstain of using a closed suction drainage|Abstain of using a closed suction drainage following total knee arthroplasty
24618|NCT03995147|Drug|Pembrolizumab|"Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks in combination with R-CHOP for 6 cycles.~Participants that respond to the combination regiment will continue to receive pembrolizumab 200 mg IV every 3 weeks for additional 35 cycles (2 years)."
24619|NCT03995147|Drug|R-CHOP Protocol|R-CHOP chemo-immunotherapy will be administered in combination with Pembrolizumab
24620|NCT03995134|Combination Product|Propofol and Remifentanil administered by TCI pump|Propofol, Remifentanil, Alaris PK (pharmacokinetic) infusion pump with TCI
24621|NCT03995121|Radiation|[11C]APP311|It has been shown that [11C]APP311 (aka [11C]UCB-J) displays high specificity and selectivity for the synaptic vesicle protein SV2A. Since this protein is expressed ubiquitously in active synapses, this tracer has the potential to be a general purpose tool for quantitative imaging of synaptic density.
24622|NCT03995108|Drug|Mavorixafor|Mavorixafor provided as four 100 mg capsules.
24623|NCT03995108|Drug|Placebo|Placebo matching to mavorixafor provided as four capsules.
24624|NCT03995095|Other|Therapeutic interview: kibo protocol|The kibo protocol is a therapeutic interview designed to address the spiritual needs of patients at the end of life.
24625|NCT03995082|Other|Patient Reported Outcome Measure Survey result feedback|Patients will receive a graph of their results from the PROM survey each time they complete a survey
24626|NCT03995069|Behavioral|3D|Practice generating grip force to the target shown on the computer screen in 3 dimensions.
24627|NCT03995069|Behavioral|1D|Practice generating grip force to the target shown on the computer screen in 1 dimension.
24628|NCT03995056|Behavioral|high-intensity aerobic interval training|"The intervention group will follow a high-intensity interval training protocol on a cycle ergometer for 2 times per week and 1 time an individualised home workout program to have a total exercise amount of 3 hours.~Leisure time physical activity at baseline as well as during the intervention period will be assessed by Polar Active devices."
24629|NCT03995043|Behavioral|Education|Receive educational SMS (text) messages about contraceptive use and family planning on SRH and access individually tailored educational resources through interactive voice response (IVR) services/system via PREVENT mobile platform.
24630|NCT03995043|Behavioral|Personal Support|Contact with a female business owner within the community (hair saloons, tailors, female clothing stores) act as both a confidential, and non-judgmental resource to answer questions and provide counselling in SRH to study participants.
24631|NCT03995043|Behavioral|Access to contraception|Will be provided by the mobile reproductive health team at contraceptive access points, and, at the health facility partners who will be providing full reproductive health services to program participants and will be the access points for Intra-Uterine Device (IUD) insertion where requested and medically suitable. Results of point of care urine HCG (pregnancy) testing (voluntary at enrollment and mandatory when accessing contraceptive services)
24632|NCT03995030|Diagnostic Test|massively paralleled sequencing|Whole genome sequencing libraries will be generated and sequenced in batches on the Illumina MiSeq. FASTQ files will be demultiplexed and then aligned to microbial genomes using Phylosift.
24633|NCT03995017|Drug|Rucaparib|Rucaparib tablet
24634|NCT03995017|Drug|Ramucirumab|Ramucirumab intravenous solution
24635|NCT03995017|Drug|Nivolumab|Nivolumab intravenous solution
24636|NCT03995004|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.
24637|NCT03995004|Drug|Dexamethasone Sodium Sulphate 4mg/1mL|Dexamethasone is a glucocorticoid commonly used in orthognathic surgery to reduce postoperative facial edema by its potent anti-inflammatory effect
24638|NCT03994991|Device|active TMS|Transcranial magnetic stimulation
24639|NCT03994991|Device|sham TMS|Sham transcranial magnetic stimulation
24640|NCT03994978|Procedure|elective sigmoidectomy|elective sigmoidectomy
24641|NCT03994965|Drug|Pimavanserin 34 milligrams (MG) [Nuplazid]|Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.
24766|NCT03993912|Drug|Daratumumab SC in combination with Lenalidomide|"Daratumumab SC 1800 mg~once every week for 8 weeks~then once every other week for 16 weeks~thereafter once every 4 weeks, until progression"
24642|NCT03994952|Device|Sway Balance Application|Participants complete the modified Balance Error Scoring System as prompted on and iPad mini. It has 5 balance stances, double limb stance, right tandem, left tandem, right single, and left single leg balance for 20 seconds each. This will only be used as measurement, not an intervention.
24643|NCT03994952|Device|Balance Tracking Systems|This is a force platform. Center of pressure data will be measured and recorded while participants are completing the modified Balance Error Scoring System. This will only be used as measurement, not an intervention.
24644|NCT03994939|Behavioral|Families Talking Together (FTT)|FTT is an evidence-based program designed to increase parent-adolescent communication about sex in order to delay sexual debut and prevent negative SRH outcomes in young adolescents (aged 10 to 14). The FTT intervention has been delivered with efficacy in multiple settings, including schools and clinics (Guilamo-Ramos et al., 2011a; Guilamo-Ramos et al., 2011b).
24645|NCT03994926|Device|Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye|Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
24646|NCT03994926|Drug|Cannabis cigarette - 4.0% THC|smoked cannabis 4.0% THC
24647|NCT03994913|Biological|CAR-CD19 T Cells|"The CAR- CD19 T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting CD19.~Fludarabine and Cyclophosphamide are used for lymphodepletion."
24648|NCT03994900|Diagnostic Test|Blood sampling for HbNO assessment|Blood sampling
24649|NCT03994887|Device|Experimental group|EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
24650|NCT03994874|Drug|PolyCore (Polydextrin, L-Carnitine, D-xylitol)|A single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours. Patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
24651|NCT03994874|Drug|Medical therapy including loop diuretic (furosemide) daily dose up to 2.5 mg/kg/day,|During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change.
24652|NCT03994861|Diagnostic Test|Assessment of disability and behavior (by questionnaires)|Assessment of disability and behavior (by questionnaires)
24653|NCT03994848|Behavioral|Spirometry Group|Patients that are provided the incentive spirometer pre-operatively and instructed to use it for 4 cycles of 10 spirometry attempts on the day prior to surgery
24654|NCT03994822|Device|Mechanical Thrombectomy using the pRESET Thrombectomy device|Clot removal using the pRESET Thrombectomy device
24655|NCT03994822|Device|Mechanical Thrombectomy using the Solitaire Revascularization Device|Clot removal using the Solitaire Revascularization Device
24656|NCT03994809|Other|Okada Purifying Therapy|The practitioner raises his/her hand forward towards the recipient with the palm directed toward the recipient. The practitioner uses his/her hands alternately during the administration of Okada Purifying Therapy. The distance between the palm and the body is usually 1-2 feet, with each session typically lasting 30 to 60 minutes.
24657|NCT03994796|Drug|Abemaciclib|Given PO
24658|NCT03994796|Drug|PI3K Inhibitor GDC-0084|Given PO
24659|NCT03994796|Drug|Entrectinib|Given PO
24660|NCT03994783|Drug|Rituximab|2 intravenous infusions of rituximab or approved biosimilar given 14 days +/- 2 days apart.
24661|NCT03994783|Drug|Methylprednisolone|Intravenous infusion of methylprednisolone
24662|NCT03994783|Drug|Intravenous Immunoglobulin|High dose (2 g/kg total) or Low dose (100 mg/kg, n=7)
24663|NCT03994783|Procedure|Plasma Exchange|Blood is removed from the patient and filtered to remove the plasma. Red and white blood cells and platelets are returned to the patient with replacement fluid.
24664|NCT03994770|Diagnostic Test|Balanced Reach Assessment and Training Protocol|Three one-hour training sessions for one week in the Balanced Reach Training Protocol
24665|NCT03994757|Behavioral|MRBI|The activities content is designed according to the children's daily routine and goals. It mainly involves bathing activities, eating activities, dressing activities, game activities, social and communication activities, and according to the needs of parents. In the treatment room, after the therapist and parents discuss the intervention methods and suggestions, they will demonstrate the intervention strategies and methods, and let the parents practice the practice, and the therapist will guide them. After discussing with parents, the therapist will give parents a homework related to children's daily routine, let the parents implement at home, and discuss with parents and record before each intervention.
24666|NCT03994757|Behavioral|Control|Traditional treatment was directly performed for children in the treatment room by the therapist. The activity content was designed according to the children's goals. After each end of treatment, therapist will give parents a homework related to traditional treatments, let the parents perform at home, and know the parents' performance at home and record before each treatment begins.
24667|NCT03994744|Drug|PD-1 inhibitor|Intravenous administration of Sintilimab (1200mg/3weeks)
24668|NCT03994744|Drug|Metformin|"Metformin treatment will be given (day20) 1 week before the second administration of Sintilimab at a dose of 2000 mg daily (1000mg BID).~To reduce GI toxicity, participants start Metformin at 1000 mg daily (500mg am, 500 mg pm) for 1 week."
24669|NCT03994731|Biological|Pegloticase with MTX|Participants will receive MTX during the Tolerability Assessment Period then MTX during the run-in period then pegloticase with MTX for 52 weeks
24670|NCT03994731|Biological|Pegloticase with placebo for MTX|Participants will receive MTX during the Tolerability Assessment Period then placebo for MTX during the run-in period then pegloticase with placebo for MTX for 52 weeks
24671|NCT03994718|Other|Music intervention|The music therapist will work with subjects for up to 60 minutes each session.
24672|NCT03994718|Other|Visual arts intervention|The visual artist will work with subjects for up to 60 minutes each session.
24673|NCT03994718|Other|Creative writing intervention|The creative writer will work with subjects for up to 60 minutes each session.
24674|NCT03994705|Biological|Descartes-11|CAR T-Cells
24675|NCT03994705|Drug|Fludarabine|Pre-conditioning chemotherapy
24676|NCT03994705|Drug|Cyclophosphamide|Pre-conditioning therapy
24677|NCT03994692|Device|PEEK eminoplasty|making obstacle at eminence using patient specefic PEEK device
30203|NCT03950154|Drug|Oxaliplatin|Oxaliplatin injection
24681|NCT03994653|Other|Risk Factor Questionnaire|For cases, the study recruiter at the Trust will present this in the clinic. Controls will complete this online or at home when volunteering to participate. The participant questionnaire will be completed by the participant.
24682|NCT03994653|Other|Clinical Questionnaire|For cases, the study recruiter at the trust will complete this form together with the participant. Controls will not complete this form.
24683|NCT03994640|Combination Product|Cannabis Cream|Topical, bilateral skin application of cannabis cream with self-massage of masseter muscles
24684|NCT03994640|Combination Product|Placebo Cream|Topical, bilteral skin application of placebo cream with self-massage of masseter muscles
24685|NCT03994627|Drug|Olaratumab|Administered intravenously (IV)
24686|NCT03994614|Other|acupuncture|Patients in the experimental group will be given acupuncture treatment for 12 weeks prior to COS. The patients will be given three times acupuncture every week except menstruation. The acupuncture acupoint locations are as follows: head acupoint(Yintang, Shenting, Baihui), abdominal acupoint (Guanyuan, Zhongji), leg acupoint(Sanyinjiao, Zusanli),waist acupoint (Shenyu, Guanyuanyu）
24687|NCT03994601|Drug|BMS-986288|Specified dose on specified days
24688|NCT03994601|Drug|Nivolumab|Specified dose on specified days
24689|NCT03994588|Procedure|Intraperitoneal Mesh hernia repair|The mesh will be inserted intraperitoneally for complex ventral hernia repair and fixed according the previously described ADMIR technique.
24690|NCT03994575|Other|Guideline recommended feedback|The ACS Reflective III Pilot program is a quality assurance program where the decision to follow the recommendations and all treatment decisions related to patient care are left to the physician's discretion and feedback to the physician with their aggregate and individual patient data is intended as a quality assurance undertaking
24691|NCT03994549|Drug|Dual GLP-1/GLP-2 Receptor agonists|Eight ascending doses of ZP7570
24692|NCT03994536|Behavioral|A Person-Centred Transition Program to Empower Adolescents With Type 1 Diabetes in the Transition to Adulthood: the STEPSTONES-DIAB Project|Behavioral: Transition program Participants will be part of a transition program that aim to prepare them for adult life and adult care wich includes eight key components: 1. A transition coordinator; 2. Education on diabetes, treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the adult diabetes service: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Preparation and transfer to adult diabetes service.
24693|NCT03994536|Other|Standard care|Participants allocated to this group will receive usual care, which includes regular follow-up visits in pediatric diabetes outpatient clinics. Usual care can vary across the two clinics, however, they all include meetings with a nurse and a physician.
24694|NCT03994510|Other|Clinical and biological assessments - a 5 Years follow-up|During each visit, a clinical evaluation will be carried out, as well as the filling of hetero-questionnaires and self-questionnaires. Two biological collections will be made: one during the inclusion visit, and the other during the last visit, 5 years after inclusion.
24695|NCT03994497|Other|Blood samples|Blood samples the day of the surgery and 4 times during the next year. Blood samples and histological slides taken at each biopsy and if there is suspicion of rejection of the graft
24696|NCT03994484|Drug|HA121-28 tablets|"Phase 1 Dose Escalation: Starting dose of HA121-28 tablets 25 mg by mouth once daily at the 1st day in 0 cycle and for 21 days ever cycle.~Phase 2 Dose Expansion: divided into low, medium and high doses according the maximum tolerated dose from Phase 1."
24697|NCT03994471|Drug|0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine - or - 2.0% Xylitol, 1.5% Glucose, and 0.02% L-carnitine|One to three, daily (short-dwell) exchanges
24698|NCT03994471|Drug|1.36% or 2.27% or 3.86% Glucose|One to three, daily (short-dwell) exchanges
24699|NCT03994458|Behavioral|Smartphone Full version application|Android smartphone experimental application include: rehabilitative self-administered evidence-based exercises (Strengthening and stretching), ergonomics, and education related to low back pain. The application includes videos, photos, text, and reminders.
24700|NCT03994458|Behavioral|Samartphone limited version application|Android smartphone placebo application include: ineffective content that does not help in treating low back pain. The application includes only five posts in the general instruction and advises section about proper nutrition and few irrelevant reminders.
24701|NCT03994445|Behavioral|Mobile Phone-Based Intervention|"We propose our intervention based on social cognitive behavior theories and the stages of the change model.~The program will be carried out using the word Mettle, it will help ex-smokers stay off cigarettes through advices generated to promote the health from religious concepts and culture perspectives ."
24702|NCT03994432|Behavioral|intervention group|"follow a mediterranean diet and practice a regular aerobic exercise according to the 7-minutes workout model."
24703|NCT03994419|Procedure|Anaesthesia for surgery|Observational study observing proportion of obese and overweight children attending for surgery. Observing adverse events following general anaesthesia for surgery in obese versus healthy weight children.
24704|NCT03994406|Drug|CLM2 topical gel|Active topical gel for forehead dermal application
24705|NCT03994406|Drug|Placebo topical gel|Placebo topical gel for forehead dermal application
24706|NCT03994393|Drug|Tremelimumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
24707|NCT03994393|Drug|Durvalumab|"During induction, patients will receive 4 cycles of durvalumab 1500mg and tremelimumab 75mg with cisplatin 75mg/m2 (or carboplatin AUC 5 if cisplatin is contra-indicated), and pemetrexed 500mg/m2 via intravenous infusion every 3 weeks.~Followed immediately by a maintenance phase of durvalumab 1500mg and pemetrexed 500mg/m2 once every 4 weeks via intravenous infusion until disease progression or intolerance."
24708|NCT03994380|Drug|RhDNAse Inhalation Solution|rhDNAse 2.5 mg nebulizer daily for 4 weeks
24709|NCT03994367|Other|High animal protein isolate|Increased dietary protein content from animal protein isolates
24710|NCT03994367|Other|High animal protein whole food|Increased dietary protein content from animal protein whole food
30204|NCT03950154|Drug|Capecitabine|Capecitabine oral agent
24713|NCT03994354|Procedure|J-P drainage and cutaneous penrose drainage insertion|Lots of the stoma wound closure technique have been developed, including subcutaneous antibiotic material implantation, wound irrigation with iodine, closure wound with a drain tube, secondary closure, delayed primary closure and pursestring closure. But there still is in debate about best skin closure test. In Division of Colorectal Surgery Shuang Ho Hospital, two current stoma wound closure methods were subcutaneous Jackson-Pratt drainage and cutaneous penrose drainage insertion.
24714|NCT03994341|Diagnostic Test|A FLIR Thermovision a320M thermal IR camera|"Clothing removed if necessary~ECG leads, temperature probes, or transcutaneous monitors will be relocated for abdominal imaging.~Axillary temperature prior to starting the thermographic imaging.~Baby's mattress slid out of the isolette and warming bed will be turned off for no more than 60 seconds. This step is necessary since infrared radiation does not pass through the Plexiglas walls of an isolette and the infant's skin surface needs to cool off slightly.~After surface cooling, thermal imaging will be recorded for ~60 sec to allow for the infrared radiation naturally emitted by the subject's body to be recorded by the infrared camera. The timestamp corresponding to the removal of the heat source will be noted, to indicate the start of the cooling of the abdomen.~After ~60 seconds of image recording, the recording will stop, the mattress pushed back into isolette.~Axillary temperature to ensure temperature stability, any clothes will be put back on."
24715|NCT03994315|Other|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
24716|NCT03994315|Other|Lacto-N-tetraose (LNT)|LNT is a human milk oligosaccharide (HMO) found in human breast milk and is a selective prebiotic for B. infantis.
24717|NCT03994302|Drug|Drug inducing antiphospholipid syndrome|Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome
24718|NCT03994289|Behavioral|Motor-assisted cycling|Participants will perform the motor-assisted cycling exercise using a physical therapy bike (RECK; Betzenweiler, Germany). Participants will perform 3×10-min bouts of motor-assisted cycling at the highest tolerable cadence. Before each bout, participants will perform 1-2 minutes of motor-assisted cycling at 5-10 rpm as a warm-up.
24719|NCT03994289|Behavioral|FES cycling|"The testing procedures will be identical to that in the motor-assisted cycling visit except for the exercise type. Participants will wear FES cuffs on the upper and lower legs, bilaterally.~. The FES cycling will be performed on the motor-assisted bike using the wearable FES equipment. The purpose of motor-assisted cycling is to provide constant cadence. The Bioness L300 Plus system (Bioness, Valencia, CA) will be worn on the upper and lower legs to stimulates the quadriceps and dorsiflexors muscles during the motor-driven cycling exercise. An embedded gyroscope of the cuff can detect the motion of the lower leg so that the electrical stimulations will be generated at appropriate timing to activate leg muscles during the cycling exercise."
24720|NCT03994276|Dietary Supplement|Chickpea powder|Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
24721|NCT03994263|Device|ITind device implant|device implanted for 5-7 days
24722|NCT03994250|Other|Kinematic Alignment for total knee replacement surgery|Using Kinematic Alignment for total knee replacement surgery
24723|NCT03994250|Other|Mechanical Alignment for total knee replacement surgery|Using mechanical alignment for total knee replacement surgery
24724|NCT03994237|Other|semi-structured interview|The tool used is a nurse card: there is no validated tool on the expectations of the caregiver in his memory referral. This is a pragmatic and practical questionnaire memory consultation request and domestic life with few items, practical use by telephone.
24725|NCT03994211|Drug|pamiparib (28 day cycles)|60 mg administered orally twice daily/ 28day cycles
24726|NCT03994211|Drug|pamiparib 60 mg|single dose of 60 mg pamiparib orally in the fasted state (at least 8 hours predose)
24727|NCT03994211|Drug|pamiparib 20 mg|single dose of 20 mg pamiparib orally in the fasted state (at least 8 hours predose)
24728|NCT03994211|Drug|itraconazole|200 mg itraconazole once a day approximately 30 minutes after completing a meal
24729|NCT03994211|Drug|rifampin|600 mg rifampin once a day in the fasted state (at least 2 hours predose)
24730|NCT03994198|Dietary Supplement|Alpha-lactalbumin|A protein fraction of whey protein, higher in tryptophan
24731|NCT03994198|Dietary Supplement|Collagen peptides|Collagen peptides from bovine sources
24732|NCT03994185|Device|Placement of WRAPSODY stent graft|Placement of WRAPSODY stent graft into the iliac arteries and/or aortic bifurcation.
24733|NCT03994172|Drug|Teriparatide or human parathyroid hormone (PTH) 1-34|Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
24734|NCT03994172|Drug|Cinacalcet|This drug is an orally active calcimimetic (drug that activates Ca-sensing receptors on target cells) that will be given daily orally to the men randomized to the Experimental Treatment Arm (#1). Cinacalcet tablets will be given simultaneously with the injection of PTH(1-34) or teriparatide. Cinacalcet will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
24735|NCT03994172|Drug|placebo tablet|The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
24765|NCT03993938|Device|PVI measurement|Masimo Radical-7® probe to be attached to patient's finger along with standard ASA monitors at the start of procedure. After placement of arterial line, stroke volume variation (SVV) and pulse pressure variation (PPV) to be recorded along with pleth variability index (PVI) every 5 minutes. Intraprocedure left atrial pressure (LAP) (v-wave and mean) to be recorded prior to and after MitraClip deployment. Data to be analyzed - age, sex, BMI; Preprocedure ejection fraction (EF), pulmonary artery pressure (PAP), rhythm, mitral regurgitation severity; heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) every 5 minutes; SVV, PPV, PVI every 5 minutes; LAP prior to mitraclip deployment; LAP after mitraclip deployment
24736|NCT03994172|Dietary Supplement|Calcium citrate tablet|Ca citrate supplements (forms 200 or 250 mg elemental Ca/oral tablet) will be used in the study. Each subject will have average dietary Ca intake quantified by a Food Frequency Questionaire. Each subject will take sufficient Ca citrate supplements to make the total Ca intake equal ~1000 mg per day (diet+supplements). Ca supplements will be spread out during the day so that any amount of supplements over 500 mg will be taken at 2 different time-points. Ca citrate supplements will be sourced by our research pharmacist will be of high-quality and consistency. Ca supplements will be started at Screening Visit 2 and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily Ca supplements at the same dose and times as during the run-in period. That daily dosing will continue from day of Randomization through the end of 48 weeks or 11 months of the trial.
24737|NCT03994172|Dietary Supplement|Vitamin D3|Subjects will be given 1000 IU vitamin D3 in tablet form to be taken orally once a day at any time during the day. Vitamin D3 supplements will be sourced by our research pharmacist and supplements selected for use in the trial will be of high quality and consistency. Vitamin D3 supplements will be started at Screening Visit 2 in the trial and given for a 4-week run-in period. Once subjects are randomized to Arm 1 or Arm 2 of the trial, subjects will continue to take daily vitamin D3 supplements at the same dose and timing as during the run-in period. That daily dosing will continue from the day of Randomization Visit through to the end of the 48 weeks or 11 months of the trial.
24738|NCT03994159|Device|"Use of the PARO emotional robot"|PARO is an advanced interactive therapeutic robot designed to stimulate patients with Dementia, Alzheimer's, and other cognition disorders.
24739|NCT03994146|Drug|Remifentanil|"Syringe containing 40 ml of Remifentanil 50 µg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
24740|NCT03994146|Drug|Sodium Chloride 9mg/mL|"Syringe containing 40 ml of Sodium Chloride 9 mg/ml for intravenous administration.~In order to maintain double blinding two identical syringes, prepared by pharmacy according to randomisation, will be simultaneously infused. One of the syringes will be abruptly stopped at the end of the operation whilst the other is tapered by stepwise decreases in infusion rate prior to the end of surgery."
24741|NCT03994133|Other|Measurement of the hydration state by bio-impedance spectroscopy|"The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care).~The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.~The measurement will be done in pre-dialytic"
24742|NCT03994120|Other|RTMS|Altering the connectivity of trans-synaptic pathways
24743|NCT03994107|Drug|Pegylated Liposomal Doxorubicin|"First phase PLD: 30mg/m2；35mg/m2；40mg/m2；IV, d1, q21d×6.~Second phase~PLD：MTD. IV, d1, q21d×6."
24744|NCT03994107|Drug|Albumin-bound paclitaxel|220mg/m2 IV for the first infusion，Subsequent infusions 260mg/m2,if no serious adverse reactions occur. d1, q21d×6.
24745|NCT03994107|Drug|Trastuzumab|8mg/kg IV for the first infusion. Subsequent infusions 6mg/kg. d1, q21d×6.
24746|NCT03994094|Other|Telephone interview|Structured, directive, telephone interview, in order to collect the outcome measures in addition to the patients electronic health record.
24747|NCT03994081|Device|tACS|XCSITE100
24748|NCT03994081|Device|Sham tACS|XCSITE100
24749|NCT03994068|Diagnostic Test|VIVO non invasive mapping|non invasive pre-procedural localization of PVC / VT origin
24750|NCT03994055|Other|Omega-3 fatty acids|Diet will include foods rich in omega-3 fatty acids.
24751|NCT03994055|Other|Antioxidants|Diet will include foods rich in antioxidant vitamins, trace elements, and polyphenols.
24752|NCT03994055|Other|Soluble fiber|Diet will include foods rich in soluble fiber.
24753|NCT03994055|Other|Probiotics|Diet will include foods rich in probiotics.
24754|NCT03994055|Other|Lactose restriction|Diet will be restricted to 5g lactose/day
24755|NCT03994055|Other|Fiber restriction|Diet will be restricted to 20g fiber/day
24756|NCT03994055|Other|Fat restriction|Diet will be restricted to 20% total energy intake
24757|NCT03994042|Device|Mental imagery neurofeedback training|Mental Imagery (MI)-neurofeedback training, 2-3 hours, 3 times/week for 4 weeks.
24758|NCT03994029|Dietary Supplement|Effect of polyphenols on hepatic steatosis and vascular elastography and intima media thickness|Measurement of effect of polyphenol supplementation vs placebo on hepatic steatosis and vascular elastography and intima media thickness
24759|NCT03994016|Behavioral|WiseGuyz|"The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement."
24760|NCT03993990|Behavioral|individual empowerment-based intervention|Participants will receive an empowerment-based intervention individually, based on five steps (i. e. problem identification, meaning and perception clarification, intervention planning, intervention delivery, and evaluation). After the principal investigator delivers a pre-discharge assessment (i. e. the self-care behavior and self-efficacy of diabetes and diabetic foot ulcer, risk factors of foot ulcer, family support, and threat belief of participant), the plan of behavioral modification will be determined by the principal investigator and participants. The subsequent follow-up and intensifying interventions will be delivered at the following time points: three days after discharge, every weeks for one month, every two weeks for subsequent two months, and then every three months for three times.
24761|NCT03993977|Diagnostic Test|Rotational thromboelastometry|ROTEM-guided protocol of hemostatic resuscitation
24762|NCT03993977|Other|Conventional treatment|Clinical judgement and conventional coagulation tests
24763|NCT03993964|Drug|Pyrotinib combine with SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
24768|NCT03993912|Drug|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression|Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression
24769|NCT03993899|Device|FineHearing strategy or HDCIS strategy|Cochlear implant with FineHearing strategy or HDCIS strategy
24770|NCT03993886|Device|CorBand|The CorBand device is a wrist-worn biosensor measuring heart rate, heart rate variability, respiration rate, skin temperature, bioimpedance, and activity.
24771|NCT03993886|Other|Activity Monitor|commercially available accelerometer to be worn on wrist
24772|NCT03993886|Other|Bioimpedance spectrometer|Commercially available bioimpedance monitor.
24773|NCT03993886|Other|ECG|Commercially available electrocardiogram machine
24774|NCT03993886|Other|respiratory rate sensor|Commercially available respiratory rate sensor.
24775|NCT03993873|Drug|TPX-0022|Oral TPX-0022 tablets
24776|NCT03993860|Dietary Supplement|Fish Powder|Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
24777|NCT03993860|Dietary Supplement|Sorghum powder|Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
24778|NCT03993821|Drug|Burosumab|Burosumab, the investigational product, is a recombinant human IgG1 monoclonal antibody targeting FGF23. It is supplied as a sterile, clear, colorless and preservative-free solution and is administered via subcutaneous injection.
24779|NCT03993808|Behavioral|Revision of congregate meal menus and recipes to align with parameters of DASH eating plan|On a programmatic level, congregate meal menus and recipes have been adapted to align with DASH eating. The changes, which include the introduction of additional servings of fruits, vegetables, seeds, grains, replacement of simple or processed carbohydrates with healthier alternatives, introduction of more fish, reduction in added salt, and replacement of animal fats and butter with olive oil, will be phased-in in stages over 6 weeks, concurrent with the start up the study's educational programs addressing nutrition, BP, and medication adherence. The fully DASH-aligned menus will begin by week 7. The dietary intervention affects all seniors eating congregate meals at the center, not only those enrolled in this protocol to study the impact of DASH implementation.
24780|NCT03993808|Behavioral|On-site blood pressure monitoring|At baseline (Month 0), and at Months 1, 3, and 6 after the full implementation of the DASH aligned congregate meals, participants will have blood pressure measured by professionals, on-site at the senior center, following established standard procedures. They will receive verbal and written information about their blood pressure results, and encouragement to share the results with their providers.
24781|NCT03993808|Behavioral|Home self blood pressure monitoring|Provision of personal Omron 10 home blood pressure monitoring device, training in proper use, and schedule for home self monitoring of BP over the course of the study.
24782|NCT03993808|Behavioral|Medical adherence education|One required educational session with the community pharmacist to learn about medication adherence strategies
24783|NCT03993808|Behavioral|Nutrition Education|One required educational session to review the elements of the DASH eating plan, how to overcome barriers to healthy eating, recipes, cooking demonstrations and materials for household members.
24784|NCT03993795|Other|A19010-W|A snus product
24785|NCT03993795|Other|B19010-F|A snus product
24786|NCT03993782|Other|A19010-R|A snus product
24787|NCT03993782|Other|B19010-O|A snus product
24788|NCT03993769|Other|A19010-F|A snus product
24789|NCT03993769|Other|B19010-F|A snus product
24790|NCT03993743|Biological|CD147-CART|Three infusions of CD147-CART cells over the course of three weeks into the hepatic artery.
24791|NCT03993730|Device|ICD|Insertion of ICD in patients with LVEF <45% and LGE on CMR.
24792|NCT03993730|Device|ILR|Insertion of ILR in patients with LVEF <45% and LGE on CMR.
24793|NCT03993717|Biological|SHINGRIX|A single intramuscular injection of the FDA-approved recombinant glycoprotein E herpes zoster (HZ/su) vaccine will be administered in the deltoid muscle of the preferred arm
24794|NCT03993704|Drug|LHF-535|Oral suspension administered once daily for 14 days
24795|NCT03993691|Device|Tomo-E scan|High-resolution limited-angle tomography positioning and examination will vary depending on injury.
24796|NCT03993691|Device|Radiograph|Standard of Care radiographic imaging of wrist.
24797|NCT03993678|Drug|IP-001|Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.
24798|NCT03993678|Device|Thermal Ablation|"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"
24799|NCT03993652|Behavioral|Kids FIRST|family- and school-based intervention to reduce unhealthy screen-time and snacking
24800|NCT03993639|Drug|Pegfilgrastim|Single dose of SC administration
24801|NCT03993626|Drug|CXD101 in Combination With Nivolumab|HDAC inhibitor in combination with anti-PD-1 monoclonal antibody
24802|NCT03993613|Biological|human apotransferrin|Intravenous infusions
24803|NCT03993600|Diagnostic Test|Sweat test (Macroduct Sweat Collection System) and skin biopsy (Punch Biopsy)|"three groups:~Healthy volunteers~Patients with Cystic fibrosis~Heterozygous subjects"
24804|NCT03993587|Other|Ultrasound assessment of vessels|Subclavian vein and related structures are examined using ultrasonography
24805|NCT03993574|Other|Self- management program|"The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program.~Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks"
24839|NCT03993314|Drug|Chloroprocaine|Adding 5 cc 1% Chloroprocaine with 10 cc sterile saline in the epidural
24840|NCT03993314|Drug|Bupivacaine|1 cc of 0.5% bupivacaine with 15 mcg fentanyl 10 cc of sterile saline in the epidural
24806|NCT03993574|Other|Standard care|"All stroke patients being discharged from the acute hospital receive the following care:~1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling.~A stroke clinic appointment that is set to occur 90-days post discharge.~A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included.~Information on local support groups.~Referrals to start physical, occupational or speech therapy, if recommended by their physician."
24807|NCT03993561|Other|Treatment summary and survivorship care plan|Individually tailored counselling session will be implemented within 1 month of treatment completion.
24808|NCT03993548|Behavioral|Wellness Element 1 - Exercise|Daily wellness element focusing on Exercise; adherence documented online daily
24809|NCT03993548|Behavioral|Wellness Element 2 - Mindfulness|Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
24810|NCT03993548|Behavioral|Wellness Element 3 - Sleep Hygiene|Daily wellness element focusing on sleep hygiene; adherence documented online daily
24811|NCT03993548|Behavioral|Wellness Element 4 - Social Connectedness|Daily wellness element focusing on Social Connectedness; adherence documented online daily
24812|NCT03993548|Behavioral|Wellness Element 5 - Nutrition|Daily wellness element focusing on Nutrition; adherence documented online daily
24813|NCT03993548|Behavioral|Wellness Element 6 - Wellness Exercises|Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
24814|NCT03993548|Behavioral|Wellness Element 7 - Motivational Messages|Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
24815|NCT03993535|Drug|selective serotonin reuptake inhibitor|open treatment based on patient preference and treatment availability
24817|NCT03993509|Device|rTMS to the right dlPFC|A Magventure MagPro 100X stimulator with a B65 active/placebo figure-8 coil will be used. The TMS coil will be placed on the head over the target. rTMS intensity will be 100% of the motor threshold (MT), adjusted for field strength difference at motor cortex and target cortex using the individual E-field model. Subjects will receive 3000 pulses/session.
24818|NCT03993496|Diagnostic Test|Abdominal Aortic Aneurysm Sac Pulsatility|"Measurements of aortic wall pulsatility will be performed using trans-abdominal ultrasound through the non-sterile field of the upper abdomen, while the surgeons operate through the groins. The pulsatilty of the aneurysm will then be measured using transverse views in 'M-Mode' of the ultrasound, and measures the aneurysm wall displacement during a cardiac cycle; the minimum diameter (diastole) and maximum diameter (systole) will be measured. These measurements will occur during surgery:~Prior to EVAR deployment~After EVAR deployment, but before balloon affixation to the aortic wall~After EVAR deployment and after affixation"
24819|NCT03993483|Behavioral|Unilateral resistance exercise|The participants performed three sets of their unilateral resistance exercise (biceps curls and knee extensions) three times per week for 10 weeks.
24820|NCT03993470|Behavioral|Short foot excercise for intrinsec muscles of the foot|to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
24821|NCT03993457|Drug|Escitalopram|Escitalopram will be started at 5 mg/day during the first week of treatment. The dose will then be increased to 10mg/day, and can be increased to 20 mg/day. Dose can be decreased to 5 mg by clinician discretion such as to increase tolerability or better manage side-effects. 5 mg will be the lowest dose allowed in the study.
24822|NCT03993457|Drug|Bupropion|Bupropion-XL will be started at 150 mg/day and increased to 300 mg/day after one week. This dose can be increased to 450 mg/day (divided in 2 doses) at Week 2 or later. Clinicians may opt to titrate bupropion-XL in a slower fashion in cases that might increase tolerability or better manage side-effects. 150 mg will be the lowest dose allowed in the study.
24823|NCT03993444|Behavioral|communication and problem solving|a program for supervisors and employees including skills training, validating communication, problem solving
24824|NCT03993444|Behavioral|psychoeducation|lecture/course for supervisors and employees on risk factors and actions for people experiencing stress and/or pain
24825|NCT03993431|Drug|Bio-active cement|A cement used for crown cementation, specially recommended for pediatric esthetic crowns
24826|NCT03993431|Drug|Packable glass ionomer|Glass ionomer cement with improved mechanical properties usually used for restoration of simple small cavities and in Atraumatic Restorative Treatment
24827|NCT03993418|Dietary Supplement|stevia|This arm will be required to consume 5 stevia drops twice daily in habitual drinks
24828|NCT03993405|Other|Ultrasonographic evaluation|Ultrasonographic measurement is assessment method to diagnosis of sarcopenia
24829|NCT03993392|Drug|TM buprenorphine|4mg TM buprenorphine, investigator choice as to brand
24830|NCT03993392|Drug|SUBLOCADE|300mg subcutaneous injection
24832|NCT03993366|Combination Product|Fiasp+Pramlintide Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin and pramlintide
24833|NCT03993366|Device|Fiasp Closed-Loop System|Closed-loop insulin delivery with Fiasp insulin alone
24834|NCT03993353|Drug|Pembrolizumab|200 mg intravenously every 3 weeks
24835|NCT03993353|Drug|Tadalafil|10 mg by mouth daily
24836|NCT03993340|Device|Rescue stenting|The subjects will receive endovascular treatment for acute stroke according to standard clinical practice. Specifically, modern endovascular thrombectomy using a stent retriever, contact aspiration thrombectomy, or both are allowed. The number of thrombectomy attempts is at the operator's discretion. After failure of standard thrombectomy procedure, rescue stenting with Solitaire will be done. Additional balloon angioplasty, glycoprotein IIb/IIIa inhibitor (GPI), or thrombolytic infusions are optional and at the operator's discretion. After successful recanalization with rescue stenting, intravenous maintenance of GPI at least for a 12 hours and then changed to oral antiplatelet are recommended.
24837|NCT03993327|Biological|Iodine I 124 Monoclonal Antibody M5A|Given IV
24838|NCT03993327|Procedure|Positron Emission Tomography|Undergo PET scan
24841|NCT03993301|Other|Probiotic A formula|Feeding baby two meals a day with Infant formula with probiotics (10^8 colony-forming unit per gram) at least.
24842|NCT03993301|Other|Probiotic B formula|Feeding baby two meals a day with Infant formula with probiotics (10^8 colony-forming unit per gram) at least.
24843|NCT03993301|Other|Regular formula|Feeding baby two meals a day with regular formula at least.
24844|NCT03993288|Drug|Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia)|Ferrum Lek® 2 tablets daily (200 mg), during 12 weeks
24845|NCT03993288|Drug|MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland)|Patients will receive MALTOFER® 2 tablets daily (200 mg) during 12 weeks
24846|NCT03993275|Device|MindMotion GO|Patients will train trunk control and balance using the MindMotion GO device 2-3 times a week. They will perform exergames in sitting or standing, according to their balance level.
24847|NCT03993262|Drug|Bortezomib|1 to 3 cycles Bortezomib with 1,3mg/m2 body surface s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
24848|NCT03993262|Drug|Placebo|1 to 3 cycles placebo (NaCl solution) s.c. + 20mg dexamethasone p.o. on days 1, 4, 8 and 11 (= 1 cycle)
24849|NCT03993249|Biological|Nivolumab|standard of care chemoradiotherapy + Nivolumab
24850|NCT03993249|Other|chemoradiotherapy|standard of care chemoradiotherapy
24851|NCT03993236|Drug|Experimental: Rosuvastatin/Ezetimibe 10|"Rosuvastatin/Ezetimibe 10/10mg~orally administered once daily for 90 days"
24852|NCT03993236|Drug|Active Comparator: Rosuvastatin 20mg|"Rosuvastatin 20mg~orally administered once daily for 90 days"
24853|NCT03993223|Behavioral|Upper trapezius muscle fatigue|Isometric contraction of scapular elevation
24854|NCT03993210|Device|MR Fingerprinting|Magnetic Resonance Imaging Machine
24855|NCT03993210|Device|QTI|Magnetic Resonance Imaging Machine
24856|NCT03993197|Behavioral|Psychological and corporal group management|"After inclusion, patient will be divided into groups of 8 patients either in pre-operative or post-operative phase. Patient care will take place entirely in pre-operative or post-operative phase.~Each group will benefit of six one hour and a half sessions.~The frequency is established as follows:~First week a session of Body Strategy ©~Second week a psychological session with group of speech (Photolanguage ©).~Third week is a break Then the cycle currently described is repeated, for a total of 6 alternate sessions"
24857|NCT03993184|Behavioral|Hot Yoga|Bikram or hot yoga is a standardized series of 26 postures with two breathing exercises. Classes will be performed at local yoga studios in Austin, Texas and participants will be required to sign in for each session. All participants will receive 12 weeks of free classes for their participation.
24858|NCT03993171|Drug|gold nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
24859|NCT03993145|Behavioral|Web-based lifestyle intervention|Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
24862|NCT03993119|Drug|Non-vitamin K antagonist oral anticoagulant|Non-vitamin K antagonist oral anticoagulant
24863|NCT03993106|Drug|sEphB4-HSA|sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
24864|NCT03993093|Other|CD4 cell count|CD4 cell count from treatment naive HIV patients
24865|NCT03993080|Device|Virtual reality relaxation|1-3.5 minute 360° videos
24866|NCT03993067|Other|Hemopatch|Hemopatch is a collagen based sealant
24867|NCT03993054|Behavioral|Cognitive behavioral stress management|The SmartManage CBSM intervention includes content that is of clinical relevance to sexual minority men dually diagnosed with HIV and cancer. Intervention content includes: co-management of HIV and cancer, strategies for self-advocacy, partnering with the health system and health providers, intimacy and disclosure concerns regarding both conditions, and contextual stressors (e.g., racial/ethnic minority status), stigmatization, assertiveness and communication skills, and self-efficacy in care coordination. Participants receive weekly 1.5 hour interactive group sessions online that focus on stress and self-management skill-building, and also receive access to didactic information regarding intervention content via the intervention website. Intervention length is 4 weeks.
24868|NCT03993054|Behavioral|Culturally-tailored cognitive behavioral stress management|This intervention will be a version of SmartManage that is culturally-tailored for Latino populations.
24869|NCT03993041|Behavioral|Cognitive-behavioral therapy (CBT)|Study therapists will deliver cognitive-behavioral therapy (CBT) based on an emotion-focused, transdiagnostic protocol. CBT targets problematic thoughts, feelings, and behaviors through goal-oriented, systematic procedures. The intervention used in this study is designed to target emotional processing with an emphasis on present-focused awareness, cognitive flexibility, emotional avoidance, awareness and tolerance of physical sensations, and situation-based emotion exposure. The intervention is designed to help individuals better understand emotional experiences in order to respond to intense emotions in a more adaptive way.
24870|NCT03993015|Other|Help to diagnosis software|Help to diagnosis software
24871|NCT03993002|Other|Normoxia with Normocarbia|PaO2 < 100 (FiO2 >= 21%) PaCO2 of 30-40
24872|NCT03993002|Other|Normoxia with Hypercarbia|PaO2 < 100 (FiO2 >= 21%) PaCO2 of 50-60
24873|NCT03993002|Other|Hyperoxia with Normocarbia|PaO2 > 250 (FiO2 >= 70%) PaCO2 of 30-40
24874|NCT03993002|Other|Hyperoxia with Hypercarbia|PaO2 > 250 (FiO2 >= 70%) PaCO2 of 50-60
24875|NCT03992989|Device|Phonak Bolero M90-M|The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss
24876|NCT03992989|Device|Roger Select|The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
24877|NCT03992976|Other|Online Chronic Pain Management Intervention for Teenagers|The intervention itself is currently under development. This development study is used to gather patient (teenager) insights, as well as insights from parents of these patients, which will inform the content and structure of the proposed intervention. This is done using qualitative-only techniques. Initial ideas for the intervention design mirror current clinical practices in paediatric chronic pain management. There are likely to be several different online modules, which include psychological techniques, medicine (advice), nursing (advice and guidance on non-pharmacological physical pain management), and physiotherapy (guidance for pacing and physiotherapy exercises). The intervention is intended to help teenagers employ a vast range of self-management techniques from these disciplines. Exact content is not yet refined as this is a development study.
24878|NCT03992963|Device|Hearing Aid without frequency lowering enabled|Each participant will be fitted with frequency lowering disabled. Disabled means standard hearing loss compensation without lowering higher frequencies in lower frequency areas. The input frequency is mapped to the same frequency in output.
24879|NCT03992963|Device|Hearing Aid with frequency lowering enabled|Each participant will be fitted with frequency lowering enabled. The principle of the frequency lowering algorithm is to lower high frequencies to a lower frequency region with the aim of ensuring high frequency audibility to improve auditory emotion recognition.
24880|NCT03992950|Other|Maneuvers for occluding esophagus|Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
24881|NCT03992937|Drug|Vaginal Micronized Progesterone|Micronized progesterone tablets at a dose of 200 mg once a day vaginally, for 12 days (Between 14'th-25'th days of the menstrual cycle) over three months.
24882|NCT03992937|Device|Levonorgestrel-Intrauterine System|Release rate of 20µg Levonorgestrel (Mirena-Intrauterine system) per day.
24883|NCT03992924|Procedure|function or imaging guided PCI|FFR may be good tools to differentiate patients with STEMI who may not need stent implantation from those who need Optical coherence tomography (OCT) can visualize the microstructure of culprit and the OCT characteristics were validated by histology
24884|NCT03992911|Drug|Simmtecan, 5-FU and l-LV|Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
24885|NCT03992911|Drug|Toripalimab|Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
24886|NCT03992911|Drug|Etoposide, Cisplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
24887|NCT03992911|Drug|Etoposide, Carboplatin|Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
24888|NCT03992898|Other|No special intervention was suitable for this observational study|Investegators divided patients into 3 corhort according to the liver condition at enrollment (i.e. chronic liver disease, compemsated cirrhosis, decompensated cirrhosis). All patients received standard medical treatment, including nutritional supplementation; administration of human serum albumin, fresh frozen plasma, antivirus treatment and appropriate treatment for complications. No special intervention was suitable for this observational study.
24889|NCT03992885|Drug|Icotinib|"Intervention: Drug: Icotinib Ectinib 125mg/ tablet, one tablet at a time, three times a day, take orally~Intervention: Drug: Carboplatin/ Cisplatin Pemetrexed 500mg/m2, intravenous infusion, day 1;Carboplatin AUC6/ Cisplatin 75mg/m2,intravenous infusion, day 1,21 days for a cycle"
24890|NCT03992872|Biological|Chikungunya|Virus Like Particle
24891|NCT03992859|Procedure|Continuous serratus plane block|Peripheral nerve catheter placed by the surgeon at the end of surgery
24892|NCT03992846|Drug|Placebo linzagolix tablets and Placebo Add-back capsule|For oral administration once daily
24893|NCT03992846|Drug|Placebo linzagolix and linzagolix tablets and Placebo Add-back capsule|For oral administration once daily
24894|NCT03992846|Drug|Placebo linzagolix and linzagolix tablets and Add-back capsule|For oral administration once daily
24895|NCT03992833|Other|lung cancer screening|"In the first reading, according to the NCCN lung cancer screening guideline, participants with a solid nodule≤ 5 mm in diameter will be referred to undergo follow-up CT 1 year after the baseline. Participants with a solid nodule 6-14 mm will be referred to undergo follow-up thorax CT 3-6 months after the baseline. Participants with a solid nodule ≥ 15 mm will be referred to a multidisciplinary team for clinical investigation.~The simulated management will be based on the volume of lung nodule and volume doubling time from the second reading, lung nodules will be reclassified according to the reference values from the European volume-based lung nodule management protocol. According to the European volume-based protocol, the solid and part-solid lung nodules will be reclassified into three groups: nodules with a volume < 100 mm3 (negative), nodules with a volume of 100-300 mm3 (indeterminate), and nodules with a volume > 300 mm3 (positive)."
24896|NCT03992820|Device|TENS machine|"The trial group will have the TENS to the area planned for injection for at least 30 minutes before injection of the local anaesthetic solution.~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
24897|NCT03992820|Combination Product|EMLA cream|"The control group will have EMLA applied on the site planned for local anaesthetic injection and after 1 hour, will be removed and immediately injected with the same anaesthetic solution (this is already a procedure practised by many of the surgeons).~Pain perception will be evaluated using two Numeric Pain Rating Scales in the study and control groups- one to assess the pain of needle penetration and the second to assess the pain of local infiltration."
24898|NCT03992807|Other|A patient decision aid|Potential participants receive a printed decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
24899|NCT03992807|Other|A usual education booklet|Potential participants receive a usual booklet about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
24900|NCT03992794|Diagnostic Test|Measurement of MR-proADM|It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
24901|NCT03992755|Drug|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
24902|NCT03992742|Behavioral|Initial phase: personalized instant messaging (PIM)|"intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A)."
24903|NCT03992742|Behavioral|Second phase: optional cocktail interventions (OCI)|For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
24904|NCT03992742|Behavioral|Initial phase: regular instant messaging (RIM)|"Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- & 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention."
24905|NCT03992742|Behavioral|Second phase: personalized instant messaging (PIM)|"For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details."
24906|NCT03992742|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
24907|NCT03992742|Behavioral|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
24908|NCT03992742|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
24909|NCT03992742|Behavioral|COSH booklet|A general smoking cessation self-help booklet
24912|NCT03992716|Drug|SmofKabiven® extra Nitrogen|SmofKabiven® extra Nitrogen (Fresenius Kabi) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
24913|NCT03992716|Drug|Olimel N9E|Olimel N9E (Baxter) is a sterile, hypertonic emulsion for parenteral nutrition, in a 3-chamber bag containing amino acids, glucose, a lipid emulsion, and electrolytes.
24914|NCT03992690|Device|Brain-machine Interfaces, Visuo-tactile Feedback and Assisted Locomotion, or the WANR protocol|Training integrating virtual-reality avatar driven by a brain-machine interface, with tactile feedback through patient's forearms, and assisted locomotion, for neurorehabilitation of SCI patients.
24915|NCT03992690|Device|Training with traditional physiotherapy protocol|Stretching
24916|NCT03992677|Other|No intervention|No intervention
24917|NCT03992664|Other|EDUCATION|"The training program will focus on four parameters: cleanliness, hydration, protection from external stimuli, and finally early detection of skin side effects.~The re-evaluation of the skin as well as the repetition of the questionnaires will be done every week for 4 weeks."
24918|NCT03992651|Device|Measurements of capnia and tissue oxygenation by optical transcutaneous sensors|Capnia and tissue oxygenation will be measured by optical transcutaneous sensors
24919|NCT03992638|Procedure|leucocyte and platelet-rich fibrin (L-PRF) in combination with CAF|Completing root coverage by coronally advanced flap technique in combination with L-PRF.
24920|NCT03992638|Procedure|CAF|Completing root coverage by coronally advanced flap technique alone
24921|NCT03992625|Device|Deep Brain Stimulation|High frequency electrical stimulation of deep brain nuclei for the treatment of movement disorders
24922|NCT03992612|Behavioral|CBT for chronic pain|12 group sessions of cognitive behavioral treatment to manage pain
24923|NCT03992612|Behavioral|MBPM- Mindfulness-Based Pain Management|8 group session of maindfulness-based treatment to management pain
24964|NCT03992313|Other|DBS HCV viral load|HCV viral load will be done in Phnom Penh by DBS using Omunis kit
24965|NCT03992300|Device|Clinical adjustment|Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
24966|NCT03992287|Dietary Supplement|Hydrolysed Red Ginseng Extract|10 ml/day, 2.4g/day for 12 weeks
24924|NCT03992599|Procedure|Laparoscopic modified complete mesocolic excision|First, complete kocherization may be required to clear possible tumor spread if the tumor is infiltrating or adhering to the duodenum or perinephric fat tissue. Second, if the tumor is locally advanced, the entire prerenal soft tissue behind Gerota's fascia may need to be cleared, especially for tumors growing toward the posterior. The third difference of mCME with the conventional CME involves the tailored resection of the mesocolon and ileal mesentery according to tumor location. After identifying the root of the middle colic artery, the site of the vascular ligation depends on the location of the tumor. When the tumor is located in the cecum and ascending colon, only the right branch of the middle colic artery is ligated. If the tumor was present in these latter sites, the root of the middle colic artery is ligated.
24925|NCT03992586|Other|Wearing pink glasses|Wearing pink-colored lenses
24926|NCT03992586|Other|Wearing clear glasses|Wearing clear glasses
24927|NCT03992573|Procedure|CGF application|CGF application into post-operative soft tissue and bone defects
24928|NCT03992560|Device|Guide CRT Software Prototype|The medical device in the trial is a software programme that allows image fusion of previously acquired MRI images with real-time X-Ray fluoroscopic images in the cardiac catheter laboratory. We are able to use the MRI information to assess the best location to place the left ventricular lead for a CRT device and then superimpose this location onto the real-time X-Ray fluoroscopic images during the left ventricular lead implantation
24929|NCT03992547|Other|Robot-assisted Gait Training|SUBAR® (CRETEM, Korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. RAGT enables training of automatically programmed normal gait pattern.
24930|NCT03992534|Dietary Supplement|LACTIN-V|Vaginal supplementation with L. crispatus CTV-05.
24931|NCT03992521|Genetic|Nucleosome positioning|Stratification of patients based on nucleosome positioning from plasma DNA.
24932|NCT03992508|Device|intermittent pneumatic compression|
24933|NCT03992508|Procedure|complex decongestive therapy|
24934|NCT03992495|Other|Exercise|All participants will be exposed to aerobic/strengthening exercises
24935|NCT03992482|Drug|Intravenous Immune Globulin (IVIG)|Intravenous Immunoglobulin (IVIG), 4 mg/ml (0.4%) eye drops two times a day for eight weeks
24936|NCT03992482|Drug|Placebo|Normal Saline Eye Drops (0.9% NaCl) two times a day for eight weeks
24937|NCT03992469|Drug|BFAHF-2|BFAHF-2 is a 0.55g circular tablet that is easy to swallow with a diameter of 0.44 inches and a thickness of 0.19 inches. The quality, safety and consistency of BFAHF-2 are established per FDA guidance under a botanical drug title. Low dose (maximum of 2 tablets bid) and full dose (maximum of 5 tablets bid). Weight based dosing will ensure an equivalent amount is given to each individual.
24938|NCT03992469|Drug|Placebo|Placebo tablets made of cornstarch
24939|NCT03992456|Biological|Panitumumab|Given IV
24940|NCT03992456|Other|Quality-of-Life Assessment|Ancillary studies
24941|NCT03992456|Other|Questionnaire Administration|Ancillary studies
24942|NCT03992456|Drug|Regorafenib|Given PO
24943|NCT03992456|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
24944|NCT03992443|Drug|CUSA-081|Participants received 1 or 2 doses of CUSA-081, 0.70 mg/2 mL, directly into the catheter lumen
24945|NCT03992430|Drug|Eteplirsen|Solution for intravenous (IV) infusion.
24947|NCT03992404|Drug|NT 201|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
24948|NCT03992404|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
24949|NCT03992391|Behavioral|Suicide Prevention Intensive Outpatient Program|participation in a suicide prevention intensive outpatient program
24950|NCT03992378|Device|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.
24951|NCT03992378|Device|Low Level Transcutaneous Vagus Nerve Stimulation|Stimulation of the ear lobe delivered by Parasym device.
24952|NCT03992365|Drug|Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)|"The evening before the colonoscopy: Take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 20 tablets.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, take 4 tablets with 250 ml of clear liquids every 15 minutes for a total of 12 tablets."
24953|NCT03992365|Drug|Polyethylene glycol 3350, sodium sulfate anhydrous, sodium bicarbonate, sodium chloride, potassium chloride, aspartame;Bisacodyl|"The day before the colonoscopy: One 5 mg tablet of Dulcolax® will be administered, do not chew or crush the tablet, in the afternoon before the day of colonoscopy. About 4 hours after administration of Dulcolax®, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes.~On the day of the colonoscopy: Starting 3-5 hours before the procedure, drink the 1000 ml Klean-Prep solution at a rate of 250 ml every 15 minutes."
24954|NCT03992352|Diagnostic Test|Age 60+ with planned HCT for Hematologic Malignancy|questionnaires, geriatric assessments
24955|NCT03992339|Drug|ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle|Enrolled patients will be treated with a fixed dose, 60 mg of ATG-010, orally, twice weekly, each 4 week (28-day) a cycle.
24956|NCT03992326|Other|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
24957|NCT03992326|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
24958|NCT03992326|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
24959|NCT03992326|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
24960|NCT03992326|Other|Radiotherapy|Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
24961|NCT03992313|Other|Community-based HCV rapid test|HCV rapid tests will be done in the village
24962|NCT03992313|Other|Facility-based HCV rapid test|HCV rapid tests will be done in the health center
24963|NCT03992313|Other|Plasmatic HCV viral load|HCV viral load will be done in provincial hospital on plasma using GenXpert
24968|NCT03992274|Other|Enhanced implementation of PrEP|During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
24969|NCT03992274|Drug|PrEP|Pre-exposure prophylaxis (PrEP) is a biomedical HIV prevention strategy. A fixed-dose of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) was approved by the U.S. FDA in 2012.
24970|NCT03992261|Drug|Halobetasol Topical Foam|Foam
24971|NCT03992248|Behavioral|Time restricted feeding|Eating within a time frame of 10hrs during the day. Outside of this time frame, participants need to refrain from food and energy containing drinks.
24972|NCT03992235|Other|Chest physiotherapy|"All patients will receive chest physiotherapy including Breathing exercise, intensive spirometry use, coughing, ambulation."
24973|NCT03992235|Other|Educational material|Exercise brochure with photos and explanations
24974|NCT03992222|Device|Physical exercise programs PEP targeted on appropriate muscle strengthening devices allows|administration of a Physical exercise program for 24 weeks.The participants will be followed at the 24 and 52nd weeks.
24975|NCT03992209|Other|Standard care|Usual operating room practice
24976|NCT03992209|Other|Protocolized care|Hand washing per protocol
24977|NCT03992196|Drug|Rotigotine 1 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 mg/24 h (5 cm^2 patch size).
24978|NCT03992196|Drug|Rotigotine 2 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 mg/24 h (10 cm^2 patch size).
24979|NCT03992196|Drug|Rotigotine 3 mg/24 h|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 3 mg/24 h (15 cm^2 patch size).
24980|NCT03992170|Drug|Daratumumab|Daratumumab is a human monoclonal antibody (mAb) IgG1 that binds to the highly expressed CD38 protein on the surface of multiple myeloma cells and, at various levels, also in other types of cells and tissues. The CD38 protein has multiple functions, such as receptor-mediated adhesion, signal transduction activity and enzymatic activity.
24981|NCT03992157|Device|ECG telemetry|ECG telemetry (holter ECG) is a portable case - attached to the belt or around the neck - connected to 6 electrodes placed on the skin next to the heart. They are worn by patients during their stay in hospital
24982|NCT03992144|Drug|Amoxicillin 500 Mg|Amoxicillin 500mg an hour before tooth extraction
24983|NCT03992144|Drug|metronidazole 400mg|400mg of metronidazole an hour before extraction
24984|NCT03992144|Drug|metronidazol 400mg and amoxicillin 500mg|400mg metronidazole TDS, amoxicillin 500mg BD for 5 days after extraction
24985|NCT03992131|Drug|Rucaparib|Oral rucaparib will be administered twice daily
24986|NCT03992131|Drug|Lucitanib|Oral lucitanib will be administered once daily
24987|NCT03992131|Drug|Sacituzumab govitecan|IV Sacituzumab govitecan will be administered Days 1 and 8 every 21 days
24988|NCT03992118|Behavioral|Parent coaching|Parents will be coached to implement behavioural strategies to address factors which are contributing to difficult mealtime behaviours and feeding challenges.
24989|NCT03992105|Other|prospective cohort|"topics included openly in the Respite Site, made up of the first 50 subjects followed prospectively"
24990|NCT03992092|Device|C-MAC VS|C-MAC Video Stylet
24991|NCT03992092|Device|Flexible Bronchoscopy|Flexible Bronchoscopy
24992|NCT03992079|Procedure|ReCOVER Enhanced Recovery Protocol|The experimental group will receive preemptive pain management before surgery, an opioid-free strategy during surgery, and an opioid-sparing multimodal pain management protocol after surgery.
24993|NCT03992066|Drug|Vadadustat|oral 150 mg tablet
24994|NCT03992066|Drug|Darbepoetin alfa|solution intravenous injection
24995|NCT03992066|Drug|Epoetin alfa|solution for intravenous injection
24996|NCT03992053|Other|sacroiliac joint injection|Image-guided sacroiliac joint injection under fluoroscopy or CT guidance and the success of intraarticular access was demonstrated by inter-articular contrast spread (the standard of care, not part of study intervention).
24997|NCT03992027|Behavioral|CF-CBT: A Cognitive-Behavioral Skills-Based Program to Promote Emotional Well-Being for Adults wtih Cystic Fibrosis|CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
24998|NCT03992027|Behavioral|Waitlist Control|Participants receive usual care for 3 months followed by CF-CBT. CF-CBT is an 8-session program introducing cognitive-behavioral coping skills for managing stress, and for prevention and treatment of anxiety and depression. The content of the program was developed to address stressors related to coping with cystic fibrosis. Participants will receive a patient workbook, and meet with a trained member of the CF team (interventionist) who will guide them through learning and practicing coping skills during 8 weekly sessions.
24999|NCT03992014|Drug|Linerixibat tablet|Linerixibat will be available as white to slightly colored film-coated round tablet to be administered as two tablets taken in the fasted state in the morning with 240 milliliter (mL) of room temperature water.
25000|NCT03992014|Drug|[14C]-linerixibat intravenous infusion|[14C]-linerixibat will be available as clear, colorless solution free from visible particulates to be administered 25 mL IV over 3 hours immediately after the oral dose.
25001|NCT03992014|Drug|Linerixibat oral solution|Linerixibat will be available as clear, colorless solution free from visible particulates to be administered 60 mL solution in the fasted state in the morning.
25002|NCT03992001|Biological|Blood component A|PRBCs obtained from whole blood after separation of plasma, buffy coat, and RBCs and successive leukoreduction of RBCs
25003|NCT03992001|Biological|Blood component B|PRBCs obtained by leukoreduction of whole blood, and successive separation of plasma and RBCs
25099|NCT03991299|Drug|Botox 200 UNT Injection|Botox will be injected into duodenums of subjects by endoscopy.
25004|NCT03991988|Drug|Montelukast|"Participants in this arm will take a pill of Montelukast daily on escalating doses: 10, 20 to 40 mg.~All participants will be initiated on 10 mg. The dose will be increased in 2-week increments to 20 mg and 40 mg as long as participants report no intolerable symptoms or adverse events."
25005|NCT03991988|Drug|Placebo oral tablet|Participants in this arm will take a matched placebo pill daily
25006|NCT03991975|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor.
25007|NCT03991975|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
25008|NCT03991962|Drug|mFOLFIRINOX|Patients will receive 6-12 cycles of mFOLFIRINOX every 2 weeks
25009|NCT03991962|Radiation|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved lymph nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
25010|NCT03991949|Other|Experimental Infant Formula|Formula fed Ad libitum
25011|NCT03991936|Drug|Placebos|Normal saline intralesional injection
25012|NCT03991936|Drug|Triamcinolone Acetonide 2.5 mg/mL|2.5 mg/mL intralesional injection
25013|NCT03991936|Drug|Triamcinolone Acetonide 5.0 mg/mL|5.0 mg/mL intralesional injection
25014|NCT03991936|Drug|Triamcinolone Acetonide 7.5 mg/mL|7.5 mg/mL intralesional injection
25015|NCT03991936|Drug|Triamcinolone Acetonide 10 mg/mL|10 mg/mL intralesional injection
25016|NCT03991923|Device|XVIVO heart preservation devices|The intervention is to preserve hearts during transportation cold, cardioplegic and non-ischemic, with a high oncotic and hormone supplemented perfusate.
25017|NCT03991910|Drug|Placebos|the control group will be given placebo inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking)
25018|NCT03991910|Drug|Ramipril 5Mg Oral Capsule|the treatment group will be given Ramipril 5 mg inside a capsule, so study participant won't be able to know the drug and doses inside the capsule (for masking)
25019|NCT03991897|Dietary Supplement|Ketogenic diet|Ketocal, a nutritionally complete ready-to-drink liquid, is foreseen to ensure adequate amounts of vitamins and minerals will be used. After 24 weeks a Modified Atkins diet will be started.
25020|NCT03991897|Dietary Supplement|Isocaloric diet|Patients will follow an isocaloric diet
25021|NCT03991884|Drug|Etoposide|Given IV
25022|NCT03991884|Drug|Doxorubicin|Given IV
25023|NCT03991884|Drug|Doxorubicin Hydrochloride|Given IV
25024|NCT03991884|Drug|Vincristine|Given IV
25025|NCT03991884|Drug|Vincristine Sulfate|Given IV
25026|NCT03991884|Drug|Prednisone|Given PO or IV
25027|NCT03991884|Drug|Cyclophosphamide|Given IV
25028|NCT03991884|Biological|Inotuzumab Ozogamicin|Given IV
25029|NCT03991884|Biological|Rituximab|Given IV
25030|NCT03991871|Device|External Counter Pulsation (ECP) therapy|35 hours ECP treatment in 35 sessions
25031|NCT03991858|Other|Phone call follow-up|A physical therapist made a phone call to the patient one month after his/her initial evaluation at the external rehabilitation clinic
25032|NCT03991858|Other|Telerehabilitation follow-up|A physical therapist made a direct follow-up through telerehabilitation to the patient one month after his/her initial evaluation at the external rehabilitation clinic
25033|NCT03991845|Drug|Vit D|Vit D supplementation was done
25034|NCT03991832|Drug|Olaparib|Olaparib is a drug that blocks a protein called poly (ADP-ribose) polymerase (PARP). PARP is important in the growth and spread of cancer cells. Because of this, blocking PARP from working is expected to stop the growth of or shrink cancer cells.
25035|NCT03991832|Drug|Durvalumab|Durvalumab is a drug that works by stopping a protein called Programmed Cell Death Ligand 1 (PD-L1) from working. PD-L1 is a protein that is thought to prevent the immune system (the body's defense against diseases) from killing cancer cells. Stopping PD-L1 from working is expected to allow the immune system to once again prevent or slow down cancer growth.
25036|NCT03991819|Drug|Binimetinib|Binimetinib is a drug that, inside the cell, blocks an important series of chemical reactions called a molecular pathway. Binimetinib blocks the MEK1/2 pathway from working. In some types of cancers, this pathway becomes too active, which can cause tumor cell growth. Blocking the MEK1/2 pathway from working is thought to slow or stop tumor cell growth.
25037|NCT03991819|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy drug that is approved by Health Canada for the treatment of patients with PD-L1 positive non-small cell lung cancer as a first treatment. PD-1 is a type of protein that binds to another type of protein known as PD-L1. When these proteins bind together, it helps prevent cells from killing each other, including cancer cells. Some drugs, like pembrolizumab, are used to block PD-1 from binding to PD-L1. When the protein is blocked, the body's immune system can kill more cells.
25038|NCT03991806|Other|Obsservational|The frailty and the health adverse events of older adults will be assessed by using a questionnaire called: Association of Centre of Excellence Self-Administered questionnaire (CESAM).
25039|NCT03991780|Drug|Fostamatinib|All patients will be given treatment with Fostamatinib. The initial treatment dose will be 100mg of Fostamatinib twice daily for 8 weeks. If after 8 weeks the participant has not experienced any side effects and are tolerant of this dose, then the dose will increase to 150mg twice daily. This dose will continue for the duration of the study.
25040|NCT03991767|Other|"POP-UP electronic alert"|"Implementation of the POP-UP electronic alert for all patients with eligibility criteria"
25041|NCT03991767|Diagnostic Test|Serology HIV|Realization of HIV serology for included patients.
25042|NCT03991754|Procedure|transcatheter aortic valve implantation|transcatheter aortic valve implantation
25043|NCT03991741|Biological|Autologous Tumor Infiltrating Lymphocytes|Autologous TILs
25044|NCT03991741|Biological|High-Dose Interleukin 2|720,000 IU/kg every 8 hours for up to 15 doses
25045|NCT03991715|Behavioral|Activity Tracker|Individually tailored daily and weekly physical activity goals established for all participants. Participants sent weekly reports for 6 weeks after cardiac rehabilitation discharge.
25046|NCT03991702|Diagnostic Test|diagnostic test|The overall motor function of the patient will be assessed using the Medical Research Council (MRC) scale and Palmar dynamometer strength
25047|NCT03991689|Behavioral|solution-focused group therapy|Participants began a 90-minute solution-focused pain management group, which lasted for six weeks, and after the group ended, the questionnaire post-test was carried out, and a total of 26 participants thus completed their group journey. The group effect was evaluated by the difference between the scores of the questionnaires before and after the group.
25048|NCT03991676|Behavioral|Values-Based Behavioral Treatment|The values-based behavioral treatment will consist of a series of three, once-weekly weight loss workshops infused with techniques to elicit values clarification and awareness in moments of dietary decision-making, and to enhance autonomous motivation for behavior change.
25049|NCT03991650|Behavioral|Monitoring with a device|Participants will be monitored by an App.
25050|NCT03991637|Device|Non-Invasive Comprehensive Metabolic Panel|The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
25051|NCT03991624|Diagnostic Test|cognitive assessment|"MMSE : Mini-Mental State Examination~5 words of Dubois~Direct Assessment of Functional Status~Trail Making Test~BREF : Fast Front End Efficiency Battery~short battery of praxies~Quality of Life in Alzheimer's Disease"
25052|NCT03991624|Other|Inhibition evaluation|"Stroop Victoria : This test consists of 3 sheets of 24 items, organized in 6 lines of 4 (points, neutral words or names of colours), from which the subject must identify the ink of the stimuli as quickly and precisely as possible.~Stop Signal task on the computer to give a response to the presentation of a target stimulus (Go signal) (e.g. pressing a button when a red circle appears on the screen, but doing nothing when a blue triangle appears), and prevent this response when the stimulus is followed or preceded by a beep (stop signal) (e.g. the appearance of a red circle is immediately preceded or followed by a beep, the subject should not press the button)."
25053|NCT03991624|Other|Assessment of mental flexibility|"a letter-number pair task. The subject sees 4 blocks of 48 letter-number pairs appear successively on a screen. When the pair appears at the top, the subject must make a parity judgment but when the pair appears at the bottom, the subject must make a consonant / vowel judgment.~a category change task, which consists in classifying a word according to one category or another according to a visual clue that appears. The task consists of 4 blocks of 48 stimuli."
25054|NCT03991624|Other|Evaluation of the update|"an update span task for which letters appear on a screen sequentially, and subjects must memorize the last three, without knowing the length of the list. The task will consist of 3 tests of training and then 20 tests. After three errors consecutive, the task ends.~an n-back task that consists of a sequential presentation of letters, during which the subject must indicate when the stimulus. The task consists of 3 levels, with n = 1, n= 2 or n = 3. For level 1 (with n = 1), the subject must press a button when the same letter appears twice in a row on the screen. This task consists of 75 letters."
25055|NCT03991624|Other|working memory|"the empan baba task, which mainly involves maintaining information, and which consists in retaining a series of letters, appearing sequentially on a screen, and whose latency time between two word presentations is required for a secondary task: the repetition of baba syllables.~the task of reading operations which consists in recalling operations series of letters whose presentation is interspersed with the reading aloud of simple operations and of their results.~the ongoing operational task of recalling a list of letters, the presentation of which is interspersed with operations that are simple to read aloud and to to solve head-on."
25056|NCT03991624|Other|episodic memory|- A recognition task with a Remember/Know paradigm
25057|NCT03991611|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate from 0 to 10 the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
25058|NCT03991611|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
25059|NCT03991611|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
25060|NCT03991598|Other|Exercise program|Exercise program in communities / Exercise program at home
25061|NCT03991585|Behavioral|Musical Contour Regulation Facilitation (MCRF)|MCRF involves 20-minute music therapy sessions comprised of seven interconnected components. Each session follows the same contour of neutral, low, and high arousal experiences facilitated through music.
25062|NCT03991572|Device|repeated transcranial magnetic stimulation with real coil|repeated transcranial magnetic stimulation with real coil is a noninvasive technique to activate and modify the activity of the neurons
25063|NCT03991572|Device|repeated transcranial magnetic stimulation with sham coil|repeated transcranial magnetic stimulation with sham coil is a placebo
25064|NCT03991559|Drug|Manganese Chloride|Administered intranasally in Arm 1 (0.05, 0.1 or 0.2 mg/kg/d) and by inhalation in Arm 2 (0.1, 0.2 or 0.4mg/kg/d) once daily in a 3-week cycle
25065|NCT03991559|Drug|Anti-PD-1 antibody|Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
25066|NCT03991559|Combination Product|Systemic therapy|Whether and which should be given depends on the treatment regimen before enrollment.
25067|NCT03991546|Behavioral|Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot|Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
25068|NCT03991533|Other|multiparametric MRI|preoperative multiparametric MRI
25100|NCT03991286|Dietary Supplement|Astaxanthin 4 mg|experimental
25101|NCT03991286|Other|placebo|Matching placebo pill
30205|NCT03950154|Biological|PD1-T cells|PD1-T cells injection
25069|NCT03991520|Drug|Anakinra 100Mg/0.67Ml Inj Syringe|The study drug is100mg/day Anakinra, which is the standard, FDA approved dose for the treatment of rheumatoid arthritis. The randomized treatment will be self-administered by the subject each evening by subcutaneous injection.
25070|NCT03991520|Drug|Placebo|The placebo is comparable to the anakinra formulation without the active medication - a solution (pH 6.5) containing anhydrous citric acid (1.29 mg), disodium EDTA (0.12 mg), polysorbate 80 (0.70 mg), and sodium chloride (5.48 mg) in water for injection
25071|NCT03991494|Drug|[14C]-pamiparib|During the treatment phase, pamiparib 60 mg administered orally twice daily
25072|NCT03991481|Biological|Cryopreserved platelets|Platelets that have undergone a process to freeze, store and reconstitute platelets, extending their expiry to 2 years
25073|NCT03991481|Biological|Liquid-stored platelets|Liquid-stored platelets as per standard practice
25074|NCT03991455|Device|Apyx device|The Apyx device enables approximation and fixation of the vaginal apex to the SSL using a deployable anchoring system.
25075|NCT03991442|Drug|Fimasartan/Amlodipine|Active Comparator: a fixed dose combination of Fimasartan/Amlodipine or placebo
25076|NCT03991429|Diagnostic Test|Simultaneous functional MRI and urodynamic studies|"Double lumen 7 Fr MRI-compatible catheters will be placed in the bladder and rectum. A Phillips Ingenia 3.0T full body MRI scanner with standard 12 channel head coil will be used. Instructions to communicate using right hand signals representing full urge and voiding or attempt of voiding will be given. Signs will be shown to the patient when filling of the bladder is begun and when filling is stopped. Also, in order to keep our noise-to-signal ratio low, all stimulators including any extra visual stimuli and the UDS machine will be removed from the MRI scanner room. The filling and voiding cycle will be repeated up to 4 times in each patient. Bladder will be aspirated after each voiding. This algorithm will be performed before, and, 3 and 6 months following BOO procedure."
25077|NCT03991429|Behavioral|Questionnaires|Each patient will provide a detailed history and undergo a complete physical examination. Each patient will have the following assessments: IPSS and Incontinence Severity Index (ISI), Patient Global impression of severity (PGI-S) and improvement (PGI-I), International Index of Erectile Function (IIEF-5), MRI Safety Screening Questionnaire.
25078|NCT03991429|Other|Post Void Residual (PVR), Uroflow and Bladder Diary|Follow-up assessments: Uroflow and PVR assessment, bladder diary, and all questionnaires will be repeated in all patients at one, three, and six months.
25079|NCT03991429|Diagnostic Test|Urinalysis|Urine sample
25080|NCT03991416|Behavioral|Understanding Your Baby|Research-based knowledge on the understanding and meeting of the baby's socioemotional needs is delivered to the parents systematically by public health visitors based on a manual, cue cards, and video clips at four time points from 1 to 10 months postpartum.
25081|NCT03991416|Behavioral|Postnatal care as usual|In accordance with Danish national guidelines, health visitors visit families during the infants first year of life, where they weigh and measure the infant. Further, they offer individual guidance and support regarding for instance feeding, sleeping, how to stimulate the infant, and the developmental stages that the infant goes through.
25082|NCT03991403|Drug|Atezolizumab(Tecentriq)|Atezolizumab(1200 mg IV);Over 60 (± 15) min (for the first infusion); 30 (± 10) min for subsequent infusions if tolerated Frequency: Day 1 of every 21 days Induction: Four or Six Cycles Maintenance : until PD
25083|NCT03991403|Drug|Pemetrexed|"Induction Period (Four or Six Cycles)~(1) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w~Maintenance Period (Until PD) Pemetrexed(500 mg/m2 IV); Over approximately10 minutes on Day 1 q3w"
25084|NCT03991403|Drug|Bevacizumab|Bevacizumab(15 mg/kg IV);Over 90 (±15) min (for the first infusion); shortening to 60 (± 10) then 30 (± 10) min for subsequent infusions if tolerated
25085|NCT03991403|Drug|Carboplatin|Carboplatin(AUC 6 IV a); Over approximately 15-30 min
25086|NCT03991403|Drug|Paclitaxel|Paclitaxel(200 mg/m2 IV); Over 3 hours
25087|NCT03991403|Drug|Carboplatin or cisplatin|Carboplatin(AUC 6 IV);Over approximately 30-60 minutes on Day 1 q3W or Cisplatin(75 mg/m²) ; Over 1-2 hours on Day 1 q3w
25088|NCT03991390|Other|Visual Feedback and Core Stability exercises protocol|"This arm consists of 5 sessions per week, 60 minutes each. One session consists of 30 minutes of conventional physiotherapy and 30 minutes of Core Stability exercises and laser visual feedback exercises, on alternate days.~All sessions will be performed by the same physiotherapist."
25089|NCT03991390|Other|Control stroke|"This arm consists of 5 sessions per week, 60 minutes each comprising usual physiotherapy treatment.~All sessions will be performed by the same physiotherapist."
25090|NCT03991377|Behavioral|Eye movement desensitization and reprocessing therapy|"EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~Patient history.~Patient preparation.~Patient assessment.~Memory desensitization.~Installing the positive cognition.~Body scan.~Closure.~Reevaluation."
25091|NCT03991377|Drug|Treatment as usual|Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
25092|NCT03991364|Other|Constant gait speed group|The speed of the robot-assisted gait treatment is constantly applied for 5 times a week for 2 weeks.
25093|NCT03991364|Other|Increasing gait speed group|The speed of the robot-assisted gait treatment is gradually increase for 5 times a week for 2 weeks.
25094|NCT03991351|Other|Exposure to images|Exposure to images
25095|NCT03991325|Diagnostic Test|upper airway sonography|clinical evaluation of upper airway, ultrasonographic assessement
25096|NCT03991312|Drug|itraconazole|Participants will receive an oral solution as described in the arm description.
25097|NCT03991312|Drug|rifampin|Participants will receive oral capsule(s) as described in the arm description.
25098|NCT03991312|Drug|mitapivat sulfate|Participants will receive an oral tablet as described in the arm description.
25102|NCT03991273|Other|Y-M2M©|The Y-M2M© group will receive classes that will be delivered onsite at a YMCA facility. Movement-to-Music (M2M©) is an instructor-guided exercise program that is coupled with music to enhance strength, cardiorespiratory capacity, range of motion, and balance.
25103|NCT03991273|Other|B-M2M©|The B-M2M© group will receive the same onsite M2M© classes as the Y-M2M© group, but they will also be provided with the option of performing home-based M2M© that will be delivered via videoconferencing.
25104|NCT03991260|Diagnostic Test|SPECT|One single injection of 99mTc- ADAPT6, followed by gamma camera imaging directly post-injection and after 2, 4 and 6 hours.
25105|NCT03991247|Behavioral|Computerized behavioral therapy program delivered by internet for insomnia management|"The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm)."
25106|NCT03991247|Other|Spa treatment|"Spa treatment is harmonized in the different stations. It consists in:~a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~an institutional follow-up: support, help and monitoring of patients during spa treatment~Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C."
25107|NCT03991234|Behavioral|Reading Intervention|Reading intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction to build skill on letter-sound associations, decoding, sight words, & contextualized reading.
25108|NCT03991234|Behavioral|Math Intervention|Math intervention provides 15 weeks (3 30-minute sessions per week) of explicit instruction on number knowledge & counting strategies to build arithmetic skill.
25109|NCT03991234|Behavioral|Coordinated Intervention|Coordinated intervention provides 15 weeks (30-minute sessions per week) of explicit instruction addressing the similar skills as in the reading intervention arm & similar objectives as the math intervention arm.
25110|NCT03991221|Other|Dental Exam|Visual examination of the child oral cavity bi non-orthodontist experts and orthodontist expert
25111|NCT03991221|Other|Orthodontics consult|Consultation with an orthodontics specialist if a malocclusion requiring early intervention is detected
25112|NCT03991221|Other|Call back at 6 month|Telephone call back at six months of inclusion in the study if a malocclusion requiring early intervention is detected
25113|NCT03991208|Drug|Malarone|Malarone
25114|NCT03991195|Dietary Supplement|Probiotic supplemented intervention|In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
25115|NCT03991195|Dietary Supplement|Functional foods|In this project, taking the method of random, double blindness and control, the functional foods group with aMCI will take BRAIN GOLDGUARD CAPSULE (Permission No. Guo-Shi-Jian-Zi G20130093) for three months. After that, cognitive changes will be test to investigate the effectiveness of functional foods.
25116|NCT03991195|Dietary Supplement|Placebo|In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
25117|NCT03991182|Other|SMAGs trained on ECD curriculum|50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
25118|NCT03991182|Other|Head women trained on ECD curriculum|Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
25119|NCT03991182|Behavioral|Head women led parent groups|Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
25120|NCT03991182|Other|Usual care of children 0-5 months|The traditional care and education of caregivers/parents for children 0-5 months
25121|NCT03991169|Drug|Ferrous Sulfate|Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight >43 kg.
25122|NCT03991156|Device|Audio-Visual Assisted Therapeutic Ambience in Radiotherapy|Audio Visual System
25123|NCT03991156|Other|Quality of Life Survey, PedsQL3.0|Quality of life survey using the PedsQL 3.0 Cancer Module
25124|NCT03991156|Other|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF)|Yale Preoperative Anxiety Scale Short Form (mYPAS-SF).[24] is a survey to measure anxiety
25125|NCT03991143|Drug|ATH3G10|intravenous
25126|NCT03991143|Drug|Placebo|intravenous
25127|NCT03991130|Drug|IL-2 and Nivolumab|Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
25128|NCT03991117|Behavioral|resistance exercise|unilateral knee extensions until fatigue with varying load and speeds of contraction
25129|NCT03991104|Drug|Oxaliplatin|Oxaliplatin (3 levels for phase I: 110 mg/m², 120 mg/m² and 130 mg/m²) is administered as a 2 h intravenous infusion in 500 mL of 5% glucose on day 1 and day 29 during the treatment course.
25130|NCT03991104|Drug|S-1 capsule|Patients received a fixed dose of S-1 with a dose of 80 mg/m2/d twice daily for 2 weeks, every 4 weeks.
25159|NCT03990844|Dietary Supplement|Okra seed|Noodle enriched with 10% and 20% Okra seed flour.
25131|NCT03991104|Radiation|Intensity modulated radiotherapy (IMRT)|The total radiation dose was set to 50.4 Gy, which was given in 28 fractions of 1.8 Gy once-daily fractions for over 5 weeks.
25132|NCT03991091|Drug|discontinuation of oxytocin administration|Discontinuation of oxytocin administration at the beginning of the active phase of the 1st stage of labor, i.e. oxytocin infusion will be stopped beyond a cervical dilatation of 6cm. In the experimental group, oxytocin can be re-started, if necessary, after 2 hours of arrest of labor.
25133|NCT03991091|Drug|continuation of oxytocin administration|continuation of oxytocin administration
25134|NCT03991065|Diagnostic Test|high digestive endoscopy|high digestive endoscopy with biopsies performed according to the sydney protocol
25135|NCT03991052|Device|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
25136|NCT03991039|Radiation|Gamma knife|Microvascular decompression
25137|NCT03991026|Behavioral|Healthy food and Education/Cooking Classes|The intervention includes providing weekly seasonal produce and healthy foods to participants in addition to an education/cooking class that will be tailored to Diabetes Mellitus, Type II.
25138|NCT03991013|Drug|TLD: fixed dose combination of tenofovir, lamivudine and dolutegravir antiretroviral therapy|TLD fixed dose combination contains tenofovir 300mg, lamivudine 300mg and dolutegravir 50mg, administered once daily orally for 48 weeks
25139|NCT03991013|Drug|ALD: combination of zidovudine, lamivudine and dolutegravir antiretroviral therapy|ALD is the World Health organization standard of care second line regimen, and contains a combination of zidovudine 300mg and lamivudine 150mg, administered orally as a fixed dose combination twice daily, and dolutegravir 50mg administered orally once daily, for 48 weeks.
25140|NCT03991000|Drug|Ferric carboxymaltose|Intravenous iron
25141|NCT03991000|Drug|Saline|Saline application according to dosing rules of iron.
25142|NCT03990987|Other|time of receiving operation|patients were randomly divided into Day group (D group) (8：00～12：00) and Night group (N group) (18：00～22：00), Patients received propofol, remifentanil, and DEX for general anesthesia maintenance
25143|NCT03990974|Drug|postoperative antimicrobial prophylaxis|The drugs are all common antibiotics used to prevent postoperative infection in each hospital.
25144|NCT03990974|Other|No postoperative antimicrobial prophylaxis|Patients will receive no antibiotics after hepatectomy unless necessary.
25145|NCT03990961|Drug|Pembrolizumab|Subjects will receive pembrolizumab treatment at a dose of 200mg IV every 3 weeks for a duration of 2 years (35 cycles).
25146|NCT03990948|Other|Blood sampling|Blood sample collection
25147|NCT03990935|Other|ginger and rosemary gel|First the participant will be asked to brush his/her teeth thoroughly with 1450 ppm fluoride toothpaste (Colgate total healthy clean toothpaste). Then an application of a thin ribbon of this gel to the teeth using a brush. The medication will be left for at least 1 minute. The participant will be asked to spit out the medication after use and not to swallow it. Also the participant will be asked not to rinse his/her mouth, eat, or drink for at least 30 minutes after use to get the best results.
25148|NCT03990922|Procedure|Continuous Paravertebral block with ropivacaine|Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
25149|NCT03990922|Procedure|"Continuous Paravertebral block with saline"|Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h).
25150|NCT03990922|Drug|Patient-controlled analgesia with morphine|Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
25151|NCT03990909|Dietary Supplement|Branched Chain Amino Acids|60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
25152|NCT03990909|Dietary Supplement|Rice Protein|60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
25153|NCT03990909|Dietary Supplement|Microcrystalline Cellulose|60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).
25154|NCT03990896|Drug|Talazoparib|"Talazoparib is a study drug that inhibits (stops) the normal activity of certain proteins called poly (ADP-ribose) polymerases also called PARPs. PARPs are proteins (made from genes which are part of DNA) that are found in all normal and cancer cells that are involved in the repair of DNA. PARPs are needed to repair mistakes that can happen in DNA when cells divide. If the mistakes are not repaired, the defective cell will usually die and be replaced. Cells with mistakes in their DNA that do not die can become cancer cells."
25155|NCT03990883|Device|Princess Filler Lidocaine|correction of nasolabial folds
25158|NCT03990857|Other|Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care|This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
25160|NCT03990831|Diagnostic Test|Functional near-infrared spectroscopy (fNIRS)|Functional near-infrared spectroscopy (fNIRS) measurement
25161|NCT03990805|Biological|JOINTSTEM|JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10^8cells/(saline), 1 time injection
25162|NCT03990805|Drug|saline|saline, 1 time injection
25163|NCT03990792|Behavioral|e-predictD intervention|The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps patients to develop their own personalized plans to prevent (PPP) depression; 3) eight intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the patient. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improving sleep, expanding relationships, problem solving, improving communication skills, assertiveness training, making decisions and managing thoughts. Patients will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 3, 6 and 9 months. The intervention also includes an initial and single 15-minute face-to-face GP-patient interview.
25164|NCT03990792|Other|Brief psychoeducational intervention|The intervention consists of an App that weekly send brief psychoeducational messages about physical and mental health (depression, anxiety, sleep hygiene, physical activity, etc.)
25165|NCT03990779|Diagnostic Test|Echocardiography|Echocardiographic examination before and after cardiopulmonary bypass
25166|NCT03990766|Drug|Theophylline|Theophylline delivered via high-volume, low-pressure nasal saline irrigation
25167|NCT03990766|Drug|Saline Nasal|Lactose delivered via high-volume, low-pressure nasal saline irrigation
25168|NCT03990753|Diagnostic Test|esophagogastroduodenoscopy|standard esophagogastroduodenoscopy
25169|NCT03990740|Procedure|Corneal sampling|Corneal samples will be taken during corneal transplants for cases and orbital exenterations for controls. The mRNA (messenger ribonucleic acid) will be extracted and a retrotranscription will be made to obtain cDNA (complementary DNA). A qPCR (quantitative polymerase chain reaction) will be able to quantify the expression of alpha-SMA, MMP 1-2-3 and 9, and EMMPRIN.
25170|NCT03990727|Diagnostic Test|Retina Analysis-mosaic|Fundus retina pattern study
25171|NCT03990727|Diagnostic Test|Autofluorescence|Fundus reflectance-functionality
25172|NCT03990727|Diagnostic Test|OCT- 1 micra|Fine tomography fundus retina
25173|NCT03990727|Procedure|Genotype analysis|Molecular target retina dystrophy analysis
25174|NCT03990714|Procedure|Right hemicolectomy|It is the resection of the right colon by a tumor and the reconstruction by an ileocolic anastomosis: intracorporeal or extracorporeal
25175|NCT03990701|Combination Product|11C-Metomidate PET/CT Scan|11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
25176|NCT03990688|Drug|AK3280|Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
25177|NCT03990688|Drug|Placebo|Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
25178|NCT03990675|Procedure|FNA, FNB|Endoscopic ultrasound guided fine needle aspiration, Endoscopic ultrasound guided fine needle biopsy
25179|NCT03990662|Other|Physiotherapy - Manual Therapy|Participants will receive four sessions of manual therapy applied to craniomandibular structures over four weeks. The application of manual therapy aims to decrease pain by treating masticatory muscle trigger points, muscle tightness, and restricted temporomandibular joint movements. Several techniques will be considered, including ventral and caudal anterior glide temporomandibular joint mobilisation, soft tissue interventions for the management of trigger points in masticatory muscles and myofascial induction therapy applied to craniomandibular structures. The structures targeted in the treatment sessions will be the temporomandibular joint, temporal muscles, masseter muscles, medial and lateral pterygoid muscles and suprahyoid muscles.
25180|NCT03990649|Drug|TAK-935|TAK-935 Tablets
25181|NCT03990649|Drug|TAK-935 Placebo|TAK-935 placebo-matching tablets
25182|NCT03990636|Drug|Metil 5-aminolevulinate|Scrubbing lip vermillion and applying the medication or placebo that is activated (or not, in case of placebo) with red light.
25183|NCT03990623|Radiation|Computed Tomography Perfusion Imaging|Undergo perfusion CT
25184|NCT03990623|Procedure|Liver Biopsy|Undergo liver biopsy
25185|NCT03990610|Procedure|Mammoplasty|Undergo standard of care breast reconstructive surgery
25186|NCT03990610|Procedure|Vascularized Lymph Node Transfer|Undergo vascularized lymph node transfer
25187|NCT03990597|Other|Placebo|Applied topically
25188|NCT03990597|Other|Questionnaire Administration|Ancillary studies
25189|NCT03990597|Drug|Wound Dressing Material|Applied StrataXRT topically
25190|NCT03990584|Procedure|three irrigation activation methods|passive ultrasonic irrigation, sonic irrigation, manual dynamic irrigation
25191|NCT03990584|Procedure|conventional needle irrigation|conventional needle irrigation
25192|NCT03990571|Drug|Avelumab|Given IV
25193|NCT03990571|Drug|Axitinib|Given PO
25194|NCT03990532|Radiation|treatment group(phase I)|"Dose-escalation plan (phase I)~Radiotherapy:~LEVEL 1: dose given at PTV-G will be 58.8Gy/28 fractions； 2.1Gy/per fraction; LEVEL 2: dose given at PTV-G will be 64.4Gy/28 fractions； 2.3Gy/per fraction; LEVEL 3: dose given at PTV-G will be 70Gy/28 fractions； 2.5Gy/per fraction Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine"
25195|NCT03990532|Radiation|treatment group (phase II)|Radiotherapy dose was prescribed according to phase I trial results; Concurrent chemotherapy: 5-Fu/capecitabine/S-1+DDP or S-1 or Capecitabine
25196|NCT03990519|Drug|JNJ-26366821|Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
25197|NCT03990519|Drug|Placebo|Participants will receive sodium chloride injection as placebo on Day 1.
25198|NCT03990506|Procedure|Epi-on PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. For masking purposes, epithelial debridement is simulated by moving a scraping instrument in front of the cornea. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen goggles. The UV-dosage is individually customized based upon Kmax; for < 45 Diopters (D) 7.2J/cm2 is used; for 45-50D 10J/cm2 is used; for > 50D 15 J/cm2 is used.
25199|NCT03990506|Procedure|Epi-Off PiXL|Photorefractive intrastromal crosslinking (PiXL) After local anaesthetics, the corneal epithelium is debrided and the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. The cornea is then illuminated with individually customized PiXL under 16:40 minutes. The UV-dosage is individually customized based upon Kmax; for < 45D 7.2J/cm2 will be used; for 45-50D 10J/cm2 will be used; for > 50D 15 J/cm2 will be used.
25200|NCT03990493|Biological|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV (1 injection)
25201|NCT03990493|Biological|Autologous Monocyte-derived Lysate Pulsed Dendritic Cells (PV-001-DC)|IV Infusion of PV-001-DC (every 3 weeks for total of 4 infusions)
25202|NCT03990480|Drug|valsartan (160 mg/d)|Group I treated with valsartan (160 mg/d, n = 100)
25203|NCT03990480|Drug|amlodipine (10 mg/d).|Group II amlodipine (10 mg/d, n = 100).
25204|NCT03990467|Biological|Plasma dosage of amikacin, piperacillin and tazobactam|Pharmacokinetic (PK) criteria will be used to judge whether the PK parameters of amikacin are predictive of those of piperacillin and tazobactam
25205|NCT03990454|Drug|SLC-391|SLC-391 is an AXL inhibitor
25206|NCT03990441|Device|TENS|TENS application using the TensMed S82 (Enraf Nonius). Current parameters: balanced symmetric biphasic square waveform, continuous stimulation, frequency 80 Hz, pulse duration modulated between 250 and 290 μs, modulation time 5 seconds. Self-adhesive electrodes of 50 x 90 mm applied paravertebrally to 2 cm. of the spinous apophysis. Use of two channels with independent intensity (mA): electrodes of the first channel applied at level T10-L1 and second channel ones at level S2-S4. Maximum intensity without reaching pain, increasing the intensity throughout the application to maintain this level. Start of the intervention when the woman expresses pain. End of the intervention when neuraxial anesthesia is applied (if the woman demands it) or after delivery.
25207|NCT03990441|Device|TENS Placebo|Same application as Intervention, but using 0,1 mA as fixed intensity on both channels.
25208|NCT03990428|Behavioral|online surveys|Survey data about supportive care needs, mood, and the experience of IC's finding meaning and purpose in the caregiving experience.
25209|NCT03990415|Behavioral|Exercise|Exercise is a behavioral intervention, the primary aim of this investigation is to elucidate if strength training is a more effective exercise intervention than walking for the improvement of balance in older adults.
25210|NCT03990389|Device|Chatbot Intervention|a chatbot will be used to monitor depression severity
25211|NCT03990376|Other|Radioisotope I-131-labeled albumin|1 mL of radioisotope I-131-labeled albumin x 2
25212|NCT03990363|Drug|Verinurad|Study treatments will be titrated in 3 steps for target low dose (3 mg), intermediate dose ( 7.5 mg) and High Dose (12 mg) Verinurad.
25213|NCT03990363|Drug|Allopurinol|Study treatments will be titrated in 3 steps: Low dose (100 mg), intermediate (200 mg) and High Dose ( 300 mg) Allopurinol
25214|NCT03990363|Drug|Placebo for Verinurad|Matching Capsule
25215|NCT03990363|Drug|Placebo for Allopurinol|Matching tablet
25216|NCT03990350|Other|Fecal Sample Collection|With permission from the parent/guardian, stool collected in a sterile container will be brought within 12 hours of defecation from home or the outpatient clinic to a separate clinical laboratory where feces will be collected through use of FLOQswab brush x 3 (Copan Diagnostics, Murrieta, CA) The swabs will be pre-labeled with a de-identified code reflecting patient number, sample number, and date and the sample will be placed into dry ice then transferred to a -80 degrees Celsius freezer until retrieval by the research staff for transfer to CHOP Microbiome Center.
25217|NCT03990350|Other|Physical Activity Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Physical Activity Questionnaire (Physical Activity Questionnaire for Older Children) with the subject and parent.
25218|NCT03990350|Other|Food Frequency Questionnaire|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the Food Frequency Questionnaire with the subject and parent.
25219|NCT03990350|Other|24-hour dietary recall diary|At the initial encounter the co-investigator Dr. David Garcia, who is a certified Spanish translator will complete the 24-hour dietary recall diary with the subject and parent.
25220|NCT03990337|Device|Ultrasound|Ultrasonography of cricoid cartilage.
25221|NCT03990324|Procedure|Manual stretching|Manual stretching for the upper trapezius and levator scapulae muscle
25222|NCT03990311|Other|Sodium Restricted Meals|2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period
25223|NCT03990311|Other|Control|Usual Care
25224|NCT03990298|Diagnostic Test|Awake endoscopy|Awake endoscopic exam will be performed to measure airway size in the retropalatal and retroglossal upper airway regions using different Inspire implant configurations and voltages. The optimal test configuration determined on endoscopy will be tested during a sleep study and compared to the standard-of-care device configuration, with improvements in sleep study outcomes indicating that awake endoscopy is useful during Inspire implant activation.
25225|NCT03990285|Drug|Axumin, Intravenous Solution|To compare 18F-fluciclovine PET uptake measures in glioblastoma patients with tumor progression versus pseudoprogression
25226|NCT03990272|Drug|AIT drops|once a day
25227|NCT03990272|Drug|placebo drops|once a day
25228|NCT03990259|Other|Running the CSP Mountain Race|The runners completed a 107,6 km mountain race
25229|NCT03990246|Other|Acid stable emulsion with solid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are crystalline. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.2% of the emulsifier sorbitan monooleate (Tween80)
25263|NCT03990025|Diagnostic Test|Linked Color Imaging|Linked Color Imaging (LCI) is a form of image enhanced endoscopy that uses a laser endoscopic system that acquires images by simultaneously using narrow-band wavelength light and white light in an appropriate balance. This enhances slight color differences in the red region of the mucosa.
47726|NCT03811002|Other|Questionnaire Administration|Ancillary studies
25230|NCT03990246|Other|Acid stable emulsion with liquid droplets|This will be a 250 mL acid stable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.2% of the emulsifier sorbitan monooleate (Tween80)
25231|NCT03990246|Other|Acid unstable emulsion with solid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are solid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20% of the lipid palm stearin with 2.5% of the emulsifier sorbitan monostearate (Span60)
25232|NCT03990246|Other|Acid unstable emulsion with liquid droplets|This will be a 250 mL acid unstable beverage emulsion in which the droplets are liquid. It will have identical similar to the other intervention, i.e. in a set of samples the emulsion lipid droplets are in the liquid state and are either acid stable or unstable and, in the other set of samples they are solid (i.e. crystallized) and are also either acid stable or unstable in the acidic environment of the stomach, and will be introduced at least 7 days apart. The emulsion will contain 20 % of the lipid palm olein with 2.5% of the emulsifier sorbitan monostearate (Span60)
25233|NCT03990233|Drug|BI 765063|mAb antagonist to SIRPα receptor, a myeloid checkpoint inhibitor
25234|NCT03990233|Drug|BI 754091|mAb antagonist to PD-1 receptor, a lymphocyte T checkpoint inhibitor
25235|NCT03990220|Dietary Supplement|Lactobacillus rhamnosus yoba 2012|"Probiotics are defined by the Food and Agricultural Organization (FAO)/WHO as live microorganisms, which when consumed in adequate amounts, confer a health benefit on the host. Lactobacillus rhamnosus GG (LGG) is the most documented probiotic bacteria, with many proven unique characteristics and therewith associated health benefits. No adverse effects of the consumption of LGG in healthy infants have been reported. The Lactobacillus rhamnosus yoba containing yoghurt drink, which is locally produced and subsequently consumed by resource-poor communities in rural Uganda has been described. The strain used in this intervention is a generic variant of LGG, called Lactobacillus rhamnosus yoba 2012. LGG is consumed as part of food all over the world, and is not a drug."
25236|NCT03990207|Device|PowerSpiral Enteroscopy System|Motorized spiral enteroscopy system
25237|NCT03990194|Drug|Leuprolide Acetate|Administration of Leptoprol implant every 3 months
25238|NCT03990181|Dietary Supplement|meal matrix & NPPS|Test meal consumed with the natural polyphenol supplement
25239|NCT03990181|Dietary Supplement|meal matrix & CS|Test meal consumed with the control supplement
25240|NCT03990181|Dietary Supplement|no-matrix & NPPS|Test drink consumed with the natural polyphenol supplement
25241|NCT03990181|Dietary Supplement|no-matrix & CS|Test drink consumed with the control supplement
25242|NCT03990168|Device|Anodal tDCS|1 mA anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The tDCS stimulation will be delivered for 20 minutes on 6 intervention days.
25243|NCT03990168|Behavioral|fluency intervention/ Delayed Auditory Feedback|Each participant complete three tasks include reading, conversation, and narration. Delayed auditory feedback will be used during these tasks. Each treatment session will take 20 minutes.
25244|NCT03990168|Device|Sham tDCS|The anodal tDCS positioned over left superior temporal gyrus and the cathode placed over the occipital lobe. The current of sham stimulation will involve 30 seconds of stimulation at the beginning of the 20 minutes on 6 intervention days.
25245|NCT03990155|Procedure|HFNCOT+ECCO2R|NIV will be discontinued, the ECCO2R setting will be unchanged (both sweep gas flow and blood flow through the artificial lung) and HFNCOT will be started, titrating the fraction of inspired Oxygen (FiO2) to obtain an oxygen saturation at periphery (SpO2) 88-92%; HFNCOT start temperature will be 31°C, the initial flow rate will be 60 L/min.
25246|NCT03990142|Diagnostic Test|Cutaneous conductance to chlorine by SUDOSCAN|"The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the connection to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®."
25247|NCT03990129|Drug|Metamizole|One week treatment with metamizole (500 mg tablets, 2-2-2)
25248|NCT03990116|Procedure|Lateral|Posture lateral kangaroo care
25249|NCT03990116|Procedure|Prone|Posture prone kangaroo care
25250|NCT03990103|Drug|S1|80-120 mg/day, PO, D1-14, every 21 days
25251|NCT03990103|Drug|Paclitaxel|20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
25252|NCT03990103|Drug|Bevacizumab|200 mg, IP, D1, every 21 days
25253|NCT03990103|Drug|Oxaliplatin|130 mg/m2, IV, D1, every 21 days
25254|NCT03990090|Drug|TG103|Administered SC
25255|NCT03990090|Drug|Placebo|Administered SC
25256|NCT03990077|Drug|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
25257|NCT03990077|Drug|Docetaxel|Docetaxel is an antineoplastic drug by inhibiting microtubule depolymerization, and attenuating of the effects of bcl-2 and bcl-xL gene expression.
25258|NCT03990064|Other|musicotherapy|receptive music therapy. The musical style of the session was chosen by the patient. The validated 'U' technique was employed.
25259|NCT03990051|Drug|Pro-ocular™ topical gel|Topical gel for forehead dermal application
25260|NCT03990051|Drug|Placebo topical gel|Topical gel for forehead dermal application
25261|NCT03990038|Drug|Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h|Group C receive the intervention Group U receives the placebo See arm description
25262|NCT03990038|Drug|Extended Release Capsule|"Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description"
25264|NCT03990025|Diagnostic Test|White Light Imaging|White Light Imaging (WLI) uses conventional white light that encompasses all bandwidths of light to illuminate areas of interest to obtain endoscopic images.
25265|NCT03990012|Procedure|IR Imaging|Subjects will undergo steady steady state and video IR imaging of the breasts.
25266|NCT03990012|Procedure|3D Scanning|Subjects will undergo 3D scanning of the breasts.
25267|NCT03989999|Procedure|Transcranial Doppler (TCD)|"In the Emergency Department (ED):~After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.~If TCD is normal (FVd>25 cm/sec and PI <1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.~If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).~No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group."
25268|NCT03989986|Behavioral|iPeer2Peer Mentorship|Mentors and participants can have up to ten Skype calls over the course of 15 weeks.
25269|NCT03989973|Diagnostic Test|Gastroscopy|Gastroscopy
25270|NCT03989960|Procedure|LISA+SNIPPV|The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.
25271|NCT03989960|Procedure|traditional InSurE|The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
25272|NCT03989947|Drug|Active BMN 111: Daily subcutaneous injection of 15 ug/kg of BMN 111|Modified recombinant human C-type natriuretic peptide
25273|NCT03989934|Behavioral|The Mind in Action|Mindfulness program for adolescents
25274|NCT03989934|Behavioral|Healthy Topics|Health education program for adolescents
25275|NCT03989921|Other|no intervention. observational study|no intervention. observational study
25276|NCT03989908|Other|Microfludic noodle|In this intervention arm, subjects will be served with noodles made using microfludic technology.
25277|NCT03989908|Other|Control noodle|In this intervention arm, subjects will be served with normal noodle.
25278|NCT03989895|Biological|Dengue Virus-1 #45AZ5 (PV-001-DV)|Intratumoral injection of PV-001-DV
25279|NCT03989882|Other|Wheat germ energy ball|wheat germ mixed other ingredients to make an energy ball
25280|NCT03989882|Other|Control|corresponding control without wheat germ
25281|NCT03989869|Other|Immediate treatment|Early Medical Abortion treatment, when ultrasound does not yet have conclusive signs of intrauterine pregnancy
25282|NCT03989856|Device|2-0 polyglican absorbable sutures|The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
25283|NCT03989856|Device|Diathermy|bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
25284|NCT03989830|Drug|second-line chemotherapy|choose appropriate regimen according to efficacy and adverse effects of first-line chemotherapy. q3W regimen, 6 cycles.
25285|NCT03989830|Drug|Recombinant human endostatin|7.5mg/m2/d，continuous intravenous pumping in 2ml/h for 5 days each cycle. Endostar(d-7) begins one week before chemotherapy(d0), first 5-day-pump(d-7 to d-2, 240ml, 2ml/h). Second 5-day-pump begins two days later (d1 to d5). the rest pumps can be done in the same manner. Three 5-day-pumps can be done during one chemotherapy cycle. Endostar will be pumped 18 weeks during 6 cycles'second-line chemotherapy.
25286|NCT03989817|Drug|Vasoactive Intestinal Peptide (VIP) and Saline|12 healthy volunteers of both genders will be included in the main study. Participants will meet twice, with at least one week in between. The main study is a double-blind, randomized, cross-over trial among placebo (sterile saline, non-active substance) and VIP. Intravenous infusion of VIP / placebo (saline) will be conducted over 120 minutes. Patients will be asked after each trial day to record headache strength, accompanying symptoms, and drug use for up to 24 post-infusion.
25287|NCT03989804|Behavioral|Targeted follow-up|2 phone calls and 1 e-mail delivered over 6-8 weeks after enrollment aiming to help and support members to get started using the fitness center and its services.
25288|NCT03989791|Dietary Supplement|absolute diet|Patients in absolute diet group were fasted from any food with intravenous infusion of 5% glucose and sodium chloride instead in the first 24 hours. Then, the patients will be given soup for the next 24 hours if there was no delayed complication or discomfort during the fasting. Finally, they will gradually transit from soup to normal diet such as porridge, noodles and rice in the third 24 hours.
25289|NCT03989791|Dietary Supplement|normal diet|Patients in normal diet group were directly given normal diet such as porridge, noodles and rice as usual after polypectomy. Meanwhile, all the patients in two groups were given PPI for 3 days intravenously and restricted from vigorous exercise for 14 days.
25290|NCT03989778|Drug|Vitamin D|Vitamin D supplementation
25291|NCT03989765|Other|Programme to reduce involuntary treatment episodes|See description of trial arms
25292|NCT03989752|Device|Wearable Robotic Exoskeleton for Ambulation|16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
25293|NCT03989739|Device|Da Vinci|
25294|NCT03989726|Procedure|AF ablation|AF ablation includes pulmonary vein isolation and/or voltage and fractionation guided ablation
25295|NCT03989713|Drug|MRD-triggered arm|"Salvage therapy:~Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / >-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~Consolidation therapy:~Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / >-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3~Observation therapy:~No treatment"
25296|NCT03989713|Drug|Prophylactic Arm|"Salvage therapy:~Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid / >-60yrs: 1g/m² bid, i.v. 3h i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min: Days: 2,3;~Consolidation therapy:~Quizartinib: 40mg, p.o., Days: 4 - 21 Cytarabine: 18-60yrs: 3g/m² bid, i.v. 3h / >-60yrs: 1g/m² bid, i.v. 3h, Days: 1,2,3; Mitoxantrone: 10mg, i.v. 30min, Days: 2,3;~Maintenance therapy:~Quizartinib: Cycle 1, Days 1-15: 40mg, p.o. and Day 16-28: 60mg, p.o."
25337|NCT03989414|Drug|Daratumumab|Daratumumab
25338|NCT03989414|Drug|Carfilzomib|Carfilzomib
25297|NCT03989700|Drug|Thiamine Mononitrate|Low dose group: thaimine mononitrate 25 mg/day per oral daily for 4 weeks High dose group: thaimine mononitrate 50 mg/day per oral daily for 4 weeks Placebo group: placebo 25 mg/day per oral daily for 4 weeks
25298|NCT03989687|Device|Fuji Triage|glass ionomer sealant
25299|NCT03989687|Other|isolation|rubber dam or cotton roll isolation
25300|NCT03989674|Dietary Supplement|Anthocyanin|25% w/w anthocyanin extract obtained from black rice
25301|NCT03989648|Other|Esmarch bandages|Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.
25302|NCT03989648|Other|simple leg elevation|simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
25303|NCT03989635|Drug|QAW039|QAW039 450mg
25304|NCT03989622|Other|evaluation of the visual field on the ground|evaluation of the visual field on the ground
25305|NCT03989609|Drug|Dexmedetomidine Injection [Precedex]|Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,
25306|NCT03989609|Drug|Midazolam|midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
25307|NCT03989596|Radiation|Hypofractionated radiotherapy|"Preoperative hypofractionated 10x 3.25 Gy radiotherapy (5 consecutive days in a week, two weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.~Radiotherapy boost 4x 4 Gy within one week in case of unresectability after 6 weeks."
25308|NCT03989596|Other|Hyperthermia|Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.
25309|NCT03989583|Other|Infrared thermography|Temperature observation in foot and footwear in healthy children
25310|NCT03989570|Procedure|transversus abdominis plane block|The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected
25311|NCT03989570|Procedure|erector spinae plane block|The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes
25312|NCT03989570|Other|control group|placebo
25313|NCT03989570|Drug|Bupivacaine|bupivacine 0.25% (20 ml on each side)
25314|NCT03989570|Drug|Saline|40 ml saline 0.9% (20 ml on each side)
25315|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|The modification of aspirin and clopidogrel/ticagrelor maintenance doses based on a biomarker assays.
25316|NCT03989557|Device|Light transmittance aggregometry|point-of-care method to assess platelet function by light transmittance aggregometry.
25317|NCT03989557|Drug|Aspirin and clopidogrel/Ticagrelor|maintenance dose of aspirin, clopidogrel and ticagrelor.
25318|NCT03989544|Biological|Tezepelumab|Tezepelumab subcutaneous injection
25319|NCT03989531|Biological|Adrecizumab|Drip infusion over 60 minutes
25320|NCT03989531|Drug|Placebo|Drip infusion over 60 minutes
25321|NCT03989518|Behavioral|Fear acquisition|Day 1. Participants are exposed to two different visual stimuli. One of these stimuli is paired with a mild electric shock (i.e. conditioned stimuli).
25322|NCT03989518|Behavioral|Imaginal extinction|Day 2 (24 hours after Day 1). Participants are exposed to mental imagery of the stimuli used during fear conditioning. Imagery is prompted through different verbal instructions presented in a pseudo-randomized order. No shocks are delivered. Prior to imaginal extinction, participants receive task specific training.
25323|NCT03989518|Behavioral|Reinstatement|Day 3 (48 h after day1). Participants are exposed to the same stimuli used during fear conditioning (day 1) and imaginal extinction (day 2). Two unsignaled shocks are delivered at the beginning of the experiment, prior to the presentation of the first visual stimulus. No further shocks are delivered. This procedure allows the study of long term effects of imaginal extinction.
25324|NCT03989505|Diagnostic Test|blood-draw for biomarker analyses|Blood will be drawn at three time-points: immediately before catherization, 12-24 hours after catheterization and 4-8 weeks after discharge. Creatinine will be measured for endpoint definition, while the markers urea, CRP (C-reactive protein), NGAL (neutrophil gelatinase-associated lipocalin), KIM-1 (kidney injury marker-1), cystatin C, suPAR (soluble urokinase-type plasminogen activator receptor), and penKid will be measured as biomarkers of interest.
25325|NCT03989492|Other|systemic and local stressors|Protocol 1: skin sympathetic nerve activity will be measured during mental math and handgrip exercise. Protocol 2: skin end organ responses will be measured at baseline and in response to systemic stressors and end-organ receptor stimulation. Protocol 3: skin end organ responses will be measured at baseline and during local heating.
25326|NCT03989479|Behavioral|Brushing demonstration using T shaped toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
25327|NCT03989479|Behavioral|Brushing demonstration using conventional toothbrush|Brushing demonstration given at baseline and reinforced at 2 weeks and 1 month
25328|NCT03989466|Biological|Alemtuzumab|Given IV
25329|NCT03989466|Drug|Itacitinib|Given PO
25330|NCT03989453|Other|Chi Kung group|The duration of the intervention is 12 weeks, with 2 sessions per week of Chi Kung. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up (Based on breathing and concentration exercises), of 10 minutes duration, a 40-45 minute Chi Kung session and finally 10 minutes of guided relaxation.
25331|NCT03989440|Drug|AXER-204|human NoGo Trap fusion protein
25332|NCT03989440|Drug|Placebo|Phosphate buffered saline formulation
25333|NCT03989427|Other|Flossing and brushing|Participants will be selected by random sampling using computer generated random numbers and allocated to Brushing and Flossing (BF) sequence, and after 1 week wash out period to Flossing and brushing (FB) sequence.
25334|NCT03989414|Drug|CC-92480|CC-92480
25335|NCT03989414|Drug|Bortezomib|Bortezomib
25336|NCT03989414|Drug|Dexamethasone|Dexamethasone
25339|NCT03989401|Other|Multimedia video health education|The experimental group conducted multimedia video education while admission.
25340|NCT03989388|Behavioral|Occupational self-analysis|"The Occupational Self-Analysis program provides participants with a space where they can learn to analyse the barriers and supports for occupational participation."
25341|NCT03989388|Behavioral|Vocational guidance|To explore participant´s job interests and learned how to find a job and define a professional profile.
25342|NCT03989388|Behavioral|Usual Rehabilitation|Usual rehabilitation: occupational therapy and/or physiotherapy.
25343|NCT03989375|Device|transcutaneous vagus nerve electric stimulator|The stimulator that can be attached to ears of the patient.We suppose that this device can reduce the incidence of perioperative neurocognitive disorders(PND)
25344|NCT03989362|Drug|Vopratelimab|Specified dose on specified days
25345|NCT03989362|Drug|Ipilimumab|Specified dose on specified days
25346|NCT03989349|Drug|Placebo|Placebo
25347|NCT03989349|Drug|Nemolizumab|Nemolizumab
25348|NCT03989336|Drug|Manganese Chloride|Administered by inhalation at 0.4mg/kg/d once daily in a 3-week cycle
25349|NCT03989336|Drug|nab-paclitaxel|Administered intravenously, 180-220mg/m2 on day 2 in a 3-week cycle (day 1 without Manganese priming)
25350|NCT03989336|Drug|Platinum chemotherapy|Administered intravenously, Cisplatin (60-80mg/m2) or Carboplatin (area under the curve [AUC] 4-6 mg/mL per min) on day 2 in a 3-week cycle (day 1 without Manganese priming)
25351|NCT03989336|Drug|Sintilimab|Administered intravenously, 200mg on day 3 in a 3-week cycle (day 2 without Manganese priming)
25352|NCT03989323|Other|Estimation of the incidence of the irAE|Assessment of the incidence of the irAE in patients treated with immunotherapy at the Hospices Civils de Lyon (irAE of all grades and from all organs) and creation of a biological collection of blood, plasma, serum and PBMCs from patients before treatment, under treatment and at the onset of irAEs.
25353|NCT03989310|Drug|Manganese Chloride|Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
25354|NCT03989310|Drug|nab-paclitaxel|Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
25355|NCT03989310|Drug|Gemcitabine|Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
25356|NCT03989310|Drug|anti-PD-1 antibody|Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
25357|NCT03989297|Radiation|Radiation|Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.
25358|NCT03989284|Behavioral|Community-based depression interventions|We conducted three types of community-based depression interventions such as peer counseling, social engagement, and combination.
25359|NCT03989271|Drug|Quercetin|Placebo
25360|NCT03989258|Diagnostic Test|Mammography outside official screening|Radiologic study
25363|NCT03989219|Procedure|plasma cfDNA methylation|plasma cfDNA will be performed in patients with pulmonary nodules (0.5-3 cm) found by CT scanning. Evaluation of benign and malignant diagnostic efficacy of cfDNA methylation in pulmonary nodules with clear pathological findings. Pulmonary nodules that could not or temporarily not require invasive examination will be performed CT follow-up and dynamically monitored methylation changes of cfDNA.
25364|NCT03989206|Drug|Nemolizumab|Nemolizumab
25365|NCT03989193|Device|Computer guided alveolar ridge splitting technique|"The bone splitting technique could be performed using the piezoelectric system, calibrating the device on D1 setting and using profuse saline irrigation. The preparation sequence begins with CS3 insert until a total depth of 10mm was achieved across the entire extension of the ridge. The procedure continued with the CS1 insert and finally the CS2 insert.~The vertical bone cuts through the cortical layer: At the distal end of the horizontal split, a vertical cut will made with the high-speed bur within the vicinity of the buccal plate to start the separation, with a full vertical depth of 13 mm. Final design of the splitting cut was L-shaped split. At the distal and the mesial end of the horizontal split, a vertical cut was made with the high-speed bur for a full vertical depth of 13mm."
25366|NCT03989180|Device|C-Scan System|"Subjects will receive detailed instructions (verbally and written) about the normal operation of the recorder and how to handle it during normal daily routine. They will be asked to document all their daily activity in a personal diary (attached)~The recorder will be secured to their lower back to test its functionality"
25367|NCT03989167|Other|Clinical decision support|Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.
25368|NCT03989141|Procedure|Repeated cannulation Buttonhole.|The intervention group (I): repeated needling into the same site in the AVF with sharp needles (4-6 pieces) at each dialysis (1-3 dialyses) creating a buttonhole tunnel track where cannulation with a blunt needle is possible.
25369|NCT03989141|Procedure|Single cannulation Buttonhole.|The control group (C): needling into the same site in the AVF with 1 sharp needle at each dialysis (6-12 dialyses) creating a buttonhole tunnel track, where cannulation with a blunt needle is possible. .
25370|NCT03989128|Other|Medical Chart Review|Undergo medical chart review
25371|NCT03989128|Other|Survey Administration|Complete survey
25372|NCT03989115|Drug|RMC-4630|RMC-4630 for oral administration
25373|NCT03989115|Drug|Cobimetinib|Cobimetinib for oral administration
25406|NCT03988842|Drug|Alteplase|Lyophilized powder for reconstitution in 50mg vials
25407|NCT03988842|Drug|Unfractionated heparin|Heparin sodium in 0.45% sodium chloride injection for intravenous use
25408|NCT03988842|Drug|Placebo|Saline solution reconstituted to mimic Alteplase 50mg vial
25409|NCT03988842|Drug|Apixaban|Apixaban tablet
48021|NCT03808701|Drug|SCT200|Recombinant Anti-EGFR Monoclonal Antibody
25376|NCT03989089|Drug|Pembrolizumab|"The planned dose of pembrolizumab for this study is 200 mg every 3 weeks (Q3W). Based on the totality of data generated in the Keytruda® development program, 200 mg Q3W is the appropriate dose of pembrolizumab for adults across all indications and regardless of tumour type.~All participants who off study treatment with stable disease (SD) or better may be eligible for up to an additional 17 cycles (approximately 1 year) of pembrolizumab treatment if they progress after stopping study treatment from the initial treatment phase. This retreatment is termed the Second Course Phase of this study and is only available if the study remains open and the participant met certain criteria as stated in the protocol."
25377|NCT03989076|Procedure|Interscalene Brachial Plexus Block|Analgesic nerve block as part of routine care with pre- and post-block ultrasonographic imaging of the diaphragm and inferior vena cava
25378|NCT03989063|Behavioral|Instructions to perform a motor task (external vs. internal focus instructions)|During the balance task, the participants will receive instructions to focus on external targets (external focus group) vs. movement of the body (internal focus group).
25379|NCT03989037|Drug|SIBP-01|IBP-01: injection; strength: 150mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
25380|NCT03989037|Drug|Herceptin|Herceptin: injection; strength: 440mg; first dose 8mg/kg (intravenous infusion, not less than 90 minutes, on the 1st day of each cycle), then 6mg/kg once every 3 weeks, totaling 6 cycles
25381|NCT03989037|Drug|Docetaxel|Docetaxel: injection; dose 75mg/m2, 75mg/m2 once every 3 weeks (intravenous infusion, not less than 60 minutes, on the 1st day of each cycle), totaling 6 cycles;
25382|NCT03989037|Drug|Carboplatin|Carboplatin: injection; dose AUC6, AUC6 once every 3 weeks (intravenous infusion, not less than 30 minutes, on the 1st day of each cycle), totaling 6 cycles;
25383|NCT03989024|Drug|Gonadorelin|Drug: Gonadotropin-releasing Hormone. Generic name: Gonadorelin. Dosage form: 600ug. Dosage: 10ug/puls. Frequency: every 90 min. Duration: 3 months
25384|NCT03989024|Drug|Clomiphene|Drug: Clomiphene. Generic name: Clomiphene. Dosage form: 50mg. Dosage: 50mg. Frequency: once a day. Duration: 3 months
25385|NCT03989011|Diagnostic Test|Carotid Artery Reactivity test (CAR test)|The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
25386|NCT03989011|Diagnostic Test|Arterial stiffness|"The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters:~Peripheral pressure parameters~Central and abdominal aneurysm pressure parameters (derived using a transfer function)~Cardiac output parameters (SEVR, ED)~Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery."
25387|NCT03988998|Drug|Radiofrequency ablation with radiotherapy|Radiofrequency ablation with radiotherapy
25388|NCT03988998|Drug|Radiofrequency ablation alone|Radiofrequency ablation without radiotherapy
25389|NCT03988985|Other|Patient-targeted feedback|The feedback for the patient contains the screening result, information about depression in general, guideline based treatment recommendations for patients and contact-information for treatment.
25390|NCT03988985|Other|GP-targeted feedback|The feedback for the general practitioner contains the screening result and guideline-based recommendations, i.e. to inform patients of their depression screening result. Nevertheless, in order to reflect routine clinical practice, the physicians will decide themselves whether or not to address depression during their consultation with the patient.
25391|NCT03988972|Device|diathermy|In women undergoing C.S, is healing power after diathermy equally to healing power after scalpel?
25392|NCT03988972|Device|scalpel|Incisions made by the scalpel will be done by the traditional method, with proper hemostasis by application of pressure to skin blood vessels and by ligating the subcutaneous bleeders.
25393|NCT03988959|Procedure|resection of mucoeidermoid carcinoma|Surgical resection parotid with preservation of facial nerve
25394|NCT03988946|Device|Transcatheter Mitral Valve Replacement via Transseptal Access|The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
25395|NCT03988933|Drug|Rifampin double dose|Double dose of rifampin for 2 months.
25396|NCT03988933|Drug|Rifampin triple dose|Triple dose of rifampin for 2 months.
25397|NCT03988933|Drug|Rifampin standard dose|Standard dose of rifampin for 4 months.
25398|NCT03988920|Drug|Tenapanor|NHE3 Inhibitor
25399|NCT03988920|Drug|Sevelamer Carbonate|Phosphate binder
25400|NCT03988907|Drug|Risdiplam|Part 1: a dose of 5 milligram (mg) risdiplam QD ; Part 2: precise dose will be based on Part 1 results
25401|NCT03988907|Drug|Midazolam|single dose administration of 2 mg midazolam
25402|NCT03988894|Device|mDASHNa App|The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
25403|NCT03988881|Procedure|Revascularization|PCI or CABG
25404|NCT03988855|Drug|DNV3837|Treatment infusions will be administered at a constant rate of 0.5 mg/kg BW/hour, resulting in a total IV infusion duration of 12 hours per day, for a total daily dose of 6 mg/kg BW DNV3837. Infusions will be administered once daily for 10 consecutive days.
25405|NCT03988855|Drug|Standard of Care|Standard of care will be administered at the discretion of the Investigator. All regimens according to current guidelines (Infectious Diseases Society of America/Society for Healthcare Epidemiology of America and European Society of Clinical Microbiology and Infectious Diseases guidance on CDI) and bezlotoxumab are acceptable.
25528|NCT03987867|Drug|Gemcitabine|Gemcitabine injection
25410|NCT03988829|Behavioral|Low-C|This is the active control group, where participants will be trained to play an experimenter developed game that requires least attentional control among all arms.
25411|NCT03988829|Behavioral|High-C|In this intervention, participants will be trained on this experimenter developed game which requires a lot of attentional control.
25412|NCT03988829|Behavioral|High-C+|A commercial video game will be used that requires a lot of demand on attentional control.
25413|NCT03988816|Drug|Roflumilast|500Mcg Tab, once daily
25414|NCT03988816|Drug|Placebo oral tablet|once daily
25415|NCT03988803|Drug|BI 425809|Film coated tablet
25416|NCT03988803|Drug|Memantine|Film coated tablet
25417|NCT03988790|Device|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
25418|NCT03988777|Device|Preoperative localisation technique|Impalpable breast lesions are preoperatively localised, either with hooked-wire (retrospective study) or Magseed (prospective study)
25419|NCT03988751|Behavioral|Ambulation|Variation in ambulatory intensity.
25420|NCT03988738|Other|Social Media Publications|Messages will be elaborated prior to participant enrollment. Messages will be evaluated by three experts.
25421|NCT03988725|Dietary Supplement|Vitamin E|Vitamin E 800 IU once daily
25422|NCT03988712|Diagnostic Test|Colonoscopy, gastroscopy, virtual colonoscopy, CT scan|Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
25423|NCT03988699|Device|Tinnitus Implant System|Device will deliver stimulation below hearing thresholds continuously or intermittently.
25424|NCT03988686|Procedure|Radical prostatectomy plus standard care|To add radical prostatectomy on the basis of current standard of care for those with oligometastatic prostate cancer
25425|NCT03988686|Drug|Standard of care for metastatic prostate cancer|androgen deprivation therapy with or without other systemic therapies based on current guidelines for metastatic prostate cancer
25426|NCT03988673|Other|Decision aid with implicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).
25427|NCT03988673|Other|Decision aid with explicit values clarification method (booklet or website)|The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
25428|NCT03988660|Diagnostic Test|Circulating fibrocytes|Peripheral blood samples were taken from the patients presented with right iliac fossa pain. Samples were collected in sodium heparin (EDTA). Circulating fibrocyte levels were determined by dual staining peripheral blood samples for CD4 and Col-1 using Fluorescence-Activated Cell Sorting (FACS) and correlated with histopathological diagnosis.
25429|NCT03988647|Drug|Pembrolizumab|Pembrolizumab administered at 200 mg IV every 3 weeks
25430|NCT03988647|Radiation|Radiation Therapy|9 Gy X 3 (27 Gy in 3 fractions), or 4-6 Gy X 5 (20-30 Gy in 5 fractions).
25431|NCT03988634|Drug|sacubitril/valsartan|"Sacubitril/valsartan (LCZ696) is available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily, for the 8 week double-blind period.~Valsartan matching placebo is available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily, for the 8 week double-blind period.~Sponsor-provided sacubitril/valsartan tablets will be administered orally twice a day for all patients during the 4 week open label extension."
25432|NCT03988634|Drug|valsartan|"Valsartan is available as 40 mg, 80 mg, and 160 mg in tablet form to be taken orally, twice daily, for the 8 week double-blind period.~Sacubitril/valsartan (LCZ696) matching placebo is available as 24/26 mg, 49/51 mg, and 97/103 mg in tablet form to be taken orally, twice daily, for the 8 week double-blind period.~Sponsor-provided sacubitril/valsartan tablets will be administered orally twice a day for all patients during the 4 week open label extension."
25433|NCT03988621|Behavioral|ViCCY|Virtual Health Coaching for You
25434|NCT03988608|Drug|Eltrombopag 25 mg|film-coated tablets containing 25 mg of eltrombopag free acid in each tablet
25435|NCT03988595|Other|Exercise Treatment|Exercise sessions will consist of individualized, walking delivered following a non-linear (i.e.,exercise intensity is continually altered and progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule across 3 to 5 individual treatment sessions/wk for 6 months. All exercise sessions will be implemented and monitored using TeleEx at the patient's home. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
25436|NCT03988582|Biological|EBV-specific T-cells|During each cycle, patients will receive intravenous (IV) EBV-CTLs at a dose of 1×106 CD3+ cells/kg on Days 1, 8, and 15, followed by a 2-week observation period.
25437|NCT03988569|Other|audiovisual decision aid|Will view AVDA and then have opportunity for questions with physician before signing consent forms
25438|NCT03988556|Device|Photobiomodulation using CareMin650 at 6 Joules (curative intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2."
25439|NCT03988556|Device|Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)|"CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2."
25529|NCT03987867|Drug|Carboplatin|Carboplatin injection
25816|NCT03985527|Device|Transvenous nerve stimulation|Acute transvenous nerve stimulation during a commercial implant of remedē® System
25440|NCT03988543|Behavioral|Patient Self-management|Enhanced care (EC) approach aimed to engage participants actively, and to increase self-efficacy, in the monitoring and managing of their symptoms. After patients complete the current EHR-integrated symptom monitoring, they will receive web-based, patient-centered information to gain knowledge on cancer-related outcomes, improve self-management skills, improve communication skills, and empower them to improve motivation and self-management.
25441|NCT03988530|Drug|Scopolamine|Subjects will self-administer DPI-386 Nasal Gel (0.2 mg / 0.12 g) or placebo nasal gel (0.12 g) on Treatment Day 1, and on Treatment Days 2 -4 all subjects will self administer DPI-386 Nasal Gel (0.2 mg / 0.12 g).
25442|NCT03988530|Other|Placebo Nasal Gel|Placebo Nasal Gel (0.12g) twice a day on Treatment Day 1.
25443|NCT03988517|Other|timing of receiving the drug|each group took levothyroxine in different timing
25444|NCT03988504|Diagnostic Test|Routine check up including genetic testing|Intervention is a routine check up including preemptive genetic testing
25445|NCT03988478|Behavioral|Detoxification & psychotherapeutic support|
25446|NCT03988465|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
25447|NCT03988452|Drug|Darunavir|Antiretroviral therapy
25448|NCT03988452|Drug|Ritonavir|Antiretroviral therapy
25449|NCT03988452|Drug|Dolutegravir|Antiretroviral therapy
25450|NCT03988452|Drug|Zidovudine|Antiretroviral therapy
25451|NCT03988452|Drug|Tenofovir|Antiretroviral therapy
25452|NCT03988452|Drug|Lamivudine|Antiretroviral therapy
25453|NCT03988439|Drug|IDP-118 Lotion|Topical
25454|NCT03988426|Biological|Octanorm|Octanorm
25455|NCT03988413|Drug|25mg|SYHA1402 25mg or Placebo 25mg
25456|NCT03988413|Drug|50mg|SYHA1402 50mg or Placebo 50mg
25457|NCT03988413|Drug|100mg|SYHA1402 100mg or Placebo 100mg
25458|NCT03988413|Drug|200mg|SYHA1402 200mg or Placebo 200mg
25459|NCT03988413|Drug|400mg|SYHA1402 400mg or Placebo 400mg
25460|NCT03988413|Drug|800mg|SYHA1402 800mg or Placebo 800mg
25461|NCT03988413|Drug|1200mg|SYHA1402 1200mg or Placebo 1200mg
25464|NCT03988387|Behavioral|Peer Support (PS)|Participants randomized to the PS arm will be assigned a trained peer supporter. The peer supporters (PSr) will establish rapport and build trusting relationships with participants in order to increase self-efficacy and motivation to adhere to the daily PrEP regimen and to engage in HIV prevention behaviors, in general. The PSrs will assess for facilitators and barriers to PrEP adherence, conduct adherence counseling, and provide ongoing social and practical support (e.g. tailored appointment reminders, accompanying participants to medical appointments, and providing skills building for effective relationships with study site providers). PSrs will communicate with the participant on at least a weekly basis either in person or by phone and will track those who miss scheduled study visits. Participants will be encouraged to contact their PSrs in case of questions or concerns. For any clinical question, the peer supporter will direct the participant to the study nurse.
25465|NCT03988387|Behavioral|Reminder and Resource Transfer (RRT)|"Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points."
25466|NCT03988387|Drug|daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]|All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF] for the first month of enrollment.
25467|NCT03988374|Drug|Dentifrices|Dentifrice on plaque, gingivitis, and bleeding.
25468|NCT03988361|Diagnostic Test|Magnetic Activated Cell Sorting|At the moment of ICSI, sibling mature oocytes will be inseminated with spermatozoa from Study group or from Control group. Following ICSI, all the inseminated oocytes will be individually cultured in the same conditions in the same culture dish. The choice of embryo(s) for transfer will be based on embryo quality. The supernumerary good-quality embryos from both arms will be frozen for further use.
25469|NCT03988348|Procedure|infraumbilical transverse incision|a 10 mm infraumbilical transverse incision will be done to allow trocar to be inserted without undue resistance from the skin so that the trocar will pass through the fascia and the peritoneum with ease
25470|NCT03988348|Procedure|intraumbilical incision|right sided curved longitudinal intraumbilical incision will be performed for initial intraperitoneal access
25471|NCT03988335|Drug|RIST4721|RIST4721 oral solution
25472|NCT03988335|Drug|Placebo|Placebo oral solution
25530|NCT03987854|Behavioral|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep. They will also be taught taught about positive affect skills (such as gratitude, positive reappraisal, and personal strengths) and mindfulness (general mindfulness and mindful eating).
25600|NCT03987321|Device|Infrarenal vena cava filter placement|Patients who are enrolled in this study are assigned to receive either Denali or Celect filter in the inferior vena cava. All other procedures are the same in both groups
25473|NCT03988322|Other|Low-dose CT screening with quantitative assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
25474|NCT03988322|Other|Low-dose CT screening with visual assessment and management of imaging biomarkers|Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
25475|NCT03988309|Diagnostic Test|Cxbladder|"The Cxbladder Triage test result will be provided to physicians for all low risk subjects on the test arm. If a low risk subject has a Cxbladder Triage negative test result then the indication is to rule out the subject without further assessment. The decision to rule-out or further evaluate is solely that of the physician and subject. If the low risk subjects are not Cxbladder Triage negative then a Cxbladder Detect test result will also be provided. The indication is further evaluation as per standard of care. Not low risk patients will be evaluated as per standard of care."
25476|NCT03988283|Biological|Personalized neoantigen DNA vaccine|At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
25477|NCT03988283|Device|TDS-IM System|The TDS-IM device utilizes the in vivo application of electrical fields to enhance the intracellular delivery of agents of interest in a targeted region of tissue
25478|NCT03988283|Procedure|Peripheral blood draw|-After trial enrollment and up to 7 days after the first vaccine dose (baseline); 2 weeks after last dose; time of progression or discontinuation (optional); other time points throughout the study if deemed pertinent to assessment of exploratory objectives (optional)
25479|NCT03988270|Other|Exercise|Participant randomized to an exercise protocol using a hand grip device that is used on a daily basis. Participant will be encouraged to increase the number of repetitions used by the hand grip device during the course of the trial
25480|NCT03988257|Dietary Supplement|Imunoglukan PH4|Children allocated to experimental group will receive Imunoglukan PH4 syrup (10 mg of pleuran and 10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
25481|NCT03988257|Dietary Supplement|Placebo (vitamin C syrup)|Children allocated to control group will receive a placebo: a vitamin C syrup (10 mg of vitamin C in 1 ml of syrup) in a dose 1 ml / 5 kg body weight, once a day in the morning, before the first meal, until signs of AGE subside (< 3 stools / 24 hours and normalization of stool consistency - grade 2-5 according to Bristol Stool Form Scale) or until the 14th day of the intervention.
25482|NCT03988244|Device|HeartLight X3|Pulmonary vein isolation
25483|NCT03988231|Drug|Receipt of enoxaparin|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
25484|NCT03988231|Drug|Placebo|Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
25485|NCT03988218|Behavioral|perceptive tests|many tests are realized: a drawing of the interior of the body a heartbeat detection test an ischemia induction test many scales: Eating Attitude Test; Body Awareness Questionnaire; Body Shape Questionnaire; Hospital Anxiety and Depression; Questionnaire de Satisfaction Corporelle et de Perception Globale de Soi
25486|NCT03988205|Behavioral|Outpatient Care Model|Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
25487|NCT03988205|Drug|CPX-351|CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
25488|NCT03988192|Device|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry.
25489|NCT03988179|Diagnostic Test|The Cholinesterase Inhibitor Prognosticator (ChIP) application for iPad|The first part of this application will be used, consisting of a visual vigilance test based on the Continuous Performance Test (CPT). Stimuli consist of a one digit number presented in the middle of the screen. For each trial the application randomly selects a specific number as the target stimulus. Patients are instructed to keep their dominant trigger finger close to the screen and press a button which is located at the bottom of the screen, whenever the target appears. In case another stimulus appears the patient is instructed to do nothing. Each stimulus is presented until the patient presses the button (maximum 3 sec.). Stimuli are presented in a random fashion with a 1, 2, 3, 4, or 5 second inter-stimuli-interval blank, which randomly varies. After an 8 stimuli practice trial, the test starts and a total of 50 stimuli are presented with a 50% target rate. Full-trial duration is approximately 5 minutes. During the trial, reaction time and accuracy of response are registered.
25490|NCT03988166|Procedure|Chronic Total Occlusion Revascularization|Teleflex's series of study guidewires and catheters will be used to facilitate the safe and effective crossing of de novo CTOs and placement of conventional guidewires beyond the lesion via either a true lumen or subintimal pathway.
25491|NCT03988166|Device|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter|GuideLiner® V3 catheter, TrapLiner® catheter, Turnpike® catheter
25492|NCT03988153|Combination Product|Probiotic Milk Formula|Drink 200 mL of PMF for 10 weeks and followed by 2 weeks of follow up period for monitor any adverse effect
25601|NCT03987308|Drug|Beinaglutide|Five-week Beinaglutide pump treatment group
25602|NCT03987308|Drug|Insulin aspart|Five-week short-term CSII (insulin aspart) treatment group
25493|NCT03988140|Device|Dental Implant Placement and subsequent prosthetic reabilithation|Surgeries to dental implant placement were performed. All patients received 3.5 mm diameter dental implants - surface blasted with TiO2 particles and machined collar of 1mm - in the interforaminal region of the mandible. The surgical sequence followed the protocol described by the implant company.A two stages protocol was used and the prostheses were placed at 4 months.The prosthetic retention system used in rehabilitation with overdentures was the O'ring and the capture of this component was done directly in the patient's mouth. After 7 and 14 days, the patients returned to occlusal adjustments and verification of prosthetic adaptation. The prostheses were made entirely of acrylic resin without metallic reinforcement and the antagonist of the patients were total edentulous and rehabilitated with muco-supported prostheses.
25494|NCT03988127|Diagnostic Test|Perfusion index|The perfusion index (PI) is the ratio of the pulsatile to the non-pulsatile blood flow in peripheral tissue. It represents a non-invasive measure of peripheral perfusion that can be continuously obtained from a pulse oximeter. We observe changes in PI before and after painful stimulation in intubated critically ill patients.
25495|NCT03988114|Drug|Abemaciclib|Administered orally
25496|NCT03988114|Drug|Nonsteroidal Aromatase Inhibitor (NSAI)|Letrozole administered orally or anastrozole administered orally (physician choice)
25497|NCT03988101|Drug|Rosuvastatin 20mg|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
25498|NCT03988101|Drug|Control|Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of rosuvastatin 20 mg once daily or equivalent.
25499|NCT03988088|Drug|Lasmiditan|Administered orally.
25500|NCT03988075|Other|Acetaminophen and hydrocodone based pain control|Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.
25501|NCT03988075|Other|Acetaminophen and ibuprofen based pain control|Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
25503|NCT03988049|Device|1,550 fracionated photothermolysis laser vs. 755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
25504|NCT03988049|Device|1,550 fracionated photothermolysis laser vs. 755 picosecond laser|All subjects will have one side of their face treated with one laser, and the other side with the other laser.
25505|NCT03988036|Drug|Pembrolizumab|Intravenous infusion; 200 mg; every 3 weeks
25506|NCT03988036|Drug|Trastuzumab Biosimilar ABP 980|Intravenous infusion; 8 mg/kg loading dose, thereafter 6 mg/kg; every 3 weeks
25507|NCT03988036|Drug|Pertuzumab|Intravenous infusion; 840 mg/kg loading dose, thereafter 420 mg/kg; every 3 weeks
25508|NCT03988023|Biological|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% HSA)
25509|NCT03988023|Other|Saline|Saline solution, 4 mL, single intra-articular injection
25510|NCT03988010|Drug|Amantadine Sulfate|200mg/500ml i.v. solution for infusion
25511|NCT03988010|Drug|Placebo (for amantadine sulphate)|500 cc 0.9% sodium chloride
25512|NCT03987997|Device|Early association of electrical muscle stimulation with cyclo-ergometer|Early electrical muscle stimulation in patients usually mobilized with cyclo-ergometer in ICU.
25513|NCT03987971|Other|acupuncture|Acupuncture on GB26, every other day, 3 times a week, 2 weeks in total.
25514|NCT03987945|Device|left atrial appendage occlusion devices|All NVAF patients who are admitted for receiving left atrial appendage occlusion procedure, including Watchman, LAmbre, Lefort, and Leftear deveices.
25515|NCT03987932|Behavioral|NEAT!2|Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
25516|NCT03987932|Behavioral|NEAT!2+Calls|Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
25517|NCT03987932|Behavioral|Delayed NEAT!2|Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
25520|NCT03987906|Behavioral|Symptom screening with Targeted Early Palliative Care (STEP)|The experimental arm receives routine symptom screening at every outpatient visit; if symptoms are above a certain threshold, then a triggered email is sent to a triage nurse, who calls the patient to offer early referral to and follow-up by a symptom control and palliative care team.
25521|NCT03987893|Drug|PEG-3350 with Electolytes|experimental arm will receive 2 doses of PEG3350 spaced over 12 hours after randomization to arm1. PEG as dose of 2litres (1 sachet dissolved in 2L of water) will be administered via a nasogastric tube.
25522|NCT03987893|Drug|Lactulose|Lactulose will be given orally (30ml QID) which shall be titrated to ensure 2-3 soft stools per day
25523|NCT03987880|Procedure|4.0 mm treatment|PiXL treatment with UV irradiation in a central 4.0-mm ring-shaped zone of the cornea.
25524|NCT03987880|Procedure|3.5 mm treatment|PiXL treatment with UV irradiation in a central 3.5-mm ring-shaped zone of the cornea.
25525|NCT03987867|Biological|CIK cell|CIK cell injection
25526|NCT03987867|Biological|Sintilimab Injection|IBI308 injection
25527|NCT03987867|Drug|Pemetrexed|Pemetrexed injection
25531|NCT03987841|Behavioral|Integrated MBSR/DSME intervention|Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 12 weekly sessions followed by monthly spaced reminders for 3 months (6 months total). A trained masters-level interventionist will deliver the integrated intervention.
25532|NCT03987815|Drug|Nivolumab|Nivolumab
25533|NCT03987802|Drug|Faster-acting insulin aspart|Faster-acting insulin aspart given as subcutaneous (s.c., under the skin) injections according to routine clinical practice. The decision to initiate treatment with commercially available Fiasp® must be made by the patient and the treating physician before and independently from the decision to include the patient in this study.
25534|NCT03987789|Other|Driving-pressure-guided group|Patients will receive PEEP levels individually set at the highest possible value (up to 15 cmH2O) providing a driving pressure (airway plateau pressure minus PEEP) lower than 13 cmH2O, in addition to recruitment maneuvers.
25535|NCT03987789|Other|Low PEEP|Patients will receive a PEEP level ≤5 cmH2O without recruitment maneuvers
25536|NCT03987776|Behavioral|Anti-inflammatory energy-restricted diet|During 6 months the participants will we asked to use recommended energy-reduced diet with anti-inflammatory properties, based on colorful vegetables and fruits, legumes, nuts, seeds, marine fish, whole-grain products, and daily use of olive oil, green/black tea, multiple spices and herbs.
25537|NCT03987776|Behavioral|Control energy-restricted diet|During 6 months the participants of control group will be asked to use recommended energy-reduced diet based on standard obesity management (55-60% carbohydrates, 25% fat, 15-20% protein)
25538|NCT03987763|Drug|IDP-122 Lotion|Topical
25539|NCT03987750|Drug|Safinamide Methanesulfonate 150mg|150 mg (free base)
25540|NCT03987750|Drug|Safinamide Methanesulfonate 100mg|100 mg (free base)
25541|NCT03987750|Drug|Safinamide Methanesulfonate matching placebo|placebo
25542|NCT03987737|Procedure|small urinary catheter placement in the rectum|The MRI technician will place a small urinary catheter in the rectum prior to MRI of the prostate to evacuate excessive gasses. This catheter will stay in the rectum during the whole MRI examination.
25543|NCT03987724|Other|Positron emission tomography (PET) imaging at rest and during supine bicycle exercise|Tumor blood flow and its heterogeneity will be measured with PET at rest and during supine bicycle exercise.
25544|NCT03987711|Drug|Warfarin|Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0.
25545|NCT03987711|Drug|Apixaban|Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants).
25546|NCT03987711|Other|No oral anticoagulation|No oral anticoagulation
25547|NCT03987698|Biological|SHR-1210|SHR-1210 injection
25548|NCT03987698|Biological|CIK cells|CIK cells injection
25549|NCT03987685|Drug|Oratopo|Oral topotecan will be supplied in topotecan capsules and oral HM30181A-US tablets
25550|NCT03987672|Dietary Supplement|Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula|Kate Farm Peptide 1.5 nutritional Formula
25551|NCT03987659|Procedure|Irrigation protocols that promote release of dECMs|Irrigation protocols that promote release of dECMs
25552|NCT03987659|Procedure|Conventional Irrigation protocols|Conventional Irrigation protocols
25553|NCT03987646|Procedure|Non-staged vestibular fresh socket therapy|a slowly resorbable membrane shield is placed above the labial plate of bone so that when the thin labial plate started its resorption process the shield remains till a complete gap fill occurred thus leading to a thicker labial plate of bone or it preserves the socket architecture until a complete bone fill occurred inside the socket
25554|NCT03987620|Drug|Ibrexafungerp|Ibrexafungerp 300mg BID for one day
25555|NCT03987620|Drug|Placebo|Matching Placebo
25556|NCT03987607|Device|neuromuscular blockade monitoring|Neuromuscular blockade monitoring via two different types of monitoring devices
25557|NCT03987594|Procedure|Transurethral fulguration of the Hunner lesion|Hunner lesion of the bladder is fulgurated with electronic surgical device under cystoscopic inspection. For the intervention, general or spinal anesthesia is required.
25558|NCT03987594|Procedure|Combination treatment of bladder hydrodistension and transurethral fulguration of the Hunner lesion|Prior to Hunner lesion fulguration, bladder hydrodistension is performed for 8 minutes at pressure of 80cmH2O. And then transurethral fulguration is performed on the Hunner lesion.
25559|NCT03987581|Behavioral|Cognitive Behavioral Therapy (CBT)|Twelve in-person counseling sessions designed to assist participants with becoming abstinent from alcohol use (or reduce use).
25560|NCT03987581|Behavioral|Mobile Contingency Management (mCM)|Abstinence (measured by breath alcohol) will be intermittently reinforced. For each breath alcohol concentration reading that tests negative, a participant will earn a virtual scratch-off lottery ticket that contains 100 different values.
25561|NCT03987581|Behavioral|Long-term incentive|This incentive is $300 for self-reported and bioverified 30-day abstinence from heavy drinking at the follow-up scheduled for 6-months after the initial quit date
25562|NCT03987568|Other|Blood draws|Blood draws at two specified timepoints - the first is during the MRI and the second is scheduled during participant's prostatectomy.
25563|NCT03987568|Diagnostic Test|Magnetic resonance imaging (MRI)|At the beginning of study magnetic resonance imaging MRI will be completed.
25564|NCT03987555|Other|Blood draws|Blood draws for serum and peripheral blood mononuclear cell isolation collected throughout treatment course
25565|NCT03987555|Other|QLQ-CIPN20 Survey|20-item self-reported survey for participant reported symptoms related to chemotherapy-induced peripheral neuropathy
25566|NCT03987555|Other|PR-CTCAE Survey|124-item survey addressing chemotherapy-induced peripheral neuropathy concerning severity of the numbness and tingling and the degree these symptoms interfere with daily activities.
25567|NCT03987529|Other|sevoflurane|volatile anesthetic
25568|NCT03987529|Other|desflurane|volatile anesthetic
25569|NCT03987529|Other|propofol|intravenous anesthetic
25570|NCT03987516|Other|Active exercising|Patients allocated to the experimental group were included in an active exercising program adapted to each patient
25603|NCT03987295|Drug|AL001|administered via intravenous (IV) infusion once a month
25571|NCT03987503|Drug|Epclusa (SOF/VEL)|a trained physician will provide research participants with two-week supply of SOF/VEL. Treatment is: 1 tablet SOF/VEL (400 mg sofosbuvir/100 mg velpatasvir) daily x 12 weeks. The initial 2-week supply is provided by Gilead Sciences and will be dispensed to participants upon enrollment. Prescriptions and insurance prior authorizations for SOF/VEL will be submitted by the study pharmacist though the UCSF Specialty Pharmacy. The study team will be notified once insurance-authorized drug is available and will bring participants' medication in 2 supplies to the study site prior to study visits.
25572|NCT03987503|Drug|Standard of care|Standard of HCV care provided by medical care provider
25573|NCT03987503|Device|Fibroscan® 430 Mini Plus|"Trained research staff will measure participants liver stiffness using liver ultrasonographic elastography. Research staff place ultrasound gel directly on participant's skin on the area of the torso. Research staff will position the participant's body on the exam table to assure the liver can be located, placing the small probe on the body's surface (skin with gel) and begin recording images of the participant's liver.~The procedure will take 15-30 minutes, depending on the ease with which the research staff is able to accurately locate the participant's liver.~Results from the FibroScan will be discussed with a trained provider."
25574|NCT03987490|Behavioral|Text Message|Vaccine reminder notification sent via text
25575|NCT03987490|Behavioral|PostCard|Vaccine reminder notification sent via standard mail
25576|NCT03987490|Behavioral|Standard of Care|No additional information given to parents
25577|NCT03987490|Behavioral|Motivational Interview|Phone-based semi-guided discussion with parents who had not yet agreed to vaccination after reminders sent
25578|NCT03987477|Behavioral|Interpretation bias modification program|Brief online program aimed at the modification of negative interpretation biases.
25579|NCT03987477|Behavioral|Waiting list|Waiting list procedure for the control group.
25580|NCT03987464|Behavioral|Planning for the Future|This intervention will include attending an advance directives meeting, a living arrangements workshop, and a psychosocial education training workshop.
25581|NCT03987464|Behavioral|Enhanced Medical Engagement|This intervention includes creating a health portfolio, health record access training, and a medical engagement workshop
25582|NCT03987464|Behavioral|Confidence Building and Social Engagement|This intervention includes mindfulness training, a pre-experience training techniques workshop and a memory strategies class.
25583|NCT03987464|Behavioral|Physical Intervention|This intervention includes physical/occupational therapy (PT/OT), a home safety assessment, and an independent exercise program.
25584|NCT03987464|Behavioral|Medical Adherence|This intervention includes using automated pillboxes to ensure medication compliance, optimizing appropriate medication use through review, and engaging with memory medications via class.
25585|NCT03987451|Drug|Semaglutide|Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks
25586|NCT03987451|Drug|Placebo (semaglutide)|Semaglutide placebo s.c. given once-weekly for 48 weeks
25587|NCT03987438|Behavioral|Lifestyle intervention with APP|The lifestyle intervention will be launched by an APP installed in participants' private mobile phones, including health knowledge education, mental health counseling, smart diet advice, intelligent exercise guidance, and target weight management. Nutrition recommendation is conducted according to the Chinese Dietary Guide, Chinese and International Guidelines of Gestation Diabetes Management. Exercise guidance is given based on the Guidelines for National Fitness of China, Chinese and International Guidelines of Gestation Diabetes Management. Psychological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP. The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together to modify the behavioral supports individually based on the feedback of their characteristics and performance recorded in the APP.
25588|NCT03987425|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
25589|NCT03987412|Behavioral|Lifestyle intervention with APP|The face to face education class will be conducted by an obstetrician, an endocrinologist and a nutritionist together. Then the lifestyle intervention will be launched by an APP that installed in participants' private mobile phones, including nutrition, exercise and phycological support. Nutrition guidance is conducted according to the Chinese Dietary Guide, Chinese and international guidelines of gestation diabetes management. Exercise support is given based on the Guidelines for National Fitness of China, Chinese and international guidelines of gestation diabetes. Phycological support is given by sending education articles on mental health. Participants are encouraged to update data about their diet, exercise and body weight through the APP, and based on the data investigators will individualize the suggestions.
25590|NCT03987399|Other|Tailored educational intervention|Educational day (lecture and workshop), clinical supervision and reminders
25591|NCT03987386|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
25592|NCT03987386|Other|Quality-of-Life Assessment|Ancillary studies
25593|NCT03987386|Other|Questionnaire Administration|Ancillary studies
25594|NCT03987386|Radiation|Radiation Therapy|Undergo conventional radiation therapy
25595|NCT03987373|Other|non-interventional|This study is a non-interventional, observational study. After completing 12-month treatment from DACAB trial, investigators would not make any interventions or impact on subjects' therapeutic strategy.
25596|NCT03987360|Other|Observational|Participants who attended different educational and cultural activities either in a community centers or public institutions like arts museums or universities.
25597|NCT03987347|Other|Observational|People who are enrolled in the Canadian Longitudinal Study on Aging. Participants undergo repeated waves of the same standardized data collection every three years. All participants are also contacted by telephone 18 months after baseline assessment to complete the Maintaining Contact Questionnaire.
25598|NCT03987334|Other|Virtual Reality Treatment|Experimental Group (VRT) subjects will undergo Virtual Reality Motor Control exercises based on augmented feedback of their performance.
25599|NCT03987334|Other|Control Group|Control Group (CT) subjects will undergo the same treatment of VRT subjects in terms of intensity, time and type, but with the VR turned off.
26135|NCT03982966|Dietary Supplement|Omega 3 fatty acids (fish oil) 1000 mg/day oral|Omega 3 fatty acids (fish oil) 1000 mg/day oral
25604|NCT03987282|Other|Enhanced usual care (EUC)|Provision of ART and medical care for HIV and other medical HIV co-morbidities provided at the HIV/AIDS treatment center with an expedited and facilitated referral to a methadone maintenance treatment (MMT).
25605|NCT03987282|Behavioral|Peer-based counseling|Peer-based counseling intervention focused on behavioral skills and strategies that patients can learn and master to achieve uninterrupted, long-term ART treatment participation while continuing OUD recovery through MMT
25606|NCT03987269|Behavioral|Embodied Virtual Reality|"The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~Shaking someone's hand~Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~Shaking hands~Having their blood pressure taken~Having their pulse taken~Fill a pill organizer~Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public."
25607|NCT03987269|Behavioral|Narrative Video|The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
25608|NCT03987256|Other|Initial rehabilitation protocol|During 12 weeks, under kinesitherapist guidance, patients will perform daily eccentric stretching and strengthening of the ECRB and periscapular musculature, manual therapies, and kinesiotaping. They will also use orthotics after 6 weeks if kinesiotaping is not effective. At weeks 1-5, patients will undergo weekly ultrasound-guided focused shockwave therapy under the following protocol: 0,15- 0,30mJ/mm2 (the highest energy flux the patient can well tolerate), 1500 shocks at 5Hz at the origin of common extensor or flexor tendon.
25609|NCT03987256|Procedure|Needling with PRP|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with PRP.~Details of PRP preparation (ACP Arthrex): 15 ml of blood, no activators or anticoagulants, poor in white blood cells (the last mm of buffy coat above the red blood cells pellet is not collected).~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
25610|NCT03987256|Procedure|Needling with saline solution|"In case of failure of proper rehabilitation and shockwave therapy, patients will have a block of the radialis nerve just above the arcade of Frohse with 1 ml of procaine 2%. Then, a single needling of the ECRB enthesis (peppering technique) will be performed as follow: , ultrasound-guided, 25 repetitions with a 20 gauge needle. At the end of the procedure, the lesion will be fulfilled with saline solution.~Excentric stretching and strengthening, as well as orthotics or kinesiotaping will be continued as long as symptoms persists during the 6 first months after the needling procedure."
25611|NCT03987243|Behavioral|Structured Pressure Ulcer Prevention Education|Structured education for performance weight shift maneuvers and pressure ulcer prevention will occur during the initial visit for each subject. The education method used aligns with principles of the social cognitive theory to facilitate learning. The purpose in providing the education is to ensure all of the participants receive uniform instruction in how to perform weight shifts and to facilitate understanding of the importance of completing them as a protective measure against pressure ulcer development. Because each participant will come into the study at varying levels of understanding about pressure ulcer risk and knowledge of how to complete weight shift maneuvers, the education component is critical to ensure all participants are provided with the same information in the same way.
25612|NCT03987243|Other|Mobile Seat Interface Pressure Mapping System (IPM)|This mobile IPM system was designed to provide visual information about seat interface pressure distribution to compensate for lack of sensation on the sitting surface. This variable will be toggled on and off between the intervention and control phases of the study. The participants will have access to the visual feedback while learning how to complete weight shift maneuvers at the initial visit and then again at home during the intervention phases (weeks 2 and 4). During the control phases (weeks 1 and 3), they will not have access to the visual feedback from the pressure map
25613|NCT03987230|Drug|Sensitive Eyes® Plus Saline Solution|Sensitive Eyes® Plus Saline Solution
25614|NCT03987230|Other|Oust™ Demodex® Wipes™|Oust™ Demodex® Wipes™
25615|NCT03987230|Other|I-LID N LASH PLUS® Eyelid Cleanser|I-LID N LASH PLUS® Eyelid Cleanser
25616|NCT03987230|Other|Blephadex Lid Wipes|Blephadex Lid Wipes
25617|NCT03987230|Other|Eye Cleanse Lid Wipes|Eye Cleanse Lid Wipes
25618|NCT03987230|Other|Blephademodex|Blephademodex
25619|NCT03987217|Dietary Supplement|Creatine Monohydrate|Given orally
25620|NCT03987217|Behavioral|Exercise Intervention|Complete POWER resistance training program
25621|NCT03987217|Other|Questionnaire Administration|Ancillary studies
25622|NCT03987204|Drug|Ivabradine|Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.
25623|NCT03987191|Drug|Multiple daily ijnection using Insulin Degludec and Insulin Aspart|Drug: Insulin Degludec and insulin Aspart Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
25624|NCT03987178|Behavioral|Dunk|"If randomized to Dunk, the subject is asked to submerge his or her head in the hot tub at least up to brow level."
25625|NCT03987178|Other|Exposure to Hot Tub|Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
25626|NCT03987165|Other|Music Therapy|"Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby."
25627|NCT03987152|Drug|Sirolimus|Daily intake of Sirolimus during Challenge and Rechallenge phase
25628|NCT03987139|Other|Hypertension|"Hypertension is induced by an infusion of noradrenaline within acceptable limits Baseline recording (10 minutes) is performed. MAP gradually increases in steps of 5-10 mmHg during ongoing TCD. When the desired maximum MAP is reached, measurement is made at steady state (10 minutes).~Noradrenaline infusion is stopped. When MAP is stabilized, new baseline is measured for 10 minutes."
25629|NCT03987139|Other|Hyper- and hypoxia|The mechanical ventilator is adjusted to mild hypoxia, normoxia and mild hyperoxia. Measurements are made for 10 minutes at normoxia and after steady state is reached, respectively. hyperoxia and hypoxia. Oxygenation is controlled by arterial blood gas before and during steady state.
25630|NCT03987139|Other|Hyper- and hypocapnia|The mechanical ventilator is adjusted to a delta PaCO2 on the ventilator for both hypocapnia and hypercapnia. Measurements are made for 10 minutes at normocapnia and after steady state is reached, respectively. hyper- and hypocapnia.
25631|NCT03987126|Dietary Supplement|Human Milk Oligosaccharides (HMO)|Sachet containing 10 grams of HMO
25632|NCT03987126|Other|Placebo|Sachet manufactured to mimic 10g of HMO
25633|NCT03987113|Other|Plasma concentration analysis during and after ex-vivo pulmonary reconditioning|The pulmonary endothelial dysfunction will be evaluated with plasma concentration of heparan sulphate, syndecan-1, endothelin-1 and i-NOS.
25634|NCT03987087|Radiation|Radiation|"Thoracic intensity modulated radiation therapy (IMRT)~+EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy"
25635|NCT03987087|Drug|Chemotherapy|EGFR TKI combination Thoracenteral innfusion chemotherapy or Thoracenteral infusion chemotherapy combination Systemic chemotherapy
25636|NCT03987074|Drug|Semaglutide|Solution for injection administered subcutaneously once weekly
25637|NCT03987074|Drug|Firsocostat|Tablets administered orally once daily
25638|NCT03987074|Drug|Cilofexor|Tablets administered orally once daily
25639|NCT03987061|Device|MOTIV BVS|MOTIVS BVS in below-the-knee artery disease
25640|NCT03987048|Other|Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.|"Data were collected regarding medical background, medical condition and management, both at admission and during the ICU stay. These included demographics, clinical, biological and therapeutic data.~Outcome at ICU discharge and at one year were also recorded."
25641|NCT03987035|Device|BeGraft Stent Graft System as bridging stent|BeGraft Stent Graft System as bridging stent
25642|NCT03987022|Drug|Ketorolac|Use of non-steroidal anti-inflammatory drug for pain control post operatively
25643|NCT03987022|Drug|Opioids|Use of narcotic for pain control post operatively
25644|NCT03987022|Other|Ice Packs|Placement of Ice packs on surgical sites post operatively
25645|NCT03987022|Drug|Tylenol|Use of pain medication post operatively
25646|NCT03987022|Drug|Motrin|Use of non-steroidal anti-inflammatory drug for pain control post operatively
25647|NCT03987022|Drug|dilaudid|Use of narcotic for pain control post operatively
25648|NCT03987009|Device|Without RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning without RAMP device
25649|NCT03987009|Device|With RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning with RAMP device
25650|NCT03987009|Device|Without RAMP and with video|Intubation with video-laryngoscope McGrath with use of the video feature and patient positioning without RAMP device
25651|NCT03987009|Device|With RAMP and without video|Intubation with video-laryngoscope McGrath without use of the video feature and patient positioning with RAMP device
25652|NCT03986996|Drug|amoxicillin, metronidazole and tetracycline|antibiotics
25653|NCT03986996|Drug|amoxicillin and tetracycline|antibiotics
25654|NCT03986983|Device|Shockwave therapy|Shockwave therapy protocol - The shockwave therapy protocol was performed in the prone position. The application was radial shockwave with 3,5bar, 15Hz of frequency and 3000 impulses.
25655|NCT03986983|Other|Aerobic exercise|Aerobic exercise protocol - 30 minutes of aerobic moderate-intensity exercise (40% of reserve heart rate) using Karvonen´s formula, performed on a step.
25656|NCT03986970|Drug|Tenofovir|Pre-exposure prophylaxis
25657|NCT03986957|Other|No interventions|No interventions - observational study
25658|NCT03986944|Drug|Placebo linzagolix tablets and Placebo Add-back capsule|For oral administration once daily
25659|NCT03986944|Drug|Placebo linzagolix and linzagolix tablets and Placebo Add-back capsule|For oral administration once daily
25660|NCT03986944|Drug|Placebo linzagolix and linzagolix tablets and Add-back capsule|For oral administration once daily
25661|NCT03986931|Other|Experimental: Pharmacist-Bidirectional Texting Group|The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
25662|NCT03986931|Other|Active Comparator: Control Group|This group will receive bidirectional texting, but no pharmacist monitoring.
25663|NCT03986918|Device|Routine Total Hip Arthroplasty|Patients undergoing routine total hip arthroplasty will receive surveys regarding survivorship and outcomes.
25664|NCT03986905|Drug|Scopolamine Nasal Gel|All subjects will receive both a patch and nasal gel: DPI-386 Nasal Gel + placebo patch, placebo nasal gel + placebo patch, or placebo nasal gel + TDS patch.
25665|NCT03986905|Other|Placebo|placebo nasal gel + placebo patch
25666|NCT03986892|Behavioral|Physical Activity|Physical Activity
25667|NCT03986866|Other|Video|A 5 minute video on the risks and benefits of opioids, alternative methods to reduce pain, and the proper handling and storage of opioids will be shown.
25668|NCT03986853|Procedure|Blood sampling|Blood sampling under general anesthesia
25669|NCT03986840|Other|Exercise training|A multicomponent exercise program
25670|NCT03986827|Behavioral|Cool Kids Anxiety Program - Social Enhanced|Specific G-CBT intervention for adolescents with social anxiety disorder
25671|NCT03986827|Behavioral|Cool Kids Anxiety Program|Generic G-CBT intervention for adolescents with anxiety disorders
25672|NCT03986801|Other|pharmaceutical interview|pharmaceutical interview at the end of hospitalization
25673|NCT03986788|Other|Weightlessness|Volunteers will be studied during parabolic flight. Cerebral blood flow will be measured in different part of the brain during weightlessness ans compared to 1g and hypergravity measurements.
25674|NCT03986775|Dietary Supplement|isomaltulose|replacement of sucrose with low-glycemic isomaltulose
25675|NCT03986775|Dietary Supplement|sucrose|conventional beverage with sucrose
25676|NCT03986762|Drug|Clavulanic Acid|~10 days of Clavulanic Acid
30432|NCT03948334|Drug|ZPL389|Dose 2 of ZPL389; once daily from week 16 to week 116.
25677|NCT03986749|Procedure|Doppler ultrasonography after bursa augmentation|Dynamic ultrasound examination with Grading of blood vessels using the modified Ohberg Score in the longitudinal scan in dynamic ultrasound of the rotator cuff tendon - primary to surgery and 3 weeks later.
25678|NCT03986736|Diagnostic Test|Laboratory analysis - upon admission|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: HMGB-1, sCK, sMb, serum NGAL, and urine NGAL
25679|NCT03986736|Diagnostic Test|Laboratory analysis - 24 hours after injury|Laboratory analysis will be performed upon admission of the patient to the hospital. Levels of the following parameters will be determined: sCK, sMb, serum NGAL, and urine NGAL
25680|NCT03986697|Drug|Biktarvy|Fixed dose combination preparation containing bictegravir, tenofovir alafenamide and emtricitabine
25681|NCT03986671|Device|Transmembrane EMG Oropharynx Probe|Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
25682|NCT03986658|Device|NeuroQore First Dawn rTMS System|All participants will receive left dorsolateral prefrontal cortex rTMS.
25683|NCT03986645|Device|MR data acquisition|MR data acquisition using CE and non-CE marked pulse sequences.
25684|NCT03986632|Behavioral|Tundra Gifts|Tundra Gifts is a home-focused intervention delivered by community health workers (CHW) that focuses on promoting healthy eating and an active lifestyle among 3-5 year olds through family and community partnerships. Primary caregivers will attend monthly interactive education session, receive a monthly gift basket that includes resources and supplies to support behavior change at home and receive ongoing social support through a Facebook site.
25685|NCT03986606|Biological|PSB205|PSB205 is a bi-functional product that has been engineered to contain two unique monoclonal antibodies.
25686|NCT03986593|Device|cryoablation|cryoablation of bone metastases by cone beam-CT image-guidance
25687|NCT03986580|Device|BARRICAID device|BARRICAID device, following limited discectomy procedure at a single LS level between L4 and S1
25688|NCT03986567|Behavioral|gamification for partner notification among youngsters|"Design a web based tool adapted to Mobile phones for partner notification of STI among youngsters 16 to 24 years old and evaluate its role in increasing the patient referral partner notification"
25689|NCT03986554|Procedure|Videofluoroscopic swallow study|The Swallowing Systems Core laboratory is fully equipped to perform VFSS with a C-arm (OEC 9900) that is dedicated solely for research purposes. VFSS recordings will be kept to a minimum and only turned on during the execution of each swallow in all sequences. Video recording and images captured during the VFSS will be synced and saved to a secure server for data analysis. VFSS allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the hyolaryngeal complex during swallowing) cannot be visualized with any other technique. Patients will swallow only water. Aspiration (bolus into trachea) is not expected to occur during this study given that the individuals recruited will have no prior history of disease or disorder, and aspiration is uncommon in healthy individuals.
25690|NCT03986554|Procedure|pharyngeal High Resolution Manometry|This procedure will only take place once during sequence 2 of the randomization B session. If desired, a small amount (< 0.5 mL) of topical 2% viscous lidocaine hydrochloride will be applied to the participant's nostril of choice prior to catheter insertion. The catheter will be placed through the nasal passage, oropharynx, and hypopharynx to the esophagus. Correct catheter placement will be verified with VFSS. With the catheter in place, the subject will perform 10 swallows of 10ml and is expected to take approximately 2.5 minutes. The catheter will then be removed and the subject will move on to sequence 3. Individuals have the option to decline this procedure if it is uncomfortable or difficult to tolerate.
25691|NCT03986541|Diagnostic Test|Immunohistochemistry|Assessment of tumour amphiregulin, epiregulin and EGFR expression by immunohistochemistry.
25692|NCT03986528|Drug|Kanglaite Injection+Chemotherapy|Participants receive Kanglaite injection 200ml by intravenous (IV) infusion once everyday continuously for 14 days of each 21-28 day cycle for at least 2 cycles PLUS Investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle for at least 2 cycles) or nab-paclitaxel(260mg/m2 by IV infusion on Day 1 or Days 1,8 of each 21-28 day cycle for at least 2 cycles) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle for at least 2 cycles) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle for at least 2 cycles) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle for at least 2 cycles) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle for at least 2 cycles).
25693|NCT03986528|Drug|Chemotherapy|Participants receive Investigator's choice of paclitaxel (135mg/m2 by IV infusion on Day 1 of each 21-28 day cycle for at least 2 cycles) or nab-paclitaxel(260mg/m2 by IV infusion on Day 1 or Days 1,8 of each 21-28 day cycle for at least 2 cycles) or pemetrexed (500mg/m2 by IV infusion on Day 1 of each 21-28 day cycle for at least 2 cycles) or gemcitabine(1000mg/m2 by IV infusion on Days 1,8 of each 21-28 day cycle for at least 2 cycles) PLUS cisplatin (75mg/m2 by IV infusion on Days 1 to 3 of each 21-28 day cycle for at least 2 cycles) or carboplatin (AUC 6 by IV infusion on Days 1 of each 21-28 day cycle for at least 2 cycles).
25694|NCT03986515|Drug|apatinib plus SHR-1210|apatinib 250mg qd, 3-5 days later SHR-1210 200mg q3w
25695|NCT03986502|Other|Media Intervention|Watch web-based financial literacy video
25696|NCT03986502|Other|Informational Intervention|Receive information on financial counseling and medical cost assistance
25697|NCT03986502|Other|Best Practice|Utilize usual clinic procedures and clinic or community-based financial resources
25698|NCT03986502|Other|Questionnaire Administration|Ancillary studies
25699|NCT03986502|Other|Quality-of-Life Assessment|Ancillary studies
25700|NCT03986489|Behavioral|Mindfulness-based dance/movement therapy (M-DMT)|M-DMT includes benefits of physical activity, group psychotherapy, mindfulness training, and an art-based intervention in a unified practice. Each session focuses on different psycho-educational topics about chronic low back pain management and links these topics with specific M-DMT activities that incorporate mindfulness-based principles and techniques.
25753|NCT03986047|Device|Thermal care|Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
25701|NCT03986489|Behavioral|Chronic pain social support group|"The therapist will facilitate open group discussions about participants' experiences with or reactions to the topic of discussion and will promote empathy among group members. The therapist will use client-centered, reflective listening techniques but will not prescribe any specific recommendations for change.~Each week, SSG participants will receive handouts with brief information about the topic discussed during the group session."
25702|NCT03986476|Dietary Supplement|Probiotics|5x10^8 colony forming units (CFU) of each probiotic strain, two capsules per day over six weeks
25703|NCT03986476|Other|Placebo|Similar in shape and taste to intervention capsules but without the probiotic components, two capsules per day over six weeks
25704|NCT03986463|Other|Circulating tumour DNA (ctDNA)|Circulating tumour DNA (ctDNA) will be isolated from blood samples
25705|NCT03986450|Other|Enhanced recovery after surge(ERAS) protocol|"The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~Preoperative care:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization"
25706|NCT03986424|Drug|Akatinol Memantine 20 mg|Akatinol Memantine 20 mg to be taken orally, once daily, in the same time of the day
25707|NCT03986424|Drug|Akatinol Memantine 10 mg|Akatinol Memantine 10 mg to be taken orally, twice daily
25708|NCT03986411|Other|Phase 1: Qualitative interviews: Health care professionals|Semi-structured interviews of health care professionals to explore current management of urinary incontinence in the community
25709|NCT03986411|Other|Phase 2: Physiotherapy for urinary incontinence|Tailored physiotherapy assessment and management for athletic women who self-report urinary incontinence
25710|NCT03986411|Other|Phase 3: Qualitative Interviews: Participants|Semi-structured interviews of a purposeful selection of the participants from Phase 2 to explore reaction to the recruitment process and the intervention
25711|NCT03986398|Other|Infection prophylaxis|Infection prophylaxis with Urell®, cranberry fruit juice extract (vaccinium macrocarpon)
25712|NCT03986385|Drug|Apatinib Capecitabine Oxaliplatin|apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
25713|NCT03986385|Drug|Capecitabine Oxaliplatin|Preoperative: Capecitabine 1000mg/m2 bid d1-14，Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
25714|NCT03986372|Biological|Platlet-rich plasma|Multiple Platlet-rich plasma injection.
25715|NCT03986359|Device|low energy extracorporeal shockwave therapy|Low-intensity extracorporeal shockwave therapy (LI-ESWT) was proved to be useful in various medical conditions; for example, neovascularization in myocardial ischemia, nonhealing wounds, ED and chronic pelvic pain syndrome
25716|NCT03986346|Device|pulsed dye laser|The scar will receive PDL 595 nm using a 7 mm spot size. First treatment will be within 1 year post injury.
25717|NCT03986346|Other|pressure therapy|Pressure garment will be prescribed for participants to manage scars.
25718|NCT03986320|Device|Keeogo™ Dermoskeleton|This device is intended for use in rehabilitation institutions to assist individuals with hemiparesis due to stroke who are able to stand and initiate a step in performing ambulatory functions.
25719|NCT03986307|Dietary Supplement|Omega-3 polyunsaturated fatty acid supplementation|Daily supplementation with omega-3 capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
25720|NCT03986307|Other|Resistance exercise|Resistance exercise training in both supplementation conditions (3 times per week for 12 weeks).
25721|NCT03986307|Dietary Supplement|Placebo - appearance-matched oil supplementation|Daily supplementation with placebo capsules (daily for 14 weeks). Each day: 3 capsules of 1.1g
25722|NCT03986294|Drug|S1 + Nal-IRI|S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.
25723|NCT03986294|Drug|Nal-IRI+Leucovorin+5-FU|Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.
25724|NCT03986281|Other|Omron Wearable Device|Omron wearable device compared to arterial line readings
25725|NCT03986281|Other|Standard Arterial Line|Omron wearable device compared to arterial line readings
25726|NCT03986268|Drug|Vit D|The aim of this study is investigating pathologic response to neoadjuvant therapy if we give replacement therapy with vitamin D3 50.000 IU weekly dosage concurrent with chemotherapy in breast cancer patients.
25727|NCT03986255|Procedure|Lumbar Puncture|"The participant is placed lateral or sitting position. Fluoroscopy may be used to guide sampling. Full aseptic technique is used throughout.~The skin is prepared with either 2% chlorhexidine/70% alcohol or iodine. 1% lidocaine is used for skin local anesthesia an entry point is identified, this may be done using fluoroscopy. This will be at the lowest intervertebral foramina interspace to minimize the risk of spinal cord injury. A small amount to head up tilt will be allowed to optimize CSF flow.~Sampling is done using a needle through needle technique. An epidural needle is used to identify the epidural space using loss of resistance to saline technique. A spinal needle (26G) is then passed through the epidural needle into the subarachnoid space. Correct entry is noted once CSF is noted in the needle hub and 5 ml taken. This sample is then sent off for analysis.~Once the CSF is sampled, the needle is removed and pressure applied to the skin entry point."
25728|NCT03986242|Device|rolling|use non- vibration rolling and the total time is 20 minutes.
25729|NCT03986242|Device|Vibration rolling|use Vibration rolling the vibration frequency is 28 Hz, and the total time is 20 minutes.
25730|NCT03986242|Other|static stretching|static stretching and the total time is 20 minutes.
25783|NCT03985826|Other|Diagnosis of and treatment for Acute lymphoblastic leukaemia in childhood|The cohort of ALL survivors has all been diagnosed and treated for ALL in childhood
26136|NCT03982940|Device|BeGraft Plus Stent Graft System as bridging stent|BeGraft Plus Stent Graft System as bridging stent
25731|NCT03986229|Other|"Evaluate the variation in the travel speed of the center of pressure with and without compression garments."|"Each evaluation will be done according to the following protocol:~Evaluation of the pain~Berg test~One test per condition starting with open eyes~Standardized instructions:~Break about 15 minutes (wash-out) between each test.~Both conditions will be tested on the same day.~Evaluation in an environment free from visual and audible interference."
25732|NCT03986216|Device|ReIn-Hand device assisted home-based practice|Practice reach-grasp-retrieve-release at home with the aid of ReIn-hand device
25733|NCT03986203|Device|Spry Belt|The Spry Belt delivers energy to the user that may help prevent bone loss. Participants will wear the device for 30 minutes a day, 5 days a week for one year. The active and sham devices are identical except for the specific energy that is delivered to the user.
25734|NCT03986190|Behavioral|Healthy Juntos|"Parent-adolescent dyads will log in to a secured website for a total of eight weeks. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which are being developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in a 15-30 minute conversation with parents regarding their family's progress periodically throughout the intervention period."
25735|NCT03986177|Behavioral|Self-management Intervention Package|"Children will receive basic asthma education, based on the National Heart, Lung, and Blood Institute A Breath of Life asthma education program. Children/caregivers in the intervention arm will also be assigned a designated nurse case manager who will provide home visits and be available via text message and phone-based support throughout follow-up. Intervention components:~Interactive education and support on use of an asthma action plan~Locally adapted patient-provider communication tool~Child-oriented educational materials in comic book format~Modeling and hands-on practice of inhaler technique (written instructions, in person, video)~Education regarding environmental trigger abatement~Patient navigation, home visits, and goal setting support from nurse manager"
25736|NCT03986164|Device|Guided surgery with bovine spongious bone substitute|"A minimally traumatic extraction will be performed aiming at the preservation of tissue integrity. After this step, milling will be performed using a sequence of guides and cutters recommended by the Raptor Implacil / Bioparts (Implacil De Bortoli) system manufacturer for implant installation (Cone Morse 3.5mm from 11-13mm Implacil De Bortoli) in computer-guided surgeries.~In the spaces between the implant and the buccal bone plate will be filled with xenogene biomaterial (Geistlich Bio-Oss 0.25-1mm). Immediately after implant installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm - Implacil De Bortoli) will be placed.~If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days."
25737|NCT03986164|Device|Conventional surgery with bovine spongious bone substitute|The sequence of cutters recommended by the manufacturer for this type of surgery and installation of the same type of implant (Cone Morse due cone 3.5mm) will be adopted. The perforations of the collar for future insertion of the implants will be performed aiming the installation of the implants with its platform installed with sub-crestal position. The implant should be installed along the palatine wall to obtain primary stability, at the center of the mesio-distal width predetermined by the final restoration, with a minimum distance of 2 mm from the adjacent tooth, and 3 mm from the free gingival margin, becoming slightly palatinate (Kan et al, 2018). Immediately after installation, the prosthetic component (Smart Line, Trunnion CM 3.5mm - T 1.5-3.5mm, height 4mm) will be placed. If necessary, the sutures of the surgical procedures will be performed with polygalactin 5.0 (Vycril Rapid®, Jonhson's Jonhson, São José dos Campos) and will be removed after 7 days.
25738|NCT03986151|Procedure|Coronary angiography +/- percutaneous coronary intervention|Comparison of the conventional radial approach with the distal radial approach (anatomical snuffbox)
25739|NCT03986138|Drug|gadopiclenol|Single intravenous bolus injection
25740|NCT03986138|Drug|Gadobutrol 1 MMOLE/ML Intravenous Solution|Single intravenous bolus injection
25741|NCT03986125|Behavioral|Emotional Awareness & Expression Therapy|emotion-focused
25742|NCT03986125|Behavioral|Mindfulness Meditation Training|meditation training and practice
25743|NCT03986112|Biological|carotid sonography and inferior vena cava sonography|Carotid and venous ultrasonography is performed in a comfortable state. Corrected blood flow after carotid ultrasound and carotid artery blood flow rate were measured. After inferior vena cava sonography, the collapsibility Index by measuring the largest and smallest diameter during the respiratory cycle will be obtained. Propofol 2 mg / kg is administered and remifentanil is maintained at 4.0 ng / mL using the Target Control System. Blood pressure and heart rate are measured at prior to induction, 1 minute after induction, immediately after intubation, and at 1, 3, 5, 7 and 10 minutes after intubation. Post-induction hypotension is considered as a decrease of 20% or more of baseline blood pressure or a mean arterial blood pressure of less than 60 mmHg. In the event of hypotension in accordance with the above definition, repeated administration of ephedrine 4 mg or phenylephrine 50 mcg is used.
25744|NCT03986099|Diagnostic Test|Monitoring virus load|Near point of care
25745|NCT03986086|Drug|MPH966|RP2D tablet
25746|NCT03986086|Drug|Placebo|MPH966 placebo table
25747|NCT03986073|Drug|TQ-F3083 capsule 5 mg|Subjects in the low dose group administrated TQ-F3083 capsule 5mg, once daily for 12 weeks.
25748|NCT03986073|Drug|TQ-F3083 capsule 10 mg|Subjects in the high dose group administrated TQ-F3083 capsule 10 mg, once daily for 12 weeks.
25749|NCT03986073|Drug|TQ-F3083 blank analog capsule|Subjects administrated one TQ-F3083 blank analog capsule orally, once daily for 12 weeks.
25750|NCT03986073|Drug|TQ-F3083 blank analog capsule|Subjects administrated two TQ-F3083 blank analog capsules orally, once daily for 12 weeks.
25751|NCT03986073|Drug|Linagliptin blank analog tablet|Subjects administrated one Linagliptin blank analog tablet orally, once daily for 12 weeks.
25752|NCT03986073|Drug|Linagliptin tablet|Subjects in the positive drug control group administrated one Linagliptin tablet orally, once daily for 12 weeks.
31201|NCT03942003|Procedure|rhomboid blocks|Rhomboid nerve block was performed
25754|NCT03986047|Other|Exercises|In addition of exercises performed with the physiotherapist at the first session, exercises will be performed at home five times over the next 7 days, for approximately 30 minutes each performing day. Three different categories of exercises will be given: 1) Functional activities exposure (sitting, sit-to-stand, lifting, bending, etc.); 2) cognitive contraction of trunk muscles and basic trunk motor control exercises; 3) mobility of the lumbar spine and preferential direction of movement. Exercises will be chosen and adapted for each participant by a physiotherapist, in function of pain presentation and intensity, and response to exercises.
25755|NCT03986047|Device|Sham|The same lower back wrap as the Thermal care group will be used, but cooled down to room temperature (opened in advance). The wrap will be worn following the same parameters (duration, frequency) than the Thermal care group.
25756|NCT03986047|Behavioral|Education for the management of acute low back pain|Participants will receive education on the management of acute low back pain by a physiotherapist . The main topics addressed will be patient reassurance, staying active, avoiding bed rest, activity modification, and sitting and bed postures/transfer. Participants will received a document that details advices covered during the session and the physiotherapist will answer any questions.
25757|NCT03986034|Drug|Venetoclax|Patients with relapsed or refractory CLL who have progressed after at least one prior line of treatment will enroll on the study. Subjects will be treated for the duration of the ramp- up phase of venetoclax at the NIH Clinical Center and receive primary response assessment after reaching the maximum dose of venetoclax. After the ramp-up phase is complete, patients will continue to follow- up at the NIH every 6 months, however subjects' medical care will be transitioned to their local hematologist /oncologist
25758|NCT03986008|Drug|Benaglutide|The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
25759|NCT03986008|Drug|Liraglutide|The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
25760|NCT03985995|Drug|CBD 800 mg p.o|cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.
25761|NCT03985995|Drug|Placebo p.o|single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
25762|NCT03985982|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
25763|NCT03985982|Drug|Placebo|injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
25764|NCT03985969|Drug|elafibranor|Elafibranor 120mg is a coated tablet for oral administration
25765|NCT03985969|Drug|CHRONO-INDOCID|CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration
25766|NCT03985943|Drug|Placebo|Placebo
25767|NCT03985943|Drug|Nemolizumab|Nemolizumab
25768|NCT03985930|Other|Distraction with virtual reality or video projection|Distraction content delivered through virtual reality goggles or video projection.
25769|NCT03985917|Other|Singing Group Intervention Program|Each session will start with (1) relaxation, vocal warm-up and breething exercises; (2) vocal technique training; (3) memorization and interpretation of music and lyrics; (4) session breaks of 20 minutes for socialization; (5) preparation of a final choir show; (6) vocal tuning tests.
25770|NCT03985917|Other|Alternative Social and Leisure Activities|Day care centers provide social and leisure activities opportunities for older adults. The control group is free to enroll in these activities.
25771|NCT03985904|Other|ART THERAPY|ART THERAPY: Nursing Interventions Classification = 4330 Weekly group intervention carried out by a mental health nurse specialist, a mental health peer support, a museum educator and a social monitor.
25772|NCT03985891|Drug|Anti-PD-1 Monoclonal Antibody JS001|Anti-PD-1 monoclonal antibody combined with chemotherapy in patients with locally advanced colon cancer (perioperative treatment)
25773|NCT03985891|Drug|Chemotherapy|Folfox
25774|NCT03985878|Drug|Eteplirsen|Eteplirsen IV infusion once weekly.
25775|NCT03985865|Drug|Intragastric quinine hydrochloride|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 10 µmol of quinine hydrochloride per kg body weight was administrated into the stomach.
25776|NCT03985865|Drug|Intragastric denatonium benzoate|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 1 µmol of denatonium benzoate per kg body weight was administrated into the stomach.
25777|NCT03985865|Drug|Intragastric placebo|A nasogastric feeding tube was positioned into the stomach, and checked with a pH strip. 0.1 ml of water (placebo) per kg body weight was administrated into the stomach.
25778|NCT03985865|Drug|Intraduodenal quinine hydrochloride|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.
25779|NCT03985865|Drug|Intraduodenal denatonium benzoate|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.
25780|NCT03985865|Drug|Intraduodenal placebo|A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
25781|NCT03985852|Other|Patient Directed Standard of Care|The pre-test genetic counseling visit will be conducted through access to an automated genetics education assistant accessed through the patient portal. The automated approach will address all the components of the pre-test counseling and contains content designed by the genetic counselors at the University of Utah and NYU. Patients will have the option to contact genetic counselors through the patient portal, by phone, or in person but this will not be required. All results will be reviewed by a genetic counselor. Negative results will be returned by the automated genetics education assistant. Genetic counselors will return results for pathogenic variants and variants of uncertain significance via phone.
25782|NCT03985839|Device|Microraptor Regenesorb suture anchor|Smith & Nephew MICRORAPTOR REGENESORB Suture Anchor is a fixation device intended to provide secure attachment of soft tissue to bone
26137|NCT03982927|Other|Laparoscopic skills workshop|One day laparoscopic skills workshop was offered to the surgical residents
25784|NCT03985813|Behavioral|Screening Wizard|Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
25785|NCT03985813|Behavioral|Treatment as usual|Participants in this group will receive usual care at their pediatric primary care practice. This involves receiving screening for depression using the Patient Health Questionnaire and clinical assessment/management by their primary care provider.
25786|NCT03985800|Other|TEAM|TEAM incorporates team-based care with traditional in-person clinic visits. The care team includes a gastroenterologist, nurse practitioner, nutritionist, social worker/behavioral health specialist, and a psychologist or psychiatrist.
25787|NCT03985800|Other|TECH|TECH uses team-based care similar to TEAM, but in-person care is substituted with telemedicine (i.e., video visits and consultations) and digital behavioral health tools.
25788|NCT03985787|Behavioral|Resistance Training|12-weeks of a full body resistance training intervention. Intervention will consist of 4 training sessions per week that are approximately 45-minutes in length. Two days will be upper body training and 2 days lower body
25789|NCT03985774|Procedure|Carotid revascularization|The ENROUTE Transcarotid Neuroprotection System has received CE Mark and is commercially available in the European Union. The ENROUTE Transcarotid NPS may be used in conjunction with carotid artery stent approved for revascularization in patients with carotid disease
25790|NCT03985761|Behavioral|Home Telerehabilitation using HoVRS|The Home Virtual Rehabilitation System (HoVRS) integrates a Leap Motion controller, a passive arm support and a suite of custom designed hand rehabilitation simulations. The Leap Motion provides camera based measurement of finger joint positions, allowing for integrated virtual arm and finger training. If the patient's arm is severely impaired, a forearm orthosis that counter-balances gravity to provide graded support to the arm during activity is issued to the subject. In this study, we utilize 3 task-based simulations that train hand manipulation and arm transport. One simulation trains hand opening integrated with pronation and supination, a second trains wrist movement, by presenting targets that subjects navigate a plane over and around buildings to collect, a third simulation, trains shoulder and elbow disassociation in a horizontal plane integrated with hand opening.
25791|NCT03985748|Device|BAN|Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
25792|NCT03985748|Device|SN|Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
25793|NCT03985735|Drug|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation. Additional cisatracurium （0.05 mg/kg）and fentanyl (30-50 μg at the end of surgery) were used as needed, in accordance with the clinical requirements.
25794|NCT03985722|Drug|Olaratumab and Trabectedin|"Dose-escalation levels:~LEVEL -1: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 0.9 mg/m2 D1 This is a security level in case level 0 causes DLT.~LEVEL 0*: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.1 mg/m2 D1.~* Dose starting level is 0."
25795|NCT03985722|Drug|Olaratumab and Trabectedin|"Dose-escalation levels:~LEVEL 2: Olaratumab 15 mg/Kg D1 and D8 + Trabectedin 1.5 mg/m2 D1"
25796|NCT03985722|Drug|Olaratumab and Trabectedin|"Dose-escalation levels:~LEVEL 3**: Olaratumab 20 mg/kg C1D1 and C1D8 (induction) + Trabectedin 1.5 mg/m2 D1 and Olaratumab 15 mg/kg D1 and D8 (maintenance) + Trabectedin 1.5 mg/m2 D1~**In the LEVEL 3 Olaratumab dose of 20 mg/kg will be considered only for the first 2 doses (as induction doses, cycle 1 days 1 and 8)) and then, the maintenance dose will be 15 mg/m2 for the rest of cycles."
25797|NCT03985709|Other|Probiotic product|Probiotic (Lactobacillus casei) once daily taken by 3 months.
25798|NCT03985696|Other|blood sample|1 blood volume (5-7 ml EDTA)
25799|NCT03985683|Other|agility tests|In control group athletes will perform T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
25800|NCT03985683|Dietary Supplement|Nutritional Interventional|Athletes were given 50 % carbohydrate in first 3 days and 70 % in next 3 days respectively.T-Test, Illinois agility test, 30 meter run test and Agility Compass drill test, before and after 6 days of intervention.
25801|NCT03985670|Drug|teripalimab plus chemotherapy|teripalimab 240mg d1 paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1
25802|NCT03985670|Drug|chemotherapy plus teripalimab|paclitaxel 150mg/m2 d1 cisplatin 70mg/m2 d1 teripalimab 240mg d3
25803|NCT03985657|Device|CPAP|Continuous positive airway pressure (CPAP). Room air at pressures between 6-8 centimeters of water (cmH2O) delivered via heated humidified tubing and a nasal mask.
25804|NCT03985631|Other|Rehabilitation intervention|Rehabilitation sessions based on Tai Chi through telerehabilitation
25805|NCT03985618|Procedure|Caesarean section|Planned pre-labour Caesarean section at 38-40 weeks. For patients planning Caesarean Section, surgical planning, precise timing and method of Caesarean section is at the discretion of the most responsible care provider, as per local procedures.
25806|NCT03985618|Procedure|Induction of Labour|Planned induction of labour at 38-40 weeks. For patients planning induction of labour, precise timing and method of induction of labour is at the discretion of the most responsible care provider, as per local procedures.
25807|NCT03985592|Behavioral|Education|Intervention description provided in elaboration on arms of the study.
25808|NCT03985579|Other|Kinesiology taping application|Application of elastic cotton strip with an acrylic adhesive that is used with the intent of treating pain and disability from athletic injuries and a variety of other physical disorders
25809|NCT03985566|Dietary Supplement|Fibre Grain|Healthy subjects will be provided with 30% Fibre Grain in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
25810|NCT03985566|Dietary Supplement|Jasmine white rice|Healthy subjects will be provided with Jasmine white rice in a mixed meal. After consumption of the meal, the glucose and insulin response will be compared.
25811|NCT03985553|Behavioral|Parenting Self-Management Program|
25812|NCT03985540|Behavioral|Behavorial; memory exercise|Memory training twice a week for 5 weeks.
25813|NCT03985540|Behavioral|Placebo; memory exercise|Placebo Memory training twice a week for 5 weeks
25814|NCT03985540|Behavioral|Behavioral: speed exercises|Speed training twice a week for 5 weeks.
25815|NCT03985540|Behavioral|Placebo speed training|Placebo Speed training twice a week for 5 weeks.
25817|NCT03985514|Drug|Antibiotic treatment (Piperacillin/Tazobactam, 4 gram x 3), followed by 8-10 days of out-hospital oral antibiotic treatment (Ciprofloxacin 500 mgx2,Flagyl 400 mgx3).|Intravenous antibiotic treatment x 3, followed by oral antibiotics for 8-10 Days.
25818|NCT03985514|Other|Active observation|In-hospital observation without antibiotics
25819|NCT03985501|Other|SCD newborn screening with the MS/MS method from Zentech|The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)
25820|NCT03985488|Radiation|Radiation exposure|Radiation exposure via Eview Fluoroscopy machine.
25821|NCT03985475|Other|skin sample|For each person included in the study, skin sampling performed as part of the medical management of skin infections will be performed, associated with the contralateral healthy skin sampling.
25822|NCT03985462|Biological|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
25823|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (text only)|The uterine fibroid Option Grid patient decision aid facilitates choice awareness and deliberation about treatment options when clinicians and patients discuss the management of uterine fibroids. The content is organized in a tabular format and is based on patients' frequently asked questions.
25824|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (text + Pictures)|The Picture Option Grid uses the same evidence as the text version while integrating images and simpler text, thus utilizing pictorial superiority to help patients better understand and remember information more easily compared to just using words.
25825|NCT03985449|Other|Uterine Fibroid Option Grid encounter patient decision aid (online)|Clinicians can click a link in the electronic health record that will lead them to the EBSCO Health website where they can click the treatment options relevant to the patient and generate a decision aid.
25826|NCT03985436|Behavioral|Trek for Surgical Success|Cognitive behavioral therapy for pain
25827|NCT03985423|Drug|Emapalumab-Lzsg|Emapalumab administered intravenously at the initial dose of 6 mg/kg, and continued at the dose of 3 mg/kg every 3 days until Study Day 15, and twice-a-week afterwards
25828|NCT03985410|Drug|ETX2514|intravenous infusion
25829|NCT03985410|Drug|Placebo|intravenous infusion
25830|NCT03985410|Drug|moxifloxacin|oral tablet
25831|NCT03985397|Other|discharge training|Providing planned discharge training according to the level of knowledge about diet, drug and individual monitoring compliance and cardiovascular risk factors of patients with acute myocardial infarction
25832|NCT03985384|Drug|Semaglutide 2 MG/1.5 ML Subcutaneous Solution|Semaglutide 2 MG/1.5 ML Subcutaneous Solution
25833|NCT03985384|Drug|Placebo|Placebo 1.5 ml, pen-injector for SC injection.
25834|NCT03985371|Drug|EDTA Eye Drops|One drop in the Band Keratopathy affected eye only, two times per day for six months.
25835|NCT03985358|Other|Opioid counseling plus standard of care instructions|Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
25836|NCT03985345|Device|intravaginal device (probe) EMY|Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
25837|NCT03985319|Drug|YYD601 20mg|Esomeprazole IR 10mg + Esomeprazole SR 10mg (Expected efficacy and effects: GERD)
25838|NCT03985319|Drug|Nexium tab 20mg|Esomeprazole magnesium trihydrate 22.3mg Effecacy and Effects: GERD and Antibiotics combined therapy to eradicate the Helicobacter pylori
25839|NCT03985306|Procedure|Inforatio technique|"We define the inforatio technique as punch biopsies taken in the periphery of the wound bed. The punch biopsies will have a diameter of two mms. The depth of the biopsies is primarily based on clinical assessment on distance to bone by assessment with a sterile wound probe and with attention to location and anatomy. The maximum depth will be 3.5 millimeters. The biopsies will be taken from one to two mms from the wound edges and with a distance of five mms between the biopsies.~Inforatio technique is applied after standard care and wound assessment."
25840|NCT03985293|Drug|Placebo|4 matching placebo tablets taken twice a day (BID)
25841|NCT03985293|Drug|PF-06882961|Participants will be randomized to one of 5 active doses (2.5, 10, 40, 80, or 120 mg), taking 4 tablets twice daily for 16 weeks.
25842|NCT03985280|Device|Cooled radiofrequency|Under guidance of combined X-ray and ultrasound the nerves will be located . After local anesthetic aplication cooled RF needle will be apply in the objective position. Cooled RF will be performed for 2:30 minutes at 60 º C degrees.
25843|NCT03985280|Drug|Intraaticular steroids and local anesthetic injections|Intraaticular steroids and local anesthetic injections
25844|NCT03985267|Behavioral|Mindfulness based Swinging Effect Intervention|Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
25845|NCT03985254|Other|Strength Training Group (STG)|"The strength training program will consist of applying resistance and progressive exercises for strength gain and will be based on the training principles recommended by the American College of Sport Medicine. The exercises were chosen based on a pilot study that successfully applied the protocol to 10 participants with FPD (data to be published) and other strength training studies (MASCALL et al, 2003; DISTEFANO et al, 2009; REIMAN et al, 2012; BALDON et al, 2014; SILVA et al, 2015).~Initially, the goal will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]), and in subsequent weeks the goal will be the development of muscle strength (load> 70% 1RM). In addition, the protocol will initially focus on strengthening the hip and trunk muscles and after four weeks of training, exercises for the knee muscles will be included."
25873|NCT03984981|Other|Assessment of process required to diagnose brain death in adult patients|Assessment of process required to diagnose brain death in adult patients (demographics, clinical, laboratory, imaging, and treatment data). No questionnaires or study visits will be used.
25874|NCT03984968|Biological|CAR-T infusion|Patients enrolled in this arm will receive CAR-T infusion
26200|NCT03982381|Drug|Metformin|Active comparator
25846|NCT03985254|Other|Strength and Power Training Group (SPTG)|Participants who are allocated to this group will perform the same exercise program performed by the STG, but with the addition of exercises that emphasize power gain. As in the other group, initially, the objective will be the development of neuromotor control and resistance (load <50% of the one repetition maximum test [1RM]). However, in subsequent weeks the goal will be to develop strength (load> 70% 1RM) and muscle power (load between 40-60% 1RM).
25847|NCT03985241|Diagnostic Test|Functional Assessment of Myocardial Ischemia by icECG|
25848|NCT03985228|Dietary Supplement|Fortified milk|Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%), enriched in whey protein (5%) and calcium (0.24%), supplemented with unsaturated fatty acids omega-3 (DHA + EPA), vitamins (D, B12, B6, B9, E, C), prebiotics (FOS) and phyto curcuminoids (sunflower lecithin). Milk had to be associated with a packet of lyophilized and concentrated probiotics (Bifidobacteria infant-type and / or Lactobacilli), at the time of consumption. Milk and probiotics had been produced or supplied by Granarolo s.p.a.
25849|NCT03985228|Dietary Supplement|Placebo milk|"Ultra high temperature UHT, partly-skimmed milk (1% fat), highly digestible (lactose <0.01%) with standard proteins of milk (3.1%) and color additive quantum satis. Milk had to be associated with a packet of maltodextrin Food Grade, at the time of consumption. Milk and maltodextrin had been produced or supplied by Granarolo s.p.a."
25850|NCT03985215|Other|Questionnaires|Pediatric Quality of Life Inventory questionnaire. Self-designed questionnaire.
25851|NCT03985202|Other|Structured exercise programme|9 week structured exercise programme. 3 sessions per week. (Intervention).The patient will be invited to the hospital for a 45-minute exercise counselling session, incorporating behaviour modification techniques. These behaviour modification techniques will be reinforced during the supervised exercise sessions. Participants will be offered 3 sessions of supervised aerobic interval exercise sessions per week on a cycle ergometer for 9 weeks.Exercise programmes will be tailored to each patient, taking previous level of activity, mobility and any barriers to exercise into consideration.
25852|NCT03985189|Drug|ME-401|ME-401 will be administered at 2 dosages as 45 mg (Cohort 1) or 60 mg (Cohort 2), daily oral administration, QD, and the trial will be initiated at Cohort 1, and medical specialists and the Efficacy and Safety Assessment Committee as needed will decide whether the Cohort will be shifted to the next stage based on their assessment of the safety and tolerability.
25853|NCT03985176|Device|ROTEM|ROTEM measurements 24,48, 72, 120, 192 and 288 hours from aneurysmal SAH
25854|NCT03985176|Procedure|EEG|Continuous EEG-monitoring after aneurysm treatment until patient transferred to ward or up to 14 days after aneurysmal SAH
25855|NCT03985176|Procedure|bilateral compression ultrasound of the lower extremity veins|to exclude asymptomatic deep venous thrombosis once over days 3 to 7
25856|NCT03985163|Other|Patient Reported Outcomes Electronic Survey|This study does not include a drug, test, behavioral or medical procedure intervention; participants will be asked to complete three surveys
25857|NCT03985150|Other|Biomechanical analysis of femoralis superficialis atherosclerotic tissue|Tissue collection during above-knee amputation; mechanical testing of tissue; microstructural testing of tissue
25858|NCT03985150|Radiation|CT or MR angiogram|Obtaining in vivo geometry of diseased artery
25859|NCT03985137|Other|mucocutaneous sampling by swab at the balano-preputial furrow.|the sample is made by the patient
25860|NCT03985124|Behavioral|Tuning in to Kids for Teachers|This is an emotion-focused intervention for teachers giving them skills in emotion coaching children in their care and also understanding and managing their own emotions.
25861|NCT03985111|Device|Central Venous Catheter|Insertion of a central venous catheter insertion pre-operatively (electively)
25862|NCT03985098|Behavioral|Motivational interviewing intervention arm|The intervention will be a phone call by a pharmacy student that will use MI strategies to identify and address the adherence barrier(s) and 5 monthly follow up calls
25863|NCT03985085|Other|Comprehensive package of sexual and reproductive health services|"Implementation of a comprehensive sexual and reproductive health care package for female sex workers in Côte d'Ivoire, combining an HIV PrEP offer (for HIV- FSW) with early treatment of HIV+ FSW, management of HBV infection (testing, vaccination and treatment), testing and treatment of sexually transmitted infections (STIs) and their consequences, a contraception offer, a quarterly screening of pregnancies, menstrual management counselling and identification of addiction.~This healthcare package will be available both in mobile clinics organized for a quarterly follow-up (10 intervention sites, each site being visited every two weeks) and in the fixed clinic of the partner community-based NGO, at the discretion of each female participant."
25864|NCT03985072|Drug|Andes-1537 for Injection|Andes-1537 subcutaneous administration will be performed on days 1 and 4 of each week at the clinic. There has to be a minimum of 48 hours between two consecutive administrations.
25865|NCT03985059|Other|Transcranial Doppler|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed in the USINV, according to the usual care. In a second step, the patient will be verticalized (from 0° to 90°). HI parameters in supine position and during verticalization will be recorded continuously by placing the transcranial Doppler helmet.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the helmet."
25866|NCT03985046|Drug|Sintilimab plus Chemotherapy|Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=6. Once every 3 weeks.
25867|NCT03985033|Other|leucocyte and platelet-rich fibrin (L-PRF)|The blood collected from each patient will be centrifuged immediately at 2700 rpm for 12 min to separate L-PRF.
25868|NCT03985020|Other|Stevia Intervention|We will use commercially available stevia sweetened soft drink Zevia.
25869|NCT03985020|Other|Water Intervention|Bottled Water
25870|NCT03985007|Drug|CDIAG regimen|Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.
25871|NCT03984994|Other|Aerobic exercise training|3 months of center-based, supervised treadmill exercise
25872|NCT03984994|Other|Strength training|3 months of center-based, supervise strength training
26201|NCT03982381|Drug|Dapagliflozin 10 MG|Experimental treatment
25875|NCT03984955|Device|Sodium hyaluronate with mannitol (Ostenil Tendon)|1ml isotonic solution contains 20.0mg sodium hyaluronate and sodium chloride, disodium phosphate, sodium dihydrogen phosphate, mannitol and water for injections.
25876|NCT03984955|Device|Platelet-Rich Plasma Injection|Platelet-rich plasma (PRP) describes an autologous blood plasma fraction enriched with platelets which is then injected at the site of tendon injury.
25877|NCT03984955|Other|Subcutaneous sham injection|Sham injection will penetrate the skin, but no therapeutic substance will be injected
25878|NCT03984929|Behavioral|Conexion Localized|The localized version of Conexion is an online health information resource on diabetes and depression tailored for the target community.
25879|NCT03984929|Behavioral|Conexion Generic|The generic version of Conexion is an online health information resource on diabetes and depression.
25880|NCT03984916|Dietary Supplement|Hesperidin Pharma|Two capsules with 250 mg of sweet orange extract with a mixture of hesperidin isomers -S and -R.
25881|NCT03984916|Dietary Supplement|Hesperidin Pharma_M|Two capsules with 250 mg of sweet orange extract each with a mixture of hesperidin isomers -S and -R and micronized.
25882|NCT03984916|Dietary Supplement|Cardiose|Two capsules with 250 mg of sweet orange extract each with more than 90% of hesperidin as isomer -S and micronized.
25883|NCT03984903|Other|Multimedia Learning of Exercises|Patients learn exercise from multimedia content.
25884|NCT03984903|Other|Face-to-face Learning of Exercises|Physiotherapist teach exercises to patients
25885|NCT03984903|Other|Manual Therapy|Myofascial Release Techniques and Joint Mobilizations to the Lumbal Area
25886|NCT03984903|Other|Home Exercise Program|Patients do at least 20 minutes motor control exercise in a day at home.
25887|NCT03984890|Drug|Vitamin D3|Vitamin D3 drops 800IU/d for 3 months
25888|NCT03984890|Drug|Traditional treatment of CGD and TB|Anti-tuberculosis drugs, interferon-gamma
25889|NCT03984877|Diagnostic Test|Diagnosis of amyloidosis|Scintigraphy and protein electrophoresis
25890|NCT03984864|Other|Exercise therapy|3-4 items from a list of 10 general exercises - intended for treatment of low back pain
25891|NCT03984838|Drug|JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet|JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
25892|NCT03984825|Drug|GSK3640254|GSK3640254 will be available as a 100 mg capsule. Subjects will be administered 200 mg GSK3640254 once daily via the oral route on Days 11 to 21.
25893|NCT03984825|Drug|Portia|Portia will be available in the form of tablets containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel.
25894|NCT03984812|Drug|GSK3732394|It is composed of an anti-CD4 adnectin, an anti-N17 adnectin, and a peptide inhibitor. This will be provided as a solution for injection in 1 (milliliter) mL glass vials with the unit dose strength of 100 mg/mL
25895|NCT03984812|Drug|Placebo|Placebo will comprise of 0.9% weight per volume (w/v) sodium chloride.
25896|NCT03984799|Procedure|Bronchoscopy|Samples obtained during bronchoscopy and blood samples will be evaluated to define inflammatory markers of COPD
25897|NCT03984786|Behavioral|Assessment Interview|An interviewer will administer a pre-treatment assessment interview. This 30-45 minute interview will be performed after randomization immediately after the initial telephone screen, where the interviewer will use the AUD section of the SCID-5.
25898|NCT03984786|Behavioral|Guidance|Guidance from a health educator through regular weekly online messages. Participants may also be contacted through emails and phone calls. The team of guides consists of registered social workers, psychologists, and graduate students, with experience delivering ICBT.
25899|NCT03984786|Behavioral|ICBT for alcohol misuse|The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
25900|NCT03984773|Behavioral|Nudge|Oncology practices will be randomly assigned to receive an intervention, in which individual clinicians will receive a weekly audit email detailing how many serious illness conversations (SIC) they have had compared to the recommended level, and a link to a list of their patients scheduled in clinic next week at high risk of short-term mortality as identified by a mortality prediction algorithm. Clinicians will have the chance to review the opt-out list and pre-commit to a serious illness conversation with appropriate patients. Clinicians will receive nudge on the day of the patient visit via text message reminding them of their pre-commitment to conduct a serious illness conversation.
25901|NCT03984760|Drug|Ferric Citrate|Take the capsules with meals or immediately after meals.
25902|NCT03984760|Drug|Sevelamer Carbonate|Take the tablets with meals.
25903|NCT03984734|Procedure|Pancreatoduodenectomy with antrectomy|
25904|NCT03984734|Procedure|Pylorus-preserving pancreatoduodenectomy|
25905|NCT03984721|Diagnostic Test|Amyloidosis typing using mass spectrometry-based proteomics|Amyloidosis typing using nanoLC-MS/MS method
25906|NCT03984708|Other|Samples|Blood sample, skin biopsy
25907|NCT03984708|Other|Indirect calorimetry|Measurement of energy expenditure by indirect calorimetry
25908|NCT03984708|Other|Electrical bioimpedance|Measurement of electrical bioimpedance
25909|NCT03984695|Behavioral|SHE-WOMEN|SHE-WOMEN is a text-Web intervention designed to increase jail-involved women's health literacy, reduce risk, and increase screening for prevention of cervical cancer, breast cancer, unintended pregnancy, and sexually transmitted infections.
25910|NCT03984682|Procedure|Joint Crisis Plan|A Joint Crisis Plan will be drafted with the patient and a nurse
25911|NCT03984669|Diagnostic Test|The Juvenile Disease Activity Score (JADAS)|The JADAS includes the following four measures: physician's global assessment of disease activity, measured on a 0-10 visual analog scale (VAS) where 0 = no activity and 10 = maximum activity; parent global assessment of well-being, measured on a 0-10 VAS where 0 = very well and 10 = very poor; the erythrocyte sedimentation rate (ESR), normalized to a 0 to 10 scale; and a count of joints with active disease.
25912|NCT03984669|Biological|(1-3)-ß-D-Glucan (BDG) assay (Fungitell)|Evaluation of the (1,3)-Beta-D-Glucans level in patients with JIA and correlation of the higher serum BDG levels with JIA activity of disease, comparatively with usual markers
26013|NCT03983889|Drug|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
26014|NCT03983889|Drug|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
25913|NCT03984656|Drug|lidocaine treatment|The index marks the upper edge of the lower rib of the selected intercostal space to avoid the vasculonervous bundle sitting at the lower part of the overlying rib.Non-targeted subcutaneous infiltration is performed in the drainage area with 5 to 10 mL of Lidocaine 20 mg / mL non-adrenaline, plane by plane, with regular aspiration until air or fluid confirming effusion.
25914|NCT03984656|Drug|serratus plane block treatment|"The Serratus plane block is located at the level of the 5th rib, on the midaxillary line, on the drainage side, ultrasound guided. The block is performed with a 70 mm needle in the ultrasound plane, and the needle is directed postero-inferior, after visualization of the structures from the surface to the depth: dorsal muscle~anterior serratus large muscle (serratus anterior)~intercostal muscle~4th and 5th ribs~pleura A single injection of 30 mL of Ropivacaine 4.75 mg / mL is performed around the Serratus muscle.~An intravenous injection of 8 mg of Dexamethasone is added to prolong the duration of the block."
25915|NCT03984643|Device|Vim-Deep Brain Stimulation|This study consists of testing additional model-derived DBS settings during initial and regular follow-up clinical visits every 6 months for up to 2 years in which individuals with DBS implants are re-evaluated by a clinician to make sure that the stimulation settings employed during the previous clinical visit remain therapeutic. It is important to note that this study is post-surgical and all procedures (i.e. stimulation settings that will be tested in the clinic) are within the FDA-approved range of stimulation settings available on the implanted pulse generator.
25916|NCT03984630|Behavioral|Dietary Fiber Intervention|Intervention included weekly group-based phone counseling with a Registered Dietitian (RD) to encourage consumption of a high fiber diet (≥30 g/day). All women reported their body weight weekly.
25917|NCT03984617|Other|Emergency visit in a French tertiary Maternity hospital (Maternity of Nancy)|total number of visits (hospitalizations and consultations)
25918|NCT03984604|Drug|CHI-921|a standardized cannabis extract in sunflower oil administered in oral liquid (oil) form
25919|NCT03984604|Drug|Placebo|Placebo is a vehicle oil will match CHI-921
25920|NCT03984591|Drug|Eplerenone|Eplerenone according to guidelines
25921|NCT03984591|Drug|Spironolactone|Spironolactone according to guidelines
25922|NCT03984578|Drug|CAPEOX|Oral Capecitabine: 1000mg/m2 twice a day from Day 1 to 14 of a 3-week cycle, and IV Oxaliplatin: 130mg/m2 on Day 1
25923|NCT03984578|Drug|Pembrolizumab|IV infusion of 200mg on Day 1 and Day 22
25924|NCT03984578|Drug|Capecitabine/ 5-FU|Capecitabine: Oral dose of 825mg/m2/day twice a day on radiation days with concurrent radiation median 50.4 Gy/ 28 fractions; or 5-FU: 225mg/m2/day concurrent with radiation
25925|NCT03984578|Drug|Pembrolizumab|IV infusion of 200mg on Day 1 of each cycle
25926|NCT03984578|Procedure|Surgical resection|Performed after all medical intervention
25927|NCT03984565|Drug|Cannabidiol|Cannabidiol sublingual product formulated in coconut oil
25928|NCT03984565|Drug|Placebo|Placebo sublingual product formulated in coconut oil
25929|NCT03984552|Behavioral|This was an observational study of medical devices (rapid tests) used for the HIV diagnosis in children up to 2 years|"These rapid tests are based on lateral flow immunochromatography technology, in which a nitrocellulose membrane is impregnated with the antigen of interest. The patient sample (blood, serum, plasma, oral fluid, etc.) is applied in this membrane which facilitates the interaction of antibodies in the sample with the antigens on the membrane. This reaction becomes visible to the naked eye thanks to a color developing revelator.~The entire testing process, from sample collection to result reading takes no more than 40 minutes and does not depend on laboratory facilities."
25930|NCT03984539|Behavioral|Cognitive Behavioural Therapy-Enhanced|CBT-E is a 20-session transdiagnostic eating disorders treatment based on the principles of cognitive behavioural therapy which has been developed over the past 40 years. The treatment focusses on tracking and modifying eating behaviours, providing psychoeducation, addressing overvaluation of weight and shape, body image, food restriction and restraint, emotion regulation, and relapse prevention.
25931|NCT03984539|Behavioral|Cognitive Behavioural Therapy-Ten|CBT-T is a 10-session treatment based on cognitive behavioural therapy. It was developed based on clinical experience as well as core components of evidence-based versions of CBT for eating disorders, including CBT-E. The aim of the intervention is to provide only the hypothesized critical elements of CBT for eating disorders so that the interventions can be provided quicker.
25932|NCT03984526|Drug|normal saline|intravenous normal saline pretreatment at the onset of dexmedetomidine infusion
25933|NCT03984526|Drug|atropine 0.6mg|intravenous atropine 0.6mg pretreatment at the onset of dexmedetomidine infusion
25934|NCT03984526|Drug|ephedrine 12mg|intravenous ephedrine 12mg pretreatment at the onset of dexmedetomidine infusion
25935|NCT03984513|Behavioral|Surviving and Thriving in the Real World|The Surviving and Thriving in the Real World intervention consists of 14 weekly concurrent adolescent and parent group sessions. The daily living skills to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning daily living skills and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
25936|NCT03984513|Behavioral|Program for the Education and Enrichment of Relational Skills|Program for the Education and Enrichment of Relational Skills is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning a get-together with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
25937|NCT03984500|Other|Education|SCTaware education (Phase II) will be compared to Ohio's current in-person SCT education (Phase I).
26015|NCT03983889|Drug|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
26132|NCT03983005|Procedure|EUS-B-FNA|Endoscopic ultrasound with bronchoscope fine needle aspiration (EUS-B-FNA) is an endoscopic technique based on a trans-esophageal needle aspiration performed by an interventional pulmonologist with the echo-bronchoscope
25938|NCT03984487|Behavioral|Surviving and Thriving in the Real World|The STRW intervention consists of 14 weekly concurrent adolescent and parent group sessions. The DLS to be targeted in the intervention include: Morning Routine (i.e., completing a morning personal hygiene routine); Laundry (i.e., sorting clothing, using a washing machine and dryer, and folding and putting clothes away); Kitchen/Cooking (i.e., cooking items in the microwave, oven, and stove, safe kitchen practices, cleaning up the kitchen after cooking, and grocery shopping); Self-Management (i.e., managing worry and stress related to learning DLS and transitioning to adulthood); and Money Management (i.e., using money to purchase items, evaluating the quality and price of items, understanding and using a checking and savings account, and budgeting money to cover expenses).
25939|NCT03984487|Behavioral|Program for the Education and Enrichment of Relational Skills|PEERS is an evidence-based social skills training program for youth with social challenges between the ages of 13-18.The program includes a teen group and a parent group that meet concurrently. Teens learn about conversations, electronic communication, joining groups, humor, handling teasing and disagreements, and planning get-togethers with other teens. Parents learn how to coach their teens to continue to use the skills when the program is complete.
25940|NCT03984461|Biological|Autologous cell therapy|Biologic material is harvested from the participant and re-injected into an osteoarthritic joint
25950|NCT03984422|Other|Smartphone application|use of smartphone application during 2 weeks to 3 months to collect frequency and duration of crises, RCS, photography of finger.
25951|NCT03984409|Dietary Supplement|Kroger low calorie orange juice beverage|Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
25952|NCT03984396|Other|Educational Materials - Patient & Clinician|deprescribing information for patient & clinician
25953|NCT03984370|Drug|ZP4207|Abdominal SC administration
25954|NCT03984370|Other|Placebo (saline)|Abdominal SC administration
25955|NCT03984357|Drug|PD-1 blocking antibody|"Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1"
25956|NCT03984357|Drug|Gemcitabine|Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
25957|NCT03984357|Drug|Cisplatin|Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
25958|NCT03984357|Radiation|Intensity-modulated radiotherapy|Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
25959|NCT03984344|Device|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
25960|NCT03984344|Device|Continuous Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
25961|NCT03984344|Device|Sham Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer TBS using a sham Magstim coil.
25962|NCT03984331|Device|Fish skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
25963|NCT03984331|Device|Cadaver skin|One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.
25964|NCT03984318|Procedure|Blood sample|Blood (plasma+serum+PBMC) collection before the start of immunotherapy, at week 6 and upon grade ≥2 irAE.
25965|NCT03984305|Device|Personal KinetiGraph® (PKG®) Watch|"The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~A wrist-worn data logger (PKG Watch) designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording."
25966|NCT03984305|Device|Personal KinetiGraph® (PKG®) Report|"The Personal KinetiGraph (PKG®) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by GKC.~The Personal KinetiGraph (PKG®) Movement Recording System consists of the following:~• A series of algorithms that analyze the uploaded data, producing a PDF that is delivered to the clinician. The PDF contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
25967|NCT03984292|Procedure|Teaching of laparoscopic skills on a box simulator|The students shall be trained a laparoscopic simulator for a variable duration and the outcome shall be compared.
25968|NCT03984279|Other|Patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control|Not applicable, all patients with indication of interventional percutaneous diagnostic or therapeutic chest-abdomen-pelvic procedure under CT control on a period of 1 year will be taken into account
25969|NCT03984266|Diagnostic Test|NGS panel|A next-generation-sequencing panel, which contains a group of genes that specifically cause disease, for mutational analysis in newborns.
25970|NCT03984240|Drug|Midazolam|Participant will be sedated by midazolam.
25971|NCT03984240|Drug|Dexmedetomidine|Participant will be sedated by dexmedetomidine.
25972|NCT03984227|Genetic|Taking peripheral blood samples|quantitative real-time polymerase chain reaction
26048|NCT03983720|Other|Neuromuscular evaluation|"Neuromuscular evaluation will be measured by the composite of the results of:~Fatigue test~Measure of voluntary isometric force~Surface electromyography~Peripheral nerve stimulation~Transcranial Magnetic Stimulation (TMS)~Perceived fatigue~Cognitive fatigue~Thermoregulation"
26049|NCT03983707|Device|Purastat®|Use of Purastat®
25973|NCT03984214|Drug|Dronabinol in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment
25974|NCT03984214|Drug|Placebo in Oral Dosage Form|Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment
25975|NCT03984201|Device|Intermittent Theta Burst Stimulation (iTBS)|Participants will receive active or sham transcranial magnetic stimulation delivered to the L-DLPFC.
25976|NCT03984188|Drug|Theophylline ER|200mg ER low-dose theophylline taken orally daily
25977|NCT03984188|Drug|Placebo oral tablet|Manufactured methylcellulose placebo tablet taken orally daily
25978|NCT03984175|Procedure|Implementation of Processes|Implementation of processes to improve compliance with low tidal volume ventilation in patients with ARDS using a computerized protocol
25979|NCT03984149|Other|Observational study|Observational study: There is no intervention.
25980|NCT03984136|Behavioral|COHIV with exchange mechanism|A WeChat-based mini program has been developed to send and receive Center for Disease Control and Prevention certified online HIV results (COHIV). WeChat is the ubiquitous communication and social networking tool in China. Participants in the intervention group will receive his friend's COHIV only when the participants share their own in exchange. If the participant already has the COHIV, the system will lead the user to send his COHIV to the friend. If the participant does not have the COHIV, the system will guide him to make online appointment at the testing clinic.
25981|NCT03984136|Behavioral|COHIV without exchange mechanism|The participants in the control group will be able to receive the friend's Center for Disease Control and Prevention certified online HIV results (COHIV) entirely at the friend's discretion without the mandatory exchange requirement. The system will also guide users on how to get an HIV test by making appointments with the MSM friendly clinics in the mini program.
25982|NCT03984123|Device|Brachial cuff, in order to achieve ischemic stimuli|
25983|NCT03984110|Drug|Ozurdex|Intravitreal injection
25984|NCT03984110|Drug|Eylea|Intravitreal injection
25985|NCT03984097|Drug|TAK-079|TAK-079 subcutaneously.
25986|NCT03984097|Drug|Lenalidomide|Lenalidomide orally.
25987|NCT03984097|Drug|Dexamethasone|Dexamethasone orally.
25988|NCT03984097|Drug|Bortezomib|Bortezomib subcutaneously.
25989|NCT03984084|Other|no intervention|no intervention
25990|NCT03984058|Behavioral|Lifestyle Intervention|A lifestyle intervention program adapted from the Diabetes Prevention Program (DPP). Study participants will start lifestyle intervention on the day of initiating PAP therapy. The 3-month program will be followed: Patient-facing Online Platform: The program will be accessible to study participant via the Web or a Web application available for the Android and iOS devices. Behavioral Weight Loss Goals and Lessons: The program begins with an introductory session that presents the basic goals for the program followed by 12 weekly multimedia lessons. Submission of self-monitoring data: Participants will submit daily weight, caloric intake, and physical activity minutes at least weekly to the study website for 12 weeks. Automated Feedback: In response to the self-monitoring data, participants receive a weekly automated message that compares participants' self-reported values to participants' goals for weekly and overall weight loss, caloric intake, and physical activity minutes.
25991|NCT03984045|Drug|Lidocaine topical|Intranasal 2% lidocaine delivered directly to SPG
25992|NCT03984045|Drug|Prochlorperazine Injection|intravenous prochlorperazine at 0.15mg/kg max 10 mg
25993|NCT03984032|Device|LMA Protector Cuff Pilot|Assessing the clinical performance of LMA Protector Cuff Pilot
25994|NCT03984032|Device|LMA Supreme|Assessing the clinical performance of LMA Supreme
25995|NCT03984019|Diagnostic Test|Cardiac condition measurements|Cardiac MRI, ECG, echocardiography, cardiac blood markers
25996|NCT03983993|Drug|Niraparib|Given PO
25997|NCT03983993|Biological|Panitumumab|Given IV
25998|NCT03983980|Drug|Tapinarof (DMVT-505)|Tapinarof cream, 1%, applied once daily
25999|NCT03983980|Drug|Vehicle Cream|Vehicle cream applied once daily
26000|NCT03983967|Biological|Immuncell-LC|Activated T lymphocyte
26001|NCT03983954|Combination Product|Naptumomab estafenatox (ABR-217620; Nap) with durvalumab (IMFINZI; MEDI4736)|Nap is given as an intravenous (I.V.) bolus injection. Durvalumab is given 1120 mg, I.V, 1- 1.5 hours after completion of the administration of Nap
26002|NCT03983941|Drug|Ropivacaine injection|Total dose not to exceed 3 mg/kg of ropivacaine.
26003|NCT03983928|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
26004|NCT03983928|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
26005|NCT03983915|Drug|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
26006|NCT03983915|Drug|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
26007|NCT03983915|Device|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
26008|NCT03983902|Procedure|Delayed cord clamping|Delayed cord clamping will occur for up to 2 minutes.
26009|NCT03983902|Procedure|Umbilical cord milking|Umbilical cord milking will occur milking of the 30 cm of the cord from placental site to baby, at a speed of 5 cm/second, 3 times in preterm newborns, 4 times in term newborns.
26010|NCT03983902|Procedure|Immediate cord clamping|Immediate cord clamping will occur in 20 seconds after birth.
26011|NCT03983889|Drug|Midazolam|Midazolam is used as a common medication for sedation in all groups.
26012|NCT03983889|Drug|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
26016|NCT03983876|Drug|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory disease"
26017|NCT03983850|Drug|Busulfan|Busulfan should be administered intravenously via a central venous catheter as a three hour infusion every 24 hours.
26018|NCT03983850|Drug|Fludarabine|Fludarabine will be infused by IV over 60 minutes.
26019|NCT03983850|Drug|Cyclophosphamide|IV cyclophosphamide will be administered over 2 hours. Slower rates of infusion may be used to decrease side effects. A fluid intake of greater than 2 L/day is recommended during and for 1 to 2 days after cyclophosphamide administration.
26020|NCT03983850|Drug|Mycophenolate Mofetil|Any oral formulation should be taken on an empty stomach, 1 hour before or at least 2 hours after meals. Oral formulations should not be administered simultaneously with antacids. Avoid inhalation or direct contact with skin or mucous membranes of dry powder contained in capsules or suspension. IV solutions should be administered over at least two hours through either a peripheral or central vein and should not be administered by rapid or bolus injection.
26021|NCT03983850|Drug|Sirolimus|Oral tablets should be administered approximately 4 hours after cyclosporine administration. Sirolimus is administered orally, once daily, without food. Patients unable to tolerate tablets may take the oral solution formulation.
26023|NCT03983824|Drug|Cytarabine|Given IV
26024|NCT03983824|Drug|Cytarabine Hydrochloride|Given IV
26025|NCT03983824|Drug|Etoposide|Given IV
26026|NCT03983824|Drug|Etoposide Phosphate|Given IV
26027|NCT03983824|Drug|Mitoxantrone|Given IV
26028|NCT03983824|Drug|Mitoxantrone Hydrochloride|Given IV
26029|NCT03983824|Drug|Nedisertib|Given PO
26030|NCT03983811|Drug|Icotinib|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated icotinib (D8-15) every 3 weeks, and continued icotinib for 2 years or until the occurrence of disease relapse, metastasis or unacceptable icotinib or chemotherapy toxicity
26031|NCT03983811|Drug|Placebo|Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
26032|NCT03983811|Other|chemotherapy|Patients in each groups need to receive 4 cycles of platinum-based doublet chemotherapy
26033|NCT03983798|Other|Simulation training in psychiatry|"Each participant will complete 6 hours of psychiatric simulation training, dealing with mood disorders, anxious disorders, eating disorders, borderline disorders, substance abuse and schizophrenia. Simulation training will be supplemented by brief lecture on concept map and portfolio at the beginning of the first hour.~Curriculum integration of simulation training in psychiatric course assure that each pathology studied is supplemented by a one-hour lecture and 1 to 3 hours clinical cases and MCQ training. A part of the medical students are supplemented by clinical practice ; whereas the other won't benefit from clinical practice."
26034|NCT03983785|Other|Pilates|In pilates group: Pilates training twice a week for 6 weeks.
26035|NCT03983785|Other|Elastic taping|Elastic taping group: Elastic taping application after the pilates training twice a week for 6 weeks Wait List
26036|NCT03983772|Dietary Supplement|RS blend|The intervention is a proprietary resistant starch blend.
26037|NCT03983772|Other|Placebo|The placebo is starch.
26038|NCT03983759|Drug|sintilimab maintenance|the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
26039|NCT03983746|Device|core stability exercises and treadmill training exercises|Forty-five children with Down syndrome included in the study. The children aged 4-6 years, and they were equally divided randomly into three groups (A), (B) and (C). Group A received traditional physical therapy intervention strategies to facilitate the balance of participated children. Group (B) received same as the group (A), with additional core stability exercises training. Group (C) received same intervention strategies as group (A) in conjunction with a treadmill exercise program. The children's balance was evaluated using the Berg Balance Scale and the Biodex Balance System. Treatment sessions were for 60 min, thrice a week, for eight consecutive weeks.
26040|NCT03983733|Other|Dietary Intervention|To carry out an interventional dietary study using standardised meals to predict an individual's metabolic response to certain foods, using their gut microbiome, metabolic profile, and other measurable characteristics such as weight, sleep and exercise.
26041|NCT03983720|Other|Evaluation of degree chronic fatigue.|Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
26042|NCT03983720|Other|Questionnaires|"Fatigue Severity Scale (FSS)~Modified Fatigue Impact Scale (MFIS)~Godin Leisure-Time Exercise Questionnaire (GLTEQ)~Scale of life quality of multiple sclerosis (SEP-59)~Center for Epidemiologic Studies Depression (CES-D)~Pittsburgh Sleep Quality Index (PSQ-I)"
26043|NCT03983720|Biological|Blood sample|Blood sample will be realized to evaluate anemia and inflammations.
26044|NCT03983720|Other|Cardiopulmonary evaluation|Cardiopulmonary evaluation will be realized with a cycle ergometer.
26045|NCT03983720|Device|Capacity of muscular oxygen extraction|Measure the capacity of muscular oxygen extraction with a cycle ergometer.
26046|NCT03983720|Device|Sleep assessment|Sleep assessment will be measured by actigraphy during 15 days.
26047|NCT03983720|Device|Metabolic fatigue|Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).
26129|NCT03983057|Drug|Anti-PD-1 monoclonal antibody|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly.
26130|NCT03983031|Drug|Rituximab|Infusion
26131|NCT03983018|Drug|Rituximab|Infusion
26050|NCT03983694|Other|Erythrocyte transfusion|The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
26051|NCT03983681|Behavioral|Strategy-Based Training to Enhance Memory (STEM)|Protocol designed to improve memory functioning in individuals with neurological injuries administered for 4 weeks (8 training sessions).
26052|NCT03983681|Behavioral|Placebo control exercises|Placebo control memory exercises will be administered for 4 weeks (8 training sessions).
26053|NCT03983668|Drug|CMP-001|Immunostimulatory therapeutic agent
26054|NCT03983668|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy
26055|NCT03983655|Device|High Frequency Low Intensity TMS|125 hz, 10 gauss, 2 times daily for 6 monts
26056|NCT03983642|Device|Wii balance board|"Numerous video games exist to interact with the Wii Balance Board. One game that has been used in prior balance studies is Wii Fit.~On the first 4 weeks, balance training started with Soccer Heading game. The participants were asked to control their avatar by leaning to left or to the right in order to avoid the objects that were thrown towards them, and try to score the balls inside the net. The participants performed 3 sets of 5 rounds (2min each), totaling 30 min, and rested for 1 min between each set.~Table Tilt game continued for the remaining 4 weeks. Participants tried to enter balls into the holes by shifting their body weight on the balance board causing it to tilt in all directions. This game was divided into multiple levels of 30 seconds each, repeated over 30 min, with a one-minute rest interval between every 10 minutes of training. Moreover, 20 extra seconds were added each time a participant has won a level."
26057|NCT03983629|Other|Collection of data and genetic analysis|Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
26058|NCT03983603|Dietary Supplement|Soft chews containing 0.5g plant stanols (delivered as plant stanol esters)|Soft chews containing 0.5g plant stanols delivered as plant stanol esters
26059|NCT03983603|Dietary Supplement|Placebo soft chew|Soft chew that does not contain plant stanols
26060|NCT03983590|Other|Visual Analogic Scale|VAS are collected in the first 24 hours after inclusion, 15 minutes, during and 15 minutes after the bed bath. Each time of collection are noted.
26061|NCT03983577|Other|Point of service delivery model|Participants will receive the pre-test survey, followed by the combined provider/telehealth genetic counseling education video for genetic testing. Afterwards, the participants will receive a post-test and patient satisfaction survey.
26062|NCT03983564|Other|Cutoff Validation|We will validate the cutoff of the combination of STOP-Bang score and DES-OSA scores with the result of a polysomnography.
26063|NCT03983551|Drug|Dipeptidyl Peptidase 4 Inhibitor|Vildagliptin 50 milligrams twice daily in addition to metformin 1000 milligrams once daily
26064|NCT03983551|Drug|Sulfonylurea|Glimepiride 2 milligrams twice daily in addition to metformin 1000 milligrams once daily
26065|NCT03983538|Other|Mathematical modeling to predict response to chemotherapy|Mathematical modeling using the patient's diagnostic core biopsy and baseline MRI of the breast will be used to predict the response to above therapy.
26066|NCT03983525|Dietary Supplement|Goji berry|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take 28 grams of goji berry once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
26067|NCT03983525|Dietary Supplement|Lutein + zeaxanthin supplementation|Those who are eligible for enrollment will be required to participate in three study visits over a three-month period, with each visit lasting approximately one and half hour. The three study visits will be separated by 45 +/- 2 days. During each study period, the participants are required to take one capsule of lutein + zeaxanthin supplementation once a day, five times per week, and will complete a set of 24 hour dietary recall, using an online automated self-administered recall system known as the ASA24.
26068|NCT03983512|Device|PULSTA TPV System|PULSTA transcatheter pulmonary valve replacement.
26069|NCT03983499|Behavioral|Special Intervention|The components of the Special Intervention (SI) integrated design are: 1) Co-location of the clinical team; 2) Shared medical plan; 3) Clinical visits with a medical provider for management of chronic medical conditions; 4) Visits with behavioral health provider for management of psychosocial chronic conditions; 5) Care coordination; 6) Six group-health education classes and two booster sessions led by a promotora. Participants in the SI arm meet with the integrated care team in the context of a regular medical visit primarily to focus on clinical/biological aspects of the chronic medical conditions (diabetes, dyslipidemia, hypertension, obesity, etc.)
26070|NCT03983486|Other|Imaging flow cytometry in multiple myeloma|Combination of immunophenotyping by flow cytometry and FISH in suspension (IS-FISH) may provide both cytogenetic and phenotypic information for a large number of cells in a single test. In this scope, a recent study demonstrated a proof of concept for IS-FISH to detect non pathological signals with the new ImageStream X technology (ISX).1
26071|NCT03983473|Other|Microbiota Sequencing|virome, bacteriome, fungome NGS sequencing
26072|NCT03983460|Drug|Dupilumab|Each single used prefilled syringe contains 300 mg of Dupilumab in 2 mL solution (150mg/mL) Dupilumab is a fully human monoclonal antibody against interleukin (IL)-4 receptor alpha that inhibits IL-4/IL-13 signaling, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
26073|NCT03983460|Drug|Optimized TCS treatment|Application of betamethasone valerate 0.1% (Betneval 0.1% cream), a potent topical corticosteroid, and if not active, application of clobetasol propionate 0.05% (Dermoval 0.05% cream), a very potent topical corticosteroid. TCS treatment will be associated with a personal therapeutic education for treatment optimization.
26202|NCT03982368|Drug|rhNGF 20 μg/ml|one drop of rhNGF 20 μg/ml will be instilled in both eyes three times daily (every 6-8 hours)
26074|NCT03983460|Procedure|Biopsies|"Four skin biopsies (5 mm diameter) and ten microbiopsies (2 & 3 mm diameter) will be performed according the following schedule:~Day 0~a 5 mm section biopsy from a non-lesional skin~a 5 mm section biopsy from an active lesion~a 3 mm section microbiopsies from a non-lesional skin~a 3 mm section microbiopsies from an active lesion~a 2 mm section microbiopsies from a non-lesional skin~a 2 mm section microbiopsies from an active lesion~Day 28~a 5 mm section biopsy on improved/healed lesion~a 3 mm section microbiopsies on improved/healed lesion~a 2 mm section microbiopsies from non lesional skin identified at V1~a 2 mm section microbiopsies on improved/healed lesion~Day 168~a 5 mm section biopsy on improved/healed lesion~a 3 mm section microbiopsies on improved/healed lesion~a 2 mm section microbiopsies from non-lesional skin identified at V1~a 2 mm section microbiopsies on improved/healed lesion"
26075|NCT03983460|Procedure|Skin prick-test|"Skin prick test is a method for medical diagnosis of allergy consisting in introducing a small amount of an allergen into the patient's skin. The allergen penetrates the epidermis by pricking the skin with a pin.~Skin Prick test for Derp and Derf will be performed at Day 0, preferentially on the forearms, avoiding lesional areas.~For the results interpretation, the two allergen Derp/Derf will be compared to 2 controls:~Negative control : saline solution~Positive control : histamine solution~Positive criteria of prick tests results are:~Positive control's diameter ≥ 3mm~And negative control's diameter < 3 mm~And tested allergen with wheal ≥ positive control, i.e. 3mm"
26076|NCT03983460|Procedure|Blood sample collection|"A 50ml blood sample will be collected by venipuncture at Day 0, Day 28 and Day 168.~More specifically a 40 ml blood sample will be drawn on heparinized tubes for immunophenotyping and a 10 mL on serum blood collection tube for analysis of AD biomarkers by mass cytometry and ELISA."
26077|NCT03983447|Behavioral|School-based intervention to promote PA and reduce ST|"This intervention was realized with all the children (1st grade-5th grade) and involved :~Physical (Environmental) adaptation of playgrounds~Time adaptation of lunch breaks~Curriculum-based program for children~Workshops and newsletters for parents~Meetings for teachers"
26078|NCT03983434|Dietary Supplement|Inulin|Inulin ingestion is not being used to diagnose, treat, or prevent IBS. Inulin is being used to study an individual's ability to ferment dietary fiber.
26079|NCT03983421|Other|Screening|Screening for Early Psychosis and Clinical High Risk of Psychosis
26080|NCT03983421|Other|Warm Hand-Off|Among those determined eligible, transfer of care between the student health and counseling center and the coordinated specialty care program outreach coordinator occurring over the phone while the student is in the counselor's office immediately following the results of the screening.
26081|NCT03983408|Dietary Supplement|Korean Red ginseng|Participants are provided with 2 Korean Red Ginseng extract tablet twice a day for total 24 weeks.
26082|NCT03983408|Dietary Supplement|Placebo|Placebo tablets, made of corn starch and cellulose, are manufactured to mimic KRG tablets
26083|NCT03983395|Biological|GBR 1302 250 ng/kg|GBR 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 250 ng/kg
26084|NCT03983395|Biological|GBR 1302 325 ng/kg|GBR 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at dose levels. Dose on D1, D8, D15, D22 is 325 ng/kg
26085|NCT03983395|Biological|GBR 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22|GBR 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 425 ng/kg on D8, D15, D22
26086|NCT03983395|Biological|GBR 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22|GBR 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, D15, D22
26087|NCT03983395|Biological|GBR1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22|GBR 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 700 ng/kg on D15, D22
26088|NCT03983395|Biological|GBR1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22|GBR 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 550 ng/kg on D8, and 900 ng/kg on D15, D22
26089|NCT03983395|Biological|GBR1302 escalating doses,1200 ng/kg D15,22|GBR 1302 is administered by intravenous (IV) infusion on Day 1, Day 8, Day 15, and Day 22 of each 28-day treatment cycle at escalating dose levels. Dose of GBR 1302 is 325 ng/kg on D1 and 700 ng/kg on D8, and 1200 ng/kg on D15, D22
26090|NCT03983395|Biological|GBR1302 at the MTD and/or RP2D dose|GBR 1302 at the MTD and/or RP2D dose in separate groups in the Q1W and/or the Q2W dose regimen.
26091|NCT03983382|Diagnostic Test|Left Ventricular Ejection Fraction|LVEF assessment at baseline, 6 months, and 12 months
26092|NCT03983369|Device|Low-Level Laser Therapy|The LLL used is the K-Laser Cube 3. The LLL is an athermal laser beam of low power, equipped with a placebo function (dummy imitating beam laser light, emitted by the same device but without physiological effect).
26093|NCT03983369|Other|Placebo|Placebo
26094|NCT03983356|Other|Training program|An internet based training program will be offered to GPs. We will also offer face-to-face seminars with academic psychiatrists.
26095|NCT03983343|Device|dermabond®|Perineal skin will be closed by adhesive glue - dermabond.
26096|NCT03983330|Behavioral|Brief Motivational Interviewing (i-BMI)|"The trained RA will ask the subjects about the priority of engaging in any desirable health-related lifestyle practice as identified in the completed baseline questionnaires and to state a targeted goal that they perceive as the easiest to achieve. Each subject will then receive an individual face-to-face brief MI (about 5 mins) with generic health advice on selected health-related lifestyle practice. They will then be informed to receive an individual brief MI intervention to assist behavioural changes or achieve goals as desired or chosen by them via WeChat or WhatsApp in smart phones throughout the study period. They will be given a self-help smoking cessation booklet with Hotline number.~The RA will then deliver brief MI to each subject individually via WeChat or WhatsApp in smart phones throughout the study period.~Readiness of quitting smoking will be assessed at 3-month follow-up. Upon request by subjects, we shall provide them with more comprehensive information on quitting."
26133|NCT03982992|Drug|Blinatumomab in combination with donor lymphocyte infusion|Continuous blinatumomab infusion in combination with allogeneic donor lymphocyte infusion
26097|NCT03983330|Behavioral|Control|Similar to the intervention group, the trained RA will first ask the subjects about the priority of engaging in any desirable health-related lifestyle practice and to state a targeted goal in which they perceive as the easiest to achieve after completing the baseline questionnaires. In addition, the subjects will be given a self-help smoking cessation booklet with Hotline (Tel.: 1833183). However, subjects in the control group will not receive brief MI and follow-up booster intervention. Subjects will be informed that they will receive follow-up telephone call at 1, 3, 6 and 12 months.
26098|NCT03983317|Device|Empower Neuromodulation System|Transcutaneous electrical nerve stimulation
26099|NCT03983304|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
26100|NCT03983291|Behavioral|FaReWell Depression|Facial massage and force exercise
26101|NCT03983278|Other|School Model|Free delivery of glasses at the school within two weeks after screening
26102|NCT03983278|Other|Referral Model|After the primary screening children referred to nearby Vision Center/ secondary center for refraction and delivery of free glasses.
26103|NCT03983278|Other|Referral Model + Cost Recovery|"After the screening children referred to Vision Center for refraction and delivery of free glasses with the option to purchase upgrade glasses"
26104|NCT03983265|Other|Bilateral Sagittal Split Osteotomy|after BSSO condyle will be re positioned by using computer guided device
26105|NCT03983252|Drug|[F-18]PBR06|PET radiopharmaceutical
26106|NCT03983239|Drug|Fedratinib|Fedratinib
26107|NCT03983239|Drug|Rifampin|Rifampin
26108|NCT03983239|Drug|Efavirenz|Efavirenz
26109|NCT03983226|Procedure|Secondary cytoreductive surgery|Tumor debulking surgery (surgery in recurrent ovarian disease)
26110|NCT03983226|Drug|carboplatin/taxane, carboplatin/gemcitabine, cisplatin/gemcitabine, liposome doxorubicin/carboplatin...|Salvage chemotherapy
26111|NCT03983213|Procedure|mpfl reconstruction|Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
26112|NCT03983200|Device|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min, bid
26113|NCT03983200|Drug|Mecobalamin|mecobalamine 0.5mg,tid
26114|NCT03983187|Device|Rotating Magnetic Therapy|Rotating Magnetic Therapy 30min/ Bid for 1 month
26115|NCT03983174|Procedure|Drainage seton with flap|Seton is placed around the external sphincter then mucosal advancement flap will be constructed
26116|NCT03983174|Procedure|EAS sparing seton|Rerouting of the seton around the internal sphincter only sparing the external sphincter
26117|NCT03983161|Drug|Fedratinib|Fedratinib
26118|NCT03983148|Behavioral|Motivational interviewing|There are 3 sessions. Each session is an about 60-minute individual motivational interviewing held by a trained registered nurse. The first session aims to develop an action plan that enables the parents to promote physical activity (PA) for their children. The second session targets to review the adherence to the action plan. The nurse will discuss the progress. In the last session, the aim is to motivate the parents promoting PA for their children in the long run. As such, the benefits of PA throughout the survivorship will be emphasized. And the nurse will work with the parents to identify the resources that can help maintain the designed action plan.
26119|NCT03983148|Behavioral|Placebo control|"Other than usual medical care received by children, parents in this group will receive an individual, face-to-face intervention which mimics the time and attention received by those in the experimental group. The intervention includes three sessions of educational talk to parents of children with cancer on healthy diet for cancer patients, adverse effects of cancer treatment, methods to minimize adverse effects.~Subjects in both groups will receive a booklet developed by the advisory committee, which contains a various kind of physical activities specially designed for children with cancer."
26120|NCT03983135|Other|Laparoscopic mini gastric by-pass|Adhesions will separated along the left edge of the stomach and the left lobe of the liver. The remnant stomach will transected at the incisura angularis level with 60 mm Endo-GIA stapler(ATW 35, EthiconEndo-SurgeryInc., Cincinnati, OH, USA). Later ante-cholic distal of the Treitz ligament hadgastro-jejunal anastomosisof nearly 150 cm jejunal loop performed with 44 mm Endo-GIA stapler. Routinely, the omentum will be divided in two and omentopexy will be performed around the anastomosis. The stapler line will supported by absorbable stitches.
26121|NCT03983135|Other|LaparoscopicRe-sleeve gastrectomy|Adhesions will be separated with blunt and sharp dissections, then the remnant stomach will completely freed. Due to dilated antral pouch or fundus, the remnant stomach will resect as a tube stomach between the pillory and left crus with 60 mm Endo-GIA stapler accompanied by 36F bougie.
26122|NCT03983135|Other|Laparoscopic Roux-en-Ygastric bypass|all adhesions will separated then after the stomach pouch will formed by the linear stapler, 100 cm of jejunum will transected from the Treitz ligament. Side-to-side gastrojejunostomy will performed for the distal jejunum with the linear stapler. The anterior face of the anastomosis will manually sutured. Proximal jejunum end hadside-to-side jejuno-jejunostomy performed 150 cm distal of the gastrojejunostomy anastomosis with linear stapler on the posterior wall and manual suturing of the anterior wall.
26123|NCT03983122|Procedure|Laparoscopic sleeve gastrectomy|Each procedure will be completed with laparoscopy with five trocars. A 36F bougie will used to calibrate the volume of the remnant stomach. Linear gastrectomy will begin 2 cm proximal of the pylor and will continue until the gastroesophageal junction. According to the intraoperative decision and experience of the surgeon, endoscopic clips would be used to ensure hemostasis of the stapler line.
26124|NCT03983109|Device|EpiFaith loss of resistance detect syringe|An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
26125|NCT03983083|Behavioral|Physical activity|Access to website created to teach cancer survivors to live more active lives, with monthly email reminders/website updates. Intervention participants will also receive exercise bands for at-home resistance training.
26126|NCT03983070|Other|Seated Rowing Ergometer|Seated rowing exercise performed at a specific percentage of maximal Watts according to pre-intervention measures
26127|NCT03983070|Other|Deadlift|Deadlift exercise performed with a set of dumbbell weights at a sepcific percentage of pre-intervention one-repetition maximum.
26128|NCT03983070|Other|Blood flow restriction|An occlusive cuff will be placed around each proximal thigh and inflated to 80% arterial occlusion during exercise sessions.
26134|NCT03982979|Device|HM3 LVAS|HeartMate® 3 (HM3) Left Ventricular Assist System (LVAS)
26138|NCT03982901|Diagnostic Test|Mental Stress Test|In this study, we compare MSIMI prevalence in the two groups (chest pain group and no chest pain group). Each subject in both groups receive the same mental stress test process, and the mental stress test process have 3 consecutive stress tests, which including: Stroop Color-Word test; Public speaking with anger recall test and Mental arithmetic test.
26139|NCT03982888|Procedure|Deep Brain Stimulation|Stimulation of the nucleus accumbens via 2 electrodes implanted in the brain per patient to reduce self-injurious behaviours.
26140|NCT03982888|Device|DBS|"Use of the Medtronic DBS device. DBS device consists of 2 parts:~DBS lead, a thin wire with 2 electrical contacts implanted into pre-determined brain regions, and~Implantable pulse generator, a small device containing the batter and computer source placed under the skin of the chest to generate electrical pulses"
26141|NCT03982875|Device|Alfred SmartBag|The Alfred SmartBag encompasses a pouch, a baseplate, and a hub, is intended to be used as a continuous ostomy monitoring system by tracking the volumetric filling of the pouch through integrated thermistor and capacitive sensors and potential leakage and skin irritation development through integrated thermistors in the wafer. The Alfred SmartBag system is indicated for daily use for both in-patient and out-patient settings to provide information to patient and medical professionals. The data is intended to aid patient self-management and to alert the clinical team to changes in the patient condition that may warrant specific intervention.
26142|NCT03982862|Drug|Triamcinolone|Triamcinolone 4mg diluted to 0.1 ml
26143|NCT03982862|Drug|Lidocaine|0.1ml 2% Xylocaine
26144|NCT03982862|Drug|Botulinum toxin A|4U Botox® diluted to 0.1 ml
26145|NCT03982849|Drug|Hydroquinone 4% Cream|Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
26146|NCT03982849|Drug|silymarin 0.7% cream|Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
26147|NCT03982836|Dietary Supplement|Soluble Dietary Fibers|All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
26148|NCT03982823|Procedure|Hand-Sewn Sleeve Gastrectomy|After laparoscopic sleeve gastrectomy, gastrectomy site is hand-sewn with 3/0 polypropylene suture and the specimen is removed transorally.
26149|NCT03982823|Procedure|Stapled Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy is performed via 60 mm linear stapler (Endo GIATM Ultra, Covidien) .
26150|NCT03982810|Drug|Antibiotics|Antibiotic prophylaxis and the occurrence of a NSQIP-adjudicated SSI during the period from 2011 to 2018. SSIs will be a composite of superficial (only skin or subcutaneous tissue of the incision), deep (deep soft tissues), and organ space (any part of the anatomy other than the incision, which has been opened and manipulated during the operation), as provided by the NSQIP.
26151|NCT03982797|Biological|Instillation of IMUNO BCG Moreau RJ|Instillation in bladder will be done once per week during first six weeks after inclusion, and 3 instillations (one per week) on month three, another three on moth six and last three on month twelve .
26152|NCT03982784|Procedure|single-injection TQLB(transmuscular quadratus lumborum block)|Inject 0.6ml/kg local anesthetics in between quadratus lumborum and psoas major under ultrasound guidance
26153|NCT03982784|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|PCIA was initiated using a pump set to deliver boluses of 1.5-2 mg of morphine with a 5-minute lockout interval and no background infusion. The maximal permitted dosage of morphine was set at 8 mg/h.
26154|NCT03982771|Drug|Bortezomib|-Bortezomib: 1.3mg/m2 subcutaneous injection on Day 1,8,15,22 every month for 9 months; And maintained with 1.3mg/m2 subcutaneous injection every two weeks from Month 9 to 21;
26155|NCT03982771|Drug|Cyclophosphamide|-Cyclophosphamide: (oral) 300mg/m2 on Day 1, 8, 15, 22 every month for 9 months;
26156|NCT03982771|Drug|Dexamethason|Dexamethasone: (oral) 40mg on Day 1,8,15,22 every month for 9 months; and maintained with 20mg (oral) every two weeks from Month 9 to 21.
26157|NCT03982758|Other|isometric handgrip exercise|Isometric session with handgrip: 4 sets of 2 minutes of contractions sustained at 30% of CVM, for each arm. The time between sets and between arms will be 1 minute rest.
26158|NCT03982758|Other|isometric of the lower limbs|Isometric session for lower limbs: 4 sets with 2 minutes of contractions sustained at 30% of 1RM. The rest interval will be 1 minute rest.
26159|NCT03982745|Device|bonfils|bonfils intubation
26160|NCT03982732|Biological|Boostrix-IPV|Receipt of Boostrix IPV at three different gestational time periods
26161|NCT03982719|Other|Brief protocol|This protocol consists of 4 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 4 weeks and 8 weeks post-fasciectomy. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery.
26162|NCT03982719|Other|Intense protocol|This protocol consists of 6 intervention sessions with an occupational therapist specialized in hand therapy that will occur at 0-3 days, 2 weeks, 3 weeks, 4 weeks, 6 weeks and 8 weeks after surgery. The occupational therapist will give recommendations about the management of swelling, wound care and functional recovery. An home exercises program will be given to the participant. The occupational therapist will make an extension splint that should be worn at night for the 3 months following surgery. Also, exercises will be performed by the patient under the supervision of the occupational therapist (supervised exercises) in each session except the first one at 0-3 days after surgery.
26163|NCT03982693|Drug|Edetate Disodium|The solution contains up to 3 g of edetate disodium adjusted based on creatinine clearance, 2 g of magnesium chloride, 100 mg of procaine hydrochloride, 2500 U of heparin, 7 g of ascorbate, 2 milliequivalent (mEq) potassium chloride (KCl), 840 mg sodium bicarbonate, 250 mg pantothenic acid, 100 mg of thiamine, 100 mg of pyridoxine, and sterile water to complete 500 mL.
26164|NCT03982693|Other|Placebo|Placebo infusions consist of 500 ml normal saline.
26165|NCT03982680|Drug|Toripalimab|3mg/kg on d1 and d15 q4W*4cycles，then 3mg/kg q3w for 1 year in total
26166|NCT03982680|Drug|Gemcitabine|1250mg/m2 on d1 and d15 q4W*4cycles
26167|NCT03982680|Drug|5- fluorine pyrimidine|400mg/m2 intravenous injection plus 5-FU 2.4g-3.6g/m2 continuous intravenous drip for 48h on d1 and d15 q4W*4cycles
26168|NCT03982667|Diagnostic Test|PCT-guided group|In the PCT-guided group, the study protocol encourages to stop the prescribed antibiotics if PCT concentration decrease by 80% or more of its peak value (or if PCT concentration is ≥0·25 and <0·5 μg/L), and strongly encourage to stop the prescribed antibiotics when it reaches a value of < 0·25 μg/L. The attending physician is free to decide whether to continue antibiotic treatment in patients who reach these thresholds. Reasons for non-adherence will be recorded. Antibiotics in the standard-of-care group will be stopped according to local or national guidelines and according to the discretion of attending physicians. Patients will be followed-up until hospital discharge.
26169|NCT03982654|Device|Bloomlife|Women use the Bloomlife sensor to collect data throughout their pregnancy. The collected data is stored locally in the device, but it is not used to provide any feedback to the patients or to the clinical team. Therefore the use of the device doesn't have an impact on clinical decision making and patients' care.
26170|NCT03982641|Procedure|all colorectal cancer surgical procedures|colorectal cancer surgical procedures
26171|NCT03982628|Diagnostic Test|Abdominal CT imaging|Routine abdominal CT imaging
26172|NCT03982615|Device|Laser-Lok abutment|"Each subject will receive two dental implants. One implant will receive (by randomization) a laser-etched (Laser-Lok) abutment."
26173|NCT03982615|Device|Standard healing abutment|Each subject will receive two dental implants. One implant will receive (by randomization) receive a standard healing abutment (not laser-etched).
26174|NCT03982602|Drug|Ketogenic diet|Subjects will be provided with the Ketogenic diet in the form of tube feeds once the decision is made to start the patient on diet.
26175|NCT03982576|Other|Nicotine replacement therapy (NRT)|4 weeks of Transdermal nicotine patches or nicotine gum
26176|NCT03982576|Behavioral|CS-CBT intervention|4 group sessions of a novel culturally specific, CBT-based intervention over 2 weeks
26177|NCT03982576|Behavioral|Path2Quit|Path2Quit is a newly developed video-text program, which delivers 6 weeks of CS video messages (1-2 times/day) and provides 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP).
26178|NCT03982576|Behavioral|Relapse prevention program|4 group sessions of a standard relapse prevention program, publicly available at smokefree.gov
26179|NCT03982576|Behavioral|SmokefreeTXT|NCI's 6-week fully automated text-based cessation program that is free to U.S. subscribers, and is available on smokefree.gov. Users can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system 24/7
26180|NCT03982563|Behavioral|Growth Mindset|Reading and writing activities designed to instill the belief that people can change.
26181|NCT03982563|Behavioral|Gratitude|Reading and writing activities designed to practice noticing and appreciating good things in life.
26182|NCT03982563|Behavioral|Behavioral Activation|Reading and writing activities designed to identify and schedule positive activities.
26183|NCT03982563|Behavioral|Study Skills|Reading and writing activities designed to learn evidence-based study strategies.
26184|NCT03982550|Behavioral|Periodized Resistance Training|Mesocycle I (weeks 1-4) will emphasize muscular hypertrophy to develop a muscular and metabolic base for more intense training in later phases. Training bouts will consist of 4-6 resistance exercises with 2-4 sets per exercise and 8-10 repetitions per set. Mesocycles II (weeks 5-8) and III (weeks 9-12) will emphasize strength development. Training bouts will consist of 4-6 resistance exercises with 3-5 sets per exercise, 4-6 repetitions per set, and linear increases in intensity over time. These parameters were chosen to maximize performance on 4-6 repetition maximum (RM) testing post-intervention, according to the principle of specificity - i.e. specific adaptation to imposed demands.The training loads used will be individually progressed in a safe and effective manner, in order to employ a progressive overload/challenge to the neuromuscular system and elicit the greatest training-induced neuromuscular adaptations possible.
26185|NCT03982537|Drug|N-Acetyl-L-Cysteine dietary supplement|Treatment will be administered on an outpatient basis, either twice daily or 48 hours prior to starting chemotherapy radiation. Eligible participants will start NAC at least 9 days before definitive or adjuvant radiation therapy.
26186|NCT03982537|Radiation|Chemotherapy and Radiation|Participants will receive definitive or adjuvant concurrent chemotherapy and radiotherapy s per standard of care.
26187|NCT03982524|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
26188|NCT03982524|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|Cognitive-behavioral therapy for patients with multiple somatoform symptoms: 20 weekly sessions individual therapy (à 50 minutes)
26189|NCT03982511|Behavioral|PCIT-Health|PCIT-Health (also known as Parents Active in Their Children's Health; PATCH) is an adaptation of Parent-Child Interaction Therapy. PCIT-Health targets (1) the parent-child relationship and (2) parenting efficacy both in general contexts (child play time and clean up time) and specifically in the context of obesity risk-related behaviors (child feeding, family mealtime, and child screen time).
26190|NCT03982485|Drug|Apatinib|Apatinib 250mg, Oral, day 2,3,4,5,6,7, every week
26191|NCT03982485|Drug|Paclitaxel|Paclitaxel 80mg/m2, Intravenous, day 1, 8, 15, 22, every 28 days for a cycle
26192|NCT03982485|Drug|Cisplatin|Cisplatin 25mg/m2, Intravenous, day 1, 8, 15, every 28 days for a cycle
26193|NCT03982485|Procedure|Surgery|Surgery
26194|NCT03982472|Other|transcutaneous electric stimulation|transcutaneous current with an amplitude around ten to hundred milliampere was applied topically to subjects
26195|NCT03982459|Behavioral|decision support tool|computerized online decision support tool
26196|NCT03982446|Genetic|Mutations|
26197|NCT03982433|Behavioral|Motivation and Cognitive Behavioral Management for Alcohol and Pain|Behavioral intervention that includes motivational, cognitive, and behavioral intervention strategies to reduce heavy drinking and chronic pain interference
26198|NCT03982420|Procedure|Transcarotid Revascularization (TCAR)|Carotid revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
26199|NCT03982407|Drug|68Ga-PSMA-11 PET/MRI|The PET/MRI exam-related patient visit will last approximately 2 to 2.5 hours, including 30-minute nursing assessment, 45-60 minutes for PSMA uptake and 60 minutes for PET/MRI scan. They will be contacted within the next 72 hours to complete a brief phone survey.
26203|NCT03982368|Drug|rhNGF 20 μg/ml + vehicle|"one drop of rhNGF 20 μg/ml will be instilled in both eyes two times daily plus one drop (40 μL) of vehicle will be instilled in both eyes once daily (every 6-8 hours).~rhNGF will be instilled in the morning and in the evening while the vehicle will be instilled in the afternoon."
26204|NCT03982368|Other|Vehicle|one drop of vehicle will be instilled in both eyes three times daily (every 6-8 hours)
26205|NCT03982355|Device|DRS probe|The Oxygenation measurements of the novel diffuse reflectance spectroscopy probe
26206|NCT03982342|Device|Cather closure of patent ductus arteriosus (PDA)|Infants assigned to this group will have a catheter run from a blood vessel in the upper leg / groin area to the heart, where an FDA-approved device will be placed within the patent ductus arteriosus to occlude or plug it, thereby closing the ductus.
26207|NCT03982342|Other|Conservative management of patent ductus arteriosus (PDA)|"Infants with a hemodynamically-significant patent ductus arteriosus randomized to this group will be treated by fluid restriction and possible diuretic use to reduce PDA symptoms, and allow time to permit the PDA to close or become reduced in size to the point where it is no longer considered hemodynamically-significant."
26208|NCT03982329|Device|navigated repetitive transcranial magnetic stimulation|
26209|NCT03982329|Procedure|physical therapy|
26210|NCT03982316|Behavioral|Telehealth Behavioral Migraine Management|1) Weekly online modules; 2) Monthly 50 minute telephone calls; 3) 3 15-minute telephone check ins.
26211|NCT03982303|Drug|Hemay102|Hemay102 was administered through i.v. infusion for 4hrs.
26212|NCT03982290|Other|Probiotic, Lactobacillus plantarum PS128|PS128 capsules, 2 capsules per day
26213|NCT03982290|Other|Placebo, microcrystalline cellulose|Placebo capsules, 2 capsules per day
26214|NCT03982277|Drug|Rifampin 300 Mg Oral Capsule|High dose rifampicin at 35mg/kg
26215|NCT03982264|Procedure|ESD procedure|ESD were all performed as the standard procedure that has been widely described and used. A diluted sodium hyaluronate solution was injected submucosally. Mucosal incision and submucosal dissection were performed by using either Hook knife (Olympus Medical, Japan) or a dual-knife (Olympus Medical, Japan) . After the resection was finished, all of the visible vessels on the artificial ulcer bed were thoroughly coagulated with argon plasma coagulation to prevent postoperative bleeding.
26216|NCT03982264|Procedure|EMR-C procedure|A transparent cap (MH-593; Olympus) was attached to the forward-viewing endoscope. After the endoscope was inserted to the rectum, the snare passed through the sheath and was looped along the inner lip of the cap. The tumor was then suctioned into the cap and the snare was pushed off and closed. After confirming the appropriate snare placement, both the tumor and the overlying mucosa were resected by electric cautery (Endocut Q, effect 2, VIO 200D; ERBE, Tübingen, Germany), and then the removed tumor was sent for pathological examination. Endoscopic examination then was repeated without the transparent cap in order to evaluate the wound carefully in case there was any perforation or bleeding and to ensure the absence of the residual tumor tissues. If there was spurting bleeding or active bleeding, hot forceps were usually to stop the bleeding.
26217|NCT03982251|Procedure|High frequency whole body vibration|1 single session ( 8 minutes) of whole body vibration therapy at 30 Hz
26218|NCT03982251|Procedure|Low frequency whole body vibration|1 single session ( 12 minutes) of whole body vibration therapy at 20 Hz
26222|NCT03982225|Drug|Polyene phosphatidylcholine injection|Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
26223|NCT03982225|Drug|Placebo|Phosphate buffered saline placebo for injection
26224|NCT03982212|Drug|Copaxone|"Agent: Glatiramer acetate (Copaxone®)~Dose: 40 mg~Route: Intratumoral injection~Schedule: At least 1 dose, up to 3 doses, with each dose being at least 48 hours apart and last dose within 96 hours of standard of care surgery."
26227|NCT03982186|Drug|JNJ-73763989|JNJ-73763989 will be administered as medium dose (Arms 1 and 3), high dose (Arm 2), and low dose (Arm 4) as subcutaneous injection.
26228|NCT03982186|Drug|Placebo for JNJ-73763989|Placebo for JNJ-73763989 will be administered as subcutaneous injection.
26229|NCT03982186|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally.
26230|NCT03982186|Drug|Placebo for JNJ-56136379|Placebo for JNJ-56136379 tablets will be administered orally.
26231|NCT03982186|Drug|Nucleos(t)ide Analog (NA)|NA treatment that is either of ETV, TDF or TAF tablets will be administered orally.
26232|NCT03982173|Drug|Tremelimumab|tremelimumab 75mg
26233|NCT03982173|Drug|Durvalumab|Durvalumab 1500mg
26234|NCT03982160|Drug|L-Arginine|Arginine Hydrochloride 60% concentration injection 15 g in 25 mL, contains arginine hydrochloride 600 mg/mL in water for injections to 25 mL.
26235|NCT03982160|Other|Placebo|Saline
26236|NCT03982134|Drug|PDR001|PDR001 is a humanized IgG4 antibody
26237|NCT03982134|Drug|Panobinostat|Panobinostat is a Histone deacetylase inhibitor (HDACi).
26238|NCT03982121|Drug|FOLFOX regimen|Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
26239|NCT03982121|Drug|Nivolumab|Nivolumab 240 mg
26240|NCT03982121|Drug|Ipilimumab|Ipilimumab 5 or 10 or 25 mg
26241|NCT03982121|Drug|GLA-SE|GLA-SE 1 or 2 or 5 or 10 or 20 μg
26326|NCT03981432|Behavioral|EX-AdLib|condition with an acute exercise set 30 minutes before the lunch meal that will be served ad libitum This will be a 30-minute exercise set at 65% of their capacities (cycling), 30 minutes before lunch.
26327|NCT03981419|Biological|GRF6021|for IV infusion
26328|NCT03981419|Other|Placebo|for IV infusion
26329|NCT03981406|Behavioral|Palliative Care|The intervention is one visit to the Fairview Clinics and Surgery Center palliative care clinic, with follow up visits as determined by the palliative care team and the patient.
26242|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knotless suture-bridge technique|"After preoperative skin preparation, a posterior portal will be established to obtain adequate visualization and an anterior portal will be established through rotator interval as a working portal. After diagnostic arthroscopy, preparation and debridement of the tendon will be performed and a high-speed burr will be used to debride and decorticate greater tuberosity.~After determination of proper anchor locations, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the reduced tendon and will be inserted to footprint without tying the medial row with anchors."
26243|NCT03982108|Procedure|Arthroscopic rotator cuff repair with knot-tying suture-bridge technique|After the same preparation procedure as in knotless suture-bridge technique, required number of suture anchors will be inserted just lateral to articular margin depending on the tear size. Then limbs of sutures will be passed from the tendon and tied in a horizontal mattress suture pattern. After the medial row is established, suture limbs will be used to form a suture bridge over the tendon and will be inserted to footprint with anchors
26244|NCT03982082|Procedure|Physical Therapy|Undergo physical therapy
26245|NCT03982082|Other|Questionnaire Administration|Ancillary studies
26246|NCT03982082|Procedure|Ultrasound|Undergo ultrasound via MuscleSound technology
26247|NCT03982069|Biological|FluMist live attenuated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.
26248|NCT03982069|Biological|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.
26249|NCT03982056|Other|this is an observational study there are no interventions|development of an index to provide appropriate information on a person's ability to float, based on Physiological and anthropometric characteristics
26250|NCT03982043|Behavioral|Text2Connect|Text2Connect is a personalized text messaging intervention for patients and parents that targets self-identified barriers to engaging in treatment to increase the likelihood that a depressed or suicidal patient will initiate recommended services.
26251|NCT03982043|Behavioral|Treatment As Usual (TAU)|Participants in this group will receive usual care at their pediatric primary care practice following referral to a mental health treatment provider.
26252|NCT03982030|Drug|Dalbavancin|Dalbavancin 1.5g IV at day 0, day 8-10
26253|NCT03982017|Other|Mobile Health Technology Platform|When the participant navigates to the program, s/he will follow the directions on how to use the program, sign the terms of agreement, put in a password and begin the welcome page. The participant will receive daily prompts to complete brief questionnaires and review specialized content.
26254|NCT03982017|Other|Usual care|Routine care at the time of hospital discharge, to be provided at the discretion of the clinicians caring for the participant.
26255|NCT03982004|Device|Epicutaneous cryoimmunotherapy|Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.
26256|NCT03982004|Drug|Topical imiquimod|Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).
26257|NCT03982004|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks
26258|NCT03982004|Other|Dermatologic Quality of Life Index|"10 questions about how much skin problems has affected the participant's life over the past week~The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3~The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired."
26259|NCT03982004|Other|Functional Assessment of Cancer Therapy|"5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)~Answers ranging from 0=Not at all to 4 = very much~Each item is rated on a 5-point Likert scale.~The higher the score on the social/family well-being and functional well-being indicate higher quality of life~The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life"
26260|NCT03982004|Drug|Intra-lesional GM-CSF|250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
26261|NCT03982004|Device|Cry-AC|-Device used to give the cryoimmunotherapy
26262|NCT03981978|Behavioral|Physical Activity|Self-report questionnaires assessing physical activity level.
26263|NCT03981965|Other|Physical activity|Physical activity as described previously.
26264|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)|6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
26265|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (12 µg)|12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
26266|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (25 µg)|25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
26267|NCT03981952|Biological|Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)|The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
26268|NCT03981952|Other|Placebo|0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
26269|NCT03981926|Other|Team-Based Connected Health (TCH)|TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
26330|NCT03981406|Behavioral|Standard of Care|Control group will receive standard of care treatment for IPF.
26331|NCT03981380|Drug|11C-PIB|Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of [11C]PiB (over 5-10 seconds).
26332|NCT03981341|Drug|Duavive (0.45 estrogens mg and 20 mg bazedoxifene)|Drug given for 3 months in each participant
26270|NCT03981913|Behavioral|Simon Task with high-density EEG recording|"The scalp electrical activity will be collected by a 256-electrodes EEG montage (Electrical Geodesics Inc).~During the task, participants will be asked to answer on a right or left button according to the color of a circle (yellow or blue) presented on the left or right side of a screen. Participants will have to ignore the stimulus position and respond only according to its color. This leads to two experimental conditions When the color of the circle and its position indicate the same answer, the situation is congruent and the answer is facilitated. Conversely, when they indicate two opposite responses, a conflict between the two alternative actions appears and must be resolved to provide a correct answer. This situation is said to be incongruent. At each trial, the stimulus is shown to the left or right of a central fixation cross. The participants then have to answer on a right or left button. At each trial, the reaction time and the accuracy of the response will be collected."
26271|NCT03981900|Drug|Tofacitinib|5 mg BID, oral administrtaion
26272|NCT03981887|Drug|Nafithromycin|Nafithromycin 200 mg as IV infusion
26273|NCT03981887|Other|Placebo|placebo administered as IV infusion
26274|NCT03981874|Other|telephonic interview|Telephonic interview
26275|NCT03981861|Drug|Metformin and Spironolactone|Oral Metformin tablet (500 mg/tablet) twice daily for 6 months. Oral Spironolactone tablet (50 mg/tablet) once daily for 6 months.
26276|NCT03981848|Other|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
26277|NCT03981822|Combination Product|VP-102 and applicator|In part A, VP-102 will be applied for either 2, 6 or 24 hours with each regimen compared to placebo. For part B, 2 of the regimens from part A will be chosen for Part B with each compared to Placebo. Only 4 arms are actually being studied.
26278|NCT03981809|Diagnostic Test|"Diagnostic test (PainsCan) for the identification of the dominant pain mechanisms in cancer survivers with persistent pain"|Easy-to-use screening tool to identify the dominant pain mechanism by using quick clinical tests and compare their accuracy and validity with complicated reference tests.
26279|NCT03981796|Biological|Dostarlimab|Dostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of its binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
26280|NCT03981796|Biological|Placebo|IV Dextrose solution with no active drug to mimic dostarlimab.
26281|NCT03981796|Drug|Carboplatin-paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types.
26282|NCT03981783|Behavioral|Best available care (BAC)|Eligible patients are assigned to a standard pulmonary rehabilitation program
26283|NCT03981783|Behavioral|Telerehabilitation (TH)|Eligible patients are assigned to a pulmonary telerehabilitation program
26284|NCT03981770|Drug|General anesthesia|For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
26285|NCT03981757|Device|NeurOS|NeurOS system pads will be placed on patients' head for monitoring.
26290|NCT03981731|Other|Cardiac coherence|"An initiation session to cardiac coherence will take place between D-10 and D-7 before the operation (during the anaesthesia consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 7 days preceding the operation.~- The anaesthetic induction will be done with a session of cardiac coherence associated with listening to the audio tape."
26291|NCT03981718|Procedure|Fat grafting|Lipoaspirates will be collected from the own subjects abdominal fat tissue, during the 2nd stage breast reconstruction and will be injected on each affected breast during the insertion of the permanent breast implant in the 2nd stage of breast reconstruction
26292|NCT03981705|Radiation|Standard Trimodality Breast Imaging|Standard breast imaging with or without core needle biopsy after neoadjuvant chemotherapy (NAC).
26293|NCT03981692|Other|Sequential dual activity|8 weeks and 2 days per week, one session 45 min. Sequential dual activity creates the idea that it may provide more workable work without creating stress while doing secondary activity during dual activity.
26294|NCT03981692|Other|Integrated dual activity|8 weeks and 2 days per week, one session 45 min. Integrated dual activity is a proven mode of work that has positive effects on geriatrics
26295|NCT03981679|Other|Biological collection|The biological collection will also include samples of blood samples collected before colonoscopy
26296|NCT03981666|Other|Questionnaires|"To patients who have given their consent for the self-screening, the research assistant will propose 3 questionnaires, which will be completed in the waiting room and returned the same day:~Ad hoc questionnaire for demographics and medical data;~Insomnia Severity Index (ISI, 7 items, Savard et al., 2005);~Edmonton Symptom Assessment System (ESAS, 10 items, Visual Analogue Scale, Bruera et al. 1991) assessing comorbidities as pain, dyspnea, anxiety or depression...~The ISI scoring will be realized by the research assistant (in the research office) immediately after its completion."
26297|NCT03981640|Other|Acute exercise|Participants will lie in a supine position with their feet attached to the pedals of a custom-arranged cycle ergometer. Participants' 40% heart rate reserve will be calculated, giving the target value to achieve during exercise based on appropriate resistance applied on the cycle ergometer, corresponding to a mild-to-moderate exercise intensity. After a 5-minute resting baseline, participants will perform dynamic cycling exercise for up to 20 minutes. They will then stop exercising, and there will be a 5-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived exertion will be taken from participants during the last 30 seconds of steady-state cycling exercise.
26298|NCT03981640|Other|Cold pressor test|Participants will lie in a supine position, and after a 3-minute resting baseline, participants will have their hand immersed in ice water for 2 minutes. This cold pressor test represents the non-exercise, physical sympathetic stressor. Participants' hand will then be removed from the ice water, followed by a 3-minute recovery period. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. Ratings of hand pain and cold perception will be taken from participants during the last 30 seconds of the cold pressor test.
26299|NCT03981640|Other|Mental stress test|Participants will lie in a supine position, and after a 3-minute resting baseline, participants will perform a mental arithmetic task for 5 minutes. This mental stress test represents the non-exercise, psychological sympathetic stressor. Participants will be instructed to subtract a given number from a randomly selected three-digit number and verbally state their answer and continue to do so for the duration of the test. Participants will then stop the arithmetic task, and a 3-minute recovery period will follow. Beat-to-beat renal blood flow velocity (Doppler ultrasound), mean arterial blood pressure (finger photoplethysmographic cuff), and heart rate (electrocardiogram) will be recorded throughout. A rating of perceived stress will be taken from participants during the last 30 seconds of the mental stress test.
26300|NCT03981627|Drug|ADO09 formulation|Subcutaneous injection of ADO09 formulation
26301|NCT03981627|Drug|NovoRapid®|Subcutaneous injection of insulin aspart
26302|NCT03981614|Drug|Binimetinib|Given PO
26303|NCT03981614|Drug|Palbociclib|Given PO
26304|NCT03981614|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
26305|NCT03981601|Drug|Lovastatin 40 MG|after tooth extraction, put teh lovastatin40 mg wif bone graft wifin tooth socket
26306|NCT03981601|Procedure|without drug with Bone graft|after tooth extraction, put teh bone graft wifin tooth socket
26307|NCT03981588|Other|Imaging studies|Patients will undergo different imaging and clinical follow-up procedures to run out cardiotoxicity
26308|NCT03981562|Drug|Vit D|Patients will take an oral vitamin D supplement once a day for 6 months.
26309|NCT03981562|Drug|Placebo Oral Tablet|Patients will take a placebo oral tablet once a day for 6 months.
26310|NCT03981549|Biological|Autologous Bone Marrow CD34+ Stem Cells|Single intravitreal injection of autologous bone marrow CD34+ stem cells. The number of cells to be injected per eye will range from 800,000 to 10 million, depending on the yield of the bone marrow aspiration and the isolation procedure.
26311|NCT03981549|Biological|Sham Therapy|Sham bone marrow aspiration procedure that penetrates the skin, but does penetrate the bone followed by sham intravitreal injection without penetration of the eye
26312|NCT03981536|Drug|AP-101|Administered by intravenous infusion (IV)
26313|NCT03981523|Drug|Benznidazole|50 mg and 100 mg tablet taken orally
26314|NCT03981523|Drug|Nifurtimox|120 mg tablet taken orally
26315|NCT03981510|Diagnostic Test|3D-Transit|3D transit investigation consists of a small electromagnetic pill and a detector located in a belt around the waist. The pill is swallowed by the participant and the belt is worn until the pill has left the gastrointestinal tract. The method is without any pain and discomfort for the child. The child will visit the hospital the first time to ingest the capsule alongside a standardized meal, and is then free to go home and proceed with daily activities (beside hard exersize) while wearing the belt with the detector. The next day, the child will again visit the hospital to check whether or not the capsule has left the tract - this is done with a computer and software. The children ingesting two capsules will do this with a certain delay.
26316|NCT03981497|Procedure|Microwave ablation (MWA)|Thermal ablation
26317|NCT03981484|Biological|Prothrombin Complex Concentrate|single dose of 25 IU/kg of 4-PCC at time of enrollment
26318|NCT03981484|Biological|Whole Blood, Plasma, Packed Red Blood Cells|site's standard resuscitation protocol
26319|NCT03981471|Behavioral|Exercise|Elderly people with or without fall history receive exercise to improve balance. Exercise interevention will be given 6 months in 2020. Outcomes (incidence of fall and biological tests) between two arms will be compared.
26320|NCT03981458|Device|Hyalofemme|Gel made with hyaluronic acid to be applied vaginally to treat atrophic vaginitis.
26321|NCT03981458|Device|Ialuril|Bladder instillation of hyaluronic acid to treat recurrent UTI.
26322|NCT03981445|Behavioral|ARTAS Adapted Patient Navigation|Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
26323|NCT03981445|Behavioral|Adherence Counseling|Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
26324|NCT03981432|Behavioral|REST-Fixed|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive a fixed meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
26325|NCT03981432|Behavioral|REST-AdLib|condition without exercise / rest condition. The participants will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
26333|NCT03981328|Device|Dexcom G6 Continuous Glucose Monitoring System|Users insert a tiny sensor wire just under their skin using an automatic applicator. The sensor can measure glucose readings in interstitial fluid throughout the day and night.
26334|NCT03981328|Device|self-monitored blood glucose|Each participant in the control group will be assigned a study blood glucose meter to measure and store their blood glucose values during the study. Therefore, the Contour® Next One system (or a comparable device) will be used. The meter has CE Mark clearance and is commercially available in Europe. Participants will receive an ample supply of meter test materials based on quantities routinely used.
26335|NCT03981315|Diagnostic Test|Bile test|Analyze bile components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
26336|NCT03981315|Diagnostic Test|Blood test|Analyze blood components related to gall stones synthesis (cholesterol, bile acids, phospholypids, etc.)
26337|NCT03981315|Diagnostic Test|Gall stone study|Study of the extracted gall stones, analyzing their composition, type, etc.
26338|NCT03981315|Diagnostic Test|Microbiological bile test|Determination of the microbiological composition of the bile
26339|NCT03981302|Other|Family nursing conversations|"The intervention is based on the concept family systems nursing developed by Wright & Maureen. Family nursing aims to change restricting beliefs and alleviate illness suffering. The Illness Beliefs model and Calgarymodels are essential components. The illness beliefs model illuminates the family's different beliefs about their problems. The Calgary models consist of the Calgary family assessment model and the Calgary intervention model and aim to support change and help the family to find new ways to handle the illness. The use of the components cannot be standardised but must be tailored to match the needs of the specific family. The family nursing conversations in this intervention will last 1,5 hour. Every family will be offered three family nursing conversations with roughly three weeks interval. If the family after three conversations express a need for follow-up, they will be offered the fourth conversation."
26340|NCT03981276|Other|Clinical rating scale to measure disease severity and progression|A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
26341|NCT03981276|Diagnostic Test|Next-Gen Sequencing (NGS)|Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
26342|NCT03981263|Device|MEAVANTI prothesis|"The experimental prosthesis is the MEAVANTI prosthesis (custom-made non-adherent prosthesis in silicone) which can be calibrated to 5 grams near the breast that remains after a mastectomy to create a visual symmetry but also a weight symmetry.~This prosthesis takes into account the curve of the breasts and the morphological details such as: skin color of the patients, size of the nipples, height of the nipples, shape of the breast.~The measurements of the patients will be taken using a 3D scanner (i.e. a scanner that corresponds to a 3d scanning and acquiring device (images), not irradiating), a scale and a colour chart."
26343|NCT03981263|Device|Standard prothesis|This prosthesis will be compared with a standard non-adherent prosthesis (class I, silicone and polyurethane film), among the models available in the three ranges of standard prostheses (Amoena, Anita and Thuasne). The brand and model will be left to the patient's choice.
26344|NCT03981250|Behavioral|12-week home-based resistance exercise programme|Participants will perform 6 exercises (press-ups, squats, squat jumps, plank, upright row and seated row) for one minute, aiming for the maximum number of repetitions. Participants will perform one exercise per day, for 6 days a week, for 12 weeks.
26345|NCT03981237|Device|Laser-activated irrigation with a pulsed Er:YAG laser|The root canals and the pulp chamber are filled with NaOCl 3%. Per canal, the laser tip is placed above the root canal entrance and activated (frequency 20 Hz, pulse energy 20 mJ and pulse length 50 μs) for 30s. TThe canal is then rinsed with NaOCl using a 27G needle, followed by a second application of laser, identical to the first.
26346|NCT03981237|Device|Ultrasonically activated irrigation|The root canals and the pulp chamber are filled with NaOCl 3%. An Irrisafe file, driven by an ultrasonic unit according to the manufacturers' instructions, is held at 1-3 mm from WL (precurved if canal is curved) and activated for 30 s. The canal is then rinsed with NaOCl using a 27G needle. This cycle is repeated three times (i.e. 3*20s).
26347|NCT03981237|Procedure|Orthograde root canal treatment|After rubber dam isolation and field disinfection, the pulp chamber is accessed. The root canal(s) is/are located and shaped using manual and mechanical NiTi instruments in combination with NaOCl (3%) irrigant. The canals are dried using paper points and obturated with gutta percha and epoxy resin sealer. The tooth is sealed with a temporary or permanent filling.
26348|NCT03981211|Drug|Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
26349|NCT03981211|Drug|Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet|4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
26350|NCT03981198|Device|Soliton Rapid Acoustic Pulse (RAP)|Treatment of legs and/or buttocks for the temporary improvement in the appearance of cellulite.
26351|NCT03981185|Device|Accelerated theta burst treatment|"All participants will receive iTBS (intermittent theta burst stimulation) to the left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to L-DLPFC using the MagPRo stimulator."
26352|NCT03981172|Behavioral|Daily snack food intake|participants consumed 60 gram portions of either low energy density or high energy density snack foods every day for two weeks.
26353|NCT03981159|Other|Physical training|Physical training for three months, twice per week (60 minutes per session).
26354|NCT03981146|Drug|Nivolumab|30 Minute IV Infusion
26355|NCT03981133|Behavioral|offer a pacifier|offer a pacifier to normal newborn infants the first days of life
26356|NCT03981133|Behavioral|no pacifier|not to offer a pacifier at 15 days of life
26357|NCT03981120|Procedure|Laser and Traditional Acupuncture|Acupuncture (traditional and laser) and photobiomodulation will be performed by a certified acupuncturist on-site with experience in reproductive health and the initial visit will include an assessment and traditional Chinese medicine (TCM) diagnosis.
26993|NCT03976063|Drug|Placebo of Nifedipine|Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
26358|NCT03981107|Other|Chest Compression Only CPR (CO-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions only~The instructions from the dispatcher in interventional arm include:~An ambulance is dispatched and is on it´s way to you~Do CPR with chest compressions only~Push hard on the chest with a pace of 100/minute without interruptions for rescue breathing."
26359|NCT03981107|Other|Standard CPR (S-CPR) performed by trained bystanders after instructions from dispatchers|"Instructions by dispatcher to bystander to provide CPR with chest-compressions and rescue breaths in a ration of 30:2~The Instructions from the dispatcher in the control arm include:~An ambulance is dispatched and is on it´s way to you~Do CPR with chest compressions and rescue breathing~Push hard on the chest 30 times and give 2 rescue breaths. The pace of the compressions should be 100/minute."
26362|NCT03981081|Drug|Prednisone|Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients
26363|NCT03981068|Radiation|Re-irradiation|Cisplatin for all eligible patients, nimorazole for all SCC
26364|NCT03981055|Device|Active Comparator: Active tDCS and Active TUS|"Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
26365|NCT03981055|Device|Sham Comparator: Sham TDCS and Sham TUS|"Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes."
26366|NCT03981055|Other|Physical Therapy|All subjects will enroll in a conventional PT balance and gait focused training program, and will receive PT 3x/week over the two weeks of stimulation for 45 minutes following the stimulation sessions when applicable.
26367|NCT03981042|Device|Monitoring|"After the anesthetic induction with sufentanil, propofol and atracurium, patients will be ventilated with mask until:~- Monitoring group: TOF ratio at the corrugator supercilli will be measured every 15 s after injection of atracurium. When TOF ratio reach 0, laryngoscopy with intubation will be performed"
26368|NCT03981029|Other|4.0mg Folic Acid received through participation in FACT (NCT01355159)|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid intervention are provided below:~Folic Acid 1.0 mg x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid"
26369|NCT03981029|Other|Placebo received through participation in FACT|"Participants in this study received either daily high-dose folic acid supplementation during pregnancy OR placebo through their participation in FACT (NCT01355159). Details of the FACT Folic Acid placebo are provided below:~Placebo x 4 tablets will be taken daily by oral administration."
26370|NCT03981016|Other|Biological collection|"blood samples collected at different times : Before surgery and during the post-operative visit and~frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery"
26371|NCT03981003|Diagnostic Test|Blood sample|2 x 4 ml tubes blood to screen for serum Neurofilament Light Chain levels
26372|NCT03980990|Drug|Metformin|Continuation of Metformin
26373|NCT03980977|Other|skin biopsy|"skin biopsy will be taken under local anesthesia using a patch of lidocaine and prilocaine. In practice, during the skin biopsy, the skin must be cleaned with chlorhexidine or alcohol, to the exclusion of any other antiseptic. The biopsy will preferably be done with a dermatome (or punch, 12 G)."
26374|NCT03980977|Other|tumor biopsy|an additional tumor sample will be taken during programmed diagnostic procedure.
26375|NCT03980977|Other|blood sample|blood sample will be taken for biological collection
26376|NCT03980964|Device|Active NMES|Daily home-based, mobile-app controlled, neuromuscular electrical stimulation (NMES) therapy
26377|NCT03980951|Procedure|Dural Puncture Epidural Technique|three labor analgesia techniques
26378|NCT03980951|Procedure|Combined Spinal Epidural without intrathecal opioids|three labor analgesia techniques
26379|NCT03980951|Procedure|epidural|three labor analgesia techniques
26380|NCT03980938|Drug|neflamapimod|40 mg neflamapimod capsule
26381|NCT03980938|Other|Placebo|matching placebo capsule
26382|NCT03980925|Drug|Nivolumab|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
26383|NCT03980925|Drug|Carboplatin|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
31202|NCT03942003|Procedure|PEC blocks|PEC I-II blocks was performed
26384|NCT03980925|Drug|Etoposide|"Subjects will receive Nivolumab 360 mg every 3 weeks (Q3W) first day of each cycle plus Carboplatin AUC5 Q3W first day of each cycle plus Etoposide 100 day 1-3 of each cycle up to 6 cycles of combined therapy (Induction Phase).~At the time of completion of 6 cycles of chemotherapy and nivolumab, participants who have not experienced disease progression will continue to receive nivolumab at a dose of 480 mg as 30 minute infusion every 4 weeks for up to 2 years (24 months) (maintenance phase).~Cycles are defined by 4 weeks or 28 days."
26385|NCT03980912|Diagnostic Test|LiverFASt|LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.
26386|NCT03980873|Behavioral|ESTEEM (Effective Sikills to Empower Effective Men)|"ESTEEM (Effective Skills to Empower Effective Men) is a 10-session intervention based on the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (Barlow et al., 2010).~Is an individually-delivered cognitive behavioral treatment with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation abilities; reducing maladaptive cognitive, affective, and behavioral avoidance patterns; and improving motivation and self-efficacy for enacting behavior change"
26387|NCT03980860|Other|Exercise Type|The implementation of 2 types of exercise programs to reduce body fat
26388|NCT03980847|Drug|Alendronate 20 mg|The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction
26389|NCT03980847|Procedure|Nanocrystal hydroxyapatite|Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
26390|NCT03980834|Behavioral|ParentCorps FUNdamentals|is a series of large-group experiential PD days (in groups of 25-40 participants from across all schools) which takes place in the first summer prior to implementation. Leaders participate in a 2-day FUNdamentals series with leaders from other schools.
26391|NCT03980834|Behavioral|ParentCorps 101 E-learning|is a self-paced interactive web-based series with 7 modules intended to help facilitators build confidence and mastery of evidence-based practices.
26392|NCT03980834|Behavioral|Training|group-based series to prepare facilitators (mental health professionals and teachers) to implement Programs with fidelity and to ensure high levels of exposure by parents and students. Mental health professionals are supported to facilitate the Program for Parents (day and after-school versions) with fidelity. Pre-K teachers and assistants are supported to implement the Program for Students in the classroom. In addition, early childhood staff (including Kindergarten teachers as needed) is trained to facilitate the Program for Students during after-school hours in parallel with the Parenting Program. All facilitators receive training on engaging parents to participate
26393|NCT03980834|Behavioral|Coaching|is one-on-one support provided in-vivo and from a distance (phone, text, email) to help users apply evidence-based practices in daily interactions with students and parents, and to support high levels of implementation fidelity and exposure. All Pre-K teachers and mental health professionals facilitating ParentCorps receive four on-site coaching visits and 10 30-minute calls for the remaining sessions in the first year for each cycle of implementation.
26394|NCT03980821|Drug|AZD4635|AZD4635 taken orally
26395|NCT03980808|Behavioral|American Sign Language-Accessible Diabetes Education|Video-based ASL interpreted diabetes educational intervention (ASL-ADE), the content of which will be derived from diabetes health information regarding symptoms and risk factors that are published by the U.S. Centers for Diseases Control and Prevention (CDC) and the National Institute for Health (NIH) National Diabetes Education Program.
26396|NCT03980808|Behavioral|Control Intervention|Non-health related video approximately the same length as ASL-ADE.
26397|NCT03980795|Other|Exercise Program|Participants met with an exercise physiologist at their monthly center appointment over a 3-month period (4 meetings). The consultations took place either together or separate from or with the dietitian's consultation (depending on appointment logistics). In addition the Exercise Physiologists telephone called each intervention participant on a weekly basis.
26398|NCT03980782|Other|Music Therapy|Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
26399|NCT03980769|Drug|Thiotepa|Given IV
26400|NCT03980769|Drug|Treosulfan|Given IV
26401|NCT03980769|Drug|Fludarabine|Given IV
26402|NCT03980769|Drug|Fludarabine Phosphate|Given IV
26403|NCT03980769|Biological|Rabbit Anti-Thymocyte Globulin|Given IV
26404|NCT03980769|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT via infusion
26405|NCT03980756|Drug|AD-206 20mg|1 tablet administered before the breakfast during 7 days
26406|NCT03980756|Drug|Esomeprazole 20mg|1 tablet administered before the breakfast during 7 days
26407|NCT03980756|Drug|AD-206 40mg|1 tablet administered before the breakfast during 7 days
26408|NCT03980756|Drug|Esomeprazole 40mg|1 tablet administered before the breakfast during 7 days
26409|NCT03980743|Behavioral|iOTA text messaging intervention|Over 6 months, participants in the iOTA arm will have monthly in-person visits with a health coach who will work with the participant to set goals for the upcoming month related to healthy eating and activity. The participant will receive daily text message health tips related to their goals, and will be prompted once a week to respond with a text indicating their weight and how they are doing with their goals. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
26410|NCT03980743|Behavioral|Health Education text messaging intervention|Over 6 months, participants in the Health Ed arm will also have monthly in-person visits with a health coach who will provide education on energy balance and problem-solving. Specific goals will not be set, but the health coach will assist participants in problem-solving any challenges. Participants will receive a weekly automated motivational text message health tip from the study related to what they learned in their health coaching sessions. Following the 6-month active treatment phase, participants will receive text messages only for another 3 months.
26411|NCT03980730|Drug|Azeliragon|Azeliragon 5 mg capsule administered orally, once daily
26412|NCT03980730|Drug|Placebo|Matching placebo capsule administered orally, once daily
26613|NCT03978988|Procedure|Intracranial thrombectomy|Intracranial thrombectomy is the endovascular procedure. In the experimental group, thrombectomy will be completed with a extracranial carotid stenting.
26413|NCT03980717|Device|Goldbal Detachable Balloon and delivery microcatheter|Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
26414|NCT03980704|Drug|IMPACT|Administration of oral immunostimulating oral supplement
26415|NCT03980704|Drug|resource protein|Administration of oral high-protein oral supplement
26416|NCT03980691|Biological|Chidamide with CAR-T or TCR-T cell therapy|HIV-1 specific therapy
26417|NCT03980678|Dietary Supplement|Mineral Rich Algae|Lithothamnion species is rich in calcium, magnesium (Mg) and 72 other trace elements absorbed from sea-water during the organisms life. Mineral-rich 'fronds' break off from the living organism, fall to the ocean floor and are harvested (AquaminF). The mineral extract in soluble form contains ~13.1% Calcium, ~1.04% Magnesium and measurable levels of 72 other trace minerals. Following or prior to a washout period (crossover intervention), participants will consume the Aquamin Soluble equivalent of 1000mg Calcium in 250 ml of orange flavored water for a 7 day loading period.
26418|NCT03980678|Dietary Supplement|Orange flavoured water with maltodextrin as the placebo|Following or prior to a washout period (crossover intervention), participants will consume 250 ml of orange flavoured water (containing 20mg of Calcium with maltodextrin) for a 7 day period.
26419|NCT03980665|Drug|Arsenic Trioxide|a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
26420|NCT03980652|Procedure|Change of gloves and sterile instruments|Change of gloves and use of separate , sterile instruments before closing the abdominal wall
26421|NCT03980639|Drug|patient treated with DMARD|Case report of cancer overall
26422|NCT03980626|Behavioral|Walking|The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
26423|NCT03980613|Other|Triage|Emergency telephone calls from cases and controls are replayed and analyzed for symptom descriptions indicating spontaneous subarachnoid haemorrhage.
26424|NCT03980600|Device|FibDex wound dressing|Treatment of donor sites of 24 patients with the dressing Type 4 (final product i.e. FibDex) until the self-detachment of the wound dressing i.e. epithelialization
26425|NCT03980600|Device|NFC wound dressing Types 1-3|Treatment of donor sites of 9 patients with the NFC dressing's (proto)Types 1-3 until the self-detachment of the wound dressing i.e. epithelialization
26426|NCT03980600|Device|Suprathel (comparator)|Treatment of donor sites of 22 patients with Suprathel dressing, which was used as a reference (comparator) product, until the self-detachment of the wound dressing i.e. epithelialization
26427|NCT03980574|Dietary Supplement|R Drink|R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
26428|NCT03980561|Drug|Varenicline|Active medication
26429|NCT03980561|Drug|Placebo|Inactive medication
26430|NCT03980548|Procedure|CABG|Patients undergoing coronary artery bypass graft and patient presented with ACS undergoing PCI
26431|NCT03980535|Procedure|Magnetic Resonance Imaging|Undergo MRI
26432|NCT03980535|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
26433|NCT03980522|Drug|KPL-914|"KPL-914 (rilonacept) will be provided in its commercially-available formulation as a lyophilized powder to be reconstituted for SC administration.~Adult subjects (≥ 18 years of age) KPL-914 will be administered as an initial loading dose of 320 mg SC, delivered as two subcutaneous injections of 160 mg SC each on Day 0, then 160 mg SC dosed once weekly for 5 subsequent weeks.~Pediatric subjects (6 to <18 years of age) KPL-914 will be administered with an initial loading dose of 4.4 mg/kg, up to a maximum of 320 mg, delivered as two subcutaneous injections of 2.2 mg/kg each with a maximum single-injection volume of 2 mL."
26434|NCT03980509|Drug|Curcumin|Curcumin is an extract from turmeric
26435|NCT03980496|Drug|Omeprazole|
26436|NCT03980483|Biological|GSK3196165|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
26437|NCT03980483|Drug|Tofacitinib 5 mg|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
26438|NCT03980483|Drug|Placebo to GSK3196165|Placebo sterile 0.9% w/v sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
26439|NCT03980483|Drug|Placebo to tofacitinib|Placebo cap (containing lactose) to be administered orally.
26440|NCT03980483|Drug|Methotrexate|Stable oral dose of MTX as SoC.
26441|NCT03980483|Drug|Folic (or folinic) acid|Folic (or folinic) acid >=5 mg/week.
26442|NCT03980470|Device|TrueFidelity|"TrueFidelity (Deep Learning Image Reconstruction, DLIR) software by GE Healthcare.~The medical device in question is a novel reconstruction algorithm for raw CT data which is based on artificial intelligence approaches, namely deep-learning iterative reconstruction (DLIR). This DLIR algorithm will be installed on the console of the CT Revolution scanning device, which is in routine clinical use for cardiac CT scans at the Department of Nuclear Medicine at the University Hospital Zurich. Purpose of this installation is the assessment of the performance of the DLIR algorithm during a limited time span of six weeks.~The algorithm will be CE-marked at the time of installation and use (statement by GE Healthcare provided separately). Its intended use is the reconstruction of CT datasets.~Of note, the novel DLIR algorithm will not substitute any clinical routine procedures currently in use. That is, diagnosis will still be made using the standard reconstruction algorithms."
26443|NCT03980457|Device|Indego Exoskeleton|Powered generated orthosis
26444|NCT03980457|Other|Standard Rehabilitation|Standard Rehabilitation
27043|NCT03975556|Behavioral|Standard healthy eating advice|Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips included in the My Plate dietary recommendations
26445|NCT03980444|Device|Basket of wire|(using a basket of wires3F) the helical type was passed through the four wires of the working channel of the orthoscope and routed to the proximal part of the rock, and the stone was routed to the bowl, then the stone was ducted The gasket was kept, and the probe of the pneumatic crusher also passed through the working channel and proceeded to break it down. Conditions were observed during the stomach as control group. Urethroscopic crushing was performed by a urologist in both groups under similar technical conditions. Findings during and after the completion of crushing include the success, stone retropulsion or parts larger than 3 mm, which requires secondary measures (SWL - ureter stenting, resection ureteroscopy), the duration of stone breakdown and traumatic ureteric complications in both groups it is registered
26446|NCT03980444|Procedure|control group, no basket|"In each group, ureteroscopy was performed using a standard F9.5 ureteroscope. After reaching the rock in group A (control), the probe of the pneumatic crusher was passed through the working channel of the ureteroscope and began crushing the rock.~During the crushing process, the minimum flow of water, flattening and the single-shot impact was used to minimize the stone's retropulsion."
26447|NCT03980431|Diagnostic Test|FBY-PET Examination Group: Patients receive FBY-PET examination after entrance|A single dose of 0.15 mCi/kg FBY will be intravenously injected and PET examination will carry out 30 minutes later.
26448|NCT03980418|Procedure|DaTSCAN SPECT/CT in VERITON-CT camera|the intervention is based on two records in the VERITON-CT; the first, in focus striatum mode and the second in brain focus mode
26449|NCT03980405|Dietary Supplement|Group 1- Control Diet|Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks
26450|NCT03980405|Dietary Supplement|Group 2- UCD Diet|Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
26451|NCT03980392|Other|Multidomain intervention program|Multidomain intervention program for physical exercise, cognitive training, nutrition, vascular and metabolic risk controls, and motivation
26452|NCT03980379|Drug|304 injection|Monoclonal antibodies, 100mg/10ml per injection
26453|NCT03980379|Drug|rituximab injection|100mg/10ml per injection ，manufactured by Roche
26454|NCT03980366|Device|Electroconvulsive Therapy (ECT)|Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
26455|NCT03980353|Other|Questionnaires|The questionnaires have two parts: a general part and a second part focused on the integration in community of the type 1 diabetes children with specific questions about blood glucose, mealtimes, sporting activities and school trips.
26456|NCT03980340|Behavioral|Short Nap Intervention|Study participants may be asked to have a 1-2 hour nap in between the breath analysis tests.
26457|NCT03980340|Behavioral|No Nap Intervention|Study participants may be asked to sit or lay down remaining awake for 1-2 hours in between breath analysis tests.
26458|NCT03980327|Dietary Supplement|probiotic|Lactobacillus probiotic
26459|NCT03980327|Dietary Supplement|medium chain triglyceride oil|
26460|NCT03980314|Drug|Nivolumab|Participants will receive nivolumab.
26461|NCT03980301|Diagnostic Test|ultrasound|screening of pregnant women with hepatitis c virus received treatment in first trimester for congenital anomalies
26462|NCT03980288|Drug|CAR-GPC3 T Cells|Pretreatment with fludarabine and cyclophosphamide CAR-GPC3 T Cells infusion
26463|NCT03980262|Behavioral|Healthy Children, Healthy Families+ (HCHF+)|HCHF+ integrates healthful eating and physical activity with parenting education (parent role modeling and child feeding practices) and was recently shown to improve parent and child nutrition behaviors for participants in the Expanded Food and Nutrition Education (EFNEP) program. OrganWise Guys (OWG) will be used for children in first and second grades (ages 6-8). Choose Health: Food, Fun and Fitness (CHFF), developed by Cornell University, will be used for children in grades three through five (ages 8-10). HCHF+ includes 9 sessions to be delivered weekly.
26464|NCT03980262|Behavioral|Money Smart|Money Smart is a financial literacy education program developed by the Federal Deposit Insurance Corporation (FDIC). Curricula are available for both adults and children.
26465|NCT03980249|Drug|Carvedilol|Carvedilol: Start at 6.26 mg PO twice daily for 1-2 weeks and if tolerated, will be increased to 12.5 mg PO twice daily for 6 cycles as tolerated.
26466|NCT03980236|Device|Livongo-Insulia Study App|Throughout the study, participants will be asked to use the LIvongo-Insulia Study App daily to receive their basal insulin dose recommendation. Participants will need to check their before breakfast blood glucose using their Livongo meter. Then, they will need to open the Livongo-Insulia Study App and accept the uploaded blood glucose(s) from the Livongo meter. Once the appropriate information is received, participants will receive an insulin dose recommendation and should confirm once the dose has been taken. Depending on their blood glucose, participants may also receive coaching messages and coaching support from the Livongo program.
26467|NCT03980223|Drug|Doxycycline Hyclate Delayed-Release 200 mg|200 mg of doxycycline taken by mouth after condomless sexual contact as post exposure prophylaxis (PEP)
26468|NCT03980210|Procedure|Hyperbaric oxygen therapy|"FiO2 0.21 - 1 ATA~FiO2 1 - 1 ATA~FiO2 1 - 2.5 ATA~FiO2 0.21 - 2.5 ATA~FiO2 0.21 - 1 ATA"
26469|NCT03980197|Other|Active surveillance and preemptive isolation|Active surveillance test and preemptive isolation is performed. If MDRO is isolated in surveillance test, contact precaution is needed.
26470|NCT03980197|Other|Control|No active surveillance and preemptive isolation. If clinical isolates are positive for MDRGNB, start contact precaution
26471|NCT03980184|Drug|Guanfacine|guanfacine 3mg
26472|NCT03980184|Other|placebo|placebo
26473|NCT03980171|Drug|Obinutuzumab|A flat dose of 1000mg IV will be given every cycle during induction. a cycle is 28 days.During maintenance 1000mg IV will be given every second cycle for upto 2 years.
26474|NCT03980171|Drug|Venetoclax|During dose escalation, the doses for venetoclax can be 400mg daily days 1-10, 800mg daily days 1-10, 400mg daily continuous or 800mg daily continuous. 6 cycles of treatment will be given during induction. Once the recommended phase 2 dose (RP2D) is established that dose will be used in dose expansion. A further 6 cycles of venetoclax will be given during maintenance if required based on response at the end of induction.
26475|NCT03980171|Drug|Lenalidomide|During dose escalation, the doses of lenalidomide can be 15mg for days 1-21 or 20mg for days 1-21. 6 cycles of treatment will be given during induction. During maintenance the dose of lenalidomide will be 10mg continuous for a further 6 cycles if required based on response at the end of induction.
26476|NCT03980145|Device|G-EO System (Reha Technology AG: Olten, Switzerland)|Electromechanically-assisted gait training addresses many of the limitations of therapist-assisted gait training and can be performed using either exoskeleton or end-effector devices. Exoskeleton devices involve programmable drives or passive elements which physically move the lower limbs, whereas, end-effector approaches involve driven footplates that have trajectories that simulate the stance and swing phases.13,14 The G-EO System (Reha Technology: Olten, Switzerland) is a novel end-effector gait training system that was developed for regaining mobility and independence in stroke survivors. This system involves minimal therapist and patient burden (e.g., quick set-up, single operate usage), there is the unique capacity for practicing walking and stair climbing movements, and the patient can receive real-time visual feedback.
26477|NCT03980145|Other|Conventional Physical Therapy|Conventional physical therapy (CPT): CPT sessions will involve a 3-5 minute warm-up, stretching, progressive strength training exercises, and gait and balance training. Additional strategies for home exercises, energy conservation, fall prevention, and appropriate assistive devices (i.e., orthotics) will be provided.
26478|NCT03980132|Drug|Lugols Strong Iodine|5 L.I. drops / 8 hours for 10 days before surgery
26479|NCT03980119|Other|HITSystem 3.0|The HITSystem 3.0 is a web-based intervention that aims to improve pediatric ART retention and adherence, and viral suppression. The HITSystem 3.0 is accessed online through a computer, using mobile broadband modems that respond to a cellular signal. The primary components include: (1) action alerts to complete time-sensitive interventions; (2) real time communication of HIV PCR results to hospitals to reduce turn-around time; (3) continuous follow-up for timely ART initiation among HIV-infected infants; (4) promotion of retention in EID care via SMS text messaging and/or patient tracing; and (5) an automated and individualized SMS text messaging component to communicate with mothers. The HITSystem has a unique dashboard that proactively monitors time-sensitive interventions along the EID cascade of care, alerting clinics, laboratories and mothers when an intervention has been missed.
26480|NCT03980106|Other|Reciprocal Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract antagonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
26481|NCT03980106|Other|Post-Isometric Inhibition Muscle Energy Technique|In this technique, the subject will be asked to contract agonist muscles against a moderate resistant force provided by the therapist to inhibit the contraction of the agonist muscle.
26482|NCT03980093|Behavioral|Education|Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.
26483|NCT03980093|Behavioral|Values|An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
26484|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 1-7~6 escalating dose level groups IV~SC"
26485|NCT03980080|Drug|Placebo|Vehicle study drug
26486|NCT03980080|Drug|OSE-127|"mAb antagonist to CD127 receptor (or IL-7Rα)~Group 8-9~2 escalating dose level groups IV"
26487|NCT03980067|Other|Virtual Reality Game|The virtual reality headset, device, and software, created by Stanford's Childhood Anxiety Reduction through Innovation and Technology (CHARIOT)program/Weightless Studio, LLC will be utilized in this study. Children in the VR intervention group will be allowed to select a distraction-based game to play with active VR content featuring interactive avatars and interactive experiences tailored to the pediatric population that allow players to do things such as control penguins sliding down a mountain while collecting pebbles for points, control puppies running in space to collect treats to the rhythm of music, and control an asteroid miner exploring an asteroid belt and collecting points based on color of asteroids collected. The game will last a minimum of 5 minutes in duration, provided participant tolerance. The participant may play longer if desired prior to receiving procedural sedation and the total length of activity played will be documented.
26488|NCT03980054|Drug|Pyrotinib|pyrotinib 400 mg, orally once daily for one year
26489|NCT03980054|Drug|Placebo|placebo 400mg, orally once daily for one year
26490|NCT03980041|Drug|IPI-549|IPI-549 (40mg QD) administered orally in 28-day cycles
26491|NCT03980041|Drug|Nivolumab|Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
26492|NCT03980041|Drug|Placebos|Placebo administered orally in 28-day cycles
26493|NCT03980015|Other|antibiotic treatment|Patients were treated with: ceftriaxone intravenously 2 g OD for 14 days or doxycycline orally 100 mg bid for 10 to 14 days or cefuroxime axetil orally 500 mg bid for 14 days or amoxicillin orally 500 mg tid for 14 days
26494|NCT03980002|Drug|FCR and Ibrutinib|"Induction treatment:~Patients <65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count <10×10^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~Ibrutinib:420mg/d"
26495|NCT03980002|Drug|BR and Ibrutinib|"Induction treatment:~Patients ≥65y and ≤75 y or <65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d"
26496|NCT03980002|Drug|Ibrutinib and Thalidomide|"Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy."
26497|NCT03979989|Drug|Tapentadol IR capsule|Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.
26498|NCT03979989|Drug|Omeprazole capsule|Omeprazole capsule containing 40 mg omeprazole.
26499|NCT03979976|Drug|Ramipril|Use of ramipril 10mg/day per 12 weeks. Telephone contact was made in the second and sixth week, to ask about possible side effects and ensure adherence
26539|NCT03979677|Behavioral|Lifestyle Modifications|Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
27150|NCT03974594|Drug|Trifluridine and Tipiracil Tablets|Trifluridine and Tipiracil Tablets given 20mg orally once under fasting or postprandial conditions per cycle
26500|NCT03979950|Behavioral|Survey|Solid Organ Transplant patients will be recruited via social media. Co-investigators will reach out to the administrators of various social media networks to share information regarding the study with their networks on our behalf. Potential participants who are interested in participating, can then follow the link to the online survey tool, which includes the participant demographic information (age, ethnicity and highest level of education) and questionnaire. The questionnaire is 30 questions long and takes approximately 15 minutes to complete. This questionnaire will be a single, cross-sectional survey. No personal information will be documented on the questionnaire. All responses will be anonymous. Participants will be recruited for 6 months.
26501|NCT03979937|Procedure|Arthrocentesis|Arthrocentesis to determine the nature of the effusion (septic or aseptic).
26502|NCT03979924|Behavioral|Trismus rehabilitation|"The patient will be followed-up by a physiotherapist during all the whole radiotherapy treatment, with short 15-min sessions, twice a week. He/she will be trained to perform regularly and by him/herself the preventive/rehabilitation exercises than the patient will do twice a day until the end of the radiotherapy treatment. The patient will then continue, in an autonomous manner, with his/her rehabilitation.~In case of trismus occurrence, the physiotherapist will advise the patient to add a passive tool to the active exercises (Jaw Trainer, Therabite, tongue depressors,…) in order to strengthen the stretching."
26503|NCT03979898|Biological|ASTROSTEM|Intravenous injection of Autologous Adipose derived mesenchymal stem cells. Dose : 15kg below : 0.5x10^7cells/5mL 15kg ~ 25kg : 1x10^8cells/10mL 25kg over : 1.5x10^8cells/15mL
26504|NCT03979885|Behavioral|Smoking cessation counseling (Quitline)|Quitline offers community-based counseling session with a cessation counselor.
26505|NCT03979885|Behavioral|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
26506|NCT03979885|Behavioral|Financial incentives for smoking cessation|Participants will receive financial incentives for bioconfirmed smoking cessation.
26507|NCT03979885|Behavioral|Financial incentives for use of evidence-based smoking cessation therapies|Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
26508|NCT03979872|Diagnostic Test|MC1R Genetic Testing|[See arm/group descriptions]
26509|NCT03979872|Other|Skin Cancer Education|[See arm/group descriptions]
26510|NCT03979872|Device|UV Photo|[See arm/group descriptions]
26511|NCT03979859|Drug|WCK 4873|
26512|NCT03979859|Drug|Placebo Oral Tablet|
26513|NCT03979846|Other|Best Practice|Receive usual care
26514|NCT03979846|Other|Computer Application|Use computer-based symptom reporting system
26515|NCT03979846|Other|Questionnaire Administration|Ancillary studies
26516|NCT03979846|Other|Quality-of-Life Assessment|Ancillary studies
26517|NCT03979833|Genetic|Whole exome sequencing|DNA from CNS hemangioblastomas and normal tissue (blood) will be analysed using whole exome sequencing.
26518|NCT03979820|Drug|BI 1467335|Film-coated tablet
26519|NCT03979820|Drug|Placebo|Film-coated tablet
26520|NCT03979820|Drug|Phenelzine sulfate|Film-coated tablet
26521|NCT03979820|Drug|Tyramine|Capsules
26522|NCT03979807|Drug|Olodaterol/Tiotropium Bromide|(Stiolto®) delivered via Respimat inhaler
26523|NCT03979807|Drug|Umeclidinium/ Vilanterol|(Anoro®) delivered via Ellipta Inhaler
26524|NCT03979794|Behavioral|Behavioral Intervention for Wellness and Engaged Living (Be-WEL)|Behavioral Intervention for Wellness and Engaged Living (Be-WEL) is a 4-session (2 preoperative, 2 postoperative) telephone intervention focused on improving emotional and physical health through relaxation, behavioral activation, increased physical activity, and adherence to medication and wound care.
26525|NCT03979781|Drug|tailored antiplatelet selection|antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
26526|NCT03979781|Drug|standard of care|antiplatelet selection using standard of care
26527|NCT03979768|Other|Diabetes risk assessment service in Norwegian community pharmacies|Two pharmacists at each pharmacy were trained to perform risk assessments and counselling. During six months, pharmacy customers equal or above 45 years old, wishing to participate contacted the pharmacy staff. Participants completed a validated diabetes risk test and a background questionnaire including a validated instrument for self-rated health.
26528|NCT03979755|Other|Application of questionnaires|Application of questionnaires described by telephone.
26529|NCT03979742|Biological|Umbilical Cord Blood Mononuclear Cell|Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)
26530|NCT03979742|Drug|Lithium Carbonate|Active Ingredients: Lithium Dose: 900-1200 mg/day in 300 mg tid or 600 mg bid
26531|NCT03979742|Other|Placebo|Placebo
26532|NCT03979742|Other|Locomotor Training|Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months
26533|NCT03979729|Other|Routine Screening Mammogram (3D + 2D)|Subjects that have undergone a routine screening mammogram (3D + 2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
26534|NCT03979729|Other|Routine Screening Mammogram (2D)|Subjects that have undergone a routine screening mammogram (2D) will be interviewed by a member of the research team who will ask a few questions to better understand how the subject made this decision and what things may have influenced her decision between different types of mammograms.
26535|NCT03979729|Other|No Screening Mammogram|Subjects will participate in a one-time facilitated focus group.
26536|NCT03979716|Device|fMRI|fMRI examination
26537|NCT03979703|Other|12 week yoga class|Intervention is a 12 week yoga class with classes twice a week. Each yoga class will last about 1 hour. Furthermore, focus group interviews will be conducted after the first and last yoga class.
26538|NCT03979690|Device|NISInspire-C System|The NISInspire-C System is a disposable robotic colonoscopy system that consists of a flexible slender insertion tube designed to ensure non-invasive, reliable and safe colorectal screening. It comprises of two components: NISInspire-C Console, and the NISInspire-C Disposable Colonoscope.
26590|NCT03979209|Drug|Nasal Mometasone Rinse|Nasal irrigation twice a day (BID) of assigned dose.
26540|NCT03979664|Device|Activapatch intellidose 2.5 using active Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
26541|NCT03979664|Device|Activapatch intellidose 2.5 using inactive Iontophoresis|Iontophoresis is a drug delivery system that uses electromigration and electro-osmosis to move charged molecules. Electromigration is the movement of ions across the skin by an electrical field. Positive ions move away from a cathode (positive charge) and towards an anode (negative charge). Negative ions move away from an anode and towards a cathode. Electro-osmosis is the volume movement of positive ions away from the opposite charge. Since skin is negatively charge, positively charged ions penetrate deep in the tissue from the negatively charged skin. 4 The use of iontophoresis was incorporated into medicine in efforts to increase the penetration of medications and avoid injection procedures. Inactive medication will be used in the study. Using a syringe, 2 cc of inactive medication will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
26542|NCT03979664|Drug|Dexamethasone|Dexamethasone sodium phosphate 4 mg/mL vial will be used in the study. Using a syringe, 2 cc of dexamethasone will be drawn and poured onto the designated medication site on the iontophoresis patch. Once the medication is poured, the patch will be applied on the skin and turned on.
26543|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level -1 = Hydroxychloroquine 400 mg by mouth once a day"
26544|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 1 (starting dose) = Hydroxychloroquine 800 mg by mouth once a day"
26545|NCT03979651|Drug|Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3)|"Standard dosing of trametinib at 2 milligrams (mg) by mouth once a day, with an escalation of hydroxychloroquine.~The escalation of hydroxychloroquine will be decided by a 3+3 design with the goal of estimating the Maximum Tolerated Dose (MTD) of trametinib plus hydroxychloroquine. A cycle of treatment will last 28 days. Patients will be evaluated weekly during the first cycle of treatment.~• Level 2 = Hydroxychloroquine 600 mg by mouth two times a day"
26546|NCT03979638|Drug|BLU-5937|Four escalating doses of BLU-5937 administered BID over the course of the study
26547|NCT03979638|Drug|Placebo|Matching placebo for BLU-5937
26548|NCT03979625|Other|Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies|Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.
26549|NCT03979612|Genetic|inclusion of subjects in the GENEPY network|The inclusion of subjects in the GENEPY network follows the genealogical study of a case (index): relatives are identified as potentially at risk. In accordance with the recommendations, but also generally at the wish of the patients (Claes 2003), the index case is then asked to inform its relatives and to propose them to go to an oncogenetic consultation of their choice. If these people reside in the Midi Pyrenees Toulouse oncogenetic consultation is open to them. If following this consultation a mutation is identified or that their genetic risk is considered important, they are proposed to join the GENEPY network for their monitoring.
26550|NCT03979599|Procedure|ultra-sound guided transversus abdominis plan block|comparing ultrasound guided transversus abdominis plan block using combination of magnisum sulphate and levobupivacaine versus levobupivacaine
26551|NCT03979599|Drug|magnesium sulphate& levobupivacaine|magnesium sulphate& levobupivacaine
26552|NCT03979599|Drug|Levobupivacaine|levobupivacaine
26553|NCT03979586|Other|Laser-assisted hyaluronic acid delivery|The facial skin remodeling corresponds to a request for repair treatment on the stigmas of heliodermia, irregularity of cutaneous texture, dyschromias, loss of radiance of the complexion, fine lines, as well as on the fine scars of the face for example, the finely depressed cicatrices sequellaires acne.
26554|NCT03979573|Diagnostic Test|Multiparametric MRI|Multiparametric prostate MRI (mp-MRI)
26555|NCT03979573|Diagnostic Test|Radiomics|Radiomics analyses will consist of image intensity normalization, image coregistration and resampling, radiomic feature extraction, combination with clinical and molecular parameters, feature extraction and machine learning, model testing on validation and test cohorts and comparison to existing clinical risk models.
26556|NCT03979573|Diagnostic Test|MR-guided Biopsy|MR-guided targeted prostate biopsies as well as systematic TRUS-guided biopsies (at least 12 cores) will be performed on a fusion-guided biopsy system. The biopsy cores can either be obtained transrectal or transperineal.
26557|NCT03979573|Diagnostic Test|Molecular Markers|Molecular markers will be analyzed on the initial and final targeted and systematic biopsy cores. The molecular panel consists of a methylation-specific PCR and a set of highly selected markers that can be detected by immunohistochemistry. The resulting data will be prospectively recorded to enable a retrospective analysis of the prognostic value.
26558|NCT03979560|Other|Intervention|Nutritional support in seven sessions spread over three months, combined with an adapted physical activity intervention (APA), also at a frequency of seven sessions spread over three months, or fourteen home sessions.
27151|NCT03974594|Drug|TAS-102|TAS-102 given 20mg orally once under fasting or postprandial conditions per cycle
26559|NCT03979547|Behavioral|Exercise intervention|"Moving Through Cancer: A Guide to Exercise for Cancer Survivors will serve as the framework for an American College of Sports Medicine certified exercise physiologist with additional Cancer Exercise training to teach proper warm up, use of equipment, exercise form, mode of activity, intensity of exercise, flexibility exercises, and cool down."
26560|NCT03979534|Other|low protein diet|Patients will be managed with a restricted protein intake (controlled protein diets with a mean target at 0.6 g / kg / day of protein, according to a choice of dietary approaches, adapted to the situation of each patient).
26561|NCT03979508|Drug|Abemaciclib|Given PO
26562|NCT03979508|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgical resection
26563|NCT03979495|Other|mFOCUS|To evaluate the effectiveness of the system, team and individual components of mFOCUS vs. standard care by conducting a 4-arm cluster randomized controlled trial (RCT) of individuals who are due for follow-up of an abnormal screen.
26564|NCT03979469|Drug|Ketamine, dexmedetomidine|Patients will receive non-opioid analgesics, such as dexmedetomidine, ketamine perioperatively
26565|NCT03979469|Drug|fentanyl, remifentanil|Patients will receive opioid analgesics, such as fentanyl and remifentanil perioperatively
26566|NCT03979456|Drug|Rituximab|After one year in the trial, the patients are split in the two dosing-arms described above. The dose-comparison phase continues four years.
26567|NCT03979443|Procedure|Discharge on the day of surgery|Patient discharge on the day of the surgery, usually within 6-8 hours after procedure
26568|NCT03979430|Other|Home spirometry|Patients will receive a tablet and a spirometer for daily home spirometry. Each patient is supposed to do the home spirometry at the same time every morning. The spirometer and the tablet are connected via Bluetooth. Data will be transferred to a webpage, which team members have access to. Alerts will be automatically send to team members, if the FVC-value decreases about 5% or more within three consecutive days or if the patient does not do the measurement on three consecutive days. Study period is one year. Patients will also conduct a survey to measure health related quality of life (K-BILD). This questionnaire, as well as a phone interview to record changes in medication and condition will be conducted at baseline and every 4 weeks. At baseline and after 3, 6, 9, and 12 months, patients will conduct a 6 minutes walking test, lung function test, blood will be drawn for biomarker analysis, and sputum, nasal swab, and urine samples will be collected and analyzed.
26569|NCT03979417|Other|Blood draw and liver resection|The samples are transferred to the research unit for immunological studies.
26570|NCT03979404|Device|Intermittent Theta Burst Stimulation|The Magstim Rapid2 Magnetic Stimulator (Magstim ®, UK) will be used to administer active TBS.
26571|NCT03979391|Diagnostic Test|Tear collection and lumbar punction|Tear collection and lumbar punction will be performed in order to detect supernumerary oligoclonal bands
26572|NCT03979365|Drug|Envarsus XR|Twice daily tacrolimus vs. Envarsus XR
26573|NCT03979365|Drug|Tacrolimus twice daily|Twice daily tacrolimus vs. Envarsus XR
26574|NCT03979352|Drug|empagliflozin|Treatment with empagliflozin 25mg orally once a day
26575|NCT03979352|Device|artificial pancreas|Insulin delivery via a closed loop single-hormone artificial pancreas system.
26576|NCT03979339|Procedure|Blood sample collection|A total volume of 32 ml of blood will be collected in each subject and separated in 4 10-mL EDTA vacutainer tubes EDTA tubes of 8 mL each.
26577|NCT03979326|Procedure|Static stretching|Static stretching lasting 3 x 45 seconds will be performed in each of the examined women three times in different phases of the menstrual cycle: follicular, ovulatory and luteal. Before and after the intervention, a series of tests assessing the influence of stretching on biomechanical parameters will be carried out
26578|NCT03979313|Drug|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
26579|NCT03979313|Drug|Placebo|Commercially available 0.9% (w/v) saline
26580|NCT03979300|Other|Learning process during role play on psychiatric interview|"Methodology: Mixed method study with:~Quantitative features:~Self-reported questionnaries :  Learning Effectiveness Inventory Scale  (18)~Sociodemographical data and others questions~Qualitative : Grounded Theory~Video-record of simulation and audio-record and briefing and debriefing, quoted with conversational analysis~Semi-structured interview of learners and teachers"
26581|NCT03979287|Other|Interferential Current and Therapeutic Exercise Program|"The Interferential Current Program will be based on a bipolar application using the Sonopuls 692 device (Enraf Nonius, Rotterdam, The Netherlands). The current parameters will be: a) 4000Hz carrier frequency; and b) 60 Hz AMF with a modulation frequency of 90 Hz. The intensity of the current will be adapted to the sensitivity of each patient.~The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~Ergonomic advices on reducing repetitive movements and/or maintained positions~A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
26582|NCT03979287|Other|Therapeutic Exercise Program|"The Therapeutic Exercise Program will be applied by a physiotherapist and will consist of:~Ergonomic advices on reducing repetitive movements and/or maintained positions~A protocol of active physiotherapy for neck and shoulder muscles. This protocol will include: active stretching exercises; isometric muscle strengthening exercises; reeducation of the ocular and neck muscles with control retraining exercises"
26585|NCT03979261|Diagnostic Test|evolution of sex ratio according to age|Histological study of the collected valves to study the differences according to the sex of the inflammatory reaction and the cellular type found.
26588|NCT03979235|Diagnostic Test|Motor function assessment|perform motor function assessment by using scales, sEMG, and inertia sensors
26589|NCT03979222|Device|Extracorporeal Membrane Oxygenation|ECMO provides extracorporeal gas exchange through use of a membrane oxygenator. Blood is drained from a central vein and returned after oxygenation into either the venous or arterial circulation dependent on configuration.
26591|NCT03979196|Other|Inpatient Management|"Admission for a minimum of three days, administration of betamethasone, and clinical reassessment by obstetrician after three days. After the initial three day admission, further management will be at the discretion of their obstetrician who will continue their care and decide if further admissions are needed.~Weekly cervical length assessment will be performed until 28 weeks and patient readmission will be decided by their Obstetrician.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
26592|NCT03979196|Other|Outpatient Management|"Avoid heavy lifting and core exercise, avoid intercourse, weekly assessment of cervical length by ultrasound and administration of betamethasone. Patients will continue with outpatient management for the remainder of their pregnancy with no admission unless the patient develops contractions, PPROM, bleeding, or the cervix is dilated to ≥1cm.~Post-intervention, women in both arms will receive the same standard of care (weekly clinic or inpatient follow-up appointments) and will be followed to delivery. Prior to delivery, participants will complete a patient Quality of Life survey and at delivery, primary and secondary outcomes will be collected."
26593|NCT03979183|Behavioral|Lumbopelvic, stretching, aerobic and relaxation exercises|Intervention program will comprises brisk walks and small choreographies, global and analytical stretching exercises, as well as lumbopelvic stabilization exercises (with intensity and volume progression)
26594|NCT03979170|Procedure|Lung tumor resection|lung tumor resection
26595|NCT03979157|Device|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
26596|NCT03979144|Behavioral|Observational study|This was an observational study of a medical device, through the usability assessment, for the registration of a self-test for the immunodeficiency virus (HIV) screening.
26597|NCT03979131|Combination Product|Avelumab addition to perioperative chemotherapy in GC and GEJC|Avelumab addition to perioperative chemotherapy in GC and GEJC. Peri-operatory treatment consisting of four cycles (each cycle is 14 days) of neoadjuvant chemotherapy (docetaxel, oxaliplatin and fluorouracil/leucovorin) plus avelumab previous to surgery. Surgery is recommended to be scheduled 4 to 6 weeks after the last dose. Afterwards (4 to 10 weeks after surgery), four cycles of adjuvant therapy with the same schema, followed by avelumab up to one year. There will be be a follow-up of 5 years.
26598|NCT03979105|Drug|Ketamine|Drug: Ketamine Side effects associated with ketamine infusion to treat acute pain, were reviewed after 48 hours of exposure and frequency of tachycardia, hypertension, hallucinations, delirium and nightmares were registrated for comparison
26599|NCT03979092|Behavioral|IP-ACLS|"Three senior consultants and 12 trainers conduct 2-day IP-ACLS training.~Pre-class activities: preparation First exposure reading on provider manual and lecturer notes about a new knowledge of ACLS to enhance self-directed learning.~Interactive lecture sessions: 10 topics Interactive lectures (15-20 minutes per topic) introduce a new knowledge, which anchor to their existing knowledge according to ACLS algorithms.~Simulation sessions: 10 sessions Skill sessions (50 minutes per session) used high-fidelity simulation mannequin in a team approach. Students learn through role-playing with different practical scenarios. Experiential learning is focused on hands-on and collaborative strategies for enhancing a deeper learning.~Debriefing: feedback and reflection Trainers provide immediate feedback and discussion throughout the scenarios. Debriefing is focused on the positive aspect and areas for improvement."
26600|NCT03979092|Behavioral|Waitlist|Waitlist group will participate in subsequent IP-ACLS training.
26601|NCT03979079|Radiation|external beam radiation therapy|
26602|NCT03979066|Drug|Atezolizumab|840mg IV every 2 weeks for 2 doses prior to surgery and 4 doses after surgery.
26603|NCT03979066|Drug|PEGPH20|PEGPH20 3ug/kg IV twice weekly for 3 weeks prior to surgery and once weekly for 3 weeks (of 28 day cycle) for two cycles after surgery.
26604|NCT03979053|Device|Multiparametric MRI Scan|Patients attending the clinic will have a MRI scan added to their standard of care.
26605|NCT03979040|Behavioral|Group Transdiagnostic Behavior Therapy|TBT was developed to address transdiagnostic avoidance via the use of four different types of exposure techniques (situational/in-vivo, physical/interoceptive, thought/imaginal, and [positive] emotional/behavioral activation). From the transdiagnostic avoidance perspective, the four exposure practices are matched to the type(s) of avoidance experienced by patients based upon their cluster of symptoms/disorders. Per protocol, the first six sessions of TBT are designed to educate on, prepare for, and practice the four different types of exposure techniques. The next five sessions are focused on practicing and refining exposure practices as participants work through their lists of avoided situations/sensation/thoughts. The final session reviews treatment progress and relapse prevention strategies.
26606|NCT03979040|Behavioral|Group Disorder-Specific Therapy (G-DSTs)|To provide an evidence-based comparison for the G-TBT condition, G-DSTs will be used that are matched to the participant's principal diagnosis. G-DSTs will include groups for the most common principal diagnoses that have VA-approved protocols and training programs, including PTSD (Cognitive Processing Therapy for PTSD) and MDD (CBT-Depression). Each of these G-DSTs have published manuals for administration and have received extensive support in the literature.
26607|NCT03979027|Dietary Supplement|Breakfast: ready-to-eat-cereal and milk|
26608|NCT03979014|Biological|Gardasill 9™ vaccine|3 doses of Gardasill 9™ vaccine 0.5 ml administered 3 times at 0, 2 and 6 month
26609|NCT03979001|Other|complete ophthalmological examination|"collection:~ophthalmological history and current treatments~occular tension measurement~measurement of visual acuity (Snellen chart)~Axial length measurement~Photograph of the posterior segment of the eye~3x3 and 6x6 macular and papillary OCT angiography"
26610|NCT03978988|Device|Carotid Stenting|emergent carotid stenting will be performed if the patient is randomized in the intervention arm. The order to treat (head first or neck first), and the choice of a previous angioplasty of the extracranial carotid artery lesion will be left to the interventionist discretion.
26611|NCT03978988|Drug|Procedural Aspirin|After carotid stenting, an intravenous bolus of 250mg of Aspirin will be given at the end of the procedure in case of absence of complication.
26612|NCT03978988|Drug|Dual dual antiplatelet therapy after 24-hours imaging follow-up|A dual antiplatelet therapy is administered after 24-hours imaging follow-up excluding intracranial hemorrhagic complications (the type and the dose of the dual antiplatelet therapy are left to the discretion of the local practice)
26614|NCT03978975|Behavioral|Food intake|"For all those session, subjects will take a standardized breakfast (570kcal) three hours before experimental session.~Control session (CON): subject will stand sited without any activity during 40 min.~Subjects will be submitted to three aquatic cycling exercise session:~session 27°C :aquatic cycling at 27°C without water jet during 40 min~session 27°C+ water jets : aquatic cycling at 27 °C with water jets during 40 min~session 18°C : aquatic cycling at 187°C without water jet during 40 min Every exercise session will be set at 70% of theorical maximal heart rate During each session, oxygen consumption and carbon dioxide production will be analysed with gas analysis system. Appetite and hunger sensation will be measured with a specific scale at different time point of each day of experimental session. Thirty minutes after the end of each experimental session subjects will have a buffet meal for lunch time."
26615|NCT03978962|Device|Guided Tissue Regeneration|"Covering oral-maxillofacial or a periodontal defects with the Resorbable Collagen Membrane in order to avoid epithelial cell infiltration and to promote periodontal tissues healing.~Covering alveolar bone defects after tooth-teeth extraction."
26616|NCT03978949|Drug|Bacillus Licheniformis|Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
26617|NCT03978949|Drug|Placebo|Two weeks prior to the start of radiation therapy, the placebo is administered three times daily until the end of radiation therapy.
26618|NCT03978936|Behavioral|Medication Therapy Management (MTM) Video Telehealthcare|"MTM is an individualized approach to optimize medication use for improved patient outcomes and is designed to empower patients to take an active role in managing patients' medications thus, providing a favorable strategy for addressing adherence issues. Five core elements define MTM: complete medication therapy review (CMR), creation of a personal medication list (PML), development of a medication action plan (MAP), intervention and/or referral for drug therapy problems, and documentation and follow-up"
26619|NCT03978936|Behavioral|Electronic Adherence Self-Management (EAM)|Participants will have a sensor which monitors their adherence to medication use
26620|NCT03978923|Device|preparation of the implant site with Piezosurgery vs drill|"The surgery was always performed by the same operator (M.M.) to reduce the bias of the study. Loco-regional anesthesia was performed with Mepivacaine hydrochloride with 1:100000 adrenaline.~For the preparation of implant sites using traditional methods, the drills were used following manufacturer's protocol by the implant system in use (WINSIX®- BioSAF IN s.r.l, Trezzano Rosa, Trezzano Rosa, Milano - Italy).~For the preparation of sites was used ultrasonic device, (Surgysonic II, Esacrom S.r.l., Imola, Italy). For the final preparation and insertion of implants, 5-6 ultrasound inserts were used in sequence as follows: tip-shape 1st insert (ES012X) and 2nd insert (ES052XG), crown-shape 3rd insert (ES040), 4th insert (ES041), 5 ° insert (ES043) and 6th insert (ES044).~The implant insertion was performed with a maximum torque of 35 Ncm. Finally, the cap screws were positioned, and the flaps were sutured in Vycril® 3.0."
26621|NCT03978910|Other|measurements of the accuracy of the reaching movements|Euclidian distance between final position and target
26622|NCT03978897|Device|Blood flow restriction tourniquet|A blood flow restriction tourniquet, which impedes arterial flow to extremity at 50% of usual flow.
26623|NCT03978897|Other|Evidence based physical/occupational therapy|Up to date physical/occupational therapy for lateral epicondylitis
26624|NCT03978884|Drug|Losartan 50Mg Tab|Take 1 tab daily
26625|NCT03978884|Drug|Losartan/Hydrochlorothiazide 50 Mg-12.5 Mg ORAL TABLET|Take 1 tab daily
26626|NCT03978884|Drug|Losartan/Hydrochlorothiazide 100 Mg-25 Mg ORAL TABLET|Take 1 tab daily
26627|NCT03978884|Drug|Amlodipine 5mg|Take 1 tablet daily
26628|NCT03978871|Behavioral|Growth Mindset|Growth emotion mindset induction
26629|NCT03978871|Behavioral|Control|Brain education
26630|NCT03978845|Drug|Lidocaine|Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
26631|NCT03978832|Drug|PERSERIS|PERSERIS is an extended-release SC injectable suspension administered once-monthly
26632|NCT03978832|Drug|Risperidone|Oral risperidone
26633|NCT03978819|Device|ANI|"ANI profiles during IPNS (bradycardia/asystole) or excessive analgesia.~During surgery continuous monitoring of ANI, HR and Remifentanil effect site concentration was done and recorded. Event markers were placed at the onset of bradycardia, asystole and the coincidence of ANI>80 + Remifentanil >6ng/mL). ANI values of 1 min before and 1 min after the event were used for analysis."
26634|NCT03978806|Behavioral|Active Comparator: peer navigator - licensed clinical social worker|The intervention is aimed to provide support with social challenges and mental health well-being. The peer navigator will meet with patients to provide support with social challenges while the licensed clinical social worker may provide cognitive behavioral therapy.
26635|NCT03978806|Other|Placebo Comparator: Control Arm (standard of care)|Control patients will have met the same inclusion and exclusion criteria as intervention patients. For all study subjects, we will communicate the outcome of the BDI-II depression screen with dialysis center staff. When a patient is diagnosed with depression, CMS Quality Incentive Program (QIP) requires a 'follow-up plan' which must include at least one of the following: 1) additional evaluation for depression; 2) suicide risk assessment; 3) referral to a practitioner who is qualified to diagnose and treat depression; or 4) pharmacologic interventions.
26636|NCT03978793|Device|MyTPill, a digital pill|MyTPill is a digital pill containing an approved medication
26637|NCT03978780|Procedure|Serratus Block|Ultrasound-guided serratus plane block performed at T3 level in the midaxillary line, superficial to the serratus muscles.
26638|NCT03978780|Procedure|Erector spinae plane block|Erector spinae plane block performed at level of the T3 transverse process, in the fascial plane deep to the erector spinae muscle.
26639|NCT03978767|Drug|Ibuprofen 600 mg|NSAID pain medication to be used in the experimental bundle for postpartum analgesia
26640|NCT03978767|Drug|Ketorolac|NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
26641|NCT03978767|Drug|Acetaminophen|Analgesic medication to be used in both treatment arms
26642|NCT03978767|Drug|Oxycodone|Analgesic medication to be used in both treatment arms
26643|NCT03978754|Diagnostic Test|ICG、CM、VM、BIS、self-report|ways to examine lymphedema
27245|NCT03973710|Dietary Supplement|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
26644|NCT03978741|Device|Yōni.Fit ® Bladder Support|Test Device for this trial is defined as Yōni.Fit ® Bladder Support . The Yōni.Fit ® Bladder Support is a translucent, flexible (i.e., collapsible), cone -shaped, 100% silicone vaginal pessary device.
26645|NCT03978741|Device|Sham Device|The sham device is only the top rim portion of the Yōni.Fit® device. It is made from the same medical grade silicone and manufactured under the exact conditions as the Yōni.Fit® device.
26646|NCT03978728|Device|Extra-corporeal membrane oxygenation|Cardiovascular shock patients received extra-corporeal membrane oxygenation suppot.
26647|NCT03978715|Other|No intervention-retrospective study|This is a retrospective study. No intervention
26648|NCT03978702|Other|Blood sampling|20 mL will be collected at each time point (day-1,day 0, day 1, day 3, day 7, 1 year after pancreatectomy)
26649|NCT03978689|Drug|CUE-101|CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer
26650|NCT03978663|Radiation|Neoadjuvant radiotherapy|Neoadjuvant radiation therapy delivered to a portion of the index tumour for high-risk breast carcinoma for immune priming prior to neoadjuvant radiation
26651|NCT03978650|Other|Observational|Participants from the Canadian Longitudinal Study on Aging will be evaluated for cognitive status, occurrence of falls, and fall-related injuries.
26652|NCT03978637|Drug|Itacitinib|Itacitinib administered orally at the specified dose.
26653|NCT03978624|Drug|Pembrolizumab|200 mg IV on day 1 and day 22
26654|NCT03978624|Drug|Entinostat|5 mg given orally on day 1, day 8 and day 15
26655|NCT03978611|Drug|Relatlimab|Participants will receive IV infusion of relatlimab in Part 1 and Part 2
26656|NCT03978611|Drug|Ipilimumab|Participants will receive IV infusion of ipilimumab in Part 1 and Part 2.
26657|NCT03978598|Drug|Etonogestrel|Immediate v. Standard insertion.
26658|NCT03978598|Device|Nexplanon|Implant.
26659|NCT03978585|Device|high tone external muscle stimulation|Participants receive self-administered home based high tone therapy for 8 weeks for 30 minutes daily after device instruction
26660|NCT03978585|Device|transcutaneous electrical nerve stimulation (TENS) therapy|Participants receive self-administered home based TENS therapy for 8 weeks for 30 minutes daily after device instruction
26661|NCT03978572|Behavioral|Resistance Training|Exercise intervention designed to improve muscular strength and power
26662|NCT03978572|Behavioral|Moderate-Intensity Continuous Cycling|Exercise intervention designed to improve cardiorespiratory fitness and muscular endurance
26663|NCT03978572|Behavioral|High-Intensity Interval Cycling|Exercise intervention designed to improve cardiorespiratory fitness, muscular endurance, and muscular strength and power
26664|NCT03978559|Drug|caspofungin|caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days
26665|NCT03978559|Drug|TMP/SMZ(trimethoprim/sulfisoxazole)|TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days
26666|NCT03978559|Drug|Methylprednisolone|40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days
26667|NCT03978546|Diagnostic Test|Humphrey Visual Field Test|SITA Standard and 24-2 and 10-2 visual field tests
26668|NCT03978546|Diagnostic Test|Optical Coherence Tomography (OCT) Scan|Circle and Wide Angle Scans
26669|NCT03978546|Diagnostic Test|Smart Perimetry - Henson 9000|24+10-2 Smart Supra test
26670|NCT03978533|Behavioral|Family Support Group|Family Support Groups will be piloted with families in community and clinical sites. Each pair of facilitators will pilot two groups of 6 families each. Each group is 4 sessions lasting 2 hours each. Each of the sessions incorporates didactic talks, family discussion, and separate breakout groups for adolescents and adults. Family Support intervention incorporates cognitive-behavioral theory of PM+ which underlies evidence-based techniques focused on stress management and behavioral activation. Family support intervention also incorporates resilience theory, which explains family protective processes that can ameliorate the negative consequences of hardships and challenges and enable healing and growth in families.
26671|NCT03978520|Drug|ABBV-105|ABBV-105 is administered orally as capsule
26672|NCT03978520|Drug|Placebo for ABBV-105|Placebo for ABBV-105 is administered orally as capsule
26673|NCT03978520|Drug|Upadacitinib|Upadacitinib is administered orally as a tablet
26674|NCT03978520|Drug|Placebo for upadacitinib|Placebo for upadacitinib is administered orally as a tablet
26675|NCT03978507|Behavioral|Intelligent cueing|1 month use of an intelligent, wearable device that provides personalized cueing only when FOG is detected
26676|NCT03978507|Behavioral|Feedback about the number of steps|Feedback about the number of steps is given in the intervention group as well as in the control group during the 1-month intervention-period.
26677|NCT03978494|Drug|Advagraf®|Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).
26678|NCT03978494|Drug|Generic tacrolimus|Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)
26679|NCT03978481|Combination Product|Helicobacter pylori eradication (combination therapy)|Antibiotic eradication therapy (triple or quadriple regimen)
26680|NCT03978468|Other|Interagency Collaboration (ICollab)|The intervention has the following components: 1) ICollab Component 1: The Nurse Clinician will review clinic and emergency room (ER) visit notes for clinicians' recommendations and communicate these to the home health nurse (HHN). 2) ICollab Component 2a: The intervention team will meet weekly by phone with HHNs (6 times/ child). The Nurse Clinician will document meeting notes for each child in the ER, communicate this information with the HHN, and share it with the primary care provider (PCP) by routing the note through the ER or faxing the note. 3) ICollab Component 2b: The Nurse Clinician will be available as a resource for the HHN during regular work hours for clinical problem-solving. 4) ICollab Component 2c: the intervention team physician will offer her contact information for clinical problem-solving about the child to the PCP. The Nurse Clinician will communicate with the PCP about the plan developed in the meetings, and changes to plan of care.
26733|NCT03978130|Other|mHealth-CR|Study participants randomized to the intervention (mHealth-CR) arm during the (in-hospital) baseline visit will receive 3 components for their home activity: (1) communication with exercise therapist (in-hospital assessment/counseling followed by regular communication post-discharge), (2) mHealth-CR software, and (3) wearable activity monitoring device.
27246|NCT03973710|Dietary Supplement|Placebo controls|placebo with a similar appearance to probiotics supplement
26681|NCT03978468|Other|Usual Care|The primary medical team identifies the need for home health nursing services for Children with Medical Complexity(CMC), and the hospital care coordinators help caregivers choose a home health agency. Hospital-based physicians write home health orders that are communicated to the home health agency. The clinic manager of the home health agency uses these orders to develop the home health plan of care, Centers for Medicare & Medicaid Services(Form CMS-485) and communicates the plan to the agencies' HHNs. PCPs oversee the home health plan of care.
26682|NCT03978455|Behavioral|Learn, Connect, and Quit Mobile Application|The Learn, Connect, and Quit (LCQ) Mobile Application is an application for electronic tablets that can: assess smokers' interest in quitting; answer smokers' questions about smoking, quitting, and available treatments; provide information about treatment options; communicate information about patients' smoking status, concerns, and treatment interest to their provider; and connect patients with treatment options including the Wisconsin Tobacco Quitline (WTQL), and other smoking intervention resources provided by their healthcare system.
26683|NCT03978442|Behavioral|Smoking Cessation Cognitive Behavioral Therapy (CBT)|12 sessions of cognitive behavioral therapy for smoking cessation, designed to help participants prepare for quitting smoking, make a quit attempt, and stay quit from smoking.
26684|NCT03978442|Drug|Bupropion|All medically eligible participants will be prescribed bupropion to begin 7 days before the quit date and continued through 12 weeks post-quit. Participants will be scheduled to begin at 150mg/day of bupropion for at least 3 days before titrating up to 300mg/day dose of bupropion.
26685|NCT03978442|Behavioral|Cognitive Processing Therapy|12 sessions of CPT, which is a well-established trauma-focused psychotherapy for PTSD that has demonstrated efficacy and effectiveness in Veterans.
26686|NCT03978442|Behavioral|Smoking Abstinence Reinforcement Therapy|Monetary reinforcement for smoking abstinence that is bioverified by breath carbon monoxide and saliva samples.
26687|NCT03978442|Behavioral|Yoked Contingency Management|Participants in the yoked control will receive the monetary reinforcement of their yoked participant regardless of smoking abstinence or session attendance.
26688|NCT03978429|Other|Community-based Pre-eclampsia/Eclampsia Detection and Management|Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
26689|NCT03978429|Other|Strengthened Referral Network from Community to Referral hospital levels|ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
26690|NCT03978416|Behavioral|Healthy Weight for Living for Hispanics|"The Healthy Weight for Living (HWL) intervention, previously developed at the Energy Metabolism Laboratory (HNRCA), is broadly informed by the same behavior change theories as other interventions. For example, it also recognizes individual and environmental factors as potential areas to support behavior change for weight regulation, and provides practical tools for facilitating new habits. However, the HWL places greater emphasis on the role of biology in influencing eating behavior, giving a central role to hunger and food cravings as modulators of eating behavior. Therefore, HWL does not emphasize self-monitoring food intake and does not require increasing physical activity for effectiveness. The new intervention also targets autonomous motivation and prioritizes ease of implementation.~Information from focus groups and sequential pilots will be used to develop a culturally tailored prototype version of Healthy Weight for Living that is acceptable for Hispanic older adults."
26691|NCT03978403|Drug|M207 3.8 mg (two 1.9 mg Patches in foil pouches)|M207 3.8 mg administered as two 1.9 mg Patches packaged in foil pouches
26692|NCT03978403|Drug|M207 3.8 mg (two 1.9 mg Patches in cups)|M207 3.8 mg administered as two 1.9 mg Patches packaged in cups
26693|NCT03978403|Drug|M207 3.8 mg (two 1.9 mg Patches packaged in cups|M207 3.8 mg administered as two 1.9 mg Patches packaged in foil pouches, Treatment A
26694|NCT03978403|Drug|Zolmitriptan 2.5 mg Nasal Spray [ZOMIG]|Zolmitriptan 2.5 mg/0.1 mL Nasal Spray [ZOMIG]
26695|NCT03978390|Behavioral|behavioral priming|Priming the children with images of superheroes in order to behave desirably during the dental injection
26696|NCT03978390|Behavioral|endowment effect|Giving the rewards to children before starting the dental treatment and telling children they can only keep it if they behave desirably during the dental procedure
26697|NCT03978390|Behavioral|Positive reinforcement|Giving rewards to the children at the end if they cooperate desirably during the treatment
26698|NCT03978364|Drug|Azacitidine combined HHT|Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days
26699|NCT03978364|Drug|Azacitidine regimen|Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle
26700|NCT03978338|Dietary Supplement|brain polypeptide solution|The experimental group will take the brain polypeptide solution 60ml per day which contains nitrogen 90mg, soybean oil ,glycerin and soybean phospholipids in 84days.
26701|NCT03978338|Other|same package of placebo|The control group was treated with the same package of placebo 60ml per day which contains soybean oil ,glycerin and soybean phospholipids in 84 days.
26702|NCT03978325|Other|Control|The control group will receive standard pre-operative care. This involves standard pre-operative advice and a moderate intensity preoperative exercise programme.
26703|NCT03978325|Other|Exercise - HIIT Intervention|"The HIIT intervention will take the form of a supervised programme, completed for at least two weeks, up to 5 days per week preoperatively. The HIIT intervention will be performed on a cycle ergometer. Exercise sessions will be individually supervised and scheduled at a time of convenience for each participant. Each exercise session will last 40 minutes and will include warm-up, exercise training and cool-down components. Lactate threshold, measured during the baseline CPT, will be used to determine the exercise intensity.~The training protocol will prescribe 15 second intervals of exercise and passive recovery. The highest resistance reached during the baseline CPET (measured in watts) will be recorded as the peak power output (PPO). During training, participants will undergo a 5-minute warm-up at 50% PPO, followed by up to 30 minutes of HIIT with intervals of 15 seconds at 100% PPO with 15 second recovery periods at 0 watts."
26704|NCT03978312|Other|Nominal consensus group|Nutrition Health Literacy Measurement Tool adaptation (NLit-UK)
26705|NCT03978312|Other|electronic tool completion|Nutrition Health Literacy Measurement Tool validation (NLit-UK)
26706|NCT03978312|Other|Patient Survey|Nutrition information cancer patient experience survey
26707|NCT03978312|Other|Friends and Family Survey|Nutrition information friend and family of cancer patients experience survey
26708|NCT03978299|Diagnostic Test|Positive Prostate-Specific Antigen test result|Positive PSA test result as part of opportunistic screening or due to the presence of symptoms suggestive of disease.
26709|NCT03978286|Drug|Vortioxetine|10 mg per day
26710|NCT03978286|Drug|Sertraline|75 mg per day
26711|NCT03978273|Device|Night-time brace + virtual-brace|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Additionally :~They will perform 5 sessions of postural rehabilitation exercises per week (each of 30 minutes) with the virtual-brace (MD).~They will have also follow up consultations with a physiotherapist every 21 days, to evaluate treatment observance and to adapt postural exercises according to the results and difficulties encountered.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
26712|NCT03978273|Other|Night-time brace only|"Patients will receive conventional treatment : wearing a night-time brace every night during 6 months.~Conventional 3D motion capture Analysis (different trunk tasks and walk) will be performed to evaluate evolution of postural parameters at D0, D90 and D180."
26713|NCT03978247|Diagnostic Test|NASHMIR|An additional blood sample will be taken upstream of the surgical procedure and a liver biopsy will be performed in all included patients. The two results obtained by the spectroscopic test and by means of the biopsy will then be compared to determine the diagnostic performance of the developped test (NASHMIR test).
26714|NCT03978234|Drug|AbobotulinumtoxinA 300 UNT|AbobotulinumtoxinA 300 UNT
26715|NCT03978221|Other|Post-extubation TDI|A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.
26716|NCT03978208|Drug|ATB-346 low dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
26717|NCT03978208|Other|Placebo|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
26718|NCT03978208|Drug|ATB-346 mid-dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
26719|NCT03978208|Drug|ATB-346 standard dose|Double blind comparison of orally administered ATB-346 versus placebo in osteoarthritis patients
26720|NCT03978195|Device|Non-invasive device for middle ear ventilation|Daily use of the device
26721|NCT03978182|Device|accelerated deep rTMS|A Magstim Rapid2 Plus1 Magnetic Stimulator connected to the Brainsway dTMS system with the H1-coil investigational device (Brainsway Ltd, Jerusalem, Israel). The coil is situated inside a helmet to achieve effective cooling during stimulation. A sham coil is also included in the same helmet. The sham coil mimics scalp sensations and the acoustic artifact of the active stimulation without inducing neuronal activation.
26722|NCT03978169|Diagnostic Test|pleuropulmonary ultrasound|three pleuro-pulmonary ultrasound scans will be performed, preoperatively on the day of surgery, post-operatively in the recovery room and the day after surgery
26723|NCT03978156|Drug|Dronabinol|2.5 mg of dronabinol. In the initial 2 to 3 days of each treatment period, study agent dose will be rapidly titrated from a starting dose of dronabinol (or placebo) 5 mg twice daily to a maximum well tolerated dose (MWTD) of up to 10 mg twice daily
26724|NCT03978156|Drug|Placebo oral tablet|Placebo oral tablet
26725|NCT03978143|Drug|Treatment A|Single 250 mg crizotinib dose as coated microsphere 1 (cMS1) formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
26726|NCT03978143|Drug|Treatment B|A single 250 mg crizotinib dose as coated microsphere 2 (cMS2) formulation will be administered on the morning of Day 1 after overnight fast of at least 10 hours.
26727|NCT03978143|Drug|Treatment C|A single 250 mg crizotinib dose as FC formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
26728|NCT03978143|Drug|Treatment D|A single 250 mg crizotinib dose as OS will be administered on the morning of Day 1 after an overnight fast of at least 10 hours.
26729|NCT03978143|Drug|Treatment E|250 mg crizotinib as cMS1 formulation will be administered with high-fat, high-calorie meal after an overnight fast of at least 10 hours.
26730|NCT03978143|Drug|Treatment F|250 mg crizotinib as cMS2 will be administered with a high-fat, high-calorie meal after an overnight fast of at least 10 hours.
26731|NCT03978143|Drug|Treatment G|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS1 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
26732|NCT03978143|Drug|Treatment H|"40 mg esomeprazole will be administered~1 hour prior to dinner on Day -5 through Day -1. A single 250 mg crizotinib dose as cMS2 formulation will be administered on the morning of Day 1 after an overnight fast of at least 10 hours."
26734|NCT03978130|Other|Usual Care|Participants randomized to the usual care group will receive a tablet computer in order to complete the weekly ADL assessment. They will also receive a wearable activity monitoring device.
48890|NCT03802058|Drug|Carboplatin|Carboplatin AUC=2 for Injection weekly
26735|NCT03978117|Dietary Supplement|Watercress Preparation|Watercress powder containing gluconasturtiin, which when added to a provided juice, will result in a target dose of up to 40 mg/day of 2-phenethyl isothiocyanate (PEITC). Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
26736|NCT03978117|Dietary Supplement|Placebo Preparation|Identical placebo powder added to a provided juice. Preparation consumed at breakfast, lunch and dinner 3x daily for 2 weeks.
26737|NCT03978104|Dietary Supplement|Okara biscuits|Consumption of okara-enriched biscuits together with habitual diet.
26738|NCT03978104|Dietary Supplement|Bio-okara biscuits|Consumption of bio-okara-enriched biscuits together with habitual diet. Bio-okara is a form of fermented okara.
26739|NCT03978104|Dietary Supplement|Control biscuits|Consumption of control biscuits together with habitual diet.
26740|NCT03978091|Drug|AZACTAM|A synthetic monobactam antibiotic originally isolated from Chromobacterium violaceum
26741|NCT03978091|Drug|Ceftazidime-Avibactam|An antibacterial combination product containing ceftazidime and avibactam
26742|NCT03978078|Other|Biological collection|- Blood samples collected at different times : Before treatment, during treatment (approximately every other month) through the end of treatment
26743|NCT03978065|Diagnostic Test|Confocal microscopy|"For this purpose live stains will be combined with a confocal imaging setup equipped with 6 laser lines. A major advantage of this technique is that tissue specimens do not need to be fixed prior to analysis. Such an approach does not only allow tissue viability and integrity assessment in an unprecedented speed and accuracy, but also promises to shed new light into quality assessment and prognosis in kidney transplantation. The investigators herein wish to establish the predictive values of this technology in kidney transplantation.~The methodology used in this trial is referred to as BIOPSYCHRONOLOGY - as a reference to dendrochronology, or tree ring dating. Leaving the biopsy sample intact facilitates its analysis, just as drills are used for tree-ring counting."
26744|NCT03978052|Dietary Supplement|EGCG|"Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up).~Participants that weight <50kg intake one oral dose in the morning for breakfast (266 mg/EGCG, 49 of Font-up"
26745|NCT03978052|Dietary Supplement|Placebo EGCG|Participants that weight >50kg intake one oral dose in the morning for breakfast and a second dose in the afternoon in (266 + 266 mg/EGCG, 49 + 49 g of Font-up)
26746|NCT03978052|Other|Personalized intervention|A personalized intervention include a physical activity plan,dietary intervention, mental health promotion interventions,
26747|NCT03978052|Other|Lifestyle recommendations|The recommendations are to balance caloric intake and physical activity to achieve and maintain a healthy body weight; consume a diet rich in vegetables and fruits;
26748|NCT03978039|Drug|Chemotherapy|treatment as per standard of care
26749|NCT03978039|Drug|Immunotherapeutic Agent|treatment as per standard of care
26750|NCT03978039|Drug|target treatment|treatment as per standard of care
26751|NCT03978039|Procedure|Surgery|treatment as per standard of care
26752|NCT03978039|Radiation|Radiotherapy|treatment as per standard of care
26753|NCT03978026|Behavioral|Nap|Each participant is compared to himself in 4 conditions,
26754|NCT03978013|Other|Pomegranate juice|Pomegranate juice
26755|NCT03978013|Other|Apple juice|Apple juice
26756|NCT03978000|Drug|IBP-9414|Oral suspension
26757|NCT03978000|Drug|Placebo|Sterile water
26758|NCT03977987|Drug|nucleos(t)ide analogue|Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
26759|NCT03977974|Drug|LY3526318|Administered orally
26760|NCT03977974|Drug|Placebo|Administered orally
26761|NCT03977948|Other|semi-structured systemic interview|Semi-structured systemic interviews will be conducted with families who have benefited from the preparation for surgery through play. Other tools such as the logbook and the socio-demographic questionnaire will also be used. The themes that will emerge from these interviews will provide a better understanding of what these families are going through, how the proposed intervention may or may not have met their expectations, and provide insights so that health care services can build their own surgical preparation programs.
26762|NCT03977935|Device|the second-generation MCCG|Patients in the experimental group swallowed the second-generation MCCG (Ankon Navicam-2).
26763|NCT03977922|Other|Diet group|The diet group will be involved in a 12-week pilot nutrition program that will be based on the anti-inflammatory diet previously studied by Allison and Ditor (2015).
26764|NCT03977896|Procedure|11C-MET PET/MRI|"Except PET/MRI imaging, all the examinations will be done according to the patient's usual care.~PET/MRI imaging will be realized within max 7 days after children enrollment, and the surgery (usual care) will be performed within max 4 days after PET/MRI imaging.~PET/MRI imaging will include the following sequences: T1axial, Diffusion, Magnetic susceptibility post-Gadolinium injection, 3DT1 pre and post-Gadolinium injection, and Arterial Spin Labelling Imaging (ASL)."
26765|NCT03977870|Other|vital status determination|consultation of national registries
26766|NCT03977844|Other|Technical Assistance|"TA for Individual Programs TA uses experts to train program staff via webinars and site visits, using the same toolkits as CEP, in a train the trainer approach. TA provides a series of webinars and as needed site visits, focused in the example of depression care on team support for assessment, treatment support as appropriate with medication and/or psychotherapy, case management and educational resources and access to intervention toolkits. It also includes webinars and training toolkits for agencies on domains of social risk factors for health (financial security and housing security) as well as disaster preparedness and recovery."
26767|NCT03977844|Other|Community Engagement and Planning|CEP for Coalitions CEP creates multi-sector networks to collaborate in evidence-based and community-prioritized toolkits or intervention materials. CEP supports a series of biweekly to monthly meetings to develop network and individual program capacity, prepare stakeholders as co-leads, and create a written training plan following CPPR principles [48, 64]. CEP councils consider local context, i.e., cultural assets and stakeholder input. Disaster preparedness and public health sectors will be encouraged to offer education/resources on social determinants and disasters within CEP training plans. CEP will be supported by a Learning Collaborative, meeting 2-3 times, using activities such as project examples, tabletop exercises and self-assessment to identify gaps and formulate goals for improvement.
26768|NCT03977844|Other|Community Resources (CR)|The CR app will primarily provide informational resources and referral information relevant to the local community. We will identify resources for depression, social determinants and disaster preparedness and response within each community during planning with local stakeholders.
26769|NCT03977844|Other|Community Resources + eBT|"The CR+eCBT app consists of the functionality of the CR app along with an interactive component to support CBT-informed coping with mood and stressors at the individual level. This component was developed previously by our group using participatory methods with community partners and includes interactive support to enhance social support networks, support cognitive restructuring (framed through partnered input as Catch it, Check it, Change it), and encourage pleasant activities [65]. Participants will receive text message notifications (with frequency set by participants, up to several times per day) and can either reply back to messages to explore content or click a link in the message to access the interactive mobile app."
26770|NCT03977831|Procedure|Radical Cystectomy|Participants are randomly and blinded assigned
26771|NCT03977818|Drug|Chemotherapy|intervention as per recommendations
26772|NCT03977805|Drug|Hetrombopag Olamine|a single oral taking
26773|NCT03977792|Drug|BOR15001L7|BOR15001L7 topically applied to infected area, 5 times a day, until complete healing of the infection.
26774|NCT03977792|Drug|Docosanol Cream 10%|Comparator product topically applied to infected area, 5 times a day, until complete healing of the infection.
26775|NCT03977779|Device|Placement of ARCHIMEDES fast biodegradable stent during the Endoscopic Retrograde CholoangioPancreatography|The ARCHIMEDES Fast biodegradable pancreatic stent will be placed during the Endoscopic Retrograde CholoangioPancreatography
26776|NCT03977766|Procedure|Chemotherapy prevalidation|"Outpatient Chemotherapy prevalidation will done~with the help of a nurse, using the digital application, for cycle 2 and 3.~by the patient alone, using the digital application, for cycle 4 and 5."
26777|NCT03977753|Drug|2LVERU® or 2LVERU® JUNIOR|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
26778|NCT03977753|Drug|Placebo|"The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.~The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day."
26779|NCT03977740|Other|chest PNF|Chest PNF technique includes oblique downward pressure at sternum, diagonal pressure at lower rib cage at supine line, caudal medial pressure at side lying, Caudal pressure at ribcage at prone lying, dorsal and caudal pressure at prone on elbow.
26780|NCT03977740|Other|Conventional|conventional chest physiotherapy treatment, which includes Deep breathing exercise, Diaphragmatic breathing exercise, segmental breathing exercise and purse lip breathing and incentive spirometer
26781|NCT03977727|Drug|Fiasp®|Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
26782|NCT03977727|Drug|Novolog®|Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
26783|NCT03977727|Device|670G hybrid closed loop continuous subcutaneous insulin infusion system|CSII
26784|NCT03977714|Device|Zirconia implants with G3-coated abutments (test implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
26785|NCT03977714|Device|Zirconia implants with control abutments (test implants, negative control abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
26786|NCT03977714|Device|Titanium implants with G3-coated abutments (control implants, test abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
26813|NCT03977480|Drug|Hemay007|Hemay007 will be orally administered.
26814|NCT03977480|Drug|Placebo|Placebo
27247|NCT03973697|Drug|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
48929|NCT03801798|Drug|GC1102|NAs antivirals+GC1102 180,000 IU
26787|NCT03977714|Device|Titanium implants with control abutments (negative control implants and abutments)|"Test and control interventions correspond to those usually applied in dental implantology. The two-step protocol will be followed. Local anesthesia will be applied. A flap will be raised to perform a progressive perforation with a gradual increase of the orifice and a profuse irrigation until the bone preparation adapts perfectly to the implant. Implants will wear a closure cap and will be covered within the gingival flap during osseointegration (eight weeks), after which they will be exposed to evaluate secondary stability and to place the abutment, for which local crestal anesthesia will be applied. To expose the closure cap, a tissue punch will generally be used. Once placed, the abutments will not be removed from the implants. All abutments will be covered with a PEEK healing cap during prosthesis fabrication. Finally, the implants will be rehabilitated with fixed prostheses according to the needs of each patient. A follow-up period of 1 year is expected."
26788|NCT03977714|Device|Zirconia implants and titanium implants, for histological and histomorphometric evaluation.|"6 implants (3 tests and 3 controls) will be used to evaluate and compare osseointegration, via histological and histomorphometrical analysis, in the area of the wisdom teeth (non useful sites that will not interfere with the rest of the study or the patient's life) - it can only be performed in patients who no longer have these teeth. The procedure will match that described for Groups A-B-C-D. In this case, implants will only remain in the mouth for 2 months, after which they will be removed for analysis. The extraction will be performed with local anesthesia. A flap will be raised to expose the implant and, using a trephine bur (1 mm wider than the implant diameter), a bone cylinder containing the implant will be extracted. The resulting bone defect and regeneration process will be similar to those following a normal molar extraction. The flap will be sutured and primary curing is expected. A new implantation will not be carried out since in this area it is totally unnecessary."
26789|NCT03977701|Behavioral|Phonological treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of speech sound targets following the methodology of Gierut and colleagues. Up to 100 productions will be targeted per 1-hour session.
26790|NCT03977701|Behavioral|Morpheme treatment|The clinician will provide models, verbal and/or tactile cues, and/or conversational recasts of targeted morphemes following the methodology of Plante and colleagues. A minimum of 50 productions will be targeted per 1-hour session.
26791|NCT03977688|Device|Cytokin Adsorption|Haemadsorption with Cytokin Adsorber (Cytosorb)
26792|NCT03977675|Drug|Ketamine|Patients are assigned to one of three ketamine doses (0.3, 0.5, or 0.7 mg/kg) that will be administered intravenously.
26793|NCT03977662|Combination Product|Co-transplantation of PTG with pancreatic islets|Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
26794|NCT03977649|Drug|erenumab|erenumab 140 mg sc every 4 weeks
26795|NCT03977649|Drug|placebo|placebo sc every 4 weeks
26797|NCT03977584|Drug|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
26798|NCT03977584|Drug|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or IV (every 4 weeks) for at least 260 weeks.
26799|NCT03977584|Other|[^18F]GTP1|IV [^18F]GTP1 will be administered up to three times. The first primary [^18F]GTP1 tau PET scan will occur during any visit in the main protocol NCT01998841 (GN28352) from Week 130 to Week 224 and the second [^18F]GTP1 tau PET scan from Week 248 to Week 260. The third and optional [^18F]GTP1 tau PET scan will supplement the two primary scans.
26800|NCT03977571|Procedure|Cytoreductive nephrectomy|Partial or complete nephrectomy by open, laparoscopic, or robotic approach.
26801|NCT03977571|Drug|Nivolumab|i.v 3mg/kg every 3 weeks for a total of 4 doses, as induction, followed by nivolumab monotherapy, 6 mg/kg or max 480 mg every 4 weeks, as maintenance
26802|NCT03977571|Drug|Ipilimumab|i.v 1 mg/kg every 3 weeks for a total of 4 doses, as induction
26803|NCT03977571|Other|Tissue sampling|Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
26804|NCT03977558|Behavioral|Intervention group|Isocaloric diet including ~50g canola oil
26805|NCT03977558|Behavioral|Control group|ESC/EAS Guidelines for the management of dyslipidemias
26806|NCT03977545|Diagnostic Test|Actigraphy|Actigraphy will be realized twice a day during 30 minutes and Lipsitz scoring system will be realized at the same moment to analyze the correlation between Lipsitz scoring system and actigraphy in each arm.
26807|NCT03977532|Other|Micro-blood sampling|capillary sampling of 40 microliters performed at the fingertip
26808|NCT03977519|Procedure|MA|Huatuo Brand needles (0.30×25mm,0.30×40mm or 0.30×75mm) will be used.Participants will receive manual acupuncture for 30 minutes each time.After acupuncture,we will twist the needles every 10 minutes for about 30 seconds.The patients will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
26809|NCT03977519|Procedure|TENS|Huatuo Brand electrode patch (50mm×50mm) and the SDZ-V EA apparatus (Suzhou Medical Appliance) will be used.Participants will receive transcutaneous electric nerve stimulation for 30 minutes each time.They will be treated in their first day of dysmenorrhea, once a day for three consecutive days. And the treatments will last for three consecutive menstrual cycles.
26810|NCT03977506|Diagnostic Test|On-road driving evaluation|"The data assessed during the road test from the two assessment grids (recommendations of the HAS and Test ride for investigation practical fitness to drive) :~road position, vehicle control, track management, safety distances, speed, visual behavior, traffic signs, vehicle overtaking, anticipatory reactions and capabilities adaptation, attentional skills, decision-making, communication with other road users, assessment of specific situations such as insertion on a 2x2 lane, mechanical management and general impressions."
26811|NCT03977493|Drug|Xeomin|One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
26812|NCT03977493|Drug|Placebo - Concentrate|One injection in each muscle.
26815|NCT03977467|Drug|Atezolizumab|In Arm A, patients with NSCLC will be randomized 1:1 to either chemotherapy plus atezolizumab at a flat dose of 1200 mg IV every 3 weeks or chemotherapy alone until progression or unacceptable toxicity.
26816|NCT03977467|Other|Chemotherapy (Arm A Only)|Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks. Platinum chemotherapy may be cisplatin or carboplatin chosen based on histology and at the discretion of the treating investigator. It should be administered according to the directions in the approved labeling.
26817|NCT03977454|Procedure|Nerve Block|"Nerve blocks (QLB/LFCNB) to be placed preoperatively with DEX/MPA, per standard of care of anesthesia block service.~QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA~LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA"
26818|NCT03977454|Procedure|Periarticular Injection (PAI)|"Intraoperatively, the surgeon will perform PAI per standard of care with the medications:~1. 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA"
26819|NCT03977454|Drug|Ropivacaine|60 ml 0.2% ropivacaine
26820|NCT03977454|Drug|Dex|10 mg DEX/ 80 mg MPA
26821|NCT03977441|Drug|Agomelatine or PIacebo|control group:Pramipexole+pIacebo experimental group:Pramipexole+Agomelatine
26822|NCT03977428|Other|standard of care|No intervention, this a patient registry and is purely an observational study
26823|NCT03977402|Other|Biological specimen collection|Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.
26824|NCT03977389|Procedure|Total wrist denervation|Study of the files
26825|NCT03977376|Other|Guide of hosting|Guide of hosting with information about hospitalization to decrease anxiety
26826|NCT03977363|Drug|Anticoagulant drugs|Anticoagulant drugs
26827|NCT03977350|Device|EEG monitoring|EEG monitoring under general anesthesia
26828|NCT03977337|Procedure|Major emergency abdominal surgery|Major emergency gastrointestinal surgery performed within 72 hours of an acute admission or an acute reoperation.
26829|NCT03977324|Procedure|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
26830|NCT03977324|Procedure|Connective Tissue Graft|CTG will be positioned in the buccal aspect of the peri-implant tissue
26831|NCT03977311|Device|Sonalleve Magnetic Resonance-guided High Intensity Focused Ultrasound (MR-HIFU)|-To be used in conjunction with radiation therapy in the treatment of locally advanced cervical carcinoma patients
26832|NCT03977311|Radiation|Radiation therapy|-Standard of Care
26833|NCT03977298|Procedure|Chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine
26834|NCT03977298|Procedure|CTG|CTG will be positioned in the buccal aspect of the peri-implant tissue
26835|NCT03977285|Procedure|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
26836|NCT03977272|Drug|Combination drug|Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly
26837|NCT03977272|Drug|Chemotherapy|modified-FOLFIRINOX
26838|NCT03977259|Other|Individually targeted fortification|"Abbott liquid protein and/or medium chain triglyceride are added routinely to ensure that the base milk has protein 1 g/dL and calories 67/dL."
26839|NCT03977246|Behavioral|Open-placebo|Application of the open-placebo intervention
26840|NCT03977246|Behavioral|Control|Application of the control session
26841|NCT03977233|Drug|Oxaliplatin|85 mg/m2 in 250 cc Dextrose solution given by IV on Day 1 of each 14-day cycle
26842|NCT03977233|Drug|Leucovorin|400 mg/m2 in 100 cc dextrose solution given with irinotecan by IV on Day 1 of each 14-day cycle
26843|NCT03977233|Drug|Irinotecan Hydrochloride|180 mg/m2 in 500cc dextrose solution given with leucovorin by IV on Day 1 of each 14-day cycle
26844|NCT03977233|Drug|5-FU|400 mg/m2 bolus and then 2400 mg/m2 via continuous infusion on Day 1 of each 14-day cycle
26845|NCT03977220|Drug|Nab-paclitaxel combined with S-1|Nab-paclitaxel combined with S-1 treating diffuse type of stage Ⅲ gastric cancer as adjuvant setting
26846|NCT03977207|Drug|Levothyroxine Sodium|Thyroid hormone supplement
26847|NCT03977207|Drug|Placebos|Placebo oral capsule
26848|NCT03977194|Drug|Carboplatin|AUC 6 every 4 weeks
26849|NCT03977194|Drug|Paclitaxel|90 mg/m² D1, 8, 15, every 4 weeks
26850|NCT03977194|Drug|Atezolizumab|1200 mg every 3 weeks
26851|NCT03977181|Behavioral|Group-based Community Health Club|GBHCs will be facilitated by trained Lay Health Counsellors (LHC). GBHCs will consist of a maximum 20 participants. GBHC sessions will held multiple times a month in each study area, allowing for flexibility for study participants. Sessions will be held at a safe and secure, centrally located area within the study community, and will be regularly monitored and assessed by the study coordinator. Participants will be invited to join a club-specific WhatsApp group to facilitate group communication and adherence support throughout the month. They will also be invited to partner up with another participant to provide mutual peer support. Permission will be sought from group-based adherence support participants before they are added to WhatsApp groups. Group adherence counsellors assigned will be members of WhatsApp groups, and will monitor all shared content to ensure that no inappropriate content or private information is shared in the group.
26878|NCT03976960|Other|Biological collection|The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
26879|NCT03976934|Drug|Tamsulosin|administration of tamsulosin tablets
26880|NCT03976934|Drug|Placebo oral tablet|sugar pills
26881|NCT03976921|Diagnostic Test|Integration of CCTA with stress CTP when indicated|When judged indicated, functional assessment with stress CTP perfusion will be performed on top of CCTA.
26882|NCT03976921|Diagnostic Test|Standard of care approach|(a) functional non-invasive tests (stress ECG, or imaging-based tests such as Stress Echo, Stress CMR, SPECT or PET) as a gatekeeper for ICA; (b) direct referral to ICA.
26852|NCT03977181|Behavioral|Individual-based Adherence Support|IAS participants will be matched to a LHC and will schedule IAS sessions once-a-month for the duration of the study. These sessions will be held at a centralized location within the study community. The sessions will be semi-structured to allow for participant-driven discussion of any adherence challenges and key-messages. The adherence curriculum will also explore motivations for PrEP and adherence and focus on practical adherence tips, environmental cues, integration of PrEP within daily routines, short-term goal-setting, problem-solving, safe PrEP disclosure and social support, risk reduction counselling, partner communication, and HIV risk perception. A subset of IAS sessions will be audio-recorded for quality assurance by investigators and the study coordinator. These recordings are for training purposes only and will not form part of the dataset. Consent for recording IAS sessions will be sought from participants during the pre-enrolment consent process.
26853|NCT03977168|Procedure|Application of circumferential pelvic compression (CPC) device|Application of circumferential pelvic compression (CPC) device used at any time within 24 hours of injury
26854|NCT03977155|Drug|BOS-589|oral tablets
26855|NCT03977155|Drug|Placebo|oral tablets
26856|NCT03977142|Diagnostic Test|Radical 7 Masimo Hemoglobin pulse co-oximeter non invasive monitor|Measure hemoglobin levels non invasively by pulse co-oximeter
26857|NCT03977129|Device|QFR-guided strategy|In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR > 0.80, then no CABG revascularization of target blood vessels will be carried out.
26858|NCT03977129|Other|CAG-guided strategy|In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.
26859|NCT03977116|Drug|SLGT2|These patients will receive SLGT2 therapy after catheter ablation.
26860|NCT03977116|Drug|Placebo|These patients will receive placebo therapy after catheter ablation.
26861|NCT03977103|Biological|High dose irradiation conditioning + Treg/Tcon|High dose irradiation based conditioning regimens followed by infusion of donor regulatory and conventional T cells and purified CD34+ hematopoietic stem cell transplantation
26862|NCT03977090|Drug|GB226|GB226 3mg/kg, q2w, iv.
26863|NCT03977090|Drug|Fruquintinib|Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
26864|NCT03977077|Drug|Albumin binding taxol|125mg/m2, d1, 8, intravenous infusion for 30min, 1 cycle every 3 weeks;Other combined chemotherapy drugs and drug doses shall be administered by clinicians according to the guidelines and the actual situation of clinical patients.
26865|NCT03977064|Behavioral|Life style change and weight reduction|Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.
26866|NCT03977051|Behavioral|Focus group|Kidneys transplant patients will discuss their attitudes and beliefs towards immunosuppressant medication adherence
26867|NCT03977038|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation (rTMS) is prescribed as first-line treatment for TRD patients (4). rTMS is safe, tolerable and non-invasive neurostimulation procedure where powerful magnetic pulses are transmitted through the skull into the underlying cortical cortex with the aim of electrical current induction within the neural tissue. This study administers a standard dose of rTMS treatment to the TRD patient sample consisting of high frequency deep TMS (HF-dTMS) stimulation over left dorsolateral prefrontal cortex (L-DLPFC), at the frequency of 18Hz, at 120% value of the individual's motor threshold, in 5 daily sessions per week, taking place each weekday, over the course of 6 weeks. The technology of dTMS, which will be used in this study, is an adaptation of the therapeutic intervention of rTMS with the advancement of possessing higher efficacy in targeting deeper brain regions of interest.
26868|NCT03977025|Diagnostic Test|Lumbar punction|Patients will be evaluated prior to surgery with the Montreal Cognitive Assessment (MoCA) to determine the presence of cognitive impairment, and CSF samples, obtained by lumbar punction, will be analyzed by immunodetection of Aβ40, Aβ42, tau and ptau with multiplex technology
26869|NCT03977012|Drug|Buprenorphine|5~20 mcg
26870|NCT03976999|Other|Biological collection|"Blood samples collected at different times : Before treatment (T1) , after chemotherapy (T2), after interval surgery (T3) and after cancer reccurence (T4)~Tissue samples (tumor tissue and healthy tissue) collected during the surgery"
26871|NCT03976986|Device|continuous-flow portable oxygen concentrator (cPOC)|SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).
26872|NCT03976986|Device|pulsed-flow portable oxygen concentrator (pPOC)|InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
26873|NCT03976973|Drug|Bromelain, Stem|An intratumoural injection of Bromelain 30-45mg or an intraperitoneal injection of Bromelain 60mg will be administered via a radiologically drain in combination with Acetylcysteine in 5% glucose.
26874|NCT03976973|Drug|Acetylcysteine|An intratumoural injection of Acetylcysteine 1.5mg or an intraperitoneal injection of Acetylcysteine 2g will be administered via a radiologically drain in combination with Bromelain in 5% glucose.
26875|NCT03976973|Procedure|Interventional radiology insertion of drain|Under radiological guidance (CT), a needle, wire, dilator will be placed directly into the tumour then a large pigtail drain (i.e. 10Fg) will be placed into the tumour by an experienced, interventional radiologist, under standard procedures.
26876|NCT03976973|Diagnostic Test|Pathology: blood testing during intervention|Blood tests are taken 3 hours after each drug intervention then 24 hours following the last drug intervention to assess for short-term systemic side effects and measure pharmacokinetics of bromelain and acetylcysteine.
26877|NCT03976973|Other|Routine follow up|Patients will have outpatient reviews at 1 week and 1, 3, 6, 9 and 12 months post drug intervention. Blood tests will be performed at 1 week and 1, 3, 6, 9 and 12 months after the drug intervention to assess for short and long term systemic side effects. At 1, 3, 6, 9 and 12 months post drug intervention, a CT-scan is part of the study protocol to assess for response and progression of disease.
26883|NCT03976908|Device|Deep Brain Stimulation|High frequency deep brain stimulation in the medial geniculate body of the thalamus.
26884|NCT03976895|Procedure|Supine position (SP)|"Infants under high flow nasal cannula (HFNC) will be positioned in the supine position.~Patients may be positioned temporarily in lateral position between periods of supine position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
26885|NCT03976895|Procedure|Prone position (PP)|"Infants under high flow nasal cannula (HFNC) will be placed in the prone position during at least 24 hours over the first 48 hours. The positioning will be standardized (chest on the bed plan and abdomen cleared) and children should be placed in the prone position immediately after randomization.~Patients may be positioned temporarily in lateral position between periods of prone position to limit ventilatory disorders, as it is usually done in critical care units during bronchiolitis."
26886|NCT03976882|Drug|Hetrombopag|Hetrombopag oral tablet 5mg once daily for 14 days from 7 days prior to chemotherapy treatment.
26887|NCT03976882|Drug|Placebo|Placebo oral tablet (vehicle) 5mg once daily for 14 days from 7 days prior to chemotherapy treatment.
26888|NCT03976869|Drug|AZD7594|During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
26892|NCT03976817|Procedure|aortic valve replacement|After median sternotomy, cardiopulmonary bypass (CPB) was established between the ascending aorta and the right atrium. The aorta was cross-clamped and a high potassium warm cardioplegia was infused and repeated every 15 minutes. The aortotomy was made above the sinuses and the aortic valve was removed. The prosthesis was chosen one size larger than the maximal sizer that could be inserted, which was also used to determine the appropriate height for insertion of the sutures along the wall of the non-coronary sinus.
26893|NCT03976804|Other|low dose CT scan|Lung cancer screening will be based on the analysis of a low dose CT scan
26894|NCT03976804|Other|blood sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
26895|NCT03976804|Other|faecal sample collection|establish a phenotyping of immunity, blood inflammation and digestive and tumour microbiota
26896|NCT03976791|Procedure|enlarged internal incision|enlarging the internal incision about 0.4mm
26897|NCT03976791|Procedure|regular 2.2mm incision|2.2mm microincision coaxial phacoemulsification
26898|NCT03976778|Other|Training program for family physicians on well-child care for children under-5 years|The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
26899|NCT03976765|Other|Rehabilitation program|The patients follow different rehabilitation programs (surgery, anesthetic, post-operative). Hospital discharge is authorized only after validation of objective, clinical and para clinic criteria
26900|NCT03976752|Drug|Genvoya|"Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat).~At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24hrs after home dosing, participants will be given another single dose of Genvoya at the clinic."
26901|NCT03976726|Device|Comparison of physcial parameters|Increasement of weight, volume expansion and decrease of density are measured.
26902|NCT03976713|Drug|Bufei Yishen granule|Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks.
26903|NCT03976713|Drug|Placebo Bufei Yishen granule|Placebo Bufei Yishen granule will be administered twice daily for five days a week for 52 weeks. The placebo granule consists of dextrin, bitter and 5% of the Bufei Yishen granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group.
26904|NCT03976713|Drug|Tiotropium Bromide Powder for Inhalation|Tiotropium Bromide Powder for Inhalation will be used once daily (18 μg each time) for 52 weeks.
26905|NCT03976700|Drug|Bufei Jianpi granule|Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
26906|NCT03976700|Drug|Placebo Bufei Jianpi granule|Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
26907|NCT03976687|Drug|EYP001a|Oral tablets
26908|NCT03976674|Behavioral|Cognitive Behavioural Therapy (CBT)|5 group sessions (2h30/session) before the surgery
26909|NCT03976648|Drug|GLPG1690|film-coated tablets of GLPG1690 for oral use
26910|NCT03976635|Device|Removable Mandibular Retractor|The appliance will be used 18 hours per day. It can only be removed for eating meals.
26911|NCT03976635|Device|Bone-anchored intermaxillary traction|The patients will be instructed to wear the upper removable appliance for 18 hours per day. The elastics should be extended from the upper appliance towards the lower mini-screws.
26912|NCT03976622|Biological|Blood samples|Blood samples: serum and PBMC
26913|NCT03976622|Biological|Skin biopsies|These superficial skin biopsies under local anesthesia in skin areas with the exception of the face and folds.
26914|NCT03976609|Procedure|Maxillary Expansion|The patients with maxillary transverse deficiency were treated with Haas expander is a tooth and tissue-borne appliance with a jackscrew located at the anterior region of the arch with its arms bent posteriorly and soldered to the first permanent molar bands. Once activated, the appliances opens the palatal suture and increase the transverse dimension of the maxilla.
26915|NCT03976583|Drug|Cpp-Acp|Remineralising agent
26916|NCT03976583|Other|Pearl powder|Natural product
26917|NCT03976570|Behavioral|Occupational Therapy|Occupational therapy to children with subthreshold attention deficit hyperactivity disorder
26918|NCT03976557|Device|BIP CVC|Central venous access with noble metal coated CVC
26919|NCT03976557|Device|Standard CVC|Central venous access with standard uncoated CVC
26920|NCT03976544|Drug|Estradiol Valerate|Estradiol valerate will be started in the beginning of the menstrual cycle in order to induce proliferation of the endometrium.
26921|NCT03976544|Drug|Micronized progesterone|If the endometrium is considered adequately proliferated, micronized progesterone is administered and frozen-thawed blastocyst transfer will take place on the 6th day of supplementation.
26922|NCT03976518|Drug|Atezolizumab|Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days).
26923|NCT03976505|Other|reading a table format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
26924|NCT03976505|Other|reading a textual format prescription on a touch screen|Task consists in reading on a touch screen, or on a tablet, two fictive medication prescriptions. One is presented in a table format and the other in a textual format. Each prescription comprises two regular medications (same doses and moments of the day) and two irregular medications (different doses or different moments).
26925|NCT03976505|Other|filling a virtual pillbox displayed on the screen as prescribed in the prescription|filling a virtual pillbox displayed on the screen as prescribed in the prescription
26926|NCT03976505|Other|eye-tracker|In the touch-screen condition an eye-tracker is used to record eye fixations and scanpaths in real time.
26927|NCT03976505|Other|cognitive tests and questionary|Once the 2nd pillbox filling is finished a battery of cognitive tests and questionnaires is administered to participants to identify Pd subtypes of impaired performances.
26928|NCT03976492|Diagnostic Test|diagnostic of specific biomarkers|Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.
26929|NCT03976479|Other|Body composition, questionnaires, biochemistry and blood pressure results|Body composition status, nutritional status, cardiovasculat status, health status, lifestyle factors
26930|NCT03976466|Device|Antibiotic local prophylaxis with medicated calcium sulfate beads|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
26931|NCT03976466|Procedure|Classical parenteral antibiotic prophylaxis|Antibiotic prophylaxis in patients with non-modifiable risk factors for periprosthetic joint infection
26932|NCT03976440|Other|Renal Replacement Therapy (RRT) start|At the discretion of the nephrologist, treatment modality will be selected among CVVH, CVVHDF or SLED. Whatever the RRT modality, the investigators will adopt RCA as the standard anticoagulation strategy
26933|NCT03976427|Behavioral|Guided Imagery|The guided imagery exercise asks participants to think about positive associations with healthy foods and imagine their future healthy selves.
26934|NCT03976414|Other|eMOM|The intervention is the use of the website (eMOM), which is the electronic adaption of the program, Mind Over Matter: Healthy Bowels, Healthy Bladder (MOM), a small-group, community-based health promotion program that builds skills and self-efficacy to make behavior changes that improve urinary and bowel symptoms among older women with incontinence.
26935|NCT03976401|Drug|AKR-001|Administered by subcutaneous injection
26936|NCT03976401|Drug|Placebo|Administered by subcutaneous injection
26937|NCT03976388|Device|Clinical Virtual Simulator|Interactive medical case delivered using touch-sensitive screens in small group sessions.
26938|NCT03976388|Other|Small-Group Discussion|Small group discussion led by a physician.
26939|NCT03976375|Biological|Pembrolizumab|IV infusion of pembrolizumab at 200 mg
26940|NCT03976375|Drug|Lenvatinib|Oral capsules (unit strength: 4 and 10 mg) at 20 mg or 24 mg total daily dose.
26941|NCT03976375|Drug|Docetaxel|IV infusion of docetaxel at 75 mg/m^2.
26942|NCT03976362|Biological|Pembrolizumab|IV infusion
26943|NCT03976362|Drug|Carboplatin|IV infusion
26944|NCT03976362|Drug|Paclitaxel|IV infusion
26945|NCT03976362|Drug|Nab-paclitaxel|IV infusion
26946|NCT03976362|Drug|Olaparib|Tablets
26947|NCT03976362|Drug|Placebo|Placebo to olaparib, tablets
26948|NCT03976349|Drug|BIIB094|Administered as specified in the treatment arm.
26949|NCT03976349|Drug|Placebo|Administered as specified in the treatment arm.
26950|NCT03976336|Dietary Supplement|Berberine|500 mg berberine (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
26951|NCT03976336|Other|Identical Placebo|500 mg (1 capsule) with breakfast and 1000 mg (2 capsules) with the evening meal, 1500 mg total
26952|NCT03976323|Biological|Pembrolizumab|IV infusion
26953|NCT03976323|Drug|Pemetrexed|IV infusion
26954|NCT03976323|Drug|Carboplatin|IV infusion
26955|NCT03976323|Drug|Cisplatin|IV infusion
26956|NCT03976323|Drug|Olaparib|Tablets
26957|NCT03976310|Drug|48 weeks of Benralizumab|Benralizumab is administered for 48 weeks (week 0 to week 48) every 4 weeks for the first 3 injections (30 mg sc per injection), and then every 8 weeks for the following 5 injections.
26958|NCT03976310|Other|Computed tomography|Computed tomography of the thorax is performed at the beginning (week 0), middle (week 24) and towards the end (week 48) of Benralizumab therapy. A sinus scan is also added on weeks 0 and 48.
26959|NCT03976297|Other|Control Tower|A workstation and software tool that extracts medical data from Mayo's data mart and electronic health record, and processes it through a prediction model that determines whether a patient is suited for a palliative care consult.
26960|NCT03976284|Behavioral|Garden-fresh produce and exercise|The Garden-fresh produce and exercise (GFPE) health promotion intervention features 10 weekly sessions that take place after Sunday services in the Lincoln Memorial Church kitchen/meeting space. Each session includes a cooking demonstration focused on how to prepare and cook a meal composed of fiber-rich plant foods minimally processed. Each session also includes brief, didactic nutrition instruction and a 10-minute bout of physical activity.
26961|NCT03976271|Procedure|hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp|For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.
26962|NCT03976258|Drug|buprenorphine/naloxone|This is an observational study. Buprenorphine/naloxone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
26963|NCT03976258|Drug|Methadone|This is an observational study. Methadone for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
26964|NCT03976258|Drug|Naltrexone Injection|This is an observational study. Naltrexone injection for opioid use disorder will be provided in a standardized way by experienced providers through already established funded treatment programs.
26965|NCT03976258|Drug|Heroin|This is an observational study. Participants using heroin will be enrolled into this group.
26966|NCT03976245|Drug|Etanercept|injection
26967|NCT03976245|Drug|tofacitinib|tablet
26968|NCT03976232|Device|Trans cranial Direct Current Stimulation (tDCS)|Active tDCS will be applied for 20 minutes with 2 mA intensity. Anode will be placed at left dorsolateral prefrontal cortex and cathode will be placed at the right cerebellar cortex.
26969|NCT03976232|Other|Craniosacral therapy (CST)|Craniosacral therapy will be given to all the participants which includes release of all major diaphragm, frontal lift, parietal lift, occipital lift, CV4 and dural tube rocking.
26970|NCT03976232|Other|tDCS+ CST|This group will receive tDCS along with CST
26971|NCT03976219|Other|ECAPS Closed Loop SCS|The purpose of this study is to determine the feasibility of recording evoked compound action potentials (ECAPs) and somatosensory evoked potentials (SSEPs) from the spinal cord (SC) and Dorsal root ganglions (DRG), and their suitability as feedback signals.
26972|NCT03976206|Biological|Very small embryonic-like stem cell|We carried out the subdermal application of VSELs with a 1-mL syringe (volume, 0.4 mL) coupled to a 30-gauge needle, in the left preauricular area (1-cm2 area), 2 cm distal from the tragus
26973|NCT03976193|Behavioral|BfitBwell program|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
26974|NCT03976193|Behavioral|6 bi-weekly PA Behavior Change counseling sessions|Well known behavior change strategies such as goal setting, and identifying barriers to PA can improve long term adherence to PA, and have been shown to enhance PA maintenance after completion of a supervised intervention among cancer survivors
26975|NCT03976180|Device|Stadard low-flow oxygen|In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%). This strategy is in accordance with current recommendations and usual care
26976|NCT03976180|Device|HFNO with low FiO2 (21%-30%)|HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
26977|NCT03976180|Device|HFNO with intermediate FiO2 (50%)|In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
26978|NCT03976180|Device|HFNO with high FiO2 (100%)|In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
26979|NCT03976167|Device|Oxygen administration with Common nasal cannula|Oxygen administration during elective flexible bronchoscopy in children with high flow nasal cannula with inspired oxygen fraction 1.
26980|NCT03976167|Device|Oxygen administration with high flow nasal cannula, device Airvo2 Fisher and Pykel|
26981|NCT03976154|Other|Thoracic Epidural Catheter Fixation Techniques|"All thoracic epidurals will be placed by a regional anesthesia resident or fellow under the direct supervision of an attending anesthesiologist using a standard epidural kit and in the paramedian approach.~Epidural placement will occur preoperatively in the same manner as our current practice criterion. There will be no difference in placement of the epidural catheter between the control groups and the treatment group. After placement, catheters will be secured with either Dermabond, Mastisol, or a Grip-Lok fixation bandage, all with overlying Tegaderms."
26982|NCT03976141|Diagnostic Test|mri|knee mri
26983|NCT03976128|Behavioral|Nordic Walking Training|The excursions will take place predominantly in flat pathways, beginning in a local park and progressing to roadside footpaths. Each session will last an hour including a warm up, NW and a cool down with stretching exercises.
26984|NCT03976128|Behavioral|Conventional endurance training|15 minutes of Treadmill training with progressive increase of velocity followed by 20 minutes of cycloergometer with progressive increase of resistance. Each session will last an hour including a warm up, training with treadmill and cycloergometer and a cool down with stretching exercises.
26985|NCT03976115|Drug|DDO-3055|Oral
26986|NCT03976115|Drug|Placebos|Oral
26987|NCT03976102|Biological|DRL_RI (Proposed rituximab biosimilar)|Proposed rituximab biosimilar, 100mg and 500mg, concentrate for solution for infusion
26988|NCT03976102|Other|MabThera®|Reference product rituximab, 100mg and 500mg, concentrate for solution for infusion
26989|NCT03976089|Behavioral|Recipe 4 Success|"The Recipe 4 Success intervention consisted of 10 weekly lessons in which parents and toddlers prepared simple snacks or meals.~All Recipe 4 Success lessons started and ended with some evidence-based information for the parents about children's self-regulation skills or healthy eating habits. Most of each lesson in Recipe 4 Success was devoted to the snack or meal preparation activities. Each week, home visitors coached the parents as they worked with their toddlers to make increasingly challenging snacks and meals. During these activities, home visitors pointed out opportunities for parents to practice sensitive scaffolding strategies. At the same time, these meal and snack preparation activities allowed children to practice multiple age-appropriate self-regulation skills."
26990|NCT03976089|Behavioral|Treatment as Usual Early Head Start|Treatment as Usual Early Head Start consisted of an evidence-based curriculum (usually Parents as Teachers) in which home visitors and parents worked with children on activities to support their physical, cognitive, and social-emotional development.
26991|NCT03976076|Drug|JBPOS0101|JBPOS0101 (investigational product)
26992|NCT03976063|Drug|Nifedipine|Loading dose: Oral Nifedipine 20 mg LP at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg LP at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
48930|NCT03801798|Other|GC1102 Placebo|NAs antivirals+GC1102 Placebo
26994|NCT03976050|Drug|HL-085|HL-085 is a MEK inhibitor with potential indication for cancers. it will be given twice daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative anti-tumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
26995|NCT03976037|Drug|Misoprostol|"Women randomized to either vaginal or buccal misoprostol-cervical Foley group will have both misoprostol and a cervical Foley placed. Patients will receive 25 micrograms of vaginal or buccal misoprostol along with the insertion of a16F Foley catheter with stylet. The Foley balloon catheter will be filled with 30cc balloon inserted digitally or by direct visualization with a speculum. The Foley bulb will be placed just above the level of the internal os and inflated with 30cc of sterile water.~vaginal or Buccal misoprostol can be repeated up to five additional times for a maximum of 24 hours or a total of 6 doses if the patient is not contracting more than 3 times per 10 minutes. If the patient is contracting more than 3 times per 10 minutes after 6 hours, oxytocin protocol is initiated."
26996|NCT03976024|Other|DHBN-FN arm|DHBN-FN will be evaluated by pharyngeal swab, anal and perineal. If the family accepts, the carriage of streptococcus in persons living under the same roof as patients with DHBN-FN will be evaluated by pharyngeal, anal and perineal swab in consultation. These swabs will be made within 10 days of diagnosis of DHBN-FN of the index
26997|NCT03976024|Other|Control arm (Erysipelas)|The carriage of streptococcus in patients with erysipelas will be evaluated by pharyngeal, anal and perineal swab on day 0 (admission).
26998|NCT03976011|Device|Transcutaneous Laryngeal Ultrasonography|"TLU will be performed during the same time period of The gold standard NF (who is performed as usually after endocrine surgeries) by an investigator blind to the NF results, between D1 and D15.~The subject will be his own control, NF and TLU being compared. When facing VF immobility, the subject will benefit from the usual clinical follow up: consultation with NF at 6 weeks and 6 months. TLU will be added to these appointments."
26999|NCT03975998|Procedure|Mitral valve repair|Minimally invasive repair of severe organic mitral regurgiation
27000|NCT03975985|Other|Core stability exercises (CSE)|"CSE are exercises focused on trunk muscle strengthening, proprioception, selective movements of the trunk and pelvis muscle, and coordination, and will be carried out in supine, sitting on a stable surface and sitting on an unstable surface (physioball). The exercise involves changes in the position of the body without resistance, aiming to improve strength, endurance, proprioception and coordination.~- TENS: Half of the patients assigned to CSE will also receive TENS (highfrequency TENS 100 Hz; 0.2 ms pulse width), administered via TENS stimulator with two disposable 0.9 mm diameter electrodes placed on the skin over the lumbar erector spinae (3 cm lateral to the L3 and L5 spinous process)."
27001|NCT03975985|Other|Conventional Physiotherapy|The common feature of CP is that it consists of a management by the physiotherapist according to the CP may consist in a variety (or combination) of multiple components such as tone normalization, exercises for maintain range of motion, passive mobilization of hemiparetic side, postural control, gait re-education to walking/standing between parallel bars or with a therapist, rehabilitation of the activity of daily living, etc.
27002|NCT03975972|Other|Occupational Therapy Based Literacy Intervention|Use of an occupational therapy-based literacy intervention that utilizes student interest to guide a prescriptive literacy intervention. Addressing reading as an occupation and making the necessary modifications to the literacy task to allows for increased engagement in the task. Increased engagement in literacy tasks, allows for opportunities to work on literacy deficit areas to address proficiency with reading ability.
27003|NCT03975959|Other|QMRP questionnaire|a single consultation for test and questionnaires for a duration of 20 minutes
27004|NCT03975946|Procedure|Rheopheresis procedure|Rheopheresis is performed using an automated monitor in a double-filtration cascade. Plasma purify from of high molecular weight proteins through a secondary filter is then returned to the patient. This technique is performed in tandem with a hemodialysis monitor.
27005|NCT03975946|Biological|Blood Sample|Biological analysis
27006|NCT03975946|Procedure|Shamapheresis procedure|Shamapheresis is performed with the same automated monitor (Plasauto, HemaT company). Extracted plasma is not treated through the secondary filter (Rheofilter) and return to the patient. This technique is performed in tandem with a hemodialysis monitor.
27007|NCT03975933|Diagnostic Test|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
27008|NCT03975933|Diagnostic Test|Free pregnancy test for the future use|We will provide a free pregnancy test in for the future use.
27009|NCT03975933|Diagnostic Test|Pregnancy test for the future use with randomzied price|We will provide an opportunity to buy a pregnancy test for the future use with randomized price.
27010|NCT03975920|Device|The Restful Jaw Device|The Restful Jaw Device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. This device replicates the dental assistant in holding the jaw during dental procedures.
27011|NCT03975907|Biological|CAR-BCMA T Cells|The CAR-BCMA T cells (study drug) used in this study are chimeric antigen receptor specifically expressing T cells targeting BCMA.
27072|NCT03975296|Drug|patient controlled intravenous analgesia(PCIA)|at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
27112|NCT03974945|Device|Passive-elastic prosthetic foot|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using their own passive-elastic prosthesis with and without visual feedback of peak propulsive force targets.
27012|NCT03975894|Biological|Serial prophylactic exchange blood transfusion (SPEBT).|"Serial prophylactic exchange blood transfusion (SPEBT) will be given via automated apheresis technology. SPEBT will be carried out on the haematology day unit or on the antenatal day unit/ward in accordance with local policies in participating units. The procedure will be carried out using standard operating procedures, by the clinical or research nurse/midwife, haematology day unit staff or specialist sickle nursing staff. Venous access will be via peripheral access if possible or by femoral line access if not.~SPEBT will be commenced between 6 and 18+0 weeks gestation. It will be repeated at 6-10 weekly intervals aiming to maintain HbS% <30%. It will continue throughout pregnancy and be stopped at the end of pregnancy.~Number of red cell units used per transfusion will depend on patient weight and pre-transfusion HbS%, but will usually be between 6 and 8 units of red cells on each occasion of exchange transfusion."
27013|NCT03975881|Other|application on smartphone|The aim of this study is to test the feasibility of our approach of preventing suicide relapse with the use of a smartphone application.
27014|NCT03975868|Other|Analysis of associated factors for cut-out in internal fixation of extracapsular proximal femoral fracture.|Identification of factors for mechanical failure of internal fixation of extracapsular proximal femoral fracture in over 75 year olds
27015|NCT03975855|Device|NeoNavia® Biopsy System|Biopsy of axillary lymph node using the NeoNavia Biopsy System. The investigator shall obtain as many/large samples as judged adequate and sufficient for diagnosis.
27016|NCT03975842|Other|Sinonasal and otologic evaluation|"At onset, each participant had:~sinonasal evaluation (several nasal signs and symptoms were evaluated, bilateral endoscopic nasal examination, computed tomography (CT) of the sinuses when sinus surgery became necessary).~otologic evaluation (evaluation of middle ear status, documentations of personal history of otologic disease, otoscopic examination, pure-tone audiometry and tympanometry)"
27017|NCT03975829|Drug|dabrafenib|dabrafenib oral, twice daily
27018|NCT03975829|Drug|trametinib|trametinib oral, once daily
27019|NCT03975816|Device|Analgesia nociception index|Monitor the maternity with Analgesia nociception index
27020|NCT03975777|Other|LO|Participants will perform an acute bout of low-intensity cycling (11 x 1 min intervals at ~73% of peak aerobic work rate interspersed with 1 min recovery periods)
27021|NCT03975777|Other|HI|Participants will perform an acute bout of high-intensity cycling (8 x 1 min intervals at ~100% of peak aerobic work rate interspersed with 1 min recovery periods)
27022|NCT03975764|Diagnostic Test|Collection of fecal sample|Analysis of fecal microbiome
27023|NCT03975751|Diagnostic Test|The Glasgow Coma Scale (GCS)|Use the common GCS, RASS and self-reported pain assessment for evaluating consciousness, agitation/sedation and analgesia.
27024|NCT03975738|Other|To be part of a blog|To be part of a blog - to respond to questions and free to comment on other participants comments
27025|NCT03975725|Device|the use of the WitCard|electrocardiogram (ECG)
27026|NCT03975725|Other|the use of WitDisplayer|a software to visualize, measure, annotate, comment, archive, and share the different ECGs acquired with the WitCard (ECGW) of different patients.
27027|NCT03975712|Other|Not applicable, no intervention|Not applicable, no intervention
27028|NCT03975699|Other|Assessment of psychological repercussions of SCD|Quantitative relevant data culled from medical files and qualitative analysis based on data gathered from child and parent interviews, were collected in the three hospitals.
27029|NCT03975686|Other|neuromuscual realigning exercise|neuromuscular realigning exercise
27030|NCT03975673|Procedure|hip replacement|Osteoarthritic patient undergoing the conventional technique or the kinematically aligned technique
27031|NCT03975660|Device|Pain Measurement Device|When participants request labor analgesia, the sensor of the pain measurement device (ROPA System (CereVu Medical, Inc. San Francisco, CA) ) will be applied to the forehead and connected to the device. Data recording is then started.
27032|NCT03975647|Drug|tucatinib|300mg given twice per day orally
27033|NCT03975647|Drug|placebo|Given twice per day orally
27034|NCT03975647|Drug|T-DM1|3.6 mg/kg given intravenously every 21 days
27035|NCT03975634|Device|Transcutaneous Spinal Stimulation|Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
27036|NCT03975621|Behavioral|Supportive Care|"Patient will receive the tablet, a pedometer (to track their steps) and an exercise band (to complete the exercise videos). Use of Nurse AMIE while receiving intervention phone calls from a patient navigator.~After 90 days, observation begins and the patient will be asked to continue using Nurse AMIE without a patient navigator's presence."
27037|NCT03975608|Behavioral|"Adaptation of CALM"|"The therapy is built up by 3-8 sessions (duration about 45-60 min) over a period of 6 months. All dimensions are explored with every patient, but the order and extent of each dimension are adapted to the individual needs of the patient.~The sessions address the 4 dimensions of the original program designed for palliative cancer patients:~Symptom management and communication with healthcare providers~Changes in self and relations with each others~Spirituality, sense of meaning, and purpose~Thinking of the future, hope, and mortality~As an adaptation, the investigators will especially focus on two other aspects which take into account the specific symptoms and challenges in patients with ALS: (i) communication skills and (ii) emotional expression and control."
27038|NCT03975595|Behavioral|Meditation Intervention A|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
27039|NCT03975595|Behavioral|Meditation Intervention B|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
27040|NCT03975595|Behavioral|Meditation Intervention C|This will be a brief meditation intervention involving guided breathing and/or attention exercises. Further information is withheld to preserve blinding.
27041|NCT03975569|Other|Probiotic vaginal gel|Total daily administration of 2.5 ml of probiotic gel, containing three lactobacilli (Lactobacillus rhamnosus GG, Lactobacillus pentosus KCA1 and Lactobacillus plantarum WCFS1). Final dosage per gram of gel: 10^9-10^10 colony forming units of lactobacilli.
27042|NCT03975556|Behavioral|Culturally tailored food and diet advice|Puerto Rico-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.
27110|NCT03974984|Drug|NSAID|NSAID administered according to standard operating procedure postoperatively
27044|NCT03975530|Behavioral|Precision Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive a customized version of Family Spirit that is unique to your circumstances. The two sites randomized to provide the Precision approach will receive additional training on how to provide it.
27045|NCT03975530|Behavioral|Standard Family Spirit|Family Spirit home-visiting sites from the Inter-Tribal Council of Michigan (ITC of MI) will be selected based on comparability and randomized to provide either Standard Family Spirit or Precision Family Spirit to their clients. The investigators will select four sites and randomize two of them to Standard Family Spirit and two to Precision Family Spirit.Both groups will receive educational Family Spirit lessons. Each lesson will take about 60 minutes. Participants will receive Family Spirit lessons based on a standard program schedule.
27046|NCT03975517|Behavioral|PrEP|Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.
27047|NCT03975504|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 5 mm
27048|NCT03975491|Behavioral|Moderate-Intensity Aerobic Exercise|The exercise intervention will consist of moderate-intensity (50−70% age-predicted maximum heart rate) treadmill walking. All exercise sessions will begin with a five-minute warm up of slow walking, 30-60 minutes of moderate-intensity walking, and a five-minute cool down of slow walking.
27049|NCT03975491|Behavioral|Wait-List Control|Participants randomized into the wait-list control group are asked to maintain their pre-study levels of physical activity and follow the recommendations provided by their physician.
27050|NCT03975478|Procedure|Gastric bypass|The GB technique consists of a 150-cm antecolic Roux limb with a 25-mm circular pouch-jejunostomy and exclusion of 50 cm of the proximal jejunum.
27051|NCT03975478|Procedure|Sleeve gastrectomy|The SG technique consists of a longitudinal resection of the stomach from the angle of His to approximately 5 cm proximal to the pylorus, using a 35 French bougie inserted along the lesser curvature.
27052|NCT03975465|Behavioral|Expiratory Muscle Strength Training|8 weeks of EMST at 75% maximum expiratory pressure (MEP)
27053|NCT03975465|Behavioral|Pharyngeal Muscle Strengthening Exercises|8 weeks of exercises designed to increase pharyngeal muscle strength for swallowing
27054|NCT03975452|Radiation|Reduced radiation volumes|Patient treated with reduced radiation volumes with the exclusion of elective pelvic nodal irradiation
27055|NCT03975439|Diagnostic Test|Hemoglobin A1C|Finger stick hemoglobin A1C
27056|NCT03975439|Diagnostic Test|Urinalysis|Urinalysis by dip stick looking for urine protein level
27057|NCT03975439|Diagnostic Test|Whole blood creatinine level|Finger stick looking for serum creatinine as an estimate of renal function
27058|NCT03975426|Procedure|open reduction and internal fixation with fixation by absorbable screws|Group A received conservative therapy involving bed rest with the affected lower extremity positioned with the hip and knee in flexion to ensure minimal tension of the muscles attached to the ASIS avulsion fracture. Group B received open reduction and internal fixation with fixation by absorbable screws.
27059|NCT03975413|Other|Fecal Microbiota Transplantation (FMT)|Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
27060|NCT03975400|Behavioral|search engine advertisement campaign|This proposal aims to explore whether targeted and proactive online outreach through search engine advertisements, coupled with engaging, informative, and interactive online resources, can effectively reduce the duration of untreated psychosis and facilitate earlier treatment initiation in New York State.
27061|NCT03975387|Drug|ASTX295|ASTX295 orally once a day for 28 days of each 28-day cycle.
27062|NCT03975374|Drug|Tobramycin/dexamethasone opthalmic solution|To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
27063|NCT03975374|Drug|Tobradex Opthalmic Solution|Tobradex Opthalmic Solution
27064|NCT03975361|Other|Bliss-Believe|"The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Samples will be obtained the day of inclusion, at the week 36, 40 and week 52.To improve the number of timepoints, patients already included in Bliss Believe can be included in this study if W36, W40, W52 can be obtained. It will be 7ml X 3 (21 ml) of blood every time.~The samples of patients included in RITUX-PLUS STUDY are already collected according to the protocol at baseline, W36, W52."
27065|NCT03975348|Device|High flow nasal cannula|High flow of warm and humidified oxygen/air mixture delivered through nasal cannula
27066|NCT03975348|Device|Continuous positive airway pressure|Positive airway pressure applied through a sealed face mask
27067|NCT03975348|Device|Facemask|Oxygen therapy through a conventional facemask
27068|NCT03975335|Behavioral|Health education|In this health education intervention, emphasis is given on evoking adolescents' internal desire to change, supporting self-efficacy to be changed, guiding self-regulatory ways along with facilitating desired changing process by empowering them with choices and skills.
27069|NCT03975335|Other|Carrier Guidance|Carrier opportunities and counselling
27070|NCT03975296|Procedure|preoperative single-shot TMQLB|"The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
27071|NCT03975296|Procedure|preoperative single-shot TPVB|The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.
27111|NCT03974958|Genetic|Tissue-library|circulating biomarkers (miRNA panel) analysis of blood samples
27073|NCT03975283|Drug|Exparel 266 MG Per 20 ML Injection|266mg of liposomal bupivacaine 266 mg, 20 mL volume, will be diluted with 20 ml of 0.25% bupivacaine (50 mg of bupivacaine) and 20 ml saline, thereby totalling 60mL volume. Total volume will be divided into two 30 ml syringes, and each will be used (per side) for the TAP blocks.
27074|NCT03975283|Drug|Bupivacaine Hcl 0.25% Inj|0.25% bupivacaine, 60mL total, divided into two 30mL syringes and delivered via TAP block on either side.
27075|NCT03975270|Drug|Sintilimab and Nab-paclitaxel|Sintilimab in Combination with Nab-paclitaxel in Patients with Advanced Recurrent or Metastatic HNSCC after 2 or More Prior Lines of Therapy
27076|NCT03975257|Device|Medical Device: Ectoin Lozenge|Application of Ectoin Lozenge (EHT02) in accordance with the instructions for use
27077|NCT03975244|Behavioral|Exercise program|Twelve-week of semi-supervised exercise program. The exercise program will combine resistance and endurance training. Both the volume and intensity of training will start at moderate intensity, and progressively be increased at higher volumes and intensities.
27078|NCT03975231|Drug|Dabrafenib|Given PO
27079|NCT03975231|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
27080|NCT03975231|Drug|Trametinib|Given PO
27081|NCT03975218|Other|Patients With Stroke|In addition to the usual care, the patient will have to complete a questionnaire analyzing the regularity of his follow-up by a physician.
27082|NCT03975205|Drug|Doxorubicin|To measure bioavailabity of Doxil versus Doxorubicin
27083|NCT03975192|Device|Percutaneous Electrical Nerve Field Stimulation|Placement of the PENFS device immediately following the last scheduled opiate dose in the PICU with active stimulation for 120 hours.
27084|NCT03975179|Procedure|Omission of intraoperative frozen section biopsy for margin status|Omitting intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
27085|NCT03975179|Procedure|Frozen section biopsy for margin status|Performing intraoperative frozen section biopsy for margin status in patients undergoing breast conserving surgery
27086|NCT03975166|Drug|Test Product|2 inhalations in one study period
27087|NCT03975166|Drug|Reference Product|2 inhalations in one study period
27088|NCT03975153|Biological|guselkumab|Treatment at the FDA-approved psoriasis dosing for 20 weeks
27089|NCT03975140|Procedure|Hypersensitive acupoint group|The first five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
27090|NCT03975140|Procedure|Hyposensitive acupoint group|The last five acupoints in the sensitization sequence were pressed using the traditional Chinese medicine acupoint pressing technique, and each acupoint was pressed for two minutes.
27091|NCT03975127|Other|SMS text|A single SMS text sent to women under 30 who are eligible for the cervical screening programme and who have been invited by letter
27092|NCT03975114|Drug|Chemotherapy|Any approved first line chemotherapy regimen at Investigators' choice
27093|NCT03975114|Drug|Durvalumab|Durvalumab 1500 mg iv Q4w until progressive or unacceptable toxicity or patient's refusal
27094|NCT03975114|Drug|Tremelimumab|Tremelimumab 75 mg iv Q4w for 4 administrations (4 months)
27095|NCT03975101|Biological|very small embryonic-like stem cell|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
27096|NCT03975088|Procedure|Sub-macular injection of Ranibizumab|In this study, authors describe a new surgical technique for the treatment of refractory non tractional DME. The technique consists of vitrectomy with ILM peeling with subretinal injection of Ranibizumab.
27097|NCT03975075|Behavioral|Psychophysiological monitoring|30 minutes of two channel (PPG and RSG) physiological monitoring with a Thought Technology ProComp 2 Encoder
27098|NCT03975075|Behavioral|Biofeedback training|Traditional resonance frequency training with the Thought Technology ProComp 2 Encoder and Biograph Infinity software. Using visual and auditory feedback of real time parameters of HRV and respiration rate and the use of controlled breathing, participants are trained to reach a relaxed state.
27099|NCT03975062|Drug|dabigatran etexilate|150 mg twice daily (BID)
27100|NCT03975049|Radiation|Chemoradiation|Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.
27101|NCT03975049|Drug|FOLFOXIRI Protocol|Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.
27102|NCT03975049|Drug|Folfox Protocol|Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.
27103|NCT03975036|Drug|Anlotinib|Anlotinib Hydrochloride Capsules
27104|NCT03975036|Drug|pd-1 antibody|Pembrolizumabinjection
27105|NCT03975023|Device|NeuroCatch Platform (NCP)|The NCP plays a proprietary 6-minute auditory stimulus sequence of tones and words that elicit involuntary evoked responses in the brain. Tone stimuli elicit N100 and P300 responses, and spoken word pairs elicit N400 responses. The NCP proprietary software identifies the latency and amplitude (timing and size) of three selected ERPs. Latency and amplitude values are reported as empirical (measured) values.
27106|NCT03975010|Drug|Buprenorphine Transdermal Patch|"This is an open-label, randomised, single-dose, 3 arms study design. Subjects will be randomised into one of 3 arms, in a 1:1:1 ratio, wearing BUP TDS 20 mg for 3 days or 40 mg for 3 days or 40 mg for 4 days. Safety follow-up will be planned at 7~9 days after patch removal.~The study patch will be applied under the cover of naltrexone to reduce opioid related side-effects. Naltrexone 50 mg will be taken orally every 12 hours, from the evening of Day 00 (13 hours prior to IMP application), until the evening of the patch removal."
27107|NCT03974997|Diagnostic Test|Determination of the circulating serum concentration of cytoquine TWEAK|Blood samples (20 ml of blood on dry tube) by venipuncture at the bend of the elbow will be made at T0, then monthly for a period of 1 year . The sera will be isolated by centrifugation and then frozen at -80 degrees Assays of the soluble form of TWEAK and TNF will be performed by ELISA blot technique developed by the team.
27108|NCT03974984|Procedure|Colon Resection|All patients undergo laparoscopic colon cancer resection.
27109|NCT03974984|Procedure|Epidural anesthesia|Epidural inserted preoperatively and kept for 1 day postoperatively
27113|NCT03974945|Device|Powered ankle-foot prosthesis|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects walk using a battery-powered ankle-foot prosthesis with and without visual feedback of peak propulsive force targets.
27114|NCT03974932|Drug|HTX-011|400 mg
27115|NCT03974932|Device|Luer lock applicator|Applicator for instillation
27116|NCT03974932|Drug|Ibuprofen|600 mg Days 4-7
27117|NCT03974932|Drug|Acetaminophen|1 g Days 1-7
27118|NCT03974932|Drug|Celecoxib|200 mg Days 1-3
27119|NCT03974919|Other|NO intervention required|NO intervention required
27120|NCT03974906|Other|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）|Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
27121|NCT03974893|Other|Vegetarian Diet|Dietary information will be collected utilizing a food record at four time points in therapy reflecting different intensities/drug exposures of treatment.
27122|NCT03974867|Drug|Prednisone 5Mg Tab|"Glucocorticoids:~d1-d7: Oral Pred. 1mg/kg/d a (maximum daily dosage is no more than 60mg); d8-d9: Oral Pred. 10mg less than d7; d10-d11: Oral Pred. 10mg less than d9; d12: Oral Pred. 10mg less than d11; d13: Oral Pred. 10mg less than d12; d14: Oral Pred. 10mg less than d13;"
27123|NCT03974867|Drug|Methylprednisolone 40 mg|"Glucocorticoids:~7 intratympanic injections of 40mg/ml Met. in 14 days, one injection every other day;"
27124|NCT03974854|Drug|XELOXIRI-3|chemotherapy with XELOXIRI-3 regimen
27125|NCT03974854|Drug|Gemcitabine|chemotherapy wth Gemcitabine regimen
27126|NCT03974841|Procedure|laparoscopic cornual resection|patients undergoing laparoscopic cornual resection due to cornual ectopic pregnancy
27127|NCT03974828|Device|Anesthesia Control Tower Notification|Real-time data will be monitored through the AlertWatch system as well as the EHR. Risk forecasts of adverse events (30 day mortality, acute kidney injury, postoperative delirium, respiratory failure), PACU length of stay, and hospital length of stay will be generated by a machine learning algorithm. Additional outputs identifying the most important predictors and their effects will be combined with risk forecasts to form a report card.
27128|NCT03974815|Device|ACTIVE|"We will use 28.26cm^2 round electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
27129|NCT03974815|Device|SHAM|"We will use 28.26cm^2 round electrodes and a 0mA current for 30 minutes per day. This montage is known as bifrontal setup(F3-Anode, F4-Cathode) and has been previously used in major depression trials."
27130|NCT03974802|Device|somofilcon A contact lens|Contact Lens
27131|NCT03974802|Device|fanfilcon A contact lens|Contact Lens
27132|NCT03974789|Diagnostic Test|Blood test|Plasma cortisol level test
27133|NCT03974789|Diagnostic Test|24-hour Urine test|Urinary free cortisol test
27134|NCT03974789|Diagnostic Test|Saliva swab|salivette® for salivary cortisol quantification
27135|NCT03974789|Diagnostic Test|Dexamethasone test|Dectancyl® 2 x 0.5 mg tablets (total 1 mg)
27136|NCT03974776|Biological|PF-06946860|PF-06946860 administered subcutaneously
27137|NCT03974776|Other|Placebo|Placebo administered subcutaneously
27138|NCT03974750|Device|Bimanual motor skill learning with the REAplan(R) rehabilitation robot|REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
27139|NCT03974737|Device|CRI device (non-invasive vitals sign measurement)|Survey administration, Orthostatic vital measurements
27140|NCT03974711|Other|"In this evaluation, no interventions are performed. It is a data collection effort only. The procedure for this study is the data collection effort."|There is no intervention performed in this evaluation. Data is being collected in an on-label standard of care lateral lumbar interbody fusion procedure.
27141|NCT03974698|Procedure|Hemiarthroplasty|Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
27142|NCT03974685|Drug|99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)|Single dose
27143|NCT03974672|Procedure|Re-laparotomy|
27144|NCT03974659|Combination Product|Transcranial magnetic stimulation|1.Patients were given 10 consecutive days bilateral cerebellar VIIa lobules Theta Burst Stimulation which was a special mode of Transcranial magnetic stimulation from one week after surgery Intermittent Theta Burst Stimulation(Positive stimulation) is used in right cerebellar VIIa lobule.Each stimulus had three 50 Hz monopulses, which were repeated every 200 ms. Each stimulation continued for 2 seconds and rested for 8 seconds. The total intervention time was 200s (600 pulses) Continuous Theta Burst Stimulation(Negative stimulation) is used in left cerebellar VIIa lobule,three 50 Hz monopulses in each stimulus, each with an interval of 200 ms, and each intervention lasted 40s (600 pulses).
27145|NCT03974646|Behavioral|Nurse-led self-management Program|Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20−30 minutes each at week three, week five and week seven.
27146|NCT03974633|Combination Product|Injection|All information is included in the Arm/group descriptions
27147|NCT03974620|Behavioral|Individual Placement and Support|Individual Placement and Support is a vocational support program that was developed in the USA, to facilitate return to employment in individuals with severe and enduring mental illnesses.
27148|NCT03974620|Behavioral|Cognitive Remediation Therapy|This is an evidence based intervention that aims to improve cognitive functioning.
27149|NCT03974607|Behavioral|Physical Activity Program (PAP)|A Physical Activity Program (PAP) will be carried out. Previously an initial measure will be made to know the little active adolescents. At the end of the PAF a retention measure will be carried out to know the scope and persistence of the variables analyzed. The PAF will be developed with a frequency of three weekly sessions, of 60 minutes, in the period of the intervention, with the exception of weeks in which there is a public holiday, where we will take measures to recover the class. A schedule for the sessions will be set according to the interests of the participants and will be the same for all. During the sessions, basic physical abilities and motor skills will be worked on with playful proposals focused on the improvement of physical and psychosocial parameters. They will always have the same monitor Graduate in Physical Activity and Sports Sciences, which will be responsible for developing the PAF.
27152|NCT03974581|Other|Primary percutaneous coronary intervention|Patient receives primary percutaneous coronary intervention as part of his treatment; decision to allocate by treating physician.
27153|NCT03974581|Other|Pharmacoinvasive strategy|Patient receives primary fibrinolysis and subsequent coronary angiography (pharmacoinvasive strategy) as part of his treatment; cases with failed fibrinolysis are scheduled for immediate rescue PCI. Decision to allocate by treating physician.
27154|NCT03974542|Behavioral|telephone outreach|The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
27155|NCT03974529|Behavioral|Intensive running|The patients who are assigned to this group will be required to finish a 90 minutes of training protocol, containing 30 minutes' warm-up stretching, and 60 minutes of supervised progressive aerobic endurance track running. The training takes place two time per week, for 24 weeks.
27156|NCT03974529|Behavioral|Physiotherapy|The patients who are assigned to this group will be required to finish a 60 minutes of physiotherapy session. The training takes place once per week, for 24 weeks.
27157|NCT03974516|Drug|Careseng 1370|Careseng 1370 should be taken around 1 hour before meal.
27158|NCT03974503|Behavioral|Exposure, Relaxation, and Rescripting Therapy|ERRT is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in trauma-exposed adults.
27159|NCT03974503|Behavioral|Sleep and Nightmare Management|This is a manualized protocol developed to be of similar length but exclude the active components of standard ERRT.
27160|NCT03974490|Other|Rhythmic auditory stimulation|Rhythmic auditory stimulation 3 times in a week, and 2 hours of physiotherapy 6 days in a week.
27161|NCT03974477|Device|SALT CONTROL H equipment to control and monitor salt during cooking process|Participants will use SALT CONTROL H at home during 8 weeks to cook meals with adequate salt content.
27162|NCT03974464|Diagnostic Test|copeptin, PS100|"Age, sex and time between dizziness onset and ED visit were collected using Resurgences® software. PS100 concentrations were measured on serum samples by electro-chemiluminescence assay. Copeptin concentrations were measured on serum samples by the Kryptor method. The positivity threshold for copeptin was set at strictly above 10 pmol/L and that of PS100 was set at strictly above 0.105 μmol/L.~And after, we compared results with results of brain imaging: Magnetic Resonance Imaging alone, CT scan alone or both. Depending on clinical presentation, the imaging tests were performed during ED stay, during hospitalization or externally. Presence or absence of stroke was established on diffusion-weighted brain MRI . In case of normal contrast CT alone, a specialized opinion should exclude the need for diffusion-weighted MRI according to clinical presentation."
27163|NCT03974451|Device|IOL implantation experimental|Implantation of of PhysIOL trifocal FineVision® POD F IOL
27164|NCT03974451|Device|IOL implantation active comparator|Implantation of the Abbott Medical Optics, Inc. Tecnis Symfony® IOL
27165|NCT03974438|Procedure|Superficial dry needling / Acupunture|Se arm-description.
27166|NCT03974425|Drug|Aflibercept Injection [Eylea]|intravitreal injection of Aflibercept in resistant DME.
27167|NCT03974412|Diagnostic Test|Diagnostic Test: This will be a formal pragmatic study of 2 diagnostic strategies|In syncope patients at least 50 years of age, a strategy of first conducting a tilt table (HUT) will provide an earlier diagnosis at less cost than a strategy of first implanting an implantable loop recorder (ILR).
27168|NCT03974399|Dietary Supplement|Bacopa Monnieri|subjects will take Bacopa Monnieri daily for 3 months
27169|NCT03974386|Device|oXiris blood purification set|Continuous venovenous hemofiltration and adsorption (CVVHA) with oXiris filter for up to 72 hours if required. The filter will be replaced every 24 hours. The setting of CVVHA is as follows: blood flow rate 200 mL/min, replacement fluid rate 2000 mL/hr, pre-dilution 50% and post-dilution 50%. If continuous renal replacement therapy is indicated after 72 hours, conventional hemofiltration filters will be used.
27170|NCT03974373|Procedure|BFP removal|The surgical procedure was performed using the technique with intrabuccal access, already consecrated in the literature (Materasso 2006). The Bichat fat ball access was made by means of a small incision no more than 3 mm in length in the soft tissue located in the lower aspect of the zygomatic counterfoot, taking care to visualize and protect with the retractor the Stensen's conduit. With the aid of blunt-tipped or hemostatic scissors dissection was performed, taking care to preserve the membrane surrounding the ball of fat. After removal of one side, pressure was removed to remove air and the procedure was started on the opposite side, after the removal of the two sides was realized simple suture with silk thread. There were no formal indications for sending the samples for anatomic and / or histological examination.
27171|NCT03974360|Drug|AMG 334|100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
27172|NCT03974334|Behavioral|OWL-Hypertension 8 Wk Trial|Our Whole Lives - Hypertension is an innovative online community and self-management program that provides access to stress reduction, mind-body techniques, nutrition, exercise, and peer support. OWL-H provides educational materials including videos of clinician-led talks (stress reactivity, nutrition, movement, etc.). OWL-H also provides subjects a facilitated community blog, private journal, peer support, and an extensive resource library. It will be tested by 26 patients with hypertension, to refine the platform based on patient feedback and outcomes.
27173|NCT03974308|Other|Comprehensive physiotherapy including balneotherapy and filling questionaire|Three-week stay in a sanatorium with comprehensive physiotherapy including balneotherapy and three time filling questionaire.
27174|NCT03974308|Other|Comprehensive physiotherapy without balneotherapy and filling questionaire|Two-week outpatient treatment with comprehensive physiotherapy without balneotherapy and three time filling questionaire
27175|NCT03974308|Other|No intervention, only filling questionaire|No physiotherapy nor balneotherapy applied but three time filling questionaire
27176|NCT03974295|Behavioral|Vaginal unprotected intercourse|Patients will allowed to engage in vaginal unprotected intercourse as many times as desired after 24 hours of pelvic rest after a frozen embryo transfer.
27177|NCT03974282|Other|University enrollment|Enrolled at the university
27248|NCT03973697|Drug|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
27178|NCT03974269|Procedure|TAVI : Transcatether Aortic Valve Implantation|TAVI procedures will be either Medtronic Corevalve, or Edwards Sapien implantations, at operator's discretion. All procedures will be supervised by one of the two senior interventional cardiologists. Hypnosis sessions will be performed by two trained anesthesiologists, and Remifentanil sedations will be administered by the rest of the anesthesiologists staff. Postoperative care will be provided in the CICU for the 3 first postoperative days at least.
27179|NCT03974256|Other|Training in the use of the automaton|2 days training on automaton use
27180|NCT03974243|Drug|Chiauranib|"In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle."
27181|NCT03974243|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
27182|NCT03974230|Other|Collection of datas|Collection of datas of examination for diagnosis and follow-up of the Fuchs Endothelial Corneal Dystrophy (FECD) including slit lamp results will be performed.
27183|NCT03974230|Biological|blood sample|Blood sample will be performed (genetic analyses).
27184|NCT03974230|Other|slit lamp examination|Slit lamp examination will be performed.
27185|NCT03974217|Drug|Talazoparib|Talazoparib is a drug that stops the activity of a protein called poly (adenosine diphosphate [ADP]-ribose) polymerase or PARP. PARP is involved in repairing damage to the DNA within the cells. When PARP is turned off by Talazoparib in cancer cells, DNA damage cannot be repaired and leads to the death of the cancer cells.
27186|NCT03974204|Procedure|Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment|At the initial diagnostic assessment, 3mL of cerebrospinal fluid and 10 ml of blood sample will be collected in order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases.
27187|NCT03974204|Procedure|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are Lack of evidence according to EANO-ESMO classification"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~When suspected metastatic meningitis symptoms arise and~at least 3 months after the initial diagnostic assessment, In order to determine the proteomic profile. Cerebrospinal fluid will be collected during a lumbar puncture aiming to diagnose leptomeningeal metastases."
27188|NCT03974204|Procedure|"Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are confirmed, probable or possible, leading to leptomeningeal metastase specific treatment"|"3mL of cerebrospinal fluid and 10 ml of blood sample will be collected:~1 month after the beginning of the specific treatment,~3 months after the beginning of the specific treatment. Cerebrospinal fluid will be collected during a lumbar puncture aiming to assess treatment response or at intrathecal injection of treatment."
27189|NCT03974191|Other|Change in function, activity, participation and other health related factors in CLBP and to identify predictors for pain, activity and work ability after 13 years.|13-year prospective longitudinal cohort study
27190|NCT03974178|Drug|Fexinidazole|Adults and Children patients will receive fexinidazole tablets every day for 10 days
27195|NCT03974152|Other|Subox Mini C with Avail 18 mg nicotine salt (protonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine salt (protonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
27196|NCT03974152|Other|Subox Mini C with Avail 18 mg nicotine (unprotonated)|Participants will be instructed to take one puff of the Subox Mini C with Avail 18 mg nicotine (unprotonated) liquid every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
27197|NCT03974152|Other|Own brand cigarette|Participants will be instructed to take one puff of a cigarette matching their typical brand every 30 seconds for 5 minutes followed by a 2nd blood draw. Next, participants will be given 90 minutes to use the product ad lib, i.e., as much as desired.
27198|NCT03974139|Drug|Metformin Oral Tablet|Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day
27199|NCT03974126|Other|40 grams of starch|40 grams of starch in form of white bread to be consumed within 15 minutes
27200|NCT03974126|Other|80 grams of starch|80 grams of starch in form of white bread to be consumed within 15 minutes
27201|NCT03974113|Drug|Fitusiran|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
27202|NCT03974100|Biological|GP2411|60 mg /mL subcutaneous injection every 6 months
27203|NCT03974100|Biological|EU authorized Prolia|60 mg /mL subcutaneous injection every 6 months
27204|NCT03974087|Device|Transcranial Direct Current Stimulation (tDCS)|2mA stimulation for 20 minutes
27205|NCT03974074|Drug|Albumin infusion|Albumin infusion (20 g, ivgtt, qd) will be performed to patients with HCC after resection in 24 h for three days.
27206|NCT03974061|Behavioral|Brief Acceptance and Commitment Therapy|Acceptance and Commitment Therapy utilizes mindfulness skills and values-guided behavioral action plans to decrease experiential avoidance and impact a broad array of psychological symptoms.
27207|NCT03974061|Behavioral|Brief Alcohol Intervention|The Brief Alcohol Intervention is a standard intervention that will be adapted for men and women living with HIV. The intervention will be matched in frequency and length to the brief ACT intervention.
27249|NCT03973697|Drug|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
27208|NCT03974048|Diagnostic Test|Blood samples for DNA methylation analysis|DNA from blood samples will be isolated and analyzed for genome-wide DNA methylation patterns using the Infinium HumanMethylationEPIC BeadChip (Illumina, San Diego, CA, USA).
27209|NCT03974035|Drug|Second infiltration pre-extubation with ropivacaine|The surgeon will proceed firstly with pre-incisional infiltration with lidocaine and adrenaline after intubation, and secondly with pre-extubation infiltration with ropivacaine at the intraoral and intranasal submucosal level in the maxilla and jaw to block the terminal branches of the maxillary and mandibular nerve
27210|NCT03974022|Drug|DZD9008|Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
27211|NCT03974009|Other|Calcaneal taping|Calcaneal taping will be given in long sitting position foot out of the edge.BSN Medical Leukotape P Sports Tape (3.8cm×137m,1.5inch× 15yds) on focusing the calcaneus with the aim of choosing dorsiflexion with eversion. First strap of tape will be applied below the medial malleolus,stretch towards lateral malleolus on affected side. Second strap of tape will be applied repetitively placing the first strap,another will be applied to fix the small tapes.
27212|NCT03974009|Other|Sham taping|Sham taping will be given to the control group patients.Simple clinical tape will be applied on calcaneus without stretch.It will be applied for 3 days/week for 4 weeks.
27213|NCT03974009|Other|Conventional therapy|Balance activities (Forward, backward and sideways walking in between 2 parallel lines;Ball kicking against wall(reducing upper limb support)to raising the distance from the wall, kicking to the fixed target; Obstacle walking and Strengthening exercises (Sit to Stand from several heights of chair, Forward & backward and sideward stepping onto blocks of several heights. Each acitivity will be given for 5 minutes.
27214|NCT03973996|Dietary Supplement|Green Tea Extract|A gummy confection with catechin-rich green tea extract (1 g/d)
27215|NCT03973996|Dietary Supplement|Placebo|A matched gummy confection formulated without green tea extract
27216|NCT03973983|Procedure|Ultrasound-guided transgluteal pudendal nerve injection (TG-PNI)|Ultrasound-guided transgluteal pudendal nerve local anesthetic injections
27217|NCT03973983|Procedure|Finger-guided transvaginal pudendal nerve injection (TV-PNI)|Finger-guided transvaginal pudendal nerve local anesthetic injections
27218|NCT03973957|Device|Indwelling pleural catheter placement|Indwelling pleural catheter placement by interventional pulmonologist
27219|NCT03973957|Drug|Fentanyl Citrate|Administration of intravenous fentanyl prior to talc slurry instillation in order to avoid pain associated with talc slurry application
27220|NCT03973957|Drug|Talc Slurry|Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
27221|NCT03973957|Device|Drainage collection bag|Attachment of one-way Heimlich valve with drainage collection bag circuit to indwelling pleural catheter after talc slurry application for purposes of drainage and pleurodesis in the outpatient setting rather than the inpatient setting.
27222|NCT03973944|Device|Cardiac resynchronization therapy|Atrio-biventricular pacing to shorten the prolonged PR interval
27223|NCT03973931|Behavioral|Nudge|Interventions will include a variety of text messages aimed at improving medication adherence.
27224|NCT03973918|Drug|Encorafenib|450mg QD 28 day cycle
27225|NCT03973918|Drug|Binimetinib|45mg BID 28 day cycle
27226|NCT03973918|Biological|Research Bloods|Baseline; pre-cycle 3; Pre-cycle 7; off Treatment
27227|NCT03973918|Biological|Tumor Tissue|at time of surgery contrast enhancing and non enhancing tumor; 20 unstained slides
27228|NCT03973905|Other|Not applicable / dataset analysis|Not applicable / dataset analysis
27229|NCT03973892|Diagnostic Test|Cere|Magnetic Rseonance imaging for brain tumour follow-up
27230|NCT03973879|Biological|PVSRIPO|Oncolytic polio/rhinovirus recombinant
27231|NCT03973879|Drug|Atezolizumab|Antibody
27232|NCT03973866|Device|Alfapump|Implantation of alfapump
27233|NCT03973853|Behavioral|Virtual reality driving stimulation program|This group will benefit of 14 one hour sessions, using the driving simulator. The program is based on a progressive training, focused on the remediation of the cognitive functions specific to driving. The tool and the type of training aim to help transfer the abilities to daily life.
27234|NCT03973853|Behavioral|TAU|This group will carry on their usual treatment during the whole length of the study. Patients will be randomized into the 2 groups. This TAU group will be the control group and will help assess the effectiveness of the stimulation program. The stimulation sessions will be proposed to the TAU group at the end of study.
27235|NCT03973840|Drug|Testosterone Undecanoate|dose was given orally and allowed to reach steady state
27236|NCT03973827|Drug|ProTrans|ProTrans is an pooled allogenic mesenchymal stromal cell treatment
27237|NCT03973814|Device|Thermax Blood Warmer|Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.
27238|NCT03973801|Other|Auricular acupuncture|National Acupuncture Detoxification Association (NADA) protocol for auricular acupressure will be initiated within 24 hours of delivery and continued until withdrawal symptoms measure 6 or less for 12 hours on the modified Finnegan score and/or the morning of expected discharge as in line with standard of care.
27239|NCT03973788|Procedure|repetitive transcranial magnetic stimulation (rTMS)|A single section of rTMS (2,000 pulses)
27240|NCT03973775|Drug|Permethrin Cream 5%|Patients will be assigned to the test product Permethrin Cream 5% to the Reference Listed Drug Product Elimite cream.
27241|NCT03973762|Device|DR Grading with CAD|A CAD system is used to make DR grading.
27242|NCT03973762|Other|DR Grading by expert panel|DR Grading by expert panel
27243|NCT03973749|Other|Low salycilate diet|Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
27244|NCT03973736|Other|application of a diagnostic and therapeutic protocol (multidisciplinary discussion and radiological CT review)|Since the introduction of the new protocol in 2012, a single central multidisciplinary team has been formalized, with weekly discussion of cases, including different specialists from all the provincial hospitals. CT scans of discussed cases are reviewed by one of two experienced radiologists based on pre-defined criteria.
27250|NCT03973684|Device|pdt experimental group|"G1-40 patients Photodynamic therapy with methylene blue as photosensitizer~device irradiation with low intensity laser (wave length = 660 nm) 9J (Jaules) per point(6 points) and radiant 90 seconds PS will be applied in sufficient quantity to cover the middle third and back of the tongue and wait for 5 minutes.six points with the distances of 1 cm between them will be irradiated."
27251|NCT03973684|Other|tongue scraper group|Tongue scrapping will be performed by the same operator in all patients. Posterior -anterior movements will be performed with the scrapper over the lingual dorsum. in order to promote the mechanical removal of tongue coating
27252|NCT03973658|Device|Hearing aids|Fitting of hearing aids (for the first time)
27253|NCT03973645|Other|Patient presenting peritonitis managed with fungal research during year 2016|Patient presenting a peritoneal fungal with panfungal PCR and BDG compared to Peritonitis score (PS) and microbiological (ED direct fungal examination)
27254|NCT03973632|Drug|SH-1028 Tablets|200mg of SH-1028 Tablets, orally once every cycle.
27255|NCT03973619|Procedure|Labial Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft (labial graft).
27256|NCT03973619|Procedure|Jugal Graft|As replacement of the damaged urethral tissue, we used a buccal mucosa graft(inner cheek - jugal graft).
27257|NCT03973606|Other|Heath literacy assessment in Arab women in East Jerusalem|The intervention is purely for evaluation and assessment, aiming to assess the level of health literacy in Arab women in East Jerusalem for designing future programs following the assessment results.
27258|NCT03973593|Behavioral|Enhancing contraceptive counseling on method continuation and switching|Health care workers and Community Health Volunteers will be trained on a contraceptive counseling package that enhances information on method continuation and switching. This will be done in the ten intervention facilities prior to enrollment of clients into the cohort study.
27259|NCT03973580|Behavioral|Attentional Bias Modification (ABM) task|Participants will be presented with a fixation cross (500ms) followed by a pair of identity-matched, angry-neutral faces (1000ms). The pair presentation is replaced by a single arrow-probe (1000ms) in the position of the neural face. Inter-trial intervals (ITI) are 500ms. Participants indicate arrow direction (left or right) by pressing one of two buttons as quickly as possible. By responding to the probe that always replaces the neutral face, participants learn to attend to the non-threat cues and away from threat cues. There are 120 trials of angry-neutral faces in total, and 40 other catch trials with neutral-neutral faces.
27260|NCT03973580|Behavioral|Control task|The control task is identical with the ABM task, except that in the 120 angry-neutral trials, the arrow-probe replaces the angry face and the neutral face with equal probabilities (60 trials each).
27261|NCT03973567|Drug|selective serotonin reuptake inhibitor (SSRI) or serotonin noradrenaline reuptake inhibitor (SNRI) antidepressants|On the basis of routine treatment for 8-12 weeks, according to the characteristics of symptoms, a combination of SSRI or SNRI antidepressant drugs was given for 12 weeks.
27262|NCT03973567|Other|conventional therapy|Anti-HP, acid suppression, gastrointestinal motility regulation, etc.
27263|NCT03973554|Other|pearl powder|natural product, support bone and joint health
27264|NCT03973554|Drug|CPP-ACP|Remineralising sugar free dental topical crème, containing bio-available calcium and phosphate
27265|NCT03973541|Behavioral|Cognitive Behavioral Therapy with Exposure therapy|Treatment will be conducted for 10 consecutive weekly 60 min sessions. In the first two treatment conditions sessions are scheduled as follows: Session one: Building a therapeutic alliance and psycho-education about social anxiety and safety and avoidance behaviors. Session two to four: Cognitive restructuring. Session five to nine: Exposure in either in vivo or VR. Session 10: Relapse prevention. Sessions one to four and ten are identical in the two of three treatment arms.
27266|NCT03973541|Behavioral|Relaxation Therapy|Relaxation Therapy
27267|NCT03973528|Drug|traditional Chinese medicine: tonifying kidney Wan|traditional Chinese medicine : tonifying kidney Wan
27268|NCT03973515|Drug|glucokinase activator|PB-201 is a kind of dual and partial GKA
27269|NCT03973515|Drug|Placebo|Placebo oral tablet
27270|NCT03973502|Drug|18F-DOPA PET|One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA. PET emission data acquisition in 3-dimensional mode will be started at 60 minutes after tracer injection for 30 minutes.
27271|NCT03973489|Behavioral|Magnetic resonance imaging (MRI)|On visits 2 and 3, subjects will undergo a baseline MRI scan approximately 1 hour after the start of each visit followed by drug administration (placebo or MA) and a second scan 1.5 hours after that.
27272|NCT03973489|Drug|Methamphetamine Hydrochloride Tablets|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
27273|NCT03973489|Drug|Placebo oral tablet|Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits.
27274|NCT03973476|Other|Phone care support by midwife|Mothers can call the midwife's telephone every working day from 8 a.m. to 8 p.m.
27275|NCT03973463|Behavioral|Elastic knee joint movement|Low resistance (7kg and 10kg) elastic band exercise 3 times a week for 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.Balanced diet reduces oil intake by 1200 calories per day. Maintains 12 weeks.
27276|NCT03973450|Other|Registration of familial forms and associated neoplasia|Retrospective registration of associated endocrine and non-endocrine neoplasia and potential familial setting
27277|NCT03973437|Device|Artificial inteligence associated ulcerative colitis severity scoring system|Patients in this group go through a flexible colonoscopy under the AI monitoring device. During the withdrawal process, inflammatory lesions are detected by AI-associated scoring system. Pictures are automatically captured and analyzed by the computer. The Mayo ES and UCEIS sores will be calculated and presented on a second screen, providing a reference for the physician to evaluate the disease severity and mucosal healing stage of the patient. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
27278|NCT03973437|Device|Conventional human scoring|Patients in this group go through a conventional colonoscopy without the AI monitoring device. During the withdrawal process, physician evaluates the disease severity and mucosal healing stage of the patient according to his personal experience. Biopsies will be taken from inflammatory region for histological examination. Videos will be recorded and re-evaluated by a group of experts to determine the final Mayo ES and UCEIS scores.
27279|NCT03973424|Behavioral|Simple|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, use a simplified form of tracking only high-calorie, high-fat foods in the study smartphone app, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
27280|NCT03973424|Behavioral|Standard|Participants have three daily goals (weighing, dietary goal, activity goal), will self-monitor (weigh on Wi-Fi enabled scale, track calorie intake, wear Fitbit activity tracker), will receive 4-5 tailored text messages each week, and will view weekly tailored feedback and lessons in smartphone app.
27281|NCT03973411|Drug|Prophylactic ondansetron|Pacients will receibe prophylactic ondansetron plus standard spinal anesthesia
27282|NCT03973411|Drug|Placebo|Pacients will receibe standard spinal anesthesia
27283|NCT03973398|Procedure|Quadratus Lumborum block|ultrasound guided Quadratus Lumborum block for postoperative pain
27284|NCT03973385|Device|Cryotherapy|patients recieving cryotherapy for skin anesthesia for artérial blood gas
27285|NCT03973359|Behavioral|Hygienic recommendations|Recommendation of protective behaviours such as frequent hand washing and avoiding risky behaviours such as kissing young children on the mouth or cheeks and sharing utensils, foods etc.
27286|NCT03973346|Other|Risk screening tool exposure|Risk screening tool is available to providers
27287|NCT03973333|Drug|IMC-C103C|Weekly IV infusions
27288|NCT03973333|Drug|Atezolizumab|Q3W
27289|NCT03973320|Other|Chart Review|This is a chart review to determine if hypotensive neuraxial anesthesia is associated with worse outcomes in Primary Total Hip Arthroplasty patients.
27290|NCT03973307|Diagnostic Test|UroX bladder cancer biomarker test|Urine test using novel UroX biomarker test for bladder malignancy
27291|NCT03973294|Device|EIT-measurement|"The use of electrical impedance tomography (EIT) (SentecTom BB2, Landquart, Switzerland) allows the investigators to obtain a visual and quantitative representation of the areas of ventilation and aeration of the lung. The fundamental principle of lung EIT relies on the application of small alternating electrical currents into the thorax and voltage measurements using electrodes on the skin surface generating cross-sectional images representing impedance change in a slice of the thorax. It is a radiation-free imaging method which has the advantage to reveal real-time information.~An array of electrodes (textile belt with 32 integrated electrocardiographic electrodes) has to be placed around the thorax to inject currents and to measure the resulting voltages on the thoracic surface."
27292|NCT03973281|Device|Materna Prep Device|Materna Prep Device
27293|NCT03973281|Device|Materna Sham Device|Materna Sham Device
27297|NCT03973255|Behavioral|Rehabilitation|Posturography, Whole body vibration
27298|NCT03973242|Device|Dual focus with narrow band imaging|dual focus mode for imaging magnification + narrow band imaging for the enhancement of mucosal vascularity and irregularity
27299|NCT03973229|Drug|Estradiol patch|Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
27300|NCT03973229|Other|Placebo patch|Placebo patch identical to the estradiol patch will be applied 24-48 hours before the MRI scan is performed.
27301|NCT03973216|Behavioral|A primary care group-based therapeutic yoga program|The intervention includes therapeutic yoga training and education sessions on benefits of yoga and effects of stress on the body.
27302|NCT03973203|Dietary Supplement|Niacin|The dose for a slow-released form of niacin will be 750-1000 mg/day. The daily niacin dose, 250 mg/day, is gradually escalated by 250 mg/month so that the full dose is reached after 3 months. The intervention time with the full niacin dose is 1 and 7 months for controls and patients, respectively, and subsequently total intervention time 4 and 10 months, respectively. At the end of the study, the daily dose will be decreased by 250 mg/month rate.
27303|NCT03973190|Procedure|Immediate alveolar regeneration after exodontia|The extractions will be performed under local anesthesia, without making a mucoperiosteal flap, making an intraassucular incision and using appropriate periotomes, elevators and forcépes, minimizing the surgical trauma of surrounding tissues. Thorough curettage of the alveolus will be performed at the time of extraction to ensure removal of all granulation tissue and stimulate bleeding from the bone base, to form blood clot and promote healing. The sutures will be removed after 7 days of surgery, except for patients in group 3, in which sutures will not be made.
27304|NCT03973190|Procedure|installation of dental implant and collection of biological material|The material was collected for histological analysis, extracted with trephine drill of 2.0 mm in diameter. Samples were removed before the incision. A linear incision was then made on the alveolar ridge in the region and flap detachment. The initial insertion of the implant was performed using the contra-angle at 30 rpm, the final insertion of the implant was performed with manual torque wrench, where the insertion torque was measured and the value was tabulated, not exceeding 60 N. cm. The component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. The prosthetic component was installed with a maximum torque of 20 N and SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden) was adapted. the tabulated values and the incision was sutured.
27337|NCT03972917|Diagnostic Test|Transvaginal ultrasonographic examination|Evaluation of endometrial thickness; myoma size and volume
27338|NCT03972904|Dietary Supplement|Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance|Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.
31203|NCT03942003|Procedure|Control groups|Infiltration analgesia was performed
27305|NCT03973190|Device|ISQ analysis|The prosthetic component already installed. On it is adapted the SmartPeg® (Integration Diagnostics AB, Göteborg, Sweden). According to the manufacturer, the device generates a series of signals with different frequencies in Hertz (Hz) and these values are immediately converted to ISQ (Implantation Stability Coefficient), providing fast and accurate monitoring. The calibration is performed on the buccal and palatal surfaces of the intermediaries, that is, each implant was submitted to 2 readings. The readings were captured and tabulated for further analysis. were repeated at intervals of 7 to 10 days, 30 days and 60 days, for evaluation of SSI in the period of osseointegration. With the objective of not subjecting the implant to torque and torque during this period and to avoid interfering with the osseointegration process, the micro-pillars were covered with the micro-pillar protection screws with digital pressure only.
27306|NCT03973177|Drug|Phenol Injection|6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.
27307|NCT03973177|Drug|Methylprednisolone Injection|Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
27308|NCT03973151|Drug|HL-085|HL-085 is one MEK inhibitor.
27309|NCT03973138|Drug|Ranibizumab|DME patients who were diagnosed through fundus manifestations and FFA examination were treated by intravitreal injections of ranibizumab (0.5mg Lucentis®; Genentech, South San Francisco, CA) under the pro re nata (PRN) treatment regimen. The retreatment were conducted if BCVA was reduced by 0.1 logarithm of the minimal angle of resolution (logMAR) value or more from maximum acuity or if OCT central subfield thickness was more than 300μm.
27310|NCT03973125|Drug|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
27311|NCT03973112|Drug|HLX10+HLX04|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. HLX04 is an anti-tumor angiogenesis drug, which is a biosimilar drug bevacizumab designed and developed by Shanghai fuhonghanlin biotechnology co., ltd. based on the protein sequence of Avastin® by Roche pharmaceutical company.
27312|NCT03973099|Dietary Supplement|PM011|PM011 is a 400 mg hard gelatin capsule containing water extracts of Nelumbinis Semen. The sprayed-dry extract of the herbal medicine used was purchased from Sun Ten pharmaceutical company in Taiwan. Each participant received twelve capsules of PM011, which divided into 2.4 g treatment or 4.8 g treatment group or placebo daily for two weeks and was instructed to take six capsules after breakfast and six capsules after dinner. Subjects in the placebo group received the equivalent amount of starch and lactose mixture capsules and administered with the same schedule.
27313|NCT03973086|Dietary Supplement|Citruslim- LD|Low Dose of 200 mg
27314|NCT03973086|Dietary Supplement|Citruslim- HD|High Dose of 400 mg
27315|NCT03973086|Dietary Supplement|Placebo|Placebo (Microcrystalline Cellulose) of 400 mg
27316|NCT03973073|Combination Product|CapulinTM|camouflage
27317|NCT03973073|Other|topical applications and NB-UVB|combination therapy of vitiligo
27318|NCT03973060|Device|Concentric-eccentric muscular work|For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.
27319|NCT03973060|Genetic|Genetic polymorphism|Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
27320|NCT03973047|Drug|Bremelanotide|Sterile aqueous solution for injection, provided as an autoinjector pen
27321|NCT03973047|Drug|Zofran|8 mg tablet (over-encapsulation in a capsule)
27322|NCT03973047|Drug|Placebo|capsule
27323|NCT03973034|Diagnostic Test|Low depth whole genome sequencing|Low depth whole genome sequencing of the peripheral blood samples from different groups.
27324|NCT03973021|Biological|Very small embryonic-like stem cell(VSEL)|Mononuclear cells were collected from peripheral blood of each patient using a machine, VSELs were isolated, and each group was injected according to different numbers after activation
27325|NCT03973008|Radiation|Adjuvant Chemoradiotherapy|DT 45Gy/25F/5W, using IMRT technology, synchronous tegio single drug chemotherapy
27326|NCT03973008|Drug|Adjuvant Chemotherapy|Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
27327|NCT03972982|Drug|Simplified intensive insulin therapy regimen|Short-term continuous subcutaneous insulin infusion to maitain near normoglycemica for 1 week, thereafter basal insulin and metformin were subsequently used. Wearable devices and smart apps will be used for lifestyle modification.
27328|NCT03972982|Drug|Traditional Short-term Intensive insulin therapy|Short-term continuous subcutaneous insulin infusion will be initiate to maitain near normoglycemica for 2 weeks, then patients will be ordinarily follow-up
27329|NCT03972969|Behavioral|Facility-based structured exercise|Structured exercise program in a facility with instruction and encouragement
27330|NCT03972969|Behavioral|Home-based structured exercise|Structured exercise program in the home with instruction and encouragement
27331|NCT03972969|Behavioral|Health education|Provision of general information about a variety of topics
27332|NCT03972956|Other|No intervention will be given to patients.|Samples are collected at the time of a scheduled surgery that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
27333|NCT03972943|Procedure|Continuous Positive Airway Pressure|Receive CPAP treatment
27334|NCT03972943|Other|Patient Observation|Undergo observation
27335|NCT03972943|Other|Questionnaire Administration|Ancillary studies
27336|NCT03972930|Radiation|Stereotactic Body Radiotherapy|Stereotactic body radiotherapy (SBRT) is hypofractionated radiation delivered using highly conformal technique, allowing for a high dose of radiation to be delivered precisely.
27339|NCT03972904|Dietary Supplement|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance|A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
27340|NCT03972891|Other|intervention break of 12 weeks|"The intervention of this study is a break of the intervention for 12 weeks under the following conditions:~no therapeutic intervention during the break~no language-specific specific exercises~language-specific strategies in everyday life can be applied, e.g. modeling techniques"
27341|NCT03972878|Other|control snack|dry fruit snack (200 kcal) + 250 ml water
27342|NCT03972878|Other|control cream|commercial spreadable cocoa and hazelnut cream (200 kcal)+ 250 ml water
27343|NCT03972878|Other|cream version 1|commercial spreadable cocoa and hazelnut cream (200 kcal), version 1+ 250 ml water
27344|NCT03972878|Other|cream version 2|commercial spreadable cocoa and hazelnut cream (200 kcal), version 2+ 250 ml water
27345|NCT03972878|Other|cream version 3|commercial spreadable cocoa and hazelnut cream (200 kcal), version 3+ 250 ml water
27346|NCT03972878|Other|control chocolate bar|commercial chocolate bar (200 kcal)+ 250 ml water
27347|NCT03972878|Other|chocolate bar version 1|commercial chocolate bar (200 kcal), version 1+ 250 ml water
27348|NCT03972865|Other|EmbrunMan race|The EmbrunMan is a long-duration triathlon including 3.8 km of swimming, 188 km of cycling and 42.2 km of running, with a cumulative vertical drop of 4000 metres. Duration of the race varies between 10 hours and 16hours depending on the athletes' performance.
27349|NCT03972826|Other|Provodine|Subjects serve as self-controls. Subjects first perform hand-hygiene with alcohol-based hand rub then doff gloves contaminated with either S. marcescens or MS2 phage and the hands are cultured using a bag-broth method to determine whether the subjects self-contaminated while doffing. Subjects then clean their hands thoroughly, perform hand hygiene with Provodine, then repeat the doffing and culture process.
27350|NCT03972813|Behavioral|Broadened information about cancers|Caregivers receive information that HPV causes more than just cervical cancer.
27351|NCT03972813|Behavioral|Information about STDs|Caregivers learn that HPV is an STD.
27352|NCT03972813|Behavioral|Information about infectious disease|Caregivers learn that HPV is infectious (but information that it is an STD is omitted).
27353|NCT03972813|Behavioral|Recommendation for children 12 years old|Caregivers are prompted to get their child vaccinated when the child is 12 years old.
27354|NCT03972813|Behavioral|Recommendation for children 18 years old|Caregivers are prompted to get their child vaccinated when the child is 18 years old.
27355|NCT03972813|Behavioral|Standard age information|Caregivers are given information about when the HPV vaccination can be given in China, but no additional recommendations.
27356|NCT03972813|Behavioral|Cervical cancer|Caregivers are told that HPV causes cervical cancer.
27357|NCT03972813|Behavioral|Blank information about communicability|Caregivers are not given any information on how HPV is spread.
27358|NCT03972787|Device|Proactive social robot|ElliQ, is a new type of robotic technology aimed at reducing loneliness and social isolation in older adults. It differs from other social/companion robots on the market, as it leverages artificial intelligence to create personalized and interactive experiences for the user, while also proactively offering prompts (such as reminding the user to stay hydrated) and suggesting and initiating various activities for the user (such as offering to play a game). This social companion adapts to the personalities and interests of the older adult, creating a personalized experience and recommending content the user may enjoy such as news, music, TED talks, and cognitive games.
27359|NCT03972774|Diagnostic Test|PET Stress Test|Cardiac positron emission tomography (PET)/computed tomography (CT) and test-result dependent management
27360|NCT03972774|Other|Non-PET Medical Management|Appropriate medical management without cardiac PET stress-imaging
27361|NCT03972761|Device|Magnetic Resonance Imaging (MRI) 3 tesla|Functional neuroimaging objectifies the activation of specific areas of the brain
27362|NCT03972748|Drug|Itraconazole 200 mg|Oral Itraconazole capsules, 200 mg, twice daily, for 60 days prior to surgery with curative intent.
27363|NCT03972735|Other|Psychiatric interview|PANSS, MADRS, PSP, YMRS
27364|NCT03972735|Other|Clinical, diagnostic and functional evaluation|ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS
27365|NCT03972735|Other|neuropsychological assessment|WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS
27366|NCT03972735|Other|NECT PROGRAM|Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.
27367|NCT03972722|Drug|GLS-010|Patients will be given 240mg GLS-010 every treatment.
27368|NCT03972709|Drug|RO7171009|Intravitreal (ITV) injections of RO7171009
27369|NCT03972709|Drug|Sham Control|ITV injections of Sham Control
27370|NCT03972696|Radiation|Irradiation|BA3S versus BA2 irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
27371|NCT03972683|Other|Handgrip Exercise Training|Signaling mechanisms that regulate blood flow will be studied before and after 7 weeks of handgrip exercise training with the non-dominant forearm. Training sessions will consist of 30 min of rhythmic contractions using a handgrip exercise device, and participants will complete four training sessions per week.
27372|NCT03972683|Drug|Acetylcholine|Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
27613|NCT03970811|Procedure|Immediate Implants|dental implants are immediately placed after tooth extraction
27373|NCT03972683|Drug|Adenosine Triphosphate|Vasodilatory sensitivity to adenosine triphosphate will be assessed during infusion of a dose of 10 μg/dl forearm volume/min administered via a brachial artery catheter over a total of 4 min.
27374|NCT03972683|Drug|Atropine|Atropine will be used to inhibit muscarinic acetylcholine receptors in order to determine the contribution of acetylcholine to vasodilation during exercise. An initial dose of 0.2 mg will be infused via a brachial artery catheter over 3 min, then a maintenance dose of 0.067 mg will be infused over 1 min prior to each of 5 subsequent experimental trials.
27375|NCT03972683|Drug|Phenylephrine|Vasoconstriction to phenylephrine will be used to assess sensitivity to alpha 1 adrenergic stimulation. Phenylephrine will be infused via a brachial artery catheter at 0.125 or 0.25 μg/dl forearm volume/min (18-35 and 60-85 age groups, respectively), adjusted according to forearm blood flow, for a total of 16 min.
27376|NCT03972683|Drug|Sodium Nitroprusside|Sodium nitroprusside will be infused via a brachial artery catheter as a control vasodilator to elevate resting forearm blood flow to a level similar to that during exercise. The dose will be adjusted to match forearm blood flow to a similar level as during handgrip exercise, with an anticipated average dose of 1 μg/dl forearm volume/min. The dose will be infused for a total of 14 min.
27377|NCT03972657|Drug|REGN5678|Administered at the assigned dose level (DL) by intravenous (IV) infusion once weekly (QW)
27378|NCT03972657|Drug|Cemiplimab|Administered at the assigned DL by intravenous (IV) infusion every three weeks (Q3W)
27379|NCT03972644|Procedure|Aortic valve replacement|Open heart surgery or transcatheter surgery
27380|NCT03972631|Behavioral|Lifestyle education|Lifestyle education include the diet principles, physical activity guideline and behavioral strategies.
27381|NCT03972631|Behavioral|Intensive lifestyle intervention|One to one intensive lifestyle intervention according to the diet and activity plan
27382|NCT03972631|Behavioral|Hypocaloric low-carbohydrate diet plan|A diet plan with restricted calorie and carbohydrate intake
27383|NCT03972618|Behavioral|Installation of water filtration system for filtering existing water source|Installation of water filtration system and education on hand washing.
27384|NCT03972605|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
27385|NCT03972592|Drug|Topical 0.1% Sirolimus|The formulation is 0.03 g rapamycin, 1.5 g Transcutol, Quantum Satis (QS) 30g Excipial® hydrocream, corresponding to a concentration at 0.1%. The cream will be packaged in 30 ml aluminium tubes.
27386|NCT03972592|Drug|Topical Vehicle|The same vehicle than the one used in the topical 0.1% sirolimus preparation will be used for the other half area of CMLM, i.e. Excipial® hydrocream. It will be packaged to maintain the double blind way of this trial and will be undistinguishable from the sirolimus cream.
27387|NCT03972579|Behavioral|Graded exposure therapy|Gradually increased contact with avoided sensory stimuli (e.g., light, noise, movement) and activities (e.g., mental exertion, physical exercise, stressful activities) in order to increase tolerance.
27388|NCT03972579|Behavioral|Pacing + mindfulness|Shifting from symptom-contingent to time-contingent activity stopping rules, minimizing activity level peaks (excessive endurance behavior) and valleys (prolonged periods of recuperative rest) to improve overall functioning.
27389|NCT03972566|Drug|INOMAX|INOMAX + PBM
27390|NCT03972553|Procedure|Sugarbaker technique for repairing parastomal hernia|The bowel will be brought through the peritoneum lateral to the edge of the retromuscular mesh and then draped over the mesh before bringing it through the anterior fascia medially.
27391|NCT03972553|Procedure|Keyhole technique for repairing parastomal hernia|The bowel will be brought through defects in the posterior rectus sheath or contiguous peritoneum, mesh, and anterior fascia.
27392|NCT03972540|Behavioral|Mindful eating intervention|A Mindful Eating Workshop™ workbook was used for standardization and reproducibility of these sessions. The group sessions were focused on teaching applied strategies to consume food with intention and attention and aimed at improving emotional relationships with food. Intervention sessions were held once a week in the evening for 2 hours per session over 8 weeks. The intervention was delivered in a large conference room on the University of Georgia campus. Participants were required to attend seven out of eight sessions. If participants missed a session, they met with the instructor 30 minutes before the beginning of the following week's session to receive individual instruction on content of the missed session.
27393|NCT03972527|Device|Photobiomodulation|Provide photobiomodulation therapy to subjects prior to each radiation therapy session.
27394|NCT03972527|Other|Routine Oral Care and Analgesia|Standard oral care, oral hygiene and oral pain protocols
27395|NCT03972501|Drug|AZR-MD-001 Vehicle|AZR-MD-001 is an ophthalmic ointment
27396|NCT03972501|Drug|AZR-MD-001 Active Dose|AZR-MD-001 is an ophthalmic ointment
27397|NCT03972488|Drug|Lutathera|7.4 GBq/200 mCi x 4 administrations every 8 +/- 1 weeks
27398|NCT03972488|Drug|long-acting octreotide|30 mg every 8 weeks during Lutathera treatment and every 4 weeks after last Lutathera treatment
27399|NCT03972488|Drug|high dose long-acting octreotide|60 mg every 4 weeks
27400|NCT03972462|Drug|NPC-12G Gel 0.2%|Period 1
27401|NCT03972462|Drug|Rapamune® 2 mg tablet|Period 2
27402|NCT03972449|Behavioral|BEAT-Speech|BEAT-Speech integrates beatboxing techniques within speech-therapy services for individuals with speech sound disorders.
27403|NCT03972449|Behavioral|Traditional Articulation Approach|The traditional approach to treating speech sound disorders focus on one or two sounds at a time until they are mastered by the client. Perceptual and production training are used with target starting at simple (isolation) and moving to more complex (sentences). A variety of cues such as shaping and phonetic placement cues are used.
27404|NCT03972423|Other|With or wiyhout a checklist|The evaluation of the impact of the use of this Checklist will be done in comparison with the standard transmission practice
27405|NCT03972410|Behavioral|EMDR|2-4 sessions individual 60-min-long treatment sessions of EMDR Recent birth trauma protocol
27406|NCT03972410|Behavioral|SEDP|2-4 sessions individual 60-min-long treatment sessions of SEDP
27460|NCT03972020|Behavioral|Cognitive Behavioral Therapy|Cognitive behavior therapies will include cognitive restructuring, relaxation, skills training, and visual imagery, among other modalities.
49351|NCT03798626|Drug|Paclitaxel|6 mg/mL concentration; administered IV
27407|NCT03972397|Device|Intercostal Nerve Cryoablation|Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYO2 cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.
27408|NCT03972397|Drug|Bupivacaine liposomal injectable suspension|Patients from both groups will receive the same volume of diluted Exparel®, which will be given in four 20ml syringes using 22-gauge needles (266mg of liposomal bupivacaine, equivalent of one 1.3% 20ml vial of EXPAREL, diluted in 50ml of preservative-free normal (0.9%) sterile saline for a total volume of 70ml).
27409|NCT03972397|Drug|Patient-controlled analgesia (PCA)|Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
27410|NCT03972384|Behavioral|Post-ICU Problem Solving|"We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population."
27411|NCT03972371|Device|The ProVee Urethral Expander System|The ProVee Urethral Expander System is supplied as a single use, sterile device and consists of a nitinol expander implant and custom implant delivery system. The delivery system is designed to allow the implant to be deployed under direct vision.
27412|NCT03972358|Drug|Mifepristone|All participants will receive 200 mg mifepristone, to be taken orally on day 1.
27413|NCT03972358|Drug|Misoprostol|All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)
27414|NCT03972345|Drug|Norditropin® FlexPro®|Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
27415|NCT03972332|Diagnostic Test|Quantitative Sensory Testing|"PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT)."
27416|NCT03972319|Dietary Supplement|2 capsules of Concentrated omega-3 triglycerides- fish 1000mg (600mg Eicosapentaenoic acid (EPA), 1400mg Docosahexaenoic acid (DHA)) per day|4 weeks course of Omega-3 (2 capsules of Blackmores Omega Daily Concentrated Fish Oil per day
27417|NCT03972306|Drug|Ocrelizumab|Administered by subcutaneous Injection
27418|NCT03972306|Drug|Ocrelizumab|Administered by Intravenous (IV) Injection
27419|NCT03972306|Drug|rHuPH20|Administered in a 2-mL glass vial as a sterile, single-use, injectable liquid to be manually mixed with SC ocrelizumab
27420|NCT03972293|Behavioral|Intern Health Study behavioral change mobile notification|The study's mobile app will be used to deliver intervention notifications. The intervention notifications appear on the participant's phone lock screen. The notifications have 3 categories: mood notifications, activity notifications, sleep notifications. Mood notifications aim to increase the participant's mood. Activity notifications aim to increase the participant's physical activity. Sleep notifications aim to increase the participant's sleep duration. To increase the category of interest, the notifications use two types of messages: life insights and tips. Life insights provide participants information on their historical data (for a given category) in order to help them self-monitor. Tips are non-data based notifications which provide general advice for improving the category of interest.
27421|NCT03972293|Behavioral|Intern Health Study mobile app|The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.
27422|NCT03972280|Biological|Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody|Recombinant anti-G-CSF receptor monoclonal antibody is a preservative-free, sterile liquid formulation that is suitable for intravenous infusion
27423|NCT03972267|Procedure|Free gingival graft|Free Gingival Graft removal from the palate donor area for socket preservation
27424|NCT03972267|Device|Enamel Matrix Derivate|EMD in contact with the palate wound for 5 min. After this time, palatal area will be covered with an individualized acetate plate which will stay in position for 2 hours after the procedure
27425|NCT03972254|Behavioral|Modified Interaction Guidance|The main steps in the procedure are to have the family identify the primary concern they are facing, highlight the strengths that the family already has in place and expand on those strengths, convey/impart caregiving and societal norms, and offer other perspectives (McDonough, 2004). The goal of this therapy is to engage the family to take an active role in the construction of their overall treatment. The individualized treatment approach focuses and builds on existing strengths.
27426|NCT03972241|Device|foot insole|arch support and toe extension
27461|NCT03972007|Device|Fotobiomodulation|A 16x28 cm LED blanket containing 160 LEDs will be used and will use a total energy per area of 60J, with a wavelength of 940nm, just before the muscle fatigue protocol and will be applied throughout the Biceps extension.
27427|NCT03972228|Combination Product|Microdevice loaded with 19 chemotherapeutic agents|The microdevice containing 19 FDA-approved chemotherapeutic agents will be placed in the suspected tumor tissue at the time of surgical resection. Multiple chemotherapeutic agents will passively diffuse into local, confined regions (several microns) of the surrounding microenvironment. The agents are released at approximately one millionth of a systemic dose. The device(s) will be removed for analysis at the time of resection, which will be performed for clinical indications independent of enrollment in this study.
27428|NCT03972215|Drug|Berberine Chloride|Traditional Chinese Medicine
27429|NCT03972215|Drug|Placebo|Placebo Control
27430|NCT03972202|Diagnostic Test|MRI|Brain MRI will be performed (no contrast) to correlate brain anatomy/function with behavioral testing.
27431|NCT03972202|Device|TMS|Repetitive TMS will be applied to transiently disrupt cerebellar speech pathways.
27432|NCT03972202|Behavioral|Speech-motor behavioral testing|Language/speaking tasks will be performed during which participants are asked to speak in response to audio/video cues; participants' responses will be recorded. For patients with cerebellar ataxia, additional diagnostic surveys may be completed.
27433|NCT03972189|Drug|TQ-B3101|TQ-B3101 300 mg given orally in fasting conditions, twice daily in 28-day cycle.
27434|NCT03972163|Behavioral|NIA Medication Management - Active Comparator|"As the attention control, we will refer staff in control offices to the National Institution on Aging (NIA)'s website on Medicines and Medication Management to review content and materials for use in Family Care Giver (FCG) support."
27435|NCT03972163|Behavioral|STOPPFrail (Screening Tool of Older Persons Prescriptions)|A screening tool used by clinicians with frail older adults with life-limiting illness to review medications
27436|NCT03972163|Behavioral|"Discontinuing Medication Appropriately and Understanding the Art of Communication about Deprescribing"|Education resoruce used by clinicians to simplify and align medications with goals of care
27437|NCT03972163|Behavioral|"Key Approaches to Support Informal Family Caregivers in Managing Medications"|Education resource used by clinicians to support Family Care Givers (FCGs)
27438|NCT03972150|Drug|BI 836880|Solution for infusion
27439|NCT03972150|Drug|BI 754091|Solution for infusion
27440|NCT03972137|Behavioral|Cognitiive-Behaivoral Smoking Cessation|Participants will be provided with five individualized smoking cessation counseling sessions designed to help them prepare to quit, set a quit date, behaviorally manage early abstinence, and to resume cessation upon lapse.
27441|NCT03972137|Behavioral|Heart Rate Variability Biofeedback|Heart Rate Variability Biofeedback: All participants will be provided with individualized training in resonance breathing using biofeedback to help improve self-regulation.
27442|NCT03972137|Drug|Nicotine patch|All participants will be offered up to eight weeks of transdermal nicotine patch, beginning on their quit date.
27443|NCT03972124|Drug|CBD 50 mg BID|CBD oil - purified to <1% THC in soft-gel capsules
27444|NCT03972124|Drug|CBD 100 mg BID|CBD oil - purified to <1% THC in soft-gel capsules
27445|NCT03972124|Drug|Placebo|Soft-gel capsules containing placebo
27446|NCT03972111|Drug|TPOXX 200Mg Capsule|TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days
27447|NCT03972085|Other|Neural gliding exercises|"Neural gliding exercises: In addition to the Electrotherapy procedure, patients were asked to actively perform knee extension, ankle dorsiflexion and head extension in the slumped posture followed by simultaneous ankle plantar flexion together with knee and head flexion (10 repetitions in 1 minute). Patients performed the exercises under a home-based program for 5 days of the week during a total period of 3 weeks.~Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach."
27448|NCT03972085|Other|Electrotherapy sessions|Electrotherapy sessions: Local Hot Pack (30 minutes), Chattanoga™ TENS (20 minutes, 80-180 Hz frequency, 50-100 wavelength) and Chattanoga™ ultrasound (1 Mhz frequency, 3 W/cm2 3 minutes) were applied for 5 days per week during a total period of 3 weeks. Subjects in ETG did not do any other exercise approach.
27449|NCT03972072|Other|Pre-defined MR-linac based IGRT and plan adaptation protocol|daily MR-imaging/MR guided radiotherapy once weekly offline plan adaptation to a total of 6
27450|NCT03972072|Diagnostic Test|salivary flow measurements|baseline, 6 month-, 12 month- and 24 month-follow up salivary flow measurements and LENT-SOMA subjective/objective evaluation of xerostomia
27451|NCT03972059|Other|Exercise training - Phase 1|Phase 1 is the first 4 weeks of the 12-week training program.
27452|NCT03972059|Other|Exercise training - Phase 2|Phase 2 is the next 4 weeks following phase 1 of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in phase 1.
27453|NCT03972059|Other|Exercise training - Phase 3|Phase 3 is the last 4 weeks of the 12-week training program. The exercise intensity during exercise bouts in this phase is increased compared to the exercise intensity applied in the previous phases.
27454|NCT03972046|Drug|Talimogene laherparepvec (T-Vec)|Talimogene laherparepvec (T-Vec) up to 4mL subcutaneous injection
27455|NCT03972046|Drug|Dabrafenib (BRAF Inhibitor)|Dabrafenib (BRAF Inhibitor) 150 mg by mouth twice a day
27456|NCT03972046|Drug|Trametinib (MEK Inhibitor)|Trametinib (MEK Inhibitor) 2 mg by mouth once a day
27457|NCT03972033|Behavioral|EMDR|"EMDR comprise 20 individual sessions in 16 weeks and will be conducted according to published treatment manuals. Psychotherapy visits are to be scheduled twice a week for weeks 1-4, then once a week for 12 weeks.~Safety criterion: If a severe worsening of symptoms is evaluated during assessments points patients would be withdrawn from their assigned treatment arm."
27458|NCT03972033|Drug|Citalopram|Citalopram will be provided for 16 weeks.
27459|NCT03972020|Behavioral|Mindfulness Based Intervention|"The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on:~(1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a window of tolerance in order to maximize the clinical utility of the intervention and tailor it to breast cancer patients."
27462|NCT03971994|Behavioral|Facial expression recognition task|We will present emotional expressions to participants. Their task will be to determine which emotion is expressed by each face. Participants' eye movements and brain activity will be recorded while they explore the face.
27463|NCT03971981|Dietary Supplement|100% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
27464|NCT03971981|Dietary Supplement|22% Xylitol Gum|Subjects were instructed to consume the gums as they normally would be consumed.
27465|NCT03971968|Procedure|Skin replacement with artificial skin|Integra® Dermal Regeneration Template is a bilayer membrane system for skin replacement. The dermal replacement layer is made of a porous matrix of fibers of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate). The epidermal substitute layer is made of thin polysiloxane (silicone) layer to control moisture loss from the wound. The silicone outer layer temporarily closes the wound to ward off infection and control fluid and heat loss. As skin cells migrate into the matrix the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, new dermal skin is produced and the silicone layer can be removed. A thin skin graft of the person's epidermis is applied to the wound area to complete the procedure. In total, the two surgical procedures are typically completed within 30 days. A person is left with flexible growing skin and minimal damage at the skin graft donor sites.
27466|NCT03971955|Other|Mixed Meal Test|a standard liquid mixed meal will be administered to the participant. The test meal with 1 kcal/ml and with the following caloric distribution Protein: 25%, Carbohydrate: 53%, Fat: 22% is given at a dose of 6 mL per kilogram body weight. Maximum dose is 360 mL and it will be ingested over 5 minutes. Blood samples will be taken 10 min prior to ingestion (t=-10), at baseline (t = 0), and at 15, 30, 60, 90, and 120 minutes.
27467|NCT03971955|Other|Dual Energy X-Ray Absorptiometry (DEXA)|DEXA Scans will be performed to obtain body composition measures (body fat and estimated muscle mass) using a General Electric (GE) Lunar iDXA whole-body scanner.
27468|NCT03971955|Procedure|Adipose Tissue Biopsy|The abdominal skin 6-10 cm lateral to the umbilicus will be cleansed with chlorhexidine. A sterile drape is placed, and the skin and adipose tissue will be anesthetized using Lidocaine. A 3-4 mm Mercedes Liposuction cannula will be inserted for aspiration of up to 2g of adipose tissue.
27469|NCT03971942|Behavioral|Neutral ABMT|In the neutral attention bias, there are 108 pairs of neutral-negative words, 54 pairs of which are used in the training group and 54 pairs of which are used in the placebo group. The word pairs in each group are repeated 4 times, with a total of 216 trial. Participants received 8 sessions over 2 weeks (1 session every other day).In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position.
27470|NCT03971942|Behavioral|Positive ABMT|In the positive attention bias, there are 54 pairs of neutral-negative words, 27 pairs of which are used in the training group and 27 pairs of which are used in the placebo group. The word pairs in each group are repeated 8 times, with a total of 216 trial.Participants received 8 sessions over 2 weeks (1 session every other day). In booster ABMT, participants received 4 sessions over 2 weeks (1 session every three days).90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position.
27471|NCT03971929|Drug|SHR0532|once daily(QD) for 4weeks
27472|NCT03971929|Drug|SHR placebo|once daily(QD) for 4weeks
27473|NCT03971929|Drug|Hydrochlorothiazide 25 mg|once daily(QD) for 4weeks
27474|NCT03971916|Drug|HBM9161(HL161BKN)|Subcutaneous injection; Single dose on Day 1
27475|NCT03971916|Drug|Placebo|Subcutaneous injection; Single dose on Day 1
27476|NCT03971903|Behavioral|Attention bias modification|The ABM training task was a variation of the computerized visual dot-probe task. During the training, each session includes 54 neutral-sad word pairs presenting 6 times (6 × 54=324 trials) during 20-minute. Participants received 12 sessions over 4 weeks (1 session every other day). In the active ABMT, 90% of the probes appeared at the neutral position and 10% at the sad position. At the placebo ABMT, 50% of the probes appeared at the neutral position and 50% at the sad position.
27477|NCT03971890|Other|Dance therapy|The experimental group will receive a dance treatment.This protocol will be administered at weekly sessions of 60 minutes with a period of 2 times / week with a total of 16 sessions, distributed over a 8-week period. They will be evaluated at baseline, after the end of the last treatment session.
27478|NCT03971890|Other|Educational group|The control group will receive an educational intervention. They will be evaluated at baseline, after the end of the last treatment session.
27479|NCT03971877|Diagnostic Test|Rapid Polymyxin NP test|From rectal swabs of patients admitted in ICU and oncohaematology ward, investigators will use first a new culture medium (SuperPolymyxin) for screening the colistin resistant Gram negative and then a new rapid test (Rapid Polymyxin NP test) to confirm this resistance. These tests will be compared to the reference test of MIC (Minimal Inhibitory Concentration) determined by the broth micro-dilution (BMD) method.
27480|NCT03971851|Other|Frailty risk groups|Patients older than 65 will be separated into groups of varying frailty risk
27481|NCT03971838|Behavioral|Positive Outcomes for Women|"Women and their children 10+ can consent to participate in the diabetes prevention programming offered through the research center. We will collect data at three time points, baseline, 4-6 months, and 12 months.~2. Instead of participating in Encourage, women may participate in other diabetes prevention programming/weight management programming offered by other entities. Researchers will consent these women into the study to complete 3 data collection points, baseline, 4-6 months, and 12 months. Additionally, researchers will consent women to obtain data from their chosen program. For instance, if a woman chooses to do a Diabetes Prevention Program through the YMCA, researchers will ask women to self report their weekly attendance and weight."
27482|NCT03971825|Drug|CC-92252|CC-92252
27483|NCT03971825|Other|Placebo|Placebo
27484|NCT03971812|Biological|Blood sample|A blood sample of two 10 mL ethylenediaminetetraacetic (EDTA) tubes will be taken at the time of the visit. This sample will be centrifuged for isolation of peripheral blood mononuclear cells (PBMC).
27609|NCT03970837|Drug|csDMARDs|Stable dose of csDMARD(s) as SoC.
27485|NCT03971799|Biological|CD33CART|"The treatment regimen will consist of lymphodepleting chemotherapy followed by CD33CART infusion:~Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD33CART infusion (starting at dose level 1 [DL1]: 3 x 105 transduced CAR-T cells/kg) on Day 0 Subjects will be evaluated for response at Day 28 (+/- 7 days) post-CD33CART infusion via bone marrow and lumbar puncture evaluation. Subjects will then proceed to allogeneic HCT or alternative therapy as clinically applicable."
27486|NCT03971786|Behavioral|Quality of life|Assessment of quality of life through measuring scales
27487|NCT03971773|Other|hypnosis|patient with cancer will undergo sessions of hypnosis
27488|NCT03971760|Other|Suction drain removal|Removal of negative pressure suction drain left in place to drain the surgical space after a neck surgery
27489|NCT03971747|Biological|AFP Specific T Cell Receptor T Cells|Autologous T cells transduced with lentivirus encoding AFP specific TCR gene
27490|NCT03971734|Drug|Regadenoson 0.05mg|Regadensoson 0.05mg administered prior to MRI
27491|NCT03971734|Drug|Regadensoson 0.1mg|Regadensoson 0.1mg administered prior to MRI
27492|NCT03971734|Drug|Regadensoson 0.2mg|Regadensoson 0.2mg administered prior to MRI
27493|NCT03971734|Drug|Regadensoson 0.4mg|Regadensoson 0.4mg administered prior to MRI
27494|NCT03971734|Drug|Regadensoson 0.7mg|Regadensoson 0.7mg administered prior to MRI
27495|NCT03971734|Drug|Regadensoson 1.0mg|Regadensoson 1.0mg administered prior to MRI
27496|NCT03971734|Drug|Regadensoson 1.4mg|Regadensoson 1.4mg administered prior to MRI
27497|NCT03971708|Drug|Lidocaine|Local anesthetic
27498|NCT03971708|Drug|Ropivacaine|Local anesthetic
27499|NCT03971695|Drug|BI 706321|Capsule or Oral Solution
27500|NCT03971695|Drug|Placebo|Capsule or Oral solution
27501|NCT03971682|Behavioral|PSYCHOPATHY.COMP program.|"The PSYCHOPATHY.COMP program is a structured individualized program for detained youth based on Compassion Focused Therapy, aimed to develop a compassionate motivation in these youth.~Treatment As Usual Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation."
27502|NCT03971682|Other|Treatment As Usual - TAU|Treatment As Usual (TAU) in Portuguese juvenile detention facilities is primarily aimed to increase educational and professional qualifications, as well as to promote behavioral regulation.
27503|NCT03971669|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
27504|NCT03971656|Dietary Supplement|Nutritional Supplement|Oral nutritional supplementation
27505|NCT03971656|Behavioral|Preoperative Dietitian Consult|Nutritional assessment
27506|NCT03971656|Behavioral|Education|Informational materials about nutrition
27507|NCT03971643|Drug|IFX-1|IV infusions of IFX-1 diluted in sodium chloride.
27508|NCT03971630|Other|Telemedicine|Patients will be followed up using the MyVENT System and APP
27509|NCT03971617|Drug|Hydrogen|each hydrogen tablet contains 80mg magnesium
27510|NCT03971617|Drug|Placebo oral tablet|matching placebo tablet
27511|NCT03971604|Drug|Vitamin A|treated with Vitamin A
27512|NCT03971604|Drug|Vitamin E|treated with Vitamin E
27513|NCT03971591|Behavioral|Guided Lifestyle Program Intervention|The Guided Lifestyle Program will receive sessions that meet twice weekly and 2-3 text messages weekly. They will also receive a participant informational binder with health and exercise information and tools as directed by ACS nutrition and physical activity guidelines.
27514|NCT03971578|Other|No Intervention Provided|No Intervention Provided
27515|NCT03971565|Biological|Blood sample 5 milliliter|The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
27516|NCT03971552|Procedure|gadolinium-enhanced extracranial magnetic resonance angiogram|288 of the 912 acute ischemic stroke patients received gadolinium-enhanced extracranial MRA additionally to the standardized stroke MRI imaging protocol.
27517|NCT03971539|Drug|BI 894416|Tablet
27518|NCT03971539|Drug|Placebo|Tablet
27519|NCT03971526|Other|MRI images review|MR images were reviewed by one junior radiologist and one senior neuroradiologist, both blinded to clinical, therapeutic and follow-up data.
27520|NCT03971513|Procedure|Trans abdominal plane|"Trans abdominal plane block is performed with ultra sound guidance.~- The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen).~- When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
27521|NCT03971500|Drug|AntiPlatelet therapy|AntiPlatelet therapy with ticagrelor + aspirin or ticagrelor alone.
27522|NCT03971500|Procedure|Percutaneous coronary intervention|PCI with DES implantation
27523|NCT03971487|Behavioral|Psychosis and cognitive assessments|Administration of MINI, PANSS and Quality of Living scales
27524|NCT03971487|Behavioral|Physical and neuro-cognitive evaluations|Physical, neurological and cognitive evaluations.
27525|NCT03971487|Diagnostic Test|Safety labs and electrocardiogram|Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
27526|NCT03971487|Biological|Ocrelizumab infusion|Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
27527|NCT03971474|Drug|Docetaxel|Given IV
27528|NCT03971474|Drug|Gemcitabine|Given IV
27529|NCT03971474|Drug|Gemcitabine Hydrochloride|Given IV
27530|NCT03971474|Biological|Pembrolizumab|Given IV
27531|NCT03971474|Drug|Pemetrexed|Given IV
27532|NCT03971474|Drug|Pemetrexed Disodium|Given IV
27533|NCT03971474|Biological|Ramucirumab|Given IV
27534|NCT03971461|Drug|Lutathera|administered intravenously every 8 weeks for a total of 4 doses
27610|NCT03970824|Biological|CT-P17|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
27611|NCT03970824|Biological|US-licensed Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
49352|NCT03798626|Drug|Cabozantinib|60 mg tablet; administered orally
27535|NCT03971448|Device|LPWB|The LPWB will be placed by clinical staff who will have been trained on the proper application of this device at the initial ED visit. At ED discharge, both populations will receive identical documentation on recommendations for weight bearing, type and frequency of analgesics, reasons to return for medical attention. The only difference will be care instructions related to the specific immobilization device. Specifically, the experimental group will be permitted to remove the LPWB as early as one week post ED visit as tolerated by the patient's symptoms.
27536|NCT03971448|Device|AKWC|If the patient is randomised to AKWC, it will be apply by a cast technician. Children with AKWC immobilization will be provided with up to two appointments in the orthopedic clinic. In case the AKWC could not been placed at initial visit, the first will be within 72 hours of the ED visit to have the fiberglass AKWC placed. The second appointment will be for cast removal.
27537|NCT03971422|Drug|Rozanolixizumab|Rozanolixizumab will be administered by subcutaneous infusion in 2 different dosages (dose 1 and dose 2) in dosage regimen 1 and 2.
27538|NCT03971422|Other|Placebo|Subjects will receive placebo at pre-specified time points.
27539|NCT03971409|Biological|Anti-OX40 Antibody PF-04518600|Given IV
27540|NCT03971409|Drug|Avelumab|Given IV
27541|NCT03971409|Drug|Binimetinib|Given PO
27542|NCT03971409|Biological|Utomilumab|Given IV
27543|NCT03971396|Other|Physiotherapists working in intensive care|Physiotherapists working in intensive care will be reached by mail or telephone. Physiotherapists will be asked to complete the prepared questionnaire.
27544|NCT03971383|Drug|Aolanti Weipang Tablets|3 tablets one time, 3 times a day(tid)
27545|NCT03971383|Drug|Placebo|3 tablets one time, 3 times a day(tid)
27546|NCT03971370|Biological|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
27547|NCT03971370|Biological|Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)|Zagreb post-exposure immunization schedule at day 0,7,21.
27548|NCT03971370|Biological|Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)|Essen post-exposure immunization schedule at day 0,3,7,14,28.
27549|NCT03971357|Drug|Netarsudil|netarsudil opthalmic solution 0.02%
27550|NCT03971357|Drug|Placebo|Placebo eye drops
27551|NCT03971331|Device|PAC catheter and critical care ultrasound examination|Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
27552|NCT03971292|Genetic|RNA sequencing|Testing interest of messenger RNA sequencing for the etiological diagnosis of unresolved patients after sequencing coding regions.
27553|NCT03971279|Drug|Dexamethasone Ophthalmic implant|intravitreal injection of ozurdex implant
27554|NCT03971266|Device|Activity Monitor|Wear a Fitbit
27555|NCT03971266|Other|Media Intervention|Complete smartphone based PRO diary
27556|NCT03971253|Drug|Peficitinib|Oral
27557|NCT03971240|Procedure|evacuation of traumatic acute subdural hematoma|craniotomy will be done with evacuation of the hematoma
27558|NCT03971227|Device|Acuity 200 (Fluoroxyfocon A) contact lens|Daily wear rigid gas permeable contact lens
27559|NCT03971227|Device|Acuity 100 (Hexafocon A) contact lens|Daily wear rigid gas permeable contact lens
27560|NCT03971214|Drug|PD-1 inhibitor JS-001|The extensive-stage SCLC patients will receive PD-1 inhibitor treatment after standard first-line chemotherapy, chest radiotherapy ± SABR for metastasis disease, and propylactic cranial irradiation untill disease progression or death.
27561|NCT03971201|Procedure|hepatic resection|removal of portion of liver containing cancer
27562|NCT03971201|Drug|Sorafenib|sorafenib either as adjuvant therapy after resection or as only treatment
27563|NCT03971188|Procedure|Trapeziectomy with Internal Brace|Trapeziectomy is performed in standard fashion. Longitudinal traction applied to thumb. Suture anchor with suture tape is inserted into drill hole at radial thumb metacarpal base. A second suture anchor is inserted into a drill hole at the radial base of the index metacarpal such that the suture tape suspends the thumb at the natural groove. Thumb position and tension assessed.
27564|NCT03971175|Procedure|Forceps biopsy|Endobronchial biopsy with the forceps
27565|NCT03971175|Procedure|Cryobiopsy|Endobronchial biopsy with the cryobiopsy probe
27566|NCT03971162|Drug|3+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 3 months,
27567|NCT03971162|Drug|6+PRN|intravitreal injection of Conbercept 0.5mg every month repeated for 6 months
27568|NCT03971149|Behavioral|EMPOWER|EMPOWER includes 4 weekly home visit and 4 follow up booster phone calls every other week for the following 8 weeks. The trained nurse interventionist will address identified adherence barriers related to knowledge deficits about heart failure and its treatment including psycho-social barriers and logistic barriers with their primary care physician if necessary.
27569|NCT03971136|Diagnostic Test|pulmonary ultrasound|The subjects will have an ultrasound on admission and on day 1, 2 and 3
27570|NCT03971123|Drug|Tricaprilin|Tricaprilin formulated as AC-SD-03 50g of AC-SD-03 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
27571|NCT03971123|Drug|Tricaprilin|Tricaprilin formulated as AC-LMP-01 50g of AC-LMP-01 (20g tricaprilin) mixed in 240mL dosing liquid at Hour 0 Day 1
27572|NCT03971123|Drug|Placebo|Matching placebo to AC-SD-03 50g of AC-SD-03P mixed in 240mL dosing liquid at Hour 0 Day 1
27573|NCT03971110|Drug|Zoladex and Casodex|The eligible subjects will receive Casodex 50 mg orally per day in combination with Zoladex 10.8 mg implant subcutaneously as neoadjuvant therapy per 12 weeks for up to 24 weeks.
27574|NCT03971097|Behavioral|Six Step Model of Self-Forgiveness|"The six-step model includes a workbook that applies Worthington's (2013) conceptualization of self-forgiveness and guides the practitioner and participant through the self-forgiveness process. Each step provides a framework for techniques and includes psychoeducation, interventions, and homework to be completed in between sessions. The individual sessions will not conflict with the timing or content of the unit's regular treatment schedule, thus, participation in the study will not affect a patient's ability to participate in TAU. All interventions will be done individually to ensure that participant confidentiality is respected throughout the therapeutic process."
27612|NCT03970824|Biological|EU approved Humira|40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
27575|NCT03971097|Behavioral|Treatment as Usual (TAU)|Treatment as Usual (TAU) includes four group therapy sessions facilitated by the social services team (counselors and social workers), two 12-step meetings facilitated by outside representatives of Alcoholics Anonymous (AA) and Narcotics Anonymous (NA), dietary, spirituality, medical care including vital signs and the administration of prescribed medication by the nursing staff, and individual needs assessment with a recommendation of appropriate aftercare.
27576|NCT03971084|Other|Sugar free gum without CPP-ACP|Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
27577|NCT03971084|Other|Sugar free gum with CPP-ACP|Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
27581|NCT03971058|Biological|IXIARO®- Japanese Encephalitis vaccine|Booster Immunisation With IXIARO®- Japanese Encephalitis vaccine
27582|NCT03971045|Drug|Pembrolizumab|Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle
27583|NCT03971032|Procedure|Hysteroscopy|Diagnostic procedure
27584|NCT03971032|Device|Infrared Spectroscopy|This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
27585|NCT03971019|Drug|statins|On the basis of dietary intervention. Simvastatin 20mg/d QN Po (half an hour before bedtime) (dosage can be adjusted according to other indicators of blood lipid level in each review), atorvastatin 10mg/d QN Po (half an hour before bedtime) (patients who can not tolerate the side effects of simvastatin can consider replacing this drug).
27586|NCT03971019|Behavioral|Dietary intervention group (control group)|Restriction of dietary components that increase LDL-C Saturated Fatty Acids Less than 7% of total energy Dietary cholesterol < 300 mg/d Increasing Dietary Ingredients for Reducing LDL-C Phytosterol 2~3 g/d Water soluble dietary fiber 10~25 g/d total energy Adjusted to maintain ideal weight or lose weight Physical activity Maintain moderate intensity exercise and consume at least 200 kcal of calories per day
27587|NCT03970993|Biological|R21 Matrix-M vaccination|vaccination with R21 will be given intramuscularly at a dose of 2μg , 10μg and 50μg. Matrix-M will be mixed with R21 at the bedside and given intramuscularly at a dose of 50μg.
27588|NCT03970993|Biological|R21 Matrix-M vaccination and CHMI|vaccination with R21 will be given intramuscularly at a dose of 2μg,10μg and 50μg. Matrix-M will be mixed with R21 at the bedside and given intramuscularly at a dose of 50μg. Volunteers will be challenged with malaria by mosquito bite.
27589|NCT03970980|Other|fraction of inspired oxygen (FIO2)|Different group receives different (70% vs. 90%) fraction of inspired oxygen (FIO2) during the surgery.
27590|NCT03970967|Device|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of radioactive sources [Ra-224 containing stainless-steel 316LVM tubes- (Alpha DaRT seeds)]. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
27591|NCT03970954|Drug|low-dose IL-2|Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.
27592|NCT03970941|Other|Cost evaluation|The cost for the hospital of the strategy of management will be evaluated.
27593|NCT03970941|Other|Questionnaire|The quality of life of patients will be measured.
27594|NCT03970928|Device|PVI|A pulse oximetry probe which transfers data to the monitor with software able to calculate PVI data. The monitor automatically and continuously calculates the respiratory variations in the photoplethysmogram from data collected noninvasively via a pulse oximetry sensor.
27595|NCT03970915|Device|Body warmer|The body warmer will be wrapped in a waterproof treatment field to avoid the risk of burns, 2 body warmer will be applied on the inguinal crease and 2 on the subclavicular fossa.
27596|NCT03970915|Device|Standard warming procedure|Warming only according to the standard procedure : survival blanket and heating in the emergency vehicle.
27597|NCT03970902|Other|Integrated Osteoporosis Care|Complex intervention in family physicians, primary caregivers, patients, informal caregivers. The intervention has a patient-tailored implementation. Family physicians: postgraduate education on osteoporosis management and integrated care, educational material. Primary care stakeholders (nurses, pharmacists, dietitians, physiotherapists): specialist training on patient-support in osteoporosis management with attention towards self-management support (nurses), treatment adherence and administration (pharmacists), fall risk, weight-bearing exercises, balance training and fear of falling (physiotherapists) and anti-inflammatory nutrition with sufficient calcium, vitamin D and protein intake (dietitians). Patients: patient-tailored complex intervention consisting of: education, support consultation(s)/telephones from an osteoporosis nurse, a pharmacist, a physiotherapist and nutritional a dietitian. Informal caregivers: education on supporting osteoporosis self-management.
27598|NCT03970902|Other|Care As Usual|No intervention Patients receive care as usual from their family physician
27599|NCT03970889|Device|Klue|Klue is a software program the uses an Apple watch to detect hand motions which are indicative of eating.
27600|NCT03970876|Biological|ATGC-100|Clostridium Botulinum Type A
27601|NCT03970876|Biological|Botox®|Clostridium Botulinum Type A
27602|NCT03970863|Diagnostic Test|Prostate Health Index|Use Prostate Health Index for the follow-up after focal therapy.
27603|NCT03970850|Diagnostic Test|NeuMoDx CT/NG Assay|NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System
27604|NCT03970850|Diagnostic Test|FDA-cleared NAATs|Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs
27605|NCT03970837|Biological|GSK3196165|GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC.
27606|NCT03970837|Drug|Tofacitinib|Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally.
27607|NCT03970837|Drug|Placebo to GSK3196165|Placebo sterile 0.9% w/v sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC.
27608|NCT03970837|Drug|Placebo to Tofacitinib|Placebo cap (containing lactose) to be administered orally.
27614|NCT03970811|Procedure|temporary restoration|temporary restoration will be placed immediately after implant placement
27615|NCT03970811|Procedure|final restoration|final restoration (loading) will be placed 3 months postsurgical
27620|NCT03970772|Drug|Glucagon Injection|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
27621|NCT03970772|Other|Glucose Tablets|Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
27622|NCT03970759|Drug|Stannous Fluoride Dentifrice|Experimental stannous fluoride (0.454%) dentifrice
27623|NCT03970759|Drug|Positive control dentifrice|Positive control dentifrice containing (0.3%) triclosan.
27624|NCT03970759|Drug|Negative control dentifrice|Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
27625|NCT03970746|Biological|PDC*lung01|PDC*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.
27626|NCT03970746|Drug|Keytruda Injectable Product|The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.
27627|NCT03970746|Drug|Alimta Injectable Product|For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.
27628|NCT03970733|Biological|VLA15|a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
27629|NCT03970733|Biological|Placebo|PBS (Phosphate Buffered Saline)
27630|NCT03970720|Drug|Metoclopramide|10 mg metoclopramide four times a day
27631|NCT03970720|Drug|Placebo|10 mg matching placebo capsules four times a day
27632|NCT03970707|Other|Small Number of Players training protocol A|8 participants each side game (4vs4), size of pitch area 25*20 m. In total, 6 consecutive 4-minutes bouts interspersed by a 3-minutes rest between each bout will be executed.
27633|NCT03970707|Other|Large Number of Players training protocol B|16 participants each side game (8vs8), size of pitch area 25*20 m. In total, 3 consecutive 8-minutes bouts interspersed by a 1-minutes rest between each bout will be executed.
27634|NCT03970694|Radiation|Radiotherapy|"Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy."
27635|NCT03970694|Drug|oxaliplatin+capecitabine|Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
27636|NCT03970668|Drug|Linagliptin 5 mg Oral Tablet|Patients received linagliptin 5mg once daily orally plus a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
27637|NCT03970668|Drug|Insulin|Patients received a basal bolus insulin scheme, if they presented hyperglycemia (glucose levels above than 140 mg/dl)
27638|NCT03970655|Drug|Bupivacaine with epinephrine|Epinephrine Group will receive 4 ml of 0.5% Bupivacaine with epinephrine
27639|NCT03970642|Other|Video directly observed therapy|The intervention group will receive individualized text reminders on their phone prior to each dose of their depression medicine. They will be requested to use the VDOT smartphone app to make a video recording of each medication dose ingested during the 3 month study period following their first visit. The app will automatically upload the video to a HIPAA compliant server. Research staff will regularly monitor videos using a password protected website and document each medication dose.
27640|NCT03970629|Device|PERSONA Total Knee|Primary Total Knee Arthroplasty
27641|NCT03970616|Drug|Tivozanib|Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day
27642|NCT03970616|Drug|Durvalumab|1500mg every 28 days
27643|NCT03970603|Other|Early Weight-Bearing|Being directed to bear weight on the affected ankle two weeks from suture button fixation for syndesmotic disruption
27644|NCT03970603|Other|Delayed/Late Weight-Bearing|Being directed to bear weight on the affected ankle six weeks from suture button fixation for syndesmotic disruption
31371|NCT03940586|Drug|Letermovir tablet|Tablet administered orally based on age/weight
27645|NCT03970590|Behavioral|CTC Intervention|"An integrated peer narrative-based intervention (VIEW > SELECT > GET), beginning with VIEW In-person viewing of VA Stories narratives, followed by SELECT a favorite Veteran] Storyteller, and then GET favorite Storyteller narrative-aligned text messages over 6 months"
27646|NCT03970590|Behavioral|Control|6-month HTN management assessment text messages without narrative component
27647|NCT03970577|Drug|Rituximab|Two injections of Rituximab (375mg/m2) separated by one week (one at time of randomization and the other one week after) and definitive withdrawal of steroid at the time of second injection of Rituximab (for a total steroids exposure of 9 weeks)
27648|NCT03970577|Drug|Prednisone|exclusive oral steroid therapy (progressively tapered with the same procedure for all patients) for a total exposure of 24 weeks (taking into account the initial oral steroid therapy administered during 8 weeks in addition with the oral steroid treatment given after randomization). Each patient will be followed up until 18 months after randomization.
27649|NCT03970564|Diagnostic Test|Neck ultrasound guide lymph node sampling|Neck ultrasound done first and lymph nodes larger than 5 mm that are technically feasible are sampled using fine needle aspiration and/or core needle biopsy
27650|NCT03970551|Other|Physical Counter-maneuver|Physical counter-maneuver targeted at minimizing the large drop in BP seen in IOH patients.
27651|NCT03970551|Other|Stress Test|Stress test involving submerging your hand in ice water.
27652|NCT03970538|Device|LimFlow System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia
27653|NCT03970525|Device|Venturi pump|The venturi pump makes use of the venturi effect to create a vacuum. The venturi effect creates a vacuum by the flow of a fluid, typically air, over an opening. In many phacoemulsification machines, this requires nitrogen tanks or a self-contained air compressor. The vacuum level is created within a rigid drainage cassette, to which the phaco aspiration tubing is connected. Since there is no milking of the aspiration line, the phaco tubing can be made rigid with low compliance.
27654|NCT03970525|Device|Peristaltic vacuum pump|"The peristaltic pump uses rollers to compress the phacoemulsification outflow tubing in a peristaltic manner, thereby creating flow and vacuum. The compression of the rollers on the tubing with the rotation of the pump physically moves fluid and creates a continuous milking action on the fluid column, The phaco machine can directly control this flow level, hence the term flow based, however, the preset vacuum level is only achieved once there is occlusion of the outflow line, typically at the phaco needle tip with cataract material."
27655|NCT03970512|Device|Apioc-A and Apioc-S Contact Lenses|Appropriately fit, document and dispense a new spherical and toric contact lens design worn for up to 35 days.
27656|NCT03970499|Procedure|brain tumor resection|Intraoperative brain ultrasound elastography and ultrasensitive doppler during surgery
27657|NCT03970486|Procedure|Dry needling|For the needle manipulation technique, the needle will be pulled in and out (sparrow pecking) and redirected in small angles (coning) for 5-10 seconds. For the in situ technique, the needles will stay (in situ) in the left and right lumbar multifidus muscles for 10 minutes after the insertion of the needle.
27658|NCT03970473|Other|Pulmonary recruitment maneuver (PRM)- 30 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 30 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
27659|NCT03970473|Other|Pulmonary recruitment maneuver (PRM)- 15 cm H2O|Pulmonary recruitment maneuver (PRM) consists of five manual pulmonary inflations where each positive pressure inflation will be performed for 5 s at a maximum pressure of 15 cm H2O in the semi-fowler position (30° head-of-bed elevation ). PRM is performed after LS when the main umbilical port is remaining and aims to remove the remaining gas following LS.
27660|NCT03970460|Device|Primary TKA with cemented modular metal-backed tibial implant|Tibial implant will be done with a cemented implant
27661|NCT03970460|Device|Primary TKA with uncemented trabecular metal|Tibial implant will be done with a uncemented implant
27662|NCT03970447|Drug|Temozolomide|Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
27663|NCT03970447|Drug|Lomustine|Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
27664|NCT03970447|Drug|Regorafenib|Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
27665|NCT03970447|Radiation|Radiation|60 Gy
27666|NCT03970434|Other|Venous blood collection|Venous blood collection
27667|NCT03970434|Other|Peripheral blood collection|Peripheral blood collection
27668|NCT03970421|Other|Observation|Check clinical status at different time intervals during 3 months
27669|NCT03970408|Procedure|MNT1|"Participants will in supine. Arm will be position in standard MNT1. Shoulder, elbow, wrist and fingers will be maintained in the required position using a costumed splint throughout all testing.~All movements will be limited to the range where pain or other symptoms are not provoked. Passive neck flexion and rotation will be added to MNT1 and will be applied as tensioning movements at level 3. All movements will be repeated three times and an average will be calculated. Myrin goniometer will be used to assess neck flexion and rotation. The movements order will be randomized using excel random generation function. Movements will be done by a single trained therapist. The end position will be held up to 10 seconds until median nerve excursion is recorded by US. For US capturing, the transducer will be positioned perpendicularly and aligned longitudinally with the median nerve at the wrist. Assessor will be blinded to participants grouping."
27670|NCT03970395|Other|Osteopathic manipulative therapy (OMTh)|The Osteopathic Manipulative Therapy includes evaluation and treatment. The evaluation considers the pelvic girdle and lower limb, thorax abdominal area, pectoral girdle and upper limbs, cervical and upper thoracic area, cranial vault, cranial base and viscero cranium. The treatment is based on balanced ligamentous tension technique, myofascial release, visceral manipulation, and balanced membranous tension technique. The OMTh lasts for 45 minutes of which 15 minutes of evaluation and 30 minutes of treatment.
27671|NCT03970395|Other|Light Touch Therapy (LTT)|The LTT is consistent with the OMT during the phase of evaluation. The treatment retains the same areas used for osteopathic approach but avoids prolonged touch in any area of the body, moving the hands every few seconds, and by flattening and softening the surface of the hands to minimize focal areas of force.
27672|NCT03970395|Other|Repositioning therapy|"It consists of strategies that guide the parents to position the baby back to sleep, by alternating head position, the use of tummy time while supervised, and the infants must spend minimal time in car seats or other devices that promote supine positions. In active counter-positioning the parents are suggested to place some toys on the side of the head where neck rotation is limited while, when using the changing table, to alternate the end of the table at which the infant's head is placed."
27673|NCT03970382|Biological|NeoTCR-P1 adoptive cell therapy|The investigational agent in this protocol is NeoTCR P1, an autologous adoptive T cell therapy (ACT) for patients with solid cancer. NeoTCR P1 is composed of apheresis derived CD8 and CD4 T cells that are precision genome engineered to express one autologous TCR of native sequence that targets a neoepitope (neoE) presented by human leukocyte antigen (HLA) receptors exclusively on the surface of that patient's tumor cells and not on other cells in the body.
27674|NCT03970382|Biological|nivolumab|Nivolumab is a human IgG4 anti-PD-1 monoclonal antibody
27675|NCT03970369|Behavioral|Usual care|Personalized goals and an activity prescription.
27676|NCT03970369|Behavioral|Monitor|Participants wear a step counter to track activity goals.
27677|NCT03970356|Other|antibiotic stewardship intervention|The intervention is multifaceted, consisting of the implementation of an algorithm for restrictive use of antibiotics as proposed in recent guidelines (Verenso, Dutch guideline), tailored in close collaboration with local stakeholders to the specific implementation setting, by means of a modified participatory-action research (PAR) approach. To support the process of intervention-tailoring and -implementation, a toolbox comprising of materials, aids and actions is developed to be used at the discretion of the local stakeholders to support implementation of the algorithm.The algorithm is congruent with the Swedish and Norwegian guidelines, which also promote more restrictive use of antibiotics in case of non-specific symptoms, even though the algorithm is more detailed.
27678|NCT03970343|Device|OPTIMIZER Smart|"Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:~Programmable Optimizer Smart Implantable Pulse Generator (IPG)~OMNI Smart Programmer~Optimizer Smart Charger~Two commercially available intravascular leads complete the system."
27679|NCT03970330|Drug|Naltrexone|4.5mg daily dose, taken orally
27680|NCT03970330|Drug|Norethindrone Acetate|5mg daily dose, taken orally
27681|NCT03970330|Drug|Placebo|daily placebo pill, taken orally
27682|NCT03970317|Device|Broad Band Light|Broad Band Light Device
27683|NCT03970304|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
27684|NCT03970291|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
27685|NCT03970278|Other|No intervention|No intervention
27686|NCT03970265|Diagnostic Test|extraction of ELF and ILF from explanted lung tissue; meropenem concentration in ELF and ILF; ELF on postoperative day 1-5 when bronchoscopy is performed within clinical routine.|Interventions will only be performed on explanted lung tissue ex vivo and on supernatant of bronchoscopy and are therefore non-invasive
27687|NCT03970252|Drug|Fluorouracil|Given IV
27688|NCT03970252|Drug|Irinotecan|Given IV
27689|NCT03970252|Drug|Irinotecan Hydrochloride|Given IV
27690|NCT03970252|Drug|Leucovorin|Given IV
27691|NCT03970252|Drug|Leucovorin Calcium|Given IV
27692|NCT03970252|Biological|Nivolumab|Given IV
27693|NCT03970252|Drug|Oxaliplatin|Given IV
27694|NCT03970252|Procedure|Therapeutic Conventional Surgery|Undergo surgery
27695|NCT03970239|Drug|Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)|"Imaging of the serotoninergic system with Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 4 Megabecquerel/kilogram (MBq/kg) of [11C]-DASB immediately prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 2.1 milliSievert (mSv).~On a separate day, subjects will receive a single intravenous administration of approximately 3.7 MBq/kg of [18F]-altanserin for 120 minutes prior to imaging using Positron Emission Tomography (PET). The effective dose in human body is about 8.4 mSv."
27696|NCT03970239|Drug|Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin)|Imaging of the serotoninergic system with Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin). During this study, subjects will receive a single intravenous administration of approximately 3.7 Megabecquerel/kilogram (MBq/kg) of [18F]-altanserin 120 minutes prior to imaging using Positron Emission Tomography. The effective dose in human body is about 8.4 mSv.
27697|NCT03970226|Drug|Tocilizumab|"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 26 cycles (approximately 2 years)."
27698|NCT03970213|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|IV TXA given during surgery
27699|NCT03970213|Drug|Normal Saline 0.9% Infusion Solution Bag|IV saline given during surgery
27700|NCT03970200|Drug|Penn Microbiome Therapy - 001|Fecal Microbiota for Transplant, enema product
27701|NCT03970200|Drug|Penn Microbiome Therapy - 002|Fecal Microbiota for Transplant, suspension product
27702|NCT03970200|Drug|Penn Microbiome Therapy - 003|Fecal Microbiota for Transplant, capsule product
27703|NCT03970200|Drug|Antibiotics|Standard of care antibiotics
27742|NCT03969927|Device|Low-Fidelity PDS|"The principal investigator recently developed a low cost ($10,000) low fidelity portable driving simulator (PDS) in the University of Kansas Laboratory for Advanced Rehabilitation Research in Simulation (LARRS) that measures 25.5 Wide, 32.5 High, and 25 Deep and requires only approximately 4 square feet of space.~This intervention uses the PDS to retrain study participants and improve their driving related skills."
27743|NCT03969927|Device|High Fidelity Fixed-Base Simulator|This intervention uses the large high-fidelity fixed-base driving simulator to retrain study participants and improve their driving related skills.
27781|NCT03969602|Other|Biomedical and surgery-specific education|Biomedical and surgery-specific education preoperatively and an exercise manual postoperatively.
27704|NCT03970187|Other|Exposure-based eye contact training in Virtual Reality (VR)|"The intervention is an App for virtual reality. The VR App provides three different virtual scenarios. Participants will be asked to stand in front of a virtual audience and to maintain eye contact with audience members. The advance to higher difficulty levels is according to a pre-defined exposure scheme. Participants will be given all instructions via the App.~There will be three sessions on one day (duration of 20 min each) in study phase 1. The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking. In the study phase 2, there will be nine sessions spanning over two weeks (duration of 20 min each, with maximally one session per day). The indication is disproportionate fear of being evaluated by others and reduced eye contact as a typical avoidance strategy in individuals with fear of public speaking."
27705|NCT03970174|Other|Care Connector care transition module|Care Connector is an electronic interprofessional communication and collaboration tool. Its features include Physician Sign-Out, documentation, interprofessional care planner, messaging, and flow planner. The newest module is a care transition module which allows physicians to electronically generate discharge summaries as well as incorporation of allied health recommendation, but also will pull information into the PODS (Patient Oriented Discharge Summary) format designed by University Health Network. This results in a patient friendly discharge instruction sheet that can be provided to patient. The intervention arm will have access to the care transition feature, while the control wards do not.
27706|NCT03970161|Device|routine ophthalmic examination|Routine ophthalmic examination, including slit lamp, intraocular pressure, and fundus examinations using direct or indirect ophthalmoscopy after pupil dilation and optical coherence tomography (OCT) examination. Patients with DM also underwent fundus fluorescein angiography (FFA) examination.
27707|NCT03970148|Procedure|Nd: YAG laser|Before treatment an optical coherence tomography (OCT) scan of the macula is performed to monitor possible macular oedema. After application of anesthetic and midriatics drops, the patient is positioned on the chin and forhead support (ND: YAG laser). Then, a contact lens (panfundoscope) is filled with methylcellulose and placed on the cornea. The laser is focused on the opacity that is to be treated and the first laser stamp of an initial power of 3 mJ is applied. The measured direct effect will guide in further adjustment of the laser beam power to achieve the desired effect. After treatment, a single drop of corticosteroid is applied to the patient and an ocular patch is applied. On follow up days an OCT scan of the macula is performed to monitor possible side effects.
27708|NCT03970135|Other|Fasting|Fasting for 24 hours or until hypoglycemia (blood glucose < 3mmol/L) or symptoms of hypoglycemia
27709|NCT03970122|Drug|GFB-887|IMP
27710|NCT03970122|Drug|Placebo|Matching
27711|NCT03970109|Drug|ANS-6637|200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
27712|NCT03970109|Drug|Placebo oral tablet|Placebo oral tablet
27713|NCT03970096|Radiation|Total-Body Irradiation|Undergo TBI
27714|NCT03970096|Drug|Thiotepa|Given IV
27715|NCT03970096|Drug|Fludarabine|Given IV
27716|NCT03970096|Drug|Fludarabine Phosphate|Given IV
27717|NCT03970096|Drug|Tacrolimus|Given IV
27718|NCT03970096|Biological|Allogeneic CD34+-enriched and CD45RA-depleted PBSCs|Given IV
27719|NCT03970096|Drug|Methotrexate|Given IV
27720|NCT03970096|Biological|Anti-Thymocyte Globulin|Given IV
27721|NCT03970096|Drug|Cyclophosphamide|Given IV
27722|NCT03970096|Biological|Allogeneic CD34-positive Enriched Peripheral Blood Stem Cells|Given IV
27723|NCT03970096|Drug|Peripheral Blood Stem Cell|Given IV
27724|NCT03970070|Other|Informational Intervention|Complete Perioperative Ostomy Self-Management Telehealth program
27725|NCT03970070|Other|Quality-of-Life Assessment|Ancillary studies
27726|NCT03970070|Other|Questionnaire Administration|Ancillary studies
27727|NCT03970070|Other|Survey Administration|Ancillary studies
27728|NCT03970057|Behavioral|Internet-based Cognitive Behavioural Therapy|"MoodUP is an iCBT intervention that is tailored to perinatal women. The core content is presented via different types of devices, such as smartphones, tablets, laptops, or desktops, connected to the internet. The program is designed as an integration of online sessions, self-monitoring, homework, peer support, and therapist support.~MoodUP consists of six online sessions focused on CBT skills for improving stress, anxiety, and depressive symptoms among at-risk antenatal women; each session takes between 30 and 40 minutes to complete. The content of the sessions will be as follows: Session 1: Managing mood, Session 2: Psychoeducation, Session 3: Cognitive restructuring, Session 4: Behavioural activation, Session5: Lifestyle modification, Session 6: Problem-solving."
27729|NCT03970057|Other|Usual Care|Participants will receive a series of six, weekly online sessions comprising general antenatal education. The content of the sessions will be as follows: Session 1: Parenthood; Session 2: Diet; Session 3: Exercise; Session 4: Breastfeeding; Session 5: Rest and sleep and Session 6: Common pregnancy problems.
27730|NCT03970044|Drug|Exenatide 2 MG|Glucagon-like peptide-1 receptor
27731|NCT03970044|Drug|Dapagliflozin 10 MG|sodium-glucose co-transporter 2 (SGLT2) inhibitor
27732|NCT03970031|Drug|MSDC-0602K|MSDC-0602K tablets
27733|NCT03970031|Drug|Placebo oral tablet|Placebo tablets
27734|NCT03970018|Other|Intra-peritoneal pressure|Measurement of intra-peritoneal pressure
27735|NCT03970005|Behavioral|Step-Based Care Model|Care model comprised of psychosocial and pharmacological interventions in which individuals start with low-intensity interventions and progress onto progressively higher-intensity interventions until their reach remission criteria.
27736|NCT03969992|Drug|AeroFact|Aerosolized SF-RI 1
27737|NCT03969992|Other|nCPAP|nCPAP (nasal continuous positive airway pressure) alone
27738|NCT03969979|Diagnostic Test|Shear wave elastography|shear wave elastogrophy will be performed
27739|NCT03969966|Other|renal replacement therapy as clinically indicated|Continuous renal replacement therapy
27740|NCT03969953|Drug|Rivaroxaban 2.5 Mg Oral Tablet|Rivaroxaban is an orally administered selective direct factor Xa inhibitor.
27741|NCT03969953|Other|Placebo|Rivaroxaban matched placebo
27744|NCT03969914|Procedure|PEEP changes|All patients will be ventilated with a tidal volume of 6 ml/kg before the RRI assessment. Further, three level of PEEP (5, 10 and 15 cmH2O) will be randomly set. For each levels of PEEP, the RRI will be evaluated
27745|NCT03969901|Drug|IMI/REL|"Age-based dosing:~12 to <18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~2 to <12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~3 months to <2 years, to be determined (TBD)~Birth to <3 months (TBD) NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention."
27746|NCT03969901|Drug|Active Control|"All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents."
27747|NCT03969888|Drug|ABBV-3067|Tablet or capsule taken orally
27748|NCT03969888|Drug|Placebo ABBV-3067|Tablet or capsule taken orally
27749|NCT03969888|Drug|ABBV-2222|Capsule taken orally
27750|NCT03969888|Drug|Placebo ABBV-2222|Capsule taken orally
27751|NCT03969862|Device|NOVEOS® system|"The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase.~This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark."
27752|NCT03969849|Drug|REGN5713-5714-5715|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
27753|NCT03969849|Drug|Matching placebo|Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
27754|NCT03969836|Device|NeurOS system|NeurOS system pads will be placed on patients' head for monitoring.
27755|NCT03969823|Drug|Tagrisso|Osimertinib 80mg once daily until disease progression
27756|NCT03969810|Behavioral|Rounding Summary|Written summary of rounds
27757|NCT03969797|Device|RADIAQBIO Heart Guardian HR-501|Arm one offers ECG data and electric shocks recorded during AED operation.
27758|NCT03969784|Other|blood draw, tumoral biopsy tissus|Patient will have specific blood draw and part of their tumoral tissu biopsied
27759|NCT03969771|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program was developed by the University of Massachusetts Medical School.
27760|NCT03969758|Drug|Ciprofloxacin|will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively.
27761|NCT03969758|Drug|Cefixime|will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and <5 cm respectively.
27762|NCT03969745|Behavioral|Time restricted feeding|Restrict energy intake window to between 8am and 4pm
27763|NCT03969745|Behavioral|Caloric restriction|Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
27764|NCT03969732|Drug|1. amyloid PET；2. T807 PET|"Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).~Dynamic PET imaging 3D acquisition will be acquired 80 minutes after injection of 10 mCi 18F-T807 (4 x 300 seconds)"
27765|NCT03969719|Drug|Placebo|Placebo
27766|NCT03969719|Drug|PF-06835919|150 mg once daily
27767|NCT03969719|Drug|PF-06835919|300 mg once daily
27768|NCT03969706|Drug|Abemaciclib 200 MG|Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle
27769|NCT03969693|Radiation|Standard treatment protocol with combined chemoradiation|As for consolidative RT used in patients with early-stage Hodgkin lymphoma, the RT field must essentially include the mediastinum.
27770|NCT03969680|Biological|Auotologous BMSCs plus autologous PRP|30 mL of bone marrow will be aspirated from the iliac crests of patients in case group. BMSCs will be isolated from bone marrow and cultured. Before injection, 30 mL of blood will also be collected from each patient to produce 3ml PRP by cenrifugation. Cultured BMSCs will be collected and suspended by 3ml autologous PRP.
27771|NCT03969680|Biological|Auotologous PRP|30 mL of blood will also be collected from each patient to produce 3ml PRP by cenrifugation.
27772|NCT03969654|Device|PERSONA Total Knee|Primary Total Knee Arthroplasty
27773|NCT03969654|Device|Vanguard Total Knee|Primary Total Knee Arthroplasty
27774|NCT03969654|Device|NexGen Total Knee|Primary Total Knee Arthroplasty
27775|NCT03969641|Biological|Quadrivalent Recombinant Influenza Vaccine|The first recombinant inactivated influenza vaccine (RIV) using an insect baculovirus expression system and recombinant DNA technology
27776|NCT03969641|Biological|Quadrivalent Inactivated Influenza Vaccine|Standard inactivated influenza vaccine (IIV) manufactured involving the use of embryonated hen eggs.
27777|NCT03969628|Diagnostic Test|ICCMS|Risk caries assessment will consider ICCMS criteria
27778|NCT03969615|Device|SuperNO2VA nasal positive airway pressure devic|SuperNO2VA nasal positive airway pressure device utilizes supplemental oxygen and an adjustable pressure limiting valve to maintain upper airway latency
27779|NCT03969615|Device|Supplemental oxygen|5lpm of supplemental oxygen
27780|NCT03969602|Behavioral|Cognitive-behavioral Therapy|The biopsychosocial approach of CBT focuses on the complex interaction between psychological, social and biological factors. The biopsychosocial model assumes that health problems are hardly ever limited to just one domain of human experience but by multiple domains of human experience. CBT helps patients understand thoughts and feelings that influence behaviors. It consists of a cognitive aspect and a behavioral aspect. The cognitive aspect is based on Becks cognitive model: the way that individuals perceive a situation is more closely connected to their reaction than the situation itself. A person's cognition has impact on their mood and emotions, their bodily reactions and their behavior. The second part of cognitive behavior therapy focuses on the actual behaviors that are contributing to the problem. The goal of CBT is to identify maladaptive thoughts and change them into more realistic and constructive thoughts to modify feelings and behavior and thereby the experience of pain.
27782|NCT03969589|Behavioral|Reproductive Life Planning-Mental Health (RLP-MH) Intervention|RLP-MH intervention is comprised of two parts: 1) an in-person interactive session in which the participant works with an RLP-MH facilitator to explore pregnancy intentions and RLP goals, consider important factors that impact those goals (e.g. mental health and physical health conditions, psychosocial and lifestyle factors, values, preferences), and identify personal action steps to address RLP goals and 2) a 15-20 minute follow-up session in person or by phone one month later to discuss progress in addressing RLP goals.
27783|NCT03969589|Other|Written Materials on Reproductive Life Planning|Participants will receive written materials on reproductive life planning, contraception, and VA resources. Participants will be given the materials and study staff will briefly discuss the content with the participant.
27784|NCT03969576|Procedure|DEB-TACE|"Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response."
27785|NCT03969576|Procedure|cTACE|"Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response."
27786|NCT03969563|Behavioral|Mindfulness-based Stress Reduction|8-week Mindfulness-based Stress Reduction class that trains participants in mindfulness, meditation, and yoga.
27787|NCT03969563|Behavioral|Brain Health Education|8-week Brain Health education class that teaches participants about brain-behavior relationships, nutrition, aging facts, sleep, and memory.
27788|NCT03969550|Other|Measure of overall survival|Measure of overall survival among AR-PML (AIDS-related PML) patients, exposed or not to maraviroc (MVC), and immune reconstitution inflammatory syndrome (IRIS) onset.
27789|NCT03969537|Other|Telemedicine follow-up visit|Study participants will experience two telemedicine (live audio/video) visits.
27790|NCT03969524|Device|MRI|Patients will undergo magnetic resonance imaging (MRI) at baseline (T0) (before NAC) and after the 2nd cycle of neoadjuvant chemotherapy(T2). Histopathological examination (gold standard) of the surgical specimen will be done for each patient and Compared to the results of MRI.
27791|NCT03969511|Procedure|direct angio-suite admission|Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CT-scan in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.
27792|NCT03969511|Procedure|standard management|Arrival is in the MRI or CT-scan room. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
27793|NCT03969485|Device|Hybrid Fractional Laser|Hybrid Fractional Laser Device
27794|NCT03969472|Drug|probiotics|apply probiotic after operation
27795|NCT03969472|Device|Electrophysiologic Therapy|Pelvic floor electrophysiological therapy is used after surgery
27796|NCT03969459|Biological|breast milk collection|3 samples of 20 ml of breast milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
27797|NCT03969459|Biological|meconium collection|3 samples of 20 ml of meconium milk will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
27798|NCT03969459|Biological|newborn feces collection|3 samples of 20 ml of newborn feces will be collected between day 0 and day 4; between day 7 and day 15; and between day 21 and day 30 after childbirth.
27799|NCT03969459|Other|questionary of pesticide exposure of the mother|maternal questionary of pesticide exposure of the mother
27800|NCT03969446|Drug|Decitabine|Given IV
27801|NCT03969446|Biological|Pembrolizumab|Given IV
27802|NCT03969433|Device|TMSi Porti|Data collections
27803|NCT03969433|Device|Bloomlife sensor|Data collections
27804|NCT03969420|Drug|Alvocidib (flavopiridol) and cytarabine (Ara-C)|Alvocidib (flavopiridol), administered intravenously, + cytarabine (Ara-C), administered by subcutaneous injection
27805|NCT03969420|Drug|Alvocidib (flavopiridol)|Administered intravenously
27806|NCT03969394|Diagnostic Test|Medical imaging|Medical Imaging consisting of 1 MRI and 1 echocardiography at baseline
27807|NCT03969381|Radiation|diffusion weighted magnetic resonance image in lymphoma|compare between result of positron emission tomography /computed tomography and diffusion weighted imaging in followup of lymphoma
27808|NCT03969368|Device|rPMS device|Pelvic floor muscle contractions will be induced by the rPMS device.
27809|NCT03969368|Procedure|Pelvic floor muscle training|Control group will undergo a pelvic floor muscle training
27810|NCT03969355|Other|Mortality|Patients who died during PICU stay
27811|NCT03969342|Device|Point of care ultrasound training|Five-day in-person training on point of care ultrasound using portable ultrasound devices followed by remote monitoring of practice scanning
27812|NCT03969329|Drug|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
27813|NCT03969316|Procedure|Transversus abdominis plane block, Quadratus lumborum block|The TAP block which is one of the abdominal truncal blocks is performed with the blockage of the nerve group which innervates the anterior abdominal muscle wall layers. However, in QL block, the local anesthetic agent spreads through the abdominal wall and paravertebral space with the help of the perimuscular fascia to maintain the somatic analgesia.
27814|NCT03969303|Device|Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)|OCT SCAN
27815|NCT03969290|Device|Verofilcon A contact lenses|Daily disposable silicone hydrogel contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
27816|NCT03969290|Device|Etafilcon A contact lenses|Daily disposable contact lenses indicated for the optical correction of refractive ametropia (myopia and hyperopia)
27817|NCT03969277|Other|Graded Motor Imagery|"The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks."
27818|NCT03969277|Other|Standard Rehabilitation|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
27819|NCT03969277|Other|Home Exercise Program|Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 4 weeks.
27820|NCT03969277|Other|Cold Application|Cold application around the elbow joint for 15 minutes in every session.
27821|NCT03969264|Other|High Carbohydrate or Tree Nut Food Snacks|Snack consumption
27822|NCT03969251|Device|Transcranial Magnetic Stimulation (rTMS)|active high frequency repetitive TMS of left Dorsolateral Prefrontal Cortex
27823|NCT03969251|Device|Sham (SS)|repetitive sham rTMS
27824|NCT03969238|Behavioral|Helpline|This helpline will aim to provide patients with new diagnosis of pain who are prescribed opioids, access to education, support and free behavioral technique to help manage their pain such as mindfulness exercises. For those with opioid use disorder, the helpline will offer support in the form of education about the disorder, opioid withdrawal symptoms, risks of overdoses, and a variety of services such as help reach appropriate care with MAT licensed providers, information on FDA-approved MAT and naloxone, and, in some cases, behavioral intervention to keep patients engaged in treatment. The opioid helpline will provide a central resource for direct services and a portal for community services. It will also serve as a referral resource for health-care professionals.
27825|NCT03969212|Drug|Baloxavir Marboxil|Participants who are IPs will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.
27826|NCT03969212|Drug|Placebo|Participants who are IPs will receive a matching placebo as tablets. HHCs of IPs will not receive study medication.
27827|NCT03969199|Behavioral|Intervention|Dietary intervention in coordination with MANNA, who will deliver low sodium meals to patients for 90 days
27828|NCT03969186|Behavioral|Intervention|Telehealth intervention monitoring weight and medication adherence accompanied by a weekly phone call to monitor symptoms.
27829|NCT03969173|Procedure|applying PEEP3|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (3 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
27830|NCT03969173|Procedure|applying PEEP6|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (6 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
27831|NCT03969173|Procedure|applying PEEP9|"The baseline atelectasis score is measured using sonography with no PEEP. And then, the baseline cardiac index is measured using transesophageal doppler for 5 minutes each with 3 cmH2O of PEEP.~Apply PEEP (9 cmH2O) according to the patient's randomized group, and maintain the PEEP until the end of the operation."
27832|NCT03969160|Behavioral|Imaginal exposure|Imaginal exposure to mental imagery of phobic and neutral stimuli
27833|NCT03969147|Device|ManMaxAirway oropharyngeal airway adjunct|Healthy volunteers will self-place the ManMaxAirway.
27834|NCT03969147|Device|Guedel Oropharyngeal airway adjunct|Healthy volunteers will self-place the standard Guedel OPA.
27835|NCT03969147|Device|No airway adjunct|Healthy volunteers will have no airway adjunct in place.
27836|NCT03969134|Biological|ChAd63-KH|The vaccine will be injected intramuscularly into the arm.
27837|NCT03969134|Other|Placebo|The placebo will be injected intramuscularly into the arm.
27838|NCT03969121|Drug|Palbociclib|Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment
27839|NCT03969121|Drug|Endocrine therapy|Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcuta-neous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopau-sal women will receive letrozole 2.5 mg QD in 28-day cycles.
27840|NCT03969108|Drug|Indocyanine Green|ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
27841|NCT03969095|Behavioral|Tongue Pressure Resistance Training|2 supervised sessions per week: Each session will be a maximum of one hour in length and will include: 1) 20 repetitions of maximum isometric presses (MIPs) with rapid rise in pressure at the anterior location. 2) 15 regular saliva swallows with the IOPI bulb in place. 3)15 effortful saliva swallows with the IOPI bulb in place. 4) 10 generalization tasks with mildly thick liquid and IOPI.
27842|NCT03969082|Behavioral|Bibliotherapy|Students will read to patients during 30 minutes. They will read aloud and pause regularly to encourage patients to reflect on what is being read, on the thoughts the poem or book has stirred or on how the reading matter relates to their own lives.
27843|NCT03969069|Device|MAPLe|Additional assessment with MAPLe
27844|NCT03969056|Behavioral|Artificial Intelligence (AI) Activity|The intervention provides participants with an automated and personalized daily step goal intervention involving a sophisticated activity analytics algorithm using advanced statistics and machine learning.
27845|NCT03969056|Behavioral|10,000 steps|The intervention provides participants with an automated daily 10,000 step goal intervention
27873|NCT03968822|Drug|Lidocaine 2% Injectable Solution, Lidocaine 1% Injectable Solution, Bupivacaine 0.25% injectable solution, Bupivacaine 0.5% injectable solution, saline, no injection -- Followed by IL 20% IV Bolus|3 mL of test solution followed by 1.5 mL/kg of IL 20% IV Solution
27846|NCT03969043|Other|MRI|"The MRI examination will consist of a series of acquisition scans:~Scanning Scan: for positioning the functional volume of interest.~Task Scans: for exploring cerebral activation in emotional and action appraisal tasks during viewing high and low arousal stimuli and a localizer task .~Anatomical MRI: for analyzing the functional images, and measuring volumes of gray and white substances.~Resting state functional scan: for exploring cerebral activation during a rest activity.~Diffusion Tension Imaging: for measuring structural connectivity.~Perfusion imaging: scan for ensuring good perfusion conditions~All functional acquisitions will be performed in multi-slices in echoplanar mode using gradient echo sequences allowing the exploitation of the BOLD contrast."
27847|NCT03969030|Other|PEBRA model|"The participants in the intervention clusters are offered the PEBRA model. In the PEBRA model the ART visit/refill is coordinated by the PE, as much as feasible according to the participants' preferences. Thus, the preferences of each participant are captured at enrolment and after a strict schedule thereafter. The PE conducts the preference assessment using a tablet-based application, called PEBRApp, accoring to a specific schedule. First, the participant will be asked his/her preference regarding different domains of DSD (see below) and this will be entered into the PEBRApp. Secondly, the chosen preferences are assessed regarding feasibility with specific questions, as not all preference options are available to everyone all the time. The preference assessment entails the following three domains of DSD:~ART Refill~SMS notifications~Support"
27848|NCT03969017|Drug|pegylated interferon (Peg IFN)α-2b|Participants in NAs+Peg IFN Group will be treated by Peg IFNα-2b （180ug per week, the dose will be changed to 135ug or 90ug per week during the treatment if patients could not tolerate the side effects of Peg IFNα-2b). Peg IFNα-2b treatment will be performed until HBsAg <0.05IU/ml, with a maximum duration of 48 weeks.
27849|NCT03969017|Drug|Nucleoside （acid）analogue (NAs)|Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
27850|NCT03969004|Drug|Cemiplimab|Intravenous (IV) infusion over 30 minutes
27851|NCT03969004|Drug|Placebo|Intravenous (IV) infusion over 30 minutes
27852|NCT03968991|Diagnostic Test|VISIODOL® (Diagnostic tool)|Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
27853|NCT03968978|Biological|Tezepelumab (APFS)|Tezepelumab subcutaneous injection, administered by Accessorized pre-filled syringe (APFS).
27854|NCT03968978|Biological|Tezepelumab (AI)|Tezepelumab subcutaneous injection, administered by Autoinjector (AI) device.
27855|NCT03968965|Device|3D MvIGS Spine Navigation|The 7D Surgical MvIGS spine navigation system is for spatial positioning and orientation of surgical instruments during pedicle screw implantation in patients undergoing posterior fixation in single or multiple levels. The surgical light containing the machine vision cameras is the sole luminaire during image guided surgery.
27856|NCT03968965|Other|2D Fluoroscopy|Pedicle screws will be placed using 2D fluoroscopy as the intraoperative imaging modality.
27857|NCT03968952|Other|SMARThealth Pregnancy|Education and Training package on high-risk pregnancies and the associated long-term cardiometabolic risks; An mHealth platform providing mobile decision support to Community Health Workers.
27858|NCT03968939|Drug|Diphenhydramine (Benadryl)|Oral Diphenhydramine (Benadryl), 25 mg
27859|NCT03968939|Dietary Supplement|Melatonin|Oral Melatonin, 3 mg
27860|NCT03968939|Behavioral|Sleep Hygiene Education|"Brochure containing information about getting a good night's sleep."
27861|NCT03968926|Other|Arterial pressure management during circulatory support by VA-ECMO|Norepinephrine continuous infusion to maintain mean arterial pressure above 65 mmHg or at a higher level depending of the perfusion pressure targeted for the patient (mean arterial pressure between 65 and 85 mmHg)
27862|NCT03968913|Drug|Anakinra injection|anakinra 150mg in 5milliliters of sterile saline will be injected into the knee joint
27863|NCT03968913|Procedure|sterile saline injection|5 milliliters of sterile saline will be injected into the knee joint
27864|NCT03968900|Behavioral|Sleep restriction condition|On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep restriction condition(4 hours, TIB [Time in Bed]; 1:00 a.m. to 5:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and receive a hospital dinner and will be discharged after breakfast served at 8:00 a.m. After each discharge, participants' smoking withdrawals will be monitored. At 7:00 p.m., participants will be re-admitted to UAB Highlands sleep unit, repeating the same conditions on the first night.
27865|NCT03968900|Behavioral|Sleep extension condition|sleep extension On day 1, participants will complete study assessments and will be fitted with an Actiwatch and instructed to continue a fixed time in bed (8 hours duration with no more than 20 min deviation) centered on habitual sleep (e.g., 11:00 p.m. to 7:00 a.m.). Naps will not be allowed. Following the one-week baseline sleep stabilization, participants will engage in the sleep extension condition (10 hours, TIB; 10:00 p.m. to 8:00 a.m.). On the day of each sleep study, participants will be admitted to University of Alabama Birmingham (UAB) Highlands Hospital sleep unit at 7:00 p.m. and receive a hospital dinner and will be discharged after breakfast served at 8:00 a.m. After each discharge, participants' smoking withdrawals will be monitored. At 7:00 p.m., participants will be re-admitted to UAB Highlands sleep unit, repeating the same conditions on the first night.
27866|NCT03968887|Other|plasma oxidized low-density lipoprotein levels|Detection of plasma oxidized low-density lipoprotein levels
27867|NCT03968874|Device|Light box therapy|The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
27868|NCT03968874|Device|Negative Ion Generator|The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
27869|NCT03968861|Drug|Xenon|Inhaled xenon gas given via purposely designed ventilator
27870|NCT03968848|Drug|acalabrutinib|A 50-mg single oral dose of acalabrutinib will be administered.
27871|NCT03968835|Other|Bacitracin|For the first 30 people, bacitracin will be applied and covered with xeroform and gauze.
27872|NCT03968835|Other|Skin Graft|For the next 30 patients, the amputated composite skin and soft tissue unit will be thinned out to become a full thickness skin graft.
28301|NCT03965312|Device|Patient monitor|Temperature will be measured using a commercially available patient monitor.
27874|NCT03968822|Drug|Lidocaine 2% Injectable Solution, Lidocaine 1% Injectable Solution, Bupivacaine 0.25% injectable solution, Bupivacaine 0.5% injectable solution, saline, no injection -- Followed by Saline Bolus|3 mL of test solution followed by 1.5 mL/kg of Saline IV Solution
27875|NCT03968809|Diagnostic Test|CardioFlux Magnetocardiography|All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.
27876|NCT03968796|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|
27877|NCT03968796|Other|Sham Transcutaneous Electrical Nerve Stimulation (TENS)|
27878|NCT03968796|Other|Kinesio Taping|
27879|NCT03968796|Other|Sham Kinesio Taping|
27880|NCT03968783|Other|Monofilament suture|1.0 monofilament synthetic absorbable suture for closure of the low transverse uterine incision
27881|NCT03968783|Other|Multifilament suture|1.0 multifilament synthetic absorbable suture for closure of the low transverse uterine incision
27882|NCT03968770|Dietary Supplement|Experimental group|Probiotic (Lactobacillus casei) once daily taken by 6 weeks.
27883|NCT03968770|Dietary Supplement|Control group|Placebo of Probiotic once daily taken by 6 weeks.
27884|NCT03968770|Other|Usual medical care|NSAIDs, once daily taken and promotion of a healthy lifestyle by 6 weeks.
27885|NCT03968757|Device|easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)|Device for creation of anastomoses during laparoscopic RYGB surgery manufactured by Ezisurg Medical.
27886|NCT03968744|Drug|Safinamide|Safinamide taken per Os for 12 weeks
27887|NCT03968731|Other|Zocular Eyelid System Treatment|Zocular products contain okra-infused Zocusome micelles that gently lift and clear the oil, debris, and residue on eyelid margins. THerefore, the ZEST treatment is expected to improve signs and symptoms of Meibomian gland dysfunction (MGD) and reduce Contact lens discomfort associated with MGD.
27888|NCT03968718|Behavioral|Systematic ePROMs Assessment|"Depending on the care setting, eligible patients will be asked to fill in one of the following e-PROMs assessment:~Edmonton symptom assessment scale (ESAS-r) (outpatients)~Distress Thermometer (inpatients)~An ad hoc questionnaire adapted from the Bench-Can and EURACAN projects plus the institutional customer satisfaction survey (patients followed by multidisciplinary teams)"
27889|NCT03968692|Diagnostic Test|Prostate-Specific Antigen test|Prostate-Specific Antigen (PSA) test as opportunistic screening or in the presence of symptoms
27890|NCT03968679|Radiation|Unilateral elective nodal irradiation|After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
27891|NCT03968653|Drug|Debio 0123|Debio 0123 will be given as an oral capsule, once daily for 3 days during each 21-day cycle.
27892|NCT03968653|Drug|Carboplatin|Carboplatin will be given as an intravenous infusion in combination with Debio 0123 on day 1 from Cycle 2 onwards.
27893|NCT03968640|Dietary Supplement|CoQ10|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
27894|NCT03968640|Dietary Supplement|Placebo|The intervention will consist of a loading dose of reduced form CoQ10 of 1,800 mg/day tid for 4 weeks to be followed by a maintenance dose of 600 mg/day once daily from weeks 5 to 12. The intervention or allocation-controlled placebo will be administered by 72 hours after injury and will continue until 12 weeks after injury or until death or discharge, whichever comes first. Oral tablets (600 mg/tablet) will be administered to CoQ10 subjects who can swallow while a liquid form (100 mg/mL) will be administered to CoQ10 subjects requiring an enteral tube for nutrition.
27895|NCT03968627|Other|Rehabilitative intervention|intensive multidisciplinar rehabilitation
27896|NCT03968614|Other|Electric dry needling and conventional PT|Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy
27897|NCT03968614|Other|Conventional PT|Eccentric Exercise, Stretching and Manual Therapy
27898|NCT03968601|Other|Mitral regurgitation surgery such as mitral valve replacement or repair|Mitral regurgitation surgery such as mitral valve replacement or repair. All kind of mitral regurgitation surgery: replacement or repair, by median sternotomy of minimally invasive surgery, with or without tricuspid plasty
27899|NCT03968588|Drug|Tacrolimus(reduced), Mycophenolate mofetil(standard)|tacrolimus target trough blood level: 3~8ng/mL MMF dose: 1.5~2g/d
27900|NCT03968588|Drug|Tacrolimus(standard), Mycophenolate mofetil(reduced)|tacrolimus target trough blood level: 5~15ng/mL MMF dose: 0.5~1g/d
27901|NCT03968575|Device|laser treatment|sub-threshold micro-pulse laser treatment
27902|NCT03968562|Drug|2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor|2% Doxycline Cream in Generic Aquaphor or Generic Aquaphor will be applied topically twice during the study visit: first for 30 minutes, then for 6 hours duration.
27903|NCT03968549|Dietary Supplement|Probiotic|Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.
27904|NCT03968549|Other|Placebo|Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
27905|NCT03968536|Behavioral|fall prevention|Training in physiotherapy sessions and ergonomic home development
27906|NCT03968523|Procedure|Novel local infiltration technique|Local analgesic infiltration in the mesh fixation site
27907|NCT03968523|Procedure|TAP block|TAP block techinque
27908|NCT03968510|Procedure|parathyroidectomy|routine parathyroidectomy will be done for the treatment of adenoma
27909|NCT03968497|Other|Postoperative pain assessment with female investigator|Postoperative pain evaluation by a female investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
27910|NCT03968497|Other|Postoperative pain assessment with male investigator|Postoperative pain evaluation by a male investigator by using visual analogue scale, numeric rating scale and Painmatcher®.
27911|NCT03968484|Biological|platelet transfusion|Transfusion of platelets
27912|NCT03968471|Behavioral|Scoring tool in Chemotherapy-induced necrosis in Ewing sarcoma|"The aim of the present study is to evaluate which is the best scoring tool to determine the histological response to chemotherapy in localized Ewing sarcoma of bone.~The study will exam all the different systems to evaluate the histological necrosis after neo-adjuvant chemotherapy in all patients with localized Ewing sarcomas of bone surgically treated between 1982 and 2012."
27913|NCT03968458|Behavioral|CON|. Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
27914|NCT03968458|Behavioral|EX-30|Condition with an acute exercise set 30 minutes before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
27915|NCT03968458|Behavioral|EX-90|condition with an acute exercise set 90 minutes before lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
27916|NCT03968445|Drug|[18F]DPA-714-PET/MRI|[18F]DPA-714-PET/MRI
27917|NCT03968432|Behavioral|MIAS&Q|There were two interventions compared in this study: 1) Be Sweet to Babies Videos and Pamphlet; and 2) Be Sweet to Babies Videos, pamphlet, and MIAS&Q. The Be Sweet to Babies vaccination pain management videos and pamphlet were provided to all participants as this information is publicly available, and demonstrates the effectiveness of the evidence-based recommended vaccination pain management strategies for infants. In addition, a pamphlet was used which was developed in partnership with CHEO and Ottawa Public Health as a knowledge translation tool. Those in the intervention arm were also given MIAS&Q included five questions and statements based on the MI approach consisted of four scaled questions and two open-ended questions, aimed to present brief informative and affirmative questions and statements to help the parents reflect on their own thoughts and support them to advocate for the use of the recommended pain management strategies during their infant's vaccination.
27918|NCT03968432|Behavioral|Be Sweet to Babies Videos and Pamphlet|The Be Sweet to Babies vaccination pain management videos and pamphlet will be provided to all participants. Be Sweet to Babies vaccination pain management videos showing parents how to use breastfeeding, upright secure holding, and a small volume of sweet solution during vaccination, will be used. This pamphlet is a knowledge translation tool previously developed in partnership with the Children Hospital of Eastern Ontario (CHEO) and Ottawa Public Health and has been publicly available on the Ottawa Public Health Website since June 2013. The content presented about pain management for infants during vaccination is the same information as the video.
27919|NCT03968419|Drug|canakinumab|Administered subcutaneously
27920|NCT03968419|Drug|pembrolizumab|200mg administered intravenously every 3 weeks
27921|NCT03968406|Procedure|Quality-of-Life Assessment|Ancillary studies
27922|NCT03968406|Radiation|Radiation Therapy|Undergo radiation therapy
27923|NCT03968406|Drug|Talazoparib|Given PO
27924|NCT03968393|Drug|Investigators can choose from one of four Non-vitamin K oral anticoagulants (NOACs): Edoxaban 60mg daily, Apixaban 5mg twice daily, Dabigatran 110mg twice daily, or, Rivaroxaban 20mg daily.|Daily administration from time of randomization to final follow-up
27925|NCT03968380|Other|Population survey with biological and physical measurements.|Individuals will be interviewed in their homes by trained interviewers. At a later date, in a location agreed with the study team, a sample of blood will be taken and we will measure fasting glucose, cholesterol level and creatinine. We will measure participants' height, weight, waist circumference and blood pressure. An Oral Glucose Tolerance Test (OGTT) will be performed on non-diabetic and/or non-pregnant participants.
27926|NCT03968367|Procedure|Magnetic activated sperm sorting|MACS is a technique which allows the spermatozoa with the best characteristics to be selected for use in assisted reproduction treatments. This technique removes apoptotic spermatozoa - those which will die without achieving fertilisation - and selects the healthy ones, thus increasing the possibility of pregnancy.
27927|NCT03968354|Biological|"Collection of additional blood tubes; Biobanking (plasma, liver tissue)."|"Preservation of liver tissue obtain by liver biopsy, constitution of a collection~Sampling of additional blood tubes for a biological collection (serum): Serum biomarker research and genetic research"
27928|NCT03968341|Other|Pharmacokinetic and pharmacodynamic study of antibiotics used in severe endophthalmitis from samples taken from treated patients|"A 5mL dry tube will be taken by puncture of the humeral vein like a conventional blood test. This tube is not usually collected unless specifically requested by the ophthalmologist. This sample will be sent quickly (within two hours) to the CHNO Medical Biology Laboratory for centrifugation, serum separation and storage at -80°C.~Samples stored at -80°C will be sent weekly to the Microbiology and Anti-infectives Laboratory at Hospital Paris Saint-Joseph, with the dosage request form duly completed with the usual information."
27929|NCT03968328|Other|Interview|Take part in interview
27930|NCT03968328|Other|Survey Administration|Respond to survey
27931|NCT03968315|Procedure|Diaphragm Fluoroscopy|Undergo diaphragm fluoroscopy
27932|NCT03968315|Procedure|Magnetic Resonance Imaging|Undergo MRI
27933|NCT03968302|Drug|ARM A Triple therapy for helicobacter pylori|The triple regimen was defined as a combination of amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
27934|NCT03968302|Drug|ARM B Quadruple therapy for helicobacter pylori|Quadruple therapy included colloidal bismuth subcitrate 240 mg twice daily,amoxicillin 1 gm twice a day, clarithromycin 500 mg twice a day and omeprazole is given in 40 mg twice a day dose.
27953|NCT03968146|Drug|Fentanyl|patients will receive an induction dose at 1 mcg/kg. If the analgesia was inadequate in the form of increase in heart rate and or arterial blood pressure by more than 20% of baseline values during surgery, this warrants the administration of intravenous fentanyl (0.5µg/kg).
27935|NCT03968276|Other|use of digital tablet|"At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool."
27936|NCT03968263|Device|Hycon device(Routine protocol)|Hycon device will be activated half a turn every 3 days.
27937|NCT03968263|Device|Hycon device(Modified protocol)|The activation period of the hycon device will be modified.
27938|NCT03968263|Device|Hycon device(Routine protocol) and Vibration(Acceledent)|Hycon device will be activated half a turn every 3 days. Vibration will be applied 2 times 10 minutes per day.
27939|NCT03968263|Device|Hycon device(Modified protocol) and Vibration(Acceledent)|The activation period of the hycon device will be modified. Vibration will be applied 2 times 10 minutes per day.
27940|NCT03968250|Behavioral|Cognitive Behavioral Therapy for Treating Fatigue|"The internet-based CBT postcancer fatigue intervention includes two face-to-face sessions with their therapist and eight web-based treatment modules, each approximately 45 minutes in length, delivered over 6 months.~The intervention will be specifically tailored to the individual needs of each patient: The CBT model of cancer-related fatigue distinguishes six perpetuating factors: 1) insufficient processing of being diagnosed with HL and being treated for it; 2) excessive fear of disease recurrence; 3) inactivity or a dysregulated (physical) activity pattern; 4) dysfunctional fatigue-related beliefs; 5) dysregulated sleep-wake pattern and 6) lack of social support. For each of these six cognitive-behavioural factors that can perpetuate fatigue a treatment module has been developed."
27941|NCT03968237|Drug|Buprenorphine/Naloxone|Controlled substances
27942|NCT03968224|Drug|Dapagliflozin/Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided in combination with Dapagliflozin 10 mg per day. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
27943|NCT03968224|Drug|Metformin|Two tablets of Metformin 850 mg every 12 hours will be provided. Each participant will receive diet and exercise intervention according to their BMI and current physical condition.
27944|NCT03968211|Biological|Salmonella typhi polysaccharide vaccine|Salmonella typhi polysaccharide vaccine
27945|NCT03968198|Drug|Autologous ASC (for Adipose-derived Stem/Stroma Cell)|After adipose tissue aspiration (liposuction) by an authorized person, ASCs were isolated and cultured during 14±2 days by the French Blood Establishment. Then, patients receive intramuscular injections of ASCs.
27946|NCT03968185|Other|Interfascial infiltration|"Injection of L-bupivacaine (50 mg) and dexamethasone (4 mg) in the interfascial space under ultrasound guidance.~Patients were kept under surveillance for at least one hour before discharge.~Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6 h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
27947|NCT03968185|Other|Standard medical treatment|"Standard medical treatment include acetaminophen, NSAIDs and muscle relaxant as first line pharmacological treatment and escalation to analgesics level II or morphine if required, as needed for low back pain, in agreement with national guidelines Route of administration (orally or iv) was let at the discretion of the attending emergency physician.~Patients were kept under surveillance for one hour before discharge. Patients were discharged home with a 7 day supply of acetaminophen 1000 mg orally every 6h, ketoprofen 100 mg, orally twice a day, and muscle relaxant as needed. Patients were instructed to take tramadol 50 mg, orally every 6h as needed for low back pain, in case of insufficient relief."
27948|NCT03968172|Behavioral|Levidex|"Web-based behavioural lifestyle intervention that provides patients with coordinated information based on their existing health beliefs, interests, etc. In Levidex, techniques and exercises will be taught in sequentially active interactive learning units (simulated dialogues) and followed-up with email and SMS reminders in the second study year. The following topics will be focused on:~Diagnosis and disease progression~Support in disease processing~Techniques for coping with stress and depressive symptoms as well as developing positive emotions~Optimisation of dietary behaviour~Optimisation of physical activity behaviour~Sleep hygiene and methods for dealing with insomnia.~The programme will accompany each patient with information material and e-mail reminders over a period of 12 months with initial 2-3 weekly tasks, later only weekly reminders and inputs every 2 weeks. All in all, the intervention programme will consist of 16 modules."
27949|NCT03968172|Behavioral|Dexilev|"Web-based information platform with optimized standard care compiled from information material of the German Multiple Sclerosis Society (DMSG). Information will be provided in sequentially activated modules over a period of 12 months, covering the following topics:~Disease progression~Invisible symptoms of multiple sclerosis~Symptomatic therapy~Immunotherapy decision support~Coping strategies~Autonomy~Fatigue~Quality of life~Physical activity~Nutritional behaviour~In addition, a reminder system with neutral e-mail reminders will be used to promote the use of the programme."
27950|NCT03968159|Drug|Pimavanserin|Pimavanserin 34 mg (provided as 2×17 mg tablets) administered orally as a single dose once daily
27951|NCT03968159|Drug|Placebo|Placebo (2×placebo tablets [size- and color-matched to pimavanserin]) administered orally as a single dose once daily
27952|NCT03968146|Procedure|Erector Spinae Plane Block|The linear multi-frequency 6-13 megahertz transducer will be used. In the prone position,under aseptic conditions, the probe will be placed in a longitudinal position 2-3 cm lateral to the vertebral column. The transverse processes of the vertebrae at (mid) level of surgery, the Erector Spinae muscle and the psoas muscle are identified. A 22 gauge echogenic needle will be inserted in an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, A test dose of 5% dextrose in water can expand the fascial plane and confirm needle-tip location prior to injection of local anaesthetic. Then, 0.5 ml/kg of bupivacaine 0.25% with 0.1 mg/kg dexamethasone and adrenaline 1 : 200000 will be injected between erector spinea muscle and transverse process, taking in consideration not exceeding the toxic dose of bupivacaine; 4 mg/kg . the same procedure will be repeated on the contralateral side.
27954|NCT03968146|Drug|additional Fentanyl|patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
27955|NCT03968146|Drug|Morphine|After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
27956|NCT03968146|Drug|rescue Morphine|Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
27957|NCT03968146|Drug|pethidine|After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
27958|NCT03968146|Drug|Ketorolac|patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
27959|NCT03968146|Drug|Acetaminophen|patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
27960|NCT03968133|Dietary Supplement|Probiotic|Oral probiotic delivered in powdered form.
27961|NCT03968133|Dietary Supplement|Placebo|Oral placebo delivered in powdered form.
27962|NCT03968120|Other|Change of ventilatory settings|Change of Positive End-Exspiratory Pressure during one-lung ventilation
27963|NCT03968107|Other|Reference ultrasound examination|Use of antenatal ultrasound examination to visualize and position the intestinal structures involved in digestive malrotation at high risk of volvulus and comparison to fetal MRI results.
27964|NCT03968081|Behavioral|Cyberball|a ball tossing playing game in which the experimentor can control the number of throws received by the participants
27965|NCT03968068|Procedure|Exercise Procedure|Patients will undergo 30 minutes of light-moderate intensity leg cycling, using the Letto-2 (Motomed, UK) in the semi-supine position.
27966|NCT03968068|Procedure|Remote Ischaemic Conditioning|Patients will undergo 4 cycles of upper limb RIC using a blood pressure cuff. Each cycle will involve inflating the blood pressure cuff to 200 mmHg for five minutes around the upper arm, followed by a period of relaxation of the cuff for a further 5 minutes. The total RIC treatment time will take 40 minutes.
27967|NCT03968055|Other|Integration with Epic|Participants will have CGM data connected to our medical record through an already established pathway (Dexcom app on iOS device to Apple HealthKit to Epic MyChart to Epic)
27968|NCT03968042|Drug|Nerve Growth Factor|Intramuscular injection for 2 weeks
27969|NCT03968042|Drug|Edaravone|Intravenous injection for 2 weeks
27970|NCT03968042|Drug|Combination of vitamin B1, B6, C, E and mecobalamine|Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
27971|NCT03968029|Procedure|suturing meniscal augmented|meniscal tear sutured + bone marrow injection/collagen membrane
27972|NCT03968029|Procedure|suturing meniscal|meniscal tear sutured
27973|NCT03968016|Device|SYSMEX HLSCL|Diagnostic device
27974|NCT03968003|Dietary Supplement|Inulin|Group A (intervention group) will receive inulin 10 g.Group B will receive placebo of isocaloric maltodextrin. Group C will receive dietary fiber advice aimed to match the recommended fiber intake for age.This study evaluates the changes of gut microbiota composition and diversity, body weight, body fat, SCFAs, plasma amino acids, satiety hormones (PYY and GLP-1), Inflammatory cytokines (IL-1β, TNF-α and IL-6) after 6-month studied period
27975|NCT03967990|Other|Refined cornmeal flour|48 g/d of refined cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
27976|NCT03967990|Other|50/50 refined cornmeal-bran mix|48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins
27977|NCT03967990|Other|Whole grain cornmeal flour|48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
27978|NCT03967977|Drug|Tislelizumab Cisplatin for Injection Carboplatin InjectionGemcitabine Gemcitabine Hydrochloride for Injection|"Tislelizumab:200 mg, Intravenous, Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: 70 mg/m2, Intravenous, Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: AUC 4.5, Intravenous, Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: 1000 mg/m2, Intravenous, Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles~(Do not repeat information already included in arm/group descriptions.)"
27979|NCT03967977|Drug|Cisplatin for Injection Carboplatin InjectionGemcitabine Gemcitabine Hydrochloride for Injection|"Placebo:200 mg, Intravenous, Day 1 of each 21-day cycle, to be administered until Progressive Disease or intolerable toxicity Cisplatin: 70 mg/m2, Intravenous, Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Carboplatin: AUC 4.5, Intravenous, Day 1 or Day 2 of each 21-day cycle, to be administered up to 6 cycles Gemcitabine: 1000 mg/m2, Intravenous, Days 1 and 8 of each 21-day cycle, to be administered up to 6 cycles~(Do not repeat information already included in arm/group descriptions.)"
27980|NCT03967964|Drug|Dehydroepiandrosterone 2.2 g|Vaginal ring with 2.2 grams DHEA.
27981|NCT03967964|Drug|Dehydroepiandrosterone 1.5 g/Testosterone 25 mg|Vaginal ring with DHEA 1.5 grams/Testosterone 25 mg.
27982|NCT03967964|Drug|Testosterone|Vaginal ring with 35 mg testosterone.
27983|NCT03967964|Drug|Testosterone Topical Gel|Gel containing 1% testosterone.
27984|NCT03967964|Drug|Dehydroepiandrosterone Oral Capsule|Capsule containing 25 mg DHEA
27985|NCT03967951|Other|CT radiomic feature evaluation|"Radiomic features will be calculated and extracted from all contrast and non-contrast CT-scans. First order features will be evaluated and high order features will be grouped in parent matrices. Parent matrices of second and third order will be chosen and evaluated.~In the second part, based on the results of inter-correlation of the operator analysis, the most significant radiomic features will be chosen. Morphological and histopathological features will be evaluated will be.~Histopathology will be performed on a biopsy specimen; percentage of Ki67 and grading will be evaluated."
27986|NCT03967938|Drug|Olaparib Oral Capsule|Olaparib tablets 300mg twice daily
27987|NCT03967925|Drug|Belimumab|Sub-cutaneous injection
28015|NCT03967561|Other|Progressive water-based aerobic training|The intervention will comprise walking/running in shallow pool with progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
28016|NCT03967561|Other|Non-progressive aerobic training|The intervention will comprise walking/running in shallow pool without progression in the training variables. The training will have 12 weeks of duration with 3 weekly sessions (of 50 minutes each).
27988|NCT03967912|Behavioral|MOVE UP|Each of the 12 group sessions will focus on incremental behavioral strategies for maintaining healthy eating, activity, and weight loss.behaviors. Body weight will be measured in-person session and participants will also to measure their body weight on their in Session 3, participants are given physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; >250 pounds = 1800 kcal/d).
27989|NCT03967886|Drug|YYD601 20mg|Patients should take drugs an hour before breakfast.
27990|NCT03967886|Drug|Nexium 20mg|Patients should take drugs an hour before breakfast.
27991|NCT03967886|Drug|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
27992|NCT03967860|Diagnostic Test|CT scan|Post surgical standard CT Scan as predictor of complication
27993|NCT03967847|Drug|Ketorolac|Oral Ketorolac
27994|NCT03967834|Other|Patient with Soft Tissue Sarcoma|"Tumor specimens will be collected for the study at diagnosis.~Clinical data (patients and tumour characteristics) will be collected during the study for each patient included."
27995|NCT03967821|Other|Questionnaire|Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
27996|NCT03967795|Drug|N2-L-Alanyl-L-Glutamine (Substance)|20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
27997|NCT03967782|Behavioral|CON|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
27998|NCT03967782|Behavioral|EX-MEAL|Condition with an acute exercise set right before lunch The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right before ad ad libitum lunch meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
27999|NCT03967782|Behavioral|MEAL-EX|. condition with an acute exercise set right after lunch. The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) right after an ad libitul buffet meal. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
28000|NCT03967769|Device|High Flow nasal Cannula|Apnoeic Oxygenation by High Flow Nasal Cannulae
28001|NCT03967756|Device|Automatic polyp detection system|When colonoscopists withdraw the colonoscopies and inspect the colons, the video streaming of colonoscopies was real-time switched to the automatic polyp detection system, which made it feasible to detect lesions in real time. When any potential polyp is detected by the system， there will be a tracing box on an adjacent monitor to locate the lesion with a simultaneous sound alarm.
28002|NCT03967730|Combination Product|Sonodynamic therapy(SDT)|Sonodynamic Therapy (SDT) Sinoporphyrin Sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection(0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15 min of each lesion. Ultrasound parameters included intensity of 2.1W/cm2 for each lesion, resonance frequency: 1.0 MHz and duty factor: 30%.
28003|NCT03967717|Other|Characterization of parameters of medical history, examination and diagnostics.|Patients receive standard of care diuretics. The study only collects data to characterize parameters of medical history, examination and diagnostics.
28004|NCT03967704|Procedure|Life quality evaluation|As part of this research, 2 additional consultations at 12 months and 24 months will be carried out by one of the rheumatologists in the department. At the consultation 12 months after his inclusion, the patient will have a clinical examination, a quality of life questionnaire to complete and additional images (x-rays). For the 24-month consultation, the patient will have a clinical examination, a quality of life questionnaire to complete and the patient may have an additional X-ray of the spine if there is height loss > 2 cm and/or pain.
28005|NCT03967691|Drug|Tocilizumab infusion|Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour
28006|NCT03967691|Drug|Saline 0.9%|100 ml NaCl 0.9% will be infused over 1 hour
28007|NCT03967678|Dietary Supplement|Three portions per week (690g beef (raw weight)) for 5 weeks|Lunches served in Human Intervention Studies Unit
28008|NCT03967665|Drug|N-acetyl-L-cysteine|NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
28009|NCT03967652|Diagnostic Test|Nanomaterial-based sensors|Chemical sensors based on Monolayer-Capped Metallic Nanoparticles (MCMNPs) can recognize and classify exhaled breath by special recognition algorithm, which achieves the purpose of disease diagnosis.
28010|NCT03967639|Procedure|Elective cardiac surgery|Elective cardiac surgery
28011|NCT03967626|Device|external cooling with the xxxxx device|external cooling with the xxxxx device
28012|NCT03967613|Device|Functional eletrical stimulation|Aplication of functional eletrical stimulation on contralesional upper limb during functional tasks
28013|NCT03967587|Device|Neosense Umbilical Catheter|The Neosense umbilical catheter is used instead of the routinely used umbilical catheter
28014|NCT03967574|Device|Transcranial direct current stimulation|"The tDCS anode was applied on the primary motor cortex area responsible for the control of the rotator cuff, as determined using transcranial magnetic stimulation and surface electromyography. The cathode was applied on the contralateral forehead, just above the eyebrow. The electrodes were soaked in saline solution to improve conductivity and the montage was secured with rubber bands and adhesive tape.~The tDCS device (Soterix Medical 1x1 tDCS device) was then gradually turned to an intensity of 2mA. This stimulation was continued for a total of 20 minutes, after which it was gradually stopped."
28017|NCT03967548|Drug|Germinal peptide eye drops|Germinal peptide eye drops of 0.004%
28018|NCT03967535|Device|MRI Brain Imaging|Up to two Magnetic Resonance Imaging (MRI) scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
28019|NCT03967535|Behavioral|Mental Health Assessment and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
28020|NCT03967522|Drug|Cabozantinib|All participants will be treated by 60 mg of cabozantinib once daily. Temporary or permanent discontinuation and/or dose reduction of cabozantinib therapy may be required for the management of some adverse reactions. When dose reduction is necessary, it is recommended to reduce to 40 mg daily, and then to 20 mg daily.
28021|NCT03967509|Behavioral|Comet|
28022|NCT03967496|Procedure|Types of Anesthesia|"General Anesthesia includes: Inhalational anesthesia and total intravenous anesthesia.~Regional blocks includes: Spinal Anesthesia, Epidural Anesthesia, Plexus Block, Peripheral Nerve Block,... etc Monitored Anesthesia Care: No anesthetic administered but care given for hemodynamic and blood sugar control intraoperatively."
28023|NCT03967496|Procedure|Access of Surgery|Type of surgical access
28024|NCT03967496|Other|Comorbidities|A patient may have more than one comorbidity
28025|NCT03967496|Drug|Preoperative Medication|Preoperative medications
28026|NCT03967496|Diagnostic Test|Routine blood test|Preoperative and Intraoperative Investigations
28027|NCT03967483|Drug|Indometacin|patient who are taken indomatacin for headaches and migraine
28028|NCT03967470|Biological|Bacterial spray|Bacterial spray containing bacteria that do not cause underarm malodor
28029|NCT03967457|Diagnostic Test|questionnaires survey|Including four kinds of questionnaires: European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 (V3); EORTC QLQ-CX24; Eligibility Criteria (FSFI); and Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFIQ-7)
28030|NCT03967457|Diagnostic Test|Urodynamic testing|"Urodynamic testing consists of important urodynamic parameters including:~Bladder capacity at the first void sense Bladder capacity at normal desire to void Bladder capacity at strong desire to void Qmax Qave Pves at Qmax Pdet at Qmax Cves at SDV Cdet at SDV Residual urine volume"
28031|NCT03967457|Diagnostic Test|Rectum dynamics testing|Rectum dynamics testing consists of important parameters of rectum activities
28032|NCT03967457|Diagnostic Test|ovarian reserve function|"Testing for ovarian reserve function consists of:~Follicle-stimulating hormone Estradiol Anti-mullerian hormone Inhibin B"
28033|NCT03967444|Device|Hyaluronic acid|Injectable gel for lip augmentation
28034|NCT03967444|Device|Hyaluronic acid|Injectable gel. Lip Augmentation and other wrinkles/folds
28035|NCT03967431|Other|Narrative Enhancement and Cognitive Therapy (NECT)|Narrative Enhancement and Cognitive Therapy includes two introduction meetings, three psychoeducation meetings, seven cognitive restructuring meetings, seven narrative enhancement meetings and one summing up meeting.
28036|NCT03967418|Behavioral|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychiatric and addictive comorbidities)
28037|NCT03967405|Device|MolecuLight PID|Hand-held, real-time fluorescence imaging device
28038|NCT03967392|Drug|Xylocaine|TREATMENT
28039|NCT03967379|Behavioral|Mobile App + enhanced standard care|An intervention to help address sexual dysfunction among HCT survivors
28040|NCT03967379|Other|Enhanced Standard Care|Standard of care administered by the institution
28041|NCT03967353|Behavioral|New management mode intervention|"Patients in routine treatment group use TB assistant APP. Medical staff strengthen health promotion of the patients,including, infection control, doctor-patient communication, etc."
28042|NCT03967327|Drug|Buprenorphine transdermal patches|It should be applied to non-irritated, intact skin of the upper outer arm, upper chest, upper back or the side of the chest. The skin should be relatively hairless. If none are available, the hair at the site should be clipped, not shaven.
28043|NCT03967327|Drug|Morphine Sulfate Sustained-Release Tablet|It will be administered orally twice (q12h) daily.
28044|NCT03967314|Other|TLIP block group (group T)|In group T, the block was performed bilaterally under aseptic conditions using the US device with a high-frequency 12-MHz linear US probe. The probe was covered with a sterile sheath and placed vertically at the L3 vertebrae level. After visualizing the hyperechoic shadow of the spinous process and interspinous muscles as an anatomical guide point, the probe was moved forward in a lateral direction to visualize the longissimus and iliocostal muscles. Using the in-plane technique, a 22-G, 50-mm block needle was inserted between the muscles in a medial-to-lateral direction in the interfascial plane. Once the needle tip was placed within the interfacial plane and after careful aspiration to rule out intravascular needle placement, 2 ml of saline was injected to confirm the accuracy of the injection site. A dose of 0.25% bupivacaine (20 ml) was then injected in each side (total 40 ml).
28045|NCT03967314|Other|Wound infiltration group (group W)|In group W, a dose of 0.5% bupivacaine (20 ml) was injected for wound infiltration into the surgery site.
28046|NCT03967301|Dietary Supplement|Probiotic|Intervention: defined as probiotic consumption
28047|NCT03967301|Dietary Supplement|Placebo|Placebo consumption. The placebo will be provided by the company that produces the probiotic.
28048|NCT03967288|Drug|Chloroprocaine Injection [Clorotekal]|1% chloroprocaine Hydrochloride Injection (50 mg/5 mL) for intrathecal use
28049|NCT03967288|Drug|Bupivacaine Hydrochloride 0.75% Injection Solution|0.75% bupivacaine Hydrochloride injection in 8.25% dextrose for intrathecal use
28050|NCT03967275|Other|bone marrow harvest|During bone marrow harvest, an additional 10 mL sample will be collected for the study.
28051|NCT03967262|Behavioral|Brief Motivational Intervention|The objective of motivational intervention is to make the patient aware of the relationship between the consumption of alcohol and other drugs and the accident, and induce them to carry out a change in habits.
28052|NCT03967249|Drug|IONIS GHR-LRx|IONIS GHR-LRx subcutaneous injection
28053|NCT03967249|Drug|SRL|Participants will receive SRL once monthly
28359|NCT03964857|Other|Blended Oil 1 (BO1)|Consumption of chicken dishes made with BO1 for a period of 8 weeks
28054|NCT03967236|Other|Collection of stool and blood samples|"For each visit, stool and blood samples will be collected during a pediatric gastroenterology day hospital stay.~This collection of stool and blood specific IVOIRE study is carried out in the context of examination already planned for the usual care of the patient."
28055|NCT03967223|Drug|GSK3377794|GSK3377794 as a single IV infusion.
28056|NCT03967223|Drug|Fludarabine|Fludarabine will be used as the lymphodepleting chemotherapy via IV administration.
28057|NCT03967223|Drug|Cyclophosphamide|Cyclophosphamide will be used as the lymphodepleting chemotherapy via IV administration.
28058|NCT03967197|Drug|Saline spray|Physiologic saline spray
28059|NCT03967197|Drug|Lidocaine Hydrochloride|Lidocaine hydrochloride 10% spray
28060|NCT03967171|Other|before uterine incision oxytocin|blood loss during elective cesarean section
28061|NCT03967171|Other|after clamping the umbilical cord oxytocin|blood loss during elective cesarean section
28062|NCT03967158|Device|Xience Sierra stent|Percutaneous coronary intervention with Xience Sierra stent
28063|NCT03967145|Behavioral|Determining quality of life|Quality of Life
28064|NCT03967132|Other|Control Infant Formula|Ready to feed infant formula, feed ad libitum
28065|NCT03967132|Other|Experimental Infant Formula|Ready to feed infant formula, feed ad libitum
28066|NCT03967132|Other|Reference Group|Human milk, breast feeding ad libitum
28067|NCT03967119|Device|Patient monitoring|Arterial blood pressure, pulse oxygen saturation, and cardiac output/stroke volume are monitored with invasive arterial catheter, pulse oxymetry, and esophageal doppler in all participants. Some dynamic variables including SVV and PPV are automatically calculated in each monitor. PWV is manually calculated in a printed plethysmographic waveform. Plethysmographic waveform amplitude (PW) is measured on a beat-to-beat basis as the vertical distance between peaks and preceding valley troughs in the waveform. The maximum PW (PWmax) and minimum PW (PWmin) are determined manually over the same respiratory cycle, and PWV is calculated. PWV=(PWmax-PWmin)/[(PWmax+PWmin)/2].
28068|NCT03967106|Other|Ischaemic Preconditioning|IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
28069|NCT03967106|Other|Sham|Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
28070|NCT03967093|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 is administered by intravenous (IV) infusion over a minimum of six 28-day cycles.
28071|NCT03967067|Procedure|liver resection|Open or laparoscopic, major or minor hepatectomy performed using the clamp-crush technique and intermittent clamping of hepatic pedicle
28072|NCT03967054|Drug|Ivermectin|Ivermectin (6 mg tablet) given monthly from July-October each rainy season as a 3-day course of approximately 300 mcg/kg/day as estimated by height bands.
28073|NCT03967054|Drug|Placebo oral tablet|placebo in the same size, color and shape at the ivermectin tablet
28074|NCT03967041|Diagnostic Test|radiological defined sarcopenia|Evaluation for sarcopaenia was performed via calculating psoas cross-sectional area at level of L3 and normalising for height
28075|NCT03967028|Procedure|cesarean section|lower segment cesarean section either elective or emergency
28076|NCT03967015|Other|Maternal Administered Malnutrition Monitoring System (MAMMS)|Participants randomized to the MAMMS arm will be provided with two insertion MUAC tapes that are UNICEF color coded and numbered to 1 mm gradations to take home with them. Participants will receive a weekly SMS asking them to measure and send their child's MUAC via SMS. SMS messages will provide actionable reminders to measure and send the child's MUAC. Both the SMS sent to the participant and SMS responses sent by the participant to the MAMMS system will be free of charge. Study staff will screen all SMS measurements returned to the MUAC system for identification of malnutrition.
28077|NCT03967002|Procedure|Test group with corticotomy surgery|"The surgery of corticotomy is performed with a piezo electric device and a personalized surgical guide just before the placement of orthodontic appliance. The initial impressions of the patient's dental arch as well as its three-dimensional radiography (CBCT) are used to create a perfectly adapted guide for minimally invasive corticotomy surgery.~The incisions are made between the roots of:~the second premolars and first premolars,~the first lower premolars and canines,~the canines and lateral incisors,~the lateral incisors and central incisors, and,~the two lower central incisors."
28078|NCT03966989|Behavioral|Performance Feedback|Performance feedback offline that benchmarks providers' own performance to that of their peers
28079|NCT03966976|Device|ECG monitoring & record|This is a mobile ECG recorder that not only records short portions of ECG on one or three leads, but also stores, processes and transmits their data to facilitate the diagnosis and to confirm the occurrence of AF arrhythmia episodes by the physician.
28080|NCT03966976|Other|Conventional follow-up|Conventional follow-up
28081|NCT03966963|Behavioral|Eye Movement Desensitization Reprocessing (EMDR)|Trauma-Focused Therapy
28082|NCT03966950|Dietary Supplement|melatonin|melatonin 10 mg per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights.
28083|NCT03966950|Drug|Placebo oral tablet|placebo taken per os in the preoperative night and the immediate postoperative night and the first and second postoperative nights
28084|NCT03966937|Other|Dry needling|"Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points."
28085|NCT03966937|Other|Control|Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
28360|NCT03964857|Other|Blended Oil 2 (BO2)|Consumption of chicken dishes made with BO2 for a period of 8 weeks
28086|NCT03966924|Device|Focal Contouring System|Single treatment of skin resection and possibly focal lipectomy (removal of loose skin and fat)
28087|NCT03966911|Device|Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter|Continuous Glucose Monitoring and frequent sample testing
28088|NCT03966898|Drug|SHR6390 Tablets|SHR6390 Tablets
28089|NCT03966898|Drug|Placebo Tablets|Placebo Tablets
28090|NCT03966898|Drug|Letrozole or Anastrozole Tablets|Letrozole or Anastrozole Tablets
28091|NCT03966885|Behavioral|Brief Intervention|The BI used in the trial combines motivational interviewing skills with cognitive behavioral therapy elements in order to assist clients with self identified substance misuse to begin to consider changing their rates of drinking and drug use. The intervention lasts 30 to 40 minutes and consists of 5 components including: 1) screening 2) identification and information on the impacts of substance misuse 3) talking about change and goal setting 4) understanding the primary reason for drinking 5) skill building with practice and 6) referral for services.
28092|NCT03966885|Behavioral|Common Elements Treatment Approach (CETA)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems, and for alcohol and substance misuse. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
28093|NCT03966872|Behavioral|Integrated Illness Management and Recovery|Education and skills training groups on illness management of chronic medical and psychiatric illness.
28094|NCT03966872|Behavioral|Chronic Disease Self-Management Program|Education and skills training groups on illness management of chronic conditions
28095|NCT03966859|Drug|Atorvastatin 20mg|oral dose, once daily for 7 days
28096|NCT03966859|Other|Lactose placebo|oral dose, once daily for 7 days
28097|NCT03966846|Dietary Supplement|Kefir|
28098|NCT03966846|Dietary Supplement|Milk|
28099|NCT03966833|Behavioral|IPT-G|14 weeks of group-based interpersonal therapy (IPT-G)
28100|NCT03966833|Behavioral|Unconditional Cash Transfer|Lump sum cash transfer
28101|NCT03966807|Behavioral|Digital-based support|Digital support will consist of referral for the participant to visit https://smokefree.gov, a website which offers a menu of internet- and text-based support options.
28102|NCT03966807|Behavioral|Traditional-based support + Nicotine replacement therapy (NRT)|Traditional support will consist of participant referral to the Indiana Tobacco Quitline (1-800-QUIT-NOW) which is a telephone hotline that connects participants to Indiana smoking cessation resources.
28103|NCT03966794|Device|Epidural Electrical Stimulation|Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.
28104|NCT03966794|Combination Product|Functional scaffold & Epidural Electrical Stimulation|Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
28105|NCT03966781|Procedure|ESWL|ESWL will be conducted under epidural anesthesia. For epidural anesthesia, bupivacaine will be used to block the T6-T12 spinal segments. The patient's eyes will be lightly covered all along the procedure. Once epidural anesthesia is achieved, the patient will be given a light sedation and ESWL will be performed using a Dornier dual focus lithotripsy system providing a maximum of 5000 at the rate of 90 shocks per minute in over 1-2 days.
28106|NCT03966781|Procedure|ERCP|Once ESWL is over, an endoscopic pancreatic sphincterotomy will be performed and complete stone removal will be attempted with subsequent stenting of the pancreatic duct in the presence of a pancreatic stricture (not detected on MRCP prior to enrolment) or in case of incomplete stone removal
28107|NCT03966781|Procedure|Sham ESWL|In the sham/control group, patients will be given a transient superficial pin-prick sensation to give the feel of epidural anesthesia. After that the lithotripsy machine the will be switched on, without establishing any form of contact with the patients body.
28108|NCT03966781|Procedure|Sham ERCP|Following sham ESWL patientswill be subjected to sham ERCP to examine the papillary area, but no pancreatic ductal intervention will be performed.
28109|NCT03966768|Device|Duramesh suturable mesh for laparotomy closure|Patients undergoing laparotomy will be closed with Duramesh suturable mesh
28110|NCT03966768|Device|Conventional suture for laparotomy closure|Patients undergoing laparotomy will be closed with conventional polydiaxonone suture
28111|NCT03966755|Behavioral|UFA dietary recommendations|The face-to-face intervention will be performed by a research nutritionist that reviews the dietary recall and provides a list of commonly available foods rich in unsaturated fatty acids (UFA) (monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA)), together with individual instructions on how to integrate the recommended foods in the daily dietary pattern based on the dietary recall, and also to emphasize that the recommended food should be consumed as listed, and not as part of processed food (i.e., guacamole for avocado, hazelnut chocolate for nuts, pesto for olive oil, fish sticks for fatty fish). Extra-virgin olive oil or canola oil or nuts will be considered first choice for daily consumption of UFA-rich food, but a list of daily food substitutes will be also provided .
28112|NCT03966742|Procedure|Drug Eluting Bead Embolization (DEB) for Desmoid Fibromatosis|"Delivery of Doxorubicin selectively into Desmoid Fibromatosis utilizing its vascular supply as a conduit, and ionic loading the doxorubicin onto embolized particles as the drug delivery vehicle.~Maximal dose is 75 mg/m2 and at least 50 mg. The bead size is 75-300 Mµ in a 2 CC syringe."
28113|NCT03966729|Other|Time (outcome)|
28114|NCT03966716|Device|Arthroplasty|Patients with an undisplaced femoral neck fracture receive a hemi or total hip arthroplasty depending on each hospital's routine for patient age and mobility.
28115|NCT03966716|Device|Internal Fixation|Patients with an undisplaced femoral neck fracture undergo a closed reduction and internal fixation with 2-3 screws or pins, or sliding hip screw device. Type of fixation depends on each hospital's routine.
28116|NCT03966703|Behavioral|mixing analysing test|The chewed gum is retrieved scanned and weighted to quantify masticatory efficiency
28117|NCT03966690|Device|Isokinetic leg extension/-flexion on a legpress device|Maximum strength and rate of leg-flexion /-extension during legpress exercise
28118|NCT03966690|Device|Isokinetic leg extension/-flexion on a legcurl device|Maximum strength and rate of leg-flexion /-extension during legcurl exercise
28119|NCT03966664|Diagnostic Test|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.|Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.
28120|NCT03966664|Diagnostic Test|In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood|Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.
28121|NCT03966664|Diagnostic Test|Biomolecular analysis of plasma proteins.|Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
28122|NCT03966651|Drug|PRRT with 177Lu-DOTATATE|Children will receive 2 Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTATATE administered intravenously at 6 weeks interval.
28123|NCT03966638|Procedure|Intra-meniscal injection of platelet-rich plasma|Intra-meniscal injection of platelet-rich plasma under echographic control
28124|NCT03966625|Diagnostic Test|tissue transglutaminase autoantibodies|celiac disease-specific autoantibodies
28125|NCT03966612|Other|Questionnaires|"Questionnaires about:~Socio-professional situation~Lifestyle~Health~NME 1~specific breast cancer survey~Imaging"
28126|NCT03966599|Diagnostic Test|Pain|Patient's pain in order to VAS
28127|NCT03966599|Diagnostic Test|Hemodynamic changes|changes in hemodynamic states
28128|NCT03966586|Behavioral|Active outreach|Participants will get bidirectional weekly SMS messaging / automated voice messaging (depending on literacy), with messages to be programmed by the participant in the enhanced counseling sessions.
28129|NCT03966586|Behavioral|Appointments|Participants in the enhanced-care intervention will be given specific appointment times/dates.
28130|NCT03966586|Behavioral|Financial support|Participants in the enhanced-care intervention will receive free clinic visits, labs, and medications. They will also receive transportation incentives on a sliding scale based on distance to clinic, to range between 200-700 INR to be given each clinic/study visit. All participants, in both the usual care and enhanced care arms, will be offered VL testing free of charge, although this will not be known to the participants prior to the visit.
28131|NCT03966586|Behavioral|Microenterprise|YRG CARE is affiliated with two microenterprise programs in bag-making and food-vending which can be leveraged as part of an intervention, particularly for women. There is an established training and mentoring program for individuals who wish to join the bag-making or food-making ventures. Participants who opt for this will be linked to the bag-making and food-vending programs, with all up-front costs (e.g. vending kiosk, training, serving materials, etc.) covered.
28132|NCT03966586|Behavioral|Enhanced counseling|Participants in the enhanced-care intervention will participant in an individual enhanced counseling program called Steps to Success, based upon a Life Steps and Problem Solving curriculum. Steps to Success will consist of five one-on-one sessions of approximately 1 to 1.5 hours each. The first session will take place at the time of the participant's second clinical visit to YRG CARE, which will be between 1-3 weeks after the participant is recruited.
28133|NCT03966586|Behavioral|Usual clinical care and counseling|Usual clinical care and counseling
28134|NCT03966573|Radiation|Radiographic imaging|Evaluating arthritis in knee and hip bilaterally. Evaluating axis deficiancy and leg length discrepancy.
28135|NCT03966573|Other|Evaluating function|Test function and physical capasity
28136|NCT03966573|Other|Forms|Forms for evaluating quality of life, pain, function
28137|NCT03966560|Drug|Brimonidine Tartrate|Brimonidine tartrate 0.15% 1 eye drop, every day for 6-months
28138|NCT03966560|Drug|Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops|Dorzolamide and timolol fixed combination 2 eye drops, every day for 6 months
28139|NCT03966560|Drug|Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension|Brinzolamide and timolol fixed combination 2 eye drops, every day for 6 months
28140|NCT03966560|Drug|Travoprost and Timolol|Travoprost and Timolol fixed combination 1 eye drop, every day for 6 months
28141|NCT03966560|Drug|Bimatoprost and Timolol|Bimatoprost and Timolol fixed combination 1 eye drop, every day for 6 months
28142|NCT03966560|Drug|Latanoprost|Latanoprost 0.005% 1 eye drop, every day for 6 months
28143|NCT03966547|Procedure|Ganglion sphenopalatine block with local anesthetic administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL as per GSPB-2018.
28144|NCT03966547|Procedure|Ganglion sphenopalatine block with placebo administered on study GSPB-2018|Block performed with bilaterally inserted q-tips with isotone NaCl as per GSPB-2018.
28145|NCT03966534|Other|Blood diversion|Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
28146|NCT03966508|Procedure|High-frequency electrical stimulation|High-frequency stimulation will be applied on the volar forearm (6-10 cm distal to the cubital fossa). To avoid any confounding effect of handedness, the arm onto which HFS will be applied twice (dominant vs nondominant) will be counterbalanced across participants. HFS will consist of 12 trains of 42 Hz electrical pulses lasting 1 s each. The time interval between each train will be 10 s. The intensity of stimulation will be 5mA. Electrical pulses will be delivered to the skin using a specifically-designed electrode designed: the cathode consists of 16 blunt stainless-steel pins with a diameter of 0.2 mm protruding 1 mm from the base. The 16 pins are placed in a circle with a diameter of 10 mm. The anode consists of a surrounding stainless-steel ring having an inner diameter of 22 mm and an outer diameter of 40 mm. This procedure induces secondary pinprick hyperalgesia (an increase in pinprick sensitivity in a large area of the skin).
28147|NCT03966495|Other|Sustainability of a research program in risk management|"No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)"
28361|NCT03964844|Other|No intervention|No intervention
28148|NCT03966482|Behavioral|Group before-after|The group was submitted to four weeks of speech therapy intervention with Semiocluded vocal tract exercise. The 12 participants were evaluated before and after the intervention with a multidimensional evaluation comprised of analysis of images generated by specialized videonasoendoscopy software, analysis of speech emissions by perceptual-auditory evaluation and acoustic analysis, and vocal self-assessment.
28149|NCT03966469|Other|Preoperative support person present|Participants who bring a support person to their preoperative appointment.
28150|NCT03966469|Other|Patient Present Only|Patient presents to their preoperative appointment without a support person.
28151|NCT03966456|Drug|Chemotherapy|compare the effecy and safety of 4 PD-1 agents single and combined with chemotherapy in chinese people.
28152|NCT03966430|Procedure|damage control surgery|"Emergency surgery stage, (a) the hybrid operating room restores mesenteric vascular patency. (b) excision of the necrotic intestine (c) retention of suspicious intestinal ducts, double stoma (d) establishment of catheter thrombolysis pathway (e) apply TAC to maintain open abdominal.~ICU phase, including (a) fluid resuscitation; (b) anti-infective and organ function support therapy; (c) continued local anticoagulation, thrombolysis (d) arrange planned re-laparotomy (e) early EN.~Definitive surgical procedures, including (a) Deterministic fascia closure or further removal of the necrotic intestine. (b) Intestinal stoma care and enteral nutrition support treatment. (c) An enterostomy was performed about 6 months after the first operation."
28153|NCT03966430|Procedure|non-damage control surgery|"The patients are diagnosed with AMI and treated for mesenteric thrombosis and ischemic bowel.~The patient retains the endoluminal catheter after the DSA was diagnosed as AMI.~After diagnosis, the operation is performed in the general operating room, and the intestinal fistula double or the anastomosis is performed according to the judgment of the surgeon.~After the operation, re-laparotomy is performed on demand."
28154|NCT03966417|Other|Exercise training|Continuous exercise training 2 times per week for a period of 12 weeks.
28155|NCT03966404|Diagnostic Test|EyeBOX device|The EyeBOX medical device tracks a patient's eye movement and calculates a BOX Score ranging from 0-20. The BOX score is interpreted as a binary classification for eye movement abnormalities, where anything equal to or greater than 10 is a positive result for the initial evaluation of concussion and everything below 10 is negative.
28156|NCT03966391|Other|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
28157|NCT03966378|Other|Grape seeds extract|Grape seeds extract powder
28158|NCT03966378|Other|Casein-phosphopeptide/amorphous-calcium phosphate|CPP-ACP paste
28159|NCT03966365|Drug|PRO-122|"PRO-122. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution free of preservatives. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: topical ophthalmic."
28160|NCT03966365|Drug|Krytantek Ofteno®|"- 1. Krytantek Ofteno®. Timolol 0.5% / brimonidine 0.2% / dorzolamide 2% ophthalmic solution. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.~- Route of administration: topical ophthalmic."
28161|NCT03966352|Other|Questionnaire|Enrolled subjects will complete a questionnaire to ascertain information on treatment considerations, obstacles, motivations, and outcomes encountered on their pathway to fatherhood.
28162|NCT03966339|Drug|Growth hormone|GH has been considered as a cogonadotropin, which plays an important role in the synthesis of ovarian steroid hormone and follicular development as a paracrine hormone.GH can regulate the growth hormone receptor and strengthen the function of mitochondria to improve the quality of the female oocyte.
28163|NCT03966326|Drug|sevoflurane and fentanil|Patients will receive standard general anesthesia
28164|NCT03966326|Drug|sevoflurane and fentanil plus PECS II block|Pacients will receive standard general anesthesia with sevoflurane and fentanil associated to PECS II block
28165|NCT03966313|Device|ventricular assist device implantation|"Blood sampling in patients under surgery for ventricular assist device implantation at five time points:~After anesthetic induction~Before starting the device~2h, 6h and 48h after starting the device"
28166|NCT03966300|Other|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
28167|NCT03966261|Other|blood sample|we perform blood sample in healthy subject before and after a meal to measure incretins concentration
28168|NCT03966248|Other|Chinese Tuina therapy|"The doctor presses the affected lower limb from the anterior superior iliac spine to the ankle;~The doctor gives the pressure on the Biguan(ST31), Futu(ST32), Heding(EX-LE2), Neixiyan(EX-LE4), Waixiyan(Dubi, ST35), Zusanli(ST36) and Sanyinjiao(SP6) of the affected lower limb;~Massage the spleen and stomach meridians of the affected lower extremes;~Roll the soft tissues around the affected knee;~Relax the gastrocnalis muscle~The doctor gives the pressure on the Xuehai(SP10), Liangqiu(ST34), Neixifeng(medial patellofemoral ligament), Waixifeng(lateral patellofemoral ligament), Neixiyan(EX-LE4) and Waixiyan(Dubi, ST35) at the same time;~Push the patella and do the passive movement of the affected knee;~Strength training of the affected knee.~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
28169|NCT03966248|Other|Physical Manual therapy|"Manual therapy: Stretching the knee joint, stretching the knee joint with valgus or abduction, stretching the knee joint with varus or adduction is suitable for patients with knee flexion and extension difficulty.Patellar manipulation by bending the knee 5-10 degrees downward is suitable for patients with patellar sliding difficulty.The lower end of the muscle length manipulation is suitable for patients with muscle tension and soft tissue tension.Soft tissue loosening is performed in the suprapatellar and peripatellar regions, medial and lateral capsule joints, and popliteal fossa.~Activity training: Mainly about the knee joint flexion and extension movement training.~Strength training: Mainly about quadriceps muscle resistance exercises~This group receives 8 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
28170|NCT03966235|Drug|Melatonin 3 mg|Melatonin was taken daily for 6 months.
28171|NCT03966235|Drug|Placebo|Placebo tablet was taken daily for 6 months.
28172|NCT03966222|Device|Endoscopic vein harvest|An endoscope is introduced adjacent to the vein, allowing its dissection under direct vision via a small incision.
28173|NCT03966222|Other|Open vein harvest|Open vein harvest
28174|NCT03966209|Drug|JS001(PD-1 inhibitor)|240mg I.V. Q3W
28175|NCT03966196|Other|Measurements of oxygen saturation and finger pressure during deep inspiration|Measurements during deep inspiration of oxygen saturation with pulse oximeter and finger pressure with pressure cuff
28176|NCT03966170|Drug|Citicoline|Citicoline as neuroprotector
28177|NCT03966170|Drug|Placebo oral tablet|placebo drug
28178|NCT03966157|Device|Nasal Bridle|Feeding tube secured with nasal bridle
28179|NCT03966144|Device|RoboHear Device|Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
28180|NCT03966131|Device|Tongue pressure recordings with the PRESLA prothesis for the Arm1 (patients wearing the complete denture for the first time)|Tongue pressure recordings during speech production, wet and dry swallowing tasks planned in 3 sessions, when the complete denture is worn for the first time, after 3 weeks, then after 3 months in order to characterise the adaptation to this new prosthesis.
28181|NCT03966131|Device|Tongue pressure recordings with the PRESLA prothesis for the Arm2 (patients used to wear the complete denture)|These measures provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during speech production in patients used to their prosthesis. They also provide to establish a spatial and temporal mapping of contacts applied by the tongue and lips to the prosthesis during swallowing) in these patients. The measurement is made at once when the new denture which replaces the old one is placed in the mouth.
28182|NCT03966118|Drug|Avelumab|Avelumab 1mg/kg Day 1 and Day 15 of a 28-day cycle
28183|NCT03966118|Drug|Ramucirumab|Ramucirumab 8mg/kg on Day 1 and Day 15 of a 28-day cycle
28184|NCT03966118|Drug|Paclitaxel|Paclitaxel 80mg/m2 on Day 1, Day 8 and Day 15 of a 28-day cycle
28185|NCT03966105|Diagnostic Test|HE and Congo red staining|Biopsies will be formalin fixed, processed routinely, and sent to the Department of Pathology for evaluation by hematoxylin and eosin and Congo red staining by pathologists. Biopsy specimens with confirmed amyloid deposits via Congo red staining will be further analyzed using immunohistochemistry for subtyping.
28186|NCT03966092|Procedure|Quadratus lumborum block|"Bilateral Quatratus lumborum block is performed with ultra sound guidance. The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen). Laterally, these three are merging to from fascia transversalis. Under fascia transversalis, we can see quadratus lumborum muscle. Punction point in lateral, 1cm in the plan separating quadratus lumborum block and fascia transversalis~20 ml of ropivacaïne 3.75mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised."
28187|NCT03966079|Drug|recombinant tissue plasminogen activator|Patients receive 20 mg of single-dose recombinant tissue plasminogen activator delivered through the catheter
28188|NCT03966066|Drug|erythromycin|3-5mg/kg.d orally for 6 months
28189|NCT03966053|Drug|Trifluoperazine|Trifluoperazine (TFP)1mg, 2mg, 5mg, or 10mg will be given once daily by mouth for 21 days
28190|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7
28191|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7
28192|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7|36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
28193|NCT03966040|Biological|Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14|36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14
28194|NCT03966027|Other|Postoperative protocol (Immediate weight bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow an immediate weight bearing rehabilitation protocol using an offloading hindfoot brace
28195|NCT03966027|Other|Postoperative Protocol (Delayed Weight Bearing)|After ORIF of the ankle fracture, the patient will be randomized to follow a standard delayed weight-bearing rehabilitation protocol
28196|NCT03966014|Drug|EM-amoxicillin 3 x 10 days|Patients will receive amoxicillin 500 milligram tid for 10 days
28197|NCT03966014|Drug|EM-amoxicillin 3 x 14 days|Patients will receive amoxicillin 500 milligram tid for 14 days
28198|NCT03966014|Drug|EM-amoxicillin 2 x 14 days|Patients will receive amoxicillin 500 milligram bid for 14 days
28199|NCT03966014|Other|Controls|No intervention.
28200|NCT03966001|Other|Transvaginal sonography at six months after cesarean section|In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
28201|NCT03966001|Other|Transvaginal sonography at twelve months after cesarean section|In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
28202|NCT03965988|Drug|DHA|Docosahexaenoic acid
28203|NCT03965988|Drug|Placebo|Placebo
28204|NCT03965975|Device|Lab Gold Standard|"First intervention (assigned to the All participants arm)."
28205|NCT03965975|Device|S-There|"Second intervention (assigned to the All participants arm)."
28206|NCT03965962|Biological|VRVg-2|"Pharmaceutical form:Powder and solvent for suspension for injection~Route of administration: Intramuscular"
28207|NCT03965962|Biological|Purified Vero Rabies Vaccine|"Pharmaceutical form:Powder and solvent for suspension for injection~Route of administration: Intramuscular"
28208|NCT03965962|Biological|Human Diploid Cell Vaccine (HDCV)|"Pharmaceutical form:Powder and solvent for suspension for injection~Route of administration: Intramuscular"
28209|NCT03965962|Biological|Rabies immune globulin (human)|"Pharmaceutical form:Solution for injection~Route of administration: Intramuscular"
28210|NCT03965949|Drug|Hormone Replacement cycle 1|Hormone Replacement cycle (cyclacur) without GnRHa suppression with luteal support (progesterone)
28211|NCT03965949|Drug|Hormone Replacement cycle 2|Hormone Replacement cycle with GnRHa suppression
28267|NCT03965546|Combination Product|TAE combined with ET140202-T cell|"Transarterial embolization(TAE) treatment~Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct -intravenous (i.v.)"
28362|NCT03964805|Other|20% oxygen|culture excusively at 20% O2 (Day 0 to Day 6)
28212|NCT03965936|Procedure|lipofilling|Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. then with blunt cannula,subcutaneous injection of the required volume of microfat is placed into temporal region.
28213|NCT03965936|Procedure|lipofilling enriched with adipose tissue derived stem cells|"Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of 75 ml fat using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe. 50 ml is used for preparation of microfat. 25 ml is used for preparation of autologous adipose tissue derived stem cells (At-ADSCs) using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Subcutaneous injection of the required volume of microfat combined with stromal vascular fraction containing adipose tissue derived stem cells, is placed into temporal region."
28214|NCT03965923|Drug|Dapivirine (DPV) Vaginal Ring (VR)|Vaginal ring containing 25 mg of DPV
28215|NCT03965923|Drug|Truvada Tablet|Tablet taken orally
28216|NCT03965910|Other|Demonstration the Importance of Early Rehabilitation in Stroke Patients Based on Diffusion Tensor Imaging Data|"Twenty-eight stroke patients aged 36-72 years admitted to the our Physical Medicine and Rehabilitation Outpatient Clinics were included in this prospective study. After the approval of the ethics committee, written informed consent was obtained from the patients after they were informed about the content and purpose of the study, the schedule of rehabilitation to be administered, and the features of cranial magnetic resonance imaging (MRI) to be performed. Patients with confirmed diagnosis of stroke by computed tomography and/or MRI techniques were randomized into two groups according to the onset of post-stroke rehabilitation. The patients were randomized according to the duration of their admission to our clinic for rehabilitation. Group 1 consisted of patients admitted to our clinic within 1-4 weeks after stroke; Group 2 consisted of patients admitted within 5-8 weeks after stroke.~Late initiation of rehabilitation in Group 2 patients is not a condition related to our clinic."
28217|NCT03965897|Behavioral|Acceptance and Committment Therapy (ACT)|Overall, the goal of the ACT intervention is to cultivate psychological flexibility: to help Veterans respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. It increases patients' awareness of behaviors that exacerbate the pain (such as struggling with it) and recognition of avoidance strategies that interfere with life engagement.
28218|NCT03965897|Other|Attention Control (AC)|Information on any other coping practices will be omitted. The group facilitators will present one topic at a time, using the Pain Manual, and the participants will discuss and reflect about issues and experiences related to each topic. If necessary, the group facilitators will raise specific discussion questions to facilitate group dialogue and participant involvement.
28219|NCT03965884|Other|Physical therapy and rehabilitation|Physical therapy and rehabilitation
28220|NCT03965871|Drug|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
28221|NCT03965871|Drug|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
28222|NCT03965871|Drug|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
28223|NCT03965871|Drug|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
28224|NCT03965858|Drug|Esketamine DPI - low dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
28225|NCT03965858|Drug|Esketamine DPI - medium dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
28226|NCT03965858|Drug|Esketamine DPI - high dose|Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
28227|NCT03965858|Drug|Placebo DPI|Placebo DPI is to be administered via dry powder inhaler.
28228|NCT03965845|Drug|Telaglenestat (CB-839)|Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
28229|NCT03965845|Drug|Palbociclib Oral Capsule [Ibrance]|Palbociclib (Ibrance) is an oral capsule administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
28230|NCT03965832|Device|HFNT during exercise|"6-minute walking test performed initially on HFNT. HFNT will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) as at baseline conditions during exercise.~Participants will then cross-over to repeat the test on baseline conditions."
28231|NCT03965832|Device|Standard oxygen therapy/RA|6-minute walking test performed on baseline conditions. Participants will then be cross over to repeat the test on HFNT
28232|NCT03965819|Dietary Supplement|Pain Bloc-R|Herbal Supplement containing Vit D3, Vit B6, Vit B12, White Willow Bark, Angelica Root, Acetyl L-carnitine HCl, Caffeine, L-Theanine, Benfotiamine, and L-Tetrahydropalmatine
28233|NCT03965819|Other|Active Comparator - Acetaminophen|DIN 02447479 Encapsulated for Blinding Purposes
28234|NCT03965819|Other|Placebo|No active ingredients
28235|NCT03965806|Behavioral|SURVEY|SURVEY
28268|NCT03965546|Biological|ET140202-T cell|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) - expression construct -intravenous (i.v.)
28269|NCT03965533|Drug|GSK2831781|GSK2831781 will be available as Dose-1 and Dose-2 as IV infusion or SC injection. Subjects will receive GSK2831781 Dose-1 IV diluted in 0.9% saline or GSK2831781 SC as multiples of Dose-2 SC.
28270|NCT03965533|Drug|Placebo|Placebo will be 0.9% saline solution which will be administered in subjects as IV infusion or SC injection.
28237|NCT03965780|Other|SPIN-SSLED Program|"The SPIN-SSLED Program is a 3-month-long (13 sessions) group training program designed to be delivered via videoconferencing to provide information and skills to improve leader support group leaders' confidence and self-efficacy to carry out their leadership roles and reduce the burden on them of leading a support group. Each session is about 90 minutes long and covers one of the 13 modules of the program.~Module topics includes: (1) The Leader's Role; (2) Starting a Support Group; (3) Structuring a Support Group Meeting; (4) Scleroderma 101; (5) Successful Support Group Culture; (6) Managing Support Group Dynamics; (7) Loss and Grief: The support group leader; (8) Loss and Grief in Scleroderma: Supporting group members; (9) Advertising and Recruitment for the Support Group; (10) The Continuity of the Group; (11) Supporting Yourself as a Leader; (12) Remote Support Groups; and (13) Transitions in Support Groups."
28238|NCT03965767|Drug|Tranexamic Acid|comparison of effect of tranexamic acid on control of bleeding when used locally in the nose or systemic use
28239|NCT03965754|Behavioral|Social norms|This intervention introduces recipients to descriptive social norms specifying that a majority of their colleagues have signed up for the program, which sets a normative standard against which recipients are expected to compare themselves and to change their behavior accordingly (i.e., when they realize that their behavior is discrepant from that of relevant others). The personal testimonial from a Geisinger medical director serves as a personal exemplar intended to further enhance the effect of the social norms with an implicit indication that the intended behavior is desirable and feasible.
28240|NCT03965754|Behavioral|Loss framing|This intervention frames the status quo as a state from which recipients, via inaction, are slated to forfeit a sizable and precise monetary amount to which they should otherwise feel entitled (via loss aversion and the endowment effect). People tend to be risk-seeking in the domain of losses; therefore, this intervention is hypothesized to increase enrollment in the hope of achieving zero loss by meeting program goals, as opposed to a sure loss via inaction.
28241|NCT03965754|Behavioral|Email reminder|This intervention is a standard email reminder that mentions the average premium savings, the speed and ease of starting the process, and the deadline for registering and having health measures on file, plus it provides two button links for registering and finding screenings.
28242|NCT03965741|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Follow clinical administration
28243|NCT03965741|Drug|Apixaban(Eliquis)|Follow clinical administration
28244|NCT03965741|Drug|Pradaxa (Dabigatran etexilate)|Follow clinical administration
28245|NCT03965728|Drug|BAY1830839|Tablet, oral.
28246|NCT03965728|Drug|Placebo|Tablet, oral.
28247|NCT03965728|Drug|Midazolam|Oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2
28248|NCT03965728|Drug|Methotrexate|Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
28249|NCT03965715|Device|3D printing AFO, anterior AFO, off-the-shelf AFO|Subjects wear different AFOs and performed gait analysis.
28252|NCT03965689|Drug|Carboplatin|Given IV
28253|NCT03965689|Drug|Paclitaxel|Given IV
28254|NCT03965689|Drug|Pevonedistat|Given IV
28255|NCT03965676|Other|Dual-Energy Computed Tomography examination|Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia < 360μmol/L (baseline DECT is in the domain of usual care).
28256|NCT03965663|Device|Vibro-tactile Feedback|The device measures the force between the prosthetic food and the ground. With this signals, vibratators are triggered. The vibrators are housed by the prosthetic socket and stimulate the stump.
28257|NCT03965650|Other|Video coaching exercises|Patients will perform physical exercises following a specifical video coaching program during 6 months.
28258|NCT03965650|Other|Routine exercises|"Routine method by advising and encouraging patients to perform exercises according to the WHO recommendations during the first 3 months of the study.~Thereafter, patients will have access to the video coaching program of physical activities during the following 3 months."
28259|NCT03965637|Drug|vitamin C|water-soluble vitamin C injection contain of 1000 mg vitamin C that given via intravenous injection
28260|NCT03965624|Drug|Ninlaro|Oral ixazomib will be given on days 1, 8, 15 of a 28-day cycle, the investigator will start with first test dose levels of ixazomib of 3 mg and process with dose escalation, in case of non-response and no severe adverse events at cycle 1 (see above) or de-escalation in case of response and severe adverse events.
28261|NCT03965611|Procedure|Oropharyngeal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
28262|NCT03965611|Procedure|Rectal swab|Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
28263|NCT03965611|Procedure|Disability rating scale (DRS-F)|Will be assessed at day 90 +/- 7 days.
28264|NCT03965585|Procedure|in-office hysteroscopy|in-office hysteroscopy with miniaturized instruments
28265|NCT03965559|Procedure|plasmapheresis|"Plasmapheresis is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy (a medical procedure performed outside the body).[Wikipedia]~DFPP is a selectively removal of the immunoglobulin fraction from the serum and, as a result, to minimize the volume of substitution fluid required. [Tanabe K. Double-filtration plasmapheresis. Transplantation. 2007 Dec 27;84(12 Suppl):S30-2.]"
28266|NCT03965546|Combination Product|Sorafenib combined with ET140202-T cell|"Sorafenib starting dose of 400mg b.i.d. a.c.~Autologous T cells transduced with lentivirus encoding an anti-AFP (ET140202) expression construct by intravenous (IV) infusion"
28271|NCT03965520|Behavioral|exercise rehabilitation by near-infrared spectrometer|We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
28272|NCT03965507|Other|Evaluation of the prevalence of sacroiliac joint dysfunction in lumbar disc herniation|
28273|NCT03965494|Drug|BGB 324 (before surgery)|Given by mouth either BEFORE therapeutic conventional surgery
28274|NCT03965494|Drug|BGB 324 (after surgery)|Given by mouth either AFTER therapeutic conventional surgery
28275|NCT03965481|Radiation|Dynamic Enhanced CT|Undergo standard CECT
28276|NCT03965481|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI scan
28277|NCT03965481|Procedure|Positron Emission Tomography|Undergo PET/MRI scan
28278|NCT03965468|Drug|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1. Durvalumab is expected to stimulate the patient's antitumour immune response by binding to PD L1 and shifting the balance toward an antitumour response.
28279|NCT03965468|Drug|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
28280|NCT03965468|Drug|Paclitaxel|A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
28281|NCT03965468|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT of all oligo-metastatic lesions
28282|NCT03965468|Procedure|Surgical resection - definitive local treatment.|Surgical resection of primary tumour for patients with single station, non-bulky tumours.
28283|NCT03965468|Radiation|Radical radiotherapy - definitive local treatment.|Conventional or moderately hypo-fractionated radiotherapy to the primary tumour for other tumour stages, or in case of medical inoperability.
28284|NCT03965455|Device|Diode laser|In the laser-assisted frenectomy, a diode laser device (GIGA Cheese II®, China) (λ= 810 nm) with a 400 µm diameter, plain-ended optical ﬁber tip was used for the procedure maintaining contact with oral mucosa at 2,5 W, 70 Hz frequency with a short pulse (140 microseconds) duration.
28285|NCT03965455|Procedure|Conventional|In the conventional frenectomy, the incisions were applied using a scalpel blade no.15 on the upper and lower surface of the haemostat until the frenum was excised.
28286|NCT03965442|Drug|Control|Patients who underwent mastectomy under standard general anesthesia
28287|NCT03965442|Drug|Esmolol|Patients who underwent mastectomy under general anesthesia with esmolol infusion
28288|NCT03965429|Other|Blood samples (additional tubes from care) longitudinal|Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
28289|NCT03965429|Other|Blood samples (additional tubes from care) at inclusion|"In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.~In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification."
28290|NCT03965416|Other|White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
28291|NCT03965416|Other|Without White Coat|We included the first and last patients in consultation every day for 10 consecutive days, and every other day the doctor consulted with the use of a white coat or without the use of a white coat.
28292|NCT03965403|Device|Arm motor function retraining with BURT|Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
28293|NCT03965390|Behavioral|Oral education|"Oral therapeutic education aims to improve dietary practices, daily hygiene and care, in an approach adapted to the characteristics and consequences of Parkinson's disease. An oral prevention package will be given to patients.~Initially, dentists expose various oral health problems commonly found in Parkinson's disease, in order to give patients the necessary information for the understanding Secondly, dentists dispenseront practical advice tailored to pathology, to maintain good oral health"
28294|NCT03965377|Behavioral|Home Safety Hero Computer Game|Home Safety Hero computer game presents players with virtual rooms in a home where vilians have planted safety risks. It involves the player taking the role of a body guard for a child. It has three phases: 1. Identifying risks in a set of rooms (e.g., burn, falling, suffocation, poisoning); 2. Identifying risks and then selecting a resolution to reduce the risk or eliminate it entirely; and 3. Identifying risk when faced with distractions typical to home environments (e.g., phone ringing, fire engine siren sounds, a moving child).
28295|NCT03965364|Device|INCRAFT|Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
28296|NCT03965351|Drug|Probenecid|This is a cross-over pilot study where participants will receive both the study medication (probenecid), as well as a placebo to see if the study medication improves magnetic resonance parameters of systolic and diastolic dysfunction that occurs in the Fontan population.
28297|NCT03965338|Diagnostic Test|fMRI|Screening
28298|NCT03965325|Other|Use of a standardized set to collect clinical and patient-centered data, to assess the trend of the Global Health Status overtime in colorectal cancer patients|Patients' data (baseline characteristics, clinical and PROMs outcomes) will be collected according to patient-centered standardized set regarding ICHOM recommendations. Data collection and the follow-up schedule are carried out at : baseline (before any treatment or surgery), 1- and 6-month follow-up and then once a year.
28299|NCT03965312|Device|Continuous temperature monitor|Temperature will be measured using a novel temperature monitor continuously for up to 72 hours. Accuracy (as compared to a commercially available patient monitor) will be evaluated.
28300|NCT03965312|Device|Neonatal Incubator|Infants at risk for hypothermia will be placed in a neonatal incubator. Their temperature will be monitored as they are treated. The infant will be treated until the infant is transitioned to skin-to-skin care, discharged, or no longer at risk for hypothermia.
28302|NCT03965299|Device|VERUM TTNS|"Daily 30-minuteTTNS intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
28303|NCT03965299|Device|SHAM TTNS|"Daily 30-minute SHAM intervention is performed 5 days a week during a treatment period of 6-9 weeks, until 3-month post assessments~During a preparation phase of several minutes, sensory and motor thresholds are assessed and stimulation intensities are adjusted for the following 30-minute treatment phase"
28304|NCT03965286|Drug|DAAs|Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) 12 weeks Daily simeprevir (150 mg) plus sofosbuvir (400 mg) 12 weeks Daily daclatasvir (60 mg) plus sofosbuvir (400 mg) 12 weeks Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) with dasabuvir (600 mg) 12weeks
28305|NCT03965273|Behavioral|Full TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Community and Social Norms Change Component; iv) Facilitated sessions with mothers' groups and (separate) fathers' groups; v) 2-days intensive facilitated workshop with selected religious leaders and influential people; vi) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vii) Trainings of girls, boys and parents with special interest in activism.
28306|NCT03965273|Behavioral|Light TP|The overall Tipping Point intervention package will span 18 months and will involve: i) Weekly facilitated training sessions with girls' groups and boys' groups; ii) Dialogue sessions jointly with girls' groups and fathers' groups, and girls' groups and boys' groups; iii) Facilitated sessions with mothers' groups and (separate) fathers' groups; iv) 2-days intensive facilitated workshop with selected religious leaders and influential people; v) Village savings and loans associations (VSLAs) formed by the girls' group members to create opportunities for girls to engage in age-appropriate income generating activities and build their potential as entrepreneurs; vi) Trainings of girls, boys and parents with special interest in activism.
28307|NCT03965260|Biological|Bacterial samples from blood or peritoneal liquids|"For each cirrhotic patient hospitalized for a bacterial infection, a blood sample or a peritoneal liquid sample was collected and analyzed for susceptibility, as it is performed in the standard of care. Our department receives only the bacterial results.~We will then describe the bacterial ecology of the center cirrhotic population in terms of infection acquisition mode, infection site, infection etiology but also drug-resistance."
28308|NCT03965247|Drug|Lithium|
28309|NCT03965247|Other|Placebo - Rayotabs|
28310|NCT03965234|Drug|Cisplatin|Given via infusion
28311|NCT03965234|Procedure|Isolated Chemotherapeutic Lung Perfusion|Undergo pulmonary suffusion
28312|NCT03965234|Procedure|Metastasectomy|Undergo metastasectomy
28313|NCT03965221|Behavioral|LYNX|Access to the LYNX mobile app which includes the Sex Pro score tool, sex diary, badges, PrEP information and video testimonials, HIV/STI testing reminders and geo-location features, and asynchronous chat feature.
28314|NCT03965221|Behavioral|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
28315|NCT03965208|Drug|Bivalirudin|titrated continuous infusion
28316|NCT03965208|Drug|Unfractionated heparin|titrated continuous infusion
28317|NCT03965195|Biological|Recombinant Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.
28318|NCT03965195|Biological|Standard Dose Quadrivalent Influenza Vaccine|Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine
28319|NCT03965182|Drug|PEG|2 sachets of PEG will be used as the bowel prep regimen.
28320|NCT03965182|Drug|PEG plus SPMC|one sachet of PEG and one sachet will be administered as the bowel prep regimen
28321|NCT03965182|Drug|SPMC|2 sachets will be administered as the bowel prep regimen.
28322|NCT03965169|Procedure|Prone spinal surgery|spinal surgery in prone position under general anesthesia
28323|NCT03965156|Procedure|1) Ultrasound guided Erector spinae block|In the lateral position, after skin sterilization, erector spinae plane block will be performed at the level of T9. Counting down from the spine of seventh cervical vertebrae, the spine of the nine thoracic vertebrae (T9). A linear low frequency ultrasound transducer (US) (3-5 MHz) will placed sagittal 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between transverse processes. A 22-gauge short bevel needle will be inserted in cranial-caudal direction towards transverse process (TP) in plane to the US transducer until needle touched the TP crossing all the muscles. The location of the needle tip will be confirmed by visible normal saline fluid separating erector spinae muscle off the bony shadow of the transverse process on ultrasound imaging. Then 20 ml of bupivacaine 0.375% plus plus 5ug/ml adrenaline (1:200000) will be injected. The procedure will be repeated following the same steps on the other side of the back.
28324|NCT03965156|Procedure|Ultrasound guided transversus abdominis plane block|in supine position and after skin sterilization. The linear high frequency transducer (6-13 MHz) will be placed in the transverse plane to the the lateral abdominal wall in the midaxillary line, between the lower costal margin and iliac crest. The three abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) are visualized. The needle inserted in plane and advanced anterior to posterior under continual visualization until the tip between the internal oblique and the transversus abdominis muscle. After negative aspiration, a 20 ml of bupivacaine 0.375% plus 5ug/ml adrenaline (1:200000) will be injected. The success of the injection will be confirmed by separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in between. The procedure will be repeated following the same steps on the other side.
28325|NCT03965143|Device|3D talar augmentation|Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
28326|NCT03965130|Drug|Glucagon|PINTA study with or without glucagon
28363|NCT03964805|Other|5% oxygen|culture excusively at 5% O2 (Day 0 to Day 6)
28364|NCT03964805|Other|20 % and 5 % oxygen|culture at 5% from Day 0 to Day 3, then at 20% from Day 3 to Day 6)
28327|NCT03965117|Drug|Norepinephrine|norepinephrine will be started at 0,1 mcg/kg/min and titrated according to its haemodynamic effect. After baseline MAP (which is > 60 mmHg), norepinephrine is targeted according baseline MAP. At T2, MAP is between 10 - 20 % above baseline (T1), at T3 MAP is between 20 - 30 % above baseline (T1).
28328|NCT03965104|Behavioral|Hypertension Canada Professional Designation Program: HC-PDP|The HC-PDP is a certification program which aims to provide training to generalist primary care providers in the screening, prevention, and management of hypertension.The competencies assessed in the program have been validated for their importance through a national survey of hypertension experts and primary care providers.
28329|NCT03965091|Drug|Fremanezumab - Dose A|Administered subcutaneously (sc) for 4 monthly doses at Visits 3, 4, 5, and 6.
28330|NCT03965091|Drug|Fremanezumab - Dose B|Administered subcutaneously (sc) for 4 monthly doses at Visits 3, 4, 5, and 6.
28331|NCT03965091|Drug|Placebo|Administered subcutaneously (sc) for 4 monthly doses at Visits 3, 4, 5, and 6.
28332|NCT03965078|Drug|topical (eye drop) anti-inflammatories|Initial treatment with topical anti-inflammatory eye drops at the discretion of the reviewing clinician
28333|NCT03965065|Device|Sutureless aortic bioprosthesis|Patients will receive a sutureless aortic bioprosthesis
28334|NCT03965065|Device|Conventional stented sutured aortic prosthesis|Patients will receive a stented sutured aortic prosthesis
28335|NCT03965052|Drug|PRO 179|"Generic name: Travoprost~Distinctive denomination: Bristrio® (PRO-179)~Active principles: Travoprost 0.004%.~Pharmaceutical form: Ophthalmic solution~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Sophia Laboratories, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: White bottle with 5 milliliters capacity, made of low density polyethylene."
28336|NCT03965052|Drug|Travatan 0.004 % Ophthalmic Solution|"Generic name: Travoprost~Distinctive denomination: Travatan®~Active ingredients: Travoprost 0.004%~Pharmaceutical form: Ophthalmic solution.~Presentation: multi-dose dropper bottle, 2.5 milliliters.~Prepared by: Alcon Laboratories Inc.~Description of the solution: transparent solution, free of visible particles.~Consult information to prescribe."
28337|NCT03965013|Drug|NNC0268-0965|2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
28338|NCT03965013|Drug|Placebo|A single dose of placebo given in Part 1
28339|NCT03965013|Drug|insulin glargine|Insulin glargine given at a fixed dose level of 0.5 U/kg
28340|NCT03965000|Other|Mixed-meal-tolerance-test|To assess the dynamics of the glucagon-incretin axis we need to perform the MMTT. Thereby the patients need to consume a body weight adjusted, standardized meal and we draw blood at fixed time points over 4 hours.
28341|NCT03964974|Behavioral|Cognitive Behavioral Therapy for Insomnia in Cannabis Users|Each CBTi-CB therapy session will review the previous week of sleep/wake diaries and summarize key sleep parameters with participants. The treatment will address cannabis use by increasing use of appropriate coping strategies and improving self-efficacy to manage insomnia and next-day consequences. The content includes: (1) Sleep Scheduling Strategies to consolidate sleep using behavioral strategies that increase the drive for sleep and stabilize the circadian timing system; (2) Sleep Hygiene to discuss behaviors, substances, and environmental conditions that can help or hinder sleep; (3) Cognitive Therapy aims to identify and alter dysfunctional beliefs about sleep and functioning that contribute to insomnia; (4) Counter-Arousal Strategies address ruminative thoughts and increased body tension interfering with ability to fall or return to sleep; (5) Relapse Prevention for Insomnia reviews treatment gains and the behavioral and cognitive strategies that were most helpful.
28342|NCT03964974|Behavioral|Sleep Education|The SE condition will be matched to the CBTi-CB condition in terms of level of attention and the non-specific aspects of receiving social support from a study therapist, without providing individualized recommendations. The current content includes: (1) Insomnia History of the participant, including triggers that initiated the problem, duration, severity, and frequency, premorbid sleep characteristics, and previous sleep treatments; (2) Sleep Education about why we sleep, sleep stages, sleep regulation at night, and sleep changes across lifespan; (3) Substance Use and Sleep and the effects of cannabis and other licit and illicit substances on sleep; (4) Environmental Factors that contribute to a sleep-conducive environment; (5) Lifestyle Factors like the effects of diet, exercise, and napping on sleep; (6) Sleep Maintenance Strategies to review treatment gains from the participant's perspective and emphasize the principles covered to maintain sleep improvements.
28343|NCT03964961|Other|Functional massage|It's a massage combined with a stretching of the muscles.
28344|NCT03964961|Other|Conventional massage|It's a regular massage made with the therapist's hands.
28345|NCT03964948|Diagnostic Test|Kidney MRI|An MRI examination will be completed per research MRI protocol.
28346|NCT03964935|Drug|Lycopene|"Prepared by solving lycopene powder in a solvent (ethanol: propylene glycol: water in the ratio of 50:30:20). The solution was then gelled by adding 8% hydroxypropyl cellulose (HPC). The concentration of the prepared gel equals to 2%.~After SRP, the gel delivered into periodontal pocket using insulin syringes, the therapeutic dose is about 2mg/0.1 ml."
28347|NCT03964935|Drug|Minocycline HCl 1mg Oral Powder|Minocycline HCl Microspheres, 1mg minocycline powder per cartridge. A locally applied antibiotic that is placed directly into the infected periodontal pocket following SCR.
28348|NCT03964935|Other|Distilled water|Used to irrigate periodontal pockets after SRP
28349|NCT03964922|Biological|blood sample|20 ml at inclusion, and 20ml at 1, 3, 6 and 12 months after allo HSCT
28350|NCT03964922|Biological|bone marrow sample|3 ml at inclusion, and 3 ml at 1, 3, 6 and 12 months after allo HSCT
28351|NCT03964909|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI
28352|NCT03964909|Procedure|Magnetic Resonance Imaging|Undergo CVR MRI
28353|NCT03964909|Procedure|Resting State Functional Connectivity Magnetic Resonance Imaging|Undergo rs-fMRI
28354|NCT03964896|Other|Survey|Complete survey
28355|NCT03964896|Other|Survey Administration|Ancillary studies
28356|NCT03964896|Behavioral|Telephone-Based Intervention|Receive telephone calls
28357|NCT03964870|Diagnostic Test|Diagnostic of polymorphisms in malignant hyperthermia|Identify and catalogue the variants or polymorphisms in the RYR1 and CACNA1S genes in the Spanish population.
28358|NCT03964857|Other|Refined olive oil (ROO)|Consumption of chicken dishes made with ROO for a period of 8 weeks
31372|NCT03940586|Drug|Letermovir intravenous|Letermovir administered intravenously based on age/weight
28365|NCT03964792|Genetic|DREPAGLOBE drug product|Each patient will receive a single IV infusion of DREPAGLOBE drug product
28366|NCT03964779|Diagnostic Test|Hormonal assay|Measurement of Thyroid stimulating hormone
28367|NCT03964779|Diagnostic Test|Antibody assay|antithyroglobulin and antithyroid peroxidase
28368|NCT03964766|Device|Rotary instrumentation|using pedo rotary files in cleaning and shaping the root canals of infected primary molars
28369|NCT03964766|Device|Hand instrumentation|using conventional hand files in cleaning and shaping the root canals of infected primary molars
28370|NCT03964753|Drug|Nab-paclitaxel and Cisplatin|Nab-paclitaxel,125mg/m(2), d1,d8, Cisplatin,75mg/m(2), d1, 3 week, 2 cycles.
28371|NCT03964753|Procedure|surgery|surgery
28372|NCT03964740|Other|Mobile App intervention|The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
28373|NCT03964727|Biological|IMMU-132|Sacituzumab govitecan will be administered at 10 mg/kg as an intravenous infusion on days 1 and 8 of a 21-day cycle until disease progression (PD), toxicity or withdrawal of consent.
28374|NCT03964701|Other|no intervention|no interventional study
28375|NCT03964688|Drug|Vitamin C|vitamin C intravenous during hospitalization, after oral, total 6 weeks.
28376|NCT03964688|Drug|Placebos|placebo intravenous during hospitalization, after oral, total 6 weeks
28377|NCT03964675|Device|SenseGuard|A single invitational visit with a respiratory rate measurement duration of 30 minutes.
28378|NCT03964662|Device|WeReha|Rehabilitation of stroke patients with the device WeReha
28379|NCT03964636|Diagnostic Test|OCT-A (optical coherence tomography)|Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
28380|NCT03964623|Diagnostic Test|OCT-A (Optical Coherence Tomography)|Included patients will have an OCT-A and will be questioned about their nicotine intake, their background and taking an oral conception
28381|NCT03964610|Diagnostic Test|color fundus photography (CFP) and OCT-A|Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
28382|NCT03964597|Diagnostic Test|Measurement of lens opacification|Measurement of OSI and ALD at inclusion and during post-IVT follow-up visits to M3, M6, and M12, +/- M18, +/- M24 and +/- M30.
28383|NCT03964584|Other|assessment of neurological and psychiatric disorders by self-administered questionnaires|Patients will be included on the day dolutegravir or bictegravir is prescribed. Neurological and psychiatric disorders will be assessed using self-administered questionnaires, at inclusion, one month, three months and six months.
28384|NCT03964571|Diagnostic Test|WOUNDCHEK|fluid swab of wound and measurement of wound onto film
28385|NCT03964558|Drug|[14C]-acebilustat solution|Acebilustat is a novel synthetic small molecule leukotriene A4 hydrolase (LTA4H) inhibitor.
28386|NCT03964545|Behavioral|neurofeedback|Patients are instructed to reduce amygdala activation by means of down-regulating the EFP. An auditory feedback interface is used with the instruction to down-regulate volume of a jingle, reflecting intensity of EFP.
28387|NCT03964532|Drug|Talazoparib|Talazoparib (formerly MDV3800 and BMN673) is an oral small molecule, selective inhibitor of PARP-1 and PARP-2.
28388|NCT03964532|Drug|Avelumab|Avelumab (formerly MSB0010718C) is a human immunoglobulin G1 (IgG1) anti-PD-L1 monoclonal antibody131 that utilizes both adaptive and innate immune mechanisms.
28389|NCT03964519|Other|Acute changes|In a crossover design, participants will be randomized to perform on Day 1, 3 sets of repetitions (depending on each treatment group) at 70% or 1RM in the full squat exercise. 48-h later, same will be performed but in the contrary crossover arm.
28390|NCT03964519|Other|Chronic changes|In a randomized control trial, participants will train during 6 weeks the full squat exercise, 2 days in the week (minimum between-days rest of 48h). Intensity will vary from 70% to 85 of 1RM, and training volume from 3 to 6 sets.
28391|NCT03964519|Other|Familiarization|Prior to any intervention, all participants will perform a familiarization of the exercise session, together with a progressive resistance test to estimate the 1 RM
28392|NCT03964506|Drug|Hyperbaric oxygen|Reduced intensity conditioning Fludarabine and Melphalan with Hyperbaric Oxygen and Allogeneic Hematopoietic Stem Cell Transplant
28393|NCT03964493|Drug|TNP-2092|TNP-2092 100mg/vial
28394|NCT03964493|Drug|Vancomycin|Vancomycin 1g/vial
28395|NCT03964467|Device|transcranial direct current stimulation|see arm/group descriptions
28396|NCT03964454|Behavioral|WIC support + home-based individual support + Breastfeeding Incentives (SC+BFI)|Participants randomized into SC+BFI will receive the same services as the Standard Care Control (SC) group (standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving) plus financial incentives (Breastfeeding Incentives, BFI) contingent on observed breastfeeding.
28397|NCT03964454|Behavioral|WIC support + home-based individual support (SC)|Participants randomized into SC will receive standard breastfeeding services from Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) plus monthly home visits that facilitate navigation to as-needed resources and referrals to services that support breastfeeding and problem solving.
28398|NCT03964441|Biological|Invasive fetal sampling, blood sampling of mother and father|to perform an exome sequencing analysis in trio
28399|NCT03964441|Biological|blood sampling from the mother to recover the circulating cell free fetal DNA|to perform a sequencing analysis of the genome of circulating free fetal DNA
28400|NCT03964415|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.
31373|NCT03940573|Device|Eclipse Insert|Rectal Control System.
28401|NCT03964415|Biological|Clade C and Mosaic gp140 HIV bivalent vaccine|Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.
28402|NCT03964415|Biological|Placebo|Participants will receive matching placebo.
28403|NCT03964402|Drug|intervention treatment|intervention treatment (any)
28404|NCT03964389|Other|Therapeutic Neuroscience Education (TNE)|A talk on Neuroscience Education (EN). This intervention aims to provide information in a clear and simple way to the participants so that through it the patients may be able to modify their attitude towards pain, inviting them to take a more active and less contemplative role. Neuroscience has shown that it is possible to have persistent pain without damage to the tissues or with damage that justifies the perceived disproportion of pain.
28405|NCT03964376|Other|Nasal High Flow|Delivery of oxygen via OptiflowTM system (AirvoTM, Fisher & Paykel Inc.) with airflow of 20 to 50 Litre/minute
28406|NCT03964376|Other|Usual Care|Delivery of oxygen at 2-4 Litre/minute via nasal cannula or 6 Litre/minute via face mask
28407|NCT03964363|Behavioral|Unsupervised home-based physical prehabilitation|Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
28408|NCT03964350|Drug|Ethanol|"The 0.8 g/kg body weight dose of gelatin alcohol will be divided into an average of 10 servings of 0.08 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol.~The 0.4 g/kg body weight dose of gelatin alcohol will be divided into an average of 5 servings of 0.08 g/kg each. The 0.4 g/kg dose is equivalent to 2 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol."
28409|NCT03964350|Other|Placebo|The placebo comparator will be individual servings of back cheery sugar-free jello.
28410|NCT03964337|Drug|Cabozantinib|Cabozantinib 40 mg by mouth daily for 4 weeks.
28411|NCT03964337|Procedure|Radical Prostatectomy|Radical prostatectomy as part of routine medical care.
28412|NCT03964324|Diagnostic Test|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
28413|NCT03964311|Other|Emergency Room Evaluation Tool (ER2)|Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
28414|NCT03964285|Other|rumination induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. For example, they will be led, in the rumination condition, to reflect on the causes, meanings and consequences of the amount of tension they feel in their muscles.
28415|NCT03964285|Other|distraction induction|The induction method is based on specific instructions given to participants on how to focus on different elements of their experience. In the distraction condition they will, for example, imagine a ship crossing the Atlantic.
28416|NCT03964272|Device|Exablate Bilateral Subthalamotomy|Exablate bilateral treatment for Parkinson's Disease Motor Features
28417|NCT03964259|Drug|Intravenous fluids|Administration of post HDMTX intravenous fluids (IVF)
28418|NCT03964246|Behavioral|Compassion Meditation (CM) intervention|"Thee CBCT-Vet includes 10 90-minute sessions that will be led by certified CBCT therapist with significant experience in administering CBCT-Vet. Sessions 1 - 4 assist participants in basic mindfulness breathing practices; sessions 4 - 8 focus on personal analysis of factors underlying difficulties with compassion for self or others; the final two sessions (9 and 10) review content and assist with relapse prevention. Session by session topics are: (1) Introduction and learning breathing meditation, (2) Focused attention, (3) Creating space, (4) Mindful awareness, (5) Re-engaging with heroic spirit, (6) Seeing ourselves in others, (7) Appreciation and gratitude, (8) Empathy and engaged compassion, (9) Putting it all together, and (10) Putting it all together 2."
28419|NCT03964246|Other|Heathy Aging Psychoeducation|The investigators will develop and test a 10-week psychoeducational group focused on topics in healthy aging to examine its feasibility as a control condition for a subsequent VA Merit-supported randomized controlled trial. This will include multiple resources for community education regarding healthy aging, including a library of videotaped community-focused talks, such as increasing happiness, mental resilience and health, nutrition, and physical activity. These resources will be incorporated into 90-minute sessions wherein the key information from talks is shown to participants, with a follow-up discussion and review period led by the group facilitator. In the context of the present feasibility study, the investigators anticipate modifying and refining the content and format of the group in response to participant feedback.
28420|NCT03964233|Drug|BI 907828|Film-coated tablets
28421|NCT03964233|Drug|BI 754091|Solution for infusion
28422|NCT03964233|Drug|BI 754111|Solution for infusion
28423|NCT03964220|Drug|Tiotropium Respimat®|Tiotropium Respimat® 1.25 mcg (on top of baseline Inhaled Corticosteroid/Long-acting beta-agonist )
28424|NCT03964220|Drug|Inhaled Corticosteroid/Long-acting beta-agonist|baseline low dose to medium/high dose, baseline medium dose ICS/LABA to high dose ICS/LABA, additional prescription/refill of high-dose-ICS/LABA following the first prescription of baseline high dose ICS/LABA
28425|NCT03964207|Drug|Tiotropium Respimat® (T1)|inhalation solution
28426|NCT03964207|Drug|Tiotropium Handihaler® (T2)|Inhalation Powder
28427|NCT03964181|Other|Change in school start times|Elementary start times changed from 9:00 a.m. to 8:00 a.m.; middle school start times changed from 8:00 a.m. to 8:50 a.m.; high school start times changed from 7:10 a.m. to 8:20 a.m.
28428|NCT03964168|Drug|Biologic Agent|Patients who discontinued a bioloic agent
28429|NCT03964155|Biological|Sample|After an exposure duration of at least 12 hours, a sample of directly-aspirated, undiluted pulmonary edema fluid will be collected concurrently with AnaConDa-S® filter collection.
28430|NCT03964142|Other|Cardiac rehabilitation|Integrated cardiac rehabilitation program including supervised physical exercise training.
28463|NCT03963882|Drug|Two cycles of neoadjuvant chemotherapy|Two cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
28464|NCT03963882|Diagnostic Test|First imaging evaluation|First imaging evaluation consists of pelvic magnetic resonance imaging (MRI) and positron emission tomography (PET)
28431|NCT03964129|Procedure|Avance Nerve Graft with Autologous BMAC|The Avance Nerve Graft will be inserted in the area of nerve injury. Between 40 to 60 ml of Bone Marrow Aspirate from the anterior or posterior iliac crest of the pelvis will be harvested. Using SmartPrep centrifuge and 60 ml BMAC kit, 7 to 10 ml of final BMAC will be obtained. Of the 7 to 10 ml of final BMAC that is yielded, half (3.5 to 5 ml) of the final concentrate, will be injected on top of the Avance Nerve Graft following coaptation. The second half (3.5 to 5 ml) of the final concentrate will be inserted into a sterile tube containing culture media and shipped overnight to Cleveland Clinic Lerner Research Institute for cell processing and colony assay to confirm that the BMAC indeed contains autologous bone marrow stem cells.
28432|NCT03964116|Other|Questionnaires set all 3 months|"This longitudinal study based upon repeated and multicentric measurement will recruit AYA with cancer in care Units dedicated to them or not. Measures will be quantitative, and repeated every 3 months by questionnaires, as well as qualitative (social network questionnaire, psychological research interview) for teenagers declaring a negative event or a death event during treatments.~Those patients presenting a high depression score will be contacted by a research psychologist for semi-directed interview."
28433|NCT03964103|Dietary Supplement|gQ-lab daily|probiotics
28434|NCT03964103|Dietary Supplement|Placebo|powdered skim milk, lactose
28435|NCT03964090|Drug|TEDD-R|Temozolomide, etoposide, doxil, dexamthasone, and rituximab (TEDD-R) given every 21 days for cycles 1-4
28436|NCT03964090|Drug|TEDDI-R|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib and rituximab (TEDDI-R) given every 21 days for cycles 1-4
28437|NCT03964090|Drug|Ibrutinib|Ibrutinib given on days -14 to day -1 prior to cycle 1
28438|NCT03964090|Drug|Cytarabine|Cytarabine on days 1 and day 5 of cycles 2-6 (all arms)
28439|NCT03964090|Drug|Isavuconazole|Isavuconazole to begin at least 3 days (and up to 7 days) prior to ibrutinib and continue throughout chemotherapy
28440|NCT03964077|Diagnostic Test|Neurogenic Bladder Symptom Score Questionnaire|Neurogenic Bladder Symptom Score Questionnaire is a self-reported 24 item questionnaire.
28441|NCT03964064|Radiation|Stereotactic Radiotherapy|"GTV: Combining localization and fusion images to delineate the tumors seen PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 80-100 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 60-80 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).~Normal Tissue Limit: Reference to TG101 Report"
28442|NCT03964064|Radiation|3D-printing Template-assisted CT-guided I125 Seed Implantation|CT-guided radioactive 125I particle therapy with 3D printing template for pancreatic cancer Preoperative planning Design and fabrication of 3D-PNCT Particle implantation Postoperative dose assessment: CT scan was performed after operation, and the image was transmitted to BTPS for dose verification . The dosimetric parameters included tumor volume, D90, mPD, V100, V150 and V200.
28443|NCT03964051|Drug|Omalizumab Injection|Omalizumab 300 mg for subcutaneous injection
28444|NCT03964038|Drug|gilteritinib|oral
28445|NCT03964038|Drug|gilteritinib mini tablet|oral
28446|NCT03964025|Device|Wearing Cardioskin™ for 14 days|The current standard of care for diagnosing AF is through the use of a 24 hour Holter device. In this study, in addition to wearing the 3-lead Holter recorder for 24 hours, the subject will be wearing the Cardioskin™ for a period of 24 hours as well, after which the subject will continue wearing the Cardioskin™ alone for an additional period of 13 days.
28447|NCT03964012|Biological|NmCV-5|Polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysaccharide antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to C reactive material (CRM) protein. The diluent is Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
28448|NCT03964012|Biological|Menactra|Menactra is available as ready to use solution containing polysaccharide antigens A,C,Y&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine
28449|NCT03963999|Diagnostic Test|Ultrasound Elastography|Ultrasound shear wave elastography
28450|NCT03963999|Drug|Contrast Enhanced Ultrasound (CEUS)|Contrast-enhanced ultrasound (CEUS) uses an intravenous injection of microbubble contrast agent.
28451|NCT03963986|Device|STIMUL group|The STIMUL Group participants in the Adaptive Physical Activity Focus (APA) program receive access to an online digital Platform, as well as a starter kit consisting of a connected pedometer measuring several physical activity indicators including the number of steps, number of so-called active minutes, sleep time, and distance travelled; a tape measure and a starter guide. They then conduct a remote assessment and motivational interview by videoconference or telephone, followed by 15-20 minute support interviews (month 1, month 3, month 6). Between these interviews, during months 1, 2, and 3, participants exchange weekly written messages with an educator on their platform. A planner of their physical activity objectives is provided.
28452|NCT03963973|Drug|RDN-929 oral capsule|low, medium and high dose
28453|NCT03963973|Drug|Placebo oral capsule|matching placebo dose
28454|NCT03963960|Device|Hemodialysis with low dialysate flow|Hemodialysis with low dialysate flow
28455|NCT03963960|Device|Conventional triweekly high-flow hemodialysis|Conventional triweekly high-flow hemodialysis
28456|NCT03963947|Biological|Beltavac® Polymerized with house dust mites|Adminstration of Beltavac® Polymerized with house dust mites according to the routine clinical practice
28457|NCT03963934|Other|Program on a nurse-led telephone 6-month-follow-up for uncontrolled hypertensive women: a patient-tailored intervention|Implementation of personalized support: The accompaniment includes 7 telephone interviews for 6 months (understanding the antihypertensive treatment, identifying the brakes and the levers when taking medication, organizing the treatment taking, making the home blood pressure)
28458|NCT03963921|Drug|HepaStem|Heterologous human adult liver-derived progenitor cells
28459|NCT03963908|Behavioral|AtEase|AtEase is a tailored pain self-management mobile app that tailors participant's feedback based on readiness to engage in pain self-management and preference for self-management strategies.
28460|NCT03963908|Behavioral|Chronic Pain Education|CBT-based Education on Pain Self-Management for Veterans
28461|NCT03963895|Drug|AB002|AB002 (E-WE thrombin) specified dose on specified day administered as a single intravenous infusion
28462|NCT03963895|Drug|placebo|placebo specified dose on specified day administered as a single intravenous injection
28465|NCT03963882|Diagnostic Test|Second imaging evaluation|Second imaging evaluation consists of pelvic magnetic resonance imaging
28466|NCT03963882|Drug|The third cycles of neoadjuvant chemotherapy|The third cycles of neoadjuvant chemotherapy (paclitaxel 175 mg/m2 and cisplatin 70 mg/m2, on day 1, once for three weeks).
28467|NCT03963882|Procedure|RH|Radical hysterectomy
28468|NCT03963882|Radiation|Radiochemotherapy|Concurrent radiochemotherapy
28469|NCT03963882|Diagnostic Test|Pathologic evaluation|Pathologic evaluation for RH patients
28470|NCT03963869|Diagnostic Test|Rapid Diagnostic Test (RDT)|Participants will be asked questions related to thei perception of malaria, knowledge and attitude about malaria, prevention and control practices, and local/state health governance, and what additional strategies should be employed to prevent mosquito transmitted diseases.
28471|NCT03963856|Other|parbolic flight|weightlessness during parabolic flight
28472|NCT03963843|Behavioral|Guided ICBT|An 8-week internet- delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a health educator with experience delivering ICBT will provide support by email once a week. The health educator will spend approximately 15 minutes per week/per client.
28473|NCT03963843|Other|SCI rehabilitation mental health education|Participants will receive information provided to SCI patients in usual care at specialized SCI rehabilitation units (the Spinal Cord Injury Rehabilitation Evidence (SCIRE) Community handouts available at: https://scireproject.com/community/handouts/). The lessons will include information on spinal cord injury rehabilitation: 1)spinal cord injury basics, 2)mental health after SCI, 3)pain after SCI, 4)understanding rehabilitation 5)summary of lessons through an online platform over 8 weeks. A health educator will check in with participants once a week to answer any content related questions. The health educator will spend approximately 15 minutes per week/per client.
28474|NCT03963830|Behavioral|MOVE UP|Each of the 12-group-sessions will focus on incremental behavioral strategies for maintaining recommended healthy eating, activity, and weight loss behaviors. Participants will monitor body weight and weight loss behaviors. Body weight will be measured at each in-person session and participants will also be encouraged to measure their body weight on their own. Beginning in Session 3, participants are given a home physical activity goal of 10 minutes/day, 50 minutes/week. The goal is raised by 5 minutes/day, 25 minutes/week every other session, the final goal being 30 minutes/day, 150 minutes/week. All subjects will be recommended to engage in an energy restricted dietary intervention that evidence demonstrates has effectively reduced body weight by 5-7% within the initial 4 months of the intervention. This will include reducing energy intake to 1200 to 1800 kcal/d based on initial body weight (<200 pounds = 1200 kcal/d; 200 to 250 pounds = 1500 kcal/d; >250 pounds = 1800 kcal/d).
28475|NCT03963817|Diagnostic Test|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 10 normal subjects in order to optimize image acquisition and interpretation.
28476|NCT03963817|Diagnostic Test|adaptive optics AO-OCT/AF instrument|Using the new adaptive optics AO-OCT/AF instrument, the study team will image 40 adult subjects with age-related macular degeneration (AMD) who have non-neovascular AMD and soft drusen or subretinal drusenoid deposits in the macula.
28477|NCT03963804|Device|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
28478|NCT03963791|Other|Eggshell powder gel|Eggshell powder gel produced from chicken eggs.
28479|NCT03963791|Other|CPP-ACP crème|A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
28480|NCT03963778|Behavioral|Improving nutritional care|The interventions will be co-designed with the action research team
28481|NCT03963765|Other|DL-PDT isolated (Standard procedure)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®)
28482|NCT03963765|Other|DL-PDT + TED with microdermabrasion (aluminum oxide crystal)|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microdermabrasion - aluminum oxide crystal (Pan Eletronic®) as a techniques of transepidermal drug delivery (TED)
28483|NCT03963765|Other|DL-PDT + TED with microneedles|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and Microneedles - motorized pen with a tip of 17 grouped needles with 0,5mm (Dermapen Beauty®- Korea) as a techniques of transepidermal drug delivery (TED)
28484|NCT03963765|Other|DL-PDT + TED with CO2 laser|Daylight photodynamic therapy with photosensitizer (MAL - Metvix, Galderma ®) and AFXL CO2 laser: roller-type ferrule, composed of one row with seven fractionating pins (7x1), 60 W, 15 mJ/pixel, 125μm/pixel, 2 mm spacing between ablation zones, density < 1% (Pixel Alma Lasers ®) as a techniques of transepidermal drug delivery (TED)
28485|NCT03963752|Drug|Ziyinxiehuo granules Herbs|Arm：Experimental: Group A Drug：Ziyinxiehuo granules Herbs .1 pack of Ziyinxiehuo granules Herbs includes shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g. Usage: administered after dissolved, 2 times per day after a meal .
28486|NCT03963752|Drug|Megestrol Acetate Tablet|Arm：Experimental: Group A Drug :Megestrol Acetate Tablet .Usage:the dose is 6-8mg/d, and the everyday total amount is taken orally in three times after a meal.
28487|NCT03963752|Drug|Leuprorelin Acetate 3.75mg Injection|Arm: Active Comparator: Group B Drug:Leuprorelinb Acetate Usage： 80μg/kg every time by subcutaneous injection, every 4 weeks for once.
28488|NCT03963739|Other|Interview|Undergo interview
28489|NCT03963739|Other|Questionnaire Administration|Ancillary studies
28490|NCT03963726|Radiation|stereotactic radiotherapy|The liver metastases were treated with Cyberknife stereotactic radiotherapy.Using multimodal image fusion to outline the target area.According to the volume, location, organ function and other factors, the dosage of radiotherapy was determined. The range of BED value of radiotherapy was 90-120 when the distance between the tumor and gastrointestinal tract was more than 5 mm (alpha/beta=10) and 70-90 when the distance between the tumor and gastrointestinal tract was less than 5 mm (alpha/beta=10).
28491|NCT03963726|Other|microwave alabation|The colorectal cancer patients with liver metastases will receive microwave ablation.3D printing template was used to assist microwave ablation.For those whose lesions are directly smaller than 5.0cm, the ablation time is about 10 min and 15 min, and the ablation time is more than 15min in patients larger than 5.0cm.
28492|NCT03963713|Radiation|Stereotactic radiotherapy|Using multimodal image fusion to outline the target area.PTV = GTV + 0-10mm Target volume radiation dose: The range of BED value of radiotherapy was 60-72 when the distance between the tumor and gastrointestinal tract or spinal cord was more than 5 mm (alpha/beta=10) and 51.3-59.5 when the distance between the tumor and gastrointestinal tract or spinal cord was less than 5 mm (alpha/beta=10).
28493|NCT03963713|Radiation|Conventionally-fractionated image- guided Intensity modulated radiotherapy|Using multimodal image fusion to outline the target area.The dose of the target volume radiotherapy dose is 30 Gy/10f or 40Gy/20f.Previous treatment and follow-up data will be analyzed to evaluate the clinical efficacy comparison of stereotactic radiotherapy and conventionally-fractionated image-guided intensity-modulated radiotherapy for spinal metastatic tumors, local control rate and side effects, and to clarify the effectiveness and safety of different doses of radiotherapy.
28494|NCT03963687|Other|Standard Nursing Education Intervention|Genetics Education Program for Nurses (GEPN) which is available free online for more than 20 years
28495|NCT03963687|Other|New Nursing Education Intervention|Web-based Genomics/ Genetics Nursing Education is a free online course that will be designed by the research team.
28496|NCT03963674|Other|Diacutaneous fibrolysis|Diacutaneous fibrolysis over the gastrocnemious muscles
28497|NCT03963661|Behavioral|c-SIGHT (computorized spatial innatention grasping home-based therapy)|C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
28498|NCT03963648|Diagnostic Test|Fractioned Exhaled Nitrogen Oxide measurements|Measurements of Fractioned Exhaled Nitrogen Oxide obtained by blowing into a mouthpiece. The NIOX VERO machine will be used for these measures.
28499|NCT03963635|Diagnostic Test|MicroB-plex Lyme Immunoassay|Subject's blood and clinical data are collected to develop a diagnostic immunoassay
28500|NCT03963622|Other|Respiratory Mechanics|"Respiratory mechanics will be assessed at the bedside and will be used to individualize ventilator parameters. Recruitability will be assessed with a one breath decremental PEEP maneuver, and search for airway closure with a low-flow pressure volume curve. If the patient has airway closure, the minimal PEEP will be set at the airway opening pressure to avoid closure. If the patient is considered recruitable, the goal is to set PEEP at or above 15cmH20 to maximize alveolar recruitment, until the plateau transpulmonary pressure reaches the safety limit. Volume control ventilation at 6ml·kg-1 will be used.~Once spontaneous breathing has started, the swing in transpulmonary pressure will be limited."
28501|NCT03963622|Other|Standard Ventilation Strategy|Patients randomized to the control arm will receive standard care. The PEEP is kept relatively low for FiO2≤0.7 and is adjusted for oxygenation based on a PEEP-FiO2 table. Standard simple conventional mechanics, routinely available on contemporary ventilators (no esophageal manometry) are recorded, but not used per protocol. Volume targeted ventilation with initial VT 6 mL·kg-1 and Plateau pressure at 30 cmH2O or below, targeting PaO2 60-80 or SpO2 90-95%, adjusted as per the protocol. Pressure-support ventilation is at physician's discretion, but recommended when FiO2 <60%, and is titrated VT 6-8 mL·kg-1.
28502|NCT03963609|Radiation|multisclice CT|assessment of the remodeling index by multisclice CT in patients with chronic stable angina
28503|NCT03963596|Procedure|Intravitreal injection|Intravitreal injection to the regimen pro re nata.
28504|NCT03963583|Behavioral|HEROIC|"The HEROIC intervention will include individualized, nurse-led sessions focused on;~a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals."
28505|NCT03963570|Behavioral|Safe Step - digital exercise program|"After receiving the Safe Step application the participants view an instruction movie on how to use the application to create and progress their own individual exercise program. The exercises, presented in video format, are organized into 10 predetermined groups with a main focus to improve balance (3 groups), increase lower-limb strength (4 groups), and improve gait/step (3 groups). The participants choose an exercise suitable for their needs from each group to compose a program of ten exercises.~They can use the app to plan their exercises, set reminders, register their exercise, and view statistics of their progress. A virtual physiotherapist deliver motivational messages and feed-back. At the end of every month, of the 1 year intervention period, the participants will receive an email asking them to report any falls during the past month by answering a short digital survey. This message will provide a new video each month with general falls prevention information besides exercise."
28506|NCT03963570|Behavioral|Control group|Participants randomized to the control condition will only be given information. They will receive exactly the same email messages as the intervention group with falls prevention information and a request to report any falls. At the end of the 12 month intervention we will, in addition to the other questions, ask if they have started to do any exercises during the intervention period. After the 12 month follow-up assessment the control group will be offered the Safe Step application.
28507|NCT03963544|Drug|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations|oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
28508|NCT03963531|Other|chemotherapy, surgery, radiotherapy, interventional radiology.|
28509|NCT03963518|Drug|Immune checkpoint inhibitor|Immune checkpoint inhibitor
28510|NCT03963492|Other|Walking|Participants will undergo training in either the CONT or INT walking interventions 2x/week for 6 weeks for a total plan of 12 training sessions.
28511|NCT03963479|Combination Product|Magnesium and Vitamin B6|Magnesium and Vitamin B6 will be given to the enrolled patients for 3 months
28512|NCT03963466|Drug|tranexamic acid|Oral tranexamic acid group(menstrual period>2days) 250mg bid（exclude menstrual period ）
28603|NCT03962777|Other|oil pulling|patients used oil pulling for four days
28929|NCT03960047|Behavioral|Virtual Reality Training|This group gets trained to cross streets using virtual reality
28513|NCT03963466|Radiation|1064-nm Q-Switched fractional laser|Device: 1064-nm Q-Switched fractional laser is used for melisma with the MASI ≥24 left side of cheek is selected to be treated with 1064-nm Q-Switched fractional laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
28514|NCT03963466|Radiation|1064-nm Q-Switched laser|Device: 1064-nm Q-Switched laser is used for melisma with the MASI ≥24 right side of cheek is selected to be treated with 1064-nm Q-Switched laser therapy (8ms, 1.5±0.5J/cm2) once 4 weeks for a total of 5 times
28515|NCT03963453|Other|Physical Exercise|Physical exercise are prescribed to be performed three times per week for a year
28516|NCT03963440|Other|Exercise Adherence Rating Scale (EARS)|"Inclusion and first questionnaires period (10 questionnaires), after geting consent, during normal patient consultation schedule for functional restoration program of the lumbar spine (1 to 3 weeks hospital in day care).~Second questionnaire period at 48h (Only EARS questionnaire) Third questionnaires period (10 questionnaires) at the end of the restoration program hospital care.~Fourth and last questionnaires period (10 questionnaires) at 3 months during a normal patient follow-up consultation No additional appointments."
28517|NCT03963427|Procedure|Breast reconstruction|Irradiated women are randomized to reconstruction with a latissimus Dorsi flap and an implant or a deep inferior epigastria perforator flap. Non-irradiated women are randomized to reconstruction with a thoracodorsal flap with an implant or with an expander and later a permanent implant in two stages.
28518|NCT03963414|Combination Product|Durvalumab + Tremelimumab in combination with carboplatin and etoposide|1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
28519|NCT03963414|Combination Product|Durvalumab in combination with carboplatin and etoposide|1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
28520|NCT03963401|Drug|PF-06700841|Starting after the Week 16 visit, subjects receiving PF-06700841 10 mg once daily will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
28521|NCT03963401|Other|Placebo|Starting after the Week 16 visit, subjects receiving placebo will start to randomly receive either the 60 mg QD dose or 30 mg QD dose until Week 52, as predetermined at randomization. All subjects will receive blinded dosing throughout the 52 weeks study treatment period in order to maintain the study blind.
28522|NCT03963388|Other|Speech therapy|Online speech therapy, delivered by specialized speech therapists. Speech therapy will be complemented by a real-time visual feedback app (the Voice Trainer app).
28523|NCT03963375|Drug|Cladribine|All participants will receive cladribine 10 mg tablets at a cumulative dosage of 3.5 mg/kg divided into 2 treatment courses as per the United States Prescribing Information (USPI) (1.75 mg/kg per treatment course; Year 1 and Year 2 treatment). Patients will be randomized 1:2:2:1 to receive a total of 2 Lumbar Punctures at specific time points during the treatment cycle.
28524|NCT03963362|Drug|GLA5PR tablet 75 mg|GLARS-NF3 tablet
28525|NCT03963362|Drug|GLA5PR tablet 150 mg|GLARS-NF3 tablet
28526|NCT03963336|Drug|LMWH|Subcutaneous LMWH 1mg/kg/day for 2 weeks
28527|NCT03963336|Drug|acetazolamide|Carbonic anhydrase inhibitor 1-2g/day for 6 months
28528|NCT03963323|Dietary Supplement|Glucosamine Sulfate/Chondroitin Sulfate Tablet|Given PO
28529|NCT03963323|Other|Placebo|Given PO
28530|NCT03963284|Procedure|cardiac surgery|pediatric cardiac surgery with cardiopulmonary bypass
28531|NCT03963284|Device|NephroCheck test|Urine of the subjects undergoing cardiac surgery with CPB will be tested by NephroCheck test
28532|NCT03963271|Diagnostic Test|ECG-Imaging|A body surface potential mapping and a cardiac + low dose CT-scan.
28533|NCT03963258|Device|whole-body vibration training|The subjects were exposed to alternating vertical sinusoidal vibration using a Galileo tilting table system.The frequency of WBV ranged from 5 to 20 Hz, and the amplitude ranged from 1 to 6 mm.The subjects were kneeled on the ground, both shoulders flexed at 90 degrees, elbows slightly flexed, their trunk bent in this position and contacted on the platform board with their palms equidistant from the midpoint of the board
28534|NCT03963258|Other|conventional upper limb training|compensatory techniques for activities of daily living, UE strength, therapist-guided techniques for facilitating normal UE movement patterns,and range of motion and traditional positioning
28535|NCT03963245|Behavioral|Meaningful Activities and Recovery|"MA&R is a new rehabilitation program for people with psychiatric disabilities. MA&R aims to enable participation in everyday activities that are meaningful to the individual.~MA&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery."
28536|NCT03963245|Behavioral|Standard Care and Treatment|"For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support"
28537|NCT03963232|Drug|Galcanezumab|Administered SC
28538|NCT03963232|Drug|Placebo|Administered SC
28539|NCT03963219|Device|ABC4D|The complete integrated system consists of a smartphone that holds the advanced decision support algorithm. The system requires regular updates of cases derived from continuous glucose monitoring (CGM) data. Each new case includes information about the problem (e.g. capillary blood glucose, meal information and physical exercise), solution (recommended insulin dose) and outcome (post-prandial blood glucose).
28540|NCT03963219|Device|Standard Bolus Calculator|Standard bolus calculator
28604|NCT03962764|Behavioral|Responsible Fatherhood Program|24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
28605|NCT03962751|Behavioral|Simultaneous Post Feedback Intervention Delivery|Simultaneous PFI delivery after baseline survey
31939|NCT03935828|Drug|Oral versus topical antibioitics|Previously described in two arms
28541|NCT03963206|Drug|Cabozantinib group|The patient starts at 60 mg / day at a distance from meals In the event of intolerance to this dose of 60 mg; specific adapted measures will be taken according to the recommendations of the good practices of use of Cabozantinib within the framework of its MA. If the symptomatic treatments are not enough, each investigator can adapt the dose of Cabozantinib reducing it to 40 or even 20 mg / day Cabozantinib will be continued for as long as radiological and / or clinical benefit is observed for the patient (no progression of the disease) or until the occurrence of unacceptable toxicity.
28542|NCT03963206|Other|ECG|ECG between day -27 / day 0 (if significant, it will be done every visit)
28543|NCT03963193|Drug|Etoposide|Etoposide 100mg/m^2 ivggt on days 1, 2, 3, Cisplatin 25mg/m^2 ivggt on days 1, 2, 3, repeated every 21 days.
28544|NCT03963193|Drug|Irinotecan|Irinotecan 65 mg/m^2 ivggt on days 1, 8, Cisplatin 30 mg/m^2 ivggt on days 1, 8, repeated every 21 days.
28545|NCT03963180|Other|coffee|All patients were asked to drink the entire 150-mL amounts within 20 minutes under the supervision of a nurse or doctor. Patients were free to drink any amount of water but no more coffee, black tea, or other forms of caffeine, such as soda. Coffee and hot water were prepared with a conventional coffee machine (Nescafe Alegria; 100 g caffeine; Nestlé. Gatwick, United Kingdom).
28546|NCT03963167|Drug|BDP/FF/G fixed combination|Fixed combination of Inhaled Corticosteroid (ICS) / Long-acting β2-agonist (LABA) / long-acting muscarinic antagonist (LAMA) that contains Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (G).
28547|NCT03963154|Biological|Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)|Implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE))
28548|NCT03963128|Dietary Supplement|Supplementation Vitamin D3|Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)
28549|NCT03963128|Dietary Supplement|Placebo|Placebo administred every two months
28550|NCT03963115|Drug|Epinephrine or normal saline|epinephreine or normal saline coated syringe before drawing allergen for injection.
28551|NCT03963102|Drug|Ameluz|Leaving on the gel for 4 hours rather than the standard 3 hours.
28552|NCT03963089|Procedure|Tidal volume_6mL/kg|Set tidal volume to 6mL/kg for 1 minute
28553|NCT03963089|Procedure|Tidal volume_10mL/kg|Set tidal volume to 10mL/kg for 1 minute
28554|NCT03963089|Procedure|Tidal volume_14mL/kg|Set tidal volume to 10mL/kg for 1 minute
28555|NCT03963089|Procedure|Fluid loading|Administer 10mL/kg of crystalloid for 5 minutes
28556|NCT03963076|Other|nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)|One spray of nasal hypertonic spray morning and evening every day during 30 days
28557|NCT03963063|Procedure|Goal-directed fluid therapy|"Patients in the group will follow our mini-fluid challenge test goal-directed therapy protocol, maintaining:~individualized optimised stroke volume by mini-fluid challenge first~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg~keep cardiac index ≧ 2.5 L/min/cm2"
28558|NCT03963063|Procedure|Non goal-directed fluid therapy|"Patients in the group will receive standard perioperative care at the discretion of care-giving anesthesiologist, maintaining:~keep mean arterial pressure ≧65 mmHg~keep systolic blood pressure ≦140 mmHg"
28559|NCT03963050|Other|Exercise Training|The ET program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.
28560|NCT03963050|Other|Exercise Training + Cognitive Training|"ET: The intervention program will consist of endurance exercises at 70% of maximal Heart Rate and resistance exercises at 85% of 1 repetition maximum.~CT: The intervention program will be configured as a cognitive rehabilitation and mainly memory rehabilitation: the participants will be trained in practicing restorative and compensatory mnemonic techniques, such as visual imagery, face-name association, calendar, notes and prompts."
28561|NCT03963050|Other|Control|NO changes in lifestyle
28562|NCT03963037|Other|Blood draw|Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.
28563|NCT03963024|Drug|"Conditioning treatment Treosulfan-TMI"|Treosulfan i.v.: 14 g/m²/d (day -6 to -4) Fludarabine i.v.: 30 mg/m²/d (day -6 to -2) Antithymocyte globulin (ATG)-Fresenius i.v.: 5/0 mg/kg (day -4 to -2) Mabthera i.v.: 200/0* mg/m2 (day -1) TMI: (10 Gy) 2 Gy bis in die (BID) (day -2 to -1) or TMI: (12 Gy) 2 Gy BID (day -3 to -1) or TMI: (14 Gy) 2 Gy BID (day -3 to -1)
28564|NCT03963024|Procedure|SCT|Stem Cell Transplant
28565|NCT03963024|Drug|GvHD prophylaxis|Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7) Mycofenolate mofetile: 10 mg/kg tid, (Maximum dose 720 mg/tid) (starting from day 0)
28566|NCT03963011|Diagnostic Test|Bowel Ultrasound|Ultrasound imaging of the bowel
28567|NCT03962998|Drug|Lactulose/Rhamnose solution|Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine
28568|NCT03962998|Drug|MB-102|MB-102 solution administered orally followed by measurement of excreted MB-102 in urine
28569|NCT03962985|Other|Guided tour at the Montreal Museum of Fine Arts|"The duration of the participation -3 months~The duration of the guided tour-45 minutes, each week~All participants will be asked to fill out some specific online questionnaires during their participations in the study"
28570|NCT03962972|Other|Frailty evaluation|It will be used a questionnaire that is called:The Centre of Excellence Self-Administered questionnaire (CESAM). The score of this questionnaire and its stratification of frailty in four levels with incident adverse health events in older community dwellers will be compare with the three validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index and Rockwood frailty index.
28571|NCT03962959|Device|TMS -low-dose iTBS|"TMS in a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect to the hippocampus and determine which stimulation protocol is more beneficial to each participant. The dose corresponds to number of stimuli per TBS session: low-dose corresponds with 600 stimuli. The iTBS paradigm is also involved the application of 3 pulses of 50 Hz applied at 5 Hz."
28606|NCT03962751|Behavioral|Sequential Post Feedback Intervention Delivery|Sequential PFI delivery over 3 weeks after baseline survey
28607|NCT03962751|Behavioral|Text Message Boosters|Text message boosters on PFI content during week of high risk drinking event
28608|NCT03962738|Drug|Lasmiditan|Administered orally
28572|NCT03962959|Device|TMS -medium-dose iTBS|"TMS in a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect to the hippocampus and determine which stimulation protocol is more beneficial to each participant. The dose corresponds to number of stimuli per TBS session: medium-dose corresponds with 1200 stimuli. The iTBS paradigm is also involved the application of 3 pulses of 50 Hz applied at 5 Hz."
28573|NCT03962959|Device|TMS -high-dose iTBS|"TMS in a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect to the hippocampus and determine which stimulation protocol is more beneficial to each participant. The dose corresponds to number of stimuli per TBS session: high-dose corresponds with 1800 stimuli. The iTBS paradigm is also involved the application of 3 pulses of 50 Hz applied at 5 Hz."
28574|NCT03962959|Device|TMS -low-dose cTBS|"TMS in a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect to the hippocampus and determine which stimulation protocol is more beneficial to each participant. The dose corresponds to number of stimuli per TBS session: low-dose corresponds with 600 stimuli. The cTBS paradigm consists of 3 pulses of 50 Hz stimulation repeated at 200-ms interval (i.e., 5 Hz) for 40 seconds (600 stimuli in total)."
28575|NCT03962959|Device|TMS -medium-dose cTBS|"TMS in a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect to the hippocampus and determine which stimulation protocol is more beneficial to each participant. The dose corresponds to number of stimuli per TBS session: medium-dose corresponds with 1200 stimuli. The cTBS paradigm consists of 3 pulses of 50 Hz stimulation repeated at 200-ms interval (i.e., 5 Hz) for 40 seconds (600 stimuli in total)."
28576|NCT03962959|Device|TMS -high-dose cTBS|"TMS in a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect to the hippocampus and determine which stimulation protocol is more beneficial to each participant. The dose corresponds to number of stimuli per TBS session: high-dose corresponds with 1800 stimuli. The cTBS paradigm consists of 3 pulses of 50 Hz stimulation repeated at 200-ms interval (i.e., 5 Hz) for 40 seconds (600 stimuli in total)."
28577|NCT03962946|Other|Questionnaires to assess Patient reported Outcomes|Adolfsson-Score questionnaire quantifies the patient`s utility of the hand. Suhm Score questionnaire quantifies the independency of a patient in his daily life.
28578|NCT03962946|Other|wrist function test|wrist function assessed by the range of motion (ROM) for both the affected and the unaffected side.
28579|NCT03962933|Diagnostic Test|Urine test|Urine test will be taken every three months after first resection of bladder tumor
28580|NCT03962920|Drug|Tigecycline|Local instillation of drug directly to the tumour tissue
28581|NCT03962907|Drug|Chlorhexidine, Lifo-Scrub sol 4%®, 500ml, B. Braun|5 - day decolonization procedure prior elective surgery. In carriers with Chlorhexidine daily showers and Mupirocin twice a day nasal ointment. In non-carriers Chlorhexidine showers will be used.
28582|NCT03962907|Drug|BACTROBAN® Nasal ong|Mupirocin, BACTROBAN® Nasal ong, 3g, GSK
28583|NCT03962894|Drug|Prednisolone|During a sequenced rollout protocol change for Lee County EMS, certain ambulance stations who are randomized to early adoption of an upcoming protocol change will administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival. Ambulance randomized to later protocol adoption will continue usual care, until the end of the study when all ambulance stations adopt the new protocol with early administration of prednisolone
28584|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
28585|NCT03962881|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 20 µg per dose
28586|NCT03962881|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2,and 6|four-dose, 60 µg per dose
28587|NCT03962868|Procedure|Experimental procedure : ESD|ESD is a new endoscopic resection procedure that allows en-bloc resection for large superficial colorectal neoplasms. It used dedicated devices and consists in a deep submucosal dissection under the lesion after surelevation thanks to submucosal fluid injection and mucosal incision all around the lesion. The en bloc resection allows a perfect pathological analysis and a very low risk of recurrence (<1.5%)
28588|NCT03962868|Procedure|Comparison procedure: WF-piece meal EMR|WF-piece meal EMR is an older endoscopic resection technique. After surelevation of the lesion thanks to fluid submucosal injection, the precancerous lesion is resected in several pieces using a polypectomy snare. At the end of the procedure when macroscopically visible adenoma has been totally resected a snare tip coagulation of the margin of the scar is performed to destroy potential non visible residual adenoma. This procedure is quicker, safer than ESD but result in more recurrent disease (from 10 to 30% for lesions larger than 25 mm).
28589|NCT03962855|Drug|Ifetroban Sodium|Ifetroban sodium 250 mg capsule once daily for 4 weeks
28590|NCT03962855|Other|Placebo|Placebo arm to match Ifetroban Sodium once daily for 4 weeks.
28591|NCT03962842|Other|Pilates method|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
28592|NCT03962829|Drug|mCPP|Healthy participants administrate one capsule of mCPP (30mg)
28593|NCT03962829|Drug|Placebo oral tablet|Healthy participants administrate one capsule of placebo (containing lactose)
28594|NCT03962816|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
28595|NCT03962816|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
28596|NCT03962816|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
28597|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, and 6|three-dose, 20 µg per dose
28598|NCT03962803|Biological|20 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 20 µg per dose
28599|NCT03962803|Biological|60 µg recombinant hepatitis B vaccine at months 0, 1, 2, and 6|four-dose, 60 µg per dose
28600|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with a new manufacturing technology
28601|NCT03962790|Device|1-DAY ACUVUE® MOIST|etafilcon A contact lenses made with the current manufacturing technology
28602|NCT03962777|Other|chlorhexidine|patients used chx moutrinses for four days
28610|NCT03962725|Drug|Neuromuscular Blocking Agents|Use of non depolarizing neuromuscular blocking agents for maintenance of general anesthesia.
28611|NCT03962725|Drug|Anesthetic Adjuncts|Use of deeper plane of inhaled anesthetics or adjuncts (opioids, propofol, dexmedetomidine or ketamine for maintenance of general anesthesia.
28612|NCT03962712|Other|Increase Minimum Wage to $15-an-hour|Increase in minimum wage to $15-an-hour
28613|NCT03962712|Other|No Increase in Minimum Wage|No increase in minimum wage
28614|NCT03962686|Drug|MetFORMIN 1000 Mg Oral Tablet|Patients in the third study cohort will receive for 4 months a 1000 mg metformin oral therapy before to practice surgical intervention for carotid artery obstruction.
28615|NCT03962673|Radiation|NB-UVB light exposure|Participants are exposed to three low dose Narrow Band UVB light.
28616|NCT03962660|Other|HaRTS-TRENDS|"HaRTS-TRENDS comprises 4, individual sessions delivered in the context of the interventionist's pragmatic harm-reduction mindset paired with a compassionate, advocacy-oriented heart-set or style. It comprises the delivery of 4 manualized components, including a) participant-led tracking of preferred smoking outcomes, b) elicitation of participants' harm-reduction goals and their progress toward achieving them, c) discussion of the relative risks of various nicotine delivery systems, and d) instruction in using ENDS. Additionally, HaRTS-TRENDS entails provision of commercially available ENDS."
28617|NCT03962660|Other|Standard Care (SC)|The 4-session, individual standard care control condition entails the well-documented and evidence-based 5 As intervention (i.e., Ask about nicotine use, Assess use, Advise to quit smoking, Assist with exploring current smoking/planning smoking cessation, Arrange follow-up). Part of arranging follow-up is the recommendation to call the smoking quit line, which can supply additional counseling and nicotine replacement therapy.
28618|NCT03962647|Dietary Supplement|2-Week Ketogenic Diet|2-Week Ketogenic Diet in Combination with Letrozole
28619|NCT03962647|Drug|Letrozole|2.5 mg taken once daily by mouth
28620|NCT03962634|Drug|Kovanaze Nasal Spray|Intra-nasal local anesthetic
28621|NCT03962634|Drug|Articaine Injection|Local anesthetic
28622|NCT03962621|Radiation|Fotona 4D 1064 nm laser|The 1064 nm laser can penetrate deep into the skin to explode pigment particles, destroy blood vessels and heat the dermal collagen by targeting melanin and haemoglobin.(1) Frac3®: 30-35 J/cm2, 1.6 ms pulse width, 4mm spot size, unilaterally accumulated 2000 shots; and (2) PIANO®: 160 J/cm2, 5s pulse width, spot size 9mm, unilaterally accumulated 20000 shots, to increase and maintain facial skin temperature to 39-40oC.
28623|NCT03962621|Radiation|Fotona 4D 2940 nm laser|Er:YAG 2940nm have been considered as a good treatment of facial aging, especially in wrinkles.(1) Smooth®: 9-10 J/cm2, 7mm spot size, which is sequentially delivered to upper and lower labial mucosa and buccal mucosa to unilaterally accumulate 5000 shots; (2) SupErficial™: 0.5-1.0 J/cm2, 7mm spot size, a single pass
28624|NCT03962608|Device|Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
28625|NCT03962608|Device|Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 48 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 54 weeks, including the screening (up to 45 days), treatment (48 weeks) and 7-day follow up period.
28626|NCT03962582|Device|Matrix back|The Matrix back will replace the individual's back and the measures will be taken.
28627|NCT03962556|Other|bimanual palpation|bimanual palpation....i..
28628|NCT03962543|Drug|PD-0325901 oral capsule|PD-0325901 capsule
28629|NCT03962517|Device|with Gait Enhancing and Motivating System-Hip (GEMS-H)|"The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.~Assessments consist of gait function, cardiopulmonary metabolic energy cost, physical performance, balance, physical level, pain, fall efficacy, depression, quality of life and activities of daily living."
28630|NCT03962517|Other|without Gait Enhancing and Motivating System-Hip (GEMS-H)|The intensity of training: between 12 and 16 in borg's rating of perceived exertion scale.
28631|NCT03962504|Behavioral|trauma-focused treatment|cognitive behavioral treatment for posttraumatic stress disorder that consists of exposure to the trauma memory.
28632|NCT03962491|Behavioral|Daily Self-Monitoring Surveys + Contingency Management|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app, with the opportunity for monetary rewards for completing daily surveys.
28633|NCT03962491|Behavioral|Daily Self-Monitoring Surveys|Asked to complete a brief (5-minute) survey with questions related to pain experience and related measures every day for 28 days using the DynamiCare smartphone app.
28634|NCT03962478|Device|biliary stent and high-intensity focused ultrasound ablation system|Self-expandable biliary nitinol alloys stent and YDME FEP-BY02 high-intensity focused ultrasound equipment
28635|NCT03962478|Device|biliary stent|Self-expandable biliary nitinol alloys stent
28636|NCT03962465|Drug|Inotuzumab ozogamicin|By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans
28637|NCT03962465|Drug|Prednisone Pill|Taken daily days 1-28 by mouth
28638|NCT03962465|Drug|Daunorubicin|By IV, given on days 1, 8, 15, and 22
28639|NCT03962465|Drug|Vincristine|By IV, given on days 1, 8, 15, and 22
28640|NCT03962465|Drug|Cytarabine|Intrathecal, administered on day 1 only
28641|NCT03962465|Drug|Methotrexate|Intrathecal, administered on days 8 and 29
28642|NCT03962465|Drug|Pegaspargase|By IV, given on day 4
28643|NCT03962452|Genetic|Next Generation Sequencing (NGS)|Determining the nucleic acid sequence
28644|NCT03962439|Behavioral|High-Demand Photography|The high-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured high-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
28672|NCT03962231|Other|Rotator Cuff Loading Exercise Program|Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
54361|NCT03759067|Drug|Clopidogrel 300 mg|clopidogrel 300mg reloading
28645|NCT03962439|Behavioral|Moderate-Demand Photography|The moderate-demand photography group will receive 2.5 hours of instruction, twice a week, in a structured moderate-demand digital photography course plus 10 hours per week working on a special project at the research site without any formal instruction.
28646|NCT03962439|Behavioral|At-Home Engagement|The placebo control group will engage, alone at home, in tasks that are relatively low in intellectual engagement such as listening to music and radio or completing work-books that rely primarily on activation of knowledge.
28647|NCT03962426|Device|SocialVille Social Cognitive Training|"SocialVille exercises in this study include 4 exercises:~Recognition: a speeded face matching task~Face to Face: a speeded facial emotion matching task~Gaze Match: a speeded gaze matching task~Face Poke: a continuous performance task with facial expressions"
28648|NCT03962413|Procedure|Endoscopic Approaches To Maxillary Sinus|"The first group (group A):~The middle meatal antrostomy approach.~The second group (group B):~The endoscopic prelacrimal recess approach~The third group (group c):~The canine fossa approach."
28649|NCT03962400|Procedure|Reinforcement Learning|New computer based procedure for determining dose using a decision support tool
28650|NCT03962400|Procedure|Heath Care Provider|Warfarin dose will be determined by a qualified health care provider
28651|NCT03962387|Other|Not applicable(observational study)|Not applicable(observational study)
28652|NCT03962374|Device|Frova|Frova will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
28653|NCT03962374|Device|Stylet|Stylet will be used to facilitate the endotracheal intubation. The success rate of first attempt of intubation will be assessed.
28654|NCT03962361|Other|Concentration of circulating microparticles.|The microparticles contained in the blood sample will be isolated by ultracentrifugation and quantified by flow cytometry. The microparticles concentration will be determined by the number of microparticles per uL of plasma, based on the volume of the sample, the flow rate of the cytometer and the number of fluorescent events.
28655|NCT03962348|Behavioral|Targeted Educational Campaign|"Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the CHS staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times: pre-exposure, after 6 months, and after 12 months from the beginning of the TEC."
28656|NCT03962348|Behavioral|Specialized Early Engagement Team|The Specialized Early Engagement Team (SEET - a Social Worker and Peer Specialist) will link detainees with first-episode psychosis (FEP), using tenets of person-centered treatment and shared decision-making, and the Critical Time Intervention model, to community-based Coordinated Specialty Care (CSC).
28657|NCT03962335|Behavioral|Vegetarian diet|7-days dietary profile with a Vegetarian diet (VD), containing inulin and resistant starch-rich foods and including no meat and fish, but containing eggs and dairy, for 3 months
28658|NCT03962335|Behavioral|Mediterranean diet with butyrate|7-days dietary profile with Mediterranean diet with oral supplementation with butyrate (MD+Bt), 2 g/day, for 3 months
28659|NCT03962335|Behavioral|Mediterranean diet|7-days dietary profile with Mediterranean diet (MD), including 2 portions per week of fish and 3 portions per week of fresh and processed meat (2 of which fresh or processed red meat), for 3 months
28660|NCT03962322|Other|Weaning TDI|"Patients will be subjected to a spontaneous breathing test (Cpap 5), that consists in applying a positive end-expiratory pressure of 5 cm H2O for 20 minutes.~A tissue doppler evaluation will then be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration and calculating the speed of muscles displacement and other derived index of muscle function in the modality of ventilation which precedes the trial, during the SBT and after extubation."
28661|NCT03962309|Other|Health self-assessment questionnaire|The health self-assessment questionnaire includes questions covering anthropometric, sociodemographics, personal and family health history, life style habits and aspects of the behavioral domain. The questionnaire will be administered as paper format or web-based electronic format according to participants' preferences.
28662|NCT03962296|Drug|Vitis vinifera extract|Three daily oral doses of 50mg tablets of Vitis vinifera extract(Entelon®, Hanlim Pharm, Seoul, South Korea) were administered to patients in this group
28663|NCT03962296|Drug|Calcium Dobesilate|Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group
28664|NCT03962296|Drug|Placebo|Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
28665|NCT03962283|Drug|Rifaximin|Rifaximin 200mcg four times daily
28666|NCT03962283|Drug|Placebo oral tablet|Placebo Rifaximin four times daily
28667|NCT03962270|Device|shock wave device|The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
28668|NCT03962257|Other|EngagedMD online learning platform|The EngagedMD online learning platform is a compilation of learning modules and questions designed to give patients at-home access to visual and audio aids in infertility treatment. It also gives patients the ability to read and sign consents from home.
28669|NCT03962244|Device|EsoSponge|Endoscopically placed an EsoSponge for Negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
28670|NCT03962244|Device|Self-Expanding Metal Stent|Endoscopically placed self-expanding-metal-stent (SEMS) for negative pressure wound therapy in the area of the esophagogastric anastomotic leaks
28671|NCT03962231|Other|Rotator Cuff Unloading Exercise Program|Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.
28702|NCT03961919|Drug|Treosulfan|Treosulfan i.v. 10 g/m²/d day -6 to -4
28673|NCT03962218|Procedure|aquatic physiotherapy|specific aquatic physiotherapy 3 times a week, for 6 weeks, including feet balance exercises (Rating of Perceived Effort (RPE)), slow walking in all directions, walking with obstacles, Ai Chi, exercises of muscular strength. Each session duration is of 40 minutes.
28674|NCT03962205|Behavioral|cognitive-behavioral life style intervention|Cognitive Behavioral life-style modification: The intervention will be composed of 12 weekly sessions. Each session will last about two hours and will be administered in a group setting (maximum 20 participants). During the first two sessions, a clinician will introduce the program to the participants and motivate them to make life-style changes.In the next eight sessions a dietician will provide participants with basics of nutrition and will coach them to use a structured diary to monitor their eating behavior and physical activity. Next, a physician will introduce to the patients various weight loss surgeries in terms of the adverse events, indications and effects of each option.The last session will be held by a psychologist and will focus on providing participants with useful strategies to promote healthy eating habits and physical activity, including problem solving and goal setting.
28675|NCT03962205|Behavioral|wellbeing intervention|This program will consist of 4 weekly group-based sessions and each meeting will last about two hours. During the sessions, participants will be coached how to self-monitor their well-being episodes in everyday life, especially those associated with life-style change, by means of a structured diary. Patients will be then ecounraged to discuss their well-being experiences during group sessions, focusing on dysfunctional thoughts/beliefs interrupting them, fostering the identification of more functional thoughts. The psychologist will also teach them how to promote well-being situations through behavioral exercises and will introduce to the participants relevant psychological well-being dimensions (based on Carol Ryff's multidimensional model) associated with patients' experiences emerged during the treatment.
28676|NCT03962205|Other|treatment as usual|The treatment as usual will involve any recommendation given to the participants by their physicians, including diet, physical activity and medication.
28677|NCT03962192|Other|Attitudinal measures|A collection of 3 distinct attitudinal instruments comprise this survey.
28678|NCT03962179|Device|VACStent|Evaluation of the suitability of the medical device for sealing leaks in the gastrointestinal tract
28679|NCT03962153|Diagnostic Test|Obstetric Ultrasonography|Obstetric Ultrasonography
28680|NCT03962127|Other|no intervention|no intervention
28681|NCT03962114|Dietary Supplement|Vitamin B3|capsules with niagen
28682|NCT03962101|Drug|OPC-61815 injection 8 mg|once daily for a maximum of 5 days
28683|NCT03962101|Drug|OPC-61815 injection 16 mg|once daily for a maximum of 5 days
28684|NCT03962088|Diagnostic Test|miRNA|"15 ml of whole blood samples are collected in Vacutainer tubes with spray-coated K2EDTA and stored at room temperature. To minimize the hemolysis and nucleic acids degradation, plasma separation undergoes within 2 h.~Within 1 h, tubes are subjected to a first centrifugation step at 2200 x g and room temperature for 15 min. Plasma supernatants are transferred to 15 mL tubes, carefully avoiding contact with the lymphocytic ring, and tubes are centrifuged a second time at 3000 x g and RT for 10 min to remove cellular debris.~Plasma samples are then collected into 1.5 mL cryovials and all the aliquots are stored at −80 °C."
28685|NCT03962075|Procedure|laparoscopic paravaginal repair|Using a 10mm laparoscope, with video camera, was introduced through the umbilical trocar. Another 5 mm in suprapubic area and two 10 mm trocars in right and left lateral abdominal sides were introduced. The larger trocar was needed to accommodate the passage of needles into the abdomen. Spacing of trocars sufficiently from each other was needed to facilitate laparoscopic suturing. Transperitoneal approach to retropubic space was used. Two to four polypropylene sutures were applied on each side. Sutures were tied with intracorporeal technique
28686|NCT03962062|Drug|Moxidectin|2mg tablets
28687|NCT03962049|Drug|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
28688|NCT03962036|Device|Bispectral index monitor|BIS monitor is a novel measure of the level of consciousness by algorithmic analysis of a patient's electroencephalogram during general anesthesia.
28689|NCT03962023|Other|Echocardiography and MRI|Analysis of echocardiography and MRI parameters
28690|NCT03962010|Drug|GX-G6|long acting anti-diabetic drug
28691|NCT03962010|Drug|Control|Control
28692|NCT03961997|Drug|Lorlatinib 50 mg|Participants will receive a single dose of lorlatinib 50 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 50 mg on Day 15 of Period 2.
28693|NCT03961997|Drug|Lorlatinib 75 mg|Participants will receive a single dose of lorlatinib 75 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 75 mg on Day 15 of Period 2.
28694|NCT03961997|Drug|Lorlatinib 100 mg|Participants will receive a single dose of lorlatinib 100 mg in Period 1. Participants will receive modafinil 400 mg daily for 19 days, and a single dose of lorlatinib 100 mg on Day 15 of Period 2.
28695|NCT03961984|Procedure|Biodesign® anal fistula plug|Patient in general anesthesia and lithotomy position. Mucosa excision of the internal fistula opening is performed. The plug was prepared in 0.9% sodium chloride, and secured to the endoluminal brush by a suture with a 2-0 vicryl tie. The narrow end of the of the plug was then pulled through the internal opening into the fistula tract. The plug was pulled until it covered the whole length of the fistula and blocked the internal opening, the excess plug material coming out through the external opening. The plug was fixed at the internal opening by reabsorbable 3-0 sutures. Special attention was paid to ensuring that the plug was covered by mucosa when closing the internal opening. The excess plug material was trimmed by the external opening that was left open for drainage.
28696|NCT03961971|Drug|MBG453|Patients receive MBG453 and spartalizumab IV over 30 minutes on Day 1. Patients then undergo stereotactic radiosurgery on Day 8. Courses with MBG453 and spartalizumab repeat every 28 days in the absence of disease progression or unacceptable toxicity.
28697|NCT03961958|Drug|Propofol reduction|Reduction of propofol target concentration
28698|NCT03961945|Device|Sponge Capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
28699|NCT03961932|Drug|Linzagolix|A single dose of 200 mg linzagolix (2 tablets of 100 mg) will be administered orally under fasting conditions
28700|NCT03961919|Drug|Fludarabine|Fludarabine i.v. 30 mg/m²/d day -6 to -2
28701|NCT03961919|Drug|ARA-C|Cytarabine i.v. 2 g/m²/d day -6 to -2
28703|NCT03961919|Procedure|Peripheral Blood Stem Cell Transplant|"Autologous stem-cell transplantation i.v.: day 0 (source: peripheral blood)~Pegylated-Filgrastim s.c. 6 mg day +3"
28704|NCT03961906|Behavioral|physiotherapy|Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
28705|NCT03961893|Device|G-EYE first and standard colonoscope|Patients undergo two successive colonoscopies, first balloon-assisted colonoscopy (G-EYE device) and then standard colonoscopy
28706|NCT03961893|Device|standard colonoscope first and G-EYE|Patients undergo two successive colonoscopies, first standard colonoscopy and then balloon-assisted colonoscopy (G-EYE device)
28707|NCT03961867|Drug|Docetaxel|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles."
28708|NCT03961867|Drug|Oxaliplatin|"S-1 (BSA <1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; >1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 100mg/m2/3w from the second to the seventh cycles."
28709|NCT03961854|Drug|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
28710|NCT03961854|Drug|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
28711|NCT03961841|Radiation|chemoradiation with weekly 5Fu and oxaliplatin|5Fu 225 mg/m2 IV daily continuous infusion；oxaliplatin 40 mg/m2/week
28712|NCT03961841|Drug|Perioperative mFLOT|Perioperative docetaxel 50mg/m2；oxaliplatin 85 mg/m2; 5Fu 2.4g/m2 civ 48 hours; repeated every 2 weeks; total of 8 cycles
28713|NCT03961841|Drug|Perioperative FOLFOX|Perioperative oxaliplatin 85 mg/m2; 5Fu 2.8g/m2 civ 48 hours; repeated every 2 weeks; total of 12 cycles
28714|NCT03961828|Drug|Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]|The fifty (50) thalassemic children infected with HCV received the new direct-acting antiviral therapy in the form of Ledipasvir (90 mg)/Sofosbuvir (400 mg); (Harvoni) as a single oral tablet /day for 12 weeks Follow up of these patients was performed for 24 weeks. Re-evaluation of these children after 24 weeks from initiation of Ledipasvir/Sofosbuvir treatment was performed by repeating clinical assessment, Fibroscan of liver , laboratory investigations including quantitative HCV RNA by PCR and serum hyaluronic acid measurement.
28715|NCT03961815|Drug|Brazikumab|Non-responders (or partial responders) to treatment from the lead-in studies may receive an induction dose regimen of intravenous Brazikumab on Days 1, 29, and 57 followed by subcutaneous Brazikumab every 4 weeks through Week 52
28716|NCT03961815|Drug|Brazikumab|Lead-in study responders to treatment will receive subcutaneous Brazikumab every 4 weeks through Week 52 starting at Day 1
28717|NCT03961802|Other|sessions of shoulder rehabilitation|3 sessions of shoulder rehabilitation per week for 3 months (36 sessions)
28718|NCT03961789|Other|patients undergoing opioid replacement therapy|patients undergoing opioid replacement therapy
28719|NCT03961776|Device|MRI-guided radiotherapy by on-board DWI sequences|The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
28720|NCT03961763|Dietary Supplement|EPA+DHA|4 g/day EPA+DHA in tablets of 1g, 4 tablets daily, over 8 weeks (56 days)
28721|NCT03961763|Other|Placebo|4 g/day olive oil placebo in tablets of 1g, 4 tablets daily, over 8 weeks (56 days).
28722|NCT03961750|Other|OTAGO|12 Week exercise class programme
28723|NCT03961737|Procedure|prostate biopsies|"Before radiotherapy treatment, prostate biopsies will be performed in each patient. From these biopsies, explants will be performed. Half of these explants will be irradiated ex vivo and the other half will not receive any prior treatment.~Then the patient will receive radiotherapy. It will be reviewed 2 years after the end of radiotherapy. New prostate biopsies will be performed to evaluate the tumor response to radiotherapy and to characterize the immunohistochemical and transcriptomic profiles of non-responder patients."
28724|NCT03961724|Device|magnetic resonance image (MRI)|serum metabolomics
28725|NCT03961711|Procedure|Telemedicine|Patients will undergo a Telemedicine encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
28726|NCT03961711|Procedure|In-Person Clinic Visit|Patients will undergo an in-person clinic encounter with the physician at the 3-week post-operative timepoint following a total hip or total knee arthroplasty.
28727|NCT03961698|Drug|IPI-549|IPI-549 is an oral, selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma). It is an orally-administered capsule that will be dosed at either 20mg/day, 30mg/day, or 40mg/day to patients in both cohorts A and B depending on the results of the safety run-in phase for each cohort.
28728|NCT03961698|Drug|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). 840 mg of the drug will be administered intravenously (IV) on days 1 and 15 in combination of each 28-day cycle for patients with TNBC. 1200mg will be administered IV on day 1 of each 21-day cycle to patients with RCC.
28729|NCT03961698|Drug|nab-paclitaxel|Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel (Taxol), a mitotic inhibitor chemotherapy, with less toxicity than solvent-based (sb) paclitaxel and achieves a 33% higher tumor uptake in preclinical models. Nab-paclitaxel will be administered intravenously (IV) at 100 mg/m2 on days 1, 8 and 15 of each 28-day cycle for patients with TNBC.
28730|NCT03961698|Drug|Bevacizumab|Bevacizumab is an anti-vascular endothelial growth factor (anti-VEGF) recombinant monoclonal antibody that is approved by the FDA for the treatment of multiple solid tumors in combination with chemotherapy. It will be administered at 15 mg/kg IV on day 1 of each 21-day cycle to patients with RCC.
28731|NCT03961672|Drug|Duvelisib|Given PO
28732|NCT03961659|Drug|Liraglutid|Liraglutid will be titrated from 0.6mg/day to 1.8mg/day during the first 2 weeks, if well tolerated. All patients will also continue on their existing dose and regimen of metformin throughout the study.
28733|NCT03961659|Drug|Dapagliflozin|Dapagliflozin will be initiated and maintained at 10mg/day every morning until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.
28794|NCT03961178|Diagnostic Test|TCT|Thin prep liquid-based cytology test for the cytology of lower genital tract
28734|NCT03961659|Drug|Acarbose|Acarbose will be initiated at 50mg three times daily for the first week, and then titrated to 100mg three times daily if appropriate.All patients will also continue on their existing dose and regimen of metformin throughout the study.
28735|NCT03961633|Behavioral|AWARE intervention|"will attend the AWARE group counseling sessions, which are 90 minutes, once a week, for 8 weeks. Each week's session is focused on a specific theme related to the cultural and gender-specific issues typical among young Asian American women. The sessions are led by staff therapists at either institution. For more info on each session's content, please see the Study Description - Detailed Description section.~Participants will fill out forms that detail their therapeutic goals (commitments) and any adverse emotional / behavioral events from the past week. Participants will also receive daily text messages that reinforce the group session themes."
28736|NCT03961620|Device|The SpotOn system that encompasses the registration unit (3M SpotOn Control Unit), disposable sensor (3M SpotOn Control Sensor) along with the cords and electric power unit.|Patients submitted to major surgical procedure will be assessed for core body temperature by employing SpotOn sensor device, before, during and after surgical procedure.
28737|NCT03961607|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
28738|NCT03961594|Other|expansion volémique|cardiac output, VVP, VVE, blood pressure, Eadyn, EtCO2 will be measured before and after ELJP. In the event of an increase of more than 10% in cardiac output during the ELJP, patients will receive a volume expansion of 500ml of balanced crystalloids. The same measurements will be repeated immediately at the end of the volume expansion and 20 minutes after the end of the infusion. Patients with a 15% increase in cardiac output at the end of volume expansion will be classified as responders.
28739|NCT03961581|Behavioral|Using electric car|Child will use little electric cars to go to the reception of operating theatre to operating room.
28740|NCT03961568|Drug|Cenobamate|active drug
28741|NCT03961555|Biological|SYN023|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
28742|NCT03961555|Biological|HRIG (HyperRab)|it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
28743|NCT03961555|Biological|Rabies vaccine|it should be administered in deltoid muscle
28744|NCT03961542|Other|Chewing|Eligible patients are randomized to receive either routine care (control group) or routine care in addition to a chewing gum intervention for five days (beginning with the second study day, i.e. the day after baseline examination): sugar-free, fruit or mint flavoured gum chewed three times daily for 20 minutes before each meal. Routine care includes standard dietary and lifestyle advice for 30 minutes following our local recommendations as well as an advice on capillary blood glucose measurement (fasting as well as 1h after starting each meal). Capillary blood glucose profiles are reevaluated seven days after starting the blood glucose monitoring. Study visits will be scheduled at screening (visit 1, where eligible patients were randomized) as well as seven days later (visit 2).
28745|NCT03961529|Drug|0.3% OPA-15406 ointment|Twice daily
28746|NCT03961529|Drug|1% OPA-15406 ointment|Twice daily
28747|NCT03961516|Device|Frequently Sampled Oral Glucose Tolerance Test and CGM|Patients will undergo a 2 hour frequently sampled oral glucose tolerance test while wearing an active FreeStyle Libre Pro sensor
28748|NCT03961516|Radiation|MRI Pancreas and Liver|Patients will undergo an MRI of the pancreas and liver
28749|NCT03961503|Drug|Daptomycin (DAP) treatment|Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
28750|NCT03961503|Drug|Vancomycin (VAN) treatment|Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
28751|NCT03961490|Other|No interventional study|No interventional study
28752|NCT03961477|Other|Interferential therapy|Exercise therapy
28753|NCT03961464|Drug|d-cycloserine|Single dose
28754|NCT03961464|Drug|Placebo|Single dose
28755|NCT03961451|Device|Podometer|Patients will be equipped with pedometers for 8 weeks, all day and must complete the number of steps each day. They will have to complete online evaluation questionnaires regularly. The main objective is to correlate the level of physical activity with the level of fatigue, quality of life and well-being weekly during an anticancer treatment.
28756|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg and will be admixed with 500 μg MPLA formulated in liposomes.
28757|NCT03961438|Biological|ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes|Vaccine administration will be done at months 0, 2 and 6 by intramuscular injection into the deltoid muscle of the non-dominant arm. The immunogen will be used at the dosage of 100 μg at months 0 and 2, and 20 μg at month 6. All immunogen dosages will be admixed with 500 μg MPLA formulated in liposomes.
28758|NCT03961425|Behavioral|NO CO2|Traditional mechanical Deairing
28759|NCT03961425|Device|CO2 Cannula|NON specific, low cost delivery system
28760|NCT03961425|Device|CO2 Cardia|Specific Commercial CO2 Diffuser
28795|NCT03961165|Drug|Butylscopolamine Bromide 20 MG/ML|1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
28796|NCT03961165|Drug|Sodium Chloride 9mg/mL|1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
28797|NCT03961152|Behavioral|PainCoach app|In response to the patient's input of the pain experienced (no pain, bearable pain, unbearable pain, or untenable pain), the app gave advice on pain medication use, exercises/rest and when to call the clinic from day 1 until day 14 after surgery.
28851|NCT03960749|Device|Sprotte 25G needle, stylet not reinserted|Lumbar puncture with small bore atraumatic needle, stylet not reinserted before needle withdrawal
28852|NCT03960749|Device|Sprotte 22G needle, stylet reinserted|Lumbar puncture with larger bore atraumatic needle, stylet reinserted before needle withdrawal
28761|NCT03961412|Behavioral|family-based intervention|The participants will identify their accompanying influential person(s) (e.g., spouse, partners, parents, children, friends) with whom they will be attending the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
28762|NCT03961412|Behavioral|Participant only intervention|Only participant will attend the 1.5-2 hour face-to-face education session on cervical cancer and screening. At the end of the intervention, time will be allowed for questions, as well as distributing fridge magnets and a pamphlet. Fridge magnets contain Pap test guidelines and availability of local clinics. The pamphlet covers the following topics: (a) information about female anatomy and cervical cancer, (b) risk factors for cervical cancer, (c) facts of cervical cancer incidence and mortality, and screening rates among American women, (d) methods to reduce cervical cancer (e.g., HPV vaccination), (e) Pap test procedure, (f) Pap test guidelines, and (g) availability of clinics and cost of Pap test. The participants will be encouraged to spread the message to family members and friends.
28763|NCT03961399|Device|Abbott Medical® CRT device with SyncAVTM stimulation function|patients with Abbott Medical® CRT device will be randomized and SyncAVTM stimulation will be activated.
28764|NCT03961399|Device|Abbott Medical® CRT device with biventricular stimulation (BiV)|patients with Abbott Medical® CRT device will be randomized and biventricular (BiV) stimulation will be activated.
28765|NCT03961386|Behavioral|FallsTalk-C|The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
28766|NCT03961386|Behavioral|FallsTalk|The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
28767|NCT03961373|Procedure|Gastrectomy with D2 lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy+ surgical D2 treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2-lymph node dissection is required with specific information about lymph node stations.
28768|NCT03961373|Procedure|Gastrectomy with D2plus lymphadenectomy|Patients who are assigned to the neoadjuvant chemotherapy + surgical D2+ extended lymphadenectomy treatment group will undergo either subtotal or total gastrectomy, depending on the location of the primary tumour. Standardized D2+ lymph node dissection plus resection of stations 8p, 12p, 13, 14v, 16a2/b1 is required with specific information about lymph node stations.
28769|NCT03961360|Drug|Aspirin 81 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
28770|NCT03961360|Drug|Aspirin 162 mg|Low dose aspirin was initially reported as having a beneficial effect at preeclampsia
28771|NCT03961347|Drug|L. johnsonii Probiotic|Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
28772|NCT03961347|Drug|Placebo Capsule|Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
28773|NCT03961334|Drug|Rivaroxaban|20mg 1x/d
28774|NCT03961334|Drug|Dabigatran|150mg 2x/d
28775|NCT03961334|Drug|Apixaban|5mg 2x/d
28776|NCT03961334|Drug|Edoxaban|60mg 1x/d
28777|NCT03961334|Drug|Aspirin|100mg 1x/d
28778|NCT03961334|Drug|Clopidogrel|75mg 1x/d
28779|NCT03961321|Radiation|stereotactic mr guided adaptive radiotherapy|Study patients will be treated with an online MR-guided hypofractionated course of radiotherapy in 5 fractions of 7.25 Gy per fraction delivered on the prostate with a simultaneous integrated sparing (SIS) of the urethra with a dose of 32.5 Gy in 5 fractions (6.5 Gy per fraction).
28780|NCT03961308|Drug|Vedolizumab SC|Vedolizumab SC liquid.
28781|NCT03961295|Drug|Vedolizumab SC|Vedolizumab SC liquid.
28782|NCT03961282|Other|Doorway Width Test|The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.
28783|NCT03961282|Other|Door Frame Color Test|The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
28784|NCT03961256|Drug|Exenatide SR|Exenatide SR 2 mg subcutaneous (SQ) weekly
28785|NCT03961243|Biological|YUVA-GT-F901|Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
28786|NCT03961230|Drug|Jueyin granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
28787|NCT03961230|Drug|Jueyin Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
28788|NCT03961217|Radiation|Radiotherapy|Radiotherapy as part of cancer treatment
28789|NCT03961204|Drug|Cladribine|Participants will not receive any investigational medicinal product (IMP) in the study. Participants will be eligible who had participated in parent studies 25643 (NCT00213135), 27820 (NCT00641537) and 28821 (NCT00725985) and had received Cladribine tablets or placebo.
28790|NCT03961191|Diagnostic Test|DNA methylation|DNA methylation for the cervical cytology
28791|NCT03961191|Diagnostic Test|high-risk HPV|High-risk HPV testing for the cervical cytology
28792|NCT03961191|Diagnostic Test|TCT|Thin prep liquid-based cytology test for the cervical cytology
28793|NCT03961178|Diagnostic Test|High-risk HPV|High-risk HPV testing for the cytology of lower genital tract
28798|NCT03961139|Other|Method of feeding; continuous feeding OR bolus feeding|"CF: Infants fed through a naso or orogastric tube in a continuous fashion using syringe pump. Each feed cycle is of 4 hours (3 hrs continuous feeding and 1 hour rest). 6 feed cycles in a day.~BF: Infants fed through a naso or orogastric tube in a gravity dependent bolus feeding every 2-3 hours. Each feed would take approximately 10 minutes."
28799|NCT03961126|Drug|Injection of autologous fatty tissue associated with autologous platelet-rich plasma.|Patients will receive 2 separate infiltrations for three months by intra and subdermal injection of autologous fatty tissue (20cc) associated with autologous platelet-rich plasma (4cc) in each half vulvar.
28800|NCT03961126|Drug|Corticosteroids (clobetasol 0.05%)|Patients will receive a maintenance treatment of topical therapy with corticosteroids (clobetasol 0.05%) that will be administered by usual clinical practice.
28801|NCT03961113|Other|Assessment by questionnaire|"At diagnosis a gerontological evaluation will be carried out including the following tests: ADL, iADL, MNA, SF 36, SPPB, FRIED criteria and GDS. The set of scales and scores of the procedure is commonly used in geriatrics to assess the fragility of the patient.~A monthly telephone reassessment conducted by an ARC will collect ADL and iADL from the first month to the eleventh month. The end-of-study consultation will be conducted by a geriatrician at the 12th month and will include the following tests: ADL, iADL, MNA, SF 36, the SPPB, the criteria of FRIED and the GDS"
28802|NCT03961100|Drug|Entrectinib 600 mg (T1)|Test formulation 1 (T1): Multi-particulate formulation 1: entrectinib film-coated mini-tablets
28803|NCT03961100|Drug|Entrectinib 600 mg (T2)|Test formulation 2 (T2): Multi-particulate formulation 2: entrectinib film-coated mini-tablets
28804|NCT03961100|Drug|Entrectinib 200 mg (R)|Reference formulation (R): entrectinib hard capsules
28805|NCT03961100|Drug|Entrectinib 200 mg (T)|Test formulation (T): entrectinib HPMC capsules
28806|NCT03961087|Drug|Coenzyme Q10|Coenzyme Q10 will be given twice
28807|NCT03961087|Drug|MECLOFENOXATE|MECLOFENOXATE will be given as 500 mg once daily.
28808|NCT03961074|Other|Iron deficiency anemia in Chinese pregnant women|Iron deficiency anemia exists in Chinese pregnant women during pregnancy
28809|NCT03961061|Behavioral|Brenner mFIT (standard care)|Families attend an orientation, in which they are then scheduled for an initial introductory 2-hour intake group session and cooking class; these occur within 2-4 weeks of the orientation. Monthly 1-hour long visits with the dietitian, counselor, and PA specialist are held for 6 months, in which the child and caregiver see the pediatrician. During the 6 months of treatment, they attend 4 group classes, choosing from topics such as meal planning, PA, and parenting. Specialized visits with the PA specialist or dietician are scheduled as pertinent issues arise. Motivational interviewing, modified by Brenner FIT for use with families, is the key to treatment; family counselors are trained in cognitive behavioral therapy, parenting support/mindfulness, and employ these approaches to assist families in developing healthy habits.
28810|NCT03961061|Behavioral|Brenner mFIT (standard care plus mobile health components)|"Brenner mFIT includes all components of the standard Brenner FIT program in addition to six mobile health components.~The six mHealth components that will be used in addition to standard Brenner Families in Training program include-~a mobile-enabled website,~diet and physical activity tracking apps and physical activity tracker~tailored self-monitoring feedback~caregiver podcasts~animated videos for adolescent patients~social support via social media."
28811|NCT03961048|Drug|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally|Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
28812|NCT03961048|Drug|Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally|Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
28813|NCT03961022|Dietary Supplement|Polyherbal supplement: ReWin(d) vs Placebo|Supplementation during 4 weeks + 72 hours post acute exercice
28814|NCT03961009|Biological|Kedrion IVIG 10%|Kedrion intravenous immunoglobulin (IVIg) 10%
28815|NCT03960996|Procedure|dacryocystorinostomy|Dacryocystorinostomy is a surgical procedure indicated in patients with lacrimal duct obstruction.
28816|NCT03960983|Device|Treatment with tongue scraper|Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.
28817|NCT03960983|Procedure|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
28818|NCT03960983|Radiation|Photodynamic Therapy|Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step
28819|NCT03960983|Procedure|Hygiene procedures for the mucosa and dentures|Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
28820|NCT03960970|Drug|Azithromycin 500 mg|Additional IV Azithromycin 500 mg to Standard Prophylaxis
28821|NCT03960970|Drug|Mefoxin 2g|Standard Prophylaxis
28822|NCT03960957|Biological|AbobotulinumtoxinA|Treatment of glabellar facial lines with 50 U AbobotulinumtoxinA
28823|NCT03960957|Other|Placebo|Treatment of glabellar facial lines with placebo
28824|NCT03960944|Other|Yoga|30 Min Yoga session included of Physical posture, Breathing exercise, Yoga games and Relaxation.
28825|NCT03960931|Other|Aquatic rehabilitation|Rehabilitation sessions using hydrophysiotherapy will occur in a pool of Grand Nancy Thermal, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
28826|NCT03960931|Other|Land based physical activities|Rehabilitation sessions on treadmill will occur at Physical Medicine and Rehabilitation Regional Institute (IRR), on the University Hospital's site, three times per week during 4 weeks, and each will last 45 min. They will begin with 10 min of warm-up, then 30 min of walking, where intensity of effort can be modulated by speed and inclination of treadmill. Sessions will end cool-down during 5 min, which will be a reduction of intensity every 30 sec. Rehabilitation will be carried out by physiotherapist chosen for the study.
32489|NCT03931434|Dietary Supplement|Aged Garlic Extract (AGE)|2400mg of Aged Garlic Extract (AGE)
28827|NCT03960931|Other|Conventional rehabilitation|Conventional rehabilitation sessions will occur in private practices in which patients receive their habitual care (same physiotherapist). This care will be guided by prescription delivered by the neurologist. This prescription suggests to work on active and passive upper and lower limb stretching, on hip and shoulder dissociation, and balance control management on unstable ground.
28828|NCT03960918|Behavioral|aerobic exercise therapy|aerobic exercise therapy: All enrolled subjects will perform a CPET before the training initiation. After CPET, the patients in the experimental group need to perform an additional bicycle training program with the intensity of 60 % maximal workload in the previous CPET (five days per week, for four weeks with a total of 20 times).
28829|NCT03960905|Other|Children with the usage of anti-infective drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
28830|NCT03960892|Behavioral|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialists, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, & van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
28831|NCT03960879|Diagnostic Test|DNA methylation|DNA methylation for the cervical cytology
28832|NCT03960879|Diagnostic Test|High-risk HPV|High-risk HPV testing for the cervical cytology
28833|NCT03960879|Diagnostic Test|TCT|Thin prep liquid-based cytology test for the cervical cytology
28834|NCT03960866|Drug|Phentolamine Mesylate Ophthalmic Solution 1%|Topical Sterile Ophthalmic Solution
28835|NCT03960866|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Topical Sterile Ophthalmic Solution
28836|NCT03960853|Procedure|pressure-controlled ventilation-volume guaranteed|patients will be allocated to pressure-controlled ventilation-volume guaranteed in operation
28837|NCT03960853|Procedure|volume controlled ventilation|patients will be allocated to pressure-controlled ventilation volume guaranteed in operation
28838|NCT03960840|Drug|YTB323 and ibrutinib|Single infusion of YTB323 and daily ibrutinib
28839|NCT03960840|Drug|YTB323 single agent|Single infusion of YTB323
28840|NCT03960827|Other|Endurance Training|Participants randomized to ET engage in four center-based ET sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. Each week, two of the sessions occur on a cycle ergometer and two involve treadmill exercise (4 total sessions per week). During all sessions, the participant's heart rate is monitored to ensure they maintain exercise intensity at 70% of heart rate reserve (± 5%). Periodically during training sessions perceptual data from participants are recorded, which is used to track the subjective experience of participants and in interpreting adherence data.
28841|NCT03960827|Other|Restistance Training|Participants randomized to RT engage in four center-based RT sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant is able to perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
28842|NCT03960814|Drug|Insulin detemir|No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
28843|NCT03960801|Drug|Remifentanil group|bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction
28844|NCT03960801|Drug|neuromuscular blockade group|Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
28845|NCT03960788|Drug|Gadoxetate Sodium|Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
28846|NCT03960775|Drug|dexmedetomidine|Dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum.
28847|NCT03960775|Drug|saline|Saline infusion during same time period.
28848|NCT03960762|Other|ESP block (Group ESP)|In group A, ESP block will be performed. US probe will be placed longitudinally 2-3 cm lateral to the T5 transverse process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block
28849|NCT03960762|Other|SAP block (Group SAP)|In group B, after lateral positioning, US probe will be placed in a sagittal plane over the midclavicular region of the thoracic cage. Then the 7th rib will be identified in the midaxillary line, followed by the identification of the following muscles overlying the 6th rib: the latissimus dorsi (superficial and posterior), teres major (superior), and serratus muscle (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus anterior muscle. 5 ml saline will be enjected for correction. Following confirmation of the correct position of the needle 20 ml %0.25 bupivacaine will be administered for block.
28850|NCT03960749|Device|Sprotte 25G needle, stylet reinserted|Lumbar puncture with small bore atraumatic needle, stylet reinserted before needle withdrawal
28853|NCT03960749|Device|Sprotte 22G needle, stylet not reinserted|Lumbar puncture with larger bore atraumatic needle, stylet not reinserted before needle withdrawal
28854|NCT03960749|Device|Spinocan 25G needle, stylet reinserted|Lumbar puncture with small bore cutting needle, stylet reinserted before needle withdrawal
28855|NCT03960749|Device|Spinocan 25G needle, stylet not reinserted|Lumbar puncture with small bore cutting needle, stylet not reinserted before needle withdrawal
28856|NCT03960736|Other|ESP block (Group A)|US probe will be placed longitudinally 2-3 cm lateral to the T5 transvers process. From superior to inferior, three muscles will be visualized on the hyperechoic transverse process; trapezius (upper), rhomboideus major (middle), erector spinae (lower). The block needle will be inserted cranio caudal direction and then for correction of the needle 5 ml saline will be injected deep into the erector spina muscle fascia. Following confirmation of the correct position 20G catheter will be inserted 5 cm in caudal direction. 20 ml %0.25 bupivacaine will be administered for block.
28857|NCT03960736|Other|TEA group (Group B)|Local infiltration with 2% of lidocaine under the skin, in T4/T5 intervertebral space will be administered. An 18 G Tuohy needle will be inserted at T4/T5 intervertebral space to identify epidural space using the loss of resistance technique. 20G catheter will be inserted 3-4 cm in caudal direction in the epidural space. Bolus dose of 0.125% bupivacaine 10 ml will be administered through the catheter after the negative aspiration for blood or cerebrospinal fluid
28858|NCT03960723|Other|Questionnaire|A questionnaire asking the patients for several questions related to the Informed Consent Form they have signed before surgery, will be administered.
28859|NCT03960710|Other|Anonymized CT examinations|The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.
28860|NCT03960710|Other|Training (1)|"An initial training phase of the artificial intelligence network will be carried out :~- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals"
28861|NCT03960710|Other|Training (2)|"An initial training phase of the artificial intelligence network will be carried out :~- Use of computer data to drive the artificial intelligence network."
28862|NCT03960710|Other|Validation (1)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by an intern at the Lyon hospitals"
28863|NCT03960710|Other|Validation (2)|"A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :~- Carried out by the neural network"
28864|NCT03960697|Behavioral|walk out from operating room|After the surgery of laparoscopic total or partial nephrectomy， patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
28865|NCT03960684|Device|Levita Magnetic Surgical System|Levita Magnetic Surgical System
28866|NCT03960671|Drug|Midazolam/diazepam/propofol|Therapeutic drug monitoring of anxiolytics
28867|NCT03960658|Drug|ketamine-enhanced prolonged exposure|Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
28868|NCT03960645|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
28869|NCT03960632|Diagnostic Test|Abbott SD Bioline Malaria Pf Plus (05FK150) and Abbott SD Bioline Malaria Pf/Pv Plus (05FK160))|Qualitative in vitro tests for the detection of Plasmodium antigens
28870|NCT03960619|Behavioral|coping skills training|We aim to test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. We propose a novel intervention protocol that uses a hybrid in-person and mHealth intervention delivery model.
28871|NCT03960606|Combination Product|PUR1900|PUR1900 contains itraconazole as the active ingredient, and it is formulated as a dry powder for oral inhalation.
28872|NCT03960593|Other|Evaluation of the influence of geriatric factors|Follow-up of patients> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
28873|NCT03960580|Drug|OPN-375|OPN-375, BID
28874|NCT03960567|Device|Videolaryngoscopy|Patient will be intubated by using videolaryngoscope
28875|NCT03960554|Drug|Denosumab Inj 60 mg/ml|Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
28876|NCT03960554|Other|Placebo|Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.
28877|NCT03960541|Drug|CD24Fc (human CD24 extracellular domain and human IgG1 Fc fusion protein)|CD24Fc will be given as IV infusion, 240 mg per infusion, q2w, total 3 doses in 4 week interval.
28878|NCT03960541|Drug|Saline Solution|Normal Saline Solution will be given as placebo with IV infusion, 150 ml per infusion, q2w, total 3 doses in 4 weeks.
28879|NCT03960528|Procedure|Erector spinae plane block|Bilateral 20 ml Bupivacaine 0.25% + lidocaine 1% injected between erector spinae muscles and transverse process under direct vision.
28880|NCT03960528|Procedure|Control group|20 ml NaCl 0,9% used for the infiltration between the transverse process and the erector spinal muscle under direct vision on each side.
28881|NCT03960502|Drug|AG-881|Single oral dose of approximately 50 mg AG-881 (free form) containing approximately 100 microcuries (μCi) of [14C]AG-881.
28882|NCT03960502|Drug|[13C315N3]AG-881|Single IV microdose of approximately 100 μg.
28883|NCT03960489|Drug|Roxadustat Tablet|Oral
28884|NCT03960489|Drug|Roxadustat Mini-tablet|Oral
28885|NCT03960476|Behavioral|PlanYourLifespan.org|The study intervention is a web-based planning tool, PlanYourLifespan.org
32490|NCT03931434|Dietary Supplement|Placebo|Placebo
28886|NCT03960463|Device|Transcu O2®|Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
28887|NCT03960450|Drug|BOS-475|topical cream
28888|NCT03960450|Drug|Vehicle|topical cream
28889|NCT03960437|Drug|Etelcalcetide|Administered intravenously at the end of each dialysis session. Dosing ranges from 5 mg to 15 mg set by the patient's physician.
28890|NCT03960424|Other|Comprehensive Outpatient Management|Patients receiving comprehensive outpatient management experience typical care received in the outpatient setting.
28891|NCT03960424|Behavioral|Diabetes Telemonitoring|Diabetes Telehealth Management (DTM), based on the 2018 ADA Standards for T2D, uses smart devices to share information between patients, caregivers, and clinicians.
28892|NCT03960411|Drug|Doxycycline 100Mg Capsule|Doxycycline capsule
28893|NCT03960411|Drug|Placebo oral capsule|Capsule manufactured to mimic doxycycline 100 mg capsule
28895|NCT03960385|Biological|CYD-TDV|Dengue vaccine
28896|NCT03960372|Behavioral|ICT activities|Public education activities using ICT to promote family communication, sharing happiness with family members, and well-being in the community.
28897|NCT03960359|Other|Clinical, microbiological and inflammatory phenotype|Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
28898|NCT03960346|Procedure|Ablation with cryoenergy|Esophageal temperature-guided ablation using cryoengery and an esophageal temperature probe.
28899|NCT03960320|Other|questionnaire|questionnaire to assess the quality of life of children using KINDL, SDQ and SF-36
28900|NCT03960307|Other|Microcirculation and Glycocalyx assessment|Non-invasive assessment of endothelial glycocalyx dimensions (PBR) and microcirculatory parameters (e.g. PPV, PVD, TVD, MFI)
28901|NCT03960294|Other|DOZE Sleep App|DOZE is an evidence-based cognitive behavioural therapy for insomnia app created specifically for use with adolescents and young adults.
28902|NCT03960281|Other|Regular dental examination|Regular dental examination, and the patient will be asked to fill a questionnaire
28903|NCT03960268|Drug|Brodalumab|interleukin 17 receptor A antagonist
28904|NCT03960255|Other|Normal standard care|Both groups will receive standardized treatment and care for diabetic foot ulcers
28905|NCT03960229|Other|MicroFluidic Sperm Sorting Chips|sperm selection of IVF treatment
28906|NCT03960229|Other|Gradient-Density Centrifugation|sperm selection of IVF treatment
28907|NCT03960216|Procedure|Scaling and root planning|Patients received non-surgical periodontal therapy in the form of full-mouth scaling and root planing (SRP), in two sessions, 1 week apart, with the use of an ultrasonic scaler (Minipiezon Electromedical Systems EMS, Nyon, Switzerland) and hand instruments, under local anaesthesia.
28908|NCT03960216|Procedure|Supragingival Prophylaxis|Supragingival removal of all deposits (plaque and calculus) with an ultrasonic scaler in two sessions, 1 week apart.
28909|NCT03960203|Diagnostic Test|InSight|Clinical decision support (CDS) system for severe sepsis detection and prediction
28910|NCT03960190|Device|Using Eureka Breast Pump with Expression Kit|Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
28911|NCT03960177|Drug|Glucarpidase|Given IV
28912|NCT03960164|Combination Product|Dermal regeneration photosynthetic matrix|Patients with clean wound will receive DRPM over the lesion which will be illuminated by a LEDs array device.
28913|NCT03960151|Drug|Rolapitant|Rolapitant 180mg PO, Days 1 and 5
28914|NCT03960151|Drug|Palonosetron|Palonosetron 0.25 mg IV, Days 1,3, and 5.
28915|NCT03960151|Drug|Olanzapine|Olanzapine 10 mg PO PM, Days 2,3,4,5,6-8
28916|NCT03960151|Drug|Dexamethasone|Dexamethasone 20 mg AM, Days 1,2 and 3
28917|NCT03960138|Device|Intermittent Theta-burst stimulation (iTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected.
28918|NCT03960138|Device|Continuous Theta-burst stimulation (cTBS)|Theta-burst stimulation (TBS), a form of repetitive transcranial magnetic stimulation (rTMS), affects brain areas stimulated directly underneath the scalp and brain areas that are functionally connected. Continuous TBS (cTBS) which is thought to temporarily dampen brain activity in that specific area.
28919|NCT03960125|Device|Photodynamic Therapy|Blue Light Therapy Exposure
28920|NCT03960125|Drug|4% Imipramine|A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
28921|NCT03960125|Drug|Base Cream|Control to 4% Imipramine
28922|NCT03960112|Device|mpMRI|mpMRI in the detection of prostate cancer in a per patient analysis using cystoprostatectomy specimen
28923|NCT03960099|Behavioral|Pictograph in Banner and Verification Alert|Patient Pictograph will be displayed in the banner at the top of the screen in the electronic health record AND patient Pictograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
28924|NCT03960086|Other|Podoactiva cutom-made foot orthoses|Children had to use the orthotics daily during the intervention period
28925|NCT03960086|Other|Podoactiva heel lifts|Children had to use the orthotics daily during the intervention period
28926|NCT03960073|Dietary Supplement|MitoQ|4 week 20mg oral daily dose of Mito Q
28927|NCT03960073|Dietary Supplement|Placebo|4 week oral daily dose of TTP placebo
28928|NCT03960060|Biological|CCT301-59|Collect blood from the patients and isolate peripheral blood mononuclear cells for the production of CCT301-59. Subjects will receive the conditioning chemotherapy regimen of cyclophosphamide and fludarabine for lymphodepletion during the production of CCT301-59 and then subjects will receive one dose of CCT301-59 via intravenous injection.
28930|NCT03960047|Behavioral|Streetside Training|This group is trained to cross streets based on streetside experiences
28931|NCT03960021|Radiation|RFA interventions|Each patient is treated with 2 RFA interventions. Abiopsy of one metastasis is done at each RF session. Histological samples are sent to the Bio-pathology department of Institut Bergonié for tumor infiltrating lymphocytes counting. Primary outcome results from this counting (stromal TILs ≥ 20% is considered as a significant level, a comparative measurement before and after RF will be performed). In parallel blood samples are performed before and after RFA to analyze the kinetics of peripheral blood T lymphocytes subsets, tumoral circulating cells and tumoral DNA.
28932|NCT03960008|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
28933|NCT03960008|Procedure|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation
28934|NCT03960008|Drug|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
28935|NCT03959995|Other|High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)|Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.
28936|NCT03959995|Other|Wellness|control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 18 months.
28937|NCT03959982|Device|HHHFA Device|Participants will be instructed to use the HHHFA for at least 4 hours during their sleep but will be allowed to use it as long as they want during sleep.
28938|NCT03959982|Diagnostic Test|Spirometry|Pre and post spirometry using albuterol.
28939|NCT03959982|Diagnostic Test|6-minute walk|6-minute walk
28940|NCT03959982|Diagnostic Test|CT scan|CT scan
28941|NCT03959982|Other|Medical Research Council dyspnea scale (MRC)|MRC questionnaire
28942|NCT03959982|Other|St. George's Respiratory Questionnaire (SGRQ)|SGRQ questionnaire
28943|NCT03959982|Other|COPD Assessment Test (CAT)|CAT questionnaire
28944|NCT03959982|Other|Pittsburgh Sleep Quality Index (PSQI)|PSQI questionnaire
28945|NCT03959982|Other|CASA-Q|CASA-Q questionnaire
28946|NCT03959982|Other|Spirehealth Tag Device|Subjects will wear the Spirehealth Tag Device to measure heart rate, respiratory rate, sleep time, physical activity (movement), and calories burned with activity.
28947|NCT03959969|Other|Educational video|An educational video on pain management after cesarean section. The educational video was put together by two general obstetrician-gynecologists, two maternal fetal medicine specialists, and a palliative care physician.
28948|NCT03959969|Other|Standard of care|The standard of care discharge instructions for postoperative patients after cesarean section that are provided at the institution.
28949|NCT03959969|Drug|Ibuprofen|Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
28950|NCT03959969|Drug|Oxycodone|Prescription given for twenty tablets of oxycodone 5 mg every 4 hours as needed for pain.
28951|NCT03959956|Diagnostic Test|Recording lung sound by a Smartscope|Lung sound will be recorded from four chest points by an electronic stethoscope called Smartscope which can also classify the recorded lung sound.
28952|NCT03959943|Procedure|Sensory nerve coaptation|A recipient sensory nerve branch of the lateral cutaneous femoral nerve (LCFN) was reattached to a donor nerve in the chest area. The anterior cutaneous branch of the second or third intercostal nerve was used as the donor nerve. Direct, end-to-end nerve coaptation was performed.
28953|NCT03959930|Device|Transdermal Fluid Removal|"The Transdermal Fluid Removal (TFR) device is designed for use on the lower limbs of patients with Chronic Heart Failure and treatment resistant peripheral oedema.~The TFR device is intended to be applied on oedematous skin of eligible patients, for periods of up to 10 hours at a time, to gently remove excess fluid through the skin, over a period of a few days during exacerbations, thereby avoiding hospitalisation for intravenous diuretics.~The TFR device is designed to be used in conjunction with standard Negative Pressure Wound Therapy (NPWT) devices which are currently CE Marked and approved for use in both acute and homecare environment."
28954|NCT03959917|Procedure|transurethral resection of the prostate|Surgical removal of benign prostatic tissue
28955|NCT03959904|Procedure|Small stitch|Wound closure will be using small stiches or larger spaced stitches
28956|NCT03959904|Other|Blood sample|A blood sample to look for biological markers of Hernia formation will be taken
28957|NCT03959904|Other|Tissue Sample|A tissue sample will be taken to measure markers of wound healing.
28958|NCT03959904|Other|Pain Score|A pain score will be recorded following the surgical procedure.
28959|NCT03959904|Other|Quality of Life Score|A Quality of Life Score will be recorded at 1 month 6 months and 12 months post surgery
28960|NCT03959891|Drug|Ipatasertib|Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
28961|NCT03959891|Drug|Fulvestrant|Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
28962|NCT03959891|Drug|Aromatase Inhibitor|Letrozole is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body's muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogen. In the absence of estrogen, tumors dependent on this hormone for growth will shrink.
28963|NCT03959891|Drug|Palbociclib|Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
54362|NCT03759067|Drug|clopidogrel 600mg|clopidogrel 600mg loading
28964|NCT03959878|Device|Constant Pressure Skin Disk|The external disk is made of Dow Corning® Silastic Q7-4850 liquid silicone rubber. Placement of the disk will be done by the gastroenterologist or interventional radiologist during the gastrointestinal gastrostomy tube (GIG) or gastrointestinal jejunostomy tube (GIJ) placement procedure. The gastroenterologist or interventional radiologist will replace the manufacturer's external, adjustable skin disk with the external, adjustable Constant Pressure Skin Disk, by sliding the former off and the latter on to the feeding tube.
28965|NCT03959865|Drug|Long-acting GLP-1RA|Dulaglutide 0.75 or 1.5 mg /week or Exenatide once weekly 2 mg
28966|NCT03959865|Drug|Short-acting GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or exenatide 10 mcg or 20 mcg bid or lixisenatide 10 mcg or 20 mcg / day.
28967|NCT03959865|Drug|Human-based GLP-1RA|Liraglutide 0.6 mg or 1.2 mg or 1.8 mg / day or dulaglutide 0.75 or 1.5 mg / week
28968|NCT03959865|Drug|Exendin-based GLP-1RA|Exenatide 10 mcg or 20 mcg day or 2 mg / week or lixisenatide 10 mcg or 20 mcg / day.
28969|NCT03959865|Drug|Fixed ratio BI/GLP-1RA combination|Insulin degludec / liraglutide (0.036/U) or insulin glargine / lixisenatide (0.5 mcg/U)
28970|NCT03959865|Drug|Flexible BI/GLP-1RA combination|GLP-1RA (Liraglutide or dulaglutide or exenatide or lixisenatide) and basal insulin (BI, glargine, degludec, detemir, NPH insulin)
28971|NCT03959852|Drug|Fentanyl|1 mg/kg of Fentanyl IV administered over at least 1 minute
28972|NCT03959852|Combination Product|Fentanyl and Ketamine|Combined dose of 0.15 mg/kg of Sub-dissociative Ketamine and 0.5 mg/kg of Fentanyl IV administered over at least 1 minute.
28973|NCT03959852|Drug|Ketamine|0.3 mg/kg of Sub-Dissociative Ketamine IV administered over at least 1 minute
28974|NCT03959839|Procedure|ESD|Rectal Endoscopic Submucosal Dissection
28975|NCT03959839|Procedure|TAMIS|Transanal Minimally Invasive Surgery
28976|NCT03959839|Procedure|TEO|Transanal Endoscopic Operation
28977|NCT03959826|Behavioral|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
28978|NCT03959826|Behavioral|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
28979|NCT03959813|Other|Psychomotricity by touching and passive mobilizations|"The patient will have a first psychomotricity session. It will be carried out remotely from the drug catches to avoid bias induced by their administration having effects on the symptoms studied.~Before and after the session, two evaluations will be offered to the patient and performed by a nurse:~A questionnaire, based on the physical experience,~The ESAS scale will be administered to the patient to assess the importance of symptoms (pain, depression, anxiety, discomfort) During the session, a touch treatment will be offered to promote awareness of the body. Passive mobilizations at the level of the members and the axis will then be proposed, to promote the pleasure of being in motion. A touch treatment will be done again to promote relaxation.~A questionnaire can be offered to the patient after 4 sessions to assess his perception of psychomotricity."
28980|NCT03959787|Other|Educational|Educational pamphlet will be given to intervention group.
28981|NCT03959774|Device|IPC NET|a digital pack with connected bracelet and connected balance will be given to the patient. IPC NET and Nokia Health applications will be downloaded. Pairing between connected objects and the smartphone will be done during the inclusion visit
28982|NCT03959761|Drug|Intraperitoneal (IP) nivolumab infusion|"Patients will be treated according to three dose-levels of nivolumab, starting 5 to 7 days after surgery + Hyperthermic Intraperitoneal Chemotherapy (HIPEC), through an Intraperitoneal (IP) catheter :~Level 1 : 0.5 milligrams/kilogram (mg/kg) IP infusion, repeated every 2 weeks for 4 infusions~Level 2 : 1 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~Level 3 : 3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions~Level -1 : 0,3 mg/kg IP infusion, repeated every 2 weeks for 4 infusions"
28983|NCT03959735|Other|High Intensity Interval Training (HIIT)|HIIT is a type of exercise involving alternating short bursts of high intensity exercise with recovery periods of rest or light exercise.
28984|NCT03959722|Dietary Supplement|Ecologic® PERFORMANCE|"Ecologic® PERFORMANCE is a probiotic formulation consisting of different probiotic bacterial strains, namely:~Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Enterococcus faecium W54 Lactobacillus acidophilus W22 Lactobacillus brevis W63 Lactococcus lactis W58~Except for the bacterial strains, Ecologic® PERFORMANCE contains the following other ingredients:~maize starch and maltodextrins~fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~vegetable protein~mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
28985|NCT03959722|Dietary Supplement|Placebo|"The placebo contains no bacterial strains, but the following ingredients:~maize starch and maltodextrins~fructo-oligosaccharides (FOS) P6 and Polydextrose P4 (strain specific prebiotics)~vegetable protein~mineral mix (Potassium chloride, Magnesium sulphate, Manganese sulphate)"
28986|NCT03959709|Procedure|immediate acellular dermal matrix-assisted implant-based breast reconstruction with prepectoral implant placement.|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. A temporary implant sizer is placed in the pocket to assess the position and shape of the prepectoral pocket. The pocket is adjusted where necessary. A sheet of ADM (DermAcell) is then selected. The DermAcell will be prepared as per the manufacture's instructions and fenestrated using size 11 blade. The DermACELL piece will be trimmed to the appropriate shape and sutured to the superior medial and lateral edges of the pectoralis major muscle. The inferior edge will be sutured to the fascia at the level of the inframammary fold. Two closed suction drains will be placed (one below the mastectomy skin flap, and one below DermACELL). The implant will be inserted to the pre-pectoral pocket and several anchor sutures will be used to secure the superior-medial edge of DermACELL to mastectomy flap.
29026|NCT03959384|Drug|Curosurf 80Mg/Ml Intratracheal Suspension|CUROSURF is a natural surfactant obtained from swine lungs containing almost exclusively phospholipids, in particular phosphatidylcholine (about 70% of the total phospholipid content) and about 1% of low molecular weight hydrophobic proteins, specific for surfactant, SP-B and SP -C. CUROSURF will be administered via endotracheopulmunary.
29027|NCT03959384|Other|Ambient Air|Ambient air aspirated in sterile syringes
29028|NCT03959371|Drug|Ruxolitinib|"Observational study including patients with myelofibrosis being treated with ruxolitinib in a real world setting. Patients are treated according to current indications."
32701|NCT03929627|Other|Cortisol awakening response|Cortisol awakening response
28987|NCT03959709|Procedure|Immediate acellular dermal matrix-assisted implant-based breast reconstruction with subpectoral implant placement|On the day of surgery, after the completion of the mastectomy, the vascularity of the mastectomy flaps will be evaluated, and debridement is performed where necessary. The reconstructive operative procedure will then proceeded with (1) elevation of the pectoralis major muscle with release of inferior attachments; (2) placement of implant subpectorally; (3) placement and suturing of DermACELL to constitute the inferolateral breast pocket; (4) placement of two closed suction drains (one superiorly between the pectoralis major and skin, and one inferiorly between the DermACELL and skin); (5) removal of sizer and placement of permanent to the pocket and (6) suture the inferior edge of DermACELL to the inferior edge of the pectoral major muscle. The skin will be closed and the dressing will be applied as standard protocol.
28988|NCT03959696|Behavioral|Notification|Clinicians will be notified of their patients aged 76-85 with an upcoming, non urgent visit who are due for colorectal cancer screening.
28989|NCT03959696|Behavioral|Training|The 2-hour continuing medical education course in shared decision making, simulated patient interaction to practice skills, and monthly calls for a year to review difficult cases with clinical and shared decision making experts.
28990|NCT03959683|Device|Trilogy Lithotrite|The Trilogy has been FDA cleared for fragmentation of urinary tract calculi in the kidney, ureter, and bladder. Trilogy is a combined piezoelectric/pneumatic device capable of fragmenting calculi and aspirating stone debris. The novel technology in Trilogy has been demonstrated in bench testing to more quickly disintegrate stones compared to other devices.
28991|NCT03959683|Device|The ShockPulse-SE Lithotripsy System|The ShockPulse-SE System is an electromechanical device capable of fragmenting calculi and aspirating stone debris. The novel technology in the ShockPulse-SE Lithotripsy System uses a single transducer and proprietary ShockPulse technology to generate both low-frequency mechanical impacts and high-frequency ultrasonic energy which quickly disintegrates stones.
28992|NCT03959657|Other|No intervention performed by authors|Observational and retrospective study, no intervention performed
28993|NCT03959631|Behavioral|Virtual Communities of practice|based on a web 2.0 platform in which there is interaction with other patients and with a multidisciplinary team of professionals. The intervention will be co-designed with a group of patients and a group of primary and specialized care professionals.
28994|NCT03959618|Other|dietary supplements questionary|Patient Questionary Patient to be carried out at the last cure
28995|NCT03959605|Genetic|blood sample for genetic test|detection of pathogenic variants among the 19 genes known to be involved in albinism
28996|NCT03959605|Diagnostic Test|Ophtalmological examination|measurement of visual acuity, OCT and OCTA
28997|NCT03959592|Drug|Lutein, zeaxanthin and mesozeaxanthin|The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
28998|NCT03959592|Other|Placebo|This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
28999|NCT03959579|Diagnostic Test|systematic endomyocardial biopsy.|"We sought to compare the long term survival of HTx recipients followed with or without systematic endomyocardial biopsy. Second, the sensibility and specificity of cardiac echo to diagnose acute allograft rejection will be analyzed.~To show the safety of non-invasively monitoring HTx recipients without systematic endomyocardial biopsy"
29000|NCT03959566|Drug|Sutezolid|Sutezolid is not licensed yet. Current experience in humans up to Phase IIA. Dose according to randomization to dosing arms 2-5.
29001|NCT03959566|Drug|Bedaquiline, Delamanid, Moxifloxacin|These three licensed drugs form the backbone of a new regimen to which sutezolid is added in arms 2-5.
29002|NCT03959566|Drug|Midazolam oral solution|Midazolam will be administered as per probe drug use in a single dose of 2 mg at day -1 and day 14 to assess the potential of sutezolid for CYP 459 3A4 enzyme induction, as measured by its influence on the ratio of AUCs of the CYP 3A4 probe drug
29003|NCT03959553|Drug|GV1001|Lyophilized peptide from hTERT
29004|NCT03959553|Drug|Normal saline|0.9% normal saline
29005|NCT03959540|Drug|Opicapone|Capsules, oral use - 50 mg Use of opicapone is only driven by the physician's decision.
29006|NCT03959540|Drug|Levodopa (L-DOPA) + Standard care|Levodopa (immediate- or controlled-release) + Standard care. Use of Levodopa and standard of care are only driven by the physician's decision.
29007|NCT03959527|Drug|zoliflodacin|Dose: 3g, oral administration
29008|NCT03959527|Drug|ceftriaxone|Dose: 500mg, Intra-Muscular (IM) administration
29009|NCT03959527|Drug|azithromycin|Dose: 1g, oral administration
29010|NCT03959514|Biological|NovoRapid|Rapid acting prandial insulin aspart
29011|NCT03959514|Biological|Fiasp|Fast acting prandial insulin aspart
29012|NCT03959514|Biological|AT247|Ultra rapid acting prandial insulin aspart
29013|NCT03959501|Drug|Dapagliflozin 10 mg|Dapagliflozin 10mg daily for 24 weeks
29014|NCT03959501|Drug|Sitagliptin 100mg|Sitagliptin 100mg daily for 24 weeks
29015|NCT03959488|Drug|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
29016|NCT03959488|Drug|Palivizumab|Approved anti-RSV monoclonal antibody
29017|NCT03959462|Device|real anodal transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
29018|NCT03959462|Device|sham transcranial direct current stimulation|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used.
29019|NCT03959449|Behavioral|Action Observation plus motor imagery|Action observation (video) and motor imagery of running.
29020|NCT03959449|Behavioral|Motor imagery|Motor imagery of running
29021|NCT03959449|Behavioral|Exercise plus action Observation and motor imagery|Real exercise of running during 6 min plus action observation (video) and motor imagery of running.
29022|NCT03959436|Drug|Carbetocin|Carbetocin as the primary uterotonic for all cesarean sections
29023|NCT03959423|Device|AHCL insulin pump system|Advanced Hybrid Closed Loop insulin pump with associated CGM and blood glucose meter
29024|NCT03959410|Diagnostic Test|Cervical biopsy|in office Cervical biopsy
29025|NCT03959397|Drug|nab-paclitaxel|nab-paclitaxel monotherapy or combination therapeutic regimen
29156|NCT03958604|Procedure|Neurostimulation|Spinal cord stimulation with burst modality for discogenic low back pain
29029|NCT03959358|Drug|Lenalidomide|Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
29030|NCT03959358|Drug|Pomalidomide|Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).
29031|NCT03959345|Drug|Combination therapy group|Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
29032|NCT03959345|Drug|Standard therapy group|Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
29033|NCT03959332|Drug|Baloxavir Marboxil|Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
29034|NCT03959319|Other|Movement Pattern Training|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
29035|NCT03959319|Other|Manual Therapy|Treatment will include 10 supervised sessions over 12 weeks and instruction in a home exercise program After randomization, participants will be scheduled with a physical therapist trained in standard procedures. Treatment will include assessment of patient goals, patient education and instruction in a home program. Patient education will focus on patient-specific tasks, identified by the participant to be symptom-producing.
29036|NCT03959306|Dietary Supplement|Black Seed Oil|Black seed oil soft gelatin capsule
29037|NCT03959306|Drug|Anti-Diabetics|standard anti-diabetic treatment prescribed for the patient
29038|NCT03959293|Drug|Durvalumab|1500 mg by 1-hour IV infusion - Every 4 weeks
29039|NCT03959293|Drug|Tremelimumab|75 mg by 1-hour IV infusion - Every 4 weeks
29040|NCT03959293|Drug|FOLFIRI Protocol|"Irinotecan: 180 mg/m² by 2-hour IV infusion,~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion"
29041|NCT03959280|Other|Tailored intervention|"The exercise program consists of 2 x 1.5-hour supervised nordic walking sessions weekly during 12 weeks and 1-hour unsupervised moderate physical activity per week from week 4.~The diet intervention includes one face-to-face consultation with a dietician and one telephone-based contact monthly, i.e. 6 diet interventions for 12 weeks.~Behavioural changes techniques will be included in diet and exercise interventions."
29042|NCT03959280|Other|Control|This intervention will include tailored instruction on CPAP use and standard advices on physical activity and nutrition at CPAP initiation.
29043|NCT03959267|Behavioral|Telephone Genetic Counseling|A genetic counselor fluent in Spanish (see letter of support) will conduct the TGC. The TGC intervention consists of two sessions. Prior to the sessions the investigators will mail participants the education materials with information to be reviewed prior to the genetic counseling session and a set of visual aids that the counselor will refer to during the session to facilitate the understanding of the information conveyed in the session.
29044|NCT03959254|Procedure|Physiotherapy post-surgical protocol for femoroacetabular impingement|"The intervention is structured in 14 weeks. Gradually the level of demand for the exercises increases over the weeks. Isometric and concentric exercises of the affected muscle groups are combined in the first weeks, as well as mobilization exercises of the joints involved in the injury. In addition, the time of permanence in a sitting, prone or supine position is prescribed. The return to the march and activities of daily life are staggered.~The number of series and repetitions to be performed is described in each exercise."
29045|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
29046|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
29047|NCT03959241|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. Methotrexate should be dose reduced, given with leucovorin rescue, or held for complications such as severe mucositis per institutional guidelines.
29048|NCT03959241|Procedure|Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide|Mobilized PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
29070|NCT03959098|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
29211|NCT03958136|Behavioral|Patient Reported Outcome (PRO)|Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.
29049|NCT03959241|Drug|Tacrolimus|Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
29050|NCT03959241|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
29051|NCT03959241|Drug|Cyclophosphamide|Cyclophosphamide [50 mg/kg ideal body weight (IBW); if actual body weight (ABW) < IBW, use ABW] will be given on Day +3 (between 60 and 72 hours after the start of the PBSC infusion) and on Day +4 post-transplant (approximately 24 hours after Day +3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
29052|NCT03959228|Drug|keto-analogs|The patients that will be included in the experimental arm will have additional keto-analogs (1 pill/5 kg).
29053|NCT03959215|Behavioral|Back in the Game|"A six-month programme of cognitive-behavioural therapy delivered by smartphone application. The intervention commences in the first week after ACL reconstruction. The smartphone app is delivered in parallel with usual rehabilitation care.~Usual rehabilitation care: all participants will be referred to physiotherapy following ACL reconstruction. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the treatment aims is at the clinical discretion of the treating physiotherapist."
29054|NCT03959215|Other|Usual rehabilitation care|Following ACL reconstruction, as per routine clinical practice, all participants will be referred to physiotherapy. Overall treatment aims, content and progressions of rehabilitation will follow current clinical guidelines. The choice of specific therapies, exercises and the number of treatment sessions needed to achieve the required treatment aims is at the clinical discretion of the treating physiotherapist.
29055|NCT03959202|Behavioral|ELDERFITNESS|In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps & minutes of moderate activity) using the smartwatch. . The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer. Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans.Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects.
29056|NCT03959202|Other|Control|General Education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life Program book from the National Institute on Aging
29057|NCT03959189|Drug|ERX-963|Active medicine
29058|NCT03959189|Drug|Placebo|Comparator
29059|NCT03959176|Drug|Brimonidine|2 drops administered once in the left eye in both study arms
29060|NCT03959176|Drug|Tropicamide|1 drop administered at two different times points in both eyes in both study arms
29061|NCT03959176|Drug|Phenylephrine Ophthalmic Product|1 drop administered at two different time points in both eyes in both study arms
29062|NCT03959163|Diagnostic Test|Quick MRI|"A quick MRI scan takes about 15 mins or less. No IV or sedation will be necessary. The participant will be required to lie flat and still during the test. A parent will be allowed to be with the participant while they are in the scanner. The machine will produce loud intermittent sounds of banging or knocking so they will have to wear protective headphones. They can listen to music if they would like. If they are less than 1 year old, they will be swaddled and can be held during the test. If a child needs to have a parent in the scanner, it is ideal if the parent can have their head near the participant's legs and arms stretched out to hold the child's hands. If the parent needs to be by the patient's head, it can be accomplished by the parent lying head to head with the child or the parent lying on the child. Ideally they are lying head to head, or just outside of the scanner reaching in."
29063|NCT03959150|Drug|Capecitabine|Oral fluorouracil
29064|NCT03959137|Other|None - Common practice|None - Common practice
29065|NCT03959124|Device|Deep brain stimulation|Brain stimulation electrodes at parameters 2.0~4.5 V；60 μs；20 Hz
29066|NCT03959124|Drug|Best medical treatment for Alzheimer's disease|Alzheimer's disease patients take medications including Exelon (Rivastigmine Tartrate), Witgen (Memantine) for at least 3 months without plan of dosage adjustment
29067|NCT03959111|Other|Stimulation at Location 1|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
29068|NCT03959111|Other|Stimulation at Location 2|Stimulation parameters will include 1) density wave adjusted to 20Hz with less than 1 ms pulse width, 2) intensity adjusted based on the tolerance of the patient (moderate tolerable stimulation without pain), and 3) treatment will be applied 1 time per day, 5 times per week for four weeks (on-site tVNS treatment plus self-administration at home).
29069|NCT03959098|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum,Eucommia ulmoides, canthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, aposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycinemax, Atractylodes japonica) at the physician's discretion.
29149|NCT03958656|Drug|Cyclophosphamide|300 mg/m^2 IV over 30 minutes on days -5, -4, and -3
29150|NCT03958656|Drug|Fludarabine|30 mg/m^2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
29071|NCT03959098|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, hinchang medical co., Korea).
29072|NCT03959098|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be dministered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
29073|NCT03959098|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
29074|NCT03959098|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
29075|NCT03959098|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
29076|NCT03959098|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
29077|NCT03959085|Drug|Cyclophosphamide|Given IV
29078|NCT03959085|Drug|Cytarabine|Given IV, IT, or SC
29079|NCT03959085|Drug|Daunorubicin|Given IV
29080|NCT03959085|Drug|Daunorubicin Hydrochloride|Given IV
29081|NCT03959085|Drug|Dexamethasone|Given PO or IV
29082|NCT03959085|Drug|Doxorubicin|Given IV
29083|NCT03959085|Drug|Doxorubicin Hydrochloride|Given IV
29084|NCT03959085|Biological|Inotuzumab Ozogamicin|Given IV
29085|NCT03959085|Drug|Leucovorin|Given PO or IV
29086|NCT03959085|Drug|Leucovorin Calcium|Given PO or IV
29087|NCT03959085|Drug|Mercaptopurine|Given PO
29088|NCT03959085|Drug|Methotrexate|Given IT or IV
29089|NCT03959085|Drug|Pegaspargase|Given IV or IM
29090|NCT03959085|Drug|Prednisolone|Given PO or IV
29091|NCT03959085|Other|Questionnaire Administration|Ancillary studies
29092|NCT03959085|Radiation|Radiation Therapy|Undergo testicular radiation therapy
29093|NCT03959085|Radiation|Radiation Therapy|Undergo cranial radiation therapy
29094|NCT03959085|Drug|Thioguanine|Given PO
29095|NCT03959085|Drug|Vincristine|Given IV
29096|NCT03959085|Drug|Vincristine Sulfate|Given IV
29097|NCT03959072|Device|Robotic CTO PCI|Randomized to robotic CTO PCI.
29098|NCT03959072|Procedure|Conventional (Manual) CTO PCI|Randomized to manual CTO PCI.
29099|NCT03959059|Device|Mixed Reality technology|combine image with real body
29100|NCT03959046|Behavioral|GIST|The GIST intervention will train physicians in an alternative way of communicating with their patients.
29101|NCT03959020|Procedure|Anti-reflux surgery|Anti-reflux surgery for verified GERD
29102|NCT03959007|Other|Aesthetic therapy sessions|Only for experimental arm at 3 times during hospitalization
29103|NCT03959007|Other|Questionnaire|Both arm at 3 times during hospitalization
29104|NCT03958994|Other|Qualitative interviews|What are the roles of organisational factors, education and policy in shaping the experiences of staff and carers who care for people with dementia?
29105|NCT03958981|Drug|Castor Oil|The intervention group will be given 60 mL of castor oil in 140 mL of orange juice
29106|NCT03958981|Drug|placebo|the control group will be given a sunflower oil as a placebo with a similar texture to castor oil
29107|NCT03958955|Drug|Delgocitinib cream|Cream for topical application.
29108|NCT03958955|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
29109|NCT03958942|Other|Ultrasound quadratus lumborum block with bupivacaine 25%|echogenic needle will be inserted in-plane with the ultrasound beam in a posterior-to-anterior direction through the quadratus lumborum muscle until the ventral fascia of the muscle penetrated. At this point, the needle directed toward the fascial plan between the quadratus lumborum and the Psoas muscle
29110|NCT03958942|Other|lumbar epideural block with bupivacaine 25%|lumbar epidural will be performed for patients in group II using a 16-gauge Touhy epidural needle by a median approach. The T12 - L1 or L1 - L2 interspaces will be chosen for the injection. The epidural space identified by the loss of resistance technique.
29111|NCT03958929|Other|Educational Video|The film follows the journey of an elderly patient scheduled to undergo glaucoma surgery, beginning with a face-to-face Q&A health session with an eye doctor. After surgery, the patient talks about his post-operative eyesight and discusses the benefits of early diagnosis and glaucoma surgery for treatment with his community.
29112|NCT03958903|Device|Amygdala recording and stimulation using Neuropace RNS|Subjects will undergo a series of different, fear-related, behavioral tasks while undergoing amygdala electrophysiology recording and stimulation using the Neuropace RNS devices.
29113|NCT03958903|Behavioral|Behavioral tasks|Subjects perform a set of fear related behavioral tasks over 2 days, with 3 tasks each day.In addition to amygdala RNS recording and stimulation, recording of electroencephalography (EEG), electromyography (EMG), and electrodermal activity (EDA) will be performed using standard techniques to capture and quantify the fear response across all tasks.
29114|NCT03958890|Drug|HLX10 100 mg in 10 ml Injection|3mg/kg IV（HLX10+cis-platinum+5FU）
29115|NCT03958890|Drug|Placebos|3mg/kg IV（placebo+cis-platinum+5FU）
29116|NCT03958877|Drug|BIIB017 (peginterferon beta-1a)|Administered as specified in the treatment arm
29117|NCT03958877|Drug|Interferon beta type 1a|Administered as specified in the treatment arm
29118|NCT03958864|Drug|CC-90001|CC-90001
29151|NCT03958656|Drug|Rimiducid|0.4 mg/kg of Rimiducid IV over 2 hours. (A maximum of 2 doses separated by at least 48 hours) Note: Rimiducid may be administered as needed based on the patient condition at the discretion of the Principal Investigator.
29152|NCT03958656|Biological|Anti-SLAMF7 CAR T cells|0.3x10^6- 12.0x10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
29153|NCT03958630|Drug|11C-ER176|PET biomarker for inflammation
29119|NCT03958851|Diagnostic Test|Doppler ultrasonography of renal arteries|"Ultrasound evaluation will be performed for all patients as well as healthy individuals.in patients with lupus nephritis,the ultrasound evaluation will be performed the 24 h prior to the renal biopsy . In the maximum long-axis section images, the largest diameter and width of each kidney will be measured. The participants will be scanned in a supine or decubitus position to achieve an ultrasound beam as close to parallel to the blood flow direction in the intrarenal artery as possible. RRI is measured as :~RRI = (peak systolic velocity - end diastolic velocity ) / peak systolic velocity. the average of three measurements will be taken."
29120|NCT03958851|Diagnostic Test|Renal biopsy|Renal biopsy is a medical procedure in which a small piece of kidney is removed from the body for examination, usually under a microscope. Microscopic examination of the tissue can provide information needed to diagnose, monitor or treat problems of the kidney.Renal biopsy will be taken according American college of Romatology guidelines 2012.The renal biopsy samples were evaluated according to the Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis 2017. the actvity index and chronicity index will be calculated.
29121|NCT03958851|Diagnostic Test|kidney function tests|blood sample will be taken to measure blood urea nitrogen (BUN) and serum creatinine(S Cr). estimated glomerular filtration rate (eGFR) will be measured using CKD-EPI Equation.These investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
29122|NCT03958851|Diagnostic Test|The 24-hour urine protein test|The 24-hour urine protein test checks how much protein is being spilled into the urine.Urine samples are collected in one or more containers over a period of 24 hours. The containers are kept in a cool environment and then sent to a lab for analysis. Specialists then check the urine for protein.This investigations will be done at the beginning of the study and every month for sex months for each patient to determine degree of response to treatment .
29123|NCT03958851|Diagnostic Test|complete blood counting (CBC)|A complete blood count is a blood panel that gives information about the cells in a patient's blood, such as the cell count for each blood cell type and the concentrations of hemoglobin.
29124|NCT03958838|Behavioral|Peer Support Integrated with Primary Care|Peer leaders will deliver support that address the four key functions of peer support, providing 1) assistance in daily self-management, 2) linkages to clinical care and community resources, 3) social and emotional support, and 4) ongoing, flexible support over time.
29125|NCT03958825|Procedure|laparoscopic hepatic sectionectomy|patients undergoing a laparoscopic left hepatic sectionectomy within an enhanced recovery after surgery programme
29126|NCT03958825|Procedure|open left hepatic sectionectomy|patients undergoing open left hepatic sectionectomy within an enhanced recovery after surgery programme
29127|NCT03958812|Diagnostic Test|Circulating tumor cells, Volatile organic compounds|Alveolar exhaled breath samples and peripheral venous blood(10ml) will be collected from each patients
29133|NCT03958786|Other|Simplified Geriatric Evaluation|"Questionnaires~Self assessment questionnaires~Mobility and balance tests"
29134|NCT03958786|Other|Sampling|- Blood samples : 35 ml will be collected at baseline, after signature of written informed consent
29135|NCT03958773|Device|Cardiovalve system|Cardiovalve System, comprised of: 1) Cardiovalve Implant; 2) Cardiovalve Delivery System (DS); 3) Cardiovalve Accessories.
29136|NCT03958747|Diagnostic Test|Ultrasound - Serial and Tibial Nerve|Participants will undergo a serial and tibial nerve ultrasound
29137|NCT03958747|Procedure|Skin Biopsy|Two skin biopsies will be obtained as 4.0 mm punch biopsies at distal end of leg in sural nerve territory (10 cm above lateral malleolus) and from the thigh
29138|NCT03958747|Other|Abbreviated Neurologic Exam|Exam to include strength assessment of the tibialis anterior and gastrocnemius and deep tendon reflex exam of the Achilles on the limb to be examined by nerve conduction velocity and ultrasound.
29139|NCT03958747|Other|Blood draw|12 ml blood sample will be taken
29140|NCT03958747|Diagnostic Test|Nerve Conduction Study|Sural and tibial nerve assessments
29141|NCT03958747|Other|QLQ-CIPN20 Questionnaire Administration|Self-reported neuropathy scoring questionnaire completed same day as blood draw.
29142|NCT03958734|Other|High-fat meal|Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
29143|NCT03958721|Drug|Capecitabine|1,000 mg/m2 twice daily taken by mouth every other week
29144|NCT03958721|Radiation|Radiotherapy|Once daily (Monday through Friday) for six weeks
29145|NCT03958708|Drug|Rifaximin 550 MG|Rifaximin 550 MG, TWICE A DAY, FOR 7 DAYS
29146|NCT03958695|Device|Tunable-tension transobturator tape, Urosling-T (Lintex, LLC)|A transobturator mid-urethral sling with the possibility of non-invasive tuning of its tension in the early postoperative period
29147|NCT03958695|Device|Transobturator mid-urethral tape, Urosling (Lintex, LLC)|A transobturator tension-free mid-urethral sling
29148|NCT03958682|Device|AR smart wearing equipment combined with 4G + satellite information transmission system|"We are going to add a pair of wearable smart glasses with AR function to the original flight helmet .During the rescue, the doctor is asked to wear the special helmet , through the device's camera system and headset, we can obtain graphics and sound of the helicopter cabin .At the same time, it also receives the historical data of patients and real-time diagnosis as well as rescue guidance from the ground medical institutions.~It can not only transmit the patient's information in the cabin to the ground medical institutions in real time, but also transmit the rescue plan of the ground medical experts to the rescue helicopter in real time to ensure the safety of patients in transit ,which will save the time for medical staff to hand over after landing and reduce errors."
29154|NCT03958630|Drug|11C-PIB|PET biomarker for amyloid
29157|NCT03958591|Drug|CSII and thereafter combination therapy with wearable devices|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Wearable devices and smart apps will be used to manage and follow-up patients.
29158|NCT03958591|Drug|CSII and thereafter combination therapy|Short-term continuous subcutaneous insulin infusion and thereafter the combination therapy of basal insulin, metformin and vildagliptin; Traditional ways such as telephone contact will be used to follow-up patients.
29159|NCT03958591|Drug|Traditionally upgrading therapy|Patients will be applied the combination therapy of basal insulin, metformin and vildagliptin for the entire 12 weeks. Traditional ways will be used to follow-up patients.
29160|NCT03958565|Biological|Tyrosine Kinase Inhibitor|Targeted therapy given as standard of care.
29161|NCT03958565|Drug|Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]|Given Q4 weeks as standard of care
29162|NCT03958565|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Given Q12 weeks for bone disease as standard of care
29163|NCT03958552|Other|Palliative Care Consultation|Trained provider will discuss illness trajectories, establish and communicate patient-directed goals that guide health care decisions, identify and treat illness-related symptoms, and identify psycho-spiritual needs and approaches to mitigate suffering.
29164|NCT03958539|Device|3D printed insoles for normal footware|"Imprints are low-cost, bespoke, 3D-printed orthotics designed to prevent diabetic foot ulceration by redistributing and lowering peak foot pressures. This is achieved by using different density zones designed specifically for the patient. The patient's foot shape and pressure zone are capture by a 3D imaging system. Once scanned the software automatically identifies the peak pressure zones, matches these with the correct material and stiffness (densities), fits the insole arch to the patient and generates the insole.~The imprints insole is divided into four pressure zones: heel, midfoot, metatarsal head region and toes. These zones are printed with different stiffness to account for the difference in loading between them. The design of the pressure zones is automatically matched to the shape of each individual foot with the help of the 3D scan."
29165|NCT03958526|Device|active tDCS|Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) contralateral to the most painful side with a constant current of 2 miliAmpers for 20 minutes.
29166|NCT03958526|Device|sham tDCS|Same protocol (electrode montage,session duration) will be used for sham stimulation. But the device won't be active for full 20 minutes.
29167|NCT03958513|Drug|Bupivacaine|1.5 ml 0.25% bupivacaine for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
29168|NCT03958513|Drug|0.9% normal saline|1.5 ml 0.9% NACl for 1 inch incision will be given before closure of ports in patients undergoing laparoscopic cholecystectomy
29169|NCT03958500|Procedure|Indocyanine green fluorescent angiography intraluminally and intraperitoneally|The use of indocyanine green fluorescent angiography to check bowel and anastomosis viability in standard low anterior rectal anastomosis
29170|NCT03958487|Behavioral|Video feedback, Feedback online|The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
29171|NCT03958474|Drug|Oxycodone|Participants receive oxycodone or placebo.
29172|NCT03958461|Procedure|Anti-infective treatment of periodontal pockets|Removing calculi from teeths' periodontal pockets
29173|NCT03958448|Procedure|Placement of extra short implants|placement of an extra short implant in the posterior edentulous ridge
29174|NCT03958448|Procedure|maxillary sinus lift, maxillary sinus elevation, maxillary sinus augmentation|
29175|NCT03958448|Procedure|placement of standard implant|placement of standard implant in the posterior edentulous ridge after maxillary sinus augmentation
29176|NCT03958422|Drug|cardiomyopeptidin|The main component of cardiomyopeptidin is the peptide active substance extracted from the ventricular myocytes of healthy young pigs.
29177|NCT03958409|Diagnostic Test|measurements to evaluate metabolic bone disease|The participants will be evaluated for a) Mineral metabolism: blood calcium, phosphorus, PTH, 25(OH) vitamin D; b) Bone turnover markers: bone-specific alkaline phosphatase, cross-linked C-telopeptide of type I collagen (CTx), and N-terminal propeptide of type I collagen (PINP); c) Bone Mineral Density using a Dual energy x-ray absorptiometry which is the standard method by which bone mass is measured clinically, we will measure bone mass at the lumbar spine, wrist, hip and total body bone mass at 3, and 18 months.
29178|NCT03958409|Diagnostic Test|standard care|Blood tests (Ca, Phos, PTH- mineral lab, 25OHVitD);Pregnancy Test (if applicable); dual energy X-ray absorptiometry (DXA); Bone Biopsy only if clinically indicated; treatment as clinically indicated.
29179|NCT03958396|Drug|Remifentanil Infusion|15 minute remifentanil Infusion of either 0.05, 0.1, 0.15 or 0.2 mcg/kg/min
29180|NCT03958383|Biological|hu14.18-IL2|A recombinant fusion protein linking the monoclonal antibody (mAb) hu14.18 with interleukin-2 (IL2), administered IT
29181|NCT03958383|Radiation|Radiation Therapy|Palliative radiation therapy
29182|NCT03958383|Biological|Nivolumab|Human programmed death receptor (PD-1) blocking antibody, given IV
29183|NCT03958383|Biological|Ipilimumab|Monoclinal antibody that targets cytoxic T-lymphocyte-associated protein 4 (CTLA-4), given IV
29184|NCT03958370|Other|Fitbit|Fitbit use during physical therapy session
29212|NCT03958123|Drug|100 μg cebranopadol|Encapsulated 100 μg cebranopadol tablet.
29213|NCT03958123|Drug|200 μg cebranopadol|Encapsulated 200 μg cebranopadol tablet.
29214|NCT03958123|Drug|400 μg cebranopadol|Encapsulated 400 μg cebranopadol tablet.
29215|NCT03958123|Drug|Placebo to cebranopadol encapsulated tablets|Matching placebo to cebranopadol encapsulated tablet.
29185|NCT03958357|Device|Advanced Gynecological Applicator configuration|The Advanced Gynecological Applicator Venezia configuration is a gynaecological applicator for intracavitary and interstitial brachytherapy. The applicator consists of tubes, caps and templates to place needles, which can be combined to reach a wide range of target areas. The tubes and possibly used needles, guide the radioactive source of the afterloader to the target volume. Dose optimization and dose fractionation is performed with the goal of adapting the dose to the target volume without exceeding the dose volume constraints for the surrounding normal tissues according to the standard cervical cancer treatment of the centre.
29186|NCT03958344|Drug|Prednisolone|Oral Tablet
29187|NCT03958344|Drug|Triamcinolone + Betamethason|A compound long acting and short acting injectable steroid
29188|NCT03958331|Behavioral|Automated Digital Reminders|Reminders from electronic monitors via texts or alarms/lights
29189|NCT03958331|Behavioral|Individualized Adherence Feedback Report|Feedback report on individual adherence behaviors
29190|NCT03958331|Behavioral|Individual Adherence Feedback Report with Social Norms|Feedback report on individual adherence behaviors compared to other adolescents with epilepsy
29191|NCT03958318|Other|Exercise plus nutritional suplementation|For 6 months, all participants in the exercise plus nutritional supplementation group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
29192|NCT03958318|Other|Exercise|For 6 months, all participants in the exercise group will be performing a three-week non-consecutive exercises programme at the facility. All exercises will be undertaken in a large indoor room. The exercise routine will be based on the Otago exercise programme.
29193|NCT03958305|Procedure|RADICAL HYSTERECTOMY|Radical hysterectomy is an operation done to treat some cancers of the cervix. The surgeon takes out the uterus and the ligaments (tissue fibers) that hold it in place. The cervix and an inch or 2 of the vagina around the cervix are also removed.
29194|NCT03958292|Device|IODIM|Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
29195|NCT03958279|Diagnostic Test|Ultrasound measurement of residual volume in the urinary bladder|Aim of this study is to asses post voiding residual volume by ultrasound scan 3th day after delivery with consecutive scan after 6 weeks, and determination of data dispersion among the population of primiparas.
29196|NCT03958279|Diagnostic Test|Questionnaire|Simple questionaire concerning voiding problems, infectious complications, medicaments and breastfeeding during puerperium period (6weeks)
29197|NCT03958266|Device|MyIBD Care|Novel mobile phone application
29198|NCT03958253|Other|Toolbox for Lung Cancer Screening|"-Toolbox of evidence-based elements that a primary care or referral site could implement to address known barriers to screening and referral, as well as required elements for screening. These elements will be designed to be adaptable to the unique needs and screening processes of the participating practices.~Patient education materials~Primary care practice educational materials~Pack-years/eligibility calculator~Local referral process guide~Smoking cessation materials and support~Shared decision-making guide~LDCT best practice guidelines"
29199|NCT03958240|Other|Blood samples, tumor biopsy specimens and ascites samples will be collected.|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~at Baseline,~every 6 months (± 1 month) during the planned visits in the center for clinical standard care and for a maximum follow-up period of 5 years from baseline.~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study at baseline and at the time of progression."
29200|NCT03958227|Other|Manuel Therapy plus Exercise Intervention|Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
29201|NCT03958227|Other|Exercise Intervention|Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
29202|NCT03958214|Behavioral|Recipe 4 Success|Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.
29203|NCT03958214|Behavioral|Usual practice Early Head Start|Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
29204|NCT03958201|Drug|Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
29205|NCT03958188|Other|Standardized computerized tomography (CT) reading grid for preoperative planning|"Using the standardized reading grid, the following data will be collected:~Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~Mesentery: moniliform venous dilatations, combed appearance.~Duodenal invasion.~Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital."
29206|NCT03958175|Other|Alouette test (reading test)|The alouette test was assessed at a fixed distance of 40 centimeters on a fixed surface to avoid errors related to hand tremors.
29207|NCT03958162|Diagnostic Test|lung biopsy|transbronchial lung cryobiopsy
29208|NCT03958149|Device|spinal collar|cervical collar to immobilise the cervical spine
29209|NCT03958136|Procedure|Metastasis biopsy|Metastasis biopsy will be performed for multi-omic analysis
29210|NCT03958136|Biological|Biomarkers blood, urine and microbiota samples|Biomarkers blood, urine and microbiota samples for multi-omic analysis
29217|NCT03958123|Drug|Placebo to moxifloxacin encapsulated tablets|Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
29218|NCT03958110|Diagnostic Test|OCT A|OCT (Optical Coherence Tomography) and Retinophotography made at the beginning and end of the Rugby season.
29219|NCT03958097|Combination Product|NK cell and PD-1 antibody|Each patient enrolled the study will received both NK cell and PD-1 antibody.
29220|NCT03958084|Diagnostic Test|Straight Leg Raise|The assessment of the flexibility of the hamstring will be realized through the test of straight leg raise (SLR). The SLR is a passive test performed unilaterally.
29221|NCT03958071|Drug|Nintedanib|Nintedanib initiators
29222|NCT03958071|Drug|Pirfenidone|Pirfenidone initiators
29223|NCT03958071|Other|Untreated Cohort|Untreated
29224|NCT03958058|Drug|Anti-borrelial antibiotic therapy|Beside symptomatic therapy, patients received oral doxycycline 100 mg (Doxy®) twice daily or ceftriaxone 2 g (Lendacin®) once daily for 14 days. Antibiotic therapy was left to the discretion of treating physicians. Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
29225|NCT03958058|Other|No antibiotic.|Patients who received symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline). Patients reported the presence of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
29226|NCT03958045|Combination Product|Rucaparib and Nivolumab|Rucaparib (600mg BID) and Nivolumab (480mg IV q4 wk)
29227|NCT03958032|Other|No intervention|No intervention is planned for the participants for the treatment of gastric cancer. Treatment decision will be in line with clinical practice guidelines. Surgical team will be blind to the participant's sarcopenia status.
29228|NCT03958019|Other|RESTORE II Program|Detailed in arm description
29229|NCT03958006|Device|Cochlear implant|Tumor resection with cochlear implant
29230|NCT03957993|Other|Occupational Therapy via Telehealth|The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.
29231|NCT03957993|Other|Standard of Care Occupational Therapy|The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
29232|NCT03957980|Other|Occupational therapy|Child/caregiver dyads in this group will participate in telehealth-based intervention sessions in their home environment. Each child/caregiver dyad will participate in up to 9 interventions sessions. All intervention sessions will last 30-60 minutes. The intervention sessions will focus on task analysis, caregiver coaching, parent education and recommendations for task and home/environmental modifications to promote the child's functional vision.
29233|NCT03957967|Other|video taken|Patients enrolled will be operated in our institution. Facial expression will be collected before and after surgery, and pain intensity will be collected at the same time. Facial expression will be analyzed using Facial Action Coding System (FACS) .This step will seek to confirm that the subset of Action Units (AUs) defined in previous studies is correlated with the presence and intensity of an acute pain or to identify a different original subset of facial AUs better correlated to pain intensity. . The developed algorithm (or model) here should be able to correlate facial AUs to pain intensity reported by the patients on the numerical rating scale. The developed model at this stage will be then validated on an additional sample of patients.
29234|NCT03957954|Biological|cLSC|Transplantation of cLSC
29235|NCT03957954|Device|Scleral contact lens (SCL)|Scleral contact lens device (SCL) will be used to stabilize and improve ocular surface.
29236|NCT03957941|Behavioral|FamilyLink Pumping|Viewing baby via FamilyLink while pumping
29237|NCT03957941|Behavioral|Standard Pumping|Not viewing baby via FamilyLink while pumping
29238|NCT03957928|Other|Low fat cookie|to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults
29239|NCT03957928|Other|Mango fruit|to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
29240|NCT03957915|Drug|INA03 administration|INA03 will be administered IV on Day 1, Day 14 of 28-day cycles. The administration of INA03 will begin at 0.1 mg/kg. Study Part I is a titration study to determine the dose for the first INA03 infusion. Patients will be enrolled in sequential cohorts of 2 patients to receive ascending starting doses of INA03, starting from the lowest starting dose (0.1 mg/kg), and followed by subsequent administrations of INA03 (D14 and beyond) at a fixed dose of 0.1 mg/kg. The starting dose will be increased every cohort of 2 patients until evidence of absence of marrow residual erythroblasts by D14 myelogram. This dose is referred to as the MEID and will be selected as the D1 dose for the study Part 2. Patient accumulation in Part I of the study will continue until no evidence of non-hematological DLT within 28 days post dosing
29241|NCT03957902|Drug|acetylsalicylic acid|Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
29242|NCT03957889|Other|Educational simulation|
29243|NCT03957876|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin.
29244|NCT03957863|Biological|Plasma collection for EPO assay|Plasma collection for EPO assay
29245|NCT03957850|Behavioral|Cognitive Reappraisal Training|The training procedure is adapted from a study by Denny & Ochsner (2014). Before the task, participants are instructed that they will be presented pictures and that these pictures will be preceded by a condition specific cue signaling the appropriate strategy during picture viewing. Participants are instructed to indicate their affective response to the image on a rating scale. The task involves 4 conditions: 1) Negative-decrease: participants are asked to view negative pictures and to decrease their affective response by reappraising the negative event. 2) Negative-attend/ 3) Neutral-attend/ 4) Positive-attend: participants are asked to view pictures and to respond naturally to them without trying to alter their affective response. The training task will be repeated over 4 training sessions.
29246|NCT03957850|Behavioral|Control Training|The task in the control group is implemented to account for unspecific effects and is as similar as possible to the CR task except that it involves no negative-decrease (i.e., no reappraisal) condition. Instead, the control task only involves the three attend conditions (negative- attend, neutral-attend, positive-attend).
29306|NCT03957395|Device|Device: Precision Novi™ system Neurostimulation procedures|SCS with Device: Precision Novi™ system
29247|NCT03957837|Diagnostic Test|Optical nerve sheath diameter ultrasound measurement|"In cases: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline before the induction of general anesthesia (5 min after the beginning of mechanical ventilation in supine position); (T2) after 10 min from 25 degrees head down positioning and with pneumoperitoneum insufflation; (T3) after 60 min from T2, in head down position; (T4) after 10 min from tracheal tube removal, in supine position.~In healthy controls: ultrasound measurement of the diameter of the optical nerve sheath at (T1) baseline in supine position; (T2) after 10 min from 25 degrees head down positioning; (T3) after 60 min from T2, in a head down position; (T4) after 10 min from positioning supine"
29248|NCT03957824|Diagnostic Test|PREVENTION-ACHD risk score|The predicted risk of sudden cardiac death according to a risk score will be tested by the actual rate of sudden cardiac death
29249|NCT03957811|Other|Whole body Vibration exercise|Intervention will consist of sessions of exercise on a whole body vibration platform, three times a week for 12 weeks.
29250|NCT03957798|Behavioral|RecoveryWarrior 2.0|"RecoveryWarrior 2.0 was developed for use with Microsoft Kinect running on a Windows personal computer. All games made use of whole-body motion detection and the same voice-recognition feature. Body motions included a variety of arm, leg, and whole-body movements to physically enact the motions of destroying or evading images of drugs and drug paraphernalia. Voice features consisted of recognition of the refusal phrase I'm Clean Players could say or shout I'm Clean in order to gain additional strength for their game play avatar. All game art was created in a hyperrealistic, idealized, heroic style."
29251|NCT03957785|Device|AlterG Treatment|All participants practiced one session a day of AlterG or TGT (for 40min), six days a week, for four weeks (for a total amount of 24 sessions). All patients were trained using BWS, FAC-tailored physiotherapist assistance, and treadmill speed (S) to allow the participant to walk with the intermittent support of one physiotherapist to help with balance and coordination (FAC 2), with the visual supervision of one physiotherapist (FAC 3), or independently without using the handrails (FAC 4). BWS, physiotherapist assistance, and S were checked and adapted to subjects' progresses across the AlterG sessions. A qualitative (using FAC) and quantitative (spatio-temporal parameters and dynamic electromyography) gait assessment before and after the end of the monthly LBPP gait training was carried out.
29252|NCT03957772|Procedure|Extrafascial injection|Extrafascial injection of local anaesthetic under ultrasound guidance
29253|NCT03957772|Procedure|Intrafascial injection|Intrafascial injection of local anaesthetic under ultrasound guidance
29254|NCT03957759|Diagnostic Test|Structured self-monitoring during an altitude ascent and stay at high altitude|Structured self-monitoring by a symptom checklist in combination with a pulse oximeter worn at the wrist in lowlanders with COPD ascending from low altitude (760m) to high altitude (3100m).
29255|NCT03957746|Other|Resistance training|3, 6 or 9 sets of biceps curl with elastic bands at 20 repetition-maximum (RM)
29256|NCT03957733|Drug|Chemotherapy|Long course CRT is followed by 4 cycles of combination chemotherapy of modified FOLFOX6 or 3 cycles of XELOX (capecitabine and oxaliplatin) and then surgery
29257|NCT03957720|Drug|DMPS|Dosage Form: DMPS: 500-1000mg per day,DMPS Frequency:BID,DMPS Duration: 6 days;
29258|NCT03957720|Drug|Penicillamine|Dosage Form: Penicillamine: 250-1500mg per day, Frequency:TID,Duration: 5 years;
29259|NCT03957720|Drug|DMSA|Dosage Form: DMSA: 750-1000mg per day,DMSA Frequency:BID,DMSA Duration: 5 years; Dosage Form: DMSA: 35mg/kg per day,DMSA Frequency:BID,DMSA Duration: 5 years;
29260|NCT03957720|Drug|Zinc gluconate|Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:BID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 140mg per time,Zinc Frequency:TID,Zinc Duration: 5 years; Dosage Form: Zinc gluconate: 210mg per time,Zinc Frequency:TID,Zinc Duration: 5 years;
29261|NCT03957707|Procedure|stereotactic surgery plus thrombolysis|stereotactic puncture and aspiration to evacuate basal ganglion hematoma with or without thrombolytic agent
29262|NCT03957694|Drug|Romiplostim|Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.
29263|NCT03957681|Drug|KHK4827|210 mg Q2W, SC
29264|NCT03957681|Drug|Placebo|Q2W, SC
29265|NCT03957668|Drug|PEG 3350|PEG 3350 17 g once daily for 14 days
29266|NCT03957668|Drug|Lactulose|Lactulose 10 g once daily for 14 days
29267|NCT03957655|Biological|2 times SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 2 times at week 0, 4
29268|NCT03957655|Biological|4 times SHED group|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 2 times at week 0,4,8,12
29269|NCT03957629|Drug|Tenofovir Disoproxil Fumarate|Oral medication of Tenofovir Disoproxil Fumarate 300mg once per day.
29270|NCT03957629|Drug|PEG-Interferon alfa 2a|Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
29271|NCT03957603|Dietary Supplement|Enteral Nutrition Suspension (TFP-DM)|Individualized dietary and lifestyle intervention combined with the recommendation of Enteral Nutrition Suspension (TPF-DM, Diason 0.75 kcal/ml)
29272|NCT03957603|Behavioral|Medical Nutrition Therpay|Individualized dietary and lifestyle intervention
29273|NCT03957590|Drug|Tislelizumab(BGB-A317 combined with chemoradiotherapy.|Tislelizumab with concurrent chemoradiotherapy
29274|NCT03957590|Drug|Placebo combined with chemoradiotherapy|Placebo with concurrent chemoradiotherapy
29275|NCT03957577|Other|Modified American Thoracic Society and National Heart and Lung Institute-Division of Lung Disease Respiratory (Mod. ATS-DLD-078)|The medical, family, smoking and occupational history of subjects will be assessed using Mod. ATS-DLD-078 questionnaire. It will be used to collect the subject's history of selected respiratory symptoms and respiratory events as well as key comorbidities.
29276|NCT03957577|Other|Modified Medical Research Council (mMRC) Dyspnea Scale|The severity of dyspnea attributable to respiratory diseases including COPD will be assessed using a 5-point mMRC dyspnea scale ranging from 0 (breathless only with strenuous exercise) to 4 (too breathless to leave the house).
29277|NCT03957577|Other|Exacerbations of Chronic Pulmonary Disease Tool (EXACT)|EXACT is a validated, self-administered, 14-item daily diary that assesses 11 respiratory symptoms and 3 additional symptoms, which together characterize COPD exacerbations. This will be completed by subjects daily using their electronic diary (eDiary). The EXACT total score will range from 0 to 100, with higher scores indicating a more severe condition.
29278|NCT03957577|Other|COPD Assessment Test (CAT)|The CAT is a validated measure of health status in COPD. It is an 8-item, subject-completed instrument that covers symptoms such as cough, phlegm, chest tightness and breathlessness, and disease impacts including physical activity, confidence, sleep and energy. Subjects will be asked to score each item on a scale ranging from 0 (no symptom or impact at all) to 5 (maximal symptom or impact).
29279|NCT03957577|Other|Evaluating Respiratory Symptoms in COPD (E-RS: COPD)|The E-RS: COPD comprises 11 of the 14 items of the parent EXACT that are specifically related to respiratory symptoms and will be completed using the eDiary. The RS-Total score is computed by taking the sum of the items comprising the instrument, with scores ranging from 0 to 40, with higher scores indicating more severe respiratory symptoms.
29280|NCT03957577|Other|Telephonic interviews|During the telephonic interviews, the potential AECOPD will be confirmed according to the AECOPD criteria, and if confirmed, the severity will be assessed according to healthcare utilization as mild, moderate or severe.
29281|NCT03957577|Other|Electronic Diary (eDiary)|Subjects will be asked to complete their eDiary every evening before bedtime. The eDiary consists of a total of 20 questions, which include screening questions for the detection of AECOPD during the study and the EXACT.
29282|NCT03957577|Diagnostic Test|Chest X-ray|A chest x-ray will be used at Screening visit to assess the subject's eligibility to participate in the study. A local radiologist will review the x-ray and notify the investigator of any abnormalities not considered to be caused by COPD.
29283|NCT03957577|Diagnostic Test|Spirometry|Spirometry measurements will be obtained using spirometry equipment. At least 3 acceptable spirometry efforts (with no more than 8 attempts) will be obtained.
29284|NCT03957577|Other|Sputum Sampling|Sputum samples will be collected from the subjects and will be analyzed for the presence and quantity of specific cell types and biomarkers to investigate the etiology of the AECOPD.
29285|NCT03957577|Other|Blood sampling|Blood samples will be collected from the subjects during the study and will be analyzed for the concentration of biomarkers to investigate the etiology of the AECOPD.
29286|NCT03957564|Drug|Neoadjuvant chemotherapy with PSOX regimen.|"Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle."
29287|NCT03957564|Other|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in plasma.|Detect the imaging data and levels of CTC, ctDNA, cfDNA, CEA, CA19-9, CA72-4 in 3 time points：Before neoadjuvant chemotherapy, After 2-3 cycles of neoadjuvant chemotherapy, 10 days after operation.
29288|NCT03957564|Other|Detect the tumor related DNA in pathological tissues after operation.|Detect the tumor related DNA in pathological tissues after operation.
29289|NCT03957564|Other|Follow-up of DFS and OS in patients with gastric cancer after operation.|Follow-up of DFS and OS in patients with locally advanced or resectable gastric or gastro-oesophageal Junction cancer.
29290|NCT03957551|Drug|Cabozantinib|"Cabozantinib is an oral small molecule potent inhibitor of pro-invasive receptor tyrosine kinases (RTKs).~Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day, in combination with pembrolizumab. The drug is taken continuously for 21 days or 3 weeks. This period of time is defined as one treatment cycle."
29291|NCT03957551|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody which will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks in combination with cabozantinib.
29293|NCT03957525|Other|Pre-Operative Preparatory Virtual Reality Program|The Influence of a Pre-Operative Preparatory Virtual Reality Program on the Self-Assessed Anxiety of Children Undergoing Elective Surgery
29294|NCT03957512|Procedure|Heart surgery|All invasive procedures
29295|NCT03957499|Drug|Bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml of normal saline (total volume 30 ml).(
29296|NCT03957499|Drug|Dexamethasone/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed with 28 ml bupivacaine 0.25% + 2 ml dexamethasone (8mg) (total volume 30 ml)d using
29297|NCT03957499|Drug|Magnesium Sulfate/bupivacaine|Ultrasound guided fascia iliaca compartment block (FICB) will be performed using 28 ml bupivacaine 0.25% + 2 ml magnesium sulphate (200mg) (total volume 30 ml).
29298|NCT03957486|Other|arterila cannulation on same arm|arterila cannulation on same arm receiving continous hemoglobin monitoring
29299|NCT03957486|Other|arterila cannulation on different arm|arterila cannulation different arm receiving continous hemoglobin monitoring
29300|NCT03957473|Device|Indigo Aspiration System|Indigo Aspiration System with CAT RX Aspiration Catheter and optional Indigo Separator 4
29301|NCT03957460|Other|SpHb monitoring|Subjects receive the continuous and noninvasive hemoglobin monitoring (SpHb monitoring).
29302|NCT03957447|Other|thermotherapy (application of heat)|Heat treatment is applied for 42 days plus a safety margin of up to 14 days, if ulcer margins have not fully collapsed and/or induration has not fully subsided. Treatment terminates earlier, if a lesion is completely closed. Thermotherapy will be applied with heat packs twice daily.
29303|NCT03957434|Other|Physiotherapy|Education, pelvic floor muscle exercises with biofeedback and home exercises.
29304|NCT03957421|Other|aquatic exercise, land based exercise|general warm up and cool down. general exercises and treadmill training at self-selected intensity.
29305|NCT03957408|Device|Visual Stimuli|Subjects will be presented various visual stimuli and may be asked to perform tasks. Their accommodative response will be measured.
29458|NCT03956199|Procedure|pulpotomy|removal of the pulp from pulp chamber
29307|NCT03957382|Device|Accero® Stent|The Accero® Stent will only be used in line with the Instructions For Use (IFU). Patients participating in this PMCF (Post- Market Clinical Follow-up) will not be exposed to any additional risk. There are no additional treatments or investigations other than done in the clinical routine.
29308|NCT03957369|Diagnostic Test|HIV-1 plasma RNA Genotyping secuencing by Sander|After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
29309|NCT03957369|Diagnostic Test|Proviral DNA genotyping sequencing|Sequencing for resistance-associated mutations will also be performed in proviral DNA to correlate with results from plasma RNA
29310|NCT03957356|Device|HLBLS-200|The amount of HLBLS-200 applied will be determined by the investigator based on the resection area.
29311|NCT03957343|Device|Pacing and Planning App|Participants will download and use the Pacing and Planning app. The app will be used to track and monitor their daily tasks and symptoms at any time, for as long as they would like to use the app. While using the app, participants will also fill out short assessments, including the Rivermead Post-Concussion Questionnaire once a month (to monitor symptoms) and an overall symptom question once a week (to rate how they feeling in general from a lot better to a lot worse).
29312|NCT03957330|Behavioral|Internet-delivered cognitive behaviour therapy|All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend ~15 mins. per week/per client.
29313|NCT03957317|Other|Eye mask and ear plugs|Subjects receive one pair of eye mask and ear plugs during their stay in the surgical ICU.
29314|NCT03957304|Drug|Dexmedetomidine|Intranasal dexmedetomidine
29315|NCT03957291|Drug|Chlorhexidine|chlorhexidine administration prior to ophthalmic surgery (compared to Povidine iodine )
29316|NCT03957291|Drug|Povidone-Iodine|Povidine iodine administration prior to ophthalmic surgery (compared to chlorhexidine)
29317|NCT03957278|Device|DAISe System|The DAISe System is indicated for revascularization of patients with acute ischemic stroke for the removal of fresh thrombi from vessels in the neurovasculature.
29318|NCT03957265|Procedure|Tapered abutment connection|Rehabilitation of completely edentulous patients with overdentures prostheses.
29319|NCT03957252|Diagnostic Test|Blood test: ClarityDX Prostate|Extracellular Vesicle profiling on patients who are suspected to have prostate cancer and will undergo a prostate biopsy. ClarityDX Prostate Risk Score will be compared with biopsy results to assess its predictive accuracy.
29320|NCT03957239|Other|Cranberry Beverage|The cranberry beverage will provide 50 kcals and 4.0 grams of fiber per day from whole milled cranberries, water, cranberry natural flavor and sucralose.
29321|NCT03957239|Other|Control Beverage|The control beverage will provide 50 kcals per day and is a color, taste matched sugar sweetened beverage formulated with water, sucrose, citric acid, cranberry natural flavor, malic acid, xanthum gum, sucralose and artificial color (red 40, blue 1).
29322|NCT03957226|Device|e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)|The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
29323|NCT03957213|Device|Acute Intermittent Hypoxia|Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
29324|NCT03957213|Behavioral|Computerized Cognitive Training|60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
29325|NCT03957187|Diagnostic Test|Ferritin, iron and iron binding capacity, high sensitive C-reactive protein (CRP) measurement|"Ferritin, iron and iron binding capacity will be measured for evaluation of ID using Cobas c-e and Elecsys.~The relation of inflammation to iron deficiency will be evaluated by high sensitive C-reactive protein measurement."
29326|NCT03957174|Drug|Reboxetine|Single dose used to increase central norepinepherine
29327|NCT03957174|Drug|Rivastigmine|Single dose to increase central acetylcholine
29328|NCT03957174|Drug|Placebo oral tablet|Single dose as control condition
29329|NCT03957161|Other|Continuation of ACEi and/or ARBs|Patients will continue or start taking ACEi and/or ARBs
29330|NCT03957148|Behavioral|Sugar-sweetened beverage reduction education for preschool children|Participants in the SSB-IMB program will receive 10 weeks of SSB related nutrition education at their child's preschool. Each week a different lesson pertaining to parental information, motivation, or behavioral skills related to SSBs will be presented via an interactive display board. Twice a week, two student educators will stand by display boards for two hours and deliver the lessons that will last 5-10 minutes with each parent. These displays will include an activity for parents to apply knowledge and skills learned during the short lesson. Educators will also provide parents with informational handouts pertaining to each lesson to reinforce concepts learned. Display board education is flexible, so that if a parent arrives while another parent is receiving education, the second educator can begin the lesson with the new parent. Multiple parents can participate in a lesson at the same time. Groups of 2-3 parents can review the lesson together, learning from each other.
29331|NCT03957135|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer
29332|NCT03957135|Procedure|open distal pancreatectomy|Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
29333|NCT03957122|Device|repetitive transcranial magnetic stimulation|"Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation~2000 pulses~intensity of 110% resting motor threshold~10 sessions (daily from Monday to Friday)~positioning of coil according to EEG position CP5/CP6"
29334|NCT03957109|Procedure|general anesthesia|
29336|NCT03957083|Drug|Oxytocin|Oxytocin administered intravenously, over 1 minute following delivery of the fetal head
29337|NCT03957070|Device|Liver Incyte|Ultrasound elasticity imaging
29338|NCT03957057|Drug|Iron Carboxymaltose|Intravenous iron carboxymaltose application
29339|NCT03957057|Drug|Iron Isomaltoside|Inravenous iron isomaltoside application
29340|NCT03957057|Drug|Ferrous sulphate|Oral ferrous sulphate application
29341|NCT03957044|Other|the education of sensory entegration with vestibular education|"Tactical, proprioceptive, visual and auditory senses were used in sensory integrity training sessions. In this group, the training program on tactile, proprioceptive, visual and auditory sensory activities was carried out for 2 weeks and 40 minutes. Sensory integrity training was performed by the physiotherapist and in the sensory room.~At the end of the training sessions, mothers were informed about the application of sensory integrity training to daily activities.Sensory integrity therapy room added tactile, proprioceptive, visual and auditory sensory materials as well as materials for vestibular sensation. Vestibular sensory materials, skateboard, swing, hammock, bowl, ball, ball pool, slide, climbing bar, thrombolin and balance board were used."
29342|NCT03956992|Other|Mouth gel|Stop using the mouth gel
29343|NCT03956979|Drug|JM-010 A group|JM-010 fixed combination drug(4/0.8mg) + Placebo 2
29344|NCT03956979|Drug|JM-010 B group|JM-010 fixed combination drug (8/0.8mg) + Placebo 1
29345|NCT03956979|Drug|Placebos|Placebo 1 + Placebo 2
29346|NCT03956966|Drug|TQL block with saline|"drug: saline 21 ml 0.9% normal saline administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac analgesia In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block, ultrasound-guided"
29347|NCT03956966|Drug|TQL block with Bupivacaine|"Drug: saline~1mL 0.9% normal saline administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol 15 mg.kg will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
29348|NCT03956966|Drug|TQL block with Bupivacaine and dexamethasone|"Drug: dexamethasone~1 mL dexamethasone 4mg administered on each side as bilateral TQL blocks drug: Bupivacaine 20 ml Bupivacaine hydrochloride 0.25% administered on each side as bilateral TQL blocks Drug: fentanyl With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, fentanyl boluses (0.5 microgram.kg) will be given in case of increase in MBP or HR of more than 20% of baseline for longer than 5 minutes.~Drug: Paracetamol Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia. Postoperatively, 1 g of paracetamol will be given by intravenous infusion to all cases every 8 hours.~Drug: Ketorolac In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases Drug: Nalbuphine Nalbuphine boluses 0.1 mg. /kg will be given as rescue analgesia if VAS is more than 3.~Device: ultrasound-guided nerve block Transmuscular quadratus lumborum block"
29349|NCT03956953|Drug|BMS-986165|Dose 1 or Dose 2 on Day 1, and from Days 5-19'
29350|NCT03956953|Other|Placebo|Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
29351|NCT03956940|Device|Intplex test|Blood sample at baseline, 15 days, 4-8-16 weeks and then every 12 weeks
29352|NCT03956927|Other|S-TPE|S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
29353|NCT03956927|Other|Questionnaires|Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
29354|NCT03956914|Other|Placebo|Placeob water 440 ml/day for 8 weeks
29355|NCT03956914|Other|Deep sea water|Deep sea water 440 ml/day for 8 weeks
29356|NCT03956901|Other|pvi guided fluid management|"GDFM Group: 500 ml bolus crystalloid after~2 ml \ kg crystalloid infusion to be started~If PVI <13 MAP is <65 mmHg, continue infusion of fluid, 1-2 µg NE bolus to be entered after 5 min.~PVI <13 MAP> 65 mmHg to continue fluid infusion If PVI> 13 MAP <65 mmHg, 250 ml bolus crystalloid \ colloid will be given and bolus 1-2 µg NE, If it continues after 5 minutes, liquid and NE doses will be repeated. Liquid treatment will be continued until PVI <13.~PVI> 13 MAP <65 mmHg 250 ml bolus fluid to be given, if continued 5 minutes later to be repeated,repetition of fluid will continue until PVl <13."
29357|NCT03956888|Drug|N-acetylcysteine|All COPD patients will be treated with N-acetylcysteine at the dose of 1200 mg per day (600 mg three times a day) for 4 weeks in addition to their current COPD medications without other mucolytic agents
29358|NCT03956875|Other|yoga|yoga is a mind-body practice that guides the body through a series of poses and breathing exercises
29359|NCT03956862|Drug|GB001|GB001 taken orally on a daily basis
29360|NCT03956862|Other|Matched Placebo|Matched placebo control taken orally on a daily basis
29459|NCT03956199|Procedure|Root canal treatment|Removal of at the entire content of the root canal system and root canal obturation
29361|NCT03956849|Other|Training COACH Conversationstarter|"After elaborating perceived barriers and facilitators via surveys and semi-structured focusgroups, a short training with the COACH Conversationstarter will be provided to a part of the participants. The COACH Conversationstarter will be provided to the participants attending the training, which they can use in the next couple of months. After a period of time all participants will be provided with a second questionnaire, and results of the group that received the COACH Conversationstarter will be compared with the group that didn't receive the COACH Conversationstarter. (A part of) the participants that used the COACH Conversationstarter will be interviewed about their experiences.~However, the study will have an observational design, since the decision if a professional is attending the training is not based on the investigator / protocol, but depending on the professional, for example logistic reasons. This is part of routine education."
29362|NCT03956836|Diagnostic Test|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII|ROTEM parameters, platelet function assay (PFA-100), von Willebrand and Factor XIII at baseline (before surgery) and after 4h and 48 after surgery in 40 patients undergoing CRC
29363|NCT03956823|Drug|telmisartan|Telmisartan group: telmisartan 80 mg once a day
29364|NCT03956823|Drug|amlodipine|amlodipine group: amlodipine 5 mg once a day
29365|NCT03956810|Other|On-demand transportation|On-demand scheduling via telephone, web portal, or the broker's mobile application.
29366|NCT03956810|Other|Usual transportation|Usual transportation scheduling via call-center.
29367|NCT03956797|Device|Recens Cooling Anesthesia Device|Application of cooling anesthesia device prior to intravitreal injection
29368|NCT03956784|Device|E-assessed clinical and biological follow up|"Clinical questionnaire: self-evaluation of pain (0 to 10), resumption of transit, bleeding, fever, pulse. In case of no filling, the patient is contacted.~An automatic alert system is defined and divide the patient according to three situations:~Normal situation~Situation requiring the nurse to call back the patient and contact the surgeon if the assessment requires medical advice~Disturbing situation requiring contact of the first-line surgeon if a potentially serious event is suspected. Each speaker's place is described for each item in the detailed protocols~Biological questionnaire:~Biological monitoring (blood count, Ionogram, C-Reactive Protein, urea, creatinine) is performed on D1, D3 and D7.~All information is accessible in real time by the surgeon who receives notifications by email and on his smartphone in case of clinical or biological abnormality on patient monitoring."
29369|NCT03956784|Other|Usual at home follow up|"An information sheet on the clinical parameters to be monitored will be given to patients and will include the following information:~Immediate complications and warning signs:~Tachycardia> 120 bpm~Dyspnea~Rectorragies and / or melena~Vomiting with or without presence of blood~Major abdominal pain (visual analogue scale> 6/10)~Fever> 38~Management to deal with complications: call the service and / or the surgeon~Actions to be performed by the patient after the exit:passage of the nurse during 10 days for anticoagulant morning and evening (identical in both study groups)~Each patient will be given a prescription to perform a C-Reactive Protein assay on D1, D3 and D7, similarly."
29370|NCT03956771|Behavioral|Real neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of the participant him/herself. Participants receive feedback of their own brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortical activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
29371|NCT03956771|Behavioral|Sham neurofeedback|Regulation of brain activity in real-time with feedback from brain activity measured with MRI from the orbitofrontal cortex of other participant. Participants receive feedback of other participant' brain activity in a screen with pictures. Participants are instructed to try to decrease the pictures transparency to reduce the orbitofrontal cortex activity. Psychotherapy strategies to decrease brain responses will be teach to the participants before the intervention.
29372|NCT03956758|Other|Semi-directed interview|Semi-directed interview on ChemSex practice
29373|NCT03956745|Behavioral|sleep-wake timing|Study participants will have one inverted day when they are scheduled to sleep ~12h opposite their usual sleep time.
29374|NCT03956745|Behavioral|constant routine|Study participants will spend ~28-50 hours awake, inactive, sitting in bed, in constant lighting and temperature.
29375|NCT03956732|Dietary Supplement|Milk Protein (high)|High protein yoghurt which contains approx. 10 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
29376|NCT03956732|Dietary Supplement|Vitamin D|One daily tablet containing 20 μg of vitamin D3, cholecalciferol.
29377|NCT03956732|Dietary Supplement|Milk Protein (medium)|Ordinary yoghurt containing approx. 3.3 g protein per 100 g. Participants will be asked to consume 300 g (=3 dl) 6 days a week.
29378|NCT03956719|Drug|Autologous adipose-derived mesenchymal stem cells|Autologous adipose-derived mesenchymal stem cells is extracted from human abdominal fat, which is crushed, filtered and immediately returned to the articular cavity through a specific device.
29379|NCT03956719|Procedure|abdominal liposuction|50 ml abdominal fat was extracted by abdominal liposuction to prepare autologous adipose-derived mesenchymal stem cells
29380|NCT03956706|Radiation|Stereotactic Radiosurgery|Stereotactic radiosurgery dose escalation by either 18, 20, or 22 Gy to the subventricular zone in addition to standard of care
29381|NCT03956693|Behavioral|HEADS: UP|"HEADS: UP comprises 9 x 2.5 hour mindfulness teaching sessions and a silent retreat in week 7. Course materials include accessible information packs and resources to complement class-based sessions.~The first week of the 9-week course is an introductory class. The purpose of the introductory class is to give participants the opportunity to meet the trainers and to decide if they want to learn more about mindfulness. The introductory session also allows participants to meet other people on the course and to share their (stroke) stories."
29382|NCT03956680|Drug|BMS-986301|Participants will receive dose 1 on Day 1 and Day 22 of cycle 1.
29383|NCT03956680|Drug|Nivolumab|Participants will receive Dose 2 on Day 1 of cycle 2.
29384|NCT03956680|Drug|Ipilimumab|Participants will receive Dose 3 on Day 1 of cycle 2.
29385|NCT03956667|Other|Live Music|Musicians from Cascade Music will provide recruited participants in the experimental arm with high-quality calming, distracting music during their Emergency Department procedure.
29386|NCT03956654|Drug|Ribociclib|combination of ribociclib and letrozole
29539|NCT03955562|Other|Footbridge|Access to a pedestrian footbridge.
29387|NCT03956641|Other|Adaptated Physical Activity|Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
29388|NCT03956628|Behavioral|stay safe program|Prevention consist of 5-6 lessons having topics about learning safety skills which includes identifying touch, safe and unsafe environment/events, bullying, the good or bad secrets and strangers.
29389|NCT03956615|Other|Blood sampling and bone marrow analysis|Bone marrow sample analysis. A blood sampling of maximally 10 ml by venous puncture (serum)
29390|NCT03956602|Other|Pretzels|To examine postprandial responses of pretzel consumption
29391|NCT03956602|Other|Brazil nuts|To examine postprandial responses of Brazil nut consumption
29392|NCT03956602|Other|Potato chips|To examine postprandial responses of potato chip consumption
29393|NCT03956602|Other|Mixed nuts|To examine postprandial responses of mixed nut consumption
29394|NCT03956589|Drug|Orkambi|Open label of Orkambi treatment during 3 months
29395|NCT03956576|Other|[Pyr]apelin-13|Peptide [Pyr]apelin-13 infusion
29396|NCT03956563|Device|Youlaser MT Group 2|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the control arm will receive 3 simulated laser treatments every 30 days.~A placebo consists in a sham device laser that simulates the acoustic signal even if it does not deliver any laser radiation to the subject."
29397|NCT03956563|Device|Youlaser MT Group 1|"Youlaser MT is a laser device including two laser sources emitting at 10600 nm (CO2) and 1540 nm (Ga-As) intended to be used for gynaecological applications.~Each patient in the active arm will receive 3 laser treatments with the laser: one treatment administration every 30 days."
29398|NCT03956550|Drug|REGN5069|Intravenous (IV) Dose every 4 weeks (Q4W)
29399|NCT03956550|Drug|Matching Placebo|Intravenous (IV) Dose every 4 weeks (QW4)
29400|NCT03956537|Device|NEO Pedicle Screw System™|The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.
29401|NCT03956537|Device|Neo Cage System™|Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
29402|NCT03956524|Biological|EuTCV|Single 0.5 mL dose of TCV of EuBiologics co., Ltd.
29403|NCT03956524|Biological|Typbar-TCV™|Single 0.5 mL dose of TCV of Bharat Biotech
29404|NCT03956524|Biological|Typhim Vi®|Single 0.5 mL dose of Vi capsular polysaccharide vaccine of Sanofi Pasteur
29405|NCT03956511|Other|Spontaneous Breathing Trial|It involves placing an infant from invasive mechanical pressure limited time cycled ventilation ventilation to endotracheal continuous positive end-expiratory pressure (ET-CPAP) for a period of 5 minutes during which saturation and heart rate are closely monitored. The infant would pass the test if there is no hypoxia or bradycardia during the test. If the infant has either bradycardia for more than 15 seconds and/or a fall in SpO2 below 85% despite a 15% increase in FIO2, the study will be stopped and ventilation will be restarted.
29406|NCT03956498|Other|Patients with cervix or vaginal cancer treated by radiotherapy and brachytherapy|"Nurse-led sexological consultations, beginning before brachytherapy and until 2 months after brachytherapy.~Questionnaires to be completed by the patient before brachytherapy, 2 months after the end of brachytherapy and 1 year after the end of brachytherapy : Female Sexual Function Index (FSFI), Quality of Life Questionnaire-Core 30 (QLQ-C30), and Quality-of-Life questionnaire cervical cancer module QLQ-CX24."
29407|NCT03956485|Other|Type of center|Tertiary versus non-tertiary
29408|NCT03956472|Procedure|Osteopathic protocol for improving drainage of LCS|Osteopathic intervention improving drainage of LCS and cerebral blood flow through opitmizing veinous circulation
29409|NCT03956472|Device|PEEP 10cmH2O|Breathing through a 10 cmH2O expiratory resistance for 10 min every 2 hours during 10h at 3842m high
29410|NCT03956472|Other|Fake Osteopathic protocol|Placebo intervention
29411|NCT03956472|Other|PEEP-Sham|PEEP 0 cmH2O (hidden)
29412|NCT03956459|Other|Patients with a cancer for which a FDG-PET scanner must be performed|"For each patient, 2 consecutive PET-CT scanners will be performed using 2 different systems of PET-CT scanners:~Discovery MI~Discovery IQ~Only one contrast agent injection (FDG) will be given for both scanners."
29413|NCT03956446|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
29414|NCT03956446|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline. Questionnaire Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
29415|NCT03956446|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
29416|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with docosahexaenoic acid (DHA)|One portion of DHA-enriched pancakes will be eaten each day for 4 weeks.
29417|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with beta-glucan (BG)|One portion of BG-enriched pancakes will be eaten each day for 4 weeks.
29418|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with anthocyanins (AC)|One portion of AC-enriched pancakes will be eaten each day for 4 weeks.
29419|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with docosahexaenoic acid and beta-glucan (DHA+BG)|One portion of DHA+BG-enriched pancakes will be eaten each day for 4 weeks.
29420|NCT03956433|Dietary Supplement|Ready-made pancakes enriched with docosahexaenoic acid and anthocyanins (DHA+AC)|One portion of DHA+AC-enriched pancakes will be eaten each day for 4 weeks.
29421|NCT03956420|Behavioral|Premedication visit|detailed information about surgery, anaesthesia and postoperative period
29422|NCT03956420|Dietary Supplement|Preoperative period|avoidance of prolonged fasting, intake of fluids with carbohydrates before surgery
29423|NCT03956420|Drug|Preoperative period|administration of melatonin 5 mg in the evening and pregabalin 75 mg one hour before entering the operating theatre
29424|NCT03956420|Other|Postoperative period|Fluids 1 ml/kg/h; Discontinuation of propofol at the moment of drainage and cardiovascular system stabilization; Fluids administered orally 2 hours after extubation; Early mobilisation
29425|NCT03956420|Other|Intraoperative period|deep temperature (necessity to maintain normothermia during the stay in the operating theatre 36 °C. Normothermia should be maintained rather than restored.
29426|NCT03956420|Drug|Intraoperative period|Pyralgin 1 g i.v. after induction of anaesthesia; in patients allergic to Pyralginum, Perfalgan 1 g i.v.
29427|NCT03956420|Drug|Intraoperative period|Ketamine 30 mg i.v. after induction of anaesthesia
29428|NCT03956420|Drug|Intraoperative period|Sevoflurane 1.5 MAC higher in patients < 60 years old
29429|NCT03956420|Drug|Intraoperative period|Propofol infusion in patients at risk of postoperative vomiting (Apfel ≥ 2 points), sevoflurane administration at the moments of strong stimuli from the operating field
29430|NCT03956420|Drug|Intraoperative period|Continuous infusion of balanced multi-electrolyte fluids 1-3 ml/kg/h
29431|NCT03956407|Device|Repetitive peripheral nerve stimulation|Active repetitive peripheral nerve stimulation will be applied to the median nerve of the affected forearm with surface electrodes. The stimulator will be set to deliver bursts of 10 Hz stimulation at 50% duty cycle (500 ms on and off). For active stimulation, intensities will be set at the highest intensity able to induce sensory paraesthesias without overt muscle contraction or pain, and adjusted if required.
29432|NCT03956394|Diagnostic Test|UltraFast ultrasound|The patient will be hospitalized by day to perform the usual follow-up of the Takayasu disease: blood sampling and Doppler ultrasound control. Then UltraFast ultrasound doppler will be assessed.
29433|NCT03956381|Device|Primary Total Hip Replacement with Trinity cup and TriFit TS stem via posterolateral surgical approach.|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
29434|NCT03956381|Device|Primary Total Hip Replacement with Trinity cup and MetaFix stem via direct anterior surgical approach|The participant will undergo surgery using the hip prostheses and surgical approach used by their surgeon Investigator. A patient specific femoral guide, generated by the OPS™ plan preoperatively, will be used during the surgical step of femoral neck resection. These are not study specific procedures as the OPS™ system is already in use by the surgeon Investigator in their standard of practice.
29435|NCT03956368|Drug|Atorvastatin 20mg|20mg (every evening orally) for 8 weeks.
29436|NCT03956368|Drug|Placebos|20mg (every evening orally) for 8 weeks.
29437|NCT03956355|Drug|Tapinarof (DMVT-505)|Tapinarof cream, 1%, applied once daily
29438|NCT03956355|Drug|Vehicle Cream|Vehicle cream applied once daily
29439|NCT03956329|Other|Standardised Digital Intervention|Video intervention designed to induce an increase in positive mood in older adults. Includes comedy clips, uplifting music and positive imagery. Intervention approximately 15-20 minutes in length. This includes 3 short comedy clips (fork handles sketch, the two Ronnie's; A room with a view - faulty towers; Tim Vine Live stand-up extract), uplifting music (Jailhouse Rock - Elvis Presley; Happy Together - The Turtles), jokes and positive imagery. The content of the intervention has been informed by patient and public involvement, focus groups with older adults, and pilot testing.
29440|NCT03956329|Other|Individualised Digital Intervention|Similar to the standardised digital intervention, however, participants will be able to individualise the intervention by choosing video clips from a limited menu of choices. Intervention approximately 15-20 minutes in length. The 4 categories include stand-up comedy (Michael McIntyre, Tim Vine and Victoria Wood), sit-com (Fawlty Towers, Only Fools and Horses and Two Ronnies), music (Elvis Presley, Last Night at the Proms, Roy Orbison) and variety (Britain's Got Talent, Strictly Come Dancing, Terry Wogan). Participants are able to select 3 of the videos, which are roughly 5 minutes in length, to reach a total of 15-20 minutes of content.
29441|NCT03956316|Device|Titan Modular Total Shoulder System|total shoulder arthroplasty using the Titan Modular Total Shoulder System
29442|NCT03956303|Drug|Chirocaine %0.5|Levobupivacaine 8 mg Chirocaine (% 0.5) +20 mcg fentanyl
29443|NCT03956303|Drug|Chirocaine Heavy 40|Chirocaine (%0.75) + Dextrose 40 mg+20 mcg fentanyl
29444|NCT03956303|Drug|Chirocaine Heavy 60|Chirocaine (%0.75) + Dextrose 60 mg+20 mcg fentanyl
29445|NCT03956303|Drug|Chirocaine Heavy 80|Chirocaine (%0.75) + Dextrose 80 mg+20 mcg fentanyl
29446|NCT03956290|Behavioral|TREAT pilot intervention|Participants will be asked to use the app and take pictures of everything they eat and drink, from the time they get up to the time they go to bed, regardless of size of meal/snacks/drink, for 2 weeks. This will generate data on their eating pattern and eating duration. Participants will be reminded through app, call or text by study staff based on personalized eating schedule. The sleep schedule will also be recorded.
29447|NCT03956277|Device|PUG|This methodology involves using ultrasound to place gastrostomy tube (g-tube itself is off the shelf).
29448|NCT03956264|Device|Virtual Reality|Deepsen offers a VR platform that provides patients with immersive contents aimed to distract, inform, soften and improve the healthcare experience
29449|NCT03956264|Drug|Kalinox|Gas mixture composed of 50% Nitrous Oxide and 50% Oxygen
29450|NCT03956251|Procedure|Combined Mineralized/Demineralized Putty Allograft|At time of extraction, 15 test patients will receive ridge preservation using Combined Mineralized/Demineralized Putty Allograft
29451|NCT03956251|Procedure|Demineralized Putty Allograft|At time of extraction, 15 control patients will receive ridge preservation using Demineralized Putty Allograft
29452|NCT03956238|Behavioral|Alcohol intoxication|Men and women assigned to moderate alcohol dose condition (target BAC .08%) or placebo control condition with NIAAA approved alcohol administration procedures
29453|NCT03956238|Behavioral|Objectification|Women assigned to objectifying gazes condition or eye contact control condition
29454|NCT03956225|Device|iLux® system|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
29455|NCT03956225|Device|LipiFlow® Thermal Pulsation System|Commercially available medical device intended for use by qualified eye care professionals to apply localized heat and pressure therapy to a patient's eyelids.
29456|NCT03956212|Drug|Doxycycline 7 days|Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
29457|NCT03956212|Drug|Doxycycline 14 days|Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
29460|NCT03956173|Other|Hypoglycemic combined with either normo or hyperglycemic clamp.|Twenty-four patients with type 1 diabetes has been recruited for a cross-over study including two experimental days, a combined hypo- and hyperlycemic clamp and a combined hypo- and euglycemic clamp, respectively. Patients will be randomised 1:1 to start with either the combined hypo- and hyperglycemic or the hypo- and euglycemic clamp. The hypo- and hyperglycemic or the hypo- and euglycemic clamp are estimated to last 255 minutes. The two clamp days will be separated by at least 30 days.
29461|NCT03956160|Other|A co-design phase aims to ensure the feasibility and relevance of the proposed intervention and evaluation.|"4 participatory co-design workshops lasting 4 hours each that will follow a user-centered design approach: identification of end-user needs, prototyping/development of the intervention (case-management procedures and platform), iterative improvement, end-user testing.~Based on the cognitive social theory underpinning the intervention, scientific literature, an overview of existing organizations and the results of the Stroke 69 and Arthur Tybra studies (patient needs following the acute phase), the advisory committee will:~Define the case-manager's profile, and required knowledge and skills~Identify the resources and tools to be proposed on the Internet platform~Test the tools and content~Refine the program evaluation criteria~Test and validate the study procedures."
29462|NCT03956147|Other|Munich Shoulder Questionnaire|Validation and Reability study
29463|NCT03956134|Drug|Tapentadol Test Product 1|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 1 contains different amounts of excipients than Tapentadol Test Product 2
29464|NCT03956134|Drug|Tapentadol Test Product 2|Tapentadol tablet containing 116 mg of tapentadol hydrochloride; Tapentadol Test Product 2 contains different amounts of excipients than Tapentadol Test Product 1
29465|NCT03956134|Drug|Tapentadol Prolonged-release Reference Product|Tapentadol PR tablet containing 116 mg of tapentadol hydrochloride
29466|NCT03956121|Other|injection of magnesium sulfate|The intervention consists to perform a study of the usual fetal heart rate with, in addition, comparison analysis of the short-term variability before and after injection of magnesium sulfate in the exposed group. Two successive short-term variability analyzes will be performed in fetuses of the control group.
29467|NCT03956108|Diagnostic Test|MRI+targeted biopsies+Stockholm3-test|MRI, evaluation in accordance with PI-RADS v2, and targeted biopsies. Stockholm3-test.
29468|NCT03956108|Diagnostic Test|PSA + systematic biopsies|Systematic biopsies and PSA test
29469|NCT03956095|Dietary Supplement|nsure Surgery Immunonutrition Shake supplements|Three Ensure Surgery Immunonutrition Shake supplements per day for seven days prior to their scheduled procedure.
29470|NCT03956082|Device|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation
29471|NCT03956069|Biological|blood sample|for patient and its parents
29472|NCT03956069|Genetic|genome sequencing|whole genome sequencing
29473|NCT03956056|Biological|Neoantigen Peptide Vaccine|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
29474|NCT03956056|Drug|Poly ICLC|• Each pool of vaccine study drug + poly IC:LC will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous (SC) injection.
29475|NCT03956056|Procedure|Blood for immune monitoring|-Baseline, day 1, day 22, day 50, day 78, week 25, and week 73
29476|NCT03956030|Other|Contraception Handout|Handout covering contraception options
29477|NCT03956030|Other|Nutritional Handout|Handout covering nutrition
29478|NCT03956017|Drug|Ubiquinone|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
29479|NCT03956017|Drug|Placebo|Take oral tablets as directed (2x200 mg for 3 days prior to surgery)
29480|NCT03956004|Other|OM1 Dell Shared Decision Making Tool|Decision aid meant to improve shared decision making among patients and providers.
29481|NCT03956004|Other|Education material from OM1 Dell Shared Decision Making Tool|Investigator-written educational material and quiz to test knowledge of osteoarthritis and treatment options.
29482|NCT03955991|Behavioral|R-CBSM|10 weekly educational modules via an electronic tablet. A participant workbook is also provided that contains a summary of the rationale for each module, outline of each technique, and homework exercises.
29483|NCT03955991|Biological|Influenza vaccine|Standard of care Influenza vaccine for that given year.
29484|NCT03955978|Drug|TSR-042|-TSR-042 is administered intravenously via a 30-minute (-5-minute/+15-minute infusion window allowed) infusion
29485|NCT03955978|Radiation|Brachytherapy|-This trial will include image-guided brachytherapy with three-dimensional (3-D) treatment planning and in cases where pelvic radiation is deemed appropriate by the treating radiation oncologist, external beam radiation therapy (EBRT) using intensity modulated radiation therapy (IMRT) technique.
29486|NCT03955978|Procedure|Endometrial biopsy|-Prior to the start of treatment with TSR-042. If this biopsy yields insufficient tumor tissue, an archival sample may be requested, with Fraction 1 of brachytherapy, with Fraction 6 of brachytherapy
29487|NCT03955978|Procedure|Blood draw for immune response|-Prior to the start of any treatment, weekly during RT (at the time of each brachytherapy treatment), prior to fourth dose of TSR-042, 6 weeks after the completion of all protocol related therapy
29488|NCT03955965|Other|Medication reconciliation|No intervention was performed other than collecting data on patients' medical files
29489|NCT03955952|Procedure|Bariatric Surgery|"Patients chosen using the following codes:~Current Procedural Terminology (CPT): 43633, 43634, 43770, 43775, 43644, 43645, 43659, 43842, 43843, 43844, 43845, 43846, 43847 International Classification of Diseases (ICD): 44.31, 43.82,44.95, 43.89, 44.38, 44.39, 44.68 Healthcare Common Procedure Coding System (HCPCS): S2082, S2085"
29490|NCT03955939|Drug|LY3295668 Erbumine|Administered orally.
29491|NCT03955939|Drug|Endocrine therapy|Administered according to label instructions.
29492|NCT03955939|Drug|Midazolam|Administered orally.
29493|NCT03955926|Dietary Supplement|preoperative oral carbohydrate loading|Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
29494|NCT03955913|Other|Archival Tumor Tissue Sample|Percentage of participants with UC and selected FGFR aberrations will be assessed through molecular testing of their archival tumor tissue.
29495|NCT03955900|Other|No intervention|Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
29496|NCT03955887|Biological|bronchoalveolar lavage fluid (BAL)|Recovery of a 10 mL volume of BAL fluid, performed as part of patient care
29497|NCT03955887|Biological|Venous blood|Collection of 3 additional blood tubes (12 ml) during a blood sample taken as part of patient care
29498|NCT03955861|Biological|adalimumab|Subcutaneous injection
29499|NCT03955861|Biological|Certolizumab|Subcutaneous injection
29500|NCT03955861|Biological|Etanercept|Subcutaneous injection
29501|NCT03955861|Biological|Golimumab|Subcutaneous injection
29502|NCT03955861|Biological|Secukinumab|Subcutaneous injection
29503|NCT03955848|Biological|Alloreactive NK cell infusion|Alloreactive NK cell infusion
29504|NCT03955835|Device|Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.|Self-expandable Credo® stent together with NeuroSpeed® PTA balloon catheter. Credo® and NeuroSpeed® are already CE approved products, for which within ACUTE an additional new indication shall be examined.
29505|NCT03955822|Other|Phone survey|Phone Survey in order to evaluate adverse effect of the permanently implanted birth control device for women (Essure) will be proposed to wmen Treated between 2002 and 2017 with Essure.
29506|NCT03955809|Drug|Ketamine 0.5|İntrarticular Ketamine 0.5 mg/kg + 0.9 Nacl Total Volume 20 ml
29507|NCT03955809|Drug|Ketamine 1|İntrarticular Ketamine 1 mg/kg + 0.9 NaCl Total Volume 20 ml
29508|NCT03955809|Drug|% 0.9 NaCl|Intraarticular %0.9 NaCl
29509|NCT03955796|Device|Hydrophobic IOL|RayOne Hydrophobic Aspheric, hydrophobic IOL
29510|NCT03955796|Device|Non-hydrophobic IOL|RayOne Aspheric, non-hydrophobic IOL
29511|NCT03955783|Drug|Venetoclax|Given by mouth
29512|NCT03955783|Drug|Selinexor|Given by mouth
29513|NCT03955770|Combination Product|High-flow oxygen therapy (HFOT)|HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher&Paykel, New Zealand).
29514|NCT03955770|Combination Product|Low-flow oxygen therapy (LFOT)|LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
29515|NCT03955757|Behavioral|Boot Camp Translation|Communities in the intervention arm will participate in the Boot Camp translation process, where stakeholders will come together to develop and implement locally relevant materials to promote adolescent vaccination.
29516|NCT03955757|Other|Control|No intervention. Communities will continue to behave as usual.
29517|NCT03955744|Other|3D translabial ultrasound|All patients will undergo 3D translabial ultrasound with vaginal manometry
29518|NCT03955731|Device|Magmaris resorbable magnesium scaffold|Implantation of Magmaris resorbable magnesium scaffold
29519|NCT03955718|Behavioral|Motherly App|The Motherly app is a behavioral intervention aimed at preventing maternal depression and promoting child development.
29520|NCT03955718|Behavioral|Educational App (Active Control)|An app with educational content about gestation, maternal health and mental health, child development, etc.
29521|NCT03955705|Drug|Nefopam 20 mg/ml|Nefopam is a benzoxazocine derivative which is non-opioid and non NSAIDs. The previous studies showed that nefopam can inhibit reuptake of serotonin, norepinephrine and dopamine.
29522|NCT03955705|Drug|Normal saline|0.9% Sodium chloride (normal saline or NSS)
29523|NCT03955692|Device|tDCS|Five sessions (active/sham) will be held on five consecutive days. The parameter of electrode size, current strength and current duration were previously tested for safety in children
29524|NCT03955679|Genetic|AVXS-101|AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). AVXS-101 will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
29525|NCT03955666|Biological|PRV-3279 or placebo|bi-specific antibody-based molecule
29526|NCT03955653|Procedure|Femoral artey access|We will study the access to the femoral artery for cardiac catheterization or percutaneous coronary intervention
29527|NCT03955640|Drug|Olaparib|Given PO
29528|NCT03955640|Procedure|Hyperthermia Treatment|Undergo hyperthermia treatment
29529|NCT03955640|Other|Questionnaire Administration|Ancillary studies
29530|NCT03955640|Other|Quality-of-Life Assessment|Ancillary studies
29531|NCT03955627|Behavioral|Relieving Joint Pain and Improving AI Adherence in Older Breast Cancer Survivors (REJOIN)|Self-management program which includes supervised exercise sessions in groups and group discussions for 8 weeks, following by an 8-week home-based version of the same program.
29532|NCT03955614|Other|pedal-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are controlled by the surgical staff using pedals.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
29533|NCT03955614|Other|ML-controlled GoSurgeryTM|"Members of the surgical team are given operative instruction workflows to use in preparation of a specific operation and to consult during the operation if needed. The workflows are projected onto screen based on the machine learning algorithm's determination of current operative step.~The operating theatre environment is recorded to observe how teamwork may be affected by the intervention."
29534|NCT03955614|Other|NoGo|The operating theatre environment is recorded to observe baseline teamwork.
29535|NCT03955601|Drug|Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''|''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
29536|NCT03955588|Diagnostic Test|aCGH|
29537|NCT03955575|Drug|Liraglutide 6 MG/ML|Liraglutide as injections.
29538|NCT03955575|Drug|Colesevelam|3 x 625 miligram 2 times a day.
29541|NCT03955549|Behavioral|Insight Enhancement Program (IEP)|"IEP is comprised of 8 sessions, administered twice weekly, across a one month period. The session duration is 60-90 minutes. IEP will be administered in a group format with 8-12 patients in each group.~During sessions, different topics representing 8 different stages of illness are discussed according to a chronological schedule. These stages are presented on an Illness March Graph (IMG) and include: Stage I: Personality formation, Stage II: Pre onset confusion, Stage III: Prodroma, Stage IV: The illness, Stage V: Resistance, Stage VI: Remission, Stage VII: Maintenance, Stage VIII: Relapse. Patients actively participate through the exchange of their own experiences and interpretations, which are then reinterpreted by the therapist and by the patients themselves."
29542|NCT03955549|Behavioral|Metacognitive Training for Psychosis (MCT)|The training consists of eight modules that are administered within the framework of a group intervention program that involves eight 1-hour group sessions with 4 to 10 patients in each group. MCT is manualized and currently available in thirty languages and can been downloaded via the following web address: http://www.uke.de/mct. Among the problematic thinking styles recognized as potential contributors to the development of delusions are attributional distortions (module 1), a jumping to conclusions bias (module 2 and 7), a bias against disconfirmatory evidence (module 3), deficits in theory of mind (module 4 and 6), over-confidence in memory errors (module 5) and depressive cognitive patterns (module 8).
29543|NCT03955549|Drug|Treatment As Usual (TAU)|"Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used."
29544|NCT03955536|Other|Group A: Group routine cardiac rehabilitation program (RCRP)|"Patient education, Chest Physiotherapy, Abdominal and chest breathing, Bronchial hygiene techniques, Segmental breathing exercises, Triflow, exercise and mobilization,graduated exercise, positioning, active joint movement, moving inside bed, sitting at the edge of the bed, transfer from bed to chair, standing walking program, up and down stairs.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
29545|NCT03955536|Other|Group B: Group RCRP and inspiratory muscle training|"use of additional virtual reality goggles in the routine cardiac rehabilitation program Virtual reality glasses installed in the patient will feel the best way to feel an environment.~Virtual reality glasses are planned to be used 15 minutes by increasing the usage period.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
29546|NCT03955536|Other|Group C: Group RCRP and virtual reality application|"nspiratory muscle training with Threshold for routine cardiac rehabilitation Training intensity~- 30% of the maximum measured inspiratory pressure per week (15 min.). Every 10 breaths after rest.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
29547|NCT03955536|Other|Group D: Group RCRP and inspiratory muscle training and virtual reality application|"In addition to the routine cardiac rehabilitation program, virtual reality and inspiratory muscle training will be performed.~Evaluations for each patient (preoperative and just before discharge) Spirometric measurements Intraoral pressure measurementDyspnea assessment (BORG), Pain assessment (VAS), Evaluation of anxiety and depression (HAD) Evaluation of functional capacity (6 minutes walking test) Quality of Life (MacNew Heart Disease Specific Quality of Life Questionnaire)"
29548|NCT03955523|Other|Single exercise bout trial|Exercise trial day: 30 min of continuous exercise at 60% VOpeak (or at the least 3 bouts of 10 min at 60% VO2peak separated by no more than 1 minute rest) - power output is set at that determined during the maximum test on the first visit, and adjusted accordingly if there is a deviation >5% VO2peak for at least 3 minutes of exercise.
29549|NCT03955523|Dietary Supplement|Single diet trial|Diet trial day The protocol of the diet trial day is identical to that of the exercise trial day, except that exercise is substituted by asking the participant to eat a standardized breakfast meal that it is commonly consumed in a fast-food chain (i.e. cheese and egg McMuffin, double portion of hash browns and an orange pop).
29550|NCT03955510|Other|Right time eating|"Right-time eating means breakfast before 8am, lunch before 1 pm and dinner before 6pm. Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the 8 week study period. Each subject will be required to do this intervention twice during the study period. One time they will have right time eating with alcohol , the second time the will have this intervention without alcohol."
29551|NCT03955510|Other|Delayed time eating|"Delayed-eating means eating each meal 3 hours later than the Right-time eating.Subjects will be asked to stick to this eating schedule for 1 week. Subjects will randomly be assigned to each eating pattern during the 8 week study period. Each subject will be required to do this intervention twice during the study period. One time they will have delayed time eating with alcohol , the second time the will have this intervention without alcohol."
29552|NCT03955510|Procedure|Sigmoidoscopy|Subjects will undergo unprepped sigmoidoscopy to collect tissue and stool sample at each intervention visits (visit 2, 3, 4, and 5). Flexible sigmoidoscopy will not require any colon cleansing and it will be very limited to the most distal (closest to the end of the anus) 20 centimeters (approximately 8 inches) of the colon and thus will be far less uncomfortable than the routine flexible sigmoidoscopy.
29584|NCT03955250|Behavioral|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning.
29553|NCT03955510|Procedure|Optional 24h circadian assessment in the Biological Rhythms lab|"Subjects may choose to participate in the 24 hour circadian assessment in the Biological Rhythms Research Lab. During this assessment, a saliva sample will be taken every hour, a mouth swab will be done every 2 hours, and rectal swab will be done twice (every 12 hours). Subjects will be kept awake in dim light on a recliner chair. Subjects can watch a television with dimmed light. Subjects will be provided with food and drink during the assessment.~If subjects choose this intervention they will be asked to complete 4 assessment during the course of the study period."
29554|NCT03955510|Other|Alcohol|Moderate alcohol drinking means 0.5 g/kg alcohol daily, which will be not more than 3-4 glasses of wine depending on subject's weight. Alcohol will always be consumed in the evening with food or after food (e.g., dinner). The timing of alcohol consumption will be consistent for each individual. Subjects will be provided with red wine for the 2 alcohol intervention weeks. The order of conditions will be random.
29555|NCT03955497|Other|Autologous Adipose-derived Mesenchymal Stem Cell Gel|The experimental group received intra-articular injection of Autologous Adipose-derived Mesenchymal Stem Cell Gel one month after operation.
29556|NCT03955497|Drug|Sodium Hyaluronate|The control group received intra-articular injection of sodium hyaluronate one month after operation.
29557|NCT03955497|Procedure|Extraction of abdominal fat|In the experimental group, abdominal fat was extracted before operation to prepare Autologous Adipose-derived Mesenchymal Stem Cell Gel.
29558|NCT03955484|Diagnostic Test|Urinary Glycosaminoglycan|Urine will be collected from patients before and after one month of medical treatment (alpha-blocker). After being centrifuged at 5000 g for 10 minutes, urine will be stored at -80 ° C. At the end of the study, urinary glycosaminoglycan levels will be studied by spectrophotometric method.
29559|NCT03955471|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
29560|NCT03955471|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
29561|NCT03955458|Drug|EXPAREL|FICB with EXPAREL + Bupivacaine HCL (single dose)
29562|NCT03955458|Drug|Ropivacaine|FICB with continuous infusion of ropivacaine
29563|NCT03955458|Drug|Bupivacaine Hydrochloride|FICB with EXPAREL + Bupivacaine HCL (Single dose)
29564|NCT03955445|Drug|LNP023|LNP023 capsules
29565|NCT03955432|Device|Reveal LINQ ICM System|The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.
29566|NCT03955419|Dietary Supplement|NO-NPO (Daesang WelLife Co., Ltd., Korea)|800 mL of carbohydrate beverage consists of 12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg.
29567|NCT03955406|Procedure|Conventional Low flow Anesthesia|During the initial wash-in period 4 L/min Fresh gas flow will be used.
29568|NCT03955406|Procedure|Low Flow Anesthesia with fixed fresh gas flow rate|Fresh gas flow rate will be 1 L/min throughout the procedure.
29569|NCT03955393|Other|18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS|18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
29570|NCT03955380|Drug|Contraloid|Oral administration of capsules, drug substance or placebo without any exipients.
29571|NCT03955367|Radiation|Prophylactic extended-field Irradiation|CTV covers pelvis and para-aortic lymph nodes region.
29572|NCT03955367|Radiation|Pelvic irradiation|CTV covers pelvis.
29573|NCT03955367|Radiation|Intracavitary brachytherapy|The total dose delivered to point A or high-risk CTV is ≥80Gy. For patients with larger-volume cervical tumor, the total dose is ≥85Gy.
29574|NCT03955367|Drug|Concurrent chemotherapy|Cisplatin based concurrent chemotherapy, including cisplatin as a single agent or cisplatin plus Paclitaxel.
29575|NCT03955354|Drug|SHR1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
29576|NCT03955354|Drug|apatinib mesylate|apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
29577|NCT03955341|Device|Diode laser disinfection|After collecting the first sample of dentin as described above, the cavity will be disinfected using Diode laser (EPIC™, BIOLASE) with 940 nm and an output power of 0.5 watt (24). A 400 µm noninitiated tip will be used for cavity irradiation, in a noncontact mode (2mm distance), 5 sec/mm2 in sweeping motion. A 2nd dentinal sample will be collected after diode laser disinfection.
29578|NCT03955341|Other|Chemical disinfection using 2% Chlorhexidine|After collecting the first sample of dentin, the cavity will be disinfected using 2% Chlorhexidine (Consepsis®, Ultradent) for 20 seconds (32). Then a 2nd dentinal sample will be collected after chemical disinfection.
29579|NCT03955328|Diagnostic Test|Magnetic Resonance Imaging|A magnetic resonance imaging is perform to detect permanent anatomical damage.
29580|NCT03955315|Biological|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
29581|NCT03955315|Procedure|Sham|Needle puncture under the muscular layer in front of the intervertebral disc
29582|NCT03955302|Behavioral|Exercise|There will be an intervention for 12 weeks. For exercises in the water, there will be an expert physiotherapist in the field of hydrotherapy that will guide the exercises in controlled sessions of approximately 45 minutes. Exercises of joint mobility, balance, strength and coordination with / without aquatic material will be included. At all times, qualified health personnel will monitor any symptom or sign that advises the removal of the subject of the study.
29583|NCT03955276|Other|Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)|Biologically targeted matched treatment (chosen by treating physician)
29615|NCT03954990|Drug|Placebo Oral Tablet|4 tablets
29585|NCT03955250|Behavioral|Mobile app attention control|The control app provides ecological momentary assessment and psychoeducation about illness.
29586|NCT03955237|Procedure|Drug: dextrose containing infusion|Drug: infusing dextrose containing or non glucose fluid according to blood glucose level
29587|NCT03955224|Device|Basic Oral Care + active LLLT|"Compliance with the Basic Oral Care Associated with~Active LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
29588|NCT03955224|Other|Basic oral Care + inactive LLLT|"Compliance with the Basic Oral Care Associated with~Inactive LLLT : 5 applications performed at three days intervals (day 1 to day 13 +/- 1 day)"
29589|NCT03955224|Other|Basic Oral Care|Compliance with the Basic Oral Care only
29590|NCT03955211|Drug|HTX-011|A single dose of HTX-011 300 mg administered via instillation into the surgical site.
29591|NCT03955211|Device|Luer lock applicator|Applicator for instillation.
29592|NCT03955198|Radiation|Radiotherapy|Radiotherapy will be administered alone
29593|NCT03955198|Combination Product|Radiotherapy + durvalumab|Radiotherapy will be administered in combination with Immunotherapy drug (Durvalumab)
29594|NCT03955185|Procedure|minimally invasive surgery|Laparoscopic or robotic assisted radical hysterectomy
29595|NCT03955185|Procedure|open abdominal surgery|Traditional open abdominal radical hysterectomy
29596|NCT03955172|Drug|Everolimus|Patients will received everolimus (CERTICAN), oral form, at the necessary dose to obtain trough levels between 6 and 8 ng/ml, during 6 months. Everolimus will replace the anti-proliferative drug they have before (azathioprine or mycophenolic acid). Everolimus will be associated with corticosteroids (prednisolone) and a calcineurin inhibitor (tacrolimus or cyclosporin).
29597|NCT03955159|Dietary Supplement|Probiotic supplementation|The probiotic is composed of the combination of Lactobacillus acidophilus and Bifidobacterium lactis, at the concentration of 109 CFU. This product presents no known hazards associated with its use. On the contrary, the use of this supplement is associated with a rebalancing of the intestinal microbiota with potential secondary benefits to the reconstitution of the intestinal symbiosis. Patients will receive 1 sachet of 1 gram per day and will be advised to dilute in 100 mL in water at room temperature for administration.
29598|NCT03955146|Drug|Pamrevlumab|Pamrevlumab: 30 mg/kg by intravenous infusion every 3 weeks for a total of 17 infusions over 48 weeks
29599|NCT03955146|Drug|Placebo|Placebo: 30 mg/kg by intravenous infusion every 3 weeks for a total of 17 infusions over 48 weeks
29600|NCT03955133|Other|Adverse Drug Reaction ADRe Profile for Polypharmacy|PADRe asks nurses to systematically check patients for the manifestation of itemised adverse side effects or undesirable effects of their primary care medicines, as listed in the BNF and manufacturers' Summaries of Product Characteristics (SmPCs), and seminal texts documenting known ADRs. Nurses are asked to share the identified problems with prescribers and pharmacists overseeing medicines charts. A full description is published (references below).
29601|NCT03955120|Behavioral|Dayzz mobile sleep training|"The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study."
29602|NCT03955120|Other|Treatment as usual|Standard medical care for specific sleep condition
29603|NCT03955107|Device|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) every 4 weeks since diagnosed with GDM，and the control grouponly once receive CGMS during the last month and have management adjusted based on the CGMS readings Other Name: iPro, Medtronic
29604|NCT03955094|Device|Intubation via AMBU® AURAGAIN™|Success rate of paediatric intubation through AMBU® AURAGAIN™
29605|NCT03955081|Device|Deep enteroscopy|A deep enteroscopy conducted with the new medical device PowerSpiral.
29606|NCT03955068|Other|Strict Classic Ketogenic Diet|Diet is administered from a 2:1 to 4:1 ratio; this means 2 to 4 parts of fat to 1 part of both protein (calculated based on RDA and whatever remaining portion of carbohydrates.
29607|NCT03955055|Device|Video Capsule Endoscopy|Patients will swallow a video capsule as soon as possible (immediately or within 10 hours, if patient is not fasting).
29608|NCT03955042|Drug|Pemetrexed|Pemetrexed 900 mg/m^2 on Day 1 of each 21-day cycle. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.
29609|NCT03955029|Other|Progressive Interval training|heating up 7 minutes at 15 watt, then alternating 30% of the maximum power reached by the patient at Vo2 max for 3 minutes and first peak at 40% of max power, second at 45%, third at 50%, fourth at 55 % and fifth to 60%, then return to calm 3 minutes at 15 watt. Total duration of the endurance session: 30 minutes. The powers of the peak will be modeled according to the Borg (if <6, increase by 5 watt the value of each peak at the next session).
29610|NCT03955029|Other|Conventional Interval training|warm up 7 minutes at 15 watt, then alternating between plateau at 30% of the max power reached by the patient at VO2 max for 3 minutes and peak at 60% for 1 minute, return to calm 3 minutes at 15 watts. Total duration of the endurance session: 30 minutes. The power of the peak will be modeled according to the Borg (if <6, increase by 5 watt the value of each peak at the next session)
29611|NCT03955016|Other|Pulmonary rehabilitation|"Rehabilitation program consisting of 2 weeks inpatient (supervised training 5 times per week), 2 weeks outpatient (supervised sessions 3 times per week) and 11 weeks home-based exercise training (weekly phone call).~During the inpatient phase, patients will receive on top of the supervised training sessions a consultation of the dietitian, PH psychologist, social worker and specialized nurse. During the ambulatory rehabilitation phase patients will have 2 session with the occupational therapist.~Every supervised training session contains:~Interval training on a cyclo-ergometer~Strength training of the upper and lower extremities~Guided walks"
29612|NCT03955003|Behavioral|Group Drumming|Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
29613|NCT03955003|Other|Attention Control|This is intended to control for time, place, and group affect.
29614|NCT03954990|Drug|Metronidazole Oral|4 tablets (2 g of metronidazole)
29616|NCT03954977|Diagnostic Test|PICC line ultrasound|NICU patient's with PICC lines will be enrolled and blinded ultrasound operators will scan the neonate to find the PICC tip location. This will be compared to the location on the patient's chest x-ray. This process will be repeated each time the patient has a chest x-ray.
29617|NCT03954964|Behavioral|Education on disposal of opioids|Current class curriculum including education about pain management with additional education about the disposal of opioids.
29618|NCT03954951|Other|Multimodality behavioral strategy|"On-line course on hypertension management based on the new ACC/AHA and ESC/ESH guidelines on hypertension management.~Weekly performance feedback reports: will include percent of patients with uncontrolled hypertension and among this group percent of visits where no change in medication was made. It will also include a comparative assessment of the performance of the physicians compared with their colleagues in the province."
29619|NCT03954938|Behavioral|Craving Manipulation|Craving will be manipulated based on instructions about cocaine associated images shown to subjects.
29620|NCT03954938|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined based on the craving manipulation condition.
29621|NCT03954938|Drug|Placebo|The pharmacodynamic effects of placebo will be determined based on the craving manipulation condition.
29622|NCT03954925|Procedure|Anatomic anterior cruciate ligament with short hamstring graft technique|ACL and short hamstring graft
29623|NCT03954925|Procedure|Anatomic anterior cruciate ligament with a standard hamstring graft technique|ACL with standard hamstring graft
29624|NCT03954912|Procedure|MAKO assisted unicondylar knee arthroplasty|MAKO assisted
29625|NCT03954912|Procedure|NAVIO assisted unicondylar knee arthroplasty|NAVIO assisted
29626|NCT03954899|Dietary Supplement|melatonin|5mg of melatonin-otc 30 minutes before sleep
29627|NCT03954899|Other|placebo|placebo 30 minutes before sleep
29628|NCT03954886|Device|Plus powered optical lens|A plus powered optical lens will be placed in front of one eye.
29629|NCT03954873|Other|Glucagon-like peptide 2|Human glucagon-like peptide 2
29630|NCT03954873|Other|Saline|Placebo
29631|NCT03954873|Other|Glucose|20% (w/v) glucose infusion for regulating plasma glucose
29632|NCT03954873|Other|Insulin|Actrapid (insulin) for lowering plasma glucose
29633|NCT03954860|Other|Drainage Tube|The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.
29634|NCT03954860|Drug|Tranexamic Acid|Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
29635|NCT03954860|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
29636|NCT03954834|Drug|Tirzepatide|Administered SC
29637|NCT03954834|Drug|Placebo|Administered SC
29638|NCT03954821|Device|prefabricated insoles|
29639|NCT03954808|Other|Motor Imagery Training|Motor imagery training will be designed for the individual basis with standard protocols
29640|NCT03954808|Other|Traditional physiotherapy|Traditional physiotherapy within a specific program
29641|NCT03954795|Procedure|TAP|Classic TAP block performed through the petit triangle (the anterior axillary line and iliac crest)
29642|NCT03954795|Procedure|OSTAP|Modified TAP (OSTAP) block performed from the medial of linea semilunaris applying local anesthetic to the area between xiphoid and anterior iliac crest.
29643|NCT03954782|Drug|Nintedanib 150 mg and 100 mg soft capsules|Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.
29644|NCT03954782|Drug|Oral treatment of placebo soft capsule|Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)
29645|NCT03954756|Drug|Apatinib and PD1|"Apatinib starting dose of 500mg, qd, oral, taken half an hour after a meal~PD-1 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks."
29646|NCT03954743|Biological|HRV Liquid|Two doses will be administered orally according to a 0, 1-2-month schedule.
29647|NCT03954743|Biological|HRV Lyophilized|Two doses will be administered orally according to a 0, 1-2-month schedule.
29648|NCT03954730|Other|Eccentric Training|First session will be performed 24 hours after pre-training tests i.e. on 4th post- operative day and subsequent sessions will be performed with lapse of 48 hours. During pre-testing, weight for the eccentric training will be determined using Standardized Brzycki formulas for lower limb. Participants will perform one set of 10 repetitions with selected weight. Intensity will be increased every week by decreasing the time of performance. Volume will be increased by increasing one set after two weeks. Eccentric training will be performed in sitting position on dynamic constant external resistance equipment.After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
29649|NCT03954730|Other|Active Release Technique|Isometric Quadriceps' contractions against therapist's resistance lasting for 10 seconds will be performed by the patient in inner range of knee extension and after relaxing; actively perform maximum full knee flexion. Patient will perform extension at knee joint again; when reaches the innermost range, therapist will apply pressure on deep fascia either through knuckles/fingers or forearm in the direction towards the hip joint and patient is asked to perform knee flexion simultaneously. The procedure is applied onto vastus lateralis, rectus femoris and vastus intermedialis thrice in a session. After session, patient will perform strengthening of quadriceps muscle as per clinical practice guidelines of National Health Service (UK).
29650|NCT03954717|Behavioral|Shepherd CAN DO Program|CAN DO Shepherd is a four-day participatory program held at the Shepherd Center, in Atlanta, Georgia or people with MS. The four-day program comprises evidence-based, comprehensive, and personalized educational and experiential opportunities aimed at empowering and enabling a person with MS to live a health life beyond their MS.
29651|NCT03954704|Drug|GS-1423|Administered intravenously once every 2 weeks
29652|NCT03954691|Other|brain tumor-immune cells communication|tumoral and immune cell isolation from biopsis
30206|NCT03950141|Drug|Apatinib and S-1|Combined with Apatinib (250mg qd po) and S-1 (40-60mg bid d1-14) as maintenance therapy in advanced HER-2 negatived GC
29653|NCT03954678|Behavioral|Exercise Group|For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
29654|NCT03954678|Dietary Supplement|Nutrition Group|Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
29655|NCT03954665|Behavioral|10 km time trial|10 km Cycling time trial test will be conducted to examine the effects of the Exogenous Ketone Salts on time
29656|NCT03954665|Behavioral|30s Wingate|30s all-out test to measure peak power output
29657|NCT03954665|Dietary Supplement|Ketone|Supplement containing exogenous ketone salts
29658|NCT03954665|Behavioral|Baseline 10 km time trial|A baseline 10 km Cycling time trial test will be conducted
29659|NCT03954665|Behavioral|Baseline 30s Wingate|A baseline 30s all-out test to measure peak power output
29660|NCT03954652|Genetic|WGS-Diagnostic|Blood sampling, shot clinical characterization, WGS-based trio sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics), functional cell biology studies (for example in fibroblast cultures), RNA-seq.
29661|NCT03954639|Drug|EXPAREL 13.3Mg/mL Suspension for Injection|Combined Sciatic and Femoral Triangle Nerve Block with EXPAREL admixed with bupivacaine (Single Dose)
29662|NCT03954639|Drug|Bupivacaine Hydrochloride|Combined Sciatic and Femoral Triangle Nerve Block with Bupivacaine HCL
29663|NCT03954626|Biological|brolucuzumab 6 mg IVT|Single intravitreal injection (IVT) of brolucizumab 6 mg
29664|NCT03954613|Combination Product|Ebicomb|Combination product and combination product plus cognitive exercises will primarily be evaluated in this study
29665|NCT03954600|Drug|NPT520-34 (125 mg)|NPT520-34, 125 mg oral capsules (size 1)
29666|NCT03954600|Drug|Placebos (125 mg)|Placebo, 125 mg oral capsules
29667|NCT03954574|Diagnostic Test|assessment of pulmonary hemodynamics during exercise by right heart catheterization|all patients undergo right heart catheterization during exercise due to clinical reasons. Results of this and other Routine clinical tests will be included in the registry
29668|NCT03954561|Procedure|endoscopist-administered abdominal compression|The endoscopist administers abdominal compression when loop formation encountered.
29669|NCT03954561|Procedure|assistant-administered abdominal compression|A assistant administers abdominal compression when loop formation encountered.
29670|NCT03954548|Device|CB-17-08 SaMD|CB-17-08 Augmented Endoscopy System, a SaMD with Computer Aided Detection (CADe) function
29671|NCT03954535|Behavioral|Free2b|The intervention will consist of a website and 9 sessions. The intervention sessions will facilitate youths' acquisition of personal and social cognitive-behavioral skills. The intervention will focus on goal setting, decision making, enhancing self-worth, coping with stress, combating distorted thinking, communication skills, using alcohol and other drugs and a review session. Each session will require approximately 20 minutes and must be finished in a single sitting. Sessions will be delivered on a weekly basis. The website will include entertainment features and resources.
29672|NCT03954535|Behavioral|Attention-Placebo|Access to the website with entertainment features and resources - but no session content.
29673|NCT03954522|Other|interview|"Child = A clinical interview (recorded, duration approximately 30 min) and a scale of acute stress (IES child) will be performed at 2 times (during the 7 days following the first visit of hospitalized kin and 1 month after the kin was discharged from ICU)~Accompanying parent/kin = Semi-directive interviews (recorded - duration approximately 30 min) will be performed at the same time as those of the child and will be recorded. The parent/kin will also complete a socio-demographic questionnaire of the family group and a depression anxiety scale (HADS)~Nursing staff = A semi-directive interview (recorded - duration approximately 30 min) will be performed only once (during the 7 days following the first visit to the hospitalized kin). The caregiver will also complete a socio-demographic questionnaire and a Moral Distress Scale (MDS-R)~Hospitalized parent = One month after ICU discharge, a depression anxiety scale (HADS) and an acute stress scale (IES) will be performed"
29674|NCT03954496|Device|transcranial direct current stimulation|This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
29675|NCT03954496|Behavioral|Intensive upper extremity motor training|This training is administered one-on-one with an occupational therapist. Activities will be focused on skills the participant wants to regain.
29676|NCT03954483|Drug|Buspirone 10 Mg Oral Tablet|Orally administered prior to experiments.
29677|NCT03954483|Drug|Triazolam 0.25 MG Oral Tablet|Orally administered prior to experiments.
29678|NCT03954483|Drug|Placebo oral tablet|Orally administered prior to experiments.
29679|NCT03954457|Behavioral|A-CWS|The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.
29733|NCT03954015|Drug|Lumason|FDA approved and used routinely for ultrasound exams of the heart and liver as well as the urinary tract in children. It contains microbubbles that are small enough to pass through the blood stream.
30283|NCT03949517|Device|Investigational software and coils in PET/MR Scan|Investigational software and coils in PET/MR Scan by General Electric Healthcare
29680|NCT03954457|Behavioral|Standard Care Control|The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
29681|NCT03954444|Drug|Oxymetazoline Hydrochloride|Test Comparator
29682|NCT03954444|Drug|Rhofade Cream, 1%|Reference Comparator
29683|NCT03954444|Drug|Placebo|Placebo Comparator
29684|NCT03954431|Diagnostic Test|Contrast-media enhanced breast CT(CE-BCT)|The breast CT device will take multiple pictures of the subject's breast and create a 3-D image of the breast.
29685|NCT03954431|Drug|Iodinated Contrast Agent|The CE-BCT diagnostic test will use an iodinated contrast agent. This drug is FDA approved for contrast-enhanced x-ray imaging examinations, though not specifically for dedicated breast computed tomography.
29686|NCT03954418|Dietary Supplement|Acesulfame K, cyclamate, saccharine, aspartame|Intervention group receives a combination of multiple artificial sweeteners
29687|NCT03954392|Behavioral|Cognitive behavior therapy with social cognitive training (CBT+SCT)|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. We will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents. In addition, the investigators will teach the teen explicitly about theory of mind and social perspective taking during each session and we will use examples from their own life to help them learn the skills.
29688|NCT03954392|Behavioral|CBT-only|The cognitive behavioral therapy is based on Beck's cognitive therapy model for the treatment of depression. The investigators will conduct individual therapy based on the Coping with Stress manual used in other depression treatment studies with adolescents.
29689|NCT03954379|Drug|Standard of Care (ACB, SA, peri-op pain management)|"INTERVENTION BEFORE SURGERY~1) Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~INTERVENTION DURING SURGERY~1) IV propofol for sedation~INTERVENTION AFTER SURGERY~1) injection of salty water through the tube in the thigh x 2"
29690|NCT03954379|Drug|IPACK and multi-modal analgesic regimen|"INTERVENTION BEFORE SURGERY~Adductor Canal Block will be done using Adductor canal catheter (tube in the thigh) + injection of freezing medication~iPACK block ( infiltration between Popliteal Artery and posterior Capsule of the Knee) - injection of freezing medication in the back of the knee~INTERVENTION DURING SURGERY~IV dexmedetomidine~IV ketamine Both for sedation~INTERVENTION AFTER SURGERY~injection of freezing medication through the tube in the thigh x 2~IV dexamethasone 8 mg 1 day after surgery"
29691|NCT03954366|Drug|Rucaparib|Rucaparib 600 mg BID commencing on Day 5 until Day 23.
29692|NCT03954366|Drug|Rosuvastatin|Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.
29693|NCT03954366|Drug|Oral Contraceptives|Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.
29694|NCT03954340|Device|iRemember Neurofeedback (NFB)|"Neurofeedback (NFB) is a treatment technique based on learning with operant conditioning, in which a feedback (or a reward) is given in proportion with the desired physiological activity in order to improve cognition and/or behavior. This research will focus on EEG-NF where electrical activity measured with EEG serves as the physiological activity to be influenced.~EEG-NFB has been successfully used as a clinical tool for over 40 years treating various disorders from Autism , ADHD , Epilepsy , OCD and depression Electroencephalography (EEG) equipment is used to measure the electrical activity representing the neuronal activity of different parts of the brain.~During the treatment, electrode(s) are placed in predetermined location. Audio and visual rewards are given when the activity is measured to be within the desired frequency range."
29695|NCT03954327|Drug|Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)|Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
29696|NCT03954327|Drug|Raltegravir|Raltegravir (RTF) 600 mg two tablets by mouth once per day
29697|NCT03954327|Drug|Placebo Oral Capsule [CEBOCAP]|Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
29698|NCT03954314|Drug|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
29699|NCT03954301|Diagnostic Test|Anthropometric measures|Q, valgity angle, subtalar joint, medial longitudinal arch and hallux valgus angles were measured with a goniometer. The height from the ground of the navicula was calculated by caliper, using the Navicular drop test. Metatarsal width was also calculated with this device. Medial longitudinal arch angle, metatarsal width and nacivular drop tests were performed under weight-bearing and non-weight-bearing conditions.
29700|NCT03954288|Diagnostic Test|serum for sclerostin ELISA test|Blood sample to measure serum sclerostin level
29701|NCT03954275|Other|no intervention|no intervention
29702|NCT03954249|Procedure|Erecto Spinae nerve block|The ESPB is a myofascial block alternative to the paravertebral block. It is performed by injecting local anesthetic in the plane between the erector spinae muscle and the spinal transverse process. The ESPB is thought to be safer than the paravertebral block because the transverse process acts as a barrier to the pleura. It has been postulated that local anesthetic spread reaches the paravertebral space and in fact, cadaveric studies have shown dye spreading to involve the ventral and dorsal rami of spinal nerves.
29703|NCT03954249|Procedure|Multimodal Analgesia|Patients in the control group will receive standard 100mg pregabalin PO, midazolam 2mg IV, fentanyl 100mcg IV.
29704|NCT03954236|Drug|topical ruxolitinib 1.5% cream|Patients will be prescribed twice daily use of topical ruxolitinib 1.5% cream (randomized half of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days. Topical ruxolitinib will be provided as topical cream. At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
33002|NCT03927157|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
29705|NCT03954236|Other|Topical vehicle/moisturizer cream|Patients will be prescribed twice daily use of vehicle/moisturizer (for contralateral side of face/body) to a maximum of 20% BSA on each side for 28 ± 3 days.At the end of the 28 ± 3 days study visit, patients will remain blinded to treatment arms. After trial completion (day 28 ± 3 days), all patients will be offered repeated treatment cycle with topical ruxolitinib or standard of care therapy.
29706|NCT03954223|Behavioral|Low sugar and carbohydrate diet|Low sugar and carbohydrate diet (LSC, <90 gm carbohydrate (CHO)/day, <25 gm added sugar/day)
29707|NCT03954223|Behavioral|Time Limited Eating|16-hour fast/8-hour feed for 3 days per week
29708|NCT03954223|Device|Continuous Glucose Monitor|CGM (used to monitor adherence and glycemic outcomes without real time feedback)
29709|NCT03954210|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is an in-person, one-on-one program with a graduate psychology research assistant who is trained in providing a standardized CBT-I. Participants will maintain a sleep diary during the course of the program to aid in tailoring the program. Each session will begin with a summary and graphing of sleep diary data and will include an assessment of treatment gains and adherence.
29710|NCT03954210|Behavioral|Active Control|Participants in the active control group will attend six weekly, in-person, one-on-one, stretching and thinking activity sessions with a graduate research assistant to control for socialization and contact with research personnel.
29711|NCT03954197|Other|No hormone|No hormonal injection before oocytes retrieval
29712|NCT03954197|Other|hCG|a subcutaneous injection of hCG (Choriogonadotropin alpha, Ovitrelle®, Merck Serono, 250 µg) is performed 36 hours before oocytes retrieval
29713|NCT03954197|Other|GnRH a|a subcutaneous injection of GnRH agonist (triptorelin, Decapeptyl, Ipsen, 0,2 mg) is performed 36 hours before oocytes retrieval
29714|NCT03954184|Behavioral|NIATx-TI with Product Training/On-line Support|NIATx-TI framework includes the product training as well as a preimplementation phase and a post-implementation phase. A NIATx-TI coach will provide the training for this arm. The coach will also assist the organizations with applying the NIATx-TI framework.
29715|NCT03954171|Other|Patients treated with platinum based-chemotherapy|"Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):~before treatment initiation (blood sample),~during hospitalisation for surgery (blood sample),~during follow-up consultations (blood sample).~If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study."
29716|NCT03954158|Drug|Crisaborole ointment 2%|BID regimen
29717|NCT03954158|Drug|Vehicle|BID regimen
29718|NCT03954158|Drug|Crisaborole ointment 2%|QD regimen
29719|NCT03954158|Drug|Vehicle|QD regimen
29720|NCT03954145|Procedure|Enamel pumicing before bonding the lingual retainer.|"Lingual surfaces of the lower incisors and canines are pumiced before bonding the lingual retainer.~Teeth are being cleaned using a brush loaded with pumice and mounted on a low speed contra-angle. Teeth are then etched and the multi-braided retainer wire is being bonded with composite onto the lingual surfaces of the lower canines and incisors."
29721|NCT03954145|Procedure|Enamel sandblasting before bonding the lingual retainer.|"Enamel is being initially prepared through sandblasting the lingual surfaces of the mandibular canines and incisors.~Sandblasting is performed with the help of a MicroEtcher IIATM (Danville) which is projecting 50 μm Al2O3 particles onto the enamel surfaces. Teeth are subsequently etched and the retainer is then being bonded with composite onto the lingual surfaces of the mandibular incisors and canines."
29722|NCT03954132|Drug|Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist|LAMA+LABA
29723|NCT03954132|Drug|Triple combination of Free or fixed Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist + inhalative corticosteroids|(LAMA+LABA+ Inhalative Corticosteroids (ICS)
29724|NCT03954106|Drug|Defibrotide|Once daily on CAR-T Day -5, -4, -3 before lymphodepletion and also every 6 hours daily on CAR-T Day 0-7.
29725|NCT03954093|Device|Transcranial direct current stimulation|tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
29726|NCT03954080|Device|Intraspinal-optimal stim therapy|During the trial, percutaneous lead(s) will be implanted, following standard clinical practices, in the posterior epidural space with the final lead position located in the optimal area to provide pain relief by stimulating neural tissue in order to create paresthesia(s) only on the painful dermatome(s). During Intraspinal-Optimal Stim, a set of electrodes in the stimulation lead(s) will deliver a charge-balanced, pulsed electrical signal with stimulation parameters (frequency, pulse width, and amplitude) within the FDA approved specifications of the commercially available external neurostimulator. These will be adjusted to produce paresthesia coverage of the painful area. Patients that will report equal or greater than 50% reduction in pain, relative to baseline pain, may undergo permanent implantation of a commercially available neurostimulator (INS). This will require a surgical intervention to implant stimulation leads, INS and anchoring hardware followed by therapy programming.
29727|NCT03954067|Biological|ASP9801|Administered by intratumoral injection
29728|NCT03954054|Behavioral|"Choizitaconso therapeutic intervention program"|"The ChoiziTaConso therapeutic education program consists in 10 standardized weekly group workshops that target the recovery of conscious protective mechanisms with respect to alcohol use."
29731|NCT03954028|Procedure|Gingival Punch Biopsy after healing of Gingival Soft Tissue Augmentation|Patients needing gingival soft tissue augmentation will receive two kinds of gingival tissue graft material in a split-mouth design. The autogenous connective tissue (CTG) graft material will be randomized to apply to one half, and commercial acellular dermal matrix (ADM) materials will be used in the opposite half. After 3 months of healing, a gingival punch biopsy will be performed in both sides to collect the tissues for analysis.
29732|NCT03954015|Diagnostic Test|Contrast Enhanced imaging|Contrast Enhanced Ultrasound (CEUS) with US Microvessel Imaging, Contrast Enhanced Dual Energy Mammography (CEDM) and Contrast Enhanced Breast MR (CEMR): Comparison of Three Methods for Early Detection of Breast Cancer.
29734|NCT03954002|Diagnostic Test|TTE and TOE|"A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded."
29735|NCT03953989|Drug|Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in die|Patients enrolled in the study, at the end of the titration phase will be treated with ranolazine 750 mg or 500 mg, 1 oral tablet twice a day for 4 months on top of standard of care treatment
29736|NCT03953976|Radiation|Intensity modulated radiation therapy (IMRT)|Intensity modulated radiation therapy (IMRT) with or without chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel). 6.5-7 weeks of radiotherapy or chemoradiotherapy
29737|NCT03953963|Device|HydraSolve T2D™|The HydraSolve T2D™ System will be used to perform the combined minimally invasive laparoscopic and mini-laparotomy procedure to selectively extract excess intra-abdominal fat from the mesentery. All patients will receive standard nutritional counseling and their medications will be adjusted to achieve target levels of blood glucose control.
29738|NCT03953950|Drug|Spironolactone|Spironolactone Starting dose: 25 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep< 140/90 mmHg, but avoid hypotension <90/60 mmHg), and serum potassium level (<5.5 milliequivalent /liter)
29739|NCT03953950|Drug|Losartan|Losartan Starting dose: 50 mg/day Target dose: 100 mg/day Titration: every 1-2 weeks, based on BP (keep< 140/90 mmHg, but avoid hypotension <90/60 mmHg), and serum potassium level (<5.5 milliequivalent /liter)
29740|NCT03953924|Other|Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI)|The MI was implemented 2 times, 20 minutes each time, the trained nurse interviewed each patient face-to-face by bedside. Based on the evaluation results and motivational interviewing, the change stages of the patients' behavior changes were identified. According to the changing stage,TTM - based intervention was given 3 times in the form of a small course, 20 minutes each time, the key point was divided into three stages.
29741|NCT03953911|Biological|Mobile Clinic|This intervention involves the availability of a free mobile clinic operated by Cedar-Sinai Medical Center providing free HPV vaccinations at school campuses.
29742|NCT03953911|Behavioral|Educational Sessions for Parents|This intervention involves providing free weekly educational sessions for parents of students at the participant schools pertaining to the HPV Vaccination.
29743|NCT03953898|Drug|Olaparib|Given PO
29744|NCT03953885|Other|Fire needle|"Participants wear eye masks and fully expose the lesions. After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation. After selecting an acupuncture needle with a specification of 0.4*40mm and ignites the alcohol lamp, the operator continuously moves the needle from the needle root to the needle tip to burn the red needle to disinfect the needle in the outer flame of the alcohol lamp.~The operator ignites the alcohol lamp, and burns the needle tip and the needle body to the outer flame of the alcohol lamp until it is completely red (the length of the needle burning red is determined by the acupuncture depth), and then rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
29745|NCT03953885|Other|Fire needle Placebo|"Participants wear eye masks and fully expose the lesions (no lesions on the head and face, external genitalia and skin folds). After selecting the acupuncture points, the surgeon routinely disinfects the hands of the operator and the acupuncture points of the participants before the operation, then selects an acupuncture needle with a specification of 0.4*40mm to prepare for operation.~The operator rapidly penetrates the skin lesion vertically, the depth of the acupuncture is based on the thickness of the skin lesion, when the operation is performed, the outer edge of the lesion is punctured to the center point, and the spacing is 0.3 to 0.5 cm."
29746|NCT03953859|Genetic|double strand break|an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
29747|NCT03953846|Device|NUsurface meniscus implant|The NUsurface® Meniscus Implant is a medical device developed for treating subjects with painful medial knee compartment due to meniscus deficiencies.
29748|NCT03953833|Biological|Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.|"Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.~Infusion time：90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle."
29749|NCT03953820|Drug|Diazepam|Film administered according to weight
29750|NCT03953820|Drug|Diastat Rectal Gel|Gel administered according to weight
29751|NCT03953807|Drug|Dexamethasone Intravitreal Implant|Implant 700 μg
29752|NCT03953794|Device|Fitbit Charge 3|Smart watch monitoring activity and movement, heart rate, sleep, and more
29753|NCT03953781|Drug|Effect of valporate on Reproductive Functions in Newly Diagnosed Epileptic Males|
29754|NCT03953781|Drug|Effect of levetiracetam on epileptic males reproductive function|
29755|NCT03953768|Device|Vagal nerve stimulation (VNS)|Implantation with vagal nerve stimulator for epilepsy
29756|NCT03953755|Procedure|Tricuspid valve repair|Tricuspid valve repair
29757|NCT03953742|Drug|CPI-200|CPI-200 will be administered via intravenous infusion on Day 1 of a 21-Day cycle
29758|NCT03953729|Drug|Ibuprofen|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the drug shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
29759|NCT03953729|Drug|Placebo|"The child and his / her guardian shall immediately upon arrival for informed about the participation in the research, being evaluated on the criteria of inclusion and exclusion described above. Soon after the signature by the responsible for the child of the Informed Consent Form (Appendix A), the placebo shall be administered at the dosage established by Clark's formula, according to the weight of each child. It will then be evaluated the degree of anxiety of the child in front of the dental treatment using the scale Children's Fear Survey Schedule-Dental Subscale (Barberio, 2017). After 30 minutes of drug administration, treatment will start."
29760|NCT03953716|Device|low level light therapy|Start using low level light therapy after the menstrual period, once a day, every 20 minutes * 5 days ( one treatment cycle), start the next course at intervals of 2 days until the next menstruation
29761|NCT03953716|Drug|DING KUN DAN|DING KUN DAN,3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
29762|NCT03953716|Drug|Simulated drug of DING KUN DAN|Simulated drug of DING KUN DAN，3.5g BID for 10 days (starting 3-5 days before menstruation) *3 menstrual cycle
29763|NCT03953716|Drug|Marvelon|Marvelon 1 pill QD*21 days (starting on the 5th day of menstruation, continuing the next cycle after 1 week of withdrawal) *3 menstrual cycle
29764|NCT03953703|Drug|Levocarnitine|Levocarnitine 1000mg once per day for 2 weeks followed by 1000mg twice per day for 10 weeks
29765|NCT03953703|Drug|Placebo|Placebo 1000mg once per day for 2 weeks followed by 1000mg twice per day to 10 weeks
29766|NCT03953690|Other|use of e-Health service|use of the e-Health e-Lupus account (at least) once a month and encouraged to advise his doctor to consult the entered data before the following consultation
29767|NCT03953677|Drug|Dexmedetomidine 100 Mcg/mL Intravenous Solution|Continuous infusion of dexmedetomidine at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
29768|NCT03953677|Drug|5% glucose Infusion solution|Continuous infusion of placebo (5% glucose) at 0.7 µg/kg/h for 2 hours and then 1 µg/kg/h at fixed dose
29769|NCT03953664|Other|Experimental-Exercise training|Each session lass 60 minutes, during which time 20 minutes are allocated for warming up and cooling down (stretching) and 40 minutes are allocated to strength or/and aerobic training exercises.
29770|NCT03953651|Other|Follow-up|Onset of Major Adverse Cardiovascular Event of death from all causes will be collected at 3 and 6 months after inclusion.
29771|NCT03953638|Diagnostic Test|Next Generation Sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
29772|NCT03953625|Other|delivery of the low back pain booklet|"When a patient arrives at the GHPSJ emergency room or in general medical consultation at the CMT and a diagnosis of common acute low back pain is made, the physician verifies the study selection criteria.~If it is randomized in the arm 2 with booklet group, the management will be the same as for the without booklet group but with the hand delivery of the booklet in addition.~All patients will be informed about the existence of the booklet. A link to the digital version on the ameli.fr website is included in the information note The patient will be contacted 3 months later by a Clinical Research Associate (CRA) to conduct a data collection."
29773|NCT03953612|Drug|PREG 300/500 mg|2 doses of PREG (300/500 mg/day)
29774|NCT03953612|Drug|Placebos|placebo
29775|NCT03953599|Biological|CD19-STAR-T cells|CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
29776|NCT03953586|Diagnostic Test|Bubble suction test and tubal peristalsis|Efficacy of this test in cases of hydrosalpnix (group A) and normal tubes (group B)
29777|NCT03953573|Other|Survey|Survey completed at 1 day, 8 days 1 or 3 months post delivery
29778|NCT03953560|Diagnostic Test|dyspnea grade ≥ II according NYHA-WHO|"Intervention Investigator from each center will recover consecutives PE patients and collect baseline, demographic and comorbidities.~In all patients enrolled in the study a short questionnaire regarding dyspnea symptoms will be performed. All patients that refer dyspnea grade ≥ II according NYHA-WHO (6) modified scale will be cited as outpatient to be evaluated~Imaging studies and right heart catheterization is the procedure agreeing with the standard care according to current ESC/ERS Guidelines.~In all patients, the following tests will be performed:~Pulsioximetry.~Electrocardiogram.~Blood sample with determination of NT-ProBNP.~Echocardiography. Only an echocardiography indicative of PH warrants further evaluation~V/Q scintigraphy. Possible CTEPH can be assumed when mismatched perfusion defects are detected by VQ scan.~Right heart catheterization & Pulmonary CT Scan are required for confirming the diagnosis"
29779|NCT03953521|Device|intermittent Theta burst stimulation|Stimulation of the left dorsolateral prefrontal Cortex with a specific repetitive transcranial magnetic Stimulation protocol (intermittent Theta burst Stimulation) according to Blumberger et al., 2018, Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018 Apr 28;391(10131):1683-1692.
29780|NCT03953508|Other|Cigarette flavor type|Participants will smoke several puffs (each) of a menthol Camel Crush and several puffs of a non-menthol Camel Crush cigarette.
29781|NCT03953495|Behavioral|Better Together|The Better Together Intervention consists of a 7 self-paced online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, post-intervention, and at a 3 month follow up.
29820|NCT03953183|Other|P3P-1mg|P3P-1mg (P3P product containing 1mg of nicotine.)
29821|NCT03953183|Other|P3P-2mg|P3P-2mg (P3P product containing 2mg of nicotine.)
29858|NCT03952884|Behavioral|No Resistance Exercise|Participants allocated to this group will not perform exercise prior to the administration of the nutritional intervention. Participants will remain at rest throughout the trial.
29782|NCT03953495|Behavioral|Better Together (delayed)|The Better Together (Delayed) Intervention consists of a 7 online relationship education modules. Following an introductory and overview module couples will complete each of the following together on their web-connected device (computer, ipad, phone). Each module includes didactic material, demonstration vignettes, and guided discussions or skills building exercises. Module 1 focuses on identifying individual and relationship strengths; Module 2 focuses on destructive communication patterns, Module 3 focuses on positive communication skills; Module 4 teaches a problem-solving technique; Module 5 focuses on stress and coping; Module 6 focuses on relationship expectations and commitment, and Module 7 provides a summary of the program. Each module takes approximately 30 minutes to an hour to complete. Metrics will be assessed at baseline, pre-intervention, post-intervention, and at a 3 month follow up.
29783|NCT03953469|Dietary Supplement|Passiflora incarnata|One-time administration of 1/8 tsp solid extract Passiflora incarnata providing 900mg of Passiflora incarnata
29784|NCT03953469|Behavioral|Audio-Guided Meditation|10 minute audio-guided meditation via HeadSpace mobile application
29785|NCT03953456|Drug|elafibranor 120mg|elafibranor 120mg is a coated tablet for oral administration, once daily
29786|NCT03953456|Drug|Placebo|Placebo is a coated tablet for oral administration, once daily
29787|NCT03953443|Other|Not interventional|
29788|NCT03953430|Other|Gait analysis|
29789|NCT03953417|Device|Bilateral accelerated intermittent theta-burst treatment|"All participants will receive bilateral accelerated intermittent theta-burst stimulation to the left and right DLPFC. Treatment will be targeted by utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold adjust to the skull to cortical surface distance.~Stimulation will be delivered to left and right-DLPFC using the MagPRo stimulator."
29790|NCT03953404|Diagnostic Test|SPLA2-IIA|bedside blood test
29791|NCT03953391|Other|Tea|Subjects walk to a nearby area and prepare a cup of 150 ml tea once every hour. The tea is consumed whilst being seated at their desks.
29792|NCT03953391|Other|Water|150 ml water is served to subjects once every hour. The water is consumed whilst being seated at their desks.
29793|NCT03953378|Other|Multi-parametric Flow Cytometry analysis on patients and healthy donors samples|"Collection of venous blood (16 mL) and synovial fluid (when available) samples, for each patient, at inclusion and in the frame of the usual medical follow-up at 3 months and between 6 and 12 months, before the onset of MTX (untreated patients) or during the course of MTX treatment (MTX-treated patients).~Collection of anonymous healthy donors blood samples, age- and sex-matched, obtained from the Etablissement Français du Sang.~Multi-parametric Flow Cytometry analysis was performed on these samples to assess CD73 expression on total memory T cells and within T helper lymphocyte subsets, their cytokine production and AMPase functions. For FoxP3 intracellular staining, cells were treated using the FoxP3 Fixation and Permeabilization kit (Life Technologies), according to manufacturer instructions. Stainings were analyzed on a LSR-Fortessa™ (BD Biosciences) with conserved settings throughout the entire study and data were analyzed using FlowJo™ Software (Tree Star v10.4)."
29794|NCT03953365|Procedure|Prophylactic Mesh|Prophylactic Mesh after closure of the abdominal wall after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
29795|NCT03953352|Other|Helical intensity-modulated radiotherapy (IMRT)|Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.
29796|NCT03953339|Procedure|Release or no release of the suprascapular nerve|
29797|NCT03953326|Behavioral|HeartPhone app|Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)
29798|NCT03953326|Drug|Acetylcholine|Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter
29799|NCT03953326|Drug|Sodium Nitroprusside|Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor
29800|NCT03953326|Drug|L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester|This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.
29801|NCT03953300|Biological|Benralizumab|Benralizumab: 30 mg/mL solution for injection in accessorized prefilled syringe (APFS) will be administered subcutaneously (SC) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
29802|NCT03953300|Biological|Placebo|Matching placebo will be administered subcutaneously with accessorized prefilled syringe (APFS) every 4 weeks for the first 3 doses - Weeks 0, 4 and 8, and then every 8 weeks - Weeks 16, 24, 32, 40.
29803|NCT03953287|Drug|Paracetamol|A randomized, cross over design
29804|NCT03953261|Drug|Curcumin supplement|Intervention is 2 grams of curcumin supplement per day
29805|NCT03953248|Drug|L-Carnitine|
29810|NCT03953222|Device|Wearable real-time feedback device|The proposed wearable device can provide real-time feedback of primary gait and posture measures through auditory feedback. The feasibility of people with Parkinson's disease (PD) to utilize to feedback to modulate and improve their gait and posture will be investigated. Two types of feedback will be studied: (a) continuous feedback involving sonification of movements to facilitate learning proper movements (such as to take big steps, swing arms, rhythmic walking, maintain upright posture, etc.) and (b) on-demand feedback where the feedback is provided only if necessary to reduce overload of information and prevent developing dependency on the system.
29811|NCT03953209|Drug|Spironolactone 50Mg Tablet|Oral administration of one spironolactone 50 mg tablet once daily for 12 weeks
29812|NCT03953209|Drug|Spironolactone 100Mg Tablet|Oral administration of one spironolactone 100 mg tablet once daily for 12 weeks
29813|NCT03953209|Drug|Spironolactone 200Mg|Oral administration of two spironolactone 100 mg tablets once daily for 12 weeks
29822|NCT03953170|Drug|Teduglutide|"Teduglutide (Gattex, Shire) was approved by the FDA in 2012 for use in adult patients with short bowel syndrome requiring parenteral support only.~The results of this study will not be used to justify a change of indication, or dose currently approved for Teduglutide, and will not be used to advertise the drug. This study meets all of the requirements for exemption from the IND regulations and an IND exemption has been confirmed by the FDA."
29823|NCT03953170|Drug|Placebo|Placebo
29824|NCT03953157|Dietary Supplement|Dietary Intervention|Receive dietary intervention
29825|NCT03953157|Behavioral|Exercise Intervention|Receive exercise intervention
29826|NCT03953157|Other|Questionnaire Administration|Ancillary studies
29827|NCT03953144|Device|VisiblePatient™ 3D Lung Modelling|The 3D virtual models provided by Visible Patient™ will be made by experts in medical image analysis using the high-resolution CT scans. Patients will have 3D virtual reconstructions of their pulmonary anatomy with the target lesion created pre-operatively.
29828|NCT03953144|Drug|IC-Green (ICG)|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
29829|NCT03953131|Procedure|Computed Tomography|Undergo PET/CT
29830|NCT03953131|Radiation|Gallium Ga 68-DOTATATE|Given IV
29831|NCT03953131|Procedure|Positron Emission Tomography|Undergo PET/CT
29832|NCT03953118|Drug|Azithromycin Oral Product|Oral azithromycin dosed at 1 gram per week for 3 weeks
29833|NCT03953118|Drug|Placebo Oral|Oral placebo tablet
29834|NCT03953105|Device|ePER|usind the ePER for weight estimation and suggestion of the defined parameter
29835|NCT03953105|Device|BT|usind the BT for weight estimation and suggestion of the defined parameter
29836|NCT03953092|Drug|YG1699|YG1699 at Multiple Doses
29837|NCT03953092|Drug|Placebos|Placebos
29838|NCT03953079|Drug|Drug: GB-102|Intravitreal injection of GB-102
29839|NCT03953079|Drug|Aflibercept|Intravitreal injection of aflibercept (2 mg dose)
29840|NCT03953066|Other|The calculation of blood IL-6 and coloctral milk melatonin|Collected maternal colostral milk will be sampled for melatonin levels.Blood samples driven before and after delivery will be evaluated for IL-6 levels in each group
29841|NCT03953053|Device|Femtosecond Laser Assissted Cataract Surgery|During routine Catarct Surgery the Femtolaser cuts a ACCC (Anterior Continous Curvilinear Capsulotomy) into the lensbag and fragmentise the cataract affilited lens body
29842|NCT03953040|Diagnostic Test|intracoronary imaging (IVUS, OCT)|Patients presenting with non STE-ACS will be subjected after performing PCI of the culprit lesion to intracoronary imaging with the help of IVUS and OCT of the non-culprit lesions to detect and image the so-called vulnerable plaques
29843|NCT03953027|Other|Survey Administration|Ancillary studies
29844|NCT03953001|Device|Adminstration Technique using Buzzy external distractor|External application of Buzzy distractor during administration of dental anesthetic
29845|NCT03953001|Drug|2% Lidocaine with 1:50,000 epinephrine|Local Dental anesthetic infiltration
29846|NCT03953001|Drug|Topical Anesthetic|20% Benzocaine gel was applied on the area of infiltration
29847|NCT03952988|Dietary Supplement|Probiotic ice cream|One portion (50g) of an ice-cream containing the probiotic B. bifidum 900791 (>10(exp7)/g) every day for 4 weeks
29848|NCT03952988|Dietary Supplement|Placebo ice cream|One portion (50g) of an ice-cream without probiotic every day for 4 weeks
29849|NCT03952975|Other|Vaginal bleeding|Vaginal bleeding was classified into four categories according to the timing. Intraoperative bleeding (defined as bleeding that occur during the LEEP procedure), early postoperative bleeding (defined as bleeding that occur between end of the LEEP procedure and home discard), late postoperative bleeding (defined as bleeding that occur within two weeks after the home discard, and required hemostatic interventions such as electrocauterization, gauze packing, or cervical suturing, excluding menstrual bleeding), and persistent postoperative bleeding (defined as vaginal bleeding that occurs more than 2 weeks after the procedure with or without required hemostatic interventions, excluding menstrual bleeding).
29850|NCT03952962|Device|Abbott Laboratories Infinity™ implantable deep brain stimulation system|Deep brain stimulation (DBS) refers to the process of delivering an electrical current to a precise location in the brain.
29851|NCT03952949|Behavioral|Default Option While Online Grocery Shopping|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up). Participants in the default condition were presented with a prefilled online shopping cart containing groceries that met nutritional requirements based on participants' gender and age."
29852|NCT03952949|Behavioral|Nutrition Education|"The nutrition education materials were adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
29853|NCT03952936|Other|Vestibular Rehabilitation|standard vestibular rehabilitation with gaze stability, balance training, habituation tailored to the subject
29854|NCT03952923|Biological|CD19-CAR-T cells|CD19-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.
29855|NCT03952910|Other|Online pain education program|Online pain education program
29856|NCT03952897|Other|balneotherapy|10 days of balneotherapy with immersion techniques using Fitero spa water.
29857|NCT03952884|Behavioral|Resistance Exercise|Prior to protein consumption participants will perform an acute bout of resistance exercise. They will warm up with two sets of 10 repetitions at 35-75% working load respectively, then perform four working sets of 10-12 repetitions at 65-70% of 1-RM. 1 min, 30 sec rest periods will be implemented between each set.
29919|NCT03952442|Other|routine nutrition education|Give nutrition education if the patient visits the clinics. Irregular survey and intervention were given to the patients.
29859|NCT03952884|Dietary Supplement|Leucine|Participants will be given 2g of leucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
29860|NCT03952884|Dietary Supplement|Dileucine|Participants will be given 2g of dileucine dissolved in 250mL of water. Drink will be consumed immediately after exercise or equivalent time point for non-exercise group.
29861|NCT03952858|Other|Telerehabilitation Group|The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.
29862|NCT03952845|Other|Capsaicinoid|This is a tolerability study on doses lower than previously published for the use of intranasal capsaicinoid in the treatment of rhinitis
29863|NCT03952832|Drug|Leflunomide|Given PO
29864|NCT03952832|Other|Quality-of-Life Assessment|Ancillary studies
29865|NCT03952832|Other|Questionnaire Administration|Ancillary studies
29866|NCT03952819|Diagnostic Test|serum sclerostin|blood samples obtained
29867|NCT03952806|Drug|Verdiperstat|300mg 2 -oral- capsules, BID
29868|NCT03952806|Drug|Placebo|Matching placebo
29869|NCT03952793|Other|extended biopsy|Additional sample are performed during a biopsy to provide tumor tissues for the organoid technique development
29870|NCT03952767|Other|Digital Physical Measures and Survey Assessments|Data from at home and in clinic visits will assess physical function and survey data will be collected
29871|NCT03952754|Behavioral|Hip Hop Nutrition-Math Curriculum|This program teaches children skills needed to understand restaurant-menu boards, how to make healthy food choices, while reinforcing the common core math concepts they are learning in school. The program consists of: 2 lessons a week, of about 1 hour each lesson, for a total of 20 lessons.
29872|NCT03952754|Behavioral|Food Explorers Program|"After-school program Food Explorers will represent Usual Care. This program comprises food and exploration activities, familiarizing children with diverse foods, nutrition concepts, tasty recipes and physical activity."
29873|NCT03952741|Behavioral|Physical Therapy|
29874|NCT03952728|Behavioral|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
29875|NCT03952728|Behavioral|Diabetes support and education|Behavioral intervention focused on diabetes support and education
29876|NCT03952715|Drug|Ibuprofen 400 mg|Each subject will receive Ibuprofen once, in between two psycho-physical assessments. Between the drug intake and the second assessment the subject will have to wait for 40 minutes.
29877|NCT03952715|Drug|Placebo oral tablet|Each subject will receive Placebo (sugar pill) once, in between two psycho-physical assessments. Between the placebo pill intake and the second assessment the subject will have to wait for 40 minutes.
29878|NCT03952702|Procedure|Myopic overcorrection|Myopic overcorrection
29879|NCT03952689|Device|Serenno Medical Automatic Urine Output measuring device|"Device that measures ongoing urine output will be connecter to the patients catheter. The urine count of the device will be compared to the gold standard measurement technique (nurse count)."
29880|NCT03952676|Device|Moving cupping|"We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)~(1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds."
29881|NCT03952676|Device|Moving cupping placebo|Using of special perforated cups, the manipulation method is the same as the intervention group.
29882|NCT03952663|Procedure|inferior alveolar nerve lateralization and dental implant placement.|inferior alveolar nerve lateralization for placement of sufficiently long dental implants.
29883|NCT03952663|Procedure|platelet rich fibrin membrane around the nerve|platelet rich fibrin membrane is prepared from the patient's blood and placed around the nerve.
29920|NCT03952429|Behavioral|Anti Alcohol App with Active Cognitive Bias|The active version includes an active form of cognitive bias modification, i.e. the user has to avoid alcohol stimuli 90% of the time, while they approach soft drinks 90% of the time.
30284|NCT03949517|Procedure|PET/MRI|Positron emission tomography (PET)/Magnetic resonance imaging (MRI) Scan
33003|NCT03927157|Other|Placebo|Placebo subcutaneous injection
29887|NCT03952637|Biological|AAV9-GLB1|The risks of administering this treatment in a subject with GMl gangliosidosis are not completely known. The major risk associated with intravenous infusion is from the subject's immunological response to the viral capsid and/or the beta-gal protein. To reduce this possibility, immune modulation therapy is being started prior to vector delivery and maintained for six months afterward. There is a theoretical risk that the integration of a small percentage of the rAAV vector DNA into the host cell genome could cause cellular transformation to cancer cells and lead to a malignancy. This has never been seen in subjects receiving intravenous AAV9 gene therapy so the risk of this complication, is likely very low.
29888|NCT03952611|Procedure|Colonoscopy|Using an instrument called colonoscope which is used to detect colonic polyps
29889|NCT03952611|Device|distal Cap|Using an instrument called cap at end of colonoscope which is used to straighten colon folds
29890|NCT03952611|Device|Endocuff|Using an instrument called Endocuff at end of colonoscope which is used to straighten colon folds
29898|NCT03952572|Drug|Cyclophosphamide|750mg/m² ivgtt on day 1
29899|NCT03952572|Drug|pegylated liposomal doxorubicin|40mg/m² ivgtt on day 1
29900|NCT03952572|Drug|Vincristine|1.4mg/m²(Maximum 2 mg) ivgtt on day 1
29901|NCT03952572|Drug|Prednisone|Prednisone100mg/m² po on day1-5
29902|NCT03952572|Drug|Doxorubicin|50mg/m² ivgtt on day 1
29903|NCT03952559|Drug|Baricitinib|Administered orally
29904|NCT03952559|Drug|Placebo|Administered orally
29905|NCT03952559|Drug|Topical corticosteroid|Administered as standard-of-care
29906|NCT03952546|Device|Saline-coupled Bipolar Sealer|The Aquamantys® System is a commercially available device used routinely used in the operating room for a wide variety of surgical cases. It allows for temperatures to stay at approximately 100°C, nearly 200°C less than conventional devices, which produces a tissue effect without the charring associated with other methods. The temperature is sufficient to shrink collagen fibers in the walls of blood vessels, effectively sealing the blood vessels, resulting in the reduction in bleeding from both soft tissue and bone. The device can be used to spot coagulate vessels that are actively bleeding or to broadly paint tissue surfaces to prevent bleeding or treat active oozing.
29907|NCT03952546|Device|Unipolar electrocautery|The Coviden ForceTriad™ energy platform is a full-featured electrosurgical system that provides electrosurgical cutting and coagulation, bipolar functionality, and vessel sealing in a single generator.
29908|NCT03952533|Dietary Supplement|Dav|Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
29909|NCT03952520|Other|Standard Intervention Mapping (IM)|"The implementation strategies for IM sites will be one-size-fits-all, identified through centralized Intervention Mapping. The IM sites will be given a set package of implementation strategies for use to implement SNaP at their sites.~Before SNaP implementation starts, the specific set of one-size-fits-all implementation strategies will be determined through a formal process with investigators, government stakeholders, and clinical representatives."
29910|NCT03952520|Other|Tailored Intervention Mapping (TIM)|The implementation strategies for TIM sites will be tailored to match site-specific barriers to implementation of SNaP at that site. The TIM sites will be able to choose implementation strategies from the set of implementation strategies offered in the IM arm, and in addition, the TIM sites will receive an expanded menu of implementation strategies that they can also choose from for use to implement SNaP at their sites, based on assessment of their site-specific barriers.
29911|NCT03952507|Drug|JNJ-64417184 600 (Oral Tablet Formulation)|Participants will receive 600 mg of JNJ-64417184 as oral tablet.
29912|NCT03952507|Drug|JNJ-64417184 (Oral Suspension Formulation)|Participants will also receive JNJ-64417184 600 mg as oral suspension.
29913|NCT03952494|Genetic|Genecept Assay|Genecept Assay, a genetic test produced by Genomind, Inc., King of Prussia, Pennsylvania,that analyzes both pharmacokinetic and pharmacodynamic genes. The current test includes the analysis of 12 pharmacodynamic genes and six pharmacokinetic CYP450 genes that have been shown in numerous clinical studies to have implications for response to treatments used for depression, anxiety, OCD, ADHD, bipolar disorder, PTSD, autism, schizophrenia, chronic pain and substance abuse. The genes assessed by the assay target major hepatic enzymes and key neurotransmitter pathways including serotonin, dopamine, norepinephrine and glutamate.
29914|NCT03952481|Drug|Lifitegrast 5% Ophthalmic Solution|Participants will received lifitegrast 5% ophthalmic solution twice a day in each eye for approximately 4 weeks.
29915|NCT03952468|Device|Transcranial Magnetic Stimulation|Administration of rapidly fluctuating magnetic field, delivered over the dorsolateral prefrontal cortex.
29916|NCT03952468|Other|Brief Cognitive Behavioral Therapy|BCBT is a well-established and efficacious treatment that is an extension of Cognitive Behavioral Therapy, a treatment that is widely implemented across VA health care systems.
29917|NCT03952455|Procedure|Bilateral surgical implantation of DBS system to Nucleus Accumbens|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
29918|NCT03952442|Other|standardized nutrition education|Give nutrition health education every two weeks and regular survey and intervention. The education booklets are made based on the guideline and characteristics of the disease.
29921|NCT03952429|Behavioral|Inactive Cognitive Bias Modification|The control version includes an placebo form of cognitive bias modification, i.e. the users avoid and approach alcohol and softdrink stimuli for an equal number of trials.
29922|NCT03952416|Behavioral|Enhanced Medical Rehabilitation (EMR)|"EMR is a set of behavioral skills that therapists can incorporate into their daily therapy sessions to increase patient engagement and achieve a high intensity of therapy, thereby improving functional and psychosocial outcomes of patients in medical rehabilitation. EMR was built on theories of behavior change, including social cognitive theory and self-regulatory theory, and their applications to patient engagement, such as the Health Action Process Approach and motivational interviewing. It has three foci: (1) a patient-directed, interactive approach stemming from patient-centered goals (Patient as boss); (2) frequent feedback to patients on their efforts and progress (Link activities to personal goals); and (3) increased rehabilitation intensity (Optimize intensity)."
29923|NCT03952403|Drug|HLX10, an engineered anti-PD-1 antibody|HLX10 will be administered as IV infusion at a dose of 4.5mg/kg on Day 1 of each 21-day cycle until loss of clinical benefit or up to 2 year.
29924|NCT03952403|Drug|HLX04, a bevacizumab biosimilar|HLX04 will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
29925|NCT03952403|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 on Day 1 of each 21-day cycle for 4 cycles, or until loss of clinical benefit whichever occurs first.
29926|NCT03952403|Drug|Pemetrexed|Pemetrexed will be administered as IV infusion at a dose of 500 milligrams per square meter (mg/m2) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, death or up to 2 year.
29927|NCT03952390|Other|control|
29928|NCT03952390|Other|sepsis|
29931|NCT03952364|Other|PredictSURE IBD™|To evaluate a test called PredictSURE IBD™ in the US population
29932|NCT03952351|Radiation|CT Coronary Angiography (CTCA)|CTCA scan in accordance with British Society of Cardiovascular Imaging CT guidelines
29933|NCT03952338|Other|Food coupons|Participants will receive 16 coupon sheets (each sheet contains $21 in coupons) over 10-15 weeks (households with 5-8 individuals will receive 32 coupon sheets) to purchase fruits, vegetables, dairy, meat/poultry/fish, eggs, nuts, and cut herbs at participating BC farmers' markets.
29934|NCT03952338|Other|Nutrition skill-building|Participants will be invited to participate in nutrition skill-building activities throughout the intervention period. To be consistent with the real-world program, the frequency and types of skill-building activities offered will vary by community partner, and participation is not required.
29935|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
29936|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
29937|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
29938|NCT03952325|Drug|Nivolumab|Nivolumab at 360 mg by intravenous infusion Q3W
29939|NCT03952325|Drug|Pembrolizumab|Pembrolizumab at 200 mg by intravenous infusion Q3W
29940|NCT03952325|Drug|Atezolizumab|Atezolizumab at 1,200 mg by intravenous infusion Q3W
29941|NCT03952325|Drug|Tesetaxel|Tesetaxel at 27 mg/m2 orally Q3W
29942|NCT03952312|Behavioral|Oncotool Intervention (symptom reporting + TKI education)|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with side effects and improve health-related quality of life. OncoTool provides symptom education and management for dealing with the numerous physical and mental side effects associated with TKIs (e.g., fatigue, nausea, skin toxicity). OncoTool is a website designed to improve TKI adherence by improving quality of life and TKI associated symptom burden, as well as providing a portal for provider-patient communication via a bi-weekly health questionnaire. Both intervention and active comparator conditions are administered to participants for 8 weeks.
29943|NCT03952312|Behavioral|Oncotool Control (health information)|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to cancer patients, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar TKI education content as the experimental content but without the side effect education or physician notification. Both intervention and active comparator conditions are administered to participants for 8 weeks.
29944|NCT03952299|Drug|Oxybutynin Transdermal Patch|Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
29945|NCT03952299|Drug|Oral Oxybutynin|Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
29946|NCT03952286|Drug|ED-Dispensing home and school supervision|"Oral prednisolone based on body weight to achieve a daily dose of 2mg/kg/day not to exceed 40 mg per day for 5 days or its equivalent (provided in the emergency department),~360 ug of budesonide inhalation powder once-daily for at-home use, and~albuterol sulfate as needed for relief of acute respiratory symptoms."
29947|NCT03952273|Combination Product|PCI with BioMatrix Alpha™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
29948|NCT03952273|Combination Product|PCI with Combo™ stent|Randomozation between either Sirolimus eluting and endothelial progenitor cell Combo™ stent or Biolimus eluting absorbable polymer coated BioMatrix Alpha™ stent
29949|NCT03952260|Other|Fasting time for clear fluid prior to anaesthesia|"This study is to evaluate the latest fasting protocol that is currently adopted and recommended by United Kingdom, France and Royal Children Hospital Melbourne.~The research question is should we change our fasting protocol for paediatric patients prior to operation The anaesthesia service is being studied. Prior to induction, the amount of abdominal contents was examined using ultrasound scan. In addition, parents will complete a questionnaire after the surgery to assess anxiety level of patients before and after the surgery."
29950|NCT03952247|Device|Single Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by single use bronchoscopy
29951|NCT03952247|Device|Conventional Multi Use Bronchoscopy for PDT|optical guidance of percutaneous tracheotomy is done by conventional multi use bronchoscopy
29952|NCT03952234|Drug|L-Citrulline|To determine the safest maximum dose of L-Citrulline which could be used as a potential treatment for adults with disorder of energy metabolism called MELAS
55530|NCT03750565|Drug|Placebo|oral capsule/tablet, QD
29953|NCT03952221|Device|Continuous ultrasound therapy|continuous US therapy once a day, 9 minutes/session for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity
29954|NCT03952221|Device|pulsed ultrasound therapy|pulsed US therapy once a day, 9 minutes/session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 3 MHz frequency, 1,5 W/cm2 SATA intensity, 50% duty cycle
29955|NCT03952221|Device|US and electrotherapy (sonotens)|US and electrotherapy (transcutaneous electrical nerve stimulation) once a day, 10 minutes /session, for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, US: 3 MHz frequency, 0,5 W/cm2 SATA intensity, TENS: application in conventional mode at 100 Hz frequency and 100 μs wavelength
29956|NCT03952221|Device|Sham ultrasound therapy|sham US therapy once a day for two weeks (10 occasions) with BTL-4825S Premium device, 5 cm2 probe, 0 MHz frequency, 0 W/cm2 SATA intensity
29957|NCT03952208|Other|Neurocognitive Testing|A comprehensive assessment of neuropsychometric measures to evaluate cognitive functioning.
29958|NCT03952182|Other|Spinal Orthosis (LSO, TLSO)|spinal orthosis prescribed for specific spinal fracture (TLSO for thoracic or high lumbar fracture, LSO for lumbar fracture)
29959|NCT03952182|Other|No orthosis|no orthotic given for spinal fracture. These patient's will be given a bending restriction
29960|NCT03952169|Dietary Supplement|Lactobacillus paracasei dietary supplement|a commercial probiotic dietary supplement
29961|NCT03952169|Other|Placebo controls|placebo with a similar appearance to probiotics supplement
29962|NCT03952156|Genetic|HMI-102|HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene
29963|NCT03952143|Drug|LY900014|Administered SC
29964|NCT03952143|Drug|Insulin Lispro|Administered SC
29965|NCT03952143|Drug|Insulin Glargine|Administered SC
29966|NCT03952143|Drug|Insulin Degludec|Administered SC
29967|NCT03952130|Drug|LY900014|Administered SC
29968|NCT03952130|Drug|Insulin Lispro|Administered SC
29969|NCT03952130|Drug|Insulin Glargine|Administered SC
29970|NCT03952130|Drug|Insulin Degludec|Administered SC
29971|NCT03952117|Device|transcranial direct current stimulation|tDCS will be administered through a pair of conductive rubber electrodes covered by saline soaked sponges (35 cm2). The current will be delivered continuously at 2 mA for 30 min through a battery-driven constant-current stimulator (Sooma Oy, Helsinki, Finland).
29972|NCT03952104|Other|Strength training|Strength training
29973|NCT03952091|Drug|TJ202, Lenalidomide and Dexamethasone|One dose of TJ202 will be given on Day 1 and Day 4 of Week 1, respectively, every week from Week 2 to Week 12, every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter.Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
29974|NCT03952091|Drug|Lenalidomide and Dexamethasone|Lenalidomide 25mg will be administered orally on Days 1 through 21 of each 28-days cycle.Dexamethasone 40 mg weekly will be administered.
29975|NCT03952078|Drug|CPI-818|Interleukin-2 inducible T-cell Kinase Inhibitor
29976|NCT03952065|Drug|Toripalimab|Infusion of Toripalimab through peripheral vein or neck artery.
29977|NCT03952052|Other|Determination of mutation|Recurrent mutation determination by digital PCR and next generation sequencing
29978|NCT03952039|Drug|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
29979|NCT03952039|Drug|Best Available Therapy (BAT)|Best available therapy (BAT)
29980|NCT03952026|Procedure|osteosynthesis of the pelvis|Osteosynthetic Fixation of the pelvic fracture
29981|NCT03952013|Other|To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure|All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
29982|NCT03952000|Behavioral|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
29983|NCT03951987|Drug|4 ml CG5503|4 ml of the CG5503 infusion solution corresponding to 40 mg CG5503 (tapentadol hydrochloride).
29984|NCT03951987|Drug|5 g charcoal powder|Oral administration of 5 g charcoal powder suspended in 100 ml tap water.
29985|NCT03951974|Behavioral|Social Emotion Regulation Strategy Development|Participants will work one-on-one with an interventionist to develop goals (in the form of implementation intentions) to develop social emotion regulation strategies to combat frequent emotional challenges.
29986|NCT03951974|Behavioral|Control|Participants will work one-on-one with an interventionist to report on their frequent emotional challenges, and report the emotion regulation strategies that they frequently use to combat them.
29987|NCT03951961|Drug|Midostaurin|50mg Midostaurin bid for 12 months
29988|NCT03951948|Other|retrospective analysis of surgical performance, clinical and radiologic outcome|retrospective analysis of surgical performance, clinical and radiologic outcome
29989|NCT03951935|Other|Oswestry Disability Index (ODI) questionnaire|Participant's level of low back pain and the extent to which the pain impacts his/ her daily life activities and social life are estimated with the standardized Oswestry Disability Index questionnaire
29990|NCT03951935|Diagnostic Test|self-paced walking test (SPWT)|walking back and forth at a self-selected pace along a hallway at the University Hospital until the onset of claudication, pain or until reaching the time limit of 30 minutes. Kinematic and electromyographic (EMG) data will be recorded every 3 minutes.
29991|NCT03951922|Behavioral|Horticultural activity|Therapeutic horticulture activities are plant-related activities that include but not limited to digging, watering, planting, weeding, trimming, fertilizing, mulching, harvesting, learning about organic farming, and exploring options to incorporate horticulture into daily activities
30072|NCT03951207|Drug|Amlodipine/Atorvastatin 5/20mg|Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
30073|NCT03951194|Biological|Autologous Platelet rich Plasma|Autologous PRP will be injected into the ovaries.
29992|NCT03951909|Behavioral|Physiotherapy activity and awareness intervention: PAAI|10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.
29993|NCT03951909|Behavioral|Psychological intervention: Teaching recovery techniques (TRT)|TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
29994|NCT03951896|Biological|PRP|A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.
29995|NCT03951896|Other|Saline injection|2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
29996|NCT03951883|Other|Increased Egg Consumption|Subjects will be instructed to use a weekly food purchase supplement for inclusion of 2 additional eggs per day to be added to subject's typical daily diet.
29997|NCT03951883|Other|Typical diet|Subjects will be instructed to maintain their current dietary patterns.
29998|NCT03951870|Behavioral|Neuromodulation via fMRI Neurofeedback task|Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
29999|NCT03951870|Biological|Hepatitis B vaccination|Subjects will be vaccinated against Hepatitis B
30000|NCT03951857|Other|Resistance exercise with a gym stick|Exercise intervention: The resistance exercise intervention is performed with a gym stick for 3 times a week for 12 weeks. Exercise load is gradually increased by the number of times the band is wound and the speed of motion by dividing into three stages in 1-4 weeks (1st stage), 5-8 weeks (2nd stage) and 9-12 weeks (3rd stage).
30001|NCT03951844|Device|BRIDGE/EMPATIA exoskeleton|The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
30002|NCT03951831|Drug|REGN2810|Cemiplimab (REGN 2810) is administered starting at week 4 at a dose of 350mg IV every 3 weeks (flat dose) for up to 55 weeks or intolerable side effect or progression of disease.
30003|NCT03951831|Drug|Degarelix|Degarelix is administered subcutaneously (SC) at a dose of 240mg once.
30004|NCT03951831|Drug|Leuprolide Acetate|Leuprolide acetate is provided at a dose of 22.5mg SC every 3 months.
30005|NCT03951831|Drug|Docetaxel|Docetaxel is administered starting at week 10 at a dose of 75 mg/m2 every 21 days for up to 6 cycles.
30006|NCT03951805|Drug|Insulin 287|Administered subcutaneously SC once weekly. Starting dose will be 70U.
30007|NCT03951805|Drug|Insulin Glargine|Administered subcutaneously SC once daily.The starting dose will be 10U.
30008|NCT03951779|Device|Exercise cardiac magnetic resonance imaging|Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
30009|NCT03951766|Behavioral|Smiling Instead of Smoking (SiS) App Version 2|The investigators have developed a smartphone app that acts as a behavioral, in-the-pocket coach and uses positive psychology exercises to enhance quitting success. It is anonymous, portable, and provides just-in-time support, an important feature for smokers who smoke under specific conditions and circumstances. To support treatment, investigators use a positive psychology approach. The smartphone app administers positive psychology exercises to enhance and/or maintain positive affect, which is hypothesized to stimulate nondaily smokers to enact healthier alternatives to smoking by broadening their thought-action repertoire, increasing confidence, and decreasing craving and defensiveness about smoking-related health information.
30010|NCT03951753|Drug|Tirzepatide|Administered SC
30011|NCT03951753|Drug|Semaglutide|Administered SC
30012|NCT03951753|Drug|Placebo|Administered SC
30013|NCT03951740|Device|Fitbit Charge 2|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
30014|NCT03951740|Device|Mio Slice|Energy expenditure (kcal) assessed by this activity tracker will be compared with indirect calorimetry (Oxycon Mobile) during a laboratory activity protocol. Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF).
30015|NCT03951740|Device|Oxycon Mobile|"The Oxycon Mobile will be used as the reference method/golden standard to calculate energy expenditure (kcal). This device (consisting of a face mask and gas analyzer unit) will be worn during the entire laboratory activity protocol.~Two groups will be assessed: patients with stable coronary artery disease (CAD) and patients with heart failure with reduced ejection fraction (HFrEF)."
30016|NCT03951727|Device|Endovascular treatment for PAD|Long femoropopliteal stenting with SuperA devices
30017|NCT03951714|Behavioral|Marketed experience application on adherence|To evaluate the effect of electronic capture of medication intake through a smartphone app on treatment's adherence
30018|NCT03951701|Other|Evaluation of the supportive care|Evaluation of interest of a systematic screening for oncological supportive care needs
30074|NCT03951194|Other|Placebo|Placebo injected into the ovaries.
30098|NCT03951012|Procedure|Blood draw|Participants will be approached during their regular clinic visits and asked if an extra tube of blood may be collected prior to the treatment. If consent is not obtained before this visit, a participant will be asked later in the same day. The amount of blood collected will be 2 teaspoons (10mL).
30099|NCT03950999|Other|Placebo|Sugar pill
55531|NCT03750552|Drug|ampreloxetine|Oral tablet, QD
30019|NCT03951688|Other|Experimental-Multi-modal exercise program|"Each home-based session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking.~Finally, participants are instructed to walk at their usual pace for at least 10 minutes."
30020|NCT03951662|Other|Alcoholic Hepatitis Group|Alcoholic hepatitis is defined as having a total bilirubin level >3mg/dL and AST level>50U/L
30021|NCT03951662|Other|Heavy Drinking Controls without Hepatitis|Normal levels of AST, ALT and total bilirubin and without evidence of cirrhosis or hepatosplenomegaly
30022|NCT03951649|Drug|Occipital Nerve Block|This is an open label randomized controlled trial evaluating response to bupivacaine occipital nerve block compared to Tylenol/Caffeine cocktail in treatment of pregnant patients seeking care of headache.
30023|NCT03951636|Procedure|Chlorhexidine|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant abutment surface will be cleaned by copious irrigation with chlorhexidine
30024|NCT03951636|Procedure|Er:YAG laser|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant abutment surface will be cleaned by copious irrigation with chlorhexidine
30025|NCT03951636|Procedure|Air Powder|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
30026|NCT03951623|Drug|HMPL-523|HMPL-523 will be oral administrated once daily for 8 weeks.
30027|NCT03951623|Drug|Placebo|HMPL-523 matching placebo will be oral administrated once daily for 8 weeks.
30028|NCT03951610|Device|Test lens|contact lens
30029|NCT03951610|Device|Control lens|contact lens
30030|NCT03951597|Drug|combined therapy using oxaliplatin and gemcitabine chemotherapy, Lenvatinib and PD1 antibody (JS001)|"Gemox chemotherapy Day1 oxaliplatin 85mg/m2+ gemcitabine 1g/m2, Day8 gemcitabine 1g/m2 Three weeks is a course of treatment with a total of 6 courses.~Lenvatinib (8mg/d), continuous use for 1 year.~PD-1 antibody (JS001) (240mg every 3 weeks), continuous use for 1 year."
30031|NCT03951584|Other|ISSNHL with vertigo|Participants who suffered from ISSNHL with vertigo will be included in this study. Participants will undergo vestibular function tests including caloric test, sensory organization test, video head impulse test and vestibular evoked myogenic potentials at baseline and 2 months after onset as primary outcome, to evaluate the damage and prognosis of vestibular function.
30032|NCT03951571|Drug|Anlotinib Hydrochloride|Before breakfast, take an Anlotinib hydrochloride placebo once a day, 12 mg (1 pill) at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
30033|NCT03951571|Drug|Placebo Oral Tablet|Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
30034|NCT03951558|Other|Diet for calciuria prevention|Dietary recommendations for water, salt, calcium and proteins according to age and DIR
30035|NCT03951558|Drug|Hydrochlorothiazide|Hydroclorothiazide recommendations for hypercalciuria
30036|NCT03951545|Procedure|First line total knee replacement for gonarthrosis .|Patients requiring 1st line total knee replacement for gonarthrosis with a Hip knee angle (HKA) between 170° and 183°. In the first group (Mechanical) the total knee replacement will be performed with a tibial cut by using extramedullary mechanical sighting and in the second group (Gyroscopic) by using gyroscopic and accelerometric navigation (I-Assist).
30037|NCT03951519|Other|oral administration of water|Volume expansion via 500 mL of water administered by the patient's nasogastric tube
30038|NCT03951519|Other|administration of saline solution|Volume expansion via 500 mL of saline (Nacl 0.9%) administered by the venous route
30039|NCT03951506|Other|Multi-modal exercise program|Each session (48) starts with 7 minutes of moderate warm-up exercises focusing on mobility and flexibility. Secondly, the strengthening exercises consist of knee extensions, knee flexions, hip abductions, ankle plantar flexions, and ankle dorsiflexions. Thirdly, a set of balance exercises including knee bends, backwards walking, walking and turning around, sideways walking, tandem stance, tandem walk,one-leg stand, heel walking, toe walking, toe to heel walking backwards, sit-to-stand, and stair walking. Finally, participants are instructed to walk at their usual pace for at least 10 minutes.
30040|NCT03951506|Other|Conventional treatment|Each session (48) consist in isotonic exercises of low intensity and joint mobility of the lower extremities. These exercises are usually prescribed in medical consultations for the treatment of knee osteoarthritis.
30041|NCT03951493|Combination Product|Zoledronic Acid 4Mg Solution for Injection + Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~20 Gy in 1 fraction;~27 Gy in 3 fractions of 9 Gy~30 Gy in 5 fractions of 6 Gy. All patients in the experimental arm receive an intravenous injection of at least 15 minutes of 4 mg zoledronic acid every month for 12 months.~The first injection must be made no more than 3 weeks before the first day of radiotherapy. It can be performed up to J1 of radiotherapy.~The injections will be carried out either at the patient's home by the nurses or in the investigator centre."
30042|NCT03951493|Radiation|Hypo-fractured radiotherapy in stereotactic conditions|"All patients receive radiotherapy i.e. treatment on D1, D3 and D5.~Several radiotherapy schemes are possible:~20 Gy in 1 fraction;~27 Gy in 3 fractions of 9 Gy~30 Gy in 5 fractions of 6 Gy."
30043|NCT03951480|Other|Manual medicine|At a rate of 3 sessions of a maximum of 30 minutes each at one week interval. Depending on the clinical evolution, it is possible to stop manual medicine sessions according to the therapist's assessment as in current practice. If the patient has an EVA pain of activity < 2, manipulations will not be continued. The patient being considered as not very symptomatic.
30044|NCT03951480|Drug|Corticosteroids infiltration|A unique echo-guided infiltration of one syringe of 1 mL of cortisone product
33004|NCT03927144|Drug|Erenumab|Erenumab Dose 1 / Dose 2 Treatment Period 52 weeks
30045|NCT03951467|Other|Interventional educational toolkit specific to low Health Literacy patients, designed with patients and health professionals.|"Two interviews between the patient and the nurse trained for the study: before discharge from hospital and a telephone reminder between 3 and 5 days after discharge.~First interview: the nurse will evolve using tools developed in the first phase of the study. The nurse will provide detailed personalized information on the patient's discharge order and illness and the action to be taken depending on the potential situations the patient may encounter.~Telephone interview: 3 to 5 days after discharge, the nurse will repeat the elements of the first interview with the patient to verify that the information has been properly understood and retained and that the patient is able to adopt appropriate behaviors in high-risk situations."
30046|NCT03951454|Behavioral|Conexiones|5 Conexiones telephone sessions
30047|NCT03951454|Behavioral|Taking Time|1 Taking Time telephone session
30048|NCT03951428|Diagnostic Test|Menstrual Blood Screening Test|The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
30049|NCT03951415|Drug|PARP inhibitor and Anti-PD-L1|olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
30050|NCT03951402|Drug|100 mg CG5503 (tapentadol hydrochloride) PR tablet|100 mg CG5503 (tapentadol hydrochloride) PR tablet.
30051|NCT03951402|Drug|Placebo matching CG5503 PR tablet|Matching placebo tablet to CG5503 PR tablet.
30052|NCT03951402|Drug|Placebo matching moxifloxacin capsule|Matching placebo capsule to moxifloxacin capsule.
30053|NCT03951402|Drug|400 mg Moxifloxacin tablet (overencapsulated)|Overencapsulated 400 mg Moxifloxacin tablet.
30054|NCT03951389|Other|Non-interventional|Non-interventional
30055|NCT03951376|Behavioral|UPRIGHT intervention|The UPRIGHT intervention design consists of two different phases consecutively implemented in two school years: intensive phase and follow-up phase. During the intensive phase, all stakeholders are trained in the UPRIGHT programme (18 skills). The follow-up phase intends not only to maintain the effect of the intensive training in youths, but also to boost the positive mental health atmosphere created in the whole school. To do so, different collective activities will be organized at school level such as celebration of thematic days, activities with the community, and outdoor/indoor activities.
30056|NCT03951363|Behavioral|interactive Obesity Treatment Approach (iOTA)|The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
30057|NCT03951350|Behavioral|Mediterranean lifestyles (ML)|Improving adherence to the Mediterranean diet pattern, improving compliance with World Health Organization (WHO) recommendations regarding activity daily physical, improved sleep hygiene and increased careful exposure to ambient light.
30058|NCT03951350|Behavioral|Information communication technologies (ICTs)|Monitoring by means of ICTs (activity wristband or smart watch) related to the frequency and intensity of physical activity, sleep quality and weekly monitoring in the group related to diet and exposure to sunlight (ML + ICTs).
30059|NCT03951337|Drug|64Cu-ATSM|64 Cu-ATSM PET/CT scan
30060|NCT03951324|Other|Interobserver agreement or Interrater agreement|Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
30061|NCT03951285|Dietary Supplement|NR in BMI-discordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
30062|NCT03951285|Dietary Supplement|NR in BMI-concordant twins|Water-soluble form of vitamin B3, nicotinamide riboside (NR) is used in this study. The NR product name is Niagen, produced by ChromaDex. NR does not cause the known side effects (vasodilation and flushing) of another vitamin B3, niacin.
30063|NCT03951272|Device|Lyoplant® Onlay/DURAFORM™ Dural Graft Implant|Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
30064|NCT03951259|Drug|SM934|In this study, the investigating intervention is oral administration of SM934. SM934 is a water-soluble derivative of arteminisin, which exerts immunosuppressive functions in vitro and in vivo.
30065|NCT03951259|Drug|Placebos|The placebo pills are made identical to the investigating SM934 in appearance.
30066|NCT03951246|Other|Cognitive and Motor Training|"In the first phase of the trial, all participants (patients and healthy children) will complete cognitive and motor functions assessment.~Then the sample of patients who have cognitive/motor impairment will be randomized to an either Intervention or Control group.~In the second phase of the trial, survivors in the Intervention Group will receive 6 sessions of cognitive and motor training during two weeks, and survivors in Control Group will undergo …..~After this treatment phase, motor and cognitive functions assessment will be conducted in all patients once again.~In the third phase, the Control Group will be provided the active intervention (i.e. 6 sessions of cognitive and motor training during two weeks), while the Intervention Group engages in passive reading.~After this, motor and cognitive functions assessment will be carried out in all patients once again."
30067|NCT03951220|Other|Diffusion Weighted Magnetic Resonance Imaging (DWMRI)|Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non‐invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer‐induced bone disease in response to therapy.
30068|NCT03951220|Other|DXA scan|Used to assess bone density
30069|NCT03951220|Other|Bloods and urine|Samples will be taken to assess bone biomarkers
30070|NCT03951207|Drug|Rosuampin 10/5mg|Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
30071|NCT03951207|Drug|Rosuampin 20/5mg|Rosuampin 20/5mg qd for 8 weeks
30075|NCT03951181|Behavioral|LEAP-MS|The LEAP-MS intervention is a co-produced, digital interactive education and activity tool, specifically developed for PwPMS. The tool includes multimedia education about being active with PMS, tailored physical activity ideas and interactive functions enabling the development of personalised activity programmes, goal setting and activity logs. The digital tool works in conjunction with support from trained physiotherapists. The feasibility study will evaluate how the LEAP-MS intervention can be used in practice.
30076|NCT03951168|Behavioral|Routine Management|Routine Management Model of Health Education for diabetes Patient will receive the Routine Management Model of Health Education for Diabetes. After the patient was admitted to hospital, the responsible nurse carried on the diabetes health education for the patient. There are no regulations on the path and time of education. Interspersed with diabetes health education at work. Follow up 2 weeks with phone call after discharge. This is the current clinical model in hospital.
30077|NCT03951168|Behavioral|Standardized Management|Standardized Management Model of Health Education for Diabetes The patients were educated by full-time diabetic education nurses according to diabetes education path. Including diabetes diet, exercise, drugs, hypoglycemia, diabetic foot, and so on. Telephone follow-up was performed at 2 weeks and 4 weeks after discharge and 12 and 24 weeks follow-up in diabetes education clinic. Develop telephone follow-up standardized content and implement telephone follow-up according to standardized content.Full-time education nurses carry on education according to diabetes mellitus health education path table.
30078|NCT03951155|Behavioral|Muscle Relaxation|"Ask the child to lie down in a comfortable position. Ask him/her to notice how their muscles feel in each part of the body. Taking one area of the body at a time (face, shoulders, arms, hands, fingers, abdomen, legs, feet, and toes).~Instruct the child to contract the muscles for 5 seconds, take a deep breath, and release.~Next, instruct the child to contract all muscles simultaneously, hold for 5 seconds, then release.~Finally, ask him/her to notice how his/her muscles feel after the exercise."
30079|NCT03951142|Drug|Losartan|This trial is open-label; therefore, the participant, the trial site personnel, the Sponsor and/or designee are not blinded to treatment. Drug identity (name, strength) is included in the label text. Storage, handling and preparation requirements will be handled in concordance with the Pharmacy Manual for losartan.
30080|NCT03951129|Procedure|hemodialysis catheter insertion|The State-Trait Anxiety Inventory (STAI) and Visual Analogue Scale (VAS) scoring will be performed after informing all groups and after the procedure
30081|NCT03951116|Drug|FCN-437|FCN-437c is a selective and potent CDK4/6 dual inhibitor, with broad antitumor activity in preclinical pharmacology models, favorable physical and pharmacokinetic (PK) properties, and acceptable toxicity profile in nonclinical studies.
30082|NCT03951103|Other|rFVIIIFc|Drug according to prescription
30083|NCT03951090|Other|Results of the brief geriatric assessment|Providers will receive results of the brief geriatric assessment with recommendations for address deficits identified through the results of the brief geriatric assessment
30084|NCT03951090|Other|No results of brief geriatric assessments|Providers will not receive results of the brief geriatric assessment. Participants will receive standard of care treatment
30085|NCT03951077|Drug|Elagolix|Capsule administered orally
30086|NCT03951077|Drug|Placebo|Capsule administered orally
30087|NCT03951064|Device|Esophageal balloon|All patients in both groups will have an esophageal balloon catheter inserted by a research investigator. The catheter will be inserted into their nare while upright (head of bed >30 degrees) to a depth slightly more than the estimated distance from the lower sternum to the back of the ear (typically around 60 cm). Gastric positioning will be confirmed with abdominal compression testing and the catheter then retracted 10 - 20cm into the lower esophagus. Placement will be confirmed with the presence of cardiac oscillations on the esophageal probe. The probe will then be secured to the patient's nasal opening using tape.
30088|NCT03951064|Procedure|Intervention Spontaneous Breathing Trial (SBT) and Extubation|Patients in the Intervention group will undergo an SBT regardless of their PEEP level. The PEEP that generates a Ptp of 0 will be considered their optimal PEEP, and this will not be lowered for the SBT. The Intervention Group SBT will consist of a trial of a pressure support of 5 cm H2O and Optimal PEEP.
30089|NCT03951064|Procedure|Control Spontaneous Breathing Trial and Extubation|Patients in the Control group will undergo an SBT when they reach a PEEP ≤8 cm H2O. This is the current standard of care based on the SBT protocol at UNC Hospitals. SBT and extubation prior to meeting these criteria will be based on primary medical team's discretion and will be recorded for analysis and safety tracking.
30090|NCT03951064|Procedure|Intervention Weaning after Tracheostomy|Based on the use of optimal PEEP in this group, and the experience in the previous study protocol, the investigators will place patients in the Intervention group on Tracheostomy Collar Trial ONLY with a speaking valve. This simulates the normal process of utilizing the upper airway to maintain lung inflation that is performed automatically when a patient does not have an artificial airway.
30091|NCT03951064|Procedure|Control Weaning after Tracheostomy|The control group will be placed on Tracheostomy Collar Trial with no requirement for speaking valve. They may utilize a speaking valve if tolerated and desired, but there is no requirement as there is in the Intervention group.
30092|NCT03951051|Drug|Olmesartan Medoxomil 40 mg|Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
30093|NCT03951051|Drug|Olmetec®|Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.
30094|NCT03951038|Procedure|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
30095|NCT03951038|Procedure|Lateral TLIPB group|"both sides of the spine, a single injection of ropivacaine by nerve stimulating needle under ultrasound-guided between the longissimus and iliocostalis muscles .~The regimen of Lateral TLIPB group is0.2% 20ml ropivacaine and the regimen of PCIA is same with PCIA group."
30096|NCT03951025|Dietary Supplement|Melatonin oral administration|One tablet with1 mg of melatonin and 82 mg of excipients
30097|NCT03951025|Dietary Supplement|Melatonin sublingual administration|One tablet with 1 mg of melatonin and 82 mg of excipients
31193|NCT03942068|Drug|albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel (nab-paclitaxel), a microtubule inhibitor
30100|NCT03950986|Other|Modified clinical reminders|Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
30101|NCT03950973|Behavioral|CareAvenue|CareAvenue is an e-health tool providing information about diabetes management and low-cost resources. Participants in this group have access to CareAvenue and receive a weekly automated phone call and text messages related to CareAvenue and its resources as well as diabetes management.
30102|NCT03950973|Behavioral|Guest Assistance Program|The Guest Assistance Program (GAP) is a resource, which provides assistance with medical and non-medical needs and resources to patients receiving medical care at University of Michigan health system. Participants in this group are provided with GAP information and receive text messages related to diabetes management.
30103|NCT03950960|Drug|BMS-986256|Specified dose on specified days
30104|NCT03950960|Drug|Itraconazole|Specified dose on specified days
30105|NCT03950947|Device|Amplatzer vascular plug|See above
30106|NCT03950947|Other|Sham Controll|Angiography of the RIMA without occlusion
30107|NCT03950934|Other|no intervention, observational study, perioperative survey|no intervention
30108|NCT03950921|Behavioral|Patient Safety Display|Digital display of catheter and pressure injury information in patient hospital room
30109|NCT03950908|Other|Single bite biopsy technique|During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.
30110|NCT03950908|Other|Double bite biopsy technique|During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
30111|NCT03950882|Drug|PXL770|Oral capsule
30112|NCT03950882|Drug|Placebo|Oral capsule
30113|NCT03950869|Behavioral|Positive Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase positive expectations.
30114|NCT03950869|Behavioral|Negative Expectation Manipulation|Participants are watching a video tape of a trauma expert who provides selective information on the development of intrusive memories. This video tape aims to increase negative expectations.
30115|NCT03950856|Drug|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
30116|NCT03950856|Drug|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
30117|NCT03950843|Drug|CKD-825|"Dosage Form: capsule~Dosage: 3 types(low/medium/high dose)~Frequency: QD(once daily) administration"
30118|NCT03950843|Drug|Placebo oral capsule|"Placebo of CKD-825~Dosage Form: capsule~Dosage: NA~Frequency: QD administration"
30119|NCT03950830|Drug|Disulfiram|Disulfiram 400mg daily, continuously
30120|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg|Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg
30121|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg|Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.
30122|NCT03950817|Drug|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.|Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
30123|NCT03950804|Drug|Eculizumab Injection|Patients receive eculizumab as deemed necessary by the primary physician
30124|NCT03950791|Behavioral|Pain Catastrophizing Class|A 2-hour class that will be delivered by a clinical psychologist to participant cohorts. Didactic content includes psychoeducation about opioid use, the risk for misuse, and opioid reduction education materials. It will also include mind-body science as it relates to pain and PC. Participants learn how to identify catastrophizing in the moment, and how to self-treat it. During the class, participants acquire skills and develop a plan to apply the learned skills to decrease physiological hyperarousal within the context of PC. Participants also acquire skills that improve the regulation of cognition and emotion, including PC reframing and thought restructuring, and develop a plan for implementing these skills in daily life. Finally, participants develop a plan to use behaviors that modulate attention and counteract helplessness.
30125|NCT03950791|Behavioral|Health Education|Education about improving lifestyle factors to improve participants' overall health.
30126|NCT03950778|Drug|Human albumin|Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
30127|NCT03950765|Behavioral|Ecological momentary intervention|Content of this intervention is based on pre-established transdiagnostic protocols for addressing the negative emotion associated with suicidal thoughts and behaviors.
30128|NCT03950752|Combination Product|Optimized Bagel|Participants will eat 132g of a bagel with an optimized composition in fatty acids in only one day, representing an ingestion of 556.5 kcal and 33g of total fat, of which 4.41g are saturated fatty acids, 24.27g are monounsaturated fatty acids, and 4.28g are polyunsaturated fatty acids.
30129|NCT03950752|Combination Product|Conventional Bagel|Participants will eat 132g of a bagel with a conventional composition in fatty acids in only one day, representing an ingestion of 589.0 kcal and 35.6g of total fat, of which 16.76g are saturated fatty acids, 13.00g are monounsaturated fatty acids, and 5.81g are polyunsaturated fatty acids
30130|NCT03950739|Drug|Treprostinil Inhalation Powder|Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
30131|NCT03950726|Procedure|ileocolic resection|Ileocolic resection through McBurney incision
30172|NCT03950453|Behavioral|Contact Control Nutrition (C+N)|Contact Control Group where parents engage in a quiet, relaxing, but stimulating activity with stress reduction benefits.
30173|NCT03950427|Behavioral|Videogame-based physical activity|videogame-based physical activity
30174|NCT03950427|Behavioral|sedentary videogame|sedentary videogame
30175|NCT03950427|Drug|Bupropion|Bupropion
30132|NCT03950713|Behavioral|Mindfulness-based Stress Reduction Program - Taiwan (MBSR-T)|The MBSR-T is focused on strategies to manage diabetes distress for new residents by three new techniques. Firstly, it involves practicing body and meditation exercises for openness to the awareness and acceptance of transferred life experiences, such as mindful attention exercise, which is assumed to allow the residents to behave in a less reactive and more reflective manner when confronted with transferred life stressors. Second, mindfulness meditation techniques were provided for difficult thoughts and feelings related to diabetes, such as paying full attention to the present moment of life and choosing to respond skillfully rather than reacting automatically to external events, thoughts or emotions as they arise. Third, a specific topic, for example on how to be mindful when life style is changed, or how to pay attention to the present moment within Chinese culture of peacefulness was discussed in each session.
30133|NCT03950700|Drug|Bupivacaine-epinephrine|BUPIROP® 0.5% ROPSOHN THERAPEUTICS S.A.S
30134|NCT03950700|Drug|Saline Solution|Saline solution 0.9% (Baxter laboratories).
30135|NCT03950687|Drug|Recombinant Human Erythropoiesis Injection (CHO cell)|rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
30136|NCT03950687|Drug|Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)|rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
30137|NCT03950674|Biological|Pembrolizumab 200 mg|IV infusion
30138|NCT03950674|Drug|Cisplatin|IV infusion
30139|NCT03950674|Drug|Carboplatin|IV infusion
30140|NCT03950674|Drug|Pemetrexed|IV infusion
30141|NCT03950674|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
30142|NCT03950674|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
30143|NCT03950674|Drug|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
30144|NCT03950674|Drug|Saline solution|IV infusion
30145|NCT03950661|Other|Walking|
30146|NCT03950648|Behavioral|Spatial Cognitive Training|map reading and route-learning skills
30147|NCT03950635|Dietary Supplement|Dietary Intervention|Consume whole-foods, fiber-rich diet
30148|NCT03950635|Dietary Supplement|Dietary Intervention|Consume high fat, low carbohydrate (ketogenic) diet
30149|NCT03950635|Other|Questionnaire Administration|Ancillary studies
30150|NCT03950622|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
30151|NCT03950622|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in each 0.5. mL dose.
30152|NCT03950609|Drug|Everolimus|Given PO
30153|NCT03950609|Drug|Lenvatinib|Given PO
30154|NCT03950596|Other|Acute resistant load exercises|"Leg bench and leg press acute resistant load exercises~Leg-bench and leg-press acute resistant load exercises"
30155|NCT03950596|Behavioral|Background Questionnaire|Background questionnaire will be filled out by participants
30156|NCT03950596|Other|Pain Questionnaire|Pain questionnaire regarding pain in the knee during previous 3 months
30157|NCT03950596|Genetic|DNA and RNA test|DNA and RNA tests will be sent to a genetic laboratory for analysis
30158|NCT03950596|Diagnostic Test|Ultrasound|Ultrasound of the knee joint and the quadriceps muscle and the pica tendon
30159|NCT03950596|Diagnostic Test|Percutaneous Needle Core Biopsy|Core Biopsy will be taken from the quadriceps femoris muscle
30160|NCT03950570|Drug|Paclitaxel|"The doses of ORIN 1001 in both dose escalation and dose expansion will be 100 mg, 200 mg, 400 mg, 600 mg,800mg, 1,000 mg, 1,300 mg, 1,500 mg The dose of paclitaxel will be constant at 175 mg/m2 given intravenously every three weeks for the dose escalation and dose expansion.~cohorts as follows: 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1,000 mg, 1,300 mg and 1,500 mg administered for 21 days (one cycle)."
30161|NCT03950544|Drug|Fosfomycin|Fosfomycin and meropenem
30162|NCT03950544|Drug|Tigecycline|Tigecycline and meropenem
30163|NCT03950544|Drug|Polymyxin B|Polymyxin B and meropenem
30164|NCT03950531|Other|No intervention|
30165|NCT03950518|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules, 12mg/d
30166|NCT03950518|Drug|Arginine hydrochloride|AHC,12mg/d AH,40g/d
30167|NCT03950518|Drug|levamisole|AHC,12mg/d AH,40mg/d LM,150mg/d
30168|NCT03950505|Drug|Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) treatment for 24 weeks|All participants will be treated with Nesinaact 25/15 (Alogliptin benzoate 25mg, pioglitazone hydrochloride 15mg) for 24 weeks. Patients who have not been prescribed any other anti-diabetic drugs at least for 12 weeks and whose HbA1c ranges from 6.5~8.5%, can be enrolled. If Patients has been prescribed metformin as monotherapy, they have to substitute metformin with nesinaact 25-15 for enrollment.
30169|NCT03950492|Device|Deep Brain Simulator|This is an open-label, safety, tolerability, and feasibility study for participants who have treatment refractory OUD that are eligible to have DBS targeting the NAc/VC.
30170|NCT03950479|Diagnostic Test|3D and 4D Transperineal Ultrasound|The evaluation of Pelvic Floor Muscles with 3D and 4D transperineal ultrasound using A Voluson E6 system (GE Healthcare, Zipf, Austria) with RAB 8-4-MHz volume transducer for all acquisitions. Measurements will be performed in axial planes. The levator hiatus area (LHA), the antero-posterior (AP) diameter and the left-right (LR) transverse diameter will be analyzed at rest, during pelvic floor contraction and on maximal Valsalva maneuver.
30171|NCT03950453|Behavioral|Parenting Mindfully for Health Nutrition (PMH)|"PMH will include included the following components:~mindfulness strategies as outlined in the MBSR manual,~mindful parenting concepts,~mindful eating and awareness of family choices;~self and child monitoring of food intake, PA and emotional reactivity;~utilizing mindfulness for emotion regulation and distress tolerance,~behavioral strategies of goal setting and implementing increasing frequency of healthy food intake and physical activity (PA)"
30176|NCT03950427|Behavioral|Counseling|Counseling for smoking cessation
30177|NCT03950414|Biological|CMV specific T-cells|"Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMV-specific CD4+ and CD8+ T cells Suspension of CMV-specific T cells in 10 mL of 0.9% NaCl with 2% Human Serum Albumin(HSA) via IV bolus injection~Low Dose Tier - Viral-Specific T cell infusion 5 x10^3 cells/kg body weight(BW)~Mid Dose Tier - Viral-Specific T cell infusion 1.25 x10^4 cells/kg BW~High Dose Tier - Viral-Specific T cell infusion 2.5 x10^4 cells/kg BW Product will be administered fresh intravenously to recipient within four hours of collection."
30178|NCT03950401|Procedure|Monocryl|subcuticular Monocryl wound closure
30179|NCT03950401|Procedure|Nylon|wound closure using nylon suture on the skin
30180|NCT03950388|Behavioral|Intervention|Wards randomly assigned to receive the intervention will have a Band 8a Psychologist based on the ward for 0.5FTE for 7 months. During this time, all patients will be involved with the proposed stepped model of care intervention at one of three levels. The level the patient receives will be decided by the multidisciplinary ward team. At Step one, all patients will have a psychological formulation developed by the psychologist in conjunction with the patient or members of the ward team. At Step 2, all qualified nurses will be trained and supervised to deliver guided self-help material of psychological interventions targeting key problem areas for patients. At Step 3, patients will be offered up to 16, one-to-one therapy sessions with the psychologist.
30181|NCT03950362|Drug|Avelumab|Administration of Avelumab 10mg/kg Infuse IV over 30-minutes: 1 cycle 5 days before External Beam RadioTherapy, then every 21 days x 8 cycles (6 months)
30182|NCT03950362|Device|Radiotherapy|60-66 Gy in 30-33 Fractions (2 Gy/fractions) given to the whole bladder
30183|NCT03950336|Dietary Supplement|Prebiotics|Oligofructose-enriched inulin [a combination of shorter chain oligofructose, Degree of Polymerisation (DP) 3 - 9 and longer chain inulin (DP ≥ 10), in a 50:50 ratio ± 10 %] 12 g/day for 12 weeks
30184|NCT03950336|Other|Low n-6 PUFA Diet|The Mediterranean diet pattern (MDP) with increased n-3 PUFA, saturated fatty acids (SFA) and monounsaturated fatty acids (MUFA) and reduced n-6 PUFAs food intake will be adopted as suitable Low n-6 PUFA diet.
30185|NCT03950336|Dietary Supplement|Maltodextrin|Maltodextrin consists of D-glucose units connected in chains of variable length (DP 3-17). The glucose units are primarily linked with α(1→4) glycosidic bonds. Maltodextrin is easily hydrolyzed by the intestinal enzymes and thus does not have an effect on colonic microbiota. Maltodextrin (12 g/days for 12 weeks) will be used as a placebo for the prebiotic treatment
30186|NCT03950336|Other|Control Diet|"Participants who will not be assigned to Low n-6 PUFA diet will be advised to follow the Canada's Food Guide recommendations (Control diet). As Canada's Food Guide Diet is also designed with the aim to support healthy eating and prevention of metabolic and chronic disorders, this diet may not be considered as a true comparator for the Low n-6 PUFA diet intervention."
30187|NCT03950323|Radiation|MRI with Facial nerve tractography|MRI with Facial nerve tractography in addition to T1 imaging, T1 gadolinium imaging and T2 imaging.
30188|NCT03950310|Device|Excimer laser catheter|The excimer laser catheter is equipped with multiple optical fibers on the periphery of the guide wire lumen corresponding to 0.014 inch, which is used for the purpose of reperfusion of barrier site of coronary artery. The connector on the front side is connected with the CVX-300 laser generator, and the tip at the top contact directly with the lesion. The laser catheter consisting of multiple optical fibers transmits the energy in the ultraviolet region from the CVX300 laser generator to the blockage in the blood vessel. The ultraviolet energy is transmitted from the tip of laser catheter, transpires the fibrous, calcified and arteriosclerotic lesion by light, and enables reperfusion in the lesion. The laser catheter has appropriate hydrophilic coating and easily follows the inside of coronary artery.
30189|NCT03950297|Drug|609A|609A is a recombinant anti-PD-1 humanized IgG4 kappa antibody that targets the human PD-1
30190|NCT03950284|Device|immediate loading with all on four technique in FFF|All cases will undergo surgery under local regional anesthesia. Injection of local anaesthesia (Articaine 4% and 1:100000 epinephrine) for regional infiltration. Sequential drilling then insertion of the dental implant fixtures and abutments on which the prefabricated temporary prosthesis will be fixed.
30191|NCT03950271|Drug|SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine|"Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles."
30192|NCT03950258|Procedure|endovascular embolization|Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
30193|NCT03950245|Other|Placebo|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.
30194|NCT03950245|Other|GLP-1 antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.
30195|NCT03950245|Other|GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.
30196|NCT03950245|Other|GLP-1 and GIP antagonism|Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.
30197|NCT03950232|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to approximately 5 years or until marketing authorization is obtained in the participant's country, whichever comes first
30198|NCT03950219|Other|Group course|Education and support
30199|NCT03950206|Other|Indocyanine green angiography|Intravenous ICG (PULSION Medical Systems SE, Feldkirchen, Germany) will be used for the intraoperative evaluation of ureteral vascularization. Twenty-five milligrams of indocyanine green will be diluted in 10 ml of soluble water, and a bolus of 0.25 mg/Kg will be injected through a peripheral vein. During laparoscopy, a NIR camera-head (KARL STORZ Gesellschaft Mit Beschränkter Haftung&amp; Co., Tuttlingen, Germany) will be used to visualize the ureteral vascularization.
30200|NCT03950193|Other|Questionnaires to evaluate psychic development of the child|Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
30201|NCT03950180|Other|Prostate Cancer Comorbidity Index (PCCI) score|Life expectancy information
30207|NCT03950128|Behavioral|Mindfulness-Based Skills Training (MBST)|"This intervention teaches students mindfulness-based skills to help manage their emotions when resolving conflict with their partners. The skills followed the ABCDE acronym. ABCDE stands for awareness, breathing, checking in with your feelings and thoughts, describing your experience, and expressing what you want to change. Students learned about the skills and had opportunities to practice them as well."
30208|NCT03950128|Behavioral|Psychoeducational|This intervention is based on the Love is Not Abuse (LINA) Curriculum (Liz Claiborne Education Development Center (n.d.)). It was adapted to be given over the course of three 50-minute sessions. The selected materials covered (a) what dating abuse is, (b) the pattern of abuse and, (c) technology and dating abuse. The curriculum is interactive and includes handouts, activities, and discussion.
30209|NCT03950115|Device|Intense Pulsed Light (IPL)|IPL therapy will be performed with the M22® (Lumenis, Dreieich, Germany). IPL treatment is going to be administered to the skin below the lower eyelid. Before treatment, the eyes will be protected with opaque goggles. Ultrasound gel is going to be applied to the patient's face from tragus to tragus including the nose in order to conduct the light, help to spread the energy evenly, and provide a degree of protection. The intensity of the IPL treatment will range from 9.8J/cm2 to 13J/cm2 according to Fitzpatrick Skin Type Grading.
30210|NCT03950102|Radiation|SBRT|Radiation dose of 27.5-50Gy in 5 fractions over 5-14 days with a radical dose as high as achievable based on mean liver dose (MLD), while fulfilling the dose constraints of OARs
30211|NCT03950089|Device|Optical Coherence Tomography Angiography (OCT-A)|Optical Coherence Tomography Angiography (OCT-A) images were acquired using an Spectral Domain Optical Coherence Tomography device (Cirrus High Definition OCT Model 5000 with Angioplex; Carl Zeiss Meditec, Dublin, California, USA). With an acquisition speed of 68,000 A-Scan per second, the OCT Microangiography Complex algorithm provided OCT-A information for three-dimensional (3D) flow reconstruction. At each visit, each subject underwent a 3 x 3 millimeter (mm) macular 3D cube acquisition in both eyes. FastTrac continuous eye tracking technology was employed to control for eye movements and minimize motion artefacts.
30212|NCT03950076|Drug|Edoxaban|Edoxaban 60mg (or 30mg as determined by clinical criteria)
30213|NCT03950076|Other|Non-anticoagulant medical therapy|Non-anticoagulant medical therapy as determined by the local investigator includes i) No antithrombotic therapy ii) Antiplatelet monotherapy, including de novo indication for antiplatelet monotherapy during course of the study
30214|NCT03950050|Drug|Ambroxol|"Ambroxol Hydrochloride therapy will be dosed up to 600 mg/day divided to twice a day starting 150 mg for the first month, 300 mg for the following month and 600 mg for the following month.~The study was conducted in accordance with the provisions of the Declaration of Helsinki, Good Clinical Practice guidelines, and local laws and regulations."
30215|NCT03950037|Drug|Albendazole|Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.
30216|NCT03950024|Diagnostic Test|functional brain MRI|The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)
30217|NCT03950011|Procedure|Enhanced recovery after surgery program|Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
30218|NCT03949998|Device|Dry Needling|Comparison between dry needling and/or manual therapy of the cervical region.
30219|NCT03949998|Other|Manual Therapy|soft tissue release, cervical traction and/or cervical mobilization
30220|NCT03949985|Other|Tests of biological hemostatic profile associated with contraceptives|Tests of biological hemostatic profile associated with contraceptives will be done before and after having stopped an estrogenic contraceptive (group 1) and during the non-use of an estrogenic contraceptive (group 2)
30221|NCT03949972|Other|Biosampling|Biosampling at initial visit and follow-up visits
30222|NCT03949959|Other|Multimodal physiotherapy|Participants will undertake their usual activities for the 5, 8 or 11 day baseline period following PRP. Participants will begin the 6 week intervention period following this period during which time they will participate in 10 sessions with an experienced postgraduate physiotherapist. After these 6-weeks, participants will have no contact with intervention personnel during the 6-week follow-up period.
30223|NCT03949946|Procedure|Magnetic resonance imaging (MRI)|MRI scan uses radio waves in a magnetic field to obtain images of the breast. It is non-invasive and participants will not be exposed to harmful radiation. An image contrast agent will be used to enhance image clarity. Participants will be scanned lying face-down on a specially-designed bed and ear protectors will be provided to screen out background noise.
30224|NCT03949933|Radiation|proton and carbon ion radiotherapy|proton and carbon ion radiotherapy
30225|NCT03949920|Drug|Migalastat|Participants will be starting Migalastat as part of clinical care. Their initiation onto Migalastat is not determined by this study or it's protocol. Interventions as part of the study will be limited to the study investigations.
30226|NCT03949907|Other|Nutritional counseling alone|"Nutritional counseling consists of a personalized dietary prescription (including sample meal plans and recipe suggestions) tailored on personal eating patterns and food preferences, in order to achieve estimated protein-calorie requirements and to take into account chewing and swallowing abilities. Regular consultation by a registered dietitian will be also provided every 10 days by means of face-to-face interviews (at scheduled follow-up visits - chemotherapy cycle) and telephone interviews (planned between chemotherapy cycles and as required by the patient). In the presence of significant reduction of normal food intake, the use of oral nutritional supplements will be also considered.~In the presence of body weight loss >10% of the weight recorded at enrollment, patients allocated to this group group will be censored and treated according to current supportive care guidelines, including home parenteral nutrition."
30227|NCT03949907|Other|Early supplemental parenteral nutrition plus nutritional counseling|"Patients will receive nutritional counseling in combination with systematic early supplemental home parenteral nutrition since diagnosis.~Supplemental home parenteral nutrition will be prescribed, provided daily and adjusted throughout the study (approximately every 10 days, until the end of the scheduled first-line chemotherapy) according to estimated protein-calorie oral intakes, in order to satisfy estimated requirements. Home parenteral nutrition will be infused mainly during night hours, using multi-chamber bags containing olive oil-based lipid emulsions, when not contraindicated."
30228|NCT03949894|Drug|Tolvaptan|30mg and 15mg of Tolvaptan Tablet
30229|NCT03949881|Biological|FEMJA transplatation|The cultivated oral mucosal epithelium will be directly grafted onto the corneal stroma. The sheet is grafted without suture onto the exposed stromal bed after removal of the conjunctiva and fibrosis from the cornea. The grafted corneal surface is then covered with a soft permanent contact lens for protection during healing (between 3 to 15 days, according to tolerance) If the stroma appears opaque because of deep stromal scars a corneal allograft will be performed 12 months after FEMJA transplantation.
30230|NCT03949868|Behavioral|High Mindfulness|"Those in the high mindfulness group will also receive questions about their memory performance over the past 30 minutes in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their memory performance throughout the day and asked to report on how their memory performance is changing over time as a part of each text message prompt."
30231|NCT03949868|Behavioral|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 8pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9am text to report on their memory performance over the past 30 minutes."
30232|NCT03949868|Behavioral|Active control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 8pm) asking them to report on the activity they are currently engaged in."
30233|NCT03949855|Drug|Belimumab|"Belimumab is a recombinant, human, IgG1λ monoclonal antibody.~Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.~Standard Weekly dose: 200 mg. administered subcutaneously. A higher weekly dose, 400 mg weekly, per protocol and based on PK analysis, may be indicated for participants with high proteinuria."
30234|NCT03949855|Drug|Placebo for Belimumab|"The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.~Standard weekly dose: 200 mg. administered subcutaneously. A higher weekly dose, 400 mg weekly, per protocol, may be indicated for participants with high proteinuria."
30235|NCT03949855|Drug|Rituximab|"Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.~Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.~Dose: 1000 mg intravenously (IV), Week 4 and -6."
30236|NCT03949842|Drug|Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists|A fixed dose of combination ICS/LABA plus LAMA once-daily was administered to COPD subjects using two separate non-ELLIPTA devices.
30237|NCT03949842|Drug|Fluticasone furoate/umeclidinium/vilanterol|The first strip will contain FF at a dose strength of 100 mcg will be blended with lactose. The second strip will be contain UMEC and VI at a dose strength of 25 mcg and 62.5 mcg blended with lactose and magnesium stearate with respectively.
30238|NCT03949829|Diagnostic Test|Cardiovascular CT|Cardiac and cardiovascular non-contrast and contrast CT
30239|NCT03949816|Other|medical consultation: different doctor-patient-centered style of communication|Different doctor-patient communication
30240|NCT03949816|Other|information letter / no medical consultation|In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
30241|NCT03949803|Behavioral|Morning Chocolate Timing|During two consecutive weeks volunteers will eat chocolate within 1 hour of their habitual wake-time (100g).
30242|NCT03949803|Behavioral|Evening Chocolate Timing|During two consecutive weeks volunteers will eat chocolate within 1 hours of habitual bedtime (100g).
30243|NCT03949803|Behavioral|No Chocolate Timing|During two consecutive weeks volunteers will not eat chocolate.
30244|NCT03949790|Procedure|ESPB and Intercostal nerve block|Erector spinae plane block + Intercostal nerve block
30245|NCT03949790|Procedure|Intercostal nerve block|Intercostal nerve block
30246|NCT03949777|Device|Aer-O-Scope Colonoscopy|resection or biopsy of colonic abnormalities for histopathalogical evaluation
30247|NCT03949764|Drug|Sofosbuvir/velpatasvir (Epclusa®)|The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
30248|NCT03949751|Drug|Acne Crème Plus|The study specific intervention product is a combination of Benzoylperoxid and Miconazolnitrat (Widmer Acne Crème Plus, 47033 Swissmedic) to apply daily in the evening on the skin from the nipple-areola complex laterally to the medial margin of the scapula and from a horizontal line through the nipple-areola complex cranially over the shoulder and dorsally to the spina scapulae. The application should be done regularly for 7 days before shoulder surgery. The study specific intervention product is authorized by Swissmedic for use in the treatment of acne and is used standardly in clinical practice.
30249|NCT03949738|Diagnostic Test|Near-infrared spectroscopy-based assessement of cerebral autoregulation.|"Cerebral autoregulation is assessed using a software that calculates correlation coefficients based on the values of cerebral oxygenation (detected by near-infrared spectroscopy) and invasively measured arterial blood pressure.~Correlation coefficients are calculated at 10-second intervals and averaged over a period of 300 seconds, resulting in an autoregulation index (cerebral oxygenation index, COx). The index can range between -1 and +1. It provides information about cerebral autoregulation capacity, with a value below 0.3 indicating intact cerebral autoregulation."
30285|NCT03949504|Procedure|New Find-risk questionnaire software|FINDrisk: software with 12 questions to define the risk of diabetes in the general population MyStar Connect: software to guide the diagnosis and the management of diabetes and its complications
30250|NCT03949725|Behavioral|Hans Kai Program|Participants in the Hans Kai program attend a health school to enhance their health knowledge and skills. Once complete, the participants form Hans Kai groups of 3 or more people, who meet on a monthly basis independently in a self-sustaining model, each meeting includes a group exercise activity, a group cooking activity, a group learning and discussion activity, and group monitoring of health biomarkers, such as blood pressure, waits circumference, and/or blood glucose.
30251|NCT03949712|Device|Transcranial Static Magnetic Field Stimulation (tSMS)|tSMS consists of a small compact cylindrical neodynium magnet (S-45-30-N, Supermagnete) with an estimated strength of up to 0.5 Tesla and a size of 30 mm x 45 mm.
30252|NCT03949712|Device|Sham Transcranial Static Magnetic Field Stimulation (tSMS)|Sham tSMS consists of a small compact metal cylinder, identical in appearance to the real tSMS device.
30253|NCT03949699|Other|Resistance training|Participants will engage in strengthening exercises using a cable tower while seated. These movements will include trunk flexion and extension, diagonal trunk rotation, and lateral trunk flexion. The goal for resistance training frequency (Weeks 1-8) will be three times per week, lasting about 30-45 minutes per session including warm-up/cool-down, for a duration of eight weeks. Resistance intensity of each exercise will also be determined based on the initial maximal strength performing that exercise: Weeks 1-4 will be 50-60% of the baseline calculated 1 repetition maximum (RM) values; Weeks 5-8 will use resistive loads equivalent to 50-60% of Week 4 1RM calculations
30254|NCT03949686|Drug|Saline Solution|0.5 ml/kg saline
30255|NCT03949686|Drug|Bupivacaine|0.5 ml/kg %0.25 bupivacaine
30256|NCT03949673|Drug|Fasinumab|Study drug will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
30257|NCT03949673|Drug|Naproxen|Naproxen will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
30258|NCT03949673|Drug|Diclofenac|Diclofenac will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
30259|NCT03949673|Drug|Celecoxib|Celecoxib will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
30260|NCT03949673|Drug|Placebo|Matching Placebo will be administered in the parent study. Samples will be collected for participants who voluntarily elect to have knee or hip joint arthroplasty during the parent study
30261|NCT03949660|Device|Stimulation for blood pressure without stand|Consists of 80 daily training sessions using epidural stimulation optimized for blood pressure for up to 6 hours of stimulation a day.
30262|NCT03949660|Device|Stimulation for blood pressure with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
30263|NCT03949660|Device|Stimulation for trunk and core without stand|Consists of 80 daily training sessions using epidural stimulation optimized for trunk/core/voluntary function for up to 6 hours of stimulation a day.
30264|NCT03949660|Device|Stimulation for trunk or core with stand|Consists of 80 daily sessions similar to the 1st intervention (without stand) plus 2 hours of epidural stimulation optimized for stand training.
30265|NCT03949634|Drug|PLD|pegylated liposomal doxorubicin is 35 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
30266|NCT03949634|Drug|CTX|cyclophosphamide is 600 mg/m2 intravenously on Days 1 of each 21-day cycle, followed by docetaxel or paclitaxel.
30267|NCT03949634|Drug|Docetaxel|docetaxel is 100 mg/m2 intravenously on Days 1 of each 21-day cycle.
30268|NCT03949634|Drug|Paclitaxel|paclitaxel is 80mg/m2 intravenously on Days 1, 8 and 15 of each 21-day cycle.
30269|NCT03949634|Drug|Doxorubicin|doxorubicin is 60 mg/m2 intravenously on Days 1 of each 21-day cycle followed by cyclophosphamide.
30270|NCT03949621|Drug|Vedolizumab SC|Vedolizumab SC liquid.
30271|NCT03949608|Other|E-learning|"The intervention consists of the presentation and installation of an internet tool to educate the patient about his heart condition and about his medications in addition to usual care. The tool is an interactive web-hosting video called Mon Coeur, mon BASIC adaptable to smartphones and tablets. The total length of the video is around 15 minutes. The e-learning is interactive because of the possibility to click in the video to have more details about a particular point. The tool includes a part about the heart and particularly about the ACS (physiopathology, diagnosis, coronarography, angioplasty). A second part includes an education about the medications prescribed. The patient will select the medication being prescribed and receive information about it."
30272|NCT03949595|Other|Data collection|
30273|NCT03949582|Other|Test food containing different types of dietary protein|"The test foods will be (in six study visits):~Soy mince/soup Chicken mince/soup Quorn mince/soup Soy mince/soup with guar gum Chicken mince/soup with guar gum Quorn mince/soup with guar gum"
30274|NCT03949569|Behavioral|Therapy Dog|Children will undergo a 5 minute unstructured session with either a certified therapy dog or with a dog who is trained and certified for animal-assisted interventions and/or animal-assisted activities. Children will be allowed to talk to, pet, and play with the therapy dog during the interaction.
30275|NCT03949569|Behavioral|Stuffed Toy Dog|Children will undergo a 5 minute unstructured session with a stuffed toy dog. Children will be allowed to talk to, pet, and play with the stuffed toy dog during the interaction.
30276|NCT03949556|Other|Videos and/or SMS|Participants assigned to one of the intervention programmes will watch videos on a website for two months then will receive SMSs for four months.
30277|NCT03949543|Other|Large Lunch Intervention|Participants were asked to consume 60% of their daily energy requirements as lunch, between 12:30 and 13:30. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as dinner.
30278|NCT03949543|Other|Large Dinner Intervention|Participants were asked to consume 60% of their daily energy requirements as dinner, between 19:30 and 20:30, each day during their two dietary interventions. Breakfast accounted for 15% of their total daily energy, a morning and evening snack for 5%. 15% was given for light meal either as lunch.
30279|NCT03949530|Drug|IDL-2965 Oral Capsule|Investigational drug
30280|NCT03949530|Drug|Placebos|Placebo
30281|NCT03949517|Drug|68-Ga RM2|Radioactive agent
30282|NCT03949517|Drug|68-Ga PSMA11|Radioactive agent
30286|NCT03949491|Procedure|3D medical models|Using 3D medical models of the abdomen, a virtual plan will assist reconstruction to clearly define and 3D model the normal and aberrant vascular anatomy of the donor site in order to decrease both operative time and dissection time. This will also allow for the proposal of incision lines to match the corresponding volumetric analysis of the transposed tissue in order to facilitate the creation of a patient specific tailored flap, which will improve the aesthetic outcomes, decrease donor site complications and improve patient satisfaction
30287|NCT03949478|Drug|Ibuprofen|Ibuprofen to be prepared in a tablet that is not distinguishable from nifedipine or placebo tablet.
30288|NCT03949478|Drug|Nifedipine|Nifedipine to be prepared in a tablet that is not distinguishable from ibuprofen or placebo tablet.
30289|NCT03949478|Drug|Placebo|Sugar pill to be prepared in a tablet that is not distinguishable from ibuprofen or nifedipine tablet.
30290|NCT03949465|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks
30291|NCT03949452|Other|Subcostal Transversus Abdominis Plane catheter|"Prior to surgery, an ultrasound guided unilateral Subcostal Transversus abdominis plane bolus dose (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) will be given on the same side of the surgical incision.~At the end of surgery, A Transversus abdominis plane catheter will be inserted unilaterally by surgeon during wound closure. Then postoperatively, Transversus abdominis plane infusion of a solution mixture prepared in multiple 50 cm syringes each syringe contain 20 ml bupivacaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivacaine is 0.2%). This solution mixture will be infused through Transversus abdominis plane catheter at a rate of 6 ml/hour for 72 hours postoperatively."
30292|NCT03949452|Other|Epidural catheter|"Prior to surgery, we will site an epidural catheter in the thoracic T7-T9 region, and inject an epidural bolus dose same as described above (consisting of amixture of 10 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be completed by normal saline to a total volume of 20 ml mixture) for intra operative analgesia.~Postoperatively, patients will receive epidural infusion of the solution mixture (same as described above) prepared in multiple 50 cm syringes each syringe contain 20 ml bupivaccaine 0.5% plus 100 mg magnesium sulphate to be balanced by normal saline to 50 ml solution mixture ( final concentration of bupivaccaine is 0.2%). This solution mixture will be infused epidurally at a rate of 6 ml/hour for 72 hours (3 days) postoperatively."
30293|NCT03949439|Procedure|Elective Cardiac Surgery|Surgical interventions (coronary artery bypass [CAB], valve replacement or valve repair).
30294|NCT03949426|Drug|KPG-818|KPG-818 Capsules (1 mg, 5 mg and 20 mg) for oral administration is the drug substance powder filled in capsule (PIC) dosage form. KPG-818 Capsules and placebo capsules are packaged in HDPE bottle capped with HDPE cap.
30295|NCT03949413|Diagnostic Test|Pediatric balance scale.|"The Pediatric Balance Scale (PBS) includes fourteen items. Each item of subsets scored as 4, 3, 2, 1 or 0. Finally, the total test score was calculated.~Each child in both groups was examined individually, using ADHD Rating Scale-IV checklist. The child's teacher was asked to write the checklist. Then the therapist interpreted the total scores obtained from the checklist and she converted it to the percentile scores based on their total scores."
30296|NCT03949400|Other|Exercise therapy and education.|Exercise therapy and education, physiotherapy rehab at Aalborg Municipality
30297|NCT03949387|Other|FES Cycling Exercise|FES cycling will use self-adhering surface electrodes (Pals Platinum, Fallbrook, CA) placed over the quadriceps, hamstrings, and gluteal muscle groups to deliver stimulation to the leg muscles.
30298|NCT03949387|Other|Passive Leg Cycling|Passive leg cycling will not involve electrical stimulation
30299|NCT03949374|Drug|CRESTOR, reference formulation of rosuvastatin|Use of ROVASRO for hypercholesterolemia
30300|NCT03949374|Drug|ROVASRO, generic formulation of rosuvastatin|Use of CRESTOR for hypercholesterolemia
30301|NCT03949361|Diagnostic Test|Indirect calorimetry|Resting energy expenditure
30302|NCT03949361|Diagnostic Test|Skin Temperature|Temperature: supraclavicular, infraclavicular, abdominal, mid-thigh, non-dominant lower arm, middle finger tip, left lower leg, left dorsal foot, ear thermometer
30303|NCT03949361|Diagnostic Test|Dual energy X-ray Absorptiometry (DXA)|Body composition
30304|NCT03949361|Diagnostic Test|Blood Sampling|thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), HbA1c, Fibroblast growth factor 21 (FGF21)
30305|NCT03949361|Diagnostic Test|FDG-PET|Dynamic PET scanning of the neck-region
30306|NCT03949361|Diagnostic Test|Capillary glucose|Prior to fluorodeoxyglucose (FDG)-PET in order to avoid hyperglycemia
30307|NCT03949361|Diagnostic Test|Biopsy of supraclavicular adipose tissue (optional)|Ultrasound guided biopsy of the supraclavicular adipose tissue
30308|NCT03949348|Procedure|Mid-urethral sling placement using autologous rectus fascia|Mid-urethral sling placement using autologous rectus fascia
30309|NCT03949348|Procedure|Mid-urethral sling placement using synthetic mesh|Mid-urethral sling placement using synthetic mesh
30310|NCT03949322|Behavioral|Adapted Physical Activity Program|The sessions in this program are similar to the adapted physical activity sessions already offered by sports therapy practitioners. This is an aerobic exercise session, with Nordic walking, and a combined session of muscle building and breathing exercises.
30311|NCT03949309|Other|Exploring health literacy levels and patients' informal needs or individual relationship between caregivers and patients.|It is a cross-sectional study coupled with a qualitative ancillary study conducted within patients hospitalized for one of the two acute cardiovascular diseases (acute coronary syndrome or acute heart failure). All patients hospitalized at Hospices Civils de Lyon for one of these two diseases and whom are going back home will be enrolled. Few patients will be interviewed during the follow-up visit at 1-month post hospitalisation. Caregivers from cardiology units will also be interviewed.
30334|NCT03949101|Drug|Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop|use one drop into subconjunctiva
30335|NCT03949101|Drug|atropine 0.01% eye drop|use one drop into subconjunctiva
30336|NCT03949088|Other|UF and Na profiling|Modulation of UF and dialysate sodium
31194|NCT03942068|Drug|Apatinib|a novel oral antiangiogenic agent targeting vascular endothelial growth factor receptor (VEGFR2)
30312|NCT03949296|Behavioral|Mindfulness Intervention|"10-session program~Introduction to mindfulness and its potential benefits~Introduction to mindful practices and yoga poses~Conditioned reactions to stress; integrating mindfulness into everyday life~Challenges and insights gained in practicing mindfulness~Using mindfulness to observe and reduce negative means of reacting to stress, and find more effective responses~Reacting vs. responding to stressors~Self-regulation and coping with stressors and communication challenges~Fostering continuity of moment-to-moment awareness while practicing different forms of mindfulness~Choosing and creating one's own blend of mindfulness practices~Maintaining momentum to practice mindfulness once the program ends"
30313|NCT03949296|Behavioral|Sleep Hygiene|"Session includes a handout with15 sleep hygiene tips:~Maintain a regular sleep pattern~Only try to sleep when feeling tired or sleepy~If unable to sleep, do something calm until feeling tired and returning to bed~Avoid caffeine & nicotine for 4-6 hours before going to bed~Avoid alcohol for 4-6 hours before going to bed~Use the bed only for sleeping and sex~Avoid naps during the day~Develop rituals to get relaxed and ready to sleep~Try a hot bath prior to bedtime~Avoid checking the clock during the night~Use a sleep diary for a few weeks to track progress~Avoid strenuous exercise before bedtime~Avoid a heavy meal before bedtime~Create a sleep environment that is quiet, comfortable, and dark~Maintain a regular daytime routine"
30314|NCT03949283|Diagnostic Test|ChemoID Assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill bulk of tumor cells, and cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
30315|NCT03949283|Drug|Standard Chemotherapy|"Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:~Liposomal Doxorubicin; Docetaxel; Paclitaxel; Carboplatin; Cisplatin; Gemcitabine; Topotecan; Carboplatin, Gemcitabine; Cisplatin, Gemcitabine; Carboplatin, Liposomal Doxorubicin; Carboplatin, Paclitaxel; Carboplatin, Docetaxel. The treating physician will NOT receive the ChemoID assay results from the ChemoID lab."
30316|NCT03949270|Behavioral|BETA-Text text messaging intervention|Patients in the text messaging arm will receive daily, weekly, and monthly text messages. The daily message asks whether or not the patient has taken their breast cancer medication. The weekly message asks about any side effects and their severity. The monthly text message asks about any barriers that the patient might be experiencing. Concerning responses to any of the text messages will prompt contact from the office of the treating physician.
30317|NCT03949257|Device|colonic transendoscopic enteral tubing|Colonic transendoscopic enteral tubing (TET) is a novel, safe, convenient, and reliable way for fecal microbiota transplantation (FMT) and the whole-colon enema treatment.
30318|NCT03949244|Drug|Latanoprost 0.005%|Latanoprost 0.005% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
30319|NCT03949244|Drug|Latanoprost bunod 0.024%|Latanoprost bunod 0.024% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
30320|NCT03949244|Drug|Normal saline 0.9%|Normal saline 0.9% will be applied to the nailfold and images of the blood flow in the nailfold capillaries will be acquired.
30321|NCT03949244|Diagnostic Test|Nailfold capillaroscopy|An imaging system and does not penetrate the skin. A video camera with a magnifying lens used for studying the movement of blood in small blood vessels at the nailfold of the 4th finger.
30322|NCT03949231|Drug|Toripalimab|Infusion of Toripalimab through peripheral vein or hepatic artery.
30323|NCT03949205|Other|Leg Extension Isometric Training|The leg extension isometric exercise will be performed tree times a week , in four 2 min bouts of isometric contraction, at a intensity of 30% of maximal voluntary contraction and an interval of two minutes between bouts.
30324|NCT03949179|Device|The Low Back Pain and Disability Drivers Management (PDDM) model|The Low Back Pain and Disability Drivers Management (PDDM) model aims to identify the domains influencing pain and disability to guide clinical decisions. The model is composed of five domains upon which the clinician can base his assessment and orientate treatment allocation and includes: 1) nociceptive pain drivers (i.e., somatic, inflammatory or mixed pain), 2) nervous system dysfunction (NSD) drivers (i.e., sensitization of the peripheral and/or central nervous system), 3) comorbidity drivers (i.e., physical and/or mental health comorbidities), 4) cognitive-emotional drivers (i.e., maladaptive cognitions and/or behaviors) and 5) contextual drivers (i.e., occupational-related and social environmental contextual drivers). This profiling will inform and lead the clinician's treatment approach based on the combined contribution of each domain driving the experience of pain and disability.
30326|NCT03949153|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|Single Nivolumab 240 mg infusion at D0
30327|NCT03949153|Procedure|Cryotherapy|Cryotherapy using interventional radiology of metastatic lymphadenopathy at D1
30328|NCT03949153|Drug|Ipilimumab Injection|In situ injection with ipilimumab at D2.
30329|NCT03949140|Procedure|Laser hair removal|Those who consent to participate in the study will be treated with 6 sessions of laser hair removal utilizing a long-pulsed laser to the natal cleft at treatment intervals of 4-6 weeks.
30330|NCT03949127|Other|Exercise Group|The group who will meet a physiotherapist who will show them strengthening and stretching muscles associated with pelvic tilt.
30331|NCT03949114|Behavioral|Evaluation|Evaluate a weak debilitating phenotype screening on the patients before surgery;
30332|NCT03949114|Behavioral|nursing care|Traditional post-operative nursing care
30333|NCT03949114|Behavioral|rehabilitation|"Postoperative vital signs were stabilized for 2 hours and then assisted to turn over; 2 to 3 hours to change position, awake without swallowing dysfunction, to fluid diet; 6 hours later, raise the bed 15 to 30 °, eat a half-flow diet.~On the first day after surgery, raise the bed 45 °, row and position training; catheter clamping training; assessment of pain, preventive analgesia. Early rehabilitation training was performed for 60 minutes each time for 5 consecutive days."
33009|NCT03927131|Biological|QIV-IB Lot A|Inactivated split-virion quadrivalent influenza vaccine - Lot A
30337|NCT03949075|Drug|Enalapril|Participants will be assigned to daily administration of ACE inhibitors (Initially 5 mg Corodil® 'Enalapril' daily followed by up to 20 mg daily dependent on the blood pressure response) combined with an 8-week training period.
30338|NCT03949075|Drug|Placebo|Participants will be assigned to daily administration of placebo (5-20 mg CaCO3) combined with an 8-week training period.
30339|NCT03949062|Drug|Ibrutinib|Ibrutinib 560mg per day administered orally on Day 1-21 of each 21-day cycle for 6 cycles
30340|NCT03949062|Drug|Lenalidomide|Lenalidomide 25mg per day administered orally on Day 1-10 of each 21-day cycle for 6 cycles
30341|NCT03949062|Drug|Rituximab|Rituximab 375mg/m2 per day administered intraveneously on Day 1 of each 21-day cycle for 6 cycles
30342|NCT03949049|Drug|Citicoline|Citacoline as neuroprotector
30343|NCT03949049|Other|Placebo|placebo group
30344|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 12%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 12%
30345|NCT03949036|Other|Crystalloid fluid administration with the target of stroke volume variation ≤ 6%|The rate of crystalloid fluid administration will be controlled to achieve the target of stroke volume variation ≤ 6%
30346|NCT03949023|Procedure|Standard of Care Cerebral Angiogram Group|"Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration)."
30347|NCT03949010|Other|Kinesiotaping with space correction technique|Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program
30348|NCT03949010|Other|Kinesiotaping with muscle inhibition technique|Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program
30349|NCT03949010|Other|Home exercise program|Home exercise program which consists of stretching exercises towards neck area
30350|NCT03948997|Radiation|Pulsed dye laser (PDL)|Pulsed dye laser (PDL, 595nm) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis
30351|NCT03948984|Behavioral|Therapeutic Music Session|The 20 minute therapeutic music session will consist of classical music performed by a pianist with or without flute accompaniment with an individual patient's ICU room.
30352|NCT03948971|Procedure|Venogram|The 5 French (5F) diagnostic catheter will be navigated into the inferior then superior vena cava and then into the internal jugular bulb on the dominant venous side (as determined from the arteriographic images). Next, a 0.027 inch microcatheter will be navigated using fluoroscopic guidance into the superior sagittal sinus and a venogram will then performed by injecting a small dose of contrast. Next, the venous sinus pressure waveforms will be recorded as the catheter is withdrawn into the jugular bulb and then in the superior vena cava to obtain a central venous pressure. Once completed, the catheters will be removed and the sheaths will be removed. Manual pressure will be held at the venous access site for a few minutes. The arterial sheath will be closed based upon standard arteriogram protocol.
30353|NCT03948958|Other|Evaluation of the catheter function|Catheter function will be measured by the CINAS (Catheter injection and aspiration classification)
30354|NCT03948958|Other|Catheter tip location, thrombus, sleeve and device damage visualization|Catheter tip location, thrombus, sleeve and device damage will be visualized by linogram
30355|NCT03948958|Other|Catheter-related colonization|TIVAD colonization will be investigated by microbiological culture of the tip and chamber content
30356|NCT03948958|Other|patient-reported outcome measures (PROM) related to the presence of the TIVAD|PROM will evaluate patient's experiences regarding the TIVAD insertion, dwell time, and removal using the Leuven Patient Reported Experiences at Port removal (Leuven PREP) questionnaire.
30357|NCT03948958|Other|Macroscopic evaluation of the port chamber and catheter|Macroscopic evaluation of the port chamber and catheter will be performed after port removal.
30358|NCT03948945|Radiation|Profile HaloTM Mixed Fractional Laser|Profile HaloTM fractional laser is the world's first hand tool with nonablative and ablative fractional laser. It includes a nonablative fractional laser with a wavelength of 1470 nm and an ablative fractional laser with a wavelength of 2940 nm. It has a good therapeutic effect on skin aging.
30359|NCT03948932|Device|Transvaginal sonography|Measurement of cervical length via transvaginal sonography prior to labor induction.
30360|NCT03948932|Device|Pressure watch|Measurement of inflation pressure in a cervical ripening balloon is PSI units.
30361|NCT03948919|Drug|Fecal microbiota|Lyophilized encapsulated fecal microbiota given daily for 8 weeks.
30362|NCT03948919|Other|Placebo|Placebo capsules identical in appearance to fecal microbiota capsules to be taken daily for 8 weeks.
30363|NCT03948893|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
30364|NCT03948893|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
30365|NCT03948867|Drug|Hydroxyurea|Hydroxyurea treatment will be provided to reduce stroke risk. Hydroxyurea treatment will be started at a fixed dose of 20.0 ± 5.0 mg/kg/day, followed by escalation to maximum tolerated dose (MTD).
30366|NCT03948867|Diagnostic Test|Elevated Arm TCD Examination|"TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke.~For children with elevated velocities at initial screening or at 1 Year who receive hydroxyurea therapy, TCD examinations will occur every 6 ± 2 months."
30430|NCT03948347|Drug|Liraglutide|The treatment arm will receive the starting dose of liraglutide of 0.6 mg/d subcutaneously once daily, and the dose will be increased to 1.8 mg/d in two weeks, and then continue to administrate this dose for 90 days.
30367|NCT03948867|Diagnostic Test|Normal Arm TCD Examination|TCD examination on children with SCA between ages 2 and 16 years of age will be completed to evaluate their risk of stroke. TCD examination for all participants will occur at initial screening, at Year 1 (12 ± 3 months), and Year 2 (24 ± 3 months). Children with normal TCD velocities at initial screening will undergo repeat TCD 12 months after enrolment. If the TCD at 12 months has changed to an elevated velocity (conditional or abnormal), the child can begin study treatment (Hydroxyurea).
30368|NCT03948854|Other|Registered dietitian|Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
30369|NCT03948854|Other|On-line video program|Education on low FODMAP diet is provided by an on-line program via a link sent through email
30370|NCT03948854|Other|Printed handout|Education on low FODMAP diet is provided through printed handout material at the initial visit.
30371|NCT03948854|Other|Dietitian-led group|Education on low FODMAP diet is provided in a dietitian-led group setting
30372|NCT03948841|Other|magnetic resonance imaging|
30373|NCT03948828|Biological|Autologous NK cell therapy|After conventional treatment, the patients were treated with autologous NK cells.
30374|NCT03948828|Drug|GnRHa combained with reverse addition therapy|Postoperative patients were treated with GnRHa combined with reverse addition treatment.
30375|NCT03948815|Other|interventional birthing room|The design of the room is based on scientific evidence on the healthcare environment in general, and on a systematic review on the effect of birthing rooms published by the investigators, and interviews with women early after birth in Sweden. The room has a large birthing pool, several lighting options with dimming function, 40 mm suspended sound absorber in the ceiling, media installation covering two walls, which offers a choice of six different programmed nature scenes with light, sound effect and Music.
30376|NCT03948802|Diagnostic Test|Interleukine 33 test in blood plasma|ELISA test for Interleukin 33
30377|NCT03948789|Procedure|Magnetic Resonance Imaging-controlled high-focussed ultrasound therapy|Magnetic Resonance Imaging-controlled high-focussed ultrasound
30378|NCT03948789|Procedure|Myomectomy (laparoscopic or open surgical)|Myomectomy (laparoscopic or open surgical)
30379|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. These will be compared to the reference technique of whole-body DXA imaging.
30380|NCT03948776|Diagnostic Test|BodyMetrix body composition ultrasound only|Investigators will make ultrasound measurements of fat and muscle thickness at 7 positions on the arm, chest wall, and leg (subject's dominant side) using the BodyMetrix BX 2000 ultrasound machine. Clear ultrasound gel will be applied to the skin, a probe placed against the skin, and the fat/muscle thickness measurement made five times at each position. The gel is then wiped away. The images are analyzed by the BodyView Software and estimations of fat and muscle mass calculated. For inpatients currently admitted to the hospital, whole-body DXA imaging cannot be performed, as so the only assessment of body composition will be with the ultrasound.
30381|NCT03948763|Biological|V941|V941 administered IM, Q3W for 9 3-week cycles
30382|NCT03948763|Biological|Pembrolizumab|Pembrolizumab 200 mg, IV for 35 3-week cycles
30383|NCT03948750|Procedure|Aqueous humour sampling|Aqueous humour sampling with Goldman-Witmer coefficient and immunoblotting
30384|NCT03948737|Drug|Alpha-Tocopherol|all of the subjects in the alpha-tocopherol group received alpha-tocopherol orally, doses adjusted by age for 4 weeks of treatment.
30385|NCT03948737|Drug|Placebo oral tablet|
30386|NCT03948724|Behavioral|Therapeutic education program|Patient follow sessions the therapeutic patient education with manual therapy, therapeutic education, therapeutic exercize
30387|NCT03948724|Behavioral|Usual Information|Patient receive usual informations
30388|NCT03948711|Device|Near-infrared spectroscopy (NIRS) monitoring of cerebral oxygenation|Monitoring before anesthesia to hospital admission. No treatment decisions made based on monitoring.
30389|NCT03948698|Other|Innovative approached to pediatric TB care|Includes integration of TB care in non-TB entry points in facilities, decentralization from higher level clinics to lower levels, strengthening screening activities and building diagnosis and treatment capacity among healthcare workers
30390|NCT03948685|Drug|Carvedilol SR|blood pressure, heart rate based titrated carvedilol SR for 24 weeks
30391|NCT03948685|Drug|Placebo|Placebo
30392|NCT03948672|Device|CleanHands System|All participants who regularly access the ICUs will wear the CleanHands system wristband while at work for 5 months and the reminding functionality is turned on.
30393|NCT03948659|Procedure|Arterio ventricular coupling|We analyse ventriculo arterial coupling (VAC) among cirrhotic patients admitted in intensive care unit, with non-invasive echography method
30394|NCT03948646|Drug|Sofpironium Bromide, 15%|Active
30395|NCT03948646|Drug|Vehicle|Vehicle gel
30396|NCT03948633|Other|Multi-faceted knowledge translation intervention|The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
30397|NCT03948620|Drug|Macrolides|Macrolide antibiotics, including erythromycin, clarithromycin and azithromycin. Prescriptions of macrolides will be identified using a drug code list based on the British National Formulary (chapter 5.1.5) and the date of the first prescription was used as the index date of exposure.
30398|NCT03948620|Drug|Penicillins|The comparison group consists of children whose mother were prescribed penicillins during pregnancy. Prescriptions of penicillins will be identified using a drug code list based on the British National Formulary (chapter 5.1.1) and the date of the first prescription will be used as the index date of exposure.
30428|NCT03948360|Device|Low-Irradiance Monochromatic Biostimulation (LIMB) Device|The LIMB System is a portable and wearable phototherapeutic system that consists of a Light Patch and Power Pack. The Power Pack delivers power to the Light Patch, which attaches to the participant and emits blue spectrum (405nm low-irradiance) light. The Light Patch contains an array of thin optical arrays that evenly illuminate the surface. The Power Pack is powered by a Lithium Thionyl Chloride (Li-SOCI2) battery.
30399|NCT03948607|Other|Electroencephalography during sustained attention task.|"The Continuous Temporal Expectancy Task (CTET) (O'Connell et al., 2009) is a very demanding discrimination task with sustained attention. It consists of the presentation on a computer screen of a visual pattern resembling a checkerboard that changes orientation at regular intervals of time. In this task the subject must respond (pressing a response button) to the appearance of rare target stimuli that have a longer duration (1120 ms) than non-target stimuli (800 ms).~SART (Sustained Attention to Response Task) (Robertson et al., 1997) is a task of inhibition (Go / No-Go task) to evaluate the capacities of sustained attention. It consists in the successive and random presentation on a computer screen of the numbers from 1 to 9. In this task the subject must respond, by pressing a response button, to the appearance of all the numbers (very non-target stimuli frequent), with the exception of the number 3."
30400|NCT03948594|Dietary Supplement|resource|1 packet resource(237ml), 1.05kcal/ml, 53.6g carbohydrate and 9g protein
30401|NCT03948594|Other|plain water|250ml plain water
30402|NCT03948581|Drug|Vedolizumab SC|Vedolizumab SC liquid.
30403|NCT03948568|Combination Product|Endocrine Therapy and Radiotherapy|Endocrine therapy and radiotherapy administered either concurrently or sequentially
30404|NCT03948555|Diagnostic Test|Magnetic Resonance Imaging (MRI) using ultrasmall super paramagnetic iron oxides (USPIOs)|All patients will undergo two MRI scans (one MRI scan pre-USPIO administration, and one MRI scan 24-36 hours following USPIO administration) and blood samples will be taken for future biomarker analysis.
30405|NCT03948542|Other|Outcome|"Nerve Recovery~NCV~Funcional assessment"
30406|NCT03948529|Drug|eltrombopag|eltrombopag at the starting dose of 50mg/day. After 2 weeks of eltrombopag initiation and in the absence of platelet response, eltrombopag will be increased every two weeks (50mg increase) up to a maximum dose of 150mg/day (2 maximum escalation from D1, with maximum dose escalation phase of 4 weeks).
30407|NCT03948516|Device|HemeChip|The basis of HemeChip technology lies in Hb electrophoresis, in which Hb types C, A2, S, F, and A0 have net negative charges in an alkaline solution. Differences in Hb mobilities allow separation to occur within the sieving medium, cellulose acetate paper. HemeChip technology is a low-cost, point-of-care translation of the electrophoresis method that has been well established, readily accepted by clinicians, and widely applied in SCD diagnosis for well over 40 years. HemeChip offers a $2 screening test for SCD (and other Hb disorders), which takes 10 minutes to run. It is mobile and easy-to-use; it can be performed by anyone after a short (30 minute) training.
30408|NCT03948503|Procedure|Mulligan concept|Mobilization with movement during an active dorsi-flexion of the ankle
30409|NCT03948503|Procedure|Placebo|Sham mobilization with movement during an active dorsi-flexion of the ankle
30410|NCT03948490|Device|ReMind iPad app|Evidence-based program to improve attention and memory through (1) cognitive training and (2) teaching compensatory skills in patients with brain tumors.
30411|NCT03948490|Device|Healthy SMS texting|Participants receive a daily message sent at a random time (within their chosen timeframe(s); e.g. 9am-9pm). Messages will focus on patient-based education-focused health-related quality of life and cognitive education such as internal and external cognitive compensatory strategy training, fatigue management, and coping skills.
30412|NCT03948490|Behavioral|In-person cognitive rehabilitation|The in-person cognitive rehabilitation will focus on the application of evidenced based strategies recommended as practice guidelines by the American Congress of Rehabilitation Medicine Cognitive Rehabilitation Task Force (ACRM-CR). The treatment occurs in two stages 1) comprehensive neuropsychological assessment and rehabilitation planning and 2) implementation of treatment planning.
30413|NCT03948477|Drug|Pantoprazole 40mg|Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
30414|NCT03948477|Drug|Placebo|Matched placebo
30415|NCT03948464|Drug|Slow release oral morphine (SROM)|Slow release oral morphine is an opioid agonist. Slow release oral morphine will be administered via daily witnessed ingestion at designated community pharmacies.
30416|NCT03948464|Drug|Methadone|Methadone is an opioid agonist. Methadone will be administered via daily witnessed ingestion at designated community pharmacies.
30417|NCT03948451|Drug|[14C]AZD5718 Oral Suspension|200 mg dose of [14C]AZD5718 Oral Suspension
30419|NCT03948425|Radiation|spectral CT|Head spectral CT
30420|NCT03948412|Device|Closed Incision Negative Pressure Wound Therapy (Prevena)|Closed Incision Negative Pressure Wound Device (Prevena) applied to closed wound at completion of operation.
30421|NCT03948412|Other|Control - Standard Dressings|Standard wound dressings applied to closed wound at completion of operation.
30422|NCT03948399|Device|Duplex scanning of carotid arteries|Measurement of carotid arteries
30423|NCT03948399|Device|ABI measurement|ankle brachial index (ABI) assessment
30424|NCT03948386|Drug|isobaric bupivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
30425|NCT03948386|Drug|hyperbaric bupivacaine|TThe anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
30426|NCT03948386|Drug|isobaric mepivacaine|The anesthesiologist and CRNA or resident performing the spinal will perform spinal anesthesia according to standard operating procedures with the randomly assigned local anesthetic.
30427|NCT03948373|Device|CPAP treatment|In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
30429|NCT03948360|Other|Standard of Care|Standard of care therapy as defined for this clinical trial is standard gauze dressing soaked in Sulfamylon (mafenide acetate) solution.
30431|NCT03948334|Drug|ZPL389|Dose 1 of ZPL389; once daily from week 16 to week 116.
30433|NCT03948334|Drug|TCS and/or TCI|Topical corticosteroids (TCS) and /or topical calcineurin inhibitors (TCI) will be used concomitantly or intermittently based on disease severity.
30434|NCT03948321|Procedure|Aminolevulinic acid photodynamic therapy|Aminolevulinic acid photodynamic therapy
30435|NCT03948308|Biological|blood sample|blood sample before, during and after infection treatment
30436|NCT03948295|Dietary Supplement|Lipid Challenge|After fasting for 10 hours, all participants will undergo a lipid challenge with Calogen. Calogen is a commercially available liquid high-energy long chain triglyceride fat emulsion used to fortify foods. Calogen provides 50 grams of long chain triglycerides per 100 mL. Participants must avoid physical activity during the 6 hour study period to avoid changes in metabolism that could affect the results of the study.
30437|NCT03948269|Behavioral|group behavioral cognitive therapy|First, we will establish a WeChat group containing the imGT group members and psychiatrists, in which everyone can talk instantly. The interactive treatments will be conducted every Friday evening for a duration of 1.5 hours via text, audio or video messaging. Table 1 summarizes the module topics and provides detailed information on the treatment program. All modules will be saved for repeated viewing after completion. Second, we will establish another WeChat program named Punched-in which participants report on aspects of their everyday life such as diet, sports, readings or mood, according to the plan made by psychiatrists, via text, audio, photo or video message. This program will only be visible to and able to be commented on by participants and psychiatrists.
30438|NCT03948256|Procedure|Control intervention|Prompt closure of EVD with subsequent observation period
30439|NCT03948256|Procedure|Experimental intervention|Gradual weaning of EVD with 5 cmH2O increase in drainage resistance daily until complete closure with subsequent observation period
30440|NCT03948243|Dietary Supplement|Licorice|Experimental :G.Glabra Licorice extract: 2 gelatin capsules (75 mg) per day for 14 days
30441|NCT03948243|Drug|Alprazolam 2 MG|substrate
30442|NCT03948243|Drug|Caffeine 100 MG|substrate
30443|NCT03948243|Drug|Tolbutamide 250 mg|substrate
30444|NCT03948243|Drug|Dextromethorphan 30mg|substrate
30445|NCT03948230|Biological|Salt with / without water|Drinks with and without a salt containing capsule
30446|NCT03948217|Other|Circadian Lighting regimen|Circadian lighting regimen with one major fluctuation, high light intensity and color
30447|NCT03948191|Drug|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. once a week for 6 weeks.
30448|NCT03948191|Drug|99Tc-MDP(99Technetium-Methylenediphosphonate Injection)|15mg i.v. infusion once a day for 10 days, 20 days apart, received 3 courses of infusions.
30449|NCT03948178|Drug|Levosimendan|Levosimendan 1 mg capsule for oral administration
30450|NCT03948165|Procedure|Distal Transradial Access|The distal radial artery needs to be punctured with specialized equipment with a 20, 21 or 22-gauge puncture needle, using a transfixion or anterior wall technique. A 0.025 in, 46 cm guide was introduced in the system, followed by the introduction of the 5 Fr, 6 Fr, 7Fr hydrophilic arterial sheath or 5 Fr, 6 Fr or 7 Fr Glidesheath Slender introducer (TerumoIS, Tokyo, Japan), after a small incision in the skin.
30451|NCT03948152|Other|Standard of Care|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the sites standard of care.
30452|NCT03948152|Other|Mask Advice Tool|Participants will have a Positive Airway Pressure (PAP) mask chosen to wear for a period of 90 days as provided by the mask advice tool.
30453|NCT03948139|Device|Functional Brace|The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.
30454|NCT03948139|Device|Hip Spica Cast|Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
30455|NCT03948126|Other|Questionnaire about geophagia (knowledge about soil/clay consumption and knowledge of the health effects of geophagy)|
30456|NCT03948113|Other|Dialysis|
30457|NCT03948100|Other|Educational Intervention|Undergo dyadic education program
30458|NCT03948100|Other|Quality-of-Life Assessment|Ancillary studies
30459|NCT03948100|Other|Questionnaire Administration|Ancillary studies
30460|NCT03948100|Procedure|Yoga|Undergo dyadic yoga
30461|NCT03948087|Device|Vacuum Removable Rigid Dressing (VRRD)|Intra-operative application of device.
30462|NCT03948074|Drug|Cannabis|Medicinal Cannabis Oil
30463|NCT03948061|Other|Cherry juice|FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.
30464|NCT03948061|Other|Placebo beverage|Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
30465|NCT03948048|Device|ECMO|ECMO is used to intervene septic shock and refractory septic shock
30466|NCT03948035|Drug|Elotuzumab|i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.
30467|NCT03948035|Drug|Carfilzomib|i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.
30468|NCT03948035|Drug|Lenalidomide|hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.
30469|NCT03948035|Drug|Dexamethasone|orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .
30470|NCT03948035|Other|autologous stem cell transplant|autologous stem cell transplant
30471|NCT03948022|Drug|Dydrogesterone 10Mg Tablet (duphaston)|40 mg daily oral tablets
30472|NCT03948022|Drug|Progesterone 50Mg/mL Oil|100 mg daily intramuscular injections
30473|NCT03948022|Drug|Crinone 8% Vaginal Gel|180 mg daily vaginal gels
30474|NCT03947996|Other|Stretching exercise|Stretching (30 minutes, 5 days per week, 8 weeks)
30475|NCT03947996|Other|Walking exercise|Walking (30 minutes, 5 days per week, 8 weeks)
30476|NCT03947983|Behavioral|Sensor-controlled digital game (SCDG)|"The SCDG will involve a narrative, the goal of which is to help an avatar in the game avoid rehospitalization by using game points, earned via the participant's real-time behaviors, in game tasks that help maintain the avatar's optimal HF health status. Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). The data from the Withings sensors will then be routed to our SCDG app.~The digital game paired with sensors will enable objective tracking of real-time behaviors such as physical activity, and weight monitoring, and provide personalized, contextually relevant feedback (e.g., reduce fluid intake or call doctor for weight gain) to motivate engagement in and generate habit formation of heart failure related self-management behaviors."
30477|NCT03947983|Behavioral|Sensor Only|Real-time behaviors of weight-monitoring and physical activity will be tracked by an off-the-shelf sensors and app (Withings). This group will also be provided with standardized evidence-based HF educational material.However, the data from the Withings sensors will not be routed to the SCDG.
30478|NCT03947970|Drug|[14C] CR845|Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries [14C] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)
30479|NCT03947957|Diagnostic Test|collection of expectoration, stools and blood|collection of expectoration, stools and blood
30480|NCT03947944|Procedure|SMILE using manifest refraction planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
30481|NCT03947944|Procedure|SMILE using vector planning|The treatments of astigmatism were planned using either the manifest refraction (manifest refraction group) or the vector planning method (vector planning group). The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a microspatula with a blunt circular tip and extracted with microforceps. The integrity of the lenticule was assessed subsequently. The treatment plan for the vector planning group involved a combination of refractive astigmatism with 60 % emphasis and corneal astigmatism with 40 % emphasis.
30482|NCT03947918|Behavioral|Short sleep|Child will be asked to sleep for less than 8 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent daily text messages or phone call reminders.
30483|NCT03947918|Behavioral|Long sleep|Child will be asked to sleep for more than 10 hours. Study team will help parent design a sleep schedule for that week. Study team will send parent text messages or phone call reminders.
30484|NCT03947905|Procedure|Virtual visit|Type of visit
30485|NCT03947892|Diagnostic Test|PET-CT|A PET-CT scan will be performed systematically for all patients included with the SUVmax, SUV peak, MTV of the lesion, and up to 3 suspicious ganglia during the visual analysis.
30486|NCT03947879|Drug|L-glutamine|15 g of L-glutamine twice daily by mouth for 3 months.
30487|NCT03947879|Other|No L-glutamine|The same patients will be given no L-glutamine for 3 months.
30488|NCT03947840|Behavioral|Physical activity|Se their physical activity level
30489|NCT03947827|Drug|Minocycline|Participants will be randomized to receive either Minocycline or placebo added to standard oral antidepressants.
30491|NCT03947801|Other|Greek Yogurt|Soccer players (11-16y) will consume 0% plain Greek yogurt following each daily practice, once before bed and once at breakfast, during a high volume-high intensity week. Dietary dairy consumption will be controlled for by instructing all groups to limit diary consumption to 3 servings/d.
30492|NCT03947801|Other|Isoenergetic carbohydrate|Soccer players (11-16y) will consume a study designed isoenergetic carbohydrate snack following each daily practice, once before bed and once at breakfast, during a high volume-high intensity week. Dietary dairy consumption will be controlled for by instructing all groups to limit diary consumption to 3 servings/d.
30493|NCT03947788|Behavioral|OKQ Training Program|The OKQ training program helps clinicians more efficiently meet the needs of women's pregnancy intentions and provide evidence-based care.
30494|NCT03947775|Drug|9-valent HPV vaccination|Gardasil-9 is a novel, 9-valent HPV recombinant vaccine, which expands the coverage of oncogenic HPV types, with the addition of HPV types 31, 33, 45, 52, and 58 to the existing quadrivalent vaccine types. The addition of these five oncogenic types is estimated to improve cancer coverage to 90% (versus 70% for the quadrivalent vaccine) [38]. With its expanded coverage of oncogenic HPV types, its proven efficacy in primary prevention and its potential role in mitigating HGAIN recurrences.
30495|NCT03947736|Diagnostic Test|cfDNA was detected by dPCR|Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
33010|NCT03927131|Biological|QIV-IB Lot B|Inactivated split-virion quadrivalent influenza vaccine - Lot B
30496|NCT03947723|Device|Radiofrequency ablation|The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
30497|NCT03947710|Other|High-protein meals|Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)
30498|NCT03947710|Other|Low- protein meals|Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)
30499|NCT03947710|Other|No meals|Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
30500|NCT03947697|Device|Neuromuscular Electrical Stimulation (Sensory)|Group will receive Electrical Stimulation up to sensory level
30501|NCT03947697|Device|Neuromuscular Electrical Stimulation|Group will receive Electrical Stimulation up to maximum tolerable level
30502|NCT03947697|Other|Resistance Training|Group will receive exercise training.
30503|NCT03947684|Device|Transcranial Magnetic Stimulation Device|The TMS device electrically stimulates the intended parts of the brain. In this study, the investigator plan to target the part of the brain cortex that is responsible for the voluntary motion of the leg muscles, whose functions are under investigation.
30504|NCT03947671|Device|Rapr Rounds Hyper/Hypothermia Wraps|Rapr Round® vest and leg wraps will placed around the torso and legs of the participant and will be adjusted to maintain normal body temperature
30505|NCT03947671|Drug|Acetaminophen|Acetaminophen will be administered as it would be per standard of care
30506|NCT03947658|Procedure|Surgical crown lengthening|Surgical lengthening of teeth with short clinical crown and prosthetic rehabilitation
30507|NCT03947645|Device|Ipsilesional stimulation|Device: ipsilesional transcranial stimulation, neuromuscular Stimulation over target muscle
30508|NCT03947645|Device|Contralesional stimulation|Device: contralesional transcranial stimulation, neuromuscular stimulation over target muscle
30509|NCT03947632|Diagnostic Test|serum ferritin and hemoglobin test|Five milliliter of blood samples were collected in two tubes (ethylenediaminetetraacetic acid and gel) at Fatimid foundation by a trained phlebotomist prior to blood transfusion to determine hemoglobin and serum ferritin.
30510|NCT03947619|Device|Impella CP® placement prior to reperfusion with Primary PCI|Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.
30511|NCT03947606|Behavioral|CASCADE (CAre Supporters Coached to be Adept DEcision partners)|CASCADE (CAre Supporters Coached to be Adept DEcision partners) is a multicomponent, nurse coach-led supportive care intervention designed to increase family caregivers' skills in providing decision support to individuals with advanced cancer. In a series of weekly, one-on-one, 15-20 minute, in-person or telephone sessions, family caregivers receive psychoeducation on principles of providing effective social support and decision partnering, decision support communication, and Ottawa Decision Guide training.
30512|NCT03947593|Other|No Intervention|No intervention is being administered.
30513|NCT03947580|Other|Use of the Dvectis Single pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Single pads compared to without using a pad."
30514|NCT03947580|Other|Use of the Dvectis Double pad|"Change in pain intensity - range of VAS (mm) between Visit 1 and Visit 2 Dvectis Double pad compared to without using a pad,~Categorisation of adverse events,~Categorisation of deficiencies of a medical device in patients enrolled in treatment groups using Dvectis Single and Dvectis Double pad,~Number of patients with adverse events,~Number of patients with deficiencies of medical device enrolled in treatment groups using Dvectis Single and Dvectis Double"
30515|NCT03947580|Other|Use of no pad|Description is not needed
30516|NCT03947567|Drug|Recombinant Human Coagulation FVIII|Participants received SCT800 for prophylaxis and/or on-demand treatment for 120 weeks.
30517|NCT03947554|Dietary Supplement|HRG80 Panax ginseng|Panax ginseng containing 63.4 mg ginsenosides
30518|NCT03947554|Dietary Supplement|Panax ginseng|Panax ginseng containing 19.6 mg ginsenosides
30519|NCT03947554|Dietary Supplement|Placebo|800 mg excipient
30520|NCT03947541|Other|Thoracolumbosacral (TLSO) brace|Patients will be required to wear the TLSO brace when out of bed, beginning on postoperative day 2 through 6 week follow-up period.
30521|NCT03947541|Other|No Bracing|Participants will not wear a brace in the study.
30522|NCT03947528|Drug|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fed condition
30523|NCT03947515|Procedure|prostate biopsy|All patients included, will report to the urology department on the date previously agreed with the surgeon. The patient will be seen by the nurse and urologist on duty as part of outpatient care or, more rarely, in ambulatory care. After verification of the patient's identity, the signature of informed consent, the absence of immediate contraindications to biopsy (haemorrhagic and infectious) and the patient's proper preparation (antibiotic prophylaxis and possible enema), the patient will be installed for the taking of samples covered by the protocol (rectal swabbing and prostate biopsies, see paragraph IX). If the patient has not taken the antibiotic prophylaxis or performed the enema, he or she will be reconvened at a later date for the biopsies. After the prostatic biopsies have been performed, the patient's participation in the study ends and his follow-up resumes according to the recommendations adapted to his pathology.
30524|NCT03947515|Other|Urinary sampling|It will be collected after the prostate massage performed by the surgeon in charge of the patient during his clinical examination for prostate cancer screening. After elimination of the first draft, the urine will be collected in 2 tubes with borated preservative
30525|NCT03947515|Other|Rectal swabbing before biopsies are performed|A rectal swab will then be taken by the urologist on the day the prostate biopsies are taken. The analysis of the digestive microbiota will eliminate contamination of prostate biopsies by bacteria from the faecal flora during transrectal sampling
30619|NCT03946787|Other|Treatment as Usual|TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
30526|NCT03947502|Behavioral|Educational intervention in neurobiology of pain|The educational intervention will intend to make the individual aware that in the processes of learning, sensitization, habituation and acquisition of beliefs about pain there are automatic unconscious mechanisms, which can be modulated through conscious behaviors. Based on this the investigators propose the active participation of patients in the process of desensitization of their central nervous system. The investigators will try to encourage attention and weaken the neuronal connections that make up the pain neuromatrix to establish new connections thanks to neuroplasticity.
30527|NCT03947489|Drug|Sarpogrelate HCL 300mg|a single oral dose administration in healthy volunteers under fasting condition
30528|NCT03947476|Device|thoracic band|Thoracic band fixation
30529|NCT03947463|Procedure|PECS block|After the induction of general anesthesia, PECS block was administered patients via ultrasound guided technique. We used Mindray M7 Portable ultrasound system using linear probe with (5-10 MHz) frequency. After cleaning the infra clavicular and axillary region with 2% chlorhexidine in 70% Alcohol solution, ultrasound probe was placed in the infraclavicular region and pectoral major and minor were identified. After identification of the landmarks, 20 gauge 50mm Visoplex needle was inserted in-plane direction. 20ml of 0.25% bupivacaine (within the safe limit of its dose) was infiltrated between pectoralis major and pectoralis minor muscle and the spread was visualized on the ultrasound screen.
30530|NCT03947450|Biological|Autologous Skin Fibroblasts|The site will be injected with autologous fibroblasts
30531|NCT03947450|Biological|Control|The site will be injected medium only without autologous skin fibroblasts
30532|NCT03947437|Biological|LEP-F1 + GLA-SE|Leprosy antigen formulated with an adjuvant.
30533|NCT03947437|Biological|Placebo|Sterile normal saline for injection.
30534|NCT03947424|Device|LP Er:YAG|LP Er:YAG applied to oral mucosa
30535|NCT03947424|Device|SMOOTH mode Er:YAG|SMOOTH mode Er:YAG applied to oral mucosa
30536|NCT03947424|Device|sham|Er:YAG laser applied to oral mucosa with no energy
30537|NCT03947411|Drug|Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
30538|NCT03947411|Drug|Xiyanping injection+Oseltamivir Phosphate|Take the dosage of Oseltamivir Phosphate recommended according to the instructions.Xiyanping injection intravenous administration of 0.4mL/kg/day ,QD for 7-10 days.support treatment such as antiasthmatic, expectorant and antipyretic use only in need.
30539|NCT03947398|Device|BLIMP balloon|Using BLIMP balloon to cross lesion
30540|NCT03947398|Device|Low profile balloon|using low profile balloon to cross lesion
30541|NCT03947385|Drug|IDE196|IDE196 dosed orally, twice daily for each 28-day cycle
30542|NCT03947372|Procedure|Appendectomy|removal of acutely inflamed appendix
30543|NCT03947359|Diagnostic Test|Fibroscan Touch 502 M probe|Measurement of liver stiffness
30544|NCT03947359|Diagnostic Test|Fibroscan Touch 502 S probe|Measurement of liver stiffness
30545|NCT03947346|Other|Urine sample|The urine collected from the first morning void will be used to assess urine creatinine and microalbumin. The fresh urine specimen will be analyzed for novel urinary biomarkers of (urinary NGAL, TGF-β1, IL-18 and KIM-1). Serum BUN, creatinine, and cystatin-C will be assessed using serum samples drawn for routine clinical care.
30546|NCT03947333|Other|My Diabetes Dashboard|The My Diabetes Dashboard is embedded within an existing patient web portal (My Health at Vanderbilt) and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy-level sensitive educational resources, and contains secure-messaging capability.
30547|NCT03947320|Drug|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
30548|NCT03947307|Device|lymphtaping using Easytape®|lymphtaping using Easytape® on day 1 after surgery by specifically trained physiotherapists. If possible the taping will be left for 7 days.
30549|NCT03947307|Procedure|compression treatment|manual lymphatic drainage followed by compression treatment using compressive stockings or compressive bandaging
30550|NCT03947307|Device|sham taping|sham taping with Leukotape® Classic, a non-elastic tape, that in all other respects resembles Easytape®.
30551|NCT03947294|Device|Q-NRG®|Energy expenditure measurements
30552|NCT03947281|Other|Almond snack|The almond intervention will be roasted, unsalted almonds provided at 56 g/day for 28 days. Almonds provide approximately 350 kcals/day.
30553|NCT03947281|Other|Cereal-based snack|The cereal-based intervention will be a prepared mix of cereal, pretzels, and bread sticks prepared at the WHNRC. It will be provided at the level of 350 kcals per day for 28 days.
30554|NCT03947268|Radiation|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced pelvic cancer.
30555|NCT03947255|Drug|brentuximab vedotin|1.8 mg/kg given intravenously (IV)
30556|NCT03947242|Drug|Pyrotinib and Trastuzumab plus Vinorelbine|Pyrotinib:400mg orally daily Trastuzumab:8mg/kg ivgtt load followed by 6mg/kg ivgtt 3-weekly for a total of 4 cycles Vinorelbine :25mg/m2 ivgtt 3-weekly for a total of 4 cycles,d1 d8
30557|NCT03947229|Drug|Clopidogrel mono-therapy|Patients will receive clopidogrel (75 mg once daily) monotherapy without co-administration of aspirin for 24 months after randomization.
30558|NCT03947229|Drug|Dual-antiplatelet therapy|Patients will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 24 months after randomization.
30559|NCT03947216|Drug|Active drug: pimavanserin 17mg (2 strength tablets)|Pimavanserin 17mg (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
30560|NCT03947216|Drug|Placebo: 2 tablets containing same excipients except active compound|Placebo (2 strength tablets) will be taken orally daily from day 1 to Visit 4 (Week 8)
30561|NCT03947216|Behavioral|Assessment of severity of ICD (impulse control disorders)|Questionnaire for impulsive-compulsive disorders in Parkinson's disease rating scale (QUIP-RS) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
30648|NCT03946488|Device|Functional electrical stimulation|Functional electrical stimulation of finger's muscles in order to open the hand
31254|NCT03941678|Dietary Supplement|Creatine monohydrate|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
30562|NCT03947216|Behavioral|Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors|Hyper- and hypodopaminergic behaviors (Ardouin's scale); Movement disorders society sponsored unified Parkinson's disease rating scale (MDS-UPDR), and daytime and night time sleep by scale for outcomes in Parkinson's disease SLEEP (SCOPA-SLEEP) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
30563|NCT03947216|Behavioral|Assessment of quality of life|Parkinson's Disease questionnaire (PDQ-39) will be administrated at day 0, day 28 (Week 4) and day 56 (Week 8)
30564|NCT03947216|Behavioral|Assessment of depression|Montgomery-Åsberg Depression Rating Scale (MADRS) will be administrated at day 0 and day 56 (week 8)
30565|NCT03947216|Behavioral|Assessment of cognition|Cognitive state of patients by Montreal Cognitive Assessment (MOCA) will be assessed at day 0.
30566|NCT03947216|Behavioral|Assessment of severity of Parkinson Disease|Clinical Global Impression Severity scale (CGIS) will be administrated at day 0 , day 7, day 14, day 28, day 42 and day 56 (week 8) and day 112 (Week 16)
30567|NCT03947216|Procedure|Blood analysis|Blood sample will be collected for analyse of safety (blood count/liver and kidney functions, electrolytes) at day 0 and day 56
30568|NCT03947216|Procedure|Cardiac monitoring|Electrocardiogram will be realized at day 0, 28 and 56.
30569|NCT03947203|Behavioral|Social media|Provided pamphlet and a private Facebook group where informational messages and content relating to oral health will be shared
30570|NCT03947190|Biological|R21/Matrix-M|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
30571|NCT03947190|Biological|ChAd63/MVA ME-TRAP|ChAd63, chimpanzee adenovirus serotype 63; ME-TRAP, multiple epitope string fused to the thrombospondin-related adhesion protein; MVA, modified vaccinia Ankara.
30572|NCT03947190|Biological|intradermal injection (ID) or direct venous injection (DVI) of PfSPZ Challenge|PfSPZ Challenge: cryopreserved Plasmodium falciparum sporozoites.
30573|NCT03947177|Behavioral|GMIT|Six 30-minute sessions delivered in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.
30574|NCT03947177|Behavioral|GMIT+|Six 30-minute sessions delivered in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will participate in parent-only support group sessions.
30575|NCT03947164|Other|biopsy|"For cases and controls, before the intervention : a questioning, clinical symptoms of POPs and urinary incontinence, a detailed clinical examination, and an urodynamic assessment (in case of POPs) and an ultrasound guided MEA biopsy.~Patients will be seen on post-operative visits between 15 days and 2 months after surgery for an examination and clinical examination."
30576|NCT03947151|Drug|Degarelix injection(s)|1 or 2 degarelix injection(s)
30577|NCT03947138|Biological|GC3107|BCG Vaccine
30578|NCT03947138|Biological|Intradermal BCG SSI inj.|BCG Vaccine
30579|NCT03947125|Drug|Buprenorphine transdermal patch on knee joint|Conventionally buprenorphine transdermal patch had been applied to anterior chest wall or upper arm. But author had applied buprenorphine transdermal patch to painful knee joint in knee osteoarthritic patients. This research is about the effect, adverse effects, and compliance of comparison conventional chest applied buprenorphine transdermal patch group with painful knee joint applied group in knee osteoarthritic patients.
30580|NCT03947112|Behavioral|Physical activity registration|At start, participants and parents fills out a Self-report questionnaire and PAQ-C, before a seven day physical activity registration takes place by use og ActiGraph. A physical activity diary are filled out every evening while the physical activity registration takes places.
30581|NCT03947099|Drug|Ketamine Hydrochloride|Participants are treated with six one-hour infusions of ketamine hydrochloride over a three week period in hopes of treating symptoms of PTSD.
30582|NCT03947086|Device|Transcranial Direct Current Stimulation (TDCS)- Active|A constant current stimulator (TCT Research Limited) will be used using electrodes of 5 × 5 cm2 embedded in saline (0.9 % NaCl) and application of 1.5 mA current for 20 minutes for 5 consecutive days. The cathode will be positioned in the right supra-orbital region, and while the anode will have the following provision in the left dorsolateral prefrontal cortex (F3).
30583|NCT03947086|Device|Transcranial Direct Current Stimulation (TDCS)- Sham|The protocol for participants receiving simulated current is identical, but the device ceases to emit current after 30 seconds of initiation of pacing.
30584|NCT03947086|Behavioral|Cognitive Training|"Considering that the effects of TDCS are potentiated when applied during the execution of a task (online) (Miniussi, & Ruzzoli, 2013), in the present study all participants received cognitive training, performed concomitantly with neurostimulation.~Cognitive training consists of two parts: standardized tasks directed to social cognition and activities that stimulate executive functions. The first part consists of tasks contained in a battery of social games (Gao & Maurer, 2009; Dillon, Kannan, Dean, Spelke, & Duflo, 2017). While the tasks directed to the executive domain are, namely: running mazes, assembling figures, completing parts of figures and the Super Lynx Memory Game. All participants, regardless of whether they underwent active or simulated stimulation, received cognitive training, respecting the ethical principles of ensuring therapeutic assistance to those involved."
30585|NCT03947073|Other|Education|Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
30586|NCT03947047|Diagnostic Test|NA-NOSE|Breath and blood samples for distinguishing biomarkers.
30587|NCT03947034|Drug|Drugs inducing hyperammonemia|Drugs susceptible to induce metabolic toxicities such as hyperammonemia
30588|NCT03947021|Radiation|Computed tomography (CT) scan|A CT scan of thorax and heart will be performed in the CT+BSPM group.
30589|NCT03947021|Device|Body-surface potential mapping|Measurement of 256-lead body-surface electrocardiogram
30675|NCT03946280|Procedure|low X-ray 3D navigation technique|catheter tracking via low X-ray 3D navigation technique
30702|NCT03946033|Diagnostic Test|Immunoscore Colon Test|Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
30590|NCT03947008|Other|Intuitive Eating Program|"A 5-week Intuitive Eating Curriculum created by a Registered Dietitian, Kaylee Frazier, will be used. The creator of this curriculum was contacted for permission and the curriculum was modified for use with college women.~The goal of the program is to challenge and eventually shift participant's mindset from the traditional diet culture towards a way of eating that is driven by their unique bodily needs. Content will focus on training participant to listen to their internal body cues for hunger opposed to restricting or eliminating foods. A list of intuitive eating principles and ways to incorporate them into daily routines will be provided to the participants throughout the sessions, coupled with homework assignments, journaling, and exercises to be completed before subsequent sessions."
30591|NCT03946995|Other|Dry Needling Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed. Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.~The treatment will be continued for 2 weeks with 2 sessions per week."
30592|NCT03946995|Other|Graston Technique Group|"Hot Pack will be applied on upper trapezius muscles before session for general relaxation for 7-10 minutes. Generalized Stretching and strengthening neck exercises will be performed.~Later, lubricant will be applied to the skin, and Graston technique will be applied using instrument over the active myofascial trigger points in upper trapezius.~The treatment will be continued for 2 weeks with 2 sessions per week."
30593|NCT03946982|Procedure|low thoracic epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces
30594|NCT03946982|Procedure|lumbar epidural|obstetric epidural catheters inserted at low thoracic intervertebral spaces (conventional)
30595|NCT03946969|Drug|Sintilimab|Sintilimab 200mg ivd d1, repeated every 3 weeks for two cycles.
30596|NCT03946969|Drug|Liposomal Paclitaxel + Cisplatin + S-1|Liposomal Paclitaxel 135mg/m2 ivd d1 + Cisplatin 25mg/m2 ivd d1-3 + S-1 40mg capsule po d1-14, repeated every 3 weeks for two cycles.
30597|NCT03946956|Behavioral|Prebooking|Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
30598|NCT03946956|Behavioral|Pictured invitation|Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
30599|NCT03946943|Drug|Anlotinib|Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
30600|NCT03946943|Drug|Toripalimab|Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
30601|NCT03946943|Procedure|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
30602|NCT03946943|Procedure|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
30603|NCT03946917|Drug|JS001|JS001 3 mg/kg, iv drip, d1, d15, q4w
30604|NCT03946917|Drug|regorafenib tablet|80/120/160 mg, po, d1-d21, Q4w.
30605|NCT03946904|Device|Er,Cr:YSGG Laser|Patients with towo similar size lesions of either Class I or class v cavities selected as subjects. in the same appointment, both cavities are prepared by the Er'Cr:YSGG. one lesion was prepared with high power laser setting first to ablate the enamel, dentin, and caries. the other lesion was prepared with low power setting to start and is aimed at applying low level laser therapy (LLLT) first before using high power.
30606|NCT03946891|Drug|Inhaled Furosemide|Subjects in the A arm will receive 1 mg/kg of inhaled furosemide Q 24 hours for 3 days. This will be followed by a washout period of a day followed by 1 mg/kg of intravenous furosemide Q 24 hours for 3 days.
30607|NCT03946891|Drug|Intravenous Furosemide|Subjects in the B arm will receive 1 mg/kg of intravenous furosemide Q 24 hours for 3 days followed by a washout period, which is then followed by 1 mg/kg of inhaled furosemide Q 24 hours for 3 days.
30608|NCT03946878|Drug|Acalabrutinib|Given PO
30609|NCT03946878|Drug|Venetoclax|Given PO
30610|NCT03946865|Other|Reiki Therapy|Reiki is a healing practice that originated in Japan. Reiki practitioners place their hands lightly on or just above the person receiving treatment, with the goal of facilitating the person's own healing response.
30611|NCT03946852|Device|Abdominal Regional Perfusion|Abdominal Regional Perfusion
30612|NCT03946826|Drug|Halometasone Cream|Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia
30613|NCT03946826|Drug|Vaseline|Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect
30614|NCT03946826|Radiation|Pulsed dye laser (PDL)|Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
30615|NCT03946813|Other|Autologous PRP preparation|For each patient, autologous PRP preparation havs to be injected to both ovaries and ultrasound (US) guide
30616|NCT03946800|Biological|MEDI1191|Subjects will receive MEDI1191 (at least twice)
30617|NCT03946800|Biological|Durvalumab|Subject will receive durvalumab every 4 weeks
30618|NCT03946787|Other|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
31255|NCT03941678|Dietary Supplement|Placebo|0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
30620|NCT03946774|Dietary Supplement|Dietary protein shake|"It is a milk based protein shake. Ingredients include a combination of the following depending on protein content: Boost Plus (a commercial supplement), Unjury (a commercial whey protein isolate), nonfat dry milk powder, Sol Carb (commercial supplement composed of a carbohydrate polymer), canola oil, and water.~In order to ensure consistency across all participants each beverage will be prepared in the Clinical Translational Research Unit Metabolic Kitchen under the supervision of a registered dietitian prior to the study participant's visit. Ingredients are individually weighed on a food scale by metabolic kitchen staff to the nearest 0.1 g and then mixed using a magnetic stir plate.~Nutritional breakdown of the smoothies (high versus low protein):~High protein drink nutrition: 500 kcal per serving, 50% protein, 17% fat, and 36% carbohydrate.~Low (standard) protein drink nutrition: 500 kcal per serving, 10% protein, 17% fat, and 73% carbohydrate."
30621|NCT03946761|Drug|Indocyanine Green|-FDA approved but being used off label
30622|NCT03946761|Device|Cancer goggle system|-The cancer goggle system is being used as a non-significant risk device
30623|NCT03946748|Drug|REGN3918|Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).
30624|NCT03946735|Behavioral|Cognitive Behavioural Therapy as an Effective Treatment for Social Anxiety, Perfectionism, and Rumination|Week one involved introducing CBT and assessing the negative effects of perfectionism, rumination, and social anxiety. Week two allowed participants to specify stressful social activities, stressful social situations, and enjoyable activities. Week three to week six allowed participants to identify automatic thoughts and thinking errors (for example, all or nothing thinking, self-criticism, dysfunctional schemas for self-evaluation, and unrealistic standards). Assignments were provided to participants with the content of exposure to anxiety evoking situations in the treatment sessions and at home. Achievable behavioural goals were set for participants in the treatment sessions and at home.
30625|NCT03946722|Drug|GnRH analogue downregulation|"Downregulation is the suppression of the ovaries during an IVF cycle in order to perform controlled ovarian stimulation and prevent premature ovulation.~Participants will be exposed to 2 weeks of downregulation using a GnRH analogue in the standard downregulation arm and 6 weeks of downregulation using a GnRH analogue in the modified downregulation arm."
30626|NCT03946722|Procedure|Uterine flushing|"Consenting participants will undergo a uterine flushing procedure. In patients randomised to the standard downregulation arm this will be performed on D6-13 prior to starting downregulation.~In patients randomised to modified downregulation this will be performed on D6-13 prior to starting downregulation and also on D21 following the second dose of GnRH analogue."
30627|NCT03946722|Other|Patient questionnaire|Patients will be offered the opportunity to complete an adenomyosis symptom assessment questionnaire at the start of their treatment, and again three months after completion of treatment.
30628|NCT03946709|Other|Action Observation|Strength, voluntary activation, and cortical responses to three conditions will be measured: 1) action observation of very strong, forceful contractions of the hand and wrist flexors 2) action observation of very weak, feeble contractions of the hand and wrist flexors 3) no action observation. Experimental conditions will be randomized and counterbalanced.
30629|NCT03946696|Other|Interactions with therapy-animals|How people interact with humans and non-humans animals during and outside visits from therapy-animal teams.
30630|NCT03946683|Radiation|Cyberknife for Early Stage Breast Cancer|Utilization of Cyberknife Robotic Radiosurgery as a 5-fraction post-lumpectomy adjuvant radiation treatment in the management of early stage breast cancer
30631|NCT03946670|Drug|MBG453|MBG453 will be administered i.v.
30632|NCT03946670|Drug|Placebo|Placebo will be administered i.v.
30633|NCT03946670|Drug|Hypomethylating agents|Decitabine will be administered i.v. Azacitidine will be administered i.v or s.c.
30634|NCT03946657|Drug|Inhalational anesthetic|Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration [MAC]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
30635|NCT03946657|Drug|Intravenous anesthetic|Propofol infusion (4-8 mg/kg of total body weight/h), oxygen/air (FiO2 of 0.40; inspiratory fresh gas flow of 2 L/min) and remifentanil IV infusion (0.1-0.25 μg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
30636|NCT03946644|Device|EVLA with keeping of securuty distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance 2 cm below the SFJ.
30637|NCT03946644|Device|EVLA without keeping a distance|The EVLA will be performed with the 1470nm diode laser and a radial fibre (Leonardo® - 1470 nm/15W, Biolitec). The exact position of the catheter tip will be fixed under ultrasound guidance without keeping a distance to the SFJ.
30638|NCT03946631|Diagnostic Test|2 hour glucose tolerance test using 75g glucose drink|intervention is a 2 hour glucose tolerance test. Involves oral intake of a 75g glucose drink followed by using point of care testing. Glucose drink is taken after at least 6 hours of fasting. Fingerstick blood glucose testing done at three time points: fasting, one hour post drink and two hours post drink.
30639|NCT03946618|Device|Medtronic Summit System, Olympus|Electrical brain stimulation with an implantable pulse generator
30640|NCT03946592|Drug|Normal saline|Inject the Drug into submental fat via subcutaneous
30641|NCT03946592|Drug|DWJ211|Inject the Drug into submental fat via subcutaneous
30642|NCT03946579|Other|self questionnaires|FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
30643|NCT03946566|Procedure|Acupuncture|Using acupuncture, electric acupuncture, moxibustion and acupoint injection treatment.
30644|NCT03946527|Drug|Lanreotide|Participants will receive lanreotide 120 mg deep subcutaneous injection every 4 weeks (±7 days) for 52 weeks, followed by an extension phase in which all patients will continue to receive lanreotide 120 mg injection every 4 weeks (±7 days) if there is no evidence of disease progression.
30645|NCT03946514|Drug|losartan/hydrochlorothiazide|losartan 100 mg/hydrochlorothiazide 25 mg single-pill combination
30646|NCT03946514|Drug|amlodipine/hydrochlorothiazide|amlodipine besylate tablets (5 mg / tablet) + hydrochlorothiazide tablets (25 mg / tablet)
30647|NCT03946501|Other|Data collection|
31256|NCT03941665|Device|Gelronate|Gel for topical use
30649|NCT03946475|Other|Intervention group|"Training of Trainers (ToT) was conducted among teacher who would deliver the messages. Remaja ASIK is Indonesian tagline meant girls who are active, healthy, smart, and creative. Nutrition education was performed in every Friday, at least 30 minutes during 20 weeks. In brief, this is the key messages of optimized food based recommendations: 1) 3 meals and 2 snack every day, 2) At least 2 portions of vegetables/day including at least 5 portions/week of green leafy vegetables, 3) At least 2 portions/day of animal protein including at least 2 portions/week of liver, 4) At least 1 portion/day of tempe or tofu, 5) At least 1 portion/day of fruit, 6) At least 3 portions/week of milk.Trained teachers delivered the messages accompanied by supervisor. The delivered topics were key messages, balance nutrition, anemia, menstruation, BMI, healthy and smart, strong bone, lunch box, safe snack, and food label."
30650|NCT03946462|Drug|NO gas delivered during cardiac surgery|intra-operative NO gas at 20ppm blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system.
30651|NCT03946462|Other|placebo gas delivered during cardiac surgery|placebo blended into the fresh gas flow of the CPB oxygenator via the INOMax delivery system. The placebo gas in this study will be 21% (or atmospheric) oxygen.
30652|NCT03946449|Drug|ARO-AAT Injection|solution for subcutaneous (sc) injection
30653|NCT03946436|Device|Active video games|Participants played the active video game Virtua tennis 4 on a playstation kinect device
30654|NCT03946436|Other|tennis training process|Participants were involved in a regular tennis training process, performed two times a week for one hour per lesson.
30655|NCT03946423|Procedure|Bariatric Surgery with Sleeve Gastrectomy|Standard of care bariatric surgery with sleeve gastrectomy
30656|NCT03946423|Behavioral|Lifestyle Intervention|All participants receive lifestyle intervention. The lifestyle intervention program is modeled closely after that used in the Diabetes Primary Prevention Trial and the LookAHEAD diabetes treatment studies. Intervention includes counseling sessions weekly for the first six months, twice a month during months 7-9, and monthly during months 10-12, and energy intake and exercise goal monitoring and guidance.
30657|NCT03946410|Diagnostic Test|Invitation to screening|Invitation to CVD screening with non contrast CT scanning, ABI measurement and blood tests
30658|NCT03946397|Other|Mulstisensory massage|7 minutes of hand massage followed by multisensory immersion (lights and music) for 23 minutes
30659|NCT03946384|Other|data collection|data collection on the history of the disease, hemophilia
30660|NCT03946358|Biological|Blood sample collection|"Four blood samples will be collected at:~baseline~2 months from inclusion (+/- 1 week)~4 months from inclusion (+/- 1 week)~the end of vaccination visit (+/- 1 week).~A total of 8 EDTA (ethylenediaminetetraacetic acid) tubes of 6 ml will be collected at each time point to perform:~PBMC collection: 6 EDTA tubes of 6 ml of peripheral blood mononuclear cell [PBMC] will be sent to the central laboratory (Biomonitoring Platform of Besançon, CHRU de Besançon located at Etablissement Français du Sang) at room temperature within 24 hours via an approved carrier for their processing, storage and immunomonitoring analysis. A sending sheet of the samples will be attached to each single sample.~Plasma collection: One 6 ml EDTA tube should be frozen in each investigation center for plasma collection.~Plasma for circulating tumoral DNA (ctDNA) collection: One 6 ml EDTA tube should be frozen in each investigation center for ctDNA collection."
30661|NCT03946358|Procedure|Tumor biopsies|A tumor biopsy will be realized and centralized at baseline and at 2 months. Collection of tumor biopsies will be guided by ultrasound or CT scan
30662|NCT03946358|Other|CT scan|"A CT scan will be planned~at baseline~at tumor evaluation visit (8 weeks)~every 8 weeks (+/- 1 week)~at end of treatment visit."
30663|NCT03946358|Drug|Atezolizumab|"Induction phase: Atezolizumab 1200 mg intravenous every 3 weeks since day 1~Boost phase: Atezolizumab 1200 mg intravenous every 3 weeks until disease progression or unacceptable toxicity until disease progression or unacceptable toxicity."
30664|NCT03946358|Drug|UCPVax|"Induction phase: UCPVax (combined with Montanide ISA51 as adjuvant) at 1 mg subcutaneously in two separate sites (one site per peptide) at day 1, 8, 15, 29, 36 and 43 (induction phase).~Boost phase: UCPVax boosts vaccine every 6 weeks for the 2 first boosts (boost 1 and boost 2) and then every 9 weeks (boost 3 to boost 5)."
30665|NCT03946345|Drug|Iohexol Inj 300 MG/ML|"Administration of iohexol: each 24 hours one bolus IV (1-5ml) during 72 hours~Blood samples are drawn for analysis of iohexol concentrations and other parameters of renal function at 2, 5 and 7 hours after administration~Urine is collected from catheter between 4 and 6 hours after adminstration to determine urine creatinine and iohexol concentrations"
30666|NCT03946332|Behavioral|Physical exercises|patients will benefit regularly from a physical exercises program during their hospitalization. When going back home, they will be given a practical help kit with specific equipment (dumbbell, elastic), an actimeter with heart rate monitoring (in order to have an objective collection of the physical practice in addition to a self-evaluation) and a physical exercises program on paper and video supports, that patients would have learnt during their hospitalization.
30667|NCT03946332|Behavioral|Optional physical exercises|patients will be proposed for the physical exercises and will practice them if they want.
30668|NCT03946319|Diagnostic Test|Introspect Health|Introspect Health is a software platform which has implemented both the monotopic and personalized, transdiagnostic assessment tools. The software is delivered via the internet using a mobile device or computer.
30669|NCT03946306|Drug|5,25% NaOCl with syringe needle irrigation alone|In group 1 (control group), a final irrigation will be made with 1.5 ml of NaOCl per canal, during 30 seconds in an up-and-down motion, with the needle 1 mm short of the working length, without binding. After this, a 30 seconds pause will be done. This step will be repeated once again.
30670|NCT03946306|Device|EDDY|In group 2, a final irrigation will be made with 1.5 ml of NaOCl per canal and the irrigant will be activated using EDDY tips, 1 mm short of the working length without binding. The activation will be performed during 30 seconds, followed by a 30 seconds pause, and the cycle will be repeated once again, according to manufacture instructions.
30671|NCT03946293|Dietary Supplement|White Bread|White bread made with commercial white flour with bran/fibre removed
30672|NCT03946293|Dietary Supplement|Wholegrain bread|Wholegrain bread made with commercial wholegrain flour.
30673|NCT03946293|Dietary Supplement|Wholegrain Enzyme|Wholegrain bread made with enzyme-treated commercial wholegrain flour.
30674|NCT03946280|Procedure|conventional X-ray based Fluoroscopy|catheter tracking via conventional X-ray based Fluoroscopy
31257|NCT03941665|Other|Aloevera|Gel for topical use
30676|NCT03946267|Device|Inverted inner limiting membrane flap technique for large full thickness macular holes|The ILM, stained with IFCG or BBG, is peeled off with ILM forceps, usually beginning near the inferotemporal vascular arcade, at least 2 disk diameters from the macular hole, in a circular manner. The peeling is extended up to the edges of the macular hole, the wide ILM flap obtained reduced by trimming with the vitreous cutter, and the annular remnant of ILM hinged to the hole's edge gently inverted upside down facing the RPE. Therefore, the hole is covered with usually more layers of inverted ILM. Attention is paid to avoid insertion and filling of the hole volume with ILM.
30677|NCT03946254|Other|Effect of strength training on executive functions in elderly people with mild cognitive impairment.|Strength training sessions will have a frequency of 3 times per week (Monday, Tuesday and Wednesday) for 20 weeks. In addition, each subject is subject to an individualized training program according to the workload in order to progressively increase the intensity of work. The workload will be modified progressively by influencing both the total volume of repetitions and the intensity of the exercises. The exercises will be controlled movements and not harmful, as guided machines will be used to facilitate the execution of actions. In addition, the largest amount of muscle groups to be able to generate strength gains in all muscle groups. The control group will perform breathing exercises and low intensity stretching during the same days and with the same duration as the experimental group
30678|NCT03946228|Behavioral|Behavioral Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
30679|NCT03946215|Other|Each participant will perform:|Part 1: Maximal incremental tests will require running at fixed slopes (+15%, 0% -15%) for stages (2min duration) of increasing velocities (0.5, 1 and 1.5 km/h) Part two: submaximal running tests will require running at constant velocity (80% VO2max uphill; 80%VO2max downhill and downhill at similar velocity as uphill)
30680|NCT03946202|Drug|Hydrogen Peroxide|Hydrogen Peroxide
30681|NCT03946189|Diagnostic Test|Obtaining arterial blood gases|Obtaining arterial blood sample
30682|NCT03946176|Dietary Supplement|Symbiotic|HD patients follow a 8-weeks oral administration of the symbiotic supplement (2 bags/day)
30683|NCT03946176|Dietary Supplement|Placebo|HD patients follow a 8-weeks oral administration of the placebo (2 bags/day)
30684|NCT03946176|Device|DVB cartridge|On the last week of the symbiotic/placebo period, patients undergo 3 dialytic sessions with the DVB cartridge
30685|NCT03946163|Dietary Supplement|cinnamon capsules|each patient will receive sixty capsules, each capsule contained 1gm of cinnamon bark powder and instructed to use it twice daily for one month
30686|NCT03946163|Drug|Placebo oral capsule|each patient will receive sixty capsules, each capsule contained placebo and instructed to use it twice daily for one month
30687|NCT03946150|Diagnostic Test|P/FP Ratio|PaO2/Fio2 X PEEP
30688|NCT03946137|Other|Chest Therapy|The sessions of chest therapy were based on airway clearance techniques (hyper manual insufflations, abdominal thoracic compressions and manually assisted cough)
30689|NCT03946137|Other|Postural Hygiene|Postural hygiene workshops were taught through a theoretical presentation with the help of slides and practical exercises in small groups (2-4 parents per group).
30690|NCT03946124|Drug|Fesoterodine|Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.
30691|NCT03946111|Drug|Naltrexone and Bupropion|Participants randomly assigned to this arm will receive 12 weeks of Naltrexone and Bupropion medication.
30692|NCT03946111|Other|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
30693|NCT03946098|Behavioral|iCBT|A newly developed iCBT protocol targeting problem gambling and Gambling Disorder
30694|NCT03946085|Dietary Supplement|Lumega-Z|A specially-formulated carotenoid supplement formula that utilizes a micronized, lipid-based liquid form of delivery.
30695|NCT03946085|Dietary Supplement|AREDS2|A commercially-available multivitamin soft gel formula.
30696|NCT03946072|Procedure|Transseptal Aortic Approach Catheter Ablation Procedure|The transseptal approach entails obtaining femoral venous access, and, guided by fluoroscopy and intra-cardiac ultrasound, starting with a transseptal needle or RF device inside the dilator of a long sheath; pulling down until the fossa ovalis in the interatrial septum is engaged on both fluoroscopy and intracardiac echo imaging; once on the left side, the long sheath is advanced over the transseptal needle, the needle and dilator are removed, and the ablation catheter can then be advanced across the mitral valve into the left ventricle.
30697|NCT03946072|Procedure|Retrograde Aortic Approach Catheter Ablation Procedure|The retrograde aortic approach entails obtaining femoral arterial access and leaving a sheath in the femoral artery. Under fluoroscopy, an ablation catheter is then advanced up the ascending aorta where the catheter tip is curved using an internal mechanism controlled on the handle of the catheter to form a large loop (to prevent the tip from traveling down a coronary artery and causing trauma such as a dissection); the curved loop is advanced around the aortic arch and down the ascending aorta. To cross the aortic valve with this loop, the catheter is typically torqued in various directions until it falls through the aortic valve and into the left ventricle.
30698|NCT03946059|Device|rTMS - iTBS|repetitive transcranial magnetic stimulation applied with intermittent theta-burst stimulation protocol
30699|NCT03946059|Device|rTMS - cTBS|repetitive transcranial magnetic stimulation applied with continuous theta-burst stimulation protocol
30700|NCT03946046|Procedure|Clinical targeting|The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
30701|NCT03946046|Procedure|Ultrasonography targeting|The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
31195|NCT03942055|Device|Sonosite Edge II Ultrasound|Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
30703|NCT03946020|Procedure|Guided bone regeneration with or without autologous bone|Autogenous bone chips were collected. On each side a bone level implant was placed. The bone dehiscence was measured and was thereafter treated according to the GBR protocol. A resorbable native collagen was adapted to the defect.
30704|NCT03945994|Other|Connecting People Intervention|Improve the resourcefulness of social networks of people with mental health problems
30705|NCT03945981|Drug|Dolutegravir + Lamivudine FDC|Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
30706|NCT03945955|Dietary Supplement|Melatonin|Participants will be randomized into two groups (Group A and Group B). Group A will initially be treated with 3 mg melatonin supplements over a 4-week period while Group B will initially receive placebo supplements over a 4-week period. After a 4-week washout period, Group A will receive placebo supplements while Group B will receive 3 mg melatonin supplements.
30707|NCT03945955|Other|Placebo|Placebo
30708|NCT03945942|Device|Near infrared spectroscopy with INVOS device|somatic and cerebral oximetry by INVOS in pediatric liver transplantation
30709|NCT03945942|Device|Near infrared spectroscopy with Foresight device|somatic and cerebral oximetry with Foresight device in pediatric liver transplantation
30710|NCT03945929|Behavioral|Distraction|"Distraction-1 Group: Cards containing approximately six optical illusion pictures were shown to the patients and as a method of distraction during the PIC insertion procedure they were asked what they saw in these cards.~Distraction-2 Group: Underwater 3D audial videos were played with visual reality (VR) goggles during PIC insertion until the procedure was completed."
30711|NCT03945916|Dietary Supplement|Dark chocolate|180 g/d dark chocolate for 15 days followed by exercise testing
30712|NCT03945916|Dietary Supplement|Placebo|Placebo: 180 g/d imitation dark chocolate for 15 days followed by exercise testing
30713|NCT03945903|Drug|Golimumab|Participants will receive subcutaneous (SC) golimumab, where doses will be based on weight and/or body surface area.
30714|NCT03945877|Other|No interventions|No interventions
30715|NCT03945864|Device|antimicrobial synthetic bone graft|It will be determined whether the silver ion-doped antimicrobial synthetic bone graft that has the capacity to fill the bone voids also has the capacity to treat the infection in the bone in 12 patients with chronic osteomyelitis
30716|NCT03945864|Device|parentaral antimicrobials and pure bone grafts|Historical data of the department will be used for comparison of the results
30717|NCT03945851|Procedure|fMRI|All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
30718|NCT03945838|Other|Complete Decongestion Therapy|"It is given in two phases. First phase includes intensive therapy which aims to reduce the volume of the extremity. Second phase aims to preserve these reductions of volume.~All patients were prescribed lymphedema specific exercises and were advised to walk (for 30 minutes everyday) daywhile taking complete decongestive therapy. They were specifically informed that exercise does not aggravate the severity of their lymphedema.~Short stretch bandages were applied to the patients with self manual lymphatic drainage. Intensive phase was given 5 days a week, and short stretch bandages applied for 23 hours a day with 1 hour interval. To increase the local pressure on the areas required, foams were added. Patients were screened with arm circumferential measurements once a week. After gaining a plateau in the volumes, patients were prescribed compression garments."
30719|NCT03945825|Biological|Advax-CpG55.2|A combination adjuvant supplied as two separate components, Advax (Sypharma Pty Ltd.) and CpG55.2 (Nikko Denka Avecia and Sypharma Pty Ltd)
30720|NCT03945825|Drug|AF03|A squalene-in-PBS emulsion stabilized by nonionic surfactants, sorbitan oleate and macrogol cetostearyl ether
30721|NCT03945825|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|2018/2019 Fluzone QIV and 2019/2020 Fluzone QIV vaccines will be given with 90 days interval
30722|NCT03945825|Biological|Quadrivalent Recombinant Seasonal Influenza Vaccine|2018/2019 Flublok QIV and 2019/2020 Flublok QIV vaccines will be given with 90 days interval
30723|NCT03945812|Drug|Granulocyte Colony Stimulating Factor|Filgrastim, Amgen, California, USA 300 mg/1.0 mL
30724|NCT03945812|Other|Platelet Rich Plasma Arm|Platelet Rich Plasma Arm
30725|NCT03945812|Other|Saline|Saline 9%
30726|NCT03945799|Drug|Anlotinib Hydrochloride|Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
30727|NCT03945773|Drug|Cabozantinib|Oral tablets of 60mg, 40mg and 20 mg.
30728|NCT03945760|Drug|Baricitinib|Baricitinib 2 mg
30729|NCT03945760|Drug|Placebo|Placebo
30730|NCT03945747|Diagnostic Test|Blood draw|Participants will undergo a blood collection for hemoglobin A1c, adiponectin, total cholesterol, LDL, HDL, triglycerides, and c-peptide at baseline and follow up in 3-6 months.
30731|NCT03945747|Diagnostic Test|Urine sample collection|Participants will undergo urine sample collection for urine microalbumin and urine creatinine at baseline and follow up in 3-6 months.
30732|NCT03945747|Diagnostic Test|DXA scan|Participants will undergo a DXA scan for lean and fat mass measurements at baseline and follow up in 3-6 months.
30733|NCT03945734|Behavioral|Expressive Helping|Expressive helping harnesses the benefits of helping others (e.g., support giving) through writing or voice-recording. Expressive helping integrates two distinct areas of research showing that writing or speaking about ones' negative experiences and engaging in support giving behaviors can improve psychological well-being.
30734|NCT03945721|Drug|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring."
30735|NCT03945721|Radiation|Radiation Therapy|radiation therapy
30736|NCT03945708|Device|CytoSorb|Addition of a hemofilter to the cardiopulmonary bypass circuit
30991|NCT03943758|Dietary Supplement|Self-prepared Low-residue diet|Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
30992|NCT03943732|Diagnostic Test|FilmArray Pneumonia|FilmArray Pneumonia testing of tracheal sample
30737|NCT03945695|Procedure|"Pneumatic Vitreolysis in combination with Drinking-Bird-Technique"|"Appropriate anesthesia and antiseptic preparation of the surgical field~Prophylactic paracentesis of the anterior chamber~One intravitreal injection of 0.2 to 0.3 ml of filtered sulfur hexafluoride gas (SF6) into the test eye Remark: Intraocular pressure of the examined eye is to be controlled before the intervention and kept at an appropriate level after paracentesis by manual application of pressure.~Patients are instructed to avoid supine position and to lie on one side or the abdomen during sleep until complete resorption of intraocular gas occured. In this period they should bend over several times during the day up to an angle of 90º or as much as possible, resembling the movement of a bird drinking water. (Hence the name drinking-bird-technique.)"
30738|NCT03945682|Other|Therapist|Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
30739|NCT03945669|Procedure|Intramedullary Nailing|fracture fixation of the tibial shaft fracture with an intramedullary nail.
30740|NCT03945669|Procedure|External Ring fixation|fracture fixation of the tibial shaft fracture with an external ring fixator.
30741|NCT03945656|Drug|Insulin 287|Participants will receive subcutaneous (s.c.) injections of insulin 287 OW for 6 weeks
30742|NCT03945656|Drug|Insulin glargine|Participants will receive daily s.c. injections of insulin glargine U100 for 12 days
30743|NCT03945643|Drug|Sildenafil|50mg administration of sildenafil, one time, one hour prior to measurements.
30744|NCT03945643|Other|Placebo|50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
30745|NCT03945630|Procedure|anterior Quadratus Lumborum Block|Interfascial plane block
30746|NCT03945630|Procedure|Standard of Care|No QLB
30747|NCT03945617|Behavioral|Unified Treatment Protocol|The Unified Treatment Protocol (UP) is a transdiagnostic psychotherapeutic treatment manual for emotional disorders, that is based on CBT principles and focuses on changing dysfunctional emotion regulation.
30748|NCT03945604|Drug|SHR-1210 + Apatinib +Fluzoparib|SHR-1210 will be administered as an intravenous infusion Apatinib tablets will be given orally Fluzoparib capsule will be given orally 28 days per cycle, until disease progression or unacceptable toxicity.
30749|NCT03945591|Drug|Bortezomib|1.3 mg/m2 IV 6 hours after graft infusion and 72 hours thereafter.
30750|NCT03945591|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours on Day +3 and +4
30751|NCT03945578|Other|Pelvic Floor muscle training|Pelvic Floor muscle training is an active exercise-based treatment designed to strengthen the pelvic floor muscles.
30752|NCT03945578|Other|Manual Visceral Therapy|Visceral manual therapy:is a manual treatment intended to the release of visceral fascias
30753|NCT03945565|Other|Fraction of inspired oxygen level|A fraction of inspired oxygen level during off-pump coronary artery bypass grafting will be set differently between the study groups: 0.3 vs 0.8.
30754|NCT03945552|Behavioral|Video Interaction Project|VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
30757|NCT03945526|Drug|Astaxanthine|
30758|NCT03945526|Drug|Placebo Oral Tablet|
30759|NCT03945513|Drug|LPRI424 (dienogest/ethinylestradiol)|One LPRI424 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
30760|NCT03945500|Device|Investigational Mobile Medical Software Application & IT Dashboard Application, FDA approved Bluetooth spirometer, FDA approved pulse oximeter|"Standardized Home Spirometry Method consists of an Investigational Mobile Medical Application embedded into an Android Tablet, an FDA approved Bluetooth spirometer, an FDA approved pulse oximeter. HIPAA compliant data will be sent to an Investigational IT dashboard maintained at the Central Monitoring Institute Server.~Volunteers will train in-center & perform baseline testing with the Standardized home spirometry method along with a baseline laboratory-based spirometry test.~Pre-Surveillance Phase: Daily home spirometry method testing for up to 8 weeks to enable normal range calibration.~Surveillance Phase: At least twice weekly home spirometry method testing for 4-10 months of participation."
30761|NCT03945487|Biological|umbilical cord-derived mesenchymal stem cell|Taken a dose of 1.0*10E6 UC-MSC/kg body weight intravenously three times at 3-week intervals, in addition to comprehensive treatment.
30762|NCT03945487|Other|Comprehensive treatment|"All patients received anti-HBV treatment with NAs (entecavir (ETV), tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)).~Strategies based on targeting abnormalities in gut-liver axis by antibiotic administration (i.e. rifaximin), improving the disturbed systemic circulatory function (i.e. longterm albumin administration), decreasing the inflammatory state (i.e. statins), and reducing portal hypertension (i.e. beta-blockers)."
30763|NCT03945474|Other|Sham|See description in sham arm.
30764|NCT03945474|Other|Osteopathic Manipulation, OMT|See description in OMT arm
30765|NCT03945461|Other|Chewing gum|xylitol based, peppermint flavored gum
30766|NCT03945448|Drug|Single dose liposomal Amphotericin and Fluconazole|Intravenous Single dose of 10mg/kg of Ambisome and fluconazole as per WHO guidelines for six months.
30767|NCT03945448|Drug|Fluconazole|Fluconazole 800mg for 2 weeks,400mg for 8 weeks and 200mg up to six months
30768|NCT03945422|Device|AccuTite/FaceTite|Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
30769|NCT03945409|Device|OPTIVENT|OPTIVENT (SIDAM SRL, Mirandola, Italy) is a new fully automated and self-calibrating system that allows a real-time monitoring and recording of airway pressure and esophageal pressure during mechanical ventilation. The system required the insertion of an esophageal balloon catheter and an airway pressure transducer.
30770|NCT03945396|Drug|Homeopathic Medication|A homeopathic mineral medicine, form of impure calcium carbonate, CaCO3, which can be found in nature in different niches, from limestone to eggshells.
30993|NCT03943719|Diagnostic Test|FilmArray blood culture identification panel|FilmArray blood culture identification panel is performed 24 hours on 24hours and 7 days a week on positive blood cultures to accelerate pathogens detection
31196|NCT03942042|Drug|Ixekizumab|Administered SC
30771|NCT03945396|Other|Multidisciplinary intervention (Exercise program, diet, motivational support)|"Exercise program: includes a five-times per week routine: warm-up during 10 to 15 minutes, then 40 minutes of aerobic exercise that will be increased progressively until reaching 60 minutes. Thereafter, muscular strength initiating 5%, and increasing until 10 to 15% of body weight. Then, 10 to 15 minutes of stretching. Finally, 5 min cool-down.~Diet: Subjects will receive a balance diet calculated based on energetic needs according FAO: 15-20% of proteins, 50-60% of carbohydrate, 20-25% of fat per day.~Motivational support: 50 min session where empathy and neutral understanding of the perspective and feelings of the adolescent, and his family, are fostered to motivate the change and to state realistic goals in reducing weight."
30772|NCT03945396|Drug|Homeopathic placebo|A 30 ml bottle of 30% alcohol-distilled water.
30773|NCT03945383|Device|Treatment with IPL device|Treatment with IPL device
30774|NCT03945370|Dietary Supplement|β-hydroxybuturate esters|Oral dietary supplement product containing β-hydroxybuturate esters
30775|NCT03945370|Dietary Supplement|Placebo drink|Oral placebo drink
30776|NCT03945357|Drug|Gemcitabine/ clindamycin|Comparison of saline solution rinse vs antibiotic rinse
30777|NCT03945357|Drug|Normal saline|Comparison of saline solution rinse vs antibiotic rinse
30778|NCT03945344|Drug|Tiotropium|Oral capsule 20 μg
30779|NCT03945344|Drug|Tiotropium|Oral capsule 20 μg
30780|NCT03945331|Device|Transcutaneous spinal cord stimulator|DS8R Electrical Stimulator For Human Research
30781|NCT03945331|Device|Epidural spinal cord stimulation system|Spectra WaveWriter Epidural Spinal Cord Stimulator System with CoverEdge 32 Electrode Surgical Lead
30782|NCT03945318|Drug|BION-1301 Single Dose|A solution for IV infusion administered as a single dose.
30783|NCT03945318|Drug|Placebo Single Dose|A solution by IV infusion administered as a single dose.
30784|NCT03945318|Drug|BION-1301 Multiple Doses|A solution for IV infusion administered as multiple doses.
30785|NCT03945318|Drug|Placebo Multiple Doses|A solution by IV infusion administered as multiple doses.
30786|NCT03945305|Device|Remote Ischemic Conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 30±2 days.
30787|NCT03945292|Drug|ARO-AAT Injection|solution for subcutaneous (sc) injection
30788|NCT03945292|Other|Placebo|sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
30789|NCT03945279|Drug|BIIB100|Administered as specified in the treatment arm.
30790|NCT03945279|Drug|Placebo|Administered as specified in the treatment arm.
30791|NCT03945266|Behavioral|Intervention group|During the intervention, all participants will start out at the Baseline level. The baseline level will last 2 weeks and there will be an assessment to determine weight gain over those 2 weeks. If weight gain has succeeded the recommended amount, participants will be adapted up to a new level of intervention that includes education on GWG, healthy eating and physical activity. After every 4 weeks, an assessment will be performed and adaptations up will be made if necessary. Adaptations include addition of exercise sessions, healthy eating recipe demonstrations, and meal replacements. Participants will weigh themselves daily, wear an activity monitor, record their diet, and complete paper and online surveys.
30792|NCT03945266|Behavioral|Control group|Participants will follow the same self-monitoring/assessment schedule but will not receive the GWG, healthy eating, and physical activity education or adaptations.
30793|NCT03945253|Drug|ASP8374|Intravenous
30794|NCT03945240|Procedure|Group 1 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, investigators will apply 635-780nm, 10 mW cw, ~ 5-105 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
30795|NCT03945240|Procedure|Group 2 -- using Pinnacle Series Laser Device|"Utilizing the Pinnacle Series Laser by Aspen Laser Systems, we will apply 830nm, 30- 50mW cw, ~ 1-20 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
30796|NCT03945240|Procedure|Group 3 -- using Phoenix Thera-Lase Device|"Utilizing the Phoenix Thera-Lase by Phoenix Thera-Lase Systems, we will apply 904nm, 40mW (pulsed) @10000Hz, ~ 4-18 J/cm2 at the following time and mW intervals. The beam will be applied at 12 application patterns equidistant and parallel to each other. Each application point will be treated for the timeframes referenced below:~Subgroup 1: 10 minutes at 5 mW~Subgroup 2: 10 minutes at 15 mW~Subgroup 3: 10 minutes at 32 mW~Subgroup 4: 15 minutes at 5 mW~Subgroup 5: 15 minutes at 15 mW~Subgroup 6: 15 minutes at 32 mW"
30797|NCT03945227|Drug|standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001|drug: standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 Arm A (consolidation only arm) will be treated with standard platinum-based concurrent chemoradiotherapy, followed by consolidation with PDR001 regimen. --For concurrent chemoradiation therapy, chemotherapeutic agents will follow the one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 D1, D8, D29, and D36; IV infusion - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 2 weeks after completion of radiation therapy (± 7 days), PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
30826|NCT03945006|Other|Balance|The patients were assessed while their bladders were empty. The static balance of the patients was measured with a Technobody® stabilometric platform. The patients were assessed while their bladders were empty. The test was performed as the patients' arms on the sides, eyes open and closed, and on two feet. Ellipse area, anterior-posterior sway, and medial-lateral sway scores were recorded.
31197|NCT03942029|Drug|LY3154207 Capsule|Administered orally as capsule
31198|NCT03942029|Drug|LY3154207 Tablet|Administered orally as tablet
30798|NCT03945227|Drug|PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001|drug:PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 Arm B (concurrent arm) will be treated with PDR001 concurrent with standard platinum-based chemoradiation, followed by consolidation with PDR001 regimen. -For concurrent chemoradiation therapy, chemotherapeutic agents will follow one of the two regimens of standard of care Paclitaxel 45 mg/m2 at D1, D8, D15, D22, D29, and D36, IV infusion; Carboplatin AUC 2 at D1, D8, D15, D22, D29, and D36, IV infusion Etoposide 50 mg/m2 D1-5, D29-33,IV infusion; Cisplatin 50 mg/m2 days 1,8,29, and 36; IV infusion - Concurrent PDR001 400mg at D1, D29 - Concurrent radiation therapy (generally, 60 Gy/30 Fx ±10%) - Consolidation therapy: after 4 weeks after last dose of PDR001, PDR001 400 mg every 4 weeks, until disease progression or an unacceptable adverse event, maximum 12 months.
30799|NCT03945214|Behavioral|Meditation|10 minute per day, 8 week digital meditation
30800|NCT03945214|Behavioral|Healthy Eating|A single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
30801|NCT03945214|Behavioral|Meditation + healthy eating|10 minute per day, 8 week digital meditation and a single 50 minute counseling session focused on eating behaviors, and three 10-minute follow-up phone calls to check-in on eating goals
30802|NCT03945201|Other|Virtual walking trails|During time on the treadmill, participants walk in front of Bionautica Trails, the virtual walking trails created by Plas.md. Participants can select between seven trails including various nature themed trails and a space setting. While walking, participants wear wireless headphones that provide audio of cardiac rehabilitation education at random intervals. These education pieces cover six categories of information: Understanding Your Heart Condition, Diet, Exercise, Medication, Managing Risk Factors, and Emotional Health.
30803|NCT03945201|Other|Standard of care|"Participants receive normal standard of care cardiac rehabilitation, completing multiple pieces of exercise equipment at increasing intervals according to the Jefferson Methodist Cardiac Rehabilitation program's protocols. Participants are given the option to use the treadmill for up to 15 minutes."
30804|NCT03945188|Drug|Etrasimod|Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks of treatment
30805|NCT03945188|Drug|Placebo|Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks of treatment
30806|NCT03945175|Drug|MYDAYIS|MYDAYIS (12.5mg — 37.5mg/day); During Visit 3, Mydayis treatment will be initiated at a dose of 12.5mg/day and will increase in increments of 12.5mg, based upon clinical response and tolerability, up to 25mg at Visit 4, up 37.5mg at Visit 5 and holding at the dose from visit 5 of up to 37.5mg at V6.
30807|NCT03945175|Drug|Placebo Oral Tablet|12.5mg Placebo at Visit 1 and Visit 2
30808|NCT03945162|Combination Product|TLD-1433 Bladder infusion and Photodynamic Therapy|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
30809|NCT03945149|Dietary Supplement|Turmipure Gold™|30 subjects will take 1000mg in 4 capsules (with 250ml water before breakfast , each day, during 5 weeks
30810|NCT03945149|Dietary Supplement|Placebo|30 subjects will take 4 capsules with 250ml water before breakfast , each day, during 5 weeks
30811|NCT03945136|Behavioral|Dynamic Interpersonal Therapy|Dynamic Interpersonal Therapy is a time-limited, manualized, interpersonal and affect-focused psychodynamic treatment that is frequently used to target depression and anxiety.
30812|NCT03945123|Dietary Supplement|Red ginseng|Red ginseng tablet 120g
30813|NCT03945110|Device|iAluRil® intravesical instillations|50ml of a sterile solution of sodium hyaluronate (1.6% 800mg/50ml) and sodium chondroitin sulphate (2% - 1 g/50ml) is administered intravesically (directly into the bladder) via a pre-filled syringe connected to a catheter and held in the bladder for at least 30 minutes.
30814|NCT03945097|Behavioral|preK|Subjects enter and education program that either focuses on learning letters and their corresponding sounds or on language comprehension skills.
30815|NCT03945084|Drug|Niraparib|"Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily <77 kg or <150,000 µL: 200 mg (2 X 100 mg capsules) daily*~* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy"
30816|NCT03945084|Other|Best supportive care|"In both treatment arms, Best Supportive Care (BSC) is defined as a comprehensive assessment of symptoms, with timely application of symptom control measures, in order to maximize patient's quality of life.~BSC does not include any active antitumoral treatment, and will be given according to local guidelines and the normal practice of each participating institution.~BSC will include use of opioid analgesics, other supportive drugs, radiotherapy, administered with the exclusive aim of improving tumor symptoms (e.g. pain, haematuria, etc.), according to Investigator's judgment."
30817|NCT03945071|Device|Punctal plug|Punctal plug will be given to subjects after intravitreal injection in half of the study subjects
30818|NCT03945058|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour daily for 4 weeks
30819|NCT03945058|Device|SHAM|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the earl lobule. Stimulator will be applied continuously for 1 hour daily for 4 weeks.
30820|NCT03945045|Procedure|Subclavian vein approach|Subclavian vein approach for Ultrasound-guided Implantation of TIVAD
30821|NCT03945045|Procedure|internal jugular vein approach|internal jugular vein approach for Ultrasound-guided Implantation of TIVAD
30822|NCT03945032|Other|TICOP|Parent moves the cursor by analogy on their mobile phone (as a visual anagogic scale) four times per year (baseline; month 4; month 8 and month 12).
30823|NCT03945019|Biological|CT-P13 SC (Infliximab)|Subcutaneous injection of CT-P13 SC
30824|NCT03945019|Other|Placebo SC|Subcutaneous injection of Placebo SC
30825|NCT03945006|Other|Incontinence Severity|The Incontinence Severity Index (ISI) was used to assess the MS patients' incontinence severity.The first item is scored between 1 and 4 and the second item is scored between 1 and 3. The total score is calculated by the multiplication of these two answers. The index score is classified as 1-2 slight, 3-6 moderate, 8-9 severe, and 12 very severe.
31199|NCT03942029|Drug|Placebo|Administered orally as tablet
31200|NCT03942029|Drug|Fluconazole Tablet|Administered orally as tablet
30827|NCT03945006|Other|Trunk impairment|Trunk impairment was assessed with the Trunk Impairment Scale (TIS) while the participants' bladders were empty. The scale evaluates static and dynamic sitting balance and trunk coordination through 17 items. Each item is scored between 0 and 3. The total score ranges between 0 and 23, and higher scores indicate a better balance performance.
30828|NCT03945006|Other|Fear of falling|Fear of falling was assessed using the Falls Efficacy Scale developed by Tinetti and colleagues. The scale has 10 items assessing the effect of fear of falling on the confidence level of the individuals while performing activities of daily living. Each items is scored by the participants between 0 (not at all concerned) and 10 (very concerned), and the total of the score ranges between 0 (low fall efficacy) and 100 (high fall efficacy)
30829|NCT03944993|Device|Pulsed Electromagnetic Fields Therapy (Dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
30830|NCT03944993|Device|Pulsed Electromagnetic Fields Therapy (Non-dominant leg)|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Fields on their non-dominant leg once a week for a total of 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.~The PEMF device produces pulsed magnetic fields at flux densities up to 1.5 mT peak."
30831|NCT03944993|Device|Sham Therapy (Control)|Participants of this arm will be not be exposed to the fields. Sham treatment will utilise the same PEMF apparatus for 10 minutes, but in non-operational mode, which is indistinguishable from when the apparatus is in operation. Duration of intervention is 6 weeks. A minimum of 5-day and maximum of 9-day interval between each treatment session shall be followed.
30832|NCT03944980|Drug|Docetaxel|Docetaxel injection
30833|NCT03944980|Biological|PD1-T cells|PD1-T cells injection
30834|NCT03944954|Drug|Marinol|Individuals will receive 0, 10, 30mg of Marinol.
30835|NCT03944954|Device|Transcranial Magnetic Stimulation|Individuals will receive excitatory or inhibitory TMS
30836|NCT03944941|Drug|Avelumab|Given IV
30837|NCT03944941|Drug|Cetuximab|Given IV
30838|NCT03944928|Other|Lung ultrasound|"For each usual consultation every 3 months, the patient will have clinical examination and pulmonary function tests (CPI score). Thoracic ultrasound will be made during the consultation (M0, M3, M6, M9 and M12). The presence, gravity and localisation of each ultrasound sign will be described. CT-scan data will be collected in the 3 months before the start of the study and during the study. To be enrolled in the study does not change to the usual follow-up.~For the thoracic ultrasound, a convex probe will be used (1 to 5 MHz). Patient will be layed down in a right lateral prone position then left. Thoracic ultrasound will be timed, saved and anonymized. 14 intercostal spaces will be explored by experimented operator.~The records will be seen a second time by same operator then a second operator. this will measured interoperator and intraoperator variability."
30839|NCT03944915|Drug|Carboplatin|Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
30840|NCT03944915|Drug|Paclitaxel|"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."
30841|NCT03944915|Drug|Nivolumab|Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.
30842|NCT03944915|Radiation|Radiation|Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13
30843|NCT03944915|Drug|Hydroxyurea Pill|One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
30844|NCT03944915|Drug|5-fluorouracil|5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
30845|NCT03944915|Drug|Filgrastim Injection|Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
30846|NCT03944915|Drug|Cisplatin|Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.
30847|NCT03944902|Drug|Cohort 1: Dose Escalation|The first 3 participants will be enrolled on a fixed dose of Niraparib and CB-839, 600mg. Participants will be evaluated for DLT's, if there are none, they will be enrolled in the next cohort.
30848|NCT03944902|Drug|Cohort 2: Dose Escalation|If no dose limiting toxicities, 3 additional participants will be enrolled in this cohort. Participants will receive a fixed dose of Niraparib and CB-839, 800mg.
30849|NCT03944889|Drug|Capsaicin|Capsaicin 50ug (low dose), Capsaicin 100ug(high dose) will be administered as a topical skin cream and will be intermixed with saline for the injectable solution.
30850|NCT03944889|Device|Delsys Trigno Galileo System|This device is a wireless surface EMG device.
30851|NCT03944889|Device|Cadwell Sierra Wave|Intramuscular EMG recording machinery
30852|NCT03944889|Device|Sonosite Ultrasound Machine|Ultrasound System
30853|NCT03944889|Device|Goniometer|A device to measure angular position
30854|NCT03944876|Drug|Botulinum toxin type A|Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
30855|NCT03944876|Drug|placebo|0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
30856|NCT03944863|Drug|Antibiotics|
30893|NCT03944564|Behavioral|Dynamic standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
55532|NCT03750552|Drug|Placebo|Oral tablet, QD
30857|NCT03944850|Behavioral|Computerized Anxiety Sensitivity Treatment|CAST is a newly developed computerized intervention designed to closely model the educational and behavioral techniques that are commonly used in the treatment of anxiety and related conditions. A psychoeducation component focuses on the nature of anxiety and its effects on the mind and body. Veterans will be taught that physiological and psychological arousal is not dangerous, although they may have developed a conditioned fear of this arousal. Interoceptive exposure (IE) exercises will also be introduced to as a way to reduce or eliminate the conditioned fear response.
30858|NCT03944837|Other|Oxygen gas|Transient maternal oxygen administration during echocardiographic and MRI imaging
30859|NCT03944824|Other|Exercise Plan using resistance bands|Exercise under the guidance of an exercise physiologist using elastic resistance bands and weekly meeting with an exercise physiologist for 12 weeks
30860|NCT03944824|Diagnostic Test|Modified Fried Frailty Scale|Patients will be screened for frailty pre and post with sit-to-stand test, timed up and go test, handgrip strength test and administered the low physical activity questionnaire. These components together consist of the Modified Fried Frailty Index.
30861|NCT03944811|Procedure|piezoelectric device|crestal approach will be used to augment the maxillary sinus with simultaneous implant placement
30862|NCT03944811|Procedure|Summers technique|Summers technique
30863|NCT03944798|Other|Frequency: Every 3 Months|every 3 months
30864|NCT03944798|Other|Frequency: Every 6 Months|every 6 months
30865|NCT03944798|Other|Imaging Modality: Chest Radiograph (CXR)|Chest radiograph (CXR)
30866|NCT03944798|Other|Imaging Modality: Chest CT|Chest computed tomography (CT)
30867|NCT03944785|Drug|XADAGO (safinamide)|XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing off episodes.
30868|NCT03944772|Drug|Osimertinib|Osimertinib given orally at 80 mg once daily
30869|NCT03944772|Drug|Savolitinib|Savolitinib will be given orally once daily at 600 mg for patients with a body weight of >55 kg and 300 mg for patients with a body weight of ≤55 kg and for Japanese patients.
30870|NCT03944772|Drug|Gefitinib|Gefitinib given orally at 250 mg once daily
30871|NCT03944772|Drug|Necitumumab|Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
30872|NCT03944772|Drug|Durvalumab|Durvalumab given IV at 1500 mg on Day 1 of every cycle
30873|NCT03944772|Drug|Carboplatin|Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
30874|NCT03944772|Drug|Pemetrexed|Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
30875|NCT03944759|Procedure|serratus anterior plan block|serratus anterior plan block
30876|NCT03944746|Other|Education Curriculum|Different educational curriculums were applied to each cohort
30877|NCT03944733|Dietary Supplement|Iron|65 mg of iron (ferrous sulfate)
30878|NCT03944733|Dietary Supplement|Gelatin|600 mg gelatin
30879|NCT03944707|Drug|LOU064 or placebo treatment|all subjects will be randomized with ratio 3:2 on Day 1 to receive LOU064 or placebo dose for 12 weeks
30880|NCT03944694|Diagnostic Test|Delirium assessment.|Full blood count analysis.
30881|NCT03944681|Drug|Droperidol Injectable Solution|An electrocardiogram analysis in: 5,10,15,20 minutes after injection of 1.25 mg of droperidol used as PONV prophylaxis.
30882|NCT03944668|Behavioral|Exercise|36 sessions of comprehensive cardiac rehabilitation over 12 weeks
30883|NCT03944655|Drug|Strepsils Anaesthetic Formula|Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.
30884|NCT03944655|Dietary Supplement|Clear Mint Drops|Oral administration of a lozenge containing glucose syrup, sugar, and flavourings
30885|NCT03944642|Behavioral|Breastfeeding support|Breastfeeding self-efficacy enhancing through professional support
30886|NCT03944616|Behavioral|Diet Beverage|Participants will receive and consume three daily servings (24 ounces) of a non-caloric commercial diet beverage of their choice sweetened with FDA approved artificial sweeteners.
30887|NCT03944616|Behavioral|Water|Participants will receive and consume three daily servings (24 ounces) of plain bottled/canned water in place of their usual commercial diet beverage. The water will be unflavored, unsweetened, non-caloric, and may be plain or sparkling. Participants randomized to consume water will be instructed to avoid intake of diet beverages.
30888|NCT03944590|Other|patient survey|patient survey on clinical outcome after screw osteosynthesis of radial head fractures
30889|NCT03944590|Other|analysis of radiographs|analysis of radiographs on radiological outcome after screw osteosynthesis of radial head fractures
30890|NCT03944577|Drug|Evolocumab (Repatha)|Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
30891|NCT03944564|Behavioral|Sitting|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
30892|NCT03944564|Behavioral|Static standing|We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
30960|NCT03943940|Biological|BM-MNC and UC-MSC|"Autologous bone marrow mononuclear cells (BM-MNCs) and allogeneic umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) under sterile conditions to treat this disease.~UC-MSC: 1-2 x 10^6 cells/kg"
30894|NCT03944551|Device|Bubble CPAP|Those assigned to the bCPAP group will receive a Total flow oxygen at a rate of 2 liters per kilogram to a maximum of 10 liters per minute using the appropriate nasal prongs for the age and size of the patient. The positive end-expiratory pressure (PEEP) provide by bCPAP will start at 8cm HO2. The FIO2 will be adjusted to obtain a saturation of oxygen of 90% or greater.
30895|NCT03944551|Other|Standard Therapy|For patients in the standard therapy group, oxygen will be delivery by nasal cannula at a flow rate of 4 Liters per minute. If a patient in the standard group after 1 hour of treatment still has a SpO2 < 90% or meeting criteria of treatment failure the patient will be move from the standard therapy group to the bCPAP group.
30896|NCT03944538|Behavioral|Lifestyle Physical Activity|The intervention consists of two primary components: a dedicated Internet website and one-on-one video chats with a behavioral coach via Zoom. The intervention focuses on the skills, techniques, resources and strategies for becoming and staying physically active with MS, but does not provide a prescription for exercise or physical activity itself.
30897|NCT03944538|Behavioral|General Wellness|The control condition provides an Internet website and one-on-one video chats that discuss materials about self-managing MS consequences and health indicators through methods other than physical activity.
30898|NCT03944525|Device|High flow nasal cannula|Oxygen-therapy via HFNC
30899|NCT03944525|Device|Continuous positive airway pressure|Non-invasive CPAP ventilation
30900|NCT03944512|Drug|Pravastatin|20 mg Pravastatin taken daily
30901|NCT03944512|Other|Placebo|Identical appearing placebo pill
30902|NCT03944499|Drug|FS-1502|"Drug: FS-1502 Dose-Escalation Phase (Phase 1a) - FS-1502 Dose-escalation will be proceeded on standard 3+3 design with starting dose of 0.1 mg/kg, IV, once per 28 days, 28 days as a cycle.~Dose level 1: 0.1 mg/kg; Dose level 2: 0.2 mg/kg; Dose level 3: 0.4 mg/kg; Dose level 4: 0.6 mg/kg; Dose level 5: 0.8 mg/kg; Dose level 6: 1.0 mg/kg; Dose level 7: 1.3 mg/kg.~Dose-expansion Phase (Phase 1b) -RP2D determined in phase 1a, IV, once per 28 days, 28 days as a cycle."
30903|NCT03944486|Other|Feasibility of On-Track|Patients to use digital application- study assessed the feasibility of the application for patients and therapists.
30904|NCT03944473|Drug|Sugammadex|Patients undergoing laparoscopic ambulatory surgery randomized into Sugammadex group will receive a dose of Sugammadex as their reversal agent
30905|NCT03944473|Drug|Neostigmine|Patients undergoing laparoscopic ambulatory surgery randomized into Neostigmine group will receive a dose of Neostigmine as their reversal agent
30906|NCT03944460|Drug|Contraloid|Oral administration of capsules, drug substance or placebo without any excipients.
30907|NCT03944447|Drug|Cannabis, Medical|Patients will be given medical cannabis recommendations and certifications commensurate with the state law in which the encounter occurs. The variations in mechanisms between the states for recommending, registering, certifying, and developing mandated treatment plans or doses will be adhered to; however, variations in state law and cannabis programs should not cause variation in the study design because the end-result is still the same with patients being treated with medical cannabis.
30908|NCT03944434|Drug|Ribociclib|ribociclib 600 mg/day orally
30909|NCT03944434|Drug|Aromatase Inhibitors, non steroideal|letrozole 2.5 mg/day orally or anastrozole 1 mg/day orally
30910|NCT03944434|Drug|LHRH agonist|Triptorelin 3,75 mg or Leuprolide 3,75 mg or goserelin 3,6 mg, as injectable.
30911|NCT03944421|Other|Red and Processed Meat|Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
30912|NCT03944421|Other|Quorn|Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
30913|NCT03944408|Procedure|stent implantation|stent implantation
30914|NCT03944395|Other|Assisted Partner Notification Services|Three options for partner Notification services; contract referral, provider referral and dual referral
30915|NCT03944369|Other|KB109|KB109 is a novel glycan
30916|NCT03944369|Other|No intervention|No intervention
30917|NCT03944356|Drug|Dabrafenib and Trametinib|Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
30918|NCT03944343|Other|Cereal based products|The cereal products are made from common Swedish cereals.
30919|NCT03944330|Dietary Supplement|standard hospital diet|patients were provided standard hospital diet that provided 25-30 kcal/kg/day
30920|NCT03944317|Drug|Sulfadoxine pyrimethamine|SP 1500/75mg tablet orally once starting from 16 weeks, at least at four weekly interval until delivery.
30921|NCT03944317|Drug|Azithromycin|A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
30922|NCT03944304|Drug|Paclitaxel|Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).
30923|NCT03944291|Procedure|Pudendal Nerve Block|Pudendal Nerve Block
30924|NCT03944278|Device|Thulium Laser|Thulium laser for skin resurfacing procedures
30925|NCT03944265|Other|Counseling|Participate in treatment decision counseling session
30926|NCT03944265|Other|Questionnaire Administration|Ancillary studies
30927|NCT03944265|Other|Medical Chart Review|Ancillary studies
30928|NCT03944252|Drug|Avelumab|avelumab 10 mg/kg iv day 1; To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
30929|NCT03944252|Drug|Cetuximab|cetuximab 500 mg/m2 plus avelumab 10 mg/kg iv day 1. To be repeated every 2 weeks (14 days) until progression of disease, refuse or inacceptable toxicity.
30930|NCT03944239|Biological|Retinal pigment epitheliums transplantation|Subretinal transplantation of clinical human embryonic stem cell derived retinal pigment epitheliums.
30931|NCT03944226|Dietary Supplement|Beetroot juice|The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
30932|NCT03944213|Device|intermittent theta burst stimulation (iTBS)|20 sessions of iTBS
30933|NCT03944200|Drug|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar."
30934|NCT03944200|Drug|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug(Sugamet SR Tab 5/1000mg®) together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 7 days. Period 2: Single oral administration of 1 tablet of test drug(DA-1229_01(A)) together with 150 mL of water containing 30 g sugar."
30935|NCT03944187|Diagnostic Test|Transvaginal sonography|Transvaginal sonography for measurement of cervical length, fetal head circumference and fetal head to cervix angle .
30936|NCT03944174|Procedure|Fixation of unstable pelvic fractures|Percutaneous fixation of both iliac bones through the sacrum using one screw
30937|NCT03944161|Dietary Supplement|Oral nutrition supplement|Hypercaloric and high protein supplement
30938|NCT03944161|Other|Nutritional advice|Advice given by the clinician
30939|NCT03944135|Other|Web platform: Neuronup|Neuronup is a web platform designed for neuropsychological rehabilitation that is focused on functional cognitive impairments resulting from normal aging and other causes. Neuronup emerged as a scientific, viable and accessible technological initiative.
30940|NCT03944122|Device|ultrasound|therapeutical ultrasound were applied to the patients
30941|NCT03944109|Drug|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
30942|NCT03944109|Drug|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
30943|NCT03944096|Procedure|FMT+MTX|FMT is performed at the beginning of the study and is repeated after 4 weeks plus MTX in the same dose.
30944|NCT03944083|Other|Treatment as usual for ADHD|Children are given treatment according to diagnostic conclusion and clinical recommendations.
30945|NCT03944070|Drug|Ranibizumab|Intravitreal Ranibizumab is approved for the treatment of wet AMD. In this study we will compare an intensive injection protocol versus the standard treat and extend protocol in wet AMD patients undergoing cataract surgery.
30946|NCT03944057|Drug|ATG-010|"ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)"
30947|NCT03944044|Other|Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol|Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.
30948|NCT03944031|Drug|LY3372689|Administered orally.
30949|NCT03944031|Diagnostic Test|[18F]LSN3316612|Administered IV.
30950|NCT03944018|Behavioral|Intervention with rehabilitation coordinator|Intervention with rehabilitation coordinator in orthopedic care
30951|NCT03944005|Procedure|Spinal Anesthesia + ACB continious catheter + iPACK + Sham LIA|"ACB - On identification of adductor canal,10ml ropivacaine 0.5% with 1:400,000 epinephrine will be injected to surround the femoral artery.Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr 0.2% ropivacaine will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of femoral condyle and popliteal artery, 20ml ropivacaine 0.5% with 1:400,000 epinephrine will be infiltrated in muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients in Group 1 will receive local infiltration 100ml of normal saline around the knee capsule of 100ml of normal saline by the surgeons as a Sham injection."
30952|NCT03944005|Procedure|Spinal Anesthesia + LIA + Sham Blocks|"ACB - On identification of adductor canal, 10ml of saline as a sham solution will be injected to surround the femoral artery. Following catheter placement, another 10ml of the same solution will be injected. Continuous infusion of 5ml/hr of saline will be infused till considered ready to discharge.~Ipack - Posterior knee infiltration will be performed following ACB. On visualization of the femoral condyle and popliteal artery, 20ml of saline will be infiltrated in the muscular space between popliteal artery and posterior femoral condyle.~Spinal anesthesia will be performed following the nerve blocks. All patients will receive 2-3ml of 0.75% preservative-free bupivacaine injected at the level of L2-3 or L3-4 intervertebral space.~LIA - Patients will receive local infiltration by the attending surgeon intraoperatively with 300mg of ropivacaine (100ml of 0.3% ropivacaine),30 mg of ketorolac, and 0.6mg of epinephrine around the knee capsule."
30953|NCT03943992|Drug|YYD601 40mg|Patients should take druges 30 minutes before breakfast.
30954|NCT03943992|Drug|Nexium 40mg|Patients should take druges 30 minutes before breakfast.
30955|NCT03943992|Drug|Placebos|The placebo YYD601 is made from microcrystalline cellulose covered with hard shell. The placebo Nexium is made from microcrystalline cellulose, Crospovidone, Magnesiumstearat and other ingredients.
30956|NCT03943979|Other|Cognitive Training|Cognitive Training (CT): 4 consecutive days, 30-45 min session involving 5 different tasks designed to train executive functions and attention, available at the Guttmann Neuropersonaltrainer platform (computerized cognitive training tool certified by the Spanish Agency for Medicines and Health Products as a Class I Health Product). The difficulty level of all the tasks was automatically adjusted on a trial-by-trial basis for both Active and Active Control conditions.
30957|NCT03943979|Device|transcranial Direct-Current Stimulation (tDCS)|tDCS: 4 consecutive days, 20 min session, delivered through multichannel tDCS (Starstim, Neuroelectrics), with an excitatory target over the r-dlPFC, and an inhibitory target on the contralateral lobe (l-dlPFC). The positioning of the multichannel tCS (electrode location and currents) was solved using the Stimweaver (Ruffini 2013). The resulting tCS montage employed 8 gelled Ag/AgCl electrodes of π cm2 size (Pistim, Neuroelectrics) placed at AF3(-1093uA), AF4 (1178uA), F3 (-1161uA), F4 (1104uA), F7 (-414uA), F8 (530uA), FC5 (1189uA), FC6 (-1332uA).
30958|NCT03943966|Diagnostic Test|18F-GP1 PET CT|PET CT scan using platelet radiotracer 18F-GP1
30959|NCT03943953|Behavioral|Information and Therapy Guides|"We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~Facial palsy: Coping with the early stages.~Facial palsy: Coping with comments, questions and staring.~Facial palsy: Communicating with confidence.~Facial palsy: Managing anxiety.~Facial palsy: Managing your mood.~Facial palsy: Building your self-esteem.~Facial palsy: Advice for friends, family and partners."
30962|NCT03943927|Other|Guided Metoprolol Management|"CYP2D6 Genotyping: Consented patients will have blood drawn for genotyping prior to surgery. Patients will be classified as poor metabolizers, intermediate metabolizers, extensive (normal) metabolizers, or ultrafast metabolizers.~Pharmacogenetic- Guided Metoprolol Management: A best practice advisory will be integrated into institutional clinical decision support systems for metoprolol dosing based on metabolic status of each patient."
30963|NCT03943914|Combination Product|Preventive strategy|In the experimental strategy, NIV is performed after inclusion in patients with moderate hypoxemia, defined by a PaO2/FiO2 ratio < 300 mmHg. The minimally required duration of NIV was 4 hours per day for at least 2 calendar days. The daily duration of NIV can be increased at the discretion of the physician in patients with signs of delayed respiratory failure under HFNC-O2 and improving under NIV. Beyond the first 48 hours, NIV and HFNC-O2 can be stopped and the patient switched to COT if respiratory rate < 25/min and SpO2 > 92% under FiO2 < 30% for at least 6 hours.
30964|NCT03943914|Combination Product|Standard of care|In the control group, patients receive oxygen from nasal cannula or high concentration oxygen mask according to the FiO2 needed to achieve SpO2 > 92%. NIV is initiated only in patients having PaO2/FiO2 ratio < 200 mmHg under COT. A trial of curative NIV is allowed at the discretion of the physician in patients who have signs of delayed respiratory failure and no other organ dysfunction. The non-improvement of respiratory conditions after 1 hour of NIV, the NIV-dependence (≥ 12 consecutive hours) or NIV-intolerance should be considered as criteria for endotracheal intubation.
30965|NCT03943901|Drug|Rituximab|Rituximab is a monoclonal antibody
30966|NCT03943901|Drug|Cyclophosphamide|Chemotherapy drug, alkylating agent
30967|NCT03943901|Drug|Doxorubicin|Chemotherapy drug, anthracycline antibiotic
30968|NCT03943901|Drug|Vincristine|Chemotherapy drug, plant alkaloid
30969|NCT03943901|Drug|Prednisone|Steroid, anti-inflammatory
30970|NCT03943901|Biological|Pegfilgrastim|Granulocyte stimulating factor, biologic response modifier
30971|NCT03943888|Drug|Sugammadex Injection 2mg/kg|Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration
30972|NCT03943888|Drug|Sugammadex Injection 4mg/kg|Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration
30973|NCT03943888|Drug|Sugammadex Injection 8mg/kg|Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration
30974|NCT03943888|Drug|Neuromuscular reversal agent injection|Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine
30975|NCT03943875|Biological|9-valent HPV vaccine, 2 dose efficacy|Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
30976|NCT03943875|Biological|9-valent HPV vaccine, 3 doses standard timing|Will be comparison group for 2 dose efficacy group.
30977|NCT03943862|Behavioral|2Share|"The peer-led group program contains of three lessons plus one booster session:~Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weigh their pros and cons of (non-)disclosing a suicide attempt.~Lesson 2: Different ways to disclose: Participants learn about the different ways to disclose and their respective pros and cons. Afterwards participants develop strategies to choose a person to disclose to, and discuss possible responses they might experience.~Lesson 3: Telling your story: Participants learn how to tell their own story.~In a booster session, participants will discuss their experiences with disclosure or non-disclosure."
30978|NCT03943849|Other|Particulate bone graft|Creos allo.gain allogenic bone particulate mineralized cortical bone will be hydrated and placed in the extraction socket.
30979|NCT03943849|Other|Autogenous dental pulp tissue|Dental pulp will be isolated from teeth extracted for non-periodontal reasons chairside, mixed with hydrated particulate bone graft, and then placed in the extraction socket.
30980|NCT03943849|Other|Resorbable collagen membrane|After placement of particulate bone graft or particulate bone graft plus autogenous dental pulp tissue, socket will be covered by a resorbable collagen membrane and sutured.
30981|NCT03943849|Other|Suture|Resorbable or non-resorbable suture material
30982|NCT03943836|Behavioral|Music|Patients in the music group will listen to classical music during their dental procedure.
30983|NCT03943823|Drug|Estrogen vaginal cream|Either Premarin or Estrace cream will be used (dependent on patient's insurance). Premarin 1 gram every night for the first 7 days, then 0.5 grams twice weekly. Estrace cream 2 grams daily for first 7 days, then 1 gram twice-weekly.
30984|NCT03943823|Drug|Trimo-San vaginal gel|Half applicator for three times a week for 1st week, then half applicator for 2 times a week.
30985|NCT03943810|Other|No intervention|There is no intervention
30986|NCT03943797|Biological|Cultivated oral mucosal epithelial cell transplantation|Cultivated oral mucosal epithelial cell transplantation (COMET) will be used to treat severe limbal stem cell deficiency so as to restore the integrity of corneal surface
30987|NCT03943784|Procedure|Endoscopic Variceal Ligation|Endoscopic varices ligation was performed with a six-shooter multiband ligator (Cook Medical, Limerick, Ireland) if medium to large varices or reddish spots, regardless of the grade of the varix, were observed. Each varix was ligated 1-2 cm above the gastro-esophageal junction, with 1 or 2 rubber bands and using no more than 5 rubber bands per session.
30988|NCT03943784|Drug|Non-Selective Beta-Blocking Agent|Patients of the Propranolol group that presented medium to large esophageal varices without contraindication to Non-Selective Beta-Blockers, received propranolol, 1 mg/Kg/day every 8 hours, titrated to reduce the basal heart rate in 25% and not exceeding 5 mg/Kg/day. Patients were evaluated monthly until this reduction in heart rate was achieved, and every three to six months thereafter.
30989|NCT03943771|Other|Anxiety, renal anatomy and surgery questionnaires|"The day before surgery, all the patients will be visited by a member of the investigator team for preoperative consultation and will be given a questionnaire evaluating their anxiety based on STAI and VAS scores. The two experimental groups will be offered their renal modelization to be manipulated (virtually or physically) before the questionnaire.~A second survey assessing basic renal anatomy and surgery understanding will also be completed by the patients.~Anxiolytics prescription prior to surgery will be collected inside the medical file."
30990|NCT03943758|Dietary Supplement|Prepackaged Low-residue diet|Subjects in the prepackaged Low-residue diet group were given three packages of the prepackaged Low-residue diet, and instructed to ingest one package per meal without any other food being allowed in the day prior to colonoscopy.
30994|NCT03943693|Device|Double shock|Patients randomized to the dual shock group will have two near-simultaneous 200-Joule shocks delivered through the two sets of pads (antero-posterior position and right infraclavicular-axillary position). The first of these shocks will be synchronized. If the first attempt with this approach fails to terminate atrial fibrillation a second attempt will be made using the same approach. If the second attempt fails the dual shock approach will be considered to have failed and further treatment will be determined by the primary team/attending cardiologist.
30995|NCT03943693|Device|Single shock|Patients randomized to single shock will then be treated initially with a 200 Joule shock through the antero-posterior pads only. A repeat attempt will be made using the same approach if the initial shock fails. If the second attempt fails, the single shock approach will be considered to have failed. Patients will be crossed over to dual shock therapy while under the same sedation episode. For cross-over patients, two near-simultaneous 200-Joule shocks will be delivered through the two sets of pads already in position. If this fails further treatment will be determined by the primary team/attending cardiologist.
30996|NCT03943680|Device|PRGF|After tooth extraction, the socket will be grafted with PRGF-Endoret
30997|NCT03943680|Device|ABB|After tooth extraction, the socket will be grafted with Geistlich Bio-Oss® Collagen
30998|NCT03943667|Drug|Gemcitabine|1000 mg/m² in IV infusion over 30-40 minutes at Day 1, 8 and 15 followed by one week of rest.
30999|NCT03943667|Drug|Paclitaxel|80 mg/m² in IV infusion over 60 minutes at Day 1, 8 and 15 followed by 1 week of rest.
31000|NCT03943654|Other|MotoMeds Healthline- illness assessment and treatment recommendation for non-emergent cases by telephone|The healthline uses a series of questions (based off of the WHO Integrated Management of Childhood Illness guidelines) asked to the parent of a sick child over the phone to remotely triage and assess the child's illness and then provide a treatment recommendation. MotoMeds is the accompanying motorcycle delivery service for basic medication delivery at nighttime.
31001|NCT03943641|Other|This is not an intervention study|This study is based on retrospective analysis of linked routinely-collected healthcare data
31002|NCT03943628|Behavioral|Familias Unidas|
31003|NCT03943615|Drug|Voxelotor|
31004|NCT03943602|Drug|Cabozantinib|Cabozantinib 60 mg/day orally
31005|NCT03943589|Drug|Imlifidase|All subjects will receive imlifidase (Day 1) prior to standard care IVIg
31006|NCT03943576|Drug|GXCPC1|The dose regimen is one single intra-articular injection of GXCPC1 containing 6.7×106 or 4×107 ADSCs in 3 mL saline. (allogeneic injection)
31007|NCT03943576|Device|HA|Hya Joint Plus synovial fluid supplement 3mL
31008|NCT03943563|Diagnostic Test|Dixon sequences acquisition|Dixon sequences acquisition
31009|NCT03943550|Drug|RO7049665|Multiple ascending doses of RO7049665 will be administered SC.
31010|NCT03943550|Drug|Placebo|Matching placebo will be administered SC.
31011|NCT03943537|Drug|Intranasal Insulin|40 units Novolin R administered intranasally using ViaNase device.
31012|NCT03943524|Device|Interax-AI|Interax-AI is a drug interactions detection module for the electronic clinical history software DrApp
31013|NCT03943511|Other|Oral Antibiotics-Close Monitoring|To receive oral antibiotics and close monitoring, defined as twice weekly telephone calls by a member of the care team, of their chest tube and valve.
31014|NCT03943511|Other|Standard of Care|No calls from the care team but waiting for the subject to contact the care team when the air leak has stopped.
31015|NCT03943498|Drug|Fingolimod|Given PO daily for 4 weeks
31016|NCT03943498|Drug|Fingolimod Hydrochloride|Given PO
31017|NCT03943498|Other|Questionnaire Administration|Ancillary studies
31018|NCT03943485|Device|The uterine manipulator which is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We adopted this device in abdominal hysterectomy.|The uterine manipulator is primarily used in laparoscopic hysterectomy to accurately locate the colpotomy site. We hypothesized that adoption of a uterine manipulator would help the surgeon to better identify the colpotomy site by moving the uterus cranially and thus providing better visualization of the colpotomy site.
31019|NCT03943472|Biological|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
31020|NCT03943472|Drug|Fludarabine|30mg/m2/d
31021|NCT03943472|Drug|Cyclophosphamide|300mg/m2/d
31022|NCT03943472|Drug|Immune inhibitors|Immune inhibitors
31023|NCT03943459|Drug|Quercetin|Quercetin 250 mg BID
31024|NCT03943446|Drug|TAK-018|TAK-018 Tablets.
31025|NCT03943446|Drug|TAK-018 Placebo|TAK-018 placebo-matching Tablets.
31026|NCT03943433|Procedure|FiO2_1.0|Alveolar recruitment is performed with 100% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
31027|NCT03943433|Procedure|FiO2_0.4|Alveolar recruitment is performed with 40% oxygen concentration after general anesthesia induction, after position change to Trendelenburg, after position change to supine, and at the end of operation.
31028|NCT03943407|Drug|Zyclara 3.75 % Topical Cream|The cream will be applied on 4x4 cm squared areas on the volar forearm. The cream will be left in place for 2h, 1 h or 30 min (sub-study 1) after which it will be removed. The technical and security procedures will be conducted in accordance with the manufacturer's instructions.
31029|NCT03943407|Drug|Prudoxin|The anti-histamine cream Prudoxin, containing 5% doxepin hydrochloride (1 g contains 50 mg of doxepin) (Healthpoint, San Antonio, TX) will be applied on the volar forearm. Two adhesive patches 4×4 cm (1mm thick, 3M foam adhesive tape, 3M, St. Paul, MN) each with a 3.5×3.5 cm center cut out (to deposit 1.2 grams of cream) will be each placed 3 cm distal and 3 cm proximal to the center of the volar aspect of each arm. Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1 h and 30 minutes.
31030|NCT03943407|Other|Histamine|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction. . A small drop of histamine dihydrochloride (1%, in saline) will be applied to a previously determined area on the volar forearm followed by a prick through the drop.
31065|NCT03943121|Procedure|Without Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus. And the side without the stent is defined as the control side.
31031|NCT03943407|Other|Cowhage|Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip. The active substance delivered (mucunain) has been calculated to be in the nanogram range. The insertion of cowhage spicule(s) rapidly and consistently produces itch with no or very little flare reaction. This insertion is conducted by forceps using a stereo-microscope, and 30-35 spicules are gently rubbed into a 1 cm diameter skin area.
31032|NCT03943407|Other|L-menthol|L-menthol (≥99.9%, TRPM8 agonist; (Sigma Aldrich, Broendby, Denmark) is dissolved in 96% ethanol at concentrations of 40%(w/v) L-menthol. A 1 mL aliquot is dispensed onto a 3 × 3 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape. In between the cotton pad and the medical tape, a layer of parafilm will be added to avoid evaporation. This configuration was subsequently applied for 1 h.
31033|NCT03943407|Other|Trans-cinnamaldehyde (CA)|CA will be obtained from Sigma Aldrich (Brøndby, Denmark) and dissolved in 90% ethanol at a concentration of 10% (vol/vol) CA. One ml aliquot of CA is dispensed onto a 3x3 cm cotton pad and placed on a 5x5 cm sheet of medical tape. Between the cotton pad and the tape, a layer of plastic film will be added to inhibit the evaporation of the solutions. This configuration will be applied for 1 h.
31034|NCT03943394|Other|fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene|"Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris [pH 8.0], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with ~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope."
31035|NCT03943381|Device|Duplex US|Duplex US (Caliper, wave forms...)in evaluation of Pelvic Veins (namely left ovarian vein). in pelvic congestion syndrome
31036|NCT03943368|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
31037|NCT03943355|Other|Patient before cohort (2005-2010)|The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.
31038|NCT03943355|Other|Patient after cohort (2011-2016)|The protocol of NOM became more aggressively and strictly adhered to since 2011.
31039|NCT03943342|Drug|Ibrutinib|Given PO
31040|NCT03943342|Drug|Venetoclax|Given PO
31041|NCT03943329|Procedure|Standard of Care|"Will receive the standard of care free-hand technique of distal screw placement, as treated by Dr. Egol or Dr. Tejwani."
31042|NCT03943329|Procedure|Distal targeting device technique of distal screw placement|The second group will be the interventional group which will use the distal targeting device technique of distal screw placement and will be treated by Dr. Konda and Dr. Leucht. All relevant data to the study will be collected intra-operatively.
31043|NCT03943303|Radiation|Natural gamma radiation from the monazite sands|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
31044|NCT03943303|Radiation|Normal sands exposure patients|Patients selected for the study will have their knee (s) affected by osteoarthrose fully submerged in the no-monazite beach sand 2 (two) times per week for 30 (thirty) minutes each session at the same location and at the same time of day.
31045|NCT03943290|Drug|ACE-083|Recombinant fusion protein
31046|NCT03943277|Other|No intervention, observational study|No intervention observational study
31047|NCT03943264|Drug|XPro1595|XPro1595 will be delivered by subcutaneous injection once a week
31048|NCT03943251|Drug|HEC113995PA•H2O tablet|2.5-、5-、10-、20-、40-、60-、80mg HEC30654AcOH tablet in day1.
31049|NCT03943251|Drug|Placebo tablet|2.5-、5-、10-、20-、40-、60-、80mg Placebo tablet in day1.
31050|NCT03943238|Biological|Infusion of Donor Hematopoetic Stem Cells and Recipient Tregs|Living donor kidney transplant recipients will receive after a preparatory regimen of total lymphoid irradiation and and anti-thymocyte globulin an infusion of purified donor CD34+ of >10 x10^6 cells /Kg, 100 x 10^6 donor T cell/ Kg and and an escalated dose of recipient Tregs starting at 25 x10^6/Kg.
31051|NCT03943212|Other|Blood Flow Rate Reduction|Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
31052|NCT03943212|Other|Control|No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.
31053|NCT03943199|Diagnostic Test|Visual Analogue Scale for pain|Will be assessed at 0´, 30´, 60´, 90 minutes and 18 hours after the application of the analgesic.
31054|NCT03943186|Device|Ectoin Lozenges Honey Lemon|application of Ectoin Lozenges (EHT02) in accordance with the instructions for use
31055|NCT03943186|Device|Hyaluronic Acid/Icelandic moss Lozenges|application of the lozenges in accordance with the instructions for use
31056|NCT03943173|Drug|Chemotherapy|Given standard chemotherapy
31057|NCT03943173|Drug|Olaparib|Given PO
31058|NCT03943173|Procedure|Therapeutic Conventional Surgery|Undergo surgery
31059|NCT03943160|Device|Diamondback 360 Extended Length Orbital Atherectomy System|All patients undergoing peripheral vascular intervention (PVI) via transradial access (TRA) and for whom TRA has been successfully achieved and peripheral lesion deemed appropriate for treatment via TRA per physician discretion.
31060|NCT03943147|Drug|BMS-986165|Specified dose on specified days
31061|NCT03943147|Drug|Placebo|Specified dose on specified days
31062|NCT03943134|Other|Minimally Processed Human Umbilical Cord Membrane|Implantation of minimally processed human umbilical cord membrane at the time of surgery
31063|NCT03943134|Other|Standard Surgical Procedures|Standard surgical intervention for at least one targeted acute upper extremity trauma
31064|NCT03943121|Procedure|Steroid-eluting stent implant|After endoscopic bilateral sinus surgery, the Steroid-eluting stents were randomly implanted in one side of the sinus.
56548|NCT03742479|Device|Restylane® Silk|Injectable Hyaluronic Acid (HA)
31066|NCT03943108|Diagnostic Test|Gait analysis|Gait recorded using a sensor on the 4th vertebrae of the lumbar spine, once a week across 6 weeks during the routine PAIDOS clinic. Critical changes in walking control, stride frequency and length will be observed as individuals change speed; effectively stressing their mobility.
31067|NCT03943095|Other|Potassium Nitrate|The test dentifrice contains 5% w/w potassium nitrate.
31068|NCT03943095|Other|Stannous Fluoride|The test and control dentifrices contain 0.454% w/w stannous fluoride (1100 ppm fluoride).
31069|NCT03943082|Behavioral|Cancer Educational Materials|Receive FRP brochure
31070|NCT03943082|Other|Follow-Up Care|Receive follow-up phone call
31071|NCT03943082|Behavioral|Questionnaire|Ancillary studies
31072|NCT03943069|Procedure|Thoracoscopic bullectomy alone|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.
31073|NCT03943069|Procedure|Thoracoscopic bullectomy with pleurodesis|Thoracoscopic stapling of emphysematous like changes (ELCs) to control the air leak from the lung bullae.in addition to mechanical pleurodesis.
31074|NCT03943056|Drug|BIIB091|Administered as specified in the treatment arm.
31075|NCT03943056|Drug|Placebo|Administered as specified in the treatment arm.
31076|NCT03943043|Drug|nab-paclitaxel|"Phase I dosing regimens:~The dose of treatment will be assigned at the time of enrolment in one of these 3 subsequent dose-levels:~- 1° level: gemcitabine 800 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 80 mg/m2 0° level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 100 mg/m2~level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 125 mg/m2~level: gemcitabine 1000 mg/m2 + oxaliplatin 80 mg/m2 + nab-paclitaxel 150 mg/m2 each administered on day 1, every 14 day~Phase II:~Gemcitabine plus oxaliplatin plus nab-paclitaxel according to RP2D."
31077|NCT03943030|Other|Pulmonary rehabilitation|The PR program will consist of supervised physical exercise sessions, which will be held 3 times a week for 8 weeks, and weekly educational sessions. Exercise sessions include aerobic exercise (30 min to 45 min) and lower limb and upper limb strength training, as well as warm-up and muscle stretching exercises after exercise. The exercise load will be individualized and determined from the patients' baseline tests, being increased progressively throughout the sessions. A baseline evaluation will be performed, which will be repeated after 9 weeks, including: clinical and laboratory parameters, endothelial function (FMD) and brachial ankle index (ABI) and exercise tests. Outcomes usually used in the assistance to evaluate PR will also be measured.
31078|NCT03943017|Other|Inspection and safety evaluation by 3 longstanding experience physicians of early clinical researches|Adjudicate each ARC's observations according to the 3 physicians perceived medical importance regarding safety; first, adjudications are performed separately. Then disagreements are settled during a final adjudication meeting between them.
31079|NCT03943004|Drug|DFP-14927|DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
31080|NCT03942991|Drug|articaine|infiltration injection of 4%artpharmadent
31081|NCT03942991|Drug|Mepivacaine 2% Injection|infiltration injection of 2% Mepecaine-L
31082|NCT03942978|Other|Longitudinal Equity Action Plan|Patients admitted to general medicine pod randomized to intervention will receive a Longitudinal Equity Action Plan (LEAP), which will include a program manager to ensure they are on appropriate medical therapy, that cardiology is consulted when appropriate, that patient is set up with appropriate follow-up appointment with cardiology, that transportation is set up for follow-up visits, and a post-discharge follow up call to remind patients of the appointment and identify any post-discharge issues. This is in addition to standard of care, and there will not be any drug or device interventions.
31083|NCT03942965|Device|Double balloon accessory device|Double balloon accessory device is used during the endoscopic polypectomy procedure
31084|NCT03942939|Other|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time|Primary Robotic-Assisted Total Knee Arthroplasty with a short tourniquet time. Short tourniquet time is defined in this study as the release of the tourniquet after the initial exposure, resulting in a total tourniquet time of only 10-15 minutes.
31085|NCT03942939|Other|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet|Primary Robotic-Assisted Total Knee Arthroplasty with the use of a tourniquet
31086|NCT03942926|Drug|Sirolimus|Patients will receive sirolimus for 6 months.
31087|NCT03942913|Other|an observational study|this study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
31088|NCT03942900|Other|Additional biological samples|"Biomonitoring blood sample will be collected: 6 EDTA tubes (6 mL) for PBMC (peripheral blood mononucleated cell), 1 EDTA tube (6 mL) for plasma freezing and 2 EDTA tubes (4 mL) for ctDNA:~at baseline,~at first tumor assessment (phase 2 in OPTIMANAL study),~at second tumor assessment (phase 4 in OPTIMANAL study),~at end-point visit.~A tumor biopsy or archived tumor sample will be mandatory at baseline."
31089|NCT03942887|Drug|Rituximab|Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
31090|NCT03942887|Drug|endoxan|Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
31091|NCT03942887|Drug|Methylprednisolone|Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
31092|NCT03942887|Drug|Prednisolone|after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
31093|NCT03942874|Behavioral|Group Reward Retraining|Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
31094|NCT03942861|Drug|Solu-Medrol|Standard treatment according to Danish Guidelines for acute severe ulcerative colitis.
31095|NCT03942848|Drug|zicotinide followed by placebo|The experimental treatment period consists of Ziconotide solution that will be prepared by each local pharmacy team, in 5 or 10 milliliter (ml) vials with constant concentration of 10micrograms/mL
31096|NCT03942848|Drug|Placebo followed by zicotinide|The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
31097|NCT03942835|Other|experience 1 : Competitive attention test in healthy participants|Comparison of behavioral measures (reaction times and percentage of correct responses) obtained twice with the CAT test in healthy participants (2 to 6 weeks apart).
31098|NCT03942835|Other|experience 2 : Competitive attention test in patients with ADHD with no treatment|Behavioral (reaction times and percentage of correct responses) and Electroencephalography (EEG) measures obtained with the CAT test in patients with ADHD with no treatment.
31099|NCT03942835|Other|experience 3 :Competitive attention test in patients with ADHD with psychostimulant treatment|Behavioral (reaction times and percentage of correct responses) and EEG measures obtained with the CAT test in patients with ADHD before and after psychostimulant treatment.
31100|NCT03942822|Dietary Supplement|Milled chia seeds|8 weeks of an isocaloric diet supplemented with 25 g/day of milled chia
31101|NCT03942809|Device|Effectiveness|Effectiveness and Practicability in anesthetized patient under controlled conditions
31102|NCT03942796|Drug|lyrica, vronogabic (pregabalin)|Patients would receive oral pregabalin is initiated at a dose of 75 mg twice daily and titrated up to 600 mg as tolerated by the patient at 1,2,3 weeks
31103|NCT03942796|Procedure|pulsed radiofrequency ablation of the dorsal root ganglion under fluroscopic guidance/ radiofrequency neurolysis/ radiofrequency denervation device name: Neuro Therm TM 1100|Patients would receive pulsed radiofrequency ablation of dorsal root ganglion using the following settings: 2-Hz frequency, 20-ms pulses in a 1 second cycle, 120 second duration and 42°C temperature. Impedance ranges between 150 and 400 Ohms at all levels under fluroscopic guidance. For each pulsed RF application, the procedure will be repeated 4 times, for a total duration of 8 minutes
31104|NCT03942783|Other|WORKWELL|Individualised, tailored work advice and work/vocational rehabilitation, including self-management and job modifications.
31105|NCT03942783|Other|Control|Published arthritis work booklets;written guidance on work problem identification; potential actions
31106|NCT03942770|Behavioral|Contingency Management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
31107|NCT03942770|Behavioral|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
31108|NCT03942757|Other|bilirubin serum level determination|bilirubin serum level before and after phototherapy treatment will be measured
31109|NCT03942757|Other|Phototherapy|Preterm infant < 35 weeks of gestation with a jaundice requiring phototherapy according to NICE guidelines can be included for the duration of the phototherapy treatment.
31110|NCT03942744|Device|on-line hemodiafiltration|on-line postdilutional hemodiafiltration with high convective transport above 21 liters
31111|NCT03942731|Other|Behavioral allergy testing protocol|skin tests followed by drug provocation test and skin retesting between 6 weeks and 6 months
31112|NCT03942718|Other|Exercise|Participants will obtain an individualized exercise program based on entrance examination on treadmill.
31113|NCT03942692|Other|Phone call questionnaire|"Questionnaire for parents of subject about :~the frequency of consultations with an allergist~the information of the general practitioner or pediatrician~the prescription of epinephrin auto-injector~the frequency of renewal of epinephrin auto-injector~the specialty of doctor who prescribed the renewal~the implementation of specific measures in schools~the frequency of renewal of specific measures in schools~the number of recurrence of anaphylactic reaction~the use of medical advice in case of recurrence of anaphylactic reaction"
31114|NCT03942679|Other|PRP|Patients in this group will receive three ultrasound guided PRP injections in the supraspinatus tendon with one week interval (Ilhanli et al., 2015). After the injection, patients will be instructed to limit the use of shoulder for at least 24 hours and to use cold therapy for pain. After the third injection, ROM, and stretching exercises will be allowed and one month after the end of injections, patients will be recommended to begin the strengthening program as tolerated. Exercise is performed with 10 repeats five sessions per week.
31115|NCT03942679|Other|physiotherapy|Patients in this group will be treated with hot pack for 15 minutes, ultrasound in continuous mode (1.5 watt/cm2 for five minutes), trans-cutaneous electrical nerve stimulation in brief-intense mode for 15 minutes, range of motion (ROM), followed by stretching and strengthening exercises with 10 repeats 15 sessions (five sessions per week for three weeks). After the physical therapy, the exercise program will be continued as homework during the follow-up period.
31116|NCT03942666|Drug|Treatment A|tablet of CHF 6532
31117|NCT03942666|Drug|Treatment B|tablet of CHF 6532
31118|NCT03942666|Drug|Treatment C|tablet of CHF 6532
31119|NCT03942666|Drug|Treatment D|50 mg tablet of CHF 6532
31120|NCT03942666|Drug|Treatment E|Placebo tablet of CHF 6532
31121|NCT03942666|Drug|Treatment F|tablet of CHF 6532
31122|NCT03942653|Drug|Goserelin Acetate|Goserelin Acetate, SQ, Q4W
31123|NCT03942653|Drug|Pembrolizumab|Pembrolizumab, IV, Q3W
31124|NCT03942640|Other|subctaneous perineural injection|"Buffered glucose preparation :~2.4 ml of Na Bicarbonate 8.4% are mixed with 500ml dextrose 5%. Patients received 8 weekly injection"
31125|NCT03942640|Other|deep prolotherapy|The injection fluid contain 1 ml of 255 glucose and 1ml of lidocaine
31126|NCT03942627|Behavioral|Mindfulness Program|The intervention consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of mindfulness practices delivered via audio recordings to assist mothers in managing stress during the NICU stay and another series for the transition home.
31127|NCT03942627|Behavioral|Infant Health Education Program|The active control condition consists of two brief videos (one introducing the NICU portion of the program and one introducing the portion of the program addressing the transition home), as well as a series of audio recordings providing information on infant health and development for mothers to use during the NICU stay and another series for the transition home.
31128|NCT03942614|Behavioral|Nordic pole walking|
31129|NCT03942601|Drug|Temsirolimus|Temsirolimus Injection (0.4 mg/mL) and 20% contrast in Group 1
31130|NCT03942601|Drug|Temsirolimus and dexamethasone sodium phosphate|Temsirolimus Injection (0.4 mg/mL), Dexamethasone Sodium Phosphate Injection, USP (3.2 mg/mL) and 20% contrast in Group 2
31131|NCT03942588|Behavioral|High-intensity interval training|
31132|NCT03942575|Device|Negative pressure wound therapy|Wound dressing with negative pressure on closed incisions
31133|NCT03942549|Device|Retropubic midurethral sling|Midurethral sling
31134|NCT03942536|Other|Focus Group Discussion|At 12-month follow-up, a purposeful, convenience sample of study participants and their significant others, Community Health Workers trained as Health Navigators, and local program staff, will be invited by research staff to participate in focus group discussions to collect qualitative data on pregnancy care, experience of navigating obstetrical emergencies, financial hardships, and Health Navigation program feasibility/acceptability. Particular attention will be paid to recruiting study subjects involved in complex obstetrical emergencies, cases that involved significant delays in transfer of care, cases resulting in significant morbidity/mortality, as well as cases that involved efficient/successful care coordination, referral, and transportation.
31135|NCT03942523|Behavioral|Behavior Change Communication to promote hygiene behavior|"Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.~This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment"
31136|NCT03942510|Other|eccentric exercise with blood flow restriction|High/low intensity eccentric training group (80% and 40% of isometric peak torque) with or not blood flow restriction.
31137|NCT03942484|Device|rPMS device|Pelvic floor muscle contractions will be induced by the device.
31138|NCT03942471|Behavioral|Mindfulness Based Stress Reduction|Mindfulness-Based Stress Reduction (MBSR) is a well-defined and systematic patient-centered educational approach which provides training in mindfulness meditation to teach adolescents with Type 1 diabetes to take better care of themselves and live healthier and more adaptive lives by learning to become more connected to the present moment through the use of breath and training for awareness of the moment.
31139|NCT03942458|Drug|Vicagrel 6mg|Vicagrel 24mg loading followed by 6mg/day for 6 days
31140|NCT03942458|Drug|Clopidogrel 75mg|Clopidogrel 300mg loading followed by 75mg/day for 6 days
31141|NCT03942445|Procedure|Gastrocnemius muscle biopsy|In all groups, a 5 mm large gastrocnemius muscle biopsy will be performed and the samples immediately managed in experimental laboratory.
31142|NCT03942432|Other|Oral Glucose Tolerance Test (OGTT)|Blood samples at T0, T30min, T120min
31143|NCT03942432|Other|Clinical exam|weight, length, waist measurement, cardiac frequency, blood pressure
31144|NCT03942432|Biological|Blood sample|Iron and cardiac markers Serum iron, serum transferrin, transferrin saturation, serum ferritin, AST, ALT, GGT, ALP, PT, Cell Blood Count, ceruloplasminemia , hyaluronic acid, cholesterolemia, HDL, LDL, triglyceridemia, hba1c
31145|NCT03942432|Device|MRI|3 Tesla abdominal MRI
31146|NCT03942432|Device|Bioimpedance|Measurement of body composition
31147|NCT03942432|Behavioral|Questionnaires|Quality of life, physical activity, alcohol consumption and eating habits
31148|NCT03942419|Drug|Atropine 0.1% Ophthalmic Solution|Atropine 0.1% ophthalmic solution administered with a microdose dispenser
31149|NCT03942419|Drug|Atropine 0.01% Ophthalmic Solution|Atropine 0.01% ophthalmic solution administered with a microdose dispenser
31150|NCT03942419|Drug|Placebo Ophthalmic Solution|Placebo ophthalmic solution administered with a microdose dispenser
31151|NCT03942406|Combination Product|BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device|Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
31152|NCT03942380|Diagnostic Test|Liquid biopsy|The intervention is a liquid biopsy as a blood sample taken in a peripheral vein. The blood samples are analyzed for cell free DNA, RNA and HPV-DNA
31153|NCT03942367|Device|Active Device (vPatch)|Electrical stimulation inducing motor response at the pelvic-floor muscles. Stimulation will be delivered by vPatch device configured to motor intensity.
31154|NCT03942367|Device|Sham Device (vPatch)|Electrical stimulation inducing sensory response at the perineum.Stimulation will be delivered by vPatch device configured to sensory intensity.
31155|NCT03942354|Drug|Bedaquiline|Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.
31156|NCT03942354|Drug|Pretomanid|Pretomanid is a nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.
31157|NCT03942354|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria
31158|NCT03942354|Drug|Linezolid|Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.
31159|NCT03942354|Drug|Clofazimine|Clofazimine is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.
31160|NCT03942354|Drug|Directly observed therapy (DOT)|Standard therapy
31161|NCT03942328|Radiation|External Beam Radiation Therapy|Undergo high-dose EBRT
31162|NCT03942328|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
31163|NCT03942328|Biological|Therapeutic Autologous Dendritic Cells|Given IT
31192|NCT03942081|Device|Ulcer Measurement Software|Photos being taken of foot ulcers. Software estimation of foot ulcer being compared to actual measured size.
56631|NCT03741907|Procedure|MLC|Gold standard
31164|NCT03942315|Other|Data collection from standard follow-up after liver transplant|All patients underwent regular follow-up every 6 to 12 months after the first year post-liver transplant (LT). Complete laboratory investigations were performed at each visit. Doppler ultrasonography was performed every 1 to 3 years after LT. Computed tomography (CT) scan and/ or magnetic resonance imaging (MRI) was performed at 1, 5, 10, 15, and 20 years after LT, or when clinically indicated. All available radiological material was reviewed. Cardiac evaluation was performed regularly in patients who received transplant for cardiac failure.
31165|NCT03942289|Other|The role of the noradrenergic system across the life span (Healthy Subjects)|A sample (n=90) of balanced distribution of healthy males and females within a continuous segment of the adult life span from 20 to 80 years old will be recruited, with approximately 7 males and 7 females subjects for each decade of age. Each participant will undergo 1) a neuropsychological examination, 2) an olfactory screening and 3) a 90 min 11C-Yohimbine positron emission tomography (PET)/magnetic resonance imaging (MRI) scan in a resting state.
31166|NCT03942289|Other|The role of the noradrenergic system across the life span (Parkinson's Disease Subjects)|Three groups of Parkinson Disease (PD) patients (each of them n=15) will be studied according to the duration and stage of the disease: early stage (the same group in Task 2); mid stage (5-7 years of disease duration; Hoehn and Yahr in Off 2-3); late stage (7-10 years of disease duration; Hoehn and Yahr in Off 3-4).
31167|NCT03942276|Other|High intensity interval training|Consists of 60 seconds sets of high-intensity exercises, characterized by heart rate> 85% of maximal heart rate (HRmax), obtained through the formula (220-age), or by the Rated Perceived Exertion between 7 and 8 on the Borg scale, which ranges from 0 to 10. Of the 60 seconds of high intensity exercise, 30 seconds will be to get up and down a 16 cm step and 30 seconds of squats, with knee flexion greater than 90º, both at the highest possible speed. The recovery between sets is light walk for 60 seconds. If the volunteers do not reach the proposed intensity zone, they will be instructed to increase the number of squats and step ascents and descents.
31168|NCT03942276|Other|Moderate intensity continuous training|Consist of performing a 30 minute walk at 50% of reserve heart rate (HRR), calculated by (HRmax - HRmax) x% + HRmax. HRmax being obtained by means of the formula (220 - age).
31169|NCT03942276|Other|Control|Consist of performing no exercise training.
31170|NCT03942250|Biological|REGE pro dressing|REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
31171|NCT03942237|Procedure|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine is given immediately after the correct position of needle tip is verified."
31172|NCT03942237|Procedure|Placebo Control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major muscle~Device: The curved (C1-5) probe of Ultrasound Scanner Philips CX50 is used for scan~Drug: single dose 0.4ml/kg 0.9% NS is given immediately after the correct position of the needle tip is verified"
31173|NCT03942224|Drug|Bortezomib|Given SC
31174|NCT03942224|Biological|Daratumumab|Given IV
31175|NCT03942224|Drug|Dexamethasone|Given IV and PO
31176|NCT03942224|Drug|Ixazomib|Given PO
31177|NCT03942211|Drug|Selexipag|Oral tablets containing 200 µg of selexipag. Depending on the iMTD, participants will receive 1 (200 µg) to 8 (1600 µg) tablets at each administration
31178|NCT03942211|Drug|Placebo|Oral tablets without active compound. Participants can receive 1 to 8 tablets at each administration
31179|NCT03942198|Drug|Taodan Granules|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
31180|NCT03942198|Drug|Taodan Granules Placebo|Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
31181|NCT03942185|Drug|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy|Oral Chinese Herbal Medicine of Clearing heat and Cooling blood therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 ~ 200ml each time for 8 weeks.
31182|NCT03942185|Drug|Oral Chinese Herbal Medicine according with syndrome differentiation therapy|Oral Chinese Herbal Medicine according with syndrome differentiation therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 ~ 200ml each time for 8 weeks.
31183|NCT03942185|Drug|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy|Oral Chinese Herbal Medicine of Promoting blood circulation and Removing blood stasis therapy, warm water decoction, 1 dose/day, divided into 2 times, 180 ~ 200ml each time for 8 weeks.
31184|NCT03942172|Device|SpotOn balance glasses|SpotOn Balance Glasses comprising of personalized visual stimuli placed on the glasses's lenses
31185|NCT03942146|Behavioral|Information on smoking cessation|Smoking cessation is recommended 6 weeks before and after surgery
31186|NCT03942133|Procedure|ultrasound-guided short-axis placement of catheter at the entrance of the adductor canal|Ultrasound probe is placed at the entrance of the adductor canal in short axis ，insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the entrance of the canal
31187|NCT03942133|Procedure|ultrasound-guided long-axis placement of catheter at the middle of the adductor canal|Ultrasound probe is placed at the middle of the adductor canal in long axis with the caphelad end of the probe aligned with the entrance of the canal. insertion of a PAJUNK Contiplex S catheter with the tip of the catheter located at the middle of the canal
31189|NCT03942107|Procedure|Group 1: single-visit RCT|both root canal treatment and post and core restoration of the coronal part of the tooth is completed in single visit prior to postoperative pain evaluation at 24, 48 and 72-h and 7-day follow-up time
31190|NCT03942107|Procedure|Group 2: two-visit RCT|after root canal treatment is completed, postoperative pain evaluation will be conducted in this group at 24, 48 and 72-h and 7-day follow-up time. post-core application will be completed at the seventh day after postoperative pain evaluation.
31191|NCT03942094|Drug|Nilotinib|"Nilotinib (Tasigna ®), capsules of 150 mg~Nilotinib 2 capsules of 150 mg, orally, twice daily"
56911|NCT03739619|Drug|Gemcitabine|Given IV
31204|NCT03941990|Drug|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
31205|NCT03941990|Other|Placebo|inhale medical air (22% O2 - 78% N2)
31206|NCT03941977|Device|Percutaneous introduction of cannula|An 8 gauge cannula is introduced at the site of the bone marrow lesion. The introduction of the cannula is guided by fluoroscopy.
31207|NCT03941977|Diagnostic Test|Magnetic resonance imaging|MRI scans will be performed on a 1.5 T (Signa Excite HD, GE Healthcare, Waukesha, WI, USA) and a specific knee coil (HD TRKnee 8 Ch High Resolution Knee Array) will be used.
31208|NCT03941977|Biological|Bone Grafting|A bone substitute consisting of calcium phosphate will be injected through the cannula, previously inserted, filling the area of the bone marrow lesion. GRAFTYS HBS® (Graftys, Aix en Provence, France) will be used.
31209|NCT03941964|Drug|venetoclax|tablet; oral
31210|NCT03941964|Drug|azacytidine|infusion; subcutaneous or intravenous
31211|NCT03941964|Drug|decitabine|infusion; intravenous
31212|NCT03941951|Behavioral|Non-impositive Program for Optimizing the Use of Antimicrobials|Quasi-experimental intervention through the development of a Program for Optimizing the Use of Antimicrobials in the participating hospitals. The intervention will consist of the development of a consensus guide on the use of new antibiotics, its dissemination in Andalusian hospitals and an audit on the prescription of new antibiotics.
31213|NCT03941938|Procedure|Cyanoacrylate reinforcement|Anastomosis Reinforcement with with nebulization of 1cc of glue on the anastomosis line
31214|NCT03941938|Procedure|No reinforcement|Nothing applied on the anastomosis line
31215|NCT03941925|Dietary Supplement|Prebiotic fructans|Prebiotic group receiving the prebiotic fructans in two doses during the 4-week intervention period.
31216|NCT03941925|Dietary Supplement|Non-prebiotic maltodextrin|Placebo group receiving the non-prebiotic maltodextrin in two doses during the 4-week intervention period.
31217|NCT03941899|Other|Levobupivacaine in QLB II|Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
31218|NCT03941886|Other|Low-dose aspirin in women with high risk of preeclampsia|Low-dose aspirin 150-162 mg/night or 100 mg/night if body weight <40 Kg, from <15 weeks till 36 weeks or, in the event of early delivery, at the onset of labor
31219|NCT03941873|Drug|Sitravatinib|Study subjects will receive sitravatinib capsule once daily
31220|NCT03941873|Drug|Sitravatinib plus Tislelizumab|Study subjects will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
31221|NCT03941873|Drug|Sitravatinib|Study subjects will receive sitravatinib capsule once daily.
31222|NCT03941873|Drug|Sitravatinib and tislelizumab|Study subjects will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
31223|NCT03941873|Drug|Sitravatinib and tislelizumab|Study subjects will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
31224|NCT03941873|Drug|Sitravatinib and tislelizumab|Study subjects will receive sitravatinib capsule once daily and in combination with tislelizumab IV once every 3 weeks.
31225|NCT03941860|Drug|Ixazomib|Given PO
31226|NCT03941860|Drug|Ixazomib Citrate|Given PO
31227|NCT03941860|Drug|Lenalidomide|Given PO
31228|NCT03941860|Other|Placebo|Given PO
31229|NCT03941860|Other|Quality-of-Life Assessment|Ancillary studies
31230|NCT03941860|Other|Questionnaire Administration|Ancillary studies
31231|NCT03941847|Other|music|listening music
31232|NCT03941834|Drug|Rimegepant|BHV3000 (rimegepant) 75mg tablet
31233|NCT03941834|Drug|Placebo|Placebo
31234|NCT03941821|Drug|Glecaprevir/Pibrentasvir|Chronic hepatitis C patients will be given Glecaprevir/Pibrentasvir treatment
31235|NCT03941808|Drug|Glisodin tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
31236|NCT03941808|Drug|Placebo tablet|4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
31237|NCT03941795|Biological|JS001(Toripalimab Injection)|recombinant humanized anti-PD-1 monoclonal antibody injection (JS001)
31238|NCT03941795|Drug|Axitinib|Axitinib is an oral, potent, multitarget tyrosine kinase receptor inhibitor.
31239|NCT03941782|Drug|Alpelisib|As a single agent, alpelisib will be administered at a starting dose of 350 mg orally once daily on a continuous dosing schedule and can be adjusted for toxicity per the recommendations in this protocol. No pretreatment will be given prior to the medication.
31240|NCT03941769|Biological|Recombinant Interleukin-7|Given IM or SC
31241|NCT03941756|Drug|Indocyanine Green|Given IV
31242|NCT03941756|Procedure|Lymphangiography|Undergo lymphangiography
31243|NCT03941756|Procedure|Lymphovenous Bypass|Undergo LVB
31244|NCT03941743|Drug|Fingolimod|Given PO
31245|NCT03941743|Drug|Fingolimod Hydrochloride|Given PO
31246|NCT03941743|Other|Questionnaire Administration|Ancillary studies
31247|NCT03941730|Biological|Therapeutic Estradiol|Given PO
31248|NCT03941717|Other|Mindfulness-Based Condition|Each script for the mindfulness-based intervention was slightly modified to fit the context of a venipuncture, and begins with instructions to take deep breaths. Both scripts aim to cultivate present moment awareness of experiences, curiosity, nonjudgement, and acceptance of experiences as they unfold. In particular, the scripts ask that the participant visualize their worries and feelings as a cloud in the sky, and probes for curious thoughts about these experiences. The temporary nature of sensations is described, and the participant is asked to keep this openness and curiosity during the venipuncture.
31249|NCT03941717|Other|Unfocused attention Condition|Each script for the unfocused attention task instructs participants to allow their mind and thoughts to roam. The aim is to encourage the participant to continue thinking and mind wandering as they typically would.
31250|NCT03941704|Dietary Supplement|Pulse-based diet|Low Glycemic Index
31251|NCT03941704|Dietary Supplement|Regular diet|Moderate Glycemic Index
31252|NCT03941691|Device|Fully Absorbable VSD Occlusion System|Under echocardiography guided treatment of VSD with a novel fully degradable clolsure system
31253|NCT03941691|Device|VSD Occluder|Under echocardiography guided treatment of VSD with commercially available occluder.
31258|NCT03941626|Biological|CAR-T/TCR-T cells immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
31259|NCT03941613|Procedure|SEEG guided RF-TC|SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.
31260|NCT03941613|Procedure|Anterior temporal lobectomy|classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
31261|NCT03941600|Behavioral|Community-based Exercise Intervention group (CBE)|The CBEI group will receive 36 (60-90 minute) one-on-one, formally directed exercise sessions by trained staff over 12 weeks. By the end the goal is to have the participants guiding their own regimens. Personalized sessions will be created for each participant based on their fitness goal(s) and preferences. Each session will include vitals, pain assessment, warm-up, stretching, cardiovascular, and strength exercises and cool-down. The participants will be monitored to ensure they are achieving at least 30 minutes of moderate-to-vigorous exercise 3 times a week. Activity monitors will also be worn to capture intensity data. At the end of each session, participants will describe their likes and dislike as well as what they gained and what they suggest for improvement. At the end of each session, the trainer will rate the participant's perceived participation during the session (1-6) using the Pittsburgh Rehabilitation Participation Scale.
31262|NCT03941600|Behavioral|Exercise Education Control group (EEG)|The EEG group will complete an intervention that consists of a one-on-one, hour-long educational session orienting participants to an online resource center, the National Center on Health, Physical Activity, and Disability (NCHPAD). NCHPAD promotes health and well-being for PwD through resources such as adapted exercise videos, information on accessible fitness equipment, personalized exercise videos tailored to PwD, and an individualized 14-week exercise program. Participants will be given an overview of NCHPAD and asked to identify resources of interest on the website. Each participant will be asked to use resources on NCHPAD to engage in physical activity for 12 weeks. Each participant will receive a weekly phone call to inquire about their physical activity, exercises engaged in, RPE during exercise, and whether any resources were used.
31263|NCT03941587|Drug|Aflibercept|Aflibercept dosage of 2mg
31264|NCT03941587|Drug|Verteporfin|Verteporfin for intravenous infusion( 6mg/m2)
31265|NCT03941587|Radiation|Laser light|Dosage rate of 25mJ/cm2
31266|NCT03941574|Drug|HLX10|HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. The excipients include 0.95 mg/mL citric acid (citric acid monohydrate), 4.56 mg/mL sodium citrate (sodium citrate dihydrate), 3.0 mg/mL sodium chloride, 30.0 mg/mL mannitol and 0.20 mg/mL polysorbate 80 (tween 80), with pH of 5.5.
31267|NCT03941561|Drug|S-1 for 9 months|S-1 for 9 months after D2 resection
31268|NCT03941561|Drug|S-1 for 1 year|S-1 for 1 year after D2 resection
31269|NCT03941548|Drug|CTP-543 QD Dose Regimen|24 mg once-daily (QD)
31270|NCT03941548|Drug|CTP-543 BID Dose Regimen|12 mg twice-daily (BID)
31271|NCT03941535|Drug|Vitamin K|Administration of intravenous Vitamin K in doses of 10mg/day, 5mg/day or 2mg/day
31272|NCT03941522|Other|Early discharge from hospital|Patients randomized to the group 23-hour stay will be discharged on the day after their surgery if they meet the discharge criteria.
31273|NCT03941509|Behavioral|Antimicrobial stewardship|Education, guidelines, communication tools and audit and feedback
31274|NCT03941496|Drug|Azacitidine Injection [Vidaza] - Phase A Group|3 TB subjects, that have become culture and smear negative after 6 months of successful ATT, will receive a cycle of AZA (SQ 75mg/m2 for 5 days). If a study participant experiences dose limiting toxicity (DLT; defined below), then 3 additional participants will be added to the current time point (n=6). If only 1 of 6 participants experience DLT/IRIS at a given time point, the study will proceed to the earlier time point. If at least 2 of 6 patients experience a DLT at a time point, then the study will not proceed to the next phase (Phase B).
31275|NCT03941496|Drug|Azacitidine Injection [Vidaza] - Phase B Group|3 TB subjects, that have become culture and smear negative after 4 months (+/- 14 days) of successful ATT, will receive a cycle of AZA (SQ 75mg/m2 for 5 days). If a study participant experiences dose limiting toxicity (DLT; defined below), then 3 additional participants will be added to the current time point (n=6). If at least 2 of 6 patients experience a DLT at a time point, then the study will not proceed to the next phase (Phase C).
31276|NCT03941496|Drug|Azacitidine Injection [Vidaza] - Phase C Group|3 TB subjects, that have become culture and smear negative after 8-10 weeks of successful ATT, will receive a cycle of AZA (SQ 75mg/m2 for 5 days). If a study participant experiences dose limiting toxicity (DLT; defined below), then 3 additional participants will be added to the current time point (n=6). If at least 2 of 6 patients experience a DLT at a time point, then the study will not proceed to the next phase (Phase D).
31277|NCT03941496|Drug|Azacitidine Injection [Vidaza] - Phase D Group|21 TB subjects, that have become culture and smear negative after 8-10 weeks of successful ATT, will receive a cycle of AZA (SQ 75mg/m2 for 5 days).
31278|NCT03941483|Drug|ASP1128|Intravenous
31279|NCT03941483|Drug|Placebo|Intravenous
31280|NCT03941457|Biological|BiCAR-NK cells (ROBO1 CAR-NK cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
31281|NCT03941444|Drug|ANAVEX2-73|Liquid oral solution
31282|NCT03941444|Drug|Placebos|Liquid oral solution
31283|NCT03941431|Drug|Jueyin granules|Jueyin granules p.o. once a day for 8 weeks.
31284|NCT03941431|Device|moving cupping therapy|Moving cupping therapy three times per week for 8 weeks.
31285|NCT03941431|Device|NB-UVB therapy|NB-UVB phototherapy three times per week for 8 weeks.
31286|NCT03941431|Drug|Jueyin placebo granules|Jueyin placebo granules p.o. once a day for 8 weeks.
31287|NCT03941431|Device|moving cupping placebo therapy|Moving cupping placebo therapy three times per week for 8 weeks.
31288|NCT03941431|Device|NB-UVB placebo phototherapy|NB-UVB placebo phototherapy three times per week for 8 weeks.
31289|NCT03941418|Dietary Supplement|Boulardii|Patients will be administered with formulation containing 500 mg of Saccharomyces boulardii and 10 mg of Vitamin D3 once daily, as an addition to their standard therapy.
31290|NCT03941418|Dietary Supplement|Placebo|Patients will be administered with placebo of same appearance, colour and taste once daily.
31291|NCT03941405|Drug|Albumin treatment|one dose per day of a 40g albumin g/l gram(s)/litre for 10 days. resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
31292|NCT03941366|Procedure|Standard of care chemotherapy with the change for avoidance of extensive surgery|All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.
31293|NCT03941353|Other|Usual care|Benchmark study with retrospective patient analysis evaluating the actual care patients with a fragile hip fracture receive
31294|NCT03941340|Drug|[14]-AST2818|Volunteer will receive a single oral dose of 80 mg /100 u Ci [14C]-AST2818 as a solution on Day 1
31295|NCT03941327|Device|AxoGuard Nerve Cuff|A porcine collagen implant will be used to make a protective sheath around the participant's exposed spinal accessory nerve during surgery. This will be performed by physically wrapping the exposed nerve with the implant and suturing the ends together. The goal is to protect nerve from adhesions and compression in the absence of normal protective lymphatic soft tissue.
31296|NCT03941314|Device|Supera® Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
31297|NCT03941314|Device|EverFlex™ Self-Expanding Peripheral Stent System|The index procedure is placing a selfexpandable stent at a femoro-popliteal location. The way the stenosis or occlusion is traversed is not part of the study. It is mandatory to prepare then the vessel with PTA (at least the size of the stent) and thereafter insert the stent. Post-PTA can be performed with same balloon, but post-PTA is not mandatory to be performed.
31298|NCT03941301|Device|Light therapy|Participants will be exposed to bright treatment light or red light 30 minutes every day for 4 weeks.
31299|NCT03941288|Drug|Cannabidiol|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
31300|NCT03941288|Other|placebo|"Cannabidiol and the matching placebo solution (excipients alone) will be provided in identical 100ml amber glass bottles. At the end of the treatment period, the treatment solutions will be tapered (10% volume each day) over 10 days.~In accordance with Food and Drug Administration guidance, prior to starting treatment and at end of 1 month treatment, we shall obtain serum transaminases (alanine and aspartate) and total bilirubin levels. These tests will also be performed if patient develops clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, or jaundice and/or dark urine); if such features develop the treatment will be interrupted or discontinued."
31301|NCT03941275|Diagnostic Test|Bi-plane fluoroscopy|In vivo acquisition of biplane cine radiographic images of the market released Medtronic SelectSecure 3830 pacing lead
31302|NCT03941262|Drug|autologous natural killer cells|Biological: SNK01
31303|NCT03941236|Drug|dasiglucagon|Glucagon analog
31304|NCT03941223|Procedure|PECSII and paravertebral blocks|Regional anesthesia for mastectomy outcomes
31305|NCT03941210|Other|Detection of molecular Biomarkers|MicroRNA expression profile analysis by flow cytometry
31306|NCT03941197|Behavioral|Ready and Healthy for Kindergarten Family Literacy program|Participants will participate in 8 parent-child health-themed literacy workshops. Participants will receive 2-3 text messages per week for 8 weeks.
31307|NCT03941171|Procedure|PAO|PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.
31308|NCT03941171|Other|Usual care after PAO|Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.
31309|NCT03941171|Other|PRT|4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
31310|NCT03941145|Behavioral|Reduced-Exertion High-Intensity Interval Training (REHIT)|REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
31311|NCT03941132|Drug|Ustekinumab|"Week 0: Loading dose of 6mg/kg Ustekinumab Intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg Ustekinumab subcutaneously."
31312|NCT03941132|Drug|Placebo|"Patients allocated to receive placebo will receive respective amounts of a saline-placebo at the same intervals.~Week 0: Loading dose of 6mg/kg saline intravenously.~Weeks 8, 16, 24, 32, 40, and 48 (6 visits): 90mg saline subcutaneously."
31313|NCT03941119|Other|VR-therapy|Wearing a Virtual Reality head mounted device allows the user to become immersed in a virtual environment. We have assembled a library of 3-10 minute 360-degree films from a variety of nature settings. The VR films were intentionally chosen to be calming in distinctive ways, as supported by the literature around nature visualization and wellbeing. By varying 1) the lengths of the films (3, 5, and 10 minutes), 2) the types of natural elements (greenery, earth, sky, water), 3) distance of view (close-ups, vistas), 4) motion (flowing water, wind in trees), 5) sound, and 6) presence of different elements (humans/animals, scenery, urban sites, etc.), the content provides a wide range of attributes that can be collaboratively selected by the individual, caregiver, or health care provider for each individual. We will display these films on commercially available VR equipment and will provide audio matching the film using commercially available headphones.
31370|NCT03940586|Drug|Letermovir capsule|Capsule (granules) administered orally based on age/weight
31314|NCT03941106|Device|Accelerated repetitive transcranial magnetic stimulation|Subjects will be given accelerated left sided rTMS and randomized to more of the same accelerated rTMS if not meeting remission criteria for depression or a different type of rTMS on the right side
31315|NCT03941093|Drug|Pamrevlumab + Gemcitabine + Nab-paclitaxel|"Drug: Pamrevlumab is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion. The dose level is 35 mg/kg.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 1000 mg/m2.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 125 mg/m2."
31316|NCT03941093|Drug|Placebo + Gemcitabine + Nab-paclitaxel|"Drug: Placebo is administered on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion.~Drug: Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 1000 mg/m2.~Drug: Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 125 mg/m2."
31317|NCT03941080|Diagnostic Test|fecal sample|patients will collect fecal samples at home prior to treatment and at 3 months after start of treatment at the time of response evaluation using a standard stool-collection-kit.
31318|NCT03941080|Behavioral|questionnaire|At the day of stool sampling, patients fill out a brief questionnaire about established factors that can change the microbiome such concurrent use of antibiotics and proton pump inhibitors.
31319|NCT03941080|Diagnostic Test|Blood sample|4 tubes of blood are collected prior to treatment and at 3 months after start of treatment at the time of response evaluation and sent to the UMCG for storage.
31320|NCT03941067|Other|Pre-event massage|Five minutes massage, combining superficial and high-frequency techniques of massage applied with the therapist hands
31321|NCT03941054|Other|Pressure Release|Subjets receive digitopressure during 90 seconds for the treatment of the Myosfascial Trigger Points
31322|NCT03941041|Behavioral|Prenatal Yoga Course|participation in a 12-week prenatal yoga course (optimally), 1 session in duration of 90 minutes per week
31323|NCT03941028|Device|3D printed titanium implant|The 3D printed titanium implant is fabricated by related companies. And some implants have been used in spinal disease in our hospital.
31324|NCT03941002|Diagnostic Test|Assesment of diaphragm function|Diaphragm function will be assessed by standard mechanical parameters as assessed by esophageal and gastric pressure measurement, as well as by an ultrasonographic examination performed by an expert operator and by the continuous ultrasonographic assessment provided by the device under investigation
31325|NCT03940989|Other|HABIT-ILE|Goal-directed, task-specific training for both the upper (UE) and lower extremity (LE) and postural control.
31326|NCT03940976|Drug|Afatinib|Afatinib is orally administered at 40mg Qd of each 28 day cycle.
31327|NCT03940963|Device|AxoGuard® Nerve Cap|Entubulation of the nerve stump into the AxoGuard® Nerve Cap following surgical excision of symptomatic neuroma
31328|NCT03940963|Procedure|Standard Neurectomy|Surgical excision of symptomatic neuroma
31329|NCT03940950|Biological|Autologous Adipose-Derived SVF (Stromal Vascular Fraction)|60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.
31330|NCT03940950|Drug|Placebo|Saline control that contains no active ingredient
31331|NCT03940924|Other|Training program|High Intensity Interval Training + Resistance Training (HIIT + RT)
31332|NCT03940911|Other|Measurement of aerobic exercise on cycloergometer|"The incremental effects tests will be performed in a service specialized in the exploration of the exercise (physiology or cardiology according to the centers) in a spacious and air-conditioned room, in the presence of a medical specialist. exercise and close to the resuscitation equipment.~Before the test, weight and height will be collected. Information on the conduct of the test will be given to the patient. A multi-derivation ECG recording will be detected throughout the duration of the test and followed by a physician experienced in the ECG effort.~O2 saturation by oximetry of hens will be recorded continuously. Blood pressure will be recorded at each level. The collection of expired gases in the face mask whose tightness will be verified to measure the fractions inspired and expired in O2 and CO2 (Sensor Medics Vmax229, Yorba Linda, CA, USA) and calculations VO2 max and VCO2.~Maximal power (W max) will be recorded Patients will be encouraged during the test."
31333|NCT03940898|Device|repetitive transcranial magnetic stimulation|"There are two types of stimulation equipment, one is the transcranial magnetic stimulator model Magpro X100 produced by Danish Medtronic, and the other is the CCY-I TMS stimulator produced by Wuhan Eride, model B9076. The stimulating magnetic head uses an 8 shaped coil, and the stimulation site is the cerebellar vermis (ie, 1 cm below the occipital bulge), and the stimulation intensity is 100% of the motor threshold.The base frequency of the iTBS mode is 5 Hz, and one short burst stimulus occurs every 200 milliseconds. In each short array, three single pulses with a frequency of 50 Hz are buried, and each 10 short burst stimulation intervals are 8 seconds, for a total of 200 short burst stimulations. The total number of stimulation pulses is 600 per day.It takes 3 minutes and 20 seconds to complete one intervention. All participants were intervened once a day for 5 times a week for 2 weeks for a total of 10 times."
31334|NCT03940885|Procedure|Erector spinea plane block group|Which will receive ultrasound-guided erector spinea plane block bilaterally and the local anesthetic injected will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
31335|NCT03940885|Procedure|Transversus abdominis plane block|Which will receive ultrasound-guided Transversus Abdominis plane block bilaterally and the local anesthetic used will be total volume 25 ml on each side consisting of 15ml of 0.5% plus 5 ml 2% lidocaine HCL plus 5 ml saline
31336|NCT03940885|Procedure|Control group|this group will receive only standard general anesthesia
31337|NCT03940872|Diagnostic Test|Self-questionnaire 3PDQ|"Visit 1 : - The patient will have to complete the 3PDQ self-questionnaire. - The investigator will conduct an interrogation and a neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visit 2 : - The patient will have to complete the 3PDQ self-questionnaire.~- An investigator, obligatorily different from the investigator of the visit 1, will conduct to the same interrogation and the same neurological examination in order to ask or not the diagnosis of parkinsonian primary pain, without knowing the result of the 3PDQ.~Visits 1 and 2 can be made on the same day. In this case the patient will fill the 3PDQ self questionnaire only once."
31338|NCT03940859|Device|intracranial stent, flow diverter and coils|Endovascular treatment was performed under general anesthesia. Patients were treated with internal trapping, stent-assisted coiling or flow diverter as appropriate. After the procedure, patients treated with conventional stent were given 75mg/d clopidogrel for 6 weeks and 100mg/d aspirin for 6months, while patients treated with flow diverter were given 75mg/d clopidogrel for 3 months and 100mg/d aspirin thereafter. All patients were recommended to undergo a 6-month angiographic follow-up.
31339|NCT03940846|Diagnostic Test|Virtual biopsy|Radiomics -the high throughput extraction of quantitative features from medical imaging- extract features that might potentially decode biologic tumor information, which might ultimately reduce the need to use invasive procedure, such as tissue biopsy.
31340|NCT03940833|Biological|BCMA CAR-NK 92 cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
31341|NCT03940820|Biological|ROBO1 CAR-NK cells|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
31342|NCT03940807|Drug|11.25mg GnRH agonist|"Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle. Ovarian stimulation will be started after 90 days desensitization.~After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
31343|NCT03940807|Drug|0.1 mg GnRH agonist|"Long protocol group women will receive a 15-days pituitary down-regulation protocol that consists of daily subcutaneous injection of 0.1mg of GnRH agonist (triptorelin acetate) started on the luteal phase of their menstrual cycle.~Ovarian stimulation will begin after 15 days desensitization. After the desensitization period, all patients will undergo standardized ovarian stimulation, follicular aspiration, fertilization of all oocytes using either standard insemination or ICSI according to the features of sperm examination, fresh embryo transfer and luteal phase support."
31344|NCT03940807|Drug|25 µg transdermal oestradiol|Add back therapy (transdermal estradiol, 25μg twice a week) will be administrated throughout down-regulation period.
31345|NCT03940794|Other|Verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. A transabdominal Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
31346|NCT03940781|Behavioral|comprehensive rehabilitation|oropharyngeal rehabilitation, cardiopulmonary rehabilitation, and therapeutic exercise
31347|NCT03940768|Dietary Supplement|Lactobacillus plantarum 299v|Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.
31348|NCT03940768|Dietary Supplement|Placebo|Administration of placebo in cancer patients who receive home enteral nutrition.
31349|NCT03940742|Drug|Tirzepatide|Administered SC
31350|NCT03940729|Drug|Chlorhexidine Topical|In the Malmö needle exchange program, people who inject drugs (PWID) are repeatedly screened for S aureus colonization during one year. Those colonized will repeatedly shower with chlorhexidine during the following year. The infection frequency will be compared between the two periods.
31351|NCT03940716|Behavioral|IntERact|"This intervention integrates motivational interviewing, cognitive behavioral skills therapy, and care management into a single behavioral counseling intervention delivered by a therapist. The intervention is delivered either in the emergency department or remotely over the subsequent 5 weeks for a total of six therapy sessions (~30 min each). A smartphone app is also loaded on the participant's phone and delivers additional behavioral intervention content, including tailored MI+CBT messages (tailored by daily survey responses), one-touch pro-social contact encouragement, psycho-educational materials, GPS-enabled just-in-time tailored alerts, and facilitated access to care management resources."
31352|NCT03940703|Drug|Tepotinib|Participants will be administered Tepotinib orally once daily at an initial dose of 500 milligram (mg). A safety monitoring committee (SMC) may decide to confirm or adapt the dose.
31353|NCT03940703|Drug|Osimertinib|Participants will receive Osimertinib at a dose of 80 mg orally once daily.
31354|NCT03940690|Drug|Anti-VEGF injections of bevacizumab|5 anti-VEGF injections of bevacizumab at months 0, 1, 2, 4 and 6, combined with laser at months 2, 4 and 6 (laser optional at month 9)
31355|NCT03940690|Device|Laser|3 sessions of laser at months 0, 1 and 2, completed if needed with laser at months 4, 6 et and 9
31356|NCT03940677|Procedure|Brain MRI|3 Tesla brain MRI for structural and perfusion evaluation, resting state analysis and functional MRI
31357|NCT03940677|Procedure|TMS-EEG|Transcranial magnetic stimulation (TMS) coupled with electroencephalogram (EEG) study
31358|NCT03940677|Behavioral|Behavioral and cognitive battery|Emotional, attentional and behavioral assessment using predefine scales and measures
31359|NCT03940677|Other|Clinical evaluation and clinical scales|Neurological evaluation, ophthalmologic assessement, Montreal cognitive assessment (MoCA), movement disorder society (MDS)- UPDRS
31360|NCT03940664|Other|immunohistochemistry on Formalin fixed and paraffin embedded blocks|
31361|NCT03940651|Drug|Spinal Anesthesia|Patients will be randomized to type of anesthesia
31362|NCT03940651|Drug|General Anesthetics|Patients will be randomized to type of anesthesia
31363|NCT03940638|Other|Data collection|Data collection
31364|NCT03940625|Diagnostic Test|Cardiac MRI and echocardiography, laboratory parameters|Cardiac MRI including cine imaging (volumetric determination of LV-EF), late gadolinium enhancement, strain analysis, T1 mapping and T2 mapping Echocardiography including 3D-EF, diastolic function and strain analysis Determination of laboratory parameters including cardiac enzymes (Troponin T and high sensitivity Troponin T) and cardiac markers (BNP and NT-pro BNP)
31365|NCT03940612|Dietary Supplement|STP4 (product with probiotics)|STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
31366|NCT03940612|Dietary Supplement|Placebo (product without probiotics)|Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
31367|NCT03940599|Device|step counter|Fitbit
31368|NCT03940599|Device|weight scale|BodyTrace weight scale
31369|NCT03940599|Device|step counter with screen covered|Fitbit with screen covered
31374|NCT03940560|Device|Duramesh Suturable Mesh|Use of Duramesh Suturable Mesh for internal load bearing closures
31375|NCT03940547|Other|Provision of flour|Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months
31376|NCT03940547|Other|Promotion of flour|Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months
31377|NCT03940534|Device|TAD|TAD is a device used to aid medication adherence.
31378|NCT03940521|Other|Bioclinical evaluation|50-100ml blood extracted for flow cytometry and qPCR
31379|NCT03940508|Behavioral|Making Connections Intervention|The MCI is a one to two session intervention that addresses barriers to mental health treatment and helps adolescents build skills to get the most out of their treatment experience. It is designed to be delivered by a trained clinician in conjunction with an evidence-based treatment.
31380|NCT03940508|Behavioral|IPT-A|IPT-A is a time-limited, manualized treatment for depression focused on maladaptive communication patterns and interpersonal interactions.
31381|NCT03940482|Behavioral|Time Restricted Eating As Treatment (TREAT) for Diabetes.|Participants will skip a meal every day and maintain a water only fast for 16 hours. A fasting diary is kept to track hours of fasting. Participants will follow this new pattern of eating for 12 weeks. They will visit the doctor's office at least 3 times in the course of the study and will be followed up with anthropometry (weight, BMI and waist circumference) and biochemical markers pertaining to Diabetes during the study visits. At 24 weeks, a follow up phone call will be made to check self-reported compliance to intermittent fasting.
31382|NCT03940469|Drug|Saline|2 ml normal saline
31383|NCT03940469|Drug|Dexamethasone Injection|8 mg dexamethasone
31384|NCT03940469|Drug|Dexmedetomidine Hydrochloride|100 microgram dexmedetomidine
31385|NCT03940456|Other|Questionnaire|Questionnaire mainly focusing on low back pain, pain related disorders, psychosocial factors and the use of alternative treatments for pain
31386|NCT03940430|Drug|Lactoferrin|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
31387|NCT03940430|Drug|Ferrous sulfate|This study aims to compare the efficacy of lactoferrin versus iron supplementation versus two combined supplementation on iron deficiency anemia in female medical Ain Shams students by using iron profile.
31388|NCT03940404|Drug|Anlotinib Hydrochloride|Anlotinib will give orally, once daily on days 1-14 of a 21-day cycle. Dose reduction is allowed.
31389|NCT03940391|Drug|Chlorpheniramine and midzolam|Administration of chlorpheniramine injection as an adjunctive sedative during sedative endoscopy.
31390|NCT03940391|Drug|midzolam|Administration of midazolam as a sedative during sedative endoscopy as routine clinical practice.
31391|NCT03940378|Drug|Levamisole Hydrochloride|Levamisole Hydrochloride Levamisole Hydrochloride 25mg/tablet; 150mg/d; po;
31392|NCT03940378|Drug|Anlotinib Hydrochloride Capsules|Anlotinib Hydrochloride Capsules Anlotinib Hydrochloride Capsules 12mg / capsule; 12mg/d; po;
31393|NCT03940365|Device|Fetal Life tocometer device|The fetal life tocometer device is a uterine contraction monitor which is less expensive to manufacture than existing contraction monitor devices and which pairs with a smart device rather than a bulky output device.
31394|NCT03940352|Drug|HDM201|Capsule
31395|NCT03940352|Biological|MBG453|LIVI (Liquid in vial) Concentrate for Solution for infusion
31396|NCT03940352|Drug|Venetoclax|Tablet
31397|NCT03940339|Other|Suboccipital myofascial release|The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.
31398|NCT03940339|Other|Conventional Physiotherapy|The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
31399|NCT03940326|Drug|Levetiracetam|Levetiracetam with initial dose of 500 mg per 12 hours which will be increased 500 mg/week to target dose of 2000 mg/day and the dose could be increased to 3000 mg/day if seizures recurred
31400|NCT03940326|Drug|Valproate|Sodium valproate with initial dose of 500 mg/day which will be increased 500 mg/week to target dose of 1500 mg/day and the dose could be increased to 2000 mg/d if seizures recurred.
31401|NCT03940313|Procedure|Prolotherapy|Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
31402|NCT03940300|Dietary Supplement|Fresh organic vegetables|"Individual participation in this program will take 12 weeks, from screening and enrollment through evaluation. Once enrolled, visits will occur on a weekly basis to ensure that participants receive each week's dose of fresh organic vegetables. At an optional Visit 13, offered 6 months after Visit 1, an additional health screening will be conducted."
31403|NCT03940287|Other|Muscle Energy Technique|"Muscle energy technique will be given in two different position. For anterior in- nominate rotation and posterior in- nominate rotation patient position will be in supine lying position.~For weakened muscle,piriformis application the patient should be side-lying position, close to the edge of the table, affected side uppermost, both legs flexed at hip and knee.~The therapists stand facing the patient at hip level,then patient should be close enough to the edge of the table for the therapist to stabilize the pelvis against his trunk. The angle of hip flexion should not exceed 60°, and then places one hand on the contralateral ASIS to prevent pelvic motion, while the other hand is placed against the lateral flexed knee as this is pushed into resisted abduction to contract piriformis.~Isometric contraction should be hold for 3-5 second and that particular method will be repeated for 7-10 times."
31404|NCT03940287|Other|Kinesiotape application|"Kinesiotaping will be applied to piriformis muscle and Sacroiliac joint (SIJ). This tape will be applied in I shape to both sides of the spine from sacrum to Anterior Superior Iliac Spine. For SIJ taping same 5 cm KT tape will be used, it will be applied from below posterior sacroiliac spine to opposite side. Here patient should be in standing position.~For Piriformis application patient will be in side lying position where the affected leg will be placed uppermost with hip in flexion, adduction, and internal rotation , then the application will be performed. The base of the tape will be placed over contralateral part of sacrum and then make a Y strip with no tension will be attached over the greater trochanter of femur."
31433|NCT03940066|Device|Biomonitor-2 and Kardia mobile|Implantable cardiac monitor and Smart-phone based electrocardiogram recording
31405|NCT03940287|Other|Conventional physiotherapy|Hydro-collator pack will be used superior to the affected area for at-least 15 minute to reduce the stiffness. Hydocollator pack will be wrap twice with a thick towel and then it will be placed to the affected part.
31406|NCT03940274|Behavioral|walking training|Participants will receive three sessions a week of BWSTT with assistive training device for 8 weeks; a total of 24 sessions. The duration of each training session will an hour. During walk-training, the participant will wear a harness which is attached to an overhead motorized lift to provide body-weight support and to prevent the risk of falling.
31407|NCT03940261|Other|High Intensity Interval Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 10, 1-minute cycling intervals at 90% of peak power output, each separated by 1-min at 10% peak power output.
31408|NCT03940261|Other|Continuous Moderate Intensity Training|Participants will complete exercise training 3x/week for 10 weeks. Exercise will consist of 30-50 minutes of cycling at 60% peak power output.
31409|NCT03940248|Radiation|Proton Accelerated Partial Breast Irradiation|38.5 Cobalt Gray Equivalent (CGE) given over 10 fractions
31410|NCT03940235|Drug|Androgen deprivation therapy (ADT)|SBRT + ADT
31411|NCT03940235|Radiation|SBRT|SBRT to all radiological documented lesions (bone or lymphnodes)
31412|NCT03940222|Device|Interactive Binocular Treatment|The specified system which stimulate the fovea of the amblyopic eye directly by detailed and movable objects, while the fixation of the non- amblyopic eye will be focused on fixed targets.
31413|NCT03940222|Procedure|Patching Therapy|Patching of the dominant eye with better best corrected visual acuity
31414|NCT03940209|Behavioral|Basic needs navigation|Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
31415|NCT03940196|Device|NovoTTF-100L(O)|Patients receive continuous TTFields treatment using the NovoTTF-100L(O) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the abdomen/pelvis. The treatment enables the patient to maintain regular daily routine.
31416|NCT03940196|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 intravenous infusion will be administered weekly for 8 weeks and then on Days 1, 8 and 15 of each subsequent 28-day cycle.
31417|NCT03940183|Drug|Trelagliptin Succinate|the experimental group will use trelagliptin succinate 100 mg for 24weeks
31418|NCT03940183|Drug|Placebo Oral Tablet|the placebo Comparator groups use placebo oral tablet for 24weeks
31419|NCT03940170|Device|vistacam proof|Light fluorescence device
31420|NCT03940170|Other|ICDASII|visual examination
31421|NCT03940170|Procedure|fissurotomy|histological validation
31422|NCT03940157|Behavioral|Oh Happy Day Class - Still I Rise|one-time, 4-hour class focused on awareness of depression and healthy self-management strategies
31423|NCT03940144|Device|the enhanced flow-based hemodynamic parameters of the FloTrac/Vigileo device|Stroke volume variation (SVV)-guided fluid therapy
31424|NCT03940131|Drug|Panitumumab|FOLFOX6 regimen consists of 2-hour infusion of oxaliplatin (85 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFOX6 regimen will be repeated at 2-week intervals. FOLFIRI regimen consists of 2-hour infusion of irinotecan (180 mg/m2) and 2-hour infusion of leucovorin (400 mg/m2 ) on Day l, followed by 5-fluorouracil bolus (400 mg/m2) on Day 1 and 46-hour infusion (2.4 g/m2). FOLFIRI regimen will be repeated at 2-week intervals.
31425|NCT03940118|Device|Catheter secretion suctioning|Catheter secretion suctioning with prior nebulization of hypertonic saline
31426|NCT03940118|Combination Product|Secretion suctioning + hypertonic saline|Catheter secretion suctioning with prior nebulization of hypertonic saline
31427|NCT03940118|Device|Ins-exsufflation|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
31428|NCT03940118|Combination Product|Ins-exsufflation + Hypertonic saline|Application of a mechanical insufflation-exsufflation device for respiratory tract secretion suctioning
31429|NCT03940105|Behavioral|Packout|Each packout provided during 3 of the 4 snack patterns will contain a variety of foods to be consumed, ad libitum, throughout the remainder of the day following the standardized lunch. There are 3 different packouts that will be provided for 3 nonconsecutive weekdays (for a total of 9 packouts). Each packout contains the same calories and types of foods. However, they differ in packaging size and variety.
31430|NCT03940092|Other|MRI|"This is a prospective, non-randomised, exploratory study on healthy female volunteers (>18 years), and female patients (>18 years) diagnosed with primary breast cancer.~Healthy volunteers will be scheduled for an 23Na-MRI examination.~Patients scheduled for primary surgery will undergo an MR examination, involving 23Na-imaging prior to their planned surgery."
31431|NCT03940092|Other|PET/MRI|Patients undergoing neo-adjuvant chemotherapy will undertake up to two (2) combined PET/MR examinations with FDG and 23Na-MRI
31432|NCT03940079|Device|computer-based cognitive game (including 3 training tasks)|"First task was short-term memory training. Participants were instructed to memorize different colored circles with ordinal numbers which would disappear later. They triggered correct colored sensor in sequence according to their memory.~Second task was divided attention training. Different colored circles with ordinal numbers would not disappear this time.The participants should trigger correct colored sensor according to their sequence.~Third task was inhibitory function training. There were red and green lights, just like the traffic light, hung up at the upper left of the scene. Red light represented prohibition of triggering the colored sensor, while green light urged to trigger it. Yellow, red, blue and green circles showed up randomly and moved toward the beige region. When the circle came extremely closer to the beige region, the traffic light was randomized to lighten up red or green.The participants should judge and trigger the correct colored sensor."
31435|NCT03940053|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days. Treatment is continued until the levels of tumor marker dropped to normal
31436|NCT03940040|Other|Usual care|Usual Care
31437|NCT03940040|Other|High flow nasal oxygen|High flow nasal oxygen
31438|NCT03940027|Procedure|EUS-guided celiac plexus neurolysis|EUS-guided celiac plexus neurolysis (EUE-CPN) is an endoscopic ultrasound-guided injection of local anesthetics and neurodegenerative agents into the abdominal ganglion area through the gastric wall, so as to achieve irreversible damage of the abdominal nerve and interrupt the pain pathway of pancreatic cancer.EUS-CPN has the advantages of less trauma, higher technical success rate and lower risk of complications compared with traditional ct-guided CPN in vitro puncture.The data showed that eus-cpn was effective in the treatment of pancreatic cancer related persistent abdominal pain up to about 70%, significantly reducing the dosage of analgesics and improving the quality of life of patients with advanced pancreatic cancer.
31439|NCT03940014|Other|Data collection from standard follow up|"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."
31440|NCT03940001|Biological|Sintilimab|Other Name: (IBI308)
31441|NCT03940001|Drug|carboplatin/paclitaxel|carboplatin AUC 2/paclitaxel 50 mg/m2 weekly
31442|NCT03940001|Radiation|Radiation|IMRT or VMAT
31443|NCT03939988|Radiation|Photobiomodulation|Immediately after the installation of the separators, the subjects will be submitted to photobiomodulation. The laser will be infrared, in continuous mode with wavelength of 808 nm. The tip will be positioned perpendicularly in the mucosa, without exerting pressure. At each point 2J of energy will be irradiated for 20 seconds, totaling 12J per tooth, 6J on the buccal side and 6J of the lingual side of the teeth.
31444|NCT03939988|Radiation|Placebo photobiomodulation|In the placebo group, the same procedures will be made, but the laser will be turned off.
31445|NCT03939975|Drug|pembrolizumab or nivolumab or JS001|ICIs therapy of nivolumab (3 mg/kg, per 2 weeks) or pembrolizumab (2 mg/kg, per 3 weeks) or JS001 (240mg, per 3 weeks) was performed until the off-treatment criteria were met. For participants with stable disease or atypical progression to ICIs therapy, thermal ablation of radiofrequency ablation or microwave ablation was performed addtionally.
31446|NCT03939962|Drug|SHR1210 combined with FOLFOX|"SHR1210, iv, 200 mg d1, 30-minute intravenous infusion, repeated every 14 days.~mFOLFOX6:Oxaliplatin 85mg/m2 ivgtt 2h d1,5-fluorouracil 400mg/m2 iv d1,leucovorin 400mg/m2 ivgtt 2h d1,5-fluorouracil 2.4mg/m2 CIV 46h, repeated every 14 days Patients who have no disease progression and can tolerate surgery receive surgery. When the investigator believes that the patient is not suitable for continued medication or according to the RECIST 1.1 standard, the evaluation is PD and the medication is over. The PD-1 monoclonal antibody does not allow for reductions and can only delay or suspend medication."
31447|NCT03939949|Behavioral|High Mindfulness|"Those in the high mindfulness group will also receive questions about their current pain intensity and unpleasantness in both the morning and evening for six days. In order to emphasize the variability in pain, participants will receive these text messages on a variable schedule. In addition, they will sent instructions every morning to pay attention to variability in their pain throughout the day and asked to report on how their pain is changing over time as a part of each text message prompt."
31448|NCT03939949|Behavioral|Low Mindfulness|"Those in the low mindfulness group, who will receive receive two text messages per day (one at at 9am and one at 9pm) for six days, each prompting them to write about the activity they are currently engaged in. They will also be prompted with the 9pm text to report on their pain intensity and unpleasantness at that time."
31449|NCT03939949|Behavioral|Active Control|"Participants in the active control group will receive 2 text messages per day for six days (one at 9am and one at 9pm) asking them to report on the activity they are currently engaged in."
31450|NCT03939936|Other|Psoriatic measurements|Psoriasis Area and Severity Index (PASI) was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
31451|NCT03939936|Other|Non-surgical periodontal treatment|Non-surgical periodontal treatment was performed baseline and after 8 weeks. Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
31452|NCT03939936|Other|saliva samples|Saliva samples were taken from patients for the evaluation of proinflammatory cytokine baseline and after 8 weeks.
31453|NCT03939923|Drug|Rocuronium|Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.
31454|NCT03939923|Drug|Neostigmine|Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)
31455|NCT03939923|Drug|Glycopyrrolate|Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)
31456|NCT03939923|Drug|Sugammadex|Reversal with Sugammadex (2mg/kg)
31457|NCT03939910|Device|Pudendal Nerve Block needle in pre-packaged kits that include both the trumpet and the needle. The needle will limits its depth of penetration to 5 mm beyond the trumpet.|Patients will receive a pudendal nerve block injection on each side as previously described 5-10 minutes before the beginning of surgery. A tubular director that allows 1.0-1.5 cm of a 15-cm-long, 22-gauge needle to protrude beyond its tip will be used to guide the needle into the pudendal trunk at lesser sciatic foramen about 1 cm inferior-medial to attachment of the sacrospinous ligament to the ischial spine. The end of the director will be placed against the vaginal epithelium just beneath the tip of the ischial spine. The needle pushed beyond the tip of the director, and 5 ml of the anaesthetic solution will be injected. The needle advanced 1 cm posterior and lateral, and another 5 mL of the anaesthetic solution will be injected into this region.
31458|NCT03939897|Drug|Abemaciclib|Given PO
31459|NCT03939897|Drug|Copanlisib|Given IV
31460|NCT03939897|Drug|Copanlisib Hydrochloride|Given IV
31461|NCT03939897|Drug|Fulvestrant|Given IM
31462|NCT03939884|Drug|MuscleCare Topical Product|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
31463|NCT03939884|Drug|Voltaren Topical|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
31464|NCT03939884|Drug|Nivea, Topical Cream|Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
31465|NCT03939871|Drug|fluvestrant + oral vinorelbine|Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
31466|NCT03939858|Procedure|Cognitive Assessment|Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.
31467|NCT03939858|Diagnostic Test|Blood Collection|16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.
31468|NCT03939858|Diagnostic Test|Bioenergetic Profiling|Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
31469|NCT03939845|Radiation|RT|external- beam radiotherapy (EBRT)
31470|NCT03939845|Procedure|TACE|transarterial chemoembolization (TACE)
31471|NCT03939832|Other|Fraction of inspired oxygen level|A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
31472|NCT03939819|Device|ViSiGi® 3D suction calibration device|ViSiGi 3D®is a non-sterile, single patient use device. The device comprises a tube with a closed, rounded tip, and holes at the distal end. The proximal end of ViSiGi 3D® includes an integral suction regulator and vented On/Off valve.
31473|NCT03939819|Device|Esophagogastroduodenoscopy (EGD) calibration|Gastroscope is an illuminated optical, slender and tubular instrument (a type of borescope) used in esophagogastroduodenoscopy.
31474|NCT03939806|Drug|Oxytocin|To be given to Oxytocin group following the clamping of the umbilical cord
31475|NCT03939806|Drug|Carbetocin|To be given to Carbetocin group following the clamping of the umbilical cord
31476|NCT03939793|Behavioral|IMPaCT Community Health Worker|"Once a CHW receives notification of a struggling patient, the CHW will visit the patient at their home within 1-2 days to initiate the IMPaCT intervention.~Elements of the standard IMPaCT intervention: During the first home visit, the CHW will use an in-depth semi-structured interview guide to get to know patients holistically and assess for unmet socioeconomic needs. This allows patients to express goals in line with their own needs and preferences. These individualized goals will become the basis for tailored action plans. The CHW will then provide hands-on, tailored support for the remainder of the 24-week study period to help patients achieve their goals.~Additional elements to help patients cope with failure: In this study, we will test a refined version of IMPaCT that incorporates two behavioral techniques for coping with failure: positive affect induction and attribution retraining."
31477|NCT03939793|Behavioral|Digital health monitoring with financial incentives|Participants are encouraged to use their glucometer to check their blood glucose via bidirectional texting and lottery-based financial incentives, which both serve to reinforce self-monitoring behavior.
31478|NCT03939793|Other|Usual Care|Usual Care
31479|NCT03939780|Diagnostic Test|[F18]RO-948|Single radiotracer IV injection with subsequent emission scan
31480|NCT03939780|Diagnostic Test|[F18]MK-6240|Single radiotracer IV injection with subsequent emission scan
31481|NCT03939780|Diagnostic Test|[F18]AV1451|Single radiotracer IV injection with subsequent emission scan
31482|NCT03939767|Drug|Aflibercept (Eylea, BAY86-5321)|As prescribed by the treating physician according to the local label. No IVT aflibercept will be provided due to a nature of observational study
31483|NCT03939754|Behavioral|Dedalo project|Physical activity, healthy food, socialization and mental activity promotion
31484|NCT03939741|Biological|SVF Containg Autologous Non Expanded ADSC|5 ml of SVF containing Autologous Non Expanded ADSC will be injected intravenously and outcome will be observed over the period of 1(one) year.
31485|NCT03939728|Radiation|Chest radiography and lung ultrasound|We'll include all patients which have, during their stay in pediatric intensive care unit, in order to have a pleural or pulmonary diagnosis, a chest radiography and then a lung ultrasound, at less than 2 hours interval.
31486|NCT03939715|Biological|DermaPure®|Surgical intervention using DermaPure®
31487|NCT03939715|Procedure|native tissue|Surgical intervention using native tissue
31488|NCT03939702|Drug|BMS-986177|An orally administered anticoagulant to prevent and treat thromboembolic events
31489|NCT03939689|Drug|I-131-1095|I-131-1095 will be administered intravenously at 100 mCi for the initial therapeutic dose, and up to 3 additional dose(s) between 75 mCi - 100 mCi each, administered at least 8 weeks apart as determined by initial dosimetry evaluation and occurrence of dose-limiting events.
31490|NCT03939689|Drug|Enzalutamide|Enzalutamide will be given orally once daily as prescribed by the physician as standard of care.
31491|NCT03939663|Drug|misoprostol|misoprostol 2 tablets
31492|NCT03939663|Drug|Placebo|starch pills manufactured to mimic misoprostol 200 mg tablets
31493|NCT03939650|Device|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
56912|NCT03739619|Biological|Nivolumab|Given IV
31494|NCT03939637|Drug|Eltrombopag|"Starting dose for eltrombopag will be based on manufacturer recommendations, and drug will be titrated to effect per guidelines.~Children 1 to 5 years: Initial: 25 mg once daily~Children ≥6 years and Adolescents: Initial: 50 mg once daily (25 mg once daily for patients of East-Asian ethnicity [e.g., Chinese, Japanese, Korean, Taiwanese])~Dose should be titrated based on platelet response. Maximum dose: 75 mg once daily."
31495|NCT03939637|Drug|Steroids|Prednisone/Prednisolone 4mg/kg/day (Max 120 mg/day) x 4 day
31496|NCT03939637|Drug|IVIG|IVIG 1 g/kg x1 (no steroids for pre-medication or adjunctive therapy)
31497|NCT03939637|Drug|Rho(D) Immune Globulin|Anti-D globulin 75 mcg/kg x1 (no steroids for pre-medication or adjunctive therapy)
31498|NCT03939624|Drug|Sodium-glucose cotransporter 2 (SGLT2) inhibitors|Exposure to SGLT2 will be defined as a prescription for a SGLT2 inhibitor alone (canagliflozin, dapagliflozin, empagliflozin) or in combination with non-DPP4 inhibitor drugs at cohort entry date.
31499|NCT03939624|Drug|Dipeptidyl peptidase-4 (DPP-4) inhibitors|Exposure to DPP-4 will be defined as a prescription for a DPP-4 inhibitor (alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin) alone or in combination with non-SGLT2 inhibitor drugs at cohort entry date.
31500|NCT03939611|Other|Foot Reflexology|Reflexology is one of the complementary health approaches; it is based on systematic pressure and stimulation with fingers to energy points in feet and hands and is a topic nowadays studied. Reflexology argues that the reflex maps in the hands and feet with all of the parts of the body are in contact. The pressure applied to each point stimulates the circulation of blood and energy like a sensor, gives a sense of relaxation, provides homeostasis. With a touch that is a different way of communication with children, is supported to create physical awareness via reflexology techniques, and is provided healthy nutrition of the stimulated tissue.
31501|NCT03939611|Other|Placebo Foot Reflexology|Placebo reflexology was performed by touch without pressure to the same rotation and to the same points as foot reflexology application. It was performed only to compare foot reflexology with a placebo effect.
31502|NCT03939585|Biological|Cellular therapy product|"Cellular therapy product: Allogeneic transplant donor lymphocytes, depleted of TCR-αβ T cells and B cells; enriched for NK cells and TCRγδ T cells.~Infused using venous catheter on post-transplant Day 28 (+ 7 days).~Single infusion of entire lymphocyte product derived from two-blood volume leukapheresis (non-mobilized)."
31503|NCT03939572|Behavioral|Accurate step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.
31504|NCT03939572|Behavioral|Deflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count deflated by 40% (i.e., their step count multiplied by 0.6).
31505|NCT03939572|Behavioral|Inflated step count feedback|After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will see their step count inflated by 40% (i.e., their step count multiplied by 1.4).
31506|NCT03939572|Behavioral|Accurate feedback + mindset intervention|"After one week of baseline step count measurement, participants will receive the intervention. Starting day 8, participants' Apple Watches will start displaying their step count. In this arm, they will simply see their accurate step count.~Additionally, participants in this arm will receive a meta-mindset intervention in the first weekly survey on day 7, which consists of a series of videos and reflection exercises to teach participants about the power of mindsets and encourage them to choose adaptive mindsets that will benefit their health. There are also short booster reflection exercises in all subsequent daily and weekly surveys, reinforcing the message about adaptive mindsets."
31507|NCT03939559|Procedure|Static, dynamic and functional balance exercises|In the first group (G1), 4 exercise packages which include static, dynamic and functional balance exercises will be taught in the first part of exercise period for 4 weeks
31508|NCT03939559|Procedure|Static, dynamic and functional balance exercises with dual task|In the second group (G2), 4 exercise packages which include static, dynamic and functional balance exercises with cognitive or motor dual task will be taught in the first part of exercise period for 4 weeks.
31509|NCT03939546|Other|B. infantis EVC001|"Bifidobacterium longum subspecies infantis strain EVC001, designated a Foods for Special Dietary Use (FSDU)"
31510|NCT03939533|Drug|CUTAQUIG|Human normal immunoglobulin
31511|NCT03939520|Drug|pirfenidone and nintedanib|The experimental group will receive pirfenidone 2403 mg per day (at least 1602 mg) in combination with nintedanib 300 mg per day (at least 200 mg) during 24 weeks.
31512|NCT03939520|Drug|pirfenidone or nintedanib|The control group will switch from one monotherapy during 24 weeks: with pirfenidone 2403 mg per day (at least 1602 mg) or nintedanib 300 mg per day (at least 200 mg) to the other monotherapy (nintedanib in patients who received pirfenidone as first line therapy before inclusion and conversely).
31513|NCT03939507|Other|AEP score available to the treating physician|the treating physician knew the AEP score results
31514|NCT03939494|Behavioral|Telehealth Encounter|Contact will be made with participants via Face Time or Skype.
31515|NCT03939481|Drug|Chemotherapy|Given chemotherapy regimen
31516|NCT03939481|Other|Functional Assessment|Functional and sensory clinician assessments
31517|NCT03939481|Other|Questionnaire Administration|Patient and physician reported responses
31518|NCT03939468|Device|DES+DCB|A hybrid strategy is defined as overlapping or slightly (2-3 mm) superimposing a new generation DES implantation for a de novo lesion (located in the larger, more proximal part of the vessel) and DCB inflation for a concomitant de novo small vessel disease
31519|NCT03939455|Other|Mobile Augmented Screening tool|Tablet-based intervention
31553|NCT03939182|Drug|Abexinostat|Two doses of the abexinostat will be tested: 30 mg/m2 and 45 mg/m2 orally twice daily, 7 days/week given every other week during a 28-day cycle.
31554|NCT03939182|Drug|Ibrutinib|Ibrutinib will be given at the FDA-approved dose for mantle cell lymphoma (MCL) of 560 mg orally daily for 28 day cycle.
31555|NCT03939169|Other|Installation of a naso-gastric feeding tube|Insertion of the feeding tube with skin-to-skin contact or whilst being held in the mother's arms, or by using the four hands technique or by performing positional support with appropriate equipment
31520|NCT03939442|Procedure|Sleeve gastrectomy with jejunoileal anastomosis|The sleeve gastrectomy was performed first, after using a sealer and divider device to dissect the omentum away from the greater gastric curvature from approximately 5 cm proximal to the pylorus up to the angle of His. Excision of the fundus and the body of the stomach was then performed with a laparoscopic linear stapler upon a 36 French orogastric tube (bougie). An isoperistaltic side-to-side anastomosis between the jejunum (at 50 cm distal to the Treitz ligament) and the distal ileum ( at 200 cm proximal to the ileocecal valve) was then created using the same linear stapler with a blue cartridge (3.5 mm). A soft Penrose drain was left at the subdiaphragmatic space, and the abdominal wound was closed.
31521|NCT03939429|Drug|QPX2015|antibiotic
31522|NCT03939429|Drug|Placebo oral capsule|Placebo comparator
31523|NCT03939416|Other|Experimental|"STANDART~Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~Sophrology: mental control of insomnia and painful perception~Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease~POLD~Rhythmic transversal muscle mobilization in posterior chain musculature.~General vertebral decompression from the sacrum and pelvis~Metameric subcutaneous mobilization~Rhythmic vertebral mobilization from the spinous processes."
31524|NCT03939416|Other|Control|"STANDART~Physical exercise: degreed joint mobilization, self muscle elongation and postural correction.~Sophrology: mental control of insomnia and painful perception~Cognitive behavioral therapy: analysis of non-assertive relationship patterns or dependence, dysfunctional beliefs, as well as their consequences, psychoeducation of the disease. Strategies for pain management, anxiety, assertiveness and acceptance of the disease"
31525|NCT03939403|Drug|Time of administration of Corifollitropin Alfa|"The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The control grup will receive the treatment on the 5th day after the cessation of hormonal contraceptive use. The used treatment will be identical in both arms. The difference between the groups will be the moment of beginning of the stimulation as well as the later administration of more FSH activity.~The intervention grup will receive the treatment on the 7th day after the cessation of hormonal contraceptive use."
31526|NCT03939390|Drug|time of administration of Corifollitropin Alfa|The treatment will be identical in both arms. The difference between the arms is the moment of the Administration of Corifollitropin Alfa: follicular phase of the menstrual cycle (control group) vs. luteal phase of the menstrual cycle (study group).
31527|NCT03939377|Other|Questionnaire and treatment|EVA questionnaire every day for 7 days. treatment (real or simulated) at J3 and J5
31528|NCT03939364|Drug|SBS-101|Isotretinoin Oral-Adhesive Film
31529|NCT03939364|Drug|Placebo|Placebo
31530|NCT03939351|Diagnostic Test|OCT-angiography and SD-OCT|Performing an OCT-angiography and SD-OCT examination
31531|NCT03939338|Other|Treg levels and CMR results|This is an observational study. Exposure: Different Treg levels and CMR results.
31532|NCT03939325|Radiation|ESWL|The impact of different frequencies on pattern of disintegration of renal stones
31533|NCT03939312|Drug|Atogepant 60 mg|Tablet containing Atogepant 60 mg
31534|NCT03939299|Procedure|OCT|Patients with coronary chronic total occlusion received successful stenting. Optimal coherence tomography imaged immediately and at 9-12 months after the index procedure to explore long-term vascular response and healing profile.
31535|NCT03939286|Other|Clinical-neurological and neuropsychological tests|The tests include established standardized questionnaires and detailed clinical neuropsychological examinations (e.g., tests on cognition and perception). In order to avoid exercise effects in multiple examinations, so-called parallel procedures should be used.
31536|NCT03939286|Diagnostic Test|Blood sampling|Venous blood sampling (40 ml) is performed according to the usual criteria of sterile working at baseline and after intervention.
31537|NCT03939286|Other|Assessment of physical activity via fitness tracker/diary|All study participants, regardless of group classification, are randomly selected for a period of one week using Fitbit Charge 2® fitness trackers. The study participants are asked in this context to pursue their regular activity and to wear the bracelets for a week throughout. All study participants are asked to document their activities in a hand-written diary.
31538|NCT03939286|Other|MRI-examinations|Standard MRI-methods, Sodium MRI, Phosphor MRS, Wholebody-Fat-MRI
31539|NCT03939273|Drug|Vancomycin Oral|500 mg thrice per day for seven days
31540|NCT03939273|Drug|Metronidazole Oral|500 mg thrice per day for seven days
31541|NCT03939273|Drug|Ciprofloxacin Pill|500 mg twice per day for seven days
31542|NCT03939273|Drug|Fluconazole Oral Product|200 mg once per day for six days
31543|NCT03939273|Drug|Placebos|seven day course of placebo tablets and capsules identical in appearance and number to active treatment
31544|NCT03939260|Other|Extracorporeal CO2 Removal|Extracorporeal carbon dioxide removal (ECCO2R), a low flow extracorporeal CO2 removal, may be used in association with ultraprotective mechanical ventilation (tidal volume < 6 ml/kg and Pplat <20-25 cmH2O).
31545|NCT03939247|Other|Active Tecaretherapy|"The Tecaretherapy: consists of using a specific device providing high frequencies (between 300 kHz and 1 MHz) supposed to accelerate the tissues healing process"
31546|NCT03939247|Other|Inactive Tecaretherapy|"Inactive Tecaretherapy: the device will not provide any current."
31547|NCT03939247|Other|CPT|Conventional physiotherapy treatment (massage, eccentric exercises, stretching)
31548|NCT03939234|Combination Product|PD-L1, PD-L2 peptides with Montanide ISA51|PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.
31549|NCT03939221|Behavioral|Infrared Lamp and Acupressure|Measure the ankle and wrist acupoints skin conductance to evaluate the basic condition of terminal hospice patients. Then investigators use the infrared lamp and acupressure(tender points, PC6 and ST36 for one minutes) for our patient for the cold limbs, pain control and constipation problems.
31550|NCT03939208|Behavioral|BRISC|
31551|NCT03939208|Behavioral|SAU|
31552|NCT03939195|Other|Follow-up|4 follow-up visits with OCT Angiography and Structural OCT B
33011|NCT03927131|Biological|QIV-IB Lot C|Inactivated split-virion quadrivalent influenza vaccine - Lot C
31556|NCT03939156|Other|Completion of questionnaires|Completion of questionnaires at the time of study entry
31557|NCT03939143|Drug|DA-1229_01(A), Sugamet SR Tab 5/1000mg®|"Period 1: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar."
31558|NCT03939143|Drug|Sugamet SR Tab 5/1000mg®, DA-1229_01(A)|"Period 1: Single oral administration of 1 tablet of reference drug together with 150 mL of water containing 30 g sugar.~The wash-out for fed study is 14 days. Period 2: Single oral administration of 1 tablet of test drug together with 150 mL of water containing 30 g sugar."
31559|NCT03939130|Dietary Supplement|Fructose|Consumption of 1.0g / kg of body mass / day of fructose.
31560|NCT03939130|Dietary Supplement|Glucose|Consumption of 1.0g / kg of body mass / day of glucose.
31561|NCT03939130|Other|Fructose and exercise|Consumption of 1.0g / kg of body mass / day of fructose + 3 weekly sessions of 60 minutes of aerobic exercise.
31562|NCT03939104|Drug|Artemether-lumefantrine+amodiaquine|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
31563|NCT03939104|Drug|Artemether-lumefantrine+placebo|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days."
31564|NCT03939104|Drug|Artesunate-piperaquine+mefloquine|"AS-PPQ: Artesunate-piperaquine will be administered according to an optimised dosing schedule using tablets of 50 mg artesunate and 250 mg piperaquine with a dosing target of 4 mg/kg/day and 20 mg/kg/day, respectively~MQ: One tablet contains 250 mg of mefloquine. The weight-based treatment schedule aims for a dosage of approximately 8 mg/kg/day (range 6.25-10.5mg/kg) mefloquine for three days, thereby approaching the WHO-recommended target range of 7-11 mg/kg per day."
31565|NCT03939104|Drug|Artesunate-piperaquine+placebo OR Artesunate-mefloquine|"AS-PPQ: Artesunate-piperaquine will be administered according to an optimised dosing schedule using tablets of 50 mg artesunate and 250 mg piperaquine with a dosing target of 4 mg/kg/day and 20 mg/kg/day, respectively~AS-MQ: Artesunate-mefloquine will be administered according to an optimised dosing schedule using tablets of 50 mg artesunate and 250 mg mefloquine with a dosing target of 4 mg/kg/day and approximately 8 mg/kg/day (range 6.25-10.5mg/kg), respectively"
31566|NCT03939091|Diagnostic Test|Ultrasonography|Renal Ultrasonography
31567|NCT03939078|Radiation|CO2 fractional ablative laser|3 intravaginal fractional ablative CO2 laser sections, with one month interval between them.
31568|NCT03939065|Device|Sensor Augmented Pump Therapy|Incorporating both insulin pump and CGM technology together (also known as SAP therapy) has the potential to better optimize glycemic control than each device alone. Participants in this arm will receive their insulin dosing via insulin pump and their blood sugars will be monitored using a Continuous Glucose Monitor.
31569|NCT03939065|Device|Standard of Care with CGM|Participants assigned to this arm will receive conventional diabetes management with daily insulin injections (or on an insulin pump if already on an insulin pump in the outpatient setting) and capillary blood glucose monitoring. These participants will also wear a blinded Continuous Glucose Monitor (CGM) for outcome assessment.
31570|NCT03939052|Dietary Supplement|Free amino acids intake|Oral consumption of eight hourly experimental meals- -4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil -4 isotopically labeled experimental meals. The same protocol will be repeated with glycomacropeptide (GMP).
31571|NCT03939026|Genetic|ALLO-501|ALLO-501 is an allogeneic CAR T cell therapy targeting CD19
31572|NCT03939026|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
31573|NCT03939026|Drug|Fludarabine|Chemotherapy for lymphodepletion
31574|NCT03939026|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
31575|NCT03939013|Diagnostic Test|Xpert HCV VL|Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
31576|NCT03938987|Biological|autologous CD19-directed chimeric antigen receptor (CAR) T-cells|Anti-CD19/4-1BB/CD3ζ CAR T-cell: autologous, unselected CD3+ lymphocytes collected from whole blood or apheresis, transfected with a lentiviral vector containing a 2nd generation chimeric antigen receptor (CAR) consisting of a scFv recognizing CD19 and dual co-stimulatory intracellular signaling domains (4-1BB and CD3ζ). All patients will receive lymphodepleting, conditioning chemotherapy in the form of cyclophosphamide (500 mg/m2/day) and fludarabine (30 mg/m2/day) on Days -5, -4, and -3 prior to a CAR T-cell intravenous, single dose administration on Day 0.
31577|NCT03938948|Device|low-level laser/light therapy|Participants will wear light therapy devices for 14 weeks
31578|NCT03938935|Procedure|Absorbable polydioxanone suture (PDS)|PDS is a Polydioxanone synthetic monofilament which is absorbable.
31579|NCT03938922|Drug|Active Investigational Treatment ENT-01|"ENT-01 will be administered in tablet form, once daily.~Other Names:~ENT-01"
31580|NCT03938909|Genetic|cif mtDNA biomarker|The aim is to evaluate the role of ccf-mtDNA as a specific and early biomarker for different clinical pictures
31581|NCT03938896|Other|platelet rich plasma|Patients were put in supine position. Betadine was used to disinfect the skin of the heel. 1 ml of local anesthesitic (lidocaine) was injected;then, by the same syringe, 2.5 ml of PRP was injected in the tenderestarea.After extraction of the needle, a bandage was puton the injected area. The patient was kept in the supine position for twentyminutes and then discharged
31613|NCT03938636|Drug|TC99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
31614|NCT03938623|Other|Training|Teaching general practitioners to use the patient-centered approach when suggesting colorectal cancer screening
31582|NCT03938896|Other|corticosteroid|Patients were put in the supine position. Injection was done usingthe medial technique. Identification of the tenderest point of the heel was done by palpation. Antiseptic solution was used to disinfect the skin overlying theheel. Then1ml of 40 mg methylprednisolone acetate and 1 ml of local anaesthetic as lidocaine 2% were injected into the plantar fascia by a 22gauge needle. After injection, participants were advised to stay sitting without foot movement for 15 minutes
31583|NCT03938883|Device|Ocular Bandage Gel (OBG)|A modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries including surgical trauma.
31584|NCT03938883|Device|Bandage Contact Lens (BCL)|A bandage contact lens protects an injured or diseased cornea from the mechanical rubbing of the blinking eyelids, therefore allowing it to heal. It is a normal (usually soft, but not always) contact lens has no power. It is not intended to improve your vision.
31585|NCT03938870|Other|L-Leucine 13C6|
31586|NCT03938857|Drug|Fentanyl|Fentanyl standard of care
31587|NCT03938857|Drug|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
31588|NCT03938857|Drug|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)
31589|NCT03938857|Drug|Dexmedetomidine|Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
31590|NCT03938844|Procedure|BURCH Colposuspension|stress urinary incontinence surgery ( burch or tot)
31591|NCT03938844|Procedure|TOT|
31592|NCT03938831|Drug|Dexmedetomidine|dexmedetomidine 0.5 micg/kg/hr infusion during operation and followed by 0.2 mic/kg/hr with fentanyl-based PCA mixture for 2 days
31593|NCT03938831|Drug|Fentanyl-based PCA infusion|Fentanyl-based PCA infusion
31594|NCT03938818|Behavioral|Tu'Washindi intervention|"The intervention includes the following components:~PrEP sensitization for men (community level). These activities will aim to provide men with basic information about PrEP and will be used to prepare men for more effective engagement in Buddy Days, described below.~Buddy Days (partner level). Buddy days will target male partner engagement by inviting couples to attend a community-wide event with health screenings, and PrEP sensitization, which aim to facilitate further communications about PrEP and increase men's support for AGYW's PrEP use.~Adherence support clubs (individual and peer levels). Support clubs will provide a forum for AGYW to discuss challenges and successes around PrEP use in relationships, including in the context of partner violence. Participation in these groups is hypothesized to increase self-efficacy for PrEP use by reducing social isolation and providing additional positive role-modeling from peer leaders."
31595|NCT03938818|Other|Control|Standard of care will include PrEP delivery according to the usual DREAMS procedures, including attendance at routine Safe Space meetings and routine PrEP provision at the Safe Space, if applicable.
31596|NCT03938805|Behavioral|Internet-based cognitive behavioral therapy for insomnia|Patients will be provided with psycho education on different cardiovascular diseases, sleep, insomnia, and provided with different behavioral techniques to improve their sleep. The participants in the intervention Group who receives the Internet-based cognitive behavioral therapy program will also have access to support given by a nurse specialized in sleep. A module is given each week during the 9-week intervention.
31597|NCT03938805|Other|Control group|Control group receiving 3 weeks internet-based education on sleep hygiene. A module is given each week during the 3 weeks.
31598|NCT03938792|Drug|PF-06741086|300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.
31599|NCT03938779|Behavioral|Pelvic Floor Muscle Training (PFMT)|PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team
31600|NCT03938779|Diagnostic Test|Pad test|Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
31601|NCT03938766|Diagnostic Test|PSMA PET/CT|Repeat PSMA PET/CT 4 weeks post initiation of clinically indicated ADT in patients with prior negative PSMA PET/CT performed for biochemical recurrence.
31602|NCT03938753|Device|Audéo M90-T|Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
31603|NCT03938740|Drug|HDV-Insulin Lispro and Insulin Degludec (-40%)|HDV-Insulin Lispro and Insulin Degludec (-40%)
31604|NCT03938740|Drug|HDV-Insulin Lispro and Insulin Degludec (-10%)|HDV-Insulin Lispro and Insulin Degludec (-10%)
31605|NCT03938714|Procedure|Hemorrhoidectomy|Excision of third and fourth degree hemorrhoids
31606|NCT03938701|Drug|OTL38|Intravenous administration of 0.0125 mg/kg OTL38 2-3 hours prior to fluorescence imaging.
31607|NCT03938701|Device|Fluorescence Imaging|"Fluorescence Imaging Rheumatoid Arthritis (RA):~Open-air camera - a camera that enables detection of fluorescent signals.~Fluorescence Imaging inflammatory bowel disease (IBD):~Molecular Fluorescence Endoscopy - a flexible fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fibre-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed during standard clinical colonoscopy."
31608|NCT03938688|Procedure|Mesh placement with Transfascial Sutures|Sutures that pass through the full thickness of the abdominal wall, which are used routinely for mesh fixation
31609|NCT03938662|Dietary Supplement|formulation containing S-Adenosyl methionine and choline|Patients will be administered with formulation containing S-Adenosyl methionine and choline once daily for the period of 24 weeks.
31610|NCT03938662|Dietary Supplement|Placebo|Placebo of same appearance, colour and taste,
31611|NCT03938649|Radiation|Conventional IMRT|"RapidArc IMRT to prostate and pelvic nodes. 76Gy to prostate, 70Gy to proximal 2/3 of seminal vesicles, and 50Gy to pelvic nodes (up to bifurcation of common iliac nodes).~38 fractions of daily treatment, Monday to Friday.~All patients will be given neoadjuvant and adjuvant androgen deprivation therapy."
31612|NCT03938649|Drug|SBRT|RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
57261|NCT03736967|Drug|Dupilumab|Administered SC q2w
31615|NCT03938584|Dietary Supplement|Vitamin C|Just after induction of anesthesia in the OR, subjects will be administered a single intravenous (IV) dose of Vitamin C at 66mg/kg/hr for 2 hours during surgery. Post-operatively (beginning the morning after surgery) Vitamin C Treatment Group subjects will receive a 4 week prescription of oral, liquid Vitamin C, 500mg by mouth two times a day. These dosages are known to be safe and effective.89-91
31616|NCT03938584|Other|Placebo|Subjects will receive IV placebo (normal saline) identically packaged. Post-operatively Placebo Control Treatment Group participants will receive a 4-week prescription of the aqueous solution base used for the treatment group without the active component (Vitamin C).
31617|NCT03938571|Procedure|Duodenal Switch|
31618|NCT03938558|Other|MS-Dance|The experimental group will perform 10 weeks of dance training
31619|NCT03938558|Other|MS-Art|The other group will contribute to the production in various ways (e.g. word art, photography, painting, …)
31620|NCT03938545|Drug|RVT-1401 (Administered via subcutaneous injection)|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
31621|NCT03938545|Other|Placebo (Administered via subcutaneous injection)|Placebo
31622|NCT03938532|Device|Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor|Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
31623|NCT03938532|Device|Tidal Volume Measurement using the Philips Respironics NM3 monitor|Tidal Volume Measurement using the Philips Respironics NM3 monitor
31624|NCT03938506|Other|cuff pressure of the endotracheal tube|The endotracheal intubation will be performed after the anesthetic induction. The cuff will be inflated using the air by the palpation method. The cuff pressure of the endotracheal tube will be measured using the manometer.
31625|NCT03938493|Other|monitoring of the endotracheal tube cuff|We will enroll adult patients who will undergo endotracheal intubation for general anesthesia of head and neck surgery. The cuff pressure of the endotracheal tube will be monitored continuously during anesthesia. The cuff pressure value will be recorded and analyzed after completing the study.
31626|NCT03938467|Drug|Antiseptic Cleanser|Contains 0.05% Chlorhexidine gluconate in sterile water for irrigation. The mechanical action of the Irrisept system removes bacteria and debris without harming underlying tissues. Irrisept has demonstrated broad spectrum bactericidal activity against antibiotic-resistant strains. Its contents are wrapped in two sequential sterilization wraps which repel water blood, and saline, making it effective against both air and water borne bacteria.
31627|NCT03938454|Drug|crizanlizumab|Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
31628|NCT03938441|Other|Intermittent Fasting|"The version of 5:2 intermittent fasting to be applied in this study will be somewhat less intensive than implemented then what has been proposed in some recent, similar studies.~On fasting days, instead of limiting the subject to a specific calorie count, the subject will be instead instructed to skip either the first or last meal of the day in order to complete a 12 to 16 hour fast, during which time they are allowed drink water or any non-caloric beverage of their choice, but not consume any calories.~Furthermore, the patient will be instructed for their remaining 2 meals to consume no more than they would on a normal, non-fasting day."
31629|NCT03938428|Other|Survey|Patients who are eligible for this study will have been previously identified as part of the PREFACES project. The pharmacist who has conducted the clinical medication review will obtain verbal permission from the patient to be contacted by the research study team. This will be documented on the referral outcome document that is returned to the YAS clinical team. A member of YAS clinical staff from the PREFACES project will forward the name and residential address of patients who have agreed to be contacted to the research paramedic for this study. A covering letter, participant information sheet, questionnaire and consent form, will be posted to potential participants. A stamped addressed envelope will be included to enable return of the completed booklet at no costs to participants.
31630|NCT03938415|Procedure|Acupuncture|Acupuncture involving the Koffman protocol (body acupuncture) for anxiety control (needles will be placed at bilateral LR-3, bilateral LI-4, GV 24.5 and GV 20) and Auricular ATP Plus (ear) for pain control (needles will be placed at points hippocampus, amygdala, hypothalamus, prefrontal cortex, Point Zero, Shen Men, vagus, insula, external genitalia). Subjects who tolerate the auricular needles will be offered replacement with ASP acupuncture needles for continued pain management post-procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
31631|NCT03938415|Other|Standardized pre-procedure medications|The clinic standardized pre-procedure medications alone (which include diazepam 5 mg by mouth (PO) x1 30 minutes prior to the procedure, an additional 5 mg PO x1 15 minutes later if desired effect is not achieved; and oxycodone/acetaminophen 5/325 mg PO x 1 30 minutes prior to the procedure. The subjects will receive local anesthetic during the vasectomy per standardized clinic protocol.
31632|NCT03938402|Other|Positive end-expiratory pressure|Different levels of positive end-expiratory pressure (i.e., 5, 10 and 15 cm H2O) will be applied to the groups.
31633|NCT03938389|Drug|Sacubitril-Valsartan Tab 97-103 MG|Participants will take Sacubitril-Valsartan for 26 weeks
31634|NCT03938389|Drug|Valsartan 160mg|Participant will take Valsartan for 26 weeks
31635|NCT03938389|Drug|Placebo Oral Tablet|Participant with take placebo for 26 weeks or if blood pressure elevated will receive standard of care blood pressure medication, amlodipine.
31636|NCT03938376|Diagnostic Test|Micro-Ultrasound guided biopsy|High-resolution imaging device
31637|NCT03938363|Other|Treadmill|Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups
31638|NCT03938363|Drug|Botulinum Toxin injection|injection of Botulinum Toxin in the two groups of CD and BS
31639|NCT03938363|Diagnostic Test|Severity scale of the disease|JRS for BS TWSTRS for CD
31640|NCT03938350|Behavioral|Dialectical Behavior Therapy (DBT) Skills Training|Standard DBT skills training is a comprehensive intervention for emotion dysregulation that includes four skills modules: (1) mindfulness skills; (2) emotion regulation skills; (3) interpersonal effectiveness skills; and (4) distress tolerance skills designed to target adaptive skills deficits that define emotion dysregulation.
31641|NCT03938337|Drug|Cohort 1 Not Previously Treated|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
31642|NCT03938337|Drug|Cohort 2 Treated Previously|Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
31643|NCT03938324|Behavioral|PiCASO Intervention Group|This mobile health intervention utilizes an established telephone/text based secure interface to allow AYAs access knowledge, experience, and instrumental/emotional support from a trained peer coach who has already developed independence an active self-manager. Peers with shared experiences provide instrumental (e.g., health maintenance skills) and emotional support that likely lead to improvements in quality of life. Involving peers in supporting AYAs with chronic conditions to promote self-management and patient activation disrupts the typical over-reliance on the parent and health care provider that often impedes developing independence.
31644|NCT03938324|Behavioral|Sham Comparator: Attention Control Group|Over 12 months the attention control group participants will receive a monthly electronic newsletter with educational content about childhood onset chronic condition management and the differences between pediatric and adult health care systems, as well as a monthly phone call from study staff to ensure receipt of the newsletter and to answer questions regarding content, and an opportunity to link them to other resources. If participants report health concerns they will be directed to contact their health care team.
31645|NCT03938311|Other|rehabilitation|"Rehabilitation treatment is arranged based on each patient's functional assessment. Encourage patients to move out of bed as soon as possible.~Definition of bed movement: Encourage and help patients to perform functional actions, focusing on activities such as sitting, standing, walking out of the bed."
31646|NCT03938298|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive standards of care, i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
31647|NCT03938298|Other|Smoking cessation counseling|"Participants in the control group will receive standard of care only, i.e. i.e. smoking cessation counseling and encouragement to use NRT. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date and again at week 1, 2, 4 and 8 after the target quit date. All participants will be followed over a 6-month period. After 6 months, participants will be asked to come to a final clinical visit.~PFT and MBW will be performed at baseline and after the 6 months follow-up period in all participants of the substudy."
31648|NCT03938285|Other|Theranova 400 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
31649|NCT03938285|Other|FxCordiax 120 membrane|Patients will receive 4 different dialysis treatment, HD with a high flux membrane, extended HD, On Line Hemodiafiltration, and the novel On Line Hemodiafiltration with an MCO membrane.
31650|NCT03938272|Biological|Oxabact OC5 - Oxalobacter formigenes Strain HC-1|Live, commensal bacteria
31651|NCT03938259|Drug|Fentanyl|identification of respiratory parameter changes following administration of fentanyl in children with and without OSA
31652|NCT03938246|Drug|TVB-2640|Oral dose, tablet, daily dosing
31653|NCT03938246|Other|Placebo|Oral dose, tablet, daily dosing
31654|NCT03938233|Behavioral|A low-cost DSME program and scalable delivery model for roll-out within the Thai primary care system|The intervention will be based on behaviour-change and social support theories, delivered in monthly group meetings by lay health workers or nurses, and aided by a suite of short films to introduce key topics and stimulate discussion.
31655|NCT03938220|Device|Electrical Cardiometry|Electrical cardiometry (EC) measurements: by the ICON_ hemodynamic monitor (ICON Cardiotronics, Inc., La Jolla, CA 92307; Osyka Medical GmbH, Berlin, and Germany, model C3, Serial no: 1725303). Four sensors of EC will be applied (1st: 5 cm above the base of the neck, 2nd: on the base of neck, 3rd: lower thorax at the level of the xiphoid and 4th: 5 cm below the 3rd electrode at the level of anterior axillary line). The ICON continuously displays HR, SV and CO.
31656|NCT03938207|Diagnostic Test|Whole-genome genotyping|Using Whole-genome genotyping from Taiwan Biobank between Dry eye syndrome and healthy control.
31657|NCT03938207|Diagnostic Test|Whole-genome sequencing|Using whole-genome sequencing from Taiwan Biobank between Dry eye syndrome and healthy control to investigate the difference among the genetic variant, gene copy number, single nucleotide variation, chromosomal recombination, and very low-level gene expression differences
31658|NCT03938207|Diagnostic Test|TCM pattern|We want to use TCM pattern to investigate the difference among Sjögren's syndrome, Dry eye syndrome and healthy subjects
31659|NCT03938207|Diagnostic Test|DNA Exome sequencing|The DNA of Sjögren's syndrome, Dry eye syndrome and healthy subjects will take to do the DNA Exome sequencing.
31660|NCT03938207|Diagnostic Test|Physical examination indicators, blood, urine and biochemical function test|To investigate the difference of Physical examination indicators, blood, urine and biochemical function test among Sjögren's syndrome, Dry eye syndrome and healthy subjects
31661|NCT03938207|Diagnostic Test|Demographics, personal health behavior, living environment, dietary status, family history|To investigate the difference among the demographics, personal health behavior, living environment, dietary status, family history of Dry eye syndrome and healthy subjects
31662|NCT03938194|Procedure|Aquablation|a novel minimally invasive water ablation therapy combining image guidance and robotics for the targeted and heat-free removal of prostate tissue
31663|NCT03938168|Diagnostic Test|Biopsy, fecal sample|Preoperatively and at 12 months after surgery, patients will obtain a fecal stool sample for microbioma analysis. Adhesions that are cut and released to acquire access to the operative field are stored for molecular and histological analyses.
31664|NCT03938142|Other|Filling in an online survey regarding goalsettings|Patients are asked to fill in an online survey regarding their individual goalsettings.
31665|NCT03938129|Other|Blood sample|1st trimester blood sample for bio-bank
31666|NCT03938129|Other|Urine sample|1st trimester urine sample for bio-bank
31667|NCT03938129|Other|Pregnancy, maternal health, and fetal health data|Pregnancy, maternal health, and fetal health data
31668|NCT03938116|Other|Healing Hearts Together|Participants in the HHT group will be assembled in groups and attend 8 weekly 2-hr sessions at UOHI led by 2 facilitators with psychology training. Sessions: 1) focus on understanding love, attachment, and their relationship to heart health; 2) provide an opportunity to share experiences related to cardiovascular disease with partners and peers; and 3) assist in identifying and improving communication patterns that may inhibit positive interactions and healthy behaviours. Participants are introduced to concepts through didactic presentations, videos, group and couple discussion and homework exercises. Participants will receive a folder containing copies of in-session and take-home exercises as well as the Hold Me Tight book to review between sessions.
31669|NCT03938103|Behavioral|Enhanced Go NAPSACC|In the Enhanced delivery model, TA coaches will help centers create an implementation team and conduct a needs assessment to identify organizational strengths and challenges. TA coaches will also provide an orientation to Go NAPSACC and its online tools and help the team develop a plan to guide their Go NAPSACC efforts. The team will then work through 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly check-ins incorporating tailored support based on the results from the needs assessment. They will also organize 2-3 meetings among teams from different centers to reflect and share lessons learned.
31670|NCT03938103|Behavioral|Basic Go NAPSACC|In the Basic delivery model, TA coaches will provide an orientation to Go NAPSACC and its online tools to the center director. The director will then work 2 cycles of Go NAPSACC over 12 months. During each cycle (6 months), centers will take self-assessments on nutrition and physical activity, choose 6 goals (3 from each), create action plans, and take action to achieve their chosen goals. Throughout this 12-month period, TA coaches will provide monthly brief check-ins.
31671|NCT03938090|Device|Optimised MultiSite Pacing|The intervention includes using optimal programming settings with MultiSite pacing configurations via the patient's CRT device. The device in use is the same for each arm, the only changes are the programming settings.
31672|NCT03938090|Device|Standard biventricular pacing|Conventional programming settings using biventricular pacing will be used
31673|NCT03938077|Device|Storytelling 4 Empowerment|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol & drug use, HIV & STIs, and tobacco prevention and cessation.
31674|NCT03938064|Drug|Prontogest 400 mg vaginal pessaries|natural progesterone in the form of vaginal suppositories 400 mg
31675|NCT03938051|Other|Experimental group|Multicomponent intervention for twice weekly 55-60 minutes 6 weeks
31676|NCT03938051|Other|Control group|20 minutes treadmill walk thrice weekly, 5-7 /10 subjective rate of perceived exertion
31677|NCT03938038|Diagnostic Test|Serial ultrasound assessments for GDT|routine ultrasound assessments of volume status and fluid responsiveness for goal-directed therapy (GDT)-based fluid resuscitation
31678|NCT03938038|Diagnostic Test|Usual care|Close hemodynamic cardiac monitoring and volume responsiveness assessment on an unscheduled basis to aid physicians in resuscitation feedback
31679|NCT03938025|Procedure|Gastric volume resected in sleeve gastrectomy|Misure of resected gastric volume and outcome
31680|NCT03937999|Drug|Bezlotoxumab|Injection: 1,000 mg/40 mL (25 mg/mL) solution in a single-dose vial.
31681|NCT03937986|Drug|Suvorexant|The pharmacodynamic effects of suvorexant maintenance will be determined.
31682|NCT03937986|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.
31683|NCT03937986|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined.
31684|NCT03937973|Behavioral|Social rejection|Social rejection paradigm
31685|NCT03937960|Other|Carbohydrate restricted group|Prescribed low carbohydrate diet with set recipes
31686|NCT03937960|Other|Standard low fat diet|Diet with less than 20% total calorie intake from dietary fats
31687|NCT03937934|Behavioral|Nutrition Education|Weekly box of healthy groceries and nutrition education including a recipe, food to make the recipe, extra fruit and vegetables.
31688|NCT03937921|Drug|Gadavist 15Ml Solution for Injection|Group 2 (n=30) will receive the clinically approved gadobutrol (Gadavist, 0.1mmol/kg) as contrast agent. The contrast agents will be administered at a flow rate of 5.0 ml/s for both groups. In this study aim, all imaging protocols will comply with standard of care and only the perfusion data will be post-processed and analyzed.
31689|NCT03937908|Drug|2g Centella asiatica water extract product|2g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
31690|NCT03937908|Drug|4g Centella asiatica water extract product|4g of Centella asiatica water extract (CAW) in a standardized product containing excipients to improve palatability, color matching and dispersability. The product (CAP) is a powder which will be dissolved in 10-12 ounce of water and consumed by mouth once on an empty stomach.
31691|NCT03937895|Biological|'SMT-NK' Inj (allogeneic Natural Killer cell)|In 120 mL, 3x10^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
31692|NCT03937895|Drug|Pembrolizumab Injection [Keytruda]|Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
31693|NCT03937882|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Thymosin beta 4 for direct instillation into each eye, four times a day (QID) for 14 days
31694|NCT03937882|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Thymosin beta 4
31695|NCT03937869|Drug|Secnidazole|One dose
31696|NCT03937856|Behavioral|Calm- Mindfulness Meditation smartphone application|Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
57262|NCT03736967|Drug|REGN3500 + Dupilumab Combo|Administered SC q2w
31697|NCT03937843|Drug|Carboplatin|Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.
31698|NCT03937843|Drug|Cisplatin|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
31699|NCT03937843|Drug|Etoposide|"Patients in cohort 2 will receive on day 1 to day 5:~a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by~a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day."
31704|NCT03937791|Biological|E7 TCR|One doe of E7 TCR T cells (1x1011 cells) will be administered intravenously over 20 to 30 minutes.
31705|NCT03937778|Behavioral|Deep pressure block|Apply deep pressure block by using blood pressure cuff.
31706|NCT03937765|Procedure|PRP harvest and preparation|"The PRP harvest and preparation will be done in the operating room with the help of the hospital blood bank. The skin graft surgery will be completed by Dr. Jason Lowe and/or one of the Orthopaedic Surgery residents. Follow up will also be completed by Dr. Lowe or one of the residents. Data analysis will be done by Drs. Lowe and Manoharan.~Each patient that will be undergoing a skin graft surgery will be randomized into either the PRP (intervention) group or the control group. Follow up and dressing changes will be the same for both groups. Each group will be prescribed a multi-modal pain regimen to reduce narcotic usage."
31707|NCT03937752|Other|3D endodanal ultrasound|Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
31708|NCT03937739|Other|Nutritional and constipation questionnaire|Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
31709|NCT03937726|Other|Boiled peanut|Desensitisation using boiled peanut for induction and initial updosing
31710|NCT03937726|Other|Defatted roasted peanut flour|Desensitisation using defatted peanut flour for induction and initial updosing
31711|NCT03937713|Drug|eszopiclone|Eszopiclone is a nonbenzodiazepine benzodiazepine receptor agonists, effective for both sleep onset insomnia and sleep maintenance insomnia
31712|NCT03937713|Behavioral|Brief behavioral therapy for insomnia|BBTI is based on the core principles that are fundamental to other empirically-supported behavioral treatments of insomnia delivered over four consecutive weeks.
31713|NCT03937700|Device|CPWalker Robotic Exoskeleton|The CPWalker rehabilitation platform is a robotic device composed by an exoskeleton linked to a walker that provides support and balance to a child during overground training. The device is able to implement user's partial body weight support (PBWS) and allows the adaptation of exercises to the patient's capabilities by means of individual controllers for each joint, which increases the modularity of the system. Each joint of the CPWalker can operate in a range of modes with varied levels of robotic assistance or resistance
31714|NCT03937687|Drug|Caffeine+TeaCrine+Dynamine|combination of caffeine, TeaCrine, and Dynamine
31715|NCT03937687|Drug|Placebo|Placebo
31716|NCT03937687|Drug|Caffeine|Caffeine
31717|NCT03937674|Behavioral|HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.|HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
31718|NCT03937661|Biological|PRP|Autologous Platelet-rich Plasma injection into the ovaries.
31719|NCT03937661|Biological|Placebo|Placebo injected into the ovaries.
31720|NCT03937648|Drug|COL-144 50mg|COL-144 50mg
31721|NCT03937648|Drug|COL-144 100mg|COL-144 100mg
31722|NCT03937648|Drug|COL-144 200mg|COL-144 200mg
31723|NCT03937648|Drug|COL-144 400mg|COL-144 400mg
31724|NCT03937648|Drug|Placebo|Placebo
31725|NCT03937635|Biological|Daratumumab|Given IV
31726|NCT03937635|Drug|Dexamethasone|Given PO
31727|NCT03937635|Drug|Lenalidomide|Given PO
31728|NCT03937635|Other|Quality-of-Life Assessment|Ancillary studies
31729|NCT03937635|Other|Questionnaire Administration|Ancillary studies
31730|NCT03937622|Other|17 items questionaire|This is a prospective multicenter observational trial. Included patients and attending physician complete a standardised questionnaire.
31731|NCT03937609|Drug|Infliximab|infliximab iv 5mg/kg
31732|NCT03937596|Drug|D-cycloserine|Daily oral D-cycloserine 100mg during the blinded phase (10 days).
31733|NCT03937596|Device|Transcranial Magnetic Stimulator|Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive daily treatments (Monday-Friday) over four weeks.
31734|NCT03937596|Drug|Placebo oral capsule|Daily oral placebo during the blinded phase (10 days).
31735|NCT03937583|Drug|Fludeoxyglucose 18F|"The performance of the 18 FDG PET-CT will require fasting of at least 6 hours, and the glycemia will have to be lower than 126 mg / dL before the injection of 3-5 MBq / kg of 18FDG. Intravenous injection will follow a period of approximately 60 minutes in a quiet room.~Computed tomography (CT) will be performed from the middle of the forehead to the feet with normal and shallow breathing using a low dose adjustment Iodinated contrast will not be administered intravenously."
31789|NCT03937193|Diagnostic Test|computerized tomography|abdomen contrast computerized tomography performed for both emergency and elective purposes in HK public hospitals.
31736|NCT03937570|Device|echo-optimization|LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.
31737|NCT03937557|Diagnostic Test|photofinder levicam|Exam frontal, bilateral Temporal and occipital scalp by photofinder levicam and compare the pros and cons with the data from scalp biopsy.
31738|NCT03937544|Biological|CD19 CAR-T CELLS|CD19 CAR-T cells will be administered after completion of the chemotherapy.
31739|NCT03937544|Drug|Cyclophosphamide|Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).
31740|NCT03937544|Drug|Fludarabine|Patients will receive lymphodepleting chemotherapies consisting of Fludarabine 25mg/m2/day IV (Day -5, Day -4, Day -3 ).
31741|NCT03937531|Procedure|Bladder Scanner|PVR will be measured by using a bladder scanner.
31742|NCT03937518|Drug|Strontium Ranelate|"Patients received strontium ranelate 2gm (one sachet daily with 50 ml water at bedtime at least 2 h after food), as the compliance of patient assessed by counting number of sachet that patient returns at every visit and safety is assessed by recording adverse effects as blood pressure and heart rate every visit and patients received physiotherapy program in the form of (US therapeutic acoustic radiation and exercise program) 3 times per week for 6 months.~Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min ("
31743|NCT03937518|Other|physiotherapy|"Ultra sound (US):~Pulsed ultrasonic waves were delivered at a 1 MHz frequency and at an intensity of 1 watt/ cm2 via a transducer with a diameter of 5 cm and effective radiating area of 3.5 to 5cm² for 9.5 min (Medserve, England) (Huang et al., 2001). Patients were positioned in a supine position with the affected knee flexed at 90° and the sound head was held stationary over the tibiofemoral joint medial to the patellar tendon to enhance energy penetration into the joint space (White et al., 2007).~Exercise program:~The subjects were treated with a group-exercise program composed of a range of motion of all lower limb and 45 min strengthening exercises with 5 min stretching exercises of lower limb muscles 3 times per week under the supervision of the same physiatrist (Fitzgerald and Oatis"
31744|NCT03937505|Drug|IS-001|intravenous injection of IS-001 investigational drug
31745|NCT03937505|Drug|No treatment|no drug injection
31746|NCT03937492|Other|GMI protocol|"This group follow GMI program split in 3 step:~left/right descrimination~visual motor imagery~mirror therapy~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
31747|NCT03937492|Other|Standard Rehabilitation Protocol|"This group follow standard rehabilitation protocol, with active and passive motion of upper limb structure, including hand, wrist, elbow, shoulder.~Patients perform this exercises 3 times every day and they have checks in therapy al least twice a week."
31748|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
31749|NCT03937479|Drug|Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
31750|NCT03937479|Drug|Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
31751|NCT03937479|Drug|Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
31752|NCT03937479|Drug|Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium|"Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication."
31753|NCT03937466|Device|Cooling mattress pad|The cooling mattress pad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
31754|NCT03937453|Diagnostic Test|MRI/MRCP|An MRI/MRCP with IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
31755|NCT03937440|Drug|Deep neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
31756|NCT03937440|Drug|Moderate neuromuscular block with 'rocunium®'|Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
31790|NCT03937180|Behavioral|Blended care|An interactive e-learning programme delivered through a secured web-based platform for patients and general practitioners (GPs), blended with face-to-face contacts between the involved GP and patient.
31791|NCT03937180|Behavioral|Usual care|"General practitioners offering usual care are expected to follow the Belgian guidelines as described in the most recent online version of Anxiety, stress and sleeping problems A toolbox for general practitioners. or Sleeping pills and sedatives. How to assist your patients in the search for other solutions? which are both available in French and Dutch."
31757|NCT03937414|Device|The OSNA assay|SLN was defatted after SLNB. If the node weighed less than 100mg, the node was only assessed by histology postoperatively. If the node weighed more than 100mg, the node was sliced to equal blocks according to the length of short axis: If the length was less than 4mm, the node was sliced into two blocks along the long axis (a, b). Intraoperatively, the block a and b were tested by TIC, and the block a was prepared for OSNA. Postoperatively, the block b was assessed by histology. If the length was more than 4mm, the node was sliced into four blocks (a, b, c, d). Intraoperatively, all blocks (a, b, c, d) were tested by TIC, and the block a and c were prepared for OSNA.
31758|NCT03937401|Drug|Oxytocin|Oxytocin infusion during MRI-HIFU treatment
31759|NCT03937388|Other|Cochlear stimulation strategy including time-fixed gaps|Investigation of the impact of time-fixed gaps (zero-stimulation periods) in the cochlear stimulation strategy on speech performance and hearing quality.
31760|NCT03937375|Behavioral|High PEEP|Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
31761|NCT03937375|Behavioral|Low PEEP|Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
31762|NCT03937362|Diagnostic Test|First clinical response evaluation (CRE-1)|Consisting of: endoscopy with bite-on-bite biopsies
31763|NCT03937362|Diagnostic Test|Second clinical response evaluation (CRE-2)|Consisting of: PET-CT, endoscopic bite-on-bite biopsies,EUS with FNA
31764|NCT03937336|Behavioral|Bike Intervention Group|A 1-month biking-based program. The biking program consists of 4 sessions/month of 120 min at physical education lessons in school, and will focus on promote biking through theory and practice lessons about cycle training skills including on-road training
31765|NCT03937336|Behavioral|Walk Intevention Group|"A 1-month walking-based program. The walking program consists of 4 sessions/month of 60 min at physical education lessons in school, and will focus on promote walking using a gamified mobile app called Mystic School, where the steps that participants walk are kept and exchanged for movements into the game to reach the end."
31766|NCT03937336|Behavioral|Parents Intervention Group|A 1-month perception parent-based program. The parent program consist on to promote active commuting focusing on parenting participation using an app mobile to find safe routes and social networks of Facebook and WhatsApp to communicate.
31767|NCT03937323|Other|Blood lymphocyte subtypes and serum cytokines|Blood samples will be taken from the patients with biliary pancreatitis and healthy volunteers to perform flow-cytometric analysis and to determine the proinflammatory cytokines
31768|NCT03937310|Diagnostic Test|Next-generation sequencing of swabs collected during surgery|Traditional swabs for culturing as well as swabs for NGS testing will be collected
31769|NCT03937297|Behavioral|Six Arts|"The Six Arts intervention is a 24 session, twice a week intervention protocol. There will be four sessions per Art, with specific sequence designed to enhance group dynamic and create harmony. Each session starts with a 15 minutes warm-up exercise, followed by the Six Art theme activity. The program design emphasizes on integrated cognitive, physical, and social activities covering all domains of Six Arts."
31770|NCT03937297|Behavioral|Cognitive Stimulation Therapy (CST)|The CST to be used involve 24 sessions of theme activities, twice a weekly intervention protocol. It is modified into CST-Hong Kong for activities that are not applicable in Hong Kong Chinese culture (e.g. word games involving alphabets)
31771|NCT03937297|Behavioral|Usual Care|usual dementia care provided by participating center
31772|NCT03937284|Other|Patients not treated|
31773|NCT03937271|Diagnostic Test|Traditional Chinese Medicine pattern|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
31774|NCT03937271|Diagnostic Test|Traditional Chinese Medicine tongue diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine tongue diagnosis.
31775|NCT03937271|Diagnostic Test|Traditional Chinese Medicine pulse diagnosis|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pulse diagnosis.
31776|NCT03937271|Diagnostic Test|Heart rate variability|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Heart rate variability.
31777|NCT03937271|Diagnostic Test|Schirmer's test|Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Schirmer's test.
31778|NCT03937258|Drug|PF-04965842|Participants will be administered a single oral 200 mg dose of PF-04965842 in the morning on Period 1 Day 1 and Period 3 Day 2 under fasted conditions. In Period 2, participants will receive oral 200 mg dose of PF-04965842 once daily (QD) in the morning of Day 1 to Day 4 under fasted conditions
31779|NCT03937258|Drug|Probenecid|In Period 3, participants will receive probenecid 1000 mg twice daily (BID) in the mornings and evenings of Day 1 to Day 3. On the morning of Period 3 Day 2, after an overnight fast of approximately 8 hours, participants will be administered probenecid 1000 mg. A single 200 mg oral dose of PF 04965842 will be administered approximately 2 hours after the probenecid dose.
31780|NCT03937232|Behavioral|Cross-Education|Home exercise program + usual care
31781|NCT03937232|Behavioral|Mirror Visual Feedback|Home exercise program + usual care
31782|NCT03937232|Other|Usual care|Hand rehabilitation provided by occupational therapists and physiotherapists in a multidisciplinary outpatient setting
31783|NCT03937219|Drug|Cabozantinib|Specified dose on specified days.
31784|NCT03937219|Biological|Nivolumab|Specified dose on specified days.
31785|NCT03937219|Biological|Ipilimumab|Specified dose on specified days.
31786|NCT03937219|Drug|Cabozantinib-matched placebo|Specified dose on specified days.
31787|NCT03937206|Dietary Supplement|NutriterraTM|Nutriterra 1000mg
31788|NCT03937206|Dietary Supplement|Placebo|Corn Oil 1000mg
31792|NCT03937167|Other|Psychotherapy group|Added to standard treatment patients will participate in a standardized group of psychological intervention. 21 sessions with 10 to 12 members closed-ended groups.
31793|NCT03937154|Drug|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer
31794|NCT03937154|Drug|Placebo|Placebo comparator
31795|NCT03937141|Drug|ADU-S100|intratumoral
31796|NCT03937128|Behavioral|Virtual Reality Job Interview Training|Participants will engage in training related to preforming well during a job interview as well as repeated job interview practice with a virtual hiring manager. Participants will receive feedback and tips on improving skills throughout the training.
31797|NCT03937128|Behavioral|Services as usual|Study participants will be receiving Vocational Village services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
31798|NCT03937115|Device|Active tDCS|2 active tDCS sessions (20 min each, 2 mA) applied to the dlPFC and right motor cortex
31799|NCT03937115|Device|Sham tDCS|1 sham tDCS session (20 min, 0 mA) applied to the dlPFC
31800|NCT03937115|Device|Active tDCS|10 tDCS sessions (2 sessions/day for 5 days, 20 mA, 20 min each) applied to the dlPFC
31801|NCT03937115|Device|Sham tDCS|10 tDCS sessions (2 sessions/day for 5 days, 0 mA, 20 min each) applied to the dlPFC
31802|NCT03937102|Procedure|cardiac output measure with TTE|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
31803|NCT03937102|Procedure|cardiac output measure with Physioflow® thoracic electrical bioimpedance|All patients included will be simultaneously monitored with transthoracic echocardiography (TTE) and the Physioflow® thoracic electrical bioimpedance device. Cardiac output is measured by the Physioflow® Thoracic Bioimpedance Device and TTE before and after passive leg raising maneuver (PLR)
31804|NCT03937089|Other|Data collection|Data collection from medical file
31805|NCT03937076|Procedure|PECS II block|"Pectoral muscles Nerve block for postsurgical pain, PECS II, based on BUPIVACAINE:~Pectoral muscles nerve block is a procedure in which local anesthetic is injected into two sites.~between the major and minor pectoral muscles, in order to anesthetize the lateral and medial nerve. This injection is referred to as PECS I block.~between the minor pectoral muscle and the anterior serratus muscle, in order to anesthetize the intercostal nerves."
31806|NCT03937063|Other|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
31807|NCT03937050|Behavioral|Intervention|"Three film-based components:~Professional development of doctors and nurses to improve screening and management of GDM. Modules will cover knowledge and relevant clinical guidelines, skills for glucose monitoring and managing medication, specialist obstetric and neonatal care, and lifestyle counselling. These films will be screened 6-monthly at routine professional development meetings.~Awareness-raising among pregnant women and family members regarding GDM and the importance of healthy lifestyles during pregnancy. The films will be culturally tailored and will be screened in waiting areas of antenatal clinics.~Structured diabetes self-management education programme for women with GDM to empower them with the necessary knowledge, skills, and confidence to manage GDM successfully. The programme will incorporate behavioural counselling and educational reinforcement. Films will be screened at weekly group sessions and optimised for viewing on mobile devices."
31808|NCT03937037|Procedure|Saline irrigation|100ml saline irrigation after CBD stone removal with routine ERCP procedure
31809|NCT03937011|Device|Robotic Suturing of gastric sleeve oversew and vaginal cuff closure|"Robotic Bariatric Sleeve gastrectomy~Robotic Hysterectomy with or without oophorectomy;"
31810|NCT03936998|Combination Product|Vancomycin plus VE416 before PNOIT|Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks followed by PNOIT
31811|NCT03936998|Combination Product|Vancomycin plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by Vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
31812|NCT03936998|Combination Product|Placebo plus VE416 with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by VE416 PO QD x 6 weeks with concomitant PNOIT
31813|NCT03936998|Combination Product|Placebo plus placebo with PNOIT|Placebo for vancomycin for 5 days and placebo for VE416 x 6 weeks, followed by placebo for vancomycin PO QD x 5 days, followed by placebo for VE416 PO QD x 6 weeks with concomitant PNOIT
31814|NCT03936972|Procedure|ilizarov circular frame and uni-planarexternal fixator|both are types of external fixators, but one is circular frame and other is uni-planar frame
31815|NCT03936959|Drug|LY3434172|Administered IV
31816|NCT03936946|Behavioral|Audio Content 1|~30 minute daily audio recordings of content 1 for 28 days
31817|NCT03936946|Behavioral|Audio Content 2|~30 minute daily audio recordings of content 2 for 28 days
31818|NCT03936933|Drug|Goserelin acetate 3.6 mg Injection|3.6 mg, Subcutaneously at every 28 days
31819|NCT03936933|Drug|ZOLADEX® 3.6mg Injection|3.6 mg, Subcutaneously at every 28 days
31820|NCT03936907|Drug|OWCP Orally Disintegrating Tablet|Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD
31821|NCT03936907|Drug|Sativex|Sativex® Oromucosal Spray
31822|NCT03936894|Drug|Canakinumab Injection [Ilaris]|Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
31823|NCT03936868|Procedure|Tendon transfer|flexor carpi radialis transfer in most of patients and boye-transfer in very few
31824|NCT03936855|Procedure|Direct composite resin|"For both groups: The teeth will have the enamel surface conditioned with 37% phosphoric acid. For the restorative procedure, the same adhesive system will be used~GROUP ACTIVE COMPARATOR~Insert resin-modified glass ionomer cement into the pulp chamber;~Complete the restoration by incremental technique using conventional composite resin in increments of 2mm;~EXPERIMENTAL GROUP~Insert Bulk Fill composite inside the pulp chamber to the height of 5 mm;~Complete the insertion of the Bulk Fill resin to the limit of the caval surface angle in the occlusal"
31825|NCT03936842|Behavioral|Breast Pain video|An educational video of approximately 10 minutes about breast pain, self-examination and breast awareness will be shown to the participant.
31826|NCT03936842|Behavioral|Semi-structure interviews|A semi-structured, face-to-face interview will be then undertaken. The principles of Grounded Theory will be used to guide the interview. All of the interviews will be recorded and transcribed securely, only referencing the patient according to their study number. Their name and hospital number will not be used.
31827|NCT03936829|Drug|Cyclophosphamide|Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
31828|NCT03936816|Other|GBS vaginal double swab|The vaginal double swab will be assessed by two different lab tests: The first one for GBS culture on selective media after enrichment of 16h and the second swab by the Cepheid Xpert GBS Assay performed on the GeneXpert Dx system which is a qualitative in vitro diagnostic test designed to detect GBS DNA from vaginal swab specimens, using fully automated real-time polymerase chain reaction (PCR).
31829|NCT03936803|Behavioral|aerobic interval training exercise .|Its consisted of cycle ergometer training, 3 days a week for 6 weeks. Aerobic interval training consisted of ( 8 )minutes warm-up, followed by 4 times of 4-minute intervals with HR at 85% of sub maximum HR, with active pauses of 3 minutes of walking at 60% of sub maximum HR. The exercise session was terminated by 5 minutes cool-down
31830|NCT03936803|Device|electro acupuncture|"electroacupuncture (EA) of (2 Hz, 4 mA) was applied at points of:liver 3 LR3,liver 14 LR 14, gall bladder 34 (GB 34) and stomach 36 (ST36) .~Duration of the session was 15 min / each, three sessions per week for six weeks"
31831|NCT03936790|Other|Ropivacaine|In case of successful spinal anaesthesia, the dose of spinally administered ropivacaine will decrease by 0.375 mg for the next participant.In case of unsuccessful spinal anaesthesia, the dose of spinally administered ropivacaine will increase by 0.375 mg for the next participant.
31832|NCT03936790|Other|Fentanyl|A fix dose of fentanyl (15 mcg) will be co-administered spinally to all participants.
31833|NCT03936777|Drug|ZX008 (Fenfluramine Hydrochloride)|Fenfluramine hydrochloride provided in a concentration of 2.5 mg/mL.
31834|NCT03936764|Other|Preoperative Pulmonary Rehabilitation|"Each prehabilitation session will last approximately 90 minutes and will include:~Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~Education to bronchial drainage techniques as well as directed coughing."
31835|NCT03936751|Device|CPAP|This is the standard treatment for OSA.
31836|NCT03936751|Device|Nasal Strips|Nasal strips were commercially available in the market for supposing treat snoring and sleep apnea but no proof that this is true. Our group previously validated nasal strips as an interesting placebo.
31837|NCT03936725|Other|1 year phone call : data collection|"Included patients are contacted by telephone at 12 months after discharge. The investigators explain to the patient that this call is in the same context as a regular follow-up rehabilitation consultation and that the data collected will also be part of a study to evaluate and improve the program in which they participated. The interview will be transcribed in writing in their computerized and secure medical file. During this 20-minute telephone conversation, the patient answers a number of questions via a standardized questionnaire, in order to gather the various criteria for judgment.~If patients do not answer the first call, a phone message will be left and they will be contacted again up to 2 times. Patients who do not respond to 3 calls will be considered lost to follow-up."
31838|NCT03936712|Dietary Supplement|Energy Drink|Each participant visited the laboratory for two formal test sessions, drinking a caffeine-containing ED (RB) and a caffeine and taurine free beverage drink (PL). All sessions were arranged in the early evening hours to avoid any time of day effects. The two definitive test sessions were separated by an interval of seven days to allow sufficient recovery between tests and to ensure caffeine washout. To avoid identification, two opaque and unmarked cans of RB or PL were ingested by each participant (i.e., 500 mL) in the presence of a researcher. The two drinks were similar in volume, texture, and appearance. One can of RB drink (i.e., 250ml) contained 80 mg of caffeine, 1 g of taurine, 27 g of carbohydrates, 0.6 g of protein, 5 mg vitamin B6 and 487 kJ of energy.
31839|NCT03936712|Dietary Supplement|Placebo Drink|The PL drink was prepared by an agri-food engineer; it did not contain any caffeine or taurine, but comprised carbonated water, carbohydrates, citric acid lemon juice reconstituted from concentrate (1 %), supplemented by flavorings, of sodium citrate, acesulfame K, sucralose, potassium sorbate and RB (a flavoring that contains propylene glycol E1520 (0.23 mL).
31840|NCT03936699|Device|Transcutaneous Nerve Stimulator (TENS)|"The Elira wearable patch system is a Radio Frequency (RF) coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.~Behavioral: Diet & Exercise Subjects to be instructed on a healthy 1200 calorie diet."
31841|NCT03936699|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
31842|NCT03936686|Other|Survey tool to assess CVD risk factor knowledge|The survey tool was used to assess the participant's knowledge level and their previous methods of education regarding cardiovascular disease risk factors.
31843|NCT03936673|Procedure|Percutaneous nephrostomy|
31844|NCT03936660|Other|Intense Education Intervention|Intervention will involve guideline-based care education.
31845|NCT03936647|Procedure|surgical clipping, simple coiling, high-porosity stenting with/ without coiling, intra-arterial flow diversion with/ without coiling|Treatment may include the most appropriate amongst surgical clipping, simple coiling, high-porosity stenting with or without coiling, and intra-arterial flow diversion with or without coiling, which will be predetermined by the treating physician prior to randomization.
31846|NCT03936647|Device|WEB embolization device|WEB embolization device
31847|NCT03936621|Drug|Omega 3 fatty acid|To evaluate the efficacy of 3.6 g omega 3 fatty acid supplements (2.4 g EPA + 1.2 g DHA)/day for 6 months versus no treatment at reducing the level of C-reactive protein (CRP) in ever smokers at high risk of lung cancer. The primary endpoint of the study is reduction of CRP.
31848|NCT03936608|Device|Programming individualized RV-LV pacing offset to optimize ECG|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. The RV-LV offset that optimizes the paced QRS morphology on ECG will be programmed.
31849|NCT03936608|Device|Nominally programming CRT device without RV-LV offset|After CRT device implant, participants will undergo physiologic evaluations at various (up to 10 or more) RV-LV offset settings including ECGs. Nominal standard-of-care CRT programming with no RV-LV offset will be programmed.
31850|NCT03936595|Other|Core exercises protocol|"Participants will perform:~Squats, 4 sets of 5 repetitions at 60% 1RM~Deadlifts, 4 sets of 5 repetitions at 60% 1RM~Lunges, 4 sets of 5 repetitions at 60% 1RM~Step ups, 4 sets of 5 repetitions at 60% 1RM"
31851|NCT03936595|Other|Structural exercises protocol|"Participants will perform:~Snatch, 4 sets of 5 repetitions at 60% 1RM~Hang clean, 4 sets of 5 repetitions at 60% 1RM~Push jerk, 4 sets of 5 repetitions at 60% 1RM~Split push jerk, 4 sets of 5 repetitions at 60% 1RM"
31852|NCT03936595|Other|Accentuated eccentric load exercises protocol|"Participants will perform:~Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~Step down - squat jump, 4 sets of 5 repetitions at 30% BM~Step down - lunges, 4 sets of 5 repetitions at 30% BM~Hip thrusts, 4 sets of 5 repetitions at 30% BM"
31853|NCT03936595|Other|Control condition|Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
31854|NCT03936582|Behavioral|Treatment|information already included in arm/group descriptions
31855|NCT03936569|Drug|Marketed Toothpaste|Marketed stannous fluoride (0.454%) toothpaste
31856|NCT03936569|Drug|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
31857|NCT03936556|Drug|Marketed toothpaste|Marketed stannous fluoride (0.454%) toothpaste
31858|NCT03936556|Drug|Marketed Cavity Protection Toothpaste|Marketed sodium monofluorophosphate (0.76 %) toothpaste
31859|NCT03936543|Other|Position change|Different position during central line catheterization
31860|NCT03936543|Other|Conventional position|Conventional position during central line catheterization
31861|NCT03936517|Drug|Prednisolone|Low dose prednisolone for the treatment of adrenal insufficiency. Usually administered once daily
31862|NCT03936517|Drug|Hydrocortisone|Standard regimens of hydrocortisone for the treatment of adrenal insufficiency. Usually administered thrice daily.
31863|NCT03936504|Behavioral|Control Group ：routine exercise rehabilitation|routine exercise rehabilitation intervention for 12 weeks, 3 times a week ，one time for 40 minutes, including 10 minutes of preparation, 30 minutes of rehabilitation training.
31864|NCT03936504|Behavioral|Experimental Group ：Tai Chi combined routine exercise rehabilitation|Intervention for 12 weeks, 3 times a week ，one time for 60 minutes, including 10 minutes of preparation，30 minutes of rehabilitation training，20 minutes of Tai Chi exercise.
31865|NCT03936491|Drug|Methylphenidate|Methylphenidate is a central nervous system stimulant used for the therapy of attention deficit disorder and narcolepsy.
31866|NCT03936491|Drug|Atomoxetine|Atomoxetine is a medication used to treat attention deficit hyperactivity disorder (ADHD).[6] Use is only recommended in those who are at least six years old.[6] It is taken by mouth.[6]
31867|NCT03936478|Radiation|MRIdian Radiation Treatment Unit|partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
31868|NCT03936465|Drug|BMS-986158|BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.
31869|NCT03936452|Drug|Sintilimab|Sintilimab 200mg ivdrip D1 Anlotinib 12mg po D1-14 Peg-aspargase 2500U/m2 im D1 combined with radiotherapy
31870|NCT03936426|Drug|Cu-64 SARTATE and Cu-67 SARTATE|Cu-64 SARTATE diagnostic drug Cu-67 SARTATE therapy drug
31871|NCT03936413|Device|Bay Labs EchoGPS Echcoardiogram|An echocardiogram will be performed in this arm using the Bay Labs EchoGPS. The Bay Labs EchoGPS system is an ultrasound system which uses the techniques of computer vision to analyze echocardiography images in real time. It then provides feedback to the user to optimize the images, and once they meet a specific level of quality it automatically records the images.
31872|NCT03936413|Device|Native Terason Echocardiogram|An echocardiogram will be performed in this arm using a native Terason echocardiography system. This system will not have any artificial intelligence assistance in image optimization or selection.
31873|NCT03936400|Behavioral|Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy|Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
31874|NCT03936387|Drug|Ropivacaine|Erector spinae blocks: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus. Repeated on contralateral side.
31875|NCT03936374|Drug|BMS-986205|Participants will receive BMS-986205 on Days 1 and 15
31876|NCT03936374|Drug|omeprazole|Participants will receive omeprazole on Days 10 to 15
31877|NCT03936361|Drug|Statins|Statin drugs (already prescribed) at ICH onset will be either continued or discontinued by the participants following qualifying ICH
31907|NCT03936140|Drug|Distilled water|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
31908|NCT03936127|Procedure|Ultrasound (US) Targeted Fusion Biopsy|Ultrasound (US) Targeted Fusion Biopsy
31909|NCT03936114|Behavioral|SMART|SMART program mindfulness training program
31910|NCT03936101|Diagnostic Test|Prenatal Genomic Sequencing|Whole genome sequencing (which initially will be masked and reported as exome only)
33961|NCT03919383|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing
31878|NCT03936348|Device|Exercise training program with and without FB|"Participants carried out a supervised RP for 8 weeks, 3 days per week. The training sessions lasted 60 minutes and included a warning up phase, the main phase and a recovery phase. After each session, Borg's perceived exertion was measured. The Rehabilitation Program (RP) included aerobic exercise on cycle ergometer and on treadmill (progressing since 10' to 30' and since 40 to 75% of the reserve heart rate (RHR) or 6-7 score based on Borg's perceived exertion), strengthening of lower and upper limb muscles groups, breathing exercises (pursed lip breathing, diaphragmatic and abdominal breathing and diaphragmatic mobility) and finally stretching exercises.~In the FB group, for restricted nasal breathing, at the beginning of the training program, the small size device was used (4 mm). The size of the device was progressively increasing according to the patient adaptation to the 5 or 6 mm device, depending on the score on Borg's perceived exertion scale."
31879|NCT03936335|Drug|dupilumab|No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
31880|NCT03936322|Device|Minimally invasive fetoscopic repair of MMC|Uses a technique to open your belly (skin, muscles and abdomen) without opening the uterus, except for a small puncture, to repair the fetal spina bifida defect during the second trimester of pregnancy.
31881|NCT03936309|Other|Scar Deactivation Surface Release Technique protocol|▪ Alternating placement of Spring Ten (0.30x40 mm) acupuncture needles to surround scar left in place for a treatment duration of 20 minutes. Needles will be placed at intervals of 1cm to 1.5 cm and will surround the scar with a maximum of 20 needles per treatment.
31882|NCT03936309|Other|Scar Infiltration with 0.25-1% Lidocaine|▪ Will consist of calculation of 3 mg/kg dose of 0.5-1% Lidocaine and a dermal followed by subcutaneous injection using 1.5 inch 25 G needle and syringe appropriate for volume based on calculated dose.
31883|NCT03936309|Other|Physical therapy|▪ Will be a referral to physical therapy specifying McKenzie protocol treatment for the presenting complaint. The McKenzie protocol is a form of standard of care physical therapy in which the physical therapist tries to find a cause and effect relationship between the positions the patient usually assumes while sitting, standing, or moving, and the location of pain because of those positions or activities. The therapeutic approach requires a patient to move through a series of activities and test movement to gauge the patient's pain response. The approach then uses that information to develop an exercise program designed to centralize or alleviate the pain.
31884|NCT03936296|Procedure|mpMR guided MR-US fusion transrectal prostate biopsy|mpMR images will be loaded to US fusion platform and registration of the will be performed. Suspicious lesions on MR which have PIRADS score 3 and above are targeted. Additional 2-4 cores biopsies will be taken them
31885|NCT03936296|Procedure|12 core standard transrectal prostate biopsy|Under the guidance of transrectal ultrasonography, 12 core biopsies taken from apex, apex lateral, mid, mid lateral, base and base lateral of right and left prostate lobe
31886|NCT03936283|Behavioral|Intervention|The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
31887|NCT03936270|Drug|Palbociclib 125mg|The Palbociclib capsules supplied for this study contains 75 mg, 100 mg or 125 mg of Palbociclib. It must be taken orally 125 mg once daily for 21 consecutive days followed by 7 days off treatment (Schedule 3/1) to comprise a complete cycle of 28 days.
31888|NCT03936270|Drug|Letrozole 2.5mg|Letrozole will be supplied as a 2.5 mg film-coated tablet. It must be taken at the recommended dose of 2.5 mg once daily.
31889|NCT03936257|Other|Breastfeeding|Infants were breastfed during 3 months minimum. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
31890|NCT03936257|Other|Conventional BIO Infant formula|Infant were fed during 6 months with a conventional BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
31891|NCT03936257|Other|TrueGreen BIO infant formula|Infant were fed during 6 months with the TrueGreen BIO infant formula. Data on growth and tolerance were collected. 10 out of 40 infants take a blood test to metabolome analysis
31892|NCT03936244|Device|Transurethral Resection of the Prostate (TURP)|Randomized allocation to M-TURP or PK-TURP
31893|NCT03936231|Other|NO Intervention|"Given the observational nature of this study, we consider that no intervention is required.~Participation in concomitant studies: given the observational condition of this study, patiens that are included in other observational and/or experimental researches, can be included in the current study."
31894|NCT03936218|Drug|Inj. Goserelin (Test) Subcutaneously|10.8 mg, subcutaneously at every 3 month
31895|NCT03936218|Drug|Inj. Zoladex (Reference) Subcutaneously|10.8 mg, Subcutaneously at every 3 month
31896|NCT03936205|Drug|Dexmedetomidine|Patients allocated to this group receive a combination of Morphine and Dexmedetomidine
31897|NCT03936192|Drug|glucosamine sulphate 1500mg and meloxicam 15mg|glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
31898|NCT03936192|Drug|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg|Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
31899|NCT03936192|Drug|Placebos|Placebo administered once daily for 12 weeks.
31900|NCT03936179|Radiation|high dose radiation therapy with concurrent chemotherapy|standard dose of 50 Gy concurrent weekly with paclitaxel (45 mg/m2) and carboplatin (area under curve 1.5 ), immediately followed by hyperfractionated radiotherapy boost of 36 Gy in 30 fractions of 1.2 Gy to residual metabolic disease as defined by PET/CT
31901|NCT03936166|Drug|CRN01941 Oral Solution|Investigational drug
31902|NCT03936166|Drug|CRN01941 Oral Capsule|Investigational drug
31903|NCT03936166|Drug|Placebo Oral Solution|Placebo
31904|NCT03936166|Drug|Placebo Oral Capsule|Placebo
31905|NCT03936153|Drug|abexinostat|abexinostat tablet
31906|NCT03936140|Drug|Inhaled iloprost|Study drug was inhaled to ventilated lung through a nebulized system in inspiratory limb after one-lung ventilation in the lateral decubitus position.
31938|NCT03935841|Dietary Supplement|3-OHB salt (NaCl)|36 gram 3-OHB salt diluted in 500 ml sterile water
31911|NCT03936088|Device|"Intervention -- Headspace mindfulness application"|"Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs."
31912|NCT03936088|Device|"Control -- My Water Balance application"|My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
31913|NCT03936075|Behavioral|the Guided Imagery and Music method|the method involves listening to the music while describing the experience to the therapist, any visual imagery that is evoked by the music, emotions, body sensations, thoughts or memories. after the music listening session, there is discussion upon making meaning of the experience and finding resources as potential coping skills
31914|NCT03936075|Behavioral|standard care and verbal counselling|the participants receive their usual cancer treatment and two individual counselling sessions
31915|NCT03936062|Drug|Sitagliptin|Sitagliptin dispensing claim is used as the exposure
31916|NCT03936049|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure group
31917|NCT03936049|Drug|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference group
31918|NCT03936036|Drug|Liraglutide|Liraglutide dispensing claim is used as the exposure
31919|NCT03936036|Drug|Sulfonylurea|2nd generation sulfonylurea dispensing claim is used as the reference
31920|NCT03936023|Drug|Saxagliptin|Saxagliptin dispensing claim is the exposure
31921|NCT03936010|Drug|Canagliflozin|Canagliflozin dispensing claim is exposure
31922|NCT03936010|Drug|DPP-4 inhibitor|DPP4 inhibitor dispensing claim is reference
31923|NCT03935997|Other|Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program|"Strengthening a Palliative Approach in Long Term Care (SPA-LTC) consists of the following core, evidence-informed components. Our team works with homes to find ways to introduce these components at a realistic pace and in a way that is realistic for their particular context.~Interdisciplinary Champion Teams (to provide leadership and support implementation) Palliative Care Education, including shareables for staff and family members Comfort Care Rounds with staff (for capacity building and reflection) Prognostic Tools to trigger end-of-life discussions Palliative Care Conferences Post-Bereavement Follow-Up for residents, families, and staff"
31924|NCT03935984|Drug|Calcitonin|Treatment with calcitonin to lower high calcium levels prior to reimaging exam
31925|NCT03935971|Drug|Dupilumab|See arm/group description
31926|NCT03935958|Dietary Supplement|Curcumin|Patients will receive curcumin (Longvida) 2000 mg, once a day, for 12 months
31927|NCT03935958|Other|Placebo|Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
31928|NCT03935945|Behavioral|Personalized Feedback Intervention|Participants in the intervention group will receive a computerized personalized feedback intervention (PFI) lasting approximately 20-30 minutes. PFI highlights discrepancies between one's own drinking and typical drinking; reframes use in terms of personal, social, financial, and health consequences; and, offers strategies for reducing alcohol use. The feedback is non-confrontational in tone, seeks to increase motivation to reduce drinking and is based on the information provided during the baseline assessment
31929|NCT03935932|Device|nasal delivery of heated and humidified air|Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
31930|NCT03935906|Other|Reach Pathway|Trial of outreach nurse offering point-of-care Hepatitis C (HCV) testing to opiate substitution therapy patients in community pharmacies, which is hypothesised to improve number of patients tested and cured of HCV.
31931|NCT03935906|Other|Education-only Pathway|Trial of community pharmacists advising opiate substitution therapy patients to attend a local blood-borne virus clinic to be tested for Hepatitis C by a specialist nurse, which represents the standard care pathway for HCV patients in the countries included in the study.
31932|NCT03935893|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
31933|NCT03935893|Drug|Fludarabine + Cyclophosphamide combination|Preparative lymphocyte depleting (immunosuppressive) combination regimen consisting of fludarabine and cyclophosphamide administered prior to TIL infusion.
31934|NCT03935880|Device|Cartiva Implant|Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
31935|NCT03935880|Procedure|Cheilectomy|Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a saggital saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
31936|NCT03935867|Behavioral|C-PROFET|An expansion of the evidence-based, multi-factorial, fall prevention program PROFET (Prevention Of Falls in the Elderly Trial), developed for older adults who experienced a fall-related injury, to an at risk community-dwelling population who have not sustained a fall-related injury requiring medical intervention.
31937|NCT03935854|Other|LCHF, Ketogenic Diet|Low Carbohydrate, Moderate Protein, High Fat Ketogenic Dietary Intervention 16 weeks
33962|NCT03919383|Drug|Toripalimab|240mg intravenously every 3 weeks
31940|NCT03935815|Drug|Ropivacaine injection|30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
31941|NCT03935815|Procedure|Sham treatment|A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
31942|NCT03935802|Radiation|radiation|
31943|NCT03935789|Behavioral|BLAST|12-week self-guided intervention using a web-based platform
31944|NCT03935776|Behavioral|Risk Factors Modification Programme|12- week supervised risk factor modification programme derived from the Euroaction study standards
31945|NCT03935776|Behavioral|Standard Healthcare|Patients are advised to adjust lifestyle without the support of the structured supervised programme
31946|NCT03935763|Other|observational disease study|observation of routine clinical practices in mCRC
31947|NCT03935750|Procedure|Anterior cruciate ligament reconstruction (ACLR)|All participants will undergo an anatomic ACLR with either a BPTB or QT autograft, as randomized.
31948|NCT03935750|Procedure|Lateral extra-articular tenodesis (LET)|Participants randomized to the BPTB or QT arms will be randomized a second time to a LET procedure or no additional surgery.
31949|NCT03935737|Diagnostic Test|Full Dose Chest X-Ray|Full dose X ray at Day 1
31950|NCT03935737|Diagnostic Test|Low Dose Chest X-Ray|Low dose X ray within 3 months from full dose
31951|NCT03935724|Biological|Neuro-Cells|Neuro-Cells is an autologous fresh stem cells containing product which modulates the secondary inflammation following a TSCI, reduces apoptosis (cell death) in the injured spinal cord, reduces scar tissue formation in the damaged spinal cord and creates a cell regenerative environment in the injured spinal cord.
31952|NCT03935698|Other|Physiotherapy|
31953|NCT03935685|Drug|Mirtazapine (Remeron)|Eligible patients should start Mirtazapine 15mg and stay there unless not tolerated, If there is no improvement in nausea dose can be increased to 30 mg and respectively 45 mg, 4 days apart. If excessive sleep, dose can be doubled. Patients should not take tryptophan while they are part of the study.
31954|NCT03935672|Procedure|PET-CT scans|"Patients will have three scans during the trial.~The 1st scan (prePET) is a baseline diagnostic scan. The patient is in a thermoplastic shell and PET CT will be used by to define a bGTV_P. bGTV_P will then be used as an adjunct to help us delineate the GTV_P.~The 2nd scan (iPET) takes place following 2 weeks (10 fractions) of chemo-radiotherapy. The patient is in a thermoplastic shell and the PET CT will be used to delineate the remaining avid disease (bGTV_iP).~The 3rd scan takes place 3 months following the last dose of radiotherapy. It will be used to ascertain whether any avid disease remains and may inform the need for further treatment."
31955|NCT03935672|Procedure|Outlining the biological GTVs (bGTV_P and bGTV_iP)|The biological GTVs (bGTV_P and bGTV_iP) will be automatically delineated by ATLAAS and verified manually by a nuclear medicine physician and a clinical oncologist. It will consist of the high FDG uptake volume based on visual assessment whilst using suitable windowing levels. Any differences in contouring will be settled either by the two doctors reaching a consensus or by a third doctor if differences between the first two cannot be resolved.
31956|NCT03935672|Procedure|Blood samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
31957|NCT03935672|Procedure|Salivary samples for cell-free DNA analysis|In order to contribute to our understanding of how disease processes may be monitored in a less invasive and less morbid manner, we will be collecting blood and saliva samples prior to, during, and after the radical treatment of OPSCC in PEARL, to see if there is correlation with disease status and FDG-PET-CT response.
31958|NCT03935659|Device|Negative Pressure Pressure Wound Therapy|Investigators will be using a Negative Pressure Wound Therapy Powered Suction Pump on primarily closed groin wounds after open common femoral artery exposure, The Negative pressure dressing will be applied in a sterile fashion in the operating room. The negative pressure dressing will be removed at day 5 postoperatively, or at discharge, whichever occurs first.
31959|NCT03935659|Procedure|Standard Wound Care|Standard sterile gauze coverage of the primarily closed groin wound.
31960|NCT03935646|Drug|Adderall IR 10mg|At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.
31961|NCT03935646|Drug|Placebo|Placebo
31962|NCT03935633|Drug|CN128 Tablets|Iron chelator， oral tablets
31963|NCT03935620|Behavioral|Enhanced Milieu teaching|"Enhanced Milieu Teaching (EMT) an evidence-based, naturalistic language intervention that has been optimized to address the specific language and communication deficits associated with DS. EMT is a parent-implemented intervention that involves home-visits during which clinicians teach parents to support their child learning language during typical parent-child interactions at home (play with toys, music, book reading, and snack time). Clinicians follow an evidence-based instructional framework called Teach-Model-Coach-Review to teach parents language support strategies."
31964|NCT03935607|Diagnostic Test|Transvaginal sonography|Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
31965|NCT03935594|Biological|PRP Injection|1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.
31966|NCT03935594|Drug|Saline Injection|1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.
31967|NCT03935581|Device|ExAblate|Auto Focusing (AF) echo imaging
31968|NCT03935568|Drug|PU-AD|3 cohorts receiving a single oral dose of PU-AD at one time.
31969|NCT03935568|Drug|Placebo|3 cohorts receiving a single oral dose of Placebo at one time
31970|NCT03935568|Drug|Placebo|2 cohorts receiving multiple oral dose of Placebo at one time
31971|NCT03935568|Drug|PU-AD|2 cohorts receiving multiple oral dose of PU-AD at one time
31972|NCT03935555|Drug|PU-H71|PU-H71 is a synthetic purine-scaffold stress chaperome inhibitor, which specifically targets HSP90 in the tumor-specific epichaperome
33963|NCT03919370|Other|No intervention|there will be NO intervention
31973|NCT03935529|Behavioral|Behavioural Activation|"Participants will receive five sessions of Behavioural Activation. Behavioural Activation uses strategies such as activity scheduling, mastery and pleasure ratings, and graded task assignments to change a participant's perception of specific situations.~Behavioural Activation is based on the behavioural model of depression (Lewinsohn & Shaffer, 1971). Specifically, that depression is a result of reduced positive reinforcement, particularly in social relationships. Behavioural Activation aims to reduce depressive symptoms by implementing a schedule of positive reinforcement by altering a participant's behaviour and/or their environment. As, in certain environmental contexts, behaviours that reduce depression will continue to occur through reinforcement and those that increase depression will decrease over time (Roane, Fisher, & Carr, 2016).~Behavioural Activation has been shown to be an effective intervention for the reduction of depressed mood."
31974|NCT03935516|Other|Cast|The use of plaster and/or fiberglass for casting of subject arm.
31975|NCT03935503|Procedure|TEP|By making a 2 cm incision under the umbilicus, skin subcutaneous tissues are passed through blunt dissections and the anterior fascia of the rectus muscle is exposed. An anterior rectus sheath with a scalpel is performed with a 15 mm incision. The rectus muscle is laterally lateralized and the balloon trocar or laparoscope itself is advanced from the midline to the symphysis pubis via the posterior rectus sheath. After the peritoneal cavity is dissected, a low pressure pneumoperitone 10 mm Hasson trocar or another 10 mm balloon caged trocar is advanced through the subumblic incision. 9-11 mmHg low pressure pneumoperitoneum is created to prevent the development of subcutaneous emphysema. For proper imaging, the patient should have complete muscle relaxation. The patient is given a position towards the light trandelenburg and non-hernia side.
31976|NCT03935503|Procedure|Lichtenstein repair|"After the inguinal incision, the skin and subcutaneous camper and scarpa tissues are passed and the external oblique aponeurosis is dissected in the direction of the extension of the fibers and the medial lateral edge of the rectus is dissected to the lateral inguinal ligament, then the spermatic cord is released and suspended.The spermatic cord is separated from the inguinal canal.~In indirect hernias, the hernia sac is dissected from the spermatic cord and rejected into the abdomen by high ligation. In direct hernia, the hernia sac is pushed in and the transverse fascia is sutured with 2-3 separe stitches."
31977|NCT03935490|Procedure|emergency transrectus sheath pre-peritoneal mesh repair (e-TREPP)|"The Trans REctussheath PrePeritoneal mesh repair (TREPP) was developed in 2006 as an open preperitoneal technique to reduce CPIP. In short: a 4-5 centimeters (cm) transverse incision is made about 1 cm above the localization of the deep inguinal ring. The anterior rectus sheath is opened. After retracting the rectus muscle medially, the preperitoneal space (PPS) is bluntly dissected and a complete overview can be achieved. All possible hernia orifices can be visualized such as: a direct, indirect, pantaloon, and/or femoral hernia. A self-expandable mesh is then positioned in the PPS. Due to the upstream principle no mesh fixation is necessary."
31978|NCT03935477|Device|WellBeing catheter|Urethral catheterisation with integral Wellbeing Catheter to measure bladder tissue oxygen tension
31979|NCT03935464|Behavioral|PUMA|Collect urine on intervention participants and screen for presence of TFV. Feedback will be provided to the participant based on the results on their adherence with provision of standard adherence counseling.
31980|NCT03935451|Drug|Apixaban 2.5 milligram|2.5 milligram daily dosing of Apixaban beginning on the first day of hospital discharge for a total of 30 days
31981|NCT03935451|Drug|Placebo Oral Tablet|placebo oral tablet that resembles the experimental drug. To be taken with the same frequency and duration
31982|NCT03935438|Other|Cardiac rehabilitation|The training program of cardiac rehabilitation, depending on the results of the patient's medical qualification, will consist of the following: free active exercises, isometric exercises, active exercises in relief with resistance, isotonic exercises, isokinetic exercises, active breathing exercises, active breathing exercises with resistance, balance exercises, general exercises- individual and in groups, interval training on a treadmill or cycling cycloergometer, continuous training on a treadmill or cycling cycloergometer, circuit training, walking training, march training with accessories, autogenic training, walking. The training program will last an average 2 weeks.
31983|NCT03935425|Device|FitMi Plus|A set of common objects that couple with a wireless sensor platform to allow the performance of functional exercises to be measured by a motivating software platform.
31984|NCT03935425|Device|FitMi Basic|A wireless sensor platform that allows movement subcomponents and point-to-point exercises to be measured by a motivating software platform.
31985|NCT03935412|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block
31986|NCT03935399|Drug|Oxytocin|oxytocin (Pitocin®), 10 IU
31987|NCT03935399|Other|Placebo|Placebo (saline)
31988|NCT03935386|Procedure|Standard Multi-layered Compression dressing|Compression therapy with a multi-layered compression dressing for the treatment of venous leg ulceration
31989|NCT03935386|Procedure|Standard Multi-layered Compression dressing with a cryopreserved skin allograft (TheraSkin)|Application of a cryopreserved skin allograft (TheraSkin) beneath compression therapy with a multi-layered compression dressing.
31990|NCT03935373|Diagnostic Test|DNA Exome sequencing|The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing.
31991|NCT03935373|Diagnostic Test|Oral microbiome|The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome.
31992|NCT03935373|Diagnostic Test|Proteomics|The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics.
31993|NCT03935373|Diagnostic Test|RNA sequencing|The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing.
31994|NCT03935373|Diagnostic Test|Cytokine|The serum of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
31995|NCT03935373|Diagnostic Test|Traditional Chinese Medicine pattern|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pattern.
31996|NCT03935373|Diagnostic Test|Traditional Chinese Medicine tongue diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine tongue diagnosis.
31997|NCT03935373|Diagnostic Test|Traditional Chinese Medicine pulse diagnosis|Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pulse diagnosis.
31998|NCT03935373|Diagnostic Test|Heart rate variability|Sjögren's syndrome patients and health subjects will take the heart rate variability.
31999|NCT03935373|Diagnostic Test|Schirmer's test|Sjögren's syndrome patients will take the Schirmer's test.
32000|NCT03935373|Diagnostic Test|Blood function test, liver function test, kidney function test, and immune function test|Sjögren's syndrome patients and health subjects will take the blood function test (WBC, RBC, Hb, HCT, Platelet, MCV, MCH, and MCHC), liver function test (AST and ALT), kidney function test (BUN and Cre), and immune function test (RF, Anti-SSA, Anti-SSB Ab, ESR, and CRP)
32001|NCT03935360|Other|Oakland-Jairath Risk Score|Oakland and Jairath developed a clinical prediction rule for safe discharge among patients with LGIB using data from their UK National Audit. They defined safe discharge as the absence of rebleeding, blood transfusion, need for endoscopic/radiologic/surgical intervention for hemostasis, readmission with LGIB, and death and developed a seven variable risk score: age, sex, previous history of LGIB admission, presence of blood on digital rectal exam, heart rate, systolic blood pressure, and hemoglobin. Using a cut-off score ≤8, they reported excellent discrimination (AUC 0.84, 95% CI 0.82-0.86), good calibration, and a 95% probability of safe discharge.
32002|NCT03935347|Drug|Cyclophosphamide|Given IV
32003|NCT03935347|Drug|Fludarabine|Given IV
32004|NCT03935347|Drug|Fludarabine Phosphate|Given IV
32005|NCT03935347|Biological|Pembrolizumab|Given IV
32006|NCT03935347|Biological|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
32007|NCT03935347|Biological|Aldesleukin|Given IV
32008|NCT03935334|Biological|Biosimilar eptacog alfa, activated (AryoSeven)|A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
32009|NCT03935334|Biological|Eptacog alfa, activated (Novoseven)|A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
32010|NCT03935321|Drug|NG-101|6 intrathecal bolus injections, each of 45mg
32011|NCT03935321|Drug|Placebos|6 intrathecal bolus injections, each of 45mg
32012|NCT03935308|Radiation|MR guided Linear Accelerator|The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
32013|NCT03935295|Drug|AbobotulinumtoxinA|Paraspinal abotulinumtoxinA injections (compared to placebo)
32014|NCT03935295|Drug|Placebos|Placebo prepared by Ipsen for use as control
32015|NCT03935295|Device|Custom Thoracolumbosacral Orthosis|Non-operative external bracing for scoliosis curves
32016|NCT03935282|Other|AH-HA Tool in the EPIC EHR|The Automated Heart-Health Assessment tool implemented in clinics' EPIC EHR will be used by providers during routine follow-up care appointments.
32017|NCT03935269|Device|Cereset Research Wearable|Cereset Research Wearable is a portable, wearable
32018|NCT03935269|Procedure|Stress management therapy|Undergo Cereset research office intervention
32019|NCT03935269|Other|Questionnaire administration|Ancillary studies
32020|NCT03935269|Other|Quality of Life Assessment|Ancillary studies
32023|NCT03935243|Behavioral|equine assisted therapy|The equine assisted group therapy is carried out by a riding therapist (nurse psychiatry HF, certified riding therapist SG-TR). There is a detailed plan for the PT.
32024|NCT03935243|Behavioral|activating control phase|The control phase includes a generally activating employment offer, such as board games, light physical activations, roundtables and artistic design.
32025|NCT03935217|Drug|Secnidazole|Oral Granules containing secnidazole
32026|NCT03935217|Drug|Placebo|Oral Granules of placebo manufactured to mimic secnidazole
32027|NCT03935204|Biological|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
32028|NCT03935204|Biological|Placebo|Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
32029|NCT03935191|Device|Dexcom CGM System|Dexcom CGM System
32030|NCT03935178|Diagnostic Test|Measuring Right Ventricular Size and Function|This study focuses on evaluating different approaches to evaluation of right ventricular size and function using the Upper Valley Right Ventricle Algorithm and novel imaging modalities
32031|NCT03935165|Drug|Indocyanine Green|"0.25 mg /(kg BW) Indocyanine Green PULSION®/ VERDYE Diagnostic Green®~- Indocyanine Green is administered Intravenously"
32032|NCT03935152|Drug|Dydrogesterone|dydrogesterone capsule
32033|NCT03935152|Drug|placebo|placebo capsule
32034|NCT03935139|Biological|glucose measurement|Glucose values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
32035|NCT03935139|Biological|lactacte measurement|Lactate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
33005|NCT03927144|Drug|Oral Prophylactic|SoC oral prophylactic (active comparator) Treatment Period 52 weeks
32036|NCT03935139|Biological|pyruvate measurement|pyruvate values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
32037|NCT03935139|Biological|glycerol measurement|glycerol values will be recorded during 5 days as following : every hour at day 0, every 2 hours at day 1, every 3 hours at days 2 to 5.
32038|NCT03935139|Procedure|Bone free flap monitoring|Bone free flaps will be monitored with a microdialysis catheter directly positioned in bone tissue.
32039|NCT03935126|Diagnostic Test|Diagnostics|Diagnostics
32040|NCT03935113|Other|Kinesio taping|In KT group, KT was applied using the insertion-origin muscle and space-correction technique of affected upper limb with stroke patients.
32041|NCT03935100|Procedure|Endoscopic clipping|Endoscopic clips fired to close mucosa over diverticular defects.
32042|NCT03935100|Other|Placebo - colonoscopy without clipping|Colonoscopy performed, no clipping of diverticula
32043|NCT03935087|Diagnostic Test|two-dimensional echocardiogram|two-dimensional echocardiogram with evaluation of left ventricle volumes and of left ventricular ejection fraction
32044|NCT03935074|Drug|intra-arterial administration of melphalan|
32045|NCT03935061|Other|Mulberry juice|On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
32046|NCT03935048|Dietary Supplement|Higher protein, low glycemic load diet|"All dietary treatments will be designed to be isoenergetic within individual participants. Energy content of the diets will be individualized to ensure weight maintenance throughout the dietary intervention period using the Harris Benedict equation x 1.35. Glycemic load for the treatment groups will be calculated using the following equation:~Glycemic Load = Glycemic Index x Grams of carbohydrates/100. Potatoes, processed potato products, and control carbohydrate foods will be provided."
32047|NCT03935035|Behavioral|internet-delivered Cognitive Therapy for PTSD (iCT)|Participants will receive 10 hours of Cognitive Therapy for PTSD over 12 weeks, with a baseline assessment at the beginning and follow up interview at the end of treatment. The treatment consists of online modules (9 core modules, 11 optional modules and parent/carer modules) and a weekly phone call with a qualified and trained therapist.
32048|NCT03935022|Other|Rice|"Each group will randomly receive, during three different experimental days, one of the following treatments by different allocation sequences:~80g of black rice Venere (Group A)~80g of black rice Artemide (Group B)~80g of brown rice (Group C) The three treatments will be separated by a 7 day wash-out period. After an overnight fast, volunteers will consume the rice serving within 10-15 min, immediately after the first basal blood collection at 8:00 a.m. (baseline). Other blood withdrawals will be carried out a 0.5, 1.0, 2.0 and 3.0 h after rice administration."
32049|NCT03935009|Behavioral|Manual toothbrush Curaprox 5460 ultra soft|Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
32050|NCT03935009|Behavioral|Electric toothbrush Play Smart Brush N°1|Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.
32051|NCT03935009|Behavioral|Electric toothbrush Play Smart Brush N°2|Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
32052|NCT03934996|Other|Runners with educational training|"Intervention will consist of an educational talk to know the anatomy and function of the Pelvic Floor Muscles and 20 minutes of both strength and endurance exercises with biofeedback. An exercise protocol will be carried out. The participants will be instruct to contract and maintain maximum force for a mean period of 6 seconds (endurance training) and rest for twice the length of the endurance training time, followed by three fast contractions in a row as strength training. It will be done twice a week, during 12 weeks.~Pelvic floor assesment: Perineometry, manual palpation, electromyography Trunk and lower limbs electromyography and kinematics"
32053|NCT03934983|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
32054|NCT03934970|Diagnostic Test|Diffusion tensor imaging of peripheral nerves|All subjects underwent evaluation using 1.5T DTI of median nerves and NCS. Patients underwent clinical evaluation using Neuropathy Deficit Score (NDS), Neuropathy Impairment Score in the Lower Limbs (NIS-LL) and Diabetic Neuropathy Examination (DNE) score.
32055|NCT03934944|Device|Phone application|Weekly foot alerts and educational video
32056|NCT03934944|Other|Usual care|Usual routine of diabetic foot education
32057|NCT03934931|Other|Streamlined weekly DOT visits|Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects
32058|NCT03934931|Other|Weekly DOT visit reminders|Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits
32059|NCT03934931|Other|Cost reimbursement DOT|Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)
32060|NCT03934931|Other|99DOTS|99DOTS-based digital adherence technology to monitor and promote adherence
32061|NCT03934931|Other|Weekly SAT dosing reminders/check-ins|Weekly SMS or IVR phone call dosing reminder/check-in for side effects
32062|NCT03934931|Other|Cost reimbursement SAT|Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
32063|NCT03934918|Other|Treatment|Patients for IOL are sent home after placement of intracervical balloon
32064|NCT03934905|Drug|sulforaphane|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets in a daily dose for 12 weeks of: two caplets for individuals <100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals >200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
32136|NCT03934398|Diagnostic Test|Actigraphy|Participants will wear an actigraph device for 7 days to measure participant's activity and sleep.
32137|NCT03934398|Diagnostic Test|Laboratory assessments|Participants will provide blood and urine samples for laboratory assessments.
32065|NCT03934905|Drug|Placebo Oral Tablet|The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or SFN caplets in a daily dose for 12 weeks of: two caplets for individuals <100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals >200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
32066|NCT03934892|Diagnostic Test|serum lactate|check lactate levels during cardiopulmonary bypass in adult cardiac operations
32067|NCT03934879|Behavioral|FitClub|Participants will rotate through each fitness module, which includes spin class, Pilates, strengthening exercises (weight training), basketball, running and rhythm, and cardio fitness. Students will meet five days per week during their first class of the day for 35 minutes and participate in two randomly assigned modules for two week periods. After 2 weeks, they participate in 2 different modules. Resting and peak heart rate (during exercise), calories burned and steps taken will be collected during each session.
32068|NCT03934879|Other|Regular School Activities|Students will participate in regular school activities.
32069|NCT03934866|Radiation|Low Dose CT scan|Low Dose chest CT scan conferring an equivalent radiation dose of less than 2 mSv to the average size patient. The study aims to keep most scans under 1 mSv (ultra-low dose), and all scans under 2 mSv.
32070|NCT03934853|Device|Dynamic Dental Navigation|Aid in dental implant placement in humans
32071|NCT03934840|Drug|Cabazitaxel|20 mg/m2 Q 21 days
32072|NCT03934840|Drug|Carboplatin|AUC 4 Q21 Days x 6 cycles with ADT
32073|NCT03934840|Drug|Abiraterone|1000 mg PO daily
32074|NCT03934840|Drug|Prednisone|5 mg PO daily on chemotherapy completion
32075|NCT03934827|Drug|MRx0518 Capsules|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
32076|NCT03934827|Drug|MRx0518/placebo Capsules|MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
32077|NCT03934814|Drug|TJ011133|TJ011133 will be administered weekly
32078|NCT03934814|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks
32079|NCT03934814|Drug|Rituximab|Rituximab will be administered weekly for 5 doses, then followed by monthly doses
32080|NCT03934801|Other|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
32081|NCT03934801|Other|Ranking Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
32082|NCT03934801|Other|Ranking Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
32083|NCT03934801|Other|Ranking Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
32084|NCT03934788|Device|oxysoft (olifilcon C)|subjects meet certain criteria will be administered randomly oxysoft on both eye for one month on daily wear single use modality.
32085|NCT03934788|Device|Si-Hy (olifilcon B)|subjects meet certain criteria will be administered randomly Si-Hy on both eye for one month on daily wear single use modality.
32086|NCT03934775|Device|Finapres Nova|Non-invasive mesurement of hemodynamic parameters and heart rate variability
32087|NCT03934762|Biological|Placebo|A placebo solution that will not include aloe vera will be applied on the quadriceps of one of the lower limbs.
32088|NCT03934762|Biological|Natural Aloe Vera|Natural aloe vera solution including peel and leaf from aloe will be applied on the the quadriceps of one of the lower limbs.
32089|NCT03934762|Biological|Aloe vera soup|Aloe vera solution including aloe vera soup will be applied on the the quadriceps of one of the lower limbs.
32090|NCT03934749|Device|Non Invasive Ventilation|NIV using standard mode or Lowenstein mode
32091|NCT03934736|Drug|HEPLISAV-B®|HEPLISAV-B®, a licensed, commercially-available hepatitis B vaccine consisting of the adjuvant cytidine phosphoguanosine (CpG) 1018 combined with the antigen recombinant hepatitis B surface antigen (rHBsAg).
32092|NCT03934723|Behavioral|Exercise|The intervention consists of 180 minutes of moderate-vigorous aerobic exercise per week for 6 weeks.
32093|NCT03934710|Drug|Placebo|Drug will be administered in solution form
32094|NCT03934710|Drug|Serotonin agonist|13ug lysergic acid diethylamide
32095|NCT03934697|Behavioral|imaginal exposure therapy|All participants will complete the same arm, which is ten sessions of imaginal exposure across a ten week time period. Each session is separated by 1 week.
32096|NCT03934684|Drug|Drug: Carfilzomib + Dexamethasone|"Drug: Carfilzomib + Dexamethasone~Carfilzomib will be administered as a 30-minute infusion.~Dexamethasone will be taken by mouth or intravenously."
32097|NCT03934684|Drug|Drug: Carfilzomib + Lenalidomide + Dexamethasone|"Drug: Carfilzomib + Lenalidomide + Dexamethasone~Carfilzomib will be administered as a 10 minute infusion.~Lenalidomide will be taken orally.~Dexamethasone will be taken by mouth or intravenously."
32098|NCT03934671|Device|Antioxidant dressing (active product)|"Antioxidant dressing (active product), covered with secondary dressing. Compression bandage if necessary.~Device: Reoxcare®"
32099|NCT03934671|Device|Usual care dressing that create a moist environment (standard clinical practice)|Usual care dressing; moist environment dressing chosen from the study centres' formulary (hydrocolloid, alginate, polyurethane foam dressings, silver dressings). Compression bandage if necessary
32100|NCT03934658|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
32101|NCT03934658|Device|NightWare Therapeutic System in Sham Mode|A wearable digital therapeutic system that will measure physiologic data when worn during sleep that does not deliver interventions.
32138|NCT03934398|Diagnostic Test|Emotional/Behavioral Assessments|Participants and parents will fill out questionnaires for emotional/behavioral assessments
32102|NCT03934645|Other|Delirium prediction model for ICU patients, version 1|The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
32103|NCT03934645|Other|Delirium prediction model for ICU patients, version 2|The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
32104|NCT03934645|Other|Early prediction model for delirium in ICU patients|The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
32105|NCT03934632|Other|Postabsorptive|Saline will be infused to mimic postabsorptive circulating amino acid concentrations
32106|NCT03934632|Other|Postprandial|An amino acid infusate will be administered to mimic postprandial circulating amino acid concentrations
32107|NCT03934632|Procedure|Immobilisation|One leg will undergo 2 days immobilisation prior to the test day
32108|NCT03934619|Device|Dolores One|Dolores One, which is a will be applied personal sounds amplification device, will be used to determine if it improves the ability to communication and improves intelligibility
32109|NCT03934606|Behavioral|Genetic testing for hereditary predisposition|Change in distress levels (HADS-Anxiety) from Baseline to Assessments #2 and #3, measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
32110|NCT03934593|Behavioral|Faith-Based (FB, BHT DSMS)|BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.
32111|NCT03934593|Other|Faith-Placed (FP, Stanford DSMP)|Standard Stanford DSMP delivered by health professional
32112|NCT03934580|Other|hallucinated meal|a breakfast meal (white bread plus ham and cheese with 250 ml still water) is hallucinated by participants under hypnosis
32113|NCT03934580|Other|Real meal|A real breakfast (white bread plus ham and cheese with 250 ml still water) is consumed by participants
32114|NCT03934567|Drug|Abexinostat|Abexinostat tablets
32115|NCT03934541|Biological|MPER-656 Liposome Vaccine|Administered by intramuscular injection
32116|NCT03934541|Biological|Placebo for MPER-656 Liposome Vaccine|Administered by intramuscular injection
32117|NCT03934528|Device|Virtual environment activity|Patients undertake an activity using simulated arm movement within a virtual reality environment every day for two months
32118|NCT03934515|Diagnostic Test|etCO2|"At the end of the procedure, therefore, for each patient two values of etCO2 are acquired which will allow to obtain two populations of values of the etCO2: the values at the endotracheal level and the esophageal level values. By statistical analysis, we will find the threshold value above which the value of etCO2 found is certain for a location of the nasogastric tube in the tracheal area. The study manager is not directly involved in the measurement and recording of etCO2 values."
32119|NCT03934515|Diagnostic Test|pH|"At the end of the procedure, for each patient two values of pH are acquired which will allow to obtain two pH value populations: a value at esophageal level and a value at the gastric level. By statistical analysis (see below), we will try to find the threshold value below which the pH is suggestive for a localization of the nasogastric tube in the gastric area. The study manager is not directly involved in the measurement and recording of pH values."
32120|NCT03934502|Drug|Evobrutinib|Participants will receive single oral dose of evobrutinib either after an overnight fast of at least 10 hours (Treatment A), within 30 minutes after start of a light meal (Treatment B), 1 hour prior to a low-fat meal (Treatment C), or 2 hours after start of a low-fat meal (Treatment D).
32121|NCT03934489|Behavioral|PERSIST|12-week group, adapted from Dialectical Behavior Therapy, that focuses on emotion regulation skills training and practice.
32122|NCT03934489|Behavioral|Facilitated Peer Support|12-week group, adapted from community-based peer support groups, that focuses on participant-generated topics and facilitated discussion.
32123|NCT03934476|Behavioral|Ketogenic diet|The study subjects randomized for this intervention will observe the ketogenic diet, as prescribed by the protocol.
32124|NCT03934476|Behavioral|Exercise HIIT|The study subjects randomized for this intervention will observe the HIIT exercise programme, as prescribed by the protocol.
32125|NCT03934450|Drug|RPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
32126|NCT03934450|Drug|SPQ|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
32127|NCT03934450|Drug|Primaquine Phosphate|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
32128|NCT03934450|Drug|Placebo|The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
32129|NCT03934437|Behavioral|mLTCR|mHealth-enhanced Linkage to Care and Retention
32130|NCT03934437|Behavioral|LTC|Linkage-to-Care Officers (Standard-of-Care)
32131|NCT03934424|Behavioral|Weight stigma|Subject will read an article depicting discrimination against individuals with higher body weights for 5-10 minutes on one day
32132|NCT03934424|Behavioral|Ethnic stigma|Subject will read a control article for weight stigma depicting discrimination against individuals from a minority ethnic group for 5-10 minutes on one day
32133|NCT03934411|Drug|Tramadol|The subjects will orally ingest 100 mg tramadol retard actavis
32134|NCT03934411|Other|Placebo|The subjects will orally ingest 100 mg calcium powder
32135|NCT03934398|Diagnostic Test|Cardiovascular Assessments|Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.
32139|NCT03934385|Behavioral|Mental Rehearsal|After each exposure session, participants complete three rehearsal/retrieval exercises that involve viewing images of spiders and completing multiple-choice and free-response questions. Exercises involve retrieving information specific to the spider exposures, reflecting on the experience, and highlighting expectancy violation (i.e., that the participant's feared outcome did not occur).
32140|NCT03934385|Behavioral|Exposure|All participants complete two exposure sessions. The first set of exposures consists of ten 30-second trials hovering one's hand 3 inches over a live tarantula. The second set of exposures consists of ten 30-second trials placing one's hand inside the spider's terrarium with all five fingertips touching the bottom.
32141|NCT03934372|Drug|Ponatinib|Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.
32142|NCT03934359|Drug|DN1508052-01|DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.
32143|NCT03934346|Other|Zinc amino acid complex|Zinc in the form of a Zinc Amino Acid Complex (ZnAA) is provided with a test diet, and the amount of zinc that dissociates from the ZnAA and is thus absorbed via an ionic zinc transport pathway is determined based on the Hill transport kinetics for the respective subject.
32144|NCT03934333|Drug|BDA MDI 160/180 mcg|Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
32145|NCT03934333|Drug|Pulmicort Flexhaler 180 mcg|Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
32146|NCT03934320|Other|FAMCAT|The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
32147|NCT03934307|Drug|ALN-AGT01|ALN-AGT01 will be administered by subcutaneous (SC) injection.
32148|NCT03934307|Drug|ALN-AGT01-Matching Placebo|Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.
32149|NCT03934307|Drug|Irbesartan|Irbesartan will be administered orally.
32150|NCT03934307|Drug|Irbesartan-Matching Placebo|Irbesartan-matching placebo will be administered orally.
32151|NCT03934294|Other|Specific acupuncture group|"In addition to routine ICU treatments, patients in the specific acupuncture group will also receive daily bilateral traditional Chinese medicine style acupuncture on the following acupuncture points: ST36 (Zu San Li), ST37 (Shangjuxu), ST39 (Xiajuxu), PC6 (Nei Guan) and LI4 (He Gu). The acupoints indications in this group are specific to treat indigestion related conditions. The treatment will take place once a day, over three days, for a total of three treatments. A total of 10 Needles will be used in each session Acupuncture treatment will be performed with sterile needles manufactured by Yu Kuang acupuncture needles 40mm with 30G."
32152|NCT03934294|Drug|Metoclopramide 10mg|Patients in all groups will receive Metoclopramide 10mg/ per 8 hours in the case of poor digestion, alongside the individualized drug treatment prescribed by the ICU medical doctor as per individual patient needs.
32153|NCT03934294|Other|Non-specific acupuncture group|Patients' in the non-specific acupuncture group (Con-Acu) will receive routine ICU treatment as well as a total of 3 daily non digestion related Traditional Chinese medicine style acupuncture treatments at the following acupoints: LI 15 (Jianyu), SJ 14 (JianLiao) LU3 (Tianfu), GB35 (Yangjiao), BL 59 (Fuyang). The selected control points are not indicated for the treatment of digestion related conditions, and are not reported to improve digestive function.
32154|NCT03934281|Device|Honey dressing Melectis G|"The protocol includes rinsing the wound with the saline, gently drying the edge of the wound, applying a thin Mélectis®G film to the entire wound surface and covering with a secondary dressing.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
32155|NCT03934281|Device|HAS recommendation dressing|"Patients included in the standard arm will receive the best available dressing according to the HAS recommendations.~Dressings will be rehabilitated based on the evolution of the wound and clinical judgement of the investigator or nurse at home as recommended."
32156|NCT03934268|Genetic|KCNQ2|The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.
32157|NCT03934255|Other|Constant Routine Protocol|Constant routine protocols are used in circadian research to examine underlying circadian rhythms in the absence of light, activity, and meals
32158|NCT03934242|Other|Questionnaire on new born's bedding|Questionnaire on new born's bedding (Child's position in the bed : dorsal, ventral or lateral, presence of pillow or stuffed in bed, presence of coverage and presence of the bed sharing) at two times (during hospitalisation and one month later)
32159|NCT03934229|Dietary Supplement|Daily intake of study product|Daily intake of Bifidobacterium animalis ssp. lactis 420 or placebo for a 6-month period
32162|NCT03934203|Drug|BI 409306|Film-coated tablet
32163|NCT03934203|Drug|Moxifloxacin|Film-coated tablet
32164|NCT03934203|Drug|Placebo matching to BI 409306|Film-coated tablet
32165|NCT03934177|Dietary Supplement|Blueberry powder|Dried, powdered blueberries will be consumed at 21 g/day in two divided doses at least 4 hours apart.
32166|NCT03934177|Dietary Supplement|Placebo powder|A placebo consisting maltodextrin will be consumed at 21 g/day in two divided doses at least 4 hours apart.
32167|NCT03934151|Procedure|intracorporeal ileocolic anastomosis|laparoscopic bowel transection and ileocolic anastomosis performed inside the abdomen with specimen retrieval in plastic bag
32168|NCT03934151|Procedure|extracorporeal ileocolic anastomosis|ileocolic anastomosis is carried out by exteriorizing the bowel through a limited laparotomy
32169|NCT03934138|Other|Educational movie on placebo mechanisms|"Educational movie on placebo mechanisms : animated video, duration : 12 minutes.~It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment)"
32275|NCT03933267|Other|Conventional Exercises|conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility exercises will be given to patients.
33006|NCT03927131|Biological|QIV-IB|Inactivated split-virion quadrivalent influenza vaccine
32170|NCT03934138|Other|Informative movie on hand washing|Animated video, duration : 11 minutes. It will be followed by the CPTs : experimentally induced pain by keeping the non dominant hand in cold water (1° Celsius) for a limited time. The duration of immersion is personal and calibrated to be around to ensure that the intensity of pain will be homogeneous (around 7/10 on the visual analogue scale with no treatment).
32171|NCT03934099|Drug|Xanthine Oxidase Inhibitor|Test drug
32172|NCT03934099|Drug|Xanthine Oxidase Inhibitor|Active comparator
32173|NCT03934099|Drug|Placebo|Matching placebo
32174|NCT03934086|Drug|rimegepant|rimegepant 75 mg
32175|NCT03934073|Other|DEXTRAIN|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.
32176|NCT03934073|Other|CONVENTIONNELLE|12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke
32177|NCT03934073|Other|CONTROLE|Only one assessment will be provided for the control group which will include, Box & Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
32178|NCT03934060|Other|Exercise|specific strength training
32179|NCT03934047|Drug|Tranexamic Acid 100 MG/ML|Visual Field Infiltration of Tranexamic Acid during the operation of total knee replacement.
32180|NCT03934008|Other|MOtivational interviewing Tool to Improve Vaccine AdherencE (MOTIVE)|The MOTIVE tool incorporates the principles of motivational interviewing (MI) and provides a flowchart approach in which parental health beliefs have a corresponding MI-based strategy to further explore and/or address the hesitancy. The tool was developed from interviews with pediatricians and pediatric pharmacists, a review of the literature focusing on vaccine health beliefs, and the Parent Attitudes about Childhood Vaccines (PACV) Survey Tool. The tool was reviewed by multiple providers and feedback was provided on its usability in clinical practice when interacting with vaccine-hesitant parents and/or caregivers. The tool was then modified based on this feedback. Pediatric providers will complete four educational sessions on vaccine hesitancy, MI, and the use of the MOTIVE tool in clinical practice prior implementation.
32181|NCT03933995|Other|no Intervention|no Intervention
32182|NCT03933982|Drug|Pyrotinib Plus Vinorelbine|Pyrotinib: 320mg/d, q.d., p.o. A course of treatment need 21 days. Vinorelbine: 60mg/m2 q.d. d1,8,15, p.o. A course of treatment need 21 day.
32183|NCT03933956|Drug|Empagliflozin 10 MG|Oral empagliflozin 10mg daily for 30 days
32184|NCT03933943|Drug|LY3361237|Administered SC
32185|NCT03933943|Drug|Placebo|Administered SC
32186|NCT03933930|Other|Lactate-directed therapy|If the lactate level elevates, we transfuse pRBC to increase Hct>30%. If Hct >30%, dopamine infusion starts.
32187|NCT03933930|Other|Goal-directed therapy|If SVV>15%, transfuse lactate ringer/normal saline alternatively to keep SVV<15%.
32188|NCT03933917|Procedure|Acute Normovolemic Hemodilution|Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight（Kg）×12-15（mL/Kg）;Blood to be removed was capped at： Vmax=EVB×(Hi-Hf)/Hav（EBV= estimated blood volume （male:70mL/Kg，female:65mL/Kg）；Hi= initial hemoglobin ；Hf=target Hb（ 10g/dL ）；Hav= the average of the initial and minimal allowable hemoglobin）.Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.
32189|NCT03933904|Drug|Sirolimus|Sirolimus (also known as rapamycin) inhibits the mTOR protein kinase and is approved by the USA FDA for the prevention of allograft rejection in renal transplant patients ≥ 13 years of age and for the treatment of lymphangioleiomyomatosis.
32190|NCT03933891|Procedure|TIPS|TIPS: Established distributary channel between the portal vein and hepatic vein via the jugular vein, portal vein blood directly shunts into the systemic circulation to reduce portal vein pressure to effectively prevent bleeding and refractory ascites.
32191|NCT03933865|Drug|HYDROmorphone Injectable Solution|Hydromorphone will be given via intramuscular injection (8 mg)
32192|NCT03933865|Drug|Ketamine|Ketamine will be given via intramuscular injection (0.1, 0.2 or 0.4 mg/kg)
32193|NCT03933865|Drug|Placebos|Placebo will be normal saline solution given via intramuscular injection.
32194|NCT03933839|Behavioral|PainCOACH|PainCOACH is an eight-week, automated, internet-based training in specific pain coping skills (such as progressive muscle relaxation, pleasant imagery and activity pacing), and guided practice with each skill.
32195|NCT03933813|Other|Iron Sucrose|Venofer (Iron Sucrose Injection USP) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
32196|NCT03933800|Device|High flow nasal cannula|High flow nasal cannula therapy
32197|NCT03933800|Device|Continuous positive airway pressure|Continuous positive airway pressure therapy
32198|NCT03933787|Drug|Saxagliptin 5mg|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
32199|NCT03933787|Drug|Placebo oral capsule|Randomised study: session 1 the volunteer will receive either saxagliptin or placebo. Session 2 the volunteer will receive the placebo or saxagliptin
32200|NCT03933787|Other|ergometric test in healthy volunteers|The volunteers will undergo an ergometric test in each session
32201|NCT03933774|Device|Tretinoin 0.05% cream|Stieva-A Cream 0.05%, 25g, GSK
32202|NCT03933774|Device|Placebo cream|Physiogel Daily Mositure Therapy Facial cream, 150mL, Stiefel
32203|NCT03933761|Drug|Pamiparib|60 mg of pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.
32204|NCT03933748|Drug|Teicoplanin-PMMA|Therapeutic drug monitoring of teicoplanin
32205|NCT03933735|Drug|TNB-383B|TNB-383B is a bispecific antibody targeting BCMA on tumor cells and CD3 on T-cells.
32206|NCT03933722|Device|Caretaker|Application of Caretaker device to subjects that have septic shock and that have an invasive arterial pressure monitor placed.
32302|NCT03933007|Drug|Colchicine,|"the day of phenotyping assay~Colchicine : 1.5 mg over 1 hour (1 mg + 0.5 mg 1 hour later)"
32303|NCT03933007|Drug|midazolam,|Midazolam 1 mg
32207|NCT03933709|Dietary Supplement|Nutritional Support System (NSS)|Envelope 1 4.9g of Spirulina, 100mg ascorbic acid, 5mg folic acid and 10mg of glutamine. Was to be added to shake 1 during the first 10 days. Envelope 2 1g PUFAs n-3 and was to be added to shake 2 which was given throughout the intervention. Envelope 3 4.9g of Spirulina Maximum, 100mg ascorbic acid, 5mg folic acid, 5.2g vegetable protein, 125mg nicotinic acid, 50mg zinc, 100 mcg selenium and 800 UI cholecalciferol. Was to be added to shake 1 from day 11 until the end of week 6, after which it was suspended for 10 days and substituted for envelope 5 and then to be retaken until the end of the intervention. Envelope 4. 1g arginine and was to be added to shake 3 from day 8 until the end of the intervention. Envelope 5 contained the same ingredients as envelope 3 with an additional 10mg glutamine and was to be added to shake 1 from the start of week 7 for 10 days, after which envelope 3 was restarted. Probiotic at a dosage of 200 mg every 12 hours for 3 days at the beginning and week 6
32208|NCT03933709|Other|deworming|nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days.
32209|NCT03933709|Other|recommended diet|WHO Diet
32210|NCT03933696|Device|Tailored Lighting Intervention|Lighting Intervention either Active or Placebo
32211|NCT03933683|Device|Pudendal nerve terminal motor latency assessment|After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
32212|NCT03933670|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
32213|NCT03933670|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
32214|NCT03933670|Procedure|MRI Ultrasound Fusion Guided Biopsy|Undergo MR/US fusion-guided prostate biopsy
32215|NCT03933657|Device|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
32216|NCT03933644|Device|Gastric Tube|SGA is inserted with a gastric tube as guide for insertion
32217|NCT03933644|Device|No gastric Tube|SGA is inserted without a gastric tube as guide for insertion
32218|NCT03933631|Drug|Pilocarpine|pilocarpine hydrochloride ophthalmic solution 2% (20 mg/mL)
32219|NCT03933631|Drug|Prednisolone|Prednisolone acetate ophthalmic suspension 1%
32220|NCT03933631|Drug|Ofloxacin|Ofloxacin Drops
32221|NCT03933618|Drug|Anastrozole 1mg|
32222|NCT03933618|Drug|Clomiphene Citrate 25mg|
32223|NCT03933618|Drug|Placebo - Cap|
32224|NCT03933605|Drug|midazolam and palonosetron group|intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
32225|NCT03933605|Drug|palonosetron group|intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
32226|NCT03933592|Procedure|Serratus anterior block|after induction of anesthesia and Patients will be placed in the lateral position with the diseased side up. A linear ultrasound transducer (10-12 MHz) will be placed over the mid-axillary region of the thoracic cage in a sagittal plane. The rib will be counted inferiorly and laterally, until the fifth rib is identified in the mid-axillary line. The following muscles will be identified easily overlying the fifth rib: the latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscle (deep and inferior). The needle (22- G, 50 - mm Touhy needle) will be introduced in-plane with respect to the ultrasound probe targeting the plane superficial to the serratus muscle. Under continuous ultrasound guidance a bolus of 30 ml of 0.25% levobupivacaine 30 mint before skin incision. At the end of surgery, surgeon will put the catheter deep to serratus muscle and get it out with chest tube and fix it followed by an infusion of 5 ml/hour of 0.125% Levobupivacaine.
32227|NCT03933592|Procedure|thoracic epidural|In group I: thoracic epidural inserted at low thoracic level in sitting position then test dose will be administered to detect any complications then a bolus of 10 ml of 0.25% levobupivacaine 30 mint before skin incision followed by an infusion of 5 ml/hour of 0.125% levobupivacaine after surgery.
32228|NCT03933579|Diagnostic Test|Deep phenotyping|Each participating hospitals will be collecting whole blood from each patient, through which DNA, RNA, serum, plasma, and peripheral blood mononuclear cells will be extracted from the buffy coat layer for further multi-omics analysis.
32229|NCT03933566|Procedure|Ultrasound-Guided Superficial Cervical Plexus Block|Ultrasound-Guided Superficial Cervical Plexus Block
32230|NCT03933566|Procedure|Landmark-Based Superficial Cervical Plexus Block|Landmark-Based Superficial Cervical Plexus Block
32231|NCT03933553|Other|Aromatherapy with essential oil|the aromatherapy by fragrance inhalation
32232|NCT03933527|Behavioral|making staining beverage rinse during in-office tooth bleaching|the subjects in experimental group should make staining beverage(coffee or tea) rinse for 30 second, four times daily.
32233|NCT03933514|Other|Plaque control|Children were instructed about the hygiene procedures
32234|NCT03933501|Drug|amoxicillin and metronidazole|375 mg amoxicillin and 250 mg metronidazole prescribed on the day of treatment, every 8 hours for 7 days.
32235|NCT03933501|Drug|Placebos|Two distinct placebo pills prescribed on the day of treatment and taken every 8 hours for 7 days.
32236|NCT03933488|Drug|TAK-994|TAK-994 tablets.
32237|NCT03933488|Drug|TAK-994 Placebo|TAK-994 placebo-matching tablets.
32238|NCT03933475|Device|Virtual reality game|Use of virtual reality games on television screens
32239|NCT03933462|Device|InnoSpire Go|Participants will use for 30 days.
32240|NCT03933462|Device|Jet Nebulizer|Participants will use for 30 days.
32241|NCT03933449|Biological|pembrolizumab|IV Q3W
32242|NCT03933449|Drug|paclitaxel|IV on Days 1, 8, and 15 of every 28-day (4-week) cycle
32243|NCT03933449|Drug|docetaxel|IV on Day 1 of every 21-day (3-week) cycle
32244|NCT03933449|Drug|irinotecan|IV on Day 1 of every 14-day (2-week) cycle
32245|NCT03933436|Other|Iodine swabs.|Children will then have their periurethral region gently cleansed for ten seconds with iodine swabs.
32246|NCT03933436|Other|Saline flush.|Children will then have their periurethral region gently cleansed for ten seconds with saline flush.
32304|NCT03933007|Drug|fexofenadine|Fexofenadine 120 mg
33007|NCT03927131|Biological|TIVV-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Victoria lineage
32247|NCT03933423|Device|Home based phototherapy and referral|CHWs will visit the household twice in a month and will counsel mother and families on use of preventive care such as routine antenatal check care and newborn care. The investigators will conduct blood grouping and rhesus (Rh) typing. If the mother is Rh negative, investigators will also measure the Rh status of the father prior to delivery to determine the risk of Rh disease in the newborn. The investigators will establish an emergency contact system both in intervention and comparison arm where mothers and family members contact and inform the research team about delivery. The trained phlebotomist will collect cord blood for measuring glucose 6-phosphate dehydrogenase and infant blood type, Rh status, direct antigen testing. The investigators will develop a protocol for treating infants at home based on the ETAT (Emergency Triage Assessment AND Treatment) AAP (American Academy of Paediatrics) guidelines and treat with LED based phototherapy
32248|NCT03933410|Drug|KB195|KB195 is a novel glycan
32249|NCT03933397|Other|Patient-Specific Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on the pain medicine(s) they take at home for pain and what was needed during their past hospital and emergency department visits to treat pain. Medicines will include opioids, either morphine or hydromorphone. A member of the outpatient SCD provider team will review the patient's medical record to determine: 1) the patient's maximum home opioid dose, and 2) previous ED analgesic medication(s) and doses that have been effective and safe in the past. The patient's regular hematologist/sickle cell team will write the treatment plans. Medications will be given every 20-30 minutes for up to 6 hours.
32250|NCT03933397|Other|Weight-based Protocol|Patients assigned to this treatment protocol will be given pain medicine(s) based on their weight. Medicines will include opioids, either morphine or hydromorphone. Plans will be written by the patients regular hematologist/sickle cell team.
32251|NCT03933397|Drug|Morphine|6mg for participants weighing 50-69.9 kgs, 8mg for participants weighing 70 - 89.9 kgs and 10mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
32252|NCT03933397|Drug|Hydromorphone|1 mg for participants weighing 50-69.9 kgs, 1.25 mg for participants weighing 60 - 69.9 kgs, 1.5 mg for participants weighing 70-89.9 kgs and 2 mg for participants weighing greater than or equal to 90 kgs. dose is given. Re-dosing is every 20-30 minutes up to 6 hours with one possible dose escalation of 25%.
32253|NCT03933384|Drug|Tenofovir alafenamide|Tenofovir alafenamide 25mg/tab once daily
32254|NCT03933384|Drug|Entecavir|Entecavir 0.5mg/tab once daily
32255|NCT03933371|Device|Colon Capsule Endoscopy|The capsule endoscopy will be ingested by the participant. This device captures images along the large bowel. This images are stored in an external memory and afterwards they are downloaded in a computer
32256|NCT03933358|Other|Thyroid hormone levels|This is an observational study. Exposure: Different thyroid hormone levels.
32257|NCT03933345|Other|Study provides naloxone to participants who wish to have it. Not required to accept naloxone and no control.|At enrollment, participants will complete a detailed survey instrument establishing histories of substance use, naloxone exposure, and other potential barriers to the uptake of naloxone training. Because extant research establishes a clear public health and ethical imperative to provide PWUIO with naloxone, we will also offer all participants training to become naloxone-equipped OD responders at enrollment. We will follow the sample for two years using a mixed-methods approach involving text-message-based exposure tracking, monthly surveys using a state-of-the-art online data collection portal, and a qualitative subsample to ensure that naloxone exposures and changes in OD risk behavior are carefully tracked and contextualized by ethnographic data about the psychosocial and sociocultural mechanisms underlying participant experiences.
32258|NCT03933332|Other|Diaphragm thickness|measured at apposition zone using ultrasonography in mm
32259|NCT03933332|Other|Cross-sectional area of rectus femoris muscle|measured at lower one-third line between Spina iliaca anterior inferior (SIAI) and upper border femur patella using ultrasonography in cm^2
32260|NCT03933332|Other|Cross-sectional area of biceps brachii|measured at biceps brachii muscle using ultrasonography in cm^2
32261|NCT03933332|Diagnostic Test|C-Reactive Protein (CRP) Level|quantitative CRP using ELISA method in mcg/mL
32262|NCT03933319|Drug|pegylated liposomal doxorubicin|Eligible patients will be treated with the PLD+trastuzumab regimen until the disease progresses or intolerable toxicity
32263|NCT03933306|Drug|Dexmedetomidine|Loading dose dexmedetomidine (0.6 mcg/kg for 10 min) administered before anesthesia induction, followed by a continuous infusion (0.5 mcg/kg/h) until 1 hour before the end of surgery.
32264|NCT03933306|Drug|Placebo|Loading dose placebo administered before anesthesia induction, followed by a continuous infusion until 1 hour before the end of surgery.
32265|NCT03933306|Other|Goal-directed blood pressure management|Blood pressure is maintained within ±10% of baseline with noradrenaline infusion and fluid management.
32266|NCT03933306|Other|Routine blood pressure management|Blood pressure is maintained according to routine practice, i.e., systolic blood pressure > 90 mmHg or within ±30% of baseline within intermittent ephedrine or phenylephrine.
32267|NCT03933293|Drug|AK102|450mg, Q4W, subcutaneous injection
32268|NCT03933293|Drug|Statins|Lipid-lowering therapies
32269|NCT03933293|Drug|Ezetimibe|Lipid-lowering therapies
32270|NCT03933280|Drug|Nalbuphine|i.v. nalbuphine bolus of 50 μg/kg.
32271|NCT03933280|Drug|Propofol|A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min
32272|NCT03933280|Drug|Dexmedetomidine|i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.
32273|NCT03933280|Drug|Benoxinate Hydrochloride 0.4% Eye Drops|Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.
32274|NCT03933267|Other|Cervical sensorimotor control training exercises|"Cervical sensory motor training exercises consisting of cervical position sense and cervical movement sense exercises with 3 levels of difficulty and 5 repetitions * 3 sets for each exercise will be given. Some exercises are:~Head relocation with laser feedback:~head relocation to neutral and predetermined position with eyes opened (in horizontal / vertical direction) (5 reps x 3 sets) Head relocation to neutral, predetermined and to specific targets with eyes opened (in diagonal directions) (5 reps x 3 sets) Head relocation to neutral and predetermined position with eyes closed (in all directions)(5 reps x 3 sets) In addition to it conventional physical therapy protocol consisting of Generalized stretching and cervical strengthening exercises along with joint mobility."
32276|NCT03933254|Diagnostic Test|Intraocular pressure measurement via ocular tonometry|Intraocular pressure and optic nerve sheath diameter changes of the patients undergoing laparoscopic cholecystectomy will be measured throughout the surgery at different times using ocular tonometry and ultrasound, respectively.
32277|NCT03933241|Behavioral|nasal irrigation|nasal irrigation after Transnasal transsphenoidal surgery for pituitary tumor
32278|NCT03933228|Procedure|Interscalene-Cervical Plexus Block|Ultrasound-Guided Combined Interscalene-Cervical Plexus Block
32279|NCT03933228|Procedure|Supraclavicular-Cervical Plexus Block|Ultrasound-Guided Combined Supraclavicular-Cervical Plexus Block
32280|NCT03933215|Drug|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
32282|NCT03933189|Other|Physical Therapy|Physical therapy modalities to treat chronic pain
32283|NCT03933176|Procedure|Restoration of carious lesions|Selective carious tissue removal followed by restoration of the cavity using composite resin.
32284|NCT03933163|Drug|Resveratrol|Drug name: Micronised resveratrol. Dosage form: 500mg capsules. Alternate name: 1,3-Benzenediol, 5-[2-(4-hydroxyphenyl)ethenyl]-, (E). Ingredients: 99.50% pure trans-resveratrol. Placebo capsules will be identical in terms of taste, smell, and appearance.
32285|NCT03933150|Device|ultrasound guided caudal epidural injection|"A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor"
32286|NCT03933137|Other|Portsmouth Physiological and Operative Severity Score for the Enumeration of Mortality and Morbidity (P-POSSUM) score|P-POSSUM score's variables are divided into physiological parameters (age, cardiac, respiratory, ECG, systolic blood pressure, pulse rate, haemoglobin, leukocyte count, urea, sodium plasma, potassium plasma, and GCS) and operative parameters (operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD).
32287|NCT03933124|Device|Virtual Reality|The Virtual Reality intervention is used for 10 minutes minimal 3 times a day on postoperative day 2-4.
32288|NCT03933111|Diagnostic Test|local sound velocity measurement|All patients are scanned by Fuji film su-9000 ultrasonic system. After the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions.Pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard divide the patients into pancreatic cancer and pancreatic cancer group.
32291|NCT03933085|Behavioral|Memory Support System (MSS)|A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
32292|NCT03933072|Procedure|obtaining of autologous human olfactory bulb, autologous sural nerve preparation|The operative procedure will be aimed to obtain one of the patient's olfactory bulbs. The operation will be performed using a minimally invasive intracranial microsurgical endoscopy-assisted or transnasal endoscopic approach. During the same operation the patient sural nerve will be prepared for a future grafting.
32293|NCT03933072|Biological|production of Glial Neuropatch|The human autologous olfactory ensheathing glia and olfactory fibroblast isolated from the olfactory bulb will be used for production of Glial Neuropatch in a laboratory facility in accordance with good manufacture procedures (GMP). The final Product will consist of the aforementioned cell suspension embedded with collagen scaffold. The European Medicines Agency/Committee for Advanced Therapies (EMA/CAT) considers that the Product Glial Neuropatch falls within the definition of a tissue engineered product of an advanced therapy medicinal product (decision EMA/CAT/293903/2018 from 22 June 2018: Scientific recommendation on classification of advanced therapy medicinal products Article 17 - Regulation (EC) No 1394/2007).
32294|NCT03933072|Procedure|microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges|The surgery will consists of laminectomy/laminotomy, midline durotomy above the area of spinal cord lesion, detethering of the spinal cord from fibrotic adhesions, resection of the posttraumatic spinal cord glial scar, delivering of cultured OEC/ONFs explants (Glial Neuropatch) to the area of spinal cord injury and finally bridging of the spinal cord gap by harvested autologous sural nerve grafts.
32295|NCT03933059|Other|Psychotherapy|Cognitive Processing Therapy is a primarily cognitive form of Cognitive Behavioral Therapy, which has been shown to be effective at reducing symptoms of PTSD.
32296|NCT03933046|Diagnostic Test|PSG|polysomnography and urine analaysis for protein levels
32297|NCT03933033|Device|Fractional Erbium Yağ Laser|Multiple sessions of Fractional Erbium Yağ Laser
32298|NCT03933033|Procedure|Platelet Rich Plasma|Multiple injections of Platelet Rich Plasma
32299|NCT03933020|Device|VR active video game intervention|The Microsoft VR active game program will consist of 3 weekly sessions of 45 minutes each combining 3 different types of exercise
32300|NCT03933020|Behavioral|Educational session|This consists of two education discussion sessions on the benefits of exercise for people with MS. The investigator MS specialists will conduct these sessions either by phone or at the time of a clinic visit and will also discuss difficulties encountered by participants with adherence.
32301|NCT03933020|Behavioral|Standard Management of Physical Activity|Routine discussion of lifestyle factors including physical activity during clinic visits
32305|NCT03932994|Behavioral|ACT on Health|This intervention consists of an online canvas course based on Acceptance and Commitment Therapy, focused on increasing healthy diet and physical activity and addressing barriers to change. The intervention also consists of weekly phone coaching calls.
32306|NCT03932981|Drug|Temozolomide|Temozolomide at a monthly standard dose of 150-200 mg/m2/day at day 1 to day 5 for a duration of treatment of 12 months
32307|NCT03932968|Procedure|pH-metry during 24 hours|For patients with gastric symptoms such as retrosternal burning, regurgitations, and epigastric pain, a pH-metry will be performed
32308|NCT03932955|Biological|MC-19PD1 CAR-T cells|T cells purified from the PBMC of subjects, transduced with anti-CD19 CAR and PD1/CD28 chimera lentiviral vector, expanded in vitro for future administration.
32309|NCT03932942|Diagnostic Test|QIAstat at pediatric emergency room|Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
32310|NCT03932929|Device|Scotchbond Universal Adhesive (3M ESPE)|Adhesive system
32311|NCT03932916|Drug|Donepezil pamoate|there are six in the 17mg dose group and twelve in the 34mg dose group，all subjects will be injected the Donepezil pamoate
32312|NCT03932903|Behavioral|AYA ADAPTS (ADherence Assessments and Personalized Timely Support).|AYA ADAPTS is a mobile app intervention that integrates contextually-tailored mobile messages and decision rules about when to deliver the messages, with the ultimate goal of improving oral chemotherapy adherence in adolescents and young adults with acute lymphoblastic leukemia. Each participant will be micro-randomized to receive messages on some days that are adapted to their current characteristics (e.g., mood, pain, location) and designed to promote adherence, and no messages (no intervention) on other days.
32313|NCT03932890|Device|Patient controlled fluid device administering high volume thirst guided fluid bolus|The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose & 0.18% sodium chloride
32314|NCT03932890|Device|Patient controlled fluid device administering low volume thirst guided fluid bolus|The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose & 0.18% sodium chloride
32315|NCT03932877|Other|MMP-14 and s-ENG levels|Venous blood sampled from the antecubital veins for measuring the serum concentration of MMP-14 and s-ENG levels. The serum MMP-14 and s-ENG levels measured using commercially available reagent kits, which is produced to detect human MMP-14 and s-ENG levels (Rel Assay Diagnostics Gaziantep, Turkey). The MMP-14 and s-ENG levels measurements were performed in accordance with the company's protocol.
32316|NCT03932864|Biological|MGTA-145|MGTA-145 will be given in various doses intravenously
32317|NCT03932864|Biological|plerixafor|240 µg/kg subcutaneously
32318|NCT03932864|Biological|Placebo|Placebo will be given in various doses intravenously
32319|NCT03932851|Other|IVF-ET|HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation
32320|NCT03932838|Other|Clinical and radiologic evaluation|Follow up post surgery: clinical and radiologic evaluation
32321|NCT03932825|Drug|Nitrous Oxide|An 1-hour session of inhaled nitrous oxide at concentrations of 50%.
32322|NCT03932825|Drug|Placebo|An 1-hour session of mixed oxygen-air gas(inspired oxygen concentration ~50%)
32323|NCT03932812|Behavioral|Options Counselor Health Educator (OC-HE) Intervention|The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
32324|NCT03932799|Other|Prospective prior authorization (PA) with hard stops in Washington|"Under Washington regulatory procedures, payment for any opioid prescription billed beyond six weeks after the injury is denied unless the prescriber has submitted a checklist attesting to completion of all best practices from the regulations/guidelines.Thus, the Washington intervention is prospective and includes a hard stop subject to an insurer's decision based on regulatory authority."
32325|NCT03932799|Other|Retrospective review (RR) with prescriber notification in Ohio|In Ohio an automated report identifies new opioid prescriptions beyond the acute phase. Ohio Workers' Compensation pharmacy and clinical staff review the medical record at 12 weeks to determine whether best practices were met. If not, the prescriber is notified via letter, and cases are reviewed again at 16 weeks. If best practices have still not been met, the prescriber and worker are notified via letter that opioid coverage will end in 4 weeks. The Ohio program relies on retrospective chart review and communication of best practices to prescribers.
32326|NCT03932786|Procedure|Biospecimen collection|Collection of tissue and saliva samples
32327|NCT03932786|Other|Vision assessment|Undergo vision assessment
32328|NCT03932786|Other|Questionnaire administration|Complete questionnaires
32329|NCT03932786|Other|Quality of life assessment|Complete questionnaires
32330|NCT03932786|Other|Laboratory Biomarker Analysis|Correlative studies
32331|NCT03932773|Device|Active rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be used to deliver 1 hertz (Hz) stimulation to right dorsolateral prefrontal cortex (rDLPFC) at 110% of a participant's rTMS motor threshold. The device passes electric current through a coil generating an alternating magnetic field. When positioned over the skull, the changing magnetic field causes electromagnetic inducted current flow in brain regions subjacent to the coil. Magnetic pulses (1.5-2.0 Tesla) lasting 100-300 microseconds at 1 Hz will be used.~Motor threshold will be defined by the TMS intensity to right motor region required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
32332|NCT03932773|Device|Sham rTMS|"A Magstim Rapid2 Stimulator repetitive transcranial magnetic stimulation (rTMS) device will be paired with sham coil. The sham coil will induce electrical current flow in the tissue above the skull but will not induce current flow in brain tissue. The sham coil will be placed over the right prefrontal scalp region to target current flow in rDLPFC. Magnetic pulses lasting for 100-300 microseconds at 1 Hz will be used.~For consistency across the rTMS conditions, motor threshold in the sham condition also will be determined by positioning the active rTMS coil over the right motor region and identifying the stimulation intensity required to induce visually perceptible movement of the contralateral abductor pollicus brevis 50 percent of the time."
32400|NCT03932214|Device|ACCUVEIN|The nurse uses the Accuvein® device to identify the veins before puncture and then proceeds as usual, under illumination of the device.
32333|NCT03932773|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidenced based, trauma-focused treatment for Posttraumatic Stress Disorder (PTSD). CPT is a recommended form of treatment in the Veterans Administration - Department of Defense Clinical Practice Guideline for PTSD. The CPT manual delineates the agenda for each of 12 sessions (60 minutes per session): 1) Introduction to CPT and Patient Education regarding PTSD, 2) Meaning of the Trauma, 3) Identification of Thoughts and Feelings related to the Trauma, 4) Remembering the Trauma, 5) Identification of Stuck points, 6) Challenging Questions about the Trauma, 7) Dysfunctional/Maladaptive Thinking patterns related to the Trauma, 8) Safety Issues, 9) Trust Issues, 10) Power and Control Issues, 11) Self-Esteem Issues, and 12) Intimacy Issues.
32334|NCT03932760|Behavioral|UPLIFT Program|UPLIFT is based on cognitive behavioral therapy and mindfulness-based practices. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
32335|NCT03932760|Behavioral|Attention Control Group|Program is based on standard prenatal, childbirth, infant feeding, and parenting education curriculum. Participants meet by videoconference using any electronic device (laptop, tablet, smart phone) from their own home.
32336|NCT03932747|Other|pre- Hydratión skin|Measurement of hydration of the skin.
32337|NCT03932747|Other|post- Hydratión skin|Measurement of hydration of the skin.
32338|NCT03932734|Other|survey|Face-Q conversion table
32339|NCT03932721|Drug|Evolocumab 140 MG/ML|Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
32340|NCT03932708|Behavioral|CDC Core Elements of Outpatient Stewardship|The intervention is described above and includes components of leadership, action of policy and practice, tracking and reporting, and education and expertise.
32341|NCT03932695|Dietary Supplement|Low dose milk peptide|what is the effect of milk peptides 1400mg on postprandial glycemia after a meal rich in carbohydrates (75g)
32342|NCT03932695|Dietary Supplement|High Dose milk peptide|what is the effect of milk peptides 2800mg on postprandial glycemia after a meal rich in carbohydrates (75g)
32343|NCT03932695|Dietary Supplement|Placebo|what is the effect of placebo on postprandial glycemia after a meal rich in carbohydrates (75g)
32344|NCT03932682|Biological|QIVc|QIVc is a quadrivalent vaccine and contains 2 influenza type A strains and 2 influenza type B lineages recommended by World Health Organization (WHO) for inclusion in the quadrivalent vaccine formulation for the influenza season corresponding to the season of conduct of study.
32345|NCT03932682|Biological|Comparator|Meningococcal Group C Polysaccharide Conjugate Vaccine (MenC vaccine, Neisvac-C)
32346|NCT03932669|Drug|Nilotinib|150-300mg daily dose of nilotinib
32347|NCT03932656|Behavioral|Combined schema-therapy and cognitive behavioral therapy|A six-week inpatient psychotherapeutic program consisting of one small group and one big group therapy per day, one individual session per week, daily sport activities, imagery and relaxation techniques. The therapeutic approach presents a combination of schema-therapy and cognitive behavioral therapy. Schema-therapy will follow guidelines for the treatment of individuals with borderline personality disorder (Farrell and Shaw 2012). A later step in the therapy - strengthening of the called Healthy Adult (that is the ability to perceive situations realistically, think rationally, plan time, set appropriate goals, or behave assertively) will be done by standard cognitive behavioral strategies (cognitive restructuring, core beliefs work, time planning, problem solving, assertiveness training). A detailed description of the program is going to be published in a paper.
32348|NCT03932656|Drug|Psychopharmaceuticals|Pharmacotherapy will be implemented according to the National Institute for Health and Care Excellence guidelines and will target comorbidities if present to such extent that warrants a pharmacological intervention. If not needed, patients will not use medication. Most patients will be recommended to hospitalization by their outpatient psychiatrists who prescribe the medication. If needed, medication will be changed to meet the guideline standards (i.e., tapering off benzodiazepines or augmentation with a mood stabilizer). The medication will be controlled but not directed by the study.
32349|NCT03932643|Drug|ONC201|"ONC201 Capsules, 125 mg~Oral ONC 201 at various dose levels will be given at weekly intervals for up to 13 cycles (52 weeks); 4-week therapy will be considered 1 cycle."
32350|NCT03932630|Other|Low carbohydrate diet|The study intervention will be an eucaloric low carbohydrate diet (15-20 % of carbohydrates) for 2 weeks.
32351|NCT03932630|Other|balanced diet|The control intervention will be a energy-matched balanced diet (50 % of carbohydrates) for 2 weeks.
32352|NCT03932617|Device|end tidal carbon dioxide by capnography|"Moreover, since PETCO2 is mainly determined by tissue CO2 production (VCO2), alveolar ventilation and CO, when stable metabolic conditions are assumed and minute ventilation is kept constant, acute changes in PETCO2 have been shown to correlate strongly with changes in CO.~Thus, PETCO2 has been suggested as a simple economic and noninvasive alternative for continuous assessment of CO in different shock states."
32353|NCT03932604|Device|Atrial sensing On mode|Single lead VDD-ICD programmed as atrial sensing On mode.
32354|NCT03932591|Procedure|kinesio taping method|Kinesio tape is an elastic, adhesive, hypo-allergenic, latex-free tape. Kinesio taping method is rehabilitative taping technique. One of the purposes of this technique is to facilitate or inhibit the muscles.
32355|NCT03932591|Procedure|Sham kinesio taping|Sham kinesio tape will be used for controlled group. 2,5 cm width, 5 cm length, skin color 2 pieces kinesio tape will be applied on medial and lateral head of gastrocnemius muscle without stretch. 5 cm length, 5 cm width, skin color 1 piece kinesio tape will be a
32356|NCT03932578|Drug|Atropine sulfate|Patients will receive intrathecal 100 μg of a 1 mg/ml preservative-free atropine sulfate solution
32357|NCT03932578|Drug|Metoclopramide|Patients will receive IV metoclopramide 10 mg in 2 ml
32358|NCT03932565|Biological|CAR-T therapy for nectin4-positive malignant solid tumor|The Intravenous minimally invasive surgery combined with intratumoral injection of Nectin4/FAP-targeted the fourth-generation CAR-T cells (expressing IL7 and CCL19, or IL12) are used to treat Nectin4-positive advanced malignant solid tumors, maximally eliminating residual cancer cells and preventing recurrence.
32359|NCT03932552|Other|Exercise|aerobic exercise program during 2 + 12 weeks, highly monitored and tailored to individual physical capacity.
32360|NCT03932552|Other|nutritional therapy|individualised nutritional intervention
32361|NCT03932526|Drug|Vinorelbine + placebo|Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.
32362|NCT03932526|Drug|Vinorelbine + Apatinib|Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
32363|NCT03932513|Drug|inarigivir soproxil|Inarigivir 200mg and 400mg oral tablets, once daily
32364|NCT03932487|Other|urinary iodine and urine BPA|urinary iodine and urine BPA
32365|NCT03932474|Combination Product|SAMEUp|One tablet per day of food supplements containing S-adenosyl methionine (SAMe) 200 mg and Lactobacillus plantarum HEAL9 1x109 CFU.
32366|NCT03932474|Other|Placebo|One tablet per day identical in shape, size, colour and taste to the SAMEUp tablet
32367|NCT03932461|Procedure|Vacuum assisted closure|The Vacuum assisted closure system consists of an abdominal dressing covering the intra abdominal viscera over the dressing there will be placed a blue sponge which will be covered by drape and connected to a vacuum pump.
32368|NCT03932461|Procedure|"Relaparotomy on demand"|Abdomen is closed at the index operation after source of peritonitis is treated. Every 48-hours the patients are evaluated for the need of relaparotomy based on clinical and paraclinical parameters.
32369|NCT03932448|Other|The proposed study is not interventional.|The proposed study is not interventional. However, if a treatable microorganism is detected, e.g. Borrelia or Anaplasma, suitable therapy, e.g. doxycycline, will be in initiated if appropriate.
32370|NCT03932435|Drug|TWLO_C|"First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
32371|NCT03932435|Drug|TWLO|"First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
32372|NCT03932435|Other|Washout period|7 days
32373|NCT03932435|Drug|TWLO_C|"Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)"
32374|NCT03932435|Drug|TWLO|"Second Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)"
32375|NCT03932422|Diagnostic Test|Evaluate if the individuals are resistant hypertensive patients|Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
32376|NCT03932409|Drug|Pembrolizumab|200mg IV given the week (7 days) prior to radiation initiation
32377|NCT03932409|Radiation|Radiation Therapy|Radiation Therapy
32378|NCT03932396|Other|Observational study|No intervention is planned outside of usual clinical practice. Only active screening for hepatotropic virus infection, mainly hepatitis C virus, HIV, and mental illness will be carried out. If any disease is detected, patients will be referred to the corresponding specialized care following the usual clinical practice.
32379|NCT03932383|Device|Custom CPAP mask|Modified CPAP mask based on 3D image capture
32380|NCT03932370|Procedure|endoscopic surgery|The procedure will be performed in an endourology room where a radiolucent operative table together with a C-arm, a video-camera unit and a Laser device are available. Irrigation fluids include normal saline and/or sterile water
32381|NCT03932357|Radiation|CBCT|measuring soft tissue thickness using a CBCT
32382|NCT03932344|Drug|Anakinra|Anakinra according to prescription
32383|NCT03932331|Drug|Acalabrutinib|Acalabrutinib 100 mg orally twice daily
32384|NCT03932318|Biological|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
32385|NCT03932318|Drug|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
32386|NCT03932318|Drug|Azacitidine|75 mg/m2 will be administered on days 1-7 of a 28-day cycle.
32387|NCT03932305|Dietary Supplement|Lutein|Lutein is a common oral supplement that may have neuroprotective effect on the human retina
32388|NCT03932305|Dietary Supplement|Placebo|Inactive placebo tablet
32389|NCT03932292|Drug|Ectoin Mouth Wash|According to medical prescription of the instruction for use under consideration (at least 4x1 ampoule (5ml) daily, rinsed in the mouth for at least 30 seconds)
32390|NCT03932292|Drug|Supersaturated solution of calcium and phosphate ions|According to medical prescription of the instruction for use under consideration (4 times a day).
32391|NCT03932266|Drug|Endostar|Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
32392|NCT03932266|Drug|Cisplatin|Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
32393|NCT03932266|Drug|Docetaxel|Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
32394|NCT03932266|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
32395|NCT03932253|Drug|FCN-159|Administered orally once a day
32396|NCT03932240|Drug|Fibrinogen Concentrate (FC)|The dose of fibrinogen concentrate will be calculated to achieve a level of 300mg/dL after drug administration.
32397|NCT03932240|Drug|Cryoprecipitate|Standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 345mg/dL
32398|NCT03932227|Device|Cardioskin|Subjects will have a 24h recording with Cardioskin, next will be unequipped.
32399|NCT03932227|Device|Holter|Subjects will have a 24h recording with Holter, next will be unequipped.
32402|NCT03932188|Behavioral|Mental Health Assessments and Computerized Cognitive Test|Participants will be asked to complete questionnaires and will be asked questions that address a broad range of personal life experiences involving social, occupational, domestic, and other behaviors.
32403|NCT03932188|Device|MRI scan|Up to two MRI scan sessions will be done, altogether totaling just under 3 hours of scanning. MR scanners measure brain anatomy and activity using very strong magnets. No X-rays or radiation are involved.
32404|NCT03932175|Behavioral|Intervention group|Behaviorial intervention on non-invasive ventilation use and adherence alongside lifestyle changes recommendations supported by an mHealth tool (MyPathway app)
32405|NCT03932162|Drug|Insulin-Like Growth Factor 1|Growth factor protein
32406|NCT03932162|Other|No Insulin-Lie Growth Factor 1|No Insulin-Like Growth Factor 1 will be given.
32407|NCT03932149|Device|Intermittent Theta Burst Stimulation (iTBS)|The target is left DLPFC and the iTBS protocol is: 70% of RMT; triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
32408|NCT03932149|Device|Sham stimulation|The target is right DLPFC and the sham stimulation protocol is: triplet 50 Hz bursts, repeated at 5 Hz; 2s on and 8s off; 600 pulses a session.
32409|NCT03932136|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a natural compound extracts from cruciferous vegetables, especially broccoli, with cytoprotective, anti-inflammatory, and antioxidant effects.
32410|NCT03932136|Combination Product|Placebo|The placebo is safe, with no therapeutical effect, and has same shape and color with SFN tablet.
32411|NCT03932123|Drug|Piperacillin and tazobactam, azlocillin, latamoxef, meropenem, vancomycin|Efficacy and safety of antibiotics
32412|NCT03932110|Diagnostic Test|omentin, visfatin|diagnostic blood test
32413|NCT03932097|Behavioral|Parenting Now|Preventive Parenting Now digital intervention emphasizing parent-teen/young adult communication on drinking/risks of drinking/risks of alcohol abuse, with the addition of a communication component on the risks of nicotine and marijuana use, with the goal of reducing alcohol, nicotine and marijuana use in college students.
32414|NCT03932097|Other|Active Control Materials|SAMHSA alcohol prevention materials for parents
32415|NCT03932084|Behavioral|Control group|"During hospitalization:~Monitor subjects' blood glucose;~One-on-one education: Education includes skills related to diabetes self-management, basic knowledge of diabetes, diet, exercise, medication, blood glucose monitoring, risks of glucose fluctuations;~Teaching patients and their families to use blood glucose meters and correctly record results. The diabetes specialist nurses demonstrate correct methods for self-monitoring blood glucose.~During discharge: Patients were given standard hospital discharge instructions and were asked to monitor their blood glucose 5 times daily after discharge.~Follow-up: If a patient FPG was less than 7 mmol/L, 2hPG was less than 10 mmol/L, or A1c was less than 7%, no intervention would be implemented. If one of these items was above the numbers, a referral would be made to an endocrinologist for medication adjustment. Participants received telephone follow-up one week after discharge, thereafter, follow-up were conducted once a month."
32416|NCT03932084|Behavioral|Glucose fluctuation targeted intervention|We set achieving goals for this intervention group (both A1c<7% and LAGE<80mg/dl). Participants received the same usual care as the control group; though additional attention was paid to glucose fluctuation on the basis of glucose control. Even the patient's FPG, 2hPG, and A1c were all well controlled, If his or her LAGE≥80mg/dl, we would carefully assess the patient's diet and exercise and daily activities first. If it was caused by lifestyle or events, the researchers worked with patients to find a self-care behavioral solution for the glucose fluctuation, and set behavioral goals, otherwise, the researchers would refer the patient to an endocrinologist for medication adjustment. During next follow-up, we evaluated the glucose fluctuation and target completion.
32417|NCT03932071|Drug|Zoledronic Acid|
32418|NCT03932058|Drug|Chemotherapy|all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
32419|NCT03932045|Device|SYB Filler (SF-01)|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
32420|NCT03932045|Device|Ellansé M|Apply up to 1.0 ml of the test device (SF-01) and the contrast device (Ellansé M) to both sides of the nasolabial fold.
32421|NCT03932032|Behavioral|Attention Bias Modification Treatment|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
32422|NCT03932032|Behavioral|Neutral Control Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
32423|NCT03932019|Drug|Jitongning tablet|Jitongning tablet,3tablets,bid,treat 12 weeks
32424|NCT03932019|Drug|Jitongning tablet,Jitongning tablet placebo|Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks
32425|NCT03932019|Drug|Jitongning tablet placebo|Jitongning tablet placebo,3tablets,bid,treat 12 weeks
32426|NCT03932006|Drug|Fengshigutong Capsule plus Imrecoxib|Fengshigutong Capsule 1.2g twice a day,Imrecoxib 0.1g twice a day,orally
32427|NCT03932006|Drug|Fengshigutong Capsule|Fengshigutong Capsule 1.2g twice a day,orally
32428|NCT03932006|Drug|Imrecoxib|Imrecoxib 0.1g twice a day,orally
32429|NCT03931993|Biological|Placebo comparator|
32430|NCT03931993|Biological|Grass MATA MPL|
32431|NCT03931980|Procedure|Robotic-assisted rectal cancer resection and Laparoscopic rectal cancer resection|we perform robotic surgery using the da Vinci Robot System Si version and laparoscopic surgery to treat rectal cancer
32432|NCT03931967|Diagnostic Test|MR-proADM|to evaluate the plasmatic level of MR-proADM and endothelin-1 in the first five days of ICU stay.
32433|NCT03931941|Drug|RBX2660|RBX2660 is a microbiota suspension administered as an enema
32434|NCT03931928|Drug|(Z)-Endoxifen supplementation according to genotype|Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)
32435|NCT03931928|Drug|(Z)-Endoxifen supplementation according to plasma levels|Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, > 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and > 25 nM receive 0 mg (Placebo)
32436|NCT03931915|Drug|TAK-385|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
32437|NCT03931915|Drug|Leuprorelin acetate|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
32438|NCT03931902|Device|intubation with Endotracheal tube|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with endotracheal tube (ETT).
32439|NCT03931902|Device|intubation with laryngeal mask airway|After masking ventilation with sevoflurane till the adequate anesthetic depth, intubation will be done with laryngeal mask airway (LMA).
32440|NCT03931889|Dietary Supplement|Vitamin D3|Cap. Cholecalciferol 40,000 IU
32441|NCT03931876|Drug|Placebos|Single ascending dose administration
32442|NCT03931876|Drug|AV-006|Single ascending dose administration
32443|NCT03931863|Drug|Ondansetron 4mg|Intravenous administration of ondansetron 4mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
32444|NCT03931863|Drug|Ondansetron 8mg|Intravenous administration of ondansetron 8mg diluted in 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
32445|NCT03931863|Drug|100ml normal saline 0.9 percent|Intravenous administration of 100ml of normal saline 0.9 percent within 10 minutes prior to spinal anesthesia.
32446|NCT03931850|Procedure|Pudendal nerve block|Pudendal nerve block is the one of peripheral nerve block. Injection local anesthetic medication around this nerve can provide analgesia around perineal area.
32447|NCT03931837|Device|Tourniquet: Systolic blood pressure + 75 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
32448|NCT03931837|Device|Tourniquet: Systolic blood pressure + 100 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
32449|NCT03931837|Device|Tourniquet: Systolic blood pressure + 150 mmHg|Spinal block without morphine. Medial parapatellar approach. Same posterior stabilized design and operated by a single surgeon. Drug: Peri-articular Transmine(15 mg/kg) combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL. Procedure/Surgery: TXA combined with multimodal local anesthetic infiltration inject into peri-articular area (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
32450|NCT03931824|Other|PRP|"A venous blood sample of 8.5 ml were obtained from patients. For the study group, the blood samples were mixed with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. Resulting material was then centrifugated for 5 minutes with RCF 1200 G speed to clump erythrocytes, and then centrifugated for 10 minutes in same speed to obtain thrombocyte concentrate. 2 ml's of the platelet rich plasma was injected to the shoulder of the subjects. For the sham injection group, same amount of blood was taken and they were given a of waiting time of same duration with the study group, with the resulting preparate being 2 ml's of 0,9% saline instead. PRP solutions were prepared with kits of Easy PRP(Neotec Biotechnology, Istanbul, Turkey).~Injections were done every two weeks, for a total of 3 times. 21 G injection needles with injection technique of posterior approach were used(18, 19). To provide blindness, all injections were done using injectors coated with non transparent tape."
32451|NCT03931824|Other|Exercise|All of the patients were also informed about proper positioning and the standard care for the affected extremity. Their process of neurological rehabilitation was not changed, which was 5 days of the week, one session of 45 minutes a day. They were also given a program of standardized ROM exercises, which included passive and active motions.
32452|NCT03931811|Device|Short wave diathermy|SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
32453|NCT03931811|Other|Prolotherapy|Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
32484|NCT03931499|Diagnostic Test|Metabolomic analysis|Blood will be collected in all patients blood before surgery and after surgery (postoperative day 1). Our study is based on a polar metabolomics profiling of plasma and/or serum using hybrid triple quadrupole mass spectrometer coupled with chromatographic system.
32485|NCT03931473|Other|Bed nets|Next-generation bed nets combining insecticides with different modes of action or a standard pyrethroid bed net
32486|NCT03931460|Drug|Medical Abortion|Medical Abortion
33964|NCT03919357|Behavioral|BMT-i|Passing the BMT-i test
32454|NCT03931798|Diagnostic Test|Visual Scanning Test|The Visual Scanning Test (VST) involved a visual search for a target between similar visual distractors, projected in the far space, so as to simulate the search within a visual field. It is overall composed by four trials, each trial contained 20 cases and made up by 20 stimuli. On about the 80% of cases, the test provided the presence of target in the left, center or in right hemispace. In the remaining 20% of cases, the test provided the presence of a catch trial (absence of the target), to assess the presence of frontal disturbances or malingering. The test is constructed according to an increasing attentional load for the target on the left-hemispace. Participants, sitting in front a blank wall, were required to actively and free explore the projected visual field to search for the visual target, naming its identification (saying YES or NO). During the task, the examiner annotated the reaction times and the errors.
32455|NCT03931785|Drug|MD-7246|Oral tablet
32456|NCT03931785|Drug|Placebo|Matching oral tablet
32457|NCT03931772|Behavioral|Automated Self-Hypnosis|Hypnosis is a very safe and validated mind-body technique for symptom management of various clinical problems. The intervention is designed by the protocol's principal investigator, Dr. David Spiegel.
32458|NCT03931759|Diagnostic Test|laparoscopic surgery|patients with diabetes mellitus in laparoscopic surgery
32459|NCT03931746|Device|Porcine xenograft|The EZ-DERM™ porcine xenograft is a biosynthetic dressing made from porcine collagen containing aldehyde crosslinking. It has been most commonly applied to the management of 2nd degree burns, both partial-thickness and full-thickness defects. This dressing can be used for two healing purposes, either for primary healing or as an intermediate in the preparation for a skin graft
32460|NCT03931733|Other|Music Therapy|Single thirty minute receptive music therapy intervention.
32461|NCT03931720|Biological|BiCAR-NK/T cells (ROBO1 CAR-NK/T cells)|The subject will be observed for any side effects during this time and all the adverse events will be recorded.
32462|NCT03931707|Genetic|Genomic sequencing|Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
32463|NCT03931694|Device|e-DOL|e-health program (smartphone and web platform)
32464|NCT03931681|Drug|OKI-179|OKI-179 single agent
32465|NCT03931668|Drug|TPN-672|single dose of TPN-672 maleate tablet
32466|NCT03931655|Diagnostic Test|Spectroscopic photoacoustic imaging|Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
32467|NCT03931642|Drug|RCHOP|"D1 : Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² IV.~From D1 to D5 : Prednisone 60 mg/m² PO."
32468|NCT03931642|Drug|Blinatumomab|Blinatumomab by continuous vein infusion
32469|NCT03931629|Procedure|CONVENTIONAL PHACO|Cataract surgery by means of Femtosecond Laser-Assisted Cataract Surgery,
32470|NCT03931616|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure management (choice of drug at discretion of treating physician), use of telemedicine for image transfer as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
32471|NCT03931616|Procedure|Regular care|A regular ambulance, the comparator, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
32472|NCT03931603|Other|MRI|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
32473|NCT03931590|Drug|[14C]-Omaveloxolone|[14C]-Omaveloxolone 50 mg capsules
32474|NCT03931577|Diagnostic Test|C-reactive protein rapid testing|Continuous (workshop and monthly web-based training) disease-focused intervention with the provision of CRP rapid testing in the primary care practices.
32475|NCT03931577|Procedure|Communication skill enhancement|Continuous (on-site and monthly online training) illness-focused intervention (enhancement of communication skills to optimise doctor-patient consultations and share decision making with the aid of patient-centred leaflets) in the primary care practices.
32476|NCT03931564|Procedure|PRESERFLO Microshunt implantation|The intervention consists of the microshunt implantation augmented with mitomycin C application.
32477|NCT03931564|Procedure|Trabeculectomy|The usual care / control group will undergo a standard fornix based trabeculectomy augmented with mitomycin C application.
32478|NCT03931551|Drug|Olaparib [Lynparza®] plus Trastuzumab [Herceptin®]|Participants will receive olaparib (300 mg tablets, orally twice daily during 21-day cycles) in combination with herceptin (intravenous dose of 4 mg/kg body weight with subsequent weekly doses of 2 mg/kg or subcutaneous dose of 600 mg every 3 weeks) until progression or unacceptable toxicity.
32479|NCT03931538|Diagnostic Test|Guidance 4.0 PCR test|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
32480|NCT03931538|Diagnostic Test|Urine Culture|All patients will have a urine culture and Guidance 4.0 PCR test run on their urine, but physicians will receive one or the other, or both depending on the treatment arm.
32481|NCT03931525|Device|Fractitional Radiofrecuency with Drug Delivery|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug
32482|NCT03931525|Device|Fractitional Radiofrecuency|Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
32483|NCT03931512|Device|transcranial direct current stimularion|aplication of direct current stimulation on the scalp wiht sponge electrodes
32487|NCT03931447|Biological|JNJ-72537634|Participants in Cohort 1 and 3 will receive Dose 1 and participants in Cohort 2 and 4 will receive Dose 2 of JNJ-72537634 as oral capsule.
32488|NCT03931447|Biological|Placebo|Participants will receive matching placebo as oral capsule in all cohorts.
32491|NCT03931421|Biological|CAR-T treatment|a novel method for treatment of multiple myeloma, in which patients' T cells are engineered into B Cell Maturation Antigen（BMCA）-Targeted CAR-T cells to eliminate myeloma cells.
32492|NCT03931408|Drug|Gentamicin Sulfate|Gentamicin will be compounded for immediate use in single-dose, disposable BD 60ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
32493|NCT03931408|Other|Placebo instillation (saline alone)|Saline will be compounded for immediate use in single-dose, disposable BD 60ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
32494|NCT03931408|Other|No instillation|Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
32495|NCT03931395|Dietary Supplement|Honey|Will give patients and families included in the honey standard of care group 40 packets of hospital approved honey to implement in the tonsillectomy post-operative care of the child
32496|NCT03931395|Other|Standard of Care|Patients will receive standard post operative medications per surgeon
32497|NCT03931382|Behavioral|Virtual Reality|The VR intervention is underpinned by experiential learning and social cognitive theory, such that user will observe successful performance and simulation to encourage imitation and reinforce success in the assessment. All participants will be undergoing a simulation assessment with the head coil.
32498|NCT03931382|Behavioral|Simulator Preparation|The mock MRI is provided by the Child Life Specialist, according to the current care plan which consists of exposing children to the MRI simulator, medical devices, and procedures. The mock MRI is located within the medical imaging facility. All participants will be undergoing a simulation assessment with the head coil.
32499|NCT03931382|Behavioral|Preparation Booklet for Non-Sedated MRI|The standard MRI preparation booklet provides access to a series of printed photos and text showing the MRI experience step-by-step to help prepare for MRI. All participants will be undergoing a simulation assessment with the head coil.
32500|NCT03931369|Drug|Tolvaptan 15 MG|Single administration of one pill of 15 MG tolvaptan
32501|NCT03931356|Other|Pulmonary function tests|analysis of lung volume and diffusion capacity
32502|NCT03931343|Procedure|Bilateral 20 ml Bupivacaine %0.25 + lidocaine %1 injected between multifidus and longissimus muscle with USG guidance|Thoracolumbar interfascial plane block: Bilateral 20 ml Bupivacaine %0.25 + lidocaine %1 injected between multifidus and longissimus muscle with USG guidance
32503|NCT03931343|Procedure|Bilateral 20 ml Bupivacaine %0.25 + lidocaine %1 injected between the erector spinae muscles and transverse process with USG guidance|Erector spinae plane block: Bilateral 20 ml Bupivacaine %0.25 + lidocaine %1 injected between the erector spinae muscles and transverse process with USG guidance
32504|NCT03931330|Device|Percutaneous neurostimulation|Percutaneous neurostimulation using NSS-2 Bridge device
32505|NCT03931317|Drug|Latanoprostene bunod 0.024% QD|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
32506|NCT03931317|Drug|Timolol maleate 0.5% BID|This is a randomized, single-center, investigator-masked, 2-period, 8-week treatment study with washout and crossover between treatment periods. There will be 2 treatments in this study: latanoprostene bunod 0.024% QD and timolol maleate 0.5% BID.
32507|NCT03931304|Procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
32508|NCT03931291|Drug|APR-246|APR-246 will be administered on Days 1-4, with azacitidine on Days 1-5, of every 28 day cycle. Patients may receive a maximum of 12 cycles.
32509|NCT03931278|Other|learning and recall of a sequence of body movements|The objective of this study to investigate, if learning and recall of a sequence of body movements (steps that realize a pattern on the ground) can be improved by self-produced music (having particular melodic-structures in relation to the pattern), compared to the same sound (a single tone) for each pattern in persons
32510|NCT03931265|Diagnostic Test|ketohexokinase|Check the isoforms of ketohexokinase in the specimen of endometrial cancer
32511|NCT03931252|Dietary Supplement|Boost VHC|8 ounce can liquid meal, calories 530kcal, Carbohydrate 46g, Protein 22g, Fat 30g
32512|NCT03931252|Dietary Supplement|Ensure High Protein|8 ounce can liquid meal, calories 160kcal, Carbohydrate 13g, Protein 16g, Fat 2g
32513|NCT03931239|Biological|Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval|An openlabel, multicentric, bridging study to assess the safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine (Adsorbed) manufactured by Serum Institute of India Pvt. Ltd in Vietnamese infants aged 6-12 weeks, given as a 3-dose regime, with 4 week intervals between the doses
32514|NCT03931226|Drug|Drug consumption|number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
32515|NCT03931187|Behavioral|Cognitive progressive muscular relaxation therapy|This therapy combines cognitive psychotherapy and progressive muscular relaxation, intervened 6 times with 1-1.5 hour each time. The whole therapy will last round 20-30 days during IVF-ET.
32548|NCT03930914|Device|Transcutaneous Electrical Nerve Stimulation (TENS) Device|Daily use of TENS device on tragus or ear lobe, as assigned treatment arm
32702|NCT03929614|Other|MOBI validation|Final version will be distributed to 176 French speaking subjects, 30 of whom are randomly selected and will fill it a second time, at after 72 hrs. To consider of its kind, Moreover, the Bem Inventory for Children will be completed by everyone as well as the SF-12 and SRS-22.
32516|NCT03931174|Behavioral|Addiction Technology Transfer Center (ATTC) Training Strategy|Participating organizations will receive training consisting of 3 components: 1) didactic workshop - full-day workshop led by a contingency management (CM) expert for both CM staff and leaders, 2) performance feedback - submission of CM session recordings for review and performance feedback at least monthly for 9 months for CM staff, and 3) staff coaching - monthly provider coaching calls led by a CM expert for 9 months for both CM staff and leaders.
32517|NCT03931174|Behavioral|Enhanced Addiction Technology Transfer Center (E-ATTC) Training Strategy|Participating organizations will receive all of the elements of the ATTC control condition. In addition, organizations will receive two additional elements: 1) Implementation Sustainment Facilitation - monthly coaching calls for CM leaders and staff focused on sustainment, 2) Pay for Performance - participating CM staff will have the opportunity to earn monthly monetary bonuses for achieving pre-defined implementation goals for 9 months.
32518|NCT03931161|Drug|Evolocumab Auto-Injector [Repatha]|Auto-Injector, 140 mg every two weeks.
32519|NCT03931161|Drug|Placebo Auto-Injector|Matching Placebo for the active comparator (Evolocumab)
32520|NCT03931148|Diagnostic Test|Geriatric Assesment with neuropsychological test more specific on decision making|The following tests will be made : MoCA, FAB, TMT, Stroop-Victoria, JAT
32521|NCT03931148|Diagnostic Test|Functional RMI|With specific test of decision making (IGT) specially adapted to the population
32522|NCT03931148|Diagnostic Test|High Resolution EEG|With specific test of decision making (BART) specially adapted to the population
32523|NCT03931135|Drug|IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section|"The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped"
32524|NCT03931122|Device|Ear Size Based Method (Ambu® AuraOnce™ Laryngeal Mask Airway)|"The Laryngeal Mask Airway (LMA) is one of the devices used to maintain airway during general anesthesia. Its appropriate size is selected according to patients body weight as recommended by the manufacturer.~However its appropriate size can also be selected via several other methods and one of them is patients external ear size. In this study the investigators will compare external ear size based method for LMA selection with the standard weight based method for LMA size selection.~Vertical Ear length: will be measured from the most dependent portion of the lobule to the furthest portion of the auricle.~Horizontal Ear length (width): from the tragus to the furthest part of the helix horizontally.~Dimension(cm2): Vertical length (L) × Horizontal length (width-W)~LMA Size LMA Cuff Length (cm) corresponding to vertical ear length.~LMA Cuff Width (cm) corresponding to horizontal ear width."
32525|NCT03931096|Other|Quality of life questionnaire|Self and proxy PedsQL 4.0 questionnaires.
32526|NCT03931083|Diagnostic Test|Screening for HSIL|The investigators will compare three different screening methods: visual assessment with portable colposcope, visual inspection after application of acetic acid, screening for high risk variants of HPV. All patients will receive cervical biopsies and histopathological examination.
32527|NCT03931070|Drug|Ramelteon|Nightly administration of Ramelteon 8 mg
32528|NCT03931070|Drug|Placebo - Cap|Nightly administration of Placebo capsule, which is indistinguishable from Ramelteon
32529|NCT03931057|Drug|ADV6209 (=gamma-cyclodextrin-Midazolam)|30 min. before anesthesia children have to swallow the anxiolytic drug (ADV6209)
32530|NCT03931057|Drug|Midazolam|30 min. before anesthesia children have to swallow the anxiolytic drug Midazolam
32531|NCT03931044|Procedure|Image-Guided Robotic Gastrectomy|The near-infrared technology, integrated in the robotic camera, will be used to detect fluorescent lymphonodes.
32532|NCT03931031|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care
32533|NCT03931018|Other|Alcohol|Administration of one dose of alcohol among two possible different doses (in males) or only one possible dose (in females) simulating a binge drinking episode under experimental conditions.
32534|NCT03931005|Other|Collaboration Decision Support Guide|Electronic toolkit intended to help organizational leaders select partners and negotiate partnerships for implementation. This will contain: 1) a brief summary of collaboration approaches associated with implementation, 2) detailed descriptions of collaboration strategies, 3) a decision analysis tool that guides the selection of collaborative strategies given the community context, and 4) sample contract or agreement language that specifies the nature of the partnership and expectations.
32535|NCT03931005|Other|General Collaboration Support|Electronic description of collaborative implementation strategies and their definitions.
32536|NCT03930992|Drug|Colaren in HIV positive|1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
32537|NCT03930992|Drug|standard treatment in HIV positive|2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
32538|NCT03930992|Drug|Colaren in HIV negative|3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
32539|NCT03930992|Drug|standard treatment in HIV negative|4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
32540|NCT03930979|Other|Clearsight non-invasive cardiac index measurements|In patients needing sedation for a painful condition, non-invasive measurements of CI, stroke volume and total peripheral resistance are performed using the Clearsight non-invasive cardiac output monitoring system.. Measurements will be taken at baseline, after 1,2 and 5 minutes of 15L O2/min, and then after another 2 and 5 minutes of flush rate oxygen and during the subsequent sedation.
32541|NCT03930966|Diagnostic Test|PDEQ, PCL-5 and demographic survey|Questionnaires
32542|NCT03930953|Drug|CC-99282|CC-99282
32543|NCT03930953|Drug|rituximab|rituximab
32544|NCT03930940|Device|remote ischemic conditioning|RIC is a non-invasive therapy that performed by an electric autocontrol device with cuffs placed on arm and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 4 to 5 times.
32545|NCT03930940|Other|Regular treatment|Regular treatment is based on associated guidelines for ICH.
32546|NCT03930927|Drug|Self Assembling peptide|enamel regeneration
32547|NCT03930927|Drug|remineralizing agent|enamel regeneration
34018|NCT03918967|Drug|CT-G20 Placebo|Single dose, oral tablet of Placebo
32549|NCT03930901|Other|Health education learning package|Health education learning package (HELP) was introduced to children in the selected schools. The package involved different items and activities during the study period, e.g. comic booklet on the intestinal parasitic infections, stand banners, posters, lectures, songs, drawing competition, puppet show, lectures, with a toolkit that involved soap, slipper (plastic clogs shoes), & nail clipper).
32550|NCT03930888|Dietary Supplement|Dietary supplement|Patients with preoperative nutritional support with special nutritional supplements vs. patients without special nutritional support.
32551|NCT03930875|Other|Aspirin Resistance testing|Aspirin resistance will be measured using platelet aggregometry (VerifyNow assay)
32552|NCT03930862|Device|Locator Attachment (positioner)|intra oral attachment
32553|NCT03930849|Behavioral|AIMS|Participants randomized to the AIMS arm be enrolled in VA's Annie text messaging program and receive the study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
32554|NCT03930849|Behavioral|AIMS plus|Participants randomized to the AIMS Plus arm will receive a weekly phone call in addition to being enrolled in VA's Annie text messaging program/study protocol. Annie text messages will ask the participate to provide feedback about specific domains related to their depression treatment and goals. The Veteran participant will receive a weekly report about their Annie responses through My HealtheVet, VA's patient portal, and instructed to share information with their care team at their next scheduled appointment. In addition, a summary of response will be provided to the participant's clinician prior to their appointment(s) during the studies 12 week time frame.
32555|NCT03930836|Behavioral|Hand Arm Bimanual Intensive Therapy Including Lower Extremities|Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface
32556|NCT03930836|Behavioral|Conventional physical and occupational therapy|Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
32557|NCT03930823|Other|Interview|One to one interview
32558|NCT03930810|Procedure|Surgical biliary diversion|Surgical interruption of enterohepatic circulation
32559|NCT03930797|Behavioral|Intimacy Enhancement|The IE intervention is grounded in cognitive behavioral couple therapy and sex therapy, and includes education and skills training with a focus on the following major topics: understanding effects of breast cancer on sex and intimacy; goal-setting; communication skills; problem-solving and engaging in activities to build intimacy; identifying and restructuring negative or inflexible thoughts; and planning ahead and preparing for challenges. Participants will be asked to participate in written and behavioral activities at home between sessions to strengthen skills acquisition.
32560|NCT03930797|Behavioral|Living Healthy Together|The Living Healthy Together (LHT) intervention focuses on delivering education and support to breast cancer survivors and their partners across a range of topics including social support, sleep and fatigue, stress and stress management, nutrition, and physical activity. Participants will be asked to engage actively with the material and to review readings and intervention material between sessions.
32561|NCT03930784|Other|Nil intervention|
32562|NCT03930771|Drug|Capecitabine|1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
32563|NCT03930771|Drug|Temozolomide|150 to 200 mg/m2 orally on days 10 through 14.
32564|NCT03930758|Combination Product|Behavior intervention of uphill exercise|40 minutes of uphill exercise
32565|NCT03930758|Combination Product|Dietary intervention of exercise before the meal|40 minutes of uphill exercise completed 1 h before the meal
32566|NCT03930758|Combination Product|Dietary intervention of uphill exercise|40 minutes of uphill exercise
32567|NCT03930758|Combination Product|Dietary intervention of exercise after the meal|40 minutes of uphill exercise started 1 hour after gthe meal
32568|NCT03930758|Combination Product|Behavior intervention of downhill exercise|40 minutes of downhill exercise
32569|NCT03930758|Combination Product|Dietary intervention of exercise before the meal|40 minutes of downhill exercise completed 1 hour before the meal
32570|NCT03930758|Combination Product|Behavioral intervention of downhill exercise|40 minutes of downhill exercise
32571|NCT03930758|Combination Product|Dietary intervention of exercise after the meal|40 minutes of downhill exercise started 1 hour after the meal
32572|NCT03930758|Combination Product|Behavioral intervention of sedentary no-exercise trial|Sedentary no-exercise trial
32573|NCT03930758|Combination Product|Dietary intervention of eating two meals|Meals eaten at 10 and 17 h during a sedentary trial
32574|NCT03930745|Other|Placebo|Placebo vaginal inserts.
32575|NCT03930745|Drug|TOL-463|TOL-463 is a non-azole vaginal anti-infective drug candidate designed as a dual-indication therapy for BV and VVC.
32576|NCT03930732|Drug|Dupilumab SAR231893|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
32577|NCT03930732|Drug|Inhaled Corticosteroid|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
32578|NCT03930732|Drug|Inhaled Long-Acting Beta Agonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
32579|NCT03930732|Drug|Inhaled Long-Acting Muscarinic Antagonist|"Pharmaceutical form: Inhaled Powder~Route of administration: Oral inhalation"
32580|NCT03930732|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
32581|NCT03930719|Diagnostic Test|Stroke screening tools|"Patients are evaluated for the presence of PSD using DSM-5 criteria (gold standard). Established delirium detection tools are evaluated for their diagnostic accuracy compared to the gold standard."
32635|NCT03930238|Behavioral|VA MapTrek|The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
32636|NCT03930238|Behavioral|Fitbit Only|Fitbit Only
34142|NCT03917784|Drug|Curcumin|Oral supplementation with curcumin 500 mg oral dosing for 3 months
32582|NCT03930706|Other|Longer administration of estradiol (Progynova®)|All women included will take exogenous hormone with daily administration of Estradiol Valerate (Progynova®), the standard dose used will be 6 mg/day (Cobo et al., n.d.). On day 7 of endometrial preparation patients will be examined with vaginal ultrasound and blood test, to evaluate the endometrial thickness and the hormones levels. In both arms the FET will take place after 6 days of Progesterone supplementation (600 mg per day, vaginal administration of Utrogestan®) According to embryo quality after warming, embryo transfer to the uterine cavity will be performed on day 5 of development under ultrasound guidance whenever possible. Following embryo transfer, luteal support will be continued with vaginally administered P (Utrogestan®). All patients 12 days after the FET will undergo the pregnancy test (blood test to evaluate hCG).
32583|NCT03930693|Dietary Supplement|Beetroot juice|Beetroot juice shot (70mL containing 400mg inorganic nitrate)
32584|NCT03930680|Drug|Dexrazoxane|One lower than FDA approved dose of dexrazoxane
32585|NCT03930667|Procedure|clips|
32586|NCT03930667|Procedure|knotting|
32587|NCT03930654|Behavioral|iPrEP|"iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~Women will receive the iPrEP intervention on an iPAD Air tablet device~iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~iPrEP uses qualitative themes~iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~Scales were modified (in some cases) for cultural competency and tailoring to women"
32588|NCT03930654|Behavioral|Usual Care|"Women will receive usual care~Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~Social worker will offer a list of substance abuse treatment referral agencies"
32589|NCT03930641|Drug|RTH258|6 mg in prefilled syringe
32590|NCT03930615|Drug|Letermovir|LET tablet or intravenous infusion at a total daily dose of 240 mg (when given with cyclosporin A) or 480 mg (when given alone).
32591|NCT03930615|Drug|Placebo|Placebo was administered as tablets matched to LET or as inactive (saline) intravenous infusion.
32592|NCT03930602|Drug|BMS-986165|Participants will receive BMS-986165.
32593|NCT03930602|Drug|Fluvoxamine|Participants will receive fluvoxamine.
32594|NCT03930589|Procedure|Remote Ischemic conditioning|BP cuff inflation for 5 min and deflation for 5 mins with 4 cycles
32595|NCT03930589|Other|Standard of care|Standard of care
32596|NCT03930576|Other|Receipt of termination services outside of legal setting|This study uses variation in gestational age to examine the impact of receipt of legal termination services compared to denial and receipt outside legal settings and birth.
32597|NCT03930563|Dietary Supplement|Pre-beetroot juice supplementation|Before administering beetroot juice to subjects.
32598|NCT03930563|Dietary Supplement|Post-beetroot juice supplementation|After administering beetroot juice to subjects.
32599|NCT03930550|Procedure|Tracheal intubation by endoscopy with flexible bronchoscope|A blinking infrared light source is placed on the anterior neck at the level of the cricothyroid membrane to serve as a guide to facilitate finding the way to the trachea
32600|NCT03930537|Device|Hip replacement|The hip replacement surgery is when a damaged hip is replaced with artificial one
32601|NCT03930524|Behavioral|Personalized Normative Feedback (PNF)|Personalized normative feedback is generated by a process in which: (1) baseline surveys gather respondent information; (2) a computer program links the data with algorithms to select appropriate feedback messages; (3) a format for feedback presentation is specified; and (4) the program generates output. Norms will focus on consuming 4/5+ drinks, total number of drinks consumed each week, and maximum drinks consumed. Normative information will be from the national Monitoring the Future (MTF) study college student sample and the University of Minnesota Twin Cities campus. All students will be sent a link to a website where they see their own personal responses in the feedback. Feedback will detail quantity and frequency of drinking (a) reported by the participant him/herself, (b) according to the participant's perception of the descriptive norm for drinking quantity and frequency for the reference group, and (c) reflecting the actual descriptive norm for the reference group.
32602|NCT03930524|Behavioral|Mobile Bridge Online Health Coach|A health coach will correspond with students via a secure online chat platform, utilizing motivational interviewing strategies to encourage students to consider their values and goals, the possibility of behavior change, and available services. The goal of the dialogue is to motivate the student to access alcohol use interventions (Web-BASICS or an in-person health promotion consultation).
32603|NCT03930524|Behavioral|Web-BASICS|Web-BASICS is delivered online and responds to individual participant input with the same motivational information and feedback as used in the in-person BASICS intervention. In-person BASICS content (Dimeff et. al., 1999) was developed for the web in studies conducted by Drs. Larimer and Lee (see preliminary studies; e.g., LaBrie et al., 2013; Lee et al., 2014; Neighbors et al., 2012a). Web-BASICS feedback contains text and graphical feedback regarding students' reported drinking quantity, frequency, peak alcohol consumption, and blood alcohol content (BAC), risks for alcohol problems based on participant family history and consumption patterns, protective behaviors the participant already uses and others he/she might consider, and a tips page with a BAC chart, information on reduced-risk drinking, and where to get more information. Participants can print and/or view their individualized content online for up to 3 months.
32604|NCT03930524|Behavioral|Health Promotion Consultation|A health promotion consultation is a confidential exploration of student drug and alcohol use. Health Promotion Consultants help students assess how their alcohol and other substance use affects their life and learn how to make healthier decisions.
32637|NCT03930225|Behavioral|Stigma Directed Psycho-educational Intervention program|psycho-educational intervention with emphasis on Stigma
32638|NCT03930212|Drug|Progesterone|received rectal progesterone suppositories 400 mg once daily
32639|NCT03930212|Drug|Placebos|received placebo suppositories rectally once daily.
32703|NCT03929601|Drug|Rituximab|Participants will receive Rituximab dosing from Week 1 to Week 4 of the trial. Rituximab will be given by IV infusion over a 3-8 hour period, at a dose of 375mg/m2 on four visits each one week apart.
32605|NCT03930524|Behavioral|Self-Monitoring (SM)|Students will be asked to self-report their alcohol use every 2 weeks in response to two main questions (frequency of 4/5+ drinking in the past 2 weeks, frequency of past 2-week 8/10+ drinking), as well as consequences of their drinking. The therapeutic role of SM is two-fold. First, SM facilitates deliberate attention to and reflection on the person's actions, the conditions under which these actions occur, and their consequences (Bandura, 1998; Kanfer, 1970). Hence, SM of drinking behaviors and consequences has the potential to promote awareness of problematic drinking and need for health services. Second, SM affords the opportunity to obtain ongoing information concerning the target behavior, which can be used to inform timely intervention decisions (Nahum-Shani et al., 2016)
32606|NCT03930511|Procedure|Pulmonary Rehabilitation|According to patients' needs and physician referral, individually tailored treatments of respiratory physiotherapy, functional training, exercise training and patient education
32607|NCT03930498|Drug|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
32608|NCT03930498|Drug|Chemotherapy|Cisplatin and Gemcitabine
32609|NCT03930498|Radiation|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
32610|NCT03930472|Behavioral|Market vouchers|Receiving $80 in vouchers good for fruits and vegetables or for SNAP-eligible foods at 4 out of 5 markets in late July and in August, 2019.
32611|NCT03930459|Procedure|Static cold storage (SCS)|The liver is flushed and cooled with specialist preservation fluid, then stored in an icebox.
32612|NCT03930459|Device|Normothermic machine perfusion (NMP)|During NMP, the liver is perfused with oxygenated blood, medications and nutrients at normal body temperature to maintain a physiological milieu.
32613|NCT03930446|Drug|Ethanol|The 0.8 g/kg body weight dose of oral alcohol (190-proof ethanol) will be divided into 4 servings of 0.2 g/kg each. The 0.8 g/kg dose is equivalent to 4 standard drinks, where a standard drink is defined as one 12 oz beer, one 5 oz glass of wine, or one 1.5 oz shot of 80 proof alcohol. Women will receive a reduced dose (0.68 g/kg) to account for sex differences in total body water
32614|NCT03930446|Other|Placebo|The placebo beverage will consist of the cranberry or orange juice plus 1% alcohol added as a taste mask. All beverages will be sprayed with an alcoholic mist to provide a strong alcoholic scent.
32615|NCT03930433|Drug|Nebivolol|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
32616|NCT03930433|Drug|Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
32617|NCT03930433|Drug|Nebivolol+Diltiazem|Patients are randomly assigned to a ratio of 1: 1: 1, divided into 3 groups.
32618|NCT03930420|Behavioral|Connect to Wellness|The research team will train LHD staff and offer them technical assistance to work with small worksites. LHD staff will be trained to deliver the Connect to Wellness program to worksites. Connect to Wellness is a program to disseminate EBIs to small worksites. Worksites receive guidance about EBIs and ongoing implementation assistance from a trained interventionist. In this study, LHD staff will be the interventionists. Worksites participating in Connect to Wellness complete three phases of activities, Assessment, Recommendations, and Implementation. LHD staff will receive Connect to Wellness intervention materials, multiple webinars delivered in real-time, access to a comprehensive intervention and training platform with features that allow them to connect with each other and with research staff, and group technical assistance calls to support their ability to recruit worksites in their communities and deliver Connect to Wellness to these worksites.
32619|NCT03930407|Procedure|The Hayman uterine compression suture.|Hayman suture is a common technique for uterine compression to stop bleeding due to uterine atony. Hayman described placement of two to four vertical compression sutures from the anterior to posterior uterine wall without hysterectomy. It is usually employed to overcome uterine atony during cesarean section.
32620|NCT03930394|Diagnostic Test|Contrast ultrasound perfusion imaging|Contrast ultrasound perfusion imaging for microvascular perfusion, and carotid ultrasound data on intima-media thickness (or plaque size) will be serially assessed in subjects started on ponatinib.
32621|NCT03930381|Other|ASTHMAXcel App|ASTHMAXcel includes interactive games, educational videos, quizzes and personalized feedback to teach different aspects of asthma management.
32622|NCT03930368|Other|low GI diet with regular supplementation of raw corn starch|Patients will be guided with a low GI diet with 60%~70% of energy from carbohydrates. RCS constituted 30%~50% of daily carbohydrate, and was supplemented as snacks every 4~6 hours (25g per time) especially at night.
32623|NCT03930355|Other|Blood transfusion|Patients who received blood transfusion in the perioperative period
32624|NCT03930355|Other|Control|Patients who did not receive blood transfusion in the perioperative period
32625|NCT03930342|Behavioral|Native-CHOICES|Native CHOICES is a behavioral intervention for prevention of prenatal alcohol exposure in women at high risk for alcohol-exposed pregnancies. The intervention uses motivational interviewing and cognitive-behavioral strategies, and targets adoption of effective contraception and reduction of alcohol use.
32626|NCT03930329|Behavioral|MBRP group|same as arm description
32627|NCT03930316|Device|NOX T3|portable sleep study device
32628|NCT03930303|Behavioral|Multimedia- based patient education|Patients will receive a 5 minutes video education before D&C
32629|NCT03930290|Diagnostic Test|Vaginal tactile imager|Vaginal elasticity evaluation by vaginal tactile imaging analysis.
32630|NCT03930277|Diagnostic Test|Electroencephalogram|Electroencephalogram for fetal brain activity monitoring.
32631|NCT03930264|Drug|Azathioprine|tablet
32632|NCT03930264|Drug|Azathioprine|oral suspension
32633|NCT03930251|Behavioral|Clinic-Based Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led twice weekly by a clinician in small groups.
32634|NCT03930251|Behavioral|Partial-Remote Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and bridge newly learned cognitive skills to everyday life. Sessions are led once weekly by a clinician in small groups and clients gain additional practice by accessing clinician-assigned computer-based exercises independently.
32640|NCT03930199|Other|Needs-based intervention (physical, psychological, or both)|Individuals identified as having physical issues (poor prosthesis fit, function, comfort or physical conditioning) will receive prosthetic care and physical therapy. This includes adjusting socket fit, component fit and repair, and in some instances replacement. Rehabilitation strategies include gait and prosthesis use retraining, balance fall-prevention, and range-of-motion training, strengthening, pain management, and activities of daily living training, based on participant-reported mobility goals. Individuals whose prosthesis use is reduced due to psychological issues will be provided with motivational interviewing and other related psychological interventions. During these interventions participant will be asked to set personal goals using a semi-structured interview that explores facilitators and barriers to wearing their prosthesis. If both physical and psychological issues are present, participant may receive both types of interventions simultaneously.
32641|NCT03930186|Drug|Apremilast|Apremilast
32642|NCT03930173|Drug|18F-fluciclovine|A single dose of 18F-fluciclovine will be administered intravenously for PET/CT imaging. The standard 10 mCi dose will be used for this study.
32643|NCT03930173|Device|PET/CT of the brain|Each subject will undergo 18F-fluciclovine PET/CT of the brain which will be performed ≤ 30 days from equivocal MRI brain
32644|NCT03930160|Other|Logistic Organ Dysfunction System Score|Variables of logistic organ dysfunction system score, including: GCS; heart rate; systolic BP; blood urea; serum creatinine; urine output; leucocyte count; platelet count; PaO2/FiO2; serum bilirubin; prothrombin time.
32645|NCT03930147|Procedure|ASV ventilation|Ventilation on ASV mode
32646|NCT03930134|Procedure|sparse uterine suture|The slowly absorbed Vicryl 1 suture with a large round needle is introduced intramyometrially right above the endometrium. The suture starts in one corner and proceeds along the lower then the upper edge returning back to the incision point. Subserous layer is closed upon using the same thread in order to cover the purse suture and to complete the haemostasis while increasing the wound thickness.
32647|NCT03930134|Procedure|one layer uterine closure|one layer classical continious uterine closure using slowly absorbed Vicryl 1
32648|NCT03930121|Other|Anodal transcranial direct current stimulation (tDCS) combined with speech-language therapy (SLT, including naming therapy and communicative-pragmatic therapy)|Two daily sessions of intensive SLT combined with tDCS of the left primary motor cortex (M1)
32649|NCT03930108|Other|SOFA score|Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
32650|NCT03930095|Behavioral|Acceptance-based Behavior Therapy|The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.
32651|NCT03930095|Behavioral|Non-directive Supportive Therapy|NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
32652|NCT03930082|Other|Frailty Index Scale|We will evaluate the frailty with a Frailty Index Scale in elderly patients undergoing gastrointestinal surgery.
32653|NCT03930069|Drug|Misoprostol|prostaglandin E1 analogue vaginally inserted two hours before hystertsopic myomectomy to evaluate intraoperative blood loss and operative time needed for completion of myomectomy
32654|NCT03930069|Drug|Vasopressin|one ampoule of vasopressin was diluted to 50 ml of normal saline, and 10 ml (4 units of vasopressin) was withdrawn in a syringe. Needle was inserted through the working channel of the hysteroscope until its tip was seen. The needle tip was pointed to the site of injection under hysteroscopic guidance during the whole injection technique. Aspiration was done first to avoid intravascular injection of vasopressin. The diluted solution was injected into the surface, especially to parts with dilated vasculature till they blanch.
32655|NCT03930056|Device|C-Brace II|"Participant will complete 3-6 orthoses sessions to complete clinical evaluations and fittings conducted by certified orthotists.~Participant will receive 10-20, one hour training sessions over 1-2 months in the lab. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention.~Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row.~Participant will take the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing."
32656|NCT03930056|Device|Traditional Care KAFO intervention|Participant will continue with use of their own KAFO. Participant will receive 10-20, one hour training sessions over 1-2 months in the lab, if Patient is not already receiving care in a therapy setting. These sessions include tuning the device and system tweaks in accordance to needs/preferences of participant, vitals signs, skin checks, pain, and exertion levels. Sessions involve training with the device, which includes putting on / taking off the device, transfer training, gait training, and balance and fall prevention. Up to 20 sessions will be conducted until minimum safety guidelines are reached during a minimum of at least 3 training sessions in a row. Participant will continue with the assigned device home to use for a 3-month period. Participant will be given an activity monitor to wear at all times except showering and instructed how to charge the device and use it. Participant will return for testing at 3, 6 and 12 months after receiving the brace for testing.
32657|NCT03930043|Diagnostic Test|Metagenomic shotgun sequencing|preforming metagenomic shotgun sequencing on patients' or volunteers' feces specimen
32658|NCT03930017|Biological|Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)|Influenza virus (quadrivalent, split virion, inactivated) of the strains that comply with the World Health Organization (WHO) recommendations (Northern Hemisphere) and European Union (EU) decision for the 2018/2019 season. The quadrivalent vaccine is propagated in fertilised hens' eggs from healthy chicken flocks.
32659|NCT03929991|Other|Observational|To record social and clinical characteristics
32661|NCT03929952|Other|Neurofeedback treatment|"20 sessions of neurofeedback of 5 minutes each consisting of :~The patient is equipped with an electroencephalography headset. The feedback visual has the form of a candle flame and is modulated by alpha synchrony.~The height of the flame is proportional to the intensity of the patient's pain. The patient has to concentrate on the height of this flame by thought to modulate it and, at the same time, to decrease the intensity of his own pain."
32662|NCT03929952|Other|functional magnetic resonance imaging (fMRI) scans|The patient in alpha synchrony related state and in rating state will undergo an fMRI
32663|NCT03929939|Behavioral|Exercise training and healthy eating|"Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan)."
32664|NCT03929926|Other|Best Practice|receive usual care
32665|NCT03929926|Behavioral|Cancer Educational Materials|Receive educational materials via mail
32666|NCT03929926|Other|Behavioral, Psychological or Informational Intervention|Receive shared decision making and lung cancer screening information
32667|NCT03929926|Other|Counseling|Undergo decision counseling session
32669|NCT03929887|Other|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core and various patient-derived samples.
32670|NCT03929861|Drug|Fluconazole (BAYT006267) 150 mg capsules|Fluconazole 150 mg
32671|NCT03929861|Drug|Fluconazole 150 mg capsules (DiflucanTM)|Fluconazole 150 mg
32672|NCT03929848|Procedure|Cuff pressure|observe and record the required cuff pressure to prevent gas leakage during mechanical ventilation for laryngomicrosurgery
32673|NCT03929835|Drug|Cannabis oil|T1/C20 CBD
32674|NCT03929835|Drug|Placebo|Olive oil with chlorophyl
32675|NCT03929822|Diagnostic Test|Contrast-Enhanced Spectral Mammography|A standard dose of contrast material for other contrast mammography examinations and for body CT scanning, 1.5 ml/kg of Iohexol350 will be injected intravenously (IV) using a power injection (3-4 ml/s) with a maximum does of 150 ml. The IV injection is performed while the patient is in a sitting position. The mammogram will be performed in a standing position.
32676|NCT03929809|Device|Cochlear Implant|adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
32677|NCT03929783|Procedure|Contrast Enhanced Digital Mammography|Undergo CEM
32678|NCT03929770|Procedure|with pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner pause the advancement for 10 sec. Next, the practitioner re-advance it to the pulmonary artery.
32679|NCT03929770|Procedure|without pause|When the practitioner or expert investigator recognize that the tip of Swan-Ganz catheter arrive in the right ventricle, the practitioner advance it continuously without pause to the pulmonary artery.
32680|NCT03929757|Biological|Ad26.ZEBOV|Participants will receive 0.5 mL IM injection of Ad26.ZEBOV as first vaccination.
32681|NCT03929757|Biological|MVA-BN-Filo|Participants will receive 0.5 mL IM injection of MVA-BN-Filo as second vaccination.
32682|NCT03929757|Biological|MenACWY|Participants will receive 0.5 mL IM injection of MenACWY.
32683|NCT03929744|Drug|LY3502970|Administered orally
32684|NCT03929744|Drug|Placebo|Administered orally
32685|NCT03929731|Diagnostic Test|Indocyanine Green Angiography|Intravenous injection of dye-indocyanine green
32686|NCT03929718|Drug|Spironolactone|receive spironolactone treatment after CTI ablation
32687|NCT03929718|Drug|No Spironolactone|no spironolactone treatment
32688|NCT03929692|Behavioral|Multi-layer health promotion program|
32689|NCT03929692|Other|Standard health education|
32690|NCT03929679|Drug|semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
32691|NCT03929666|Drug|ZW25|"Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC)~Part 2: RD identified in Part 1"
32692|NCT03929666|Drug|Capecitabine|Administered orally twice daily (PO bid)
32693|NCT03929666|Drug|Cisplatin|Administered IV
32694|NCT03929666|Drug|Fluorouracil|Administered IV
32695|NCT03929666|Drug|Leucovorin|Administered IV
32696|NCT03929666|Drug|Oxaliplatin|Administered IV
32697|NCT03929653|Other|Personalized therapy model with Molecular Tumor Board and Next Generation Sequencing|This study is to observe this therapy model outcomes
32698|NCT03929640|Drug|Acetaminophen|Acetaminophen 650 mg tablet every 6 hours
32699|NCT03929640|Drug|Placebo|Placebo oral tablet every 6 hours
32700|NCT03929640|Drug|Ibuprofen|Ibuprofen 600 mg tablet every 6 hours
32704|NCT03929601|Drug|Abatacept|Participants will receive initial Abatacept dosing at Week 16 of trial. Abatacept will be given by a subcutaneous (SC) formulation weekly for two years, and dosing be will determined according to weight: Up to 25 kg: 50 mg (0.4 mL); 25 to <50 kg receive 87.5 mg (0.7 mL), and > 50 kg receive 125 mg (1.0 mL). Abatacept treatment will continue for full 24-month period regardless of whether participants have progressed to stage 3 type 1 diabetes during treatment.
32705|NCT03929588|Device|Hand-held device supported by a mobile application|Hand-held device supported by a mobile application to obtain refractive error of the eye.
32706|NCT03929588|Device|Phoropter|Manual refraction and ETDRS chart
32707|NCT03929588|Device|Autorefractor|Automated refraction
32708|NCT03929575|Dietary Supplement|Placebo of calcium|Ingestion of 250 mg of calcium
32709|NCT03929575|Dietary Supplement|Rhodiola|Ingestion of 250 mg of Rhodiola
32710|NCT03929575|Dietary Supplement|Rhodiola and Cordyceps|Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
32711|NCT03929562|Behavioral|Brief advice|One 10-minute brief advice session
32712|NCT03929562|Behavioral|Health coaching|Two 50-minute health coaching sessions will use a non-confrontation motivational interviewing (MI) style. Intervention delivery will include expressing concern about unhealthy drinking, providing feedback linking alcohol use and health (related to surgery and general health), advising the patient regarding abstinence or alcohol use reduction, and working with the patient to set a drinking goal if he/she is ready to change. We will also include a personalized feedback component to address the links between pre-operative alcohol use and postoperative morbidity/mortality.
32713|NCT03929549|Device|RCMP titration|An overnight titration polysomnogram with gradual mandibular protrusion and assessment of polysomnographic parameters (i.e. AHI, oxygen saturation, etc.) at various magnitudes of protrusion.
32714|NCT03929523|Device|End-ischemic Hypothermic Oxygenated Machine Perfusion (HOPE)|"In the experimental group, ECD liver grafts will first undergo a classical static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until transport to the transplantation center. They will then undergo a hypothermic oxygenated perfusion (HOPE) via the portal vein for a period of 1 to 4 hours (minimum 1 hour) after the back-table phase (graft preparation), in parallel with the recipient hepatectomy, using the CE-certified Liver Assist® perfusion pump/device (Organ Assist®, the Netherlands) with Machine Perfusion Solution (Belzer-MPS, CE-certified)."
32715|NCT03929523|Device|classic static cold storage|The control group will consist of a classic static cold (4°C) storage with Institute George Lopez (IGL-1)® solution from graft harvesting until liver transplantation, which is the gold standard procedure in liver transplantation
32716|NCT03929510|Drug|14C-PF-06651600|Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
32717|NCT03929510|Drug|14C-PF-06651600 IV|IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity
32718|NCT03929510|Drug|PF-06651600|Oral solution 200mg
32719|NCT03929497|Drug|Lu AF11167|Lu AF11167 - 2 or 4 mg/day; tablets, orally
32720|NCT03929484|Device|Nasal reservoir cannula|The experimental oxygen mask (nasal reservoir cannula) fits over a standard nasal cannula. The system is designed to reduce administered oxygen to deliver an equal or higher fraction of inspired oxygen (FiO2) per oxygen delivered (L/min) compared with a standard nasal cannula alone.
32721|NCT03929471|Other|Target weight correction protocol|The intervention group will undergo target weight correction process based on time averaged fluid overload measurement (by bio-impedance).
32722|NCT03929445|Device|Endotracheal tube introducers|"Endotracheal tube introducers (gum elastic bougie) for emergency intubation The endotracheal tube introducer (ETI) is an effective and inexpensive adjunct to difficult airway management that is easy to use.~ETI is solid introducer 60-70 cm long with a 35 - 40 distally angulated (Coude) tip. They are easy to use, widely available, and have been used as adjuncts to difficult direct laryngoscopy for many decades.~The gum elastic bougie is usually guided by tactile clicks as the device passes the cartilage rings of the trachea. After Supraglottic devices are removed, an ETT can subsequently be railroaded over the bougie."
32723|NCT03929432|Device|Active Transcranial Direct Current Stimulation with SLT|"Soterix Medical 1×1 transcranial Direct Current Stimulator for Clinical Trials (1x1 tDCS-CT).~Excitatory stimulation to the left hemisphere will be achieved through a 1x1 montage utilizing two carbon-rubber electrodes and 5x7 EASY pad sponges (A-tDCS [excitatory]left target; C-tDCS [inhibitory]right hemisphere). Each PWA will have a unique 5-digit tDCS program code for each treatment phase. One code will instruct the 1x1 tDCS-CT to administer active stimulation as describe above (i.e., 1.5 mA for 20 min). The other will administer 1.5 mA for only a few seconds to simulate active stimulation. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment"
32724|NCT03929432|Device|Sham Transcranial Direct Current Stimulation with SLT|Control condition in which only SLT is administered.Participant receives 1.5 mA for only a few seconds to simulate active stimulation, then the stimulation will cease. SLT will consist of Semantic Feature Analysis, Phonological Component Analysis, and Verb Network Strengthening Treatment
32725|NCT03929419|Drug|intranasal insulin|application of 160 units human insulin
32726|NCT03929419|Drug|Placebo spray|nasal spray containing placebo solution
32727|NCT03929406|Device|Brain Tissue Imprint|"Brain Tissue Imprint procedure (BTI) is performed during DBS surgery. Before the implantation of the electrode, the surgeon uses a dilator. It is a rigid stylet with a blunt end, intended to prepare the way for the final electrode. This dilator is lowered gently through the cerebral parenchyma up to the target then removed to be replaced by the electrode.~In our BTI study, the standard dilator used in DBS surgery will be replaced by a CE marked Medical Device. This brain imprint kit will be used for each hemisphere. The procedure is the following:~The guide tube with the first stylet is set up to the target~Withdrawal of the first stylet and insertion of the second stylet for one minute to have a spontaneous and adequate tissue adhesion~Withdrawal of the guide tube containing the stylet. This last step will prevent contamination of the harvested material on the stylet during the removal."
32728|NCT03929393|Behavioral|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social suppo
32765|NCT03929081|Behavioral|Cognitive Behavioural Therapy (CBT)|CBT teaches the patient with Obsessive-Compulsive Disorder to refrain from compulsive acts.
32729|NCT03929393|Other|Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
32730|NCT03929380|Other|Squat protocol|60% of 1RM weight for 100 squat reps
32731|NCT03929367|Drug|Oxytocin|Single IV administration of oxytocin
32732|NCT03929354|Behavioral|Risk Factors Modification Programme|12-week supervised risk factor modification programme derived from the EuroAction Study standards.
32733|NCT03929354|Behavioral|Standard Care|Patients advised to adjust lifestyle without the support of the structured supervised programme.
32734|NCT03929341|Diagnostic Test|Coronary Computed Tomography Angiography (CCTA)|Cardiac imaging test that is able to detect changes is cardiac vessels and the heart.
32735|NCT03929341|Other|Cardiac Link|Clinical patient flow pathway that will enable radiologist to activate expedited cardiology referral for patients who exhibit clinically significant changes during CCTA.
32736|NCT03929328|Procedure|High flow oxygen therapy in spontaneous breathing trial|Patients were randomized to undergo a spontaneous breathing trial with high flow oxygen therapy that is connected on endotracheal tube. Patients tolerating the spontaneous breathing trial underwent extubation.
32737|NCT03929315|Behavioral|OLV technique on tracheo-bronchial model|Models will range in size from 6 yrs to 6 weeks.
32738|NCT03929302|Device|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, AMI Inc., Dallas, Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared will be used only in Phase-2 of the study. Phase-1 doesn't include any intervention.
32739|NCT03929289|Behavioral|Social Facilitation|During the functional Magnetic Resonance Imaging (fMRI) scan, the subject will perform cognitive tasks measuring eye movements and attention alternatively observed by a familiar peer (in an adjacent room) or not.
32740|NCT03929276|Device|high-intensity laser therapy & exercises|A total of 15 sessions of high-dose laser treatment- i Lux Laser (Mectronic Medicale, Italy)- (in the first phase, 8 Watt for the analgesic effect; in the second phase, 12 Watt in burst mode for the biostimulation effect; and finally in the third phase with 8 Watt) will be applied.
32741|NCT03929276|Device|Shame laser & exercises|Sham laser treatment (the same device to be used, 0 watts) will be given.
32742|NCT03929276|Other|exercise|Passive stretching, active assisted range of motion exercises and codman pendicular exercises (10 repetitions, 2 sets) will be applied to the shoulder joint.
32743|NCT03929263|Behavioral|Real-time fMRI neurofeedback|Participants will attempt to regulate own and/or their partner's brain activation in a specified brain region via real-time fMRI neurofeedback.
32744|NCT03929250|Drug|2g Centella asiatica water extract product|2g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
32745|NCT03929250|Drug|4g Centella asiatica water extract product|4g Centella asiatica water extract product is a powder containing Centella asiatica water extract and excipients to improve palatability, color matching and dispersability in water. It will be consumed on an empty stomach orally suspended in 10-12 ounces of water.
32746|NCT03929237|Other|observe when return to school after surgery|Short written questionnaire asking when they returned to school and what accommodations, if any, the school made available for them
32747|NCT03929224|Drug|Medicinal honey and bacitracin|Treat healing surgical site with medicinal honey and bacitracin
32748|NCT03929224|Drug|Bacitracin|Treat healing surgical site with bacitracin
32749|NCT03929211|Drug|CPI-613|Given intravenously, CPI-613 dose will be 2,000 mg/m² and will not escalate.
32750|NCT03929211|Drug|Hydroxychloroquine|Given by mouth, hydroxychloroquine will be dose escalated from 600 mg to 1,200 mg orally given 2 hours before the CPI-613 infusion on days 1-5 of every 28 day cycle in a 3+3 dose escalation design.
32751|NCT03929198|Other|Healthy Lifestyle|6 week Diet, Exercise training, Behavioral modification
32752|NCT03929185|Diagnostic Test|blood analysis with SCENT B1|analyze blood samples with chemoresistive sensors
32753|NCT03929185|Diagnostic Test|tissue analysis with SCENT B1|analyze tumor biopsies collected during surgery with chemoresistive sensors
32754|NCT03929172|Biological|AAVLP-HPV|20μg/injection formulated in a ready to use solution containing 100mM sodium citrate, 2.5 mM MgCl2, 0.001% pluronic F-68, pH 6.0 for i.m. injection as 0.5 mL per injection.
32755|NCT03929172|Drug|Placebo|0.5 mL 100 mM Sodium Citrate, 2.5 mM MgCl2, 0.001% Pluronic F-68, pH 6 for i.m. injection as 0.5 mL per injection.
32756|NCT03929159|Procedure|Biospecimen Collection|Undergo blood biospecimen collection
32757|NCT03929146|Drug|Exparel|Patients will receive a local injection of liposomal bupivacaine near the end of their shoulder arthroplasty operation.
32758|NCT03929146|Procedure|Interscalene Nerve Block|Patients will undergo a pre-operative interscalene nerve block performed by the anesthesiology team.
32759|NCT03929133|Device|automatic screening machine on congenital heart disease|
32761|NCT03929107|Biological|Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells|patient's T cells were seperated and engineered into Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells, and retransfused into the patient for treatment of their B cell lymphoma.
32762|NCT03929094|Drug|Paclitaxel for Injection（Albumin Bound）|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
32763|NCT03929094|Drug|Gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
32764|NCT03929081|Behavioral|Inference Based Approach (IBA)|The Inference Based Approach aims at strengthening reality testing in patients with Obsessive-Compulsive Disorder, by teaching the patient to actively rely on sensory information.
32766|NCT03929068|Drug|carbidopa-levodopa|Motivated by the success of dopaminergic drugs in treating rigidity associated with Parkinson's disease, some neurologists have used carbidopa-levodopa to attempt to improve spasticity in ALS and PLS patients.
32767|NCT03929068|Drug|Placebo Oral Tablet|Placebo will be given to maintain blinding of participants and study team.
32768|NCT03929055|Device|Physiological assesment|"Arterial blood gas analysis.~esophageal pressure variation during inspiration and expiration~Arterial blood pressure, central venous pressure (CVP), heart rate.~diaphragmatic contraction detected by ultrasound"
32769|NCT03929042|Device|Posture correction girdle|Our research team has designed a prototype of posture correction girdle based on the clinical, textile science, material and ergonomics engineering analyses as an alternative to hard brace for AIS. The design of the posture correction girdle incorporates different mechanisms, such as 1) compression and pulling forces through a close fit of the intimate apparel, 2) lumbar flexion by using supporting belt, 3) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system.
32770|NCT03929029|Drug|Nivolumab|Nivolumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
32771|NCT03929029|Biological|NeoVax plus Montanide|Montanide® is an activator of immunity that enhances response to vaccination through slow release of the peptides from the injection site and its ability to create an inflammation and stimulate the recruitment of specific cells of your immune system. Montanide® will be mixed with the personalized neoantigen vaccine
32772|NCT03929029|Drug|Ipilimumab|Ipilimumab is an antibody that prevent cancer cells from suppressing the immune response so that the body can attack and kill the cancer
32773|NCT03929016|Drug|DNDI-0690|capsules of 10, 100 and 200 mg
32774|NCT03929016|Drug|Placebo of DNDI-0690|capsules of matching placebo
32775|NCT03929003|Behavioral|Inspired|The investigators will be studying the ability of using videogame-based rewards to increase smoking abstinence when they are made contingent on meeting abstinence goals.
32776|NCT03928990|Device|ActiGraph accelerometer|ActiGraph accelerometer + calibration with Cortex MetaMax3B ergospirometer
32777|NCT03928977|Diagnostic Test|Functional Magnetic Resonance Imaging|fMRI sequences done with motor paradigm (right and left arm), followed by resting state acquisition
32779|NCT03928938|Device|Electronic patient reported outcomes|Electronic patient reported outcomes-tool
32780|NCT03928925|Other|Bougie|disposable tracheal tube introducer of approximately 70 cm in length
32781|NCT03928925|Other|Endotracheal Tube with Stylet|endotracheal tube preloaded with a removable, malleable stylet
32782|NCT03928899|Procedure|New procedure|An optimal management on the timing and mode of delivery of pregnant women with GDM, by a comprehensive assessment and consideration of their fetal weight, gestational age, and cervical ripeness.
32783|NCT03928886|Device|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using patient-assisted compression mode|Patient-assisted mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure. The patient-assisted compression feature enables the patient to personally refine breast compression using a hand-held remote control after the compression has been initiated by the operator, which is required to ensure proper breast positioning.
32784|NCT03928886|Device|bilateral two-view (CC and MLO) FFDM (full field digital mammography) using standard compression mode|"Standard compression mode of Senographe Pristina (a commercial mammography medical device consisting of the Senographe Pristina FFDM system -2D- and Senographe Pristina DBT option -3D-) for FFDM imaging procedure.~Study-related compressions will consist of the first and second CC and MLO compressions performed on each breast during each subject's exam."
32785|NCT03928873|Device|Low energy ESWT|1500 impulses and 0.006mJ/mm2, 3bar, once per week for 4 weeks
32786|NCT03928873|Device|High energy ESWT|1500 impulses and 0.01mJ/mm2, 5.8bar, once per week for 4 weeks
32787|NCT03928873|Device|Sham ESWT|sham treatment using ESWT Probe with only vibration without transferring energy once per week for 4 weeks
32788|NCT03928860|Other|OMT session|Patients with PAD will be received 30 minutes of osteopathic manual treatment for one session. During application, the patient was in the supine position. OMT treatment session include, sub occipital release technique, supraclavicular release technique, sternal mobilization, omentum minus release, liver pumping, diaphragmatic mobilization, grand manevra technique, hip mobilization, knee mobilization and ankle mobilization. Each technique was applied for 3 minutes to patients.
32789|NCT03928847|Drug|Epigallocatechin-3-gallate (EGCG)|Epigallocatechin-3-gallate (EGCG) capsules
32790|NCT03928834|Behavioral|Adapted Nzira Itsva|Adolescents will be provided an enhanced adherence package consisting of VL testing using DBS, including the NI intervention and low-cost genotyping and drug resistance monitoring. Participants receiving the intervention will have their first session after recruitment and enrollment, and will schedule up to 4 additional booster sessions at a time convenient for them spaced approximately 1 month apart. This may be modified after the formative assessment.
32791|NCT03928821|Biological|PGT121|20 mg/kg administered intravenously
32792|NCT03928821|Biological|PGDM1400|20 mg/kg administered intravenously
32793|NCT03928821|Biological|10-1074|20 mg/kg administered intravenously
32794|NCT03928821|Biological|VRC07-523LS|20 mg/kg administered intravenously
32795|NCT03928808|Biological|Fecal Microbiota Transplantation (FMT)|Nasogastric administration of OpenBiome 25 g/mL solution administered nasogastrically once weekly for 4 consecutive weeks
32796|NCT03928795|Procedure|elective caesarean section|elective caesarean section
32797|NCT03928782|Radiation|5 Gy or 10 Gy units of whole-body radiation|8 subjects will be received 5 Gy units of whole-body radiation or 10 Gy units of whole-body radiation.
32798|NCT03928756|Behavioral|Push Notifications with Tailored Intervention Content|Participants will receive a push notification with a therapeutic message (e.g., about stress, mood, substance use motives, tools to reduce risky substance use) tailored to their recent daily or weekly survey responses. Messages include visual (memes, images, videos) and written content.
32799|NCT03928756|Behavioral|Push Notifications with Engaging, Non-therapeutic Content|Participants will receive a push notification with an engaging, non-therapeutic message (e.g., fun facts).
32800|NCT03928756|Behavioral|No Push Notifications|Participants will not receive a push notification.
32801|NCT03928743|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
32802|NCT03928743|Other|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
32803|NCT03928730|Procedure|resection and removal|Surgical resection or removal for histopathological examination
32804|NCT03928717|Behavioral|Text-Based Adherence Game|A mobile health intervention facilitated by a cloud-hosted web application and designed to promote adherence to HIV care through text message-delivered gamification strategies including peer comparison, point reinforcement, feedback on adherence outcomes, facilitation of social support, and use of an engaging and culturally-relevant story-line.
32805|NCT03928717|Behavioral|Standard of Care (SOC)|A 10- to 20-minute in-person intervention led by a trained HIV treatment adherence counselor focused on providing basic knowledge of HIV and HIV treatment, motivating participants to engage in HIV treatment, and problem-solving barriers to adherence.
32806|NCT03928704|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
32807|NCT03928704|Other|Placebo|Subjects will receive placebo at pre-specified time-points during the Double-Blind Treatment Period.
32808|NCT03928691|Drug|Magnesium Sulfate|4 gram MgSo4 diluted in 150 cc saline infused IV within 30 minutes as loading dose then the patient will receive the maintenance dose of 1gram MgSo4 per hour for 6 hours.
32809|NCT03928678|Procedure|enhanced recovery after surgery program in colorectal cancer surgery|to determine the feasibility of implementation of the ERAS protocol in our institute and its impact on hospital length of stay and outcome of surgery.
32810|NCT03928626|Behavioral|Regulation of craving|Participants in the ROC-T condition will be trained to use a strategy that instructs them to think of the negative outcomes associated with alcohol drinking while looking at alcohol-related images.
32811|NCT03928626|Behavioral|Control (NO REGULATION)|In the CONTROL condition, participants would simply observe non-alcohol-related images and allow natural responses to come
32812|NCT03928613|Behavioral|tablet based Cognitive Training based on location information|Participants perform Tablet based Cognitive training using interactive voice services and tags three times (minimum 30 minutes per time) a week for 6 weeks
32813|NCT03928600|Combination Product|Cervical Foley combined with Misoprostol|Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug
32814|NCT03928600|Drug|Dinoprostone 10mg insert OR|Application for 24h of Dinoprostone 10mg insert
32815|NCT03928600|Drug|Misoprostol|Application of vaginal misoprostol 25ug 4/4h until 150ug
32816|NCT03928587|Dietary Supplement|2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.|One lozenge once daily for 12 months
32817|NCT03928587|Dietary Supplement|Placebo|Placebo once daily for 12 months
32818|NCT03928574|Procedure|Ultrasound-Guided Plane Block|Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
32819|NCT03928574|Procedure|Conventional Block|Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
32820|NCT03928561|Device|Active intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, air cleaners are switched on. The number of air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of active air cleaners in the EEC
32821|NCT03928561|Device|Placebo Intense Pure Air XL air cleaner|Cat allergen is nebulized in the EEC. When the concentration is stable, placebo air cleaners are switched on. The placebo effect is obtained thanks to the removal of air cleaners filters prior to the exposure. The number of placebo air cleaners placed in the EEC is defined according to the volume of the EEC and the air renewal. Patients are exposed to cat allergen in the presence of placebo air cleaners in the EEC.
32822|NCT03928535|Device|High-FlowNasal Cannula|High-flowoxygenwas applied immediately after extubation through specific nasal cannula. Flow was initially set at 10 L/min and titrated upwards in 5-L/min steps until patients experienced discomfort.Temperature was initially set to 37°C, unless reported too hot by patients, and FIO2 was regularly adjusted to the target peripheral capillary oxygen saturation (SPO2) of greater than 92%. After 24 hours, high-flow was stopped and, if necessary, patients received conventional oxygen therapy.
32823|NCT03928535|Device|Noninvasive Ventilation|Full face mask NIV was continuously delivered immediately after extubation for a scheduled period of 24 hours after extubation. Afterward, NIV was withdrawn and oxygen was administered by Venturi mask.Both PEEP and inspiratory pressure supportwere adjusted to target a respiratory rate of 25/min and adequate gas exchange (arterial oxygen saturation [SaO2] 92%, with pH of 7.35). The FIO2 was adjusted to maintain SPO2 at less than 92%. Sedatives to increase tolerance to NIV were not allowed.
32824|NCT03928522|Drug|hand mixed vancomycin|hand mixed vancomycin powder into cement
32825|NCT03928522|Drug|hand mixed tobramycin|hand mixed tobramycin into cement
32826|NCT03928522|Device|pre-mixed tobramycin|this cement is already pre-mixed with tobramycin
32827|NCT03928509|Other|No intervention|No intervention
32828|NCT03928496|Drug|AbobotulinumtoxinA|Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck
32829|NCT03928496|Drug|Normal saline|Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
32830|NCT03928483|Behavioral|Modified WW Food program|Participants will receive a structured, holistic, behavioral weight management program that encourages development of healthy habits to help individuals eat healthier, move more, and shift to a more helpful mindset.
32831|NCT03928470|Drug|EsoDuo Tab. 20/800mg|Nexium Tab. 20mg
32832|NCT03928457|Other|Parental questionnaire|Parental questionnaire on pregnancy history and environmental exposure
32833|NCT03928457|Other|Daily continuous recording of radiofrequency exposure levels|Daily continuous recording of radiofrequency exposure levels (6 weeks) by placing a dosimeter inside the incubator
32928|NCT03927781|Drug|Pregabalin 300mg|One 300mg capsule will be administered PO 1 hour before surgery
32834|NCT03928457|Other|Follow-up of daily infants environmental and clinical parameters|Follow-up of daily infants environmental and clinical parameters: morphological characteristics, drugs, ventilatory support, dietary management, clinical outcomes, incubator data (temperatures…)
32835|NCT03928457|Other|Nocturnal polysomnography|Nocturnal polysomnography (at 3 and 6 weeks of life, between 8 pm and 8 am) with recording of sleep (electroencephalography, electrooculography),
32836|NCT03928457|Diagnostic Test|cerebral hemodynamics|cerebral hemodynamics (near infrared spectroscopy)
32837|NCT03928457|Diagnostic Test|activity of the autonomic nervous system|activity of the autonomic nervous system (electrocardiography, analysis of heart rate variability)
32838|NCT03928444|Procedure|intradermal injection of adipose derived stem cells to one side of the face|"Lipoaspiration for preparation of ADSC will be done according to the following technique:~Under local anesthesia using strict aseptic technique, a small incision will be done in the lateral aspect of the thigh or lower abdomen, through which the infiltration cannula will be introduced to inject the local anesthetic solution using the wet technique. This will be followed 15 minutes later by lipo-aspiration of (50 ml fat ) using a blunt tipped cannula under the negative suction pressure of a 60 ml syringe.~Autologous adipose tissue derived stem cells (At-ADSCs) will be separated from the lipo-aspirate using enzymatic digestion and differential centrifugation in the Center of Excellence for Research in Regenerative Medicine and its Application (CERRMA), Alexandria Faculty of Medicine.~Viability of collected cells will be checked using trypan blue stain. Characterization of the isolated ADSCs population will be performed by flow cytometry."
32839|NCT03928444|Procedure|intradermal injection of saline to one side of the face|intradermal injection of saline to one side of the face
32840|NCT03928431|Other|Maternal microbiota|See arm descriptions
32841|NCT03928418|Behavioral|In-person counseling session|Brief alcohol reduction counseling is provided by a trained counselor to the study participant at the HIV clinic during two sessions that are 3 months apart.
32842|NCT03928418|Behavioral|Live phone call booster session|Brief alcohol reduction counseling booster sessions every 3 weeks delivered via a live phone call from a trained counselor to the study participant given within 3 months and in between two in-person counseling sessions.
32843|NCT03928418|Behavioral|Technology (IVR or SMS) booster session|Brief alcohol reduction counseling booster sessions once to twice a week delivered via a choice of interactive voice response (IVR) or short message service (SMS) phone technology to the study participant given within 3 months and in between two in-person counseling sessions.
32844|NCT03928405|Other|Exercises with Nintendo Wii virtual reality device|In the first session, each Nintendo Wii components were introduced to each individual. The selected games and how they were played were taught to each individual by the physiotherapist and practically taught. The games were played with the help of physiotherapists in the first session so that individuals could transfer the correct weight on the Nintendo Wii balance board and to use the game console's control. The patient was supported with verbal and physical feedback when the patient played incorrectly during the games in the next sessions. Games that require serious balance and coordination were considered as a difficult activity for the patient and were not used in this study. The difficulty of the games was set to the simplest level for each patient. As the patients were successful the games' difficulty level was upgraded. The difficulty of the games has been increased according to the classification determined by the Nintendo Wii device.
32845|NCT03928392|Behavioral|SCUBA with Occupational Therapy (OT)|Study participants will complete two OT sessions in conjunction to their regular SCUBA diving activity. OT intervention includes breathing techniques, mindfulness strategies and a journal activity.
32846|NCT03928392|Behavioral|Self-Contained Underwater Breathing Apparatus (SCUBA) without OT|Study participants will continue their regular SCUBA diving activity through the Wounded American Veterans Experience SCUBA (WAVES) program. They will complete two dives.
32847|NCT03928379|Drug|LY3305677|Administered SC
32848|NCT03928379|Drug|Placebo|Administered SC
32849|NCT03928366|Drug|Propofol|sedation
32850|NCT03928366|Drug|Remifentanil|remifentanil
32851|NCT03928353|Drug|PB2452 Infusion|30 minute - 24 hour infusion
32852|NCT03928353|Drug|Placebo - Sodium Chloride|30 minute - 24 hour infusion
32853|NCT03928353|Drug|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo
32854|NCT03928353|Drug|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagerlor 180 mg 24 hours following PB2452 or Placebo
32855|NCT03928353|Drug|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
32856|NCT03928353|Drug|PB2452 Infusion|30 minute - 16 hour infusion
32857|NCT03928353|Drug|Placebo - Sodium Chloride|Placebo - Sodium Chloride
32858|NCT03928340|Drug|Metformin|"40 patients will be treated with metformin~(1 gm twice daily (with the 2 main meals)), combined with insulin therapy"
32859|NCT03928340|Drug|Insulin|40 patients will be treated with insulin alone. (Insulin dosage will be adjusted according to endocrinological recommendations)
32860|NCT03928327|Drug|TAK-788|TAK-788 Capsules
32861|NCT03928327|Drug|Itraconazole|Itraconazole Oral solution
32862|NCT03928327|Drug|Rifampin|Rifampin Capsules
32863|NCT03928314|Drug|ORIC-101|ORIC-101 once daily for 21 days of each 28-day cycle
32864|NCT03928314|Drug|Nab-paclitaxel|75 mg/m2 Days 1, 8, and 15 of each 28-day cycle
32865|NCT03928301|Behavioral|Wholetones Music|Participants listened to the Wholetones music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
32866|NCT03928301|Behavioral|Classical Music|Participants listened to the classical music for 10 nights consecutively. Participants began playing the music 30 minutes before going to bed and were asked to allow it to play continuously throughout the night.
32867|NCT03928288|Drug|Cabergoline 0.5 MG|Medication
32868|NCT03928288|Drug|Placebo - Cap|Placebo capsule
32869|NCT03928275|Biological|Interleukin-2|IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion.
33008|NCT03927131|Biological|TIVY-IB|Inactivated split-virion trivalent Influenza Vaccine containing Influenza B virus - Yamagata lineage
32870|NCT03928275|Biological|Combination therapy Bacillus Calmette Guerin and Interleukin-2|"BCG (OncoTICE solutions 1-8 x 10-8 Colony Forming Units (CFU)) will be administered at a maximum dose of 3.2 million CFU per treatment at a maximum of 1.6 million CFU per lesion (max 2 lesions).~IL-2 is prepared as 4 million International Units (IU) per 0.8ml at a total dose of 500,000 IU in 0.1ml of sterilized saline (0.9%, m/v)/lesion (in remaining lesions)."
32871|NCT03928262|Biological|Benralizumab|Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.
32872|NCT03928249|Dietary Supplement|Eriocitrin|"A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed.~Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara)~At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio."
32873|NCT03928236|Other|Limited Intraoperative Benzodiazepine|policy for limited use of intraoperative benzodiazepine
32874|NCT03928236|Other|Liberal Intraoperative Benzodiazepine|policy for liberal use of intraoperative benzodiazepine
32875|NCT03928223|Other|exploratory survey on Itch modification by color viewing|"Patients relate their itch to a color of the Manchester Color Wheel (MCW) and choose a color of the MCW aimed at counteracting their itch. They complete the ItchyQoL (German version), which is a standard tool to assess itch-related quality of life. Then patients look at their antipruritic monochrome color for five minutes on a lap-top screen. Itch intensity (0-10 NRS) will be assessed at baseline and again after the patients looked at this color for 5 minutes."
32876|NCT03928210|Drug|Digoxin|Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.
32877|NCT03928197|Behavioral|Tilt Test|Volunteers need to lay down for 15 minutes and afterwards stand up for 15 minutes
32878|NCT03928197|Device|Inbody S10|Bio-electrical impedance measurement every 5 minutes
32879|NCT03928197|Device|Tape measurements|Every 5 minutes, circumference of every leg is measured using a tape measure
32880|NCT03928197|Device|SOMNOtouchTMNIBP, Vivisol, Belgium|Continous measurement of blood pressure, heart rate and saturation
32881|NCT03928184|Drug|Lorecivivint|Healthcare professional-administered intra-articular injection; performed on Day 1
32882|NCT03928184|Drug|Placebo|Healthcare professional-administered intra-articular injection; performed on Day 1
32883|NCT03928171|Other|Intra-abdominal pressure during laparoscopy|Insufflation pressure of the abdomen during laparoscopy
32884|NCT03928158|Drug|LCZ 696|100 mg tablet
32885|NCT03928158|Drug|Enalapril|5 mg tablet
32886|NCT03928145|Drug|Chlorthalidone 25 mg|Chlorthalidone 25 mg taken orally in the morning for 12 weeks.
32887|NCT03928145|Drug|Hydrochlorothiazide 50 mg|Hydrochlorothiazide 50 mg taken orally in the morning for 12 weeks.
32888|NCT03928145|Drug|Amiloride 20 mg|Amiloride 20 mg taken orally in the morning for 12 weeks.
32889|NCT03928145|Drug|Amiloride 10 mg|Amiloride 10 mg taken orally in the morning for 12 weeks.
32890|NCT03928132|Behavioral|CPD Workshop on Depression and Diabetes|2 parallel face-to-face onsite workshops on diabetes and depression in primary care given by experts in French (control and experimental) using Powerpoint presentations.
32891|NCT03928119|Behavioral|public education and network construction|Publication education includes multiple methods of acute myocardial infarction knowledge education. Network construction includes regional connection of ST-Segment Elevation Myocardial Infarction patients transfer for percutaneous coronary intervention treatment, as well as physicians skill improvement in primary hospital.
32892|NCT03928106|Other|pharmacists' recommendation|For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
32893|NCT03928093|Drug|Pregabalin|Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant < 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
32894|NCT03928080|Diagnostic Test|Bleeding on brushing|Index tests are bleeding on brushing and aMMP-8 Gold standard: clinical diagnosis performed by specialist
32895|NCT03928067|Behavioral|PNF + SAF|Personalized normative feedback (PNF) to correct misperceived peer drinking norms abroad + sojourner adjustment feedback (SAF) to promote cultural engagement abroad.
32896|NCT03928054|Other|Kinesio Taping and therapeutic alliance|bandage used in the treatment of orthopedic diseases and the technique of therapeutic approach in the known patient with therapeutic alliance
32968|NCT03927456|Drug|Fulvestrant|Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
32897|NCT03928041|Device|Device: EVOS Lumbar Interbody System (EVOS-HA)|All subjects will receive the EVOS Lumbar Interbody System (EVOS-HA) device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease and spondylolisthesis.
32898|NCT03928028|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is an adjunctive treatment focused on increasing set-shifting ability and developing meta-cognition.
32899|NCT03928028|Behavioral|Family Based Treatment|Family Based Treatment (FBT) is an evidence based treatment in which parents are responsible for adolescent re-nourishment. They play an active role in treatment and their self-efficacy to make decisions regarding their child's treatment is empowered.
32900|NCT03928015|Drug|Adjunctive dronabinol|5mg BID and adjusting within the range of 2.5mg - 10mg BID, minimum of 48 hours, as an adjunct to systemic analgesics
32901|NCT03928015|Drug|Systemic analgesics|multimodal analgesia including opioid and non-opioid analgesics
32902|NCT03928002|Other|4D Flow magnetic resonance imagery|acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information
32903|NCT03928002|Procedure|Cardiac catheterization|pulmonary vascular resistance calculation ;
32904|NCT03927989|Behavioral|Text messaging plus nicotine replacement therapy|Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.
32905|NCT03927989|Other|Standard Care at Lung Cancer Screening|Brief advice to quit smoking prior to lung cancer screening
32906|NCT03927976|Behavioral|Path2Quit - culturally specific text message intervention|SMS text delivers over 6 weeks with links to 20-120 second video clips from PTF. The message library contains 155 videos and assessment questions. First message is tailored to wake-up times, and the topic of the video (e.g., Never Quit Quitting) accompanies the text. Messages are pushed to participants 1-2 times/day, with 24/7 access to messages pulled from 3 keywords (HELP1, JONES, SLIP). Participants also receive inquiry texts, designed to push videos of interest/relevance to the individual. The cultural adaptations are infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
32907|NCT03927963|Drug|Dexmedetomidine|Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
32908|NCT03927963|Drug|Propofol|Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
32909|NCT03927950|Drug|escitalopram|escitalopram 10-20mg per day 12 weeks
32910|NCT03927950|Drug|bupropion|bupropion 150-300mg per day 6 weeks
32911|NCT03927937|Procedure|AUTOTRANSPLANTATION TOOTH|Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
32912|NCT03927924|Procedure|High-intensity focused ultrasound|Energy employed to exert its effect through thermal and mechanical destruction of cancer tissue
32913|NCT03927911|Drug|EXPAREL and Bupivacaine|Drug: EXPAREL and Bupivacaine HCl 0.5%
32914|NCT03927911|Drug|Standard of Care|Standard of Care
32915|NCT03927898|Drug|Toripalimab|Participants receive Toripalimab (240mg)/q3w till progression of disease after SBRT
32916|NCT03927898|Radiation|Stereotactic Body Radiotherapy|Participants receive SBRT (BED>80Gy) to oligometastatic lesions followed by Toripalimab (240mg)/q3w
32917|NCT03927885|Other|Placebo|Given open labeled placebo PO
32918|NCT03927885|Other|Quality-of-Life Assessment|Ancillary studies
32919|NCT03927885|Other|Questionnaire Administration|Ancillary studies
32920|NCT03927885|Other|Waiting List|Assigned to a waiting list
32921|NCT03927872|Other|blood biomarkers|assessment of serum BNP, D-Dimer and CK-MB and CRP and globulin /albumin ratio stroke outcome
32922|NCT03927859|Other|a mail letter, a phone call and a phone call plus mailed letter|"All patients will be administered an intervention that will contain one or more of 3 possible interventions (a mail letter, a phone call and a mail plus phone call). Some patients will also be assigned into a condition where none of the interventions will be present.~Patients at Black Creek CHC will only be offered a phone or a phone plus incentive intervention or a no intervention."
32923|NCT03927846|Behavioral|Nurse-guided Web-based Cognitive Behavioral Therapy|nurse contact is to support and enhance participants' motivation to engage in the web-based CBT program.
32924|NCT03927833|Device|Phototherapy lights|Phototherapy lights used continuously or timed, following an algorithm based upon TSB levels.
32925|NCT03927820|Other|Benefits investigation|The study pharmacist will review the prescribed inhaler for 1) insurance coverage and 2) clinical appropriateness. The pharmacist will conduct a benefits investigation at time of hospital admission. The benefits investigation involves running test claims for inhalers to determine the most cost-effective inhaler for the patient's insurance plan. The study pharmacist will utilize clinical practice guidelines to assess appropriateness of the prescribed inhaler. Based on this review, the study pharmacist will submit a pharmacy consult to the inpatient pharmacist on the patient's healthcare team who will pend the inhaler orders (changing the patient's prescribed inhaler, if necessary) for the prescriber to send to the Meds to Beds discharge pharmacy. The Meds to Beds pharmacist will counsel the patient on inhaler use techniques prior to discharge.
32926|NCT03927807|Drug|Misoprostol|"This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity."
32927|NCT03927794|Other|Self-Assembling Peptide P11-4|Self-Assembling Peptide P11-4 promotes in depth biomimetic remineralization of hard tissue. It is a small peptide comprising 11 amino acids that when applied to an initial carious lesion diffuses into the body of the lesion, re-assembles itself into fibrils forming larger fibers and hence a 3-dimensional (3-D) matrix. Natural remineralization driven by saliva is promoted through the surface of the P11-4 by increasing the surface area for calcium phosphate deposition. As a result, mineralization of the subsurface lesion occurs possibly due to the formation of de novo hydroxyapatite crystals on the surface of the P11-4 fibers.
32969|NCT03927443|Drug|SDP-133|one drop
32929|NCT03927768|Diagnostic Test|Predictive Model|Anonymized, post-processed MRI imaging data will be analyzed to construct a model predicting benign vs malignant lesions. Model will be tested on a second cohort.
32930|NCT03927768|Diagnostic Test|Breast Imagers|Anonymized research sequence with the addition of modeling data (Aims 1A and 1B) will be read by three blinded breast imagers and final evaluation compared to the full protocol.
32931|NCT03927755|Other|Education|Physicians will undergo training on how to rapidly obtain appropriate images.
32932|NCT03927742|Device|Microsoft Band 2|Microsoft Band 2 application with UV message activated
32933|NCT03927742|Device|Microsoft Band 2 without UV messaging|Microsoft Band 2 application without UV message activated
32934|NCT03927729|Drug|Methoxyflurane|Pain will be treated with inhaled methoxyflurane (Penthrox®).
32935|NCT03927716|Drug|SB206 12%|Topically once daily
32936|NCT03927716|Drug|Placebo|Topically once daily
32937|NCT03927703|Drug|SB206 12%|Topically once daily
32938|NCT03927703|Drug|Placebo|Topically once daily
32939|NCT03927690|Drug|LKA651|LKA651 IVT
32940|NCT03927690|Drug|LKA651|LKA651 IVT
32941|NCT03927690|Drug|Lucentis|Lucentis IVT
32942|NCT03927690|Drug|Lucentis|Lucentis IVT
32943|NCT03927677|Drug|Xanthine Oxidase Inhibitor|LC350189 200mg qd
32944|NCT03927664|Other|Radiological assessment|Radiological assessment of findings in the peritoneum, omentum, mesentery, ascites and other abdominal findings
32945|NCT03927651|Drug|ICG|Indocyanine green (ICG) is a Food and Drug (FDA)-approved tricarbocyanine dye that is fluorescent under near-infrared (NIR) light. ICG solutions for injection often contain sodium iodide. ICG is water soluble and when introduced intravenously, it is bound by plasma proteins, namely albumin. The intravascular half-life of ICG is 3-4 minutes with rapid hepatic clearance.
32946|NCT03927638|Behavioral|sit/stand|Subjects will be asked to both sit and stand during a single trial.
32947|NCT03927625|Drug|Ascorbate-Meglumine|Patients receiving SRS treatment for cancer metastatic to the brain from an extracranial primary site with a contrast-enhanced MRI scan showing 1-3 brain metastases, including post-operative patients with 1-3 residual metastases, at the Duke Comprehensive Cancer Center will be consented to receive ascorbate formulated with meglumine as MRI-guided Adjunctive Chemotherapeutic
32948|NCT03927612|Device|Virtual reality perspective taking training|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the alternate perspective condition, participants will then experience the scenario again from the counterpart's perspective, including internal thoughts of the virtual counterpart.
32949|NCT03927612|Device|Virtual reality control perspective|Virtual reality system provides first-person perspective of a virtual social interaction in a school cafeteria as the subject attempts to complete a goal. A virtual counterpart interferes with this goal. In the control perspective condition, participants will then experience the scenario again from identical perspective.
32950|NCT03927599|Other|Data Collection|Colleciton of data from medical records only
32951|NCT03927586|Other|cognitive training|visuospatial, attention, memory, and executive abilities
32952|NCT03927586|Other|physical exercise training|endurance, balance, and mobility
32953|NCT03927573|Drug|GEM3PSCA|Infusion of GEM3PSCA, administered intravenously, continuously over 7 days, 2 cycles
32954|NCT03927560|Procedure|Robotic Assisted Percutaneous Coronary Intervention|Robotic Assisted Percutaneous Coronary Intervention
32955|NCT03927547|Device|Inclined Sleep|Study participants randomized to the interventional arm will be instructed to sleep on inclined wedge mattress.
32956|NCT03927534|Behavioral|Mindful Eating|The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
32957|NCT03927521|Procedure|Focal HIFU using PET-MRI/68Ga-PSMA imaging guidance|Focal HIFU treatment will be conducted with the Focal One® device using the PET-MRI/68Ga-PSMA imaging. The treatment area will be defined using PET-MRI/68Ga-PSMA imaging data and 3D biopsies.
32958|NCT03927508|Drug|r-tPA|Pulse spray and infusion
32959|NCT03927508|Device|The Bashir™ Endovascular Catheter|The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
32960|NCT03927495|Drug|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. During the period of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
32961|NCT03927495|Radiation|palliative radiotherapy|3D conformal radiation therapy will be administered for esophageal lesion or nearby lymph node. Stereotactic body radiation will be administered for metastatic lesion.
32962|NCT03927495|Drug|KN046|Cisplatin+paclitaxel will be administered once every three weeks for four cycles. After completion of radiotherapy, KN046 will be administered once every two weeks until progressive disease, unacceptable toxicity or up to 2 years.
32963|NCT03927482|Behavioral|CARES mobile smart phone app|The CARES smart phone mobile app contains a number of features to support safety while drinking and reduced alcohol consumption plus regular test messages for personal support
32964|NCT03927482|Behavioral|Check Your Drinking|Check Your Drinking is an online alcohol assessment that provides normative feedback on the user's drinking habits relative to his/her peers. Alcohol interventions that provide normative feedback are rated by the NIAAA Alcohol Intervention Matrix as effective and low cost, and with few administrative or structural barriers to implementation thus making it suitable for community colleges.
32965|NCT03927469|Other|age, sex, hemiplegic side, stroke duration, First hospitalisation duration (day)|This is a retrospiective descriptive study
32966|NCT03927456|Drug|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
32967|NCT03927456|Drug|Placebo|Placebo 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
32971|NCT03927430|Procedure|pars plana vitrectomy with membrane peeling|23-gauge pars plana vitrectomy with peeling of the epiretinal and internal limiting membrane as well as air- or gastamponade
32972|NCT03927404|Device|Active vacuum test prosthesis|The experimental socket system uses an active vacuum pump to push air out of the socket. The level of vacuum is controlled by hardware that automatically detects the socket fit based on in-socket motion and adjusts vacuum as needed to eliminate this motion.
32973|NCT03927391|Drug|Enzalutamide|enzalutamide treatment
32974|NCT03927378|Drug|Ketamine|Ketamine (0.5 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
32975|NCT03927378|Drug|Placebos|Placebo (20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
32976|NCT03927365|Device|Inhalation from a salt particle inhaler with or without content|Inhalation from inhaler with (active) or without (placebo) content
32977|NCT03927352|Biological|SCT630|Administered by subcutaneous injection
32978|NCT03927352|Biological|Adalimumab|Administered by subcutaneous injection
32979|NCT03927339|Diagnostic Test|pre and post excercise group|"Treadmill Training Protocol~Each eligible participant in the patients group was then prospectively assigned to undergo exercise session of full-body-free weight treadmill training. Once the participants were prepped, they performed stretching for 5 min and slow walking for 3 min as a warm-up exercise before starting the training. Stretch was carried out similarly to all the subjects to quadriceps femoris and the hamstring. In the warm-up time period , it was enforced for 3 min at the speed of1 km/h. Then patients began the walking trials and walked at 1 to 1.34 m/s on an electric car treadmill (JACO fitness: JACO-212C)."
32980|NCT03927326|Drug|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine
32981|NCT03927313|Drug|Linezolid|For both experimental arms: 1.2g linezolid 28 days, followed by 600mg linezolid for 28 days
32982|NCT03927313|Drug|High dose rifampicin|For both experimental arms: additional 25mg/kg (making a total of 35mg/kg) rifampicin, for the first 56 days of treatment
32983|NCT03927313|Drug|Aspirin|For only one of the experimental arms: 1000mg of aspirin daily for 56 days.
32984|NCT03927313|Drug|Standard of Care anti-tuberculous therapy|10mg/kg oral rifampicin, 5mg/kg oral isoniazid, 15mg/kg oral ethambutol, 25mg/kg oral pyrazinamide daily for 56 days.
32985|NCT03927313|Drug|Dexamethasone|Dexamethasone according to doses of Thwaites criteria for the first 8 weeks of anti-tuberculous treatment. Doses differ according to participants Medical Research Council (MRC) grade. Given orally if participant can swallow and intravenously if they cannot.
32986|NCT03927300|Device|Telemonitoring Software|Recovery of retrospective data in dialysis patients follow or not follow by a telemonitoring application.
32987|NCT03927287|Diagnostic Test|Free PSA ratio test in patients after definitive treatment for localized prostate cancer|Free PSA ratio blood test done on biobank samples of patients after radical prostatectomy who developed biochemical recurrence.
32988|NCT03927274|Drug|Topotecan|Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
32989|NCT03927261|Drug|PRGN-3006 T Cells|Participants will receive a single intravenous (IV) administration of PRGN-3006 T Cells, and will be monitored for safety in the clinic for at least 7 days following infusion, and for safety, efficacy and correlative endpoints up to 12 months following infusion.
32990|NCT03927248|Drug|Nivolumab|See description in Arms/Groups section
32991|NCT03927235|Procedure|Transbronchial Cryobiopsy|Transbronchial Cryobiopsy in the Diagnosis of Diffuse Parenchymal Lung Diseases
32992|NCT03927222|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
32993|NCT03927222|Drug|Temozolomide|Temozolomide is a chemotherapy drug given to all enrolled patients at the post-RT clinic visit as dose-intensified TMZ (100 mg/m2/day for 21 days).
32994|NCT03927222|Biological|Tetanus-Diphtheria Toxoid (Td)|Before the first DC vaccination, patients will receive 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Prior to pp65 DC vaccination #4,(3±1) weeks after leukapheresis 2 the vaccine site will receive a pre-conditioning intradermal injection of Td (1 flocculation unit (Lf), in 0.3 mL of saline for a total of 0.4 mL).
32995|NCT03927222|Biological|GM-CSF|Granulocyte macrophage-colony stimulating factor (GM-CSF) is a sterile, white, preservative-free lyophilized powder in a vial containing 250 mcg that will be reconstituted in 0.5 mL of sterile water for injection and used as an adjuvant with the DC vaccine.
32996|NCT03927222|Biological|111-Indium-labeling of Cells for in vivo Trafficking Studies|111-In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs labeled with 111-In (50 μCi / 5 x 10^7 DCs) and given i.d. as the fourth vaccine. In up to 16 patients, the fourth vaccine will be labeled with 111-In (50 μCi / 5 x 10^7 DCs) prior to injection.
32997|NCT03927209|Drug|BI 1467335|tablet
32998|NCT03927196|Behavioral|extended counseling|Patients are handed out information leaflets on the correction of risk factors, SMS reminders, extended statins counseling.
32999|NCT03927183|Other|person-centred practice|The structure and content of the intervention is constructed on principles for person-centredness. Each patients in the intervention are allocated a hospital-initiated nurse care manager during one year after surgery. Self-management support is primarily conducted between the patient and the nurse care manager. The primary goal of the support is to facilitate patients own resources in managing illness and health education on e.g. physical activity and diet. The support also comprises patient-held documentation and health plan. Other components of the intervention comprise accessibility and continuity which is secured by a structured clinical care pathway with planned care and defined care contacts. The patient has continuous access to the nurse care manager by telephone and face-to-face contact according to a structured follow-up plan. An interdisciplinary team as well as a patient education program constitutes distinct parts of the support during the year after surgery.
33000|NCT03927170|Combination Product|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
33001|NCT03927170|Combination Product|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
33012|NCT03927118|Procedure|intravitreal dexamethasone implant application|Peripapillary RNFL thickness measurements and colored fundus photographs were compared before and 6 months after intravitreal DEX implant injection. The cup-to-disc ratios of fundus photographs were calculated using the Image-J program.
33013|NCT03927105|Drug|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens.
33014|NCT03927105|Drug|cabiralizumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.1 Binding of PD-1 to its ligands, programmed death-ligands 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T-cell responses to both foreign antigens as well as self-antigens.
33015|NCT03927092|Other|Multiple Sclerosis Knowledge Questionnaire|A 25-item self-administered questionnaire
33016|NCT03927079|Biological|measure of intra-alveolar antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
33017|NCT03927079|Procedure|broncho-alveolar lavage (BAL)|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic concentration
33018|NCT03927079|Biological|blood test to measure plasmatic antibiotic concentration in µg/ml|included patients will have a broncho-alveolar lavage (BAL) to measure intra-alveolar antibiotic concentration, and a blood test to measure plasmatic
33019|NCT03927066|Other|Assigned Interventions|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
33020|NCT03927040|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized emitters in the head cap worn by the subject. The device provides global treatment to forebrain. For each of the 120 days of in-home treatment, a single 1-hour treatment will be administered by the subject's caregiver, who will position the device on the patient's head and monitor treatment.
33021|NCT03927027|Drug|Isosulfan Blue|Given SC
33022|NCT03927027|Procedure|Axillary Lymph Node Dissection|Undergo ALND
33023|NCT03927027|Procedure|Mapping|Undergo ARM
33024|NCT03927027|Other|Quality-of-Life Assessment|Ancillary studies
33025|NCT03927027|Other|Questionnaire Administration|Ancillary studies
33026|NCT03927014|Other|thiol/disulfide levels|Venous blood will sample from the antecubital veins for measuring the serum concentration of thiol/disulfide levels. The serum thiol/disulfide levels will measure using commercially available reagent kits, which is produced to detect human thiol/disulfide levels (Rel Assay Diagnostics Gaziantep, Turkey). The thiol/disulfide levels measurements were performed in accordance with the company's protocol.
33027|NCT03927001|Device|NeVa Stent Retrievers|mechanical neurothrombectomy
33028|NCT03926988|Device|NeVa Stent Retriever|mechanical neurothrombectomy
33029|NCT03926975|Device|Scleral Lens|The contact lens will be worn on one eye.
33030|NCT03926975|Other|No lens|No lens worn on the contralateral control eye
33031|NCT03926962|Drug|WCK 4873|100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
33032|NCT03926962|Drug|Placebo Oral Tablet|Visually matching placebo
33033|NCT03926949|Other|Parenteral Nutrition|Olimel 7.6% E 1000 ml will be infused over 4-5 hours at outpatient infusion clinic for 5-10 days within 14 days prior to surgery.
33034|NCT03926949|Other|Standard Nutrition Care|Participants will receive nutrition therapy by registered dietitians within 14 days prior to surgery. Patients with SGA B and SGA C will receive advanced nutrition care and specialized nutrition care, respectively.
33035|NCT03926936|Drug|Fulvestrant|intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
33036|NCT03926923|Other|no intervention|There will be no intervention. The blood sample is taken while a routine blood sampling.
33037|NCT03926910|Diagnostic Test|Detection of hypovolemia using a ventricular stimulation without atrial pacing|"Upon the return in intensive care:~Baseline measurements: 1) Three measurements of blood pressure during inspiration and 3 during expiration will be collected for averaging systolic blood pressure, diastolic blood pressure, mean arterial pressure and ΔPP. Data from a pulmonary artery catheter will be also collected.~Realization of VESAP pacing with adjustment of the pacemaker (PM) at a heart rate 5 bpm higher than the heart rate of the patient. After 20 seconds of stimulation, recording of the blood pressure curve as done at baseline during at least 3 respiratory cycles,~Then vascular filling with 500 ml of physiologic saline solution over 10 minutes and new set of measurement (same than at baseline)~Second realization of VESAP pacing, and new set of measurement (same than at Baseline)~Then, if the ΔPP is >10%, new vascular filling with 500 ml of physiologic saline solution over 10 min and new set of measurements as previously performed."
33038|NCT03926884|Dietary Supplement|Three-seeds mixture|mixture of white mustard seeds, radish seeds and beefsteak plant (Korean perilla, a species of Perilla in the mint family, widely cultivated and edible for humans; a daily food for Korean people; many Japanese people drink as tea) seeds
33039|NCT03926884|Dietary Supplement|Control|warm water with negligible amount of the three-seeds mixture
33069|NCT03926663|Drug|Dexmedetomidine|"Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa."
33040|NCT03926871|Other|Ergonomic Training|The ergonomic training consisted of an educational program in Ergonomics with a duration of 60 (sixty) minutes divided into a theoretical exposition and videos of the occupational tasks performed by the workers themselves. Theoretical lecture covered topics such as ergonomics, human anatomy, worker health, prevention measures to minimize the risks of musculoskeletal diseases. A better way of performing the work to protect the musculoskeletal system was demonstrated.
33041|NCT03926845|Other|Isobutylamido-thiazolyl-resorcinol Cream 0.2%|Each bottle contains Isobutylamido-thiazolyl-resorcinol cream 0.2% to be applied on the entire face twice daily for 12 weeks.
33042|NCT03926845|Other|Vehicle|Each bottle contains vehicle cream to be applied on the entire face twice daily for 12 weeks.
33043|NCT03926832|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea Syndrome (OSAS) management when moderate-to-severe. Subjects with OSA will be trained in the use of CPAP and will be instructed to use it every night for 3 months. These subjects will then return for a post-treatment completion of questionnaires (ESS and FAS) and compliance analysis.
33044|NCT03926819|Drug|HBI-002|Oral liquid carbon monoxide drug product.
33045|NCT03926806|Other|Plain yoghurt|cups of 200 g yoghurt
33046|NCT03926806|Other|Vitamin B yoghurt|cups of 200 g yoghurt
33047|NCT03926793|Drug|GB002|GB002 low dose or high dose for inhalation
33048|NCT03926793|Drug|Placebo|Placebo for inhalation
33049|NCT03926793|Device|Generic Dry Powder Inhaler|Generic dry powder inhaler for GB002 or Placebo delivery
33050|NCT03926780|Drug|Rivaroxaban 20 MG|30 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive rivaroxaban 20 mg per day
33051|NCT03926780|Drug|Warfarin Sodium|30 Patients with evidence of LV thrombus as assessed by trans-thoracic echocardiography (TTE) will be assigned randomly to receive warfarin sodium by a dose starting from 3 mg per day and titrated accordingly to target an INR of 2-3
33052|NCT03926767|Other|Pain Neuroscience Education (PNE)|A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
33053|NCT03926767|Other|Orofacial Manual Therapy|A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.
33054|NCT03926767|Other|Orofacial Exercises|Two mandibular exercises: Mandibular body—condylar cross-pressure chewing technique and Post-isometric relaxation stretches—laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
33055|NCT03926767|Other|Neck Motor Control Exercises|A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
33056|NCT03926754|Drug|Mirabegron|"Study A The maximum tolerated dose up to a maximum of 300 mg per day for 26 weeks.~Study B One single dose of 300 mg at day one followed by 150 mg x 2 for 1 week (8-11 days)."
33057|NCT03926741|Drug|GSNO|patient will use a nebulizer to inhale (breathe in) a solution of GSNO followed by repeated measurements of airway function (breathing tests)
33058|NCT03926728|Biological|CTH522-CAF01 IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
33059|NCT03926728|Biological|CTH522-CAF09b IM|On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
33060|NCT03926728|Biological|CTH522 ID|24 microgram CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 ml syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
33061|NCT03926728|Biological|CTH522 TO|24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.
33062|NCT03926728|Biological|Placebo (Saline)|Placebo only given as IM, ID and TO
33063|NCT03926715|Other|Nutritional status|
33064|NCT03926702|Drug|Radiopharmaceuticals|All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
33065|NCT03926689|Behavioral|SMS messages|A package of at least monthly SMS messages delivered to all adults in households with an individual in the 1000-day period between pregnancy and a child turning 2 years of age.
33066|NCT03926689|Behavioral|Standard SII SBCC|Home visits/IPC; community events including food demo and key life events; and Bhanchhin Aama radio program episodes
33067|NCT03926676|Other|grandio blocks|nano hybrid composite blocks
33068|NCT03926676|Other|emax|ceramic blocks
57263|NCT03736967|Drug|Placebo|Administered SC q2w
33070|NCT03926663|Drug|Bupivacaine|patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) preincisional local infiltration of the nasal mucosa.
33071|NCT03926650|Device|Masimo Sedline Monitor Patient State Index|Masimo Sedline Monitor shows frontal electromyography and patient state index, Train of four monitor shows muscle strength on adductor pollicis muscle
33072|NCT03926637|Other|Multiple Sclerosis Performance Test (MSPT)|Administered as specified in the treatment arm.
33073|NCT03926624|Drug|DFP-10917|DFP-10917 Powder for Injection. Active ingredient: 4-amino-1-(2-cyano-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone monohydrochloride
33074|NCT03926624|Drug|Cytarabine|cytosine arabinoside (ara-C)
33075|NCT03926624|Drug|Azacitidine|Azacitidine
33076|NCT03926624|Drug|Decitabine|Decitabine
33077|NCT03926624|Drug|Mitoxantrone|Mitoxantrone
33078|NCT03926624|Drug|Etoposide|Etoposide
33079|NCT03926624|Drug|Fludarabine|Fludarabine
33080|NCT03926624|Drug|Idarubicin|Idarubicin
33081|NCT03926611|Drug|LOU064 Arm 1|Low dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
33082|NCT03926611|Drug|LOU064 Arm 2|Medium dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
33083|NCT03926611|Drug|LOU064 Arm 3|High dose of LOU064 orally in the morning (once daily) and matching placebo in the evening from Day 1 to 85
33084|NCT03926611|Drug|LOU064 Arm 4|Low dose of LOU064 orally, twice daily from Day 1 to 85
33085|NCT03926611|Drug|LOU064 Arm 5|Medium dose of LOU064 orally, twice daily from Day 1 to 85
33086|NCT03926611|Drug|LOU064 Arm 6|High dose of LOU064 orally, twice daily from Day 1 to 85
33087|NCT03926611|Drug|Placebo arm|Matching placebo, orally, twice daily from Day 1 to 85
33088|NCT03926598|Behavioral|Patient and/or Family Member Intervention|On the Patient Login Screen, log in using your last name and session ID provided by the research team on the Surveys Screen, click on a pending survey when the survey opens, respond to the survey submit the survey log out of the Guide-Goals Application.
33089|NCT03926598|Behavioral|Certified Diabetes Educator Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
33090|NCT03926598|Behavioral|Physician Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patient Screen, add a new patient on the Edit Patient Screen, add the Diabetes Family Responsibility Questionnaire on the Edit Patient Screen, create a survey access code to share with the patient.
33091|NCT03926598|Behavioral|Front Desk Staff Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status Screen, add comments needs to be followed up regarding ketosis education in the comments for provider text box on the Visit Status Screen, add a goal for the patient log out of Goals-to-Guide application.
33092|NCT03926598|Behavioral|Nurse Intervention|On the Provider Login Screen, log in using the username and password provided by the research team on the Patients Screen, choose patient Will Owens on the Visit Status screen, change HbA1C value to 10% on the Visit Status screen, change Nephropathy evaluation to Abnormal log out of Guide to Goals application.
33093|NCT03926572|Other|A biobank will be created from blood samples taken at admission, days 3 and days 7|A biobank will be created from the blood samples taken on admission, days 3 and 7 of admission. The prognostic value of the preselected biomarkers will be analyzed and a proteomic analysis will be performed to identify new biomarkers. The prognostic value of these new biological parameters will be compared to the usual surveillance parameters that will be collected during the follow-up (clinical, echocardiographic and hemodynamic parameters)
33094|NCT03926559|Drug|Morphine.|Pregnant patients with a perineal tear postpartum receive 2mg of morphine through their epidural. This will be a one time dose immediately postpartum.
33095|NCT03926546|Behavioral|ERP for Individuals|Comparing Group vs. Individual ERP for OCD
33096|NCT03926533|Other|Telehealth|Telehealth visits will be conducted from a private telehealth lab room in the Vanderbilt ICU Recovery Center using a live and interactive approach where providers and patients interact and communicate in real-time using Zoom, a secure video-conferencing platform recommended by Vanderbilt Telehealth.
33097|NCT03926520|Device|Electroconvulsive Therapy (ECT)|Stimulus method of delivery will be RUL electrode placement, and ultra-brief (UB) pulse width (0.25-0.37ms). At the first ECT session, seizure threshold (ST) will be determined by titration with the empirical dose titration method and subsequent treatments will be approximately 6 times the ST. Following other NIMH sponsored multicenter ECT studies (PRIDE, U01 MH055495), stimulus settings will be adjusted as needed during the ECT course based on seizure quality and treatment efficacy. Participants will be administered anesthesia.
33098|NCT03926520|Other|Simulated Electroconvulsive Therapy (S-ECT)|The participant is brought to the ECT suite for the length a session would normally take (approximately 2 hours). While in the ECT suite, conducting gel will be placed on the scalp of the S-ECT subjects to parallel the ECT procedures in the ECT active group. A Band-Aid will also be placed on the arm of the S-ECT subjects to parallel the Band-Aid placed at the IV site for the ECT active group. Participants will not be administered anesthesia.
33102|NCT03926481|Behavioral|Evaluate Healthy Lifestyle Program on cognitive outcomes|The healthy lifestyle program will be delivered once a week for 17 weeks as part as regular clinical care. It will include an group classes taught by health coaches and dieticians. These classes will focus on diet, exercise, and behavior modification. We plan 2 cohorts of 15 subjects (n=30). In-person research assistant-led assessments will occur at baseline and 17 weeks.
33268|NCT03925181|Behavioral|Counselling Group|All sessions will be based off of SAMHSA's recovery curriculum but tailored to the participants recovering from the ICU and their caregivers. Throughout the 6-weeks, the sessions will be holistic, strengths-based, hopeful, respectful, relational, and subjective, while emphasizing social relationships, social contexts, and meaning and purpose.
33103|NCT03926468|Diagnostic Test|Liquid biopsy|Before onset of treatment, cell-free DNA (cfDNA) is extracted from venous blood sample for next-generation DNA sequencing (NGS) using a commercially available platform (Roche Foundation ACT) For this purpose, 4 x 10 ml of venous blood will be collected from each patient. Two tubes (Streck) will be sent to service provider (Roche), one tube will be used for droplet digital polymerase chain reaction (ddPCR, QX200 Droplet Digital PCR System, BioRad) and ddPRC/NGS analyses and one is collected and stored in Auria Biobank (www.auria.fi) for possible future analyses.
33104|NCT03926455|Biological|Typhax (investigational typhoid fever candidate vaccine)|
33105|NCT03926455|Biological|Placebo|Placebo is administered to the control group on Day 0 and 28
33106|NCT03926455|Biological|Active Comparator Typhim Vi|A single dose of commercial typhoid fever vaccine Typhim Vi is administered on Day 0, followed by placebo control on Day 28
33107|NCT03926442|Other|Italian Herb meal|Italian Herb in active breakfast meal
33108|NCT03926442|Other|Cinnamon Meal|Cinnamon in active breakfast meal
33109|NCT03926442|Other|Pumpkin Spice meal|Pumpkin Spice Mix in active breakfast meal
33110|NCT03926442|Other|Placebo meal|Placebo in breakfast meal
33111|NCT03926429|Other|Standardised data collection|The following variables will be retrospectively assessed by medical record review using a standardised data collection form:demographics; gender, age; family or personal history of spondyloarthritis, psoriasis, uveitis, inflammatory bowel disease; clinical presentation; mono, oligo or polyarthritis, dactylitis, inflammatory joint pain, enthesopathy, axial symptoms, fever, extra-articular manifestations (conjunctivitis, anterior uveitis, circinate balanitis, skin rash); time interval between infection and musculoskeletal manifestations; causal microorganism if known, or triggering event; HLA-B27; radiographic sacroiliitis; treatments and outcomes (complete recovery at one year follow-up, relapse within 6 months after onset, or spondyloarthritis according to the ASAS criteria).
33112|NCT03926416|Biological|CodaVax-H1N1|Live-attenuated vaccine against influenza A H1N1, A/California/07/2009
33113|NCT03926416|Biological|Fluzone quadrivalent|Fluzone® (QuadriFlu - TIV), inactivated, quadrivalent influenza vaccine
33114|NCT03926403|Other|"State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire)"|"Patients will be given, a State-Trait Anxiety Inventory (Spielberger Self-Assessment Questionnaire) that will be collected on the same day. Each patient's initial anxiety score will be calculated so as to select only patients who are at least moderately anxious about their management (score ≥ 46)."
33115|NCT03926403|Procedure|hypnosis techniques|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from experimental management based on hypnosis techniques.
33116|NCT03926403|Procedure|local anaesthesia|Patients requiring facial surgery under local anaesthesia in an ultra-short circuit will benefit from conventional management (local anaesthesia).
33117|NCT03926390|Dietary Supplement|Bovine colostrum|1st 6 hour bovine colostrum
33118|NCT03926390|Other|Placebo|Distilled water
33119|NCT03926377|Procedure|bone densitometry|Patients with bullous pemphigoid will benefit from bone densitometry at the initiation of treatment, at 3 months (theoretical end of the treatment of attack) and at 6 months (theoretical end of the treatment).
33120|NCT03926377|Biological|blood test|Blood test of serum calcium, phosphoremia, albumin, 25 OH vitamin D and cortisol at 8 hours to highlight possible correlations between changes in bone mineral density and phosphocalcic parameters and 8 hours cortisolemia.
33121|NCT03926377|Procedure|radiographs of the thoracic and lumbar spine|standard radiographs of the thoracic and lumbar spine will be done at the initiation of treatment and at 6 months.
33122|NCT03926377|Procedure|Clobetasol propionate|Clobetasol propionate (Dermoval® 0,5% cream), administered for 6 months.
33123|NCT03926364|Other|Patients with referred pain|The project does not affect treatment or does not offer any intervention.
33124|NCT03926351|Dietary Supplement|Omega-3 capsules|BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
33125|NCT03926351|Dietary Supplement|Olive oil|Soft gelatine capsule containing 1000 mg olive oil, refined.
33126|NCT03926338|Drug|Neoadjuvant therapy with PD-1 inhibitor plus COX inhibitor|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 cycles) and Celecoxib (oral 200mg once daily for 12 weeks) followed by colectomy
33127|NCT03926338|Drug|Neoadjuvant therapy with PD-1 inhibitor|Toripalimab (IV given over 30 min at a dose of 3mg/m2 on day 1, every 2 weeks for 6 cycles) followed by colectomy
33128|NCT03926312|Device|Smart device-based cardiac rehabilitation|A smart device coupled with remote monitoring will be used to increase physical activity of patients after myocardial infarction with a history of low physical activity.
33129|NCT03926299|Device|FotonaSmooth SP® Spectro laser device|dual laser treatment with thermal Nd:YAG and ablative Er:YAG (Fotona medical device), 4 laser sessions 4-8 weeks apart.
33130|NCT03926299|Drug|Clobetasol propionate 0.05% ointment|6 months standard treatment with topical steroid cream (high dose for the first two months, medium dose for the next two months, low dose for the last two months)
33131|NCT03926286|Drug|FMP-30|FMP-30 containing frozen human fecal microbiota administered as (3) units of FMP30 enema on Day 0 and Week1
33132|NCT03926260|Other|ctDNA analysis|blood sample at Baseline, 3weeks, 9 weeks after treatment, at progression if applicable
33133|NCT03926247|Behavioral|Immigrant Well-Being Project|The IWP intervention emphasizes a sustainable and replicable partnership model between community-based organizations and universities that involves Mexican immigrants and undergraduate advocates working together to: a) increase immigrants' abilities to navigate their communities; b) improve immigrants' access to community resources; c) enhance meaningful social roles by valuing immigrants' culture, experiences, and knowledge; d) reduce immigrants' social isolation; and e) increase communities' responsiveness to immigrants through changes in policy and practice. The IWP is administered by university students enrolled in a service learning course, and has two elements: 1) Learning Circles, which involve cultural exchange and one-on-one learning opportunities, and; 2) Advocacy, which involves collaborative efforts to mobilize community resources related to health, housing, employment, education, and legal issues.
33299|NCT03924960|Behavioral|Control|Usual care control group
33134|NCT03926234|Other|Four-level Chinese Emergency triage scale|a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
33135|NCT03926221|Behavioral|Parent Behavior Change Intervention (PBC-I) and Transdiagnostic Sleep and Circadian Intervention (TranS-C)|PBC-I will be administered to the parent and TranS-C will be administered to the teenager. Both interventions are cognitive-behavioral and comprised of six weekly sessions. Parent and teenager sessions will be held in parallel.
33136|NCT03926208|Procedure|Soak and Scrub|Betadine soak and scrub in addition to standard clorihexadine scrub (standard of care).
33137|NCT03926208|Procedure|Clorihexadine scrub|Clorihexadine scrub (standard of care).
33141|NCT03926182|Drug|AST2818 Tablets|AST2818 Tablets: Period 1 Fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once) and 4 hours after dosing on day 1. Period 2 Allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1.
33142|NCT03926182|Drug|AST2818 Tablets|AST2818 Tablets: Period 1 allocated high-fat meal prior to dosing with 80 mg AST2818 tablet (p o, once) and fasted 4 hours after dosing on day 1. Period 2 fasted from 10 hours prior to dosing with 80 mg AST2818 tablet (p o, once)and 4 hours after dosing on day 1.
33143|NCT03926169|Drug|Risankizumab|Risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS)
33144|NCT03926169|Drug|Placebo for risankizumab|Placebo for risankizumab is administered as a subcutaneous (SC) injection in pre-filled syringe (PFS)
33145|NCT03926156|Drug|Rivaroxaban|Rivaroxaban will be used as the anticoagulation drug for the intervention group. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no approved antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food
33146|NCT03926156|Drug|Warfarin|Warfarin will be used as the anticoagulation drug for the control group. Warfarin decreases blood clotting by blocking an enzyme called vitamin K epoxide reductase that reactivates vitamin K1. Without sufficient active vitamin K1, clotting factors II, VII, IX, and X have decreased clotting ability. The anticlotting protein C and protein S are also inhibited but to a lesser degree. A few days are required for full effect to occur and these effects can last for up to five days, and the final dose will be adjusted according to PT and related INR.
33148|NCT03926130|Drug|Mirikizumab|Administered IV
33149|NCT03926130|Drug|Mirikizumab|Administered SC
33150|NCT03926130|Drug|Ustekinumab|Administered IV
33151|NCT03926130|Drug|Ustekinumab|Administered SC
33152|NCT03926130|Drug|Placebo|Administered IV
33153|NCT03926130|Drug|Placebo|Administered SC
33154|NCT03926117|Biological|Ziltivekimab|human IgG1k anti-human IL-6 monoclonal antibody
33155|NCT03926091|Drug|Docetaxel|Docetaxel chemotherapy (injection)
33156|NCT03926091|Drug|Cyclophosphamide|Cyclophosphamide chemotherapy (injection)
33157|NCT03926078|Other|3D optical surface image|3D optical surface images will be acquired and used to calculate the EHI
33158|NCT03926078|Radiation|Chest radiography|Chest radiographies will be acquired and used to calculated the HI and EHI
33159|NCT03926078|Radiation|CT scan|CT scans will be acquired and used to calculate the HI and EHI
33160|NCT03926065|Other|Plain Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables without added flavoring (b) the baseline portion size of vegetables
33161|NCT03926065|Other|Plain Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables without added flavoring (b) 200% of the baseline portion size of vegetables
33162|NCT03926065|Other|Enhanced Vegetables Served in 100% Portion Size|Lunch includes (a) vegetables with added flavoring (b) the baseline portion size of vegetables
33163|NCT03926065|Other|Enhanced Vegetables Served in 200% Portion Size|Lunch includes (a) vegetables with added flavoring (b) 200% of the baseline portion size of vegetables
33164|NCT03926052|Drug|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
33165|NCT03926052|Drug|Placebo|Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.
33166|NCT03926039|Behavioral|sharing decision-making program|Sharing decision-making talks and decision-making assistance tools used in the process
33167|NCT03926026|Drug|Fluticasone Propionate|NCX 4251 Ophthalmic Suspension, 0.1%
33168|NCT03926026|Drug|Placebo|NCX 4251 Ophthalmic Suspension, 0%
33169|NCT03926013|Drug|JNJ-63898081|JNJ-63898081 will be administered.
33170|NCT03926000|Drug|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
33171|NCT03926000|Drug|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
33172|NCT03925987|Behavioral|Exposure therapy|10 weekly sessions of group-based exposure therapy
33173|NCT03925974|Drug|KN026|10 mg/kg QW
33174|NCT03925974|Drug|KN026|20 mg/kg Q2W
33175|NCT03925961|Other|Preoperative education|The intervention is focused around providing patients with educational information in the pre-operative setting and determine if this improves patients' surgical experience.
33213|NCT03925493|Behavioral|Graded Exercise Stress test (GXT) with Target Heart Rate Range|Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.
33176|NCT03925948|Behavioral|PLAN 4 Success-Diabetes|The study intervention—PLAN 4 Success-Diabetes—consisted of four 1 to 1 ½-hour weekly health literacy training and disease knowledge education sessions for four weeks (4 in-person sessions), followed by two home visits and monthly phone counseling for over 6 months (5 phone sessions). The intervention is theory-driven and builds on von Wagner's model to incorporate key elements such as health literacy, disease knowledge, and self-efficacy for better glucose outcomes.
33177|NCT03925935|Biological|AB-205|Engineered human umbilical vein endothelial cells
33178|NCT03925909|Dietary Supplement|Eriocitrin|The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
33179|NCT03925896|Drug|LMP2 Antigen-specific TCR T cells|All enrolled subjects will be infused with EBV TCR-T cells. The project which enrolls 27 patients, according to the patient's HLA subtypes will be divided into HLA-A2, HLA-A11, HLA-A24 three groups, 9 patients in each group. Using a dose climbing method, each group will be divided into three dose subgroups. In the first dose subgroup, 5×106/kg TCR-T cells will be returned, and in the second dose subgroup, 1×107/kg TCR-T cells will be returned. The third dose subgroup 5 x 107/kg TCR-T cells will be returned.
33180|NCT03925883|Behavioral|Patient navigation|Receive up to 6 live phone calls with a patient navigator for education, barrier assessment, and barrier resolution to follow up colonoscopy
33181|NCT03925870|Drug|KN046|Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
33182|NCT03925857|Biological|Allocetra-OTS|Allocetra-OTS contains allogeneic donor mononuclear enriched cells in the form of a liquid suspension with at least 40% early apoptotic cells. The suspension is prepared with Ringer's lactate solution.
33183|NCT03925844|Other|Classification according to the cardiovascular risk|All patients are cognitively assessed at the beginning of the study and their cardiovascular risk is calculated. After 5 years of follow-up, patients are re-evaluated cognitively and their cardiovascular risk is recalculated.
33184|NCT03925818|Drug|Bismuth Subcitrate Potassium|Pylera capsules
33185|NCT03925818|Dietary Supplement|Gastrus|Gastrus 1 tablet
33186|NCT03925792|Behavioral|Lifestyle Medicine|diet, sleep, exercise and mindfulness
33187|NCT03925779|Drug|Dexmedetomidine|dexmedetomidine sedation
33188|NCT03925779|Drug|Propofol|propofol sedation
33189|NCT03925779|Drug|Remifentanil|Remifentanil sedation
33190|NCT03925740|Drug|MI Varnish|Application of different varnish materials versus the standard 1.23% ACP fluoride.
33191|NCT03925740|Drug|PreviDent Varnish|PreviDent Varnish
33192|NCT03925740|Drug|1.23% ACP fluoride|1.23% ACP fluoride
33193|NCT03925727|Drug|tavilermide ophthalmic solution|BID topical dosing
33194|NCT03925727|Other|Placebo|BID topical dosing
33195|NCT03925714|Other|life style|life sryle control only
33196|NCT03925714|Drug|Metformin|metformin twice daily
33197|NCT03925714|Drug|Nigetella salivata|NS twice daily
33198|NCT03925701|Drug|Vildagliptin|vildagliptin twice daily
33199|NCT03925701|Drug|vildagliptin\metformin|vildagliptin\metformin twice daily
33200|NCT03925675|Drug|PET/CT with F-Fluciclovine (Axumin)|Comparison between PET/CT, MRI / MRS imaging, and biopsy histopathology. Data from each modality will be analyzed separately as described above to determine tumor recurrence and/or presence of radiation changes. Different metabolic profiles measured in areas of imaging changes and depicted by PET imaging will be characterized. Biopsy locations from stereotactic MRI data will be co-localized with PET/CT and MRSI to correlate biopsy histopathology with MRI+, MRSI+ and PET+ lesion data.
33201|NCT03925662|Drug|Folfox with avastin|Folfox with avastin only
33202|NCT03925662|Drug|Mebendazole|Folfox with avastin with mebendazole
33203|NCT03925649|Drug|HB-adMSCs|single infusion of HB-adMSCs
33204|NCT03925636|Dietary Supplement|Specific Carbohydrate Diet|The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.
33205|NCT03925623|Other|Novel approaches for the design of child resistant closures|"Two novel designs for child resistant closures are tested.~One is sized based on the anthropometric properties of adults and children's hands such that it should disallow children from engaging the system and enable adults (the physically based design strategy). The other replicates the first design, but is sized such that either of the two populations should be able to engage the closure.~In testing this way, we begin to differentiate the paradigm that holds the children out (the cognitively based design strategy-- they do not understand and/or a physical one- they are unable to use the closure).~Results (proportion of children opening within the first or second five minute periods of test and time to opening during the same) from each of these, will be compared to results from the third treatment, a standard, commercially available push and turn system."
33206|NCT03925597|Dietary Supplement|Fiber supplement|3 week sequential supplementation with each fiber supplement
33207|NCT03925584|Other|Music Therapy|Standardized music playlist will be played centrally at the subjects head or feet for a period of 20 minutes once during a 12-hour shift for 14 days or until mechanical ventilation has been discontinued, whichever is first
33208|NCT03925571|Other|musicotherapy|If the patient is randomized in the experimental group, he listens the Music-care® playlists and chose two closed to his musical tastes. The playlists are unique compositions create by Music-care® (french company), not known from the general public, categorized by theme (jazz, rock, world music…).
33209|NCT03925558|Dietary Supplement|Probiotics|
33210|NCT03925558|Dietary Supplement|Placebo|
33211|NCT03925532|Biological|Denosumab|Given SC
33212|NCT03925519|Other|Supervised aerobic exercise|
33214|NCT03925493|Behavioral|Heart rate monitors|Heart rate monitors (HRM) will be given to half of the patients randomly assigned to exercise stress testing group. Patients will receive a polar heart rate chest strap and polar watch. Patients will be asked to wear both, the chest strap and the watch during cardiac rehabilitation. Ultimately, we hope that the use of HRM is not necessary, but it may be needed to assure that patients in the THHR are able to consistently know their HR and adjust their exercise prescription. This will also increase the likelihood that there is a difference in heart rates between the THRR group from the RPE group.
33215|NCT03925480|Drug|Azithromycin 500 mg Oral Tablet x 4|A single prophylactic dose of antibiotic given during labour
33216|NCT03925480|Drug|Matching Placebo|Matching Placebo
33217|NCT03925467|Other|Acupuncture|"Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21."
33218|NCT03925428|Drug|Entinostat|Given PO
33219|NCT03925428|Drug|Molibresib|Given PO
33220|NCT03925402|Drug|Ertapenem|Ertapenem injection
33221|NCT03925402|Drug|Carbapenems|Other carbapenems injection
33222|NCT03925389|Procedure|External septorhinoplasty|A surgical procedure to repair defects or deformities of both the nasal septum and the external nasal pyramid through an external incision at the columella.
33223|NCT03925376|Procedure|Redo cardiac surgery|Redo cardiac surgery is technically challenging due to scarring of tissues resulting in loss of tissue planes, adhesions, multiple comorbid factors and risk of injury during re-entry.Suggested techniques in coronary artery surgery with a left internal mammary artery include routing the graft through a slit in the pericardium to minimize the possibility of adherence to the sternal table.
33224|NCT03925363|Device|Physical activity mobile-application|The active group will be given the feedback app and the control group the blind app
33225|NCT03925350|Drug|Niraparib|300 mg PO daily
33226|NCT03925337|Device|Computer Aided Diagnostic Software|The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
33227|NCT03925324|Biological|Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg
33228|NCT03925324|Other|Placebo|1.5 mL/kg Lactated Ringer's Solution
33229|NCT03925311|Procedure|endometrial biopsy and blood sampling|patient will be performed endometrial biopsy and collected blood samples at particular time points
33230|NCT03925285|Drug|Bevacizumab-800CW|Two to four days prior to surgery bevacizumab-800CW will be administered intravenously
33231|NCT03925272|Procedure|Collection of samples (blood, stool, etc.)|
33232|NCT03925272|Genetic|Genetic determinants analysis|
33233|NCT03925272|Procedure|Sample obtained after surgery performed in the context of care|
33234|NCT03925259|Behavioral|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a 'third wave' behaviour therapy delivered on a one to one basis.
33235|NCT03925246|Drug|Nivolumab|"Nivolumab (Opdivo) is a potent human monoclonal antibody (mAb) of the IgG4 isotype designed to directly block the interaction between Programmed Cell Death 1 (PD-1) and its ligands, Programmed Death Ligand 1 (PD-L1) and PD-L2.~Nivolumab is administered by a 30 minutes intravenous infusion at dose of 240 mg every 2 (+/- 2 days) weeks for 8 cycles (4 months), followed by a dose of 480 mg administered by a 60 minutes intravenous infusion every 4 weeks (+/-3 days) (beginning at cycle 9) for a total therapy duration of 1 year (maximum 16 cycles of treatment) or until progression, death, unacceptable toxicity."
33236|NCT03925233|Drug|Trastuzumab|Trastuzumab Injection
33237|NCT03925233|Drug|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride Injection
33238|NCT03925233|Drug|Epirubicin hydrochloride|Epirubicin hydrochloride injection
33239|NCT03925233|Drug|Fluorouracil|Fluorouracil injection
33240|NCT03925233|Drug|Paclitaxel|Paclitaxel injection
33241|NCT03925233|Drug|Gemcitabine|Gemcitabine injection
33242|NCT03925233|Drug|Cisplatin|Cisplatin injection
33243|NCT03925233|Drug|Recombinant Human Endostatin|Recombinant Human Endostatin Injection
33244|NCT03925233|Drug|Pirarubicin hydrochloride|Pirarubicin hydrochloride injection
33245|NCT03925233|Drug|Pyrrolidine|Pyrrolidine tablets
33246|NCT03925233|Drug|Ixabepilone|Ixapilone Injection
33247|NCT03925233|Drug|Tamoxifen citrate|Tamoxifen citrate tablets
33248|NCT03925233|Drug|Vinorelbine tartrate|Vinorelbine tartrate injection
33249|NCT03925233|Drug|Carboplatin|Carboplatin injection
33250|NCT03925233|Drug|Methotrexate|Methotrexate injection
33251|NCT03925233|Drug|Eribulin mesylate|Eribulin mesylate injection
33252|NCT03925233|Drug|Toremifene citrate|Toremifene citrate tablets
33253|NCT03925233|Drug|Anastrozole|Anastrozole tablets
33254|NCT03925233|Drug|Letrozole|Letrozole tablets
33255|NCT03925233|Drug|Exemestane|Exemestane tablets
33256|NCT03925233|Drug|Fulvestrant|Fulvestrant injection
33257|NCT03925233|Drug|Olaparib|Olapani pill
33258|NCT03925233|Drug|Bevacizumab|Bevacizumab injection
33259|NCT03925233|Drug|Apatinib mesylate|Apatinib mesylate tablets
33260|NCT03925233|Drug|Pattozumab|Pattozumab injection
33261|NCT03925233|Drug|Capecitabine|Capecitabine tablets
33262|NCT03925233|Drug|Ear particles|Ear particles
33263|NCT03925233|Drug|Aidi Injection|Aidi Injection
33264|NCT03925233|Drug|Cyclophosphamide|Cyclophosphamide injection
33265|NCT03925220|Behavioral|The SUPPER Project|Substance Use Promoted by Eating family meals Regularly
33266|NCT03925220|Behavioral|Improving nutrition and physical activity among youth|A brief intervention focused on improving nutrition and physical activity among youth
33267|NCT03925194|Drug|Anakinra|Application of Anakinra once daily for 28 days
33300|NCT03924947|Drug|Pancrelipase|Delayed release capsules
33269|NCT03925168|Behavioral|Music therapy|Music therapy will be administered according to the Eyre (2008) decision tree model. According to this model, the patient chooses his or her preferred musical intervention at the beginning of each session. Choices include: sing songs, compose a song, listen to songs, play instruments, have an imagery experience, listen to music, improvise, and use music for relaxation.
33270|NCT03925155|Drug|EZ scrub vaginal chlorhexidine 4% solution|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
33271|NCT03925155|Drug|10% provodine-iodine vaginal preparation|Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
33272|NCT03925142|Other|Controlled healthy vegetarian diet|The controlled healthy vegetarian diet will follow the Dietary Guidelines for American's recommendations. All foods and beverages will be provided during intervention to achieve the desired eating pattern.
33273|NCT03925142|Other|Controlled beef diet|The controlled beef diet will incorporate various cuts of lean unprocessed red meat into the healthy vegetarian eating pattern, as approved by the American Heart Association's Food Certification Program. The beef diet will isocalorically replace starchy vegetables and/or refined grains with 6 oz. of beef/day for five weeks.
33274|NCT03925129|Device|high frequency TENS treatment|Treatment with high frequency for minimum of 1 hour after misoprostol administration
33275|NCT03925129|Device|Sham TENS treatment|Treatment with sham TENS device for minimum of 1 hour after misoprostol administration
33276|NCT03925116|Other|COntraceptive pathway|alternative way of aiding patients in deciding contraception method
33277|NCT03925103|Procedure|3D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 3 dimensional display system
33278|NCT03925103|Procedure|2D VATS lobectomy|pulmonary lobectomy carried out by video-assisted thoracoscopic surgery with a 2 dimensional display system
33279|NCT03925090|Drug|Cisplatin+Toripalimab|chemotherapy and monoclonal antibody
33280|NCT03925090|Drug|Cisplatin+placebo|chemotherapy
33281|NCT03925077|Other|Movement-to-Music|The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.
33282|NCT03925077|Other|Standard Exercise Training|The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
33283|NCT03925064|Other|myocardial performance index|fetal right ventricular myocardial performance index measured with tissue doppler
33284|NCT03925051|Drug|Prolia®|mAb targeting RANKL. human monoclonal antibody targeting RANKL.
33285|NCT03925051|Drug|CMAB807|human monoclonal antibody targeting RANKL.
33286|NCT03925038|Behavioral|Augmented Care: Electronic media dashboard|A participant-specific dashboard that highlights patterns of patient electronic communications usage relevant to understanding participants' mental health will be developed and used to augment treatment as usual.
33287|NCT03925038|Behavioral|Treatment as Usual|Participants will receive psychotherapy as treatment as usual.
33288|NCT03925025|Drug|Magnesium Sulfate|Treatment in addition to standard therapy
33289|NCT03925025|Drug|Nimodipine|Treatment in addition to standard therapy
33290|NCT03925012|Behavioral|Intervention|
33291|NCT03924999|Combination Product|Combined decongestive treatment (CDT) & Combined exercise|Combined decongestive treatment consists of manual lymphatic drainage and compression bandaging for 30 sessions.
33292|NCT03924999|Combination Product|Intermittent pneumatic compression & Combined exercise|Intermittent pneumatic compression for 5 days a week, for 6 weeks (totally, 30 sessions).
33293|NCT03924999|Combination Product|Combined exercise|30 minutes aerobic exercise program including treadmill training consisted of a 5-minute warm-up and cool-down period and 25-minute submaximal aerobic exercise 5 days a week, for 6 weeks. Exercise intensity was calculated from the initial 6MWT. Each session was completed with 15 minutes of strengthening and stretching exercises.
33294|NCT03924986|Drug|Tislelizumab combined with Gemcitabine Plus Cisplatin|Study subjects will receive Tislelizumab, Cisplatin and Gemcitabine on day1 of every 3 weeks, and study subjects will receive Gemcitabine on day8 of every 3 weeks.
33295|NCT03924986|Drug|Placebo combined with Gemcitabine Plus Cisplatin|Study subjects will receive Placebo, Cisplatin and Gemcitabine on day1 of every 3 weeks, and study subjects will receive Gemcitabine on day8 of every 3 weeks.
33296|NCT03924973|Behavioral|ESDM followed by treatment as usual|"The intervention was ESDM, delivered by professionals, one therapist per child, 12 hours per week during 2 years.~Then, they will receive the treatment as usual during 3 years in this current follow-up study.~Precise description of the 2 years ESDM treatment can be found in the published protocol of IDEA.~What is called treatment as usual is what the community can usually offer. That is what the control group in IDEA received.~In IDEA-2, both control and interventional group of IDEA will receive treatment as usual during 3 years.~Treatment as usual comprises of different types of interventions, such as speech pathology therapy, occupational therapy and other types of therapy more or less specific to ASD in the community.~All the interventions received by the children will be monitored in IDEA-2. All different treatment approaches will be quantified (type, frequency, intensity and duration)."
33297|NCT03924960|Behavioral|High-intensity interval training|Participants in this group will perform a 20-25 minutes of aerobic exercise with a maximum capacity of 3-4 minutes (HRmax 80-95%) and active recovery for 3-4 minutes (HRmax 30-50%), five exercise sessions per week for 6 weeks.
33298|NCT03924960|Behavioral|Moderate-intensity continuous training|Participants in this group will perform a 30-45 minute ergometric cycling exercise at 65-70% of the measured maximum heart rate (HRmax), five exercise sessions per week for 6 weeks.
33302|NCT03924908|Behavioral|VRH|Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
33303|NCT03924908|Behavioral|VR|Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
33304|NCT03924895|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
33305|NCT03924895|Procedure|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
33306|NCT03924882|Drug|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
33307|NCT03924869|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT
33308|NCT03924869|Biological|Pembrolizumab|IV infusion
33309|NCT03924869|Drug|Placebo|IV infusion
33310|NCT03924856|Drug|Pembrolizumab|Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle
33311|NCT03924856|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2, IV infusion on Days 1 and 8 of each 21-day cycle
33312|NCT03924856|Drug|Cisplatin|Cisplatin 70 mg/m^2, IV infusion on Day 1 of each 21-day cycle
33313|NCT03924856|Procedure|Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])|Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.
33314|NCT03924856|Drug|Placebo|Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
33315|NCT03924830|Procedure|Bulk without surface sealant|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds.
33316|NCT03924830|Procedure|Bulk with Biscover|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, biscover surface sealant will be applied according to the manufacturer's instructions.
33317|NCT03924830|Procedure|Bulk with Permaseal|Adhese SE self-etch adhesive system will be applied according to the manufacturer's instructions in 53 teeth.Then, the Tetric N-Ceram Bulk fill composite will be used in increments of no more than 4 mm, using the bulk restoration technique, and each increment will be photoactivated for 40 seconds. After the restoration is completed, Permaseal surface sealant will be applied according to the manufacturer's instructions.
33318|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 2 ml/kg Ringer's solution acetate within 1 hour after induction.
33319|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 8ml/kg Ringer's solution acetate within 1 hour after induction.
33320|NCT03924804|Drug|Ringer's solution acetate|Intravenous infusion of 16ml/kg Ringer's solution acetate within 1 hour after induction.
33321|NCT03924791|Drug|Lidocaine|In combination with dexamethasone or methylprednisolone acetate
33322|NCT03924791|Drug|Methylprednisolone Acetate|In combination with lidocaine
33323|NCT03924791|Drug|Dexamethasone|In combination with lidocaine
33324|NCT03924778|Behavioral|DASH diet|brief description
33325|NCT03924778|Behavioral|standard American diet|describe
33326|NCT03924765|Device|Powered hip exoskeleton|The study team will be testing a powered hip exoskeleton and its capability to improve locomotion in stroke survivors.
33327|NCT03924752|Device|Powered hip exoskeleton|The study team will test a powered hip exoskeleton and its capability to improve locomotion.
33328|NCT03924739|Behavioral|Nurse-coordinated integrated care model for AF|Participants in the intervention group will participate in a 13-week, nurse-coordinated integrated care model comprising the following care components intended to comprehensively address the needs of AF patients: 1) a risk profile assessment and shared decision-making regarding OAC use; 2) an empowerment-based educational module on AF self-care; 3) nurse-initiated telephone support; and 4) patient-initiated contact for professional advice.
33329|NCT03924726|Procedure|Micro-osteoperforation (MOP)|Micro-osteoperforation technique is used to accelerate orthodontic tooth movement.
33330|NCT03924713|Behavioral|Supportive services|Assessment of behavioral, medical, and social needs, development of individual goals and action plan, follow-up to assist and work to ensure identified needs/goals are met. CHWs use their professional judgement to assess how long follow-up is required.
33331|NCT03924700|Procedure|Biportal endoscopy|Biportal endoscopic spine surgery (BESS)
33332|NCT03924700|Procedure|Microdiscectomy|Using microscope for discectomy
33333|NCT03924687|Behavioral|Acceptance and Commitment Therapy (ACT) bibliotherapy for chronic pain|"The intervention consisted of the book Libérez-vous de la douleur par la méditation et l'ACT (Dionne, 2014) and a participant workbook, along with two phone calls of approximately 15 minutes each and weekly e-mails presenting the week's content. Participants also had access to audio meditation exercises on the book's website (http://liberezvousdeladouleur.com/meditations/)."
33334|NCT03924674|Other|Education, clinical decision support tools|"Interventions will include:~Education (webinars) for physicians and nurses regarding AAP IVF guidelines, including evidence on safety of isotonic maintenance IVF~Implementation of algorithms, ordersets and checklists to guide choice of IVF and clinical indications to start/stop IVF;~Tools to promote discussion about timing and necessity of routine lab draws~Education and feedback for physicians regarding costs and harms of routine lab testing"
33335|NCT03924661|Device|Aortic Valve Replacement|SJM™ Masters Series Hemodynamic Plus (HP) 15mm aortic mechanical heart valve as a replacement device for patients with a diseased, damaged, or malfunctioning aortic valve
33336|NCT03924648|Other|Endocan levels|Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
33337|NCT03924635|Combination Product|Symbicort® and salbutamol|Salbutamol is a short-acting β-agonist and Symbicort® (fixed dose combination of inhaled corticosteroid plus long-acting β2-agonist) is an anti-inflammatory reliever for asthma. Symbicort® will be given in a Turbohaler®. Salbutamol will be given in a pressurised metered dose inhaler.
33338|NCT03924622|Device|Mepilex|Mepilex Border Sacrum dressing is a multi-layered soft silicone dressing that is a recommended strategy to augment standard nursing interventions (i.e., repositioning, offloading) to prevent pressure injuries. The dressing will be placed on the sacrum.
33339|NCT03924622|Device|LiquiCell|LiquiCell is a thin layer of low-viscosity fluid contained in a series of bursa-like pouches. Baffles within each pouch channel the liquid to disperse pressure and the volume of liquid in the pouch is so small that there is no pressure-build up. LiquiCell is available commercially as a 36 X 18-inch mattress overlay (LiquiCell Shear Reducing Mattress Overlay) with a soft pliable top and a non-slip bottom. The overlay is positioned from the shoulders to below the hips to minimize shear.
33340|NCT03924609|Diagnostic Test|Intensive screening / routine screening|Recommendation and results of bone imaging such as bone scan or PET/CT, or bone CT /MR are collected.
33341|NCT03924596|Drug|AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid)|AKBA-Incense 2 capsules daily, 30% 3-acetyl-11-keto-ß-boswellic acid, from ZeinPharma
33342|NCT03924596|Drug|Potassium Sodium Hydrogen Citrate|Uralyt-U (Potassium Sodium Hydrogen Citrate, 10g orally in 3 divided doses with pH target 6.2-6.8 for Calcium Oxalate stones and 7.0-7.2 for Uric Acid stones)
33343|NCT03924583|Diagnostic Test|Duplex ultrasonography|Ultrasound examination of whole vena cava venous system with central venous catheter inserted, using duplex US method to detect catheter related thrombosis
33344|NCT03924570|Behavioral|IPASS|IPASS is behavioral package to improve transitions of care by providing a framework to hands off.
33345|NCT03924557|Diagnostic Test|Genotype-guided Supportive Care|In this arm, supportive care will be administered based on the results of the genotype test.
33346|NCT03924544|Drug|Decorin|Antifibrotic agent
33347|NCT03924544|Drug|Mitomycin c|Antifibrotic agent
33348|NCT03924531|Behavioral|Mindful Awareness Program|2-hour mindfulness training for 6 weeks.
33349|NCT03924531|Behavioral|Health Promotion Program|Health Promotion Program
33350|NCT03924518|Drug|Granisetron Hydrochloride|Granisetron will be diluted with 0.9% saline to ensure that the therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
33351|NCT03924518|Drug|Placebo（Normal saline）|therapeutic drug and placebo are identical in appearance, and 50 ml syringes will serve as the containers for all intravenous drugs.
33352|NCT03924505|Behavioral|Implementation Manual with External Facilitation Intervention|Participating organizations will receive the implementation manual and the external facilitation (EF) intervention. The manual provides instructions for organizations wanting to implement a high quality naloxone program. The EF will assist syringe service programs to integrate naloxone delivery within their organization. As part of these efforts, we will use a measurement framework to understand naloxone delivery within SSPs along the four phases of the implementation process—exploration, preparation, implementation and sustainment (EPIS).
33353|NCT03924505|Behavioral|Implementation Manual only|Participating organizations will receive the implementation manual.The manual provides instructions for organizations wanting to implement a high quality naloxone program.
33354|NCT03924492|Drug|ZULRESSO (brexanolone) injection|ZULRESSO
33355|NCT03924479|Device|PowerBreathe (Breathing muscle training)|The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.
33356|NCT03924466|Drug|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
33357|NCT03924453|Diagnostic Test|Pearl Powered by Proov|Participants self test in their homes and report back data via uploading onto an app and taking surveys.
33358|NCT03924440|Diagnostic Test|Proov (Ovulation Double Check) Test|Rapid response urine progesterone test strips, Proov (formerly named Ovulation Double Check
33359|NCT03924427|Drug|BMS-986165|Oral tablet administration
33360|NCT03924414|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic acid 5mg/100 ml IV infusion: Zoledronic acid-5 mg (ZA) is an FDA approved therapy for men and postmenopausal women for the treatment and prevention of osteoporosis.
33361|NCT03924414|Other|Placebo|Normal Saline 100 ml (placebo) IV infusion
33362|NCT03924401|Drug|Abatacept|All patients will receive 8 doses of abatacept (10 mg/kg intravenously on days -1, +5, +14, +28, +56, +84, +112, and +150) in addition to conventional GVHD prophylaxis.
33363|NCT03924388|Device|Epidural spinal cord stimulation|The measurements will be obtained in 2 positions of supine and ~ 70° upright adjusted by the tilt-up table.
33364|NCT03924388|Device|Trnascutaneous electrical spinal cord stimulation.|The measurements will be obtained in 2 positions of supine and ~ 70° upright adjusted by the tilt-up table.
33365|NCT03924362|Procedure|PCNL|Percutaneous Nephrolithotomy is a means of treating large kidney stone burdens.
33367|NCT03924336|Procedure|Advanced- platelets rich fibrin (A-PRF) + open flap debridement|Elevation of flap.Thorough debridedment of the defects using curettes and ultrasonic scalers.clinical measurements will be then recorded , one PRF of the required size will be filled into the intraosseous defect, and the other will be used to prepare the membrane that will be used to cover the defect as abarrier. The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures
33368|NCT03924336|Procedure|Open flap debridement alone|Elevation of flap.Thorough debridedment of the defects using curettes and ultrasonic scalers.clinical measurements will be then recorded.After debridement and intraoperative recordings, interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
33369|NCT03924323|Drug|Escitalopram|8-weeks of treatment followed by 1-week taper down period
33370|NCT03924323|Other|Placebo|Matching oral administration of inactive substance once daily
33371|NCT03924310|Device|FeetBack System Active|Commercially available hand prosthesis with feedback device turned on
33372|NCT03924310|Device|FeetBack System Passive|Commercially available hand prosthesis with feedback device turned off
33373|NCT03924297|Device|chilipad|Chilipad is a commercially available pad designed to be placed between the top of a mattress and bed sheets. It allows for precise temperature regulation in one's bed.
33374|NCT03924284|Diagnostic Test|PB2 gene RT-PCR; NS gene RT-PCR|PB2 gene RT-PCR: RT-PCR targeting the PB2 gene of influenza A virus NS gene RT-PCR: RT-PCR targeting NS gene of influenza A virus
33375|NCT03924271|Diagnostic Test|Iron deficiency testing|Blood sample for complete iron status
33376|NCT03924258|Diagnostic Test|Iron status testing|Blood sample for iron status testing
33377|NCT03924245|Drug|Entinostat|Given by mouth
33378|NCT03924245|Drug|Olaparib|Given by mouth
33379|NCT03924219|Other|CMV T cell Immunity Assay|Flow cytometry based assay quantifying IFN-gamma expression in T cells following CMV peptide stimulation (Viracor)
33380|NCT03924206|Device|Smoke evacuation system|The smoke evacuation system removes the surgical smoke directly near the electrocautery tip, where it is generated
33381|NCT03924193|Drug|Lisdexamfetamine Dimesylate|Participants randomly assigned to this arm will receive 12 weeks of LDX medication.
33382|NCT03924193|Behavioral|Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of Cognitive-Behavioral Therapy
33383|NCT03924193|Other|Combination LDX and Cognitive-Behavioral Therapy|Participants randomly assigned to this arm will receive 12 weeks of LDX and Cognitive-Behavioral Therapy
33384|NCT03924180|Dietary Supplement|Dietary Supplement for PKU patients|For both treatment groups, the objective in total protein will be 1g / kg / day of ideal weight, in 3-6 doses / day, including natural proteins and supplemented by the products under study.
33385|NCT03924167|Behavioral|Weaving Healthy Families Program|The Weaving Healthy Families program is created from integrating the widely disseminated, ecological, innovative, and culturally grounded Framework of Historical Oppression, Resilience, and Transcendence (FHORT) with the the Celebrating Families! evidenced-based program (EBP). The goal of this program is to reduce and postpone Alcohol and other Drug (AOD) use, decrease and prevent violence in families, and promote resilience and wellness (including mental health) among NA adults and youth. This intervention seeks to promote wellness by targeting key behavioral (AOD), mental/emotional (emotional regulation/anger management, cognitions, resilience), social and familial (healthy and safe relationships, the family environment, and parenting), cultural (values, traditions), and physical (nutrition) factors.
33386|NCT03924154|Drug|RVT-1201|RVT-1201 600 mg immediate-release tablet
33387|NCT03924154|Drug|Placebo|Inactive pill manufactured to mimic RVT-1201 600 mg immediate-release tablet
33388|NCT03924141|Behavioral|Training in de-escalation|Will receive one hour of de-escalation training
33389|NCT03924128|Device|Photobiomodulation|The Photobiomodulation device should cover the entire knee junction, with time of application from 6 to 8 minutes and device turned on.
33390|NCT03924115|Device|Transmedial Psychoeducational Program to improve adherence full or partial (PS)|Intervention consists of a transmedial Psychoeducational Program, which includes cognitive, behavioral and affective aspects to generate knowledge and skills that improve self-efficacy in the elderly, it is a program based on communication in health. The proposed transmedial narrative will allow older adults to assemble information from messages arranged through various media, including audiovisual capsules that will be transmitted on screens located in the Health Center and the development of a mobile application incorporated in the cellular that will be delivered with a data plan for one year. This intervention is designed to strengthen the personal resources of the elderly (such as self-efficacy, empowerment, knowledge) that promote self-care in health.
33391|NCT03924102|Diagnostic Test|Cardiac Perfusion and Metabolism with [11C] Acetate PET/CT|A rest and stress imaging study will be conducted on the PET/CT scanner with [11C] Acetate.
33392|NCT03924089|Dietary Supplement|Oral nutritional supplement with probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), with probiotics.
33393|NCT03924089|Dietary Supplement|Oral nutritional supplement without probiotics|Oral nutritional supplement specifically developed for undernourished hemodialysis patients enriched with functional nutrients (extra virgin olive oil, omega 3 fatty acids, whey protein, antioxidants and carnitine), without probiotics.
33394|NCT03924089|Other|Dietary recommendations|Dietary recommendations
33395|NCT03924076|Dietary Supplement|UHT Milk + Lactobacillus plantarum IS-10506|125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
33396|NCT03924076|Dietary Supplement|UHT Milk|125 ml UHT milk given to placebo group
33397|NCT03924063|Device|Hemiverse|Implantation of the hemiverse shoulderprothesis
33398|NCT03924050|Drug|TORIPALIMAB INJECTION(JS001 )|TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
33399|NCT03924037|Behavioral|Intergenerational Knowledge Sharing group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the Intergenerational Knowledge Sharing group will attend 12 weekly groups taught by tribal elders that focuses on sharing knowledge about the tribe.
33400|NCT03924037|Behavioral|Support group|Participants will attend a CBPR developed 12-session individual treatment for suicidal behavior. In addition to receiving the 12-session individual treatment, participants that are assigned to the support group will attend 12 weekly support groups led by a behavioral health specialist that focuses on social support of the youth.
33401|NCT03924024|Device|Accelerated intermittent theta burst treatment|"All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator."
33402|NCT03924011|Device|Photobiomodulation therapy (PBMT)|PBMT sessions will be planned 2x/week after RT.
33403|NCT03924011|Device|Sham laser|Sham laser sessions will be applied 2x/week after RT.
33404|NCT03923998|Drug|Neoadjuvant chemotherapy|Three weekly concurrent chemotherapy with cisplatin 100 mg /m2
33405|NCT03923998|Radiation|Neoadjuvant radiotherapy|Preoperative radiotherapy over 5 weeks- Dose 180-200cgys per day/ total 4500 cgys
33406|NCT03923998|Procedure|Resection and reconstruction|Resection and reconstruction of mandibular/maxillary segment with prefabricated fibular graft
33407|NCT03923985|Dietary Supplement|Probiotic containing Lactobacillus Crispatus|1 tablet / day of probiotic (275 mg of live probiotic lactic ferments: 10 Mld L. fermentum (SGL 10), 10 Mld L. gasseri, 10 Mld L. casei, 10 Mld L. acidophilus, 10 Mld L. crispatus) during 2 months.
33408|NCT03923959|Drug|Tranexamic Acid Injectable Solution|100 cc normal saline mixed with 1g of tranexamic acid in solution
33409|NCT03923959|Other|Placebo|100 cc normal saline
33410|NCT03923946|Behavioral|Compassion focused therapy|Compassionate Imagery intervention based on compassionate imagery exercises in The Compassionate Mind Workbook by Irons and Beaumont, 2017
33411|NCT03923946|Behavioral|Befriending|An active control arm of active listening akin to befriending
33412|NCT03923933|Drug|Chlorthalidone|Chlorthalidone
33413|NCT03923933|Drug|Bumetanide|Bumetanide
33414|NCT03923920|Procedure|Biopsy|During clinically-scheduled spinal stenosis surgery, ligamentum flavum tissue (which may contain surrounding tissue and subcutaneous fat) that is removed during the procedure will be sent to pathology to be analyzed with amyloid-specific staining.
33415|NCT03923907|Behavioral|EIM intervention group|As in arm description
33416|NCT03923894|Dietary Supplement|Blueberry Yeast Fermentation Freeze Dying Powder Extract|Blueberry Yeast Fermentation Freeze Dying Powder Extract 2.07 g/day for 8 weeks.
33417|NCT03923894|Dietary Supplement|Placebo|Placebo 2.07 g/day for 8 weeks.
33418|NCT03923881|Device|MSOT Acuity Echo|Optoacoustic imaging with the MSOT Acuity Echo
33419|NCT03923868|Drug|D-0120|D-0120 monotherapy dose escalation, oral, multiple dose for up to 28 days
33420|NCT03923855|Device|BTL-899|BTL-899 therapy
33421|NCT03923842|Drug|Denosumab Inj 120 MG/1.7ML|Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.
33422|NCT03923842|Drug|Chemotherapy as clinical standard of care|platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
33423|NCT03923829|Drug|Zinc Sulfate|systemic administration of Zinc sulfate with scaling and root planing
33424|NCT03923829|Procedure|scaling and root planing|scaling and root planing
33425|NCT03923816|Drug|Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).|comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
33426|NCT03923803|Diagnostic Test|C- reactive protein|the measurement will be done by chemileumeniscence
33427|NCT03923803|Diagnostic Test|Pro calcitonin|the measurement will be done by chemileumeniscence
33428|NCT03923790|Behavioral|Educational Packet|The patient will receive an educational packet.
33429|NCT03923790|Behavioral|Phone call at 72 hours by discharge nurse navigator|Patients will receive a phone call at 72 hours by the discharge nurse navigator (standard of care) to assure that they have received their medications and follow-up appointments
33430|NCT03923790|Behavioral|Telehealth visit at 7 days, 1 month, 3 months, and 5 months after discharge|A stroke prevention trained nurse practitioner or MD or social worker will review the participant's hospital records and depression, dietary, and sleep apnea screens,will reinforce the care plan based on patient-specific needs.They will counsel patients on salt reduction, the Mediterranean diet, and the importance of diet and exercise for stroke prevention.Along with the pharmacist they will also review the BP data to determine the need for medication adjustment and will discuss the side effects and interactions.The social worker will assess the need for medication assistance and other resources. The care plan will be shared with primary care providers (PCP)and patients will be referred to a PCP if they do not have one. The social worker will also will assist uninsured patients in applying for Texas County Indigent Care programs.
33431|NCT03923790|Behavioral|Educational messages every other week|The messages will be sent to the participants cellular phones and will contain one of the following: a reminder to monitor BP, information from about lifestyle and diet for BP reduction, or a message from the pharmacist about medication adherence
33432|NCT03923790|Diagnostic Test|BP monitoring by QardioARM with periodic transmission of BP data|Participants will be prompted to transmit BP logs through the telemonitoring device every 2 weeks until average BP is < 130/80, then monthly thereafter. Uncontrolled BP will prompt a call from the pharmacist to discuss medication adherence and the need for further titration.
33433|NCT03923777|Other|Active Surveillance|Agreeing to postpone treatment while continuing with a CT scan surveillance regimen to follow tumor growth. SABR should be offered if either the tumor is >3 cm in size or the VDT decreases to <400 days.
33434|NCT03923764|Dietary Supplement|High protein and energy diet|Intervention group receives nutritional counseling to increase protein and energy in their diet to reach their estimated protein need (1.3 g/kg). Kontrol group continues their usual diet.
33435|NCT03923764|Other|Habitual Diet|Patients continue their usual diet
33436|NCT03923751|Other|Invitation to regional anesthesia survey|An invitation letter sent to Head of Anesthesiology and Intensive Care Department of Polish Hospital
33437|NCT03923738|Drug|Tocilizumab|TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
33438|NCT03923725|Drug|Artemether-lumefantrine+ Amodiaquine (AL+AQ)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days."
33467|NCT03923517|Device|RHAPSODY online program and MEET online sessions|"internet-based information and skill-building program (RHAPSODY) specifically developed for family carers of care recipients with young onset dementia (Kurz, et al., 2016).~MEET is a software for online meetings."
33569|NCT03922659|Combination Product|Transcranial magnetic stimulation and Cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
60403|NCT03712202|Drug|Dacarbazine|Given IV
33439|NCT03923725|Drug|Artemether-lumefantrine + placebo (AL+PBO)|"AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are currently under development. They will be identical in size, shape and color. We aim for a similar taste of amodiaquine and the placebo."
33440|NCT03923725|Drug|Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)|"AS-MQ: Artesunate-mefloquine will be administered according to an optimised dosing schedule using tablets of 25 or 100 mg artesunate and 50 or 200 mg mefloquine with a dosing target of 4 mg/kg/day and 8.3 mg/kg/day, respectively.~PPQ: One tablet contains 250 mg of piperaquine. The weight-based treatment schedule in appendix 2 aims for a dosage of approximately.~24 mg/kg/day in patients <25 kg (range 16.7 - 31.3 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~18 mg/kg/day in patients ≥25 kg (range 15.2 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day."
33441|NCT03923725|Drug|Artesunate-mefloquine+placebo (AS-MQ+PBO)|"AS-MQ: Artesunate-mefloquine will be administered according to an optimised dosing schedule using tablets of 25 or 100 mg artesunate and 50 or 200 mg mefloquine with a dosing target of 4 mg/kg/day and 8.3 mg/kg/day, respectively.~PBO: Placebo tablets for mefloquine are currently under development. They will be identical in size, shape and colour. We aim for a similar taste of mefloquine and the placebo."
33442|NCT03923712|Behavioral|Supervised Exercise Programme|The methodology will be multicomponent, including aerobic, strength, coordination-cognitive and balance-agility. The physical exercise sessions will be designed in such a way that they work the dimensions but being attractive and motivating for the participants. Each session will include 10 minutes of warm-up with smooth running and mobility exercises; 35-40 minutes of aerobic, strength, coordination-cognitive and balance-agility progressively developed; and 10 minutes back to calm at low intensity with stretching exercises. Nutritional intervention will not be included. For quality purposes, we will use small groups (10-15 pers). After each session participants will be asked about their subjective perception of the effort and the intensity will be controlled by heart rate monitors.
33443|NCT03923699|Device|Anesthesia Control Tower monitoring|Real time data will be monitored through the AlertWatch® system as well as the patient's EHR.
33444|NCT03923686|Procedure|EUS-guided drainage using LAMS with DPS|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
33445|NCT03923686|Procedure|EUS-guided drainage using LAMS alone|Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
33446|NCT03923673|Procedure|Pericardiotomy|The minimally invasive procedure that creates a small opening in the sac that surrounds the heart.
33447|NCT03923660|Other|Incremental Concentric-eccentric exercise test|Patients will perform incremental exercise test on semi recumbent eccentric ergometer
33448|NCT03923660|Other|Incremental Eccentric-concentric exercise test|Patients will perform incremental exercise test on semi recumbent concentric ergometer
33449|NCT03923647|Device|Laparoscopy|Laparoscopic insertion with carbon dioxide via open technique at the umbilicus
33450|NCT03923634|Device|Princess® RICH|Princess® RICH is injected into lateral canthal lines and/or perioral rhytids
33451|NCT03923621|Procedure|EPSiT|Specialised fistuloscope to indentify sinus tracts, cautery tracts, remove causative hair, irrigation.
33452|NCT03923621|Procedure|Excision|Surgery to remove all affected tissue, followed by wound closure.
33453|NCT03923608|Diagnostic Test|Maximal muscle strength Test|1RM test performed in 5 different tools (Elastic Band, Pulley, halter, digital dynamometer and isokinetic dynamometer)
33454|NCT03923608|Diagnostic Test|Exhaustion test|Test performed until individual exhaustion in 5 different tools (Elastic Band, Pulley, halter and isokinetic dynamometer)
33455|NCT03923595|Other|Adherence intervention research|dedicated management
33456|NCT03923582|Behavioral|Health Curriculum Training|"This is a randomized, controlled, single blinded, trial, stratified by health profession, of the intervention versus waitlist control assessing knowledge, attitude change and skill development. At the end of the intervention as compared with waitlist controls…~Participants will significantly increase knowledge about sexual health and sexual health care.~Participants will significantly improve attitudes about provision of sexual health services, sexual health communication skills, and comfort in addressing sexual health care in routine care.~Participants' sexual health communication, history taking, and counseling skills will be significantly improved as assessed by independent evaluators blinded to trial assignment.~Secondary analyses will assess whether at post-test, sexual health knowledge, attitudes and skills will vary by health discipline, and test for differential intervention effects by discipline."
33457|NCT03923569|Diagnostic Test|Overnight polysomnography|Overnight polysomnography with evaluation of each form of epileptiform activity during each vigilance state and memory scores at the overnight retention test
33458|NCT03923569|Diagnostic Test|blood sample|blood sample for genetic testing of the Apolipoprotein E
33459|NCT03923569|Diagnostic Test|high-resolution MRI scan|Evaluation of anomalies in brain structure and functional resting state connectivity
33460|NCT03923569|Behavioral|neuropsychological evaluation|neuropsychological evaluation including episodic memory tests before an overnight polysomnography
33461|NCT03923556|Drug|Sugammadex|Administration of Sugammadex intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 0.03-0.07 mg/kg) at the end of the surgery before tracheal extubation
33462|NCT03923556|Drug|Neostigmine|Administration of Neostigmine intravenously at a dose appropriate for the reversal of neuromuscular blockade (usually 2-4 mg/kg) at the end of the surgery before tracheal extubation
33463|NCT03923543|Diagnostic Test|Neutrophil to lymphosit ratio|
33464|NCT03923530|Drug|Eplerenone|50mg daily
33465|NCT03923530|Behavioral|Kansas City Cardiomyopathy Questionnaire|administered at baseline and 8 weeks
33466|NCT03923530|Diagnostic Test|Serum potasium|within the last 30 days is required before initiating eplerenone, repeat blood draw within the first week and starting eplerenone and 4 weeks after starting eplerenone
60404|NCT03712202|Drug|Doxorubicin|Given IV
33468|NCT03923504|Other|Physical Activity Intervention (PAI)|Patients have the ability to participate in 1-2 training sessions per week offered under the direct supervision of a master's level clinical exercise physiologist, as well as 1-2 sessions at home. PAI sessions consist of slow aerobic warm-up, followed by 20 minutes of strength training, 15 minutes of progressive intensity aerobic exercise (AE), and then 10 minutes of stretching for cool-down.
33469|NCT03923504|Other|Healthy Living Control|Patients randomized to the control arm will attend a centralized meeting to participate in organized health workshops. Each session lasts 60 minutes and matches the number of visits made by the PAI group.
33470|NCT03923491|Behavioral|Healthy Feeding, Healthy Eating|Home Based Motivational Interviewing to Improve Diet Quality of Preschoolers
33471|NCT03923491|Behavioral|Reading Readiness|Active Control that uses Motivational Interviewing to improve Reading Readiness of Preschool Children
33474|NCT03923465|Procedure|Procedure: Periodontal surgery with entire papilla preservation (EPP) technique|After local anesthesia injection an modified flap is designed according to minimally invasive microsurgical techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
33475|NCT03923465|Device|EMD application|Application of Pref-Gel for 2 minutes and then the application of Enamel Matrix Derivatives (EMD) on the surgically exposed root surface.
33476|NCT03923465|Device|Bone substitutes application|Following the application of EMD, filling the bone defect with bone substitutes.
33477|NCT03923452|Behavioral|Mindfulness-based Stress Reduction|"Mindfulness-based stress reduction is a manualized mindfulness training protocol that has been researched for over 20 years. The original protocol will be used, with the exception of the prescribed home practice duration (i.e. 30 mins of practice). Rather, the program will be modified to set up participants for success by providing them with instruction to build on their meditation practice, beginning with 8 minutes a day."
33478|NCT03923439|Device|Multi-b diffusion sequence MRI|Patients will be explored with the multi-b diffusion sequence on a new 3T research magnet equipped with high gradient system.
33479|NCT03923426|Other|Zavicefta Treatment|Non-interventional - Retrospective Chart Review
33480|NCT03923413|Other|Blood samples|Blood samples for MP evaluation
33481|NCT03923387|Device|MynxGrip|Vascular Closure
33482|NCT03923387|Other|Manual compression|Manual compression is a commonly used method to achieve hemostasis of femoral artery
33483|NCT03923374|Drug|Subutex / Buprenorphine|Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.
33484|NCT03923374|Diagnostic Test|Fetal & Neonatal MRI|Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.
33485|NCT03923374|Diagnostic Test|DNA/Genetic/Pharmacokenetic Blood Draws|Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.
33486|NCT03923361|Drug|Diprivan|Similar to the high-intensity propofol treatments in Phase 1, the anesthesiologist will administer an induction dose of propofol followed by a continuous infusion, insert an airway, and begin mechanical ventilation. Propofol dosing will be adjusted with the goal of achieving a burst-suppression state with a SR of 40-60 for 12-15 minutes.
33487|NCT03923348|Device|Leva device|The leva® Pelvic Digital Health System by Renovia Inc is a novel tool for subjects with urinary incontinence to train and strengthen pelvic floor muscles via directional mechano-transductive feedback on performance in the privacy of their own homes.
33488|NCT03923335|Other|DNA methylation detection|detecting the methylation status of colorectal cancer specimen
33489|NCT03923322|Drug|Botanical Tincture|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
33490|NCT03923322|Other|Placebo|Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
33491|NCT03923296|Device|Blood measurement and monitoring|Blood from a single fingerprick will be used to used to measure and monitor patients blood parameters
33492|NCT03923270|Drug|Durvalumab|Participants in all arms will be administered 1500 mg of Durvalumab intravenously every 4 weeks.
33493|NCT03923270|Drug|Tremelimumab|Participants in arm B will be administered 75 mg of Tremelimumab intravenously every 4 weeks for up to 4 doses.
33494|NCT03923270|Drug|Olaparib Pill|Participants in arm C will be self-administer 300 mg of Olaparib orally.
33495|NCT03923270|Radiation|Thoracic Radiotherapy|Thoracic Radiotherapy will be administered at 3 Gray units X 10 fractions
33496|NCT03923257|Drug|177Lu-DOTA-tyr3-OCTREOTATE|This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.
33497|NCT03923257|Procedure|Peptide Receptor Radiotherapy (PRRT)|PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
33525|NCT03923010|Drug|Itraconazole|Participants will receive itraconazole 200 mg orally once daily for 7 days and at the discretion of the treating physician on Day 14. Participants will also get their regular clinical care at the discretion of their treating physician.
33526|NCT03922997|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 mg intravenously on the first day of each 21-day cycle.
33567|NCT03922685|Combination Product|Dietary manipulation (25% carbohydrate diet) and behavioral (sedentary)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. There was no exercise during this trial.
33498|NCT03923244|Diagnostic Test|OSDI survey|"Normal patient consultation schedule for cataract surgery with:~Preoperative appointment scheduled for the patient~Post-operative appointment 1 month before surgery No additional appointments.~After geting consent and during the two consultations:~Completion of a quality of life survey by the patient. Collection of the patient's history and general and ophthalmological treatments. Questionnaire of 12 items on quality of life to be completed. For each question, the patient must answer on the frequency of the discomfort felt, from never to all the time.~An analysis of the ocular surface is performed by a non-invasive and non-contact device for 4 minutes. This consists of taking different photographs of the eye and eyelids, allowing each to study a part of the tears.~Schirmer test is performed, consisting of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes."
33499|NCT03923231|Drug|Atazanavir 300mg/ Ritonavir 100 mg once daily|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care
33500|NCT03923231|Drug|Atazanavir 250 mg / ritonavir 80 mg|There is no intervention in this study - participants will all be receiving atazanavir (usually boosted with ritonavir) as part of their routine clinical care. This dose of 250/ 80 is for participants weighing between 15 and 25 Kg
33501|NCT03923218|Other|LL-37 levels in Gingival crevicular fluid|Collected gingival crevicular fluid
33502|NCT03923218|Other|Serum Vitamin D3 levels|Collected serum
33503|NCT03923218|Other|Clinical parameters|Recorded plague index, gingival index, probing depth, clinical attachment level
33504|NCT03923205|Other|Dietary Intervention|The effect of a buckwheat beverage on postprandial glucose metabolism in healthy individuals and those with T2D controlled by medication and diet will be studied.
33505|NCT03923192|Device|Vistacam|device for early proximal caries detection
33506|NCT03923179|Drug|Pyrotinib|Pyrotinib, 400mg qd
33507|NCT03923179|Drug|Etoposide|Etoposide, 50mg，qd,d1-21,Q4W
33508|NCT03923166|Drug|Pyrotinib|400mg qd
33509|NCT03923166|Drug|capecitabine|capecitabine 500mg tid
33510|NCT03923153|Device|Inspiratory muscle training with PowerBreathe (IMT Technologies Ltd., Birmingham,England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
33511|NCT03923153|Device|Sham group with PowerBreathe (IMT Technologies Ltd., Birmingham, England)|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 10% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
33512|NCT03923140|Drug|Tranilast|5mg/kg.d for juvenile patients with a maximum dose of 0.3g per day; 0.1g each time, three times a day for adults patients
33513|NCT03923127|Other|Elan and HealthDot|Patients with elective surgery will wear two devices (HealthDot and Elan) after surgery in hospital and after discharge at home for up to 2 weeks (HealthDot) or 3 weeks (Elan).
33514|NCT03923114|Radiation|Ga-68-NODAGA-exendin-4 PET/CT|PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
33515|NCT03923101|Diagnostic Test|Topographic, tomographic and biomechanical analysis.|"The study is based upon data obtained during routine medical follow-ups using~the Pentacam high resolution (Oculus, Wetzlar, Germany)~the Corvis ST (Oculus, Wetzlar, Germany)~the Anterior-Segment Optical Coherence Tomograph (AS-OCT) Casia 2 (Tomey, Nagoya, Japan)~the Ocular Response Analyzer (Reichert Technologies, New York, USA)."
33516|NCT03923088|Behavioral|jacobson's progressive muscle relaxation technique|This involves tensing specific muscle groups for 5-7 seconds, followed by 20 seconds of relaxation. The method can be demonstrated chairside, and should be practiced and rehearsed by the patient at home. Four major muscle groups are commonly tensed and relaxed. These are: 1) feet, calves, thighs, and buttocks; 2) hands, forearms, and biceps; 3) chest, stomach, and lower back; and 4) head, face, throat, and shoulders
33517|NCT03923088|Behavioral|audio-visual distraction technique|audiovisual distraction not only leads to full involvement of scenes (visual and auditory), but it also induces a positive emotional reaction resulting in a relaxed experience.
33518|NCT03923075|Drug|Dexmedetomidine|INFUSION BEFORE INDUCTION OF ANAESTHESIA
33519|NCT03923075|Other|0.9% saline|INFUSION BEFORE INDUCTION OF ANAESTHESIA
33520|NCT03923062|Device|chemicalpeeling|"Cleansing and degreasing the face with alcohol .~The patients must be sitting at an angle of 45.~A 2 × 2 cm cotton gauze will be used to apply TCA 20%.~We will apply the acid from the midline to the right side of the forehead and under the right eye, covering the right cheek and perioral area.~We then will wait for a few minutes and will observe the frost developing.~The patient will be then allowed to wash her face."
33521|NCT03923062|Device|cryopeeling|Cryopeeling will be performed by spraying the freezing substance(Liquid Nitrogen) on the face at 1-2cm distance and moving along the affected area until freezing appear.
33522|NCT03923062|Combination Product|microneedling|"Tranexamic acid will be used in aconcentration of 4mg/ml ,1ml will be used fo half of the face.~After gentle cleansing, topical analgesic cream will be applied over the area to be treated.~The microneedles will be used, the skin will be stretched and microneedling will be carried out in vertical, horizontal, and both diagonal directions for about four to five times. Tranexamic acid, 0.5 to 1 ml (4 mg/mL), will be applied over this area, and the procedure will be repeated four to five times in the above-said directions"
33523|NCT03923049|Diagnostic Test|hybrid PET/MRI|On the day of the procedure, subjects will undergo a PET scan followed by MRI scan.
33524|NCT03923036|Drug|Antineoplastic Agents|Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
33568|NCT03922672|Behavioral|Group piano training|The group piano training is scheduled over 4 months of a two-hour weekly group piano lesson. There is also a 3-hour weekly practice at home.
33527|NCT03922984|Procedure|MRI with Arterial Spin Labeling (ASL)|Week 0 (Before initiation of chemoradiation): MRI with ASL will be performed along with patient's standard of care imaging session Week 3: contrast-enhanced research MRI with ASL Week 6: contrast-enhanced research MRI with ASL Week 10: MRI with ASL will be performed along with patient's standard of care imaging session Week 18: MRI with ASL will be performed along with patient's standard of care imaging session Week 26: MRI with ASL will be performed along with patient's standard of care imaging session Week 34: MRI with ASL will be performed along with patient's standard of care imaging session
33528|NCT03922971|Other|Option 1: National comparison|Ability to view center's rate compared with all others.
33529|NCT03922971|Other|Option 2: National comparison with benchmarking|Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
33530|NCT03922945|Drug|VI-0521 oral capsule|Phentermine/Topiramate
33531|NCT03922945|Drug|Placebo oral capsule|Inactive drug
33532|NCT03922919|Drug|Cefotaxime Injection|Systematic use of cefotaxime.
33533|NCT03922919|Procedure|Rectal swab|Rectal swab every 3 days during hospitalization and then 30 days after the first antibiotic infusion
33534|NCT03922919|Drug|Cefotaxime/ceftriaxone|ceftriaxone or cefotaxime infusion at the discretion of the prescribing physician
33535|NCT03922906|Device|Pure-Vu System|Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g. blood.
33536|NCT03922893|Other|Family History Information|The family history ascertainment focuses on self-reported family history of first-, second-, and third-degree family members, including types of malignancies/ pre-malignant lesions and age at diagnosis.
33537|NCT03922893|Genetic|ORAGENE|Approximately 2-4mL of saliva may be collected in specialized Oragene DNA Self-Collection Kit tubes or buccal swab-based collection devices.
33538|NCT03922893|Genetic|Blood|For select participants, 1-2 tubes of blood will be drawn for DNA and RNA analysis
33539|NCT03922893|Other|Skin Biopsy|In certain circumstances, for Memorial Sloan Kettering participants and their family members, it may be necessary to obtain a skin biopsy.
33540|NCT03922880|Drug|ADI PEG20|ADI-PEG 20 will be administered at a dose of 36mg/m2 intramuscularly once a week.
33541|NCT03922880|Drug|Nivolumab|Nivolumab 240mg + Ipilimumab 1mg/kg for up to 8 total doses of ipilimumab. One ipilimumab has completed, nivolumab 480mg will be given every 4 weeks.
33542|NCT03922880|Drug|Ipilimumab|Ipilimumab 1mg/kg with Nivolumab 240mg for up to 8 total doses of ipilimumab. The first four doses of ipilimumab will be scheduled once every 3 weeks. The 5th-8th doses of ipilimumab will be scheduled once every 6 weeks with nivoumab 240mg every 3 weeks.
33543|NCT03922867|Behavioral|CBT|A web-based educational platform to deliver cognitive behavioral therapy (CBT) for insomnia
33544|NCT03922854|Other|Non-interventional data collection only|There is no clinical intervention. This study is just capturing data from devices used part of routine clinical care. The results of this data collection will be analysed to inform study results.
33545|NCT03922841|Other|Pleural disease management|History, physical examination, pleural drainage, lab/radiographic investigations
33546|NCT03922828|Diagnostic Test|CT scans|CT surveillance, Lung biopsy, Lung resection
33547|NCT03922815|Drug|rescue fentanyl|a rescue dose of fentanyl 0,5 mcg per kilogram of body
33548|NCT03922815|Drug|rescue propofol|propofol in a single dose of 0,5 mg/kg of body weight
33549|NCT03922802|Device|Noninvasive Spinal Stimulation with Gait Training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
33550|NCT03922802|Other|Conventional Gait Training|Subjects will perform locomotor activities without transcutaneous electrical spinal cord stimulation
33551|NCT03922789|Diagnostic Test|6 minute walking test|change of 6MWT pre to post pulmonary rehabilitation
33552|NCT03922776|Procedure|Blood sample collection|"Participants will receive the following interventions because they are enrolled in the study: blood sample collection~at diagnosis, before chemotherapy (pre-CT)~after chemotherapy (post-ct) Collection of two blood samples (5mL),~before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment~and then, after chemotherapy (post-CT), up to 3 months after enrollment"
33553|NCT03922763|Procedure|Anatomical cut|Surgeon-derived cut based on patient's anatomy
33554|NCT03922763|Procedure|Cutting guide|Angle cut at 132.5 degrees based on cutting guide
33555|NCT03922750|Drug|Insulin 287|Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
33556|NCT03922750|Drug|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine OD for 16 weeks
33557|NCT03922737|Procedure|In-person office visit|Post-operative visit to occur in-person with provider
33558|NCT03922737|Procedure|Teleheath visit|Post-operative visit to occur via telehealth software platform with provider
33559|NCT03922724|Drug|IOC|"e-ATG40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg/m2~/day IV on days -9 and -5. Cyclophosphamide 5 mg/kg orally daily on days -9 through -2"
33560|NCT03922724|Drug|GVHD prophylaxis|High-dose, posttransplantation cyclophosphamide (PTCy) on days +3 and +4 (50 mg/kg /day on RIC arm and 25 mg/kg/day on IOC arm), sirolimus on days +5 through +60, and mycophenolate mofetil (MMF) on days +5 through +25.
33561|NCT03922724|Drug|RIC|e-ATG 40 mg/kg/day IV on days -14 and -13. Pentostatin 4 mg /m2/day IV on days -11 and -7. Cyclophosphamide 5 mg/kg orally daily on days -11 through -4. Busulfan IV, pharmacokinetically dosed, on days -3 and -2.
33562|NCT03922724|Procedure|allo HCT|Stem cell transplant
33563|NCT03922711|Drug|Pridopidine|Oral capsule
33564|NCT03922711|Drug|Placebo|Oral capsule
33565|NCT03922698|Other|No interventions|No interventions - observational study
33566|NCT03922685|Combination Product|Dietary manipulation (25% carbohydrate diet) and behavioral (exercise)|The 25% carbohydrate diet consisted of Pulmocare-vanilla liquid, white roll, butter, and string cheese in proportions to achieve 33% of weigh-maintenance diet containing 25% carbohydrate, 20% protein, and 55% fat. Exercise was walking 1 hour on level treadmill at 50% of maximal effort starting 40 minutes after the beginning of the meal
60405|NCT03712202|Biological|Nivolumab|Given IV
33570|NCT03922646|Behavioral|Neurocognitive Empowerment for Addiction Treatment (NEAT)|NEAT will be conducted in person, in groups of 6-14, and consist of 14, 1.5-hour sessions. Each NEAT session will consist of (1) a didactic, psychoeducation portion describing the concepts and skills of focus, (2) written material with descriptions of the concepts/skills in verbal and pictorial (cartoon) formats, (3) practicing with cognitive tasks relevant for each skill, (4) discussion of how they can monitor and practice each skill in their daily life. Specifically, we will provide psychoeducation, cognitive exercises, time-management and daily practice focused on domains of attention (focused and divided attention; attentional biases), memory (declarative, prospective, emotional memory), flexibility and inhibition, and problem-solving. Each session will discuss the relevance of these functions for the recovery from drug addiction and for managing affective/motivational symptoms commonly related to substance use (i.e., craving, anxiety, depression, trauma).
33571|NCT03922646|Behavioral|Active Control|The active control intervention will be composed of active, but non-essential aspects of the larger treatment program (i.e., those that treatment programs do not believe are necessary or central to their program, for example, art classes, exercise classes, chore time, or extra 12 steps meetings). This will ensure that subjects are not being prevented from accessing treatment that is already known to be helpful in substance use recovery, that the active control condition and NEAT intervention have equivalent credibility and expectancies, and optimizing the generalizability of findings.
33572|NCT03922633|Drug|E3112|Intravenous infusion.
33573|NCT03922633|Other|Placebo|Intravenous infusion.
33574|NCT03922620|Drug|Liposomal bupivacaine|Local infiltration of 20cc of Liposomal Bupivacaine infiltrated to the surgical area
33575|NCT03922620|Drug|Peripheral Nerve Block|Peripheral Nerve Block performed by anesthesia team (blocks will be given by same anesthesia provider utilizing same technique every time in order to reduce variations in delivery of peripheral nerve block).
33576|NCT03922607|Drug|ABBV-157|ABBV-157 will be administered orally as capsule
33577|NCT03922607|Drug|Placebo for ABBV-157|Placebo for ABBV-157 will be administered orally as capsule
33578|NCT03922594|Diagnostic Test|Differential diagnosis for infectious causes of microcephaly|Zika virus, cytomegalovirus, rubella, toxoplasmosis
33579|NCT03922581|Behavioral|Mindfulness-Based Cognitive Therapy|The intervention consists of MBCT for the prevention of depression relapse with adaptations for discussing trauma and PTSD. Participants attend eight, weekly 90-minute group sessions involving skills training and in-class practice. Participants will return one month after the intervention has ended for a follow-up assessment.
33580|NCT03922568|Other|Density Gradient Centrifugation|semen was layered over 50 % and 90% discontinuous Density Gradient layers in a 15ml conical tube, then centrifuged at 250 g for 8 min at room temperature. supernatant was aspirated and the resulted pellet was washed using Sperm wash media and centrifuged at 250 g for 8 min at room temperature. The final pellet was re suspended in residual volume
33581|NCT03922568|Device|Physiological ICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. Hyaluronan bound sperms are selected for oocyte injection
33582|NCT03922568|Device|Magnetic Activated Cell Sorting|Semen processing is done by double layer density gradient method. The resulted pellet is labeled with Annexin V microbeads followed by separation on MACS column, the eluted fraction contains non apoptotic sperms suitable for oocyte injection.
33583|NCT03922555|Drug|ASTX727|ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
33584|NCT03922542|Combination Product|riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
33585|NCT03922542|Combination Product|Riboflavin 0.1%|Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
33586|NCT03922529|Behavioral|MACRO|Modified application of cardiac rehabilitation for older adults (MACRO) intervention transforms Cardiac Rehabilitation by organizing relative to participants' goals of care and composite risks rather than central emphasis on cardiovascular disease (CVD). Participants are engaged, assessed for their goals of care as well as their risks, and education is initiated to best facilitate informed choices regarding realistic and practical strategies. Selection of site-, home-, or hybrid-based care is based on which option will best meet that individual participant's preferences and comprehensive needs. preferences and needs, and utilizing a flexible range of options (site-, home, or hybrid).
33587|NCT03922529|Other|Standard of Care|Participants will follow the standard of care hospital practice that is recommended for the participant. The study will follow the participant for the course of the study to see the comparison to the MACRO arm
33588|NCT03922516|Diagnostic Test|ULDCT|Ultra-Low-Dose-CT (ULDCT) of the chest using tin filters with third-generation dual-energy CT devices. The projected dose used will be approximately 0.2 mSv per ULDCT of the chest.
33589|NCT03922503|Procedure|Advanced- platelets rich fibrin (A-PRF) with Demineralized freeze-dried bone allograft (DFDBA)|In A-PRF assigned group, one PRF will be cut into small pieces and added to the Demineralized freeze-dried bone allograft (DFDBA) in a ratio of 1:1 and the mixture is applied into the intraosseous defect, and the other will be used to prepare the membrane to cover the defect as a barrier.The mucoperiosteal flaps will be repositioned and secured in place using4-0 silk sutures.
33590|NCT03922503|Procedure|Collagen membrane with Demineralized freeze-dried bone allograft (DFDBA)|After debridement and intraoperative recordings, in the control group, Demineralized freeze-dried bone allograft (DFDBA) will be applied to the bone defect without overfilling and is protected by a collagen membrane, then interrupted sutures using 4-0 silk sutures will be placed to reposition the flaps.
33591|NCT03922490|Device|Lipogems Device PLUS debridement|Lipogems is the name of the technology used to obtain stem cells from the abdomen, which will then be injected into the knee after knee arthroscopy.
33592|NCT03922490|Procedure|Debridement only|Patients will undergo knee arthroscopy as a standard treatment for their condition but will not receive the fat-derived stem cell treatment nor will undergo any additional procedures.
33593|NCT03922477|Drug|Atezolizumab|Atezolizumab will be administered to participants by IV infusion at a fixed dose starting on Day 22 of Cycle 1. In subsequent cycles (Cycles 2 and beyond), IV atezolizumab will be given every 2 weeks (Q2W) on Days 8 and 22 of each 28-day cycle.
33594|NCT03922477|Drug|Hu5F9-G4|Two priming doses of 1 mg/kg of Hu5F9-G4 will be administered to participants by continuous IV infusion on Days 1 and 4 of Cycle 1, followed by loading doses of 15 mg/kg IV on Day 8 and 30 mg/kg IV on Day 11. Starting on Day 15 of Cycle 1, Hu5F9-G4 maintenance will be given by IV infusion at a dose of 30 mg/kg once a week (QW) of each 28-day cycle. Dosing for de-escalation, if needed: Hu5F9-G4 will be given as two priming doses of 1 mg/kg IV on Days 1 and 4, followed by loading doses of 10 mg/kg IV on Day 8 and 15 mg/kg on Day 11. Starting on Day 15, maintenance treatment with Hu5F9-G4 will be given by IV infusion at a dose of 15 mg/kg once a week (QW).
33595|NCT03922464|Device|Poly-L-lactic acid (Sculptra® Aesthetic)|"Sculptra® Aesthetic is a commercially available product that is licensed for sale in Canada. It is an injectable implant that contains microparticles of poly-L-lactic acid (PLLA), a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. Sculptra® Aesthetic is suitable for increasing the volume of depressed areas, particularly to correct skin depressions, such as in skin creases, wrinkles, folds, scars and for skin aging. Sculptra® Aesthetic is also suitable for large volume corrections of the signs of facial fat loss (lipoatrophy).~The safety and efficacy of Sculptra® Aesthetic has been investigated in the literature and is generally considered safe and effective. PLLA has been used successfully to reverse HIV‐associated lipoatrophy as well as to rejuvenate the face, neck, décolletage, hands, abdomen and gluteal regions."
33596|NCT03922451|Drug|piperacillin-tazobactam|Administered for infection treatment or prophylaxis per hospital protocol
33597|NCT03922451|Drug|Cefazolin|Administered for infection treatment or prophylaxis per hospital protocol
33599|NCT03922425|Other|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
33600|NCT03922412|Procedure|PLANTAR BLOCK|"Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of mepivacain 1% (200mg)~Plantar block 10 minutes later : patient in supine position. Medial midfoot injection of 5 ml of the mixture labelled  BLOC PLANTAIRE  containing 5 ml of Ropivacaine 0,5% (25mg) with 0,5 ml dexaméthasone (2mg)~Distal deep fibular block : patient in supine position, injection around the dorsal foot artery of 2 ml of the mixture labelled  BLOC FIBULAIRE  containing 2 ml of Ropivacaine 0,5% (10mg)."
33601|NCT03922412|Procedure|Sciatic popliteal block|"1-Sciatic popliteal block : patient in lateral position, injection of 20 ml of the mixture labelled  BLOC POPLITE  containing 20 ml of ropivacaine 0,5% (100mg) with 2mg (0,5 ml) of dexamethasone"
33602|NCT03922399|Procedure|Laser and Surgery|Laser and Surgery in patients with major burn scars Evaluating after three years treatment
33603|NCT03922386|Device|XFINE leads|Pacemaker subjects with at least one XFINE passive lead
33604|NCT03922373|Drug|Group A: Benzonatate 100mg|Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
33605|NCT03922373|Drug|Group B: Benzonatate 200mg|Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
33606|NCT03922373|Drug|Group C: Benzonatate 400mg|Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
33607|NCT03922360|Behavioral|Smartphone-based Financial Incentives|"Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.~Best Practices + Financial Incentive- Women assigned to this condition will receive the best practices treatment described above plus the remote incentives intervention.~Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples < 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced and incentives will be contingent on submitting a negative saliva cotinine test."
33608|NCT03922360|Behavioral|Best Practices|Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at three assessments that take place during pregnancy.
33609|NCT03922347|Diagnostic Test|Screening program including 2 consecutive tests|visual acuity test by Snellen chart, fundus imaging by fundus photography (Visucam Pro NM; Carl Zeiss Meditec AG, Germany)
33610|NCT03922347|Diagnostic Test|Screening program with mobile health|Peek Acuity and Peek Retina installed on smart phones (Samsung Galaxy S8)
33611|NCT03922334|Behavioral|Patient Navigation Program|A postpartum patient navigation program is designed to reduce barriers to care, enhance access, and improve multiple postpartum health outcomes, including retention in care, contraception uptake, vaccination, and depression screening.
33612|NCT03922321|Drug|RVT-1401 (Administered via subcutaneous injection)|RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
33613|NCT03922308|Other|Placebo|Participants will receive injection of placebo matched to SHP655.
33614|NCT03922308|Drug|SHP655|Participants will receive injection of SHP655.
33615|NCT03922308|Other|Standard of Care|Participants will receive PEX as Standard of Care (SOC).
33616|NCT03922295|Procedure|Endoscopic tympanoplasty|"In the double flap group, graft is placed via elevation of both posterior and anterior flaps.~In the single flap group, graft is placed via elevation of posterior flap only"
33617|NCT03922282|Procedure|Gasless BABA|BABA robotic-thyroidectomy that is using elevation of flap instead of using carbon dioxide.
33618|NCT03922282|Procedure|Classic BABA|BABA robotic-thyroidectomy that is using carbon dioxide.
33619|NCT03922256|Other|molded brace|The moldable brace utilized in the current study will be pre-fabricated and of the short-arm brace variety , which is primarily indicated for non-displaced fractures of the distal radius or distal ulna. The braces are available in multiple sizes for both right and left hands.
33620|NCT03922243|Other|retrospective|Retrospective study to assess treatment done by dental students
33621|NCT03922217|Device|Mindful My Way|Mindful My Way (MMW) is a mobile application created for iOS, designed to delivered a form of mindfulness-based therapy to depressed older adults
33622|NCT03922204|Drug|MCLA-145|full-length IgG1 bispecific antibody specifically targeting PD-L1 and CD137
33623|NCT03922191|Other|Data extraction from medical files|Data extraction from medical files
33624|NCT03922178|Device|Pressure/Volume Combination Catheter|Hemodynamic data routinely collected and data collected by means of the placement of a Pressure/Volume Combination Catheter (Pressure/Volume Combination Catheter,Leycom,The Netherlands) will be collected simultaneously. The catheter will be placed and held in place as long as the patient is in a position to be assisted by extracorporeal circulation. This means that the placement of the catheter will follow the heparinization of the patient and the placement of the cannulas necessary for the realization of extracorporal circulation. It will be removed from the left ventricular cavity before removal of extra-corporal cannulas.
33625|NCT03922178|Device|Transthoracic echocardiography|A complete transthoracic echocardiography will be performed the day before the surgical procedure, as per standard of care. It will establish the presence of the inclusion and exclusion criteria and evaluate the contractile function of the left ventricle. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
33626|NCT03922178|Device|Transesophageal echocardiogram|A transesophageal echocardiogram will be performed during the cardiac surgery, as per standard of care, using an Acuson Sequoia system (Siemens AG, Germany). It will facilitate the placement of the pressure/volume combination catheter and collect echographic data.
33627|NCT03922165|Procedure|Adenotonsillectomy|Routine AT per clinical care.
33628|NCT03922152|Radiation|Short course radiotherapy|An accelerated hypo-fractionation 2D-radiotherapy is delivered for palliation in patients with advanced esophageal cancer.
33629|NCT03922139|Drug|OnabotulinumtoxinA Injection|"Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle."
33630|NCT03922126|Other|Peer counseling|Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
33631|NCT03922126|Diagnostic Test|HIV/STI self-testing kits|Kits to self-test for HIV/STIs
33632|NCT03922113|Other|Patient follow up|Patient follow up during one month
33633|NCT03922100|Drug|NMS-03592088|NMS-03592088 will be administered orally once daily for 21 consecutive days of each treatment cycle. A treatment cycle will comprise 21 days of NMS-03592088 administration (Day 1 to 21) followed by 7 days of rest for a total of 28 days (4 weeks) period.
33634|NCT03922087|Other|No intervention|No intervention
33635|NCT03922074|Procedure|Sedation directed by an endoscopist|"The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure."
33636|NCT03922074|Procedure|Sedation directed by an anesthesiologist|The choice of the drugs and the target level sedation are directed by an anesthesiologist
33637|NCT03922061|Biological|dmLT|double mutant [LT(R192G/L211A)] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)
33638|NCT03922061|Biological|fIPV|fractional-dose inactived polio vaccine
33639|NCT03922048|Drug|HTX-011|Single-dose instillation of approximately 0.17 mL/kg (total dose does not exceed 10.5 mL) of HTX-011.
33640|NCT03922048|Device|Luer lock applicator|Applicator for instillation.
33641|NCT03922048|Drug|Bupivacaine HCl|Bupivacaine HCl 0.25% (without epinephrine) 0.5 to 1.0 mL/kg (total dose not to exceed 75 mg).
33642|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1.
33643|NCT03922048|Drug|HTX-011|Dose to be determined from Cohorts 1 and 2.
33644|NCT03922048|Drug|HTX-011|Dose to be determined from Cohort 1 Part A.
33645|NCT03922035|Other|Best Practice|Receive standard peri?/post?transplant supportive care
33646|NCT03922035|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
33647|NCT03922022|Behavioral|EIM exercise classes and intervention|This is a complex intervention. On recruitment, they will be seen by a nurse and counselled using motivational technique. They will then undergo a 12-week class. The exercise levels will be regularly feedback to the patients by use of mobile devices and trackers. Peer support is formed during the 12-week class. Resources to continue exercise will be provided to patients. Regular monitoring of physical improvement will be feedback to patients to encourage continued exercise.
33648|NCT03922009|Device|Virtual Reality|The primary objective of this study was to evaluate the use of VR to reduce anxiety in spinal anesthesia patients compared with controls
33649|NCT03921996|Procedure|Radical prostatectomy (RP) followed by ePLND|ePLND is performed either before or after radical prostatectomy and includes the removal of all nodal and fibro-fatty tissue
33650|NCT03921996|Procedure|Radical prostatectomy (RP) only|Radical prostatectomy
33651|NCT03921983|Other|Oxygen supplementation|short term O2 supplementation during 1 hour
33676|NCT03921736|Drug|Estracomb TTS|Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
33677|NCT03921723|Drug|Dolutegravir dispersible tablet|DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
33859|NCT03920241|Other|Control Group|A group of participants, matched by age, gender, and meditation experience is selected to compare their performance on experimental lab tasks in relation to the MBSR and CCT participants.
33652|NCT03921970|Procedure|ESP block (Group ESP)|US probe will be placed longitudinally 2-3 cm lateral to the T7 transvers process. From superior to inferior; trapezius (upper), rhomboideus major (middle), erector spinae (lower) muscles will be visualized on the hyperechoic transverse process. The 22G, 50 mm block needle (Braun Stimuplex Ultra 360, Germany) will be inserted in a cranio caudal direction and then for correction of the needle 5 ml normal saline solution will be enjected into the erector spina muscle fascia (figure). Following confirmation of the correct position of the needle, a dose of 20 ml %0.25 bupivacaine was administered. The same procedure will be performed at the other site (totally 40 ml %0.25 bupivacaine).
33653|NCT03921970|Procedure|Control Group|The patients in this group will be performed no block. They will receive opioid analgesia and ibuprofen treatment
33654|NCT03921957|Radiation|stereotactic radiotherapy|first level : W1 : 3 fractions - W2 : 2 fractions - W3 : 3 fractions second level : W1 3 fractions - W2 : 3 fractions - W3 : 3 fractions Third level : W1 : 4 fractions - W2 : 2 fractions - W3 : 2 fractions Fourth level : W1 : 4 fractions - W2 : 4 fractions
33655|NCT03921944|Diagnostic Test|CT scan of the shoulders|studies of both operative and nonoperative shoulders
33656|NCT03921931|Other|White light stimulation|Stimulation of the retina with white light
33657|NCT03921918|Device|Breast Pump|Hydraulic Breast pump
33658|NCT03921905|Diagnostic Test|ABI measurement|ABI measurement wil be done with an automatic device to diagnose PAD in patients with CAD
33659|NCT03921892|Behavioral|Parenting Education|Parenting education such as positive parenting interactions with their child, knowledge of developmental milestones and interactions with the child to support that development, as well as co-parenting skills will be provided either in-person or on-line to adolescent fathers
33660|NCT03921879|Drug|OT-82 Dose Escalation|The starting OT-82 dose level will be16.5mg/m2 given orally as an oral suspension once daily on Days 1-3, 8-10, and 15-17 of each successive 28-day cycle. Dose escalation will follow a modified 3+3 design. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
33661|NCT03921879|Drug|OT-82 Dose Expansion|A total of 25 patients evaluable for disease response will be treated with OT-82 on Days 1-3, 8-10, and 15-17 of the 28-day cycle at the MTD or maximum tested dose determined from Stage 1. This may include patients treated at that dose in Stage 1 plus expansion at that dose during Stage 2. Evaluability for disease response requires that patients receive at least one dose of OT-82. There is no maximum duration of OT-82 treatment; however, treatment will be discontinued if there is unacceptable toxicity, disease progression, withdrawal of consent by the patient, noncompliance with study requirements, intercurrent illness, development of symptoms or conditions listed as exclusion criteria, or closure of the study by the Sponsor.
33662|NCT03921866|Drug|Palbociclib|Palbociclib
33663|NCT03921853|Other|Behavioral|The 20-week RT program will consist of three sessions per week, each lasting for 1 hour that will be applied to both control obese (CG) and morbid obese (MO) group. All sessions will start with 15 minutes warm-up with continuous walking and joint mobility and flexibility exercises, 5 minutes of cool down and stretching, in order for preventing injuries. Sessions will include 4 to 8 RT exercises targeting different muscle groups; 1. forearm, 2. knee flexors and 3. extensors, 3. trunk, 4. chest, 5. shoulder elevators, 6. horizontal shoulder flexors and 7. extensors, and 8. plantar flexors. The exercises for each muscle group will be performed in 3 sets of as many repetitions (continuous concentric/eccentric voluntary contraction) possible in 1 minute followed by 2.0 minutes of passive recovery. Before the RT program, each participant will be measure using the subjective modified Borg scale (1-10 points), in order of identifying the muscle failure into 1 minute of exercise.
33664|NCT03921840|Behavioral|ELDERFITNESS|"In person training: Participants will receive a 2-hour in person education session with the exercise trainer. Self-monitoring: Subjects will self-monitor subjects' level of physical activity (steps & minutes of moderate activity) using the smartwatch. The Google calendar and Fitbit apps will send messages and alerts to the subject's smartwatch that encourage subjects to achieve subjects' daily goals. If a participant has low activity for 3 consecutive days, the research assistant will call the participant to either encourage the participant to adhere to the plan or provide a modified plan after consulting the exercise trainer.~Phone consultation: Subjects will have biweekly phone consultation with the research team members to receive guidance and adjustment on activity plans. Financial incentives: The intervention will include financial incentives. Specifically, when the daily activity goal is achieved for more than four days per week, a $5 reward will be given to subjects."
33665|NCT03921840|Other|Control|General education on physical activity for older adults and continue daily activity and healthcare routine. Participants will also receive a Go4Life program book from the National Institute on Aging.
33666|NCT03921827|Device|Enhance External Counterpulsation Therapy|EECP therapy would be administered to this group for 1-hour a day for a total of 35 sessions
33667|NCT03921814|Device|Treatment with IPL device|Exposure of body parts to the IPL device
33668|NCT03921801|Behavioral|Strength training + biofeedback|Home based strength training intervention for plantarflexor muscles conducted three times per week for 14 weeks. In addition, gait retraining session using real-time electromyography biofeedback performed once per week.
33669|NCT03921775|Drug|Remimazolam Tosilate|For induction and maintenance of general anesthesia
33670|NCT03921775|Drug|Propofol|For induction and maintenance of general anesthesia
33671|NCT03921762|Procedure|Cataract surgery with Artis Active IOLs|Patients will be implanted with the Artis Active IOLs during cataract surgery
33672|NCT03921762|Procedure|Cataract surgery with AT Lara IOLs|Patients will be implanted with the AT Lara IOLs during cataract surgery
33673|NCT03921749|Device|Shockwave|"Both shockwave interventions will be administered without local anaesthesia. Three sessions will be administered at one-week intervals. During each session, 2000 pulses (1000 shots at the patellofemoral and tibiofemoral borders of the target knee and 1000 shots on the subchondral bone of the medial tibia condyle of the affected knee) will be delivered at 5 Hz. Energy flux density was 0.20 mJ/mm2 for patients in the focused group while radial shock waves were transmitted with 0.17 mJ/mm2 corresponding to a 3-bar energy level setting."
33674|NCT03921736|Drug|Perindopril|4 mg/day p.o. for 12 months
33675|NCT03921736|Drug|Hydrochlorothiazide|hydrochlorothiazide 25 mg/day p.o. for 12 months
33678|NCT03921723|Drug|Dolutegravir oral suspension|DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
33679|NCT03921723|Drug|Dolutegravir oral solution|DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
33680|NCT03921710|Drug|CAPA-IVM|Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin [SAGE, Denmark] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
33681|NCT03921710|Drug|Standard-IVM|Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
33682|NCT03921697|Device|Werable sensors|Parkinson Disease Patients monitored by werable sensors
33683|NCT03921684|Drug|Capecitabine|Capecitabine 825 mg/m2 orally twice-daily, 5 days a week for a total of 28 days, given with radiation therapy
33684|NCT03921684|Radiation|Radiation therapy|1.8 Gy/day, 5 days a week for a total of 28 days, given with Capecitabine
33685|NCT03921684|Drug|mFOLFOX6|oxaliplatin 85 mg/m2, leucovorin 400 mg/m2 and fluorouracil 400 mg/m2 IV, fluorouracil 2400 mg/m2 IV (a 46 hrs CI), day 1 of each treatment cycle, every 2 weeks, given with nivolumab
33686|NCT03921684|Drug|Nivolumab|Nivolumab 240mg IV, day 1 of each treatment cycle, every two weeks, given with mFOLFOX6
33687|NCT03921671|Combination Product|Ramucirumab|Combination of ramucirumab (10 mg / kg) + carboplatin (AUC 5) and paclitaxel (200 mg / m2) in patients with carcinoma thymic (or thymoma B3 with areas of carcinoma), relapsed and / or metastatic, in the first line.
33688|NCT03921645|Drug|aerosol antibiotics|use of inhaled Antibacterial drug combined with intravenous antibiotics to treatment multiple drug resistance GNB ventilator associated pneumonia.
33689|NCT03921632|Behavioral|Smiles Matter Oral Health Education Series|Three sessions scheduled 2 weeks apart consisting of 15-20 minutes of didactic learning, 10 minutes of a group/personal exercise, and 10 minutes of questions that the patients have on the topic discussed that day
33690|NCT03921619|Device|Shoulder Sling|soft shoulder sling that is placed around the forearm, with a strap draped over the shoulder
33691|NCT03921606|Behavioral|Motivational Interviewing (i-BMI)|A brief MI via WhatsApp/WeChat
33692|NCT03921606|Behavioral|Individual face-to-face generic health advice|Individual face-to-face generic health advice (about 5 minutes) on a health-related lifestyle practice such as eating more vegetables and fruits, eating less high salt, fat or sugar foods, consuming less sugary drinks, engaging in more exercise of any kind or intensity, reducing alcohol consumption or reducing weight (if overweight or obese). A self-help booklet on smoking cessation published by the Hong Kong Council on Smoking and Health with Hotline will be also provided in the SOPCs.
33693|NCT03921593|Procedure|Solid Organ Pancreas Transplantation with or without Kidney Transplantation|Deceased donor pancreas transplantation
33694|NCT03921580|Other|Control Canned Tuna|210 g/day
33695|NCT03921580|Other|Enriched Canned Tuna Variety 1|210 g/day
33696|NCT03921580|Other|Enriched Canned Tuna Variety 2|210 g/day
33697|NCT03921567|Drug|Lidocaine Hydrochloride|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and in perioperative and postoperative period will be given lidocaine 1.5mg / kg / h-1, continuously during surgery and 48 hours after surgery.
33698|NCT03921567|Drug|Lidocaine Hydrochloride and Ketamine|at induction of anesthesia will be given lidocaine 2mg / kg / i.v., bolus, and ketamine 0.15mg / kg / , bolus, i.v .; lidocaine will continue during the operation and in the postoperative period with a dose of 1.5mg / kg / h-1, continuously, during the operation and 48 hours after the operation
33699|NCT03921567|Drug|Placebo|will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
33700|NCT03921554|Drug|Baricitinib|Baricitinib will be taken by mouth as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will be limited to the 2 mg tablet and will be used without splitting. Dispersion will be permitted to aid in swallowing.
33701|NCT03921541|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
33702|NCT03921541|Drug|Placebo|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
33703|NCT03921541|Drug|Pegzilarginase|Individualized disease management which includes severe protein restriction, essential amino acid supplementation and the ammonia scavengers when indicated
33704|NCT03921528|Biological|SRK-015|SRK-015 is a fully human anti-proMyostatin monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/lambda isotype that binds to human pro/latent myostatin with high affinity. SRK-015 will be administered every 4 weeks by intravenous infusion.
33785|NCT03920852|Drug|Ruxolitinib cream|Ruxolitinib 1.5% cream applied twice daily.
33786|NCT03920839|Drug|INCMGA00012|INCMGA00012 administered intravenously every 3 weeks.
33787|NCT03920839|Drug|Gemcitabine|Gemcitabine administered intravenously on Days 1 and 8 of 21-day cycles.
33788|NCT03920839|Drug|Cisplatin|Cisplatin administered intravenously on Day 1 of 21-day cycles.
33707|NCT03921502|Procedure|Gall bladder transmural drainage with LAMS|Placing a PAL Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL 15x10 mm or 10x10 mm will be *placed on it to generate the anastomosis between the aforementioned structures.
33708|NCT03921489|Procedure|Subchondroplasty|Calcium phosphate mineral compound injected into the bone marrow lesions
33709|NCT03921476|Other|Online survey|Online survey completion through Northwestern's REDCap
33710|NCT03921450|Device|1 Hz rTMS|1 Hz stimulation at 110% of resting motor threshold over supplementary motor area
33711|NCT03921450|Device|iTBS|50 Hz theta burst stimulation at 80% of resting motor threshold over supplementary motor area
33712|NCT03921450|Drug|Placebo|1 Hz stimulation with the placebo TMS coil without any magnetic emission
33713|NCT03921437|Radiation|decision support intervention|CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
33714|NCT03921424|Biological|V114|15-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) present in Prevnar 13™ plus 2 additional serotypes (22F, 33F) in each 0.5 mL dose.
33715|NCT03921424|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in each 0.5 ml dose.
33716|NCT03921424|Biological|Pneumovax™23|23-valent pneumococcal polysaccharide vaccine containing 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) in each 0.5 mL dose
33717|NCT03921411|Biological|Nemolizumab|Nemolizumab
33718|NCT03921372|Diagnostic Test|Isometric exercise|Squatting for 5 minutes
33719|NCT03921359|Behavioral|SMARTfit training|For SMARTfit training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session. There is an additional cognition component that can be manipulated using features provided by SMARTfit.
33720|NCT03921359|Behavioral|Conventional physical training|For conventional physical training, participants receive three 1-hour training sessions per week for 8 weeks. During each week, participants will receive physical training focused on six tasks, which are the functional tasks individuals with PD commonly have difficulty with. The six tasks are paired into 3 pairs: (1) sit-to-stand and multi-plane locomotor tasks, (2) gait and reach & grasp, and (3) floor-to-stand; stand-to-floor and single limb standing. Participants will focus on practicing one pair of tasks during each session.
33721|NCT03921346|Device|Mobile device app (PedAMINES™) 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
33722|NCT03921346|Device|Mobile device app (PedAMINES™) 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
33723|NCT03921346|Device|Mobile device app (PedAMINES™) 3rd drug|To prepare 4 mL/kg dextrose 10%
33724|NCT03921346|Device|Mobile device app (PedAMINES™) 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
33725|NCT03921346|Device|Conventional method 1st drug|To prepare 0.01 mg/kg epinephrine (0.1 mL/kg of 0.1 mg/mL concentration)
33726|NCT03921346|Device|Conventional method 2nd drug|To prepare 0.1 mg/kg midazolam (of 5 mg/mL concentration ad 10 mL sodium chloride 0.9%)
33727|NCT03921346|Device|Conventional method 3rd drug|To prepare 4 mL/kg dextrose 10%
33728|NCT03921346|Device|Conventional method 4th drug|To prepare 1 mmol/kg sodium bicarbonate (of 4.2% = 0.5 mmol/L concentration)
33729|NCT03921333|Dietary Supplement|Low dose response efficacy of plant extracts|300mg
33730|NCT03921333|Dietary Supplement|Middle dose response efficacy of plant extracts|500mg
33731|NCT03921333|Dietary Supplement|High Dose response efficacy of plant extracts|700mg
33732|NCT03921333|Dietary Supplement|Placebo|Cellulose microcrystalline
33733|NCT03921320|Procedure|Bilateral sequential sympathectomy|Bilateral videothoracoscopic sequential R4 sympathectomy
33734|NCT03921320|Procedure|Unilateral sympathectomy|Unilateral videothoracoscopic R4 sympathectomy in dominant side (right side)
33735|NCT03921320|Procedure|Contralateral sympathectomy|Contralateral (left side) videothoracoscopic R4 sympathectomy
33736|NCT03921294|Drug|Emicizumab|bispecific monoclonal antibody binding to activated Factor IX and Factor X
33737|NCT03921281|Other|scalp acupuncture treatment|"The parameters for scalp acupuncture are set as follows:~Scalp acupoint selection: The Motor Area of Jiao's Scalp acupuncture and Si shencong (EX-HN1).~Acupuncture manipulation: Disposable stainless steel needles will be manually inserted in at an approximately 15-degree angle to a depth of 1.5-2.0 cm respectively along the upper point and middle point of the motor area on the scalp. The acupuncture direction of Si shencong (EX-HN1) acupoint is toward the Baihui (GV20) acupoint. the needles will be rotated for at least 200 revolutions per minute for 1 minute every 20 minutes for a total of 60 minutes.~Treatment course: three times a week, 12 weeks in total."
33738|NCT03921281|Other|Rehabilitation Treatment|The children with CP will receive the conventional rehabilitation programs as mentioned above. The rehabilitation programs will be carried out three times a week (once every other day) for 12 weeks, and every time, the rehabilitation treatment (PT and OT) will last approximately for 1 hour. All rehabilitation treatments will be carried out by qualified therapists.
33739|NCT03921268|Drug|AZD1402|AZD1402 (PRS-060) is presented as a solution and dry powder for oral inhalation and belongs to a new class of therapeutics, Anticalin® proteins, which are modified lipocalins. AZD1402 is an inhaled IL-4Rα antagonist, which is being developed as controller therapy for asthma.
33740|NCT03921255|Other|Cognitive Bias Modification|There is support that CBM-I may work through the process of cognitive restructuring, and specifically, threat reappraisal. Threat appraisal is a tendency to overestimate the likelihood of harm (i.e., likelihood bias) and/or the negative consequences of anticipated harm (i.e., Clark & Beck, 2010), producing avoidance, thus interfering with effectively reappraising threat, thereby creating a vicious cycle (Beck et al., 1985; Clark & Beck, 2010). CBM-I procedures ensure that an interpretation bias is triggered by the ambiguous scenarios, and participants are then guided to solve the key word in accordance with a healthy response (Grey & Mathews, 2000). The observed effects of CBM-I may stem from active generation of benign or positive meanings in response to ambiguous situations, where threats were previously interpreted (Beadel et al., 2014).
33741|NCT03921242|Drug|Metformin|Newly Initiated and regular metformin dosage as prescribed by each patient's medical care provider
33742|NCT03921242|Drug|Sulfonylurea|Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
33743|NCT03921242|Drug|DPP-4 inhibitor|Newly initiated and regular DPP-4 inhibitor dosage as prescribed by each patient's medical care provider
33744|NCT03921242|Drug|SGLT2 inhibitor|Newly initiated and regular SGLT2 inhibitor dosage as prescribed by each patient's medical care provider
33745|NCT03921242|Drug|GLP1 receptor agonist|Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
33746|NCT03921229|Behavioral|Tele-coaching|"Patients will meet with a tele-coach, who is a care team member, via video-calling, on a regular basis for six months to identify and address treatment adherence concern(s)."
33747|NCT03921190|Procedure|Local anesthesia|Patients scheduled for a dental procedure that requires local anesthesia will be given the injection using two 2 techniques; an open-mouth and closed-mouth techniques
33748|NCT03921177|Dietary Supplement|Multiple micronutrient supplement|Preconception to 12-weeks gestation: daily (coded) multiple micronutrient supplement containing 15-nutrients (vitamins and minerals) providing an approximate recommended dietary allowance for pregnant women, approximating the UNICEF UNIMAP formulation (UN micronutrient preparation).
33749|NCT03921177|Drug|Placebo Oral Tablet|Preconception to 12-weeks gestation: identical tablet
33750|NCT03921164|Procedure|Trans-oesophageal Doppler|"As required by the standard of care of the interventional neuroradiology procedure, the neuroradiologist also cannulates the femoral artery. At the end of the procedure, during catheter withdrawal, pressure waveforms are recorded in the descending thoracic aorta just in front of the esophageal Doppler probe.~Descending aortic velocity is measured with a transesophageal Doppler CardioQ-ODM+ (Deltex Medical, Chichester, UK) in order to construct the VP Loop in descending thoracic aorta."
33751|NCT03921164|Procedure|Trans-thoracic echocardiography|Estimation of ventricular diastolic pressure by measuring mitral and aortic flow gradients by echocardiography (EPIQ G7 Philips© or similar) Determination of left ventricular volumes during the cardiac cycle by echocardiography (3D EPIQ G7 Philips© or similar).
33752|NCT03921164|Procedure|Applanation tonometry|"Measurements using the SphygmoCor radial tonometer (AtCor Medical, Pty Ltd, Sydney, Australia), the most widely used tonometer in clinical research for non-invasive central pressure measurement and pulse wave analysis. The central blood pressure is then estimated using a validated radial-aortic transfer function.~The tonometer requires prior calibration by mean (MAP) and diastolic (PAD) blood pressure measured with the conventional brachial cuff as validated in the literature."
33753|NCT03921151|Drug|Mirtazapine 15 MG Oral Tablet|15mg of mirtazapine oral table prior to scan
33754|NCT03921151|Other|Placebo oral capsule|Oral placebo consisting of dextrose in gelatin capsule prior to scan
33755|NCT03921138|Other|Histopathologic tube anomalies|Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
33756|NCT03921125|Device|Massimo for Pleth variability index|To assess fluid response
33757|NCT03921112|Device|lung ultrasound|bedside lung ultrasound will be done for patients
33758|NCT03921112|Other|routine tools|chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
33759|NCT03921099|Drug|Ascorbic Acid|ascorbic acid is an antioxidant that is expected to prevent nephrotoxicty induced by Vancomycin.
33760|NCT03921086|Drug|Antihypertensive medication according to the study's algorithm|"Patients with stage 1 hypertension will receive monotherapy and risks of hypotension are negligible. A single antihypertensive lowers blood pressure (BP) on average by 10/5 mmHg.~Patients with stage 2 hypertension will be initiated on two medications and this is recommended by all international hypertension guidelines and studies have shown prompt BP control with minimal side effects.~For borderline patients, the investigators will elect to not treat them for blood pressure ranges of BP: 135-140/85-90 mmHg and give them a letter on discharge to be followed up at their local clinic. The letter will detail that they are potentially hypertensive patients and need to be followed up closely in future.~Patients with Stage 3 hypertension will be referred to the in-hospital physician as per the algorithm."
33761|NCT03921073|Drug|T-VEC|Participants will receive intralesional injections of T-VEC of up to 4cc. Dosing of T-VEC is dependent of the size of the lesion.
33762|NCT03921060|Drug|Denosumab|treatment with denosumab every 6 months for up to 5 years
33763|NCT03921047|Procedure|Biospecimen Collection|Undergo collection of blood samples
33764|NCT03921047|Other|Laboratory Biomarker Analysis|Correlative studies
33765|NCT03921034|Drug|Ropivacaine|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
33789|NCT03920839|Drug|Pemetrexed|Pemetrexed administered intravenously on Day 1 of 21-day cycles.
33790|NCT03920839|Drug|Carboplatin|Carboplatin AUC5 or AUC6 administered intravenously on Day 1 of 21-day cycles.
33791|NCT03920839|Drug|Paclitaxel|Paclitaxel administered intravenously on Day 1 of 21-day cycles.
33766|NCT03921034|Drug|Saline|All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
33767|NCT03921021|Drug|Telomelysin|OBP-301, the investigational product (IP) is formulated in 20 mM Tris pH 8.0, 25 mM NaCl with 2.5% glycerin, USP by volume. OBP-301 will be injected into the target tumor lesions.
33768|NCT03921008|Drug|Paclitaxel|-Commercial supply
33769|NCT03921008|Radiation|Radiation therapy|-Patients may be treated with electrons, 3D conformal photon radiotherapy, intensity modulated photon radiotherapy (IMRT), proton radiation therapy, or a combination of these.
33770|NCT03921008|Procedure|Research blood draw|-Within 1 week (prior to cycle 1 of paclitaxel preferred but not required), pre-radiation therapy (any time weeks 5-7 as long as radiation therapy has not started), post-radiation therapy (day of last fraction), 14 days post-radiation therapy, and within 2 weeks post-surgery
33771|NCT03920982|Diagnostic Test|Determination of the blood concentration of indoxyl sulfate (IS)|IS concentration will be determined in blood of patients with septic shock and acute kidney injury. IS blood concentration will be done every day during 7 first days after patient will be admitted in intensive care unit. Relation between IS peak serum concentration and mortality at day 28 will be determined.
33772|NCT03920969|Behavioral|Sports activity|Evaluation of physical activity using the International Physical Activity Questionnaire (IPAQ) short version.
33773|NCT03920956|Other|ABPM service by Pharmacists|Patients will receive ABPM services provided by a pharmacist and complete a patient satisfaction survey
33774|NCT03920943|Other|Measurement of temperature using non-invasive means|The study intervention will involve paramedics using the TAT device to measure temperature non-invasively,the first measurements made at least 5 minutes after insertion of the temperature probe (control measurement #1), and also prior to departure from the sending facility (control measurement #2). Once the patient is in the transport vehicle and the vehicle in motion for at least 10 minutes, the paramedics will measure the patient's temperature non-invasively using the TAT. If the transport time exceeds 1 hour, additional measurements taken at 1 hour intervals for the duration of transport (up to a total of 8 hours).
33775|NCT03920930|Procedure|Late local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
33776|NCT03920930|Procedure|Early local infiltration analgesia|The local infiltration analgesia is applied in a total of 4 steps during the preparation of the knee joint: 1. after the skin incision, 2. after the capsule incision, 3. after complete exposure of the knee joint, 4. when the posterior knee capsule is reached.
33777|NCT03920917|Procedure|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
33778|NCT03920917|Procedure|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional cavo-tricuspid isthmus ablation will be performed with a radiofrequency catheter.~Additional superior vena cava-right atrial septal linear ablation will be performed with a radiofrequency catheter.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
33779|NCT03920904|Other|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
33780|NCT03920891|Procedure|Cryoballoon Pulmonary Vein isolation|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm second or third cryoballoon catheter will be used.~Esophageal temperature will be monitored to prevent esophageal injury.~Cryoablation will be performed for 180 secs at -45°C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and cryoablation times will be evaluated.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
33781|NCT03920891|Procedure|Radiofrequency Pulmonary Vein isolation and Additional Right Atrial linear ablation|"Pulmonary vein isolation will be performed using a radiofrequency catheter.~Additional left atrium posterior wall isolation, left atrium anterior wall linear ablation, cavo-tricuspid isthmus ablation, superior vena cava-right atrial septal ablation.~If any other trigger came from beyond pulmonary vein is detected after the administration of isoproterenol, additional local radiofrequency ablation will be followed.~Evaluated the procedure and radiofrequency ablation time.~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
33782|NCT03920878|Drug|Aflibercept injected Pre- and Post-operatively|Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
33783|NCT03920878|Drug|Aflibercept injected intraoperatively|Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
33784|NCT03920865|Drug|Risdiplam|5 milligram (mg) oral dose administered in fasted state
33860|NCT03920228|Drug|PTX-022|PTX-022 QTORIN
33792|NCT03920826|Device|transcranial alternating current stimulation|The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).
33793|NCT03920826|Device|sham stimulation|Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.
33794|NCT03920813|Drug|Mercaptopurine|Dose of mercaptopurine was adjusted to maintain a target white blood cells (WBC) between 2.0-3.0 × 109/L.
33795|NCT03920800|Other|Data extraction from medical files|Data extraction from medical files
33796|NCT03920800|Biological|Immunohistochemistry|Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.
33797|NCT03920787|Dietary Supplement|Inofolic Combi|Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg. 2 capsules every day for 1 month.
33798|NCT03920787|Other|Placebo|2 capsules every day for 1 month
33799|NCT03920761|Device|EarlySense Insight system|a small piezoelectric sensor pad that can be placed under the mattress and provide contact-free monitoring by measuring and recording a patient's vital signs and motion parameters
33800|NCT03920761|Device|Advanced Neonatal Epidermal System|a system of neonatal non-invasive adhesive sensors. Sensors are attached directly on the patient's body and are capable of continuously measuring and recording heart rate, respiratory rate, oxygen saturation, and skin temperature.
33801|NCT03920748|Other|Group D|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 3-4 is defined as Group D
33802|NCT03920748|Other|Group E|According to Cormack-Lehane (CL) Classification; laryngoscopic view grade 1-2 is defined as Group E
33803|NCT03920722|Drug|Rituximab|1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
33804|NCT03920722|Drug|placebo|Placebo-Rituximab 1 gram IV on Day 1 and 15 after premedication with 100 mg méthylprednisolone, 1 gramm paracetamol and 5 mg dexchlorpheniramine
33805|NCT03920709|Other|Blood sample and Nasal swabs (right an left) samples|"Nasal swabs (right and left) will be performed (FLOQSwabTM)~Blood samples of 20 mL EDTA will be taken in addition to the current care report"
33806|NCT03920683|Other|Data collection|Retrospective : data from medical record Prospective : vital statuts from follow-up phone call
33807|NCT03920670|Device|Neuromuscular stimulation|AMG and EMG neuromuscular blockade monitoring
33808|NCT03920657|Drug|Deferasirox|Fixed dose of 3.5 mg/kg/day of DFX FCT
33809|NCT03920644|Drug|Scopolamine Transdermal Patch [Transderm Scop]|Current Motion Sickness treatment, 1 patch behind the ear.
33810|NCT03920644|Drug|Scopolamine|IND, up to 6 administration of intranasal gel.
33811|NCT03920644|Drug|Placebo Patch|Placebo Patch, 1 patch behind the ear.
33812|NCT03920644|Drug|Placebo Gel|Placebo Gel,up to 6 administration of intranasal gel.
33813|NCT03920631|Drug|Nivolumab|Nivolumab (1 mg/Kg or 3 mg/kg) every 2 weeks per cohort dose level and schedule
33814|NCT03920631|Biological|Microtransplantation|HLA-mismatched peripheral blood stem cells
33815|NCT03920618|Drug|Entecavir|Patients would receive treatment of oral entecavir (ETV) 0.5 mg once per day.
33816|NCT03920618|Drug|Tenofovir Disoproxil Fumarate|Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.
33817|NCT03920618|Drug|Tenofovir Alafenamide|Patients would receive treatment of oral tenofovir alafenamide (TAF) 25 mg once per day.
33818|NCT03920605|Drug|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
33819|NCT03920605|Drug|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
33820|NCT03920605|Drug|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
33821|NCT03920592|Behavioral|Virtual Reality of Bullying|"Immersive videos (360º) filmed by 12-14 year old pupils who, guided by professional actors, represented the subjective experience of bullying.~Eight different potential situations designed depending on the sex of the pupil were filmed:~Girls:~Classmates steal her personal diary~Classmates tear her clothing~Classmates insult her and steal her belongings~Classmates deliberately exclude her in class~Boys:~Classmates exclude him while playing with a ball~Classmates bother him in the dining room~Classmates insult and steal him in class~Classmates insult him and steal his belongings"
33822|NCT03920579|Drug|CKD-386 formulation 1|A single oral dose of 1 tablet under fasting conditions for each period
33823|NCT03920579|Drug|CKD-386 formulation 2|A single oral dose of 1 tablet under fasting conditions for each period
33824|NCT03920579|Drug|D326, D337 and D013|A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period
33825|NCT03920566|Other|Anti-Xa level|Anti-Xa level taken before commencing enzalutamide and repeated after 4 weeks of treatment
33826|NCT03920553|Biological|Hyaluronic acid|Topical application of hyaluronic acid following Laser assisted frenectomy
33827|NCT03920540|Combination Product|GC1111|GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
33828|NCT03920540|Combination Product|Comparator|Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.
33829|NCT03920527|Drug|Itraconazole 400 mg|Duration of itraconazole
33830|NCT03920514|Drug|hCG|Women will be given hCG before or with IUI
33831|NCT03920501|Behavioral|Tele-Critical Care|Daily multidisciplinary rounds with a board certified physician through tele-critical care focusing on: 1) diagnosis; 2) active problems; and 3) therapeutic goals. In addition, the management of health care quality indicators will be conducted by a specially trained (Science of Improvement) board-certified intensive care physician.
33861|NCT03920228|Drug|Placebo|Placebo topical
60406|NCT03712202|Other|Quality-of-Life Assessment|Ancillary studies
33832|NCT03920475|Drug|Sertraline or venlafaxine|Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
33833|NCT03920475|Diagnostic Test|Immune parameters|Serum was taken before, during an after treatment for measurement of different immune parameters.
33834|NCT03920462|Device|Programme of intelligent electric bike for health|It is a programme of 6 excursions with an intelligent electric bike for health and connected vests during 1 month (two excursions per week according the weather)
33835|NCT03920449|Drug|Botulinum Toxins|In group I (BT injection), 21 U will be injected in 3 divided doses through the internal anal sphincter at 3,9, and 12 o'clock. In the Egyptian market two commercial forms are available; botulinum toxin type A (Botox 100 IU/vial; Coolock, Dublin, Ireland), and abobotulinumtoxin A (Dysport 500 U/vial; Ipsen Biopharm Ltd, Wrexham, UK). In case of Dysport it should be remembered that dosing is on a ratio of approximately 1 to 3, meaning that 50 IU of Botox have the same effect as 150 IU of Dysport.
33836|NCT03920449|Procedure|Posterolateral internal sphincterotomy|In group II (PIAS), A 1.5 to 2-cm circumferential skin incision will be placed at 5 o'clock position outside the anal verge using an electrocautery device. Dissection will be proceeded through the intersphincteric groove to separate both IAS and external anal sphincter (EAS). Then, the IAS will be identified by its characteristic white fibers, separated from the anal mucosa, and assessed under direct vision. Subsequently, about 50 % of the IAS will be divided at 5 o'clock position and any skin tags or hypertrophied anal papillae will be removed leaving the skin incision open to allow drainage.
33837|NCT03920436|Dietary Supplement|infrared water group|This group takes 1,8 L of drinking water using a tumbler that emits far infrared rays at room temperature.
33838|NCT03920436|Dietary Supplement|sham group|This group takes 1,8 L of drinking water using a tumbler at room temperature.
33839|NCT03920423|Procedure|improvement of arterial depth|deepen radial arterial depth by injection of saline to more than deep cutoff point relative to result.
33840|NCT03920410|Other|serotonergic stimulation|Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.
33841|NCT03920410|Other|no serotonergic stimulation|Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
33842|NCT03920397|Biological|Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation|The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 [T3], 6 [T6], 12 [T12], 18 [T18], and 24 [T24] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
33843|NCT03920384|Behavioral|Experimental intervention arm|Psychological therapy for psychosis with new therapy components
33844|NCT03920384|Behavioral|Active control arm|Standard psychological therapy for psychosis without new therapy components
33845|NCT03920371|Other|gamma camera imaging|Following the administration of the routine radiopharmaceutical and the standard wait before clinical diagnostic imaging, additional research gamma camera imaging is carried out
33846|NCT03920358|Device|FRED and FRED Jr|Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm
33847|NCT03920345|Device|MultiZYTE|Subjects can be treated either unilateral or bilateral, depending on their condition and the recommended treatment by the surgeon. The decision is a clinical one and is not influenced by the decision of whether to be included in the study or the subsequent outcomes and QoL analysis.
33848|NCT03920319|Drug|Bupropion|Bupropion 150 mg sustained release
33849|NCT03920319|Other|Placebo|
33850|NCT03920306|Drug|oral anti-acid treatment|This study investigates a bundle of three commonly used treatments
33853|NCT03920267|Drug|BMS-986165|Administered orally
33854|NCT03920254|Drug|TD-1473 Dose A|See Arm description
33855|NCT03920254|Drug|TD-1473 Dose B|See Arm description
33856|NCT03920254|Drug|TD-1473 Dose C|See Arm description
33857|NCT03920241|Behavioral|Mindfulness-Based Stress Reduction|"The MBSR is an 8-week standardized program (Kabat-Zinn, 1990) consisted of 2.5-hour of face-to-face weekly sessions, and 45 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. During the program, different mindfulness practices are performed, including focused attention on the breath, open monitoring of awareness in body-scanning, prosocial meditation (i.e. loving kindness and compassion) and gentle yoga.~Training is delivered by certificated instructors by the University of Massachusetts Centre for Mindfulness (https://www.umassmed.edu/cfm/)."
33858|NCT03920241|Behavioral|Compassion Cultivation Training|"The CCT is an 8-week standardized program (Jinpa, 2010; Jazaieri et al. 2013, 2014) consisting of 2.5-hour of face-to-face weekly sessions and 30 minutes of daily home formal and informal practices. Training will be conducted in groups of 20-30 participants. The CCT consists of six sequential steps: 1) Settling the mind and learn how to focus it; 2) Loving kindness and compassion for a loved one practice; 3) Loving kindness and compassion for oneself practice; 4) compassion toward others, embracing shared common humanity and developing appreciation of others; 5) compassion toward others including all beings; and 6) active compassion practices (Tonglen) which involve explicit evocation of the altruistic wish to do something about others' suffering.~CCT program is delivered by certificated instructors by the University of Stanford Centre for Compassion and Altruism Research and Education (http://ccare.stanford.edu/)."
33959|NCT03919409|Drug|TS-161 Placebo|TS-161 matching placebo capsules
33862|NCT03920215|Drug|Observational OC-01|long-term follow-up study is to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study.
33863|NCT03920189|Diagnostic Test|echocariographic ultrasound|left ventricular diastolic function description
33864|NCT03920176|Diagnostic Test|Computed tomography coronary angiography|CTCA >64 detector row scanner
33865|NCT03920176|Other|ASSIGN Score|ASSIGN Cardiovascular Risk Score
33866|NCT03920163|Other|Enhanced Recovery Measures|Perioperative measures
33867|NCT03920150|Drug|Vitamin D3|Patient will be treated with 3 doses of alcoholic solution for 3 months.
33868|NCT03920150|Drug|Vitamin D oily capsules|Patient will be treated with 3 capsules for 3 months.
33869|NCT03920150|Drug|Vitamin D oily capsules|Patient will be treated with weekly capsules for an individually calculated number of weeks.
33870|NCT03920137|Behavioral|UP-ST Therapy|Phase 1 analyses will focus primarily on demonstrating feasibility and utility of the new UP-ST intervention. Feasibility will be determined by examining the proportion of individuals who 1) complete each module of the UP-ST treatment, 2) complete a full course of the UP-ST treatment, and by 3) benchmarking participant ratings of treatment credibility, expectancy, and satisfaction with corresponding ratings from our previous clinical trials examining the UP or ST interventions. The investigators will include and examine outcomes on the same measures that will be used in phase 2, but due to the sample size our analyses for Phase 1 will focus on intraindividual effect sizes (with 95% CI) for continuous smoking, anxiety, and depression outcomes
33871|NCT03920137|Behavioral|Standard Therapy|In the control group therapists will hold standard smoking cessation therapy sessions.
33872|NCT03920137|Device|Nicotine Patch|Nicotine patches will be worn in tandem with UP-ST therapy
33873|NCT03920124|Other|Step and walk-based high intensity interval exercise|"Four hospital-based trials will include two step-based (3 x 20 sec with 120 sec rest, or 3 x 60 sec with 60 sec rest) and two walking-based (e.g. 3 x 60 sec with 60 sec rest or 3 x 180 sec with 180 sec rest) interval exercise protocols, in a randomised and counterbalanced order.~Unsupervised (At home) exercise intervention will incorporate patients' preferred stair and/or walking-based interval exercise (from those completed during hospital trials). Initially patients will complete their chosen protocol three days per week, and then gradually progress exercise load (i.e. reps, work-to-rest ratio, and/or sessions per week) as appropriate, to a maximum of 6 x 60 sec stepping / 5 x 180 sec walking, five times per week (i.e. maximum of ~30 min daily or ~150 min weekly)."
33874|NCT03920111|Biological|IMOJEV|live attenuated Japanese encephalitis (JE) vaccine IMOJEV®
33875|NCT03920098|Other|Altered metabolic milieu during first full term pregnancy|The altered metabolic milieu is defined as a fasting glucose level >100 mg/dL at the first trimester of pregnancy by national guidelines. Altered metabolic milieu during the second trimester (24-28 weeks of pregnancy) is defined as a fasting glucose levels > 92 mg/dL and/or plasma glucose levels > 153 mg/dL two hours afterload in the oral glucose tolerance test according to ADA guidelines or a fasting glucose >100 mg/dL and/or > 140 mg/dL two hours afterload in the oral glucose tolerance test according to national guidelines.
33876|NCT03920085|Device|OneTouch Verio|OneTouch Verio Blood Glucose Monitoring System.
33877|NCT03920085|Device|OneTouch Select Plus|OneTouch Select Plus Blood Glucose Monitoring System.
33878|NCT03920085|Device|OneTouch Ultra|OneTouch Ultra Blood Glucose Monitoring System.
33880|NCT03920059|Drug|Mycophenolate Mofetil|"Description Each capsule contains Mycophenolate mofetil 250 mg. Presentation / Packing Cap 250 mg (white to off white powder, light blue/peach hard gelatin, imprinting with MMF on cap and 250 on body) x 10 x 10's.~Storage Store below 30 degree Celcius."
33881|NCT03920046|Behavioral|Control Group|The prevalence of laryngospasm in sedation applied to endoscopic intervention whose parents no smoking.
33882|NCT03920033|Radiation|Salvage radiation therapy|Salvage radiation therapy for biochemical recurrence
33883|NCT03920020|Other|the concentric isokinetic exercise group|concentric isokinetic exercises
33884|NCT03920020|Other|the eccentric isokinetic exercise group|eccentric isokinetic exercises
33885|NCT03920020|Other|the control group|conventional physiotherapy and standard therapeutic exercises predetermined by us
33892|NCT03919981|Other|Blood sampling|25 mL blood sample will be collected on citrate tubes for osteoclastic analysis.
33893|NCT03919968|Behavioral|Martial Arts|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of fight simulation and / or play activities. The activities will be carried out in a way adapted for the elderly. Will be used kickers, gauntlets, thorax and head protectors, shin guards, gloves, and other devices.
33894|NCT03919968|Behavioral|Functional Training|The training will be performed 3 times a week, for 12 weeks, during 60 minutes, being that will be divided into 20 min of general exercises, 20 min of specific exercises and 20 min of play activities. The activities will be carried out in a way adapted for the elderly. Will be carried out neuromotor control / coordination, balance, flexibility and static and dynamic stabilization. They will also have acceleration and deceleration activities, rotation and counter-rotation, extension and counter-extension, flexion and counter-flexion.
33895|NCT03919955|Drug|Atomoxetine|Atomoxetine 80 mg, per mouth, before bed
33896|NCT03919955|Drug|Oxybutynin|Oxybutynin 5 mg, per mouth, before bed
33897|NCT03919955|Drug|Placebo|Placebo, per mouth, before bed
34138|NCT03917810|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
33898|NCT03919942|Other|OxyFlower gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
33899|NCT03919942|Other|Chlorhexidine gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal.
33900|NCT03919942|Other|Placebo gel|the region with pericoronitis was debrided using gauze and curettes, with copious irrigation with sterile saline solution. At this moment, the gel was applied topically under the pericoronal hood, with a standard volume of 2microIiters, using a dosing syringe. Then, participants received instructions on oral hygiene and how to use the gel at home, twice a day for one week. After 30 days, it was performed third molar removal or distal wedge removal
33901|NCT03919929|Drug|Exenatide 2 MG [Bydureon]|Exenatide once weekly for 12 weeks
33902|NCT03919929|Other|Weight loss diet|Prescribed weight loss diet to match weight loss in Drug arm
33903|NCT03919916|Procedure|Serratus plane block|Placement of initial local anaesthetic bolus and catheter for continuous infusion in the plane between latissimus dorsi and serratus anterior in the midaxillary line at the level of the 5th rib
33904|NCT03919916|Drug|Patient controlled analgesia|Computerised pump device facilitating the patient self administration and titration as needed of morphine
33905|NCT03919890|Drug|ONO-7684|Single ascending doses for cohorts A1-A8 and multiple ascending doses cohorts B1-3
33906|NCT03919890|Drug|ONO-7684 Placebo|Placebo comparator
33907|NCT03919877|Other|Dietary|Dietary counseling based on results of CGM analyses.
33908|NCT03919864|Behavioral|CONNECT Intervention|Participants will be included in a multi-component e-tool with brief educational videos, an assessment of multidimensional supportive care needs, a tailored resource list and an optional automated referral to a caregiver navigator. Two weeks after baseline participants will receive re-education and an optional referral.
33909|NCT03919864|Behavioral|CONTROL Group|Participants will receive a generic printed list of hospital, community, and national supportive care resources.
33910|NCT03919851|Drug|Antibiotics|Administration of antibiotics
33911|NCT03919838|Dietary Supplement|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive two probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
33912|NCT03919838|Dietary Supplement|Placebo - No probiotics|A half of the participants will be randomly allocated to the placebo group. They will receive two no probiotics lozenge before falling asleep for 8 weeks. Clinical examination will be conducted before study and after 8 weeks.
33913|NCT03919812|Dietary Supplement|Cholecalciferol supplementation|supplementation received by subject according to their vitamin D status: insufficiency or deficiency.
33914|NCT03919799|Drug|KD025|ROCK-2 Inhibitor
33915|NCT03919799|Drug|Placebo|Inactive substance
33916|NCT03919786|Procedure|topical local anesthesia of pulmonary vein combined with vagus nerve block|"Injecting 1% lidocaine 1.5ml+0.375% ropivacaine 1.5ml into vascular sheaths of all pulmonary vein of the surgery side at the beginning of surgery operation.~Wrapping all pulmonary vein of the surgery side with cotton sheet infiltrated with 1% lidocaine+0.375% ropivacaine at the end of surgery operation.~Blocking vagus nerve above the aortic vein on the right side of the trachea with 1% lidocaine 1ml+0.375% ropivacaine 1ml after exposing the pleural apex."
33917|NCT03919773|Drug|IVIG|"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."
33918|NCT03919773|Drug|Albumin|This will be the matching placebo used in the study.
33919|NCT03919760|Behavioral|NAVIGATE|"NAVIGATE was developed in consultation with clinical and research experts, biostatisticians, health economists, consumers, family members, advocacy groups, and government officials. It is a form of coordinated specialty care for first episode psychosis consisting of 4 key intervention components:~individualized medication management using a decision support tool;~a package of psychoeducation and a blend of evidence-based psychotherapies called individual resiliency training (IRT);~supported employment and education (SEE);~a family education program"
33920|NCT03919721|Behavioral|Applied Behavioral Analysis|Children are receiving Applied Behavioral Analysis therapy to treat their autism. Therapy is comprised of 15-20 discrete programs that are intended to shape specific behaviors. Tutors collect data on child's performance towards goals. For each child, some of the programs will be tracked with paper data collection methods, others will use electronic data collection. This study is to test the usefulness of the electronic data collection system to replace paper in existing interventions.
33921|NCT03919708|Device|Retinal Birefringence Imager|Device is a hand-help object approximately the size of a brick, and is held, by the user, 30cm away from the patient/subject. The subject peers in to an aperture that includes a fixation target that is in the shape of a smiley face. During this time, a ring of LED lights illuminates the eye and captures an image of the retina in approximately 3 seconds. The results instantaneously identify the presence of amblyopia / strabismus.
33922|NCT03919695|Behavioral|Behavioral and Structural Intervention|"The intervention has two components; a structural component and a behavioral component.~Structural component: This component is about receiving work payments via mobile money instead of cash.~Behavioral component: This component includes feedback on alcohol screening, counseling, client-centered goal setting, self-monitoring, financial literacy training, and text message reminders of life/savings and healthy living goals."
33923|NCT03919695|Behavioral|Screening and Referral|Alcohol screening and referral
33960|NCT03919396|Device|Breath-O orthokeratology lenses|"Specially designed rigid gas permeable lenses which~reshapes corneal profile for myopia control~has higher elasticity compared to traditional lens material."
33924|NCT03919682|Other|Experimental: Training, Phase 1|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
33925|NCT03919682|Other|Experimental: Training, Phase 2|Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
33926|NCT03919669|Drug|All Subjects|All subjects will be given the experimental tau PET radioligand [18F]MK-6240
33927|NCT03919656|Drug|Dapagliflozin 10 mg|Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
33928|NCT03919656|Drug|Placebo Oral Tablet|Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
33929|NCT03919630|Other|Thrust Mobilization|Once therapist has assessed subject and has found the patients most comparable sign they will be performing a high velocity thrust at the end of the patients available range, as described by Maitland's Approach. The thrust will be performed only once. The therapist will perform either a localized cervical rotation thrust which primary movement is rotation or a longitudinal cephalad C1 and C2 thrust, both targeting the upper cervical spine
33930|NCT03919630|Other|Non-Thrust Mobilizations|Therapists will perform unilateral posterior to anterior mobilization (UPA) or central posterior to anterior (CPA) mobilizations grades I-IV as described above by Maitland concepts at levels C0-C3 which reproduce the patient's most comparable sign. Therapists will be instructed to perform 3x 30 second bouts of mobilizations at that level.
33931|NCT03919617|Drug|REMD-477|4-Week, open-label, once weekly subcutaneous injection with 70mg REMD-477.
33932|NCT03919604|Procedure|Extracorporeal Life Support|Any extracorporeal blood treatment technique for respiratory and/or cardiac support
33933|NCT03919591|Other|Challenge virus RSV-A Memphis 37b|Each subject will receive one titre of virus, which will be up to approximately 4.5 log10 PFU.
33934|NCT03919578|Biological|Recombinant Hepatitis B vaccine|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from Serum Institute of India and then formulated and filled at Bio Farma.
33935|NCT03919578|Biological|Recombinant Hepatitis B (Bio Farma)|Recombinant Hepatitis B vaccine is an inactivated HbsAg produced in yeast cells (Hansenula polymorpha) using recombinant DNA technology. It is a whitish liquid produced by culture genetically engineered yeast cell which carry the relevant gene of the HbsAg. The inactivated HbsAg (bulk) is imported from The Janssen Vaccine Corp and then formulated and filled at Bio Farma.
33936|NCT03919565|Drug|Tenofovir Disoproxil Fumarate|Patients would receive oral Tenofovir Disoproxil Fumarate 300mg once per day.
33937|NCT03919565|Drug|Peginterferon Alfa-2a|Patients would receive subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.
33938|NCT03919565|Drug|Peginterferon Alfa-2b|Patients would receive subcutaneous injection of Peginterferon Alfa-2b 80 μg once per week.
33939|NCT03919552|Drug|Docetaxel,Carboplatin|Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.
33940|NCT03919552|Drug|Docetaxel,Cisplatin|Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.
33941|NCT03919552|Radiation|Carboplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.
33942|NCT03919552|Radiation|Cisplatin-based concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
33943|NCT03919539|Diagnostic Test|5hmc testing|NGS
33944|NCT03919526|Biological|anti-CD19/CD22 CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-CD22 CARs
33945|NCT03919526|Drug|Fludarabine|30mg/m2/d
33946|NCT03919526|Drug|Cyclophosphamide|300mg/m2/d
33947|NCT03919513|Device|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
33948|NCT03919500|Drug|EPO|Infants in EPO group are administered 500IU/kg intravenously within 72 hours after birth every other day for 2 weeks.
33949|NCT03919500|Drug|Normal saline|Infants in control group are administered normal saline with the same volume and period as EPO.
33950|NCT03919487|Procedure|Back to back colonoscopy|After first colonoscopy performing with polypectomy, the 2nd colonoscopy will be performed right after the 1st colonoscopy, and if the missed lesion during the 1st colonoscopy will be found, it should be removed.
33951|NCT03919474|Diagnostic Test|microvascular markers|follow up of microvascular biomarkers during patient follow up
33952|NCT03919461|Drug|Propranolol and etodolac|A perioperative combined drug regimen
33953|NCT03919461|Other|Placebo|Placebo
33954|NCT03919448|Biological|Bevacizumab|Single-dose infusion
33955|NCT03919435|Drug|Trimethoprim Sulfamethoxazole|Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks
33956|NCT03919422|Procedure|T2 paravertebral block|Ultrasound guided T2 thoracic paravertebral block is added in ICTP group. After interscalene brachial plexus block and superficial cervical plexus block have been administrated, selective 2nd thoracic nerve root(T2) will be blocked with 10 ml of 0.25% ropivacaine(naropin).
33957|NCT03919422|Procedure|interscalene brachial plexus block and superficial cervical plexus block|An ultrasound-guided IC block using an ultrasound machine (Sonosite, USA), and an linear array probe with a sterile cover and a 22G(Gauge) block needle is performed. An in-plane approach, advancing the needle along the longitudinal axis of the ultrasound transducer and visualizing the entire shaft is employed. Twenty ml of 0.375% ropivacaine(naropin) is injected around brachial plexus and 10 ml of 0.25% ropivacaine around superficial cervical plexus.
33958|NCT03919409|Drug|TS-161|TS-161 capsules
33965|NCT03919344|Other|Critical airway closure pressure (Pcrit) measurment|Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
33966|NCT03919331|Diagnostic Test|Assessment of tidal volume using Electrical Impedance Tomography (EIT) during high flow nasal canula(HFNC)|After information and consent, patients under HFNC for de novo acute hypoxemic respiratory failure will undergo a ten minutes 4cmH2O continuous positive airway pressure(CPAP) test while monitored with 1)chest Electrical Impedance Tomography (EIT) 2) a pneumotachograph inserted on the ventilator circuit between the mask and the Y-piece and connected to a differential pressure sensor, and 3) respiratory inductance plethysmography (RIP). Airway flow signal will be acquired using an analog/digital converter and stored for further analysis with acknowledge software. This will allow converting EIT data into tidal volume (TV), and estimating TV under HFNC. RIP signals will allow evaluating asynchronism between chest and abdomen by calculating the phase angle, thus quantifying respiratory distress. Patients monitored with an arterial catheter, arterial blood gas measurements will be done during CPAP and HFNC. These measures will be collected the first day of HFNC, and everyday up to three days
33967|NCT03919318|Other|Root Canal Filling Sealers|Root Canal Obturation
33968|NCT03919292|Drug|Neratinib|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion). Doses of Neratinib are escalated in small groups of patients during the dose expansion portion of the study.
33969|NCT03919292|Drug|Divalproex Sodium|Combination of Neratinib and Divalproex Sodium (Valproate) will be given to patients with advanced solid tumors (dose escalation) and Ras-mutated cancers (dose expansion).
33970|NCT03919279|Device|active tVNS|tVNS using TENS device from Schwa-Medico (TENSeco2) + auricular electrode applied on the left ear (Schwa-Medico) + conductive gel class I; 25 Hz stimulation 1 hour daily for 1 month
33971|NCT03919266|Procedure|Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy
33972|NCT03919266|Procedure|Control: usual antibiotic treatment|usual antibiotic treatment
33973|NCT03919253|Combination Product|pyrotinib maleate tablets+nab-paclitaxel|pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
33974|NCT03919240|Biological|CAR T-cell therapy|Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
33975|NCT03919227|Procedure|empty bladder before inserting UAS|In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.
33976|NCT03919227|Procedure|do not interfere with the filling degree of bladder|In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
33977|NCT03919214|Other|Automated Messaging|This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg.
33978|NCT03919201|Other|Resistance band exercise intervention|Resistance band exercise intervention (12 weeks, 5x per week, 60 minutes per day)
33979|NCT03919201|Other|No exercise intervention group|Control group: no exercise intervention
33980|NCT03919188|Procedure|computer adjusted air temperature control to minimize Body Heat Loss (BHL) compared to current|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): First parameter : computer adjusted air temperature control to minimize Body Heat Loss (BHL) compared to current
33981|NCT03919188|Procedure|air temperature control (ATC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): second parameter : air temperature control (ATC)
33982|NCT03919188|Procedure|skin servocontrol (SSC)|Currently there are no guidelines for setting incubator parameters. The Cochrane database point out for further research (Sinclair, 2002). The investigators aim at evaluating 3 different incubator settings for the INOTHERM incubator (Mediprema, France): Third parameter : skin servocontrol (SSC).
33983|NCT03919175|Drug|Umbralisib|Umbralisib is an investigational drug which blocks a protein called PI3K. PI3K is a protein that plays a role in the way cells grow. In this type of cancer, PI3K is increased and more active than usual. This helps the cancer cells to grow and survive.
33984|NCT03919175|Drug|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
33985|NCT03919162|Drug|PQ912|PQ912 150 mg tablets
33986|NCT03919162|Other|Placebo|Placebo tablets to mimic PQ912 150 mg tablets
33987|NCT03919136|Device|Wrist-worn measurement device (LiveMetric)|Evaluation of the wrist-worn measurement devices accuracy referenced to interventional (A-line) measurements.
33988|NCT03919123|Other|Evaluation of laparoscopic promontofixation|Evaluation of Functional Outcomes and Quality of Life After Laparoscopic Promontofixation (PFL). Unicentric Retrospective Cohort Study (PeSuLife)
33989|NCT03919110|Diagnostic Test|Collection of biological samples|"Investigators are building a collection of biological samples to perform biological assays and multiple analyses so-called omics: genomics (on the entire genome), proteomics (on all proteins) etc...This will make it possible to identify the genetic mutations or biological markers present or absent in these diseases, making it possible to confirm a diagnosis or to eliminate differential diagnoses."
33990|NCT03919097|Other|Medical Data extraction|Data extraction from the patient's Medical Files
34139|NCT03917797|Biological|MSC treatment|Umbilical cord-derived Mesenchymal Stromal Cell
33991|NCT03919084|Other|THRIVE screening and referral|The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
33992|NCT03919084|Other|Pharmacy Care Program services|Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
33993|NCT03919084|Other|Patient Navigation Services|In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
33994|NCT03919084|Other|Motivational Interviewing|Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
33995|NCT03919084|Other|Linkage to Community Partner Organization|The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
34001|NCT03919058|Other|Baseline activity (control regime)|This is a baseline measurement of physical activity during which subjects will be instructed not to change activity patterns during four days and to note all activities they perform.
34002|NCT03919058|Other|Increased sitting time (sit regime)|Participants have to spend 14h of their day sitting, 1h walking and 1h standing, for four consecutive days. According to the compendium of Ainsworth et al. (2011), this corresponds with a daily workload of activities (DWA) of 27 metabolic equivalents (MET's) per day.
34003|NCT03919058|Other|Non-exercise physical activity (sit less regime)|Each day (4 days in total) will consist of 3h walking, 4h standing and 9h sitting. These time frames are chosen to result in a comparable DWA increase as the exercise regime compared to the sit regime (+7 MET's)27. The additional 2h of walking and 3h of standing, compared to the sitting regime, will be done in a minimum of four bouts with a time interval of > 1h. The subjects will be instructed to walk on a slow pace. i.e. 2-3 km/h (e.g. walking during shopping and work related walking in an office).
34004|NCT03919058|Other|Structured exercise (exercise regime)|One hour of sitting in the sit regime will be replaced with 1 training session (1h) on a cycle ergometer in the research center. The remaining hours of each day (4 days in total) have to be spent as follows: 13h sitting, 1h walking and 1h standing for daily care. The intensity of the training session (50-60% of Wmax) results in a DWA of 34.5 MET's according to the compendium of physical activities. Duration of training sessions will be adapted individually with ActivPAL data of the sit less and sit regime to identically match DWA increase between the sit less and exercise regime, compared to the sitting regime.
34005|NCT03919045|Drug|Saline injection|Half of the patients will be randomized to saline injections into the neck and head muscles
34006|NCT03919045|Procedure|Placebo|Half of the group will be treated with needle stings without injections
34007|NCT03919032|Other|This is an observational study without intervention|This is an observational study without intervention
34008|NCT03919019|Other|Macuprev Group|oral supplementation (Macuprev) 2 capsules per day for 6 months
34009|NCT03919019|Other|Placebo Group|oral placebo 2 capsules per day for 6 months
34010|NCT03919006|Other|non surgical periodontal treatment|SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
34011|NCT03919006|Other|Gingival crevicular fluid, saliva and serum collection|GCF with filter paper using the intracrevicular method, saliva and serum collection
34012|NCT03918993|Drug|Tadalafil 5mg tablet|Once-a-day 5 mg dose of tadalafil for 8 weeks
34013|NCT03918980|Drug|LOU064|LOU064 will be administered as oral capsules in parts 1 to 6.
34014|NCT03918980|Drug|Placebo|Matching placebo capsules will be administered in parts 1,2, 4 and 6.
34015|NCT03918967|Drug|CT-G11|Multiple dose, oral tablet of CT-G11 Experimental Drug
34016|NCT03918967|Drug|CT-G20|Single dose, oral tablet of CT-G20 Experimental Drug
34017|NCT03918967|Drug|CT-G11 Placebo|Multiple dose, oral tablet of Placebo
34019|NCT03918954|Device|Virtual sensory room|A pair of virtual reality glasses (Oculus Go) with installed the program Calm Place, a program designed for anxiety reduction.
34020|NCT03918954|Other|Sensory room|A room with calming elements that patients can use to feel calm.
34021|NCT03918941|Device|Carey|mobile application
34022|NCT03918941|Other|conventional information|leaflet, internet link and oral information
34023|NCT03918915|Drug|SYD-101 Dose 1|Sterile topical ophthalmic solution
34024|NCT03918915|Drug|SYD-101 Dose 2|Sterile topical ophthalmic solution
34025|NCT03918915|Drug|Vehicle|Sterile topical ophthalmic solution without active ingredient
34026|NCT03918902|Behavioral|Qestinnaires|Questionnaires
34027|NCT03918889|Drug|Dexmedetomidine Injectable Product|dexmedetomidine infusion at 0.5 µg•kg−1 for 10 min before tracheotomy then adjusted to 0.3µg•kg−1•h−1
34028|NCT03918889|Drug|Midazolam injection|midazolam infusion at 0.05 mg•kg−1 ten minutes before tracheotomy then adjusted to 0.02mg•kg−1•h−1
34029|NCT03918863|Other|Neuromuscular electrical stimulation|Exercise protocol associated with neuromuscular electrical stimulation on vastus medialis and gluteus medius. Parameters: rectangular pulse shape, biphasic, symmetrical, pulse duration of 200μs, interbust interval of 10ms and frequency of 2.500Hz modulated in 50 bursts.
34030|NCT03918863|Other|Exercise|Same protocol of exercises of the other group, without association of electrical stimulation.
34031|NCT03918850|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
34032|NCT03918850|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
34033|NCT03918837|Other|Sham rTMS|Participants will undergo sham rTMS for five days with two daily fifteen minutes rTMS sessions.
34034|NCT03918837|Other|Active rTMS|Participants will undergo active rTMS for five days with two daily fifteen minutes rTMS sessions.
34035|NCT03918824|Other|Data extraction from medical files|Data extraction from medical files
34036|NCT03918811|Procedure|Positive Pressure Extubation Technique|Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
34037|NCT03918811|Procedure|Traditional Extubation Technique|Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
34038|NCT03918798|Drug|Chloroprocaine 1% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
34039|NCT03918798|Drug|Chloroprocaine 2% Injectable Solution|All the eligible patients will be administrated by Chloroprocaine 1 % according to the randomization criteria.
34040|NCT03918785|Dietary Supplement|Rice germ|25 g twice a day.
34041|NCT03918785|Dietary Supplement|Wheat-based supplement|25g twice a day.
34042|NCT03918746|Behavioral|internet Attachment-Based Compassion Therapy (iABCT)|"The internet version of Attachment-Based Compassion Therapy (iABCT) will be developed to be totally self-applied over the Internet through the website www.psicologiaytecnologia.com designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and University of Valencia). The iABCT will consist of eight sequential modules: Module 0) Welcome module: approaching to the compassion; Module 1) Preparing ourselves for compassion. Kind attention; Module 2) Discovering our compassionate world; Module 3) Developing our compassionate world; Module 4) Understanding our relationship with compassion; Module 5) Working on ourselves; Module 6) Understanding the importance of forgiveness; Module 7) Consolidating the practice of compassion~The content will present through texts, audios, videos, pictures, vignettes, and interactive exercises. Downloadable PDF files will be available so that users can review them offline."
34043|NCT03918733|Procedure|surgical treatment|surgical treatment will be done of failed root canal treated teeth
34044|NCT03918733|Procedure|Non surgical retreatment|Non surgical retreatment will be done.
34045|NCT03918720|Behavioral|Trekkers Family Health Empowerment Programme|Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
34046|NCT03918707|Diagnostic Test|Rapid Whole Genome Sequencing (rWGS)|rWGS will be performed on blood samples from subjects in the prospective group in addition to standard of care laboratory testing and imaging studies. Blood samples will also be obtained from biological parents (if available), to determine if variants are inherited or de novo and for variant segregation.
34047|NCT03918694|Dietary Supplement|Vitamin C|Daily use of Vit C tablets
34048|NCT03918694|Dietary Supplement|Placebo|Daily use of placebo tablets
34049|NCT03918681|Other|Therapeutic Intervention|Instruction for all participants in the experimental group will begin with transitioning foot strike pattern from a rearfoot strike to a non-rearfoot strike running pattern (NRFS) and increasing preferred step rate by 5-10%. Each participant program thereafter will be progressed individually according to the clinical investigators follow up assessments of running mechanics and participant pain and function with running. Intervention gait retraining sessions will include drills for reinforcement to include soft landing single leg bounding, adequate time to practice, and pre-class and post-class video assessment with feedback.
34050|NCT03918668|Behavioral|Women with recent diagnosis of breast cancer|To evaluate dietary habits of a group of women with pre and post-surgical breast cancer
34051|NCT03918642|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
34052|NCT03918642|Behavioral|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
34053|NCT03918629|Biological|Clostridium difficile|Toxoid-based Clostridium difficile vaccine
34054|NCT03918629|Biological|Placebo|Normal saline solution (0.9% sodium chloride)
60407|NCT03712202|Drug|Vinblastine|Given IV
34055|NCT03918616|Drug|Memantine, Dopamine receptor-agonists|The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.
34056|NCT03918603|Other|ventral décubitus|Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
34057|NCT03918590|Drug|nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)|NSAID
34058|NCT03918590|Drug|Theratears tear drop, (Akron, Ann 111 Arbor, MI)|preservative-free Artificial Tears
34059|NCT03918590|Other|patching|no drug/ patching
34060|NCT03918577|Other|Caloric Vestibular Stimulation|Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
34061|NCT03918564|Device|Laparoscopic Gastric Vest (LGV)|"The Laparoscopic Gastric Vest (LGV), branded the ReShape Vest™, is a long-term, silastic, implantable system that is placed around the stomach to encompass the gastroesophageal junction to the Incisura Angularis.~The main materials used to make the LGV is Implant Grade Silicone (95%) and Barium Sulfate (5%).~The LGV is indicated for weight reduction for obese people with a Body Mass Index (BMI) between ≥35 kg/m2 and ≤55 kg/m2. It is indicated for use in adult patients (≥22 to ≤65 years) who have failed one or more conservative weight reduction alternative(s), such as supervised diet, exercise, and behavior modification program(s)."
34062|NCT03918551|Drug|Febuxostat|Febuxostat is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 120 mg of febuxostat.
34063|NCT03918551|Drug|Adenuric|Adenuric is manufactured by Menarini - Von Heyden GmbH, Germany (MAH: Menarini International Operations Luxembourg S.A., Luxembourg). Each film-coated tablet contains 120 mg of febuxostat.
34064|NCT03918538|Behavioral|Home rehabilitation exercise program|After pre-test, the intervention participants received a 60 minutes of teaching regarding the home rehabilitation exercise program, with a printed exercise manual. The intervention participants also received a weekly phone call from the interventionist to enhance their exercise adherence and helping to overcome exercise barriers.
34065|NCT03918525|Other|Sindhi families|It is an observational study and no intervention is involved
34066|NCT03918512|Other|nine online self-administered questionnaires|"patients will be invited to complete the following nine online self-administered questionnaires at baseline, 7 days and 3 months:~Demographical and clinical characteristics at baseline~Consolidated version of the CSS-48 questionnaire~Lumbar pain numeric rating scale (NRS)~Radicular pain NRS~Zurich Claudication Questionnaire (ZCQ) (physical function subscale)~Oswestry Disability Index (ODI)~Fukushima LSS Scale 25 (FLS-25)~12-Item Short Form Health Survey (SF-12)~Anchoring questions : 1 anchoring question about patient acceptable symptom state (at baseline, 7 days and 3 month) and 1 anchoring question about patient minimal clinically important difference (at 3 months)."
34067|NCT03918499|Drug|Cyclophosphamide|Given IV
34068|NCT03918499|Biological|IRX-2|Given SC
34069|NCT03918499|Biological|Pembrolizumab|Given IV
34070|NCT03918486|Device|Caretaker|Application of Caretaker device to subjects that are scheduled for elective surgeries.
34071|NCT03918473|Other|Mobilization with Movement|The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.
34072|NCT03918473|Other|Thrust Mobilization|The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
34073|NCT03918460|Device|ANEUFIX|ANEUFIX is administered through translumbar injection into the AAA using imaging techniques to guide the place of injection.
34074|NCT03918447|Drug|Bardoxolone methyl oral capsule|Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
34075|NCT03918447|Drug|Placebo oral capsule|Capsule containing an inert placebo
34076|NCT03918421|Other|Clinical examination and patients' questionnaires regarding activity and participation (preliminary Immunogloblin M (IgM)-Rasch-built overall Disability Scale (RODS), and finalized IgM-RODS)|Rasch-built overall Disability Scale (RODS) is a disease-specific, patient-based, linearly weighted scale that captures activity and social participation limitations to detect activity limitations in patients with Immunogloblin M (IgM) anti-myelin-associated-glycoprotein peripheral neuropathy. For this study, the preliminary RODS is a 146 item patient-reported outcome instrument that assesses activity and social participation limitation. Rasch Measurement Methods examine the extent observed data (patients' actual responses to scale items) accord with predictions of those responses from a mathematical model.
34077|NCT03918408|Combination Product|PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution|Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
34078|NCT03918395|Dietary Supplement|Placebo beverage|A placebo beverage will be consumed both post-exercise and pre-bed
34079|NCT03918395|Dietary Supplement|Protein-polyphenol beverage|A protein-polyphenol beverage will be consumed both post-exercise and pre-bed
34080|NCT03918382|Other|Electronic Patient-Reported Outcome|Weekly reporting of patient-reported outcomes on a tablet for closer contact between patient and clinic during radiotherapy.
34140|NCT03917797|Drug|Standard of Care|Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate
34141|NCT03917797|Drug|Placebo|MSC infusion vehicle
62299|NCT03697564|Drug|Cabiralizumab|4mg/kg IV on day 1 and 15 Q4W
34081|NCT03918369|Procedure|Laparoscopic right hemicolectomy with intracorporeal anastomosis.|Intracorporeal anastomosis group The laparoscopic right hemicolectomy with intracorporeal mechanical side-to-side isoperistaltic anastomosis. In this procedure, intracorporeal division of the mesoileum and transverse colon is performed, as shown in the animation. The ileum and transverse colon are divided with the Endopath® Echelon Flex ™ 60 stapler. The specimen is inserted in a plastic bag. Side-to-side isoperistaltic mechanical anastomosis is performed using the same endostapler. A running suture is performed of the mechanical suture orifice, with another reinforcing suture with Monocryl ™ (poliglecaprone 25) or with STRATAFIX ™ Spiral Knotless barbed suture. The specimen is extracted through a Pfannestiel minilaparotomy (3.5-4 cm) Wound Protector
34082|NCT03918369|Procedure|Laparoscopic right hemicolectomy with extracorporeal anastomosis.|Laparoscopic right hemicolectomy with extracorporeal anastomosis with the technical features of each center
34083|NCT03918356|Device|electrical impedance myography|Electrical impedance myography (EIM) is a new electrodiagnostic method of quantitative muscle evaluation. It utilizes concepts of bio impedance, the ability of biological tissue to impede externally applied electrical current.
34084|NCT03918356|Other|healthy control group|healthy control
34085|NCT03918343|Other|Blood sample|blood samples (4 times; 14ml per visit)
34086|NCT03918317|Device|AirXpanders AeroFormtissue expander|The AeroFormdevice will be placed in an immediate fashion at the time of mastectomy in a submuscular, prepectoral or dual-plane approach. The tissue expander will be minimally inflated intraoperatively to minimize dead space and while facilitating tension free closure. Participants will undergo standard postoperative management, and will be given instructions on utilization of the device, including daily expansion until desired volume is reached as determined b surgeon and participant agreement.
34087|NCT03918291|Other|Addition of whole-body vibration to squat training|
34088|NCT03918291|Other|Squat training|squatting exercises for 12 weeks, 3x/week
34089|NCT03918278|Biological|MK-0482|IV infusion
34090|NCT03918278|Biological|pembrolizumab|IV infusion
34091|NCT03918265|Drug|Tacrolimus|On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
34092|NCT03918252|Drug|Nivolumab Injection|Receive preoperative nivolumab, 240mg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
34093|NCT03918252|Drug|Ipilimumab Injection|Receive preoperative nivolumab, 3mg/kg IV, on Day -42, -28 and Day -14 (+/- two days for each timepoint) + ipilimumab 1mg/kg IV on Day -42 prior to planned surgery on Day 0 (to allow for scheduling surgery may take place between Day -3 and Day +10).
34094|NCT03918239|Drug|SHP643|Participants will receive injection of SHP643.
34095|NCT03918226|Procedure|exploratory laparotomy|Patients presenting with acute abdomen were operated. Exploratory Laparotomy of patients was done. Further procedure was done according to peroperative findings. Ileostomy for perforation of gut, stricturoplasty for strictutre, biopsy for mesentric lymphadenopathy
34096|NCT03918213|Diagnostic Test|High-Resolution anorectal manometry with the use of solid-state catheter|High resolution anorectal manometry with the use of solid-state catheter will be performed to eligible subjects willing to participate in the study
34097|NCT03918200|Other|Serum amyloid A level|For determination of SAA level, a 5-ml sample of venous blood will be taken from each participant under aseptic conditions, and centrifuged at 2500 g for 15 minutes at 4°C c. separated into serum aliquots,and stored frozen at −80°C until analysis of SAA ,which will be done by a double-antibody sandwich Enzyme Linked Immunosorbent Assay (ELISA) kits supplied by cusabio,USA according to manufacturers instruction .Each sample was tested in duplicate and the average will be taken. A cut off level of 30 mg/L SAA level will be chosen to reflect a real increase in its level
34101|NCT03918174|Device|Dart splint orthosis|The Dart Splint orthosis was fitted to the subjects in the research group on their first evaluation session. They received oral and written instructions regarding the donning and manner of exercise. Specifically, they were instructed to use the Dart splint orthosis at home. For each 10-minute exercise session, they were asked to perform 5 minutes of radial-extension under resistance and then 5 minutes ulnar-flexion under resistance. In addition, this group was required to fill in a chart at the end of each practice session (morning, noon and evening), throughout the intervention period.
34102|NCT03918174|Other|Conventional treatment|The control group activated the wrist mostly in the sagittal plane. This group was instructed to perform at home active wrist motion similar to that practiced during the supervised therapy sessions. The prescribed instructions were similar to the exercises performed during the sessions. Specifically, they were instructed to exercise at home for 10-minute in each session, three times a day (morning, noon and evening), throughout the intervention period.
34103|NCT03918161|Device|MRE exam|Magnetic Resonance Elastography
34104|NCT03918148|Drug|SGLT-2i|Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
34105|NCT03918148|Drug|DPP-4i|Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
34106|NCT03918135|Drug|Paracetamol|"1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 100 patients~Other Names:~Perfalgan~Paracerol"
34107|NCT03918135|Drug|Ibuprofen|"400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen"
34108|NCT03918122|Other|Self-Assessment via pre and post survey|Master Preceptor Fellows will assess and evaluation professional development, knowledge, clinical practices and master preceptor knowledge before the Master Preceptor Fellowship and After completion of the Master Preceptor Fellowship
34109|NCT03918109|Drug|OTO-313|single intratympanic injection of gacyclidine
34110|NCT03918109|Drug|Placebo|single intratympanic injection of placebo
34111|NCT03918096|Other|Questionnaire|Questionnaire to the parents after the hospital discharge
34112|NCT03918083|Behavioral|Wellness|Assess the feasibility of an integrated, prescriptive, and trackable wellness intervention amongst residents at Orange Park Medical Center (OPMC) by combining five wellness elements including: exercise, mindfulness, sleep, social connectedness, and nutrition.
34113|NCT03918070|Device|Yukon Choice PC and Yukon Chrome PC|The Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease.
34114|NCT03918057|Behavioral|Cognitive Behavioural Therapy for Insomnia|Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.
34115|NCT03918057|Other|Active Control|Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
34116|NCT03918031|Behavioral|PFI for Smoking & Distress Tolerance|Personalized Feedback Intervention for smoking and distress tolerance.
34117|NCT03918031|Behavioral|PFI for Smoking Only|Personalized Feedback Intervention for smoking only (no distress tolerance component)
34118|NCT03918018|Device|BORA Band SpO2 Validation Study|"Qualified healthy volunteers will be enrolled into the study. Subjects will recline for the study. Reference sensor(s) will be placed on each subject to evaluate the SpO2 accuracy and performance. Shield material may be used between any adjacent finger sensors to prevent optical crosstalk.~Simultaneous data collection will be set up for device under test and the control pulse oximeter. The data from the test device will be collected by the sponsor or trained Clinimark Study staff. Data will be collected for 1 second intervals data analysis. The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.~The investigational device will only be placed on the wrist. The control pulse oximeter may be alternated through fingers between subjects."
34119|NCT03918005|Other|Low glycemic load diet|Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
34120|NCT03917979|Behavioral|Individual GIM|Participants are provided with a series of 10 individual GIM sessions, scheduled once every two weeks. Frequency may change if clinically indicated. Individual GIM sessions begin with a discussion of important issues related to the client's life and symptoms, forming a focus for the session. Then, the therapist provides suggestions to help the client become highly relaxed and focused in preparation for the music-listening portion of the session. The therapist plays specially-selected music from the Western classical tradition to match the client and the focus for the session, and engages in verbal dialogue with the client to help them explore their own internal imagery while listening to the music. After the music ends, the therapist and client engage in discussion about their imagery in metaphoric connection to their therapeutic process. This may include arts-based approaches to process the session. Sessions last approximately 90-120 minutes.
34121|NCT03917979|Behavioral|Waitlist Control|Participants complete an initial wait list period of 26 weeks, equivalent to the treatment and 6-week follow-up period for the experimental arm. They are then provided with four Group GIM sessions scheduled once per week. Group GIM sessions start with a group discussion about events or feelings from the week and issues related to depression and wellbeing. Then the therapist provides suggests to help the clients relax and focus in preparation for the music-listening period. Group members will explore a theme or issue related to therapy while focusing on whatever comes to them as the music is played. After the music, there will be a time to work with the imagery experienced during the music. This may be in the form of discussion or other art forms. The session ends with a discussion about gains and insights from the music and imagery. Sessions last 90-120 minutes.
34122|NCT03917966|Drug|SHR-1210+Paclitaxel+nedaplatin|neoadjuvant chemotherapy:SHR-1210, 200mg,q2w, a total of 3 times; paclitaxel 135-200mg/m2 ivgtt d1, nedaplatin 75mg/m2 ivgtt d1, q3w, for 2 cycles.The patient was evaluated after 2 cycles of neoadjuvant chemotherapy. The surgery was performed 3-4 weeks after the completion of neoadjuvant chemotherapy.
34123|NCT03917953|Device|Transcutaneous Electrical Acupoint Stimulation|"Patients in the experimental group will be treated for 20 min TEAS, twice a week, for a total of 4 weeks of treatment.The same intervention was performed in the sham group (electrode patches were attached at corresponding acupointswithout electroacupuncture stimulation).~Acupoint selection: baihui (DU20), taichong (LR3), taixi (KI3)."
34124|NCT03917940|Dietary Supplement|Omega 3 fatty acids 1000 mg per day + glimepiride 2 mg or 3 mg oral|Omega 3 fatty acids 1000 mg per day oral
34125|NCT03917940|Drug|Glimepiride|glimepiride 2 mg or 3 mg per day oral
34126|NCT03917927|Device|Eztetic dental implant|narrow diameter dental implant
34127|NCT03917914|Drug|Bisoprolol|As in arm description
34128|NCT03917914|Drug|Placebo Oral Tablet|As in arm description
34129|NCT03917901|Other|Anxiety Sensitivity Training|Computerized Single-Session Anxiety Sensitivity Reduction Program
34130|NCT03917901|Other|Health Control|Computerized Single-Session Health Information Control
34131|NCT03917888|Diagnostic Test|lung ultrasound|lung ultrasound will be performed daily in mechanically ventilated patients after 48 hours of ventilation to screen for ventilator associated pneumonia
34132|NCT03917875|Behavioral|Personalized feedback intervention|The novel integrated PFI will be developed and modeled from past PFIs targeting hazardous drinking. Participants will view feedback on the computer screen. The computer program/algorithm will determine the proper normative feedback to participants.
34133|NCT03917862|Combination Product|TDM-621|The TDM-621 is a topic hemostatic product which will be used during ascending aortic surgery.
34134|NCT03917849|Behavioral|Exercises program for patellar tendinopathy|To compare the effectiveness of the inertial flywheel resistance program versus slow heavy resistance in patients with chronic patellar tendinopathy
34135|NCT03917836|Diagnostic Test|endoscopy and histology|diagnostic evaluation of chronic gastritis
34136|NCT03917823|Device|Cryoneurolysis|The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods for the target intercostal nerves.
34137|NCT03917823|Device|Sham comparator|For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
34143|NCT03917784|Drug|Starch|Oral supplementation with starch 500 mg oral dosing for 3 months
34144|NCT03917771|Other|Early lymphedema detection|Face-to-face consultation in Rehabilitation for early detection of lymphedema after surgery (1,6,12 months). Lower Limb measurement and care education
34145|NCT03917771|Other|Usual follow-up|Usual follow-up carried out in GO consultation
34146|NCT03917758|Drug|SGLT2 inhibitor|Start of the treatment with SGLT2i.
34147|NCT03917745|Behavioral|eHealth mindfulness intervention|The web-based intervention consists of eight sessions including psycho-education about the mechanisms of stress, coping and relaxation, especially related to pregnancy, practicing mindfulness skills (i.e. mindful breathing, mindful moving, observing and letting-go of thoughts and emotions with a non-judgmental attitude), sharing experiences, and doing home assignments. The sessions have been developed specifically for pregnant women and acknowledge pregnancy-related distress. An online coach will review questions and home assignments of the participants. Women will start the training at 16 weeks gestation.
34148|NCT03917732|Behavioral|cognitive training|"The cognitive training the investigators are planning consists of three modules which, in their entirety, are intended to help improve bladder dysfunction, which leads to psychological distress in patients: psychoeducation, training of cognitive functions and training in behavioural therapeutic techniques.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
34149|NCT03917732|Behavioral|pelvic floor training|"At the beginning of the training, perception of the pelvic floor is the most important factor. The patients should learn the motor skills to consciously perceive and feel the pelvic floor muscles. This requires a lot of concentration and movement control. After this perception phase, the learned movements are internalized. The fine coordination of the pelvic floor muscles is more harmonious and the tensing and relaxing of the muscles becomes easier over time. In the last phase of the training, the movements and muscle activations should be internalised in such a way that they are anchored as automated movement patterns.~The training will take place over six weeks, with two sessions per week in the first three weeks. In the following three weeks the frequency will be reduced to once a week so that there will be 9 sessions. The duration of each training session is 90 minutes."
34150|NCT03917719|Drug|Edasalonexent|100 mg/kg/day
34151|NCT03917706|Other|Questionnaire|Patients will be contacted by phone in order to fill in a questionnaire regarding their quality of life.
34152|NCT03917693|Dietary Supplement|Phytin, rice extract|Consumption of a rice extract, called phytin for a period of 2 weeks
34153|NCT03917693|Other|MCC, placebo|Consumption of MCC, a placebo, for a period of 2 week
34154|NCT03917680|Diagnostic Test|Factor XII dosage|Factor XII (FXII, Hageman factor) will be measured in plasma. It is converted to FXIIa by an activator. The FXIIa protease cleaves a chromogenic substrate and releases p-nitroaniline (pNA), which can be measured photometrically.
34155|NCT03917680|Genetic|p.Thr328Lys mutation detection|Sequencing of exon 9 of franking introns of FXII, for identification of the p.Thr328Lys mutation.
34156|NCT03917680|Diagnostic Test|Videocapillaroscopy|It is an optical method to visualize the most superficial part of the cutaneous microcirculatory network. It provides morphological information.
34157|NCT03917667|Diagnostic Test|EWGSOP2|EWGSOP2 criteria (Writing Group for the European Working Group on Sarcopenia in Older People 2) will be followed to determine the diagnosis of sarcopenia, considered as a dichotomous variable -yes/no- in presence of low grip strength + low muscle mass + low gait speed.
34162|NCT03917641|Biological|Khat leaves|One of the two compressions (one per each eye) the patient will use will contain the Khat leaves.
34163|NCT03917628|Drug|SCT630|SCT630 single s.c. injection
34164|NCT03917628|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
34165|NCT03917615|Other|pelvic floor contraction|Ultrasound examination will be performed to asses urinary bladder displacement being a marker for pelvic floor muscle function
34166|NCT03917602|Procedure|human amniotic membrane plug with vitrectomy|using human amniotic membrane plug with vitrectomy to try to close large macular hole
34167|NCT03917576|Other|Behavioral|The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.
62419|NCT03696628|Other|echocardiography|heart testing
34168|NCT03917576|Other|Exercise training intervention|Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at ~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
34169|NCT03917563|Device|WATCHMAN LAA occluder|WATCHMAN LAA occluder
34170|NCT03917550|Behavioral|Recovery (Transdiagnostic & self)|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors. In addition, specific intervention designed to improve self-compassion, unconditional self-acceptance, self-esteem and self concept clarity were added.
34171|NCT03917550|Behavioral|Transdiagnostic|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
34172|NCT03917537|Genetic|HNSCC patients have used Nivolumab|Using Whole-Genome Analysis on Cancer Tissue of Patients with Platinum-refractory Head and Neck Squamous cell carcinoma Who Underwent Nivolumab to Precisely Predict Responders: An Observational Biomarker Study
34173|NCT03917511|Behavioral|Robotic training with mirror therapy|Participants will receive 18 intervention sessions for about 6 consecutive weeks in a clinical setting (1 hour per session, 3 sessions per week). For each intervention session, participants will first receive 20 minutes mirror therapy followed by 40 minutes robotic-assisted training (robotic-assisted training includes 10 minutes active/passive training mode and 30 minutes robot-participant interactive training mode).
34174|NCT03917511|Behavioral|Robotic-assisted training|The training procedure will be the same as the robotic-assisted training with mirror therapy group except that sham mirror therapy will be provided in the first 20 minutes in the intervention session.
34175|NCT03917498|Radiation|Single Pre-Operative Radiation Therapy - with Delayed Surgery|Single Pre-Operative Radiation Therapy - with Delayed Surgery
34176|NCT03917472|Drug|Brolucizumab|Intravitreal injection
34177|NCT03917472|Drug|Aflibercept|Intravitreal injection
34178|NCT03917459|Drug|LCZ696|LCZ696 50 mg = 24 mg/26 mg bid sacubitril/valsartan; 100 mg= 49 mg/51 mg bid sacubitril/valsartan or 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tablets
34179|NCT03917459|Drug|Enalapril matching placebo|Placebo to Enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets
34180|NCT03917459|Drug|Enalapril|Enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets
34181|NCT03917459|Drug|LCZ696 matching placebo|Placebo to LCZ696 50 mg = 24 mg/26 mg bid sacubitril/valsartan; 100 mg= 49 mg/51 mg bid sacubitril/valsartan or 200 mg = 97 mg/103 mg bid sacubitril/valsartan film-coated tabletsLCZ696 50 mg, 100 mg and 200 mg
34182|NCT03917446|Drug|Propofol bolus|Each patient gets propofol bolus in three doses. 0.25 mg/kg, 0.5 mg/kg and 1 mg/kg. After each dose patient's blood pressure, heart rate and haemodynamic values calibrated with PICCO device (cardiac output, cardiac index, stroke index, stroke volume, stroke volume variation, dPmax) are recorded in 15 seconds intervals for 10 minutes.
34183|NCT03917433|Behavioral|Virtual Reality Exposure Therapy|Participant completes virtual reality exposure therapy for acrophobia involving walking across a plank at higher and higher levels in a virtual city environment.
34184|NCT03917433|Behavioral|Tactile Feedback|In the real world, the participant walks across an actual wooden plank on the floor, which mirrors the plank in the virtual world.
34185|NCT03917433|Behavioral|Point-based Rewards|Participant has the opportunity to pop balloons upon reaching the ends of the plank to gain points. Participant's popping instrument in the virtual world upgrades as more points are accumulated.
34186|NCT03917420|Drug|Tenofovir 300Mg Oral Tablet|Once daily dose of the combo tab x 5 days pre-sampling
34187|NCT03917420|Drug|Emtricitabine 200 MG|Once daily dose of the combo tab x 5 days pre-sampling
34188|NCT03917407|Drug|DUR-928 (Moderate AH)|"A total of no more than two doses of DUR-928 will be given, with 72 hrs between each dose. A second dose of the assigned study treatment (test drug) will be repeated 3 days after Dose 1 to patients who are still hospitalized. If a patient meets the discharge criteria prior to Day 4, the patient will receive only one dose of DUR 928.~Patients of Part A (MELD 11-20) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~Cohort 1A: 30 mg of DUR-928in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 2A: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 3A: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion."
34189|NCT03917407|Drug|DUR-928 (Severe AH)|"Dose escalation to the next cohort will be determined after review of safety, tolerability and pharmacokinetic data of the previous cohort. Dose escalation for Part B will follow the same requirements as for Part A. The dose levels for Part B are planned to be the same as Part A.~Patients of Part B (MELD 21-30) will follow the dose escalation procedure based on cohort; each patient will receive an intravenous infusion dose of:~Cohort 1B: 30 mg of DUR-928 in 100 mL 5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 2B: 90 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion.~Cohort 3B: 150 mg of DUR 928 in 100 mL5% dextrose or 0.9% sodium chloride administered over approximately 2 hrs via IV infusion More details on preparation and administration of study drug will be provided in the Investigation Product Manual for this study."
34190|NCT03917394|Drug|rHuEPO|rHuEPO was administrated daily with 10000 IU or 20000 IU
34191|NCT03917394|Drug|Iron sucrose|Iron sucrose was administrated daily with 100mg or 200mg
34192|NCT03917381|Biological|GEN1046|GEN1046 will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
34193|NCT03917368|Other|Ultrasound scan of the internal jugular veins|Participants, lying at their hospital bed, will maintain their head in a fixed position on the longitudinal axis, while an operator gently places a linear probe L12-RS (7.5-11 MHz), smeared with gel, on one side of the neck, at the middle level. A 15-sec video clip of the ultrasound images will be recorded. This procedure will be repeated on the other side of the neck. In addition, three electrodes will be placed on participants' chests and connected to the ultrasound system for simultaneously measuring the ECG signal.
34194|NCT03917355|Behavioral|Nonverbal synchrony, therapeutic alliance|Association between motor synchronisation in psychiatrist/patient dyad and patient therapeutic adherence in patients with a first psychotic episode will be measured, 6 months after the first post hospitalisation consultation, using video without sound. Nonverbal synchrony, therapeutic alliance and treatment will evaluated.In this purpose, videos of patients and psychiatrist will be made (for all patients included), and the images will be analyzed.
34195|NCT03917342|Device|EEG measure|Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
34196|NCT03917329|Other|ACT and PBS group workshop|Acceptance and Commitment Therapy and Positive Behaviour Support Group Workshop. Three sessions of approximately three hour duration. Groups will consist of 5-10 parents or 5-10 members of education staff. The group will include both didactic and experiential elements.
34197|NCT03917316|Other|Language and neuropsychological tests|Tests related to language, narrative and specific and general cognitive function
34198|NCT03917303|Drug|Adalimumab|episodic treatment with subcutaneous adalimumab for 6 months
34199|NCT03917303|Drug|standard step-up care|conventional step-up care starting with corticosteroids
34200|NCT03917290|Behavioral|Neuromuscular training|Training will be conducted with a research assistant under the supervision of Dr. Howell (PI), a certified athletic trainer, who will meet with participants either at the individual or small group level (3-4 participants maximum). Training will be done within the Children's Hospital Colorado network-of-care locations, dependent on the location of participants.
34201|NCT03917277|Device|Musculoskeletal ultrasound|"Ankle sonographic examination will be performed using Samsung UGEO H60 ultrasound machine in use since 2016. In order to optimize reproducibility, all examinations will be performed by a single examiner. Multiplanar (longitudinal/transverse) scanning will be done in B- and PD-mode to identify pathologies defined by the OMERACT network in the following structures:~Talocrural joint:synovial fluid (scored 0-3);synovitis with synovial hypertrophy and PD signal (each scored 0-3); bone erosion with distance between cortices and presence/absence of DP signal~Tibialis anterior,tibialis posterior, extensor digitorum longus, fibularis brevis,fibularis tertius,and calcaneal tendons: presence/absence of tenosynovitis, thickening, hypoechogenicity, nodularity, fusiform aspect, and DP signal~Calcaneal enthesis: presence/absence of thickening,hypoechogenicity,calcification, cortical irregularity,and DP signal~Retrocalcaneal and calcaneal bursa: presence/absence of bursitis and DP signal"
34202|NCT03917264|Procedure|Peri-implantitis debridement|Mechanical cleaning of titanium implants, peri-implantitis debridement.
34203|NCT03917264|Other|Dental hygiene procedures|Titanium scalers and nylon brushed used for implant cleaning
34204|NCT03917251|Diagnostic Test|Coronary flow and pressure measurement in patients with ventricular pacing|Coronary flow and pressure measurement in patients with ventricular pacing
34205|NCT03917238|Radiation|gallium-68-exendin injection followed by PET/CT scan|After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
34206|NCT03917225|Drug|MIN-102|Once-daily dosing with a volume specified by the pharmacokineteic specialistto achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
34207|NCT03917225|Drug|Placebo|Once-daily dosing with a volume specified by the pharmacokinetic specialist. Oral Suspension.
34208|NCT03917212|Other|No intervention|No intervention, observational study with metabolic characterisation
34209|NCT03917186|Drug|Sevoflurane|administration of sevoflurane
34210|NCT03917186|Drug|Desflurane|administration of Desflurane
34211|NCT03917173|Procedure|Surgery plus HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin and cisplatin v
34212|NCT03917173|Procedure|Standard surgery|Standard surgery without HIPEC CO2
34213|NCT03917160|Device|EMS device|EMS treatment will be performed
34214|NCT03917147|Procedure|Office Hysteroscopy|Patients underwent office hysteroscopy with a 5-mm continuous-flow hysteroscope and endometrial biopsies were taken using miniaturized instruments. Histopathological examination was conducted to confirm the diagnosis.
34215|NCT03917134|Drug|cephalosporin + Metronidazole Vaginal|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and metronidazole vaginal ovules 500mg twice a day for 5 days after performing laparoscopic hysterectomy
34216|NCT03917134|Drug|cephalosporin + Placebos|administration of cephalosporin in doses of 2 grams administered intravenously before surgery and vaginal ovules of placebo twice a day for 5 days after performing laparoscopic hysterectomy
34217|NCT03917121|Device|Jet injector|"The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using Madajet XL injector as per the manufacturer's instructions.~A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
34248|NCT03916848|Procedure|Combined Micro-Macro SEEG Electrodes|The novel combined micro-macro electrodes will then be used during the surgical implantation procedure. The use of these novel electrodes will not change the surgical procedure, which is conducted using robotic assistance to ensure optimal accuracy. The macro electrode recordings will be used for routine clinical analysis and the duration of recording and subsequent analysis of the recordings will not be affected by the micro electrode data captured for research purposes. The clinical SEEG also involves electrical stimulation of the brain which will not be affected by the study.
34218|NCT03917121|Device|Needle attached dental syringe|"The injection site will be dried with a sterile cotton swab and benzocaine 20% topical anesthetic gel/ Opahl® (Dharma Research, Inc., Miami, FL, USA) will be applied to the site using a cotton applicator for 2 mins prior to injection.~Articaine hydrochloride 4% with epinephrine 1:100,000 anesthetic solution/ ARTINIBSA 4%® (Inibsa Dental S.L.U., Lliçà de Vall, Barcelona, Spain) will then be delivered using standard needle-attached syringe in a classical local infiltration.~A classical formocresol pulpotomy treatment procedure will be performed using formocresol/ Pyrocresol® (Pyrax Polymars, Roorkee, Uttarakhand, India) for fixation and polymer reinforced zinc oxide-eugenol/ Zinconol® (PREVEST DentPro, Digiana, Jammu, India) for restoration.~Primary and secondary outcome variables will be measured and recorded via selected tools at pre-specified time points.~All treated molars will be finally restored with stainless steel crowns or definitive restorations as indicated."
34219|NCT03917108|Device|retraction cord|retraction cord ( Ultra dent sizes #0, #00, #000 ) is placed in the gingival sulcus using blunt instrument and using cotton roll isolation.
34220|NCT03917108|Device|subgingival clamp|subgingival clamp (KSK clamps W8A, #44, #42, #43) or (Brinker clamps B5, B6) is placed to retract the gingiva with rubber dam isolation
34221|NCT03917095|Device|The Colonic Transendoscopic enteral Tubing.|The medications were infused into the colon through the Colonic Transendoscopic enteral Tubing(TET).
34222|NCT03917095|Drug|Glutamine|The medications were infused into the colon
34223|NCT03917095|Drug|Mesalazine|The medications were infused into the colon
34224|NCT03917082|Drug|Tamoxifen Citrate|current standard of care is 5 years endocrine therapy after early breast cancer. Intervention will test if 2 years is adequate for population with low recurrence risk based on genomic tissue based test
34225|NCT03917069|Drug|Chemotherapeutic Combinations|nab-paclitaxel 260mg/m2 d1+Carboplatin AUC=5 d1+ endostatin 15mg d1-14，q28d
34226|NCT03917069|Drug|chemotherapy|paclitaxel 175 mg/m2 d1+Carboplatin AUC=5 d1, q21d
34227|NCT03917056|Procedure|Cap-assisted endoscopic sclerotherapy using long needle|Participants were treated with CAES using long needle.
34228|NCT03917056|Procedure|Cap-assisted endoscopic sclerotherapy using short needle|Participants were treated with CAES using short needle.
34229|NCT03917043|Drug|APG-2449|Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
34230|NCT03917030|Procedure|Open flap debridement with osteoplasty|Treatment of furcation grade II defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to >90 degrees relative to the apico-coronal axis of the toot.
34231|NCT03917030|Procedure|Open flap debridement without osteoplasty|Treatment of furcation grade II defect with open flap debridement only.
34232|NCT03917017|Device|Radiomics and Watson artificial intelligence|"The artificial intelligence platform developed by IBM Watson can provide treatment decisions and corresponding theoretical basis to guide surgical decisions based on the key clinical data of liver cancer patients.~The imaging histology can be used to conduct intraoperative navigation surgical resection and treatment monitoring, and established a prognosis model to predict the prognosis of patients by grading the results of postoperative follow-up and microvascular invasion of pathological liver cancer, so as to better achieve accurate diagnosis and treatment of the disease."
34233|NCT03917004|Drug|Nitroglycerin|"The starting rate of nitroglycerin was 0.25 μg / kg / min and the mean arterial pressure (MAP) decreased to 80% of the baseline but not less than 70%.The drug infusion rate was adjusted so that the MAP was maintained in the range to the suture, and the administration was stopped and the blood pressure was gradually returned to the pre-depressurization level."
34234|NCT03916991|Other|Exercise|Hip focused Neuromuscular Activation Exercise
34235|NCT03916978|Biological|PRP|Autologous Platelet-rich Plasma injection into the ovaries.
34236|NCT03916978|Other|Placebo|Placebo injected into the ovaries.
34237|NCT03916952|Diagnostic Test|Six Minute Walk Test|The patients walked as far as possible for 6 minutes--over two separate trials. In one trial, an examiner walked with the participant. In the second trial, the participant walked independently. A paired T test was performed to see if there was a significant difference in the distance walked or gait speed between the trials.
34238|NCT03916939|Other|osteopathy|osteopathy treatment
34239|NCT03916939|Other|simulated osteopathy|simulated osteopathic sessions
34240|NCT03916926|Device|"A simple medical strategy consisting of silver diamine fluoride (SDF)"|Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL)
34241|NCT03916926|Device|"B typical dental strategy consisting of atraumatic restorative treatment (ART) with glass ionomer cement + Fluoride varnish (FV)"|GC Fuji (for ART) and FluoriMax Advantage Arrest, Elevate Oral Care LLC., West Palm Beach, FL (for FV)
34242|NCT03916913|Radiation|Local radiation therapy|Local radiotherapy on all sites of disease including primary and metastatic lesions
34243|NCT03916900|Procedure|Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
34244|NCT03916900|Procedure|Root canal treatment|Root canal treatment is an often straightforward procedure to relieve dental pain and save teeth. Patients typically need a root canal when there is inflammation or infection in the roots of a tooth. During root canal treatment, an endodontist who specializes in such treatment carefully removes the pulp inside the tooth, cleans, disinfects and shapes the root canals, and places a filling to seal the space.
34245|NCT03916887|Behavioral|Golf instruction|Non-golfers instructed to golf over 10 weeks
34246|NCT03916861|Device|Bioelectrical Impedance Analysis|We use Inbody S20 analysis to measure fluid status before each hemodialysis session to guide fluid removal.
34247|NCT03916861|Procedure|Physician-guided|This intervention used physical examination as guided to adjust fluid therapy together with the chart record of intake and output per day
34249|NCT03916835|Device|Pain evaluation ( FLACC scale) before and during the cleaning care with and without music therapy.|"Each child will benefit two cleaning cares during hospitalization. One with music therapy and the other without music therapy.~Every time, the preparation will be the same with an equipment installation in order to keep comparability and blind.~Child will be videotaped without sound during the care. The order of music therapy intervention will be randomized."
34250|NCT03916822|Diagnostic Test|Alloantigen-specific B-cells|Alloantigen-specific B-cells which express CD154 and their subsets which also co-express cytokines, memory and naive markers, and additional derivatives of these markers will be measured with flow cytometry
34251|NCT03916809|Other|EMST|Expiratory muscle strength training (EMST) is an exercise program designed to strengthen the muscles of expiration by increasing expiratory load during breathing exercises using either resistive or pressure threshold devices. The EMST150 is a commercially-available device considered non-significant risk (NSR). The EMST150 device will be used for this study.
34252|NCT03916796|Other|Exercise|-The exercise part will consist of an evaluation and treatment as prescribed by a physical therapist including aerobic & dynamic stretching warm-up, strength training, balance training, and flexibility training. Will also include a home exercise program (HEP). Physical therapists will have specialized training in cancer rehabilitation obtained through the ReVital certification process.
34253|NCT03916796|Other|Enhanced Recovery after surgery|-The protocols include instructions for patient care from the time of pre-surgical admission to discharge, including directives regarding diet, labs, IV fluids, pain management, prophylactic medications, management of indwelling catheters and drains, and activity.
34254|NCT03916796|Other|Psychological screening with counselling services as needed|-The psychological screening will be completed by the Radiation Oncology nurse at the consult visit
34255|NCT03916796|Other|Dietary Counseling Services|-Patients will have a baseline nutrition counseling visit with a Registered Dietician. This may include a nutrition assessment and nutrition counseling to set priorities, establish goals, and create an individualized plan
34256|NCT03916783|Behavioral|Combination intervention|"The FDA will be a matched savings account held in the child's name with the parent or caregiver as the co-signer, in a financial institution registered by the Central Bank (Bank of Uganda). The account opened will be matched with money from the program up to a match cap of 72,000 Uganda shillings (an equivalent of $20) a month per family for the 9-month intervention period.~The FDAs will be complemented with four sessions of Financial Literacy and Management (FL&M) and two sessions of cancer education conducted over a 4-week period. The two cancer-specific education sessions will use UCI materials to address: 1) definitions of cancer, potential causes, signs and symptoms, and importance of cancer testing; 2) debunking cultural explanations for the causes of cancer and misconceptions (beliefs, values, norms and prevailing attitudes)regarding cancer that largely impede service use."
34257|NCT03916770|Device|Sham vibrator|The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
34258|NCT03916770|Device|Real vibrator|The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
34259|NCT03916757|Biological|V-Boost|Open label setting
34260|NCT03916744|Drug|GDC-9545|GDC-9545 will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
34261|NCT03916744|Procedure|Surgery|Breast cancer surgery will take place on Day 15 (+/-2 days).
34262|NCT03916731|Device|Implant of STARgraft AV shunt in the upper arm and subsequent use for hemodialysis access|After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function
34263|NCT03916731|Device|Implant of standard ePTFE AV graft in the upper arm and subsequent use for hemodialysis access|Same as for STARgraft AV but with standard grafts to provide controls
34264|NCT03916718|Behavioral|Care EcoSystem|This is a care management program and health care outcomes feasibility study utilizing the dementia Care Ecosystem (CE) program developed at UCSF and tailored to high need Ochsner PWD (patient with dementia) and their CGs (caregivers). Dyads (CGs and PWD) will receive a tailored clinical assessment addressing dementia severity, PWD and CG needs, education/strategies to management common dementia issues, medical issues and medication reconciliation, caregiver wellness strategies, linkages to community-based resources, advance care planning, education about the risk of ED and hospitalization, and care coordination with other specialties. Dyads will be followed on a monthly basis to monitor needs, provide support, and problem solve issues.
34265|NCT03916705|Other|High Velocity Low amplitude spinal manipulation (HVLA-SM)|HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
34266|NCT03916692|Dietary Supplement|Carbohydrate drink|Meal replacement drink containing 200 kcal
34267|NCT03916692|Dietary Supplement|Energy smart Carbohydrate blend|Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
34268|NCT03916692|Dietary Supplement|Liquid Dextrose|Liquid Dextrose drink of 200 kcal
34269|NCT03916679|Biological|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
34270|NCT03916666|Procedure|Epiduroscopy|Endoscopic intervention
34271|NCT03916653|Procedure|osseous resection using piezoelectric device|In this group piezoelectric device will be used for osseous resection in crown lengthening procedure with copious irrigation of sterile saline.
34272|NCT03916653|Procedure|Osseous resection using conventional rotary instruments|For osseous resection in crown lengthening procedure, conventional rotary instruments will be used with copious irrigation of sterile saline.
34273|NCT03916640|Drug|ADO09 formulation|Subcutaneous injection of ADO09 formulation
34274|NCT03916640|Drug|Placebo|Subcutaneous injection of 0.9% NaCl
34275|NCT03916640|Drug|Symlin®|Subcutaneous injection of pramlintide
34276|NCT03916640|Drug|Humulin®|Subcutaneous injection of human insulin
34277|NCT03916640|Drug|Humalog®|Subcutaneous injection of insulin lispro
34278|NCT03916627|Drug|cemiplimab|Administered intravenous (IV)
34279|NCT03916627|Drug|Platinum Doublet|Administered intravenous (IV)
34313|NCT03916393|Other|Bitrex solution|Bitrex solution at 0.5 ppm will be included in the treatment sequence together with the four PF-06651600 formulations.
34314|NCT03916380|Dietary Supplement|Grapefruit Juice|Single 8 ounce administration of oral grapefruit juice
34315|NCT03916367|Radiation|CT-guided Radioactive I-125 Seeds Implantation|The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
63043|NCT03691623|Drug|Placebo|Oral suspension for 5 days
34280|NCT03916614|Behavioral|Screening Tool for Relief of Trauma (START)|The Screening and Tool for Awareness and Relief of Trauma (START) was developed for patients that come from communities with sustained and persistent trauma. It consists of six screening questions adapted from the validated Primary Care PTSD Screen,[30] with input from focus groups, surveys and in-depth interviews with victims of violence. The full START intervention requires 30-45 minutes of structured conversation at the end of which the participant leaves with a better understanding of trauma symptoms as well as on-the-spot instruction on a set of techniques designed to alleviate the symptoms of PTSD. Based on the results of their screening, the participant will be offered up to four techniques to alleviate their symptoms
34281|NCT03916614|Behavioral|standard of care|Screening for PTSD and referral for outpatient services if warranted as well as usual care from Violence Prevention and Outreach Program (VPOP) staff.
34282|NCT03916601|Drug|SAR341402|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
34283|NCT03916601|Drug|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
34284|NCT03916601|Drug|Insulin Aspart|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
34285|NCT03916601|Drug|SAR341402|"Pharmaceutical form: suspension for injection~Route of administration: subcutaneous"
34286|NCT03916588|Behavioral|Individualized Care Plan|Medical, neuropsychological, and social assessment of patient's cognitive, behavioral, medical, and environmental needs with a focus on improving quality of life, reducing health care utilization, and improving staff/family caregiving burden along with a specific plan to address and monitor identified patient and staff/facility needs
34287|NCT03916562|Behavioral|Manipulation of spatiotemporal coordination during walking|A description of the intervention is included in the description of the study arms.
34288|NCT03916549|Device|Acupuncture|The acupuncture procedure is performed by one well trained person, 1 time per week in total of 10 weeks on the same day time. Sterile, disposable, stainless steel acupuncture needles (40x0.25 mm diameter) were inserted to corporal acupoints, with initial gentle stimulation by quick rotation of 1080°, after then leaving needle in located place for twenty minutes. Needling deep - 0.5-1 cm. If the intent was to invigorate - the needle was inserted to the flow of energy; if harmonization needed - the needle was placed perpendicular to the point flow of energy; if sedation was needed, needles were placed against to the flow of energy on channel. The selection of acupoints was based according by traditional Chinese medicine, literature findings.
34289|NCT03916536|Procedure|Holmium Laser|Holmium laser enucleation of large sized prostate
34290|NCT03916536|Procedure|Thulium Laser|Thulium laser enucleation of large sized prostate
34291|NCT03916536|Procedure|Bipolar diathermy|Bipolar enucleation of large sized prostate
34292|NCT03916523|Procedure|Sustained lung inflation|"Preterm infants will receive a total of 15 sustained lung inflations during the first 4 days of life as follows:~On day 1 of life (a total of 6 sustained lung inflations, 20 cmH2O for 21 seconds each) once at enrollment and then once every 4 hours~On day 2 of life (a total of 3 sustained lung inflations, 15 cmH2O for 21 seconds each) once every 8 hours.~On day 3 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours.~On day 4 of life (a total of 3 sustained lung inflations 10cmH2O for 21 seconds each) once every 8 hours."
34293|NCT03916523|Procedure|Continuous positive airway pressure (CPAP)|Preterm infants will receive CPAP for respiratory support.
34294|NCT03916523|Procedure|Mechanical ventilation|Preterm infants in this group will receive mechanical ventilation for respiratory support
34295|NCT03916510|Biological|Enadenotucirev|Enadenotucirev is a live replicating oncolytic adenovirus; it is considered a BioSafety Level 1 (BSL-1) infectious substance.
34296|NCT03916510|Drug|Capecitabine|Capecitabine is a chemotherapy drug licensed for use in rectal cancer, it is a non-cytotoxic pre-cursor of the cytotoxic 5-fluorouracil. Due to Capecitabine not being taken on Enadenotucirev dosing days it is considered an investigational medicinal product within this trial.
34297|NCT03916510|Radiation|Radiotherapy|50 Gy/25#
34298|NCT03916497|Diagnostic Test|Quantiferon CMV|Evaluate and compare interferon gamma (IFNy) production by T CD8 cells exposed to CMV antigens in CMV seropositive kidney transplant recipients, hemodialysis and control patients
34299|NCT03916484|Behavioral|AllyQuest HIV Medication Adherence app-delivered intervention|"AQ provides daily ART reminders and calendar; weekly tailored message; monthly appointment and refill reminders; social support via daily chat wall; daily challenge featuring skills-building and articles; education center; narrative collections; in app account rewards daily use by adding or subtracting small financial reward dependent on daily app use; personalized profile and avatar. Participants have 24-hour access to all features of the AQ app."
34300|NCT03916484|Behavioral|AllyQuest HIV Medication Adherence app-delivered intervention + NSC|In AQ+, participants receive all of AQ and have the added ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve ART adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. AQ+ includes unprompted check-in messages from the NSC counselor and scheduled in-app NSC sessions approximately every other week.
34301|NCT03916471|Device|Solyx™ SIS System|Single-incision sling system
34302|NCT03916471|Device|Obtryx™ II System (Halo)|Transobturator Mid-urethral Sling System
34303|NCT03916445|Other|Connor Davidson Resilience Scale (CD-RISC 10)|questionnaires about resilience (Connor Davidson Resilience Scale(CD-RISC 10)) and quality of life (EQ-5D-5L)
34304|NCT03916432|Device|HELIOS biodegradable polymer sirolimus-eluting stents|HELIOS biodegradable polymer sirolimus-eluting stents
34305|NCT03916419|Device|ViewRay MR-Linear Accelerator|-Radiation will be delivered by this machine
34306|NCT03916419|Radiation|Radiation therapy|-60Gy in 15 fractions
34307|NCT03916419|Drug|Paclitaxel|-50 mg/m^2 intravenous
34308|NCT03916419|Drug|Carboplatin AUC|-2 mg/mL/min intravenous over 30 minutes
34309|NCT03916419|Biological|Durvalumab|-10 mg/kg
34310|NCT03916406|Drug|PF 06835919|300 mg
34311|NCT03916406|Drug|Midazolam|7.5 mg
34312|NCT03916393|Drug|PF-06651600 20 mg|PF-06651600 in four (4) different oral formulations will be administered in different periods.
63157|NCT03690882|Other|systematic review of medical imaging|
34316|NCT03916341|Other|EC with nicotine|Use an EC with nicotine for up to 30 minutes
34317|NCT03916341|Other|EC without nicotine|Use an EC without nicotine for up to 30 minutes
34318|NCT03916341|Other|control|sham control
34319|NCT03916341|Other|TC with nicotine (own brand)|smoke a TC
34320|NCT03916341|Other|research TC with very low level nicotine|smoke a research TC with very low level nicotine
34321|NCT03916328|Drug|B/F/TAF|A third of the women will be randomized to Bictergravir /Emtricitabine / Tenofovir alafenamide (B/F/TAF; Biktarvy®).
34322|NCT03916328|Drug|TDF/3TC/EFV or DTG or NVP|A third of the women will remain on Tenofovir Disoproxil Fumurate.(TDF) containing ART.
34323|NCT03916328|Other|DMPA|Two thirds of the women will be on DMPA for contraception.
34324|NCT03916315|Behavioral|Transdiagnostic Treatment|"The Unified Transdiagnostic Protocol (PUT) is a cognitive-behavioral treatment focused on emotions. The PUT was developed to be applicable to anxiety disorders, mood disorders, as well as other disorders in which anxiety and emotional dysregulation play an important role, such as many somatoform and dissociative disorders.~The PUT proposal includes 8 modules, of which 5 are nuclear, it is recommended to give these modules between 11 to 17 sessions with a duration of one hour each."
34325|NCT03916289|Other|No intervention would be taken|No intervention would be taken. Patients enrolled would be managed by this tiered diagnosis and treatment system and receive standard treatment according to clinical guidelines of osteoporosis.
34326|NCT03916276|Behavioral|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
34327|NCT03916276|Behavioral|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
34328|NCT03916276|Behavioral|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
34329|NCT03916263|Drug|Metformin|Traditional care including diet, exercise and metformin
34330|NCT03916263|Other|One-On-One Dietary Instruction|Participant receives one-on-one dietary counseling from study personnel
34331|NCT03916263|Other|Video Dietary Instruction|Participant receives video dietary instruction
34332|NCT03916250|Drug|PF-06700841 cream|PF-06700841 will be applied topically
34333|NCT03916250|Drug|White petrolatum|White petrolatum will be applied topically
34334|NCT03916237|Other|Home assessment|Home assessment for environmental hazards according to protocol established by Environmental Health Watch (Healthy Home Audit https://www.ehw.org/healthy-home-audit/)
34335|NCT03916237|Other|Home remediation|Low level home remediation according to previously established protocol (Kercsmar CM, Dearborn DG, Schluchter M, et al. Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources. Environ Health Perspect. 2006;114(10):1574-80)
34336|NCT03916237|Other|Referral to Medical Legal Partnership|Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
34337|NCT03916237|Other|Asthma SDH screening tool|11 question tool used to assess risk and determine benefit of home assessment and/or medical legal partnership referral.
34338|NCT03916211|Biological|MSCs treatment|intramuscular injection of adipose stem cells treat diabetic foot
34339|NCT03916198|Drug|Polydeoxyribonucleotides|Just after arthroscopic rotator cuff repair, 3cc polydeoxyribonucleotide will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
34340|NCT03916198|Drug|Normal saline|Just after arthroscopic rotator cuff repair, 3cc normal saline will be injected, and 2 weeks after the surgery the same amount of the material will be injected.
34341|NCT03916185|Biological|RSV ΔNS2/Δ1313/I1314L Vaccine|10^6 plaque-forming units (PFU); administered as nose drops
34342|NCT03916185|Biological|RSV 6120/ΔNS2/1030s Vaccine|10^5 plaque-forming units (PFU); administered as nose drops
34343|NCT03916185|Biological|RSV 276 Vaccine|10^5 plaque-forming units (PFU); administered as nose drops
34344|NCT03916185|Biological|Placebo|Administered as nose drops
34345|NCT03916172|Behavioral|The Open Door Approach to Parenting Teenagers (APT)|APT works on a one-to-one or couple basis. It offers 6 weekly 50-minute appointments with an optional 7th review session. The practitioners delivering the intervention have qualifications in psychology, or significant experience of working with adolescent populations, and have undertaken training and supervision in the model. Its aim is to help the parent manage the parenting of their teenager more effectively and establish a more balanced relationship by eliciting their views, feelings, and understanding of their teenager and their relationship, discussing their parental identity and role, carefully examining communication, responses, and information giving, and supporting appropriate boundary making. This is achieved through a collaborative development of strategies, psychoeducation and behavioural experiments.
34346|NCT03916159|Procedure|Extrauterine placental transfusion (Intervention group)|At delivery by caesarean section, the infant is born with the placenta still attached via the umbilical cord and placental transfusion is performed at least 1 minute but not more than 10 minutes by holding the placenta ~40-50cm above the babies' heart level while respiratory support by mask continuous-positive-airway-pressure (CPAP) is initiated simultaneously.
34347|NCT03916159|Procedure|Delayed cord clamping (Control group)|At delivery by caesarean section, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 30 seconds with initiation of respiratory support by mask CPAP after cord clamping.
34348|NCT03916146|Behavioral|Parent Training Intervention|Adapted version of the Family Check-Up/Everyday Parenting intervention
34349|NCT03916133|Diagnostic Test|Intervention group|6s PBV mapping will be conducted
34350|NCT03916120|Genetic|Genetic analysis|Collect 2ml intravenous blood from patients after anaesthesia.
34351|NCT03916107|Procedure|Levator muscle and tarsus resection|Shortening the levator muscle with resection of tarsus to correct severe ptosis
34352|NCT03916107|Procedure|Frontalis flap|Using frontal muscle flap to correct severe ptosis
34353|NCT03916094|Drug|HLX22|Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
34354|NCT03916081|Drug|ARQ-151 cream 0.05%|0.05% active concentration
34355|NCT03916081|Drug|ARQ-151 cream 0.15%|0.15% active concentration
34356|NCT03916081|Drug|ARQ-151 cream Vehicle|Cream placebo
34357|NCT03916068|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric oxygen therapy at 2.4 atmospheres for 90 minutes for 30 sessions.
34358|NCT03916068|Drug|Trental Pill|Trental 400 mg three times daily, in combination with Vitamin E 400 IU twice daily
34359|NCT03916068|Dietary Supplement|Vitamin E|Vitamin E 400 IU twice daily, in combination with Trental 400 mg three times daily
34360|NCT03916055|Behavioral|Exposure and response prevention (ERP)|"The intervention consists of 10 modules/chapters for children/adolescents, delivered over 10. Each of the 10 modules includes age-appropriate texts, animations and exercises. The intervention is primarily based on ERP techniques. During the treatment, participants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their caregiver/parent, the participant is instructed to provoke premonitory urges (a sensation usually felt before a tic is expressed), while still suppressing tics, which is known as 'exposure'.~The parent is provided with her/his own separate login to the internet platform, which consists of 10 separate modules/chapters. The parent intervention consists mainly of information regarding parent coping strategies, social support and functional analysis relating to tics. Both the child/adolescent and the parent have individual access to the same therapist."
34361|NCT03916055|Behavioral|Education on tics|"The active comparator is designed to match the experimental intervention in all aspects except for the module content (same platform, same treatment length, same therapist support etc.). The intervention consists mainly of psychoeducational information about TD/PTD and common comorbid conditions, and reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors, strategies for describing tics to other people, among others. Problem-solving and development of expertise in tic disorders is emphasised. The intervention does not include any information on ERP or functional analysis and interventions.~As in the experimental intervention, the parent is provided with her/his own separate login to the internet platform. The parent intervention consists mainly of information regarding parent coping strategies and social support. Both the child and the parent have individual access to the same therapist."
34362|NCT03916042|Drug|Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Reproxalap Opthalmic Solution (0.25% Novel Formulation) administered QID for four weeks, followed by BID administration for eight weeks
34363|NCT03916042|Drug|Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
34364|NCT03916029|Behavioral|facilitator|Training and employment of community members to assist the diagnosis and management of otitis media
34365|NCT03916016|Behavioral|Enhanced Integrated Behavioral Health Care|The intervention involved moving from HFHC's previous collaborative model, where medical and behavioral providers worked with each other episodically, to a more fully integrated collaborative care model with care coordination, shared treatment plans, shared service provision, and shared record keeping. To achieve this enhanced level of integration, HFHC changed its current primary care workflow to include a behavioral health specialist who conducted assessments, provided initial counseling (individual or group), and coordinated referrals to care management and/or community-based health services.
34366|NCT03916016|Behavioral|Usual Care|A collaborative model where medical and behavioral providers worked with each other episodically
34367|NCT03916003|Drug|primaquine|Primaquine regimen over 7 days (1.0 mg/kg/day for 7 days)
34368|NCT03915990|Diagnostic Test|umbilical and middle cerebral artery Doppler|Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient.
34369|NCT03915977|Behavioral|Post ICU recovery program|Standardized follow up program
34370|NCT03915964|Drug|Baricitinib|Administered orally.
34371|NCT03915964|Drug|TNF Inhibitor|Administered SC
34372|NCT03915951|Drug|encorafenib|self-administered orally
34373|NCT03915951|Drug|binimetinib|self-administered orally
34374|NCT03915938|Drug|Ketamine|S-ketamine will be administered in precalculated infusion rates to obtain a plasmatic level of 60 ng/ml
34375|NCT03915938|Drug|Placebo|Administered in an identical way than ketamine.
34376|NCT03915912|Behavioral|Mindfulness meditation|The study intervention consists of seven mindfulness sessions (six 1-hour telephone sessions and one 1-hour in-person session). The six weekly telephone-based mindfulness sessions will occur in a one-on-one format and will be followed by one in-person, one-on-one session, which will occur at the post-chemoradiation standard of care clinic visit.
34377|NCT03915899|Behavioral|WIN (Welcome Incoming Neighbor)|WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
34378|NCT03915886|Drug|JNJ-0440|JNJ-0440 tablets will be administered orally.
34379|NCT03915886|Drug|Placebo|Matching placebo tablets will be administered orally.
34380|NCT03915873|Diagnostic Test|The von Willebrand Antigen level|blood sample
34381|NCT03915860|Drug|Trifarotene|Topical Cream
34848|NCT03912168|Other|Question Prompt List|Question prompt list for common orthopaedic conditions
34382|NCT03915847|Procedure|Single layer closure|Uterine incision will be approximated with continuous unlocked suture, including a narrow band of the endometrial layer, without trimming incision edges.
34383|NCT03915847|Procedure|Double layer closure|The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
34384|NCT03915847|Procedure|Doble layer closure with trimming|Uterine incision will be trimmed and old scar tissue will be removed. The first layer suture penetrated the whole thickness of the uterine wall, including a narrow band of the endometrial layer. Second layer sture is acontinous sture performed in a lateral-to lateral position , imbricating first layer.
34385|NCT03915834|Device|Endovascular treatment|Mechanical thrombectomy and/or Aspiration
34386|NCT03915821|Device|ECT|"Electroconvulsive therapy was administered by using bidirectional constant current, brief-pulse devices. During the procedure, the patients were sedated using propofol or thiopenthal. Succinylcholine (1 mg/kg) was used as muscle relaxant, and glycopyrrolate (0.2 mg) or atropine was used as an anticholinergic agent when necessary. The mean charges were 351 (SD, 143) mC for the unilateral electrode placement group, 417 (SD, 192) mC for the bitemporal electrode placement group and 260 (SD, 76) mC for the bifrontal electrode placement group, (Brus, Ole MSc, 2017).~The average course of treatment for depression is 6 to 12 treatments, but some patients may require as many as 20 treatments,"
34387|NCT03915808|Dietary Supplement|Conjugated linoleic acid group|supplementation of 3.2 g/day conjugated linoleic acid in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
34388|NCT03915808|Dietary Supplement|Sunflower oil group|supplementation of equivalent sunflower oil in 8 capsules, and receive education sessions every four weeks (Dietary and lifestyle counselling, featured with low fat and low added sugar, moderate physical activity)
34389|NCT03915782|Device|Remote ischemic conditioning|Remote ischemic conditioning (RIC): Four cycles of [5 minutes of brachial cuff inflation at 200 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation] started as soon as possible after Magnetic Resonance Imaging (MRI).
34390|NCT03915782|Device|Patients with a sham procedure of remote ischemic conditioning|Sham procedure: Four cycles of [5 minutes of brachial cuff inflation at 30 millimeters (mm) of mercury (Hg) followed by 5 minutes of cuff deflation] started as soon as possible after Magnetic Resonance Imaging (MRI).
34391|NCT03915769|Drug|Ozanimod|Ozanimod is an orally bioavailable, small molecule compound that activates the sphingosine 1-phosphate 1 receptor (S1P1) and the S1P 5 receptor (S1P5), although it is more selective towards S1P1 over S1P5
34392|NCT03915769|Other|Placebo|The placebo is a capsule that contains no study medication but looks exactly like the study medication capsule.
34393|NCT03915756|Procedure|Drainage of surgical wound|Introduction of a drain before full fascial closure
34394|NCT03915743|Other|palliative care|complex and multi-faceted individualized palliative care
34395|NCT03915730|Other|Initial periodontal therapy|Scaling and root planing and polishing with specific curettes were performed to patients with CP and oral hygiene education was provided to each patient.
34396|NCT03915717|Device|EchoMark|EchoMark is implanted during surgery to mark the at-risk blood vessels to enable EchoSure ultrasound-based monitoring
34397|NCT03915717|Device|EchoSure|EchoSure ultrasound scans are performed to monitor the free flap
34398|NCT03915704|Device|Shotblocker|Injection was administered with ShotBlocker.The Shotblocker application to all children in this group was done by the second researcher. After the injection, the shotblocker was wiped with 70% alcohol.
34399|NCT03915704|Procedure|Control|No intervention was made in the children.
34400|NCT03915704|Device|Buzzy|Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed.The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
34401|NCT03915691|Procedure|Catheter ablation of atrial tachycardia: Ripple Mapping guided.|Ripple Mapping (CARTO3v6 mapping system, Biosense Webster Inc) is used to map the atrial tachycardia mechanism. The Ripple Map is interpreted and catheter ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using Ripple Mapping. This can include lesions created at previous ablation procedures.
34402|NCT03915691|Procedure|Catheter ablation of atrial tachycardia: Conventional mapping guided.|Conventional activation mapping (CARTO3v6 mapping system, Biosense Webster Inc) is used to map the atrial tachycardia mechanism. The resultant (activation) map is interpreted and ablation directed to the site of the heart identified as putative to the arrhythmia mechanism. All ablation lesions are confirmed to have conduction block across them using conventional mapping. This can include lesions created at previous ablation procedures.
34403|NCT03915678|Drug|Association atezolizumab + G100 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~G100 will be administered by intra-tumoral at fixed dose (20µg), once weekly for at least 6 weeks and for a maximum of 12 weeks. Treatment by G100 will start one week before atezolizumab administration (e.g, Day -7, impregnation phase). Note that a maximum of 3 lesions can be injected.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration:~Short course irradiation on injected metastasis: 2 fractions of 2 Gy for a total dose of 4 Gy,~High dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
34404|NCT03915678|Drug|Association atezolizumab + G100 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~G100 will be administered by intra-tumoral at fixed dose (20µg), once weekly for at least 6 weeks and for a maximum of 12 weeks. Treatment by G100 will start one week before atezolizumab administration (e.g, Day -7, impregnation phase). Note that a maximum of 3 lesions can be injected.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration:~Short course irradiation on injected metastasis: 2 fractions of 2 Gy for a total dose of 4 Gy,~High dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
34849|NCT03912168|Other|3 questions list|3 questions from the AskShareKnow model
34405|NCT03915678|Drug|Association atezolizumab + G100 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~G100 will be administered by intra-tumoral at fixed dose (20µg), once weekly for at least 6 weeks and for a maximum of 12 weeks. Treatment by G100 will start one week before atezolizumab administration (e.g, Day -7, impregnation phase). Note that a maximum of 3 lesions can be injected.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration:~Short course irradiation on injected metastasis: 2 fractions of 2 Gy for a total dose of 4 Gy,~High dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
34406|NCT03915678|Drug|Association atezolizumab + G100 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~G100 will be administered by intra-tumoral at fixed dose (20µg), once weekly for at least 6 weeks and for a maximum of 12 weeks. Treatment by G100 will start one week before atezolizumab administration (e.g, Day -7, impregnation phase). Note that a maximum of 3 lesions can be injected.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration:~Short course irradiation on injected metastasis: 2 fractions of 2 Gy for a total dose of 4 Gy,~High dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
34407|NCT03915678|Drug|Association atezolizumab + G100 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~G100 will be administered by intra-tumoral at fixed dose (20µg), once weekly for at least 6 weeks and for a maximum of 12 weeks. Treatment by G100 will start one week before atezolizumab administration (e.g, Day -7, impregnation phase). Note that a maximum of 3 lesions can be injected.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration:~Short course irradiation on injected metastasis: 2 fractions of 2 Gy for a total dose of 4 Gy,~High dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
34408|NCT03915678|Drug|Association atezolizumab + G100 + RT|"A treatment cycle consits of 3 weeks. Atezolizumab will be administered as a 1-hour infusion on day 1 every 3 weeks (1200 mg).~G100 will be administered by intra-tumoral at fixed dose (20µg), once weekly for at least 6 weeks and for a maximum of 12 weeks. Treatment by G100 will start one week before atezolizumab administration (e.g, Day -7, impregnation phase). Note that a maximum of 3 lesions can be injected.~Radiotherapy will start at least one week after the first administration of atezolizumab and at the latest before the 2nd administration:~Short course irradiation on injected metastasis: 2 fractions of 2 Gy for a total dose of 4 Gy,~High dose irradiation in stereotactic conditions on non-injected metastasis: 3 to 5 fractions for a total dose between 27 Gy and 60 Gy."
34409|NCT03915665|Drug|Chlorhexidine|Chlorhexidine gel 1% one single application after mechanical biofilm removal through manual instruments
34410|NCT03915665|Device|Air-powder|Erythritol powder using air-powder device
34411|NCT03915652|Behavioral|Rheum iCMP|Selected iCMP nurses will receive a 4-hour training using unique educational materials already developed by our team that specifically address lupus-related racial, ethnic and socioeconomic disparities, as well as clinical information about lupus. These iCMP nurses will then reach out to high-risk lupus patients to ensure that patients attend scheduled rheumatology appointments, fill prescriptions for lupus-specific medications, and obtain recommended lupus screening labs and preventive care.
34412|NCT03915639|Procedure|Peri-incisional injection|The surgeons are planned to inject the cocktail mixture or ropivacaine to muscles and the subcutaneous tissue beneath the fixation sites and incision site using a 22-gauge needle in a sterile fashion prior to skin incision.
34413|NCT03915626|Drug|Rivastigmine (RLD) transdermal patch|brand name patch
34414|NCT03915626|Drug|Rivastigmine (generic) transdermal patch|generic patch
34415|NCT03915613|Drug|Humulin R|"The investigator and/or designee will instruct the study participant on how the intranasal insulin spray should be administered. Each study participant is to receive a single dose of Humulin R 160 U.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Humulin R insulin will be sourced as 100 units/mL in a vials of 10 mL from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
34416|NCT03915613|Drug|Diluent|"The investigator and/or designee will instruct the study participant on how the intranasal placebo spray should be administered. Each study participant is to receive a single dose of placebo.~The nasal spray bottles provide a deliverable volume of 0.1 mL/spray. Diluent will be sourced as 10 mL/vial from Eli Lilly. 16 sprays in alternating nostrils (8 per nostril) will be administered per dose."
34417|NCT03915600|Other|Quinoa|Personalized diet added with quinoa
34418|NCT03915600|Other|Flaxseed|personalized diet added with flaxseed
34419|NCT03915600|Other|Quinoa and Flaxseed|personalized diet added with quinoa and flaxseed
34420|NCT03915587|Device|CardioQ-EDM and CipherOx-CRI|A CardioQ-EDM probe will be placed on the day of surgery after induction of general anesthesia. The anesthesiologist will inform the investigator of plans to provide a fluid or blood bolus per clinical judgement in addition to the protocolized 10 ml/kg bolus provided after induction. While the anesthesiologist is preparing to administer volume expansion, a co-investigator will collect pre-fluid bolus data. Measurements will be recorded for data analysis at the completion of the trial. Additionally, a CipherOx-CRI probe will be placed on the patient's index finger (recorded data will be interpreted post hoc) and a bedside ultrasound will be performed by either the principal investigator (PI) or one of two co-investigators to measure the IVC CI. Ultrasound cine-loops will be recorded, and CI will be calculated post-hoc. Data will be recorded on the Data Collection Form for each fluid bolus administered. The PI and co-investigators will manage all aspects of investigational devices.
34421|NCT03915574|Device|25G Dural Puncture Epidural|Dural puncture created with a 25 gauge spinal needle
34422|NCT03915574|Device|Standard Epidural|Control group - standard epidural (no dural puncture)
34484|NCT03915028|Other|Spa therapy|"The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks.~Each day, the patient receives at least four treatments, among which:~Cure of Drink (in addition to 4 daily cares)~Bath in running water: Bath~Bath in running water: Pool at 32 ° C~Bath with aerobain~Immersion shower bath~Shower of high pressure under immersion in swimming pool~General penetrating shower~General jet shower~Local jet shower~Local mud bath at the feet~Single poultice~Multiple poultice~Compress~Mobilization pool~Massages under water"
34423|NCT03915561|Drug|Parecoxib Injectable Product|Dynastat (parecoxib sodium) is rapidly converted to valdecoxib following injection and reduces the production of prostaglandins that are important mediators of pain and inflammation. After intravenous injection with 40mg Dynastat, the onset of analgesia was 7-14 minutes and reached a peak effect within 2 hours. After a single dose, the duration of analgesia was dose and clinical pain model dependent and ranged from 6 to greater than 24 hours and maximal daily dose of Dynastat is 80mg. According to recommendation of acute postoperative pain management and product information, the timing of first injection will be at 10 minutes before anesthetic induction, and second injection will be 6 to 12 hours after first injection.
34424|NCT03915561|Drug|Normal saline|Placebo group (0.9% saline, group S) will be received intravenous injection with 10ml 0.9% saline alone (transparent solution) twice.
34425|NCT03915548|Behavioral|The Behavioral Activation/ Problem Solving Intervention|The interventionist presents the rationale for BA/PS, promotes a positive problem orientation, and educates about the framework for problem-solving and action planning. The interventionist then administers the Canadian Occupational Performance Measure to elicit participant priorities, motivation, and long-term goals. The interventionist then guides the participant in using the BA/PS framework to set a goal, brainstorm solutions to challenges, and create a detailed action plan for the coming week.
34426|NCT03915548|Behavioral|Attention Control Condition|The interventionist provides education regarding nine cancer survivorship topics (i.e., healthy diets, physical activity, lymphedema management, smoking cessation, stress management, communication with providers, body image and sexuality, communication with social supports, work accommodations) during the control telephone contacts.
34427|NCT03915535|Dietary Supplement|Eicosapentaenoic acid + Docosahexaenoic acid|Monoglyceride Omega-3 fish oils
34428|NCT03915535|Dietary Supplement|Eicosapentaenoic acid|Monoglyceride Omega-3 fish oil
34429|NCT03915522|Procedure|Single adductor canal block|The operated leg is slightly externally rotated and prepared for a block with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and after a subcutaneous injection of 2 ml of 1% lidocaine a total of 20 ml of 0'5% ropivacaine is injected into the canal using a 22 gauge ultrasound-visible needle. In the end, a sterile apposite is placed at the puncture site
34430|NCT03915522|Procedure|Simulated adductor canal block|The operated leg is slightly externally rotated and prepared with 2% chlorhexidine and sterile dressing. The adductor canal is identified using ultrasound image at the mid-thigh level and at this leve a subcutaneous injection of 2 ml of 1% lidocaine . After, a sterile apposite is placed at the puncture site.
34431|NCT03915509|Device|Evaluation of the effect of surface properties on the stability of the different implants with resonance frequency analysis|Lasak Impladent Implants (sandblasted)
34432|NCT03915496|Drug|PF-04965842 200 mg|PF-04965842 200 mg administered as two tablets to be taken orally once daily for 12 weeks
34433|NCT03915496|Drug|PF-04965842 100 mg|PF-04965842 100 mg administered as two tablets to be taken orally once daily for 12 weeks
34434|NCT03915496|Drug|Placebo|Placebo administered as two tablets to be taken orally once daily for 12 weeks
34435|NCT03915483|Device|transcranial direct current stimulation (tDCS)|sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
34436|NCT03915470|Drug|XF-73|XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
34437|NCT03915470|Drug|Placebo|Placebo to match XF-73 nasal gel for colour and viscosity.
34438|NCT03915457|Other|Dry immersion Control Group|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
34439|NCT03915457|Other|Thigh cuffs intervention|Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
34440|NCT03915444|Drug|nab-Paclitaxel + Cisplatin + Gemcitabine|"Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days."
34441|NCT03915431|Biological|NCS-01|single infusion
34442|NCT03915431|Biological|Placebo|single infusion
34443|NCT03915418|Procedure|Connected tools|At home, parents will record their child's sleep for 3 consecutive nights Then, on the date scheduled for the inclusion of the children and after the recording of the 3 nights at home, the child will spend a night in a hospital environment to carry out the recording by polysomnography and tools connected simultaneously.
34444|NCT03915405|Drug|KHK2455|orally, once daily.
34445|NCT03915405|Drug|Avelumab|IV Administration
34446|NCT03915379|Drug|JNJ-67571244|JNJ-67571244 will be administered intravenously.
34447|NCT03915366|Drug|Valganciclovir Oral Solution [Valcyte]|Treatment for CMV
34448|NCT03915366|Drug|Tuberculostatic Agents|Treatment for tuberculosis
34449|NCT03915353|Other|No Intervention|No Intervention
34450|NCT03915340|Drug|Propafenone|Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
34451|NCT03915340|Drug|Rytmonorm|Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
34452|NCT03915327|Drug|Intravenous iron dextran|Enrolled subjects would receive intravenous iron dextran within 24 hours of the subject's inclusion.
34485|NCT03915015|Diagnostic Test|MRI|MRI
34486|NCT03914989|Other|olfactory enrichment (essential oils)|Participants will be exposed to either a higher or lower concentration of essential oils nightly for two hours as they are going to sleep, using a nebulizing fragrance diffuser, rotating through seven different scents, one per night.
34559|NCT03914495|Dietary Supplement|Inulin|Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.
65283|NCT03674229|Other|Questionnaire Administration|Ancillary studies
34453|NCT03915314|Diagnostic Test|Neuropsychological tests|The investigators do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Quality of Recovery Score - 40 (QoR-40),CAGE Alcoholism Questionnaire,blood albumin、hemoglobin content、ALT、AST、BUN、Cr、1 day before the surgery（baseline);serum biomarkers of endothelial dysfunction，blood brain barrier disruption and neuronal injury to be measured at 2 time points,1 day before the surgery（baseline）and postoperative day 1； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery.
34454|NCT03915301|Procedure|Satisfaction assessed by the VAS [followed by its scale information in the Description]|Erector spinae plane block provided in thoracic part of spine, VAS scale 0-10
34455|NCT03915288|Other|Group continuous training at moderate intensity|70 minutes for intervention, where 10 minutes were warm up (breathing exercises, walking, stretching), 30 minutes of continuous aerobic training at moderate intensity (60-80% FCM), with fast walking or endless tread with the floor inclined to reach the desired intensity. Also on bicycle, rowing and elliptical; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
34456|NCT03915288|Other|Group high Intensity Interval Training|70 minutes for intervention, where 10 minutes were for warm-up (Respiratory exercises, walking, stretching), 30 minutes consisted of an intensity of interval training. That is, the participants who underwent 30 minutes of aerobic exercise consisted of a protocol created for this experimental group that we named 30-30. 30 seconds at moderate intensity (60-80% FCM) and 30 seconds at high intensity (80-90%). ; Then, 20 minutes of strength training (40-60% maximum strength) with dumbbells and theraban. Ends with 10 minutes of cooling with walking and breathing exercises.
34457|NCT03915288|Other|Group control|This group did not perform supervised exercise nor were they given exercise recipes or formal intervention programs. Only continued with the usual care and gave directions to maintain a healthy lifestyle based on proper nutrition and usual activities.
34458|NCT03915262|Biological|Search for exocrine pancreatic insufficiency at week 0 and 12|"We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin.~We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease.~We will gather the total caloric and fat intake with a diet record."
34459|NCT03915236|Device|MON4STRAT Strategy|Meropenem infusion guided by daily Therapeutic Drug Monitoring (adjusted in order to reach predetermined PK/PD targets) using MON4STRAT device.
34460|NCT03915236|Other|Control group|Meropenem 1 gram infused every 8 hours over 30 minutes, consistent with standard-of-care treatment and published guidelines. Meropenem doses will be modified according to SmPC recommendations.
34461|NCT03915223|Drug|Solumedrol (steroidal anti-inflammatory drug)|Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug)
34462|NCT03915197|Diagnostic Test|Pneumological evaluation|Consultation with a pneumopediatrician: collection of respiratory symptoms, respiratory treatments, evaluation of the atopic site and environmental risk factors for bronchial aggression, especially passive smoking
34463|NCT03915184|Biological|CT053|A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
34464|NCT03915171|Diagnostic Test|Next generation sequencing|NGS can provide genetic and MSI test for patients
34465|NCT03915158|Procedure|bariatric surgery|sleeve gastrectomy
34466|NCT03915145|Other|Kinesio tape application|Kinesio tape application will be performed.Taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
34467|NCT03915145|Other|Sham Kinesio tape application|Sham kinesio tape application will be performed. Sham taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
34468|NCT03915145|Other|No intervention|The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
34469|NCT03915132|Drug|Nimotuzumab|Nimotuzumab 200mg/m2 IV on d1 of a week before radiotherapy , and 100mg/m2 IV on d1 weekly for 7 cycles
34470|NCT03915132|Radiation|VMAT|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume.
34471|NCT03915119|Other|GFT AI training|navigates a cluttered environment of stationary and moving/pursuing virtual obstacles to reach a way-point as quickly and efficiently as possible. Block order and difficulty, as well as the behavior of the obstacles in each block, will be driven by the AI and statistically weighted to specifically target the perceptual-motor and neuromechanical mechanisms based on each athlete's visit 1 performance
34472|NCT03915106|Device|Brace|Wear a rigid brace
34473|NCT03915106|Procedure|Surgical correction using implants|Surgical correction of spine using implants (metallic rods and metallic screws)
34474|NCT03915093|Other|Educational nursing protocol|It is a booklet given to study group ,which contains Knowledge and practice about thoracoscopy, pre - post operative care and home care instructions
34475|NCT03915093|Other|Routine hospital care|The routine care given by physicians and nurses after thoracoscopic surgery
34476|NCT03915080|Drug|Advate|
34477|NCT03915067|Drug|BOTOX High Dose|BOTOX will be injected into the platysma muscle
34478|NCT03915067|Drug|BOTOX Low Dose|BOTOX will be injected into the platysma muscle
34479|NCT03915067|Drug|Placebo|Placebo will be injected into the platysma muscle
34480|NCT03915054|Drug|AREG-IVM medium|"Oocytes in CAPA-IVM medium will be mature in AREG+FSH medium. Per case (6mL) 5940 µL Basal Medium~60 µL IVM MIX Do not need to filtrate media."
34481|NCT03915054|Drug|STD medium|Oocytes in CAPA-IVM medium will be mature in FSH+hCG+GH medium. Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
34482|NCT03915041|Device|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
34483|NCT03915041|Device|VR +sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
34613|NCT03914001|Device|mpMRI|all eligible patients will undergo mpMRI 4 weks after initial TURBT
34487|NCT03914976|Procedure|patient having to undergo a high risk programmed digestive surgery|The objective is to determine if there is an association between the mean intraoperative values and within 24 hours postoperative ΔPCO2 and the occurrence of major post-operative complications at day 28 in high-risk surgery (major hepatectomy, esophagectomy or duodeno- cephalic pancreatectomy)
34488|NCT03914963|Biological|Fibrin sealant hemipelvis|Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis) after pelvis bilateral lymphadenectomy.
34489|NCT03914963|Biological|Control hemipelvis|Contralateral hemipelvis not treated with fibrin sealant
34490|NCT03914950|Diagnostic Test|PET/CT results with TOF/without TOF|Diagnostic CT of the abdomen with parenteral (Visipaque=Iodixanol) and oral (water) contrast medium within the TOF-18F-FDG PET/CT
34491|NCT03914937|Other|Virtual reality|A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.
34492|NCT03914937|Other|Music|Music of the patient's choice will be played
34493|NCT03914924|Behavioral|Exercise Program|"The 12-week program consisting of 16 exercise sessions in a total of supervised and individually prescribed aerobic and muscle-strengthening exercise of approximately 60 minutes duration. The exercise sessions will be delivered as follow:~4 weeks - supervised exercise sessions 2x / week~8 weeks - supervised exercise sessions 1x / week~In addition, they will receive counseling for unsupervised exercise sessions in their community, to accumulate a minimum of 150 min/week."
34494|NCT03914924|Behavioral|Lifestyle Education Program|"The 12-week program consisting of 18 education classes of 30 minutes duration delivery by a health educator team. Participants receive a comprehensive education workbook to accompany the sessions, containing 20 chapters. The classes will be delivered as follow:~initial class to program introduction~4 weeks - education classes 2x / week~8 weeks - education classes 1x / week~final class to program graduation"
34495|NCT03914911|Device|Smart Biopsy Device|The radiologist will perform a routine ultrasonic guided biopsy procedure using the smart biopsy system, with the device readings not visible (i.e. the radiologist will be blinded to device readings)
34496|NCT03914898|Other|Nurse led intervention group|This program is based on cognitive restructuring tecniques.
34497|NCT03914885|Genetic|ATLCAR.CD30|Administered at a dose of 2 x 10^8 cells/m2
34498|NCT03914885|Drug|Bendamustine|Administered as a dose of 70mg/m2/day over 3 consecutive days; maybe dose reduced per treating physician discretion based on prior toxicities and the patient's clinical status
34499|NCT03914885|Drug|Fludarabine|Administered at a dose of 30mg/m2/day over 3 consecutive days; given concomitantly with bendamustine
34500|NCT03914872|Biological|Neoantigen DNA Vaccine|The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines.
34501|NCT03914872|Device|Integrated electroporation device|"Ichor Medical Systems~All study injections will be given intramuscularly using an integrated electroporation device"
34502|NCT03914859|Biological|IN VITRO FERTILIZATION|Using exposure biomarker as a reliable means of evaluating gamete quality to estimate the chances of success in in vitro fertilization.
34503|NCT03914846|Procedure|Ultrasound|Undergo ultrasound with elastography
34504|NCT03914833|Other|Inclusion Questionnaires|During the inclusion visit, neuropsychologist tests the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Scale) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
34505|NCT03914833|Other|Questionnaires at inclusion, M1 and M3|During the inclusion visit, the 1-month visit and the 3-month visit; neuropsychologist grading of the scales: SCAT3 (Sport Concussion Assessment Test 3ème version), Trail-making test (TMT), Wechsler Adult Intelligence Scale (WAIS) TAP, HAS (Hospital Anxiety and Depression scale) ; PSQI (Pittsburg Sleep Quality Index) ; RPQ (Rivermead Post concussion symptoms Questionnaire) ; and RHFUQ (Rivermead head injury follow-up questionnaire)
34506|NCT03914820|Procedure|HIPEC CO2|Prophylactic surgery plus HIPEC CO2 performed with mitomycin
34507|NCT03914820|Procedure|Standard surgery|Standard surgery without HIPEC CO2
34508|NCT03914807|Other|Whole (3.25%) cow's milk recommendation|Children randomized to the whole milk recommendation will receive a recommendation a primary care recommendation to consume 500 mL of whole fat (3.25%) milk instead of transitioning to reduced fat (1%) milk at 2 years of age. The primary care physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children in the whole milk recommendation group will be provided with the same age-appropriate nutritional recommendations as children in the reduced fat recommendation group as part of routine healthcare according to the Rourke Baby Record.
34509|NCT03914807|Other|Reduced (1%) fat milk|Children randomized to the reduced fat group will receive a primary care recommendation to transition from whole milk to 500 mL reduced fat (1%) milk daily once the child is two years of age (consistent with current guidelines). The physician will verbally make this recommendation during the recruitment well-child visit. Parents will also be reminded bi-monthly by phone calls made by a research assistant. Children who receive the reduced fat recommendation will be provided with the same age-appropriate nutritional recommendations as children who receive the whole fat recommendation as part of routine healthcare according to the Rourke Baby Record.
34510|NCT03914794|Drug|Pemigatinib|Participants will take Pemigatinib once daily on days 1 through 28 of each cycle prior to standard of care TURBT.
34511|NCT03914781|Behavioral|SPIN-SELF Program|The SPIN-SELF program utilizes social modelling through educational videos of scleroderma patients who describe their own challenges and what they have done to cope with living with scleroderma, as well as videos of patients and health professionals who teach key self-management techniques. The program includes sections on general self-management skills, including goal-setting and self-monitoring), progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with using self-management techniques to cope with SSc symptoms. The program's 9 modules focus on (1) coping with pain; (2) skin care, finger ulcers and Raynaud's; (3) sleep problems; (4) fatigue; (5) gastrointestinal symptoms; (6) itch; (7) managing emotions and stress; (8) coping with body image concerns due to disfigurement; and (9) effective communication with healthcare providers.
65356|NCT03673670|Drug|RPL554 Suspension|A PDE3/4 inhibitor
34512|NCT03914768|Biological|Immunomodulatory DC vaccine to target DIPG and GBM|This study will inject DC vaccine cells near lymphoid tissue close to the tumor. The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day. The cells will be repeatedly infused every month for six consecutive months depending on the response and the condition of the patient. The amount of DC vaccine cells per injection is based on prior report at 5-10x106. An initial dose escalation scheme will be imposed.
34513|NCT03914755|Drug|Tucatinib|Administered via oral tablet
34514|NCT03914742|Drug|PARP Inhibitor BGB-290|Given PO
34515|NCT03914742|Drug|Temozolomide|Given PO
34516|NCT03914742|Procedure|Therapeutic Conventional Surgery|resection surgery
34517|NCT03914729|Procedure|Primary Closure|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the wound are approximated and sutured in the midline: subcutaneous fat - with a running suture, skin - with a separate running suture.
34518|NCT03914729|Procedure|Gluteus Maximus Fascia Plasty Flap|A symmetrical elliptical incision of skin and subcutaneous fat around primary and secondary orifices is performed. The cyst is excised en bloc down to the sacral fascia and removed. The lateral edges of the gluteus maximus muscles fascia bilaterally are mobilised in the direction from the fixation point to the sacrum and for 3-4 cm in lateral direction. The fascia flaps edges are approximated and fixed in the midline with a running suture. The subcutaneous fat is closed with a running suture, skin is closed with a separate running suture.
34519|NCT03914716|Diagnostic Test|Study group|Subjects will have physical, imaging examinations and provide samples for biological markers
34520|NCT03914703|Procedure|EZ Pass Suture Passer|Instruments used to help with rotator cuff or ACL repair
34521|NCT03914690|Drug|Erythropoietin|EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
34522|NCT03914690|Drug|Normal saline|Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.
34523|NCT03914677|Drug|Mecamylamine Oral Tablet|nicotinic antagonist (ganglionic blocker)
34524|NCT03914664|Diagnostic Test|Electroencephalogram (EEG) testing procedure|EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG
34525|NCT03914651|Drug|300IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 300IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of ovarian hyperstimulation syndrome（OHSS）.
34526|NCT03914651|Drug|150IU rFSH Gonal-F® starting dose during controlled ovarian stimulation|On menstrual cycle day 2 or day 3, 150IU rFSH Gonal-F® will be administrated daily till the day of trigger. The dosage of rFSH can be adjusted only if there is a risk of OHSS or insufficient follicular growth.
34527|NCT03914638|Drug|Salbutamol 4Mg Tablet|Salbutamol 4 mg, three times daily
34528|NCT03914638|Drug|Placebo oral capsule|Placebo, three times daily
34529|NCT03914625|Drug|Asparaginase Erwinia chrysanthemi|Given IV or IM
34530|NCT03914625|Biological|Blinatumomab|Given IV
34531|NCT03914625|Drug|Cyclophosphamide|Given IV
34532|NCT03914625|Drug|Cytarabine|Given IT or IV
34533|NCT03914625|Drug|Dexamethasone|Given PO or IV
34534|NCT03914625|Drug|Doxorubicin|Given IV
34535|NCT03914625|Drug|Doxorubicin Hydrochloride|Given IV
34536|NCT03914625|Drug|Leucovorin|Given PO or IV
34537|NCT03914625|Drug|Leucovorin Calcium|Given PO or IV
34538|NCT03914625|Drug|Mercaptopurine|Given PO
34539|NCT03914625|Drug|Mercaptopurine Oral Suspension|Given PO
34540|NCT03914625|Drug|Methotrexate|Given IT or IV
34541|NCT03914625|Drug|Prednisolone|Given PO or IV
34542|NCT03914625|Drug|Prednisone|Given PO or IV
34543|NCT03914625|Drug|Thioguanine|Given PO
34544|NCT03914625|Drug|Vincristine|Given IV
34545|NCT03914625|Drug|Vincristine Sulfate|Given IV
34546|NCT03914612|Drug|Carboplatin|Given IV
34547|NCT03914612|Drug|Paclitaxel|Given IV
34548|NCT03914612|Biological|Pembrolizumab|Given IV
34549|NCT03914612|Other|Placebo|Given IV
34550|NCT03914612|Other|Quality-of-Life Assessment|Ancillary studies
34551|NCT03914612|Other|Questionnaire Administration|Ancillary studies
34552|NCT03914586|Device|oXiris filter|Continuous Renal Replacement Therapy with oXiris filter
34553|NCT03914560|Other|Burn injury|minor burn injury
34554|NCT03914547|Behavioral|REDCHiP|REDCHiP includes seven group-based sessions and three individual sessions. REDCHiP uses a three-pronged approach to reduce parents' FH. It uses T1D education and problem-solving to enhance parents' knowledge and skills. It uses child age-appropriate behavioral parent training to promote parents' skills and confidence in managing disruptive child behaviors and reducing their reliance on hypoglycemia avoidance behaviors. It uses cognitive-behavioral therapy strategies to help parents reduce maladaptive thinking/coping related to hypoglycemia fear.
34555|NCT03914547|Behavioral|ATTN|Provides a similar attention control. ATTN includes seven group-based sessions and three individual sessions.
34556|NCT03914534|Drug|Valproic Acid 500 MG|Administration of 500 mg of Valproic Acid
34557|NCT03914534|Drug|Valcote 500 mg|Administration of 500 mg of Valproic Acid
34558|NCT03914508|Behavioral|Memory + Behavioral Weight Loss|BWL and memory enhancement (M+BWL) will be integrated to capitalize on the strengths of both treatments. All participants will be taught general behavioral weight loss skills including to decrease caloric intake and increase physical activity, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss. The proposed M+BWL program provides memory interventions based on the literature, including eating attentively, memory of previous meal, memory skills for planning, effects of diet on memory and the relationship between memory and satiety. The M+BWL program will also utilize experiential learning during the group program such as practicing memory enhanced skills during eating.
34560|NCT03914495|Dietary Supplement|Placebo|Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.
34561|NCT03914482|Device|MRI|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality
34562|NCT03914469|Behavioral|Behavioral Intervention Group|The active intervention will include eight tele-delivered health coach sessions, three tele-based outcome assessments, and two semi-structured interviews at 6 months and 12 months post-intervention. Each tele-based outcome assessment is roughly 45-60 minutes and will be conducted by a member of the research team. Each intervention session will be delivered by a trained health coach over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
34563|NCT03914456|Other|rehabilitation treatment|
34564|NCT03914443|Biological|Nivolumab|240 mg or 360 mg
34565|NCT03914443|Drug|5-FU|750 or 800 mg^2
34566|NCT03914443|Drug|CDDP|70 or 80 mg/m^2
34567|NCT03914443|Drug|DTX|70 mg/m^2
34568|NCT03914430|Other|Food|The intervention represents a breakfast meal (cereals with cultured products) or breakfast skipping (water control)
34569|NCT03914417|Drug|Imiquimod 3.75% Cream|Approximately two weeks after Day 0, the entire treatment area was treated with imiquimod 3.75% cream. Subjects utilized the 2 weeks on, 2 weeks off, 2 weeks on regimen. Subjects were followed every 2 weeks during treatment (week 2, 4 and 6) and then at 4 and 8 weeks post last-imiquimod application (week 10 and 14).
34570|NCT03914404|Drug|γ-linoleic acid and placebo(Thioctic Acid)|"γ-linoleic acid (Evoprim soft capsule) twice a day and 4 capsules at a time.~Thioctic Acid(LipoA HR Tab. 600mg) placebo once a day and 1 tablet at a time."
34571|NCT03914404|Drug|Thioctic Acid and placebo(γ-linoleic acid)|"Thioctic Acid(LipoA HR Tab. 600mg) once a day and 1 tablet at a time.~γ-linoleic acid (Evoprim soft capsule) placebo twice a day and 4 capsules at a time."
34572|NCT03914365|Procedure|Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)|Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
34573|NCT03914352|Drug|PD-1 antibody|In this group participants were treated with PD-1 antibody (240mg, Intravenous drip infusion, Q14 days) since the15 days after hepatic resection and at the interval of 15 days.
34574|NCT03914352|Procedure|TACE|In this group enrolled patients were treated with TACE at the30 days after hepatic resection.
34575|NCT03914339|Procedure|Periodontal and orthodontic treatment|Eighteen periodontally compromised patients who give be given both periodontal and orthodontic treatment
34576|NCT03914339|Procedure|periodontal treatment|Eighteen periodontally compromised patients who give be given periodontal treatment alone.
34577|NCT03914326|Drug|Semaglutide|Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state
34578|NCT03914326|Drug|Placebo|Placebo tablets to be taken with water at the same time every morning in a fasting state
34579|NCT03914313|Device|Robotic Treatment plus VR|The patients included will be divided into three groups of 30 patients each. In this group patients will undergo a rehabilitation training with the Lokomat-Pro, in which the exoskeleton device is equipped with a screen with virtual reality. The rehabilitation protocol consists of 24 training sessions (3 sessions per week, for 8 weeks, each session lasting about 45 minutes). The Lokomat-Pro will be used to improve gait, whereas motor and cognitive function will be normally trained by using conventional neurorehabilitation. Patients will be evaluated at baseline (T0), immediately (T1) and after 3.month (T2) of treatment.
34584|NCT03914287|Other|Self-Myofascial release|The Self-Myofascial release protocol for the lower limbs using a Foam Roller will include: Self-Myofascial release of the plantar region using and Solid Ball Massage; release of the myofascial components of the back of the leg using a Foam Roller; release of the myofascial components of the anterior part of the leg using a Foam Roller; release of myofascial components of the hamstring region using a Foam Roller; release of the myofascial components of the adductor muscles using a Solid Ball Massage in a sitting position; release of the myofascial components of the abductor muscles using a Foam Roller in lateral decubitus; and release of the myofascial components of the pelvitrochanteric muscles using a Foam Roller in a sitting position.
34585|NCT03914274|Device|Technical sock|Socks were of two types: technical socks, designed for high performance sports use (Lurbel brand, models Tierra and Set), and non-technical socks for everyday use. The socks had different composition: Tierra (50% regeneractiv, 25% cool-teak, 17% polyamide ions, 8% lycra); Set (75% cotton, 17% polyamide, 8% lycra) and cotton (98% cotton, 2% elastane).
34586|NCT03914261|Drug|Risankizumab|Risankizumab will be administered as intravenous (IV) or subcutaneous (SC) injection.
34587|NCT03914235|Combination Product|Tumescent Anesthesia|A tumescent solution is prepared with 2% lidocaine (10ml), 1:1000 epinephrine (0.4ml) and 7.5% sodium bicarbonate (4ml) dissolved in 0.9% saline solution (40ml) and applied from 3 to 20ml (depending on the pathology to be repaired) at the incision site.
34588|NCT03914235|Drug|Lidocaine|Apply 3 to 20 ml at the incision site, depending on the pathology to be repaired(carpal tunnel syndrome, trigger finger or Quervain syndrome).
34589|NCT03914235|Device|Pneumatic tourniquet|Level of the forearm at 250 mmHg, after exsanguination with Esmarch bandage.
34590|NCT03914235|Procedure|Open release of the tendon|Standard surgical procedure for carpal tunnel syndrome, trigger finger and Quervain syndrome.
34591|NCT03914222|Device|CardioSpire (Respirix) Device|Patients will blow into the device through a small tube, which analyzes the signals in the airway patterns.
34592|NCT03914209|Other|EHL clotting factor|This study shall not implement any intervention that might alter the normal development of the daily life activities of hemophilia patients included in the study. They will continue with the prophylactic regimen prescribed by their hematologist. Patients will also be asked to continue to develop their physical, work, entertainment and leisure activities in the same way as at baseline.
34614|NCT03914001|Procedure|Second look TURBT|after mpMRI all patients will subjected to second look TURBT
65357|NCT03673670|Drug|Placebo|A placebo solution
34593|NCT03914196|Diagnostic Test|Liver Stiffness Ultrasound|Research imaging will include liver assessments of stiffness (ultrasound shear wave elastography), tissue attenuation (if available), and blood flow (gray-scale and Doppler imaging).
34594|NCT03914183|Device|mCPN Intervention|"Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened"
34595|NCT03914183|Device|Control|Use of standard of care insulin pen needle
34596|NCT03914170|Drug|Folfirinox + cetuximab|Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)
34597|NCT03914157|Device|Low-energy extracorporeal ultrasound shockwave therapy (SWT)|SWT delivers 10% energy of the traditional SWT used for clinically indicated lithotripsy, evokes neovascularization, and improves regional blood flow and function in various ischemic tissues.
34598|NCT03914144|Other|Catheter insertion|A data collection sheet will be assigned for every patient who is recruited for the study. The clinician caring for the patient will be asked to fill in this form after the delivery has occurred. The form essentially will describe if the patient received any catheter during the delivery and if so, an indwelling catheter or an intermittent (in/out) catheter and how many episodes this occurred.
34599|NCT03914131|Drug|Xinnaoning Capsule|Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
34600|NCT03914131|Other|Xinnaoning Capsule Simulator|Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
34601|NCT03914118|Drug|Preoperative modafinil + postoperative placebo|200 mg modafinil pre-operatively and placebo immediately post-operatively.
34602|NCT03914118|Drug|Preoperative modafinil + postoperative modafinil|200 mg modafinil pre-operatively and 200 mg modafinil immediately post-operatively.
34603|NCT03914118|Drug|Preoperative placebo + postoperative placebo|Placebo pre-operatively and placebo immediately post-operatively.
34604|NCT03914105|Procedure|Without music|"The starting condition will be without music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be no music for the duration."
34605|NCT03914105|Procedure|With music|"The starting condition will be with music: the subjects, after a rest period of 10 minutes, will perform a test of induced pain for 6 minutes. There will be music for the duration."
34606|NCT03914092|Drug|triamcinolone acetonide injection|,1 mm percutaneous intralesional injection
34607|NCT03914092|Behavioral|Smith Accent method of voice therapy|regular sessions of smith accent voice therapy (about 24 sessions, twice session / week) for 3 months
34608|NCT03914066|Behavioral|A group-based treatment of overweight and obesity|The intervention is a group treatment of overweight and obesity in primary care inspired by cognitive behavioural therapy. The main goal of the group treatment is for the participants to obtain and maintain healthy lifestyle habits, with emphasis on diet and physical activity. Every group has 8-12 participants and is led by two persons; the main group leader is either a primary care nurse or a physiotherapist with special training. The groups meet six times (2 hours every time) once a month over a 6-8 month period. Every group session has a set agenda with different topics, for example a healthy diet, recommended physical activity or how to deal with setbacks. Between group sessions there are home assignments. The home assignments are followed-up at the next session and participants are encouraged to share experiences with each other in order to inspire, challenge and help fellow group participants. Data is collected prior to the start of group treatment, after 6-8 and 12 months.
34609|NCT03914040|Other|IPSE program|"Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours."
34610|NCT03914027|Behavioral|Telerehabilitation|"Each patient will have the opportunity to have minimum one VC per week the first month, one Video Consultation each second week the second month one VC a month the rest of the trial. Here the physiotherapist, via history will extract the information needed to calibrate the daily TR program according to the patient's physical status and needs.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA. Instead of ergometer bike training, the patient will receive some easy training tools such as elastics, weights and a fitness-step that can be used in the different exercises showed by the VPA to reach the same intensity of workout. The VPA will then be animated to motivate and encourage the patient to exercises at home."
34611|NCT03914014|Other|connective tissue manipulation|From the estimated date of ovulation to the onset of menstrual bleeding, connective tissue massage will be applied to the sacral, lumbar, lower thoracic and anterior pelvic regions for 5 days per week. The application will take 10 min. During the massage treatment, the physiotherapist will touch the end of the middle finger with the skin of the patient and apply the skin to the pull. The patient will be in the supine position during the treatment of the anterior pelvic region while the patient is in the sitting position during the treatment of the back area.
34612|NCT03914014|Other|placebo ultrasound|From the estimated date of ovulation to the beginning of the next menstrual bleeding, placebo ultrasound will be applied a total of 10 minutes (5 minutes for sacral and lumbar, and lower thoracic regions and 5 min for the anterior pelvic region). Placebo ultrasound application will be performed with superficial circular movements without applying excessive pressure. During the application, the device will only be switched on, the dose will not be adjusted and the patient will be given an image of ultrasound dose.
34615|NCT03913988|Behavioral|Lucid Dream|Lucid dream techniques are a set of strategies to induce the ability to obtain conscious awareness during the dream state and include mental suggestions before sleep.
34616|NCT03913988|Behavioral|Stress Reduction|Stress reduction techniques are a set of strategies designed to reduce anxiety and include meditation and guided imagery.
34617|NCT03913988|Behavioral|Sleep Hygiene Techniques|Sleep hygiene is a set of techniques intended to enhance sleep quality and quantity and include maintaining consistent sleep-wake times and avoiding stimulating activities before bed.
34618|NCT03913975|Other|Neuromuscular training|The novel training program with real-time biofeedback added consists of 2 sets of 10 repetitions per session with a progression in exercise intensity (Squat: 40 repetitions during week 1; Squat Jump: 80 repetitions during weeks 2-3; Tuck Jumps: 120 repetitions during weeks 3-6) over the 6-week training period.
34619|NCT03913962|Other|indirect calorimetry|Patients will be separated in different subgroups. Subgroups will be constituted according the disease status (i.e. active vs inactive) to assess the impact of the pathology on physical fitness and according to treatments to assess the effect of treatment on physical fitness.
34620|NCT03913949|Drug|APG-2575|Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
34621|NCT03913936|Other|YES portal|The YES portal is designed to collect and assess participants' toxicities and symptoms, as well as informational needs in between visits with their clinician
34622|NCT03913923|Biological|BCD-217|Combination of anti-CTLA-4 and anti-PD-1 monoclonal antibodies, 1mg/kg and 3 mg/mg, respectively, given Q3W as IV infusion
34623|NCT03913923|Biological|BCD-100|Anti-PD-1 monoclonal antibody, 1 mg/kg, given Q2W as IV infusion
34624|NCT03913923|Other|Placebo|Placebo
34625|NCT03913910|Procedure|Lipogems|Autologous micro-fragmented adipose tissue is injected in the internal orifice, mucosal, submucosal and muscular layer, then in the fistula tract and external orifice in addition to anal flap.
34626|NCT03913897|Other|distraction methods|The children in the groups were distracted by virtual reality goggles and kaleidoscope 2 minutes before venipuncture, until the process was over
34627|NCT03913884|Procedure|Concentrated growth factor|CGF fibrin matrix was placed in one socket which was randomly selected (test side). The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
34628|NCT03913884|Other|Non-Concentrated growth factor Group|To control group, extraction of the tooth on the opposite site was performed and the socket left to heal naturally. The flap was sutured with 4/0 atraumatic silk suture (½ cutting edge, 75 cm, Doğsan, İstanbul, Turkey) for each surgical site.
34629|NCT03913871|Behavioral|Texts to support healthy eating|The intervention arm will receive tailored text messages to encourage healthy eating (increase consumption, fruits, vegetables and water; and a reduce intake of sugar sweetened beverages). Participants will receive an average of 1-2 messages per day for 4 weeks.
34630|NCT03913871|Behavioral|Texts to support physical activity|The intervention arm will receive tailored text messages to support increased minutes of physical activity per day. Participants will receive an average of 1-2 messages per day for 4 weeks.
34631|NCT03913858|Procedure|Obesity Surgery with Low-Flow Anesthesia|Group 1 had 1 liter/minute (50% O2, 50% air) flow administered.
34632|NCT03913858|Procedure|Obesity Surgery with High-Flow Anesthesia|Group 2 had 4 liter/minute (50% O2, 50% air) flow administered.
34633|NCT03913845|Drug|lidocaine with epinephrine|One of the most commonly used local anesthetic agents in surgical practice is lidocaine. Lidocaine as a local anesthetic is characterized by a rapid onset of action (typically within 2-5 minutes of injection) and intermediate duration of efficacy and thus is often favored in the outpatient setting for pre-incisional injections. Of note, however, its effects general only last up to 2 hours. Epinephrine (adrenaline) vasoconstricts arteries, delaying the resorption of lidocaine, and thus almost doubles the duration of anesthesia.
34634|NCT03913845|Drug|Normal saline with epinephrine|Several mechanisms could explain the inability to void postoperatively, including nerve conduction impairment from anesthesia. Multiple studies have investigated the use of various types of anesthesia and downstream effects on postoperative urinary retention. It is postulated that denervating the regional pelvic nerves for pain control may lead to denervation of the bladder for a transient period of time, block both the afferent and efferent pathways of the voiding mechanism, affect the urethral retro-resistance pressure and impact urethral length thereby contributing to voiding dysfunction postoperatively. The use of normal saline in this setting may have a reduction in rates and duration of postoperative urinary retention following retropubic midurethral sling placement.
34635|NCT03913832|Device|sirolimus drug coated balloon (SCB)|"Magic TouchTM (Concept Medical) is a sirolimus drug coated balloon (SCB) for PCI, based on a polymer-free and Nano based drug delivery technology. Magic Touch SCB is a product of CMI proprietary drug delivery technology Nanolute. It is indicated (CE approved) for ISR, small vessels, bifurcation lesions & de novo lesions."
34636|NCT03913832|Device|paclitaxel releasing coronary balloon catheter|SeQuent PleaseTM (B. Braun Melsungen AG, Vascular Systems,Berlin, Germany) is a paclitaxel releasing coronary balloon catheter.
34637|NCT03913819|Drug|First line treatment: oral NSAID and anticholinergic agents|oral NSAID and anticholinergic agents
34638|NCT03913819|Drug|Second line treatment: additional treatment for pain control|Gabapentin, tramadol, Lyrica
34639|NCT03913819|Drug|Third line treatment: A course of intravesical hyaluronate will be given.|A course of intravesical hyaluronate will be given.
34640|NCT03913819|Procedure|Fourth line treatment: surgical intervention|Consideration of hydrodistention and augmentation cystoplasty
34641|NCT03913806|Drug|Bevacizumab-IRDye800CW|dose finding:10mg; 25mg; 50mg
34663|NCT03913572|Procedure|Injection of adipose-derived stem cells into perianal fistula|The plastic surgery team will perform fat graft harvest. Tumescent solution will be infiltrated into the area of liposuction, generally the abdomen, flanks, or thighs. Approximately a00ml of liposuction aspirate will be retrieved. It will be washed and condensed down to about 5-25 ml of good-quality fat graft using the REVOLVE System by Acelity. This will then be loaded into a syringe fitted with an injection cannula. The colorectal surgeon will perform an exam under anesthesia and determine if any additional procedure such as ligation of fistula tract, fistulotomy, endorectal advancement flap, or seton placement/exchange is needed. Severity of disease at time of surgery will be recorded by the attending surgeon. Following any indicated procedure, the lipoaspirate will be injected into the soft tissues around the fistula tract.
34642|NCT03913793|Other|Exercise based-cardiac rehabilitation (EB-CR) program|The exercise group underwent an outpatient EB-CR program (phase II) according to the American College of Sports Medicine guidelines for exercise prescription for cardiac patients.[19] Sessions were 3 days/week for 8 weeks. The program included: (1) Warm up (10 minutes): stretching exercises. (2) Aerobic exercise training using treadmill (30 - 60 minutes/session): with target heart rate (HR) at 45 - 75% of HR reserve. The maximal HR (HR max) was derived from that obtained during exercise stress test (EST). Patients who had ischemic/arrhythmic manifestations during EST, exercise intensity was prescribed at a HR below the ischemic threshold (10 beats below). (3) Cool down (10 minutes): light intensity treadmill walking. Supervision was provided according to the risk status of each patient that was determined according to the American Association of cardiovascular and Pulmonary Rehabilitation criteria for risk stratification.
34643|NCT03913780|Other|Aerobic exercise more force|The work force for aerobic exercise is 50 to 70% of your maximum heart rate (HRM) achieved in the stress test according to the Naughton protocol. For strength, between 30% to 50% of 1 RM was determined, prolonging a percentage of heart rate that did not surpass 70% of the FCM nor the subjective uptake of physical effort to more than 6 on the modified Borg scale.
34644|NCT03913754|Other|Psycho-social consequences of lupus erythematosus|It will be necessary to take into account the psychosocial experience of the disease [47] and to allow a narrative exploration of this experience and its psycho-social consequences both for the patients and their spouses (ie the experiential dimension of the disease in connection with the life trajectory, the life of a couple, elaborate representations concerning the disease). The purpose of this approach is not only to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inclusion in the socio-cultural condition of the patients, but also to allow an analysis of the inscription. of the disease in the relationship and its implications (relational, affective, sexual) and its impact on the possibilities of social participation.
34645|NCT03913741|Drug|tisotumab vedotin|Tisotumab vedotin will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial
34646|NCT03913728|Other|Drug level blood tests|All information included previously.
34647|NCT03913728|Other|Telephone Interview|All information included previously.
34648|NCT03913715|Behavioral|Ostomy Self-Management Training|include the dose and intensity of the intervention in the description, if applicable
34649|NCT03913702|Drug|Ketorolac Tromethamine|2ml of injectable Ketorolac (30mg/ml) will be mixed with 8ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 60mg of active substance in 10ml).
34650|NCT03913702|Drug|Methylprednisolone Acetate|1ml of injectable Methylprednisolone (80mg/ml) will be mixed with 9ml of lidocaine HCL (1% without epinephrine) and delivered into the subacromial joint (total of 80mg of active substance in 10ml)
34651|NCT03913689|Device|StimRouter Neuromodulation System|An implantable neuromodulation device that treats chronic peripheral nerve pain.
34652|NCT03913676|Behavioral|Velibra|"Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention."
34653|NCT03913663|Other|vestibuloocular training|using vestibulo ocular training program for training neglect patient
34654|NCT03913663|Other|regular exercise training for hemiplegic patients|Traditional gait training program.
34655|NCT03913650|Procedure|0.25% bupivacaine|nerve block procedure will be decided by patients' will for post-op pain
34656|NCT03913637|Behavioral|Strategy Training|Occupational therapists deliver Strategy Training in older adults' homes to enhance real-world application. Strategy training optimizes engagement in meaningful daily activities through generating self-selected goals, monitoring daily activities, scheduling activities, and problem-solving solutions to barriers experienced when engaging in activities.
34657|NCT03913637|Other|Enhanced Usual Care|In this comparison condition, usual care will be enhanced by connecting older adults with MCI to resources available to meet their needs, and notify appropriate physicians when required. Enhanced Usual Care provides a usual care comparison while providing the participants with close monitoring of changes in symptoms.
34658|NCT03913624|Other|Neuromuscular electrical stimulation|
34659|NCT03913611|Other|Accelerated rehabilitation protocol|Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
34660|NCT03913611|Other|Traditional rehabilitation protocol|Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
34661|NCT03913598|Other|patient questionnaire|self-administered patient questionnaire regarding the different aspects of internet and social media use in dermatology patients
34662|NCT03913585|Behavioral|Lifestyle intervention|Upon inclusion and consent all patients receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is systematically registered and collated with existing Electronic Patient Record (EPR) data and the patients risk of developing a lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All patients receive digital feedback including a personal health profile and targeted advice. Patients at high risk of lifestyle-related disease(s) are offered targeted prevention activities at the GP including a health examination and if needed a health dialog. Patients with health risk behavior are offered behavior counselling in the municipality and community health services, if necessary. Patients diagnosed with a lifestyle related disease and patients with a healthy lifestyle are not offered any further services.
34664|NCT03913559|Drug|Inotuzumab ozogamicin|dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
34665|NCT03913559|Drug|Methotrexate|Intrathecal (IT) therapy
34666|NCT03913559|Drug|Hydrocortisone|Intrathecal (IT) therapy
34671|NCT03913546|Procedure|Spinal manipulative therapy|Participants in the actual spinal manipulative therapy group will be assessed through the activator basic method protocol. SMT will be performed with an Activator IV (Activator Methods International, Phoenix, AZ) setting the force at level 3 for the low thoracic spine (T7-T12), and level 4 for the lumbar spine and pelvis.
34672|NCT03913546|Other|Sham spinal manipulative therapy|Participants in the sham SMT group will undergo a protocol identical to the actual one, with the exception that a sham mechanical thrust (force set at level 0) will be delivered to the targeted areas. In the force level 0 no excursion of the stylus occurs, but the instrument produces the same clicking sound as in the actual SMT condition
34673|NCT03913533|Device|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method|Heart rate assessment using the Neonatal Resuscitation Program 6-sec assessment method At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate by listening to the heart beat for 6-sec and then compute the heart rate of the newborn infant.
34674|NCT03913533|Device|Heart rate assessment using Tap-based smartphone application|At birth, the clinical team will place the stethoscope on the infant chest and calculate heart rate using a Tap-based smartphone application by tapping the screen for 3 beats at that time a heart rate will be displayed.
34675|NCT03913520|Other|Outcome research|patients will undergo an evaluation of their outcome at 30 days postoperatively
34676|NCT03913507|Device|Macroduct® Advanced Model 3710 SYS, Wescor|for each subject, both methods will be tested in order to compare the efficacy of the new sweat collection method (Macroduct® Advanced Model 3710 SYS, Wescor) to the method currently used in clinical routine.
34677|NCT03913494|Device|Transoral Neurostimulation Device (Snoozeal)|Use of the Transoral Neurostimulation Device for 20 minutes, morning and night, every day for at least 4 weeks.
34678|NCT03913481|Procedure|Acute normovolemic hemodilution|In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
34679|NCT03913481|Procedure|Standard care|Best available treatment without ANH
34680|NCT03913468|Drug|Intravenous Ascorbic Acid|1.5 grams IV ascorbic acid q6h, 50 mg IV hydrocortisone q 6 hours, and 200mg IV thiamine BID administered (as documented in medical record)
34681|NCT03913455|Drug|Guadecitabine|Guadecitabine 30 mg/m2 subcutaneously Days 1-5
34682|NCT03913455|Drug|Carboplatin|Carboplatin AUC 4 IV Day 5
34683|NCT03913442|Drug|Colchicine 0.8 mg orally once daily|Colchicine 0.8 mg orally once daily for 3 months
34684|NCT03913442|Drug|Placebo oral capsule|Placebo 0.8 mg orally once daily for 3 months
34685|NCT03913429|Procedure|Infiltration|"Infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla (blockage of terminal branches of the maxillary nerve) after intubation and previous to surgical incision.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 1amp Lidocaine 2% in physiological saline (SF) 100ml"
34686|NCT03913429|Procedure|Maxillary nerve blockade|"Bilateral ultrasound-guided maxillary nerve block by suprazygomatic route after intubation and previous to surgical incision performed by the anesthesiologist.~A total of 5ml of Ropivacaine 0.37% infiltrated on each side. Together with adrenaline infiltration performed by the surgeon at the intraoral and intranasal submucosal level in the maxilla.~A total of 50ml of the following preincisional mixture is infiltrated: ½ amp Adrenaline + 110ml SF."
34687|NCT03913416|Device|3D printed model|Before surgery, the surgeon will have a 3D printed model of the pulmonary malformation as well as the lung, the rib cage and the tracheal trunk based on the initial scanner images. He will then be able to train and plan the surgical strategy, as well as to discuss the pulmonary exclusion with the anesthetist.
34688|NCT03913416|Other|Control group|The control group is composed of patients operated with standard surgery
34689|NCT03913403|Procedure|ECHO|Echocardiogram at baseline and 24 hours later
34690|NCT03913403|Procedure|Blood Draw|Blood Draw for Troponin Levels - 5ml at baseline and 24 hours later
34691|NCT03913377|Device|Spectacles|Subjects' own habitual spectacles
34692|NCT03913377|Device|ACUVUE OASYS®1-Day with HydraLuxe™ Technology|Test 1
34693|NCT03913364|Dietary Supplement|Probiotic|B. bifidum 900791-containing ice cream
34694|NCT03913364|Dietary Supplement|Placebo|Placebo ice-cream
34695|NCT03913351|Behavioral|Lifestyle modification|The program consists of education on glycemic index, balanced diet, interpretation of food labels, food exchanges, healthy eating out techniques and healthy cooking methods.
34696|NCT03913338|Procedure|LasikXtra|By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.
34697|NCT03913338|Procedure|LASIK|Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.
34698|NCT03913325|Other|PREVSAM model|A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
34699|NCT03913325|Other|Treatment as usual (standard treatment)|Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
34700|NCT03913312|Biological|Unrelated cord blood|Unrelated cord blood comes from Shandong cord blood bank. TNC>1.5*107/kg;HLA 4-5/6
34701|NCT03913286|Device|Cortimo|The Cortimo comprises an implanted brain activity sensor and a wearable powered arm orthosis.
34732|NCT03913013|Behavioral|Family-Focused Treatment with MCC App|12 sessions of family-focused therapy plus use of a mobile app that enhances the skill training taught in the sessions.
34733|NCT03913000|Drug|ID-085|Hard capsules for oral administration formulated at a strength of 200 mg
34734|NCT03912974|Drug|Escitalopram|see 'arm description'
34735|NCT03912974|Drug|Placebo oral capsule|see 'arm description'
34846|NCT03912194|Behavioral|relaxation strategies|Participants will generate and refine relaxation techniques with the aid of a therapist
34702|NCT03913273|Procedure|AMI transtibial amputation|Two Agonist-antagonist myoneural interfaces (AMIs) were surgically constructed during a modified transtibial amputation procedure. Each AMI was made of natively innervated and vascularized muscle segments - an agonist and antagonist - that were surgically connected in series within the amputated residuum. Tarsal tunnels, including segments of each tunnel's native tendon component, were procured from the amputated joint. The tunnels were affixed to the residual limb tibia and the AMIs were constructed by coaptation of an agonist and an antagonist muscle to either end of the tendon passing through the tunnel. Consequently, the force produced by one muscle stretches its partner such that the AMI can communicate signals from the mechanoreceptors in both muscles to the central nervous system.
34703|NCT03913273|Procedure|Standard transtibial amputation|A standard transtibial amputation was performed according to traditional techniques. No surgical construction of agonist-antagonist myoneural interfaces (AMIs) was performed.
34704|NCT03913260|Drug|LY3375880|Administered SC
34705|NCT03913260|Drug|Buffer Matrix (No LY3375880)|Administered SC
34706|NCT03913260|Device|Autoinjector (AI)|AI used to administer LY3375880 or Buffer Matrix
34707|NCT03913260|Device|Manual Syringe|Manual syringe used to inject LY3375880
34708|NCT03913247|Other|Size Measurement using a measuring tape, a caliper and a metric|Each patient will have the following measure: measure of the span, the tibia, the ulna, the distance between the hill and the knee, the head, the trunk and the leg. The different measures will be done using a measuring tape and with a caliper. Before leaving the intensive care unit, each patients will be measured according to the WHO standard, that is to say strictly lengthened, using a metric for patient younger than 2 and stand up using a stadiometer for patient older than 2.
34709|NCT03913234|Drug|Ribociclib, Trastuzumab, Letrozole|Phase IB: letrozole 2.5mg (fixed dose), trastuzumab (8mg/kg loading followed by 6mg/kg q 3weeks, fixed dose) plus ribociclib (dose escalation from 200mg to 600mg) to identify recommended phase iI dose (RPIID) Phase II: letrozole, trastuzumab (same as phase IB) plus ribocicilb RPIID
34710|NCT03913221|Drug|Caffeine Citrate 5 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 5 mg/kg IV.
34711|NCT03913221|Drug|Caffeine Citrate 10 mg/kg|Loading dose of caffeine 20 mg/kg IV followed by two daily doses of 10 mg/kg IV.
34712|NCT03913208|Procedure|Priority to freeze|Priority for cryopreservation and later on embryo transfer in artificial cycle with endometrium preparation by the exogenous administration of estrogen-progesterone.
34713|NCT03913208|Procedure|Fresh embryo transfer|usual strategy of giving the priority for fresh embryo transfer
34714|NCT03913195|Drug|ibalizumab-uiyk|Ibalizumab-uiyk is an IgG4 monoclonal antibody targeting domain 2 of the extracellular portion of the CD4 protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
34715|NCT03913182|Drug|apatinib|500mg po Qd
34716|NCT03913169|Other|Educational Implementation of Interprofessional Curriculum|The intervention utilized in this project will involve a 2-year curriculum. The year one/pre-clinical curriculum will be presented to pre-clinical doctor of osteopathic medical students (DO) and physician assistant students (PA) students. The year two/clinical curriculum will be presented to third year DO students and second year PA students once clinic sites are identified.
34717|NCT03913156|Other|B2970 Metabolic Texture Modified Protein Substitute|The study product is a powdered phe-free protein substitute supplemented with long chain polyunsaturated fatty acids (LCP's), containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements and has been designed for use in the management of proven PKU in children aged 6 months to 5 years.
34718|NCT03913143|Drug|QR-110|RNA antisense oligonucleotide for intravitreal injection
34719|NCT03913143|Other|Sham|Shame intravitreal injection (no experimental drug administered)
34720|NCT03913130|Drug|QR-110|First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration
34721|NCT03913117|Biological|pNGVL4aCRTE6E7L2|Naked pNGVL4aCRTE6E7L2 DNA plasmid
34722|NCT03913117|Biological|TA-CIN|TA-CIN is a single fusion protein comprised of HPV16 L2, E7 and E6 proteins linked in tandem.
34723|NCT03913104|Drug|Mifepristone|Patients will have MifeprexⓇ (mifepristone) shipped to a preferred address via an online mail order pharmacy rather than standard care at clinic visit.
34724|NCT03913091|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL
34725|NCT03913091|Drug|0.5% Bupivacaine HCL|0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)
34726|NCT03913078|Behavioral|Group Fitness|Traditional Group Fitness consisting of aerobic and strength exercises performed in a group setting and led by a trained instructor.
34727|NCT03913078|Behavioral|PlayFit|Modified sports fitness exercise program consisting of games played in groups and led by a trained instructor.
34728|NCT03913065|Diagnostic Test|CT|"Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI)."
34729|NCT03913052|Procedure|Intra-articular Viscosupplement Application|Injection containing hyaluronic acid, chondroitin sulphate and glucosamine is performed once when the knee joint was in the supine position and the knee is in the extension.
34730|NCT03913039|Procedure|Transperineal biopsy Protocol|"Transperineal biopsy approach with avoidance of rectal flora~MRI-ultrasound fusion-guided biopsies with reduced number of biopsy cores, where clinically indicated~Rectal swab to identify the presence of fluoroquinolone resistant (FQR) bacteria~Multi-antibiotic prophylaxis~Urine culture, prostate tissue culture and rectal swab culture to define contemporary, region-specific antibiotic resistance patterns."
34731|NCT03913026|Biological|Transplant with an expanded ECT-001 cord blood|"Patients will receive a conditioning regimen (such as: cyclophosphamide 120 mg/kg, fludarabine 75mg/m2 and TBI 12 Gy or cyclophosphamide 50 mg/kg, fludarabine 150 mg/m2, thiotepa 10 mg/kg and TBI 4 Gy).~The cord to be expanded will undergo CD34+ selection. The CD34- product is cryopreserved and will be thawed and infused on Day +1 post-transplant. The CD34+ product will be placed in a closed culture with UM171 for a 7-day expansion and is infused on Day 0.~Patients will receive standard supportive care and GVHD prophylaxis (such as MMF and tacrolimus). Tacrolimus will be discontinued on Day 100 post-transplant unless GVHD arises."
34736|NCT03912961|Other|Picture of the retina with a handheld retinal camera|Patient with diabetes will have their undiluted and dilated images taken, with the images being centered on the macula and on the optic disc.
34737|NCT03912935|Other|comparison between two different intubating position|Comparing to different position (sniffing and BUHE) in endotracheal intubation for rapid sequence induction in simulated emergency cases
34738|NCT03912922|Other|Activity regime|Activity regime of 4 days followed by a test day.
34739|NCT03912909|Drug|Empagliflozin Oral Tablet [Jardiance]|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
34740|NCT03912909|Drug|Placebo Oral Tablet|Participants will be randomly assigned to receive either Empagliflozin 10mg/daily or Placebo and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 4-week treatment phases will be separated by a 4-week wash out (drug-free) period. The study will consist of a total of 5 visits conducted over approximately 18 weeks; one screening visit, one baseline visit, 1 short visit at the start of the second treatment phase and 2 comprehensive testing visits, each at the end of the two treatment phases
34741|NCT03912896|Behavioral|Taekwondo|Children will participate in a 7-week taekwondo program.
34742|NCT03912870|Other|Value of Flow Cytometry in Infectious Point of Care|"To validate the diagnostic orientation properties of two new biomarkers (CD64, CD169) for patients with infectious syndromes arriving in emergency departments. This prospective observational study will focus on the quantification of these biomarkers on a hematology tube background (Pr Morange laboratory) without modifying the usual diagnostic and therapeutic procedures. The results of these assays will be compared with the diagnoses made at the end of treatment in order to determine their sensitivity and specificity.~This study is the preliminary study, necessary to determine the detection characteristics of these biomarkers."
34743|NCT03912857|Drug|Camrelizumab|"Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd"
34744|NCT03912844|Procedure|SIRT followed by liver resection or liver transplantation|The ESSURE registry is a prospective observational study. Patients are only asked to be enrolled when they are treated with SIR-Spheres microspheres followed by liver resection/liver transplantation or when SIRT has been performed with the intention to downsize/ downstage the tumor, to induce hypertrophy of the contralateral lobe, making the patient eligible for a future liver resection/transplantation. In no way will participation in the registry influence the way in which the patient is treated according to the treating clinician, or will it influence the quality of the treatment. If a patient is included in the registry, a documented decision of a multidisciplinary tumour board for the treatment algorithm including SIRT must be available. The follow-up periods depend on the treating clinician and local practice and guidelines. Typically, the follow ups are done every three months. So data of a single patient will be included over two years after the treatment.
34745|NCT03912831|Drug|KITE-439|A single infusion of E7 T-cell receptor (TCR) T cells (KITE-439)
34746|NCT03912831|Drug|Cyclophosphamide|Administered intravenously
34747|NCT03912831|Drug|Fludarabine|Administered intravenously
34748|NCT03912818|Drug|Carboplatin|Given IV
34749|NCT03912818|Drug|Cisplatin|Given IV
34750|NCT03912818|Procedure|Cystectomy|Undergo cystectomy
34751|NCT03912818|Drug|Doxorubicin|Given IV
34752|NCT03912818|Biological|Durvalumab|Given IV
34753|NCT03912818|Drug|Gemcitabine|Given IV
34754|NCT03912818|Drug|Methotrexate|Given IV
34755|NCT03912818|Drug|Vinblastine|Given IV
34756|NCT03912805|Biological|botulinum toxin, Type A|topical liniment
34757|NCT03912805|Biological|Vehicle|Vehicle Formulation
34758|NCT03912779|Behavioral|C2Hear RLOs|Freely available online RLOs
34759|NCT03912779|Behavioral|Printed hearing aid booklet|Departmental printed hearing aid booklet (standard care)
34760|NCT03912766|Diagnostic Test|serum copeptin|routine surgical method using resectoscope inserted into the urinary bladder
34761|NCT03912753|Behavioral|Comunică|Comunică is based on the Information-Motivation-Behavioral Skills (IMB) model of health behavior change, which postulates that individuals must possess the requisite information for enacting sexual health, motivation to change their HIV risk and alcohol use, and behavioral skills necessary for reducing their risk. Therefore, Comunică includes MI to provide accurate information about HIV transmission, alcohol abuse, and local GBM-affirmative health resources and build motivation to improve behavioral skills (via CBST). CBST is a therapeutic approach used in the treatment of various behavioral problems, such as alcohol abuse and depression and more recently HIV risk. CBST can help modify cognitions driving unhealthy behaviors, promote awareness of contextual triggers and unhealthy behavioral patterns, and teach coping skills to improve health. Comunică also draws upon minority stress theory recognizing that stigmatizing societal contexts compromise health behavior.
34762|NCT03912753|Other|Education Attention Control|The EAC condition consists of eight self-administered modularized topics, content-matched with the Comunică sessions, which we have generated based on our HIV-prevention education with GBM in the US and Romania.
34763|NCT03912740|Drug|Dexmedetomidine|Patients in the dexmedetomidine-remifentanil group will receive an infusion of 0.6 mcg/kg in half an hour followed by an infusion of 0.6 mcg/kg/hour.
34764|NCT03912740|Drug|sodium chloride|Patients in the remifentanil group will receive an infusion of 0.9% sodium chloride instead of dexmedetomidine (identical infusion rate)
34765|NCT03912740|Drug|Remifentanil|Both groups will have remifentanil analgesia guided by the Nol-Index
34766|NCT03912727|Dietary Supplement|Alpha-Lipoic acid plus renal replacement therapy|Alpha lipoic acid (ALA) is a vitamin-like antioxidant
34767|NCT03912727|Other|renal replacement therapy|standard renal replacement therapy
35646|NCT03905577|Behavioral|Placebo Action observation|Placebo Action Observation
34768|NCT03912714|Procedure|Laparoscopic appendectomy|Surgery will be performed under general anaesthesia. The laparoscopic appendectomy can be performed with the use of 3 trocars; one subumbilical, one suprapubic and one in the lower right quadrant of the abdomen. The appendix is removed using a laparoscopic endostapler enabling a safe and complete appendectomy with the cross stapling line at coecal base. Laparoscopic appendectomy will be performed by a gastrointestinal surgeon with sufficient experience in laparoscopic appendectomies (>20).
34769|NCT03912714|Procedure|Endoscopic appendix biopsies|Appendix biopsies will only be taken when the scope easily slides into the lumen of the appendix (the scope will not be pushed into the appendix lumen)
34770|NCT03912701|Diagnostic Test|Vitalpac early warning score (VIEWS)|The Vitalpac early warning score (ViEWS) is an early warning system aimed primarily at prediction of the first 24-hour mortality in emergency patients and has not been used to assess intensive care unit discharge.
34771|NCT03912688|Device|acupoint stimulation|
34772|NCT03912688|Device|single acupoint|
34773|NCT03912688|Device|dual acupoints|
34774|NCT03912675|Procedure|Integra® dermal substitute and RigeneraTM protocol|Integra® dermal substitute enriched with the autologous dermal micro-grafts obtained with RigeneraTM protocol
34775|NCT03912662|Device|Mesh augmented reinforcement|Abdominal wall sutureline reinforcement with ProgripTM Self-Gripping Polyester Mesh
34776|NCT03912649|Device|RemovAid|The RemovAid device is used for removal
34777|NCT03912636|Behavioral|Diaphragmatic breathing|Subjects will perform Diaphragmatic breathing after the test meal.
34778|NCT03912636|Behavioral|Deep Slow Breathing|Subjects will perform Deep Slow Breathing after the test meal.
34779|NCT03912636|Behavioral|Normal breathing|Subjects will perform Normal Breathing (as a control) after the test meal as a control.
34780|NCT03912623|Other|SPA Treatment with therapeutic education and physical activity|3 weeks SPA Treatment plus therapeutic education plus physical activity
34781|NCT03912623|Other|Week end|access to the station for a week end after maintenance of usual treatment during 6 months
34782|NCT03912610|Diagnostic Test|Functional magnetic resonance examination|Functional magnetic resonance examination by a Ultra high field magnetic resonance instrument named MAGNATOM 7T.
34783|NCT03912597|Device|Virtual Reality|The 4-minute virtual reality video depicts a day in a life of a student with depression. The one-take video, filmed with a 360° camera, is designed to provide users with an immersive experience that simulates what it feels like to have depression. The user interface consisted of a Google Cardboard VR headset attached to a smartphone.
34784|NCT03912597|Device|Brochure|Participants read an informational brochure about depression depicting standard information about depression, including symptoms and information on how to support someone with depression.
34785|NCT03912597|Device|Standard Video Control|The 4-minute standard video depicts a similar storyline as was shown in the VR video. The standard video is filmed from a third-party perspective with multiple takes edited into a final video, following the standard filming style of these videos. The standard video will be viewed from a laptop with headphones attached.
34786|NCT03912571|Diagnostic Test|Structural 3T MRI|measures of global and hippocampal atrophy)
34787|NCT03912571|Diagnostic Test|MRI Based Perfusion Imaging|brain blood flow
34788|NCT03912571|Diagnostic Test|VR-CO2 MRI Scans|reduced vaso reactivity to carbon dioxide
34789|NCT03912558|Procedure|Butterfly device implantation|The Butterfly device will be positioned and deployed with cystoscopy guidance
34790|NCT03912545|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
34791|NCT03912532|Biological|NGM282|NGM282
34792|NCT03912532|Other|Placebo|Placebo for NGM282
34793|NCT03912519|Procedure|Parallel placement of 16 gauge electrodes|Parallel technique
34794|NCT03912519|Procedure|Perpendicular placement with 22 gauge electrodes|Perpendicular technique
34795|NCT03912493|Device|Game Based Virtual Reality Exercises|A game-based virtual reality device named USE-IT will be added to the rehabilitation program. USE-IT is a technological rehabilitation system designed by the Department of Physiotherapy and Rehabilitation at Hacettepe University. It is a smart gaming device which has been used in patients who suffer from movement loss in their upper extremities due to various neurological and orthopedic reasons.
34796|NCT03912493|Other|Conventional Physiotherapy and Rehabilitation|The conventional physiotherapy and rehabilitation program includes the application of Transcutaneous Electrical Nerve Stimulation (TENS), cold pack, therapeutic ultrasound, Codman Exercises, Wand exercises, shoulder wheel exercises, finger ladder exercises, strengthening exercises with elastic band and capsule stretching.
34797|NCT03912480|Biological|Stem cells from human exfoliated teeth|Intravenous infusion of pulp mesenchymal stem cells
34798|NCT03912467|Other|Pressure Ulcer Evaluation|Patient was evaluated according to presence of pressur ulcer or not
34799|NCT03912454|Other|Autologous Bone Marrow Aspirate Concentrate (BMAC) Injection|Subjects will undergo bone marrow aspiration from the iliac crest. Bone marrow will be concentrated and injected into the symptomatic lumbar disc.
34800|NCT03912441|Biological|BCD-147|Bispecific anti-HER2 monoclonal antibody
34801|NCT03912428|Drug|Celecoxib|COX-2 inhibitor
34802|NCT03912415|Biological|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
34803|NCT03912415|Biological|Bevacizumab|IV infusion
34804|NCT03912415|Drug|Paclitaxel|IV infusion
34805|NCT03912415|Drug|Cisplatin (or Carboplatin)|IV infusion
34806|NCT03912415|Other|Placebo|Placebo
34807|NCT03912402|Biological|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
34808|NCT03912402|Biological|Bevacizumab|IV infusion
34809|NCT03912402|Drug|Paclitaxel|IV infusion
34810|NCT03912402|Drug|Cisplatin (or carboplatin)|IV infusion
34811|NCT03912389|Biological|BCD-100|Anti-PD-1 monoclonal antibody, IV infusion
34812|NCT03912389|Drug|Pemetrexed|IV infusion
34813|NCT03912389|Drug|Cisplatin (or carboplatin)|IV infusion
34814|NCT03912389|Other|Placebo|IV infusion
34845|NCT03912194|Behavioral|cognitive-behavioral withdrawal regulation strategies|Participants will generate and refine individualized withdrawal regulation strategies with the aid of a therapist
34815|NCT03912376|Diagnostic Test|Quest Hyperspectral Imaging System|In this camera 3 sensors are combined for optimal spectral imaging. For 2D reference, and to facilitate annotating the data, a high resolution (full HD) color image, recorded with an RGB-sensor, is included with each hyperspectral dataset.
34816|NCT03912363|Other|Rotating fluids protocol|"IV fluids at a rate of 100-150 ml/hr will be administered:~For blood glucose < 100 mg/dL or less: IV fluids with 5% dextrose~For blood glucose between 101-140 mg/dL: IV fluids without 5% dextrose~For blood glucose > 140 mg/dL on two consecutive occasions: insulin infusion protocol (Study arm 2)"
34817|NCT03912363|Other|Insulin infusion protocol|"Regular insulin at 1 unit/ml AND IV fluids at a rate of 100-150 ml/hr will be administered:~For blood glucose < 80 mg/dL: No insulin AND IV fluids with 5% dextrose~For blood glucose 80-100 mg/dL: Insulin at 0.5 U/hr AND IV fluids with 5% dextrose~For blood glucose 101-140 mg/dL: Insulin at 1.0 U/hr AND IV fluids with 5% dextrose~For blood glucose 141-180 mg/dL: Insulin at 1.5 U/hr AND IV fluids with 5% dextrose~For blood glucose 181-220 mg/dL: Insulin at 2.0 U/hr AND IV fluid without dextrose~For blood glucose > 220 mg/dL: Insulin at 2.5 U/hr AND IV fluids without dextrose"
34818|NCT03912350|Drug|Balovaptan|Participants will receive 1 tablet of balovaptan once daily (QD) on Days 1 through 14.
34821|NCT03912324|Procedure|Unipolar voltage subtraction map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury~Mapping of echocardiographic unipolar voltage subtraction after atrial septal puncture~the electrode map data is transferred to the core lab by network to calculate the unipolar voltage subtraction color map (within 10 minutes)~Increase radiofrequency ablation time by 2 to 5 seconds in areas with high potential in unipolar voltage subtraction color map~Decrease radiofrequency ablation time by 2 to 5 seconds in areas with low potential in unipolar voltage subtraction color map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure and Ablation time, and perfusion saline dose~Rhythm follow-up after the procedure in accordance with the study design."
34822|NCT03912324|Procedure|CT myocardial thickness map guided PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~Prepared myocardial thickness map with CT DICOM images conducted prior to procedure.~Increase radiofrequency ablation time by 2 to 5 seconds in thick areas in CT myocardial thickness map~Decrease radiofrequency ablation time by 2 to 5 seconds in thin areas in CT myocardial thickness map~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
34823|NCT03912324|Procedure|Empirical PV isolation group|"Pulmonary vein isolation will be performed using a radiofrequency catheter~Esophageal temperature will be monitored to prevent esophageal injury.~The procedure is performed by adjusting radiofrequency energy according to the traditional method and experience of the practitioner.~Evaluation of success rate and time of pulmonary vein isolation after bilateral pulmonary vein primary columnar resection~Evaluate time to complete isolation after additional ablation~Evaluation of Procedure time, Ablation time, and perfusion saline dose~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
34824|NCT03912298|Other|Opioid Taper Pain perception|Pain Responses: The primary dependent variable, pain, will be measured using two highly reliable and valid pain induction techniques, the CPT and QST, employing procedures consistent with those described in the literature. Order of pain testing will vary, and three aspects of the pain response will be captured at each study session: evoked pain; temporal summation; and conditioned pain modulation, which map on to the hypothesized peripheral, spinal and supra-spinal mechanisms of OIH. Protocols for each assay have been uploaded.
34825|NCT03912285|Drug|Amlodipine10mg|Amlodipine 10mg will be administered orally twice a day for 9 days
34826|NCT03912285|Drug|Losartan potassium 100mg|Losartan 100mg will be administered orally once a day for 9 days
34827|NCT03912285|Drug|Amlodipine plus Losartan|"Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan"
34828|NCT03912272|Behavioral|High-intensity Interval Training|In the high-intensity interval training group, subjects will receive respective prescribed exercise once a week.
34829|NCT03912272|Behavioral|Usual Care Control|In the usual care control group, obesity-related health briefing, dietary caloric restriction advice, and lifestyle counseling/consultation will be provided.
34830|NCT03912259|Drug|dupilumab SAR231893|Pharmaceutical form: solution Route of administration: subcutaneous
34831|NCT03912259|Drug|placebo|Pharmaceutical form: solution Route of administration: subcutaneous
34832|NCT03912259|Drug|Emollient (moisturizer)|Pharmaceutical form: cream Route of administration: topical use
34833|NCT03912246|Biological|biological samples|collection of blood, urine, saliva, stool, skin and mouth swabs, tears
34834|NCT03912246|Procedure|lumbar puncture|collection of cerebrospinal fluid
34835|NCT03912233|Drug|VX-121|VX-121 tablet for oral administration.
34836|NCT03912233|Drug|TEZ|TEZ tablet for oral administration.
34837|NCT03912233|Drug|VX-561|VX-561 tablet for oral administration.
34838|NCT03912233|Drug|TEZ/IVA|100 mg TEZ/150-mg IVA, film-coated fixed-dose combination (FDC) tablet for oral administration.
34839|NCT03912233|Drug|IVA|150-mg film-coated tablet for oral administration.
34840|NCT03912233|Drug|Placebo|Matched Placebo.
34841|NCT03912220|Drug|Nicotinamide riboside|The experimental arm will investigate the effects of nicotinamide riboside on nerve degeneration and regeneration.
34842|NCT03912220|Drug|Placebo Oral Tablet|Placebo drug that looks like the experimental drug, nicotinamide riboside tablets.
34843|NCT03912207|Biological|BCG Danish|BCG Danish 1331 is on the WHO list of pre-qualified vaccines and has a well-defined side effect profile. BCG is licensed for delivery via the intradermal route. It is not licensed for delivery via the aerosol route.
34844|NCT03912207|Other|Saline placebo|Saline is a routinely used placebo.
34847|NCT03912194|Behavioral|early withdrawal exposure|Exposure to the first 4 hours of abstinence across 4 separate sessions
34850|NCT03912155|Other|Multi-scale analysis of physiological brain networks|It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
34851|NCT03912142|Diagnostic Test|three dimensional Transperineal Ultrasound Scan|Diagnostic test: three dimensional transperineal ultrasound scan
34852|NCT03912129|Genetic|blood sample|"A first systematic approach by Targeted-Next Generation Sequencing will be used on the entire cohort of patients with pSE. This step will be performed on a sequencing chip specifically developed to detect anomalies in known genes involved in autoimmunity.~In patients for whom no mutations are identified, a whole exome sequencing (WES) approach will be applied to patients and their parents to seek to identify mutations in new genes that may be related to pSE.~In patients for whom this WES approach is unsuccessful, the search for somatic lymphocyte mutations, or copy number variants will be performed before considering a complete genome sequencing .~If several candidate genes are identified, the clinical data provided by the CEREVANCE and the phenotypic analyses carried out prior to genetic analyses by the CEDI laboratory will guide the choices to prioritize the study of the identified variants."
34853|NCT03912116|Other|CLARIX FLO|100mg CLARIX FLO
34854|NCT03912116|Other|Saline|Saline
34855|NCT03912103|Other|Interdisciplinary Deprescribing and Medication Optimization Intervention|as current
34856|NCT03912077|Behavioral|Culturally Adapted Cognitive Behavioural Therapy|7-session psychosocial intervention
34857|NCT03912064|Drug|Ipilimumab|Ipilimumab is an antibody that acts against CTLA-4
34858|NCT03912064|Biological|CD25hi Treg depleted DLI|Donor lymphocyte product
34859|NCT03912051|Device|asymmetric balloon|Asymmetric balloon for treatment of intranasal bleeding
34860|NCT03912038|Other|No intervention.|No intervention
34861|NCT03912025|Other|Relationship between positive mindset and exercise capacity|No intervention. Cross-sectional study looking at the relationships between questionnaire scores and outcomes
34862|NCT03912012|Drug|Iohexol renal clearance measurement|intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
34863|NCT03912012|Device|microcirculation assessment through Laser Doppler associated to iontophoresis.|endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
34864|NCT03912012|Device|Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement|carotid ultrasound (during Day 1)
34865|NCT03912012|Biological|Blood sampling|37 mL of blood sample will be performed at Day 1
34866|NCT03912012|Biological|Urine sampling|The urinary collection will be done during the Day 1, on the first morning urination
34867|NCT03912012|Device|High-resolution peripheral quantitative computed tomography (HR-pQCT)|assessment of the Body Mass Index by HR-pQCT (during the Day 1)
34868|NCT03912012|Radiation|Dual-energy X-ray (DXA)|assessment of bone parameters by DXA (during the Day 1)
34869|NCT03911986|Device|R Test 4 External Loop Recorder|The R-Test 4 is an externally worn, re-usable, battery-powered, lightweight ECG monitor, which records events triggered by cardiac arrhythmias. It is worn for 7 days. Cardiac monitoring is triggered by tachycardia or detection of irregular pulses or patient may trigger recording, if the participant experience symptoms (e.g. palpitations). The patient wears 2 chest leads (on one, the R-Test device is attached, weight 42g). The R-Test 4 is CE marked, and uses an FDA-approved algorithm for automatic detection of atrial fibrillation, and permits 5 minutes of pre-event recording and 5 minutes of post-event recording.
34870|NCT03911973|Drug|Gedatolisib|Gedatolisib, 150-180MG IV
34871|NCT03911973|Drug|Talazoparib|.75-1.00mg
34872|NCT03911960|Behavioral|Acceptance and Commitment Therapy|2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch
34873|NCT03911960|Behavioral|Enhanced Usual Care|2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
34874|NCT03911947|Device|Vibrolung|Device for vibroacoustic respiratory therapy
34875|NCT03911934|Other|Polypharmacy intervention|A physician from the Department of Clinical Pharmacology prepares a critial medication review before the first visit in the outpatient clinic through critical review of the patient's medical journal and communication with the patient's GP. During the visit in the outpatient clinic, medications are changed based on the medication review with consent from the patient. After the visit the GP is notified of the changes. It is possible to see the patient more than one time in the outpatient clinic (might be needed if tapering or lots of changes) and possible to follow-up on medication changes by telephone with the patient.
34876|NCT03911934|Other|Usual care|Usual care in the geriatric outpatient clinic with geriatric assessment from a trained geriatrician
34877|NCT03911921|Drug|RSYRT decoction|Compound granules of traditional Chinese medicine
34878|NCT03911921|Drug|Astragalus membranaceus|One herb
34879|NCT03911908|Combination Product|Cerebral oximetry (near infrared) based CPR-Algorithm|If NIRS values do not increase over time until ROSC (target: >40 % after 10 min), interventions are suggested in a modified CPR/NIRS algorithm.
34880|NCT03911895|Device|Stent more than 26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
34881|NCT03911895|Device|Stent equal to or less than26 mn length|stent length in patients undergoing PCI (Drug Eluting Stent)
34882|NCT03911882|Dietary Supplement|Celergen Administration|The food supplement Celergen was administered on a daily basis for a total of 3 months (90 days) to participating fibromyalgia patients
34916|NCT03911583|Behavioral|Intense physical activity group (IPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
34917|NCT03911570|Drug|Glucosamine Sulfate|Therapy with the prescription formulation of crystalline glucosamine sulfate
35684|NCT03905291|Drug|Placebo|normal saline
34885|NCT03911856|Other|Echocardiography|We hypothesize that non-invasive indices of RV (echocardiograph-derived strain and strain rate) and pulmonary (gas exchange-derived lung diffusion and surface area) function during light exercise will successfully identify and discern patients with known RV dysfunction (PAH/HFpEF with RV failure) from those with known pulmonary dysfunction (PAH/HFpEF with pulmonary fibrosis). Additionally, we hypothesize that our assessment techniques will identify subtle derangements in RV and pulmonary function in newly diagnosed PAH and HFpEF patients, and that this may guide early and targeted therapeutic intervention.
34886|NCT03911856|Other|Pulmonary Gas Exchange|We hypothesize that breathing hyperoxia will increase exercise capacity by reversing RV and pulmonary derangements, and that the mechanisms of action will be related to the underlying dysfunction (e.g., reducing PVR, increasing RV functional reserve, increasing gas diffusion).
34887|NCT03911843|Drug|omega-3 supplementation|Supplementation with Ω-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at a dose of 50-60 mg/kg/day for 12 months, currently underway or completed after 12 months of omega-3 administration, in 42/65 T1D children
34888|NCT03911843|Drug|Vitamin D supplementation|Cholecalciferol 1000 ui/die
34889|NCT03911830|Other|Exercise followed cold water immersion|Rehabilitation program of 17 sessions with 30 minutes of exercise followed by 15 minutes of submerged recovery at 17 ° C (3 sessions per week / 6 weeks).
34890|NCT03911817|Drug|Midodrine|The oral vasoactive drug (Midodrine) at a dose of 10-20 mg every 8 hours will be used in one arm .After the blood pressure goal is met for more than 24 hours without IV vasopressor ,midodrine will be discontinued prior to discharge
34891|NCT03911804|Procedure|bolus group and infusion group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus/hr of 0.15% ropivacaine for epidural analgesia. In contrast, patients in the infusion group are administered 0.3 ml/kg/hr 0.15% ropivacaine at a constant rate for epidural analgesia.
34892|NCT03911778|Other|Improvement of symptoms|Improvement of symptoms on the Patient Global Impression of Improvement Index (PGI-I) scale (score 1, 2, or 3) at 6 weeks postoperatively
34893|NCT03911765|Behavioral|digital cognitive training|Digital cognitive exercises, used in the intervention group, have the primary objective of stimulating executive functions, and will be made available through the Internet using the BrainHQ platform.
34894|NCT03911752|Other|Semi-structured interviews|Semi-structured interviews were used to obtain the main data in this study.
34895|NCT03911752|Other|Canadian Occupational Performance Measure|The Canadian Occupational Performance Measure was used with the group of people with Acquired Brain Injury to know their occupational priorities.
34896|NCT03911739|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
34897|NCT03911739|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
34898|NCT03911726|Radiation|Single PET/MR-measurement|A single PET/MR-measurement using [18F]Fallypride with a duration of 180min. Within this measurement, the dopamine receptor agonist apomorphine is applicated.
34899|NCT03911713|Drug|VX-561|VX-561 tablets for oral administration.
34900|NCT03911713|Drug|IVA|150-mg film-coated tablet for oral administration.
34901|NCT03911713|Drug|Placebo|Placebo matched to IVA.
34902|NCT03911713|Drug|Placebo|Placebos matched to VX-561.
34903|NCT03911687|Behavioral|CONCERN CDS system notification|"The CONCERN CDS will trigger based on analytics of nursing documentation that indicates recognition and concern of patient changes. The CONCERN CDS will alert the care team of the patients risky state to increase team-based situational awareness (i.e., shared understanding of the patient situation) of patients predicted to be at risk for patient decompensating in need of rapid intervention to prevent mortality and associated harm.~Version 1: Burn in phase to evaluate adoption and adaptation to the algorithm being studied. Expected time frame - 3 months~Version 2: Version 2 refined based on continuous monitoring of data. Expected time frame - 3 months~Version 3: Version 3 refined based on continuous monitoring of data. Expected time frame - 3 months"
34904|NCT03911674|Other|Oral manual stimulation of feeding in preterm infants|Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
34905|NCT03911661|Other|Fearon warfarin dosing algorithm|Blood test drawn by patient using a point of care INR monitor
34906|NCT03911661|Other|Usual care|Historical management of warfarin by patient's usual care providers
34907|NCT03911648|Drug|0.5 ml.kg-1 bupivacaine 0.25%|Caudally
34908|NCT03911648|Drug|0.5 ml.kg-1 bupivacaine 0.25% with the addition of 3 mg/kg lidocaine 1%|Caudally
34909|NCT03911635|Procedure|URAGPI technique|the Urethral Advancement, Glanuloplasty and Preputioplasty
34910|NCT03911622|Device|MRI|medical device that is used as an imaging tool for soft tissues
34911|NCT03911609|Other|Exercise|Subjects will perform isometric (static) handgrip exercise at submaximal intensity for four minutes. The exercise will be performed while the subject is seated, and the elbow bent at around 90° and unsupported. Subjects will be asked to rate their pain using numerical pain rating scale that ranges from 0 (no pain) to 10 (worst pain), perceived exertion (RPE) from 0 (Nothing at all) to 10 (extremely strong), and perceived stress from 0 (not stressed at all) to 10 (extremely stressed). The ratings of pain intensity, RPE and perceived stress will be provided before, at the middle and at the end of the exercise.
34912|NCT03911609|Other|Cognitive Task|The mental math task, which is also known as serial subtraction test, will be performed for four minutes. Subjects will be asked to rate their pain intensity and perceived stress before, at the middle and at the end of the mental math task.
34913|NCT03911596|Device|Smart Autofocusing Eyeglasses|The smart eyeglasses system is meant to be a next generation alternative technology which replaces the generic eyeglasses used for correction of refractory defects in human vision. These smart eyeglasses do not fix any internal eye problems. They just externally compensate for the loss of eye focusing functions caused by presbyopia. This system is a medical assistive device which is meant to improve the quality of life of presbyopic patients.
34914|NCT03911583|Behavioral|Control Group (CG)|The control group does not receive these notifications (PUSH)
34915|NCT03911583|Behavioral|Moderate physical activity group (MPA)|The women of the experimental group receive PUSH notifications remembering the objective set in consultation and encouraging them to achieve it.
35131|NCT03909737|Other|Placebo to pregnant women|Placebo to pregnant women at antenatal care visits and during delivery
34918|NCT03911557|Drug|Durvalumab and Tremelimumab|Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
34919|NCT03911544|Device|BIS monitor|Participants allocated to the intervention group will receive TIVA anesthesia adjusted by the BIS monitoring in addition to clinical signs of poor anesthesia.
34920|NCT03911531|Diagnostic Test|Whole Exome Sequencing|Whole exome sequencing (WES) provides more detailed information through greater resolution, identifying single base-pair changes and small insertions and deletions. WES performs sequencing on the protein-coding exons, which are contained in 1-2% of the genome but make up over 85% of all known pathogenic mutations.
34921|NCT03911531|Diagnostic Test|Whole Genome Sequencing|Whole Genome Sequencing (WGS) has emerged in recent years as a diagnostic tool that sequences the entire genome and can pick up insertions or deletion of bases, structural variants and intronic single nucleotide variations.
34922|NCT03911518|Procedure|Loop drainage|Loop drainage will occur via 2 small incisions, approximately 2 cm, with the cuff from the base of a sterile glove pulled through and then tied off.
34923|NCT03911518|Procedure|Incision and drainage|The wound will be incised with a #11 blade scalpel along the point of maximal fluctuance, approximately 2-3 cm, and then all loculations bluntly dissected with a set of Kelly clamps. After drainage of pus, the wound will be loosely packed with gauze.
34924|NCT03911505|Biological|ATB200|Enzyme Replacement Therapy via intravenous infusion
34925|NCT03911505|Drug|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
34926|NCT03911492|Procedure|SCPP Management => 65 mmHg|A lumbar intrathecal catheter will be inserted pre-operatively for the measurement of Intrathecal pressure (ITP) and the collection of cerebrospinal fluid (CSF) samples. SCPP will be calculated as the difference between Mean Arterial Pressure (MAP) and the ITP.
34927|NCT03911479|Procedure|Bariatric Surgery|Bariatric Surgery - convencionals Roux-en-Y gastric bypass (RYGB) and vertical gastrectomy (Sleeve; SG)
34928|NCT03911466|Drug|Buprenorphine Injection|Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).
34929|NCT03911466|Drug|Buprenorphine Sublingual Product|Sublingual buprenorphine (BUP-SL), administered daily.
34930|NCT03911453|Drug|Rucaparib|Patients will be treated with single agent rucaparib for 3wks and then proceed to surgery. Core-biopsies (at the time of diagnosis) and tumor from the surgical resection will be assessed for change in expression of PD-L1 by Immunohistochemical assay (IHC).
34931|NCT03911440|Drug|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
34932|NCT03911440|Drug|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
34933|NCT03911427|Other|Active oat beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
34934|NCT03911427|Other|Control rice beverage|Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month
34935|NCT03911414|Drug|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
34936|NCT03911414|Drug|Open-label Treatment with N-acetylcysteine|Open-label Treatment with N-acetylcysteine
34937|NCT03911401|Drug|0.3% OPA-15406|Twice daily
34938|NCT03911401|Drug|1% OPA-15406|Twice daily
34939|NCT03911401|Drug|Placebos|Twice daily
34940|NCT03911388|Biological|G207|Single dose of G207 infused through catheters into region(s) of tumor. If G207 is safe in the first cohort of patients, subsequent patients will receive a single dose of G207 infused through catheters into region(s) of tumor followed by a 5 Gy dose of radiation to the tumor (which includes progressive leptomeningeal disease or any site of gross tumor progressing in the brain parenchyma) within 24 hours of virus inoculation.
34941|NCT03911375|Other|Mindfulness Based Stress Reduction (MBSR)|"Psycho-educational program of stress reduction based on mindfulness. Program of 30 hours of duration divided into 9 sessions with a weekly frequency of 2.5 h and an intensive session between week 6 and 7 of the program with a duration of 7.5 hours.~Each week the theoretical contents necessary to understand the attention development practices proposed in mindfulness-based interventions will be covered. In addition, basic concepts of the psychobiology and psychology of stress and pain are explained. The subjects will have a homework load of approximately 45 minutes per day during the duration of the intervention."
34942|NCT03911362|Behavioral|Lumbopelvic Stabilisation Exercises Group|Lumbopelvic stabilisation exercises will be taught the basic movement, starting with co-contraction of the transversus abdominis (TA) muscle and other muscles together with diaphragm breathing, and continuing the exercises with upper and lower extremity movements together with TA and multifidus contraction.
34943|NCT03911362|Behavioral|Pelvic Floor Exercises Group|The pelvic flor exercise will be in the form of contraction-release for rapidly contracting muscle fibres, and for slowly contracting muscle fibres, slow contraction by counting to ten, hold for a count of ten, then gradually relax by counting to ten
34944|NCT03911336|Drug|Group A - test:Tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
34945|NCT03911336|Drug|Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID|Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
34946|NCT03911336|Drug|Group C - Control 2: tooth extraction and intake of a Non-Nsaid|Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
34947|NCT03911323|Other|diabetic retinopathy|Patients with diabetes enrolled will undergo nonmydriatic fundus imaging and seven-field stereoscopic photography. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the AI algorithm will be compared to the diagnosis of seven-field stereoscopic photography by ophthalmologist. Sensitivity and specificity will be calculated to evaluate the performance of AI algorithm.
34948|NCT03911310|Diagnostic Test|[18F]PSMA-11|[18F]PSMA-11 PET/CT
34949|NCT03911310|Diagnostic Test|[68Ga]PSMA-11|[68Ga]PSMA-11 PET/CT
34950|NCT03911297|Other|Women with polycystic ovary syndrome|Prospective cohort study in women with polycystic ovary syndrome to identify the risk of developing metabolic disease
34951|NCT03911271|Drug|0.1% atropine and 0.01% atropine|0.1% atropine loading dose for 6 months followed by 0.01% atropine for 18 months
34952|NCT03911271|Drug|0.01% atropine|0.01% atropine for 24 months
34953|NCT03911271|Drug|0.9% Sodium-chloride|Placebo for 24 months
34954|NCT03911258|Procedure|nasopharyngeal swab versus nasal wash|The type of procedure will be determine according to patient collaboration
34955|NCT03911245|Other|Retrospective study. Analyze of data in medical records|Retrospective study. Analyze of data in medical records
34956|NCT03911232|Drug|sugammadex|standard general anesthesia protocol with sugammadex
34957|NCT03911219|Behavioral|Assessments of Patient-Reported Outcomes with EHealth system support|Regular use of web-based application tool (eHealth system support - EHSS) with symptom self-reporting and alert function to the patient in addition to clinical routine assessments
34958|NCT03911219|Behavioral|Assessments of Patient-Reported Outcomes paper-based|In the control arm, paper-based QoL questionnaires will be provided.
34959|NCT03911206|Behavioral|Inspiratory muscle training (IMT)|IMT exercises at home will gradually ramp up
34960|NCT03911206|Behavioral|Exercise alone|Subjects will be asked to exercise 2x/week for 6 weeks in person at the Duke research facility and again 2x/week at home for 30 minutes.
34961|NCT03911206|Behavioral|IMT and Exercise|Combining IMT training and exercise
34962|NCT03911193|Drug|Cabozantinib|Patients will be treated with cabozantinib 60 mg/daily (cycles each 28 days) until progression, toxicity or patient refusal.
34963|NCT03911180|Device|Proximal femoral nail with straight parallel blade|Petrochanteric fixation with Heracles proximal femoral nail
34964|NCT03911167|Procedure|open, laparoscopic, and robotic|Radical resection of rectal cancer in robotic, laparoscopic, and open approach
34965|NCT03911154|Device|Philips SmartSleep Technology|"During the 4 nights of sleep restriction (5 hours time in bed), subjects will have one of the following SmartSleep stimulation modalities each night in a randomized order. All subjects will receive all 4 stimulation modalities:~Continuous Fixed Interval~Block~In-Phase Adjustable~Sham: No auditory stimulation while wearing the SmartSleep headband"
34966|NCT03911141|Behavioral|Gamification|"Participants have an 8-week ramp-up period where daily goals increase from baseline to the step target, and sign a pledge agreeing to try their best to meet their goals.~Participants are entered into a game. Each week they receive 70 points. Each day they're told their step count and points. If the step goal was met they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 40 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner who gets a weekly email with the participant's progress. We hold a 3-way phone call with the participant and supportive sponsor to discuss ways they can help the participant meet their goal. Every 8 weeks, have a follow up call if the participant is stuck in a lower level and restart them back at the middle level.~In the follow-up period, participants continue to get a daily text stating if they met their step goal."
34967|NCT03911141|Behavioral|Financial|"Participants are informed that each week money is placed in a virtual account for them. Each day the participant is informed of their step count on the prior day. If the step goal was achieved, the balance remains. Each day the goal is not achieved, the participant is informed that some of the money was taken away. We will use an 8-week ramp-up period in which daily goals are increased gradually from baseline to targets.~During the follow-up period, participants in this arm will continue to receive a daily text message stating whether or not they achieved their step goal on the prior day."
34968|NCT03911128|Other|Observational|Observational study - no intervention
34969|NCT03911115|Other|Food preference questionnaire|This is an online questionnaire administrated once to the participants, to assess food preferences after bariatric surgery. The investigating team will also collect data on the type of surgery, anthropometry, nutrition, taste, smell, disgust and intolerance as well as sociodemographic data.
34970|NCT03911102|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
34971|NCT03911089|Other|UCD Anamix Infant|UCD Anamix infant with DHA and ARA is an amino acid based infant medical food containing only the essential amino acids, carbohydrate, fat, vitamins, minerals and trace elements.
34972|NCT03911076|Biological|PVX-2|pNGVL4a-Sig/E7(detox)/HSP70 (naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
34973|NCT03911076|Other|Placebo|PBS and PGC
34974|NCT03911063|Behavioral|CBT sessions|weekly 20-40 min CBT sessions during 8 weeks; Both the talking sessions (i.e., placebo) and CBT sessions will be performed via telemedicine either via a HIPAA secure telemedicine platform or the telephone based on the preference of the individual patient.
34975|NCT03911063|Behavioral|Talking Sessions|20-40 min talking sessions (i.e., placebo) for 8 weeks; The placebo talking sessions will be performed by an acute care and palliative care board certified, New York State licensed nurse practitioner at the NYU Dysautonomia Center who is familiar with each FD subject enrolling in the study and an expert in familial dysautonomia. The NP will focus the 20-40 minute conversation on typical medical questions and concerns that the FD patient routinely calls the Center to discuss.
34976|NCT03911050|Dietary Supplement|Apple consumption|Apple blends (600 g) One single dose
34977|NCT03911050|Dietary Supplement|Control group|Breakfast without any apple-related products
34978|NCT03911037|Drug|G-CSF|G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
34979|NCT03911037|Drug|Placebo|Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
35002|NCT03910790|Device|19 gauge needle liver biopsy|Obtaining liver tissue with a 19 gauge core needle and whether a good core biopsy can be obtained without the use of suction and secondly to determine the diagnostic yield and safety of 19 gauge core needle for liver biopsy.
35003|NCT03910777|Diagnostic Test|Early Warning Score|National early warning score (NEWS) is another early warning scoring system recommended by the Royal College of Physicians in London to detect early clinical deterioration in hospitalized patients
35132|NCT03909737|Other|Placebo to infants|Placebo to infants at 6 and 14 week EPI visits
34980|NCT03911024|Behavioral|HIV|At the completion of each EMA, participants in the intervention group (n=50) will receive messages that address:1) unsafe sexual behaviors, 2) alcohol/drug use, 3) PrEP interest, and 4) HIV testing. In addition, participants will have access to a button in the app that will link them to resources when/if they are the victim of sexual assault. Finally, intervention arm youth will be asked to set a behavioral goal related to HIV prevention during this session. Those goals will include increasing condom use, PrEP use, non-occupational post-exposure prophylaxis (nPEP) use, reducing number of sexual partners, not having sex with using drugs or drinking alcohol, avoiding IV drug use, getting testing for HIV, and testing and treating sexually transmitted infections (STIs) as needed
34981|NCT03911024|Behavioral|General health|Participants in the attention control condition (n=50) will answer the same EMA items as the Intervention group. However, the intervention messages will contain content related to nutrition, physical activity, sleep hygiene, and tobacco use. Finally, control arm youth will be asked to set a behavioral goal related to general health during this session.Those goals will include getting 7+ hours of sleep, eating >= 5 servings of fruits or vegetables, not using tobacco products, exercising at least 60 minutes.
34982|NCT03911011|Other|Fresh air|Fresh air insufflation of 2 L/min toward mouth/nose.
34983|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery|Bolus of rocuronium 0.1 mg/kg at the discretion of anesthetist to keep the TOF between 1-3 out of 4 during surgery
34984|NCT03910998|Drug|Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2|Bolus of rocuronium 0.1 mg/kg IV will be given during surgery for a TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
34985|NCT03910985|Drug|Duovent HFA|bronchodilation
34986|NCT03910972|Biological|Sm-TSP-2/Alhydrogel® vaccine|The Sm-TSP-2/Alhydrogel® candidate vaccine contains recombinant Sm-TSP-2 adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10mM imidazole buffer containing 2mM phosphate and 15% sucrose, with pH 7.4 ± 0.1. The final concentrations of Sm-TSP-2 and Alhydrogel® in the drug product are 0.1mg/ml and 0.8mg/ml respectively.
34987|NCT03910972|Biological|Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701|The Sm-TSP-2/Alhydrogel® candidate vaccine co-administered with the immunostimulant, AP 10-701. b) AP 10-701, also known as Gluco-Pyranosylphospho-Lipid A Aqueous Formulation (GLA-AF), is a Toll-like Receptor-4 agonist. Point-of-injection formulations with this immunostimulant will be prepared immediately prior to vaccination by adding an appropriate volume of AP 10-701 to Sm-TSP-2/Alhydrogel® and withdrawing an appropriate volume to administer the desired amount of Sm-TSP-2 plus 5µg GLA-AF.
34988|NCT03910972|Biological|ENGERIX-B Hepatitis B Vaccine|Recombinant hepatitis B vaccine containing 10 mcg recombinant hepatitis B surface antigen per dose
34989|NCT03910959|Other|Animal-assisted therapy|Therapy in the presence and with interaction with an animal. Involved animals can be all species that live at REHAB Basel and are part of the AAT program. All animals are trained for the specific service with vulnerable patients.
34990|NCT03910959|Other|Conventional therapy|Parallelled conventional therapy sessions (treatment as usual)
34991|NCT03910946|Drug|Tuberculin, Purified Protein 5Unt/0.1 mL Solution|Tuberculosis (diagnosis)—Tuberculin, purified protein derivative (PPD) is indicated as a diagnostic aid in the detection of Mycobacterium tuberculosis infection. It is also indicated when BCG vaccination or isoniazid prophylaxis is being considered
34992|NCT03910933|Other|elearning patient information|The videos will standardize patient teaching about anticoagulants, warfarin, INR testing, and warfarin safety for Patient Self-Testing, and Patient Self-Management. eKITE, will provide a user-friendly interface to provide health education about anticoagulation. eKITE will teach concepts to the patient, facilitate sustained patient knowledge (6 month evaluation), reduce stress associated with learning, actively engage patients in their anticoagulant management (preference, satisfaction and knowledge).
34994|NCT03910881|Other|Open-platform patient support system (PSS) app|The PSS app enables tracking and visualization of patient-selected health outcomes and sharing of select outcomes with family and providers. The CF clinical team and the family jointly decide which aspects of daily life to track, how often, and the content and frequency of patient-generated reports. Examples of daily care that can be tracked include symptoms (respiratory, gastrointestinal, pain), energy level, appetite, sleep, exercise, mood, medications, therapies, school/work attendance. Prior to a clinic visit, the patient/family generates a report of the outcomes they have been tracking, to help prepare for the visit and identify successes and areas of struggle. This information facilitates meaningful conversations during the visit and promotes shared decision-making. Patients/families can view their progress at any time and share selected outcomes with family and friends as often as desired.
34995|NCT03910855|Behavioral|Mindfulness Based Intervention|The mindfulness-based intervention consists of four 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to stroke survivors and their family caregivers. Participants will be provided handouts for the information covered during these talks and discussions.
34996|NCT03910855|Other|Health Education Program|The health education program consists of four 2-hour sessions covering various health topics (e.g. diet, nutrition and exercise) that pertain to stroke survivors. Participants will be provided handouts for the information covered during these talks and discussions.
34997|NCT03910842|Biological|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
34998|NCT03910829|Behavioral|Action Observation|Action observation training
34999|NCT03910829|Behavioral|Motor Imagery|Motor imagery protocol
35000|NCT03910829|Behavioral|Placebo Action Observation|Placebo Action Observation
35001|NCT03910803|Drug|Brodalumab|"Brodalumab is a human monoclonal IgG2κ antibody directed against human interleukin-17 receptor A (IL-17RA). It is expressed in a Chinese Hamster Ovary (CHO) cell line. Brodalumab is comprised of 1312 amino acids and has an estimated molecular mass of 144,000 Daltons.~Brodalumab Injection is a sterile, preservative-free, yellow solution, delivered via subcutaneous injection. . Each Brodalumab single dose prefilled syringe delivers 1.5 mL of solution containing 210 mg of brodalumab formulated in glutamate (6.5 mg), polysorbate 20 (0.15 mg), proline (36 mg), and Water for Injection, USP at pH 4.8."
35004|NCT03910764|Other|no intervention|Investigators review patients' medical records and collect personal data, underlying diseases, indwelling catheter duration, laboratory data, diagnosis, treatment and prognosis.
35005|NCT03910751|Device|Transcatheter Aortic Valve Implantation with ACURATE Neo Aortic Bioprosthesis|Transfemoral TAVI using the Boston Scientific ACURATE Neo Aortic Bioprosthesis
35006|NCT03910738|Drug|Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection|Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
35007|NCT03910738|Drug|Placebo 4 mL Solution for Injection|Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
35008|NCT03910738|Procedure|MRI|Conventional MS sequences (OFSEP recommendations) and unconventional MRI sequences (Baseline, week 30 and 66)
35009|NCT03910738|Behavioral|Assessment of impact of MS on cognition; quality of life; fatigue; anxiety/depression and work and activities|BICAMS; SF-36 and EQ-5D-3L; MFIS; HADS; WPAI:MS (at baseline, week 30 and 66)
35010|NCT03910738|Behavioral|Assessment of disability|EDSS (Baseline, week 30 and 66)
35011|NCT03910725|Other|Electrocardiographic imaging|ECGi is a non-invasive body surface mapping technique that collects electrocardiographic data using 252 leads, and combines it with subject specific anatomic data acquired from cross sectional imaging to recreate epicardial electrograms.
35012|NCT03910712|Drug|Pyrotinib|Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.
35013|NCT03910712|Drug|Trastuzumab|Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).
35014|NCT03910712|Drug|Aromatase inhibitor|The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
35015|NCT03910699|Device|Three-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a three-row circular stapler, defunctioning colostomy is performed.
35016|NCT03910699|Device|Two-row circular stapler|Para-aortic lymph node dissection, inferior mesenteric artery skeletonisation and ligation below left colic artery origin, nerve-preserving total mesorectal excision, rectum division with a linear stapler, sigmoid colon division and circular stapler envil fixation with a purse-string suture, end-to-end colorectal anastomosis creation with a two-row circular stapler, defunctioning colostomy is performed.
35017|NCT03910686|Combination Product|Transcranial magnetic stimulation and cognitive behavioral therapy|Transcranial magnetic stimulation on different side with/without cognitive behavioral therapy
35018|NCT03910673|Drug|Fosfomycin disodium|Fosfomycin (a phosphonic acid derivative) formulated as a disodium salt.
35019|NCT03910660|Drug|Talabostat Mesylate plus Pembrolizumab|"BXCL701 tablets dosage strengths include 0.2 mg tablets for oral administration.~The starting dose regimen of BXCL701 is 0.4 mg QD on Days 1-14 every 21 days. The BXCL701 dose regimen for any patient depends on the cohort enrolled during the Lead-in Stage. Additional dosing schedules 0.6 mg QD may also be evaluated during the Lead-in Stage.~On days when PD studies are being performed, BXCL701 should be administered at the study center and should be administered at approx. the same time of day on each treatment day in the cycle. In cycles in which PD are not evaluated, BXCL701 also should be administered at approx. the same time of day on each treatment day in the cycle.~Patients may continue to receive study treatment until the development of discontinuation criterion are met, or closure of the study by the sponsor; no maximum duration of therapy has been set.~The PEMBRO dose will be 200 mg, administered as an IV infusion over 30 minutes on Day 1 of each 21-day cycle."
35020|NCT03910647|Drug|pantoprazole|effect of this drug on renal function
35021|NCT03910634|Drug|Fluorouracil|1.33g/body surface QW1, continuous intravenous infusion for 72 hours, repeated for 4 weeks
35022|NCT03910634|Radiation|Intensity modulated radiation therapy|Radiotherapy for 5-6 weeks，50-60Gy
35023|NCT03910634|Drug|carboplatin|Carboplatin (AUC 2), QW1, intravenous drip, repeat for 4 weeks
35024|NCT03910621|Drug|Miglustat|capsule, oral use
35025|NCT03910608|Device|MagPro X100 device (MagVenture, Farum, Denmark)|Each cPAS experimental session contained 100 pairs of stimuli at 0.2 Hz. The experimental conditions differed in the interstimulus interval of the paired pulses. DLPFC stimulation precedes IPL/MPFC stimulation by 10 ms (DLPFC+10) or by 4 ms (DLPFC+4), and IPL/MPFC stimulation precedes DLPFC stimulation by 4 ms (IPL/MPFC+4) or by 10 ms (IPL+10).
35026|NCT03910595|Other|Mepitel Film|Mepitel film is a barrier film that may help in reducing radiation dermatitis by limiting friction.
35027|NCT03910582|Procedure|personalized frozen-thawed embryo transfer|The blastocysts were delayed or advanced transferred after ovulation depending on the endometrium dating in RIF group
35028|NCT03910582|Procedure|routine frozen-thawed embryo transfer|The blastocysts were transferred 5 days after ovulation regardless of endometrium dating in control group.
35029|NCT03910556|Drug|Propofol|intraoperative factors
35030|NCT03910543|Drug|Tofacitinib 5 mg twice daily|Tofacitinib will be administered at a dose of 5 mg twice daily
35031|NCT03910530|Drug|INCMGA00012|Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.
35032|NCT03910530|Drug|INCB001158|Part 1: INCB001158 75 or 100 mg twice daily administered orally.
35033|NCT03910530|Drug|INCMGA00012 + INCB001158|Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .
35034|NCT03910517|Other|No intervention|No intervention
35035|NCT03910504|Drug|Rocuronium 0.3 mg*kg|Patients randomized to the control group will receive rocuronium at 0.3 mg*kg ev bolus at the induction of anesthesia.
35036|NCT03910504|Drug|No Rocuronium|Patients randomized to the interventional group will not receive neuromuscular blockade at the induction of anesthesia.
35070|NCT03910244|Drug|Placebo oral capsule|Matching placebo will be given.
35071|NCT03910231|Drug|Tolvaptan Oral Tablet|Tolvaptan, to block V2R
35133|NCT03909737|Other|No intervention to pregnant women|No intervention to pregnant women
35487|NCT03906799|Drug|OMT-28|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
35037|NCT03910491|Behavioral|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE emphasizes the 3 Ps (Praise, Paraphrase, and Point-out-Behavior). The training initially focuses on parenting skills including giving attention to the child's positive behaviors and ignoring minor misbehaviors. The second phase of training includes teaching techniques for giving children effective commands to set age-appropriate limits. The PriCARE curriculum also includes trauma and stress education components in order to contextualize the use of these skills with the types of behaviors and problems demonstrated by many children who have experienced psychosocial adversity and chronic familial stress. Throughout the curriculum, caregivers are encouraged to practice the skills. PriCARE has been evaluated in the primary care setting and has shown promise. There have been limited studies on PriCARE for foster caregivers.
35038|NCT03910478|Device|DBS Self-Collection Kit|Kit for self-collection of Dried Blood Spot (DBS) samples
35039|NCT03910478|Other|Standard Control Strategy|Standard of care with office-based testing.
35040|NCT03910452|Drug|Busulfan|3 days of IV Busulfan. An alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of conditioning regimen for myelosuppressive properties as per package insert and standard of care.
35041|NCT03910452|Drug|Alemtuzumab|5 days of IV Alemtuzumab. A humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complement-mediated lysis and antibody-dependent cellular toxicity. For this study, being used as part of the conditioning regimen per package insert and standard of practice.
35042|NCT03910452|Drug|Cyclophosphamide|2 days of IV Cyclophosphamide. This is an antineoplastic, and for this study is bine used for its immunosuppressive mechanism of action per package insert and standard of care
35043|NCT03910452|Drug|Sirolimus|Post Peripheral blood stem cell infusion. It is used for its immunosuppressive mechanism of action.
35044|NCT03910452|Radiation|Total Body Irradiation|2 fractionated doses on -2 day. It is used for its immunosuppressive mechanism of action. It is SOP for conditioning for transplant.
35045|NCT03910452|Biological|Allogeneic peripheral blood stem cell|IV infused donor peripheral blood stem cell. Stem cells are cells that give rise to the blood cells - red blood cells that carry oxygen, white blood cells that help the body to fight infections, and platelets that help make the blood clot. Collected and infused per the standard of operating procedures established by the Department of Transfusion Medicine.
35046|NCT03910439|Biological|Avelumab|Avelumab 800 mg IV over 60 minutes (+/- 20 minutes) on days 1 and 15 of each 28-day cycle
35047|NCT03910439|Radiation|External beam radiotherapy|5 Gy per fraction will be delivered on 5 consecutive treatment days for a total dose 25 Gy
35048|NCT03910426|Other|Blood sampling|Blood is sampled before a midweek dialysis session once every year with a maximum of 3 samples in total.
35049|NCT03910426|Other|Nails collection|At the occasion of the blood sampling, finger nails are cut and collected.
35050|NCT03910426|Other|Stool collection|At the occasion of the blood sampling, patients are asked to bring a stool sample.
35051|NCT03910426|Other|Physical Functioning|A subgroup of patients are asked to perform some physical tests.
35052|NCT03910426|Other|Sleep|A subgroup of patients are asked to sleep 2-3 nights with a Motionwatch (Actigraphy) to recording their arm movements.
35053|NCT03910413|Diagnostic Test|Duel Energy CT|Enrolled subjects will complete a dual energy ct for evaluation of esophageal varices
35054|NCT03910400|Diagnostic Test|Computation of quantitative flow ratio|"After stents were implanted whenever technically possible in the STEMI patients, the investigators created a temporary artificial stenosis inside the stent by partially inflating a balloon catheter during pharmacologic hyperemia.~Computation of QFR was performed offline, using a prototype software package (QAngio XA 3D prototype, Medis Medical Imaging System, Leiden, the Netherlands). In the first step, 2 diagnostic angiographic projections with the artifical stenosis, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR."
35055|NCT03910387|Drug|Gemcitabine|Given gemcitabine/nab-paclitaxel combination therapy
35056|NCT03910387|Drug|Nab-paclitaxel|Given gemcitabine/nab-paclitaxel combination therapy
35057|NCT03910387|Drug|Telotristat Ethyl|Given PO
35058|NCT03910374|Procedure|Dural closure|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF and fibrinogen) compared to the fibrin sealants as an adjunct for dural repair
35059|NCT03910361|Drug|Evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to pioglitazone 15mg qd
35060|NCT03910361|Drug|Pioglitazone|pioglitazone 15mg tablet qd + placebo tablet matching to evogliptin 5mg qd
35061|NCT03910348|Device|Whole-body vibration exercise|The WBV training consisted of a high frequency (30-40 Hz) vibration stimulus at a low setting on a Power Plate pro5 vibration platform (Performance Health Systems, LLC, Northbrook, IL, USA).
35062|NCT03910348|Other|High-impact exercise|In the high-impact exercise program, the patients were asked to jump using a jump-rope at the beginning of each session
35063|NCT03910335|Diagnostic Test|LSS Screen|Patients will fill out a questionnaire with 13 questions related to presence or absence of clinical symptoms of lumbar spinal stenosis (neurogenic claudication)
35064|NCT03910322|Dietary Supplement|Bif195|Two different doses of the bacterial strain Bif195 is compared to placebo
35065|NCT03910322|Dietary Supplement|Placebo|Placebo
35066|NCT03910309|Device|TLIF with Titan TT/TO interbody cage|fusion surgery
35067|NCT03910296|Behavioral|Acceptance & Commitment Therapy|ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.
35068|NCT03910257|Behavioral|nutrition education module|12 activities of nutrition education module will deliver by the teacher. The activities consists of coloring my meal plate, playing pictures, story telling: Zizi and Ziko, pictures station, fruits and vegetables card, cooking class, planting bean sprouts, field visit to fruits and vegetables garden, making collages, dot to dot, watching video, making healthy snacks
35069|NCT03910244|Drug|Pomalidomide Oral Product|Pomalidomide, a third generation derivative of thalidomide, given orally at a starting dose of 4 mg/day for days 1-28 of six 28-day cycles. The dose may be reduced to 3 or 2 mg/day based on specific AE criteria.
35072|NCT03910218|Behavioral|NCM4HIV|Participant will receive NCM4HIV intervention which includes Personalized HIV prevention education, behavior goal-setting,behavioral self-monitoring, PrEP eligibility screening,PrEP/nPEP services (labs, medication), healthcare planning/coordination, MI counseling approach, assisting with cognitive appraisals (clarifying misconceptions),promoting health seeking and coping behaviors that incorporate the situational, personal, social, and resource needs affecting health
35073|NCT03910218|Behavioral|Usual Care|Participant will receive usual care which includes Housing, food, and clothing needs,health assessment, basic healthcare, limited anticipatory guidance, mental health counseling, substance use treatment referrals, PrEP/nPEP referrals
35075|NCT03910192|Behavioral|Mindfulness-based coaching|16 week mindfulness-based protocol focused on home-based and weekly group practice of mindfulness meditation and mindful movement.
35076|NCT03910192|Behavioral|Dietary cardiovascular risk reduction coaching|Regular in-person meetings, phone calls, or email from study coordinator instructing them on how to integrate exercise and dietary changes in their lifestyle to reduce their risk of future cardiovascular events.
35077|NCT03910166|Procedure|drug-coated balloon catheter（Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
35078|NCT03910166|Procedure|Intracranial artery stent system（APOLLO）|stent assisted angioplasty
35079|NCT03910153|Dietary Supplement|MSPrebiotic|MSPrebiotic digestion resistant starch from potatoes (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the potato resistant starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
35080|NCT03910153|Other|Placebo|Corn starch (30 g) will be mixed in 1 glass (approximately 250 mL) of non-heated fluid or non-heated semi solid food and consumed. If the subject is on any medications, the corn starch will be administered either 2 hours before medications or 2 hours after participants have taken their medications.
35081|NCT03910140|Procedure|TILA-TACE treatment|TACE was performed through the transfemoral route using a 5-Fr catheter (Shepherd-hook modified Angiographic Catheter, HANACO Medical, Tian Jin, China ) that was advanced from celiac artery to common hepatic artery, proper hepatic artery, hepatic artery and ultimately to tumor feeding arteries which are defined by angiography. Then, a coaxial microcatheter (2.8 Fr Marguerite II, ASAHI INTECC GMA CO., LTD, Nagoya, Japan) was selectively inserted through a 5-Fr catheter into the tumor feeding artery, into which, 5% sodium bicarbonate was infused alternatively with doxorubicin-lipiodol emulsion. Finally, the artery was embolized with PVA (Embosphere®, BioSphere Medical, Paris, France) and microcoil ( Tornado ®, COOK Medical, USA).
35082|NCT03910127|Drug|TQB2450|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
35083|NCT03910127|Drug|Anlotinib|a multi-target receptor tyrosine kinase inhibitor
35084|NCT03910127|Drug|Anlotinib|matching placebo
35085|NCT03910114|Drug|Magnevist|GBCA enhancement
35086|NCT03910114|Drug|Dotarem|GBCA enhancement
35087|NCT03910114|Drug|Gadovist|GBCA enhancement
35088|NCT03910101|Procedure|Hand surgery and intensive rehabilitation|Spasticity-correcting upper-limb surgery comprised lengthening of tendons, release of muscles, and occasionally correction of deformities. Rehabilitation starts the first post-operative day and comprised physiotherapy and occupational therapy. Patients are also taught a home-training program. Up to 1 week of intensive in-hospital rehabilitation followed 3 weeks after surgery and a new home-training program are designed.
35089|NCT03910088|Drug|Pregabalin 100Mg Oral Cap|giving a drug to relieve post-dural puncture headache
35090|NCT03910088|Drug|Hydrocortisone|Giving drug to relieve post-dural puncture headache
35091|NCT03910088|Drug|Acetaminophen|giving a drug to relieve post-dural puncture headache
35092|NCT03910088|Other|oral fluids|giving oral fluids to maintain good hydration
35093|NCT03910088|Drug|Caffeine|giving a drug to relieve post-dural puncture headache
35094|NCT03910088|Drug|Diclofenac|giving a drug to relieve post-dural puncture headache
35098|NCT03910062|Procedure|Lower limb angiography via the reperfusion cannula and NIRS monitoring|Data collection only (lower limb angiography, lower limbs NIRS values).
35099|NCT03910049|Drug|Indocyanine Green|Indocyanine green will be administered intravenously to patients enrolled in this study after the completion of total thyroidectomy in order to assess the visibility of parathyroid glands and to assess the possible correlation of ICG score with post-operative parathormone levels in order to predict post-thyroidectomy hypoparathyroidism.
35100|NCT03910036|Biological|platelet rich plasma|Thirty ml of venous blood was taken from every patient and collected in sodium citrated sterile tubes. Platelet concentrates obtained by adjusting centrifuge at 1800 rpm for 15 min to separate erythrocytes, then at 3500 rpm for 10 min to concentrate the platelets. The preparation was done by a single laboratory technician. Thus 5 ml of PRP were obtained, 0.2 mL of 10% calcium chloride was added to the final product to activate the platelets and injected immediately without storage.
35101|NCT03910023|Other|Usual care comporting a home-exercise program (UCHE)|"The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program."
35130|NCT03909737|Drug|Azithromycin to infants|Azithromycin to infants at 6 and 14 week EPI visits
35102|NCT03910023|Other|Spa therapy|the spa-therapy intervention consists of 18 consecutive days of spa-therapy (excepting Sundays), that must occur with 60 days of randomisation. The latter will combine mineral water with physical and hydrotherapeutic treatments, including massages, heat and water exercises.
35103|NCT03910010|Drug|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Pain. They will be requested to take two capsules four times a day and report their pain on paper forms organized as a calendar or on REDCap.
35104|NCT03909984|Device|Nightwatch|Nocturnal monitoring for 2 months with three different seizure detection devices.
35105|NCT03909971|Drug|Lorlatinib|ALK inhibitor-treated ALK-positive NSCL treatment
35106|NCT03909958|Other|Electroacupuncture+Routine rehabilitation training Group|"Electroacupuncture： Major acupoints: Jiaji points. With urinary and stool dysfunction:+Shenshu (BL23) ,Huiyang(BL35).~Localization:Jiaji points of the upper 1 and the lower 1 segment of the Spinal cord injury plane, a total of 4 points.~Operation: Insert Jiaji points By using Hwato-brand disposable acupuncture needles(0.30mm*50mm), with 0.5 inch from the median line and a depth of 50 to 60mm with perpendicular insertion.Then, participants will receive electroacupuncture treatment by connecting Han's pain irritant instrument (HANS100A) for 30min with the stimulation frequency of 2 /100 Hz and intensity of 1-2mA. Once a day, 5 days a week and rest 2 days, a week is one course and the duration need 12 courses.~Routine rehabilitation training:~Same as Routine rehabilitation training Group."
35107|NCT03909958|Behavioral|Routine rehabilitation training Group|"Routine rehabilitation training:~Participants with good spinal stability will receive sitting training as early as possible, and will carry out standing training if participants had no adverse reactions (postural hypotension, etc.) after sitting training. Muscle strength training will be performed in recovery phase, and functional movement training will be selected according to participants' conditions. Functional movement training and transfer training will be performed for 20min each time and once a day;Standing and walking training, 2 times a day, 30min each time."
35108|NCT03909945|Dietary Supplement|Annona muricata|Patients with prehypertension or stage 1 hypertension, in dietary measures, will received daily one tablet of 796 mg of aqueous extracts of Annona muricata leaves. During 60 days
35109|NCT03909932|Other|Observational study : no intervention|Observational study : only exporting data
35110|NCT03909919|Procedure|Standard Care or Usual Clinical Practice|The guidelines for the management according to the heart failure in primary care will be the treatment guidelines for the Standard Care.
35111|NCT03909906|Drug|Euphytose®|(50mg Valeriana officinalis L., 40mg Passiflora incarnate L., 10mg Crataegus sp., 10mg Ballota nigra L.)
35112|NCT03909906|Drug|Placebo Oral Tablet|Placebo comparator
35114|NCT03909880|Device|kinesio tape|Kinesio taping(kinesio taping;kinesio holding corporation,USA) is given between the pretest and the posttest. The taping is operated by a physical therapist who is the co-host of this experiment in 614 room, Research Building, National Yang-Ming University. Posttest will be started immediately after taping. After posttest, kinesio tape will be removed. There are 3 types of taping conditions. Kinesio tape is pulled from 5 cm distal wrist joint line to medial epicondyle and 5 cm at both ends of the head and tail without tension .All participants will receive all conditions of taping. They will be randomly assigned to any taping conditions. In order to wash out the effect of taping, the interval of any condition is at least 7 days.
35116|NCT03909841|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB)|Cognition using Cambridge Neuropsychological Test Automated Battery (CANTAB)
35117|NCT03909841|Other|Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)|Quality of Life using Chinese (Hong Kong) 12-item Short-Form Health Survey (version 2)
35118|NCT03909815|Device|Dual mobility cup|Patients with a displaced femoral neck fracture eligible for THA receive a dual mobility cup, as opposed to a standard cup in the control group.
35119|NCT03909815|Device|Standard cup|Patients with a displaced femoral neck fracture eligible for THA receive a standard cup, as opposed to a dual mobility cup in the experimental group.
35120|NCT03909802|Behavioral|Self-and family management of diabetic foot ulcers programs|The intervention combines self-management and family management focusing on behavioral changes in patients with diabetic foot ulcers. Self-management focuses on intensive health education of physical activities, diet, medication, foot care, and blood glucose control. Family management focuses on problem-solving, establishing roles, and effective involvement in providing care amid individuals suffering DFU.
35121|NCT03909802|Other|Usual care|Usual care
35122|NCT03909789|Dietary Supplement|Plant based bioequivalent Nitrate supplementation|The nitrate supplement consists of nitrate-rich beetroot extract 20mg, thiamine mononitrate 90mg, potassium nitrate 480mg, ascorbic acid 150mg, folic acid 200mcg, methylcobalamin 200mcg, calcium 115mg, pomegranate fruit extract 5mg and green coffee bean extract 115mg.
35123|NCT03909789|Dietary Supplement|Placebo|Placebo
35124|NCT03909776|Drug|Cisplatin|Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
35125|NCT03909763|Drug|Danazole combined with berberine|Danazole combined with berberine
35126|NCT03909750|Procedure|Lipoaspiration|Close syringe microcannula harvesting subdermal fat and perivascular stem/stromal cells
35127|NCT03909750|Procedure|AD-cSVF|Isolation of AD-cSVF
35128|NCT03909750|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
35129|NCT03909737|Drug|Azithromycin to pregnant women|Azithromycin to pregnant women at antenatal care visits and during delivery
35134|NCT03909724|Drug|Sunitinib Malate|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
35135|NCT03909724|Drug|TAS 102|After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
35136|NCT03909698|Other|Blood and urine sampling|During a period of maximum 6 days blood is sampled at different time points and urine is collected during documented time intervals.
35137|NCT03909685|Behavioral|Mobile Mental Health App|The Mobile Mental Health App is an app that utilizes artificial intelligence to identify symptoms and provides targeted, tailored solutions for its users.
35138|NCT03909672|Other|Cupping Therapy|application of cupping therapy with two acrylic type 1 cups (4.5 cm internal diameter, Dong Yang ® brand) with a distance of 3 cm each cup, parallel to the L1 to L5 vertebrae bilaterally
35139|NCT03909659|Behavioral|Dietary sodium reduction|A supply of a reduced-sodium added-potassium salt substitute
35140|NCT03909646|Drug|Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram|A layer of methylaminolevulinc acid 160 mg/g cream (about 1 mm thick) is applied to the lesion, with a clinical margin of 5-10 mm surrounding of normal skin and then covered by an occlusive dressing. After 3 hours the occlusive dressing will be removed and the area is illuminated with Omnilux or Actilite (Galderma). After PDT the treatment site is covered again with the above mentioned occlusive dressings during 48 hours. Treatment is performed by an authorized nurse in the hospital. Two sessions should be administered with an interval of one week between sessions.
35141|NCT03909646|Drug|5Fluorouracil|5-FU is applied on the treatment area by the patient in a thin layer twice daily during 4 weeks.
35142|NCT03909646|Other|Surgical excision|Local anesthesia with lidocain 1% (1-2ml) will be used before performing standard surgical excision with 5 mm safety margin followed by routine histological examination. The skin will be closed using cutaneous sutures, which will be removed after 1-2 weeks. The surgical excision will take place in the hospital by the treating physician
35143|NCT03909633|Behavioral|a series of tests|all patients in every group will do a series of tests,including DSST、DST、MoCA、WCST、HADS
35144|NCT03909620|Diagnostic Test|Low-dose computed tomography of chest|Eligible subjects will undergo a single round of LDCT screening. The LDCT will be considered as positive if a solid nodule or part-solid nodule of size ≥6 mm or non-solid nodule of size ≥20 mm is identified. Evaluation of positive nodules will be performed as per existing standard recommendations
35145|NCT03909607|Drug|Ketamine 0.75 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 0.75mg/kg
35146|NCT03909607|Drug|Ketamine 1.0 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.0 mg/kg
35147|NCT03909607|Drug|Ketamine 1.5 mg/kg|Patients with moderate to severe pain will receive Ketamine at a dose of 1.5 mg/kg
35148|NCT03909594|Drug|Bupivacaine|Bupivacaine
35149|NCT03909594|Drug|Ketamine|Ketamine
35150|NCT03909581|Procedure|Endoscopic coronary arterial bypass|is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)
35151|NCT03909581|Procedure|Percutaneous Coronary Intervention|will be performed using standard techniques at the discretion of the operator (50 participants)
35152|NCT03909568|Procedure|Third molar surgery|Comparing complete removal of third molar with removal of crown only on contralateral side
35153|NCT03909555|Other|Complications assessment|Records of cardiovascular diseases (CVD), carotid ultrasonography, electrocardiogram, echocardiography, fundus photography, urinary albumin excretion, Toronto Clinical Neuropathy Scale and Composite Autonomic Symptom Score.
35154|NCT03909529|Drug|Digoxin 250 MCG Oral Tablet|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
35155|NCT03909529|Drug|Spironolactone 25 mg/ 5 mL S/F Suspension|The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
35156|NCT03909516|Device|iovera°|"The iovera° device will be prepared by the trained Anesthesiologist User Guide. If at any time the device does not perform as expected the Investigator and Anesthesiologist will follow procedures as outlined in the User Guide. Start and end time will be recorded. Once localized anesthesia of the block area is achieved, the Anesthesiolgist, or designee, will complete the iovera° treatment. Upon completion of block, The Anesthesiologist or designee will assess the treatment areas for adverse events. Adductor Canal Block required, the formulation, or cocktail, of medications used are to be recorded in the medical record. Start and end time will be recorded.~Local Infiltration Analgesia - 20cc 0.5% ropivicaine only"
35157|NCT03909503|Device|Porcine-derived collagen wound dressing|Patients who meet the inclusion criteria will be treated with porcine-derived collagen dressings. The dressing will be used in accordance with its label. After cleansing the wound, the dressing will be placed on the wound. Appropriate primary and secondary dressings will be placed over the intervention product. Patients will visit the clinic once per week to have their dressings re-applied. Wound evaluations will take place once per week with the intervention lasting up to twelve weeks. Concomitant standard of care such as compression for venous ulcers will be provided according to individual patient needs.
35158|NCT03909490|Other|Preference elicitation tool|Ranking tool to assess patient preferences for trigger finger treatment
35159|NCT03909490|Other|handout|handout with information about trigger fingers
35160|NCT03909477|Diagnostic Test|Hyperpolarized Xenon-129 MRI of the lungs|Participants will be imaged using MRI using hyperpolarized xenon-129 gas as a contrast gas
35161|NCT03909477|Diagnostic Test|Computed Tomography (CT)|Participants will undergo a CT scan of the thoracic cavity
35162|NCT03909477|Diagnostic Test|Pulmonary Function Tests (PFTs)|Participants will have their lung function evaluated using PFTs
35163|NCT03909477|Diagnostic Test|Six Minute Walk Test (6MWT)|Participants >35 years of age will perform the six minute walk test as a measure of exercise capacity
35164|NCT03909477|Diagnostic Test|Cardiopulmonary exercise testing (CPET)|Participants <35 will perform cardiopulmonary exercise testing as a measure of exercise capacity
35165|NCT03909477|Diagnostic Test|Sputum analysis|Participants will provide a sputum sample that will be analysed for eosinophils
35166|NCT03909477|Diagnostic Test|Blood analysis|Participants will have their blood drawn and analysed for eosinophil count.
35168|NCT03909451|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
35169|NCT03909451|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
35170|NCT03909438|Procedure|Endovascular Thrombectomy|Endovascular therapy includes direct mechanical thrombectomy or intravenous thrombolysis with mechanical thrombectomy. Endovascular Thrombectomy Device: Trepo trevor Retriever Device: SolitaireTM FR Revascularization Device
35171|NCT03909412|Drug|Carfilzomib|Carfilzomib will be administered over 10 minutes for the 20 mg/m2 and 27 mg/m2 dose and over 30 minutes for all higher doses.
35172|NCT03909412|Drug|Cyclophosphamide|Cyclophosphamide dosed at 2gm/m2 administered over 1 hour.
35173|NCT03909412|Drug|Dexamethasone|Dexamethasone 40mg IV/PO to be administered as a premedication.
35174|NCT03909412|Drug|Granulocyte Colony-Stimulating Factor|On day 7 subjects will initiate high dose G-CSF injections at 14mcg/kg daily (with a cap of 1440mcg daily).
35175|NCT03909373|Other|PSFS|Patients will complete the patient specific functional scale. no intervention being administered
35176|NCT03909360|Procedure|drainage tube|sub-hepatic drainage tube for laparoscopic cholecystectomy
35177|NCT03909347|Behavioral|PLAN|The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance
35178|NCT03909347|Behavioral|Standard of Care|The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
35179|NCT03909334|Drug|Osimertinib|Osimertinib 80 mg orally on Day 1
35180|NCT03909334|Drug|Ramucirumab|Ramucirumab 10 mg/kg intravenously (IV) over 60 minutes on Day 1
35181|NCT03909321|Behavioral|Beach tennis training group|Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
35182|NCT03909321|Behavioral|Control Group (Health Education)|Control group (CG) will attend BT lectures (10 min) and technical exercises (i.e., serve, volley, forehand and backhand exercises) throughout 10 min plus lectures on health education during 20 min, lasting 40 min in total. This session will be performed once a week throughout 12 weeks.
35183|NCT03909308|Behavioral|Beach Tennis session|The Beach Tennis training session will be composed by a warm up of 5 min of BT in which technical exercises (i.e., serve, volley, forehand and backhand) will be performed After that, 3 BT small games of 12 min with a 2 minute interval between games using the conventional rules of sport will be performed. Before the session and after each small game, data regarding heart rate, blood pressure and rate perceived exertion will be recorded.
35184|NCT03909295|Drug|LCZ696|LCZ696 50 mg,100 mg,200 mg film coated tablets
35185|NCT03909282|Procedure|Lumpectomy|Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
35186|NCT03909282|Radiation|Partial breast irradiation prior to surgery|Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
35187|NCT03909269|Device|Continuous glucose monitoring|Continuous glucose monitoring five times over 17 weeks
35188|NCT03909269|Diagnostic Test|Glycaemic markers|Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.
35189|NCT03909269|Radiation|Erythrocyte life span|Erythrocyte life span measured by Crom-51 labelling over 4 weeks
35190|NCT03909269|Device|Carbon monoxide (CO)-rebreathing method|Measurement of total blood volume, plasma volume and erythrocyte volume
35191|NCT03909256|Other|NUTRI-HAB|"The rehabilitation program is a coordinated multidisciplinary effort involving several specialists e.g. clinical dietitians, nurses, physiotherapists, occupational therapists (responsible for dysphagia management in Denmark), psychologists and social workers.~The program includes group sessions with patient education on how to handle the different aspects of living with eating problems and other late effects. Practical kitchen exercises, physical activity sessions and instruction in swallowing training are included. Individual counseling sessions with clinical dietitians and other health professionals (e.g. physicians) are offered depending on participants' needs.~Participants stay at the premises and all meals throughout the day are served in the dining room or in the café. Foods of different textures and flavors are served to inspire participants and to allow them to experiment.~Between the initial stay and follow-up participants are contacted twice by a clinical dietitian."
35192|NCT03909217|Procedure|TECAS Procedure|"Location:~Cranial electrical stimulation acupoints: Baihui (DU20) and Yintang (DU29).~Auricular electrical stimulation zone: the distribution area of auricular branch of the vagus nerve.~Two electrodes electric stimulation at a frequency of 4/20 Hz will be employed on the cranial acupoints and the auricular zone respectively. The TECAS treatment will consistent of two sessions per day (30 minutes) for 8 consecutive weeks."
35193|NCT03909217|Drug|Escitalopram|Each subject shall receive oral administration Escitalopram (10-20mg/day, q.d.), as prescribed by clinical psychiatrist with respect to patients' conditions for 8 consecutive weeks.
35194|NCT03909217|Drug|Insomnia medication|For patients with severe insomnia, stabilizers and benzodiazepines could be prescribed and must be recorded in the case report form.
35241|NCT03908762|Device|iSage App with connected glucometer|Providers prescribe an insulin dosing plan to patients and provide them with a connected glucometer. The patient's plan is administered through a mobile application. In addition, patients receive education and guidance on insulin administration.
35488|NCT03906799|Drug|Placebo|1 capsule given daily orally from Visit 3 (Day 1) to Visit 8 (Day 99 ± 3 days).
35195|NCT03909204|Procedure|LAPEC|Laparoscopic-Assisted Percutaneous Endoscopic Cecostomy: Initially, one to tree-laparoscopy port technique will be used, with hand placement of seroperitoneal sutures for cecal fixation. After than during colonoscopy a cecal position will be visualized and colonic lumen will be insuflated. After than the PEC tube will be introduced into the cecum using the dilators and sheath. Intravenous antibiotics will be given prior to the procedure and will continued parental temporary and later orally after catheter insertion. One weeks later, antegrade colonic enema will start during an out-patient visit including an educational training of the patient to the catheter manipulation. Antegrade enema solution will start at dose of 2ml/kg and will be increased up to 20ml/kg or a maximum dose of 2000 mL daily. Adjuvant of colonic motility stimulants are allowed during follow-up.
35196|NCT03909191|Diagnostic Test|serum HBV RNA|serum HBV RNA level was determined by using HBV-SAT kit at different time point
35197|NCT03909178|Procedure|Hip Arthroscopy Surgery with Acetabular Labral Repair|"The research coordinator will, perform a baseline assessment, and randomize the patients into the study at this visit.~Randomization will be assigned utilizing an electronic randomization program. Patients are prospectively identified and randomized into one of two study arms: arthroscopic surgery (AS) or physical therapy (PT). A third study arm, dependent upon improvement with PT, was created as patients crossed over (CO) from PT to AS after a lack of improvement after a minimum of 8 weeks of PT. AS consisted of labral repair.~Any subject randomized to surgery will be seen by Dr. Martin to be consented separately for the arthroscopic procedure, which is standard of care. Those receiving surgical management will be scheduled for the post-operative physical therapy protocol within 2 weeks of their operative date, once a surgical date has been scheduled."
35198|NCT03909178|Procedure|Physical Therapy Focused on the Hip and Hemi-pelvis|"The research coordinator will, perform a baseline assessment, and randomize the patients into the study at this visit.~Randomization will be assigned utilizing an electronic randomization program. Patients are prospectively identified and randomized into one of two study arms: arthroscopic surgery (AS) or physical therapy (PT). A third study arm, dependent upon improvement with PT, was created as patients crossed over (CO) from PT to AS after a lack of improvement after a minimum of 8 weeks of PT. AS consisted of labral repair or debridement, if repair was not possible, and PT consisted of a uniform, comprehensive PT protocol guided by selected physical therapists.~Those randomized to the physical therapy side will be referred to PT. Those receiving conservative management will be scheduled for physical therapy."
35199|NCT03909165|Drug|Sugammadex 2 mg/kg|For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.
35200|NCT03909165|Drug|Sugammadex 4 mg/kg|For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
35201|NCT03909165|Drug|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
35202|NCT03909165|Drug|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
35203|NCT03909152|Drug|Onapristone ER|50 mg PO BID (with dosage adjustments) until POD, unacceptable toxicity or withdrawal of consent.
35204|NCT03909139|Biological|BMAC|A bone marrow biopsy needle will be inserted through an arthroscopy portal and directed to the acetabuloplasty site. Bone Marrow is aspirated, then centrifuged. From the centrifuged sample, the buffy coat layer (layer of cells, found between the red blood cells and the plasma layers), is removed. The buffy coat layer contains mesenchymal stem cells. This is called BMAC or Bone Marrow Aspirate Concentrate. Around 1mL of the BMAC sample is placed into cryo-vials for cell count analysis, where the number of different types of stem cells are counted. The remainder of the BMAC will be injected into the intra-articular space.
35205|NCT03909126|Biological|Boostrix administered during gestational diabetes screening|Boostrix administered during gestational diabetes screening
35206|NCT03909126|Biological|Boostrix administered in high volume obstetric clinic|Boostrix administered in high volume obstetric clinic
35207|NCT03909113|Dietary Supplement|amino acid based formula|amino acid based formula
35209|NCT03909074|Biological|36-71 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
35210|NCT03909074|Biological|36-71 months old children-control EV71 vaccine.|Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.
35211|NCT03909074|Biological|6-35 months old children-experimental EV71 vaccine.|Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.
35212|NCT03909061|Behavioral|Wheelchair Maintenance Training|Wheelchair Maintenance Training Program: WMTP training consists of three parts. It starts with an overview of basic wheelchair maintenance items, continues with the second section discussing how to inspect the parts of a wheelchair and finishes with the third section discussing how to perform wheelchair maintenance on a wheelchair. Throughout the course, there are videos and pictures demonstrating the activities discussed in the training program. Participants will also be informed when a repair requires professional assistance and where such assistance may be found.
35213|NCT03909048|Behavioral|Interactive - Psychoeducation|Individuals will receive interactive psychoeducation in the lab over the course of a week period. Each session will take approximately 30 minutes.
35214|NCT03909048|Behavioral|Non-interactive Psychoeducation|Individuals will receive non-interactive psychoeducation over the course of a week period. Each session will take approximately 30 minutes.
35242|NCT03908762|Behavioral|Magnet|Patients are given a refrigerator magnet with an insulin titration algorithm and are asked to follow the instructions on the magnet.
35243|NCT03908736|Drug|Zinc Picolinate 15 Mg|zinc picolinate, 15 mg/day for 6 months
35244|NCT03908723|Other|Panretinal photocoagulation|Intravitreal Aflibercept with PRP to the peripheral vascular lesions
35215|NCT03909035|Other|Medication therapy management|"The intervention is in the form of a pharmacist-led medication review aimed at detecting potentially inappropriate prescribing. It includes:~A patient-pharmacist interview to collect comorbidities, medication, laboratory results, self-medication, adherence, medication patient's knowledge.~A pharmacist's evaluation of the prescriptions based on the patient's conditions and on the current recommendations for clinical practice.~Detailed feedback to the general practitioner.~An appointment with the patient to explain the modifications made by the general practitioner (GP)"
35216|NCT03909009|Device|rTMS + Neuronavigation|Repetitive Transcranial Magnetic Stimulation (Neuro-MS/D) + Neural Navigator
35217|NCT03908996|Behavioral|Profile by Sanford weight management plan|The purpose of this study is to observe weight changes in patients who completed endometrial cancer treatment, are clinically overweight, and who participate in the Profile by Sanford weight management program. An exploratory purpose is to examine the bacterial content of the patient's gut by examining stool specimens before starting the Profile by Sanford weight management program and after 6 months of participation in the Profile by Sanford weight management program.
35218|NCT03908983|Device|Kalios Implant|KALIOS is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of KALIOS is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
35219|NCT03908970|Drug|1% OPA-15406|Twice daily
35220|NCT03908970|Drug|Placebos|Twice daily
35221|NCT03908957|Drug|Ga68-Dolacga Injection|Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv
35222|NCT03908944|Drug|Methadone|Individuals in this group will receive an identical anesthetic without the addition of remifentanil. They will be given methadone 0.2 mg/kg IV at the beginning of the anesthetic. A lidocaine bolus of 1.5 mg/kg will be given with induction of anesthesia followed by an infusion of lidocaine at 2 mg/kg/hr until the end of surgery.
35223|NCT03908944|Drug|Standard of Care|Standard of Care patients will be given an infusion of remifentanil 0.15-0.25 mcg/kg/min as part of their intraoperative anesthetic regimen. The infusion will be maintained until the end of surgery and will be discontinued upon emergence. Prior to emergence, 100-200 mcg of fentanyl will be titrated for additional analgesia after emergence.
35224|NCT03908931|Radiation|MRI|Follow up of osteochondral surgery by MRI and clinical examination
35225|NCT03908918|Other|Mindfulness app|Mobile app-delivered mindfulness intervention delivered over 4 weeks.
35226|NCT03908905|Diagnostic Test|Polysomnography|Sleep screening, neurocognitive assessment, activity monitoring questionnaires, blood sample
35227|NCT03908892|Drug|zanthoxylum nitidum tincture|Local application with zanthoxylum nitidum tincture soaked blocks for the sick nail(s) for 30 minutes, twice a day.
35228|NCT03908892|Drug|tetracycline ointment|Local use of 1% tetracycline ointment for the sick nail(s), 3 times a day
35229|NCT03908879|Procedure|Standard intraosseous (IO) catheter confirmation procedure|The physician will evaluate the ability or inability of the intraosseous (IO) catheter to stand upright unassisted, the ability or inability to aspirate blood or bone marrow from the IO catheter, and whether or not there is visible or palpable extravasation of infusate from the IO catheter insertion site or surrounding subcutaneous tissue during IO catheter use.
35230|NCT03908879|Procedure|Color flow Doppler intraosseous (IO) catheter confirmation procedure|The high frequency probe of a portable ultrasound with color flow Doppler is placed adjacent to the intraosseous (IO) catheter, visualizing the IO space in long or short axis. Color flow Doppler signal will be turned on during IO use and the physician will determine if the Doppler signal is in the intraosseous space or the extraosseous space. Saved data of the ultrasound image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
35231|NCT03908879|Procedure|Pressure transduction intraosseous (IO) catheter confirmation procedure|The intraosseous (IO) catheter will be attached to a pressure transducer to demonstrate a waveform on the telemetry monitor. Physicians will evaluate for the presence of a pulsatile waveform with objective measurements of a systolic pressure, diastolic pressure and mean pressure. Saved data of the waveform image will be reviewed independently by at least two blinded reviewers. If the conclusions from the blinded reviewers are discordant then a third blinded reviewer will evaluate the saved data.
35232|NCT03908866|Other|PICC(Peripherally inserted central catheter)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.
35233|NCT03908866|Other|CVC(Central venous catheter )|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, using the Seldinger technique. A suitable sterile field will be established.
35234|NCT03908840|Biological|TBI 302|TBI 302 administered once a week in first 3 weeks and no treatment in week 4 (28 days is 1 cycle). Followed once weekly treatment of TBI 302 for 3 weeks followed by no treatment in week 4 (cycle 2)
35235|NCT03908827|Biological|Bone Mineral Aspirate Concentrate (BMAC)|A single BMAC injection will be performed into the arthritic joint
35236|NCT03908814|Drug|Whole Human Anti-PD-L1 Antibody Injection (LDP)|Dose escalation study evaluating six dose levels (0.1, 0.3, 1, 3 , 10and 20 mg/kg) of LDP.
35237|NCT03908801|Behavioral|Specialized water dance intervention|Group activity in a warm pool (32-34 °C) led by two SWAN leaders. During each session, nine songs are played and the participants, assisted by a support person, perform dance movements rhythmically to the mood of the music. The songs are chosen to stimulate different movement patterns and to emphasize different emotions.
35238|NCT03908788|Device|Intplex test|Blood sample at each tumor assessment
35239|NCT03908775|Device|C-MAC videolaryngoscope|An intubating device that is used for nasotracheal intubation in children undergoing dental interventions. Nasotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
35240|NCT03908775|Device|Direct Laryngoscope|An intubating device that is used for nasotracheal intubation. Nasotracheal intubation was applied by anesthesiologist with direct laryngoscope.
35308|NCT03908164|Biological|Pertussis containing vaccine|Participants will receive a pertussis containing vaccine licensed for use in pregnancy at one of three time periods.
35309|NCT03908151|Device|CMK21 Hip system|Total hip arthroplasty
35245|NCT03908710|Other|Treatment of hypertension using blood pressure self-measurement at home|The primary aim of the present study is to investigate whether home blood pressure recording via Bluetooth and continuous communication between doctor and patient will give improved blood pressure values when comparing the initial values with the blood pressure values recorded after 3 months. Secondary examinations include treatment of hypotension and adverse events, the patient's experience, the user's potential problems with the blood pressure cuff, app downloading, problems with history issues or problems with technical
35246|NCT03908697|Device|Mira monitor comparison to ClearBlue monitor|Testing first morning urine with hormone test sticks at home
35247|NCT03908684|Other|Imaging|
35248|NCT03908671|Biological|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine
35249|NCT03908658|Other|Inspiratory muscle Training and Nasal High Flow|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Nasal High Flow will support respiratory muscles and thus reduce the work of breathing. By this mechanism the endurance of the respiratory muscles will increase in parallel with the strenght
35250|NCT03908658|Device|Inspiratory muscle training and Venturi mask|Inspiratory muscle Training will be used to increase respiratory muscle strength. Initial settings will depend on patient's maximal inspiratory pressure. Venturi mask is usually applied after extubation in every day clinical practice for oxygen supplementation
35251|NCT03908645|Device|Artificial intelligence assisted bowel preparation quality scoring system|After receiving standard bowel preparation regimen, patients go through colonoscopy under the AI monitoring device. During the withdrawal process, bowel preparation quality is monitored by AI-associated scoring system. Whenever a sub-score below 2 points is detected, endoscopist will be alarmed up to three times to wash and suck the colonic contents. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
35252|NCT03908645|Device|Conventional human scoring|After receiving standard bowel preparation regimen, patients go through conventional colonoscopy without the AI monitoring device. During the withdrawal process, after washing and sucking the colonic contents according to endoscopist's personal experience, bowel preparation quality is evaluated by human. Videos will be recorded and re-evaluated by experts to determine the final BBPS score. The withdrawal time is targeted at least 6min in accordance with colonoscopy quality practice. All detected polyps will be removed and obtained for histological assessment, with the possible exception of diminutive(less than 5mm) rectal polyps.
35253|NCT03908619|Drug|Omeprazole 20mg|Omeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
35254|NCT03908619|Drug|Esomeprazole 20mg|Esomperazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
35255|NCT03908619|Drug|Rabeprazole Sodium 20mg|Rabeprazole 20mg bd/ Amoxicillin 1g bd/ Clarithromycin 500mg bd for 14 days
35256|NCT03908619|Drug|Vonoprazan|Vonoprazan 20mg bd/ Amoxicilllin 1g bd/ Clarithromycin 500mg bd for 7 days
35257|NCT03908606|Procedure|Scaling and root planing|Supra and subgingival scaling and root planing.
35258|NCT03908593|Drug|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
35259|NCT03908580|Drug|Meditoxin|Meditoxin® (Botulinum toxin type A) was injected up to 360 U.
35260|NCT03908567|Drug|Intranasal Drug|Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
35261|NCT03908567|Drug|Oral Tablet|Oral dosing with tablets 3 times a day
35262|NCT03908567|Other|Intranasal Placebo|Intranasal administration of solution without betahistine dihydrochloride; Dosing 3 times a day
35263|NCT03908554|Other|WORKPLACE HEALTH PROMOTION PROGRAM|WHPP was PMR training, posture and breath exercises, and ergonomic suggestions.
35264|NCT03908528|Dietary Supplement|Alpha-lipoic acid|600 mg Alpha-lipoic acid daily (an antioxidant that's in many foods, and it's made naturally in the investigator's bodies).
35265|NCT03908528|Drug|Chemotherapy|four cycles of doxorubicin (also known as Adriamycin) plus cyclophosphamide followed by weekly taxol for 12 weeks.
35266|NCT03908515|Device|Foldable Capsular Vitreous Body (FCVB)|FCVB can be regarded as an artificial vitreous and consists of a thin vitreous-shaped capsule, a drain tube, and a valve. After foldable implantation into the eye, then silicone oil is injected into the capsule which inflated to support the retina. The capsular material of FCVB is silicone rubber. The capsule was fabricated a computer simulation of the human and rabbit vitreous cavities. The control of the intraocular pressure is achieved with adjusting the amount of injected medium through the tube-valve system. After the medium was injected into the capsule through the tube-valve system, the valve was subsequently fixed onto the sclera surface similar to the glaucoma valve.
35267|NCT03908489|Procedure|vital pulpotomy primary molars using garlic oil|vital pulpotomy using garlic oil
35268|NCT03908489|Procedure|vital pulpotomy using mta|mta vital pulpotomy
35269|NCT03908476|Device|Burst-capable SCS system|Subjects will be given Burst stimulation using a market-released Abbott SCS system. Burst stimulation may be achieved through surgical or non-surgical means.
35270|NCT03908476|Device|DRG Stimulator|Subjects will be implanted with a market-released Abbott DRG stimulation system.
35271|NCT03908463|Device|Percutaneous coronary intervention|All coronary intervention procedures will be performed according to current standard techniques.
35272|NCT03908450|Device|PTCA of coronary de novo lesion PCB|PTCA of coronary de novo lesion with drug coated balloon
35273|NCT03908450|Device|PTCA of coronary de novo lesion SCB|PTCA of coronary de novo lesion with drug coated balloon
35274|NCT03908437|Drug|buprenorphine/naloxone|"A mobile team will be led by a nurse practitioner (able to prescribe buprenorphine/naloxone in PA) and include a peer recovery specialist (PRS), and a case manager. The team will rapidly confirm opioid use disorder and risk of overdose, complete informed consent, and begin induction procedures for a transitional (one month) course of buprenorphine/naloxone treatment. During this time, the dedicated case manager and PRS will work with the participants to help them become engaged in existing medication assisted treatment programs"
35754|NCT03904680|Drug|Methotrexate|Methotrexate 2.5 mg tablet
35275|NCT03908424|Other|Epidural Blood patch.|"An epidural blood patch is a surgical procedure that uses autologous blood in order to close one or many holes in the dura mater of the spinal cord, usually as a result of a previous lumbar puncture. A small amount of the patient's blood is injected into the epidural space near the site of the original puncture; the resulting blood clot then patches the meningeal leak. An epidural needle is inserted into the epidural space at the site of the cerebrospinal fluid leak and blood is injected. The clotting factors of the blood close the hole in the dura."
35276|NCT03908411|Procedure|Paratracheal pressure|Paratracheal pressure is applied by 30N force with the ultrasound transducer.
35277|NCT03908411|Procedure|Sellick's maneuver|Conventional Sellick's maneuver is applied by 30N force
35278|NCT03908372|Drug|Docetaxel|Induction CT: Docetaxel 75mg/m2 IV on d1, every 21 days for two cycles
35279|NCT03908372|Drug|Cisplatin|Induction chemotherapy:cisplatin 75mg/m2 IV on d1,every 21 days for two cycles.Concurrent chemoradiotherapy:cisplatin 100mg/m2 IV on d1 of each 21 days for at least two cycles during 70 Gy radiotherapy
35280|NCT03908372|Radiation|IMRT|IC+IMRT arm:the patients with complete response will receive 60Gy to the gross target volume of nasopharynx, partial response 64Gy, and the absence of response or stable will receive 70Gy. CCRT arm: 70Gy to the gross target volume of nasopharynx.
35281|NCT03908359|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
35282|NCT03908359|Procedure|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
35283|NCT03908346|Other|Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest|a decision aid has been created that is a four page document meant to support surrogate decision makers for comatose survivors of cardiac arrest
35284|NCT03908333|Drug|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
35285|NCT03908333|Drug|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
35286|NCT03908333|Drug|Cisplatin|25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
35287|NCT03908333|Drug|Gemcitabine|1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
35288|NCT03908320|Other|Menstrual Cycle Timing|Quit date is set to menstrual phase.
35289|NCT03908320|Other|Menstrual Cycle Timing|Menstrual cycle timing of quit date is monitored
35290|NCT03908320|Drug|NRT Patch|NRT patch is provided
35291|NCT03908320|Behavioral|Cessation Counseling|Cessation counseling is provided
35292|NCT03908307|Drug|OZURDEX|Implant 700 μg
35293|NCT03908294|Diagnostic Test|Lab tests, non-invasive fibrosis (Fibroscan/ARFI)|Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
35294|NCT03908281|Behavioral|Fasted Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
35295|NCT03908281|Behavioral|Postprandial Exercise|Exercise training will take place 3 times per week and will progress to 60 minutes at a workload corresponding to 80% of Ventilatory Threshold.
35296|NCT03908268|Behavioral|Family Nurture Intervention (FNI)|The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will attend eight group FNI sessions within sixteen weeks.
35297|NCT03908268|Behavioral|Standard Children's Learning Center (CLC) Program|Typical, age-tailored CLC curriculum taught by CLC teachers. Children attend CLC as usual and parents do not take part in group sessions.
35298|NCT03908255|Drug|Branch Chain Amino Acid|Nutritional supplementation
35299|NCT03908255|Other|maltodextrin|Placebo
35300|NCT03908242|Drug|salvianolic acid A|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
35301|NCT03908242|Drug|Placebo|salvianolic acid A/Placebo 90 mg bid; salvianolic acid A/Placebo 180 mg qd
35302|NCT03908229|Procedure|Trainee colonoscopy|Colonoscopy performed by trainee
35303|NCT03908229|Procedure|Experienced physician colonoscopy|Experienced physician colonoscopy
35304|NCT03908203|Procedure|Minimally invasive one-level lumbar deformity correction|The study treatment represents modified technique of MIS TLIF: one level screws fixation using Wiltse approach at one side, the other side - percutaneously, one level decompression, correction of segmental deformity by performing vertebrotomy and then intervertebral fusion.
35305|NCT03908190|Behavioral|Personalized Support for Progress|Participants will receive the Personalized Support for Progress Intervention from a peer support provider including sessions with the peer support provider to complete a prioritization task, develop a personalized care plan, and receive support for implementing the personalized care plan.
35306|NCT03908177|Device|Ceramic Dental Implant|The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
35307|NCT03908177|Device|Titanium Dental Implant|The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading after 4 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
35483|NCT03906825|Dietary Supplement|CEAG|Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA
35312|NCT03908125|Device|Eversense® CGM system|Continuous Glucose monitoring device that lasts up to 90 days
35313|NCT03908112|Behavioral|Standard Community Concussion Care (SC)|temporary rest, gradual increase in activity, and return to school and sports. In some cases vestibular an balance therapy are necessary, aerobic exercises, medication, counseling.
35314|NCT03908112|Behavioral|SC plus Simple Convergence Exercises (SC+)|In addition to standard community care in this intervention the participants must perform convergence therapy every day at home
35315|NCT03908112|Behavioral|SC plus Office-based Vergence/Accommodative Therapy (SC+OBVAT)|In addition to standard community care in this intervention the participants must come to the office once a week for a 1-hour therapy session with a therapist. Office-based vergence/accommodative therapy is performed for 12 weeks with home reinforcement.
35316|NCT03908099|Behavioral|Fit-For-Fertility program|The Fit-for-Fertility Program aims at implementing progressive and sustainable lifestyle changes. Participants will attend individual sessions with a dietitian and a kinesiologist every 6 weeks for the first 6 months, then every 8 weeks for the 6 following months, and then every 12 weeks until end of the study. Follow-up by telephone/e-mail will be offered between in-person meetings. These professionals will be trained in motivational counselling skills. Participants will also benefit from weekly group sessions divided into 2 parts: 1) Workshops covering 8 different topics (45 minutes) addressing healthy lifestyle and 2) Supervised classes of physical activity where one of 8 different types of exercise (45 minutes) will be practiced. Women will be required to attend all 8 different sessions within the first 6 months. Pregnant women will be met to set new lifestyle objectives specific to pregnancy, including optimal gestational weight gain based on the Institute of Medicine guidelines.
35317|NCT03908099|Other|Standard of care|The control intervention will consist of immediate initiation of usual fertility care, as recommended by each fertility specialist, for a maximum of 24 months. The experimental intervention will be the Fit-for-Fertility Program alone for the first 6 months, then in combination with usual fertility care for an additional 12 months and thereafter, usual fertility care can continue to be provided alone for a maximum follow-up of 24 months. The lifestyle program is provided for a maximum of 18 months if there is no pregnancy, or otherwise, up to the end of pregnancy or to a total study follow-up of 24 months (whichever comes first).
35318|NCT03908086|Other|Risk factors in RA cohort|
35319|NCT03908086|Other|Risk factors in general population|
35320|NCT03908073|Device|Transcutaneous vagal nerve stimulation|The use of a transcutaneous vagal nerve stimulator by the participant
35321|NCT03908060|Drug|Methadone|One intravenous administration of methadone (0.2 mg/kg ideal body weight)
35322|NCT03908060|Drug|Morphine|One intravenous administration of morphine (0.2 mg/kg ideal body weight)
35323|NCT03908047|Other|magnetic resonance imaging|functional magnetic resonance imaging and diffusion tensor imaging after tibialis nerve stimulation
35324|NCT03908034|Other|presence of uncontrollable risk factor|the presence of an uncontrollable / unremovable risk factor for a disease
35325|NCT03908034|Other|induction of anticipated regret|higher level of elaboration on potential regret
35326|NCT03908021|Diagnostic Test|Microbiome analysis and 16S rRNA gene-based analysis|microbial DNA is extracted from the saliva and 16s library is prepared for sequencing.
35327|NCT03908008|Drug|Botox (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
35328|NCT03908008|Drug|MT10107 (Botulinum toxin type A)|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
35329|NCT03907995|Behavioral|Cognitive Behavioral Therapy|The form of treatment will involve 6 group sessions every two weeks about an hour each. Sessions consist of teaching a different coping technique in each session to help cope with disaster or other events.
35330|NCT03907982|Procedure|DC Cardioversion|DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
35331|NCT03907982|Procedure|Pulmonary vein isolation|The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
35332|NCT03907982|Device|Implantable loop recorder|The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.
35333|NCT03907969|Drug|AZD7648|Core: AZD7648 will be administered orally
35334|NCT03907969|Drug|Pegylated liposomal doxorubicin (PLD)|The starting dose of PLD is 40 mg/m2, administered by intravenous infusion once every 4 weeks, for a maximum of 6 cycles
35335|NCT03907969|Drug|Olaparib|The starting dose of olaparib is 300 mg twice daily, administered orally on a continuous schedule in a 4-week cycle
35336|NCT03907956|Other|Dry Needling with Fascial Winding Technique|"For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp."
35337|NCT03907943|Procedure|carotid endarterectomy|Surgical treatment of ICA stenosis.
35484|NCT03906825|Dietary Supplement|placebo|placebo
35338|NCT03907930|Procedure|percutaneous nephrolithotripsy|removal of kidney and upper ureteric stones through small incision in the loin using nephroscope after disintegration by lithoclast
35339|NCT03907917|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
35340|NCT03907904|Device|CPOM Optical Neuromonitor|Prior to induction of anesthesia, the CPOM monitor will be secured to the temporal region of the participant's forehead to measure and record the cerebral hemodynamic data before, during, and following intubation. Hemodynamic, respiratory, body temperature, and anesthetic data will be continuously digitally records. The CPOM device will be detached after extubation in the operative room.
35341|NCT03907891|Behavioral|Motivational social support from nurse|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages.
35342|NCT03907891|Behavioral|Motivational social support from nurse with additional support from significant other|A 60-minute motivational interviewing session with a nurse, followed by 6 weeks of daily motivational social support text messages from both a nurse and the patient's self-identified significant other.
35343|NCT03907891|Behavioral|Attention control|A 60-minute session with a nurse focused on American Heart Association educational videos and written information.
35344|NCT03907878|Biological|Ligelizumab|Liquid in vial
35345|NCT03907865|Drug|Softacort|Group 1: 4 times daily for the first 12 days of the treatment period and then 2 times daily for 2 additional days Group 2: 3 times daily for the first 8 days of the treatment period and then 2 times daily for 3 additional days
35346|NCT03907852|Drug|TC-210 T Cells|TC-210 T Cells
35347|NCT03907852|Drug|fludarabine|fludarabine
35348|NCT03907852|Drug|cyclophosphamide|cyclophosphamide
35349|NCT03907852|Biological|anti-PD1|anti-PD1
35350|NCT03907839|Other|clinical trials|examined two type of training on cognitive parameters for COPD patients
35351|NCT03907826|Drug|PD-1 blocking antibody|Toripalimab is an antibody targeting PD-1 developed by Shanghai Junshi Biosciences Co., Ltd.
35352|NCT03907826|Radiation|IMRT|IMRT 60-66Gy, 1.8-2.0Gy/f/day
35353|NCT03907813|Drug|Exparel|liposomal bupivacaine wound infiltration
35354|NCT03907813|Other|Saline infiltration|saline wound infiltration
35355|NCT03907800|Drug|Nab-paclitaxel|125 mg/m² weekly, infusion, 3 weeks on 1 week off, applicated for four cycles.
35356|NCT03907800|Drug|Carboplatin|AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles
35357|NCT03907800|Drug|Herceptin|In case of HER2-positive, patients receive Herceptin weekly during all cycles.
35358|NCT03907787|Dietary Supplement|Zingiber officinale and Acmella oleracea|Subjects were supplied for four weeks with two tablets/day and there was the evaluation of pain intensity, by a 30-days Visual Analogue Scale (VAS) and b) the assessment of knee function by Western Ontario and McMaster Universities Arthritis Index and by Tegner Lysholm Knee Scoring collected at baseline, at 15 and 30 days after treatment, Health-related quality of life, by the ShortForm36, inflammation by C-reactive protein and Erythrocyte Sedimentation Rate, body composition by dual-energy X-ray absorptiometry measured at baseline and 30 days after treatment.
35359|NCT03907761|Procedure|Hydrodissection|high velocity stream of normal saline is given to the dissection area by help of 10 ml syringe
35360|NCT03907748|Other|Music Intervention|After training, caregivers will deliver the music intervention to the person with dementia whom they care for. The music intervention will include: a) singing familiar/preferred music followed by discussions facilitated by the caregiver about any associated meanings or memories; b) movement to music (e.g. upper body and arms imitating familiar dance movements to music); c) instrument playing; and d) listening to familiar/preferred relaxing or enlivening music (dependent upon symptoms present in the moment). These methods are known to assist in emotion regulation and increase cognitive reserve (e.g. attention and perceptual-motor function).
35361|NCT03907748|Other|Reading Intervention|After training, caregivers will deliver the reading intervention to the person with dementia whom they care for. The reading intervention will include: a) the caregiver reading aloud to the person they are caring for; b) the person with dementia reading aloud to their caregiver; and c) discussion of the text and personal responses. Strategies to engage the person with dementia and to create opportunities for meaningful dialogue will be provided, as well as guidance on selecting reading material that is accessible to the person's level of cognitive impairment.
35362|NCT03907735|Other|Myometrial tissue sample collection|Myometrial tissue samples by core needle biopsy under ultrasound guidance
35363|NCT03907722|Other|Long pentraxin 3|Primary PCI
35364|NCT03907709|Behavioral|In-Home Addiction Treatment Program|"Treatment was delivered per treatment protocol~Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors~Urine drug screens administered randomly~Appointments were scheduled per protocol for 52 weeks~Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program"
35365|NCT03907696|Other|Anti-stigma interventions curriculum|educational curriculum aimed at reducing stigma
35366|NCT03907683|Behavioral|Short Message with Text and Optional Image|"Messages can be up to 256 characters of text and with or without an image. Move more and sit less messages were written to target established cognitive and affective constructs associated with physical activity (e.g., prompts to action plan, guidance for maximizing pleasure by regulating intensity)."
35367|NCT03907657|Drug|Perflutren lipid microsphere|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
35368|NCT03907657|Drug|Sulfur hexafluoride lipid microspheres|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed. Lumason will be used as a secondary contrast agent only if Definity(perflutren) is unavailable.This drug will be administered using the dosing range and administration type within the Lumason prescribing information. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity (or Lumason) will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with sonography staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
35369|NCT03907644|Device|Transcranial Alternating Current Stimulation (tACS)|The tACS stimulator delivers very low (2mAmp) current with surface electrodes to the skull.
35370|NCT03907631|Other|Standard of care|care decisions driven by local physicians; this is an observational cohort
35371|NCT03907618|Diagnostic Test|ovarian reserve|To assess ovarian reserve in patients with Type 1 Diabetes Mellitus aged 18-40 years; ultrasonographic and laboratory parameters will be looked at.
35372|NCT03907605|Other|anti- mullerian hormone|All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay
35373|NCT03907592|Dietary Supplement|L-carnitine supplementation|Supplementation of 1000 mg L-carnitine-L-tartrate in combination with 3000 mg L-leucine per day throughout the study period.
35374|NCT03907592|Dietary Supplement|Leucine supplementation|Supplementation of 4000 mg L-leucine per day throughout the study period.
35375|NCT03907592|Procedure|Resistance training|Resistance training at the gym, twice a week for 24 weeks (48 training units in total).
35376|NCT03907579|Behavioral|Inflatable colon educational module|Participants attend a brief educational presentation in an inflatable colon, learning about colorectal cancer prevention and screening.
35377|NCT03907566|Other|The Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals|Swallowing function will be evaluated by the Turkish Oropharyngeal Dysphagia Screening Test for Patients and Professionals
35378|NCT03907553|Diagnostic Test|targeted genome sequencing|
35379|NCT03907540|Drug|KD025|KD025 tablet 200 mg, development candidate
35380|NCT03907540|Drug|[14C]-KD025 solution for infusion, 20 μg/mL|test investigational medicinal product
35381|NCT03907540|Drug|[14C]-KD025 capsule, 200mg|test investigational medicinal product
35382|NCT03907527|Biological|PRGN-3005 UltraCAR-T cells|Given IP or IV
35383|NCT03907514|Behavioral|"FALE Application"|"FALE is a digital tool, in the form of an application for smartphones, which aims to demonstrate empathy and facilitate communication between the adolescent patient and the dentist. The application contains 14 questions regarding dental anxiety, feelings and patient coping preferences regarding dental care."
35384|NCT03907501|Dietary Supplement|Synbiotic|an herbal prebiotic plus probiotic
35385|NCT03907501|Dietary Supplement|Probiotic|Triphala alone
35386|NCT03907501|Dietary Supplement|Placebo|Inert capsule
35399|NCT03907475|Drug|Capecitabine|Given PO
35400|NCT03907475|Drug|Carboplatin|Given IV
35401|NCT03907475|Biological|Durvalumab|Given IV
35402|NCT03907475|Drug|Gemcitabine|Given IV
35403|NCT03907475|Drug|Gemcitabine Hydrochloride|Given IV
35404|NCT03907475|Drug|Nab-paclitaxel|Given IV
35405|NCT03907475|Drug|Paclitaxel|Given IV
35406|NCT03907475|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
35407|NCT03907462|Behavioral|SMART 2.0|SMART 2.0 uses a fully integrated system of modalities that includes: 1) a popular consumer-level wearable, wireless scale, and corresponding app; 2) a highly tailored and interactive text messaging system; 3) multiple social media streams; 4) social network mechanisms of influence; and 5) technology-mediated health coaching.
35408|NCT03907449|Diagnostic Test|Preview Rapid Strep A test|Rapid assay for the detection of type A streptococcal infection of the throat.
35409|NCT03907436|Other|USDA Diet|Participants will receive counseling and education on USDA Guidelines for Americans, 2010
35410|NCT03907436|Other|Mediterranean Diet|Participants will receive counseling and education on a Mediterranean diet.
35411|NCT03907423|Drug|Rosuvastatin10 mg tablet|Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
35412|NCT03907423|Drug|Placebo Oral Tablet|Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
35413|NCT03907410|Other|Nominal Financial Incentives|The nominal financial incentives will consist of fixed-ratio incentives for each inhaled corticosteroids (ICS) actuation (25 cents for children on 4 daily ICS doses and 50 cents for children on 2 daily doses), with a maximum of $1 per day.
35414|NCT03907410|Other|Daily Adherence Reminders/Adherence Performance Feedback|Study participants will receive automated daily text message or push notification reminders and automated weekly feedback summarizing their adherence performance through Way to Health, a mobile health, electronic monitoring platform.
35415|NCT03907397|Biological|Peanut Protein|up to 9043 mg
35416|NCT03907384|Behavioral|Mat Pilates training|This group completed 12-weeks of training
35485|NCT03906812|Other|Telemetry|Bed type assignment
35417|NCT03907371|Drug|Donepezil Hydrochloride|Donepezil will be used with a dosage of 5 milligram at 8 am for one week (Week 1), then 10 milligram at 8 am for 23 weeks (Week 2-24).
35418|NCT03907371|Other|Placebo|Placebo will be used with a dosage of one half pill at 8 am for one week (Week 1), then one pill at 8 am for 23 weeks (Week 2-24).
35419|NCT03907358|Procedure|phacoemulsification|
35420|NCT03907345|Behavioral|Exposure|The exposure session comprises a hierarchy of 7 steps, reaching from (1) holding a glass with the spider 30cm in from the body / face, to (7) letting the spider walk on the arm. The exposure session has a duration of 120 minutes. Prior to the exposure, participants receive psychoeducation on anxiety and phobias. A house spider (Tegenaria domestica) is used for the exposure.
35421|NCT03907332|Other|Home visits|An experimental design, a cluster randomized controlled trial (RCT) will be used. A total of 32 clusters will be randomized with block randomization of electoral areas with a) resident staff midwives and b) resident Community Health Nurse midwifes. All women residing in an electoral area will receive the same intervention for practicality and to prevent contamination.
35422|NCT03907319|Device|SIS System|Software technology for visualization of anatomical structures in the brain
35423|NCT03907306|Procedure|Wound healing|The measurement of a wound area is committed on the 2nd, 8th, 14th, 21nd and 30th day after operation. By means of the mathematical formulas the wound healing speed will be defined. The wound process will be researched with the help of cytological method. The wound prints will be taken on the 2nd, 8th, 14th, 21nd and 30th day after operation. Microbiological research of a wound will be held on the 2nd, 8th, 14th, 21nd and 30th day after operation (in study groups before and after the usage of CAP, in control groups once). The pain assessment will be measured by a visual analogue scale on the 2nd, 3rd,4th, 5th, 6th, 7th, 8th, 14th, 21nd and 30th day after operation. The life quality will be researched by means of Health Status Survey on the 8th and 30th day before operation.
35424|NCT03907293|Behavioral|Exercise-based cardiac rehabilitation|Moderate intensity aerobic exercise, lifestyle advice, and psychological support.
35425|NCT03907280|Drug|BI 1265162 (T1)|oral solution
35426|NCT03907280|Drug|BI 1265162 (T2)|Solution for inhalation
35427|NCT03907280|Drug|BI 1265162 (R)|concentrate for i.v. solution
35428|NCT03907280|Drug|BI 1265162 (T3)|Solution for inhalation
35429|NCT03907267|Drug|Taurine Solution|Taurine Solution
35430|NCT03907267|Dietary Supplement|Normal Saline|Normal Saline
35431|NCT03907254|Other|Service Dog Training Program|Participants will spend one hour, two times a week working with professional service dog trainers in order to shape the dog's behavior for it's future role as a service dog for service members with mobility impairments.
35432|NCT03907241|Drug|Octanorm 16.5%|Human normal immunoglobulin
35433|NCT03907228|Dietary Supplement|RHT-3201|PROBIOTIC
35434|NCT03907215|Drug|ACT541468|50 mg; film-coated tablet for oral use
35435|NCT03907215|Drug|ACT541468 placebo|film-coated tablet for oral use
35436|NCT03907215|Drug|Citalopram|20 mg; tablet tor oral use; for single- or repeated dosing
35437|NCT03907202|Drug|Daily injection of KBP/placebo for up to 28 days|Daily sub-cutaneous injection of KBP-089/Placebo into a lifted skin fold of the abdominal wall.The injection will be administered in the morning before breakfast.
35438|NCT03907176|Drug|HTX-011|300 mg
35439|NCT03907176|Device|Luer lock applicator|Applicator for instillation
35440|NCT03907176|Drug|Ibuprofen|600 mg
35441|NCT03907176|Drug|Acetaminophen|1 g
35442|NCT03907163|Drug|Dronabinol|Capsules containing 5 mg Dronabinol
35443|NCT03907163|Other|Placebo|capsules identical in appearance to dronabinol
35444|NCT03907150|Diagnostic Test|Strain ultrasound|Post-interpretation of recorded ultrasound loops
35445|NCT03907124|Drug|Genetically-guided treatment with FDA-approved psychotropic drugs|Psychiatric patients in this experimental arm will receive genetically-guided treatment with psychotropic medications
35446|NCT03907124|Drug|Treatment as usual (TAU)|All subjects assigned to TAU group, which is the control arm, will continue to receive FDA-approved psychotropic medications for psychiatric indications investigated in this study
35447|NCT03907111|Device|Chitosan Gauze|Gauze made by chitosan material
35448|NCT03907111|Device|placebo|traditional gauze
35449|NCT03907098|Drug|Endostar|an anti-angiogenesis drug
35450|NCT03907098|Drug|Chemotherapy|Physician's choice
35451|NCT03907085|Other|HILT + exercise|High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
35452|NCT03907085|Other|Placebo HILT + exercise|Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
35453|NCT03907072|Drug|WVE-210201 (suvodirsen)|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
35454|NCT03907072|Drug|Placebo|Buffered saline solution
35455|NCT03907059|Dietary Supplement|whey protein|supplementation individually adjusted to 1.6g/kg/day
35456|NCT03907059|Dietary Supplement|soy protein|supplementation individually adjusted to 1.6g/kg/day
35457|NCT03907046|Drug|Apixaban|Apixaban is an oral anticoagulant of the Factor Xa inhibitor class.
35458|NCT03907046|Drug|Aspirin|Aspirin is an oral antiplatelet drug.
35486|NCT03906812|Other|Unmonitored|Bed type assignment
35459|NCT03907033|Drug|Liposomal bupivacaine|Liposomal bupivacaine is a novel formulation of local bupivacaine and allows prolonged release of the medication, thereby providing longer lasting effects. It is approved by the FDA and has been shown to provide excellent pain control after surgery.
35460|NCT03907033|Drug|Bupivacaine Hydrochloride|We currently administer local plain bupivacaine during vaginal hysterectomy to decrease pain in the postoperative period. Bupivacaine is an anesthetic that works by blocking nerve conduction and producing a numbing effect.
35461|NCT03907020|Dietary Supplement|Barley|Assessing the metabolic availability of lysine in barley.
35462|NCT03907007|Device|Percutaneous electrical nerve stimulation|Stimulation and medication at the same instant
35463|NCT03907007|Device|Percutaneous electrical nerve stimulation|Stimulation is given without administering medication
35464|NCT03906994|Other|Video game Mario Kart Wii|Subjects will place a patch over the better-seeing eye and play the video game Mario Kart Wii for a total of 40 hours over a 1 month perior
35465|NCT03906981|Other|Plaque from each subject will be collected but there will be no intervention|No intervention
35466|NCT03906968|Device|SinuSonic Device|A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion
35467|NCT03906955|Behavioral|Efficacy for Lifestyle PA|The intervention group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for engaging in lifestyle physical activity.
35468|NCT03906955|Behavioral|Efficacy for Work-life Balance|The time-matched control group is asked to participate in three (10-minute) video chats during the first three weeks of six weeks of engaging in lifestyle physical activity. Participants in this group will receive information that addresses outcome expectations in week one (e.g. physical, social, and self-evaluative outcomes and intrinsic and extrinsic motives), self-efficacy in week two (e.g. the four efficacy sources: vicarious experiences, mastery experiences, social persuasion, and perceptions of physiological and affective responses to behavior), and self-regulatory strategies in week three (e.g. goal-setting, self-monitoring, and planning) for work-life balance.
35469|NCT03906942|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content in the form of 152 BET I CAN challenges [1]. Behavior challenges are intended to increase a participant's capabilities to set a goal and to create positive habits. Emotion challenges are intended to increase a participant's capabilities to cope with negative emotions and to cultivate positive emotions. Thought challenges are intended to increase a participant's capabilities to challenge negative assumptions and to create a new narrative for their life. Interaction challenges are intended to increase a participant's capabilities to communicate and connect with others. Context challenges are intended to increase a participant's capabilities to read cues and to change cues in the environment. Awareness challenges are intended to increase a participant's capabilities to know herself/himself and to know the issue. Next steps challenges are intended to increase a participant's capabilities to make a plan and to stick with a plan.
35470|NCT03906929|Device|buried intramedullary K-wire|Using of buried kirschner wire in pediatric forearm fixation
35471|NCT03906929|Device|exposed intramedullary K-wire|Using of exposed kirschner wire in pediatric forearm fixation
35472|NCT03906916|Diagnostic Test|1,3-β-D-glucan quantification|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be evaluated by 1,3-β-D-glucan test and by means of blood culture to confirm the diagnosis
35473|NCT03906916|Drug|Micafungin|Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
35474|NCT03906903|Device|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
35475|NCT03906903|Behavioral|Cognitive Stimulation|Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
35476|NCT03906877|Procedure|Acid hyaluronic injection laryngoplasty|Hyaluronic acid is injected into the paralyzed vocal fold
35477|NCT03906877|Behavioral|Voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises"
35478|NCT03906877|Other|Sham of injection|Injection of physiological saline under the skin of the neck (sham of injection).
35479|NCT03906877|Other|Sham of voice therapy|"15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture."
35480|NCT03906864|Other|Care Pathway|"The intervention group had the following as part of the integrated care pathway:~Medical assessment on admission for risk factors for falls.~A weekly assessment of complications including pain, deep venous thrombosis, anaemia, wounds and pressure ulcers, etc. The Confusion Assessment Method and the Geriatric Depression Scale were utilized.~Physiotherapy and occupational therapy guidelines with recommended milestones (set for the full, partial and non-weight bearing groups)~Physiotherapy Clinical Outcome Variables Scale (PTCOVS)16 was used by the physiotherapists in the intervention group to assess the baseline mobility, to define outcome goals and to direct treatment plans.~A postoperative hip precaution handout (containing information on avoiding hip prosthesis dislocation in patients with total hip replacement or hemiarthroplasty) was given to patients and their caregivers."
35481|NCT03906851|Behavioral|Activity and diet|Physical activity: use of physical activity in theoretical subjects (3 x 30 min/week), physically active breaks (5 x 5 min/week), physical education (2 x 45 min/week) Nutrition: focus on school meals
35482|NCT03906838|Drug|Ropivacaine injection|Regional Anesthesia Nerve Block: Incremental injections up to total of 20 mL of 0.5% ropivacaine is administered.
35755|NCT03904680|Drug|Vitamin D|Vitamin D 200,000 IU ampules
35489|NCT03906786|Behavioral|motivational interviewing|The intervention will consist of 4 structured medical consultations in the form of a motivational interviewing compared to usual care, covering a 12-month intervention period. In both groups, the frequency of visits (c / 3 months) and the variables collected will be the same.
35490|NCT03906773|Other|Patient Centered Medical Home Based Electronic Framework for Advance Care Planning|The intervention tested a pre-visit ACP workflow centered around a framework sent via secure Electronic Health Record (EHR)-linked patient portal in a real world clinical setting. The primary objectives were to determine its impact on frequency and quality of ACP documentation.
35491|NCT03906760|Other|Magnetic resonance imaging (MRI)|MRI protocol associating sagittal and axial (+/- coronal) sequences in T2 + / - turbo spin T1 weighting with fat saturation.
35492|NCT03906747|Other|Interviews, questionnaire and focused group discussions|"To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged."
35493|NCT03906747|Other|Review of medical records|"Electronic medical records will be reviewed to collect the following data:~Proportion of patients who fits criteria of EOL who died within 48 hours;~Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration"
35494|NCT03906734|Procedure|Septal myectomy|Transaortic septal myectomy
35495|NCT03906734|Procedure|alfieri stich|Transaortic Mitral valve repair using alfieri technique
35496|NCT03906734|Procedure|Subvalvular intervention|Transaortic Mitral valve subvalvular intervention including anterior mitral leaflet secondary cord cutting, papillary muscle release
35497|NCT03906721|Drug|Placebo|Sugar pill used to condition patients.
35498|NCT03906721|Drug|Oxycodone|An opioid used for analgesia.
35499|NCT03906721|Other|Essential Oil|An aromatic oil used for conditioning.
35500|NCT03906708|Other|Diffusion Capacity of the Lung for Carbon Monoxide (DLCO)|Infant lung function testing
35501|NCT03906695|Drug|ASTX727 LD|oral decitabine + cedazuridine
35502|NCT03906682|Behavioral|RAP Club|RAP Club was adapted from a trauma treatment program called Structured Psychotherapy for Adolescents Responding to Chronic Stress (SPARCS). Core program components include psychoeducation, mindfulness, and cognitive-behavioral strategies.
35503|NCT03906682|Behavioral|Healthy Topics|Co-investigator Dr. Sibinga developed the Healthy Topics curriculum to function as an active control condition for randomized controlled trials in both clinic-based and school-based studies of mindfulness instruction for urban youth. Adapted from the Glencoe Health Curriculum (McGraw Hill), it was designed to control for the effects of a positive adult, time and attention, a small group learning environment, engaged instruction, and interesting material. The Healthy Topics curriculum has been successfully implemented as an effective active control condition, with student engagement and participation comparable to the intervention arm. The curriculum includes information about nutrition, exercise, sleep, drug use, and other topics related to physical health.
35504|NCT03906669|Drug|Letrozole|PO daily for 14 days
35505|NCT03906669|Drug|Letrozole and Prometrium|PO daily for 14 days
35506|NCT03906669|Drug|Tamoxifen and Prometrium|PO daily for 14 days
35507|NCT03906656|Device|C-Brace|The C-Brace consists of individually fabricated thigh, calf and foot components. An ankle joint, unilateral or bilateral fitting, or an individual spring element connects the foot and calf components. The sensor system continuously measures the flexion of the knee joint and its angular acceleration. This allows the C-Brace to detect the user's current walking phase, so it can regulate the hydraulic resistances as well as control the flexion and extension of the knee joint.
35508|NCT03906656|Device|KAFO/SCO|Current knee ankle foot orthosis that the subject was wearing at baseline
35509|NCT03906643|Drug|HS-201|HS-201 will be administered intravenously as a single dose
35510|NCT03906630|Diagnostic Test|Telehealth clinical exam|This is a pseudo telehealth clinical exam for patients presenting with shoulder pain
35511|NCT03906630|Diagnostic Test|Standard clinical exam|This is a standard in-person clinical exam for patients presenting with shoulder pain
35512|NCT03906617|Drug|Intercostal nerve block and wound infiltration with liposomal bupivacaine|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 266mg of liposomal bupivacaine with 24 ml of 0.5% bupivacaine will be used.
35513|NCT03906617|Drug|Intercostal nerve block and wound infiltration with bupivacaine/epinephrine + dexamethasone|Intercostal nerve block and wound infiltration with liposomal bupivacaine during robotic lung resection surgery. 42 ml of 0.5% Bupivacaine/epinephrine with 8mg dexamethasone will be used.
35514|NCT03906604|Procedure|Carpal Tunnel Procedure (open)|Patients with bilateral CTS will have one side released with incisionless thread carpal tunnel release and the contralateral side released with the mini-open carpal tunnel release.
35515|NCT03906591|Procedure|allogenic bone ring|allogenic bone ring with simultaneous dental implant placement
35516|NCT03906591|Procedure|autogenous bone ring|autogenous bone ring with simultaneous dental implant placement
35517|NCT03906578|Dietary Supplement|Vivomixx®|Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
35518|NCT03906578|Other|Placebo|Placebo with similar appearance to probiotic
35519|NCT03906565|Drug|utidelone injection|utidelone monotherapy in patients with advanced or metastatic CRC by iv transfusing utidelone injection
65708|NCT03670966|Drug|Mycophenolate Mofetil|Given IV or PO
35520|NCT03906552|Other|nonpharmalogocial methods|neonates received acupressure (acupressure group) or massage (massage group) before heel lancing procedure
35521|NCT03906539|Drug|Atorvastatin 10mg|Atorvastatin 10 mg per day
35522|NCT03906539|Dietary Supplement|Virgin Coconut Oil (VCO)|Capsule VCO (1000 mg/day)
35523|NCT03906539|Other|Placebo|Placebo capsule - 1 capsule per day
35524|NCT03906526|Drug|VTX-2337|Motolimod
35525|NCT03906526|Drug|Nivolumab|IV Nivolumab
35526|NCT03906513|Device|OMK2|OMK2 (including citicoline 2%, high molecular weight hyaluronic acid 0.2%, cyanocobalamin and 0.01% BAK, Omikron Italia SRL) is a Class IIa device CE marked registered in Medical Devices Database of Italian Ministry of Health (identification number of registration: 1170558).
35527|NCT03906500|Behavioral|High schools High on Life|"The intervention consist of three main components.~Environmental factors of the school environment~The component targeting the high school environment consisted of two separate elements:~Revision of school alcohol policy~Appointment of coordinator(s) of student committees organizing events, where alcohol is sold, and student introduction committee.~Student component~The Student components consisted of three main elements:~Online education for the student committees organizing events where alcohol is sold and the student introduction committee~Pocket movie campaign competition~Social norms campaign~Parent component~The parent component consisted of three separate elements:~Parent Information Meeting~Parent Information Folder~Parent Information Website"
35528|NCT03906487|Behavioral|Assessment measures MINI, PCL5 and BDI-II and definition of 5 SDM|"This group will have two visits:~the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ;~the last to characterize the SDM by defining 5 personal memories"
35529|NCT03906487|Behavioral|Assessment measures MINI and definition of 5 SDM|"This group will have two visits:~the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary;~the last to characterize the SDM by and defining 5 personal memories"
35530|NCT03906474|Biological|Blood-stage controlled human P. falciparum malaria infection|Volunteers will be challenged with malaria by administering a small amount of P. falciparum infected blood intravenously.
35531|NCT03906461|Device|Radiofrequency Ablation|The Tacticath Contact Force Ablation Catheter, Sensor Enabled (TactiCath SE) is designed to facilitate electrophysiological mapping of the heart chambers and to transmit radiofrequency (RF) current to the catheter tip electrode for intracardiac ablation purposes.
35532|NCT03906448|Combination Product|TTFields with adjuvant temozolomide|Patients will begin study treatment with temozolomide and TTFields within 2 weeks of the baseline evaluation, and no later than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and a maximum of 12 cycles of adjuvant temozolomide will be given, depending on tolerability and toxicity.
35533|NCT03906435|Behavioral|Cognitive Behavioral Therapy|The intervention group will receive standard NICU and follow up care information plus a total of 5 CBT sessions split between the NICU and outpatient clinic visits post discharge from NICU. The CBT sessions will address PPCV in parents and parenting skills to address this. The CBT sessions will be standardized with a manual for study investigators to follow during sessions, and made with Dr. Richard Shaw from Stanford University, who wrote the prior CBT manual for anxiety, depression, and PTSD for NICU parents. Study staff will be trained to give the standardized CBT sessions using the manual via pilot sessions. There will be 3 CBT sessions given in the Parkland NICU before discharge and then 2 in the THRIVE follow up clinic at Children's Medical Center after discharge from the NICU.
35534|NCT03906422|Device|3M Unitek 0.016 orthodontic archwire|Placement of 3M Unitek 0.016 archwire for orthodontic treatment
35535|NCT03906422|Device|"Device: 0.016 Ormco 27oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 27oC NiTi orthodontic archwire"
35536|NCT03906422|Device|"Device: 0.016 Ormco 35oC NiTi orthodontic archwire"|"Placement of 0.016 Ormco 35oC NiTi orthodontic archwire"
35537|NCT03906409|Other|Constant|Participants will be provided with their daily energy requirements in a continuous drip across the day (1 ml/minute).
35538|NCT03906409|Other|Bolus|Participants will be provided with their daily energy requirements in two bolus feeds. One at 08:00-08:15 and one at 20:00-20:15
35539|NCT03906396|Device|Xbox 360 Kinect|A session 30 minutes of exercise game activities using the Xbox 360 Kinect will be performed by each participant. Games uses for the activity are Sports Kinect and Sports Kinect 2. Xbox 360 Kinect - the players themselves become the ''game controller'' via their body movements and gestures, Kinect-enabled game titles lend themselves comfortably to the class of exercise games.
35540|NCT03906383|Other|Remote Ischemic Conditioning|Brief reversible restriction of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
35541|NCT03906370|Diagnostic Test|Diagnostic criteria for MS|The diagnosis healthy/diseased was made by 2017 Mc Donald criteria.
35542|NCT03906357|Drug|Pemigatinib|
35543|NCT03906344|Drug|INCB052793|
35544|NCT03906331|Drug|LOXO-292|Open-label expanded access
35545|NCT03906318|Drug|Itacitinib|
35546|NCT03906305|Other|Dry needling in a myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application over a myofascial trigger point by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into taut bands of the following shoulder spastic muscles (when a trigger point was present): upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy~Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
35571|NCT03906110|Behavioral|Personalized One on One Education|"Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided."
65709|NCT03670966|Drug|Sirolimus|Given PO
35547|NCT03906305|Other|Dry needling in a non myofascial trigger points area plus physical therapy based on Bobath concept|"Other: Dry Needling Participants will receive dry needling application carried out over a non trigger point area by an experienced physical therapist with clinical experience in neurological patients, that will be inserted into a non trigger point spastic muscle of the shoulder area: upper trapezius, supraspinatus, infraspinatus and deltoid anterior.~Other: Physical Therapy Participants will receive physical therapy treatment based on the modulating Bobath technique. This technique will be applied using the general parameters, carrying out similar action protocols with every patient, based on the aim of normalizing upper limb muscle tone.~Device: stainless steel needles (0.3mm x 50mm)"
35548|NCT03906292|Drug|Imatinib|Imatinib 400 mg QD and asciminib 60 mg QD
35549|NCT03906292|Drug|Nilotinib 300 mg|Nilotinib 300 mg BID and asciminib 20 mg BID or 40 mg QD
35550|NCT03906292|Drug|Dasatinib|Dasatinib 100 mg QD and asciminib 80 mg QD
35551|NCT03906292|Drug|Asciminib|Asciminib
35552|NCT03906266|Diagnostic Test|NRS 2002, nutric, SGA and adductor pollicis|NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
35553|NCT03906253|Device|Fractionated Laser Resurfacing|A rejuvenating laser that makes tiny holes in the very superficial part of the skin.
35554|NCT03906240|Behavioral|Moral Elevation intervention|The intervention will be administered twice per week for 8 sessions total. The intervention will include two types of moral elevation exercises related to witnessing virtuous behavior and subsequently setting session goals aimed to facilitate social engagement.
35555|NCT03906227|Device|ENUMERATION OF CD5+ B Cells|A blood test is done to assess what percentage of CD5+ is present within CD19+. The result is then used to guide choice of arm.
35556|NCT03906214|Other|Web-based Survey|"Participants will be directed to online forms to report general information (ex. age, sex, test results, family history), suspected medication-related acute attacks, and uneventful use of possibly risky medication. If a patient has multiple medication-related acute attacks, the patient/caregiver will be able to submit multiple report forms that will be linked. In addition to the report forms, patients will be asked to review a list of Medications of Interest and report current or past use."
35557|NCT03906201|Dietary Supplement|Ecdysterone|Food supplement of plant origin with pronounced biological activity and potentially hypoglycaemic
35558|NCT03906201|Other|Placebo|no pharmacologic effect
35559|NCT03906188|Other|LitEmotion|LitEmotion is a serious video game programmed for helping managing emotions. The experimental group will play during 3 weeks while the control group will not play. The sample will play during 21 days, one session daily, around 45 minutes. After the 21 sessions the group will stop playing during 3 weeks. Therefore, the scales are done three times. In the very beginning (before playing), 21 days after playing, and, finally, 21 days no playing.
35560|NCT03906175|Device|Whole-body hyperthermia|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization). The hyperthermia will be applied using Heckel-HT3000 MPIIb.
35561|NCT03906162|Behavioral|Motivational interviews|"During the 12-week intervention, the participants will receive seven telephone calls from a physical therapist. The interviews will be held in week 1, 2,3,5,7,9, and 12.~The telephone call will consist of a motivational interview focused on enhancing the daily level of physical activity in the participants.~MI is a form of counselling aiming at prompting increases in self-efficacy, which may leave people more open to and invested in changing their behaviours and shows potential for significant effects for exercise behaviour change.~In addition to the telephone based motivational interviews, the experimental group will also receive the base intervention which is described in detail under the control intervention paragraph."
35562|NCT03906162|Behavioral|Base intervention|"The base intervention consists of a physical activity monitor (PAM) for everyday use in the intervention period and a pamphlet with information about Danish recommendations on physical activity in aging populations. The PAM will be the Garmin Vivofit 3 monitor linked to a pre-specified Garmin Connect account. The participants will be asked to install the Garmin Connect application on their smartphone and use the given ID/password in the app. The participants will be asked to wear the monitor 24-hours a day for the 12-week intervention period. The participants can use the PAM as they like but they will be asked to try to use the PAM and the application to enhance their daily level of physical activity."
35563|NCT03906149|Combination Product|Whole-body hyperthermia + standard medical care|Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
35564|NCT03906149|Combination Product|Standard medical care|Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
35565|NCT03906136|Biological|Secukinumab/Adalimumab-Biosimilar|Secukinumab 150 mg, s.c. Secukinumab 300 mg, s.c. Adalimumab-Biosimilar, s.c.
35566|NCT03906136|Other|Standard-of-care|Patients will receive treatment according to local practice standards by their treating physician following the current treatment recommendations.
35567|NCT03906123|Drug|NBP|NBP soft capsules
35568|NCT03906123|Drug|Placebos|Soft capsules manufactured to mimic NBP
35569|NCT03906110|Behavioral|Community Colorectal Cancer Awareness, Research, Education & Screening (C-CARES) Materials|Educational materials (photonovella +DVD) + Fecal Immunochemical Test (FIT) kit. Offers colorectal cancer screening information using a novella format. Materials describe colorectal cancer and screening tests that are available, and procedures for completing FIT kit.
35570|NCT03906110|Behavioral|Contact Message|Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
35572|NCT03906110|Diagnostic Test|Fecal Immunochemical Test (FIT)|The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
35573|NCT03906097|Other|Play and Competition-Based Cognitive Therapy|The intervention group was received play and competition-based cognitive therapy for 10 weeks, 3 days a week, 1 hour per day; the control group was the group who continued the special education program
35574|NCT03906084|Procedure|Corticotomy and low laser therapy|Corticotomy is carried out under local anesthesia followed by low-intensity laser therapy that is started on the selected experimental side on the same day as placement of the coil spring
35575|NCT03906084|Procedure|Corticotomy facilitated Orthodontics|Corticotomy is carried out under local anesthesia in right side.
35576|NCT03906071|Biological|Nivolumab|Nivolumab is an antibody directed at the programmed death receptor-1 (PD-1), blocking its interaction with PD-L1 and PD-L2.
35577|NCT03906071|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of several closely related receptor tyrosine kinases.
35578|NCT03906071|Drug|Docetaxel|Docetaxel is an anti-neoplastic agent that acts by disrupting the microtubular network in cells.
35579|NCT03906058|Drug|Anlotinib|All patients enrolled in the study will accept anlotinib treatment as a palliative treatment .
35580|NCT03906045|Drug|BGF-MDI|Budesonide, Glycopyrronium and Formoterol Fumarate.
35581|NCT03906032|Device|TFNA IM Nail|IM nail
35582|NCT03906032|Device|Sliding hip screw|SHS surgical fixation
35583|NCT03906019|Procedure|ESP Block|Erector spinae plane block performed with 0,25% bupivacaine (0,5 mL/kg-max 20mL), under general anesthesia before the start of the surgery.
35584|NCT03906019|Diagnostic Test|FLACC score|For up to 7 years old patients, Face, Legs, Activity, Cry and Consolability (FLACC) scores during postoperative 24h period.
35585|NCT03906019|Diagnostic Test|NRS score|Patients older than 7 years, NRS scores during postoperative 24h period.
35586|NCT03906006|Drug|ABP-671|Drug: ABP-671, single oral dose
35587|NCT03906006|Other|Placebo|Other: Placebo, single oral dose
35588|NCT03905980|Procedure|vaginal delivery|pregnancy ended by vaginal delivery
35589|NCT03905980|Procedure|Cesarean section|pregnancy ended by cesarean delivery
35590|NCT03905967|Procedure|TACE|TACE will be performed one day after oral administration of lenvatinib. TACE with either cTACE or DEB-TACE can be used, depending on the condition of each center.
35591|NCT03905967|Drug|Lenvatinib|Lenvatinib will be taken within 3 days of randomization (dose: 8 mg qd for patients <60kg, and 12 mg qd for patients >60kg)
35592|NCT03905954|Other|Usual care|For this cross sectional survey, participants will be receiving usual care according to there health care systems
35593|NCT03905941|Drug|Metformin|Metformin 2000 mg/day will be used in this study. Metformin is a antihyperglycemic agent that is used as a first line medical therapy to treat type 2 diabetes mellitus. It is also used to prevent progression of impaired glucose tolerance. It decrease hepatic glucose production and increase insulin sensitivity.
35594|NCT03905941|Drug|Oral combined hormonal contraceptives|"Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause."
35595|NCT03905928|Other|Nicotine Containing ECIG with tobacco flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a tobacco flavor."
35596|NCT03905928|Other|Nicotine Containing ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 18mg/ml nicotine concentration and a strawberry vanilla flavor."
35597|NCT03905928|Other|Placebo ECIG with Tobacco Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a tobacco flavor."
35598|NCT03905928|Other|Placebo ECIG with Strawberry Vanilla Flavor|"Participants will be provided with an EGO style ECIG to be used for 28 days. The EGO style ECIG is a vape pen-style device that comprises of a rechargeable battery and a tank containing liquid. Those in this intervention group will receive an ECIG with 0mg/ml nicotine concentration and a strawberry vanilla flavor."
35599|NCT03905915|Device|Virtual reality (VR) session with AQUA module|A device with virtual reality is given to the patients with a film of 15 minutes
35600|NCT03905902|Biological|DCVAC/OvCa|activated autologous dendritic cells
35601|NCT03905902|Biological|DCVAC/OvCa placebo|placebo for activated autologous cells
35602|NCT03905889|Drug|Abemaciclib|Subjects will by given oral Abemaciclib every 12 hours for 14 days followed by 7 days off (i.e. a 21 day cycle). The initial dose will be 100 mg (Dose level 1) followed by 150 mg (Dose Level 2) depending on tolerability and toxicity assessment of the combination of medications. If at Dose Level 1 subjects cannot tolerate the combination of medications, the Abemaciclib would not be increased, and the dose will remain stable at 100 mg (Dose Level -1).
35603|NCT03905889|Drug|Sunitinib|Subjects will take oral Sunitinib daily for the 21-day cycle. Dosing will be at 50 mg for both Dose Levels 1 and 2. If the combination of the 2 medications is not tolerated by Subjects at Dose Levels 1 a lower dose of Sunitinib (37.5 mg) will be given (Dose Level -1).
35604|NCT03905876|Other|Questionnaire|Questionnaire to evaluate psychological experience
35605|NCT03905863|Device|Natrox® Oxygen Wound Therapy|A battery-operated device which delivers 98% pure humidified oxygen to the wound bed through water electrolysis via a sterile oxygen delivery system.
35606|NCT03905850|Drug|somapacitan|5 mg/1.5 ml and 10 mg/1.5 ml doses administered s.c. (subcutaneously, under the skin)
35607|NCT03905837|Drug|Lidocaine|Intravenous or paravertebral lidocaine
35608|NCT03905837|Drug|Remifentanil|intravenous remifentanil
35609|NCT03905824|Biological|Allogenic stromal mesenchymal cells derived from the umbilical cord|Platelet-poor plasma (PPP) scaffold embedded in allogenic stromal mesenchymal cells derived from the umbilical cord added to the traditional treatment for osteochondral lesions of the talus
35610|NCT03905824|Procedure|Debridement and microfracture|Debridement and microfracture in LOC is the traditional treatment for osteochondral lesions of the talus
35611|NCT03905811|Drug|Terazosin 5 MG|5 milligrams by mouth daily at bedtime
35612|NCT03905811|Drug|Placebo oral capsule|1 capsule by mouth daily at bedtime
35613|NCT03905798|Drug|Lorazepam|"The usual dose of lorazepam in adults is 4 mg administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 4 mg may be added but the dose should not exceed 8 mg as the sum of initial and additional doses.~The usual dose of lorazepam in children aged 3 months or older is 0.05 mg/kg (up to 4 mg) administered intravenously. The drug should be given slowly with the administration rate at 2 mg/min as a guide. If necessary, 0.05 mg/kg may be added but the dose should not exceed 0.1 mg/kg as the sum of initial and additional doses."
35614|NCT03905785|Behavioral|Samarthan|Samarthan intervention was designed as group program, training parents in cognitive-behavioural techniques for managing child's difficult behaviour and issues. Program was focused on parent-child problem solving method and positive interaction.
35615|NCT03905772|Other|Voluntary exercise|The participants will perform 36 maximal voluntary contractions, 3 times per week for 8 weeks.
35616|NCT03905772|Other|Wide pulse responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in responder group in acute fase.
35617|NCT03905772|Other|Wide pulse non responder group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 1 ms, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks. This group will be classified in non responder group in acute fase.
35618|NCT03905772|Other|Pulsed current group|The participants will perform 36 contractions with the following current parameters: pulsed current (100 Hz, pulse duration 250 μs, Ton: 6 s, Toff: 18 s), 3 times per week for 8 weeks.
35619|NCT03905759|Drug|Dronedarone|Dronedarone (200 mg twice daily starting from day before operation till 5 days after)
35620|NCT03905759|Drug|Amiodarone|Group A:-amiodarone (200 mg three times per day)21 administered 6 days prior to surgery through 6 days after surgery
35621|NCT03905759|Drug|Colchicine|Colchicine will be used at the dose of 1 mg orally, twice daily, preoperatively (1 days), and of 0.5 mg, twice daily, until hospital discharge
35622|NCT03905746|Other|blood sample at Day 0|"40mL blood (plasma and PBMCs) will be performed at D0 (inclusion), at the time of routine exams.~(20 ml will be used for study analyzes ; 20mL will constitute the biological collection)"
35623|NCT03905746|Other|blood sample at Day 2 and Day 7|20mL blood (plasma and PBMCs) will be performed at Day 2 and Day 7 from recruitment, at the time of routine exams. These two samples will constitute the biological collection.
35624|NCT03905733|Device|Optiflow|supply of oxygen at 2 L / min/ kg through Optiflow
35625|NCT03905720|Procedure|Acupuncture|A licensed acupuncturist will assess participants' symptoms and administer acupuncture needles in accordance with traditional Chinese medicine principles and the study protocol. Treatments will provided daily for up to four hospital days.
35626|NCT03905720|Behavioral|Pain Counseling|Participants will receive sessions with a counselor trained in pain management. The pain counselor will explain, review, and discuss the contents of a Pain Control booklet. Sessions will include pain assessment, pain education, and coping skills, provided daily for up to four hospital days.
35627|NCT03905707|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
35628|NCT03905694|Drug|Lumasiran|Lumasiran will be administered by subcutaneous (SC) injection.
35629|NCT03905681|Device|Transcutaneous Electrical Nerve Stimulation|Application of TENS pads and wearing of the TENS device.
35630|NCT03905668|Other|Video Monitoring|Patients may have video monitoring for up to seven days while in the ICU. The video system will be placed in an unobtrusive area in the patient's ICU room.
35631|NCT03905668|Other|Accelerometer Monitoring|Patients may have accelerometer monitoring for up to seven days while in the ICU. Commercially available accelerometer units, which have been validated in previous clinical studies, will be used.
35632|NCT03905668|Other|Electromyographic Monitoring|Patients may have electromyographic monitoring for up to seven days while in the ICU.
35633|NCT03905668|Other|Noise Level Monitoring|Patients may have noise level monitoring (in decibels) for up to seven days while in the ICU.
35634|NCT03905668|Other|Light Level Monitoring|Patients may have light level monitoring for up to seven days while in the ICU.
35635|NCT03905655|Drug|Placebo Oral Tablet|Number of placebo tablets administered orally depends on the arm
35636|NCT03905655|Drug|Nitazoxanide|Number of Nitazoxanide 300 mg extended release tablets administered orally depends on the arm
35637|NCT03905642|Drug|Arikayce™|Amikacin (aminoglycoside) in a liposomal formulation.
35638|NCT03905629|Other|None (retrospective observational study)|"This multi-centric retrospective observational cohort study is conducted using the PMSI. Predictive ability of HFRS estimated on the basis of 3 binary outcomes: 30-day in-patient mortality (main outcome), 30-day emergency and potentially avoidable readmission, length of stay >15 days. Odds ratios (ORs) and c-statistics calculated and compared to the original UK results in order to validate the use of the HFRS in France. Other secondary objectives include:~Evaluate agreement between HFRS and Charlson or Elixhauser comorbidity indices~Evaluate ability of HFRS combined with comorbidity indices (Charlson on one hand, and Elixhauser on other hand), to predict 30-day in-patient mortality, 30-day emergency and potentially avoidable readmissions, and long length of stay~Identify specific risk associations in France of a high risk of frailty (as assessed by the HFRS) with individual, organizational and territorial factors"
35639|NCT03905616|Device|functional Magnetic Resonance Imaging|In a 2-hour session, the subject we be shown different control and experimental conditions (all being visual stimuli) in perceptive tasks.
35640|NCT03905603|Drug|ACTH|ACTH (Cosyntropin) 250 mcg will be given once during the study.
35641|NCT03905603|Drug|rhCG|rhCG (Ovidrel) 250 mcg will be given once during the study.
35642|NCT03905590|Procedure|Periapical surgery with amniotic membrane|periapical surgery will be done followed by amniotic membrane placement over the defect
35643|NCT03905590|Procedure|periapical surgery without amniotic membrane|periapical surgery will be done without placement of membrane over the defect.
35644|NCT03905577|Behavioral|Action Observation|Action Observation training
35647|NCT03905564|Drug|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg combination|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Tecnandina, S.A. TENSA).
35648|NCT03905564|Drug|Diclegis (Registered Trademark)|Delayed-release tablet containing a fixed-dose combination of doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg (product of Duchesnay Inc.).
35649|NCT03905551|Procedure|Cold Dialysis|Dialysate temperature reduced to 35oC for a period of 7 months.
35650|NCT03905551|Procedure|Typical Dialysis|Dialysate temperature is set at 37oC for a period of 7 months
35651|NCT03905551|Procedure|Exercise|Aerobic Intradialytic exercise training
35652|NCT03905538|Drug|[18F]FLT-PET/CT|Dose of 0.07 mCi/Kg [18F]FLT to max of 5 mCi (± 20%) will be given intravenously.
35653|NCT03905525|Drug|CFZ533|Biological
35654|NCT03905525|Other|Placebo|liquid placebo for injections
35655|NCT03905512|Drug|SEL-212|SEL-212
35656|NCT03905512|Drug|SEL-037|SEL-037, PEGylated uric acid specific enzyme (uricase)
35657|NCT03905512|Drug|SEL-110|ImmTOR (SEL-110)
35658|NCT03905512|Drug|KRYSTEXXA®|KRYSTEXXA®, PEGylated uric acid specific enzyme (uricase)
35659|NCT03905499|Device|Robotic mediated therapy with MJS (multi joint system) Tecnobody|The intervention will include 18 30-minutes trainings evenly distributed over a time period of 6 weeks and will be administered by the same two physiotherapists at the Schulthess clinic based on the standardized protocol
35660|NCT03905486|Drug|Pregabalin 300mg|Group 1: will receive pregabalin as a monotherapy. Pregabalin will be administered according to the treatment recommendations for fibromyalgia in the package insert [Pfizer Inc., 2012] starting by 50 mg twice daily increasing to 300 mg twice daily according to the efficacy and tolerability for 3 months.
35661|NCT03905486|Drug|Combined pregabalin 300mg and milancipran 100mg|Group 2: will receive a combined pregabalin and milancipran. Pregabalin will be administered as group 1, while milancipran will be administered according to the treatment recommendations for fibromyalgia, starting by 50 mg once daily for 1 week then increased to reach 100 mg daily (50 mg twice daily) based on efficacy and tolerability for 3 month.
35662|NCT03905473|Behavioral|Accelerometer measurements|To validate the questionnaires about physical activity, some patients will be wearing an accelerometer for one week. An accelerometer is a little device worn in a belt around the hip, which can measure intensity of the patient's activity level. The accelerometer is worn 24 hours a day for one week and is only removed when bathing.
35663|NCT03905460|Diagnostic Test|Point-of-care ultrasound|Focused ultrasound of the heart, lungs and pleurae
35664|NCT03905447|Drug|PC945|Nebulized PC945 5mg OD for 28 days with an optional extended treatment period of a further 56 days.
35665|NCT03905447|Drug|Standard of Care|Standard of Care antifungal medication
35666|NCT03905434|Genetic|miRNA sampling|Blood samples for miRNA testing will be collected from all subjects (control and patients diagnosed with acute ischemic stroke)
35667|NCT03905408|Drug|Glucose|Escalating dose (50 mL, 100 mL, 150 mL, 200 mL) of dextrose 50%
35668|NCT03905395|Behavioral|Meditation and mindfulness|Women in the intervention arm will 3 times receive a three hours work shop with introduction to meditation and mindfulness over a 7 week period from a certified meditation instructor. Questionnaires before and after the intervention.
35669|NCT03905382|Other|Qualitative|Focus group and 1:1 telephone interviews
35670|NCT03905369|Other|Decision aid and SDM booster|The investigators develop the decision aid and SDM booster. The scope of the investigators of decision making combines the clinical and patient perspective. The decision aids are developed for patients with TC either newly diagnosed or patients with advanced disease, presently in the follow-up at the participating centers, covering the whole treatment trajectory of these patients (Figure 4). Three treatment decisions are considered: 1) the extent of thyroid resection, 2) the use of RAI, and 3) the initiation of TKIs.The SDM-booster is developed alongside the decision aids, as the SDM-booster (or values clarification exercise) is often a component developed together with a decision aid. The SDM-booster aims to shape patients' values regarding aspects of the decision and ensuing treatment preferences.
35671|NCT03905369|Other|Deliberation training|The investigators develop the deliberation training. It makes physicians more aware and responsive to patients' values. The communication training for physicians will consist of 1) an e-learning SDM-training lasting 40 minutes and, 2) an individual values deliberation training lasting 2 hours.
35672|NCT03905356|Behavioral|Exercise Therapy|Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.
35673|NCT03905343|Drug|Ribociclib|Ribociclib 600mg p.o. d1-21, q4w in combination with endocrine treatment for 3 years.
35674|NCT03905343|Other|Mono-chemotherapy|mono-chemotherapy for at least 12 weeks (afterwards, maintenance endocrine therapy ± ribociclib inhibitor is allowed) and up to 3 years.
35675|NCT03905343|Other|Endocrine-Therapy|The choice of endocrine therapy is up to the investigator, but the chosen endocrine therapy has to be registered to be used in combination with ribociclib in the investigated indication.
35678|NCT03905317|Drug|Bevacizumab Injection|Bevacizumab maintenance therapy starts 1-2 months later after the chemotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, and the drug is given every 3 weeks until disease progression or intolerable toxicity occurs.
35679|NCT03905317|Radiation|chest radiation|The patients receive SBRT radiotherapy for the primary (if any) and metastatic lesions or divided radiotherapy with or without concurrent chemotherapy.
35680|NCT03905317|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
35681|NCT03905304|Biological|Medytoxin|Intramuscular injection up to 300U.
35682|NCT03905304|Biological|Botox|Intramuscular injection up to 300U.
35683|NCT03905291|Drug|MT921|Formulated as an injectable solution
35685|NCT03905278|Behavioral|Parental guidance|A psychological intervention including 4 sessions to assess how participants communicate with their children about the disease and take stock of their questions and difficulties. To identify children's reactions and needs. Practical situation are analyzed and worked through role play centered on communicational difficulties to enhance communicational self-efficacy and mutual support among participants. Emotional regulation strategies are learned through relaxation exercises. A relaxation booklet is given to the participants to practice at home too. Moreover, all participants receive an informational booklet containing age-appropriate recommendations on communication with children about cancer.
35686|NCT03905265|Drug|Moxidectin Oral Product|The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required
35687|NCT03905252|Other|sample analysis|blood and 2-hour urine samples
35688|NCT03905239|Diagnostic Test|algorithm|clinical examination and procalcitonin assessment
35689|NCT03905213|Device|dressing MEPORE|assignation to three different authorised and on label dressing: conventional dressing (MEPORE)
35690|NCT03905213|Device|dressing MEPILEX|assignation to three different authorised and on label dressing: absorbent(MEPILEX)
35691|NCT03905213|Device|dressing PICCO|assignation to three different authorised and on label dressing:vacuum Therapy dressing(PICCO)
35692|NCT03905200|Diagnostic Test|3D-speckle tracking imaging|The strain peak value and strain peaking time of each segment (including 16 segments) of the left ventricular myocardium can be obtained by 3d-sti technology.
35693|NCT03905187|Behavioral|Modified CR|Stress management involved modified cardiac rehabilitation
35694|NCT03905187|Behavioral|Traditional CR|Traditional cardiac rehabilitation
35695|NCT03905187|Behavioral|Education|Education
35696|NCT03905174|Device|custom made device|surgical intervention to place custom made orthopaedic device
35697|NCT03905161|Other|6-minute walk test|The 6-minute walk test (6MWT) is widely used in the clinic to measure treatment efficacy and disease progression in patients with neuromuscular diseases and is found valid and reliable to measure decrease in walking speed for neuromuscular patients.
35698|NCT03905148|Drug|BGB-283 (lifirafenib)|RAF Dimer Inhibitor
35699|NCT03905148|Drug|PD-0325901|MEK Inhibitor
35700|NCT03905135|Drug|rhIL-15|IL-15 will be administered by continuous intravenous infusion in a dose-escalation fashion with a starting dose of 1 mcg/kg/day, a second dose level of 2 mcg/kg/day, a third dose level at 3 mcg/kg/day, and a fourth dose level at 4 mcg/kg/day on days 1-5 of each of six cycles.
35701|NCT03905135|Biological|Avelumab|Avelumab (IV over 1 hour) will be administered at a dose of 10 mg/kg on days 8 and 22 of each of six cycles.
35702|NCT03905122|Device|bioreactans tool|It is a completely non-invasive method by bioreactance method and it can be done to measure the intra-body fluid status with the help of the probes.
35703|NCT03905109|Drug|ABX464|ABX464 is a new anti-inflammatory drug. In the treatment arm, patients will receive 50 mg of ABX464 orally once daily during 112 days.
35704|NCT03905109|Drug|Placebo|In the placebo group, patients will receive 50mg ABX464-matching-placebo orally once daily during 112 days.
35705|NCT03905096|Drug|BI 425809|Film coated tablet
35706|NCT03905096|Drug|Donepezil|Film coated tablet
35707|NCT03905083|Other|Exercise Rehab|Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
35708|NCT03905057|Device|Dornier Aries 2 (with active applicator)|Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
35709|NCT03905057|Device|Dornier Aries 2 (with sham applicator)|Sham ESWT - No shockwave administered
35710|NCT03905044|Other|eyes with congenital cataracts|observation
35711|NCT03905031|Device|InfraScanner 2000|The InfraScanner is a portable screening device that measures lateralized differences in optical density (OD) to determine the presence of intracranial hematoma. A difference in OD>0.2 is abnormal and suggestive of intracranial hematoma.
35712|NCT03905018|Drug|Tadalafil 20 MG|tadalafil 20 mg orally ,after a single administration
35713|NCT03905005|Procedure|Mandibular reconstruction with free tissue transfer.|Mandibular reconstruction with free tissue transfer (free-flap bony reconstruction) requires the use of a titanium plate to secure bony segments until bony healing is complete. Plates are made of titanium but can be customised to the anatomical shape of the mandible by two different techniques: flexing (bending) of the plate before surgery, or printing of the plate from titanium alloy powder bed fusion techniques (additive manufacturing, such as selective laser melting).
35714|NCT03904992|Other|Progressive web app|Access to a progressive web app for the promotion of healthy habits in preescholers through the participant's smatphone
35715|NCT03904979|Other|Writing exercises|Participants will be given journals with writing prompts to be completed throughout their pregnancy.
35716|NCT03904966|Device|Kinesio tape|Kinesio tape will be applied on the plantar heel (the most painful area) of the patients for the treatment of plantar fasciitis, in addition to the extracorporeal shock wave therapy
35717|NCT03904966|Device|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy will be used for all patients with plantar fasciitis. (5 sessions for 5-week)
35718|NCT03904953|Other|Pilates Training|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
35719|NCT03904953|Other|Conventional exercise programme|Stretching of erector spine, hip flexors, hamstring muscles and gastro-soleus muscles; back-strengthening of cervical, thoracic and lumbar spine and posture exercises will be taught to the patients in the first session and the patients will be requested to repeat the exercises three times a week for 8 weeks individually at home.
35720|NCT03904940|Device|Total Contact Insole|Ethyl vinyl acetate insole shaped in the cast of the patient's foot.
35721|NCT03904940|Device|Ethyl vinyl acetate flat insole|Flat insole made of the same material ethyl vinyl acetate
35722|NCT03904927|Other|Radiation, Surgery or Radiofrequency ablation|Patients with 1-3 metastases located in less than 2 organs/ lymphatic drainage regions treated with combined chemotherapy and radiation, surgery or radiofrequency.
35801|NCT03904368|Procedure|Ovum pick up|34 to 36 hours after HCG triggering
35723|NCT03904927|Drug|Chemotherapy|"First-line chemotherapy (previously without chemotherapy), paclitaxel 175mg/m2, d1+cisplatin 25mg/m2, d1-3, repeated every 28 days, intravenous infusion, a total of 4 cycles.~If patients have a history of chemotherapy, use a regimen of docetaxel 75mg/m2, d1, intravenous infusion, repeated every 21 days for a total of 4 cycles. If previously use docetaxel but not irinotecan, then use a regimen of irinotecan 180mg/m2, d1, d15, repeated every 28 days for a total of 4 cycles. If both docetaxel and irinotecan have been used, the investigator could decide the chemotherapy regimen."
35724|NCT03904914|Other|TOCI|TOCI staging evaluated
35725|NCT03904901|Dietary Supplement|Probiotics|Individuals will receive individual capsules containing the daily dose of lyophilized probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus lactis, Bifidobacterium lactis and Bifidobacterium bifidum) and will be advised to remain at room temperature, ingest with water and drink before bed.
35726|NCT03904901|Dietary Supplement|Placebo|The placebo product had only the excipient, microcrystalline cellulose, and was identical to the active product in relation to color, shape, size and packaging.
35727|NCT03904888|Procedure|r-TAPP|Robot-assisted repair
35728|NCT03904888|Procedure|l-TAPP|Laporoscopic repair
35729|NCT03904888|Procedure|local anesthetics|local anesthetics will be administred
35730|NCT03904875|Other|collection of data about each acute exacerbation of COPD|COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.
35731|NCT03904862|Drug|CX 4945|CX-4945 is supplied as 200 mg capsules delivered orally as a formulated API
35732|NCT03904849|Drug|Cannabidiol|Cannabidiol oral solution
35733|NCT03904849|Drug|Placebo|Placebo oral solution
35734|NCT03904836|Drug|Tobramycin|5 milligrams per kilogram intravenous for one dose
35735|NCT03904823|Drug|famitinib po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
35736|NCT03904823|Drug|HS-10296 po|Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
35737|NCT03904810|Behavioral|Exercise intervention|HIIT groups performed 30-meter shuttle runs on a rooftop covered field whereas MICT group ran on a footpath with an overall flat and non-slippery road surface. All training sessions were preceded by a 5-minute self-pace warm-up jogging and ended with a 5-minute self-pace jogging or walking cool-down. Each session of MICT consisted of 30 minutes of continuous exercise at an intensity of 60% of heart rate reserve (HRR); [i.e., (maximal HR - resting HR) × intensity + resting HR]. For each HIIT session, the intensity was set at 90% HRR for high-intensity bouts, interspersed with active recovery at 70% HRR. All exercise sessions were supervised by qualified athletic coach or strength and conditioning coach.
35738|NCT03904797|Behavioral|Young Children's Participation and Environment Measure (YC-PEM) electronic patient-reported outcome (e-PRO)|"Participants were primary caregivers (n=149) recruited from a large, urban early intervention program. All caregivers were approached by early intervention staff the month prior to the child's annual evaluation of progress.~Each caregiver confirmed his or her eligibility online by verifying that they were at least 18 years old; could read, write, and speak English or Spanish; had internet access; and had a child between 0-3 years old who had received early intervention for at least 3 months.~Participants enrolled online and provided consent, signed a HIPAA authorization for service record release, and then proceeded to completing a demographic questionnaire and YC-PEM e-PRO to receive an online report of their responses to share with their child's EI team."
35739|NCT03904784|Behavioral|school withdrawal teenagers|The teenagers will have 4 interview with medical team alone or with his familly in order to have questionnaries, schools reports, psychological evaluation.
35740|NCT03904771|Behavioral|Nutrition counselling + peer support|Behavioral nutrition counselling and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by a nutrition therapist.
35741|NCT03904771|Behavioral|Social activation + peer support|Social activation and peer support, delivered in small groups. Includes six sessions extending over 8 weeks, with participatory activities facilitated by group leader.
35742|NCT03904758|Diagnostic Test|Pepsin in saliva test|The presence of pepsin in the saliva will be tested in both groups of patients.
35743|NCT03904745|Drug|Atosiban|6,75mg of atosiban will be administered intravenously 30 minutes before embryo transfer
35744|NCT03904732|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose acetylsalicylic acid, Aspirin (75-150 mg)
35745|NCT03904719|Drug|CM082 plus JS001|CM082: 150mg once a day orally (taken within half an hour after breakfast) JS001: An intravenous infusion of a solution having a concentration of 1-3mg/ml was prepared with 0.9% physiological saline, and administered once every three weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
35746|NCT03904706|Other|Audits only|Formalized audit teams with monthly meetings at each facility.
35747|NCT03904706|Other|Audits with community feedback|This intervention will implement the audits as described in arm 1; however, key community representatives (approximately 3-5 members) will be identified to attend monthly follow-up meetings with audit team leaders to discuss the community aspects (phase one and two-delays) that could have prevented the death, near miss or severe adverse outcome. Information regarding the cause(s) of death in the community will be collected by the LHW or CMW, who reports to the health facility on a monthly basis.
35748|NCT03904693|Drug|FDC macitentan/tadalafil|Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
35749|NCT03904693|Drug|Macitentan 10 mg|Film-coated tablet with 10 mg macitentan, to be administered orally once daily.
35750|NCT03904693|Drug|Tadalafil 40 mg|Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.
35751|NCT03904693|Drug|Placebo FDC|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
35752|NCT03904693|Drug|Placebo macitentan|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
35753|NCT03904693|Drug|Placebo tadalafil|Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
35756|NCT03904667|Other|Watson on oncology surgery decision evaluation|Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
35757|NCT03904654|Behavioral|Mindfulness-based cognitive therapy (MBCT)|MBCT is an evidence-based psychotherapy which combines mindfulness skills with cognitive therapy strategies.
35758|NCT03904641|Radiation|aPDT|For aPDT, PapacarieMblue (Fórmula e Ação) will be used. It will be left for 5 minutes in the cavity. The carious tissue will be removed and the application of the PapacarieMblue will be repeated. The tissue will then be irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ.
35759|NCT03904641|Procedure|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
35760|NCT03904628|Drug|TG02 capsules oral administration, BIW in every 28d|TG02 capsules150mg oral administration, BIW in every 28d
35761|NCT03904628|Drug|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 200mg oral administration, BIW in every 28d
35762|NCT03904628|Drug|TG02 capsules oral administration, BIW in every 28d|TG02 capsules 250mg oral administration, BIW in every 28d
35763|NCT03904615|Dietary Supplement|Whey Protein|30 g of whey protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
35764|NCT03904615|Dietary Supplement|Collagen Protein|30 g of collagen protein in flavored water, twice daily, during hospitalization and for 30 days post-discharge
35765|NCT03904615|Dietary Supplement|Placebo|30 g of maltodextrin in flavored water, twice daily, during hospitalization and for 30 days post-discharge
35766|NCT03904602|Device|Edema Wear fuzzy wale compression garment|net-like compression structure of Lycra spandex elastic yarn with longitudinal fuzzy wales (similar to corduroy fabric)
35767|NCT03904589|Diagnostic Test|Quality of Life assessment|Quality of life will be assessed by means of the Seattle Angina Questionnaire and the Patient Health Questionnaire.
35768|NCT03904576|Drug|BI 1358894|Film-coated tablet
35769|NCT03904576|Drug|Placebo|Film-coated tablet
35770|NCT03904563|Drug|Bevacizumab|Every patients are treated with 6 courses of Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for 6 courses.
35771|NCT03904563|Radiation|chest radiation|split-course chest radiation
35772|NCT03904563|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
35773|NCT03904550|Drug|Cisatracurium + Neostigmine|Maintenance neuromuscular blockade with boluses of cisatracurium to keep train-of-four (TOF) 1-2 twitches. For reversal, neostigmine with glycopyrrolate
35774|NCT03904550|Drug|Rocuronium + Sugammadex|Maintenance neuromuscular blockade with boluses of rocuronium to keep TOF 1-2 twitches. For reversal, sugammadex
35775|NCT03904537|Biological|anti-PD-1 antibody-activated TILs|Participants would received one dose anti-PD-1 antibody-activated TILs at the final cycle of XELOX regimen chemotherapy
35776|NCT03904524|Behavioral|SET-to-Meet|The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
35777|NCT03904511|Other|Souroubea-Platanus Preparation|Extracts of S. Sympetala and P. occidentalis.
35778|NCT03904511|Other|Placebo|Placebo
35779|NCT03904498|Drug|Tolcapone|Tolcapone 100 mg tablets
35780|NCT03904498|Drug|Placebo|Placebo tablets
35781|NCT03904485|Radiation|cardiac magnetic resonance(CMR) T2 mapping|T2 value before transplant，3 month and 6month after transplant
35782|NCT03904472|Behavioral|Web-based CBTI|Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
35783|NCT03904459|Other|no intervention|
35784|NCT03904446|Drug|Methylergonovine|0.2 mg of intramuscular methylergonovine at the time of cesarean section following standard IV oxytocin infusion.
35785|NCT03904446|Drug|Normal Saline (placebo)|1 ml of normal saline intramuscular at the time of cesarean section following standard IV oxytocin infusion
35786|NCT03904433|Other|Coconut oil|Coconut oil given in coffee with cream
35787|NCT03904433|Dietary Supplement|Caprylic acid|Caprylic acid given in coffee with cream
35788|NCT03904433|Other|Sunflower oil|Sunflower oil given in coffee with cream
35789|NCT03904433|Other|Glucose|Glucose dissolved in water
35790|NCT03904420|Other|Clinical Education and Treatment Model|Patients will have self directed equipment education and standardized programming approaches
35791|NCT03904420|Other|Traditional Model|Standard clinical practice and education
35792|NCT03904407|Other|Lactobacillus Probiotic Capsule|"One over-the-counter, probiotic capsule taken by mouth once daily for 4 weeks. Each capsule contains 10 billion cells comprised of:~Lactobacillus crispatus LbV 88~Lactobacillus jensenii LbV 116~Lactobacillus gasseri LbV 150N~Lactobacillus rhamnosus LbV 96"
35793|NCT03904407|Other|Matching Lactobacillus Probiotic Placebo Capsule|Lactobacillus Probiotic placebo capsules identical in appearance taken by mouth once daily for 4 weeks
35794|NCT03904394|Other|Exercise|Four sets of 7 minutes at 65% of VO2peak interspersed with 3 min of passive recovery
35795|NCT03904381|Drug|5-fluorouracil|5-fluorouracil subconjunctival injections were a first-choice therapy for bleb failure and were administered according to predetermined criteria.
35796|NCT03904381|Procedure|Transconjunctival needling|Transconjunctival needling was administered according to predetermined criteria.
35797|NCT03904381|Procedure|Transconjunctival revision|Transconjunctival revision was administered according to predetermined criteria.
35798|NCT03904368|Procedure|Open myomectomy|laparotomy then enucleation of the myoma followed by closure of the myometrial cavity
35799|NCT03904368|Drug|Gonadotropins|Gonadotropin stimulation of follicular growth
35800|NCT03904368|Drug|Human chorionic gonadotropin|HCG triggering of ovulation
35802|NCT03904368|Procedure|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
35803|NCT03904355|Drug|Gonadotropins|Gonadotropin stimulation of follicular growth
35804|NCT03904355|Drug|human chorionic gonadotropin|HCG triggering of ovulation
35805|NCT03904355|Procedure|Ovum pick up|34 to 36 hours after oocyte retrieval
35806|NCT03904355|Procedure|Embryo transfer|Transfer of 2 grade 1 embryo on day 2,3 or 5 from oocyte retrieval
35807|NCT03904342|Behavioral|Sophie CBT System|The Sophie CBT system is a tablet-based system that delivers self-paced cognitive behavioral therapy educational curriculum in the format of 6 discrete modules.
35808|NCT03904342|Behavioral|iHope CBT|Licensed therapists will use the iHope HIPAA-compliant telemedicine platform to deliver cognitive behavioral therapy to patients via telephone, videoconferencing, and/or text chat.
35809|NCT03904329|Drug|Oral Anticoagulant|Oral tablets of anti coagulations either warfare or NOACs
35810|NCT03904316|Biological|Biodesign Otologic graft|Acellular matrix derived from porcine small intestine submucosa
35811|NCT03904316|Other|Autologous temporalis fascia|An autologous graft for tympanic membrane repair
35812|NCT03904303|Drug|A 06 ad|Colonic cleansing before colonoscopy and CT colonografi
35813|NCT03904290|Other|PFO Closure|Subject will undergo percutaneous closure of PFO/ASD utilizing FDA-approved PFO/ASD closure device(s).
35814|NCT03904264|Device|Receiver in the canal (RIC) hearing aids|The RIC hearing aids fitted to subjects in arm 1 of the study will be manufactured by Widex.
35815|NCT03904251|Drug|Gemtuzumab Ozogamicin|Given IV
35816|NCT03904251|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
35817|NCT03904238|Behavioral|Cognitive-Behavior Therapy for Hypersomnia (CBT-H)|"The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia."
35818|NCT03904225|Drug|Tegafur-Gimeracil-Oteracil|oral administration for 12 months
35819|NCT03904212|Procedure|Adipose tissue injection|Injection with freshly harvested autologous adipose tissue
35820|NCT03904212|Procedure|saline|injection with saline
35821|NCT03904199|Drug|Insulin|Participants will receive long-acting insulin and/or rapid-acting insulin per protocol
35822|NCT03904186|Behavioral|QUIT|QUIT is a transdiagnostic Cognitive Behavioral Therapy-based smoking cessation protocol designed to address distress intolerance, anxiety sensitivity, and anhedonia in people living with HIV who smoke. QUIT is delivered in 9 60-minute individual weekly sessions over a 10-week period. Sessions are active, with treatment components practiced within and outside of the session. Participants will also receive the transdermal nicotine patch for 8 weeks, starting when they attempt to quit smoking during week 7 of the study.
35823|NCT03904186|Behavioral|Time-Matched Control (TM)|Participants will receive a standard smoking cessation treatment, based on the clinical practice guidelines from the U.S. Department of Health and Human Services, Treating Tobacco Use and Dependence. Treatment will be delivered in nine, 60-minute sessions over a ten-week period. The treatment is based on a treatment protocol developed and used previously by Dr. Zvolensky. Because clinical guidelines recommend that all smokers attempting to quit smoking receive pharmacotherapy, participants will also receive the transdermal nicotine patch for 8 weeks.
35824|NCT03904173|Diagnostic Test|Multi-parameter tests|Prosigna Breast Cancer Prognostic Gene Signature Assay (PAM50) risk of recurrence (ROR) analysis CE marked assay termed Prosigna™ using digital bar code technology (NanoString Technologies Inc.).
35825|NCT03904160|Behavioral|Weight management|Please see the arm descriptions.
35826|NCT03904147|Device|Tricuspid valve repair|Transcatheter TriClip placement in the tricuspid valve to repair the valve and correct regurgitation
35827|NCT03904134|Other|Donor Search Prognosis Score|Patients will be placed on a study arm after receiving a Donor Search Prognosis Score, which is based on HLA allele frequencies and race/ethnicity. This score predicts the likelihood of successfully identifying a 10/10 matched unrelated donor.Worse search prognosis is associated with racial and ethnic minority status but not with other patient and disease biology characteristics that might influence the success of hematopoietic cell transplantation (HCT). Thus, the use of donor search prognosis in this trial as a tool for biologic assignment to matched unrelated donors vs. mismatched donors provides a mechanism to minimize bias from disease characteristics.
35828|NCT03904121|Procedure|Curative operation|Postoperative morbidity, mortality, functional outcome, survival
35829|NCT03904108|Drug|Ramucirumab|platinum doublets chemotherapy plus ramucirumab, intravenously(IV)
35830|NCT03904095|Procedure|Psoas Compartment Block Group (GROUP I)|Psoas Compartment Block will perform preoperative to all patients in Group I. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
35831|NCT03904095|Procedure|Erector Spinae Plane block ( Group II)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
35832|NCT03904095|Procedure|Control Group (GROUP III)|Control group will receive no intervention. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
35833|NCT03904082|Procedure|Erector Spinae Plane block ( Group ı)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
35834|NCT03904082|Procedure|Serratus Anterior Plane block ( Group ıı)|SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
35835|NCT03904082|Procedure|Control Group (GROUPIII)|Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
35836|NCT03904069|Drug|AMG 553|AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy
35837|NCT03904056|Procedure|ISQ-RP|"Patients were treated with single-spot targeted retinal photocoagulation directed toward areas of retinal nonperfusion detected by fluorescein angiography. In this group, laser treatment was performed in two sessions (week 0 and 2), with a shot duration of 100 ms, but spots were placed 1/2 burn apart and power modulated in order to generate moderately white spots on the retina.~Retinal photocoagulation was performed with single-spot full-scatter PRP using Purepoint green diode laser (Alcon, Fortworth, Texas) with an Ocular Mainster PRP 165 lens with a dynamic field of view of 180 degrees, and a 200 micron spot size (which produces a 392 micron spot size on the retina). Intravitreal injection of 0.5 mg (0.05 ml) ranibizumab (Lucentis®) (IVR) were performed 180 minutes after the first laser session (week 0) by a single retina specialist."
35838|NCT03904056|Procedure|ETDRS-PRP group|Panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab
35839|NCT03904043|Radiation|Radiation therapy|-Monday-Friday treatment is strongly recommended
35840|NCT03904043|Drug|FOLFOX regimen|-CAPOX can be given as alternative
35841|NCT03904043|Other|Functional Assessment of Cancer Therapy-Colorectal cancer (FACT-C) questionnaire|-Baseline, completion of chemotherapy (3-8 weeks after the end of chemotherapy), and 10 to 14 months after radiotherapy
35842|NCT03904043|Procedure|Rectal biopsy samples|-Multiple biopsy samples of the rectal tumor will be taken from the patient tumor prior to treatment initiation for genomic extraction.
35843|NCT03904043|Procedure|Blood for ctDNA|-Prior to the start of treatment, Post radiation therapy labs (with standard of care (SOC) CBC/CMP prior to start of cycle 1 of chemotherapy), Day 1 of cycle 2 of chemotherapy (with SOC CBC/CMP), Completion of chemotherapy (3-8 weeks after the end of chemotherapy), 10-14 months after the start of radiotherapy
35844|NCT03904030|Other|Rehabilitation with or without Anti-Gravity Treadmill|The study will include patients with grade III-IV primary knee osteoarthritis. The investigators will take 27 patients to the both groups. The investigators will look after more specifically the anti-gravity treadmill rehabilitation and traditional rehabilitation after arthroplasty. Follow-up is one year. Functional tests will be made and questionnaires will be given to the patients before operation and after operation. After 6 to 8 weeks, 4 months and 12 months of operation questionnaires will be fil up again. After six month the investigators will send a questionnaire and there will be asked possible rehabilitation sessions, use of drugs and possible complications after knee arthroplasty.
35845|NCT03904017|Other|Oxygen|100% Oxygen air
35846|NCT03904017|Other|placebo|medical air
35847|NCT03904004|Procedure|Peroral endoscopic myotomy|Endoscopic myotomy after performing a tunnel to reach the muscular layer through a mucosal incision
35848|NCT03904004|Procedure|Neumatic dilatation|Inflation of a ballon of specific diameter in the gastro-oesophageal junction
35849|NCT03904004|Procedure|Botulinum toxin injection|Injection of botulinic toxin to inhibit the contraction of the gastro-oesophageal junction muscular layer
35850|NCT03904004|Procedure|Laparoscopic Heller Myotomy|Five or six small incisions are made in the abdominal wall and laparoscopic instruments are inserted. The myotomy is a lengthwise cut along the oesophagus, starting above the lower oesophageal sphincter (LOS) and extending down onto the stomach a little way. The oesophagus is made of several layers, and the myotomy only cuts through the outside muscle layers which are squeezing it shut, leaving the inner mucosal layer intact.
35851|NCT03903991|Other|Temperature recording|Tympanic and oesophageal temperatures will be recorded during the procedure
35852|NCT03903978|Behavioral|Cognitive Behavioral Therapy|"The training protocol consists of 6 weekly modules:~0.Welcome:Introduction module to the program, with an explanation about the tools and the way to use CORE~Psychoeducation: Explanation of psychological wellbeing and the concept of resilience~Autonomy, building my way: Enhancement of autonomy~Mindfulness and self-compassion:Training in mindfulness, savoring, and an attitude of self-compassion~Overcoming obstacles: Development of coping strategies to deal with daily difficulties in life~Connecting to others:Acknowledge the relevance of relationships and how they can be helpful in the construction of well-being~Purpose in life and personal growth:Approach the future with a positive attitude, planning goals for the future."
35853|NCT03903978|Behavioral|Healthy lifestyle|"Beginning of a lifestyle change The patient will learn to identify healthy and risky behaviors and recognize obstacles that prevent them from adopting a healthy lifestyle.~Physical activity The importance of moving on and activating behavior will be taught through regular exercise information to improve mood.~Diet This module is dedicated to teaching the importance of diet for good physical and mental health. The Mediterranean diet will be taken as an example for a balanced and balanced diet, because it does not differ from the habits of other countries.~Sleep The importance of good sleep will be addressed with information and strategies for understanding the relationship between sleep and overall health."
35854|NCT03903952|Dietary Supplement|Vitamin B12 and folate|Vitamin B12 and folate levels in blood
35855|NCT03903939|Drug|Iloprost|continuously infusion for 72 hours 1 ng/kg/min
35856|NCT03903939|Drug|Isotonic saline|continuously infusion for 72 hours equal volume to Iloprost
35857|NCT03903926|Biological|5000 volunteers (6-35 months)-EV71 vaccine|two doses EV71 vaccines will be administrated on day 0, 30 respectively
35858|NCT03903913|Drug|S-1226|The drug product S-1226 has two components delivered by inhalation. It is a mixture of perfluorooctylbromide (PFOB) nebulized with a medical gas mixture containing CO2. The PFOB component remains the same but the medical gas component contains 4%, 8% or 12% CO2.
35859|NCT03903900|Behavioral|Lifestyle-oriented Occupational Therapy added to current treatment of chronic non-malignant pain|The participants are recruited from the outpatient cohort admitted at The Multidisciplinary Pain Center (MPC) at Naestved Hospital (Zealand Region, Denmark). The participants receive both, the current treatment based on Cognitive Behavioural Therapy (CBT) and delivered by physicians, nurses, physical therapists and a social worker as usual care, and a lifestyle-oriented Occupational Therapy intervention. The Occupational Therapy intervention targets meaningful daily occupations, physical activity, and eating habits and routines. The intervention is delivered by graduated occupational therapists once á week during the 15 weeks after the initial 5-weeks compulsory psychoeducation course at the MPC. The intervention contains in-person contacts with OTs every other week (e.g. two 1-hour individual sessions at the hospital and/ or at-home and five 2-hours group sessions) and seven phone consultations in the opposite weeks.
65751|NCT03670667|Other|Non-Interventional|Non-Interventional
35860|NCT03903887|Biological|anti-PD1 antibody-activated TILs|Participants would receive one dose of anti-PD1 antibody-activated TILs at the final cycle of docetaxel and cisplatin (DP) regimen chemotherapy.
35861|NCT03903874|Behavioral|Deep south Interactive voice response system supported Active Lifestyle (DIAL)|12 months of automated telephone physical activity counseling with community health worker support
35862|NCT03903861|Other|Glucose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose-alone over 4 hours of recovery before a subsequent bout of exercise.
35863|NCT03903861|Other|Galactose alone|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of galactose-alone over 4 hours of recovery before a subsequent bout of exercise.
35864|NCT03903861|Other|Glucose and galactose|Young men or women will complete a glycogen depleting bout of exercise followed by the provision of glucose and galactose over 4 hours of recovery before a subsequent bout of exercise.
35865|NCT03903848|Other|Exercise|Single session of treadmill walking and resistance exercise
35866|NCT03903835|Drug|Enzalutamide Oral Capsule [Xtandi]|Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
35867|NCT03903835|Drug|Abiraterone Oral Tablet [Zytiga]|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
35868|NCT03903835|Drug|Carboplatin|Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x [GFR ml/min + 25].
35869|NCT03903835|Drug|Cabazitaxel 60 mg Solution for Injection|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
35870|NCT03903835|Drug|Docetaxel Injectable Solution|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
35871|NCT03903835|Drug|Radium Chloride Ra-223|Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
35874|NCT03903809|Drug|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
35875|NCT03903809|Drug|ESPO|Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
35876|NCT03903796|Drug|HS-10234|Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily
35877|NCT03903796|Drug|TDF|Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily
35878|NCT03903783|Other|Cefotaxime|"Patients with C3G antibiotic therapy will receive cefotaxime. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
35879|NCT03903783|Other|Ceftriaxone|"Patients with C3G antibiotic therapy will receive ceftriaxone. On the day of inclusion (T0, + 24 hours), a stool culture is performed on the first stool issued after the start of antibiotic therapy to detect BMR carriage and to evaluate the initial flora and fecal abundance initial relative in culturable multiresistant bacteria. In the absence of stool emission by the patient, an eswab rectal swab will be performed.~72 hours (± 24 hours, T1) after the start of antibiotic therapy, a stool sample will be taken and at the end of antibiotic therapy (+ 24 hours, T2) or during the oral relay to evaluate the modification of the initial flora and the relative fecal abundance of culturable multiresistant bacteria. In the case of normal transit (daily bowel movement), the bowel movement 72 hours after the start of antibiotic therapy will be analyzed. In the absence of stool emission by the patient, an eswab rectal swab will be performed."
35880|NCT03903770|Device|Upper extremity rehabilitation|Participants receive the SUPER intervention 3 times per week for 1 hr, during 4 weeks. For participants with a low recovery potential for hand function, the SUPER interventions consists in robot-assisted reaching movements and unilateral and bilateral VR activities. The robot-assisted activity consists of a reaching task to six targets placed at maximal reach distance. For the VR activity, we use a reach and grasp VR activity based on a shopping task. Participants with good potential for hand recovery also receive 30 min of electromyography-triggered muscle stimulation, combined with the VR activity. The muscle stimulation is triggered when the participant attempts to grasp a virtual object and helps with hand opening movements.
35881|NCT03903757|Other|DNA methylome and total RNA sequencing|Epigenomics tools combined with bioinformatic analysis to correlate putative useful clinical biomarkers with clinical features
35882|NCT03903744|Procedure|Cardioneuroablation|The electroanatomical map of the right (RA) and left (LA) atrium will be created and anatomically-based ablation of GP will be performed. Ablation in the RA is started from the supero-posterior area (superior right atrial GP), to the middle-posterior area (posterior right atrial GP). In the LA, ablation is started at the site of the anterior right GP and is continued downwards along the anterior part of a common vestibulum of the right pulmonary veins (PV), opposite to the right-sided ablation lesions. Finally, area of right inferior GP, close to the RIPV is ablated under intracardiac echocardiography control. Using this technique, GP's located close to the left PV are not ablated. We use a pure anatomic approach without identification of GP.
35883|NCT03903731|Device|Total knee arthroplasty with Journey II BCS Total Knee System|Journey II BCS Total Knee System
35884|NCT03903718|Drug|Oseltamivir|75 mg capsules orally twice a day from Day 2 to Day 7
35885|NCT03903718|Biological|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody administered as a single IV infusion at either dose 1 or dose 2 on Day 2.
35886|NCT03903718|Drug|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 2.
35887|NCT03903705|Drug|Fruquintinib in Combination with Sintilimab|"Dose Escalation Stage:~Cohort A: Fruquintinib 3 mg QD, oral dosing, 3 weeks on/1 weeks off+Sintilimab 200mg Q4W, intravenous dosing.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 3 weeks on/1 weeks off+Sintilimab 200mg Q4W, intravenous dosing Dose de-escalation level: Fruquintinib 2 mg QD, oral dosing, 3 weeks on/1 weeks off+Sintilimab 200mg Q4W, intravenous dosing Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.~Dose Expand Stage:~Fruquintinib + Sintilimab Patients will be treated at RP2D until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria."
35888|NCT03903692|Device|Marine polysaccharide dressing|The MPS-Ag dressing used in this study has a unique gelling action which helps to remove dead, damaged, and infected tissues from the wound by trapping and removing them later at dressing changes. It is designed to provide intimate contact with the wound for gentle healing. It also contains ionic silver.
35889|NCT03903692|Device|Carboxymethylcellulose dressing|The CMC-Ag dressing used in this study incorporates two technologies to help eliminate the key barriers to healing that are exudate, infection, and bioburden. It can be used on chronic and acute wounds that are infected or at risk of infection with varying exudate levels.
35890|NCT03903679|Device|Laryngeal mask airway|Patients will be maintained with laryngeal mask airway during the septal surgery.
35891|NCT03903679|Device|Endotracheal tube|Patients will be maintained with endotracheal tube during the septal surgery.
35892|NCT03903666|Other|Nocturnal gaz exchanges measurement|Nocturnal gaz exchanges at patient's home BRIEF neuropsychological questionnaire VINELAND-II neuropsychological questionnaire Clinical OSA assessment Dysautonomia assessment
35893|NCT03903653|Drug|Botulinum toxin type A|"Use of chemodenervation (botulinum toxin A) for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
35894|NCT03903653|Device|Serial Casting|"Using Serial Casting in conjunction with Botox injection for treatment of lower extremity spasticity in ABI inpatients with regards to ankle range of motion.~(a total of 350-400 units of botulinum toxin A per treated limb)"
35895|NCT03903640|Device|Optune|-Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS.
35896|NCT03903640|Biological|Nivolumab|-Standard of care
35897|NCT03903640|Biological|Ipilimumab|-Standard of care
35898|NCT03903627|Other|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
35899|NCT03903614|Behavioral|SML|SML consists of supervised handwriting practice, fitness exercises, and fine motor speed drills that preferentially belabor a participant's right eye, ear, hand and leg during therapy.
35900|NCT03903614|Behavioral|CON|CON consists of supervised handwriting practice, fitness exercises, and fine motor speed drills on the participant's dominant hand.
35901|NCT03903601|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) to diagnose ischemic changes in the brain.
35902|NCT03903601|Diagnostic Test|Blood samples collection|Trimethylamine N-oxide (TMAO) concentration, oxidative stress markers and endothelial dysfunction markers will be determined in blood samples.
35903|NCT03903601|Diagnostic Test|Neuropsychological tests|Cognitive functions assessment
35904|NCT03903588|Device|Optical Coherence Tomography|Imaging of the Retina
35905|NCT03903575|Procedure|En masse anterior teeth retraction|After extraction of the four premolars the posterior teeth will be tied-together and the six anterior teeth will be retracted by sliding mechanics.
35906|NCT03903575|Procedure|Two-Step Retraction|After extraction of the four premolars the posterior teeth will be tied-together and the canines will be retracted by sliding mechanics. After the distalization of the canines they will be tied to the posterior teeth and the incisors will be retracted by sliding mechanics.
35907|NCT03903562|Biological|V503|0.5 mL 9vHPV VLP Vaccine
35908|NCT03903549|Drug|[18F]P17-059|Injection of < 10 mCi [18F]P17-059 followed by PET/CT scanning
35909|NCT03903536|Procedure|Thrombectomy|A small procedure where surgeons make a cut in the hemorrhoid and drain the blood.
35910|NCT03903536|Procedure|Hemorrhoidectomy|A surgery to remove the hemorrhoid, including the blood vessels and clot.
35911|NCT03903523|Device|Lumen apposing metal stent (LAMS)|Stent positioning
35912|NCT03903510|Device|Virtual Reality (VR)|Participants in the experimental group will receive an AppliedVR virtual reality headset during their cast removal.
35913|NCT03903497|Device|NBI|optical assessment of diminutive colorectal polyps by NBI mode using the WASP assessment
35914|NCT03903484|Other|Deprescribing toolbox and intervention|Pharmacist-led deprescribing plan with the patient which will include the patient's deprescribing goals. The intervention advocates for deprescribing according to recognized algorithms and guidelines which will be included in a resource toolbox/website.
35915|NCT03903471|Device|22G-ProCore Endobronchial Ultrasound Needle|EchoTip Procore® Endobronchial HD Ultrasound Biopsy Needle, COOK
35916|NCT03903471|Device|22G-Standard Endobronchial Ultrasound Needle|EchoTip® Ultra Endobronchial High Definition Ultrasound Needle, COOK
35917|NCT03903458|Drug|Tinostamustine|First-in-human administration of the combination of Tinostamustine and Nivolumab.
35977|NCT03902899|Other|Educational intervention (oral presentation)|A brief oral presentation (30-45 minutes) which focused on making endoscopists aware of the significance and characteristics of serrated polyps.
35978|NCT03902886|Diagnostic Test|gait analysis|gait analysis using an optoelectronic system and a surface EMG
35979|NCT03902873|Other|Real-time audiovisual feedback|During the chest compressions, doctors receive audiovisual feedback on the depth and speed of the appropriate chest compressions.
67047|NCT03659994|Dietary Supplement|Placebo|Placebo
35918|NCT03903445|Behavioral|Masayang Pamilya Para Sa Batang Pilipino Program (MaPa Kids)|"MaPa Kids is an 8-session parenting program delivered weekly to groups of parents (N=15 per group).~The program includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behavior; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behavior, and consequences for noncompliance, rule-breaking, and aggressive behavior; 6) problem solving with children; and 7) mindfulness based stress reduction."
35919|NCT03903445|Behavioral|Masayang Pamilya Para Sa Tinedyer Pilipino Program (MaPa Teens)|"MaPa Teens is a 9-session parenting program delivered to groups of parents and children aged 10-17 (N=15 dyads per group).~The program includes the following content: 1) one-on-one time with parents and teens, 2) positive reinforcement of positive behavior, 3) managing anger and stress, 4) establishing rules and routines, 5) family budgeting, 6) accepting responsibility for actions, 7) resolving family conflicts, 8) keeping safe in the community and resolving conflicts, and 9) reflection and moving on."
35920|NCT03903432|Other|MRI|candidates for ESS will be referred to conventional CT scans of the sinuses. If surgery is to be performed, the patients will sign an informed consent and be referred for a sinus MRI.
35921|NCT03903419|Diagnostic Test|Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.|"This study is a non-randomized, prospective, feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy for glioblastoma.~Patients with clinical symptoms of relapse within 3 to 9 months of follow-up after the end of radiotherapy, and/or with doubtful MRI between radiation-related complications and recurrence, will be referred for both 68Ga-PSMA and 18F-FDOPA PET-CT."
35922|NCT03903406|Drug|ixazomib in combination with lenalidomide and dexamethasone|Patients with RRMM who have received at least one prior therapy will receive Ixazomib in combination with lenalidomide and dexamethasone within the routine clinical practice in accordance with prescription. Duration of therapy - until disease progression or unacceptable toxicity.
35923|NCT03903380|Other|Manual Therapy and Usual care exercise protocol for neck pain|Manual Therapy protocol between four to eight sessions and exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
35924|NCT03903380|Other|Manual Therapy and Augmented reality exercise protocol|Manual Therapy protocol between four to eight sessions and Augmented reality exercise protocol will be progressively added to the intervention (from the fouth session of MT approximately).
35925|NCT03903367|Drug|Fentanyl Citrate|standard GA and receive fentanyl infusion 2 mcg/kg/h after tracheal intubation and stopped at the end of the operation ,When HR or MBP increased ≥20% from base line readings, incremental dose of fentanyl will be given (2mcg /kg).
35926|NCT03903354|Other|Incidence of infections within 7 days postoperatively|Measure blood glucose concentration intraoperatively and evaluate incidence of infections 7 days after surgery
35927|NCT03903341|Other|fMRI|bold signal in visual pathway
35928|NCT03903328|Other|Sarcopenia assessment|Sarcopenia assessment by measurement of Skeletal Muscle mass index, hand grip strength and usual gait speed for 5 meter distance, as per the guidelines of Asia Working group for Sarcopenia study, was carried out.
35929|NCT03903315|Other|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment|Comparison between patients with Patients with central malignant airway obstructions undergoing medical treatment alone versus medical and endoscopic treatment with reference to mortality and complications.
35930|NCT03903302|Drug|CS1-Sodium Valproate|Single and multiple dose evaluation of CS1
35931|NCT03903289|Procedure|Automated red cell exchange|Erythrocytapheresis is an automated red cell exchange procedure that removes blood that contains HbS from the patient while simultaneously replacing that same volume with packed red cells free of HbS.
35932|NCT03903289|Procedure|Manual red cell exchange|Active Comparator: Manual red cell exchange
35933|NCT03903289|Procedure|Simple red cell transfusion|Active Comparator: Simple red cell transfusion
35934|NCT03903276|Other|rehabilitation|Tens
35935|NCT03903263|Diagnostic Test|survey on sleep disorders|self-administered patient questionnaire regarding the different aspects of sleep disorders in patients with dermatologic diseases
35936|NCT03903250|Dietary Supplement|A-GPC|Taken orally in liquid form
35937|NCT03903250|Dietary Supplement|Sugar|Taken orally in liquid form
35938|NCT03903237|Other|retrospective chart review|retrospective report review of HZ patients treated between 2005 and 2018 in the Department of Dermatology at the University Hospital Basel
35939|NCT03903224|Procedure|Combined Modified Pectoralis and Transversus Plane Blocks|"Modified pectoralis nerve block (Pecs II) aims to block at least the pectoral nerves, the intercostobrachial, intercostals III-IV-V-VI. This will cover dermatomes T2, T3 and T4. The probe is positioned under the lateral third of the clavicle .After locating the subclavian muscle, the axillary artery and the axillary vein we move the probe distally towards the axilla, until the pectoralis minor is identified. We start counting the ribs , from r1 under the axillary artery, we move distally and laterally until the lateral border of pectoralis minor is reached. The serratus anterior muscle which covers r2, r3, r4 is the point of entrance into the axilla.~Blocking of multiple anterior branches of intercostal nerves (Th2-6) using a transversus thoracic muscle plane (TTP) block is used as an additive to pecs II to cover the internal mammary region"
35940|NCT03903224|Procedure|Erector Spinae block|The patient is placed in a sitting position and The T5 spinous process is located by palpating and counting down from the C7 spinous process. Under complete aseptic conditions a linear ultrasound probe is then placed in a transverse orientation at the level of the T5 transverse process. The tip of the transverse process is centred on the ultrasound screen and the probe is then rotated into a longitudinal orientation to produce a parasagittal view. From T1 to T5 the erector spinae, rhomboid major and trapezius muscles are visible posterior and superficial to the transverse processes.
35941|NCT03903211|Drug|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
35942|NCT03903185|Drug|Ledipasvir / Sofosbuvir Oral Product|45 mg of ledipasvir and 200 mg of sofosbuvir orally, once daily with food
35943|NCT03903172|Device|Abdominal binder|Abdominal binder
35944|NCT03903159|Behavioral|Positive Peer Journaling (PPJ)|"PPJ is a journaling practice to support addiction recovery. PPJ encourages past 24 hour review and upcoming 24 hour planning to improve quality of life in recovery and reduce relapse. PPJ uses standard lined journals with column headings under which individuals make bullet-pointed lists. On the left hand page, past 24 hours is recalled, itemizing good and bad things that happened and things for which one is grateful. Wishes for others are also expressed on this page. On the right hand page, values-based activities for the upcoming 24 hours are planned via headings representing valued life domains such as recovery, work/school, spirituality, home and household, and health."
35945|NCT03903146|Behavioral|Early Childhood Obesity Risk-Reduction Program in Hispanics|"Sessions Prenatal (40 min): Includes a colorful binder with information about breastfeeding. Set her goals and action plan for breastfeeding. Past experiences with breastfeeding. Benefits of adopting a healthy behavior, describe and discuss infant feeding and qualms about mixed feeding, barriers to EBF and self-efficacy.~Prenatal Calls (10 min.): Discuss strategies available to accomplish mother's breastfeeding goals. Answer questions. Follow-up call until delivery.~Hospital visit (30 min.): PC visit mother at the hospital stay to support the participant in her effort to breastfeeding.~Postpartum home-visit (40 min.) IBCLC performs a home visit to assess infant feeding pattern, breastfeeding techniques with hands-on assistance if needed. Provide supplemental breastfeeding devices as needed. Answer all questions.~Postpartum calls (10 min.): PC/IBCLC ask about problems/concerns and answer questions. Repeat phone calls as needed (at least 1 a month)."
35946|NCT03903133|Drug|Vitamin E|vitamin E supplementation for three months (400-600 mg/day) (400 mg/day in those weighed less than 20 kg and 600 mg/day in those weighed at least 20 kg)
35947|NCT03903120|Behavioral|ASSIST|"Integral stimulation based treatment (watch me, listen to me, say what I say) for CAS that is based on principles of motor learning and neuroplasticity and includes a systematic approach to adaptive practice. Treatment includes a focus on prosody, use of visual, tactile, auditory cues, slowing speech rate, and large amounts of practice."
35948|NCT03903107|Procedure|Conventional fluoroscopy guided HBP|conventional standard approach his bundle pacing using fluoroscopy
35949|NCT03903107|Procedure|Electroanatomic Mapping (fluoroless) guided HBP|his bundle pacing using electroanatomic mapping system with no or minimal fluoroscopy
35950|NCT03903094|Other|Non-Interventional|Overview of anticholinergic burden, rather than to evaluate specific drugs
35951|NCT03903081|Drug|HEC110114 tablet|administered orally once daily
35952|NCT03903081|Drug|Placebo Oral Tablet|Placebo will be administered orally at a dose and frequency matched to HEC110114
35953|NCT03903068|Device|NEXALIN ADI AC stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. The three electrodes are placed in this way to enhance the performance of the Nexalin ADI device. When the device is activated, there will be a weak current passing through the forehead electrode and each mastoid electrode. The current intensity of Nexalin ADI treatment defaults to 15.00 mA and the duration defaults to 40 minutes. Both are preset to default parameters and cannot be changed.
35954|NCT03903068|Device|Pseudo-stimulator|When the patient is ready for the treatment, place an electrode on the patient's forehead and place an electrode in each of the mastoid areas behind each ear. When the device is started, no current flows through the electrodes, but the instrument's operating procedures, parameter displays, and prompts are the same as for a real instrument.
35955|NCT03903055|Diagnostic Test|MDS group|patients diagnosed as MDS with high risk，aged 18-80，men/wemen
35956|NCT03903029|Drug|Low-dose (10mg) rosuvastatin|Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
35957|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
35958|NCT03903016|Drug|Insulin Lispro SAR342434|Pharmaceutical form:solution for injection Route of administration: subcutaneous
35959|NCT03903003|Device|high flow nasal oxygen device (POİNT)|With POINT device (peri-operative insufflatory nasal therapy); patients are heated at higher flow and applied to humidified oxygen.
35960|NCT03903003|Device|Face mask|In order to protect the mother from hypoxia, preoxygenation is performed with face mask before induction of anesthesia.
35961|NCT03902990|Other|Dual task|The patients in the dual task group received cognitive tasks during treadmill training sessions.
35962|NCT03902990|Other|Treadmill Training|Standard treadmill training
35963|NCT03902990|Other|Standard exercise programme|Standard exercise programme for Parkinson Disease
35964|NCT03902977|Procedure|quilting|After mastectomies or ALND dissections using standard technique for wound closure multiple sutures (monocryl 3.0) every 3 to 4 cm in the site of the mastectomy (1 or 2 rows) or in the dissected axilla.Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
35965|NCT03902977|Procedure|conventional suture|After mastectomies or ALND dissections standard technique for wound closure. Placement of one drain into the breast and axilla or in the axillary cavity by a separate stab incision
35966|NCT03902951|Drug|Abiraterone Acetate|Given PO
35967|NCT03902951|Drug|Apalutamide|Given PO
35968|NCT03902951|Drug|Leuprolide Acetate|Given SC
35969|NCT03902951|Other|Quality-of-Life Assessment|Ancillary studies
35970|NCT03902951|Other|Questionnaire Administration|Ancillary studies
35971|NCT03902951|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
35972|NCT03902938|Biological|Biodesign Otologic graft|Patient's mastoid cavity will be covered with porcine small intestine submucosa, Biodesign.
35973|NCT03902938|Other|Autograft temporalis fascia|Patient's mastoid cavity will be covered with covered with autograft.
35974|NCT03902925|Procedure|Topical lidocaine 2% jelly plus sub-tenon ropivacaine 10% injection|Lidocaine 2% jelly applied to conjunctival fornices for 5 minutes then injection of 2-4 ml of ropivacaine 10% in the sub-tenon space with a blunt cannula through a temporal inferior incision
35975|NCT03902925|Procedure|Peribulbar injection|Peribulbar injection of 4-6 ml of ropivacaine 10%
35976|NCT03902912|Drug|Prednisolone|prednisolone oral 10 mg/day from day one of the subsequent menstrual cycle to day LH 7 of that cycle. Then, the participants will be given a tailing off dose of 5 mg/day for 3 days followed by 2 mg/day for 3 days and then 1 mg/day for 3 days.
36420|NCT03899402|Drug|Insulin|Standard of care insulin for pump or injection and serves as a control
35980|NCT03902847|Behavioral|motor imagery|All subjects had to imagine that he/she was performing each exercise during 1 set of 12 repetitions prior to the real execution of this. During the second phase (the second and third week), subjects had to complete the set both imagining, with visual mental motor imagery, and actively performing the exercises.
35981|NCT03902847|Behavioral|Action observation|A video was shown in third-person perspective. All subjects watched one person performing each exercise during 1 set of 12 repetitions. During the second phase (the second and third week), subjects had to perform actively the exercises while they watched the video.
35982|NCT03902847|Behavioral|Motor Control Exercises|The subjects were asked to perform 3 sets, of 10-12 repetitions each six exercise, with a total duration of approximately 30-35 minutes. The exercises program had to do it once a day, 6 days a week, for 3 weeks.
35983|NCT03902834|Other|Fitbit|Use the wearable technology (Fitbit) and proven behavioural change techniques to precondition patients prior to lung cancer surgery
35984|NCT03902821|Other|XR-NTX and Certified Recovery Mentor|All consented participants will be offered an injection of extended-release naltrexone 3-7 days prior to release from prison. All consented participants will also be introduced to Certified Recovery Mentors one month prior to release.
35985|NCT03902795|Diagnostic Test|Microperimetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
35986|NCT03902795|Diagnostic Test|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
35987|NCT03902782|Procedure|ESP block|"ESP with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham intercostal block with 20 ml Normal Saline"
35988|NCT03902782|Procedure|Intercostal block|"Intercostal block with 20 ml of Bupivacaine 0.25%, Epinephrine 5mcg/ml and Dexamethasone 10mg.~Sham ESP with 20 ml Normal Saline"
35989|NCT03902782|Procedure|Sham ESP block|As described earlier
35990|NCT03902782|Procedure|Sham Intercostal block|As described earlier
35991|NCT03902782|Drug|Bupivacaine-epinephrine|As described earlier
35992|NCT03902782|Drug|Dexamethasone injection|As described earlier
35993|NCT03902782|Drug|Normal saline|As described earlier
35994|NCT03902769|Procedure|Prescribing conventional chemotherapy while with holding allo-SCT|Prescribing conventional chemotherapy (chemotherapy consolidations or autologous SCT) while with holding allo-SCT
35995|NCT03902756|Other|Endotracheal cuff inflation|Endotracheal cuff inflation is putting the air in to the endotracheal tube cuff to make the proper sealing.
35996|NCT03902743|Other|Anticipatory Care Plan group|The Anticipatory Care Plan will be delivered by a trained nurse. At the initial visit, the nurse will conduct a hollistic assessment using the EasyCare Assessment Tool. Following this visit, the nurse will draft a strucutred summary report of the home visit to include patient goals, preferences for care, identified problems and action list. The nurse will then consult with a pharmacist to identify any potential inappropriate prescribing. The nurse will then meet with the participants GP and review and provide feedback. The nurse will then re visit participants and discuss the report and agree a support plan and actions for follow up.
35997|NCT03902730|Other|Traditional Back Squat|Participants will complete traditional back squat in this four treatment crossover design.
35998|NCT03902730|Other|Barefoot Back Squat|Participants will complete barefoot back squat in this four treatment crossover design.
35999|NCT03902730|Other|Box Squat|Participants will complete box squat in this four treatment crossover design.
36000|NCT03902730|Other|Traditional Back Squat with Chains|Participants will complete traditional back squat with chains in this four treatment crossover design.
36001|NCT03902717|Procedure|Minimally invasive cardiac surgery|Patients will undergo minimally invasive cardiac surgery
36002|NCT03902704|Device|Cleverscope|the device is used in patients without difficult airways predictors
36003|NCT03902704|Device|Laryngoscope / Videolaryngoscope C-MAC® Storz|the device is used in patients with difficult airways predictors
36004|NCT03902691|Drug|Pegol-Sihematide|Participants received Pegol-Sihematide by subcutaneous injection once every 4 weeks ; the dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
36005|NCT03902691|Drug|ESPO|Participants received ESPO by subcutaneous injection or subcutaneous injection weekly. The dose was adjusted throughout the study to maintain a hemoglobin target range of 10.0-12.0 g/dL.
36006|NCT03902678|Procedure|EUS guided fine needle aspiration of portal vein thrombus|endoscopic ultrasound guided fine needle aspiration of portal vein thrombus which did not fulfill criteria of malignancy by imaging technique
36007|NCT03902665|Drug|Up-front allogeneic hematopoietic stem cell transplantation (HSCT)|"Patients classified as fit/unfit are included in the HSCT program. There are two early approaches allowed. A) Patients will be left untreated until HSCT B) Patients will receive 1 short course of chemotherapy before HSCT (Ara-C and anthracycline).~Selection of strategy A or B, will be patient based on disease characteristics and dynamics or presence of high tumor load.~Conditioning for haplo-HSCT should be started as soon as possible, within day 45 after initial diagnosis. This is to avoid delayed transplantation. Two dosing levels of the Thiotepa-Busulfan-Fludarabine (TBF) based protocol are allowed based on the clinical condition of the patient: fit patients below 70 will receive the TBF with 2 days of Busulfan, whereas patients with poorer clinical condition or above the age of 70 will receive a dose-reduced TBF, in which Busulfan may be reduced to 1 day only."
36008|NCT03902652|Procedure|Intervention (21% oxygen during CC+SI)|"Infants randomized into the 21% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 21% oxygen."
36145|NCT03901586|Other|Satisfaction assessment|Patient will be asked to assess their satisfaction concerning the Richter procedure and its long term effect
67164|NCT03659136|Drug|Exemestane|Tablet
36009|NCT03902652|Procedure|Intervention (100% oxygen during CC+SI)|"Infants randomized into the 100% oxygen CC+SI group will receive a SI with a PIP of 25-30 cmH2O while receiving chest compression.~The SI will be delivered over a period of 20 seconds. This will be followed by PEEP of 5-8 cm water fro 1sec. The use of 20sec SI will be repeated 3 times, which results to 60sec of chest compression. At that time the clinical team will perform an assessment of the newborn's heart rate.~If heart rate is >60/min continue with standard care as per local hospital policy (standard hospital practice guideline). If heart rate remains <60/min continue with CC+SI for another 20sec at which time a further assessment should be performed. If heart rate remains <60/min continue with CC+SI.~During CC+SI the clinical team will only use 100% oxygen."
36010|NCT03902626|Other|Physiotherapy students|
36011|NCT03902626|Other|Medical students|
36012|NCT03902613|Drug|Lurasidone|Participant will have an open label trial of lurasidone for eight weeks.
36013|NCT03902600|Radiation|Moderately Hypofractionated RT|Patients will be treated with moderately hypofractionated radiation treatment
36014|NCT03902587|Device|Samsung's E-cervix technology|While patients are having their routine cervical ultrasound assessments which requires a 5 minute time period, we will use the built-in software to obtain additional E-cervix measurements to evaluate the consistency of the cervical os. This will be done within the standard 5 minute period which is typically done to observe for dynamic changes. The measurements will be obtained with the same sonogram machine, using updated software.
36015|NCT03902574|Drug|Brexpiprazole ODT 2mg with water|Brexpiprazole ODT 2mg is administered with water.
36016|NCT03902574|Drug|Brexpiprazole ODT 2mg without water|Brexpiprazole ODT 2mg is administered without water.
36017|NCT03902574|Drug|Brexpiprazole conventional tablet 2mg|Brexpiprazole conventional tablet 2mg is administered with water.
36018|NCT03902561|Device|one time colonoscopy in inpatients|All the inpatients with indication of colonoscopy will be prepared with 4 liters polyethylene glycol bowel cleansing prior to colonoscopy. Colonoscopy will be performed as regular practice under conscious sedation.
36019|NCT03902548|Drug|[18F]P16-129|Injection of < 10 mCi [18F]P16-129 followed by PET/CT scanning
36020|NCT03902535|Other|Comprehensive Geriatric Assessment|Complete comprehensive geriatric assessment
36021|NCT03902535|Other|Quality-of-Life Assessment|Complete quality of life assessment
36022|NCT03902535|Other|Questionnaire Administration|Complete questionnaires
36023|NCT03902522|Drug|PRO 140|2 injections of PRO 140 (2 X 2 mL/inj.)
36024|NCT03902509|Drug|Pirfenidone|pirfenidone capsule made in China
36025|NCT03902509|Drug|basic treatment|glucocorticoid and expectant treatment etc.
36026|NCT03902496|Other|HIT-6 Questionnaire|Headache Impact Test
36027|NCT03902496|Device|Avulux Spectacles|Avulux™ Optical Filter in the Form of Spectacle Lenses
36028|NCT03902496|Device|Sham Spectacles|Sham
36029|NCT03902483|Device|renal doppler ultrasound|renal doppler ultrasound measuring renal resistive index
36030|NCT03902470|Procedure|Thoracic epidural anaesthesia video assisted thoracoscopic surgery|Patients in (TEA) group will pre-medicated using midazolam 3—4 mg (IV)and fentanyl 50 mcg (IV). Then An epidural catheter will be inserted between T3—T4 and T4—T5 . A test dose (5 ml) of 2% lidocaine will be given, followed by 15-20 ml of bupivacain 0.5%.
36031|NCT03902457|Procedure|Maxillary sinus augmentation|Maxillary sinus augmentation procedures have become increasingly popular procedures before placement of dental implants in posterior maxillae that have suffered severe bone loss due to sinus pneumatization, alveolar bone atrophy, or trauma.
36032|NCT03902444|Device|Credo® Stent, NeuroSpeed® PTA balloon catheter|a self-expanding stent is used together with a PTA balloon catheter
36033|NCT03902431|Behavioral|ABCS training|Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
36034|NCT03902418|Drug|emtricitabine/tenofovir|Women recruited at ante-natal clinics, counseled about PrEP, and provided medication and follow up if desired
36035|NCT03902405|Behavioral|Active CEASAR Intervention|Healthy and stimulant-use related pictures will be presented on a computer screen. Using a joystick, participants will be trained to pull in pictures that are presented in portrait orientation, and push those presented horizontally. In the active experimental condition, pushed pictures will exclusively be stimulant-related pictures.
36036|NCT03902405|Behavioral|Placebo CEASAR|In the control condition, stimulant cues and healthy cues will be randomized and stimulant use-related pictures will be equally divided into push and pull conditions.
36037|NCT03902392|Dietary Supplement|NaturOx Group (A)|Comparison between dietary supplement and placebo
36038|NCT03902392|Other|Placebo Group (B)|Comparison between dietary supplement and placebo
36039|NCT03902379|Other|Internet-Based Intervention|Receive CCI intervention
36040|NCT03902379|Other|Quality-of-Life Assessment|Ancillary studies
36041|NCT03902379|Other|Questionnaire Administration|Ancillary studies
36042|NCT03902379|Other|Survey Administration|Ancillary studies
36043|NCT03902366|Diagnostic Test|Neuropsychological assessment|Clinical research staff will complete a standardized neuropsychiatric study visit protocol with eligible participants who provide informed consent. The protocol will be conducted twice for each participant (baseline and 6 months later).
36044|NCT03902366|Behavioral|Neuroimaging|Subjects, well characterized with respect to their substance use, will be evaluated with fMRI tasks, rsMRI, high resolution anatomical MRI, standard DWI and high angular resolution diffusion imaging (HARDI) at baseline and 6 months later.
36045|NCT03902353|Other|Screening of adult without diagnosis of PH carrying an heterozygous EIF2AK4 mutation.|will be performed : a clinical evaluation (dyspnea assessed by New York Heart Association functional class (I-IV), signs of right heart failure), a 6min walk test, a Computerized Tomography scan of the chest, an electrocardiogram, an echocardiography (measurement of the velocity of tricuspid regurgitation, measurement of Tricuspid Annular Plane Systolic Excursion (TAPSE) and Tei index, pericardial effusion, dilatation and hypertrophy of the right ventricle), an abdomina ulstrasound, a stress Test (ventilation oxygen peak and ventilation oxygen specific, minute ventilation, dead-space ventilation / dead space, ventilatory reserve, alveolar-arterial gradient, pulse oxygen, PaO2), a lung function tests and measurement of Diffusing capacity or transfer factor of the Lung for Carbon mOnoxide (DLCO) and Nitric Oxide (DLNO), and a blood sample.
36046|NCT03902340|Device|ActiTENS|ActiTENS is a rechargeable box, weighing 64g attached by Velcro to an adhesive support, which can be positioned on the skin at any position chosen by the patient. The patient will use the programme (P4) prescribed by his doctor and will regulate the intensity of stimulation using an application downloaded to his smartphone which will communicate with the box via Bluetooth.
36047|NCT03902340|Drug|Level 2 Analgesic Treatments|"There are 4 level 2 oral analgesic treatments indicated for chronic nociceptive pain of moderate to severe intensity (between 4 and 7 on a simple numerical scale of 11 points) (12):~Tramadol immediate release formulation (IR, one intake every 6 hours) or prolonged release formulation (PR, one intake every 12 hours); maximum posology 400mg/24h.~Dihydrocodeine: 60mg every 12 hours; maximum posology 120mg/24h.~Combination of paracetamol and codeine in a fixed combination every 6 hours; maximum posology of codeine: 300mg/24h.~Combination of paracetamol and tramadol in a fixed combination; maximum posology of tramadol: 8 tablets/24h ie 300mg/24h."
36048|NCT03902327|Dietary Supplement|NAC group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + N - acetylocysteine supplementation (1600 mg /d, 400 mg x 4 times a day)(30 people).
36049|NCT03902327|Dietary Supplement|Control group|Nutrition intervention focused on the treatment of carbohydrate metabolism disorder + placebo (4 times a day) (30 people).
36050|NCT03902314|Drug|Lidocaine Iv|Intravenous infusion
36051|NCT03902314|Drug|Saline Solution|Intravenous infusion
36052|NCT03902301|Dietary Supplement|Lactobacillus group|Nutrition intervention focused on the treatment of insulin resistance + Lactobacillus rhamnosus supplementation (6x10 9 of lactobacillus rhamnosus x 2 times a day) (35 people).
36053|NCT03902301|Dietary Supplement|Dietary group|Nutritional intervention focused on the treatment of insulin resistance (35 subjects).
36054|NCT03902288|Other|Fresh pomegranate juice|Pomegranate seeds (arils) were separated by hand, and fresh pomegranate juice was prepared by squeezing the seeds using a fruit squeezing machine. Fresh pomegranate juice was given at 1.5 mL/kg of body weight for the fasted recruited patient with type 2 diabetes (FSG < 15.8 mmol/L). Blood was collected before and after 1 and 3 hours of ingesting the juice.
36055|NCT03902275|Other|Quantra-Algorithm|Hemotherapy based on Quantra-Algorithm
36056|NCT03902275|Other|ROTEM-Algorithm|Hemotherapy based on Basic-Algorithm
36057|NCT03902262|Procedure|appendicectomy|
36058|NCT03902249|Drug|Dexamethasone|
36059|NCT03902236|Other|Reaction Time and Postural Control|Reaction Time and Postural Control: With ''Fitlight TrainerTM'', 6 light emitting diode (LED) lights placed at certain points on the wall are randomly lit and expected to deactivate them as fast as possible. In the protocol, the leds will be placed according to the physical structure of the person, and the scores of 29 LED's will be kept in seconds. The scores will be compared cystic fibrosis, bronchiectasis and healthy groups.
36060|NCT03902236|Other|Muscle oxygenation|Muscle oxygenation will be assessed with wearable lactate threshold predicting device in cystic fibrosis, bronchiectasis and healthy groups.
36061|NCT03902236|Other|Exercise capacity|Exercise capacity will be assessed with incremental shuttle walk test in cystic fibrosis, bronchiectasis and healthy groups.The patient is required to walk around two cones set 9 metres apart (so the final track is 10 metres) in time to a set of auditory beeps played on a CD. Initially, the walking speed is very slow, but each minute the required walking speed progressively increases.The patient walks for as long as they can until they are either too breathless or can no longer keep up with the beeps, at which time the test ends The number of shuttles is recorded. Each shuttle represents a distance of ten metres
36062|NCT03902236|Other|Balance|Balance will be assessed with functional reach test in cystic fibrosis, bronchiectasis and healthy groups Functional Reach measures the maximum distance a person can reach forward, the distance of the person standing at the edge of the wall with a 90-degree shoulder flexion and the maximum distance to the front of the thumb will be noted.
36063|NCT03902223|Diagnostic Test|Enhanced Screening Protocol for Cardiac Sarcoidosis.|To utilize enhanced screening tests for cardiac sarcoidosis in an undiagnosed and potentially under-diagnosed patient population to determine the rate of missed cardiac sarcoidosis diagnosis. Following testing by the standard screening tests, this intervention includes a subsequent echocardiogram and a wearable ECG, also known as a Holter Monitor or ambulatory ECG.
36064|NCT03902223|Diagnostic Test|Routine Screening for Suspected Cardiac Sarcoidosis|To utilize standard of care screening tests for cardiac sarcoidosis. This includes symptom check and a standard ECG.
36065|NCT03902210|Behavioral|Online Yoga|60 minutes per week of online yoga through Udaya.com
36066|NCT03902210|Behavioral|Podcast|60 minutes per week of podcasts
36067|NCT03902197|Biological|CD19 hsCAR-T|CD19 hsCAR-T will be administered by I.V. infusion
36068|NCT03902184|Biological|IPH4102|Patients will receive a flat dose of 750mg
36069|NCT03902184|Drug|Gemcitabine + Oxaliplatin|Patients will receive a dose ranging from 800-1000 mg/m2 of gemcitabine and 75-100mg/m2 of oxalipatin, according to local practice .
36070|NCT03902171|Device|Soberlink|Soberlink delivers real-time blood alcohol results to people who support individuals in recovery from alcohol use disorder. In-Home Addiction Treatment program Care Team monitors and responds to results as part of care to improve treatment outcomes.
36071|NCT03902158|Device|Glasses|The patient will wear virtual reality glasses during anesthesia
36072|NCT03902158|Behavioral|Distraction techniques|The patient will undergo distraction techniques
36073|NCT03902145|Other|Egg|One egg per day for 6 months
36074|NCT03902132|Other|Core Stability exercises group|Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).
36075|NCT03902132|Other|Traditional low back physical therapy group|The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
36076|NCT03902119|Device|INYBI tool|Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.
36146|NCT03901586|Other|Quality of life|The Quality of life will be assessed with 3 questionnaires (I-Qol / PISQ-12/PFDI-20)
36077|NCT03902119|Other|Manual suboccipital inhibition|Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
36078|NCT03902106|Drug|salbutamol|subjects ingest salbutamol
36079|NCT03902106|Other|exercise|subjects undergo 6 weeks of endurance training (3 times weekly)
36080|NCT03902093|Diagnostic Test|Morphology changes with extended wear hearing aid|Possible changes in morphology due to wearing an extended wear hearing aid device will be assessed with imaging
36081|NCT03902080|Drug|Vibegron|oral administration
36082|NCT03902080|Drug|Placebo|oral administration
36083|NCT03902067|Biological|UC-MSC|0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability>80%, and endotoxin<0.1 EU， at the concentration of 2x10(7) cells/ml.
36084|NCT03902067|Biological|Control Group|Routine treatment without catheter infusion
36085|NCT03902054|Biological|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
36086|NCT03902054|Biological|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
36087|NCT03902054|Biological|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Beijing Minhai Biotechnology Co. Ltd..
36088|NCT03902054|Biological|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
36089|NCT03902054|Biological|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
36090|NCT03902041|Drug|Eltrombopag|The patients will receive Eltrombopag treatment after transplantation
36091|NCT03902028|Other|Reinforced multidisciplinary follow-up|Reinforced multidisciplinary follow-up
36092|NCT03902015|Device|Nuance Phone case|"participants will receive a phone (iPhone) with the Nuance Phone case and a designated app required for the use of the device. Participants will first undergo hearing test via the app, and afterwards (in case they are not excluded based on hearing status), will receive a introduction on how to use the app and the device. Before starting the clinical trial, children will undergo three adjustments days in which they will practice using the device in school. During this period the researchers will make sure that the participants are adapting to the use of the device, and in any case there is a problem, will be able to contact a representative of Nuance Hearing who will be available to support technical issues."
36093|NCT03902002|Drug|Omaveloxolone 50 mg capsules|Capsules containing 50 mg of omaveloxolone
36094|NCT03901989|Device|zeolite|given for a period of 12 months
36095|NCT03901989|Device|cellulose|given for a period of 12 months
36096|NCT03901976|Device|bed exit detection|bed exit detection to avoid patients fall
36097|NCT03901963|Drug|Daratumumab|Daratumumab 1800 mg will be administered by SC injection weekly during Cycles 1 and 2, every 2 weeks during Cycles 3 through 6, and every 4 weeks from Cycle 7 onward until confirmed progressive disease (PD), unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles.
36098|NCT03901963|Drug|Lenalidomide|Lenalidomide 10 mg will be administered orally from Day 1 to Day 28 (continuously) of each 28-day cycle until confirmed PD, unacceptable toxicity, or until end of study treatment for a maximum of 36 cycles. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
36099|NCT03901950|Drug|XNW7201 tablets|A wnt pathway inhibitor
36100|NCT03901937|Drug|ω-3 polyunsaturated fatty acid|CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
36101|NCT03901937|Procedure|Intestinal surgery for Crohn's Disease|Patients receive bowel resection due to complications of Crohn's Disease
36102|NCT03901924|Other|Volume Support Mode Mechanical Ventilation|This is a spontaneous mode of mechanical ventilation that depends on the patient's efforts. A target volume (6 cc/kg of IBW), PEEP and FiO2 are set by the medical team, and the ventilator varies the inspiratory pressure support with each breath to achieve the target volume. The respiratory rate is fully dependent on the patient. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
36103|NCT03901924|Other|Assist Control Mode Mechanical Ventilation|This is a controlled mode of mechanical ventilation that is independent of patient's efforts. A tidal volume (6 cc/kg of IBW), respiratory rate, PEEP and FiO2 are set by the medical team. Sedation while on mechanical ventilation will be set at a goal RASS of 0 to -2.
36104|NCT03901898|Behavioral|Training, audit, and reminders|Briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter), and re-audit at 6 months.
36105|NCT03901898|Behavioral|Intervention after 6 months (wait list)|After 6 months, practices receive the intervention: briefing and training for participating practices, baseline practice audit, addition of electronic prompts to patient records, GP-endorsed patient reminders (in person, phone and letter).
36106|NCT03901885|Other|Female Sexual Function Index questionnaire|Assessment of FSFI (Female Sexual Function Index) questionnaires preoperatively and postoperatively (4 months).
36147|NCT03901586|Other|Gynecological assessment|An optional gynecological consult is proposed to the patients to better estimate the gynecological long-term impact of the procedure
36148|NCT03901573|Drug|NT-I7|"Dose Escalation (Phase 1b) - NT-I7 IM (intramuscular) on Day 1 of each Cycle until MTD or RP2D is achieved.~Dose Expansion - NT-I7 IM (intramuscular) on Day 1 of each Cycle, at Maximum Tolerated Dose (MTD) or RP2D defined in escalation phase"
36149|NCT03901573|Drug|atezolizumab|"Dose Escalation - atezolizumab IV (intravenous) on Day 1 of each Cycle~Dose Expansion - atezolizumab IV (intravenous) on Day 1 of each Cycle"
36150|NCT03901560|Other|Music Therapy|
36151|NCT03901547|Behavioral|Communication Skills Training|Education training in the serious illness communication guide (SICG) by Ariadne labs.
36421|NCT03899402|Drug|Semaglutide|Injectable weekly GLP-1RA given as open label experimental drug
36107|NCT03901872|Device|Contemporary endovascular venous intervention by Zelante pharmacomechanical thrombolysis|All patients will undergo ultrasound guided micro puncture venous access of the enrolled ipsilateral lower extremity popliteal vein followed by a diagnostic venogram to define thrombus burden and anatomic extent of DVT. Prior to and every 30 minutes during the endovascular procedure, an activated clotting time (ACT) will be obtained. Intravenous unfractionated heparin will be administered to keep the ACT between 250 - 300. A Zelante catheter will be utilised to perform pharmacomechanical thrombolysis of the enrolled lower extremity. If there is involvement of the popliteal and/or femoral vein, pharmacomechanical thrombolysis should also be performed of these veins. Venous stenting may be implemented to address areas of residual venous stenosis or outflow obstruction following pharmacomechanical thrombolysis. Stent placement in the common iliac, external iliac, and common femoral vein are routinely done to address inflow or outflow issues after pharmacomechanical thrombolysis.
36108|NCT03901846|Device|ColdZyme|ColdZyme is a Class I medical device (CE-marked) with the following composition: glycerol, water, Tris buffer, CaCl2, menthol and trypsin
36109|NCT03901833|Behavioral|Telemedicine Support|Telemedicine intervention
36110|NCT03901833|Other|Standard of Care|Standard of Care
36111|NCT03901820|Device|Medication Interaction System of Dr App (SIMDA)|A module for the electronic clinical records allowing detection of the potential drug interactions
36112|NCT03901807|Device|Toraymyxin PMX 20R Extracorporeal Hemoperfusion Cartridge|TORAYMYXIN PMX-20R (PMX) is an extracorporeal hemoperfusion cartridge intended for the selective removal of endotoxin from circulating blood through direct hemoperfusion (DHP). Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 mL/minute, (range of 80 to 120 mL/minute).
36113|NCT03901794|Device|Non-invasive hemodynamic monitor|MAP, HR, CO, SVI, from Non-invasive hemodynamic monitor
36114|NCT03901781|Combination Product|ST266 via Intranasal Delivery|ST266 administered by non-invasive trans-cribriform intranasal delivery using the SipNose intranasal device.
36115|NCT03901768|Drug|Dexamethasone|a syringe having 4ml of 4mg/ml of dexamethasone is used for intravenous injection.
36116|NCT03901768|Drug|Triamcinolone|1ml of 40mg triamcinolone is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
36117|NCT03901768|Drug|Placebos|A syringe having 4ml of saline is used for intravenous injection. 1ml of saline is mixed in the syringes containing solution for intrarticualar local infiltration. The solution is injected intraarticularly.
36118|NCT03901755|Drug|Alprolix|Extended half-life factor IX product
36119|NCT03901742|Other|Protein-enriched nutrition|Protein-enriched enteral nutrition with a polymeric infant formula
36120|NCT03901742|Dietary Supplement|High Protein-enriched Nutrition|High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
36121|NCT03901742|Other|Standard Enteral Nutrition|Cow's milk based infant formula.
36122|NCT03901729|Drug|BAY 1753011|Tablet; 30mg or 5mg unit; 30mg once daily in the morning; Oral
36123|NCT03901729|Other|Placebo BAY 1753011|Tablet; Once daily in the morning; Oral
36124|NCT03901729|Drug|Furosemide|Tablet; 40mg unit; 80mg once daily in the morning; Oral
36125|NCT03901729|Other|Placebo Furosemide|Tablet; Once daily in the morning; Oral
36126|NCT03901716|Drug|Sufentanil|Patients in Group S received sufentanil 0.1 mcg/kg.
36127|NCT03901716|Drug|Fentanyl|Patients in Group F received fentanyl 1 mcg/kg.
36128|NCT03901716|Drug|Remifentanil|Patients in Group R received remifentanil target-controlled infusion with effect-site target concentration of 1ng/ml.
36129|NCT03901716|Drug|Midazolam|Patients in all groups received midazolam to achieve moderate levels of sedation as assessed by the Narcotrend (NT; between B1 and C2).
36130|NCT03901703|Other|Physiotherapy and Rehabilitation|The children in each group will receive 6 weeks of functional strengthening exercises targeting each muscle group according to the arm they are included in.
36131|NCT03901690|Drug|Betaglucin soluble gel 0.2%|With the prior informed consent of the 51 study participants, 5 grams of 0.2% soluble betaglucin gel will be self-applied every 12 hours for 5 days. Both groups will receive an unlabeled tube so that none of the study participants will know what topical treatments they are receiving.
36132|NCT03901690|Drug|Imiquimod 5% cream|With the prior informed consent of the 51 study participants, 1 gram of 5% imiquimod will be self-applied once a day for 5 days. Both groups will receive an unlabeled tube so that neither study participant knows what topical treatments they are receiving.
36133|NCT03901677|Other|Tai-chi training|Group exercise apply with physiotherapist
36134|NCT03901651|Diagnostic Test|Colonoscopy with Retroview scope combing forward and retroflexed withdrawal technique|"Colonoscopy using a combined forward and retroflexed evaluation of the colonic mucosa. using the Retroview™ scope. The operator will be blind to the standard colonoscopy findings.~The operator will record the polyps and adenoma encountered, describing the size and location."
36135|NCT03901651|Diagnostic Test|Colonoscopy with standard colonoscope and forward withdrawal technique|"A standard colonoscopy with forwarding viewing withdrawal technique. An HD colonoscope with I-scan technology will be used by one expert endoscopist.~Each polyp and adenoma will be recorded, including the size and location."
36136|NCT03901638|Drug|Tllsh2910|Tllsh2910 80mg twice per day orally for 12 weeks
36137|NCT03901638|Drug|Placebo|Placebo
36138|NCT03901625|Device|Manual Toothbrush|A manual toothbrush is used to clean teeth surfaces.
36139|NCT03901625|Device|Dental floss|A dental floss is used to clean inter-proximal areas.
36140|NCT03901625|Device|Waterjet|A waterjet is used to clean inter-proximal areas.
36141|NCT03901625|Device|Electric Toothbrush|An electric toothbrush is used to clean teeth surfaces.
36142|NCT03901612|Drug|Ropivacaine 0.2%|Continuous post operative regional analgesia
36143|NCT03901612|Drug|saline 09%|Continuous post operative regional analgesia
36144|NCT03901599|Other|Alveolar ventilation monitoring estimated by the capnographic ventilation|Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.
36422|NCT03899402|Drug|Dapagliflozin|Oral daily SGLT2 Inhibitor given as experimental drug
36152|NCT03901547|Behavioral|Profile feedback|Providing participants their personal documentation rate of SICG in the electronic medical record
36153|NCT03901547|Other|Maslach burnout inventory|Maslach burnout inventory
36154|NCT03901547|Other|Emotion Regulation Skills Question (ERSQ)|This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL). This validated instrument consists of 27 items, and includes subscales related to nine competencies of coping with negative emotion (awareness, sensations, clarity, understanding, acceptance, tolerance, readiness to confront, compassionate self-support and modification) which can be summed to a total score (TOTAL).
36155|NCT03901547|Other|Semi-structured interview|Interviewer asked subjects are a series of questions based on interview guide. Current guide designed to assess subject perception of implementation of training in clinical encounters, most recent encounter with patient with serious illness, barriers to documentation and coaching by faculty on communication. Interviews will be recorded and expected duration is 20-40 minutes.
36156|NCT03901547|Behavioral|Priming|"Participants will be provided a list of 30 patients they have encountered before that 1) have at least one documented note and 2) have a high probability for having serious illness as determined by electronic medical record screening. Participants will be asked 4 yes or no questions on each patient. Questions: 1) do you believe this patient has serious illness?; 2) would you be surprised if this patient died in the next year?; 3) would the patient benefit from the serious illness conversation guide? and 4) If you saw this patient again, would you use the serious illness conversation guide with him/ her?"
36157|NCT03901534|Device|Auto-CPAP|Use of Auto-CPAP
36158|NCT03901534|Other|Withdrawal of Auto-CPAP|Withdrawal of Auto-CPAP
36159|NCT03901508|Device|TDCS|20 minutes, 2 electrodes (C3/FP2)
36160|NCT03901495|Other|Diaana|"Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals."
36161|NCT03901482|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
36162|NCT03901482|Drug|Placebos|Placebo for STS101
36163|NCT03901469|Drug|ZEN003694|Bromodomain Inhibitor
36164|NCT03901469|Drug|Talazoparib|PARP Inhibitor
36165|NCT03901456|Behavioral|Care to Plan|Care to Plan (CtP) is an online care planning tool that provides a succinct and clear overview of various types of ADRD caregiver interventions, administers a brief validated assessment of risk, and generates individualized service recommendations for Alzheimer's disease and related dementia (ADRD) caregivers as well as resources that link users to a selected recommendation. For family caregivers who wish to complete the tool with the guidance of a CtP interventionist (a Riverside Health System social worker/Senior Care Navigator), the interventionist will discuss CtP recommendations with caregivers and help caregivers enroll in a tailored support service if so desired.
36166|NCT03901456|Behavioral|Usual Care|Receive care as usual.
36167|NCT03901443|Other|Survey on itch|self-administered patient questionnaire regarding the different aspects of itch
36168|NCT03901430|Behavioral|Group navigation model|In a series of peer group sessions facilitated by Guadalupe Fuentes, a CHW who designed the model, we will create a culturally-appropriate, non-stigmatizing group intervention. The group process will allow participants to explore their own MEH, better understand the ways that mental health influences well-being and everyday dynamics of their lives, and to develop empowering knowledge and action plans through the support of other women.
36169|NCT03901417|Device|Fraxel Restore (Non-ablative Fractional Laser)|In the study, one side of the face will be treated with non-ablative fractional laser monthly for three months.
36170|NCT03901417|Device|Fraxel Restore (Non-ablative fractional laser) and SkinPen (Microneedling Device)|In the study, one side of the face will be treated with a combination of non-ablative fractional laser and microneedling monthly for three months.
36171|NCT03901404|Procedure|Myomectomy Operation|Patients undergoing myomectomy for myoma uteri
36172|NCT03901391|Diagnostic Test|Whole Exome Sequencing|Whole Exome Sequencing
36173|NCT03901378|Drug|Pembrolizumab|Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:
36174|NCT03901365|Other|Neuroscience pain education|In Neuroscience pain education (NPE) sessions, patients were informed about the pain experience and the neurophysiological process about pain. NPE was performed by the method proposed by Louw et al (12). NPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
36175|NCT03901365|Other|Traditional patient education|In traditional patient education (TPE) sessions were aimed to explain to patients a proposed treatment or efficacy of a certain manual therapy technique or approach, have focused heavily on biomechanical and anatomical models. These models would imply that injury, disease, and muscle guarding may lead to altered movement patterns, asymmetrical loading, and resultant pain and dysfunction. TPE was administered 4 sessions per week for four weeks. Trainings were conducted in the form of face-to-face interview and 45-50 minutes of one-to-one sessions.
36176|NCT03901365|Other|Manual therapy|Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
36177|NCT03901352|Drug|Placebo|Matching placebo tablets for oral administration
36178|NCT03901352|Drug|Mirogabalin|Mirogabalin tablets for oral administration
36423|NCT03899402|Drug|Placebo to Dapagliflozin|Placebo to Dapagliflozin given as a control to the experimental drug
36179|NCT03901339|Drug|Sacituzumab Govitecan|Sacituzumab Govitecan (IMMU-132) is an antibody drug conjugate composed of the humanized monoclonal antibody, which binds to trophoblastic cell-surface antigen-2 (Trop-2); SN-38, a topoisomerase I inhibitor; and CL2A.
36180|NCT03901339|Drug|Eribulin|Eribulin (per NCCN guidelines)
36181|NCT03901339|Drug|Capecitabine|Capecitabine (per NCCN guidelines)
36182|NCT03901339|Drug|Gemcitabine|Gemcitabine (per NCCN guidelines)
36183|NCT03901339|Drug|Vinorelbine|Vinorelbine (per NCCN guidelines)
36184|NCT03901326|Diagnostic Test|CT-FFR|When subjects are randomized to the CTA/CT-FFR arm, FFR based on the coronary CTA imaging will be measured. DeepFFR workstation is very dedicated software utilizing the original CTA imaging to meter simulated FFR values in artificial intelligence model.The first step is to extract a 3D coronary artery model and generate coronary centerlines which are similar to the routine reconstruction of coronary CTA. The centerlines are extracted using a minimal path extraction filter. Then a novel path-based deep learning model, referred to DeepFFR, is used to predict the simulated FFR values on the vascular centerlines. Deep learning algorithm is used to establish characteristic sample database of coronary hemodynamics characteristic parameters. When deep training model is proved to be valid, it is applied to a new lesion-specific measurement. Lesion-specific CT-FFR is defined as simulated FFR value 2-3cm downstream of an interest lesion.
36185|NCT03901313|Drug|Treatment A - 400 mg Fasting|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning under fasting conditions
36186|NCT03901313|Drug|Treatment B - 400 mg Fed|Single oral 400 mg (2 × 200 mg capsules) dose of pexidartinib in the morning within 30 minutes (min) after a low-fat standard breakfast meal
36187|NCT03901313|Drug|Treatment C - 200 mg Fed|Single oral 200 mg (1 × 200 mg capsule) dose of pexidartinib in the morning within 30 min after a low-fat standard breakfast meal
36188|NCT03901300|Behavioral|Fundamental Motor Skills App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized experimental group.
36189|NCT03901300|Behavioral|Unstructured Physical Activity App|Lessons will be provided over the app each week with notifications sent 5 days/week over 12 weeks specific to randomized active comparator group.
36190|NCT03901287|Other|dual energy CT scans|The procedure involves post processing and analysis of reconstructed images from dual energy CT scans available at the Bordeaux University Hospital and used in routine care, which will allow us to collect morphometric data (bronchial wall thickness and cross sectional area of small pulmonary vessels) and to assess pulmonary perfusion by studying iodine mapping and quantifying pulmonary perfusion blood volume (PVB)
36191|NCT03901274|Behavioral|Clinical Services Support|The CSS framework packages together evidence-based practices of family engagement, modular evidence-based practice, quality assurance, and implementation support. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
36192|NCT03901274|Behavioral|Patient Centered Enhancements|The two PCEs are: enhancing mental health literacy and stigma reduction, and improving family-school-mental health partnerships. Depending on their time of enrollment, participants can be involved in this condition for one to three years. They will be asked to complete assessments during their therapy sessions periodically throughout the trial.
36193|NCT03901261|Procedure|Neuro-imaging, Lumbar puncture|Optional Lumbar Puncture will be performed at inclusion visit Optional Neuro-Imaging (MRI (Magnetic Resonance Imaging) will be performed within 3 months after inclusion visit
36194|NCT03901248|Other|No Intervention|Observational study
36195|NCT03901235|Biological|Mesenchymal Stromal Cells|Suspension of mesenchymal stromal cells for intratissular injection
36196|NCT03901222|Device|tDCS|20 minutes of anodal tDCS (C3 & C4/FPZ) 2mA or sham
36197|NCT03901209|Device|Mid-face osteotomy|The mid-face osteotomy - typically according to LeFort I - is performed using a pulsed erbium-doped yttrium aluminium garnet (Er:YAG) laser driven by the CARLO robot arm.
36198|NCT03901196|Diagnostic Test|Elemental analysis|LIBS multi elemental analysis of the specimen
36199|NCT03901183|Other|Plant-based Diet|Patients are guided to change their nutrition to a plant-based diet.
36200|NCT03901170|Drug|Letrozole 2.5mg|oral administration of letrozole 2.5mg/tab, 1tab once per day from stimulation Day 7 to hCG Day.
36201|NCT03901157|Dietary Supplement|Yogurt A: Active|Free fat yogurt containing oil-filled alginate gels
36202|NCT03901157|Dietary Supplement|Yogurt B: Control|Free fat yogurt containing the same amount of fat as the active one, and empty alginate gels
36203|NCT03901144|Drug|Cream 1107.57|Moisturizing cream for topical application
36204|NCT03901144|Drug|Glycerol cream|Moisturizing cream for topical application
36205|NCT03901144|Drug|Paraffin cream|Emollient cream for topical application
36206|NCT03901131|Drug|Norethisterone enantate/estradiol valerate (Mesigyna, BAY98-7040)|Follow clinical administration
36207|NCT03901118|Drug|chiauranib|in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily
36208|NCT03901118|Drug|etoposide|50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most
36209|NCT03901118|Drug|paclitaxel|60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most
36210|NCT03901105|Drug|flortaucipir F18|No study drug will be administered. Scans previously acquired from Study I8D-MC-AZES (NCT02245737, Eli Lilly and Company sponsor) at baseline will be read by independent, blinded readers.
36211|NCT03901092|Drug|flortaucipir F 18|No study drug will be administered. Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.
36212|NCT03901053|Device|Reaktiv AFO|This device is a carbon fiber ankle foot orthosis (brace) that contacts the foot and lower leg. It consists of a foot plate that is designed to protect the foot, a carbon fiber strut on the back that stores and returns energy, and a cuff that goes below the knee. It has a custom geometry and alignment that is specific to the individual.
36213|NCT03901053|Device|PhatBrace AFO|Although lighter and thinner than the Reaktiv it has a similar overall design. The posterior strut is typically longer and the footplate is thinner, more compliant and less customized. Further, the device is formed into a single piece.
36459|NCT03899116|Other|deflation of pneumatic tourniquet|gradual deflation with variable degrees
36214|NCT03901040|Device|endoscopic ultrasound|endoscopic ultrasound with boutlinum toxin injection in the antrum of the stomach to decrease satiety
36215|NCT03901027|Behavioral|Therapeutic Conversation Interventions|Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
36216|NCT03901014|Other|Standard American diet|Standard American diet with 50% energy from carbohydrate, 30% from fat, and 20% from protein.
36217|NCT03901014|Other|Very low carbohydrate diet|Ketogenic diet with <50g carbohydrate, 60-75% energy from fat, and 20% from protein
36218|NCT03901001|Drug|sirolimus and oseltamivir|Sirolimus 1 mg daily and oseltamivir 75 mg bid for 5 days, both given orally. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
36219|NCT03901001|Drug|Oseltamivir|oral oseltamivir 75 mg bid alone for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
36220|NCT03900988|Drug|N-acetyl cysteine|N-acetyl cysteine will be administered at 100 mg/kg daily as a continuous IV infusion (in 1000ml of 5% dextrose) over 24 hrs and oseltamivir 75 mg bid orally for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
36221|NCT03900988|Drug|5% Dextrose|5% dextrose 1 liter given over 24 hrs and oral oseltamivir 75 mg bid for 5 days. Extension of dosing to 10 days for oseltamivir and the study drug is allowed if there is slow recovery, lack of improvement, or deterioration.
36224|NCT03900949|Drug|Daunorubicin|Anthrocycline component of the standard induction 7+3 chemotherapy regimen for treatment of AML.
36225|NCT03900949|Drug|Cytarabine|Component of standard 7+3 chemotherapy regimen for treatment of AML.
36226|NCT03900949|Biological|Gemtuzumab Ozogamicin|Anti-CD33 monoclonal antibody given during induction at different dose levels.
36227|NCT03900949|Drug|Midostaurin|An oral multi-kinase inhibitor with effects against FLT3, given through induction and consolidation.
36228|NCT03900936|Diagnostic Test|Neuropsychological tests|This study is not an intervention as such. We are simply comparing the scores of MCI patients who subsequently went on to develop dementia vs those who did not.
36229|NCT03900923|Drug|98% pure CBD|A Bayesian optimal interval (BOIN) design will be used, such that participants will be assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts
36230|NCT03900910|Other|Gastric cancer prevention|Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.
36231|NCT03900897|Device|MED-EL SYNCHRONY PIN Cochlear Implant|Subjects will be implanted with the MED-EL SYNCHRONY PIN Cochlear Implant System with +FLEX24, +FLEX28, +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO 2 (single-unit) external audio processors.
36232|NCT03900884|Drug|Venetoclax|At commencement of study: Venetoclax will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 100 and 800 mg/day depending on dose escalation results and recommendation of the safety committee.
36233|NCT03900884|Drug|Palbociclib|At commencement of study: Palbociclib will commence at 100 mg daily (oral) for days 1-21 of each 28 day cycle. This is a dose finding study so doses will be adjusted between 75 and 125 mg/day depending on dose escalation results and recommendation of the safety committee.
36234|NCT03900884|Drug|Letrozole|Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
36235|NCT03900871|Drug|Acetylsalicylic acid|Aspirin (aspirin), also known as acetylsalicylic acid (acetylsalicylic acid), is a salicylic acid drug commonly used as a painkiller, antipyretic and anti-inflammatory drug. There is growing evidence that aspirin has a preventive effect on certain cancers, especially gastrointestinal cancers, and that taking aspirin every day can reduce the risk of colon cancer, and in vitro experiments have also shown that aspirin inhibits the growth of a variety of cancer cells and induces apoptosis.
36236|NCT03900858|Drug|Isoniazid；Rifapentine|1 months (12 doses) of three-weekly rifapentine at a dose of 450mg plus isoniazid at a dose of 400mg given under direct observation
36237|NCT03900845|Device|Dynamic Air Exchange - Rising Edge Design (DAE-RED)|The DAE-RED suspension system expels perspiration to the prosthesis exterior using a hybrid battery-powered pump and a body-weight activated pump. To use the DAE-RED, subjects will be fit with a modified patellar tendon-bearing socket that fits over a custom liner and sock. Up to four air intake ports are located proximally on the liner, approximately 25 mm superior to the socket brim. These ports incorporate a microvalve that allows air to flow into the liner-skin interstitial space while still maintaining a vacuum suspension. Distally, the pin lock has a 3-mm hole along its longitudinal axis that allows perspiration to be expelled into a distal reservoir. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot with Unity pump and foot cover.
36324|NCT03900117|Drug|concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
36238|NCT03900845|Device|Perforated elastomeric liner|The unique element of this perforated elastomeric liner are small perforations (~0.3 mm diameter), uniformly distributed on a 4 x 5 mm grid, but with no perforations on the distal umbrella, that allow perspiration to be exuded into the liner-socket interstitial space. To use the perforated elastomeric liner, subjects will be fit with a modified patellar tendon-bearing socket that fits over a sock and the perforated elastomeric liner with a pin lock. The sock, worn between the socket and the liner, is used to absorb perspiration that is transported through the perforations in the liner. When needed for residual limb volume control, additional socks will be donned and included in tare weighing. The prosthesis will also include: a standard aluminum pylon, pyramid adapters, and an Ossur Proflex XC prosthetic foot and cosmesis.
36239|NCT03900845|Device|As-prescribed prosthesis|The individual's as-prescribed suspension system is the prosthesis prescription that the patient and their clinical care team believes is the best prosthesis for their needs.
36240|NCT03900832|Other|Without Heating|Subject will complete walking protocol without any heating procedure
36241|NCT03900832|Other|Warm Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 38-41°C. Subjects will remain in the tub for ≤ 30 minutes. If the HR increases more than 15 -20 bpm, or a significant BP drop occurs (e.g. BP >20 mmHg), the subject will be removed from the bath even if the time is <30 min."
36242|NCT03900832|Other|Neutral Bath|"Subjects will sit in a warm bathtub with water up to their shoulders, while one arm will be out of water for BP and HR measurement. The water temperature and internal temperature (Tcore), BP and HR will be measured throughout the bath.~The water temperature will be controlled between 35 - 37°C. Subjects will remain in the tub for ≤ 30 minutes."
36243|NCT03900832|Other|Heating Suit|The mean skin temperature Tsk will be controlled with a water-perfused suit worn by subjects. Whole-body heating will be accomplished by perfusing warm water (~ 45 - 50 °C) through the suit to elevate the Tsk to ≤ 38 °C (100 oF). Warm water is through plastic tubes, and subjects' skin will not directly touch warm water. The heating will be continued until the ∆Tcore reaches ~ 0. 6 - 1.0 °C. This may take approximately 60 - 90 min.
36244|NCT03900832|Other|Lower limb warm water immersion|Subjects will sit on a chair and put their lower legs and feet in a bucket with warm water. The water level will be just below the knees (depth of approximately 40 cm). The water temperature will be monitored and controlled at ~38 - 42 °C throughout the 30 minutes. BP, HR, Tcore, the skin temperature and skin blood flow (e.g. on a thigh and/or forearm) will be measured before, during and after the lower limbs warm water immersion.
36245|NCT03900832|Other|Gardner walking protocol|The Gardner protocol begins at 2 mph and 0% grade for 2 minutes. The grade increases by 2% every 2 minutes (the speed remains 2 mph) until the subject says they want to stop or 22 minutes maximum. BP and HR will also be measured throughout the protocol.
36246|NCT03900819|Other|dexterity measurement|4 non-invasive tests will be performed
36247|NCT03900806|Behavioral|online cognitive rehabilitation|The cognitive rehabilitation program will be based on the protocol of a frequently used meta-cognitive strategy approach applied in many rehabilitation centers in the Netherlands. The program consists of several modules that can be used in a flexible way, depending on the specific individual problems and goals. Therapists have undergone additional training in issues related to cancer-related cognitive impairment and problems occupationally active cancer survivors might experience at work. In both intervention arms, participants will receive access to a secured personal webpage, where all content relevant to the treatment sessions can be obtained.
36248|NCT03900793|Drug|Losartan|Losartan will be administered orally daily on days 1-42 (6 weeks) with dose level assignments per Table 1 of the protocol. Dosing will be performed based on weight in kilograms and rounded to the nearest 12.5 mg (half of 25 mg tablet). Dose level 1 dosing will not exceed 50 mg daily and dose levels 2 and 3 dosing will not exceed 100 mg daily. Doses should be taken at approximately the same time daily and patients should fast for > 4 hours prior to dosing
36249|NCT03900793|Drug|Sunitinib|Sunitinib will be administered orally daily on days 1-28 (4 weeks), followed by 14-day rest period (2 weeks). Dosing will be performed based on body surface area (BSA) in mg/m2 per Table 1 of the protocol. Doses should be taken at approximately the same time daily.
36250|NCT03900780|Procedure|PGT-A|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage (day 5/6), TE biopsy, vitrification of all embryos in the blastocyst stage, PGT-A by NGS and finally embryo transfer of genetically normal embryos in cumulative frozen-thawed embryo transfer cycles
36251|NCT03900780|Procedure|Control|ovarian stimulation, oocyte aspiration, embryo culture until the blastocyst stage, fresh embryo transfer of the morphologically best embryo on day 5/6, vitrification of supernumerary embryos and embryo transfer in cumulative frozen-thawed embryo transfer cycles if not pregnant from the fresh cycle.
36252|NCT03900767|Other|Electronic Health Record intervention|AAC-Out
36253|NCT03900767|Other|Electronic Health Record intervention|AAC-In
36254|NCT03900767|Behavioral|Smoking Cessation Intervention|Receive standard Utah Quitline treatment
36255|NCT03900767|Behavioral|Telephone-Based Intervention|Receive text messages
36256|NCT03900767|Behavioral|Telephone-Based Intervention|Receive phone calls
36257|NCT03900754|Drug|Oxytocin|Intranasal administration of oxytocin
36258|NCT03900754|Drug|Placebo|Placebo
36259|NCT03900741|Procedure|Submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a submerged healing protocol
36260|NCT03900741|Procedure|Non-submerged healing|Bone regeneration of peri-implantitis defects using a bone xenograft and a resorbable collagen membrane, with flap suturing using a non-submerged healing protocol
36261|NCT03900728|Device|Auriculotherapy with needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
36262|NCT03900728|Device|Auriculotherapy with beads|A trained co-investigator will place the beads onto prespecified acupoints of the participant's ears. An adhesive disk will adhere the beads to the ears.
36263|NCT03900728|Device|Placebo Adhesive disks|Single-use adhesive disks without needles or beads.
36264|NCT03900715|Drug|Luspatercept|Luspatercept
36460|NCT03899103|Drug|Rituximab|First course Course Rituximab at Randomization.
36265|NCT03900702|Behavioral|Gaze-driven training games|Training games are played on a PC with attached eye-tracker. Games include embedded training principles to improve attentional control including resistance to distraction and inhibitory control.
36266|NCT03900689|Other|Part 1 Survey Group|At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.
36267|NCT03900689|Other|Part 2 Focus Group|If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
36268|NCT03900676|Drug|VB-1953 - 2%|Topical Gel
36269|NCT03900676|Drug|VB-1953 - 0% (Vehicle)|Topical Gel
36270|NCT03900663|Device|Anthropometric measures|Measure body weight , height , chest circumference , mid upper arm circumference,skin fold thickness , head circumference
36271|NCT03900650|Behavioral|High provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
36272|NCT03900650|Behavioral|Low provocation manipulation|Participants will engage in a laboratory task and will then report their emotions following the task.
36273|NCT03900650|Behavioral|Alcoholic beverage|Participants will consume an alcoholic beverage (vodka mixed with fruit juice) that is the equivalent of 3-4 standard alcoholic drinks based on their body weight.
36274|NCT03900650|Behavioral|Non-alcoholic beverage|Participants will consume a nonalcoholic beverage (fruit juice) that is the isovolemic equivalent of 3-4 standard alcoholic drinks based on their body weight.
36275|NCT03900637|Drug|Leuprorelin acetate|In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
36276|NCT03900637|Drug|Letrozole|2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
36277|NCT03900637|Genetic|MammaPrint|In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
36278|NCT03900624|Drug|Dexamethasone|Non-randomized, open-label, prospective use of intravenous dexamethasone for children admitted to the PICU with status asthmaticu
36279|NCT03900611|Device|peripheral electrical stimulation|The subjects will undergo 8-week home-based peripheral electrical simulation on the median nerve. The peripheral electrical simulation will be performed once a day for 30 minutes. The stimulation will be active or sham depend on the group assignment.
36280|NCT03900598|Drug|JNJ-67856633|JNJ-67856633 capsule will be administered orally.
36281|NCT03900585|Behavioral|Interval walking|Interval walking administered by an app on the patient's telephone. Interval walking for 150 minutes/week for 10 weeks.
36282|NCT03900572|Biological|HPV Vaccine|Intramuscular injection, 3 doses
36283|NCT03900572|Drug|Placebo|Intramuscular injection, 3 doses
36284|NCT03900559|Behavioral|NO-FEAR Airlines|"NO-FEAR Airlines is an Internet-based self-applied treatment program that allows people with Flying Phobia the exposure to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines contains 6 scenarios related to the flight process: (1) flight preparation, (2) airport, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway, and landing, (6) sequences with images and auditory stimuli related to plane crashes."
36285|NCT03900546|Device|MostCare|CO measurement using echocardiography and PRAM before and after noradrenaline dose change due to clinical reason
36286|NCT03900533|Behavioral|Adjunctive group emotion regulation skills training|The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual
36287|NCT03900533|Behavioral|Treatment as usual|Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
36288|NCT03900507|Procedure|endometriosis surgery|"Medical treatment was initiated in patients with abdominal incision due to endometriotic focus in the incision line.~however, patients with surgical excision indications were the study group."
36289|NCT03900494|Device|VHC 1|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
36290|NCT03900494|Device|VHC 2|Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
36291|NCT03900481|Procedure|Vertical gastric plication|Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
36292|NCT03900468|Device|Activa PC™ Neurostimulator System|Implanted DBS system consisting of a Neurostimulator, Leads, Extensions, and potential accessories including Burr Hole Cover, Clinician Programmer, Clinician programmer Therapy Application Software, Clinician Programmer Communicator, Application Card, External Neuro Stimulator (ENS), Patient Programmer, and Antenna.
36293|NCT03900455|Device|Hydrocellular polyurethane foam multilayer dressing|Application of a multilayer foam with 4 flaps that can be adapted to several areas of the body (including the sacrum) and consists of: an external polyurethane film, which is impermeable to liquids and bacteria using dynamic transpiration, which can form an impenetrable barrier to protect the skin; a protective layer that shields the skin against accidental knocks and helps to spread the pressure; a highly absorbent and leak-proof layer that traps the exudate inside; a layer of hydrocellular polyurethane foam; and, finally, in contact with the skin, a perforated evenly covered layer of silicone gel adhesive. in addition to Standard preventive care
36325|NCT03900104|Procedure|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles|Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
36294|NCT03900455|Procedure|Standard preventive care|Pressure Ulcer risk assessment using the Braden scale within 8 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <17, daily inspection of the skin in the various pressure points and moving the patient at list every 4 hours. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure
36295|NCT03900442|Drug|PTX-100|IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles
36296|NCT03900429|Drug|MGL-3196|Tablet
36297|NCT03900429|Drug|Placebo|Matching Tablets
36298|NCT03900416|Behavioral|Mindfulness App|Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
36299|NCT03900403|Other|Walnut Intake|40g of daily walnut intake for 12 weeks
36300|NCT03900390|Procedure|cross-preconditioning|After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.
36301|NCT03900377|Drug|SyB L-0501RI|The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
36302|NCT03900364|Procedure|partial nephrectomy|Partial nephrectomy is the standard technique for organ-sparing resection of renal tumors. The EAU Guidelines recommend partial nephrectomy to all patients with T1 tumours and can be performed either with an open, pure laparoscopic or robot-assisted approach, based on surgeon's expertise and skills.
36303|NCT03900351|Procedure|Wii fit protocol of virtual reality games|the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .
36304|NCT03900351|Procedure|Regular exercise rehabilitation protocol|It will be according to the criterion of Adams et al. (2012).
36305|NCT03900325|Drug|Nimacimab|2.5 mg/kg
36306|NCT03900325|Drug|Placebo|0.9% sodium chloride
36307|NCT03900312|Behavioral|Asdzaan Be'eena' Program|The program will consist of 11 sessions conducted with girls ages 8-11 and their female caregivers. 5 of the 11 sessions will be taught to groups of 8-12 girls and their mothers, and 6 of the sessions will be taught to individual girl/female caregivers' dyads. The mix of group- and home-based lessons is based on findings from the formative phase about preference for certain topics to be taught in groups vs. individual dyads. Each of the sessions (group and individual) will be 60-90 minutes in duration and delivered by a trained Family Health Coach (FHC). Group sessions will take place at a local community center in a private room. Individual dyad sessions will take place in the girls'/female caregivers home or another private place of their choosing such as our local Johns Hopkins offices. The program will be conducted over 2.5-3 months with one session occurring every week for 11 weeks.
36308|NCT03900299|Procedure|oncoplastic breast surgery|oncoplastic breast surgery with level 1 or 2 according to the case using intra operative frozen section to assess the margin
36309|NCT03900286|Dietary Supplement|Total Dietary Replacement|Total Dietary Replacement
36310|NCT03900273|Other|No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS)|Novel measures of Cognitive and Everyday function
36311|NCT03900273|Other|Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)|Established measures of Cognitive and Everyday Function
36312|NCT03900260|Device|Softec HP1 Intraocular Lens|The Softec HP1 IOL is a single-piece, biconvex, ultraviolet absorbing intraocular lens designed for insertion into the posterior chamber of the human eye for visual correction of Aphakia in adults over the age of 21, and as a replacement of a damaged (cataract) natural lens.
36313|NCT03900247|Device|REMAP EEG based BCI and SEM-Glove BioServo|EEG-based brain computer interface (BCI) will be adapted to individual ALS patients and modified to control external robotic devices
36314|NCT03900234|Other|No intervention will be administered|No intervention will be studied. Clinical and ultrasound examinations will be used to find the prevalence of CVD.
36315|NCT03900221|Other|No intervention|No intervention
36316|NCT03900208|Diagnostic Test|Hystological analysis of ventricular tissue|Sections (4μm thick) will be stained with hematoxylin and eosin stain (H&E) for diagnosis. After diagnosis, sections of the representative heart tissue will be stained with a PicroSirius Red/Fast Green for fibrosis evaluation. All stained samples will be examined under digital and light microscope. Beside the location of adipose/fibrous tissue in the right or left ventricles and in the septum, seven high magnification fields (40x) will be evaluated in five regions of the myocardium.
36317|NCT03900195|Other|BottlePEP|Positive expiratory device with a bottle
36318|NCT03900182|Device|Hyperbaric Oxygen Therapy|The Hyperbaric Oxygen Therapy (HBOT) patients were placed in a chamber that was pressurized with air to 2.5 ATA during 15 min and were supplied 100% oxygen for 25 mins, followed by a 5-min air break. This cycle was repeated once and followed by 100% oxygen for 10 min, after which time the chamber was depressurized to 1 ATA over 15 min with 100% oxygen for a total treatment time of 100 min.
36319|NCT03900169|Genetic|Genetic|Lipid profile
36320|NCT03900156|Other|goal-setting|The interviewer will have access to key information from the initial assessment such as details of identified risks. Areas where the participant would like to make changes or improvements will be identified and prioritized, and up to five specific, realistic and achievable goals will be identified.
36321|NCT03900143|Device|Tightra vaginal device|Vaginal device for improvement of vaginal symptoms, reduce vaginal laxity, improve sexual functioning, and treat stress urinary incontinence.
36322|NCT03900130|Dietary Supplement|Preload|"In the 2 x 2 factorial design we vary two factors:~caloric load of the preload such that it is either high calorie or low.~protein to carbohydrate ratio of the preload such that it is either high or low"
36323|NCT03900117|Radiation|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 40Gy/10f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 28Gy/7f is delivered to the residue tumor.
36326|NCT03900104|Procedure|Cervical injection of technetium 99 m-labeled human albumin colloid particles|Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
36327|NCT03900091|Diagnostic Test|Multiplex PCR assay for meningitis|CSF from cases to be analysed with a FilmArray ME Panel
36328|NCT03900091|Diagnostic Test|Multiplex vertical flow microarrray assay for meningitis|CSF from cases will also undergo analysis with a newly developed prototype for point-of-care diagnostic tool for CNS infections identification. The tool is a DNA-based vertical flow microarray technology printed on paper.
36329|NCT03900091|Diagnostic Test|Profiling of blood proteins by multi-analyte Profiling technology|Blood from cases and controls to be analysed using Luminex technology to identify protein profiles associated with severe and non-severe infection. Myxovirus protein A (MxA) will also be analysed by the Luminex assay, to associate MxA levels with severe/non-severe infection.
36330|NCT03900091|Other|Typing and whole genome sequencing|Pathogenic strains isolated from nasopharyngeal swabs from cases and controls will undergo whole genome sequencing (WGS) and typing .
36331|NCT03900078|Other|Incisional negative pressure wound therapy|A negative pressure dressing is applied to the skin incision.
36332|NCT03900078|Other|Wound dressing with adhesive tapes|Regular adhesive wound tapes are applied over the closed skin.
36333|NCT03900065|Procedure|Preconditioning|Foam-mediated intermittent negative pressure will be applied to the skin of the planned flap for 5 days before surgery.
36334|NCT03900052|Device|Haptic cane|• A haptic biofeedback cane was designed and manufactured to measure the user applied axial cane load, compare the load to the targeted 20% BW threshold, and then deliver a vibrotactile feedback in the cane handle when the loading was greater than threshold. The cane data acquisition was temporally synchronized to the motion analysis system and recorded axial cane loads at 100 Hz for later analysis. The haptic biofeedback cane consisted of a conventional bariatric walking cane (Patterson Medical Ltd) with a loadcell (Digi-Key100 LBS. Load Cell) placed inside a 3D printed modular cane foot. A microcontroller (Sparkfun™ Pro Micro), SD disk storage (Sparkfun™ OpenLog), eccentric rotating mass vibration motor (model 306-109, Precision Microdrives Limited), USB communications port, and battery completed the system.
36335|NCT03900052|Device|typical cane|Typical training cane loading training
36336|NCT03900039|Device|Highly Cross Linked Polyethylene and oxidized zirconium femoral head|"Differing bearing surfaces:~Conventional polyethylene versus cobalt Chrome heads~Conventional polyethylene versus Oxidized Zirconium heads~Highly Cross-linked polyethylene versus Cobalt Chrome heads~Highly Cross-linked polyethylene versus Oxidized Zirconium heads"
36337|NCT03900026|Drug|Evolocumab|REPATHA (evolocumab) is a human immunoglobulin G2 (IgG2) monoclonal antibody that has high affinity binding to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); it will be administered via subcutaneous injection
36338|NCT03900026|Other|Placebo|Placebo cartridges will contain vehicle only; placebo will be administered via subcutaneous injection.
36339|NCT03900013|Procedure|Injectable platelet rich fibrin combined with DFDBA|The i-PRF will be mixed with bone graft then will be placed into the intraosseous defect
36340|NCT03900013|Procedure|Demineralized Freeze Dried Bone Allograft|Demineralized Freeze Dried Bone Allograft alone will be placed into the intraosseous defect
36341|NCT03900000|Other|Physiotherapy|Ambulatory leg-muscle oriented physiotherapy (2 x 45 minutes per week for at least 8 weeks) at Aachen University Hospital. Daily protocol of leg muscle training, exercises, sufficient fluid intake of 2liter/day, pressure stockings.
36342|NCT03899987|Drug|Aspirin|Given PO
36343|NCT03899987|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
36344|NCT03899987|Biological|Recombinant Interferon Alfa-2b|Given IV
36345|NCT03899987|Drug|Rintatolimod|Given IV
36346|NCT03899974|Other|Test meal|"Participants received in random order the three test meal (700Kcal, 80g available carbohydrates) containing breads prepared with amylose-rich wheat flours (70% or 85%) or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.~After 4 hours, all participants consumed a standard lunch (700 kcal, 100 g available carbohydrates) identical on all the three experimental days to evaluate the second meal effect from breakfast to lunch."
36347|NCT03899961|Drug|Oxytocin|Oxytocin 2.5 U i.v.
36348|NCT03899961|Drug|Carbetocin|Carbetocin 100 µg i.v.
36349|NCT03899948|Behavioral|Teacher Anxiety Program for Elementary Students|TAPES consists of three core components: 1) training in evidenced-based anxiety reduction strategies that teachers will implement to identify and assist specific anxious students and classroom-wide strategies helpful to all students, 2) evidenced-based material for teachers to review with parents regarding how to reduce student anxiety at home, thus improving school-home communication and shared goals and 3) training in how to conduct 5 brief (30 minute) teacher-parent-student meetings to teach and practice the TAPES anxiety-reduction strategies.
36350|NCT03899948|Behavioral|Teacher Anxiety Training|The TAT is a 3-hour professional development training for teachers. Training focuses on recognizing the signs and symptoms related to child anxiety and utilizing classroom-wide strategies to help reduce anxiety in the classroom.
36351|NCT03899935|Procedure|Laparoscopy|Laparoscopy for endometriosis
36352|NCT03899922|Drug|Drugs inducing uveitis|Drugs susceptible to induce uveitis
36353|NCT03899909|Drug|GLPG3121 SAD|GLPG3121 oral suspension, single ascending doses
36354|NCT03899909|Drug|Placebo SAD|Placebo oral suspension
36355|NCT03899909|Drug|GLPG3121 MAD|GLPG3121 oral suspension, multiple ascending doses, daily for 13 days
36356|NCT03899909|Drug|Placebo MAD|Placebo oral suspension, daily for 13 days
36357|NCT03899883|Drug|Pegloticase 8 MG/ML [Krystexxa]|One time dosing of pegloticase will be administered. Participants will receive an infusion of pegloticase over two hours in the outpatient clinical and translational research center (CTRC) at Children's Hospital Colorado, and will be monitored after infusion.
36415|NCT03899428|Drug|Sorafenib|Prescribed by physician.
36416|NCT03899428|Drug|Lenvatinib|Prescribed by physician.
36417|NCT03899428|Drug|Regorafenib|Prescribed by physician.
36418|NCT03899428|Drug|Cabozantinib|Prescribed by physician.
36461|NCT03899103|Drug|Mycophenolate Mofetil|Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards
36358|NCT03899870|Procedure|Rectal resection|Patients underwent anterior or low anterior resection. Patients with tumors in the lower third of the rectum where anal sphincters could not be preserved underwent abdominoperineal resection. In majority of the cases, inferior mesenteric artery (IMA) was ligated caudal to the origin of the left colic artery. For the tumors of the upper rectum, partial excision of the mesorectum was performed up to the minimum of 5 cm from the inferior aspect of the tumor. For the tumors of the middle and low rectum a total mesorectum excision was done with the minimum distal mucosal margin of 1 to 2 cm. Ileostomy was performed in cases where colon was poorly prepared, anastomotic leak test was positive or colonel anastomosis was made. In most of the cases, open surgery was performed. Laparoscopic surgery was performed in selected cases. Wide local excision was performed in selected cases with T1 tumors without locoregional lymphadenopathy.
36359|NCT03899870|Drug|Neoadjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered neoadjuvant therapy. In the neoadjuvant therapy, we used 45 Gy in 25 fractions with concurrent 5-fluorouracil [5-FU] and patients were operated 8 to 10 weeks after neoadjuvant therapy. In some cases, especially the elderly patients with multiple co-morbidities, we used short-course pelvic radiation therapy which included 25 Gy in 5 fractions over 1 week.
36360|NCT03899870|Drug|Adjuvant therapy|Patients with locally advanced disease (T3, T4) or lymph nodal positive disease were offered adjuvant therapy. In most of the cases, FOLFOX (leucovorin, 5-FU, oxaliplatin) regimen was used and for elderly patients who could not tolerated this regimen, we used oral capecitabine.
36361|NCT03899857|Drug|Pembrolizumab|Pembrolizumab will be added to standard of care
36362|NCT03899844|Other|Blood collection, PiB PET/MRI, and cognitive testing|Blood and imaging results will be analyzed for amyloid beta. Cognitive testing will be performed to determine clinical and cognitive status.
36363|NCT03899831|Behavioral|Function-Based Elopement Treatment (FBET)|"The Function-Based Elopement Treatment (FBET) includes 12 appointments over 16 weeks. FBET focuses on parent-training, with the parent implementing procedures with therapist support. The goals of FBET are:~to create a safer environment~teach adaptive skills to replace elopement~arrange the environment and rewards to reduce elopement~and teach caregivers how to respond if elopement occurs Psychoeducation is emphasized, including discussions of elopement as a learned behavior, reinforcement, functions of elopement, extinction, and descriptions of treatment components. The FBET manual includes scripted text, examples, caregiver completed activities, and checks for understanding."
36364|NCT03899831|Behavioral|Parent Education Program (PEP)|The Parent Education Program (PEP) will include 12 appointments over 16 weeks, focused on general education about autism spectrum disorder and resources about elopement prevention. PEP will be administered by a Board Certified Behavior Analyst (BCBA). Participants randomized to the PEP study arm can receive the FBET intervention after completing the 16 week study period.
36365|NCT03899818|Device|drug-eluting balloon|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES)
36366|NCT03899818|Device|drug-eluting stent|Patients will be randomized to drug-eluting balloon (DEB) or standard therapy with second generation drug-eluting stent (DES).
36367|NCT03899805|Drug|Eribulin|The ability of chemotherapy to kill cancer cells depends on its ability to halt cell division. Usually, the drugs work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die. The faster the cells are dividing, the more likely it is that chemotherapy will kill the cells, causing the tumor to shrink. They also induce cell suicide (self-death or apoptosis).
36368|NCT03899805|Drug|Pembrolizumab|The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells.
36369|NCT03899792|Drug|LOXO-292|Oral LOXO-292
36370|NCT03899779|Other|Face-to-face hypnotherapy|12 weeks treatment with face-to-face hypnotherapy (6 individual, bi-weekly sessions)
36371|NCT03899779|Other|Online hypnotherapy|12 weeks treatment with online hypnotherapy
36372|NCT03899779|Other|Online psychoeducation|12 weeks treatment with online psychoeducation
36373|NCT03899766|Other|Animal Assisted Intervention|Operators of AAI and their dog meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
36374|NCT03899766|Other|Clowns|Hospital clowns meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
36375|NCT03899766|Other|Musicians|Musicians meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
36376|NCT03899753|Device|2-Octyl Cyanoacrylate and Mesh|2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
36377|NCT03899753|Device|2-Octyl Cyanoacrylate|Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
36378|NCT03899740|Other|Brainstorming 1|Expert recommendation statements will be collected for peer evaluation.
36379|NCT03899740|Other|Ranking - Round 1|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
36380|NCT03899740|Other|Ranking - Round 2|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
36381|NCT03899740|Other|Ranking - Round 3|Each participant will rank each statement using a likert scale: strongly disagree -- disagree -- neutral -- agree -- strongly agree.
36382|NCT03899727|Device|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study
36419|NCT03899415|Biological|TCR redirected T cells|HBV antigen specific TCR redirected T cell Infusions. Subjects will receive 1x10^4 - 5x10^6 TCR redirected T cells by IV infusion.
36383|NCT03899714|Other|Cryotherapy|Crushed ice in a plastic bag will be used, as it is a widely accessible and financially convenient method of cryotherapy. One half of a kilogram of ice will be placed in a plastic bag. The plastic bags will be 17 cm wide and 22 cm long. The air will be squeezed out of the bag and it will be sealed. The bag will be wrapped in a wet towel and applied to the tested area. Every five bags of crushed ice will be kept in an insulated foam container containing one kilogram of dry ice. Dry ice has a temperature of negative 80 degrees Celsius, and is used to keep the bags of crushed ice in a frozen state till the participants are briefed and the testing began.
36384|NCT03899701|Procedure|PEC I and PEC II blocks|Participants will get a PEC I block with 10ml of 0.375% ropivacaine and a PEC II block with 20ml of 0.375% ropivacaine using ultrasound guidance.
36385|NCT03899688|Procedure|Maxillary sinus augmentation|Surgical technique for increasing the vertical bone height of the posterior maxilla an antrostomy of about 5 mm in height and 10 mm long will be prepared using a diamond insert mounted on a sonic-air surgical instrument. The Schneiderian membrane will be elevated and clinical measurements will be performed using an UNC 15 probe. The space obtained underneath the sinus mucosa will be filled with the xenograft and a resorbable collagen membrane will be placed to cover the antrostomy only at the randomly selected control sites.
36386|NCT03899675|Dietary Supplement|Placebo|On the first day of collection, the volunteers will not take placebo intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of placebo and will be advised to consume 1 hour before the procedure.
36387|NCT03899675|Other|Caffeine|On the first day of collection, the volunteers will not take caffeine intake, the data will be collected in a standardized way, respecting the times defined for the analysis of the cardiac activity. Then the collection will be continued. On the next day of evaluation, volunteers will receive a capsule containing 300 mg of caffeine and will be advised to consume 1 hour before the procedure.
36388|NCT03899662|Other|Cognitive Training|Cognitive training included memory, attention, velocity, intelligence
36389|NCT03899662|Other|Physical Training|Physical training included aerobic, strength, flexibility and balance.
36390|NCT03899649|Drug|SOC|Standard of Care treatment
36391|NCT03899649|Device|NanoKnife System|Irreversible Electroporation
36392|NCT03899636|Drug|Modified FOLFIRINOX Regimen|Chemotherapy regimen of leucovorin, fluorouracil, irinotecan, and oxaliplatin
36393|NCT03899636|Device|NanoKnife System|IRE using NanoKnife System
36394|NCT03899610|Drug|Neoadjuvant chemotherapy+Durvalumab+Tremelimumab|"Neoadjuvant treatment:~Standard chemotherapy + Durvalumab + Tremelimumab Durvalumab : 1500mg q3 weeks (total 3 dosing) Tremelimumab : 75mg q 3 weeks (total 3 dosing) Chemotherapy regimen: Paclitaxel 175 mg/m2 , Carboplatin AUC 5-6 q3 weeks (total 3 dosing)~Interval debulking surgery~Adjuvant treatment:~Standard chemotherapy + Durvalumab Durvalumab; 1120mg q3 weeks (total 12 dosing) Chemotherapy regimen: Paclitaxel 175mg/m2, carboplatin AUC 5-6 q 3weeks (total3 dosing)"
36395|NCT03899597|Drug|Oxytocin|The intervention group (ARTCON) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery oxytocin exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
36396|NCT03899597|Other|Normal saline|The control group (SA) will receive the standard assignment for the elective caesarean section, but at least one hour before surgery placebo exposure will be performed with cardiotocographic (CTG) monitoring and obstetrical supervision.
36397|NCT03899584|Drug|4-Aminopyridine|Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
36398|NCT03899584|Drug|Placebo oral capsule|The placebo arm will include a placebo of microcrystalline cellulose.
36399|NCT03899571|Drug|Oseltamivir Oral Capsule for 5 days post-exposure|Patients will receive oseltamivir for 5 days after last influenza exposure.
36400|NCT03899571|Drug|Oseltamivir Oral Capsule for 10 days post-exposure|Patients will receive oseltamivir for 10 days after last influenza exposure.
36401|NCT03899558|Device|Humidified nasal high-flow device|Humidified nasal high-flow device which delivers warmed, humidified air at flow rates of up to 60 litres per minute via a nasal cannula interface. Intended delivery at 30 L/min at 37 degrees Celsius, if tolerated.
36402|NCT03899545|Other|Serratus Plane Block|0.5 ml /kg Bupivacaine/lidocaine mixture will be injected onto the serratus muscle
36403|NCT03899545|Other|Serratus Plane Block plus Pectoral I Block|0.5 ml / kg %0.25 Bupivacaine/ %1 lidocaine mixture will be injected onto the serratus muscle and injected between the pectoralis minor/pectoralis major muscles.2/3 of the total drug will be applied for the serratus plane block and 1/3 of the total drug for the pectoral I block. If the total amount of the drug is less than 30 ml, it will be completed with isotonic saline to 30 ml.
36404|NCT03899532|Device|Remote Ischemic Conditioning|Standard manual blood pressure cuff
36405|NCT03899532|Other|No-Remote Ischemic Conditioning|No-Remote Ischemic Conditioning
36406|NCT03899506|Drug|Olanzapine|Patients receiving Olanzapine per the ED protocol
36407|NCT03899506|Drug|Midazolam|Patients receiving Midazolam per the ED protocol
36408|NCT03899493|Other|Observation|Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
36409|NCT03899480|Biological|Haploidentical Natural Killer (NK) Cells|infusion with N-803 activated NK cells
36410|NCT03899467|Drug|GT0918|anti-tumor activity
36411|NCT03899454|Drug|Garcinia-mangostana-L-rind and Solanum-Lycopersicum-Fructus mixture-extract|Administration of mixed extract of Garcinia mangostana 400mg and Solanum Lycopersicum Fructus 200mg (OKSI(R) POM TR 193324351)
36412|NCT03899454|Drug|Placebo Control|Placebo Control
36413|NCT03899441|Other|Video|Two short animated videos - one that reviews minimally-invasive surgery and sentinel lymph node mapping and biopsy for endometrial cancer treatment. This video as reviews possible complications. The second video reviews peri-operative instructions.
36414|NCT03899428|Drug|Durvalumab|Durvalumab 1500 mg IV (intravenous infusion)
36424|NCT03899389|Diagnostic Test|plasma samples collection|Trimethylamine N-oxide (TMAO) concentration will be determined in plasma samples
36425|NCT03899376|Radiation|Volumetric modulated arc therapy|VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk
36426|NCT03899376|Radiation|conventional radiotherapy|Radiotherapy focus on pelvis area
36427|NCT03899363|Procedure|custom thermoplastic orthosis|extended the DIP by a custom thermoplastic orthosis or the Kirschner wire through the joint
36428|NCT03899350|Other|No intervention|No intervention
36429|NCT03899337|Drug|Acalabrutinib|100mg capsule, PO, BD
36430|NCT03899337|Drug|Cyclophosphamide|750mg/m^2, IV bolus
36431|NCT03899337|Drug|Doxorubicin|50mg/m^2, IV bolus
36432|NCT03899337|Drug|Vincristine|1.4mg/m^2, IV infusion
36433|NCT03899337|Drug|Prednisolone|40mg/m^2, PO, OD
36434|NCT03899337|Drug|Rituximab|375mg/m^2, IV infusion
36435|NCT03899324|Drug|Bumetanide white, oblong, scored tablet|Bumetanide with a titration period
36436|NCT03899324|Drug|Placebo white, oblong, scored tablet|placebo intake identically to group 1
36437|NCT03899311|Other|protein-sparing modified fast diet|a PSMF diet follow the usual care format in the Center
36438|NCT03899298|Biological|Amniotic and Umbilical Cord Tissue Procedure|Amniotic and Umbilical Cord Cell Therapy with protocols dependent on the patient condition. Protocols include options for IV, Injection, Intranasal and/or Nebulizer.
36439|NCT03899285|Drug|Citalopram 20mg or 40 mg (phase 2)|For non-responders, a randomisation 1:1 was chosen. The group A will receive 40 mg and the group B will receive 20 mg once daily of citalopram for 14 days.
36440|NCT03899259|Drug|Baricitinib|Administered orally
36441|NCT03899259|Drug|Placebo|Administered orally
36442|NCT03899246|Drug|Eight Percent Topical Capsaicin|See arm description
36443|NCT03899233|Device|Fractional CO2 laser|Low power fractional CO2 laser with a power of 12 watts, spacing 800 micrometer (7.3% density), and dwell time 300 microsecond
36444|NCT03899233|Drug|Tranexamic acid intradermal microinjections|Tranexamic acid 500mg/5ml ampules
36445|NCT03899220|Behavioral|Project Matter|This intervention includes 5 face-to-face therapy sessions with a trained clinician plus a bidirectional text component that queries mood, substance use, and medication adherence. Both the intervention group and the enhanced treatment as usual (E-TAU) involve a one-session behavioral engagement in care intervention as well as substance use treatment counseling.
36446|NCT03899207|Other|training +acupressure|".Training+acupressure group; received training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. In addition to the training, acupressure was applied by the researcher twice a week and 24 times in total. Acupressure application was continued with the same frequency until the end of the study (24 times in total for 3 months). One month after the first home visit, reminder training for coping with premenstrual symptoms was given to the women"
36447|NCT03899207|Other|training|"Training Group; received the training for coping with PMS prepared under the guidance of HBM and The Booklet of Training for Coping with Premenstrual Symptoms including information about the training given. One month after the first home visit, reminder training was given to the women."
36448|NCT03899194|Dietary Supplement|fish oil capsules|fish oil capsules(1000mg，EPA 180mg；DHA 120mg)
36449|NCT03899194|Drug|escitalopram|escitalopram 10-20 mg/d
36450|NCT03899181|Device|Translumbosacral Neuromodulation Therapy (TNT)|A probe with 2 pairs of bipolar steel ring electrodes, will be placed in the rectum. At each site a mapping procedure is performed with single stimulus coil to assess the motor threshold intensity, defined as the minimum level of magnetic stimulation intensity required to achieve an anal and rectal MEP response of 10 microvolts and an anterior tibialis MEP of 20 microvolts with 50% of trials.The intensity for TNT at each site is capped at a maximum of 150% above this threshold to comply with safety guidelines. Thus, intensity of magnetic stimulations will be individualized. Bilateral lumbar stimulations (rTLMS) are administered at L2/L3 disc space, and sacral stimulations (rTSMS) at S2/S3 level. Next a 70 mm double air film self-cooling coil is positioned randomly over one of the 4 sites, held in place by a coil fixator and 300 or 450 stimulations are delivered. After a 5 min rest the cycle is repeated (Total =600-900/site).The coil is moved to the opposite side and it is repeated.
36451|NCT03899181|Other|Sham TNT Therapy|This is the sham TNT treatment as mentioned in the different ARMs using the fake coil with no magnetic stimulations.
36452|NCT03899168|Other|Social Tag Popularity|The relative size of treatment tags in a tag cloud was either larger for antidepressant treatments or psychotherapy treatments.
36453|NCT03899168|Other|Confidence in Prior Attitudes|Participants thought back of situations in which they were either confident or doubtful about their own knowledge. This should elicit a mindset where participants are more or less confident about their own prior attitudes.
36454|NCT03899168|Other|Source Credibility|The source credibility of the community that allegedly collected and labelled the blog posts was either high or low in terms of expertise. Either experts (high credibility) or first semester students (low credibility) did allegedly collect blog posts. This was indicated by banners on top of the navigation platform in the internet browser.
36455|NCT03899155|Drug|Nivolumab|Solution for IV Injection
36456|NCT03899142|Biological|a human hepatitis B immunoglobulin solution for injection for intramuscular administration|intramuscular administration
36457|NCT03899129|Procedure|simultaneous working length control using E-CONNECT S|E-CONNECT S (Eighteeth medical technology Co., Ltd, china) is an endomotor with integrated apex locator newly introduced in the market with continuous WL measuring function. It contains an optional module for rotary instrumentation, allowing the device to function as a low-speed handpiece, apex locator, or a combination of both. This motor has an attention-grabbing property that when an instrument reaches the predetermined working length, the motor automatically stops the instrumentation. Thus, it can be concluded that automatically stopping instrumentation when the instrument reaches the working length would decrease postoperative pain compared with manually controlling the working length by using stoppers during instrumentation (separate length determination and root canal preparation).
36458|NCT03899129|Procedure|separate length determination and root canal preparation using Root ZX apex locator.|Using manual control of the working length by using stoppers during instrumentation (separate length determination and root canal preparation) using Root ZX apex locator.
36462|NCT03899090|Behavioral|Float pool|Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
36463|NCT03899090|Behavioral|Float chair|Subject floats supine in a zero-gravity chair in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.
36464|NCT03899077|Drug|Apalutamide|Apalutamide 240mg daily for 6 months (i.e. 6 28-day cycles); oral use
36465|NCT03899077|Drug|Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial|Leuprorelin acetate 45mg for 6 months; subcutaneous use
36466|NCT03899077|Drug|Goserelin Acetate 10.8 MG Subcutaneous Implant|Goserelin acetate 10.8mg for 6 months; subcutaneous use
36467|NCT03899077|Drug|Triptorelin Pamoate|Triptorelin pamoate 22.5mg for 6 months; intramuscular use
36468|NCT03899077|Drug|Degarelix acetate|Degarelix acetate 80mg for 6 months; subcutaneous use
36469|NCT03899064|Drug|Application of MC2-01 Cream, irradiation|Repeated applications of MC2-01 Cream (CAL/BDP, 0.005%/0.064%), followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
36470|NCT03899064|Drug|Application of MC2-01 Cream|Repeated applications of MC2-01 Cream, CAL/BDP, 0.005%/0.064%, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
36471|NCT03899064|Drug|Applications of MC2-01 vehicle, irradiation|Repeated applications of MC2-01 cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
36472|NCT03899064|Drug|Applications ofh MC2-01 vehicle|Repeated applications of MC2-01 vehicle, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
36473|NCT03899064|Drug|Control, irradiation|No application but irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
36474|NCT03899064|Drug|Control|No application, no irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
36475|NCT03899051|Procedure|interdental papilla reconstructive surgery with PRF|Papilla reconstruction would be done with platelet rich fibrin
36476|NCT03899051|Procedure|interdental papilla reconstructive surgery with subepithelial connective tissue graft|Papilla reconstruction would be done with subepithelial connective tissue graft
36477|NCT03899038|Procedure|spinal anesthesia|Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
36478|NCT03899025|Radiation|CT|CT = computed tomography of the hand/wrist HRpQCT = high resolution peripheral quantitative CT scan of the hand/wrist
36479|NCT03899012|Procedure|Incisional Hernia Surgery|Verification of the accuracy in the collection of 21 selected variables in the Spanish EVEREG Incisional Hernia Surgery Registry
36480|NCT03898999|Other|Overall status|An assessment is made of the participants measuring both the joint range of the ankle and the balance and risk of falls.
36481|NCT03898986|Biological|Live attenuated influenza vaccine (LAIV4)|LAIV4 vaccine dosage is 0.2 mL. The vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose-divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
36482|NCT03898986|Biological|Inactivated Influenza Vaccine (IIV4)|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection.
36483|NCT03898973|Biological|Quadrivalent inactivated influenza vaccine (IIV)|Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
36484|NCT03898960|Device|Geometric Clot Extractor (GCE) Device|Geometric Clot Extractor (GCE) Device
36485|NCT03898947|Procedure|Diagnostic hysteroscopy and targeted endometrial biopsy|Diagnostic hysteroscopy and targeted endometrial biopsy
36486|NCT03898934|Drug|Vitamin D|receive 6000iu daily for 8 weeks
36487|NCT03898934|Drug|Placebo Oral Tablet|placebo for the same period
36488|NCT03898921|Radiation|stereotactic body radiotherapy (SBRT)|Radiotherapy dose is 36-54 Gy, irradiated in 3 times, every other day, completed within 1 week.
36489|NCT03898921|Procedure|Radiofrequency ablation (RFA)|RFA with a safe margin, RFA again if residual,no more than 3 times.
36490|NCT03898908|Drug|encorafenib|"Encorafenib 75mg and 50mg (capsules) for a 450mg daily for oral administration during 56 days and after local radiation treatment.~If no progression of disease progression (PD) is reported, treatment will continue until PD, unacceptable toxicity or death."
36491|NCT03898908|Drug|binimetinib|Binimetinib 15mg (tablets) for a 45mg/12 hours for oral administration during 56 days and after local radiation treatment.
36492|NCT03898908|Radiation|Whole brain radiation therapy|"The whole brain planning target volume (PTV) will receive 30 Gy in 10 fractions.~Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks."
36493|NCT03898908|Radiation|Radiosurgery/stereotactic radiosurgery|"Dose selection must be based on previously published Radiation Therapy Oncology Group (RTOG) data, with dose modification left up to the treating physician. The total dose will depend on the size of the metastatic lesion(s) and proximity to critical structures.~Suggested doses are as follow: 1 fraction x 15-25 Gy; 3 fractions x 9-11 Gy; 5 fractions x 6-7 Gy; or 6 fractions x 5-6 Gy.~For GTV > 20 mm hypofractionated stereotactic radiotherapy could be preferred. Treatment will be delivered once daily, alternate-day, 3 fractions per week."
36522|NCT03898635|Drug|Linezolid|To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.
36581|NCT03898193|Drug|Singulair|Singulair, 5 mg Chewable Tablets, marketed by Merck Sharp & Dohme B.V., the Netherlands
36582|NCT03898180|Biological|Pembrolizumab|IV infusion
36583|NCT03898180|Drug|Lenvatinib|oral capsule
36494|NCT03898895|Combination Product|Radiotherapy+anti-PD-1|The total radiation dose is over 40Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death, termination of the study or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
36495|NCT03898895|Drug|Gemcitabine+cisplatin|Cisplatin 25mg/m2 intravenously (day 1 and day 8) and then gemcitabine 1000mg/m2 intravenously (day 1 and day 8) every 3 weeks (1 cycle), for 8 cycles.
36496|NCT03898882|Drug|oxytocin|PK measurements of oxytocin
36497|NCT03898882|Device|Shore durometer|The investigators will take serial readings from a digital durometer at the uterine fundus at 3, 6, 9 and 12 minutes following OXT administration to provide data that will inform an estimate of the timing of peak effect. Shore durometers measure the hardness of materials on a scale of 0-100 Shore Units (SU). Preliminary (unpublished) data provided a range of 10-56 SU after oxytocin administration at cesarean delivery. Durometer readings were also shown to correlate positively with the obstetrician's manual assessment of uterine contractility, which is traditionally used to determine the success or failure of uterotonic therapy.
36498|NCT03898869|Diagnostic Test|Intraoperative NIRS monitoring|Near infrared spectroscopy non invasively used to register changes in tissue oxygen amount during endovascular revascularization
36499|NCT03898856|Drug|Crofelemer|125 mg tablets taken by mouth twice daily for 28 days
36500|NCT03898856|Diagnostic Test|Diagnostic tests for cause of chronic diarrhea|Diagnostic tests include: Esophagogastroduodenoscopy, Colonoscopy, biopsies of the upper gastrointestinal tract (duodenum) and lower gastrointestinal tract (colon), genetic testing for Congenital sucrase-isomaltase deficiency (CSID),Prometheus IBcause Chronic Diarrhea panel, Thyroid Panel, Stool osmolality, Stool Ova and Parasites, Stool Culture, Stool Qualitative Stool Fat, Stool Reducing Substances, Laxative Screening, Lactulose Hydrogen Breath Test, Gastrin Level, Calcitonin Level, Vasoactive Intestinal Polypeptide(VIP) level.
36501|NCT03898843|Other|Animal assisted therapy|Patients of AAT group will leave their hospital bedroom to go in the session room, where they will meet a dog, who has come with his veterinary student master. Animal assisted therapy session will last at most 20 minutes, in which the patient is going to interact with the dog, pet him, play with him, etc.
36502|NCT03898843|Biological|Nasal swab sampling|All patients will have nasal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
36503|NCT03898843|Behavioral|STAI-Y and POMS Questionnaires|Before and after AAT or sham session, patients will answer State-Trait Anxiety Inventory Y (STAI-Y), Profile of Mood States (POMS) questionnaires.
36504|NCT03898843|Procedure|physiological parameters measure|Before and after AAT or sham session, blood pressure, heart rate dans respiratory rate will be measured.
36505|NCT03898843|Other|Visual Analog Scale (VAS)|Before and after AAT or sham session, pain will be evaluated thanks to VAS
36506|NCT03898843|Behavioral|Impact of Event Scale - Revised (IES-R)|Patients will answer IES-R questionnaire 3 months after AAT or sham session
36507|NCT03898843|Behavioral|satisfaction questionnaire|Patients of the AAT group will answer satisfaction questionnaire at the end of the AAT session and 3 months after AAT
36508|NCT03898843|Biological|Rectal swab sampling|All patients will have rectal swab sampling at inclusion and 7 days after AAT session or sham session in order to screen multidrug resistant bacteria
36509|NCT03898817|Other|taking of cutaneous cells|Taking of cutaneous cells by biopsy Sample of blood
36510|NCT03898804|Device|BCI and FES|The intervention consists of surgical implantation of the device components, BCI and FES that will interface with computers that process and decode neural information, compute stimulation parameters, and control communication between the device components. The device will be tested during research sessions spanning a 13-month period.
36511|NCT03898791|Drug|LY3295668 Erbumine|oral capsules
36512|NCT03898765|Diagnostic Test|Dry blood spot screening|Dry blood spot measurement of biomarker for screening biliary atresia
36513|NCT03898752|Dietary Supplement|Omega 3|Omega 3: 1g daily for 3 months CoQ10: 100 mg daily for 3 months Multivitamin: 1 normal multivitamin tablet daily for 3 months
36514|NCT03898739|Other|Cervical Traction from different angles|Intermittent traction will be applied, maximum force will be 16 kg, minimum force will be 12 kg, traction cycle of each minute consists of 20 seconds static traction at the maximum force then released down to the minimum force for 20 seconds then repeated for 20 seconds static traction. Traction session time will be 15 minutes, and the traction force will be increased progressively with speed (50%) of increment of force
36515|NCT03898726|Biological|laparoscopical l cuff closure|closure of vaginal cuff following hysterectomy
36516|NCT03898713|Diagnostic Test|Intelligence quotient|intelligence quotient (IQ) is a total score derived from several standardized tests designed to assess human intelligence
36517|NCT03898700|Behavioral|strength based coaching|strength based and solution focused coaching
36518|NCT03898687|Device|SLN Biopsy with Magtrace®/Sentimag®|Identification of SLN by means of Magtrace®/Sentimag® and SPIO-MRI
36519|NCT03898674|Drug|Intra venous fluid|Volume of intra venous fluid administered during GDT protocol
36520|NCT03898661|Drug|Collagenase histiolyticum|local injection of collagenase histiolyticum into the esophageal stricture, 1 day before balloon dilation
36521|NCT03898648|Other|Waiting room task|"The waiting room task consists in a computerized neuropsychological task in which the participant is asked to freely choose a chair to sit in a waiting room. In a row of four chairs, the two in the middle are occupied by two males or females. One of the two subjects sitting either has a neutral face, or express a negative emotion (fear or anger).~To make their decision, participants must press the S keyboard button to go left or the L keyboard button to go right in a time limit of 1500 milliseconds.~One third of the time, the cursor moves in the opposite direction to that requested by the participant. For example, if the subject presses S, the cursor moves to the right instead of to the left.~Those reverse trials are used to evaluate their motivation to correct the movement of the cursor.~The participant will repeat the task 360 times for the assessment to be completed."
36523|NCT03898622|Drug|Levothyroxine|levothyroxine with a safe dose for our population with high cardiovascular risk of 0.25mcg so that the patient's weight range between 50-80kg maintains a dosage of 0.3-0.5mcg / kg / day that does not affect the thyroid axis) fasting levothyroxine (in the case of taking a drug that interacts with absorption, use of it is changed according to the specified hours, see Table 2), and adjusted according to TSH levels > 1 and normal T4L
36524|NCT03898609|Other|Dietary intervention|3 weeks
36525|NCT03898596|Diagnostic Test|ECG|An ECG collects superficial readings of heart activity
36526|NCT03898583|Drug|Microarray patch A|Microarray patch
36527|NCT03898583|Drug|Microarray patch B|Microarray patch
36528|NCT03898583|Drug|Placebo|Microarray patch vehicle
36529|NCT03898583|Drug|Daivobet|Daivobet Gel
36530|NCT03898570|Behavioral|Patient reported outcomes|"Patients will download the research app onto their phone and enter pertinent medical history and surgical history data similar to standard registries for specific procedures. Over the next 12 months the investigators will obtain patient-reported outcomes (PROs) using the patient's phone.~Specifically, the investigators will obtain daily activity data, weekly 6-minute-walk tests, and quarterly quality of life surveys"
36531|NCT03898557|Behavioral|Provision of HIV self-test with Commitment and planning prompts|The interventions will use behavioral interventions such as commitment and planning prompts to increase the update of HIV self-testing
36532|NCT03898557|Behavioral|Provision of HIV self-test|This arm will receive a HIV self-test
36533|NCT03898544|Device|Group primary TKA|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors (IR) on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
36534|NCT03898544|Device|Group TKA revision|"Assessment by gait kinematics analysis The total knee arthroplasty will be performed as usual with the dedicated instrumentation.~The gait kinematics analysis will be performed with the KneeKG system on a treadmill, with infrared sensors on the leg. This system is not invasive. The IR sensors are positioned on the pelvis, the distal femur and the tibial crest. This system records the flexion/extension, the varus/valgus and the rotation during the walking (1 minute of walking)."
36535|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, simple mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a simple mobility The aim is to define the types of particles that cause the most tissue inflammation"
36536|NCT03898531|Procedure|hip prosthesis removed metal / polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
36537|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, simple mobility|"Patients are hospitalized in order to change for their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a simple mobility.~The aim is to define the types of particles that cause the most tissue inflammation"
36538|NCT03898531|Procedure|hip prosthesis removed ceramic/ polyethylene, double mobility|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/polyethylene. It's a double mobility.~The aim is to define the types of particles that cause the most tissue inflammation."
36539|NCT03898531|Procedure|Primary implanted hip prosthesis|"Patients are hospitalized in order to have a first hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The patients will be received a first prosthesis."
36540|NCT03898531|Procedure|hip prosthesis removed metal/metal|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by metal/metal. The aim is to define the types of particles that cause the most tissue inflammation"
36541|NCT03898531|Procedure|hip prosthesis removed ceramic/ceramic|"Patients are hospitalized in order to change their hip prosthesis at the hospital la Croix-Rousse in Lyon.~Patients have to complete before the surgery a survey on occupational and environmental exposures to mineral dust.~The prosthesis removed is composed by ceramic/ceramic. The aim is to define the types of particles that cause the most tissue inflammation"
36542|NCT03898518|Other|12-week jump rope exercise program|Each jump rope exercise session of the program was performed for 50 minute, with a 5 minute warm-up and cool-down. Sessions were performed once a day, 5 days a week, for 12 weeks. The program consisted of various main jump rope exercises (1 line 2 jump, jumping feet together, running jumping, open side jump, open back and forth jump, rock paper scissor jump). The warm-up and cool-down consisted of static stretching, walking, and jogging. Intensity of exercise was gradually increased form 40-50% heart rate reserve (HRR) in weeks 1-4 and 60-70% HRR in weeks 9-12. Each training session was supervised by the researchers. Ever subject wore a heart rate monitor during the whole training session in order to maintain the designated training intensity.
36543|NCT03898505|Dietary Supplement|AvoMax (Low Dose)|AvoMax (Low Dose) is a natural spray-dried avocado powder, which contains 50 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
36544|NCT03898505|Dietary Supplement|AvoMax (High Dose)|AvoMax (High Dose) is a natural spray-dried avocado powder, which contains a total of 200 mg of a combination of bioactive polyhydroxylated fatty alcohols (PFAs), avocadyne and avocadene.
36579|NCT03898206|Other|Prolonged sitting|See Prolonged sitting arm description
36580|NCT03898193|Drug|Montelukast|Montelukast, 5 mg Chewable Tablets, manufactured by Pharmtechnology LLC, Republic of Belarus
36545|NCT03898505|Other|Placebo|Placebo product is powder containing only non-medicinal ingredients used in the test product: Oryza sativa (rice) bran extract (65-70% w/w of total placebo formulation), sodium bicarbonate, rosemary extract, xylitol, silicon dioxide, microcrystalline cellulose, rice hull powder, strawberry flavour.
36546|NCT03898492|Other|Physical training|Training two times/week for an hour each time in 8 weeks. The training included strength training, aerobic training, balance training and flexibility training. The training was modified to the participants and initiated by the staff at the center.
36547|NCT03898479|Drug|CTP-543|Once or twice daily dosing
36548|NCT03898466|Drug|Fluticasone furoate|Inhaled corticosteroid
36549|NCT03898466|Other|Matching placebo|Placebo inhaler
36550|NCT03898453|Behavioral|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient stabilisation Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care and questionnaires Follow-up 8 (three month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)
36551|NCT03898453|Behavioral|support psychotherapy|"Visit 0 : patient inclusion (questionnaires and interview) Visits 1-7: several methods could be used: psychoeducation about cancer and psychotherapy, positive interaction and activity schedule, emotional support , relaxation, prevention techniques… Questionnaires will be completed by patients at visit 5 and 7.~Follow-up 8 (one month after) : data recovery (questionnaires) Follow-up 9 (six month after) : data recovery (questionnaires)"
36552|NCT03898427|Device|Wrist Actigraphy Devices|A watch-like wearable sensor
36553|NCT03898427|Device|Polysomnography|Sleep Monitor
36554|NCT03898427|Device|Videography|Thermal Camera
36555|NCT03898401|Combination Product|Platelet rich plasma|After isolation of the PRP, calcium chloride (0.5ml) was added to the 5 ml of PRP isolate to activate the thrombin cascade, thereby causing degranulation of platelets, releasing growth factors and cytokines, and starting the transformation of the PRP to platelet rich fibrin matrix (PRFM) Before the PRFM became too gelatinous for passing through a needle (less than 10 minutes), two injections will be given through a 27-gauge needle in the posterior vaginal wall and perform clinical evaluations at 0, 1, 3, and 6 months.
36556|NCT03898388|Procedure|Bone Marrow Concentrate treatment|Correlate patient outcomes 6 months after receiving the Regenexx SD treatment with measurements of synovial fluid collected before treatment
36557|NCT03898375|Other|Walking with different optic flow speeds|Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
36558|NCT03898362|Other|pneumatically powered wheelchair or scooter|a wheelchair or scooter powered by compressed air will be used for 6 months. Compressed air is a novel power source and no batteries are used in these devices.
36559|NCT03898362|Device|battery powered wheelchair or scooter|a wheelchair or scooter powered by a battery will be used for 6 months. These are conventional mobility devices that the participants are using or in the process of obtaining
36560|NCT03898349|Other|Annie text messaging system|Annie text messaging system for patient self-management of HCV treatment including medication, lab, and appointment reminders, and motivational messages.
36561|NCT03898349|Other|Annie text messaging system with Usual implementation|"Three comparison sites received usual implementation of the automated text messaging system Annie only, which involves an orientation/training meeting and the option of attending twice-monthly Annie clinical adoption calls"
36562|NCT03898349|Other|Annie text messaging system with Augmented implementation|"Four facilities received the automated text messaging system Annie and our augmented implementation strategy. These facilities had regular facilitation calls, a site visit to assist with implementation, and were given the toolkit, in addition to receiving usual implementation assistance"
36563|NCT03898336|Other|broad-spectrum micronutrient|daily intake of capsules containing a blend of Vitamin B3 (NADH), Vitamin B6 (pyridoxal-5-phosphate), folic acid (5-MTHF), Vitamin B12 (methylcobalamin), Vitamin D3 (25-hydroxyvitamin D3), Magnesium (magnesium oxide), Zinc (zinc methionine), Iron (ferric phosphate), Selenium (selenomethionine), Phospholipids, L-carnitine (L-carnitine-L-tartrate)
36564|NCT03898336|Other|placebo|daily intake of capsules
36565|NCT03898323|Device|Alcohol Approach Bias Modification (active)|Computerized training - Active intervention
36566|NCT03898323|Device|Alcohol Approach Bias Modification (sham)|Computerized training - Sham intervention
36567|NCT03898310|Dietary Supplement|Cranberry extract capsules|Participants in the treatment arm will receive cranberry extract capsules.
36568|NCT03898310|Dietary Supplement|Placebo capsule|Participants in the placebo arm will receive placebo capsules.
36569|NCT03898297|Radiation|[18F]FPEB|Radiotracer: [18F]FPEB
36570|NCT03898297|Radiation|[11C]APP311|Radiotracer: [11C]APP311, [11C]UCB-J
36571|NCT03898284|Diagnostic Test|Impulse Oscillometry|Impulse Oscillometry will be performed in addition to usual care
36572|NCT03898271|Other|Virtual World|Participants will complete a synchronous PTSD training in an immersive virtual world environment.
36573|NCT03898258|Other|Qualiveen full version|Qualiveen full version questionnaire with 40 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
36574|NCT03898258|Other|Qualiveen short-form|Qualiveen short-form questionnaire with 8 questions for assessing the quality of life in relation to bladder dysfunction in persons with neurogenic bladder
36575|NCT03898245|Device|apply tDCS|Intensity 2mA, 20minues, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
36576|NCT03898245|Device|Sham tDCS|Intensity 0mA, 40 seconds, 4 times (post operation in 30min, in 4hrs, next day morning and next day afternoon) anodal tDCS applied over the left DLPFC cathodal tDCS applied over the right DLPFC
36577|NCT03898232|Radiation|Computed Tomography (CT) Scan of the Lumbar Spine|Patients in the cohort who have not received a 12 month post-op CT scan will be asked to enroll in the study and undergo a CT of the lumbar spine.
36578|NCT03898206|Other|Breaking up sitting with walking breaks|See Breaking up sitting with walking breaks arm description
36585|NCT03898167|Behavioral|Telephone Recall|Participants receive a scripted telephone recall from a trained patient navigator.
36586|NCT03898167|Behavioral|Mailed HPV Self-Sampling Kit|Participants receive a mailed kit that allows them to self-collect a cervical sample in their home and return it to a laboratory for human papillomavirus (HPV) testing.
36587|NCT03898167|Behavioral|Patient Navigation|Participant receives telephone call from patient navigator within 3-5 days of receipt of self-collection kit. Patient navigator provides one-on-one education on cervical cancer screening and self-collection of cervical sample.
36588|NCT03898154|Drug|Dexamethasone|Intraoperative: Single intraoperative dose of 10 mg intravenous dexamethasone
36589|NCT03898154|Drug|Methylprednisolone|Postoperative: A 6-day oral methylprednisolone (oral GC) taper course. The oral GC taper course begins on the day of surgery and includes 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day 6
36590|NCT03898141|Other|Placebo (PL)|"Participants will get deceptive and receive an inert cream (=placebo intervention) that reduces pain."
36591|NCT03898141|Other|Dog only (DO)|In the dog intervention a dog will be present during the second measurements. However, participants will only learn the true aims of the presence of the dog after the study (delayed informed consent).
36592|NCT03898141|Other|Animal-assisted placebo (AAPL)|Participants receive the placebo intervention in the presence of a dog.
36593|NCT03898128|Drug|Anti-CD22 Immunotoxin|Clinical data (treatment, survival, adverse events) of patients treated with anti-CD22 immunoconjugates from 2014 will be collected
36594|NCT03898115|Behavioral|CHG Education|"The CHG educational intervention will include educational outreach and audit and feedback implementation strategies"
36595|NCT03898102|Drug|Regorafenib|regorafenib plus zinc gluconate
36596|NCT03898102|Dietary Supplement|Zinc gluconate supplement|Zinc gluconate supplement
36597|NCT03898089|Other|Core Stability Exercise|The participants in the core stability exercise group will be included in a treatment program for 3 days per week for 6 weeks. Traditional physiotherapy methods will be applied to all participants. Traditional physiotherapy will include heat modality (a hot pack for 15 minutes), electrotherapy (transcutaneous electrical nerve stimulation (TENS), a 50 Hz conventional TENS with a pulse duration <150 microseconds).Each training session will be lasted 60 min, starting with a 10-min warm up program mainly consisting of core strength exercises and ending with a 5-min cool-down program (stretching). Progression of exercises will be tailored to individual patients' ability, fatigue and pain. Exercises will be designed from 1 set to 3 sets, from 8 to 15 repetitions and contractions from 5 seconds to 10 seconds.
36598|NCT03898089|Other|Core Stability Exercise plus Myofascial Release Technique Group|In addition to the core stabilization exercise group myofascial relaxation technique will be performed with roller massager (Theraband®, The Hygenic Corporation, Akron, OH.) for 3 days per week for 6 weeks. The myofascial relaxation technique will be performed along the superficial back line (plantar fascia gastrocnemius muscles, hamstring muscles, sacrolumbar fascia, erector spinae muscles) bilaterally. Myofascial relaxation will be done to the anatomical structures indicated by roller massage technique. Applications will be made in 3 sets of 30sec for each zone (1 min rest between sets) and 7/10 according to VAS.
36599|NCT03898076|Device|Flash Glucose Monitoring|Continuous Glucose Monitoring (CGM) values will be downloaded from CGM device for a period of 90 days.
36600|NCT03898076|Other|A1c|A1c levels will be collected from Hospital EMR prior to CGM data downoad
36601|NCT03898076|Other|Predictive A1c|Predictive A1c will be calculated based on the first 15 days of CGM data using time in range (TIR), coefficient of variation (CV), mean amplitude of glycemic excursion (MAGE), mean of daily differences (MODD), continuous overall net glycemic action (CONGA). Predictive A1c will be correlated with actual A1c.
36602|NCT03898063|Behavioral|90 DAYS film|the intervention conditions include exposure to a film, 90 DAYS (approx 20 minutes long), an entertainment film detailing a woman's decision to tell her romantic partner that she is HIV-positive.
36603|NCT03898063|Behavioral|Film epilogue|a 90-second epilogue developed by the research team making tangible connections between the film and one's own potential HIV status disclosure. Highlights safe strategies for disclosure.
36604|NCT03898063|Behavioral|HIV pamphlet on disclosure|A standard-of-care brochure given to newly diagnosed HIV patients about the importance of status disclosure
36605|NCT03898050|Procedure|transcutaneous cardiac pacing|transcutaneous cardiac pacing
36606|NCT03898037|Behavioral|weight loss intervention|weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.
36607|NCT03898037|Drug|metformin intervention|metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.
36608|NCT03898024|Drug|SHR-1222|Pharmaceutical form: water injection; Route of administration: subcutaneous
36609|NCT03898024|Drug|Placebo|Pharmaceutical form: water injection; Route of administration: subcutaneous
36610|NCT03898011|Drug|Lamotrigine|Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
36611|NCT03898011|Drug|Lamictal|Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
36612|NCT03897998|Drug|Naloxone|"Intravenous Naloxone will be administered based on the participant's weight, with 0.15 mg/kg given as an initial bolus plus 0.2 mg/kg/hr during the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
36613|NCT03897998|Other|Saline|"Intravenous Normal Saline (0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment."
36614|NCT03897985|Device|Narcotrend TM|Measurement of anesthesia depth
36617|NCT03897959|Device|Kohli vs Foley catheter|Alternative suprapubic catheter used for bladder drainage.
36618|NCT03897946|Biological|Birth dose hepatitis B vaccine|Groups A and C will receive a birth dose of hepatitis B vaccine within 24 hours of life.
36619|NCT03897933|Procedure|Erector Spinae Plane block ( Group I)|ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
36620|NCT03897933|Procedure|Control Group (GROUP II)|Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
36621|NCT03897920|Other|Doppler ultrasound assessment of renal arteria resistive index|A high frequency probe will be used together with the use of color or power Doppler to help vessel localization. As resistance to blood flow progressively increases from the hilar arteries toward the more peripheral parenchymal vessels, renal arteria resistive index (RRI) will be done at the level of the arcuate or interlobar arteries, adjacent to medullary pyramids. Measurements will be repeated in different parts of both organs (superior, median, and lower) when at least three reproducible waveforms have been obtained. An RRI will be calculated with the following formula: (peak systolic velocity - end diastolic velocity)/peak systolic velocity, and the mean value of three measurements at each kidney is usually considered. An RRI value 0.60 ± 0.01 (mean ± SD) is usually taken as normal with a value of 0.70 being considered the upper normal threshold
36622|NCT03897907|Other|Psychologically Informed Education Video|"The education session will teach participants how the body processes nociception and experiences pain, and pain does not mean tissues are being damaged. Additionally we will use the framework called the Common Sense Model of Self-Regulation which advocates for education to address five cognitive dimensions: (1) identity (the effort to evaluate symptoms and label the illness); (2) cause (the subjectively formulated belief of what is causing the symptoms); (3) time-line (the patient's perception of how long the problem will last); (4) consequences (the patient's predictions of how the illness will affect them in different areas of their life); and (5) controllability (the patient's belief regarding their outcome and personal ability to change it)"
36623|NCT03897907|Other|Anatomy Education Video|Participants in the control education group will watch a video on the iPad equal in length to the psychologically informed education video. The control video will discuss basic anatomy of the knee and provide no psychosocial education or positive reinforcement about their condition.
36624|NCT03897894|Behavioral|Child Friendly Space|Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
36625|NCT03897881|Biological|mRNA-4157|Personalized cancer vaccine
36626|NCT03897881|Biological|Pembrolizumab|Intravenous infusion
36627|NCT03897868|Drug|HCP1803|HCP1803
36628|NCT03897868|Drug|Amlodipine|Amlodipine
36629|NCT03897868|Drug|Losartan|Losartan
36630|NCT03897868|Drug|Placebo|Placebo
36631|NCT03897855|Other|Post Traumatic Stress Disorder|"The test Think / No-Think"
36632|NCT03897842|Device|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
36633|NCT03897803|Diagnostic Test|strain elastography|strain elastography as apart of muscle ultrasound examination of the biceps brachii, forearm flexor, rectus femoris and tibialis anterior muscles will be performed to the patients and control groups at baseline evaluation and after 6 months follow up in the patients groups only.
36634|NCT03897790|Other|Transcranial Doppler (DTC)|Evaluation of Vasoconstrictor Vasoreactivity with Transcranial Doppler
36635|NCT03897777|Behavioral|Exercise Training effect on Hypertension and Gut Dysbiosis|the proposed research will: 1) Characterize gut microbial community structure in AA with hypertension in two important compartments that make up the overall gut bacteria in the colon (fecal and colon mucosa); 2) Quantify the relationship between aerobic exercise training and gut bacteria to identify SCFA microbes that adapt to exercise and benefit BP.
36636|NCT03897764|Procedure|Intraoperative superior hypogastric plexus block|SHP is situated anterior to L5-S1 vertebral bodies, caudal to the bifurcation of the aorta. An injection of 20 ml of bupivacaine 2,5 mg/ml or saline 9 mg/ml was done retroperitoneally in the area.
36637|NCT03897738|Dietary Supplement|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
36638|NCT03897738|Dietary Supplement|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
36639|NCT03897738|Dietary Supplement|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
36640|NCT03897725|Other|Telehealth Coaching|Telehealth coaching to promote adherence
36641|NCT03897699|Device|Transcranial Direct Current Stimulation|A non-invasive neuromodulation technique that can modulate neural activity. Weak electrical current (~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively.
36642|NCT03897699|Behavioral|Mindful Breathing|MBT is a mindfulness-based intervention that guides participants to pay attention to the present experience. Participants will be trained to become aware of mind-wandering, disengage, and shift attention back to the present experience. Participants will practice mindful breathing using a computerized application that they will be able to access on the web.
36643|NCT03897699|Other|Sham|Weak electrical current (~2mA) is applied to the scalp using anodal and cathodal electrode sponges, which increase or decrease cortical excitability respectively. Sham stimulation will serve as a control condition with current applied only for the first and last 30 seconds of the 20-minute session.
36644|NCT03897686|Device|"hydrous biopolymer with silver ions Argiform"|4.0 ml for one injection with one-week interval between injections. Course - 2 injections.
36645|NCT03897686|Device|saline solution|4.0 ml for one injection with one-week interval between injections. Course - 2 injections.
36646|NCT03897673|Dietary Supplement|Early Iron|iron syrup for the first three months (84 days) and placebo syrup for the fourth month
36647|NCT03897673|Dietary Supplement|Delayed Iron|placebo syrup for the first month (28 days) and iron syrup for the second, third, and fourth months
36732|NCT03896919|Diagnostic Test|HLA-DQ by luminex technology in kidney transplantation|HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample
36648|NCT03897660|Dietary Supplement|Omega-3 + vitamin K2 (TG form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
36649|NCT03897660|Dietary Supplement|Omega-3 + vitamin K2 (EE form of omega-3)|"The intervention is a randomized double bond cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. A questionnaire will document the side effects felt by participants during the omega-3 supplement taking day."
36650|NCT03897660|Dietary Supplement|Omega-3 + vitamin K2 [MaxSimil (MAG form of omega-3)]|"The intervention is a randomized double blind cross over design testing the pharmacokinetics of a monoglyceride formulation compared to a triglyceride and an ethyl ester form.~Treatments are randomly assigned on days 0, 7 and 14 of the clinical study. Blood samples will be collected at time 0, 1, 2, 4, 5, 6, 8, 9, 10, 12 and 24 hours. Each participant will perform all three treatments, with a minimum of 6 days between treatments. At each blood draw time points, a questionnaire will be administered to the particpant to monitor if they experiencec side effects with the dietary supplement they ingested in the morning."
36651|NCT03897647|Device|General Electric (GE) VScan|This is a small, point-of-care, hand-held device used for ultrasound (POCUS). It uses sound waves to generate images without using any radiation.
36652|NCT03897634|Device|Remote Microphone|Experienced hearing aid users will be trained on and use a remote microphone for 30 days. Pre- and Post- measures will be taken to determine benefit. Participant characteristics will also be assessed (such as self-efficacy) to explore personality factors that may contribute to benefit from devices.
36653|NCT03897621|Drug|Tranexamic Acid|tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
36654|NCT03897621|Drug|Placebo|Patients in the placebo group will receive normal saline (a bolus of sodium chloride 0.9%, 0.1 mL/kg or maximal dose of 10 mL).
36655|NCT03897608|Behavioral|short form 36|"The Short Form (SF)-36 Health Survey was used to measure HRQL. The SF-36 generates a profile of HRQL outcomes by measuring health across eight different dimensions: physical functioning, role limitation because of physical health, social functioning, vitality, bodily pain, mental health, role limitation because of emotional problems and general health. Responses to each question within a dimension are combined to generate a score from 0to100; where100 indicates good health"
36656|NCT03897595|Device|Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head|Hip replacement using Medacts's Mpact cup
36657|NCT03897569|Other|frontal projection angle, ankle dorsiflexion|Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
36658|NCT03897556|Dietary Supplement|Guarana herb|The intervention is a functional food bar produced in a licensed commercial kitchen that contains guarana powder as well as dates, raisins, oats, spirulina, walnuts, flour, coconut butter, soybean oil, xanthan gum and chocolate chips.
36659|NCT03897556|Other|Usual Care|Participant will receive 'usual-care' for cancer survivors. At the end of the study, after completing the Final Visit, they will receive 21 guarana energy bars to thank them for being in the study.
36660|NCT03897543|Drug|ABX196|ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).
36661|NCT03897530|Behavioral|Smoking Cessation Intervention|View and purchase hypothetical tobacco products during four distinctly different ETM
36662|NCT03897530|Other|Functional Assessment|Visual attention is evaluated via eye-tracking equipment
36663|NCT03897530|Other|Questionnaire Administration|Ancillary studies
36664|NCT03897517|Dietary Supplement|Proprietary Botanical Blend|Oral administration of capsules containing proprietary botanical blend 30 minutes prior to carbohydrate ingestion.
36665|NCT03897517|Dietary Supplement|Placebo|Oral administration of capsules containing rice flour (placebo) 30 minutes prior to carbohydrate ingestion.
36666|NCT03897504|Procedure|feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap|the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
36667|NCT03897491|Drug|5-aminolevulinic acid|5-aminolevulinic acid powder for oral solution
36668|NCT03897478|Diagnostic Test|ISCDX blood test|"The ISCDX test is based on gene expression changes that occur as a result of the ischemic stroke. When the stroke occurs, the immune system in the body reacts and causes changes in gene expression in several types of cells, including white blood cells, related to activation of innate and adaptive immune systems.~The ISCDX test distinguishes between cardioembolic and large artery atherosclerotic origin of stroke using a gene signature. The pattern or signature of up or down regulation for all genes for a patient determines whether the patient's pattern of gene expression is more like the pattern seen in other cardioembolic patients or more like the pattern seen in patients with large artery atherosclerotic cause of stroke."
36669|NCT03897465|Device|Lomatuell Pro|Patients will receive Lomatuell Pro dressings during 3 weeks. Lomatuell Pro® may be left in place up to 7 days; additional dressing changes can be performed as often as necessary according to the instruction for use.
36670|NCT03897465|Device|UrgoTul|Patients will receive UrgoTul dressings during 3 weeks. UrgoTul® may be left in place up to 7 days; ; additional dressing changes can be performed as often as necessary according to the instruction for use.
36671|NCT03897452|Drug|Fentanyl (5 microgram/ml) prediluted ampoules|"Bolus; Fentanyl (5 microgram/ml) 0,5 microgram/kg (0.1 ml/kg) is administered over 1 min starting 3-5 min before the lighter skin breaking procedure.~Fentanyl (5 microgram/ml) 2 microgram/kg is administered over 10 min before the start of the more painful procedur ( pleura drainage or tracheal intubation)."
36672|NCT03897439|Drug|Nicotine patch|Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
36673|NCT03897439|Drug|Varenicline Tartrate|VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
36674|NCT03897439|Drug|Bupropion|BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
36675|NCT03897426|Behavioral|Mediterranean Diet - Remote Coaching using a Mobile App|Patients randomized to the intervention arm will be then given an instruction booklet on using Mobile App, directed to a website for additional instruction on its use, and have the app set up to establish connectivity to the RD.
36676|NCT03897413|Drug|S-888711|Administered orally as three 0.25 mg tablets
36677|NCT03897413|Dietary Supplement|Calcium Antacid|Calcium carbonate 4000 mg chewable tablets
36678|NCT03897400|Other|AMH levels in young women with crohn's disease will be considered.|Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
36679|NCT03897374|Diagnostic Test|Genetic Testing|Buccal swab
36680|NCT03897361|Genetic|CTNS-RD-04|Peripheral blood autologous CD34+ enriched cell fraction transduced with lentiviral vector, pCCL-CTNS, that contains the human CTNS complementary deoxyribonucleic acid (cDNA) sequence.
36681|NCT03897348|Drug|Lacosamide|Oral medication
36682|NCT03897348|Drug|Placebo|Oral medication
36683|NCT03897335|Drug|Aminophylline|Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
36684|NCT03897335|Drug|Placebos|The placebo group will not receive any aminophylline treatments for the first post-op five days
36685|NCT03897309|Biological|VXA-G1.1-NN|Monovalent GI.1 tableted vaccine
36686|NCT03897309|Biological|VXA-G2.4-NS|Monovalent GII.4 tableted vaccine
36687|NCT03897309|Biological|Placebo Tablets|Tablets matching in number and appearance to active vaccine doses
36688|NCT03897296|Diagnostic Test|High resolution anorectal manometry, water perfused catheter|High resolution anorectal manometry with the use of water-perfused catheter will be performed to eligible subjects willing to participate in the study
36689|NCT03897283|Drug|TQB2450|TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle
36690|NCT03897283|Drug|Anlotinib|Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.
36691|NCT03897270|Procedure|Photoacoustic Imaging|Undergo photoacoustic imaging of the breast
36692|NCT03897257|Drug|UHE-103A1 cream|Investigational mono-therapy cream (containing drug A [low dose])
36693|NCT03897257|Drug|UHE-103A2 cream|Investigational mono-therapy cream (containing drug A [low dose])
36694|NCT03897257|Drug|UHE-103B cream|Comparator mono-therapy cream (containing drug B)
36695|NCT03897257|Drug|UHE-103A1B cream|Investigational combination-therapy cream (containing drug A [low dose] + drug B)
36696|NCT03897257|Drug|UHE-103A2B cream|Investigational combination-therapy cream (containing drug A [high dose] + drug B)
36697|NCT03897244|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid, for 14 days)
36698|NCT03897244|Drug|Bismuth High-dose dual therapy (rabeprazole, amoxicillin, tripotassium dicitrate bismuthate)|Bismuth-High-dose dual therapy (rabeprazole 20 mg qid + amoxicillin 750 mg qid + tripotassium dicitrate bismuthate 300 mg qid, for 14 days)
36699|NCT03897244|Drug|Amoxicillin-Metronidazole Bismuth quadruple therapy|Amoxicillin-Metronidazole Bismuth quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 600 mg bid + amoxicillin 1000 mg bid + metronidazole 500 mg tid, for 14 days)
36700|NCT03897231|Other|questionnaire|Participants will be invited to participate in the study during their dialysis treatment at the participating hemodialysis outpatient centres. Allocated nurses at Copenhagen University Hospital, Rigshospitalet (MS, AB, LFH), Copenhagen University Hospital, Hillerød (MPL) and Copenhagen University Hospital Herlev (CPB) will be responsible for recruitment. Eligible patients will be informed orally and in writing about the study. Participants who wish to participate will be asked to provide informed consent and, following this, complete a paper-based questionnaire during treatment. Patients who have difficulty reading Danish and patients with visual or physical impairments that impinge on their ability to complete the questionnaires will be interviewed using a structured interview approach based on the questionnaires.
36701|NCT03897218|Dietary Supplement|oatmeal flakes with prebiotic food supplements|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
36702|NCT03897218|Dietary Supplement|millet flakes|The study participants should consume the prescribed amount of the study product every day. The intake should be divided into 1-2 meals. It is not necessary to limit or change normal eating habits.
36703|NCT03897205|Drug|Imlifidase|Imlifidase is an IgG degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
36784|NCT03896568|Procedure|Therapeutic Conventional Surgery|Undergo surgery
70149|NCT03635567|Drug|Placebo to pembrolizumab|IV infusion
36704|NCT03897205|Other|Plasma Exchange|The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins (Igs) and then the plasma is passed back to the subject.
36705|NCT03897192|Drug|Bevacizumab|Anti-vascular endothelial growth factor (VEGF)
36706|NCT03897166|Device|Trimodality|Positron Emission Tomography coupled with Computed tomography and immediately followed by Magnetic Resonance Imaging
36707|NCT03897153|Device|SONAS® Ultrasound Device|The SONAS® Ultrasound Device is intended for non-invasive transcranial ultrasound and used with a commercially approved contrast agent (e.g., Lumason®/SonoVue®).
36708|NCT03897140|Diagnostic Test|Diagnostic Test: Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance feedback to users during image acquisition. For this study, RNs will use EchoGPS to perform limited echocardiogram examinations.
36709|NCT03897127|Drug|Cytarabine|"Induction therapy: 200 mg/m2 i.v. (continuously) d1-7~Consolidation therapy:~Patients age 18-60 years~o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3~Patients age >60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3"
36710|NCT03897127|Drug|Daunorubicin|Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3
36711|NCT03897127|Drug|CPX-351|"Induction 1:~Patients age 18-60 years~o CPX-351 55 mg/m2 daunorubicin / 125 mg/m2 cytarabine [125 U/m²] i.v. (90 min) d1,3,5~Patients age >60 years o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3,5~Induction 2:~• Patients age 18-60 years~CPX-351 55 mg/m2 daunorubicin / 125 mg/m2 cytarabine [125 U/m²] i.v. (90 min) d1,3~• Patients age >60 years~CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3~Consolidation therapy:~o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine [65 U/m²] i.v. (90 min) d1,3"
36712|NCT03897114|Dietary Supplement|Cocoa group|Athletes perform the same training program and they take 5 g of cocoa (83 mg of flavonoids per gram of cocoa) mixed with low-fat milk for 10 weeks.
36713|NCT03897114|Dietary Supplement|Placebo group|The athletes perform the same training program and they take for 10 weeks 5 g maltodextrin mixed with low-fat milk for 10 weeks
36714|NCT03897088|Drug|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
36715|NCT03897088|Drug|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
36716|NCT03897075|Drug|Tildrakizumab|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
36717|NCT03897075|Drug|Placebo|PART 1: Double-blind Placebo-controlled PART 2: Double-blind Active Treatment Extension PART 3: Observational Safety Follow-up
36718|NCT03897062|Drug|Suvorexant 20 mg|Placebo controlled double blind suvorexant vs placebo
36719|NCT03897062|Other|placebo|Placebo controlled double blind suvorexant vs placebo
36720|NCT03897049|Behavioral|Trans Women Connected|The intervention will address the unique needs of transgender women and the lack of evidence-based, transgender-specific HIV prevention. It is a mobile app delivered sexual health promotion program that engages transgender women through a strengths based approach to HIV prevention and sexual health that uses the power of social networks to identify and encourage protective factors that support the health of transgender women. This approach recognizes the social and structural barriers that transgender women face. In the context of these barriers, which include stigma and discrimination in a number of interconnected spheres, individually-focused behavioral interventions are insufficient. This intervention takes a more comprehensive approach that intentionally targets community strengths and challenges. The mobile app will include more than 30 interactive activities including resource maps, PrEP/PEP content, and communication forums.
36721|NCT03897049|Behavioral|General Health App|The control group will download a mobile app that addresses general health behaviors and concerns, including sexual health topics.
36722|NCT03897036|Drug|CX-4945|API powder-in-capsule in 200 mg strength
36723|NCT03897023|Biological|Gut Microbiota|Status of microbiota
36724|NCT03897010|Device|Socket Graft|5 patients had bilateral decayed upper premolar or anterior teeth, in one side SCPC graft was inserted in socket and in the contralateral site was a control, 5 months months postoperative core biopsies were taken from both grafted sockets and control ungrafted sockets during implant insertion. The biopsy samples from SCPC-grafted and control ungrafted sockets were fixed, decalcified and embedded into paraffin wax. All samples were serially sectioned in serial 5μm-thin sections were stained separately with Hematoxylin and Eosin staining, Sirius red and Mason trichrome and immunostaining with osteopontin.
36725|NCT03896984|Drug|Radium-223 (Xofigo, BAY88-8223)|Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
36726|NCT03896984|Drug|Abiraterone|Abi is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
36727|NCT03896984|Drug|Enzalutamide|Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
36728|NCT03896971|Drug|Combination of thrombopoietin mimetic and cyclosporin A|This is a controlled interventional study that will be carried out in the Clinical Hematology Unit, at the Department of Internal Medicine , Assiut University Hospital. Patients will be recruited among those who attending the outpatient clinic or admitted in the unit.
36731|NCT03896932|Other|minipooled- Intravenous immunoglobulin(MP-IVIG)|The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
37627|NCT03889639|Drug|Placebo|"Pharmaceutical form: Film coated tablet~Route of administration: Oral"
36733|NCT03896906|Device|High-flow nasal cannula|Apply high ﬂow heated (34 °C) and humidified nasal oxygen with the OptiFlow System (Thrive, Fisher & Paykel®, Aukland New Zealand) using a ﬂow of 30 liter/minute and an inspiratory oxygen fraction (FiO2) of 1.0. Increase the oxygen flow to 60 liter/minute over the course of the first minute. Ask the patients not to speak during anesthesia induction and keep the mouth closed.
36734|NCT03896906|Device|simple mask|Perform standard preoxygenation by oxygen insufflation via a face mask using the standard anesthesia ventilators (semicircular system) with 100% oxygen ﬂow of 12 liter/minute. The patients breathe with tidal volume.
36735|NCT03896893|Other|Skin antisepsis|1% aqueous chlorhexidine gluconate
36736|NCT03896893|Other|Emollient|Aquaphor skin cream
36737|NCT03896880|Diagnostic Test|blood culture|"During the febrile episode, two blood samples per patient will draw from two separate sites including central venous catheter if present and directly injected to Bact/Alert® bottles and incubated in Bact/ALERT system instrument (bioMérieux Diagnostics, Lyon, France).~A-Identification of microorganisms including:~Isolation of microorganisms:~Blood culture samples with positive signals will be cultured on blood agar, chocolate agar , MacConkeys agar and Sabouraud dextrose agar (SDA) plates.~B-Identification of the bacterial organism~Pure colonies of isolated microorganisms were identified by:~Morphology on agar,Gram stain film was made from the growth to identify morphology of the organism ,Biochemical tests~C-For fungi isolate the following will perform:~Microscopic examination of Lactophenol cotton blue (LCB) wet mounts.~Culture on Brilliance Candida differential agar"
36738|NCT03896880|Other|Anti fungal susceptibility testing or antibiotic susceptibility testing|isolation of microbes from positive blood culture and anti fungal susceptibility testing or antibiotic susceptibility testing according to isolated microbes by disc diffusion method and Vitek2
36739|NCT03896880|Other|phenotypic identification methods of the isolated organism by Vitek2 (BioMerieux,France)|The VITEK 2 is an automated microbial identification system that utilizing growth-based technology. With its colorimetric reagent cards, the VITEK 2 offers a state of the art technology platform for phenotypic identification methods.
36740|NCT03896880|Other|Identification of the isolated organism by multiplex PCR|FilmArray blood culture identification (BCID) is automated multiplex PCR assay, the FilmArray blood culture identification which directly identifies common pathogens, including 7 genera/ species of Gram-positive bacteria, 10 genera/species of Gram-negative bacteria, and 5 species of Candida (as well as 3 resistance determinants) in the positive blood culture bottles. The assay requires about 2 min of hands-on sample processing time and 1 h of instrument time (which includes DNA isolation, amplification, and detection).
36741|NCT03896867|Device|Anapod™ Humi-Therm Heated Humidification System Breathing Circuit|"For the Anapod™ group, the BairHugger™ blanket will be connected, but the unit will not be turned on. The Anapod™ will be used with a starting circuit temperature set at the standard 45°C (note, this is temperature at the unit - NOT the temperature of the gas reaching the trachea). In the event that the patient's rectal temperature falls below 35.6C, the BairHugger™ warming system will be activated (Hypothermic Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the Anapod system will be turned off - and the BairHugger turned on with the warming unit set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
36742|NCT03896867|Device|Bair Hugger™ Warming Blanket|"For the BairHugger™ group, the blanket will be used with a starting temperature set at HIGH. The BairHugger™ unit will be attached to the warming unit and started as soon as possible. In the event that the patient's rectal temperature falls below 35.6C, the Anapod™ warming system will be activated (Rescue). In the event that rectal temperature increases to a value of ≥37.5C, the BairHugger™ warming unit will be set to ambient (meaning cool operating room temperature will be blown over the patient (Hyperthermic Rescue)."
36743|NCT03896854|Biological|CART-19|CART-19 Split intravenous infusion of CART-19 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19 cells/kg).
36744|NCT03896841|Other|Observation|Ocular Findings Observations
36745|NCT03896828|Dietary Supplement|Mixed-macronutrient meal|"Participants will be provided a mixed-macronutrient meal (liquid drink) at hours 0 and 3, mimicking the energy and macronutrient composition of breakfast and lunch in Western society (38). 20% of daily energy intake will be provided as breakfast and 30% at lunch. Macronutrient composition will reflect a diet providing 55% energy needs from carbohydrate (CHO) and 1.2g/kg/d protein. The remaining energy requirements, as determined by total energy intake, will be met with dietary fat (estimated to be ~0.2 and 0.3g/kg fat for breakfast and lunch, respectively), similar to previous liquid mixed-meal approaches."
36746|NCT03896815|Drug|INCB054329|
36747|NCT03896802|Procedure|Physiological assesment|"Arterial and mixed venous blood gas analysis.~Alveolar and physiologic dead space via volumetric capnometry, as well as carbon dioxide (CO2) production, end-tidal CO2 and mixed expired CO2~Respiratory system (Crs), chest wall (Ccw) and lung (Cl) compliance measurement via an end-inspiratory and end-expiratory pause.~Arterial blood pressure, central venous pressure (CVP), heart rate, cardiac output through the arterial pulse contour and transpulmonary thermodilution methods (PiCCO technology). Global end-diastolic volume, Intra-thoracic blood volume, Extravascular lung water will also be assessed. Respiratory hold maneuvers (at PEEP, and +10, +15 and +20 cmH2O) will be performed and CVP and cardiac output will be measured in the last 3 s of the 12 s inspiratory hold. Venous return curve will constructed and the zero-flow pressure recorded as the mean systemic filling pressure.~Urine flow in 1h and determination of the fractional excretion of sodium and creatinine."
36777|NCT03896620|Diagnostic Test|Blood Test - Stage 4 Sarcomas|"Blood samples (10 mL each time) will be collected at the following points:~Prior to the start of treatment~Every six weeks after initiation of chemotherapy for one year, or until disease progression"
36778|NCT03896620|Diagnostic Test|Biopsy Sample of Tumor|A biopsy sample from the tumor will be collected before the start of treatment.
36779|NCT03896594|Drug|HL237|Experimental
36780|NCT03896594|Drug|Placebo Oral Tablet|placebo with same properties except for active ingredient
36781|NCT03896581|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
36782|NCT03896581|Other|Placebo|Subjects will receive placebo at pre-specified time-points.
36783|NCT03896568|Biological|Oncolytic Adenovirus Ad5-DNX-2401|Given IA
36749|NCT03896776|Behavioral|Keep It Up! 3.0|KIU! is an online HIV prevention intervention developed for high-risk young men who have sex with men (YMSM) who recently tested HIV negative. Content was developed in collaboration with YMSM-serving CBOs and subjected to usability testing with diverse YMSM. The Information-Motivation-Behavioral Skills model and eLearning principles guided development of highly interactive, engaging, and culturally relevant health messages. KIU! involves 7 modules completed across 3 sessions done at least 24 hours apart, totaling ~1 hour of main content, plus 2 booster sessions at 3- and 6-month follow-ups. Each module is based on a setting or situation relevant to YMSM (e.g., connecting to the gay community and meeting guys through apps), with developmentally appropriate behavior change content embedded. KIU! uses diverse delivery methods (e.g. videos, animation, games) to address HIV knowledge gaps, motivate safer behaviors, teach behavioral skills, and instill self-efficacy for preventive behaviors.
36750|NCT03896763|Other|Either supine or prone positioning and either CMV or HFOV|"Supine positioning: Subjects randomized to supine positioning will remain supine.~Prone positioning: Subjects randomized to prone positioning will be positioned prone ≥16 hours/day for a maximum of 28 days.~CMV strategy: Low tidal volume to obtain exhaled Vt of 5-7 ml/kg (ideal body weight), PIP goal limited to ≤ 28 cm H2O and lung recruitment maneuver to identify best PEEP then maintained per PEEP-FiO2 grid.~HFOV strategy: Frequency at 8-12 Hz, amplitude (delta-P) 60-90 and mPaw recruitment maneuver."
36751|NCT03896750|Drug|PA-824|PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
36752|NCT03896737|Drug|Daratumumab plus Velcade Cyclophosphamide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
36753|NCT03896737|Drug|Velcade Thalidomide Dexamethasone|To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
36754|NCT03896724|Biological|R21 adjuvanted with 25mcg Matrix-M|Vaccine
36755|NCT03896724|Biological|Rabies Vaccine|Vaccine
36756|NCT03896724|Biological|R21 adjuvanted with 50mcg Matrix-M|vaccine
36757|NCT03896711|Behavioral|MEMORI Corps program|Activity-based companion care program. Delivered by trained senior volunteers, supported by a clinical team, over a 12-week intervention period (8 hours per week, 2 or 3 days per week) for each person with dementia/family caregiver dyad. Primary roles of the volunteers are to provide in-home supervision, peer-to-peer companionship, and a evidence-based individualized activity program that focuses on meaningful, engaging and enjoyable activities that match PWD abilities and interests.
36758|NCT03896711|Other|Augmented Waitlist Control|"Persons with dementia/caregivers will continue any services and supports being used, will receive a free copy of A Caregiver's Guide to Dementia: Using Activities and Other Strategies to Prevent, Reduce and Manage Behavioral Symptom103), written educational materials on management of CG stress/well-being, and bi-weekly check-in calls to answer any questions about the materials. Volunteers randomized to waitlist control will continue with usual activities (volunteer or other), and will receive additional written educational materials on cognitive health (NIA) and exercise and Physical Activity (Go4Life), referrals to the Baltimore City Commission on Aging and Retirement Education for volunteering opportunities, and bi-monthly check-in calls to answer questions and maintain engagement. Waitlist dyads will be followed at specified intervals by the research team and then offered an opportunity for participation in the intervention arm."
36759|NCT03896698|Device|Transcranial Ultrasound Stimulation|TUS activate the brain cells
36760|NCT03896685|Drug|Bedaquiline 100 MG|Bedaquiline: 400 mg QD x 2 weeks, followed by 200 mg 3x/week
36761|NCT03896685|Drug|Delamanid 50 MG Oral Tablet|Delamanid: 100 mg BID
36762|NCT03896685|Drug|Clofazimine Pill|Clofazimine: 100 mg QD
36763|NCT03896685|Drug|Linezolid Pill|Linezolid: 600 mg QD up to Week 16, followed by 300 mg QD or 600 mg 3x/week according to a secondary randomization
36764|NCT03896685|Drug|Control arm MDR-TB regimen, designed according to latest WHO guidelines|Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
36765|NCT03896672|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure will be applied three times daily during 7 consecutive days, if the physiotherapist follow the previous training. Each application should during 30 minutes. Pressure should be adjusted in 15 centimeters of water.
36766|NCT03896659|Drug|Hydrocortisone Oral|Hydrocortisone 160 mg tablet
36767|NCT03896659|Drug|Placebo Oral Tablet|Hydrocortisone-matched Placebo tablet
36768|NCT03896646|Procedure|Computed Tomography|Undergo SPECT/CT HIDA scan
36769|NCT03896646|Other|Hepatobiliary Iminodiacetic Acid Scan|Undergo SPECT/CT HIDA scan
36770|NCT03896646|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT HIDA scan
36771|NCT03896646|Radiation|Yttrium Y 90 Glass Microspheres|Undergo radioembolization with yttrium Y 90 glass microspheres
36772|NCT03896646|Procedure|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere radioembolization
36773|NCT03896633|Drug|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
36774|NCT03896633|Drug|Azopt 1%|Azopt 1%, RLD
36775|NCT03896620|Diagnostic Test|Blood Test - Stage 2-3 Sarcomas Preoperative RT|"Blood samples (10 mL each time) will be collected at the following points:~Prior to the start of treatment~Four weeks after the last chemotherapy cycle~Four weeks after the end of radiation therapy~Four weeks after surgery~Every four months after surgery up until month 24 months after surgery is completed, or until disease progression"
36776|NCT03896620|Diagnostic Test|Blood Test - Stage 2-3 Sarcomas Postoperative RT|"Blood samples (10 mL each time) will be collected at the following points:~Prior to the start of treatment~Four weeks after surgery~Four weeks after the end of radiation therapy~Four weeks after your last chemotherapy cycle~Every four months after surgery up until month 24 months after surgery is completed, or until disease progression"
36785|NCT03896555|Device|ExacTrac position verification|Repeated measurement of patient head position with ExacTrac X-ray Monitoring
36786|NCT03896542|Device|Commercial video game.|Stroke patient had played with commercial video game, along 12 sessions.
36787|NCT03896542|Device|rehabilitation video game|Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
36788|NCT03896529|Behavioral|Anticipatory psychological stress|Unpredictable delivery of low-level electrical stimulation to left ankle periodically throughout psychology tasks (virtual navigation). Established procedure for inducing anticipatory stress.
36791|NCT03896503|Drug|ATR Kinase Inhibitor M6620|Given IV
36792|NCT03896503|Drug|Topotecan|Given IV
36793|NCT03896503|Drug|Topotecan Hydrochloride|Given IV
36796|NCT03896477|Biological|Pneumosil|One single dose contains 2μg of polysaccharide for serotypes 1, 5, 6A, 7F, 9V, 14, 19A, 19F and 23F, and 4μg for serotype 6B formulated with aluminium phosphate as an adjuvant in an appropriate buffer
36797|NCT03896477|Biological|Prevenar 13|One single dose contains 2.2 µg of the following pneumococcal polysaccharides serotypes - 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F - and 4.4 µg of pneumococcal polysaccharide serotype 6B, all conjugated to CRM197 and absorbed onto aluminum phosphate
36798|NCT03896477|Biological|Synflorix|One single dose contains 1μg of polysaccharide for serotypes 1, 5, 6B, 7F, 9V, 14, and 23F, and 3μg of serotypes 4, 18C, and 19F formulated with aluminum phosphate as an adjuvant.
36799|NCT03896464|Procedure|Soft tissue hamstring autograft|Patients will be prescribed to receive a soft tissue hamstring autograft to for ACL reconstruction.
36800|NCT03896464|Procedure|Quadriceps tendon autograft|Patients will be prescribed to receive a quadriceps tendon autograft to for ACL reconstruction.
36801|NCT03896451|Device|Total knee endoprothesis|Total knee endoprosthesis after knee joint osteoarthritis
36802|NCT03896438|Device|Transcranial Direct Current Stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
36803|NCT03896425|Device|Transcranial direct current stimulation (tDCS)|Three different stimulation montages will be programmed: right, left and sham. During the Ramp periods, 2 mA current will be delivered to both AF3 and AF4 with an ascending (RampUp) and descending ramp (RampDown) over 30 sec via two saline soaked electrode sponges (~ 25cm²; current density = 0.08 mA/cm²). In this way, all subjects experience the same sensation on both sides to blind them to condition. During the Constant period, current will be set based on the Condition: Right - 2mA AF4 anode-AF3 cathode; Left - 2mA applied to AF3 anode-AF4 cathode; Sham - current turned off.
36804|NCT03896412|Other|Detecton of circulating tumor DNA|7 blood samples to design a molecular probe
36805|NCT03896399|Procedure|Laparoscopic ischemic conditioning followed by esophagectomy|All included patients will receive a laparoscopic ischemic conditioning followed by an Ivor-Lewis esophagectomy after an interval of 13-15 days.
36806|NCT03896386|Other|Use of seizure diary|"The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end"
36807|NCT03896373|Other|Blood samples|Blood samples
36808|NCT03896360|Behavioral|Food order behavioral intervention plus standard care|Subjects in the Food order behavioral intervention plus standard care will receive standard counseling by a registered dietitian and additional carbohydrate last food order behavioral counseling by a member of the research team at baseline and Weeks 4, 8 and 12.
36809|NCT03896360|Behavioral|Standard Care|Subjects will receive standard counseling by a registered dietitian at the baseline visit. Standard counseling will be similarly reinforced at weeks 4, 8 and 12.
36810|NCT03896347|Other|ViBone®|Viable bone allograft
36811|NCT03896347|Other|Demineralized Bone Matrix|Demineralized Bone Matrix
36812|NCT03896347|Other|Bone Morphogenetic Protein|Bone Morphogenetic Protein
36813|NCT03896334|Behavioral|Supervised Isometric Handgrip Training|The participants randomized to the experimental group will perform 24 weeks of isometric handgrip exercise training, three times/week for 16 minutes with time to rest.
36814|NCT03896334|Behavioral|Sham comparator - stretching and relaxation exercises|The participants randomized to the control group (active comparator) will perform 24 weeks of stretching and relaxation exercise training, three times/week for 16 minutes with time to rest.
36815|NCT03896321|Drug|Antiplatelet Agents|effect of dual antiplatelet in management of coronary artery ectasia
36816|NCT03896321|Drug|Anticoagulants|effect of oral anticoagulants in management of coronary artery ectasia
36817|NCT03896295|Drug|M281|M281 injection administered as intravenous infusion
36818|NCT03896282|Other|Mobilization at a dedicated daycare facility|"All THA's are performed using a standard posterolateral approach with simple posterior soft-tissue repair. No infiltration anesthesia (LIA) is used in THA's. All TKA's are performed with a standard medial parapatellar approach without the use of tourniquet. Physiotherapy is started as soon as possible after surgery in the dedicated day care facility. Time till first mobilization is recorded as is total time mobilized supervised by a physiotherapist before discharge.~Patients are discharged if fulfilling the discharge criteria before 8 pm. Number of hours spent in hospital in total is recorded."
36819|NCT03896269|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
36820|NCT03896256|Drug|ketamine infusion|Ketamine will be used in subanesthetic doses for patients with refractory chronic migraine to see if it improves pain after a 5-day continuous infusion.
36821|NCT03896243|Diagnostic Test|Uterine artery ligation (UAL)|"Uterine artery ligation (UAL) We will invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during C-section.~They will evaluated for their ovarian reserve via hormones and antral follicle count (AFC)"
36822|NCT03896230|Drug|Ketamine Injectable Product|Three different doses of ketamine will be administered.
36823|NCT03896217|Drug|Simvastatin|Simvastatin 40mg for first 4 weeks and 80mg (if tolerated) thereafter up to 17 weeks
36824|NCT03896204|Behavioral|telephone-suppoted joint protection technique|After joint protection technics training, patients will be followed up with telephone support for 1 month.
36825|NCT03896204|Behavioral|joint protection technique training|Training will be given to individuals about joint protection technique
36826|NCT03896191|Procedure|Revision TKR surgery|This study will follow the cohort of patients who have an unstable primary TKR with which they are dissatisfied. They will be assessed before and after their revision TKR surgery.
36827|NCT03896191|Other|No intervention.|This study will also make a case-control comparison between patients with a stable primary TKR and an unstable primary TKR.
36828|NCT03896178|Other|None, observational study|None, observational study
36829|NCT03896165|Other|Reiki|Reiki is a complementary health approach where trained providers place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. A Reiki practitioner will perform the initial teaching and instruct the parent how to perform a simple 15-minute Reiki session. Parents will complete a return demonstration using light touch with their adolescent. Parents will be asked to complete a minimum of 15 minutes of Reiki with their adolescent at least five days per week for the four-week intervention period.
36830|NCT03896152|Drug|LNP023|approximately 2 year of Treatment with LNP023
36831|NCT03896139|Drug|Kinase inhibitor|Patients treated with kinase inhibitors for cancer or other conditions
36832|NCT03896126|Other|Observational|There is no intervention. This is an observational study attempting to establish parameters of normal and abnormal vagal tone in healthy control and gastroparesis patients, as there is currently no metric to determine what dose of vagal stimulation is required to treat gastroparesis.
36833|NCT03896113|Drug|Celecoxib 200mg capsule|Patient confirmed with endometrial cancer will received twice daily 200 mg Celecoxib, 15 days before the surgery.
36834|NCT03896087|Diagnostic Test|Abbott RealTime HCV assay from DBS; COBAS® AmpliPrep/COBAS TaqMan HCV Test from DBS; cobas® HCV for use on the cobas® 6800/8800 Systems from PSC and DBS; Aptima® HCV Quant Dx Assay from DBS|The trial intervention will consist of testing DBS, PSC and plasma samples obtained from trial participants using the centralised molecular assays for detection of HCV RNA.
36835|NCT03896074|Drug|Atezolizumab|Atezolizumab administered intravenously at 1200 mg every 3 weeks
36836|NCT03896074|Drug|Bevacizumab|Bevacizumab intravenously at 15 mg/kg every 3 weeks
36837|NCT03896061|Device|Laparoscopic sleeve procedures|Laparoscopic sleeve procedures with powered stapler
36838|NCT03896035|Behavioral|Behavioral Intervention Group|The behavioral intervention is designed for older Veterans with cLBP and depression and will include 8 individual telephone sessions delivered by health coaches over a period of 10-20 weeks (up to 5 months total, accounting for additional time between sessions if needed).
36839|NCT03896022|Device|Acupressure with Beads|Single-use gold-plated 1.2mm beads/balls attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
36840|NCT03896022|Device|Acupuncture with Needles|Single-use 1.2mm acupuncture press needles attach to pre-specified acupoints on the participant's ears with adhesive disk/tape.
36841|NCT03896022|Device|Placebo Adhesive Disks|Single-use adhesive disks without needles or beads.
36842|NCT03896009|Drug|AXS-07 (MoSEIC meloxicam and rizatriptan)|AXS-07 taken once upon onset of a qualifying migraine.
36843|NCT03896009|Drug|Meloxicam|Meloxicam taken once upon onset of a qualifying migraine.
36844|NCT03896009|Drug|Rizatriptan|Rizatriptan taken once upon onset of a qualifying migraine.
36845|NCT03896009|Drug|Placebo|Placebo taken once upon onset of a qualifying migraine.
36846|NCT03895996|Drug|AVT001|autologous dendritic cell therapy
36847|NCT03895996|Other|Placebo|matched placebo
36848|NCT03895983|Procedure|Percutaneous primary coronary intervention|Percutaneous primary coronary intervention
36849|NCT03895970|Drug|Lenvatinib plus Pembrolizumab|Lenvatinib 12mg, once a day, oral at least 38 days of each 6 weeks cycle. Pembrolizumab 200mg, every 3 weeks, intravenous infused of each 6 weeks cycle. Number of cycle: until progression or unacceptable toxicity develops.
36850|NCT03895957|Behavioral|Virtual Reality Exposure Therapy VR Mind+|Virtual Reality Exposure Self-Therapy led by a participant
36851|NCT03895957|Behavioral|Virtual Reality Exposure Therapy VR Mind|Treatment with Virtual Reality Exposure Therapy led by a therapist
36852|NCT03895957|Behavioral|Cognitive Behavioral Therapy|Standard treatment for social phobia led by a therapist
36853|NCT03895944|Biological|ET190L1-ARTEMIS™ T cells -iv low dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10^6
38325|NCT03883789|Diagnostic Test|FibroScan|FibroScan will be used to assess liver stiffness
36854|NCT03895944|Biological|ET190L1-ARTEMIS™ T cells -iv middle dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10^6
36855|NCT03895944|Biological|ET190L1-ARTEMIS™ T cells - iv high dose|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10^6
36856|NCT03895918|Other|Educational Activity|Undergo parenting skills intervention
36857|NCT03895918|Procedure|Patient Monitoring|Undergo medication adherence monitoring
36858|NCT03895918|Other|Questionnaire Administration|Ancillary studies
36859|NCT03895905|Diagnostic Test|colposcopy and colposcopic biopsy|high-risk hpv positivity and colposcopy and cervical biopsy results will be evaluated. thus, it will be defined whether colposcopy will be performed routinely at high-risk hpv.
36860|NCT03895892|Behavioral|20 km time trial|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
36861|NCT03895892|Behavioral|Wingate test|30 second all-out effort on a bike will be conducted to measure the effect of different drinks on peak power output
36862|NCT03895892|Dietary Supplement|Ketone/Caffeine|Dietary supplement containing ketone salts and caffeine
36863|NCT03895892|Dietary Supplement|Ketone|Dietary supplement containing only ketone salts
36864|NCT03895892|Dietary Supplement|Water Placebo|Dietary supplement containing only water
36865|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every 2 weeks
36866|NCT03895879|Drug|Tocilizumab|Tocilizumab sc (162 mg) once every week
36867|NCT03895866|Other|The participants were assigned to different groups according to the results of HPV detection.|The participants were assigned to different groups according to the results of HPV detection
36868|NCT03895853|Other|Best Practice|Receive standard of care
36869|NCT03895853|Dietary Supplement|early metabolic resuscitation|Given Intravenous
36870|NCT03895840|Drug|Zilretta|Zilretta (triamcinolone acetonide extended-release injectable suspension) is indicated as an intra-articular injection for the management of pain due to knee osteoarthritis.
36871|NCT03895827|Behavioral|Recovery Initiation and Management after Overdose (RIMO)|RIMO uses motivational interviewing and linkage assistance techniques to get people who have had a recent opioid overdose reversal to go to medication-assisted treatment (MAT), stay in MAT, and, if they drop out, go back to MAT treatment.
36872|NCT03895827|Other|Passive Referral to Treatment Control|Currently neither first responders or emergency department staff regularly refer people to any kind of substance use after an opioid overdose reversal. In the passive referral condition they will at least get a brochure with information on recently expanded and publicly-funded medication-assisted treatment in their community.
36873|NCT03895814|Behavioral|Protective Step Training|Participants will undergo 6, 1 hour visits (over the course of 2 weeks) where they will be exposed to repeated slips on a treadmill.
36874|NCT03895801|Drug|IFX-1|intravenously administered
36875|NCT03895801|Drug|Placebo-IFX-1|intravenously administered
36876|NCT03895801|Drug|Glucocorticoid (GC)|orally administered
36877|NCT03895801|Drug|Placebo-Glucocorticoid (Placebo-GC)|orally administered
36878|NCT03895788|Drug|niraparib|Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
36879|NCT03895788|Drug|Brivanib|Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
36880|NCT03895749|Dietary Supplement|NEO40 Daily|Per Capsule: N5-carbamoylornithine 100 mg, crataegus laevigata 100 mg, L-ascorbic acid 50 mg, vitamin B-12 0.05 mg, vitamin C 50 mg.
36881|NCT03895736|Biological|blood sampling|Sampling of 15 ml of blood during a blood test at Day 0, Day 1 and Day 3
36882|NCT03895723|Procedure|laparoscopic and robotic liver resection|laparoscopic and robotic procedure for liver resection
36883|NCT03895723|Procedure|open surgery|using open surgery procedure for liver resection
36884|NCT03895697|Drug|dasiglucagon|Glucagon analogue
36885|NCT03895684|Drug|SP-2577 Seclidemstat|Dose escalation and dose expansion of SP-2577.
36886|NCT03895671|Drug|Ponatinib|"Induction phase (first three cycles)~- ponatinib: 45 mg/day orally continuously~Following the results of disease evaluation after 3 cycles:~Cohort A: AP-CML If a CHR and complete cytogenetic response are obtained after 3 months, ponatinib will be decreased at 30mg/day. If CHR and/or CCyR are not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Cohort B: MBC-CML If a CHR is obtained during the induction phase, ponatinib daily dose will be reduced to 30 mg/day. If CHR is not reached, ponatinib may be maintained at 45mg/day for another 3 cycles if decided by the investigator.~Maintenance therapy:~Ponatinib will be decreased to 30 mg/day. During maintenance therapy, If a major molecular response is reached, ponatinib will be decreased to 15mg/day"
36887|NCT03895671|Drug|Azacitidine|"Induction phase (first three cycles), Following the results of disease evaluation after 3 cycles and Maintenance therapy:~- 5-azacitidine : 75 mg/m² subcutaneously day 1 to day 7, every 4 weeks~No dose modification of 5-Azacitidine is planned in both cohorts. Azacitidine may be stopped at 24 months in case of MR4 defined as 0.0032%<MR4≤0.01%;"
36889|NCT03895619|Other|Safer conception strategies|Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
36890|NCT03895606|Other|Data collection|This study is an observational study collecting perioperative data. There is no intervention regarding this study.
36891|NCT03895593|Other|rescue fecal microbiota transplantation|Fecal microbiota transplantation refers to the infusion of fecal microbiota from healthy donor into patients' gastrointestinal tract.
36892|NCT03895580|Other|In-store POP education|Six in-store nutrition counseling sessions with a registered dietitian nutritionist.
36893|NCT03895580|Other|Online POP education|Education on the use of an online grocery shopping, an online recipe tool, a grocery pickup service, a home grocery delivery service, and a phone application that promotes healthy food selection.
36894|NCT03895567|Drug|A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection)|"Parenteral ceftriaxone~Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche)."
36895|NCT03895567|Drug|B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 1 ceftriaxone 500mg + Na-CDC 125mg + dicalcium phosphate (binder)"
36896|NCT03895567|Drug|C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg)|"Rectal ceftriaxone formulations~Formulation 2 ceftriaxone 500mg + Na-CDC 125mg + mannitol (binder)"
36897|NCT03895554|Procedure|cardiac PET stress test|Volunteers will undergo cardiac PET stress testing
36898|NCT03895541|Diagnostic Test|SuperSonic image|3 examen performed assessed to compared evaluation type: Cardiac magnetic resonance imaging, standard ultrasound imaging and ultrafast imaging
36899|NCT03895528|Drug|Lonafarnib|Farnesyl transferase inhibitor
36900|NCT03895515|Drug|Fiasp®|Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.
36901|NCT03895502|Drug|12-month Edoxaban|Prescription of Edoxaban for 12 months
36902|NCT03895502|Drug|3-month Edoxaban|Prescription of Edoxaban for 3 months
36903|NCT03895489|Device|Journey II|Smith and Nephew Richards (SNR) Journey II Knee prosthesis
36904|NCT03895489|Device|Stryker|Stryker Triathlon Total Knee prosthesis
36905|NCT03895489|Device|Zimmer|Zimmer Persona® The Personalized Knee prosthesis
36906|NCT03895476|Diagnostic Test|palatal wound will not cover|after harvesting the graft from the palate the wound will be left uncovered with secondary healing intention
36907|NCT03895476|Diagnostic Test|palatal wound covered with platelet rich fibrin|after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
36908|NCT03895476|Diagnostic Test|palatal wound covered with a collagen sponge and cyanoacrylate|after harvesting the graft from the palate a collagen sponge will be sealed with cyanoacrylate in position
36909|NCT03895476|Diagnostic Test|palatal wound covered with a stent|after harvesting the graft from the palate a stent that will be prepared for the patient, will be placed on to cover the wound
36910|NCT03895450|Behavioral|Aerobic Exercise Protocol|Participants randomized to AEP will be asked to exercise 20 minutes per day or until symptom exacerbation, 5-6 days per week either at home, outdoors or at a fitness facility of choice. The assigned exercise prescription target will be 70-80% of the maximum HR achieved during the treadmill test. HR monitors will be provided to monitor exercise intensity.
36911|NCT03895450|Behavioral|Stretching Protocol|Participants will follow a stretching protocol for 20 minutes a day, 6 days a week. Individuals in the SP group will be given a booklet explaining a low-impact breathing and stretching program developed at the University of Buffalo. All stretches will explained and demonstrated by a member of the study team prior to commencement of the program. Stretches focus on lower extremity muscles. During the protocol HR should be low as to not exceed 50% of age predicted max. A HR monitor will be worn during stretching.
36912|NCT03895437|Biological|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
36913|NCT03895437|Other|TOL-3021 Placebo|TOL-3021 Placebo
36914|NCT03895424|Dietary Supplement|IFAC|This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
36915|NCT03895424|Dietary Supplement|MIFAC|This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
36916|NCT03895424|Dietary Supplement|Control Ferrous Sulfate|This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
36917|NCT03895411|Drug|sotalol|Oral sotalol 2.5mg/kg/time, per 12h
36918|NCT03895411|Drug|Propafenone|Oral Propafenone 5mg/kg/time, pre 8h
36919|NCT03895411|Drug|betaloc|Oral betaloc 0.5mg/kg/time ,pre 12h
36920|NCT03895398|Other|nutrition and psychosocial intervention with community participatory|community participation to ensure the intervention is given to the study subject (underfive children)
36921|NCT03895385|Drug|Bimekizumab|Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
36922|NCT03895372|Drug|PF-06826647 or Placebo|Delivered orally (tablet) once daily (QD) for 16 weeks during the Investigational Treatment Period
36923|NCT03895372|Drug|PF-06826647|Delivered orally (tablet) once daily (QD) for 24 weeks during the Extension Period
36924|NCT03895359|Radiation|Stereotactic Body Radiation|For patients randomized to the SMRT arm, SBRT is to be delivered over 5 fractions delivered over 5 to 15 days.
36925|NCT03895359|Drug|Transarterial Chemoembolization|Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
36926|NCT03895346|Behavioral|Mindfulness|Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)
36927|NCT03895346|Behavioral|Brain Games and Puzzles|Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
36928|NCT03895333|Other|Audiological profiling and bone mineral densitometry measurement|bone mineral densitometry measurements and hearing test patients, osteoporosis according to whether the hearing test will be analyzed.
36929|NCT03895320|Behavioral|Sexual Health Risk Assessment|The self-assessment ('Sexual Health Risk Assessment'), will pertain to sexual and reproductive health. The self-assessment, will include a valid clinical prediction tool, established to predict STI positivity.
37102|NCT03893942|Other|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
70973|NCT03629080|Biological|placebo|Saline will be used for placebo.
36930|NCT03895320|Behavioral|Sexual Health Score|The results of the 'Sexual Health Risk Assessment' will produce a score ('Sexual Health Score'). The 'Sexual Health Score' will be presented as a number (0/10) and will be organized by category: Low, Medium or High Risk.
36931|NCT03895320|Behavioral|Sexual Health Messaging|After the score ('Sexual Health Score') the participant will receive personalized messaging ('Sexual Health Messaging') that relates to their score and risk level (i.e. Low, Medium or High). Short messages that indicate key steps the person can take to lower their risk for STIs will be displayed on the screen that correspond to their 'Sexual Health Score.'
36932|NCT03895320|Behavioral|Water SSB Quiz|The self-assessment ('Water SSB Quiz') will pertain to consumption of water, soda and sugar sweetened beverages. There will not be a comparable clinical prediction tool in the control self-assessment ('Water SSB Quiz).
36933|NCT03895320|Behavioral|Water SSB Score|The results of the 'Water SSB Quiz' will produce a score ('Water SSB Score'). The 'Water SSB Score' will be presented as a number (0/10).
36934|NCT03895320|Behavioral|Water SSB Messaging|After the score ('Water SSB Score') the participant will receive personalized messaging ('Water SSB Messaging') that relates to their score. Short messages that indicate key steps the person can take to meet the recommended daily intake for water and sugar sweetened beverages will be displayed on the screen that correspond to their 'Water SSB Score.'
36935|NCT03895320|Behavioral|STI Screening|All participants regardless of group, will be offered a STI screening kit immediately after receipt of their respective program (intervention or control). Participants will have the option of completing the kit at the first study visit, taking it with them after the first study visit is over, or receiving it later from one of our staff either at our local project office or the kit can be dropped off at a location the participant chooses. Completed kits can be returned to our office or picked up by a study staff. (NOTE: while the STI screening kit will be available to all participants should they request it at subsequent study visits, e.g. the 3- and 6-month follow-ups, the STI screening kit will only be explicitly offered by the study team at the first study visit immediately after participants complete their respective quiz).
36936|NCT03895307|Other|kinesio tape|two 15 cm I type kinesio tape applied longitudinally
36937|NCT03895307|Other|local anesthetic|local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection
36938|NCT03895307|Other|local serum physiologic|serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
36939|NCT03895294|Other|Health care under the strategic purchase-Clinical pathway|1) purchase of DAA by the MoHSP; 2) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in internal medicine, hepatology or Infectious disease; 3) daily supervised drug administration by a nurse or weekly treatment dispensing by pharmacist; 4) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, week of the end of treatment (8, 12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support. In case of identifying any Drug-related Problem, the respective pharmaceutical intervention was made.
36940|NCT03895294|Other|Usual care process prior strategic purchase-clinical pathway|1) diagnosis of the patient (confirmed by quantitative HCV RNA test); 2) prescription of the treatment by a specialist in hepatology; 3) weekly treatment dispensing by pharmacist; 4) patient use; 5) Pharmaceutical Care (includes: consultation with pharmacist at weeks 0, 4, 8, week of the end of treatment (12 or 24) and week of evaluation of effectiveness (week 12 or 24 after the end of treatment); health education and administrative support). In case of identifying any Drug-related problem, the respective pharmaceutical intervention was made.
36941|NCT03895281|Diagnostic Test|FilmArray Meningitis/Encephalitis (ME) Panel|The FilmArray ME pouch is a closed system disposable that houses all the chemistry required to isolate, amplify and detect nucleic acid from multiple meningitis and encephalitis pathogens within a single CSF specimen obtained from a lumbar puncture. The rigid plastic component (fitment) of the FilmArray ME pouch contains reagents in freeze-dried form. The flexible plastic portion of the pouch is divided into discrete segments (blisters) where the required chemical processes are carried out. The user of the FilmArray ME Panel loads the sample into the FilmArray ME pouch, places the pouch into the FilmArray instrument/Module, and starts the run. All other operations are automated.
36942|NCT03895268|Device|ALiA Analyser|NPS specimens shall be tested with the investigational device
36943|NCT03895268|Device|Influenza A+B Test Kit|NPS specimens shall be tested with the investigational device
36944|NCT03895255|Procedure|Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
36945|NCT03895255|Procedure|Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization|Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
36946|NCT03895242|Behavioral|Group 1:Supine-Prone|After the infants were treated and fed, supine position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in supine position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the supine positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the prone position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the prone position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
36976|NCT03894982|Other|Group Classes|Family Learning on Asthma Topics classes will aim to emphasize, encourage, and support teaching methods that include standardized instructions. There will be three topics lasting approximately 45 minutes: General Asthma Knowledge; Asthma Triggers, Medications, and Self-Management. These topics were chosen based on the EPR-3 guideline recommendations to ensure the continuity of messaging. Each class size will be approximately 8 persons and will be taught by a Certified Asthma Educator (AE-C) and will be held in the Family Learning Center at the Children's Hospital Colorado. Classes will be taught in both English and Spanish.
36947|NCT03895242|Behavioral|Group 2:Prone-Supine|After the infants were treated and fed, prone position was first given and waited for 60 minutes to stabilise (no data was collected during this time). After 61 minutes, it was allowed to stay in prone position for 2 hours. From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min. At the end of two hours, the infant was given the supine position after the routine requirements such as diaper replacement were completed. Infants were waiting for 60 minutes to stabilize after the supine position (no data was collected during this time). From the 61st minute, heart rate and oxygen saturation were evaluated in each infant in the prone positions at intervals of 15 min over a period of 120 min.
36948|NCT03895229|Drug|Empagliflozin 10 MG Oral Tablet [Jardiance]|Empagliflozin is a sodium-glucose co-transporter 2 inhibitor approved for treatment of type 2 diabetes mellitus
36949|NCT03895203|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
36950|NCT03895203|Drug|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
36951|NCT03895203|Other|Placebo|Subjects will receive placebo at pre-specified time-points.
36952|NCT03895190|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
36953|NCT03895177|Diagnostic Test|contrast enhanced computed tomography|pancreatic protocol CT with 80kVp tube voltage and more than 500mA tube current acquire late arterial phase and portal venous phase using volus tracking method
36954|NCT03895164|Behavioral|Enhanced NE|Standard nutrition education package from primary health care enhanced with local specific food-based complementary feeding recommendation
36955|NCT03895164|Behavioral|Standard NE|Standard nutrition education package from primary health care
36956|NCT03895151|Dietary Supplement|Milk supplementation|Fresh milk from local farmer. No artificial sweetener and preservatives. Brandless.
36957|NCT03895151|Other|Food Based Recommendation (FBR) nutrition education|Food Based Recommendation is result of OPTIFOOD WHO that analysed local food to optimize nutritional status according to problem nutrient.
36958|NCT03895138|Other|Standard Glucommander Protocol (SGP)|Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.
36959|NCT03895138|Other|Optimized Glucommander (OGM)|The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.
36960|NCT03895125|Behavioral|[year1] dual-task training with task priority strategy|postural focus: focus mainly on postural performances while dual-tasking suprapostural focus: focus mainly on suprapostural performances while dual-tasking
36961|NCT03895125|Behavioral|[year2-3] dual-task training with internal and external focus|internal focus: focus mainly on body movements external focus: focus mainly on object in the environment
36962|NCT03895112|Drug|AVID200|dose cohorts of 21-day cycles
36963|NCT03895099|Drug|Desogestrel early follicular phase|Start of ovarian stimulation in early follicular phase
36964|NCT03895099|Drug|Desogestrel medium follicular phase|Start of ovarian stimulation in medium follicular phase
36965|NCT03895099|Drug|Desogestrel ovulatory phase|Start of ovarian stimulation in ate follicular phase
36966|NCT03895099|Drug|Desogestrel late follicular phase|Start of ovarian stimulation in ovulatory Phase
36967|NCT03895099|Drug|Desogestrel luteal phase|Start of ovarian stimulation in luteal phase
36968|NCT03895086|Other|Specific Physical Activity|An individual one hour face-to-face session conducted by adaptated physical activities teachers followed by eight telephone sessions by physical therapists and adaptated physical activities teachers (4 sessions each)
36969|NCT03895086|Behavioral|Classic Physical Activity|"One session per week in groups conducted by adaptated physical activities teachers of Siel Bleu association"
36970|NCT03895073|Other|healthy volunteers|the questionnaire has been assessed by both groups, healthy and heart failure
36971|NCT03895060|Device|autogenous ring blockls with GBR covered by collagen membrane|"A crestal incision is made using No. 15 blade extending over the anterior maxilla, an anterior vertical releasing incision is made and a full mucoperiosteum flaps elevated to provide access to the alveolar ridge and the lateral aspect of the maxilla~Autogenous onlay ring blocks is taken by a trephine bur from the chin area and then fixed by screws to the deficient maxillary alveolar height.~Equally autogenous and xenograft bone particles is packed around the screw to fill the defect area completely.~The collagen membrane is fixed to the alveolar ridge by bone tacks and the mixture of autogenous and xenograft bone is then packed.~The flap will then be closed using interrupted 4/0 resorbable sutures."
36972|NCT03895047|Other|tomographic EEG Neurofeedback Training|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex, the insula and the anterior cingulate cortex and deliver feedback for the patient
36973|NCT03895021|Behavioral|Pisando Fuerte|"Pisando Fuerte, a linguistically and culturally appropriate version for Spanish speakers of an evidence-based fall prevention program (Stepping On [SO])."
36974|NCT03895008|Other|Cardia and Non-cardia gastric cancer|We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
36975|NCT03894995|Other|Installation of ventilation|The intervention is installation of a ventilating structure, in this case a window in the house roof.
37058|NCT03894280|Drug|Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals|2 inhalations in one study period
37059|NCT03894280|Drug|SERETIDE DISKUS® 250/50 inhalation powder/GSK|2 inhalations in one study period
36977|NCT03894969|Biological|GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E|2 doses of the investigational NTHi-Mcat vaccine will be administered 2 months apart to all subjects in all the groups. The vaccine will be given intramuscularly (IM) in the upper deltoid of non-dominant arm
36978|NCT03894969|Biological|Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)|2 doses of the Shingrix vaccine will be administered at days 1 and 61 to all subjects in groups Sh_NTHi-Mcat_1, 3 and 6. The vaccine will be given intramuscularly (IM) in the upper deltoid of the non-dominant arm
36979|NCT03894943|Diagnostic Test|PET/CT scan|Patient receive a PET/CT scan of their cerebrum and lumbar spine prior to surgery, 4-6 weeks after surgery and 6 months after surgery
36980|NCT03894943|Diagnostic Test|Quantitative Sensory Testing|Patients undergo a battery of quantitative sensory tests prior to surgery, 4-6 weeks after surgery and 6 months after surgery
36981|NCT03894930|Behavioral|Metta meditation|Administered 5 days per week for 8 weeks.
36982|NCT03894917|Other|Comprehensive Geriatric Assessment (CGA)|Assessments will be done for participants that are 65 years or older.
36983|NCT03894904|Drug|Papaverine|"1mL volume bolus will be given from the research syringe as soon as the arterial catheter is placed. Another subsequent 1mL bolus will be given one hour after the initial bolus if needed."
36984|NCT03894904|Drug|Heparin|"1mL volume bolus will be given from the research syringe as soon as the arterial catheter is placed. Another subsequent 1mL bolus will be given one hour after the initial bolus if needed."
36985|NCT03894891|Drug|Nivolumab|Nivolumab is a type of immunotherapy that tries to enhance participants own immune system to fight cancer
36986|NCT03894891|Drug|Cisplatin|Cisplatin is a chemotherapy medication used to treat a number of cancers
36987|NCT03894891|Drug|Docetaxel|Docetaxel (Taxotere®) is a chemotherapy drug. It is used to treat many types of cancer including head and neck
36988|NCT03894891|Radiation|Radioimmunotherapy|Radiation Therapy to shrink or kill tumors.
36989|NCT03894865|Other|procedure1|The students will be asked to bend forward with his knees straight, feet together and hands freely and loosely hanged. if there was scoliosis the rib cage rotated and a hump appeared. Positive test indicated the presence of a rib hump and negative if there was any hump appeared
36990|NCT03894865|Other|procedure2|Measurement of the angle of trunk rotation (ATR) by using a scoliometer HD smartphone application.
36991|NCT03894852|Diagnostic Test|PCR and cytogenetics|detection of SRSF2 gene mutation and cytogenetic studies
36992|NCT03894839|Other|glutaraldehyde disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
36993|NCT03894839|Other|Chlorhexidine gluconate disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
36994|NCT03894839|Other|Sodium hypochlorite disinfection and microwave application|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
36995|NCT03894839|Other|glutaraldehyde disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
36996|NCT03894839|Other|Chlorhexidine gluconate disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
36997|NCT03894839|Other|Sodium hypochlorite disinfection and ozone therapy|Combination of the chemical disinfection which could be done by patients and professional disinfection methods which is done by dentists
36998|NCT03894826|Drug|Vorinostat 100 MG|Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks
36999|NCT03894813|Drug|"Probiotics and Metronidazole"|Oral probiotics (Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) (qd, 30 days)+Metronidazole Suppositories (qd, 7 days)
37000|NCT03894813|Drug|Metronidazole Vaginal|Metronidazole Suppositories,qd, 7 days
37001|NCT03894800|Drug|Methoxyflurane (M)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention inhalation of metoxyflurane 3 ml and NaCl i.v. will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
37002|NCT03894800|Drug|Fentanyl (F1)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.025 mg i.v. and NaCl for inhalation will be administered(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
37003|NCT03894800|Drug|Fentanyl (F2)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention fentanyl 0.05 mg i.v. and NaCl for inhalation will be administered.(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
37004|NCT03894800|Drug|NaCl (C)|The subjects will undergo CPT (cold pressor test) to determine the analgesic effect of the drugs, in this intervention NaCl i.v. and NaCl inhal will be used - placebo(13,14) The CPT will be conducted using a temperature-controlled bath with circulating 3°C water (FP 45-HE Refrigerated/Heating Circulator, Julabo Labortechnic, 77960 Seelback, Germany). The subjects submerge their right hand to the wrist with fingers abducted for up to 90 s. The endpoints are NRS scores every 10 s.This test will be performed 3 times for each session.
37060|NCT03894280|Other|Activated Charcoal suspension|oral suspension before and after inhalation of study Investigational Products
37103|NCT03893942|Other|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
37005|NCT03894774|Behavioral|Intensive in-patient psychotherapy treatment|Intensive non-pharmaceutical in-patient intervention with high degrees of individual psychotherapy (5 sessions a week, psychodynamic and specific trauma therapy), group therapy (music-, arts-, sports- and concentrative movement therapy - each one session a week) as well as an ongoing milieutherapeutic setting where patients live during the whole treatment (approximately a 1:1-Ratio caregiver per patient is given) of 6 to 8 month treatment duration.
37006|NCT03894774|Other|Treatment as usual|Combination of behavioral or psychoanalytic outpatient psychotherapy and pharmacotherapy
37007|NCT03894761|Other|Night Pain in Patients with Rotator Cuff Syndrome|The pain severity was evaluated using a 10 cm visual analogue scale , where 0 represented no pain, while 10 represented unbearable pain.At evaluation, the average of the pain during night for the last one week were inquired.
37008|NCT03894748|Drug|Botulinum Toxin Type A|20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
37009|NCT03894722|Procedure|Control|During the third molar extraction the saline solution will be used in the control group.
37010|NCT03894722|Procedure|0.5% concentration of PVP-I|During the third molar extraction 0.5% concentration of PVP-I solution will be used in the test group.
37011|NCT03894722|Procedure|1 % concentration of PVP-I|During the third molar extraction 1 % concentration of PVP-I solution will be used in the test group.
37012|NCT03894722|Procedure|3 % concentration of PVP-I|During the third molar extraction 3 % concentration of PVP-I solution will be used in the test group.
37013|NCT03894709|Behavioral|family-centered care model|Teaching and training family caregivers to enhancing their skills for providing care for hip-fractured older persons The content of teaching material provided including management of wound, nutritional and balanced diet, rehabilitation exercises, home environment and behavioral problems after a hip surgery
37014|NCT03894696|Drug|Direct Acting Antivirals|follow up chronic HCV patients recieving DAAs to detect anxiety and depression
37015|NCT03894683|Drug|Melatonin 10 mg|Melatonin tablets (10 mg)
37016|NCT03894683|Drug|Placebo Oral Tablet|Placebo tablets manufactured the same as melatonin tablets
37017|NCT03894670|Other|Standard mixed breakfast meal|"The standard mixed breakfast meal consists of:~150 g yoghurt, 20 g muesli; 50 g wheat bun; 22 g rye bread; 25 g cheese; 25 g marmalade; 8 g butter; Total energy content: 500 kcal Macronutrient composition: 34 E% fat, 17 E% protein, 49 E% carbohydrate"
37018|NCT03894670|Other|SmartBar™|SmarBar™ (Medtronic, North Haven, MA, USA). Weight: 72 g; Total energy content: 260 kcal Macronutrient composition: 7 E% fat, 19 E% protein, 74 E% carbohydrate.
37019|NCT03894657|Diagnostic Test|Nasal brushing|Nasal scrapping at visit V0
37020|NCT03894657|Other|Sputum sample|"Visit V0 : 1 Aliquot for Sputum biobank~Visit V1 : 2 Aliquots~for Sputum biobank~for pharmacokinetic (PK) study~Visit V2 : 2 Aliquots~for Sputum biobank~for pharmacokinetic (PK) study"
37021|NCT03894657|Other|blood sample|"Visit V0 : Additional 14 mL~5 mL in ethylenediaminetetraacetic acid (EDTA) tube for DNA Analysis~3 mL in Dry tube for Serum biobank~6 mL in acid citrate dextrose (ACD) tube for peripheral blood mononuclear cell (PBMC) biobank~Visit V1 : Additional 9 mL~2x3 mL in dry tube for pharmacokinetic (PK) study~3 mL in Dry tube for Serum biobank~Visit V2 : Additional 6 mL~3 mL in dry tube for pharmacokinetic (PK) study~3 mL in Dry tube for Serum biobank"
37022|NCT03894657|Drug|Orkambi|"Study the predictive value for improvement of the respiratory function after 24 weeks of Orkambi treatment.~Orkambi treatment is part of usual care."
37023|NCT03894644|Other|Simulation technology|The intervention involves three consecutive sessions of the PeriopSim™ Instrument Trainer, followed by two consecutive sessions of the PeriopSim™ for Burr Hole Surgery (https://periopsim.com).
37024|NCT03894631|Procedure|KDB/Phacoemulsification|50 eyes of 50 patients will receive combined KDB/phaco surgery
37025|NCT03894631|Procedure|Trabectome/Phacoemulsification|The contralateral 50 eyes of the same 50 patients will receive combined Trabectome /phaco surgery
37026|NCT03894618|Drug|SL-279252|The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
37027|NCT03894605|Device|thalassemia|thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion
37028|NCT03894592|Other|Virtual reality|Trauma patients enrolled in the study will be offered Virtual Reality experieince per the protocol
37029|NCT03894579|Biological|Study Product: SNK01|SNK01 administered using an intravenous line (IV) to all patients at weeks 1, 2, 3, and 4
37030|NCT03894566|Other|No intervention - birth cohort study|There are no interventions because it is a birth cohort study
37031|NCT03894553|Device|ExAblate Neuro|Unilateral stereotactic focused ultrasound lesioning of the contralateral mesencephalon
37036|NCT03894527|Behavioral|Single Bout of Exercise|An exercise condition, which will be walking at a moderate intensity (~70% VO2peak). Time will vary based upon individual fitness levels to burn ~400kcals (estimated 0.5 - 1hr). Oxygen consumption will be measured during exercise via a metabolic cart to confirm energy expenditure. Participants will then rest following the exercise procedure for 20 minutes. Between 20 and 45 minutes following exercise, oxygen consumption will be measured to understand and capture excess post-exercise oxygen consumption (EPOC). Following this, participants will be provided with a standardize dinner and snack to consume in the AMP lab.
37037|NCT03894527|Behavioral|Control Condition|A control (no-exercise) condition. Participants will report to the AMP lab to rest for the same duration as the exercise bout and consume the standardized dinner and snack.
37100|NCT03893942|Other|Langer Mindfulness Scale (LMS)|The LMS is a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
37101|NCT03893942|Other|Mindful Attention Awareness Scale (MAAS)|The MAAS is a 15-item questionnaire, designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present
37038|NCT03894501|Behavioral|Mindfulness Oriented Recovery Enhancement|MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
37039|NCT03894501|Behavioral|Methadone program behavioral treatment as usual|In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
37040|NCT03894488|Diagnostic Test|FilmArray Gastrointestinal (GI) Panel|The FilmArray GI Panel tests for 22 of the most commonly associated pathogens related to gastroenteritis—all from one patient sample, one easy to use reagent, and results are available in about one hour.
37041|NCT03894475|Device|AioCare|AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
37042|NCT03894475|Device|Spirometer USB CPFS/D (MGC Diagnostics)|Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
37043|NCT03894462|Behavioral|Attempted Suicide Short Intervention Program|ASSIP is a manualized, three-session intervention: In Session 1, the therapist guides the patient in telling the story of their attempt. The session is video recorded. In Session 2, the therapist and patient sit side-by-side to view selections of the video, working together to understand the feelings and events that preceded the attempt. The patient is assigned a homework task. In Session 3, the therapist and patient create a summary of the suicide attempt and what led up to it, along with creating a personal safety plan.
37044|NCT03894462|Behavioral|Zero Suicide Usual Care|Participants will have access to outpatient treatment in facilities that are adopting NYS Zero Suicide protocols. Those who do not engage in care will nonetheless experience enhanced transition and follow-up contact from the services from which they are discharged
37045|NCT03894449|Combination Product|Prebiotic + Iron Forificant|A combination dosage of prebiotic (Inulin or GOS) and Iron Fortificant (FeSO4 or NaFeEDTA) will be given to the study subjects.
37046|NCT03894436|Combination Product|Ultrasound assessment of diaphragm thickness in B-mode|assess the thickness of diaphragm needed as a tool for prediction of extubation and proper timing of weaning from mechanical ventilation in the ICU which is measured by B mode ultrasound in ventilated cancer patients
37047|NCT03894397|Device|Electrical stimulation of the BNST|Electrical stimulation of the BNST
37048|NCT03894384|Diagnostic Test|Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)|Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
37049|NCT03894371|Device|Thermage FLX|Thermage FLX system for the correction of mild to moderate laxity of the skin of the face, neck, and eyelids.
37050|NCT03894358|Dietary Supplement|FeFum and 7.5 g prebiotic mixture|"The 3 weeks intervention will consist of 24 g of wheat-based instant cereal and 90 ml of water per portion and will contain 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 7.5 g prebiotics mixture~The absorption study test meals will consist of 24 g wheat-based instant cereal and 90 ml of water per portion and additionally:~Test meal 1 will be composed of: 3.6 mg of Fe as 57FeFum and 0 g prebiotic mixture added extrinsically.~Test meal 2 will be composed of: 3.6 mg of Fe as 1.5 mg iron as 58FeFum, 2.09 mg iron as 56FeFum and 7.5 g prebiotic mixture added extrinsically."
37051|NCT03894358|Dietary Supplement|FeFum and 3 g prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) plus 3 g prebiotics mixture per portion
37052|NCT03894358|Dietary Supplement|Fefum and no prebiotic mixture|Standard wheat-based instant cereal containing 3.6 mg FeFum and AA (molar ratio Fe:AA between 2.5 and 3) per portion.
37053|NCT03894345|Drug|Prazosin|Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy
37054|NCT03894332|Diagnostic Test|Electrical Impedance Tomography (EIT)|"After enrollment, a silicon EIT belt of proper size with 16 electrodes was placed around the patient's chest between the 4th and 6th intercostal spaces, and connected to the EIT device. All patients were ventilated in Pressure Support Ventilation (PSV) mode, with a dedicated ventilator connected to the EIT device.~We acquired 5-min EIT data records at baseline (during PSV), during the first (SBT_0) and the last (SBT_30) 5 minutes of SBT, and, when the patient was extubated, during spontaneous breathing soon after (SB_0) and 30 minutes after extubation (SB_30).~EIT and ventilator data were recorded at a sample of 20 Hz. The last 3 minutes of each record were analyzed.~We measured respiratory rate (RR); Vt changes from baseline, expressed as percent (dVt%); dEELI variations from baseline, expressed in mL; the Global Inhomogeneity index (GI); Impedance ratio (IR) and the Center of Ventilation (CoV)."
37055|NCT03894306|Other|Medication lock box|given a lock box and instructed on how to use the device.
37056|NCT03894306|Other|medication lock bag|given a lock bag and instructed on how to use the device.
37057|NCT03894306|Other|brief counseling|After completing the per-intervention survey, a research assistant or investigator will perform brief counseling, including educational handouts and information on safe medication storage
37061|NCT03894267|Device|Cutimed Siltec Heel and Sacrum dressing|The dressing has been developed to facilitate exudate management in the treatment of wounds. Newly formed tissue enjoys optimal protection under a moist environment. The foam core with super-absorbers ensures reliable absorption in slightly to heavily exuding wounds. This core has an excellent retention capacity, even under compression. Hydrogen bridges bind the water so securely that, even when subject to pressure, the water is not released. Vertical absorption through the polyurethane foam and the hydro- phobic wound contact layer minimizes the risk of macerations in the peri-ulcer skin.
37062|NCT03894254|Other|no intervention|This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
37063|NCT03894241|Behavioral|physical activity|"Participants will assist to the three different sessions at the same weekday (e.g., Monday) and at the same daytime to avoid differences in preceding school activities or circadian rhythms. Participants will undergo a Sedentary condition (SC), sitting and watching a documentary on TV as has been used previously, and two different PA protocols consisting in Moderate-Intensity Continuous Training (MICT), i.e., continuous outdoor walking, and Cooperative High-Intensity Interval Training (C-HIIT), composed of a circuit training with a partner (physical education teacher)"
37064|NCT03894215|Drug|AGEN2034|PD-1 antibody
37065|NCT03894215|Drug|AGEN1884|CTLA-4 antibody
37066|NCT03894189|Drug|Doxapram Hydrochloride|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
37067|NCT03894189|Drug|Theophylline|the diaphragmatic function will be assessed measuring right and left diaphragmatic thickening fraction in the two groups to be compared as a primary outcome using ultrasound. following the administration of the selected drug
37068|NCT03894176|Other|Plasma PTX3 concentration|Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
37069|NCT03894150|Drug|F0002-ADC|Every 21 days for 1 cycle, continue treatment until a maximum 16 cycles. Dose Escalating: 0.3 - 4.8 mg/kg
37070|NCT03894137|Dietary Supplement|Grains of Paradise (Aframomum Melegueta)|This is a randomized, double blind, crossover design testing the effect of grains of paradise on resting energy metabolism
37071|NCT03894124|Drug|Doravirine|Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
37072|NCT03894111|Other|decesased patients|mortality ratio
37073|NCT03894098|Procedure|Nerve block|High ankle nerve block
37074|NCT03894085|Drug|Paroxetine|Paroxetine treatment for 4 weeks usage:20-80mg Qd
37075|NCT03894072|Device|CPAP|Conventional CPAP
37076|NCT03894072|Device|HFHO|A device that can provide heated humidified oxygen up to 30-60 liter per minute, FiO2 (fraction of inspired oxygen) 0.21-0.95
37077|NCT03894059|Other|Educational Intervention|Additional training provided to ambulance telecommunicators in participating sites to help increase recognition of agonal breathing in the presence of out-of-hospital cardiac arrest.
37078|NCT03894046|Drug|ETX2514/Sulbactam + Imipenem/Cilastin|ETX2514/1.0 g sulbactam IV infused every 6 hours (q6h) plus 1.0 g imipenem/1.0 g cilastatin IV infused every 6 hours(q6h)
37079|NCT03894046|Drug|Colistin + Imipenem/Cilastin|2.5 mg/kg colistin IV infused every 12 hours (q12h) plus 1.0 g imipenem/1.0 g cilastatin IV infused every 6 hours (q6h).
37080|NCT03894046|Drug|ETX2514/Sulbactam + Imipenem/Cilastin|ETX2514/1.0 g sulbactam IV infused every 6 hours (q6h) plus 1.0 g imipenem/1.0 g cilastatin IV infused every 6 hours(q6h)
37081|NCT03894033|Device|Ascyrus Medical Dissection Stent (AMDS)|The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
37082|NCT03894007|Drug|Docetaxel|75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.
37083|NCT03894007|Drug|Carboplatin|AUC 6 iv, day 1 every third week, 4 courses preoperatively.
37084|NCT03894007|Drug|Trastuzumab|600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.
37085|NCT03894007|Drug|Pertuzumab|840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.
37086|NCT03894007|Drug|Epirubicin|90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively
37087|NCT03894007|Drug|Cyclophosphamide|600 mg/m2 iv, day 1 every third week, 3 courses preoperatively
37088|NCT03894007|Drug|Atezolizumab|840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.
37089|NCT03894007|Drug|Trastuzumab emtansine|3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.
37090|NCT03893994|Other|Stretching exercises|Stretching exercises will be applied 6 days a week, 30sec / 5 reps
37091|NCT03893981|Other|Proprioception and Balance Program|Balance Trainer device and playing ball in tandem position for using to improve balance, vibration and reposition exercises for using to improve proprioception. Progressive of training will increase after each 2 weeks.Patients will be taken to the treatment program 3 days in a week for 8 weeks.
37092|NCT03893981|Other|Strengthening Program|Exercises which include open and closed kinetic chain exercise will be applied to strength knee and hip muscle. Progressive of training will increase after each 2 weeks. Patients will be taken to the treatment program 3 days in a week for 8 weeks.
37093|NCT03893968|Behavioral|Information by an assistant nurse|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by an assistent nurse.
37094|NCT03893968|Behavioral|Information by a doctor|Information received by patients after ambulatory hand surgery under local anaesthetic about postoperative self care given by a doctor.
37095|NCT03893955|Drug|ABBV-927|intravenous infusion
37096|NCT03893955|Drug|ABBV-368|intravenous infusion
37097|NCT03893955|Drug|ABBV-181|intravenous infusion
37098|NCT03893955|Drug|Docetaxel|intravenous infusion
37099|NCT03893942|Other|Questionnaires administration|Psychological and quality of life questionnaires
70978|NCT03629054|Drug|Metformin HCl (fixed dose combination)|single dose
37104|NCT03893942|Other|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
37105|NCT03893942|Other|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
37106|NCT03893942|Other|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
37107|NCT03893929|Diagnostic Test|New Biological markers for prostate cancer diagnosis and management|To identify potential new blood and urine markers for the diagnosis, risk stratification and prognosis prediction for prostate cancer in Chinese population.
37108|NCT03893916|Procedure|MEG - EEG HR|"MEG : Magnetoencephalography is the study of the magnetic fields produced by the electrical activity of the brain.~MEG signals are obtained while the patient is placed in a device specific to this technique. The latter comprises a recording chamber, recording sensors which are placed in a cryostat and an electronic measuring system. The magnetic fields are measured while the subject is placed in a shielded magnetic chamber protecting it from variations in the ambient magnetic field (displacement of metal masses, sector ...).~EEG HR: High Resolution EEG is defined as the recording of cerebral electrical activity with 128 electroencephalographic electrodes and with high temporal resolution usually followed by the use of source localization tools. The HR EEG is therefore derived from standard EEG techniques, but requires a higher number of electrodes and the use of source localization tools."
37109|NCT03893903|Drug|IDH1R132H peptide vaccine|"The vaccine is applied by s.c. injection with 300 μg IDH1R132H peptide emulsified in 0.5 ml 33% DMSO / 0.5 ml Montanide® per dose.~Patients receive 3 doses in two week intervals for 6 weeks, followed by re-resection. 4 weeks after surgery, treatment will be resumed consisting of 5 additional vaccinations in 4 week intervals, followed by maintenance vaccines until progression in three months intervals after a pause of 16 weeks."
37110|NCT03893903|Drug|Avelumab|"Avelumab is a humanized anti-PD-L1 antibody approved for patients with Merkel cell carcinoma and urothelial cancer. It is applied by i.v. infusion with 10 mg/kg per dose.~Patients receive 3 doses of Avelumab in 2week intervals for 6 weeks, followed by re-resection. Avelumab will be administered in monthly intervals starting 4 weeks after the surgery until progression."
37111|NCT03893890|Biological|Previously Treated with EN3835|No treatment to be administered - Observational only
37112|NCT03893877|Device|nasal cannula|experimental group will be applied nasal cannula
37113|NCT03893877|Device|nasal mask|active comparator group will be applied nasal mask
37114|NCT03893864|Dietary Supplement|Administration of a product with Fitosomed Ubiquinone|Healthy runner athletes, > 50 years old, without any chronic illness, without any other nutritional supplementation or drug intervention, took 100 mg/d of fitosomed Ubiquinone with lunch, daily, during one month, maintaining their usual training sessions.
37115|NCT03893864|Procedure|Coenzyme Q10 level in muscle biopsies|Determination of the muscle Ubiquinone concentration, the metabolic and structure characteristics of the muscle before and after one month of supplementation
37116|NCT03893864|Diagnostic Test|Coenzyme Q10 level in plasma, blood cells, urine cells|Determination of Ubiquinone concentration in different tissues before and after one month of supplementation or not
37117|NCT03893864|Diagnostic Test|Total antioxidant capacity after strenous exercise|Determination of the Total Antioxidant Capacity after strenous exercise in the Climate Chamber
37118|NCT03893851|Behavioral|Interactions Competencies with Children - for Teachers (ICC-T)|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
37119|NCT03893825|Drug|TV-46000|subcutaneous (sc) injection
37120|NCT03893825|Drug|Placebo|Matching Placebo
37121|NCT03893812|Device|MRI|diffusion weighted MR
37122|NCT03893812|Device|Ultrasound|Color Doppler ultrasound
37123|NCT03893799|Drug|Iron sucrose (FeS) and Stannous Protoporphyrin (SnPP)|Escalating doses of iron sucrose and stannous protoporphyrin
37124|NCT03893786|Device|Robotic Rehabilitation|"Fifteen patients with Parkinson's Disease will perform ten 45-minute training sessions of the upper limb bilaterally with the Armeo®Spring, an electromedicad device aimed at improving force and coordination in neurologically affected patients.~The device was built to sustain the forearm during the upperlimb training and is equipped with a VR screen with which the patient may interact during the playful and motivating rehab."
37125|NCT03893773|Device|doppler ultrasonagraphy|"The following parameters will be measured:~Hepatic artery Resistance index (HARI), Diameter, peak systolic velocity (HAPSV, cm/s).~Portal vein peak velocity (PVPV) and diameter at the anastomotic and non-anastomotic sites.~Hepatic vein peak velocity and wave form"
37126|NCT03893760|Diagnostic Test|Ventriculo-arterial coupling assessment (R-V/A)|R-V/A was achieved by computing the R-Elv/P-Ea ratio (Right ventricular elastance/Pulmonary arterial elastance). R-Elv was computed as PAPm / end-systolic area (ESA) of the right ventricle. P-Ea was obtained as (PAPm-PCWP)/ right ventricle stroke volume (R-SV).
37127|NCT03893747|Biological|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
37128|NCT03893747|Biological|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
37129|NCT03893747|Biological|The third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) producted by 40 L reactor
37130|NCT03893747|Biological|The first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the first batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
37131|NCT03893747|Biological|The second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor|500 subjects will be randomized to receive the second batch of inactivated EV-A71 vaccine (vero cell) producted by 150 L reactor
37132|NCT03893747|Biological|The third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor|500 subjects will be randomized to receive the third batch of inactivated EV-A71 vaccine (vero cell) proudected by 150 L reactor
37133|NCT03893734|Drug|methadone|Patients in the methadone group will receive a syringe of methadone at induction of anesthesia and a syringe of saline at the end of anesthesia
37134|NCT03893734|Drug|Hydromorphone|Patients in the hydromorphone group will receive a syringe of saline at induction of anesthesia and a syringe of hydromorphone at the end of anesthesia
37135|NCT03893721|Diagnostic Test|arsenic exposure|analysis of hair samples for Arsenic using Agilent graphite tube atomizer 120
37136|NCT03893708|Behavioral|Prenatal yoga|The prenatal yoga classes will be offered at Urban Wellness (2024 N. 7th St., Phoenix, AZ 85006). Classes will be offered Tuesdays's from 4:15-5:30 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
37137|NCT03893708|Behavioral|Pregnancy education|Pregnancy education classes will be offered at the Arizona Biomedical Collaborative Building on ASU Phoenix Campus. Classes will be offered on Tuesday's from 5:30-6:45 pm and Saturday's from 9:00-10:15 am. Participants will be able to attend both classes if they so choose but are only asked to attend 1/week. Participants will be asked to arrive to class at least 10 minutes early in order for the research team to collect their weight in a private room. Additionally, if participants have attended at least 70% of classes (1 per week for 8/12 weeks), participants will be able to attend sessions up until birth (beyond the 12-week intervention) if they so choose. If participants decide to attend classes beyond the 12-week intervention the investigators will continue to collect their weight at each session.
37138|NCT03893695|Drug|GT90001 and Nivolumab|Stage1:Dose de-escalation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.
37139|NCT03893682|Drug|CG-806|CG-806 will be given in ascending doses starting at 150 mg PO BID until the maximum tolerated dose or recommended dose is reached.
37140|NCT03893669|Biological|NBP607|1 dose, 0.5ml, Intramuscular (IM) injection
37141|NCT03893669|Biological|Agrippal|1 dose, 0.5ml, Intramuscular (IM) injection
37142|NCT03893643|Other|no intervention|no intervention in an observational study
37143|NCT03893630|Drug|Acetylsalicylic Acid 81 mg|Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
37144|NCT03893630|Drug|Acetylsalicylic Acid 162 mg|Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
37145|NCT03893630|Other|Control|Standard of Care
37146|NCT03893617|Drug|Propranolol|A single oral dose (80mg) of propranolol will be administered in a blinded capsule at the start of the baseline monitoring period of the acute stress study visit.
37147|NCT03893617|Drug|Placebo oral capsule|A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
37148|NCT03893617|Behavioral|Acute stress task|Participants will complete speech and arithmetic tasks, performed in front of an audience (e.g., researcher staff members) and recorded by a video camera to assess non-verbal behaviors and evaluate performance. The task will be initiated following completion of baseline sample collection during the acute stress study visit and will take approximately 15 minutes.
37149|NCT03893617|Behavioral|No stress task|Participants will sit quietly for 5 minutes, read a short passage aloud for 5 minutes, and read a list of numbers aloud for 5 minutes. The task will be initiated following completion of baseline sample collection during the no stress study visit and will take approximately 15 minutes.
37150|NCT03893604|Device|tDCS|20 minutes of anodal tDCS (C3/FP2) 2mA or sham
37151|NCT03893591|Diagnostic Test|Anti Xa levels|one Blood sample
37152|NCT03893578|Device|Mitral valve-in-valve|The Synecor Conveyor System shall be used to position the Edwards SAPIEN 3 valve at the mitral location.
37153|NCT03893565|Drug|Placebo|Commercial saline solution will be administered as placebo during Induction and Maintenance Phase
37154|NCT03893565|Biological|GSK2831781|Subjects will receive different doses of GSK2831781 during Induction and Maintenance Phase.
37155|NCT03893552|Device|Negative expiratory pressure|Using a cough assist, a negative expiratory pressure will be applied while recording the respiratory flow in patients suffering from sleeping disorders or snoring.
37156|NCT03893539|Device|Ion Endoluminal System™|The Ion™ Endoluminal System, Model IF1000, is a software-controlled, electro-mechanical system designed to assist qualified physicians to navigate a catheter and endoscopic tools in the pulmonary tract using endoscopic visualization of the tracheobronchial tree for diagnostic and therapeutic procedures.
37157|NCT03893526|Drug|Entresto|Single dose administration of entresto
37158|NCT03893526|Drug|Sitagliptin|Single dose administration of sitagliptin
37159|NCT03893526|Drug|Valsartan|single doses administration of valsartan
37160|NCT03893526|Drug|Placebo|placebo day
37161|NCT03893513|Device|Transthoracic Electrical Bioimpedance|Non-invasive hemodynamic monitor
37162|NCT03893513|Device|Pulse Contour Analysis|Invasive hemodynamic monitor
37163|NCT03893500|Device|Home-based 6 minute walk test|Participants will receive a loaner Apple Watch with the Walk.Talk.Track. (WTT, produced by PHaware) app downloaded. Participants will perform a daily 6MWT at home using the Apple Watch and WTT app. They will undergo a history and physical, blood draw, echocardiogram and in-clinic 6MWT at the baseline and 12-week follow up visit.
37164|NCT03893487|Drug|Fimepinostat|Fimepinostat capsules
37165|NCT03893487|Procedure|Therapeutic Conventional Surgery|Undergo surgery
37166|NCT03893474|Diagnostic Test|OCT|Optical Coherence Tomography of study eye.
37167|NCT03893474|Diagnostic Test|Visual Acuity|Visual acuity measured by ETDRS
37168|NCT03893461|Radiation|x|Stereotactic body radiation therapy for localized NSCLC
37169|NCT03893448|Biological|V114|V114 15-valent pneumococcal conjugate vaccine containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL intramuscular administration.
37170|NCT03893448|Biological|Prevnar 13™|Prevnar 13™ 13-valent pneumococcal conjugate vaccine containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
37171|NCT03893448|Biological|RotaTeq™|A total of 3 RotaTeq™ 2 mL oral dosings at ~2, 4, and 6 months of age.
37172|NCT03893448|Biological|Pentacel™|A total of 3 Pentacel™ 0.5 mL IM dosings at ~2, 4, and 6 months of age.
37173|NCT03893448|Biological|RECOMBIVAX HB™|A total of 3 RECOMBIVAX HB™ 0.5 mL IM dosings at ~2, 4, and 6 months of age.
37174|NCT03893448|Biological|VAQTA™|One VAQTA™ 0.5 mL IM dosing at 12 to 15 months of age.
37175|NCT03893448|Biological|M-M-R™|One M-M-R™ 0.5 mL subcutaneous (SC) dosing at 12 to 15 months of age.
37176|NCT03893448|Biological|VARIVAX™|One VARIVAX™ 0.5 mL SC dosing at 12 to 15 months of age.
37177|NCT03893448|Biological|HIBERIX™|One HIBERIX™ 0.5 mL IM dosing at Visit 5.
37178|NCT03893435|Drug|Sacubitril / Valsartan Oral Tablet [Entresto]|Sacubitril/Valsartan with the recommended starting dose: 24 mg/26 mg PO BID. After 2-4 weeks, the dose will be doubled to the target maintenance dose of 97 mg/103 mg PO BID (if tolerated) for 6 months.
37179|NCT03893422|Other|WB-010|Medical food formulation
37180|NCT03893422|Other|WB-011|WB-011 medical food product
37181|NCT03893422|Other|Placebo|Placebo Capsules identical to those containing WB-010 and WB-011.
37182|NCT03893396|Device|Coronary angioplasty|Procedure used to open clogged heart arteries. Involves the insertion of a tiny balloon and/or a stent to widen the artery.
37183|NCT03893370|Device|RejuvenAir System|RejuvenAir Metered CryoSpray
37184|NCT03893370|Device|Sham Control Procedure|Sham Control Procedure
37185|NCT03893357|Other|Data extraction from medical files|Retrospective data extraction from the medical files
37186|NCT03893344|Diagnostic Test|detection of STAT4 gene|Individuals within both groups will be subjected to STAT4 gene polymorphism typing using both PCR and flow cytometry from a peripheral blood sample
37187|NCT03893331|Device|AcQMap System|To evaluate procedural and long-term outcomes when using the diagnostic AcQMap System as an imaging and mapping system for ablation of arrhythmias in accordance with the Instructions for Use (IFU).
37188|NCT03893318|Drug|IV lidocaine|an amide-type, short-acting local anesthetic and delivered as an aqueous solution for intravenous administration. It has a half-life of 1.5-2 hours. A traditional method of administration is via epidural delivery. Epidural lidocaine is effective and this effect is due, in part, to systemic absorption. Systemic (intravenous) administration of lidocaine is a Food and Drug Administration approved method of delivery. Low plasma levels are needed for effective use, 0.5µg/mL to 5.0µg/mL. Given this low concentration required and the short half-life, continuous infusion of lidocaine is thought to be generally safe with low risk of complication.
37189|NCT03893318|Drug|Placebos|Saline
37190|NCT03893292|Procedure|Total knee replacement|Patients will undergo total knee replacement surgery.
37191|NCT03893292|Device|COOLIEF|The superior lateral genicular nerve, superior medial genicular nerve, and inferior medial geniculate nerve will be ablated.
37192|NCT03893279|Behavioral|Smell and Taste and questionnaire|The questionnaire must be completed before the antibiotic is taken, if a change of antibiotic is planned (stop of a treatment or addition of another treatment) and at the end of the antibiotic treatment.
37193|NCT03893266|Other|Interviews|An interview will be realized with each patient in order to precise the issues they have to reconcile their diabetes and their work. Some questions will be posed to the patients and they respond as they wish.
37194|NCT03893253|Other|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
37195|NCT03893253|Other|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
37196|NCT03893240|Diagnostic Test|SPK-3006 Neutralizing Antibody|Collected during a single study visit to establish the occurrence of neutralizing antibodies to SPK-3006 capsid in participants with LOPD on an enzyme replacement regimen.
37197|NCT03893227|Other|Questionnaire|Patients and healthy controls will fill out a questionnaire
37198|NCT03893214|Behavioral|virtual reality exposure for acrophobia|"The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase."
37199|NCT03893214|Behavioral|movie|Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
37200|NCT03893201|Other|Questionnaires|Questionnaires to assess quality of life
37201|NCT03893175|Drug|Ibuprofen|400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
37202|NCT03893175|Drug|Acetaminophen|500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
37203|NCT03893175|Drug|Placebo|By mouth
37204|NCT03893175|Drug|Oxycodone|5 mg by mouth every 6 hours as needed for pain
37205|NCT03893162|Dietary Supplement|Multi-strain probiotic|"The intervention in this study is a multi-strain probiotic which contains:~Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Lactobacillus salivarius, Lactococcus lactis ssp. lactis, Streptococcus thermophilus.~Each capsule contains minimum 2 billion live microorganisms per capsule, equivalent to 10 billion live microorganisms per gram."
37206|NCT03893162|Other|Placebo|Visually identical capsules in identical packaging containing no active bacteria.
37242|NCT03892837|Procedure|Conventional treatment for benign airway stenosis|Including, but not limited to: laser, high frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation and metal stent placement
37316|NCT03892408|Device|Optiflow ™|supply of 100 % of oxygen at 70 L / min through Optiflow ™ (Fisher and Paykel Healthcare Limited, Auckland, New Zealand) plus standard oxygen supply through rigid bronchoscope during apnea period.
37207|NCT03893149|Behavioral|Active-Start intervention|Supervised exercise training. The intervention is a physical activity intervention that consist of 5 times per week before starting the first school-class (8:00-8:30 a.m.), 5 times per week. Each session was previously planned and described in a manual dedicated to the study. These sessions were designed by the research team and delivered by a graduate in Sport The intervention program included sports games adapted to the age of the participants, playground games, dance and other recreational activities. The intensity of the main part of the sessions was moderate-to-vigorous according to a previous study and this intensity was confirmed by accelerometry. Also, different activities favoring social interactions were designed to facilitate the interactions between the participants at the end of the sessions (cold-down).
37208|NCT03893149|Behavioral|No Intervention|No-exercise
37209|NCT03893136|Biological|Tocilizumab|The scramble TA group is given bioagents such as IL-6R antibody, CD20-antibody, TNF-alpha antibody, and other bioagents which are safe to use in human to treat other refractory diseases. The sham group is given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
37210|NCT03893136|Drug|Leflunomide|The scramble TA group is given new molecules such as Leflunomide, Iguratimod, and other molecules which are safe to use in human to treat other refractory diseases. The sham group is also given cyclophosphamide. And the prednisone is the basic drugs to be used in TA.
37211|NCT03893123|Other|Observational study, prostate cancer is outcome of interest|Observational study
37212|NCT03893110|Procedure|surgical stabilization of the spine due to primary and secondary spinal tumors|Posterior instrumentation with pedicle screw system
37213|NCT03893097|Drug|Praziquantel|40 mg/kg at baseline
37214|NCT03893097|Drug|Artesunate + Mefloquine|4mg/kg artesunate and 8 mg/kg mefloquine at baseline (3 consecutive days) and repeated at Week 6 and Week 12
37215|NCT03893084|Other|Pregnancy preparation training|Pregnancy preparation education; folic acid use, physical activity, nutrition, addictions counseling issues are included.
37216|NCT03893071|Drug|Hydroxypropyl-β-cyclodextrin|HP-β-CD will be administered as Trappsol® Cyclo 25% (250mg/mL) by slow intravenous infusion over a period of 8 up to 9 hours.
37217|NCT03893045|Drug|ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution
37218|NCT03893045|Drug|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
37219|NCT03893032|Drug|Modafinil 200mg|single 200 mg dose
37220|NCT03893032|Drug|mixed amphetamine salts|single 10 mg dose
37221|NCT03893032|Drug|Placebo|single oral-administration placebo tablet
37222|NCT03893019|Biological|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
37223|NCT03893006|Device|Level of vehicle automation|From no automation of the vehicle to full automation through warnings, shared control and partly automated automation levels.
37224|NCT03892993|Other|Decision Aid|Use decision aid
37225|NCT03892993|Other|Questionnaire Administration|Ancillary studies
37226|NCT03892980|Device|Nipple-Sparing Mastectomy|Nipple-sparing mastectomy using da Vinci Xi Surgical System.
37227|NCT03892967|Other|E2C2 Collaborative Care|Stepped collaborative care to address moderate and severe levels of sleep disturbance, pain, anxiety, depression, fatigue, and functional decline.
37228|NCT03892941|Device|Imaged based fitting|Mapping of the electrical input of the cochlear implant will be based on an individualized natural frequency alignment as estimated with imaging methods.
37229|NCT03892928|Drug|Dexmedetomidine group|Propofol group：2-5 mg/kg.h propofol during the whole colonoscopy； Dexmedetomidine group：0.1mcg/kg continuous infusion for 15min（the patients older than 65 years old, 0.5 mcg/kg was continuous infusion for 15min）, 0.7-1mcg/kg.h during the whole colonoscopy
37230|NCT03892915|Combination Product|evidence-based depression treatment|We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
37231|NCT03892902|Drug|ACT-541468|Film-coated tablet for oral use at a dose strength of 50 mg.
37232|NCT03892902|Drug|Zopiclone 7.5 mg|Over-encapsulated to maintain blinding.
37233|NCT03892902|Other|Placebo|Matching to maintain blinding.
37234|NCT03892889|Combination Product|ABILIFY MYCITE|Abilify MyCite tracks drug ingestion and is composed of an Aripiprazole tablet embedded with a sensor (Abilify MyCite). Abilify MyCite Patch (wearable) detects the signal from the sensor after ingestion and transmits data to a smartphone. Abilify MyCite App, a smartphone app, which is used with a compatible smartphone to display medication ingestion information for the subject. Web-based portal or dashboard for investigators and caregivers.
37235|NCT03892876|Diagnostic Test|Auditory High Frequency Tetanizing Stimulation|50 ms tone pips presented at high frequency for 120 seconds
37236|NCT03892876|Diagnostic Test|Sham Comparator|auditory tone pips with interstimulus interval (ISI) 1 sec
37237|NCT03892863|Device|active repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
37238|NCT03892863|Device|sham repetitive transcranial magnetic stimulation|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex
37239|NCT03892850|Behavioral|Nurse prescription|Pharmacological nurse prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
37240|NCT03892850|Behavioral|Medical prescription|Pharmacological medical prescription. Subjects are individuals who request a same day consultation for minor acute pathologies and meet the selection criteria
37241|NCT03892837|Procedure|PRP|PRP treatment following the conventional treatment for benign airway stenosis which contain a concentrate of platelet-rich plasma protein derived from whole blood.
37243|NCT03892824|Device|Vine™ Embolic Protection System|"The system includes the implant and the Vine™ Inserter (inserter) manufactured by Javelin Medical LTD (Israel). The inserter comprises a Motor Unit and a Needle Unit (Needle Unit) available in two sizes. The system is operable when the Needle Unit is loaded with the implant (labeled Loaded Needle Unit) and connected to the Motor Unit. A flag indicating the needle orientation is attached to the needle luer. The implant is automatically deployed from the needle upon activation of the operating button."
37244|NCT03892811|Other|Three study conditions|Continuous fluoroscopy (at 30 frames/second) will be used for intermittent periods to capture 10 swallows in the initial sucking sequence of each of three study conditions: 1) Dr. Brown's Ultra-Preemie bottle nipple, 2) Dr. Brown's Preemie bottle nipple, and 3) Dr. Brown's Level 1 bottle nipple.
37245|NCT03892798|Other|No interventions are planned|No interventions are planned
37246|NCT03892785|Drug|Prednisone treatment|tapering prednisone regimen
37247|NCT03892785|Drug|Tocilizumab treatment|Tocilizumab 162 mg/week subcutaneous from W0 to W51 (52 injections)
37248|NCT03892785|Drug|Methotrexate treatment|"Methotrexate subcutaneous from W0 to W51 (52 administrations).~W0: 7.5 mg/week~W1: 0.2 mg/Kg/week~W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51"
37249|NCT03892785|Other|Questionnaires|HAQ, SF-36, FACIT-fatigue
37250|NCT03892785|Biological|Blood samples|Additionnal blood samples for immunomonitoring
37251|NCT03892772|Drug|SAS0421a|treatment will be given for 3 days
37252|NCT03892772|Drug|SAS0421b|treatment will be given for 3 days
37253|NCT03892772|Drug|SAS0421c|treatment will be given for 3 days
37254|NCT03892772|Drug|SAS0421d|treatment will be given for 3 days
37255|NCT03892772|Drug|placebo|placebo will be given for 3 days
37256|NCT03892759|Other|Osteopathic Manipulative Therapy|A set of hands-on techniques used by Osteopathic Physicians for the assessment and treatment of somatic dysfunction.
37257|NCT03892746|Device|Active tDCS + task oriented practice|Participants in this arm will receive active tDCS(2mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 5 days a week for 3 weeks.
37258|NCT03892746|Device|Sham tDCS + task oriented practice|Participants in this arm will receive sham tDCS(0mA) to the motor cortex(targeting the triceps) of the weaker upper limb for 2 30 minute cycles during each 2 hour upper limb training session. While receiving tDCS the participant will be performing task oriented practice for the weaker upper limb. Participants will receive these interventions for 5 days a week for 3 weeks.
37259|NCT03892733|Behavioral|calorie health education knowledge and skills|45 minute intervention done by health educator to give participants skills to use calorie information posted in fast-food restaurants
37260|NCT03892720|Other|Quality-of-Life Assessment|Ancillary studies
37261|NCT03892720|Other|Questionnaire Administration|Ancillary studies
37262|NCT03892720|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
37263|NCT03892707|Drug|Exposure of interest (within routine clinical practice):Vitamin B complexes Milgamma® and Milgamma® compositum|"Millgamma®: 2 mL injection solution containing thiamin hydrochloride 100 mg, pyridoxine hydrochloride 100 mg, cyanocobalamin 1 mg, lidocaine hydrochloride 20 mg.~Milgamma® compositum: 1 tablet containing benfotiamine 100 mg, pyridoxine hydrochloride 100 mg."
37264|NCT03892694|Device|RejuvenAir System|Bronchial metered cryospray using RejuvenAir® System.
37265|NCT03892694|Other|Sham|Sham control procedure
37266|NCT03892681|Other|hepatocyte-specific contrast agent, extracellular contrast agent|The type of contrast agent for the 1st MRI will be performed using hepatocyte-specific contrast agent (Primovist). The participant will undergo the 2nd MRI using extracellular contrast agent (Gadovist).
37267|NCT03892668|Drug|Tranexamic Acid|Women will receive TXA (amoun co) as a single bolus intravenous injection of 10 mg/kg (maximum 1 g) slowly over 10 min. Tranexamic acid will be given 15 min before skin incision, followed by a continuous infusion of 1 mg/kg/h dissolved in 1 L of saline for 6 h (maximum 1 g /6 h).
37268|NCT03892668|Drug|oxytocin|Women will receive 10 IU oxytocin (mina farm) in 500 ml saline at a rate of 120 ml/h before and during the course of the operation.
37269|NCT03892668|Drug|placebo|Women will receive 500 ml saline infusion at a rate of 120 ml/h before and during the operation
37270|NCT03892642|Drug|Avelumab|"Induction phase:~once weekly for weeks 1-6,~once every 2 weeks at week 8, 10, and 12~Maintenance phase:~Once every week for weeks 1-3~Once every 2 weeks starting at week 5, until the next BCG treatment"
37271|NCT03892642|Biological|BCG|"Induction phase (cycle 1):~• Once weekly for weeks 1-6~Maintenance phase (Month 3, 6, and 12):~• Once weekly for 3 weeks"
37272|NCT03892629|Behavioral|Baduanjin exercise|Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
37273|NCT03892629|Device|Instrument rehabilitation|Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
37274|NCT03892616|Drug|BI 1358894 (B)|Tablet formulation 2 (TF2), fed
37275|NCT03892616|Drug|BI 1358894 (C)|Tablet formulation 2 (TF2), fasted
37276|NCT03892616|Drug|BI 1358894 (D)|Tablet formulation 2 (TF2), fed
37277|NCT03892616|Drug|BI 1358894 (E)|Tablet formulation 2 (TF2), fasted
37278|NCT03892616|Drug|BI 1358894 (A)|Tablet formulation 1 (TF1), fed
37279|NCT03892603|Other|Strengthening exercises program|Participants from this group will be given a progressive shoulder strengthening exercises program based on 1 RM that will involve isometric, concentric and eccentric contractions. The exercises will target shoulder internal/external rotators and abductors and the scapular muscles. They will have to exercise every other day for 12 weeks. At each session with the therapist (6 over a 12 week period), strength will be reassessed and the program will be progressed accordingly. Any questions or concerns will also be addressed and participants will be requested to complete a paper based or digital record of their exercise participation.
37317|NCT03892395|Dietary Supplement|B-vitamin supplementation on bone health|An intervention study to investigate the effect of B-vitamin supplementation for 2-years on bone health
37280|NCT03892603|Other|Motor control exercises program|Each session will start with a series of clinical tests that will look at the influence of different corrections to alleviate symptoms during upper limb movements.The tests will be performed in a sequential format through four key areas: thoracic repositioning, scapula facilitation, humeral head procedures and neuromodulatory techniques. If a correction reduces pain, that technique will then be performed as exercises and incorporated into the participant's functional movement. In addition, motor control exercises during arm elevation, progressed through a standardized 6-phase retraining sequence, will be executed. Retraining phases will be graded according to: 1) resistance applied on the shoulder; and 2) use or non-use of feedback. Once participants reach pain free execution, the program will be progressed into re-education exercises according to the participants' work, sport and activities of daily living and will incorporate activities involving the upper and lower limbs.
37281|NCT03892603|Other|Education and advice|Each participant will be given written information about the shoulder (anatomy and function), basic pain science and will be directed to the Internet to watch a series of carefully selected educational videos. Comprehensive written advice will include: Information about the shoulder and the condition; Pain neuroscience; Activity modification (when to increase and decrease); Pain management (night and day); A series of educational videos to watch with 2 questions to answer per video: a) what was the most important message? and b) was there anything you didn't understand in the video?
37282|NCT03892590|Biological|Gut microbiota|Status of microbiota
37283|NCT03892577|Drug|Precision oncology including targeted therapy and immunotherapy|Therapeutic regimens are based on the clinicopathological features, genomic alterations, advices from multidisciplinary tumor board and willings from patients.
37284|NCT03892564|Drug|MC2-01 Cream, irradiation|One application of MC2-01 Cream, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
37285|NCT03892564|Drug|MC2-01 Cream, no irradiation|One application of MC2-01 Cream. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
37286|NCT03892564|Drug|MC2-01 vehicle, irradiation|One application of MC2-01 vehicle, followed by irradiation. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
37287|NCT03892564|Drug|MC2-01 vehicle, no irradiation|One application of MC2-01 vehicle. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
37288|NCT03892564|Drug|Control, irradiation|Untreated, irradiated site. Visual evaluation of application site using a visual scale that rated the degree of erythema, edema and other signs of cutaneous irritation
37289|NCT03892551|Other|Assessment of symptoms patients presenting when admitted to ED|Questionnaire with a predefined list of 35 symptoms
37290|NCT03892551|Other|Reason for patient presentation at ED|Exploratory interview assessing reason for patient presentation at ED
37291|NCT03892551|Other|physicians rating of severity of illness|numeric scale ranging from 0 (perfect condition) to 10 (extremely ill)
37292|NCT03892551|Diagnostic Test|Assessment of vital signs|Assessment of vital signs (heart rate, blood pressure, body temperature, respiration rate, peripheral capillary haemoglobin oxygen saturation)
37293|NCT03892551|Other|Clinical Frailty Scale|Assessment of frailty by Clinical Frailty Scale (CFS): assess patients' frailty level from 1, very fit, to 9, terminally ill
37294|NCT03892551|Other|Impaired mobility on presentation (IMOP)|Assessment of IMOP: defined as being unable to stand unaided or walk without help
37295|NCT03892551|Other|Assessment of suspected diagnosis and differential diagnoses|Assessment of treating physician's suspected diagnosis and differential diagnoses. Answers will be recorded in free text form.
37296|NCT03892525|Drug|Selicrelumab|escalated dose in intratumoral injection, every 3 weeks, for 3 cycles
37297|NCT03892525|Drug|Atezolizumab|1200mg IV every 3 week until progression or relapse for maximum 1 year
37298|NCT03892512|Drug|Esmolol Hydrochloride|Patients will receive hypotensive anesthesia via I .V infusion with esmolol ( Esmolol Hydrochloride )
37299|NCT03892512|Drug|Dexmedetomidine|The Patients will receive hypotensive anesthesia via I .V infusion with dexmedetomidine (Percedex )
37300|NCT03892499|Drug|Olinciguat|Oral Tablet
37301|NCT03892499|Drug|Itraconazole|Oral Capsule
37302|NCT03892486|Other|The high PUFA diet group|Assumptions of nutritional intervention: in a randomized manner volunteers will be assigned to one of two groups: a control group which will receive general nutritional recommendations, based on the Polish nutrition pyramid, and the intervention group which will receive nutritional recommendations, based on the Polish nutrition pyramid and will consume at least 4 tablespoons of olive oil or 30 grams of nuts every day for 12 weeks.
37303|NCT03892473|Other|Community mental health teams (CMHT)|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
37304|NCT03892473|Other|Care as usual (CAU)|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
37305|NCT03892460|Device|neuromuscular electrical stimulation|bilateral quadriceps exercise with neuromuscular electrical stimulation
37306|NCT03892447|Drug|Alprostadil|Alprostadil 0.2~0.3ug/kg.h,iv,1h/d,14d
37307|NCT03892447|Drug|Sodium Ferulate|Sodium Ferulate 2~6mg/kg.d,iv,14d
37308|NCT03892447|Drug|Dopamine|Dopamine3～5 ug/kg·min,iv,3 h/d,14d
37309|NCT03892434|Drug|Intravitreal bevacizumab and dexamethasone implant Injection|Bevacizumab 1.25mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion, and Dexamethasone 0.75mg implant is injected using injector.
37310|NCT03892434|Device|Intravitreal dexamethasone implant|Dexamethasone implant insertion using approved kit
37311|NCT03892421|Drug|Rituximab|Rituximab 375 mg/m²
37312|NCT03892421|Drug|Carboplatin|Carboplatin AUC5
37313|NCT03892421|Drug|Cytarabine Injection|Cytarabine 2000 mg/m² qd 2 days
37314|NCT03892421|Drug|Dexamethasone|Dexamethasone 40 mg
37315|NCT03892421|Drug|Filgrastim 0.3 MG/ML|One subcutaneous injection daily for 5 days
37809|NCT03887988|Procedure|Secondary reconstruction|Second surgical reconstruction of the fracture after a primary reconstruction.
37318|NCT03892395|Dietary Supplement|Control group; Vitamin D, a daily capsule containing 10 µg/day vitamin D|Vitamin D, a daily capsule containing 10 µg/day vitamin D
37319|NCT03892382|Device|rTMS|High frequency rTMS to induce the long term potentiation in the left dorsolateral prefrontal cortex.
37320|NCT03892369|Other|Ethanol|Ethanol administration
37321|NCT03892343|Diagnostic Test|Cardiac MRI|Cardiac Magnetic Resonance Imaging (Siemens Skyra 3T): will be performed using protocols and techniques already in use in our group. All CMR scan derived parameters will be analysed with the investigator blinded to treatment allocation as in previous studies.
37322|NCT03892330|Drug|Vincristine|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
37323|NCT03892330|Drug|Oxytetracycline/ Cyclophosphamide|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
37324|NCT03892330|Drug|Liposomal doxorubicin|The dosage of Liposomal doxorubicin is half of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
37325|NCT03892330|Drug|Doxorubicin|Dosage according to Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
37326|NCT03892330|Drug|Pharmorubicin|The dosage of pharmorubicin is 2 times of doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
37327|NCT03892330|Drug|Pirarubicin|The dosage of pirarubicin is equal to doxorubicin dosage in Children Wilms tumor diagnosis and therapy recommendations: Wilms Tumor-2016 (WT-2016) (2-6) Chemotherapy.
37328|NCT03892317|Behavioral|Pharmacist led medication adherence interventions|Medication adherence interventions which will be tailored to individual patient need
37329|NCT03892304|Other|Self-report written questionnaire|"Patient questionnaire filled-out in presence of clinical nurse. Gynecological options and contraceptive choices were recorded. Close-ended questions used (yes/no): contraception use; contraceptive pill use; contraceptive implant; intrauterine device; tubal sterilization; mechanical contraception; other type of contraception use; previous term delivery; gynecological follow-up; previous Pap smear. If Yes was noted, more details were requested (contraception name, delivery date, gynecological follow-up frequency, last Pap smear date).~Other gynecological history and management data not included in the 2014 questionnaire: age at first menstruation, menstrual cycle regularity without hormonal contraception, age at menopause, previous human papilloma virus vaccination, recurrent vulvovaginal candidiasis, urinary incontinence, fertility/infertility data, and infertility treatment with assisted reproductive technologies. Results were compared with those obtained in 2014 (121 women)."
37330|NCT03892278|Behavioral|Water-based aerobic training|Participants who will be randomized for the intervention in the aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle and participants will carry out three 3-minute series of each exercise. In the first mesocycle (weeks 1-2) the intensity will correspond to 80-85% of heart rate corresponding to the anaerobic threshold (HRat). In the second mesocycle (weeks 3-4) the intensity will correspond to 85-90% of HRat. In the third mesocycle, the intensity will correspond to 90-95% of HRat from weeks 5-7. In the fourth mesocycle, the intensity will correspond to 95-100% of HRat from weeks 8-10. In the fifth mesocycle (weeks 11-13) the intensity will correspond to the 100-105% of HRat for 2 minutes and <85% of HRat for 1 minute. The last mesocycle (weeks 14-16) the intensity will correspond to the 105-110% of HRat for 2 minutes and <85% of HRat for 1 minute.
37331|NCT03892278|Behavioral|Water-based aerobic and combined training|Participants who will be randomized for the intervention in the aerobic and combined training group will perform 8 weeks of aerobic training and more 8 weeks of aerobic and resistance training in same session. In aerobic training the participants will perform three 3-min series of each exercise. The intensity will correspond to 80-85% of heart rate of anaerobic threshold (HRat) (weeks 1-2), 85-90% of HRat (weeks 3-4), 90-95% of HRat (weeks 5-7), 95-100% of HRat (weeks 8-10), 100-105% for 2 min and <85% of HRat for 1 min (weeks 11-13) and 105-110% for 2 min and <85% of HRat for 1 min (weeks 14-16). Resistance training will be divide into two blocks of exercises perform each repetition at maximal effort, speed and amplitude. Participants will perform 2 sets of 30 s for each block in the first mesocycle (weeks 9-10), 3 sets of 20 s in the second mesocycle (weeks 11-13) and 4 sets of 15 s in the third mesocycle (weeks 14-16).
37332|NCT03892278|Behavioral|Control group|The control group will perform a weekly session composed of 30 minutes of therapeutic and playfull exercises in the aquatic environment, involving games, relaxation, massage and conversation.The participants will receive instructions to perform the movements as slowly as possible to avoid physical effort.
37333|NCT03892265|Other|Observational Study|No intervention is included in this observational study.
37334|NCT03892239|Behavioral|RunIn3 Prevention Program|"The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.~Through a website we will make available informative texts, videos and infographics in order to increase the participant's knowledge regarding topics such as: musculoskeletal symptoms; foot strike patterns; training workload; running shoes; warming-up/cooling-down, stretching; and concomitant strength training."
37335|NCT03892239|Behavioral|Feedback Based Surveillance|The intervention will be delivered online. Every two weeks we will send a link to participants that will direct them to an online questionnaire. The online questionnaire will collect information on complaints and symptoms related to running, and the volume, intensity and frequency of running practice within the 2-week period. If the participant reports any symptom and if she/he accepts a suggestion regarding running training, an algorithm embedded in the online system will automatically suggest a training volume for the next two weeks based on the distance and/or duration reported by the participant.
37336|NCT03892213|Drug|Benznidazole|Benznidazole single dose (2.5 mg/kg) at Day 1. Benznidazole single dose (2.5 mg/kg) at Day 9*. Benznidazole multiple dose (2.5 mg/kg twice daily) from Day 12* until Day 15.
37368|NCT03891927|Dietary Supplement|extra virgin olive oil|During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
37337|NCT03892213|Drug|E1224|"E1224 multiple dose 400 mg loading dose once daily for 3 days (i.e. from Day 4 to Day 6 followed by maintenance dose 100mg once daily for 9 days (from Day 7 to Day15).~On Day 9 and from Day 12 to Day 15, E1224 and benznidazole will be given concomitantly."
37338|NCT03892200|Behavioral|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention assisted living communities.
37339|NCT03892187|Behavioral|Intervention Group|Walking prescriptions plus weekly coaching calls prior to surgery.
37340|NCT03892174|Other|Treatment protocol with adsorption|Adsorption while patients are in the OR on the extracorporeal circuit
37341|NCT03892161|Drug|Darunavir/ritonavir 800/100 mg tablet|Standard dose DRV/r administered
37342|NCT03892161|Drug|Rifampicin 600mg QD tablet and DTG 50mg BD|Rifampicin and DTG added
37343|NCT03892148|Drug|Furosemide|Protocol for the use of diuretics
37344|NCT03892148|Drug|Hydrochlorothiazide|Protocol for the use of diuretics
37345|NCT03892135|Other|Interviews with parents of children with juvenile idiopathic arthritis|Interviews with parents of children with juvenile idiopathic arthritis
37346|NCT03892135|Other|Interviews with children with juvenile idiopathic arthritis|Interviews with children with juvenile idiopathic arthritis
37347|NCT03892135|Other|Interviews with Physicians|Interviews with Physicians
37348|NCT03892122|Drug|Propofol Fresenius|"Propofol will be infused with TCI (Target Controlled Infusion) pump. TCI system has been developed to provide improved convenience and control during intravenous anaesthesia. The basic principle is that the anesthetist sets and adjusts the target blood concentration— and depth of anesthesia—as required on clinical grounds.~Infusion rates are altered automatically according to a validated pharmacokinetic model. TCI technology uses different pharmacokinetic modeling to control the infusion rate of the pump, which allows for a direct control of the sedative agent brain concentration rather than its blood concentration. (de vito 2017) The development of target-controlled infusion (TCI) technology has increased the number of indications for propofol sedation in clinical practice. Furthermore, several studies have demonstrated that propofol-based TCI allows for the accurate control of sedation during DISE and results in an authentic reproduction of the sleep process."
37349|NCT03892122|Drug|Dexmedetomidine|is a selective alpha-2 adrenergic receptor agonist, which seems to act on the locus coeruleus (LC) or to the preoptic hypothalamus to decrease wakefulness, with almost no effect on respiratory depression. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsyn¬aptic alpha2-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique as¬pect that patients remain easily arousable and cooperative. Comparing with propofol, dexmedetomidine provides a state of sedation closer to natural sleep and lesser upper airways muscular relaxing effect, even at the increased anesthetic dosage Otherwise, Dexmedetomidine is characterized by a slightly longer onset of action (5-10 minutes), and patients take longer timing to recover..The sedative action of Dexmedetomidine can be reached by means of infusion technique (starting dose: 1 μg/kg over 10 minutes; maintenance infusion rate: 0,7 μg/kg/h).
37350|NCT03892109|Other|No Cord impression material|the no cord self- retracting impression material placed directly in the tray
37351|NCT03892109|Device|cord|Cords were placed in the gingival sulcus with use of a cord packer, and left in situ for 10 min before making the impression. None of the retraction cords were immersed in any solution or medicaments prior to insertion.
37352|NCT03892109|Other|Gingitrac|packed into the sulcus
37353|NCT03892096|Diagnostic Test|Blood-based cell-free cfDNA qPCR assay|Up to 30mL of blood via venipuncture
37354|NCT03892083|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different neurological conditions, including children with cerebral palsy.
37355|NCT03892070|Dietary Supplement|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB will be provided for 12 weeks twice daily
37356|NCT03892070|Dietary Supplement|Mannitol|1.5 g twice daily for 12 weeks
37357|NCT03892057|Behavioral|Internet-based Positive Psychological Intervention|"The investigator's culturally-tailored internet-based Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well- being, e.g., mindfulness/meditation. The current 5-week Internet-based intervention will be delivered via a secure website which participants will access at home (or in a public setting with Wi-Fi) using an assigned username and password. The on-line program includes didactic material and home practice with participants logging into the website 3-4 times per week for 15 to 20 minute sessions. In addition to weekly on-line instruction, participants are assigned homework as a means of incorporating skills learned into their day-to-day activities."
37358|NCT03892044|Drug|Duvelisib|Given PO
37359|NCT03892044|Biological|Nivolumab|Given IV
37360|NCT03892018|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
37361|NCT03892005|Procedure|Total Hip Arthroplasty using MOTIVATION HIP Total Hip System|To systemically document the clinical safety and performance of the commercially available MOTIVATION HIP Total Hip System in primary THA.
37362|NCT03891979|Drug|Antibiotics and Pembrolizumab|"Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29."
37363|NCT03891966|Procedure|Rigid Splint|50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
37364|NCT03891966|Procedure|Soft Dressing|50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
37365|NCT03891953|Drug|DKY709|Novel immunomodulatory agent
37366|NCT03891953|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2
37367|NCT03891940|Procedure|patients recieving anterior cervical spine surgery|Anterior cervical discectomy with fusion, or ACDF, is a surgery designed to relieve spinal cord or nerve root pressure in the neck by removing all or part of a damaged disc
37369|NCT03891914|Drug|Positron Emission Tomography using 18F-FCH|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
37370|NCT03891914|Drug|Positron Emission Tomography using 18F-FDG|Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions
37371|NCT03891901|Drug|Imatinib|Tablets, administered orally
37372|NCT03891901|Drug|Isoniazid|300 mg tablets, administered orally
37373|NCT03891901|Drug|Rifabutin|300 mg capsules, administered orally
37374|NCT03891888|Procedure|Intramedullary Bone Graft|Patients in this group will undergo standard treatment for their open tibia shaft fracture (irrigation and debridement of their open fracture and reamed intramedullary nailing), but will also have the reamings from the medullary canal preparation collected and packed into the exposed fracture cortex
37375|NCT03891875|Combination Product|Subcutaneous elamipretide through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
37376|NCT03891875|Combination Product|Subcutaneos placebo through the elamipretide delivery system|Subjects will be randomized in a 2:1 ratio to receive either elamipretide or placebo through the elamipretide delivery system. Subjects will dose daily for up to 48 weeks.
37377|NCT03891862|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
37378|NCT03891862|Drug|Placebo oral capsule|non-active dosage form
37379|NCT03891849|Drug|Octreotide Injection|Patients admitted in intensive care unit after variceal hemorrhage treated with norepinephrine perfusion will received an additional octreotide perfusion during one hour.
37380|NCT03891823|Device|MitraClip|Study participants will be randomized to MitraClip device to determine treatment efficacy in improving LV remodelling or functional capacity.
37381|NCT03891823|Drug|Medical Therapy|Study participants will be randomized to medical therapy to determine treatment efficacy in improving LV remodelling or functional capacity.
37382|NCT03891810|Behavioral|Calm|"The intervention ran for 8-wks with a 4-wk follow-up period. Intervention participants completed 7 days of Calm during Week 1. For the remaining weeks (Week 2- Week 8) intervention participants were asked to meditate during the weekday from a 10-minute meditation of their choice. Throughout the intervention, the Calm College group were sent reminder texts/emails via Google Voice to participate in the meditation sessions if participants are not meditating for more than 30 minutes a week (see Participant Scripts)."
37383|NCT03891797|Other|Cognitive Processing Therapy|Group-based psychotherapy.
37384|NCT03891784|Drug|Abemaciclib|Given PO
37385|NCT03891771|Device|Telemonitoring sensors|This complex platform entails several sensors aimed at detecting falls, nocturia and environmental variables in the participant's home. Sensors are non-intrusive and its only wearable component is the panic button which must be carried by the participant.
37386|NCT03891758|Biological|DPT-IPV-Hib|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
37387|NCT03891758|Biological|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
37388|NCT03891758|Biological|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
37389|NCT03891732|Diagnostic Test|MRI prostate|plain biparametric MRI prostate
37390|NCT03891719|Procedure|Unilateral cleft lip rhinoplasty|"Perform marking with methylene blue tattoo marks~Inject Local anesthetic solution with epinephrine~Harvest auricular cartilage~Make the incisions parallel the lip scar, extende into the marginal incision and encompass any alar webbing. The incisions outline the entirety of the lower lateral cartilage and create sliding chondrocutaneous flap. This flap combines with reverse U incision.~Harvest septal bony cartilaginous unit for grafting the caudal septum and suspend the medial crural cartilages~Create dome symmetry at the cartilage level and reconstruct nasal tip with other grafts (shield-type tip graft, cap graft, alar batten graft)~Dorsal augmentation~Lip reconstruction and alar base repositioning.~Closure and repair vestibular deficiency with the reverse-U component of the chondrocutaneous flap at the alar rim."
37391|NCT03891706|Drug|tumor-specific TCR-T cells|T cells prepared in vitro
37392|NCT03891693|Device|Passeo-18 Lux and SUPERA® stent|Angioplasty of Arteriovenous Fistula (AVF) performed using Passeo-18 Lux and SUPERA® stent for patients with cephalic arch stenosis
37393|NCT03891680|Drug|Botox Injectable Product|Intra articular Botox injection
37394|NCT03891680|Device|Radiofrequancy|Genicular nerves radiofrequancy
37395|NCT03891667|Drug|Disulfiram 500 MG|Patients will receive 2 250 mg capsules of disulfiram or 2 matching capsules of placebo.
37396|NCT03891654|Diagnostic Test|Dynamic Contrast Enhanced Computed Tomography|Patients will receive DCE-CT prior to the start of standard of care, Stereotactic Body Radiation Therapy (SBRT), as well as 6 hours post administration of SBRT and 6 weeks post administration of SBRT.
37397|NCT03891641|Behavioral|Treadwell Tredlr|Complete treadling exercise 3x per week (15 min sessions) for 6 weeks.
37398|NCT03891628|Behavioral|Modified Attachment and Biobehavioral Catch-up|Intervention targets include enhancing nurturance and following the child's lead, as well as supporting use of kangaroo care, swaddling, and breastfeeding.
37399|NCT03891628|Behavioral|Modified Developmental Education for Families|Intervention targets include supporting developmental monitoring and parental engagement in activities that promote cognitive and motor development.
37400|NCT03891628|Behavioral|Safe Environment for Every Kid|Intervention involves screening for common challenges and providing community resources to address identified needs.
37401|NCT03891615|Drug|Niraparib|"Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells through deadly DNA damage."
37402|NCT03891615|Drug|Osimertinib|Osimertinib blocks mutated EGFR, which may cause tumor regression (when the tumor starts to shrink) and prevent the spread of the cancer.
37511|NCT03890718|Procedure|doroodgar method|Increase cornea stromal thickness in patients with advance ectasia by donor lenticule created during small incision lenticule extraction (SMILE)
37403|NCT03891602|Behavioral|Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale)|Perceived Smoking-Related Stigma will be measured using the 5-item Cataldo Lung Cancer Stigma Scale (Smoking-Related Subscale). The response scale is 1 = strongly disagree, to 4 = strongly agree, and scores range from 5 to 25 (high stigma). Cronbach's alphas were 0.75 to 0.89 in prior studies.
37404|NCT03891602|Behavioral|Patient Trust in the Medical|Medical Mistrust will be measured using the 5-item Patient Trust in the Medical Profession Scale.80 The five-point Likert responses measure the extent to which patients perceive their clinician to be honest, caring more about convenience, thorough and careful, and trusted. The range of scores is 5 to 25 (higher mistrust). Reliability and validity have been well established with a Cronbach‟s alpha of 0.84.
37405|NCT03891602|Behavioral|Decision Conflict Scale - Lung Cancer Screening|The DCS is a 16-item Likert-response item scale that has been modified for the lung cancer screening and smoking cessation contexts. The DCS was developed by O‟Connor,74-75 and validated in many health decisions including breast cancer screening with Cronbach‟s alphas ranging from 0.78 to 0.81. 74-75 Despite its name, the DCS measures more than decision conflict to encompass personal perceptions of perceived decision-making quality such as feeling the choice is informed, values based, and likely to be implemented as well as expressing satisfaction with the decision. 74-75 The DCS is comprised of items with response options ranging from 1 (strongly disagree) to 5 (strongly agree). The items are summed to total scale score with lower scores reflective of higher decision conflict and higher scores reflective of lower decision conflict.
37406|NCT03891602|Behavioral|Shared Decision Making Questionnaire - Patient|Shared Decision Making Process will be measured from the patient perspective using the 9-item Shared Decision Making Questionnaire (SDM-Q-9),77 which has been validated with a Cronbach‟s alpha of 0.94.
37407|NCT03891602|Behavioral|Stage of Readiness for Smoking Cessation - Contemplation Ladder|Among current smokers
37408|NCT03891602|Behavioral|Primary Care Clinicians' Lung Cancer Screening Survey|Includes items to assess attitudes, barriers, and knowledge of lung cancer screening guidelines.
37409|NCT03891589|Behavioral|Nutritional education program|These programs were a process of providing information or knowledge to mother of the children consisting of information on initiation of complementary feeding, variety, and frequency of food, nutrient requirements and diet pattern for children (the amount and types of food), and benefits of Taburia. All this information provided through class-based activities and group discussion by using leaflet and food model conducted by the researchers. Education materials developed based on CFR models from our previous study by applying the LP approach. There was also a demonstration on administering complementary feeding (demo and cooking class) to improve skills of the mother on food from selection, design, handling and preparing, based on requirements of the children. This activity conducted through training once per month for the first four months of the intervention. Components of complementary feeding promoted in this study are based on CFR using LP approach from our previous research.
37410|NCT03891589|Dietary Supplement|Home fortification (Taburia)|Taburia is a multivitamin and mineral fortification to provide sufficient amount of nutrient for optimal growth and development of children aged 6-59 months. Every sachet of Taburia prepared to fulfill minimum nutrient requirements for children aged 6-59 months. Each sachet is one gram in weight and contains vitamin A (417 mcg), B1 (0.5 mg), B2 (0.5 mg), B3 (5.0 mg), B6 (0.5 mg), B12 (1 mcg), D3 (5 mcg), E (6 mg), K (20 mcg), C (30 mcg), folic acid (150 mcg), pantothenic acid (3 mcg), Iodium (50 mcg), Iron (10 mg), Zn (5 mg) and Selenium (20 mcg). One sachet of Taburia given to the subject by adding it to their breakfast and must be finished. The frequency of Taburia consumption per week follows the finding of the LP analysis from the previous study. Taburia intervention complemented by health education related to benefits, administration of Taburia, and its side effects. Compliance will be evaluated directly by the researcher based on empty Taburia sachet and conducted every month.
37411|NCT03891576|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
37412|NCT03891563|Other|This is an observational study|No intervention is taking place.
37413|NCT03891550|Drug|Epclusa|sofosbuvir (SOF) 400 mg/Velpatasvir(VEL) 100 mg fixed-dosage combination once-daily for 12 weeks for all HCV genotype patients with and without hepatic decompensation
37414|NCT03891524|Drug|JNJ-70033093 25 mg|Participants will receive JNJ-70033093 25 mg (1*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.
37415|NCT03891524|Drug|JNJ-70033093 50 mg|Participants will receive JNJ-70033093 50 mg (2*25 mg capsules) BID orally for 10 to 14 postoperative days.
37416|NCT03891524|Drug|JNJ-70033093 100 mg|Participants will receive JNJ-70033093 100 mg (1*100 mg capsule) BID, orally for 10 to 14 postoperative days.
37417|NCT03891524|Drug|JNJ-70033093 200 mg|Participants will receive JNJ-70033093 200 mg (2*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.
37418|NCT03891524|Drug|Placebo|Participants will receive placebo matching to JNJ-70033093, orally.
37419|NCT03891524|Drug|Enoxaparin 40 mg|Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.
37420|NCT03891511|Device|MRI scann|MRI will be performed in the TMJ of participants affected with TMD
37421|NCT03891498|Drug|MgSO4|The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
37422|NCT03891485|Biological|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, or other second line according to physician's choice)
37423|NCT03891472|Drug|Patients will receive initial chemotherapy, followed by evaluation of the response to the treatment, followed by SBRT, followed by chemotherapy.|mFOLFIRINOX > SBRT > mFOLFIRINOX > Surgical Intervention
37424|NCT03891459|Behavioral|spray+ manipulation|Participants in spray+ group received placebo manipulation and were told they sprayed was oxytocin (in fact, it was saline);
37425|NCT03891459|Behavioral|control manipulation|Participants in control group were told they sprayed saline (in fact, it was saline).
37596|NCT03889925|Drug|Hymovis|Patients will receive 2 intra-articular injections of autologous conditioned plasma and hyaluronic acid once a week for 2 weeks and a third injection on the third week of ACP.
37426|NCT03891446|Drug|Bimatoprost SR|"Patients from Stage 2 of lead-in studies 093/095 are eligible to receive up to 2 additional Bimatoprost SR administrations of the same dose in the study eye through completion of Month 12 visit.~Patients from lead-in studies 091/092 will not receive additional Bimatoprost SR administrations in the study eye.~Fellow eye of all patients will receive only standard of care based on the investigator's judgment"
37427|NCT03891433|Drug|Meropenem|Carbapenems group intervention.
37428|NCT03891433|Drug|Ertapenem 1000 MG|Carbapenems group intervention.
37429|NCT03891433|Drug|Piperacillin, Tazobactam 4-0.5G Solution for Injection|Piperacillin/Tazobactam group intervention.
37430|NCT03891420|Drug|Galidesivir|Galidesivir IV infusion
37431|NCT03891420|Drug|Placebo|Placebo IV infusion
37432|NCT03891407|Diagnostic Test|Self-Testing Education and Promotion|Camp members will receive the Self-Testing Education and Promotion (STEP locally referred to as Mate Yako Afya Yako) intervention and will receive HIV-counseling and oral HIV self-testing kits.
37433|NCT03891394|Diagnostic Test|Human epididymis protein 4|Human epididymis protein 4 serum level in predicting persistent proteniuria
37434|NCT03891381|Device|Tetragraph quantitative monitoring|Neuromuscular monitoring will be guided by information provided by the Tetragraph
37435|NCT03891368|Other|Virtual Learning Collaborative|InSHAPE teams consisting of health mentors, supervisors, and senior leaders from each mental health agency randomized to the VLC will be invited to attend an in-person initial kick-off meeting followed by once per month 90-minute VLC sessions. The VLC is organized into three stages: Prework, Action, and Continuous Improvement. VLC faculty, including interventionists with expertise in implementation science, quality improvement, and subject matter (i.e., InSHAPE) experts, will facilitate VLC sessions following a structured protocol to standardize the planning and execution of the VLC across three cohorts enrolled in the study.
37436|NCT03891368|Other|Technical Assistance|Scheduled calls will occur at 1 month, 2 months, 8 months, and 14 months following their participation in initial InSHAPE training following randomization and follow a structured protocol. At the end of each scheduled conference call, the coach will schedule the next call with the site.
37437|NCT03891355|Drug|Carfilzomib|Carfilzomib
37438|NCT03891355|Drug|Lenalidomide|Lenalidomide
37439|NCT03891355|Drug|Dexamethasone|Dexamethasone
37440|NCT03891342|Drug|Fluid bolus administration|"Fluid bolus administration either fast in 5 minutes or slow in 30minutes."
37441|NCT03891329|Device|Acticor/Rivacor ICDs/CRT-Ds|pre-defined device programming, measurements and follow-up schedule
37442|NCT03891329|Device|Plexa S DX|Implantation, measurements and follow-up schedule
37443|NCT03891316|Diagnostic Test|HFIP and Sevoflurane are measured after 3 consecutive days of work.|Concentration of Hexafluorisopropanol and Sevoflurane are measured in urine by gas chromatography
37444|NCT03891303|Other|Allogenic blood transfusion (ABT)|During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients. However, TR group additionally received ABT.
37445|NCT03891290|Other|Collecting recorded videos of Colonoscopy screening tests of the general population|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
37446|NCT03891277|Drug|Ferrous succinate|"Ferrous succinate sustained-release tablets（Ferrous succinate 0.2g）1 tablet, Qd,po during or after breakfast, Lasting for 12 weeks.~placebo with almost the same size, color and smell as Ferrous iron will be used with 1 tablet, Qd, po during or after breakfast, Lasting for 12 weeks."
37447|NCT03891264|Drug|Cannabidiol|Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution. The recommended starting dosage is 2.5mg/kg taken twice daily (5mg/kg/day). After one week, the dosage will be increased to a maintenance dosage of 10 mg/kg twice daily (20 mg/kg/day). At the end of the first week, the patient will increase the dose to 10 mg/kg twice daily for the following week.
37448|NCT03891251|Other|Collecting recorded videos of Colonoscopy screening tests|To evaluate, in objective way, the usability of the future alpha version of the APDS device by testing the sensitivity and specificity of its results achieved from running it on the collected recorded videos of Colonoscopy screening tests of the general population.
37449|NCT03891238|Drug|Avelumab|Patients will receive avelumab at standard dosage of 10 mg/kg as a 1-hour intravenous infusion once every 2 weeks (Q2W).
37450|NCT03891225|Procedure|Amniotic Membrane implantation|Surgical procedure will be performed with Longemire Traverso technique. At the end of all pancreatic, biliary and duodenal anastomosis, the AM will be implanted.
37451|NCT03891212|Behavioral|Placed in prone position for at least 16 consecutive hours a day.|Patients assigned to the prone group had to be turned within the first hour following randomization. They were placed in prone position for at least 16 consecutive hours. Patients assigned to the control group had to be turned within the first hour following randomization. They were placed in supine position for at least 16 consecutive hours.
37452|NCT03891199|Procedure|Robotic-Arm Assisted THA|The study will examine the acetabular cup placement of THA patients and compare results for patients who undergo THA with robotic-arm assistance with those who undergo traditional THA.
37453|NCT03891186|Behavioral|Metacognitive Training in Schizophrenia (MCT)|"MCT is a group program with eight modules referring to common cognitive and biases in solving problems in schizophrenia. The following topics of MCT are: attribution blaming and taking credit (module 1), jumping to conclusions (modules 2 and 7), changing beliefs (module 3), deficits in theory of mind and social cognition (modules 4 and 6), overconfidence in (memory) errors (module 5) and depression and low self-esteem (module 8). Each session lasts 45 to 60 minutes and follows a protocol defined in the manual Metacognitive Training for Psychosis (MCT) that is currently available in 35 languages (available in www.uke.de/mkt)."
37454|NCT03891186|Other|Treatment As Usual (TAU)|In both groups will be maintained the TAU.
37455|NCT03891173|Drug|L-DOS47|L-DOS47 lyophilized powder reconstituted and diluted for iv injection
37456|NCT03891173|Drug|Cisplatin|Cisplatin concentrate for solution for iv infusion
37457|NCT03891173|Drug|Vinorelbine|Vinorelbine concentrate for solution for iv infusion
37625|NCT03889652|Diagnostic Test|Oct scans|Oct scans to assess thickness of RNFL and GCC before and after cataract extraction surgery in both groups
37458|NCT03891160|Other|3D model of heart|To assess if a 3D printed cardiac model improves visualization of VAD and cannula placement sites in CHD-HF patients as compared to 2D imaging. The investigators will prospectively enroll CHD-HF patients at multiple centers and randomize to group A (3D printed models will be used for pre-VAD planning) or Group B (controls).
37459|NCT03891147|Other|Electro-acupuncture|
37460|NCT03891134|Dietary Supplement|Branched Chain Amino Acid|Participants were purposively sampled to receive one sachet enriched BCAA twice a day(7.2g) for 5 weeks.
37461|NCT03891121|Device|Occlusal Splint|Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.
37462|NCT03891121|Drug|Botulinum toxin type A|We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
37463|NCT03891108|Drug|BMS-986231 Formulation A|Participants will be administered BMS-986231 Formulation A as IV infusion for 48 hours.
37464|NCT03891108|Drug|BMS-986231 Formulation B|Participants will be administered BMS-986231 Formulation B as IV infusion for 48 hours.
37465|NCT03891108|Drug|BMS-986231 Formulation C|Participants will be administered BMS-986231 Formulation C as IV infusion for 48 hours.
37466|NCT03891108|Drug|BMS-986231 Formulation D|Participants will be administered BMS-986231 Formulation D as IV infusion for 48 hours.
37467|NCT03891095|Drug|Oxytocin|intranasally administrated
37468|NCT03891095|Drug|L-DOPA|orally administered
37469|NCT03891095|Drug|Placebos|intranasally administrated and orally administered
37470|NCT03891082|Procedure|B-Lynch|A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
37471|NCT03891082|Procedure|BALLOON INSERTION|Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
37472|NCT03891069|Device|AHA Exergame System|The AHA Exergame System consists of a mobile computing platform running a set of parameterizable exergames purposely designed for elderly fitness training. The platform is equipped with a 1000 lumens video projector capable of creating a 2.05m by 1.16m floor projection display and a Kinect V2 sensor to serve as game controller. The AHA exercise-based computer games have been designed for and tested with elderly people and were adapted for the functional limitations of PD patients. The system includes five different games that aim to train patients motor ability, cardiorespiratory and muscular strength.
37473|NCT03891056|Procedure|metabolic surgery|The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
37474|NCT03891043|Dietary Supplement|Selenium|A 100 micrograms of Selenium was given to be taken twice a day.
37475|NCT03891043|Other|Placebo|Placebo pill of 100 micrograms of starch was given to be taken twice a day.
37476|NCT03891030|Other|Checklist Based Box system intervention|The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
37477|NCT03891017|Other|vacuum casting|Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
37478|NCT03891017|Other|hydrostatic casting|Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
37479|NCT03891004|Procedure|Subcuticular Skin Closure|We will only close the subcuticular layer with suture
37480|NCT03891004|Device|Tissue Adhesives|No subcuticular closure will be done. Only tissue adhesives applied to the approximated skin
37512|NCT03890692|Procedure|flexible nasoendoscopy|"nasopharyngeal endoscopy : After washing nasal cavities with a sterile physiologic solution to remove secretions or scabs, and decongesting them with an oxymetazoline solution in the subjects with turbinate hypertrophy,~Endoscopy will be performed by passing the endoscope along either the floor of the nose or just under the middle turbinate. the condition of the nasal mucosa\ septum\ turbinates and the presence of discharge The postnasal space will be assessed . All abnormalities will be recorded .the images will be recorded and assessed separately by two independent otolaryngologists"
37513|NCT03890679|Diagnostic Test|rapid whole genomic sequencing (rWGS)|rWGS and NewbornDx are genomic sequencing platforms
37481|NCT03890991|Behavioral|SCOPE-DM|The 12-week programme aims to support motivation and enable capability for managing diabetes. To this end, the sessions will integrate the knowledge and practical skills components offered in traditional diabetes education with psychological techniques and principles for behavioural change: problem solving, goal-setting and monitoring. The programme offers the potential for older people to learn about their condition and treatment in a psychologically-motivating and confidence-enhancing structure - as such the emphasis is on empowering individuals to make choices and lifestyle changes in line with treatment recommendations through the use of problem solving, goal setting and feedback, and not just on knowledge transfer which has not been shown to be successful in behavioural change. The content and delivery format will largely be informed by motivational interviewing
37482|NCT03890991|Behavioral|SCOPE-DM with 3 months' supply of glucometer|Participants in this arm will participate in the SCOPE-DM programme and use the glucometer for 3 months.
37483|NCT03890991|Behavioral|SCOPE-DM with 6 months' supply of glucometer|Participants in this arm will participate the in SCOPE-DM programme and use the glucometer for 6 months.
37484|NCT03890978|Other|promotional Exclusive breastfeeding text messages|promotional Exclusive breastfeeding text messages will be send to women via mobile phone
37485|NCT03890965|Other|Reflex locomoction therapy|"The intervention of the stimulation of the reflex locomotion is carried out in this study in a sitting position in a conventional chair, an unorthodox posture in the usual treatment of Vojta therapy.~The reflex stimulation is performed by the passive pressure exerted by the weight of the wrist (pisiform) on the rubber sphere. Simultaneously the patient has to exert a slight pressure with the heel towards the ground with his foot. This foot will be the opposite of the wrist that has the sphere under the pisiform.~Alternating each diagonal 4 times, 5 minutes each. Total session 20 minutes, 2 times x day, every day according to degree of affectation."
37486|NCT03890952|Drug|Nivolumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
37487|NCT03890952|Drug|Bevacizumab|Treatment with the combination of Nivolumab and bevacizumab every 2 weeks
37488|NCT03890939|Device|BiPAP AutoSV Advanced System One|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
37489|NCT03890939|Device|Dreamstation BiPaP AutoSV|A mode of positive airway pressure used to treat sleep apnea. The difference between this device and the other experimental device is in the algorithm of the pressure settings.
37490|NCT03890939|Device|ResMed S7 VPAP Adapt Device|A mode of positive airway pressure used to treat sleep apnea. This device is widely used by physicians to treat sleep apnea and will be the active comparator to the two experimental devices.
37491|NCT03890926|Radiation|radioactive Iodine-125 seed implantation under the guidance of 3D template|3D-PNCT assisted with CT-guidance for radioactive Iodine-125 seed brachytherapy is a conventional treatment for patients with local recurrent rectal carcinoma. Retrospective data on the effectiveness and adverse effects of the past radioactive Iodine-125 seed implantation is collected.
37492|NCT03890900|Other|T2DXcel mobile application|T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
37493|NCT03890887|Drug|BI 1291583|Tablet
37494|NCT03890887|Drug|Itraconazole|Oral solution
37495|NCT03890861|Behavioral|Physical activity|Promotion of physical activity to the current federal physical activity guidelines.
37496|NCT03890861|Behavioral|Successful Aging|Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
37497|NCT03890848|Behavioral|Wechat application reminder intervention|precautions and rehabilitation progress reminders and other news by optimized WeChat applet regularly
37498|NCT03890848|Behavioral|routine guidance during discharge|rehabilitation exercise guidance during routine discharge
37499|NCT03890835|Procedure|MTA Pulpotomy.|Pulpotomy using MTA.
37500|NCT03890835|Procedure|Biodentine Pulpotomy|Pulpotomy using Biodentine
37501|NCT03890809|Drug|BMS-986165|Oral administration
37502|NCT03890796|Behavioral|Activity Scheduling|AS is strategy for behavioral activation that has also been used with success in people with dementia, after the training of their caregivers. A certified occupational therapist will train up the caregivers of dementia in conducting AS activities for participants in experimental group
37503|NCT03890796|Behavioral|Educational|A serial of dementia care education program with a weekly theme of topics like: importance of exercise and healthy eating, sleep management, counselling, acceptance therapy, commitment therapy, reminiscence therapy.
37504|NCT03890783|Other|Evaluation of phonation quality|"Evaluation of phonation quality by :~Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia"
37505|NCT03890783|Other|Evaluation of swallowing quality|"Evaluation of swallowing quality by:~Self-evaluation: completion of the Deglutition Handicap Index questionnaire~Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation"
37506|NCT03890783|Other|global quality of life questionnaire|Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H&N35 questionnaires
37507|NCT03890770|Drug|BMS-986165|Oral administration
37508|NCT03890757|Other|ultrasound guided paravertebral or serratus anterior block|"Patients groups will be as follow:~Group (I): Serratus plane block will be performed with the patient in the lateral position and the arm abducted. Using a high-frequency linear ultrasound probe ,Group (II): thoracic paravertebral block will be performed in the sitting position. The spinal level chosen for needle insertion will be two segments below the upper most fractured rib or midway between the upper most and lowest fractured rib, 2-2.5 cm distance from the midline in the same injury site"
37509|NCT03890744|Drug|ModraDoc006/r|Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
37510|NCT03890731|Drug|BAY73-4506 (Regorafenib, Stivarga)|Regorafenib is administered orally as 20 or 40 mg tablets at the dose that each patient received during the last cycle of the feeder trial. The dose may be either 60, 80, 120 or 160 mg once daily for 3 weeks of every 4-week cycle (3 weeks on, 1 week off).
70979|NCT03629054|Drug|Empagliflozin|single dose
37514|NCT03890666|Drug|Albuterol eMDPI DS|"Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 4 component devices:~Device 1: Albuterol eMDPI~Device 2: Albuterol eMDPI Patient-facing smart device application (App)~Device 3: Digital Health Platform (DHP, Cloud solution)~Device 4: Provider-facing dashboard (dashboard)"
37515|NCT03890666|Drug|albuterol|Standard of care albuterol-administering rescue inhaler
37516|NCT03890653|Behavioral|Performance-Based Financing|Incentive-based payments
37517|NCT03890653|Behavioral|Decentralized Facility Financing|Financing not linked to service delivery.
37518|NCT03890640|Procedure|Ultrasound-guided TECI|When performing an ultrasound-guided thoracic epidural catheter insertion (TECI), an 18-gauge Tuohy needle will be used for interlaminar epidural access. All procedures will be performed with a paramedian approach under ultrasound-guidance and using the loss of resistance technique with saline. If the needle is deemed to be in the epidural space when the loss of resistance occurred, fluoroscopic views will be obtained to confirm which the catheter tip is located in the epidural space or not.
37519|NCT03890627|Device|Thoracic bio-reactance|Cardiac output variation measured by thoracic bio-reactance, between inclusion and one year after hemodynamic evaluation by right cardiac catheterization, to discriminate stable patients from those that degrade.
37520|NCT03890614|Other|Creation of three-dimensional myeloma organoids using marrow aspirates|Bone marrow aspirates will be collected from participants with multiple myeloma being evaluated for relapsed disease to create three-dimensional constructs using a three-dimensional bioprinting methodology for automated organoid biofabrication.
37521|NCT03890601|Biological|blood sample|"A single 15 mL blood draw is planned for this study, as follow:~10 mL citrated tube (2 tubes) for APTT, PT, D-Dimers, LA, aCL, aβ2GP1, aβ2GP1-dm1 and TGA~5 mL EDTA tube for blood count~During a follow up visit, a 5 ml citrated tube and a 5 mL EDTA tube are collected from each patient for their routine laboratory evaluation. One additional citrated tube will be required to measure thrombin generation and aβ2GP1-dm1."
37522|NCT03890588|Other|CKD enhanced clinical decision support|The CKD-CDS intervention provides clinical recommendations at any primary care visit for patients with a deficit in any of 5 key elements of CKD care.
37523|NCT03890575|Procedure|Airway stent implantation|The 3D printed airway stents were implanted to treat malignant stricture involving carina and bronchi distal to carina.
37524|NCT03890562|Other|Auricular acupressure|Auricular acupressure will be applied to five specific acupressure points using a stainless-steel acupressure probe. The five auricular points are: (1) Shen Men, 2) Sympathetic, (3) Kidney, (4) Lung, and (5) Liver. (Tyme, 2001). These sites have been identified by the National Acupuncture Detoxification Association and used for the treatment of withdrawal in adults.
37525|NCT03890549|Diagnostic Test|SnoreLab (smart phone application for snoring recording)|The investigators selected 3 appropriate downloadable smart phone applications for snoring recording and make validation with the golden standard of polysomnography.
37526|NCT03890523|Procedure|Airway stent implantation and removal|The retrievable airway stent modified with 3D printing were implanted to treat benign diseases involving carina and bronchi distal to carina. The stents were removed because of stent-related complications or tracheobronchial healing.
37527|NCT03890510|Other|Ringer's Lactate solution|Patients in both groups will receive Ringer's lactate solution continuously during operation with different infusion volume.
37528|NCT03890510|Procedure|Spine surgery under general Anesthesia in the prone position|The surgery, general anesthesia, and the placement of the prone position will be performed according to the standard procedures.
37529|NCT03890497|Biological|IPV|The inactivated poliovirus vaccine (IPV) developed by Salk was the first available polio vaccine licensed in 1955 in the United States. The current formulation of IPV got licensed in 1987 and has a higher potency than the original Salk IPV. Almost 100% of children two months of age or older who receive 2-3 doses of intramuscular (IM) IPV achieve high antibody levels against the all three serotypes. IPV (.5mL) can be administered subcutaneously (SC) or IM and fractional (0.1 ml) doses of IPV are generally administered intradermally
37530|NCT03890484|Behavioral|Peer Type|The type of peers (close friends or new peers) will be manipulated between arms.
37531|NCT03890471|Behavioral|Preoperative telephone call three days before surgery|Patients will receive a provider-initiated telephone call three days before surgery. In order to standardize counseling across providers, each provider will use a telephone script addressing the following components: Purpose of the surgery, alternatives to the surgery, surgical benefits, surgical risk (such as infection, bleeding, injury to other organ systems), potential surgical complications (such as mesh erosion, voiding dysfunction, urinary retention requiring indwelling catheter), bowel complaints (such as nausea, vomiting, constipation, diarrhea), and postoperative expectations (such as Foley management, pain management, activity restrictions, and diet. The following ERAS-specific components will be incorporated into the counseling: management of chronic medical conditions, cessation of alcohol and tobacco, and daily exercise until surgery. Questions from patients and total counseling time will be recorded.
37532|NCT03890458|Drug|DEVIT-3|The physicians gave the women in the experimental group vitamin D oral drops in an ampoule of 300,000 IU and a vial of 50,000 IU to take during the IVF treatment. Written and verbal information about how to take vitamin D was provided to the participants by the nurses. The women took 300,000 IU vitamin D orally for the first week. In the second week of the treatment, 50,000 IU vitamin D (15 drops/day) was used as maintenance dose until the pregnancy test day.
37533|NCT03890432|Device|GLUCOSAFE 2|Use of GLUCOSAFE 2 software for nutrition management and insulin-therapy
37534|NCT03890432|Device|Local protocol control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
37535|NCT03890432|Device|Historical control group with routine care|Use of the local protocols (electronic or paper version) for nutrition management and blood glucose control.
37536|NCT03890419|Other|Green light|Green light exposure
37537|NCT03890419|Other|Clear light|Full spectrum light exposure
37538|NCT03890406|Drug|Rocuronium: PTC(Post-tetanic count) 1~2|Deep neuromuscular blockade will be maintained using continuous infusion of rocuronium.
37539|NCT03890406|Drug|Rocuronium: TOF(Train-of-four) 1~2|Moderate neuromuscular blockade will be maintained using continuous infusion of rocuronium.
37594|NCT03889964|Other|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing|Measurement of lung function, electrocardiography, echocardiography and cardiopulmonary exercise testing
37540|NCT03890393|Device|Electromyography|Muscle activity was bilaterally tested with needle electromyography at rest status, targeting at myofascial trigger points (MTrPs) in the frontal, temporal, sternocleidomastoid (SCM), splenius capitis, splenius cervicis and trapezius of each subject.
37541|NCT03890380|Device|Magneto Wire|Patients will be treated with Magneto Wire
37542|NCT03890367|Biological|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
37543|NCT03890367|Biological|Meningococcal group A, C, W-135 and Y conjugate vaccine|Pharmaceutical form:Powder and solvent for suspension for injection Route of administration: Intramuscular
37544|NCT03890367|Biological|Meningococcal group C polysaccharide conjugate vaccine adsorbed|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
37545|NCT03890354|Procedure|Hand-Sewn Repair|gastotomy to identify and remove gastric subepithelium tumor and hand sawn repair
37546|NCT03890341|Drug|Drospirenone/Ethinylestradiol|A single oral dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets will be administered on Days 1, 13 and 19.
37547|NCT03890341|Drug|Midazolam|Midazolam 2 mg will be administered orally on Days 1, 13 and 19.
37548|NCT03890341|Drug|JNJ-64530440|A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.
37549|NCT03890328|Procedure|radiofrequency ablation|apply RF therapy to the treatment of splenic trauma
37550|NCT03890315|Diagnostic Test|Functional MRI|"In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses."
37551|NCT03890302|Drug|FB704A|Administered by IV infusion
37552|NCT03890302|Drug|Placebo|Identical in appearance and same excipients as FB704A, but without active compound. Administered by IV infusion
37553|NCT03890289|Drug|Idelalisib|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
37554|NCT03890289|Drug|Obinutuzumab|Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
37555|NCT03890276|Other|HMS EL&C training module|No additional information
37556|NCT03890276|Other|Videos used to supplement live trainer|[Cherrie to add]
37557|NCT03890263|Behavioral|Chronic Pain Self-Management Support|"Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program."
37558|NCT03890250|Other|Aerobic exercise|A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
37559|NCT03890250|Other|Neuromuscular electrical stimulation|Bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds
37560|NCT03890237|Behavioral|Her Spaces|Her Spaces will comprise a set of activities leveraging the Her Spaces curriculum and program model which includes curriculum-based sessions for 11-13 year old girls, with 40 sessions delivered weekly over the course of 10 months
37561|NCT03890237|Behavioral|Act With Her|Act With Her was designed to facilitate adolescent transitions to adulthood via improvements across the six GAGE domains (education, bodily integrity, health, psychosocial well-being, voice and agency, and economic empowerment). Project activities fall into three main categories: curriculum-based programming with adolescent girls and boys, community transformation, and systems strengthening. Act With Her will work with 10-13 year old girls and boys for 10 months and implement community-level and high-level system strengthening work up to 24 months (in rural and pastoralist areas).
37562|NCT03890237|Behavioral|Act With Her + Asset Transfer|This arm will implement the Act With Her program described above, using program curricula with 10-13-year-old girls and boys over 10 months and conducting community-level systems strengthening up to 24 months. Additionally, the girls participating in this arm will receive one of three asset transfer options. The packages will be of equal value (115 USD) - one will include school supplies, one will include hygiene supplies, and will be a combination of both. Each adolescent girl will choose which package she would like to receive and will receive components of the package at 3 timepoints over the course of the first 10 months of the project.
37563|NCT03890237|Behavioral|Act With Her (simple)|This arm will implement the Act With Her curricula described above with 10-13 year old girls and boys over 10 months. The adolescent groups will follow the same model (near-peer, same-sex mentors, 40 weekly meetings for girls, 18 meetings for boys, 4 of which are joint sessions for boys and girls, 6 sessions for parents), but will not include community-level systems strengthening activities
37564|NCT03890224|Device|home ventilators|The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
37565|NCT03890211|Device|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
37566|NCT03890198|Biological|LCAR-C182A cells|Patients receive fludarabine (3×300 mg/ m^2) and cyclophosphamide (3×30 mg/m^2) IV on days -5 to-3, and then Patients receive CAR-T cells. PS：The specific dose of fludarabine and cyclophosphamide is adjusted according to the individual condition of the subject and the judgment of the investigator.
37626|NCT03889639|Drug|SAR442168|"Pharmaceutical form: Film coated tablet~Route of administration: Oral"
37567|NCT03890185|Combination Product|Chemo + Low dose RT|Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1, Cisplatin 75mg/m2 IV D1.Radiathion therapy (LDFRT) using 50 cGy of radiation per fraction BID on the day of chemotherapy and the day after during induction i.e. 50 cGy x 4 times per cycle given for total of 2 cycles every 21 days.
37568|NCT03890185|Drug|Chemo alone|Chemo alone: Intervention will include chemotherapy using Docetaxel 75mg/m2 IV D1 and Cisplatin (CDDP) 75mg/m2 IV D1 given for 2 cycles every 21 days.
37569|NCT03890172|Other|20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly|topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
37570|NCT03890172|Other|standard treatment|Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
37571|NCT03890159|Behavioral|Computer Assited Cognitive rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The computer-aided cognitive rehabilitation group will perform simulation-based exercises, including exercises related to attention, in a special computer program (Cogniplus TR version) during therapy hours. The total duration of intervention will be 1 month.
37572|NCT03890159|Behavioral|Conventional Cognitive Rehabilitation|Patients will receive their therapies 1 day a day, 2-3 days a week. The home (paper pen) exercise group will take the necessary exercises on paper suitable for their respective levels and the daily tasks suitable for their functional needs and interests. The total duration of intervention will be 1 month.
37573|NCT03890133|Behavioral|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-healthcare Qigong exercise that has been practiced by Chinese people for at least eight hundred years.It consists of eight sets of simple movements. By combining meditation with slow, graceful movements,deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear."
37574|NCT03890133|Drug|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
37575|NCT03890120|Drug|Cilofexor|100 mg tablet administered orally once daily
37576|NCT03890120|Drug|Placebo|Tablet administered orally once daily
37577|NCT03890107|Device|PhotoniCare TOMi Scope|PhotoniCare TOMi Scope imaging using a near-infrared laser
37578|NCT03890094|Drug|Sufentanil|Patients were applied sufentanil and midazolam intravenously and topical anesthetized.
37579|NCT03890081|Other|Questionnaire|Translate and culturally adapt the original English version of the Coping Strategies Questionnaire into Turkish
37580|NCT03890068|Drug|Anlotinib Hydrochloride|48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
37581|NCT03890055|Drug|Anlotinib Hydrochloride|Best supportive care
37582|NCT03890042|Drug|Dienogest group|VISANNE 2MG Tablet once daily
37583|NCT03890042|Drug|Gestodene-Ethinyl Estradiol|Gynera tablet once daily
37584|NCT03890042|Radiation|Ultrasound|ultrasound assessment of uterine volume
37585|NCT03890042|Other|visual analogue scale|visual analogue scale for assessment of pain
37586|NCT03890029|Behavioral|Intervention Training|After pre-testing and randomization, intervention participants will meet in small groups of 10 per group for 90 minutes/week over five weeks for resilience training. Participants needing extra help will receive it at the end of each session. Controls will be on a minimal attention list, not being trained. After five weeks, all participants will be post-tested.
37587|NCT03890029|Behavioral|Control Condition|While intervention participants receive resilience training, the control group will not receive training but will receive minimal attention of a bi-monthly telephone call to indicate to participants that they are still enrolled in the study. A monthly flyer will be mailed to them about wellness and PTSD in recent news coverage. Following completion of an intervention group, participants and controls will be scheduled for post-testing that will be identical to the pre-testing and will occur within two weeks after the final treatment session. After the post-testing and 3-month follow up testing, the controls will be offered the resilience training.
37588|NCT03890016|Diagnostic Test|20'Whole Blood ClottingTest (WBCT)|"1ml of blood drawn from snake bite victims in clean glass test tubes of 1 cm diameter Kept undisturbed for a period of 20 minutes (measured by a stop watch). At the end of 20 minutes the tube is tilted to see if the blood has clotted or not.~If a well formed clot is not formed, the test is recorded as 'abnormal'.~If the clot seems well formed, it is further observed for a period of 30 minutes to look for dissolution of the formed clot and would be termed clot lysis. Clot lysis indicates an unstable clot."
37589|NCT03890016|Diagnostic Test|Modified Lee and White (MLW) Method Clotting Time|"The blood collected in three additional test tubes would be utilised for MLW.~The three test tubes would be kept on a rack at ambient temperature.~The blood sample would be drawn in a 5cc syringe and 1 ml would be added in the three test tubes consecutively.~The test tube would be left undisturbed for 5 minutes, after that the first tube would be tilted approximately to check for clot formation every 30 seconds while the other tubes are left undisturbed.~After the blood in the first tube has clotted, the time would be noted and the second tube would be tilted every 30 seconds and examined.~Following its clotting, the third tube would be examined. The time at which the third tube is recorded as the CT value.~Once clotted, then the sample in the all three test tube would be assessed at 20 minute and 30 min to look for breakup or lysis of the clot."
37590|NCT03890003|Device|AID System|AID system
37591|NCT03890003|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
37592|NCT03889990|Device|IQOS|"Smoke IQOS"
37593|NCT03889977|Other|Resistance exercise|2 major muscle groups (lower extremity, chest)
37595|NCT03889938|Diagnostic Test|Serum and urinary assessment|Assess bioactive lipid mediators in blood and biopyrins in urine
37597|NCT03889925|Biological|Autologous conditioned plasma|Patients will receive 3 intra-articular injections of autologous conditioned plasma dosed at once a week for 3 weeks.
37598|NCT03889912|Drug|Cemiplimab|Each patient will receive intralesional injections of cemiplimab every week (QW) into the lesion at the assigned dose level for 12 weeks prior to scheduled surgery
37599|NCT03889899|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
37600|NCT03889886|Drug|SDP-4 Ophthalmic Solution (0.1%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
37601|NCT03889886|Drug|SDP-4 Ophthalmic Solution (1.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
37602|NCT03889886|Drug|SDP-4 Ophthalmic Solution (3.0%)|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
37603|NCT03889886|Drug|Vehicle|Investigational product (IP) will be administered via topical ocular instillation, one drop per eye, twice daily (BID) for 12 weeks (84 days). Both eyes will be treated.
37604|NCT03889873|Behavioral|Narrative Writing|An writing task in which participants are given a description of a possible future self (that varies 3 factors: topic; drinking vs. smartphone; perspective: 1st vs. 3rd-person; and social network: specifically asked to be included vs. not specifically asked to be included). Participants are asked to imagine that future self vividly and to write about the thoughts and feeling describe themselves and their experiences, the characteristics they hope or wish they will ideally possess, the characteristics that they would need to have and the roles they will take on or things they will be doing. Participants are given 20 minutes to think and write. They will write and think about the same future on each of three lab-sessions (which occur at 1-week intervals).
37605|NCT03889847|Device|Fibreoptic intubation with silicone double lumen tube|Fibreoptic intubation with silicone double lumen tube
37606|NCT03889847|Device|Fibreoptic intubation with PVC double lumen tube|Fibreoptic intubation with PVC double lumen tube
37607|NCT03889834|Procedure|Autologous Blood Transfusion|Autotransfusion of packed red blood cells (200 ml) stored at 4 or -80°C for 31 days
37608|NCT03889834|Other|No transfusion|no transfusion
37609|NCT03889821|Behavioral|Parent-implemented Early Start Denver Model|The Parent-implemented Early Start Denver Model (P-ESDM; Rogers et al., 2012) consists of 12 consecutive sessions, each session approximately 1 hour long, that promote parental ability to support and interact with their young children with autism spectrum disorder (ASD). Intervention sessions are conducted in the clinic setting by therapists trained to fidelity by ESDM-certified parent trainers. The manualized intervention has a detailed parent-training curriculum, a specific coaching intervention method, and a therapist fidelity measure. Therapists introduce skills through descriptions, interaction, modeling, coaching, and feedback.
37610|NCT03889821|Behavioral|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction (MBSR) protocol is derived from the work by Dykens et al. (2014), which is based on the stress reduction and relaxation program (Kabat-Zinn, 1982, 1990). In this study, it is offered as 6 weekly sessions that run concurrent with the P-ESDM intervention. Participants work one-on-one with a therapist for instruction and practice in mindfulness skills as well as discussions of stress, coping, and homework assignments.
37611|NCT03889808|Diagnostic Test|Determination of serum anti-toxin Abs for C. difficile|
37612|NCT03889795|Drug|Metformin|Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
37613|NCT03889795|Drug|Simvastatin|Simvastatin oral pill will be taken daily in the evening.
37614|NCT03889795|Drug|Digoxin|Digoxin oral pill will be taken daily in the morning.
37615|NCT03889769|Diagnostic Test|OSNA test|Analysis of lymph node with OSNA
37616|NCT03889756|Drug|Ketamine infusion|The dose of ketamine established in prior research (0.5 mg/kg over 40 minutes) will be used in this study to minimize risks. The maximum total single dose allowed in this study will be 40mg, corresponding to a weight of 80kg.
37617|NCT03889756|Drug|Midazolam infusion|The weight-based midazolam dosing established in prior ketamine trials in adults (0.045mg/kg) will be used to minimize risks, as this is considered a very low dose compared to the sedation literature. The maximum total dose allowed in this study will be 3.6mg per infusion, corresponding to a weight of 80kg.
37618|NCT03889743|Drug|Dexamethasone treatment during 3 days|Dexamethasone 1,5 mg oral tablets, may be halved into 2 x 0,75 mg. The exact daily dose of dexamethasone will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
37619|NCT03889743|Drug|placebo treatment during 3 days|1,5 mg oral tablets, may be halved into 2 x 0,75 mg. The exact daily dose of lactose (instead of dexamethasone) will be 0.3 mg/kg (maximum 6.0 mg). The recommended administration of all tablets is to crush the tablets to a smooth powder and then mix with jelly or yogurt. The dissolved dexamethasone is given by mouth and it is recommended to give it in relation to a meal/breastfeeding. If a child vomits within 30 min, the same dose will be given one more time after a break.
37620|NCT03889717|Dietary Supplement|vitamin D|vitamin d drops will be given daily to the 2 groups of neonates ( 1st group will be given 400 iu /day and 2nd group will be given 1000 iu per day ) when they reach 100 cc per kg enteral feeding .. until they reach 40 weeks gestational age
37621|NCT03889704|Device|Omnistim® FX²|The Omnistim® FX² is a neuromuscular stimulation device that provides patterned electrical neuromuscular stimulation (PENS) via cutaneous electrodes placed over relevant musculature. The device mimics physiologic patterns of neuron firing.
37622|NCT03889691|Procedure|Third molar surgery|Surgical extraction of impacted lower third molar tooth under local anesthesia
37623|NCT03889678|Diagnostic Test|Color flow doppler|Color flow doppler proximal to vein insertion site to document flow
37624|NCT03889665|Other|Suspension training|Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
37628|NCT03889639|Drug|Locally approved intravenous contrast medium for contrast enhanced MRI|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
37629|NCT03889626|Drug|Apatinib|Apatinib: 500mg qd po, q4w
37630|NCT03889626|Drug|Capecitabine|Capecitabine: 1000mg/m2 bid po, d1-14, q3w
37631|NCT03889613|Other|prospective follow-up with videocapsule|prospective follow-up with videocapsule
37632|NCT03889600|Other|REDD-CAT|After obtaining informed consent from a participant and gathering baseline data, the study RA will send a flag in the EMR to notify the nurse care manager that a patient has enrolled in the REDD-CAT pilot. The nurse care manager will then incorporate the administration of the REDD-CAT to the patient as part of standard care discharge planning. He or she will utilize the REDD-CAT results report as a guideline for generating appropriate referrals to address unmet social needs identified.
37633|NCT03889587|Procedure|Innervation|There will be simultaneous innervation of vascularized iliac or fibular bone flaps through neurorrhaphy between the nerves innervating iliac or fibular bones and recipient site.
37634|NCT03889587|Procedure|Non-innervation|This will be the traditional method of vascularized iliac or fibular bone flaps, and neurorrhaphy will not be performed.
37635|NCT03889561|Behavioral|Drink Tap|The Drink Tap intervention consists of increased access to safe and appealing drinking water, multicultural water promotion, and soda taxes.
37636|NCT03889548|Other|Mental Imagery|Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
37637|NCT03889535|Device|Resin strip crowns|"Technique:~I.Select shade of resin-based composite II.Rubber dam isolation III.Select primary incisor celluloid crown form with mesiodistal width similar to the tooth to be restored and trim the selected crown form to fit.~IV.Remove decay with slow speed round bur. Perform pulp therapy, if indicated. V.Reduce incisal edge by 1.5 mm VI.Reduce interproximal surfaces by 0.5 to 1.0 mm with feather edge at gingival margin. The interproximal walls should be approximately parallel.~VII.Reduce buccal surface by 1.0 mm and lingual surface by 0.5 mm with feather edge at gingival margins.~VIII. Round line angles IX.Etch for 15 to 20 seconds, rinse and air dry X. Apply bond and polymerise XI. Fill crown form to 2/3 full with composite resin and seat onto the tooth. Remove excess material with hand instrument. Polymerise.~XII. Remove celluloid crown form with scaler XIII. Finish and polish"
37638|NCT03889535|Device|Zirconia crowns|I.Choose appropriately sized crown based on tooth's dimension; evaluate occlusion. II.Rubber dam isolation. III.Remove decay, perform pulp therapy if indicated. IV.Prep mesial half of incisal edge to complete thickness of 001 donut bur. V.Prep and blend distal half of incisal edge to create uniform incisal reduction. VI. Create chamfer margin at gum line at least half the thickness of bur tip. VII. Taper incisal half lingually to create a thin incisal edge. VIII. Remove cingulum and 0.75-1.25mm of lingual enamel; blend together forming smooth, slightly concave surface extending to tissue. IX. Thin incisal half. X.With 004 flame bur, remove chamfer margin at tissue level. Keep bur parallel to long axis of tooth. Remove chamfer in incremental steps, XI. Extend tip of bur full 2mm subgingivally. While hugging bur axially along root surface, make 3 circumferential passes. XII.Clean tooth and control bleeding. XIII.Cement crown with pure glass ionomer cement
37639|NCT03889522|Diagnostic Test|Bioelectrical Impedance Analysis|BIA is a radiation-free and clinically accessible measure of body composition [47, 49]. An electrode is placed on the youth's extremities and they are asked to sit for 10 minutes. The youth's height and weight is manually inputted and the measure is obtained (approx. 90 seconds to complete). BIA sends a low level of electrical current through the body and measures the impedance to the current based on fat, muscle, bones providing a measure of body composition.
37640|NCT03889522|Diagnostic Test|Total Body Dual-energy X-ray Absorptiometry|The DXA total body scan provides measurements of percent body fat, lean and fat free mass throughout the body. Youth lay on a table while the machine moves around them. The process takes about 3 minutes and 20 seconds.
37641|NCT03889522|Diagnostic Test|Blood draw|Blood will be drawn to assess the following labs: HbA1c, leptin, lipid panel and comprehensive metabolic panel.
37642|NCT03889496|Radiation|indium-111-exendin SPECT/CT|SPECT/CT imaging after injection with In-111-DTPA-exendin-4
37643|NCT03889483|Device|NeuroCatch™ Platform|The NeuroCatch™ Platform consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
37644|NCT03889470|Drug|NTG 1 MG/ML Injectable Solution|administered after sheath placement
37645|NCT03889457|Other|anticoagulation choice|Type of anticoagulant chosen by the patient (oral or injectable).
37646|NCT03889431|Dietary Supplement|Iodine capsule|225 µg of iodine daily as a capsule of potassium iodide
37647|NCT03889431|Other|Iodized Salt|450 g iodized salt provided for the household weekly. Salt iodine content was 30 to 40 mg iodine /kg salt as KIO3
37648|NCT03889418|Behavioral|Electronic medical recorded clinical decision support [EMR CDS]|The opioid management tool has quick links to the Opioid Risk Tool (ORT), health maintenance reminders for risk mitigation tasks (pain management agreements; urine drug screening; prescribing naloxone); Pain Scale and depression/anxiety screen. The frequency with which providers are prompted to complete mitigation tasks is based on patients' level of risk for aberrant drug behavior defined by the ORT score. Additionally, the EMR CDS flags patients as high risk if one of the following criteria are met: (1) co-prescriptions for benzodiazepines; (2) active diagnosis of substance abuse in the last 12 months; or (3) MEDD >=90 mg. The ORT score, morphine equivalent daily dose (MEDD), and hyperlinks to the Louisiana pharmacy drug monitoring program data are visible in the prescription writer. If MEDD >=90 mg, the calculated MEDD is displayed in red font to alert the prescribing provider of high dosage. An Epic banner appears in charts to alert providers of existing pain management agreements.
37682|NCT03889132|Procedure|Bariatric Surgery|Subjects with obesity (N=60) will be undertaken a hypocaloric diet and a periodic follow up, also 30 of them will undergo bariatric surgery
37649|NCT03889418|Behavioral|Stepped opioid collaborative care model [CCM]|The licensed clinical social worker (LCSW) will provide counseling services as indicated (behavioral activation, psychotherapy, crisis planning, facilitating connection to substance abuse counseling and treatment); meet weekly with the consulting psychiatrist for complex case review and care plan adjustments; and supervise the community health worker (CHW) case management and depression/anxiety care management activities. The CHW will update assets and barriers to recovery and self-management and help patients navigate community resources. The clinical pharmacist will review and reconcile active medication lists, assess medication side effects, drug interactions and adverse events; monitor analgesia; recommend algorithm based anti-depression medication titration as indicated. The consulting psychiatrist will directly co-manage patients with severe mental illness, substance abuse and complex medication regimens.
37650|NCT03889405|Device|Invu|The subject will undergo continuous recording of the uterine contraction and the fetal heart rate (FHR) for 30 to 60 min using Invu™ , Cardiotocograph (CTG) and Intrauterine Pressure Catheters (IUPC).
37651|NCT03889392|Procedure|Kidney transplantation and nephrectomy|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
37652|NCT03889379|Drug|Administration of albuterol|Participants will inhale nebulized albuterol at a concentration of 2.5mg diluted in 3mL of normal saline for 20 minutes.
37653|NCT03889366|Drug|Aprepitant 125 mg|Single dose in the fasted state during treatment period 1,2 or 3
37654|NCT03889353|Device|BCI sessions|up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
37655|NCT03889340|Device|IQool|Subjects will undergo hypothermia therapy with the IQool system
37656|NCT03889327|Behavioral|Neuropsychological Feedback & Psychoeducation (Cognition)|The customary practice of providing feedback on neuropsychological test performance can address patient misperceptions of cognitive impairment by distinguishing between perceived and objective neuropsychological test performance. Explaining how normative data is derived by comparison to same age peers, patients are able to better understand their current cognitive functioning. The proposed intervention will employ both psychoeducation and neuropsychological feedback for participants assigned to the treatment group, and psychoeducation for participants assigned to the control group. Both groups will watch 3 brief videos (exactly the same length in time) and answer two qualitative questions following each video.
37657|NCT03889327|Behavioral|Psychoeducation (Health)|Information on importance of healthy eating habits and benefits of a healthy diet including medical outcomes such as reduced blood pressure, and decreased risk of stroke and cardiovascular disease. This intervention will also cover recommended serving sizes for daily helpings of fruits and vegetables, and ways to incorporate fruits and vegetables into meals throughout the day. The control intervention will include expert testimony from a nutritionist and expert dietician.
37658|NCT03889314|Drug|Rosuvastatin 20mg|Statin Therapy
37659|NCT03889314|Other|Placebo|Placebo
37660|NCT03889301|Behavioral|E-E Video|The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.
37661|NCT03889301|Behavioral|Discussion|Structured psychoeducation and pamphlet about anxiety and depression.
37662|NCT03889288|Device|Medical device - electronic-pain killer|Treatment sessions with the medical device (no-marked EC): 2 sessions before surgery and 4 or 5 sessions until 48 hours after surgery. Each treatment sessions takes 45 minutes. Each session is spaced by 12 +/-3 hours.
37663|NCT03889275|Biological|MEDI5395|Subjects will receive multiple doses of MEDI5395 over several days.
37664|NCT03889275|Biological|Durvalumab|Durvalumab will be administered periodically for a maximum of 2 years or until radiologically confirmed disease progression, clinical deterioration, withdrawal of consent, or unacceptable toxicity
37665|NCT03889262|Other|Hippotherapy|Hippotherapy is a therapeutic method in which a mechanical horse is used for therapeutic purposes.
37666|NCT03889262|Other|Neurodevelopmental Therapy|Neurodevelopmental therapy (NDT) is a hands-on treatment approach used by physical therapists, occupational therapists, and speech-language pathologists. NDT was developed to enhance the function of children who have difficulty controlling movement as a result of neurological challenges, such as cerebral palsy and head injury. During treatment interventions, repeated experience in movement ensures that a particular pattern is readily accessible for motor performance. The more a patient performs certain movements, the easier these movements becomes.
37667|NCT03889249|Drug|Tenecteplase|Stroke Thrombolytic
37668|NCT03889249|Drug|Alteplase|Stroke Thrombolytic
37669|NCT03889236|Other|Fasting mimicking diet Prolon|5-day fasting mimicking diet
37670|NCT03889236|Dietary Supplement|Food supplement Endocalyx|Food supplement
37671|NCT03889236|Dietary Supplement|Placebo|Placebo
37672|NCT03889223|Procedure|Anatomical intervention with USG and comfort evaluation with NRS|The anatomical evaluation of the two neuraxial positioning techniques sonographically and comparison of comfort with the 7-point NRS
37673|NCT03889210|Other|HVMN Ketone|Water-based, flavoured sport beverage
37674|NCT03889210|Other|Placebo|Water, stevia, malic acid, and thickening agent
37675|NCT03889197|Other|Sodium supplementation algorithm guided by urine sodium concentration|4 mEq/kg/d sodium added the first time urine [Na] below threshold; for each subsequent time urine [Na] below threshold, add additional 2 mEq/kg/d.
37676|NCT03889184|Other|rehabilitating meals-on-wheels service|the meals-on-wheels service will be specifically targeted for old people discharged from hospital, receiving exercise rehabilitation in the municipality or already receiving meals-on-wheels
37677|NCT03889171|Behavioral|Behaviour|Comparison to psychological, medical and emotional Influencing communication and achievement factors to Oncogenetics tests
37678|NCT03889158|Biological|Typhoid Vaccine/Ascorbic Acid|All participants will receive the typhoid vaccine and Vit C.
37679|NCT03889145|Drug|Telmisartan 80mg|Telmisartan 80mg
37680|NCT03889145|Drug|Amlodipine10mg|Amlodipine 10mg
37681|NCT03889145|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
37683|NCT03889119|Radiation|Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System.|SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer.
37684|NCT03889106|Drug|Ribavirin|Standard of care: Intravenous administration of ribavirin at currently recommended dosages. Loading dose of 30 mg/kg (maximum 2 g), followed by 15 mg/kg (maximum 1 g) intravenously QDS for four days, followed by 7.5 mg/kg intravenously (maximum 500 mg) TDS for six days.
37685|NCT03889093|Other|Yttrium-90|This is to evaluate the immunologic effects of yttrium 90.
37686|NCT03889080|Diagnostic Test|functional MRI|functional MRI scan of the brain
37687|NCT03889067|Biological|Salmonella Typhi challenge|The challenge agents will be delivered in 30 ml of sodium bicarbonate solution, preceded by 120 ml of solution of sodium bicarbonate to neutralise gastric acid.
37688|NCT03889054|Behavioral|Education program|"The education sessions will be given in 3 opportunities (15-30, 45 and at 90 days from diagnosis of the exacerbation) and it will be individualized. The program will include measures of self-care and self-management recommended in patients with COPD:~Plan of action in an exacerbation.~Education related to COPD.~Information on pharmacological medication.~Management of the exacerbation.~Management of stress and / or anxiety.~Nutritional recommendations.~Physical exercise recommendations.~Healthy lifestyle recommendations. The first session will last 90 minutes and will be explain according to the contents of the manual Controlling COPD. A presentation designed for this purpose will be displayed and this manual will be provided to patients to carry out their reading at home. The second and third sessions will last 15 minutes and the purpose will be to resolve doubts."
37689|NCT03889041|Other|Quality of life assessment|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
37690|NCT03889015|Dietary Supplement|Probiotic yogurt|Probiotics are found in different dairy products including yoghurt, that are known as carriers of probiotics. These products can be easily integrated in daily meals to reduce cariogenic streptococcus mutans bacteria in dental biofilm
37691|NCT03889015|Dietary Supplement|xylitol chewing gum|Xylitol is widely used as an added sweetener in sugar-free products. It has been found to prevent dental caries through reducing dental plaque and limiting salivary streptococcus mutans counts and their produced levels of lactic acid
37692|NCT03888989|Biological|Quadrivalent inactivated influenza vaccine (IIV)|Quadrivalent inactivated influenza vaccine (IIV), Intramuscular Injection
37693|NCT03888976|Procedure|Cholecystectomy|Cholecystectomy with repair of duodenal wall.
37694|NCT03888963|Procedure|PRF|patients will receive pulsed radiofrequency, 4 cycles (each cycle, 2 minutes) on the thoracic paravertebral nerves number 2,3, and 4 under fluroscopic guidance
37695|NCT03888963|Procedure|SHAM|patients will be subjected to the same procedure like PRF group without giving PRF
37696|NCT03888950|Diagnostic Test|FDG PET-CT|FDG PET/CT for oncological imaging of adult patients
37697|NCT03888924|Drug|Bacille Calmette-Guerin vaccine|"One dose (0.1 mL) contains 50 μg of the semi-dry mass of BCG bacilli, i.e. from 150,000 to 600,000 of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~One ampoule or vial with the powder contains: 0.5 mg (from 1.5 mln to 6 mln) of live BCG bacilli (Bacillus Calmette-Guerin), the Brazilian Moreau substrain.~Powder: monosodium glutamate. Solvent: isotonic solution of sodium chloride."
37698|NCT03888924|Drug|Placebo|isotonic solution of sodium chloride (2mL vials).
37699|NCT03888911|Dietary Supplement|High dose IQP-LU-104 (5120mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
37700|NCT03888911|Dietary Supplement|Low dose IQP-LU-104 (2560mg)|1 sachet to be taken 2 times daily orally, together with 2 main meals
37701|NCT03888911|Dietary Supplement|Placebo|1 sachet to be taken 2 times daily orally, together with 2 main meals
37702|NCT03888898|Other|Reusable respirator fit test and competency evaluation|Feasibility of rapid conversion to reusable elastomeric respirator use during public health emergency
37703|NCT03888898|Other|Control fit test evaluation|control comparator for fit testing time threshold
37704|NCT03888885|Behavioral|Sport Education Model|A total number of 25 lecturers participated in the 12-hour CPD workshop on Sport Education curriculum on June 2018. The content of the workshop focused on the development of a Sport Education season, the changing roles of teachers and students, the assessment of personal and social responsibility, and the application of sport education season and related pedagogies on handball, badminton, swimming and physical conditioning. The Sport Education courseware and class materials were then designed by the eligible lecturers. The intervention was lasted for 10-lesson, 1-day per week and the duration for each lesson was around 90 minutes. The specific five phases in Sport Education model of team selection, teacher-directed, pre-season, formal competition and cumulating event were included. The eligible lecturers led the lessons according to the designated course wares and lesson plans for each sport.
37705|NCT03888872|Device|High tone power therapy|"1- High Tone Power Therapy (HiTop 191): (For group I). The high tone power therapy through using a device (HiTop 191; gbo Medizintechnik, Rimbach, Germany).~The intensity of the electrical stimulation will be adjusted to a pleasant level that did not produce any pain or discomfort. Duration: 60 min (Each one electrode to both thighs to the knee, each one electrode to both thighs to the groin). Position: lying / setting, Number of sessions: 10, Frequency of sessions: 3 times per week."
37706|NCT03888872|Other|Selected Physical Therapy Program|"Selected physical therapy program: (For both groups).~Wobble board training:~Active range of motion exercises (AROM):~Gentle manual stretching exercises for both UL & LL:~Graduated gait training:"
37707|NCT03888859|Biological|ET1402L1-ARTEMIS™ T cells -IV|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct -intravenous (i.v.) arm
37708|NCT03888859|Biological|ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: intra-hepatic artery (i.a.) arm
37709|NCT03888859|Biological|ET1402L1-ARTEMIS™ T cells -Intratumoral Injections|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1) -ARTEMIS™2 expression construct: Intratumoral Injections (i.t.) arm
37710|NCT03888846|Drug|Pentoxifylline|Topical gel version of pentoxifylline to be administered intraorally.
37711|NCT03888846|Drug|Colchicine|Colchicine therapy is provided to patients with oral ulcers as part of supportive care routinely offered by Behcet's Clinic-Istanbul.
37713|NCT03888820|Drug|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
37714|NCT03888820|Drug|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
37715|NCT03888807|Drug|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
37716|NCT03888807|Drug|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
37717|NCT03888794|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging on pregnant women after 18 weeks of pregnancy with US diagnosis of congenital CNS fetal abnormality.
37718|NCT03888781|Device|Echocardiography|An echocardiogram (also called an echo) is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of your heart. These echoes are turned into moving pictures of your heart that can be seen on a video screen.
37719|NCT03888768|Drug|MonoFer|Administration of IV Monofer will be given according to body weight as recommended by the drug manufacturer.
37720|NCT03888755|Drug|Icatibant|Participants will receive icatibant 30 mg SC injection in the abdominal area.
37721|NCT03888729|Drug|sofosbubir/velpatasvir|SOF/VEL (400 mg/100 mg) FDC once daily
37722|NCT03888729|Drug|sofosbubir/velpatasvir/voxilaprevir|SOF/VEL/VOX (400 mg/100 mg/100 mg) FDC once daily
37723|NCT03888716|Drug|KL1333|25 and 100 mg KL1333 encapsulated tablets
37724|NCT03888716|Drug|Placebo Oral Tablet|25 and 100 mg placebo encapsulated tablets
37725|NCT03888703|Device|Fractional ablative CO2 laser|Three treatments with a fractional ablative CO2 laser 8 weeks apart
37726|NCT03888690|Device|Virtual Reality Headset|Standardized procedures, with or without Virtual Reality Headset.
37727|NCT03888677|Drug|5-FU, epirubicin and cyclophosphamide|Tailored dose escalation of epirubicin and cyclophosphamide.
37728|NCT03888664|Drug|gamma interferon|1st two weeks: gIFN 100 ugr/three times a week from the 3rd week: gIFN 200 ugr/ three times a week for the following 22 weeks From the 25th week: no treatment for the following 24 weeks
37729|NCT03888651|Other|Quality-of-Life Assessment|Complete quality of life assessment
37730|NCT03888651|Other|Questionnaire Administration|Complete questionnaire
37731|NCT03888638|Procedure|Hepatectomy|Removal of a part of the liver because of tumor
37732|NCT03888625|Procedure|Conventional ILM Peeling|peeling with complete removal of the internal limiting membrane (ILM)
37733|NCT03888625|Procedure|Inverted ILM Peeling|the inverted ILM peeling technique - the technique of Inverted flap described by Michalewska, in which the ILM is left in the edge of the macular hole and the free area is inverted over the macular hole before fluid-air exchange
37734|NCT03888612|Drug|ARV-110|Daily oral dosages are predetermined by cohort review committee after the initial starting dose cohort after the first 28 days of treatment
37735|NCT03888599|Behavioral|knowledge questioannaire|", all enrolled undergraduate student received directly on your email the online questionnaire based on the Fluid Survey tool, which was an on line survey tool (https://fluidsurveys.com/)"
37736|NCT03888586|Device|Trigger Point Dry Needling Technique|The type of needle and the depth of the entrance varied depending on the estimated muscle thickness (0.25 - 25 mm, 0.25 - 30 mm and 0.25-40 mm). The disposable stainless-steel sterile needles were inserted through the skin over the trigger point in the taut band of muscle using the fast-in/out technique. Forward and backward needling was repeated until the local twitch responses were obtained. The depth of the needle was changed depending on the muscle thickness. After the first local twitch response, the needle was moved up and down 3 to 5 mm in only vertical directions until no more local twitch responses were elicited. After removing the needle, the insertion area was compressed with a piece of cotton
37737|NCT03888586|Other|Deep Friction Massage Technique|For supporting the normal healing conditions, the deep and transverse friction causes hyperaemia in the involved soft tissue, which results in increased blood ﬂow to the area.
37738|NCT03888573|Other|Stretching protocol|Patients within Stretch Group will receive stretching protocols to the cervical musculature at the side of symptoms. Traction Group will be treated with traction from 15-degree flexion, 30-degree lateral bending, and 15-degree rotation toward the painful side.
37739|NCT03888560|Device|Micro-osteoperforations|MOPs will be performed using SIA Excalibur Mini-Implant with dimension 1.6 mm in width and length of 6 mm, screw 3 mm depth into buccal bone of intervention sites
37740|NCT03888547|Other|Occupational Therapy Health & Wellness Education|The OT Health and Wellness Program will have four weeks of education and individual integration intervention modules. One of the investigators will lead each of these weekly modules under the direct supervision of the Principal Investigator. Investigators will be trained to provide the standardized educational module for each topic area and for using outcome measures. Each module will have an identified theme and information provided in each group will be education to topic, evidence based literature on intervention strategies, lifestyle, or environmental modifications that improve performance of daily activities that will last approximately 45 minutes. After, group sharing of ideas and individual identification of weekly goals for integration of 1-3 targeted interventions will occur and last approximately 30-45 minutes).
37741|NCT03888534|Drug|Ixazomib|Ixazomib intravenous injection in combination with reduction chemotherapy.
37742|NCT03888521|Behavioral|Resound Relief smartphone app|The intervention is a smartphone app which has been developed to include a wide range of sounds and techniques aimed at reducing the impact of tinnitus.
37743|NCT03888508|Other|SIT|"sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done."
37744|NCT03888495|Behavioral|Gender Socialization Training workshop|Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.
37745|NCT03888495|Behavioral|Financial Literacy Training Intervention|Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.
37746|NCT03888495|Behavioral|Family Planning Counseling and Services|Family planning counseling sessions and linkage to services.
37747|NCT03888482|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
37748|NCT03888482|Device|Somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
37749|NCT03888469|Device|Verofilcon A contact lenses|Investigational daily disposable soft contact lenses
37750|NCT03888469|Device|Etafilcon A contact lenses|Commercially available daily disposable soft contact lenses
37751|NCT03888456|Other|osteopathic treatment|the intervention will be based on 2 phases: 1) assessment to identify areas with somatic dysfunction, 2) treatment to improve the function of the area identified
37752|NCT03888456|Other|sham|the sham intervention will consists of 2 overlapping phases as the intervention group but without applying any technique
37753|NCT03888443|Device|"Bimanual 3D Motion Analysis  Be-API "|"Movements will be measured using an optoelectronic system (12 cameras) which captures the displacement of 26 markers placed on the upper limbs and trunk of the child, according to the standards of the International Society of Biomechanics.~The child is installed on a chair and table height (equipment adapted and approved for pediatrics). A game board is installed in front of the child, with objects to handle, set and placed according to its anthropometry (joystick, steering wheel, buzzer, board, chip)."
37754|NCT03888430|Procedure|PtcCO2 measure during intubation|Transcutaneous measure during intubation. Non invasive measure without any risk according to the literature
37755|NCT03888417|Device|Therapeutic plasma exchange (TPE)|All TPEs were performed by the centrifugation technique using the Fresenius Kabi COMTEC machine
37756|NCT03888404|Other|Pregnancy preferences (Aim 1)|The primary exposure of interest for Aim 1 will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
37757|NCT03888404|Other|Sociocultural environment (Aim 2)|For Aim 2 will assess the roles of contextual and individual variables on pregnancy decision-making and care-seeking outcomes (including state political environment, stigma, social emotional and instrumental support, feelings about the pregnancy, SES).
37758|NCT03888404|Other|Pregnancy preferences (Aim 3a)|The primary exposure of interest for Aim 3a will be pregnancy preferences, measured with the Desire to Avoid Pregnancy scale.
37759|NCT03888404|Other|Pregnancy (Aim 3b)|The exposure of interest for Aim 3b will be experiencing pregnancy. DAP level will be examined as an effect modifier.
37760|NCT03888391|Device|Active TNS|
37761|NCT03888378|Drug|0.3% Topical Minocycline Ointment|Compare the safety and efficacy of three treatment regimens: 0.3% topical minocycline ointment, 1% topical minocycline ointment and topical vehicle ointment
37762|NCT03888378|Drug|1% Topical Minocycline Ointment|Compare the safety and efficacy of three treatment regimens: 0.3% topical minocycline ointment, 1% topical minocycline ointment and topical vehicle ointment
37763|NCT03888378|Other|Topical Vehicle Ointment|Compare the safety and efficacy of three treatment regimens: 0.3% topical minocycline ointment, 1% topical minocycline ointment and topical vehicle ointment
37764|NCT03888365|Other|Non-interventional|Non-interventional
37765|NCT03888339|Procedure|Commercially available high abutments placement|Patients will be randomly selected for the commercially available high abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, conventional high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
37766|NCT03888339|Procedure|Modified shape abutments|Patients will be randomly selected for the modified shape abutments option. Two or three implants will be placed following the drilling protocol suggested by the manufacturer. Implants will be placed 0.5mm subcrestal. Once the implants have been placed, periapical radiographs and clinical pictures will be taken. Implants will be uncovered 10 weeks after being placed. After performing the incision and elevation a minimal flap, modified high transmucosal abutments will be screwed using the torque recommended by the manufacturer. Once the abutments have been screwed, periapical radiographs and clinical pictures will be taken. The abutments will not be unscrewed thereafter throughout the study.
37767|NCT03888326|Device|1x1 anodal tDCS|20 minutes of 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
37768|NCT03888326|Device|Sham tDCS|Sham 2mA anodal tDCS applied by a Soterix Medical 1x1 tDCS device while the participants are doing the robotic rehabilitation
37769|NCT03888326|Behavioral|Robotic Rehabilitation|10 days of robotic rehabilitation targeted at proprioception. Therapy is conducted for 1 hour each day for 10 consecutive days (excluding weekends), in combination with either anodal or sham tDCS.
37770|NCT03888313|Other|Pretreatment group consultation|A consultation in group with several patients and one surgeon
37771|NCT03888300|Other|Physiotherapy|Chest Physiotherapy, physical exercises
37772|NCT03888287|Device|Watch Rx system|The Watch Rx system consists of a Watch Rx smartwatch, Watch Rx application and a WatchRx Web Interface. The Watch Rx smartwatch will be worn on the patient's wrist. The smart watch will send alerts to the caregivers through the Watch Rx app when it is time to administer the medication. The Web Interface will be used to store the medical documentations
37773|NCT03888287|Other|Parkinson's Disease Inpatient Clinical Knowledge and Management Program|Parkinson's Disease Inpatient Clinical Knowledge and Management Program educates clinical staff and measures difference in knowledge of medication adherence and compliance for hospitalized Parkinson's Disease patients
37774|NCT03888274|Device|ClearUP Sinus Pain Relief|Microcurrent Device Treatment
37810|NCT03887975|Procedure|Monoplane Occlusion|Monoplane and lingualized occlusion effect on force distribution
37811|NCT03887975|Procedure|Lingualized occlusion|Monoplane and lingualized occlusion effect on force distribution
37775|NCT03888261|Behavioral|Mind-Body Approaches for Medical Conditions|"The intervention programme of the present trial is delivered in a group-based format (15 participants per group) and overall applies three therapeutic components:~Contemplative practices~Psychoeducation~Dialogue, including therapist-group dialogue as well as participant-participant dialogue."
37776|NCT03888248|Device|Whole-body vibration|Home-based whole-body vibration therapy by standing on Galileo Med 15 platform for 9 mins twice a day for 5 days per week
37777|NCT03888248|Other|Muscle strengthening exercises|Daily muscle strengthening exercises to be performed at home following a group education session by paediatric physiotherapist
37778|NCT03888235|Procedure|Immediate corrective exercises|"For anterior malrotation: place the foot on the malrotated side on a chair seat, flex the other knee to touch the seat edge and pull with both hands up on the seat while leaning back, to drive the thigh against the (ASIS), thus pushing it backwards.~For posterior malrotation, lie supine, thigh on the posterior side extended. On the anterior side, knee flexed and foot on the assistant's sternum as he/she leans forward, pressing down on the extended thigh just above the knee. Downward pressure pulls on the ASIS sartorius and AIIS rectus femoris insertions, rotating the ilium anteriorly."
37779|NCT03888235|Device|Immediate use of pelvic support belt|Participants will be fitted with a pelvic support belt which will be tightened around the pelvis under the ASISs and used whenever they are undergoing an activity which has previously been associated with exacerbation of their back pain.
37780|NCT03888235|Other|Delayed treatment|Participants will continue the treatments they are currently using to relieve their low back pain for one month prior to being treated with the intervention.
37781|NCT03888222|Drug|Placebo Oral Tablet|"Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) ."
37782|NCT03888222|Drug|Bosutinib Oral Tablet|Fifteen (15) patients in group 1 will receive the 100 mg of Bosutinib one (1) tablet orally once daily for 3 months (90 days) .
37783|NCT03888209|Device|tDCS|20 minutes of anodal tDCS (C3/FP2 or C4/FP1 depending on side of lesion) 2mA or sham
37784|NCT03888196|Dietary Supplement|Panax Ginseng Supplementation|500 mg/day of Panax Ginseng
37785|NCT03888196|Dietary Supplement|Placebo Supplementation|500 mg/day of Cellulose
37786|NCT03888183|Drug|salt solution without 0.15% HA|received AIM Artificial Tears (4 to 8 times per day) with 12 weeks
37787|NCT03888183|Drug|preservative-free 0.15% HA|received Per-Young Eye Drops (4 to 8 times per day) with 12 weeks
37788|NCT03888170|Other|No intervention|No intervention
37789|NCT03888157|Drug|Liraglutide|Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
37790|NCT03888144|Drug|Oxycodone|5 mg of oxycodone taken by mouth every 6 hours for 5 days
37791|NCT03888144|Drug|Ketorolac|10 mg of ketorolac taken by mouth every 6 hours for 5 days
37792|NCT03888131|Drug|CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo|Fixed combination of beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg (BDP/FF)
37793|NCT03888131|Drug|Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo|Fixed combination of 160 µg budesonide + 4.5 µg formoterol fumarate (BUD/FF)
37794|NCT03888118|Device|Luna EMG|The duration of the overall therapeutic intervention in both groups will be the same.
37795|NCT03888105|Drug|REGN1979|Administered by intravenous (IV) infusion
37796|NCT03888092|Drug|Z650|receive oral Z650 once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
37797|NCT03888079|Drug|Local anesthetic|1% or 2% lidocaine with 1:100,000 epinephrine, augmented by intravenous sedation and analgesia
37798|NCT03888079|Drug|general anesthetic|Endotracheal intubation, intravenous narcotic agents, and inhaled agents
37799|NCT03888066|Drug|Patiromer|The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
37800|NCT03888066|Drug|Placebos|The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
37801|NCT03888053|Biological|BB-101|Within each cohort, 8 subjects will be randomized to receive BB-101 and 4 subjects to receive placebo.
37802|NCT03888040|Other|Exercise|• Participant performed 4 sets of 8 repetition of two different resistance training regimes. Participant visit 3 days per week for 8 weeks period.
37803|NCT03888027|Behavioral|WalkMORE group|Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
37804|NCT03888014|Device|GLOW800|The treatment group will consist of patients who require a medically necessary craniotomy. If an investigator deems that it will be useful to see blood vessels better with indocyanine green (ICG) videoangiography (VA), patients may be consented for the use if ICG VA using augmented reality (GLOW800). This will not add additional time or risk to their surgery
37805|NCT03888014|Drug|indocyanine green (ICG)|This is a standard medication which can be given IV during a surgery to better visualize blood vessels under the microscope
37806|NCT03887988|Procedure|"Primary early reconstruction"|Primary surgical reconstruction of the fracture within 3 weeks after injury
37807|NCT03887988|Other|Nonsurgical|Nonsurgical treatment of fracture
37808|NCT03887988|Procedure|"Primary delayed reconstruction"|Primary surgical reconstruction of the fracture more than 3 weeks after injury
37880|NCT03887403|Other|Usual care|
37812|NCT03887962|Device|Virtual Environment Biofeedback|Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
37813|NCT03887962|Device|Treadmill walking with no Virtual Environment Biofeedback|Treadmill walking. Flat screen / no virtual environment to act as attentional control.
37814|NCT03887949|Device|Group VCV|Volume controlled ventilation
37815|NCT03887949|Device|Group PCV|Pressure controlled ventilation
37816|NCT03887949|Device|Group PCV-VG|Pressure controlled ventilation with volume guarantee
37817|NCT03887936|Drug|Testosterone gel 1.62%|Testosterone gel 1.62%, apply 2 pumps to upper arm and shoulder.
37818|NCT03887936|Drug|Placebo|Matching placebo gel, apply 2 pumps to upper arm and shoulder
37819|NCT03887923|Behavioral|Vestibular Physical Therapy|Balance, Gaze Stabilization, Habituation, and Walking exercises
37820|NCT03887910|Other|Enhanced Intervention|Participants randomized to the Enhanced Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated and addressed with either referrals with matched community resources or thorough education. In addition, they will be given a set of six developmental toys.
37821|NCT03887910|Other|Intervention|Participants randomized to the Intervention group will receive the Family Connects program, an evidence- based structure that begins at the birthing hospital stay, followed by 1 to 3 nurse home visits between 4 to 12 weeks of infant age, a follow-up contact one month later and a discharge home visit six months later and a final follow-up contact one month after that. During the home visits, the nurse engages with the mother and completes a holistic health and psychosocial assessment, during which the unique risks and family needs across 12 family domains are evaluated. For each screened domain, the nurse is able to systematically address them, which may result in an immediate intervention; either referrals with matched community resources or thorough education.
37822|NCT03887897|Procedure|Tracheal Intubation|Tracheal intubation performed by attending anesthesiologists using either Airtraq laryngoscope or Macintosh laryngoscope
37823|NCT03887884|Drug|CVT-301|Levodopa Inhalation Powder
37824|NCT03887884|Drug|Sinemet|Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
37825|NCT03887871|Drug|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration after meal
37826|NCT03887871|Drug|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
37827|NCT03887858|Drug|Harnal-D Tab.|Harnal-D Tab. 1T single oral administration under fasting
37828|NCT03887858|Drug|Chong Kun Dang Tamsulosin HCl Tab.|Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration under fasting condition
37829|NCT03887845|Procedure|Surgery|The respective surgical approach for any abdominal surgery
37830|NCT03887832|Other|SMBI digital app|Digital platform on the smartphone for the media package
37831|NCT03887832|Behavioral|media package|The SMBI app contains a <1 minute video of a mother and baby or just mother, a reflection question about the video, a few questions about their mood and stress, and some prompts and suggestions on what to do if they have problems.
37832|NCT03887832|Other|standard newborn and infant care|Recommended standard pediatric primary care will be provided for infants up to 6 months.
37833|NCT03887819|Diagnostic Test|Hystological evaluation|The original tissues samples will be fixed in 10% neutral buffered formalin and embedded in paraffin blocks. Sections (4 μm thick) will be stained with hematoxylin and eosin stain (H&E) for diagnosis. The immunohistochemistry for anti-LCA, anti-CD68, and anti-CD3 will be performed to identify the inflammatory infiltrate.
37834|NCT03887793|Other|VACs|The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems. It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
37835|NCT03887780|Drug|Rivaroxaban (Xarelto,Bay 59-7939)|15 mg and 20 mg (OD)
37836|NCT03887754|Drug|Risperidone|It is antipsychotic drug used by dose: 0.25 mg per day in children weighing less than (20 kg); 0.5 mg per day in persons weighing more for 8 months.
37837|NCT03887754|Device|hyperbaric oxygen therapy|Sessions were done at pressure 1.5 ATA (atmosphere absolute) with 100% oxygen concentration, each lasting for one hour either in multiplace chamber or in monoplace chamber.
37838|NCT03887754|Drug|Non specific Multivitamin|control group received non specific multivitamins as placebo for 8 months.
37839|NCT03887741|Biological|Plasmapheresis|Patient will have monthly plasma exchange with young ApoE 33 plasma. Each exchange will be 1.5 volume of patient's plasma
37840|NCT03887741|Biological|Plasma infusion|Infuse every two weeks with ApoE33 young plasma (1unit) for 6 months
37841|NCT03887715|Device|Vagus Nerve Stimulation (VNS)|VNS is an implantable device that delivers stimulation to the vagal nerve.
37842|NCT03887702|Other|Best Practice|Receive best practice
37843|NCT03887702|Other|Laboratory Biomarker Analysis|Correlative studies
37844|NCT03887702|Drug|Tenofovir Alafenamide|Given PO
37845|NCT03887689|Behavioral|Modified prolonged exposure|Participants will receive three sessions of modified prolonged exposure therapy.
37846|NCT03887676|Drug|Arbaclofen|Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg
37847|NCT03887676|Other|Placebo|Administered orally as disintegrating tabs, round, white and beveled edges
37848|NCT03887650|Drug|Liposomal Bupivicaine 1.3%|10mL Liposomal Bupivacaine 1.3% (133 mg) mixed with 10mL of 0.5% Bupivacaine (total volume 20mL) in single injection interscalene brachial plexus block
37849|NCT03887650|Drug|Bupivacaine 0.5%|20mL 0.5% Bupivacaine with 5 mg PF dexamethasone and 5 mcg epinephrine (total volume 20.5mL) in single injection interscalene brachial plexus block
37850|NCT03887637|Drug|DAAs|Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.
37851|NCT03887624|Drug|Ethosuximide|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
37852|NCT03887624|Drug|Placebo|2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
37853|NCT03887624|Drug|Escitalopram|1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
37854|NCT03887611|Device|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
37855|NCT03887598|Device|Ultrasound diagnosis|Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
37856|NCT03887585|Procedure|Achilles tendon lengthening|Achilles tendon lengthening by triple hemisection for Achilles tendon contracture
37857|NCT03887572|Other|MOVIN|MOVIN is a multi-component unit-based intervention comprised of five components that are implemented simultaneously in a hospital unit. The five components are: 1) psychomotor skills training, 2) unit ambulation culture, 3) communication, 4) resources, 5) ambulation environment.
37858|NCT03887559|Behavioral|Group-based stabilization and skill training in addition to individual treatment|"Group-based stabilization and skill training, weekly 2-hour sessions during 20 weeks. Based on the manual Tilbake til Nåtid (Back to here and now) (Holbæk, 2014) developed by clinicians in the highly specialized national trauma clinic 'Modum Bad's Trauma Clinic'."
37859|NCT03887559|Other|Treatment as usual|Treatment as usual: conventional individual treatment (outpatient). Not standardized.
37860|NCT03887546|Device|Inspiratory muscle trainer|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
37861|NCT03887546|Procedure|Respiratory exercise|Respiratory exercise program involving nasal breathing and maximum exhalation during 12 weeks, 5 days/week, 15 minutes/day.
37863|NCT03887520|Diagnostic Test|Blood draw for Lp(a)|Collect sample for Lipoprotein(a) testing
37864|NCT03887507|Other|Vojta Therapy|Each session will consist of a 45-minute Vojta thera between py protocol based on three exercises, 15 minutes per exercise: Crawling reflex, and 1st phase and 2nd phase Rolling reflex.
37865|NCT03887507|Other|Standard Program|The program consist in balance exercises targeting core stability, exercises of coordination and Pilates as well as individual sessions using the Bobath concept.
37866|NCT03887494|Device|Implantation|Implantation of Y-Strut + cementoplasty in the femoral neck
37867|NCT03887481|Device|High-definition active tDCS (HD-tDCS) + Language/Cognitive Intervention(s)|"Device: Active HD-tDCS Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (Supramarginal Gyrus, Middle Frontal Gyrus or Middle Temporal Gyrus depending on the variant of Primary Progressive Aphasia). The stimulation will be delivered at an intensity of 2 milliamperes (mA) in a ramp-like fashion for a maximum of 20 minutes.~Behavioral: Language/Cognitive Intervention(s) For nfvPPA, participants will complete the n-back task (1-back and 2-back) for visual letters and auditory words. For lvPPA, participants will be asked to recall a total of two different lists, consisting of 10 semantically and phonologically unrelated word sequences each. For svPPA, one list of 12 semantically related written words with corresponding pictorial representations will be presented incrementally (pairs, triplets, etc.) and participants will be instructed to match words with pictures."
37868|NCT03887481|Device|Sham + Language/Cognitive Intervention(s)|"Device: Sham Current will be administered in a ramp-like fashion but after the ramping phase the intensity will drop to 0 mA. Current under the Sham condition will last for a maximum of 30 seconds.~Behavioral: Language/Cognitive Intervention(s) For nfvPPA, participants will complete the n-back task (1-back and 2-back) for visual letters and auditory words. For lvPPA, participants will be asked to recall a total of two different lists, consisting of 10 semantically and phonologically unrelated word sequences each. For svPPA, one list of 12 semantically related written words with corresponding pictorial representations will be presented incrementally (pairs, triplets, etc.) and participants will be instructed to match words with pictures."
37869|NCT03887468|Device|EvoCit|hemodialysis using the combination of the Evodial dialyzer with a citrate enriched dialysate
37870|NCT03887468|Device|EvoHep|hemodialysis using the combination of the Evodial dialyzer with a conventional bicarbonate based dialysate and systemic anticoagulation using unfractionated heparin
37871|NCT03887455|Drug|BAN2401|10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.
37872|NCT03887455|Drug|Placebo|Biweekly (once every 2 weeks) administered i.v. infusion.
37873|NCT03887442|Drug|Paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, every week.
37874|NCT03887442|Drug|Cetuximab + Paclitaxel|Cetuximab 250 mg/m2 and Paclitaxel 80 mg/m2, both may be infused intravenously, every week. Cetuximab will be administered prior to paclitaxel.
37875|NCT03887429|Drug|SXC-2023|SXC-2023 oral capsules
37876|NCT03887429|Drug|Placebos|Matching Placebo oral capsules
37877|NCT03887416|Drug|Dapagliflozin 10 MG Oral Tablet [Farxiga]|"The investigational medicinal product (IMP) is dapagliflozin10 mg given once daily (film coated tablets, oral use).~Dapagliflozin will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: 10 mg, Green, plain, diamond shaped, film coated tablet (orally)"
37878|NCT03887416|Drug|Placebo Oral Tablet|"The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient"
37879|NCT03887403|Behavioral|Multimodal Intervention|
37881|NCT03887390|Behavioral|Depression Medication Choice|The Depression Medication Choice tool is a series of cards emphasizing issues that are important for the patient and the health care professional when choosing antidepressants: weight change, sexual issues, sleep, cost, side effects, and stopping approach. The Depression Medication Choice tool uses clear language and is designed to improve the understanding of patients regarding the different attributes of antidepressants, and for use during clinical encounters.
37882|NCT03887377|Drug|Botulinum Toxins|We will be comparing botulinum toxin following breast reduction surgery to placebo injection. We will then compare photos of each breast reduction scar at set intervals following surgery.
37883|NCT03887377|Drug|Normal saline|Normal saline will serve as the placebo control on the contralateral breast
37884|NCT03887364|Other|Group A-Diaphragmatic breathing|Patient was in casual and agreeable position in which gravity helped the stomach, for example, a semi fowler's position. Hand was put on the rectus abdominis just beneath the foremost costal edge and requested that the patient take in gradually and profoundly through the nose. Persistent was told to keep the shoulder casual and upper chest very, enabling the belly to rise marginally. At that point persistent was guided to remain loose and breathed out gradually through the mouth. The patient rehearsed this 3 to 4 times and the rest time frame was given so patient couldn't hyperventilate.This group was given 10 reps of 3 sets with 4 weeks of follow up
37885|NCT03887364|Other|Group B-Icing and Airflow Stimulation|"Patient was lying comfortable in semi fowler position. Facial muscle icing was given using ice pack wrapped in cloth over cheeks and nose in butterfly pattern and over forehead for 5 minutes. Ice pack was applied on the patients face (around the cheek & nose) and accessory muscles (sternocleidomastoid muscles, upper trapezius) for single session of 5 to 10 minutes.~After that airflow stimulation was given with the help of table fan. Table fan was placed on the central area of face. Duration of the fan for the patient was at least 5 minutes to relive dyspnea and distance kept approximate of 60 centimeter (2 rulers)."
37886|NCT03887338|Other|Transnasal Fiberoptic Laryngoscopy|Use of Transnasal Fiberoptic Laryngoscopy during NIV titration to optimalize the NIV settings to laryngeal responses during the NIV treatment.
37887|NCT03887325|Drug|Maxipost|To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
37888|NCT03887325|Drug|Saline|To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
37889|NCT03887312|Behavioral|t-CETA|Cognitive Behavioural Therapy (CBT) based approach delivered over the telephone. Components are available for common problems, including anxiety, depression, PTSD, conduct problems, substance abuse, and safety issues (including self-harm or suicidal ideation), and a tailored treatment package is produced for each child based on the presenting problem(s) and response to treatment. There are components for use with both child and caregiver.
37890|NCT03887312|Behavioral|Médecins du Monde treatment as usual|Case manager-led care, with referral to a psychotherapist or psychiatrist as necessary. Médecins du Monde's approach is based on a joint collaboration between mental health trained case managers (who undergo extensive training by experts in the field on topics including Psychological First Aid, Child Protection, Gender Based Violence, etc.) and psychotherapists from different schools (providing Eye Movement Desensitization and Reprocessing [EMDR] for trauma, Interpersonal Therapy [IPT] for depression, Cognitive Behavioural Therapy [CBT], motivational counselling, familial or systemic therapy, and integrative approaches). Thus the number and content of sessions, and the person delivering treatment (case manager, psychotherapist, psychiatrist) vary.
37891|NCT03887299|Combination Product|ReliaTect™ Post-Op Dressing (contains chlorohexidine gluconate or CHG)|Dressing will be applied in the operating room at the end of case and be in place until postoperative day 7
37892|NCT03887299|Other|Standard Wound Care|Wound care will be administered as standard protocol in our institution
37893|NCT03887286|Device|Philips EPIQ 7 ultrasound machine|Standard transthoracic echocardiography
37894|NCT03887286|Device|Philips Lumify Broadband sector array transducer|Portable hand-held ultrasound device
37895|NCT03887273|Biological|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
37896|NCT03887260|Drug|Morphine PCA pump|Morphine given postoperatively.
37897|NCT03887260|Procedure|ESP block|Regional anaesthesia technique performed under ultrasound guidance before surgery
37898|NCT03887260|Drug|Fentanyl|Fentanyl administration during procedure, calculated per patient's weight and duration of surgery (minutes).
37899|NCT03887247|Behavioral|Basic Email|Encrypted emails sent separately to each of: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. The emails identify the concurrent prescriptions, detail the patient's prescription history, include relevant VA/DoD guidelines, state the risk of concurrent prescribing to patient, and provide action steps and relevant resources.
37900|NCT03887247|Behavioral|Coordinated Email|Encrypted email with the following providers copied together on one message: the patient's opioid prescriber(s), benzodiazepine prescriber(s), and/or primary care manager. The email identifies the concurrent prescriptions, details the patient's prescription history, includes relevant VA/DoD guidelines, states the risk of concurrent prescribing to patient, and provides action steps and relevant resources. The message encourages the prescribers to coordinate with each other and provides provider contact information to facilitate this communication.
37901|NCT03887234|Procedure|Coracoclavicular ligament reconstruction|Arthroscopically conducted ligament reconstruction for the treatment of an AC dislocation
37902|NCT03887221|Drug|Safinamide 50 mg|Safinamide 50mg film-coated tablets will be administered to subjects in Cohort 1. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
37903|NCT03887221|Drug|Safinamide 100mg|Safinamide 100mg film-coated tablets will be administered to subjects in Cohort 2. The subjects will receive the tablets orally in the morning, at 8:00±1hour, under fasting conditions, with 240 mL (total volume) of still mineral water. A mouth-and-hand check will be performed immediately after dosing to ensure treatment compliance.
37904|NCT03887208|Procedure|Laser therapy|non-ablative fractional laser therapy of skin
37905|NCT03887208|Biological|Autologous ADSC injection|Subcutaneous injection of autologous ADSC
37906|NCT03887208|Procedure|Normal saline injection|Subcutaneous Normal saline injection
37951|NCT03886896|Drug|Lidocaine|Lidocaine infusion during surgery
37907|NCT03887195|Other|Training mandatory module about the therapeutic relationship|"The training programme is composed by:~2 lectures (optional)~6 supervision sessions by Balint type groups (5 of which are mandatory);~5 role-plays (all required);~2 OSCE with patient actors (all required). This teaching is initiated by two lectures on the relationship, the awareness, the listening, the empathy, the therapeutic distance, and the personal impacts that affect the relationship.~It included six sessions of Therapeutic Relation Training Groups inspired by the Balint groups. Five role-play sessions are also organized from January to May, the students could play the doctor or the patient. The scenarios are about the following themes: announcement of bad news; accompaniment of chronic disease; management of aggressiveness and hostility; etc. After the role-play, a feedback done by the teacher and the group helps to elaborate what has happened. Finally, a formative assessment will be made during the Clinical Objective Structured Examination."
37908|NCT03887182|Diagnostic Test|functional MRI|Additional sequence (DTI) and functional MRI (fMRI) during the MRI which is done as part of the usual care
37909|NCT03887182|Diagnostic Test|Automated Cortical Brainstem Auditory Evoked Potential|Automated Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
37910|NCT03887182|Genetic|whole exome sequencing|A study of all the DNA-encoding exons of the child/parent from a sample taken as part of the usual care
37911|NCT03887182|Diagnostic Test|Standard Cortical Brainstem Auditory Evoked Potential|Standard Cortical Brainstem Auditory Evoked Potential correspond to a non-invasive EEG
37912|NCT03887182|Diagnostic Test|multidisciplinary consultation|"multidisciplinary consultation is composed of:~an ENT consultation and audiometry~a speech therapy assessment~a psychometric evaluation"
37913|NCT03887169|Drug|Methionine|Administration of methionine from D1 to D60
37914|NCT03887169|Drug|Vitamin B12, B9, B6, C supplementation|In case of hyperhomocysteinemia
37915|NCT03887169|Diagnostic Test|Methionine/homocysteine Dosage|Plasma concentration control of methionine and homocysteine from D0 to D75
37916|NCT03887169|Diagnostic Test|Thoracic CT scan|At D60
37917|NCT03887169|Diagnostic Test|Abdominal and liver ultrasound.|At D60
37918|NCT03887169|Diagnostic Test|Brain MRI|In case of abnormal neurological examination
37919|NCT03887156|Diagnostic Test|Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test|Calculation of ex vivo capacities of CD4neg INkT expansion of the peripheral blood from an identified donor for an allograft. Sample is collected before mobilization and the blood culture and analysis using the Predictor test are performed by the central lab.
37920|NCT03887130|Drug|oral vinorelbine|Oral vinorelbine 60 mg/m² on day 1 & day 8, for cycle 1, and then 80 mg/m² on day 1 & day 8, every 3 weeks for subsequent cycles
37921|NCT03887130|Drug|Capecitabine|Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14
37922|NCT03887130|Drug|Gemcitabine 1250 mg/m²|Gemcitabine 1250 mg/m² on day 1 & day 8
37923|NCT03887130|Drug|Gemcitabine 1000 mg/m²|Gemcitabine: 1000 mg/m² on day 1 & 8
37924|NCT03887130|Drug|Paclitaxel|Paclitaxel 175 mg/m² on day 1
37925|NCT03887130|Drug|Docetaxel|Docetaxel 75 mg/m² on day 1
37926|NCT03887117|Other|IQOS + Exercise Training Program|Switch to IQOS use + participation in a training program
37927|NCT03887117|Other|No Training|Switch to IQOS use only, without participation in a training program
37928|NCT03887117|Other|Cigarette Smoking + Exercise Training Program|Continue to smoke cigarettes + participation in a training program
37929|NCT03887117|Other|Smoking Abstinence + Exercise Training Program|Switch to smoking abstinence + participation in a training program
37930|NCT03887104|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
37931|NCT03887091|Other|Postwire|Postwire© is a web-based, video platform
37932|NCT03887078|Behavioral|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks pre and or post-surgery.
37933|NCT03887065|Drug|JM-4|Novel small human peptide derived from erythropoietin
37934|NCT03887052|Device|ASSURE™ Wearable Cardioverter Defibrillator (WCD)|WCD with shock alarms and shock functionality disabled
37935|NCT03887039|Other|clinical examination|clinical examination for all the oral findings
37936|NCT03887026|Drug|Norketotifen|Norketotifen oral capsule
37937|NCT03887026|Drug|Placebo|Placebo oral capsule
37938|NCT03887013|Drug|Trimetazidine|Trimetazidine is given as 20mg every time and three times per day (Tid) or 20mg every time and two times per day (when renal function is declined).
37939|NCT03887000|Other|magnesium|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
37940|NCT03887000|Other|placebo|Fibromyalgia patients taking either magnesium or placebo according to the randomized plan
37941|NCT03886987|Device|Blue Non Sterile Powder Free Nitrile Examination Gloves|Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
37942|NCT03886961|Device|Reflux Band|The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.
37943|NCT03886948|Drug|LY3074828|Administered subcutaneously (SC)
37944|NCT03886948|Device|PFS|PFS used to administer LY3074828
37945|NCT03886948|Device|AI|AI used to administer LY3074828
37946|NCT03886935|Diagnostic Test|Metabolomics|
37947|NCT03886922|Drug|Levcromakalim|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
37948|NCT03886922|Drug|Saline|Intravenous infusion of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cranial arteries in healthy volunteers after glibenclamide administration.
37949|NCT03886909|Behavioral|Exercise|The exercise intervention is an at least 3 weeks lasting (till the day transplant is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
37950|NCT03886909|Behavioral|Prehabilitation Education|Participant will receive a prehabilitation and stem cell education class which will be held at the Penn State Cancer Institute.
37952|NCT03886883|Other|Exercise induced hypoalgesia (EIH)|An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
37953|NCT03886883|Other|Static stretch (SS)|Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
37954|NCT03886883|Other|Rest|The participants rested in a seated position for 10 minutes
37955|NCT03886883|Other|Conditioned pain modulation (CPM)|A CPM response was induced by way of the cold pressor test.
37956|NCT03886870|Behavioral|Lifestyle and work intervention|"The intervention period lasted for a year with three institution-based stays, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan. At all three stages: The intervention contains activity training with a focus on the joy of movement, strength- and cardio-training. There were lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. Exercise programs was designed to use at home. The Cognitive Information Processing model of career guidance was the mainframe for the work dimension. All participants had talks with the work consultant at baseline, 6 and 12 months. Two work lectures, Duties and rights as employees and Work as medicine. When needed the work consultant contacted the employer in order to facilitate changes."
37957|NCT03886870|Behavioral|Lifestyle intervention|"The intervention period lasted for a year with three institution-based stay, 4 weeks at baseline and 2 weeks at 6 and 12 months. At baseline, participants got a functional assessment and an individual adjusted rehabilitation plan.~At all three stages: The intervention contains activity training with focus on joy of movement, strength- and cardio-training. There was lectures and cognitive therapy to promote self-care and lifestyle change. The intervention contained lectures on diet, nutrition and cooking-classes. Participants set goals at baseline and adjusting these during the progress. They developed exercise programs designed to use at home."
37958|NCT03886857|Device|transcutaneous spinal cord stimulation|noninvasive electrical stimulation of the human lumbar spinal cord
37959|NCT03886844|Dietary Supplement|Human milk fortifier based on human milk (Prolacta)|Intervention is started with an enteral intake of 100 ml/kg until 32 weeks corrected for prematurity, afterwards a human milk fortifier based on bovine milk is administered until estimated date of birth or 52 weeks corrected for prematurity (weight <10. percentile) according to ESPGHAN(=European Society for paediatric gastroenterology, hepatology and nutrition) guidelines
37960|NCT03886831|Drug|PRT543|PRT543 will be administered orally
37961|NCT03886818|Device|Standard dressings|Standard dressings will be used from surgery to wound healing
37962|NCT03886818|Device|PICO strategy|The PICO system with negatif pression will be used from surgery to day 7. After that, standard dressing will be used untill the wound Healing.
37963|NCT03886805|Other|Dual task with variable- and fixed-priority instructions|The participants will be asked to perform dual-task activities focused, interchangeable or simultaneously, on balance (motor tasks) and on cognitive tasks performance, according to the instructional priority established by the physical therapist.
37964|NCT03886805|Other|Dual-task with variable-priority instructions|The participants will be asked to spend half the session focused on balance (motor tasks) and the half the session focused on cognitive tasks performance, according to the instructional priority established by the physical therapist.
37965|NCT03886792|Behavioral|Triggered reinforcement|This group will participate in a home-based experimental intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray secured anterior to the trunk. This intervention will involve reinforcement of biceps muscle activation in the affected arm if the infant generates a muscle contraction above a pre-set threshold (V). The threshold needed to trigger a toy to move and make sounds (reinforcement) will be set at baseline as determined by surface electromyography (SEMG). During the training time-points, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
37966|NCT03886792|Behavioral|Social interaction|This group will participate in a home-based dose-equivalent control intervention for 10 minutes, twice/day for 10 days within 2 weeks. The infants will be supported in sitting with a tray. This control program will combine social interaction between infant/parent with the opportunity for self-initiated play with toys repeatedly placed on the tray. A toy will be placed in front of the infant seat and tray but it will not be connected to the SEMG unit nor will the infant have an SEMG electrode attached over the biceps. During the intervention, the parent or care-giver will be allowed to sing or talk to the infant but are not to shake the toys or place dowel-based rattles or toys in either palm of the infant.
37967|NCT03886779|Drug|Bromfenac|0.7 MG/ML [Prolensa]
37968|NCT03886779|Drug|Nepafenac|3 MG/ML [Ilevro]
37969|NCT03886766|Drug|Hot-melt extruded amorphous solid dispersion of Efavirenz|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, oral administration (product 1)
37970|NCT03886766|Drug|Hot-melt extruded amorphous solid dispersion of Efavirenz homogenized to drug rich particles|Hot-melt extruded amorphous solid dispersion of Efavirenz, 50 mg, homogenized to drug rich particles, oral administration (product 2)
37971|NCT03886766|Drug|Efavirenz solution|Efavirenz solution, 3 mg, oral administration (product 3)
37972|NCT03886753|Other|Registry|Collect data on subjects
37973|NCT03886753|Other|PK microsampling of blood|Obtain 5 microsamples of blood from subjects via a fingerstick.
37974|NCT03886740|Procedure|Reducing symptoms of Eustachian tube dysfunction|One of two methods of reducing Eustachian Tube dysfunction will be performed and the Eustachian Tube Dysfunction Questionnaire-7 (ETDQ-7) scores will be compared
37975|NCT03886727|Device|Rubber Dam Set|Rubber dam set is the generic name of an isolation device that consists of a rubber sheet that isolates the tooth from saliva, a clamp to hold the rubber sheet on the tooth to be isolated, and a metal frame to keep the rubber sheet in a stretched position during dental procedures.
37976|NCT03886727|Device|Dental Cotton Roll|Cotton roll is the generic name of a disposable isolation device made of cotton in a cylindrical form. Cotton rolls are used to isolate the teeth from saliva, by being placed in the cheek and tongue during placement of sealants or filings.
37977|NCT03886714|Diagnostic Test|Screening for Fabry disease|Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.
37978|NCT03886714|Diagnostic Test|Screen for α-galactosidase mutation|If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).
37979|NCT03886701|Drug|Doravirine (DOR)|Non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV-1 infection in adults in combination with other antiretroviral agents.
37980|NCT03886701|Drug|Rifapentine (RPT)|Rifamycin anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
37981|NCT03886701|Drug|Isoniazid (INH)|Anti-tuberculosis agent indicated for the treatment of latent and active tuberculosis infection.
37982|NCT03886688|Drug|HEC53856|oral administration
37983|NCT03886688|Drug|placebo|oral administration
37984|NCT03886675|Other|CO2 flushing|As above
37985|NCT03886675|Other|Saline flushing|As above
37986|NCT03886662|Drug|LB-100|"Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes."
37987|NCT03886649|Drug|Copanlisib|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The only dose level 1 (DL1) is 60 mg copanlisib.
37988|NCT03886649|Drug|Venetoclax|Duration of IMP administration: a maximum of twelve 28-day cycles of the combination treatment. Copanlisib will be administered i.v. on days 1, 8, and 15 of each cycle. The starting dose is dose level 1 (DL1): 600 mg venetoclax.
37989|NCT03886636|Other|neuroscience pain education|A total of 4 NPE (Neuroscience paine education) sessions were held, once each week, before an MT session. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, one-on-one sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain.
37990|NCT03886636|Other|manual therapy|In our study, Manual therapy (MT) was individualized according to each patient's response to treatment. In this method, the physiotherapist identifies and performs techniques suitable for the patient's symptoms. If the selected techniques do not have a direct positive effect on the patient's symptoms, they are replaced with other techniques.MT were performed in a total of 8 sessions, held twice a week for 4 weeks. Treatment sessions lasted an average of 40-45 minute.The entire treatment program was carried out by the same physiotherapist who is trained and experienced in this area.
37991|NCT03886636|Other|home exercises|All participants in all groups were assigned the home exercise program. The program aims to increase strength and flexibility of the abdominal, erector spinae, gluteal, quadriceps, and hamstring muscles. The participants were then asked to perform all of the exercises with 10 repetitions of each exercise 3 times a day for 4 weeks.
37992|NCT03886623|Procedure|4-day systematic oral hygiene|he intervention proposed would include a 4-5 day systematic oral hygiene program. Using a pea-sized amount of Colgate Total Clean Mint Toothpaste with a Battery‐operated Oral‐B Pro‐Health Type 3744 toothbrush, all surfaces, tongue-side, check-side, and biting surfaces of the participants teeth will be brushed. The tongue will be brushed with a GUM Dual Action Tongue Cleaner and flossing will be done with GUM Flossmate handle and Oral B Guide Floss in between the contacts of each tooth. The mouth will then be rinsed with Crest Pro‐Health mouthwash rinse for 30 seconds twice daily. A Medline Remedy Phytoplex lip balm will then be applied.
37993|NCT03886623|Other|Standard of Care oral care|Standard of Care oral care. Currently, the intensive care units utilize a commercially available pre-package oral hygiene kit. This includes mouthwash swabbing every 2 hours with Careline Alcohol‐Free mouthwash or Sage Alcohol Free mouthwash, teeth brushing (with Sage Toothette Oral Care, Sodium Bicarbonate Toothpaste and Sage Suction Toothbrush) every 12 hours, deep oral suctioning every 8 hours and prior to oral Endotracheal tube (ET) retaping, and Paroex Oral Rinse chlorohexidine gluconate (15ml) swabbed onto oral surfaces every 12 hours (SICU patients only). Mouth care is documented every two hours.
37994|NCT03886610|Other|Healthy controls|individuals without spinal cord injury
37995|NCT03886610|Other|Subacute SCI patients|individuals with spinal cord injury ≥ 2 weeks
37996|NCT03886610|Other|Chronic SCI patients|individuals with spinal cord injury ≥ 24 months
37997|NCT03886597|Other|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
37998|NCT03886597|Other|Table Olives|At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.
37999|NCT03886597|Other|Table Olives|All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.
38000|NCT03886584|Other|Monitoring source test|Internal- and external-monitoring correct responses and inversions
38067|NCT03885947|Biological|Cord blood stem cells|CD34 selected VPA expanded umbilical cord blood cells used in combination with or without unmanipulated umbilical cord blood .
38068|NCT03885947|Drug|Valproic Acid|Valproic Acid (VPA) expanded cord blood stem cells
38069|NCT03885947|Drug|Fludarabine|Fludarabine 150 mg/m2
38001|NCT03886558|Other|A multicomponent intervention program was developed consisting of two 60-minute sessions per week, held on non-consecutive days, for a period of 8 months.|The sessions consisted of a warm-up phase (10') in which individuals performed joint mobility exercises and walked at a rate of 3 km/h. Afterwards, muscular strength work was carried out on the upper and lower limbs, including calisthenic exercises, and the use of dumbbells or medicine balls (1-3kg). Generally, the exercises were organized in two sets of 10-15 repetitions, resting for two minutes between sets. Communal ball games and relay games were then practiced (over a distance of 30 meters). Finally, 10 minutes were devoted to relaxation and stretching exercises. multicomponent intervention program was designed and monitored by a specialist in gerontogymnastics.
38002|NCT03886545|Other|Assessment of physical and functional capacities|Comparaison of physical and functional capacities between caregivers with work-related musculoskeletal disorders of the shoulder healthy subjects matched in age and gender;
38003|NCT03886532|Other|Medical Marijuana|registry and blood samples
38004|NCT03886519|Procedure|BRAP (Bevel/rotate/advance procedure)|Trichiasis surgery using the BRAP procedure
38005|NCT03886519|Procedure|Trabut|Trichiasis surgery using the Trabut procedure
38006|NCT03886506|Biological|PLX-PAD|PLX-PAD 300×106 cells in a mixture containing 10% DMSO, 5% human serum albumin and Plasma-Lyte, will be administered via 30 IM injections (0.5 mL each) delivered into the leg twice,at 8 weeks interval.
38007|NCT03886493|Drug|Dupilumab|dupilumab 600 mg SQ on day 1, and then 300 mg SQ on days 8,15, 22, 29, 36, 43.
38008|NCT03886480|Device|SaeboVR|Use of the SaeboVR rehabilitation system for approximately 1 hour, 3 times per week for 4 weeks. Each intervention session will consist of the participant engaging in a series of virtual occupations involving their affected upper extremity and will include a 5 minute warm up activity followed by 3, 15 minute sessions of virtual occupation practice separated by 2, 5 minute breaks. The virtual occupations will include: grocery shopping, grocery storage, breakfast preparation, pet shopping, pet feeding, pet bathing, garden planting, garden harvesting, dinner preparation, closet organizing, and soup kitchen volunteering.
38009|NCT03886467|Other|Community-based nutrition education|Nutrition education will be included in community development training. The nutrition education will target child nutrition, particularly consumption of animal-source foods and especially milk. The importance of dietary diversity will also be emphasized. Demonstrations of food preparation techniques will also be included in the training.
38010|NCT03886441|Drug|Beclomethasone propionate|Beclomethasone propionate inhaled twice daily during radiotherapy
38011|NCT03886428|Other|100% portion size|Entree portion size 100% of baseline
38012|NCT03886428|Other|125% portion size|Entree portion size 125% of baseline
38013|NCT03886428|Other|150% portion size|Entree portion size 150% of baseline
38014|NCT03886428|Other|175% portion size|Entree portion size 175% of baseline
38015|NCT03886415|Drug|Jaktinib hydrochloride tablets|Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
38016|NCT03886402|Device|GID SVF-2|Treatment of erectile dysfunction with the subjects own cells
38017|NCT03886389|Dietary Supplement|PreOP|Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.
38018|NCT03886376|Other|Massage|The intervention group will receive 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
38019|NCT03886376|Other|Superficial Massage|The placebo group will receive 12 minutes of only one sliding pressure The superficial massage will be performed on the legs, arms and the back.
38020|NCT03886363|Behavioral|MBSR|Described previously
38021|NCT03886350|Other|blood and sputum samples|Blood and sputum samples for research purpose collected during routine tests performed at steady state and acute exacerbation
38022|NCT03886337|Device|Germicidal lighting|Germicidal ambient lighting
38023|NCT03886324|Combination Product|GIE Medical Drug Coated Balloon|Stricture patients treated by DCB
38024|NCT03886311|Drug|Talimogene Laherparepvec 100000000 PFU/1 ML Injection Suspension [IMLYGIC]|Talimogene laherparepvec, 1Bil is given intratumorally every 2 weeks according to tumor size
38025|NCT03886311|Drug|Nivolumab IV Soln 100 MG/10ML|NIVOLUMAB 240 mg IV over 30 min q 2 weeks
38026|NCT03886311|Drug|Trabectedin 0.25 MG/1 VIAL Intravenous Powder for Solution|TRABECTEDIN 1.2 mg/m2 CIV over 24 hours q3 weeks
38027|NCT03886298|Procedure|radiofrequency splanchnic denervation|the authors will denervate the splanchnic nerves via radiofrequency
38028|NCT03886298|Procedure|retrocrural celiac denervation|the authors will denervate the splanchnic nerves in the retrocrural space via injection of alcohol
38029|NCT03886285|Other|Questionnaire|Completion of the questionnaire by the patient after consultation with the general practitioner
38030|NCT03886272|Drug|BI 730357 (Test)|tablet
38031|NCT03886272|Drug|BI 730357 (Reference)|tablet
38032|NCT03886259|Other|Neuromuscular exercises (NEMEX-TJR) and pain neuroscience education|"60min. of neuromuscular exercises (NEMEX-TJR) training two times a week for 3 months (12 weeks, 24 sessions). Physiotherapists will instruct and supervise the participants during the neuromuscular exercises. The aim of the neuromuscular exercise program is to restore normal movement, improve sensorimotor control, re-establishing normal motor program strategies and muscle activation.~60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function."
38033|NCT03886259|Other|Pain neuroscience education|60min. of pain neuroscience education at the beginning of intervention period and after 6 weeks. Both sessions will take 60min. and will be conducted by physiotherapists. The aim of the pain neuroscience education is to increase the pain neuroscience knowledge of the patients leading to a better understanding of their chronic pain and thereby engaging the patients in the treatment of their chronic pain and impaired function.
38034|NCT03886246|Drug|Spesolimab|Solution for infusion
38035|NCT03886246|Drug|Spesolimab|Solution for injection
38070|NCT03885947|Drug|cytoxan|Cytoxan 50 mg/m2
38071|NCT03885947|Drug|Thiotepa|Thiotepa 10 mg/m2
38036|NCT03886233|Drug|Corticosteroid Series|immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
38037|NCT03886220|Drug|Elagolix|Elagolix will be administered orally
38038|NCT03886220|Drug|Placebo|Placebo will be administered orally
38039|NCT03886207|Other|ginger powder footbath|38-40° C warm water footbath with an additive of dried ginger powder reaching up to mid-calf level, as practiced in anthroposophic medicine
38040|NCT03886207|Other|warm water only footbath|38-40° C warm water footbath without any additive reaching up to mid-calf level
38041|NCT03886194|Procedure|interventional treatment in pulmonary|Thrombolytic group: urokinase 20,000 units / kg body weight, 2 hours intravenous drip; or rtPA 50mg, 2 hours intravenous drip; and interventional treatment group: intracavitary catheter contact thrombolysis (urokinase 500,000 u 5 minute pulse Give), catheter thromboembolism, thrombus aspiration and mechanical thrombectomy.
38042|NCT03886181|Device|Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
38043|NCT03886168|Other|Signal processing intervention of a biomedical device|This is a signal processing intervention of an FDA approved biomedical device for study participants that have received the cochlear implant based on clinical recommendations (i.e. not study related). Based on image processing of pre- and post-implant CT, cochlear segmentation, electrode scalar localization, and definition of the electrode-to-neural interface, the investigators will manipulate the stimulus delivery of the incoming signal within the FDA approved clinical software and thereby is within the electrical and clinical specifications of the FDA approved device and accompanying software.
38044|NCT03886155|Procedure|Biopsy|During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
38045|NCT03886142|Procedure|radiofrequency|radiofrequency of the genicular nerves
38046|NCT03886142|Procedure|platelet rich plasma injection|intra articular injection of platelet rich plasma
38047|NCT03886129|Diagnostic Test|Transcranial Doppler Ultrasound (TCD)|Participants will undergo an assessment of brain blood flow using TCD, with two small ultrasound probes held in place on the temples with a customised headframe. During the assessment, heart rate, breathing and blood pressure will also be monitored using a 3 lead ECG, nasal capnography and Finometer® respectively. The assessment will comprise three recordings. Firstly, participants will sit quietly for 5 minutes. Next, they will be asked to sit quietly for one minute before standing and remaining standing for 5 minutes. Lastly, they will be asked to stand and then complete a squat-stand manoeuvre in time with a computer sequence. A tilt sensor attached to the thigh will measure the efficiency and angle of the squatting motion. The squat-stand manoeuvre will consist of 15 squats and participants will be informed that they should try and complete all 15 squats if possible.
38048|NCT03886116|Other|Exercise|3 sets of 10 forearm exercises performed twice in the Morning and Evening for 6 weeks.
38049|NCT03886103|Drug|14C labeled PXL770|Single administration
38050|NCT03886090|Behavioral|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice
38051|NCT03886090|Behavioral|rest|Seated rest following motor skill practice
38052|NCT03886090|Behavioral|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in a horizontal position.
38053|NCT03886077|Drug|glecaprevir/pibrentasivir|12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
38054|NCT03886064|Other|Multi-behavioral intervention|The interventional group will then meet regularly under the aegis of the trainer to work on modifying each person's risk factors. The one-hour sessions will be scheduled every two weeks for two months and then every month for two months and then every three months until the end of the study (13 sessions). These sessions will be behavior change sessions, focused on goal setting, action planning, and problem solving. Trainers will facilitate these sessions and use motivational interviewing techniques
38055|NCT03886051|Procedure|Connective Tissue Graft before Orthodontic treatment|Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage will be done using sub - epithelial connective tissue graft. Orthodontic treatment will be 3 months following the grafting procedure.
38056|NCT03886051|Procedure|Orthodontic treatment only|Scaling and root planing will be performed and after resolution of periodontal inflammation, orthodontic treatment will be initiated.
38057|NCT03886038|Biological|Shingrix|immunization with 2 doses of a subunit vaccine against herpes-zoster (Shingrix) administrated with at least 2 months apart
38058|NCT03886025|Other|Anodal transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
38059|NCT03886025|Behavioral|Cognitive training|Iowa Gambling Task will be used for cognitive training
38060|NCT03886025|Other|Sham transcranial Direct Current Stimulation (tDCS)|Non-invasive brain stimulation
38061|NCT03886012|Device|Otoband|The Otoband will be used by participants during migraine associated vertigo (MAV). We expect the research subjects to use the device for at least 20 minutes, with the hardware limiting any one session to a duration of 30 minutes, up to 4 times per calendar day. The Otoband will be set to the effective power level during the course of a given calendar day.
38062|NCT03886012|Device|Otoband sham|The Otoband will be used by participants during migraine associated vertigo (MAV) for a maximum of 30 minutes, up to 4 times per calendar day. The Otoband will be set to an ineffective power level (considered a sham device) during the course of a given calendar day.
38063|NCT03885999|Device|Fecobionics|Fecobionics is a new device for studying defecation
38064|NCT03885986|Radiation|Ultrasound|role of ultrasound in comparison to magnetic resonance imaging in diagnosis of benign cystic lesions of knee
38065|NCT03885973|Drug|Lactobacillus plantarum|Fermented milk containing probiotic Lactobacillus plantarum for three weeks
38066|NCT03885973|Drug|Placebo|Fermented milk containing placebo for three weeks
38072|NCT03885947|Biological|TBI|TBI 400cGy
38073|NCT03885934|Biological|V114|V114 15-valent PVC containing 13 serotypes present in Prevnar 13® (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and 2 unique serotypes (22F and 33F) in each 0.5 mL IM administration
38074|NCT03885934|Biological|Prevnar 13|Prevnar 13® 13-valent PCV containing 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) in each 0.5 mL IM administration.
38075|NCT03885921|Drug|Ezetimibe|oral tablet
38076|NCT03885921|Drug|Atorvastatin|oral tablet
38077|NCT03885921|Drug|Simvastatin|oral tablet
38078|NCT03885908|Other|in-person geriatric co-management|The geriatrics service sees these patients for at least 2 postoperative days, if deemed clinically necessary by the geriatrician. During the inpatient hospital course, the geriatrics service will ensure the execution of preoperative recommendations and will discuss with the surgical team, who will act as a primary team, any additional recommendation in order to improve postoperative care.
38079|NCT03885908|Other|automated geriatric co-management|Following completion of the eRFA, the summary of impairments as well as the recommendations generated by the study team (hard-copy or email) will be provided in real-time to the thoracic surgery team for their attention.
38080|NCT03885895|Drug|Tranexamic Acid Injectable Product|Ampoules used for intradermal injection
38081|NCT03885895|Device|Q switched KTP (532nm)|LASER
38082|NCT03885882|Drug|E0302 SR1|E0302 SR1, oral tablet.
38083|NCT03885882|Drug|E0302 SR3|E0302 SR3, oral tablet.
38084|NCT03885882|Drug|E0302 SR2|E0302 SR2, oral tablet.
38085|NCT03885882|Drug|E0302 IR|E0302 IR, oral tablet.
38086|NCT03885869|Other|Ankle Joint Position Sensation Evaluation|In this test, individuals are placed in the supine position with their eyes closed for prevent visual cues; measurements are performed with the plex of the goniometer, 1.5 cm below the lateral malleol, the fixed arm parallel to the long axis of the fibula and the movable arm parallel to the long axis of the 5th metatarsal. Desired target angles were defined as 10 ° dorsi flexion, 10 ° plantar flexion and 20 ° plantar flexion. Individuals are instructed to focus on the position of the ankle joints in space for 5 s by bringing the feet in neutral position to the target position by the researcher. This procedure is repeated 3 times and the patient is expected to learn this position. The target angle is then asked to repeat in the testing phase. The measurement is repeated 3 times for each target angle. As a result criterion; By recording the absolute value of the deviation amounts from the target angles; The averages of the deviations during the 3 repetitions are averaged.
38087|NCT03885869|Other|Knee Joint Position Sensation Evaluation|Bilateral knee joint position sensation will be evaluated in the literature with an analogue inclinometer(BASELINE®),which is a valid and reliable method for measuring joint position sensations.Measurements were planned to made in the sitting position,with the eyes of the individual closed and the joint to be evaluated bare,without any socks or shoes worn,fixing the inclinometer with a strap to the lower leg perpendicular to the knee flexion axis.In this measurement,the knees of the participants are passively shifted from the initial (90°flexion)position to the 30°flexion position,at this point 5 sec is waited and after they are told to keep this angle in mind,the starting position is returned.This procedure is repeated 3 times and the patient is expected to learn this position.After the individuals are rested for 5 s,they are asked to actively perform the target angle again.The same procedure was planned to be repeated 3 times for each angle at 45° and 60° knee flexion target angles.
38088|NCT03885869|Other|The Evaluation of Plantar Sensation|"In the plantar sensory evaluation of the participants, Semmes-Wenstein Monofilament, which is frequently used in the literature and to be a reliable method in the diagnosis of neuropathy, was aimed to be tested by touching 7 regions on the foot base .~In this evaluation, the individual is in the supine position, the physiotherapist is at the foot end of the patient; monofilament should be applied 90⁰ to the surface.~The filament thickness which is the first feeling of the individual is recorded by being asked whether the individual is feeling. The 3 most commonly used monofilaments for patients with diabetic neuropathy are 4.17, 5.07 and 6.10 monofilaments. The highest monofilament value is the hardest and most difficult bending monofilament."
38089|NCT03885869|Other|The Evaluation of Balance|In order to evaluate the static and dynamic balances of the participants, determination of open and closed postural oscillations and stability limits were planned with Prokin branded isokinetic balance system.
38090|NCT03885869|Other|Evaluation of Dual Task Performance|"In order to evaluate double task performances, it is planned to evaluate 1 dynamic and 1 static 2 different performances, including Time Up and Go Test (TUG) and single leg standing time. For each performance; the single task, the motor second task and cognitive seconder tasks separately, and again for each application to be performed in such a way that two trials, the average time was planned to record. Motor and cognitive tasks for each test are planned as described below.~Motor Task (TUG): Carrying cup full of water on tray. Cognitive Task (TUG): Counting the days of the week backwards from the current day Motor Task (Single Leg Standing Time): Hand-Over ball transfer Cognitive Task (Single Leg Standing Time): Counting backward month names from the current month"
38091|NCT03885869|Other|General Evaluation Form|A form, which is prepared by us, including demographic information and physical characteristics of the individuals.
38092|NCT03885856|Other|single row repair technique|single row repair technique
38093|NCT03885856|Other|double row repair technique|double row repair technique
38094|NCT03885843|Procedure|Renal nerve stimulation, mapping and denervation|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal nerve stimulation, mapping and denervation procedure after randomization.
38095|NCT03885843|Procedure|Sham Procedure: Renal angiography|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal
38096|NCT03885830|Drug|Bosutinib|Subjects will be enrolled into this group if they are receiving bosutinib per standard of care. This is an observational study and no interventions will be made.
38097|NCT03885830|Drug|Dasatinib|Subjects will be enrolled into this group if they are receiving dasatinib per standard of care. This is an observational study and no interventions will be made.
38098|NCT03885830|Drug|Imatinib|Subjects will be enrolled into this group if they are receiving imatinib per standard of care. This is an observational study and no interventions will be made.
38099|NCT03885830|Drug|Nilotinib|Subjects will be enrolled into this group if they are receiving nilotinib per standard of care. This is an observational study and no interventions will be made.
38100|NCT03885817|Behavioral|Exercise training and nutritional guide|30 minutes of a combination of sensorimotor- and strength training guided by a physical therapist twice a week. In addition 90 minutes a week of moderate intensity aerobic training or 45 minutes a week of high intensity aerobic training. Once a month the participants will fill out the form, PG-SGA SF, and he or she will be referred to a nutritionist if the score is 2 or higher. The intervention period lasts as long as the participants receives adjuvant chemotherapy, i.e. 3 - 6 months.
38101|NCT03885817|Other|Standard follow-up care|standard recommendations regarding physical activity and nutrition during the period with adjuvant chemotherapy.
38102|NCT03885804|Drug|Quadratus lamborum dexmedetomidine intravenous|Patients will receive quadratus lamborum block on the same surgical side then a bolus of 0.5 ml/Kg bupivacaine 0.25% in addition to 2ml normal saline will be injected then dexmedetomidine (precedex 200 micrograms per 2ml, Abbott laboratories, Abbott park, IL, USA) which will be prepared in concentration 1μg/ml. 1ml/kg loading dose will be given over 10 min followed by 0.5 ml/kg/h infusion maintenance dose till the end of surgery
38103|NCT03885804|Drug|Quadratus lamborum dexmedetomidine perineural group(|Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
38104|NCT03885791|Device|vaginal cryotherapy|"Both groups will be given the same instructions for use, which will include intravaginal placement of one tube for 10 minutes while resting in a supine position. A lubricant may be used for comfort with insertion.~Patients will perform their first intervention in the office with a repeat examination within 10 minutes of completing therapy. Patients participating in Specific Aims #2 will perform the intervention once daily at home. Patients will be asked to complete a short diary for each session, which will include the time of day, duration of application, pain score prior to and after application, and presence of any pelvic floor disorder symptoms prior to and after application."
38105|NCT03885778|Drug|Besifovir dipivoxil|150mg Besifovir dipivoxil, single dose, oral
38106|NCT03885765|Diagnostic Test|Predictive data|"The novel predictive data in this study includes 5 predefined variables derived from thoracic CT scans:~(i) Expiratory to inspiratory ratio of mean lung density (MLDe/i), total; (ii) MLDe/i of the section to be excised / MLDe/i total; (iii) Percentage of emphysema according to voxel thresholding at -950 HU (PVOX-950), total; (iv) PVOX-950 for the section to be excised; (v) Iodine concentration [I] of the section to be excised / [I] total."
38107|NCT03885765|Procedure|Lung resection|Surgical resection will be characterised by type (pneumonectomy, bi-lobectomy, lobectomy, or lobectomy with anastomosis resection), whether or not lymph node dissection was performed, and whether or not the resection was atypical.
38108|NCT03885752|Drug|chewed mint gum|In the preoperative waiting area before transferring to the operating room, patients in group G chewed mint gum for 2 minutes and then spit it out.
38109|NCT03885752|Other|swallow twice|asked to swallow twice without any additional treatment.
38110|NCT03885739|Other|Continuous Pericapsular Nerve Group block|Continuous Pericapsular Nerve Group block to standardize the approach. Injections were performed using a curvilinear low-frequency ultrasound probe (3.5- to 5-MHz). The lateral border of iliopsoas tendon in an oblique axial plane at level of iliopectineal eminence provides target for needle placement. Toggling the transducer was necessary to optimize visualization of the iliopsoas tendon secondary to anisotropy. Injections were performed using an 18-gauge Tuohy needle under sterile conditions. Then, 10 mL 0.25% bupivacaine was administered and a 20-G polyamide catheter (connect to a filter) was advanced into the space. The end point of the catheter placement was the direct visualization of microbubbles in a peritendinous distribution using a bolus of agitated saline applied through threaded catheter connected to not purged filter. After catheter placement patients received a 0.1% bupivacaine continuous infusion at a constant rate.
38111|NCT03885726|Device|Precision Flow Plus|High velocity nasal insufflation
38112|NCT03885726|Device|Treatment as Usual|Conventional therapy per institution
38113|NCT03885713|Biological|Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use) per clinical practice or adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus) per clinical practice or golimumab (subcutaneus 50 mg milligram(s)-subcutaneus) per clinical practice or vedolizumab (infusion 300 mg milligram(s)) per clinical practice or ustekinumab (subcutaneous 90 mg milligram(s)-subcutaneus) per clinical practice
38114|NCT03885700|Behavioral|Educational program for 2 months|"The intervention was suggested based on the recommendations for adolescents' healthy diet and physical activity, it was derived from the 2008 Physical Activity Guidelines for Americans and Dietary Guidelines for Americans, 2010 by the U.S. HHS, Physical activity guidelines for children and adolescents by CPS 2012. The Food Guide Pyramid by the USDA, Nutrition &Healthy Eating by Mayo clinic & CDC website. The program was modified according to the age of the child. This plan was typically pursued in a School-based Intervention to Promote Healthy Lifestyles in Sousse, Tunisia, by Harrabi et al. The 1st month covered the healthy diet & the 2nd month covered the physical activity as follow:~1st & 5th week: A 60-minutesession in health education.~2nd & 6th week: Group counselling.~3rd & 7th week: Students were divided into 8 groups & each group was asked to make presentation about a task related to the topic.~4th & 8th week: Discussing the presentation."
38115|NCT03885687|Behavioral|Exercise with Music|The Exercise with Music intervention is recorded exercise playlist, which provide exercise instructions tailored to patients' musical choices and exercise capacity.
38116|NCT03885687|Behavioral|Exercise|The exercise group will receive exercise brochure and will be advised to exercise at least twice daily.
38117|NCT03885674|Other|Video Call Reminder Condition|Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
38118|NCT03885674|Other|Automated Text Message Reminder Condition|Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
38119|NCT03885661|Drug|Icosapent Ethyl 1000 MG [Vascepa]|Icosapent ethyl is an ethyl ester of the omega-3 fatty acid eicosapentaenoic acid (EPA). The empirical formula of icosapent ethyl is C22H34O2 and the molecular weight is 330.51. The chemical name for icosapent ethyl is ethyl all-cis-5,8,11,14,17-icosapentaenoate.
38120|NCT03885635|Procedure|Hemiarch repair|Current standard of surgical repair consisting of ascending aortic replacement with open distal anastomosis at level of proximal arch under a period of hypothermic circulatory arrest . No surgical or endovascular intervention is carried out in the mid arch or descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
38121|NCT03885635|Procedure|Extended arch repair|Surgical replacement of the ascending aorta along with intervention on the arch and descending aorta. Techniques for distal aspect of extended arch technique include but are not limited to total arch replacement along with TEVAR, Frozen Elephant Trunk procedure or surgical proximal arch replacement with bare metal stents in arch and descending aorta. Intra-operative management, including cannulation, cardioplegia, cerebral perfusion technique, and neurologic monitoring will be done according to each institution's current standard of practice.
38122|NCT03885622|Device|ANTHEM™ CR Total Knee System|The ANTHEM CR Total Knee System is a CE marked device. It is a cruciate retaining (CR) total knee system. It is intended to be used in patients for primary total knee replacement surgery where the posterior cruciate ligament and collateral ligaments remain intact. It is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties.
38123|NCT03885609|Device|ToothWave|RF-utilizing powered toothbrush for teeth whitening
38124|NCT03885609|Device|powered toothbrush|regular powered toothbrush with no RF
38125|NCT03885596|Drug|CA-008|Drug: CA-008 4.2 mg reconstituted in saline
38126|NCT03885583|Procedure|thoracic epidural block|thoracic epidural block with bupivacaine 0.25% will be given in the 8th thoracic space using ultrasound
38127|NCT03885583|Procedure|paravertebral block|paravertebral block with 0.25 bupivacaine will be given at the level of the incision using ultrasound
38128|NCT03885570|Procedure|Mitral valve replacement|Blood transfusion
38129|NCT03885557|Other|Group I Experimental DOS|After the application of hot pack treatment of 7-10 minutes, dynamic oscillatory stretch(DOS) technique (30 repetitions each of 2 seconds stretch duration in one session) was applied to DOS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
38130|NCT03885557|Other|group II SS group|After the application of hot pack treatment of 7-10 minutes , Static stretching (2 repetitions each of 30 seconds in one session) was applied to SS group. An experienced orthopedic manual physical therapist provided these techniques to patients .
38131|NCT03885544|Other|Controlled Lacto-ovo vegetarian diet|Subjects will be randomized and assigned into an intervention to consume the controlled lacto-ovo vegetarian (LOV) diet for 3 weeks. All foods will be provided to subjects during the intervention. Each subject's energy requirement will be estimated using sex-specific equations published by the Institute of Medicine for weight maintenance during the intervention.
38132|NCT03885544|Other|Controlled Unprocessed red meat diet|The unprocessed red meat diet will be the same as the LOV diet except that one 3-ounce portion of unprocessed red meat per day, 7 days per week (21 oz/wk) will be included. The unprocessed red meat will include beef tenderloin and pork loin. All foods will be provided to subjects during the intervention.
38133|NCT03885544|Other|Controlled processed red meat diet|The processed red meat diet will be the same as the LOV diet except that one 3-ounce portion of processed red meat per day, 7 days per week (21 oz/wk) will be included. The processed red meat will include a variety of beef and pork luncheon meats with different methods of preservation. All foods will be provided to subjects during the intervention.
38134|NCT03885531|Device|Total knee arthroplasty with Journey II CR Total Knee System|TKA with Journey II CR Total Knee System
38135|NCT03885518|Other|Playground Stencils|The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
38136|NCT03885479|Diagnostic Test|ELISA for the semi-quantitative analysis of serum food-specific IgGs against food-derived antigens|An enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative analysis of serum food-specific IgGs against 7 food-derived antigens (Wheat, rice, beans, cow milk, eggs, chicken and beef)
38137|NCT03885466|Behavioral|Nordic Walking exercise|Participants will initially train 3 times per week for 3 months. Training sessions will be led by trained peer- and/or student-instructors. Nordic walking sessions (starting at 20 and progressing to 60min/session) will include a warm-up, strengthening, and dynamic balance and stretching exercises in addition to Nordic walking, as per the Saskatoon Health Region guide (Saskatoon Health Region, 2014). Training (distance and intensity) will be progressive and individually set.
38138|NCT03885440|Other|Age|Age<40 years old is chosen as the cutoff value.
38139|NCT03885440|Other|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
38140|NCT03885427|Drug|Ketamine|evaluate sedative, and analgesic effects of oral or nebulized ketamine
38141|NCT03885414|Behavioral|In-session Virtual Reality exposure therapy|A series of exposure exercises (speech exercises) in front of a virtual audience, focusing on promoting inhibitory learning, with audio-feedback.
38142|NCT03885414|Behavioral|Internet-administered transition program|Four-module internet program with weekly therapist guidance, focusing on transitioning to in-vivo exposure in everyday settings.
38143|NCT03885401|Behavioral|Enhanced care planning|The intervention includes (1) screening for unhealthy behaviors, mental health needs, and social needs, (2) creation of a care plan, (3) quarterly updates to the plan, (4) a clinical navigator and community health worker to support accomplishing the care plan, (5) registry of community resources and programs, and (6) messaging and video-visit system for team members.
38144|NCT03885388|Drug|MTX|multicourse methotrexate chemotherapy
38145|NCT03885388|Drug|MTX+ACTD|combination use of methotrexate and actinomycin
38146|NCT03885362|Device|Dexcom G6 and Abbott Freestyle Libre|Dexcom G6 - continuous glucose monitoring device - blinded. CE mark 2018 Abbott Freestyle Libre - flash glucose monitoring device. CE mark 2014
38176|NCT03885102|Behavioral|Intradialytic exercise intervention|50% aerobic exercise, 50% resistance training thrice a week for 60 min per dialysis session, and health literacy counselling
38177|NCT03885102|Behavioral|Usual Care|Usual care with no exercise intervention or health literacy counselling
70980|NCT03629054|Drug|Linagliptin|single dose
38147|NCT03885349|Behavioral|SBIP+ ADAPs-IMP|Standard batterer intervention program plus Individualized Motivational Plans adapted to alcohol and/or drug abuse problems. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consisted of six modules in which different intervention techniques were applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP included a set of motivational strategies to increase treatment compliance and motivation for change and had four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement (in this case, one of the goals has to be related to ADAPs); (b) three group sessions where participants share their goals; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
38148|NCT03885349|Behavioral|SBIP+IMP|Standard batterer intervention program plus Individualized Motivational Plans. The SBIP consist of 70 hr of a cognitive-behavioral intervention including discussion topics such as sexism, sex roles, and gender equality. The intervention phase consist of six modules in which different intervention techniques are applied (i.e., group dynamics, roleplaying, videos, training in cognitive restructuring, emotion management skills). The IMP include a set of motivational strategies to increase treatment compliance and motivation for change and has four main strategies: (a) five individual motivational interviews, to identify IPV related personal goals and follow up their achievement; (b) three group sessions where participants share their goals, explain their progress to the group, and receive feedback, support and advice from the group; (c) therapists follow-up and reinforcement of participants' goals; and (d) use of retention techniques.
38149|NCT03885336|Other|No Interventions|There are no interventions in this study. Participants are observed.
38150|NCT03885323|Device|RF utilizing powered toothbrush|RF utilizing Powered toothbrush
38151|NCT03885323|Device|Control placebo with no RF|Placebo control, with no RF
38152|NCT03885310|Device|GIE Drug Coated Balloon|The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers.
38153|NCT03885297|Drug|Saxenda|Obesity pharmacotherapy
38154|NCT03885297|Other|Lifestyle modification|Tier 3 NHS weight management
38155|NCT03885297|Diagnostic Test|Metabolomics|Small molecule intermediates and products of metabolism
38156|NCT03885297|Diagnostic Test|miRNA|Small non-coding RNA molecules
38157|NCT03885284|Drug|mFOLFIRINOX|"Chemotherapy will consist of mFOLFIRINOX in 14-day cycles x 12 as used in the PRODIGE 24 study:~Irinotecan 150 mg/m2 IV day 1~Oxaliplatin 85 mg/m2 IV day 1~Leucovorin 400 mg/m2 IV day 1~5-fluorouracil 2,400 mg/m2 IV days 1-3 (no bolus)~Pegfilgrastim 6 mg SC on-body injector day 3 (optional, up to investigator's discretion, can alternatively do day 4 without on-body injector)~Suggested supportive care medications: fosaprepitant 150 mg IV day 1, dexamethasone 12 mg IV day 1, ondansetron 16 mg IV day 1, dexamethasone 4 mg PO q AM days 2-3, ondansetron 8 mg PO BID days 2-3."
38158|NCT03885284|Radiation|Proton beam radiation|Proton beam radiation will consist of 5 daily doses of 5 GyE total, ideally administered Monday through Friday but can be administered within 7 business days, between cycles 6 and 7
38159|NCT03885271|Other|Hall Technique|The Hall technique is a simplified method of utilizing stainless steel crowns in treatment of carious primary molars. The SSC is cemented onto the carious tooth using glass ionomer cement. Since there is no need for carious lesion removal, the use of local anesthesia is not mandate
38160|NCT03885271|Other|Formecresol Pulpotomy|Pulpotomy is a procedure in which the coronal pulp is amputated, and the remaining radicular pulp tissue is treated with a medicament to preserve the pulp's health .This technique involves administration of local analgesia, Isolation of the tooth with rubber dam, Complete caries removal and then access to the pulp chamber using drills
38161|NCT03885258|Drug|Melatonin Replacement Therapy|Melatonin (Aché Pharmaceutics, Brazil), 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.
38162|NCT03885245|Drug|L-ctirulline|8 weeks of treatment with 15 g/day of orally administered (powder form mixed with water) L-citrulline
38163|NCT03885245|Drug|Matching Placebo|8 weeks of treatment with orally administered matching placebo (to 15 g/day of L-citrulline)
38164|NCT03885232|Behavioral|Experimental: PIVOT with MI|Providers in participating intervention clinics will be trained in the PIVOT-MI strategy in which a presumptive format is used to initiate the childhood vaccine recommendation with all parents followed by use of motivational interviewing (MI) with parents who voice resistance to that recommendation. Parent participants will receive PIVOT-MI.
38165|NCT03885232|Other|Active Comparator: Control|Providers at participating control clinics will deliver care as usual. Parent participants will receive standard care.
38166|NCT03885219|Drug|Nab-paclitaxel and S-1|Nab-paclitaxel: 120 mg/m2 d1, 8, S-1:Body surface area < 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 , < 1.5 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14; repeat every 21 days.
38167|NCT03885206|Other|Level of healthcare services|Patiens judged to be eligible for admittance to a municipal acute care wrad will be admitted to hospital as an intervnetion, to be able to compare same patient groups.
38168|NCT03885180|Drug|Warfarin Sodium|Extending warfarin anticoagulation
38169|NCT03885167|Other|Specimen Collection|No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
38170|NCT03885154|Drug|Valproic Acid (VPA)|IV VPA load 20mg/kg, followed by continuous infusion of 1mg/kg/hr for 24 hours
38171|NCT03885154|Drug|Dihydroergotamine (DHE)|0 hour: 0.50 x (wt in kg) x (0.014) =Xmg 8 hour: 0.75 x (wt in kg) x (0.014) =Xmg 24 hour: 1.00 x (wt in kg) x (0.014) =Xmg
38172|NCT03885141|Drug|Zolpidem|Zolpidem or Placebo if there is a wake up during the night
38173|NCT03885128|Device|High frequency extra thoracic oscillations vest|Oscillations applied extra thoracic through vest device aiming for airway clearance
38174|NCT03885128|Device|Intrathoracic oscillatory quake|Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions
38175|NCT03885115|Behavioral|Intervention|Involves 12-weeks of education related to healthy behaviors, nutrition, and exercise from certified fitness instructors.
38288|NCT03884049|Procedure|Embolization|transcatheter arterial embolization of neovessels around the knee
38178|NCT03885089|Drug|Infliximab [infliximab biosimilar 3]|<Psoriasis> The usual dose is 5 mg as Infliximab (Genetical Recombination) [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner according to condition of patients. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks.
38179|NCT03885076|Procedure|Blood collection and bone marrow aspirate|Blood and bone marrow samples will be collected for the trial alongside routine tests.
38180|NCT03885063|Behavioral|Benjamin Rose Institute Care Consultation (BRI-CC)|The BRI-CC is a telephone-based intervention designed for adults with chronic conditions and has been used in persons with dementia and their caregiver (CG). This assessment is guided by the use of assessment tools with domains that trigger specific and pertinent needs of the dyad such as relationship strain, depression, financial concerns, memory problems, and difficult behaviors. To address unmet needs, the care consultant and dyad develop action plans with specific action steps pertinent to the dyad. The intervention involves maintenance and support where the care consultant (CC) continues the relationship with the dyad through regular telephone contact, email and mail. CC use a web-based reporting system, to maintain and track dyad information, assessments, action plans, completed tasks, and ongoing contacts. At a minimum, the care consultant will contact the dyad by telephone once per month over the duration of the study period (i.e. 6 months).
38181|NCT03885050|Other|Ross score|modified score used for evaluation of heart failure in children, as a diagnostic tool for severity of heart failure
38182|NCT03885037|Drug|Infliximab [infliximab biosimilar 3]|<Rheumatoid arthritis> The usual dose is 3 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have an incomplete response or reduced effects. These adjustments should be made in a stepwise manner. The maximum dose is 10 mg for every kg of body weight at the dosing interval of 8 weeks and 6 mg for every kg of body weight at a reduced dosing interval. The minimum dosing interval is 4 weeks. This drug should be given in combination with methotrexate.
38183|NCT03885024|Other|Retention Video|Participants assigned to the retention training arm will watch a brief training video that will include information on how to retain peers in clinical trials.
38184|NCT03885011|Drug|CSF-1|This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
38185|NCT03885011|Drug|CSF-1 Component #1|"This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week."
38186|NCT03885011|Drug|CSF-1 Component #2|This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
38187|NCT03884998|Drug|Copanlisib|Given IV
38188|NCT03884998|Biological|Nivolumab|Given IV
38189|NCT03884985|Other|Visual stimulation|In the experiments, participants will sit in front of a computer monitor located a less than a meter of distance and will analyze the content of images extracted from collections of natural and computer-generated scenes. Subjects will be asked to report verbally or by pressing keys on a keyboard on image characteristics such as the locations of the objects present in the scenes, their number and/or their identities. Some experiments will involve a search paradigm in which subjects will have to report on the location and/or fine characteristics of a target element among a field of distracting similar elements, and/or visual discrimination tasks. The duration of the interval of time in which the image is maintained on the screen may be varied between few tens of milliseconds to several seconds. In a set of experiments, the eye movements performed by the subjects during the execution of the visual tasks will be recorded as explained below.
38190|NCT03884972|Drug|Trabectedin|Given IV
38191|NCT03884972|Drug|Venetoclax|Given PO
38192|NCT03884959|Biological|HepaStem Infusion|HepaStem will be infused intravenously into the portal vein, either (1) via a permanent mesenteric PAC inserted surgically in an affluent of the portal vein; or (2) through a transient percutaneous transhepatic catheter inserted in to the portal vein under radio guidance.
38193|NCT03884946|Other|Getting Off App|"A mobile phone application based on the Getting Off methamphetamine treatment manual. Participants download the app and progress through the sessions of the Getting Off intervention through the administration of games, activities, lessons, quizzes, and tutorials. There are 24 sessions total in the app, each addressing a different component of the methamphetamine treatment process. The fundamental basis of the app is gay-specific cognitive behavioral therapy, with elements of motivational interviewing, social support theory, and health belief model dynamics included."
38220|NCT03884712|Device|CalmiGo|The CalmiGo handheld device is a device of similar size to an inhaler that uses guided breathing, aromatherapy and grounding techniques to regulate breathing to bring users a sense of calm and relaxation. The CalmiGo handheld device is being tested in this study to alleviate participants' anxiety and panic attack symptoms.
38255|NCT03884374|Behavioral|Sham Breathing and Attention Training (BAT)|Sham-BAT intervention will incorporate most of the general aspects of the BAT intervention but without the specific instructions related to mindfully attending to the breath in a non-evaluative manner.
70981|NCT03629054|Drug|Metformin HCl|single dose
38194|NCT03884933|Other|Mobile team community mental health services|The intervention focuses on changing mental health care systems to be able to provide community-based mental health care for people with severe mental illness. This will be done through the development and implementation of multidisciplinary community mental health teams (CMHTs) in each of the implementation sites, consisting of at least one nurse, psychiatrist, psychologist, social worker, and peer worker (person with lived experience of a severe mental illness). The structure and delivery method of the community mental health teams is part of an evidence-based service delivery model providing flexible, assertive community mental health teams providing integrated services to people with severe mental illness (SMI) in order to structurally attain their recovery goals, as well as timely and appropriate care in the event of a crisis.
38195|NCT03884920|Dietary Supplement|Polyherbal formulation|Test candidate will be administered per oral before / with meal in two divided doses
38196|NCT03884907|Procedure|The patients will receive human bone graft screws surgically|All patients undergo Hallux valgus correction according to the Austin procedure using human bone graft screws.
38197|NCT03884894|Diagnostic Test|molecular assay|performed with blood culture simultaneously
38198|NCT03884894|Diagnostic Test|Blood culture|performed with molecular assay simultaneously
38199|NCT03884881|Diagnostic Test|metagenomic next generation sequencing|Pathogens in the NGS group will be tested by NGS，then according the NGS results, adjust antibiotics
38200|NCT03884881|Diagnostic Test|Conventional pathogen detection|Morphological detection, microbial culture, nucleic acid amplification technology, serological pathogen antibody titer detection and specific pathogen PCR detection. Then, according to the pathogen results, adjust antibiotics
38201|NCT03884881|Drug|Meropenem，Imipenem，Caspofene，Osstat|Meropenem，Imipenem，Caspofene，Osstat
38202|NCT03884868|Other|Iconographies to communicate risks|Use of iconographies to communicate the risks of the different possible diagnosis after a positive FIT during the screening program nurse visit.
38203|NCT03884855|Other|Classical Cardiac Rehabilitation|Patients benefit from classical cardiac rehabilitation during 3 months.
38204|NCT03884855|Other|Karate rehabilitation|Patients benefit from cardiac rehabilitation with traditional karate during 3 months. Patients will have four 60-minute group sessions four times a week, during which they will have 45-minute individual exercises and 15-minute pairs of exercises. The course of the sessions has been protocolised.
38205|NCT03884842|Biological|Dupilumab/Dupixent|a monoclonal antibody designed for the treatment asthma and atopic dermatitis.
38206|NCT03884842|Biological|Placebo|Matched placebo
38207|NCT03884829|Drug|CYC140|CYC140 single agent
38208|NCT03884816|Other|Determine the Incidence and Retention Rate|Determine the incidence of HIV and the retention rate of MSM/TGW/TGM/Intersex at risk for HIV infection
38209|NCT03884803|Behavioral|E-health website|Access to the e-health intervention (website)
38210|NCT03884803|Other|Standard Care|Control group to continue with standard care
38211|NCT03884790|Device|surgical repair of long bone defects|"Current treatment of bone defects usually implies the use of bone grafts and/or biocompatible materials, to create a scaffold that bridges the defect, favoring the migration of cells from the neighboring tissues to fill the gap. Autograft and Allograft are the treatments most currently used for large bone loss, but both treatments have significant disadvantages. Different types of synthetic materials have been tested for repair of long bone gaps.~However, at the moment, there is not any bone substitute with the ideal/desirable osteoinductive, osteoconductive and mechanical properties. GreenBone Implant is a synthetic, acellular, reabsorbable, new generation bone graft, being suitable for surgical reconstruction of bone defects."
38212|NCT03884764|Procedure|pulsed radiofrequency|patients with chronic pelvic pain due to chronic prostatitis will receive pulsed radiofrequency on sacral root number 3 and ganglion impar denervation and the patients will be followed for 6 months to assess pain severity radiofrequency procedure: patients will positioned prone on the operating table and under x-ray guidence sacral foramen number 3 will be identified and through it radiofrequency needle will be advanced to target the sacral root ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
38213|NCT03884764|Procedure|ganglion impar denervation|patients with chronic pelvic pain due to chronic prostatitis will receive ganglion impar denervationand and the patients will be followed for 6 months to assess pain severity ganglion impar procedure: under x-ray guidance the sacrococcygeal junction is identified and spinal needle will be introduced through it to target ganglion impar and 4 ml of alcohol 50% will be injected
38214|NCT03884751|Biological|CAR-GPC3 T Cells|CAR-GPC3 T Cells injection
38215|NCT03884738|Other|Concentric Exercise|"Leg Curl Machine: 1st week - 1st day is 10 maximum repeat test. 2nd week - 2 days of training - 2 sets of 6 repeats. %60 percent of maximum load.~3rd week - 3 days of training - 3 sets of 6-8 repeats. %60-80 of maximum load. 4th-8th week - 3 days of training - 3 sets of 8-12 repeats. when 3 sets of 12 achieved, load was increased with 2.5kg."
38216|NCT03884738|Other|Nordic Eccentric exercise|"st week - 1 day - 2 sets of 5 repeats.~nd week - 2 days - 2 sets of 6 repeats.~rd week - 3 days - 3 sets of 6-8 repeats.~th week - 3 days - 3 sets of 8-10 repeats. 5-8th weeks - 3 days - 3 sets of 12-8 repeats. When achieved 3 sets of 12 repeats with full range, speed was increased."
38217|NCT03884738|Other|Neuromuscular Electrical Stimulation|8 weeks, three times per week, 15 minutes of bilateral hamstring stimulation. 100 Hz. frequency, 600 microsecond duration rectangular current
38218|NCT03884725|Drug|Fibrinogen Concentrate|Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 [mm] − MCF [mm]) * body weight [kg] / 140 [mm*kg/g] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
38219|NCT03884725|Other|control|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 0.9% saline (SF0,9%) prepared based on ROTEM measurement of maximum clot firmness (MCF). 0.9% saline is to be infused over 1 to 2 minutes. After 0.9% saline infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
38221|NCT03884699|Procedure|Accuracy of planned transverse Maxillary distance using Mimics software after fixation using Patient specific implant|"Virtual planning: based on clinical evaluation and 3D cephalometric analysis. Virtual osteotomies mimicking segmental Lefort I and a bilateral sagittal split osteotomy.~Designing the virtual cutting guide. Virtual movement into the desired positions of the segmented maxilla and mandible, based on: clinical evaluation, 3D cephalometric analysis and the desired occlusion.~Once the optimal position of the maxilla is achieved, a patient specific implant will be virtually designed to fix the segmented maxilla in its new position.~Fabrication of the cutting guide using additive manufacturing technique from polymer material.~Fabrication of PSI from titanium alloy using additive manufacturing technique."
38222|NCT03884686|Other|Web-based education resource|Intervention includes fact sheets, question and answers, short videos featuring patients and/or clinicians.
38223|NCT03884673|Drug|DTG+ 3TC|It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
38224|NCT03884660|Device|remede System|Patients undergoing a remede System implant attempt. Study devices will be used per approved indications for use for each geography.
38225|NCT03884647|Device|DELPhI (software as a medical device)|DELPhI software is acquiring and analyzing the TMS evoked response recorded with the EEG.
38226|NCT03884634|Device|Dabir Micropressure Overlay|"The study intervention is the use of the Dabir micropressure overlay on the operating room table during surgical operations. The device is positioned on top of a standard foam pad and gel heat exchanger. The overlay is already in use in some (but not all) adult cardiac operating rooms.~The overlay will be present on the operating room table for all adult cardiac operations. On odd calendar dates the device will be powered on, and on even calendar dates the device will be powered off."
38227|NCT03884621|Other|EHP Group|The Enhanced post-discharge home-based care program (EHP) plus usual care
38228|NCT03884595|Diagnostic Test|IG, IPF, NRBC, CRP, PCT, presepsin|Assessment of blood cell count parameters and inflammation markers - IG, IPF, NRBC, CRP, PCT, presepsin according to study group.
38229|NCT03884582|Device|Cova Monitoring System 3|Healthy Volunteers
38230|NCT03884556|Drug|TTX-030|Variable dose and schedule
38231|NCT03884556|Drug|Pembrolizumab|Dose and schedule per standard of care
38232|NCT03884556|Drug|Docetaxel|Dose and schedule per standard of care
38233|NCT03884556|Drug|Gemcitabine|Dose and schedule per standard of care
38234|NCT03884556|Drug|nab paclitaxel|Dose and schedule per standard of care
38235|NCT03884543|Procedure|Individualized high PEEP strategy|Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
38236|NCT03884530|Drug|Ticagrelor (Brilique) 90|Drug name Brilique 90 ml Drug form tablet
38237|NCT03884530|Drug|Aspirin 75mg|Drug name Aspirin 75 ml Drug form tablet
38238|NCT03884517|Drug|BAT8003|Phase 1 dose titration study from BAT8003 0.2mg/kg to 10mg/kg, then choose a proper dose for amplification study based on DLT result
38239|NCT03884504|Device|Ventricular Assist Device System|Ventricular Assist Device System
38240|NCT03884491|Drug|Vortioxetine IV|an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours
38241|NCT03884491|Drug|Vortioxetine SLA|5-25 mg of sublingual formulation A of vortioxetine
38242|NCT03884491|Drug|Vortioxetine SLB|5-25 mg of sublingual formulation B of vortioxetine
38243|NCT03884491|Drug|Vortioxetine SLC|formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
38244|NCT03884478|Behavioral|Personalized Normative Feedback|Personalized Normative Feedback (PNF) is a popular social norms-based intervention strategy which presents individuals with a personalized, individual report designed to correct misperceived peer norms using a graphical display. Bar charts compare actual alcohol use statistics for the peer group to A) participants' estimates of peer drinking and, B) their own self-reported drinking.
38245|NCT03884465|Drug|Inhaled dry powder treprostinil (LIQ861)|Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
38246|NCT03884452|Drug|Atorvastatin|Tablets taken orally once daily in the morning
38247|NCT03884452|Drug|Simvastatin|Tablets taken orally once daily in the morning or evening
38248|NCT03884452|Drug|Ezetimibe|Tablet taken orally once daily in the morning or evening
38249|NCT03884452|Drug|Placebo for Ezetimibe|Tablets taken orally once daily in the morning or evening
38250|NCT03884439|Drug|Infliximab [infliximab biosimilar 3]|<Crohn's disease> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter. After a dose at Week 6 is given, the dose may be increased or the dosing interval may be reduced for patients who have reduced effects. At an increased dose, the dose may be adjusted to 10 mg for every kg of body weight. At a reduced dosing interval, the dose of 5 mg for every kg of body weight may be given at the minimum dosing interval of 4 weeks. <Ulcerative colitis> The usual dose is 5 mg as Infliximab [Infliximab Biosimilar 3] for every kg of body weight given as an intravenous infusion. After an initial dose is given, the subsequent doses are given at Weeks 2 and 6, and every 8 weeks thereafter.
38251|NCT03884413|Other|questionnaires|Longitudinal observational study. Collection of health data using self-administered questionnaires online.
38252|NCT03884400|Procedure|Specimens obtained from surgical, phlebotomy or other non-invasive procedure|Biospecimen Collection
38253|NCT03884387|Other|Patient Decision Aid|The Patient Decision aid used in this project is a tool designed to facilitate shared decision making in patients with lumbar herniated disk. It is intended to complement counseling with health professionals and help patients become involved in decision making by making explicit the decision that needs to be made, providing information about the advantages and disadvantages of having or not having surgery, knowledge of treatment outcomes, and by clarifying personal values.
38254|NCT03884374|Behavioral|Breathing and Attention Training (BAT)|Participants will receive mindfulness-based mental training regimen to independently practice mindfulness meditation.
38256|NCT03884374|Device|Transcranial Direct Current Stimulation (tDCS)|A Soterix 1x1 Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two bicarbon rubber electrodes encased in saline-soaked sponges
38257|NCT03884374|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA (30s ramp up/down) of stimulation at the beginning of the session.
38258|NCT03884361|Diagnostic Test|Vaginal Microbiome as result of aminocentesis|we will take a blood samples and a vaginale samples after and before the aminicentesis and check if the sample that we took after is different and contain microrganisms , if we find a different o we can say that as result of the Elective Amniocentesis
38259|NCT03884348|Drug|proton pump inhibitor, amoxicillin, clarithromycin|non-resistant group with treatment of proton pump inhibitor, amoxicillin, clarithromycin
38260|NCT03884348|Drug|proton pump inhibitor, amoxicillin, metronidazole|clarithromycin-resistant group with treatment of proton pump inhibitor, amoxicillin, metronidazole
38261|NCT03884335|Procedure|laparoscopic radical prostatectomy|The surgery was carried out by laparoscopy. Intraoperative anesthetic maintenance was performed with TCI of propofol infusion for bispectral index between 40 and 60, restrictive administration of fluids or goal-directed parenteral fluid administration, normothermia, normotension and optimal intraoperative analgesia were maintained following the criteria of ERP. Afterwards, patients were awoken from general anaesthesia and transferred to the post-anaesthesia care unit (PACU) for a 6-hour follow-up prior to transfer to conventional ward.
38262|NCT03884322|Other|Prepod|the prepod is either a 4 way stretch polyester blend fleece with 8 to 10% lycra, or a 95%cotton5% lycra blend knit. It comes in 4 different sizes to assure a pod that has a conforming but not restricting fit so that the infant is free to stretch in any direction at any time but is loosely held in a position of physiological flexion (the fetal position) when not stretching.
38263|NCT03884322|Procedure|Joint compression exercises|Each premature infant enrolled as a control subject received approximately 10 minutes of joint compression exercises provided by a NICU trained physical or occupational therapist 5x a week. The exercises consisted of waking the infant slowly, gently if necessary just before feeding with a simple range of motion stretching program then stabilizing an extremity and applying force distally to proximally for 6 repetitions with a brief pause between each compression.
38264|NCT03884309|Other|Experimental Hydrolyzed Protein Infant Formula|fed ad libitum
38265|NCT03884296|Biological|FluMist|Quadrivalent, live, attenuated influenza vaccine, intranasal spray
38266|NCT03884283|Device|FIBERGRAFT BG Matrix|Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with local bone autograft and bone marrow aspirate (BMA)
38267|NCT03884270|Behavioral|Hypnotherapy|7 sessions of self-administered gut-directed hypnotherapy for functional dyspepsia
38268|NCT03884257|Device|Passeo-18 Lux treatment group|Percutaneous endovascular angioplasty with the Passeo-18 lux
38269|NCT03884257|Device|IN.PACT Admiral treatment group|Percutaneous endovascular angioplasty with the IN.PACT Admiral
38270|NCT03884244|Other|chewing gum|The group who take chewing gum after operation
38271|NCT03884231|Procedure|MRI imaging procedure|MRI imaging procedure is performed in each subject with Infinity DBS
38272|NCT03884218|Other|Infra red thermal imaging|thermal image using a non-touch, non-ionising, thermal camera system
38273|NCT03884192|Drug|Consolidation Sintilimab|Sintilimab consolidation therapy after concurrent chemoradiation, 200mg IV, every 3 weeks, until progressive disease (PD, unless patients can continuously benefit from study treatment per investigators' judgement), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Sintilimab will be given at a maximum of 12 months.
38274|NCT03884166|Diagnostic Test|bronchoscopy|Patients will undergo bronchoscopy to sample respiratory tissue in different heights in order to analyze mucociliary clearance
38275|NCT03884153|Device|CRP apheresis|"selective CRP apheresis by use of the PentraSorb-CRP"
38276|NCT03884127|Drug|Ezetimibe 10mg|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
38277|NCT03884127|Drug|Orlistat 120 MG|On the basis of the intervention of life style, drug intervention therapy was carried out for a period of 12 weeks
38278|NCT03884114|Other|High-fidelity simulation|The first evaluation modality studied is high fidelity (HF) simulation. In our study, this modality is considered to be the gold-standard assessment method of clinical assessment, because HF simulation corresponds to the modality which reflects the best clinical competence in hospital settings. The HF pediatric manikin used (SimBaby), is able to reproduce all the signs of an asthma exacerbation (coughing, wheezing, tachypnea, chest indrawing, seesaw respiration, cyanosis). In the simulation room, participants can use the same items that those present in the simulation game (a glass of water, paracetamol, short acting beta-agonist, controller treatment (Fluticasone), an asthma spacer with a facial mask, saline nose drops to perform nasal irrigation, oral steroids in tablets (prednisone), and a phone).
38279|NCT03884114|Other|Simulation game|"EfficAsthme is a simulation game used on a tablet computer. This simulation game was developed to train parents on the management of asthma exacerbations of their children. For the purpose of the study, EfficAsthme is diverted from its original use to assess students' clinical skills. The training scenario A polluted atmosphere is used in this study. Participants need to observe the signs presented by the child, and to determine the severity of the asthma exacerbation. From a menu on the right of the screen, the participant can choose several actions, especially to provide the short acting beta-agonist."
38280|NCT03884114|Other|Multiple choice questionnaire|The third evaluation modality corresponds to a multiple choice questionnaire (MCQ) including 15 questions. As for HF-simulation and the simulation game, the MCQ starts with the same briefing and continues with 15 questions regarding the management of a moderate asthma exacerbation.
38281|NCT03884101|Drug|Lenvatinib|Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
38282|NCT03884101|Biological|Pembrolizumab|Pembrolizumab 200 mg intravenous (IV) infusion given on Day 1 of each cycle.
38283|NCT03884101|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
38284|NCT03884101|Drug|Carboplatin|Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
38285|NCT03884088|Other|Limits of Stability|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
38286|NCT03884075|Drug|Semaglutide|Semaglutide once weekly
38289|NCT03884049|Procedure|Sham embolization|Sham transcatheter arterial embolization of neovessels in the knee
38290|NCT03884036|Biological|Vitamin D|Vitamine D
38291|NCT03884010|Other|No intervention|Cross-sectional
38292|NCT03883997|Other|No intervention|Cross-sectional
38293|NCT03883984|Drug|Cysteamine Bitartrate|Cysteamine bitartrate administered four times per day (QID) for 8 weeks. 125mg tablet QID.
38294|NCT03883984|Drug|Placebo Oral Tablet|Placebo administered for 8 weeks. 125mg tablet QID.
38295|NCT03883971|Other|3D printed model|Same as previously reported in arm descriptions
38296|NCT03883971|Other|Placebo|nothing other than the ultrasound
38297|NCT03883958|Procedure|Erector Spinae Plane Block|ESPB will be performed in sitting or lateral decubitus position. The target vertebral level will be correspond to the approximate mid-point of the extent of fractured ribs. The tip of the transverse process of the target vertebra will be identified using the high-frequency linear placed in cephalocaudal orientation about 3 cm to the spinous process. The skin and subcutaneous tissue will be infiltrated with 2-3 ml of 2% lignocaine. With the transducer fixed over the targeted TP, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be advanced in-plane to the ultrasound beam in a cephalo-caudal direction to contact the TP. Correct needle tip position will be confirmed by doing alternating aspiration to confirm lack of inadvertent vascular puncture with injection of 1-2 ml of saline and visualizing linear fluid spread deep to erector spinae muscle, separating it from the TP. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
38298|NCT03883958|Procedure|Paravertebral Block|TPVB will be performed at a spinal level midway between the uppermost and the lowest fractured rib with the patient in sitting or lateral decubitus position (with patients lying on their unaffected side). The ultrasound-guided technique will be used. A high-frequency linear transducer will be used to confirm the levels of the fractured ribs. The most cephalad and most caudad fractured ribs will be identified first. The fractured rib in the middle will be then identified, and the rib will be then traced back medially. After skin and subcutaneous tissue infiltration with 2-3 ml of 2% lignocaine, a 22-gauge 88-mm needle (Spinocan, B. Braun, Germany) will be inserted in a lateral-to-medial direction until the needle tip entered the paravertebral space. 1-2 ml of Saline will be injected into the paravertebral space while observing the pleura being moved deeply. A bolus dose (2ml/segment) of plain bupivacaine 0.5% plus 4mg of Dexamethasone will be injected.
38299|NCT03883945|Drug|AIV001|intradermal injection
38300|NCT03883945|Drug|Vehicle|intradermal injection
38301|NCT03883932|Behavioral|Fatherhood Focused FVEP (F3)|F3 is designed to focus specifically on the importance of fathering within a cognitive-behavioral intervention.
38302|NCT03883932|Behavioral|Family Violence Education Program (FVEP)|FVEP is a court-mandated program intended to treat those arrested for intimate partner violence (IPV).
38303|NCT03883919|Drug|5-FU|-Standard of care drug
38304|NCT03883919|Drug|Leucovorin|-Standard of care drug
38305|NCT03883919|Drug|Liposomal Irinotecan|-Standard of care drug
38306|NCT03883919|Drug|Paricalcitol|-Investigational drug
38307|NCT03883919|Procedure|Serum and plasma blood samples|-baseline, day 1 of each cycle beginning with cycle 2
38308|NCT03883919|Procedure|Tumor biopsy|"The first 5 patients in each arm will be required to undergo a mandatory tumor biopsy from the primary pancreatic site or metastatic site, if safe and feasible, prior to cycle 1~After Cycle 3 of treatment, all patients who had a baseline biopsy will be required to undergo a mandatory biopsy of the same site if safe and feasible."
38309|NCT03883906|Biological|Viral Specific T-cells (VSTs)|VSTs will be infused into stem cell transplant recipients
38310|NCT03883893|Drug|Intravenous acetaminophen|Intravenous acetaminophen will be given in the OR.
38311|NCT03883893|Other|Normal saline|Normal saline will given if randomized to this group.
38312|NCT03883880|Other|Epigallocatechin gallate|Colored solution prepared with epigallocatechin gallate to be consumed daily for two weeks during the epigallocatechin gallate intervention.
38313|NCT03883880|Other|Epigallocatechin gallate control|Colored control solution to be consumed daily for two weeks during the epigallocatechin gallate intervention.
38314|NCT03883880|Other|Linoleic acid|Colored emulsion prepared with linoleic acid to be consumed daily for two weeks during the linoleic acid intervention.
38315|NCT03883880|Other|Linoleic acid control|Colored control solution to be consumed daily for two weeks during the linoleic acid intervention.
38316|NCT03883880|Other|Capsaicin solution|Colored solution prepared with capsaicin to be consumed daily for two weeks during the capsaicin intervention.
38317|NCT03883880|Other|Capsaicin control|Colored control solution to be consumed daily for two weeks during the capsaicin intervention.
38318|NCT03883841|Drug|Iron Sucrose Solution for Injection|intravenous infusion of iron sucrose
38319|NCT03883828|Drug|Chlorhexidine gluconate solution|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
38320|NCT03883828|Drug|Mupirocin Ointment|Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
38321|NCT03883815|Other|Active Video Games Therapy|"Interventions were completed in 1-week periods, after 3 clinical visits. All individuals underwent both neurodevelopmental therapy and active video games therapy. Demographic data of individuals were recorded and muscle tone and gross motor functions were evaluated at the first visit. The games determined by the physiotherapist were explained and experienced by individuals. During the second visit, individuals played 4 games that were previously determined and experienced for about 45 minutes. On the last visit, individuals underwent neurodevelopmental therapy. During both treatment sessions, the accelerometer was fitted on a flexible belt by attaching it to the dominant wrist. Individuals were instructed not to remove the device during both treatment sessions.~One session individuals treated with exercises which weight transfer and postural reactions were facilitated.~Other session they played Nintendo Wii games in accordance with their current level and skills."
38322|NCT03883802|Drug|Foxy-5|Lyophilized powder for solution for intravenous infusion
38323|NCT03883802|Drug|FOLFOX regimen|6 months treatment regimen
38324|NCT03883802|Procedure|Tumour resection (colon cancer surgery)|Surgical removal of patients colon cancer
38326|NCT03883776|Drug|Al18F-NOTA-octreotide|One intravenous injection of 4 MBq/kg
38327|NCT03883776|Device|PET/CT|"Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection."
38328|NCT03883776|Other|Venous blood samples|Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
38329|NCT03883763|Drug|bupivacaine S75:R25 plus 8% glucose|Spinal anesthesia, 5 mg/mL
38330|NCT03883763|Drug|bupivacaine S50:R50 plus 8% glucose|Spinal anesthesia, 5 mg/mL
38331|NCT03883737|Other|PNM|an asymmetric rectangular biphasic current (250 microseconds, 10 Hz)
38332|NCT03883724|Behavioral|Brief behavioral treatment of insomnia (BBTI)|The BBTI consists of a 45- to 60-minute individual intervention session followed by a 30-minute follow-up session 2 weeks later and 20-minute telephone calls after 1 and 3 weeks. The brief behavioral treatment component will focus on four behaviors that promote sleep through homeostatic, circadian, or association mechanisms. 50 These four interventions are simple to conceptualize and implement, and constitute the core of efficacious multi-modal behavioral treatments for insomnia.
38333|NCT03883724|Behavioral|Information-only control (IC)|The IC condition is intended to emulate the behavioral treatment information generally to available patients. It includes instructions to review hand out on healthy sleep practices. We will also use patient education videos on insomnia developed locally and widely used in clinical research. The content of these videos overlap substantially with BBTI but without individualized behavioral instructions. Two weeks later, IC participants will receive a 10-minute follow-up telephone call to encourage continued participation. Participants will be referred to the brochures for specific sleep-related questions.
38334|NCT03883711|Other|Database|Create a database containing clinical characteristic, clinical presentation, flow indexes and treatment of consecutive incident patients with ACS or myocardial injury.
38335|NCT03883698|Drug|Sofosbuvir|Sofosbuvir is the backbone of the most of the currently used anti-HCV treatment regimens
38336|NCT03883698|Drug|Daclatasvir 60 mg|Daclatasvir, in combination with sofosbuvir, is approved for the treatment of hepatitis C virus infection in absence of liver cirrhosis
38337|NCT03883685|Dietary Supplement|Probiotane|probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
38338|NCT03883685|Dietary Supplement|Placebo|Placebo
38339|NCT03883672|Behavioral|Personality and transactional factors|"Pre-admission transplant questionnaire: given and collected by the transplant physician during the pre-graft consultation before entering hospitalization (approximatively 15 days before). To be completed by the patient on site (approximately 45 minutes to complete the questionnaire)~Transplant admission questionnaire: given during the first days of hospitalization. To be completed within 6 days and returned to the transplant physician (approximately 30 minutes to complete the questionnaire)~Post-transplant follow-up questionnaire: given in consultation at 6 months by the transplant physician (between 30 and 45 minutes to complete the questionnaire in consultation)"
38340|NCT03883659|Other|Smartphone|patients with frozen shoulder in the smartphone group will use the smartphone to conduct the home exercise program. The patients will be asked to follow the description to have mobility assessment at least 1 week and do the individualized exercise themselves.
38341|NCT03883659|Other|traditional paper hangouts|patients with frozen shoulder in the smartphone group will use the paper hangouts to conduct the home exercise program. The content of the paper hangouts were description of the home exercise.
38342|NCT03883646|Behavioral|Mindfulness|Mindfulness-based Relapse Prevention. Guided meditation/discussion (Group sessions).
38343|NCT03883646|Behavioral|Relapse Prevention|Relapse Prevention. Cognitive behavioral principles/strategies (Group sessions).
38344|NCT03883633|Behavioral|ReCODE Protocol|Functional medicine approach to address symptoms of Alzheimer's and cognitive decline
38345|NCT03883620|Biological|Dengushield 1 mg/kg (Cohort 1) intravenous|Participants will be administered Dengushield 1 mg/kg as slow intravenous injection.
38346|NCT03883620|Biological|Dengushield 3 mg/kg (Cohort 2) intravenous|Participants will be administered Dengushield 3 mg/kg as slow intravenous infusion.
38347|NCT03883620|Biological|Placebo 3 mg/kg (Cohort 2) intravenous|Participants will be administered Placebo 3 mg/kg as slow intravenous infusion.
38348|NCT03883620|Biological|Dengushield 7 mg/kg (Cohort 3) intravenous|Participants will be administered Dengushield 7 mg/kg as slow intravenous infusion.
38349|NCT03883620|Biological|Placebo 7 mg/kg (Cohort 3) intravenous|Participants will be administered Placebo 7 mg/kg as slow intravenous infusion.
38350|NCT03883620|Biological|Dengushield 12 mg/kg (Cohort 4) intravenous|Participants will be administered Dengushield 12 mg/kg as slow intravenous infusion.
38351|NCT03883620|Biological|Placebo 12 mg/kg (Cohort 4) intravenous|Participants will be administered Placebo 12 mg/kg as slow intravenous infusion.
38352|NCT03883607|Drug|Elafibranor 80mg|Once daily oral intake of elafibranor 80 mg during 3 months
38353|NCT03883607|Drug|Elafibranor 120mg|Once daily oral intake of elafibranor 120 mg during 3 months
38354|NCT03883594|Behavioral|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
38355|NCT03883581|Drug|dextromethorphan HBr and quinidine sulfate|All eligible and enrolled study participants will be administered the study drug, Nuedexta, as recommended by their treating neurologists.The drug will be administered per the efficacy and safety protocol, with no changes in administration method or recommended dose for individuals with ALS. Prior to commencing treatment with Nuedexta, participants will undergo a comprehensive bulbar evaluation of swallowing, airway protection, speech functions, and complete validated patient-reported surveys. Following 30 days of Nuedexta treatment, participants will be e-evaluated using the same battery of assessments.
38356|NCT03883555|Device|High flow nasal therapy (HFNT) : Optiflow™|"HFNT will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs.~Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance"
38357|NCT03883555|Device|Non invasive ventilation (niv)|"NIV will be delivered through a face mask connected to a dedicated ventilator with pressure support applied in a noninvasive ventilation mode (Monnal T75, Airliquide Medical Systems, Antony, France).~The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort."
38358|NCT03883542|Genetic|genomic mutations study|"Sequencing of the DNA samples extracted from the subgroups~serous BOT tissue,~serous BOT tissue with non-invasive implants and~serous BOT tissue with micropapillary grow pattern will undergo a panel testing for Type 1 genes (small panel 15-40 mutations) AND p53 AND BRCA testing~Sequencing of the DNA samples extracted from the serous BOT tissue with invasive implants will undergo a more comprehensive examination (large panel +- 1000 genes checked)"
38359|NCT03883529|Other|Writing about and reviewing birth experience|Writing about and reviewing birth experience with a known midwife from antenatal care about 6 weeks post-partum.
38360|NCT03883516|Other|Pre-briefing with the current SE treatment guidelines|instruction of the study participants according to the evidence-based guideline for the treatment of SE published by the American Epilepsy Society prior to the simulation training
38361|NCT03883516|Other|"Pre-briefing with a consolidated one page SE treatment guide"|"instruction of the study participants with a consolidated one page SE treatment guide prior to the simulation training"
38362|NCT03883516|Other|No Pre-briefing|no instruction of the study participants prior to the simulation training
38363|NCT03883503|Other|Beer 5%o|Weight adjusted beer to reach 0.8 blood alcohol content will be given over the time course of 1 hour to the participants
38364|NCT03883503|Other|Beer 8.5%o and water|Weight adjusted beer to reach 0.8 blood alcohol content and water will be given over the time course of 1 hour to the participants
38365|NCT03883503|Other|Beer 8.5%o and stock|Weight adjusted beer to reach 0.8 blood alcohol content and stock will be given over the time course of 1 hour to the participants
38366|NCT03883503|Other|Water|Water equivalent to the calculated volume of beer will be given over the time course of 1 hour to the participants
38367|NCT03883490|Diagnostic Test|ECG|A 12-lead ECG will be taken for each participant.
38368|NCT03883490|Diagnostic Test|Blood test and biobanking|All patients will undergo venepuncture and blood sample will be taken for full blood count, renal function and plasma will be stored for future biomarker analysis.
38369|NCT03883490|Diagnostic Test|Trans-thoracic Echocardiogram|A standard TTE will be undertaken to measure severity of AS as well as bi-ventricular function. Speckle-tracking data will be performed offline to assess diastolic function.
38370|NCT03883490|Diagnostic Test|Vicorder recording|Measurement of carotid-femoral PWV will be made using the Vicorder technique.
38371|NCT03883490|Diagnostic Test|Magnetic Resonance Imaging|Patients will undergo a stress MRI scan of their heart and aorta on a 3T scanner, including 4D flow.
38372|NCT03883477|Device|Endoscopic Release|Retrograde endoscopic release of the A1 pulley for treatment of trigger finger will be performed using a commercially available device by A.M. Surgical, Inc. This device has been cleared for marketing, sale and use by the U.S. Food and Drug Administration (FDA) for use as an Orthopedic manual surgical instrument based on its similarity in structure and function to previously used devices.
38373|NCT03883477|Procedure|Standard Open Release|Standard open surgical release of the A1 pulley for treatment of trigger finger.
38374|NCT03883464|Other|Diet|Restriction in postoperative fat diet
38375|NCT03883451|Other|Helmet Model|helmet model worn by football players
38376|NCT03883438|Procedure|Modified coronally advanced flap and acellular dermal matrix graft|Evaluation of the effectiveness of vertical incisions in the management of multiple gingival recessions (Miller Class I&II ≥3 mm) treated with coronally advanced flap and acellular dermal matrix graft
38377|NCT03883425|Other|interRAI-HC assessments|Standardized geriatric assessments done with the interRAI-HC instrument (Canadian French version 9.1) by trained nurses
38378|NCT03883412|Other|Exercise|16 weeks of treatment
38379|NCT03883412|Drug|Liraglutide|16 weeks of Liraglutide
38380|NCT03883399|Other|Survey|Survey among colorectal surgeons
38383|NCT03883373|Procedure|alveolar bone graft with cancellous bone and a cortical block|alveolar bone graft with cancellous bone only
38384|NCT03883373|Procedure|alveolar bone graft with cancellous bone only|alveolar bone graft with cancellous bone only
38385|NCT03883360|Drug|Cannabidiol (CBD)|Participants receive a single dose of CBD (600 mg p.o.) per day for 12 weeks.
38386|NCT03883360|Drug|Placebo|Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
38387|NCT03883347|Drug|Dexmedetomidine|Intravenous administration of dexmedetomidine 0.6 mcg / kg within 10 minutes prior to regional anesthesia and 0.6 mcg / kg / h after performing regional anaesthesia until the end of the surgery
38388|NCT03883347|Drug|Remifentanil|Intravenous administration of remifentanil 1 mcg / kg within 10 minutes prior to regional anesthesia and 0.025 mcg / kg / h after performing regional anaesthesia until the end of the surgery
38389|NCT03883334|Drug|Metisoprinol|Immunodulator
38390|NCT03883321|Other|Cognitive behavioral stress management|Management of patients in 10 group sessions with cognitive and behavioral therapies associated with relaxation in order to learn how to manage stress
38391|NCT03883308|Behavioral|Multi-domain cognitive training|The cognitive exercises are designed to train executive functions and memory.
38392|NCT03883308|Behavioral|Cross-word puzzle training|The active control group will be asked to complete a variety of crossword puzzles using the same curriculum assigned to the TG group.
38393|NCT03883295|Procedure|Control|The specimens will be root canal treated conventionally
38394|NCT03883295|Procedure|NeoMTA Plus|The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
38395|NCT03883282|Other|Not Provided|Not Provided
38396|NCT03883269|Drug|Erythromycin 4% topical gel formulation|Erythromycin 4% topical gel formulation, BID, 4 weeks
38397|NCT03883269|Drug|Clindamycin 1% topical lotion formulation|Clindamycin 1% topical lotion formulation, BID, 4 weeks
38398|NCT03883269|Drug|70% topical ethanol solution|70% topical ethanol solution, BID, 4 weeks
38399|NCT03883256|Device|high flow nasal cannula|High flow nasal cannula is a device that delivered heated and humidified high flow gases to at or near body temperature to avoid drying and possible injury to the nasal mucosa. In this study, subjects perform a constant-load exercise test with high flow nasal cannula.
38400|NCT03883256|Device|nasal cannula|Nasal cannula is a device that delivered oxygen to patients. In this study, subjects perform a constant-load exercise test with nasal cannula.
38401|NCT03883243|Device|Telecoaching|A telecoaching application linked to a step counter will be installed on a patients smartphone for 8 weeks. The application shows a daily goal (expressed as amount of steps per day) to the patient. This goal is weekly revised and patients themselves are able to increase the goal every week with 500 or 1000 steps/day. Every evening, they are able to check the daily feedback platform, which gives them insights in their physical activity pattern of the day and previous weeks. At a regular basis, 'tip of the day' messages appear as a pop-up, to keep patients motivated.
38402|NCT03883230|Diagnostic Test|GLYWD|As mentioned in the group description, GLYWD is a plastic test tube and a chromatic test that contains two solutions. When combined with a wound exudate and incubated at RT, it will change colour to red if there is a pathological bacterial wound infection present.
38403|NCT03883217|Device|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
38404|NCT03883204|Drug|Aripiprazole|Initial dose: 10 mg.
38405|NCT03883204|Drug|Risperidone|Initial dose: 2 mg.
38406|NCT03883191|Other|L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder|Taking 1 pack of L. rhamnosus bv-77, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics powder three times a day before meals for three months.
38407|NCT03883191|Other|Placebo|Taking 1 pack of placebo powder three times a day before meals for three months.
38408|NCT03883178|Procedure|Minimal-invasive endoscopic transgluteal approach|Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
38409|NCT03883165|Other|high-intensity neck strengthening|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a higher number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions,as well as dumbbell shoulder shrugs."
38410|NCT03883165|Other|low-intensity neck strengthening|All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions. Participants will perform a standardized set of general resistance exercises targeting the chest, shoulders, back, upper and lower extremities, and core. Additionally, they will also perform a lower number of repetitions of manual resistance neck strengthening exercises in sagittal plane flexion and extension, coronal plane lateral flexion in both directions, and axial plane rotation in both directions, as well as dumbbell shoulder shrugs.
38411|NCT03883165|Other|Control group|"All subjects will exercise 2 days per week for 12 weeks under the direct supervision of a study-assigned strength coach with a minimum of 1 day of rest between exercise sessions.~Participants will perform a standardized set of general resistance exercises targeting only the chest, shoulders, back, upper and lower extremities, and core, without resistance exercises specifically targeting the neck."
38412|NCT03883139|Behavioral|JASPER|JASPER is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by the adult's responses to the child.
38413|NCT03883139|Behavioral|DTT (Discrete Trial Training)|"DTT is an adult-led, highly structured, behavioral teaching approach, is considered to have the strongest evidence as a standard of care for young children with autism. DTT emphasizes didactic, adult-led instruction."
38414|NCT03883126|Behavioral|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
38415|NCT03883126|Behavioral|Contingency management|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
38416|NCT03883113|Biological|MVA-NP+M1|Trial Vaccine
38417|NCT03883113|Biological|Saline|Sodium Chloride Placebo
38418|NCT03883113|Biological|H3N2 (A/Belgium/2417/2015)|Challenge Agent
38419|NCT03883100|Drug|HQP1351|40 mg tablet, taken orally once every other day
38420|NCT03883087|Drug|HQP1351|40 mg tablet, taken orally once every other day of a 28-day cycle
38421|NCT03883074|Device|hyaluronic acid with chondroitin + sulphate + magnesium trisilicate|Melt in mouth tablets (1100 mg)
38422|NCT03883074|Device|Placebo|tablets with the same aspect of the active device
38423|NCT03883061|Other|regular medical treatment|regular medical treatment
38424|NCT03883048|Other|Observation of bronchiectasis with pulmonary hypertension|Interleukin 1 beta, IL - 18, endothelin 1 in peripheral blood and bronchoalveolar lavage from patients will be examined through enzyme linked immunosorbent assays (ELISA). NLRP3 inflammasome, ASC, Caspase 1 mRNA expression from peripheral blood mononuclear cells and mucous membrane of the bronchial lung tissues will be examined through RT-PCR method.
38425|NCT03883035|Other|DCNN-based models|DCNN-models could assist the endosocopists of experimental group in real-time
38426|NCT03883022|Drug|with U-VANCO (vancomycin hydrochloride)|1 gm or 2 gm mixed with autogenous cancellous bone graft
38427|NCT03883022|Drug|without U-VANCO (vancomycin hydrochloride)|no vancomycin added
38428|NCT03882996|Drug|Ezetimibe|Ezetimibe 10 mg daily in the morning
38429|NCT03882996|Drug|Atorvastatin|Atorvastatin 10 mg daily in the morning. Atorvastatin dose could be titrated up (by doubling the dose up to a maximum of 80 mg daily) to achieve the target low-density-lipoprotein cholesterol (LDL-C) level of 100 mg/dL (2.59 mmol/L) after a minimum of 4 weeks of treatment.
38430|NCT03882983|Drug|Antria Cell Preparation Process|"Biological/Vaccine: Stromal Vascular Fraction The SVF obtained from adipose tissue will be added to the graft~Other Names:~Stromal Vascular Fraction~Adiployx Biological/Vaccine:"
38431|NCT03882970|Drug|Tirzepatide|Administered SC
38432|NCT03882970|Drug|Insulin Degludec|Administered SC
38433|NCT03882957|Behavioral|Sustained attention|participants will complete a sustained attention task
38434|NCT03882957|Behavioral|media multi-task|participants will complete multiple media tasks at the same time
38435|NCT03882957|Other|Video|participants will watch a video of media tasks being completed
38436|NCT03882931|Other|Theta Burst Transcranial Magnetic Stimulation|Theta Bursts are short bursts of stimulation at high frequencies, which are applied 5 times per second
38437|NCT03882931|Other|Focused Ultrasound|Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
38438|NCT03882931|Other|Sham|The investigators will simulate theta bursts pulses similar to the Theta Burst Transcranial Magnetic Stimulation groups but without stimulation.
38439|NCT03882918|Drug|OV101|Each subject will be titrated to his or her maximal tolerated daily dose, up to a maximum daily dose of 15 mg at bedtime.
38440|NCT03882905|Drug|Ezetimibe|10 mg tablet, oral, once daily
38441|NCT03882905|Drug|Placebo|one tablet, oral, once daily
38442|NCT03882905|Drug|Simivastatin|Once daily administration at dose to be determined
38443|NCT03882905|Drug|Statin|Statin administered orally once daily at dose determined by treatment prior to enrollment by personal physician
38444|NCT03882892|Drug|Ezetimibe|Ezetimibe 10 mg tablets
38445|NCT03882892|Drug|Atovastatin|Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg
38446|NCT03882892|Drug|Placebo|Placebo tablets matched to ezetimibe
38447|NCT03882879|Behavioral|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 6 months, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief
38448|NCT03882879|Behavioral|Pre-Intervention Study Visit|At the pre-intervention study visit, the study logistics will be reviewed, informed consent process will occur, the subject will complete a battery of pre-intervention assessments focused on overall mobility, gait, balance, mood, cognition, and quality of life, and the subjects will be prompted to share their expectations of and goals for the karate classes.
38449|NCT03882879|Behavioral|Bimonthly Online Survey|All participants in both arms will receive a personalized email every two months directing them to indicate how frequently they have attended karate classes, how frequently they have engaged in exercise, how frequently they have fallen, whether their PD medication regimen has changed, and they will complete brief surveys about mood, camaraderie, and overall quality of life.
38450|NCT03882879|Behavioral|6-month Study Visit|All participants in both arms will complete questionnaires and assessments of their PD symptoms, cognition, mood, camaraderie, and quality of life. Subjects will meet with a member of the study team to complete a series of physical and cognitive assessments. At this visit, subjects will review the initial expectations they shared at the pre-intervention visit and indicate if they thought their goals were achieved for the class.
38451|NCT03882879|Behavioral|12-month Study Visit|At the 12-month study visit, the assessments from the baseline and 6-month study visit will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
38452|NCT03882866|Procedure|3D-printed non-coplanar template|3D-printed non-coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed non-coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed non-coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
38453|NCT03882866|Procedure|3D-printed coplanar template|3D-printed coplanar template is used in the intervention group. Iodine-125 seed implantation therapy is assisted using 3D-printed coplanar template as a guide in patients with locally advanced pancreatic cancer. 3D-printed coplanar template is designed and printed according to a preoperative CT scan and treatment planning system.
38454|NCT03882853|Other|Conservative exercise group|The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
38455|NCT03882853|Other|Tree pose added exercise group|"The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed."
38456|NCT03882840|Biological|NK cell therapy|Infusion of itNK cells
38457|NCT03882814|Drug|pethidine|Pethidine 50 mg intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. Opioid analgesia (pethidine HCl - 50 mg I.M.) was given following amniotomy.
73520|NCT03609216|Procedure|Conventional Surgery|Undergo bladder sparing
38458|NCT03882814|Drug|Placebo - Concentrate|Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
38459|NCT03882801|Drug|MK-7264|In Periods 1 and 2 (7 days each) participants receive 4 tablets (180 mg) of MK-7264 QHS.
38460|NCT03882801|Drug|Placebo|In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
38461|NCT03882788|Drug|Isoflurane|"n volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.~Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB."
38462|NCT03882788|Drug|Fentanyl|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.~The anesthetic may be supplemented with dexmedetomidine 0.05 mcg/kg/hr but not to exceed 1.0 mcg/kg/hr. Narcotic-based anesthetic will be used by the cardiac anesthesia team and the CPB technician throughout the operative case."
38463|NCT03882788|Drug|Dexmedetomidine|"In narcotic based anesthetic technique, no volatile anesthetics will be used past induction.~Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.~The anesthetic may be supplemented with dexmedetomidine 0.05 mcg/kg/hr but not to exceed 1.0 mcg/kg/hr. Narcotic-based anesthetic will be used by the cardiac anesthesia team and the CPB technician throughout the operative case."
38464|NCT03882788|Device|Electroencephalogram|EEG monitoring will be done for baseline in the pre-operative period for 15-20 minutes, during surgery and post-operatively up to 48 hours and prior to discharge for 15-20 minutes.
38465|NCT03882788|Behavioral|Bayley III|Neurological and behavioral testing with Bayley Exam III will be done at 18-24 months after anesthesia exposure.
38466|NCT03882775|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute STEMI during emergency PCI operation.
38467|NCT03882775|Drug|Heparin|heparin with or without gpi during emergency PCI.
38468|NCT03882762|Drug|Cebranopadol 200 μg tablet|200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.
38469|NCT03882736|Procedure|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two different well-known flaps for gluteal augmentation
38470|NCT03882723|Device|Evaluated masks used for NIV with mechanical ventilators|Order of the masks were randomly chosen. Investigators randomly assigned all masks for paper raffling from container. All subjects performed 20 minutes on each mask followed by 5 minutes wash out interval between masks. EPAP levels will be 0, 2, 4, & 5 (5 minutes for each level) while IPAP remains at 5 higher than EPAP. FiCO2 and EtCO2 were collected at 4:00, 4:30 and 5:00 minute mark for each EPAP level. Also, subjective mask comfort was assessed via visual analog scale (VAS) with 1 referring to least comfortable and 5 being the most comfortable after 5 each EPAP setting.
38471|NCT03882710|Drug|Metoprolol XR|Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
38472|NCT03882684|Diagnostic Test|In-situ imprinting detection|The loss of imprinting (LOI) and copy number variation (CNV) from biopsies will be tested by LiSen in-situ imprinting detection.
38473|NCT03882671|Device|EpiTel Epilog|EEG recording device
38474|NCT03882671|Device|Empatica E4|PPG, sweat level, temperature and accelerometry recording device
38475|NCT03882671|Device|GENEActiv|Temperature, light level and accelerometry recording device
38476|NCT03882645|Other|China Heart Diet|"This study took the DASH Diet as the basic model and developed a China Heart Diet (CHD) according to the principles in the 2016 dietary guidelines for Chinese residents. The nutrients compositions in CHD are set as following: fat % of total kcal: 25-27% (saturated: 6%; monounsaturated: 12%; polyunsaturated: 8%); carbohydrate % of total kcal: 55-60%; protein % of total kcal: 17-19%; dietary fiber: 30 mg/day; sodium: 3000 mg/day; potassium: 3700 mg/day; magnesium: 500 mg/day; calcium: 1200 mg/day. We will measure the actual intake of every meal for all subjects during 4-week intervention to better estimate their nutrients compositions. All subjects will be advised to avoid other food during the study period, and we collect the information of them if they eat."
38477|NCT03882645|Other|traditional diet|The nutrients compositions in traditional diet are set as following: fat % of total kcal: 32-34% (saturated: 15%; monounsaturated: 11%; polyunsaturated: 7%); carbohydrate % of total kcal: 50-55%; protein % of total kcal: 10-12%; dietary fiber: 10.8 mg/day; sodium: 5700 mg/day; potassium: 1616 mg/day; magnesium: 330 mg/day; calcium: 366 mg/day. These sets mainly come from national nutrition survey. We will measure the actual intake of every meal for all subjects during 4-week intervention to better estimate their nutrients compositions. All subjects will be advised to avoid other food during the study period, and we collect the information of them if they eat.
38478|NCT03882632|Device|Fat Grafting for Fecal Incontinence|Autologous adiopse tissue harvesting/grafting using Lipogems
38479|NCT03882619|Behavioral|Calligraphy|Participants will (1) detect the emotion him or herself; (2) do the calligraphy activity by writing positive terms (e.g., peace, life); (3) detect emotion again; (4) share the experience with group members.
38480|NCT03882606|Device|Scharioth Macula Lens (SML, Medicontur)|magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient
38481|NCT03882593|Procedure|Analysis of arterial filters after CPB|At the end of surgery, the arterial filter is withdrawn from cardiopulmonary bypass circuit to be prepared and analysed by SEM.
38482|NCT03882580|Drug|Anti-Cancer Agents|Drugs and treatments used in cancer inducing cardiovascular and metabolic side effects
38483|NCT03882567|Other|Electro Neuro adaptative Regulator|The SCENAR device has been previously described and generates high-amplitude, pulsed, damped biphasic sinusoidal current that is delivered to the tissue via a pair of concentric electrodes placed in direct contact with the target area. The intensity of the interactive waveform adjusts in response to changes in skin impedance
38536|NCT03882073|Procedure|Standard amputation procedure|Amputation is performed via standard techniques at either the BEA or AEA level. No construction of agonist-antagonist muscle pairs will be performed.
38537|NCT03882060|Drug|erythropoietin|Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
38484|NCT03882554|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
38485|NCT03882541|Other|Music therapy|To evaluate the effect of music in patients anxiety and pain during perioperative process in surgical intervention with regional anaesthesia without sedatives or anxiolytics.
38486|NCT03882541|Drug|Sedation with midazolam|To evaluate the effect of sedation (in comparation with music group) in patients anxiety and pain durin perioperative process in surgical intervention with regional anesthesia without music
38487|NCT03882528|Biological|Plasmodium falciparum malaria parasite|Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
38488|NCT03882515|Other|Myofascial Release|With the right hand in hand exerts caudal pressure in the superior fibers of the muscle, both sides by a minute and a half each. In the ventral decubitus, apply pressure and slip from T12 to the base of the skull nine times. Thumb in the individual's acromion and with the other to hold the pressure and slide in the direction of the other acromion three times. Hand at the base of the skull and with the contralateral tenar region perform pressure and slip in caudal direction on both sides by three times. Hand at the base of the skull and with the contralateral thumb exerting pressure and slip of C3 the distal insertion of the upper fibers on both sides. Thumbs at the base of the skull, exerting lateral traction of the fascia in opposite directions. Dorsal decubitus, thumbs above clavicles, perform detachment of fibers for one and a half minutes. Patient sitting, support the head of the metacarpals beside the spinous process from T1 to T12 and exert pressure and slip three times each.
38489|NCT03882515|Other|Continuous Surface Slip Technique|"Individual in the ventral decubitus, position the entire palmar surface bilaterally in the spinous process of T1 in the caudal direction, performing superficial smoothing in a smooth and rhythmic movement up to T12.~Return of the hands from the caudal direction towards the cranial direction, bypassing the lateral borders of the trapezius muscle following the direction of the inferior, middle and superior fibers.~Continue surface smoothing with a smooth and rhythmic movement until the distal insertion of the trapezius upper fibers into the skull and resume step 1 slowly and continuously for 10 minutes."
38490|NCT03882515|Other|Without intervention|Evaluation and re-evaluation without intervention
38491|NCT03882502|Other|anodal transcranial direct current stimulation (tDCS)- accompanied naming therapy or sham stimulation|anodal tDCS or sham stimulation will be combined with an intensive naming training and the number of items that could be named will be assessed immediately after the intervention.
38492|NCT03882489|Drug|Isobaric 2-chloroprocaine|The doses of isobaric 2-chloroprocaine will be administrated intrathecally and will be adjusted according to the observed responses in the previous subjects.
38493|NCT03882476|Diagnostic Test|InSight|Clinical decision support (CDS) system for sepsis detection
38494|NCT03882463|Device|Continuous glucose monitoring with the stop insulin pump function|"Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology."
38495|NCT03882450|Procedure|Flexible fiberoptic laryngoscopy|Flexible fiberoptic laryngoscopy with examination and video documentation of laryngeal function preoperatively (if the participant is not intubated and is stable enough to do so) and postoperatively with a 2.4mm flexible laryngoscope will be performed.
38496|NCT03882450|Procedure|Laryngeal ultrasonography|Laryngeal ultrasonography will be performed using a portable ultrasound system while the participants are awake.
38497|NCT03882437|Biological|RP-A501|RP-A501 is a gene therapy product consisting of a rAAV9 capsid containing the human LAMP2B transgene which will be administered as a single IV infusion.
38498|NCT03882424|Biological|TRS003|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
38499|NCT03882424|Biological|China-approved Bevacizumab|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
38500|NCT03882424|Biological|US-licensed Avastin|25mg/mL (4 mL/vial) Injection，Single dose of 3mg/kg Intravenous infusion for 90 minutes
38501|NCT03882411|Behavioral|Electronic shared decision making (eSDM) tool|The web application includes depression screening, behavioral activation, and a patient preference driven treatment selection decision aid. Treatment options will include medications, cardiac rehab/exercise program, and therapy. Providers will receive a patient preference report in real time with options for coordination of care.
38502|NCT03882398|Other|Balance|"Balance program (10 minutes)~Balance on bosu ball and ball drills Coordination in rings with single leg stance and ball drills Straight line walk with head up Straight line walk and hip flexion, knee flexion and head up~(Duration: 10 minutes. Sets: 2 minutes per exercise. Rest: 30 seconds between exercises)"
38503|NCT03882398|Other|Endurance|"Progressive-cycle program (15-25 minutes)~Warming up Pedalling with 0 resistance (2 minutes)~Main Part* Week 1-2 : 3x2 minutes Week 3-4 : 4x2 minutes Week 5-6 : 5x2 minutes Week 7-8 : 6x2 minutes~Return to resting stage Pedalling with 0 resistance (1 minute)~(*Pedalling with resistance set at 3-4. Rest: 2 minutes between sets or 120 beats/minute. One more set added every two weeks and workout intensity maintained at 70% of heart rate reserve-HRR)"
38504|NCT03882372|Device|Nasal high flow|See arm description.
38538|NCT03882060|Drug|Normal saline|Control group, no intervention.
38539|NCT03882047|Drug|Mometasone furoate|Mometasone furoate nasal spray, 200 mg once daily
38540|NCT03882047|Drug|Fluticasone propionate|Fluticasone propionate nasal spray, 200 mg once daily
38541|NCT03882047|Drug|Mometasone furoate placebo|Mometasone furoate placebo matching nasal spray, once daily
38542|NCT03882047|Drug|Fluticasone propionate placebo|Fluticasone propionate placebo matching nasal spray, once daily
73521|NCT03609216|Procedure|Radical Cystectomy|Undergo radical cystectomy
38505|NCT03882359|Diagnostic Test|Echocardiogram|"Images will be recorded in parasternal long, short axis, apical four, two, and three chamber views according to the American Society of Echocardiography (ASE) 17 segment model. Each assessment will include one round of low MI imaging (<0.3) and one round of very low MI imaging (<0.2) in each of the pre-specified windows according to the 2014 ASE Sonographer Guidelines.~A baseline echocardiogram will be performed prior to the administration of DEFINITY® or MVT-100. Assessments will be made three times, once from 0 - 1 ½ minutes following injection, once between 1 ½ minutes to 3 minutes following IV injection and once from 3 - 4 ½ minutes following IV injection. Assessments at each time point will include one round of low MI imaging (<0.3) and one round of very low MI imaging (<0.2). Each round will include the views in the following order: parasternal long, parasternal short, apical 4, apical 2 and apical 3."
38506|NCT03882359|Drug|MVT-100|After randomization, MVT-100, the experimental drug, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
38507|NCT03882359|Drug|Definity|After randomization, Definity, the active comparator, is administered via IV infusion or bolus administration and echocardiograms are subsequently obtained.
38508|NCT03882346|Combination Product|LifeLiver|LifeLiver is an extracorporeal bioartificial liver (BAL) system. The system has shown remarkable detoxification capacity and sustained hepatic functions and also provides a bridge to transplant for patients who are unable to receive timely liver transplantation.
38509|NCT03882333|Other|Acute exercise|30 min acute exercise (bicycle at stationary cycle)
38510|NCT03882320|Procedure|Patient Controlled Analgesia (PCA)|Patient Controlled Analgesia (PCA)
38511|NCT03882307|Drug|sofosbuvir and daclatasvir|oral tablets
38512|NCT03882294|Other|Probiotics|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
38513|NCT03882294|Other|Placebo|Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
38514|NCT03882281|Drug|HQP1351|Orally, single dose of 30mg on day 1 and day 8.
38515|NCT03882268|Behavioral|MIYCN interventions|"Capacity building for health provider and nutritional counselors (training on MIYCN SBCC from A&T)~Available and dedicated space for MIYCN counseling with standard layout, logo and specifications.~Availability of standardized MIYCN-specific BCC materials and job aids~Regular counseling services offered by a dedicated counselor hired by A&T~Routine counselling on IFA and calcium supplementation from dedicated counselor during ANC contact~Counseling on weight monitoring and availability of standard weighing scales~Breastfeeding and complementary feeding related counseling regularly offered as a service by a dedicated counselor~Dedicated community worker to identify and mobilize beneficiaries needing services in the community; use of mass media to improve awareness; scheduled follow ups"
38516|NCT03882255|Drug|Ponesimod dose range (2 - 20 mg)|Participants will receive ponesimod oral tablet at a dose of 2 mg in Treatment period 1 and as an up-titrating regimen (dose range: 2mg-20mg) in Treatments period 2.
38517|NCT03882255|Drug|Placebo Propranolol|Participants will be administered placebo propranolol oral capsule from Day 1 to Day 19 in Treatment A of Treatment period 2.
38518|NCT03882255|Drug|Propranolol 80 mg|Participants will receive propranolol 80 mg long acting oral capsule from Day 1 to Day 19 in Treatment B of Treatment period 2.
38519|NCT03882242|Behavioral|Facilitation of a school-based program|Participants deliver the prevention program (described in previous research) to school-children.
38520|NCT03882229|Device|MED-EL CI and ABI systems|"Cochlear Implant (CI) and external audio processor~Auditory Brainstem Implant (ABI) and external audio processor."
38521|NCT03882216|Procedure|soft tissue augmentation using pouch technique|crestal incision with split thickness flap without vertical releasing incision till the mucogingival line then apply the harvested connective tissue graft through it.
38522|NCT03882216|Procedure|soft tissue augmentation using modified pouch technique|tunneling will be done at the pontic site till the mucogingival line then a distant vertical incision near the tunnel at the lining mucosa where the harvested connective tissue graft wll be applied .
38523|NCT03882203|Drug|CLAME-FluBu|Cladribine combined with cytarabine and mitoxantrone/VP16 sequential with Fludarabine combined with busulifan
38524|NCT03882190|Drug|GnRHa|patients in the experimental group are supposed to receive GnRHa preoperatively and postoperatively according to their individual situation
38525|NCT03882177|Drug|Pravastatin|Tablets, administered orally
38526|NCT03882177|Drug|Rifafour|Fixed-dose combination (isoniazid, rifampin, pyrazinamide, and ethambutol) tablets, administered orally
38527|NCT03882177|Dietary Supplement|Vitamin B6|Administered orally.
38528|NCT03882164|Diagnostic Test|Blood-Bile Ratio of Tacrolimus|Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
38529|NCT03882151|Diagnostic Test|electrical source imaging|automated analysis of surface EEG with electrocal source imaging
38530|NCT03882138|Procedure|open flap debridement|Modified Widman flap surgery followed by meticulous debridement, root planning and thorough irrigation with normal sterile saline solution
38531|NCT03882125|Behavioral|Mindfulness-based relapse prevention|Psychosocial intervention integrating mindfulness practice and cognitive behavioral relapse prevention approaches
38532|NCT03882112|Drug|HIP1601 40mg|Single dosing of HIP1601 40mg, orally
38533|NCT03882099|Diagnostic Test|Determination of Vitamin D by ELISA|Blood samples
38534|NCT03882086|Other|foot reflexology|Four sessions foot reflexology was applied for 15 minutes in each foot, every other days between postpartum 14th- 20th day
38535|NCT03882073|Procedure|Modified amputation procedure|A fishmouth incision will be made. Radial and ulnar (BEA) or humoral (AEA) osteotomies will be performed. Segments of the flexor carpi radialis (FCR), extensor carpi radialis longus (ECRL), flexor digitorum profundi (FDP), extensor digitorum communis (EDC), flexor pollicis longus (FPL) and extensor pollicis longus (EPL) will be isolated, as well as the biceps (B) and triceps (T) groups in the AEA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. Sensory nerve endings of the distal median, ulnar and radial nerves will then be isolated and redirected to discrete skin patches in the proximal residual forearm or proximal brachium. Coaptation of the FCR/ECRL, FDP/EDC, FPL/EPL and B/T muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
38543|NCT03882034|Drug|Pegvisomant|"A fixed dose of pegvisomant 10-mg started on Day 1 of intervention and continued daily afterwards, will be administered subcutaneously according to manufacturer s recommendations. Thereafter, we will titrate the dosage to normalize serum IGF-1 concentrations as follows:~Increase the dosage by 5 mg increments every 4-12 weeks according to the study schedule of activities, if IGF-1 concentrations are greater than +2 SD for age and gender, to a maximum dose of 30mg per day.~Decrease the dosage by 5 mg decrements every 4-12 weeks according to the study schedule of activities, if IGF-1 concentrations are below -2 SD for age and gender, to a minimum dose of 5mg."
38544|NCT03882021|Procedure|A specific electrophysiology mapping protocol is applicable with the GRID catheter.|The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.
38545|NCT03882008|Drug|Abatacept|All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
38546|NCT03881995|Drug|IGlarLixi|Dose titration will be done based on the subjects fasting blood glucose
38547|NCT03881995|Drug|Insulin Glargine 100 UNT/ML|Dose titration will be done based on the subjects fasting blood glucose
38548|NCT03881982|Other|PIMPERNEL Novel Electronic Log: Pain display can be seen|Pain scores are displayed on the screen when the participant presses the corresponding button
38549|NCT03881982|Other|PIMPERNEL Novel Electronic Log: Pain display is hidden|Participants press the buttons to record their pain score but the score is not on display (the screen is turned backwards).
38550|NCT03881969|Behavioral|Financial Payment of £100|No financial payment
38551|NCT03881956|Behavioral|Health-promoting lifestyle education program|The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
38552|NCT03881943|Drug|Ticagrelor 60 mg|Potent antiplatelet agent, 60mg twice daily for 3 months
38553|NCT03881943|Drug|Aspirin 100 MG Oral Tablet, Enteric Coated|antiplatelet agent, 100mg once daily for 3 months
38554|NCT03881930|Other|Balance rehabilitation with modified visual input|Patients will perform the exercises alternatively: while keeping their eyes closed or their vision will be obstructed by a opaque mask or disturbed by moving luminous dots projected on the environment in a dark room without any visual reference cues.
38555|NCT03881930|Other|Balance rehabilitation with no modified visual input|Patients will perform the exercises while keeping their eyes openned
38556|NCT03881917|Diagnostic Test|Cystatin c and beta 2 microglobulin kits|Kits for measurement concentration
38557|NCT03881904|Drug|0.075mg gestodene/0.03mg ethinylestradiol|OCPs will be started from day 2 of the cycle preceding COH and continued for 21 days, then induction of ovulation using antagonist protocol will be started.
38558|NCT03881891|Behavioral|Follow-app intervention arm|The intervention includes implementation and evaluation of the effectiveness of a mobile phone-based text messaging system (FollowApp.Care) to collect patients' assessments of their post-op symptoms (pain intensity) and to use that data to improve their quality of care (pain experience) in the dental office setting
38559|NCT03881878|Drug|TAHP and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Tastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~Atezolizumab (1200mg, IV)~Trastuzumab (600mg, SC)~Pertuzumab (420mg, IV)"
38560|NCT03881878|Drug|TAHP plus AC and AHP|"(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~Docetaxel (75mg/m2, IV)~Atezolizumab (1200mg, IV)~Tastuzumab (600mg, SC)~Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks"
38561|NCT03881852|Drug|AXS-12 (Reboxetine)|Dosed orally, twice daily for up to 3 weeks
38562|NCT03881852|Drug|Placebo|Dosed orally, twice daily for up to 3 weeks
38563|NCT03881839|Other|emergency|The objective of this research will be to assess, in patients presenting in an emergency department, the prior consultation of medical information on a website, the impact on the emergency consultation decision and the relevance of this consultation.
38564|NCT03881826|Other|collection of clinical data and biological samples|"nutritional assessement~cachexia symptoms~urine, feces and blood samples"
38565|NCT03881813|Device|Orthodontic retainers|Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
38566|NCT03881800|Other|titration- blood sample|Ceftazidime titration
38567|NCT03881787|Drug|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
38568|NCT03881787|Drug|Cetuximab injection|Cetuximab injection
38569|NCT03881774|Biological|CAR-T cells|collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
38570|NCT03881761|Biological|CD19/CD20 bispecific CAR-T cells|collecting blood for CAR-T cells culture three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CD19/CD20 bispecific CAR-T cell with a dose of 1-3x106/kg
38571|NCT03881748|Other|Manual acupuncture|"Manual acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes."
38658|NCT03881059|Drug|BMS-986165 Dose B|Participants will receive BMS-986165 dose B QD.
38572|NCT03881748|Other|Electro-acupuncture|"Electro-acupuncture twice a week for 20 treatments.~Acupuncture will be administered on an outpatient basis in private rooms with participants lying supine. The acupuncturist will disinfect the selected acupuncture points with alcohol and then needle them so that the participant achieves a de qi sensation if possible, which is often described as a pressure or achiness feeling. Acupuncture needles will be left in place for approximately 20 minutes.~Electrical stimulation will be applied to the needles concomitantly and continuously to acupuncture points by placing lead wires on the needles connected to an electro-acupuncture stimulator such as the Model IC-1107. The stimulator will be set on the Dense-Disperse wave setting with low frequency at 2-10 Hz and high frequency at 100-110 Hz. The needles will not be manually stimulated after electrical stimulation is applied."
38573|NCT03881735|Drug|Enasidenib|Given PO
38574|NCT03881735|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
38575|NCT03881722|Dietary Supplement|Mg alginate|Mg alginate after feedings
38576|NCT03881709|Behavioral|Using an E-Book|The intervention group will receive the biopsy decision support intervention delivered by a nurse using an E-Book containing a comprehensive information about prostate biopsy.
38582|NCT03881683|Diagnostic Test|HRD and BRCA mutations|Compare BRCA1/2 and HRD genes mutation detected from blood sample (20 ml) and biopsy
38583|NCT03881670|Device|Lotrafilcon B|commercially available contact lens
38584|NCT03881670|Device|lotrafilcon B with Hydraluxe|commercially available contact lens
38585|NCT03881657|Behavioral|Reverse Colocated Integrated Care|A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.
38586|NCT03881657|Behavioral|Usual Care|Behavioral health services without primary care or integrated care services
38587|NCT03881644|Drug|Imigran|All patients will undergo this intervention on one of two study days
38588|NCT03881644|Other|Isotonic Saline|All patients will undergo this intervention on one of two study days
38589|NCT03881644|Other|Pituitary adenylate cyclase-activating peptide-38|All patients will undergo this intervention on both study days
38590|NCT03881631|Behavioral|Mindfulness Based Stress Reduction Program|Group-based intervention
38591|NCT03881631|Behavioral|Living Well Program|Group-based intervention
38592|NCT03881618|Procedure|electroacupuncture+auricular pressure,|electroacupuncture+auricular pressure for 20 minutes
38593|NCT03881605|Diagnostic Test|MRI screening|A standard contrast-enhanced MRI and Chemical Exchange Saturation Transfer (CEST) MRI of the brain will be performed at baseline, 4 months, 8 months and 12 months.
38594|NCT03881579|Behavioral|nurse-led supportive care assessment|Trained project nurses will conduct systematic assessment and provide coaching to patients in the experimental arm
38595|NCT03881553|Device|NEATCAP|NEATCAP: Neurosensory, Environmental Adaptive Technology is a sound attenuating earmuff that reduces unsafe high-frequency noise.
38596|NCT03881553|Device|SVS mattress|SVS mattress: Stochastic Vibratory Stimulation is a mattress that provides gentle, random, vibrotactile stimulation.
38597|NCT03881540|Other|tDNA-MI group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements and motivational interviewing counseling. .
38598|NCT03881540|Other|tDNA-CC group|tDNA care with structured low calorie meal plan of 1200-1500 kcal/day with conventional foods + 1-2 serving of diabetes specific meal replacements+ 150 min/week of moderate intensity exercise + and conventional counselling.
38599|NCT03881540|Other|UC group|Meal plan of 1200-1500 kcal/day using conventional foods + 150 min/week of moderate intensity exercise + and conventional counselling
38600|NCT03881527|Device|Aortic valve replacement using a nitinol blade|A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure
38601|NCT03881527|Procedure|aortic valve replacement|Aortic valve replacement in a standard fashion
38602|NCT03881488|Drug|CTX-471|IV infusion every 2 weeks
38603|NCT03881475|Other|questionnaire|"During consultations in occupational medicine (periodic visit and / or visit at the request of the employee), the nurses (or physicians) will propose the passation of the questionnaire to the voluntary agents.~The questionnaire, composed of 79 items with 2 validated questionnaires (HAD and MBI), will be filled using a digital tablet (via the REDCAP software).~Time required to complete the questionnaire 10 minutes."
38659|NCT03881059|Drug|Ustekinumab|Participants will receive ustekinumab SQ injection QD.
38660|NCT03881059|Other|Ustekinumab Placebo|Participants will receive ustekinumab SQ matching placebo QD
38733|NCT03880409|Drug|2% lidocaine with 1:000,000 epinephrine|2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
38604|NCT03881462|Procedure|Axillary nerve block for artificial deltoid muscle palsy|"Axillary nerve block block (AXNB):~The ultrasound probe is placed transversally in the infraclavicular region with the arm in 90° abduction. The brachial plexus and its cords are identified l lateral to the brachial artery. The posterior cord is identified by ultrasound and is blocked - or, if the axillary nerve visible too - the axillary nerve is selectively blocked when it leaves the posterior cord and lies on the subscapular muscle accompanied by the posterior circumflex humeral artery. Using an in-plane technique, a short bevel connected to a nerve stimulator with the setting 0.5 mA current intensity, 0.1 ms impulse duration and 2 Hz impulse frequency for dual guidance, will be advanced until its tip is positioned near the nerve without eliciting motor contractions. After careful negative (for blood) aspiration local anesthetic will be applied until the targeted neuronal structure is surrounded by the injected fluid."
38605|NCT03881449|Combination Product|ABILIFY MYCITE|Initiation of ABILIFY MYCITE will commence immediately, with subjects wearing the patch and using the smartphone app for a total of 3 months from baseline visit to the 3 month visit. Following the initial 90-days, the physician and patient may determine to use ABILIFY MYCITE anytime during the following 9 months. Following this period (up to 12 months), the subjects will not use ABILIFY MYCITE and return to standard care. A safety follow-up phone call will occur at 2 weeks after the 12 month/early termination (ET) visit. In addition, individuals in the ABILIFY MYCITE arm will evaluate satisfaction with the use of ABILIFY MYCITE.
38606|NCT03881436|Diagnostic Test|MRI with DTI sequence|"At the end of the planned sequence, but before any contrast agent injection:~Acquisition of a an additional anatomical T2 SPACE sequence~Acquisition of a tractography DTI sequence"
38607|NCT03881423|Drug|Rocuronium Bromide|DEEP block to PTC 1-3
38608|NCT03881410|Procedure|different types of ultrasound technique|Shear-wave elastography-guided or Convention ultrasound-guided
38609|NCT03881397|Behavioral|Family Media Use Plan|A tool developed by the American Academy of Pediatrics that engages teens and parent to discuss internet safety ideas and develop rules around technology use together.
38610|NCT03881397|Behavioral|Media Use Resources Awareness|Resources offered to parents and teens that include tools and publicly available resources for safe technology use among teens
38611|NCT03881384|Other|ctDNA level during neoadjuant chemotherapy|Draw blood from each enrolled patient every time before chemotherapy and measure the ctDNA level in plasma.
38612|NCT03881371|Drug|Safinamide|At baseline (Day 1), eligible patients will be randomised to receive safinamide (initial 50 mg titrated to 100 mg the day after the Visit 3/week 2, ideally at day 15). The investigational medicinal product (IMP) will be taken in the morning at breakfast time, in addition to the morning dose of L-dopa and other (if any) PD medications.
38613|NCT03881371|Other|Placebo|At baseline (Day 1), eligible patients will be randomised to receive matching placebo, orally OD. Placebo will be added to the standard stabilized treatment as a control of the safinamide group, hence patients on placebo will have benefit from other ongoing anti-PD medication
38614|NCT03881358|Device|ortho-k lenses and thinner spectacles|Conventinally designed (Emerald) ortho-k lenses (target for -4.00D) and thinner specs during day time
38615|NCT03881358|Device|newly designed ortho-k lenses|Newly designed (Topaz) ortho-k lenses for high myopia (target for full correction)
38616|NCT03881345|Drug|Anticoagulants|anticoagulation according to the main diagnosis
38617|NCT03881345|Procedure|Open surgery|removal of blood clots with open surgery
38618|NCT03881345|Procedure|Thrombolysis|removal of blood clots with thrombolysis
38619|NCT03881345|Procedure|Venous stenting|elimination of vein obstruction by stenting
38620|NCT03881319|Drug|Conventional gynecologic treatment|Taking NSAIDs or oral contraceptives.NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.
38621|NCT03881319|Device|Low dose acupuncture|Six acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Inner Pass(PC6)
38622|NCT03881319|Device|High dose acupuncture|Twelve acupoints: Three Yin Intersection( SP6)、Grandfather Grandson(SP4)、 Sea of Blood(SP10) 、Sea of Qi(RN6)、Origin Pass(RN4) 、Middle Extremity(RN3)、Inner Pass(PC6) 、Supreme Rush(LR3) 、Joining Valley(LI4) 、Supreme Stream(KI3) 、Uterus(EX-CA1) 、Leg Three Miles(ST36)
38623|NCT03881306|Procedure|D-TACE using CalliSpheres and Oxaliplatin|D-TACE for NEN liver metastases Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin
38624|NCT03881293|Drug|lidocaine 2% gel|Transurethral instillation of 5 ml lidocaine 2% gel
38625|NCT03881293|Drug|water soluble lubricant|Transurethral instillation of 5 ml water soluble lubricant
38626|NCT03881280|Behavioral|Parenting education program|"Parenting education program through the app Fammeal. It includes educational content, tailored to parents and centered on positive parenting child-feeding practices. The app will also include a virtual-pet game for children, in order to help them self-regulate their intake.~Through the app, parents will:~Fill in a registration questionnaire, which will tailor recommendations.~Receive information and video content recommendations.~Set goals related to their child's lifestyle and tracking progress.~Earn points by watching the contents.~Invite children to play a serious game.~Exchange messages with other users.~The investigators created a support website that connects to the main server to get data gathered from the mobile app and game."
38627|NCT03881267|Other|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
38628|NCT03881267|Other|Additional Outer Dressing Application|Application of Moisture retentive dressing, and a multi-layer compression dressing
38629|NCT03881267|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
38630|NCT03881254|Other|Human Autologous Homologous Skin Construct|Application of a autologous human derived skin polar units
38631|NCT03881254|Other|Additional Outer Dressing Applicaiton|Application of Moisture retentive dressing, and a multi-layer compression dressing
38632|NCT03881254|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
38633|NCT03881254|Other|Fibracol Wound Dressing|Application of Collagen Alginate Dressing
38634|NCT03881228|Behavioral|Increasing the completion of IPT|Behavioral intervention with three components to increase the completion of IPT among children
38635|NCT03881215|Procedure|Platelet Rich Plasma|Platelet Rich Plasma
38636|NCT03881215|Procedure|intra-uterine balloon|intra-uterine balloon
38637|NCT03881202|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
38638|NCT03881189|Device|SUNEKOS® 200|The intradermal injection procedure was performed bilaterally, on the area around the eyes including the eyelids, using periosteal and subepidermal injection techniques. This injective procedure consists of micro-wheals of 0.2 ml just above the periosteum and micro-wheals of 0.1 ml very superficially, just under epidermis.
38639|NCT03881176|Device|PoNS Treatment|"The study site will deploy either PoNS Treatment Schedule A or PoNS Treatment Schedule B. Both PoNS Treatment Schedules will consist of three stages: an in-clinic training program, a home training program, and an extended home training program.~During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week. Daily evening sessions and training sessions on weekends will always be performed independently, at-home by the subject"
38640|NCT03881163|Drug|N-acetylcysteine (NAC)|Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.
38641|NCT03881150|Other|Comprehensive assessment|Includes evaluation about physical activity, diet, tobacco consumption, overweight/obesity, blood pressure, self-efficacy, and medications. Additionally, levels of lipids and glycaemia will be reviewed from clinical chart.
38642|NCT03881150|Other|Counseling|Physical activity, diet, smoking, and medication compliance counseling will be provided by the physiotherapist across exercise sessions, using a self-efficacy approach. A booklet was designed in order to support the individual counseling.
38643|NCT03881150|Other|Group education|Group education sessions about physical activity, diet, smoking, and medication compliance (without individual counseling), as actually performed in each center.
38644|NCT03881150|Other|Exercise sessions in hybrid program|"10 supervised exercise sessions over 4-6 weeks of aerobic and resistance training will ensue, supervised by a physiotherapist. Exercise sessions are 10 minutes in duration at the beginning of the program, and are progressed to 60 minutes by the end as tolerated.~Intensity of exercise will be moderate."
38645|NCT03881150|Other|Exercise sessions in standard program|"18-22 supervised exercise sessions are delivered over the 8-12 week program. These sessions include aerobic and resistance training and a similar progression of duration as the experimental group.~Intensity of exercise will be moderate."
38646|NCT03881150|Other|Transition to unsupervised phase|After 4-6 weeks with face-to-face exercise sessions in hybrid program, all patients will be monitored through mobile technology. Delivery methods will include voice calls biweekly, and text messaging three per week through to 10-12 weeks from program initiation. The content will promote physical activity, healthy diet, and medication adherence.
38647|NCT03881137|Other|Geriatric assessment with management|"A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs.~The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT."
38648|NCT03881111|Biological|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
38649|NCT03881111|Drug|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
38650|NCT03881111|Drug|Cisplatin|80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
38651|NCT03881111|Drug|5-FU|800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
38652|NCT03881098|Procedure|Bronchoscopies|"Bronchoscopy: Your nose, throat, vocal cords and windpipe are sprayed with Lidocaine (numbing medicine) to help keep you from coughing and to numb your airways. A tube with either a white light or the fluorescent light (bronchoscopy) is put down through your nose or mouth into your throat. Your nose, throat, vocal cords and lungs will be checked for any unusual areas while the tube goes down. You might have medicine sprayed into your mouth. You may be given a shot into your vein or muscle to help you be more comfortable.~Endobronchial Biopsy: Very tiny pieces of lung tissue (about the size of the head of a pin) will be taken from the lining of your lungs using forceps and a small brush. These tissues will be taken to a laboratory and tested."
38653|NCT03881098|Procedure|Sputum Sample|Subjects will be asked to perform the early morning spontaneous cough technique over a six-day period to provide for pre-screening evaluations. If moderate atypia is detected in a pre-screening specimen, additional sputum samples will be collected prior to each subsequent bronchoscopy. If this cannot be performed prior to bronchoscopy with adequate results, the sputum collection may be done after bronchoscopy. The sputum will be collected in containers containing Saccomanno's fixative.
38654|NCT03881098|Procedure|Venipuncture|Thirty milliliters of blood will be withdrawn from each subject, and the blood will be sent to the biorepository for analysis and storage.
38655|NCT03881072|Other|Ultrasounicelastography|Observing the correlation between endometrial elasticity score, endometrial blood flow index (PI, RI, S/D, endometrial thickness, morphology) and clinical pregnancy rate.
38656|NCT03881059|Other|BMS-986165 Placebo|Participants will receive BMS-986165 matching placebo QD
38657|NCT03881059|Drug|BMS-986165 Dose A|Participants will receive BMS-986165 Dose A QD.
38661|NCT03881033|Other|Peep 5cmH2O|Face mask ventilation with peak inspiratory pressure according to the group P7+5 means face mask ventilation with peak inspiratory pressure 7cmH2O plus PEEP 5 cmH2O.
38662|NCT03881033|Other|Peak inspiratory pressure|Face mask ventilation with peak inspiratory pressure according to the group P12 means face mask ventilation with peak inspiratory pressure 12cmH2O without PEEP.
38663|NCT03881020|Drug|Silver diamine Fluoride 38%|In the intervention group 38% Silver Diamine Fluoride will be applied to the surface of the isolated lesion for a period of 1 minute followed by glass ionomer restoration at the same visit.
38664|NCT03881020|Procedure|Conventional atraumatic restorative treatment|In the active comparator group caries will be removed from primary molars using sharp excavators then teeth will be restored using glass ionomer filling material at the same visit.
38665|NCT03881007|Other|Mouthwash with LCM|Subjects will mouthwash daily with LCM and before/after sex
38666|NCT03881007|Other|Mouthwash with placebo|Subjects will mouthwash daily with placebo and before/after sex
38667|NCT03880981|Drug|Ibuprofen 600 mg|ibuprofen 600mg Po q 6 hours prn pain
38668|NCT03880981|Drug|Acetaminophen|acetaminophen 600mg po q6 hours prn pain
38669|NCT03880968|Drug|tapering or discontinuation of etanercept|Active AS patients initially managed with ETN 50mg weekly for 12 weeks, and then randomized into subgroups with different tapering or discontinuation strategies according to ASDAS at week 12. Patients who achieved inactive disease (ASDAS<1.3, group A) at week 12 were either assigned to sequential tapering group (A1) or discontinuation group (A2), and those who reached low disease activity (LDA) (1.3≤ASDAS<2.1, group B) were designated to sequential tapering group (B1), delayed tapering group (B2) or discontinuation group (B3).
38670|NCT03880955|Device|ReUnion RSA System|The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
38671|NCT03880942|Other|Informative story book|Patients will be given a colorful story book that tells the hospital and operation procedure named 'Elif Ameliyat Oluyor'(Elif is undergoing surgery) and will be asked to read the book with children at least once before the operation.
38672|NCT03880942|Other|Non Informative Story Book|Patients will be given a non-medical colorful story book called 'Çiftlik Öyküleri-Kamp' (Farm Stories-Camp) and will be asked to read the book with children at least once before the operation.
38673|NCT03880929|Other|no intervention|no intervention
38674|NCT03880916|Drug|Duloxetine|"Phase I (preemptive): 2weeks before operation (30mg for 2weeks)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)"
38675|NCT03880916|Drug|Placebo|Phase I (preemptive): 2weeks before operation (Placebo for 2weeks) Phase II (maintenance): 6weeks after operation (Placebo for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
38676|NCT03880903|Drug|normal saline and salbutamol|patients will recieve treatment with nebulized salbutamol and normal saline every 4 to 6 in hours
38677|NCT03880903|Drug|hypertonic saline and salbutamol|patients will recieve treatment with nebulized salbutamol and hypertonic saline 3% in adose of 4ml every 4 to 6 hours
38678|NCT03880903|Drug|Hypertonic saline|patients will recieve treatment with nebulized hypertonic saline 3% in adose of 4ml every 4 to 6 hours
38679|NCT03880890|Procedure|sphenoidotomy versus sphenoid nasalisation|sphenoidotomy opening of sphenoid sinus ostum and cleaning of the sinus sphenoid nasalization in which bilateral extended sphenoidotomy, the posterior aspect of the nasal septum is resected, along with the sphenoid rostrum, the intersinus septum, and other intrasphenoid partitions, creating a common cavity with a broad drainage pathway .
38680|NCT03880877|Drug|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
38681|NCT03880877|Genetic|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
38682|NCT03880877|Genetic|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
38683|NCT03880877|Genetic|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
38684|NCT03880877|Drug|Leucovorin and 5-FU|Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)
38685|NCT03880864|Radiation|Ultrasound|Lung ultrasound
38686|NCT03880851|Radiation|Plan adaptation of Radiation Treatment in case of anatomical changes|Image guided radiotherapy is given to 60Gy in 20 fractions. Intervention: Radiation treatment plan adaption in case of volume changes of target volume or not meeting OAR constraints due to volume changes.
38687|NCT03880838|Behavioral|Personal testimonial|Participants will receive a letter promoting a plant-based diet. This letter will feature a personal testimonial about the benefits of a plant-based diet. Presenting this information to participants might encourage them to make behavioral changes to improve their health.
38688|NCT03880838|Behavioral|Forks Over Knives Documentary|Participants will be mailed the documentary Forks Over Knives, which provides scientific arguments promoting a plant-based and whole foods diet. The behavioral effect of this documentary comes from watching the documentary and potentially choosing to order a free cookbook (participants are given this opportunity in the letter accompanying the documentary). The effect of the diet itself is not a central part of the intervention, as people can choose to adopt or not adopt any part of the diet.
38689|NCT03880838|Behavioral|Commitment nudge|At the end of the letter promoting a plant-based diet, participants will be asked to write dates and personal signatures committing to watching the documentary. They will be asked to mail back this written commitment. Stating one's intentions to implement certain behavior is meant to increase the likelihood of follow-up behavior. This request might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
38729|NCT03880422|Other|Educational Intervention|Attend educational meeting
38730|NCT03880422|Behavioral|Exercise Intervention|Complete exercise program
38690|NCT03880838|Behavioral|Prevention nudge|As part of the letter promoting a plant-based diet, one paragraph will describe the risks of not taking action. This phrasing reframes the status quo as contributing to future loss (e.g., costs of medication and operations). In effect, the letter encourages participants to focus on preventing this loss by taking action. This additional text might nudge more people to watch the documentary and make some behavioral changes to prevent negative health outcomes.
38691|NCT03880825|Drug|Metformin 500 mg Oral Tablet|single dose
38692|NCT03880825|Drug|Levoketoconazole 150 - 600 mg (BID)|escalating dose from 150 mg to 600 mg (BID)
38693|NCT03880812|Other|Societal cost|Annual societal cost information to the US for carpal tunnel release surgery was displayed.
38694|NCT03880799|Behavioral|Mindfulness Session|one hour mindfulness session conducted by a certified mindfulness teacher with the breast cancer patient
38695|NCT03880786|Device|pudendal PNE test lead|All patients eligible for release surgery will be implanted a PNE test lead (Medtronic) which will be placed (transforaminal or transgluteally) next to the pudendal nerve, at the level of the ischial spine, after surgical release and connected to an external stimulation device. The PNE lead will be fixed at the ischial-spinal ligament with an absorbable suture to prevent dislocation. If a bilateral dissection is needed, bilateral test leads will be placed. Stimulation will be switched on at the second postoperative day, according to the sensory threshold described by the patient. After three weeks the PNE test lead will be removed at the outpatient clinical visit.
38696|NCT03880773|Device|Stapler|for transection of the pancreas and pancreatic stump treatment
38697|NCT03880773|Device|ultrasonic shears|for transection of the pancreas and pancreatic stump treatment
38698|NCT03880760|Other|L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32|Taking 1 L. johnsonii MH-68, B. animalis subsp. lactis CP-9 and L. salivarius AP-32 mix probiotics capsule twice a day before meals for six months.
38699|NCT03880760|Other|Placebo|Taking 1 placebo capsule twice a day before meals for six months.
38700|NCT03880747|Procedure|Vagus nerve-preserving distal gastrectomy|Laparoscopic distal gastrectomy with the preservation of the celiac and hepatic branch of the vagus nerve.
38701|NCT03880734|Drug|Cholecalciferol|ingredients-Cholecalciferol (40,000 IU),Microcrystalline Cellulose (58.1 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
38702|NCT03880734|Other|Placebo oral capsule|ingredients- Microcrystalline Cellulose (303.8 gm),Butylated Hydroxy Toluene (0.2 mg),Magnesium Stearate (3 mg),Gelatin Capsule Shell (1 mg)
38703|NCT03880721|Procedure|Microwave abaltion|Use microwave ablation to treat hepatocellular carcinoma
38704|NCT03880695|Drug|Anlotinib+ Liposomal Doxorubicin|Anlotinib : 12 mg, qd, po day 8-21 every 3 weeks Liposomal Doxorubicin: 50 mg/m2, day 1 every 3 weeks
38706|NCT03880630|Other|Inspiratory muscle training|Patients will perform 3 inspiratory loading tests (15%, 30%, and 50% of maximum inspiratory pressures) on 3 separate days with the sequence will be randomized. Patient will then be trained with individualized IMT program based on the results of 3 inspiratory loading tests.
38707|NCT03880604|Procedure|Triple tourniquets|A number 1 polyglactin suture was tied around the cervix to occlude the uterine arteries, and polythene tourniquets were tied around the infundibulopelvic ligament to obstruct the ovarian vessels
38708|NCT03880604|Drug|TA|1-gram tranexamic acid (10 ml) in 100 ml saline infusion
38709|NCT03880604|Other|placebo to TA|placebo to 1-gram tranexamic acid (10 ml) in 100 ml saline infusion
38710|NCT03880578|Drug|Levothyroxine Sodium|thyroid hormone replacement
38711|NCT03880565|Device|Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation|Early use of ECMO
38712|NCT03880565|Device|Standard Advanced Cardiac Life Support (ACLS) Resuscitation|Standard life support resuscitation
38713|NCT03880552|Other|Primigravid women with singleton pregnancy at 35th week over|Primigravid women with singleton pregnancy at 35th week over; only observational study will be done in this group and the data will be recorded.
38714|NCT03880539|Drug|bezlotoxumab|Adding BEZLO to SOC oral VAN pulse/taper
38715|NCT03880539|Drug|Vancomycin Oral|SOC vancomycin pulse/taper
38716|NCT03880513|Diagnostic Test|Cardiovascular status and quality of life|Psychosocial and cardiovascular evaluation includes medical history, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, transthoracic echocardiography, cardiac MRI, and quality of life assessment
38717|NCT03880500|Other|Spinal Manipulative Therapy|The patient lies in sidelying position, with the hip of the upper leg flexed to 90° and the foot of the flexed leg hooked behind the popliteal space of the downside leg. The chiropractor faces the subject at a 45°-angle, fixates the flexed knee with his own knee/thigh. The fingers of the cephalic hand reach under the patient's upper arm to contact the upside lateral surface of the superior spinous process. The fingers of the caudal hand hook down-side aspect of the spinous process, the forearm contacts the patient's buttock and thigh. The cephalic hand thrusts lateromedially and caudocranially, from upside toward downside (push). The caudal hand thrusts lateromedially in the opposing direction, from downside toward upside (pull). SMT is repeated after the patient turns to left side lying.
38718|NCT03880487|Drug|KP-1199|Single dose and Multiple ascending doses of KP-1199 oral capsules
38719|NCT03880487|Drug|Placebo oral capsule|Single dose and Multiple dose identical to active treatment but without KP-1199.
38720|NCT03880487|Drug|Oxycodone oral capsule|10 mg Oxycodone Capsules
38721|NCT03880474|Biological|MVA-NP+M1|Trial Vaccine
38722|NCT03880474|Drug|Saline|Sodium Chloride Placebo
38723|NCT03880461|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention
38724|NCT03880448|Drug|Metronidazole|Metronidazole 500mg/8h/7days
38725|NCT03880448|Drug|Placebo|Cornstarch 500mg/8h/7days
38726|NCT03880448|Procedure|periodontal surgery|periodontal surgery
38727|NCT03880435|Device|Hyalobarrier® gel endo|Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, preoperatively immediate after the hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
38728|NCT03880422|Dietary Supplement|Dietary Intervention|Receive diet plan
38734|NCT03880409|Drug|4% articaine with 1:000,000 epinephrine|4% articaine with 1:000,000 epinephrine is dental local anesthesia
38735|NCT03880396|Radiation|hypofractionated Rth with platinol|hypofractionated Rth with weekly cisplatin 40mg/m2
38736|NCT03880383|Behavioral|Coaching|Parents will interact and communicate regularly with a coach in person or by telephone. Coaches will be responsible for: identifying developmental concerns, proactive health promotion, guidance and training for developmental stimulation, parent support and education about child development, navigation of the health care system and self-management techniques. The frequency of coaching will be: once a month (minimum), for 18 months, at an average of 2.5 hours per month.
38737|NCT03880383|Behavioral|Online parent education|Parents will be provided access to an online platform which will provide educational resources and access to parent-parent support. Online resources on child development are curated by researchers and representative of parent groups, and linked to this online platform. The themes covered in the online tool include resources on child development, accessing health care services and managing emotions and family dynamics. These topics range from: practical tips for managing day-to-day challenges, strategies to cope and support the child's transitions from one stage to another, practical tips when looking for developmental services for the child: knowing where and how to access services.
38738|NCT03880383|Behavioral|Online peer support|Parents will have access to a secure online social media tool to connect to other parents going through a similar experience. Through this tool, parents can help support each other, and share their experiences and knowledge. This will put each family at the centre of each network (family, friends, health providers), allowing family networks to link with one another. Families will be able to find resources, create connections with the coach, health providers and other families, thus creating a network to support one another.
38739|NCT03880370|Behavioral|Questionnaires / scales|EVA, ROLAND MORRIS, OWESTRY and Global Questionnaire of Physical Activity (GPAQ)
38740|NCT03880370|Diagnostic Test|Ultrasound imaging|Rectus abdominis dominant side & non-dominant side external oblique dominant side & non-dominant side internal oblique dominant side & non-dominant side transversus abdominis dominant side & non-dominant side lumbar multififidus l4-l5-s1 gluteus medius dominant side & non-dominant side
38741|NCT03880370|Diagnostic Test|FLEXIBILITY|weight-bearing lunge hip lateral rotation straight leg raise fingertip to floor test
38742|NCT03880370|Diagnostic Test|FUNCTIONAL TESTS|Star excursion balance test (sebt) prone bridging test Side bridging test Modified biering-sørensen
38743|NCT03880357|Drug|Betamethasone Scalp Suspension 0.064%;0.0005%|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
38744|NCT03880357|Drug|Taclonex®|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
38745|NCT03880357|Drug|Placebo topical suspension|applied once daily by gently rubbing to the affected area(s) of the scalp for approximately 4 weeks.
38746|NCT03880344|Device|Vibration Therapy|Vibration therapy as a pre-operative rehabilitation programme 3 times a week for 3 months + Normal Regular out-patient department physiotherapy
38747|NCT03880344|Combination Product|Physiotherapy|Physiotherapy as post-operative rehabilitation programme for 6 months.
38748|NCT03880331|Procedure|Debridement|Aggressive vs Minimal Debridement
38749|NCT03880318|Procedure|Joint Preserving Surgery in spasmodic flat foot|extensor digitorum longus, peroneus brevis and tertius lengthening together with calcaneal osteotomies
38750|NCT03880305|Diagnostic Test|complete blood count|complete blood count
38751|NCT03880292|Procedure|Document intraoperative Maneuvers|Monitoring procedure during surgery
38752|NCT03880279|Biological|TAC01-CD19|Dose-escalating cohorts plus expansion groups
38753|NCT03880266|Drug|Glycopyrronium cloth, 2.4%|Pre-saturated 100% polypropylene, nonwoven, fabric cloth with glycopyrronium
38754|NCT03880266|Drug|Vehicle|Pre-saturated 100% polypropylene, nonwoven, fabric cloth
38755|NCT03880253|Drug|CTP-692|Placebo or CTP-692
38756|NCT03880240|Device|Transcranial Alternating Current Stimulation (tACS)|tACS is a non-invasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head. tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
38757|NCT03880240|Other|Sham Transcranial Alternating Current Stimulation|Placebo Control, simulation of transcranial alternating current stimulation without receiving any stimulation
38758|NCT03880227|Device|Active anodal tDCS|active anodal tDCS with behavioral tasks to assess visual attention
38759|NCT03880227|Device|Sham tDCS|sham tDCS with behavioral tasks to assess visual attention
38760|NCT03880201|Procedure|ultrasound guided supraclavicular block|"The linear transducer will be applied firmly above the clavicle in the coronal oblique plane the 22-gauge needle will be inserted at the lateral side of the ultrasound probe using In-plane approach. The needle will be advanced towards the target nerves inferior, lateral and superficial to subclavian artery respectively. Local anesthetic solution is injected between 20 to 25 ml.~Motor block will be assessed as follow Radial nerve = Push the arm by extending the forearm at the elbow against the resistance, musculocutaneous nerve = Resisting the pull of the forearm at the elbow, median nerve = Thumb and second digit pinch, ulnar nerve = Thumb and fifth digit pinch.~Sensory block will be assessed by using piece of ice in the distribution of median, ulnar, radial and musculocutaneous nerves."
38761|NCT03880201|Device|Masimo SET pulse oximetry (Masimo Corporation, Irvine, CA, USA)|Masimo reading of PI values will be recorded every minute (at both index and fifth digits) for 20 minutes then every 3 minutes for 30 minutes.
38762|NCT03880175|Behavioral|FCC (Força à Comunidade e Crianças) program- direct beneficiary|Households are directly linked to the FCC implementing organization
38763|NCT03880175|Behavioral|FCC (Força à Comunidade e Crianças) program- non-direct beneficiary|Households live in FCC implementing communities but are not directly linked to the FCC implementing organization
38764|NCT03880175|Behavioral|Anti Stigma Information|Adults in the households are provided anti-stigma information
38765|NCT03880175|Behavioral|HIV/AIDS Information|The households receive information about HIV infection and AIDS
38766|NCT03880175|Behavioral|ART Information|The households receive information about antiretroviral therapy.
38767|NCT03880175|Behavioral|HIV/AIDS and ART Information Combined|The households receive both information about HIV/AIDS and information about antiretroviral therapy.
38768|NCT03880175|Behavioral|High coupon value|The HIV testing coupons distributed to households in this group have higher values.
38769|NCT03880162|Other|Low carbohydrate diet|A energy deficient (30% deficit) low carbohydrate diet (10% of carbohydrates)
38770|NCT03880162|Other|Energy-matched standard diet|Energy-matched (30% deficit) standard diet (50% of carbohydrates)
38771|NCT03880149|Dietary Supplement|Omega-3|Each omega-3 capsule contains 600 mg, including 400 mg EPA + 200 mg Docosahexaenoic acid (DHA) and 400 IU of vitamin E for 5 omega-3 capsules. Omega-3 dosage: 1 g per 15 kg body mass
38772|NCT03880149|Other|Placebo|Medium-chain triglyceride (MCT) and vitamin E
38773|NCT03880136|Drug|CTP-543|Once daily dosing
38774|NCT03880123|Drug|Selinexor|"Selinexor will be taken orally on Days 1, 8, 15, and 22 of each cycle at the following dose levels (DLs):~DL 1: 40 mg; DL 2: 60 mg; DL 3: 80 mg; DL 4: 100 mg~The selinexor product is provided as 20 mg tablets in wallet-sized blister packs. Selinexor should be taken together with ixazomib."
38775|NCT03880123|Drug|Ixazomib|"Ixazomib will be taken orally on Days 1, 8, and 15 of each cycle at the same dose level: 4 mg.~The ixazomib product is provided in strengths of 4.0, 3.0, and 2.3 mg capsules as the active boronic acid. Ixazomib should be taken on an empty stomach (no food or drink) at least 1 hour before or at least 2 hours after food."
38776|NCT03880097|Procedure|Research Biopsy|"The Research Biopsy is a biopsy in addition to the standard of care biopsies that the patient will have to inform their diagnosis. The actual procedure is not any different to the standard per-cutaneous biopsy, this is just an additional procedure, solely for research purposes."
38777|NCT03880084|Other|Observation|To systematically assess the onset of delirium, quantify the level of agitation/sedation, estimate the grade of pain and survey the level of dyspnea in patients undergoing non invasive mechanical ventilation
38778|NCT03880071|Behavioral|DBT+ACT|- The experimental group (DBT+ ACT) will have: 25 therapy group sessions (1 sessions of 2 hours once a week) 25 individual interview sessions (1 sessions of 1 hour once a week) will receive 25 group sessions and 25 individual ones during 6 months.
38779|NCT03880071|Behavioral|DBT|"The control group (DBT) will have:~50 therapy group sessions (1 session of 2h30 once a week) 50 individual interview sessions (1 sessions of 1 hour once a week)"
38780|NCT03880058|Drug|SLI-F06|Active treatment
38781|NCT03880058|Drug|Formulation buffer|Placebo treatment
38782|NCT03880045|Drug|Topical TA|A gauze soaked with 2 g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride0.9%
38783|NCT03880045|Drug|vasopressin|intraoperative perivascular injection of one ampoule of vasopressin containing 20 units in 1 ml after dilution in 19 ml of normal saline during myomectomy
38784|NCT03880045|Other|placebo to TA|(120 ml of sodium chloride 0.9%) used to compress the myoma bed for 5 min.
38785|NCT03880032|Behavioral|Cognitive Behavioral Therapy Intervention for Anxiety|Happy Mother Healthy Baby (HMHB) is a CBT-based psychosocial intervention for expectant women experiencing anxiety during their pregnancy. Strategies such as empathetic listening, thought challenging, behavior activation, problem management, take-home exercises, and family involvement are employed by HMHB.
38786|NCT03880019|Drug|Olaparib|Given orally (PO)
38787|NCT03880019|Drug|Temozolomide|Given PO
38788|NCT03880006|Behavioral|Case management|Case management intervention is a multi-step process to coordinate care and provide a family-like support system for people living with HIV. Individuals are assigned to a specific case manager who will provide support throughout the study. The case management approach has five key components: 1) initial meeting between person living with HIV and case manager; 2) follow up meeting between case manager and participant; 3) biweekly automatic text messages sent to participant; 4) monthly phone calls from case manager; and 5) face-to-face meetings between case manager and participant every 6 months.
38789|NCT03879993|Other|Exercise group|Resistance training 3 times per week (45-60 minutes of resistance training)
38790|NCT03879980|Drug|Bilateral QL block|Bilateral lateral Quadratus Lumborum block using 20 ml of 0.25% bupivacaine each injection as preemptive analgesia.
38791|NCT03879980|Drug|Non-QL block|Only received fentanyl IV during surgery.
38792|NCT03879967|Device|Allograft block graft|The graft used is a mineralized, cortico-cancellous, delipidized, lyophilized allogenic block.
38794|NCT03879928|Drug|FM101 for SAD|The study drug (FM101) will be administered orally as SAD doses
38795|NCT03879928|Drug|Placebo for SAD|The study drug (placebo) will be administered orally as SAD doses
38796|NCT03879928|Drug|FM101 for MAD|The study drug (FM101) will be administered orally as MAD doses
38797|NCT03879928|Drug|Placebo for MAD|The study drug (placebo) will be administered orally as MAD doses
38798|NCT03879915|Procedure|Dental Implant placement|Surgical placement of dental implant not associated with prior or concurrent bone augmentation
38799|NCT03879889|Drug|Nicotine patch|Four weeks of nicotine patch will be provided at the first contact, which will be prescribed using the guidelines based on the subject's daily cigarette consumption. At week-4 visit, four more weeks of NRT will be provided.
38800|NCT03879876|Genetic|Human T Lymphoid Progenitor (HTLP) injection|Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture)
38801|NCT03879863|Drug|Reproxalap Ophthalmic Solution (0.25%) QID|Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks
38802|NCT03879863|Drug|Vehicle Ophthalmic Solution QID|Vehicle Ophthalmic Solution administered QID for twelve weeks
38803|NCT03879863|Drug|Reproxalap Ophthalmic Solution (0.25%) QID to BID|Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks
38804|NCT03879863|Drug|Vehicle Ophthalmic Solution QID to BID|Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks
38805|NCT03879837|Drug|Fluticasone propionate pressurized metered dose inhaler|110 mcg per actuation
38806|NCT03879837|Drug|Flovent HFA pressurized metered dose inhaler|110 mcg per actuation
38807|NCT03879837|Drug|Placebo pressurized metered dose inhaler|no active content
38808|NCT03879824|Procedure|Secondary Radial Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the right radial artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
38809|NCT03879824|Procedure|Secondary Femoral Artery Access|Patients undergoing transcatheter aortic valve implantation (TAVI) will receive secondary arterial access via percutaneous access of the contralateral femoral artery for the purpose of insertion of a standard pigtail catheter for aortic route angiography during TAVI.
38810|NCT03879811|Drug|TMZ|Oral TMZ at 150mg/m2
38811|NCT03879811|Drug|Nivolumab|Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
38812|NCT03879798|Drug|DS-3201b|Patients will receive oral daily DS-3201b following a standard 3+3 dose-escalation design.
38813|NCT03879798|Drug|irinotecan|Irinotecan 125 mg/m^2 intravenously on days 1 and 8 every 3 weeks in a 21-day cycle.
38814|NCT03879785|Other|Screening|Screening and validation of assessment tool translated into Spanish
38815|NCT03879772|Drug|Mometasone furoate nasal spray|intranasal administration
38816|NCT03879772|Drug|Beclomethasone dipropionate nasal spray|intranasal administration
38817|NCT03879772|Drug|Placebo nasal spray|intranasal administration
38818|NCT03879772|Drug|Chlorpheniramine maleate syrup|oral administration
38819|NCT03879759|Drug|NAC 2400mg/day|2400mg/day 2 x 600mg b.d
38820|NCT03879759|Drug|Placebo|4 matched placebo tablets/day
38821|NCT03879746|Drug|Tamsulosin|drug will be used in treatment of premature ejaculation
38822|NCT03879746|Drug|Paroxetine Hydrochloride|drug will be used in treatment of premature ejaculation
38823|NCT03879746|Other|placebo|tablets without active substance will be given to patients suffering from premature ejaculation
38824|NCT03879733|Behavioral|Thrive by Three|"The intervention consists of the following components:~Measurement of daycare quality with CLASS (Classroom Assessment Scoring System) 3 times during the intervention period~Feedback to group staff on 8 CLASS-quality dimensions~Monthly supervision of staff on two levels: supervision of daycare staff, and supervision of supervisors~Competence building with all staff: 3 full training days, plus 2 extra training days for pedagogical leaders/supervisors~Written material to parents, supervisors, and staff~Web page for staff and parents: tf3.no"
38825|NCT03879733|Behavioral|Treatment as usual (TAU)|The wait-list control group will continue with their daily activities and work in the childcare as usual. The wait list control group will have received general information about the study prior to consenting, however no materials or are provided by project. The child-care centers in the control conditions will receive a gift certificate of 3000 Norwegian Crones (NOK) by the end of the intervention period.
38826|NCT03879720|Procedure|Endoscope assisted endotracheal intubation [EAEI]|Endoscope assisted endotracheal intubation [EAEI] performed by anesthesiologist with endoscopist assistance.
38827|NCT03879707|Drug|Melatonin 5 mg|Melatonin is known to induce sleep
38828|NCT03879707|Drug|Placebo Oral Tablet|Placebo
38829|NCT03879707|Drug|Magnesium 500Mg Oral Tablet|Magnesium plays a role in supporting deep, restorative sleep by maintaining healthy levels of GABA, a neurotransmitter that promotes sleep. Research indicates supplemental magnesium can improve sleep quality, especially in people with poor sleep
38830|NCT03879694|Biological|Incomplete Freund's Adjuvant|Given SC
38831|NCT03879694|Drug|Octreotide Acetate|Given IM
38832|NCT03879694|Biological|Sargramostim|Given SC
38833|NCT03879694|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
38834|NCT03879681|Dietary Supplement|Jelly confectionary Snakes|"The participants will be randomized by computer generated randomisation to receive either the jelly snake (n=120) or no intervention (n=120) apart from standard institutional management.~All children randomised into the snake group will be offered a chewy jelly snake once alert and cooperative in PACU or on the ward once University of Michigan Sedation Scale (UMSS) is 025,26. The UMSS is a simple observational tool that assesses the level of alertness on a five‐point scale ranging from 1 (wide awake) to 5 (unarousable with deep stimulation).~The children randomized into the control group will receive a chewy jelly snake as a treat at discharge."
38835|NCT03879668|Device|eIPOS|Electronic version of IPOS
38836|NCT03879655|Drug|VTS-270|Lumber intrathecal infusion of VTS-270
38837|NCT03879642|Behavioral|REDCHiP|10 week video-based telemedicine intervention to reduce hypoglycemia fear
38838|NCT03879629|Drug|Carvedilol|oral Carvedilol maximally tolerated doses 3.125 mg to 25 mg twice a day
38839|NCT03879616|Behavioral|An Enhanced Reminder|"This study will be a randomized trial over a 6-month period (March 8 through September 7, 2019) in 3 GI endoscopy clinics (Franklin, Rock Creek, and Lone Tree). All members currently receive a text reminder 7 days prior to their procedure, which rolls over to a telephone reminder if the text cannot be delivered or the member's phone is not text-enabled. Members will be randomized either to receive this standard IVR-T protocol (control) or to receive an enhanced reminder (intervention) protocol.~Data from the randomized trial, for both intervention and control participants, will be analyzed to develop a statistical prediction rule that identifies members at highest risk of missing their procedure."
38840|NCT03879603|Biological|VRC-WEVVLP073-00-VP|VRC-WEVVLP073-00-VP is composed of 1:1:1 ratio of WEE, EEE, and VEE virus-like particles (VLP)
38841|NCT03879603|Other|VRC-GENMIX083-AL-VP|VRC-GENMIX083-AL-VP is an adjuvant
38842|NCT03879590|Drug|Doxophylline|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
38843|NCT03879590|Drug|Budesonide|Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
38844|NCT03879577|Drug|Docetaxel|Administered to all patients for a minimum of 4 cycles for 12 weeks.
38845|NCT03879577|Drug|Herceptin|Administered for 18 cycles every three weeks (52 weeks) for each patient starting at the first day of treatment with docetaxel.
38846|NCT03879577|Drug|FEC|Only administered to patients who received docetaxel and herceptin and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
38847|NCT03879577|Drug|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
38848|NCT03879577|Drug|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
38849|NCT03879577|Drug|LHRH agonist|Administered to all premenopausal patients.
38850|NCT03879564|Drug|Ketamine|ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
38851|NCT03879564|Drug|Normal saline|NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
38852|NCT03879551|Device|repetitive Transcranial Magnetic Stimulation|By defining intensity of 80% of the resting Motor Threshold detected from motor area for Rt Abductor Pollicis Brevis (APB), we will apply repetitive Transcranial Magnetic Stimulation (rTMS) using 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magnetic Stimulator with high frequency (25Hz), Stimuli will be delivered for total 2000 pulse (divided on 50 trains with 40 pulses per train with inter-train interval 30 seconds) for each hemisphere (coil placed tangential over the optimal position of hand motor area detected for Real group and the same coil placed perpendicular with hand of coil pointing upward over occipital cortex for Sham group). Sessions will be consecutive for ten days period with repetition of consecutive 5 sessions as boosting doses on 5 days period over the follow up visits every month for the next 3 months.
38853|NCT03879538|Drug|Nitrous Oxide|a total of three treatments (6 total exposure hours) over one week with 2 or 3 days between each session.
38854|NCT03879538|Drug|Oxygen|a total of three treatments (6 total exposure hours) over one week with 2 or 3 days between each session.
38855|NCT03879525|Other|EMR-based-interventional method|Questionnaire delivery method. Participants will complete standard care anxiety and depression screening and quality of life assessment directly into the patient entered section of the EMR, administered on arrival in the clinic.
38856|NCT03879525|Other|Telephone-based-standard method|Questionnaires delivered via phone. Participants will complete standard care anxiety and depression screening and quality of life assessment via phone. Standart delivery method.
38857|NCT03879512|Drug|depletion of regulatory T cells|oral metronomic cyclophosphamide
38858|NCT03879512|Procedure|reoperation|(sub)total resection of relapsed tumor in order to improve clinical condition of the patient and to acquire tumor tissue for vaccine generation
38859|NCT03879512|Biological|cancer vaccine|4 weekly intradermal injections of lysate-loaded dendritic cells 3 monthly boost vaccine with tumor lysate further boost vaccines every three months
38860|NCT03879486|Other|Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy|The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
38861|NCT03879460|Drug|Naltrexone Hydrochloride|50 mg per os naltrexone hydrochloride
38862|NCT03879447|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
38863|NCT03879447|Procedure|Chuna manual medicine|Chuna is a Korean manual therapy directed at the spine and joints that incorporates various spinal manual medicine techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manual medicine will be administered to the pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
38864|NCT03879447|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will usually be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
38865|NCT03879447|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea) at the physician's discretion.
38866|NCT03879447|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
38867|NCT03879447|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
38868|NCT03879447|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
38869|NCT03879447|Procedure|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary regardless of type or dose, and patterns of use will be investigated and recorded as a pragmatic clinical study.
38870|NCT03879434|Device|Ostenil® Mini|Ostenil® Mini is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 1.0 % sodium hyaluronate from fermentation
38871|NCT03879421|Procedure|Accelerated corneal collagen cross linking|This strategy is based on the underlying pathology of the disease. Corneal collagen cross linking (CXL) idea was based on the fact that a photosensitizer substance like riboflavin (vitamin B2) can interact with ultraviolet irradiation (Ultraviolet-A) to strengthen the corneal tissue inter and intrafibrillar collagen bonds thus preventing further thinning, corneal protrusion and reduces corneal irregular astigmatism.
38872|NCT03879408|Drug|440 mg naproxen sodium with 1000 mg acetaminophen|440 mg naproxen sodium with 1000 mg acetaminophen administered as a single dose of two naproxen sodium 220 mg tablets and two acetaminophen 500 mg tablets
38873|NCT03879408|Drug|220 mg naproxen sodium with 650 mg acetaminophen|220 mg naproxen sodium with 650 mg acetaminophen administered as a single dose of one naproxen sodium 220 mg tablet and two acetaminophen 325 mg tablets and one placebo tablet
38874|NCT03879408|Drug|10 mg hydrocodone + 650 mg acetaminophen|10 mg hydrocodone with 650 mg acetaminophen administered as a single dose of two hydrocodone 5 mg + acetaminophen 325 mg tablets and two placebo tablets
38875|NCT03879408|Drug|440 mg naproxen sodium|440 mg naproxen sodium administered as a single dose of two naproxen sodium 220 mg tablets and two placebo tablets
38876|NCT03879408|Drug|Placebo tablet|Single dose of four placebo tablets
38877|NCT03879395|Procedure|Abdominal surgery with metastasectomy|Emergency or elective surgery on indications related to abdominally metastasized malignant melanoma
38878|NCT03879382|Biological|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
38879|NCT03879382|Drug|Fludarabine|30mg/m2/d
38880|NCT03879382|Drug|Cyclophosphamide|300mg/m2/d
38881|NCT03879369|Diagnostic Test|Hormonal assay|LH , FSH and Free testosterone index (FTI) levels
38882|NCT03879356|Drug|N-acetyl cysteine|effect of N-acetyl cysteine in Aluminum phosphide poisoning patients
38883|NCT03879343|Other|Known diagnosis of attention deficit / hyperactivity disorder|Clinical group includes subjects with clinical diagnosis of attention deficit / hyperactivity disorder
38884|NCT03879330|Device|NIRS monitoring|aSAH patients will be given continuous NIRS and blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring of 4 hours. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
38885|NCT03879317|Device|Continuous NIRS monitoring|Septic shock patients who have continuous NIRS and blood pressure monitoring at same time will be included. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP.
38886|NCT03879304|Other|multimodal physiotherapy program with RV|Physiotherapy Programm includes: respiratory physiotherapy, stretching, massage, resistance training, aerobic training and adaptation and training with virtual reality glasses.
38887|NCT03879304|Other|multimodal physiotherapy program|Multimodal physiotherapy Programm includes: respiratory physiotherapy, stretching, massage, aerobic training and resistance training.
38888|NCT03879291|Other|pinpointIQ|The study will utilize physIQ's multivariate analytical methods that detect vital sign relationship changes compared to a patient's individual baseline. Changes in vital signs relationships may be indicative of current or future important clinical events. These changes are indicated through the Multivariate Change Index (MCI), which is a scalar index between 0 and 1, where values close to 0 indicate no significant change from baseline and values close to 1 indicated greater changes from baseline
38889|NCT03879278|Drug|NPT189|NPT189 is a recombinant immunoglobulin Fc fusion of GAIM (GAIM-IgG1Fc) as a potential treatment for peripheral amyloidosis.
38890|NCT03879265|Diagnostic Test|Noninvasive chromosome screening|Screening based on MALBAC-NGS technology
38891|NCT03879252|Device|Toothbrush|Brushing teeth three times a day (extra-soft toothbrush) with a 1.4% baking mouthwash solution.
38892|NCT03879252|Drug|Mouthwashes|Mouthwashes three times a day with a 1.4% baking mouthwash solution.
38893|NCT03879239|Device|Vibrating capsule|Vibrating Capsule administered 5 times per week
38894|NCT03879226|Device|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for the applications during the training and/or detraining periods will be 30 Joules (J) per site (510 J per lower limb). PBMT will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
38895|NCT03879226|Device|Placebo|Placebo will be applied bilaterally using the direct contact method with light pressure on the skin at different sites, namely 9 sites on the knee extensor muscles, 6 sites on the knee flexor muscles, and 2 sites on the plantar flexor muscles. The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo will be applied before and after each training session and during the detraining period, depending on the group to which the volunteers are allocated.
38896|NCT03879213|Dietary Supplement|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
38897|NCT03879213|Dietary Supplement|Control breakfast|Control drink + buttermilk biscuit sandwich
38898|NCT03879200|Other|Group antenatal care|Care will be provided in group sessions in dialogue sensitive to language and cultural issues. Group numbers will be around 8; the woman with partner or other companion welcome. The content of the sessions will be designed in collaboration with midwives and Somali born women, following the present parental education and findings from the focus groups. The sessions will be held at the antenatal clinic led by one or two midwife, assisted by the trained female Somali interpreter.
38899|NCT03879187|Dietary Supplement|High-fat, high-energy diet|Participants consumed a diet that was high in fat and high in energy
38900|NCT03879174|Drug|Pembrolizumab + Tamoxifen|"The choice of the 200 mg Q3W as an appropriate dose for the switch to fixed dosing is based on simulations performed using the population PK model of pembrolizumab showing that the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient exposures in the exposure range established in melanoma as associated with maximal efficacy response and 3) will maintain individual patients exposure in the exposure range established in melanoma that are well tolerated and safe.~A fixed dose regimen will simplify the dosing regimen to be more convenient for physicians and to reduce potential for dosing errors. A fixed dosing scheme will also reduce complexity in the logistical chain at treatment facilities and reduce wastage."
38901|NCT03879161|Device|Vu-Path™|Femoral arterial access in eligible participants will be performed using the Vu-Path™.
73522|NCT03609216|Other|Chemoradiotherapy|Undergo chemoradiotherapy
38902|NCT03879148|Other|Erector spinae plane block|Erector spinae plane block was performed to the patients under aseptic conditions
38903|NCT03879135|Biological|rVWF|Recombinant von Willebrand factor
38904|NCT03879135|Biological|rFVIII|Recombinant Factor VIII
38905|NCT03879122|Drug|Ipilimumab 5 MG/ML|Ipilimumab will be administered on day 1 of each cycle every 3 weeks. In arm 3, ipilimumab should be started at least 2 weeks but no later than 120 days after surgical castration or the first dose of LHRH analogue. Patients should receive 2 doses of ipilimumab (6 weeks). It will be followed, 3 weeks later, by 3 cycles of docetaxel and by 2 additional doses of ipilimumab and 3 more cycles of docetaxel. Four weeks later, Nivolumab will be administered on day 1 every 2 weeks until a maximum of 24 doses (48 weeks)
38906|NCT03879122|Drug|Nivolumab 10 MG/ML|Nivolumab will be administered every 2 weeks, until clinical progression or a maximum of 24 doses. Nivolumab should be started 4 weeks after the last dose of docetaxel, providing all the adverse effects have recovered, as if a new cycle of docetaxel were to be administered
38907|NCT03879122|Drug|Docetaxel|"Docetaxel should be given on day 1 every 21 days, for up to 6 cycles (1 cycle = 21 days). Docetaxel should be started within 7 working days from the date of randomization in the arm 1 and 2.~In arm 3, docetaxel will be given 3 weeks after the last dose of the previous treatment, providing all the side effects are grade ≤1."
38908|NCT03879122|Drug|ADT (androgen deprivation therapy)|Androgen deprivation therapy per the standard of care
38909|NCT03879109|Drug|Chemotherapy FOLFIRINOX, 6 cycles|"oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU : 400 mg/m2 (bolus)~5FU : 2400 mg/m2 (continuous infusion)"
38910|NCT03879109|Radiation|Radiochemotherapy|Reirradiation consists in conformational intensity modulated external irradiation (Intensity-modulated radiotherapy Volumetric Modulated Arc Therapy or tomotherapy) delivering a 30.6 Gy dose with high-energy photons in fractions of 1.8 Gy per day (17 fractions) 5 days a week With Concomitant chemotherapy including Capecitabine 1600 mg/m²/day, five days a week.
38911|NCT03879109|Procedure|Surgery|"Surgery will be performed at:~Arm A: 8 weeks (±1) after the end of treatment~Arm B: 6 weeks (±1) after the end of treatment~Surgical procedures are defined into three categories:~Total mesorectal excision (TME)~Extended-TEM (e-TME)~Pelvic exenteration (PE)"
38912|NCT03879096|Other|Therapeutic Exercise and Education|Intervention will consisted of 30 minutes of strength exercises followed by 20 minutes of endurance with aerobic training, individualised based on the evaluations of muscular strength and endurance as well as the determination of the aerobic-anaerobic zone transition. Sessions lasted 1 hour, carried out twice a week, during 12 weeks. This intervention will be complemented by nutritional education.
38913|NCT03879083|Other|Addition of palatal rugae to the complete denture surface|The addition and reproduction of the patient's own palatal rugae to the complete maxillary denture palatal surface.
38914|NCT03879083|Other|The removal of the palatal rugae from the complete denture surface|The removal of the palatal rugae from the complete maxillary denture palatal surface to become a smooth surface
38915|NCT03879070|Device|Ankle active and passive mobilization using an Ankle mobilization device|The treatment consists in 20 rehabilitation sessions, 5 times/week for 4 weeks. The device is capable of generating ankle dorsi/plantarflexion movements using two activation modes: passive and assistive. In the passive mode the device generates a movement pattern which the patient follows passively without exerting any force on the device. During the assistive mode, the device follows the active movement of the patient. During the intervention, these two modes will be alternated.
38916|NCT03879057|Drug|Surufatinib/humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
38917|NCT03879044|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
38918|NCT03879031|Diagnostic Test|Cluster of Clinical tests to measure lumbar stability|"All subjects will be submitted to a cluster of clinical test before the starting of the first session, and at the ending of the last session of the physical therapy program. This cluster will include:~Aberrant Movements (AM) Test,~Active Straight Leg Raise Test (ASLR) Test,~Supine Bridge Test (SuBT),~Right Side Bridge Test (RBT),~Left Side Bridge Test (LBT),~Prone Bridge Test (PrBT),~Passive Lumbar Extension (PLE) Test,~Prone Instability Test (PIT)."
38919|NCT03879018|Behavioral|Reach training with visual feedback|Reach training will be accomplished using an Oculus Rift and Touch 3D headset. Active markers will be placed on the shoulder, elbow, wrist, and finger in order to capture limb movement in real time. During each training session, participants will first be familiarized with the task and then will reach from a home position to 4 virtual targets that are presented in the front of the participant and within the workspace where most natural arm movements are performed.Targets will be presented in a pseudorandom order and participants will reach a total of 400 times
38920|NCT03879005|Other|renal scintigraphy|"99mTc-DTPA Scintigraphy Five mci of 99mTc-DTPA will be injected by IV route together with diuretic. Dose will be adjusted according to the age and weight of the patients. A total of 20 min dynamic imaging followed by calculation of GFR and SRF according to the built-in processing protocol Gate's method.~99mTc-DMSA scintigraphy Five mci of 99mTc- DMSA will be injected by IV route with adjustment according to age and weight. Static images will be acquired in the posterior, anterior, andposterior oblique projections for 60 s each."
38921|NCT03878992|Drug|Genotropin miniquick 0.5 mg, injection|GH will be given as an injection. Muscle biopsy will be obtained from m. vests laterals of the dominant leg. Fat biopsies will be obtained from subcutaneous abdominal fat. Tracers will be given as a bolus followed by continuous infusion for 6 hours. For palmitate tracer the infusion will be for only 1,5 hours followed by a one hour break and then another 1 hour infusion. Blood tests will be drawn from a venous catheter placed on the dorsal side of the hand.
38922|NCT03878979|Drug|Nivolumab 480mg and surgical resection|One dose of Nivolumab 480mg given four weeks prior to surgical resection.
38923|NCT03878966|Device|Inserting polymer free drug eluting stent in the coronary arteries|• Early invasive strategy with percutaneous coronary intervention will be done for the patients presenting with NST ACS who meet the inclusion criteria using Polymer-free drug eluting stents instead of the polymer-permanent drug eluting stents .
38924|NCT03878953|Drug|rhPTH(1-84)|Participants will receive a SC injection of initial dose of 50 mcg of rhPTH(1-84) once daily (QD) in the thigh (alternate thigh every day). If albumin-corrected serum calcium (ACSC; [mg/dL] = serum calcium [mg/dL] +0.8*[4-serum albumin (g/dL)]) is >2.25 mmol/L (>9.0 mg/dL), a starting dose of 25 mcg will be considered. At 4 week intervals the rhPTH(1-84) dose may be increased in 25 mcg increments to a maximal dose of 100 mcg SC QD. At any time during the study as needed for safety reasons, rhPTH(1-84) doses may be decreased in 25 mcg decrements to a minimum of 25 mcg QD. If the ACSC is >2.97 mmol/L (>11.9 mg/dL), then the investigational product should be stopped until the calcium level is corrected.
38925|NCT03878940|Diagnostic Test|Abdominal ´yes-no´ pathway|A set of blood samples, a FIT, and an abdominal US (and a TVUS in women)
38926|NCT03878927|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
38927|NCT03878927|Drug|Gemtuzumab Ozogamicin|Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.
38928|NCT03878914|Drug|Corticosteroids|Patients will be divided into two groups based on time to remission with initial standard dose of corticosteroids. Patients who respond within 10 days (Group A) will receive a total of 8 weeks of corticosteroid therapy whereas those who respond between 10 days to 28 days (Group B) will receive ≥12 weeks ((maximum of 16 weeks) of corticosteroid therapy.
38929|NCT03878901|Combination Product|high risk warm|Bair HuggerTM Forced-air Warming System to 30min pre- and entire operation warming, combined fluid warming
38930|NCT03878901|Combination Product|moderate risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System cotton blanket warming and fluid warming through operation
38931|NCT03878901|Combination Product|low risk warm|30 min prewarming The Bair HuggerTM Forced-air Warming System and cotton blanket warming through operation
38932|NCT03878901|Other|passive warming|cotton blanket warming through operation
38933|NCT03878888|Drug|Exparel 266 MG Per 20 ML Injection|patients receive Exparel in bilateral TAP blocks for open abdomen surgery
38934|NCT03878875|Diagnostic Test|Session One Test Battery|"Prior to noise exposure:~Test battery - High-frequency audiometry, Distortion Product Otoacoustic Emissions, Middle Ear Muscle Reflex, Speech-in-Noise test, Tinnitus Functional Index (Around 35 minutes with breaks if required)~Extended Frequency Audiometry (~ 8 min): Participants will be asked to press the button when they hear a sound through the headphones in a soundproof booth.~DPOAE (~ 5 min): A small tip will be placed in participants' ear and they will hear a sound. The tip measures a response from hair cells in the cochlea and they will not need to do anything.~MEMR (~ 8 min): A small tip placed in both ears and again a sound heard, however, this sound will gradually get louder until an involuntary muscle reflex is noted.~Speech-in-Noise Test (~ 5 min): Participants asked to repeat back a list of words as best as they can.~TFI (~ 8 min): Participants given a self-report sheet in which they have to fill out aspects of any tinnitus experienced."
38935|NCT03878875|Diagnostic Test|Session Two Test Battery|"Exposure at single loud music event (Important that this is part of participants' normal recreational routine, and specifically require that attendance is not prompted by participation in this study): Participants to use sound level meter provided from the Audiology Department at Charing Cross Hospital to measure sound levels inside the loud event.~Morning after exposure: Repeat test battery from session one - Ideally as soon as event is over."
38936|NCT03878875|Diagnostic Test|Session Three Test Battery|1 week later (recovery): Repeat test battery.
38937|NCT03878849|Drug|2X-121|Every patient will receive daily oral administrations of 3 x 200 mg 2X-121 hard gelatin capsules in a 28-day cycle.
38938|NCT03878849|Device|2X-121 DRP®|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
38939|NCT03878836|Other|Routine assessments|Routine assessments, no specific intervention
38940|NCT03878823|Drug|ODM-209|co-administered with glucocorticoid and mineralocorticoid, orally daily
38941|NCT03878810|Behavioral|Exergaming|A video game-based physical activity training applied using a commercial game console.
38942|NCT03878784|Drug|Imigran|All patients will undergo this intervention on one of two study days
38943|NCT03878784|Other|Isotonic Saline|All patients will undergo this intervention on one of two study days
38944|NCT03878771|Biological|Platelet rich fibrin gel in Orabase|applied on oral mucositis and /or ulcer 3 times per day
38945|NCT03878771|Drug|Dermovate cream in Orabase|applied on oral mucositis and /or ulcer 3 times per day
38946|NCT03878758|Device|BD Nano™ PRO|Insulin Pen needle
38947|NCT03878758|Device|33G Artsana Insupen Extr3me|Insulin Pen Needle
38948|NCT03878758|Device|34G Artsana Insupen Extr3me|Insulin Pen Needle
38949|NCT03878758|Device|Simple Diagnostics Comfort EZ™|Insulin Pen Needle
38950|NCT03878732|Diagnostic Test|Bindex measurement|One time bone density measurement with ultrasound device
38951|NCT03878719|Drug|binimetinib|taken orally
38952|NCT03878719|Drug|encorafenib|taken orally
38953|NCT03878693|Drug|Fomepizole|IV 4-MP.
38954|NCT03878693|Drug|APAP|Oral APAP
38955|NCT03878680|Other|Study questionnaires|"Completion of the International study of Asthma and Allergies in Children(ISAAC)core questionnaires:~Core questionnaire on wheezing.~Core questionnaire on rhinitis.~Core questionnaire on atopic dermatitis."
38956|NCT03878667|Dietary Supplement|Curves Calcium|Curves Essential Bio-Available Calcium (providing 800 mg/d of calcium [as calcium citrate malate and calcium citrate], 400 IU/d of Vitamin D, 300 mg/d of magnesium, 4 mg/d of zinc, 2 mg/d of copper, 2 mg/d of manganese, 198 mg/d of potassium, 100 mg/d of trace mineral complex, and 2 mg/d of boron).
38957|NCT03878667|Dietary Supplement|Calcium Carbonate|Calcium (providing 950 mg/d as carbonate)
38958|NCT03878667|Dietary Supplement|Placebo|Dextrose placebo
38959|NCT03878654|Drug|Tauroursodeoxycholic Acid|Naturally occurirng bile acid
73583|NCT03608761|Drug|Rebamipide|rebamipide 2%
38960|NCT03878641|Behavioral|Children in Grade 1 to 5 with literacy and language needs|The investigators deliver a telepractice-based intervention targeting: (a) Word reading and phonics instruction, (b) applying a comprehension monitoring strategy to improve text reading accuracy, and (c) complex sentences use in written text. Participants receive 3 online 50-minute tutoring session weekly across 15 weeks.
38961|NCT03878628|Drug|Adipose tissue-derived mesenchymal stem cells|CSCC_ASC(22), a ready-to-use suspension containing 22 million adipose tissue-derived mesenchymal stem cells per millilitre
38962|NCT03878615|Procedure|elective surgery, according to deprtement routine|none, descriptive study
38963|NCT03878602|Procedure|Delayed umbilical cord clamping|Umbilical cord will be clamped after 1 min after the birth of the newborn
38964|NCT03878602|Procedure|Immediate umbilical cord clamping|Umbilical cord will be clamped immediately after the birth of the newborn
38965|NCT03878589|Drug|Oxytocin (OT)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal oxytocin (OT) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
38966|NCT03878589|Drug|Placebo (P)|During the 4 week intervention, participants will self-administer twice daily 24 IUs intranasal placebo (P) and will be contacted once a week for assessment of adverse effects and for download of the smartwatch data. During the last week of the intervention period, three assessment sessions will follow that will be identical to the baseline sessions.
38967|NCT03878576|Other|REFERENCE: white bread - BGL0 [RP]|Determination of glycemic response after consumption of BGL0.
38968|NCT03878576|Other|TEST: b-glucan enriched bread - BGL2 [IP1]|Determination of glycemic response after consumption of BGL0.
38969|NCT03878576|Other|TEST: b-glucan enriched bread - BGL3 [IP2]|Determination of glycemic response after consumption of BGL0.
38970|NCT03878576|Other|TEST: b-glucan enriched bread - BGL4 [IP3]|Determination of glycemic response after consumption of BGL0.
38971|NCT03878563|Device|Cellvisio 100 Series (fibered confocal microscopic system)|"This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD."
38972|NCT03878524|Procedure|Biopsy|Solid Tumor Biopsy for BCa, PCa or PanCa and Bone marrow biopsy for AML
38973|NCT03878524|Drug|ABIRATERONE|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38974|NCT03878524|Drug|ENZALUTAMIDE|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38975|NCT03878524|Drug|VENETOCLAX|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38976|NCT03878524|Drug|PALBOCICLIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38977|NCT03878524|Drug|All-trans Retinoic Acid|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38978|NCT03878524|Drug|BORTEZOMIB|Given IV (infusion) or Given SC; Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38979|NCT03878524|Drug|CABAZITAXEL|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38980|NCT03878524|Drug|OXALIPLATIN|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38981|NCT03878524|Drug|FLUOROURACIL|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38982|NCT03878524|Drug|FOLINIC ACID|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38983|NCT03878524|Drug|CARBOPLATIN|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38984|NCT03878524|Drug|PANOBINOSTAT|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38985|NCT03878524|Drug|VORINOSTAT|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38986|NCT03878524|Drug|PEMBROLIZUMAB|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38987|NCT03878524|Drug|BEVACIZUMAB|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38988|NCT03878524|Drug|IPILIMUMAB|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38989|NCT03878524|Drug|NIVOLUMAB|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38990|NCT03878524|Drug|EVEROLIMUS|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38991|NCT03878524|Drug|SIROLIMUS|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38992|NCT03878524|Drug|CELECOXIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38993|NCT03878524|Drug|OLAPARIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38994|NCT03878524|Drug|AFATINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38995|NCT03878524|Drug|CABOZANTINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38996|NCT03878524|Drug|SORAFENIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38997|NCT03878524|Drug|DASATINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38998|NCT03878524|Drug|ERLOTINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
38999|NCT03878524|Drug|IDELALISIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39000|NCT03878524|Drug|IMATINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39001|NCT03878524|Drug|LENVATINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39002|NCT03878524|Drug|PERTUZUMAB|Given IV (infusion); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39003|NCT03878524|Drug|PONATINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39004|NCT03878524|Drug|RUXOLITINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39005|NCT03878524|Drug|SUNITINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39006|NCT03878524|Drug|TRAMETINIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39007|NCT03878524|Drug|VEMURAFENIB|Given PO (orally); Initial dosing and any subsequent dose modifications will be guided by manufacturer package inserts and institutional dosing guidelines; Drug will be combined with another agent from the list.
39008|NCT03878511|Dietary Supplement|Lactose|Lactose monohydrate 810 mg, silicon dioxide 20 mg, and magnesium stearate 14 mg
39009|NCT03878511|Dietary Supplement|Placebo|Dextran 40 EP 671 mg, silicon dioxide 20 mg and magnesium stearate 14 mg
39010|NCT03878498|Other|therapeutic management|therapeutic management of anal fistula in Crohn Disease
39011|NCT03878485|Device|MRIdian Linac System from ViewRay|"0.35T MRI combined with a linear accelerator~This device will be used for the Stereotactic MRI-guided Adaptive Radiotherapy"
39012|NCT03878485|Radiation|Stereotactic MRI-guided Adaptive Radiotherapy|-The MR-linac will be delivering the radiation
39013|NCT03878472|Drug|SHR1210|In 28 ± 3 and 14 ± 3 days before surgery, every patients will received SHR-1210 (200mg iv q2w).
39014|NCT03878472|Drug|apatinib|In 28 ± 3 and 14 ± 3 days before surgery, every patients will received apatinib (250mg orally every day until 10 ± 2 days before surgery).
39015|NCT03878472|Drug|S1|In 28 ± 3 and 14 ± 3 days before surgery, every patients will received S1 (30mg/m2, bid, po, d1-d9).
39016|NCT03878459|Drug|Pioglitazone 45 mg|patients will be started on 15 mg and the dose escalated to the maximal tolerated dose
39017|NCT03878459|Drug|Placebo|PATIENTS WILL RECEIVE PLACEBO
39018|NCT03878446|Drug|somapacitan|Somapacitan injected under the skin once a week for a total of 52 weeks
39019|NCT03878446|Drug|Norditropin®|Norditropin® injected under the skin once a day for a total of 52 weeks
39020|NCT03878433|Drug|Glisodin|500 mg/day between 12 weeks
39021|NCT03878433|Other|placebo|Placebo group (20 patients) will receive 2 pills of placebo per day + sunscreen for 6 months
39022|NCT03878420|Device|Valeda PBM treatment|The Valeda Light Delivery System delivers 590, 660 and 850 nm wavelengths of light to the study eye. The Valeda Light Delivery System will treat through the open eyelid with the 590 nm and 850 nm wavelengths together. The 660 nm wavelength will be treated through the closed eyelid.
39023|NCT03878420|Device|Valeda Sham treatment|The sham mode emits an approximate 100x reduction in the highest dose for the 660 nm wavelengths as compared to the treatment mode, producing a slightly duller light. The 850 nm (NIR) wavelength (which is not visible light) is not provided in the sham treatment.
39024|NCT03878407|Other|Monitoring of ARCH variants|Blood samples will be tested for mutations, before patients are given Standard of Care chemotherapy/radiation or after given Standard of Care chemotherapy/radiation. Another testing is done after 3 months and after 1 year if positive for ARCH.
39025|NCT03878394|Other|aerobic exercise and balance exercises|The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
39026|NCT03878394|Other|aerobic exercise and balance exercises with cognitive exercises|The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
39027|NCT03878381|Combination Product|Skin Care Cream|The skin care regimen we will be testing includes ingredients such Hyaluronic acid 1%, Vitamin E Acetate, Vitamin A Acetate, Co-enzyme Q 10, L-Arginine, L-glutamine, Phytonadione, Argireline Peptide solution, GABA, Vitamin C, glycolic acid, and Fenugreek.
39028|NCT03878381|Drug|Placebo|The placebo will be a formula with no active ingredients
39029|NCT03878368|Dietary Supplement|Sulforaphane|Intervention soup with dietary sulforaphane
39030|NCT03878368|Dietary Supplement|Placebo|Control soup without dietary sulforaphane
39031|NCT03878355|Procedure|radical endoscopic sinus surgery (RESS) plus Draf 3 surgery.|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected. The technique for the Draf 3 frontal drillout procedure was described in detail in previous publications with resection of the superior nasal septum, central frontal sinus floor, and frontal beak region, resulting in a widely patent, oval-shaped, common frontal sinus neo-ostium"
39032|NCT03878355|Procedure|radical endoscopic sinus surgery (RESS)|"The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected"
39033|NCT03878355|Procedure|functional endoscopic sinus surgery (FESS)|FESS was performed by Messerklinger technique with middle turbinate preservation
39034|NCT03878342|Radiation|Radiotherapy|two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
39035|NCT03878342|Other|No Radiotherapy|No Irradiation- Active surveillance
39036|NCT03878329|Behavioral|remote home monitoring|Will use telemedicine to guide behavior changes in outcomes
39037|NCT03878316|Drug|Instranasal Oxytocin|Intranasal Oxytocin - concentrated formulation - 20U per pump
39038|NCT03878303|Drug|AC0058TA|25 mg capsules
39039|NCT03878303|Drug|Placebo AC0058TA|equivalent dose of investigational product
39040|NCT03878290|Behavioral|Resilience, Stress, and Ethnicity (RiSE)|Group based stress reduction program focused on helping minorities develop coping and empowerment skills
39041|NCT03878277|Drug|Starbucks® Cold brew - 325ml bottle|Starbucks® Cold brew 325ml bottles daily [205mg caffeine] will be provided to the participants. Participants will be instructed to drink 1 bottle every morning between 6 and 9 am for 6 days prior to the post-intervention visit. The 7th day is the post-intervention visit, and participants will be asked to drink 1 bottle the morning of the study visit
39042|NCT03878264|Drug|CORT118335 Oral|CORT118335 900 mg spray-dried dispersion in bottle and vehicle for oral administration
39043|NCT03878264|Drug|14C-CORT118335 intravenous|14C-CORT118335 solution for infusion 100 µg containing not more than 37 kiloBequerel (1 µCi) 14C
39044|NCT03878264|Drug|14C-CORT118335 oral|14C-CORT118335 oral solution 150 mg containing not more than 3.3 megaBequerel (90 µCi) 14C
39045|NCT03878251|Device|Quantitative attention evaluation criteria in intellectual disability|Quantitative interactive attention evaluation tests by using games on touchscreen and or eye tracking (oculometer)
39046|NCT03878238|Dietary Supplement|Probiotic Bths-003|Probiotic with maltodextrin as a carrier.
39047|NCT03878238|Other|Placebo|Placebo with maltodextrin base.
39048|NCT03878225|Dietary Supplement|KME|The ketone mono ester beverage is given five times daily for five days. Each bottle contains 65 mL of the ketone mono ester; beta-hydroxy-byturate.
39049|NCT03878225|Other|Placebo|The placebo beverage is given five times daily for five days. The placebo beverage consists of water, added a bitter flavour, sweetener and starch to mimic the active, dietary supplement with the ketone monoester beverage.
39050|NCT03878212|Other|mHealth application with interactivity|a mHealth device with interactivity with nurse case manager
39051|NCT03878212|Other|mHealth application|a mHealth device
39052|NCT03878199|Drug|Ruxolitinib|PO, B.I.D.
39053|NCT03878199|Drug|CPX-351|Given IV
39054|NCT03878186|Other|Usual Care (UC)|Usual Care: single in-person psycho-educative session with information about HIV, transmission, natural history of the disease, importance of antiretroviral adherence. All the information is based on guidelines and information sheets from InfoVIHt
39083|NCT03877926|Biological|AV7909|AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance is identical in composition and manufacturing process to commercial BioThrax. BioThrax is currently licensed for post-exposure prophylaxis and pre-exposure prophylaxis of anthrax disease in persons at high risk of exposure. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.
39055|NCT03878186|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT): Usual Care + Cognitive-behavioral therapy program intervention (AppraHIV). This intervention involves 7 in-person weekly sessions based on Adjuvant Psychological Therapy centered in three areas: cognitive appraisal, affect and adherence and self-care, everyone with different techniques: cognitive techniques, diaphragmatic breathing, scheduling pleasurable activities, use of pillbox, solving problems, planning for the future, etc. The intervention was manualized (according to Template for Intervention Description and Replication TIDieR), piloted and validated.
39056|NCT03878173|Other|No intervention|No intervention
39057|NCT03878160|Other|Focus Group|Focus groups will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. The interview guide will be piloted with 3-4 participants and refinements will be made as needed before conducting the focus groups. Focus groups will be conducted until thematic saturation is reached. Focus groups will be audio-recorded for transcription and data analysis.
39058|NCT03878160|Other|Individual Interview|Individual Interviews will focus on exploring (a) changes after ACS, such as psychosocial changes and health behavior changes; (b) specific preferences for the MBCT intervention; and (c) potential barriers and facilitators of group videoconferencing and (d) blood spot data collection. Individual interviews will use the same interview guide as focus group participants. Individual interviews will be conducted until thematic saturation is reached. Individual interviews will be audio-recorded for transcription and data analysis.
39059|NCT03878147|Behavioral|Brain Powered Games|Brain Powered Games (BPG) is a computerized cognitive rehabilitation therapy (CCRT) program for neurocognitive assessment and treatment of Sub-Saharan African school-age children suffering from neurological symptoms. BPG is especially intended to help children infected with HIV. BPG consists of 5 core games evaluating different cognitive abilities (learning, memory, language, attention). Each game includes a visual tutorial, several adjustable settings on the administrative side (Admin), and records gameplay data for research purposes.
39060|NCT03878134|Device|PHOTON COUNTING CT|Enrolled patients will undergo the requested clinical diagnostic CT study on the PCCT system using the standard detector, with or without IV and/or oral contrast as indicated. They will also undergo a brief PCCT scan as part of the examination. The scan will thus include both clinically indicated radiation exposure with the standard detector and research radiation with the PCCT detector.
39061|NCT03878121|Biological|Ad4-Env145NFL|10^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.
39062|NCT03878121|Biological|Ad4-Env150KN|10^8 vp doses of Ad4-Env150KN formulated as a liquid for intranasal administration.
39063|NCT03878121|Biological|VRC-HIVRGP096-00-VP (Trimer 4571) with alum|500-mcg dose of protein boost vaccine formulated for intramuscular administration.
39064|NCT03878095|Drug|Ceralasertib|Given PO
39065|NCT03878095|Drug|Olaparib|Given PO
39066|NCT03878082|Drug|Propacetamol 1g|pain control with IVPCA and propacetamol 1g every 6 hours for 2 days
39067|NCT03878082|Drug|Propacetamol 2g|pain control with IVPCA and propacetamol 2g every 6 hours for 2 days
39068|NCT03878082|Drug|IVPCA|pain control with IVPCA
39069|NCT03878069|Biological|elapegademase-lvlr|"Patients transitioning from Adagen: For patients currently receiving Adagen at ≤ 30 U/kg/wk or an unknown Adagen dose, the suggested dosage of Revcovi is 0.2 mg/kg/wk IM. For patients currently receiving Adagen at > 30 U/kg/wk the suggested equivalent Revcovi dosage (mg/kg/wk) is the Adagen dosage in U/kg/wk divided by 150.~At the investigator's discretion, the total weekly dose may be divided and administered in multiple IM injections, increased by 0.033 mg/kg/wk if trough ADA activity is < 30 mmol/hr/L, dAXP is > 0.02 mmol/L, and/or the immune reconstitution is inadequate.~Adagen-naïve patients: The suggested starting Revcovi dosage is 0.2 mg/kg twice weekly IM based on ideal body weight, for a minimum of 12 to 24 weeks until immune reconstitution is achieved. At the investigator's discretion, the dosage may be gradually increased to maintain trough ADA activity > 30 mmol/hr/L, dAXP < 0.02 mmol/L, and/or to maintain adequate immune reconstitution."
39070|NCT03878056|Device|Vaginal: UpholdTM Lite Vaginal Support - Boston Scientific|Apical prolapse reconstructive surgery by Transvaginal mesh vs Robotic sacral colpopexy
39071|NCT03878043|Other|Follow-up Care|Follow up care provided upon readmission to patients who were diagnosed with a TSDH upon initial visit.
39072|NCT03878030|Drug|nusinersen|Subjects will receive nusinersen and be observed with motor assessments for 24 months
39073|NCT03878017|Procedure|skin marking of clip axillary lymph node for localisation|to determine the feasibility of skin marking to localize clipped ln
39074|NCT03878004|Biological|GamTBvac vaccine|introduction of GamTBvac (lyophilisate for preparation of solution for subcutaneous administration, 5.35 mg / dose) twice into a shoulder with an 8-week interval.
39075|NCT03878004|Biological|placebo|introduction of placebo twice into a shoulder with an 8-week interval.
39076|NCT03877991|Drug|CBD-sesame oil capsule|A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
39077|NCT03877991|Drug|CBD-LNL capsule|A capsule containing Cannabidiol dissolved in self nano emulsifying formulation
39078|NCT03877991|Drug|CBD powder form capsule|Powder of Cannabidiol filled in a hard gelatin capsule, without formulation.
39079|NCT03877978|Biological|Nephrocheck test|Nephrocheck® measurement on urine sample at different timepoints.
39080|NCT03877965|Drug|Digoxin|Drug administered per standard of care, with a dosing regimen within the labeled dose range of 7.5-20 mcg/kg/day divided in 2 or 3 equal doses
39081|NCT03877952|Drug|14C-CORT125281|14C-CORT125281 360 mg capsule for oral administration containing not more than 2.5 megaBequerel (67 μCi) 14C
39082|NCT03877939|Diagnostic Test|Blood samples collection for analysis|"Blood samples:~Blood samples will be collected for the determination of the levels of various biomarkers (Kisspeptins and miRNAs), which are molecules that regulate the expression of proteins and can serve as markers for predicting pregnancy viability. Additionally, after biochemical or week 10 of clinical pregnancy confirmation, blood samples will be collected for KIR and HLA-C typing, Oral glucose tolerance test (OGTT) and analysis of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b.~Uterine biopsy (only in patients with BP):~Uterine biopsy samples will be collected also after biochemical pregnancy confirmation for the determination of the levels of miRNAs related with insulin resistance, miR-424-5p and miR-15b."
39084|NCT03877926|Biological|BioThrax|BioThrax (Anthrax Vaccine Adsorbed; AVA), is currently licensed for post-exposure prophylaxis and pre-exposure prophylaxis of anthrax disease in persons at high risk of exposure.
39085|NCT03877887|Diagnostic Test|echo cardiogram|Assessment of left ventricular systolic and diastolic function
39086|NCT03877874|Drug|Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)|Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Epidrone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
39087|NCT03877861|Device|Readiband Sleep Tracking|Once a patient has consented to study progression, a Readiband™ Sleep Tracker device will be provided to the patient, along with necessary instructions. Patients will return home with the device and fatigue data will be obtained from the device at subsequent standard care follow-up visits. In addition, surveys related to fatigue and quality of life will be administered via secure electronic survey to participants.
39088|NCT03877848|Device|Percutaneous Coronary Intervention (PCI)|Patients enrolled to the study will undergo angiography followed by PCI according to current guidelines.
39089|NCT03877835|Procedure|Peripheral nerve blocks|LSIB + SSNB
39090|NCT03877822|Behavioral|Habitual activity|Two days of habitual physical activity, under normal free-living conditions
39091|NCT03877822|Behavioral|Bed rest|Two days of bed rest, to induce whole-body physical inactivity
39092|NCT03877809|Drug|Sirolimus 0.5 mg|Daily administration of 1 or more tablets
39093|NCT03877796|Device|Drug Response Predictor® (DRP)|A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
39094|NCT03877783|Dietary Supplement|mediterranean diet|The recommended Mediterranean diet is based on lean meat, fish, eggs, vegetables, fruits, berries, and nuts. Extra-virgin olive oil is the recommended additional fat source for use in food preparation and dressings. Recommended exclusions or restrictions include dairy products, cereals, added salt, refined fats, and sugar. Participants in the intervention group will receive weekly deliveries of olive oil and mixed nuts, free of cost, and they will receive recipes for Mediterranean meals on a regular basis. During the study, the intervention group will receive written, personalized advice from a project dietician on how to improve their Mediterranean diets. This written personalized advice will be based on the reported food intake, its coherence with a Mediterranean diet, and its adherence to the recommended intakes of energy and nutrients for each participant.
39095|NCT03877783|Behavioral|individualized fitness program|The exercise intervention will consist of individualized training programs designed to improve cardiovascular fitness (VO2). A personal trainer will distribute the training program instructions and monitor the training during the entire intervention. Support will be provided via text messages. The training intensity will be based on results from an extensive pre-test of individual physical fitness performance, and we will adjust the intensity over the study period, as fitness improves. The goal is to engage participants in training three times per week, for up to one hour per training session. The individualized training programs will consist of brisk walks, jogging, and cycling, tailored to each participant. To ensure that the training intensity is sufficient to improve cardiovascular fitness, heart rate will be monitored during each session.
39096|NCT03877783|Other|recommended modified pharmacological treatment|"Hyperglycemia: first metformin till target level of HbA1c 1) 53-58 mmol/mol for patients with ≤2 coexisting chronic illnesses or 2) 59-64 mmol/mol for those with established cardiovascular disease (CVD). We will recommend a second glucose-lowering drug when HbA1c is not achieved and which reduce CVD even when the participant does not have a manifest CVD.~Hypertension: will be treated to achieve a target level according to European guidelines. Start with a combination of a renin-angiotensin system (RAS)-blocker and a thiazide in low dose or a combination of a RAS-blocker a calcium channel blocker in low dose. If the target is not reached within 12 weeks additional drugs should be added.~Dyslipidemia: Patients with a CVD risk of 2-8% within 5 years should receive treatment with atorvastatin 10mg +ezetimib 10mg; CVD risk 8-20%, atorvastatin 20mg + ezetimib 10mg and CVD risk > 20% atorvastatin 40-80mg +ezetimib 10mg."
39097|NCT03877744|Behavioral|interactive virtual presence|parents will install car seat through remote guidance via interactive virtual presence
39098|NCT03877744|Behavioral|live technician|parents will install car seat through guidance from a live certified technician who is present
39099|NCT03877731|Procedure|isolated septal myectomy|
39100|NCT03877731|Procedure|septal myectomy + edge-to-edge mitral valve repair|
39101|NCT03877731|Procedure|septal myectomy + posterior leaflet sliding plasty|
39102|NCT03877731|Procedure|septal myectomy + secondary chordae transection|
39103|NCT03877718|Drug|Arm 1: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 18.75 mg)
39104|NCT03877718|Drug|Arm 2: CL-H1T|One capsule of CL-H1T (total dose: sumatriptan succinate 90mg/promethazine HCl 37.5 mg)
39105|NCT03877718|Drug|Arm 3: Sumatriptan Succinate 100 mg capsule|One capsule of sumatriptan succinate 100 mg
39106|NCT03877718|Drug|Arm 4: Promethazine HCl 18.75 mg|One capsule of promethazine HCl 18.75 mg
39107|NCT03877718|Drug|Arm 5: Promethazine HCl 37.5 mg|One capsule of promethazine HCl 37.5 mg
39108|NCT03877718|Other|Placebo|One capsule of placebo
39109|NCT03877705|Drug|Listerine ready tabs|Technically, it's a rectangular-shaped, bilayer-compressed tablet that once chewed, creates just enough liquid to swish around your mouth to get a whole-mouth clean feeling.As manufacture claimed the tablet is easy to use just in three simple steps: chew (to activate), swish (to clean), then swallow as unlike mouthwashes which may contain alcohol and other ingredients not intended for ingestion, Listerine Ready Tabs are alcohol-free and safe to swallow which is highly suitable for bedridden patients.
39110|NCT03877692|Drug|Experimental dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
39170|NCT03877237|Drug|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
39171|NCT03877237|Other|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
39111|NCT03877692|Other|Standard dosing of labetalol|Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
39112|NCT03877679|Drug|Triamcinolone|Triamcenolone +napolycarboxylate
39113|NCT03877679|Drug|Turmeric paste|Topical turmeric paste (a mixture of curcumin powder and vegetable glycerin base in a ratio of 1:8 by weight) Mix with 85ml carbapol gel (125ml H2O + 0.5g carbapol + triethanolamine 3 drops) prepared in the Faculty of pharmacy-Cairo University
39114|NCT03877653|Device|Wireless neuromodulation|A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.
39115|NCT03877640|Device|BTL EMSELLA|High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.
39116|NCT03877627|Procedure|Pelvic and Peritoneal Lymphadenectomy|Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
39117|NCT03877614|Other|ASCVD risk score|ASCVD score< 10% will be in the control or low-risk group
39118|NCT03877601|Drug|Bevacizumab-IRDye800CW|Topical administration of Bevacizumab-IRDye800CW during the endoscopic procedure.
39119|NCT03877601|Diagnostic Test|Fluorescence endoscopy|Device: Molecular Fluorescence Endoscopy platform A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope.
39120|NCT03877588|Dietary Supplement|Oral Nutritional Support|Preoperative oral nutritional support is provided according to malnutrition grade
39121|NCT03877575|Other|No specific intervention. Collection of clinical data|
39122|NCT03877562|Drug|Olanzapine|Olanzapine 10 mg oral tablet
39123|NCT03877562|Drug|CORT118335|CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
39124|NCT03877562|Drug|Placebo|Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
39125|NCT03877549|Drug|Dexamethasone, Normal Saline|Dexamethasone or Normal Saline given in the epidural space
39126|NCT03877536|Drug|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|Participants will receive 1 tablet per day throughout study duration (96 weeks).
39127|NCT03877523|Dietary Supplement|Cocarnit|a metabolic complex
39128|NCT03877510|Drug|IPX203 140 mg|35 mg - 140 mg CD-LD extended release capsules
39129|NCT03877510|Drug|IPX203 210 mg|52.5 mg - 210 mg CD-LD extended release capsules
39130|NCT03877510|Drug|IPX203 280 mg|70 mg - 280 mg CD-LD extended release capsules
39131|NCT03877510|Drug|IPX203 350 mg|87.5 mg - 350 mg CD-LD extended release capsules
39132|NCT03877497|Behavioral|Adapted SBIRT for transgender women|Transgender women will be screened for substance use. Those at moderate risk or less will be randomized into the study into either the intervention arm (SBIRT-A) or the control arm (CONTROL-C). Those at higher risk will be ineligible for the study and referred for substance use treatment services
39133|NCT03877484|Device|ALLEVYN Gentle border|ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
39134|NCT03877471|Genetic|Cell therapy|Ovary injection with MSC-like cells through transvaginal ultrasound,3 injection points for each ovary.
39135|NCT03877458|Other|L. acidophilus TYCA06, B. longum BLI-02 and B. bifidum VDD088|Taking 1 mix probiotics capsule at bed time everyday for three months.
39136|NCT03877458|Other|L. reuteri GL-104|Taking 1 probiotic capsule at bed time everyday for three months.
39137|NCT03877458|Other|Placebo|Taking 1 placebo capsule at bed time everyday for three months.
39138|NCT03877445|Device|exposition half-face|Patients will be included in the study and exposed on a half-face from Day1 to Day5. The other half-face will serve as unexposed control. The effect of blue light on the melasma lesions will be assessed from Day 1 to Day 6 using chromametry and a modified Melasma Area and Severity Index on standardized photographs
39139|NCT03877432|Device|Dermatome stimulation|Dermatome (S2-S4) stimulation is aimed at improving the function of bladder storage and bladder capacity. A total of 8 serial cystometrograms will be performed: 2 control fills, followed by 4 fills with stimulation, followed by 2 control fills. The minimum (or threshold) stimulation amplitude (T) necessary to elicit the genito-anal reflex was first determined for each subject. Subsequently, each subject received a randomized sequence of cystometric fill trials with and without continuous dermatome stimulation. The dermatome stimulation was randomly stimulated at stimulation amplitudes of 1, 2, 3, and 4 T.
39140|NCT03877406|Drug|Empagliflozin 10 MG|addition of empagliflozin 10 MG
39141|NCT03877406|Drug|Hypoglycemics Oral|dose escalation of hypoglycemics oral
39142|NCT03877393|Combination Product|Probiotic supplementation + gluten-free diet|The probiotic and gluten-free diet group (PRO-GFD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10^9 colony forming units (CFU) per day divided in two equal doses, comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175, and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
39143|NCT03877393|Combination Product|Placebo supplementation + gluten-free diet|The placebo and gluten-free diet group (PLA-GFD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will follow the elimination diet containing no gluten.
40138|NCT03869528|Drug|5 sprays of 10% lignocaine|5 sprays of 10% lignocaine
39144|NCT03877393|Combination Product|Probiotic supplementation + gluten-containing diet|The probiotic and gluten-containing diet group (PRO-GD) will receive one capsule containing the probiotic mixture powder (Sanprobi Stress; Sanprobi sp. z o.o., sp.k., Szczecin, Poland) in the amount of 3 × 10^9 colony forming units (CFU) per day divided in two equal doses comprising two bacteria strains: Lactobacillus helveticusRosell®-52, Bifidobacterium longumRosell®-175 and excipients: potato starch, magnesium stearate, and the capsule shell of hydroxypropyl methylcellulose. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
39145|NCT03877393|Combination Product|Placebo supplementation + gluten-containing diet|The placebo and gluten-containing diet group (PLA-GD) will receive one capsule containing only the excipients, i.e. maize starch, maltodextrins, and the capsule shell. The participants will be asked to consume supplements before breakfast. The group will stay with their current diet.
39146|NCT03877380|Other|semi-structured interview|Semi-strucured interview to identify the difficulties when first applying for a personalised autonomy allowance by beneficiaries and their relatives
39147|NCT03877367|Other|Upper extremity manipulation|An upper extremity (glenohumeral, humeroulnar and radioulnar joints, bilaterally) or a lower extremity (coxofemoral, tibiofemoral, and tibiotalar, bilaterally) manipulation series.
39148|NCT03877354|Other|Data from anaesthesia records for ventilation setting screening|Data from anaesthesia records will be retrospectively screened for the ventilation settings
39149|NCT03877354|Other|Data from intensive care records for ventilation setting screening|Data from paediatric intensive care charts will be retrospectively screened for the ventilation settings
39150|NCT03877341|Device|X-RAY|x-ray on lumbosacral antro-posterior and lateral and dynamic veiws CT lumbosacral +mri lumbosacral
39151|NCT03877328|Other|BiotechCoachForAll|Participants randomized to the intervention group will receive the Virtual Coach program and a training program will be assigned to them to work on it for an 8-week period. The exercise-based rehabilitation program will be implemented through the FitForAll platform and will include aerobic and strength training elements designed to improve both aerobic capacity and muscle strength. Aerobic training will involve the activation of a large skeletal muscle mass through a given walking exercise of 30 minutes in duration. Strength training program will involve upper and lower body muscle groups with the subject completing a number of training sets at a fixed percentage of a repetition maximum. The programs must be repeated on a three- time per week basis. The subject will be trained in performing the given programs by dedicated site personnel after the randomization to the study and before leaving the study center.
39152|NCT03877328|Other|FitForAll|The control subjects will also perform all the intervention approaches described as usual care methodology (exercise through the FitForAll, counselling, advices) but without the assistance of the virtual coach. Usual care will consists of education and counseling of the subjects on the underlying disease and the existing comorbidities, discussion on behavioral strategies to increase adherence to prescribed diet and medications, advices on how to increase physical activity and on committing strategies to improve their ability to perform daily activities, detailed education on monitoring the signs and symptoms of decompensation, including daily weighing and advisement on what to do in case of development of signs and symptoms.
39153|NCT03877315|Device|Stemmed shoulder arthroplasty, Biomet Comprehensive® Total Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
39154|NCT03877315|Device|Stemless shoulder arthroplasty, Biomet Comprehensive® Nano Shoulder System.|A total shoulder prosthesis used in treating glenohumeral osteoarthritis
39155|NCT03877302|Other|reflexology|foot reflexology
39156|NCT03877289|Drug|Oxybutynin|Oxybutynin is a tertiary amine anticholinergic. It exerts both antispasmodic and antimuscarinic activity on smooth muscle. It also exerts analgesic and local anaesthetic effects.
39157|NCT03877289|Other|"Orasweet Liquid Placebo"|A formulated Oxybutynin placebo that is nearly identical in appearance, volume, weight, taste, and smell.
39158|NCT03877276|Dietary Supplement|Breakfast|a prepared meal consisting of pastry and 2 cooked egg whites
39159|NCT03877276|Dietary Supplement|Spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and spinach
39160|NCT03877276|Dietary Supplement|Kale smoothie|prepared blended kale smoothie, consisting of banana, avocado, orange juice, and kale
39161|NCT03877276|Dietary Supplement|Blended smoothie|a prepared blended smoothie, consisting of banana, avocado, and orange juice
39162|NCT03877276|Dietary Supplement|V spinach smoothie|a prepared blended spinach smoothie, consisting of banana, avocado, orange juice, and a varying amount (low, medium, high) of spinach
39163|NCT03877276|Dietary Supplement|Sodium oxalate drink|a prepared sodium oxalate drink
39164|NCT03877263|Diagnostic Test|Endocervical swab for detection of STI|After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.
39165|NCT03877263|Diagnostic Test|Vaginal swab for detection of STI|"After we collect the samples, they will be evaluated using the Hologic APTIMA Chlamydia trachomatis and Neisseria gonorrhoeae assays.~We will then compare the results from a vaginal vs. endocervical specimens within and between the groups"
39166|NCT03877250|Diagnostic Test|Pre-Treatment Biopsy|Participants screened for participation will include those with a diagnosis of advanced NSCLC who have undergone a pre-treatment biopsy prior to start of therapy with a PD-(L)1 inhibitor or who are medically able to undergo a biopsy if (1) no pre-treatment biopsy has been obtained and (2) no PD-(L)1 inhibitor has been started.
39167|NCT03877250|Diagnostic Test|On-Treatment Biopsy|All participants who receive at least 1 dose of PD-(L)1 inhibitor will be referred for a biopsy. The biopsy should be obtained within 4 weeks of first on-treatment imaging (usually performed ~6-9 weeks after beginning therapy) and will be performed in participants regardless of radiologic response.
39168|NCT03877250|Diagnostic Test|Biopsy at Disease Progression|All participants who develop disease progression after initial response to PD-(L)1 blockade will be considered for an additional, optional biopsy. Biopsies at disease progression are often obtained per standard of care within 4 weeks of documented progression on imaging and prior to the initiation of further systemic therapy.
39169|NCT03877250|Diagnostic Test|Peripheral Blood-Based Studies|All participants will have peripheral blood obtained on Day 1 of cycles 1-4 (0, 3, 6, and 9 weeks). At each time point, peripheral blood sample will be collected pre-treatment and used for analysis of T cell subsets and TCR sequencing.
39174|NCT03877211|Other|speech audiometry in noise|Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.
39175|NCT03877211|Other|Psychophysical tuning curves in forward masking|Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
39176|NCT03877211|Other|Electrically-evoked Auditory Brainstem Response (EABR)|Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.
39177|NCT03877211|Other|Tonal audiometry|Tonal audiometry will be performed with headphones
39178|NCT03877211|Other|Auditory canal examination|Otoscopic examination of external auditory canal and eardrum
39179|NCT03877198|Device|Automated oxygen control by the CLiO2 algorithm|Automated oxygen control for 24 hours by the CLiO2 algorithm, preceded by a 1 hour wash-out period
39180|NCT03877198|Device|Automated oxygen control by the Oxygenie algorithm|Automated oxygen control for 24 hours by the Oxygenie algorithm, in case of switch in ventilator preceded by a 1-hour wash-out period.
39181|NCT03877185|Diagnostic Test|Live birth rate|Live Birth Rate and Blastulation Rate according to the protocol of COS
39182|NCT03877172|Device|High-flow nasal cannula|To provide high-flow nasal cannula in the immediate postoperative period after lung resection surgery as compared to conventional face-mask therapy, in a randomized sequence, for 30 minutes.
39183|NCT03877159|Other|There is no intervention.|There is no intervention. This is a retrospective study analysing archived tumour samples.
39184|NCT03877146|Behavioral|Controlled Breathing Intervention|Participants in the controlled breathing intervention will be provided with headphones to listen to the guided intervention audio file. The intervention will guide participants to breathe at a rate of six breaths per minute (approximately 50% of their normal breathing rate).
39185|NCT03877133|Device|Near-infrared spectroscopy|Regional oxygen saturation probe is applied to the skin near the kidney bilaterally and is connected to the regional oxygen saturation monitor.
39186|NCT03877120|Drug|Dexmedetomidine 0.004 MG/ML|Experimental studies and single case reports suggest the α2-agonist dexmedetomidine is effective in managing the autonomic symptoms seen with alcohol withdrawal.
39187|NCT03877120|Drug|Diazepam Injectable Solution|diazepam start with 5-20 mg IV as a dose response, steps until a maximum dose of 120 mg diazepam.
39188|NCT03877107|Diagnostic Test|Urinary symptoms profile questionnaire|Validated questionnaire (international) with validated french translation, before and after lumbar puncture, and after surgery if surgery is realized
39189|NCT03877107|Diagnostic Test|Micturition calendar|Micturition calendar on 2 consecutive days, before and after lumbar puncture, and after surgery if surgery is realized
39190|NCT03877094|Behavioral|Nature virtual reality video|the patient will receive a head-set dispositive to watch a nature virtual reality video during the whole procedure of breast biopsy
39191|NCT03877081|Biological|Probiotics|Administration of oral probiotics with 2 doses a day
39192|NCT03877081|Other|Placebo|Administration of oral placebo with 2 doses a day
39193|NCT03877068|Device|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay up to 10 days using the Dexcom Studio software to download the Dexcom receiver data.
39194|NCT03877068|Diagnostic Test|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay up to 10 days.
39195|NCT03877055|Drug|Copanlisib|Treatment will be with intravenous copanlisib on days 1, 8, 15 of 28 day cycles.
39196|NCT03877055|Drug|Ibrutinib|Oral ibrutinib daily in 28 day cycles. A cycle is defined as 28 days of therapy.
39197|NCT03877042|Device|Cruciate-retaining (CR) prostheses|One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
39198|NCT03877042|Device|Posterior-stabilized (PS) prostheses|One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
39199|NCT03877016|Procedure|TENS|TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
39200|NCT03877003|Other|Eggs|Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
39201|NCT03876990|Diagnostic Test|Multiplex PCR|Quick adaptation of antibiotic treatment according to the species identified and to the results of the resistance markers present in the multiplex PCR
39202|NCT03876990|Diagnostic Test|Current strategy alone|Identification of bacteria and micromyces isolated in blood cultures after subculture by mass spectrometry (MALDI-TOF) and determination of their sensitivity to antibiotics or antifungals by antibiotic susceptibility testing or antifungigram
39203|NCT03876977|Procedure|Robotic laparoscopic decompression of pudendal nerve entrapment|"Robotic laparoscopic decompression of pudendal nerve entrapment.~Transperitoneal Laparoscopic Robotic assistance"
39204|NCT03876964|Device|Transcatheter Aortic Valve Replacement|Minimally invasive replacement of the aortic valve through a catheter.
39205|NCT03876951|Diagnostic Test|Vacuum-assisted biopsy|Patients will be submitted to percutaneous vacuum-assisted biopsy (VAB), followed by breast surgery.
39206|NCT03876938|Drug|aprepitant|aprepitant 125 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy aprepitant 80 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
39207|NCT03876938|Drug|olanzapine 10 mg|olanzapine 10 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 10 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
39905|NCT03871348|Drug|SAR441000|"Pharmaceutical form: concentrate for solution for injection~Route of administration: intratumoral"
39208|NCT03876938|Drug|olanzapine 5 mg|olanzapine 5 mg orally, dexamethasone 12 mg iv, ondansetron 8 mg iv before chemotherapy olanzapine 5 mg orally D2-4, dexamethasone 8 mg/day orally D2-4
39209|NCT03876925|Drug|CT053PTSA|Patients will received oral CT053PTSA once daily until disease progression or intolerable toxicity or subject's withdrawal from treatment ,each cycle is defined as 28 days
39210|NCT03876912|Drug|Gn-RH antagonist|18F-PSMA PET/CT before, 2-3 weeks after ADT and at CRPC in 35 patients. 18F-FDG PET/CT in a subgroup of 10 patients before ADT. Additional 18F-PSMA PET/CT after the end of early chemotherapy/RT in another subgroup of 21 patients.
39211|NCT03876899|Dietary Supplement|Evening Primrose Oil|botanical oil derivative from the seeds of Evening Primrose (Oenothera biennis),1,300 milligrams t.i.d.
39212|NCT03876899|Dietary Supplement|Placebo|Pill
39213|NCT03876886|Drug|Epirubicin|Epirubicin 90mg/m2 iv d1 or divide into two days
39214|NCT03876886|Drug|Cyclophosphamide|cyclophosphamide600mg/m2 iv d1,q14d*4cycles;with G-CSF support: 3ug/kg ih
39215|NCT03876886|Drug|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d*4cycles
39216|NCT03876886|Drug|Carboplatin|carboplatin AUC=3 iv d2, q14d*8cycles;with G-CSF support: 3ug/kg ih
39217|NCT03876886|Drug|Paclitaxel|paclitaxel 175mg/m2 iv d1, q14d*8cycles
39218|NCT03876873|Procedure|Head Rotation During Face Mask Ventilation|Participants will receive face mask ventilation in either a neutral head position (practice standard position) or a head rotation position (45 degree angle).
39219|NCT03876873|Device|Medline Top Valve Anesthesia Mask|Face mask used per standard of care to provide oxygen to subjects before surgical procedures.
39220|NCT03876860|Device|Silicone Dilator|Addition of silicone band to standard vaginal dilator
39221|NCT03876860|Device|Standard Dilator|Standard vaginal dilator
39222|NCT03876834|Other|respiratory training|Respiratory training was done by using threshold inspiratory muscle trainer(Respironics, New Jersey , USA, No.8373-0730)
39223|NCT03876808|Device|Bair Hugger™ Temperature Management Unit Model 750|Forced-air temperature management unit used for preoperative and intraoperative participant warming
39224|NCT03876808|Device|3M™ Bair Paws™ Flex Gown|Bair Paws™ patient warming gown used for preoperative and intraoperative participant warming
39225|NCT03876795|Biological|Bone Marrow Concentrate|Bone Marrow Concentrate injection
39226|NCT03876782|Diagnostic Test|IOLMaster|IOL power calculation will be done with IOLMaster
39227|NCT03876782|Diagnostic Test|Verion|IOL power calculation will be done with Verion
39229|NCT03876756|Other|postpartum acute urinary retention|Collection of risk factors
39230|NCT03876756|Other|no postpartum acute urinary retention|Collection of risk factors
39231|NCT03876743|Other|Group 1-Knee Arthroscopy|Will have all of their post-operative prescriptions sent down to the pharmacy on the day of surgery to be collected.
39232|NCT03876743|Other|Group 2-Knee Arthroscopy|Will have all prescriptions sent to pharmacy with the exception of an opiate prescription. Instead, they will be handed a physical paper prescription. They will be instructed to only fill the prescription if absolutely needed.
39233|NCT03876743|Other|Group 1-ACL reconstruction|Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
39234|NCT03876743|Other|Group 2-ACL reconstruction|Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
39235|NCT03876730|Other|ICF CP Core Set|Core set
39236|NCT03876717|Drug|Colesevelam Hydrochloride|Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
39237|NCT03876717|Drug|Placebo oral capsule|Inactive placebo tablets over-encapsulated with DB caps AAA
39238|NCT03876704|Drug|High dose of fat-Soluble Vitamin|Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion
39239|NCT03876704|Drug|Conventional dose of fat-Soluble Vitamin|Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion
39240|NCT03876691|Other|Patients|Patients who are considered as terminally ill and would not benefit from aggressive treatment, who physicians suggest to family about a do-not-resuscitate.
39241|NCT03876691|Other|Physician|The current emergency medical department departments within the preparation of the attending physician
39242|NCT03876678|Other|Lactobacillus Salivarius AP-32|Taking 1 probiotic capsule two times everyday for 7 days.
39243|NCT03876678|Other|Bifidobacterium Animalis subspecies Lactis CP-9|Taking 1 probiotic capsule two times everyday for 7 days.
39244|NCT03876678|Other|Placebo|Taking 1 placebo capsule two times everyday for 7 days.
39245|NCT03876665|Other|No intervention|No intervention
39246|NCT03876652|Device|Pacemaker with Closed Loop Stimulation (CLS)|In active mode of closed loop sensor (CLS), evaluate its impact on quality of life and recurrence of syncope.
39247|NCT03876639|Other|Application of emulsion|Daily application of the assigned formulation on the non-dominant volar forearm for 4 weeks
39248|NCT03876639|Procedure|Measurement of physiological skin parameters|Weekly measurement of physiological skin parameters using confocal Raman spectroscopy, Corneometer® CM 825, Sebumeter®, Skin-pH-Meter®, AquaFlux® and Epsilon®
39249|NCT03876639|Procedure|Tape stripping|Removal of 40 adhesive strips after application of a model drug-loaded emulsion and determination of the transepidermal water loss
39250|NCT03876626|Other|PositiveLinks RX Mobile App|A mobile app designed with tools to facilitate patient self-monitoring, patient-provider communication, medication refills, and social support.
39251|NCT03876626|Other|PositiveLinks RX Portal|An online portal that interacts with the mobile app to enable users to engage with participants though messaging and medication refill tracking.
39252|NCT03876613|Behavioral|Different music types|the type of music that reduces anxiety best and most effectively.
39574|NCT03873948|Other|Evaluation of arginine serum level|correlation of serum arginine level with periodontal and cardiovascular disease
39253|NCT03876600|Procedure|Replacement of permanent pacemakers for elective wear.|"START's intervention is a replacement of permanent pacemakers for elective wear, for the both arms the surgical intervention is the same. The surgical procedure is the same in the both arms.~The differences are in conventional hospitalization, patient comes to hospital one day before operation and he can go out one day after operation. In ambulatory patient come to hospital operation days and he can got out the same day."
39254|NCT03876587|Drug|Pyrotinib Maleate combine with Docetaxel|Pyrotinib Maleate combine with Docetaxel as the first-line treatment to HER2-positive Metastatic Breast Cancer
39255|NCT03876574|Procedure|DSA-guided implantation of hepatic artery infusion pump|Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
39256|NCT03876574|Drug|Gemcitabine|Given intra-arterially for 30 minutes
39257|NCT03876574|Drug|Floxuridine|Given intra-arterially continuously for 14 days
39258|NCT03876574|Drug|dexamethasone|Given intra-arterially continuously with 5-FUDR
39259|NCT03876561|Procedure|Pelvic floor prehabilitation|The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 session per week before stoma closure and 1 session per week during 6 weeks following stoma closure. The prehabilitation will be performed according to a predefined protocol based on a biofeedback strategy.
39260|NCT03876548|Device|Cadexomer Iodine Gel|Subjects will apply gel product to keloid scar site every other day for 28 days following keloid scar revision surgery.
39261|NCT03876535|Other|Nanomix eLab® System molecular diagnostic test (non-interventional)|This is not an interventional study. It involves performance equivalence demonstration of a point of care diagnostic system to FDA cleared predicate devices currently used in sepsis and SIRS diagnosis.
39262|NCT03876509|Diagnostic Test|Impedance Cardiography|"Impedance Cardiography will be conducted in patients with suspected Pulmonary Hypertension within an interval of 24 hours to right-heart catheterization. Usually, 8 electrodes will be attached on the neck and thorax of the patient. These electrodes will produce current (max 400µA) and measure the voltage which is produced by the current running through the body. The Signal will be analyzed for specific signs of Pulmonary Hypertension.~At the same time electrocardiography and non-invasive continuous blood pressure will be measured."
39263|NCT03876496|Device|SensableCare System|"The Sensable®Care Mattress has sensors embedded in it. Sensable®Care System is able to identify if the subject is stirring in bed, sitting up from the bed, attempting to leave the bed, or being out of the bed. If the subject is found to be in any of these four scenarios, four different types of alerts/notifications will warn clinicians: Stirring Notification, Sitting Up Notification, Bed Leaving Alert, Out of Bed Alert, will be generated by Sensable®Care System respectively.~Once these four alerts/notifications are generated, designated attending nurses or caregivers equipped with a mobile app will receive audible, vibratory, and/or visual alerts from the Dashboard with subject's room number and type of alert displayed mobile app. Thus, interventions/assistance can be carried out presumably early. Harm to patient safety may be prevented."
39264|NCT03876483|Behavioral|Virtual peer support group|Intervention package will consist of a WhatsApp group setup and organized by the study. Participants will be divided into 1-3 WhatsApp groups, each with 10-55 youth. Each group will be facilitated by a study staff member trained as a counselor. The facilitator will send weekly messages to the group. Messages from the facilitator will not contain overtly HIV-related language. These messages are intended to spark unstructured discussion among study participants, or with the facilitator, at any time through the WhatsApp group or individually. Subsequent messages from the study will answer participant questions or correct misinformation. Standard operating procedures (SOPs) will be developed for standardizing responses to the questions received so that study staff follow national guidelines and local practice standards to respond.
39265|NCT03876470|Other|Hepatitis C treatment as chosen by provider|Participants' providers will determine the type of HCV treatment as appropriate.
39266|NCT03876457|Device|Endovascular thrombectomy with stent retrievers: Trevo®, Solitaire®, and EmboTrap Revascularization Device|Patients randomized to endovascular thrombectomy arm will receive thrombectomy plus medical management. They will be treated with thrombectomy devices (stent‐retrievers) with/without suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke within 24 hours of symptom onset. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and EmboTrap Revascularization Device. Stent retrievers will be used as the primary mode of thrombectomy with adjunctive use of the aspiration devices approved by the FDA (MicroVention SOFIA Catheter, and the Penumbra thrombectomy system) permitted in the study.
39267|NCT03876457|Other|Medical Management|Patients will receive standard AHA guideline-directed medical therapy, which will include IV-tPA in patients presenting within the first 3 hours from last-seen-normal and meeting other FDA label criteria. For non-tPA treated patients, this will include aspirin 325 mg on day 1 followed by aspirin 81 mg or 325 mg thereafter, which will be determined by treating physician and standard deep venous thrombosis prevention therapy. Intravenous anticoagulation and dual anti-platelet therapy will be discouraged without clear documented reasoning. Post-tPA patients will be treated based on standard study site protocols for these patients.
39268|NCT03876444|Drug|Intravenous Methylprednisolone|Intravenous Methylprednisolone will be used in the intervention group
39269|NCT03876444|Drug|Oral Pednisolone|Oral Prednisolone will be used in the Control Group
39270|NCT03876431|Device|Easy-Flex|The Easy-Flex device will be used to increase knee flexion and extension ROM.
39271|NCT03876431|Other|Exercise|After total knee replacement surgery, exercise program including strengthening, stretching and patient training will be applied.
39272|NCT03876418|Diagnostic Test|Intra-abdominal Pressure|Aggressive screening, prevention and treatment of intra-abdominal hypertension
39273|NCT03876405|Device|smartskin non-invasive sensory feedback|"The sensory feedback system used was a simple non-invasive, non-electronic system based on air-mediated pressure. A silicone glove with bulbs (35 mm in length) volar in every fingertip was made and applied on a VariPlus Speed hand (OttoBock), size 7¾.~The sensory feedback system was embedded in the prosthetic socket."
39274|NCT03876392|Diagnostic Test|magnetic resonance imaging|Compare bone marrow biopsy with magnetic resonance imaging to detect bone marrow metastases
39275|NCT03876366|Other|online survey|Part 1: online survey (quantitative) with questions on basic socio-demographic data, medical data and family characteristics (e.g. age, ethnicity, education) and information about FP.
39276|NCT03876366|Other|focus group meeting|Part 2: At the end of the online survey, participants are invited to attend one of the consecutively performed focus groups conducted according to standardized focus group methodology and moderated by a clinical psychologist and a specialist in reproductive medicine.
39277|NCT03876353|Other|Floss|All participants will have half of their mouth flossed. Each participant will act as their own control.
39278|NCT03876340|Other|Treatment algorithm|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures. The thermograms will be used to dictate the initial treatment.
39279|NCT03876340|Other|Current treatment|Digital infrared thermograms will be obtained during the first contact with the patients. Temperature recordings of the injured and healthy skin will be used to calculate the temperature difference between the structures, but the results will be kept sealed until the study is finished. The patients will receive the usual standard of care as dictated by the surgical team.
39280|NCT03876327|Procedure|fecal microbial transplantation|Fecal microbiota transplantation (FMT) is a technique in which intestinal microbiota are transferred from a healthy donor to the patient, with as primary goal to introduce - or restore - a stable and 'healthy' microbial community in the gut.
39281|NCT03876314|Behavioral|Physical Activity Condition|Subjects will attend group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. At every session, exercise specialists will record the amount of time spent in the aerobic and strength training portions of the program and HR (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE) from each participant during the middle portion of aerobic activity and RPE during the middle portion of strength training. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.
39282|NCT03876301|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
39283|NCT03876288|Device|GI Neuromodulation|The investigators would include follow up with: No treatment; temp GES only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
39284|NCT03876288|Drug|Immunotherapy|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
39285|NCT03876288|Procedure|Pyloric Therapies|The investigators would include follow up with: No treatment; temp gastric electrical stimulation (GES) only; temp followed by Perm GES; Other device therapies; specific pain therapies; drug therapies, including investigational drugs; immunotherapy; pyloric therapies; psychological/behavioral therapies; nutritional support; radiological and surgical therapies; infection rates related to procedures; if enrolled in any therapy research trials; morbidity and mortality after specific therapies; other treatments used.
39286|NCT03876262|Drug|Moxidectin|2mg tablets, encapsulated for blinding
39287|NCT03876262|Drug|Ivermectin|3mg tablets, encapsulated for blinding
39288|NCT03876249|Other|exposure to RSV|No intervention will be given, children naturally exposed to RSV in their early life
39289|NCT03876210|Combination Product|PK101|PK101-001 + PK101-002 (combination)
39290|NCT03876210|Drug|PK101-001, PK101-002|coadministration
39291|NCT03876197|Biological|Autologous adipose-derived mesenchymal stem/stromal cells or placebo|Intraglandular injections of Autologous adipose-derived mesenchymal stem/stromal cells or placebo
39292|NCT03876184|Other|Aesthetic archwires|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
39293|NCT03876184|Other|Control group|During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
39294|NCT03876171|Behavioral|Haitian youth and family intervention study: family functioning|A weekly group therapy with the youth, the parents and other members of the family.
39295|NCT03876171|Behavioral|Haitian youth intervention study: youth psychoeducational|Weekly one and one psychoeducational module will be delivered to the youth.
39296|NCT03876171|Behavioral|Haitian family intervention study: family psychoeducational|Weekly psychoeducational module will be delivered to the family.
39297|NCT03876171|Behavioral|Diversion Programs|Youth will attend individual psychological counselling at an assigned Juvenile Services Department (JSD) diversion program.
39298|NCT03876158|Device|Prometra II Programmable Pump system(Flowonix Medical)|This valve gated Prometra II Programmable Pump system will be replacing prior peristaltic Synchromed II pump
39575|NCT03873935|Other|Evaluation of periodontal status|Clinical examination
39299|NCT03876145|Other|Minimal ovarian stimulation|After obtaining informed consent to participate in the study, the subjects will be randomly divided into the following 4 groups: The group of minimal ovarian stimulation with rec-FSH or HMG. The group of mild ovarian stimulation with rec-FSH or HMG. In all 4 experimental groups, after reaching at least three follicles the size of 12 millimeters (mm), daily administration of 0.25 milligram (mg) Cetrotide (antagonist GnRH) will be started and after reaching at least three follicles the size of 17 mm, 500 microgram Ovitrelle (recombinant Human curionic gonadotropin) will be prescribed. 36 hours later, ovulation process will be done. On the day of Ovitrelle administration, serum levels of estradiol and progesterone will be also evaluated. Based on the patient's condition and the quality of obtained oocytes and embryos, 2 embryos will be transferred.
39300|NCT03876119|Drug|Intraarterial alteplase|See arm/group descriptions.
39301|NCT03876119|Drug|Placebo|See arm/group descriptions.
39302|NCT03876106|Drug|LUT014|Topical
39303|NCT03876080|Other|Dry needling|The use of a solid filiform needle to treat trigger points
39304|NCT03876080|Other|Sham needling|Simulated needling
39305|NCT03876067|Drug|Ozone|"Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:~50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).~At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution"
39306|NCT03876067|Drug|Cardioplegic Solutions|in which in which only cold blood cardioplegia
39307|NCT03876054|Device|Spinal cord stimulation (SCS)|Subjects will be implanted with market-released Abbott SCS systems
39308|NCT03876054|Device|Dorsal root ganglion stimulation (DRG)|Subjects will be implanted with market-released Abbott DRG system
39309|NCT03876041|Drug|solumedrol|intravenous solution for injection
39310|NCT03876041|Drug|Dexamethasone phosphate|intravenous solution for injection
39311|NCT03876028|Biological|Tisagenlecleucel|Infusion
39312|NCT03876028|Drug|Ibrutinib|Oral (tablets or capsules)
39313|NCT03876015|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
39314|NCT03876002|Drug|[18F]PBR06|Subjects will undergo PET imaging using 1 single intravenous (IV) injection of [18F]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
39315|NCT03875989|Procedure|Anterior colporraphy|It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.
39316|NCT03875989|Procedure|vaginal patch plastron|It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
39317|NCT03875976|Procedure|Fast Track Protocol|Fast Track Care consists in educational preoperative preparation for patients, particular strategies for controlling pain and intensive early rehabilitation protocol
39318|NCT03875976|Procedure|Standard Care Protocol|Standard Care Protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol
39319|NCT03875963|Other|Antibiotic loaded bone filler|Defect management by placement of antibiotic loaded Stimulan as a bone void filler [calcium sulfate bone void filler (10 cc of STIMULAN(R) Rapid Cure, Biocomposites Ltd, UK) combined with the following antibiotic combination: 1g Vancomycin, 240mg Tobramycin].
39320|NCT03875950|Behavioral|Clinician training intervention|This intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers delivering PrEP to adolescent girls and young women to prevent HIV in Kenya.
39321|NCT03875937|Drug|Tranexamic 1 gram|To be administered intramuscularly (2 injections)
39322|NCT03875924|Other|VWD treatments|Modalities and types of treatments in VWD patients for severe hemorrhagic events: INN, quantities, duration of treatment
39323|NCT03875911|Drug|Mitomycin C|Three delivery methods of Mitomycin-C in Trabeculectomy
39324|NCT03875898|Other|150 g bread fortified (15 g mix fibre)|Daily consumption of 150g of a bread fortified in fibre mix (15g) during eight weeks.
39325|NCT03875898|Other|150 g unfortified bread|Daily consumption of 150g of an usual bread in fibre-unfortified bread during eight weeks
39326|NCT03875885|Behavioral|CONNECT|A novel web-based intervention with input from an advisory panel of cancer caregivers, oncology providers, and psychosocial oncology professionals empowering caregivers with needs to seek services by providing education about the benefits of supportive care resources, systematically identifying their unmet needs, and connecting them with tailored supportive care resources.
39327|NCT03875885|Behavioral|CONTROL|This group will receive a generic resource list.
39328|NCT03875872|Drug|Propofol|Patients who had surgeries and were anaesthetized with propofol at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
39329|NCT03875872|Drug|inhalation anaesthetics|Patients who had surgeries and were anaesthetized via inhalation at Queen Mary Hospital, Hong Kong from Jan 2015 to Dec 2017
39330|NCT03875859|Drug|Remetinostat|Topical 1% remetinostat gel
39331|NCT03875846|Diagnostic Test|Intraoperative Hemodynamic Pressures|Secondary analyses will examine the Ankle-Brachial Index, and the absolute limb pressures. In addition, the changes in flow rate of contrast before- and after- intervention will be examined as an indicator of perfusion.
39332|NCT03875846|Diagnostic Test|Contrast Flow Rate|A secondary analysis will examine the rate of contrast flow during pre-intervention and post-intervention angiograms, and correlate these findings with hemodynamic measurements recorded during surgery.
39333|NCT03875833|Device|Collagen Nerve Wrap Conduit|The collagen nerve wrap conduit will be placed on all exposed radial and ulnar nerves at the time of free flap harvest.
39334|NCT03875820|Drug|RO5126766|"RO5126766 will be supplied as 0.8mg hypromellose (HPMC) capsules for oral administration. The capsule fill consists of RO5126766 and the inactive ingredients mannitol and magnesium stearate.~RO5126766 will be administered on a twice weekly (Monday and Thursday or Tuesday and Friday) schedule for 3 weeks followed by 1 week off in every 4 week cycle, under fasting conditions (approximately 1 hour prior or 2 hours after a meal). The starting dose, based on the previous Phase I trial will be 3.2 mg given orally as a single daily dose. This can be escalated to a maximum of 4mg (as per dose escalation rules in the protocol)."
39335|NCT03875820|Drug|VS-6063|"VS-6063 is formulated as a white to off-white oval tablet for oral administration and supplied in single unit dose strength of 200 mg in 120 cc (HDPE) bottles. In addition to VS-6063, formulation components include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, and magnesium stearate.~Patients will receive VS-6063 orally immediately after a meal twice daily (approximately every 12 hours) for 3 weeks followed by 1 week off in every 4 week cycle. The starting dose will be 200mg. This can be escalated to a maximum of 400mg (as per dose escalation rules in the protocol)."
39336|NCT03875807|Procedure|ACLR done at 0 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 0 degrees knee angle flexion (KFA)
39337|NCT03875807|Procedure|ACLR done at 30 degrees KFA|Patients randomized to this arm will undergo the following intervention: Anterior Cruciate Ligament Reconstruction (ACLR) done at 30 degrees knee angle flexion (KFA)
39338|NCT03875794|Other|Osteopathic Manipulation|Using osteopathic manipulation as an intervention to increase milk supply in lactating women.
39339|NCT03875781|Drug|Chemotherapy|"Arm A : Experimental~Intervention Type : Drug~Intervention Name : Modified FOLFIRINOX (experimental arm)~Intervention Description : preoperative chemotherapy: Modified FOLFIRINOX regimen comprised oxaliplatin 85mg/m2 + irinotecan 180mg/m2 + Folinic acid 400 mg/m2 at day1, then 5-FU given as a continuous infusion over 46h every two weeks. Six cycles are planned preoperatively."
39340|NCT03875781|Drug|Radiochemotherapy|"Arm B: Active comparator~Intervention Name : preoperative standardized radiochemotherapy (control arm)~Intervention Description : preoperative radiochemotherapy with concurrent capecitabine 825 mg/m2/12h 5 days/week and intensity modulated radiation therapy using a simultaneous integrated boost technique with 45 Gy in 20 fractions in pelvic volume and 50 Gy in 20 fractions to the tumor."
39341|NCT03875768|Behavioral|Tracking Plus Coaching|For 6-months, participants will track their diet daily using Nutritionix and receive automated feedback daily via text message based on their Dash score and responsive coaching.
39342|NCT03875755|Dietary Supplement|Myo Inositol|One soft gel capsule containing MI 600 mg and folic acid 200 μg twice a day, until delivery.
39343|NCT03875755|Other|Placebo|One soft gel capsule of placebo (folic acid 200 μg) twice a day until delivery.
39344|NCT03875742|Device|Ultraplex 360(Braun)|"This group will use as first needle the ultraplex 360 (Braun)"
39345|NCT03875742|Device|STIMUPLEX D SH, 30°(Braun)|"This group will use as first needle the  STIMUPLEX D SH, 30° (Braun)"
39346|NCT03875729|Biological|teplizumab|Treatment
39347|NCT03875729|Biological|Placebo|Control
39348|NCT03875716|Radiation|Radiation therapy|Radiation therapy
39349|NCT03875690|Drug|Injection of methylprednisolone|Patients will receive 20mg/kg IV of methylprednisolone at the time of anaesthetic induction. Methylprednisolone will be infused in a ready-to-use 50 mL bag of sodium chloride 0.9% during 30 minutes at anaesthesic induction.
39350|NCT03875690|Drug|Injection of sodium chloride|patients in the placebo group will receive 50 mL of sodium chloride 0.9% in a ready-to-use bag during 30 minutes at anaesthesic induction.
39351|NCT03875690|Biological|Blood samples|electrolyte panel and glycemia performed within the first 24 hours after surgery.
39352|NCT03875677|Device|HD-tDCS group|5 sintered Ag/AgCl ring electrodes will be used at a radius of ~5cm. The electrodes will be placed inside plastic electrode holders which will be filled with gel to have better contact with the scalp.
39353|NCT03875677|Device|Conventional tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
39354|NCT03875677|Device|Sham HD-tDCS group|A pair of 25 cm2 rubber electrodes enclosed in saline-soaked sponges and affixed to the head with rubber bands.
39355|NCT03875664|Drug|Liposomal bupivacaine|Extended-release local anesthetic
39356|NCT03875664|Drug|Placebo - injection|Injectable normal saline solution
39357|NCT03875651|Device|SYNERGY 4.50 mm and 5.0 mm Coronary Stent System|The SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System), manufactured by BSC, is a device/drug combination product comprised of two regulated components: a device (Coronary Stent System) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating).
39358|NCT03875638|Drug|Levetiracetam|Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability
39359|NCT03875638|Drug|Placebo oral capsule|The placebo is a capsule that is identical in appearance to the levetiracetam
39360|NCT03875625|Procedure|Bariatric surgery|Use of the normal bariatric surgery procedures commonly conducted in our hospital, such as: Laparoscopic Roux-en-Y gastric bypass (RYGB) and Laparoscopic sleeve gastrectomy (LSG)
39361|NCT03875625|Behavioral|Dietitian led life style modification intervention|Intensive 6 months life style changes supervised by diatitians.
39362|NCT03875625|Behavioral|Conventional care (control)|receive routine care
39363|NCT03875599|Other|Pulmonary Rehabilitation|Respiratory Physiotherapy, Exercise Therapy, Patient Education
39364|NCT03875573|Drug|Durvalumab|an anti PD-L1 intravenous administration at 1500 mg every 4 weeks for 19 weeks.
73584|NCT03608761|Biological|autologous serum|AS for 3 months
39365|NCT03875573|Radiation|Stereotactic Body Radiotherapy|Pre-operative radiation therapy (boost dose) 3x8 Gy on the primary tumour at week 5. Given over 3 days in 3 fractions (1X8 Gy daily)
39366|NCT03875573|Drug|Oleclumab|an anti-CD73 intravenous administration at 3000 mg every 4 weeks for 19 weeks.
39367|NCT03875560|Biological|IC14|recombinant chimeric anti-human CD14 monoclonal antibody
39368|NCT03875560|Drug|Placebo|Inactive
39369|NCT03875547|Drug|Refixia®|Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
39370|NCT03875508|Drug|Risankizumab|Risankizumab to be injected subcutaneously (SC)
39371|NCT03875508|Device|Autoinjector|Single dose pre-filled autoinjector containing risankizumab for SC injection
39372|NCT03875495|Drug|Temferon|Genetically modified autologous HSPCs
39377|NCT03875443|Other|Instructional video|Video (produced by AO Trauma and Prof. Daniel Rikli) includes a stepwise and structured explanation of the different fluoroscopic views necessary to evaluate intraoperatively with the fluoroscope different aspects of the proximal femur. The video is publically available under: (https://www.aointeract.org/#/watch/video/L3YxL3ZpZGVvcy8xOTc=/intraoperative-imaging-of-femur).
39378|NCT03875443|Other|Reduction algorithm|Intraoperative reduction algorithm (developed by PD Henrik Eckardt); each step in the algorithm will be checked and documented with the fluoroscope and archived using the store function of the fluoroscope.
39379|NCT03875430|Dietary Supplement|Humulus lupulus L|Patients with this intervention will receive a dietary supplement to relieve the symptoms of menopause
39380|NCT03875417|Procedure|liver resection|resection of one or more HCC nodules within the liver
39381|NCT03875417|Procedure|Thermic ablation|ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves
39382|NCT03875417|Procedure|Transcatheter arterial chemoembolization|embolization of HCC nodule via drug-eluted microbeads.
39383|NCT03875404|Diagnostic Test|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
39384|NCT03875391|Drug|Oxytocin|Drug: Oxytocin nasal spray
39385|NCT03875391|Drug|Placebo|Drug: Placebo nasal spray
39386|NCT03875378|Drug|Transdermal estrogen|Transdermal estradiol (0.045mg)/levonorgestrel (0.015mg) weekly patch
39387|NCT03875378|Drug|Placebos|Placebo weekly patch
39388|NCT03875365|Procedure|POPE|Patients who have undergone Per-oral Plication of the Esophagus (POPE) procedure.
39389|NCT03875352|Procedure|CHG technique|The CHG technique includes treatment using dressing with chlorhexidine.
39390|NCT03875352|Procedure|HMG technique|The HMG technique includes treatment using hydrophilic methacrylate gel and transparent foil.
39391|NCT03875339|Behavioral|Navigator Guidance|Use of a dedicated Navigator to determine if follow-up and compliance rates can be improved for those infants initially demonstrating an abnormal hearing result.
39392|NCT03875326|Device|1 mA HD-tDCS|Participants will receive HD-tDCS at 1 mA for 30 minutes, for between 5-30 sessions.
39393|NCT03875326|Device|2 mA HD-tDCS|Participants will receive HD-tDCS at 2 mA for 30 minutes, for between 5-30 sessions.
39394|NCT03875326|Device|3 mA HD-tDCS|Participants will receive HD-tDCS at 3 mA for 30 minutes, for between 5-30 sessions.
39395|NCT03875326|Device|Sham|Participants will receive sham (placebo) HD-tDCS for 30 minutes, for between 5-30 sessions.
39396|NCT03875313|Drug|CB-839|CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.
39397|NCT03875313|Drug|Talazoparib|Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.
39398|NCT03875300|Behavioral|Foodwise in Pregnancy|A 7 week programme of nutrition and lifestyle advice, delivered in community venues by trained Healthy Lifestyle Support Workers (HLSWs). Participants must meet study inclusion criteria.
39399|NCT03875287|Drug|Decitabine|"DOSING REGIMEN(S):~Level -1 5mg daily days 1-10~Level 1 5mg daily days 1-14~Level 2 10mg daily days 1-14~Level 3 15mg daily days 1-14"
39400|NCT03875287|Drug|Cedazuridine|"DOSING REGIMEN(S):~Level -1 100mg daily days 1-10~Level 1 100mg daily days 1-14~Level 2 100mg daily days 1-14~Level 3 100mg daily days 1-14"
39401|NCT03875274|Drug|Ropivacaine, Morphine|Morphine added to ropivacaine for fascia iliaca compartment block
39402|NCT03875274|Drug|Ropivacaine, Saline|Normal saline added to ropivacaine for fascia iliaca compartment block
39403|NCT03875261|Drug|Cannabinoid treatment|Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
39404|NCT03875248|Device|Blood pressure measurement|Measure optically the blood pressure through the use of a smartphone
39405|NCT03875235|Drug|Durvalumab|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
39406|NCT03875235|Drug|Placebo|IV infusion every 3 weeks with gemcitabine plus cisplatin up to 8 cycles followed by monotherapy every 4 weeks until disease progression or other discontinuation criteria.
39407|NCT03875209|Biological|10E8.4/iMab|bispecific monoclonal antibody
39408|NCT03875196|Device|Pelvic Floor Muscle Training With Biofeedback|Biyofeedback: The Biyofeedback allows the patient to see the results of her behavior immediately By a perineometer device or electromyelography that is placed in the vagina, the patient sees how she hears the pelvic floor muscles, hears the sound or hears her voice, and detects how much she needs to contract.
39502|NCT03874520|Other|Video triage|The operator will offer the parent calling regarding the sick child to assess the child on video, as compared to the current standard; on the telephone.
39409|NCT03875196|Device|Extracorporeal Magnetic Innervation|Extracorporeal Magnetic Innervation: The patients are seated in a special chair connected to an external power unit and a magnetic field generator inside with their clothes on. In order to coincide the spreading magnetic field with pelvic floor muscles, the urethral and anal sphincters, the perineum of the patients should be placed in the center of the chair. In this way, the perineum tissues are stimulated by emitted magnetic field waves. Thus no electrical current passes through the device to the patient's body and the patient is exposed to only the magnetic current.
39410|NCT03875183|Drug|INL1|Capsules
39411|NCT03875183|Other|Placebo|Capsules
39412|NCT03875170|Other|Experimental|The technique will be carried out with the subjects in the positions of supine, prone and lateral position, for the flexor muscles of the hip, hamstrings and quadriceps, where the musculature and the joint to be treated will be taken to a range of functional mobility. The subject will be asked to perform an isometric contraction, with a series of 3 seconds for sustained contraction and a rest between contraction of 2 to 3 seconds after activating the Golgi apparatus, making an inhibition of the stimulus and bringing the joint and muscle to the highest possible range of motion without pain.
39413|NCT03875170|Other|Control|The active stretching technique will be performed for the hip, quadriceps and hamstring flexors with a voluntary antagonist activation to relax the agonist muscle, holding the movement to be performed for 30 seconds to stimulate the neuromuscular spindle and produce a relaxation of the muscle fibers.
39414|NCT03875157|Biological|IBI318|0.3mg Intravenous infusion, first day of first cycle and afterwards Q2W
39415|NCT03875157|Biological|IBI318|1mg Intravenous infusion, first day of first cycle and afterwards Q2W
39416|NCT03875157|Biological|IBI318|3mg Intravenous infusion, first day of first cycle and afterwards Q2W
39417|NCT03875157|Biological|IBI318|10mg Intravenous infusion, first day of first cycle and afterwards Q2W
39418|NCT03875157|Biological|IBI318|30mg Intravenous infusion, first day of first cycle and afterwards Q2W
39419|NCT03875157|Biological|IBI318|100mg Intravenous infusion, first day of first cycle and afterwards Q2W
39420|NCT03875157|Biological|IBI318|300mg Intravenous infusion, first day of first cycle and afterwards Q2W
39421|NCT03875157|Biological|IBI318|600mg Intravenous infusion, first day of first cycle and afterwards Q2W
39422|NCT03875157|Biological|IBI318|Intravenous infusion, first day of first cycle and afterwards Q3W
39423|NCT03875157|Biological|IBI318|Intravenous infusion, first day of first cycle and afterwards Q3W
39424|NCT03875157|Biological|IBI318|Intravenous infusion Q3W
39425|NCT03875144|Procedure|PIPAC|Pressurized IntraPeritoneal Aerosol Chemotherapy of Cisplatin 10.5mg/m² + Doxorubicin 2.1 mg/m² every 6 weeks
39426|NCT03875144|Drug|Cisplatin|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
39427|NCT03875144|Drug|Pemetrexed|standard intravenous chemotherapy for mesothelioma (Cisplatin 75mg/m² + Pemetrexed 500mg/m²)
39428|NCT03875131|Other|Biomarkers of Dementia and Cognitive Decline|"Biomarkers will be obtained at baseline, 6, 12, 18, and 24 months.~The six questionnaires listed below will be administered at the baseline visit, and repeated at the 24-month visit to evaluate cognitive decline.~Mini-Mental Status Evaluation~Hachinski Ischemic Scale~Cognitive Subscale of Alzheimer's Disease Assessment Scale~Disability Assessment for dementia~Quality of life improvement as assessed by:~Minnesota Living with Heart Failure Scale~Anti-Clot Treatment Scale (ACTS) Quality of Life Survey"
39429|NCT03875118|Behavioral|The mouth-opening training with follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks. Subjects in the intervention group received additional 6 follow-up phone calls (at 1, 2, 3, 4, 8 and 12-week after discharge) from the interventionist to enhance mouth-opening exercise adherence.
39430|NCT03875118|Behavioral|The mouth-opening training without follow-up telephone calls program|Subjects in both groups received two 30-minute individual trainings on the mouth-opening exercises before discharge from the hospital. Subjects were instructed to practice the mouth-opening exercises three times a day, every day, for 12 weeks.
39431|NCT03875092|Biological|Pembrolizumab|IV infusion
39432|NCT03875092|Drug|Paclitaxel|IV infusion
39433|NCT03875092|Drug|Nab-paclitaxel|IV infusion
39434|NCT03875092|Drug|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
39435|NCT03875092|Drug|Saline placebo for pembrolizumab|IV infusion
39436|NCT03875079|Drug|RO6874281|"Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule."
39437|NCT03875079|Drug|Pembrolizumab|"Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)"
39438|NCT03875066|Other|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
39573|NCT03873961|Device|Low-level Laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
39439|NCT03875066|Other|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
39440|NCT03875053|Diagnostic Test|Monitoring Device|Patients wear the home sleep apnea machine overnight. Patients undergoing standard of care CRT wear the home sleep apnea machine a second time 3 months after completion of CRT.
39441|NCT03875053|Other|Quality-of-Life Assessment|Ancillary studies
39442|NCT03875053|Other|Questionnaire Administration|Ancillary studies
39443|NCT03875040|Behavioral|kinesiophobia|patients who have a high-level or low-level kinesiophobia have been evaluated.
39444|NCT03875027|Procedure|proximal femur replacement|patient with proximal femur fracture or those in whom previous surgery on hip is failed and treated with replacement of proximal femur implant
39445|NCT03875014|Device|surgery with implant for hip fracture|hip replacement with bipolar hemiarthroplasty or total hip arthroplasty dual mobility done and patients was followed
39446|NCT03875001|Drug|BI 1358894|tablet
39447|NCT03875001|Drug|Placebo|tablet
39448|NCT03874988|Behavioral|Portion-Controlled Meals|Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.
39449|NCT03874988|Behavioral|Enhanced Self-Monitoring|Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.
39450|NCT03874988|Behavioral|GLB-SCI|Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.
39451|NCT03874988|Behavioral|GLB-SCI+|Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
39452|NCT03874975|Drug|oral vitamin D|vitamin D and UVB versus UVB alone in psoriatic patients and evaluate patients by PASI score before and after treatment and measure serum vitamin D before and after treatment
39453|NCT03874962|Other|Routine oral cleaning and professional oral care group|Besides routine oral cleaning was conducted by caregivers, professional oral care intervention was conducted by dental hygienists, and it included muscle massage, oral cleaning, and oral health education once a week.
39454|NCT03874949|Device|SEALITE Regular|Patients are treated with SEALITE Regular sealer (zinc oxide eugenol sealer). The SEALITE Regular powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control.
39455|NCT03874949|Device|SEALITE Ultra|"Patients are treated with SEALITE Ultra sealer (zinc oxide eugenol sealer containing 1% Enoxolone).~The SEALITE Ultra powder is mixed with SEALITE Liquid according to the manufacturer instructions and added to gutta percha in the root canal for permanent obturation. The apical obturation is assessed by a postoperative radiographic control."
39456|NCT03874936|Drug|Dexamethasone 24mg Solution for Injection|Administrated i.v.
39457|NCT03874936|Drug|Saline Solution for Injection|administrated i.v.
39458|NCT03874923|Other|Fluid challenge|After randomisation, patient will receive 250 ml or 500 ml of fluid challenge. VO2 will be assessed before fluid challenge, immediately, 30 minutes and 60 minutes after fluid challenge.
39459|NCT03874897|Drug|CAR-CLDN18.2 T-Cells|"Pretreatment with fludarabine, cyclophosphamide,~• Chimeric Antigen Receptor T Cells Targeting Claudin18.2"
39460|NCT03874884|Drug|Olaparib|During dose escalation doses of olaparib that can be administered are 50mg BD, 100mg BD, 150mg BD,200mg BD,250mg BD or 300mg BD. The recommended phase 2 dose of olaparib will be used during dose expansion. Olaparib will be given on days 2-15 of each 42 day cycle for upto 4 cycles.
39461|NCT03874884|Combination Product|177Lu-PSMA|A fixed 7.4Gbq administered activity of 177Lu-PSMA will be given 6 weekly for upto 4 cycles.
39462|NCT03874871|Procedure|Function preserving gastrectomy|Function preserving gastrectomy include pylorus preserving gastrectomy, proximal gastrectomy, and partial gastrectomy.
39463|NCT03874871|Procedure|Standard gastrectomy|Standard gastrectomy include distal gastrectomy and total gastrectomy with standard lymphadenectomy according to the Japanese gastric cancer treatment guideline.
39464|NCT03874858|Drug|Nilotinib|Nilotinib oral 300 mg QD hard capsules
39465|NCT03874845|Behavioral|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
39466|NCT03874845|Behavioral|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
39467|NCT03874832|Drug|Dihydroergotamine|Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
39468|NCT03874819|Device|Medium cut-off dialyzer|Treatment using a Medium Cut-Off Dialyzer
39469|NCT03874819|Device|High-flux dialyzer|Treatment using a high-flux dialyzer
39470|NCT03874806|Drug|Ropivacaine 0.25%-NaCl 0.9% Injectable Solution|0.25% ropivacaine administered through a nerve catheter
39471|NCT03874806|Drug|Ropivacaine 0.2%-NaCl 0.9% Injectable Solution|0.2% ropivacaine administered through a nerve catheter
39472|NCT03874793|Behavioral|Mindfulness-Based Cognitive Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
39473|NCT03874793|Behavioral|Muscle Relaxation Therapy|Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
39474|NCT03874780|Device|Vibe Delivery system|delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
73974|NCT03605680|Drug|Centanafadine SR|200 mg, BID, oral tablets
39475|NCT03874767|Behavioral|Patient Mobility|A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
39476|NCT03874754|Device|Tailored Technology-Enhance Home-based exercise program (iHBE)|The tailored technology enhanced home-based exercise (iHBE) program is a 4-week program with 1 assessment home visit session, 4 home visits during exercise. The detail activities are presented in table 1. The technologies, a wearable device, and a smartphone application, will be used as a tool to monitor physical performance (heart rate [HR], step count), provide immediate feedback, send daily reminding message through Mobile Ecological Momentary Assessment (mEMA). The coded raw data without personal identification information from the wearable device will be sent to the servers where the investigators can store it in the database alongside the mEMA data and create custom reports showing Heart Rate (HR) 30 minute before each Ecological Momentary Assessment (EMA) survey, showing HR and previous self-report responses before/ after each automatically triggered EMA.
39477|NCT03874741|Drug|SCT200|"Anti-EGFR monoclonal antibody DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression~Other Names:~• SCT200"
39478|NCT03874728|Other|Minimal shoes|A minimal shoe (Vivobarefoot Ltd., London, UK) will be used.
39479|NCT03874728|Other|Standardised conventional shoes|The Go Walk 4.0-Pursuit shoe for women (Skechers USA, Inc.) and the Superior 2.0-Jeveno shoe for men (Skechers USA, Inc) will be used.
39480|NCT03874728|Other|Barefoot|Participants will conduct the assessments barefoot.
39481|NCT03874728|Other|"Smart shoe insoles"|Arion pressure-measuring insoles (Eindhoven, The Netherlands) will be used in the study.
39482|NCT03874715|Drug|Insulin Aspart SAR341402|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
39483|NCT03874715|Drug|Insulin Aspart|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
39484|NCT03874715|Drug|Insulin glargine U100|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
39485|NCT03874676|Other|PEACE Rounds|PEACE Rounds are a routine process for providing self help to clinicians who care for difficult patients from the perspective of ethics and the need for cross-disciplinary communication. PEACE Rounds participants will be interviewed about how they experience the rounds and for their perspective on the effects on their own wellness and resilience.
39486|NCT03874663|Device|Directly assisted oral HIV self-testing (HIVST)|"To determine the ability of participants with unknown HIV status to correctly perform oral HIVST;~To compare the results of the oral HIVST with confirmatory rapid finger prick HIV test.~To explore participants attitudes and preferences towards oral HIVST.~To explore the feasibility, acceptability and appropriateness of using a mobile photo verification app to verify HIV self-testing results."
39487|NCT03874650|Behavioral|Activity Planning Group|Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
39488|NCT03874650|Behavioral|Activity Engagement Group|Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
39489|NCT03874650|Behavioral|Waitlist Group|Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
39490|NCT03874637|Device|Treament|Placement of the FemPulse System with therapy delivery
39491|NCT03874637|Device|Sham Control|Placement of the FemPulse System without therapy delivery
39492|NCT03874624|Diagnostic Test|two-dimensional speckle tracking|Analysis of myocardial left atrial strain using two-dimensional speckle tracking echocardiography.
39493|NCT03874611|Other|electrophysiological data from DBS|For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
39494|NCT03874598|Procedure|Ear acupuncture|Patients in the intervention group are treated twice a week for five weeks using semi-standardized ear acupuncture.
39495|NCT03874598|Behavioral|Psychoeducation|Patients of the control group receive a 1,5 h psychoeducation group concerning sleep improving behaviour.
39496|NCT03874585|Behavioral|Group counseling and nicotine replacement|Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.
39497|NCT03874585|Behavioral|Group counseling, nicotine replacement, and text messaging support|Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
39498|NCT03874572|Biological|Allogeneic adipose derived stem/stromal cells|Culture expanded allogeneic adipose derived stem/stromal cells
39499|NCT03874559|Diagnostic Test|Blood Draw|Serum samples will be obtained from each patient enrolled
39500|NCT03874546|Other|Questionnaire|"Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7)."
39501|NCT03874533|Device|Self-adjustment tests|"For patients with an implant Cochlear™, we will be trained during workshop, to use a tablet how to do some tests ; They will do alone, by themselves the tests, just after the workshop and 8 to 30 days later.~Self audiometric test : digit triplet test, consonants discrimination test, Self-fitting of cochlear implant"
39503|NCT03874507|Other|Virtual Reality/Augmented Reality Headset|"A virtual reality (VR) headset is a device the participant will wear over his/her head and eyes like a pair of goggles. It blocks out all external light and shows him/her an image on high-definition screens in front of his/hers eyes. It implies a complete immersion experience that shuts out the physical world.~Augmented reality (AR) headset is a device that the participant will wear over his/hers head and eyes and it adds digital elements to a live view."
39504|NCT03874494|Drug|Brexpiprazole|Brexpiprazole 2-4 mg/day
39505|NCT03874494|Drug|Aripiprazole|Aripiprazole 10-20 mg/day
39506|NCT03874481|Other|Observation|follow up regularly for MACE
39507|NCT03874468|Device|X-ray|standing anteroposterior radiographs of the full-length lower limb with patients in the standing position. ( HKA Long Film Radiographs ).
39508|NCT03874455|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
39509|NCT03874442|Other|CliniPup serious game|"The interactive game is played at home by the children on a computer or tablet before the surgery. The SERES Pain in Children-game is created with realistic scenarios based on scientific literature about perioperative pain and fear in children. The primary goal of the game is to provide the children insight in the impact of their personal choices on their well-being and on their environment by giving the children information about the day of the surgery. The ultimate aim of the game is to create a change in behaviour, enhance children's coping strategies and reduce the burden of pain and fear in the children and parents."
39510|NCT03874429|Device|T2259|HA and Trealose
39511|NCT03874429|Device|Vismed multi|HA
39512|NCT03874416|Other|Specific rehabilitation|"Experimental rehabilitation of working memory:~3 sessions per week during 3 months, for a total 36 sessions."
39513|NCT03874416|Other|Non-specific rehabilitation|Usual non-specific rehabilitation treatment for moderate to severe TBI in healthcare facilities: 2-3 sessions per week for 3 months.
39514|NCT03874403|Procedure|DSA|The changes on DSA on NIVATS and VATS
39515|NCT03874390|Other|ozone|gaseous ozone was applied on periodontal pocket two times in one week.
39516|NCT03874377|Behavioral|Mindfulness|Mindfulness refers to the experience of paying attention to the present moment in a nonjudgmental manner. The mindfulness intervention consists of 6 weekly sessions focused on: experiential mindfulness exercises, such as mindful eating, loving kindness practices, breath awareness, and mindful movement; hunger and satiety awareness; improving responses to emotions; practicing acceptance and being non-judgmental; and tolerating negative feelings and sensations, including those related to hunger and cravings. Participants will be assigned brief homework exercises (approximately 10 minutes) daily in between appointments.
39517|NCT03874377|Behavioral|Usual Care|Participants will receive the recommended standard of medical management of overweight and obesity. The clinic team conducts a comprehensive evaluation of the patient to assess dietary and activity behavior change needs of each patient and family, as well as obesity-associated comorbidities. In addition to management of comorbidities, goals for improved physical activity and dietary behaviors are set with the patient and family at each visit.
39518|NCT03874364|Device|Lidocaine gel|10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
39519|NCT03874364|Other|Counselling|Patients receive a brochure in the waiting room explaining the procedure in details.
39520|NCT03874364|Other|Monitor|Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
39521|NCT03874364|Device|Lubricating gel|10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
39522|NCT03874364|Other|No counselling|Patients won't receive a brochure in the waiting room explaining the procedure in details.
39523|NCT03874364|Other|No monitor|Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
39524|NCT03874351|Device|non-invasive transcranial direct current stimulation (tDCS)|Non-invasive remotely supervised transcranial direct current stimulation at intensity 1.5mA or sham applied by participants at home for 20 minutes per day on 60 consecutive days, over the area of the dorsolateral prefrontal cortex, using sponge saline-premoisturized electrodes of size 5x5cm, the anode on the left, the cathode on the right.
39525|NCT03874338|Drug|Colchicine Pill|Participants in the main CLEAR SYNERGY trial are randomized to colchicine/spironolactone versus placebo in a 2x2 factorial design. The substudy is interested in the evaluation of biospecimens obtained from patients in the colchicine vs placebo group.
39526|NCT03874325|Drug|Durvalumab|1500 mg Durvalumab will be administered intravenously every 4 weeks for 6 months.
39527|NCT03874325|Drug|Anastrozole 1mg|Participants will self administer 1 mg anastrozole by mouth daily for 6 months.
39528|NCT03874325|Drug|Letrozole 2.5mg|Participants intolerant to anastrozole will self administer 2.5 mg letrozole by mouth daily for 6 months. Exemestane may be substituted.
39529|NCT03874325|Drug|Exemestane 25 MG|Participants intolerant to anastrozole will self administer 25 mg exemestane by mouth daily for 6 months. Letrozole may be substituted.
39530|NCT03874312|Diagnostic Test|Linear ultrasound (US) assessment of the internal jugular vein|Evaluation of jugular vein distensibility at rest and after Valsalva maneuver by US at the time of the RHC. US-guided IJV is routinely performed at the time of vein cannulation.
39531|NCT03874286|Diagnostic Test|Liver Transplant|Patients will obtain a research blood draw and a liver biopsy at 4 months and 12 months post transplant. Liver biopsy's are routinely performed in the liver transplant population. We will be obtaining a liver biopsy at this particular time point to compare the biopsy results with the peripheral blood results.
39532|NCT03874273|Drug|Crizotinib|Crizotinib 280mg/m2 twice a day (for 24 months maximum)
39533|NCT03874260|Drug|Fenofibrate|statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
39534|NCT03874247|Drug|pelubiprofen 45mg|bid for 3 days after meal
39535|NCT03874247|Drug|pelubiprofen placebo|bid for 3 days after meal
39536|NCT03874234|Drug|GSK3186899|GSK3186899 will be available as white to slightly colored, spray dried powder in a bottle to be administered orally along with mixture of propylene glycol and water.
39537|NCT03874234|Drug|Placebo|Placebo will be available as white to slightly colored, blend powder in a bottle to be administered orally along with mixture of propylene glycol and water.
39538|NCT03874208|Other|MRI sequence|An additional sequence to conventional MRI exam (Diffusion tensor imaging) lasting less than 10 min (depending on the MR scanner type and sequence used).
39539|NCT03874208|Other|MRI|MRI exam
39540|NCT03874195|Behavioral|Access to PCforMe for review|Intervention Arm subjects will receive access to PCforMe.
39541|NCT03874195|Behavioral|Access to three nationally-recognized Palliative Care websites for review|Subjects in the Active Control arm will receive a list of three nationally-recognized websites to receive information on palliative care
39542|NCT03874169|Device|E4 wristband|A biosensor watch that monitors the patient's heartbeat, heart rate variability, skin conductance, and temperature in order to discover if they are having a GI bleed
39543|NCT03874156|Drug|Atorvastatin 40mg|Oral tablet fabricated and labelled at Krageroe Tablettproduksjon AS
39544|NCT03874156|Drug|Placebo Oral Tablet|Oral tablet fabricated and labelled at KrageroeTablettproduksjon AS
39545|NCT03874143|Other|mHealth Intervention for Quality of Care|Does use of a specially equipped smartphone make a difference in the diagnosis and treatment by RCom of malaria, pneumonia and diarrhea in children aged 2 to 59 months
39546|NCT03874130|Drug|Scopolamine|IV Scopolamine
39547|NCT03874117|Other|Twice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
39548|NCT03874117|Other|Thrice weekly hemodialysis|Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.
39549|NCT03874104|Dietary Supplement|Extensively Hydrolysed Formula containing Pre- & Probiotics|Extensively Hydrolysed Formula containing Pre- and Probiotics
39550|NCT03874091|Procedure|bilateral ESP block with 0,25% Bupivacaine+ Adrenaline|Regional anaesthesia technique performed under ultrasound guidance before surgery
39551|NCT03874091|Procedure|ESP block continuous infusion with 0,125% Bupivacaine+Adrenaline|Continous infusion of Local Anaesthetic (LA) given postoperatively via the catheter.
39552|NCT03874091|Drug|Morphine PCA pump|Morphine given postoperatively.
39553|NCT03874065|Other|Medical Chart Review|Collection of data from participant's medical chart
39554|NCT03874052|Drug|Ruxolitinib|Given PO
39555|NCT03874052|Drug|Venetoclax|Given PO
39556|NCT03874039|Device|Gas sensor|The gas sensor is an airtight gas capsule attached with a floating solid phase microextraction (SPME) tube. SPME uses a fiber coated with a nontoxic liquid (polymer), and a nontoxic solid (sorbent). The fiber coating extracts the compounds from the gas being released from the skin. Only the glass sample is in contact with the skin.
39557|NCT03874039|Device|Sweat Sensor|The sweat sensor is a soft, flexible device that rests on the skin and collects secreted sweat through capillary action. The device is held in place by medical-grade acrylic adhesive film.
39558|NCT03874026|Drug|Folfiri/Cetuximab|"Cetuximab 400 mg/mq intravenously (iv) with load dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT (load dose of cetuximab), irinotecan will not be administered."
39559|NCT03874013|Drug|MOD-4023|"MOD-4023 is a long-acting modified recombinant human growth hormone (r-hGH) which utilizes C-terminal peptide (CTP) technology. It will be provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a multi-dose disposable pre-filled PEN.~MOD-4023 will be administered as a SC injection once weekly, using a delivery device."
39560|NCT03874013|Drug|Genotropin|"Genotropin® is dispensed in a 2-chamber cartridge. The front compartment contains recombinant somatropin, glycine, mannitol, sodium dihydrogen phosphate anhydrous and disodium phosphate anhydrous. The rear compartment contains m-Cresol and mannitol in water for injections.~A delivery device (GenotropinÒ) will be used for daily (evening/bedtime) SC administration of Genotropin® into the region of the upper arms, buttocks, thighs or abdomen (8 locations). Injection sites should be rotated.~Dose regimen for Genotropin®: 0.025 mg/kg/day (or 0.175 mg/kg/w divided equally to 7 injections over a week)."
39561|NCT03874000|Biological|Sintilimab|Given IV
39562|NCT03874000|Drug|Metformin Hydrochloride|Given PO
39563|NCT03873987|Drug|Current Formulation of Oritavancin|Current formulation of oritavancin (3 hour infusion of 1200 mg in 1000 ml of D5W)
39564|NCT03873987|Drug|New Formulation of Oritavancin|New formulation of oritavancin (1 hour infusion of 1200 mg in 250 ml of saline)
39565|NCT03873974|Diagnostic Test|DualDur dark-field microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Manual evaluation.
39566|NCT03873974|Diagnostic Test|DualDur dark-field automatic microscopic test|Morphologically identify the presence of Borrelia burgdorferi sensu lato bacteria (in a broader sense) which are present in the body fluid, hence to verify Borreliosis. Software evaluation.
39567|NCT03873974|Diagnostic Test|Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
39568|NCT03873974|Diagnostic Test|Bózsik Western blot IgM and IgG|Borrelia qualitative in vitro test in order to detect and reliably identify IgG and IgM antibodies against Borrelia burgdorferi from human serum or plasma.
39569|NCT03873974|Diagnostic Test|Standard Polymerase chain reaction|Standard PCR test for Lyme borreliosis.
39570|NCT03873974|Diagnostic Test|enzyme-linked immunosorbent assay (ELISA) IgM and IgG|Standard ELISA test for Lyme borreliosis.
39571|NCT03873974|Diagnostic Test|DualDur Polymerase chain reaction|DualDur PCR test for Lyme borreliosis.
39572|NCT03873961|Device|High-intensity laser therapy|tissue photobiostimulation for pain reduction and healing enhancement.
39576|NCT03873922|Other|Ketogenic diet intervention|Ketogenic, really low carbohydrate containing (15-20 g/day), meals will be offered to the participants.
39577|NCT03873909|Other|Fruit Smoothie|Fruit Smoothie with 150-200 g mamey sapote fruit
39578|NCT03873909|Other|Matrix-Free Shake|Shake containing mamey sapote extracted carotenoids (2 g, 845 µg sapotexanthin and 1.21-1.51 mg cryptocapsin
39579|NCT03873896|Diagnostic Test|Stimulated skin wrinkling test|Stimulated skin wrinkling induced by the application of EMLA (eutectic mixture of local anesthetic) cream to the finger pads of blocked and unblocked fingers of study volunteers (test applied to both study arms)
39580|NCT03873896|Procedure|Digital Nerve Block|A digital nerve block is performed by injecting a total of 3 millilitres of 2% Lidocaine at the base of the ring finger of randomized hand of the volunteer. The effect of the block is confirmed clinically before proceeding with the study data collection. Please see the description for more details on the procedure
39581|NCT03873883|Drug|EOS100850|Monotherapy
39582|NCT03873870|Diagnostic Test|68Ga -DOTATATE PET scans|PET scan using 68Ga-DOTATATE contrast
39583|NCT03873857|Drug|Venetoclax|tablet;oral
39584|NCT03873844|Behavioral|Speed of Processing Training|"Speed of Processing Training (SOPT). Speed of processing training involves trainer-guided practice of computer-based video games. The games require the player to identify targets that are presented very briefly. SOPT has the primary aim of improving the fluid ability of mental processing speed such that trainees can process increasingly more information and increasingly more complex information over briefer periods of time. The training primarily involves practice with feedback. Trainers also offer suggestions, encouragement, and personalized modifications of difficulty for the trainee according to a specified protocol. At a display speed and task difficulty level tailored to their ability, trainees practice blocks of 16 trials. Trainees receive immediate feedback after each trial and see their total correct trials at the end of each block of trials. Trainers tell the trainees that their goal is to achieve performance of 10 to 12 correct trials for each training block."
39585|NCT03873844|Behavioral|Transfer Package from CI Therapy|Behavioral Contract. At the outset of treatment, the therapist negotiates a contract with the participant and caregiver, if one is available.Daily home diary. During treatment, the participants catalog the ADL and IADL for the part of the day spent outside the laboratory. Daily administration of the Cognitive Task Activity Log (CTAL). The CTAL collects information about attempts by the participant to complete ADL and IADL. Problem Solving. The therapist helps participants to think through any barriers to completing ADL and IADL independently. Home skill assignments during treatment. Participants are assigned on a written check-off sheet 10 specific ADL tasks. Home skill assignments after treatment. Toward the end of treatment, a written individualized post-treatment program is developed containing a list of up to 10 IADL for each day of the week. Post-treatment telephone contacts. Participants are contacted during the 12 month period after treatment to evaluate treatment outcomes.
39586|NCT03873831|Behavioral|Animal-assisted intervention|The therapy dog is present during the session.
39587|NCT03873831|Behavioral|Social skills group|"The group program is 10 weeks in duration, with 1-hour long sessions once per week. Children will be taught new social skills each week using an established teaching interaction procedure, in which the therapist first describes the target skill, provides a rational and context for the behavior, divides the skill into smaller steps, demonstrates the behavior, and has each learner role-play the skill while providing feedback in the form of praise and tokens and corrective instruction. The last week involves a probe free-play session, in which children are assessed in a more naturalistic environment without any corrective feedback from therapists."
39588|NCT03873818|Biological|Ipilimumab|Given IV
39589|NCT03873818|Biological|Pembrolizumab|Given IV
39590|NCT03873805|Biological|Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes|Given IV
39591|NCT03873805|Drug|Cyclophosphamide|Given IV
39592|NCT03873805|Drug|Fludarabine|Given IV
39593|NCT03873805|Drug|Fludarabine Phosphate|Given IV
39594|NCT03873792|Diagnostic Test|Physician diagnoses a history of asthma or eczema or allergic rhinitis or health pregnant women|Physician diagnoses a history of asthma or eczema or allergic rhinitis
39595|NCT03873779|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
39596|NCT03873766|Drug|Intrapleural Medications|The IPFT group will receive a total of 5-6 doses of alteplase 10mg and DNase 5 mg twice daily x 3 days. delivered through a chest tube or small bore catheter into the pleural space. The doses will be given twice a day. If the first IPFT dose is given in the evening on the first day, they will only receive a total of 5 doses of the dual-agent IPFT (alteplase and DNase).
39597|NCT03873766|Procedure|Surgery|The surgical arm will have either open surgery or a Video assisted Thoracoscopic Surgery (VATS) approach at the discretion of the surgeon
39598|NCT03873766|Procedure|Pleural Sampling|Pleural fluid may be sampled by the responsible clinical service in the course of clinical care for patients with suspected pulmonary infection or by consulting service after identification of patient. Some patients will have a thoracentesis or tube drainage, and others will have no intervention at the time of referral for study eligibility review. Enrollment reflects real world clinical care and patients will be considered for enrollment regardless of sampling techniques or timing prior to evaluation
39599|NCT03873766|Procedure|Pleural fluid drainage|All patients in the study must have tube thoracostomy for drainage of the pleural space. This may have been done by the clinically responsible team or by the study team. Physicians may select chest tubes of any type, but the minimum size is 14 French. For patency, chest tubes 14-20 French should be kept at negative 20 suction and flushed daily. Large bore chest tubes (>20French) may be kept at negative 20 suction at the discretion of the physician managing the chest tube and do not require daily flushing. Supportive care will follow Institutional Guidelines.
39600|NCT03873766|Radiation|Protocol Image #1|"Once the chest tube is placed, imaging is obtained within 24-48 hours to assess the fluid drainage. The choice of image, either Chest X-ray or CT Chest, is up to the discretion of the treating physician. Based on the imaging, patients will be separated into 2 groups:~A: Complete drainage/re-expansion of the lung: If there is complete drainage of the pleural fluid collection and lung re-expansion based on image #1, patients will follow usual clinical care without randomization and be observed until discharge. Patients will remain in the study and their data will be collected.~B: Incomplete drainage/incomplete lung re-expansion: For those patients that have incomplete drainage of the pleural fluid collection on image #1 and/or the lung does not re-expand."
39601|NCT03873766|Other|Surgical Consultation|A thoracic surgery consultation will be obtained on all patients with incomplete drainage and/or the lung does not re-expand, to determine surgical candidacy. Those patients that the surgical team deem unsafe for surgery will receive clinically appropriate guideline centered, non-surgical, care. These patients will not be randomized but they will remain in the study and their data will be collected. Criteria deeming patients unfit for surgery include, but are not limited to: inability to tolerate single lung ventilation, severe chronic obstructive pulmonary disease (COPD), and risk of surgery prohibitive. Patients not excluded from surgery will be randomized.
39602|NCT03873766|Radiation|Protocol Image #2: Chest X-ray PA/Lateral|The morning after intervention completion (surgery or last dose of IPFT), a chest X-ray PA/lateral will be obtained (protocol image #2). Based on Image #2 the patient will be categorized into one of three groups: satisfactory improvement of pleural fluid collection, unsatisfactory improvement in pleural fluid collection on imaging, or treatment failures.
39603|NCT03873766|Behavioral|Quality of Life|Quality of life will be measured at 30 day and 90 day and 1 year clinical follow-up using the SF-36 quality of life survey and return to work questionnaires
39604|NCT03873753|Other|Cleaning|Gauze and mineral water
39605|NCT03873753|Other|No oral cleaning|Absence of cleaning
39606|NCT03873740|Biological|EV71 inactived vaccine（Vero cells）|The EV71 inactived vaccine（Vero cells） was manufactured by Sinovac Biotech Co., Ltd.
39607|NCT03873740|Biological|EV71 inactived vaccine（Human diploid cells）|The EV71 inactived vaccine（Human diploid cells） was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.
39608|NCT03873727|Biological|Prevenar13 (PCV13) and Pneumovax (PPS23)|One dose of PCV13 at Month 0 and one dose of PPS23 at Month 12
39609|NCT03873727|Biological|Placebo / Pneumovax (PPS23)|One dose of Placebo at Month 0 and one dose of PPS23 at Month 12
39610|NCT03873727|Biological|Blood sample|an additional 5 mL sample of blood at one of the visits, preferably at the first visit, concerning patients included in Parisian centers who did not participate in SPLENEVAC 1 study.
39611|NCT03873714|Device|Pipeline™ Flex Embolization Device with Shield Technology™|Pipeline™ Embolization Device / Pipeline™ Flex Embolization Device with Shield Technology™
39612|NCT03873701|Diagnostic Test|bedside ultrasonography|Patients suspicious to urinary tract infection with kidney involvement are being examined by ultrasonography to detect hydroneprhosis. The treating clinicians fill out questionnaires to validate the impact of the bedside ultrasonography on the patient care and treatment.
39613|NCT03873688|Other|expiratory muscle training|The intensity of training will been determined after assessment of maximal expiratory pressure (MEP). The first training session will perform under the supervision of a physiotherapist, patients will perform training at home. MEP measurement will reevaluate every two weeks and the intensity of training will set according to MEP levels.
39614|NCT03873675|Diagnostic Test|parathyroid hormone|10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient
39615|NCT03873662|Diagnostic Test|Blood sample|Biochemical markers will be recorded as follows: as soon as possible after the arrival of the patient and insertion of a intravenous line, blood will be drawn for the analysis of arterial blood gases, which are a standard test in patients admitted to emergency department. Blood will be analysed in a bed-side analyzer. Serum lactate and base-excess (BE) will be documented from this blood sample. Another blood sample will be drawn parallelly for biochemical tests which will be sent to the laboratory. These tests standard in patients admitted to emergency department. Serum concentration of NSE and S100B protein will be analysed and recorded from this sample. A sample of blood for the evaluation of the early dynamics of the serum concentration of NSE and S100B will be redrawn after 12 and 48/24 hours after admitting the patient.
39616|NCT03873649|Other|Bronchoscopy with lavage|"Bronchoscopy will be performed according to standard clinical procedures. Bronchoscopy will be performed under conscious sedation with continuous cardiopulmonary monitoring and the subject's upper airway will be anesthetized with topical lidocaine. The bronchoscope will be passed through the naris or mouth to the upper airway and then into the lower airway. 360cc of sterile saline will be instilled into 2 sub-segments by instilling and aspirating 3 aliquots of 60cc sequentially into each sub-segment.~Venipuncture to obtain peripheral blood mononuclear cells (PBMCs) for the proposed assays.~Cells collected will be analyzed for various T-cell subsets and gene expression to help determine the type of immune response."
39617|NCT03873636|Other|Stimulation via Soterix Medical noninvasive brain stimulation system|Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
39618|NCT03873610|Behavioral|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
39619|NCT03873610|Behavioral|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 introduces and reinforces stress and symptom management for adolescents with NF. The program consists of 8 weekly 45 minute sessions, delivered through videoconferencing.
39620|NCT03873597|Behavioral|Tele-coaching + Usual Care|The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
39621|NCT03873584|Other|Fatigue|Iron deficiency anemia with fatigue symptoms
39622|NCT03873545|Procedure|Cryopreserved Osteochondral Allograft|This tissue is a laser-etched, cryopreserved fresh osteochondral allograft that was developed as a single-stage alternative for articular cartilage restoration.
39623|NCT03873532|Drug|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 21-day treatment cycle).
39906|NCT03871348|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
39624|NCT03873532|Drug|Capecitabine|Capecitabine is given at 1250 mg/m2 by oral administration twice a day (BID, one dose each in the morning and evening, with a total dose of 2500 mg/m2 per day) for 2 weeks followed by 1 week of drug interruption. Each course of treatment will last 3 weeks. Capecitabine tablets should be swallowed with water within 30 minutes after a meal.
39625|NCT03873519|Other|Chromatic Environment|Rooms where chemotherapy sessions are delivered will be modified to show warm/cold color temperature in walls and equipment.
39626|NCT03873519|Other|Room Orientation|Room will be facing North or South
39627|NCT03873506|Drug|transplantation of hUC-MSCs|Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
39628|NCT03873493|Drug|Venetoclax|tablet; oral
39629|NCT03873493|Drug|Ibrutinib|capsule; oral
39630|NCT03873480|Procedure|Administration of Marcaine without Epinephrine prior to the start of surgery|The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
39631|NCT03873467|Behavioral|Group Lifestyle Balance|The Group Lifestyle Balance (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB is a direct adaptation of the Diabetes Prevention Program, both developed at the Diabetes Prevention and Support Center at the University of Pittsburgh. The GLB is designed for delivery in a group-based, community setting, and has resulted in weight-loss in a variety of settings, such as community centers, churches, worksites, and healthcare systems. The GLB curriculum used in this study has been adapted for people with stroke.
39632|NCT03873467|Other|Usual Care|Participants randomized to the wait-list control group will receive usual care for 6 months before beginning the modified GLB program.
39633|NCT03873454|Device|Sennheiser non-occlusive headphones|Patients listened to music of their choice using non-occlusive headphones
39634|NCT03873454|Device|Sennheiser non-occlusive headphones without music|Patients wore non-occlusive headphones but had no music playing
39635|NCT03873454|Other|No Sennheiser non-occlusive headphones|Patients did not wear non-occlusive headphones and did not listen to music
39636|NCT03873441|Other|Computer Games-Aided Balance Training Protocol|"1) Sitting Balance exercises while playing the interactive computer games starting with bi manual object placed in hands for controlling the games, then using the head rotation movements to control the games progressing to use of trunk motions to control games while balancing on the compliant surfaces in order to progress by increasing the balance costs.~(2) Standing Balance exercises progressing from a fixed support surface to uneven, compliant surfaces like progression from standing over ground to sponge to air bladder as child tolerates increased balance costs.~(3) Progression then to balancing while performing the visuomotor and visuospatial game tasks such as playing the games starting with bi-manual object placed in hands for controlling the games, then using the head rotation movements to control the games and then progressing to use of trunk motions to control games while balancing on compliant surface.~(4) Progression to single-leg stance and stepping activities."
39637|NCT03873441|Other|Conventional Balance Training Protocol|"The following is a summary of the conventional physical therapy balance training protocol:~Active-assisted stretching exercises for lower limb musculature focusing on postural control and improvement in dynamic stability,~Balance and weight bearing exercises with multi-directional reach outs associated with trunk movements on fixed surface gradually progressing to unstable movable and compliant surfaces,~Weight transfer exercises with multi-directional reach outs and~Stepping exercises in different directions on variety of surfaces."
39638|NCT03873428|Other|FES PET|FES injection
39639|NCT03873415|Drug|BMS-986165|Oral administration
39643|NCT03873389|Drug|Ocrelizumab|Patients who are beginning this medication based on patient's treating physician's recommendation will be enrolled in the study.
39644|NCT03873376|Behavioral|Opt-in; Receive offer to order self-sampling kit|Women in the opt-in arm receive an offer to order a HPV self-sampling kit, in addition to information about the study. Women who order, receive a kit that includes a self-sampling brush (Evalyn, Rovers Medical Devices), with instructions for use and a pre-paid envelope for returning the brush for HPV testing. The women are also informed that they can attend ordinary screening, i.e. performed by a physician. Women who choose self-sampling and test positive for high-risk HPV will be 1:1 allocated to follow-up by their general practitioner or a gynecologist. Women who test negative for high-risk HPV return to the ordinary screening program
39645|NCT03873376|Behavioral|Opt-out; Receive self-sampling kit unsolicited|Women in the opt-out arm receive the self-sampling kit directly, without having ordered it themselves. The kit has the same contents, and the follow-up is the same, as that described for the opt-in arm.
39646|NCT03873376|Behavioral|Control; Receive open reminder to be screened by physician|Similar to the procedure of the national screening program, women in the control arm receive a reminder to be screened by their general practitioner, and continues in the ordinary screening program
39647|NCT03873363|Device|PS TKA|Implantation of a posterior stabilized (cruciate substituting) Total Knee Arthroplasty.
39648|NCT03873363|Device|CR TKA|Implantation of a cruciate retaining Total Knee Arthroplasty.
39649|NCT03873350|Other|Consumption of kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
39650|NCT03873350|Other|Consumption of heat-sterilized kombucha|The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
39651|NCT03873337|Behavioral|Persistence Targeted Smoking Cessation in Schizophrenia|All participants will receive 8 weeks of smoking cessation counseling
39652|NCT03873337|Behavioral|Clearing the Air|All participants will receive 8 weeks of smoking cessation counseling
39653|NCT03873337|Drug|Nicotine patch|All participants will receive 10 weeks of nicotine patch
39654|NCT03873324|Drug|CPL500036 compound|IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).
39655|NCT03873324|Drug|Placebo|matching placebo capsules
40139|NCT03869528|Drug|10 sprays of 10% lignocaine|10 sprays of 10% lignocaine
39656|NCT03873311|Drug|Azacytidine, HAG Regimen|HAG Regimen（Cytarabine 10mg/(m2.d) for 14 days, granulocyte colony-stimulating factor(G-CSF) 200ug/(m2.d) for 14 days until absolute neutrophil count(ANC) ≥ 10X109／L，Homoharringtonine(HHT) 1mg/(m2.d for 14 days)) +Azacytidine（75mg/m2 one time/week）
39657|NCT03873298|Drug|Inhaled nitric oxide|Inhaled nitric oxide delivered through a pulsatile nitric oxide drug delivery system
39658|NCT03873285|Genetic|Genetic diagnostic by mendeliome or genome|For cases not explained by a mendeliomes: genome and transcriptome on fibroblast culture
39659|NCT03873272|Device|Cryotherapy|Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.
39660|NCT03873272|Device|Compression Therapy|Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
39661|NCT03873272|Device|Loose glove/sock|Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
39662|NCT03873259|Device|Burst Wave Lithotripsy|Fragment upper urinary tract stones
39663|NCT03873246|Drug|OC-01|OC-01
39664|NCT03873246|Drug|Placebo|placebo
39665|NCT03873233|Device|Aisys Carestation ventilator and normal endotracheal tube|Fraction of Inspired Oxygen (FIO2) 0.3 End Expiratory Pressure (EEP) at +5 cm H2O Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 Tidal Volume: 6 mL/kg Zero inspiratory pause Respiratory frequency will be adapted to produce an End-Tidal CO2 35-40 mmHg
39666|NCT03873233|Device|Evone ventilator and Tritube|Fraction of Inspired Oxygen (FIO2) 0.3 Ratio of duration of inspiration to the duration of expiration (I:E ratio) 1:1 End Expiratory Pressure (EEP) at +5 cm H2O Flow: start with 10 L/min and adjusted along with the peak inspiratory pressure to produce a tidal volume of 6 mL/kg and End-Tidal CO2 35-40 mmHg
39667|NCT03873220|Device|Wrist Actigraphy Devices|A watch-like wearable sensor
39668|NCT03873220|Device|Sleep Monitor|Remote Sensor
39669|NCT03873220|Device|Polysomnography|Sleep Monitor
39670|NCT03873220|Device|Videography|Thermal Camera
39671|NCT03873207|Device|PopSole™ offloading device|Offload Device Distribution to remain in use at all times during ambulation and activity instruction to stay off of feet as much as possible for 3 days, then limit ambulation to 10 minutes per hour for 4 weeks and no sports, kicking, running or exercise for 4 weeks. Devices will be provided for both feet to maintain symmetry and gait stability between the two feet.
39672|NCT03873207|Device|padded insole|the control arm will be provided with standard padded insole to wear inside footwear
39673|NCT03873194|Other|Meditation|Participants will be instructed to find a comfortable position, with a straight back, feeling the general state of their bodies (tensions, pains, heat, cold, etc.), to relax and pay attention to their own breathing, being aware of the air that gets into and out of the lungs. The women will be told that whenever their attention disperses (to another focus such as a thought, a sound, a body sensation, a judgment, etc.) they should go back to the original focus (breathing) with no feeling/judgment about the loss of focus. The practice involves focus and attention exercises and the gradual insertion of other anchors (focus points) as participants improve their skills in this practice.
39674|NCT03873194|Other|conventional treatment|"Early prenatal care, when possible, is recommended as the first measure. Prenatal appointments usually take place fortnightly or weekly for hypertensive pregnant women. Extensive lab testing including specific tests for the first trimester, as well as tests for the diagnosis of superimposed pre-eclampsia and for the evaluation of lesions in target organs.~Drug treatment is only used when non-drug measures against hypertension are inefficient to decrease blood pressure levels and diastolic pressure is 90 mmHg or higher (in the first half of pregnancy) and over 100 mmHg (after 20 weeks)."
39675|NCT03873181|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in laparoscopic abdominal, gynecological, or urological surgeries.
39676|NCT03873168|Device|HEMOBLAST™ Bellows|Surgeon has chosen to use HEMOBLAST™ Bellows as an adjunct to hemostasis when control of minimal, mild, or moderate bleeding by conventional procedures is ineffective or impractical in gynecological, urological, vascular, ENT and head and neck surgeries.
39677|NCT03873155|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness based cognitive group therapy (MBCT) is a structured eight-week programme (although an extra introductory week will be added in the current study) that combines mindfulness-based exercises with cognitive therapy.
39716|NCT03872843|Drug|Ibuprofen 400 MILLIGRAM in 1 TABLET ORAL TABLET, FILM COATED|Designated coated 7 days supply of pain medication (Ibuprofen 400 milligram) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times a day as needed until the stent will be removed in clinic a week later.
74252|NCT03603431|Drug|MRG-110|Multiple ascending doses of MRG-110
39678|NCT03873142|Behavioral|Mindful Parenting|The mindful parenting intervention is an adaption for parents of the Mindfulness-Based Cognitive Therapy (MBCT) for depression (Kabat-Zinn, 1990), and the Mindful-Based Stress Reduction program (MBSR; Kabat-Zinn, 1990). The mindful parenting intervention will follow the manual developed by Bögels and Restifo (2014). The intervention consists of 9x3hour sessions. Eight of these sessions are run on consecutive weeks and the final session is run eight weeks after the eighth session. These groups involve group discussions around parenting, meditation exercises, and yoga, amongst other things.
39679|NCT03873129|Behavioral|mobile health app (mHealth)|A-CHESS is a mobile health app for participants to interact with their treatment team for 12 months.
39680|NCT03873116|Drug|BCX7353 capsules|BCX7353 capsules administered orally once daily
39681|NCT03873116|Drug|BCX7353 capsules|BCX7353 capsules administered orally once daily
39682|NCT03873116|Drug|Placebo oral capsule|Matching placebo capsules administered orally once daily
39683|NCT03873090|Other|SBRT|hypofractionated accelerated RT for prostate cancer with FFF (Free Flattened Filter) beam. The schedule will be [ 4 x 9.5 Gy = 38 Gy ] delivered in 5 alternative days, corresponding to an NTD2 between 95 and 119 Gy for an α/β estimate between 3 and 1.5 Gy.
39684|NCT03873077|Procedure|local infiltration analgesia|10 mL ropivacaine 7.5 mg/mL and 10 mL lidocaine 10 mg/mL
39685|NCT03873051|Behavioral|Challenge-Focused Program|Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
39686|NCT03873051|Behavioral|Rewards-Focused Program|Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
39687|NCT03873038|Drug|MK-2060|Single ascending doses (8 mg, 20 mg, or 40 mg) of MK-2060 will be administered via IV infusion.
39688|NCT03873038|Drug|Placebo|Single doses of placebo will be administered via IV infusion.
39689|NCT03873025|Combination Product|Pembrolizumab and CXD101|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allow the immune system to destroy these cancer cells. CXD101 is a histone deacetylase (HDAC) inhibitor which kills cancer cells by blocking the vital functions of HDAC enzymes.
39690|NCT03872999|Other|Functional brain imaging without any contrast agent|"During the functional magnetic resonance imaging (fMRI) protocol, the subject will perform the attentional task while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (ET) = 30 ms, Repetition Time (RT) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
39691|NCT03872986|Device|SDF|Combined Silver Diamine Fluoride (SDF) and Potassium Iodide (KI)
39692|NCT03872986|Device|Giomer|Beautifil II dental restorative material
39693|NCT03872986|Device|GIC|Equia forte dental restorative material
39694|NCT03872973|Other|Neuromuscular Training|"The experimental group will perform neuromuscular exercise for 6 weeks.~The other experimental group will perform neuromuscular exercises with strobe glasses."
39695|NCT03872973|Other|Strobe Glasses|Stroboscopic glasses, which is characterized by intermittent vision obstruction, is a clinical tool that allows clinicians to examine sensory feedback in a progressive manner without fully seeing visual information.
39696|NCT03872960|Procedure|Transfer to cardiac arrest centre|Patients in the intervention arm will be taken directly to a the catheter lab of a heart attack centre.
39697|NCT03872947|Biological|TRK-950|Intravenously over 60 minutes
39698|NCT03872947|Drug|Irinotecan|Intravenously over 30 - 90 minutes
39699|NCT03872947|Drug|Leucovorin|Intravenously over 30 - 90 minutes
39700|NCT03872947|Drug|5-FU|Intravenously bolus and intravenously over two days
39701|NCT03872947|Drug|Gemcitabine|Intravenously over 30 minutes
39702|NCT03872947|Drug|Cisplatin|Intravenously over 60 minutes
39703|NCT03872947|Drug|Carboplatin|Intravenously
39704|NCT03872947|Biological|Ramucirumab|Intravenously over 60 minutes
39705|NCT03872947|Drug|Paclitaxel|Intravenously
39706|NCT03872947|Biological|Nivolumab|Intravenously over 30 minutes
39707|NCT03872947|Biological|Pembrolizumab|Intravenously over 30 minutes
39708|NCT03872947|Drug|Imiquimod Cream|Topically
39709|NCT03872934|Behavioral|implant anxiety|to determine the type of music that reduces anxiety in patients undergoing implant surgery.
39710|NCT03872921|Drug|norUrsodeoxycholic Acid|oral treatment
39711|NCT03872908|Device|Chilled gloves|Chilled glove for non-dominant hand (patients treated with paclitaxel)
39712|NCT03872908|Device|Surgical gloves|Surgical gloves (patients treated with oxaliplatine)
39713|NCT03872869|Other|Hip school or Tai CHi for arthritis|Eighty-nine individuals were randomized to one of the three intervention groups 30 individuals to Tai Chi,30 individuals to Hip School and 29 individuals to the control group
39714|NCT03872856|Device|BP-ICAN|"One of two home blood pressure monitor devices will be used.~Omron 7 Series Wrist cuff~Omron 10 Series Upper Arm cuff"
39715|NCT03872843|Drug|Norco 5milligram-325milligram Tablet|Designated coated 7 days supply of pain medication (Norco 5 milligram-325milligram Tablet) will be sent home with discharged subjects. Pain medication is administered/scheduled 4 times per day until the stent will be removed in clinic a week later.
39832|NCT03871881|Other|Neuropsychological assessment|A special designed neuropsychological test battery of validated tests to assess function of cognitive domains
39717|NCT03872830|Drug|Felbinac Trometamol Injection|"Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
39718|NCT03872830|Drug|Placebos|"Placebo diluted to 100 ml with 0.9% sodium chloride injection,a 30-minute period using a Microinjection pump.~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).the drug was given 3 times,3 times/day,once every 8 hours."
39719|NCT03872817|Other|Intervention ProLiSMentAl|"Using different methods and pedagogical techniques, mental health literacy psychoeducational intervention called ProLiSMentAl consist of 4 sessions of 90 minutes: 1) improvement social anxiety recognition; 2) prevention strategies; 3) self-help strategies; 4) knowledge of first aid strategies and 5) knowledge of professionals and treatments available."
39720|NCT03872804|Procedure|Autologous punch mini grafts:|"Under local anesthesia, multiple 1mm holes will be made in the depigmented treatment area using 1mm punch graft instrument inserted to a depth of 2-4 mm to remove a small column of depigmented skin that is to be discarded. The punches will be situated at or very close to the border of the lesion to avoid leaving an achromic fissure and will be separated by 5-8 mm distance from each other.~On the donor area mostly is the gluteal area, punches will be harvested using the same sized punches very close to each other so that maximum number of grafts can be taken from a small area.~Then the harvested-punch minigrafts will be inserted into the recipient chambers, pressed firmly by saline soaked gauge for hemostasis and secured by sterile strips or a compression bandage if applicable."
39721|NCT03872804|Procedure|Transverse needling|Needling will be done for selected treatment patch using a 30 G disposable insulin syringe, going from the pigmented margins of the lesion into the vitiliginous patch, Position of the needle will be kept close to the dermoepidermal junction and movement will be from normal skin towards the lesion. Needle pricks may lead to oozing of a small drop of blood which will be managed by physical pressure. No dressings will be needed. The procedure will be repeated for selected lesions weekly for a duration of 3 months.
39722|NCT03872804|Procedure|Punch minigrafts followed by transverse needling|In a third lesion, punch minigrafts will be done as mentioned in line 1 and will be left to stabilize for 3 months then transverse needling will be done weekly for the margins of the lesion as well as the areas of the punch grafts toward the vitiliginous area.
39723|NCT03872804|Other|Oral pulse steroid with narrow band|"A fourth lesion will be chosen as a control lesion, to which no surgical treatment will ba attempted.~All lesions will receive NB-UVB therapy according to standard protocol twice weekly and the patients will continue on the oral mini pulse dexamethasone at 2.5 mg dose for two consecutive days weekly all through the study period"
39724|NCT03872791|Biological|KN046|KN046 at a dose level of 3 or 5 mg/kg via intravenous infusion on Days 1 and 15 of 28-day cycle
39725|NCT03872791|Drug|Nab-paclitaxel|Nab-paclitaxel at dose level of 100 mg/m2 via intravenous infusion on Days 1, 8 and 15 of 28-day cycle
39726|NCT03872778|Drug|[177Lu]-NeoB|[177Lu]-NeoB: peptide receptor radionuclide therapy
39727|NCT03872778|Drug|[68Ga]-NeoB|[68Ga]-NeoB radioactive diagnostic agent
39728|NCT03872765|Device|Laser surgery|Use of CO2 laser to perform surgeries to treat chronic anal fissure
39729|NCT03872752|Behavioral|FL lay leader training and workshop implementation|Intervention components will include a training course for community lay leaders, enabling them to acquire the skills to lead food literacy workshops. This includes raising their knowledge about nutrition recommendations and food labels, raisin self efficacy, and improving nutrition related organization and preparation skills.
39730|NCT03872739|Procedure|enhanced computed tomography|undergoing enhanced computed tomography
39731|NCT03872700|Drug|Intranasal fentanyl|Fentanyl Citrate
39732|NCT03872700|Drug|Placebo|Sterile Water Up to 5Cc
39733|NCT03872687|Device|single tufted brush with IDB|Subjects in this group will receive a single tufted brush and interdental brushes of an appropriate size that will fit the interdental spaces around the implant.
39734|NCT03872687|Device|interdental brushes|Subjects in this group will only receive interdental brushes
39735|NCT03872674|Biological|high-flow humidified oxygen-delivery system (OptiFlow THRIVE)|stand oxygenation arm will receive oxygen at 5 L/min via nasal cannula, while Optiflow THRIVE arm will receive oxygen at 50 L/min via Optiflow THRIVE during the procedure.
39736|NCT03872661|Drug|IBI308|IBI308 was given 200 mg iv infusion on day 1 of each 21-day cycle for 4 cycles.
39737|NCT03872661|Drug|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg on day 1 of each 21-day cycle for 4 cycles.
39738|NCT03872661|Drug|Pemetrexed|Pemetrexed was given 500 mg/m^2 i.v. injection on day 1 of each 21-day cycle for 4 cycles.
39739|NCT03872661|Drug|Carboplatin|Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 4 cycles.
39740|NCT03872661|Procedure|Thoracic surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
39741|NCT03872635|Other|oral carbohydrate liquid|patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
39742|NCT03872622|Other|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire|Blood tests, intestinal biopsies, stool samples, environmental exposure questionnaire and FFQ questionnaire.
39743|NCT03872596|Drug|Seroquel IR 300mg|Administered during Part A, administered orally BID with water, over 5 days.
39744|NCT03872596|Drug|Seroquel IR 25mg|Administered during Part B, as a single, 25mg dose taken with water.
39745|NCT03872596|Drug|Quetiapine Formulation A 300mg|Administered during Part A, administered orally BID with water, over 5 days.
39746|NCT03872596|Drug|Quetiapine Formulation B 300mg|Administered during Part A, administered orally BID with water, over 5 days.
39747|NCT03872596|Drug|Quetiapine Formulation 25mg|Administered during Part B, as a single, 25mg dose taken with water.
39748|NCT03872583|Other|Understanding MRI in MS (website)|Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
39833|NCT03871855|Drug|SHR-1702|Administered IV
39749|NCT03872583|Other|Control website|Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
39750|NCT03872570|Drug|Phenylephrine|intravenous administration
39751|NCT03872570|Drug|Norepinephrine|intravenous administration
39752|NCT03872557|Dietary Supplement|Tyrosine (TYR) Supplementation|L-Tyrosine dietary supplement will be provided as 500 mg capsules and 4 (four) 500 mg capsules are to be given before OGTT. The capsules are formed from animal gelatin, and the contents are formulated with magnesium stearate as a flow agent, but without binders, coatings or colorings and also have no added flavorings, sugars, salt, artificial sweeteners, preservatives or salicylates. The capsules are to be administered with less than eight ounces of water to minimize dilution of gastric acidity.
39753|NCT03872518|Device|Urovac|The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. The Urovac is simply a regular plastic handheld urinal attached by tubing to a pump that evacuates urine to a reservoir. There is also a removable cloth-covered platform to reduce spills.
39754|NCT03872505|Drug|Durvalumab|IV administration of 5 treatments;every 2 weeks for 2 treatments and then every 4 weeks for 3 treatments
39755|NCT03872505|Radiation|Radiation Therapy|The second dose of durvalumab will be given in conjunction with an RT boost, consisting of 8 Gy in 3 fractions for a total of 24 Gy.
39756|NCT03872505|Drug|Carboplatin|IV administration weekly for 12 weeks
39757|NCT03872505|Drug|Paclitaxel|IV administration every week for 12 weeks
39758|NCT03872492|Other|Digital Assessment on mobile|"The digital assessment is composed on 5 tests:~My daily survey~My evaluation~My cognition~My emotions~My voice~Data will also be collected passively."
39759|NCT03872479|Drug|AGN-151587|Participants will receive a single dose of AGN-151587 administered via subretinal injection in the study eye. Up to 5 cohorts across 3 doses will be enrolled in this study.
39760|NCT03872453|Drug|BHV3500 10mg|one dose
39761|NCT03872453|Drug|BHV3500 20mg|one dose
39762|NCT03872453|Drug|BHV3500 5mg|one dose
39763|NCT03872453|Drug|BHV3500 matching placebo|one dose
39764|NCT03872453|Device|Intranasal Aptar Pharma Unit Dose System|one dose intranasal device
39765|NCT03872427|Drug|Glutaminase Inhibitor CB-839 Hydrochloride|Given PO
39766|NCT03872427|Other|Pharmacodynamic Study|Correlative studies
39767|NCT03872414|Behavioral|Anterior cingulate cortex activation|"Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.~The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing."
39768|NCT03872414|Behavioral|Primary auditory cortex activation|"Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as control/placebo condition in the current design (placebo comparator)."
39769|NCT03872401|Drug|Evolocumab|Administered subcutaneously using an autoinjector pen.
39770|NCT03872401|Drug|Placebo|Administered subcutaneously using an autoinjector pen.
39771|NCT03872388|Drug|Atorvastatin|"Patients will receive Atorvastatin per ASCVD guidelines dosed as either a moderate intensity (20mg/day) or high intensity statin (80mg/day). Tablets are available in either 20mg or 80mg and will be dispensed as per standard of care for up to 24 months as part of the study.~Patients may also receive capecitabine concurrently with Atorvastatin per physician discretion as standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day."
39772|NCT03872388|Drug|Capecitabine|Patients not eligible to receive atorvastatin in group II will be enrolled into non-statin observation group with/without capecitabine treatment. Capecitabine administration will be dosed as per standard of care. Standard of care dosing of Capecitabine is a 21 day cycle consisting 14 days on and 7 days off. The starting dosing will be per physician discretion, but may be up to 2500mg/m2 per day.
39773|NCT03872375|Dietary Supplement|Meal-Replacement Therapy|The meal replacement shake, consumed once per day on two consecutive days, will over a given week lead to negative energy balance and induce weight loss.
39774|NCT03872375|Behavioral|Dietary Counseling|A Registered Dietitian of Nutrition will provide consultation on how to induce moderate weight loss.
39775|NCT03872362|Diagnostic Test|radiomics|The high-throughput extraction of large amounts of quantitative image features from medical images
39776|NCT03872349|Other|Monounsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in monounsaturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
39777|NCT03872349|Other|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in saturated fatty acids and will have a duodenal gastroscopy and a kinetic study at the end of the 4-week period.
39778|NCT03872336|Drug|Experimental labetalol dose|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
39779|NCT03872336|Other|Current standard of care|Subjects who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the standard dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
39780|NCT03872323|Procedure|Endovascular treatment|The arteries injuries are repaired by endovascular treatment.
39781|NCT03872323|Procedure|Open surgery|The arteries injuries are repaired by open surgical operation.
39834|NCT03871855|Drug|Camrelizumab|Administered IV
74253|NCT03603431|Drug|Placebo|Multiple doses of Placebo
39782|NCT03872310|Device|STARSTIM|Right DLPC was located as F4 according to the international 10-20 EEG system. Anodal tDCS was delivered with the anodal pole on the right DLPFCand the cathodal pole on the left cheek of the participant to avoid contaminating other brain regions during electrical stimulation via a pair of rubber electrodes housed in saline-soaked sponge coverings (5x5 cm^2). The direct current was applied with 1.5 mA for 15 min which can facilitate visual short-term memory and create an excitatory effect for up to 90 min. The anodal tDCS stimulated the right DLPC for 15 min with 1.5 mA in active tDCS condition. The sham tDCS condition followed identical tDCS protocol and same 15-min duration except the stimulation time only lasted for the initial 30s so that the participants felt the same initial tingling sensation (if any, only in some participants) but without the actual stimulation. The investigators will perform assessments of adverse effects after each session by a standardized questionnaire.
39783|NCT03872297|Dietary Supplement|Placebo supplement|"Consumption of a non active food complement during 3 months.~Tests performed :~2 blood tests :~2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
39784|NCT03872297|Dietary Supplement|Naticol supplement|"Consumption of the active food complement during 3 months containing Naticol.~Tests performed :~2 blood tests :~2 body composition analysis via Dual-energy X-ray absorptiometry (DXA)~2 stool collections The first one of these analysis was performed at the beginning, second at the end of the study."
39785|NCT03872284|Other|oculomotor movement recordings, neurovisual assessment|Each participant will have a neurovisual assessment and an oculomotor movement recording with an eye tracker (infra red cameras).
39786|NCT03872271|Procedure|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
39787|NCT03872271|Procedure|ileal pouch-anal anastomosis with diverting loop ileastomy|Defunctioning ileostomy has demonstrated its benefits (rate and seriousness of anastomotic leakage) in cancer for low colorectal and coloanal anastomoses, whereas there are no such good quality evidences in case of ileal pouch-anal anastomosis (IPAA) performed for inflammatory bowel disease (IBD). However, most surgical teams do protect systematically IPAA by an ileostomy.
39788|NCT03872258|Behavioral|Control|Counseling on physical activity
39789|NCT03872258|Behavioral|Intervention group|Program of combined exercise and a Smartband for 6 months.
39790|NCT03872245|Biological|Probiotics|The patients will receive Adomelle 1caps/12h during 10 weeks
39791|NCT03872245|Procedure|PENS T6|The patients will undergo percutaneous electrical neurostimulation of dermatome T6 weekle, during 10 weeks
39792|NCT03872232|Drug|Ezetimibe/Rosuvastatin|PO, Once daily(QD), 8weeks
39793|NCT03872232|Drug|Telmisartan|PO, Once daily(QD), 8weeks
39794|NCT03872219|Combination Product|Nature-based materials|In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
39795|NCT03872206|Biological|HPN536|Dose escalation: HPN536 will be administered once weekly via IV infusion Dose expansion: HPN536 will be administered at the RP2D once weekly via IV infusion
39796|NCT03872193|Other|Exercise|Virtual Reality Exercies
39797|NCT03872180|Drug|Bendamustine|Given IV
39798|NCT03872180|Biological|Obinutuzumab|Given IV
39799|NCT03872180|Drug|Venetoclax|Given PO
39800|NCT03872167|Device|BIPAP, Intelligent automatic mode defined by assured volume with pressure support|Correction of night ventilation through an automatic mode of ventilation with assured volume with pressure support
39801|NCT03872167|Device|BIPAP, manual tritration.|Correction of night ventilation through a manual titration of non-invasive mechanical ventilation using polysomnography.
39802|NCT03872154|Other|Checklist-guided shared decision-making|"Physicians will receive a checklist and a decision aid for shared decision-making during code status discussion.~Ancillary project: Physicians will receive a checklist to communicate the futility."
39803|NCT03872141|Diagnostic Test|Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer|Quantitative measures that include additional aspects of peripheral neuropathy, such as pain, thermal allodynia, numbness and tingling are needed. We propose to evaluate several pharmacodynamics biomarkers in patients before and during chemotherapy: changes in nerve conduction velocity and amplitude, quantitative sensory testing (QST), computer based cognitive assessment, and rate of drop-out from treatment. The tests from this list that best correlate with decreased CIPN would be added to EORTC QLQ-CIPN20 scores and will provide an early indication of CIPN and/or CICI.
39804|NCT03872128|Drug|Pregnenolone|300mg
39805|NCT03872128|Drug|Pregnenolone|500mg
39806|NCT03872128|Other|placebo|placebo
39807|NCT03872115|Device|PDVibe2|The PDVibe2 is owned by Resonate Forward, LLC and will be loaned to Virginia Commonwealth University (VCU) for this project. The device is non-invasive, lightweight, untethered, contains a rechargeable battery, and is worn on both feet and ankles. PDVibe2 delivers vibration when activated by an easy to access switch on the device or by remote. The internal circuitry has been miniaturized, is encased in a small box, and is attached to the ankle using a soft flexible band.
39808|NCT03872089|Other|Infrared Thermography|Measurements of the temperature of the plantar arch by thermal imaging (Infrared Thermography)
39809|NCT03872076|Other|Experimental|"The Drom Jump technique with the legs flexed will be performed with the patient standing in front of a bench 30 cm high by 100 cm wide. The physiotherapist will be placed lateral to the athlete. The subject will be asked to jump up from the box or bench, with the hip and knees in semi-reflexion, with his hands on his hip and he will be asked for an explosive jump, followed by a jump downwards falling the floor of the same way.~The technique of lateral jumps on cones will be carried out by means of unipodal jumps, achieving a distance of 50 cm between cones. The physiotherapist will stand in front of the athlete. The subject will be asked to perform a lateral unipodal explosive jump by flexing the hip and knee."
39862|NCT03871608|Other|Examination of functional etiologies on DTM Disorders|Evaluating functional etiologies accessible to rehabilitation, consists of 4 categories (Orofacial dyspraxia, parafunctions, posture, Chewing) and includes 11 items in total
39810|NCT03872076|Other|Control|"Elastic bands will be combined with isometric exercises in 3 sets of 10 repetitions each. The exercises they will perform are front squat. On the one hand, separating the legs at the height of the shoulders with hip and knee flexion, with the elastic band above the knees, maintaining the position 20 seconds.~In the following exercise, with the elastic band on the ankle, in unipodal support at the same time that the contralateral limb is free of support, the hip will be flexed at 45º with full knee extension, requesting the athlete to keep the tension 20 seconds, performing 3 sets of 10 repetitions."
39811|NCT03872063|Other|Experimental|The intervention by myofascial induction will consist of the application of two techniques: global technique of myofascial induction of the pectoralis major muscle (once the tissue is placed in tension, the direction of fascia release in that region should be followed and as a result of the release, the caudal hand can move to the pelvis in any direction, to the right or to the left) and telescopic technique for the upper extremity of the subject's dominant arm (gently tractioning the upper limb of the subject, making a slight external rotation, so slow and progressive). The subjects will then perform the eccentric exercises, which will also be done by control group subjects
39812|NCT03872063|Other|Control|The intervention by eccentric exercises will consist of two exercises using an elastic band. In the supine position, with the elastic band on the contralateral side attached to a fixed body perpendicular to the subject's hand performing a slow and constant movement of external rotation against resistance in an approximately 45 degree arc; holding for 5 seconds and relaxing slowly (perform 3 sets of 12 repetitions). The second exercise, with the elbow in 90 degrees of flexion and a shoulder abduction also of 90 degrees, with the elastic band in front of the subject, executing a movement against resistance performing an external rotation.
39813|NCT03872050|Diagnostic Test|No intervention apart from tests, including interview|No interventions
39814|NCT03872037|Procedure|Selective removal of carious tissue and restoration with Maxxion|Molars subjected to selective removal and restored with Maxxion
39815|NCT03872037|Procedure|Control|Molars subjected to selective removal and restored with Ketac Molar Easymix
39816|NCT03872024|Device|3 XXL probe prototypes of the FibroScan 630 Research Model|"After the patient informed consent form signature and during the patient pre-operative routine hospitalization, the following examinations will be done:~An ultrasound examination~One examination with the FibroScan® 430 mini fitted with the XL+ probe (commercial reference)~Three examinations with the FibroScan® 630 Expert - Research model fitted with the 3 XXL probe prototypes."
39817|NCT03872011|Drug|Vitamin C,thiamine,hydrocortisone|"Vitamin C (2g) will be diluted in 100ml 0.9%NACL and administered ivd every 6 hours for 5 days or until participant is discharged from the ICU.~Thiamine(200mg) will be diluted in 100ml 0.9%NACL and administered ivd every 12 hours for 5 days or until participant is discharged from the ICU. Hydrocortisone was administered 200 mg/d as a continuous infusion for 5 days or until participant is discharged from the ICU."
39818|NCT03872011|Drug|Placebo|Normal saline (0.9% NaCl solution) volume to match all components
39819|NCT03871998|Other|Skin barrier protection in the first 2 months of life|Skin barrier protection in the first 2 months of life using a commercially available moisturiser from birth 2 months. Twice daily, whole-body application.
39820|NCT03871985|Procedure|Subglottic secretion lavage combined with aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion lavage combined with aspiration was performed every 4 hours: Underwent preoxygenation before cuff pressure checking, and was maintained between 30 and 35 cmH2O. After aspirating secretions from the mouth, nose, and airway, 2-5 mL distilled sterile water was instilled through the subglottic lumen, and then the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat lavage and aspiration until the irrigation fluid is clear. After washing, cuff pressure checking and was maintained between 25 and 30 cmH2O.
39821|NCT03871985|Procedure|Subglottic secretion aspiration|Ventilator-associated pneumonia preventive measures were applied to all patients according to VAP bundle. Subglottic secretion aspiration was performed every 4 hours:Underwent preoxygenation before cuff pressure checking ,and was maintained between 25 and 30 cmH2O. After aspirating secretions from the mouth, nose, and airway, the negative pressure suction device is connected with the outer opening of the side cavity of endotracheal intubation for suction with a negative pressure of 100 mmHg, and each suction was kept under 15 seconds. Repeat suction until the secretion is completely absorbed.
39822|NCT03871972|Drug|Umbilical Cord Blood Unit|3 infusions of umbilical cord blood (UCB) unit (TNC > 2.0ⅹ107cells/kg) each 4 months apart and take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)
39823|NCT03871959|Drug|Pembrolizumab|200 mg, intravenous (IV), to be administered on Day 1 of every 3-week cycle i.e. Q3W.
39824|NCT03871959|Drug|DEBIO1143|3 escalating dose level (100 mg, 150 mg, 200 mg) of Debio 1143 administered daily for 14 days over a 21-day cycle period.
39825|NCT03871946|Diagnostic Test|oral glucose tolerance test (OGTT)|Implementation of OGTT: The patient was seated in a quiet room after 10-12 h of overnight fasting, and blood samples were drawn. Thereafter, 75 g glucose solution dissolved in 300 mL of water was administeredwithin 5 min. Two hours after this,another blood sample was drawn. During the test, the patient wasn't allowed to rest and eat, but not smoke.
39826|NCT03871933|Other|Measurement of lung function, electrocardiography, echocardiography and autonomic function|Measurement of lung function, electrocardiography, echocardiography and autonomic function
39827|NCT03871920|Other|physical therapy treatment|any treatment chosen by treating physiotherapist
39828|NCT03871907|Behavioral|Digital technology|Lifestyle-Focused Text Messaging
39829|NCT03871894|Other|Indirect calorimetry based nutritional intervention till patient in ICU(Intensive care unit)|Nutrition therapy based on indirect calorimetry (IC) measurements(measured resting energy expenditure and/or substrate utilization) and to be adjusted according to the variations shown by IC.
39830|NCT03871894|Other|Standard and fixed nutritional intervention till patient in ICU|Fixed standard nutritional therapy 40 Kcal/Kg IBW/day and 1.5 to 2 g protein /Kg IBW/Day throughout the period of ICU stay
39831|NCT03871881|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging (MRI) of the brain's macro- and microstructures. Furthermore, brain regional interactions and activity is examined with quantitative functional-MRI (fMRI)
40258|NCT03868566|Drug|SNP-612 dose2|Subjects will take dose2 once a day orally for 12 weeks
39835|NCT03871842|Device|active tDCS|Considering that the daily outpatient use of tDCS equipment is not feasible for most patients, the Pain and Neuromodulation group of the Hospital de Clínicas de Porto Alegre developed a portable tDCS device for home use that has a safe protocol, in addition of being easy to use so that the patient can use it at home without help. The safety protocol embedded in the device does not, for example, allow the appliance to be used for more than 20 minutes per day. The device can also provide the assisting staff with data such as the time the patient used the equipment, providing an accurate picture of the patient's adherence to this type of equipment. This tDCS equipment for home use has already been validated in a pilot study and will be used in this work.
39836|NCT03871842|Device|sham tDCS|The sham intervention will be applied exactly equal to active intervention, but the electric stimulus will last just for 30 seconds.
39837|NCT03871829|Drug|Carfilzomib 20 mg/m^2|Carfilzomib 20 mg/m^2 will be administered intravenously (IV).
39838|NCT03871829|Drug|Carfilzomib 70 mg/m^2|Carfilzomib 70 mg/m^2 will be administered IV.
39839|NCT03871829|Drug|Dexamethasone 40 mg|Dexamethasone 40 mg will be administered as IV infusion or orally.
39840|NCT03871829|Drug|Dara-SC 1800 mg|Dara-SC 1800 mg will be administered by SC injection.
39841|NCT03871829|Drug|Dexamethasone 20 mg|Dexamethasone 20 mg will be administered as IV infusion or orally.
39842|NCT03871816|Other|Saliva, Blood, or Existing Tissue Sample Collection and Analysis|Saliva or blood sample (or both) or existing tissue sample analysis will be collected from the participants with metastatic PC for genetic testing to determine if DNA-repair defects are present.
39843|NCT03871803|Drug|Controlled withdrawal of beta-blockers|Controlled withdrawal of previos doses of beta-blockers after diagnosis of chronotropic incompetence
39844|NCT03871803|Diagnostic Test|Cardiopulmonary Exercise Testing|Cardiopulmonary Exercise Testing to evaluate the chronotropic incompetence and the primary endpoint (functional capacity)
39845|NCT03871790|Diagnostic Test|Analysis of molecular tumor particularities and neoepitopes|Parallel sequencing DNA and RNA from both tumor and blood, as well as analysis of the presence of tumor-specific antigens (neoepitopes) in blood
39846|NCT03871777|Other|Placebo mouthwash|Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
39847|NCT03871777|Other|Chlorhexidine mouthwash|After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
39848|NCT03871764|Diagnostic Test|blood sample , doppler of uterine vessel and placenta|blood sample for factor V and doppler examination of uterine arteries , placenta pathology post partum
39849|NCT03871751|Behavioral|Safe and Sound Protocol|The auditory intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
39850|NCT03871738|Other|Proprioceptive training|"The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes."
39851|NCT03871725|Combination Product|Sonodynamic therapy (SDT)|Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
39852|NCT03871712|Behavioral|Motivational interview|The participants will be called twice with 2-4 weeks interval after the randomisation. This will be after 8 weeks of sick leave.
39853|NCT03871712|Behavioral|Stratified vocational advice|The participants will be called after the randomisation. The amount of calls/meetings will be decided after each call, but with a maximum of 4 for the high risk group. This may include physical meetings.
39854|NCT03871699|Drug|Ferric carboxymaltose|Administration of Ferric Carboxymaltose intravenously, one dose only.
39855|NCT03871686|Behavioral|Brief Internet-based Behavioral Activation Intervention|A brief Internet-based behavioral activation intervention consisting of 4 sessions.
39856|NCT03871673|Dietary Supplement|sweet polvilho|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
39857|NCT03871673|Dietary Supplement|Cornstarch|100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
39858|NCT03871660|Device|FreeStyle Libre Pro|Flash glucose monitoring device. Measures patients interstitial glucose levels continuously.
39859|NCT03871647|Drug|Beta blocker|perioperative beta blockers
39860|NCT03871621|Drug|Diabetes Medicines|Anti-diabetic medications except SGLT2 inhibitors
39861|NCT03871621|Drug|Dapagliflozin|Dapagliflozin tablet (10 mg)
40259|NCT03868566|Drug|SNP-612 dose3|Subjects will take dose3 once a day orally for 12 weeks
39863|NCT03871608|Other|Assessment of symptoms on DTM Disorders|Examining the symptoms of the patient, consists of 5 categories (Muscle examination, Areas of cellulalgic infiltrates, Mandibular kinetics, Joint sounds, Thrust)and includes 21 items
39864|NCT03871595|Drug|BI 894416|Oral
39865|NCT03871582|Other|No intervention|Cross-sectional
39866|NCT03871569|Other|bucco-dental teleexpertise|A bucco-dental consultation remotely using telemedicine system
39867|NCT03871556|Diagnostic Test|LOGIQ P6 Diagnostic Ultrasound|Ultrasound measurements of subcutaneous fat thickness
39868|NCT03871543|Device|AquaComfort Plus|Test Lens 1
39869|NCT03871543|Device|Acuvue Oasys 1-Day|Test Lens 2
39870|NCT03871530|Other|Coordinate A|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
39871|NCT03871530|Other|Coordinate B|"PIEB Next Bolus: 45 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
39872|NCT03871530|Other|Coordinate C|"PIEB Next Bolus: 45 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
39873|NCT03871530|Other|Coordinate D|"PIEB Next Bolus: 45 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
39874|NCT03871530|Other|Coordinate E|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 5 mL"
39875|NCT03871530|Other|Coordinate F|"PIEB Next Bolus: 30 minutes, PIEB Interval: 40 minutes, and PIEB volume: 8 mL"
39876|NCT03871530|Other|Coordinate G|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 8 mL"
39877|NCT03871530|Other|Coordinate H|"PIEB Next Bolus: 30 minutes, PIEB Interval: 60 minutes, and PIEB volume: 5 mL"
39878|NCT03871530|Other|Coordinate I|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 5 mL"
39879|NCT03871530|Other|Coordinate J|"PIEB Next Bolus: 15 minutes, PIEB Interval: 40 minutes, and PIEB volume: 6.5 mL"
39880|NCT03871530|Other|Coordinate K|"PIEB Next Bolus: 15 minutes, PIEB Interval: 50 minutes, and PIEB volume: 8 mL"
39881|NCT03871530|Other|Coordinate L|"PIEB Next Bolus: 15 minutes, PIEB Interval: 60 minutes, and PIEB volume: 6.5 mL"
39882|NCT03871530|Other|Coordinate M|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
39883|NCT03871530|Other|Coordinate N|"PIEB Next Bolus: 30 minutes, PIEB Interval: 50 minutes, and PIEB volume: 6.5 mL"
39884|NCT03871517|Drug|Indobufen|Indobufen inhibits platelet aggregation by reversibly inhibiting the platelet cyclooxygenase enzyme thereby suppressing thromboxane synthesis.
39885|NCT03871517|Drug|Aspirin|Aspirin is a salicylate (sa-LIS-il-ate). It works by reducing substances in the body that cause pain, fever, and inflammation.
39886|NCT03871504|Other|Submaximal isometric exercise|The exercise is a submaximal isometric contraction
39887|NCT03871491|Drug|Azithromycin|The study intervention is a single 2 g dose of directly observed oral azithromycin, to be administered as four 500 mg pills or tablets directly after randomization. By random allocation, participants will receive 2 g of oral azithromycin.
39888|NCT03871491|Drug|Placebo|Identical appearing placebo, administered as a single oral dose directly after randomization.
39889|NCT03871478|Drug|Lidocaine|See Arm Description
39890|NCT03871478|Drug|Bupivacaine|See Arm Description
39891|NCT03871478|Drug|Lidocaine and Bupivacaine|See Arm Description
39892|NCT03871465|Drug|Triamcinolone SASD injection|2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.
39893|NCT03871465|Procedure|Physiotherapy|The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
39894|NCT03871465|Drug|Triamcinolone injections & Physiotherapy|"2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles."
39895|NCT03871452|Procedure|Ankaferd Blood Stopper in theTraumatic Bleeding|"ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.~The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses"
39896|NCT03871439|Drug|PF-05221304 Formulation A|50mg
39897|NCT03871439|Drug|PF-05221304 Formulation B|50mg
39898|NCT03871426|Procedure|manual therapy|Manual Cervical Traction, Trunk Stabilization Maneuver
39899|NCT03871413|Device|TRV-chair|Repositioning maneuvers in TRV-chair
39900|NCT03871413|Procedure|Manual repositioning maneuver|Treatment with manual repositioning maneuver
39901|NCT03871400|Procedure|Anterior cervical discectomy and fusion|primary, 2-level, contiguous
39902|NCT03871387|Drug|Deep Group|"Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 0 & PTC= 1~2 (TOF = train-of-four. PTC = post-tetanic count)~TOF and PTC are assessed by acceleromyography (TOF-Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme [MSD], Oss, the Netherlands) injection to reverse muscle relaxation.~Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2"
39903|NCT03871387|Drug|Control Group|"Continuous Rocuronium (Rocnium®, Hanlim Pharm. Co., Ltd., South Korea) infusion during surgery~Titrate Rocuronium (Rocnium®) infusion rate to maintain TOF = 1~2~TOF and PTC are assessed by acceleromyograph (TOF‐Watch® SX, Organon Ltd., Drynam Road, Swords, Co. Dublin, Ireland).~At the end of surgery, IV Sugammadex (Bridion®, Merck Sharp and Dohme [MSD], Oss, the Netherlands) injection to reverse muscle relaxation.~Sugammadex dose = 2mg/kg at TOF ≥2 or 4mg/kg at TOF < 2"
39904|NCT03871361|Drug|Abatacept 125 MG/ML Prefilled Syringe|Abatacept 125 MG/ML Prefilled Syringe [Orencia] weekly
40260|NCT03868553|Other|No intervention|observational study
39907|NCT03871335|Diagnostic Test|Investigation of the work-related musculoskeletal disorders|Structured questionnaires will be used to determine the prevalence of the work-related musculoskeletal disorders and work-related factor. Photogrammetric method will be used to evaluate working posture.
39908|NCT03871322|Dietary Supplement|Vitamin D and K2 supplementation|if supplementation of vitamin D and K2 changes the time to fracture healing
39909|NCT03871322|Dietary Supplement|Vitamin D supplementation|if supplementation of vitamin D alone changes the time to fracture healing
39910|NCT03871322|Dietary Supplement|Placebo|Placebo control group
39911|NCT03871309|Device|Tigertriever|Mechanical Thrombectomy
39912|NCT03871257|Drug|Carboplatin|Given IV
39913|NCT03871257|Other|Quality-of-Life Assessment|Ancillary studies
39914|NCT03871257|Other|Questionnaire Administration|Ancillary studies
39915|NCT03871257|Drug|Selumetinib|Given PO
39916|NCT03871257|Drug|Selumetinib Sulfate|Given PO
39917|NCT03871257|Drug|Vincristine|Given IV
39918|NCT03871257|Drug|Vincristine Sulfate|Given IV
39919|NCT03871244|Procedure|Less red blood cell transfusions|The instructions given to caregivers will be to consider prescribing a red blood cell transfusion only if the hemoglobin level is ≤ 70 g per L.
39920|NCT03871244|Procedure|More red blood cell transfusion (standard transfusion strategy in PICU)|The instructions given to caregivers will be to prescribe a red blood cell transfusion according to their usual standard practice
39921|NCT03871231|Device|Unpinning Termination Therapy|The Cardialen External Stimulation System (CESS) is the research delivery system for the proprietary Cardialen Unpinning Therapy (UPT) therapy. The CESS is a custom designed and built research device. It is comprised of off-the-shelf commercial components (power supplies, waveform generators, laptop computer, monitor, rack, ECG system, leads, etc.) combined with a custom electrical circuit board and custom software.
39922|NCT03871218|Biological|Hyaluronic acid group|Applicaton of topical Hyaluronic acid
39923|NCT03871205|Biological|Neoantigen loaded DC vaccine|Patients will be vaccinated with autologous mature dendritic cells loaded with neoantigen, DC vaccine will be injected subcutaneously 6 times, once a week.
39924|NCT03871192|Diagnostic Test|FACET JOINT UNDER CT GUIDANCE|injection of triamcinolone in the facet joint under CT guidance
39925|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER CT GUIDANCE|injection of triamcinolone around the dorsal ramus under CT guidance
39926|NCT03871192|Diagnostic Test|FACET JOINT UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone in the facet joint under fluoroscopy guidance
39927|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE|injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
39928|NCT03871192|Diagnostic Test|FACET JOINT UNDER ULTRASOUND GUIDANCE|injection of triamcinolone in the facet joint under ultrasound guidance
39929|NCT03871192|Diagnostic Test|NERVE BLOCK UNDER ULTRASOUND GUIDANCE|injection of triamcinolone around the dorsal ramus under ultrasound guidance
39930|NCT03871166|Other|Blood transfusion|"Observational post-ad-hoc design to compare patients admitted with an ARDS and separated into different groups according to their mean hemoglobin concentration during their stay on the intensive care unit.~Approximately 1000 adult patients admitted from 2007 to 2018 to the Charite ARDS center will be enrolled in the study. They are followed up until their discharge from the ICU.~[Time Frame: 01/2007 - 12/2018]"
39931|NCT03871153|Device|Durvalumab|"Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1"
39932|NCT03871153|Drug|Paclitaxel|Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
39933|NCT03871153|Drug|Carboplatin|Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
39934|NCT03871153|Radiation|Radiation|1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
39935|NCT03871153|Procedure|Surgical Resection|Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
39936|NCT03871140|Other|diagnosis|therre is no intervention diagnosis or treatment for patients
39937|NCT03871127|Procedure|Percutaneous coronary intervention|Using sirolimus eluting stent
39938|NCT03871127|Procedure|coronary artery bypass graft|coronary artery bypass graft
39939|NCT03871114|Drug|Triamcinolone Acetonide in orabase|treatment of OLP with topical steroid
39940|NCT03871101|Procedure|Scalpel|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with scalpel for placing the healing abutment.
39941|NCT03871101|Device|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
39942|NCT03871088|Dietary Supplement|Omega-3 fatty acids|12-week double-blind, randomized controlled trial
39943|NCT03871075|Device|intermittent pneumatic compression|Intermittent pneumatic compression is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 120 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
39944|NCT03871075|Behavioral|exercise|Participants will be asked to walk for exercise five days/week, working up to 50 minutes of exercise per day. The intervention includes a) group meetings at the medical center with the coach and other PAD participants; b) regularly scheduled individual telephone check-in by the coach c) weekly remote monitoring by the coach; d) use of the activity monitor to monitor exercise intensity and duration.
39945|NCT03871075|Device|Sham device|The sham control device is a non-invasive intervention, consisting of an air pump inside inflatable cuffs that are wrapped around the feet, ankles, and calves. The cuffs rapidly inflate to a pressure of 25 mm Hg, which is sustained for three seconds, followed by rapid deflation. Participants will be asked to wear the device for two hours daily. The device will inflate 180 times/hour.
39946|NCT03871075|Behavioral|Health Education|Participants attend health-education lectures and receive telephone calls at the same frequency as the exercise group. On-site lectures are delivered by faculty and staff at the medical center. Telephone calls review health-related handouts from the NIA website that are mailed in advance of the telephone call. Content does not include exercise information.
39947|NCT03871062|Procedure|Two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.2 ml subconjunctival injection
39948|NCT03871062|Procedure|topical anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times
39949|NCT03871049|Drug|Bupivacaine with dexamethasone|bupivacaine with dexamethasone
39950|NCT03871049|Drug|Bupivacaine|bupivacaine
39951|NCT03871036|Drug|Tremelimumab|See experimental arm description for more details.
39952|NCT03871036|Drug|Durvalumab|See experimental arm description for more details.
39953|NCT03871036|Drug|Paclitaxel|See experimental arm description for more details.
39954|NCT03871023|Device|Smith & Nephew PICO Negative wound pressure versus standard dresing|To investigate if negative wound pressure improves wound outcome
39955|NCT03871023|Device|PREVENA Negative pressure wound versus standard dressing|To investigate if negative wound pressure improves wound outcome
39956|NCT03871010|Device|Midline catheter|Midline catheter is used for administration of intravenous therapy, and is inserted in a larger vein.
39957|NCT03870997|Behavioral|Diabetes Digital Intervention|The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.
39958|NCT03870997|Behavioral|Generic Digital Intervention|The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
39959|NCT03870984|Dietary Supplement|wNUTS, low-caloric diet plus nuts|15g of nuts and 15g of hazelnuts in association with low caloric diet
39960|NCT03870984|Other|w/oNUTS, low-caloric diet without nuts|low caloric diet
39961|NCT03870971|Other|blood glucose measurement|After the patient has performed the manual reading, the investigator or staff member will obtain another capillary blood sample and a reference reading by means of the YSI 2300 Stat plus analyzer will be performed and recorded. If patients need more than one attempt to get a successful blood glucose reading, the number of attempts will be documented. A questionnaire needs to filled by the participant
39962|NCT03870958|Procedure|GIC sealant (GC Fuji TRIAGE®)|Children allocated to this group will receive the same dietary advices and brushing instructions. Additionally, all MIH molars from will receive a GIC sealant (GC Fuji TRIAGE®, GC Europe, Leuven, Belgium).
39963|NCT03870958|Procedure|Control|Children allocated to this group will receive the same dietary advices and brushing instructions.
39964|NCT03870945|Biological|MB-CART2019.1|This is a prospective, multi-center, open phase I/II trial to evaluate feasibility, dosage, safety and toxicity as well as efficacy of ex vivo expanded autologous T cells genetically modified to express anti-CD20 and CD19 immunoreceptor (MBCART2019.1) in patients with relapsed or resistant aggressive CD20 and CD19 positive B-NHL/CLL/SLL.
39965|NCT03870932|Other|Motor Imagery physical therapy|
39966|NCT03870932|Other|Conventional physical therapy|
39967|NCT03870919|Drug|Palbociclib|"The included patients will first receive the following systemic treatment according standard of care:~Non-steroidal aromatase inhibitor (letrozole)~Palbociclib~Monthly Luteinizing hormone-releasing hormone (LHRH) analogue for non-menopausal patients only. Surgical bilateral oophorectomy is an acceptable option."
39968|NCT03870919|Other|locoregional treatment|After 6 courses of systemic treatment initiation, the loco-regional treatment of the primary tumour will be performed: surgery (conservative or mastectomy) with or without radiotherapy, or radiotherapy
39969|NCT03870906|Behavioral|Occupational-specific health talk|Health talk will provide information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
39970|NCT03870906|Behavioral|WhatsApp interaction|Individual WhatsApp interactions last 3-month and consist of 2 parts. First part is regular WhatsApp message. The schedule will be adjusted according to the participants' quitting status. Second part is real-time discussion intervention based on participants' socio-demographic characteristics, smoking habit at baseline and updated smoking status obtained during online conversation. At 3-month follow-up, participants who are still smoking are encouraged to join an additional 1-month online group chat moderated by a smoking cessation counselor.
39971|NCT03870906|Behavioral|Phone follow-up/counselling service|The intervention outcomes and participants' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
39972|NCT03870906|Biological|Text message|Participants will receive regular text messages with similar frequency to those in the intervention group.
39973|NCT03870893|Behavioral|hippotherapy|16weeks hippotherapy program
39974|NCT03870880|Drug|Risperidone ISM 75 mg|Monthly intramuscular (IM) injection in the gluteal or deltoid muscle.
39975|NCT03870880|Drug|Risperidone ISM 100 mg|Monthly IM injection in the gluteal or deltoid muscle.
39976|NCT03870867|Other|No intervention|No intervention
39977|NCT03870854|Procedure|PEFA VT ablation technique|Catheter ablation guided by PEFA technique
39978|NCT03870841|Drug|PC945|PC945, nebulized
39979|NCT03870828|Diagnostic Test|Bronchoalveolar lavage and taking bronchial mucosa samples|"Regional anesthesia and sedation with use of lidocaine and midazolam will be performed, according to anesthesia protocols applied in respective endoscopy units. Intravenous cannula will be inserted prior to BF. During endoscopy, the patient will be monitored according to safety protocols applied in respective endoscopy units.~Bronchoalveolar lavage will be performed in the bronchus from the middle robe of right lung or the lingula of left lung (B4, B5). Localization will be chosen based on HRCT results and will be recorded in patient's medical history. Sterile solution of 0, 9% NaCl will be instilled. 200 ml fluid will be applied with a syringe in portions of 25 ml or 50 ml. It is recommended that minimum 60 % of the lavage fluid is retrieved."
39980|NCT03870828|Diagnostic Test|6minute walk test|a submaximal exercise test which entails measurement of distance walked over a span of 6 minutes. Blood pressure, pulse oximetry are measured directly before and after the test. The participant is also periodically asked about their dyspnea sensation
39981|NCT03870828|Diagnostic Test|Arterial blood gas|If SpO2 is measured to be < 92%, an artery (radial or femoral) is punctured in order to take a sample of arterial blood. Then, the artery is compressed in order to prevent bleeding/ hematoma.
39982|NCT03870828|Procedure|Blood drawing|A vein will be punctured in order to take a blood sample for further tests
39983|NCT03870815|Procedure|CABG|Patients who undergoing CABG
39984|NCT03870815|Procedure|PCI|Patients who undergoing PCI with second-generation DES
39985|NCT03870802|Other|Characterization of breast stem & immune system cells infiltrated in the mammary gland|Isolation, quantification and characterization of breast stem and immune cells of samples obtained during the prophylactic mastectomy in women presenting different tumor progression risks.
39986|NCT03870776|Drug|MAP4343|Daily oral administration of MAP4343
39987|NCT03870776|Drug|Placebo|Daily oral administration of Placebo
39988|NCT03870763|Drug|Dimethyl Fumarate|Administered as specified in the treatment arm.
39989|NCT03870763|Drug|Peginterferon Beta-1a|Administered as specified in the treatment arm.
39990|NCT03870763|Drug|Placebo|Administered as specified in the treatment arm.
39991|NCT03870750|Other|Supportive Palliative Care|focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects
39992|NCT03870750|Other|Clinical Management|physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education
39993|NCT03870750|Other|Best Practice|Given standard of care
39994|NCT03870750|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
39995|NCT03870750|Other|Questionnaire Administration|Ancillary studies
39996|NCT03870750|Other|Quality-of-Life Assessment|Ancillary studies
39997|NCT03870750|Other|Survey Administration|Ancillary studies
39998|NCT03870737|Device|Active TNS|Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
39999|NCT03870711|Drug|lidocaine spray|10% lidocaine spray 4 puffs
40000|NCT03870711|Drug|Placebo|Sterile water 4 puffs
40001|NCT03870698|Procedure|Laparoscopic group|The patients in laparoscopic group will underwent pylorus preserving pancreaticoduodenectomy in laparoscopic manners.
40002|NCT03870685|Procedure|TAP Block|Transversus Plane block
40003|NCT03870685|Procedure|Surgical Site Infiltration|Surgical Site Infiltration
40004|NCT03870685|Drug|Exparel|liposomal bupivacaine
40005|NCT03870672|Device|Contralaterally Controlled Functional Electrical Stimulation|Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.
40006|NCT03870672|Device|New rTMS approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using five 1-min trains of 300 pulses each (total 1500 pulses) for a period of 10 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
40007|NCT03870672|Device|Conventional rTMS approach|Facilitation of M1 will be achieved using 5Hz rTMS. Eight 1-min trains of 300 pulses each will be delivered over a period of 15 min (2400 pulses total).Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
40008|NCT03870672|Device|Sham rTMS approach|In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
40009|NCT03870659|Radiation|Breast MRI|Magnetic resonance imaging to the breast
40010|NCT03870646|Combination Product|Hypertonic saline of NaCl (7%) in combination with hyaluronic acid|Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
40011|NCT03870646|Combination Product|Isotonic saline of NaCl (0,9%)|Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
40012|NCT03870633|Other|Medical Chart Review|Undergo medical chart abstraction
40013|NCT03870633|Other|Interview|Complete telephone interview
40014|NCT03870633|Other|Questionnaire|Ancillary studies
40015|NCT03870633|Other|Quality-of-Life Assessment|Ancillary studies
40261|NCT03868540|Drug|BI 1291583|tablet
40016|NCT03870607|Dietary Supplement|prebiotics in combination with probiotics|Administration of prebiotics in combination with probiotics before the start of Ch-RT
40017|NCT03870594|Diagnostic Test|glycated hemoglobin|hemoglobin A1c level in blood
40018|NCT03870581|Behavioral|AI-based social software management model|a AI-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
40019|NCT03870581|Behavioral|Human-based social software management model|a Human-based miniprogram, embedded in the Wechat social software, to manage participants' warfarin therapy, such as dose adjustment, INR monitoring alert, etc.
40020|NCT03870555|Drug|TAK-954|TAK-954 infusion administered intravenously.
40021|NCT03870555|Drug|TAK-954 Placebo|TAK-954 placebo-matching infusion intravenous.
40022|NCT03870542|Procedure|kidney transplantation|Kidney transplant for end-stage renal disease from deceased kidney donors
40023|NCT03870529|Drug|Vitamin A Compound|Participants randomized to this arm will receive 7 consecutive days of of Vitamin A compound without disease progression or unacceptable toxicities. Within 21 days of completion of treatment participants will undergo surgical resection
40024|NCT03870529|Procedure|Therapeutic Conventional Surgery|Participants randomized to this arm will receive surgical resection
40025|NCT03870516|Procedure|Mitral valve replacement|Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.
40026|NCT03870516|Device|Speckle tracking echocardiography|We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function
40027|NCT03870503|Drug|oxytocin|The patient will be received oxytocin 20 IU by intravenous infusion
40028|NCT03870503|Drug|oxytocin plus misoprostol|The patient will be received oxytocin 20 IU by intravenous infusion plus 400 mic gm sublingual misoprostol
40029|NCT03870503|Drug|Carbetocin|The patient received Carbetocin 100 mic gm
40030|NCT03870490|Drug|VNRX-5133 + cefepime|IV infusion (3 doses)
40031|NCT03870477|Device|THP Hip Fracture Plating System with telescoping lag screws|The fracture plates are contoured plates used in conjunction with telescoping lag screws that are 7.5mm in diameter with lengths ranging from 70mm to 130mm in 5mm increments.
40032|NCT03870464|Diagnostic Test|CT-scans extended|CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
40033|NCT03870464|Diagnostic Test|MRI scan of the brain|MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
40034|NCT03870464|Other|Prospective registration of irAEs|irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
40035|NCT03870464|Behavioral|Quality of Life questionnaires|Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
40036|NCT03870451|Device|VascuTherm5 vascular compression device|VascuTherm5 vascular compression unit to function as an intermittent external pneumatic compression device
40037|NCT03870438|Drug|Lamivudine Oral Solution|In the intervention arm, HIV-1 negative children with HIV-1 positive mothers who have an HIV-1 viral load ≥ 1000 copies/ml will receive lamivudine syrup orally (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8 kg). The intervention will last a maximum of 10 months (until the baby is 12 months old or until the confirmed end of breastfeeding). Breastfeeding will be considered to be ceased if the mother confirms she is no longer breastfeeding for 2 consecutive monthly visits
40038|NCT03870425|Other|Distribution pattern of dietary proteins (minced meat)|Study effect of an even or skewed distribution pattern of dietary protein
40039|NCT03870412|Drug|PEG-rhG-CSF|The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
40040|NCT03870399|Drug|Tamoxifen|The treatment to be used will be tamoxifen 20mg orally once daily.
40041|NCT03870386|Procedure|EUS-BD with LAMS|Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy
40042|NCT03870386|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
40043|NCT03870373|Device|Pulse Oximeter|Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
40044|NCT03870360|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
40045|NCT03870360|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
40046|NCT03870360|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
40047|NCT03870360|Behavioral|HOLA Component 4|One booster walking session twice a month for six months post intervention for reinforcement, then one booster walking session a month for eighteen months.
40048|NCT03870360|Behavioral|Healthy lifestyles education program|Biweekly telephone check in calls for the first 16 weeks followed by monthly check in calls during the two year follow up period.
40049|NCT03870347|Diagnostic Test|Endoscopic ultrasound|Upper endoscopy using an echoendoscope to obtain ultrasound images of the pancreaticobiliary system and adjacent structures.
40140|NCT03869515|Other|No intervention|It's an observational study, so no intervention will be carried out.
40050|NCT03870334|Drug|BT-11 1,000 mg|Subjects will be randomized to receive BT-11 1,000 mg once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (BT-11, or placebo).
40051|NCT03870334|Drug|Placebo|Subjects will be randomized to receive Placebo once daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (BT-11, or placebo).
40052|NCT03870321|Other|Core training|"In the first week different types of abdominal exercises will be performed: standard, with trunk rotation, extension of the back raising the upper extremity of the body and legs, extension of the back raising one arm and the contralateral leg. In the same way, the subject will raise from the quadruped position one arm and the contralateral leg on each side, and we will ask for the exercise of the front plate, positioning itself in a position of four support points: feet and elbows. When performing the rear bridge exercise the subject will raise the trunk resting on both feet, while in the lateral bridge exercise will be done with support on the right and left side. All exercises will be done for 30 seconds, in 3 series).~During the next three weeks we will continue with the same training, but for each week we will increase 10 seconds per exercise."
40053|NCT03870308|Diagnostic Test|Functional MRI|A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
40054|NCT03870295|Diagnostic Test|Sympathetic skin response (SSR) measure|Ankle - ground distance measurement, hand and foot cutaneous temperature reading, low intensity electrical stimulations on hand and on foot to determine SSR at these two points and DN4 questionnaire to assess the possible presence of neuropathic pain
40055|NCT03870282|Behavioral|Sleep Extension|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
40056|NCT03870269|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
40057|NCT03870256|Drug|misoprostol|Patient receive 600mic gm sublingual misoprostol
40058|NCT03870256|Drug|Carbetocin|Patient receive 100 mic gm carbetocin IV
40059|NCT03870256|Drug|TA|The patient receives 1gm oral tranexamic acid
40060|NCT03870243|Device|Bubble CPAP|To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
40061|NCT03870243|Device|Low flow oxygen|To see the effectiveness of low flow oxygen in children with severe pneumonia
40062|NCT03870230|Device|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT
40063|NCT03870230|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device
40064|NCT03870230|Device|Pattern Electroretinography (pERG)|to assess the neuronal function of the retina, pattern ERG will be performed
40065|NCT03870230|Device|Optical coherence tomography (OCT)|to assess the morphology of the retina, OCT will be performed
40066|NCT03870217|Behavioral|Site selection|Turning off electrodes on the electrode array based on imaging and psychophysical measures
40067|NCT03870204|Diagnostic Test|POC-CCA rapid urine test|Fresh urine samples will be tested by POC-CCA
40068|NCT03870191|Other|Injection of either twin block or trigger point injection.|Study participants will be randomized into either group and will receive the intervention.
40069|NCT03870178|Device|Transcranial direct current stimulation (tDCS)|The noninvasive and nonpharmacological weak electrical current applied to the scalp to modulate cortical excitability.
40070|NCT03870165|Behavioral|Resistance exercise|Participants will perform leg press and leg extension immediately prior to ingestion of salmon or isolated mixture
40071|NCT03870165|Other|Salmon|Participants will ingest salmon immediately after resistance exercise
40072|NCT03870165|Dietary Supplement|Isolated amino acids and fatty acids|Participants will ingest a mixture of isolated amino acids and fatty acids immediately after resistance exercise
40073|NCT03870152|Procedure|Electrocautery Ablation (EC)|For the purposes of the trial, one round of EC treatment consists of two individual EC treatments with a post-EC AFB in between to check for a response to the 1st EC treatment. Within each round, the second EC treatment will only be administered if the post-treatment AFB confirms presence of persistent high grade disease. Patients in the intervention arm will receive up to three rounds of EC treatment (no more than one round annually) to all their HGLs identified at baseline.
40074|NCT03870139|Device|Cerebral stimulation|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various health conditions. However, its ergogenic effect still has controversial results.
40075|NCT03870139|Device|Peripheral stimulation|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia. Moreover, recent evidence has shown that PES can activate brain motor areas such as primary motor cortex.
40076|NCT03870126|Other|Flavored beverage|Consume one beverage at the beginning of each visit of the cross-over sequence
40077|NCT03870113|Biological|Vaccinated group|Develop highly reactive DC vaccines targeting HPV 16/18 E6/ E7 protein and DC vaccine would be injected to patients once a week, six doses in total.
40078|NCT03870100|Drug|SHR-1222|Pharmaceutical form: water injection Route of administration: subcutaneous
40079|NCT03870100|Drug|Placebo|Pharmaceutical form: water injection Route of administration: subcutaneous
40080|NCT03870087|Device|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
40106|NCT03869853|Behavioral|Entrepreneurial stimulation and integrated education|one month cycle of stimulation of business with integrated education on nutrition, health, and gender empowerment
40107|NCT03869853|Behavioral|Entrepreneurial stimulation|one month cycle of stimulation of business
40108|NCT03869840|Device|Sensor to spot check blood levels|Sensor to check blood levels, not used as intervention
40262|NCT03868540|Drug|Placebo|tablet
40081|NCT03870061|Behavioral|All Babies are Equal Initiative (conditional cash transfer program)|New Incentives, an NGO, offers cash incentives to caregivers for bringing their child to clinics for the first five visits of the Nigerian Routine Immunization schedule. These small cash transfers can provide some material benefit to new caregivers from poor communities. At a minimum, they help offset time and transport costs. The following vaccines are directly incentivized by the New Incentives' program: tuberculosis (BCG vaccine); diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae Type B (Pentavalent Vaccine), pneumococcal bacteria (PCV vaccine), measles vaccine.
40082|NCT03870048|Device|transcranial direct current stimulation|A tDCS device (Soterix) will deliver a small direct current through two sponge surface electrodes (5cm × 5cm, soaked with 15 mM NaCL). The positive electrode will be placed over the motor cortex representation of the more affected leg, and a second electrode will be placed on the forehead above the contralateral orbit.
40083|NCT03870022|Device|Pivot Breath Sensor System|Collect breath sample from the Pivot Breath Sensor to measure the carbon monoxide in the participant's exhaled breath, along with recording responses to user documentation questions and rating scales.
40084|NCT03870022|Device|Similar Carbon Monoxide breath sensor system|Collect breath sample from a similar breath sensor to measure the carbon monoxide in the participant's exhaled breath.
40085|NCT03870009|Other|ARDS patients|"The patient will be installed on the scanner bed. Two series of tomographic sections will be acquired: one during an expiratory break, the other during an inspiratory pause.~cyclic hyperinflation measured by semi-automatic segmentation and by manual segmentation"
40086|NCT03869996|Procedure|fast track care protocol|fast track care consists in educational preoperative preparation for patients, particular strategies for controlling pain and bleeding and intensive early rehabilitation protocol.
40087|NCT03869996|Procedure|standard care protocol|standard care protocol consists in the same surgical intervention without educational preoperative preparation for patients and intensive early rehabilitation protocol.
40088|NCT03869983|Other|Omnipaque™ (iohexol) Injection|755 mg/mL iohexol (350 mgI/mL), 80 mL infused intravenously over approximately 20 seconds
40089|NCT03869983|Other|CE-Iohexol|755 mg/mL iohexol (350 mgI/mL)/50 mg CAPTISOL®/mL, 80 mL infused intravenously over approximately 20 seconds
40090|NCT03869970|Behavioral|REST|The REST group will be recommended to return to school and light physical and cognitive activity as soon as tolerated- but no sooner than 48 hrs post-injury per current consensus recommendations. Notifications from the Fitbit app will be turned off, and step goal will be set at 500, to minimize positive feedback and reminders from achievement of activity goals
40091|NCT03869970|Behavioral|ACTIVITY|ACTIVITY group will be encouraged to engage in light to moderate physical activity with the goal of reaching 10,000 steps a day for one or more days during the first week. Subjects will be encouraged to engage in low-risk activities (e.g. walking). Subjects will be instructed to avoid activities that may increase risk of re-injury (e.g. bike riding, climbing, trampoline, sports). Fitbit notifications will be turned on and step goals will be set at 10,000. The simple goal of reaching 10,000 steps is clear to patients regardless of health literacy level, and real-time feedback provides continuous motivation.
40092|NCT03869970|Behavioral|mHEALTH|mHEALTH group will be instructed to download the SuperBetter© app. In addition to the pre-programmed general resilience goals, research assistants will help the subjects to set personal mental, social, and emotional rehabilitation goals and milestones for acute recovery from mTBI (e.g. return to school for ½ the day, have an improvement in symptoms). These goals/milestones will give the patient an opportunity to celebrate the achievement of improvement from mTBI with the goal of generating a positive contextual frame for recovery.
40093|NCT03869957|Dietary Supplement|Intervention group|0.1-0.2 g n-3 PUFA/kg body weight/day for 7 days
40094|NCT03869944|Drug|Lamivudine Oral Solution|"During the EPI-2 visit, HIV-1 negative children of mothers with a detectable plasma HIV-1 VL (≥ 1000 copies/mL) will be initiated on PrEP, lamivudine syrup (7.5 mg twice daily if 2 to 4 kg; 25 mg twice a day if weight <8 kg; and 50 mg twice a day if weight >8 kg) for 10 months, until the child is 12 months old. A monitoring on the mother's VL and child's diagnosis will take place at 6 and 12 months.~Mothers with undetectable plasma HIV-1 VL (< 1000 copies/mL) and HIV-1 negative children will not be offered PrEP but the mother's VL and child diagnosis will be monitored at 6 and 12 months: If the VL is ≥ 1000 copies/mL, the child will be initiated on PrEP until the child is 12 months old.~Children infected with HIV-1 will be referred to the National Program for immediate ART."
40095|NCT03869931|Drug|Fenofibrate|Fenofibrate 100 mg or 300 mg (according to CrCl)
40096|NCT03869918|Other|Exercise Program|Exercise at home or through a class as chosen by the subject.
40097|NCT03869905|Drug|Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day)
40098|NCT03869905|Drug|Placebo first then Aquamin®|4 capsules per day; 2 to be taken in the morning and 2 in the evening
40099|NCT03869892|Drug|Trifluridine/tipiracil hydrochloride (S95005)|Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest; This treatment cycle will be repeated every 4 weeks.
40100|NCT03869892|Drug|Capecitabine|Film-coated tablets, Capecitabine (1250 mg/m²/dose) will be administered orally BID on Days 1-14 of each cycle. This treatment cycle will be repeated every 3 weeks.
40101|NCT03869892|Biological|Bevacizumab experimental|Concentrate for solution for infusion, Bevacizumab (5 mg/kg, IV) administered every 2 weeks (Day 1 and Day 15). This treatment cycle will be repeated every 4 weeks.
40102|NCT03869892|Biological|Bevacizumab control|Concentrate for solution for infusion, Bevacizumab (7.5 mg/kg, IV) will be administered on Day 1 of each cycle.This treatment cycle will be repeated every 3 weeks.
40103|NCT03869879|Other|Feedback-assisted physical therapy|The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
40104|NCT03869879|Other|Traditional physical therapy|Therapists will treat these patients with traditional therapeutic modalities and practices.
40105|NCT03869866|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine)|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
40136|NCT03869554|Diagnostic Test|Detection of Fabry disease|Systematic detection of Fabry disease
40109|NCT03869827|Other|necrotizing enterocolitis|Collection of necrotizing enterocolitis diagnosis, as well as its severity, are based on the classification of Belle modified in 3 stages: 1) Suspected, 2) Proven, 3) Advanced
40110|NCT03869814|Diagnostic Test|Non-invasive Liquid Biospy|Non-invasive Liquid Biospy
40111|NCT03869801|Procedure|erector spinae plane block|Ultrasound-guided bilateral Erector spinae plane (ESP) block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
40112|NCT03869801|Procedure|quadratus lumborum block|Ultrasound-guided bilateral Quadratus lumborum (QLB) type 2 block performed before the surgery. Perioperative and postoperative routine analgesic protocol will be performed (consist of intravenous analgesics and intravenous patient-controlled analgesia) with no additional intervention (block) Standard Pain Followup and Monitorization will be performed.
40113|NCT03869775|Device|perfusion index monitor|perfusion index measured in patients undergoing spinal anesthesia with non-invasive perfusion index monitor
40114|NCT03869775|Diagnostic Test|ewing test|ewing tests will be applied to diabetic patients undergoing spinal anesthesia for cardıovascular autonomous neuropathıa diagnosis
40115|NCT03869762|Drug|Xgeva|Denosumab is a human monoclonal antibody (IgG2) that targets and binds with high affinity and specificity to RANKL, preventing the RANKL/RANK interaction from occurring and resulting in reduced osteoclast numbers and function, thereby decreasing bone resorption and cancer induced bone destruction.
40116|NCT03869762|Drug|Xtandi|"Enzalutamide is a potent androgen receptor signalling inhibitor that blocks several steps in the androgen receptor signalling pathway. Enzalutamide competitively inhibits binding of androgens to androgen receptors, inhibits nuclear translocation of activated receptors and inhibits the association of the activated androgen receptor with DNA even in the setting of androgen receptor overexpression and in prostate cancer cells resistant to anti-androgens.~Enzalutamide treatment decreases the growth of prostate cancer cells and can induce cancer cell death and tumour regression."
40117|NCT03869749|Behavioral|Learning to BREATHE Plus|Activities include psycho-education about stress and emotion regulation, and practices of body scanning, non-aerobic yoga, and meditation, which are designed to cultivate and provide opportunities to practice present-focused, non-judgmental attention.
40118|NCT03869749|Behavioral|Health and wellness|The Health Education Wellness Program (modeled after Hey Durham) (Bravender, 2005) will provide didactic information on substance use, nutrition/body image, stress management, exercise, and signs of depression/suicide.
40119|NCT03869736|Drug|Nitrous Oxide|1-hour sessions of inhaled nitrous oxide at concentrations of 25% or 50% (randomly assigned) to be administered weekly for 4 weeks.
40120|NCT03869736|Drug|Placebo|1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration ~23-30%) to be administered weekly for 4 weeks.
40121|NCT03869723|Procedure|Virtual planning using customized surgical devices|Preoperative modeling was conducted by obtaining scans of patient maxillofacial skeleton and angioscans of the lower extremities. The planning phase was then carried out by the surgeon and the engineer (from MATERIALISE, Leuven, Belgium) so as to define the clinical and technical parameters of the reconstruction. This stage consisted of discussing and determining osteotomy lines, donor side, anastomosis site, and overall reconstruction contour. Resection was decided by the surgeon. 3D modeling and the manufacture of cutting guides and customized osteosynthesis plates were then undertaken
40122|NCT03869723|Procedure|Conventional surgery|Classical surgery for mandibular reconstruction with fibula free flap
40123|NCT03869710|Device|Ultrasound-guided Dry-Needling Therapy|The needle will be insert under ultrasound guidance to elicit the myofascial response on the neck of the patients
40124|NCT03869697|Drug|SCB-313|1 intrapleural injections of SCB-313 on Day 1 for the SAD cohort, and 3 intrapleural injections of SCB-313 on Days 1, 2 and 3 for the MAD cohort.
40125|NCT03869684|Drug|MT-0814|Randomly assigned dose
40126|NCT03869684|Drug|Placebo|Placebo manufactured to mimic MT-0814
40127|NCT03869671|Behavioral|PrEP uptake/adherence intervention|The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses). The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
40128|NCT03869671|Behavioral|Harm reduction standard of care|Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
40129|NCT03869658|Behavioral|COCO application|All participants will complete a screening survey to determine their eligibility for the study, if eligible and willing to participate, he or she will sign an informed consent form. Once participants are enrolled in the study, a demographics questionnaire will be completed along with 5 days of food tracking on the COCO application. Between days 3 and 7, participants will complete two 24-hr diet recall, one a day, and a patient satisfaction questionnaire.
40130|NCT03869645|Device|CAPERE Thrombectomy System|Mechanical thrombectomy of acute thrombus in peripheral vasculature with the CAPERE Thrombectomy System
40131|NCT03869632|Drug|YL-13027|Daily doses by oral administration on each day of each 28 day cycle. Starting dose is 60mg, with escalation to 360mg, and subsequent dose escalation using a modified Fibonacci algorithm.
40132|NCT03869619|Other|Real-life epidemiological platform of lymphoma in France|"The REALYSA database will be described with the following characteristics:~Number of patients included per month in total and according to subtype of lymphoma~Number of patients in each region in total and according to subtype of lymphoma"
40133|NCT03869606|Device|NICOM by Cheetah Medical|Observational measurement, Cardiac Output, Pre- and Post Anesthesia
40134|NCT03869593|Genetic|Sample analysis|Here, to determine the importance of the mutation we will analyze the blood content of patients presenting E. coli and S. aureus bacteremia
40135|NCT03869567|Device|cone beam CT|Just after thrombectomy, a cone beam CT will be done, while patient is on angiography table, in order to determine if hemorrhage image is due to contrast accumulation or blood-brain barrier disruption.
40141|NCT03869489|Device|Anodal left dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the left dorsolateral prefrontal cortex of participants
40142|NCT03869489|Device|Anodal right dorsolateral prefrontal cortex tDCS stimulation|Anodal tDCS will be applied to the right dorsolateral prefrontal cortex of participants
40143|NCT03869489|Device|Sham tDCS stimulation|Sham tDCS stimulation will be applied
40144|NCT03869476|Diagnostic Test|Non-invasive diagnosis score|"spleen fibrosis by elastography~plasma cytokines levels~mutationnal landscape by NGS~CD34 circulating cells"
40145|NCT03869463|Other|Computerized Cognitive Training|Participants will complete 8 weeks of computerized cognitive training through the Peak platform on mobile devices.
40146|NCT03869463|Other|Control|This group will not receive computerized cognitive training.
40147|NCT03869450|Device|Restylane Volyme|Hyaluronic based filler
40148|NCT03869450|Device|Restylane Defyne|Hyaluronic based filler
40149|NCT03869450|Device|Restylane Lyft Lidocaine|Hyaluronic based filler
40150|NCT03869437|Drug|Cefiderocol|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function).
40151|NCT03869437|Other|Best Available Therapy|Standard of care was determined by the investigator
40152|NCT03869424|Other|Active Placebo labelled as antidepessant|Participants receive an active nasal spray that is in fact a placebo.
40153|NCT03869411|Behavioral|supervised aerobic exercise or home-based aerobic exercise|"The aerobic exercise and home exercise programs are consisted of 50 minutes per time, 3 times per weeks and totally 3 months.~The aerobic exercise group will perform the exercise program under one physical therapy and one aerobic dance teacher supervised. The home exercise group will do the exercise program based on ACSM's aerobic exercise recommend, and will used the home exercise record form to make sure their cooperation."
40154|NCT03869398|Dietary Supplement|Tums|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
40155|NCT03869398|Dietary Supplement|Calcitriol|start their calcitriol 0.25mcg PO BID and Tums 1,500mg PO TID 5 days before surgery. The five days is determined due to the time it takes vitamin D to have an effect on the guts reabsorption of calcium.
40156|NCT03869385|Drug|Albutein® 200 g/L or Plasbumin® 20|The initial dose of the trial drug must be started within 6 to 24 hours after the beginning of the septic shock. Starting dose: 60 g human albumin 20% (Albutein® 200 g/L, infusion solution) over 2-3 h Daily administration of the trial drug will be based on the serum albumin concentration measured each day. Dose adjustment will follow a predetermined schedule with the aim of maintaining a serum albumin concentration of at least 30 g/l. Administration of the trial drug will continue for a maximum of 28 study days after randomisation and only as long as the participant is being treated in the ICU.
40157|NCT03869372|Device|rTMS|In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
40158|NCT03869359|Other|Gluten-free diet with gluten powder|The subjects will sprinkle gluten powder over their meals, twice a day. (14 g/day vital gluten: Real Foods, Edinburgh, United Kingdom). Plastic sachet marked with B (WePack, Derbyshire, United Kingdom). Free of fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
40159|NCT03869359|Other|Gluten-free diet with placebo powder|The subjects will sprinkle placebo powder over their meals, twice a day. (14 g/day rice starch: Doves Farm Foods Ltd., Berkshire, United Kingdom) Plastic sachets marked with A (WePack, Derbyshire, United Kingdom). Low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs).
40160|NCT03869333|Biological|InvaplexAR-DETOX|Detoxified Shigella flexneri 2a Artificial Invasin Complex
40161|NCT03869333|Other|Placebo|Saline
40162|NCT03869320|Drug|ACT-1004-1239|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg. For the ADME subpart, a single oral dose of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given simultaneously with the ACT-1004-1239 capsule. For the absolute bioavailability subpart, a single intravenous dose of a maximum of 1 μCi of 14C radiolabeled ACT-1004-1239 will be given at the expected tmax after the administration of the ACT-1004-1239 capsule.
40163|NCT03869320|Other|Placebo|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
40164|NCT03869320|Drug|ACT-1004-1239 (Food-effect subpart)|ACT-1004-1239 will be available for clinical study use as hard gelatin capsules for oral administration formulated in strengths of 1, 10, and 100 mg.
40165|NCT03869320|Other|Placebo (Food-effect subpart)|Matching placebo is available as matching capsules for oral administration, formulated with the same excipients but without ACT-1004-1239.
40166|NCT03869307|Other|Exercise|The exercise programme includes exercises identified in literature to target scapular and rotator cuff muscles.
40167|NCT03869294|Drug|GS|Gemcitabine plus S-1 (GS) was used to treat advanced pancreatic cancer
40168|NCT03869281|Procedure|Pancreas transplantation alone|Pancreas transplantation
40169|NCT03869268|Drug|Aspirin|Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
40170|NCT03869268|Drug|Ticagrelor|Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
40171|NCT03869255|Procedure|Nasal swab|In hospitalized patiens, a nasal swab will be performed within the first 48 hours and on the 7th day. In community patient, only one swab will be performed
40172|NCT03869242|Device|NovoTTF-200A|newly diagnosed GBM patients treated with NovoTTF-200A concomitant to RT and TMZ.
40173|NCT03869229|Biological|Intra-articular injection of ADMSC|Intervention: Intra-articular injection of Adipose-derived Mesenchymal Stem Cells (ADMSC)- ultrasound guided intra-articular injection of at least 10 million of ADMCS per procedure, maximum four procedures (i.e. injections per joint), minimum number of cells pre protocol 40 million
40219|NCT03868839|Drug|Telmisartan Pill|telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
40174|NCT03869216|Behavioral|Educational Shared Decision-Making Intervention|The intervention includes a web-based patients' decision aid about PSA-based prostate cancer screening, risks and preferences. The providers receive a summary of the USPSTF 2018 guidelines and main components of the AHRQ SHARE curriculum, a link to a video of a prototypical shared decision making conversation, and a laminated shared decision making reminder card.
40175|NCT03869203|Other|Enhanced recovery after surgery (ERAS)|The patients in the ERAS group were given a pre-treatment drug [300 mg (gabapentin, Neurontin 300mg) and 10 mg oxycontin (oxycontin, Oxycontin CR 10mg) and 2 mg prednisolone (prednisolone 10 mg, Solondo 5mg)] on the evening before surgery. And pre-operative fasting should not exceed 6 hours, and clear liquid fasting should not exceed 2 hours. In addition, 400 ml of oral carbohydrate should be taken 2 to 4 hours before surgery to ensure adequate blood sugar and encourage regular diet (light meal) as soon as possible within a tolerable range after surgery. The initial pain after surgery is actively controlled by oral drugs such as celebrex and IR codon, and injections such as tramadol and demerol. On the first postoperative day, the urinary catheter is removed and CPM (continuous passive motion) rehabilitation is started.
40176|NCT03869190|Drug|Atezolizumab|"For the control, + EV, + Nira, + Isa, and + Lina arms, Atezolizumab will be administered intravenously (IV) at a fixed dose of 1200 mg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.~For the Atezo + Hu5F9-G4 and + TCZ arms, Atezo will be administered IV at a fixed dose of 840 mg every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle."
40177|NCT03869190|Drug|Enfortumab Vedotin|Enfortumab vedotin will be administered at a dose of 1.25 mg/kg IV on Days 1 and 8 of each 21-day cycle.
40178|NCT03869190|Drug|Niraparib|Niraparib will be administered at a dose of 200 mg once daily (QD) by mouth.
40179|NCT03869190|Drug|Hu5F9-G4|Participants will receive an 1-mg/kg priming dose IV on Day 1 followed by three weekly IV doses of 30 mg/kg on Days 8, 15, and 22. During Cycle 2, participants will receive weekly IV doses of 30 mg/kg on Days 1, 8, 15, and 22. For all subsequent cycles, participants will receive 30 mg/kg on Days 1 and 15. Cycle = 28 days.
40180|NCT03869190|Drug|Isatuximab|During Cycle 1 participants will receive isatuximab IV weekly (on Days 1, 8, and 15). For all subsequent cycles, isatuximab will be administered only on Day 1. Cycle = 21 days.
40181|NCT03869190|Drug|Linagliptin|Partcicpants will take one 5-mg tablet of linagliptin orally once a day (QD) during each 21-day cycle.
40182|NCT03869190|Drug|Tocilizumab|Tocilizumab will be administered by IV infusion at a dose of 8 mg/kg every 4 weeks (Q4W) on Day 1 of each 28-day cycle.
40183|NCT03869177|Other|Implementation support program|"The complex intervention consists of the following elements, and our program will support their implementation:~A dedicated person to coordinate family involvement and support in the clinical unit.~General training of health care personnel on how to involve relatives and give them adequate support.~Family psychoeducation in single family groups.~General measures to implement family involvement for patients with primary psychotic disorders in the psychiatric outpatient clinic."
40184|NCT03869164|Device|ValveClamp|ValveClamp is an easy-to-operate transcatheter edge-to-edge mitral valve repair system with larger coaptation width
40185|NCT03869151|Diagnostic Test|CBC|lymphocyte and monocyte count
40186|NCT03869138|Behavioral|Virtual-reality based dance training|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
40187|NCT03869125|Diagnostic Test|Blood pressure measurement|Blood pressure monitoring using automated office blood pressure measurement (AOBPM), office blood pressure measurement (OBPM), and 24-hour ambulatory blood pressure monitoring
40188|NCT03869112|Behavioral|Physical activity intervention|Physical activity group will be given a charge 2 FitBit device to monitor their PA specially steps count, step targets will be discussed with the participants with a view to increasing their daily physical activity over the 6 week period. A recent protocol has been described that encouraged an increase of 500 steps weekly. This was well tolerated by participants (Demeyer, Louvaris et al. 2017). This will be an unsupervised, home-based intervention.
40189|NCT03869112|Other|Pulmonary rehabilitation group|Pulmonary rehabilitation group is a 6-week intervention of supervised exercise and group education and will follow the BTS guidelines. (Bolton, Bevan-Smith et al. 2013)
40190|NCT03869099|Other|Pneumonia Case Management Practices|Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
40191|NCT03869086|Other|Freeze dried blueberry powder|36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
40192|NCT03869086|Other|Anthocyanin free, sugar-matched placebo|36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
40193|NCT03869073|Drug|Evolocumab|Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
40194|NCT03869073|Drug|Placebo|Preservative free 0.9% sodium chloride. Three pre-filled shrouded syringes for subcutaneous injection in abdomen.
40195|NCT03869060|Biological|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5
40196|NCT03869047|Drug|Dexmedetomidine +bupivacaine|patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
40197|NCT03869047|Drug|Bupivacaine|patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
40217|NCT03868852|Drug|Apatinib mesylate tablets|Apatinib mesylate tablets were orally administered 250 mg QD from 1 week before radiotherapy to the whole radiotherapy period. (Appatinib is no longer used after radiotherapy)
40218|NCT03868852|Radiation|Three-dimensional conformal intensity modulation|Three-dimensional conformal intensity modulation (IMRT) technique was used for post-operative radiotherapy. The radiation dose was 45-54 Gy.
40257|NCT03868566|Drug|SNP-612 dose1|Subjects will take dose1 once a day orally for 12 weeks
40198|NCT03869034|Combination Product|TAI+PD1|Patients receive Sintilimab on the first day of TAI+PD1 treatment. On the day 2-3 during the same hospitalization, the FOLFOX chemotherapy regimen of TAI is perform for 48 hours continuous infusion. The TAI+PD1 treatment repeats every 3 weeks, and the hematological parameters are reviewed before the start of each course of TAI+PD1 treatment. Those who meet the inclusion criteria can be prescribed according to the plan. Patients with G2 toxicity have to delay the planned treatment until the toxicity is reduced to G1. If the toxicity does not return to a state in which treatment can be continued after 2 weeks of active treatment, the treatment need suspended for safety.
40199|NCT03869021|Other|3D printed surgical guide constructed|A printed surgical guide ( to direct through the surgery and make results predictable), the guide is designed by Mimics 19.0, Materialise NV,Belgium and printed with self cure resin
40200|NCT03869021|Other|free hand surgery|A control group in which patients are randomly assigned and surgeries are planned without surgical guides and performed free handed
40201|NCT03869008|Device|gammaCore Sapphire|"gammaCore SapphireTM (non-invasive vagus nerve stimulator) is intended to provide non-invasive vagus nerve stimulation (nVNS) on the side of the neck. gammaCore provides a mild electrical stimulation to the vagus nerve, which runs through the neck and carries information to the central nervous system.~Subjects will be instructed to use the gammaCore Sapphire to stimulate 2 minutes on each side of the neck, twice a day, every day. The subject controls the intensity level of the electrical stimulation."
40202|NCT03869008|Device|Sham Device|The Sham device delivers no electrical stimulations but subjects randomized to the Sham device will received the same instructions to use the Sham device to stimulate 2 minutes on each side of the neck, twice a day, every day for the first 4 weeks after randomization.
40203|NCT03868995|Procedure|Sham injection|Dextrose water injection to subcutaneous layer at tender point
40204|NCT03868995|Procedure|Tendon injection|Dextrose water injection to injured tendon
40205|NCT03868982|Device|Neurally adjusted ventilatory assist|NAVA uses the diaphragm activity to deliver mechanical ventilation
40206|NCT03868969|Drug|Fosfomycin Oral Suspension|Man with urinary tract infections with BLSE enterobacteriaceae will be treated by fosfomycin 1 packet by day for 21 days
40207|NCT03868956|Diagnostic Test|Colour doppler ultrasound with or without D-dimer test|"Positive CDUS: anticoagulant treatment~Negative CDUS: no anticoagulant treatment~Non diagnostic CDUS : reference to routine D-dimer test~Negative test : no anticoagulant treatment~Positive test : second CDUS 7 days (±2) after first one~No change in CDUS : no anticoagulant treatment~Change in CDUS : anticoagulant treatment"
40208|NCT03868943|Drug|Soliramfetol|Solriamfetol will be dosed by flexible dose titration starting at 75 mg daily in all patients and escalating after 7 days (1 week) to 150 mg daily and then after 7 days to 300 mg daily for a total duration of 3 weeks (flexible dose titration period).
40209|NCT03868930|Behavioral|STEP-Home|This group will meet for 2 hours a week for 12 weeks. The core skills of Emotional Regulation (ER) (45-minutes) and Problem Solving (PS) (45-minutes) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention Training (AT) augments PS and ER core skills and is interspersed throughout group and individual sessions.
40210|NCT03868930|Behavioral|PCGT|The PCGT group will also meet for 2 hours a week for 12 weeks. It is a nonspecific and supportive intervention to control for the nonspecific benefits of the group experience (e.g., therapist contact, instillation of hope, expectation of improvement). It will focus on identifying and discussing current life stressors that contribute to reintegration difficulties, psychoeducation, and promotion of wellness and physical health.
40211|NCT03868917|Procedure|thoracic paravertebral block using pressure measurement technique|The continuous thoracic paravertebral block using ultrasound machine is combined with pressure measurement during needle advancement.
40212|NCT03868904|Device|OCS Lung System|No active interventions are part of this study. This study will collect long-term survival and BOS data in subjects who were part of the INSPIRE trial.
40213|NCT03868891|Device|EarPopper|This device has a handle attached to a nose probe that delivers a constant airflow into the nose. The EarPopper is turned on and while one nostril is pinched with one finger, the nose probe is sealed in the other nostril. Participants will swallow and will complete an exercise diary recording whether a popping or pressure change was felt in the left, right or both ears. When an increase in ear pressure is felt, participants will swallow 5 times. This will be marked in the exercise diary. In addition, participants will slowly blow air out through their mouths for about 5-10 seconds while the EarPopper is on and placed into the nostril. The amount of time participants are able to blow will also be recorded in the diary.
40214|NCT03868891|Device|EMST150|This device consists of a handheld plastic tube with a mouthpiece on one end and an adjustable valve on the other end. Each participant will close his/her lips around the mouthpiece and breathe out against resistance. The EMST150 will be adjusted to the point where airflow stops. Each day, participants will blow into the EMST150 5 sets of 5 times with a 10-15 second rest between each use and a 1-2 minute rest between each set of 5. Participants will adjust the resistance of the device each week and enter device settings and document exercise sets performed in an exercise diary.
40215|NCT03868878|Other|Capoeira training|The Capoeira training protocol, based in the modern styles was applied by an instructor with 16 years of experience. The protocol followed the directions of the ABADÁ Capoeira system, being adapted to the sample of older adults of the present study. The experimental protocol for Capoeira progressive training program lasted 12 weeks and was performed twice a week with duration of 60 minutes each. Each session was divided in three parts, being: 1) initial part: consisting of 10 minutes warm-up with recreational activities at low intensity; 2) main part: consisting of 30 minutes of basic movements in the modality and; 3) final part: consisting of 20 minutes with theoretical instructions related to Capoeira and musicality (singing and touch of typical instruments). In order to perform the Capoeira progressive training program, the technical improvement naturally occurred every week, resulting in a higher speed in movements execution and thus to a gradual increase in training intensity.
40216|NCT03868865|Behavioral|Integrative mind-body-medicine group program|The mind-body-medicine group program focuses on support in coping with the disease, in lifestyle modification and in reduction of chemotherapy induced side effects. The self-contained modules of the mind-body-medicine group program can be followed in an individual order, to allow adoption to different chemotherapy concepts and continued access is possible. Patients can join in the group program eleven times for six hours each visit. They participate in every one of the eleven modules once.
40220|NCT03868826|Procedure|Orthopaedic surgery and/or rehabilitation|The avulsion is repaired and hereafter the patient follows rehabilitation. Some are treated conservatively and only follow rehabilitation.
40221|NCT03868813|Behavioral|Semi-structured Interview|One-on-one semi-structured interviews
40222|NCT03868800|Other|SDM-DC|The SDM-DC intervention is designed for patients with kidney failure who must make a decision regarding type of dialysis: haemodialysis or peritoneal dialysis. SDM-DC consists of patient and his or her relative(s) being given a patient decision aid called 'Dialysis choice' and booked for meetings with a dialysis coordinator. There were optional videos describing other patients' experiences making this decision. The dialysis coordinators were trained in the why, what and how in relation to SDM-DC and to deliver the intervention by tailoring to patients' needs and using three different communication skills: mirroring, active listening and value clarification.
40223|NCT03868787|Device|TENS|TENS units are small, inexpensive, portable, battery-powered devices which deliver mild, alternating electrical currents via electrodes positioned on the skin near the anticipated dermatomal distribution of pain.
40224|NCT03868787|Device|Sham TENS|Non-active TENS unit
40225|NCT03868774|Procedure|repetitive transcranial magnetic stimulation|rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
40226|NCT03868761|Behavioral|Sonoma Rises|All participants will receive the intervention, Sonoma Rises, a mobile app designed by psychologists at the National Center for PTSD for wildfire survivors to facilitate recovery from disaster. Users can access evidence-informed tools to help cope with stress, heal from loss, prioritize self-care, connect with others, manage anger, and track their mood using validated assessments. There are also tools designed just for teens and users are linked to psychoeducation on disaster and health and other mental health resources and services.
40227|NCT03868748|Dietary Supplement|Beta-arbutin|Beta-arbutin capsules
40228|NCT03868748|Other|Placebo|Placebo capsules containing non-medicinal ingredients
40229|NCT03868735|Device|CleanSweep Closed Suction System|Device with balloon sweeping technology
40230|NCT03868722|Drug|Acalabrutinib|Acalabrutinib 100 mg BID from cycle 1 day 1 for 3 cycles of 28 days.
40231|NCT03868722|Drug|Venetoclax|Venetoclax, ramp up during the first five weeks starting cycle 1 day 1, 7 days treatment on each dose level (20-50-100-200-400 mg), thereafter 400 mg once daily for a total of 3 cycles of 28 days.
40232|NCT03868709|Drug|Penehyclidine inhalation|Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients
40233|NCT03868709|Drug|Placebo inhalation|Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
40234|NCT03868696|Procedure|MUA with sham ultrasound|Standard MUA with sham ultrasound
40235|NCT03868696|Procedure|MUA with active ultrasound|Standard MUA guided by ultrasound
40236|NCT03868683|Other|Glucose Reference 1|30 g of glucose dissolved in 250 ml of water
40237|NCT03868683|Other|Glucose Reference 2|30 g of glucose dissolved in 250 ml of water
40238|NCT03868683|Other|Glucose reference 3|30 g of glucose dissolved in 250 ml of water
40239|NCT03868683|Other|Sucrose|30 g of Sucrose dissolved in 250 ml of water
40240|NCT03868683|Other|Regular Bake beans in tomato sauce|Bake beans in tomato sauce containing 14 g of sugar
40241|NCT03868683|Other|Bake beans in tomato sauce, reduced sugar|Bake beans in tomato sauce containing 12.2 g of sugar
40242|NCT03868683|Other|Bake beans in tomato sauce, low GI|Bake beans in tomato sauce containing 7.2 g of sugar
40243|NCT03868670|Device|responsive neurostimulation|The RNS® System is a novel, implantable therapeutic device that delivers responsive neurostimulation, an advanced technology designed to continuously monitor brain electrical activity, detect abnormal electrical activity and respond by delivering imperceptible levels of electrical stimulation to normalize that activity before an individual experiences seizures. This is an Early Feasibility Study determining the safety and efficacy of NAc-RNS in the treatment of LOC eating in treatment-refractory obesity.
40244|NCT03868657|Drug|Moxifloxacin|Moxifloxacin is solely used to cause a known and for the drug well documented effect, namely blockade of the Kv11.1 channel.
40245|NCT03868657|Drug|Placebo|Placebo
40246|NCT03868644|Behavioral|Voluntary Counseling and Testing for HIV (VCT)|Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).
40247|NCT03868644|Behavioral|Condoms|Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
40248|NCT03868631|Dietary Supplement|Whey protein supplement|19 g whey protein isolate (contains 2 g leucine) was consumed daily by one intervention group.
40249|NCT03868631|Dietary Supplement|Soy protein supplement|26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
40250|NCT03868618|Device|Genio™ system|The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.
40251|NCT03868605|Device|EMR and ESD|Endoscopic mucosal resection using a resection snare Endoscopic submucosal dissection using an electrosurgical knife
40252|NCT03868605|Device|Over- the- scope full- thickness resection device|Endoscopic resection of neoplastic lesions of the colon using the over- the- scope full- thickness resection device
40253|NCT03868592|Procedure|Gastric sleeve/bariatric surgery|weight loss
40254|NCT03868579|Procedure|Biopsy|Undergo biopsy
40255|NCT03868579|Other|Medical Chart Review|Review medical chart
40256|NCT03868579|Procedure|Thoracoscopy|Undergo pleuroscopy
76265|NCT03587766|Drug|Fexinidazole|Drug: fexinidazole (FEXI)
40263|NCT03868527|Other|Data collection|Data collection for biostatistical analysis about hematological diseases
40264|NCT03868514|Device|TiLOOP® Bra Pocket|Primary or secondary breast reconstruction following mastectomy with titanised polypropylene mesh TiLOOP® Bra Pocket
40265|NCT03868501|Behavioral|n-back task|All participants will be asked to finish the 3-back task and the 1-back task. The 3-back task and the 1-back task will be carried out at intervals to avoid the influence between different tasks. The sequence of the 3-back task and the 1-back task will be counterbalanced across participants.
40266|NCT03868488|Behavioral|Imagery tasks|All participants need to finish both visual imagery tasks and auditory imagery tasks. Visual imagery tasks and auditory imagery tasks will be carried out at intervals to avoid the influence of different tasks. The sequence of imagery tasks will be counterbalanced across participants.
40267|NCT03868475|Procedure|Vacuum-assisted percutaneous excision|The intervention group will undergo the vacuum assisted percutaneous excision (VAPE). All VAPE procedures will be performed on a digital supine table using the ATEC© Breast Biopsy System hand piece (Hologic) with a 9-gauge needle and a 10 or 20 mm aperture providing 6-mmHg of suction strength to completely excise the breast lesion.
40268|NCT03868475|Procedure|Open surgical excision|The control group will undergo standard open surgical excision of the breast lesion. This will be done in the operating room using preoperative image-guided localization with radioactive seed (I-125) or in the procedure room of the Breast Care Centre if appropriate (i.e. lesion is palpable and localization is not required).
40269|NCT03868462|Device|Optos P200TE|The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.
40270|NCT03868462|Device|Predicate Device|The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
40271|NCT03868449|Other|Question Prompt List|Question prompt list
40272|NCT03868449|Other|3 questions|3 questions from the AskShareKnow model
40273|NCT03868436|Drug|Methoxyflurane 3mL|As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROX™ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROX™ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROX™ inhaler with the Activated Carbon (AC) chamber.
40274|NCT03868423|Drug|Brigatinib|90 mg orally QD for 7 days followed by 180 mg orally QD continuously thereafter. One cycle of therapy will consist of 28 days of treatment.
40275|NCT03868423|Other|Laboratory Biomarker Analysis|Correlative studies
40276|NCT03868423|Other|Quality-of-Life Assessment|Ancillary studies
40277|NCT03868423|Other|Questionnaire Administration|Ancillary studies
40278|NCT03868410|Device|New rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using five 1-min trains of 300 pulses each (total 1500 pulses) for a period of 10 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 3 days a week for 5 weeks, i.e., for a total of 15 sessions.
40279|NCT03868410|Device|Conventional rTMS Approach|Participants in this arm will receive rTMS-based facilitation of the ipsilesional primary motor cortex (iM1) before the start of each session. iM1 will be facilitated using a widely-used approach of stimulation delivered to inhibit the contralesional motor cortices located in the non-stroke hemisphere. Low-frequency rTMS (1-Hz) can inhibit the excitability of targeted regions. Therefore, this low-frequency approach will be delivered to suppress the excitability of the non-stroke hemisphere. A total of 1500 pulses will be given for 25 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training for a total of one hour. Participants will receive these interventions 3 days a week for 5 weeks, i.e., for a total of 15 sessions.
40280|NCT03868397|Diagnostic Test|Liver MRI|"Liver MRI including 4D flow sequence is performed twice in liver transplantation recipients, before and 1 month-after transplantation.~In donor candidates, liver MRI including 4D flow sequence is performed twice in 1-3 weeks to assess repeatability of the technique."
40281|NCT03868371|Dietary Supplement|High phosphorous containing meal|A meal with a high phosphorous content
40282|NCT03868371|Dietary Supplement|Low phosphorous containing meal|A meal with a low phosphorous content
40283|NCT03868358|Device|transcranial magnetic stimulation|"The stimulations were performed by MagStim Rapid2. Participants in active comparator will receive active transcranial magnetic stimulation(Real Stimulation) daily for two weeks.~Participants in sham comparator will receive no stimulation(Sham Stimulation) daily for two weeks"
40284|NCT03868319|Procedure|lung protective ventilation strategy|low tidal volumes and positive end-expiratory pressure mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
40285|NCT03868319|Procedure|nonprotective ventilation|large tidal volume and zero PEEP mechanical ventilation during robot-assisted laparoscopic radical cystectomy for bladder cancer
40286|NCT03868306|Other|CBC , Iron study and Haemoglobin electrophoresis .|The study will conducting on 100 patients of microcytic hypochromic anaemia who recruited from the hematology outpatient clinic , Assiut University Children Hospital . Beside history and clinical examination , the studied cases will be subjected to the following investigations Complete blood count ( CBC ) with comparison of MCV , RBCs count , RDW and RDWI . Determination of serum ferritin , serum iron and total iron bending capacity ( TIBC ) . HB electrophoresis . Patient with HBA2 more than 3.2 % are identified as beta thalassemia trait and patients with serum ferritin less than 12 ng / ml are identified as IDA cases. Validity of both discrimination indices are evaluated by calculating there sensitivity , specificity , positive predictive value , negative predictive value and Youden index ( YI ) Based on statistical criteria in ideal test should have high sensitivity and specificity and Youden index.
40287|NCT03868293|Device|Focused ultrasound|Pulsed low intensity focused ultrasound
40288|NCT03868280|Procedure|Antegrade femoral nailing Supine Position|Antegrade femoral nailing in Supine Position using a Fracture Table
40289|NCT03868280|Procedure|Antegrade Femoral Nailing Lateral Position|Antegrade femoral nailing in Lateral Position using a Free drape
40290|NCT03868254|Device|XEN Group|Participants medical charts will be extracted until the target number of eyes for the primary analysis has been reached. A screening log for participants treated with XEN 45 Gel Stent on or after 1 January 2014 to identify eligible participants. For each eye selected, all retrospective data available from baseline (day when decision was made to implant XEN 45 Gel Stent) until Last Visit (date of the last follow-up visit available prior to 1 October 2018 or date on which the patient had an SSI for glaucoma, whichever occurs first) will be extracted from existing medical records.
40291|NCT03868241|Device|Coated devices|Gold-silver-palladium coated devices (endotracheal tube, central venous catheter and urinary catheter) will be used whenever necessary. All three devices are required to be inserted as soon as possible after randomization and need for all three devices are the main inclusion criteria
40292|NCT03868241|Device|Control|Devices without coating available at each participating intensive care unit
40293|NCT03868228|Procedure|Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC)|Use of CapnoPen device to aerosolise Oxaliplatin 92mg/m2 chemotherapy 6-8 weekly intervals for intraperitoneal distribution via laparoscopy.
40294|NCT03868215|Diagnostic Test|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy and before surgical resection.
40295|NCT03868202|Drug|Estradiol Transdermal Product|Hormone replacement therapy will be given to postmenopausal women for up to 1 month.
40296|NCT03868189|Other|Electroneuromyography with ultrasound|Patients whose electroneuromyography examination will be performed using an ultrasound
40297|NCT03868189|Other|Electroneuromyography without ultrasound|Patients whose electroneuromyography examination will be performed without ultrasound (fake tracking)
40298|NCT03868176|Other|short message service|short message service
40299|NCT03868150|Drug|Amiodarone Injection|Patients stratified into the amiodarone study group were administered amiodarone until day of discharge. Amiodarone administration began intraoperatively with the administration of a 150 mg IV amiodarone loading bolus prior to separation from coronary pulmonary bypass, followed by 1 mg/min IV amiodarone for six hours (360 mg), then 0.5 mg/min IV amiodarone for 18 hours (540 mg), then transitioned to 400 mg oral amiodarone twice a day until discharge. In total, patients in the amiodarone treatment group received 1,050mg of IV amiodarone plus 800mg/day of oral amiodarone thereafter until discharge.
40300|NCT03868150|Device|Intraoperative Rapid Atrial Pacing|Intraoperative rapid atrial pacing for 30 seconds after cannulation and prior to initiation of cardiopulmonary bypass by having the surgeon attach insulated forceps to the superior right atrial free wall and connected to a temporary pacemaker to burst pace at a rate of 800 bpm for 30 seconds (pulse width 1.0 ms, output: 20 mA) Patients are monitored for successful atrial fibrillation induction defined as 30 seconds of sustained atrial fibrillation on ECG.
40301|NCT03868137|Drug|Ibuprofen|3 doses of Ibuprofen 800 mg
40302|NCT03868137|Drug|Placebos|Placebo
40303|NCT03868124|Combination Product|G2TR intraocular implant containing travoprost|Provided in Arm/Group descriptions
40304|NCT03868124|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (Timolol Maleate ophthalmic solution, 0.5%)
40305|NCT03868111|Drug|Sufentanil|The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
40306|NCT03868111|Drug|Remifentanil|The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
40307|NCT03868098|Drug|Crisaborole 2%|Crisaborole ointment 2% (application rate A, B, C) for 15 days (double blind)
40308|NCT03868098|Drug|Placebo ointment|Placebo ointment (vehicle)
40309|NCT03868085|Diagnostic Test|dual energy x-ray absorptiometry|DXA scan
40310|NCT03868072|Drug|XELJANZ 5Mg Tablet|XELJANZ 5Mg Tablet 1T single oral administration under fasting
40311|NCT03868072|Drug|Chong Kun Dang Tofacitinib Tablet|Chong Kun Dang Tofacitinib Tablet 1T single oral administration under fasting
40312|NCT03868059|Drug|LPCN 1021|LPCN 1021 is gelatin capsule product provided as 112.5 mg testosterone undecanoate per capsule.
40313|NCT03868046|Drug|Treatment with immune checkpoint inhibitors.|Treatment with approved immune checkpoint inhibitors, namely ipilimumab, nivolumab, pembrolizumab, atezolizumab and avelumab, alone or in combination, administered per standard protocol.
40314|NCT03868046|Diagnostic Test|Blood tests.|Patients will undergo ordinary blood tests obtained at specific moments predefined per protocol and extraordinary blood tests at the time of the detection of an eventual irAE.
40315|NCT03868033|Drug|Zoledronic Acid|Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
40316|NCT03868033|Drug|Denosumab|Continuous Denosumab treatment in arm 1 for two years or as a 2nd year treatment in arm 2 for one year
40317|NCT03868020|Procedure|Computed Tomography|Undergo PET/CT
40318|NCT03868020|Radiation|Fluciclovine F18|Given IV
40319|NCT03868020|Procedure|Positron Emission Tomography|Undergo PET/CT
40320|NCT03868007|Device|RIC|The RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
40321|NCT03868007|Device|sham-RIC|The sham-RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60mmHg for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
40322|NCT03867994|Drug|Atorvastatin|
40323|NCT03867994|Drug|Carvedilol|
40324|NCT03867994|Drug|saline|
40325|NCT03867981|Behavioral|Internet-based weight loss program|12-month, Internet-based weight loss/maintenance program.
40326|NCT03867981|Behavioral|Brief phone coaching|Some individuals will receive 3 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
40327|NCT03867981|Behavioral|Extended phone coaching|Some individuals will receive 12 weeks of phone coaching. Coaching calls will occur 1x/week, starting at week 5. Once coaching calls are completed, the participant will not have any other contact with their coach.
40328|NCT03867968|Behavioral|TIPS Intervention|Web-based training for family member.
40329|NCT03867968|Behavioral|Control|Traumatic Brain Injury website for family members.
40330|NCT03867955|Other|Collection of datas|Collection of datas by videopupillometer results: pupil diameter and variation of the pupillary diameter.
40331|NCT03867942|Drug|Monolayer group|Monolayered combination of gemigliptin and rosuvastatin
40332|NCT03867942|Drug|Bilayer group|Bilayered combination of gemigliptin and rosuvastatin
40333|NCT03867929|Other|25-Hydroxy vitamin D|27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency
40334|NCT03867916|Behavioral|Patient Navigation Program|Use patient navigation program
40335|NCT03867916|Other|Quality-of-Life Assessment|Ancillary studies
40336|NCT03867916|Other|Survey Administration|Ancillary studies
40337|NCT03867903|Device|Babysparks Application|mHealth application, BabySparks©, will be implemented for infant and toddler developmental activities through 24 months of age. (Currently, BabySparks is only designed to work on the developmental milestones through 24 months of age, and therefore the use of the application will no longer be applicable to the patient after reaching a developmental age of 24 months. If the subject has not reached a developmental age of 24 months at the time he/she is chronologically 24 months, the subject/family will be able to continue to utilize the application for a maximum of 24 months from the time they began to use the application or until reaching a study endpoint of reaching 24 months developmentally or death, whichever the infant reaches first.)
40338|NCT03867903|Other|pre and post-test Redcap Survey|Prior to starting the use of the application, parents will be given a REDCap survey to complete to determine their current awareness and interventions being implemented with their child related to reaching developmental milestones. Data entered into application by the subject's caregivers will be stored by BabySparks.After completion of the use of the application (subject reaches a study endpoint), the caregivers will be asked to complete a REDCap survey asking them about their experience with the application.
40339|NCT03867890|Other|no intervention|
40340|NCT03867877|Other|Periodized training with motor practice|Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.
40341|NCT03867877|Other|Simple Periodized Training|Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
40342|NCT03867864|Device|Necklace with essential oil for the first 4 weeks|The necklaces contain essential oil.
40343|NCT03867864|Device|Necklace without essential oil for the first 4 weeks|The necklaces do not contain essential oil.
40344|NCT03867864|Other|Washout|Washout (do not wear the necklace) for one week for two groups, then two groups cross-over.
40345|NCT03867864|Device|Necklace with essential oil for last 4 weeks|The necklaces contain essential oil.
40346|NCT03867864|Device|Necklace without essential oil for last 4 weeks|The necklaces do not contain essential oil.
40347|NCT03867851|Drug|IBsolvMIR|Study drug IBsolvMIR
40348|NCT03867851|Drug|Heparin|Clinical praxis
40349|NCT03867838|Device|compliant support|Participants will be given compliant arm support and their reachable workspace measured
40350|NCT03867825|Device|Non-invasive hemodynamic monitoring|Impedance cardiography
40354|NCT03867799|Drug|Nivolumab|Immunotherapy
40355|NCT03867786|Behavioral|Exercise|Participants will complete an acute exercise visit.
40356|NCT03867786|Behavioral|Video Control|Participants will complete a video control visit.
40357|NCT03867773|Behavioral|Time restricted feeding|TRF subjects will consume food ad libitum during the feeding window (4-h or 6-h window), and refrain from eating during the fasting window (20-h or 18-h window)
40358|NCT03867760|Behavioral|Recorded Hypnosis Intervention|The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
40359|NCT03867760|Behavioral|Recorded Relaxation Intervention|The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
40360|NCT03867747|Radiation|Cardiac Radiosurgery|Image-guided stereotactic body radiation therapy
40361|NCT03867734|Drug|Aztreonam|2g IM Aztreonam
40362|NCT03867721|Device|Ventilator|Comparison of two ventilators for mouthpiece ventilation
40363|NCT03867708|Radiation|ASD device closure|transcatheter secundum ASD device closure
40364|NCT03867695|Drug|Ropivacaine|At the end of the lobectomy VATS procedure, 0,5 mL/kg of 0.375% ropivacaine will be administered.
40365|NCT03867695|Drug|sterile saline|Patients will receive a placebo injection with 0,5 mL/kg of sterile normal solution
40399|NCT03867461|Other|Adjustment to Mean Arterial Pressure (100-110 mmHg range)|Mean arterial pressure will be adjusted to fall in the 100-110 mmHg range
40369|NCT03867669|Other|Open Bay Unit|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
40370|NCT03867669|Other|Single patient room|The eligible infants will be randomized at birth/admission to either the single patient room (experimental) or the open bay unit (Comparator)
40371|NCT03867656|Other|GLP-2|GLP-2 injection
40372|NCT03867656|Other|GIP|GIP injection
40373|NCT03867656|Other|Placebo|Placebo injection
40374|NCT03867630|Procedure|Transforaminal Block|Epidural block via neural foramen of lumbar spine
40375|NCT03867617|Other|Regulatory T cells|Single infusion of expanded regulatory T cells.
40376|NCT03867617|Drug|Tocilizumab|Treatment during first month post-transplant.
40377|NCT03867617|Other|Bone marrow|Infusion of donor bone marrow cells.
40378|NCT03867617|Procedure|Kidney transplant|Living donor kidney transplantation.
40379|NCT03867617|Other|Immunosuppressive drug therapy|Immunosuppressive drug therapy.
40380|NCT03867604|Procedure|Sham injection|Injection to the subcutaneous layer at upper trapezium level
40381|NCT03867604|Procedure|Fascia injection|Injection to the fascia below upper trapezium muscle
40382|NCT03867591|Other|Gastro-AD®|"The product under study is Gastro-AD® fermented soy powder in the form of orodispersible flavored powder packed in non-transparent sachets.~Content: 1 g of Gastro-AD® powder per sachet + flavoring agents."
40383|NCT03867591|Other|Placebo|The placebo product will have very similar appearance, color, texture and taste as the Gastro-AD® flavored sachet. The placebo sachets contain the respective amount of maltodextrin (1 g) and exactly the same flavoring and coloring agents as Gastro-AD® powder flavored sachets.
40384|NCT03867578|Diagnostic Test|HR-MRI|The first 5 patients will undergo HR-MRI scans using different sequence parameters. Results in these patients will then be assessed along with standard CT Imaging to determine which sequences appear to best identify peritoneal disease. The optimal HR-MRI sequences will then be used for the next 19 patients in the Testing phase to formally define their performance compared to standard imaging.
40385|NCT03867578|Diagnostic Test|Standard CT Imaging|Standard CT scans will be performed for preoperative imaging in all patients.
40386|NCT03867578|Diagnostic Test|Ultrasound|Ultrasound Elastography will be performed using an FDA-Approved diagnostic GE ultrasound scanner
40387|NCT03867565|Other|Nutritional intervention|Indirect calorimetry Weight development Nitrogen balance Food records Physical activity Nutritional risk screening and assessment Inflammatory response Wound healing as number of days from burn to no more need of dressing changes via health care facility Frequency of infections as the number, sort, dose, and length of antibiotic treatment(s) from burn to no more need of dressing changes via health care facility
40388|NCT03867552|Procedure|Altered gas (80% CO2, 15% N2O, 5% O2)|Assessement of pain degree after laparoscopic surgery with the altered gas (80% CO2, 15% N2O, 5% O2)
40389|NCT03867552|Procedure|Standardized gas (100% CO2)|Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
40390|NCT03867539|Other|Differing pain management strategy|"We aim to investigate an alternative (vs standard) pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated."
40391|NCT03867513|Other|Multimodal imaging|All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
40392|NCT03867500|Drug|Niacin|All participants will receive intravenous Niacin and each participant will serve as their own saline control on the second study
40393|NCT03867500|Other|Saline|All participants will serve as their own controls with a saline infusion study day.
40394|NCT03867487|Drug|Empagliflozin 10 MG|Participants will take a 10 mg oral tablet of empagliflozin, an orally-active inhibitor of sodium-glucose co-transporter 2 (SGLT2)
40395|NCT03867487|Drug|Placebo Oral Tablet|Participants will take an identical appearing oral tablet with zero active ingredient.
40396|NCT03867474|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The intervention group will be delivered in a group-based format, for one three-hour session per week for an 8-week period. Each session will consist of mindfulness practice (e.g. lying down body scan, sitting meditation, mindful eating, mindful movements such as walking and light hatha yoga movements) along with an inquiry about the practice. Strategies on stress reactivity, responding to stress, and some basic content on cognitive behaviour therapy principles will also be taught. Participants will be placed in dyads during the group. Homework practice will be given to complete on a daily basis for approximately 30-45 minutes. During week six participants will attend an all-day silent meditation retreat on a Saturday (Total of 10 sessions = 8 sessions, 1 orientation, and 1 all-day retreat).
40397|NCT03867461|Procedure|Venous Sinus Stenting|Venous sinus stenting is performed under general anesthesia. Patients are loaded with aspirin and clopidogrel before the procedure. After induction, the right femoral vein is accessed and an 8 F sheath is placed. Intravenous heparin is administered. A 0.070-0.088 guide catheter is navigated into the ipsilateral jugular vein near the jugular bulb. Pre-stenting manometry is performed in every patient. To do so, a Renegade Hi-Flo microcatheter is navigated into the superior sagittal sinus and then used to measure ipsilateral venous pressures across the site of outflow obstruction (this will be the time point where the study intervention will be performed).
40398|NCT03867461|Other|Adjustment to end-tidal carbon dioxide concentrations ( 38-40 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the End-tidal carbon dioxide concentrations will be adjusted to fall in the 38-40 mmHg range
40400|NCT03867461|Other|Adjustment to Mean Arterial Pressure (60-80 mmHg range)|Mean arterial pressure will be adjusted to fall in the 60-80 mmHg range
40401|NCT03867461|Other|Adjustment to end-tidal carbon dioxide concentrations (24-26 mmHg range)|End-tidal carbon dioxide concentrations will be adjusted to fall in the 24-26 mmHg range
40402|NCT03867409|Behavioral|message delivered via virtual technology|The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
40403|NCT03867396|Device|CROS|Advanced Bionics CROS
40404|NCT03867396|Device|Hearing Aid|Advanced Bionics Naida hearing aid
40405|NCT03867396|Other|Cochlear Implant Alone|No hearing device on contralateral ear
40406|NCT03867383|Drug|Calcium Chloride|"All included in intervention description.~1 gram of calcium chloride in total 60 milliliters normal saline"
40407|NCT03867383|Drug|Placebo|60 milliliters normal saline
40408|NCT03867370|Biological|TORIPALIMAB INJECTION(JS001 )|During the neoadjuvant period, the patients will receive a single JS001 intravenous infusion of 480 mg . After the operation, the patients wil receive JS001 240 mg Q3W.
40409|NCT03867357|Drug|GnRH agonist|Zoladex is a gonadotropin-releasing hormone agonist, or GnRH-A. It is an implant that is injected under the skin (subcutaneously). The implant gradually dissolves and releases the drug over the time between injections. There are two dosages of Zoladex: Zoladex 10.8 mg, which is injected once every 3 months, and Zoladex 3.6 mg, which is injected once a month.
40412|NCT03867331|Biological|5 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
40413|NCT03867331|Biological|15 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
40414|NCT03867331|Biological|30 microgram VLPM01|VLPM01 is an alpha-VLP pre-erythrocytic malaria vaccine which targets circumsporozoite protein (CSP), adjuvanted with 0.75 mg alum.
40415|NCT03867331|Other|Plasmodium falciparum challenge|Expose forearms to five (5) Plasmodium falciparum (strain NF54; clone 3D7) bites
40416|NCT03867318|Drug|Atorvastatin|Atorvastatin administered orally QD as 10 mg tablets.
40417|NCT03867318|Drug|Ezetimibe|Ezetimibe administered orally QD as 10 mg tablets
40418|NCT03867318|Drug|Placebo for Ezetimibe|Single placebo tablet administered orally QD
40419|NCT03867318|Drug|Placebo for Atorvastatin|Single placebo tablet administered orally QD
40420|NCT03867305|Device|MOBIDERM|Use of a MOBIDERM mobilizing band after total knee prosthesis
40421|NCT03867292|Other|Myofascial|"The aim of the application of the crossed hands technique is to produce a deep fascial release, placing the subject in prone position, while the standing physiotherapist will contact with one hand on the spine at the level of the thoracolumbar hinge and with the other hand on the sacrum, so that the hands are crisscrossed. The crossed hands technique will be performed between 90 seconds and 5 minutes.~The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally."
40422|NCT03867292|Other|Electrotherapy|The application of the TENS, will be performed for 10 minutes by means of a device, model Compex in the lumbar area, subjects will receive a TENS application of low frequency (less than 40Hz). The electrode - (black) in proximal position or on the most painful zone. The electrode + (red) will be placed distally.
40423|NCT03867279|Other|Flossing|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground. The subjects included in this group will perform the exercises while a compression band is applied to the ankle.
40424|NCT03867279|Other|Reeducation exercises|The reeducation exercises are: lunge and hold (the subject performs a lunge increasing the dorsiflexion of the ankle, advancing the tibia as much as possible without taking off the heel of the floor and without valgus of the knee, 15 repetition of 10 seconds of duration each); back squat (squat with a pike supported on scapulae); and chaturanga (from the prone position with extension of elbows and spine, the subject raises upper antero iliac spines performing a shoulder flexion and raising the pelvis to the ceiling maintaining the hip flexion and knees extended and keeping the heels touching the ground.
40425|NCT03867266|Procedure|Ablation with radiofrequency|Ablation point by point on the cavo tricuspid isthmus guided by an index lesion
40426|NCT03867253|Drug|ORY-2001 Low dose|0.6mg ORY-2001 capsule
40427|NCT03867253|Drug|ORY-2001 High dose|1.2mg ORY-2001 capsule
40428|NCT03867253|Drug|Placebo|Placebo capsule
40429|NCT03867240|Drug|Gabapentin|Gabapentin (10 mg/kg up to 600 mg) will be given 30 minutes prior to being transported to the operating room. The gabapentin will be in the standard liquid with a concentration of 250mg/5mL. Starting postoperative day 1, patients in the experimental group will receive gabapentin three times daily. Dose of gabapentin will be 100 mg for patients <50 kg and 200 mg for patients > 50 kg. Gabapentin will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with gabapentin for the remainder of their doses upon discharge.
40475|NCT03866941|Behavioral|causes of abuse synthetic cannibinoids|Epidemiological data (age, sex, residence, occupation, route of abuse, the cause of abuse and smoking) (2) Symptoms and signs (seizures, psychosis, hallucinations) (3) Injuries and their relation to violence (type of wound, type of instrument, number of injuries, external or internal injuries and assailant or victim).
40476|NCT03866928|Drug|Stiripentol|1500 mg of stiripentol b.i.d.
40430|NCT03867240|Other|Placebo|Placebo will be given 30 minutes prior to being transported to the operating room. Placebo will be identically appearing to gabapentin. Starting postoperative day 1, control group will receive placebo medication at the same interval with the appropriate number of capsules or liquid for their weight to match the experimental group. It will be continued for 5 days postoperatively. If patients are discharged prior to postoperative day 5, they will be provided with placebo for the remainder of their doses upon discharge.
40431|NCT03867227|Device|left atrial appendage occluder implantation|all patients will get implantation of LAA occluder
40432|NCT03867214|Drug|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
40433|NCT03867214|Drug|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
40434|NCT03867201|Biological|Erenumab|Administered by pre-filled syringe
40435|NCT03867201|Other|Placebo|Administered by pre-filled syringe
40436|NCT03867188|Drug|Liposomal Bupivacaine|A 25 gauge or larger bore needle will be used to inject the liposomal bupivacaine at the site of operation following the prescription guidelines provided by Exparel®. The maximum dose allowable for this study is 266mg or 20 mL as indicated in the FDA package insert.
40437|NCT03867175|Radiation|Stereotactic Body Radiation Therapy|Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)
40438|NCT03867175|Biological|Pembrolizumab|Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.
40439|NCT03867162|Biological|Live Attenuated Tularemia Vaccine|Subjects will be vaccinated with a bifurcated needle; approximately 0.06 mL of the reconstituted vaccine will be placed on the volar surface of the forearm and applied by multiple puncture.
40440|NCT03867149|Other|neuroimaging|neuroimaging including high-resolution imaging of the thalamus, DTI and resting state fMRI
40441|NCT03867149|Other|Neuropsychological assessment|neuropsychological assessment of memory, language, executive functions and mood
40442|NCT03867136|Drug|Ultra Short All oral Regimen|Pyrazinamide 1500 mg daily; Levofloxacin ≤50kg 500 mg daily, >50kg 750mg daily; Linezolid: 600 mg daily; Cycloserine ≤50kg 500 mg daily, >50kg 750mg daily; Clofazimine 100 mg daily; All treatment is taken daily;
40443|NCT03867136|Drug|Standardized Shorter Regimen|Pyrazinamide ≤50kg 1500 mg daily, >50kg 1500mg daily;Levofloxacin 400 mg daily,; Prothionamide ≤50kg 500 mg daily, >50kg 750mg daily; Ethambutol: ≤50kg 750 mg daily, >50kg 1000mg daily; Clofazimine: 100 mg daily; Amikacin 600mg daily; High-dose isoniazid 600mg daily. Pyrazinamide ≤50kg 1500 mg daily, >50kg 1500mg daily;; All treatment is taken daily.
40444|NCT03867123|Drug|2-OHOA|Arm 1: Daily for 6 weeks. Arm 2: daily, two 28-day cycles
40445|NCT03867123|Radiation|RT|In Arm 1: Fractionated focal irradiation of 1.8-2 Gy/fraction/day, 5 days/week, 6 weeks. Total dose up to 60 Gy
40446|NCT03867123|Drug|TMZ|Arm 1: 75 mg/m2/day, daily, 6 weeks Arm 2: 200 mg/m2/day, daily the first 5 days of two 28-day cycles (in case of toxicity, TMZ dose may be reduced to 150 mg/m2/day at Cycle 3 to allow for recovery)
40447|NCT03867110|Drug|Placebo|
40448|NCT03867110|Drug|Ezetimibe 10 mg|
40449|NCT03867110|Drug|Atorvastatin 10 mg|
40450|NCT03867110|Drug|Atorvastatin 20 mg|
40451|NCT03867110|Drug|Atorvastatin 40 mg|
40452|NCT03867110|Drug|Atorvastatin 80 mg|
40453|NCT03867097|Drug|Placebo IV infusion|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
40454|NCT03867097|Drug|Iloprost Injection, for intravenous use|Study drug will be initiated at a starting dose of 0.5 ng/kg/min up to 2.0 ng/kg/min. Subjects will receive study drug for 5 consecutive days as an IV infusion over 6 hours each day via a peripheral line.
40455|NCT03867084|Biological|Pembrolizumab|IV infusion of Pembrolizumab 200 mg.
40456|NCT03867084|Drug|Placebo|IV infusion of 0.9% normal saline.
40457|NCT03867071|Other|recombinant erythropoietin injection|Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).
40458|NCT03867071|Other|placebo injection|Intravenous injection 0,9% saline solution.
40459|NCT03867058|Behavioral|Electrode selection/electrode configuration|Electrodes will be chosen based on their spatial tuning curves. Focused stimulation will be applied to electrodes with good temporal processing acuity.
40460|NCT03867045|Device|Usability of an electronic symptom management application|Usability of an electronic symptom management application in a pilot group of patients receiving cabozantinib for mRCC through data analytics and feedback from users
40461|NCT03867032|Behavioral|Auditory training|Training with psychophysical tests (amplitude modulation detection on single electrodes) for improving speech recognition
40462|NCT03867019|Diagnostic Test|Heart rate variability parameters monitoring|"No intervention- only additional monitoring of heart rate, physical tests and filling of questionnaires:~Heart rate variability parameters monitoring- by wearing a Polar watch (RS800CX).~Isometric grip test- by using a Jamar Hand Held Dynamometer.~Questionnaires:~Dizziness Handicap Inventory (DHI) - hebrew version.~Stait-Trait Anxiety Inventory (STAI)"
40463|NCT03867006|Dietary Supplement|Protein|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days.
40464|NCT03867006|Dietary Supplement|Protein and Carbohydrate|In addition to their normal meal, patients will eat 30g of whey protein every lunch during 90 days and eat 60g of carbohydrates 2h after every diner during 90 days.
40465|NCT03866993|Biological|AK105|IV infusion
40466|NCT03866993|Drug|Paclitaxel|IV infusion
40467|NCT03866993|Drug|Carboplatin|IV infusion
40468|NCT03866993|Drug|Placebo|IV infusion
40469|NCT03866980|Biological|AK105|IV infusion
40470|NCT03866980|Drug|carboplatin|IV infusion
40471|NCT03866980|Drug|pemetrexed|IV infusion
40472|NCT03866980|Drug|placebo|IV infusion
40473|NCT03866967|Biological|AK105|intravenous (IV) infusion
40474|NCT03866954|Combination Product|EE-TP|Ecoli thymidine phoshorylase encapsulated within autologous erythrocytes
40477|NCT03866915|Diagnostic Test|Aortic pulse wave velocity measurement|Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography
40478|NCT03866915|Diagnostic Test|6 minutes walking test|This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
40479|NCT03866902|Behavioral|Nutrition and Physical Activity Intervention|"Mothers. Twelve weekly classes for one hour focused on nutrition and exercise education and coping skills training followed by a forty five minute exercise class for mothers. Then they will return for one hour for continued support and a forty-five minute exercise class.~Children. Twelve weekly classes for one hour focused on Color Me Healthy and one hour of free play. Then 6 monthly continued support classes where a Color Me Healthy class will be reviewed and they will have one hour of free play."
40480|NCT03866902|Other|English for Second Language Intervention|"Mothers. Control group mothers will receive 12 weekly English for Second Language classes for one hour and forty-five minutes. Then 6 monthly one hour and forty minute follow-up classes receiving English for Second Language material.~Children. Control group children will receive 12 weekly one hour and forty five minutes of having books read to them. Followed by 6 monthly meetings for one hour and 45 minutes being read to and coloring with crayons."
40481|NCT03866889|Other|Strength|"In the performance of the squat exercise (Back Squat), the subjects will be standing, with an Olympic bar behind their neck, supported on both trapezoids, while the hands will help to hold and stabilize the bar, taking it from below.~For hamstring curl, the subject will be in the prone position, clinging to the backrest, with the legs under the arm that lifts the weight.~The deadlift exercise will be performed from the standing posture, holding the bar with your arms extended and the trunk straight, while your hands will hold the bar at the height and separation of the hips.~Finally, in the quadriceps chair the subject will find himself sitting with his back straight and supported on the back of the seat, while the legs will go under the arm that lifts the weight."
40482|NCT03866889|Other|Normal activity|The subjects included in the control group will continue to perform the same strength training plan that they did before starting this one. The periodicity will be the same (4 days / week) and with the same intensity.
40483|NCT03866876|Other|Eucapnic pH|Collection of Biological marker (proposed by Racinet): eucapnic pH
40484|NCT03866863|Other|Intrauterine growth restriction (IUGR)|Collection of number of patient's diagnosed with IUGR as defined in accordance with the consensus-based definition for early and late IUGR : birthweight < 3rd centile using French AUDIPOG curves adjusted for term and sex or estimated fetal weight < 10th centile combined with umbilical artery pulsatility index > 95th centile or breakage of growth.
40485|NCT03866850|Behavioral|Phase duration|We will vary the phase duration in the stimulation, and examine detection threshold, spatial spread of neural excitation, and speech recognition as the outcomes.
40486|NCT03866837|Dietary Supplement|Galacto-oligosaccharides|Galacto-oligosaccharides are classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, are components of cow's milk and have been used repeatedly in clinical trials without adverse effects.
40487|NCT03866837|Dietary Supplement|Bovine lactoferrin|Bovine lactoferrin is classified as Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration, is a component of cow's milk and has been used repeatedly in clinical trials without adverse effects.
40488|NCT03866837|Dietary Supplement|Multiple micronutrient powders with 5 mg iron|The multiple micronutrient powders are composed of Vitamin A, 400 μg; Vitamin D, 5 μg; Tocopherol Equivalents, 5 mg; Thiamine, 0.5 mg; Riboflavin, 0.5 mg; Vitamin B6, 0.5 mg; Folic Acid, 90 μg; Niacin, 6 mg; Vitamin B12, 0.9 μg; Vitamin C, 30 mg; Copper, 0.56 mg; Iodine, 90 μg; Selenium, 17 μg; Zinc, 4.1 mg; Phytase, 190 FTU; Iron, 5 mg [(as Ferrous fumarate, 2.5 mg and sodium iron ethylenediaminetetraacetate (NaFeEDTA), 2.5 mg].
40489|NCT03866824|Drug|injection of Platelet Enhanced Plasma(PRP)|intra-articular injection
40490|NCT03866824|Drug|injection of corticosteroids|intra-articular injection
40491|NCT03866824|Device|RMI|A CONTROL RMI at 1 year follow-up.
40492|NCT03866811|Behavioral|Dr. Erica|The 10 week texting intervention contains the follow characteristics to increase engagement: (1) Dr. ERICA (Emergency Room Interventions to Improve the Care of Adolescents): The persona and brand of the intervention is Dr. Erica, a relatable, empathetic, straightforward and reliable female doctor; (2) Personalization: Information collected at baseline will be incorporated into each individualized program; (3) Interactivity: The majority of text message algorithms contain 3-4 two-way automated messaging conversations. (4) Feedback loops: The investigators will collect feedback from participants to prompt action; (5) Visual stimuli: Texts include emojis, memes, and other visual stimuli, similar to current teen texting behaviors; (6) Social media: The investigators designed sexual health comic strips posted as an Instagram story; (7) Links and role modeling: Texts contain links to testimonials, influencers, and evidence-based websites.
40494|NCT03866785|Diagnostic Test|interview|The goal is to evaluate the needs, the constraints and representations of patients on the practice of physical activity.
40495|NCT03866785|Diagnostic Test|Adult Physical Activity Questionnaire (APAQ)|The goal of this questionnaire is to evaluate the sedentary lifestyle of patients.
40496|NCT03866785|Device|Activity actigraph|An activity actigraph will use by the patient for a week. It measures the level of physical activity and the sedentary lifestyle of patients.
40497|NCT03866785|Other|Peer training|"The goal of the peer training will organize once a week for 3 weeks for a patient.~After this training, they will have :~Skills in physical activity advice~Knowledge of functional signs (symptoms)~Knowledge to examine heart rate and perceived effort rate"
40498|NCT03866785|Other|Physical Activity Program|"During the Physical Activity Program, patients will be supervised by peers and a clubs and sports associations labeled sport-health by Olympic and Sports Committee of the Loire Department.~The peer will coach the patient once a week minimum for 3 months."
40499|NCT03866772|Drug|Misoprostol Oral Tablet|50 mcg oral consumption
40500|NCT03866772|Device|double balloon device for cervical ripening|insertion for 6 hours and followed by the above mentioned protocol
40501|NCT03866759|Behavioral|Determine the Incidence and Point Prevalence|Determine the Incidence and Point Prevalence of human immunodeficiency virus (HIV) Infection and the Most Common Sexually Transmitted Infections in Individuals With Sexual Risk Behavior.
40502|NCT03866746|Drug|Aflibercept Injection|Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.
40503|NCT03866746|Other|micropulsed yellow laser|Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
40504|NCT03866733|Other|continous erector spinea block|Ultrasound guided erector spinea block will be performed while the patient is in left lateral position ) the US probe will be placed in longitudinal parasagittal plane lateral to the T5 spinous process. An 18-gauge epidural needle will be inserted in-plane in a cranial-to-caudal direction until the tip is deep to erector spinae muscle. A 5 cm of epidural catheter will be threaded in cephalad direction. The same steps will be performed on the other side, after the negative aspiration for blood, bolus dose 15 ml of 0.25% bupivacaine will be injected in each of the catheters followed by a continuous infusion of 0.125% plain bupivacaine at the rate of 0.1 ml/kg/h.
40505|NCT03866733|Drug|intravenous narcotics|intervention: injection of boluses of intra venous Narcotic drugs (fentanyl) in the dose of (1-2mcg/kg) during the surgery after induction of anesthesia then fentanyl infusion through the postoperative first 24 hours postoperative till extubation then intravenous pethidine till 48 hours after surgery.
40506|NCT03866720|Other|Carbohydrate rich breakfast|A porridge breakfast meal fed at a carbohydrate delivery rate of 7.3 mg/kJ of each participants resting metabolic rate.
40507|NCT03866720|Dietary Supplement|Whey protein enriched breakfast|A porridge breakfast meal in which 15 grams of whey protein is substituted in place of carbohydrate and a small portion of fat.
40508|NCT03866707|Other|One-time blood draw|"Subjects will have a one-time blood draw of 5-10mL. Quantity of blood drawn for study and routine care will not exceed the maximum safe blood volume for subject size.~Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray. This covers over 850,000 CpG methylation sites and is available in the investigator's Genomics Core Facility. Dr. Langefeld has analyzed numerous methylation studies, both array-based and next generation sequencing.~Metabolomic analysis will be performed by mass spectrometry when funds are available."
40509|NCT03866707|Other|Evaluation of CpG methylation|Evaluation of CpG methylation sites will be completed using the MethylationEPIC BeadChip (Infinium) microarray.
40510|NCT03866707|Other|Metabolomic analysis|Metabolomic analysis will be performed by mass spectrometry when funds are available.
40511|NCT03866694|Behavioral|BRIGHT|Dyadic therapeutic parenting intervention (BRIGHT) beginning in third trimester of pregnancy through six months postpartum focusing on child-parent relationship, mental health, infant social-emotional development, and recovery. Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic.
40512|NCT03866694|Other|STAR/TAU+|Monthly handouts for mothers in recovery with information about child development and recovery from substance misuse while parenting and the standard of care at participant's high risk maternal-fetal medical clinic
40513|NCT03866681|Drug|sirolimus|The dose of sirolimus is adjusted according to monitored serum concentration, maintain Rapamycin concentration ranging from 4 to 10ng/ml.Warfarin was administered orally at a dose of 1mg per day for a year,then gradually reduced to stop.
40514|NCT03866668|Drug|Esomeprazole|Esomeprazole Dosage (Weight Less Than 20 kg) -- 10 mg QD for 8 weeks Esomeprazole Dosage (Weight 20 kg or Greater) -- 10 mg QD for 4 weeks followed by 20 mg QD for 4 weeks
40515|NCT03866655|Device|OWise|OWise Breast Cancer is a supportive care digital tool for breast cancer patients. The tool can be accessed as a mobile phone application or as a website. The tool has various tools for self-managing and self-monitoring treatment and symptoms such as an appointment calendar, a symptom-tracker, a modifiable question list and a recording device for consultations.
40516|NCT03866642|Device|Cadence Total Ankle Replacment|Cadence Total Ankle prosthesis
40517|NCT03866629|Drug|Lifitegrast|Lifitegrast ophthalmic solution 5%
40518|NCT03866616|Behavioral|Brain Builders Parenting Class|Brain Builders Parenting Class group sessions goal is to increase parental knowledge of brain development and increase responsive parenting
40519|NCT03866616|Behavioral|Control (Usual care)|"This arm receives usual care (control group) consisting in: WIC participants will attend their usual appointments completed at the WIC clinics."
40520|NCT03866603|Genetic|Blood Test|LRRK2 hotspot mutations and the whole GBA gene will be sequenced. If LRRK2 hotspots and GBA sequencing are both negative and the subject has an early PD onset and/or a PD family history and is willing to participate in further genetic screening, 68 PD associated genes will be sequenced. In case of the negative result and if the participant has an early disease onset and/or a PD family history and is willing to participate in extended genetic screening, Whole Genome Sequencing (WGS) will be performed.
40521|NCT03866590|Diagnostic Test|Genetic test|Detection of PKLR mutations via Next Generation Sequencing
40522|NCT03866577|Biological|Biological: M254|M254 administered as intravenous infusion
40523|NCT03866577|Drug|Placebo|Placebo administered as intravenous infusion
40524|NCT03866577|Biological|Intravenous immunoglobulin (IVIg)|IVIg administered as intravenous infusion
40525|NCT03866564|Diagnostic Test|Echocardiography|Cardiac ultrasound to measure left ventricular systolic function.
40526|NCT03866564|Diagnostic Test|Neuropsychological Testing|Standard clinical testing designed to establish or exclude the presence of cognitive dysfunction.
40527|NCT03866564|Diagnostic Test|Pain Catastrophizing Scale|Clinically accepted quantitative assessment of chronic pain burden.
40528|NCT03866564|Diagnostic Test|Nocturnal Polysomnography|Routine overnight sleep study to measure apnea-hypopnea index.
40529|NCT03866551|Device|Reprieve Cardiovascular System|The Reprieve Cardiovascular System (RCS) shall be utilized to maximize fluid removal over a maximum duration of 72 hours.
40530|NCT03866538|Drug|Withdrawal of Oral Budesonide|The intervention arm will taper and stop budesonide therapy (withdrawal).
40531|NCT03866525|Biological|OH2 injection|Oncolytic Type 2 Herpes Simplex Virus
40532|NCT03866525|Drug|HX 008 injection|Anti-PD-1 antibody
40533|NCT03866512|Behavioral|Forearm immobilization|Two days of forearm immobilization
40534|NCT03866499|Drug|BPI-7711|180 mg, oral, QD
40535|NCT03866499|Drug|Gefitinib|250 mg, oral, QD
40536|NCT03866499|Drug|Placebo Tablet|250 mg gefitinib placebo tablet, QD
40537|NCT03866499|Drug|Placebo capsule|180 mg BPI-7711 placebo capsule, QD
40538|NCT03866473|Device|Retilux|670nm wavelength light
40539|NCT03866473|Device|Sham Light Device|Broad spectrum light device
40540|NCT03866460|Diagnostic Test|Distortion product otoacoustic emission measurement (DPOAE)|Hearing will be measured at baseline and 3-9 months after completion of treatment with IA carboplatin chemotherapy.
40541|NCT03866447|Drug|Vitamin D analog|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every month for 3 months. Any local or systemic clinical side effects of the medications will be noted during each follow up visit.
40542|NCT03866447|Drug|Adapalene|Patients will be clinically and photographically evaluated at baseline and at each follow up visit every
40543|NCT03866434|Drug|SPD422|Participants will receive 1 mg of SPD422 (2*0.5 mg) capsule orally on Day 1 and 8 in fasted state.
40544|NCT03866434|Drug|Omeprazole|Participants will receive 40 mg of Omeprazole orally once daily on Days 2 - 8.
40545|NCT03866421|Diagnostic Test|MR spectroscopy of the liver|Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
40546|NCT03866421|Diagnostic Test|Fibroscan of the liver|Transient Elastography for Measurement of liver fibrosis.
40547|NCT03866421|Device|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
40548|NCT03866421|Diagnostic Test|Oral glucose tolerance test (OGTT)|OGTT with incretin hormones. Measured for three hours.
40549|NCT03866421|Diagnostic Test|Intra venous glucose infusion (IIGI)|This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.
40550|NCT03866421|Radiation|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
40551|NCT03866421|Biological|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
40552|NCT03866421|Other|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
40553|NCT03866408|Behavioral|Immediate weight loss|Upper body obese subjects will undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
40554|NCT03866408|Drug|Pioglitazone|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
40555|NCT03866408|Behavioral|Deferred weight loss|Upper body obese subjects will complete a weight-stable period of 4 months and subsequently undergo behavioral intervention with a life coach and a physical activity program of their choice for 4 months.
40556|NCT03866408|Drug|Placebo|Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
40557|NCT03866395|Drug|Ivabradine|Ivabradine 5 mg twice a day
40558|NCT03866382|Drug|Cabozantinib|Given PO
40559|NCT03866382|Drug|Cabozantinib S-malate|Given PO
40560|NCT03866382|Biological|Ipilimumab|Given IV
40561|NCT03866382|Biological|Nivolumab|Given IV
40562|NCT03866369|Drug|Moxifloxacin|Single oral dose at D-8
40563|NCT03866369|Drug|Placebo|Single oral dose at D-1
40564|NCT03866369|Drug|Lanifibranor|Single daily oral dose during 14 days
40565|NCT03866369|Drug|Placebo|Single daily oral dose during 14 days
40566|NCT03866356|Behavioral|intervention group|The women in the intervention group were provided care according to SICP
40567|NCT03866343|Other|Diet low or high in advanced glycation endproducts|All subjects will undergo an intervention consisting of a prescribed diet containing either a low or high quantity of AGEs during 4 continuous weeks.
40568|NCT03866330|Biological|Intraarticular injection of WJMSC|ultrasound guided intra-articular injection of at least 10 million of Wharton's jelly-derived mesenchymal stem cells per procedure
40569|NCT03866317|Drug|Secukinumab|All subjects will receive secukinumab 300 mg injections subcutaneously at week 0, 1, 2, 3, 4, then every 4 weeks until week 12.
40570|NCT03866304|Device|Device: S2 Picosecond laser|Each subject will receive up to 16 laser treatments.
40571|NCT03866291|Other|No intervention, observational|See above
40572|NCT03866265|Dietary Supplement|Food Grade Extract of Salmon Polar Lipids (FGE-Salmon-PLs)|Each participant will be administered per day a capsule of the FGE-Salmon-PLs food supplement (containing 0.125 g of FGE-Salmon-PLs) for a period of 28 days in a double blind randomized, crossover and placebo-controlled design.
40573|NCT03866265|Other|Placebo|Each participant will be administered per day a placebo capsule (containing 0.125 g of glycerin) for a period of 28 days in a double blind randomized, crossover design.
40574|NCT03866252|Drug|LSD|LSD administration per os
76266|NCT03587766|Drug|Placebo Oral Tablet|Drug: fexinidazole
40579|NCT03866213|Diagnostic Test|BiliSpec|BiliSpec will quantitatively measure the bilirubin content of a neonatal blood sample.
40580|NCT03866200|Drug|resveratrol|125 mg/day or 5 ml once per day for 90 days
40581|NCT03866200|Drug|Placebo|5 ml once per day for 90 days
40582|NCT03866187|Biological|ChAd155-hIi-HBV low dose formulation|Subjects in group A1 receive one dose of ChAd155-hIi-HBV low dose formulation at Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
40583|NCT03866187|Biological|ChAd155-hIi-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in groups C1 and C2 receive one dose of ChAd155-hIi-HBV high dose formulation at Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm."
40584|NCT03866187|Biological|HBc-HBs/AS01B-4 low dose formulation|Subjects in group A1 receive two doses of HBc-HBs/AS01B-4 low dose formulation, one at Day 113 and one at Day 169 and subjects in group A2 receive four doses of the low dose formulation, one dose each at Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
40585|NCT03866187|Biological|HBc-HBs/AS01B-4 high dose formulation|Subjects in group B1 receive two doses of HBc-HBs/AS01B-4 high dose formulation, one at Day 113 and one at 169; subjects in group B2 receive four doses, one dose each at Days 1, 57, 113 and 169; subjects in group C1 receive four co-administered doses at Days 1, 57, 113 and 169 and subjects in group C2 receive two co-administered doses at Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
40586|NCT03866187|Biological|MVA-HBV low dose formulation|Subjects in group A1 receive one dose of MVA-HBV low dose formulation at Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
40587|NCT03866187|Biological|MVA-HBV high dose formulation|"Subjects in groups B1 and B3 receive one dose of MVA-HBV high dose formulation at Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm.~Subjects in group C1 receive three co-administered doses of the vaccine at Days 57, 113 and 169 and subjects in group C2 receive one co-administered dose of the vaccine at Day 169, by intramuscular injection in the deltoid of the dominant arm."
40588|NCT03866187|Drug|Placebo|Subjects in group A3 receive four doses of placebo, one each at Days 1, 57, 113 and 169 and subjects in group B3 receive two doses of placebo one each at Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Subjects in group C2 receive 2 co-administered doses of placebo at Days 1 and 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
40591|NCT03866161|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment
40592|NCT03866148|Device|Reveal LINQ|Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
40593|NCT03866122|Device|Temperature monitored|NTM and a patient monitor will continuously collect temperature for up to 72 hours. Additionally, Bempu and Thermospot may monitor temperature for up to 72 hours.
40594|NCT03866109|Drug|Temferon|Genetically modified HSPCs
40595|NCT03866096|Other|Experimental|The player will perform exercises of balance, stability, and strengthening of the abdomen, back and gluteus. All these exercises will be carried out in first instance on flat surfaces and later on unstable surfaces to increase the difficulty of it. The training will be done in different levels of difficulty, once the participant managed to master the initial level, advance to the next level to complete the three levels of difficulty during the 6 weeks of training. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of the intervention of the experimental group will last 20 minutes
40596|NCT03866096|Other|Control|Neuromuscular training will be applied through balance and stability exercises on both flat and unstable surfaces. There will be 3 repetitions of each exercise with a duration of one minute and breaks of 30 seconds between each repetition and 2 minutes of rest between exercises. The duration of each session of the control group is 10 minutes.
40597|NCT03866083|Drug|Extracorporeal Cytokine hemadsorption therapy|Hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for Jianfan Biotechnology Co., Zhuhai, China). The hemoperfusion apparatus will be connected in front of the hemodialyzer in series.
40598|NCT03866083|Drug|Standard Medical Treatment|Standard Medical Treatment
40599|NCT03866070|Other|Experimental|Two exercises will be done to strengthen the external rotation (using elastic bands): standing with 90 degrees of shoulder abduction and elbow flexion and also in standing with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. Dumbbell exercises will be performed through 4 exercises: flexion in the horizontal plane of 135º, external rotation in lateral decubitus, horizontal abduction with external rotation, and extension in prone position. There will be 5 repetitions each exercise of 3 seconds each, with 2 minutes of rest between exercises.
40600|NCT03866070|Other|Control|Two exercises will be done to strengthen the external rotation, using elastic bands. The first, standing, with 90 degrees of shoulder abduction and elbow flexion. The second, also in standing, with the shoulder in neutral position and the elbow flexed to 90 degrees. Subjects will perform 3 sets of 10 repetitions with the band slightly stretched, at a distance of 0.70 m from the wall. The band will be subject to a surface, at an equal distance from the subject's elbow to the ground. The repetitions will last one second in concentric external rotation and two seconds in eccentric external rotation, with a rest of 30 seconds between series.
40601|NCT03866031|Other|implant-supported mandibular overdenture|The implant-supported overdentures will be placed in immediate functional loading on the same day of implants placement. A direct restorative protocol will be applied to modify the existing prosthesis to implant-supported overdentures.
40602|NCT03866018|Other|Adapted physical activity|12 sessions of one hour of adapted physical activity.
40603|NCT03866005|Dietary Supplement|Diabetes Visual Function Study (DiVFuSS) softgels|The adjunctive nutritional supplement will be the multi-component formula used in the Diabetes Visual Function Supplement Study (Western IRB number 1129944 Olympia, WA), containing the macular carotenoids lutein and zeaxanthin, as well as antioxidants (vitamins B1, B12, C, D, E, lipoic acid, coenzyme Q10, resveratrol), omega3 fatty acids (EPA/DHA) and botanical extracts (Pycnogenol™ [patented extract of French maritime pine bark, Pinus pinaster], grape seed and green tea extracts, curcumin).
40604|NCT03866005|Other|canola oil placebo softgels, 2 per day|Placebo containing canola oil, 2 softgels per day
40605|NCT03865992|Dietary Supplement|Curcumin|Given capsules for oral administration
40606|NCT03865992|Other|Placebo|Given capsules for oral administration
40607|NCT03865992|Other|Nanoemulsion|Given nanoemulsion curcumin PO
40608|NCT03865992|Other|Quality-of-Life Assessment|Ancillary studies
40609|NCT03865992|Behavioral|Questionnaire|Ancillary studies
40610|NCT03865979|Device|Viz RECRUIT|Viz RECRUIT includes the following modules: Viz ICH, Viz VOLUME, Viz VIEW and Viz HUB
40611|NCT03865953|Drug|LAT8881|LAT8881 oral capsule
40612|NCT03865953|Drug|Placebo|Placebo oral capsule
40613|NCT03865940|Drug|Lidocaine|6 mL of 1% lidocaine
40614|NCT03865940|Drug|Guanfacine|250 mcg
40615|NCT03865927|Other|Placebo Oral Tablet|see Arm/Group description
40616|NCT03865927|Drug|GKT137831|GKT137831 is a NOX enzyme inhibitor
40617|NCT03865901|Diagnostic Test|Mellitus GCD59 Test|An ELISA for screening for the risk of gestational diabetes
40618|NCT03865888|Drug|Cyclosporins|Cyclosporins eye drops to be administered in dry eyes
40619|NCT03865888|Drug|Tacrolimus|Tacrolimus eye drops to be administered in dry eyes
40620|NCT03865875|Behavioral|Exercise Program|Participants will start the exercise program within 2 weeks of enrollment and will continue until surgery. This program will consist of twice weekly individualized sessions with a trainer.
40621|NCT03865875|Behavioral|Nutrition Program|Each patient enrolled will undergo nutritional assessment at their initial post-enrollment visit to develop an individualized nutrition plan to be implemented up until when the patient undergoes surgery.
40622|NCT03865862|Other|Experimental|The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
40623|NCT03865862|Other|Control|Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
40624|NCT03865849|Device|Cooled radiofrequent treatment|In the cooled radiofrequency group a treatment of 60°C measured at the tip and on average 80°C in the targeted tissue is applied during 150 seconds using the Coolief system.
40625|NCT03865849|Device|Conventional radiofrequent treatment|In the conventional radiofrequency group a treatment of 80°C at the tip is applied during 90 seconds at each nerve.
40626|NCT03865836|Biological|ATB200|
40627|NCT03865836|Drug|AT2221|
40628|NCT03865823|Procedure|pus sample|A pus sample from the fistula will be taken by the doctor during this first consultation or, failing that, in the operating room before disinfection.
40629|NCT03865797|Other|Experimental|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.The intervention will be done before the training session.
40630|NCT03865797|Other|Control active|Each session will last approximately 15 minutes, taking place during 2 days a week, in a period of 4 weeks. The intervention will be done before the training session. The intervention by motor control will consist of the application of a series of Core exercises. The objective of the application of these exercises is to increase the control of the Core, and therefore improve the stability both central and of members. The exercises will be carried out with the subjects in different positions of prone, lateral and supine position, for the Core musculature. The exercises (13) will be repeated 10 times each and there will be 8 different exercises: roll up, mermaid, raised crossed, stretch two leg back, shoulder bridge and leg pull up.
40631|NCT03865784|Other|Experimental|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done, proceed to ask the subject to lean forward applying the rest of the strip, except the distal edge, with a tension of between 15 and 25%, finally requesting the subject to rejoin straining the distal base without tension, on the twelfth dorsal spinous process.
40665|NCT03865511|Drug|TAGRISSO® 80mg (Osimertinib)|Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.
40693|NCT03865238|Biological|Placebo|Subjects are to receive a 0.5 mL IM injection of placebo. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to < 2 years of age will receive a booster vaccination on Day 366.
40694|NCT03865225|Other|Biofeedback|9 x 10 minutes biofeedback sessions over period of three days
40632|NCT03865784|Other|Control|The intervention through Core exercises will consist in the application of a protocol of four Core stabilization exercises. The objective of the application of the technique based on this type of exercise is to improve muscle strength, endurance and neuromuscular control. This protocol will consist of the following exercises: abdominal plate, bilateral plate, hunting dog and gluteal bridge. The intervention by Kinesiotape will be performed with the subject in a sitting position with both arms relaxed throughout the body, while the physiotherapist will place the bases of the strips without tension, on the sacroiliac joint. Once this is done the tape will be placed without tension and sn movement of the subject.
40633|NCT03865771|Behavioral|Neuropsychological testing|memory, executive testing, behaviour questionnaire, visual attention,
40634|NCT03865771|Behavioral|Neuropsychological procedure|Rey auditory verbal learning test, Delayed recall : 1h, 5h, 24h (after one night sleep)
40635|NCT03865771|Other|Video EEG and polysomnography|Video EEG : 10 electrodes + 3 electrodes for PSG 2h wake EEG Whole night EEG
40636|NCT03865758|Device|IN2L computer system|Therapists will use the IN2L computer system to choose videos, music, games and exercise specific to the rehabilitation needs and personal preferences of patients.
40637|NCT03865745|Dietary Supplement|Korean Red Ginseng|Take one pack of the product (3g) once a day for 24 weeks
40640|NCT03865719|Behavioral|Healthy Habits for Life|Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
40641|NCT03865706|Drug|Inulin Oral Suspension|Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube
40642|NCT03865706|Drug|Placebo Oral Suspension|250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor
40643|NCT03865706|Drug|Broad-spectrum antibiotics|Standard of care treatment for infections
40644|NCT03865693|Device|scarmbler therapy|Scrambler therapy is a patient-specific electrocutaneous nerve stimulation device.
40645|NCT03865680|Drug|CPP-ACP|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
40646|NCT03865680|Drug|Duraphat|The fluoride varnish applications will be applied with identical intensive protocols every 2 weeks for 6 weeks. The application of will be according to manufacturer's instructions.
40647|NCT03865667|Device|PROFEMUR® Preserve Femoral Stem|Total Hip Total Hip Arthroscopy
40648|NCT03865654|Other|Communication Tool|Summarizes recommendations for clinicians and patients for surveillance mammography and follow-up care for breast cancer survivors
40649|NCT03865641|Device|Virtual reality rehabilitation|Task-specific training has been shown to be more effective when tasks were ordered in a random practice sequence using repetition and positive feedback. VR is an interactive and enjoyable intervention. VR creates a virtual rehabilitation scene in which the intensity of practice can be systemically manipulated.
40650|NCT03865615|Drug|Oxytocin|intranasal oxytocin 40IU/mL
40651|NCT03865615|Drug|Placebo|Placebo
40652|NCT03865602|Behavioral|Sepsis Transition And Recovery (STAR)|In the STAR program intervention, a centrally located nurse navigator facilitates the application of four evidence-based core components of post-sepsis care (i.e., review of medications, new impairments, comorbidities, and palliative care) to patients prior to and during the 30 days after hospital discharge. The STAR navigator will provide telephone and EHR-based support within the hospitalization and to patients across all discharge settings with remote monitoring at specified intervals following hospital discharge. Patients will continue to receive STAR directed services for 30 days following their discharge and then will be transitioned back to the next appropriate care location.
40653|NCT03865602|Behavioral|Usual care|Patients and their providers will not have access to the STAR program. Patients will continue to receive usual care throughout their stay and discharge, consisting of: patient education and follow-up instructions at discharge, which are not specific to sepsis; routine recommendations for follow-up visits with primary care providers; arrangements for home health services or care management follow-up based on each patient's needs but not specifically tailored to the sepsis population; discharge to post-acute setting with no sepsis-specific follow-up. All aspects of usual care will be determined by treating clinicians independent of trial assignment.
40654|NCT03865589|Diagnostic Test|Ultrasound Elastography|Ultrasound shear wave elastography
40655|NCT03865576|Diagnostic Test|Non-invasive ICP measurement|Intracranial pressure will be measured non-invasively using transorbital Doppler ultrasound. Values will be compared to ICP measured by lumbar puncture or implanted ICP sensors
40656|NCT03865563|Drug|Retrograde venous infusion of gemcitabine/lipiodol|Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
40657|NCT03865550|Drug|Isotonic saline|Placebo
40658|NCT03865550|Drug|Ketamine Injectable Solution|Active comparator
40659|NCT03865537|Procedure|Cold snare EMR|Participants will have their large polyp removed without electrocautery
40660|NCT03865537|Procedure|Hot snare EMR|Participants will have their large polyp removed with electrocautery
40661|NCT03865537|Procedure|Eleview injection|Participants will have their polyp submucosally injected with Eleview
40662|NCT03865537|Procedure|Placebo injection|Participants will have their polyp submucosally injected with placebo
40663|NCT03865524|Device|Total knee arthroplasty implanted with GPS navigation system|Obese patients undergoing Total Knee Arthroplasty, GPS achieved alignment
40664|NCT03865524|Device|Total knee arthroplasty implanted with standard guides.|Obese patients undergoing Total Knee Arthroplasty, alignment achieved by using standard guides
40695|NCT03865225|Other|Sham-Biofeedback|9 x 10 minutes sham-biofeedback sessions over period of three days
40666|NCT03865511|Genetic|Tumor biopsies|"Tumor biopsies performed at baseline and clinical progression will be processed (fixed) on site, and sent to Nantes University Hospital for analysis.~The following analysis will be performed:~Analyses performed on a regular basis, in order to allow subsequent inclusion in other clinical trials :~C797S testing (digital PCR)~MET amplification (dPCR/FISH)~Histological examination of the tissue sample (to identify small cell transformation)~Expression of proteins by immunohistochemistry: PD-L1 (Ventana SP263 antibody); CD73 ; CD4; CD8.~At the end of inclusions, deep sequencing analysis to identify acquired mutations and copy number variations (amplifications)."
40667|NCT03865511|Genetic|ctDNA analysis|"ctDNA analysis by Collection of plasma (two 10-ml Streck tubes) at each time point indicated in the trial.~These samples will be sent at room temperature by courier to the central laboratory (Nantes University Hospital). There they will be centrifuged, and plasma will be frozen (-80°C).~Analyses :~Detection of the EGFR activating mutation in plasma at baseline By dPCR (characterization of patients enrolled)~Detection of the EGFR activating mutation at d7 and m1 by dPCR (early detection of response to osimertinib)~Analysis of the plasma samples collected at clinical progression in order to identify acquired mechanisms of resistance by NGS (and comparison with analysis of the biopsies).~Kinetics studies of the alterations"
40668|NCT03865498|Behavioral|Twitter for Hispanic caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our Hispanic Twitter network for social support
40669|NCT03865498|Behavioral|Twitter for African American caregivers|This group will be asked to follow and use (i.e., retweet, reply, like) our African American Twitter network for social support.
40670|NCT03865485|Behavioral|Parenting for Lifelong Health (PLH)|The Parenting for Lifelong Health (PLH) initiative is focused on the development, evaluation, and dissemination of parenting programs to reduce violence against children and improve child wellbeing in LMIC. It was established to address the need to develop low-cost, evidence-based parenting programs that can be integrated within existing service delivery systems in LMIC. The PLH for Young Children from 2-9 y. (PLH 2-9) program includes general content like one-on-one time/child-led play; praising and rewarding children; instructions, household rules, and routines; managing difficult behaviours: ignore and consequences; reflection and moving on. Core activities during sessions include group discussions illustrated vignettes, role-plays, collaborative problem solving, practicing skills at home.
40671|NCT03865472|Other|Questionnaire Administration|Ancillary studies
40672|NCT03865472|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
40673|NCT03865472|Procedure|Sham Intervention|Undergo sham rTMS
40674|NCT03865459|Other|Video group|Patients in the video group started to watch the relaxing video about 5-10 minutes before cystoscopy, and continued to watch video during the whole procedure.
40675|NCT03865446|Drug|Dacomitinib|anti-cancer agent
40676|NCT03865433|Other|Aerobic Exercise|Sub-symptom threshold aerobic exercise at a dose of 30 minutes per day, five days per week.
40677|NCT03865433|Other|Placebo/Stretching|A detailed, progressive stretching program to be performed for approximately 20-30 minutes per day, five days per week
40678|NCT03865407|Drug|Allopurinol|Allopurinol dosed to target uric acid levels of 3-5 mg/dL.
40679|NCT03865394|Biological|Application of autologous ADSC stem cells in fibrin gel|Chronic wounds in diabetic foot ulcer will be covered with ADSC suspended in fibrin gel - three doses will be administered at two weeks intervals.
40680|NCT03865394|Procedure|Standard care in diabetic foot ulcer|Chronic wounds in diabetic foot ulcer will be treated with standard procedure.
40681|NCT03865381|Device|Onduo App|The Onduo App is a software application which tracks data relevant to diabetes care, such as, but not limited to, medication, meal logs and glucose readings, and activity data. The Onduo App connects wirelessly to a Care Team Console through the Internet. The Onduo App may also connect wirelessly to commercially available FDA-regulated (i.e., cleared and approved) medical devices and non-medical devices through the subject's Smartphone.
40682|NCT03865368|Other|Whole Body Vibration Training|Whole Body Vibration Training (WBVT) method has been used as an alternative to conventional strengthening exercises. In this method, the patient stands on the platform of the WBVT device in a static position or performs dynamic exercises, the mechanical vibration produced by the device is transferred to the body
40683|NCT03865355|Other|Non- interventional|Translational, observational study
40684|NCT03865342|Behavioral|Noom Coach DPP|Subjects receiving the smartphone app will receive the DPP core curriculum for 16 weeks and then the post-core curriculum for 36 weeks through the app. The Noom mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve DPP goals. The participant can log their food intake, weight, steps, exercise, in addition to participating in the DPP group interaction through the application.
40685|NCT03865329|Behavioral|Intervention- Home-based Pulmonary Rehabilitation|Participants enrolled in the intervention arm will be offered a Home-based pulmonary rehabilitation program with health coaching.
40686|NCT03865316|Device|SedLine Vs Comparator Test Group|Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.
40687|NCT03865290|Drug|Ondansetron 8mg|Oral Ondansetron 8 mg
40688|NCT03865290|Drug|Placebo|Oral matched placebo
40689|NCT03865277|Radiation|standard radiochemotherapy or dose-escalated radiochemotherapy|"Patients will receive simultaneous radiochemotherapy, however the simultaneous chemotherapy is standard and not part of the evaluation in this trial. Present standard chemotherapy is cisplatinum 40 mg/m²/week (chemotherapy over the whole course of radiotherapy).~Radiotherapy is applied to doses of 54 Gy(RBE)/ 1.8 Gy(RBE) per fraction to the adjuvant region, 70 Gy(RBE)/ 2 Gy(RBE) per fraction to the tumor and involved lymphonodes and, if hypoxic and randomized to the intervention arm, 77 Gy(RBE)/ 2.2 Gy(RBE) per fraction to the primary tumor and lymphonode metastases > 2 cm.~Radiotherapy is always applied with 5 fractions per week."
40690|NCT03865264|Other|Recovery Enhancement Program|Behavioral, nutritional, physical and opioid-reduction pain medication
40691|NCT03865251|Device|Kinesiology tape|Application for 0%, 50%, and 100% of maximal KT stretch to the calf muscle during lying and standing positions
40692|NCT03865238|Biological|EV71vac|Subjects are to receive a 0.5 mL IM injection of EV71vac. Study drug is administered on Day 1 and Day 57 of the study. Subjects 2 months to < 2 years of age will receive a booster vaccination on Day 366.
40696|NCT03865212|Drug|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1|Given IT and IV
40697|NCT03865199|Behavioral|Narrative Intervention|"Participants in the intervention group will first view a digital story on a tablet with headphones that will combine a fictional patient's abortion story with basic medical and social facts regarding abortion. After viewing the narrative, participants will be asked to write a narrative either on a tablet provided or on paper with the prompt: Patients have different thoughts and feelings about their experiences when they have this procedure. Tell a story (about yourself or someone else, real or imaginary) that might help another patient feel supported."
40698|NCT03865186|Behavioral|Psychoeducation Program|"The program titled, Psychoeducation Program for Emotion Identification and Expression in Those Diagnosed with Schizophrenia was conducted with the patients in the intervention groups once a week for ten weeks."
40699|NCT03865186|Behavioral|no intervention|
40700|NCT03865173|Other|Telephone Interview|Telephone Interview
40701|NCT03865160|Drug|Atropine eye drops, 0.01%|One drop of the above mentioned drug will be installed into each at bedtime.
40702|NCT03865160|Drug|Placebo (NaCl 0.9%) eye drops|One drop of the above mentioned placebo will be installed into each at bedtime.
40703|NCT03865147|Drug|Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)|Investigational Drug
40704|NCT03865147|Drug|EMLA cream|Active Comparator
40705|NCT03865147|Drug|Post Operative Analgesia (Paracetamol, Ibuprofen)|Standard of Care
40706|NCT03865134|Diagnostic Test|Snellen Test|Visual acuity measurement
40707|NCT03865134|Diagnostic Test|Autorefractometer|Refraction measurement
40708|NCT03865134|Diagnostic Test|Titmus Stereo Fly Test|Stereopsis measurement
40709|NCT03865134|Diagnostic Test|Optical Kohlerans Tomography|Retinal development measurement
40710|NCT03865134|Behavioral|Investigation of Visual Motor Integration|Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
40711|NCT03865134|Behavioral|Peabody Developmental Motor Scales - II|Evaluation of motor development
40712|NCT03865134|Behavioral|World Health Organization Quality of Life - BREF|Assesment of quality of life
40713|NCT03865134|Behavioral|State - Trait Anxiety Inventory|Assesment of anxiety
40714|NCT03865121|Drug|Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)|Patients will receive incremental doses of Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY) starting with 3 bilateral puffs per day (3 mg total) for 3 days, followed by 5 bilateral puffs per day (5 mg) for 3 days, followed by 8 bilateral puffs per day (8 mg) for 4 days, followed by 10 bilateral puffs per day (10 mg) for 10 days.
40715|NCT03865108|Procedure|Ultrasound imaging|This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
40716|NCT03865108|Procedure|Cervical speculum examination|This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
40717|NCT03865082|Drug|Tilsotolimod|9 doses of Tilsotolimod Intratumoral injection administered as a dose of 8mg at Day -7 (7 days prior to the start of Cycle 1), Day 1 and Day 8 of Cycle 1, and on Day 1 of Cycles 2 through 7.
40718|NCT03865082|Drug|Nivolumab|Specified dose on specified days.
40719|NCT03865082|Drug|Ipilimumab|Specified dose on specified days.
40720|NCT03865069|Other|Mode of ventilation (Volume Guarantee)®|This is a volume-targeted mode of ventilation aimed at delivering the set tidal volume of gas by automatically adjusting the peak inspiratory pressure (PIP) on a breath-by-breath basis. Theoretically this should minimise variation in tidal volume delivery as lung compliance and the infant's condition changes. This function is achieved by an automated servo-controlled mechanism. The upper PIP limit can be set by the clinician as a safety mechanism.
40721|NCT03865069|Other|Mode of ventilation (Volume control Ventilation)|Volume-Controlled ventilation (VCV) is a type of 'volume targeted' mode. It aims to target be supported the desired tidal volume by delivering a set volume (chosen by the clinician) irrespective of the underlying lung mechanics. The ventilator will generate whatever peak inspiratory pressure is necessary to deliver this volume. There is constant inspiratory flow pattern (a square flow waveform) and peak volume and inspiratory pressure delivery are achieved at the end of inspiration. During the 'control period' of 12 hours without VG, infants will using VCV A/C (assist control) as is our current clinical standard.
40722|NCT03865056|Device|Optiflow (High-flow Nasal Cannula)|Optiflow will be applied for 20 minutes
40723|NCT03865056|Device|Non-invasive Ventilation|non-invasive ventilation will be applied for 20 minutes
40724|NCT03865030|Device|audiovestibular function|"Hearing test- includes a pure tone audiometry, speech audiometry and discrimination level.~tympanometry- Includes inserting headphones into the participants ears and computer calculation the compliance of the eardrum.~otoacoustic emission: Includes headphones insertion and calculation of the inner ear audiological function.~Video head impulse test.~- Dizziness handicap inventory questionnaire. questionnaire filled by the participants provides a subjective data regarding the severity of the dizziness."
40725|NCT03865017|Biological|Regulatory T cells|The trial will be carried out in Alzheimer's disease patients. The investigators will isolate CD4+CD25+ Tregs from these patients, expand and injection.
40726|NCT03865017|Other|Saline|Saline+cell suspension solution infusion
40727|NCT03865004|Drug|Paracetamol+Morphine|1gr paracetamol plus 0.1 mg/kg morphine were performed simultanously
40728|NCT03865004|Drug|Dexketoprofen plus Morphine|Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
40729|NCT03865004|Drug|Placebo plus Morphine|100 cc NaCl plus 0.1 mg/kg morphine were performed simultanously
40730|NCT03864991|Device|e-device for step count (fit-bit)|Patients in this group will receive fitbit device to count their daily steps and record it into their log books.
40731|NCT03864991|Behavioral|e-messages for log book|Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.
40732|NCT03864991|Behavioral|e-messages for log book & fit-bit|Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.
40733|NCT03864978|Drug|Rifaximin delayed release 400 mg tablet|Rifaximin delayed release
40734|NCT03864978|Drug|Placebo|Placebo
40735|NCT03864965|Other|Advance Care Planning|The provider will guide advance care planning conversations with patients identified with mild or moderate dementia during their third office visit, approximately three months after the first visit.
40736|NCT03864939|Drug|dHAM|A dehydrated human amnion membrane (dHAM, 1x3cm) is placed around the neurovascular bundle (NVB) on the left and right side and vesicourethral anastomosis (VUA) during radical retropubic prostatectomy (RRP).
40737|NCT03864939|Drug|No dHAM|A standard radical retropubic prostatectomy (RRP) without dHAM is performed (Walsh, 2005).
40738|NCT03864926|Drug|Envarsus XR|"Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR."
40739|NCT03864926|Drug|Tacrolimus|Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
40740|NCT03864913|Drug|Testosterone injection|SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
40741|NCT03864913|Behavioral|PedsQL questionnarie|Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
40742|NCT03864913|Other|Masculinizing effects questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
40743|NCT03864913|Other|Medication experience questionnaire|Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
40744|NCT03864900|Behavioral|The medication adherence intervention|The health belief model based medication adherence intervention comprised two main components: a 60-minute individual face to face instruction and six follow-up telephone calls.
40745|NCT03864887|Procedure|Oxygen supply of high-low-high procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 60% FIO2 (phase I, high oxygen), half-hour measurement at 40% FIO2 (phase II, low oxygen) and half-hour measurement at 60% FIO2 (phase III, high oxygen).
40746|NCT03864887|Procedure|Oxygen supply of low-high-low procedure|The protocol consisted of 1-hour resting, 3-minute baseline measurement, half-hour measurement at 40% FIO2 (phase I, low oxygen), half-hour measurement at 60% FIO2 (phase II, high oxygen) and half-hour measurement at 40% FIO2 (phase III, low oxygen).
40747|NCT03864887|Device|Optical monitor for hemodynamic parameter.|Near infrared spectroscopy probes of tow wavelengths were attached on the subjects' foreheat to detect the changes of hemodynamic parameters.
40748|NCT03864874|Diagnostic Test|Intraoperative intracavitary lung ultrasonography|Ultrasonography on the deflated lung for detection of lung nodules
40750|NCT03864822|Device|High-Definition Transcranial Direct Current Stimulation|Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
40751|NCT03864809|Behavioral|sleep disturbance|we observe sleep disturbance among patients with psoriasis and atopic dermatitis and control group
40752|NCT03864783|Dietary Supplement|Curcumin (Meriva®)|"Experimental drug:~Meriva® 500 mg tablet (contains 1 mg curcumin)"
40753|NCT03864783|Drug|Placebo Oral Tablet|"Placebo:~Contains same ingredients as Meriva®, apart from curcumin. Similar in appearance to Meriva®."
40754|NCT03864770|Device|Extracorporeal shock wave therapy|Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
40755|NCT03864770|Procedure|General physical therapy|The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
40756|NCT03864757|Device|thyroplasty implant|Short-term implantation of thyroplasty implant, VOIS, and evaluation of voice quality and glottal closure. After evaluation, remove VOIS and perform medialization of vocal folds using conventional thyroplasty.
40757|NCT03864731|Device|Bone conduction device (ADHEAR)|adhesive bone conduction device
40758|NCT03864718|Procedure|photodynamic therapy|Intralesional 5-aminolevulinic acid gel 2% was directly injected into the fistula. The internal and external orifices were closed. After an incubation period of 2 h, the fistula was irradiated using an optical fibre connected to a red laser (MULTIDIODE 630 PDT, INTERmedic, Spain) operating at 1 W/ cm for 3 min (180 Joules).
40759|NCT03864705|Diagnostic Test|Measurement of plasma metformin levels|Subjects on chronic metformin therapy will have their plasma metformin levels measured during a regular check-up with glycated hemoglobin assessment.
40760|NCT03864679|Other|Exercise|Subjects will perform a cycling test with 5 min incremental intensity exercise and 1 h cycling test exercising at a moderate-intensity (load will be selected in incremental intensity exercise).
40761|NCT03864666|Drug|Cilostazol 100 mg|One Cilostazol 100 mg at 08:00 and another at 20:00, two oral doses (total daily dose of 200 mg)
40762|NCT03864666|Drug|PMR 200 mg|Two PMR 200 mg at 08:00, single oral dose (total daily dose of 400 mg)
40806|NCT03864341|Behavioral|Substance use services|Referral to substance use services (SBIRT and peer counselor/social work contact) available at Bellevue Hospital
40763|NCT03864653|Behavioral|MoodGym|"MoodGym is a preexisting Internet-based CBT program that uses interactive content and character-driven narratives to help alleviate symptoms of depression and comorbid anxiety. The program also aims to improve the individual's functioning by promoting the development of skills and strategies to manage depression.~MoodGym consists of an introduction module, five structured intervention modules, and a workbook of assessments. Each MoodGym session takes place entirely on an Internet-connected tablet while in the physical co-presence of a Study Counselor, who can answer questions should they arise. Each session takes approximately one hour to complete."
40764|NCT03864627|Drug|MOR106|MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
40765|NCT03864627|Drug|Placebo|Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).
40766|NCT03864614|Drug|SAGE-217|SAGE-217
40767|NCT03864601|Drug|14C-JNJ-56136379|14C-JNJ-56136379 25 mg dose formulated as a polyethylene glycol (PEG)-based oral solution containing 3,145 kilo Becquerel (kBq) of 14C labeled JNJ-56136379, with a maximal total radiation burden of 1,000 micro Sievert.
40768|NCT03864588|Drug|Ropivacaine|For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
40769|NCT03864575|Drug|Celecoxib 400 mg|Celecoxib 400 mg/day in combination with nivolumab fixed dose
40770|NCT03864549|Dietary Supplement|Femina II|2 capsules per day until delivery
40771|NCT03864549|Other|Placebo|2 capsules per day until delivery
40772|NCT03864536|Behavioral|Cognitive Prescriptions|Personalized information on their risk factor profile across five CogRx domains (physical activity, cognitive activity, diet, sleep, social activity) and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home.
40773|NCT03864523|Drug|Pioglitazone|
40774|NCT03864497|Procedure|Myocardial perfusion imaging|
40775|NCT03864484|Device|iPad Application + Usual Rehabilitation|The experimental group receives usual rehabilitation. In addition, the experimental group will watch movies using the iPad application for 3 minutes, once daily for 5 weeks.
40776|NCT03864484|Behavioral|Usual rehabilitation|The control group receives usual rehabilitation.
40777|NCT03864471|Other|HCOACDM|The intervention, the HCOACDM, involves case screening, comprehensive assessment, and care coordination, and will be given over a 6-month period.
40778|NCT03864471|Other|Routine care|The routine care services include home visits, telephone checkups, meals on the wheel, and health promotion activities.
40779|NCT03864458|Drug|KHK7791|oral administration
40780|NCT03864458|Drug|Placebo|oral administration
40781|NCT03864445|Drug|KHK7791|oral administration
40782|NCT03864445|Drug|Placebp|oral administration
40783|NCT03864432|Drug|Gemigliptin 25mg|Gemigliptin 50mg 1/2T
40784|NCT03864432|Drug|Gemigliptin 50mg|Gemigliptin 50mg 1T
40785|NCT03864432|Drug|Gemigliptin 100mg|Gemigliptin 50mg 2T
40786|NCT03864432|Drug|Gemiglptin 50mg multiple dose|Gemigliptin 50mg 1T * 10days
40787|NCT03864419|Biological|Rituximab or Rituximab Hyaluronidase Human|Given IV or SC
40788|NCT03864419|Drug|Cyclophosphamide|Given IV
40789|NCT03864419|Drug|Vincristine|Given IV
40790|NCT03864419|Drug|Methotrexate|Given IV
40791|NCT03864419|Drug|Doxorubicin|Given IV
40792|NCT03864419|Drug|Doxorubicin Hydrochloride|Given IV
40793|NCT03864419|Drug|Prednisone|Given PO
40794|NCT03864419|Drug|Etoposide|Given IV
40795|NCT03864406|Drug|Tybost (Cobicistat)|Each tablet of Tybost contains 150 mg of cobicistat.
40796|NCT03864406|Drug|Prezcobix (Darunavir/Cobicistat)|Each tablet of Prezcobix contains 800 mg of darunavir and 150 mg of cobicistat.
40797|NCT03864406|Drug|Xarelto (Rivaroxaban)|Each tablet of Xarelto contains 10 mg of rivaroxaban.
40798|NCT03864406|Drug|Eliquis (Apixaban)|Each tablet of Eliquis contains 5 mg of apixaban.
40799|NCT03864393|Other|Multimodal overground locomotor training|Locomotor training sessions use various movement drills emphasizing power, stability, and stepping in a specific direction: forward, backward, lateral, rotational. Sessions also have an additional focus on gait initiation or steady-state walking. After circuit-style warm up exercises, participants perform overground movement drills that are specific to the emphasis of the individual training session, culminating in practicing everyday overground walking. Participants wear a heart rate monitor to ensure that the majority of the training session is performed at an aerobic intensity greater than 60% age predicted heart rate maximum (220-age +/- 5 bpm).
40800|NCT03864380|Diagnostic Test|Color retinography|Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
40801|NCT03864380|Diagnostic Test|OCT-A|Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
40802|NCT03864380|Diagnostic Test|Blood pressure measurement|Blood pressure measurement within 1 month before and within 1 hour after the marathon
40803|NCT03864367|Device|Device - Prism Medical FGA-700 Bariatric Floor Lift|This group will be using a Mobile Weight-Support Therapy (MWeST) device (the Prism Medical FGA-700 Bariatric Floor Lift) to determine if it improves mobilization of older patients with traumas of their legs.
40804|NCT03864354|Procedure|Osteopathic Manipulative Treatment|Osteopathic Manipulative Treatment (OMT) is a cost-effective, noninvasive treatment that is used to optimize the body's structure and function. By improving the biomechanical, autonomic, and circulatory mechanisms involved in the disease process of asthma, OMT can help maximize respiratory function. The specific OMT protocol used in this study included the following: supine OA joint myofascial release (MFR), supine cervical spine Still technique, supine thoracic inlet MFR, supine rib raising soft tissue, supine rib MFR, supine abdominal diaphragm MFR, seated thoracic spine Still technique, and seated posterior rib Still technique. Treatments were performed by Predoctoral Osteopathic Manipulative Medicine (OMM) Fellows at Des Moines University (DMU) and supervised and checked by one of two board-certified OMM/NMM physicians from the OMM Department at DMU. The treatment lasted an average of 21 minutes and repeated three times, spaced one week apart.
40805|NCT03864341|Behavioral|Referral to homelessness prevention services|Referral to Homebase homelessness prevention services offered by community-based organizations in NYC
40846|NCT03864042|Drug|rosuvastatin|taken orally
40807|NCT03864341|Behavioral|Follow-up|Follow-up to assist participants in receiving homelessness prevention services
40808|NCT03864328|Drug|RVT-1601|Inhaled RVT-1601 administered TID via eFlow nebulizer
40809|NCT03864328|Drug|Placebo|Inhaled Placebo administered TID via eFlow nebulizer
40810|NCT03864315|Device|HGM|To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study
40811|NCT03864302|Behavioral|Motor Imagery|Motor imagery (MI) is a psychological technique for improvement of motor skills.(24) MI skill training (MIST) has been used and explored in several disciplines including Sports, Music, Education, Psychology and Medicine.(18) The literature has found positive effects on performances in professional athletes but also on rehabilitation of stroke patients.(25,26) MI is a cognitive imagery of a physical performance, e.g. a high jumper imagine a high jump, prior to performance. MI is not as effective as physical practice, but more effective compared to no training.(27) Further, MI combined with physical practice has been found to be more effective in skill performance in sports compared to physical practice alone.(18) MIST has shown promising results on surgical performances in flexible cystoscopy performed by doctors.(28)
40812|NCT03864289|Behavioral|Parent skills training|Parents of children with autism spectrum disorder attend the parental training course once a week, and there was a total of eight courses with each course lasting 3 hours
40813|NCT03864276|Drug|inhalation (desflurane) group|Anesthesia is induced and maintained with desflurane and sufentanil
40814|NCT03864276|Drug|total intravenous (propofol) anesthesia|Anesthesia is induced and maintained with propofol and sufentanil
40815|NCT03864250|Drug|Tacrolimus|The initial dose of TAC is 0.05-0.1 mg/kg/d, taking 2 hours before and after meals. The interval is strictly 12 hours. The blood concentration is measured after taking the drug. According to the concentration of blood drug valley, the dose of tacrolimus (blood concentration of ≤10ng/ml) is adjusted. If the blood drug concentration is low, the drug dose (≤0.1mg/kg/d) is increased accordingly. After 6 months of treatment, the drug is discontinued. The TAC dose is maintained at the original dose after 6 months of treatment with complete or partial remission of urinary protein until the end of the 48-week trial.
40816|NCT03864250|Drug|Prednisone|The initial dose of prednisone is 0.5 mg/kg/d orally (maximum dose 40 mg/d), and after 8-12 weeks, the dose was gradually reduced until discontinuation. TAC treatment is given at the same time (the treatment plan is the same as the experimental group).
40817|NCT03864237|Behavioral|Alcohol texts|A text message each day for 10 weeks, containing factual information about campus drinking norms.
40818|NCT03864237|Behavioral|Attention control|"A text message each day for 10 weeks, containing this day in history facts."
40819|NCT03864224|Behavioral|GLA:D Back|GLA:D Back is a 10-week program based on first-line recommendations of patient education and structured exercise taught in a group format.
40820|NCT03864211|Procedure|Thermal ablation|Radiofrequency ablation or microwave ablation is performed under CT or ultrasound guidance for one to three target lesions. Toriplimab will be administrated within 5-10 days after ablation.
40821|NCT03864211|Drug|Toriplimab|All enrolled patients received toriplimab infusions 3mg/Kg once every 2 weeks infusions once every 2 weeks.
40822|NCT03864198|Dietary Supplement|Genante|A dietary supplement for male infertility
40823|NCT03864185|Biological|Rituximab (genetical recombination)|Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.
40824|NCT03864185|Other|Placebo|Administer placebo IV infusion once weekly for 4 doses.
40825|NCT03864172|Dietary Supplement|Usual intake + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice
40826|NCT03864172|Dietary Supplement|Usual intake+SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF)
40827|NCT03864172|Dietary Supplement|Adequate calcium + placebo fruit juice|Participants will consume 200 mls of placebo fruit flavoured juice added with 600 mg calcium to meet RNI
40828|NCT03864172|Dietary Supplement|Adequate calcium+ SCF fruit juice|Participants will consume 200 mls of fruit flavoured juice containing 12 g soluble corn fiber (SCF) added with 600 mg calcium to meet RNI
40829|NCT03864159|Other|Suction cups|The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member. The intervention through the suction cups will be performed with the subject in prone position, on the stretcher. The suckers are placed in the proximal part where the posterior musculature of the leg originates and in the distal part of the biceps femoris, semitendinosus and semimembranous insertion. This administration of the suckers will be applied during a period of 7 minutes in each member.
40830|NCT03864159|Other|Foam roller|Each session will last 18 minutes, taking place two days a week, in a period of 4 weeks. The intervention will be carried out before starting the training session. The intervention through the self-administration of Foam roller has the objective of increasing the flexibility of the isquitibial musculature. The technique will be performed with the subject sitting on the floor, placing the Foam roller on the back of the thigh, requesting the athlete to perform cranial and caudal movements during the established time. The stretching exercise with the Foam roller will be done during 2 minutes in each member.
40831|NCT03864146|Behavioral|Brief Behavioral Compliance Enhancement Treatment|This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
40832|NCT03864133|Drug|Omidria|Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.
40833|NCT03864094|Drug|Ephedrine|0,1 mg/kg
40834|NCT03864094|Drug|Phenylephrine|1 microg/kg
40835|NCT03864094|Drug|Norepinephrine|0,1 microg/kg
40836|NCT03864094|Drug|Sodium chloride|0,1 ml/kg
40837|NCT03864094|Drug|Propofol|2 mg/kg
40838|NCT03864094|Drug|Remifentanil|1,7 microg/kg
40839|NCT03864068|Other|Placebo|Placebo
40840|NCT03864068|Drug|Inositol powder|1gm/bid, 2gm/bid or 3gm/bid of Inositol powder
40841|NCT03864042|Drug|losartan|taken orally
40842|NCT03864042|Drug|dextromethorphan|taken orally
40843|NCT03864042|Drug|caffeine|taken orally
40844|NCT03864042|Drug|omeprazole|taken orally
40845|NCT03864042|Drug|midazolam|taken orally
40851|NCT03864029|Drug|KUVAN|retrospective data on the effectiveness of past treatment with KUVAN®. It includes blood Phe level, physical development status, intelligence development status, etc., during treatment with KUVAN
40852|NCT03864016|Drug|Induction and maintenance of anesthesia|The hypnotic agent used is Propofol and the morphine agent used is Sufentanil.
40853|NCT03864016|Drug|Adaptation of sufentanil doses according to the usual protocol|At induction the target concentration of sufentanil is 0.5 ng/ml. The sufentanil dose is decided by the anaesthetist, taking into account the operating times (induction, TIO, incision, opening and sternal spacing, CEC, closure), the usual data provided by the monitoring: heart rate, blood pressure, BIS, EtCO2, modification of insufflation pressures.
40854|NCT03864016|Drug|Adjustment of sufentanil doses according to pupillometry|At induction, the target concentration of sufentanil is 0.5 ng/ml. The dose of sufentanil is then adjusted according to the dilation reflex obtained with the PPI (Pain Pupillary Index) at predefined times.
40855|NCT03864003|Behavioral|Community Health Workers and Teleaudiology as a Culturally-Relevant Approach to Improving Access to Hearing Health Care|In this project, remote hearing aid fittings will be delivered by an audiologist with patient-site support from a local facilitator for a cohort of older adults (>50 years) from a rural area that has been identified as under-resourced for hearing health care.
40856|NCT03863990|Drug|PAH medication|Any PAH-targeted medication
40857|NCT03863977|Drug|Dexamethasone|After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
40858|NCT03863977|Drug|Bupivacaine|After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
40859|NCT03863964|Diagnostic Test|blood test|8 blood samples will be drawn: 1 at time of admission, then 15 min, 30min, 1h, 1.5h, 2h, 2.5h, and 3h post-treatment with TXA. Blood samples will be processed for ROTEM® analysis and for plasma concentration of TXA. TXA plasma concentrations will be modeled with a non-linear mixed-effects strategy using Monolix 4.1 and NONMEM(®) 7.2.
40860|NCT03863938|Drug|Tegoprazan 50mg|K-CAB
40861|NCT03863925|Device|Target controlled infusion, Schnider model|Target controlled infusion (TCI) is an intravenous drug delivery system estimating pharmacokinetics after input of patient's data, e.g. age, sex, body height, body weight. Schnider model is one of TCI model to deliver Propofol. After target concentration at effect site (e.g. the brain) is keyed in, the computerized infusion pump will calculate dosage of bolus and infusion rate for each individual, and calculated concentration of propofol at plasma and brain will be displayed. The clinicians should evaluate the patient's sedation level in response to calculated propofol concentration and titrate target concentration to achieve desired sedation level.
40862|NCT03863925|Behavioral|Bolus injection of Propofol|Bolus intravenous injection is a traditional way to deliver anesthetic, and the dosage and amount of medication is based on clinical experience and patients' response.
40863|NCT03863912|Other|Disney movie|Disney movie on portable DVD Player.
40864|NCT03863912|Other|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys|EORTC QLQ-C30 and EORTC QLQ-FA12 surveys
40865|NCT03863899|Procedure|Nerve block|drug mixture: 10-15 ml 0.5% bupivacaine plus 5 ml 1% lidocaine plus 1 mg dexamethasone plus 50 ug adrenaline
40866|NCT03863899|Procedure|Local infiltration|15-20 ml of mixture of 0.5% bupivacaine and 1% lidocaine (1:1)
40867|NCT03863899|Procedure|TAVI|Insertion of an aortic valve prothesis through the aorta accessed through femoral artery
40868|NCT03863899|Drug|Additional intraoperative analgesia|Administration of any analgesics during the operation
40869|NCT03863899|Drug|Additional postoperative analgesia|Administration of any analgesics within first 24 hours after the operation
40870|NCT03863886|Procedure|Endoscopic ultrasound catheter (UM-2R/3R, Olympus)|A miniprobe ultrasound catheter (UM-2R/3R, Olympus) will be passed into the colonoscope's accessory channel at the time of colonoscopy to measure the thickness of the different colon wall layers (mucosa, submucosa, muscular propria, and total wall thickness) in the cecum and rectum.
40871|NCT03863873|Procedure|Platelet-Rich Plasma Injection Group|Platelet-Rich Plasma Injection Group
40872|NCT03863860|Drug|Fluzoparib capsules|Fluzoparib capsules
40873|NCT03863860|Drug|Placebo capsules|Placebo capsule
40874|NCT03863847|Procedure|Neurofeedback|The patients will receive neurofeedback on pain related brain-activity, and through training, learn to control said brain-activity.
40875|NCT03863847|Procedure|Sham|The patients will receive sham neurofeedback on non-pain related brain-activity, and through training, learn to control said brain-activity.
40876|NCT03863834|Device|InModeRF|InModeRF minimally invasive treatment based on Radiofrequency-assisted lipolysis (RFAL) technology
40877|NCT03863821|Device|HHHFNC|"HHHFNC setting:~Flow rate: 40L/min~FiO2: 0.4~HHHFNC will use 30-min before 6-MWT and 30-min after 6-MWT"
40878|NCT03863808|Behavioral|Cognitive Behavioural Therapy|"Following assessment a one on one session will be given comprising education cognitively targeting false ideas and beliefs on the nature of pain, differentiating nociception due to a painful stimulus and the transition of such a stimulus to a centrally sensitized experience due to misinformation, maladaptive behaviour and fear avoidance. Upon completion of the session assessment using the NPQ will be done to assess the understanding of the patient and further address any shortcomings in future exercise sessions.~Another SEMG recording of the Flexion Relaxation phenomenon will be upon completion of the educational session and a SEMG biofeedback session will begin to help the patient regain their sense of control over their body and function.~After the SEMG biofeedback session a graded exposure exercise program of strengthening and functional training starting from the least feared movements to the most over 10 sessions over 5 weeks."
40879|NCT03863808|Other|Strengthening exercises|Strengthening exercises in a gradual manner to the Multifidus and Transversus Abdominis muscles.
40880|NCT03863795|Other|Survey Administration|Respond to SurveyGizmo survey online
40881|NCT03863782|Other|No intervention|No specific intervention. Collection of clinical data
40882|NCT03863769|Other|Lumbar Spinal Stenosis|Posture and Performance testing: ABC-6 Scale, low back pain NRS, buttock or leg pain NRS, five times sit-to-stand, timed up-and-go, PGIC, eyes open force plate assessment (30 seconds), and eyes closed force plate assessment (30 seconds).
40883|NCT03863756|Radiation|EOS|The new EOS-technology (EOS imaging, Paris, France) based on a low-dose X-ray system allows 3D modeling of the spine based on 2-dimensional
40948|NCT03863288|Drug|Oxytocin intranasal spray 80IU|Oxytocin intranasal spray liquid administration
40884|NCT03863743|Other|integrated care pathway|Incidence of POUR after undergoing total hip or knee replacement and integrated care pathway will be evaluated.
40885|NCT03863743|Other|physician's standard of care|Incidence of POUR will be evaluated in standard of care treatment.
40886|NCT03863730|Dietary Supplement|Profermin Plus, FSMP, probiotics|Participants will have to supply their normal intake with Profermin Plus, FSMP, Prbiotics product twice every day for 24 weeks.
40887|NCT03863730|Dietary Supplement|Fresubin, dietary supplement|Participants will have to supply their normal intake with the control product, Fresubin, dietary supplement twice every day for 24 weeks.
40888|NCT03863717|Other|Arm Endurance Exercise Training|Pulmonary Rehabilitation Program including Upper Limb Endurance Exercise Training with arm cycle ergometer
40889|NCT03863717|Other|Control|Pulmonary Rehabilitation Program without Upper Limb Endurance Exercise Training
40890|NCT03863704|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|To apply transcutaneous electrical stimulation using a TENS unit to the ear or the leg.
40891|NCT03863691|Drug|Amisulpride 300 MG|A single dose of 300 mg amisulpride that looks identical to placebo control capsules.
40892|NCT03863691|Drug|Placebo oral capsule|A placebo capsule with no inert pharmacological effect. Looks identical to the amisulpride capsules.
40893|NCT03863678|Other|Neurodevelopemental therapy (NDT)|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions).
40894|NCT03863678|Other|Neurodevelopemental therapy (NDT) and dry needling|NDT treatment will be given for 45 minutes, 3 sessions per week in 4 weeks period (total of 12 sessions). Dry needling will be applied on M. Gastrocnemius, M.Quadriceps, M.Flexor Carpi Radialis, and M.Biceps Brachii muscles, 60 seconds (sec) for each muscle groups at the end of the NDT treatment.
40895|NCT03863665|Device|A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci|Telemetric home monitoring is a promising strategy to facilitate home BP monitoring after stroke, which should improve adherence and optimize medication to better control BP. Telemetry allows patients with hypertension to monitor their own BP and automatically send the information to a secure website, available to their clinicians to monitor and adjust their treatment.
40896|NCT03863652|Procedure|Percutaneous coronary intervention via snuffbox approach|After local anesthesia on left or right anatomical snuffbox with lidocaine hydrochloride using a 26 gauge needle, the puncture is performed using a 20 gauge needle with the through-and-through puncture technique or a 21 gauge open needle with anterior wall puncture technique. After successful puncture, 0.025-inch straight wire or 0.018-inch hair wire are inserted, followed by an insertion of the 5Fr. or 6Fr radial sheath (Prelude® Radial; Merit medical, UT, USA or Radifocus® Introducer II or Glidesheath Slender®; Terumo Corporation, Tokyo, Japan). The selection of puncture device is at physician discretion.
40897|NCT03863639|Diagnostic Test|Neuroimaging Procedures|"Subjects will complete neuroimaging procedures at 2-6-week postpartum or during hospitalization after delivery prior to discharge, which will consist of high-resolution anatomic, perfusion and resting-brain fMRI sequences; all of which will be acquired on a 3-Tesla General Electric magnetic resonance scanner~provided by the Brain Imaging and Analysis Center (BIAC) at Duke University. No contrast agent will be administered in these imaging procedures."
40898|NCT03863639|Diagnostic Test|Neuropsychological Assessment Procedures|Once identified as meeting study criteria and consented for participation, parturients will be tested during hospitalization or as outpatients for controls, and at 2-6 weeks postpartum with the following cognitive battery. Wechsler Test of Adult Reading (WTAR), CANTABeclipse Computerized Cognitive Assessment Measures, Stroop Color-Word Test, Controlled Oral Word Association Test, EuroQol, Beck Depression Inventory Revised
40899|NCT03863626|Other|Frusemide IV shots|"giving frusemide by IV shots~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade comparing its administration timed 60 minutes prior to the morning Frusemide shot versus given after. (This will be in a second level of randomization)"
40900|NCT03863626|Other|Frusemide IV infusion|"giving frusemide by continuous IV infusion~And if developed diuretic resistance (diminishing diuretic effect despite incremental dose of IV loop diuretic), adjuvant oral Metolazone will be given for sequential nephron blockade"
40901|NCT03863613|Device|Pessary|A soft, flexible, silicone pessary (Arabin®, Dr Arabin GmbH & Co KG, Germany) will be inserted through the vagina, upward around the cervix.
40902|NCT03863613|Procedure|Cervical cerclage|Cervical cerclage using Mc Donald technique, under anaesthesia
40903|NCT03863613|Drug|Vaginal progesterone|Cyclogest® 400mg, Actavis, United Kingdom, applied once daily at bedtime
40904|NCT03863600|Behavioral|Midwife-led continuity of care|Midwives from governmental hospitals provide antenatal and postnatal case-load-care in rural villages governmental clinics
40905|NCT03863587|Biological|HLX12|healthy volunters receive HLX12 (8mg/kg) once
40906|NCT03863587|Biological|Cyramza (Ramucirumab)|healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
40907|NCT03863574|Drug|Saroglitazar Magnesium 2mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.
40908|NCT03863574|Drug|Saroglitazar Magnesium 4mg|Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.
40909|NCT03863574|Drug|Placebos|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
40910|NCT03863561|Behavioral|Diabetes self-management education (DSME) program|Diabetes educators customized care paths for their patients based on their individual responses to the SCPI questions. Patients met with an educator five to seven times over the course of three to four months.
40911|NCT03863548|Other|complication|collection of post-operative bleeding complications
40912|NCT03863535|Drug|Conbercept|Participants were randomized (1:1) to receive IVC+PRP or PRP monotherapy. Patients in IVC+PRP group with diabetic macular edema (DME) received 3 monthly IVC injections along with standard PRP within 1 week after the first injection. Those without DME received 1 lVC injection and standard PRP within 1 week after the injection . Re-treatments in both groups were at the investigators'discretion.
40913|NCT03863535|Procedure|Panretinal coagulation|The PRP monotherapy group received standard PRP between day 1 and month 2; thereafter, re-treatments in both groups were at the investigators'discretion.
40949|NCT03863288|Drug|Placebo|Placebo intranasal spray liquid administration
40914|NCT03863522|Procedure|Fine needle aspiration|Fine needle aspiration is a type of biopsy procedure to diagnose suspicious lesions. After giving numbing medicine, a thin needle is inserted into the breast to obtain a sample. This procedure is followed by the standard of care and will last about 10 minutes. The sample will be analyzed by a diagnostic cartridge and by the cytopathologist.
40915|NCT03863522|Device|Cancer Detection cartridge|The Cancer Detection cartridge has the ability to measure methylated gene changes in breast cells. The device will not be in contact with the patients. The FNA samples will be smeared on a slide which will be placed into the cartridge for analysis.
40916|NCT03863509|Behavioral|Cigarettes|smokes daily
40917|NCT03863509|Behavioral|E-Cigarettes|E-cigarette usage >/= 5 days/week
40918|NCT03863496|Procedure|Scoliosis surgery|All patients will be implanted with telescopic connector Medtronic CD Horizon Legacy 4.5 and 5.5 under X-ray control (C-arm), intraoperative spinal deformity surgery safety control (NIM Eclipse, Stealth Station S7) and standard anesthetic support.
40919|NCT03863483|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
40920|NCT03863483|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
40921|NCT03863483|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
40922|NCT03863483|Drug|Placebo|0.9% sodium chloride injection as placebo will be administered intravenously at a fixed dose of 100 milliliters (mL) on Day 1 of each 21-day cycle.
40923|NCT03863470|Behavioral|Early mobilization intervention|The intervention consists of 3 components: 1) A simplified mobilization goal (using the Surgical Optimal Mobility Score) will be defined during daily morning ward rounds and displayed on the doors of patients' rooms; 2) a facilitator will communicate to the care team regarding mobility goals; 3) clinicians will receive feedback on patient's mobility as mobility scores will be made available electronically on the ICU board - a dashboard for monitoring patient care in the ICU
40924|NCT03863457|Drug|Fluoroglutamine [18F]F-GLN|Evaluate the kinetics and biodistribution of [18F]F-GLN in primary and metastatic breast cancer.
40925|NCT03863444|Other|Prenatal Preparation Education|Intervention, provided by researchers, includes video, counseling, and skill practices. Video contains (1) Newborn Reaction, including rooting reflex, correct latch-on posture, assuring newborn having enough milk intakes; (2) Newborn Care, including holding, dipper-changing, clothes-changing, and swaddle the newborn; and (3) Partner Support, including the importance of partner support and the content how partner provide support to the postpartum women. After watching the video, the researcher will provide participants counseling, and then each pair of participants will have skill practice.
40926|NCT03863444|Other|Routine care|Routine care, provided by clinic nurses, includes antenatal breastfeeding education (i.e., providing education sheet, explaining the benefits and importance of breastfeeding, exclusive breastfeeding for six months, responsive breastfeeding, maintaining milk production, immediately skin-to-skin touch after delivery, and room-in) and demonstration of newborn care (i.e., newborns holding posture, breastfeeding holding posture, and newborn latch-on posture) by pictures and baby models.
40927|NCT03863431|Other|High-fat diet|"Participants will consume a high fat diet for 14 days with approximately 65% of energy from fat. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
40928|NCT03863431|Other|High-carbohydrate diet|"Participants will consume a high fat diet for 14 days with approximately 70% of energy from carbohydrate. The diet will also provide an energy excess, at 130% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
40929|NCT03863418|Dietary Supplement|Lactobacillus rhamnosus GG|PROBIOTIC
40930|NCT03863418|Other|placebo|placebo
40931|NCT03863405|Drug|Metformin|metformin 850 mg bid for RA patients with moderate to high disease activity provided by DAS-28 score greater than 3.2
40932|NCT03863405|Drug|Conventional DMARDs|methotrexate, leflunomide, hydroxychloroquine or sulfasalazine
40933|NCT03863405|Drug|Placebo Oral Tablet|oral tablet
40934|NCT03863392|Drug|Misoprostol|induction of labor
40935|NCT03863379|Diagnostic Test|whole body DXA|Measurements of body composition may be used to study how lean body mass and body fat change during health and disease and have provided a research tool to study the metabolic effects of obesity and various wasting conditions. DXA measurements are based in part on the assumption that the hydration of fat-free mass remains constant at 73%.
40936|NCT03863366|Drug|Prucalopride|1mg prucalopride tablet, encapsulated in white capsule
40937|NCT03863366|Other|Placebo|Lactose placebo tablet, encapsulated in white capsule
40938|NCT03863353|Behavioral|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
40939|NCT03863340|Behavioral|interruptions of work tasks|"During each activity two interruptions/breaks were selected randomly from a set of ten predetermined actions:~Active break types:~Move shoulder and upper back~Swing arms near the body~Three slow but forceful elevations of the shoulders, a relaxation exercise based on the principles developed by Jacobson~Stand up and stretch~Slowly turn head in all possible directions.~Passive break types:~Tell a couple of jokes~Stand up and have a drink~Relaxing the trapezius~Questions on actual posture and feelings of comfort / discomfort.~A short rest on the couch"
40940|NCT03863327|Other|No intervention|There will be no intervention as a part of this protocol.
40941|NCT03863314|Device|Virtual Simulation|Virtual simulation of workplace-related scenarios of pre-recorded videos using the same actors
40942|NCT03863314|Other|In-person Simulation|In-person simulation of workplace-related scenarios with live actors
40943|NCT03863301|Radiation|MR-guided single dose preoperative PBI|A single dose of 20Gy to the gross tumor volume (GTV) is prescribed, to the clinical target volume (GTV + 20mm margin) 15Gy is prescribed.
40944|NCT03863288|Procedure|fMRI|functional mri (fMRI) scan with affective/cognitive tasks
40945|NCT03863288|Drug|Oxytocin Intranasal Spray 10IU|Oxytocin intranasal spray liquid administration
40946|NCT03863288|Drug|Oxytocin intranasal spray 24IU|Oxytocin intranasal spray liquid administration
40947|NCT03863288|Drug|Oxytocin intranasal spray 48IU|Oxytocin intranasal spray liquid administration
76374|NCT03586973|Drug|Cabozantinib|Cabozantinib tablet
40950|NCT03863275|Device|functional apparatus|The EMG activity will be recorded during different shots: T0. The activity of the muscles of the mastication in the position of clinical rest for a minute, in maximum intercuspidation. (It will be measured with a dynamometer to standardize the force), and with the use of the equipment. T1 The patient's citation is scheduled six months after the use of myofunctional device Sn1 and the test will be performed again measuring electrical activity of right and left masseter and right and left temporal muscle at clinical rest for one minute, in maximum intercuspation, and with the use of the equipment To avoid the effects of fatigue, a rest period of at least 5 minutes between each of the recordings will be allowed
40951|NCT03863275|Other|Diagnosis and observation|Six months of observation in the control group: patients group the efforts are controlled. to obtain models and have an observation of the molar classification, and to verify if the terms of the inclusion in the study are taken into account, once it is confirmed that the activity is observed in the muscular activity of the chewing muscles, in two stages , at the beginning of the session and six months later. .
40952|NCT03863249|Procedure|SCALE AND ROOT PLANING|"SRP will be performed two quadrants at a time under local anaesthesia at approximately weekly intervals.~Each session will be carried out with the following materials: - Ultrasound device (SONICflex 2003 / L) and curettes (Hu-Friedy Manufacturing, Illinois, USA)."
40953|NCT03863249|Drug|ADJUNTIVE ANTIBIOTICS|"The antimicrobial adjunctive agents selected by 'Echevarne' laboratories analysis will be started at the second SRP visit.~The antibiotic will be selected among AMOXICILIN, METRONIDAZOLE, AMOXICILIN + METRONIDAZOLE AND AZITROMYCIN."
40954|NCT03863249|Diagnostic Test|MICROBIAL SAMPLING|"Before treatment, the 10 deepest interproximal sites in each quadrant will be selected and exposed to microbial sampling. Two sterilized paper points will be inserted into the pocket of each site and will be keep in place for 60 s. The twin paper points will be remove and distributed in two vials and transfer for microbiological processing.~The subgingival microbiota will be harvested from the sampling sites 2 months after the completion of active therapy."
40955|NCT03863236|Dietary Supplement|regular diet|The control group (group 1) will continue their regular diet.
40956|NCT03863236|Dietary Supplement|nutritional support Resource 2.5|The intervention group (group 2) will get preoperative nutritional support (Resource 2.5 Compact/fibre combact) two weeks before the operation and the nutritional support will continue 10 days after the operation.
40957|NCT03863223|Drug|Pyrotinib, Trastuzumab, Docetaxel|Pyrotinib 400mg orally daily until progressive disease
40958|NCT03863223|Drug|Placebo, Trastuzumab, Docetaxel|Placebo 400mg orally daily until progressive disease
40959|NCT03863210|Other|"60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk"|"All participants were exposed to the intervention. The intervention consisted of a 60-minute lecture titled Change of lifestyle and nutrition habits to reduce cardiovascular risk. The lecture was delivered in family medicine offices by four specialists of family medicine individually to the groups of 6-8 participants. The lecture was verbal, harmonized among four family physicians, and contained instructions for changing nutrition habits, smoking habits and instructions for increasing physical activity. At the end of the lecture, each participant received a personally tailored decision aid, which included the list of her risk factors, assessment of the 10-year risk of fatal CVD (based on the data provided by the participants before the lecture), and instructions on what she should do in terms of changing the lifestyle habits."
40960|NCT03863197|Behavioral|Progressive strength training|Progressive Supervised Home-based Strength Training
40961|NCT03863184|Drug|Acalabrutinib|Acalabrutinib, oral, 100 mg BID, continuous
40962|NCT03863184|Drug|Lenalidomide|Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles
40963|NCT03863184|Drug|Rituximab|Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
40964|NCT03863171|Diagnostic Test|Arterial spin labeling (ASL) magnetic resonance imaging|Arterial spin labeling (ASL) magnetic resonance imaging test
40965|NCT03863171|Diagnostic Test|Fundus fluorescein angiography|Fundus fluorescein angiography test
40966|NCT03863158|Other|No intervention|No intervention / medical records only
40967|NCT03863145|Drug|CB-03-10|CB-03-10, 100 mg capsule for oral use
40968|NCT03863132|Device|TAVR|Repair of defective aortic valve by microsurgical Intervention.
40969|NCT03863119|Drug|Vamorolone|2.0 mg/kg/day, 4.0 mg/kg/day, or 6.0 mg/kg/day at physician discretion
40970|NCT03863106|Other|Metastatic gastroenteropancreatic and lung neuroendocrine tumors|Patients with metastatic GEP and lung NETs will be selected via the Cancer Database on NEN of the Hospices Civils de Lyon. Data from this database will be matched with the French nationwide claims and hospitalization database (SNDS database), allowing access to the corresponding healthcare resources use and their related costs. Data regarding clinical and tumour characteristics and treatments patterns will be collected via the database between 1 January 1990 and 31 of December 2017.
40971|NCT03863093|Device|Electro Medical Systems AIRFLOW®|An erythritol powder will be used by Electro Medical Systems AIRFLOW® and then Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
40972|NCT03863093|Device|Electro Medical Systems Piezo|Electro Medical Systems Piezo will be used for supra- and subgingival ultrasonic instrumentation
40973|NCT03863080|Drug|RVT-1401|Subcutaneous administration of RVT-1401
40974|NCT03863080|Drug|Placebo|Subcutaneous administration of Placebo
40975|NCT03863067|Procedure|Epiduroscopy|Using epiduroscopy to treat the ligamentum flavum hypertrophy with Resaflex ,an instrument with Quantum Molecular Resonance for tissue coablation.
40976|NCT03863054|Device|NATROX™ Topical Oxygen Therapy System|"A small battery-powered electrochemical oxygen generator to concentrate atmospheric oxygen and feed to wound site through a dressing-like oxygen distribution system"
40977|NCT03863041|Other|Additional sequence performed during MRI scan|An additional sequence will be performed during the MRI scan.
40978|NCT03863028|Other|Simulation training|It is not a randomized trial - all three groups are exposed to simulation training.
40979|NCT03863015|Drug|Tocilizumab 20 Mg/mL Intravenous Solution|Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion
40980|NCT03863015|Drug|isotonic saline|A one hour infusion of 100mL isotonic saline
41044|NCT03862482|Device|Brånemark 2, Swede-Vent 1, Screw-Vent 2.|Brånemark implant placed at sites 1 and 4, Swede-Vent implant placed at site 3, Screw-Vent implant placed at sites 2 and 5.
40981|NCT03863002|Biological|Mesenchymal Stem Cell|Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
40982|NCT03862989|Procedure|Radiofrequency catheter ablation|A catheter is inserted into the heart and signals are recorded from the heart whilst at rest or whilst being stimulated by a catheter, in order to determine the site to ablate. Radiofrequency is then delivered to the target site in order to disrupt the pathological electrical activation which is causing the abnormal heart rhythm.
40983|NCT03862976|Diagnostic Test|computerized cardiotocography|computerized cardiotocography (C-CTG)
40984|NCT03862963|Behavioral|Standard of diabetes care|The standard of diabetes care consisted of standard treatment protocols used by the MOH Diabetes Clinic. These included placing T2D patients on anti-hyperglycemic agents appropriate to their HbA1c levels (including sulfonylureas, metformin, and insulin) and providing oral and written information about the importance of maintaining a healthy weight, eating a healthy diet, and getting regular exercise. Participants in the control group were instructed not to make changes in their diet and activity levels during the study.
40985|NCT03862963|Behavioral|Lifestyle Intervention|The lifestyle intervention consisted of a high-fiber, low-fat, mostly plant-based diet and 30-60 minutes per day of culturally-relevant, moderate intensity exercise. Participants initially received 12 weeks of group educational classes and some prepared meals and then followed the lifestyle intervention on their own for the remaining 12 weeks. Group classes included informative sessions on healthy eating, exercise (both aerobic and strength training), and stress management, as well as hands-on cooking classes. Classes were delivered as a combination of PowerPoint presentations, practical workshops, dine-outs, shopping tours, and cooking classes with spouses.
40986|NCT03862950|Drug|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
40987|NCT03862950|Drug|Metformin|Active medication
40988|NCT03862937|Dietary Supplement|Exercise training + whey protein|Whey protein (2x / day - 20g for breakfast and 20g for dinner).
40989|NCT03862937|Other|Exercise training + placebo (maltodextrin)|Maltodextrin (2x / day - 20g for breakfast and 20g for dinner).
40990|NCT03862924|Device|Standardized Research Electronic Cigarette|Participants will receive SREC weekly and eill be encouraged to replace their usual combustible cigarette with the SREC whenever they would normally smoke.
40991|NCT03862911|Radiation|palliative radiotherapy|Radiotherapy for patients in the standard arm should follow the principles of palliative radiotherapy as per the individual institution, with the goal of alleviating symptoms or preventing imminent complications. Patients in this arm should not receive stereotactic doses or radiotherapy boosts. Recommended dose fractionations in this arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
40992|NCT03862911|Radiation|Stereotactic ablative radiotherapy|"Lung:~Tumors 5 cm or less surrounded by lung parenchyma 48 Gy/4# 12, or 54 Gy/3# 18, daily or every second day Within 2 cm of mediastinum or brachial plexus 60 Gy/8# 7.5, daily~Bone: Any bone 35 Gy/5# 7, or 24 Gy/2# 12, daily Brain: Stereotactic lesions (no whole brain RT) <2cm 24 Gy/1# 24, once 2-3 cm 18 Gy/1# 18, once Metastases only: 35Gy/5# to metastases 7 Gy to PTV, daily Whole brain + Mets: 35Gy to metastases 7 Gy to PTV, daily 20 Gy whole brain 4 Gy WBRT, daily Liver: 54 Gy/3# 18, every second day Adrenal: 60 Gy/8# 7.5, daily Lymph Node: 40 Gy/5# 8, daily"
40993|NCT03862898|Other|Lumbar stabilization exercises|Patients performed exercises to stabilize and strengthen paravertebral muscles. Three sets of ten repetitions with a minute break between each.
40994|NCT03862885|Drug|Avapritinib|Avapritinib will be administered orally (PO) at a dose of 300 mg once daily (QD) in continuous 28-day cycles.
40995|NCT03862872|Dietary Supplement|Anti-Aging Formula|Anti-Aging Formula contains 1050 mg of EPA and 350 mg of DHA from anchovies, sardines, and/or mackerel whole body oil, 120 mg of GLA from Borage (Borago officianalis) seeds, 2.5 mg of zeaxanthin from Capsicum annuum L. fruit, 5 mg of lutein from Tagetes erecta flower, and 25 μg (1000 IU) of vitamin D3 (cholecalciferol) from lanolin per 4 capsule daily dose. This dosage form is the same as is commercially marketed in Canada under license Natural Product Number (NPN) 80077254.
40996|NCT03862872|Dietary Supplement|Control Fish Oil|The control fish oil is a soft gelatin capsule containing 1,106 mg of triglyceride fish oil from anchovies, sardines, and/or mackerel whole body oil. A four capsule per day dose provides 816 mg EPA and 572 mg DHA, which is only slightly less EPA+DHA than is provided within a four capsule per day dose of Anti-Aging Formula. This minor difference would not be expected to alter clinical outcomes.
40997|NCT03862872|Other|Inert Placebo|The inert placebo is a soft gelatin capsule containing 1040 mg of corn oil.
40998|NCT03862859|Drug|Warfarin|Dose adjusted Warfarin targeting an international normalized ratio of 2-3.
40999|NCT03862846|Drug|REN001|Once daily
41000|NCT03862833|Drug|IL2|"Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40"
41001|NCT03862833|Drug|Zoledronic Acid|4 mg at day +15 post graft
41002|NCT03862820|Diagnostic Test|dynamic ultrasound|move abdomen with ultrasound probe to predict intraabdominal adhesions
41003|NCT03862807|Drug|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
41004|NCT03862794|Behavioral|new social norm feedback letter with bar chart|letter with the percentile prescribing the practice is on and a bar chart, comparing prescribing to the national average
41005|NCT03862794|Behavioral|standard social norm feedback letter|social norm feedback letter used as standard practice, without specific information about the prescribing percentile
41006|NCT03862781|Procedure|Right Hemicolectomy|Minimally invasive approach (robotic or laparoscopic) with the creation of an anastomosis.
41007|NCT03862768|Procedure|surgery|Surgery requires at least removal of all drug-resistant lesions.
41008|NCT03862768|Drug|Imatinib 400 MG|Imatinib 400 MG/d should be taken once the patients resume oral diet
41009|NCT03862768|Drug|Imatinib escalation|Imatinib 600 MG/d
41010|NCT03862768|Drug|Sunitinib|Sunitinib 37.5 MG/d
41045|NCT03862469|Procedure|Blood Draws|8 blood draws over one menstrual cycle
41046|NCT03862456|Other|Azithromycin|azithromycin (500 mg/24h/3 days)
41047|NCT03862456|Other|Metronidazole|metronidazole (500 mg/8h/7 days)
41187|NCT03861390|Drug|60 mg Prednisone|Immediately following exit from the wood smoke chamber, subjects will receive 60 mg of prednisone per randomization schema
41011|NCT03862755|Drug|Chemoprophylaxis with Low Molecular Weight Heparin (LMWH)|Early chemoprophylaxis means low-molecular weight heparin (LMWH) 3075 IU (WHO Units) injection subcutaneously QD no later than 24 hours after surgery. Early ambulation means activity out of bed no later than 24 hours after surgery. According to different risk level, patients received different thromboprophylaxis strategies. Early ambulation alone was for patients at low risk (Caprini 0-4), early chemoprophylaxis plus early ambulation was for patients at moderate (Caprini 5-8) or high risk (Caprini ≥9).
41012|NCT03862729|Procedure|Minimally invasive surgery|Intracranial hematoma will be removed by intraoperative stereotactic computer tomography-guided endoscopic surgery, or surgical aspiration followed by alteplase clot irrigation (1·0 mg every 8 h for up to nine doses). CTA will be performed before operation in all the patients for intraoperative navigation, and the minimally invasive surgery will be performed within 24 hours after intracerebral hemorrhage onset.
41013|NCT03862729|Procedure|conventional treatment|Conventional treatment includes medical treatment and conventional craniotomy.
41014|NCT03862716|Drug|IDegLira|Dose is titrated to achieve fasting normoglycemia
41015|NCT03862716|Drug|insulin degludec|In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.
41016|NCT03862716|Drug|Metformin|Dose is titrated to 2000 mg per day or maximal tolerated dose
41017|NCT03862716|Behavioral|Lifestyle Therapy|Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving
41018|NCT03862703|Device|mHealth intervention, PTSD Help app.|Experimental group will receive the app, PTSD Help.
41019|NCT03862690|Drug|BIAsp 30|Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
41020|NCT03862677|Other|No intervention|Observational study, no intervention
41021|NCT03862664|Procedure|Collection of data|The investigators will retrieve retrospectively the medical record of donors who underwent hepatic lobectomy for liver transplantation
41022|NCT03862651|Drug|Cangrelor|Cangrelor is an intravenous analog of adenosine triphospate with a potent, selective and specific affinity for P2Y12 receptors.
41023|NCT03862638|Other|Yoga Therapy|Yoga therapy is therapeutic application of yoga, specifically designed to treat the condition using physical posture, breathing exercises, guided relaxation and meditation.
41024|NCT03862625|Device|a modular adaptive seating system|
41025|NCT03862625|Other|home exercise program for scoliosis|
41026|NCT03862612|Procedure|regional anaesthesia with Levobupivicaine 0.25% 30mls with two methods either erector spinae plane block or serratus anterior plane block|Erector Spinae Plane Block will be compared to the Serratus Anterior Plane Block in patients undergoing Video assissted thoracic surgery
41027|NCT03862599|Device|Extra-corporeal shockwave therapy (ESWT)|low-intensity extra-corporeal shockwave therapy
41028|NCT03862599|Other|Standard care|Cialis and vacuum pump
41029|NCT03862586|Drug|N-acetyl cysteine|
41030|NCT03862586|Drug|Placebos|
41031|NCT03862573|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
41032|NCT03862560|Other|Strength training program|Strength training program in female soccer players
41033|NCT03862547|Diagnostic Test|A peripheral blood sample from the cubital vein|"Evaluation of NGF and Cytokine levels A portion of each blood sample and medium conditioned by PBMC will be used for the enzyme immunoassay of NGF and pro and anti-inflammatory cytokine levels (TNF alfa and IL-10).~Expression analysis of TrKA and p75NTR receptors and intracellular cytokines in PBMCs The remaining part of each blood sample and PBMC of the in vitro experiment will be used for the cytofluorimetric evaluation of the expression of TrKA, p75NTR and the pro and anti-inflammatory cytokines and reactive oxygen species."
41034|NCT03862534|Procedure|CAF|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised, coronally advanced and sutured to cover the recession
41035|NCT03862534|Procedure|CAF + CTG|After the cementum enamel junction (CEJ) was restorated, a split thickness flap was raised. Then a connective tissue graft was harvested from the palate and sutured over the exposed root. Finally the flap was coronally advanced and sutured to cover the recession
41036|NCT03862521|Other|Low carbohydrate diet|Low carbohydrate diet
41037|NCT03862521|Other|Very low carbohydrate diet|Very low carbohydrate diet
41038|NCT03862508|Other|Plyometric exercises|"Jump Drop Jump, dropping the subject from a height of 30cm and then make a vertical jump.~Long jumps asking the athletes to take momentum and make a leap forward trying to reach the greatest possible distance.~Jump Countermovement jump unilaterally, alternating the lower extremities. Jumps 180º with the athletes maintaining a semi-squat position. Jump Countermovement jump repeatedly starting from an upright position and the upper extremities in both hips.~All the exercises will be done through 8 repetitions per session during the first two weeks, increasing two repetitions every two weeks (until reaching 12 repetitions at the end of the intervention).~For the realization of each one of the exercises, the ballasted weight will be used (Powerinstep® model)."
41039|NCT03862495|Diagnostic Test|C. trachomatis and N. gonorrhoeae|In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
41040|NCT03862495|Drug|Azithromycin|Azithromycin 1g administered as a single oral dose
41041|NCT03862495|Other|Partner notification and treatment|Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
41042|NCT03862482|Device|Brånemark 2, Swede-Vent 2, Screw-Vent 1.|Brånemark implant placed at sites 2 and 5, Swede-Vent implant placed at sites 1 and 4, Screw-Vent implant placed at site 3.
41043|NCT03862482|Device|Brånemark 1, Swede-Vent 2, Screw-Vent 2.|Brånemark implant placed at site 3, Swede-Vent implant placed at sites 2 and 5, Screw-Vent implant placed at sites 1 and 4.
41048|NCT03862443|Behavioral|Fixed Incentive|The Fixed Incentive intervention is a fixed reward, in which participants are eligible for fixed weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
41049|NCT03862443|Behavioral|Drawing Incentive|The Drawing Incentive intervention is a drawing reward, in which participants are eligible for weekly payments based on toothbrushing performance collected through smart powered toothbrush synced to a smartphone app.
41050|NCT03862430|Drug|NVX-108|0.1 mL/kg (2% w/vol emulsion)
41051|NCT03862430|Drug|Placebo Saline Infusion|0.1 mL/kg Saline Infusion
41052|NCT03862417|Other|Schroth exercises|An exercise program begun individually and then continued in groups.
41053|NCT03862404|Drug|Bupivacaine-epinephrine|See previous description
41054|NCT03862404|Drug|Normal saline|See previous descreption
41055|NCT03862391|Drug|Analgesics|while patients are in the PACU after general anesthesia, if patients' VAS scores are higher than 3, we will give them 50 mg of deksketoprofen as analgesic.
41056|NCT03862391|Drug|Antiemetics|while patients are in the PACU after general anesthesia, if patient' Nausea and vomiting scores are higher than 1, we will give them 4 mg of ondansetron
41057|NCT03862365|Genetic|Nerve conduction Studies|Patients will be genotyped for comparison of patients With and without pain, With different clinical subgroups as mentioned.
41058|NCT03862352|Device|Covered coronary stent|Insertion of covered coronary stent as part of standard care
41059|NCT03862326|Behavioral|Exercise|From lying to sitting to active exercises with focus on the pelvic floor
41060|NCT03862313|Device|active-rtACS treatment|For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
41061|NCT03862313|Device|sham-rtACS treatment|For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
41062|NCT03862287|Drug|Lidocaine|See arm description.
41063|NCT03862287|Drug|Bupivacaine Hcl 0.5% Inj_#2|See arm description.
41064|NCT03862274|Other|CLN2 Treatment|Patients that have a TPP1 enzyme deficiency and/or confirmed molecular diagnosis of pathogenic variants in the TPP1 gene are eligible to participate if they are receiving cerliponase alfa.
41065|NCT03862261|Other|Integrated pediatric TB services|"pediatric TB services will be integrated into key child healthcare services: maternal neonatal and child health (MNCH) services, under-5 clinic, pediatric outpatient services, nutrition services, pediatric antiretroviral therapy (ART) services and primary health care:~Integration of the screening into all the child health care services with introduction of a specific case detection tool and updated presumptive TB register.~Improvement of diagnosis capacities and their integration in all levels of care and all services."
41066|NCT03862248|Drug|6EH³RZ|New high-dose isoniazid retreatment regimen (6EH³RZ) - H 15mg/kg
41067|NCT03862248|Drug|6EHR³Z|New high-dose rifampicin retreatment regimen (6EHR³Z) - R 30mg/kg
41068|NCT03862248|Drug|6EHRZLfx|WHO levofloxacin-strengthened regimen (6EHRZLfx)
41069|NCT03862235|Diagnostic Test|Cardiovascular Magnetic Resonance|The patients underwent to CMR examination on a Philips Achieve 1.5 device. Images were acquired coupled to the electrocardiogram and during respiratory pause, in four chambers, short axis and long axis of the left ventricle, in the same exact location in different sequences. A gradient - echo sequence (steady-state free precession) was used to evaluate cardiac function (functional evaluation). We will also evaluate T1 weighted images (T1 -relaxation times) and T2, performed sequentially, through spin-echo pulse (black-blood), triple inversion recovery sequence, for the morphological evaluation
41070|NCT03862235|Diagnostic Test|Transthoracic echocardiography|The images were collected by the Vivid E9. The patients were submitted to one-dimensional (M-mode), two-dimensional (B-mode), and three-dimensional (three-dimensional) echocardiographic studies. The images obtained were associated with pulsed, continuous and color Doppler.
41071|NCT03862222|Other|Retinal Imaging|Retinal imaging will be conducted on the Heidelberg SPECTRALIS (FDA 510k cleared) device, routinely used in clinical care in ophthalmology. Optical Coherence Tomography (OCT) and Angiography (OCT-A) sequences will be conducted, as well as a sequence examining macular pigment (MPOD).
41072|NCT03862222|Other|Pupillometry|Participants will complete a task studying pupillary response to light
41073|NCT03862222|Other|Contrast Sensitivity|Participants will complete a task evaluating contrast sensitivity
41074|NCT03862222|Diagnostic Test|Neuropsychological Evaluation|Neuropsychological evaluation will be completed, including testing in domains of memory, executive function, visuospatial ability, language, processing speed. Results will be used for research purposes only.
41075|NCT03862222|Genetic|APOE genotyping|APOE genotyping will be completed during screening to assign participants to the correct group. Results will not be shared with participants as part of the study.
41076|NCT03862222|Other|blood draw|Blood will be drawn and banked for proteomic, biomarker, and GWAS analysis
41077|NCT03862222|Other|Gait Assessment|Gait assessment will be conducted by trained researcher
41078|NCT03862222|Other|Actigraphy|Actigraphy monitors will be worn by all participants for 2 weeks after each visit to examine physical activity, movement, and sleep patterns.
41079|NCT03862209|Other|Community mental health team|CMHT will provide home-based treatment inclusive of crisis resolution services and procedures for early recognition of subclinical psychosis and bipolar disorder, and intensive case management. Integrated care (i.e. health and social care interventions) will be provided to all clients. Furthermore, health and social care evidence-based interventions for severe mental illness (SMI) will be employed during home treatment, such as family-based interventions, motivational interviewing, and cognitive behavioural therapies, combined with medication management and identifying employment (paid and non paid options) and support in finding and maintaining this employment, recovery groups and housing opportunities.
41119|NCT03861871|Drug|Fenfluramine Hydrochloride|Oral Solution 2.5mg/mL
41274|NCT03860844|Drug|Etoposide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41080|NCT03862196|Behavioral|Tailored text messages to improve retention in HIV care|Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.
41081|NCT03862183|Other|continuing medical education program|educating all the involved doctor the same medical knowledge on hypertension control
41082|NCT03862170|Drug|Ciprofloxacin|Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy
41083|NCT03862170|Drug|Cefazolin|
41084|NCT03862157|Drug|Azacitidine|Given IV or SC
41085|NCT03862157|Drug|Pevonedistat|Given IV
41086|NCT03862157|Drug|Venetoclax|Given PO
41087|NCT03862144|Drug|Netupitant/Palonosetron|
41088|NCT03862131|Device|MyoStrain®|MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
41089|NCT03862118|Other|PRP|platelet rich plasma will be delivered by intradermal method using mestherapy needle.
41090|NCT03862105|Other|Mobile Health app tool - Twistle|The investigators propose to use radical cystectomy as a model to examine the utilization of an electronic, internet-based mobile health intervention that can prospectively collect Patient Reported Outcome data while providing timely feedback to patients and clinicians. This mobile health intervention will utilize a well-established platform (Twistle) that can be accessed through multiple technologies, including laptops, smartphones, and other computer-based systems.
41091|NCT03862092|Diagnostic Test|Salivary VZV DNA PCR|Varicella-zoster virus (VZV) DNA PCR of saliva sample
41092|NCT03862079|Other|Best Practice|Given standard of care
41093|NCT03862079|Procedure|Fecal Microbiota Transplantation|Undergo FMT
41094|NCT03862079|Drug|Nystatin|Given PO
41095|NCT03862079|Drug|Piperacillin-Tazobactam|Given PO
41096|NCT03862066|Other|Blood collection|5 milliliters (mL) of blood will be collected at the time of surgery
41097|NCT03862066|Other|Tissue collection|Left over tissue will be collected at the time of surgery
41098|NCT03862053|Drug|Manuka honey|manuka eyedrops applied to the ocular surface
41099|NCT03862040|Drug|Cefiderocol|Administered intravenously, at a dosage determined based on renal function.
41100|NCT03862040|Drug|Standard of Care Antibiotic|Standard of care antibiotic treatment for pneumonia
41101|NCT03862027|Device|Esophageal Balloon catheter|"Pressures [Esophageal Pressure (Pes), Airway Pressure (Paw), and Transpulmonary Pressure (Ptp)] are measured directly through the ventilator. The waveforms of Paw, Pes, and Ptp will be visualized on the ventilator. Ptp is obtained from Paw - Pes. All patients will have baseline measurements recorded of ICP, CPP, and MAP.~PEEP will be increased on the ventilator to achieve a Ptp between 0 and +2 cm H2O (Optimal PEEP).~Measurements of Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and mean arterial pressure (MAP) will be repeated 5 minutes after the change in PEEP."
41102|NCT03862014|Device|SDF only|Molar with MIH will be treated with SDF
41103|NCT03862014|Device|SDF+ARR|Molar with MIH will be treated with SDF+ARR
41104|NCT03862001|Behavioral|LungCARE|"The LungCARE intervention involves patient and PCP components. The patient component consists of watching a short, educational video, answering questions about lung cancer screening preferences, and receiving a patient report and handout.~The PCP component consists of receiving a similar report (physician report) prior to the patient visit. This report is based on the patient's risk factors and lung cancer screening preferences. It contains additional information about documenting discussions related to risk, screening, and referrals in the electronic medical record system."
41105|NCT03861988|Drug|Ketamine|0.5 mg/kg over 40 minutes, intravenous.
41106|NCT03861988|Drug|Normal saline (placebo)|Normal saline infusion over 40 minutes, equivalent volume to ketamine infusion.
41107|NCT03861962|Other|"DNA sequencing called new generation (or NGS)"|"Redo HLA-typings with a method exploring all the genes (add DQA1, DRB3 / 4/5, DPB1 and DPA1), i.e. DNA sequencing called new generation, when this has not been done after the graft as part of the standard care"
41108|NCT03861949|Other|5 cmH2O CPAP|
41109|NCT03861949|Other|head-up position|
41110|NCT03861936|Biological|Botulinum toxin type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1.
41111|NCT03861936|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles on Day 1.
41115|NCT03861910|Dietary Supplement|hypoallergenic formulas|hypoallergenic formulas used for cow milk allergy treatment
41116|NCT03861897|Other|KRP-NI + KM|Non instrumental pleural chest physiotherapy (KRP-NI), 2 sessions a day on weekdays and 1 session a day on weekends and mobilization physiotherapy (KM), 1 session per day except weekend during the hospitalization. The combination of the two physiotherapy is KRP-NI + KM. Afterward, 3 sessions per week, renewable until M3 of non instrumental pleural respiratory physiotherapy. If necessary the doctor can prescribe sessions of mobilization physiotherapy
41117|NCT03861897|Other|KM|Mobilization physiotherapy (1 session per day except weekend) during the hospitalization. Afterward, if necessary the doctor can prescribe sessions of mobilization physiotherapy(KM).
41118|NCT03861884|Diagnostic Test|Cognitive assessments|Cognitive assessment and MRI at 3T and/or 7T
41120|NCT03861858|Behavioral|DBT-A|DBT-A is a multimodal therapy which consists of weekly individual therapy, weekly multifamily skills groups, as needed phone coaching, and weekly consultation team for the therapists.
41121|NCT03861845|Device|Standard off-the-shelf pillbox|Then the participant will receive a store bought one-dose per day pillbox.
41122|NCT03861845|Device|Custom off-the-shelf pillbox|Then the participant will be administered an off-the-shelf pillbox that was purchased specifically for the participant's preferences, routine, medication regimen, and skills/abilities.
41123|NCT03861845|Device|Custom designed and manufactured pillbox|Then the participant will describe any design preferences for the pillbox. The researcher will design and manufacture the pillbox using a 3D printer, publically available 3D printing object repository, and computer aided design software.
41124|NCT03861845|Behavioral|Education & Training|The participant will receive education and training on how to use the pillbox and how to incorporate the pillbox and taking medications into their daily routine.
41125|NCT03861845|Behavioral|Reflection on medication routines|The participant will reflect on his or her daily routine, medication regimen, and use of existing pillboxes. The participant will also engage in a hands-on standardized pillbox task.
41126|NCT03861832|Dietary Supplement|KB220Z|Acts to enhance dopamine
41127|NCT03861832|Dietary Supplement|Placebo|A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
41128|NCT03861819|Behavioral|Vigorous-intensity interval training (VIIT)|Subjects will be fitted with a heart rate monitor around the chest and a baseline 4ml blood sample will be drawn. Vigorous intensity interval training will correspond to heart rate (HR) range of 80-90% of heart rate at age-predicted heart rate maximum (220-age). After approximately 5 minutes of warmup subjects will perform 10 intervals of VIIT: 30 seconds of vigorous intensity exercise followed by 60 seconds of rest. Rated Perceived Exertion (RPE) will be rated by 15-point Borg scale; should correspond to HR/10 at end of each interval. The subject will self-adjust the intensity of the exercise bouts and will be encouraged by the researcher to achieve the desired intensity. The exercise session will finish with a short cool-down period and will last no more than 25 minutes in total. A 4ml blood sample will be drawn immediately following the exercise session and 2-hours after exercise cessation.
41129|NCT03861806|Behavioral|PAS true|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.
41130|NCT03861806|Behavioral|PAS sham|Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to not modulate corticospinal excitability.
41131|NCT03861793|Biological|ALKS 4230|SC injection administered in the back of the arm or the abdomen
41132|NCT03861793|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion over 30 minutes
41133|NCT03861780|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
41134|NCT03861780|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
41135|NCT03861780|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
41136|NCT03861767|Drug|Metformin ER|tablet
41137|NCT03861767|Drug|Placebo|Matched placebo in doses of 1, 2 and 3 tablets to coincide with the 500, 1000, and 1500 mg arms.
41138|NCT03861754|Behavioral|Lifestyle modification|
41139|NCT03861741|Genetic|WES|A peripheral venous blood sample will be processed internally, and externally subjected to WES. Only genetic material from relatives of probands in which a mutation has been identified will be sequenced.
41140|NCT03861741|Diagnostic Test|MRI|A MRI of the thoracic aorta will be performed in all relatives able to attend the Glenfield Hospital and who have no contra-indications to this imaging modality; pulse-wave velocity will be recorded.
41141|NCT03861741|Diagnostic Test|TTE|TTE screening will be performed by a trained physiologist. Aortic diameter will be measured from the parasternal long-axis view at the sinuses of Valsalva and at the widest level of the ascending aorta. All measurements will be made in end-diastole.
41142|NCT03861741|Other|Questionnaire|Acceptability questionnaires will be submitted to assess a baseline score of depression/anxiety that will be compared with a follow up value at three months
41143|NCT03861728|Device|0.01% Hypochlorous acid|Randomized to treatment 0.01% Hypochlorous acid four times a day to the affected eye for 2 weeks. (Avenova is a FDA approved device)
41144|NCT03861728|Other|Placebo|Placebo to be used four times a day to the affected eye for 2 weeks
41145|NCT03861715|Diagnostic Test|live birth rate|The blastulation rate and live birth rate according to the protocol of COS
41146|NCT03861702|Drug|FOLFOX regimen|FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)
41147|NCT03861702|Drug|Liposomal Irinotecan|Liposomal Irinotecan
41148|NCT03861689|Diagnostic Test|MRI pelvis|MRI pelvis monitoring every 6 months; FiLAC to treat fistula tract at week 6-10
41151|NCT03861663|Device|Ultrasound|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
41152|NCT03861650|Other|Bone Marrow Aspirate Concentrate|A rich MSCs prepration made by centrifugation and concentration of aspirated bone marrow
41153|NCT03861650|Other|Saline|Physiological saline is added in control group to act as placebo
41154|NCT03861637|Other|ESA for correction of PTA to 12-13g/dl|To assess the impact of full correction of chronic PTA(to near normal values) on cardiovascular system and quality of life in renal transplant recipients with stable graft function using erythropoietin stimulating agents in comparison to partially treated PTA with HB level between 12-13g/dl.
41184|NCT03861403|Drug|TRX518|Administered by IV infusion
41185|NCT03861403|Drug|Cyclophosphamide|Administered by IV infusion
41186|NCT03861403|Drug|Avelumab|Administered by IV infusion
41155|NCT03861624|Procedure|Intramedullary nailing with standard SIGN nail|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
41156|NCT03861624|Procedure|External Fixation with uniplanar Dispofix external fixator|Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
41157|NCT03861611|Drug|Ketorolac|Participants may be randomized to receive Ketorolac oral medication 10 mg, every 8 hours for 5 days as needed
41158|NCT03861611|Drug|Ibuprofen|Participants may be randomized to receive Ibuprofen oral medication 600 mg, every 8 hours for 5 days as needed
41159|NCT03861611|Drug|Diclofenac|Participants may be randomized to receive Diflofenac oral medication 50 mg, every 8 hours for 5 days as needed
41160|NCT03861611|Behavioral|Educational Intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)
41161|NCT03861598|Drug|Carvedilol|Carvedilol orally starting at 6.25 mg and increasing to 12.5 mg if tolerated after 1-2 weeks for a total of 4 cycles of treatment.
41162|NCT03861585|Other|Semantic group|"The semantic task has to categorise semantically (i.e., type of contexts or type of objects) one image at each trial."
41163|NCT03861585|Other|Emotional group|"The emotional task has to evaluate the emotional content (i.e., neutral, positive or negative) of one image at each trial."
41164|NCT03861572|Other|Isokinetic eccentric training|Training sessions will be performed in the same isokinetic dynamometer used in previous evaluations, twice a week, with a minimum interval of 72 hours between sessions.
41165|NCT03861572|Other|Traditional eccentric training|Training sessions will be performed at university gym, twice a week, with a minimum interval of 72 hours between sessions.
41166|NCT03861559|Drug|mometasone furoate nasal spray|intranasal administration
41167|NCT03861559|Drug|placebo nasal spray|intranasal administration
41168|NCT03861546|Behavioral|Healthy lifestyle Shared Medical Appointment (SMA) program|Social network-based, culturally-tailored healthy lifestyle SMA program for high risk SAs will be piloted to collect pre-post data on diet and exercise habits, and to determine feasibility and acceptability. Patients will participate in physician-led group visits every other week focused on improving dietary and exercise practices to reduce weight. Biometric measurements (weight, height, blood pressure) will be collected, point of care glucose and lipid testing will be done.
41169|NCT03861533|Other|survey|Cross-Reference
41170|NCT03861520|Device|Midtrimester anomaly scan|A detailed anomaly scan to detect soft markers at 16 to 24 weeks pregnancy
41171|NCT03861520|Genetic|Fetal Karyotyping|Fetal karyotyping after birth to confirm chromosomal anomaly diagnosed clinically
41172|NCT03861507|Device|Prostate Brachytherapy|High dose - rate (HDR) brachytherapy
41173|NCT03861494|Behavioral|Enhanced Stroke Education|In addition to the general stroke education materials and verbal education, the enhanced stroke education group will receive a personalized verbal and written information addressing the patient's specific risk factors including their current status and goals, laboratory values and goals, and current blood pressure and goal. Specific stroke type and etiology is discussed, medication including indication, dose, frequency, physical activity goals, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, and education over the importance of keeping follow up appointments including Stroke Clinic. Verbal feedback of key points is encouraged.
41174|NCT03861494|Behavioral|Usual Stroke Education|The usual stroke education group will receive general stroke education including written and verbal information about signs and symptoms of stroke, best practice to engage medical treatment if stroke occurs, general information about heart healthy diet and need for daily physical activity as well as need for compliance with medication recommendations. The education is incorporated with routine patient care and as allowed during quiet times. On the day of discharge, the patient will receive written materials reviewing stroke symptoms, risk factors, heart healthy diet and follow up appointments. The patient will receive written and verbal information about medications including indication, dose, frequency, physical activity goal, smoking cessation resources, appropriate diet, stroke signs and symptoms and best practice if one sees a stroke (BE-FAST), phone number to call for non-urgent questions, the importance of keeping follow up appointments including Stroke Clinic.
41175|NCT03861481|Drug|Rozanolixizumab|Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
41176|NCT03861481|Other|Placebo|Subjects will receive placebo in a specified sequence during the treatment period.
41177|NCT03861468|Other|Care pathway|Screening for OSA using a combination of bicarbonate assay and STOP-BANG questionnaire and further management by a pneumologist as necessary
41178|NCT03861455|Drug|Dupilumab|patient receive dupilumab 300 mg every 2 weeks after a 600 mg-loading dose of dupilumab on day 0
41179|NCT03861455|Drug|placebo|patient receive placebo
41180|NCT03861429|Behavioral|Me & My Wishes|Me & My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me & My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
41181|NCT03861416|Drug|L-arginine 1.4% 500 ml|Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
41182|NCT03861416|Drug|L-arginine 1.4% 250 ml + placebo 250 ml|Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.
41183|NCT03861416|Drug|Placebo solution|Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
41188|NCT03861390|Drug|Placebo|Immediately following exit from the wood smoke chamber, subjects will receive a matching placebo to the 60 mg of prednisone per randomization schema
41189|NCT03861377|Drug|Remifentanil R2|0,7 microg/kg
41190|NCT03861377|Drug|Remifentanil R4|1,1 microg/kg
41191|NCT03861377|Drug|Remifentanil R8|1,7 microg/kg
41192|NCT03861364|Drug|Propofol|2,4 mg/kg
41193|NCT03861364|Drug|Propofol|1,4 mg/kg
41194|NCT03861351|Device|Mini WELL Toric Ready intraocular lens|The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.
41195|NCT03861338|Drug|Sublocade|The monthly Sublocade buprenorphine extended-release (BXR) injection will be administered in two doses (100 mg and 300 mg). Following a 4 day induction onto oral buprenorphine, the first 300 mg injection of Sublocade will be administered. A second 300 mg Sublocade injection will be administered 1 month later and the third and final monthly injection of 100 mg of Sublocade will be administered 2 months post the successful buprenorphine induction.
41196|NCT03861312|Behavioral|Neck Laterality|"Patients who belonged to the neck group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
41197|NCT03861312|Behavioral|Foot Laterality|"Patients who belonged to the foot group performed the recognition of laterality with certain parameters. The execution of the recognition began with a test to familiarize themselves with the program at the Basic level and then followed the laterality test. It was done with 20 images and 4 seconds for each image in the Vanilla program"
41198|NCT03861299|Procedure|Awake craniotomy|Awake craniotomy
41199|NCT03861299|Procedure|Craniotomy under general anesthesia|Craniotomy under general anesthesia
41200|NCT03861273|Biological|PF-06838435/ fidanacogene elaparvovec|Gene Therapy
41201|NCT03861260|Procedure|Rigid cystoscopy with urethral dilatation|Patients will have a general anaesthetic and a rigid cytoscopic examination of the bladder dilated with sterile water. The urethra will be dilated from FR20 in incremental diameter increases of 2 to French 32 if possible.
41202|NCT03861260|Procedure|Flexible cystoscopy and installation of Glycosaminoglycan layer replacement (laluril)|Patients will undergo flexible cystoscopy and intravesical installations of Hyaluronic acid (HA) + Chondroitin Sulphate (CS) (GAGs) weekly for 4 weeks and then at 8 weeks and 12 weeks.
41203|NCT03861247|Drug|Phosphate-binder intervention|Use phosphate-binders according to KDIGO Guidelines, Chinese Guidance for Diagnosis and Treatment of Mineral and Bone Disorder in Chronic Kidney Disease and drug specification .
41204|NCT03861247|Dietary Supplement|Phosphorus-restricted dietary intervention|Use low phosphorus diet and prolong the time of hemodialysis according to the phosphorus balance evaluation if necessary
41205|NCT03861234|Drug|BI 836880|Solution for Intravitreal (IVT) injection
41206|NCT03861221|Device|CBBCT|To compare the differences between various lesions' presentation on CBBCT and on other approaches under diverse breast conditions.
41207|NCT03861208|Other|diet|foods with high satiation (high protein and high fiber foods) are offered to modify children's hunger and fullness ratings postprandial
41208|NCT03861208|Other|usual diet|foods representing the usually provided foods at childcare are offered
41209|NCT03861195|Procedure|laparoscopic surgery|patients affected by uterine diseases that undergo treatment
41210|NCT03861182|Biological|Biological functionalization of the prosthetic materials by PRF|The biological functionalization of the prosthetic materials by host PRF would improve the biological colonization of materials and thus reduce the risk of prosthetic release.
41211|NCT03861169|Device|Transluminal viscoelastic delivery and trabeculotomy|Ab‐interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
41212|NCT03861156|Drug|D0316|D0316 was orally given once a day in a 21-day cycle
41213|NCT03861143|Drug|BT-11 (500 mg)|Subjects will be randomized to receive BT-11 low-dose (500 mg) once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (high-dose BT-11, low-dose BT-11, or placebo).
41214|NCT03861143|Drug|BT-11 (1000 mg)|Subjects will be randomized to receive BT-11 low-dose (1000 mg) once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (high-dose BT-11, low-dose BT-11, or placebo).
41215|NCT03861143|Drug|Placebo|Subjects will be randomized to receive Placebo once-daily for 12 weeks. All tablets administered (placebo and BT-11) will have the same appearance and size. Each subject will receive blister packs of the study drug (high-dose BT-11, low-dose BT-11, or placebo).
41216|NCT03861117|Procedure|Assisted strategy|Daily spontaneous breathing trial (SBT) with 7 cmH2O pressure support and 5 cmH2O positive end-expiratory pressure are performed to assess weanability. In case of success, a SBT with T-piece is performed to determine if the patients is at high risk of extubation failure. In this case and/or in the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
41217|NCT03861117|Procedure|Non assisted strategy|Daily spontaneous breathing trials (SBT) with T-piece are performed to assess weanability. In the presence of risk factors, systematic non-invasive ventilation is applied after extubation.
41218|NCT03861104|Other|medical educational video|information based on visual and auditory communication
41219|NCT03861091|Drug|risedronate|Risedronate 150 mg Oral Given once 7 - 21 days prior to initiation of SBRT
41220|NCT03861091|Drug|Matching placebo|Dose not applicable, given once 7-21 days prior to initiation of SBRT
41221|NCT03861078|Other|Own Brand Cigarette|Effects of own brand cigarette use.
41222|NCT03861078|Other|ECIG 6 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 6 mg nicotine, sweetened liquid
41223|NCT03861078|Other|ECIG 6 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 6 mg nicotine, unsweet liquid
41224|NCT03861078|Other|ECIG 0 mg nicotine, sweetened|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, sweetened liquid
41225|NCT03861078|Other|ECIG 0 mg nicotine, unsweet|Effects of using a 30 Watt ECIG filled with 0 mg nicotine, unsweet liquid
41321|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at TVOR|Ultrasound scan
41226|NCT03861065|Procedure|Tertiary Wound Closure|The wound will be closed with what is considered tertiary wound closure. This means, rather than leaving the wound open, the wound will be partially closed after surgery, and then completely closed 4-7 days after surgery.
41227|NCT03861065|Procedure|Historical Wound Closure|Participants wounds are left partially open to heal.
41228|NCT03861052|Drug|Tirzepatide|Administered SC
41229|NCT03861052|Drug|Dulaglutide|Administered SC
41230|NCT03861039|Drug|Tirzepatide|Administered SC
41231|NCT03861026|Device|Bilateral NIRS (Masimo, O3TM Regional Oximetry)|Bilateral NIRS (Masimo, O3TM Regional Oximetry) will be used to measure rSO2 intraoperatively. The NIRS electrodes will be placed on fronto-temporal area and baseline values of rSO2 obtained according to manufacturer's guidelines in the operating room prior to induction of anesthesia. The NIRS screen will be concealed in the control group to ensure blinding.
41232|NCT03861013|Behavioral|Multidimensional stress prevention program (GeDStress)|The multidimensional stress prevention program (GeDStress) is composed of 8 session of 2-hour weekly sessions and integrated cognitive and behavioral strategies, mindfulness-based activities, emotional regulation and social skills exercises. Brief homework activities were given between sessions. The groups were composed by a maximum of 8 students and were led by two trained clinical psychologists.
41233|NCT03861000|Drug|[C-11]T-1650|radio-labeled drug
41234|NCT03861000|Drug|BPN14770|selective compound
41235|NCT03860987|Drug|goserelin|Goserelin will be administered SC at 10.8 mg every 12 weeks
41236|NCT03860987|Drug|Enzalutamide|Enzalutamide will be given orally at 160mg once daily
41237|NCT03860987|Drug|Abiraterone|Abiraterone will be taken orally at 1000 mg once daily
41238|NCT03860987|Drug|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
41239|NCT03860987|Drug|Prednisone|Prednisone will be taken orally at 5mg twice a day for each dose, or 10 mg once a day. Doses should be taken about 12 or 24 hours apart
41240|NCT03860987|Procedure|Radical Prostatectomy|Radical Prostatectomy
41241|NCT03860974|Drug|Serratus Plane block (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
41242|NCT03860974|Drug|Paravertebral block (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane (20 mL of local anesthetic for unilateral surgery; 16 mL of local anesthetic each side for bilateral surgery).
41243|NCT03860961|Other|Questionnaire Administration|Ancillary studies
41244|NCT03860961|Other|Survivorship Care Plan (SCP)|Given survivorship care plan
41245|NCT03860961|Other|Treatment Plan|Given treatment plan
41246|NCT03860948|Drug|Savolitinib Test Preparation|Test preparation (T): dry granulation savolitinib tablets.
41247|NCT03860948|Drug|Savolitinib Reference Preparation|Reference preparation (R): wet granulation savolitinib tablets.
41248|NCT03860935|Drug|AG10|TTR stabilizer administered orally twice daily (BID)
41249|NCT03860935|Drug|Placebo Oral Tablet|Non-active control administered orally twice daily (BID)
41250|NCT03860922|Device|Magnetic Resonance Imaging|all patient will undergo Magnetic resonance imaging and magnetic imaging arthrography of the ankle joint.
41251|NCT03860896|Drug|GB004|GB0004 high dose
41252|NCT03860896|Drug|Placebo|Placebo
41253|NCT03860896|Drug|GB004|GB004 low dose
41254|NCT03860883|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
41255|NCT03860883|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of skin surrounding the original melanoma site, to ensure that any remaining scattered melanoma tumour cells that may have been left behind after the first initial biopsy/surgery are removed."
41256|NCT03860870|Drug|Clenbuterol Oral Product|Subjects ingest 4x20 microgram clenbuterol tablets
41257|NCT03860857|Radiation|Amyloid PET scan|Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18
41258|NCT03860857|Drug|Tau PET scan using MK-6240|Tau Positron Emission Tomography scan using radio tracer MK-6240
41259|NCT03860857|Behavioral|Neurocognitive testing|A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.
41260|NCT03860857|Other|MRI|High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.
41261|NCT03860844|Drug|Isatuximab SAR650984|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41262|NCT03860844|Drug|Dexamethasone|Pharmaceutical form: Solution for injection or tablet Route of administration: Intravenous or oral
41263|NCT03860844|Drug|Fludarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41264|NCT03860844|Drug|Cytarabine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41265|NCT03860844|Drug|Liposomal daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41266|NCT03860844|Drug|Daunorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41267|NCT03860844|Drug|Idarubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41268|NCT03860844|Drug|Filgrastim|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
41269|NCT03860844|Drug|Mitoxantrone|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41270|NCT03860844|Drug|Doxorubicin|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41271|NCT03860844|Drug|Vincristine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41272|NCT03860844|Drug|PEG Asparaginase|Pharmaceutical form: Solution for injection Route of administration: Intramuscular
41273|NCT03860844|Drug|Cyclophosphamide|Pharmaceutical form: Solution for injection Route of administration: Intravenous
76377|NCT03586934|Drug|Acetaminophen|Acetaminophen Tablet
41275|NCT03860844|Drug|Methotrexate|Pharmaceutical form: Solution for injection Route of administration: Intravenous
41276|NCT03860831|Drug|Ketamine + midazolam|Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
41277|NCT03860818|Other|Health services delivery|Technology-enabled pharmacist intervention
41278|NCT03860805|Procedure|Laparoscopic tubal ligation|Laparoscopic tubal ligation
41279|NCT03860805|Procedure|Laparoscopic bilateral salpingectomy|Laparoscopic bilateral salpingectomy
41280|NCT03860792|Behavioral|Ketogenic Diet|Three-month 1:1 ketogenic diet intervention (approximately 70% fat, <10% carbohydrate, and 20% protein).
41281|NCT03860792|Behavioral|Therapeutic Lifestyles Changes Diet|Three-month diet intervention that is low in fat and cholesterol, high in fruits, vegetables, and whole grains, and moderate in protein.
41282|NCT03860766|Other|Photobiomodulation|An LED blanket with 267 infrared lamps with predetermined doses will be used, given a wavelength of 940nm, for 6 weeks, it will be applied by all extension of the quadriceps and hamstrings bilaterally, just before the force training protocol for the groups intervention or simulation for the sham group. Photochemical or photophysical effects are expected from its application.
41283|NCT03860753|Drug|Pioglitazone|For the current trial we will follow recommended adult initial dosing at 30 mg/d to reach maintenance dose of 45 mg/d by week 2, which is within standard titration parameters as per the investigator's brochure.
41284|NCT03860753|Drug|Placebo|Pill capsules will look same as that of active drug.
41285|NCT03860740|Other|Exercise|Exercise intervention adapted to maximum rate of oxygen consumption measured during incremental exercise (VO2level) of each patient, working between 60% to 100% VO2level. The activity will be walk-run in a treadmill. 10 sessions minimum
41286|NCT03860740|Other|Stretching|Stretching and relaxing exercise during 30 minutes. Same number of sessions as intervention group
41287|NCT03860727|Diagnostic Test|Welch Allyn IExaminer|Fundus Examination
41288|NCT03860714|Diagnostic Test|Neuropsychological tests|We do the neuropsychological tests, Mini-Mental score examination (MMSE),Charlson Comorbidity Index(CCI)，Clinical Dementia Rating(CDR),Quality of Recovery Score - 40 (QoR-40),Geriatric Depression Scale (GDS),CAGE Alcoholism Questionnaire，Pure Tone Audiometry，blood albumin、hemoglobin content、ALT、AST、BUN、Cr、serum folic acid、vitamin B12、homocysteine and branched chain amino acid content 1 day before the surgery（baseline）； 1 day before the surgery（baseline）； Confusion Assessment Method（CAM)，Numerical Rating Scale（NRS）once before discharge from PACU and 1、2、3 days after surgery twice a day； QoR-40 1 day after surgery； Neuropsychological tests and MMSE 6±1 days and one month after surgery.
41289|NCT03860701|Procedure|Remote ischemic conditioning|An appropriately sized blood pressure cuff will be inflated around a limb (systolic blood pressure + 15 mmHg) for different periods of time (1 to up to 4 minutes), times (1 to up to 4 times) and consecutive days (1 to up to 2).
41290|NCT03860688|Drug|TED + glucose|Teduglutide, up to 0.05mg/kg, subcutaneous, single dose Glucose, 25g, oral, single dose
41291|NCT03860675|Diagnostic Test|Assessment of walking-related fatigability|participants perform two six-minute walking test (6MWT), with 3-5 days in between. Before and after the 6MWT, three screenings test (spasticity, muscle strength, balance) are executed and the participants have to indicate the severity of eleven possible symptoms (= symptom inventory, SI) on a VAS scale. These screening tests and SI are continued every 10 minutes for half an hour. During a third test session, participants perform a 6-minute vigilance alphabet test in rest and while doing a 6MWT to investigate the relationship between cognitive and motor fatigability.
41292|NCT03860662|Diagnostic Test|Nociceptor flexor reflex|The nociceptive flexion reflex (NFR) is a physiological, polysynaptic reflex allowing for painful stimuli to activate an appropriate withdrawal response
41293|NCT03860662|Drug|Botox|botox
41294|NCT03860662|Drug|Baclofen|baclofen
41295|NCT03860649|Other|Nordic Walking|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
41296|NCT03860649|Other|Jogging|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
41297|NCT03860649|Other|Dance|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
41298|NCT03860649|Other|Pilates Training|24 sessions will be held twice a week, with each session taking an average of 60 minutes.
41299|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at ET|Ultrasound scan
41300|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at HCG|Ultrasound
41301|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at TVOR|Ultrasound
41302|NCT03860636|Diagnostic Test|Endometrial Pattern on Ultrasound at co-ordination scan|Ultrasound
41303|NCT03860636|Diagnostic Test|Endometrial thickness at HCG|Ultrasound
41304|NCT03860636|Diagnostic Test|Endometrial thickness at TVOR|Ultrasound
41305|NCT03860636|Diagnostic Test|Endometrial thickness at ET|Ultrasound scan
41306|NCT03860636|Diagnostic Test|Endometrial thickness at coordination scan|Ultrasound scan
41307|NCT03860636|Diagnostic Test|Endometrial volume at HCG|Ultrasound scan
41308|NCT03860636|Diagnostic Test|Endometrial volume at TVOR|Ultrasound scan
41309|NCT03860636|Diagnostic Test|Endometrial volume at ET|Ultrasound scan
41310|NCT03860636|Diagnostic Test|Endometrial volume at coordination scan|Ultrasound scan
41311|NCT03860636|Diagnostic Test|Blood test for progesterone at HCG|Blood test
41312|NCT03860636|Diagnostic Test|Blood test for progesterone at TVOR|Blood test
41313|NCT03860636|Diagnostic Test|Blood test for progesterone at ET|Blood test
41314|NCT03860636|Diagnostic Test|Blood test for progesterone at coordination scan|Blood test
41315|NCT03860636|Diagnostic Test|Change in endometrial pattern between TVOR and ET|Ultrasound scan
41316|NCT03860636|Diagnostic Test|Blood test for estradiol at HCG|Blood test
41317|NCT03860636|Diagnostic Test|Blood test for estradiol at TVOR|Blood test
41318|NCT03860636|Diagnostic Test|Blood test for estradiol at ET|Blood test
41319|NCT03860636|Diagnostic Test|Blood test for estradiol at coordination scan|Blood test
41320|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at HCG|Ultrasound scan
41322|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at ET|Ultrasound scan
41323|NCT03860636|Diagnostic Test|Endometrial blood flow (doppler) at coordination scan|Ultrasound scan
41324|NCT03860636|Diagnostic Test|Contractility at embryo transfer on a subgroup of participants|Ultrasound scan
41325|NCT03860636|Diagnostic Test|Change in endometrial pattern between coordination scan and ET|Ultrasound scan
41326|NCT03860636|Diagnostic Test|Change in endometrial pattern between HCG and ET|Ultrasound scan
41327|NCT03860610|Diagnostic Test|Muscle strength test|Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
41328|NCT03860610|Diagnostic Test|Dynamic stability test during level and uphill walking|Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
41329|NCT03860610|Diagnostic Test|Postural stability test|The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
41330|NCT03860610|Diagnostic Test|EuroQol Group Health questionnaire (EQ-5D-5L)|Overall health will be assessed using the EQ-5D-5L health questionnaire
41331|NCT03860610|Diagnostic Test|HOOS/ KOOS|Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
41332|NCT03860610|Diagnostic Test|Muscle activity test|Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
41333|NCT03860610|Diagnostic Test|Passive range of motion|Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
41334|NCT03860597|Drug|Memantine|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
41335|NCT03860597|Drug|Placebos|To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
41336|NCT03860584|Dietary Supplement|MFGM-enriched full-fat dairy milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content). This delivers MFGM at ~10-times that in full-fat dairy milk, which reflects that consumers obtain MFGM from dairy foods other than whole milk.
41337|NCT03860584|Dietary Supplement|Soy phospholipid/lecithin milk|MetS adults with metabolic endotoxemia will be enrolled to complete a 2-arm, double-blind, randomized controlled, crossover trial to test the independent benefits of MFGM. For each 2-wk arm, they will receive MFGM-enriched full-fat dairy milk (3 servings/d) or a matched dairy milk that instead contains soy phospholipid/lecithin (control). Milks have been formulated with soy lecithin or MFGM at 10% phospholipid (relative to total lipid content).
41338|NCT03860571|Drug|BT-11 Placebo|BT-11 Placebo (Finished Product),
41339|NCT03860571|Drug|BT-11 Active|BT-11 active - 500 mg Oral Tablets
41340|NCT03860558|Other|Lifestyle Intervention|Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.
41341|NCT03860558|Other|No Intervention|Participants will not undergo an intervention.
41342|NCT03860545|Diagnostic Test|urine and blood analysis|concentration of ischemia modified albumin assessed in blood before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation; concentration of urinary excretion of brush-border enzymes of the proximal renal tubules assessed before operation, immediately and one hour after cardiopulmonary bypass, 24 hours after operation, serum creatinine levels will be evaluated on the day of the operation and 24 h and 48 h postoperatively
41343|NCT03860532|Drug|HMPL-011 tablets|Eligible subjects will recieve 1200 mg HMPL-011 tablets under fed and diet circumstance.
41344|NCT03860532|Drug|HMPL-011 capsules|Eligible subjects will recieve 1200 mg HMPL-011 capsules under fed and diet circumstance.
41345|NCT03860519|Behavioral|Electronic Medication Monitors on ICS and SABA - Active Mode|"The patients in the intervention group will have sensors that are active, so that these patients receive reminders about when to use their inhalers medications."
41346|NCT03860519|Behavioral|Electronic Medication Monitors on ICS and SABA - Silent Mode|"The patients in the control group will have sensors that are silent, so that these patients do not receive reminders about when to use their inhalers medications."
41347|NCT03860519|Behavioral|Asthma App Tracking of ICS/SABA Usage - Active Mode|Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
41348|NCT03860519|Behavioral|Asthma App Tracking of ICS/SABA Usage - Silent Mode|Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
41349|NCT03860519|Behavioral|NorthShore Connect Real Time ICS and SABA Usage Feedback - Yes|Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
41350|NCT03860519|Behavioral|NorthShore Connect Real Time ICS and SABA Usage Feedback - No|Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
41456|NCT03859583|Dietary Supplement|Capsaicin|4 tsp of cayenne in a breakfast omelette
41351|NCT03860519|Behavioral|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - Yes|Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
41352|NCT03860519|Behavioral|Asthma Nurse Monthly Phone Calls for ICS/SABA Usage Feedback - No|Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
41353|NCT03860506|Drug|PSI-697|
41354|NCT03860506|Drug|Placebo|
41355|NCT03860493|Procedure|Perfusion evaluation with indocyanine green|"1. At least 10 minutes before surgery, will receive a weight-scaled dose of indocyanine green by IV and the time of administration and any adverse reactions will be recorded. The Surgeon/researcher will visualize and record the images given by the KARL STORZ VITOM II ICG System and the IC-Flow camera.~3. The surgery will proceed as planned pre-operatively. The surgeon will conduct the surgery under white light and will categorize initial visualization of the organs."
41356|NCT03860480|Procedure|ESP with Bupivacaine 0.5%|Regional anesthesia procedure with Bupivacaïne 0.5%
41357|NCT03860480|Procedure|ESP with Saline 0.9%|Regional anesthesia procedure with Normal Saline
41358|NCT03860467|Other|collection of patient data|Patient data will be collected using the in-house digital patient record systems and the local digital electroencephalogram (EEG)-database
41359|NCT03860441|Other|Computerized cognitive training|Intervention used CogniFit platform with Personalized brain training sub-option
41360|NCT03860428|Drug|Ibuprofen|In the medical treatment arm the in-tention is to close the ductus arteriosus.
41361|NCT03860428|Drug|Paracetamol|In the medical treatment arm the in-tention is to close the ductus arteriosus.
41362|NCT03860428|Other|Expectant Management|Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
41363|NCT03860415|Dietary Supplement|Vivomixx|Two months of 2 sachets vivomixx each morning and 2 sachets each night. Each sachet of viviomixx contains 450 billion live bacteria.
41364|NCT03860415|Dietary Supplement|Placebo|Two months of 2 sachets placebo each morning and 2 sachets each night. Each sachet of placebo contains 450 billion live bacteria.
41365|NCT03860402|Other|Temperature|temperature of drug
41366|NCT03860389|Other|Exercise|An exercise programme will be delivered in the school for a period of up to 16 weeks. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
41367|NCT03860363|Device|Blood drainage post cardiac surgery|Blood drainage post cardiac surgery with Thoraguard Surgical Drainage System.
41368|NCT03860350|Dietary Supplement|Aged Garlic Extract|
41369|NCT03860350|Dietary Supplement|Placebo|
41370|NCT03860337|Dietary Supplement|Alginate Sausage|Alginate sausage
41371|NCT03860337|Other|Control Sausage|Control Sausage
41372|NCT03860324|Procedure|Single-shot erector spinae plane block|Single-shot Erector Spinae Plane block with 30ml of ropivacaine 0,5% + adrenaline 150mcg.
41373|NCT03860324|Procedure|Single-shot fascia iliaca block|Single-shot Fascia Iliaca block with 40ml of ropivacaine 0,2%
41374|NCT03860311|Device|Bladder Ultrasound|"Bladder fullness will be assessed upon enrollment and if not full, the patient will receive hydration, determined by treating physician, and the bladder ultrasound will be repeated every 30 minutes until the patient states that the bladder is full, or until bladder is deemed full based on a previously validated bladder fullness qualitative scale, at which point patients in this group will proceed to undergo pelvic ultrasound."
41375|NCT03860311|Other|Standard of Care|Per institution protocol, patients in the standard of care group will have urethral (bladder) catheter placed immediately after the order for pelvic ultrasound and will undergo retrograde bladder filling as determined by the radiologist/ultrasonographer to the point necessary to fully visualize pelvic structures.
41376|NCT03860298|Device|NaviFUS System|Using NaviFUS System treatment for 10 minutes in drug resistant epilepsy. The site of the NaviFUS exposure is where the future surgery will be removed. Patients will concomitant use of anti-epileptic drugs (AEDs).
41377|NCT03860285|Other|Short form 36 quality of life survey|Prospective non-comparative observational study of cohorts
41378|NCT03860272|Drug|AGEN1181|an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody
41379|NCT03860259|Device|Auriculotherapy cryopuncture device without nitrogen gas|Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
41380|NCT03860259|Device|Auriculotherapy cryopuncture device with nitrogen gas|Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
41381|NCT03860246|Diagnostic Test|Portable ECG monitor|Recording of ECG rhythm on a portable monitor (Kardia Mobile)
41382|NCT03860233|Drug|Oxytocin|40 IU administered intranasal, within 1 hour prior to sleeping for 14 days
41383|NCT03860233|Drug|Placebo|Intranasal spray to mimic Oxytocin intranasal spray
41384|NCT03860220|Drug|NEWSTATIN TS|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with triple therapy (Newstatin TS 40/5/10mg) ; 1 tab qd for 8 weeks
41385|NCT03860220|Drug|CADUET|Wash out/run in period with Amlodipine 5mg for 6 weeks and then treatment with dual therapy (Caduet 5/10mg) ; 1 tab qd for 8 weeks
41386|NCT03860207|Biological|Humanized 3F8 Bispecific Antibody|Phase I Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.Phase II Hu3F8-BsAb is given IV over ~1-3 hours on Days 1 and 8 for each cycle.
41387|NCT03860207|Other|Blood draw|In cycle 1, blood is drawn for PK studies.
41388|NCT03860194|Dietary Supplement|Protison with High Protein 51(Original Flavor)|Contents of each supplement sachet has a calorie of 88 kcal, 12.8 g protein( including 8.5 g whey protein concentrate), 1.2 g leucine, 7.3 g carbohydrates, 0.8 g fat and 120 IU vitamin D per serving. This supplement was added 200 ml water and stirred well, then drank before meal.
41389|NCT03860181|Procedure|Subcuticular Sutures|This intervention closes incisions after shoulder arthroplasty using subcuticular sutures with Dermabond.The deep layer closure will require interrupted sutures.
41457|NCT03859583|Dietary Supplement|Control|breakfast omelette without cayenne pepper
41390|NCT03860181|Procedure|Metal Staples|This intervention closes incisions after shoulder arthroplasty with metal staples. The deep layer closure will require interrupted sutures,
41391|NCT03860181|Device|PRINEO|The closure system uses the Dermabond PRINEO (which is similar to clear tape stuck over the wound) placed over running sutures for both the deep and subcuticular layer.
41392|NCT03860168|Other|PICU Up!|The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
41393|NCT03860155|Biological|allo-APZ2-ACLF|"Administration of 2 x 10e6 allogeneic ABCB5-positive stem cells/kg bodyweight, each at Day 0, Day 4 and Day 11 into peripheral vein (arm) by use of a perfusor.~allo-APZ2-ACLF will be in a concentration of 1 x 10e7 cells/mL in Human Serum Albumin/Ringer-Lactate/Glucose (HRG)-solution."
41394|NCT03860142|Behavioral|Archet scale|Parents will be asked to answer questions about their child's nutrition by using a new scale : Archet scale
41395|NCT03860129|Drug|Isoflurane|Group A: Isoflurane (0.5 MAC)
41396|NCT03860129|Drug|Sevoflurane|Group B: Sevoflurane (0.5 MAC)
41397|NCT03860129|Drug|Desflurane|Group C: Desflurane (0.5 MAC)
41398|NCT03860116|Behavioral|APP-based case management service|The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
41399|NCT03860116|Behavioral|Standard-of-care followup service|When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.
41400|NCT03860090|Device|Pacemaker implant|Implantation of endovenous cardiac stimulation device.
41401|NCT03860090|Device|Defibrillator implant|Implantation of endovenous cardiac defibrillation device.
41402|NCT03860090|Procedure|AXILLARY VEIN ACCESS|Fluoroscopy-guided axillary puncture to get vein access
41403|NCT03860090|Procedure|CEPHALIC VEIN ACCESS|Optimized cephalic vein cutdown to get vein access
41404|NCT03860077|Drug|Very Low Nicotine Content Cigarettes|Very Low Nicotine Content Cigarettes
41405|NCT03860077|Drug|Normal Nicotine Content Cigarettes|Normal Nicotine Content Cigarettes
41406|NCT03860064|Other|Non intervention|Non
41407|NCT03860038|Drug|TJ202 and Dexamethasone|one dose of TJ202 16 mg/kg or an adjusted dose will be administered on Day 1 and Day 4 of Week 1, then every week from Week 2 to Week 12, then every 2 weeks from Week 13 to Week 24 and then every 4 weeks thereafter, until the subjects experience an onset of endpoint events like intolerance or PD. DEX 40 mg will be administered on Day 1 and Day 4 of Week 1, respectively and then 40mg weekly thereafter.
41408|NCT03860025|Other|No intervention.|No intervention.
41409|NCT03860012|Drug|Folic Acid|Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
41410|NCT03859999|Diagnostic Test|Analysis of primary radiograph and available demographics|Multivariate analysis of the fracture x-ray features measured by computer, together with the database demographic and outcome data will be used to develop the best model /decision rule to predict likelihood of MUA success
41411|NCT03859986|Drug|ALX-101 Gel Vehicle|ALX-101 Gel Vehicle
41412|NCT03859986|Drug|ALX-101 Gel 5%|ALX-101 Gel 5%
41413|NCT03859973|Drug|BI 425809|Tablet
41414|NCT03859973|Drug|Placebo|Tablet
41415|NCT03859960|Diagnostic Test|body composition|fat mass % (FM%) and fat-free mass (FFM%)% of arms, legs, trunk, android, gynoid and total body
41416|NCT03859960|Diagnostic Test|glucose, insulin, glycohemoglobin|In the morning after 12 hours overnight fast, all individuals underwent a 75 gram (g) oral glucose tolerance test (OGTT). Blood samples were taken before loading glucose and then 30, 60, 90 and 120 minutes after taking glucose solution in order to measure serum glucose and insulin levels. Glycohemoglobin (HbA1c) was measured in blood samples taken before the OGTT. We calculated the Matsuda index and Homeostasis model assessment index (HOMA-IR) using glucose and insulin levels.
41417|NCT03859947|Device|Heated humidiﬁed high-flow nasal cannula|Non-invasive ventilation with a nasal cannula
41418|NCT03859934|Drug|Melatonin|Melatonin treatment
41419|NCT03859934|Drug|Placebo Oral Tablet|Placebo treatment
41420|NCT03859921|Drug|Dydrogesterone|Progesterone
41421|NCT03859921|Drug|Placebo|Placebo with appearance similar to Dydrogesterone
41422|NCT03859908|Drug|Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
41423|NCT03859908|Drug|Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML|As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
41424|NCT03859882|Other|Sleep deprivation|40 hours of continuous awaking in the sleep laboratory in order to compare before and after sleep deprivation for each treatment (Caffeine vs. placebo).
41425|NCT03859869|Drug|Pancrelipase|Pancrelipase is administered orally as capsules with a meal or snack
41426|NCT03859869|Drug|Placebo|Placebo is administered orally as capsule with a meal or snack
41508|NCT03859141|Biological|Trivalent influenza vaccine (contains B/Victoria strain)|One dose of trivalent influenza vaccine (contains B/Victoria strain): 0.25 ml per dose containing 7.5μg antigen.
41427|NCT03859856|Other|hormone panel and ultrasonography|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH, LH, E2 and AMH hormone levels and ultrasonography for antral follicle count and ovarian volume measurement will be done.
41428|NCT03859843|Combination Product|PRP|Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.
41429|NCT03859843|Other|Chemical peeling (Salycilic acid)|SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.
41430|NCT03859843|Other|Chemical peeling (Jessener's solution)|is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.
41431|NCT03859830|Device|Artis Dialysis System, ArtiSet PrePost and Ultra HDF Line|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
41432|NCT03859830|Device|AK200 Ultra S, extracorporeal circulation conduct of blood purification|The HDF session will be performed in post-dilution volume-controlled mode, with a minimum target total convective volume (VCtot) of 16 L and blood flow rate (QB) set at 200-300 mL/min.
41433|NCT03859817|Other|Comparison of eGFR values and ketonemia in diabetic patients|To verify if there is a correlation between the level of ketones and an alteration of the renal function in the diabetic patient, the values of the prognostic markers indicated in the protocol and the data downloaded by the glucometers will be evaluated in addition to the blood tests of the patients
41434|NCT03859804|Procedure|Standard transrectal 12 core biopsy|TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral
41435|NCT03859804|Procedure|MRI- US fusion prostate biopsy (FPB)|FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)
41436|NCT03859791|Other|THA|Study participants have received a total hip arthroplasty due to arthritis. We do not make further intervention.
41437|NCT03859778|Other|survey|French pharmacy students will be contacted by email thanks to the student associations and scolarity departments. Answer to the survey will be done online
41438|NCT03859765|Behavioral|HCT Symptoms and Steps|HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.
41439|NCT03859752|Biological|TR1801-ADC|Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
41440|NCT03859739|Drug|MK-8558|Single dose of MK-8558 administered as a tablet at a dose up to 1600 mg.
41441|NCT03859726|Diagnostic Test|NIRS|Near-infrared spectroscopy (NIRS) offers non-invasive, in-vivo, real-time monitoring of tissue oxygenation. Changes in regional tissue oxygenation as detected by NIRS may reflect the delicate balance between oxygen delivery and consumption.
41442|NCT03859726|Diagnostic Test|Sublingual microcirculation|The sidestream dark field (SDF) imaging devices provide high contrast images of the microvasculature.
41443|NCT03859713|Behavioral|Physical Therapy|Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.
41444|NCT03859713|Behavioral|Cognitive Behavioral Therapy|Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction
41445|NCT03859713|Behavioral|Mindfulness|Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.
41446|NCT03859700|Biological|DBV712 250 mcg|DBV712 250 mcg, once daily
41447|NCT03859687|Biological|Vitamin A supplementation|liquid oral vitamin A supplementation
41448|NCT03859687|Biological|No vitamin A supplementation|No vitamin A supplementation
41449|NCT03859661|Dietary Supplement|Fitabisc|Fitabisc is a chocolate cookie with vanilla cream filling which contains the most important antioxidants Vitamin C, Vitamin E, and the mineral Selenium. Fitabisc is not commercially available and for the purposes of this study it will be manufactured by Calerrific Ltd, which already produces a biscuit called CalBisc 100 as a simple calorie and nutritional supplement. Production takes place in a BRC Global Standard Grade A certified bakery operated by Farringford Foods in Portadown, Northern Ireland.
41451|NCT03859635|Procedure|Ultrasound Guided LB Erector Spinae Plane Block|All the erector spinae plane blocks will be placed preoperatively using Liposomal Bupivacaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
41452|NCT03859635|Procedure|Ultrasound Guided SB Erector Spinae Plane Block|All the erector spinae plane blocks will be placed preoperatively using Standard Bupivacaine. All procedures will be placed under the supervision of the attending anesthesiologist on the acute pain service or the attending anesthesiologist in the operating room.
41453|NCT03859635|Procedure|Surgeon Infiltration|SI group - at the end of the surgery, the surgeon will infiltrate liposomal bupivacaine under thoracoscopic guidance along the intercostal nerves from T4-T8.
41454|NCT03859609|Procedure|Spinal Fusion|Spinal alignment was evaluated according to two different score-systems
41455|NCT03859596|Procedure|MGB/OAGB|BARIATRIC PROCEDURE INVOLVED CREATION OF SLENDER GASTRIC POUCH OF 12-15CM IN LENGTH AND BILIO-PANCREATIC LIMB OF 150-200 CM
41458|NCT03859570|Drug|Pentoxifylline|Pentoxifylline (PTX) is a methylxanthine derivative that is a nonselective inhibitor of cyclic nucleotide phosphodiesterase (PDE). This enzyme, which has at least 5 subtypes, is responsible for inactivation of the important second messengers, Cyclic adenosine monophosphate (AMP) and cyclic guanosine monophosphate (GMP)
41459|NCT03859570|Drug|Placebos|Placebo
41460|NCT03859544|Other|Retrospective study|Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
41461|NCT03859518|Other|blood and skin samples|To study the presence and type of ILC and NK in the blood and skin of vitiligo patients compared to control subjects.
41462|NCT03859505|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated in a single session and they will receive a total dose of 0 J.
41463|NCT03859505|Device|Active PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated in a single session and will receive a total dose of 220.05 J.
41464|NCT03859492|Device|Contrast Enhanced Digital Mammography|High-resolution, low-energy, full-field digital mammography (FFDM) image and contrast-enhanced image
41465|NCT03859479|Procedure|Cold snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the snare will be opened and encircled the polyp without air aspiration. Then, the snare will be captured the polyp with at least 1-2 mm of surrounding normal tissue. The polyp will be guillotined and would not be lifted or tented until complete closure is achieved. After resection, the mucosal defect the marginal mucosa was carefully observed, with used of magnification and image enhancement. If residual polyp tissue was recognised, additional removal using the cold snare technique or biopsy forceps will be performed. If a submucosal injection prior to snaring was necessary it will be permitted. After polypectomy all patients will be observed for 3-4 days in-hospital
41466|NCT03859479|Procedure|Hot snare polypectomy|After a target polyp was identified, it should be placed at the comfortable position. Then the polyp with minimal normal tissue will be captured by the snare. The ensnared polyp should be tented away from the colonic wall and removed by one the types of electric currents. After resection, the mucosal defect will be washed thoroughly and the marginal mucosa was carefully observed, with used of magnification and image enhancement, such as near focus imaging or narrow band imaging. If a submucosal injection prior to snaring was necessary it would be permitted. If residual polyp tissue was recognised, additional removal using coagulation or biopsy forceps will be performed. After polypectomy all patients will be observed for 3-4 days in-hospital
41467|NCT03859466|Device|Shockwave Therapy|"Surgically invasive device, transient use only for the time of surgical intervention, intended for use in direct contact with the heart, intended to correct defect of the heart.~Throughout the study, investigators are permitted to use their clinical judgement when prescribing concomitant medications and treatments for trial patients. Local prescribing information and institutional guidelines should be followed as applicable"
41468|NCT03859440|Device|DSiHy Silicone hydrogel soft contact lens|•Device: DSiHy (test lens) Silicone hydrogel soft contact lens for daily disposable wear.
41469|NCT03859440|Device|CE-marked Silicone hydrogel soft contact lens|"・Device: Silicone hydrogel soft contact lens CE-marked for daily disposable wear.~Other Name : MyDay"
41470|NCT03859427|Drug|Carfilzomib|Once weekly IV over 30 minutes on day 1, 8 and 15 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 day 1 and 56 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
41471|NCT03859427|Drug|Carfilzomib|Twice weekly IV over 10 minutes on day 1, 2, 8, 9, 15 and 16 of each 28 day cycle. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 27 mg/m2 beginning with cycle 1 day 8 and thereafter. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent.
41472|NCT03859427|Drug|Lenalidomide|Once daily orally 25 mg days 1 to 21 of each cycle. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
41473|NCT03859427|Drug|Dexamethasone|Once daily orally or by IV 40 mg days 1, 8 and 15 of each cycle. Also day 22 of cycles 1 to 9. 12 cycles or until progression, unacceptable toxicity, death, loss to follow up or withdrawal of consent
41474|NCT03859414|Drug|Therapeutic Dose 1|CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
41475|NCT03859414|Drug|Therapeutic Dose 2|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
41476|NCT03859414|Drug|Supra-therapeutic Dose|CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
41477|NCT03859414|Drug|Placebo|CHF 5993 placebo pMDI
41478|NCT03859401|Device|EnMPC (Ensemble Model Predictive Control) AP Controller|This AP controller has the ability to anticipate exercise activity by use of trends seen during the Data Collection Period.
41479|NCT03859401|Device|rMPC (Naïve Model Predictive Control) AP Controller|This AP controller does not have the ability to anticipate exercise activity.
41480|NCT03859375|Other|microbial skin counts in the disinfection area after paints of skin disinfectants|microbial skin counts in the disinfection area after 2 and 3 paints of skin disinfectants (chlorhexidine in alcohol [CHX] and povidone iodine in alcohol [PI])
41481|NCT03859362|Drug|Ertapenem Injection|1 g of ertapenem q24h, 30 min infusion
41509|NCT03859141|Biological|Trivalent influenza vaccine (contains B/Yamagata strain)|One dose of trivalent influenza vaccine (contains B/Yamagata strain): 0.25 ml per dose containing 7.5μg antigen.
41547|NCT03858972|Drug|Tesetaxel|Tesetaxel plus reduced dose of capecitabine
41482|NCT03859349|Diagnostic Test|Targeted Sampling|After CLNS assessment, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
41483|NCT03859349|Diagnostic Test|Systematic Sampling|Following routine biopsy of lymph nodes, patients with proven malignant mediastinal lymph nodes will be referred for chemoradiation and patients with proven benign mediastinal lymph nodes will undergo surgical resection as per standard of care guidelines. Final pathology from the resected specimen will be considered the gold standard for analysis of sensitivity and specificity.
41484|NCT03859336|Device|Transdermal Neuromodulation Stimulation|The TEN device administers a tuned high frequency electrical stimulation delivered to the cervical plexus (C2-C4) on the back of the neck for 20 minutes. This stimulation will activate common trigeminovagal pathways modulating noradrenergic signaling to attenuate sympathetic activity. This stimulation can subsequently regulate the activity of several deep-brain nuclei within the ascending reticular activating system (RAS). Nuclei in the RAS regulate powerful neuromodulators like norepinephrine (NE), acetylcholine (ACh), and serotonin (5-HT). The investigators will examine whether this modulation from TENS will decrease anxiety and improve sleep quality in the study participants.
41485|NCT03859323|Drug|SHP681|Participants will receive SC injection of SHP681 in the abdomen.
41486|NCT03859323|Other|Placebo|Participants will receive SC injection of placebo matched to SHP681 in the abdomen.
41487|NCT03859310|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
41488|NCT03859297|Behavioral|Rumination-Focused CBT|"RF-CBT targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effectively coping with rumination. RF-CBT specifically targets rumination through psychoeducation, adopting a functional analytic approach to the learned habitual behavior of rumination, and a focus on shifting process style. The adolescent is taught to notice triggers to ruminate as well as the consequences of rumination and to shift into practicing a more adaptive strategy such as an attention training exercise, behavioral activation, thinking in a concrete way, or active problem-solving. RF-CBT directly teaches adolescents to recognize rumination or when the participant gets stuck in their head and to notice the influence this has on their mood."
41489|NCT03859297|Behavioral|Relaxation-based Therapy|Sessions will include progressive muscle relaxation, simple breathing techniques, and guided imagery that focus on bodily and somatic relaxation. Adolescents randomized to Relaxation Therapy (RelaxT) will also receive exercises to do as homework in between sessions, parallel to the RF-CBT group.
41490|NCT03859284|Other|flowable resin composite|gold standard
41491|NCT03859284|Other|self adhering flowable|moist bonding self adhering flowable composite
41492|NCT03859284|Other|self adhering flowable with adhesive|moist bonding self adhering flowable composite with the aid of an adhesive system.
41493|NCT03859271|Behavioral|Brief motivational interviewing|Children and parents will receive BMI and instant messaging delivered by a trained research nurse. At the time of recruitment, both children and parents will receive an education talk on the significance of and misconceptions about regular physical activity for cancer survivors and strategies for overcoming barriers to engaging in physical activity. Parents will then receive a face-to-face BMI to motivate their children to engage in regular physical activity. Parents will also be encouraged to motivate their children to intensify their physical activity levels progressively, with the ultimate goal of achieving the Global Recommendations on Physical Activity on Health suggested by the World Health Organization. Additionally, they will be invited to download a mobile health application from the Centre for Health Protection, Department of Health, HKSAR website that contains information on physical activity.
41494|NCT03859271|Behavioral|Placebo control|Children and parents will receive the education talk on physical activity and ask to download the mobile health application that contains information on physical activity at the time of recruitment similar to the intervention group. However, parents will not receive BMI and instant messaging throughout the study period.
41495|NCT03859258|Device|Transvaginal sonography|Niche is assessed using TVS, SIS and office hysteroscopy
41496|NCT03859245|Behavioral|Photobiomodulation|Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.
41497|NCT03859245|Behavioral|Ketogenic diet|Experimental group will follow a clinically prescribed ketogenic diet.
41498|NCT03859232|Other|Delta Dry® Waterproof Pantaloon|Cast with newer waterproof material developed to reduce the skin complications associated with traditional cotton liners.
41499|NCT03859232|Other|Cotton Padding|Cast with traditional cotton liner.
41500|NCT03859219|Drug|Rozanolixizumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous infusion"
41501|NCT03859219|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous infusion"
41502|NCT03859206|Other|Medical thoracoscopy|• With the closed biopsy forceps, step by step, fibrinous septae were perforated, the pleural space was irrigated with saline and fluid and fibrinopurulent material were aspirated and removed from the pleural cavity, the entire pleural cavity was inspected and biopsies were obtained from suspicious areas carefully by the biopsy forceps under vision. Multiple lesions were encountered, multiple biopsies were taken & If no lesion, biopsy from parietal pleura was obtained from any sites.
41503|NCT03859193|Behavioral|Nutritional Video|A 10 - 15 minute video
41504|NCT03859180|Behavioral|Focused breathing|Focused breathing is a series of focused, controlled breaths that aid in relaxation. Each participation in this group will be taught how to do focused breathing by the study investigator. Once determined to be able to perform focused breathing, participants will be asked to practice it for 4 minutes, twice a day, for 6 weeks. If they choose to do so, they may practice focused breathing if they become anxious at other times. They will be asked to keep a diary of each time they practice and/or use focused breathing.
41505|NCT03859167|Other|Stress Test|Participants will reach maximum exercise on a treadmill and results will be collected and recorded.
41506|NCT03859141|Biological|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
41507|NCT03859141|Biological|Quadrivalent influenza vaccine|One dose of quadrivalent influenza vaccine: 0.25 ml per dose containing 7.5μg antigen.
41510|NCT03859128|Biological|TORIPALIMAB INJECTION(JS001 )|Arm A: Toripalimab 240mg IV(Injection of Vein) Q3W Arm B: Placebo 240mg IV(Injection of Vein) Q3W
41511|NCT03859115|Procedure|TENS (transcutaneous electrical nerve stimulation)|transcutaneous nerve stimulation with electrical pulse generation
41512|NCT03859115|Procedure|sham intervention|sham stimulation without electrical pulse generation
41513|NCT03859102|Dietary Supplement|Pre-operative Carbohydrate PreLoad drink|Pre-operative Carbohydrate PreLoad drink, 1 sachet given the night before surgery. One sachet given 2-4hours before surgery.
41514|NCT03859102|Drug|Oral Gabapentin pre-op|One dose of Gabapentin pre-operatively, 300mg orally.
41515|NCT03859102|Drug|Oral Lansoprazole pre-op|One dose of Lansoprazole pre-operatively, 30mg orally.
41516|NCT03859102|Drug|Intravenous Paracetamol intra-operatively|One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
41517|NCT03859102|Drug|Intravenous Dexamethasone intra-operatively|One dose of Dexamethasone intra-operatively as an anti-emetic, 8mg intravenous.
41518|NCT03859102|Drug|Intravenous Ondansetron intra-operatively|One dose of Ondansetron intra-operatively as an anti-emetic, 4mg intravenous
41519|NCT03859102|Drug|Infiltration of surgical wounds with local anaesthetic|Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
41520|NCT03859102|Drug|Intravenous Magnesium intra-operatively|One infusion of intravenous Magnesium Sulphate intra-operatively as an analgesic, 50mg/kg given over 30minutes.
41521|NCT03859102|Drug|Post-operative Gabapentin analgesia|Post-operative oral Gabapentin 300mg, three times daily as an analgesic.
41522|NCT03859102|Drug|Post-operative oral Paracetamol analgesia|Post-operative Paracetamol as an analgesic. Initially intravenously, then orally. One gram four times daily.
41523|NCT03859102|Drug|Post-operative Ondansetron anti-emesis|Intravenous Ondansetron administered post-operatively as prophylactic anti-emesis. 4mg three times daily, for 24 hours. Then as required.
41524|NCT03859102|Procedure|Early extubation|Removal of the endotracheal tube in the Intensive Care Unit as soon as is safe.
41525|NCT03859102|Procedure|Early mobilisation/physiotherapy|Mobilisation (active and passive limb movements, deep breathing) with the assistance of nurse/physiotherapist to occur as soon as possible post-operatively.
41526|NCT03859102|Other|Encourage early oral food intake|Patients will be encouraged to start eating as soon as possible post-operatively
41527|NCT03859089|Other|Medical Cannabis|N/A - Observational Cohort Study
41528|NCT03859076|Behavioral|MB-BP|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions & a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, & specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, & stress reactivity. Students learn a range of mindfulness skills (body scan exercises, meditation and yoga). Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified; for those without a physician, the investigator works to provide access within health insurance constraints.
41529|NCT03859076|Other|Enhanced Usual Care Control|Those in the control group receive an educational brochure from the American Heart Association (product code 50-1731) and a validated home blood pressure monitor (Omron, Model PB786N), that has an evidence-based approach to lower blood pressure. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for it. For participants with uncontrolled hypertension who do not have a physician, the investigator works to provide access within constraints of their health insurance. Additionally, participants randomized to the control group are asked to refrain from engaging in any type of formal mindfulness practice more than weekly during the first six months of study involvement.
41530|NCT03859063|Behavioral|Intervention|Participants randomized to the intervention arm will be followed with monthly meetings by a stroke coordinator for 18 months. The stroke coordinator will assess the patients risk factors within the domains of physical function, cognitive function, social function, medication and lifestyle factors and make a treatment plan targeting the individual needs for further follow-up.
41531|NCT03859063|Behavioral|Control|Community based follow-up as usual
41532|NCT03859050|Other|bronchoscopy with intrabronchial administration of lipopolysaccharide|The PI will administer intrabronchial LPS into the lungs of healthy volunteers and then obtaining macrophages by bronchoalveolar lavage (BAL) 24, 48, 72, 96, or 120 hours later.
41533|NCT03859037|Other|Umbilical cord milking|100 babies will have squeezing of blood from umbilical cord towards baby
41534|NCT03859024|Drug|Oxycodone|oxycodone tablet
41535|NCT03859024|Drug|Acetaminophen|acetaminophen tablet
41536|NCT03859024|Drug|Gabapentin|gabapentin tablet
41537|NCT03859024|Drug|celebrex|Celebrex tablet
41538|NCT03859024|Drug|Bupivacaine|bupivacaine injection
41539|NCT03859024|Drug|Ibuprofen 800 mg|ibuprofen tablet
41540|NCT03859024|Drug|Dexamethasone|Dexamethasone injection
41541|NCT03859011|Other|Acupuncture|"Patients will have DBC Spring Ten acupuncture needles (manufactured in China) manually inserted bilaterally on five standardized acupuncture points according to the treatment points of GB20, BL10, BL11, SI3, BL62 at 6-8 mm depth for 20 minutes each using a tonification technique to elicit a de qi response.~After those needles are removed, the number of additional needles and additional acupuncture points used will be chosen at the acupuncturist's discretion."
41542|NCT03859011|Other|Usual Care|Physical therapy, oral medications and topical ointments pre the discretion of the primary physician
41543|NCT03858998|Other|Case Management Intervention|A 90-day case management intervention to link hospitalized HIV-infected participants with local HIV clinics.
41544|NCT03858998|Other|Control|Current routine HIV care in Tanzania.
41545|NCT03858985|Device|Cervical Transcutaneous Vagus Nerve Stimulation (Active Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
41546|NCT03858985|Device|Cervical Transcutaneous Vagus Nerve Stimulation (Sham Comparator)|Both sham and active nVNS treatment produce low-voltage electrical signal that induce reliable sensation on subject skin on upper anterior cervical area (overlying carotid artery).
41549|NCT03858959|Device|topical agent|"HBX protocol consisted in product application into the periodontal pocket (starting from the base) with a delivery syringe, second saline solution irrigation after 60 seconds to flush-out the product and Teflon-curettes debridement to remove the deposits.~CHX protocol consisted in Teflon-curettes debridement to remove the deposits, associated with a first saline solution irrigation, and product application into the periodontal pocket (starting from the base) with a delivery syringe."
41550|NCT03858946|Procedure|Simple trapeziectomy|A curvilinear incision is made over the base of the 1. metacarpal towards the tendon of the extensor pollicis brevis in the distal part of the anatomical snuffbox. The joint is opened as widely as possible and the trapezium is dissected free in a proximal direction until the articulation with the scaphoid is reached. Then trapezium is removed taking care not to damage tendon of the flexor carpi radialis. The joint capsule is closed and skin sutured in the usual manner. At the completion of the procedure two small shame incision are made (1 cm each) involving only epidermis on the volar aspect of the palm and forearm. Each of them will be closed with one stitch
41551|NCT03858946|Procedure|Weilby|The first part of the surgical procedure is identical to simple trapeziectomy. In addition, the tendon sheath of the first extensor compartment is divided. After this, a strip consisting of approximately one-third of flexor carpi radialis tendon is dissected using two small incisions on the volar aspect of the wrist and distal forearm. The distally based tendon strip is tunneled to its insertion on the second metacarpal bone. Then the strip of tendon is winded around the abductor pollicis longus tendon and the rest of the tendon at least twice, pulling those tendons together into the space created after excision of the trapezium. The tendons are sutured together with non-absorbable sutures while the skin is sutured in the usual manner
41552|NCT03858933|Device|eBrainFit Platform|Alpha/Theta regulation with eyes open
41553|NCT03858933|Device|eBrainFit Platform|Amygdala regulation with eyes open
41554|NCT03858920|Device|Fibroscan of Liver|A non-invasive diagnostic device used to measure liver scarring
41555|NCT03858920|Procedure|Low-dose non-contrast CT|CT scan as part of routine research care
41556|NCT03858894|Drug|DE-117 Ophthalmic Solution QD|DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye
41557|NCT03858894|Drug|DE-117 Ophthalmic Solution BID|DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
41558|NCT03858881|Behavioral|PROJECT PERSONALITY|"PROJECT PERSONALITY is self-administered by youth via Qualtrics and is 30 minutes in duration. The intervention includes five elements: 1. An introduction to the brain, including a lesson on neuroplasticity (how and why our behaviors are controlled by thoughts and feelings in the brains, which have potential for change); 2. Testimonials from older youths who describe their views that people's traits are malleable, given the brain's plasticity; 3. Additional vignettes written by older youths, describing times when they used growth mindsets to persevere through social and emotional setbacks; 4. A summary of selected scientific studies suggesting that personality can, and often does, change in positive ways over time; and 5. An exercise in which the participants write notes to younger students, drawing on scientific information to describe the malleability of people's personal traits"
41559|NCT03858881|Behavioral|VR PERSONALITY PROJECT|The VR PERSONALITY PROJECT contains similar elements as PROJECT PERSONALITY, including a lesson on neuroplasticity; testimonials from older youths; information about research on the malleability of personal traits; and an exercise wherein the participant provides advice to a student in the VR environment who has experienced a peer-related setback. Content is delivered by characters in the VR environment (hired/filmed actors) who guide youths through the program, providing scientific information and personal stories. Completion time is 30-40 minutes. The key difference between the VR and web-based mindset intervention is the delivery system, and by extension the level of immersion each program offers. The VR program is designed to be immersive, fun and interactive; youth choose to speak to various scientists and students within the VR environment and navigate themselves from scene to scene. In the online program, participants automatically view a series of text-based activities.
41560|NCT03858881|Behavioral|SHARING FEELINGS PROGRAM|The web-based supportive therapy (ST) intervention, called the Sharing Feelings Program, is delivered via Qualtrics, self-administered by youth, and 30 minutes in duration. It aims to encourage youths to identify and express feelings to close others and does not teach specific skills or beliefs. It is designed to control for nonspecific aspects of intervention, including engagement in a technology-based program. It mirrors the web-based growth mindset intervention as closely as possible, including vignettes written by older youths who describe times when they benefited from sharing their feelings with friends or family.
41561|NCT03858868|Behavioral|Church and park-based intervention|Multiple components involving motivational messages and concrete opportunities for physical activity at the church and the local park.
41562|NCT03858868|Behavioral|Standard health education on physical activity|Participants will receive publicly available brochures, tip sheets, etc. about physical activity
41563|NCT03858855|Procedure|Aromatherapy and Essential Oils|Use bergamot essential oil
41564|NCT03858855|Procedure|Aromatherapy and Essential Oils|Use chamomile essential oil
41565|NCT03858855|Procedure|Aromatherapy and Essential Oils|Use ginger essential oil
41566|NCT03858855|Procedure|Aromatherapy and Essential Oils|Use almond essential oil
41567|NCT03858855|Other|Subject Diary|Complete journal
41568|NCT03858842|Other|epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD|epidemiology, characteristics, healthcare resources and associated costs of patients diagnosed with non-IPF PF-ILD and SSc-ILD
41569|NCT03858829|Other|Psychometric analysis|Psychometric analysis
41570|NCT03858816|Other|Mixture probiotics|The mixture probiotics capsule
41571|NCT03858816|Other|Placebo|The placebo contains the same excipient ingredients but without the live bacteria.
41572|NCT03858803|Behavioral|Families Matter 2|Parents training in communication, youth sexual development, parental monitoring, parental use of positive reinforcement, risks facing adolescents and their management.
41573|NCT03858803|Behavioral|Living as a Safer Teen|Prevention intervention for adolescents 13-18 that provides information, motivation, and behavioral skills to prevent STIs, HIV, and unplanned pregnancy.
41574|NCT03858790|Device|PINS Spinal Cord Stimulator|Subjects will be implanted with PINS spinal cord stimulator
41575|NCT03858777|Diagnostic Test|cell free DNA|All groups will have blood draws and cfDNA measured
41576|NCT03858751|Drug|Placebo oral capsule|Placebo capsule before bedtime
41577|NCT03858751|Drug|LTM1201AZ|LTM1201AZ oral capsule before sleep
41578|NCT03858751|Drug|LTM1201AT|LTM1201AT oral capsule before sleep
41579|NCT03858751|Drug|LTM1201AG|LTM1201AG oral capsule before sleep
41580|NCT03858751|Drug|LTM1201AD|LTM1201AD oral capsule before sleep
41581|NCT03858738|Device|Thermographic breast examination performed by Braster device|Patient undergo contact thermography examination with the use of liquid crystal contact thermography device- Braster.
41582|NCT03858725|Drug|D569 Tab.|D569 Tab. 1T single oral administration under fasting condition
41583|NCT03858725|Drug|CKD-374 5mg Tab.|CKD-374(Tofacitinib) 5mg Tab. 1T single oral administration under fasting condition
41584|NCT03858712|Other|Active Care Team Alert|"2) Active care team alert via office practice nurse monitoring of ePRO oral responses scored at 3, indicating moderate-severe (grade ≥3) toxicity.~Office practice nurses will monitor ePRO oral responses and respond to those scored at 3 per disease center symptom management protocol.~The ePRO oral responses from the remaining participants will additionally be monitored by office practice nurses who will respond to ePRO responses with scores of 3, indicating a moderate-severe toxicity (grade 3 or higher)."
41585|NCT03858712|Other|Passive Care Team Alert|"Primary care teams are assigned an EHR inBasket pool through which PP messages are delivered. Providers will be responsible for reviewing ePRO responses via inBasket, selecting mark as reviewed button as mandated for all clinical messages within 48 hours per policy."
41586|NCT03858699|Other|Recording of electroencephalographic (EEG) data|Non-invasive brain activity will be measured with electroencephalography (EEG). EEG uses scalp sensors to monitor the brain's electrical activity. EEG sensors are placed on the scalp and passively record neural activity with high time resolution.
41587|NCT03858686|Drug|FP-025 capsules|FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
41588|NCT03858686|Drug|Placebo FP-025 capsules|Placebo FP-025 capsules, BID will be administered to subjects in either Period 1 or Period 2, and given for 12 consecutive dosing days.
41589|NCT03858673|Procedure|VTH via the Tsuzi method with residual uterine ligament ligation|VTH via the Tsuzi method with residual uterine ligament ligation
41590|NCT03858660|Other|No intervention|No intervention
41591|NCT03858634|Drug|KPL-716|solution for injection
41592|NCT03858634|Drug|Placebo|solution for injection
41593|NCT03858621|Drug|fentanyl NOL guided|Intervention is NOL monitoring in this group that will help to guide intravenous administration of fentanyl during surgery.
41594|NCT03858608|Dietary Supplement|Counterweight Plus|Total diet replacement followed by food reintroduction and weight maintenance.
41595|NCT03858608|Other|Usual asthma care|Usual asthma management
41596|NCT03858595|Device|Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain|"Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis."
41597|NCT03858582|Drug|pembrolizumab|pembrolizumab 200mg
41598|NCT03858582|Radiation|Radiation|52.8Gy/24Fx or 59.4Gy/27Fx
41599|NCT03858569|Procedure|active management of third stage of labor|Active management of the third stage of the labor will be done administering oxytocin and cord traction.
41600|NCT03858556|Procedure|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
41601|NCT03858556|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
41602|NCT03858556|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41603|NCT03858556|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
41604|NCT03858556|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41605|NCT03858556|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
41606|NCT03858556|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
41607|NCT03858556|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
41608|NCT03858543|Drug|Poly-L Lactic Acid|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
41609|NCT03858543|Device|Fractional laser treatment|After initial treatment, reassessment will be conducted at 3 follow-up visits. Photographs will be taken for blinded evaluators to compare post-treatment to the original pre-treatment photographs. At final visit, a questionnaire will be administered to rate treatment satisfaction.
41610|NCT03858530|Diagnostic Test|Ultrasound Examination|Grayscale ultrasound, Doppler ultrasound, ultrasound elastography with or without ultrasound intravenous contrast will be performed.
76378|NCT03586934|Drug|Celecoxib 200mg|Celecoxib Tablet
41611|NCT03858517|Device|ReUnion TSA System|The ReUnion TSA System is designed as an anatomical total shoulder or hemi-shoulder endoprosthesis to address advanced arthritic disorders affecting the shoulder joint in subjects having intact or repairable rotator cuff function. The ReUnion TSA System consists of a completely modular shoulder platform including a Humeral Stem, Humeral Head and Glenoid. The intended purposes of the ReUnion TSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
41612|NCT03858504|Behavioral|Exercise|The children with enthesitis related arthritis will be randomized into one of the exercise groups as yoga or home exercises and will perform the exercise program for 2 times a week for 8 weeks according to their groups.
41613|NCT03858491|Drug|Cobicistat|Cobicistat will be added to the treatment with osimertinib. The initial dose will be 150 mg cobicistat, which equals the dose used in the treatment of HIV-infected patients. If this dose is well tolerated and the increase in exposure of osimertinib is not sufficient, the dose of cobicistat will gradually be escalated to 600 mg per day (150 mg cobicistat, four times per day).
41614|NCT03858478|Drug|Biktarvy arm|BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
41615|NCT03858465|Drug|Ephedrine|intravenous 25 mg of ephedrine
41616|NCT03858465|Drug|Phenylephrine|intravenous 0,3 mg of phenylephrine
41617|NCT03858452|Procedure|Muscles exercises program|
41618|NCT03858439|Other|Dietary|Low sodium, low protein dietary recommendation
41619|NCT03858426|Other|no intervention|no intervention
41620|NCT03858413|Diagnostic Test|No intervention|No intervention
41621|NCT03858387|Drug|imipenem, meropenem, piperacillin/tazobactam and sulbactam|"imipenem: imipenem studies were carried out during administration (0 to 24-48 h after the start of imipenem). Blood samples were obtained by direct venipuncture at 0, 0-0.5 h, 0.5-2.5 h, 2.5-4 h after the start of imipenem.~meropenem: meropenem studies were carried out during administration (0 to 24-48 h after the start of meropenem). Blood samples were obtained by direct venipuncture at 0, 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h after the start of meropenem.~piperacillin/tazobactam: piperacillin/tazobactam studies were carried out during administration (0 to 24-48 h after the start of piperacillin/tazobactam). Blood samples were obtained by direct venipuncture at 0, 0-0.5 h, 0.5-2 h, 2-4 h, 4-6 h after the start of piperacillin/tazobactam.~sulbactam: sulbactam studies were carried out during administration (0 to 24-48 h after the start of sulbactam). Blood samples were obtained by direct venipuncture at 0, 0-1 h, 1-3 h, 3-5 h, 5-8 h, 8-12 h after the start of sulbactam."
41622|NCT03858374|Device|transferred by air-suspending mattress|Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .
41623|NCT03858374|Device|transferred by slide board|When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.
41624|NCT03858374|Device|transferred by bedsheet|When patients need to be transferred from bed to bed, just lift the bedsheet.
41625|NCT03858361|Device|Atrial Flutter Ablation|Catheter-based electrophysiological (EP) intervention.
41626|NCT03858335|Other|Constraint-induced movement therapy|The constraint-induced movement therapy (CIMT) program requires children to wear forearm splint on the unaffected arm 24 hours for 3 weeks. The program consists of 5 sessions per week for 3 weeks.
41627|NCT03858322|Drug|Paclitaxel|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
41628|NCT03858322|Drug|Cyclophosphamide|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
41629|NCT03858322|Drug|Carboplatin|The drug work by damaging the RNA or DNA that tells the cell how to copy itself in division. If the cells are unable to divide, they die.
41630|NCT03858309|Behavioral|Breathing Group 1|The 8-week breathwork intervention incorporates a set of breathing practices under the guidance of a certified yoga teacher.
41631|NCT03858309|Behavioral|Breathing Group 2|The 8-week breathwork intervention incorporates a set of slow breathing practices under the guidance of a certified yoga teacher.
41632|NCT03858296|Behavioral|Internet-delivered emotional awareness training|Emotional awareness training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
41633|NCT03858296|Behavioral|Internet-delivered Cognitive reappraisal training|Cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
41634|NCT03858296|Behavioral|Internet-delivered awareness and reappraisal training|Emotional awareness and cognitive reappraisal training is delivered via an internet platform during 4 weeks and includes therapist contact several times per week via the platform.
41635|NCT03858283|Behavioral|Mindfulness Based Health Care (MBHC) Program|Mindfulness Based Health Care (MBHC) Program for Caregivers of Alzheimer's Disease Patients. The duration of this group was 8 weeks. The program included one session per week, with each session lasting 1 hour and 30 minutes
41636|NCT03858270|Drug|Memantine|Memantine will be started at 10 mg tablet once/day for a week at bedtime. After one week Memantine will be administered at 10 mg tablet twice/day for 51 weeks.
41637|NCT03858270|Other|Placebo|Placebo will be started at 10 mg tablet once/day for a week at bedtime. After one week Placebo will be administered at 10 mg tablet twice/day for 51 weeks.
41638|NCT03858257|Device|High flow nasal oxygen|The Optiflow device (Fisher and Paykel Healthcare, Auckland, New Zealand) will be used.
41639|NCT03858257|Device|Standard oxygenation|Supplemental oxygen through a facemask.
41640|NCT03858231|Drug|Norco 5Mg-325Mg Tablet|1 tablet up to 4 times per day for 7 days
41641|NCT03858231|Drug|Ibuprofen 600 mg|1 tablet up to 4 times per day for 7 days
41642|NCT03858231|Drug|Acetaminophen 325Mg Tab|1 tablet up to 4 times per day for 7 days
41643|NCT03858218|Other|questionnaires set|questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
41644|NCT03858205|Other|Quality-of-Life Assessment|Ancillary studies
41645|NCT03858205|Other|Questionnaire Administration|Ancillary studies
41646|NCT03858205|Radiation|Radiation Therapy|Receive low-dose radiation therapy
41647|NCT03858192|Procedure|Colorectal surgery procedure|Elective admission for colorectal surgery
41648|NCT03858192|Procedure|Emergency abdominal surgery|Emergency admission necessitating emergency surgery
41649|NCT03858192|Drug|Antibiotics|Treatment for infection and reason for admission
41650|NCT03858179|Device|PBMT|PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
41651|NCT03858179|Device|Placebo|Placebo PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). The placebo PBMT will per performed using the dose of 0 J per diode. The sounds and signals emitted from the device as well as the information displayed on the screen will be identical, regardless of the type of treatment (active or placebo). Placebo PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
41652|NCT03858166|Drug|PEG-rhG-CSF|6mg PEG-rhG-CSF was administrated subcutaneously at different time after chemotherapy.
41653|NCT03858153|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise.
41654|NCT03858153|Behavioral|Nutrition Education|12 weeks of implementing eating tips and tracking food.
41655|NCT03858127|Other|Collection of urine sample|Collection of urine sample for measurement of LH and FSH
41656|NCT03858127|Other|Examination of genitalia|Examination of genitalia
41657|NCT03858127|Other|Video messaging|Short video of infant recorded at home by the parents
41658|NCT03858114|Other|Mild-to-moderate physical activity|"According to ACSM guidelines, mild-to-moderate Physical Activity (PA) will be established as ≤ 60% of the Heart Rate Reserve (HRR). Baseline HR will be registered for all participants for three days, and the mean data will be utilized. PA intervention will consist of three phases:~warm up (10 minutes), up to 40% of HRR, with slow, dynamic movements and stretching for principal muscular groups;~Active phase (45 minutes), from >40% to 60% HRR, with static and dynamic exercises for postural control and spine mobility, and balance exercises, with activation of core muscles;~cool down (10 minutes), < 40% of HRR, with cardiorespiratory cool-down exercises followed by relaxation, and post-stretch exercises to return muscles to a pre-exercises length."
41659|NCT03858114|Other|Cultural group program|A cultural group program with 12-weeks thematic meetings on places of historical and artistic interest in the city of Cagliari, Sardinia, with one visit/week to the same sites. The participants will be accompanied by expert tour guides to museums, monuments, city parks and archeological sites.
41660|NCT03858088|Procedure|Liver transplantation|Liver transplantation from deceased donors
41661|NCT03858075|Drug|BLU-782|oral capsules
41662|NCT03858075|Drug|Placebo|oral capsules
41663|NCT03858075|Drug|BLU-782 taken with food|oral capsules
41664|NCT03858062|Device|Insulin pump therapy (with or without glucose sensor)|Patients' own insulin pump with fast-acting insulin analog and optionally with own glucose sensor
41665|NCT03858062|Device|Artificial pancreas (Inreda Diabetic)|Bi-hormonal reactive closed loop system without mealtime announcement
41666|NCT03858049|Drug|Crinone|Participants will receive 90 milligram (mg) of intravaginal Crinone gel daily in the morning in the treatment period for approximately 75 days.
41667|NCT03858049|Drug|Duphaston|Participants will receive 10 mg of Duphaston orally twice a day in the treatment period for approximately 70 days.
41668|NCT03858036|Drug|Ricrolin+|1 to 2 drops of Ricrolin+ will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the Ricrolin+ pre-treatment period, the eye will be examined at the slit lamp to detect the presence of a yellow flare in the anterior chamber, indicating adequate riboflavin saturation of the corneal tissue. If the yellow flare is not detected, Ricrolin+ will continue to be instilled 1 drop every 2 minutes for an additional 5 to 10 minutes; and the anterior chamber will be rechecked for yellow flare. This process will be repeated as necessary. During the irradiation period, 1 to 2 drops of Ricrolin+ to cover the cornea (in the same manner as during the riboflavin pre-treatment) before the start of irradiation and every 5 minutes during irradiation until irradiation is complete.
41669|NCT03858036|Device|VEGA UV-A system|The VEGA light will be administered for 30 minutes. The VEGA light will stop automatically every 5 minutes for Ricrolin+ administration.
41670|NCT03858023|Other|Hippotherapy|The hippotherapy program consists of 2 sessions per week for 15 weeks. One session is 30-minute session. The program involves 2 therapists and 3 personnel for safety issues.
41671|NCT03858010|Diagnostic Test|Wheeze and me questionnaire|validation of questionnaire assessing disease control and quality of life in preschool children with recurrent wheeze
41672|NCT03857997|Biological|Patient blood sampling|sequencing by WGS and RNA-seq
41673|NCT03857997|Biological|Parents blood sampling|sequencing by WGS
41674|NCT03857984|Other|Blood sampling|blood sample before and after a single HD
41675|NCT03857971|Device|Coronary Optical Coherence tomography|Optical coherence tomography imaging is performed of non-obstructive, non-culprit coronary lesions to assess plaque morphology.
41676|NCT03857958|Procedure|endoscopic retrograde cholangio-pancreatography|In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
41677|NCT03857945|Other|Preoperative mobility device(s) training|Patients in Group 1 (the intervention, that is the mobility device training group group) will receive training on the mobility device(s) with the physical therapy visit during their standard pre-operative care.
41678|NCT03857932|Procedure|Participants receive SLNB as well as non SLNs resection|Participants only receive SLNB preoperative CT lymphography SLNB with stained non-SLN resection SLNB with ARM dissection
41734|NCT03857490|Behavioral|Lower leg heat therapy|Home-based 8 weeks of lower leg repeated heating.
41679|NCT03857919|Device|TearCare|The TearCare SmartLids will be applied to the external surface of each eyelid. The TearCare System will be turned on and heat will be delivered to the eyelids for 15 minutes. Immediately following the thermal portion of the procedure, the SmartLids will be removed and the doctor will manually express the meibomian glands.
41680|NCT03857919|Device|LipiFlow|The LipiFlow activators will be placed between the inner eyelid and the corneal surface of each eye. The LipiFlow System will be turned on and heat and pressure will be delivered to each eyelid for 12 minutes.
41681|NCT03857906|Device|Intra-Aortic Ballon Pump insertion|The IABP (Ultraflex IAB 7.5F, 2.5mm; Arrow International, Reading, PA) was inserted percutaneously through the right femoral artery in the previous 1 - 6 hours before the scheduled surgery. Positioning of the IABP was guided by radioscopy. The balloon size was based on the patient's height (30, 40 or 50 cc). Transesophageal echocardiography was used to confirm correct IABP placement before and after CABG
41682|NCT03857893|Device|Dynamic Quadripolar Radio-Frequency treatment|"Novel low-energy Dynamic Quadripolar Radio-frequency thermal treatment through Eva™ Device. Eva™ Device combines both advanced VDR™ technology (Vaginal Dynamic Radiofrequency) and RSS™ (Radiofrequency Safely System) technology."
41683|NCT03857893|Drug|pH-Cream|1g of Cetomacrogol cream (pH-cream) to self-administered with a vaginal applicator for 12 weeks (one dose every three days)
41684|NCT03857867|Device|Tactile Stimulation Glove|A glove device produces non-painful sensory (tactile) vibratory stimulation to the fingertips of Parkinson's patients.
41685|NCT03857867|Device|Sham Stimulation Glove|Sham Device to mimic tactile stimulation glove.
41686|NCT03857854|Drug|Pirfenidone|treatment group
41687|NCT03857854|Drug|Placebos|placebo group
41688|NCT03857841|Biological|UNEX-42|UNEX-42 is a preparation of extracellular vesicles that are secreted from human bone marrow-derived mesenchymal stem cells suspended in phosphate-buffered saline.
41689|NCT03857841|Biological|Phosphate-buffered saline|Phosphate-buffered saline
41690|NCT03857828|Other|Blood sample and semen sample|"Blood sample for measuring level of testosterone and estradiol E2.~serum sample for measuring clusterin level."
41691|NCT03857815|Radiation|anti-PD-1 antibody|"In patients with inoperable hepatocellular carcinoma or recurrence after local or regional therapy, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1~5 Evaluable lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (IBI308) is injected intravenously 200mg every three weeks."
41692|NCT03857802|Behavioral|Sleep hygiene intervention|"An individual education will be carried out following a bidirectional feedback method. It is intended to develop skills to make conscious and autonomous decisions. The explanation will consist:~Information and reading with discussion of the educational sheet: The 9 tips for a healthy sleep will be read, point by point. The nurse will be open to discuss those that generate doubt.~Confrontation: even if the patient does not ask any questions about it, it will be necessary to ask if he has understood the advice.~Participated information: Questions will be asked to the patient such as: Did you already know any of these tips?.~A telephone call per month will be made as an educational reinforcement to the intervention."
41693|NCT03857789|Other|Questionnaire|A 40 question frailty questionnaire.
41694|NCT03857776|Other|Open dialogue about complementary alternative medicine|1-hour dialogue about CAM with a nurse specialist as an Integrated part of conventional oncology care
41695|NCT03857776|Other|Standard care|Standard care including referral to a homepage about CAM
41696|NCT03857763|Combination Product|Apatinib,Paclitaxel,Cisplatin,RT|Apatinib Mesylate Tablets 250mg qd p.o. d1-35; Paclitaxel：50mg/m2 iv d1，8，15，22，29; Cisplatin: 30mg/m2 iv d1，8，15，22，29; RT：41.4Gy/23f , 1.8Gy/f，5 f/w
41697|NCT03857750|Drug|Rocuronium|0.6 mg/kg
41698|NCT03857737|Procedure|endoscopic submucosal dissection|Endoscopic submucosal dissection is an endoscopic procedure which can achieve en bloc resection of GI tumor. ESD is characterized by three steps: injecting fluid into the submucosa to elevate the lesion from the muscle layer, circumferential cutting of the surrounding mucosa of the lesion, and subsequent dissection of the connective tissue of the submucosa beneath the lesion. The ESD procedure will be carried out by experienced endoscopists.
41699|NCT03857737|Procedure|Surgery|Surgery for EGC include Distal, proximal, or total gastrectomy, which will be performed according to the location and macroscopic tumor type by experienced surgeons.
41700|NCT03857724|Procedure|prolapse surgery|prolapse surgery
41701|NCT03857711|Procedure|CABG|Coronary artery bypass grafting
41702|NCT03857711|Procedure|CABG-RFA|CABG+ prophylactic epicardial bipolar radiofrequency ablation of the ostia of the pulmonary veins
41703|NCT03857711|Procedure|CABG-RFA+ amiodaron|CABG+ RFA + amiodaron (CABG+RFA + class III antiarrhythmic drug- amiodarone)
41704|NCT03857698|Other|Conservative Physical Therapy|"Patients who were discharged from the hospital and received the sutures will be supervised 2 days a week for 8 weeks. Exercise programs will be promoted individually.~Ice application for pain, edema control~Patellar mobilization~Three-way straight leg lifting exercises~Isometric exercises around the hips and knees~Active assisted, active, resistant knee range of motion exercises~Heel shift exercises in supine and sitting~Hip abduction on the side lying~Stretching exercises for patients with gastrosoleus, hamstring, hip flexor muscles~Neuromuscular Electrical Stimulation (NMES) for quadriceps muscle of patients will be applied. The isometric quadriceps contraction observed during the procedure will be required to actively participate in the patients."
41705|NCT03857698|Other|Body Stabilization Exercise|"In the first session, breathing control and alet abdominal hallawing of movement will be taught to the patients with the help of the pressure biofeedback device. The degree of difficulty of the exercises will be improved by using different positions, by adding rotations to the motion, making the pelvic control more difficult and increasing the number of repetitions. In case of exacerbation of symptoms, the level will not be advanced. Exercises will be advanced according to the patient's initial level and response to exercise.~Consecutive shoulder flexion and extension in supine~Building a bridge~Lower body and hip flip~Single leg extension with bilateral arm elevation~Resilient leg stretch with bilateral arm elevation~Hip external rotation in lateral hospitalization~Side-lying arm opening~Shoulder girdle retraction on ball, horizantal abduction and extension"
41706|NCT03857685|Procedure|In-vitro model|In-vitro model of posterior capsule opacification by culturing the lens capsule
41707|NCT03857672|Behavioral|Hypnotic Cognitive Therapy (HYPNOCT)|The HYPNOCT intervention will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into the participant's belief system (note that traditional CT uses purposeful argument and logic to make these changes; in this condition the investigators add a hypnotic automaticity to this process). Thus, HYPNOCT is a hybrid intervention (more than the sum of CT and hypnosis) that overlaps with both hypnosis and CT. The participant will relax in a comfortable position and listen to the clinician speak. However, unlike standard hypnosis for pain, the post-induction suggestions will focus on changes in cognitive content and processes (as opposed to changes in sensory experience).
41708|NCT03857659|Diagnostic Test|Point-of-care ultrasound (POC-US)|POC-US evaluation will be conducted using the portable ultrasound machine, which is capable of straight-line measurements for assessment of the amniotic fluid, as well as ellipse measurements for determination of abdominal circumference. POC-US evaluation will be conducted every 4 weeks from 28-36 weeks.
41709|NCT03857659|Diagnostic Test|Routine antenatal care|Routine care with fundal height measurement at each antenatal appointment every 2 weeks from 28-36 weeks. As well as clinically indicated obstetric ultrasound by a Registered Diagnostic Medical Sonographer (RDMS)
41710|NCT03857659|Diagnostic Test|Formal ultrasound|Formal growth ultrasound performed between 36-38.6 weeks by RDMS.
41711|NCT03857646|Drug|Intralipid, 20% Intravenous Emulsion|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
41712|NCT03857646|Drug|SMOF lipid|Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
41713|NCT03857633|Diagnostic Test|Cardiac MRI 1 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41714|NCT03857633|Diagnostic Test|Cardiac MRI 2 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41715|NCT03857633|Diagnostic Test|Cardiac MRI 3 - Without Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps.~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41716|NCT03857633|Diagnostic Test|Cardiac MRI 3 - With Gadolinium Contrast|"Cines for cardiac function and volumes, T2 myomaps, Resting perfusion and strain analysis, Tagging (strain), T1 myomaps, Late gadolinium enhancement~During the MRI scan participants would be required perform a short period of low intensity exercise involving peddling on an adapted cycle for 10-15 minutes to provide additional data on cardiac function under exertion."
41717|NCT03857633|Diagnostic Test|Peripheral Whole Blood Samples|20ml EDTA whole blood samples - collected sequentially during study - max 8 time points
41718|NCT03857620|Other|Best Practice|Receive usual care
41719|NCT03857620|Other|Informational Intervention|Receive OPTI-Surg program materials
41720|NCT03857620|Other|Questionnaire Administration|Ancillary studies
41721|NCT03857620|Other|Informational Intervention with Coaching|Receive OPTI-Surg program materials plus individual coaching
41722|NCT03857607|Genetic|Whole exome sequencing|Whole exome sequencing will be used to identify causative genes in ATP1A3 mutation negative patients, to confirm causality in ambiguous phenotypes and to identify modifier genes.
41723|NCT03857607|Diagnostic Test|Broadband Near Infrared Spectroscopy (broadband-NIRS)|A novel NIRS technology will be used to explore brain metabolism during paroxysmal events in ATP1A3-related disease
41724|NCT03857607|Diagnostic Test|Transcranial Magnetic Stimulation (TMS)|TMS will be employed to explore motor cortex function in patients with ATP1A3-related disease.
41725|NCT03857581|Drug|Clozapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
41726|NCT03857581|Drug|Olanzapine|Subjects will be randomly assigned to clozapine or olanzapine and followed for up to 12 weeks with weekly visits.
41727|NCT03857568|Drug|SHR0410|drug will be dosed repeatedly
41728|NCT03857568|Drug|Placebo|Placebo will be dosed repeatedly
41729|NCT03857542|Drug|AGN-190584|Ophthalmic solution, one drop, dosed bilaterally, once daily for 30 days
41730|NCT03857542|Other|Vehicle|Matching AGN-190584 ophthalmic solution dosed bilaterally, once daily for 30 days
41731|NCT03857529|Device|transcranial direct current stimulation and electrical stimulator|"Contralaterally Controlled Functional Electrical Stimulation: An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator will be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).~Transcranial direct current stimulation (tDCS): TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration."
41732|NCT03857516|Device|Multipolar left ventricular lead implantation|Multipolar left ventricular lead implantation with measurements of pacing thresholds in varrious pacing configurations.
41733|NCT03857503|Diagnostic Test|iFR|"Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.~Angiograms will be made in at least two projections, and the treating physician will record his estimation of stenosis severity.~Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures. iFR, Pd/Pa, and FFR measures will be repeated after intervention for those lesions that undergo PCI."
41735|NCT03857477|Genetic|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
41736|NCT03857477|Other|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
41737|NCT03857477|Procedure|MRI Scan|MRI scan will be offered to men identified within the top 10% genetic risk score profile.
41738|NCT03857477|Procedure|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
41739|NCT03857464|Diagnostic Test|Near Patient Testing|Near-patient testing will be conducted at Foothills Hospital rapid response lab. Negative results using C. DIFF QUIK CHEK COMPLETE® will be reported immediately to the patient wards. Positive results will be confirmed using nucleic acid testing at the centralized testing facility.
41740|NCT03857464|Diagnostic Test|SOP for C. difficile diagnostics|Two-step testing algorithm for Clostridium difficile at centralized testing facilities. No change from the current protocol.
41741|NCT03857451|Diagnostic Test|Clinical gait analysis|Three dimensional gait analysis consisting of joint kinematics, kinetics and dynamic EMG data will be introduced into the diagnostic scheme
41742|NCT03857438|Drug|Ongoing treatment for bipolar mania|Prescribed by the following doctor during hospitalization and after discharge
41743|NCT03857438|Diagnostic Test|Audiovisual recording during guided presentation|Seven tasks such as explaining the reason to come to hospital/participate in the activity, describing happy and sad memories, counting up to thirty, explaining two emotion eliciting pictures
41744|NCT03857425|Drug|Clostridum Butyricum Capsule|Clostridum Butyricum Capsule 3*420mg,twice daily for 8 weeks
41745|NCT03857425|Drug|Bacillus Coagulans Tablets|Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
41746|NCT03857425|Drug|Clostridum Butyricum Capsule plus Bacillus Coagulans Tablets|Clostridum Butyricum Capsule 3*420mg, twice daily for 8 weeks and Bacillus Coagulans Tablets 3*350mg, three times daily for 8 weeks
41747|NCT03857412|Procedure|Capsular polishing|Capsular polishing taking place during cataract surgery
41748|NCT03857412|Other|Non capsular polishing|No capsular polishing taking place during cataract surgery
41749|NCT03857399|Drug|Caspofungin|Considering the possibility of fungal infection, we take empiric therapy for the patients with persistent fever and agranulocytosis using caspofungin for injection.
41750|NCT03857386|Procedure|PECS group|Pecs block performed using ultrasound guidance
41751|NCT03857386|Procedure|Control group|Local infiltration anesthesia performed during the operation
41752|NCT03857360|Dietary Supplement|Pentabiocel|Pentabiocel is the trade name of the product containing the probiotic mixture of: Lactobacillus paracasei LMG P-17504, Lactobacillus plantarum CECT 4528, Bifidobacterium breve Bbr8 LMG P-17501, Bifidobacterium breve BL10 LMG P-17500 and Bifidobacterium animalis subsp lactis Bi1 LMG P -17,502.
41753|NCT03857360|Dietary Supplement|Placebo|Placebo is composed of maltodextrin which is easily digestible, being absorbed as rapidly as glucose. Maltodextrin listed by the U.S. Food and Drug Administration (FDA) as a safe food additive.
41754|NCT03857347|Other|Psychoeducation Group for FND|he intervention is a psychoeducation based group.
41755|NCT03857334|Biological|Injection of autologous platelet rich plasma|
41756|NCT03857334|Drug|Injection of cortivazol : Altim®|Corticosteroids
41757|NCT03857321|Drug|Insulin|20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
41758|NCT03857321|Other|Placebo|Matching placebo (sterile saline) to 20 IU Humulin® R U-100
41759|NCT03857321|Device|intranasal nebulizer-like device|Participants will be assigned to receive placebo or regular insulin (U100, 20 IU) administered through an intranasal nebulizer-like device.
41760|NCT03857308|Behavioral|Mindfulness Training|"This stress reduction training will last 14 days and teach participants skills in concentration, monitoring of present-moment bodily experience, and acceptance of experience. Participants are encouraged to mentally welcome all physical and emotional experience. Each day will consist of approximately 25 to 30 minutes of training.~A full explanation of the mindfulness training compared to the reappraisal training could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
41761|NCT03857308|Behavioral|Reappraisal Training|"This stress reduction training will last 14-days. Each day consists of 25 to 30 minutes of daily practice in Coping control. Participants are encouraged to reframe and reappraise life events, both past and present, and encouraged to solve personal problems through active change.~A full explanation of the reappraisal stress reduction program compared to the mindfulness program could interfere with study blinding procedures. A complete description can be provided after data collection is complete."
41762|NCT03857295|Other|No interventions|No intervention
41763|NCT03857282|Other|Aerobic Exercises|5 to 10 min warm up exercises than 30min bicycle exercise and 5 to 10 min cool down exercises
41764|NCT03857282|Other|Tai Chi Exercises|5 to 10 min warm up exercises and 30 min Tai Chi exercises and than than 5 to 10 min cool down exercises.
41765|NCT03857269|Other|Acupoint Massage|The operators is trained for two weeks. At 9 o'clock in the morning, the elderly are organized by Nursing home to perform acupressure.Intervention frequency will be monday to saturday per week for 6 months.
41766|NCT03857269|Other|lavender essential oil|Modulated by an international aroma therapist,The cotton ball containing essential oil is replaced by the operator at 9 am.Intervention frequency will be monday to saturday per week for 6 months.
41767|NCT03857269|Other|Acupoint Massage and lavender essential oil|At the same time as the acupressure, patients began to smell the essential oil.Intervention frequency will be monday to saturday per week for 6 months.
41768|NCT03857256|Drug|CP105F|Natural Health Product
41769|NCT03857256|Drug|Placebo|tablet manufactured to mimic the CP105F beta-glucan
41770|NCT03857243|Device|dual transcranial direct current stimulation|Mild, non-invasive battery powered direct current applied to the head over the motor areas. No shaving or invasive procedures needed.
41805|NCT03856918|Procedure|PEEP 6 cm of water|PEEP of 6 cm of water will be applied during one-lung ventilation.
41806|NCT03856918|Procedure|PEEP 9 cm of water|PEEP of 9 cm of water will be applied during one-lung ventilation.
42020|NCT03855267|Drug|Propofol 20 MG/ML|Pump propofol to keep bispectral index within 40 # 60
41771|NCT03857230|Drug|Follitropin alfa (Primapur)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
41772|NCT03857230|Drug|Follitropin alfa (Gonal-F)|"During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F.~Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur."
41773|NCT03857217|Device|Extra-Corporeal Membrane Oxygenation|ECMO is implanted in cardiac surgery patients.
41774|NCT03857204|Device|SAMPL plain wave algorithm|SAMPL's plain-wave algorithm allowing portable US or Wireless Probe scanning - thus enabling clinicians with more flexible point-of-care locations when performing US scans for fetal weight assessment.
41775|NCT03857191|Dietary Supplement|Nutritional psychocomportemental rehabilitation|Nutritional psychocomportemental rehabilitation
41777|NCT03857152|Diagnostic Test|Contrast enhanced spectral mammography (CESM)|"Contrast enhanced spectral mammography (CESM) will be undertaken in addition to routine practice.~CESM is a specialist mammography test that aims to 'highlight' areas of concern within the breast in more detail than a standard mammogram.~The difference between CESM and a standard mammogram (x-ray of the breast) is the use of a special dye (called contrast medium) that is injected into the veins before the mammogram images are taken. The contrast enhanced images give more detailed information to the breast radiologists (expert doctors trained to analyse breast imaging)."
41778|NCT03857139|Drug|Nicotine patch|Participants will receive the transdermal nicotine patch (TNP) to use during the first 2 weeks post-quit. We chose the TNP because of the extensive empirical literature supporting its effectiveness and safety, ease of use, and relatively benign side effect profile. Anxiety and depressive symptoms predict poor smoking cessation outcomes among individuals receiving NRT , suggesting that emotional disturbance influences relapse even in the context of NRT.
41779|NCT03857126|Other|Signal acquisition|ECG-PCG-CTG synchronized signals acquisition over a monitoring phase of 30 minutes. These signals will be acquired with passive non invasive sensors (abdominal and thoracic).
41780|NCT03857113|Procedure|PSMA-radioguided surgery|PSMA-radioguided surgery
41781|NCT03857100|Other|Audit and feedback - letter and report|letter describing project and report of participants' outlier status and how participants compare to peers
41782|NCT03857087|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
41783|NCT03857087|Procedure|Magnetic Resonance Imaging|Given PET/MRI
41784|NCT03857087|Procedure|Positron Emission Tomography|Undergo PET/MRI
41785|NCT03857074|Device|Green Light Exposure|To test whether exposure to a narrow band of green light (520-540 nm) at low intensities (1-10 cd/m2) decreases interictal epileptiform discharges in patients with epilepsy. The overall hypothesis for this open-label trial is based on findings in patients with migraine that indicate an engagement of thalamocortical inhibitory circuits by green light.
41786|NCT03857061|Device|smartphone, smartwatch, WearCOPDv2 application|"WearCOPD2 consists of hardware and software components.~6.1 Hardware The hardware for wearCOPDv2 consists of three main components; (1) a smartwatch, (2) a phone, and (3) a server.~6.2 Software~The wearCOPDv2 system has two main software components:~Data collection service~Participant user interface"
41787|NCT03857048|Other|Weight Loss|12-wk weight loss intervention using a meal replacement strategy (Health & Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal
41788|NCT03857048|Other|Exercise training|16-wk supervised endurance exercise training program
41789|NCT03857048|Other|Overfeeding|3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
41790|NCT03857035|Other|Piezosurgery group|Piezosurgery technique will be examined about impacted third molar surgery.
41791|NCT03857022|Device|Enhanced External Counterpulsa|The EECP therapy was given as a 1-hour session, once daily, for a total of 35 sessions. The daily urine amount, blood pressure, time for taper off positive inotropic agents, length of hospital stay, and will be monitored daily in the hospital stay. Patients will be followed-up if he or she can be released from hospital and the mortality, readmission for heart failure, and 6-minute walking distance will be checked at the end of 6th month. Plasma natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-pro-BNP) levels will be checked at enrollment, day 35, and 6th month.
41792|NCT03856996|Biological|Stable CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
41793|NCT03856996|Biological|Transient CH505TF gp120|Administered by IM injection in the deltoid of the non-dominant arm
41794|NCT03856996|Biological|Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE)|Admixed with Stable CH505TF gp120 or Transient CH505TF gp120 for IM injection in the deltoid of the non-dominant arm
41795|NCT03856983|Other|Point light display|Experimental group who will do usual rehabilitation and visualization of point-light human actions
41796|NCT03856970|Drug|Microgestin®|30 μg/1500 μg tablets for oral administration
41797|NCT03856970|Drug|Levothyroxine|600 μg tablets for oral administration
41798|NCT03856970|Drug|Glyburide|5 mg tablets for oral administration
41799|NCT03856970|Drug|Digoxin|0.25 mg tablets for oral administration
41800|NCT03856970|Drug|IW-3718|500-mg film-coated tablets for oral administration
41801|NCT03856957|Device|Endocuff colonoscopy|Colonoscopy performed with Endocuff for mucosal inspection and interventions (eg. polypectomy).
41802|NCT03856957|Device|control|colonoscopy without endocuff
41803|NCT03856944|Device|ReSTOR Toric|ReSTOR Toric bilateral IOL implantation
41804|NCT03856918|Procedure|PEEP 3 cm of water|PEEP of 3 cm of water will be applied during one-lung ventilation.
76379|NCT03586934|Drug|Celecoxib 400 mg|Celecoxib Tablet
41807|NCT03856905|Other|Physical therapy program|It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.
41808|NCT03856905|Device|Extracorporeal shock wave therapy|It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.
41809|NCT03856905|Device|Functional electrical stimulation|It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
41810|NCT03856892|Other|Hatha yoga|Novice subjects engage in an intensive full yoga practice of hatha breath based practices and inner meditative techniques along with body-based asana. Intensive level uses breath, management of abdomen, inner focus in all practices.
41811|NCT03856892|Other|Not-breath-based yoga practices|Subjects engage in a limited regular hatha yoga practice that is mainly body-based asana at a less intensive level without abdomen, breath or inner focus. Subjects have begun as novices six months prior to active intervention group and move at a simple pace through practice.
41812|NCT03856879|Behavioral|Proactive E-consult|E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
41813|NCT03856866|Drug|Hydroxychloroquine|Hydroxychloroquine: 4mg/kg/day, divided bid.
41814|NCT03856866|Drug|Placebo|Liquid suspension compounded to mimic the active hydroxycholoquine interventional agent.
41815|NCT03856853|Drug|Pirfenidone|pirfenidone for SSc-ILD treatment
41816|NCT03856853|Other|placebo|as control
41817|NCT03856827|Drug|IW-6463|IW-6463 Tablet
41818|NCT03856827|Drug|Matching Placebo|Matching Placebo Tablet
41819|NCT03856814|Device|ELVeS® Radial® 2ring slim fiber used for EndoVenous Laser Ablation|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
41820|NCT03856801|Other|Exercise|Whole-body vibration training in hypoxia and normoxia condition
41821|NCT03856788|Drug|Saline|40 mL sterile normal saline
41822|NCT03856788|Drug|Bupivacaine|40 mL 0.25% bupivacaine
41823|NCT03856775|Device|Quantitative EEG and Seizure detector|Paediatric intensive care unit nurses, residents or fellows will perform hourly review of a bedside graphical display of the previous hour's epoch of quantitative EEG for seizure patterns. One page of quantitative EEG data represents one hour of recording. The graphical display will include a seizure-detection marker, seizure probability indicator, bilateral rhythmicity spectrogram and bilateral amplitude integrated EEG.
41824|NCT03856762|Dietary Supplement|Healthy Jiangnan diet|Healthy Jiangnan diet supplement from Monday to Friday for three months
41825|NCT03856762|Dietary Supplement|Mediterranean diet|Mediterranean diet supplement from Monday to Friday for three months
41826|NCT03856762|Dietary Supplement|Shanghai typical diet|Shanghai typical diet supplement from Monday to Friday for three months
41827|NCT03856749|Other|Wheelchair skills training|"The wheelchair user and caregiver will be trained together on wheelchair skills, using the principles of the Wheelchair Skills Training Program, as outlined in the Wheelchair Skills Program Manual. Each training session will be with a trainer-to-dyad ratio of 1:1 1 dyad = 1 manual wheelchair user + his/her caregiver. Training will continue until the goals have been met and retained (for at least one subsequent session), using up to 4 training sessions that will each last 30-60 minutes at intervals of 1-10 days.~Prior to the first training session, the trainer will be provided with the wheelchair skills test questionnaire results from the assessment immediately preceding training to provide him/her time to individualize the training session."
41828|NCT03856736|Other|HIIT and MCT|High Intensity and Moderated Exercise
41829|NCT03856736|Other|MCT|Moderated exercise
41830|NCT03856736|Other|Control|Weekly lectures and educational approach
41831|NCT03856723|Other|Renal Replacement Therapy|"Indications for RRT were defined as previously reported.~Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 ;~severe sepsis, persistence of hypotension (for more than 6 h) despite preload optimization and use of vasopressors or catecholamines (norepinephrine or epinephrine >0.1 μg/kg/min),~refractory fluid overload (worsening pulmonary edema, PaO2/FiO2 <300 mm Hg or fluid balance >10% of body weight),~low probability of rapid renal recovery according to the judgment of the intensivists and nephrologists."
41832|NCT03856710|Device|self-gripping mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
41833|NCT03856710|Device|Stapled mesh|The initial laparoscopic approach will be the same for both groups until the process of selection and placement of the mesh (ProGripTM self-gripping mesh versus standard 'lightweight' (large pore) polypropylene mesh fixed with SecurestrapTM) which would be decided by randomization by sealed envelope into one of the 2 intervention groups: Group 1 (Self-gripping Mesh), Group 2 (Stapled Mesh).
41834|NCT03856697|Drug|Abivertinib Maleate Capsules|patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
41835|NCT03856697|Drug|Placebo Gefitinib Tablets|patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
41836|NCT03856697|Drug|Gefitinib Tablets|patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
76380|NCT03586934|Drug|Ropivacaine|Ropivicaine nerve block (injection)
41837|NCT03856697|Drug|Placebo Abivertinib Maleate Capsules|patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
41838|NCT03856684|Behavioral|Self-sampling kit sent at home|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
41839|NCT03856684|Behavioral|Self-sampling kit sent at home + SMS reminder|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~After 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
41840|NCT03856684|Behavioral|"Letter offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear.~Women are invited to ask the kit online, on our website.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
41841|NCT03856684|Behavioral|"SMS offering a self-sampling kit on request+ SMS reminder"|"Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request).~Women are invited to ask the kit by answering 1 by SMS.~For the women who ask the kit, after 2 months without return, a SMS reminder about the available self-sampling kit is sent to the woman. We call return :~the receipt of the vaginal self-sample at the laboratory~the performance of a pap smear~Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
41842|NCT03856671|Drug|Neomycin,metronidazole|Orally intake neomycin 1g and metronidazole 0.2g four times before surgery
41843|NCT03856658|Combination Product|FUDR via HAI pump|Both the FUDR and the HAI pump are experimental because they are being used to treat hepatic liver metastases of pancreatic adenocarcinoma. They have not yet been approved for this indication, although they are both approved for other indication. FUDR will be delivered via the HAI pump for 6 months, in 28 day cycles: 2 weeks of therapy, followed by 2 weeks of heparinized saline.
41844|NCT03856645|Drug|OKG-0301|OKG-0301 is an experimental ophthalmic antiviral and immunomodulatory therapeutic
41845|NCT03856632|Drug|Liraglutide|Liraglutide will be administered with a starting dose of 0.6 mg once daily and subsequent increments to 1.2 mg once daily (after at least one week) and to 1.8 mg once daily (after at least a week on 1.2 mg). This will be taken for 3 consecutive months in conjunction with RFM program prior to catheter ablation. Treatment will resume post ablation and will be continue for 6 months.
41846|NCT03856632|Other|RFM|The program involves weight management and exercise regimen (30 minutes for 2 to 4 times a week), hyperlipidemia management (lifestyle measure changes and initiation of statins and fibrates if necessary), management of obstructive sleep apnea (initiation of Continuous Positive Airway Pressure (CPAP) if necessary), management of hypertension (reduction of salt intake, initiation of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor blockers (ARB) medications if necessary), diabetes management (lifestyle measure changes, endocrine review and initiation of metformin if necessary) and smoking cessation and alcohol abstinence or reduction. This program will be performed at start of study participation all throughout the follow up period.
41847|NCT03856632|Drug|Anti Arrhythmics|The choice of antiarrhythmic drug will be at the discretion of the managing physician, but will generally include either a class IC or class III antiarrhythmic drug. If necessary, and clinically indicated, amiodarone may be used. Therapy will be initiated at the start of study participation and will be discontinued 6-12 weeks after the ablation, as deemed clinically appropriate by the managing electrophysiologist.
41848|NCT03856632|Procedure|Afib Catheter Ablation|The procedure will be performed according to usual clinical practice. The primary approach will be antral pulmonary vein isolation (PVI), preferably performed by cryoballoon ablation, though radiofrequency may be used as deemed necessary by the operator for clinical reasons. This will be performed after 3 months of RFM or RFM + Liraglutide program.
41849|NCT03856619|Drug|TERIFLUNOMIDE HMR1726|"Pharmaceutical form: Tablet~Route of administration: Oral"
41850|NCT03856606|Behavioral|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
41851|NCT03856606|Behavioral|Prolonged sitting with interval exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
41852|NCT03856593|Behavioral|Letter A|The letter will be signed by the Chief Medical Examiner-Coroner and County Health Officer of Los Angeles County to notify prescribers of the death in their practice. The letter includes the decedent's name, date of birth and date of death, and outlines the annual number and types of prescription drug deaths seen by the medical examiner, discusses the value of and way to access the State's prescription drug monitoring program and includes five Centers for Disease Control and Prevention (CDC) guideline-recommended safe prescribing strategies: 1) Avoid co-prescribing of opioids with benzodiazepines, 2) prescribe minimal dose necessary for acute pain, 3) consider slow tapers with pauses to below 50 MME per day, 4) avoid prescriptions lasting greater than 3-months for pain, and 5) prescribe naloxone in conjunction with opioids for patients taking > 50 MME per day. The letter also states that CURES review is required by law as of October 2, 2018.
76381|NCT03586934|Drug|Ketorolac|ketorolac injection
41853|NCT03856593|Behavioral|Letter B|"This letter includes all the details in Letter A plus additional text involving an if/when/then statement along with an injunction to providers to share safety information with patients so that they identify as a safe prescriber. Specifically, the additional text reads as follows: When your next patient presents with pain, keep the above 5 recommendations close at hand to assist with their safe care. Also, be comfortable voicing your concern about prescribing safety with them so that they are also aware of the dangers scheduled drugs may carry. If/when/then is a form of pre-suasion that provides simple rules that tie goals to specific actions and has been used successfully to encourage behavior in many areas including medication adherence and drug abuse rehabilitation."
41854|NCT03856580|Behavioral|Alternative long-acting PrEP injection strategies|"Participants in the two intervention groups will complete injection procedures (e.g., self-injection, injection by healthcare providers at drop-in clinics) to determine if this could facilitate improved adherence to an inert version of long-acting cabotegravir injections"
41855|NCT03856580|Behavioral|mHealth adherence app|"Participants in the two experimental arms will be given a smartphone application, designed to facilitate adherence (this app will be developed during earlier phases of the study using in-depth interviews and design session groups)"
41856|NCT03856567|Other|VR System|Use of virtual reality to deliver exposure therapy
41857|NCT03856567|Other|Control|Use of conventional delivery of exposure therapy
41858|NCT03856554|Procedure|Unilateral Transforaminal Interbody fusion|TLIF via unilateral factectomy and insertion of one cage
41859|NCT03856554|Procedure|Bilateral Transforaminal Interbody fusion|TLIF via bilateral factectomy and insertion of two cages
41860|NCT03856541|Drug|SHR-A1403|SHR-A1403 is a humanized anti C-Met immunoglobulin G2 (IgG2) monoclonal antibody conjugated with microtubule inhibitor. SHR-A1403 is provided as the lyophilized powder,40 mg/vial.SHR-A1403 was given intravenously per 3 weeks at the day 1.Intravenous infusion over 30 min
41861|NCT03856528|Other|collection of patient data|Patient data will be obtained using digital patients records systems. The following data will be assessed: Demographics and baseline patient characteristics (e.g., gender, age, hospital admission and discharge dates), diagnoses, comorbidities (history of meningitis and/or encephalitis, epileptic disorders, remote stroke, remote intracranial bleeding, remote autoimmune disease, neurodegenerative disorders), laboratory features (blood cultures, lumbar puncture), features of neuroimaging (e.g., time admission-to-CT), therapeutic features (incl. time admission-to-treatment), Patients' outcome measures (Glasgow Outcome Score)
41862|NCT03856515|Drug|Nicotine-Containing Standard Research Electronic Cigarette|E-cigarettes with Nicotine
41863|NCT03856515|Device|Non-Nicotine Standard Research Electronic Cigarette|E-cigarettes without Nicotine
41864|NCT03856502|Drug|8 mg of dexamethasone|Effect of intrathecally administered dexamethasone in spinal anaesthesia for surgical correction of the hip fracture.
41865|NCT03856502|Drug|12,5 mg of 0,5 % of levobupivacaine|Local anaesthetic standardly used in spinal anaesthesia for surgical correction of the hip fracture by the particular hospital's protocol.
41866|NCT03856489|Other|Richards-Campbell Sleeping Questionnaire (RCSQ)|This five-item visual analogue scale was designed as an outcome measure for assessing the perception of sleep in critically ill patients. The scale evaluates perceptions of depth of sleep, sleep onset latency, number of awakenings, time spent awake, and overall sleep quality.
41867|NCT03856463|Behavioral|Lay Navigator Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning and documenting goals of care.
41868|NCT03856463|Other|Usual Care|Usual care as provided by local oncologists
41869|NCT03856450|Device|DTS|Subjects undergo wrist imaging using DTS.
41870|NCT03856450|Device|X-ray|Subjects undergo wrist imaging using standard X-ray imaging.
41871|NCT03856450|Device|MRI or CT|Subjects may undergo wrist imaging using MRI or CT.
41872|NCT03856437|Behavioral|Framed HPV vaccination messages|Digital multimedia messages consisting of text and imagery conveying the benefits of being vaccinated against HPV or the costs of not being vaccinated against HPV.
41873|NCT03856424|Procedure|Modality 1|Pressure support ventilation (PSV) modality
41874|NCT03856424|Procedure|Modality 2|T-Piece modality
41875|NCT03856424|Procedure|Modality 3|High-flow oxygen
41876|NCT03856411|Drug|TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
41877|NCT03856398|Device|C- MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
41878|NCT03856385|Behavioral|Mindful Walking|Weekly 60 minute mindful walking sessions involving observations of bodily sensations, experiences, and breath. Discussion of mindful walking experiences and encouragement to meet physical activity goals.
41879|NCT03856372|Radiation|Hypofractionated|daily fractions, five fractions per week.
41880|NCT03856372|Radiation|Conventional|daily fractions, five fractions per week.
41881|NCT03856359|Drug|Rifaximin 550 milligrams (MG)|Rifaximin (Xifaxan, Salix Pharmaceuticals, Bridgewater, N.J.) (See Package Insert) is a drug that is approved by the FDA for use in humans for the treatment of Hepatic Encephalopathy, Traveler's Diarrhea and Irritable Bowel Syndrome. It is commercially available. It will be used in accordance with approved labeling as pertains to dosage and administration for Hepatic Encephalopathy, contraindications and warnings. However, it will be used investigationally in this trial as rifaximin is not FDA approved for the treatment of Alzheimer's Disease.
41882|NCT03856346|Diagnostic Test|Biometry|Biometry for phaco-vitrectomy procedures pre- and postoperatively
41883|NCT03856333|Other|Assigned Interventions|exercises, physical agents
41884|NCT03856320|Behavioral|Educational Video|An educational video describing obesity treatment options available in the VA.
41885|NCT03856307|Diagnostic Test|point of care ultrasound|to evaluate the reliability of simple pre-specified ultrasound findings acquired at the bedside with a hand-held apparatus with regards to five clinical scenarios most commonly encountered in the hospital, i.e. vaginal bleeding in early pregnancy, pre-eclampsia, prolonged/obstructed labor, antepartum hemorrhage (APH) and high risk pregnancies encountered in ANC.
41886|NCT03856294|Drug|Rikkunshito|Rikkunshito, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
41887|NCT03856294|Drug|Placebos|Placebo, 2,5g dissolved in 200 mL lukewarm water, three times daily, 30min before meal intake
41888|NCT03856281|Device|Intermittent Pneumatic Compression|Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period
41889|NCT03856268|Procedure|'Surgical Menopause' Group|Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
41890|NCT03856268|Drug|'Drug-Induced Menopause' Group|Women undergoing gonadal suppression via leuprolide acetate (Lupron [AbbVie Inc.]) will be enrolled at the University of Colorado-Denver.
41891|NCT03856255|Device|Micro-Tech Endoscopic Gauge|Use of Micro-Tech Endoscopic Gauge to measure any polyp detected during a screening or surveillance colonoscopy.
41892|NCT03856242|Drug|Tamsulosin Oral Capsule|Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
41893|NCT03856242|Procedure|TURP|Routine transurethral prostatic resection
41894|NCT03856229|Drug|Conventional steroid regimen|Subjects will receive the conventional steroid regimen with prednisolone or equivalent (with methylprednisolone): Day 1 to 5: 40 mg orally every 12 h; Day 6 to 10: 40 orally every 24 hours; and Day 11 to 21: 20 mg orally every 24 h.
41895|NCT03856229|Drug|Shortened steroid regimen|"Subjects with Moderate PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5);40 mg orally every 24 hours (Day 6 to 8).~Subjects with severe PCP. Prednisolone (or equivalent with methylprednisolone) 40 mg orally every 12 h (Day 1 to 5),40 mg orally every 24 hours (Day 6 to 10); and 20 mg orally every 24 h (Day 11 to 14)."
41896|NCT03856216|Procedure|Allogeneic Bone Marrow Transplantation|Given IV
41897|NCT03856216|Biological|Anti-Thymocyte Globulin|Given IV
41898|NCT03856216|Drug|Bendamustine|Given IV
41899|NCT03856216|Biological|Filgrastim-sndz|Given IV
41900|NCT03856216|Drug|Fludarabine|Given IV
41901|NCT03856216|Biological|Inotuzumab Ozogamicin|Given IV
41902|NCT03856216|Drug|Melphalan|Given IV
41903|NCT03856216|Drug|Methotrexate|Given IV
41904|NCT03856216|Procedure|Peripheral Blood Stem Cell Transplantation|Given IV
41905|NCT03856216|Biological|Rituximab|Given IV
41906|NCT03856216|Drug|Tacrolimus|Given IV and PO
41907|NCT03856190|Other|Fasting and plant-based nutrition|The experimental intervention is divided into an initial part with periodic fasting for 7-10 days on an outpatient basis, which is followed by a build-up phase. This group part then receives a diet change with a specific normocaloric nutrition including the concept of time restricted eating (TRE, 16/8h) and according to the following criteria: 1) plant-based, 2) rich in prebiotics, 3) enriched with kitchen spices and kitchen herbs known for their anti-mycotic and anti-inflammatory potential.
41908|NCT03856190|Other|Standard Nutrition Counselling|The control group receives a diet considered to be fundamentally beneficial to health in the sense of the recommendations of the German Association for Nutrition (DGE), which contain a reduced intake of arachidonic acid and, as a result, modulate an anti-inflammatory effect.
41909|NCT03856177|Behavioral|Emotion Induction|Described in arm
41910|NCT03856164|Drug|Tranexamic Acid|Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
41911|NCT03856164|Drug|Placebo|100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.
41912|NCT03856151|Device|"HEALTHY BOX Powered heating pad"|Using heating device without direct contact to the skin (a piece of cork wood pad placed between skin and heating device) on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
41913|NCT03856125|Other|PENS plus exercise|"The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle~Needle will be placed at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's~The percutaneous electrical stimulation will be realized with a transcutaneous electric nerve stimulation (TENS) current:~TENS Frequency - 2 Hz~TENS Pulse width - 250 microseconds~Duration - 30 minutes.~TENS Intensity - Increased at an intensity of visible motor response of the innervated musculature and maximal tolerable intensity.~Administration - One per week"
41914|NCT03856125|Other|Sham PENS plus exercise|"The technique will be performed on the radial nerve, the places of the needle's. The technique will be performed ultrasound-guided on the radial nerve, the places of the needle's insertions will be the following:~Needle will be placed at under the lateral intermuscular septum between the triceps brachii and brachialis, approximately 10cm superior to the lateral epicondyle.~Needle wil be placed at the at the upper third of the forearm on the posterior interosseous nerve after passing the arcade of Froshe's.~The current will not be working, and the needles will be placed during 30 minutes.~- Administration - One per week"
41915|NCT03856112|Drug|Dexamethasone|Given PO
41916|NCT03856112|Drug|Ixazomib|Given PO
41917|NCT03856112|Drug|Ixazomib Citrate|Given PO
41918|NCT03856112|Drug|Venetoclax|Given PO
41919|NCT03856099|Drug|TTAC-0001|"Investigational product (IP): TTAC-0001~Treatment groups: 3 dose groups~Dose group A : TTAC-0001 16 mg/kg on D1 and D15~Dose group B : TTAC-0001 20 mg/kg on D1 and D15~Dose group C : TTAC-0001 24 mg/kg on D1 and D15~Cycle: 4 weeks (28 days per cycle)"
41920|NCT03856086|Behavioral|Baseline questionnaire|Baseline questionnaire on the day of the patient's surgery.
41921|NCT03856086|Behavioral|NCCN Problem List|NCCN Distress Thermometer
41922|NCT03856086|Behavioral|FACT-GP|Greater overall quality of life
41923|NCT03856086|Behavioral|HADS|Lower anxiety and depression
41924|NCT03856086|Behavioral|CSS-CG|web-based CSS-CG
41925|NCT03856073|Behavioral|Novice|Using the simulate device, the novices in bronchoscopy are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
41926|NCT03856060|Other|Questionnaire Administration|Complete questionnaires
41927|NCT03856060|Other|Video|Watch videos of doctor and patient interaction in different settings
41928|NCT03856047|Drug|NNC0174-0833|Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
41929|NCT03856047|Drug|Placebo (NNC0174-0833)|Participants will get one dose of Placebo (NNC0174-0833) once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
41930|NCT03856047|Drug|Liraglutide 3.0 mg|Participants will get one dose of liraglutide 3.0 mg once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg daily. The participants will continue on 3.0 mg of liraglutide, once daily up to 26 weeks.
41931|NCT03856047|Drug|Placebo (Liraglutide 3.0 mg)|Participants will get one dose of Placebo (liraglutide 3.0 mg) once daily. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using pre-filled PDS290 pen-injector. Participants will gradually increase their dose every week until they reach the target dose of 3.0 mg. The participants will continue on Placebo (liraglutide 3.0 mg), once daily up to 26 weeks.
41932|NCT03856034|Device|Fetoscopy|Patients will receive fetoscopic repair of myelomeningocele. Patients with an anterior placenta will undergo the laparotomy with uterine exteriorization approach. Patients with a posterior placenta will undergo the percutaneous approach (or, if patient prefers, the laparotomy with uterine exteriorization approach).
41933|NCT03856021|Procedure|Microfracture with Bone Marrow Aspirate Concentrate|Bone Marrow Aspirate Concentrate harvested and prepared from the iliac crest
41934|NCT03856021|Procedure|Microfracture|All surgeons will use a 2 mm microfracture pick to perform the microfracture procedure. Using the 2 mm pick, surgeons will make 5 holes per 10 cm2.
41935|NCT03856008|Other|Exercises focused on flexor muscles|Exercises emphasis flexor muscles.
41936|NCT03856008|Other|Exercises focused on extensor muscles|Exercises emphasis extensor muscles.
41937|NCT03855995|Procedure|Whole blood sample|Whole blood samples will be collected from all enrolled children hospitalised and suspected of having an AESI or meningitis.
41938|NCT03855982|Drug|Drug inducing myocarditis|Drugs susceptible to induce myocarditis
41939|NCT03855969|Procedure|Removal of a central venous access device|We are interested in those patients for which a central venous access device was removed.
41940|NCT03855956|Other|KB174|KB174 is a novel mixture of oligosaccharides.
41941|NCT03855956|Other|Maltodextrin|Maltodextrin is a commercially available easily digestible polysaccharide.
41942|NCT03855943|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
41943|NCT03855943|Behavioral|CBT|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
41944|NCT03855930|Diagnostic Test|functional MRI|During the study, standard motor and sensory paradigms will be performed to establish anatomical and functional patterns in the non-painful state. The patient will then be asked to urinate (to an external collecting tube system).
41945|NCT03855917|Drug|Sofosbuvir 400mg [Sovaldi]|Four weeks.
41946|NCT03855917|Drug|Glecaprevir/pibrentasvir (300mg/120mg)|Four weeks.
41947|NCT03855904|Device|TC-325|TC-325 compounds of inorganic, non-absorbable powder which acts locally at the mucosal tissue. When spraying the powder on to the blood, it will become a stable barrier sheet because of the effect of clotting factors accumulation and, then the normal healing process can be promoted.
41948|NCT03855891|Diagnostic Test|blood test|Blood test for spectrum and level of cardiospecific micro-RNA
41949|NCT03855865|Drug|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
41950|NCT03855865|Drug|Vortioxetine|Vortixetine (10 mg with available dose increase to vortioxetine 20 mg oral daily after 3 weeks of administration).
41951|NCT03855865|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration or oral daily).
41952|NCT03855852|Procedure|Xenograft and Collagen membrane|Placing the implant with collagen membrane and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
41953|NCT03855852|Procedure|Xenograft and APRF|Placing the implant with APRF and xenograft at esthetic zone of maxillary ridge with 2-4 mm thread exposure .
41954|NCT03855839|Device|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle activity, reduce musculoskeletal pain and discomfort.
41955|NCT03855839|Device|Compression shirt|Compression shirts are designed for recreational sport activities and can be bought in any local sports store
41956|NCT03855826|Drug|Nifekalant hydrochloride|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
41957|NCT03855826|Drug|Amiodarone|Both groups were given conventional treatment except for arrhythmia drugs.Only nyficarine hydrochloride or amiodarone hydrochloride could be used according to random results, and the antiarrhythmic drugs should be replaced according to the protocol rules.
41958|NCT03855813|Other|Intra rater reliability|Patients will perform the 30 seconds chair stand test as a self-test twice at home with approximately two days apart. The last self-test should be performed approximately one week before the testing with a physical therapist.
41959|NCT03855813|Other|Inter rater reliability|Same patients performing the self-test will be tested by a physical therapist approximately one week after the last self-test. The physical therapist will be blind to the self-test results.
41993|NCT03855488|Behavioral|Imagery enhanced cognitive bias modification|Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.
42021|NCT03855267|Drug|Propofol 20 mg/ml , etomidate 2 mg/ml|Propofol was mixed with etomidate in different proportions.keep bispectral index within 40 # 60.
77836|NCT03576053|Other|Serotonin|Serotonin electrophoresis
41960|NCT03855800|Diagnostic Test|Blood, stool, pancreatic juice and cyst fluid collection|Blood and stool will be collected at baseline from all study participants. Those in the Immediate Surgery group may undergo endoscopic pancreatic juice collection before surgery, either at the time of a clinically indicated endoscopic ultrasound (EUS) exam or during an optional pre-operative research endoscopy. Pancreatic cyst fluid will also be obtained from all participants in the Immediate Surgery group, either at the time of surgery, or during a clinically indicated preoperative EUS FNA procedure, or both. Pancreatic juice and cyst fluid will be collected opportunistically from participants in the Clinical Follow-up group who undergo a clinically indicated EUS, EUS FNA, or endoscopy exam.
41961|NCT03855800|Procedure|Pancreatic Surgery|Surgical resection of pancreatic cyst
41962|NCT03855800|Procedure|Endoscopy Exam|Clinically indicated endoscopic ultrasound
41963|NCT03855787|Procedure|Ureteroscopy|Ureteroscopy for 1.5cm or less renal stones.
41964|NCT03855774|Genetic|Polymorphisms|Classification of sleep disorders using 22 genetic polymorphisms
41965|NCT03855761|Behavioral|Occupational Therapy|Detailed narrative assessment and person-centered participation in meaningful activities
41966|NCT03855761|Behavioral|Case management; psychological services|Weekly consultation with case managers to address housing and therapy needs
41967|NCT03855748|Other|Healthy group|"Subjects undergo the following activities:~Walking~Jogging (8-11 km/h)~Maximal 5 meters sprint acceleration~Single leg drop jump from 35 cm height~Horizontal jump with single leg landing with a distance of 100% and 150% of leg length~Maximal change of direction at 45, 135, 180 degrees~Single-leg cross-country skiing exercise"
41968|NCT03855735|Behavioral|Intervention Group (IG)|The developed short manual for the teaching of different communication models competences will enable those who have been arbitrarily assigned to the intervention group and their relatives to develop secure communication competences. The intervention group will also have access to the digital app.
41969|NCT03855722|Procedure|RIPC|Remote Ischaemic Preconditioning
41970|NCT03855722|Procedure|Sham-RIPC|Sham procedure
41971|NCT03855709|Diagnostic Test|microbiological culture and sensetivity|microbioloical culture will be used to detect microbiological profile in hepatic patients with infections, drug sensitivity to detect resistent bacteria which will be confirmed using PCR detection of resistent gene
41972|NCT03855696|Biological|MG1113|MG1113
41973|NCT03855696|Other|Placebo of MG1113|Placebo of MG1113
41974|NCT03855683|Behavioral|Unified Protocol for The Treatment of Emotional Disorders|Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
41975|NCT03855631|Genetic|Intervention on primary cultured cells|The intervention includes primary cultured cells, reprograming them into mesenchymal stem cells and CRISPR/Case9 gene therapy treatment on patients' cells
41976|NCT03855579|Drug|Levosimendan|Intraoperative infusion of Levosimendan
41977|NCT03855579|Drug|Milrinone|Intraoperative infusion of Milrinone
41978|NCT03855566|Behavioral|Intensive behavioral therapy for obesity|Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
41979|NCT03855553|Behavioral|Family Based Treatment|"10 families will be randomized to receive 10 - 16 weeks of Family Based Treatment (FBT), the gold standard in eating disorder treatment for adolescents. FBT is a highly structured behavioral intervention in which caregivers are charged with the primary task of re-feeding their child and normalizing his or her eating behaviors and weight status."
41980|NCT03855553|Behavioral|Enhanced Cognitive Behavioral Therapy|10 families will be randomized to receive 10 - 16 weeks of Enhanced Cognitive Behavioral Therapy (CBT-E), a clinically validated treatment for adolescent eating disorders. CBT-E is a short-term, individual treatment focused on normalizing eating behaviors and modifying underlying cognitions that contribute to the maintenance of eating disorder behaviors (e.g., over-importance of shape and weight in one's self-evaluation).
41981|NCT03855540|Diagnostic Test|ECHOcardiography|"ECHO parameters~LA diameter~LVEDD~LVEF~Diastolic dysfunction~Valvular disease"
41982|NCT03855540|Diagnostic Test|Peripheral blood samples for plasmatic biomarkers|"Coagulation~D - dimer~Fibrinogen~Inflammation and fibrosis~Hs - CRP~AGEs~Soluble RAGE~Hemodynamics (LA stretch)~Apelin~NT - proBNP~Hs - troponin~MiRNA~miRNA - 1~miRNA - 133~miRNA - 29b~miRNA - 208a~miRNA - 208b~miRNA - 499"
41983|NCT03855540|Diagnostic Test|Athens insomnia scale questionnaire|Athens insomnia scale questionnaire
41984|NCT03855540|Diagnostic Test|ECG Holter monitor|Patient receives ECG Holter monitor if included to the control group
41985|NCT03855540|Diagnostic Test|ECG event recorder|Patient receives ECG event recorder for twice daily (or if symptoms), 90 seconds duration ECG monitoring if included to the control group
41986|NCT03855527|Drug|Silver Diamine Fluoride|SDF will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
41987|NCT03855527|Drug|Chlorhexidine|Chlorhexidine will be applied as a cavity disinfected after atraumatic restorative technique (Antimicrobial effect)
41988|NCT03855527|Procedure|Atraumatic Restorative Treatment without Disinfection|Atraumatic Restorative Technique will be performed without cavity disinfection
41989|NCT03855514|Other|NuShield|NuShield® is a dehydrated placental allograft.
41990|NCT03855501|Other|Mineral trioxide aggregate|Apexification treatment was done with mineral trioxide aggregate
41991|NCT03855501|Other|Calcium hydroxide|Apexification treatment was done with calcium hydroxide
41992|NCT03855488|Behavioral|Standard cognitive bias modification|Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.
42018|NCT03855293|Procedure|Rhexis protection shield|In the study group the anterior capsule will be used as a protection shield during pacoemulsifikation and removed after the phacoemulsifikation
41994|NCT03855488|Behavioral|Neutral Control Condition|Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
41995|NCT03855475|Behavioral|Aerobic exercise|Participants will complete 12 weeks of supervised aerobic exercise, 3 times per week, on a treadmill or stationary bicycle
41996|NCT03855475|Behavioral|Stretching|Participants will complete 12 weeks of supervised stretching, 3 times per week
41997|NCT03855462|Device|MCT oil injection|"The patient treatment is the classical surgical procedure which is used for retinal detachment with MCT oil :~Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous.~MCT ablation after 4 to 6 weeks (after effective retinopexy)~after MCT ablation, total follow-up duration by patient is 6 months."
41998|NCT03855449|Behavioral|Task Analysis Intervention Group|Will conduct 9 week in-person group sessions of the DECIDE curriculum with recruited volunteers. This is part 1 or phase I of the eventual pilot clinical trial. Participants will attend weekly group sessions to learn problem-solving skills and management of their diabetes.
41999|NCT03855423|Dietary Supplement|Tocotrienol-rich Fraction (TRF)|TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol
42000|NCT03855410|Behavioral|S4E|The face-to-face version of S4E (i.e., Storytelling for Empowerment) is registered as a best-practice with the Substance Abuse and Mental Health Services Administration's (SAMHSA) National Registry of Evidence-Based Practices and Programs.The S4E mHealth app was developed in collaboration with youth in Southeast Michigan. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol and drug use, HIV and STIs. We now propose to develop modules focused on tobacco prevention and cessation. S4E aims to increase self-efficacy and communication about health risk behaviors. The face-to-face version of S4E has been shown to prevent and reduce substance use, including cigarette use, as well as increase (1) substance use prevention knowledge, (2) communication about health risk behaviors, and (3) perception of harm and self-efficacy in refusing licit and illicit substances.
42001|NCT03855410|Behavioral|Attention-Matched Control Group|Participants in the Attention-Matched Control group will receive a PDF version of the tobacco module material, an enhancement to the usual care they would receive should they not join the study. Participants in this group will also receive usual care. The Clinic's usual care includes standard risk behaviors intake form, pamphlets highlighting resources on sexual, physical, and mental health, and other healthcare services.
42002|NCT03855397|Other|Microneedle|A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.
42003|NCT03855397|Other|Hypodermic needle|30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
42004|NCT03855397|Other|Flat patch|A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
42005|NCT03855384|Drug|TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|TQB2450 1200mg IV ，cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
42006|NCT03855384|Drug|placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)|placebo 1200mg IV ，cisplatin 75 mg/m^2 IV or carboplatin AUC 5 IV on Day 1 of each week in 3-week cycles (6 cycle maximum); plus 5-FU 750 mg/m^2/day IV continuous from Day 1-5 of each 3- week cycle (6 cycle maximum).
42007|NCT03855371|Drug|Decitabine|20mg/m2/d, intravenously, d1-d5, q4w
42008|NCT03855371|Drug|Arsenic Trioxide|0.16mg/kg/d, intravenously, d1-d5, q4w(maximum dose: 10mg/d)
42009|NCT03855358|Drug|TQB2450 Injection and Anlotinib Hydrochioride Capsules|TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
42010|NCT03855345|Procedure|Conventional treatment|The treatment will consist of oral hygiene orientation, with instructions of brushing technique and recommendation of the daily use of dental floss. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with ultrasound equipment and curettes for root scaling and straightening. After the use of ultrasound and curettes, bicarbonate jet will be used to remove dental biofilm. Treatment will be performed in 2 to 4 sessions under local anesthesia (typically 2% mepivacaine with 1: 100,000 noradrenaline). Gracey periodontal curettes (numbers 3/4, 7/8, 11/12 and 13/14) and Mc Call curettes for removal of the dental calculus will be used. Other biofilm-retaining factors, such as carious lesions, condemned teeth, and ill-adapted restorations, will be removed during these periodontal treatment sessions.
42011|NCT03855345|Radiation|aPDT|aPDT will be performed at the end of each periodontal treatment session, at sites with bags greater than or equal to 4 mm. The photosensitizer PapaMBlue® (F & A Ltda, São Paulo, Brazil) will be deposited in the pouches with a syringe, with the application in coronal direction, and a time of 1 min of pre-irradiation will be adopted so that the substance can stain bacterial biofilm (according to the manufacturer's information). Next, the diode laser emitting wavelength of ʎ=660 nm, with power of P=100 mW, will be applied. The laser will be applied to the mucosa, over the oral epithelium with an optical fiber. Irradiation will be performed until the entire periodontal pocket is illuminated for 2 min at each point. Each irradiation point will be approximately 0.4cm2, which will result in energy density of 30 J/cm2 in 2 min irradiation. The irradiation will have a constant power density of 250 mW/cm2.
42012|NCT03855332|Drug|Sildenafil|See above
42013|NCT03855332|Drug|Cilostazol|See above
42014|NCT03855332|Drug|Placebo|Overencapsulated placebo
42015|NCT03855319|Behavioral|SMR neurofeedback training to MCI|The intervention consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta training was recorded at channel Cz according to the international 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed.A 32 channels system (EEGDigitrcak Biofeedback plus module, Inc Elmiko Medical) was used for the SMR/theta Neurofeedback training.
42016|NCT03855306|Drug|Glibesyn|1 tablet contains 5 mg Glibenclamide
42017|NCT03855306|Drug|Daonil|1 tablet contains 5 mg Glibenclamide
42019|NCT03855280|Drug|APVO101|APVO101: 35 - 75 IU/kg; twice weekly
42089|NCT03854786|Dietary Supplement|Pacebo|Methyl Crystalline Cellulose
42022|NCT03855254|Behavioral|communication type|Positive and negative communication types are the way that the practitioner communicates to the participant about the potential effectiveness of the osteopathic treatment. The control is a neutral communication condition.
42023|NCT03855241|Behavioral|Informational Sheet|The informational sheet details how use opioid medicines safely, and lists ways to properly dispose of leftover opioids
42024|NCT03855241|Behavioral|DisposeRx Drug Disposal kit|DisposeRx is a powder that is activated with water and traps leftover drugs (i.e. pills, capsules, caplets, liquids or tablets) in a semi-solid gel. The trapped drug cannot be retrieved from the resulting gel material for misuse, abuse or to leach into landfills. The participant can then throw away the biodegradable solid material in the prescription bottle into the trash, as it is safe for the environment.
42025|NCT03855228|Drug|Mometasone furoate nasal spray (MFNS)|Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days.
42026|NCT03855228|Drug|Loratadine|Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days.
42027|NCT03855228|Drug|Placebo nasal spray|Daily dose of placebo administered as a nasal spray for 15 days.
42028|NCT03855228|Drug|Placebo tablet|Daily dose of placebo administered as an oral tablet for 15 days.
42029|NCT03855215|Diagnostic Test|ACTIM CRP Rapid Test (Medix, Biochemica)|The implementation of CRP point of care tests will be conducted at commune health centres (CHCs), the primary access point for public health services in Vietnam. In the intervention CHCs, healthcare workers will be trained on the use and interpretation of CRP testing in ARI. healthcare workers can decide to follow the test results or not.
42030|NCT03855202|Biological|CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg
42031|NCT03855202|Biological|PS+CBMNC|autologuous umbilical cord blood mononuclear cells 48 hours after birth ,dose is 25 million cells/kg ,PS,dose is 70mg/kg
42032|NCT03855202|Biological|PS|PS,dose is 70mg/kg
42033|NCT03855202|Other|Placeo|0.9% sodium chloride installation after 24 hours
42034|NCT03855189|Drug|Mometasone Furoate (MF)|Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
42035|NCT03855189|Drug|Beclomethasone Dipropionate (BDP)|Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) [336 mcg total dose per day] for 4 weeks.
42036|NCT03855189|Drug|Placebo|Placebo nasal spray administered for 4 weeks.
42037|NCT03855176|Drug|Vaqta Injectable Product|Inactive vaccine against hepatitis A virus
42038|NCT03855163|Behavioral|Inspection visits|Normative intervention aimed at enforcing compliance with legal occupational health and safety requirements
42039|NCT03855163|Behavioral|Guidance workshops|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
42040|NCT03855163|Behavioral|Online risk assessment tool|Pedagogical intervention aimed to motivate managers and employee representatives to comply with legal occupational health and safety requirements
42041|NCT03855137|Drug|Atogepant 30 mg|Tablets containing 30 mg atogepant
42042|NCT03855137|Drug|Atogepant 60 mg|Tablets containing 60 mg atogepant
42043|NCT03855137|Drug|Placebo|30 mg/60 mg tablets containing atogepant-matching placebo
42044|NCT03855124|Device|Posture shirt|Posture shirts are designed, and marketed to the general public and health service providers to improve posture and consequently alter muscle actitity, reduce musculoskeletal pain and discomfort.
42045|NCT03855111|Other|Standard Acupuncture / Moxibustion|Standard (Fixed) Active Acupuncture / Moxibustion protocol aimed at reducing lower limb neuropathic pain/discomfort.
42046|NCT03855111|Other|Individualized (Tailored) Active Acupuncture / Moxibustion|Individualized (tailored) protocol Acu/Moxa - Active. Acu/Moxa prescription based on TCM assessment. Protocol aimed at reducing lower limb neuropathic pain/discomfort.
42047|NCT03855098|Other|Biomarkers of Fruit and Vegetable Intake|"Cross-over study where participants will visit the Human Intervention Centre (in UCD) on 3 occasions (3 study days) with a minimum one week between each visit. The order of consumption of the test foods will be randomized. The test foods are mixed vegetables (spinach and lettuce), green beans and mixed berried (strawberries and blueberries). The following definition of portion sizes will be used; green beans (120g), lettuce (20g), spinach (90g), strawberries (96g) and blueberries (75g).~For each study day, the participants will arrive fasting and provide a urine sample (0h sample). For 24h prior to the study day participants will avoid the test foods. Participants will consume the food and urine samples will be taken at 2, 4, 6 and 24 h post consumption."
42048|NCT03855072|Procedure|customized fixation plate|"All cases will undergo one surgery under general anesthesia.~Incision was made medial to external oblique ridge from the asendindg ramus to second molar region~Amucoperiosteal flap was reflected to expose the lateral mandibular ramus to the posterior border and the sigmoid notch~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~3D virtual planning and 3D mandible model represented fom CBCT in MIMICS~The customized fixation plate is positioned to fix the proximal and distal segment together after setback"
42049|NCT03855072|Procedure|maxillomandibular fixation|"All cases will undergo one surgery under general anesthesia.~incision was made medial to external oblique ridge from the asendindg ramus to second molar region .~The intraoral vertical osteotomy is accomplished by using an oscillating saw to make the cut from the sigmoid notch through the inferior border of the mandible.~Patient is placed in maxillomandibular fixation (MMF) using a prefabricated occlusal splint to assure accuracy of the mandibular position."
42050|NCT03855059|Drug|Placebos|This will be a saline solution of given IV or perineural.
42051|NCT03855059|Drug|Dexamethasone Sodium Phosphate|This will be the active drug solution given IV or perineural.
42052|NCT03855046|Drug|IncobotulinumtoxinA 50 U Intramuscular Powder for Solution|"Sparing surgical removal of fissure without internal sphincter incision is held under spinal anesthesia in surgical room at lithotomy position using electrocoagulation.~After that Botulinum Toxin Type A is injected into the internal anal sphincter at 1, 5, 7 and 11 o'clock (localization of injection points), 10 U at each point (40 U in total). Botulinum toxin type A (a 50 U vial) is diluted with 1.0 ml of 0.9% saline solution."
42108|NCT03854617|Drug|Oral NVB Metronomic|50mg three times weekly on Mondays (or Tuesdays), Wednesdays (or Thursdays) and Friday (or Saturdays). A cycle is a 3 weeks period.
42053|NCT03855046|Procedure|Lateral subcutaneous sphincterotomy.|The patient is positioned on the table like for perineal lithotomy. After spinal anesthesia, the anal canal and then the surgical field are treated with 70% ethanol. Under the rectal speculum control, sparing surgical removal of fissure without internal sphincter incision is held using electrocoagulation.Then, in a 3 or 9 o'clock position, a narrow (eye) scalpel is inserted into the intersphincteric groove separating the external and internal sphincters, the scalpel blade is turned to the rectal lumen, and the internal sphincter is dissected up to the wall of the anal canal mucosa under the control of the finger inserted into the anal canal. After controlling hemostasis, the operation is ended with the introduction of the vent tube and hemostatic sponge.
42054|NCT03855033|Behavioral|Media Aware Sexual Health - High School|Media Aware Sexual Health is a web-based comprehensive sexual health education program for high school students that uses a media literacy approach.
42055|NCT03855020|Diagnostic Test|Plasma EBV DNA|Parameters analyzed will include (1) the changing pattern of plasma EBV DNA concentrations during chemotherapy and radiotherapy (2) half-life values (t1/2) of plasma EBV DNA clearance rate
42056|NCT03855007|Drug|Iguratimod|Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.
42057|NCT03855007|Drug|MTX|MTX，7.5mg to 15mg, po, once per week (Qw) prescribed if needed and adjusted due to patient response or unacceptable toxicity develops.
42058|NCT03855007|Drug|HCQ|HCQ，200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.
42059|NCT03855007|Drug|Pred|Pred, 5-15mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response
42060|NCT03854994|Biological|Anti-CD19 CAR-T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
42061|NCT03854981|Behavioral|Exercise|Subjects will be asked to exercise 5 days/week in addition to receiving standard care before bariatric surgery.
42062|NCT03854981|Procedure|Standard Care|Standard preoperative care of bariatric surgery
42063|NCT03854968|Other|Quality control|The performance of the home mechanical ventilator of all patients in the study will be evaluated with a portable device
42064|NCT03854955|Other|iScribes|Device-based scribing service.
42065|NCT03854942|Drug|Placebo|Placebo oral tablet daily
42066|NCT03854942|Drug|Naltrexone|Naltrexone (Nemexin) oral tablet 50 mg daily for 2 days, Naltrexone (Nemexin) oral tablet 100 mg daily for 5 days
42067|NCT03854929|Drug|Ciprofloxacin|"Fluoroquinolone, ATC code: J01MA02~DNA-gyrase and topoisomerase IV inhibitor"
42068|NCT03854929|Drug|Azithromycin|"Macrolide, ATC code: J01FA10~Binds to ribosomal 50S sub-unit inhibiting translocation of peptides thereby suppressing bacterial protein synthesis."
42069|NCT03854916|Other|Caminemos Juntas App|A tailored mobile app that encourages Latinas and Hispanic women to walk together using location-based services.
42070|NCT03854916|Other|World Walking App|A mobile app that encourages users to walk.
42071|NCT03854903|Drug|Palbociclib|Palbociclib is taken orally.
42072|NCT03854903|Drug|Bosutinib|Bosutinib is taken orally.
42073|NCT03854903|Drug|Fulvestrant|Fulvestrant is given as an intramuscular injection.
42074|NCT03854890|Drug|Indocyanine Green|Indocyanine Green will be injected to the submucosal layer around the lesion one day before surgery.
42075|NCT03854877|Behavioral|Health behaviour intervention|The intervention uses the principles of acceptance-commitment therapy (ACT). It aims to increase healthy eating and good sleep. Based on personal needs participants can choose task for physical activity, relaxation, healthy eating, sleep eg. Their get regular feedback and support from their personal trainer via phone and computer.
42076|NCT03854864|Other|survey|to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
42077|NCT03854851|Drug|Naldebain|In Naldebain group, patients will be injected with Naldebain (150 mg/2 ml, IM injection) between 12 and 24 hours prior to surgery.
42078|NCT03854851|Drug|Morpine|In Morphine group, patients will receive morphine as needed after surgery.
42079|NCT03854838|Drug|Tolipalimab|Radiation begun the day after the first dose of Toripalimab. Toripalimab (3mg/Kg dose every 2 weeks for 10 cycles, one cycle is two weeks ) will be administered as an intravenous infusion over 60 minutes.
42080|NCT03854838|Radiation|Reirradiation|intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks
42081|NCT03854825|Procedure|Cardiac surgery|
42082|NCT03854812|Drug|Magnesium Sulphate|a loading of 50 mg/kg in 15 minutes of Magnesium sulphate, and will be followed by continuous infusion at 1 ml/kg/h of 15 mg/ml solution
42083|NCT03854812|Drug|Fentanyl|loading of 1 mcg/kg in over 15 minutes of fentanyl then will receive continuous infusion starting at 1 ml /kg/h. of 0.5 mcg/ml solution
42084|NCT03854812|Drug|Propofol|0.5-1.5 mg/kg bolus of propofol over 10 minutes to achieve target Ramsay sedation scale (RSS) of 3 (respond to command), if RSS afterwards does not reach 3 a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, and will be followed by 1-2.5 mg/kg/hr infusion to maintain Intraoperative BIS readings between 60 - 80
42085|NCT03854799|Drug|Avelumab|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
42086|NCT03854799|Drug|Capecitabine|"Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion."
42087|NCT03854799|Radiation|EXTERNAL--‐BEAM IRRADIATION 50.4 GY|Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
42088|NCT03854786|Dietary Supplement|Oxyjun|Oxyjun is the proprietary single ingredient product containing high concentrated well standardized aqueous extract of Terminalia arjuna.
42090|NCT03854773|Other|Erector spinae plane block (Group ESPB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
42091|NCT03854773|Other|Thoracal paravertebral block (Group TPVB)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
42092|NCT03854773|Other|Control group (group C)|Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit. Postoperative patient evaluation will be performed by an anesthesiologist blinded to the procedure.
42093|NCT03854760|Behavioral|anesthesiologist with limited experiment|Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
42094|NCT03854747|Other|cervical spinal stabilization exercise|The cervical region is one of the most affected regions of the musculoskeletal system due to the intensive proprioceptors. Studies have shown that many position sense proprioceptors are over the deep group cervical muscles such as longus colitis and longus capitis. The deep group cervical muscles, which perform a dynamic ligament function, have an important role in maintaining the stability of the spine as well as the proprioceptive sense. In particular, proprioceptive receptors, which are commonly found in the deep suboccipital muscles; There are cervical and reflex connections with vestibular, visual and postural control systems.
42095|NCT03854734|Behavioral|Community Event|Formative focus group data was used to design an educational community event to improve information share and vaccine education/knowledge.
42096|NCT03854734|Behavioral|Educational Material|Formative focus group data was used to design educational messaging to be electronically distributed to intervention participants
42097|NCT03854721|Drug|VAX014|Solution for intravesical infusion, 3.33x10^10 rBMCs per vial
42098|NCT03854708|Drug|3 pmol/kg*min pancreatic polypeptide|PP 3 pmol/kg*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
42099|NCT03854708|Drug|10 pmol/kg*min pancreatic polypeptide|PP 10 pmol/kg*min was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. Human PP (CS Bio, Menlo Park, USA) was dissolved in a 0.9 % saline solution containing 5 % albumin to reduce absorption of PP to the syringe and tubing.
42100|NCT03854708|Drug|Placebo|Placebo (saline solution) was intravenously infused 30 minutes before the meal until the end of the meal. For this purpose, a cannula was inserted into the subjects' forearm vein. The placebo consists of a 0.9 % saline solution containing 5 % albumin.
42101|NCT03854682|Procedure|Radiofrequency microtenotomy|A longitudinal incision of about 3 cm will be made over the most tender part of the foot taking care to avoid the weight bearing part of the sole, and the tissues dissected down to the affected plantar fascia. After initiating sterile isotonic saline flow of 1 drop every 1-2 s from a line connected to the RF system, the TOPAZ tip will be placed onto the fascia and the micro debridements carried out in a grid like pattern on and throughout the symptomatic fascia area. After debridement, the wound will be irrigated with copious amounts of normal saline solution and closed in layers. A local anaesthetic will be injected into the skin and subcutaneous tissues around the wound and standard wound dressings will be applied
42102|NCT03854682|Behavioral|Strength training|Non-surgical treatment consists of one-legged heel lift to primarily activate the windlass effect and increase the mechanical stress on the tendon. The exercise is performed on a step, a thick book or the like, so the heel movement finishes below the horizontal level. The exercise is performed every other day with as many sets as possible and as heavy as possible, but not heavier than eight repetitions can be performed per. set. The load progressed from two to one leg +/- backpack. The exercise is performed as 3 s/2 s / 3 s concentric, isometric and eccentric respectively followed by 2 min rest. Patients continue to exercise 4 weeks after patient acceptable symptom state (PASS) has been achieved
42103|NCT03854669|Device|pain reporting accuracy|pain reporting accuracy will be assessed by the Focused Analgesia Selection Task (FAST) procedure. The FAST is based on recording a subject's pain reports in response to repeated administration of thermal noxious stimuli of various intensities, applied on the non-dominant arm with the Medoc® Thermal Sensory Analyzer II. The subjects will receive 1 of 7 designated temperatures (44°C, 45°C, 46°C, 47°C, 48°C, 49°C, and 50°C), each presented 7 times in a random block-ordered design (49 stimuli in total).
42104|NCT03854656|Other|Time-restricted eating|"Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority."
42105|NCT03854643|Other|Pilates group|Pilates exercises were performed three times a week for 4 weeks, totaling 12 treatment sessions. Each session lasted 40 minutes and was performed by a researcher with training in the method and previous training in the exercise. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
42106|NCT03854643|Other|Control group|These patients did not receive any type of intervention. The patients were evaluated as follows: initial assessment, after two weeks, after four weeks and a follow up after three months.
42107|NCT03854630|Drug|Engerix-B|The vaccine contains HBsAg which was produced by genetic engineering yeast. It stimulates the active immunity generated by human immune system toward the HBsAg.
42109|NCT03854617|Drug|Oral NVB Weekly|60mg/m2 weekly for cycle 1 and 80mg/m2 weekly for subsequent cycles in the absence of grade 3 or 4 toxicity. A cycle is a 3 weeks period
42110|NCT03854604|Other|postoperative pain assessment|evaluation of the efficacy of PI as an objective measure for postoperative pain assessment in pediatric population undergoing adenotonsillectomy.
42111|NCT03854591|Other|No intervention|No intervention
42112|NCT03854578|Drug|BI 1358894|Film-coated tablet
42113|NCT03854578|Drug|Placebo matching BI 1358894|Film-coated tablet
42114|NCT03854578|Drug|Citalopram|Film-coated tablet
42115|NCT03854565|Diagnostic Test|Glycocalyx measurement，respiratory mechanics measurement|ELASA measure glycocalyx, measure plateau pressure, driving pressure
42116|NCT03854552|Drug|BI 764198|capsule
42117|NCT03854552|Drug|Placebo|capsule
42118|NCT03854539|Other|Transdermal Vagus Nerve Stimulation|intermittent transdermal stimulation of the aurical vagus
42119|NCT03854526|Other|Evaluation of the quality of direct and indirect partial dental coronal restorations in adults|"The medical and dental anamnesis is registered. In addition to the medical history questionnaire, the patient completes the self-assessment questionnaire on oral health. Then, a complete and intra-oral clinical examination is performed. The collection of clinical data is done on the dentist's chair. All data are included in the e-CRF.~All radiographic procedures will be performed according to national guidelines. If the investigator deems it clinically necessary, a panoramic X-ray will be taken and stored in the patient's HER system. Periapical radiographs (using a parallelogram technique with a radiographic film holder) will be taken for teeth with periapical radiolucency on panoramic X-ray, or with defective coronal restoration, or when the clinician needs more information for diagnosis or planning."
42120|NCT03854513|Device|dialysis machine|A machine used in dialysis that filters a patient's blood to remove excess water and waste products when the kidneys are damaged
42121|NCT03854500|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
42122|NCT03854500|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
42123|NCT03854487|Behavioral|Mirror therapy|A mirror is placed at the midsagittal plane of the patient. The patients in the mirror therapy group watched the mirror illusion of the non-affected arm in the mirror and moved together with the affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
42124|NCT03854487|Behavioral|Sham mirror|A transparent glass wall is placed at the midsagittal plane of the patient. The patients in the sham mirror group watched the movements of the affected arm through the transparent glass wall and moved together with the non-affected arm. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
42125|NCT03854487|Behavioral|Covered mirror|A covered mirror is placed at the midsagittal plane of the patient. The patients in the control group watched the movements of the non-affected arm and moved together with the affected arm behind the covered mirror. The treatment programme for all groups consisted of 12 sessions (4 per week for 3 weeks), each lasting for 30 minutes. The movement practice involved 5 table-top tasks and the patient was instructed to perform as many trials as possible in each session with a maximum of 30 trials per task, giving a total of 150 trials per session. Treatment activities are graded according to the severity of the patient's upper extremity impairment.
42128|NCT03854461|Behavioral|Personalised dietary advice and educational material|As within arm/group description
42129|NCT03854461|Behavioral|Educational material|As within arm/group description
42130|NCT03854448|Device|holter monitoring|"Transthoracic Echocardiography (TTE) Left atrial ( LA) volume will be measured using standard apical two- and four-chamber views on the frame just prior to mitral valve opening and as specified by current American Society of Echocardiography guidelines (10) LA volume is indexed to body surface area. Mitral inflow velocity is obtained in the apical four-chamber view by placing a pulsed-Doppler sample volume between the tips of the mitral leaflets. Mitral annular velocity is assessed during the early phase of diastole(e=) using pulsed-wave Doppler sampling of septal mitral annular motion from the four chamber view.~24 to 48 hours Holter monitoring after 1 month after PCI"
42131|NCT03854435|Other|Heart rate assessment (stethoscope)|Immediately after birth heart rate will be evaluated by auscultation
42132|NCT03854435|Other|Heart assessment (umbilical cord palpation)|Immediately after birth heart rate will be evaluated by palpation of the umbilical cord
42133|NCT03854422|Device|left position|colonoscopy will be performed in 3 different locations. Left position, the patient will be in the left-side position during the entire colonoscopy
42134|NCT03854422|Device|left supine position|Colonoscopy in the Left supine position
42135|NCT03854422|Device|dynamic position|Colonoscopy in the Dynamic position
42136|NCT03854409|Drug|Aripiprazole|Injection.
42137|NCT03854396|Drug|Prasterone|Nightly intravaginal prasterone insert (6.5 mg prasterone at a concentration of 0.50%) for 24 weeks.
42138|NCT03854396|Drug|Placebo|Nightly intravaginal placebo insert (Witepsol H-15, a mix of synthetic triglycerides) for 24 weeks.
42139|NCT03854383|Drug|Isosorbide mononitrate|Administration of isosorbide mononitrate vaginaly together with misoprostol in induction of labor in postdate women
42140|NCT03854383|Drug|Misoprostol|Used intravaginally to ripe the cevix in induction of labor
42141|NCT03854370|Other|Baby shampoo|baby shampoo will be used to prepare the surgical site prior to incision
42142|NCT03854370|Other|Betadine|Betadine (Povidone- iodine) will be used to prepare the surgical site prior to incision
42143|NCT03854370|Other|Peridex|Peridex (Chlorhexidine) will be used to prepare the surgical site prior to incision
42144|NCT03854370|Other|TechniCare|TechniCare (chloroxynel) will be used to prepare the surgical site prior to incision
42145|NCT03854357|Procedure|Subscapularis Rehabilitation|Specific subscapularis rehabilitation exercises which are not included in the current, standard rehabilitation protocol assigned to total shoulder arthroplasty patients post-operatively.
42146|NCT03854357|Procedure|Standard Rehabilitation|Standard post-operative rehabiliation protocol assigned to all total shoulder arthroplasty patients postoperatively
42147|NCT03854344|Drug|Lidocaine Hydrochloride|Injected subcutaneously for skin graft harvesting
42148|NCT03854344|Drug|Liposomal bupivacaine|Injected subcutaneously for skin graft harvesting
42149|NCT03854331|Behavioral|Resilience program|The resilience program consists of different modules that are based on research on mentalization, mindfulness, parent management training, improving self-control and self-efficacy, cognitive behaviour therapy, social learning theory and neuroscience. The MyResilience program is also informed by cognitive bias modification and self-control training research. These techniques have been found to be effective in improving engagement in health behaviours and reducing symptoms and negative behaviours in clinical groups
42150|NCT03854305|Drug|PRV-6527|Treatment
42151|NCT03854305|Drug|Placebo|Comparator
42152|NCT03854292|Procedure|Hysteroscopic tubal electrocoagulation|Unilateral or bilateral electrocoagulation of the cornual end of the tube and the surrounding part of the uterine horn was performed using a hysteroscopicelectrocoagulating roller ball.
42153|NCT03854279|Device|tonsillar dissection|The tonsils will be removed by bizact device
42154|NCT03854266|Drug|Low dose alteplase|Low dose alteplase is 4 milligram per pulmonary artery (maximum dose 8 milligram) infused in the pulmonary arteries over 2 hours
42155|NCT03854266|Drug|Unfractionated heparin|Unfractioned heparin is administered in a peripheral vein with an initial dose of 80 international units per kilo (IU/kg) bolus followed by 18 IU/kg as continuous infusion with dose adjustment every 6 hours and once daily when activated partial thromboplastin time (APPT) is 1.5-2.3 times control value.
42156|NCT03854266|Device|Infusion catheter|A sidehole catheter (Unifuse, AngioDynamics, US) catheter will be advanced to the pulmonary arteries to facilitate the catheter directed thrombolysis
42157|NCT03854253|Procedure|Long introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-25cm
42158|NCT03854253|Procedure|Short introducer sheath|The investigators will perform transradial coronary angiography and percutaneous coronary interventions using introducer sheath 6Fr-10cm
42159|NCT03854240|Other|Classic block (Group C) and modified block (Group M) groups|Classic block (Group C) and modified block (Group M) will be performed following induction of general anesthesia, with patients in the prone position by using ultrasound device
42160|NCT03854227|Drug|PF-06939999|0.5 mg QD orally on a continuous basis
42161|NCT03854227|Drug|PF-06939999|0.5 mg BID orally on a continuous basis
42162|NCT03854227|Drug|PF-06939999|1 mg BID orally on a continuous basis
42163|NCT03854227|Drug|PF-06939999|2 mg BID orally on a continuous basis
42164|NCT03854227|Drug|PF-06939999|4 mg BID orally on a continuous basis
42165|NCT03854227|Drug|PF-06939999|8 mg BID orally on a continuous basis
42166|NCT03854227|Drug|PF-06939999|16 mg BID orally on a continuous basis
42167|NCT03854227|Drug|PF-06939999|30 mg BID orally on a continuous basis
42168|NCT03854227|Drug|PF-06939999|60 mg BID orally on a continuous basis
42169|NCT03854214|Device|Functional Electric Stimulation cycling|The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 RPM. Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
42170|NCT03854214|Device|Passive cycling|The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
42171|NCT03854201|Behavioral|Personalized Exercise Counseling (PEC)|At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
42172|NCT03854188|Procedure|Acupuncture|Use acupuncture therapy in the treatment of chronic pelvic pain.
42173|NCT03854175|Drug|sildenafil citrate|25mg vaginally every 6 hours (a half of 50 mg tablet is crushed and dissolved in 2cc of distilled water and injected in to vagina) starting from day 2-14 of the cycle
42174|NCT03854175|Drug|Estradiol Valerate 2 MG|2mg 6-8 hourly from the day 2-14 of the cycle to prepare the endometrium
42175|NCT03854162|Device|SMART Guide|The device manufactured according to a digital plan based on patient anatomy. Guiding sleeves are used, through which bone drills are applied. These sleeves sit in a plastic template that is a negative of the patient's dentition, so that the guide is properly stabilized during the operation. The position of the sleeves is calculated from the surgical plan in a way that they guide the drills in the planned position.The material of the template is medical plastic, the sleeves are made of medical steel.The device is applied by the dentist during the implant surgery. The template is placed on the remaining dentition of the patient and stabilized this way. By this, the sleeves are also stabilized in their planned position. Access through the soft tissue can be prepared through the given sleeve with a circular trephine, but the system also supports flap surgery. As access has been established, the dentist performs the surgical protocol as planned.
42177|NCT03854136|Procedure|Excision of tumor|Wide margin excision of tumors +/- limb preservation
42178|NCT03854110|Drug|GP-2250|GP-2250 monotherapy for pharmacokinetics; GP-2250 plus gemcitabine for tolerability and biomarker assessments
42179|NCT03854097|Device|Active Intermittent Negative Pressure (INP)|Application of -40mmHg negative pressure on the lower limb
42180|NCT03854097|Device|Placebo Intermittent Negative Pressure (INP)|Application of -10mmHg negative pressure on the lower limb
42181|NCT03854084|Other|The cranial osteopathic techniques|Technique of the temporal bones in favor of the free movement. Ear Pull technique: the hands of the osteopath holds the auricle of the individual with the thumb, index and the middle finger in a tweezer shape and with the elbows resting over the stretcher. Ruddy technique: The osteopath puts the thumbs on the eyelid of each eyeball.
42182|NCT03854084|Other|Control group|Simulation of the techniques was used in the interventional group
42183|NCT03854071|Other|intravenous fluid challenge|Patients will undergo a receive a pre-load increasing stress test with intravenous fluids depending on tolerability
42184|NCT03854058|Diagnostic Test|magnetic phrenic nerve stimulation|cervical and cortical stimulation of N. Vagus
42185|NCT03854045|Other|Telepsychiatry|Receive telepsychiatry with clinician obtaining initial data and presenting it to the psychiatrist
42186|NCT03854032|Biological|Nivolumab|Given IV
42187|NCT03854032|Biological|IDO1 Inhibitor BMS-986205|Given PO
42188|NCT03854032|Procedure|Therapeutic Conventional Surgery|Undergo Surgery
42189|NCT03854032|Other|Questionnaire Administration|Ancillary studies
42190|NCT03854019|Drug|Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)|DM/Q 20mg/10mg one capsule once daily for 1 week, followed by DM/Q 20mg /10 mg twice daily for subsequent 4 weeks, and finally DM/Q 20mg/10mg once daily for 7days.
42191|NCT03854019|Drug|Placebo|Placebo once daily for 1 week, followed by placebo twice daily for subsequent 4 weeks, and finally placebo once daily for 7days.
42192|NCT03854006|Procedure|Cryoballoon pulmonary vein isolation|During cryoballoon pulmonary vein isolation, under local anaesthesia, diagnostic catheters are placed in the coronary sinus. The cryoballoon is advanced to the left atrium via a steerable sheath after single transseptal puncture and inflated at the PV(pulmonary vein) ostia. A spiral mapping catheter is advanced through the balloon inner lumen and positioned in the PV at the closest achievable proximity to the cryoballoon in order to record real-time PV potentials during PV isolation. During PV isolation the potentials from the PV are recorded. The TTI is defined as the time of the last recording of a PV potential before sustained isolation. Isolation of all PVs is reassessed at the end of the procedure by documentation of entrance- and exit-block.
42193|NCT03853993|Biological|Quadrivalent influenza vaccine|Received single dose QIV (15µg/0.5ml)
42194|NCT03853993|Biological|Trivalent influenza vaccine (contains B/Victoria strain)|Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
42195|NCT03853993|Biological|Trivalent influenza vaccine (contains B/Yamagata strain)|Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
42196|NCT03853980|Device|Focal Contouring System|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
42197|NCT03853967|Other|Low dose CT scan|low dose CT scan
42198|NCT03853954|Device|Methoxyflurane|Methoxyflurane (Penthrox) inhaler, 3mL inhalation vapour, liquid
42199|NCT03853941|Behavioral|Intervention|Theory-based communication training programme delivered to healthcare professionals
42200|NCT03853928|Dietary Supplement|Probiotics|"Each 50 ml bottle contains Lactobacillus casei 3.3 x 107 CFU / day, Lactobacillus plantarum 3.3 x 107 CFU / day, Streptococcus faecalis 3.3 x 107 CFU / day and Bifidobacterium brevis 1.0 x 106 CFU / day (BIOFLORA®, BIOSIDUS SA, Argentina) .~Medication Reference intervention. Name of the active substance: Placebo. Administration way: Oral 5 ml orally every 12 hours for 10 consecutive days (Cycle, monthly)~Likewise, both branches will explicitly request the non-consumption of alcohol and the consumption of a non-hypercaloric Mediterranean diet throughout the study for all patients in each branch (ANNEXIII)."
42202|NCT03853902|Behavioral|Mindfulness Program|Mindfulness Program
42203|NCT03853889|Procedure|USG guided ONSD measurement preepidural|Measurement of the diameter of the optic nerve sheath preepidural and postepidural anesthesia
42204|NCT03853863|Behavioral|in-school walking training with minimalist shoes|Participants in the MSW group will be given a pair of minimalist shoes for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks. Similar to previous minimalist footwear studies, the intervention duration will be gradually increased over the 12-week training. In brief, subjects will wear the minimalist shoes for 1 out of 5 school days at the first week; 2 days at the second week, and so on until fully use of the minimalist shoes at the fifth week.
42205|NCT03853863|Behavioral|in-school walking training with protective shoes|Participants in the TSW group will be given a pair of given a pair of protective shoes with arch support for all in-school activities (i.e., 5 days/week and 7 hours/day) for 12 weeks,while follow the same wearing pattern as the MSW group.
42206|NCT03853850|Behavioral|Mobile phone text messages|From their babies' day of birth until 6 months of age, participating mothers will receive supportive and educational text messages to promote breastfeeding. Messages will be on benefits of breastfeeding, newborn hunger cues, proper latch technique, healthy infant feeding practice, and maternal self care. Messages will be sent regularly, initially several messages every day during the babies' first few weeks of life, then few messages every week. A total of 158 (***) messages will be sent. Messages will be sent in English or in Spanish depending on participant language preference.
42207|NCT03853837|Diagnostic Test|rest-exercise echocardiography|an echocardiogram performed during rest and exercise
42238|NCT03853564|Other|Phone-Call Intervention|Mothers of the PCG arm will participate in 6-session of telephone call during which a trained collaborator will ask details on different domains of infants behavioral development.
42273|NCT03853252|Other|Skin biopsy|Skin biopsy on a location preliminarily anesthetized Disinfection protocol Combined required blood tests (HIV, Hepatitis B)
42208|NCT03853824|Other|Increased postoperative surveillance|Increased postoperative surveillance can include either of the following; i) admission to a higher care ward than had been planned at the time of surgery, ii) an increase in the frequency of nursing observations in the postoperative period, iii) ensuring that the patient is placed in view of the nursing station, and not in a remote location in the postoperative ward, or iv) allowing family members to stay with the patient in the ward in the postoperative period.
42209|NCT03853824|Other|Usual postoperative care|Participating sites randomised to the control arm will provide usual postoperative care to patients. The care will be left to the discretion of the healthcare providers.
42210|NCT03853811|Device|Ankle Foot Orthosis (AFO)|The intervention group will receive the custom AFO to use in their standard Mitchell shoe.
42211|NCT03853798|Drug|AG-348|Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
42212|NCT03853785|Biological|MMR vaccine|Intralesional injection of 0.5 ml MMR vaccine in the largest lesion . Injections will be repeated into the same lesion every 2 weeks for a maximum of three treatment sessions.
42213|NCT03853785|Biological|Candida antigen|Intralesional injection of Candidal antigen with a dose of (0.1ml -0.3ml) by an insulin syringe in the largest wart at the first visit. Injections will be repeated for all patients into the same lesion every 2 weeks for a maximum of three treatment sessions.
42214|NCT03853785|Drug|Topical Podophyllin|It will be applied to the wart by using a cotton tipped swab once a week . The procedure will be limited to 10 cm2 per session .Surrounding skin will be protected by Vaseline. Podophyllin will be washed 4 hour after application . The procedure will be repeated every week till 6 weeks .
42215|NCT03853746|Drug|Ocrelizumab|Patient will be treated with two courses of ocrelizumab (Ocrevus) for one year and then will stop the medication and will be monitored for the return of the disease activity. Those who experience return of the disease activity can go back on the medication.
42216|NCT03853733|Radiation|rectal cancer radiotherapy|Conformal three-dimensional radiotherapy to deliver to the primary tumor and the enlarged pelvic nodes a total dose of 39Gy in 13 sessions of 3Gy in 17 days.
42217|NCT03853720|Procedure|balloon-occluded retrograde transvenous and endoscopic obliteration of high-risk gastric varices|"Catheterization of the left renal vein and the inferior diaphragmatic vein and occlusion with a balloon placed in the distal portion of this vein.~Endoscopic access to the gastric cavity, gastric varices identification and flow measurement, including velocity, by endoscopic Doppler ultrasound (US). The balloon in the draining vein will be inflated and the velocity will be reassessed. Endoscopic puncture of the varices will be done and the embolization will be conducted under balloon-occlusive conditions (Injection of Cyanoacrylate: Lipiodol mixture 1:1 slowly and gradually). Balloon will be kept inflated and a microcatheter will be used through its lumen inside the variceal bed to inject occlusive agent (cyanoacrylate) mixed with Lipiodol.~At the end of the procedure an occlusion device (plug amplatzer 2) will be placed."
42218|NCT03853707|Drug|Carboplatin|Given IV
42219|NCT03853707|Drug|Ipatasertib|Given PO
42220|NCT03853707|Drug|Paclitaxel|Given IV
42221|NCT03853707|Other|Quality-of-Life Assessment|Ancillary studies
42222|NCT03853707|Other|Questionnaire Administration|Ancillary studies
42226|NCT03853681|Diagnostic Test|additional blood sampling|additional blood sampling
42227|NCT03853668|Behavioral|exercise|control group (n=40) did aerobic exercises on treadmill for 10 weeks experimental group (n=40) did combined aerobic and resisted exercises for 10 weeks
42228|NCT03853655|Radiation|Post-operative adjuvant radiotherapy|"Conventional treatment planning, as well as intensity-modulated radiation therapy (IMRT) planning, would be allowed on the study with patients being stratified on the RT technique.~Treatment would be delivered on telecobalt unit (gamma-rays/linear accelerator (6MV photons). All fields would be treated daily.~Phase I: 46 Gray(Gy) in 23 fractions over 4.5 weeks Phase II: 14Gray in 7 fractions over 1.5 weeks~For IMRT, inverse planning would be done on a commercial TPS configured to deliver IMRT using 6MV photons. Patients shall be treated using the simultaneous integrated boost (SIB) technique with 5 fractions being delivered every week."
42229|NCT03853642|Other|Blood sampling|Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
42230|NCT03853629|Other|None. Not applicable|None. Not applicable
42231|NCT03853616|Biological|MB-CART19.1|MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
42232|NCT03853603|Dietary Supplement|Santa herba|Santa herba dry extract; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
42233|NCT03853603|Dietary Supplement|Placebo|Maltodextrin; 400 mg/day. 2 capsules/day; 1 capsule twice daily with the main meals (lunch and dinner)
42234|NCT03853590|Procedure|Roux-en-Y gastric bypass|Creation of a small pouch from the stomach and connection of the newly created pouch directly to the small intestine so that swallowed food bypasses most of the stomach and the first section of the small intestine.
42235|NCT03853590|Procedure|Laparoscopic adjustable gastric banding|Placement of a soft silicone ring with an expandable balloon in the center, around the top part of the stomach to create a two-compartment stomach, with a much smaller top part above the band. The subject will eat enough food only to fill the top part of the stomach decreasing caloric consumption.
42236|NCT03853577|Other|TMS/EEG|navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
42237|NCT03853564|Behavioral|Video-Feedback Intervention|Mothers and infants of the VFG arm will participate to a 6-session video-feedback intervention structured as follows: 4 sessions of video-review discussions with a trained clinician + 2 sessions of integrative intervention aimed at translating into practical caregiving the insights developed during the video-review discussions.
42300|NCT03853044|Drug|Chidamide|Chidamide 20mg per day administered orally on Day 1, 4, 8, 11 of each 21-day cycle for 6 cycles
42239|NCT03853551|Drug|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both epidermal growth factor receptor - Tyrosine kinase inhibitors (EGFR-TKI) sensitizing and resistance mutations in nonsmall cell lung cancer (NSCLC) with a significant selectivity margin over wild-type EGFR.
42240|NCT03853538|Drug|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one hemiface.
42241|NCT03853538|Other|Semisolid vaseline|Product is applied to one hemiface.
42242|NCT03853525|Drug|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
42243|NCT03853525|Other|Semisolid vaseline|Product is applied to one side of the inguinal region.
42244|NCT03853512|Drug|BAY207543 (Bepanthol, Bepantol® Derma Spray)|Product is applied to one side of the inguinal region.
42245|NCT03853512|Other|Semisolid vaseline|Product is applied to the other side of the inguinal region.
42246|NCT03853499|Other|No intervention (observational study)|No intervention (observational study)
42247|NCT03853473|Procedure|Remote Ischemic Preconditioning|Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
42248|NCT03853460|Procedure|epidural catheter|ultrasound low frequency probe will be used to determine the depth of the posterior complex to assists placement of midline thoracic epidural
42249|NCT03853460|Procedure|nerve block catheter|ultrasound guided placement of bilateral quadratus lumborum catheters
42250|NCT03853447|Diagnostic Test|Diagnostic imaging|MRI assessments including magnetic resonance cholangiopancreatography (MRCP) and diffusion weighted imaging (DWI) combined with gold standard EUS
42251|NCT03853434|Procedure|Embolization|Angiographic embolization
42252|NCT03853421|Drug|Sevuparin|The study will consist of three dose cohorts (3, 6 and 9 mg/kg sevuparin). Subjects in each cohort will receive a single dose of sevuparin or placebo subcutaneously on Day 1.
42253|NCT03853408|Procedure|Cholecystectomy|Cholecystectomy (removal of the gallbladder) for acute cholecystitis
42254|NCT03853395|Diagnostic Test|Tests for drug levels and anti-drug antibodies|Measurement of drug levels and anti-drug antibodies will be undertaken using commercially available enzyme-linked immunosorbent assays (ELISAs) and/or radioimmunoassays
42255|NCT03853382|Behavioral|Cognitive analytic informed brief therapy|"The brief CAT-informed therapy will take place over two sessions. Session one will last around 90 minutes. In session one, we will discuss with the participant their experience of self-harm and begin to support them to make sense of patterns in their self-harming behaviour. This will be done by thinking about the events that come before or follow self-harm, as well as thoughts and emotions associated with self-harm; it will also be done by thinking about ways that the participant relates to him/herself and other people. By the end of the first session, the researcher and the participant will have collaboratively developed a written diagram which shows patterns in the participant's self-harm.~Session two will involve revisiting the mapping of patterns. The researcher and participant will the collaboratively develop 'exits' or ways to break patterns and cycles of thinking, feeling and behaviour. Both sessions will have structured endings."
42256|NCT03853369|Drug|Nifekalant hydrochloride|Treatment is not limited. Patients who have used or will use Nifekalant hydrochloride.
42257|NCT03853356|Device|Orthoss|Orthoss® granules. Orthoss® granules mixed with local bone and pedicle bone marrow aspirate.
42258|NCT03853343|Dietary Supplement|Seaweed extract|1 capsule 3 times per day
42259|NCT03853343|Dietary Supplement|Placebo|1 capsule 3 times per day
42260|NCT03853330|Device|Ultrasound|Ultrasound-guided Thoracic Epidural Analgesia and Erector spinae plane block.
42261|NCT03853330|Drug|Bupivacaine HCl Inj 0.25%|Bupivacaine HCl Inj 0.25% will be used in both blocks by the same dose of 7.5-12 ml
42262|NCT03853330|Drug|Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution|infusion of Bupivacaine Hydrochloride, 0.125%-0.9% Injectable Solution at 5-7 ml/h will be used in both blocks and also for breakthrough pain after both blocks as a bolus of 5-10 ml.
42263|NCT03853317|Biological|Avelumab|For the treatment of adults and pediatric patients 12 years and older with Metastatic Merkel Cell Carcinoma (MCC).
42264|NCT03853317|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
42265|NCT03853317|Biological|haNK™|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
42266|NCT03853304|Other|+ Folic acid|Salt fortified with folic acid
42267|NCT03853304|Other|+ Vitamin B12|Salt fortified with vitamin B12
42268|NCT03853304|Other|DFS|Salt fortified with iron and iodine
42269|NCT03853291|Behavioral|PICT Workbook|The length of PICT and the delivery model will be informed by observational research that has been approved as part of this protocol (the first participant in the observational phase of this work will be enrolled on March 7, 2019). Lacking knowledge from the information gleaned from the observational and field-testing phases of this study we cannot specify with 100% certainty what the intervention will look like. However, it is likely that PICT will consist of 4-5 weekly 30-minute sessions); the expected delivery model will likely include a combination of online (video observation) and telephone coaching.
42270|NCT03853291|Behavioral|Information Pamphlet|Pamphlet with information about pain and dementia and links to Alzheimer's Association
42271|NCT03853278|Behavioral|colorectal cancer self-management|The intervention includes a colorectal cancer self-management information booklet, a DVD, two individual skill training and 12 follow-up telephone calls. These are to establish participants' self-management skills and healthy lifestyle, including physical activity and healthy eating fruits and vegetables.
42272|NCT03853265|Behavioral|Simulated dental office visit|An immersive first-person point of view (POV) video simulation of the dental office in the three-dimensional environment (using a virtual reality headset) which allows participant to look around the room as they move down the hallways which is to be watched/experienced by the participant as often as possible between the initial visit and the follow up visit
42274|NCT03853239|Procedure|face mask ventilation crossover nasal ventilation|Group A was first ventilated through the face mask, and the tidal volume was measured under pressure-controlled mode (10, 15, 20 cm H2O) ;Switched to volume-controlled (6,8,10ml/kg predicted body weight)mode, the actual tidal volume was recorded, and the air leakage was calculated. Then, put a nasal RAE tube in one side of the nostril, inflate the cuff, make the catheter in a natural position after inflation, clip the other side of the nostril, close the lip with tape, connect the breathing circuit, record the actual tidal volume; measure the expired tidal volume during pressure-controlled ventilation (10, 15, 20 cm H2O).Subject will start with one technique and then cross over to the other technique.
42275|NCT03853239|Procedure|nasal ventilation crossover face mask ventilation|Group B first placed a nasal RAE tube in one side of the nostril, the cuff was inflated, the catheter was in a natural position after inflation, the other side of the nostril was clamped, the lip was closed with tape, the breathing circuit was connected, and the amount of tidal volume was measured under pressure-controlled mode ( 10,15,20cm H2O) ; switch to volume-controlled ventilation mode (6,8,10ml/kg predicted body weight), record the actual tidal volume; pull out the tracheal tube, perform mask ventilation, record the actual tidal volume and tidal volume under volume-controlled mode(6,8,10ml/kg predicted body weight) and pressure-controlled mode (10, 15, 20 cm H2O) , respectively.Subject will start with one technique and then cross over to the other technique.
42276|NCT03853226|Procedure|All monitoring|For all patients, data from trans-esophageal Doppler, trans-thoracic echocardiography (TTE) and hemodynamic data are collected at the end of the procedure. During catheter withdrawal, pressure waveforms are recorded at two predefined aortic locations: in the ascending aorta and in the descending thoracic aorta just in front of the esophageal Doppler probe.
42277|NCT03853213|Behavioral|Cognitive Bias Modification Training|"In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The letter appears in the neutral location on 90.6% of trials, thereby reinforcing participants' attending away from threat. In task 2, participants view a word or phrase corresponding to a threatening (e.g., dying) or benign (e.g., sleep) interpretation of a sentence (e.g., You have been waking up tired recently). They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback (Correct) is given for rejected threat interpretations and for benign interpretations. Otherwise, negative feedback (Incorrect) is given."
42278|NCT03853213|Behavioral|Attention Control Training|In task 1, participants view a pair of threat-neutral words and then a single letter (E or F). Participants' task is to tap a button as quickly and accurately as possible to indicate whether they see E or F. The target letter is equally likely to appear in the threat location as the neutral location. Thus, participants' patterns of attention are not trained toward or away from threat. In task 2, participants view a word or short phrase corresponding to either a threatening or benign interpretation of a sentence that follows it. They are asked to tap a button to indicate whether the word or phrase was related to the sentence. Positive feedback and negative feedback are equally likely to be given regardless of whether participants endorse the threatening or benign interpretations.
42279|NCT03853200|Drug|QMix Root Canal Irrigant|Endodontic irrigant recommended for final irrigation
42280|NCT03853200|Drug|17%EDTA+2%Chlorhexidine|two endodontic irrigants will be used in this group in a sequential manner
42281|NCT03853200|Other|EDTA|17% EDTA irrigation solution
42282|NCT03853187|Radiation|Zr-89 labelled durvalumab PET/CT|Patients will undergo a Zr-89 labelled durvalumab (MEDI4736) PET/CT and dedicated perfusion-CT prior to treatment with durvalumab (MEDI4736) and in- and ex-vivo In-111-oxine labelled CD8+ T-cells after two courses of treatment, prior to surgery.
42283|NCT03853187|Drug|Durvalumab (MEDI4736)|Patients will receive two courses of durvalumab (MEDI4736)at a fixed dose of 750mg Q2W intravenously, prior to scheduled resection of NSCLC.
42284|NCT03853174|Other|ET+RT+ NMES|ET+RT+ NMES Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
42285|NCT03853174|Other|ET+RT|"ET+RT~Endurance training, resistance training were performed but no neuromuscular electrical stimuation for this group."
42286|NCT03853161|Other|Vapotherm|A form of non invasive ventilation used in newborns
42287|NCT03853161|Other|NIPPV|A form of non invasive ventilation used in newborns
42288|NCT03853148|Behavioral|Otago|Exercise program for strength and balance
42289|NCT03853148|Behavioral|Gentle yogic breathing|yogic breathing
42290|NCT03853148|Behavioral|Behavioral Activation|Behavioral Activation incorporates daily planners and worksheets to identify and rate reinforcing behaviors and is often used in conjunction with other interventions because components of these interventions are easily incorporated into the daily planner based activities.
42291|NCT03853135|Diagnostic Test|measurement of serum endocan|measurement of serum levels of endocan
42292|NCT03853122|Other|Best current practice exercise programme|Therapeutic Physical Exercise programme based on the protocol of Afredson. This protocol includes an eccentric programme with two eccentric exercises performed twice daily, 3 sets of 15 repetitions each
42293|NCT03853122|Other|Experimental exercise programme|Therapeutic Physical Exercise programme structured in blocks oriented to specific neuromuscular adaptations based on the characteristics of the neuromuscular system, once daily, three times/week, sets, repetitions and load based on individually performed tests.
42294|NCT03853109|Drug|AMG 404|AMG 404 will be examined for safety, tolerability, PK, and PD of AMG 404 in subjects with advanced solid tumors.
42295|NCT03853096|Drug|Cefazolin|Cefazolin 100mg/mL, 3mL in three locations will be administered around a surgical incision on the anterior shoulder in a standard deltopectoral approach interval. This will be a one time administration. Administration and route will be subcutaneous.
42296|NCT03853083|Device|Hypoxi Equipment|Using the Hypoxi exercise equipment to try and improve lipedema fat tissue
42297|NCT03853083|Device|Recumbent Bicycle|Recumbent bike is a piece of exercise equipment used as the comparison group
42298|NCT03853070|Device|ED Coil / Electro-detach Generator v4|The ED Coil is used for vascular embolization with a platinum coil at the target lesion in a patient's blood vessel. The ED Detach Generator is intended to for use solely to detach the platinum coil from the delivery catheter of the ED Coil.
42299|NCT03853057|Other|body positions|positive pressure ventilation at different body positions
77863|NCT03575832|Other|Questionnaire Administration|Ancillary studies
42301|NCT03853044|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
42302|NCT03853044|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle.
42303|NCT03853044|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
42304|NCT03853044|Drug|Prednisone|Prednisone 60mg/m2 , Maximum 100 mg , (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
42305|NCT03853031|Procedure|LVEDA cm2 guided intraoperative fluid in TEE /Study Group|Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2
42306|NCT03853031|Procedure|CVP guided intraoperative fluid in CVP / Control group|Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
42307|NCT03853018|Device|CWAT intervention|Participant in the intervention group will wear an activity tracker for 12 weeks.
42308|NCT03853018|Device|CWAT + motivation intervention group|Participant in the intervention group will wear an activity tracker for 12 weeks and are also motivated by the researcher via a lifestyle data platform.
42309|NCT03853005|Other|HVHDF|Patients will receive HVHDF treatment for at least 48 hours. HVHDF will be performed via indwelling central venous catheter. The blood flow will be 180-240 ml/min, and ultrafiltration rate will be 35-50 ml/kg/h during HVHF. The substitute fluid will be infused with pre-dilution. Heparin will be used for anti-coagulation, whose initial dose will be 15-25 U/kg, and maintenance dose is 5-15 U/kg/h. aPTT time maintained between 60-80 second and will be checked every 12 hours.
42310|NCT03853005|Other|controlled|supportive care
42311|NCT03852992|Drug|Post-Laser Minoxidil 2%|2ml of 20mg/ml sterile solution, applied post-laser procedure
42312|NCT03852992|Drug|At-Home Minoxidil 5%|2ml of 50mg/ml foam q24 h for duration of study
42313|NCT03852992|Device|Laser|Fractional ablative, deep mode, 5% fractional coverage
42314|NCT03852992|Drug|Post-laser 5mg minoxidil|0.25ml of 20mg/ml sterile solution, applied post-laser procedure
42315|NCT03852992|Drug|Post-laser 10mg minoxidil|0.5ml of 20mg/ml sterile solution, applied post-laser procedure
42316|NCT03852992|Drug|Post-laser 20mg minoxidil|1ml of 20mg/ml sterile solution, applied post-laser procedure
42317|NCT03852979|Drug|Paclitaxel|weekly paclitaxel 80 mg/m2 for 12 weeks
42318|NCT03852979|Drug|Carboplatin|weekly carboplatin AUC=2 for 12 weeks
42319|NCT03852979|Procedure|conisation|if tumor is reduced to <2 cm, patients will be treated with a conisation
42320|NCT03852966|Behavioral|CBT-i/ADHD|Cognitive Behavioral Therapy for insomnia adjusted for patients with ADHD
42321|NCT03852953|Other|Under- or overdiagnosed cancer|Diagnosed with a cancer that was visible on prior mammograms
42322|NCT03852953|Other|Screening|Invited or attended BreastScreen Norway
42323|NCT03852940|Other|Parenteral nutrition|
42324|NCT03852940|Other|Enteral Nutrition|
42325|NCT03852927|Procedure|Computer guided contouring|Using virtual planing and rapid prototyping a surgical guide will be fabricated, and will be used for bone contouring of the bone lesion.
42326|NCT03852914|Device|Sodium hyaluronate 2%|Each patient will receive a single injection of SH 2% and will be followed for 6 months. At 6 months follow up visit patients could be offered a second injection whenever and when they comply with the criteria established for re-treatment and will be followed for additional 6 months.
42327|NCT03852901|Drug|Jardiance 25 mg|This study involves a screening visit (Visit 0) and 3 study visits (Visits 1, 2 and 3) to the NIA Clinical Unit. In this pilot study, each enrolled participant will have a baseline visit (Visit 1)
42328|NCT03852888|Biological|Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level|Each patient will have to complete a total of 8 urine samples after treatment with methotrexate. The 8 samples will be taken over one week (just before taking, then 2 hours after taking treatment and then on D3, D4, D5, D6, D7, D8 before the new dose of methotrexate).
42329|NCT03852875|Other|Education|Same
42330|NCT03852875|Other|Control|Same
42331|NCT03852862|Drug|Serratus plane block and paravertebral block|Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)
42332|NCT03852862|Drug|paravertebral block|Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
42333|NCT03852849|Behavioral|Personal involved intervention strategies|Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.
42334|NCT03852849|Drug|The dosage of 400mg EFV|The dosage of 400mg EFV will be used in the antiviral therapy.
42335|NCT03852836|Other|ultra-rapid acquisition of bile ducts images|On top of the conventional SPACE sequence, 2 supplementary sequences will be performed with the ultra-rapid sequence (sequence CS-SPACE) either acquired in apnoea or synchronized with the breath.
42336|NCT03852823|Drug|SG001|intravenous injection SG001 through Filter membranes with aperture of 0.2-1.2 microns within 60mins
42337|NCT03852797|Drug|Oxytocin|Oxytocin solution, 20nM concentration
42338|NCT03852797|Drug|Ketamine|Ketamine in solution, 10-4M to 10-7M
42339|NCT03852797|Drug|Propofol|Propofol in solution, 10-4M to 10-7M
42340|NCT03852797|Drug|Etomidate|Etomidate in solution, 10-4M to 10-7M
42341|NCT03852784|Other|Bone and joint infection with Streptococcus peumoniae|description of the osteoarticular infection with Streptococcus peumoniae
42342|NCT03852771|Device|Cirvo(TM) therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression to the lower leg.
42343|NCT03852758|Behavioral|Outdoor Exercise|2 outdoor exercise sessions per week
42344|NCT03852758|Behavioral|Indoor Exercise|2 indoor exercise sessions per week
42345|NCT03852745|Behavioral|Cognitive Behavioral Therapy|cognitive behavioral therapy; focus on learning skills including acceptance and commitment
42411|NCT03852160|Drug|Esketamine 84 mg|Participants may receive 84 mg (maximum uptitrated esketamine dose). The dose may be decreased/may remain same based on the efficacy and tolerability.
42346|NCT03852732|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
42347|NCT03852719|Drug|Bulevirtide|daily subcutaneus injections
42348|NCT03852706|Other|LORETA|Twenty sessions of neurofeedback training using LORETA in combination with z-scores.
42349|NCT03852706|Other|Treatment as usual|Treatment-as-usual
42350|NCT03852693|Other|Histopathological review|Histopathological review
42351|NCT03852680|Procedure|aneurysm clipping|treatment of wide necked intracranial aneurysms using different modalities as open surgery by clipping or endovascular techniques as coiling and flow diversion
42352|NCT03852667|Behavioral|Pain Neuroscience Education|The PNE intervention consisted of 2 sessions of 30 minutes. In the first session, the main goal is to explain the patient why pain is important and why people can't live without it. Besides it is explained why objective findings such as x-rays, MRI, CT scans, etc. often lack significant findings despite the pain that the patient experiences. This first session of pain education might help the patient understand that pain is necessarily a result from tissue damage. Furthermore, the session explains the right approach to conquer pain and to avoid going down in this vicious circle of low back pain. The second session of PNE, is a revision of the first session, continuing on what was unclear from the first session.
42353|NCT03852667|Other|Exercise therapy|The exercise therapy varies form analytical exercises in the first sessions, to functional and sports related exercises near the following sessions. The first session focuses on the lumbar neuromuscular control of the patients: first a voluntary contraction of the Transversus Abdominis muscle, the Multifidus muscle and the pelvic floor muscles is learned. When the subject is able to maintain the combined contraction for 10 times, the exercises evolve to more complicated tasks. In the final stage, more functional and sport specific tasks will be exercised.
42354|NCT03852654|Drug|18F-DCFPyL|"Subjects with biopsy proven prostate cancer, no prior local therapy, and:~PSA ≥ 10 ng/dl, or Gleason Sum ≥ 4+3, or clinical stage ≥cT2c Staging by 99mTc-MDP or NaF PET bone scan, and Diagnostic CT (pelvis) or MRI will undergo 18F DCFPyL PET CT scan."
42355|NCT03852641|Other|Length of feeding|Feeds will be given via nasogastric tube over 15-30 min versus 2 hr
42356|NCT03852628|Drug|2mg Buprenex and 380mg Vivitrol|Daily 2mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
42357|NCT03852628|Drug|8mg Buprenex and 380mg Vivitrol|Daily 8mg SL BUP (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8 ) IM NLTRX
42358|NCT03852628|Drug|Placebo (SL pill qd, IM injection q4weeks)|Daily SL placebo (84 pills total, taken sublingual every day for 12 weeks) and Q4wks (given intramuscular, 3 injections total: at baseline, week4 and week8) IM Placebo
42359|NCT03852615|Diagnostic Test|Pre operation Blood sample for AMH|Blood sample for Anti Mullarian Hormone (AMH) analysis will be taken during preparation for surgery, while inserting vein line and taking the customary blood samples.
42360|NCT03852615|Diagnostic Test|3 month post operation blood sample for AMH|Additional blood sampling that will include a single tube containing 3 cc of blood for analysis of AMH will be taken three month from operation.
42363|NCT03852589|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. PLMA will inserted by anesthesiologist with C-MAC videolaryngoscope.
42364|NCT03852589|Device|Blind|PLMA will inserted by anesthesiologist with digital finger.
42365|NCT03852576|Drug|KSP/QRH dimer|KSP-QRH-E3-IRDye800 (Peptide 919288G)
42366|NCT03852563|Drug|BAY207543 (Bepanthol)|Product is applied to one hemiface.
42367|NCT03852563|Other|Semisolid vaseline|Product is applied to one hemiface.
42368|NCT03852550|Other|e-health application|In the first part of this study, an e-health application (MyREADY Transition BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
42369|NCT03852537|Drug|Methylprednisolone|Patients who meet inclusion criteria will be randomized into the standard or the individualized biomarker-concordant arms. Steroids will be administered per predefined protocol. In the standard-dose arm, patients will receive 1 mg/kg methylprednisone (or oral equivalent) for a total of 5 days. In the biomarker-adjusted arm, all patients will receive steroids once at the time of admission, then daily at 10AM. In order to account for varying turnaround time at different laboratories, CRP levels will be drawn with early morning labs, and used to determine the steroid dosing for the day per predefined dosing table.
42370|NCT03852524|Drug|Methylnaltrexone|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving methylnaltrexone (study drug) will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
42371|NCT03852524|Other|Placebo|Randomization of methylnaltrexone to placebo will be at a 1:1 ratio. Those receiving placebo will receive a subcutaneous dose pre-surgery and daily for three days following surgery.
42372|NCT03852511|Biological|NG-350A|NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
42412|NCT03852160|Drug|Placebo|Participants will receive matching placebo as nasal spray.
42373|NCT03852498|Drug|Genetic|Lenti-D Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with Lenti-D lentiviral vector that encodes an ABCD1 cDNA for human adrenoleukodystrophy protein, suspended in a cryopreservation solution) is administered intravenously. Lenti-D Drug Product is administered by IV infusion following myeloablative conditioning with busulfan and fludarabine.
42374|NCT03852485|Device|SD-OCT|Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
42375|NCT03852472|Drug|Avacopan|Active treatment
42376|NCT03852472|Other|Placebo|Placebo
42377|NCT03852459|Drug|S-Ibuprofen|Topical Gel 5%
42378|NCT03852459|Drug|Vehicle|Vehicle Gel
42379|NCT03852446|Drug|Indoximod HCL (F2) tablets|The doses will be ascending per cohort from 600 mg to 2400 mg
42380|NCT03852446|Drug|Indoximod base formulation|Single oral administration of 1200 mg
42381|NCT03852446|Other|Placebo|The matching placebo doses will be ascending per cohort from 1 to 4 tablets
42382|NCT03852446|Drug|Indoximod HCL (F2) tablets|Single oral administration of 1200 mg
42383|NCT03852433|Drug|Bulevirtide|daily subcutaneus injections
42384|NCT03852433|Drug|Peginterferon Alfa-2a|weekly subcutaneus injections at a dose 180 mcg
42385|NCT03852407|Drug|Thymoglobulin|ATG: 2.5 mg /kg/day on day -2 and -1 (day 0 is allogenic transplantation)
42386|NCT03852407|Drug|Melphalan|140mg/m² on day -2
42387|NCT03852407|Drug|Fludarabine|30mg/m² on days -5,-4,-3,-2,-1.
42388|NCT03852394|Other|Respiratory mechanics assessment|The study protocol consisted of two consecutive phases; in the first step measurements of static respiratory mechanics and end expiratory lung volume (EELV) were performed after 30 minutes of MV in volume control mode. In the second step transdiaphragmatic pressure (Pdi) was calculated by means of a sniff maneuver (Maximal Pdi) after 30 minutes of spontaneous breathing trial. Linear regression analysis and Pearson's correlation coefficient was used to asses the association between Maximal Pdi values and static and dynamic mechanical features and the association between Maximal Pdi and Pdi/Maximal Pdi.
42389|NCT03852381|Device|Spinal Cord Stimulation|Paresthesia-based SCS(PB-SCS), with stimulating frequencies between 30 to 80 Hz that confer a tingling sensation. Three different paresthesia-free SCS (PF-SCS) modes that use frequencies in the range of 400-10,000 Hz include Burst, High Frequency stimulation at 1.2 kHz and High Density stimulation at 400 Hz.
42390|NCT03852368|Other|Exercise|The effects of exercise with different intensity on the executive functions of adolescents
42391|NCT03852355|Drug|Radiofrequency|), received bilateral 3rd occipital nerve RF under fluoroscopic guidance. Levobupivacaine (0.3 mL; 0.75%) and triamcilonone (1 mg) were injected at each level
42392|NCT03852355|Drug|Steroids|received systemic steroids oral prednisolone tablet, 10 mg/day
42393|NCT03852329|Device|Lateral skull base navigation|"Patient preparation: The participant is prepared for the surgery according to clinical standards.~System setup: The hardware components of the investigational device are set up~Tripod fixation: The tripod with integrated registration fiducials is fixed on the participant's skull.~CBCT imaging: A CBCT image of the participant is acquired~Image processing: The CBCT data is loaded on the navigation platform. The registration fiducials are automatically detected in the image data and relevant anatomy is segmented using an otologic planning software.~Measurements: The navigation software is started, and the fiducial positions and segmentations loaded. The measurements are conducted.~Treatment: The surgery is conducted by the surgeon according to clinical standards"
42395|NCT03852303|Drug|ivermectin|evaluate effect of ivermectin on frequency of seizures
42396|NCT03852264|Behavioral|Pet dog|Children will interact freely with their pet dog for 25 minutes.
42397|NCT03852264|Behavioral|Unfamiliar dog|Children will interact freely with an unfamiliar dog for 25 minutes
42398|NCT03852264|Behavioral|Nonsocial control|Children will play with age-appropriate toys/games for 25 minutes.
42399|NCT03852251|Biological|AK104|Subjects will receive AK104 by intravenous administration.
42400|NCT03852251|Drug|Oxaliplatin|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
42401|NCT03852251|Drug|Capecitabine|Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
42402|NCT03852238|Other|Blood test and self-administrated questionnaires|
42403|NCT03852225|Diagnostic Test|Intra-arrest echocardiography|Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
42404|NCT03852212|Other|Manipulation|Thrust technique application
42405|NCT03852199|Other|Test protocol for proprioceptive force sense in case group|"The FS in the knee region was measured by the pressure, biofeedback device (Stabilizer ™, Chattanooga Group Inc., Chattanooga, TN).~Surface EMG device (Noraxon USA, Inc., Scottsdale, AZ) was used to measure activation levels of M. Vastus Medialis Obliquus (VMO), M. Vastus Lateralis (VL) and M. Rectus Femoris (RF) muscles. Due to the characteristics of the Bipolar Ag/AgCl surface electrodes, the distance between the electrodes was set to 1 cm and the electrode width to 2 cm. The electrode placement was determined according to the SENIAM (Surface ElectroMyoGraphy for the Non-Invasive Assessment of Muscles) criteria."
42406|NCT03852186|Behavioral|Cognitive behavioral therapy|Group based psychotherapy
42407|NCT03852186|Behavioral|Acceptance and commitment therapy|Group based psychotherapy
42408|NCT03852173|Behavioral|Wasserschulen|"Schools receive following materials and trainings:~one training sessions for teachers (at the beginning of the intervention)~refillable water bottles for each school student~drying rack for water bottles for each classroom~educational material for each class and for school events~informational material for parents"
42409|NCT03852160|Drug|Esketamine 28 mg|Participants will receive 28 mg esketamine as nasal spray (Initial dose for elderly participants with 65-74 years of age on Day 1 and then uptitrated to 56 mg on Day 4).
42410|NCT03852160|Drug|Esketamine 56 mg|Participants will receive 56 mg esketamine as nasal spray (Initial dose for participants with 18-64 years of age) on Day 1. The dose may be increased/may remain same based on the efficacy and tolerability. Participants with 65 to 74 years of age will receive esketamine 56 mg from Day 4 onwards.
42413|NCT03852160|Drug|Escitalopram|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for escitalopram is 5 mg once daily (for elderly participants) and 10 mg once daily (for adults). The dose may be increased to 10 mg (for elderly participants) and 20 mg (for adults) once daily at the discretion of treating physician/investigator.
42414|NCT03852160|Drug|Sertraline|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for sertraline is 50 mg once daily and may be increased up to 200 mg once daily.
42415|NCT03852160|Drug|Duloxetine|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for duloxetine is 60 mg once daily and may be increased to 120 mg once daily.
42416|NCT03852160|Drug|Mirtazapine|Mirtazapine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for mirtazapine is 15 to 30 mg once daily and may be increased to 45 mg once daily.
42417|NCT03852160|Drug|Agomelatine|Agomelatine can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for agomelatine is 25 mg once daily and may be increased to 50 mg once daily after 2 weeks.
42418|NCT03852160|Drug|Bupropion|Bupropion can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for bupropion is 150 mg once daily and may be increased to 300 mg once daily after 4 weeks.
42419|NCT03852160|Drug|Trazodone Prolonged Release|Trazodone prolonged release can be selected as the oral antidepressant medication based on investigator's discretion. The initial dose for trazodone prolonged release is 75 to 150 mg once or twice daily and may be increased up to 450 mg (adults) and 300 mg (elderly).
42420|NCT03852147|Procedure|: hemodynamic management|"Control group: hemodynamic management of patients is done according to usual practices by maintenance of blood pressure by norepinephrine as well as optimization of SV by vascular filling and use of dobutamine if necessary.~Experimental group: perioperative hemodynamic management is based on an algorithm that includes RQ measurement and includes volume expansion, norepinephrine, FiO2 enhancement, RBC transfusion and dobutamine."
42421|NCT03852134|Procedure|MOCC Group|After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.
42422|NCT03852134|Procedure|DCC Group|"The OB provider will hold the baby at or below the level of placenta, provide warmth, stimulate the baby to breathe and suction the mouth/nose if needed for the first 30 seconds.~After these initial 30 seconds, if the baby is breathing then the obstetrician will continue DCC for a total of 60 seconds before clamping and cutting the cord close to the umbilicus and handing over the baby to the neonatal team for further stabilization as per standard NRP practice. If the baby is not breathing after the initial 30 seconds of DCC, then the OB provider will clamp and cut the cord close to the umbilicus and hand over the baby to the neonatal team to continue resuscitation of the baby as per the standard NRP guidelines."
42423|NCT03852121|Behavioral|Bibliotherapy|"Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves."
42424|NCT03852108|Other|Comfort Care|Face, Hand and body care for 15 to 45 minutes
42425|NCT03852095|Other|minor trauma|following the management of the patient's fracture in the emergency department, the patients / parents are recalled 2 months (J60) after the visit to the emergency room, and are interviewed by following the pre-established interrogation form, which checks the good agreement of the patient. treatment performed with the given sheet and recommendations, and assesses the satisfaction.
42426|NCT03852082|Procedure|percutaneous coronary intervention|Patients with coronary heart disease co-morbid depression post percutaneous coronary intervention.
42427|NCT03852069|Dietary Supplement|Inulin|Patient receive Inulin as dietary supplement (16g/d) in combination with dietary advice to enhance the consumption of inulin-rich vegetables
42428|NCT03852069|Dietary Supplement|Placebo|Patient receive maltodextrin as dietary supplement (16g/d) in combination with dietary advice to enhance the consumption of vegetables poor in inulin
42429|NCT03852056|Drug|MFP Fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
42430|NCT03852056|Drug|Stannous fluoride toothpaste|Whole mouth brushing with a toothpaste, 2 times/day for 1 minute each time for the duration of the study,
42431|NCT03852043|Behavioral|High-intensity interval training|The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.
42432|NCT03852043|Behavioral|Moderate-intensity continuous training|The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
42433|NCT03852030|Behavioral|Text or email message|Text or email messages sent to research participants
42434|NCT03852017|Behavioral|Audio Program|
42435|NCT03852004|Other|ostheopathy|standardized osteopathic treatment
42436|NCT03852004|Other|simulated osteopathic treatment|standardized simulated osteopathic treatment
42437|NCT03851991|Drug|Arbidol|oral
42438|NCT03851991|Drug|Placebos|controle
42439|NCT03851978|Behavioral|Pharmacist Vaccine Education|When an eligible patient presents to the pharmacy for prescription pick up or drop off, the pop-up note will notify the technician to get a pharmacist for education. The pharmacist will educate the patient on the vaccine and then recommend that the patient receives the vaccine.
42440|NCT03851965|Diagnostic Test|Soluble Urokinase Plasminogen Activator Receptor|Preoperative and postoperative determination of the Soluble Urokinase Plasminogen Activator Receptor levels in patients undergoing non-cardiac major surgery.
42474|NCT03851679|Other|urine collection|6 hour and 24 hour urine collection after Cesarean Section
78207|NCT03573427|Device|Trans-atrial septal placement LV lead for CRT|
42441|NCT03851952|Device|Optilume Drug Coated Balloon|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
42442|NCT03851939|Combination Product|Transarterial Chemoinfusion (TAI) Combine Toripalimab|Transarterial Chemoinfusion (TAI) Combine Toripalimab
42443|NCT03851926|Radiation|Hypofractionated volumetric radiotherapy in 20 fractions|Hypofractionated radiotherapy at 3 Gy per fraction for localized prostate cancer.
42445|NCT03851900|Other|Teethmate Desensitizer (TM)|Desensitizing agent will be applied to sensitive teeth.
42446|NCT03851900|Other|Clearfil SE Bond 2|Desensitizing agent will be applied to sensitive teeth.
42447|NCT03851900|Other|Distilled water|Placebo will be applied to sensitive teeth as a negative control.
42448|NCT03851887|Combination Product|TAI combine SBRT|TAI combine SBRT
42449|NCT03851874|Procedure|Bariatric surgery|Bariatric surgery
42450|NCT03851861|Other|Mediterranean Diet|"Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consumption of ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fresh fruits (including natural juices); d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish or seafood (at least one serving of fatty fish); f) ≥3 weekly serving of nuts or seeds; g) select white instead of red meats or processed meats (burgers, sausages); h) cook at least twice a week with a tomato herb sauce.~Participants will be instructed to eliminate or limit the consumption of the following foods: cream, butter, margarine, cold meat, paté, duck, carbonated and/or sugared beverages, pastries, industrial bakery products and desserts, French fries or potato chips, and out-of-home pre-cooked cakes and sweets. For usual drinkers, the main source of alcohol should be wine."
42451|NCT03851848|Other|Joint mobilization (JM)|Joint mobilization (JM) is a manual therapy to move the joint in a desired direction. It is commonly used for improving the joints' ROM and pain intensity, and to overcome joint restriction.
42452|NCT03851848|Other|Myofascial release (MFR)|Myofascial release (MFR) is a technique in which a slow, sustained pressure is applied to the restricted soft tissue in order to restore optimal length, reduce pain and improve function.
42453|NCT03851835|Drug|Ondansetron Oral Solution|Six doses of oral ondansetron (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
42454|NCT03851835|Drug|Oral Placebo|Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
42455|NCT03851809|Drug|Wendan decoction combination in acute brain injury|In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
42456|NCT03851796|Behavioral|TEENS+Parents as Coaches|Parents as Coaches teaches parenting strategies to facilitate healthy weight loss in adolescent children; adolescents are in a group based behavioral weight management treatment.
42457|NCT03851796|Behavioral|TEENS+Parent Weight Loss|Parent Weight loss teaches core behavioral weight loss strategies and techniques for parent weight loss; adolescents are in a group based behavioral weight management treatment.
42458|NCT03851783|Device|Solar-powered oxygen|Constant and reliable administration of oxygen, using solar panels to power an oxygen concentrator and deliver medical grade oxygen at 1-5L/min.
42459|NCT03851770|Other|Characterization of Vagus nerve stimulation|Characterization of Vagus nerve stimulation induced larynx evoked motor potential. Patients participating in the study will be asked to come to perform the experiment (duration maximum 1 hour) at the Neurophysiology Department of Saint Luc .
42460|NCT03851757|Device|waist-shaped interdental brush|use four times each per interdental space
42461|NCT03851757|Device|cylindric interdental brush|use four times each per interdental space
42462|NCT03851744|Other|Sea Level|Carbohydrate consumed at 1.8 g/min during treadmill exercise at SL
42463|NCT03851744|Other|High Altitude|Carbohydrate consumed at 1.8 g/min during treadmill exercise at HA
42464|NCT03851731|Drug|Naltrexone|Intranasal spray
42465|NCT03851731|Drug|Naloxone|Intranasal spray
42466|NCT03851731|Drug|Naltrexol|Intranasal spray
42467|NCT03851718|Device|Acupuncture Procedure|Each session will run about 30~40 minutes at the Family Medicine Clinic and performed by a licensed acupuncturist. The expense of all three sessions will be reimbursed by the project, not billed to the participant. The following points CV17, ST18 (bilateral), ST36 (bilateral), SI1(bilateral) and LR3(bilateral) , adopted from TCM classic text and previous studies done in China, will be used for all three sessions .
42468|NCT03851718|Behavioral|Power pumping|It suggests the mom to set at least one hour and two hours preferably for the power pumping at least three days within a 5 weekday period, preferably on 3 consecutive days. During this one hour, the moms will be advised to pump for 20 minutes, rest for 10 minutes, pump for 10 minutes, then rest for 10 minutes and pump for 10 minutes. Alternatively they can also opt to pump and rest for every 10 minutes during the hour.
42469|NCT03851705|Drug|Inclisiran for injection|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
42470|NCT03851705|Drug|Placebos|Sterile normal saline (0.9% sodium chloride in water for injection)
42471|NCT03851692|Other|Intravenous Cannulation (iv placement)|The aim of our study is to determine whether one should make intravenous attempts placement during the early induction period (at 60seconds) or lately (90 or 120 s) and waiting until the child receives additional sevoflurane inhalation anesthesia.
42472|NCT03851679|Diagnostic Test|B-Type natriuretic peptide (BNP) serum values|"evaluation BNP serum values:~pre- Cesarean Section (30 minutes before surgery)~post- Cesarean Section (6 hour and 24 hour after surgery)"
42473|NCT03851679|Device|Pulmonary echography|"Pulmonary echography:~pre- Cesarean Section (30 minutes before surgery)~post- Cesarean Section (6 hour and 24 hour after surgery)"
42580|NCT03850795|Drug|HC-1119|oral once daily 80 mg
42475|NCT03851666|Dietary Supplement|12 weeks daily administration Cereal 1|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
42476|NCT03851666|Dietary Supplement|12 weeks daily administration Cereal 2|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of product.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation.~The daily dose administrated is 15 grams."
42477|NCT03851666|Other|12 weeks daily administration Placebo|"The subjects will come to a visit every 4 weeks for a total period of 12 weeks. At the first, the second and the third visit the subjects will be supplied with a 5-week supply of placebo.~Each daily administration will be supplied in a sachet. Subjects will be instructed to mix the contents of the sachet with 200mL of water and drink the solution within 5 minutes after preparation."
42478|NCT03851653|Behavioral|Lifestyle Intervention|Cognitive-behavioural intervention for weight loss and lifestyle change
42479|NCT03851640|Drug|HC1119|oral
42480|NCT03851640|Drug|placebo|oral
42481|NCT03851627|Drug|Testosterone Undecanoate|1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter
42482|NCT03851627|Drug|Placebo|Placebo Arm
42483|NCT03851614|Biological|Durvalumab|Durvalumab is a human immunoglobulin G (IgG)1 kappa monoclonal antibody directed against human PD-L1. Durvalumab selectively binds human PD-L1 with high affinity and blocks its ability to bind to PD-1 and cluster of differentiation (CD)80. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgG1 heavy chain that reduces binding to the complement component C1q and the Fc gamma receptors responsible for mediating antibody dependent cell mediated cytotoxicity.
42484|NCT03851614|Drug|Olaparib|Olaparib (AZD2281) is a potent oral poly Poly (ADP-ribose) Polymerase (PARP) enzyme inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents. Olaparib specifically traps PARP1 and PARP2 enzymes at sites of damaged DNA; the trapped PARP1- or PARP2-DNA complex is cytotoxic and produces clinical response. Although olaparib also binds to PARP3, recent investigations have suggested PARP-3 inhibition does not contribute towards anti-cancer activity.
42485|NCT03851614|Drug|Cediranib|Cediranib (AZD2171) is a potent oral small molecule Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinase inhibitor, specifically inhibiting all three VEGF receptors (VEGFR-1, -2 and -3). It has additional inhibitory activity against stem cell factor receptor tyrosine kinase, and less potency against platelet-derived growth factor receptor tyrosine kinases. Cediranib exerts its anti-angiogenic property by competitively inhibiting the ATP binding site on the VEGF receptors.
42486|NCT03851601|Other|blood samples|Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
42487|NCT03851588|Other|Placebo|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
42488|NCT03851588|Drug|Dolutegravir 50 mg|Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
42489|NCT03851575|Other|Accelerated treatment of endocarditis|For the three main bacteria species we shorten the duration of antibiotic treatment
42490|NCT03851575|Other|Usual guideline therapy|Usual guideline therapy
42491|NCT03851562|Drug|Alprostadil 20 micrograms|Intravenous infusion of PGE1 (Days 0, +1 and +2)
42492|NCT03851562|Drug|Placebo|Intravenous infusion of physiological saline solution
42493|NCT03851549|Device|New BGMS (US)|New blood glucose monitoring system / In vitro diagnostic device (IVDD)
42494|NCT03851536|Procedure|Transvaginal Ultrasound Guided ET|Use of TVUS to guide ET
42495|NCT03851536|Procedure|Transabdominal Ultrasound Guided ET|Use of TAUS to guide ET
42496|NCT03851523|Other|No intervention|No intervention
42497|NCT03851471|Drug|Jiu-wei-zhen-xiao Granule|Patients will be treated for 12 weeks, with oral administration of 5g once of Jiu-wei-zhen-xiao Granule,three times a day, based on the conventional treatment for HCC, such as antiviral treatment, supportive treatment or symptomatic treatment.
42498|NCT03851445|Drug|Screening Platform|The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
42499|NCT03851432|Drug|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 25 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
42500|NCT03851432|Drug|Janagliflozin plus metformin|Janagliflozin: Tablets, Oral, 50 mg, Once daily, 52 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
42501|NCT03851432|Device|Placebo plus metformin|Placebo: Tablets, Oral, 25/50 mg, Once daily, 24 weeks The patient's stable dose of background therapy of metformin should be continued throughout the study.
42502|NCT03851419|Diagnostic Test|Diagnosis of (Neuro)cysticercosis|"Serological tests for cysticercosis~Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis~Stool testing for T. solium"
42503|NCT03851406|Device|5% Hypertonic Saline|Subjects will inhale 15 mL of 5% HS for 15 minutes delivered by an ultrasonic nebulizer with a coached cough maneuver
42504|NCT03851393|Other|Induction of cough with inhaled citric acid|perform artificially induced cough by inhalation of citric acid at various strengths
42505|NCT03851393|Procedure|Peptest™ analysis of saliva pepsin|collect patient saliva for analysis of pepsin levels
42506|NCT03851393|Diagnostic Test|Peptest™|The Peptest™ lateral flow device
42507|NCT03851380|Behavioral|Psychological / Functional Assessment|Psychological and functional assessment battery to characterize participants.
42508|NCT03851380|Other|Structural and Functional MRI|Structural and functional magnetic resonance imaging session.
42581|NCT03850795|Drug|Enzalutamide|oral once daily 160 mg
42509|NCT03851380|Device|Transcranial Magnetic Brain Stimulation and MR Image Guidance|MRI guided transcranial magnetic stimulation and measurement of targeting accuracy.
42510|NCT03851367|Procedure|Sling suspension using red cord|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
42511|NCT03851367|Procedure|Gym ball exercises|3 weeks duration, 15 sessions, and 30 minutes a day for five consecutive days a week. Back pain, endurance of trunk muscles (flexors, extensors and side flexors), and standing posture were evaluated pre and post interventions.
42512|NCT03851354|Other|Ultrasound meal acommodation test|to observe their tolerance a 500 ml of solution with glutamine, or Caseinate and the protocol will be carried out will be given. Ultrasound measures will be performed and observing changes in Cross Sectional Area of the gastric antrum of the first measurement at the time after administration. Gastric residue will be measured.
42513|NCT03851341|Combination Product|Janumet XR tablet 100/1000 mg|To administrate the Janumet XR tablet
42514|NCT03851341|Combination Product|GLH1SM tablet 100/1000 mg|To administrate the GLH1SM tablet
42515|NCT03851328|Other|BPMH structured interview|creating a standardized medication list by interviewing patient and/ or relatives according to Best Possible Medication History (BPMH) after patient transfer to medical ward
42516|NCT03851315|Device|permanent left bundle branch area pacing|Implant the pacing lead in the left bundle branch area instead of traditional RV pacing site(septal or apical). Successful LBBAP was defined as the paced QRS morphology of right bundle branch block pattern in lead V1 and QRS duration (QRSd) less than 130ms.
42517|NCT03851302|Other|Active Remote Ischemic Conditioning|The active RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The active RIC will be achieved via blood pressure cuff inflation to 200 mmHg.
42518|NCT03851302|Other|Sham Remote Ischemic Conditioning|The sham RIC protocol involves 5 cycles of 5-min inflation and 5-min deflation on the non-target arm. The sham RIC will be achieved via blood pressure cuff inflation to 10 mmHg below the subjects' diastolic blood pressure which would not cause the blood occlusion.
42519|NCT03851302|Other|Isometric hand exercise|Participants will be instructed to pinch a dynamometer with thumb and index finger at different intensities and durations. The intensities of pinch force will be 10%, 25%, and 50% of the maximal voluntary contraction (MVC). For each intensity, durations of 2, 4, and 6 s will be employed, which resulted in nine different combinations delivered in pseudorandom order. Participants will perform 2 sets of the isometric hand exercise (18 pinches in total). The interval between each pinch will be 2 seconds, with 30 second intervals between each set.
42520|NCT03851289|Combination Product|platelet-rich fibrin and calcium sulfate|
42521|NCT03851289|Combination Product|platelet-rich fibrin and xenograft|
42522|NCT03851276|Radiation|Multi-sliced computed tomography (MSCT)|Surgery planning done based solely on MSCT.
42523|NCT03851263|Biological|Evolocumab|Subcutaneous injection, using a pre-filled auto-injector pen. Each pen contains 1.0 ml fluid (containing 140 mg evolocumab) which is injected in the abdomen, thigh or outer area of upper arm every 2 weeks (q2w).
42524|NCT03851250|Drug|MRx-4DP0004|Participants randomised to receive MRx-4DP0004 will take it in addition to their regular asthma medication.
42525|NCT03851250|Drug|Placebo|Participants randomised to receive placebo will take it in addition to their regular asthma medication.
42526|NCT03851237|Drug|64Cu-DOTA-ECLIi|-The first five patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i
42527|NCT03851237|Device|CTI/Siemens Biography 40 PET/CT|-Standard of care
42528|NCT03851224|Procedure|control group|immediate implant with immediate loading using no graft
42529|NCT03851224|Procedure|study group|immediate implant with immediate loading using autogenous bone graft
42530|NCT03851224|Procedure|study group 2|immediate implant with immediate loading using (Geistlich Bio-Oss®) xenograft
42531|NCT03851198|Procedure|Standard Care or Usual Clinical Practice|The guidelines for the management according to the mild cognitive impairment in primary care will be the treatment guidelines for the Standard Care.
42532|NCT03851172|Drug|Ketorolac Ophthalmic|Preoperative administration of Ketorolac 0.5% eye drops
42533|NCT03851172|Drug|Nepafenac Ophthalmic|Preoperative administration of Nepafenac 1 mg eye drops
42534|NCT03851172|Drug|Cyclopentolate Ophthalmic|Preoperative administration of Cyclopentolate eye drops
42535|NCT03851159|Dietary Supplement|Nyaditum resae®|Heat-killed Mycobacterium manresensis
42536|NCT03851159|Other|Mannitol|Placebo
42537|NCT03851146|Biological|LeY CAR T cells|Autologous peripheral blood T-lymphocytes transduced with the anti-LeY-scFv-CD28-ζ vector (LeY CAR T cells)
42538|NCT03851133|Other|Blood Sample Collection|Participants will be asked to donate blood at baseline (+/- 30 days of diagnosis date) and at the time of follow-up (approximately 6 months and approximately 12 months after baseline).
42539|NCT03851133|Other|Tumor Sample collection|At the time of tissue biopsy and surgical resection (if applicable), pancreatic tumor tissue and tissue from site of metastasis will be collected.
42540|NCT03851133|Other|Data Collection|Participants will be asked to complete a 3 page screening tool at the time of their in-person clinic visit, as well as questionnaires at baseline and at 6 and 12 months.
42541|NCT03851120|Dietary Supplement|Probiotic and LC-PUFA|Probiotic and LC-PUFA
42542|NCT03851120|Dietary Supplement|Placebo|Placebo
42543|NCT03851120|Behavioral|Psychosocial stimulation and healthy eating education|Psychosocial stimulation and healthy eating education
42544|NCT03851107|Behavioral|Engagement in 6-week community-based activity program|Participants engage in a 6-week community-based activity program of their choice. In order to engage in the selected activity, an Occupational Therapist (OT) will meet with each youth in their home. Using the PREP 5 steps (Make goals; Map out a plan; Make it happen; Measure the process and outcomes; Move forward) the youth will choose a community program. The OT will then search for the appropriate program, identify and remove potential environmental barriers for participation in that activity (e.g., accessibility, equipment) and educate program instructors regarding the youth's specific needs. This process, which includes up to 12 hours of working with the OT, will set the stage for enrolment of the youth in a community program for a period of 6 weeks - the actual intervention phase.
42545|NCT03851094|Behavioral|Wellth app|The intervention is the use of Restful, the Wellth self-management app. There is no clinical treatment intervention, as all participants will be receiving PAP therapy per standard of care. Restful is a smartphone-based patient engagement tool that utilizes concepts from behavioral economics to help patients improve their adherence to therapy. The intervention includes a financial and social incentive reward program.
42546|NCT03851081|Biological|Inotuzumab Ozogamicin|Given IV
42547|NCT03851081|Other|Quality-of-Life Assessment|Ancillary studies
42548|NCT03851081|Drug|Vincristine Sulfate Liposome|Given IV
42549|NCT03851068|Device|Foldax Tria Aortic Valve|Aortic Valve Replacement
42550|NCT03851055|Drug|Zinc|One arm will receive Zinc Second arm will receive placebo
42551|NCT03851042|Device|Virtual Reality Head set in PACU|Use of VR headset to determine post op satisfaction in PACU, decreased pain reduction and opioid consumption
42552|NCT03851042|Other|No intervention|Routine post laparoscopic hysterectomy management (no VR headset)
42553|NCT03851029|Other|Tai chi|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
42554|NCT03851029|Other|Aerobic Training|"Session:~• 3 times a week for 30-45 min.~Duration:~• For 6 weeks~Warm-up:~• 10-15 mints~Cool-down:~• 10-15 mints or stretching's~Exercises time:~• 20-30 mints"
42555|NCT03851016|Behavioral|Life Story Book|Life Story Book intervention of three 1-hour visits with participants to create a life story book
42556|NCT03851016|Behavioral|Care as Usual|Three weeks will be care as usual
42557|NCT03851003|Procedure|Endometrial suturing|Suturing will include endometrium during cesarean incision repair
42558|NCT03851003|Procedure|Non- endometrial suturing|Suturing will not include endometrium during cesarean incision repair
42559|NCT03851003|Device|Vaginal ultrasonography|All women will be invited six month post operation for vaginal sonographic evaluation of the uterine scar
42560|NCT03851003|Other|Questionnaire|All women will be invited six month post operation for filling questionnaire concerning possibility of uterine scar defect ( spotting, pelvic pain, fertility abnormalities )
42561|NCT03850990|Behavioral|Placebo pill and no placebo pill|The placebo pills will be green and white gelatin capsules containing microcrystalline cellulose and other inert ingredients.
42562|NCT03850964|Drug|Pazopanib|gel capsule, with 25mg-similar fills
42563|NCT03850964|Drug|Placebo oral capsule|identical gel capsule without active pharmaceutical ingredient
42564|NCT03850951|Device|Lingual appliances|Patients with moderate crowding will be treated without extraction using lingual appliances.
42565|NCT03850951|Device|Labial appliances|Patients with moderate crowding will be treated without extraction using labial appliances.
42566|NCT03850938|Device|Conventional Kyphoplasty|The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.
42567|NCT03850938|Device|Kyphoplasty with Rotary Cutter|The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.
42568|NCT03850925|Procedure|Laser therapy|4 consecutive sessions of laser therapy
42569|NCT03850912|Other|eSyM App Usage|Patients (and/or proxy) will report their cancer-related symptoms and receive tailored feedback via eSyM
42570|NCT03850912|Other|SASS Questionnaire|"A subset of eSyM+ and eSyM- patients will be asked to complete a research questionnaire called the SASS Questionnaire asking about their Self-efficacy, Attainment of information needs, Symptom burden, and Satisfaction with care (see PROMIS, CAHPS, IAM/AIM question banks - Appendices C through G). The questionnaire will stop being administered once 1800 total surveys have been received."
42571|NCT03850886|Dietary Supplement|Niacinamide Oral Tablet|Nature's Life Niacinamide 1000 mg
42572|NCT03850886|Drug|Antidiabetic|Metformin or Sulphonylurea
42573|NCT03850873|Drug|TQB3616|TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
42574|NCT03850860|Other|empirical antibiotherapy|comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
42575|NCT03850847|Other|Step 1: Semi-structured Interviews|"Cover SDMs' experience around:~withdrawal of life sustaining therapies~organ donation among those who were approached (including with the medical team and the organ donation organisation)~understanding of the situation~views on any gaps in the quantity or quality of information and discussion they received concerning their loved one's end-of-life care or donation process~Explore factors they perceived to influence their decision to consent to organ donation or not (or that would have influenced their decision for those not approached), and how such factors may have changed over the course of making this decision and since the decision (or since the event for those not approached)."
42576|NCT03850847|Other|Step 2: National Telephone Survey|Explore SDM's beliefs and experiences around end of life and assess which beliefs are associated with the decision taken at the end of life, including decision to donate organs or not (and the strength of this association)
42577|NCT03850834|Drug|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
42578|NCT03850834|Drug|placebo enteric-coated tablets|There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested
42579|NCT03850821|Behavioral|Connect Social Mechanisms Intervention|"The Get-to-Know-You small group sessions (30 minutes) were designed to increase friendship building skills and involved interactive student-led discussions and activities designed to foster the assets needed to build and support friendships, group cohesion, and staff connections through PA. The PA component of the program (60 minutes) was designed to promote a positive PA social experience and meet youth social affiliation goals. Available games to choose from were novel, inclusive, emphasized teamwork, and centered on social goals. Three different PA stations were offered each program day in which youth rotated. One day each week was designated as a choice day, whereby youth activity preference ratings were used to determine which activities were offered that day."
42582|NCT03850782|Drug|Bimatoprost (SR)|"Study Eye: Cycles 1 - 3 administrations through the Month 18 visit.~Fellow Eye: Standard of care or Bimatoprost SR"
42583|NCT03850769|Drug|nab-paclitaxel and S-1|Nab-Paclitaxel: 120 mg/m2 d1, 8, S-1: Body surface area < 1.25 m2, 80 mg/d; Body surface area ≥ 1.25 m2 < 1.50 m2, 100 mg/d; Body surface area ≥1.5 m2, 120 mg/d; Bid, d1-14;
42584|NCT03850756|Diagnostic Test|Early kidney damage biomarkers|In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
42585|NCT03850756|Diagnostic Test|Predisposition to kidney injury biomarkers|In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.
42586|NCT03850756|Diagnostic Test|Tobacco consumption|In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
42587|NCT03850730|Drug|Pazopanib|Active pharmaceutical ingredient plus excipients filled into a capsule for the lower dosing necessary in this study
42588|NCT03850717|Device|acupuncture|insert in filiform needles into skin and other soft tissue to treat the illness or disorders
42589|NCT03850704|Drug|Selinexor|
42590|NCT03850691|Drug|Aldesleukin: All Patients|"Cycle 1:~(600,000 U/kg/dose) given as a bolus infusion once every 8 to 12 hours over 5 days or until no longer tolerated (to a maximum of 10 doses). Administered as an inpatient.~Days 1-5 and Days 15-19 (all patients)"
42591|NCT03850691|Drug|Nivolumab: Cohort 1 (Cutaneous)|"Cycle 1: 6 Week Duration Nivolumab 240 mg IV~Cycle 2: 6 Week Duration Nivolumab 240 mg IV on Day 1, 15 and 29~Cycle 3: 4 Week Duration Nivolumab 240 mg IV on Day 1 and 15~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
42592|NCT03850691|Drug|Nivolumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Nivolumab 3 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Nivolumab 1 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Nivolumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Nivolumab on Day 8 using the same dose regimen as used Cycle 1 Day 29.~Patients may continue maintenance nivolumab 240 mg IV every 2 weeks OR nivolumab 480 mg IV every 4 weeks per 2018 FDA approval at discretion of the treating physician and independent of this study"
42593|NCT03850691|Drug|Ipilimumab: Cohort 2 (Ocular)|"Cycle 1: 6 Week Duration Ipilimumab 1 mg/kg IV on Day 29~OR for a high risk patient with an excellent performance status, the following regimen may be given at the discretion of the treating investigator:~Ipilimumab 3 mg/kg IV on Day 29~Cycle 2: 6 Week Duration Ipilimumab on Day 8 and on Day 29 using the same dose regimen as used Cycle 1 Day 29~Cycle 3: 4 Week Duration Ipilimumab on Day 8 using the same dose regimen as used Cycle 1 Day 29"
42594|NCT03850678|Device|Hearing Aid|Hearing Aid
42595|NCT03850665|Procedure|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
42596|NCT03850665|Procedure|Anterolateral approach|Anterolateral approach surgery to replace the hip.
42597|NCT03850652|Dietary Supplement|Prebiotic (Synergy-1) + Iron supplement|In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily. In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
42598|NCT03850652|Dietary Supplement|Placebo (Maltodextrin) + Iron Supplement|participants will be required to take one 7 g sachet of placebo (maltodextrin) daily. In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
42599|NCT03850639|Behavioral|Internet-based exposure therapy|The treatment is a three week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach the memory of the traumatic event and situations they since the traumatic events are associated with fear and anxiety. Other interventions include psychoeducation, and breathing retraining to facilitate exposure.
42600|NCT03850626|Biological|Immunotherapy|subcutaneous injection
42601|NCT03850613|Behavioral|E-painting mobile app|The subjects can use the newly developed mobile app to draw their own pictures at the time convenient to them.
42602|NCT03850600|Other|Diet-CD|CD patients will self-select into the intervention arm to follow the diet for 8-10 weeks during their third trimester of pregnancy.
42603|NCT03850587|Drug|Celecoxib 200mg|comparator medication
42604|NCT03850587|Drug|Tramadol 37.5Mg+ Celecoxib 200mg|experimental medication
42605|NCT03850587|Drug|Tramadol 75mg+ Celecoxib 200mg|experimental medication
42606|NCT03850587|Drug|Tramadol 150mg+ Celecoxib 200mg|experimental medication
42607|NCT03850574|Drug|HM43239|Daily (QD), continuous dosing
42608|NCT03850561|Dietary Supplement|Coenzyme Q10 200|Coenzyme Q10 200 mg/day
42609|NCT03850561|Dietary Supplement|Coenzyme Q10 400|Coenzyme Q10 400 mg/day
42610|NCT03850548|Other|Prosthetic joint infection with Cutibacterium acnes|patients having a prosthesis infection with C.acnes identified by specific PCR
42611|NCT03850535|Drug|Idasanutlin|Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
42612|NCT03850535|Drug|Cytarabine|Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
42613|NCT03850535|Drug|Daunorubicin|Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m^2 QD as IV infusion.
42614|NCT03850535|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)|After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
42615|NCT03850522|Biological|PD-L1 peptide|PD-L1 peptide (100 micrograms) emulsified with the adjuvant Montanide ISA-51 given subcutaneously 10 times every second week over the course of 26 weeks including a five-week break.
42619|NCT03850509|Drug|Matching Placebo|Matching Placebo BID Oral for 12 weeks
42620|NCT03850496|Device|Revitive IX Neuromuscular Stimulation Device|Neuromuscular stimulation footplate device with a pre-programmed 30 minute varying electrical stimulation sequence.
42621|NCT03850483|Drug|PF-06700841|PF-06700841 topical cream
42622|NCT03850483|Drug|Vehicle (Placebo)|Vehicle topical cream
42623|NCT03850470|Diagnostic Test|clinical examination|Thorough examination including history, screening, motion testing, strength testing, special testing
42624|NCT03850470|Other|MRI|Low field MRI .25 Tesla
42625|NCT03850457|Other|No intervention|The treatments will be determined by their neonatologists and no additional investigational drugs will be applied to the infants included in this study.
42626|NCT03850444|Biological|pembrolizumab|
42627|NCT03850444|Drug|carboplatin|
42628|NCT03850444|Drug|paclitaxel|
42629|NCT03850444|Drug|pemetrexed|
42630|NCT03850431|Behavioral|Social Norms|One or more messages that point out common behavior(s) by people. The appointment reminder also includes basic appointment information: date, location, and phone number(s) for scheduling changes.
42631|NCT03850431|Behavioral|Behavioral Instructions and Intentions|One or more messages that provide easy-to-understand instructions or implementation intentions. The appointment reminder also includes basic appointment information: date, location, and phone number(s) for scheduling changes.
42632|NCT03850431|Behavioral|Consequences for Self|One or more messages that highlight a potential negative consequence for the patient if s/he no-shows. The appointment reminder also includes basic appointment information: date, location, and phone number(s) for scheduling changes.
42633|NCT03850431|Behavioral|Consequences for Others|One or more messages that highlight a potential negative consequent for others if the patient no-shows. The appointment reminder also includes basic appointment information: date, location, and phone number(s) for scheduling changes.
42634|NCT03850418|Drug|azacitidine|azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated
42635|NCT03850405|Dietary Supplement|Dark Chocolate|20 patients (10 male, 10 female) will undergo a diet containing 25g of dark chocolate (70%), corresponding to ca. 145 kcal which will be detracted from the total caloric intake.
42636|NCT03850392|Device|cryotherapy (Thermogel - Artsana or Cryo+ - Cryonic)|cold application (ice 30 min or cold CO2 2 min) twice during 1 day at an 8 hour-interval
42637|NCT03850379|Drug|Levofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
42638|NCT03850379|Drug|Ciprofloxacin|This is a prospective study comparing consecutive patients who will be be receiving ciprofloxacin prophylaxis vs. levofloxacin prophylaxis for Stem cell transplant till engraftment defined as ANC >1000
42639|NCT03850366|Drug|Bortezomib|GVHD prophylaxis
42640|NCT03850327|Device|BIOMONITOR III|Patients with ICM indication receive a third-generation implantable cardiac monitor
42641|NCT03850314|Dietary Supplement|Glycine|Glycine powder to be dissolved in water.
42642|NCT03850301|Drug|XBD173|7 days treatment
42643|NCT03850301|Drug|Etifoxine|7 days treatment
42644|NCT03850288|Other|Neuropsychological assessment : Stroop task|"Stroop task is an interference task assessing cognitive inhibitory control. This paper-and-pencil task aims to evaluate the inhibition of an automated process such as reading by asking participants to name the color of color names written in a different color ink.~This test is non-invasive."
42645|NCT03850288|Other|Neuropsychological assessment : Go No Go task|"Go No Go task assessing motor inhibitory control. This computer-based task is designed to evaluate motor inhibition by asking participants to respond to a stimulus as quickly as possible by inhibiting another distractor stimulus.~This test is non-invasive."
42646|NCT03850275|Dietary Supplement|E+shots|The 4oz adaptogen-rich (E+shots) was E+ Shots (Isagenix International, LLC) containing approximately 90mg caffeine from green tea Camellia sinesis leaf extract (50%) and yerba maté extract (25%) along with a proprietary blend of adaptogenic herbs, including: eleutherococcus senticosus, crateagus oxycantha, rhodiola rosea and Schisandra chinensis.
42647|NCT03850275|Dietary Supplement|Caffeinated placebo|~100mg of synthetic caffeine
42648|NCT03850275|Dietary Supplement|Placebo|~3mg caffeine
42649|NCT03850262|Radiation|MRI|"The study will be done on 1.5T MR unit (Siemens) and 1.5T MR unit (Philips) at Assuit University Hospital, or 1.5T MR unit (G.E.) at Eman General Hospital.~The field of view varied between 14 cm and 16 cm, and slice thickness varied between 3 and 4 mm, with 0.5 mm intersection gap.~Imaging sequences included sagittal PD proton density, T2 and STIR, axial PD, coronal STIR and coronal oblique."
42650|NCT03850210|Device|Short Splint|Short Splint that permits maximal wrist flexion and up to 45° of wrist extension with a block to 30° of MCP joint extension.
42651|NCT03850210|Device|Traditional Long Splint|Traditional splint is a forearm-based dorsal thermoplastic splint that immobilizes the wrist in neutral position with a block to 30° of metacarpophalangeal (MCP) joint extension
42652|NCT03850197|Device|EarPopper|"The EarPopper is 510(K) regulated (510(K) Number K073401) and is marketed as a safe and effective way to aid muscle-assisted ET opening. It is a Politzer device, and aids ET opening by blowing a constant stream of air into the nasal cavity. It consists of a single nose piece connected to an air pump with no adjustable pressure settings. During the study, the subject will be asked to place the nose piece into one of the nostrils while occluding the contralateral. The subject will then perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
42653|NCT03850197|Device|Tympanometry|The Tympanometer is 510(K) regulated (510(K) Number K083861) and is marketed as a way to measure auditory impedance and acoustics reflex by producing controlled levels of test tones and signals. It will be used before and after each maneuver for both the EarPopper and Tubomanometry tests to assess middle ear pressure change.
42710|NCT03849716|Other|Cheek swab|Cheek swab obtained for genetic analysis
42711|NCT03849703|Behavioral|Full Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the coparenting and then romantic relationship curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
42908|NCT03848182|Drug|Gemcitabine|Gemcitabine will be administered on days 1, 8, 15 every 28 days
42654|NCT03850197|Device|Tubomanometry|"Tubomanometry is an established test of Eustachian tube function. It is an easily-administered test used in clinical laboratories. It consists of a nosepiece and an ear canal pressure probe coupled to a manometer and air pump. When the nosepiece and ear canal probe is in place, a maneuver, such as swallowing, will cause the tubomanometer to generate a bolus of air at 30, 40, or 50 mbar through the nosepiece. In the event that the Eustachian tube opens, the tympanic membrane will be displaced, which in turn will be sensed by the ear probe. This event will be recorded as a Eustachian tube opening. For this test, the investigators will ask the subject to perform the maneuvers (swallow, Fish, blowing out into the EMST-150)."
42655|NCT03850184|Diagnostic Test|The Exercise in Mental Illness Questionnaire (EMIQ)|Questionnaire assessing prescription behaviour, knowledge, barriers and behaviour of physical activity in mental health professionals
42656|NCT03850171|Other|Exercise Training|Participants from the experimental study arm are assigned to a 12-week exercise training programme integrated in a multidisciplinary oncology rehabilitation programme at the Inselspital Bern, Spital AG Thun, or Bürgerspital Solothurn. The exercise programme will comprise 2 weekly exercise sessions lasting 90 min, supervised by experienced exercise therapists. The sessions start with approximately 40 min cycling on an ergometer at moderate intensity, increasing on a weekly basis if possible. After the cycling training, patients continue the exercise session with 40 min of strength training, stretching, relaxation, coordination and balance training. In addition, patients will be instructed to perform at least one additional endurance-related activity per week in their own time with a duration of 30-60 min at moderate intensity levels (e.g. walking, bicycling).
42657|NCT03850158|Drug|Indocyanine Green|Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
42658|NCT03850132|Behavioral|FAM-SOTC-PL|"The adapted FAM-SOTC-PL intervention was delivered at the home of the participants and focuses on supporting the effective, cognitive, and behavioural domains of the bereaved family caregivers experience by targeting concerns/issues in these categories. The FAM-SOTC-PL comprises of the following five components:~Drawing forward narratives about the pre- and post-loss experience.~Asking therapeutic/interventive questions, emphasising on the most pressing concerns also assessing health issues.~Validating/acknowledging emotional responses.~Assessing the need for specific information and recommendations regarding bereavement.~The use of commendation/commending strengths, by focusing on and affirming the strengths of the family caregiver."
42659|NCT03850119|Procedure|Nanofat injection|Lipoaspirate, harvested during the surgery, is centrifuged for 1 minute at 2000 rpm to discard infiltration fluid. The residual fat is passed back and forth between two 10cc syringes interlocked with Tulip connecting pieces (2.4, 1.4 and 1.2 diameter, each 10 passes for a total of 30 passes). This is injected intradermally before the intradermal sutures are placed. The donor site is always entirely sutured (both sides) by the same person.
42660|NCT03850106|Dietary Supplement|Placebo|Placebo
42661|NCT03850106|Dietary Supplement|Indus810|Active product
42662|NCT03850093|Drug|Gabapentin1200 mg|patients received 1200mg gabapentin 2 hrs preoperative
42663|NCT03850093|Drug|bisoprolol 2.5mg|patients received 2.5mg bisoprolol 2 hrs preoperative
42664|NCT03850093|Drug|placebo|patients received oral placebo 2 hrs preoperative
42665|NCT03850080|Drug|Autologous Conditioned Serum|"Fifteen patients with clinical and radiological signs of OA of the knee were recruited for this study. 50mL of whole blood were taken using a special syringe containing CrSO4-coated grade glass beads in order to promote IL-1ra synthesis and aggregation.The incubation period lasted 7 hours after which, the blood-filled syringes were centrifuged and the serum supernatant was filtered and aliquoted into four 3mL portions. The aliquots were stored at -20oC until their use was necessary.~Patients received 1 intra-articular injection for 4 consecutive weeks at the site of OA."
42666|NCT03850067|Drug|CC-90011|CC-90011
42667|NCT03850067|Drug|Cisplatin|Cisplatin
42668|NCT03850067|Drug|Carboplatin|Carboplatin
42669|NCT03850067|Drug|Etoposide|Etoposide
42670|NCT03850067|Drug|Nivolumab|Nivolumab
42671|NCT03850054|Procedure|AADI glaucoma shunt|"Implantation of the nonvalved AADI glaucoma shunt instead of the Bearveldt tube shunt, in eyes with intractable glaucoma.~It is not a RCT study, but a prospective evaluation of the AADI device, and the study has been approved as a quality control study at the Department of Ophthalmology, at Odense University Hospital"
42672|NCT03850028|Other|89Zr-atezolizumab PET scans|"The anti-PDL1 antibody atezolizumab, labeled with Zirconium-89 (89Zr) will be used as a molecular imaging tracer for PET scanning.~These 89Zr-atezolizumab PET scans will be performed before and after induction therapy (R-CHOP) and at suspected relapse during or after consolidation treatment with atezolizumab (treatment trial HOVON 151)."
42673|NCT03850015|Diagnostic Test|Standard echocardiography|Patients will undergo standard echocardiography, with and without contrast
42674|NCT03850015|Other|High frame rate echocardiography|Following standard echocardiography, the test is repeated using high frame rate ultrasound
42675|NCT03850002|Other|Early detection of CLAD by Lung Clearance Index (LCI)|Lung transplant candidates without prior CLAD (evaluated in study part I) will be followed over a period of 3 years to evaluate the potential of LCI to detect early CLAD
42676|NCT03849989|Procedure|Skin biopsy|"Skin biopsy:~Tissue samples will be taken by punch biopsy according to the daily routine of the Department of Dermatology of the Maastricht UMC+.~Steps:~Skin desinfection with chlorhexidine digluconate 1% solution~Local anaesthesia with lidocaine hydrochloride 1%~Biopsy specimens are taken with sterile punch device (disposable biopsy punch delivered by kai medical)~Biopsy specimens are retrieved with sterile pincer and cut with sterile blade~Wound is stitched with a single transcutaneous stich using absorbable suture (vicryl 4.0).~Wound will be treated with R/ fusidic acid ointment 3 to 5 times per day for two weeks~In the first week after laser therapy the wound will be covered by R/ Urgotull non-adhesive gauze, R/ Cutisoft cotton non-sterile gauze and R/ Klinipress exsupad absorbing bandage."
42677|NCT03849976|Behavioral|Therapeutic communication|Patients will be accompanied to the operating room by a stretcher bearer trained in therapeutic communication
42678|NCT03849963|Drug|Hyperpolarized [13C]Pyruvate|Injection of hyperpolarized [13C]pyruvate, a stable isotope, during magnetic resonance spectroscopic imaging.
42901|NCT03848247|Other|Injection of NGF|Half the participants will be injected in a neck muscle with NGF (Neck pain group).
42679|NCT03849950|Other|SMARTCare|"Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.~An education program for patients in the intervention arm that targets training in core self-management skills and is comprised of an introduction and 5 education modules.~An introductory call from a health coach prior to initiating treatment and 5 subsequent calls: prior to the first dose of treatment; 7-14 days following the first dose of treatment; within 2 weeks of coaching session 2; and timing is flexible for the last 2 sessions, but to be completed within 4 months following the first dose of treatment.~Optional sub-study: A sub-set of patients will participate in an end of study interview to gain further insight into SMARTCare."
42680|NCT03849950|Other|Control|1. Ambulatory nurses will undertake 4 hours of training consistent with the evidenced-based guidelines for SMS in routine care.
42681|NCT03849937|Behavioral|Changing Talk Online (CHATO)|Three, one-hour online training modules highlighting barriers and ineffective communication behaviors with older adults while teaching and modeling alternative, effective communication strategies.
42682|NCT03849924|Behavioral|Self-affirmation|Self-affirmation implementation intentions in the form of a questionnaire.
42683|NCT03849911|Diagnostic Test|Neurophysiological Prognosis|SEP and EEG evaluation for Neurological Prognosis of Cardiac Arrest
42684|NCT03849911|Diagnostic Test|Multimodal Prognosis for poor early neurological outcome|Brain CT, SEP and EEG evaluation
42685|NCT03849898|Procedure|Surgery|Surgical fracture treatment
42686|NCT03849898|Other|Non-Surgical fracture treatment|Non-Surgical fracture treatment
42687|NCT03849885|Diagnostic Test|aerobic and anaerobic culture|4 tissue biopsies taken per subject will be sent to our lab for aerobic and anaerobic culture.
42688|NCT03849872|Drug|ONO-5788|Investigational Drug
42689|NCT03849872|Drug|[14C]-ONO-5788|Investigational Drug
42690|NCT03849859|Device|Single plastic stent|Deployment of single plastic stent
42691|NCT03849859|Device|Multiple plastic stents|Deployment of multiple plastic stents
42692|NCT03849846|Other|Focus groups|Participants will also complete a sociodemographic questionnaire. The moderator will conduct the discussion using a semi-structured interview guide, based on the construct of the Theory of Planned Behaviour. The interview guide has been developed to identify the beliefs that determine the participants' attitudes (advantages/disadvantages), subjective norms (approval/disapproval of important others) and perceived behavioural control (facilitators/barriers) related to a hypothetical participation in the NutriQuébec study. The participants will also be questioned about their preferences regarding the recruitment as well as their concerns about the security, use and share of data.
42693|NCT03849833|Dietary Supplement|cholecalciferol, Vitamin D3|Vitamin D3 as dietary supplement
42694|NCT03849820|Device|Robotic-assisted partial nephrectomy|Application of the da Vinci surgical robot to assist the partial nephrectomy
42695|NCT03849820|Other|Open partial nephrectomy|Open surgery to conduct the partial nephrectomy
42696|NCT03849807|Other|Experimental group|the intervention group will receive 4 weeks of chiropractic care along with usual care(Cognitive-Behavioral, psychosocial Therapy).
42697|NCT03849807|Other|Control group|Participants in the group will receive usual health (Cognitive-Behavioral, psychosocial Therapy) care or wish to engage in during the course of the study as well as receiving a passive movement control intervention delivered by a chiropractor 3 times per week in the same hospital setting as the group receiving chiropractic care.
42698|NCT03849794|Other|Experimental Group|"Chiropractic Care A chiropractor will see participants in the experimental group about 3 times per week using a pragmatic approach for 4 weeks, and each session will be approximately 15-20 minutes in duration. The spinal adjustments performed in this study will be high-velocity, low-amplitude thrusts to the spine, pelvic joints, extremities or instrument-assisted adjustments~Physiotherapy:~Physiotherapists will see participants in each group 3 times per week for four weeks. Each session will be approximately 20 minutes in duration. Physiotherapy interventions are likely to include stretches and exercises, massage and mobilization as required."
42699|NCT03849794|Other|Control group|The control group will receive the same physiotherapy intervention as the experimental group at the same frequency of care. The control group will also attend three passive movement sessions with the chiropractor each week, primarily to minimise the psychological effect of the interaction with the chiropractor, but also to act as a physiological control. These passive movement sessions will be 10 minutes in duration.
42700|NCT03849781|Device|NeoBeat with a visible display|NeoBeat (Laerdal Medical) is a CE approved novel heart rate meter, able to detect heart rate in newborns within seconds of birth. The NeoBeat uses ECG dry-electrodes in a snug-fit abdomen-shaped buckle for rapid application around the newborn`s abdomen or thorax. It allows healthcare providers to reliably assess heart rate of the newborn immediately after birth and continuously during resuscitation.
42701|NCT03849768|Drug|HS-10296|Drug: HS-10296 110 mg/55 mg + placebo The initial dose of HS-10296 110 mg once daily can be reduced to 55 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
42702|NCT03849768|Drug|Gefitinib|Drug: Gefitinib 250 mg + placebo The initial dose of Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
42703|NCT03849755|Device|PEPPER system|The PEPPER system offers insulin dosing advice that is highly adaptive to the insulin needs of individuals by using Case-Base Reasoning (CBR) approach.
42704|NCT03849742|Other|Quality-of-Life Assessment|Ancillary studies
42705|NCT03849742|Other|Questionnaire Administration|Ancillary studies
42706|NCT03849742|Procedure|Supportive Care|Receive Uber rides
42707|NCT03849729|Drug|Phentermine|This is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI >35 kg/m2 with comorbidities or BMI > 40 kg/m2).
42708|NCT03849729|Other|Placebo|his is a randomized, control trial to investigate the effect and safety of Phentermine in patients with obesity who need a bariatric surgery (BMI >35 kg/m2 with comorbidities or BMI > 40 kg/m2).
42709|NCT03849716|Other|Blood sample|Blood samples obtained for biomarker analyses
42712|NCT03849703|Behavioral|Full Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Intervention group will receive the romantic relationship and then coparenting curricula. The lessons last between 45-60 minutes and are based on evidence based curricula.
42713|NCT03849703|Behavioral|Partial Intervention #1|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the romantic relationship curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
42714|NCT03849703|Behavioral|Partial Intervention #2|Participants will receive 10 lessons on a weekly basis per semester for two semesters, for a total of 20 lessons. This Partial Intervention group will receive the coparenting curriculum and a control curriculum. The lessons last between 45-60 minutes and are based on evidence based curricula.
42715|NCT03849690|Drug|TAK-906|TAK-906 capsules.
42716|NCT03849690|Drug|Esomeprazole|Esomeprazole capsules.
42717|NCT03849677|Other|Endothelial function and inflammation|Analysis of endothelial function, oxidative stress
42718|NCT03849664|Drug|Cytoflavin® solution|Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
42719|NCT03849664|Drug|Cytoflavin® enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
42720|NCT03849664|Drug|Placebo solution|Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
42721|NCT03849664|Drug|Placebo enteric-coated tablet|2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
42722|NCT03849651|Drug|Cyclophosphamide|"Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.~intravenously (IV) once daily (QD) on day -9"
42723|NCT03849651|Biological|Fludarabine|"Fludarabine phosphate is a synthetic purine nucleoside analog. It acts by inhibiting DNA polymerase, ribonucleotide reductase and DNA primase by competing with the physiologic substrate, deoxyadenosine triphosphate, resulting in inhibition of DNA synthesis.~fludarabine phosphate IV QD on days -8 to -4"
42724|NCT03849651|Drug|Thiotepa|Thiotepa is a cell-cycle nonspecific polyfunctional alkylating agent.
42725|NCT03849651|Drug|Melphalan|"Melphalan, a derivative of nitrogen mustard, is a bifunctional alkylating agent. Melphalan is active against tumor cells that are actively dividing or at rest.~melphalan IV QD on days -2 to -1"
42726|NCT03849651|Biological|G-csf|G-csf (granulocytic colony stimulating factor), is a biosynthetic hematopoietic agent that is made using recombinant DNA technology in cultures of Escherichia coli. G-CSF stimulates production, maturation and activation of neutrophils. In addition, endogenous G-CSF enhances certain functions of mature neutrophils, including phagocytosis, chemotaxis and antibody--dependent cellular cytotoxicity.
42727|NCT03849651|Drug|Mesna|Mesna is a synthetic sulfhydryl (thiol) compound. Mesna contains free sulfhydryl groups that interact chemically with urotoxic metabolites of oxaza-phosphorine derivatives such as cyclophosphamide and ifosfamide. Following glomerular filtration, mesna disulfide is rapidly reduced in the renal tubules back to mesna, the active form of the drug.
42728|NCT03849651|Device|CliniMACS|Cells for infusion are prepared using the CliniMACS
42729|NCT03849651|Biological|ATG (rabbit)|"Anti-thymocyte globulin is a purified, pasteurized, gamma immune globulin, obtained by immunization of rabbits with human thymocytes.~rabbit anti-thymocyte globulin IV daily over 6 hours on days -5 to -3,"
42730|NCT03849651|Drug|Blinatumomab|"Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that mediates formation of a synapse between T cells and the CD19+ target cell, resulting in lysis of that CD19+ cell.Blinatumomab will be given to patients with a history of CD19+ malignancy as determined by St. Jude hematopathologist review of current and historical specimens and reports.~blinatumomab IV for 28 days beginning at least 1 week post-DLI"
42731|NCT03849651|Biological|TCRα/β+|IV on day 0 and may receive an additional dose on day 1
42732|NCT03849651|Biological|CD19+|IV on day 0 and may receive an additional dose on day 1
42733|NCT03849651|Biological|CD45RA-depleted DLI|infusion IV
42734|NCT03849638|Other|Gait training with real time biofeedback|"Patients presenting asymmetry of the kinematic parameters of the step to the evaluation with sensorized treadmill, will undergo gait training program.~The training program consists of 20 session (1 session/day) of gait training. Daily gait training will last 30 minutes as distributed:~5 minutes of heating at a comfortable speed for the patient~Three 5-minute sessions of gait training with biofeedback interspersed with a break of 5 minutes each."
42735|NCT03849625|Drug|aspirin, NSAIDs, paracetamol|Perform skin test and/or provocation test with aspirin, paracetmol, or suspected NSAIDs in questionable cases
42736|NCT03849612|Device|AID System|AID system
42737|NCT03849612|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
42738|NCT03849599|Biological|PRV-300|Treatment
42739|NCT03849599|Biological|Placebo|Control
42740|NCT03849573|Behavioral|"OncoTool Intervention (MBSR + HT education)"|OncoTool is a website intended to improve self-management practices for helping cancer patients cope with stress and improve health-related quality of life. OncoTool provides mindfulness-based education and management for dealing with the numerous physical and mental side effects associated with hormone therapy (e.g., muscle and joint pain, vaginal dryness, depressive symptoms). OncoTool is a website designed to improve hormone therapy adherence by improving quality of life, and hormone therapy associated symptom burden. Both intervention and active comparator conditions are administered to participants for 8 weeks.
42741|NCT03849573|Behavioral|"Oncotool Control (health +HT education)"|OncoTool is a health promotion website with health education on subjects like nutrition and exercise specific to breast cancer survivors, as well as general advice on lifestyle choices and prevention. The Oncotool control has similar HT education content as the experimental content but without the CBT and MBSR state. Both intervention and active comparator conditions are administered to participants for 8 weeks.
42902|NCT03848234|Drug|Estradiol|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
42742|NCT03849560|Biological|Grippol® Quadri|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Quadri into the upper third of the outer surface of the shoulder (the deltoid muscle).
42743|NCT03849560|Biological|Grippol® Plus, trivalent (Yamagata lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Yamagata lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
42744|NCT03849560|Biological|Grippol® Plus, trivalent (Victoria lineage)|Single intramuscular injection of 0.5 ml (1 dose) of vaccine Grippol® Plus, trivalent (Victoria lineage) into the upper third of the outer surface of the shoulder (the deltoid muscle).
42745|NCT03849547|Other|App Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Guidance through smartphone application as home program."
42746|NCT03849547|Other|Home Balance training|"Training specially designed for balance ability of chronic ankle instability groups.~Follow the usual home program provided in clinics."
42747|NCT03849534|Device|Soft occlusal appliance|According to Best Practice in Sweden the soft occlusal appliance is ranked as gold standard for children with mixed or primary dentition
42748|NCT03849534|Behavioral|Jaw exercises|The participants do three exercises twice a day. Open and closing mouth against resistance as well as stretch
42749|NCT03849534|Behavioral|Counseling|The patients are instructed to minimize jaw parafunctions, chewing chewing gum etc, to do exercises, to take pain-killers or NSAIDs etc.
42750|NCT03849521|Diagnostic Test|MRI|Enhanced carotid calcification presented by UTE MR.
42751|NCT03849508|Drug|Norepinephrine|"Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
42752|NCT03849508|Drug|Phenylephrine|"Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg"
42753|NCT03849495|Drug|CKD-370|Test drug
42754|NCT03849495|Drug|D745|Reference drug
42755|NCT03849482|Diagnostic Test|Multiparametric Magnetic Resonance Imaging|Multiparametric MRI evaluation includes Conventional MRI, Diffusion-Weighted MRI and Dynamic Contrast-Enhanced MRI
42756|NCT03849482|Diagnostic Test|Fine Needle Aspiration Cytology|Ultrasound-Guided Fine Needle Aspiration Cytology
42757|NCT03849482|Diagnostic Test|Clinical Evaluation|Patient's history and physical examination, reporting signs and symptoms suggestive of malignancy (pain, facial nerve weakness, fixation to skin and surrounding tissues, trismus, skin ulceration, lymphadenopathy, numbness, weight loss)
42758|NCT03849482|Diagnostic Test|Final Histopathological Diagnosis|Final Diagnosis of the Disease from the Pathology Report after Surgical Resection of the Lesion
42759|NCT03849469|Biological|XmAb®22841|Monoclonal bispecific antibody
42760|NCT03849469|Biological|Pembrolizumab (Keytruda®)|FDA-approved humanized monoclonal antibody
42761|NCT03849456|Drug|GWP42006|Oral solution containing cannabidivarin 50 mg/mL in sesame oil with anhydrous ethanol, sucralose, strawberry flavouring, and β-carotene.
42762|NCT03849443|Drug|Tranexamic Acid Injectable Product (1000 mg intravenous bolus)|Intravenous methods to decrease blood loss
42763|NCT03849443|Drug|Vitamin C 250 MG Oral Tablet|Oral method of placebo
42764|NCT03849443|Drug|Tranexamic Acid 650Mg Tablet|Oral method of treatment group
42765|NCT03849417|Other|ECT|ECT administered as part of normal clinical management
42766|NCT03849404|Biological|Adalimumab|Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
42767|NCT03849391|Dietary Supplement|Skate group|This group takes 500 mg/day Skate Skin extract for 12 weeks
42768|NCT03849391|Dietary Supplement|Placebo group|This group takes 500 mg/day Placebo for 12 weeks
42769|NCT03849378|Dietary Supplement|Sargassum Horneri Extract group|This group takes 1,000 mg/day of Sargassum Horneri Extract for 12 weeks.
42770|NCT03849378|Dietary Supplement|Placebo group|This group takes 1,000 mg/day of Placebo Extract for 12 weeks.
42771|NCT03849365|Drug|TOOKAD VTP|TOOKAD® VTP consists of the combination of a single, 10-minute IV infusion of TOOKAD® at the dose of 3.66 mg/kg, followed by the illumination of the zone to be treated with a 753-nm laser light delivered through transperineal interstitial optical fibers at a power of 150 mW/cm and light energy of 200 J/cm applied over 22 minutes and 15 seconds.
42772|NCT03849352|Behavioral|Lifestyle changes with the support of health technology|Written instructions will be provided to participants, to include how to download supportive apps on smartphones. Participants will be asked to complete a 3 day food diary using an online platform (MyFood24) prior to attending a face to face consultation which will reinforce the participant's responsibilities. Participants will be assisted to set specific diet and lifestyle goals. 3 fortnightly follow ups will be arranged via 15 minute telephone consultations, three 24 hour dietary diaries will be completed via MyFood24 prior to each fortnightly digital consultation. Participants will be asked to measure their daily activity via a pedometer on their smart phones. Participants will be asked to complete the Godin leisure time questionnaire to assess changes in leisure time exercise.
42773|NCT03849339|Drug|CKD-387|Test drug
42774|NCT03849339|Drug|D635|Reference drug
42775|NCT03849326|Other|Questionnaires|Quality of life Depression Physical pain Social provisions Quality of sleep
42776|NCT03849326|Biological|blood test|complete blood count and cytokine concentration
42777|NCT03849326|Other|Maximal effort test|The maximal effort test with VO2max recordings will be assessed during the first visit to the laboratory.
42778|NCT03849326|Device|actigraphy|assessment of sleep quality
42779|NCT03849326|Device|Neuromuscular evaluation|"The maximum isometric force produced by the knee extensors will be measured on the ergometer~the intensity of muscular electrical activity recorded by surface electromyography~Peripheral nerve stimulation~Transcranial magnetic stimulation~Magnetic resonance imaging (optional)"
42780|NCT03849313|Drug|Adalimumab|"AVT02, a proposed similar biological product (biosimilar) of Humira which contains adalimumab . Adalimumab is a recombinant, fully human monoclonal immunoglobulin G1 (IgG1) antibody that binds specifically and with high affinity to the soluble and transmembrane forms of tumor necrosis factor (TNF)-α thereby inhibiting the binding of TNF-α with its receptor, and inhibiting TNF -α's biological function.~Tumor necrosis factor-α is a naturally occurring cytokine that is key to normal inflammatory and immune responses. Elevated levels of TNF-α are found in the synovial fluid of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis patients and psoriasis plaques and play an important role in both the pathologic inflammation and joint destruction that are hallmarks of these inflammatory diseases"
42781|NCT03849300|Other|Aqua aerobic exercise program|12 week aqua aerobic exercise program
42782|NCT03849287|Drug|CKD-333, formula I|Test drug
42783|NCT03849287|Drug|CKD-333, formula II|Test drug
42784|NCT03849287|Drug|CKD-330, D090|Reference Drug
42785|NCT03849274|Combination Product|Smart Scar Care Pad=Pressure Garment|Smart Scar Care Pad (SSCP) + conventional Pressure Garment in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
42786|NCT03849274|Device|Pressure Garment|Conventional Pressure Garment (PG) alone in the management of HS in adult with total hip replacement (THR) and total knee replacement (TKR)
42787|NCT03849261|Drug|CKD-387|Test drug
42788|NCT03849261|Drug|D635|Reference drug
42789|NCT03849248|Other|Maternal scent cloth|The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
42790|NCT03849235|Dietary Supplement|Standardised meal|Standardised meal consisting of 300 kcal; 16% protein, 49% carbohydrates and 35% fat
42791|NCT03849222|Procedure|Apexification|
42792|NCT03849222|Drug|MTA|
42793|NCT03849222|Drug|Ca(OH)2|
42794|NCT03849222|Drug|Apical matrix|collagen membrane (Biocollagen; Bioteck:Turin, Italy)
42795|NCT03849209|Device|Stylet slow-pull technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed, with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously.
42796|NCT03849209|Device|Standard suction technique|During endosonographic examination, the pancreatic mass was evaluated with color Doppler to avoid the involvement of vessels. The needle (20 Gauge, EchoTip ProCore 20G with ReCoil Stylet™, Cook Medical, Bloomington, IN, USA) was sharpened by withdrawing the stylet approximately 2 mm, and then was advanced into the lesion: 15 to-and-fro movements within the lesion were performed using a 10-mL suction syringe.
42797|NCT03849196|Drug|2L PEG-Asc|PEG-Asc powder
42798|NCT03849196|Drug|Bisacodyl 10Mg Suppository|bisacodyl 10 mg suppository
42799|NCT03849196|Drug|1L PEG-Asc|PEG-Asc powder
42800|NCT03849183|Drug|Nitroglycerin|Subcutaneous nitroglycerin injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
42801|NCT03849183|Drug|Normal saline|Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
42802|NCT03849170|Behavioral|Stress Inoculation Technique|Teaches athletes to use cognitive-behavioral techniques to reduce their stress response during sporting events.
42803|NCT03849170|Other|Health Intervention|Will provide basic dietary and lifestyle guidelines that athletes should follow in their daily lives to maintain their health
42804|NCT03849157|Procedure|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
42805|NCT03849144|Behavioral|Therapy dog activity|Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
42806|NCT03849144|Behavioral|Low impact exercise|The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
42807|NCT03849131|Biological|Biological collection|"Blood samples will be collected only once at enrollment, before initiation of a checkpoint inhibitor.~It will include:~DNA samples collection~RNA samples collection~Blood sample collection"
42808|NCT03849118|Diagnostic Test|89Zr-girentuximab|Single IV administration on Day 0, followed by diagnostic scan on Day 5 +/- 2 days.
42809|NCT03849105|Radiation|4-L-[131I]iodo-phenylalanine (131I-IPA)|"Study participants will receive by intravenous infusion an escalating activity of 4-L-[131I]iodo-phenylalanine (131I-IPA).~Additional therapy is received in the form of externally administered radiotherapy"
42810|NCT03849092|Behavioral|Financial incentives|Cessation programs in municipalities will offer a financial incentive of 1200 DKK to smokers with low socioeconomic status who abstinence from smoking (validated abstinence).
42811|NCT03849092|Behavioral|Campaigns|Municipalities will design campaigns target smokers with low socioeconomic status, recommending to get support during smoking cessation at smoking cessation programs.
42812|NCT03849079|Other|Hyponut|Prick tests with hyponut
42813|NCT03849066|Other|Parent-Reported Symptom Assessment|As the basis for PRSA, the investigator will use the PediQuest Memorial Symptom Assessment Scale (PQ-MSAS), which is an adapted pediatric-specific version of the validated adult MSAS that assesses 24 physical and psychological symptoms over the past week. The study instrument is designed to be completed by a full-proxy parent, and 2 versions tailored for specific age groups are available (0-3, 3-18 years-old). Spanish versions are available for both instruments. The PQ-MSAS contains 24 symptom items, each with 4-point scores for domains of frequency, severity, and extent of bother. Based on these components, a global symptom score and individual symptom scores can be calculated (0-100 scale, with 100 being the worst).
42814|NCT03849053|Other|Mézières Therapy for Low back pain|Spinal muscular global stretching
42815|NCT03849040|Procedure|Endobronchial Ultrasound|All patients will undergo EBUS-TBNA as per routine care, except for the one difference where the procedures will be video-recorded so that they can be used for computer analysis at a later time. Static images will be obtained from EBUS videos in order to perform segmentation. Segmentation will be conducted by both an experienced endoscopist and NeuralSeg.
42816|NCT03849027|Drug|Methoxyflurane|Inhaled methoxyflurane will be administered using the disposable field inhaler device (Penthrop®) according to the recommended dosing schedule.
42817|NCT03849027|Drug|Placebo|The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
42818|NCT03849014|Procedure|Dynamic Hip Screw|Dynamic Hip Screw fixation: Fracture will be reduced under image intensifier. The incision will be made 4-5 cm with a lateral approach. The fascia lata will be incised and the vastus lateralis muscle will be splited along the axis of the femur, without stripping the periosteum. A135° angle guide will be inserted in the lower half of the femoral neck. Soft tissue will be protected while reaming. The barrel of the plate will be guided to the hip screw by direct palpation to minimize the soft-tissue injury. After the insertion of the cortical screw, soft tissue will be protected with 4.5mm drill sleeve during drilling and tapping.
42819|NCT03849014|Procedure|Proximal Femoral Nail|Proximal Femoral Nail fixation: Fracture will be reduced under image intensifier. The incision 4-5 cm with a lateral approach that extended from the cranial part to the tip of the greater trochanter. The proximal femur will be reamed using a 17-mm reamer under soft tissue protection through the muscular mass, after palpating the greater trochanter tip. The nail will be then introduced manually into the femoral shaft. The guide wire of the anti-rotational hip blade then introduced. The hip blade should be introduced in the direction of the lower half of the femoral neck. Drilling will be performed under soft-tissue protection with a retractor. The blade will be inserted, and a distal static locking screw and end cap will be inserted under soft tissue protection with a drill sleeve.
42820|NCT03849001|Behavioral|Exercise Conditions|Light Exercise
42821|NCT03849001|Behavioral|Exercise Conditions|Moderate Exercise
42822|NCT03849001|Behavioral|Exercise Conditions|Vigorous Exercise
42823|NCT03849001|Behavioral|Exercise Conditions|Seated Rest
42824|NCT03848975|Other|Simulation training for ECV|Intervention for the ECV group is a ECV simulation training. The group will have theoretical courses and five simulation sessions with four ECV simulation on a model (i.e., a total of 20 ECV), associated with clinical practice in the delivery room.
42825|NCT03848975|Other|Simulation training for VE|Intervention for the VE group is a simulation training. The group will have theoretical courses and five simulation sessions with four VE simulation on a model (i.e., a total of 20 VE), associated with clinical practice in the delivery room. The investigators will us Kiwi® Omni Cup Vacuum Delivery System, as this is the vacuum system chosen for clinical practice in our obstetric service.
42826|NCT03848949|Device|Evenup|Orthotic which increases effective leg length.
42827|NCT03848936|Other|Survey|Survey includes age, gender, cerebral palsy type, education, mental status, working status, living conditions, comorbidities, pain, spasticity, contractures, deformities, mobility status and gross motor function classification system level
42828|NCT03848910|Device|Investigational device - Sound Processor|"At visit 1 the subjects will complete self-reported assessments with respect to pre-study experience using precursor Sound Processor (comparator). At visit 1 the subjects will then receive the Investigational device (Sound Processor) which should be used during the following 6 weeks. At visit 3 the subjects will complete self-reported assessments regarding Investigational device and participate in audiology tests regarding both Sound Processors, comparator and Investigational device. The subject shall decide their preferred choice made by selection between Investigational device and the comparator."
42829|NCT03848897|Other|Metrology of motor behavior|Biomechanical, physiological, psychological and behavioral analyses
42830|NCT03848884|Behavioral|Adherence monitoring and education|Standardized medication counseling and education combined with individual patient customized guidance and counseling - administered monthly.
42831|NCT03848871|Drug|Enstilar|Enstilar foam applied to affected area once daily
42832|NCT03848858|Behavioral|EMDR plus TAU|The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
42833|NCT03848845|Drug|GSK2857916|GSK2857916 will be available as 20 milligrams per millilitre (mg/mL) solution for IV infusion, supplied as frozen liquid. GSK2857916 solution will be diluted in normal 0.9% saline to the appropriate concentration for the dose.
42834|NCT03848845|Drug|Pembrolizumab|Pembrolizumab will be available as 100 mg/4 mL solution that should be stored under refrigeration at 2-8 degree Celsius. Pembrolizumab injection (solution) will be diluted prior to IV administration in 0.9% sodium chloride injection or 5% dextrose injection.
42835|NCT03848832|Drug|GWP42003-P|GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
42836|NCT03848832|Drug|Placebo|Placebo oral solution containing the excipients sesame oil and anhydrous ethanol with added beta-carotene, sweetener (sucralose) and strawberry flavoring.
42837|NCT03848819|Device|VitaBreath device|The VitaBreath (Philips, Respironics) is a portable, handheld, battery powered, non-invasive ventilation device, that has been shown by our group to reduce activity-related shortness of breath in patients with COPD. It delivers 18 cmH2O inspiratory and 8 cmH2O expiratory pressures, but can only be used during recovery periods. In our study patients will perform consecutive bouts of exercise alternated by two minute of recovery in order to allow the use of the VitaBreath device during the first minute of each recovery period.
42903|NCT03848234|Device|Placebo|2 trans dermal patches to be changed twice a week for the duration of 8 weeks.
79495|NCT03563937|Drug|Apixaban|2.5 mg or 5 mg, twice daily
42838|NCT03848806|Drug|HAT1|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
42839|NCT03848806|Drug|Calcipotriol|During the treatment phase, patients will be ask to apply the product twice daily on all lesional areas. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
42840|NCT03848793|Drug|HS-20004|treatment
42841|NCT03848780|Drug|Desflurane|
42842|NCT03848767|Device|AID System|AID System
42843|NCT03848767|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control except during meal challenges.
42844|NCT03848754|Drug|Gemtuzumab Ozogamicin|"Induction: GO 3mg/m2 on Day 1, 4, and 7~Maintenance: 2mg/m2 intravenous administration on day 1, in a 28-day cycle."
42845|NCT03848754|Drug|Pracinostat|"Induction: 45mg or 60mg administered orally 3 days a week with 48 hours between dosing (e.g. Monday, Wednesday, and Friday) for three consecutive weeks, followed by 1 week of rest, in 28-day cycles.~Maintenance: (In addition to GO, only if induction dose escalation occurs) 45mg orally 3 days a week with 48 hours between dosing, for three consecutive weeks, followed by 1 week of rest, in a 28-day cycle."
42846|NCT03848741|Behavioral|Non-Exercise Control|Participants will not perform structured exercise and will continue with their normal physical activity for 12-weeks.
42847|NCT03848741|Behavioral|Resistance Exercise Training|Participants will complete a 12-week whole-body progressive resistance exercise training program.
42848|NCT03848741|Dietary Supplement|Placebo|Participants will be given placebo capsules to consume for 12-weeks.
42849|NCT03848741|Dietary Supplement|HMB+VitD|Participants will be given HMB+VitD capsules to consume for 12-weeks
42850|NCT03848728|Other|SEARCH Youth combination intervention|"Administration of life-stage assessment tool~Structured choice clinic access~Rapid feedback of VL results~Provider e-collaboratives with chat groups for discussions of challenging cases using de-identified information"
42851|NCT03848715|Biological|Endotoxin|Endotoxin
42852|NCT03848715|Biological|Placebo|Placebo
42853|NCT03848702|Device|Distal radius fracture brace|The distal radius fracture brace is constructed from biocompatible materials (like polylactic acid; PLA) and the skin is protected by commercially available and approved waterproof padding (like Aquacast®). The major brace components are connected and reinforced with carbon rods and plastic bolt-nut connections. PLA is extensively used, for example in surgical implants, but also as biological alternative for plastics. Aquacast® is approved and used as waterproof padding in swim plaster. The biomechanical function of the distal radius brace has been tested successfully in an ex vivo setting (results to be published). The DRFB includes the distal forearm, wrist an base of the hand. The thumb and fingers are free and the DRFB provides more movement than classical casting.
42854|NCT03848689|Other|fluoroquinolone preprescription authorization|Requires authorization from Infection Control consult prior to prescribing fluoroquinolone
42855|NCT03848689|Other|Control|Does not require authorization from Infection Control prior to prescribing fluoroquinolone
42856|NCT03848676|Diagnostic Test|Evaluation of patients resistance to immunotherapies in Multiple Myeloma|There are only collections of the samples.
42857|NCT03848663|Behavioral|Traditional Remapping|Shifting text outside of scotoma
42858|NCT03848663|Behavioral|Personalized Remapping|Shifting text based on individual letter-based perimetry
42859|NCT03848650|Device|OpSens Medical OptoWire|"The OptoWire is FDA approved to measure pressure in coronary vessels during diagnostic angiography and coronary interventions.~The OptoWire Deux pressure wire (OpSens Medical, Quebec, Canada) is a novel technology utilizing optical coherence technology to enhance FFR assessment of the coronaries."
42860|NCT03848650|Procedure|FFR|A guide wire-based procedure that can accurately measure blood pressure and flow through a specific part of the coronary artery. FFR is done through a standard diagnostic catheter at the time of a coronary angiogram (a.k.a. cardiac catheterization).
42861|NCT03848637|Drug|CKD-375|Test drug
42862|NCT03848637|Drug|D387|Reference drug
42863|NCT03848624|Device|Cycling Group|Electrical pulses from a stimulator can stimulate the target muscles to generate muscle contraction to support a continuous cycling motion
42864|NCT03848611|Drug|CM082 plus JS001|CM082：150mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
42865|NCT03848598|Diagnostic Test|Evaluation of local tendon deformation|Ultrasound-based speckle tracking to evaluate the local tendon tissue displacement during isometric exercise.
42866|NCT03848585|Device|Pilloxa Pillbox|A Pilloxa Pillbox is used for the prescribed immunosuppressants.
42867|NCT03848585|Other|Non active Pilloxa Pillbox|A Pilloxa Pillbox with reminders disabled and without active mobile application is used for the prescribed immunosuppressants.
42868|NCT03848572|Diagnostic Test|Repetitive assessment of PRECISE-DAPT score|The PRECISE-DAPT score, which takes into consideration age, creatinine clearance, haemoglobin, white blood-cell count and previous spontaneous bleeding, will be reassessed every 3 months during the 12-month follow-up period
42869|NCT03848559|Device|Airway management with a submerged model|Airway management with a submerged manikin using different airway devices in randomized order
42870|NCT03848546|Behavioral|PDA|"Subjects receive personal dietary fiber advice to increase their fiber intake. This advice will be provided using an online web-portal, where subjects can choose high-fiber alternatives that closely match their own intake. The aim is to swap product for low in fiber for a high fiber alternative (such as white bread, whole wheat bread)."
42871|NCT03848546|Other|Control (no intervention)|No intervention
42904|NCT03848221|Drug|Systane Complete|Systane Complete is an artificial tear.
42905|NCT03848221|Drug|Sensitive Eyes Rewetting Drops|Sensitive Eyes Rewetting Drops is a rewetting drop.
42872|NCT03848533|Drug|melatonin|"The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)"
42873|NCT03848533|Drug|metformin|"For the intervention with metformin, prolonged-release tablets will be used to reduce adverse effects and improve adherence to treatment. It will be contained in bottles labeled Medication 1 to maintain masking. This intervention will be indicated in two groups (Melatonin plus metformin and metformin plus placebo)"
42874|NCT03848533|Drug|Placebo|"The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)"
42875|NCT03848520|Procedure|TKA|TKA performed in the past
42876|NCT03848507|Drug|albumin 20%|Intravenous administration of 20% albumin during cystectomy
42877|NCT03848494|Procedure|Surgery|Laparoscopic floppy Nissen, laparoscopic-left thoracoscopic Collis-Nissen, laparoscopic gastric fundus wrapped around the stomach
42878|NCT03848481|Drug|CBDV Compound|CBDV is obtained from the Cannabis sativa L. plant and contains a negligible quantity (less than 0.2%) of THC
42879|NCT03848481|Drug|Placebo|Placebo oral solution contains matching excipients.
42880|NCT03848468|Procedure|Hemorrhoidectomy|excision of 3rd and 4th degree hemorrhoids
42881|NCT03848455|Diagnostic Test|genetic diagnosis|The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.
42882|NCT03848442|Other|'Uptime' participation|The intervention are designed for each individual and are consistent with the model for participation-based interventions. The interventions are goal-oriented (meaningful and family/client-selected goals), family/client-centered (promoted self-determination and decision making), collaborative (partnership between caregivers), strength-based (built on participant and caregiver strengths) and ecological (natural environment and real-life experiences). Design of the intervention comprised three steps: 1) Preparation period (6 weeks); 2) Intervention period (12 weeks); 3) Follow-up period (12 weeks)
42883|NCT03848429|Procedure|Surgery for mechanical complications of acute myocardial infarction|Surgical treatment of post-AMI left ventricular free-wall rupture: sutured and sutureless repair. Surgical treatment of post-AMI ventricular septal defect: infarctectomy and infarct exclusion repair. Surgical treatment of post-AMI papillary muscle rupture: mitral valve repair and replacement
42884|NCT03848416|Biological|Ixekizumab|Administered SC
42885|NCT03848403|Biological|Ixekizumab|Administered SC
42886|NCT03848390|Behavioral|Conventional diet|The conventional diet arm will be asked to consume a hypocaloric diet, and they will be allowed to eat at any time of the day with no time restriction.
42887|NCT03848390|Behavioral|Modified Time-restricted Feeding|The modified time-restricted feeding arm will be asked to consume any food but will be asked to consume this food for only a 9 hour daytime period.
42888|NCT03848390|Behavioral|Physical activity|At least 30 minutes of physical activity per day 5 times per week.
42889|NCT03848390|Behavioral|Restricted consumption of sweetened beverages|Restricted consumption of juice, soda, and other sweetened beverages.
42890|NCT03848364|Behavioral|Hip Hop Stroke 2.0|HHS2.0 is an innovative, multimedia program, a brief 3-hour (1hr/day for 3 days), school-based intervention designed to educate at-risk populations concerning stroke symptoms and calling 911 immediately in the event they occur (stroke literacy). HHS2.0 is accessed and delivered via a web link online as self-administered, interactive modules that target 4th and 5th grade children in the school system (ages 9-11) using narrative cartoons and multimedia games.
42891|NCT03848351|Behavioral|Oral Hygiene Instruction (OHI)|OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
42892|NCT03848351|Procedure|Professional supragingival scaling and polishing|Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
42893|NCT03848338|Procedure|Electrocochleography|Electrocochleography measurement Intra-operatively and Post-operatively at follow-up appointments along with correlative measurements (Impedance, eCAP, PTA, Speech)
42894|NCT03848325|Behavioral|Sleep deprivation|Eight hour opportunity for sleep followed by 24 hours of sleep deprivation.
42895|NCT03848312|Behavioral|Cognitive Training|Participants will be completing a total of 45 computerized sessions.
42896|NCT03848312|Behavioral|Computerized Cognitive Stimulation|Participants will be completing a total of 45 computerized cognitive stimulation sessions.
42897|NCT03848299|Other|Experimental: Single Arm|"All participants will have to consume the same standardized breakfasts from the second to the seventh day, except the ones that are intolerant or allergic to lactose or/and gluten. In those cases, they will follow an adapted diet for their intolerance or allergies.~Day 2 and 3: 110 g white bread.~Day 4 and 5 : 110 g white bread and 30 g butter or 55 g white bread, 50 g dark chocolate for lactose intolerant.~Day 6 and 7: Glucose drink (50g).~The bread will be replaced by gluten-free bread for gluten intolerant participants."
42898|NCT03848286|Drug|KL-A167 Injection|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
42899|NCT03848260|Device|Magnetic device prototype|The device prototype comprises a near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and receiver (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet affixed to the paralytic upper eyelid, and a bio-signal acquisition module. The efficacy and safety of the device prototype was assessed using the device prototype.
42900|NCT03848247|Other|Injection of Isotonic saline|Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).
42909|NCT03848182|Biological|TT vaccine booster|One human TT childhood vaccine booster will be administered on day 8
42910|NCT03848169|Other|Radiofrequency|See previous page
42911|NCT03848156|Other|biopsy|Biopsy of nasal polyp for RNA sequencing
42912|NCT03848143|Drug|onabotulinum toxin A|Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
42913|NCT03848130|Other|Mulligan Knee Taping with Home Exercises|Each patient in group I i.e. taping group with home exercises was given 40 minutes session. Each session started in sitting or lying position with leg extended and mulligan tape was used. Taping was started in the middle of patella, at the level of superior aspect of patella and pulled the tape medially and fixed the tape at medial border. This tilts the lateral border of patella away from femur and produced skin wrinkling. Besides this, home exercises such as quads isometrics and self stretchings & ROMs were also guided. This session was repeated three times a week for one month (Total 12 sessions/ one month).
42914|NCT03848130|Other|Lateral wedge insoles with Home Exercises|Each patient in group II i.e. lateral wedge insole with home exercises group was given 20-minute session. In each session, Lateral wedge insoles of 7mm made of silicon or ledos material were advised and home exercises in the same way. This session was repeated once a month but evaluations were obtained after a complete week for one month. (Total 4 sessions/one month)
42915|NCT03848130|Other|Traditional Physiotherapy with Home Exercises|Each patient in group III i.e. traditional physiotherapy with home exercises group was given 40 to 45-minute session. Each session started in lying position. In each session, therapeutic ultrasound with 1.5MHz frequency and continuous mode for 7 minute was given. Then passive stretchings of the following muscle groups was done; calf, hamstring, quadriceps, hip flexors and hip adductors & abductors and followed by strengthening exercises manually and with quadriceps bench. Home exercises were guided in the same way. This session was repeated 3 to 4 times a month. (Total 12 to 16 sessions/ one month)
42916|NCT03848117|Other|Cyriax approach i.e. DTF massage and Mill's manipulation|Each patient in group I i.e. Cyriax group was given 20-minute session. Each session started in sitting position and initially deep transverse friction massage was done at lateral compartment of the elbow joint and immediately after that mill's manipulation at elbow joint with flexion at wrist joint in pronated arm position. This session was repeated three times a week for one month (Total 12 sessions/ one month).
42917|NCT03848117|Other|Mulligan approach i.e. Taping and MWM|Each patient in group II i.e. Mulligan group was given 30 to 45-minute session. Each session started in sitting position and it included mobilization with movement which was given in such a way that initially lateral glide at elbow joint was performed and after holding it, I asked the patient to make a fist and open the fist. In this way, I repeated this procedure 36 times and after 12 repetitions, a short rest period was given. Taping was applied after mobilization around the elbow joint over extensor carpi radialis muscles. This session was repeated three times a week for one month (Total 12 sessions/ one month).
42918|NCT03848104|Other|bone and joint infection treated with cefoxitin|the patients had cefoxitin in combination in continuous parenteral administration to treat their bone / joint infection
42919|NCT03848091|Other|Antibiotic pretreatment|a strategy with antibiotic pretreatment before one-step exchange arthroplasty in patients who bacteria responsible for the infection has been indentified (puncture, blood cultures,...)
42920|NCT03848078|Device|Optical Coherence Tomography|"OCT is an imaging technique, which is able to produce real-time, in vivo, cross-sectional images of lesions with a depth of 1,5-2 mm. OCT imaging is based on light-interferometry, calculating the interference of an optical beam reflected by the tissue with a reference. In such ways, microscopic details of lesions and tissues can be visualized. This information can be used to identify a lesion as BCC, and to specify the subtype. Therefore, we assume that the use of the OCT might reduce the number of biopsies and the accompanying morbidity.~The investigator scans 6mm of skin with the OCT (30 seconds) and decides whether the lesion is a BCC or not."
42921|NCT03848065|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
42922|NCT03848065|Biological|Pneumococcal 13-valent Conjugate Vaccine (PCV13)|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B in each 0.5. mL dose.
42923|NCT03848039|Biological|Gardasil-9|administration by intramuscular injection of the 9-valent HPV vaccine according to a 3-dose vaccination schedule (0, 2, 6 months).
42924|NCT03848039|Drug|Placebo|administration by intramuscular injection of the placebo according to vaccination schedule of the 9-valent HPV vaccine (0, 2, 6 months)
42925|NCT03848026|Other|Middle ear fluid viscosity|The patients were subdivided into two groups according to median viscosity level
42926|NCT03848026|Other|Tympanostomy tube extrusion time|Tympanostomy tube extrusion time of the all patients recorded prospectively.
42927|NCT03848013|Device|Q switched Nd YAG laser|Laser device emitting Q switched Nd YAG aiming for skin toning
42928|NCT03848013|Device|Fractional CO2 laser|Laser device emitting fractionated ablative laser aiming for skin resurfacing
42929|NCT03848000|Other|Exercise Programme|Two sessions per week for 12 consecutive weeks. 30 minute education talks covering topics regarding the physical and mental health benefits of exercise and behaviour change. The following 30-60 minute exercise sessions will utilise pad-boxing, football, body-weight training and circuit training.
42930|NCT03848000|Behavioral|NHS Standard Care|Weekly one-to-one cognitive-behavioral counselling alcohol addiction support session lasting 1 hour. Drug therapy will be offered if indicated in line with standard therapy.
42931|NCT03847987|Drug|RO7017773 Phase I Capsule|Participants will receive 1 single oral dose of RO7017773 Phase I Capsule.
42932|NCT03847987|Drug|RO7017773 Phase II Tablet Unflavored|Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2.
42933|NCT03847987|Drug|RO7017773 Phase II Tablet Sweetened/Flavored|Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2.
42934|NCT03847974|Drug|LIB003|SC Q4W dosing
43037|NCT03847285|Other|solid organ transplantation|solid organ transplantation: kidney, heart, pancreas, lung and liver transplantation
42935|NCT03847961|Device|hemoperfusion with cytokine adsorption column (CA330)|Hemoperfusion treatments are performed using a perfusion machine via centrally inserted standard dialysis catheters at a prescribed blood flow rate of 100-300ml/min. In the beginning, lower flow rate is recommended, if there is no discomfort, then gradually increases. Each patient received 2 hemoperfusion treatments within 24 hours with a target duration for each treatment of 120-180 minutes (minimum of 120 minutes). The shorter the interval between the two hemoperfusion is, the better. It is suggested that the second hemoperfusion be performed within 0-5 hours after the first one.
42936|NCT03847935|Procedure|surgery|A1 pulley release of finger
42937|NCT03847935|Procedure|corticosteroid injections|corticosteroid injection to A1 pulley
42938|NCT03847935|Other|Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education,
42939|NCT03847935|Other|Modality Hand Therapy|orthosis fabrication, therapeutic exercise for range of motion to digits, ice massage, nodule massage, patient education, plus modalities such as ultrasound, iontophoresis
42940|NCT03847922|Drug|Nitrous Oxide + Oxygen Gas (Product)|Self-administered 50% nitrous oxide / 50% oxygen mixture will be given to the intervention group, starting just before the beginning of the urethral bulking procedure.
42941|NCT03847922|Drug|lidocaine gel 2%|6mL of 2% lidocaine gel will be inserted and injected into the urethral canal approximately 10 minutes prior to the procedure for each participant regardless of group assignment.
42942|NCT03847922|Other|Room air|Room air will be administered via the Pro-Nox machine to participants in the control group, starting just before the beginning of the urethral bulking procedure.
42943|NCT03847909|Drug|DCR-PHXC|Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection
42944|NCT03847909|Drug|Sterile Normal Saline (0.9% NaCl)|Sterile Normal Saline (0.9% NaCl) for subcutaneous (SC) injection, administered at same injection volume as DCR-PHXC, to serve as placebo
42950|NCT03847883|Drug|Intravenous Solution Ateplase|Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
42951|NCT03847870|Diagnostic Test|MORU in-house ELISA test followed by IFA if positive|An in-house rickettsial IgG ELISA test will be used for this study to determine previous rickettsial infections by measuring IgG levels. All specimens will be tested for IgG antibodies using ELISA tests for scrub typhus (Orientia tsutsugamushi strains Karp, Kato, Gilliam and TA716), murine typhus (Rickettsia typhi strain type Wilmington), and spotted fever rickettsiosis (Rickettsia honei and Rickettsia conorii). If the sample tests positive, it will be retested for the same antigens using the IFA test. The sample will be considered positive if both the ELISA and the IFA are positive.
42952|NCT03847857|Biological|Porcine Fibrin Sealant (PFS)|McKeown esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
42953|NCT03847857|Procedure|McKeown esophagectomy|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
42954|NCT03847844|Biological|Umbilical cord derived mesenchymal stem cell|Umbilical cord derived mesenchymal stem cell
42955|NCT03847844|Other|Placebo|Normal saline
42956|NCT03847831|Behavioral|Active School Flag Program|Schools enrolled in the program take part in the 17 actions described in the PPASF.
42957|NCT03847818|Drug|Pyrotinib+Trastuzumab+Docetaxel+Carboplatin|"Drug: Pyrotinib Pyrotinib: 400mg orally daily~Drug: Trastuzumab Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;~Drug: Docetaxel Docetaxel: 75mg/m2 for a total of 6 cycles~Drug: Carboplatin Carboplatin: AUC=5 or 6 for a total of 6 cycles"
42958|NCT03847805|Other|Scapulothoracic and glenohumeral stabilization exercises|The experimental group followed a program that included three scapulothoracic stabilization exercises and three for glenohumeral stability, while subjects in the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue. Three series, with 10 repetitions of each exercise, with one minute rest between series.
42959|NCT03847805|Other|Glenohumeral stability exercises|the control group only performed the glenohumeral stabilization exercises. Two weekly sessions were carried out over a period of 6 weeks, and each session lasted 30 minutes. The intervention was conducted before starting the training session, to avoid muscle fatigue.
42960|NCT03847792|Drug|Group DB/Dexamethasone-Bupivacaine|The patient will receive an intra-articular injection of 18ml bupivacaine 0.25% added to 8mg dexamethasone.
42961|NCT03847792|Drug|Group FB /Fentanyl-Bupivacaine|The patient will receive an intra-articular injection of 1 ug/kg fentanyl added to 18ml of 0.25% bupivacaine.
42962|NCT03847792|Drug|Group PB/Placebo-Bupivacaine|Patients will receive an intra-articular injection of 2ml isotonic saline added to 18ml of 0.25% bupivacaine.
42963|NCT03847779|Other|"Rest"|Cutaneous perfusion and vasomotion assessment at rest in supoine position
42964|NCT03847779|Other|"Exercise"|Cutaneous perfusion and vasomotion assessment after the 6minute-wlaking test
42965|NCT03847779|Other|"Foot lowering"|Cutaneous perfusion and vasomotion assessment after foot lowering
42966|NCT03847779|Other|"Hyperthermia"|Cutaneous perfusion and vasomotion assessment during hyperthermia
42967|NCT03847766|Behavioral|PRO-based follow-up|Diagnose specific questionnaires are used to screen patients in need of contact to the outpatient clinic
43038|NCT03847272|Drug|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4 and W16)
42968|NCT03847766|Behavioral|PRO-based telephone consultation|diagnose-specific questionnaires are used to support communication between clinician and patient during a phone consultation
42969|NCT03847753|Other|Organic Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42970|NCT03847753|Other|Substance Use Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42971|NCT03847753|Other|Schizophrenia Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42972|NCT03847753|Other|Mood disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42973|NCT03847753|Other|Neurotic disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42974|NCT03847753|Other|Eating Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42975|NCT03847753|Other|Personality Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42976|NCT03847753|Other|Intellectual Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42977|NCT03847753|Other|Developmental Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42978|NCT03847753|Other|Behavioral Disorders|Individuals were considered to have a specific mental disorder from the date they received a relevant diagnosis registered in the Danish Psychiatric Central Research Register.
42979|NCT03847740|Device|Isometric Trumb Force handle|Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
42980|NCT03847727|Drug|BR as Maintenance|Patients of the study group who have achieved at least a partial response after 6 cycles of BR induction will receive additionally 4 cycles of BR every 3 months as maintenance therapy.
42981|NCT03847714|Dietary Supplement|Omni-Biotic Stress Repair|The probiotic supplement is a commercially available food for special medical purposes and includes 9 bacterial strains with at least 7.5 billion organisms (7.5 × 109 Colony Forming Units/g) per 1 portion (= 3 g).
42982|NCT03847714|Dietary Supplement|placebo|similar looking and tasting powder
42983|NCT03847701|Other|Balanced diet high in Slowly Digestible Starch|The carbohydrates present in high Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
42984|NCT03847701|Other|Balanced diet low in Slowly Digestible Starch|The carbohydrates present in low-Slowly Digestible Starch diet were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during three months.
42985|NCT03847688|Device|Transcranial Magnetic Stimulation|Patient receive Transcranial Magnetic Stimulation for treatment resistant depression as part of their routine care.
42986|NCT03847675|Behavioral|Reach out and Read|"The research assistant introduces the adapted 'Reach out and Read program and informs participants about the benefits of reading to children at an early age and coaches the participants on the actual reading behavior: how to read, pointing at the words, letting the child take his/her time, not making it like homework, and stresses on the fact of removing distractors (TV, phone, iPad, etc.).~A schematic pamphlet (Appendix 1) highlighting the importance of reading Arabic to children and the impact of such reading on children's brain development, vocabulary acquisition and behavior in addition to the impact on the parent child bond and relationship is given to the parents."
42987|NCT03847649|Drug|Durvalumab|1500 mg IV, 60 min, Day 1 every 4 weeks
42988|NCT03847649|Drug|Prednisone|0.5mg/kg; PO, Daily cycles 1 & 2
42989|NCT03847649|Drug|Prednisone|10mg, PO, Daily cycles 1 & 2
42990|NCT03847636|Device|CryoBalloon ablation|Endoscopic cryoablation (cryogen is contained nitrous) using a CryoBalloon catheter to ablate up to 4 separate DA.
42991|NCT03847623|Dietary Supplement|Curcumin|Natural compound, active ingredient of turmeric, in bi-daily dosing
42992|NCT03847623|Other|Placebo|Placebo tablets at bi-daily dosing
42993|NCT03847610|Drug|Phenoxymethyl Penicillin|Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
42994|NCT03847610|Device|Microneedle array|The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
42995|NCT03847597|Procedure|Explantation of the femoro-popliteal arterial segment from the amputed limb|Explantation of the femoro-popliteal arterial segment from the amputed limb
42996|NCT03847584|Other|Survey|The survey is based on the Theory of Planned Behaviour and assesses intention to participate in NutriQuébec as well as attitude, subjective norm, and perceived behavioural control. The salient beliefs underlying the determinants of individual's intention to participate in the NutriQuébec study most frequently cited in the focus groups (from a preliminary elicitation study: 2018-042 A-1/18-05-2018) were used to develop the survey questions. The survey also assesses the preferences regarding the recruitment. Sociodemographic questions are also asked.
42997|NCT03847571|Drug|Acetazolamide|Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)
42998|NCT03847558|Diagnostic Test|FSH((Follicle Stimulating Hormone) and LH (Luteinizing Hormone) hormone for females and Testosterone hormone for males|assess of sexual maturation by clinical examination and hormonal studies (FSH.LH,Testosterone)
42999|NCT03847545|Drug|Fampridine|sustained-release tablet 10 mg morning and evening.
43039|NCT03847272|Other|Ophthalmologic examination|Best corrected visual acuity (BCVA) testing, Slit Lamp Exam, tonometry, dilated indirect ophthalmoscopy, optical coherence tomography (OCT), Fluorescein angiography and Indocyanin green angiography
43000|NCT03847532|Genetic|Sanger sequencing method|Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
43001|NCT03847519|Drug|ADXS-503|A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with squamous and non-squamous NSCLC.
43002|NCT03847519|Drug|Pembrolizumab|a programmed death receptor-1 (PD-1)- blocking antibody.
43003|NCT03847506|Drug|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Candesartan cilexetil 8 mg placebo
43004|NCT03847506|Drug|Candesartan cilexetil/Amlodipine besylate|Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg + Ezetimibe/Rosuvastatin 10 mg/10 mg placebo + Candesartan cilexetil 8 mg placebo
43005|NCT03847506|Drug|Candesartan cilexetil|Ezetimibe/Rosuvastatin 10 mg/10 mg + Candesartan cilexetil 8 mg + Candesartan cilexetil/Amlodipine besylate 8 mg/5 mg placebo
43006|NCT03847493|Other|Endothelial Glycocalyx|Non-invasive assessment of endothelial glycocalyx dimensions.
43007|NCT03847480|Radiation|FDG-PET guided dose painting|The radiation dose inside the gross tumor volume is increased according to the voxel intensity (SUV - standardized uptake value) of pre-treatment FDG PET.
43008|NCT03847467|Drug|2'-Fucosyllactose|Human milk oligosaccharide prebiotic dietary supplement
43009|NCT03847467|Other|Placebo|Dextrose
43010|NCT03847454|Combination Product|REACH|The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
43011|NCT03847454|Other|Standard of care|Standard of care for rehabilitation treatment for musculoskeletal patients.
43012|NCT03847441|Drug|Calcipotriol|Calcipotriol ointment (0.005%)
43013|NCT03847441|Device|Narrow Band UVB|NB-UVB (311nm) phototherapy
43014|NCT03847441|Diagnostic Test|vitamin D3 level|vitamin D3 (ng/ml)
43015|NCT03847428|Drug|Durvalumab|Durvalumab IV (intravenous)
43016|NCT03847428|Drug|Bevacizumab|Bevacizumab IV (intravenous)
43017|NCT03847428|Other|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
43018|NCT03847415|Diagnostic Test|ultrasound|to evalute abnormal uterine bleeding in postmenopausal women using 3D(dimensional) ultrasound assessment of endometrial volume .Doppler assessment of endometrium and hysteroscopy and to correlate this finding with pathological finding of endometrial biopsy
43019|NCT03847402|Behavioral|The early integrated intervention for GDD|The early integrated intervention for GDD integrates developmental approaches with strategies of applied behavior analysis.
43020|NCT03847402|Behavioral|The early integrated intervention for ASD|The theoretical underpinnings of the early integrated intervention for ASD originate from Early Start Denver Model.
43021|NCT03847402|Behavioral|The early integrated intervention for ADHD|The methods of the early integrated intervention for ADHD includes behavior training, sensory integration training and psychological counseling
43022|NCT03847402|Behavioral|community intervention for ASD|TEACCH (Treatment and Education of Autistic and related Communication- handicapped Children) intervention or ABA(applied behavior analysis) intervention
43023|NCT03847402|Behavioral|Community intervention for GDD|community intervention based on developmental approaches
43024|NCT03847402|Behavioral|community intervention for ADHD|School and family education
43025|NCT03847389|Drug|Clobetasol propionate 0.05% Topical Oil|thin film application of the oil twice daily
43026|NCT03847376|Drug|Rilpivirine Long Acting (RPV LA)|Participants will receive RPV LA injectable suspension containing 300 milligram per milliliter (mg/mL) of RPV by intramuscular (IM) injection. A starting dose of 900 milligram (mg) RPV LA (3 milliliter [mL] suspension) will be administered with subsequent doses of 600 mg RPV given at 4-week intervals.
43027|NCT03847363|Procedure|epidural anesthesia|epidural anesthesia
43028|NCT03847363|Procedure|nerve block|paravertebral or serratus anterior plane block
43029|NCT03847337|Other|Telehealth-Screening Tool for Autism in Toddlers (STAT)|Structured autism screening tool
43030|NCT03847337|Other|Telehealth-Autism Spectrum Disorder-Pediatrics (ASD-PEDS)|Semi-structured autism screening tool
43031|NCT03847324|Other|Pain Neuroscience Education|"This program is mainly based in Explain Pain concept, used in multiple rehabilitation programs. Its aim is to change the subject's pain understanding, teaching them the biological processes underneath the pain construct, as a mechanism to reduce itself and its related maladaptative thoughts and behaviors."
43032|NCT03847324|Other|Multimodal Physiotherapy|This intervention will be divided in pain neuroscience education, orthopedic manual therapy and therapeutic exercise.
43033|NCT03847324|Other|Usual Care|Usual care will be divided in: preoperative biomedical group-based education, postoperative hospital rehabilitation and home-based postoperative physiotherapy.
43034|NCT03847311|Drug|Sulfasalazine|This group will receive supplies for 3 months of sulfasalazine at an initial dose of 0.5 gram three times a day for a week then at a dose of 1 gram three times a day for the remainder of the 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
43035|NCT03847311|Drug|Placebos|This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
43036|NCT03847298|Other|Physical activity and physical fitness assessment|Physical fitness was assessed using Munich Physical Fitness Test (MFT). The SenseWear Armband metabolic holter device was used to record the physical activity level for consecutive 7 days. The functional exercise capacity of the individuals was assessed by the six-minute walking test (6MWT) and cardiorespiratory capacity was assessed by maximal exercise test on the treadmill.
43040|NCT03847272|Other|Questionnaires|VFQ-25 and SF-36
43041|NCT03847272|Biological|Blood samples|Additional blood samples for immunomonitoring
43042|NCT03847259|Diagnostic Test|mechanical posture changes|evaluated by Posture screen mobile, (BackPEI) questionnaire , VISUAL ANALOG SCALE (VAS), Depression Anxiety Stress Scales-21(DASS-21).
43043|NCT03847246|Drug|Baraclude® tablets,1.0 mg|oral,once,under fasting condition
43044|NCT03847246|Drug|Entecavir tablets,1.0 mg|oral,once,under fasting condition
43045|NCT03847233|Device|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
43046|NCT03847220|Diagnostic Test|BOMET-QoL questionnaire|study to evaluate the utility of the BOMET-QoL questionnaire in patients with BC and BM
43047|NCT03847207|Drug|HTL0030310|Solution for Subcutaneous injection
43048|NCT03847207|Drug|Pasireotide|Pasireotide 600 μg for subcutaneous injection
43049|NCT03847207|Drug|Placebo|Matching placebo Solution
43050|NCT03847194|Behavioral|Promoting Resilience in Stress Management (PRISM)|PRISM was developed based on stress and coping theory to be a brief, disease non-specific, skills-based intervention targeting adolescent resilience resources. PRISM teaches 4 pillars of resilience including stress management, goal setting, cognitive restructuring and benefit-finding in a one-on-one training program consisting of two, 45-60 minute sessions and supported by 6-months of booster sessions and a fully developed digital app for practice and tracking. A family session follows the individual sessions and was designed for the adolescent to communicate to his/her caregiver(s) the skills learned, and how the caregiver(s) could best support ongoing practice.
43054|NCT03847168|Drug|KN026|Patient will be intravenously administrated with one dose of KN026 every week or every other week.
43055|NCT03847155|Drug|Nicotine patch|The patients will receive a nicotine patch for the period of a maximum of 7 days.
43056|NCT03847155|Other|Placebo patch|The patients will receive a placebo patch for the period of a maximum of 7 days.
43057|NCT03847142|Other|ASTHMAXcel mobile application|ASTHMAXcel is a mobile application (patient-facing) that delivers guideline-based asthma education.
43058|NCT03847142|Other|Outpatient primary care|Usual care delivered through the outpatient primary care setting
43059|NCT03847129|Other|Biofeedback training|Before the biofeedback training, the baseline pinch force detected from a pinch-holding-up activity is recorded to set the target level according to the baseline data. With the aim for improving the performance, a 94% peak force value detected at the baseline is set as the target threshold for the training. Each participant attends a 30-minute biofeedback protocol per session, two times a week for six to eight weeks. Once the pinch force value exceeds the target range, visual and auditory cues are provided to inform the subjects to modify the performance.
43060|NCT03847129|Other|Home-based tendon gliding and resistance training|The participants receive similar doses of home-based tendon gliding exercises and resistance training with an anti-stress ball for 30 minutes at a frequency of 2 times a week for 6 to 8 weeks, also combined with the regular diabetic care treatment. Six to eight telephone visits are carried out to remind the patients to comply with the exercise program during the training period.
43061|NCT03847103|Other|Robotic-assisted Therapy with Bilateral Practice|40-minute robotic-assisted therapy with bilateral practice program for wrist and forearm repetitive movement training was performed during each session.
43062|NCT03847103|Other|Unilateral Task-specific Training|40 -minute unilateral task-specific training using various tasks: picks up beans with spoon, pouring water from one glass to another glass, opening and closing a drawer, drinking from a mug, and wiping the table were chosen for facilitating multitude of upper extremity functions. Three tasks per session were chosen for various specific components of hand-arm function training.
43063|NCT03847103|Other|Sensorimotor Stimulation Program|10-minute sensorimotor stimulation program with repetitive range of motion exercises of upper extremity, proprioceptive neuromuscular facilitation and Rood approach
43064|NCT03847090|Drug|Reloxaliase|Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
43065|NCT03847090|Drug|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
43066|NCT03847077|Behavioral|iPad counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive multimedia counseling using the drawMD OB/GYN iPad application.
43067|NCT03847077|Behavioral|Standard Counseling|Women with leiomyomata confirmed on imaging who presented as a new patient to the gynecology clinic at a single institution were randomized to receive standard counseling.
43068|NCT03847051|Diagnostic Test|MRI|Brain MRI without intravenous contrast
43069|NCT03847038|Procedure|Preventive strategies advice and dementia risk estimate disclosure|The BBRC-DemPrev-2018 study is a multimodal lifestyle-interventional, longitudinal, and prospective study of participants with a subjective perception of cognitive decline (SCD) or with mild cognitive impairment (MCI). Participants are disclosed their 5-year dementia risk estimate
43070|NCT03847012|Other|exercise|The test order will be random. After at least 12 times of cardiopulmonary rehabilitation training, the test will be performed again.
43071|NCT03846986|Dietary Supplement|Apple Juice1|Apple Juice1
43072|NCT03846986|Dietary Supplement|Apple Juice2|100% Apple Juice with enzyme-treated apple pomace fiber
43073|NCT03846986|Dietary Supplement|Raw Apple|Raw Apple
43074|NCT03846973|Drug|Tranexamic Acid|intravenous infusion of 1 g infusion to be given and completed over 8 h in the hospital
43075|NCT03846973|Other|Placebo|placebo (normal saline) infusion to be given and completed over 8 h in the hospital
43076|NCT03846960|Device|using specially adapted VNscope|surfactant administration via thin catheter using a specially adapted VNscope
43077|NCT03846960|Drug|surfactant administration|surfactant administration via thin catheter using a specially adapted VNscope
43078|NCT03846947|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
43151|NCT03846349|Device|EMT threshold|EMT threshold is a small portable device producing a positive expiratory pressure when the patient is exhaling.
43079|NCT03846934|Device|Ultrasonography thoracic|Thoracic ultrasonography will be performed as soon as possible after admission to the ED, without delaying the start of treatment and in addition to routine thoracic radiography.
43080|NCT03846921|Diagnostic Test|Laboratory blood test|Laboratory blood test will be analyzed to determine whether there is a rise in alpha-defensin
43081|NCT03846908|Other|MCT|patients will receive fat load with MCT
43082|NCT03846908|Other|SFA|patients will receive fat load with SFA
43083|NCT03846908|Other|MUFA|patients will receive fat load with MUFA
43084|NCT03846895|Device|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
43085|NCT03846869|Diagnostic Test|major cations|blood sample
43086|NCT03846856|Other|Biopsy|Biopsy taken during surgical procedure
43087|NCT03846843|Drug|OCR-002 - Treatment A|Single 5 g oral dose of OCR-002 administered under fasting conditions
43088|NCT03846843|Drug|OCR-002 - Treatment B|Single 5 g oral dose of OCR-002 administered under fed conditions
43089|NCT03846843|Drug|OCR-002 - Treatment C|Single 5 g IV dose of OCR-002 administered under fasting conditions
43090|NCT03846843|Drug|OCR-002 - Treatment D|Single 5 g oral dose of OCR-002 administered under fasting conditions following the discontinuation of lactulose
43091|NCT03846843|Drug|OCR-002 - Treatment E|6 g OCR-002 per day (2 tablets TID for 6 g total daily dose)
43092|NCT03846843|Drug|OCR-002 - Treatment F|12 g OCR-002 per day (4 tablets TID for 12 g total daily dose)
43093|NCT03846843|Drug|OCR-002 - Treatment G|21 g OCR-002 per day (7 tablets TID for 21 g total daily dose)
43094|NCT03846830|Device|Incremental Velocity Error (IVE)|A lightweight headband has electronics attached that detect head velocity and move a laser target at a fraction of the head velocity.
43095|NCT03846830|Behavioral|Traditional Vestibular Rehabilitation (VPT)|Standard of care, meta-analysis vetted, eye and head motion exercises to reduced morbidity associated with dizziness and imbalance.
43096|NCT03846817|Other|Physiotherapist-led treatment|12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
43097|NCT03846804|Diagnostic Test|Karius Test|Next-generation sequencing of blood and synovial fluid samples for pathogen identification in children with musculoskeletal infections
43098|NCT03846791|Other|Observational Study Post MAKO Robotic Surgery|To assess clinical outcomes and surgery related resource use in the year post surgery for patients undergoing hip replacement surgery using the MAKO robot
43099|NCT03846765|Drug|Phenylephrine|"Phenylephrine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Phenylephrine will be started at 0,2 μg/kg/min and adjusted according to the patient's hemodynamic status. The dose will be adjusted to MAP during a 30-minute study period."
43100|NCT03846765|Drug|Dobutamine|"Dobutamine will be administered continuously after intubation in order to maintain blood pressure in a range from MAPbaseline -20% to normal (preoperative) values (MAPbaseline). If MAP decreases to a value lower than MAPbaseline -20%, a higher dose of vasopressor will be administered. If MAP increases to a value above MAPbaseline, the dosing rate will be decreased.~Dobutamine will be started at 2 μg/kg/min; and adjusted according to the patient's hemodynamic status .The dose will be adjusted to MAP during a 30-minute study period."
43101|NCT03846752|Procedure|radial artery access for complex PCI|Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
43102|NCT03846752|Procedure|femoral artery access for complex PCI|Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
43103|NCT03846739|Drug|Oxytocin nasal spray|Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
43104|NCT03846739|Drug|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
43105|NCT03846726|Procedure|standard TME surgery|radical resection for rectal cancer
43106|NCT03846713|Procedure|non-thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into normal saline at room temperature.
43107|NCT03846713|Procedure|thermosoftening|By using airway exchange catheter, tube exchange is performed from single to double lumen tube that was put into warm normal saline (40°C).
43108|NCT03846700|Device|aquablation|"minimally invasive, robot-assisted and ultrasound-guided ablation of the prostate in targeted way and in heat-free way working by high pression water jet"
43109|NCT03846700|Device|holep|holmium laser enucleation of prostate
43110|NCT03846700|Device|pvp|photoselectivevaporization of prostate
43111|NCT03846661|Device|Physiomesh|difference in risk for recurrence and postoperative complication
43112|NCT03846648|Drug|Cypep-1|"Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~CyPep-1 topical formulation 1% (w/w)~Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest."
43113|NCT03846622|Other|Calculation of scoring systems for bleeding|
43114|NCT03846609|Device|double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is used for removal of colonic polyp
43115|NCT03846609|Device|no double balloon interventional platform (DiLumen)|double balloon interventional platform (DiLumen) is not used for removal of colonic polyp
43116|NCT03846596|Biological|Additional blood tube|Additional blood tube during care
43661|NCT03842501|Dietary Supplement|Placebo|Calorie reduced diet plus Placebo
43117|NCT03846583|Drug|Tucatinib|Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
43118|NCT03846583|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
43119|NCT03846583|Drug|Trastuzumab|"• Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system."
43120|NCT03846583|Drug|Aromatase Inhibitor|These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
43121|NCT03846570|Drug|Formoterol-beclomethasone|formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler
43122|NCT03846570|Drug|Placebo|Matching placebo (identically package) administered BID
43123|NCT03846557|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the Acurate Neo Transcatheter Heart Valve
43124|NCT03846544|Drug|CFA-double pick up|In the study group, 225 IU of rFSH will continue after the first oocyte retrieval (OR). Antagonist administration will be initiated when at least one follicle measuring ≥14 mm will be present in the ultrasound. If one or more follicles ≥17 mm are observed, patients will undergo a second triggering with hCG 5000 IU and a second OR will be performed. In case of patients with no follicular development following 10 additional days of rFSH post-OR
43125|NCT03846531|Device|Nano-Pulse Stimulation (NPS)|The Pulse generator delivers electrical pulses (nanosecond duration) that are applied directly to targeted lesion using sterile treatment tips with micro-needles.
43126|NCT03846518|Device|Hyrax|Rapid maxillary expansion using the Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars.The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
43127|NCT03846518|Device|mini Hyrax|Rapid maxillary expansion using the mini Hyrax expander. Appliance anchorage will be performed by bands adapted to the first maxillary molars and arms of the screw contoured to adapt to palatal faces of the first and second maxillary bicuspids, in wich will be bonded by resin. The screw will be positioned perpendicularly to the palate sagittal midline, between second maxillary bicuspids and first maxillary molars, and 5 mm apically from marginal gingiva of palatal face of the first maxillary molars. The activation protocol will be 2 turns a day up to obtain transverse overcorrection. After the active period of RME, the screws will be fixed with ligature wire and the appliance will be kept as a retainer for 6 months.
43128|NCT03846505|Drug|Oxytocin|A 40-IU dose of oxytocin will be self-administered 30 minutes prior to the start of each weekly ABCT session.
43129|NCT03846505|Other|Placebo|A placebo will be self-administered 30 minutes prior to the start of each weekly ABCT session.
43130|NCT03846492|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain stimulation modality that does not require general anesthesia or surgical implantation of a device. tDCS utilizes low intensity electrical current either to increase cortical excitability with an anodal electrode or to suppress cortical excitability with a cathodal electrode. It uses 3 AAA batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
43131|NCT03846479|Drug|Itacitinib|for up to 56 days
43132|NCT03846466|Drug|KHK4323 IV/S|IV / Single administration
43133|NCT03846466|Drug|KHK4323 SC/S|SC / Single administration
43134|NCT03846466|Drug|KHK4323 IV/M|IV / Multiple administration
43135|NCT03846466|Drug|Placebo IV/S|IV / Single administration
43136|NCT03846466|Drug|Placebo IV/M|IV / Multiple administration
43137|NCT03846466|Drug|Placebo SC/S|SC / Single administration
43138|NCT03846453|Biological|0.25% HL036 Ophthalmic Solution|0.25% HL036 Ophthalmic Solution consists of all components of the drug product solution with 0.25% Active Pharmaceutical Ingredient (API)
43139|NCT03846453|Biological|Placebo|The placebo solution consists of all components of the drug product solution with the exception of API
43140|NCT03846440|Other|No intervention|Cross-sectional
43141|NCT03846427|Drug|Zanubrutinib|Zanubrutinib at a dose of 160 mg PO BID
43142|NCT03846414|Drug|PEG-rhG-CSF|PEG-rhG-CSF was administered 24 hours after the end of chemotherapy for each chemotherapy cycle.
43143|NCT03846401|Device|fiberoptic bronchoscopy|"Will be performed according to British Thoracic Society guidelines 2013.~-Microbiological methods The specimen (tracheal aspirate & BAL) will be collected under aseptic conditions in a sterile container and immediately sent to the laboratory for microbiological analyses.~Samples will be apply for:~Direct smear by Gram stain and ZeihlNelseen stain~Samples culturedinBact/alert bottle(BioMérieux, France).~Isolation of causative organism from positive cases by:~Subculture on MacConkey , blood , chocolate agar , Sabouroud`s agar and Lowenstien Jensen media.~Identification of isolated organism and drug sensitivity test by Automated Vitek2 Compact(BioMérieux, France).~Multiplex PCR for detection of Respiratory viruses in lower respiratory tract"
43144|NCT03846388|Diagnostic Test|follicular stimulating hormone|in the serum of our patients
43145|NCT03846388|Diagnostic Test|Anti-mullerian hormone|in the serum of our patients
43146|NCT03846388|Radiation|Basal antral follicle count|by ultrasound
43147|NCT03846375|Behavioral|Psychotherapy|DBT is a well-established treatment for recurrent self-harm and suicidal thoughts. The program is principle-based, but the skills training follow a manualized curriculum.
43148|NCT03846375|Other|Pre-intervention testing|Pre-intervention testing for baseline measures.
43149|NCT03846362|Other|HSCT|allogenic HSCT from 5-8 HLA-MM family donor as a first choice for patients with initial high risk of relapse and for patients with MRD2>0,1% and initial intermediate risk
43150|NCT03846349|Device|IOPI|IOPI is a portable device with a tongue bulb used to reinforce upper airway muscles.
43152|NCT03846336|Other|Upper extremity function|Upper extremity function was evaluated with 9-Hole Peg Test (9-HPT). The 9-HPT is a brief, standardized, quantitative test of upper extremity function. It consists of moving nine pegs into one of the nine holes on a peg board, then back into an open box. Both the dominant and non-dominant hands are tested twice.
43153|NCT03846336|Other|Shoulder position sense|Shoulder position sense was evaluated with a Dualer IQTM digital inclinometer (J-TECH medical, Salt Lake City, UT, USA). The absolute error scores (in degrees) for shoulder abduction and flexion at 30° and 60° was calculated. The upper extremity of the participant was positioned with the arm in the scapular plane for the abduction movement and in the sagittal plane for the flexion movement. After returning to the starting position, participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position. The measurement was repeated 2 more times for a total of 3 trials for each limb (non-dominant and dominant), with a 30-second rest period separating trials.
43154|NCT03846323|Other|Visiting policies: 24 hours a day, 7 days a week|
43155|NCT03846323|Other|Restriction of visiting policies < 6 hours|
43156|NCT03846310|Drug|AB928|AB928 is an A2aR and A2bR antagonist
43157|NCT03846310|Drug|AB122|AB122 is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
43158|NCT03846310|Drug|Carboplatin|Carboplatin administered as part of standard chemotherapy regimen
43159|NCT03846310|Drug|Pemetrexed|Pemetrexed administered as part of standard chemotherapy regimen
43160|NCT03846310|Drug|Pembrolizumab|Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
43161|NCT03846284|Drug|Bupivacaine|caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.
43162|NCT03846284|Drug|Magnesium sulfate 50mg|caudal block with bupivacaine 0.25% 1mg/kg plus Magnesium sulfate 50 mg diluted in 10 cm saline.
43163|NCT03846284|Drug|Magnesium sulfate 30 mg|"caudal block with bupivacaine 0.25% 1mg/kg diluted in 10 cm saline.~+ I.V injection of Magnesium sulfate 30mg/kg diluted in 10 cm saline over 10 mins then, fol I.V infusion one ampule of Magnesium sulfate 500mg diluted in 50 cm saline with rate 10 mg/kg/h."
43164|NCT03846271|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
43165|NCT03846271|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
43166|NCT03846258|Drug|Low bicarbonate solution (22 mmol/L)|Participants randomized to this arm will be started on CRRT using Phoxillum as the replacement fluid.
43167|NCT03846258|Drug|High Bicarbonate solution (32 mmol/L)|Participants randomized to this arm will be started on CRRT using Prismasate as the replacement fluid.
43168|NCT03846245|Other|No intervention|No intervention
43169|NCT03846232|Other|No intervention|No intervention
43170|NCT03846219|Drug|IMU-838 (30 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (1 tablet per day) and then start taking the full assigned dose from Day 7 onwards (2 tablets once daily).~Extended treatment period (optional): patients will receive 30 mg/day IMU-838 for up to 9.5 years. Patients on active treatment during the main treatment period will be randomized to continue their previous treatment assignment. Identical to the start of the main treatment period, all patients will receive half the assigned dose during the first 7 days of the extended treatment period and will then continue with the full assigned dose.~Once the results of the main treatment period are available, investigators and patients currently in the extended treatment period will be unblinded and investigators may then recommend switching the dose to a more effective dose or to an equally effective dose but with a lower risk for adverse events."
43171|NCT03846219|Drug|IMU-838 (45 mg/day)|"Main treatment period: All patients will receive half the assigned dose during the first 7 days of the main treatment period (1 tablet per day) and then start taking the full assigned dose from Day 7 onwards (2 tablets once daily).~Extended treatment period (optional): patients will receive 45 mg/day IMU-838 for up to 9.5 years. Patients on active treatment during the main treatment period will be randomized to continue their previous treatment assignment. Identical to the start of the main treatment period, all patients will receive half the assigned dose during the first 7 days of the extended treatment period and will then continue with the full assigned dose.~Once the results of the main treatment period are available, investigators and patients currently in the extended treatment period will be unblinded and investigators may then recommend switching the dose to a more effective dose or to an equally effective dose but with a lower risk for adverse events."
43172|NCT03846219|Drug|Placebo|"Main treatment period: All patients will receive 1 tablet per day during the first 7 days of the main treatment period and then start taking 2 tablets once daily from Day 7 onwards.~Extended treatment period (optional): Patients receiving placebo during the main treatment period will be randomized to 30 or 45 mg/day IMU-838. Identical to the start of the main treatment period, all patients will receive half the assigned dose during the first 7 days of the extended treatment period and will then continue with the full assigned dose.~Once the results of the main treatment period are available, investigators and patients currently in the extended treatment period will be unblinded and investigators may then recommend switching the dose to a more effective dose or to an equally effective dose but with a lower risk for adverse events."
43173|NCT03846206|Dietary Supplement|mediterranean diet|a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months
43174|NCT03846193|Biological|GT005|A recombinant non-replicating adeno-associated viral (AAV) vector encoding a human complement factor
43175|NCT03846180|Drug|Terlipressin|Continuous or intermittent intravenous infusion of terlipressin was given.
43176|NCT03846180|Drug|Somatostatin|Continuous or intermittent intravenous infusion of somatostatin was given.
43177|NCT03846180|Drug|Octreotide|Continuous or intermittent intravenous infusion of octreotide was given.
43178|NCT03846167|Drug|Imaging Drug FluorThanatrace (FTT)|[18F]FTT is an investigational radioactive PET drug used to see PARP-1 activity in tumors. This radioactive imaging drug is injected into the body to see how it goes into places where there is active breast cancer. Using an imaging scan called Positron Emission Tomography (PET/CT), the radioactive drug can be seen in the body.
43207|NCT03845933|Procedure|Colon polypectomy|Polyp search and resection will be performed during the withdrawal phase in both groups. Insertion polypectomy will not be performed. All proximal colon polyps will be removed irrespective of their size and appearance.
43946|NCT03840226|Drug|Placebo Oral Tablet|Placebo tablets
43179|NCT03846154|Behavioral|Comprehensive family intervention including individual sessions of FORNET|"A group intervention once a week for about 20 weeks, including psychoeducation on mental health and drug abuse, anger management, roles within families, developing plans for the future, communication skills, sex education.~Access to schools and school material~Family visits~Their parents received training regarding agriculture and microcredit projects, and financial assistance~FORNET if affected by trauma-related symptoms, and/or acting aggressive~If needed medical assistance /.) If needed, legal assistance"
43180|NCT03846141|Other|Placebo|Inhalation of room air for 20 min per day during 7 days
43181|NCT03846141|Other|Hydrogen|Inhalation of 4% hydrogen for 20 min per day during 7 days
43182|NCT03846128|Biological|blood sample|blood sample performed on C1D1, C1D14, C2D1, C3D1 and C6D1
43183|NCT03846115|Behavioral|Peer-Led Seeking Safety app|This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.
43184|NCT03846115|Behavioral|Control app|This app offers the Seeking Safety content but without the enhanced features
43185|NCT03846102|Drug|Levobupivacaine|Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
43186|NCT03846102|Drug|Placebo|Sodium Chloride 0,9% for injection/infusion.
43187|NCT03846102|Drug|Acetaminophen|Acetaminophen 500 milligram tablet
43188|NCT03846102|Drug|Morphine|Morphine 1 mg/ml solution for infusion.
43189|NCT03846102|Procedure|Fascia Iliaca Compartment Block with Levobupivacaine|Ultrasound guided Fascia Iliaca Compartment Block with levobupivacaine placed in the emergency department by an emergency physician.
43190|NCT03846102|Procedure|Fascia Iliaca Compartment Block with placebo|Ultrasound guided Fascia Iliaca Compartment Block with placebo placed in the emergency department by an emergency physician.
43191|NCT03846089|Procedure|Graft reperfusion|antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
43192|NCT03846076|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
43193|NCT03846063|Other|Home-based rehabilitation program|The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
43194|NCT03846050|Behavioral|BAC feedback/warning|Participants will receive a warning when their BAC reaches a set limit. The cutpoint for this warning is not disclosed but is well below the legal limit for driving. Warning will notify them that their results indicate it is not safe for them to drive.
43195|NCT03846050|Behavioral|No BAC feedback/warning|Participants will receive no information on their current intoxication and will be asked to report less information on their driving decisions.
43196|NCT03846037|Other|Proprioceptive exercise on the vibratory platform|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the vibratory platform
43197|NCT03846037|Other|Proprioceptive exercise on the ground (stable surface)|Unipodal support over the non-dominant lower limb with the contralateral limb in a knee flexion near 90ºon the ground
43198|NCT03846024|Device|RibFx Orthosis Belt|Each patient in the interventional arm will be fitted with a RibFx orthosis belt, which is to be worn during the majority of their day (excluding showering/bathing). It will be encouraged (though not mandatory) to wear at night. Patients in both the control and interventional arm will be expected to participate in pulmonary hygiene / toilet exercises with guided and independent incentive spirometry as per our normal routine and standard of care. There are no other interventions or procedures that the patients will be subjected to for the research trial- other procedures/interventions will be performed only if the clinical care team feels they are indicated.
43199|NCT03846011|Other|24-h urine collection|Collecting 24-h urine prior and after stone removal surgery
43200|NCT03845998|Procedure|use the three-finger method|The size of the laryngeal mask airway was determined by choosing the laryngeal mask that best matched the combined widths of the patient's index, middle and ring fingers.
43201|NCT03845998|Procedure|use the weight-related method|The size of the laryngeal mask airway was determined by the patient's weight.
43202|NCT03845985|Behavioral|Seeking Safety + Signs of Safety toolkit|"Seeking Safety is an existing, present-focused, first-stage manualized treatment for trauma and addiction. Session content engages clients in themes relevant to addiction and trauma, and to help them learn a specific skill to target symptoms of both AUD and PTSD (e.g., Coping with Triggers, Asking for Help).~Signs of Safety is a culturally and linguistically Deaf-accessible toolkit to be used alongside Seeking Safety. The toolkit includes a therapist guide and population-specific client materials (e.g., visual handouts; ASL teaching stories on digital video). It is designed for Deaf/signing clinicians, as well as non-signing clinicians working with ASL interpreters."
43203|NCT03845972|Procedure|SSFTB|Patients who underwent major knee surgery and had already planned to perform subsartorial femoral triangle block (SSFTB) were included in the study. They were measured the outcomes the night before surgery. The saphenous nerve and nerve to vastus medialis were blocked at the subsartorial femoral triangle level by experienced anesthesiologists. After standard monitor, the distal femoral triangle was identified 2 cm proximal to the opening of adductor canal by ultrasound guidance. At this level, The location of nerve to vastus medialis was confirmed by nerve stimulator and it was blocked with 0.5% levobupivacaine 5 ml. Then, 0.5% levobupivacaine 10 ml would be injected perifemoral artery. The outcomes were re-assessed 30 min after block.
43204|NCT03845959|Drug|TD0019 oral capsule|TD0019 are green, hard capsule with size 0, containing yellow herbal powder with special smell of herbal.
43205|NCT03845959|Drug|Placebo oral capsule|Placebo
43206|NCT03845946|Behavioral|angioedema|electronic tracking book
43271|NCT03845283|Behavioral|Online Behavioral Weight Loss Program|A self-guided, online program that helps participants reduce excess calories and gradually increase physical activity.
43208|NCT03845920|Combination Product|tdcs (sham/anodal) + drug (placebo/tyrosine)|"tDCS= A DC Stimulator Plus (neuroConn, Germany) with one 5 cm x 7 cm rubber electrode (anode) and a 10 cm x 10 cm (cathode; reference electrode), encased in saline soaked sponges will be used. The anode will be positioned over the left dlPFC, centered on F3 in the 10e20 electroencephalography (EEG) system, while the cathode on the contralateral supraorbital ridge (Fp2).Current will be delivered at 1.5mA for 20 min plus 30 s fade in/fade out periods.For sham stimulation, the current will be faded in over 30 s, at 1.5mA and then will be switched off.~Drugs= 2.0 g of L-Tyrosine and 2.0 g of the placebo microcrystalline cellulose will be dissolved in 400ml of orange juice as per previously published protocols."
43209|NCT03845907|Device|Gen 1B|Diagnostic Ultrasound and Optoacoustic Imaging
43210|NCT03845907|Device|Gen 1|Diagnostic Ultrasound and Optoacoustic Imaging
43211|NCT03845894|Drug|Liposomal bupivacaine|Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)
43212|NCT03845894|Drug|Bupivacaine with adjuvants|Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
43213|NCT03845881|Drug|Oxycodone|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
43214|NCT03845881|Drug|Placebo Oral Tablet|The primary endpoint will be pain scores, calculated by the Visual Analog Scale. This score will be collected daily during the hospital examination and by phone surveys for two weeks following discharge. Investigators hypothesize that the non-opioid pain regimen will provide equivalent relief as compared to the opioid regimen.
43215|NCT03845868|Other|Dietary and environmental exposure (Observational study)|Not Available
43216|NCT03845855|Other|virtual reality|Virtual reality with a game
43217|NCT03845855|Other|robotic gait|robotic gait therapy
43218|NCT03845842|Behavioral|Volitional help sheet|Participants are asked to choose from a list of strategies for avoiding cannabis use.
43219|NCT03845829|Procedure|In situ laser assisted fenestration|In situ laser assisted fenestration for the left subclavian artery during the procedure of TEVAR for type B aortic dissection
43220|NCT03845816|Behavioral|Self-Compassion Scale (SCS) questionnaire|all included patients with chronic pain will answer the Self-Compassion Scale (SCS) questionnaire
43221|NCT03845803|Other|Reducing sedentary behaviour|Implementing sit/stand workstations at work
43222|NCT03845790|Other|Blood and microdialysis samples|Blood and microdialisys pharmacocinetic samples on one of the two antibiotics prescribed in routine use
43223|NCT03845777|Diagnostic Test|Using Antiseptic solution|Using of iodine including antiseptic solutions. The investigators investigate the urine iodine status of staff before and after the using of antiseptic solution
43224|NCT03845764|Diagnostic Test|Rapid on-site evaluation|Specimens obtained with endoscopic sampling procedures are stained with a rapid method (i.e., Diff Qui) and submitted to on-site cytologic review
43225|NCT03845751|Drug|HIFU hemi-ablation combined with ADT.|Hemi-ablation of the cancer-harbouring prostatic lobe will be carried out using HIFU energy. Short-term 3-month ADT will be administered concomitantly.- Short-term ADT is administered as a single subcutaneous injection of 3-month depot of 22.5 mg of leuprolide acetate (luteinizing hormone-releasing hormone [LHRH] agonist). Additionally, oral antiandrogen bicalutamide 50 mg once per day is given for two weeks, starting one week before the LHRH agonist injection. The ADT protocol starts within 1 month prior to the scheduled HIFU session
43226|NCT03845738|Device|OsseoSpeed EV implant|The investigational product (OsseoSpeed EV implant) is already included in a restoration in the subject at enrollment, thus this study does not involve the installation of any investigational products.
43227|NCT03845712|Drug|MT1621|deoxythymidine/deoxythymidine substrate enhancement therapy
43228|NCT03845699|Device|Diagnostic algorithms that detects/predicts hypoventilation|Produce mild and moderate respiratory depression (hypoventilation) using a controlled intravenous infusion of fentanyl while measuring/recording respiratory rate, tidal volume, body activity, and body position.
43229|NCT03845686|Diagnostic Test|Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)|The goal of this test is to measure brain activity during subacute and chronic post-stroke period using a widely available non-invasive neuroimaging tool - functional Magnetic Resonance Imaging (fMRI). Because fMRI relies in part on cerebral blood flow, which is altered in stroke, measuring longitudinal changes in neural activity with fMRI requires that we control for concomitant changes in blood circulation. To do this, we will employ a novel dual-echo perfusion fMRI sequence, which will allow us to separately estimate neural and vascular contributions to fMRI.
43230|NCT03845673|Dietary Supplement|Psyllium|Psyllium fiber (Konsyl; Konsyl Pharmaceuticals, Easton, Md)
43231|NCT03845673|Dietary Supplement|Bowel recipe|consisted of 1 cup of unprocessed wheat bran, 1 cup of applesauce, and 1/4 cup of prune juice.
43232|NCT03845660|Behavioral|Electronic Alert|"Patients randomized to the intervention will have an alert of their prognosis based on the best available prognostic models for inpatient and 1-year mortality generated with information from their electronic health record, which will consist of a pop-up when the provider accesses a patient record to enter a progress note after the definitions for inclusions into the study have been registered."
43233|NCT03845647|Procedure|contralateral central lymph node dissection|contralateral central lymph node dissection
43234|NCT03845621|Device|Conventional Mouthguard|Use of a conventional custom-made mouthguard while playing water polo
43235|NCT03845621|Device|Occlusal-adjusted Mouthguard|Use of an occlusal-adjusted custom-made mouthguard while playing water polo
43236|NCT03845608|Combination Product|Pulmonary Recruitment Maneuver|Pulmonary recruitment maneuver will be performed manually using positive-pressure ventilation to inflate the lungs and lower the diaphragm, which can increase intraperitoneal pressure mechanically and remove residual carbon dioxide from the peritoneal cavity.recieve100 mg hydrocortisone in 250 ml normal saline at end of surgery and carbon dioxide will be removed by applying gentle abdominal pressure and removing carbon dioxide by passive exsufflation
43304|NCT03845075|Drug|Tesofensine|During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)
43503|NCT03843840|Device|Combined Coaxial Optical Coherence Tomography|Taking images of the retina with two wavelengths
43237|NCT03845595|Device|(LF-rTMS) group|"The (LF-rTMS) (low frequency repetitive transcranial magnetic stimulation) group received 1-hertz (HZ) stimulation at 90% of motor threshold to the hot spot of the primary cerebral cortex, using a 70-mm figure- 8 coil and Magstim Rapid2 stimulator (Magstim Company, USA). Contralesional 1 HZ *rTMS* applied over the primary motor area hot spot at 90% of Active motor threshold . Each rTMS session consisted of 1,200pulses; lasting 20 minutes The optimal site of stimulation on the skull are known as the hot spot . Hot spots were found by searching for loci that triggered maximum visible contraction in the contralateral first dorsal interosseous *FDI* muscle, while the patient is contracting his whole limb as much as possible ."
43238|NCT03845595|Other|Control group|neurodevelopmental technique (NDT) ( including Bobath and Brunnstrom approaches , proprioceptor and exteroceptor stimulation for the weak and inhibition for the hyperactive muscle groups, proprioceptive neuromuscular facilitation (PNF) specific techniques, Approximation and weight bearing, placing technique). Task-oriented training (moving, grasping and releasing bottles ,cups , small toys). Active participation of the whole hemiparetic upper extremity in different motor task training with coordination and Bilateral arm training exercise.
43239|NCT03845582|Drug|ALK-001 oral capsule|Daily administration for 24 months
43240|NCT03845582|Drug|Placebo oral capsule|Daily administration for 24 months
43241|NCT03845569|Other|Dietary protein intake reduction|Following two days of controlled diet at 2.2g/kg/d of dietary protein, intake was reduced to 1.2g/kg/d for five days, and protein metabolism was measured on days 1, 3, and 5.
43242|NCT03845569|Other|Three day Controlled Diet|Three days of a controlled diet providing 2.2g/kg/d of dietary protein with protein metabolism measured on day 3. This was used to model the habitual intake of this cohort.
43243|NCT03845543|Device|Luminor-14 Paclitaxel eluting balloon|Patients will be treated with the Luminor-14 paclitaxel eluting balloon
43244|NCT03845530|Diagnostic Test|Blood Test|Blood test taken and sent for laboratory analysis
43245|NCT03845517|Drug|Placebo|Placebo
43246|NCT03845517|Drug|PF-06700841 15 mg|PF-06700841 15 mg
43247|NCT03845517|Drug|PF-06700841 30 mg|PF-06700841 30 mg
43248|NCT03845517|Drug|PF-06700841 45 mg|PF-06700841 45 mg
43249|NCT03845504|Device|Intermittent Theta Burst Stimulation|Daily open-label sessions delivered to left DLPFC over up to 6 weeks using the MagVenture MagPro rTMS Research System at currently FDA approved parameters (www.magvitatms.com). The TBS parameters will be 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% active motor threshold, as measured from the right first dorsal interosseous muscle by a hand-held 700-mm figure-of-eight coil. rTMS will be applied for 9 min delivering a total of 1800 pulses/session.
43250|NCT03845491|Device|Mechanical Thrombectomy|Treatment of LVO with mechanical thrombectomy
43251|NCT03845478|Behavioral|Control Group (CG)|The control group is subjected to follow a hypocaloric diet and receives information about the benefits of achieving 10,000 steps a day in weight loss and improved body composition.
43252|NCT03845478|Behavioral|Intervention Group (IG)|This group in addition to fulfilling a hypocaloric diet identical to the control group, and receive identical information about physical activity that the control group, it has a system of prescription, monitoring and establishing an objective to achieve 10,000 steps a day.
43253|NCT03845465|Behavioral|Check It|Adolescents will complete a health behavior contract and receive an educational packet at baseline. Adolescents will complete a positive affect interview at baseline. They will receive automated text messages 5 days/week for 8 weeks. Messages will be tailored to include adolescents' responses to the baseline interview, including reminders to engage in gratitude and self-affirmation. Additionally, to induce positive mood they will be texted gift cards codes valued at $5.00. Further, caregivers will be asked to provide weekly positive affirmations to their adolescents, focused on non-diabetes strengths.
43254|NCT03845465|Behavioral|Education|Adolescents will complete a health behavior contract and receive an educational packet with information about diabetes management.
43255|NCT03845439|Other|Lumbar puncture|Lumbar puncture
43256|NCT03845426|Other|Root canal treatment.|Once pulpal necrosis has been diagnosed, root canal treatment will be carried out by the patient's general practitioner. This is an end point for the tooth in the study.
43257|NCT03845413|Behavioral|Control|Schedule an appointment to attend tobacco cessation at Basic Health Unit
43258|NCT03845413|Behavioral|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program|12-home visits by the Community Health Worker + referring to an appointment for the participant to attend the tobacco cessation program
43259|NCT03845387|Drug|KDT-3594|oral administration, dose titration
43260|NCT03845387|Drug|Pramipexole|ER formulation, oral administration, dose titration
43261|NCT03845374|Device|Hyper-CL™ lens|Use of the Hyper-CL™
43262|NCT03845361|Procedure|Radial artery cannulation|Radial artery cannulation
43263|NCT03845348|Other|TD03|Shampoo TD 3 days
43264|NCT03845348|Other|TD07|Shampoo TD 7 days
43265|NCT03845348|Drug|Ketoconazole 2% Shampoo|Ketoconazole 2% Shampoo
43266|NCT03845335|Device|dental implant-supported restoration|During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant
43267|NCT03845322|Drug|Curcumin Pill|Curcumin (turmeric extract), over the counter supplement (1 capsule/three times a day). According to the Company, each capsule contains: 270 mg of pure curcuminoids (curcumin) and 3 mg of black pepper extract. Recommended serving size is 3 capsules per day in total, the patients will receive 810 mg of pure curcumin and 9 mg of black pepper extract (peperine/BioPerine) per day.
43268|NCT03845322|Drug|Placebo pills|The placebo pill is a vegetarian cellulose capsule, with cellulose powder inside. The composition is cellulose and magnesium stearate.
43269|NCT03845309|Behavioral|Self-Care Behavior|Limitations on liquid and sodium intake will be established in accordance with the NYHA functional classification, and patients will be provided with dietary assessments and nutrition advice according to personal characteristics such as age, physical activity level, and comorbidities. Additionally, suggestions on lifestyle changes were provided by referring to the advice for patients with heart failure from the American Heart Association.
43270|NCT03845296|Drug|Rucaparib|Given PO
43272|NCT03845283|Behavioral|Physical Activity Intervention|An program designed to help participants gradually increase their physical activity and maintain an active lifestyle. The program encourages bouts of moderate-to-vigorous physical activity. Participants in this group will receive a Fitbit Versa to help them monitor their physical activity that they will be advised to wear daily. Participants will receive brief (5-10 minute) lessons weekly for the first 3 months and monthly for the last 3 months.
43273|NCT03845283|Behavioral|Bite Counter|Participants will receive a Bite Counter device to help them monitor and reduce their within-meal consumption. Participants will be asked to wear the device daily.
43274|NCT03845283|Behavioral|Virtual Reality|This program allows participants to practice behavioral weight loss skills using a virtual reality system compatible with their home device. This program helps patients practice these skills in the following artificial settings: at home, at work, at the gym, and at a party. Each participant will be asked to play through each scene at least once during their participation, though they are encouraged to use the program regularly.
43275|NCT03845283|Behavioral|Virtual Meetings|Participants will attend virtual meetings using their own device. Each virtual meeting focuses on a specific topic that will help patients lose weight. Participants are asked to virtually attend at least 6 meetings during their participation. There is no limit to how many they can attend. The meeting topics will rotate and repeat on a schedule.
43276|NCT03845270|Drug|pertuzumab + trastuzumab + docetaxel|Cycle 1 : D1 : pertuzumab 840 mg, D2 : trastuzumab 8 mg/kg + docetaxel 75 mg/m² Subsequent cycle : D1 : pertuzumab 420 mg + trastuzumab 6 mg/kg + docetaxel 75 mg/m²
43277|NCT03845257|Diagnostic Test|Blood sampling, FeNO, bronchoalveolar lavage, bronchoscopic tissue sampling|Blood sampling (eosinophil count; eosinophilia is defined as >300/µl (or >150/µl during oral glucocorticosteroid treatment); FeNO: Measurement of fractional nitric oxide (NO) concentration in exhaled breath; Bronchoscopy: BAL: total leukocyte counts and leukocyte differential counts including eosinophils, PSB sampling: eosinophil count/100 cells, endobrochial biopsy: tissue eosinophil count/100 cells.
43278|NCT03845244|Device|Flow reduction first|-10L/min q 1hr
43279|NCT03845244|Device|FiO2 reduction first|- 0.1 q 1hr
43280|NCT03845244|Device|Simultaneous (flow and FiO2) reduction|-10L/min and -0.1 q 1hr
43281|NCT03845231|Biological|Flucelvax|Cohort 1 will receive IM quadrivalent IIV (Flucelvax ) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).
43282|NCT03845231|Other|Human Challenge virus|A dose of 10 to the 7th power 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
43283|NCT03845205|Behavioral|Integrated AUD Treatment|IAT will include computer-delivered BI in the hospital, nurse-delivered alcohol monitoring counseling at each outpatient LT follow-up visit, and at-home participation in web-based, 7-session CBT4CBT, supplemented by tailored text messages.
43284|NCT03845192|Device|ORI measurement by Radical 97|"ORI measurement is done from the beginning of the induction of anaesthesia until the end of the induction of anaesthesia or until the end of the stay in the operating theatre. The measurement to ORI is done by the Radical-97 device by Masimo®."
43285|NCT03845179|Other|Placebo|Saline infusion
43286|NCT03845179|Other|GIP receptor antagonist|Used for infusion on study days
43287|NCT03845179|Drug|DPP-4 inhibitor|Oral administration of DPP-4 inhibitor in active treatment period
43288|NCT03845179|Other|Placebo tablet|Oral administration of placebo tablet in placebo treatment period
43289|NCT03845166|Drug|XL092|oral doses of XL092
43290|NCT03845153|Drug|Metformin Retard 850 mg|tablet
43291|NCT03845153|Other|Placebo|placebo tablet
43292|NCT03845140|Drug|L-PZQ ODT|Participants will receive single oral dose of L-PZQ ODT 50 mg/Kg on Day 1.
43293|NCT03845140|Drug|Biltricide®|Participants will receive single oral dose of Biltricide® 40 mg/kg crushed tablet on Day 1.
43294|NCT03845140|Drug|L-PZQ ODT|Participant will receive single oral dose of L-PZQ ODT 60 mg/kg as decided by the IDMC.
43295|NCT03845127|Device|Revivent TC Ventricular Enhancement System|Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.
43296|NCT03845127|Drug|GDMT|Guideline Directed Medical Therapy
43297|NCT03845114|Other|Continous exercise|60-minute continuous exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
43298|NCT03845114|Other|Interval exercise|Participants will perform a 60-minute interval exercise on the ergocycle at 60% of VO2 peak (moderate intensity).
43299|NCT03845114|Other|Reduction of basal insulin by 40%|Participant's insulin basal rate will be reduced by 40% 1 hour before exercise onset.
43300|NCT03845114|Other|Reduction of basal insulin by 80%|Participant's insulin basal rate will be reduced by 80% 1 hour before exercise onset.
43301|NCT03845101|Behavioral|CBT augmented with VR|The patients receiving the in VR exposure will be immersed using an Oculus Go head-mounted display enabling viewing of 360° live recorded VR environments. Five exposure scenarios have been developed based on general themes of the LSAS, patient feedback and clinical experience from a therapist panel. The five scenarios are as follows: 1) standing in line in a supermarket; 2) attending a party; 3) attending a formal meeting and giving a presentation; 4) small talking/debating in a canteen; and 5) entering an auditorium. Each scenario has four to six scenes of increasing difficulty as well as a neutral scene developed to familiarize patients with the VR setting and deescalating the anxiety response. The order of the scenarios viewed in these five sessions will be chosen by therapists based on the needs of the group. The last two VR exposure sessions are devoted to individual work with one or two previously explored virtual environments closest to the patient's difficulties.
43302|NCT03845101|Behavioral|CBT in vivo|The therapeutic intervention is manual-based cognitive behavioral group therapy (CBT) adapted from the approach of Turk, C., L., Heimberg, R.G. & Magee, L. (2008). The treatment will consist of a total of 14 weekly two-hour group sessions performed in accordance with the manual to ensure a uniform and equal treatment for every patient throughout the study. Every session will be led by two trained clinical psychologists with practical experience in CBT and in vivo exposure.
43303|NCT03845088|Procedure|temporomandibular jont reconstruction with costochondral transplantation|temporomandibular jont reconstruction with costochondral transplantation guided by virtual mandibular position
43305|NCT03845075|Drug|Placebo|During Part 1 subjects will be randomized to matching placebo treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol
43306|NCT03845049|Other|Inclusion examinations|Pregnancy test, Visual acuity, ocular pressure, color retinophotography, OCT-SD (the Heidelberg SDOCT Spectralis, or the Cirrus HD-OCT, model 5000, Zeiss), OCT-angiography and fluorescein angiography and wide-field angiogram
43307|NCT03845049|Drug|Aflibercept Injection [Eylea]|Intravitreal injection of aflibercept at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
43308|NCT03845049|Drug|SHAM injection|Intravitreal injection of SHAM at inclusion, M1, M2, M3 and M4. An additional injection may be planned for M5, on the decision of the clinician and on clinical arguments only.
43309|NCT03845049|Other|Examinations during study (every month)|visual acuity, ocular pressure, OCT-SD, OCT-angiography and ocular fundus and a pregnancy test at M6
43310|NCT03845036|Behavioral|DASH Diet plus Home-Based Exercise|The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
43311|NCT03845036|Behavioral|Home-Based Exercise|The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
43312|NCT03845023|Drug|AD036 Dose 1|AD036 Dose 1 oral capsule administered before sleep
43313|NCT03845023|Drug|AD036 Dose 2|AD036 Dose 2 oral capsule administered before sleep
43314|NCT03845023|Drug|AD036 Dose 3|AD036 Dose 3 oral capsule administered before sleep
43315|NCT03845023|Drug|Placebo|Placebo oral capsule administered before sleep
43316|NCT03845010|Drug|Sotalol|Patients will be titrated to the maximal tolerated dose of sotalol with a targeted dose of 80 thrice daily (TID)
43317|NCT03845010|Drug|Flecainide and verapamil|Patients will receive maximal tolerated dose of flecainide and verapamil with titration to a maximal dose of 200 mg of flecainide and 240 mg of verapamil per day
43318|NCT03845010|Procedure|Catheter ablation|Patients will undergo VPB/VT ablation using a percutaneous transfemoral approach according to standard clinical routine
43319|NCT03844997|Drug|Palcociclib|Palbociclib is an investigational (experimental) drug that works to induce early G1 arrest by inhibiting CDK4/6, which are two types of CDKs that are overexpressed in AML cell cancer lines. Palbociclib is experimental because it is not approved by the Food and Drug Administration (FDA).
43320|NCT03844997|Drug|CPX-351|CPX-351 (daunorubicin and cytarabine) liposome for injection is a combination of daunorubicin and cytarabine in a 1:5 molar ratio encapsulated in liposomes for intravenous administration. CPX-351 is an investigational (experimental) drug that works as formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. CPX-351 is experimental because it is not approved by the Food and Drug Administration (FDA).
43321|NCT03844984|Drug|ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg.
43322|NCT03844984|Drug|Midazolam|This group will receive midazolam 0.05 mg/Kg
43323|NCT03844984|Drug|Normal saline|This group will receive normal saline 10 mL
43324|NCT03844984|Drug|ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.
43325|NCT03844984|Drug|Lidocaine|This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.
43326|NCT03844971|Procedure|Computer assisted arthrocentesis of|Under general anesthesia : patients specific preoperative prefabricated surgical guide will be used intraoperative for arthrocentesis of temporomandibular joint for patients with anterior disc displacement with reduction
43327|NCT03844958|Other|Red Furu|"50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day"
43328|NCT03844958|Other|Tofu|"50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day"
43329|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.01%|Topical sterile ophthalmic solution
43330|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
43331|NCT03844945|Drug|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
43332|NCT03844945|Other|Netarsudil Ophthalmic Solution Placebo|Topical sterile ophthalmic solution
43333|NCT03844932|Drug|ST-0529|ST-0529 utilizes SmPill® technology to encapsulate the otherwise insoluble cyclosporine in a presolubilized, lipid-based formulation.
43334|NCT03844919|Device|rTMS + CBIT|"Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total).~The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10."
43335|NCT03844919|Behavioral|Sham rTMS + CBIT|Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.
43336|NCT03844906|Drug|SAGE-718|SAGE-718 in combination with Ketamine
43337|NCT03844906|Drug|Placebo|Placebo in combination with Ketamine
43338|NCT03844893|Procedure|Mini bal|Mini-BAL is a minimally invasive technique frequently used in the investigator's local intensive care units (ICUs) to obtain alveolar fluid samples from mechanically ventilated patients. This is typically done for microbial analysis.
43339|NCT03844880|Behavioral|Emotional Awareness and Expression Therapy|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
43340|NCT03844880|Behavioral|Cognitive Behavior Therapy|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
43368|NCT03844711|Other|Inspiratory muscle training|The training will start with a minimum load of 30% and will be progressed until reaching 60% of the PImax. Inspiratory muscle training will start with a minimum load of 30% and progress to 60% of the MIP. The patients will perform daily training, being two sets of 30 breaths, one in the morning and one in the afternoon.
43341|NCT03844867|Dietary Supplement|Filippo Cea and Carmel|"Subjects will be given a subjective organoleptic assessment of both the almonds (Filippo Cea and Carmel) administered blindly and randomly.~Motility test: Each subject will be subjected to gastrointestinal motility study according to international guidelines, i.e. he will be evaluated in 3 different days. The test will be made in response to test-meal ('NutriDrink') or Filippo Cea almonds (12 gr. fat=24 gr. almonds) or Carmel almonds (12 gr. fat = 24 gr. almonds)."
43342|NCT03844854|Other|Stabilization occlusal splint and manual therapy|Providing stabilization occlusal splint and manual therapy
43343|NCT03844841|Drug|Propofol|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced via the continuous infusion of propofol using a target-controlled infusion (TCI) pump. The effect-site propofol concentration will be initially set to 1.5 µg/ml, unless the patient is already sedated by fentanyl. Subsequently, an effect-site propofol concentration of 1 µg/ml will be chosen adjusted stepwise (using steps of 0.3 µg/ml) to reach a target score of 2-3 on the MOAA/S scale. In case of pain fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
43344|NCT03844841|Drug|Dexmedetomidine|At minimum 5 minutes before start of sedation for atrial fibrillation ablation a bolus of fentanyl (20-50 µg) will be administered. Thereafter, sedation is induced with a loading dose of dexmedetomidine (0.8 µg/kg) over 10 minutes. The maintenance dexmedetomidine dose is adjusted to the appropriate sedation criteria for CA (0.4 µg/kg/h) and for a target score of 2-3 on the MOAA/S scale. In case of pain, additional fentanyl can be administered bolus-wise (10-30 µg) at the cardiologists discretion.
43345|NCT03844828|Device|IOL implantation experimental|Mono- or bilateral implantation of trifocal toric intraocular lenses POD FT. If both eyes of the same patient qualify for the implantation of a trifocal toric lens, a bilateral implantation will be performed. If only one eye qualifies for a trifocal toric lens, the contralateral eye will be implanted with the spherical trifocal IOL POD F (both lenses: (PhysIOL, Liège, Belgium).
43346|NCT03844815|Drug|Decitabine|"Decitabine will be administered intravenously at a dose of 20mg per day for 10 days during Cycle 1 (28 day cycle)~Decitabine will be administered intravenously at a dose of 20mg per day for 10 days of Cycle 2 (28 day cycle).~Decitabine will be administered intravenously at a dose of 20mg per day for 5 days of each 28 day maintenance cycle"
43347|NCT03844815|Drug|Venetoclax|Venetoclax administered orally on days 1-21 of cycle 1, cycle 2 and maintenance (28 day cycles). Dose levels will be assigned at time of enrollment anywhere from 100mg-400mg. Dose escalation will follow the 3+3 study design.
43348|NCT03844802|Other|Dry needling and exercise|"Dry needling in those assessed muscles (anterior scalene, sternocleidomastoid, levator scapulae, splenius of the head, inferior fibers of the trapezius muscle and postero-inferior serratus) that present active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for dry needling will be the so-called rapid entry and exit technique described by Hong, and evoking between 4 and 6 local twitch responses.~Patients will also perform therapeutic neck exercises at home."
43349|NCT03844802|Other|Sham dry needling and exercise|"Patients in this group will undergo sham-dry needling. For that purpose, sham dry needling will be carried out in those assessed muscles (anterior scalene, sternocleidomastoid, levator scapulae, splenius of the head, inferior fibers of the trapezius muscle and postero-inferior serratus) that present active or latent myofascial trigger points, according to the diagnostic procedures described by Travell and Simons. The intervention technique chosen for these participants will be to insert the needle in a location in the same muscle, but far away (at least 1-1.5 cm) from the location of the myofascial trigger point. Likewise, the needle will be inserted without evoking local twitch responses.~at a distance of 1,5 cm from the active or latent trigger point. Patients will also perform therapeutic neck exercises."
43350|NCT03844789|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Eligible participants will be use the t:slim X2 with Control-IQ Technology & Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology & Dexcom G6 CGM
43351|NCT03844789|Device|Standard of Care|Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.
43352|NCT03844776|Drug|Co-Amoxiclav|amoxicillin + clavulanic acid orally
43353|NCT03844776|Drug|Paracetamol|paracetamol orally
43354|NCT03844776|Drug|Chlorhexidine mouthwash|0.2% chlorhexidine mouthwash
43355|NCT03844776|Drug|Normal saline|0.9% normal saline irrigation
43356|NCT03844776|Drug|Amoxicillin 500 Mg|Amoxicillin 500 orally
43357|NCT03844776|Drug|Metronidazole|metronidazole 500 mg orally
43358|NCT03844763|Drug|Avelumab|Avelumab: 10 mg/kg every 2 weeks, untill PD or major toxicity
43359|NCT03844763|Drug|CTX|CTX: 50 mg Daily untill PD or major toxicity
43360|NCT03844763|Radiation|RT|RT: 8 Gy single shot day 8
43361|NCT03844750|Procedure|Hepatectomy|Undergo liver resection.
43362|NCT03844750|Biological|Pembrolizumab|Given IV
43363|NCT03844750|Drug|FOLFOX regimen|Given IV
43364|NCT03844737|Device|VisuXL®|Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
43365|NCT03844724|Device|ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
43366|NCT03844724|Device|Peripheral Balloon Dilatation Catheter|Digital subtraction angiography（DSA）
43367|NCT03844711|Other|Electrical diaphragmatic stimulation|"Stage I: In the first day (group 1) the parameters will be with 30 Hz frequency and the second day (group 2) will be with 80 Hz, with one-day interval between interventions. The TEDS will be applied with symmetrical biphasic pulsed current, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue.~Stage II: The TEDS will be applied with symmetrical biphasic pulsed current, the parameters will be with 30 Hz frequency, pulse width 0.4 ms, rise time of 1 second (s), 1s lift, 2 s descent, maintaining respiratory rate of 15 rpm, intensity required to obtain visible muscle contraction, for 20 minutes or until muscle fatigue."
43595|NCT03843112|Drug|Vivag Plus|Contains two lactobacilli strains; l. gasseri and l. rhamnosus
43369|NCT03844711|Other|Conventional physiotherapy|It consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resistance exercises.
43370|NCT03844685|Drug|Promensil|1 tablet (80 mg) /day of MCE-11 (Promensil) taken orally for 24 months
43371|NCT03844685|Drug|Placebo Oral Tablet|Placebo tablet (80 mg) (without active principle) given once a day for 24 months
43372|NCT03844672|Behavioral|Low Power|Participants will receive a low power e-cigarette to use for 3 weeks
43373|NCT03844672|Behavioral|High Power|Participants will receive a high power e-cigarette to use for 3 weeks
43374|NCT03844672|Behavioral|Low Concentration|Participants will receive a low concentration e-liquid to use for 3 weeks
43375|NCT03844672|Behavioral|High Concentration|Participants will receive a high concentration e-liquid to use for 3 weeks
43376|NCT03844659|Other|"Song Weightless by Marconi Union"|"Patients will be randomized to the intervention group (the song Weightless by Marconi Union will be playing) during subjects labor epidural placement. The intervention in this study is solely the addition of music."
43377|NCT03844659|Other|No Song|No song will be played during subjects labor epidural placement.
43378|NCT03844646|Device|CGM|Intermittent use of a continuous glucose monitor (CGM)
43379|NCT03844646|Other|Dietitian|Monthly meetings with a dietitian
43380|NCT03844633|Drug|Depo-Provera Injectable Product|Depo-Provera Injectable Product -- Shot administered within 48 hours of childbirth
43381|NCT03844633|Drug|Placebos|Placebos -- Shot administered within 48 hours of childbirth
43382|NCT03844620|Other|Best Practice|Receive SOC
43383|NCT03844620|Other|Laboratory Procedure|Undergo ctDNA testing
43384|NCT03844620|Other|Quality-of-Life Assessment|Ancillary studies
43385|NCT03844620|Other|Questionnaire Administration|Ancillary studies
43386|NCT03844620|Drug|Regorafenib|Given PO
43387|NCT03844620|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
43388|NCT03844607|Device|Active Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
43389|NCT03844607|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning of session).
43390|NCT03844594|Drug|Eptifibatide Injection|Recommendation: first, intravenously or intraductal injection of 135ug / kg (completed in 5 minutes), followed by continuous intravenous infusion of 0.75ug / kg / min for 24 hours.
43391|NCT03844581|Device|interferential current|Treatment was applied using four vacuum electrodes with wet sponge, two of them were put under the patient lumber region on a distance from lumber spinous process by five cm on each side and the other two were applied over the suprapubic region parallel to iliac crest.
43392|NCT03844581|Drug|Propiverine Hydrochloride|propiverine hydrochloride 20 mg/once per day in the morning
43393|NCT03844568|Device|nocturnal nasal continuous positive airway pressure|applying nasal continuous positive airway pressure at 7.5-10cmH2O for at least 4 hours during nighttime
43394|NCT03844555|Drug|Elafibranor|120mg oral single dose
43395|NCT03844542|Device|Therapeutic plasma exchange|Perform therapeutic plasma exchange in patients with sepsis induced multi-organ failure
43396|NCT03844529|Device|Sunmax FULLSGEN with Lidocaine|Subject who voluntarily sign the informed consent form (day -14~1) will be randomly assigned to investigational or control group and have intradermal allergy test. After the injection treatment by randomly choosing the device, every subject would have 6 follow-up visits.
43397|NCT03844516|Other|Peak oxygen uptake test with pacing|Peak oxygen uptake test with paced heart rate
43398|NCT03844516|Other|Peak oxygen uptake test without pacing|Peak oxygen uptake test without paced heart rate
43399|NCT03844503|Dietary Supplement|Cereal Bar no fiber|Cereal Bar no fiber
43400|NCT03844503|Dietary Supplement|Cereal bar with 10 g fiber|Cereal bar with 10 g fiber
43401|NCT03844503|Dietary Supplement|Cereal bar with 20 g fiber|Cereal bar with 20 g fiber
43402|NCT03844490|Other|CESSATION OF CORD PULSE|"In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made."
43403|NCT03844490|Other|CONTROL|In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
43404|NCT03844477|Procedure|single-injection QLB(quadratus lumborum block)|"Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified."
43405|NCT03844477|Procedure|Placebo control|"Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion~Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan~Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified."
43406|NCT03844451|Drug|Liposomal Bupivacaine|At the conclusion of the procedure, liposomal bupivacaine will be administered as a V2 nerve block.
43407|NCT03844451|Drug|Bupivacaine and Epinephrine|At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
43408|NCT03844438|Drug|LPM3480226|The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
43409|NCT03844425|Device|Conventional VFR|Conventional retainers
43410|NCT03844425|Device|VFR from DLP|DLP has better finishing compared to FDM but it is more expensive.
43411|NCT03844425|Device|VFR from FDM|FDM has poorer finishing compared to DLP but it is cheaper.
43412|NCT03844412|Drug|5% lidocaine/5 mg/ml 0.02% estradiol compound cream|Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
43496|NCT03843879|Procedure|Transversus Abdominis Plane Block|Single-injection transversus abdominis plane block with 30 mL of 0.25% Bupivacaine with 1:400,000 epinephrine
43413|NCT03844412|Drug|Nortriptyline|Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
43414|NCT03844412|Drug|Placebo cream|The comparison treatment will be an identical-appearing placebo Moisturel™ cream
43415|NCT03844412|Drug|Placebo pill|The comparison treatment will be an identical-appearing placebo pill
43416|NCT03844399|Device|Ablation|The medical device will passively record image data during the standard care ablation
43417|NCT03844399|Device|Biopsy|The medical device will passively record image data during the standard care biopsy
43418|NCT03844386|Biological|MVA.tHIVconsv3|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
43419|NCT03844386|Biological|MVA.tHIVconsv4|viral-vector, MVA, expressing immunogens derived from conserved yet immunogenic regions of HIV-1
43420|NCT03844386|Other|Placebo|The appropriate amount of Sodium Chloride for Injection USP, 0.9% will be drawn into a syringe.
43421|NCT03844373|Dietary Supplement|STOCKHOLM|STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.
43422|NCT03844360|Drug|Bortezomib|bortezomib was administered follow the doctor's advice.
43423|NCT03844360|Drug|Eltrombopag|eltrombopag was administered follow the doctor's advice.
43424|NCT03844360|Drug|Imatinib|imatinib was administered follow the doctor's advice.
43425|NCT03844360|Drug|dasatinib|dasatinib was administered follow the doctor's advice.
43426|NCT03844360|Drug|Pegaspargase|pegaspargase was administered follow the doctor's advice.
43427|NCT03844360|Drug|Anti-Infective Drugs|anti-infective drugs was administered follow the doctor's advice.
43428|NCT03844347|Behavioral|Stress management sessions|Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
43429|NCT03844334|Device|WEB Aneurysm Embolization System|Subjects aged ≥ 18 years, but ≤ 80 years requiring treatment for single ruptured or unruptured intracranial aneurysms.
43430|NCT03844321|Behavioral|Mindfulness-Based Cognitive Therapy|8 sessions of online mindfulness-based cognitive therapy
43431|NCT03844321|Behavioral|Mindfulness Light|3 sessions of online mindfulness therapy
43432|NCT03844308|Behavioral|Isha Kriya Meditation|Isha Kriya (IK) meditation is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day practice. This regimen was chosen because it excels in simplicity and is a great way to introduce meditation to beginners. It does not incorporate a spiritual or religious focus. It was developed by the Isha Institute of Inner Sciences, a nonprofit foundation located at McMinnville, Tennessee.
43433|NCT03844295|Device|Activated Inspire® Upper Airway Stimulation System|At first, INSPIRE® device will be active a month
43434|NCT03844295|Device|Inactivated Inspire® Upper Airway Stimulation System|"After 15 days wash-out INSPIRE® device will be inactivated for a second period of one month."
43435|NCT03844282|Diagnostic Test|Clinical assessment (SCAT5)|The SCAT5 is a standardized tool for evaluating sports-related concussions designed for use by physicians and licensed healthcare professionals in patients aged 13 years and above. It is a ten minute paper-based assessment which includes immediate and office/off-field assessments. SCAT5 incorporates the Maddocks' questions, Glasgow Coma Scale (GCS), cervical spine assessment and symptom evaluation, in addition to cognitive and neurological screening.
43436|NCT03844282|Diagnostic Test|ImPACT|ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing) is a neurocognitive assessment administered online in a controlled environment. ImPACT has two components: baseline testing and post-injury testing, both of which are used to determine if a patient can safely return to sporting activity post-concussion.
43437|NCT03844282|Behavioral|CANTAB|"Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks. These tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.~The CANTAB touchscreen battery (www.camcog.com) will be utilised to perform neuropsychological assessments within RESCUE-RACER, whose study-specific protocol may include assessments of: Spatial Working Memory (working memory and strategy), Reaction Time (processing and psychomotor speed), Paired Associated Learning and the Multi-Tasking Test."
43438|NCT03844282|Diagnostic Test|I-PAS|I-PAS™ is a portable, head-mounted, neural functional assessment tool. With its integrated clinical eye tracking and digital display, the FDA has cleared (K171884) fourteen tests and an unmatched list of variables for clinical use for a variety of conditions. This utility of this device will be investigated for motorsport-related concussion.
43439|NCT03844282|Biological|Saliva sample|Micro RNA's (MiRNA's) are easily measured in saliva and have proven to have both diagnostic and prognostic use in sports-related concussion across the adolescent and adult populations, with levels persisting for some weeks after the concussive event. RESCUE-RACER will collect saliva samples for analysis of biomarkers of concussion, which may include MiRNA and other neuronal markers of injury.
43440|NCT03844282|Other|fMRI|RESCUE-RACER participants will be invited to complete a functional MRI scan, whose 90-minute protocol may include: multi-parametric mapping (MPM), susceptibility weighted imaging (SWI), diffusion weighted imaging (DWI) and functional MRI (fMRI) with blood oxygenation-level dependent contrast (BOLD), ideally completed at 7T (Tesla).
43497|NCT03843879|Drug|Intravenous Lidocaine|Continuous intravenous lidocaine infusion
43498|NCT03843866|Other|4-0 Monocryl|sutures and steri-strips
43499|NCT03843866|Other|Adhesive Glue|Adhesive Glue
43500|NCT03843853|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1
43501|NCT03843853|Drug|S-1|S-1 (20mg、25mg), capsule, 40~60mg, Bid,p.o, d1~14
43441|NCT03844269|Device|AKL-T01|"AKL-T01 digital treatment is a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty based on the user's ability. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task. Performance on these tasks are assessed in isolation and when performed together to calculate a performance index for each individual user. A personalized multitask treatment regimen is automatically configured and delivered to the user and is optimized adaptively to increase multitask performance. As players proceed through the treatment periodic recalibration occurs to maintain an optimal difficulty level."
43442|NCT03844256|Combination Product|nivolumab 480mg|Immuno-chemoradiotherapy
43443|NCT03844256|Combination Product|nivolumab 3mg/kg, ipilimumab 1mg/kg|Immuno-chemoradiotherapy
43444|NCT03844256|Combination Product|nivolumab 1mg/kg, ipilimumab 3mg/kg|Immuno-chemoradiotherapy
43445|NCT03844243|Drug|NGF|Intramuscular injection
43446|NCT03844243|Drug|Isotonic-saline|Intramuscular injection
43447|NCT03844230|Other|Control - Inhibition|Taste and spit up water 10 minutes before drinking a glucose load
43448|NCT03844230|Other|Experimental I- Inhibition|Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole
43449|NCT03844230|Other|Experimental II- Inhibition|Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole
43450|NCT03844230|Other|Control- Stimulation|Taste and spit up water 10 minutes before drinking a glucose load
43451|NCT03844230|Other|Experimental I- Stimulation|Taste and spit up sucralose 10 minutes before drinking a glucose load
43452|NCT03844230|Other|Experimental II- Stimulation|Drink sucralose 10 minutes before drinking a glucose load
43453|NCT03844230|Other|Sensory Evaluation|Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
43454|NCT03844217|Drug|Macimorelin 0.5mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.5mg/kg body weight Macimorelin
43455|NCT03844217|Drug|Macimorelin 0.75mg/kg body weight|oral Macimorelin stimulation test with the dose of 0.75mg/kg body weight Macimorelin
43456|NCT03844204|Device|Thermal servo-controlled system|All patients will be positioned under the infant warmer. In the treatment group, a probe positioned on the skin of the neonate will guide the thermal exposure in a servo-controlled modality. In the control group, thermal exposure will be determined manually by setting the power of the heater at the maximum output.
43457|NCT03844191|Drug|RUC-4 Compound|single subcutaneous administration of RUC-4
43458|NCT03844178|Procedure|The option for compensation of Pupil centroid shift was ON|The option for compensation of Pupil centroid shift was ON
43459|NCT03844178|Procedure|The option for compensation of Pupil centroid shift was OFF|The option for compensation of Pupil centroid shift was OFF
43460|NCT03844178|Drug|installation of Tetracaine 1%|installation of Tetracaine 1%
43461|NCT03844178|Procedure|Photorefractive keratectomy (PRK)|periorbital skin will be prepared with povidone iodine 5%. Iris registration will be performed in all eyes before epithelial removal. Ethylalcohol 20.0% into a 9.0 mm well for 20 seconds will be applied on the central cornea, and then the epithelium of the central 9.0 mm area will be removed by hockey knife. Excimer laser ablation will be performed by Wavelight Allegretto EX500 (Alcon, Fort Worth, TX, USA)
43462|NCT03844165|Behavioral|Diet change (red rice)|This interventions specifically aims to reduce liver inflammation, by replacing white rice in the diet with equal amounts of red rice and lentils. This will also enable for the research team to tests specific scientific hypotheses regarding the effects of diet on insulin resistance, liver pathology and the gut microbiome in NAFLD.
43463|NCT03844165|Behavioral|Yoga|All 84 study participants take part in the yoga intervention. This is an intensive programme organized and delivered by experienced practitioners under direction of Dr Leena Mohan at the Holistic Health and Research Institute. This will evaluate whether physical activity alone improves metabolic health of the liver.
43464|NCT03844152|Dietary Supplement|Fermented whey concentrate|The investigated dietary supplement is a form of lacto-fermented whey concentrate (FWC), which has been deproteinised and then diluted (1/20) in sugar-free flavoured water to improve palatability. The main solute within the lacto-fermented whey is L-(+)-lactic acid (7%), produced through bacterial fermentation of the milk sugar lactose. The research team will provide non-descriptive bottles of drink to all volunteers. The flavour of the FWC will be masked by the flavoured water. In order to assess compliance and minimize an initial treatment effect, a 14 day run-in period during which only flavoured water is to be consumed will be completed by all volunteers. At the same time, this period will act as a wash-out, as volunteers will be asked to abstain from the use of any dietary supplements during this period and the rest of the study. The daily energy content of the FWC is 4kcal.
43465|NCT03844139|Device|Feeding pump and glycerin syringe|The continuous group use feeding pump and the intermittent group use syring to give dysphagia patients after stroke prescribed nutrition through nasogastric tube.
43466|NCT03844126|Other|Transition classes|90 minutes spent with patients and their families (separately) to review the changes and challenges associated with healthcare transition and help alleviate some of the barriers traditionally associated with this process.
43467|NCT03844113|Drug|Carnosine|Each participant will be given a daily oral dose 2 g of carnosine for 6 months
43468|NCT03844113|Drug|Placebo|Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
43469|NCT03844100|Drug|efficacy and safety of CNU® Capsule|All subjects take 250mg CNU capsule orally 1 capsule per time, 2 times a day (morning, evening / at meal or after meal) for 12 weeks.
43470|NCT03844087|Device|Multiplanar neuromuscular training|See arm description
43471|NCT03844074|Biological|bevacizumab|1.25 mg, intravitreal injection
43472|NCT03844074|Biological|ranibizumab|0.5mg, intravitreal injection
43473|NCT03844061|Drug|Belimumab|Belimumab decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. The background above provides a robust rationale for the investigation of belimumab in the treatment of dcSSc.
43502|NCT03843853|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg d1
43474|NCT03844061|Drug|Rituximab|Rituxan® (rituximab) is a genetically engineered IgG1 kappa chimeric murine/human monoclonal antibody containing murine light- and heavy-chain variable region sequences and human constant region sequences. The antibody reacts specifically with the CD20 antigen found on the surface of malignant and normal B cells, and established B cell lines. Studies have shown that rituximab binds via its Fc domain to human complement and lyses lymphoid B cell lines by complement dependent cytotoxicity through the induction of apoptosis and via antibody-dependent cell mediated cytotoxicity. Rituximab is approved by the U.S. Food and Drug Administration (FDA) to treat some types of cancer, rheumatoid arthritis and vasculitis.
43475|NCT03844061|Other|Placebo Subcutaneous Injection|Normal Saline
43476|NCT03844061|Other|Placebo Infusion|Normal Saline
43477|NCT03844061|Drug|MMF|MMF belongs to a group of medicines known as immunosuppressive agents. It is used with other medicines to lower the body's natural immunity.
43478|NCT03844048|Drug|Venetoclax|oral; film-coated tablets or tablets for oral suspension
43479|NCT03844035|Diagnostic Test|Periimplant crevicular fluid (PICF) collection|Prior to PICF sampling, supragingival plaque was removed by sterile curets and, after air drying, the surfaces were isolated by cotton rolls. Filter paper strips (periopaper, proflow Inc., Amityville, New York, USA) were placed in sulcus for 30s. Care was taken not to avoid mechanical trauma and strips contaminated with blood or saliva were discarded. The absorbed PICF volume was estimated by a calibrated instrument (periotron 8000, proflow Inc., Amityville, NY, USA). Then, the strips were sealed into sterile tubes before freezing at -80⁰C. The readings were converted to an actual volume (µl) by reference to the standard curve.
43481|NCT03844009|Other|Computer integrated debriefing|At the end of each computer-based simulation, the participant had a computer integrated debriefing of his performance during the neonatal resuscitation simulation and a debriefing based on an auto-evaluation of his non-technical skills.
43482|NCT03843996|Device|Treatment - Stratamed|To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
43483|NCT03843983|Device|Lipiflow® application|"Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment."
43484|NCT03843970|Drug|Levobupivacaine Hydrochloride 0.5%|The solution is called L solution, which contains a combination of 0.5% isobaric levobupivacaine with fentanyl. Injectable Solution.
43485|NCT03843970|Drug|Isobaric bupivacaine 0.5%|The solution is called B solution, which contains a combination of 0.5% isobaric bupivacaine with fentanyl. Injectable Solution.
43486|NCT03843957|Other|mPATH-CRC|mPATH-CRC is a self-administered iPad program that patients use in primary care clinics to help them receive CRC screening. The mPATH-CRC program also includes health questions to assist clinics with patient check-in, thereby incentivizing its use for all patients.
43487|NCT03843957|Other|"high touch Implementation strategy"|"The high touch strategy consists of pre-implementation activities, training, and ongoing support.~Pre-Implementation Activities~Clinic champion identified.~Study team meeting with clinic champion~Implementation adaptations as needed for clinic flow~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~Phone/email technical support, as needed.~Scheduled phone-calls with clinic champion to review QA data and explore potential barriers.~Implementation adaptations as needed for clinic flow~Goal-triggered follow-up on-site trainings~Additional on-site trainings as requested.~Months 7 - 12~• Phone/email technical support, as needed"
43488|NCT03843957|Other|"low touch Implementation Strategy"|"Clinics randomized to receive the low touch implementation strategy will receive:~Pre-Implementation Activities~• N/A~Implementation Kick-Off (Day 1)~• On-site training with key clinic personnel~Months 1 - 6~• Phone/email technical support, as needed.~Months 7 - 12~• Phone/email technical support, as needed"
43489|NCT03843944|Drug|Safinamide|Overnight switch from rasagiline 1 mg OD to safinamide 50 mg OD
43490|NCT03843931|Behavioral|GLA:D|The GLA:D exercise and education program is an 8-week treatment program delivered by GLA:D certified physiotherapists. It consists of 2 educational sessions over 2 weeks (1/week in week 1 and 2) and 12 exercise sessions over 6 weeks (2/week in weeks 2 thru 8) The 2 educational sessions provide knowledge of OA, treatment and self-management, with a special focus on exercise and its benefits. The exercise part lasts for 6 weeks with 2 exercise sessions per week of approximately 1 hour (12 sessions total). The exercise sessions are group based at a facility supervised by a GLA:D certified physiotherapist. The goal is the obtain muscle control and stability in situations resembling daily life and/or more strenuous activities.
43491|NCT03843931|Drug|Intra-articular saline injection|"Four [4] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible."
43492|NCT03843918|Drug|LAE001|LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
43493|NCT03843918|Drug|Placebo|Placebo BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The placebo dose adopted for the phase II study will be same as LAE001 (RP2D dose).
43494|NCT03843905|Other|no intervention|The aim of this translational research project is to study the impact of these new prognostic tools on surgical and oncologic results in a prospective cohort of patients who underwent CRC surgery at the Digestive Surgery Department of the University Hospital of Clermont-Ferrand (France)
43495|NCT03843892|Drug|OFEV|twice daily
43596|NCT03843112|Drug|Placebo - Cap|Vaginal supplements
43504|NCT03843827|Device|Laryngeal Mask Airway|The aim of this study is to compare between cLMA and I gel regarding insertion success rate, the time of insertion, leaking pressure, assessment of position by fiber optic, hemodynamic, Spo2 for each device during insertion and maintenance of general anaesthesia and postoperative complications in obese patients
43505|NCT03843827|Device|I gel Airway|I gel is a new type of laryngeal mask and doesn't have an inflatable cuff. Because of its thermoplastic elastomer structure, it exactly adapts to the supraglottic tissue by binding with body temperature, thus minimising air leakage
43506|NCT03843814|Procedure|APT MRI|
43507|NCT03843801|Device|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of transmural anterior-posterior sutures in the stomach in order to achieve a gastric remodelling. Patient will be kept overnight after the procedure.
43508|NCT03843788|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Starting 8 hours after cesarean section, the TENS unit will be applied with charges above and below the incision. The device will be set to high frequency (>75 Hz) for pain relief. Intensity of stimulation will be set to patient threshold using the forearm as a guide. Stimulation will be turned on titrated to the level which is felt but not painful for the patient. It will remain on until the patient is discharged, to be removed for toilet and showering at the patient's discretion. Once the TENS unit is applied and turned on, the patient will not have to do anything else to maintain the therapy.
43509|NCT03843775|Drug|Binimetinib|Dose level 1 binimetinib 45 mg PO BID. Dose level 2 binimetinib 60 mg oral BID 21 days on/7 days off.
43510|NCT03843775|Drug|Encorafenib|encorafenib 450 mg oral QD 21 days on/ 7 days off
43511|NCT03843749|Drug|Pyrotinib|Pyrotinib in Combination With Trastuzumab
43512|NCT03843736|Behavioral|Lifestyle intervention|"Balance the diet;~Limit high-calorie and high-fat food intake, reduce eating out, and establish regular eating habits;~Monitor body weight, avoid sedentary, get more sun and regular activities;~Mental health regulation."
43513|NCT03843736|Drug|Probiotic Agent|Patients have to take a probiotic powder (product name: Tangwen Tai, lactobacillus plantarum LP45 + Lactobacillus acidophilus La28 + Bifidobacterium lactobacillus BAL531) twice a day for three months.
43514|NCT03843736|Drug|Oral contraceptive|The patient needs to take drospirenone ethinyl estradiol tablets (trade name: Yousi Yue) 1 tablet daily for 3 months.
43515|NCT03843723|Other|Pre-flight evaluation|All the participants receive the interventions as part of their routine medical care during their annual visit for CF follow-up. Oxygen saturation are measured by pulse oximetry. Exercise testing is performed by 6MWT and CPET. Pre-flight evaluation is performed by HAST.
43516|NCT03843710|Drug|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
43517|NCT03843697|Device|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (>18) male and female with inflammatory bowel disease (chorn's disease, ulcerative colitis), unresponsive to biological drugs, will participate in a 4-week observation period during which no change in drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window.
43518|NCT03843684|Device|3D-printed foot orthoses|3D printed foot orthoses with arch support
43519|NCT03843684|Device|5 degrees lateral wedge insoles|Insoles with a lateral inclination set at 5 degrees
43520|NCT03843671|Drug|Hyperbaric oxygen|Hyperbaric oxygen therapy
43521|NCT03843671|Device|Hyperbaric chamber|Hyperbaric chamber
43522|NCT03843658|Other|There is no intervention, but a diagnosis.|Cohorts will be determined by the primary rheumatology diagnosis.
43523|NCT03843645|Procedure|general anesthesia|surgical procedure under general anesthesia
43524|NCT03843645|Procedure|regional anesthesia|surgical procedure under regional anesthesia
43525|NCT03843632|Biological|VARIVAX™|All participants will receive one dose subcutaneous (sc) Varicella Virus Vaccine Live on Day 1. Participants 13 years and older will also receive a second dose sc Varicella Virus Vaccine Live on Day 43.
43526|NCT03843606|Other|Modified ketogenic diets|Different diet composition
43527|NCT03843593|Behavioral|Demographics Questionnaire|A brief questionnaire will collect basic demographic information (i.e., age, gender, racial background, ethnicity, employment status, marital status) at time of enrollment.
43528|NCT03843593|Behavioral|Adjuvant Treatment Beliefs Scale10|This brief PRO measure asks patients to indicate the likelihood, using a 5-point Likert type scale (1 [definitely not], 2 [probably not], 3 [maybe], 4 [probably], 5 [definitely]) of six positive (e.g., reduced risk of recurrence, greater chance of being cured) and five negative outcomes (e.g., side effects, health status) of adjuvant treatment.
43529|NCT03843593|Behavioral|Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11|FACT-M is a 51-item patient-self report measure for the assessment of quality of life (QOL) in patients with American Joint Committee on Cancer stages I through IV melanoma.
43530|NCT03843593|Behavioral|Functional Assessment of Chronic Illness Therapy - Treatment Satisfaction - General (FACIT-TS-G)13|FACIT-TS-G is a brief, 8-item self-administered measure designed to assess general treatment satisfaction in patients.
43531|NCT03843593|Behavioral|Decisional Regret14|This is a set of 5 questions examining level of regret for treatment decisions (in this case, decision to pursue adjuvant therapy), with answers scored on a 5-point Likert-type scale (i.e., 1 [Strongly Agree], 2 [Agree], 3 [Neither Agree Nor Disagree], 4 [Disagree], 5 [Strongly Disagree].
43532|NCT03843593|Behavioral|Clinician Preference for Treatment|This is a single item to be completed by Medical Oncologists that will indicate their preference as to whether they prefer that their patient accepts nivolumab therapy.
43533|NCT03843580|Device|optiflow|we use Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (thrive-optiflow) during general anesthesia for suspension laryngoscopy
43534|NCT03843567|Other|Endoscopic characterisation training|"Included in the training material is an overview of Resect and Discard, endoscopic platforms (NBI, BLI and i-Scan), NICE classification, SIMPLE classification, BASIC classification and example still images and videos of both classifications in use. Still images will be used to ensure participants have the best opportunity to observe and learn Kudo Pit Patterns and other polyp features without movement artefact before observing videos, which are more challenging to interpret. The training will last approximately 1 hour."
43535|NCT03843554|Other|Standard of Care Oral Hygiene|Standard of care oral hygiene- weekly oral care visits with soft-bristled toothbrushing.
43536|NCT03843554|Procedure|Oral mucosal deterging and dental prophylaxis|Subjects will receive a professional dental prophylaxis including periodontal surface debridement [a light-touch, gentle form of instrumentation performed with an ultrasonic instrument to promote plaque removal, to facilitate biofilm disruption and endotoxin flushing, but yet with the preservation of the periodontal cementum].
43537|NCT03843541|Drug|N-acetylcysteine (NAC) 600 mg|NAC will be administered twice a day, morning and evening, during treatment period.
43538|NCT03843541|Drug|Ambroxol hydrochloride 30 mg|Ambroxol hydrochloride will be administered twice a day, morning and evening, during treatment period.
43539|NCT03843541|Other|placebo|Placebo will be administered twice a day, morning and evening, during treatment period.
43540|NCT03843528|Drug|Vorinostat|Vorinostat will be administered concurrent with low-dose azacitidine post-transplant, on days 1-7 and 15-21 of 28 day cycles. This is an oral medication.
43541|NCT03843528|Drug|Azacitidine Injection|Azacitidine will be administered on days 1-5 of each 28 day cycle, either by IV or subcutaneous injection. The dose of azacitidine will be fixed, with no dose-escalation.
43542|NCT03843515|Drug|Nivolumab|Neoadjuvant nivolumab flat dose 400mg
43543|NCT03843502|Dietary Supplement|Kava Dietary Supplement|Participants will be given three 75mg kava capsules.
43544|NCT03843489|Device|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
43545|NCT03843489|Device|Reference CO-oximetry sensor|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
43546|NCT03843476|Device|Patient Specific Rod|Posterior spinal fusion rod
43547|NCT03843463|Drug|Escitalopram 10mg|Escitalopram tablet
43548|NCT03843463|Drug|Placebo|Sugar pill manufactured to mimic escitalopram 10 mg tablet
43549|NCT03843463|Behavioral|Computer-delivered naming treatment|15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
43550|NCT03843437|Device|Tencel Therapeutic Garments|Children age 6 months to 3 years will wear a Tencel full body suit with feet and mittens, while children age 3-6 years will wear Tencel long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
43551|NCT03843437|Device|Cotton Therapeutic Garments|Children age 6 months to 3 years will wear a cotton full body suit with feet and mittens, while children age 3-6 years will wear cotton long-sleeve shirts and pants that do not cover the hands and feet. Children will wear the study garments at night but may also wear garments during the day if desired.
43552|NCT03843424|Behavioral|eSOC program|American Medical Association (AMA) recommended staged approach to childhood obesity screening and counseling
43553|NCT03843424|Behavioral|FBT program|An intensive,comprehensive, behavioral intervention aligned with the US Preventive Services Task Force recommendations for childhood obesity screening and counseling.
43554|NCT03843398|Procedure|Colorectal cancer resection via minilaparotomy|According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.
43555|NCT03843398|Procedure|Laparoscopic colorectal cancer resection|This is one of the routine procedures used for colorectal cancer resection.
43556|NCT03843385|Drug|encapsulated faecal microbiota filtrate|Multidonor stool mixed with sterile normal saline, homogenized, filtered, centrifuged, air pressure filtered, encapsulated in hypromellose capsules and frozen.
43557|NCT03843385|Drug|encapsulated faecal microbiota|Multidonor stool mixed with sterile normal saline, homogenized, filtered, encapsulated in hypromellose capsules and frozen.
43558|NCT03843385|Drug|Placebo|Sterile saline encapsulated in hypromellose capsules and frozen.
43559|NCT03843372|Device|transnasal high flow|All of participants will be received one night transnasal high flow therapy and another night for continuous positive airway pressure.
43560|NCT03843359|Drug|GSK3745417|GSK3745417 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 2 mg per vial. GSK3745417 will be administered as IV injection for up to 5 minutes.
43561|NCT03843359|Drug|Pembrolizumab|Pembrolizumab is available as solution for infusion or lyophilized powder for reconstitution to be administered at a dose of 200 mg Q3W. It will be administered as an IV infusion for 30 minutes.
43562|NCT03843333|Behavioral|Tai Ji Quan: Moving for Better Balance|TJQMBB is an evidence-based, Centers for Disease Control and Prevention (CDC)-recommended, group falls prevention program based in Tai Chi that has been shown to reduce falls risk, improve physical function, and improve cognition. The program is delivered in 1-hour sessions twice weekly over 24 weeks, with the first 12 weeks spent learning the basic Tai Ji Quan forms and the second 12 weeks focused on variations in practice that progressively increase physical and cognitive demands. A physical therapist at Dartmouth is an authorized TJQMBB trainer and will train the CHWs to deliver the intervention and provide remote supervision monthly.
43597|NCT03843099|Behavioral|Behavioral Weight Loss + Future Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
43659|NCT03842514|Dietary Supplement|Soya lecithin|The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
43563|NCT03843333|Behavioral|Behavioral Activation|BA is a brief intervention for depressive symptoms that focuses on engagement in positively-reinforcing activities and decreasing activity avoidance. CHWs will be trained by Dartmouth psychologists to deliver a brief behavioral activation program to encourage participants to increase their involvement in meaningful activities. BA will be delivered in one-hour sessions in the home every other week for 12 weeks. Supervision will be provided remotely on a weekly basis.
43564|NCT03843333|Other|Resource Navigation|CHWs will assess participants' unmet psychosocial needs and assist them in identifying and connecting them with resources to address these needs.Types of assistance may include identifying transportation services, assisting with applications for benefits, linking participants to Meals on Wheels and other local food resources, and connecting participants to community programs for older adults. We expect that participant needs and services delivered will vary and acknowledge that this intervention component will not be standardized due to the nature of this work.
43565|NCT03843333|Other|Enhanced Usual Care|Comparison participants will receive a detailed resource guide on community supports for older adults. The research team will facilitate referrals to local resources (e.g. the Dartmouth Aging Resource Center) if desired by participants. Data from research assessments of cognition, depressive symptoms, mobility, and functional status will be provided to the primary care team for follow-up and intervention as needed.
43566|NCT03843320|Device|SAPIEN 3|Transcatheter aortic valve replacement
43567|NCT03843320|Device|SAPIEN XT|Transcatheter aortic valve replacement
43568|NCT03843320|Device|INSPIRIS RESILIA|Surgical aortic valve replacement
43569|NCT03843320|Device|EDWARDS INTUITY|Surgical aortic valve replacement
43570|NCT03843320|Device|Carpentier-Edwards PERIMOUNT Magna-Ease|Surgical aortic valve replacement
43571|NCT03843307|Device|Avazzia Tennant Biomodulator® PRO|High-voltage pulsed current (HVPC) electrical stimulation with Reactions and BEST™ (Bio-Electric Stimulation Technology) microcurrent that measure and change with tissue electrical characteristics.
43572|NCT03843294|Biological|TAA-T cells|"TAA-T cells will be generated from lymphocytes obtained from patient's peripheral blood mononuclear cells (PBMCs).~For Group B Patients (post auto-HSCT): Study treatment will begin any time after neutrophil engraftment or Day 30 post auto-HSCT whichever comes first.~Both TAA-T cells and Nivolumab will be given at fixed dose with allowed dose de-escalation of both agents as follows:~TAA-T cell dose: 2 x 107 cells/m2.~Nivolumab: For patients <18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a fixed dose of 240mg every 2 weeks."
43573|NCT03843281|Drug|Paracetamol|s. above
43574|NCT03843281|Drug|Placebo|s. above
43575|NCT03843281|Drug|Morphine|s. above
43576|NCT03843268|Device|AMPS Gondola|Gondola is a portable device that runs on batteries and is fitted on both patient's feet when the patient is lying down. The device has been designed for the stimulation of two areas of both feet (first toe and metatarsal) through mechanical impulses set up for pressure, duration and sequence (Automated Mechanical Peripheral Stimulation - AMPS); the treatment requires less than 2 minutes.
43577|NCT03843268|Device|Sham Gondola|The Sham treatment consist in the stimulation of the same areas through mechanical impulses different for pressure since attached to the steel stick point is positioned a rigid plastic circle with a diameter (12mm); thanks to this the induced pressure ishence lower and the surface contact bigger
43578|NCT03843255|Other|Part 1: DCM Cohort|Patients with a confirmed diagnosis of DCM will have samples that undergo whole genome sequencing and biomarker analysis
43579|NCT03843255|Other|Part 2: Heritable CV Diseases and Family Members|Biomarker analysis will be undertaken on samples
43580|NCT03843242|Device|Pacemaker with Fixed long AV delay|Fixed AV delay was applied in the first 3 months of pacemaker implantation according to previously proposed definition.
43581|NCT03843242|Device|Pacemaker with VpS® algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In Vp-suppression algorhithm on group, Vp suppression algorithm of Enitra 8 DR-T pacemaker will be turned on at 3month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
43582|NCT03843242|Device|Pacemaker with IRSplus algorithm on|"After first 3 months of pacemaker implantation, the patients will be randomized into two groups (Vp-suppression algorithm on group vs. IRS-plus algorithm on group) using a centralized randomization system.~In IRS-plus algorithm on group, IRS plus algorithm of Enitra 8 DR-T pacemaker will be turned on at 3 month visit after enrollment.~The patient will be followed at 3-month after enrollment and at 6-month and 12-month after applying the specific algorithm."
43583|NCT03843229|Drug|Cinobufacini injection|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
43584|NCT03843229|Procedure|Transarterial Chemoembolization(TACE)|TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible.
43585|NCT03843229|Drug|cinobufacini tablet|The treatment group receives Cinobufacini injection 20ml via hepatic artery during TACE operation , Cinobufacini injection 20ml+5% Glucose injection 500ml from the second day of TACE until 7th day, and Cinobufacini tablet 3 tablets Tid for 2 months.
43586|NCT03843216|Other|observation|patients not treated
43587|NCT03843216|Other|Physiotherapic scoliosis specific exercise|Specific exercise according to the SEAS (Scientific Exercises Approach to Scoliosis) protocol
43588|NCT03843216|Device|brace|different kind of braces being elastic, rigid or very rigid. All devices are custom made. The hours of application per day varied from 18 to 24h.
43589|NCT03843203|Device|Transcranial Direct Current Stimulation - tDCS|- Intervention: tDCS is a therapeutic method that modulates the membrane potential, where anodic stimuli induce cortical excitability and cathodic stimuli reduce it
43590|NCT03843190|Behavioral|Take of Pounds Sensibly (TOPS)|Peer led
43591|NCT03843177|Other|No intervention|No intervention will be performed. Only assessment will be done.
43592|NCT03843151|Drug|BI 1358894|tablet
43593|NCT03843151|Drug|Itraconazole|oral solution
43594|NCT03843125|Drug|Baricitinib|Administered orally.
43598|NCT03843099|Behavioral|Behavioral Weight Loss + Healthy Thinking|Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
43599|NCT03843086|Device|Low Intensity Linear Shockwave Device for the treatment of Erectile Dysfunction|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients using low intensity shockwave therapy. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)"
43600|NCT03843073|Device|Connected Urinary Catheter|Patients will use the Connected Catheter to empty the bladder during the course of treatment.
43601|NCT03843060|Drug|AZD9977|Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
43602|NCT03843060|Drug|Itraconazole|Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.
43603|NCT03843047|Drug|3 mg/mL nicotine strength e-liquid|Availability of 3 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
43604|NCT03843047|Drug|6 mg/mL nicotine strength e-liquid|Availability of 6 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
43605|NCT03843047|Drug|12 mg/mL nicotine strength e-liquid|Availability of 12 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
43606|NCT03843047|Drug|24 mg/mL nicotine strength e-liquid|Availability of 24 mg/mL nicotine strength e-liquid in the Experimental Tobacco Marketplace
43607|NCT03843034|Genetic|Measure endometrial markers|Endometrial biopsies will be taken from participants in both groups
43608|NCT03843021|Other|VAD Infection Prevention Survey|Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
43609|NCT03843008|Dietary Supplement|Melatonin|Participants in the Melatonin Group will receive 3mg of melatonin each evening for up to seven days for a maximum total of 21mg of melatonin.
43610|NCT03842995|Behavioral|Genetic Counselor|Standard of Care
43611|NCT03842995|Behavioral|Trained Healthcare Provider|Neonatologists and Neonatology Nurse Practitioners that receive training to deliver whole genome sequencing results
43612|NCT03842982|Drug|HIPEC|"HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours."
43613|NCT03842969|Drug|RO7234292 (RG6042)|Intrathecal injection
43614|NCT03842956|Procedure|Primary wound closure in Allgower Technique vs. secondary open wound healing of pin-sides after removal of the fixated-externe|We compare the outcome of primary wound closure (Allgower) and secondary open wound healing by comparing infection-rates, use of antibiotics, reoperation-rates, satisfaction of the patients and optical results using the Vancouver scar scale
43615|NCT03842943|Drug|Pembrolizumab|Preoperative infusions
43616|NCT03842943|Drug|Talimogene Laherparepvec|Preoperative intralesional injection
43617|NCT03842930|Procedure|Endovascular embolization|Endovascular embolization of the Lumbar Arteries
43618|NCT03842917|Other|Biological samples|Urine and blood samples
43619|NCT03842917|Other|Blood pressure measurement|Home blood pressure self-measurement and hospital blood pressure measurement
43620|NCT03842904|Drug|Trimbow pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
43621|NCT03842904|Drug|Fostair pMDI|Clinical Trial of an Investigational Medicinal Product (CTIMP)
43622|NCT03842865|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
43623|NCT03842852|Procedure|Inguinal hernia repair|The grupo one underwent open repair and laparoscopic repair
43624|NCT03842839|Drug|Tiotropium|Tiotropium will be used once daily for 2 years.
43625|NCT03842839|Drug|Olodaterol / Tiotropium|Tiotropium or dual bronchodilators will be used, (including but not limited to Olodaterol / Tiotropium) will be used once daily for 2 years.
43626|NCT03842826|Diagnostic Test|Palpation, resistance and stretch tests|Palpation, resistance and stretch tests performed by 2 blinded examiners.
43627|NCT03842813|Device|DES-CRE8|Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.
43628|NCT03842800|Other|MRI|Patients and volunteers will receive an MRI.
43629|NCT03842800|Drug|Ketamine|Ketamine will be administered to a subset of healthy controls that agree to receive the drug as part of receiving an MRI.
43630|NCT03842787|Other|Biological analysis|"Biological and research analysis:~Quantification of ficolin-3, anti-ficolin-3 antibodies, ficolin-2, anti-ficolin-2 antibodies~Purification of patients' antibodies (anti-ficolin-3 and -2)~Evaluation of effects of anti-ficolin-3 and anti-ficolin-2 purified antibodies Investigation of ficolin-3 and ficolin-2 deposition in renal biopsy"
43631|NCT03842774|Dietary Supplement|Exract of Gelidium elegans|Exract of Gelidium elegans will be given to the test group.
43632|NCT03842774|Dietary Supplement|Placebo|Placebo supplement will be given to the test group.
43633|NCT03842761|Drug|BI 685509|Tablet
43635|NCT03842735|Other|exercise and rehabilitation counselling|The intervention consists in a standardized physical exercise (PE) and rehabilitation counselling indications (RCI). PE is done 5 days/week (2 days in autonomy by the patient with parents support and 3 days supervised). Each session lasts 30 minutes and this is supervised by one therapist for all patients. Patients are enrolled in an EP composed by three different types of exercises, each carried out for 10 minutes per session: muscle strength exercises for upper and lower extremities preceded by warming up, aerobic exercises and stretching. The kind of exercise is differentiated by age range (children, 5-12 years and adolescents, 13-18 years).
43636|NCT03842735|Behavioral|rehabilitation counselling|RCI, which have to be followed daily, consist in some practical advice was given on how to adopt an active lifestyle during the recovery (e.g., getting up to go to the bathroom, getting up to move to the window to talk with visitors, sit on chair to have school lessons).
43637|NCT03842722|Device|Protoporphyrin IX - Triplet State Lifetime Technique|Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.
43638|NCT03842709|Drug|Pramipexole Oral Tablet|Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
43639|NCT03842709|Other|Placebo|Administration of placebo
43640|NCT03842696|Drug|Vorinostat|Vorinostat 30, 45 or 60 mg/m2 BID PO from 10 days prior to transplant (day -10), until day +100 post-transplant (110 total days of dosing).
43641|NCT03842696|Procedure|Blood and Marrow Transplant (BMT)|Undergo allogeneic BMT according to local site institutional practice.
43642|NCT03842696|Drug|Tacrolimus|Tacrolimus will begin on day -3. Intravenous or oral dosing is permitted.In the absence of GVHD, it is recommended that tacrolimus or cyclosporine tapering begin on day +100 post-transplant as per local site BMT program clinical practice guidelines. In the presence of GVHD, it is recommended that tacrolimus or cyclosporine be continued at therapeutic dosing.
43643|NCT03842696|Drug|Methotrexate|Methotrexate will be used in combination with tacrolimus for standard GVHD prophylaxis. It will be given at a dose of 5 mg/m2/dose once daily intravenously on days +1, +3, +6, and +11. Standard criteria for administration will be followed per local site institutional BMT program clinical practice guidelines.
43644|NCT03842683|Other|CGM|This study seeks to assess CGM accuracy and develop prediction models for hypoglycemia detection and no intervention is therefore applied.
43645|NCT03842670|Behavioral|Cognitive Behavior Therapy|The CBT condition will include 8 weekly, 60-minute sessions, and will be delivered according to the Epstein & McCrady (2009) cognitive-behavioral treatment manual, excluding material provided in the platform treatment. The treatment manual and accompanying client workbook provide detailed therapist instructions for each session, client exercises, worksheets, and homework assignments. The treatment focuses on cognitive and behavioral coping skills training, and emphasizes problem-solving as an overall approach to dealing with drinking. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
43646|NCT03842670|Behavioral|Mindfulness Based Relapse Prevention|The MBT condition will be adapted from the 8-week version of the mindfulness-based relapse prevention (MBRP) manual (Bowen et al., 2011; Witkiewitz et al., 2005). The main adaptation will be to eliminate the relapse prevention/CBT components and focus attention on mindfulness practices. The mindfulness practices in MBT are designed to increase awareness of triggers and decrease reactivity to distress or discomfort in the presence of triggers (Witkiewitz & Bowen, 2010). The relevant worksheets and homework assignments focusing on mindfulness tools will be maintained from the MBRP manual. Treatment sessions may be audio-recorded for supervision and to ensure that the treatment is being delivered as intended.
43647|NCT03842657|Combination Product|anticoagulation of the dialysis circuit|Each patient included in this study will receive two heparin-free dialysis sessions with heparin-grafted membrane (control group) or RCA with calcium-free citrate-containing dialysate and calcium reinjection according to the ionic dialysance (experimental group), alternatively
43648|NCT03842644|Device|Tension reduction device|Continue using this device for 3 months post surgery.
43649|NCT03842631|Drug|Timolol Maleate 0.5% Oph Soln|External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
43650|NCT03842605|Other|Strength training|
43651|NCT03842592|Diagnostic Test|Treadmill Stress test|Ventricular arrhythmia will be assessed by ECG Holter and during treadmill stress test, both being performed 3 months and 1 year after acute myocarditis
43652|NCT03842579|Other|Resistance training|Supervised progressive explosive type heavy-resistance training two times per week
43653|NCT03842579|Other|High-protein diet|Daily supplementation with milk-based protein-rich products
43654|NCT03842579|Other|Recommendations|Provided with the official national recommendations on nutrition
43655|NCT03842553|Other|No Intervention: anonymous online survey|
43656|NCT03842540|Behavioral|SpeakOut|"SpeakOut aims to increase social communication about contraception between adolescent IUD and implant users and their peers. SpeakOut has four components:~Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~Digital materials for recipients to keep and/or share with friends.~Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut."
43657|NCT03842540|Behavioral|PartyWise|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. Staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
43658|NCT03842527|Device|Ultrasound|Gastric ultrasound of the stomach antrum to assess contents 1 hour prior to C-section surgery. Scans will be completed in both supine (lying on back) and right lateral decubitus (positions) positions. The completion of both scans will take 5-10 minutes total
43660|NCT03842501|Dietary Supplement|Release Supplement|Calorie reduced diet plus Release supplement
43662|NCT03842488|Drug|Experimental: RAL QD|Prescription of 2x RAL 600mg (1200MG) once daily
43663|NCT03842488|Drug|Active comparator: DRV/cb|Prescription of DARUNAVIR/COBICISTAT 800 Mg-150 Mg once daily
43664|NCT03842475|Procedure|Roux-en-Y gastric bypass (RYGB)|Bariatric surgery
43665|NCT03842462|Other|nCPAP|infants receive primary non-invasive respiratory support by mean of nCPAP
43666|NCT03842462|Other|NIPPV|infants receive primary non-invasive respiratory support by mean of NIPPV
43667|NCT03842462|Other|NHFOV|infants receive primary non-invasive respiratory support by mean of NHFOV
43668|NCT03842449|Diagnostic Test|BabyCO|An expired CO measurement will be performed by BabyCO and the result will be returned to the smoking pregnant woman by the consultant.
43669|NCT03842449|Other|Biological samples|"The nature of the samples taken during the delivery are:~maternal blood,~cord blood~placenta fragment"
43670|NCT03842436|Device|Digital pill|Digital pills over encapsulating Truvada
43671|NCT03842436|Drug|Truvada|Truvada prescribed with digital pills for PrEP
43672|NCT03842423|Procedure|Brachial Plexus Anaesthesia|Regional anaesthesia for treatment of upper extremity injuries.
43673|NCT03842410|Device|Single-Incision Sling|Solyx Single-Incision Sling for correction of stress urinary incontinence done in the office.
43674|NCT03842397|Device|Kephalios Device 1|The Kephalios Device 1 is an adjustable annuloplasty ring, to be implanted by open surgery, having a hollow structure that comprises a flat rigid ring surrounding a deformable cage. The unique feature of the Kephalios Device 1 is that its annular shape and dimension can be finely adjusted percutaneously by an external actuator (three-balloon catheter) independently in the three areas corresponding to P1, P2 and P3
43675|NCT03842384|Behavioral|distress tolerance training|The proposed intervention will initially target motivational processes in combination with introductory strategies for managing physical and emotional distress through a single, brief, computer-delivered session followed by eight weeks of theoretically-informed text messages intended to enhance motivation and promote distress tolerance.
43676|NCT03842384|Other|treatment as usual|standard outpatient buprenorphine treatment
43677|NCT03842371|Other|Metabolic level of BCAAs in monocytes and macrophages|Metabolic level of BCAAs in monocytes and macrophages
43678|NCT03842358|Device|Hand-held hybrid probe|Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
43679|NCT03842332|Behavioral|Life Skills and Resilience Program|The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
43680|NCT03842319|Other|Microbiota analysis|From the feces and oral cavity samples, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
43681|NCT03842319|Other|Immunological analysis|A study of immunological cell populations, inmunogenetics and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
43682|NCT03842319|Other|Proteome analysis|A study of host and microbiota proteome will be carried out from samples using mass spectrometry
43683|NCT03842319|Other|Metabolome analysis|A study of host and microbiota metabolome will be carried out from samples using MS-based as well as NMR-based methods
43684|NCT03842319|Other|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies
43685|NCT03842319|Other|Diet evaluation|Biochemical analysis and questionaries for diet adherence and exercise registration
43686|NCT03842319|Other|MedDiet|The high-intensity Mediterranean diet will include the promotion of the following: a) abundant use of olive oil (>40 g/d) for cooking and dressing dishes; b) consumption of >2 daily servings of vegetables; c) >2-3 daily serving of fresh fruits; d) >3 weekly servings of legumes; e) >3 weekly servings of fish or seafood; f) >1 weekly serving of nuts or seeds; g) select white meats instead of red meats or processed meats; and h) cook regularly with tomato, garlic and onion adding or no other aromatic herbs, and dress vegetables, pasta, rice and other dishes with tomato, garlic and onion adding or no other aromatic herbs. Two main meals per day should be eaten (seated at a table, lasting more than 20 minutes). A recommendation to drink a glass of wine per day during meals is given. Limited consumption is advised for cured ham, red meat, chocolate, cured or fatty cheeses
43687|NCT03842280|Device|Diaphragm ultrasound assessment & Esophageal pressure measurement|Diaphragm ultrasound assessment and/or Esophageal pressure measurement before, during and after spontaneous breathing trial
43688|NCT03842267|Drug|Gemigliptin 50mg|"The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~Dapagliflozin 10 mg / day~Metformin ≥ 1,000 mg / day"
43689|NCT03842267|Drug|Gemigliptin Placebo|"The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~- The subjects should visit a study site 9 times during the treatment period for about 52 weeks in total.~Background therapy should be administered at the same time every day, keeping the same dosage administered before the study, according to the following criteria:~Dapagliflozin 10 mg / day~Metformin ≥ 1,000 mg / day"
43690|NCT03842254|Drug|Erythropoietin|Subcutaneous injection of erythropoietin 10,000 units
43691|NCT03842241|Device|Non-custom made foot orthoses|Foot orthoses is an orthotic devices which are used to support arch and rear-foot and put it in a good alignment.
43692|NCT03842228|Drug|Copanlisib|Given IV
43693|NCT03842228|Drug|Copanlisib Hydrochloride|Given IV
43694|NCT03842228|Biological|Durvalumab|Given IV
43695|NCT03842228|Drug|Olaparib|Given PO
43696|NCT03842215|Device|smart physical exam|Use smart physical exam to collect functional performance
43947|NCT03840226|Drug|Magnesium Oxide|Magnesium tablets
43697|NCT03842202|Drug|Semaglutide|Participants will receive gradually increasing doses of semaglutide (subcutaneous [s.c.], in the thigh, abdomen or upper arm) injection once weekly, until they reach a dose of level of 2.4 mg, which they will continue for 5 weeks.
43698|NCT03842202|Drug|Placebo|Participants will receive once weekly injections of semaglutide matched placebo.
43699|NCT03842189|Drug|M281|Participants will receive once weekly intravenous (IV) infusions of M281
43700|NCT03842176|Procedure|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
43701|NCT03842176|Procedure|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
43703|NCT03842150|Diagnostic Test|biliary atresia screen score|The investigators aim to develop a scoring system according to clinical, laboratory, imaging features of biliary atresia in the derivation dataset and tested in the validation datasets.
43704|NCT03842137|Device|tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of active tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
43705|NCT03842137|Device|sham tDCS|Each participant will undergo 5 consecutive (i.e., business days) sessions of sham tDCS delivered to the DLPFC. During each session, participants are engaging in tasks that activate the cognitive control network.
43706|NCT03842124|Other|Force gauge|The investigators postulate that use of bidirectional traction (superior and inferior directions) and feedback from a digital force gauge is associated with minimal lead displacement compared to conventional lead extraction.
43707|NCT03842085|Drug|Recombinant Humanized Bispecific Monoclonal Antibody MBS301|The patients confirming to the eligibility criteria will be assigned to the 5 dose groups (2mg/kg, 6mg/kg, 10mg/kg,15mg/kg, and 20 mg/kg, respectively) based on the sequence of inclusion. MBS301 will be administered intravenousely on day 1 of each 21-day cycle for each patient.The first intravenous infusion for each patientwill be last for 90 minutes.It could be changed to 60 minutes for the subsequent infusions if the drug is well tolerated.
43708|NCT03842072|Device|Cervical collar|cervical collars prescribed will be use immediately following anterior cervical discectomy and fusion surgery.
43709|NCT03842059|Device|Computer-aided detection|We developed an artificial intelligent computer system with a deep neural network (PX-1) to analyze real-time video signals from the endoscopy station
43710|NCT03842059|Device|Standard colonoscopy|Standard colonoscopy
43711|NCT03842046|Procedure|phenylephrine infusion|In parturients allocated to the phenylephrine group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
43712|NCT03842046|Procedure|norepinephrine infusion|In parturients allocated to the norepinephrine group group, a phenylephrine infusion will be initiated as soon as spinal anesthesia is established
43713|NCT03842033|Behavioral|PEAKmAAP|"The PEAKmAAP group will use a mobile app that will help manage asthma."
43714|NCT03842033|Behavioral|PEAKmAAP-DS|This group will use the mobile app to help manage asthma. the primary care provider will receive monthly reports to help him/her know how the participants asthma symptoms are over time.
43715|NCT03842033|Behavioral|NutriMap Usual Care|This group will use a non-asthma related app daily to record their daily intake of fruits and vegetables.
43716|NCT03842020|Other|Blood pharmacokinetic samples|1 or 3 sample(s) will be taken in the following time windows: [H0-H3]; [H5-H9] and just before the next set [H24], depending if the child is or is not admitted to hospital
43717|NCT03842007|Diagnostic Test|Rectal Barostat Study|Contractions will be recorded with a balloon inserted into the rectum and inflated
43718|NCT03842007|Diagnostic Test|Fecoflowmetry|Rectum will be filled with a small amount of paste.Two thin catheters will be inserted into the anus to measure pressures and electrical activity (electromyography or EMG). Subjects will be asked to sit on a commode, contract (squeeze) your anal muscles, blow into a balloon, and expel the paste into the commode.
43719|NCT03841981|Diagnostic Test|Anthropometric and physical examination|"Weight and height.~Waist-to-hip ratio.~Body composition: Bioelectrical impedance and [Dual energy X-ray absorptiometry (DEXA)]."
43720|NCT03841981|Diagnostic Test|Indirect calorimetry, accelerometer and seven-day dietary recall|Energy availability assessment.
43721|NCT03841981|Diagnostic Test|Biochemical, hormonal and metabolic phenotyping|"Lipid profile.~Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.~Sex steroid profile.~Hypothalamic-pituitary-adrenal axis study.~Ferrokinetic study.~Subclinical chronic inflammatory markers."
43722|NCT03841981|Diagnostic Test|Sonographic studies|"Polycystic ovarian morphology.~Carotid intima-media thickness.~Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness."
43723|NCT03841981|Diagnostic Test|24-hour Ambulatory blood pressure monitoring|A&D TM2430EX oscillometric devices (A&D Company Limited, Tokyo, Japan).
43724|NCT03841981|Procedure|Percutaneous biopsy|Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
43725|NCT03841981|Diagnostic Test|Cardiovascular autonomic function studies|Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.
43726|NCT03841981|Diagnostic Test|Oral smear and feces specimen|Microbiome studies.
43727|NCT03841968|Procedure|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
43728|NCT03841968|Procedure|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
43729|NCT03841955|Device|PICC with high pressure tolerance|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the experimental group and given the intervention.
43730|NCT03841955|Device|rontine central venous catheter|Subjects signed informed consent, meet the inclusion criteria and did not meet the exclusion criteria, and were randomly admitted to the control group and given the intervention.
43976|NCT03839979|Diagnostic Test|BIOLINE HCV kits|We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.
43731|NCT03841942|Other|clinically-based spacing strategy|All patients (as there are free from symptoms) will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission is maintained (CDAI < 150 for CD, Partial Mayo score < 3 for UC), patients will have a second step of a 2 weeks infliximab infusion spacing which will be maintained until the end of the study.
43732|NCT03841942|Other|Trough level-based strategy|"patients will have at inclusion a determination of the infliximab trough level. According to this dosage, only patients with a trough level ≥ 7 µg/ml will have a first step of a 2 weeks spacing of their infliximab infusion interval. Then, at the next infliximab infusion, if clinical remission (CDAI < 150 for CD, Partial Mayo score < 3 for UC) is maintained and if infliximab trough level is still ≥ 7 ug/ml, patients will have a second step of 2 weeks infliximab spacing until the end of the study.~Patients with a baseline infliximab trough level < 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study."
43733|NCT03841929|Other|Hemodynamic report|The multimodal data comprising the clinical, biochemical, NIRS data and TNE where available will be used by the study team in such cases to reach a description of the hemodynamic status of the study infant and will be provided to the Clinical team.
43734|NCT03841916|Diagnostic Test|transvaginal ultrasound|transvaginal ultrasound to measure endometrial thickness
43735|NCT03841903|Diagnostic Test|spinal cord MRI|high-resolution spinal cord MRI sequences on a 3Tesla magnet (Siemens Prisma) with high contrast between SC and CSF as well as high contrast within the SC (grey-white matter contrast)
43736|NCT03841890|Device|the Clarus Video System as a video stylet|video-guided intubation
43737|NCT03841890|Device|the Clarus Video System as a lightwand|The endotracheal tube will be initially guided into larynx in the dimly lit operating room by a bright glow moving in the anterior soft tissue of the neck and finally by the image of the trachea rings on the video screen.
43738|NCT03841890|Device|direct laryngoscope|Macintosh laryngoscope size 3
43739|NCT03841877|Procedure|endodontic treatment|The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
43740|NCT03841864|Other|IV placement using ultrasound guidance vs traditional method|Ultrasound guided IV placement
43741|NCT03841851|Procedure|sub epithelial connective tissue graft|"Local anesthesia will be injected intra-orally at the implant site.~Atraumatic extraction of badley decayed teeth in the aesthetic area traditional drilling for immediate implant placement .~immediate temporization .~subepithelial connective tissue graft from the palate"
43742|NCT03841838|Other|Energy drink|Two 12 oz bottles of commercially available energy drink
43743|NCT03841838|Other|Placebo drink|Two 12 oz bottles placebo drink. Placebo drink will contain carbonated water, lime juice, and cherry flavoring.
43744|NCT03841825|Behavioral|Oral hygiene instructions|Oral hygiene instructions and motivation
43745|NCT03841812|Drug|Remifentanil & Propofol|0.3ug/kg/min remifentanil & 3mg/kg/min propofol
43746|NCT03841812|Drug|Sevoflurane|1% Sevoflurane applyed during intra-operation.
43747|NCT03841812|Drug|Sulfentanyl|0.01ug/kg/min Sulfentanyl infused during operation
43748|NCT03841786|Other|Phosphorus-supplemented study diet|Participants will be instructed to consume a normal diet and will take a total of 1,000 mg of supplemental phosphorus per day in the form of neutral sodium phosphorus (K-Phos neutral®) for 1 week.
43749|NCT03841786|Other|Control Diet|Participants will be asked to consume a normal diet supplemented with sodium and potassium chloride tablets commensurate with the extra sodium and potassium content consumed during the study diet period for 1 week
43750|NCT03841773|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
43751|NCT03841773|Drug|Placebo SL Tablets|Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
43752|NCT03841760|Diagnostic Test|PSMA PET/CT|"For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes."
43753|NCT03841747|Drug|Pembrolizumab|200 mg Pembrolizumab intravenously (IV) every 3 weeks (Q3W).
43754|NCT03841747|Drug|Paclitaxel|80 mg/m2 paclitaxel intravenously (IV) on Days 1,8, and 15 of each 28 day cycle.
43755|NCT03841734|Drug|treatment|8 patients will be treat with bosentan at 145 mg per day during 14 days
43756|NCT03841721|Drug|Linezolid oral tablet 300 mg/day for 5 day|Linezolid oral tablet 300 mg/day for 5 day and blood sample were obtained by direct venipuncture at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hour after drug administration in day 5
43757|NCT03841708|Device|Pleth variability index|The utility of a early goal directed therapy will be evaluate by the pleth variability index (PVI). If above>13% in a well sedated patients perfectly synchronized with the ventilator providing at least 6ml/kg of ideal body weight, a fluid challeng with 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
43758|NCT03841708|Device|Standard non invasive monitoring|In the control group patients will be hemodynamically resuscitated in the early phases after ROSC based on standard non invasive monitoring such as SatO2, EtCO2, non invasive blood pressure and continuous ECG. If deemed necessary by the treating physician a fluid challenge of 10ml/kg of NaCl 0,9% will be administrated. Patient will be constantly re-assessed until the hemodynamic goals of a mean arterial pressure above 65 mmHg, a capillary refill time below 3 seconds, a decreasing trend on lactates and a urinary output above 0.5/ml/kg/h will be achieved. The second fluid challenge will always be performed with 100 ml of albumin 20%. The third fluid challenge if necessary will be performed with 10 ml/kg of NaCl 0.9%.
43759|NCT03841695|Device|RMTC finger-hand robot (Mirror Hand)|The robotic hand will apply on the patient's affected hand and the sensor glove will apply on the patient's un-affected hand, the patient can manipulate their affected hand by their un-affected hand and do the task oriented bimanual training.
43760|NCT03841695|Other|Conventional OT|The focus of occupational therapy is to help individuals achieve health, well-being, and participation in life through engagement in activities (American Occupational Therapy Association [AOTA], 2014). For stroke rehabilitation, occupational therapy includes retraining in self-care skills, addressing ongoing deficits such as weakness, sensory loss, and cognitive impairments that limit engagement in activities of daily living, and training in community reintegration and modifying tasks or environments.
43761|NCT03841682|Behavioral|I-CARE2|"I-CARE2 intervention synergistically integrates 2 proven national programs: the Program to Encourage Active and Rewarding Lives (PEARLS) for depression care and the Group Lifestyle Balance (GLB) program for weight loss and cardiometabolic risk reduction.~The PEARLS program provides problem-solving therapy (PST) as first-line for treating depression, with as-needed antidepressant medication intensification. Adapted from the original Diabetes Prevention Program, the GLB program promotes healthy lifestyle change for weight loss and increased physical activity."
43762|NCT03841669|Behavioral|Aerobic Exercise Group|Guidelines for exercise programming (ACSM, 2018) will be followed including a warm up and cool down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity related injury. The exercise group will receive moderate to vigorous intensity aerobic exercise for 60 minutes per day, twice a week, for 12 months. They will also exercise on their own for 30 minutes, 1 time a week, for 12 months. This gives a total of 3 exercise sessions a week. The prescribed intensity will be based on their maximal fitness testing heart rate and then calculated per a research grade method. They will maintain a minimum heart rate from their specific calculation that will be monitored by Polar Heart Rate straps.
43763|NCT03841669|Behavioral|Physical Activity & Health Information Group|This group will not partake in the aerobic fitness sessions but will be asked to wear a daily monitoring device every 6 weeks. They will also complete all baseline, 6-month, and 12-month visits.
43764|NCT03841656|Procedure|PARORISKIMPLANT|Patients attending periodontal and implant treatment at the Department of Periodontology of the Dental Faculty at Strasbourg, France, between 2000-2015.
43765|NCT03841643|Device|patient-specific implant|solid titanium implant that functions as a guiding template for harvesting, and as an implant for reconstruction of the cranial defect
43766|NCT03841643|Device|cement|norian cement for reconstruction of the cranial defect
43767|NCT03841630|Drug|LY3437943|Administered subcutaneously (SC)
43768|NCT03841630|Drug|Placebo|Administered SC
43769|NCT03841617|Drug|Thyrogen|intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria
43770|NCT03841617|Radiation|I-131|therapeutic dose administered orally to treat thyroid cancer at week 8. 5-7 days later, the post-treatment I-131 Whole Body scan w/SPECT is performed; then administered once annually if the patient needs to be re-treated with radioactive iodine.
43771|NCT03841617|Radiation|I-124|one capsule ingested orally once at Week 3, and Week 8; then administered once annually to subjects who meet criteria.
43772|NCT03841617|Other|Thyroid hormone withdrawl|withdrawal of thyroid hormone during weeks 4 through 8
43773|NCT03841604|Drug|Safinamide Methanesulfonate|50 mg, 100 mg
43774|NCT03841604|Drug|Safinamide methanesulfonate matching placebo|50 mg, 100 mg
43775|NCT03841591|Drug|Insulin|Women with GDM will receive insulin and tailored according to their blood glucose levels to achieve glycemic control. Starting dose will be 30unit (20 unit intermediate dose + 10 unit rapid acting insulin) in the morning and before breakfast). In the 2nd trimester, we will start with half of the previous dose and if post dinner glucose level remain elevated additional injection of rapid acting insulin will be given just prior to dinner. If fasting glucose is elevated, intermediate acting insulin can be given along with the dinner dose of rapid acting insulin.
43776|NCT03841591|Drug|Metformin|Women with GDM will receive metformin and tailored according to their blood glucose levels to achieve glycemic control. They will receive an initial metformin dose of 500 mg once or twice daily (according to initial blood glucose level) with food and increased 500 mg every one or two weeks toward targets or up to a maximum daily dose of 2500 mg divided doses with each meal.
43777|NCT03841591|Other|Assessment of weight gain|Body weight will be measured monthly from the start of treatment till delivery.
43778|NCT03841578|Dietary Supplement|Healthy|25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
43779|NCT03841565|Biological|Daratumumab|Given IV
43780|NCT03841565|Drug|Dexamethasone|Given PO
43781|NCT03841565|Drug|Pomalidomide|Given PO
43782|NCT03841552|Device|Augmented Feedback|An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
43783|NCT03841552|Other|Control Group|Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
43784|NCT03841539|Behavioral|Mediterranean Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, olive oil, seafood, nuts and beans. It is low in red and processed meats, solid fats and added sugars.
43785|NCT03841539|Dietary Supplement|Study Supplement|Randomized to take a daily dose of either 2 grams of Omega 3 fatty acids or 2 grams of a Placebo.
43786|NCT03841539|Behavioral|Low-fat Diet|Diet consisting of fruits, vegetables, whole grains, low-fat dairy, and low-fat protein, with fat contributing no more than 25% of calories.
43787|NCT03841526|Drug|Glucagon RTU Injection|0.15 mg injection
43788|NCT03841526|Other|Vehicle for Glucagon RTU Injection|0.15 mg injection
43977|NCT03839979|Diagnostic Test|ACCU-CHEK kits|For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
43789|NCT03841513|Procedure|Laparoscopic Burch Colposuspension|The Burch Colposuspension is an anti-incontinence procedure where non-absorbable monofilament suture is used in the retropubic space to form a suture bridge between the anterior vagina and Cooper's ligament, thereby gently elevating the anterior vaginal wall and providing urethral support.
43790|NCT03841500|Device|Biocomposite intereference screw femoral tunnel fixation|ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
43791|NCT03841500|Device|Endobutton (Tightrope) femoral tunnel fixation|ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
43792|NCT03841487|Device|Aspiration thrombectomy|In the aspiration thrombectomy group, aspiration thrombectomy was performed for patients with ST elevation myocardial infarction who underwent primary percutaneous coronary intervention (PCI). In the PCI alone group, the STEMI patient received conventional primary PCI without aspiration thrombectomy during the procedure.
43793|NCT03841474|Drug|Psychiatric treatment with sertraline|Psychiatric treatment with sertraline (range from 50 mg/day to 200mg/day according to clinical appearance) of newly recognized depression in patients after PCI
43794|NCT03841474|Drug|Psychiatric treatment with escitalopram|Psychiatric treatment with escitalopram (range from 10 mg/day to 20 mg/day according to clinical appearance) of newly recognized depression in patients after PCI
43795|NCT03841461|Other|International Physical Activity Questionnaire-Short Form|IPAQ has been developed to obtain valid and comparable information about the level of physical activity based on individual reports on daily physical activity in the international arena. This form consists of 7 questions; provides information about time spent in walking, moderate and violent activities, and time spent sitting. The calculation of the total score of the short form includes total of duration and frequency whom walking, moderate activity and severe activity. The energy required for the activities is calculated by the MET-minute score.Standard MET values for these activities has been established. These; Walking = 3.3 MET;Moderate Severe Physical Activity = 4.0 MET;Severe Physical Activity = 8.0 MET;Seating = 1.5 MET.Classification is based on the numerical data obtained.Accordingly,there are 3 activity levels: Inactive,minimal active and very active.
43796|NCT03841461|Other|The Pittsburgh Sleep Quality Index|It is a scale that provides information about the sleep quality of the individuals and the type and severity of the sleep disorder in the last month. It consists of 24 questions, 19 of which are evaluated. The PSQI consists of 1 total score and 7 sub-dimensions (subjective sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbance, sleep medication use, daytime dysfunction). Each item in the scale has a value between 0 (no distress) and 3 (serious distress). The sum of the scores related to the seven sub-dimensions gives the total PSQI score. The score of each sub-dimension ranges from 0 to 3. The total PSQI score ranged from 0 to 21. While the sleep quality of the patients with a total score of 5 and below is considered as 'good'; >5 refers to poor sleep quality.
43797|NCT03841461|Other|The Fatigue Severity Scale|Each question on this scale, which is composed of Likert type questions: 1.I strongly disagree 2.I do not agree 3.No tend to disagree 4. Indefinitely. The score of the scale, which consists of 9 questions, varies between 9-63. People are asked to mark the appropriate options for each question taking into account their status in the last 1 month period.
43798|NCT03841461|Other|General Information Form|A form, which is prepared by us, including the purpose of the study, demographic information, daily working hours and assignment durations.
43799|NCT03841448|Drug|Placebo|Normal saline (0.9% NaCl) matching volume of cemdisiran doses will be administered SC.
43800|NCT03841448|Drug|Cemdisiran|Cemdisiran will be administered by subcutaneous (SC) injection.
43801|NCT03841435|Radiation|Hypofractionated Radiotherapy|Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
43802|NCT03841422|Procedure|video-assisted nasal self-packing|video-assisted nasal self-packing
43803|NCT03841409|Other|Collection of blood samples|Nine blood samples will be collected to determine bupivacaine pharmacokinetics at T10min, T20min, T30min, T45min, T60min, T90min, T120min, T180min, and T240min. T0 will be defined as the end of bupivacaine injection.
43804|NCT03841396|Drug|Sodium chloride|All participants received a single dose of sodium chloride as placebo
43805|NCT03841383|Diagnostic Test|Echo stress dipyridamole|Echo stress dipyridamole
43806|NCT03841370|Procedure|endodontic treatment|Color measurements of endodontically treated teeth (incisors, canines or premolar) will be collected regardless of technique, treatment time and sealer used.
43807|NCT03841357|Drug|Abatacept Injection|Supplied as a weekly injection via a pre-filled syringe
43808|NCT03841357|Other|Usual Care|Usual care will be defined by the clinical management team but includes steroid joint injections and non-steroidal anti-inflammatory drugs
43809|NCT03841344|Device|MRI|Evaluation of the utility of candidate endpoints in PAH trials
43810|NCT03841331|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
43811|NCT03841331|Drug|Matching Placebo Tablets|Placebo Tablets
43812|NCT03841318|Biological|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
43813|NCT03841318|Biological|biopsy of the labial salivary gland|Part of the biopsy of the labial salivary gland
43814|NCT03841305|Procedure|Liver preparation before major hepatectomy|Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.
43815|NCT03841292|Drug|Varenicline|Varenicline (Champix®), Pfizer Canada Inc., Kirkland, Quebec. Dispense for 12 weeks. One tablet (0.5mg) once daily for first three days, then one tablet (0.5 mg) twice daily for next four days, then 1 mg (one 1mg tablet) twice daily for the remainder of 12 weeks. Dose adjustments due to adverse events will be allowed (i.e. decrease to 0.5 mg twice daily).
43816|NCT03841292|Device|Active tDCS|Active 2mA tDCS (Nuraleve, Canada) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session
43817|NCT03841292|Device|Sham tDCS|Shame tDCS (Nuraleve, Canada) (30 seconds of 2mA and 19.5 minutes of 0 mA) with the anode placed over the left dorsolateral prefrontal cortex (dlPFC) and the cathode placed over the right dlPFC for 20 minutes per session.
43818|NCT03841279|Diagnostic Test|MRI|Magnetic resonance imaging (MRI) produces detailed images of the body's internal structures without relying on radiation. It is used to diagnose and also gauge efficacy of treatment.
44007|NCT03839797|Behavioral|Standard Health Education|Standard Health Education
43819|NCT03841266|Diagnostic Test|recurrence risk evaluation|Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.
43820|NCT03841253|Procedure|Trans-epithelial PTK|The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.
43821|NCT03841253|Device|EpiMaster Application Software|The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
43822|NCT03841227|Device|Active-tDCS|Active home-based tDCS applied at home. 5 days a week for 4 weeks.
43823|NCT03841227|Device|Sham-tDCS|Sham home-based tDCS applied at home. 5 days a week for 4 weeks.
43824|NCT03841201|Drug|Lenvatinib|oral
43825|NCT03841201|Drug|Nivolumab|iv infusion
43826|NCT03841188|Other|Nutritional orientation|Nutritional orientation with emphasis in rich calcium food
43827|NCT03841149|Other|Ultrasound Imaging|3D volume calculation using on-line and off-line softwares
43828|NCT03841136|Drug|anlotinib|anlotinib 12mg PO QD CBP(AUC 5mg/mL/min，or DDP（75mg/m2）D1 etoposide（100mg/m2）D1~D3
43829|NCT03841123|Other|Dietary Counseling|"The intervention will consist of an individualized, face-to-face, 20 to 30 minute counseling session to mothers by trained health workers who will address healthy eating practices during the first two years of life. A printed, colorful and illustrated material will be used to assist mothers in appropriate food choices, mainly to avoid the introduction of sugar and ultra-processed foods. In addition, they will receive a booklet which addresses the Ten Steps of Healthy Feeding for children from Birth to Two years of life. The research team will focus on Step2: Do not give added sugar or foods with added sugar, and Step8:Do not offer ultra-processed foods as candies and soft drinks. To reinforce the intervention, mothers will receive telephone calls up to the infant reach six months."
43830|NCT03841110|Drug|FT500|FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy
43831|NCT03841110|Drug|Nivolumab|Immune Checkpoint Inhibitor
43832|NCT03841110|Drug|Pembrolizumab|Immune Checkpoint Inhibitor
43833|NCT03841110|Drug|Atezolizumab|Immune Checkpoint Inhibitor
43834|NCT03841110|Drug|Cyclophosphamide|Lympho-conditioning agent
43835|NCT03841110|Drug|Fludarabine|Lympho-conditioning agent
43836|NCT03841097|Drug|Extended Release Tacrolimus Tablets|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
43837|NCT03841097|Drug|Immediate Release Tacrolimus Capsule|The primary objective is to assess the change in pulse wave velocity (PWV) and vascular compliance measurements from baseline to 12 months after transplant in kidney recipient subjects on LCPT compared to those on IR-Tac.
43838|NCT03841084|Drug|Oxygen|"Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit"
43839|NCT03841071|Other|ROM/CFS intervention|The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
43840|NCT03841058|Drug|Abaloparatide|80 mcg delivered SC by a pen
43841|NCT03841058|Drug|Placebo|A pen to deliver a SC dose of placebo
43842|NCT03841032|Drug|Coppertone, BAY1183345|Lotion, for 4 weeks
43843|NCT03841019|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of MST in four weeks (three sessions per week)
43844|NCT03841019|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive twelve sessions of ECT in four weeks (three sessions per week)
43845|NCT03841006|Device|MRI|dynamic MRI pelvis
43846|NCT03840993|Drug|MT-2990|IV
43847|NCT03840993|Drug|Placebo|IV
43848|NCT03840967|Drug|Niraparib|Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
43849|NCT03840954|Other|Neuromuscular Electrical Stimulation|"The application of NMES will be performed with the patient positioned in the supine position in the bed. Self-adhesive electrodes will be positioned at the motor points of the quadriceps and anterior tibial muscles respectively. A symmetrical biphasic pulsed current with a frequency of 80 Hz, a pulse width of 500 μs and an intensity at the motor threshold will be applied up to the maximum tolerated by the patient. ON and OFF time and total session time will be used according to protocol with progressive increase of the total intervention time and reduction of OFF time of the NMES. The device used will be the Neurodyn II model, manufactured by IBRAMED.~Patients will receive NMES for as long as they remain hospitalized or for up to 3 weeks."
43850|NCT03840915|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 75 milligrams per meter square (mg/m^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
43851|NCT03840915|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
43852|NCT03840915|Drug|Pemetrexed|Pemetrexed will be administered intravenously at a dose of 500 mg/ m^2 over 10 minutes every 21 days.
43853|NCT03840915|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered intravenously at as dose of 100 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).
43854|NCT03840915|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a dose of 1250 mg/m^2 over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).
43855|NCT03840915|Drug|Docetaxel|Docetaxel will be administered intravenously at a dose of 75 mg/m^2 over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
44008|NCT03839784|Combination Product|Neurocognition Interventions|EEG, Neurocognitive Battery Testing, and Immune Profiles
43856|NCT03840915|Drug|M7824|M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 and pemetrexed.
43857|NCT03840915|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
43858|NCT03840915|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).
43859|NCT03840915|Drug|M7824|M7824 will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with M7824 alone.
43860|NCT03840902|Drug|M7824|Participants will receive intravenous infusion of 1200 milligram (mg) M7824 over 1 hour every 2 weeks (q2w) during cCRT and up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
43861|NCT03840902|Drug|Placebo|Participants will receive intravenous infusion of placebo matched to M7824 over 1 hour q2w during cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
43862|NCT03840902|Drug|Durvalumab|Participants will receive intravenous infusion of durvalumab 10 milligram per kilogram (mg/Kg) over 1 hour q2w up to 1 year after cCRT until unacceptable toxicity, confirmed disease progression assessed by investigator.
43863|NCT03840902|Drug|Etoposide|Participants will receive etoposide 50 mg/m^2 intravenously over a minimum of 30 minutes up to 60 minutes daily on Day 1 to 5 and Day 29 to 33 during cCRT.
43864|NCT03840902|Drug|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m^2 intravenously over 10 minutes or according to local standards on Days 1, 22, and 43 during cCRT.
43865|NCT03840902|Drug|Carboplatin|Participants will receive carboplatin intravenously based on area under curve (AUC) 2 over 30 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
43866|NCT03840902|Drug|Paclitaxel|Participants will receive paclitaxel intravenously at a dose of 45 mg/m^2 over 60 minutes on Day 1, Day 8, Day 15, Day 22, Day 29, Day 36, and Day 43 during cCRT.
43867|NCT03840902|Drug|Cisplatin|In combination with etoposide, participants will receive cisplatin 50 mg/m^2 intravenously over 60 minutes on Days 1, 8, 29, and 36 during cCRT. In combination with pemetrexed, participants will receive cisplatin 75 mg/m2 intravenously over 60 minutes on Days 1, 22, and 43 during cCRT.
43868|NCT03840902|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Participants will receive IMRT 5 fractions per week for about 6 weeks (Total 60 gray [Gy]).
43869|NCT03840889|Other|Data collection|"he different modes of active data collection:~Data collection by telephone~Data collection by mail~Collection from discharge database summaries (PMSI)"
43870|NCT03840876|Device|WEI NASAL JET (WNJ)|Jet ventilation was achieved with WEI NASAL JET (WNJ) connected to a manual jet ventilator (Driving pressure: 40 psi, fraction of inspired oxygen: 100% O2, Respiratory rate: 25/min, I/E ratio: 40%)
43871|NCT03840863|Dietary Supplement|Commercially-Available Energy Drink|Participant will consume 2 cans of an energy drink (16 oz./can) per day. One in the morning and one in the afternoon.
43872|NCT03840850|Other|Personalized Risk Communication for People with Type 2 Diabetes|The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy. These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
43873|NCT03840837|Drug|Rivastigmine transdermal patch|Titration of transdermal rivastigmine, as per arm description.
43874|NCT03840811|Drug|Cefixime|Mandatory rescue therapy consisting of cefixime 400 mg orally in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
43875|NCT03840811|Drug|Ceftriaxone|Mandatory rescue therapy consisting of ceftriaxone 250 mg intramuscularly in a single dose: on patient request, at the onset of symptoms or on the 5th study day after inoculation.
43876|NCT03840811|Drug|Ciprofloxacin|Mandatory antibiotic treatment failure therapy: Ciprofloxacin 500 mg orally in a single dose: if the subject has a positie test of cure 1 week post initial antibiotic treatment
43877|NCT03840811|Biological|Neisseria gonorrhoeae strain FA1090 A26|0.4 mL of a suspension containing 10^5 - 10^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter.
43878|NCT03840811|Biological|Neisseria gonorrhoeae strain FA7537|0.4 mL of a suspension containing 10^5 - 10^6 CFU of Neisseria gonorrhoeae, in phosphate-buffered saline, delivered to the anterior urethra through a No.8 pediatric French catheter
43879|NCT03840798|Other|Child Abuse Clinical Decision Support system|"The investigators are implementing the following aspects of the Electronic Health Record (EHR) based child abuse- clinical decision support (CA-CDS) system.~a universal child abuse screen (CAS)~an embedded child abuse alert system~alerts to physicians and advanced practice providers~physical abuse order sets"
43880|NCT03840785|Other|Argentine tango|"Argentine tango sessions will consist of:~Body perception and body control: sitting, standing then moving around four axes : space, time, energy, gravity.~Awareness of oneself, of other and music: listening, communication, touch, empathy, kinesthesia, letting go, feeling"
43881|NCT03840772|Drug|Eribulin|Treatment with eribulin
43882|NCT03840759|Other|inpatient geriatric consultation team|For the intervention group, a geriatric physician was consulted and recommendations were made by the geriatric consultant after a complete CGA.
43883|NCT03840746|Other|Tomato, onion and lovage soup (TOL)|Soup
43884|NCT03840746|Other|TOL soup with inulin|Soup
43885|NCT03840707|Behavioral|LIFEwithIBD|"LIFEwithIBD programme is a psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for inflammatory bowel disease patients~Treatment as Usual (TAU): Standard personalized treatment of inflammatory bowel disease"
43886|NCT03840694|Other|Conventional Nicotine Cigarette|Participants will smoke two conventional nicotine cigarettes prior to one of the MRI visits. They will also use these cigarettes exclusively for one week during the second phase of the study.
43978|NCT03839979|Diagnostic Test|ErKameter 3000 mercury manometer|For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
43887|NCT03840694|Other|Reduced Nicotine Cigarette|Participants will smoke two reduced nicotine cigarettes prior to one of the MRI visits. They will also use these cigarettes exclusively for one week during the second phase of the study.
43888|NCT03840681|Other|Augmentation|non invasive technique to increase bone width and eliminate need for second surgery
43889|NCT03840668|Device|USB Eye Mask|To evaluate the acceptance of the USB eye mask via questionnaire and also to monitor the use of USB eye mask over a period of 3 months.
43890|NCT03840655|Procedure|Near-Infrared Imaging Thoracoscopy|Sympathicotomy performed by near-infrared imaging thoracoscopy
43891|NCT03840642|Behavioral|Mirror Me|Mirror Me is a telehealth parent training intervention that teaches parents to promote their child's social imitation during play and daily routines. It uses content from Reciprocal Imitation Training (RIT), an evidence-based NDBI that teaches social imitation within affect-laden playful interactions. Mirror Me presents intervention content in four interactive modules. Program development was guided by the technology acceptance model, media richness theory, and principles of instructional design.
43892|NCT03840642|Behavioral|Remote Coaching|Trained therapists will provide feedback to parents as they use the RIT techniques with their child at home. All sessions will follow a similar format including a discussion of accomplishments and challenges, parent practice with feedback, problem solving, and planning for the next week
43893|NCT03840629|Other|No study intervention.|
43894|NCT03840616|Drug|VT-1161 150 mg capsule|During Part 1, administered orally once daily for 2 days. During Part 2, administered orally once weekly for 11 weeks starting on Day 14.
43895|NCT03840616|Drug|Fluconazole 150 mg|During Part 1, administered orally 3 sequential doses (every 72 hours).
43896|NCT03840616|Other|Placebo|During Part 2, administered orally once weekly for 11 weeks starting on Day 14.
43897|NCT03840603|Diagnostic Test|Film Array RP2 Assay guided|Nasopharyngeal swab sample collected from subjects with a suspected LRTI for the Film Array RP2 assay plus a blood sample for the PCT assay.
43898|NCT03840590|Device|CSK AI system|CSK system is equipped with the endoscopic mainframe and alarms the examiners when suspect lesions appear.
43899|NCT03840590|Device|Standard Colonoscopy|This is the routine examination in nowadays clinical practice. Both the equipment and the procedure are as usual as clinical routine.
43900|NCT03840577|Device|Monitorization of sedation by Bispectral Index|"The BIS value of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The objective of BIS will be between 40 and 60.~According to the BIS of the patient at the time of the evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target BIS, with 20% modifications of the current dose at the time of evaluation.~The dose of sedative used will be recorded in the electronic medical record. The BIS values will be saved in the equipment and downloaded every 72 hours."
43901|NCT03840577|Other|Monitorization of sedation by clinical scales|"The BIS monitor will be placed on the patient but it will be left blind to the nursing team, the BIS values will be stored in the equipment and downloaded every 72 hours.~The RASS of the patient will be evaluated twice per nursing shift (every 4 hours) and will be recorded in the electronic medical record. The RASS will be evaluated by a research team member.~According to the patient's RASS at the time of evaluation, the dose of sedative administered in a continuous infusion pump will be increased or reduced in order to reach the target RASS. The modification of infusion speed will be done by the nurse in charge of the patient. The dose of sedative applied will be recorded in the electronic medical record."
43902|NCT03840564|Other|Point of care (POC)|All the analyzes will be done in delocalized
43903|NCT03840551|Other|Biomechanical analysis with inertial sensors (XSENS) and motion capture (BTS)|The kinematics of lower limbs, trunk and upper limbs will be calculated both with inertial sensors (XSENS) and motion capture marker-based system (BTS ). Inertial sensors and markers will be placed on the subjects clothes and on the skin (totally non-invasive) to identify body segments. Then subjects will perform their motor tasks normally. Lately, through the data post-processing, the kinematics evaluated with both the systems will be used to describe how well the task is performed in terms of ACL prevention, through derived biomechanical parameters.
43904|NCT03840538|Drug|Probiotic Product - Cap|probiotic capsule complex composed of L.acidophilus, L. bulgaricus, Streptococcus thermophilus, and Bifidobacterium bifidus
43905|NCT03840525|Behavioral|The Qigong Intervention|Qigong is a low-impact, slow-movement, meditative form of exercise that has helped relieve mental and physical stressors.
43906|NCT03840525|Behavioral|Sham Qigong|This intervention includes similar body movements to qigong; however, it does not have the meditative or breath work.
43907|NCT03840512|Drug|CBD|"CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).~Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin."
43908|NCT03840499|Drug|Optimal medical therapy|Optimal medical therapy
43909|NCT03840486|Device|Non-rebreather mask (NRBM)|The non-rebreather mask (NRBM) will be used to assist in the delivery of oxygen. Participants will be placed on NRBM at different flow rates (15 LPM (Liter per minute), 35 LPM, or Flush rate at 55 LPM).
43910|NCT03840486|Device|Non-invasive ventilator mask (NIV)|The NIV is a non-invasive face (nasal) mask for oxygen delivery. Participants will receive oxygen at 50% FiO2 for 3 minutes, 75% FiO2 for 3 minutes or 100% FiO2 for 3 minutes each.
43911|NCT03840486|Device|Nasal cannula EtO2 sensor|The nasal cannula EtO2 sensor will be placed on the participant's face under the mask to detect the EtO2 levels.
43912|NCT03840486|Drug|Oxygen (NRBM)|Oxygen will be delivered via the NRBM. Participants will receive oxygen at different flow rates (15 LPM (Liter per minute), 35 LPM, or flush rate at 55 LPM).
43913|NCT03840486|Drug|Oxygen (NIV)|Oxygen will be delivered via the NIV mask. Participants will receive oxygen at 50% FiO2, 75% FiO2 or 100% FiO2 for 3 minutes each.
43914|NCT03840473|Behavioral|MET|The patient was in a supine position with the cervical spine in the opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were in a lengthened position.19 The moderate isometric contraction (approximately 75% of maximal) of the upper trapezius muscles was elicited for a period of 5 seconds followed by 3 seconds of relaxation while reaching the new barrier. The technique was repeated four times in each session.
44006|NCT03839797|Behavioral|Cadet Healthy Personal Skills|7.5 hour skills training group intervention
43915|NCT03840473|Behavioral|ICT|The patient lying in the supine position with the cervical spine in opposite lateral flexion to the treating part so that the upper trapezius muscle fibers were kept in a lengthened position.18,22 The physiotherapist applied gradually increasing pressure to the MTrPs until the subject perceived the first noticeable pain. At that moment, the pressure was maintained until the discomfort and/or pain eased by around 50% as perceived by the patient, at which time the pressure was increased until the discomfort appeared again. This process was maintained for 90 seconds.
43916|NCT03840473|Behavioral|Conventional Intervention|Hot packs (75°C) for 20 minutes and active stretching exercises for the upper trapezius muscle (slow, 5 repetitions per session, 10-second hold and 10-second relaxation between two repetitions). Active stretching exercises were done by all the participants under the supervision of the physical therapist. This approach was standardized for all participants.
43917|NCT03840447|Behavioral|Chronic Disease Self-Management programme|"The primary aim of the intervention is to achieve greater self-management of the chronic condition by changing the role of the passive citizen to empowerment in self-confidence and self-reliance. The intervention consists of a series of 6 workshops (with 7 to 8 activities), 2.5 hours each, which are held once a week for 6 weeks. One professional and one peer will volunteer together to lead a series of workshops. To this end, professionals and peers will be recruited and trained in the CDSMP principles.~Over 6 workshops, citizens set realistic health goals, learn to self-manage pain and discomfort, to self-manage their diet, self-manage physical activity, mood and the way the disease influences their personal relationships. The intervention is designed to actively involve citizens."
43918|NCT03840434|Diagnostic Test|MyotonPRO|Each patient will perform a stress test to trigger the painful. Measurements will be done by intramuscular punction as usually, and by non invasive tool : MyotonPRO
43919|NCT03840421|Drug|gemcitabine and cisplatin|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
43920|NCT03840421|Drug|cisplatin and fluorouracil|Patients receive fluorouracil (800mg/m2 d1-5) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
43921|NCT03840421|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 30～33 fraction with five daily fractions per week for 6-7 weeks to a total dose of 68～70 Gy to the primary tumor
43922|NCT03840421|Drug|cisplatin|IMRT concurrently with cisplatin 100 mg/m² every 3 weeks for 2 cycles.
43923|NCT03840408|Other|Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation|Patients will be treated with mitochondria-targeted system therapy and radiofrequency ablation in the primary tumor sites
43924|NCT03840408|Procedure|Surgery|Patients will be treated with surgery
43925|NCT03840395|Device|Pharyngeal Electrical Stimulation (PES)|The Phagenyx® system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation to the oropharynx. The Phagenyx® devices are CE labelled (2012) and will be used in accordance with their intended use label.
43927|NCT03840369|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) works by delivering a magnetic pulse to a focal brain region. TMS has a high degree of safety and has been studied as an intervention for many mental health and neurological conditions. Repetitive TMS (rTMS) delivers pulses at a set time interval in order to modulate neural activity in that region.
43928|NCT03840369|Device|Sham Repetitive Transcranial Magnetic Stimulation|The sham TMS coil will make a similar sound to the real rTMS coil, but will not deliver a magnetic pulse. This is a no-treatment device.
43929|NCT03840356|Other|Postoperative|No intervention is planned in the study. This study is simply evaluating the consistency with which patients report their pain levels to different members of the medical team.
43930|NCT03840343|Biological|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Two MSC infusions of 2.5x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
43931|NCT03840343|Biological|Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose|Two MSC infusions of 5.0x10^5 cells/kg at time zero and three months; single kidney, intra-arterial delivery
43932|NCT03840330|Other|Experimental: High-intensity interval training group|16 weeks of High-intensity interval training
43933|NCT03840330|Other|Experimental: Moderate-intensity interval training group|16 weeks of Moderate-intensity interval training
43934|NCT03840317|Biological|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells
43935|NCT03840304|Other|Yoga@work|Each session included warm-up practices(for the large joints, spine, and extremities), Physical postures (Asana), breathing exercises (pranayama) and supine meditation/relaxation (savasana).
43936|NCT03840291|Drug|Edoxaban|Edoxaban will be used for resolution of left atrial appendage thrombi
43937|NCT03840278|Device|Bihormonal iLet Bionic Pancreas|Bihormonal iLet Bionic Pancreas using insulin and dasiglucagon
43938|NCT03840278|Device|Insulin-only Bionic Pancreas|Insulin-only iLet Bionic Pancreas using just insulin
43939|NCT03840278|Drug|Dasiglucagon|Experimental stable glucagon for use in the iLet Bionic Pancreas
43940|NCT03840265|Procedure|carotid endarterectomy|In this project the following parameters will be assessed both in asymptomatic and symptomatic patients underwent carotid endarterectomy: 1) hemodynamic modeling of effect of the supraaortic arteries anatomic variations and pathologies 2, preoperative stroke risk prediction based on comparative analysis of CTA results of plaque morphology and ultrasound-based plaque elastography analysis, 3) cerebral flow measurement by transcranial Doppler sonography(TCD), 4) presence recent of silent brain ischemia on DWI-MRI, 5) OCT angiography could be a useful non-invasive method for evaluation of the outcome of carotid interventions
43941|NCT03840252|Other|3D gait analysis|
43942|NCT03840239|Drug|Capecitabine, Oxaliplatin|Drug: Capecitabine, Oxaliplatin
43943|NCT03840239|Radiation|External beam radiotherapy|External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume
43944|NCT03840239|Procedure|Surgery|'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries
43945|NCT03840239|Other|Watch and wait strategy|Watch and wait strategy recommendation and discussion for cCR patients
43948|NCT03840213|Behavioral|Filling a questionnaire and interviewDescription|"The questionnaire focuses on the dietary practices of patients treated with chemotherapy. It consists of 35 questions, completing an average of 20 minutes.~Interviews will be conducted with patients who have changed their diet since the beginning of their treatment in order to further develop the results of the quantitative survey."
43949|NCT03840200|Drug|Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib|Ipatasertib, 300 mg administered PO QD for 7 days (run-in period prior to Cycle 1), then administer 300 mg PO QD for each cycle. Each cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
43950|NCT03840200|Drug|Part 1, Dose level 2b and dose level 3: Ipatasertib|Ipatasertib, 400 mg administered PO QD for 7 days (run-in period prior to Cycle 1), then administer 400 mg PO QD for each cycle. One cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
43951|NCT03840200|Drug|Part 1, Dose Level 1 and Dose Level 2b: Rucaparib|Rucaparib is administered 400 mg twice daily (BID) for each cycle. One cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
43952|NCT03840200|Drug|Part 1, Dose Level 2a and Dose Level 3: Rucaparib|Rucaparib is administered 600 mg twice daily (BID) for each cycle. One cycle has 28 days. Doses are administered until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
43953|NCT03840187|Diagnostic Test|Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system
43954|NCT03840174|Biological|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)
43955|NCT03840174|Other|Placebo|Saline solution administered as a 0.5 mL IM injection
43956|NCT03840161|Device|non-invasive tissue glucose prediction|Generation of non-invasive and invasive glucose readings for comparison with a standard laboratory reference glucose determination method (YSI glucose analyzer)
43957|NCT03840148|Drug|Cefepime/VNRX-5133|Patients will also receive meropenem placebo administered via IV over 30 minutes.
43958|NCT03840148|Drug|Meropenem|Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
43959|NCT03840135|Drug|Polyoxidonium 6 mg/ml|"Nasal and sublingual spray Polyoxidonium 6 mg/ml will be administered at a dose of 0,15 mg/kg daily for 7 days:~in children aged from 1 to 2 years - 1 sublingual spay 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 intranasal spay (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 intranasal spay (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 intranasal spay (in each nasal passage) 2 times a day (every 12 hours)."
43960|NCT03840135|Other|Placebo|"Placebo nasal and sublingual spray will be administered for 7 days:~in children aged from 1 to 2 years - 1 sublingual spay 2 times a day (every 12 hours); in children aged from 2 to 5 years - 1 intranasal spay (in each nasal passage) 2 times a day (every 12 hours; in children aged from 5 to 8 years - 1 intranasal spay (in each nasal passage) 3 times a day (every 8 hours); in children aged from 8 to 12 years - 2 intranasal spay (in each nasal passage) 2 times a day (every 12 hours)."
43961|NCT03840122|Other|ACB + IPACK block with injection of local anesthetic|"ACB + IPACK block with injection of local anesthetic which is comprised of the following agents and amounts:~Ropivacaine 5mg/ml (49.25ml)~Epinephrine 1mg/ml (0.5ml)~Ketorolac 30mg/ml (1ml)~Clonidine 0.1mg/ml (0.8ml)~Saline 48.45ml"
43962|NCT03840122|Other|ACB + IPACK block without injection|ACB + IPACK block without an injection of local anesthetic
43963|NCT03840109|Behavioral|Questionnaire|Participants will take an online questionnaire which includes their evaluation of one of 18 different emotional support messages randomly assigned through the Qualtrics survey system. Participants answer a series of closed ended scales regarding quality of the support message, supporter's competence, amount of emotional improvement they experienced after reading the message, and likelihood to seek support from the person writing the message.
43964|NCT03840096|Device|Breg Flex|All subjects in the treatment group will receive quadriceps Neuro Muscular Electrical Stimulation using Breg Flex device on the affected leg to guide and monitor of knee HEP during the 6 weeks prior to surgery and 12 weeks following surgery.
43965|NCT03840083|Behavioral|Sleep|Participants will sleep (either a mid-day nap or normal overnight sleep)
43966|NCT03840070|Device|Potenfill|Maximum: 22ml
43967|NCT03840057|Drug|Azithromycin Injection|Azithromycin, a semi-synthetic macrolide antibiotic derived from erythromycin. The role of azithromycin as a prokinetic agent was first reported in a retrospective cohort study, which showed azithromycin to be equivalent to erythromycin in accelerating gastric emptying in patients with gastroparesis. The aim of this intervention arm is to evaluate the effectiveness of azithromycin as a prokinetic agent in the management of UGIB.
43968|NCT03840057|Drug|Metoclopramide Injectable Solution|Metoclopramide, a 5-HT4 agonist and a dopamine D2-receptor antagonist, is approved for short-term treatment of gastroparesis. The use of metoclopramide as a prokinetic agent in the setting of UGIB has been previously studied, but the number of subject involved was too low to adequately power the studies. The aim of this intervention arm is to further evaluate the effectiveness of metoclopramide as a prokinetic agent in the management of UGIB.
43969|NCT03840057|Drug|Sodium chloride 0.9%|Normal saline is used as a placebo control.
43970|NCT03840044|Other|Cold air exercise test|Subjects will perform a submaximal 90 minutes exercise test in a controlled cold air environment (-5°C, 60% relative humidity) in a climate chamber with evaluation pre§/during*/post§ of heart rate (HR)§* and blood pressure (BP)§*, spirometry§*, PNIF§, FeNO§, electrocardiogram (ECG)§*, body & exhaled air temperature§*, capsaicin cough threshold test§, histamine bronchial challenge test§, and sampling of nasal fluid§, induced sputum§, and venous blood§.
43971|NCT03840031|Other|High Fe OFSP meal labelled with Fe-58|400 gram steamed, mashed OFSP high Fe with 0.33 mg FeSO4-58 daily for 10 days
43972|NCT03840031|Other|Control OFSP meal labelled with Fe-57|400 gram steamed, mashed OFSP control with 0.33 mg FeSO5-57 daily for 10 days
43973|NCT03840018|Other|Letter by post to patients|Patients received an informative letter by post, in which their doctor invited them to seek an appointment for a medication review
43974|NCT03840005|Drug|Ursonorm|Ursodeoxycholic acid
43975|NCT03839992|Diagnostic Test|spirometry|measure spirometry and lung CT
43979|NCT03839966|Behavioral|Interpretation Bias Modification for Loneliness|Participants will receive eight treatment sessions. They will be presented with ambiguous training scenarios on a computer screen. Scenarios will be presented in two discrete formats: a word-sentence relatedness task (adapted from Beard & Amir, 2008 and Beard, Weisberg, & Amir, 2011), and a sentence completion and comprehension task (adapted from paradigms used by Mathews and Mackintosh (2000), Steinman and Teachman (2010), and Beard and Amir (2008)). Both of these formats have been used to reduce maladaptive threat interpretations and increase benign interpretations.
43980|NCT03839966|Behavioral|Healthy Habits Psychoeducation and Relaxation|Participants will receive eight computerized sessions consisting of psychoeducation on healthy behaviors as well as relaxing video clips with pleasant music (e.g., videos of rainforests, wildlife, and space). These sessions will be matched for time with the active condition, lasting approximately 25-30 minutes each. Psychoeducation will cover the topics of exercise, diet, hygiene, social support, healthy activities, and sleep. The relaxing videos will be presented after the psycho-education in each session. At the conclusion of the study, participants will be provided with the active IBM treatment free of charge if they wish to receive it.
43981|NCT03839953|Behavioral|Supervised Exercise Program|This intervention is a 12-week supervised exercise program at an established cardiac rehabilitation facility.
43982|NCT03839953|Other|Best Medical Therapy|After undergoing revascularization for critical limb ischemia, patients will receive best medical therapy under the supervision of a vascular internal medicine specialist. This care will include advice on smoking cessation, physical activity guidelines, blood pressure regulation, statin administration and possible anti-platelet administration.
43983|NCT03839940|Drug|Dexamethasone|Given as mouthwash
43984|NCT03839940|Other|Placebo|Given as mouthwash
43985|NCT03839940|Other|Questionnaire|Ancillary studies
43986|NCT03839940|Other|Quality-of-Life Assessment|Ancillary studies
43987|NCT03839940|Drug|Everolimus|Standard of care
43988|NCT03839927|Other|Validity and reliability of Life-Space Assesment|Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
43989|NCT03839914|Drug|Vancomycin powder|For the intervention group, the use of 1g vancomycin powder to be placed in the deep wound and subcutaneous layer prior to closure.
43990|NCT03839901|Other|Home exercise program|Home exercise programme with participants followed up at week 1, 4, 6 and 8.
43991|NCT03839888|Drug|0.125% Atropine|patients used 0.125% atropine eyedrop per night before sleep for 7 days.
43992|NCT03839875|Drug|Gynomax® XL Vaginal Ovule|tioconazole, tinidazole, lidocaine
43993|NCT03839862|Drug|TNF-inhibition|Initiation of immunosuppression with any TNF-inhibitor, e.g. infliximab, etanercept or adalimumab
43994|NCT03839849|Procedure|: i-PRF|The description of this intervention has been already given before
43995|NCT03839849|Procedure|saline|The description of this intervention has been already given before
43996|NCT03839836|Other|Backpack child's body weight|Children are asked to walk naturally, facing forward, with their hands out of pockets; wearing light, comfortable clothes, with the BP placed correctly. As the children start walking, the researchers select the foot of the first step inside the bars, in the Optogait software. After being instructed to 'walk slowly at a comfortable speed', the children walk from a point two metres in front of the bar and stop at a point two metres behind the last bar, to minimize effects of acceleration and deceleration . A three-minute interval occurs between individual assessments to transmit the data, as well as to prepare for the next assessment. Only steps in the sensor areas are included in the analysis. Recording six to eight strides is reported as sufficient to obtain representative data for unimpaired adults. Subsequently, five experimental conditions are measured: without BP, BP loads of 5%, 10%, 15%, and 20% of body weight. The order of these loaded conditions are random.
43997|NCT03839823|Combination Product|Docetaxel / Capecitabine|"Docetaxel (IV Infusion) / Capecitabine (Tablets for oral use):~Docetaxel once, on day 1 of the 3-weeks cycle Capecitabine twice daily, on Days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle.~Docetaxel (60 - 75 mg/m²)/capecitabine (1600 - 2500 mg/m²)"
43998|NCT03839823|Combination Product|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion )~Capecitabine twice daily on days 1 to 14, followed by a 1-week rest period, in 3 weeks cycle Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2 [oral] or (25 to 30 mg/m2 [IV infusion]"
43999|NCT03839823|Combination Product|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2) (on Day 1 in 3-weeks cycles)/ gemcitabine (1000 - 1250 mg/m2/day)~OR~Paclitaxel (80 - 90 mg/m2) (on Day 1 and Day 8 in 3-weeks cycles) / gemcitabine (800 1000 mg/m2)"
44000|NCT03839823|Drug|Ribociclib|dose: 600 mg Days 1 to 21 of each 28 day cycle Tablets for oral use
44001|NCT03839823|Drug|Letrozole OR Anastrozole|"Letrozole:~Dose: 2.5 mg All days of every cycle without interruption). Tablets for oral use~Anastrozole:~dose: 1 mg All days of every cycle without interruption. Tablets for oral use~The NSAI (letrozole or anastrozole) will be decided by the treating physician."
44002|NCT03839823|Drug|Goserelin|dose: 3.6 mg Day 1 of each 28 day cycle Subcutaneous implant
44003|NCT03839823|Combination Product|Capecitabine / Vinorelbine|"Capecitabine (Tablets for oral use) / Vinorelbine (Capsule for Oral use/IV infusion )~Capecitabine twice daily on days 1 14, followed by a 1-week rest period, in 3 weeks cycle Vinorelbine, once, on Day 1 and Day 8 in 3 weeks cycles~Capecitabine (1600 - 2500 mg/m2/day)/vinorelbine (60 to 80 mg/m2 [oral] or (25 to 30 mg/m2 [IV infusion]"
44004|NCT03839823|Combination Product|Paclitaxel / Gemcitabine|"Paclitaxel (IV Infusion) / Gemcitabine (IV Infusion):~Paclitaxel via 3-hour intravenous (IV) infusion on Day 1 in 3-weeks cycles, OR Paclitaxel via 1 hour intravenous (IV) infusion on Day 1 and day 8- in 3-weeks cycles.~Gemcitabine at via 30 minute IV infusion on Day 1 and Day 8 in 3 weeks cycles.~Paclitaxel (175 mg/m2)/ gemcitabine (1000 - 1250 mg/m2/day)~OR~Paclitaxel (80 - 90 mg/m2)/ gemcitabine (800 1000 mg/m2)"
44005|NCT03839810|Other|stochastic resonance electrical stimulation|"stochastic resonance electrical stimulation is applied in the upper extremity during motor functional training.~Sham comparator group uses sham stimulation - same electrode location, but no electrical current is applied during motor functional training"
44013|NCT03839758|Procedure|TSA standard|Glenoid preparation will be done with 2D CT-Scan
44014|NCT03839758|Procedure|RTSA standard|Glenoid preparation will be done with 2D CT-Scan
44015|NCT03839758|Procedure|TSA Blueprint|Glenoid preparation will be done with Blueprint software
44016|NCT03839758|Procedure|RTSA Blueprint|Glenoid preparation will be done with 2D CT-Scan
44017|NCT03839745|Other|Electronic Cigarette|E-cigarette Device: The delivery device will be a variable wattage all-in-one device with operating wattage of 7.0 - 75.0 W, which is inclusive of the three power levels we intend to study.
44018|NCT03839732|Diagnostic Test|Score of abdominal aorta calcifications|Radiographs showing VC will be used to assess whether the computer assisted VC scoring (primary objective) and Quantitative Vertebral Morphometry (QVM, limited to lumbar spine, secondary objective n.1) through the Calcify2D software are less variable with respect to the traditional visual scoring of VC and QVM.
44019|NCT03839719|Procedure|Group PI|Before rinsing with the mouthrinse, Ultrasonic scaling was done in the 1st and 4th quadrant without any mouth rinse (placebo mouthrinse) and fall out samples were collected in the blood agar plates kept at a distance of 0.5 m and 1 m from the oral cavity.
44020|NCT03839719|Procedure|Group OC|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
44021|NCT03839719|Procedure|Group CHX|After ultrasonic scaling of the 1st and 4th quadrant minimum 30min interval maintained. After interval of 30min rinsing the mouth with the either OC/CHX/Placebo (OC= Ocimum sanctum mouthrinse, CHX=Chlorhexidine Gluconate mouthrinse) mouthrinse) done for 60s, Ultrasonic scaling was again done in the 2nd and 3rd quadrant and fall out samples were collected in the newly placed blood agar plates kept at 0.5 m and 1 m away from the patient.
44022|NCT03839706|Device|PET MRI|18F-Fluorodeoxyglucose Positron Emission Tomography combined with Primovist MRI
44023|NCT03839693|Biological|botulinum toxin, Type A|topical liniment
44024|NCT03839693|Biological|Vehicle|Vehicle Formulation
44025|NCT03839680|Procedure|Endoscopy|The endoscopy procedure uses an endoscope to examine the interior of a hollow organ or cavity of the body.
44026|NCT03839667|Behavioral|intensive diet intervention|the participants will be instructed to restrict the total daily calorie intake to 800 kcal by receiving the very-low-calorie meal replacement formula for 2 consecutive days per week. They will be allowed to maintain their normal diet in the remaining 5 days, but need to restrict total intake to 2000 kcal per day.
44027|NCT03839667|Behavioral|Enhanced physical activity intervention|the participants will take high-intensity exercise in accordance with High Intensity Interval Training (HIIT) prescriptions, with maximum heart rate and relative maximal oxygen uptake monitored. They will take both aerobic and resistance training exercise consecutively, and total training time will be expected to reach at least 150 minutes per week.
44028|NCT03839667|Behavioral|Standard education|the participants will receive no extra intervention but diabetes health education, which will be carried out in large classrooms, in groups, and over the telephone. The education is mainly consisted of instructions on healthy diet and exercise plans, prevention for acute and chronic complications and self-glycemic monitoring.
44029|NCT03839654|Device|continuous positive airway pressure|The CPAP treatment group received both baseline medicine and CPAP treatment for 7 days preoperatively.
44030|NCT03839641|Other|High fat meal|60% fat meal
44031|NCT03839641|Other|Low fat meal|20% fat meal
44032|NCT03839628|Other|Reduced Physical Activity|Participants will reduce their level of physical activity for 2-weeks as defined as approximately 75% reduction from their baseline level of physical activity.
44033|NCT03839615|Procedure|guided bone regenerations|"intra oral procedures.~Flap will be done.~In the study group: bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral mineral will be packed then covered at the defected area by a native collagen membrane which will be stabilized by tacks.~In the control group: : bone decortication will be done using surgical round bur, autogenous bone will be harvested by trephine bur ,mixed 1:1 with anorganic bovine bone derived mineral and packed at the defected area then covered by a titanium reinforced polytetraflouroethelene membrane which will be stabilized by tacks.~The site will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
44034|NCT03839602|Radiation|Reducing CTV|CTVs were delineated in line with tumor stage, i.e. tumor invasion.
44035|NCT03839589|Behavioral|Mindfulness Based Stress Reduction Adapated (MBSR-A)|Mindfulness-based stress reduction (MBSR) is a group-based intervention developed in 1979 by Dr. Jon Kabat-Zinn to provide mindfulness training in order to decrease stress and improve overall well-being. MBSR has been shown to be effective for a series of patient outcomes including depression, anxiety disorders, sleep disorders, and chronic pain management. MBSR is a structured intervention delivered through an 8-week course of up to 30 participants who meet for 2.5 hours per week.
44036|NCT03839576|Behavioral|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
44037|NCT03839576|Behavioral|Computerized training|Attention, memory, speed of processing, and executive functioning.
44038|NCT03839563|Behavioral|Exercise|Each session will last 60 min, consisting of 10 min of warm-up, 45 min of exercise, and a 5-min cool-down.
44039|NCT03839550|Combination Product|Apatinib Mesylate +SHR-1210|"Apatinib mesylate tablets: 250 mg, orally once a day. Take about half an hour after a meal with warm water (the daily dose should be as much as possible.~SHR-1210: 200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks. A total of 6 months of treatment,starting 4-8 weeks after radical hepatic resection."
44040|NCT03839550|Procedure|Hepatic Arterial Infusion(HAI)|Twice standard HAI treatment, the first treatment was performed 4-8 weeks after radical hepatic resection, and the second treatment was given 4-8 weeks after the first treatment (the specific time interval depends on the recovery of liver function of the patient). The specific dosage regimen is 80-100 mg of epirubicin or 50 mg of epirubicin + oxaliplatin 50 mg per HAI treatment.
79634|NCT03563157|Drug|5-Fluorouracil|5-FU; Fluorouracil Injection
44041|NCT03839537|Other|Exposure measurement|"2 measurements per subject (in warm season and in cold season)~Devices placed inside taxi vehicles on the passenger seat in a sampling bag"
44042|NCT03839537|Other|Spirometry test|"2 measurements per subject - before and after the work shift - in warm and cold seasons~Subject will inhale and exhale in the device"
44043|NCT03839537|Diagnostic Test|Exhaled carbon monoxide test|"2 measurements per subject - before and after the work shift - in warm and cold seasons~Subject will exhale in the device"
44044|NCT03839537|Diagnostic Test|Skin allergy test|- Performed by a physician during the inclusion clinical examination
44045|NCT03839537|Diagnostic Test|Spirometry test|- Performed by a physician during the inclusion clinical examination
44046|NCT03839537|Diagnostic Test|Fractional Exhaled Nitric Oxide Testing|- Performed by a physician during the inclusion clinical examination
44047|NCT03839524|Drug|TG4050|Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
44048|NCT03839511|Procedure|Hyperinsulinemic-hypoglycemic clamp|Subjects will arrive at the inpatient unit in the morning after at least a 10 hour overnight fast. Upon arrival to PBRC, participants will be admitted to the inpatient unit. Following measurement of weight, vitals, and pregnancy test (women only), the 4-hour hypoglycemic clamp procedure (30 minute baseline, 120 minute insulin infusion, and 90 minute recovery) will be performed. Upon completion of the clamp procedure, participants will be provided lunch (Standard American Diet). Following lunch, the CGM sensor will be removed and pending a stable blood glucose level in the normal range, the participant will be discharged from the inpatient unit. This completes the study.
44049|NCT03839498|Drug|Axitinib|"Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3.~Starting dose level 1: 5 mg every morning; 5 mg every evening. Dose level 2: 7 mg every morning; 7 mg every evening. Dose level 3: 10 mg every morning; 10 mg every evening. Dose level -1: 3 mg every morning; 3 every evening. Dose level -2: 2 mg every morning; 2 mg every evening.~Axitinib is supplied as 1 and 5-mg tablets and is administered orally twice a day with or without food, each morning and evening (i.e., every 12 hours). Axitinib will be given as self-administered."
44050|NCT03839485|Drug|Endodontic treatment using Guedes-Pinto Paste|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
44051|NCT03839485|Drug|Endodontic using Guedes-Pinto Paste without antibiotic|Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
44052|NCT03839472|Procedure|CBI|CBI with 5 liters normal saline in 1 liter increments up to 2 hours after TURBT procedure.
44053|NCT03839459|Drug|Denosumab|120mg of Denosumab will be administered subcutaneously once every 4 weeks
44054|NCT03839446|Drug|mitoxantrone + etoposide + gemtuzumab ozogamicin|10 mg/m2 mitoxantrone days 1-5 + 100mg/m2 etoposide days 1-5 + 3mg/m2 gemtuzumab ozogamicin on day 6.
44055|NCT03839433|Drug|Ciclesonide|
44056|NCT03839420|Device|CZM IOL|implantation of CZM IOL
44057|NCT03839420|Device|Competitor IOL|implantation of Competitor IOL
44058|NCT03839407|Device|MUSE Meditation Device|The MUSE Meditation Device guides users in mindful meditation using real-time feedback on brain wave activity.
44059|NCT03839394|Behavioral|Telephone|A series of educational pamphlets on CVD risk reduction plus a telephone-based CVD risk reduction curriculum will be administered by Clinic-Based Case Managers (CCMs). Six modules will be given over 24 weeks in a rotating fashion on topics relevant to CVD risk. Subjects will be given the pamphlets every 2 weeks corresponding with the first time they receive the telephone - based module.
44060|NCT03839394|Other|Educational pamphlets|A series of 6 handouts will be given to controls once monthly over 6 months on the same topics presented in the telephone modules. Educational packets will be primarily drawn from free printed material available at www.learningaboutdiabetes.org and the American Heart Association website.
44061|NCT03839368|Procedure|fixation of angle fracture|open reduction and internal fixation of angle fracture
44062|NCT03839355|Drug|Apixaban|Dosage either 5mg or 2.5mg for 2 years
44063|NCT03839355|Drug|Warfarin|Dosage assessed by your treating physician for 2 years
44064|NCT03839342|Drug|Binimetinib|MEK inhibitor, 45mg oral tablet
44065|NCT03839342|Drug|Encorafenib|BRAF inhibitor, 450mg oral capsule
44066|NCT03839329|Behavioral|Acceptance and Commitment Training|Acceptance and Commitment Therapy is an acceptance- and mindfulness-based psychotherapy that aims to foster psychological flexibility.
44067|NCT03839316|Device|tDCS|A constant current stimulator (ZMI Electronics LTD.,Taiwan,2012) will be used through 2 saline-soaked surface gel-sponge electrodes (22 cm2 active area). Real stimulation consisting of thirty minutes of 2 mA direct current with the anode placed over the ipsilesional and the cathode over the contralesional motor cortex (C3 and C4 of the international 10-20 EEG electrode system).
44068|NCT03839316|Device|sham tDCS|For sham tDCS, the same electrode positions were used. The current was ramped up to 2 mA and slowly decreased over 30 seconds to ensure the typical initial tingling sensation
44069|NCT03839303|Device|Infra-zygomatic Mini Implant Supported Appliance|"leveling and alignment of the four maxillary incisors~infra zygomatic mini-implant will be placed bilaterally~wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~orthopedic force will be delivered from the mini-implants to the wire frame work"
44070|NCT03839303|Device|high pull head gear|"acrylic maxillary splint is made with flying tubes~high pull head gear is adapted to be inserted in the flying tubes"
44071|NCT03839290|Procedure|Early neonatal cheiloplasty|
44072|NCT03839277|Device|Endocuff Vision|Endocuff Vision is attached to the tip of colonoscope before intubation.
44073|NCT03839264|Diagnostic Test|Graft stenosis and thrombosis|
44074|NCT03839251|Drug|abilify maintena|aripiprazole 400mg or 300mg, IM, Once a month
44075|NCT03839238|Biological|hESC derived MSC like cell|Different dosage of hESC derived MSC like cell for the meniscus injured patients
44120|NCT03838809|Device|surface electromyography-biofeedback|Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
44076|NCT03839225|Other|Community intervention|"Community intervention will be built depending on contextual factors and will contain the following elements:~Cross-sector intervention, including sectors to define the intervention as primary health care services, education services (language, knowledge to prevent health problems and resilience strategies), family welfare units, Integral Care and Reparation Unit for Victims (UARIV), Ministry of Labour, national and international social support network, among others.~The leader will be chosen by the community, with the capabilities to coordinate the community-based network.~Mental health providers at the local level, who must develop psychosocial and mental diagnoses and interventions, based on experience and evidence, respectively. This team will include psychiatry, psychologists (one an expert in clinical psychology) and a community team involved in the implementation of mental interventions."
44077|NCT03839212|Behavioral|HOLA Component 1|At week 1 and week 8 participants will meet individually with Community Health Worker (CHW) for 30 minutes for a manualized social and physical activation session.
44078|NCT03839212|Behavioral|HOLA Component 2|A CHW led 45 minute (10 minutes of stretching and warm up, followed by 30 minutes of walking with a 5 minute cool down) group walk session of six participants at a time done 3 times a week that utilized interval training that slowly gradually increases in intensity.
44079|NCT03839212|Behavioral|HOLA Component 3|A CHW led pleasant event discussion, asking each participant to identify a pleasant event. This task is done in conjunction with the cool down of HOLA 2.
44080|NCT03839212|Behavioral|HOLA Component 4|One booster walking session twice a month for three months post intervention for reinforcement.
44081|NCT03839173|Other|Human milk based human milk fortifier|A human milk fortifier with added minerals made from donor human milk
44082|NCT03839160|Procedure|Serratus anterior plane block|Serratus anterior plane block was applied in Group S. It was performed at the end of the operation following the skin closure, while the patient lay on his side with his arm above the head. After proper site cleaning, the first and second ribs were identified with a linear probe in the midclavicular line. The USG probe was advanced caudally in the sagittal plane, and the fourth and fifth ribs were visualized. The USG probe was then directed posteriorly and the serratus, latissimus dorsi and intercostal muscles were visualized. Bupivacaine 0.25% 30 mL was administered to the lower plane of the serratus muscle through an inserted catheter under the guidance of USG through the in-line technique. Afterwards, 0.12% bupivacaine hydrochloride was maintained at the rate of 0.1ml/kg/hr.
44083|NCT03839160|Drug|Intravenous patient-controlled-analgesia morphine|Morphine solution was prepared at a concentration of 0.5 mg/mL with the device programmed to 2 mg of bolus dose and 10 min of locking time.
44084|NCT03839147|Behavioral|Education and counseling|After obtaining informed consent, the data collection form, Spielberger State Anxiety Scale and VAS scoring scale were applied to both groups by face to face interview during the day giving appointment for HSG. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher was repeated briefly on the morning of the HSG procedure and any questions of the patients were answered.
44085|NCT03839134|Device|DentalVibe® Comfort Injection System|Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.
44086|NCT03839134|Drug|Lidocaine Epinephrine|Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
44087|NCT03839121|Device|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of CRT patients
44088|NCT03839108|Other|Paraffin wax|Paraffin group patients will be told to take of jewellery and dip their hands into the bath of melted wax (52 ºC) with hands open and hand wrist in neutral position for 10 times .In paraffin wax group, patients will be treated 5 days a week for 2 weeks period. Paraffin wax bath will be applied for 20 minutes in every physical therapy session.
44089|NCT03839108|Drug|Prolotherapy|. Prolotherapy is a nonsurgical regenerative injection technique that introduces small amounts of an irritant solution to the site of painful and degenerated tendon insertions (entheses), joints, ligaments, and in adjacent joint spaces during several treatment sessions to promote growth of normal cells and tissues.Hypertonic dextrose solution is most common used agent. In prolotheraphy group, %15 dextrose solution will be applied to medial and lateral aspect of proximal interphalangeal joints (PIJ), distal interphalangeal joints and carpometacarpal joint of thumb for 3 sessions once a week period
44090|NCT03839082|Other|Usual Care then FitBit|Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).
44091|NCT03839082|Other|FitBit then Usual Care|Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.
44092|NCT03839069|Procedure|minor salivary gland transplantation|The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
44093|NCT03839056|Device|IC+PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~This intervention is included in the clinical practice routine"
44094|NCT03839056|Device|PIEB+PCEA high flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
44121|NCT03838796|Drug|lenvatinib|for patients <60kg, lenvatinib 8mg bid po for patients >60kg, lenvatinib 12mg bid po
79635|NCT03563157|Drug|Leucovorin|Leucovorin Calcium
44095|NCT03839056|Device|PIEB+PCEA standar flow|"Ropivacaina 0,1 % is used with fentanilo 2ug/ml Also if during the dilation period a greater or equal AVE appears to 4 (inadequate analgesia) the patient can be administered a bolus of PCEA of the same solution.~If the patient is administered PCEA, the programed intermittent epidural bolus is delayed automatically 20 minutes with regard to the time in which it would have to be administrated.~If after two bolus of PCEA the analgesia keeps on being ineffective a clinical bolus is administered by the anaesthetist of 4ml of lidocaína to 1 %.~In the group of pure boluses 10ml / h of perfusion will be administered through the high flow and standard flow infusion system, and the maximum sensory level achieved will be compared.~This intervention is included in the clinical practice routine"
44096|NCT03839043|Behavioral|Brief behavioral intervention|"Quit for a bit- *advice to quit from the am. of surgery until one week post-surgery, a special emphasis on morning abstinence* risks of smoking to perioperative outcomes, includes wound infections, breathing problems, and heart problems*reduction of these risks if able to quit for a bit*the fact that most smokers don't experience cravings or increased stress around the time of surgery. Subjects will receive written summarizing instructions and a brief abstinence brochure. Quit for good- 3 out of the 5A's smoking cessation intervention, including Asking, Advising and Assistance will be provided. The advice endorses immediate, sustained quitting (quit for good), accent on the health and economic benefits of long-term abstinence. Assistance includes a method of setting the date of surgery as the quit date, enlisting social support, anticipation of withdrawal symptoms, and the need for complete abstinence. Subjects will receive written summarizing instructions and a 5As brochure."
44097|NCT03839043|Other|SMS Program|"Quit for a bit- Subjects will get SMS messages focused on maintaining abstinence from the morning of surgery until one week after surgery. SMS content focus on the benefits of abstinence to surgical recovery rather than sustained benefits to overall health. Around day 7 postoperatively, messages will encourage subjects to consider extending their abstinence beyond 7 days.Quit for good- Subjects will get SMS messages focused on general advice for maintaining abstinence, focusing on the long-term health benefits rather immediate benefits to recovery from surgery. SMS content focus on the the surgical date as the quit date, general advice and support for quitting based on the standard Truth Initiative (UbiQUITxt) message library and there will be no references to effects of short-term abstinence on surgical outcomes."
44098|NCT03839030|Other|MBHP-Educa|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
44099|NCT03839030|Other|Long-term meditation|This intervention is a meditative practice which the individuals will practice in their daily life following the MBHP-educa protocol
44100|NCT03839030|Other|Cognitive stimulation|This intervention is a lecture about neuroscience for education which the individuals will practice in their daily life in schools.
44101|NCT03839017|Device|SIMMAXMARCHERYAN2|Digital cognitive aid during the management of simulated war wounded.
44102|NCT03839004|Behavioral|Integrated approach to pregnancy|Yoga classes, mindfulness classes, coaching, nutrition counselling and osteopathy
44103|NCT03838991|Other|Blood sample|A study specific blood sample will be collected.
44104|NCT03838991|Other|Waste bone tissue|For 3 patients of each group, patients having a scheduled surgery, a piece of waste bone tissue will be collected after surgery.
44105|NCT03838978|Device|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
44106|NCT03838965|Device|biobeat sensor|biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
44107|NCT03838952|Drug|Herbal medicine|Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
44108|NCT03838939|Other|Therapeutic education|"Individual and group therapeutic education sessions will consist of :~acquisition by patient of self-care skills such as performing subcutaneous injection,~acquisition by patient of safety skills such as identifying symptoms that should lead to consult general practitioner, and stop treatment ..."
44109|NCT03838926|Drug|Trichostatin A|Intravenous Infusion
44110|NCT03838900|Device|Loop|The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
44111|NCT03838887|Device|ultrasound machine|Ultrasound machine with a vocal software
44112|NCT03838874|Drug|Low-Dose Bupivacaine|10 mg
44113|NCT03838874|Drug|Mepivacaine|70 mg
44114|NCT03838861|Behavioral|NEMO: NEw MOdel of follow-up|The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
44115|NCT03838848|Drug|KN046|KN046, Q2W, intravenous injection (IV) for 90-120 minites.
44116|NCT03838835|Behavioral|Augmented equine-facilitated CBT group program|Consists of CBT strategies including 1) providing psychoeducation about anxiety, 2) teaching coping strategies when anxious,and 3) identifying and addressing dysfunctional thoughts that maintain anxiety.
44117|NCT03838835|Behavioral|TAU is equine-facilitated group therapy|TAU is equine-facilitated group therapy at GallopNYC, which consists of horseback riding and integrates strategies to support the development of cognitive, physical, emotional, and social skills.
44118|NCT03838835|Other|WLC|WLC consists of youth who are not yet receiving any services at Gallop NYC.
44119|NCT03838822|Dietary Supplement|Cofactors|Oral administration of 1g nicotinamide riboside, 3g L-carnitine, 20g serine and 5g N-acetylcystein, first as single compounds, then combined, on 5 days
44363|NCT03836859|Other|Placebo|Vehicle: formulation containing L-methionine as excipient.
44122|NCT03838796|Procedure|TACE|The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
44123|NCT03838783|Drug|Insulin Degludec|50% of the patient's daily basal insulin dose delivered through once daily insulin degludec injected in the morning; 50% of the basal insulin to be delivered through previously established CSII
44124|NCT03838770|Device|Active tDCS|Active target 2.5 mA tDCS (n=60)
44125|NCT03838770|Device|sham tDCS|sham left-anodal dorsolateral prefrontal cortex (DLFPC) montage
44126|NCT03838744|Drug|Standard arm: Trabectedin in monotherapy|Trabectedin in monotherapy
44127|NCT03838744|Drug|Experimental arm: Trabectedin + Olaparib|Trabectedin given in combination to olaparib
44128|NCT03838731|Drug|REGN1908-1909|Single subcutaneous (SC) dose of REGN1908 and REGN1909
44129|NCT03838731|Drug|Placebo|Single subcutaneous (SC) dose of matching placebo
44130|NCT03838705|Procedure|hypoxia|It was accepted that hypoxia developed in patients with SpO2< 92 or falling over 20% compared to preoperative values.
44131|NCT03838705|Procedure|normooxy|It was accepted that patients with SpO2 between 100-92 mmHg
44132|NCT03838692|Drug|Ponatinib|A daily oral dose at 45 mg.
44133|NCT03838679|Diagnostic Test|Best-corrected Visual acuity testing (BCVA)|Best-corrected visual acuity (BCVA) will be measured using Early Treatment of Diabetic Retinopathy Study (ETDRS) charts at 4 meters and 1 meter, respectively.
44134|NCT03838679|Diagnostic Test|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
44135|NCT03838679|Diagnostic Test|Color fundus photography (CFP)|Color fundus photography is a non-invasive, fast and reliable imaging method providing a true-to-life depiction of the ocular fundus.
44136|NCT03838679|Diagnostic Test|Optical coherence tomography angiography (OCTA)|OCTA, an extension of conventional OCT, offers noninvasive imaging of the retinal and choroidal vasculature.
44137|NCT03838679|Diagnostic Test|Polarization-sensitive optical coherence tomography (PS-OCT)|PS-OCT, a functional exten- sion of conventional OCT technology, enables differentiation of retinal layers based on their distinct interference with the polarization state of the probing light beam, as opposed to mere light intensity.
44138|NCT03838679|Diagnostic Test|Microperimetry (MP)|Microperimetry allows testing of retinal sensitivity at specific locations in the area of the fovea, parafovea or even more peipheral areas of the macula.
44139|NCT03838679|Diagnostic Test|Adaptive-optics optical coherence tomography (AO-OCT)|AO-OCT, an extension of conventional OCT, offers non-invasive imaging of the retina with improved lateral resolution of up to 2-3 μm.
44140|NCT03838679|Diagnostic Test|Fluorescein angiography (FA)|FA imaging is a standard imaging technique used for the diagnosis of vascular pathologies of the retina such as choroidal neovascularization.
44141|NCT03838666|Drug|Suspension of human autologous MSC 3P|Single administration of the suspension of human autologous MSC 3P in 1.5 ml on the surface of the repaired rotator cuff tendon
44142|NCT03838640|Device|EPIQ 5|As described in summary Trade name of the device Philips EPIQ 5
44143|NCT03838614|Behavioral|Rhythmical auditory stimulation gait training and muscle power training (RAS-MPT)|The RAS-MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive two levels of training within each 60-minute session: (1) RAS-treadmill training and (2) MPT.
44144|NCT03838614|Behavioral|Rhythmical auditory stimulation gait training (RAS)|The RAS group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive RAS-treadmill training repeatedly within each 60-minute session.
44145|NCT03838614|Behavioral|Muscle power training (MPT)|The MPT group will attend a 60-minute training session once a week and home exercises (twice/week) for 12 weeks. Participants will receive muscle power training repeatedly within each 60-minute session.
44146|NCT03838614|Other|Controls|Participants in the control group will receive no intervention during the study period, but continue with their normal daily activities and usual medical care. They will receive the same training as the RAS-MPT group after the study.
44147|NCT03838601|Drug|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
44148|NCT03838575|Drug|2% alcoholic chlorhexidine skin prep (SKIN PREP)|This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
44149|NCT03838575|Device|Iodophor Antimicrobial Incise Drapes (DRAPE)|This intervention describes the application of a single Iodophor Antimicrobial Incise Drape to be applied topically onto the prepared and draped surgical field by sterile, gloved members of the surgical team before the surgical incision is performed. Only after the skin preparation solution has dried completely can the incise drape be applied.
44150|NCT03838575|Device|Gentamicin-impregnated implants/ sponges (SPONGE)|This intervention describes the implantation of Gentamicin-impregnated collagen implants at the time of fascial closure. Each sponge (10 by 10 cm) contains 280mg of collagen and 130mg of gentamicin. The sponges gradually degrade and the gentamicin solution permeates into surrounding tissues to create a high local antimicrobial concentration within the surgical wound.
44151|NCT03838575|Other|NONE (Control)|"Any skin preparation of the surgeon's choice may be used in the control arm apart from 2.0% Alcoholic Chlorhexidine Skin Prep.~No drapes or sponges of any kind may be used."
44182|NCT03838302|Procedure|Transvaginal tissue retrieval via a posterior colpotomy|Transvaginal retrieval via a posterior colpotomy for removing tissue by laparoscopic surgery with uterus preservation
44183|NCT03838302|Procedure|Transabdominal retrieval via trocar|Transabdominal retrieval via trocar for removing tissue by laparoscopic surgery with uterus preservation
44152|NCT03838562|Other|Vestibular rehabilitation with virtual reality|"Both group follow four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Optokinetic application with three-dimensional head-mounted is used in the experimental group."
44153|NCT03838562|Other|Standard optokinetic stimulator or dynamic visual surround|"Both group follow four weeks of vestibular rehabilitation program with 2 sessions of physical therapy per day and one collective session of balance exercices per day, five day per week. More orthoptist care and muscle strengthening.~The exercises performed include rotating exercises, static balance exercises with eyes open and closed, head fixed and with head oscillation. Exercises on unstable planes and on dynamic force platforms. Different walking and eye stabilization exercises.~Only visual misinformation is distinct in both groups. Standard optokinetic stimulator (stimulopt) or dynamic visual surround (smart equitest) are used in the control group."
44154|NCT03838549|Procedure|Prophylactic mastectomy with immediate breast reconstruction|It is an endoscopic approach for prophylactic mastectomy using an axillary single port
44155|NCT03838536|Dietary Supplement|Whole Egg Powder|Breastfeeding mothers will consume the equivalent of 5 whole eggs per week for 3 months.
44156|NCT03838536|Dietary Supplement|Egg White Powder|Breastfeeding mothers will consume the equivalent of 5 egg whites per week for 3 months.
44157|NCT03838523|Other|Open Label Placebo|See group description
44158|NCT03838510|Behavioral|REBOOT|The brief counseling intervention will utilize Motivational Interviewing and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address overdose risk behaviors and determine readiness for change in substance use.
44159|NCT03838497|Biological|Prevenar13|Prevenar13 for both arms
44160|NCT03838484|Drug|Nicotine Patch, 7 Mg/24 Hr|Nicotine patch, 7 mg/24 hour will be applied to the skin.
44161|NCT03838484|Drug|Placebo patch|Placebo skin patch will be applied to the skin.
44162|NCT03838445|Device|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
44163|NCT03838432|Device|Steep Pulse Device|Applying the steep pulse to treat the patients with Prostate cancer
44164|NCT03838419|Radiation|intraoperative radiotherapy|IORT with 21 Gy prescribed to the 90% isodose line
44165|NCT03838419|Radiation|whole breast irradiation|hypofractionated WBI Total dose 40.05 Gy (15 x 2.67 Gy)
44166|NCT03838406|Genetic|BRCA 1|The investigators evaluated the incidence of BRCA loss in patients with advanced gastric cancer and observed the treatment outcome and prognosis.
44167|NCT03838406|Drug|Chemotherapy|"FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days."
44168|NCT03838393|Other|multidisciplinary management|pharmacological and non.pharmacological treatment (specially trained nurses, psychologists and physiologists)
44169|NCT03838380|Other|Smartphone application|Mobile management group participants were given monitoring system devices including a glucometer with Bluetooth connectivity and an accelerometer to detect physical activity level. The mobile phone application specifically designed for this study was installed at enrollment for the mobile management group to collect clinical data and messages from the patients. The application consisted of four sections: clinical data, nutrition and diet, medication, and messaging system and information. Patients allocated to the mobile management group recorded their blood glucose level and diet via the smartphone application, and health care providers regularly scanned clinical data and messages from patients and sent return messages with tailored medical and nutritional guidance.
44170|NCT03838367|Drug|350 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
44171|NCT03838367|Drug|525 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
44172|NCT03838367|Drug|700 mg leronlimab|leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
44173|NCT03838367|Drug|AUC 5 Carboplatin|Carboplatin is an anticancer drug chemotherapy drug.
44174|NCT03838367|Drug|Maximum Tolerated Dose (MTD) of leronlimab|The decision on the MTD will be made following the results obtained from Phase I studies
44175|NCT03838354|Drug|Chidamide|Chidamide 2.5 mg po biw, every four weeks for one cycle. It will be given three cycles.
44176|NCT03838354|Drug|Chidamide|Chidamide 5 mg po biw, every four weeks for one cycle. It will be given three cycles.
44177|NCT03838341|Device|AtriClip™ LAA Exclusion System|The left atrial appendage is closed from the epicardial side of the heart. Operative access is totally thoracoscopic. The designed and dedicated clip - AtriClip® (AtriCure, Ohio, USA) is introduced to the left pleura through thoracoscopic port.
44178|NCT03838341|Drug|Oral anticoagulation therapy|Anticoagulation therapy discontinuation - according to the standard of care at the discretion of the Investigator.
44179|NCT03838328|Drug|Tranexamic Acid|Tranexamic acid will be delivered by loading dose plus maintenance infusion until the end of the operation.
44180|NCT03838315|Other|Neural Mobilization with Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique"
44181|NCT03838315|Other|Neural Mobilization without Soft Tissue Mobilization|"Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack~Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute."
44458|NCT03836027|Other|No intervention|No intervention
44184|NCT03838289|Radiation|multimodal magnetic resonance imaging or computed tomography|multimodal magnetic resonance imaging including T1 Flair,T2 Flair, magnetic resonance angiography (MRA), perfusion-weighted imaging (PWI), diffusion-weighted imaging (DWI), enhanced gradient echo T2 star weighted angiography (ESWAN); multimodal computed tomography including non-contrast CT, volume perfusion CT
44185|NCT03838276|Procedure|AL 150 BPL100|Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb
44186|NCT03838276|Procedure|AL 100 BPL 150|Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
44187|NCT03838263|Drug|Nivolumab|2 nivolumab infusion (240 mg IV) 2 weeks apart (on day 1 and day 15) followed by standard chemoradiation.
44188|NCT03838263|Radiation|Chemoradiation|Standard of Care chemoradiation for 7 weeks (70 Gray delivered to the tumor by IMRT) with high-dose cisplatin (100mg/m2) at week 1, 4 and 7
44189|NCT03838250|Biological|Cellgram™ (Bone marrow-derived MSCs)|Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
44190|NCT03838237|Diagnostic Test|Cardiological evaluation|"Baseline evaluation~FAbry STabilization indEX (FASTEX)~12 leads ECG~Blood samples for microRNA, TnT HS and NT-proBNP dosages~2D echocardiogram~Cardio-pulmonary test~Contrast-enhanced CMR including:~Cine images~T2 mapping sequences~T1 mapping sequences before and 15' after contrast medium administration~Late Gadolinium Enhancement (LGE) imaging~Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated"
44191|NCT03838224|Other|dry needling|"Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times."
44192|NCT03838224|Other|Sham needling|Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
44193|NCT03838211|Device|Anodal tDCS|Anodal transcranial direct current stimulation (tDCS), 9 sessions with 20 minutes stimulation each (current intensity of 1mA)
44194|NCT03838211|Behavioral|Intensive cognitive training|Intensive cognitive training of a letter memory updating task and a 3-stage Markov decision making task, 9 sessions
44195|NCT03838198|Behavioral|MI-Enhanced Safety Plan at Hospitalization (1st Component)|"The MI-enhanced safety plan intervention component is delivered during hospitalization and includes an individual and family meetings. The goal of the individual meeting with the adolescent is to develop an individualized safety plan for use during a suicidal crisis. This best practices approach of safety planning is augmented with Motivational Interviewing (MI) as a core strategy to explicitly elicit adolescents' motivation and commitment to behavior change (i.e. use safety plan; adaptive coping), address barriers or ambivalence, and strengthen self-efficacy. The focus of the family meeting, which is similarly guided by MI, is to prepare parents/guardians, with input from the adolescent, for how they may support the adolescent in implementing the individualized safety plan after discharge and on strengthening parents' commitment and self-efficacy."
44196|NCT03838198|Behavioral|MI-Enhanced Text Boosters (2nd Component)|For participants randomized to receive text boosters, booster text messages will be sent daily for 4 weeks. The messages will be tailored to encourage use of individualized coping strategies identified as part of safety planning at hospitalization and will include additional adaptive coping tools and resources. The text message content and tone will be consistent with principles of MI.
44197|NCT03838198|Behavioral|MI-Enhanced Booster Call (3rd Component)|The focus of the post-discharge booster phone call with adolescent and with parent, each conducted separately, will be to to further adjust the safety plan to better meet post-discharge needs, to further enhance adolescents' motivation and commitment to use coping strategies, and to further support adolescents' and parents' self-efficacy to manage suicidal crises.
44198|NCT03838185|Drug|J147|Single oral dose of J147
44199|NCT03838185|Drug|Placebo|Single oral dose of corn oil
44200|NCT03838172|Other|Family impact scale|The family Impact Scale (FIS) will be completed by the parents
44204|NCT03838146|Behavioral|Types of Exercise|moderate intensity exercise
44205|NCT03838133|Drug|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
44206|NCT03838133|Drug|Naropin®|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. 50 mg (0.5%, 10 mL)
44207|NCT03838133|Drug|Normal Saline|Normal Saline (0.9% sodium chloride, 10ml)
44237|NCT03837899|Drug|Durvalumab / Tremelimumab Combination Therapy|"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase. HL cohort will only receive durvalumab monotherapy in the dose expansion phase."
44208|NCT03838120|Other|Procedure/Surgery: bupivakain % 0,5|In this study, 5 patients were included in each volume group and at least 3 applications out of 5 had to be successful to consider the volume to be sufficient. After a successful group, the volume was reduced by 2 ml's and the same procedure was followed until a final group with unsuccessful anesthesia was found (≤2 successful blockades). The study was ended at this point and MEV was determined as the volume used in the last successful group. The researcher which determined the success of blockade was blinded to the study protocol. BMI, ASA Score, Successful blockade onset time Regression time of sensorial blockade Regression time of motor blockade Time of first additional analgesic requirement
44209|NCT03838107|Behavioral|observation and measure of trajectory of recovery in CRPS|Child participants enrolled in this study will undergo three sessions, which will include psychosocial measures, brain imaging, and quantitative sensory testing. Parent participants will also complete three sessions, which only include psychosocial measures.
44210|NCT03838094|Biological|Biodentine|it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
44211|NCT03838094|Biological|MTA|MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
44212|NCT03838081|Behavioral|Spielberger State Anxiety Inventory (STAI-S),|STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
44213|NCT03838081|Behavioral|Dental Fear Scale (DFS)|DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
44214|NCT03838081|Behavioral|Modified Dental Anxiety Scale (MDAS)|MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25
44215|NCT03838081|Behavioral|Visual Analog Scale (VAS)|"VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable"
44216|NCT03838068|Biological|Biodentine|Biodentine is considered a calcium silicate cement that was introduced as a 'dentine replacement' material, comparable to MTA in terms of biocompatibility and induction of a calcific barrier .
44217|NCT03838068|Biological|MTA|Mineral trioxide aggregate is considered the new gold standard for vital pulp therapies, that provides long-term seal, acceptable bio-compatibility and dentinal bridge formation as reported by various human studies.
44218|NCT03838055|Procedure|Injection of tracer ( ICG) and detection of sentinel lymph nodes|Pelvic SLN's defined by ICG injected cervically
44219|NCT03838042|Drug|Nivolumab and Entinostat|Patients entering phase I will receive one week entinostat without nivolumab (priming phase) before receiving the combination treatment of nivolumab and entinostat.
44220|NCT03838029|Drug|Propranolol and etodolac|A perioperative combined drug regimen
44221|NCT03838029|Other|Placebo|Placebo
44222|NCT03838016|Behavioral|Babble Boot Camp|The Babble Boot Camp is an experimental study to investigate whether earliest and proactive activities and routines can positively influence the speech and language development of children who were diagnosed with classic galactosemia at birth. A speech-language pathologists implements the intervention by teaching parents to foster and expand earliest signals of communication, prespeech activities such as coo and babble, vocabulary growth, sentence complexity, and use of language to communicate. Examples are intentional eye contact, reinforcing babble with rewarding play activities, and repeating a child's rudimentary sentence with slight expansions to scaffold longer sentences.
44223|NCT03838003|Procedure|ERIC protocol|ERIC protocol is an aerobic exercise protocol with 5 levels of intensity
44224|NCT03837990|Drug|Helicobacter Pylori eradication therapy|Eradication therapy includes the administration of a proton pump inhibitor (PPI) and antibiotics. Triple therapy with a PPI (lansoprazole or esomeprazole), clarithromycin, and amoxicillin is the first-line regimen. Quadruple therapy with a PPI, bismuth, metronidazole, and tetracyclin is the second-line therapy.
44225|NCT03837977|Drug|Liposomal Irinotecan|Arm I
44226|NCT03837977|Drug|Fluorouracil|Arm I
44227|NCT03837977|Drug|Folinic Acid|Arm I
44228|NCT03837977|Drug|Docetaxel|Arm II
44229|NCT03837964|Drug|BI 1291583|Tablet
44230|NCT03837951|Other|Figure-of-eight tape measure measurements on both hands|Tape measure is wrapped around the wrist and hand and a measurement reading is taken. this is repeated 3 times.
44231|NCT03837951|Other|Volumeter measurements|Volumeter measurements to uninjured participants had 3 measurements taken of each hand.
44232|NCT03837938|Drug|Levopront® syrup 30 mg/5 ml|The first study drug administration will be performed at the clinical site on the day of randomization; the last study drug administration will be performed in the evening before Day 8 (±1).
44233|NCT03837938|Drug|Libexin®|The first study drug administration will be performed at the clinical site on the day of randomization; the last study drug administration will be performed in the evening before Day 8 (±1).
44234|NCT03837925|Drug|Atorvastatin 40mg Tablet|Patient participation for 6 weeks of treatment
44235|NCT03837925|Drug|Placebo comparator|Patient participation for 6 weeks of treatment
44236|NCT03837912|Behavioral|Patient reported safety experiences fed back to PC providers|The intervention will involve three key stages: a) Measurement: Patients will be invited to complete the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) questionnaire using a tablet-computer. b) Feedback: Using a bespoke online tool, the information will be processed and presented to each centre in the form of a Feedback Report, which will offer comparisons with other centres along with a set of recommendations for addressing the problems identified. c) Action planning and change: centres will form an Action Planning Team, which will be responsible for analyzing the report, considering which area(s) should be improved, and developing, implementing and monitoring an action plan to address the safety problems identified.
82375|NCT03541564|Drug|Moxifloxacin|Specified dose on specified days
44238|NCT03837886|Dietary Supplement|Sodium bicarbonate|The subjects should ingest 0.3g.kg of sodium bicarbonate 90 minutes before the beginning of the protocol task.
44239|NCT03837886|Dietary Supplement|Calcium carbonate|The subjects should receive gelatinous capsules containing 0.3 g.kg -1 of Calcium Carbonate
44240|NCT03837873|Drug|Rituximab|rituximab 750mg/m2 i.v. on day 0
44241|NCT03837873|Drug|Etoposide|50mg/m2, continuous i.v. on day 1-4
44242|NCT03837873|Drug|Vincristine|0.4mg/m2, continuous i.v. on day 1-4
44243|NCT03837873|Drug|Doxorubicin|10mg/m2, continuous i.v. on day 1-4
44244|NCT03837873|Drug|Dexamethasone|30mg/day, i.v. on day 1-5 for R-DA-EDOCH regimen; 40mg/day, i.v. on day 1-4 for R(2)-DHAP regimen
44245|NCT03837873|Drug|Cyclophosphamide|750mg/m2, i.v. on day5
44246|NCT03837873|Drug|Lenalidomide|25mg/day, p.o. on day 0-9
44247|NCT03837873|Drug|Cisplatin|100mg/m2 continuous i.v. on day 1
44248|NCT03837873|Drug|Cytarabine|2g/m2 q12h, i.v. on day 2
44249|NCT03837860|Drug|Oxycodone/Placebo|Oxycodone 20 mg plus placebo
44250|NCT03837860|Drug|Oxycodone/Risperidone|Oxycodone (20mg) plus Risperidone (2 mg)
44251|NCT03837860|Drug|Oxycodone/Ziprasidone|Oxycodone (20mg) plus Ziprasidone (80 mg)
44252|NCT03837847|Behavioral|Health Coaching Calls|12 weekly health coaching calls
44253|NCT03837834|Other|Functional Electrical Stimulation Leg Cycling Exercise|FES- leg cycling for 45 minutes (3 min warm up + 40 min HIIT + 2 min cooldown). The FES will be applied via surface electrodes and the stimulation intensity based on your tolerance level.
44254|NCT03837821|Drug|Abemaciclib|Abemaciclib 200 mg oral, every 12 hours
44255|NCT03837808|Drug|Nimotuzumab|nimotuzumab 200mg/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
44256|NCT03837808|Drug|Cisplatin|cisplatin 40mg/m2/week in concurrent with IMRT, d1,d8,d15,d22,d29,d36 of RT
44257|NCT03837795|Device|Neurofeedback treatment|A treatment that developed to train adults with sensory modulation disorder by applying EEG (Curry 7 EEG system, Neuroscan-Compumedics). This treatment will aim to normalize the Alpha power (amplitude).
44258|NCT03837782|Procedure|minimally invasive surgery|Each participating site required accreditation by the trial management committee to ensure proper surgical technique during minimally invasive surgery. No individual surgeons performed only the open approach or only the minimally invasive approach. The committee members reviewed the patients' outcomes and the videos to ensure the adequacy of the surgeon's technique.
44259|NCT03837769|Device|Aktiia OBPM PulseWatch wrist device|The optical signals at the wrist are recorded non-invasively. The BP measurements are further determined from these optical signals and are compared to the reference BP readings.
44260|NCT03837756|Drug|Saline|Placebo
44261|NCT03837756|Drug|Lefitolimod|A TLR9 agonist administered s.c. once weekly for 8 weeks.
44262|NCT03837756|Drug|3BNC117 and 10-1074|Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.
44263|NCT03837743|Drug|DUR-928 Topical Solution|Topical solution containing active drug
44264|NCT03837743|Drug|Vehicle Topical Solution|Topical solution containing no active drug
44265|NCT03837717|Behavioral|Holding|Mothers will be assisted with holding their infants (and the cooling blanket) for a single 30-minute period, with the use of a thin foam barrier for thermal protection. Mothers and infants will not be skin-to-skin.
44266|NCT03837717|Other|Saliva collection|Saliva will be collected from infants (via syringe suction) and mothers (via passive drool), and tested for levels of cortisol and oxytocin
44267|NCT03837717|Behavioral|No Holding|Saliva will be collected from Mothers and infants, and vital sign information will be collected from infants in the same manner as the Holding intervention, with the exception of having mother's hold their infants.
44268|NCT03837704|Other|IQOS|AAA patients will switch from cigarette smoking to ad libitum IQOS use, with no flavor variant restrictions.
44269|NCT03837704|Other|Cigarette|AAA patients will continue to smoke their cigarettes ad libitum, with no brand restrictions.
44270|NCT03837704|Other|Smoking Cessation|AAA patients who have completely quit smoking will continue to remain abstinent from smoking cigarettes or using any tobacco or nicotine-containing product(s)
44271|NCT03837691|Device|Placement of Snowshoe Suture Anchors|Snowshoe suture anchors from g-Cath EZ Delivery Catheters are placed in the stomach with the aid of a Transport, g-Lix and g-Prox device
44272|NCT03837691|Behavioral|Moderate Intensity Diet & Exercise Program|After placement of the snowshoe suture anchors in the stomach, subjects are asked to follow a moderate intensity diet and exercise program
44273|NCT03837665|Biological|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is blood plasma that has been enriched with platelets.
44274|NCT03837652|Other|Use of bone-borne palatal expander & maxillary osteotomy|Application of bone-borne palatal expander in conjunction with maxillary osteotomy for expansion of constricted maxillae
44275|NCT03837639|Other|Arm ergometer|Arm-crank exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard
44276|NCT03837639|Other|Treadmill ergometer|Walking exercise group will be performed twice a week for 12 weeks. In the first weeks of training, each session will consist of 15 bouts, two active minutes and two minutes of passive interval, consisting of 60 minutes of session (30 minutes of active exercise). After the first three weeks of training, the exercise time will progressively increase by one minute every 3 weeks and the recovery period will be decreased, completing, at the end, a maximum volume of 10 bouts of five minutes of exercise and one minute of passive interval. The intensity of the exercise will be determined by the load equivalent to the range of 13 - 15 of The Borg Rating of Perceived Exertion, considered as somewhat hard to hard.
44337|NCT03837093|Drug|ILT101|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
44277|NCT03837639|Other|Control group|Patients randomized to control group will attend to meetings with the researcher team twice a week during the 12 weeks. At these meetings, patients will perform manual tasks, with or without the use of artistic materials, cultural programs, cooking classes and home care, without any exercise component. This CG practice will be performed in order to minimize the effects of the patient's bi- weekly commitment and displacement to the training site, to minimize the influence of the patient- researcher contact and also minimize the convivial effect among the patients themselves, which will occur in the other two groups.
44278|NCT03837626|Drug|Placebo - Cap|6 months of 1 pill a day
44279|NCT03837626|Drug|Amiloride Pill|5 mg day for 6 months
44280|NCT03837613|Procedure|tumor resection and neck dissection|Surgical removal of the tumor with adequate safety margins. In addition to neck dissection to dissect the cervical lymph nodes.
44281|NCT03837561|Drug|Cunox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
44282|NCT03837561|Drug|Botox|Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
44283|NCT03837548|Other|Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
44284|NCT03837548|Other|The other Training with Neurofeedback|Neurofeedback the brain activities by Magnetoencephalography
44285|NCT03837535|Procedure|Surgery|Neuro, Lung/thorax, GI, Gynecologic, Urologic, Orthopedic, Vascular surgery
44286|NCT03837522|Diagnostic Test|Procurement Biopsy: Frozen section|Frozen sections are prepared by freezing and slicing the tissue sample; importantly, they can be done in about 15 to 20 minutes. Frozen sections are done when an immediate answer is needed, but do not provide optimal quality.
44287|NCT03837522|Diagnostic Test|Procurement Biopsy: Permanent section|Permanent sections are prepared by placing the tissue in fixative (usually formalin) to preserve the tissue, processing it through additional solutions, and then placing it in paraffin wax. After the wax has hardened, the tissue is cut into very thin slices, which are placed on slides and stained. The process normally takes several days.
44288|NCT03837509|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1.
44289|NCT03837509|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose.
44290|NCT03837509|Biological|Daratumumab SC|Daratumumab 1800 mg co-formulated with rHuPH20 (2000 U/mL) and administered subcutaneously once weekly for Cycles 1 and 2, once every 2 weeks for Cycles 3 to 6, and then once every 4 weeks.
44291|NCT03837496|Other|STRIDE|STRIDE is a brief, group-based, virtual (videoconference) cognitive-behavioral intervention. The intervention incorporates adherence problem-solving, cognitive restructuring, relaxation training, symptom management, coping skills training, and mindfulness techniques.
44292|NCT03837496|Other|Medication Monitoring Control|Care provided as standard by the hospital and medication monitoring
44293|NCT03837483|Genetic|OTL-103|Autologous hematopoietic stem cells collected from mobilized peripheral blood transduced ex vivo with a lentiviral vector encoding the WAS cDNA
44294|NCT03837470|Drug|0.9% Sodium Chloride|Intravenous infusion of 0.25ml/kg/min of 0.9% sodium chloride intravenously for a total of 60 minutes
44295|NCT03837470|Drug|Furosemide 40 mg|Bolus intravenous injection of 40 mg furosemide
44296|NCT03837457|Drug|Cobomarsen|At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
44297|NCT03837431|Diagnostic Test|Skin slit|Skin slit microscopy, RDT and PCR
44298|NCT03837431|Diagnostic Test|Dental broach|Dental broach RDT and PCR
44299|NCT03837431|Diagnostic Test|Tape disc|Tape disc PCR
44300|NCT03837405|Behavioral|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
44301|NCT03837405|Behavioral|Mindfuless|Mindful eating app use plus group sessions to learn mindfulness
44302|NCT03837392|Diagnostic Test|Initial Screening at Enrollment (14-20 weeks pregnant)|At initial screening, eligible participants will complete several interviews, questionnaires, and tasks to determine psychological history, current functioning, history of trauma, coping styles, and demographic variables. This visit will last about 3 hours.
44303|NCT03837392|Diagnostic Test|Pregnancy Planning Visit|This visit will last about 1 hour. Participants will complete diagnostic interviews, self report measures, psychophysiological stress task, and blood and saliva collection.
44304|NCT03837392|Behavioral|Group Intervention: ACT Session|ACT is a cognitive-behavioral therapy that seeks to promote psychological flexibility. The ACT group will be a 3-hour group session.
44305|NCT03837392|Behavioral|Group Intervention: Psychoeducation Session|Psychoeducation participants will be presented with information about depression and anxiety symptoms that may occur during the perinatal and postpartum periods. This will be a 3-hour group session.
44306|NCT03837392|Diagnostic Test|Follow Up Assessments: 34-36 weeks pregnant and 6-week postpartum|The follow-up assessments at 34-36 weeks pregnancy and 6-weeks postpartum will be completed via REDCap, an online secure survey platform in order to reduce participant burden.
44307|NCT03837392|Diagnostic Test|Follow Up Assessments: 3 and 6 months post-intervention|3-months post-intervention and 6-months post-intervention follow-up assessments will be completed in-person and will last about 3 hours, consisting of a structured clinical interview (primary outcome measure), psychophysiological data collection, and collection of blood and saliva specimens.
44308|NCT03837379|Behavioral|Treatment as Usual|Participants in the Treatment As Usual condition will receive educational material on quitting smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.
44336|NCT03837106|Other|Rehabilitation program|3-month rehabilitation program comprising exercise and education specific to musicians. The program will be supported by an online platform containing more than 50 exercise videos, narrated powerpoint presentations, informative videos, quizzes, and forums for communicating with a physiotherapist and for organizing group exercise sessions.
44309|NCT03837379|Combination Product|Goal2Quit + NRT Sampling|"Participants in the Goal2Quit + NRT Sampling condition will receive a download code to download the Goal2Quit mobile application. Goal2Quit is a mobile app for cigarette smokers with elevated symptoms of depression. Within the app, users identify values, create activities, schedule activities, rate mood daily, and track cigarette smoking. Participants in Group B will also receive a two-week starter kit sample of nicotine replacement therapy (NRT; 14mg patch and 4mg lozenge). Participants will be asked to utilize Goal2Quit regularly, at least once per day, as well as the NRT sample in an attempt to quit smoking. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment."
44310|NCT03837366|Behavioral|Activity tracker and health coaching|Use of an activity tracker alone or in combination with health coaching on physical activity behaviors.
44311|NCT03837353|Drug|DKN-01 300 mg|DKN-01 300 mg intravenously (IV)
44312|NCT03837353|Drug|DKN-01 600 mg|DKN-01 600 mg IV
44313|NCT03837353|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2, Day 1 of every 3 Weeks
44314|NCT03837353|Drug|DKN-01 150 mg|DKN-01 150 mg intravenously (IV)
44315|NCT03837340|Other|CMHT|Community mental health teams (CMHTs) delivering evidence-based interventions to people with SMI, inspired by the Flexible Assertive Community Treatment (FACT) service delivery model.
44316|NCT03837340|Other|CAU|Care as usual (CAU) usually consisting of inpatient psychiatric care or outpatient care prescribing medication.
44317|NCT03837314|Device|"Bioinduction Picostim Deep Brain Stimulation system"|Neurostimulation of the subthalamic nucleus region.
44318|NCT03837301|Procedure|NESS-EFTR with sentinel lymph node navigation|Non-exposure Simple Suturing Endoscopic Full-Thickness Resection with sentinel lymph node navigation (basin dissection) for early gastric cancer patients
44319|NCT03837288|Procedure|Cerclage|Cervical cerclage under effect of spinal anaesthesia
44320|NCT03837275|Procedure|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique|Sinus Floor Elevation Between Hydrodynamic Ultrasonic Maxillary Sinus Floor Elevation Technique (Intralift Technique) and implant placement
44321|NCT03837275|Procedure|closed maxillary sinus lift|transdcrestal sinus lift and immediate implant placment
44322|NCT03837262|Combination Product|Flash Glucose Monitoring and structured education|A feasibility study assessing the use of flash glucose sensing technology with structured education to improve glycemic outcomes in T2D adults and children
44323|NCT03837249|Device|Personal Sleep Monitoring|Wearable Sleep Self-Monitoring Device (Actigraphy)
44324|NCT03837236|Other|Study group|Evaluation parameters will be performed to the patients. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.
44325|NCT03837223|Drug|GnRH agonist|In High Responder patients (HR) (more than 18 follicles with diameter ≥ 12mm at ovulation induction), the trigger was obtained with triptorelin 0.2 mg sc. In this cohort if less of 18 oocytes were retrieved, patients were considered at intermediate risk of OHSS and fresh transfer was performed. An adequate support of the luteal phase was initiated: HCG 1500 IU / sc the day of the pick up + estradiol 4 mg + vaginal progesterone 400 mg daily (Rescue protocol).
44326|NCT03837210|Drug|Pylorin|Poly Herbal formulation
44327|NCT03837197|Device|Kidney-Hypothermic oxygenated|"Kidney perfusion will be performed through the renal artery at 25-30 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (20 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 2 hours for kidneys."
44328|NCT03837197|Device|Liver-Hypothermic oxygenated|"Liver perfusion will be performed through the portal vein at a 5 mmHg pressure.~Flow, pressure and temperature will be monitored and registered on a Universal Serial Bus (USB) memory system during organ perfusion. Gas analysis of the effluent perfusate will be accomplished at the start of perfusion (T0) then every 30 minutes. Two perfusate samples will be collected at the beginning and at the end of perfusion to rule out bacterial or fungal contamination.~HOPE will start by flushing the organ at low flow values (30 ml/min) with new oxygenated perfusion fluid during back-table preparation. Organ will be treated with continuous HOPE until transplant. Organ perfusion will be continuously monitored. Minimal perfusion time will be 1 hour for livers."
44329|NCT03837184|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB). Onasemnogene abeparvovec-xioi will be administered as a one-time intravenous infusion over approximately 60 minutes. Dosage will be determined by the participants weight.
44330|NCT03837171|Biological|Liberal Red blood cell transfusion|"Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure.~After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians"
44331|NCT03837171|Biological|Restrictive Red blood cell transfusion|Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
44332|NCT03837158|Procedure|early loading|two TiZr implants on SLA surface
44333|NCT03837158|Procedure|immediate loading|four TiZr implants on SLA surface
44334|NCT03837132|Behavioral|Palliative care assessment|Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
44335|NCT03837119|Other|pregnancy outcome|descriptive statistics of variables
44338|NCT03837093|Drug|Placebo|Subcutaneous injections starting with induction course with once-daily administration for 5 consecutive days, followed by maintenance course with once every weeks administration during three weeks
44339|NCT03837080|Other|Nutrition Education|Every patient will receive one individual and two group counselings on specific nutrition-related recommendations for chronic pain patients.
44340|NCT03837054|Biological|Blood collection and Micronuclei assay on binucleate lymphocytes in culture|"The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures."
44341|NCT03837041|Other|Reconditioning Proprioception|Proprioceptive training using Delos Postural Proprioceptive System
44342|NCT03837028|Other|FSFI|Sexual dysfunction was assessed via the self-administered Female Sexual Function Index Questionnaire which was adapted to the Turkish population. This is a 19-item questionnaire that covers six domains: desire; arousal, lubrication, orgasm, satisfaction, and pain. The full score is obtained by adding the six domain scores. FSFI scores range from 2.0 to 36.0, with higher scores indicating better sexual functioning.
44343|NCT03837015|Drug|Estring Vaginal Ring|Estradiol vaginal ring, containing 2mg estradiol designed for slow release over 30 days
44344|NCT03837015|Other|RepHresh Pro-B|Probiotic supplement containing 2.5 billion CFU of Lactobacilli reuteri RC-14 and Lactobacilli rhamnosus GR-1, administered vaginally or orally
44345|NCT03837002|Other|foot care protocol|foot assesment, foot care, foot care education
44346|NCT03836989|Device|electrical stimulation device (tens unit)|An electrical stimulation device with adjustable voltage. useful fro both Sensory and Subsensory
44347|NCT03836976|Other|Auditory gamma sensory stimulation|"Gamma-conditioning stimulation will be~administered in 2 blocks of 3 min each. During each block, participants will be presented with a continuous~tone at the CF (500 or 1200 Hz) that will be amplitude modulated at 40 H"
44348|NCT03836963|Behavioral|cognitive training|Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
44349|NCT03836963|Behavioral|active control cognitive training|The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.
44350|NCT03836963|Behavioral|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
44351|NCT03836963|Behavioral|memory strategy training|the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
44352|NCT03836950|Device|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45� from the midline. One rTMS session will consist of 40 trains of 5sec each at 110% of resting motor threshold and 15Hz will be provided at the left DLPFC.
44353|NCT03836950|Device|MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)|The coil will be held tangentially to the skull at approximately 45� from the midline. The sham coil will not release any stimulation, but it will look, feel and sound like the real rTMS
44354|NCT03836937|Drug|Obeticholic acid|Farnesoid X receptor ligand which is a semi synthetic bile acid analogue
44355|NCT03836924|Drug|Perampanel|Perampanel tablets.
44356|NCT03836911|Other|serious game|Effect of serious game on elderly in comparison of the physical activity adapted meeting
44357|NCT03836911|Other|classic program|Effect of serious game on elderly in comparison of the physical activity adapted meeting
44358|NCT03836898|Device|Presbyopic posterior chamber phakic intraocular lens IPCL|Presbyopic posterior chamber phakic intraocular lens IPCL (EyeolUK, United Kingdom) has a refractive optic and diffractive trifocal pattern on its anterior optical surface to correct both distance and near refractive errors. Presbyopic addition is manufactured in a range of +1.0 to + 4.0 diopters (D) in 0.5 D steps.
44359|NCT03836885|Drug|Apremilast|Apremilast tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg in morning; Day 2: 10 mg in morning and 10 mg in evening; Day 3: 10 mg in morning and 20 mg in evening; Day 4: 20 mg in morning and 20 mg in evening; Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter patients will be dosed at 30 mg twice daily (every 12 hours) for a total of 12 weeks.
44360|NCT03836885|Drug|Placebo|Placebo Oral tablets. Titration will occur in the initial five days of treatment as per dosing in psoriasis as follows: Day 1: 10 mg in morning; Day 2: 10 mg in morning and 10 mg in evening; Day 3: 10 mg in morning and 20 mg in evening; Day 4: 20 mg in morning and 20 mg in evening; Day 5: 20 mg in morning and 30 mg in evening. Day 6 and thereafter patients will be dosed at 30 mg twice daily (every 12 hours) for a total of 12 weeks.
44361|NCT03836872|Device|Acupuncture|Patients in the experimental group will receive, in addition to standard care, a standardised 30-minute acupuncture session needling specific acupoints although there will be flexibility in case some points cannot be punctured (e. g. in case of lymphoedema), and alternative points (as in routine practice) may be selected by the acupuncture practitioner using their discretion to maintain an equal dose of treatment to all patients. Bilateral acupoints will be stimulated. These points will include Waiguan (SJ5), Jianjing (GB21), Yanglingquan (GB34), Hegu (LI4), Jiexi (ST41) and Taixi (K3). In addition, joint specific acupoints will also be used, depending on where the joint symptoms are present.
44362|NCT03836859|Drug|rhNGF 20μg/mL|"Study Eye (For subjects randomized to rhNGF group) Day 1: One drop instilled into study eye (35 μL, corresponding to 0.70 μg of rhNGF).~Day 2, 3, 4, 5, 6: One drop six times a day (every 2h) into study eye (210 μL, corresponding to 4.20 μg of rhNGF).~Total dose in the study eye will be 31 drops (1085 μL, equivalent to 21.7 μg rhNGF) over 6 days."
44364|NCT03836846|Behavioral|CBT Mobile App|TAU and the additional treatment of a Mental Health App (What's Up?). This app will be used to guide adolescents through cognitive behavioral therapy and acceptance commitment therapy techniques, as well as to assist in developing coping mechanisms to prevent readmission.
44365|NCT03836846|Behavioral|Treatment as usual|TAU as per standard of care
44366|NCT03836833|Drug|ABC/3TC/LPV/r granules (30/15/40/10 mgs)|"This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day"
44367|NCT03836833|Drug|LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)|"Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day"
44368|NCT03836820|Other|Clinical pilates exercise|Clinical pilates exercises will be performed three days in a week. Treatment will continue an hour in per session for 8 weeks.
44369|NCT03836820|Other|Aerobic exercise|Progressive aerobic walking exercise will be performed three days in a week. Exercise intensity will be 50- 80% of maximal heart rate and exercises will be performed 45 minutes in per session for 8 weeks.
44370|NCT03836820|Other|Clinical Pilates and Aerobic Exercise|Both clinical pilates exercises and progressive aerobic walking exercises will be performed three days in a week for 8 weeks.
44371|NCT03836807|Drug|Ketoprofen|40 mg KLS granules (corresponding to 25 mg ketoprofen)
44372|NCT03836807|Other|Placebo|0 mg KLS granules
44373|NCT03836781|Drug|Ketorolac|Ketorolac 3% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
44374|NCT03836781|Drug|Chlorhexidine 2%|Chlorhexidine 2% topical subgingival irrigation was put into the periodontal pocket using an insulin syringe
44375|NCT03836768|Drug|DTRMWXHS-12|DTRMWXHS-12 capsules: 150 mg, 300 mg
44376|NCT03836755|Diagnostic Test|Metacos|Evaluation of stability of implant by RSA technique
44377|NCT03836742|Procedure|Hemofiltration with regional citrate anticoagulation|To reduce risk of metabolic alkalosis during hemofiltration treatment, ACD-A citrate solution was proposed instead of most commonly used trisodium citrate solution and relatively low target citrate concentration (2.8 mmol/L) was adopted. In case of pH increase above 7.5 or bicarbonate concentration above 40 mmol/L filtrate flow was decreased from initial 35 ml/kg/hour down to 25 ml/kg/hour which reduced bicarbonate delivery by 25%. If metabolic alkalosis persisted, the second step involved reduction of blood flow from initial 5 times down to 4 times filtrate flow, which reduced citrate flow by the same factor.
44378|NCT03836729|Drug|Tenofovir alafenamide/emtricitabine|TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.
44379|NCT03836729|Drug|GSK3640254|GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
44380|NCT03836716|Drug|Arimoclomol|Active treatment
44381|NCT03836703|Drug|Feroglobin single daily use|Feroglobin single daily use ( IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
44382|NCT03836703|Drug|Feroglobin twice daily dose|Feroglobin twice daily dose ( IRON FUM&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
44383|NCT03836690|Biological|CD62L- Tem|Donor memory T cells that have been depleted of CD62L+
44384|NCT03836677|Combination Product|BGF|Treatment with Budesonide/Glycopyrronium/FormoterolFumarate
44385|NCT03836677|Combination Product|GFF|Treatment with Glycopyrronium/Formoterol Fumarate
44386|NCT03836664|Drug|Timolol|Timolol is a clear solution supplied in a plastic ophthalmic dispenser.
44387|NCT03836664|Drug|Placebo|Placebo is normal saline solution that will be supplied in container matched to Timolol container.
44388|NCT03836651|Other|Dietary Antioxidant (V8® Low Sodium 100% vegetable juice)|Following completion of baseline data collection, participants will be randomized to one of two groups. Participants randomized to the intervention group will receive a month's supply of the V8® 100% Low-Sodium Vegetable juice as the dietary antioxidant intervention. Participants will be asked to drink one V8® juice each day for 30 days. Each V8® juice can is 11.5 ounces and can be consumed in divided amounts or all at once. The average daily intake of lycopene is estimated to be 5mg, one can of V8 juice provides 24 mg of lycopene. Thirty days duration for the intervention of V8® juice is based on previous data that indicates plasma antioxidant concentrations rise significantly within a two-week period and a plateau effect is reached within 4 weeks.
44389|NCT03836651|Other|Control group|The control group will continue to be medically managed by their health care provider as usual. The control group will have the same visit and call schedule as the intervention group.
44390|NCT03836638|Drug|30 Units of botulinum toxin|30 Units of botulinum toxin to upper face
44391|NCT03836638|Drug|50 Units of botulinum toxin|50 Units of botulinum toxin to upper face
44392|NCT03836625|Other|CareConekta|CareConekta is a smartphone app that uses the phone's GPS to prospectively characterize mobility and allow for intervening in real-time. CareConekta uses the phone's built-in GPS system to record location coordinates.
44393|NCT03836612|Other|No intervention|Observation of routine clinical practice
44394|NCT03836599|Drug|Verinurad|Participants will receive verinurad 24 mg in cohort 1 and 12 mg in cohort 2 once daily.
44395|NCT03836599|Drug|Allopurinol|Participants will receive allopurinol 300 mg once daily.
44396|NCT03836599|Drug|Placebo|During Run-in Period, participants in cohort 1 will receive placebo matching allopurinol capsule once daily from Day -7 to Day -1. During treatment period, participants in cohort 1 will receive placebo matching allopurinol capsule and placebo matching verinurad capsule once daily from Day 1 to Day 7.
82376|NCT03541564|Other|Placebo|Specified dose on specified days
44397|NCT03836586|Behavioral|Cognitive-Behavioral Intervention|This intervention comprises three components: 1) general education about pain (e.g., pain pathways) and a rationale for the intervention (e.g., gate control theory); 2) impact of positive and negative pain-related thoughts on neural process of pain; and 3) a guided imaginal pain exposure exercise.
44398|NCT03836586|Behavioral|Pain Education|General information about the neurobiology of pain and knee osteoarthritis will be given to participants assigned to this intervention.
44399|NCT03836573|Behavioral|Smoking Cessation iPad Decision Aid Tool|Patients will be provided with the iPad-delivered decision aid. The patient will answer a series of questions and based on their responses be shown information based on the group of which they are a member: 1. Uninterested in quitting cigarettes (Harm-reduction Group); 2. Interested in quitting and using e-cigarettes (E-cigarette Cessation Group); 3. Interested in quitting but does not use e-cigarettes (Standard Smoking Cessation Group). Upon visiting the patient, the physician will address smoking cessation with the patient incorporating the provided decision aid results.
44400|NCT03836560|Drug|Nicotine patch|nicotine patch given for 8 weeks
44401|NCT03836560|Drug|Nicotine gum|nicotine gum given as requested
44402|NCT03836547|Behavioral|Coaching and Weight Loss for patients with dyspnea|Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
44403|NCT03836534|Behavioral|adherence to treatment of patients coming out of emergencies|Phone contact of patients within 48 hours of the consultation
44404|NCT03836521|Device|Transcatheter aortic valve replacement|
44405|NCT03836508|Device|Medium cut-off|"All the dialysis sessions in this arm will be performed with the medium cut-off membrane (MCO) manufactured by Baxter International Corp. membrane for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to high-flux membrane manufactured by Fresenius.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
44406|NCT03836508|Device|High-Flux|"All the dialysis sessions in this arm will be performed with the high-flux membrane manufactured by Fresenius for three months. This membrane will exclusively be used in hemodialysis. After third month, all patients will be switched to MCO manufactured by Baxter International Corp.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
44407|NCT03836495|Dietary Supplement|lysine and phosphorus|addition of lysine and essential amino acid and/or phosphorus an essential mineral
44408|NCT03836482|Device|Selective Cytopheretic Device|Treatment will be delivered for 6 hours a day for up to 6 consecutive days.
44409|NCT03836456|Behavioral|Mindfulness-based Stress Resilience Training|Mindfulness is a form of cognitive training that cultivates self-regulative ability and enhances resilience
44410|NCT03836456|Behavioral|Health Enhancement Program|This is a validated active control developed to serve as a control for mindfulness-based studies.
44411|NCT03836443|Other|"western diet meal"|"A western diet meal (high saturated fat, high refined sugar, high fructose) will be administered in each group (800 kcal/meal) after an overnight fast."
44412|NCT03836430|Behavioral|Newborn Behavioral Observation-Family Wellness (NBO-FW)|The intervention has been described in the arm description.
44413|NCT03836417|Diagnostic Test|Microarray analysis|Microarray analysis to identify gene expression profiles that distinguish IPF from NSIP
44414|NCT03836404|Device|Iliac crest reconstruction surgery|When autologous bone graft is needed for the treatment of non-unions or bone defects, is harvested from the pelvic iliac crest. Harvested tricortical graft blocks are used to facilitate fusion of joints (ie pubis symphysis, sacroiliac joint), to structurally support metaphyseal areas of articular impaction injuries and to fill in metaphyseal bone voids. The GreenBone device, with its inherent physical and biomimic properties, possesses similar structural properties to bone, thus, being the ideal material to be used for the treatment of the bone defect (3- 4cm) induced from the harvested tricortical iliac crest, restoring therefore the pelvic anatomy and minimising the risk of chronic pain, haematoma formation and herniation of the abdominal contents.
44415|NCT03836391|Behavioral|Nudge|Nudge is a smartphone-app-based micro-randomized trial that tests the effect of 7 intervention message types based on behavior change techniques on daily goal attainment. Participants have three daily goals: weigh daily, red foods goal, and active minutes goal.
44416|NCT03836378|Procedure|BioXclude™|The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
44417|NCT03836365|Other|Preoperative counseling office visit|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
44418|NCT03836365|Other|Preoperative counseling phone call|All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
44419|NCT03836352|Other|DPX-Survivac|SubQ injection (q9w)
44420|NCT03836352|Drug|Cyclophosphamide|PO (BID)
44421|NCT03836352|Drug|Pembrolizumab|IV Infusion (q3w)
44422|NCT03836326|Other|Sensorimotor intervention|Sensorimotor intervention involves, stroking of the whole body including the oral structures, trunk and limbs. This intervention does not involve any drugs or medical procedure.
44423|NCT03836326|Other|Control|Routine care provided by health professionals in the NICU
44424|NCT03836313|Device|iovera°|"Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks."
44545|NCT03835338|Device|Pulmonary Vein Isolation|Pulmonary Vein Isolation by RF Ablation
44425|NCT03836300|Behavioral|Parent-Infant fragile x Intervention (PIXI)|"Phase 1 will include parent education about early infant development and FXS with support of Parents as Teachers programming.~Phase 2 includes direct parent coaching around parent-child interaction based on an empirically based parent-mediated early intervention, the Intervention within the British Autism study of Infant Siblings- Video-feedback Intervention to promote Positive parenting (i-BASIS-VIPP), and repeated comprehensive assessments of family and child functioning."
44426|NCT03836287|Drug|Sofpironium Bromide, 15%|Active
44427|NCT03836287|Drug|Vehicle|Vehicle gel
44428|NCT03836274|Dietary Supplement|AYMES MONACO|AYMES MONACO is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
44429|NCT03836261|Drug|Acalabrutinib|Acalabrutinib,
44430|NCT03836261|Drug|Venetoclax|Venetoclax
44431|NCT03836261|Drug|Chemoimmunotherapy|fludarabine/cyclophosphamide/rituximab (FCR), bendamustine/rituximab (BR)
44432|NCT03836261|Drug|Obinutuzumab|Obinutuzumab
44433|NCT03836248|Other|Osteopathic treatment|"5 osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and treatment of necessary elements and a control of osteopathic treatment at the end of the session."
44434|NCT03836248|Other|Sham osteopathic treatment|"5 sham osteopathic treatment sessions lasting 20 to 40 minutes. Each session include diagnosis according to the specific methodology geometric model of osteopathy and only contacts for no intent to treat. At the end of the session a control of the sham osteopathic treatment is performed."
44435|NCT03836248|Other|Current practice Medication treatment|Analgesic medication of level 1 or a combination of level 1 and 2. Acetaminophen 1 g x 3 / day Ibuprofen 400mg x 3 / day
44436|NCT03836222|Drug|PCS499|MR tablet
44437|NCT03836222|Drug|Trental|comparator tablet
44438|NCT03836209|Drug|Gilteritinib|"Induction: 120 mg orally daily x 14 days starting on day 8~Consolidation: 120 mg orally daily x 14 days starting on day 8 of each cycle (up to 4 cycles)"
44439|NCT03836209|Drug|Midostaurin|"Induction: 50 mg orally twice daily x 14 days beginning on day 8~Consolidation: 50 mg orally twice daily x 14 days beginning on day 8 of each cycle (up to 4 cycles)"
44440|NCT03836209|Drug|Daunorubicin|"First Induction: Daunorubicin 90 mg/m²/day IV Days 1,2,3~Second Induction, if needed: Daunorubicin 45 mg/m²/day IV Days 1,2,3"
44441|NCT03836209|Drug|Cytarabine|"Induction: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Second Induction, if needed: Cytarabine 100 mg/m²/day continuous infusion x 7 days starting Day 1~Consolidation: Cytarabine 3 g/m² (1.5 g/m² for age ≥ 55) every 12 hours IV Days 1,3,5 for 6 doses for up to 4 cycles"
44442|NCT03836196|Radiation|LDR Brachytherapy and External Beam Radiation Therapy|Low Dose Rate Brachytherapy (LDR-PB) and External Beam Radiation Therapy (EBRT)
44443|NCT03836183|Diagnostic Test|Pleuropulmonary ultrasound with clinical examination|Pleuropulmonary ultrasound associate with a clinical examination
44444|NCT03836170|Procedure|Laparoscopic cholecystectomy|A special catheter was inserted into the peritoneal cavity, and then about 2-5 liters of carbon dioxide was injected. After reaching a certain pressure, four small holes of 0.5-1.5cm were opened in the abdomen to dissect the structure of the triangle of the gallbladder. The gallbladder duct and gallbladder artery were cut off and closed, and then the entire gallbladder was removed.
44445|NCT03836157|Drug|Mirvetuximab Soravtansine|The dose will not be recalculated unless the patient has ±10% weight change.
44446|NCT03836157|Drug|Bevacizumab|Subject will receive IMGN853 first followed by bevacizumab. There is no planned delay between the IMGN853 and bevacizumab administration.
44447|NCT03836144|Dietary Supplement|Potassium citrate|
44448|NCT03836118|Procedure|Homologous intrauterine insemination (IUI)|"Patients were treated with HMG/rFSH according to classic protocols of therapy and monitoring. An injection of uHCG 5000 IU/ rHCG 250 mg was given to trigger ovulation. On the day of insemination, the semen sample was obtained through masturbation after a 2-5 day abstinence period and collected in a sterile cup. TMSC was determined by multiplying grade A or grade A + B sperm motility percentages by sperm volume and concentration. To evaluate sperm viability Eosin and Nigrosin (E&N) staining was carried out according to WHO standards. Sperm capacitation was performed using density gradient centrifugation or swim-up procedure in order to remove seminal fluids and enhance sperm quality for IUI.~IUI was performed a t36 hours post-HCG. A fraction of the washed motile spermatozoa was inserted up to the uterine fundus and expelled into the uterine cavity. Daily treatment with micronized progesterone was prescribed for 14 days after IUI. Serum ß-HCG was determined 14 days after IUI."
44449|NCT03836105|Drug|cemiplimab|No investigational agents will be provided to enrolled patients by the sponsor as part of this study. Patients will have recently initiated or be planning to initiate treatment with commercially available cemiplimab for CSCC in a real-world setting per standard of care. In addition to (or substituting for) cemiplimab, patients may receive other therapies as deemed necessary by their physicians for the treatment of CSCC or comorbid conditions.
44450|NCT03836092|Procedure|Radiofrequency ablation|RF applications were delivered with a maximal temperature of 43°C at the catheter tip (SmartTouch Navistar Thermocool catheter) and at the power between 25-50 watts. The primary end points during RF ablation were either complete elimination of areas with CFAE or conversion of AF to normal sinus rhythm (SR). When areas with CFAE were completely eliminated but the atrial arrhythmias persisted (organized atrial flutter or atrial tachycardia), they were subsequently mapped and ablated (occasionally in conjunction with ibutilide, 1 - 2 mgs intravenously over 10 minutes).
44451|NCT03836079|Device|preCARDIA system|Intermittent occlusion of the SVC
44452|NCT03836066|Drug|Atezolizumab-Bevacizumab|Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
44453|NCT03836053|Drug|AMG 420|28 day continuous Intravenous infusion of either 400 mcg/d or 600 mcg/d followed by 2 treatment free weeks
44461|NCT03836001|Drug|Serlopitant Tablet|Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.
44462|NCT03836001|Drug|Placebo Oral Tablet|The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.
44463|NCT03835988|Device|Geniculate Artery Embolization|Embolization is a procedure completed by an Interventional Radiologist in which abnormal blood vessels are blocked for treatment purposes. In the case of geniculate artery embolization, abnormal blood vessels which supply your knee joint are blocked in an effort to reduce inflammation and subsequently and reduce pain and improve joint function.
44464|NCT03835975|Biological|13vPnC|Pneumococcal conjugate vaccine
44465|NCT03835975|Biological|PPSV23|Pneumococcal polysaccharide vaccine
44466|NCT03835975|Biological|20vPnC|Pneumococcal conjugate vaccine
44467|NCT03835962|Device|NeuroCatch™ Platform|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
44468|NCT03835949|Drug|TJ004309|Antibody to CD73
44469|NCT03835949|Drug|Atezolizumab|Humanized monoclonal antibody to PD-L1
44470|NCT03835936|Other|High frequency compression of the chest wall group|The protocol in the high frequency compression of the chest wall group device consists of the Smart Vest® application, with a fixed frequency of 13 Hz and a time of 15 minutes. The selected mode will be the normal (fixed parameters) and the pressure of 4 units (12 cm H2O). The patient remains seated on his parents, and with a cotton garment between the vest and the skin of the patient to prevent skin lesions.
44471|NCT03835936|Other|Manual maneuvers physiotherapy group|20 minutes of manual maneuvers physiotherapy based on prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of spontaneous expiration and continues to the residual volume. The physiotherapist through the cough provoked or stimulation of the trachea gets expectoration of sputum, to be able to assess its weight.
44472|NCT03835923|Behavioral|lifestyle intervention|"intervention phase 1 (baseline - month 6): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity. The intervention is accompanied by regular oral and written feedback.~intervention phase 2 (month 6 - month 12): Patients receive an individual exercise plan, nutritional recommendations and advices to increase daily activity without additional oral or written feedback."
44473|NCT03835923|Behavioral|usual care|Recommendation for lifestyle intervention at baseline and after 6 months (e.g. salt reduction, restricted alcohol consumption and smoking cessation, 10,000 steps/day, 150 minutes/week moderate intensity exercise)
44474|NCT03835910|Behavioral|Social Incentives and Gamification to Promote Exercise|The intervention will provide social incentives and gamification to promote physical activity.
44475|NCT03835910|Procedure|Corticosteroid Injection given in A-B order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in A-B order.
44476|NCT03835910|Behavioral|No Social Incentive applied|No social incentive will be applied
44477|NCT03835910|Procedure|Corticosteroid Injection given in B-A order|The study will compare corticosteroid injections with lidocaine to lidocaine only in a crossover design. These participants will receive the medication in B-A order.
44478|NCT03835884|Drug|AR-13503 Implant Low Dose|AR-13503 Implant Low Dose (10.6 µg) administered as an intravitreal implant into a single eye
44479|NCT03835884|Drug|AR-13503 Implant High Dose|AR-13503 Implant High Dose (21.2 µg) administered as an intravitreal implant into a single eye
44480|NCT03835884|Drug|Aflibercept|Intravitreal Injection
44481|NCT03835884|Other|Sham|Sham injection (Touch eye only; no injection)
44482|NCT03835871|Drug|Placebo|Intervention: Drug: placebo
44483|NCT03835871|Drug|400 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 400 µg HFA per day
44484|NCT03835871|Drug|200 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 200 µg HFA per day
44485|NCT03835871|Drug|100 µg per day Beclomethasone|Intervention: Drug: Beclomethasone 100 µg HFA per day
44546|NCT03835338|Device|LAA Isolation|LAA Isolation by RF Ablation
44486|NCT03835858|Other|Respiratory physiotherapy|The protocol consists of 20 minutes of FR based on nasal washes in sitting, prolonged slow expiration: passive technique of expiratory help applied to the baby through a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continuing to the residual volume. The physiotherapist through the the provoked cough or stimulation of the trachea achieves the expectoration of the sputum.
44487|NCT03835845|Device|PICO7Y|The PICO 7Y pump maintains NPWT at -80 mmHg (nominal) to two wound surfaces simultaneously. Exudate is managed by the dressings through a combination of absorption and evaporation of moisture through the outer film. The PICO 7Y kit is intended to be used for up to 7 days on low exuding wounds. For moderately exuding wounds the system is intended to be used for up to 4 days without a dressing change. For 7 days use on moderately exuding wounds additional dressings will be supplied.
44488|NCT03835832|Other|The participants do not receive any intervention for this study|The participants do not receive any intervention for this study
44489|NCT03835819|Drug|Pembrolizumab|Pembrolizumab is an immunotherapy that activates a patient's own immune system to recognize and kill tumor cells
44490|NCT03835819|Drug|IMGN853|Mirvetuximab soravtansine is an antibody-drug conjugate.
44491|NCT03835806|Other|Elastikon|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape, spray adhesive and then Elastikon which is our traditional blister treatment approach.
44492|NCT03835806|Other|Rocktape|This randomized controlled trial will compare the traditional method of treating blisters with a multi-step approach of percutaneous drainage, paper tape and then Rocktape which is our novel blister treatment approach.
44493|NCT03835793|Diagnostic Test|CAC-score|Testing for possible unfavourable health effects of early surgical menopause
44494|NCT03835780|Other|No intervention|A observation of outcomes in usual practice
44495|NCT03835767|Other|Peanut flour and Oat flour (placebo for peanut flour)|Peanut flour (12% light roast) with 50% protein content is manufactured by Byrd Mill. Oat flour is manufactured by GF Harvest.
44496|NCT03835767|Other|Dry Milk Powder and Corn Starch (placebo for Milk powder)|Dry milk powder with 36% protein content is manufactured by Giant Food. Corn starch is Argo brand.
44497|NCT03835767|Other|Baked milk and Rice milk (placebo for Baked milk)|Baked milk will be in the form of a muffin provided by the NIH CC Nutrition Department. Rice milk is manufactured by Rice Dream brand.
44499|NCT03835741|Device|FreeO2|an automated adjustment of oxygen during patient hospitalisation by FreeO2 device
44500|NCT03835741|Other|manual titration|a manual adjustment of oxygen during patient hospitalisation by hospital staff
44501|NCT03835728|Drug|Ocrelizumab|Subjects will be randomized in a 1:1 fashion to receive infusion of Ocrelizumab (2 doses at 300 mg and 1 dose at 600 mg) or matched placebo. The 2 300 mg doses will be administered at day 2 and day 14. The 600 mg dose will be administered during the 6 month visit. The drug will be administered via infusion three times throughout the trial period: after the initial screening, at two weeks from initial infusion, and at 6 months.
44502|NCT03835728|Drug|Saline|This will be the matching placebo used in the study.
44503|NCT03835715|Drug|Vortioxetine|Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8
44504|NCT03835702|Other|SAM Clinic Intervention|SAM Clinic is a sleep provider led team comprised of either a sleep clinician or sleep nurse practitioner along with sleep nurses and or durable medical equipment representative. The provider interacts with each patient personally. Various modes of trouble shooting of PAP related issues are tailored to solve PAP adherence issues including mask complaints, nasal issues, pressure intolerance, anxiety, and other related barriers to PAP adherence. When the provider is seeing patients individually other patients have the opportunity to interact and offer informal interpersonal support to other participants in dealing with similar PAP issues. The provider makes an individualized follow-up plan for each patient, which may include another SAM visit or referral back to the non-sleep provider.
44505|NCT03835689|Behavioral|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focused on skill learning for parents
44506|NCT03835676|Drug|Treprostinil|"After inclusion and baseline measurements, patients will receive treprostinil in addition to background therapy for 24 months. Follow-up assessment will include:~Clinical, echocardiographic, laboratory assessments will be repeated at 1, 3, 6, 12, 18, and 24 month (or when there is clinical indication)~CMR will be performed at 6 monthly intervals for 2 years.~Peak power output at 6,12, 18 and 24 month~Right-side cardiac catheterization will be performed at 6, 12 , 18 and 24 months (or when there is clinical indication)"
44507|NCT03835663|Diagnostic Test|No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes|Standard upper GI endoscopy with biopsies
44508|NCT03835637|Drug|ORIC-101|Capsule or oral suspension
44509|NCT03835624|Diagnostic Test|interleukin 33|serum and synovial fluid samples will be obtained from patients and serum samples from controls to measure interleukin 33 and its quantitative expression in peripheral blood mononuclear cells by PCR
44510|NCT03835611|Other|Game based treadmill Platform|"The protocol for the intervention group will be:~Warm up exercised consisting of rhythmical large movements (10minutes)~Dynamic standing balance training by playing commercial games with head rotations while standing on a compliant surface to increase balance demands. (10 Minutes)~DT treadmill training, consisting of playing commercial computer games while walking on the treadmill at a self-selected comfortable speed. Participants will be allowed to take rest when required and total effective DT treadmill walking will be for 30minutes. Treadmill speed will be aimed to progress depending on participant performance and documented. An overhead safety harness will always be provided to participants while walking on the treadmill. (25minutes)"
44511|NCT03835611|Other|Control Group|"Warm-up exercise consisting of rhythmical large movements (10 minutes).~Core standing balance exercises on a sponge surface (10 minutes).~Treadmill walking for 20 minutes, which includes rests periods... An overhead safety harness will be provided to participants while walking on the treadmill~Overground walking in an obstacle course. Participants will be instructed to walk along a curved path (marked by tape) and avoid obstacles placed randomly. The obstacle will be thin sponge pads with 10-12 inches in diameter (15minutes)."
44512|NCT03835585|Device|Gun lock|A cable-style gun lock that can be applied to a wide variety of guns for safe storage. The application of this device to most firearms renders them impossible to use properly while the device is in place and locked.
44513|NCT03835585|Other|Suicide Risk Assessment|Thorough suicide risk assessment according to guidelines established by research (Joiner et al., 1999; Chu et al., 2015). This is used to determine the severity of suicide risk and appropriate actions to be taken.
44514|NCT03835585|Behavioral|Safety Planning|A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley & Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.
44515|NCT03835585|Behavioral|Lethal Means Counseling|A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
44516|NCT03835572|Other|CircaHealth: a course on circadian rhythms and health|Participants will receive videos, behavioral modification checklists, and quizzes every week for six weeks.
44517|NCT03835572|Other|Sleep hygiene materials|Participants in the control group will receive weekly materials from the National Sleep Foundation and American Academy of Sleep Medicine on sleep hygiene
44518|NCT03835559|Procedure|Cyanoacrylate closure|After successful access of target vein and insertion of guidewire under any type of anesthesia, the procedure of cyanoacrylate closure is performed. A 5 French introducer and catheter is advanced and positioned 5.0 cm caudal to the junction with proximal saphenous vein compression by the ultrasound probe, two injections of approximately 0.10 mL glue are given 1 cm apart, followed by a 3min period of compression, and then repeat injections and 30sec ultrasound probe and hand compression sequences until the entire length of the target vein is treated. The catheter is removed.
44519|NCT03835559|Procedure|Surgical stripping|All types of anesthesia (general, spinal, regional block, or local anesthesia) can be used. The surgical stripping is performed with a proper incision in the groin, with division and ligation of the saphenous vein and division of all tributaries. The saphenous vein is then removed using a stripper.
44520|NCT03835533|Drug|NKTR-214 (Cohort A)|NKTR-214 will be administered intravenously every 3 weeks for up to 2 years
44521|NCT03835533|Drug|Nivolumab (Cohort A, B and C)|Nivolumab will be administered intravenously every 3 weeks for up to 2 years to cohort A, every 4 weeks for up to 2 years for cohort B and C.
44522|NCT03835533|Radiation|Stereotactic body radiation therapy (SBRT) (Cohort B)|Radiation therapy will be administered at 30 - 50 Gy in 1 - 5 doses, starting on Day 1 or 2 of Cycle 1
44523|NCT03835533|Drug|CDX-301 (Cohort B and C)|CDX-301 will be subcutaneously once a day for 5 days for cohort B. CDX-301 will be subcutaneously once a day for 10 days of immune-priming lead-in for cohort C.
44524|NCT03835533|Drug|Poly-ICLC (Cohort B)|Poly-ICLC will be administered intramuscularly twice weekly for 3 weeks starting on Day 1 of Cycle 1
44525|NCT03835533|Drug|INO-5151 (Cohort C)|INO-5151 will be administered intramuscularly on Day 8 of the Immune-priming Lead-in, and on day 1 of Cycle 1, 2 and 3, then every 12 weeks thereafter
44526|NCT03835533|Device|Cellectra 2000|Electroporation device
44527|NCT03835520|Drug|Immunotherapeutic Agent|Immunotherapy will be administered according to standard of care and reimbursement modalities in Belgium.
44528|NCT03835520|Drug|Molecular Target|Targeted agents will be administered according to standard of care and reimbursement modalities in Belgium. Targeted agents will be administered according to manufacturer's instructions.
44529|NCT03835507|Drug|recombinant human erythropoietin(rhEPO)|Injection of erythropoietin every months (total 12 months)
44530|NCT03835494|Other|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.|Transthoracic echocardiography at rest, during PLR, HG and CPX (including blood gas analysis in both groups). Additionally Fallot patients will undergo routine blood testings.
44531|NCT03835481|Drug|BI 730357|Film-coated tablet
44532|NCT03835481|Drug|Placebo to match BI 730357|Film-coated tablet
44533|NCT03835468|Dietary Supplement|Galacto-oligosaccharides|GOS is a form of prebiotic, which enhance the growth of beneficial gut bacteria
44534|NCT03835468|Dietary Supplement|Maltodextrin|sugar based placebo
44535|NCT03835442|Drug|Baclofen|baclofen 10mg tid for 4 weeks
44536|NCT03835442|Other|Placebos|placebo tid for 4 weeks
44537|NCT03835429|Device|MyTAP oral appliance plus mouth shield|The midline traction oral appliance (MyTAP, AMI Inc., Dallas Texas) is currently marketed as a medical device to treat snoring and obstructive sleep apnea and is FDA cleared.
44538|NCT03835416|Dietary Supplement|Foods rich in high quality protein|Along with a weight reduction diet (by instruction), participants will receive high quality protein foods provided to them to include in their daily diet (see study arm description).
44539|NCT03835403|Other|Activation of HeartRunners|Activation of volunteer citizen first-responders to respond to nearby cardiac arrests
44540|NCT03835390|Behavioral|SIMDiscovery|The SIMDiscovery program consists of nine stations that were designed to mirror the different stages of the perioperative process. The stations mirror the different stages of the surgical process and provide patients and their families with education regarding what they can anticipate during each aspect of the intervention.
44541|NCT03835377|Other|Iron-biofortified beans|Iron-biofortified beans (Phaseolus vulgaris L MIB465)
44542|NCT03835377|Other|Control beans|Control beans (Phaseolus vulgaris L Jamapa variety), identical in color and size
44543|NCT03835364|Device|Blood measurement|Single fingerprick to measure haemoglobin and haematocrit measurements using the Aptus Home, anaemia home monitoring system.
44544|NCT03835351|Device|Urinary Catheter|An intraoperative urinary catheter will be inserted which will be taken out at the end of the case
44547|NCT03835338|Device|LAA Occlusion|LAA Occlusion by implantation of the WATCHMAN LAAC Device
44548|NCT03835325|Dietary Supplement|Cogmax®|Research participants will receive 2 capsules of Cogmax® per day (after lunch) for 12 weeks.
44549|NCT03835312|Procedure|Sequential transplantation|After successful matching of umbilical cord blood stem cells, patients will receive pretreatment and chemotherapy under protective isolation, followed by thawing and reinfusion of umbilical cord blood stem cells. Immunosuppressive agents will be used for GVHD prevention and anti-infection support will be provided after reinfusion. The status of umbilical cord blood stem cell implantation, immune reconstruction and therapeutic effect will be evaluated. Islet transplantation will be performed in those who meet the conditions. The long-term prognosis will be observed by long-term follow-up.
44550|NCT03835299|Behavioral|Fear Intervention|Coping information related to the fear that was identified by the participant will be presented via a computer tablet.
44551|NCT03835286|Drug|Vitamin C|6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
44552|NCT03835286|Drug|Placebos|Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
44553|NCT03835273|Other|3D motion capture system|Small reflective markers and inertia measurement units will be placed on the chest of the patients using hypoallergenic adhesive and a motion capture system will pick up a 3D image via these markers non-invasively.
44554|NCT03835273|Other|Incentive spirometry|Incentive spirometry is a non-invasive device for assessment of pulmonary function.
44555|NCT03835273|Other|Questionnaires|Two validated, European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) and Oesophago-Gastric Module 25 (EORTC QLQ-OG25) and one non-validated satisfaction questionnaire regarding the usability and acceptability of the 3D motion capture system [7,8]
44556|NCT03835260|Device|Pivot Breath Sensor|The Pivot Breath Sensor measures the level of carbon monoxide in exhaled breath and displays the carbon monoxide value to the user.
44557|NCT03835221|Device|methafilcon A toric contact lenses|Bilateral daily wear of methafilcon A toric contact lenses
44558|NCT03835221|Device|fanfilcon A toric contact lenses|Bilateral daily wear of fanfilcon A toric contact lenses
44559|NCT03835208|Behavioral|High/low carbohydrate distribution|A total of 2x3 days, were the patient follow a detailed diet plan. For 3 days they follow a diet plan where the majority of the carbohydrates are located on either the first part of the day(HMK) or the last part of the day(LMK). 4 days of washout are placed between the two interventions. They will not receive food but will be guided by a trained dietitian and the use of a meal plan.
44560|NCT03835195|Other|Diabetes Disease Management Program|The attention is carried out in a single physical place, in the city of Medellin. The scheme of intervention in the comprehensive Diabetes Clinic is based on the concept of disease management. The intervention is composed of 5 phases, which apply to all the patients cared for in the institution (access, reception, entry, clinical consultation, management plan, education, pharmaceutical care). The healthcare team consists of 5 endocrinologists, an endocrinologist pediatrician, 7 general practitioners trained in diabetes, 5 pharmacists trained in diabetes and certified in education for patients with diabetes and 3 nutritionists.
44561|NCT03835195|Other|Usual Care Process|The patients are treated in the cardiovascular risk clinic (general practitioners) of their Primary Healthcare Provider Institution or by specialists in internal medicine, pediatrics or endocrinology in the different Provider Institutions of Health Services of the insurance service network of health or in private doctors' offices assigned to the insurer. In some cases there is assisted consultation (general practitioner - specialist). There is no defined periodicity for follow-up; Appointments are assigned to need, according to the criteria of the treating physicians. In some cases there is remission to educational activities, not necessarily focused on type 1 diabetes.
44562|NCT03835182|Device|Ultrasound group|Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back
44563|NCT03835182|Device|Short wave diathermy group|SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes
44564|NCT03835182|Other|Control group|superficial heat, analgesic physical modality and exercise only
44565|NCT03835143|Procedure|subinguinal varicocelectomy|varicocele ligation done at the level of subinguinal region
44566|NCT03835117|Drug|Wide-spectrum nutritional supplement|Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
44567|NCT03835117|Other|Placebo|Inactive placebo comparator
44568|NCT03835104|Device|CRP point-of-care testing|CRP point-of-care test using a fingerprick of blood and producing a result within 4 minutes, using the Afinion 2 (Abbott)
44569|NCT03835091|Other|BRASS score|Brainstem response on neurologic examination
44570|NCT03835078|Device|methafilcon A contact lenses|Bilateral daily wear of methafilcon A contact lenses
44571|NCT03835078|Device|fanfilcon A contact lenses|Bilateral daily wear of fanfilcon A contact lenses
44572|NCT03835065|Procedure|Closed Reduction|The primary goal of closed reduction is to maintain appropriate bony alignment and angulation to allow for appropriate healing.
44573|NCT03835065|Other|Long Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be extended to the shoulder joint if the patient is assigned to the long arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
44574|NCT03835065|Other|Short Arm Fiberglass Cast|A stockingette and webril will first be applied, after which the short arm fiberglass portion of the cast will be applied. After short arm casting has been appropriately placed, randomization group will be revealed. Casting will be complete at this point if the patient is assigned to the short arm cast group. The mold will then be applied and cast construct will be bivalved and taped.
44575|NCT03835039|Device|NIRS|Monitoring cerebral and perirenal perfusion using NIRS
44576|NCT03835013|Drug|Saline 0.9%|Intravenous infusion of 0.9% saline
44577|NCT03835013|Drug|GLP-1 7-36 amide (0.6pmol/kg/min)|Intravenous infusion of GLP-1 7-36 amide 0.6pmol/kg/min
44578|NCT03835013|Drug|GLP-1 7-36 amide (1.2pmol/kg/min)|Intravenous infusion of GLP-1 7-36 amide 1.2pmol/kg/min
44579|NCT03835013|Drug|Glucagon (25ng/kg/min)|Intravenous infusion of glucagon 25ng/kg/min
44580|NCT03835013|Drug|Glucagon (50ng/kg/min)|Intravenous infusion of glucagon 50ng/kg/min
44581|NCT03835000|Procedure|Orthopedic surgery|before and after surgery, patient will need medical imaging to asses their conditions
44582|NCT03834987|Other|Neurodevelopmental Assessment|Developmental assessment at baseline and longitudinally as measured by age and ability-appropriate scales, including: the Mullen Scales of Early Learning, the Peabody Scales of Motor Development, the Vineland 3, and Beery Visual Motor Integration
44583|NCT03834974|Behavioral|Social Media Feed with Indoor Tanning|Participants will be invited to follow a public social media feed on the social media platform to be determined by interviews and surveys of tanners. Participants will be incentivized to create content relating to sun safety and skin health for the public social media feed. Participants have the opportunity to win further incentives for content that receives the highest engagement from the audience.
44584|NCT03834974|Behavioral|Social Media Feed without Indoor Tanning|Participants will be invited to follow a public social media feed on the social media platform to be determined by interviews and surveys of tanners. Participants will be incentivized to create content relating to staying healthy during college for the public social media feed. Participants have the opportunity to win further incentives for content that receives the highest engagement from the audience.
44585|NCT03834961|Drug|Larotrectinib|Given PO or via NG or G tube
44586|NCT03834948|Drug|AO-176|Humanized mAb targeting CD47
44587|NCT03834935|Drug|Elidel (pimecrolimus 1%)|topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
44588|NCT03834935|Drug|Cold Cream|Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed
44589|NCT03834922|Other|Prospective data collection|No intervention. It's a prospective data collection.
44590|NCT03834909|Drug|Standard dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
44591|NCT03834909|Drug|Pregnancy-adjusted dose Truvada®|TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
44592|NCT03834896|Other|AYMES MADRID|AYMES MADRID is a gum-based commercial thickener, that can be utilised to modify fluid consistencies to Stage 1, 2 or 3 (as per the National Descriptors for Texture Modification) to enhance the safety of fluids in those with dysphagia.
44593|NCT03834883|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
44594|NCT03834883|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
44595|NCT03834870|Behavioral|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES)|Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) screening tool.
44596|NCT03834857|Device|StentrodeTM|Implantation of Stentrode TM device
44597|NCT03834844|Behavioral|Meditation|Guided Meditation for 10-15 minutes daily for 6 days/week for 6 weeks
44598|NCT03834844|Other|AF Education|6 weekly education modules on topics related to AF
44599|NCT03834844|Other|Phone Calls|Weekly phone call to discuss patient concerns or questions
44600|NCT03834831|Dietary Supplement|Coenzyme Q10|Coenzyme Q10
44601|NCT03834831|Dietary Supplement|Selenium|Selenium
44602|NCT03834818|Behavioral|COMPAS Participants|"The schedule of events for this study are as follows:~Day 1 Pre-Surgery:~Download the Medable App~Register to the study~Validated Questionnaires~Active Task~Every Day~9:00 a.m. Daily Questions~9:00 p.m. Daily Questions~Outcome Surveys and Active Task:~Day 1 Pre-Surgery~1-Week Post Operation~2-Weeks Post Operation~1-Month Post Operation~3-Months Post Operation~6-Months Post Operation"
44603|NCT03834805|Other|lung and liver elastography measurement of fetus|Other: lung and liver elastography measurement of fetus
44604|NCT03834792|Other|No intervention but exposure|Different sleep disorders will be considered as an exposure. The data elements included in the database: demographics, date of the sleep study, study type, all available polysomnography indices, symptoms, sleep schedule, comorbidities, medications, social history, electrocardiography, positive airway pressure treatment related variables.
44605|NCT03834779|Behavioral|DOORS-CHW Intervention|"The behavioral intervention has been developed for a collaborative CHW and re-entry program intervention that targets HIV outcomes, substance use and recidivism in HIV+ jail releasees.~Participants will be randomized to the DOORS+CHW intervention versus TAU and all participants will undergo study follow-up visits at 3, 6 and 12 months. In other words, participants randomized to the intervention arm will meet with the CHW and a staff member from DOORS. One of the primary study aims is a randomized controlled trial of an intervention which has a reasonable probability of improving the health and well-being of the subject by improving linkage to social services and the HIV clinic. The control arm will receive standard of care (referrals to case management)."
44606|NCT03834766|Drug|AMPH ER Tab 5, 10, 15 and 20 mg|Amphetamine
44607|NCT03834766|Drug|AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg|Placebo
44608|NCT03834753|Biological|bevacizumab|1.25 mg, intravitreal injection
44609|NCT03834753|Biological|ranibizumab|0.5mg, intravitreal injection
44650|NCT03834506|Drug|Docetaxel|IV infusion
44651|NCT03834506|Drug|Prednisone|Oral tablets
44652|NCT03834506|Drug|Placebo|IV infusion
44653|NCT03834506|Drug|Dexamethasone|Oral tablets
44654|NCT03834493|Biological|Pembrolizumab|IV infusion
44655|NCT03834493|Drug|Enzalutamide|Capsules/Tablets
44614|NCT03834701|Device|EUS guided radiofrequency ablation|The EUS-RFA system (Taewoong, Seoul, Korea) utilized for EUS-RFA consists of an 19-gauge needle electrode (140-cm long), a radiofrequency generator, and an inner cooling system that circulates chilled saline solution during the RFA procedure. The inner metal part is insulated over its entire length, with the exception of the terminal 5 to 20mm for energy delivery. The needle electrode is attached to a radio frequency current generator (VIVA RF generator; Taewoong) and to a cooling pump. The generator, in addition to providing radio frequency current, allows the control of physical power and impedance parameters.
44615|NCT03834688|Drug|Venetoclax|"Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)~Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days)."
44616|NCT03834688|Drug|Bendamustine|Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle.
44617|NCT03834688|Drug|Rituximab|Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle.
44618|NCT03834675|Diagnostic Test|transpulmonary thermodilution|Thermodilution was attempted via PICC and via CICC
44619|NCT03834662|Drug|AVID200|A TGFβ receptor ectodomain-IgG Fc fusion protein inhibitor of TGFβ
44620|NCT03834649|Procedure|partially de-epithelized connective tissue graft|graft procedures to obtain simultaneous tissue augmentation in the horizontal and vertical dimensions. The donor site was prepared with a full-thickness coronal dissection and a partial-thickness apical dissection.The objectives were to use a single procedure to achieve simultaneously apico-coronal and buccolingual augmentation,to have a smaller open wound in the donor site and less patient discomfort, and to guarantee better revascularization of the onlay section aided by the submerged connective tissue section of the graft.
44621|NCT03834649|Procedure|Mucograft|"For preprosthetic defects, a standard mucosal augmentation procedure, which is well reported in the literature, was performed. The surgical site produced by the surgery leaves a denuded area supraperiosteally that is addressed by grafting with a xenogeneic collagen membrane (Mucograft).~purpose of the surgery is to improve the quantity of attached mucosa to facilitate the final dental reconstruction"
44622|NCT03834636|Procedure|Restorations with nanoparticulated composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanoparticulated composite (Z350, 3M ESPE)
44623|NCT03834636|Procedure|Restorations with nanoparticulated composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanoparticulated composite (Z350, 3M ESPE)
44624|NCT03834636|Procedure|Restorations with nanohybrid composites and self etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a self-etching dental adhesive (SingleBond Universal, 3M ESPE), selective enamel etching, and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
44625|NCT03834636|Procedure|Restorations with nanohybrid composites and total-etch adhesives|The restorations will be placed according to the protocol developed for the care, following the guidelines of the manufacturers, with a total-etching dental adhesive (SingleBond 2, 3M ESPE), and use of a nanohybrid composite (IPS Empress Direct, Ivoclar Vivadent).
44626|NCT03834623|Drug|CC-122|Oral CC-122 at 2 mg daily, 5 days out of 7
44627|NCT03834623|Drug|Nivolumab|240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
44628|NCT03834610|Drug|L-arginine 5 gm oral caps|oral L-arginine 5 gm daily for 8 weeks
44629|NCT03834610|Drug|Tadalafil 10 MG|oral daily tadalafil 10mg for 8 weeks
44630|NCT03834610|Diagnostic Test|serum testosterone level|measurement of serum testosterone level
44631|NCT03834610|Diagnostic Test|HbA1C|measurement of HbA1C levels
44632|NCT03834610|Device|penile doppler|penile doppler to measure the degree of erection and penile vasculature
44633|NCT03834597|Device|conventional Macintosh laryngoscope|After closure of surgical, anesthesiologist will perform the conventional Macintosh laryngoscope to assess post-thyroidectomy vocal cord mobility.
44634|NCT03834597|Device|GlideScope®|Patient will be left for a while until hemodynamic stabilization then examination with GlideScope® will be commenced to assess postthyroidectomy vocal cord mobility by another experienced anesthesiologist
44635|NCT03834584|Drug|AG-636|AG-636 will be administered orally intermittently in 28-day cycles.
44636|NCT03834571|Drug|Carboplatin|Given IV
44637|NCT03834571|Drug|Cisplatin|Given IV
44638|NCT03834571|Drug|Paclitaxel|Given IV
44639|NCT03834571|Procedure|Patient Monitoring|Undergo active monitoring
44640|NCT03834571|Radiation|Radiation Therapy|Undergo radiation
44641|NCT03834558|Other|Mixed exercise program|"A progressive program of high intensity strength and myofascial conditioning will be carried out in 2 non-consecutive weekly sessions (24 weeks). Each session will include:~A) Warm up on a cycle ergometer~B) Strength circuit: 6 exercises will be included to strengthen different muscle groups (2 in the upper extremities, 2 in the trunk and 2 in the lower extremities). 3 sets of 10-15 repetitions until the failure. The load will be set to 70% of 1 maximal resistance.~C) Self-myofascial conditioning: 10 repetitions, in the direction of the fibres of each muscle group, with different materials. 7 muscle groups will be worked (quadriceps, hamstrings, abductors, gluteus, pectoralis, full back and trapezius).~D) At the end, static stretches will be performed"
44642|NCT03834532|Other|Breast reconstruction decision aid|The breast reconstruction decision aid is a web-based, interactive tool that participants will use after the first breast surgery visit and before a plastic surgery visit or surgery. The decision aid provides information about post-mastectomy breast reconstruction and helps the participant clarify their preferences related to the procedure.
44643|NCT03834532|Other|Educational website|The educational website contains information on healthy living with breast cancer including, physical activity and nutrition.
44644|NCT03834519|Biological|Pembrolizumab|IV infusion
44645|NCT03834519|Drug|Olaparib|Oral tablets
44646|NCT03834519|Drug|Abiraterone acetate|Oral tablets
44647|NCT03834519|Drug|Prednisone|Oral tablets
44648|NCT03834519|Drug|Enzalutamide|Oral tablets or oral capsules
44649|NCT03834506|Biological|Pembrolizumab|IV infusion
44657|NCT03834480|Other|Ultrasound guided Sacroiliac intra-articular injection|At the level of the sacral hiatus, the sacral cornuae were identified. posterior aspect of the sacroiliac joint, at 4.5 cm depth the SIJ was found. localal anesthetic was injected at the medial edge of the transducer, the spinal needle was advanced in a medial to lateral direction, under direct vision, until the needle was positioned in the SIJ. Local steroid solution or PRP 4ml volume was injected according to the study group and patient enrollment. If the injection is extra-articular, injectate (hyperechoic solution as it contains particulate steroid) can be seen spreading medially over the sacrum. The visual analog score, Oswestry Disability Index (ODI) score and the overall success rate basal, after one week,after one month,after three and six month's follow-up period after the initial block.
44658|NCT03834467|Other|Arm 1 - Elevation Stimulus Video|Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
44659|NCT03834467|Other|Arm 2 - Control Stimulus Video|Subjects will watch a nature video.
44660|NCT03834454|Drug|Bupivacaine|5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
44661|NCT03834454|Drug|Bupivacaine|7.5 mg hyperbaric bupivacaine 0.5% and 25 mcg fentanyl for spinal anesthesia
44662|NCT03834441|Other|Oral HRSN screening|Verbal screening delivered by an RA
44663|NCT03834441|Other|Written HRSN screening|Patient completes written screen on iPad.
44664|NCT03834428|Behavioral|Text Message Intervention|A text message will be sent once daily (between noon and 3p) to remind participants to ambulate at least 3 times each day while hospitalized.
44665|NCT03834428|Behavioral|ICOUGH protocol|Education will be provided about the ICOUGH protocol which includes: Incentive spirometry (a breathing device that expands the lungs), Coughing and deep breathing, Oral hygiene (for example using a toothbrush), Understanding (patient and family education), Getting out of bed at least three times daily, and Head-of-bed elevation to prevent choking.
44666|NCT03834415|Dietary Supplement|Lactobacillus reuteri DSM17038|Oil drops of L. reuteri containing 1x10>8 CFU
44667|NCT03834415|Other|Placebo for Probiotics|Oil drops mimicking in consistency and flavor to experimental product
44668|NCT03834389|Behavioral|Case- based Learning|critical thinking, self efficacy, focus group interview
44669|NCT03834376|Drug|Pimodivir|Pimodivir will be administered as tablets taken orally, twice daily (2 tablets of 300 milligram [mg]) over a time period of 5 days.
44670|NCT03834363|Drug|Fentanyl|Fentanylpatch 12 mcg/hr, change patch every three days.
44671|NCT03834363|Drug|Morphine Retard|Morphine retard capsules 10 mg bid.
44672|NCT03834363|Drug|Placebo patch|Placebo patch, change patch every three days.
44673|NCT03834363|Drug|Placebo oral capsule|Placebo oral capsule bid
44674|NCT03834350|Other|BREATHES Program|Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.A small device will be attached to track real-time medication use.
44675|NCT03834324|Device|FES|Functional Electrical Stimulation during cycling with Virtual Reality Feedback
44676|NCT03834311|Device|isokinetic strengthening|isokinetic upper extremity (forearm) strengthening
44677|NCT03834311|Other|exercise band strengthening|upper extremity (forearm) strengthening with exercise band
44678|NCT03834298|Other|Four Food Elimination Diet|Food allergens are thought to initiate eosinophilic inflammation and dietary elimination of trigger allergens is an effective treatment for EoE. Previous work demonstrates that in both children and adult EoE patients, the food antigens including cow's milk, wheat, egg, soy, peanut/tree nut and fish/shell fish, are the most common food triggers causing esophageal inflammation. Participants will be assigned to single arm treatment / intervention with a diet restricted of the four most common food allergens, milk, soy, wheat and egg, or a four food elimination diet (FFED). With the goal to optimize diet treatment, in Aim 2, eligible participants will undergo sequential food reintroductions based on protocol.
44679|NCT03834272|Combination Product|LUM Imaging System|Patients will be injected with one of 2 study doses of LUM015 and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
44680|NCT03834259|Procedure|sitting position|keeping the patient in a sitting position after spinal anaesthesia
44681|NCT03834259|Procedure|supine position|keeping the patient in supine position after spinal anaesthesia
44682|NCT03834233|Drug|Nivolumab|Nivolumab 3mg/kg IV every 14 days until disease progression, unacceptable toxicity or up to 12 months.
44684|NCT03834207|Device|Use of the C3-Cloud IT system|Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
44756|NCT03833713|Behavioral|SMS Assessments|Once-weekly SMS assessments of motor vehicle risks
44693|NCT03834181|Device|"Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b"|"All patients will be monitored before and after the bariatric surgery:~During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~Prolonged follow-up: weight, exercise, blood pressure and heart rate"
44694|NCT03834168|Other|standardized Study Diet|Standardized diet consisted with eucaloric meals with 4.5 gm of sodium per day for 5 days.
44695|NCT03834155|Other|Hospital-based CR + Movn Application|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application
44696|NCT03834155|Other|Choice of Hospital or home-based CR + Movn Application|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application
44697|NCT03834155|Other|Hospital-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that will receive hospital-based CR and access to the Movn mobile application, plus encouraging nudge messages
44698|NCT03834155|Other|Choice of Hospital or home-based CR + Movn Application + Nudge|Participants will be randomly assigned to a group that has opportunity to opt in to hospital-based cardiovascular rehabilitation or home-based cardiovascular rehabilitation. All will have access to the Movn Application, , plus encouraging nudge messages
44699|NCT03834142|Device|NSS-2 Bridge|The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
44700|NCT03834129|Drug|Dexmedetomidine|Two administrations, before anesthesia and during surgery, by intravenous infusion of dexmedetomidine 1 μg/kg in 250 ml of physiological serum for 30 minutes
44701|NCT03834129|Drug|sodium chloride 0.9%|Two administrations, before anesthesia and during surgery, by intravenous infusion of 250 ml of physiological serum for 30 minutes
44702|NCT03834116|Device|Inspiratory muscle training|A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
44703|NCT03834103|Behavioral|Self-rehabilitation program and protein supplement|"Participants follow a home-based self-rehabilitation program consisting of the realisation of a set of physical exercises using an elastic band. The exercises have to be performed 3 times a week, and are associated with a protein supplementation.~The rehabilitation follow-up by the physician is planned once a week, by phone, and with face-to-face appointments at inclusion, 6 weeks and 3 months follow-up."
44704|NCT03834090|Device|rESWT|rESWT was administered once per week for 3 weeks using a ShockMaster 500 device with 1.8 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses.
44705|NCT03834090|Other|Supervised exercises|A program including post-isometric relaxation, and progressive resistance exercise (eccentric wrist extension) on the wrist extensors
44706|NCT03834077|Other|Tissue flossing|Electrotherapy (transcutaneous electrical nerve stimulation) and Ultrasound in addition to tissue flossing.
44707|NCT03834077|Other|Placebo comparator|Conventional physiotherapy in addition to flossing without tension
44708|NCT03834064|Behavioral|Oral health promotion strategy|The proposed intervention is comprised of four components : (a) planned action including a behavioral contract Activity 1) with caregivers and action planning for oral health (Activity 2), (b) caregiver capacity building with didactic training (Activity 3), observational learning and caregiver practice (Activity 4); (c) environmental adaptations with location of oral health activities and reminder posters - physical environment (Activity 5) and administrative oral health support- (social environment (Activity 6); and (d) reinforcement with caregiver coaching (Activity 7).
44709|NCT03834051|Drug|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation Enema
44710|NCT03834038|Drug|Lyophilized Fecal Microbiota Transplantation|Lyophilized FMT
44711|NCT03834025|Behavioral|Phase 1 Condition 1|Providers assigned to this condition will be sent recruitment materials that are 'recruitment as usual' (Phase 1 Condition 1). These materials will not include prosocial messaging and will not include an additional mention of practice support available for participation.
44712|NCT03834025|Behavioral|Phase 1 Condition 2|Providers assigned to this condition will be sent recruitment materials that include an additional mention of practice support available for participation, but will not include prosocial messaging (Phase 1 Condition 2).
44713|NCT03834025|Behavioral|Phase 1 Condition 3|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging, but do not include an additional mention of practice support available for participation (Phase 1 Condition 3).
44714|NCT03834025|Behavioral|Phase 1 Condition 4|Providers assigned to this condition will be sent recruitment materials that include prosocial messaging and an additional mention of practice support available for participation (Phase 1 Condition 4).
44715|NCT03834025|Behavioral|Phase 2 Condition 1|Providers who enroll in the study and are assigned to this condition will be in this group. At this time the investigators are not disclosing the phase 2 conditions, and will disclose these at the end of the study.
44757|NCT03833700|Drug|E7386|E7386, tablets, orally.
44788|NCT03833492|Behavioral|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
44716|NCT03834025|Behavioral|Phase 2 Condition 2|Providers who enroll in the study and are assigned to this condition will be in this group. At this time the investigators are not disclosing the phase 2 conditions, and will disclose these at the end of the study.
44717|NCT03834025|Behavioral|Phase 2 Condition 3|Providers who enroll in the study and are assigned to this condition will be in this group. At this time the investigators are not disclosing the phase 2 conditions, and will disclose these at the end of the study.
44718|NCT03834012|Drug|Beclomethasone 800 µg per day|Intervention: Drug: Beclomethasone 800 µg HFA per day
44719|NCT03834012|Drug|Placebo|Intervention: Drug: placebo
44720|NCT03834012|Drug|Beclomethasone 400 µg per day|Intervention: Drug: Beclomethasone 400 µg HFA per day
44721|NCT03834012|Drug|Beclomethasone 640 µg per day|Intervention: Drug: Beclomethasone 640 µg per day
44726|NCT03833986|Other|Stress management program|Nurses stress management program will be an experiential teaching program consisting of six sessions of stress management strategies for public health centers nurses. the workshop will be in a warm quite room with efficient light, temperature, and ventilation. The intervention group will receive handouts copies of the stress management program for each session at the end of the study.
44727|NCT03833973|Behavioral|Overtraining Monitoring|Athletes will be thoroughly monitored (i.e. training workload, match activities or event/race performance, markers of inflammation and oxidative stress as well as cell-free DNA) throughout the season in order to establish novel biomarkers that could function as either predictors or diagnostic tools of overtraining.
44728|NCT03833947|Drug|lignocaine+bicarbonate|ETT cuff was filled with mixture of 2% lignocaine with bicarbonate
44729|NCT03833947|Drug|lignocaine+dexamethasone|ETT cuff was filled with mixture of 2% lignocaine with dexamethasone
44730|NCT03833934|Diagnostic Test|Plasma Next Generation Sequencing (NGS)|Liquid biospys
44731|NCT03833921|Drug|Abiraterone Acetate|1000 mg orally daily until disease progression
44732|NCT03833921|Drug|Prednisone|5 mg oral low dose prednisone, twice daily
44733|NCT03833908|Device|MAF-1217|Patients will be enrolled at screening (2 weeks before surgery), then will be randomized with a 1:1 ratio to 2 groups of 23 patients each: A. patients receiving MAF-1217 B. patients receiving just standard antibiotic therapy
44734|NCT03833895|Drug|Norepinephrine|0.05ug/kg/min Norepinephrine during Cesarean Section Operation
44735|NCT03833895|Drug|Phenylephrine|0.5ug/kg/min phenylephrine during Cesarean Section Operation
44736|NCT03833895|Drug|Ringer's Solution|Ringers solution with an intraoperative maintenance dose of 0.1 ml/kg/min. No vasoactive agent
44737|NCT03833882|Device|MAF1217|The study population will have to self-administer the study treatment in a TID posology.
44738|NCT03833882|Other|Cationorm|The study population will have to self-administer the study treatment in a TID posology.
44739|NCT03833869|Procedure|Assisted hatching|Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer
44740|NCT03833856|Procedure|colonoscopy perforation|The development of perforation after colonoscopy
44741|NCT03833843|Diagnostic Test|imaging|ECG, Echocardiography and cardiac magnetic resonance imaging
44742|NCT03833830|Diagnostic Test|Optical Coherence Tomography angiography (OCTA)|There will be an OCTA measurement (observational study) for both groups. Group allocation will be made due to previous anti-VEGF treatments (longterm treatment group >20 injections and shortterm treatment group < 5 injections).
44743|NCT03833817|Behavioral|Talking about Cancer (TAC)|The TAC intervention is a six session intervention designed to teach the techniques of distress tolerance and communication skills in order to assist patients and their caregivers in discussing the patients' prognoses.
44744|NCT03833804|Other|Processing of clinical notes in the EHR data collected during routine care|Clinical notes collected in the first day of hospital admission during usual care as input to natural language processing and machine learning algorithm.
44745|NCT03833791|Behavioral|education and modifying diet|The control group maintains a sedentary lifestyle and is only subjected to follow a hypocaloric diet
44746|NCT03833791|Behavioral|education, modifying diet and physical activity prescription|"One group, in addition to fulfilling a hypocaloric diet identical to the control group, is subjected to prescribe moderate physical activity.~Other group, in addition to fulfilling a hypocaloric diet identical to the control and moderate group, is subjected to prescribe intense activity."
44747|NCT03833778|Other|intervention group|The CED patients play the tablet-CED-quiz, while they wait for their doctor's appointment, so that gaps in the CED knowledge can be clarified during the doctor's consultation.
44748|NCT03833765|Procedure|CAF+XCM|After flap elevation according to the Coronally Advanced Flap procedure for multiple recession defects, a Xenogeneic Collagen Matrix was applied and then covered by the flap.
44749|NCT03833765|Procedure|CAF alone|Coronally Advanced Flap procedure alone was performed to treat multiple recession defects
44750|NCT03833752|Diagnostic Test|Diagnostic Flexible Cystosocpy|Endoscopic Visualization of the Lower Urinary tract using either a flexible cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
44751|NCT03833752|Diagnostic Test|Diagnostic Rigid Cystoscopy|Endoscopic Visualization of the Lower Urinary tract using either a rigid cystoscope for the purpose of aiding the establishment of a Urological Diagnosis.
44752|NCT03833739|Device|Fixed appliance|
44753|NCT03833726|Procedure|Experimental: LED group|5 Sessions of 8 minute 405 nm Blue Light Emitting Diode, LED, with a power of 1.66 W / m2, 7 days apart.
44754|NCT03833726|Procedure|Sham Comparator: Control|5 Sessions of 8 minute with device off and heated gel, 7 days apart.
44755|NCT03833713|Behavioral|SMS Dialogue|Once-weekly SMS dialogue sessions or micro-interventions and use behavior change techniques (BCTs) including self-monitoring with performance feedback and goal support
44758|NCT03833687|Device|Profhilo®|Profhilo® (IBSA Farmaceutici Italia S.r.l.) is a resorbable medical device 2.25 ml non-pyrogenic pre-filled syringe, containing 2 ml of 3.2% hyaluronic acid for intradermal use (32 mg H-HA + 32 mg L-HA dissolved in 2 ml of saline buffered sodium chloride.
44759|NCT03833674|Other|Daily AIH Block|Daily sessions of AIH (dAIH) with use of short episodes of low oxygen (9% O2)
44760|NCT03833674|Other|Sham dAIH Block|Daily sessions of sham dAIH which includes breathing room air (21% O2)
44761|NCT03833674|Other|Respiratory Strength Training Block|Respiratory strength training using a hand-held device that resists inspiration or expiration.
44762|NCT03833674|Other|AIH + Strength Training Block|AIH followed by respiratory strength training.
44763|NCT03833661|Drug|M7824|Participants will receive an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity, study withdrawal, or up to 24 months
44764|NCT03833648|Other|UControl Pain App with Education|The intervention will include educational information on pain management, e.g., using acetaminophen and NSAIDs to manage pain, as well as information on addiction and safe storage of medications.
44765|NCT03833635|Other|osteopathic manipulative treatment|OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect
44766|NCT03833635|Other|Sham|the sham intervention consists in a stable skin-to-skin contact with the participant
44767|NCT03833622|Other|Shared Decision Aid Assessment|Provide feedback on a shared decision making tool to aid in discussion on goals of care in the emergency department
44768|NCT03833609|Behavioral|Online yoga training (Group A)|The yoga training program is a structured low-intensity Vishwas-Raj (18). This yoga program consists of stretching, strengthening, meditation and deep breathing, and has been shown to be effective among adults with RA. Participants will be asked to complete three individual 1-hour sessions per week for 12 consecutive weeks by watching a previously filmed session led by a qualified yoga instructor and posted on Facebook. They will also take part in a 1-hour virtual group session per week using a video-conferencing platform. Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
44769|NCT03833609|Behavioral|Online aerobic dance training (Group B)|The aerobic dance program is a low to moderate intensity level program and will also use a video. The video, adapted for youth with JIA, was developed with feedback from a JIA patient with experience in aerobic dance and a physiotherapist with experience in pediatric rheumatology. The aerobic dance program will have the same characteristics in terms of frequency, total number of sessions and total duration as the yoga program (i.e., three 1-hour individual sessions and one 1-hour virtual group session per week for 12 weeks). Participants will also participate in weekly e-consultations with a research coordinator and discussions on Facebook with other participants.
44770|NCT03833596|Drug|Prednisone|All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
44771|NCT03833596|Dietary Supplement|Exclusive Enteral Nutrition|2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
44772|NCT03833583|Device|Soterix Medical mini-CT tDCS stimulator|"Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.~Stimulation will last 20 minutes per day, three days per week, for 5 weeks"
44773|NCT03833570|Dietary Supplement|Rapid Release Capsules Melatonin, 10 mg|Melatonin is a dietary supplement which is naturally produced in the body and closely involved in the natural sleep cycle. recently topical and systemic melatonin supplements. have been proposed as a new therapeutic modality for oral mucositis due to its anti-cancer, anti-inflammatory, and anti-oxidant effects.
44774|NCT03833570|Drug|Miconaz oral gel|Antifungal agent
44775|NCT03833570|Drug|BBC oral spray|Topical anesthetics and anti-inflammatory agent
44776|NCT03833570|Drug|Oracure gel|Topical analgesic gel
44777|NCT03833570|Other|Alkamisr sachets|Sodium bicarbonate mouthwash
44778|NCT03833557|Procedure|Nanohydroxyapatite Pulpotomy|Biphasic calcium phosphate 500-1000 Um Straumann BoneCeramic
44779|NCT03833557|Procedure|MTA pulpotomy|Angleus grey MTA
44780|NCT03833557|Procedure|Formocresol Pulpotomy|Buckley`s Fromocresol. diluted full strength foromocresol
44781|NCT03833544|Other|Exercise training|Progressive resistance training of hip, knee, and ankle flexors.
44782|NCT03833531|Behavioral|ImRS|ImRs is a PTSD treatment that specifically addresses the troubling memories of the traumatic event and the personal meaning of the event and consist of 12 to 18 sessions in maximum 6 months.
44783|NCT03833531|Behavioral|SFT|SFT is a treatment for personality disorders that takes at least one group-session per week, for the duration of one year.
44784|NCT03833518|Other|Rehabilitation using motorized glove for stroke and spinal cord injury|Individuals with hand impairment due to stroke or spinal cord injury will wear a motorized glove (Gloreha Sinfonia), or exoskeleton, as part of a rehabilitation protocol to improve dexterity. For each exercise, participants will attempt to do the action, receiving assistance as necessary via powered motors that can move each finger through its passive range of motion based on the current and target position.
44785|NCT03833518|Other|Functional MRI for stroke and spinal cord injury|All participants will undergo 3 functional MRI's (fMRI's), two at the beginning of the experiment to document brain activity related to movement intention and ability to sense movement. A third MRI will be performed after the rehabilitation is completed to document the change in brain activity related to movement intention and ability to sense movement.
44786|NCT03833518|Other|Transcranial magnetic stimulation (TMS) for stroke and spinal cord injury|Stimulation of the nervous system may be performed using a magnetic stimulator. TMS of the central nervous system is optional. Whether or not a participant undergoes TMS will depend upon their consent, their eligibility for TMS (i.e. no seizure history), and their neurological response to TMS.
44787|NCT03833505|Other|Bitestrip|The parents of the patients were asked to complete a survey that included questions about the demographic data, medical history of the patient, clinical findings of E. For diagnosis of sleep bruxism, a single-use BiteStrip® device (Up2dent, Inc.), including an electromyographic electrode, small display screen and lithium cell, was used to record the increased electromyographic activity of the masticatory muscles during sleep and bruxism, other harmful oral habits, family life and habits.
44789|NCT03833479|Other|No Further Treatment|No further treatment
44790|NCT03833479|Drug|TSR-042|Fixed 500 mg TSR-042 dose Q3W for the first 4 doses followed by a fixed 1000 mg TSR-042 dose Q6W for up to 24 months
44791|NCT03833466|Drug|metformin and chemotherapy|"Drug: Metformin Metformin is orally administered as 500mg bid for 7 days and escaladed to 500mg tid if adverse events are tolerated.~Drug: Cisplatin Cisplatin is given at 75mg/m2 intravenously on day 1 of each 21 day cycle.~Drug: Paclitaxel Paclitaxel is given at 175mg/m2 intravenously on day 1 of each 21 day cycle."
44792|NCT03833453|Behavioral|EMDR|EMDR is a PTSD treatment that specifically addresses troubling memories of and the personal meaning of the traumatic event and consists of 12 to 18 sessions in a maximum of 6 months.
44793|NCT03833453|Behavioral|DBT|DBT is a treatment for personality disorders (PD) focused on emotion regulation. It takes at least one group-session per week, and one individual coaching session every two weeks, for the duration of one year.
44794|NCT03833440|Drug|Durvalumab (MEDI4736)|"1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day"
44795|NCT03833440|Drug|Monalizumab (IPH2201|"750 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~c=cycle D= day"
44796|NCT03833440|Drug|Oleclumab (MEDI9447)|"3000 mg every 2 week x 4 doses, followed by 3000 mg every 4 weeks. C1D1, C1D15, C2D1, C2D15 and CXD1 for the orther cycles, 1 cycle = 28 days.~c=cycle D= day"
44797|NCT03833440|Drug|AZD6738|"240 mg bid in Cycle 1, Days 1-7, followed by 7 days on treatment in each cycle between Days 22 and 28.~CxD22-D28 for each cycle, 1 cycle = 28 days EXCEPT FOR CYCLE 1 : at C1D1,C1D29 and cycle 1 = 35 days~c=cycle D= day"
44798|NCT03833440|Drug|DOCETAXEL|"75 mg/m2, every 3 weeks. CxD1 for each cycle, 1 cycle = 21 days~c=cycle D= day"
44799|NCT03833427|Drug|Selumetinib|Selumetinib oral capsules administered BID at escalating dose levels. Selumetinib administered only in weeks 1&2 of each 3-week treatment cycle.
44800|NCT03833427|Biological|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1 of each 3-week treatment cycle.
44801|NCT03833414|Procedure|triceps lifting and olecranon osteotomy approaches|two different surgical approaches for distal humerus fracture
44802|NCT03833401|Procedure|Autologous tissue transplantation|Root canal disinfection and revascularization with patient's own minced pulp tissues
44803|NCT03833401|Procedure|Root canal revascularization|Root canal disinfection and revascularization without tissue transplantation
44804|NCT03833388|Drug|TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
44805|NCT03833388|Drug|Placebo to TOP1630 0.1% Ophthalmic Solution TID OU|Bilateral ocular drug administration
44806|NCT03833375|Other|Decision Aid|Shared-decision making tool
44807|NCT03833362|Drug|Narlaprevir|yellow film-coated 100 mg. tablets
44808|NCT03833362|Drug|Ritonavir|100 mg tablets encapsulates in gelatin capsules (for blinding purposes)
44809|NCT03833362|Drug|Placebo Narlaprevir|yellow film-coated 100 mg. tablets identical to Narlaprevir tablets
44810|NCT03833362|Drug|Placebo Ritonavir|100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules
44811|NCT03833362|Drug|Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b|180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials
44812|NCT03833362|Drug|Ribavirin|"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight <75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight <65 kg) - 1400 (patient weight >105 kg) mg/day with Peginterferon alfa-2b"
44813|NCT03833349|Behavioral|Spinning Class|Spinning Class twice a week for six weeks.
44814|NCT03833349|Behavioral|Yoga Class|Yoga Class twice a week for six weeks.
44815|NCT03833349|Behavioral|Dance Class|Dance Class twice a week for six weeks.
44816|NCT03833336|Other|Placebo|The group assigned to placebo will receive an infusion of normal saline solution plus oral lactose capsules identical to oral medication.
44817|NCT03833336|Drug|Ferric carboxymaltose|The group assigned to receive intravenous iron will receive intravenous ferric carboxymaltose ajusted by weight and Hb levels according to study protocol plus oral placebo
44818|NCT03833336|Drug|Ferroglycine Sulfate|One group assigned to receive oral iron will receive two 100 mg oral capsule of ferroglycine sulfate plus intravenous placebo (normal saline solution)
44819|NCT03833336|Drug|Sucrosomial Iron|One group assigned to receive oral iron will receive or two oral capsule containing 30 mg of pyrophosphate sucrosomial iron plus intravenous placebo (normal saline solution)
44820|NCT03833323|Combination Product|Implantable System for Remodulin (treprostinil)|All patients will be implanted with the Implantable System for Remodulin (treprostinil).
44821|NCT03833310|Diagnostic Test|Osteoprotegerin marker in serum in inflammatory bowel disease|I will measure Osteoprotegerin and Soluble Receptor activator of nuclear factor kappa-Β ligand markers in serum of patient with inflammatory bowel disease
44822|NCT03833297|Drug|Drugs inducing hepatological toxicity|Drugs susceptible to induce hepatological toxicities
44823|NCT03833284|Behavioral|Participant Barriers to TVU Screening|Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.
44824|NCT03833284|Behavioral|Provider Barriers to TVU Screening|Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
44825|NCT03833271|Biological|Influenza vaccine, Immune function|Comparing immune function and seroconversion after immunizing healthy children and juvenile idiopathic arthritis (JIA) children treated with different type of medication with influenza vaccine.
44826|NCT03833258|Behavioral|Rehabilitation with no precautions|Patients will recover from total hip replacement surgery being guided by pain only and not by the precautions imposed upon them by clinicians.
44866|NCT03832907|Device|Dexcom G6 CGM - Continues Glucose Monitoring sensor system|A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.
45158|NCT03830619|Diagnostic Test|collect samples|collect serum samples and clinical features
44827|NCT03833245|Behavioral|Patient Navigation|The patient navigation (PN) intervention will initiate following participant recruitment. It is important to note that PN sessions do not strictly coincide with specific weeks of pregnancy since the women can be recruited up to ≤25 weeks of gestation. The prenatal portion of the intervention includes 10 sessions delivered within approximately 14 weeks. The postnatal portion of the intervention will be delivered as 4 sessions over 8 weeks. Women who complete the intervention before delivery will receive regular calls/texts until delivery wherein the navigator will encourage and reinforce abstinence and treatment retention. All contact will be reported by staff in a patient contact log developed for the study that will be used to quantify level of patient contact.
44828|NCT03833232|Device|omentopexy with cyanoacrilate glue|apposition of omentum with cyanoacrilate glue on gastric section
44829|NCT03833219|Behavioral|Weekly feedback|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week.
44830|NCT03833219|Behavioral|End of intervention period incentive|Notify participant about potential incentive at the end of the intervention period, but do not provide weekly feedback about performance.
44831|NCT03833219|Behavioral|Loss-framed weekly incentive|Send push notification reporting user's handheld phone use while driving compared to distribution for driver cohort (age, geographic area) each week. Pay participant weekly according to where they fall on the distribution each week.
44832|NCT03833206|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
44833|NCT03833193|Radiation|Hypofractionated radiotherapy|Radiation: Hypofractionated radiotherapy at 3Gy/f
44834|NCT03833180|Drug|VLS-101|Open-Label VLS-101
44835|NCT03833167|Biological|Pembrolizumab 400 mg|Administered by IV infusion on Day 1 of each 42-day cycle
44836|NCT03833167|Drug|Placebo|Administered by IV infusion on Day 1 of each 42-day cycle
44837|NCT03833154|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] for up to 24 months or until progression or other discontinuation criteria are met.
44838|NCT03833154|Other|Placebo|Matching placebo for infusion every 4 weeks iv for up to 24 months or until progression or other discontinuation criteria are met.
44839|NCT03833141|Other|Survey Administration|Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.
44840|NCT03833128|Drug|Low Dose REN001|Once daily for 12 weeks
44841|NCT03833128|Drug|High Dose REN001|Once daily for 12 weeks
44842|NCT03833115|Other|vaginal gel containing or not sodium lauryl sulfate|Prevention
44843|NCT03833102|Other|biological analysis|ST types will be determined for all individualized bacterial strains. For all the bacterial strains, RNAs expression will be analyzed at three different growth phases: early exponential phase, mid exponential phase and early stationary phase. Expression of RNAIII and SprD will be evaluated by quantitative polymerase chain reaction.
44844|NCT03833089|Combination Product|Targeted serum potassium level|In the following order, following advices end prescriptions will be provided: 1) Potassium rich dietary advice, 2) Potassium supplementation, 3) mineralocorticoid receptor antagonists,
44845|NCT03833076|Device|Medical device Procto|Medical device Procto presents itself as cream
44846|NCT03833063|Drug|botulinum toxin A|glabellar injections with botulinum toxin A
44847|NCT03833063|Drug|Placebos|glabellar injections with sodium chloride
44848|NCT03833037|Other|Soft tissue sarcomas in adults|Adult sinovial sarcoma
44849|NCT03833024|Drug|Micronized Purified Flavonoid Fraction|After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
44850|NCT03833024|Drug|Placebo|After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment
44851|NCT03833011|Procedure|Osteopathic Manipulation|Osteopathic manipulation
44856|NCT03832985|Genetic|Receive an adult-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
44857|NCT03832985|Genetic|Receive a pediatric-onset result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have received an adult-onset genomic result.
44858|NCT03832985|Genetic|Control - No Result|Assess the psychosocial outcomes and the lived experience of MyCode pediatric participants and parents who have not received an adult-onset genomic result.
44859|NCT03832972|Other|estrogen level|Women are tested at different times in their menstrual cycle, if there is a cohesion between performance and level of estrogen
44860|NCT03832959|Device|EnsoETM|The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
44861|NCT03832946|Drug|TD139|TD139 is a galectin-3 inhibitor designed to modulate the fibrogenic response to tissue injury. It is administered as inhalation once a day.
44862|NCT03832946|Drug|Placebo|Placebo is administered as inhalation once a day
44863|NCT03832933|Behavioral|High Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 32%:40%:28%.
44864|NCT03832933|Behavioral|Standard Protein Diet|16 week weight loss and 36 weight loss maintenance intervention. Approximate macronutrient distributions (carbohydrate:protein:fat) will be 53%:21%:25%.
44865|NCT03832920|Other|Analgesia Nociception Index|A monitor of nociception for patients under general anesthesia
44905|NCT03832608|Other|No intervention|There is not intervention to be administered, only collection of data through various tests and questionnaires.
44867|NCT03832907|Diagnostic Test|POC BG - Point-of-Care Blood Glucose monitoring|Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
44868|NCT03832894|Drug|Estradiol Valerate|Oestradiol supplementation starting from day of trigger through out the luteal phase
44869|NCT03832881|Diagnostic Test|ADAMTS13, VWF assay|
44870|NCT03832868|Behavioral|Pre-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
44871|NCT03832868|Behavioral|Post-visit timing of receipt of the ICDs implantation decision aid|The intervention is the timing of receipt of the decision aid. The decision aid is designed to facilitate informing patients and helping to reach a decision.The implantable cardioverter-defibrillators (ICDs) implantation decision aid presents treatment options, risks, and benefits in lay terms.It is currently utilized in all of the Emory cardiac electrophysiology clinics as part of usual clinical care.
44872|NCT03832855|Biological|pING-hHER3FL|Plasmid vaccine containing HER3
44873|NCT03832842|Diagnostic Test|Blood sample|Blood sample
44874|NCT03832829|Device|Indirect composite restoration|Restoration of tooth with extensive substance loss
44875|NCT03832816|Drug|Placebo|Placebo vapor (distilled water)
44876|NCT03832816|Drug|Vaporized THC alone|Acute exposure to vaporized THC
44877|NCT03832816|Drug|Vaporized CBD alone|Acute exposure to vaporized CBD
44878|NCT03832816|Drug|Vaporized CBD with THC|Acute exposure to vaporized CBD with THC
44879|NCT03832803|Behavioral|Empty bladder|No drinking protocol.
44880|NCT03832803|Behavioral|Full bladder|Followed drinking protocol
44881|NCT03832790|Other|observation|observation
44882|NCT03832777|Device|Repetitive Transcranial Magnetic Stimulation|Subjects will receive both active and placebo rTMS, in a crossover modality.
44883|NCT03832764|Device|ANSPEC-PRO|Device monitors for 140 minutes continuously the pain levels in awake patients in PACU/ICU
44884|NCT03832751|Other|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
44885|NCT03832738|Drug|JTE-451 Tablets|Active drug tablets containing JTE-451
44886|NCT03832738|Drug|Placebo Tablets|Placebo tablets matching in appearance to the active drug tablets
44887|NCT03832725|Other|High Protein (HP) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HP diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
44888|NCT03832725|Other|High carbohydrate (HC) weight loss diet|"Newly diagnosed Type 2 Diabetic (NT2DM) subjects will be placed on a HC diet for 6 months with all food provided for weight loss and remission of NT2DM.~Intervention with the HP diet will be 6 months. If subjects have not had remission of Type 2 Diabetes by the end of the 6 months, they will be referred to an endocrinologist for pharmaceutical treatment"
44889|NCT03832712|Procedure|Deep Brain Stimulation|Surgical implantation of intracranial leads for deep brain stimulation, extension cables and implantable pulse generator
44890|NCT03832712|Drug|Best Medical Treatment|Unselective β-blockers such as Propanolol
44891|NCT03832699|Drug|Dydrogesterone 10 MG|Oral progesterone 10 mg TID
44892|NCT03832699|Drug|Endometrin 100Mg Vaginal Insert|Vaginal Endometrin 100 mg twice daily
44893|NCT03832686|Other|Virtual Coach|The smartphone application, tailored to patients with HNC, will monitor patient progress while also providing a direct line to health care providers should any questions or concerns arise concerning their treatment. The mobile application will also feature instructional videos that describe the swallowing exercises in detail, providing patients with another resource to help improve their overall rehabilitation experience. Finally, home practice reminders and prompts will be used to help patients integrate the exercises into their daily routine.
44894|NCT03832673|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks (for 3 cycles)
44895|NCT03832673|Drug|Epacadostat|Epacadostat 300 mg (BID) orally continuously every 28 days (for 3 cycles)
44896|NCT03832660|Behavioral|Lifestyle|A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3−, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3− in 70 ml bottle.
44897|NCT03832660|Drug|Sacubitril/Valsartan|Angiotensin receptor neprilysin inhibitor Sacubitril / Valsartan: The treatment period begins on day 1 with initial dosing of sacubitril/valsartan, followed by uptitration every 2 to 4 weeks to the target dose of 97/103 mg twice daily. 3 doses of sacubitril/valsartan available throughout the study are 24/26 mg, 49/51 mg, and 97/103 mg, each taken by mouth twice daily. If the patient discontinues the study medication, the patient is advised to return to the clinic for an end-of-study visit. Patients undergo treatment for 4 months.
44898|NCT03832647|Combination Product|Epiduo|100 per arm Adapalene/ Benzoyl Peroxide
44899|NCT03832647|Drug|Salicylic Acid|Salicylic Acid
44900|NCT03832647|Other|Hydréane légère|moisturizer
44901|NCT03832634|Diagnostic Test|Fetal Genome Profiling.|Once pregnancy is achieved, patients will undergo non-invasive collection of trophoblast cells (trophoblast retrieval and isolation from the cervix, TRIC) at an early gestational age, approximately 5-6 weeks. The patient will also be screened with blood work for carrier status for genetic conditions.
44902|NCT03832621|Drug|Temozolomide|temozolomide 150 mg/sqm daily on days 1-5 every 4 weeks
44903|NCT03832621|Drug|Nivolumab|nivolumab 480 mg i.v. every 4 weeks
44904|NCT03832621|Drug|Ipilimumab|low-dose ipilimumab 1 mg/Kg i.v. every 8 weeks
44906|NCT03832595|Other|Intervention Arm|"An EHR in-basket message will be sent to the patient's PCP which identifies the patient's high-risk CKD status and indicates that the patient will receive:~Nephrologist led electronic consultation: review of the patient's EHR with recommendations sent to the PCP every ~6 months,~Medication therapy management: PharmD led telephonic medication therapy management with the patient every ~6 months,~and Nurse led CKD patient education, every ~6-12 months~unless the PCP opts the patient out of the interventions (by responding to the EHR in-basket message and providing an opt-out reason or requesting an office consultation with nephrology)."
44907|NCT03832595|Other|Usual Care|Patients in the usual care arm will continue to receive CKD care guided by their PCPs as per usual care practices (i.e., specialty consultation, pharmacotherapy, nurse education, etc. may be ordered by the PCP according to their usual practice).
44908|NCT03832582|Drug|Annexin|All patients will undergo a 99mTc-annexin V-128 scintigraphy (SPECT)
44909|NCT03832569|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
44910|NCT03832569|Drug|Placebo|Placebo 200mg IV every 3 weeks over 30 minutes
44911|NCT03832556|Other|CT scan|CT scan with biphasic injection of contrast product
44912|NCT03832556|Other|MRI examination|MRI with injection of contrast
44913|NCT03832530|Behavioral|Safer conception counseling inclusive of periconception PrEP|Observational evaluation of factors associated with uptake of and adherence to daily, oral TDF/FTC PrEP and other safer conception methods (including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive during follow-up) over 9 months.
44914|NCT03832517|Drug|Single intravenous doses of RC-01|Intravenous single escalating doses of RC-01
44915|NCT03832517|Drug|Single intravenous doses of placebo|Intravenous single doses of placebo to match RC-01
44916|NCT03832517|Drug|Multiple intravenous doses of RC-01|Multiple ascending doses of RC-01 given intravenously two or three times daily for 10 days
44917|NCT03832517|Drug|Multiple intravenous doses of placebo|Multiple doses of placebo to match RC-01 given intravenously two or three times daily for 10 days
44918|NCT03832504|Other|No intervention|The participant will rest in a seated position.
44919|NCT03832504|Other|Fan|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure.
44920|NCT03832504|Other|Skin Wetting|Tap water (~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
44921|NCT03832504|Other|Fan + Skin wetting|A fan placed in front of the participant will provide an airflow of 4 m/s throughout the exposure. In addition, tap water (~18°C) will be applied every 5 minutes to the face, neck, upper and lower arms and upper and lower legs using a spray bottle.
44922|NCT03832491|Other|Home based therapy|Airway clearence techniques
44923|NCT03832491|Other|Game and home based therapy|Game based approach programme and airway clearence techniques
44924|NCT03832478|Device|Virtual Reality Headset Given|Samsung Gear VR Headset with guided mindfulness meditation app
44925|NCT03832465|Drug|Levofloxacin film-coated tablet|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
44926|NCT03832465|Drug|Levofloxacin intravenous solution|"50 participants are randomly assigned to receive intraluminal eradication of H. pylori.~with medicaments containing levofloxacin powder or levofloxacin solution."
44927|NCT03832452|Drug|Lucerastat (Treatment A)|2000 and 4000 mg; hard capsules for oral administration
44928|NCT03832452|Other|Placebo|hard capsules for oral administration
44929|NCT03832452|Drug|Moxifloxacin|400 mg; film-coated tablets for oral administration
44930|NCT03832452|Drug|Lucerastat (Treatment B)|1000 mg; hard capsules for oral administration
44931|NCT03832452|Drug|Lucerastat (Treatment C)|4000 mg; hard capsules for oral administration
44932|NCT03832439|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
44933|NCT03832439|Dietary Supplement|microcrystalline cellulose|Placebo
44934|NCT03832426|Drug|Narlaprevir|100 mg film-coated tablets
44935|NCT03832426|Drug|Ritonavir|100 mg film-coated tablets
44936|NCT03832413|Diagnostic Test|DELPhI (TMS-EEG analysis)|We perform an evaluation not an intervention. the DELPhI evaluation comprises of an automated analysis to EEG data recorded during TMS (Transcranial Magnetic Stimulation) to the M1L (Primary motor cortex).
44937|NCT03832400|Biological|MET-2|MET-2 is a defined consortium of human commensal bacteria derived from a healthy donor, which has the full metabolic functional capacity of fecal microbiota.
44938|NCT03832400|Drug|Placebo oral capsule|Placebo oral capsule which is identical to the MET-2 capsules.
44939|NCT03832387|Device|Non-invasive mechanical ventilation|
44940|NCT03832387|Device|Continuous positive airway pressure|
44941|NCT03832387|Device|Venturi mask|
44942|NCT03832387|Device|Reservoir mask|
44943|NCT03832374|Other|Descriptive|
44944|NCT03832361|Drug|IMGN853|IMGN853 6 mg/kg intravenously every 3 weeks until disease progression
44945|NCT03832348|Device|PET scan imaging|3 PET scans will be performed after each 3 first infusions of Pembrolizumab
44946|NCT03832335|Diagnostic Test|Measurement of aniseikonia tolerance|Adding sizeglasses of different percent before right and left eye and measure the impact on stereopsis
44947|NCT03832322|Procedure|Water exchange colonoscopy|During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.
44948|NCT03832322|Procedure|CO2 insufflation colonoscopy|During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
44949|NCT03832309|Behavioral|Do we speak to them in a way that convinces them to have the dream|During induction, and depending on what group they are randomized to, the physician will speak to them about having a dream while on the drug
45015|NCT03831841|Behavioral|Multicomponent exercise programe|An intervention consisting of training by a multicomponent program 3 times a week, working on aerobic capacity, flexibility, balance and strength.
44950|NCT03832309|Behavioral|Speaking to them as a regualar person|During induction, if the patient is in group 1, the resident performing procedural sedation will remind the patient about what the patient wanted to dream and ask them to focus on that as the ketamine is being administered. If the patient is in group 2, the resident performing procedural sedation will give no specific instruction to the patient at this point.
44951|NCT03832296|Behavioral|Weight-Loss Maintenance|Over the course of the first 6-months, participants will build their self-efficacy to maintain weight loss on their own, empowered to do what is needed to achieve personal goals and long-term behavior change (months 7-18). The first 6 months of I-CAN will prepare participants for successful independent weight-loss maintenance in months 7-18. During the 12-month independent weight-loss maintenance phase participants exercise on their own and maintain their weight loss (or increase weight loss if they choose) with the only contact from interventionists being two newsletters at months 9 and 15.
44952|NCT03832296|Behavioral|Health Education (Attention Control)|Participants in the control group will attend an individual session during month 1, and a monthly face-to-face group meeting during months 2-6. The sessions will provide attention, social interaction, and physician-based health education. Participants will receive a newsletter during months 9 and 15.
44953|NCT03832283|Diagnostic Test|CAD-MDD/CAT-DI screening via MyChart|Patients will receive invitations via MyChart to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
44954|NCT03832283|Diagnostic Test|CAD-MDD/CAT-DI screening during clinic visit|During routine in-clinic visits, medical assistants or providers will ask patients to complete the CAD-MDD to screen for major depressive disorder (MDD). For patients who screen positive for MDD, CAT-DI will launch automatically and assess depression severity. CAT-DI assigns a score of 0 to 100 in four severity categories (<50=normal, 50 to 65=mild, 66 to 75=moderate, and >75=severe).
44955|NCT03832283|Other|CAT-DI monitoring via MyChart|Patients with active MDD will receive invitations via MyChart to complete the CAT-DI to assess MDD severity and remission. A normal CAT-DI score (<50) will indicate that a patient's MDD is in remission.
44956|NCT03832283|Other|PHQ-9 monitoring during clinic visits|During routine in-clinic visits, medical assistants or providers will ask patients to complete the PHQ-9 to assess MDD severity and remission. A PHQ-9 score < 5 will indicate that a patient's MDD is in remission.
44957|NCT03832270|Behavioral|Parents InC|Based on social learning theory, Parents InC has been designed specifically for parents of children with an ADHD diagnosis with a particular focus on parenting sense of self competence.
44958|NCT03832270|Behavioral|Incredible Years|Also based on social learning theory but focus is not specifically on ADHD.
44959|NCT03832257|Other|ECHO CT Intervention|weekly video conference between hospitalist and skilled nursing facilities
44960|NCT03832257|Other|Matched Non-Participating Facilities|Matched Non-Participating Facilities
44961|NCT03832244|Diagnostic Test|Sub-mental ultrasonography|Sub-mental ultrasonography including tongue-base thickness, retropalatal distance and the distance between lingual arteries
44962|NCT03832231|Device|Shear Wave Elastography|Ultrasound technology to assess tissue stiffness
44963|NCT03832218|Diagnostic Test|Psychiatric assessment|"Psychiatric assessment and neuropsychological tests~Test : Wechsler Intelligence Scale for Children (WISC-V)~Test :Behavior Rating Inventory of Executive Function (BRIEF) : BRIEF-Parents, BRIEF-Teacher~Global Assessment of Functioning Scale~Scale : Brief Psychiatric Rating Scale (BPRS)~Test : Children Depression Inventory (CDI)~Scale : Revised-Children's Manifest Anxiety Scale (R-CMAS)~Survey : Pediatric Quality of Life Inventory Version 4.0 (PedsQL™ 4.0)~Scale : Conners' scale (parents and teachers)"
44964|NCT03832205|Device|Capaciflector monitoring|Non-invasive capaciflector monitoring of respiratory rate and heart rate.
44965|NCT03832192|Behavioral|care.coach Avatar (HELP-Protocolized)|care.coach human-in-the-loop avatar system with software-directed protocols based on the Hospital Elder Life Program (HELP).
44966|NCT03832179|Drug|Bevacizumab|Bevacizumab
44967|NCT03832179|Drug|Ranibizumab|Ranibizumab
44968|NCT03832179|Drug|Aflibercept|Aflibercept
44969|NCT03832179|Drug|Ozurdex|Ozurdex
44970|NCT03832166|Other|Fruits and Vegetables|Fruits and vegetables delivery, once/week for 24 weeks
44971|NCT03832166|Other|Cooking|Nutrition education and cooking instruction class, one class/week for 6 weeks
44972|NCT03832153|Procedure|thrombus aspiration|Thrombus aspiration will be performed by experienced interventional cardiologists according to standard practices, as previously described. The intracoronary blood samples will be collected as well during the same procedure and- along with peripheral blood samples- they will be analyzed for the presence of specific miRNAs. The aspirated thrombi will be preserved in 10% formalin solution and will be analyzed using the micro/nano-CT scanners.
44973|NCT03832127|Drug|18F-Fludarabine|Two PET with 18F-Fludarabine : one at Baseline, the second one at the end of treatment of myeloma
44974|NCT03832114|Drug|LNP023|Increasing doses of LNP023 up to 200 mg.
44975|NCT03832101|Behavioral|MATB|MATB has two multitasking tasks and two attention tasks. The two multitasking tasks evaluates performance on multiple cognitively demanding assignments in both the auditory and visual domains. The two attention tasks measures performance in sustained and selective attention
44976|NCT03832088|Diagnostic Test|Berg Balance Scale|Berg Balance Scale performed for balance disorder
44977|NCT03832088|Diagnostic Test|Timed Up and Go Test|Timed Up and Go Test for walking speed
44978|NCT03832088|Diagnostic Test|Jamar hand dynamometer|Jamar hand dynamometer for grip strength which correlates with muscle strength of patient
44979|NCT03832088|Diagnostic Test|Calf circumference|Calf circumference for muscle mass evaluation. Calf circumference is an anthropometric measurement which correlates with muscle mass.
44980|NCT03832075|Diagnostic Test|Berg Balance Scale|Berg Balance Scale is 14 item scale for detecting balance disorder.
44981|NCT03832075|Diagnostic Test|Timed Up and Go Test|Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.
45081|NCT03831217|Procedure|mid urethral sling surgery|patients with clinically and/or urodynamically proven stress urinary incontinence underwent mid urethral sling surgery under general anesthesia.
45298|NCT03829618|Drug|Topical lidocaine|1% lidocaine topically applied in 4 mL aliquots
44982|NCT03832075|Diagnostic Test|Korebalance Balance System|"Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady & balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions."
44983|NCT03832062|Other|Leftover surgical tissue homogenization|Leftover surgical tissue homogenization
44984|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses|0.5mL intramuscular dose - 3 doses (0, 2 and 6 months)
44985|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses|0.5mL intramuscular dose - 2 doses (0 and 6 months)
44986|NCT03832049|Biological|9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose|0.5mL intramuscular dose - 1 doses (0 months)
44987|NCT03832036|Diagnostic Test|Paraspinal Mapping and Quantitative Sensory Pain Test|Participants will be tested at baseline.
44988|NCT03832023|Other|Screening and initiating preventive therapy in communities|Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
44989|NCT03832010|Drug|Crisaborole|Participants will be instructed to apply crisaborole to affected areas with eczema.
44990|NCT03832010|Drug|Hydrocortisone Ointment|Participants will be instructed to apply hydrocortisone to affected areas with eczema on face, armpits or groin.
44991|NCT03832010|Drug|Triamcinolone ointment|Participants will be instructed to apply triamcinolone to affected areas on the body excluding face, armpits or groin.
44992|NCT03832010|Drug|Aquaphor|Participants will be instructed to moisturize all over the body with Aquaphor.
44993|NCT03831997|Drug|Dextrose 5% W/ Sodium Chloride 0.225%|D5 1/4NS is comprised of 5% dextrose in a 0.225% sodium chloride (NaCl) solution. D5 1/4NS is initially slightly hypertonic to plasma, with an osmolarity of 321 mOSm/L. As the glucose component is rapidly metabolized, 0.225% NaCl solution remains and is hypotonic to plasma at an osmolarity of 77 mOsm/L. Because of the hypotonicity of the 1/4NS, it shifts into the intracellular compartments, followed by free water, and allows for volume expansion.
44994|NCT03831984|Drug|0,09% Bromfenac|topical 0,09% Bromfenac, one drop twice daily 3 days before surgery
44995|NCT03831984|Drug|0,1% sodium hyaluronate|topical 0,1% sodium hyaluronate, one drop twice daily 3 days before surgery
44996|NCT03831971|Drug|ANS-6637|Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8
44997|NCT03831945|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
44998|NCT03831945|Biological|10-1074|10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
44999|NCT03831945|Biological|Normal Saline Placebo|2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
45000|NCT03831932|Drug|Glutaminase Inhibitor CB-839|Given PO
45001|NCT03831932|Drug|Glutaminase Inhibitor CB-839 Hydrochloride|Given PO
45002|NCT03831932|Drug|Osimertinib|Given PO
45003|NCT03831919|Device|SYNC III|Hoya SYNC III design spectacle lenses
45004|NCT03831919|Device|single vision lenses|single vision spectacle lenses with no addition
45005|NCT03831906|Diagnostic Test|Xpert MTB/RIF Ultra (Ultra)|"The intervention will consist of the WHO standard of care for children with severe pneumonia plus the study intervention consisting in rapid detection of TB on the day of hospital admission using the Ultra assay performed on 1 NPA and 1 stool sample.~The sample flow will be organised to reduce time-to-results to 3 hours. Ultra will be performed at the hospital laboratory using a standard GeneXpert device, or implemented directly inward using a one-module, battery-operated GeneXpert device (G1 Edge).~Drugs will be available at the inpatient level to enable immediate initiation of TB treatment, as soon as a positive Ultra result is available."
45006|NCT03831893|Other|Nopal food product 1|Dried Nopal incorporated in a food product
45007|NCT03831893|Other|Nopal food product 2|Dried Nopal incorporated in a food product
45008|NCT03831893|Other|control|Food Product without nopal
45009|NCT03831880|Drug|Genotropin|Genotropin (dose [mg] at time of enrollment) given subcutaneously once daily
45010|NCT03831880|Drug|somatrogon|0.66 mg/kg/week given subcutaneously once weekly
45011|NCT03831867|Other|Pilates|The intervention program consisted in the realization of exercises of the Pilates Method. The duration of the program was 32 weeks, with a frequency of two weekly sessions and a duration per intervention of 10 minutes. During this time the experimental group developed the intervention program with the Pilates Method.
45012|NCT03831854|Drug|Lamotrigine 300 MG|300 mg of oral Lamotrigine. One of the key studies in this area was reported at the Society of Neuroscience meeting in 1997 and later published in the Archives of General Psychiatry. This study reported that, in healthy subjects 300 mg oral lamotrigine significantly decreased ketamine-induced perceptual abnormalities as assessed by the Clinician-Administered Dissociative States Scale (P<.001).31 Furthermore lamotrigine increased the immediate mood-elevating effects of ketamine (P<.05).
45013|NCT03831854|Drug|Placebo|300 mg of oral Placebo
45014|NCT03831854|Drug|Ketamine|1mg/kg bolus at induction followed by 5 microgm/kg/min infusion till the end of the surgery
45016|NCT03831815|Drug|Cisatracurium|Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
45017|NCT03831802|Device|Embrace with Alert and Mate apps|Patients will wear the device on their wrist as often as possible during the day and night. The Embrace Watch contains sensors and memory recordings of electrodermal activity, temperature and physical activity from the wearer. This group will receive notifications on the mobile phone when seizure takes place. Quality of life questionnaires will be filled by the patients at the first follow-up and final assessments.
45018|NCT03831802|Device|Embrace with Mate app only|Patients will wear the device on their wrist as often as possible during the day and night. This group will just use the Mate app that summarizes Embrace Watch data for the owner and captures contextual information around events.This group will not receive any alert notification on the mobile phone when a seizure takes place.
45019|NCT03831789|Device|Cerebellar targeted rTMS|10 Hz cerebellar rTMS (250 pulses)
45020|NCT03831776|Drug|Bosutinib|Bosutinib, provided by Pfizer, starting dose of 200mg QD and stepwise dose escalation (> 300 mg/d > 400 mg/d) during the first three months. A pharmacological study will be performed in the French cohort (BOSUSTEP Substudy). BOS residual plasma concentration (Cmin) will be checked after initiation, before each dose step in the French cohort, and at M3 also for Nordic patients in ancillary studies.
45021|NCT03831776|Drug|Ropeginterferon|Ro-Peg-Interferon α2b will be supplied by AOP Orphan to be administered by subcutaneous injections from prefilled injection pens. RoPegIFN will be given in an open-label fashion. Patients assigned to RoPegIFN will start with 50 μg injected subcutaneously every 14 days, in combination with Bosutinib.
45022|NCT03831763|Device|ColdZyme|"ColdZyme® Mouth Spray is a CE-marked medical device with the following composition: glycerol, water, cod trypsin, ethanol (<1 %), calcium chloride, trometamol and menthol.~ColdZyme® Mouth Spray consists of a 20 ml bottle, pump, spray nozzle and protective cap."
45023|NCT03831750|Other|Stress Reduction Intervention|The tri-component intervention is comprised of guided videos for breath-work (5-15 min), stretching (5-15 min), and meditation (10-30 min). The intervention will be delivered online via an access restricted website.
45024|NCT03831737|Behavioral|stretching exercises|"Head/neck stretches~Head tilt side to side~Cross-chest stretch Torso stretches~Side stretch~Mid-back stretch Lower limb~Standing quadriceps stretch~Standing hamstring stretch"
45025|NCT03831724|Device|EndoFLIP™ System with FLIP Topography Module|The EndoFLIP system with the EF-322N catheter will be used. The EndoFLIP system is a tool that assesses esophageal, esophago-gastric junction (EGJ)/lower esophageal sphincter (LES), and pylorus function. It allows the measurement of LES and pylorus distensibility as well as esophageal contractile activity in response to distension. The system uses impedance planimetry to measure luminal cross-sectional area (CSA) along an axial plane during volume-controlled distention.
45026|NCT03831711|Drug|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
45027|NCT03831711|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
45028|NCT03831711|Procedure|Positron Emission Tomography|Undergo PET/MRI
45029|NCT03831711|Device|Investigational software and coils in PET/MR scan|General Electric (GE) Healthcare non-approved PET scanner coils and software
45030|NCT03831698|Drug|Omega-3 fatty acid ethyl esters (2 gram)|Omega-3 fatty acid ethyl esters (2 gram)
45031|NCT03831685|Other|Blood sample|Patients meeting the inclusion criteria and none of the non-inclusion criteria will benefit from 2 venous blood samples in order to precise the initial blood lactate level, e.g. at the first medical contact, and the final blood lactate level, e.g. at the hospital admission.
45032|NCT03831659|Other|self-questionnaires|After collecting their non-opposition, a self-questionnaire will be given to them. This questionnaire is validated in the literature concerning the diagnosis of migraine. It includes questions about medical history and possible headaches
45033|NCT03831633|Drug|Akynzeo|"1 single oral dose of NEPA (capsule) on Day 1 to be administered approximately 1 hour prior chemotherapy (containing 300 mg netupitant and 0.5 mg palonosetron).~- Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
45034|NCT03831633|Drug|Standard of Care|"oral aprepitant 125mg (Day 1) and 80mg daily (on Day 2 and Day 3)~IV ondansetron 8 mg on Day 1~Dexamethasone 12 mg on Day 1 and 8 mg daily from Day 2 to Day 4"
45035|NCT03831607|Drug|KHK7791|KHK7791 30 mg, 20 mg ,10 mg or 5 mg tablets
45036|NCT03831594|Device|Galvanic Vestibular Stimulation|Electrical current (under 1.5mA) applied to the mastoid processes to stimulate the balance organs in the inner ear
45037|NCT03831594|Other|Standard Physiotherapy|45 minutes of standard physiotherapy treating impairments and functional problems
45038|NCT03831581|Procedure|Erector Spinae Plane Block|In patients with chest pain, ultrasound-guided Erector Spinae Plane Block block was performed at T5 transverse process in the cephalo-caudal direction with Tuohy 18 gauge needle in plane until the needle tip was located in the interfascial plane between the transverse process and the erector spinae muscles, 20 ml of bupivacaine 0.5% was administered and a catheter was inserted if indicated.
45039|NCT03831555|Behavioral|PREP-C|"The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) tool assesses a patient's psychosocial readiness to start HCV treatment. There are nine sections in the survey:~Motivation: reasons client wants to begin HCV treatment, concerns about treatment, and the importance of treatment~Information: knowledge about HCV treatment and one's own HCV disease status~Medication Adherence: current prescribed medications and adherence to them in the prior month~Self-efficacy: self-confidence about adhering to HCV treatment~Social Support and Stability: stability of financial, housing, and social support resources~Alcohol and substance use: alcohol and substance use behaviors and current treatment~Psychiatric Stability: current psychiatric status, previous and current treatment~Energy Level: sleep and fatigue~Cognitive Functioning: perceived difficulty with communication in health care setting, problem-solving ability, and memory."
45040|NCT03831542|Behavioral|direct follicular aspiration|direct follicular aspiration
45041|NCT03831542|Behavioral|follicular flushing|follicular flushing
45122|NCT03830905|Drug|Placebo|Participants will receive Placebo once a day during 3 days
45382|NCT03829150|Drug|Metronidazole|Metronidazole (Flagyl) 500 mg bid daily for 7 days
45042|NCT03831516|Diagnostic Test|Non Invasive Electroanatomical Mapping|All patients will undergo non contrast CT chest and be fitted with the Medtronic CardioInsight wearable 252 electrode vest. Non invasive electroanatomical maps of the ventricular arrhythmia will be created. All patients will be then brought to the electrophysiology laboratory and undergo an invasive electrophysiology study and ablation of the ventricular arrhythmia.
45043|NCT03831503|Biological|INO-A002|Participants will receive one or two 1 ml IM injections (in different arms) into the deltoid region at day 0 (all groups), and in addition on day 3 (in the 2 mg and 4 mg cohorts).
45044|NCT03831503|Device|CELLECTRA® 2000|Inoculation will be followed by electroporation with the CELLECTRA® 2000 device.
45045|NCT03831503|Device|Dengue Fever Antibodies (IgG)|To determine if the subject is Dengue seronegative at baseline
45046|NCT03831490|Diagnostic Test|history|combining these 4 interventions will great an algorithm predicting preeclampsia
45047|NCT03831477|Device|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
45048|NCT03831464|Drug|Metformin Hydrochloride|"The intervention will consist in IMP treatment during 30 months with half of the patients treated with Metformin Glucophage SR. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.~During the first month of the trial a dose of 1x500mg will be used in order to avoid as much as possible some well-known mainly gastrointestinal side effects of metformin treatment ."
45049|NCT03831464|Drug|Placebo Oral Tablet|The intervention will consist in IMP treatment during 30 months with half of the patients treated with matched placebo. Tablets of 500mg will be used at a dose of 2x500mg preferably taken during the evening meal.
45050|NCT03831451|Behavioral|Stroke preparedness intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
45051|NCT03831451|Behavioral|Healthy lifestyle stroke risk reduction intervention|Face-to-face interaction with research staff lasting between 5-10 minutes
45052|NCT03831438|Drug|AVID200|Intravenous infusion of AVID200 Q2 weeks for 3 doses
45053|NCT03831425|Dietary Supplement|Coenzyme Q10|6 week trial of either treatment with CoenzymeQ.
45054|NCT03831425|Other|Placebo|6 week trial of either treatment with Placebo
45055|NCT03831412|Behavioral|CBT-I|Targeting insomnia symptoms to reduce suicidal ideation and sleep problems related to traumatic experience.
45056|NCT03831412|Behavioral|ERRT|Targeting post-trauma nightmares to reduce suicidal ideation and sleep problems related to traumatic experience.
45057|NCT03831399|Dietary Supplement|Leucine|Administration 6 g/day of leucine at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
45058|NCT03831399|Dietary Supplement|Placebo|Administration 6 g/day of lactose at noon (12 pm) and in the late afternoon (8 pm) for 13 weeks
45059|NCT03831386|Procedure|Vacuum-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via suction.
45060|NCT03831386|Procedure|Gravity-Based IPC|An indwelling pleural catheter is placed inside the chest cavity to drain fluid from around the lungs. One end remains inside the body while the other drains via gravity.
45061|NCT03831373|Other|Physical exercise|Three physical exercise programs, two of resistance training with elastic bands and one of stretching exercises, all performed in a sitting position.
45062|NCT03831360|Behavioral|Yoga|Hatha yoga for depressed adolescents
45063|NCT03831360|Behavioral|Group CBT|Group cognitive behavioral therapy for depressed adolescents
45064|NCT03831347|Behavioral|Hatha Yoga|12 weeks of Hatha Yoga
45065|NCT03831334|Drug|oral minoxidil|Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
45066|NCT03831321|Drug|Diclofenac Sodium|50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
45067|NCT03831321|Device|Cystoscopy|Diagnostic cystoscopy
45068|NCT03831321|Drug|Lubricant Gel|To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
45069|NCT03831308|Diagnostic Test|clinical and physical assessment|information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
45070|NCT03831295|Biological|Anti-OX40 Antibody BMS 986178|Given IT or IV
45071|NCT03831295|Drug|TLR9 Agonist SD-101|Given IT
45072|NCT03831269|Drug|Azithromycin|Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
45073|NCT03831269|Other|nbUVB|The patients will be randomly distributed to start nbUVB sessions and clinical improvement will be compared to that of Azithromycin
45074|NCT03831256|Diagnostic Test|Traditional integrated prenatal screening|biochemical prenatal screening with or without nuchal translucency by US
45075|NCT03831256|Diagnostic Test|Second-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS after a positive traditional prenatal screen
45076|NCT03831256|Diagnostic Test|First-tier Non-invasive prenatal screening (NIPS)|genomics based NIPS at first trimester
45077|NCT03831256|Diagnostic Test|Invasive prenatal testing for fetal aneuploidy|amniocentesis or chorionic villi sampling (CVS)
45078|NCT03831243|Radiation|Stereotactic body radiotherapy|Treatment will be prescribed to the periphery of the target, i.e. 80% of the dose should cover 95% of the PTV. The organ at risk (OAR) dose constraints will be in accordance with the recommendations from the report of the American Association of Physicists in Medicine (AAPM) task group 101. Image-guidance will consist of cone-beam CT in combination with 6 degrees of freedom corrections using robotic couch.
45079|NCT03831243|Radiation|3D-conformal radiotherapy|In the standard setting, 95% of the PTV should receive 95% of the prescribed dose while near maximum dose (Dnear-max) in the PTV should not exceed 107%. Image-guidance will consist of portal images showing the relevant bony anatomy.
45080|NCT03831230|Genetic|collection of blood, urine, tumor and ascite samples|collection of blood, urine, tumor and ascite samples during ovarian surgery
45157|NCT03830632|Other|Traditional Training|
45082|NCT03831204|Device|biopac|"Acoustic cardiography was performed for all participants using the BIOPAC system with Student Lab software version 3.7.2. An electrocardiogram was obtained by two electrodes placed at the right upper limb and the lower left limb. Simultaneously heart sounds were recorded with a specific sensor placed at the mitral focus."
45083|NCT03831204|Diagnostic Test|prognostic scores|Effect and GWTGHF were calculated for every patient
45084|NCT03831191|Drug|LY3375880|Administered SC
45085|NCT03831191|Drug|Placebo|Administered SC
45086|NCT03831178|Dietary Supplement|Docosahexaenoic acid (DHA)|Participants will take 11 capsules of DHA oil for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
45087|NCT03831178|Drug|Placebo oral capsule|Participants will take 11 capsules of placebo (corn/soy oil blend) for 12-18 weeks (84-126 days), beginning on day 1 of initial cycle of chemotherapy, and continuing for 4-6 cycles of chemotherapy prior to definitive breast surgery. Study will end when subject undergoes breast surgery.
45088|NCT03831165|Combination Product|Melatonin|The volunteers will receive information about the study and sign the free and informed consent form (ICF). After, will be delivered bottle identified by letters (abc, bca or cab) with its drug without patient and investigator know its nature. It will only be revealed which drug was used by every woman at the end of the study; but occurring worsening of herpetic disease, the blind will be broken for proper assessment of the participant. If the employee drug is melatonin, this case will be considered as therapeutic failure in the final statistical analysis.
45089|NCT03831165|Drug|Acyclovir 400 MG|These individuals will be instructed to take 2 tablets of 200mg acyclovir (400 mg) twice daily for 90 days
45090|NCT03831152|Drug|ADV7103|Single group assignment
45091|NCT03831139|Behavioral|TIM&SARA|
45092|NCT03831126|Drug|Betamethason Sodium Phosphate|First measurement: 12-36 hours after betamethasone treatment Second measurement: within five days after betamethasone treatment and two weeks Third measurement (neonatal measurement): 1-8 weeks after birh
45093|NCT03831113|Drug|Buprenorphine: Magnitude Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
45094|NCT03831113|Drug|Buprenorphine: Frequency Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
45095|NCT03831113|Drug|Buprenorphine: Dosing Group|Dose reductions will continue until the subject is no longer taking buprenorphine or is at the lowest tolerable dose.
45096|NCT03831100|Behavioral|BRIGHT|The BRIGHT intervention consists of 5 weekly, 60-minute, tablet-based, one-one telehealth sessions with a licensed therapist. BRIGHT Therapist: A licensed clinical psychologist with extensive experience managing pyscho-oncologic concerns in patients with HNC will deliver BRIGHT.
45097|NCT03831100|Behavioral|Active Control|The control intervention in this study will be matched to replicate the frequency, intensity, and delivery method of BRIGHT. Participants in the AC arm will thus undergo 5 weekly, 60-minute, tablet-based video sessions in which they undergo non-manualized discussions with a non-trained member of the study team.
45098|NCT03831087|Diagnostic Test|TAVR-CMR|CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
45099|NCT03831087|Diagnostic Test|TAVR-CT|CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
45100|NCT03831074|Device|Implantation of an intraocular lenses: iMics 1 NY-60 & NY-60G|
45101|NCT03831061|Other|Cognitive stimulation|
45102|NCT03831048|Device|OCS Heart System|Preserving and assessing donor after circulatory death hearts for transplant
45103|NCT03831048|Other|Cold Storage|Active comparator intervention
45104|NCT03831035|Other|Genetic analyse by whole exome sequencing|Exome sequencing requires analytic, bio informatic and interpretation steps.
45105|NCT03831022|Other|Capillary refill time and skin mottling score measurement at the admission to the emergency department|Patients who meet the inclusion criteria and none of the non-inclusion criteria will benefit from capillary refill time and skin mottling score measurement at the admission to the emergency department (ED) and followed during their hospital stay to precise the destination after ED (home, ICU, ward) and 30- and 90-days mortality after hospital admission.
45106|NCT03831009|Procedure|Open reduction internal fixation (ORIF)|Open fracture reduction followed by internal fixation using a plate and screws. The goal is an osteosynthesis that allow for early range-of-motion exercises, but weightbearing is usually not tolerated until 6 weeks postoperatively.
45107|NCT03831009|Other|Conservative treatment|Conservative treatment involves ankle protection with a functional brace (AirCast) for 6 weeks. Participants will be instructed to bear weight as tolerated and to actively do standardized range-of-motion exercises.
45108|NCT03830970|Dietary Supplement|Canned mixed beans|Black, navy, pinto, red and white kidney beans
45109|NCT03830970|Dietary Supplement|White Rice|Minute Rice Long Grain White Rice
45110|NCT03830957|Drug|Ivabradine|7.5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 7.5 mg
45111|NCT03830957|Drug|Metoprolol|5 mg oral single dose if the heart rate would not reach to 60/minute then give another dose, 5 mg
45112|NCT03830944|Diagnostic Test|Blood sampling|Assessment of complete blood count, biochemistry, inflammatory biomarkers, adhesion molecules
45113|NCT03830944|Diagnostic Test|transthoracic echocardiography|Assessment of the ventricular anatomy, size, function, speckle tracking, myocardial strain, valvular function.
45114|NCT03830944|Diagnostic Test|Late Gadolinium-Enhancement Cardiac Magnetic Resonance|Assessment of the ventricular anatomy, function, viability, degree of fibrosis, quantification of infarct size, mass.
45115|NCT03830944|Diagnostic Test|Coronary Angio Computed Tomography|Assessment of coronary plaque anatomy, morphology, vulnerability features, quantification of epicardial adipose tissue
45116|NCT03830918|Drug|Niraparib|Given PO
45117|NCT03830918|Other|Quality-of-Life Assessment|Ancillary studies
45118|NCT03830918|Other|Questionnaire Administration|Ancillary studies
45119|NCT03830918|Procedure|Supportive Care|Receive best supportive care (surveillance)
45120|NCT03830918|Drug|Temozolomide|Given PO
45121|NCT03830905|Drug|XC221|Participants will receive 200 mg XC221 once a day during 3 days
45123|NCT03830892|Other|E-cigarette Lab Session 15 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
45124|NCT03830892|Other|E-cigarette Lab Session 15 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
45125|NCT03830892|Other|E-cigarette Lab Session 30 watts, 10 mg nicotine|E-cigarette paired with low nicotine, low device power
45126|NCT03830892|Other|E-cigarette Lab Session 30 watts, 30 mg nicotine|E-cigarette paired with low nicotine, low device power
45127|NCT03830892|Other|Own Brand Session - E-cigarette|E-cigarette paired with own brand liquid and preferred power
45128|NCT03830892|Other|Own Brand Session - E-cigarette/Cigarette|Own brand cigarette OR E-cigarette paired with own brand liquid and preferred power
45129|NCT03830879|Other|No intervention|This cohort study have any no intervention.
45130|NCT03830866|Biological|Durvalumab|IV infusion every 4 weeks
45131|NCT03830866|Drug|Cisplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
45132|NCT03830866|Drug|Carboplatin|Platinum based Standard of Care Chemotherapy administered concurrent with radiation therapy
45133|NCT03830866|Radiation|external beam radiation therapy (EBRT) + brachytherapy|Radiation therapy per standard of care
45135|NCT03830814|Procedure|Echocardiography|Basal two dimensional and three dimensional echocardiographic parameters were compared to those obtained 3 months after starting the sacubitril/valsartan treatment
45136|NCT03830801|Device|IVLCM tethered capsule|Obtaining biopsies for genomic sequencing of BE for the assessment of EAC risk using IVLCM tethered capsule
45137|NCT03830788|Radiation|Radiation by brachytherapy|Brachytherapy by Iodine 125 delivering 144 Gy to the prostate
45138|NCT03830788|Radiation|Radiation by SBRT|SBRT delivers 7.25 Gy per fraction, in five fractions, corresponding to a total dose of 36.25 Gy to the prostate. Fiducials are implanted in the prostate.
45139|NCT03830775|Procedure|Platelet-rich plasma (PRP)|"PRP is obtained from obtaining an autologous blood sample, which is then condensed in a small commercial centrifuge to isolate a concentrated sample of platelets and growth factors. This sample contains high concentrations of Platelet-derived growth factors (PDGF), transforming growth factors β (TGFβ), insulin-like growth factor-1 (IGF1), and vascular endothelial growth factor-1 (VEGF) all of which aid in healing of soft tissues. (Padilla) The blood sample is autologous, the concentration is prepared in the clinic, and the complications of the injection are no greater than any other injection given in the clinic.~All patients will have a blood sample prepared for PRP. The patient will then be blinded and half will randomly be assigned to PRP injection (2cc) and half will be randomly assigned to placebo (2cc of 0.9% sterile saline)"
45140|NCT03830762|Drug|Xanamem|Oral Xanamem capsules 20mg or 30mg, administered PO once daily. Xanamem is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343.
45141|NCT03830762|Drug|Matching Placebo|Matching placebo which is identical in appearance to the test product (20mg, 30mg Xanamem™ QD) except that it contains no active ingredient.
45142|NCT03830749|Drug|Eltrombopag|Eltrombopag Oral Tablet 25-75 mg daily for 12 weeks plus pulsed dexamethasone
45143|NCT03830736|Combination Product|Oat Beverage 1|Oat based beverage with added different concentration of extracted oat component.
45144|NCT03830736|Combination Product|Oat Beverage 2|Oat based beverage with added different concentration of extracted oat component.
45145|NCT03830736|Combination Product|Oat Beverage 3|Oat based beverage with added different concentration of extracted oat component.
45146|NCT03830736|Combination Product|Oat Beverage 4|Oat based beverage with added different concentration of extracted oat component.
45147|NCT03830736|Combination Product|Control product|Glucose based beverage without added test components is used as control product
45148|NCT03830723|Drug|Follitropin delta|Study medication doses during all 3 insemination will be personalized using a suggested algorithm
45149|NCT03830697|Other|Acupuncture intervention|Patients in the experimental group were given acupuncture treatment for 12 weeks prior to COH. If the patient has a good COH timing during acupuncture treatment, he or she will enter the COH cycle at any time.The acupuncture intervention program of the test group is as follows:Acupoint group 1: Baihui（DU20）, Zhongyu（RN12）, Tianshu （ST25）(bilateral), Guanyuan（RN4）, uterus (bilateral)（EX-CA1）, Dahe（KI12） (bilateral),Zusanli （ST36）(bilateral), Sanyinjiao（SP6） (bilateral), Taichong （LR3）(both sides).
45150|NCT03830684|Drug|Baicalein Tablets 400mg|4 Baicalein Tablets and 2 placebo per time, three times a day
45151|NCT03830684|Drug|Baicalein Tablets 600mg|6 Baicalein Tablets per time, three times a day
45152|NCT03830684|Drug|blank control 0mg|6 placebo per time, three times a day
45153|NCT03830671|Drug|18-month regimen containing 6 anti-TB drugs|Investigational regimen:3Am-Mfx-PZA-X-Y-Z/3Am3-Mfx-PZA-X-Y-Z/12 Mfx-PZA-X-Y-Z.X、Y、Z are the drugs susceptible or possibly susceptible to mycobacterial bacilli(The candidated drugs to be selected are:Cs-Cycloserine,Pto-Protionamide,Clr-Clarithromycin,PAS-sodium para-aminosalicylate,E-ethambutol,Bdq-Bedaquiline,Cfz-Clofazimine,Lzd-linezolid).The abbreviation of the name of each drug in the regimen is explained as follows: PZA—pyrazinamide，Am—Amikacin，Mfx—moxifloxacin）and the total duration of the regimen is 18 months
45154|NCT03830658|Behavioral|Structured Intervention on Self-care with AVF (SISC-AVF)|"Theoretical Part: structured intervention involved an educational group session with the purpose of teaching patients how to identify situations that can compromise AVF working. Each presentation allowed a maximum of eight patients and took 30 minutes. Each presentation was assessed in the end by asking participants to identify the signs and symptoms of infection, thrombosis and steal syndrome and to describe the care to be taken during dialysis and in the period outside dialysis.~Practical Part: started a week after the theoretical part, lasting for two weeks, and was given to each participant in an appropriate room at the beginning of the HD treatment. Interactive training sessions were conducted using an informal approach with the objective of developing skills of inspection and palpation of the AVF arm. Inspection had the purpose of enabling participants to identify situations that could compromise the working of the AVF. Each patient was given two 15-minute sessions."
45155|NCT03830645|Biological|Platelet Rich Plasma|Application of platelet rich plasma through the intercostal tube into the pleural space
45156|NCT03830632|Other|Plyometric Training|
45159|NCT03830606|Drug|Nab-paclitaxel,S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mg BID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)
45160|NCT03830593|Procedure|Laparoscopic Adrenalectomy|minimally invasive lateral transperitoneal adrenalectomy
45161|NCT03830580|Other|Positive stimulation (singing)|A nurse or assistant trained in singing with an operal singer sings a lullaby She sits next to the incubator and sings from the time the sucrose is administered (2 minutes before the fundus exams is performed) until the end of the examination - taking into account the child's reaction
45162|NCT03830567|Other|Pharmacist prescription|Pharmacist prescribed hormonal contraception (initiation or continuation).
45163|NCT03830567|Other|Clinician prescription|Clinician prescribed hormonal contraception (initiation or continuation).
45164|NCT03830554|Other|Organic Atlas cedar wood essential oil (Cedrus Atantica)|At first day of admission, Intervention group received an intervention kit consist of 5 small glass essential oil bottles. Each essential oil bottle contains a small cotton ball saturated with two drops of Organic Atlas cedar wood essential oil (Cedrus Atantica). Participants were asked to open the bottle, inhale the smell directly and put it opened at 20 cm beside bed during night.
45165|NCT03830541|Other|Oral care delivery analysis in participants with ASD|The analysis of oral health status, tooth loss, oral rehabilitation, characteristics of routine dental treatment and treatment in general anaesthesia in persons with ASD
45172|NCT03830515|Device|microMend|Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
45173|NCT03830502|Procedure|Surgical sterilization|Surgical sterilization either standard salpingectomy or tubal ligation with Pomeroy technique
45174|NCT03830489|Drug|polyethylene glycol|The experimental arm will take 4 L polyethylene glycol solution (PEG) in split dose plus bisacodyl and 3 days of fiber-free diet
45175|NCT03830489|Drug|polyethylene glycol plus ascorbic acid|The control arm will take 2 L polyethylene glycol solution (PEG) plus ascorbic acid in split dose plus 1 day of fiber-free diet
45176|NCT03830476|Behavioral|Acceptance- and Commitment therapy group for parents to children with disabilities|ACT groups adjusted for parents to children with (any kind of) disabilities.
45177|NCT03830476|Behavioral|Treatment as usual.|Treatment as usual within outpatient disability services.
45178|NCT03830463|Drug|CTP-692|Single oral dose
45179|NCT03830463|Drug|Placebo|Single oral dose
45180|NCT03830437|Other|Evaluation of newborn stress|Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.
45181|NCT03830437|Other|Evaluation of body weight trend|Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
45182|NCT03830424|Procedure|Pain stimulus|Pain stimulus - intramuscular K vitamin administration, heel lancing = standard healthcare procedure
45183|NCT03830424|Dietary Supplement|Non-pharmacological pain relief|Administration of sucrose/mother milk during pain stimulus
45184|NCT03830411|Drug|Sintilimab|Sintilimab will be administered intravenously at a fixed dose of 200 milligrams (mg) on Day 1 of each 21-day cycle.
45185|NCT03830411|Drug|Docetaxel|Docetaxel 75 milligrams per square meter (mg/m^2) will be administered intravenously on Day 1 of each 21-day cycle.
45186|NCT03830411|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
45187|NCT03830398|Drug|Paracetamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
45188|NCT03830398|Drug|Deksketoprofen trometamol|The investigators apply paracetamol during a week in preoperative room 45 min before ECT
45189|NCT03830398|Drug|Placebo|The investigators apply placebo during a week in preoperative room 45 min before ECT
45190|NCT03830385|Drug|PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin|All patients enrolled in the study will accept Paclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin as their firstline chemotherapy
45191|NCT03830372|Device|VR Tier One|"10 sessions of 20 minutes virtual terapeutic game~Thanks to using VR googles and the phenomenon of total immersion VR Tier One terapy game allows to completely separate the patient from the hospital environment and provides an intense visual, auditory and kinesthetic stimulation. Depending on the stage of therapy it can have a calming and mood-improving effect or it can motivate and cognitively activate the patient. The additional aim of the game is to help the patients regain their emotional balance, let them recognize their resources in order to bring them to power in the rehabilitation process and trigger the natural recovery mechanisms."
45192|NCT03830372|Other|Control|10 sessions of 20 minutes of Schultz Autogenic Training
45193|NCT03830359|Other|T2769|55 patients treated by T2769 for 42 days
45194|NCT03830346|Other|Instrument-assisted|instrument-assisted soft tissue mobilization techniques (applied with the subject in prone position. The technique lasted 20 seconds in a parallel direction and 20 seconds in a perpendicular direction on the posterior shoulder and scapula muscles. While the dominant hand was used to hold the instrument, the other hand was used to tighten the skin medially to ensure an even area of treatment) and post-isometric horizontal adduction stretches (carried out with the subject in the supine position, passively adducting the arm horizontally until the first motion barrier and performing active horizontal abduction for 5 seconds at 25% of force. The arm was then taken to the new motion barrier, repeating this process three times).
45236|NCT03830086|Drug|Sevoflurane|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Rocuronium
45195|NCT03830333|Drug|Ceftolozane/Tazobactam|Ceftolozane 1000 mg / Tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive Ceftolozane 500 mg / Tazobactam 250 mg.
45196|NCT03830333|Drug|Metronidazole|Metronidazole 500 mg by IV infusion every 8 hours for 4 to 14 days.
45197|NCT03830333|Drug|Meropenem|Meropenem 1000 mg by IV infusion every 8 hours for 4 to 14 days. Participants with CrCL of 30 to ≤ 50 mL/min will receive IV infusion every 12 hours.
45198|NCT03830333|Drug|Placebo|Saline by IV infusion every 8 hours for 4 to 14 days.
45199|NCT03830320|Drug|[64Cu]FBP8|Injection of Copper-64 radiopeptide to detect thrombosis
45200|NCT03830320|Device|PET/MR|Whole body imaging using Siemens mMR PET/MR scanner
45201|NCT03830320|Procedure|Blood Collection|A total of 9 cc of blood sampled before, during, and after imaging for clinical chemistry
45202|NCT03830320|Procedure|Electrocardiogram|A standard 12-lead ECG will be obtained pre-and-post injection with radiotracer
45203|NCT03830307|Device|NSS-2-Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care
45204|NCT03830294|Other|different temperature-controlled breast prostheses|Two types of temperature-controlled breast prostheses were applied to patients in each group
45205|NCT03830281|Drug|LY900014|Administered SC
45206|NCT03830281|Drug|Insulin Lispro|Administered SC
45207|NCT03830268|Dietary Supplement|No MCT intake with breakfast, no lunch|Water given with a regular standardize breakfast and water given at noon without lunch.
45208|NCT03830268|Dietary Supplement|No MCT intake with lunch, no breakfast|Water given in the beginning of the metabolic study day without breakfast and water given at noon with a regular standardize lunch.
45209|NCT03830268|Dietary Supplement|10g of Betaquik|BQ10 given with a regular standardize breakfast and BQ10 given at noon without lunch.
45210|NCT03830268|Dietary Supplement|10g of Betaquik with low-carbs breakfast|BQ10 given with a low-carbs standardize breakfast and BQ10 given at noon without lunch.
45211|NCT03830268|Dietary Supplement|20g of Betaquik|BQ20 given with a regular standardize breakfast and BQ20 given at noon without lunch.
45212|NCT03830268|Dietary Supplement|10g of Betaquik with lunch, no breakfast|BQ10 given in the beginning of the metabolic study day without breakfast and BQ10 given at noon with a regular standardize lunch.
45213|NCT03830242|Diagnostic Test|<Sup>18<Sup>F-FDG PET/CT dynamic scan|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
45214|NCT03830242|Diagnostic Test|B-ultrasonography|The purpose of this study is to carry out <Sup>18<Sup>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of <Sup>18<Sup>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
45215|NCT03830216|Device|Connected insulin pen and smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is paired with a smartphone app with dose calculator.
45216|NCT03830216|Device|Inactive connected insulin pen without smartphone app|The InPen system is a reusable pen injector for single-patient use by people with diabetes age 12 and older for the self-injection of a desired dose of insulin. The pen injector is inactive and not paired with a smartphone app or dose calculator.
45217|NCT03830203|Drug|BAT1806|8 mg/kg
45218|NCT03830203|Drug|Actemra(EU-licensed)|8 mg/kg
45219|NCT03830190|Other|Parkinson's disease nurse specialist care|Specialized nursing care provided by a Parkinson's disease nurse specialist
45220|NCT03830177|Drug|Natural Treatment|The participant will be given the treatment, which contains all natural ingredients, and a kit of all necessary materials to take home with them, which will include a set of instructions. The kit will contain the instruction handout and their treatment. They will be instructed to apply the treatment to their scalp, wait seven minutes, and then rinse their scalp. They will perform this entire procedure once per day for 14 days.
45221|NCT03830164|Drug|Atorvastatin|Given PO
45222|NCT03830164|Drug|Pentoxifylline|Given PO
45223|NCT03830164|Dietary Supplement|Vitamin E Compound|Given PO
45224|NCT03830151|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
45225|NCT03830151|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
45226|NCT03830138|Genetic|Oxidized-LDL gene polymorphism|Oxidized-LDL gene polymorphism will be measured by RFLP. In addition, Oxidized-LDL will be measured in the plasma by ELISA
45227|NCT03830125|Drug|BBT-877, Single dose|Single dose of BBT-877, 5 dose levels, oral capsule
45228|NCT03830125|Drug|Placebo group|Placebo matched to BBT-877, oral capsule
45229|NCT03830125|Drug|BBT-877, Multiple doses|Multiple doses of BBT-877, 14 days, 6 dose levels, oral capsule
45230|NCT03830112|Behavioral|Pilates exercise with Theraband|The experimental group will perform all the exercises with Theraband® in the same manner than active comparator group.
45231|NCT03830112|Behavioral|Pilates exercise|The active comparator group will perform all the exercises without Theraband®
45232|NCT03830086|Drug|Midazolam|Used for general anesthesia for gynecological laparoscopic procedures, together with Propofol, Sufentanil, Rocuronium, Sevoflurane
45233|NCT03830086|Drug|Sufentanil|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures together with Bupivacaine; and for general anesthesia for gynecological laparoscopic procedures, together with following drugs: Midazolam, Propofol, Rocuronium, Sevoflurane
45234|NCT03830086|Drug|Propofol|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Sufentanil, Rocuronium, Sevoflurane
45235|NCT03830086|Drug|Rocuronium|Used for general anesthesia for gynecological laparoscopic procedures, together with the following drugs: Midazolam, Propofol, Sufentanil, Sevoflurane
45237|NCT03830086|Drug|Bupivacaine|Used for regional anesthesia (spinal or combined spinal-epidural anesthesia) for gynecological laparoscopic procedures, together with Sufentanil
45238|NCT03830073|Genetic|Measurement of VDR genetic polymorphism|VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.
45239|NCT03830060|Diagnostic Test|Measurement of cortisol|Cortisol will be measured by immunofluorescence and correlated with ANA and hs-CRP
45240|NCT03830047|Device|nd yag laser|nd yag laser will be applied on the vulval warts
45241|NCT03830034|Drug|Amino Acid chelated iron tab 15 mg|"Contain 75 pregnant women will recommended to take ferrotrone(iron chelated amino acid containing 15mg elemental iron) a dose recommended by the company of the product.~Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins & milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline & then 4, 8 & 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
45242|NCT03830034|Drug|Ferrous Fumarate tab 350 mg( 115 mg elemental iron)|"75 pregnant women will recommended to take ferrous fumarate e.g. Hema-caps (ferrous fumarate 350 mg with elemental iron 115mg) prepared by another egyptian pharmaceutical company (Amoun pharmaceutical company) once daily but in sever cases of iron deficiency anemia (Hb<9g/dl) this dose can be doubled as recommended by the company of the product.~Some instructions will be given to all the pregnant women included in our study as follow: Iron tablets should be taken at night or at least 1 hour prior to food to maximise absorption.~Substances that inhibit absorption such as tannins & milk should be avoided but fruit juice contain ascorbic acid taken in conjunction with iron supplements increases their absorption.~Follow up will be done for all the pregnant women included in our studies at baseline & then 4, 8 & 12 weeks after treatment at each visit breif history for outcomes and adverse effects will reviewed."
45243|NCT03830021|Behavioral|Salt reduction program|Dietary and behavioural change program, led by nutritionists, including low sodium dietary advice; use of aromatic herbs and spices in food instead of salt; motivational activities; food diaries; restrict salty processed foods; eat more fresh foods and seasoning advice; problem solving exercises; digital bulletins; individual counselling reinforced at each clinic visit and shopping counselling at local supermarket.
45244|NCT03830021|Behavioral|Healthy lifestyle program|Participants receive an educational healthy lifestyle program that includes 1) methods to cook healthier and the Mediterranean diet based on a high intake of fresh fruit and, vegetables, beans, grain legumes, lentils, nuts, cereals, and olive oil as source of fat; moderate intake of fish, poultry, yoghurt and cheese, low intake of salt, red meat, processed meats and sugar; 2) physical activity; 3) drink more water and reducing alcohol consumption; and 4) sleep education.
45245|NCT03830008|Behavioral|Problem Management Plus|PM+ is a new, brief, psychological intervention program based on CBT techniques that are empirically supported and formally recommended by the WHO. The full protocol was developed by the WHO and the University of New South Wales, Australia. The manual involves the following empirically supported elements: problem solving plus stress management, behavioural activation, facing fears, and accessing social support. These elements have been recommended in recent WHO guidelines.
45246|NCT03829995|Other|Drug counseling|Participants can contact a hospital pharmacy department by phone or mail and ask questions regarding drug-related issues.
45247|NCT03829982|Behavioral|Exposure to bright light during the day|Participants will be exposed to bright light (1250 lux) between 8:00 and 18:00 and to dim light (5 lux) between 18:00 and 23:00.
45248|NCT03829982|Behavioral|Exposure to dim light during the day|Participants will be exposed to dim light (10 lux) between 8:00 and 18:00 and to dim light (1250 lux) between 18:00 and 23:00.
45249|NCT03829969|Biological|Toripalimab|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy
45250|NCT03829956|Device|Intraoral tongue stimulator (Snoozeal)|Electrical stimulation of the tongue muscle to improve muscle tone to treat primary snoring and mild obstructive sleep apnea.
45251|NCT03829943|Diagnostic Test|Vitamin D|Blood will be drawn for Vitamin D level
45252|NCT03829930|Drug|Entinostat|"Entinostat is formulated for oral administration. A food effect is evident for entinostat; exposure is significantly reduced when entinostat is administered with a high fat meal. Accordingly, entinostat is to be administered on an empty stomach, at least 1 hour before and 2 hours after a meal. Entinostat tablets should not be split, crushed, or chewed. Consult the individual clinical protocols for specific dosing instructions.~Dose level 1: 3mg PO weekly. Dose level 2: 5mg PO weekly."
45253|NCT03829930|Drug|Enzalutamide|Dose level 1: 160 mg PO daily. Dose level 2: 160 mg PO daily.
45254|NCT03829917|Drug|Miltefosine and Paromomycin|28 days of miltefosine plus 28 days of Paromomycin cream
45255|NCT03829917|Drug|miltefosine|28 days of miltefosine
45256|NCT03829917|Drug|paromomycin|28 days of paromomycin creaam
45257|NCT03829904|Drug|VGH-BPH1|A scientific Chinese granule powder
45258|NCT03829904|Drug|Placebo (Corn starch pill manufactured to mimic VGH-BPH1)|Corn starch pill manufactured to mimic VGH-BPH1
45259|NCT03829891|Drug|Beinaglutide|"Beinaglutide for 8 weeks,~Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )"
45260|NCT03829891|Drug|glargine|"Glargine for 8 weeks,~Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )"
45261|NCT03829878|Drug|CP101|Orally administered donor derived full spectrum microbiota
45262|NCT03829878|Drug|Placebo|Placebo for CP101
45263|NCT03829865|Diagnostic Test|High resolution esophageal manometry|High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
45264|NCT03829852|Drug|Regorafenib|Treatment was performed based on physician's discretion
45265|NCT03829839|Drug|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin
45266|NCT03829839|Drug|Lorazepam 1 mg|Oral administration of 1mg lorazepam
45267|NCT03829839|Drug|Placebo nasalspray|The placebo nasalspray contain identical ingredients except for the active agent itself.
45268|NCT03829839|Drug|Placebo Oral Tablet|The placebo pill contain identical ingredients except for the active agent itself.
45269|NCT03829826|Biological|HyQvia|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
45270|NCT03829813|Other|Music therapy|20 to 40 minute music therapy treatment session with a qualified music therapist.
45271|NCT03829800|Dietary Supplement|Ensure® Abbott Nutrition|Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
45272|NCT03829800|Dietary Supplement|Glucerna® Abbott Nutrition|Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
45273|NCT03829800|Dietary Supplement|Diasip® Nutricia Advanced|Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
45274|NCT03829800|Dietary Supplement|Glicolab®|Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
45275|NCT03829787|Device|Eye tracking|Subjects will be assessed for attentional biases, reward sensitivity, and cognitive control using eye tracking technology
45276|NCT03829774|Device|Primary Relief v 2.0|The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
45277|NCT03829774|Drug|Paracetamol|A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
45278|NCT03829761|Device|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of 1Hz stimulation, for a total of 1800 pulses delivered.
45279|NCT03829761|Device|Sham transcranial magnetic stimulation|Sham transcranial magnetic stimulation (TMS). Participants will undergo 10 daily sessions (Mon-Fri) of 30 minutes of sham stimulation. Sham stimulation will imitate the active rTMS but does not have active stimulation.
45280|NCT03829748|Procedure|Intermittent aspiration|Endoscopic ultrasound is done for the localization of the lesion and to localize the site of puncture.Prior to the puncture of the lesion the stylet is removed and a vacuum syringe is prepared with 10 cc of vacuum allowing the generation of continous pressure inside and connected to the end of the needle. Once the lesion is punctured 15 movements in and out of the lesions will be made while the syringe is opened and closed on and off for a total of 3 times each pass. A total of 4 passes will be done in each lesion.
45281|NCT03829735|Other|Human biological samples|Collection of capillary blood for HbsAg testing. Collection of 12 mL of blood for HbsAg positive women and 1 mL for HbsAg positive children.
45282|NCT03829722|Drug|Nivolumab|Given intravenously (IV), 240 mg every 2 weeks for 4 doses concurrent with radiation therapy (RT). Following completion of RT, 480 mg given every 4 weeks for 4 doses.
45283|NCT03829722|Drug|Carboplatin|Given IV once per week during radiation therapy (AUC=1).
45284|NCT03829722|Drug|Paclitaxel|Given IV once per week during radiation therapy (30mg/m^2)
45285|NCT03829722|Radiation|Radiation Therapy|Given 5 days/week for a total of 35 doses (70 gray total).
45286|NCT03829709|Other|Rehabilitation|The first training session each week will be held at the LAERF under the direct supervision of the investigator and the other two home-based training sessions under the supervisor's distance supervision. They will receive the Threshold® IMT linear loading device, and guidelines for handling, posture and asepsis. The initial training load for each participant will be adjusted to 25% of PiMáx. Participants will be trained and instructed to do the exercise program on their own at home. Once a week, during the return to the laboratory the researcher will determine the new values for load (1st week 25%, 2nd week 35%, 3rd week 40%, 4th week 45%, 5th week 50%).
45287|NCT03829696|Drug|Mifeprex® (Mifepristone 200 mg)|Participants will receive Mifeprex® (mifepristone 800 mcg) from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period and would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
45288|NCT03829696|Drug|Misoprostol 800 mcg|Participants will receive misoprostol from a clinician when they are not pregnant. Participants who have an unintended pregnancy during the study period would like to have a medication abortion will consult with a clinician for an over-the-phone evaluation of contraindications and gestational age. Participants who take the medications will be evaluated again in-person at a subsequent follow-up visit.
45289|NCT03829696|Drug|ella® (ulipristal acetate emergency contraception 30 mg)|Participants will receive one dose of ella (emergency contraception) from a clinician at the same time of receiving mifepristone and misoprostol, in case the participant should have unprotected intercourse or failed contraception and want to prevent unintended pregnancy.
45290|NCT03829696|Diagnostic Test|AccuHome® Pregnancy OTC Test|Participants will receive 6 AccuHome® pregnancy tests, which are midstream urine pregnancy tests and provide results within 3 minutes. Participants may request additional tests to be mailed to them by the study at any time.
45291|NCT03829683|Drug|Vitamin C|200mg/kg/24hours
45292|NCT03829683|Drug|Dextrose 5% in water|50mL intravenously every 6 hours
45293|NCT03829670|Diagnostic Test|Cytochrome P450 test|Blood samples will be drawn for cytochrome P450 testing.
45294|NCT03829657|Drug|ampreloxetine|Oral tablet, QD (Daily)
45295|NCT03829657|Drug|Placebo|Oral tablet, QD
45296|NCT03829644|Device|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I device, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks. As this brace is semi-rigid, it does not prevent motion - only reduces motion in the lumbar areas. Our prior work and that of others have shown that this type of bracing does not reduce spinal function and is not associated with atrophy.
45297|NCT03829631|Device|Horizon 627 Lumbar Brace, Aspen Medical Company, Oak Canyon, Irvine, CA 92618|The brace is an FDA Class I, one-size adjustable design to fit waists ranging from 24-70 inches. Participants will be instructed to wear the brace for six weeks during the daytime
45299|NCT03829618|Drug|Nebuliser solution|2% lidocaine dose at 2 mg/kg (max 160 mg) applied via jet nebulizer
45300|NCT03829618|Drug|Nebuliser Suspension|2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
45301|NCT03829605|Other|Measurement of hydrogen sulfide|Hydrogen sulfide will be measured by ELISA and correlated with nitric oxide and hyperglycemia
45302|NCT03829592|Drug|misoprostol in a neutral media|giving misoprostol in a neutral media
45303|NCT03829592|Drug|misoprostol in an acidic media|giving misoprostol in an acidic media
45304|NCT03829592|Drug|misoprostol in an alkaline media|giving misoprostol in an alkaline media
45305|NCT03829579|Drug|Esketamine|Participants will self-administer esketamine nasal spray, under the supervision of the healthcare professional at the site of care. A starting dose of 56 milligram (mg) will be administered intranasally into each nostril on Day 1 with subsequent doses of 56 mg or 84 mg administered during Weeks 1-4 (2 treatment sessions per week). For participants who respond, treatment is continued as follows: 56 mg or 84 mg of esketamine nasal spray during Weeks 5-8 (once weekly), and Week 9 onwards (every 2 weeks or once weekly), with period re-evaluation to determine the need for continued treatment. Doses will be adjusted based on efficacy and tolerability to the previous dosing.
45306|NCT03829566|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
45307|NCT03829566|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
45308|NCT03829566|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
45309|NCT03829566|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
45310|NCT03829566|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
45311|NCT03829566|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
45312|NCT03829566|Biological|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
45313|NCT03829566|Biological|Autologous Stem Cells|Infusion of patient's own stem cells
45314|NCT03829553|Radiation|Hypofractionated radiotherapy|4005 cGy/ 15 fractions / 3 weeks to ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2.67Gy for 4 fractions in patients with intact breast
45315|NCT03829553|Radiation|Conventional radiotherapy|5000 cGy/ 25 fractions / 5 weeks ipsilateral chest wall or whole breast and regional lymph regions (including supraclavicular and internal mammary lymph nodes) and sequential tumor bed boost of 2Gy for 5 fractions in patients with intact breast
45316|NCT03829540|Biological|CD4CAR|CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose (total dose of up to ~4x106 T Cells/KG)
45317|NCT03829527|Behavioral|Psychotherapy|Psychological intervention combining a standardized treatment manual with a smartphone application
45318|NCT03829514|Drug|Fenofibrate|40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides >150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.
45319|NCT03829501|Drug|KY1044|A human anti-ICOS monoclonal antibody
45320|NCT03829501|Drug|KY1044 and atezolizumab|A human anti-ICOS monoclonal antibody in combination with anti-PD-L1 monoclonal antibody (atezolizumab)
45321|NCT03829488|Drug|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion|Plasma-Lyte 148 (approx. pH 7.4) IV Infusion is a sterile, clear, non-pyrogenic isotonic solution and when administered intravenously is a source of water, electrolytes and calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water & electrolytes or as an alkalinising agent.
45322|NCT03829488|Drug|0.9% SODIUM CHLORIDE 9g/L injection BP|Sodium chloride (0.9% saline) infusion is a sterile, non-pyrogenic solution of sodium chloride in Water for Injections. The concentration of sodium chloride is 154mmol/L. Sodium chloride (0.9%) intravenous infusion is indicated for extra-cellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.
45323|NCT03829475|Drug|Bezlotoxumab|This is a a fully human monoclonal antibody that binds to C. difficile toxin B, and is indicated to prevent recurrence of CDI in adults at risk for recurrent CDI (rCDI).
45324|NCT03829475|Drug|Placebo|placebo is an infusion of normal saline.
45325|NCT03829475|Drug|Fecal Microbiota Transplantation|FMT is an infusion of prescreened donor stool that will be administered via colonoscopy
45326|NCT03829462|Drug|Regorafenib|regorafenib tab 40 mg i.e 160 mg/day
45327|NCT03829462|Drug|Irinotecan|irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
45328|NCT03829449|Drug|rVA576 (Coversin)|The study population will consist of patients who have completed participation in clinical trials under other Akari protocols and who wish to continue to receive rVA576 (Coversin).
45476|NCT03828383|Device|Limited in-home technology|Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
45337|NCT03829423|Diagnostic Test|Breast MRI interpretation|Analysis and interpretation of breast MRI sequences by a specially developed breast MRI interpretation algorithm
45338|NCT03829410|Drug|Onvansertib|Onvansertib orally.
45339|NCT03829410|Biological|Bevacizumab|Bevacizumab intravenously.
45340|NCT03829410|Drug|FOLFIRI|FOLFIRI intravenously.
45341|NCT03829397|Diagnostic Test|Questionnaire|Questionnaire
45342|NCT03829384|Biological|mRNA-1944|mRNA encoding Chikungunya antibody
45343|NCT03829384|Other|Placebo|Saline
45344|NCT03829371|Drug|Velcade|Subcutaneous use
45345|NCT03829371|Drug|Melphalan|Oral use
45346|NCT03829371|Drug|Prednisone|Oral use
45347|NCT03829371|Drug|Lenalidomide|Oral use
45348|NCT03829371|Drug|Dexamethasone|Oral use
45349|NCT03829358|Drug|Lactobacillus plantarum IS-10506|Fermented milk containing probiotic Lactobacillus plantarum IS-10506 to be consumed once daily for three weeks.
45350|NCT03829358|Drug|Placebo|Fermented milk containing placebo to be consumed once daily for three weeks.
45351|NCT03829345|Drug|Olaparib|Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.
45352|NCT03829332|Biological|Pembrolizumab|IV infusion
45353|NCT03829332|Drug|Lenvatinib|oral capsule
45354|NCT03829332|Drug|Placebo for lenvatinib|oral capsule
45355|NCT03829319|Biological|Pembrolizumab|IV infusion Q3W
45356|NCT03829319|Drug|Carboplatin|IV infusion Q3W
45357|NCT03829319|Drug|Cisplatin|IV infusion Q3W
45358|NCT03829319|Drug|Pemetrexed|IV infusion Q3W
45359|NCT03829319|Drug|Lenvatinib|Oral capsule once daily
45360|NCT03829319|Drug|Placebo matching lenvatinib|Oral capsule once daily
45361|NCT03829293|Device|High-flow nasal cannula oxygenation group|usual care + High-flow nasal oxygenation (HFNO) therapy during GI endoscopy under sedation (with a flow at 70L/min and FiO2 50%) through a dedicated system, the THRIVETM (Fisher&Paykel, New-Zealand)
45362|NCT03829280|Behavioral|Cognitive Adaptation Training|Psychosocial treatment using environmental supports to bypass cognitive and motivational problems and improve adaptive behavior
45363|NCT03829280|Behavioral|Community Treatment|Medication follow-up and case management as provided in usual community care in the setting
45364|NCT03829267|Behavioral|SNAP Intervention|SNAP: social network accountability partners, a psychosocial intervention to increase physical activity in persons with multiple sclerosis
45365|NCT03829267|Behavioral|eJournal Intervention|1-hour online each week engaged in an active journaling activity
45366|NCT03829267|Behavioral|Waitlist control|Participants in this condition will be waitlisted until there is an opening in one of the other 2 conditions.
45367|NCT03829254|Drug|NUC-7738|NUC-7738
45368|NCT03829241|Drug|Troriluzole|100mg capsule
45369|NCT03829241|Drug|Placebo|100mg capsule
45370|NCT03829228|Dietary Supplement|Proglucamune|Following screening and enrollment, participants were treated with 2 tablets of Proglucamune per day for a total duration of 8 weeks. Each Proglucamune tablet contained ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
45371|NCT03829215|Device|CAERVest cooling device|The CAERVest device will be filled and placed on the supine patient's chest immediately after return of spontaneous circulation. After admission to the emergency department, the device will be removed, when a temperature below 34°C is reached.
45372|NCT03829202|Device|Own mechanical knee|Daily use of own mechanical knee
45373|NCT03829202|Device|RheoKnee microprocessor prosthetic knee|Daily use of RheoKnee microprocessor prosthetic knee
45374|NCT03829189|Dietary Supplement|inulin|prebiotic supplement
45375|NCT03829189|Dietary Supplement|maltodextrin|placebo supplement
45376|NCT03829176|Genetic|Whole Genome Sequencing|Participants in this arm will have their sample analyzed by whole genome sequencing (WGS), and a report will be included in their medical record. Analysis will be phenotype-driven (gene list will be curated based on primary indication for testing and other available medical history information), and may include genes on ACMG 59 list if participant elects for these results. This report will include pathogenic, likely pathogenic, and suspicious VUS results identified in the genes analyzed.
45377|NCT03829163|Device|Hydraulic Adjustable Walker|The HAW is a based on a conventional walker but has innovative telescoping legs with a leg adjustment assembly that includes at least one valve and at least one tube that delivers hydraulic fluid into the legs and allows a user to control the length of each leg. The legs of the walker are hydraulically adjustable, so that the front legs may be shortened and the back legs extended, or two side legs shortened and the two opposing side legs extended, so as to allow the walker to be securely placed on two different steps. This allows the user to be able to stand on a stair without worrying about sharing the same stair with the device. It also ensures that the height of the walker continues to be the right height for the user to minimize loss of balance.
45378|NCT03829163|Device|Conventional Walker|A walker consists primarily of a metal frame with four legs which are stabilized by crossbars. These walker frames come in a variety of shapes and sizes; many consist primarily of two inverted U-shaped leg modules connected by crossbars. Regardless of the shape or form of the leg modules, each walker frame forms a 3-sided box with an opening in which the user may stand.
45379|NCT03829150|Drug|Dexlan|Dexlansoprazole MR 60 mg qd for 7 days
45380|NCT03829150|Drug|Amoxicillin|Amoxicillin (Amolin) 1 g bid. for 7 days
45381|NCT03829150|Drug|Clarithromycin 500mg|clarithromycin (Klaricid) 500 mg bid for 7 days
45383|NCT03829137|Device|Verum laser acupuncture|The patients lay in the supine position before treatment and the gallium aluminum arsenide LaserPan (RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany) will be applied to each selected acupoints for 3 weeks, total of 9 sessions.
45384|NCT03829137|Device|Sham laser acupuncture|The acupuncture points and procedure of the control group are identical to the experimental group but there are no laser beam energy.
45385|NCT03829124|Drug|Propofol|Propofol 10mg/ml IV push slowly 0.5-2mg/kg
45386|NCT03829124|Drug|Ketamine|Ketamine 50mg/ml IV push slowly 0.5- 1mg/kg
45387|NCT03829111|Drug|Clostridium butyricum CBM 588 Probiotic Strain|Given PO
45388|NCT03829111|Biological|Ipilimumab|Given IV
45389|NCT03829111|Biological|Nivolumab|Given IV
45390|NCT03829098|Other|Intervantions for anastomotic leakage after esophagectomy|nil by mouth regime; antibiotic treatment according to local protocols; NG tube placement (with/without suction); NG tube repositioning (with/without suction); tube placement though anastomotic defect; endoVAC/endoSponge placement; stent placement (stent type if applicable); endoscopic clipping; nasoduodenal/nasojejunal feeding tube placement; radiologic drainage (thoracic cavity, mediastinum); bedside surgical chest tube placement; reoperation; reoperation approach; reoperation procedure (drainage only, suturing of the leak; resection of the leak and re-anastomosis; repair of anastomosis with muscle flap; disconnection and cervical esophagostomy; surgical jejunal feeding tube).
45391|NCT03829085|Other|EARLY ORAL REFEEDING|the oral refeeding will be started after admission. Patients will receive a low fat solid diet with more and less 1500 calories, 35 g fat day
45392|NCT03829072|Other|Cooking Education|cooking Education and adapted physical activity on patients after allo stem cell transplantation
45393|NCT03829072|Other|adapted physical activity|cooking Education and adapted physical activity on patients after allo stem cell transplantation
45394|NCT03829046|Drug|Placebo|12 weeks of treatment
45395|NCT03829046|Drug|Evolocumab|12 weeks of treatment
45396|NCT03829033|Radiation|Radiotherapy|Radiotherapy with either photons or protons.
45397|NCT03829020|Drug|Bortezomib|Given SC
45398|NCT03829020|Drug|Metformin Hydrochloride|Given PO
45399|NCT03829020|Drug|Nelfinavir Mesylate|Given PO
45400|NCT03829007|Diagnostic Test|PD-L1 imaging|89Zr-durvalumab injection followed by a PET/CT scan 5 days after injection
45401|NCT03829007|Drug|Durvalumab|Durvalumab treatment is initiated after the PET/CT scan in a fixed dose of 1500 mg iv q4w
45402|NCT03828994|Behavioral|Tech-PN|"text messaging(daily medication reminders and tri-weekly messages following the 14-day treatment period)~enhanced community health nurse visits on day 3-5, 14 and 30~field based treatment visits~clinical assistance with notification, testing and treatment"
45403|NCT03828981|Procedure|fast-track recovery program|"Pre-operative: fast-track management counseling, fast-track educational video,tobacco cessation, daily physical activity, light meal 6 hours and clear liquids up to 2 hours before surgery, no bowel preparation, a warm blanket, medication.~Intra-operative: vaginal wound infiltrative anesthesia, early remove of urine catheter.~Post-operative: early oral intake liquids and food, early mobilization, avoiding opioids by use of pregabaline for postoperative pain."
45404|NCT03828968|Diagnostic Test|bladder scan|Measurement of vesical volume by bladder scan
45405|NCT03828955|Dietary Supplement|Soybean peptides|Subjects receive two bags soybean peptides per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
45406|NCT03828955|Dietary Supplement|Placebo|Subjects receive two bags starch placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
45407|NCT03828942|Drug|drug inducing hematological toxicity|Drugs susceptible to induce hematological toxicities
45408|NCT03828929|Drug|Vitamin C|IV vitamin C, 1500mg in 50ml of normal saline every six hours, infused over one hour and IV Thiamine 200mg in 50ml of 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
45409|NCT03828929|Drug|Normal saline|50ml of IV normal saline every six hours and 50ml of IV 5% dextrose every 12 hours, for 4 days or until discharge from the intensive care unit, whichever comes first.
45410|NCT03828916|Other|NuShield|SOC surgery with the addition of NuShield
45411|NCT03828903|Device|Cryoprobe|"The probe (ERBE Elektromedizin GmbH; Tubingen, Germany of 2.4mm) will be placed perpendicular to the surface of the parietal pleura with the tip of the probe extended well beyond the tip of the scope using the marking on the probe and with direct visualization.~The tip of the cryoprobe will be attached to suspicious part of parietal pleura .~The frozen tissue is going to be extracted by gently pulling of the probe.~Freezing will be carried out for 6 to 10 seconds depending on the visual assessment of pleural texture.~The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar.~The biopsy sample will be released from the probe by thawing in the saline.~The semirigid pleuroscope will be reintroduced through the port and the pleura will be revisualized for bleeding."
45412|NCT03828890|Diagnostic Test|Screening eye exam using Optos technology|Retinal imaging using Optos technology to identify Diabetic Retinopathy
45413|NCT03828877|Other|Group A ( Group Acupuncture)|Group A; Acupunctur will be done with Pres Needle (0.22x1.5 mm).Acupuncture will be done points fo SP 6, LI 4 , ST 36 , LİV 3, LU 9 ,LU 7.
45414|NCT03828864|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
45415|NCT03828864|Device|Placebo Pulsed Shortwave Therapy|Placebo Pulsed Shortwave Therapy device placed over the site of pain for 16 hrs per day
45416|NCT03828851|Other|Domiciliary care - Activities of Daily Living|Home-based ADL training.
45417|NCT03828838|Drug|Lu-177 PSMA-617|Two cycles of Lu-177 PSMA (3GBq and 3-6 GBq)
45443|NCT03828669|Behavioral|Recovery Toolkits|"Recovery Toolkits are presented to patients in a branded bag and include a brochure, a self-help behavioral pain medicine book, a downloadable app, earbuds, and access to digital behavioral medicine (the My Surgical Success program including online educational videos)"
45418|NCT03828825|Other|Patent Foramen Ovale closure|"The Patent Foramen Ovale closure is realized under trans-thoracic echocardiography control. If necessary, the operator will use trans-esophageal echocardiography to implant the prosthesis. One day after the procedure, a clinical assessment and an electrocardiogram are performed. At 3 months the consultation corresponds to a trans-thoracic echocardiography validation of the closure accompanied by a bubble test (Valsalva maneuver) and a clinical assessment. At 12 months, the visit corresponds to a consultation with a clinical assessment and an electrocardiogram. At 36-months and 60-months, the visits will be done following the on-site visits provided for in the usual care or during a telephone call from the attending cardiologist to retrieve the results of the clinical examination, electrocardiogram and MACCE (major cardiac and cerebral vascular events). A consultation dedicated to the study may be proposed to patients according to what is provided in the usual care."
45419|NCT03828812|Behavioral|Breakfast promotion|Recommendation of having breakfast daily
45420|NCT03828812|Behavioral|Nighttime snack reduction|Recommendation of reducing frequency of nighttime snacking
45421|NCT03828799|Combination Product|Folfirinox + regorrafenib|folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days
45422|NCT03828786|Procedure|Endometrial scratching|Endometrial Biopsy by aspiration with a pipelle
45423|NCT03828773|Drug|Posaconazole|Posaconazole is a triazole with broad-spectrum activity, to include Candida species, Aspergillus species, and other fungal pathogens, including the Zygomycetes. Posaconazole is available as slow release tablets (300mg/day) and as intravenous (IV) formulation (300mg/day) and is licensed and approved in Switzerland for the prevention of IFI, including mold and yeast infections, in patients >18 years who are at high risk of developing these types of infection (patients with long-term neutropenia or HCT recipients). Furthermore, international guidelines recommend posaconazole for primary antifungal prophylaxis in high-risk patients, such as AML patients with prolonged neutropenia. Posaconazole is available in Switzerland under the name of Noxafil® in capsules of 100mg, suspension of 40mg/mL and intravenous formulation of 300mg/16.7 mL.
45424|NCT03828773|Drug|Fluconazole|Fluconazole is an antifungal with activity against most Candida species. Fluconazole is licensed and approved in Switzerland for prophylaxis of IC in patients with neutropenia induced by chemotherapy or radiotherapy at a daily dose of 200 to 400 mg once daily. Fluconazole (200 mg or 400 mg once daily) is still currently used as primary antifungal prophylaxis (standard of care) in all 7 centers participating in this trial. Fluconazole is available in Switzerland under the name of Diflucan® in capsules of 50 mg, 150 mg and 200 mg and in powder for preparation of suspension (50 mg/5 ml and 200 mg/5 ml (forte)) or perfusion (2 mg/1 ml). Several generics of Diflucan® are authorized in Switzerland. Prescribing Diflucan® or any of its generics will remain at the discretion of and based on the standard operating procedures (SOP) at each institution.
45425|NCT03828760|Behavioral|Music listening|Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
45426|NCT03828747|Drug|Semorinemab|Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
45427|NCT03828747|Drug|Placebo|Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
45428|NCT03828747|Drug|[18F]GTP1|[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
45429|NCT03828734|Device|Alpha TMS|TMS will be administered at the frequency of each subject's endogenous alpha oscillation (8-12Hz)
45430|NCT03828734|Device|Theta TMS|TMS will be administered at the frequency of each subject's endogenous theta oscillation (4-7 Hz)
45431|NCT03828734|Device|Arrhythmic TMS|TMS will be administered arrhythmically; i.e. a sequence of pulses with randomized timing
45432|NCT03828721|Other|Rx for Success Smartphone Application|"The Rx for Success (RS) mobile application (app) was developed by the non-profit, Children, Inc. The app is designed to be informational and motivational with both video and cueing content. The app uses a View It, Cue It, Do It model that allows parents to quickly download the smartphone app, view brief videos of age-indexed, research-based language enrichment practices; and regulate a push notification cueing program. Videos embedded in the RS app provide a summary of dialogic reading tailored for the child's age, and suggestions for encouraging verbal interactivity and social-emotional engagement through dialogic reading. Key behaviors reinforced by the app include discussing the story before reading to build interest and enthusiasm, followed by interactive reading modeled by specific types of verbal/behavioral prompts for the parent to make and responses to what the child says or does."
45433|NCT03828721|Other|Control - screen time reduction|Control families will receive a new, specially designed children's book regarding limiting screen-based media use and encouraging healthy/active alternatives (Baby Unplugged: Play, Hutton/Jones, blue manatee press), which lists American Academy of Pediatrics screen time recommendations on the back cover.
45434|NCT03828708|Other|Iron in infant formula|Participants will receive the same low-iron (5 mg/L) infant formula. Infants in the standard iron group will add iron supplement to pre-made infant formula so the iron content will be 12 mg/L.
45435|NCT03828695|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
45436|NCT03828682|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Tacrolimus Extended Release Oral Tablet [Envarsus]
45437|NCT03828682|Drug|Mycophenolate Mofetil|Mycophenolate mofetil capsules or tablets
45438|NCT03828682|Drug|Mycophenolic Acid Oral Product|mycophenolic acid tablets
45439|NCT03828682|Drug|Tacrolimus|Twice daily tacrolimus
45440|NCT03828682|Drug|Methylprednisolone|Methylprednisolone taper
45441|NCT03828682|Drug|Prednisone|Prednisone taper
45442|NCT03828682|Drug|Rabbit Anti-Human T-Lymphocyte Globulin Injectable Solution [Thymoglobulin]|Rabbit Anti-Human T-Lymphocyte Globulin
45444|NCT03828656|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
45445|NCT03828643|Drug|Secukinumab|Secukinumab 300 mg without loading dose at weeks 0, 1, 2, 3 and 4.
45446|NCT03828643|Drug|Secukinumab|Secukinumab 300 mg with loading dose at weeks 0, 1, 2, 3 and 4.
45451|NCT03828604|Behavioral|Stress; Trier Social Stress Task|Standardized acute psychosocial stressor
45452|NCT03828604|Behavioral|Placebo Trier Social Stress Task|Active control version of the TSST
45453|NCT03828591|Procedure|Intensive psychological support|Two meeting with a psychologist during the hospitalization (the first two days after surgery; the second one at the moment of the hospitalization discharge)
45454|NCT03828591|Procedure|Standard psychological support|Two meetings with a psychologist: the first meeting is one month before surgery; the second meeting is one month after surgery
45455|NCT03828578|Procedure|High flow oxygen therapy|High flow oxygen therapy delivered via Airvo2
45456|NCT03828565|Procedure|ScvO2 Perioperative continue monitoring|"ScvO2 Perioperative continue monitoring with PreSep® system. If SvcO2 is less than 65% or decreases by more than 10% of its base value, the other parameters affecting ScvO2 (BIS (40-60% objective), Hb (objective> 8g / dL), SaO2 (objective> 94%)) are evaluated. If, after correcting for these parameters, the ScvO2 is not corrected, the preload-dependence parameters are evaluated (variation of the pulsed pressure) to guide the vascular filling: VF of 250 mL of crystalloids if PPV> 13%, norepinephrine if PPV<9%, reassess if PPV between 9 and 13%.~If VF or norepinephrine does not correct ScvO2 (> 65%), a measurement of arterial lactate is performed. If lactatemia is> 2 mmol / L, a positive inotrop is introduced after ETO if possible. If lactatemia is <2 mmol / L, a return to the evaluation phase of the parameters influencing ScvO2 is necessary."
45457|NCT03828552|Other|Questionnaire|"Parents will be recruited in a Pediatric Resuscitation Department of the Mother and Child Hospital for 3 months. The doctor taking care of a child and his parents meeting the eligibility criteria will distribute, during the stay, a questionnaire accompanied by a pre-stamped envelope to the two parents not opposing the study.~A phone call and / or an email reminder by the intern in the month of the exit will invite each parent to return the questionnaire.~The completed questionnaire will be mailed back by the parents using the pre-stamped envelope."
45458|NCT03828539|Biological|Erenumab|Pre-filled syringe
45459|NCT03828539|Drug|Topiramate|Pill
45460|NCT03828526|Other|High Fidelity Simulation|Teaching strategy based on high fidelity simulation, which simulates the reality of health care to promote meaningful learning.
45461|NCT03828526|Other|Traditional teaching strategy|Classroom-based strategy
45462|NCT03828513|Device|High flow nasal cannula oxygen is applied|Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after High flow nasal cannula oxygen. Pulmonary function tests and blood gas parameters are compared.During the procedure, the patient's blood pressure, heart rate, oxygen saturation, any complications that may develop will be recorded.Induction of anesthesia; difficult airway management, difficult mask and / or difficult intubation incidence, Mallampati scores, the use of one of the difficult intubation techniques during intubation, perioperative mechanical ventilation parameters (ventilation mode, tidal volume, respiratory frequency, end of tidal CO2 (carbon dioxide) pressure, PEEP usage, SpO2 (saturation oxygen), airway peak pressure, urine volume, arterial blood gas parameters are recorded.
45463|NCT03828513|Device|High flow nasal cannula oxygen is not applied|Apply preoxygenation with facemask. Prior to induction of general anesthesia, preoxygenation will be applied with an oxygen supplement of 5 l / min to an endtidal O2> 90%.Atelectasis evaluation with lung ultrasound is performe and score in 6 different areas before and after preoxygenation.
45464|NCT03828500|Behavioral|Assistant-encouraged fasting up to ASA/CAS guideline limits|Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
45465|NCT03828487|Device|Masimo O3 Neonatal Sensors|Regional Oximetry sensor for Neonates
45466|NCT03828487|Device|510(k) cleared sensor|Cleared Regional Oximetry sensor for Neonates
45467|NCT03828474|Drug|Acetazolamide Pill|Acetazolamide pill
45468|NCT03828461|Behavioral|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
45469|NCT03828448|Drug|Ublituximab|- anti-CD 20 monoclonal antibody administered via IV infusion
45470|NCT03828448|Drug|Umbralisib|- PI3K Delta Inhibitor oral daily dose
45471|NCT03828435|Device|rTMS|Magnetic stimulation will be given using a hand-held figure-of-eight coil with an median winding diameter of 70 mm or a cone coil (Magstim Co., Whitland, Dyfed, UK) connected to one Magstim Rapid2 Package (Magstim Co., UK). The figure-of-eight coil will be placed tangentially to the scalp with the handle pointing backwards, which is thought to preferentially activate the corticospinal cells trans-synaptically (Kaneko et al., 1996), while the cone coil will be placed along the anterioposterior axis to induce a posterior-to-anterior current in the cortex.
45472|NCT03828422|Diagnostic Test|imaging|
45473|NCT03828409|Procedure|Short stitch|The rectus sheath are cleaned off the subcutaneous fats. Short stitch technique uses smaller needle and suture material. The suture is placed nearer to each other as compared to our conventional long stitch technique. It has inter-suture distance of 5mm and 5mm distance from rectus edge. The suture will be started at one end and sutured continuous until the other end. Hence, this technique is applied without tension.
45474|NCT03828409|Procedure|Long stitch|Long stitch uses a larger needle and suture material. The suture is placed 1cm from the linea alba and 1 cm from previous suture. This technique include mass closure sutures at the midline laparotomy
45475|NCT03828383|Device|In-home technology|Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.
45477|NCT03828370|Behavioral|B-SMART Intervention Group|The B-SMART mobile web app will contain four modules: 1) Supporting Abstinence, 2) Shared Positive Activities, 3) Common Challenges for Family Members with IID, and 4) Effective Communication. Within each module there will be a series of learning activities, including presentation text, interactive engagement, and videos. All app content will be available in both English and Spanish, based on user language preference.
45478|NCT03828370|Behavioral|Usual and Customary Information Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on the IID installed in their vehicle and the manufacturer information provided about the IID in PDF format, in both English and Spanish. This constitutes a UC group, as such pamphlets are widely available to DWI offenders who have IIDs installed in their vehicles. Thus, providing this pamphlet represents a standard information provision for first-time DWI offenders and their CFMs.
45479|NCT03828357|Other|Study MRI scan|At least forty-five (45) days after system implantation or after a system revision, Subjects will undergo a study-related MRI scan at 1.5T.
45480|NCT03828344|Biological|hUC-MSC suspension|Patients will be treated at dose of 0.75×10^6 cells/kg of body weight (Cohort 1) or 1.5×10^6 cells/kg of body weight (Cohort 2) via a single IV infusion using a blood transfusion kit.
45481|NCT03828344|Biological|Placebo|Placebo contains the same cell suspension as BX-U001 but without cells.
45482|NCT03828331|Other|Prosthetic/Bicycle Configuration|The investigators will measure the biomechanics (motion, forces, and muscle activity) and metabolic rates while subjects ride using an initial bike fit and three taller pylon lengths (PL) for the affected leg (AL) in increments of 6.8 mm using a pedal attachment position (PAP) beneath the prosthetic forefoot. Then, using the optimal (most efficient) PL, the investigators will measure the biomechanics and metabolic rates while subjects ride using three shorter crank arm lengths (CALs) for the AL in decrements of 6.8 mm using a PAP beneath the prosthetic forefoot. On Day 2, the investigators will repeat the protocol of Day 1, but have riders use a PAP beneath the pylon for their AL.
45483|NCT03828318|Other|Patient Activation Booklet and nursing support for patients with LARS|The LARS Patient-Centered Program will consist of an educational booklet and nursing support made available only to patients randomized to the intervention group.
45484|NCT03828305|Other|Training and creation of the Network-CPR|Training and creation of the Network-CPR that will cover the city. This network will be created with certain population groups that are routinely in contact with susceptible persons of OHCA (police, firemen, teaching staff, health personnel, merchants, pharmacists, university students, etc.), in addition, relatives of people with heart disease will be included. In the case of elderly people who are alone, they will include their neighbors or caregivers. In the city, there are 2,105 people with heart disease susceptible to OHCA. The research team and the health personnel of the participating primary care centers (PCC) will offer training courses on basic CPR maneuvers and use of the AED, following the protocol of the Center Català de Ressucitació (CCR). The training is aimed at training 430 people (20% of the relatives of people with heart disease) and will be made by trainers accredited by the CCR. There will be a total of 30 sessions with groups of approximately 15 people.
45485|NCT03828305|Other|Control Group|No intervention
45486|NCT03828292|Drug|GSK2857916|GSK2857916 will be available as lyophilized powder 100 mg/vial in single-use vial for reconstitution. It will be administered at a calculated dose of 2.5 mg/kg or 3.4 mg/kg as an IV infusion on Day 1 of each cycle over 30 minutes.
45487|NCT03828279|Diagnostic Test|functional and antigenic C1 inhibitor|Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
45488|NCT03828266|Other|No intervention|Patients will undergo routine clinical practice. There is no additional intervention.
45489|NCT03828240|Other|HIP fracture REhabilitation Programme for the elderly with hip fractures|Eight-week activity-based intervention for elderly with hip fractures; one intervention during the hospital stay, four interventions at the elderly's municipality.
45490|NCT03828227|Drug|OPTIMOX plus bevacizumab|"Adapted FOLFOX7 (aFOLFOX7)-bevacizumab for 6 cycles~Bevacizumab: 5 mg/kg IV (day 1, every 2 weeks (q2w)),~Folinic acid (FA): 400 mg/m² IV/2h (day 1, q2w),~Oxaliplatin: 85 mg/m² IV/2h (day 1, q2w),~5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w),~No 5-FU bolus.~then Adapted LV5FU2 (aLV5FU2)-bevacizumab (until progression or or unacceptable limiting toxicity)~Bevacizumab: 5 mg/kg IV (day 1, q2w),~FA: 400 mg/m² IV/2h (day 1, q2w),~5-FU continuous infusion 2400 mg/m² IV/46h (day 1-2, q2w)~No 5-FU bolus"
45491|NCT03828227|Drug|Capecitabine plus bevacizumab|"Bevacizumab: 7.5 mg/kg intravenous infusion [IV] (day 1; q3w),~Capecitabine: 1000 mg/m² orally twice a day (day 1 through day 14, q3w)."
45492|NCT03828214|Device|Robotic exoskeleton for walking assist|Participants will have two testing sessions in this within-subject design experiment. The conditions under which walking will be evaluated are control (normal) walking, walking with the exoskeleton assistance and walking immediately following exoskeleton walking. The conditions under which stair walking (ascending and descending) will be evaluated include control (normal) stairs and exoskeleton assisted stairs. Assistance is provided by The Honda Walking Assist (HWA) System is a robotic device developed by Honda R&D Corporation ®, Japan.It's computer-activated motors use hip angle information to guide assistance delivered through the thigh straps to the legs in time with the walking cycle. The maximum torque delivered is 4 Newton-meters.
45493|NCT03828201|Drug|Delamanid|"Frequency: daily Route of administration: oral~Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth."
45494|NCT03828201|Drug|Levofloxacin|"Frequency: daily Route of administration: oral~Levofloxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis."
45495|NCT03828201|Drug|Bedaquiline|"Frequency: daily Route of administration: oral~Bedaquiline is indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability."
45521|NCT03828006|Dietary Supplement|Red Rice Yeast|Participants will take one tablet per day of a dietary supplement based on red rice yeas for a period of six months
45522|NCT03828006|Other|Placebo Group|Participants of this group will take one tablet of placebo per day for a period of six months
45496|NCT03828201|Drug|Clofazimine|"Frequency: daily Route of administration: oral~Clofazimine has shown activity against multidrug-resistant tuberculosis (MDR-TB) and is now recommended by the World Health Organization (WHO) to treat drug resistant tuberculosis as a Group B drug. It is thought that clofazimine acts by inhibiting the formation of matrixes within the DNA and thus delaying the growth of the bacterium. Clofazimine first received FDA approval in 1986, although its use in the treatment of MDR-TB has not been approved by any stringent regulatory authorities and it is therefore used off-label for this function."
45497|NCT03828201|Drug|Linezolid|"Frequency: daily Route of administration: oral~Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics."
45498|NCT03828201|Combination Product|WHO approved MDR-TB treatment regimens|"In patients with Rifampicin-resistant (RR-TB) or MDR-TB who were not previously treated with second-line drugs and in whom resistance to fluoroquinolones and second-line injectable agents was excluded or is considered highly unlikely, a shorter MDR-TB regimen of 9-12 months may be used instead of the longer regimens.~In patients with RR-TB or MDR-TB, a regimen with at least five effective TB medicines during the intensive phase is recommended, including pyrazinamide and four core second-line TB medicines - one chosen from Group A, one from Group B, and at least two from Group C1 (conditional recommendation, very low certainty in the evidence). If the minimum number of effective TB medicines cannot be composed as given above, an agent from Group D2 and other agents from Group D3 may be added to bring the total to five.~In patients with RR-TB or MDR-TB, it is recommended that the regimen be further strengthened with high-dose isoniazid and/or ethambutol (1)."
45499|NCT03828188|Dietary Supplement|Red Ginseng Concentrated Powder|Red Ginseng Concentrated Powder(4.9 g/day) for 12 weeks.
45500|NCT03828188|Dietary Supplement|Placebo|Placebo for 12 weeks.
45501|NCT03828175|Procedure|spinal anesthesia monitoring|"After attaching all standard monitors (ECG, NIBP, pulse oximeter) and the COP bio-impedance monitor recording basal data (COP, CI, SV, CPI, Do2, DO2I, SVR, SVV.~During sitting position intrathecal anesthesia was conducted in the sitting position under complete aseptic condition using heavy bupivacaine 15mg (3ml) plus 10 mic dexamedatomedine 25G needle after 2 ml Lidocaine skin infiltration. lithotomy position till anesthesia level documented T4 and fixed and lower urinary tract endoscopy then shifting the patient to prone position and after adjustment of the prone position precautions 2 bellows one under the chest and one under the pelvis with pliable free moving abdomen jell ring under the patient head knees and in front of heels, then the basal data recording and after that data recording every 10 minutes till end of the operative procedure. Blood sampling at basal, postoperative"
45502|NCT03828162|Drug|Anticoagulants|
45503|NCT03828149|Combination Product|Drug:OP0201|Drug: OP0201
45504|NCT03828149|Combination Product|Drug: Placebo|Drug: Placebo
45505|NCT03828136|Device|Bio2 Vitrium® Cervical Interbody Device|For spinal fusion procedure at one level (C3 to T1) of the cervical spine.
45506|NCT03828136|Device|Allograft Ring or Block|Standard of Care
45507|NCT03828123|Biological|Suspension of human autologous MSC 3P in 1.5 ml|Intrathecal application of Autologous Multipotent Mesenchymal Stromal Cells 3P suspension
45508|NCT03828110|Device|Robotic Assisted Gait Training (Lokomat)|The RAGT treatment consisted of sessions lasting 45 minutes each performed with the commercially available Lokomat device. The same exercises were offered to the children with preset duration, speed, and difficulty. For all patients, the initial body-weight support was set at 50%, and was then gradually decreased according to the individual functional capacity. The guidance force was initially set to 100% for all children, and then gradually reduced.
45509|NCT03828110|Procedure|Physiotherapy|The physiotherapic sessions aimed at strengthening the gluteus and quadriceps muscles, stretching the hip flexor and hamstrings muscles, increasing static balance, increasing dynamic balance, increasing functional abilities, improving ground gait and climbing stairs.
45510|NCT03828097|Dietary Supplement|Experimental supplement|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
45511|NCT03828097|Dietary Supplement|Placebo|Subjects in both arms will consume two pills daily. Prior to and following 12 weeks of supplementation, participants will arrive to the laboratory following an overnight fast in order to donate blood as well as fill out EuroQoL and POMS questionnaires.
45512|NCT03828084|Drug|Decitabine|Combination drugs containing decitabine and tetrahydrouridine
45513|NCT03828071|Procedure|Autologous hematopoietic stem cell transplantation|"Stem cell mobilization and collection: Peripheral blood stem cells were mobilized with cyclophosphamide (2.0 g/m2) for 2 days and granulocyte colony-stimulating factor (G-CSF) at 5-10 μg/kg per day was administered when the level of peripheral leucocytes was < 1×109/L. Peripheral leukocyte counts were monitored, and harvesting was performed when the peripheral white blood cell level rebounded .~Conditioning and reinfusion of stem cells: The conditioning regimen consisted of intravenous cyclophosphamide (40 mg/kg/day × 4 days) 5 days before transplantation (a total dose 160 mg/kg) and rabbit antithymocyte globulin (ATG) (2.5mg/kg/day × 3 days) 4 days before transplantation. The dose of cyclophosphamide and ATG could be reduced according to the patients' condition."
45514|NCT03828058|Drug|Envarsus XR|Envarsus XR to be administered orally, once a day. Dosage will be adjusted as determined by trough blood levels.
45515|NCT03828058|Drug|Prograf|Prograf 2 mg BID to be administered orally, twice a day. Dosage will be adjusted as determined by trough blood levels.
45516|NCT03828045|Drug|Apremilast|Apremilast
45517|NCT03828032|Procedure|Mannitol injection|Standard mannitol injection to decrease intracranial pressure of patients
45518|NCT03828032|Procedure|Hypertonic saline injection|Standard Hypertonic saline injection to decrease intracranial pressure of patients
45519|NCT03828019|Biological|Adalimumab (ADA)|Adalimumab is a fully-human monoclonal antibody to TNF-α, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
45520|NCT03828019|Drug|Conventional immunosuppression (CON)|The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.
45593|NCT03827473|Other|Questionnaire Administration|Ancillary studies
45523|NCT03827993|Behavioral|dedicated sexual health clinic appointment|Intervention will consist of a dedicated sexual health clinic appointment with a physician provider focused on sexual health in this population. This provider will perform a focused history and physical, and will then determine need for appropriate treatment and management, which may consist of recommendations for medications, psychosocial counseling, physical therapy, and/or dilator use, but are not required.
45524|NCT03827980|Other|no intervention, only clinical examination|standardised interview and clinical examination
45525|NCT03827967|Biological|PalloV-CC|The PalloV-CC vaccine uses yeast cell wall particles (YCWP) to serve as an efficient vaccine delivery system as they can contain a broad range of antigenic material, they are rapidly phagocytized by antigen presenting cells, and they are inherently immunogenic. The PalloV-CC vaccine utilizes silicate-capped YCWP to deliver allogenic colon cancer tumor lysate. The vaccine will be given to subjects with resectable colon cancers neoadjuvantly shortly before surgery in order to study the effect of the vaccine on the tumor microenvironment using a well-validated immune scoring system for colon cancer and other immunologic tests.
45527|NCT03827941|Other|1 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
45528|NCT03827941|Other|20 Hz Auricular transcutaneous electrical nerve stimulation|High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
45529|NCT03827928|Behavioral|Yoga/meditation|A 6-week yoga and meditation program with psychoeducation components, delivered through community-based yoga sessions. This program offers structured instruction: 10 minutes of breathing exercises to calm the nervous system, 45 minutes of gentle yoga to improve strength, flexibility, and balance, 15 minutes of guided meditation to enhance attention control, emotional regulation, and self-efficacy, and 20 minutes of facilitated discussion with psychoeducation to build community connection and skills in resilience.
45530|NCT03827915|Device|Double sequential external defibrillation|DSED is the process of using two defibrillators near simultaneously at their highest allowed energy setting and aims to treat refractory atrial fibrillation. The first set of pads is placed in the traditional anterolateral position and the second set can be either placed adjacent to the first set (antero-lateral) or in the antero-posterior position. Shocks are then delivered simultaneously or near simultaneously
45531|NCT03827902|Device|Telcare 2.0 BGM|Blood glucose meter that uploads blood glucose measurements to a cloud server that providers can access and use to monitor patients' glycemic trends.
45532|NCT03827889|Procedure|WMP of fluoride varnish|Application of fluoride varnish (drug of the intervention - Duraphat, Colgate) on all teeth, regardless of the lesions found
45533|NCT03827889|Procedure|TWLP of fluoride varnish|application of the fluoride varnish (drug of the intervention - Duraphat, Colgate) only on the teeth with active initial caries lesions detected through visual examination after prophylaxis
45534|NCT03827889|Behavioral|DHP (educational intervention)|The control group will receive diet and hygiene guidance (educational intervention) through verbal explanations and teeth brushing practices
45535|NCT03827876|Drug|Enstilar 0.005%-0.064% Topical Foam|Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira
45536|NCT03827863|Device|TTE|TTE to detect the heart function
45537|NCT03827850|Drug|ERDAFITINIB|Daily in a range from 3 mg to 9 mg
45538|NCT03827837|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
45539|NCT03827837|Drug|Famitinib|a small-molecule multikinase inhibitor
45540|NCT03827824|Device|Hysteroscopy & virtual reality glasses|Hysteroscopy. Virtual reality glasses. VAS. STAI scale.
45541|NCT03827824|Device|Hysteroscopy|Hysteroscopy. VAS. STAI scale.
45542|NCT03827798|Drug|CFZ533|s.c.
45543|NCT03827798|Drug|Placebo to CFZ533|s.c.
45544|NCT03827798|Drug|LYS006|p.o.
45545|NCT03827798|Drug|Placebo to LYS006|p.o.
45546|NCT03827785|Device|rTMS treatment group|For rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the iTBS pattern everyday. Treatment will lasted for 30 days.
45547|NCT03827785|Device|sham rTMS treatment group|For sham rTMS treatment, we will stimulate the dorsal lateral prefrontal cortex of each patients using the sham iTBS pattern and sham coil everyday for 30 minutes. Treatment will lasted for 30 days.
45548|NCT03827772|Other|Fecal Microbiota Transplantation|30 grams of stool homogenized with 100 mL of normal saline administered a single time via nasojejunal tube.
45549|NCT03827772|Other|Standard of care treatment|Nutritional supplementation, supportive management.
45550|NCT03827746|Other|Tampa Kinesiophobia Scale, Berg-Balance Test, International Physical Activity Questionnaire-Short Form, Falls Efficacy Scale|"Tampa Kinesiophobia Scale: The TSK is a 17-item self report checklist using a 4-point Likert scale that was developed as a measure of fear of movement or (re)injury.~Berg-Balance Test: 14-item scale designed to measure balance of the older adult in a clinical setting.~International Physical Activity Questionnaire-Short Form: This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.~Falls Efficacy Scale: A 16- item self-administered questionnaire designed to assess fear of falling in mainly older population"
45551|NCT03827720|Device|SENSE Device|Non-invasive radiofrequency (RF) sensor
45552|NCT03827707|Behavioral|Noise|Noise applied via headphones during 60 min after meal ingestion
45553|NCT03827707|Behavioral|Silence|Headphones without sound applied during 60 min after meal ingestion
45554|NCT03827694|Diagnostic Test|Non-Invasive Testing for PIMI|galactomannan assay, fungal PCRs, cell-free next-generation DNA/RNA sequencing, RNAseq
45594|NCT03827460|Behavioral|Abstinence from alcohol|Participants will undergo a laboratory alcohol infusion session that terminates 2 weeks of monitored abstinence from alcohol
45595|NCT03827460|Behavioral|Usual drinking|Participants will undergo a laboratory alcohol infusion session during a period of usual drinking behavior
45555|NCT03827681|Procedure|Trans Intrahepatic Portosystemic Shunt|"The most common approach is through the right internal jugular approach.~After infiltrating the puncture site with 2% lignocaine and puncturing the vein a guide wire is advanced into the IVC followed by a 9F/10F vascular sheath.~A wedged venogram is performed with a peripherally placed hepatic vein catheter, which may identify a portion of the portal vein to facilitate subsequent puncture.`~A stiff guide wire is then passed through the catheter and the vascular sheath is advanced into the right hepatic vein. With the vascular sheath in place a rigid needle with 15-20 degrees of distal angulation is advanced over the guide wire and through the vascular sheath to enter the hepatic vein."
45556|NCT03827681|Procedure|Self Expanding Metallic Stent|"At upper endoscopy, a 0.35 Superstiff radiological guidewire with a soft tip (supplied with the stent insertion kit) is delivered into the stomach under direct vision and the endoscope is removed.~The stent delivery device is then advanced over the guidewire into the stomach, and the distal portion of the stent delivery system is withdrawn to allow inflation of the gastric balloon.~The gastric balloon is then inflated with 100 mL of air, and the whole delivery system is withdrawn until resistance is felt, which signifies that the balloon is impacting at the cardia, thus anchoring the distal end of the stent during deployment.~After stent deployment, the gastric balloon is deflated and the stent delivery system is withdrawn. The stent is then examined endoscopically. When deployed, the stent is 135 mm long and 25 mm wide."
45557|NCT03827681|Drug|Vasoactive Agent|Vasoactive Agent
45558|NCT03827668|Drug|PF-06650833 alone|In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
45559|NCT03827668|Drug|PF-06651600 alone|In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
45560|NCT03827668|Drug|PF-06650833 together with PF-06651600|In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
45561|NCT03827655|Drug|TAK-954 Placebo|TAK-954 placebo-matching IV infusion
45562|NCT03827655|Drug|TAK-954|TAK-954 IV infusion
45563|NCT03827642|Drug|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
45564|NCT03827642|Drug|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
45565|NCT03827642|Drug|Treatment C: Naloxone HCl Intravenous (IV) Injection|Participants received naloxone HCl IV injection following a 10 hour fast.
45566|NCT03827642|Drug|Treatment D: Naloxone HCl Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
45567|NCT03827629|Drug|Treatment A: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
45568|NCT03827629|Drug|Treatment B: Naloxone Nasal Spray|Participants received naloxone nasal spray following a 10 hour fast.
45569|NCT03827629|Drug|Treatment C: Naloxone HCL Intramuscular (IM) Injection|Participants received naloxone HCl IM injection following a 10 hour fast.
45570|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)
45571|NCT03827616|Radiation|Hypofractionated IMRT using helical Tomotherapy.|60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.
45572|NCT03827603|Drug|Ibrutinib|Ibrutinib and rituximab combination for the treatment of steroid refractory AIC (warm type AIHA and PRCA) with underlying CLL.
45573|NCT03827590|Drug|Test|three times a day for five days
45574|NCT03827590|Drug|Active Comparator Control 1|three times a day for five days
45575|NCT03827590|Drug|Active Comparator Control 2|three times a day for five days
45576|NCT03827590|Drug|Placebo|three times a day for five days
45577|NCT03827577|Procedure|Surgical removal of primary and/or of all oligometastases|Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
45578|NCT03827577|Radiation|Non-surgical LAT|Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
45579|NCT03827577|Drug|Standard medical therapy|platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
45580|NCT03827564|Device|Intranasal Tear Neurostimulator (ITN) [TrueTear®]|The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.
45581|NCT03827551|Behavioral|Delivery of oral hygiene advices|Patients will benefit from hygiene advice and maintenance of good oral health. No treatment will be administered as part of this study. Patients will continue their usual treatment according to the contraindications. Patients will benefit from salivary sampling and a collection of oral bacteria contained in the dental plaque using paper tips. These reviews will be conducted during the Inclusion Visit and the 6 month Follow-Up Visit.
45582|NCT03827525|Behavioral|Cognitive and Behavioral Therapy|9 sessions of Cognitive and Behavioral Therapy will be realised with the patient by a clinical psychologist. They will last between 1h and 1h30.
45583|NCT03827512|Other|Doppler arterial waveforms analysis|terminology used when describing arterial Doppler waveforms
45584|NCT03827499|Dietary Supplement|HMB dietary supplementation|Intervention groups including HMB supplementation (Ex-HMB and NoEx-HMB) will receive a 3 g daily dose of free acid HMB in powder form dissolved freely into 250 mL of water during a 24-week intervention
45585|NCT03827499|Other|Multicomponent physical exercise program|Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
45586|NCT03827486|Other|Standard of care (exercise)|Exercise program according to the standard of care
45587|NCT03827486|Other|Domicilary exercise program|Domicilary exercise program according to protocol (evidence based medicine)
45588|NCT03827473|Drug|Abiraterone Acetate|Given PO
45589|NCT03827473|Drug|Antiandrogen Therapy|Given per standard of care
45590|NCT03827473|Drug|Docetaxel|Given IV
45591|NCT03827473|Drug|Prednisone|Given PO
45592|NCT03827473|Other|Quality-of-Life Assessment|Ancillary studies
45596|NCT03827447|Drug|Vancomycin Oral Capsule|125 mg capsules every 6 hours for 14 days.
45597|NCT03827447|Drug|Placebo Oral Capsule|Gelatin pill manufactured to mimic 125 mg Vancomycin oral capsule
45598|NCT03827434|Device|Continuous glucose Monitoring Devices and Clarity Software|Patients with DM2 at the intervention group will be managed by Continuous glucose Monitoring and Clarity software
45599|NCT03827434|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
45600|NCT03827408|Drug|Midazolam group (MDZ)|IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
45601|NCT03827408|Drug|Dexmedetomidine group (DEX)|IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
45602|NCT03827408|Drug|Combination of Midazolam and Dexmedetomidine (MDZ/DEX)|Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(
45603|NCT03827395|Biological|HEV 239|Hepatitis E vaccine against HEV genotypes 1 and 4. The HEV 239 vaccine is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368-606 of the capsid protein of a genotype 1 HEV strain. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 µg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.
45604|NCT03827395|Other|Placebo|0.9% Sodium Chloride Injection, USP (Normal Saline) is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection (WFI). Each mL contains sodium chloride 9 mg and may contain HCl or NaOH for pH adjustment (pH 5.3 [4.5 - 7.0]).
45605|NCT03827382|Behavioral|Lifestyle Intervention|Physical activity program: 5 sessions of cardio Training per week, combined with resistance Training 2 times per week Nutritional counseling
45606|NCT03827369|Diagnostic Test|ICU patient|Our study is to measure the coefficient of variation of the HCV of the radial arterial pulse among ICU patients with multiple organ failures (MOF). Patients admitted to Taoyuan General Hospital were recorded during the 6 months study.
45607|NCT03827356|Device|Inspiratory muscle trainer (IMT)|The device incorporate a unidirectional valve independent of flow to guarantee constant resistance and included a specific pressure setting (in cm H2O).
45608|NCT03827317|Radiation|[18F]GE-226|[18F]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
45609|NCT03827304|Device|Virtual Reality Distraction from Burn Pain|Patients wore a VR headset while undergoing a burns dressing change
45610|NCT03827291|Drug|Exparel|Bilateral administration on each side of 30 ml aliquot containing 10 ml of liposomal bupivacaine (133 mg) and 20 ml of 0.25% bupivacaine (50 mg) in the fascial plane between the QL and psoas major muscles.
45611|NCT03827291|Other|Thoracic epidural analgesia|Historical cohort that received thoracic epidural analgesia
45612|NCT03827278|Drug|Voriconazole|"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"
45613|NCT03827265|Device|repetitive transcranial magnetic stimulation (rTMS)|A rTMS system is an electromagnetic device that non-invasively delivers a rapidly pulsed magnetic field to the cerebral cortex in order to activate neurons within a limited volume without inducing a seizure. The device is intended to be used to treat patients meeting clinical criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Illnesses, Fourth Edition (DSM-IV). This guidance is issued in conjunction with a Federal Register notice announcing the classification of rTMS systems for the treatment of MDD.
45614|NCT03827239|Other|Activity/Moderate Exercise|3-hour sedentary period with 3 minute activity breaks of moderate exercise every 30 minutes
45615|NCT03827213|Drug|Exparel|A shot of long acting local anesthetic for post operative pain management
45616|NCT03827213|Device|Indwelling Catheter|ropivacaine, given through a catheter inserted between the shoulders
45617|NCT03827200|Drug|Ambrisentan|Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
45618|NCT03827187|Other|Motor imagery based EEG-BCI|Information gathered in this study may be useful when considering diagnosis of prolonged disorder of consciousness and successful adoption of device could lead to assistive communication intervention with therapeutic benefits. Participants undergo quick assessment to test ability to engage in task, if successful this implies they are minimally conscious, have some awareness of self and memory intact to remember commands. During training participant undergoes multiple sessions whereby they are conducting two different imagined movements to move a sound across the azimuthal plane in a direction dictated by an auditory cue. Participant will receive auditory feedback on the position of the sound which acts as a reflection of how well the participant is engaged in the task in terms of performance and consistency across trials. The participant will move on to use the imagined movements to answer a series of biographical, situational, basic logic and numbers/letters questions.
45619|NCT03827174|Other|Return To Work Coordination|External and internal coordination regarding sick leave. Establishment of a common return to work plan between employer och employee.
45620|NCT03827174|Behavioral|Behaviour Change Ability Program|"Return to work coordination~Education for employers and employees in pain neuroscience, validation and problem-solving.~Patient-specific goal setting for return to work~Exercise and behavioural skills training related to return to work"
45621|NCT03827161|Dietary Supplement|Glucosamine|Given PO
45622|NCT03827161|Other|Placebo|Given PO
45623|NCT03827148|Other|Pharmaceutical Care|Pharmaceutical care is an individualized patient-centric health service delivered by pharmacists that incorporates, but is not limited to, disease education, therapy management, self-care and self-management of disease and therapy as well as motivational guidance.
45624|NCT03827135|Other|Traditional physical therapy|"Cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
45653|NCT03826927|Other|treatment with NOACs or VKAs|treatment with NOACs or VKAs initiated or continued for prevention of ischemic events
83120|NCT03535727|Drug|Gemcitabine|IV over 30 minutes; Days 4 and 11
45625|NCT03827135|Other|Cyriax manipulation|"Experimental group was given cyriax manipulation protocol along with the cervical isometrics and muscle strechings.~Traction with rotation was not given in cases of bilateral arm pain. cervical isometrics 10 repetitions×1 set, 4 days/week and targeted muscle strechings (trapezius, scalenes and sternocleidomastoid) 10 repetitions×1 set, 4 days/week.~Total of 4 sessions were given each consisting of 40 mins."
45626|NCT03827122|Drug|onabotulinumtoxinA|Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.
45627|NCT03827109|Behavioral|Group educational activities|Group educational topics include nutrition, stress, IBD and school, and disease management, and are taught by experts in each content area. s.
45628|NCT03827109|Behavioral|IBD educational website|Website with age-appropriate educational information, including information from the group educational activities.
45629|NCT03827109|Behavioral|Monthly check-in calls from program coordinator|Phone calls from coordinator to encourage youth to do something fun with a friend (comparison group) or mentor (Mentoring Program). For those in the Mentoring Program, the coordinator will also ask about the mentee's relationship with the mentor.
45630|NCT03827109|Behavioral|Mentor|Mentees will be matched with a mentor for a year-long, 1:1 mentee-mentor relationship. Matching mentors and mentees is based on gender (same), age, geographical proximity, ethnicity, and interests. Mentors and mentees are expected to have weekly contact (e.g., text, phone), with in-person contact 1 - 2 times per month, one of which can be attending a group activity together.
45631|NCT03827109|Behavioral|Fun group activities|"Program participants vote on fun group activities to participate in for support and to learn self-management skills through experiential opportunities and modeling."
45632|NCT03827109|Behavioral|Parent support group|Parents participate in a social/support group facilitated by an Investigator while mentees and mentors are socializing during group events.
45633|NCT03827096|Drug|Suspension of human autologous MSC 3P in 1.5 ml|During the posterolateral spine fusion operation, 1.5 ml of cell suspension was mixed with 5cc of beta-tricalcium phosphate foam and 3.5 ml of patient's blood, and inserted between the right transverse processes of the lumbar spine.
45634|NCT03827083|Other|cerebral pulse oximetry|Cognitive Functions by Cerebral Pulse Oximetry After General Anesthesia and Spinal Anesthesia
45635|NCT03827070|Drug|Afatinib|Used Afatinib particles of which had an average size of 22 μm and a volume concentration of small particles (<5 μm) - only 19%
45636|NCT03827070|Drug|Talcum powder|Used Talcum powder particles of which had an average size of 24.5 μm and a volume concentration of small particles (<5 μm) - only 11%
45637|NCT03827057|Behavioral|Reconsolidation of Traumatic Memories (RTM)|"RTM is a trauma-focused, but not cognitive behavioral, therapy: it involves brief exposure to the trauma memory, but does rely on conscious responses to correct the symptoms of PTSD. RTM was first used to treat phobias in the 1970s, and has more recently been refined to focus on reconsolidation to update long-term memories, reconfiguring the salience structure of the original memory, and incorporating those changes into the overall memory structure. Reconsolidation is a neural mechanism for updating long-term memory, inserting new information that contradicts an essential element of the memory, which makes it possible to change the emotional tone and salience of the memory. It is hypothesized that RTM can thereby achieve quicker, greater, and more durable responses than with traditional exposure therapies."
45638|NCT03827057|Behavioral|Prolonged Exposure (PE)|PE is a trauma-focused cognitive behavioral therapy (TFCBT) that depends on exposure to the feared stimulus as a central effector of change, utilizing extinction, which theorizes that if a trigger that previously elicited a fear response is presented enough times without reinforcement, the response fades. Previous researchers have shown that extinction involves the creation of a new blocking memory which prevents expression of the original fear memory. While PE has more evidence to support its efficacy in PTSD than other approaches, and a majority achieve a clinical response (e.g., decrease in CAPS score of 10 or more), many do not achieve complete remission of symptoms, and the blocking memory may be fragile, so subsequent triggers may result in relapse.
45639|NCT03827044|Drug|Avelumab|Avelumab is a fully human monoclonal antibody (MoAb) of the immunoglobulin G (IgG) 1 subtype which specifically binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
45640|NCT03827031|Other|revision of the prescription drug|The doctor will perform a clinical examination and then exchange in a collaborative interview with the clinical pharmacist; on this basis, the doctor will establish a new out-patient prescription and the pharmacist will perform an exit interview with the patient.
45641|NCT03827031|Other|Strengthening the city-hospital link|organization of a telephone appointment between the doctor and the attending physician and / or specialist
45642|NCT03827018|Combination Product|mavrilimumab|1 mL of 150 mg in a pre-filled syringe
45643|NCT03827018|Combination Product|placebo|1 mL of placebo in a pre-filled syringe
45644|NCT03827005|Dietary Supplement|L-arginine|NOW Foods, Bloomingdale, IL
45645|NCT03827005|Dietary Supplement|Placebo|InHealth Specialty Pharmacy, Fargo, ND
45646|NCT03826992|Drug|Vyxeos|Vyxeos Dose: daunorubicin 44 mg/m2 and cytarabine 100 mg/m2 administered via intravenous infusion over 90 minutes on days 1, 3, and 5.
45647|NCT03826992|Drug|Venetoclax|"Venetoclax Dose:~Dose Level 0- allometrically scaled to 400 mg~Dose Level 1- allometrically scaled to 600 mg~Dose Level -1- allometrically scaled to 250 mg"
45648|NCT03826979|Other|Pliates method treatment|The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
45649|NCT03826966|Device|reSET|reSET is a mobile app created by Pear Therapeutics, Inc., which has previously been approved by the FDA.
45650|NCT03826953|Other|Nurse Led Allergy Clinic|Project to investigate if it is feasible to establish a nurse-led primary care-based allergy clinic intervention in NHS Lothian, and to understand the acceptability and estimate the impact of this service on improving access and outcomes in patients with allergic conditions.WE will undertake a mixed-methods longitudinal evaluation of the community-based nurse-led allergy clinic.
45651|NCT03826940|Drug|Lovastatin 60 MG|60 MG Lovastatin per day for 3 consecutive days
45652|NCT03826940|Drug|Placebos|60 MG Placebo per day for 3 consecutive days
46699|NCT03818932|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
45654|NCT03826914|Dietary Supplement|CardioFlex Q10|CardioFlex Q10 is a cardiovascular health supplement developed to increase collagen production, repair connective tissues, and help the body metabolize fats and protein. CardioFlex Q10 contains high amounts of lysine, proline and vitamin C, which the body requires to produce connective tissue (collagen). CardioFlex Q10 also includes additional supporting nutrients such as vitamin E, selenium, bio flavonoids, Coenzyme Q10 (Ubiqionol) and magnesium. The ingredients in CardioFlex Q10 help regulate the body's production of cholesterol, strengthen the arteries and heart, and reverse oxidation.
45655|NCT03826914|Dietary Supplement|Placebo|Isocaloric maltodextrin placebo that looks and tastes identical to CardioFLex Q10
45656|NCT03826901|Drug|delgocitinib|Cream for topical application
45657|NCT03826875|Drug|Fluoxetine|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life
45658|NCT03826875|Drug|Placebo|Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
45659|NCT03826862|Radiation|CT three-dimensional reconstruction|All patients will receive CT three dimensional reconstruction before surgery
45660|NCT03826849|Behavioral|Insomnia Coach|Insomnia Coach is a mobile application that provides psychoeducation and self-management tools for insomnia symptoms based on cognitive behavioral therapy for insomnia (CBT-I)
45661|NCT03826836|Behavioral|Mindfulness-based stress reduction|Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
45662|NCT03826823|Device|HSG cannula|a thin catheter originally designed for IUI was introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum was loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye was injected slowly and the procedure was watched on the screen and x-ray films were taken.
45663|NCT03826810|Radiation|aPDT|For the aPDT the PapacarieMblue (Fórmula e Ação) was used. It was left for 5 minutes in the cavity. The carious tissue was removed and the application of the PapacarieMblue was repeated. The tissue was then irradiated in a single spot with a red laser, of wavelength of 660 nm, for 300 s, with the energy of 500mJ. These parameters were also applied in the vestibular root of the teeth, to try and prevent sensitivity.
45664|NCT03826810|Procedure|ART|Removal of infected dentin with a curette only, followed by cavity cleaning and restoration with glass ionomer cement.
45665|NCT03826784|Combination Product|BHA|BHA active ingredients include a blood-derived component and beta-tricalcium phosphate. It is applied directly to the bone fracture and nearby viable bone at the time of wound closure.
45666|NCT03826771|Behavioral|Power training|high-intensity lower extremity resistance training
45667|NCT03826771|Behavioral|Stretching|upper and lower body range of motion exercises
45668|NCT03826758|Other|E-DYNAMIC Clinical Decision Support|Clinical decision support system
45669|NCT03826745|Other|Plasma/Urine|Plasma of normal male and female normotensive, hypertensive, and/or resistant hypertensive subjects.
45670|NCT03826732|Behavioral|Guided self-help based on ACT|ACT-based self-help book and regular support by trained facilitators
45671|NCT03826719|Biological|NBP607QIV|Purified inactivated influenza virus surface antigens of four strains(quadrivalent)
45672|NCT03826719|Biological|Agrippal|Influenza virus surface antigens of three strains(trivalent)
45673|NCT03826706|Device|C-MAC Videolaryngoscope D blade|C-MAC videolaryngoscope D blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
45674|NCT03826706|Device|McGrath MAC Videolaryngoscope X3 blade|McGrath MAC videolaryngoscope X blade An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
45675|NCT03826693|Drug|Nitrous Oxide|OCD participants in this arm will receive 50%oxygen/50% nitrous oxide admixture for 60 minutes.
45676|NCT03826693|Drug|Nitrogen|OCD participants in this arm will receive 50%oxygen/50% nitrogen admixture for 60 minutes.
45677|NCT03826680|Procedure|Flexible fiberoptic laryngoscopy|Patients who will undergo thyroidectomy will be evaluated by awake flexible fiberoptic laryngoscopy and during surgery by direct laryngoscopy under general anesthesia
45678|NCT03826680|Procedure|Direct laryngoscopy|Patients who will undergo thyroidectomy evaluated before by ENT physician, will be evaluated by anesthesiologist in means of MCL score by direct laryngoscopy during surgery under general anesthesia
45679|NCT03826667|Device|PEEK Suture Anchors|"Subjects who have received PEEK Suture Anchors in the shoulder:~Healicoil PK Preloaded Suture Anchors, Bioraptor 2.3 PK Suture Anchors, Bioraptor Curved 2.3 PK Suture Anchors, Bioraptor Knotless Suture Anchors, Multifix S Ultra Knotless Fixation System, Footprint Ultra PK Suture Anchors, Twinfix Ultra PK Suture Anchors, SpeedScrew, SpeedLock"
45680|NCT03826654|Dietary Supplement|fortified oil|35 g fortified sunflower oil
45681|NCT03826654|Dietary Supplement|Placebo|plain oil
45682|NCT03826641|Drug|HCP1805|Dapagliflozin/Metformin (Xigduo XR) 10/1000mg
45683|NCT03826641|Drug|HCP1801|Dapagliflozin/Metformin 10/1000mg
45684|NCT03826628|Drug|rapamycin|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
45685|NCT03826628|Drug|placebo|Apply to the affected area once a day, approximately half an hour before retiring for bed in the evening, for 26 weeks
45686|NCT03826615|Drug|Gabapentin|Patients receive gabapentin 100mg orally for 3 times a day during the period of first and second cataract operations
45687|NCT03826602|Drug|Tucatinib|150mg administered orally twice daily
45688|NCT03826602|Drug|Metformin|850mg administered orally
45689|NCT03826602|Drug|Iohexol|1500 mg administered intravenously (IV)
45690|NCT03826589|Drug|Avelumab|an anti-programmed cell death ligand 1
45691|NCT03826589|Drug|Axitinib|a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR
45692|NCT03826576|Behavioral|Multicomponent intervention|"The multicomponent intervention will be consist of:~Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~Nutritional and food allergen analysis of the menu of the restaurant~Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~Marketing campaign about healthy and food allergen adapted menus in the restaurants"
45693|NCT03826563|Drug|oral melatonin tablets (NatureMade brand)|melatonin tablets
45694|NCT03826563|Other|Placebo|pill placebo
45695|NCT03826550|Drug|Diclofenac Sodium Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
45696|NCT03826550|Drug|Solaraze 3% Topical Gel|Twice daily for 60 days. Each patient is expected to receive 120 doses
45697|NCT03826550|Other|Placebo|Twice daily for 60 days. Each patient is expected to receive 120 doses
45698|NCT03826537|Other|Honey substance|Honey substance containing 5.1 mg/kg tutin and 23 mg/kg hyenanchin
45699|NCT03826524|Drug|Epinephrine|Epinephrine 1mg 1:10000 (10cc) per dose
45700|NCT03826511|Other|Tiszasüly hot mud-pack therapy|Patients received Tiszasüly hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
45701|NCT03826511|Other|Kolop mud-pack|Patients received Kolop hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
45702|NCT03826498|Biological|CP CB-MNC injection|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
45703|NCT03826498|Other|Standard therapy|The standard therapy can include drugs, special psychology training etc.
45704|NCT03826485|Drug|PRIC|Pranlukast hydrate 50mg
45705|NCT03826485|Drug|Pranlukast hydrate|Pranlukast hydrate 225mg/2.25g
45706|NCT03826472|Other|Almond Butter|Natural almond butter
45707|NCT03826459|Procedure|Non-Locking Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running & non-locking technique. The second layer cannot be of a locking technique.
45708|NCT03826459|Procedure|Locked Uterine Closure|The first layer of the two-layer uterine closure will be sutured with a running & locking technique. The second layer can be locking or non-locking.
45709|NCT03826446|Procedure|Surgery|laparoscopic and open complete mesocolic excision with central vascular ligation in right colon cancer.
45710|NCT03826433|Biological|Peripheral iv|6*10^7 cells
45711|NCT03826420|Behavioral|SCF Supervision with Secure Confinement Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
45712|NCT03826420|Behavioral|SCF Supervision with Work Release Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
45713|NCT03826420|Behavioral|SCF Supervision with GPS Supervision Sanctioning|Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
45714|NCT03826394|Behavioral|Exercise Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be exercise specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
45715|NCT03826394|Behavioral|Dietary Intervention|Education based sixteen week intervention where participants will be provided with core information every three weeks and supplementary information through technological means at other time points. All provided information will be diet specific. Individualised and group support provided throughout the first twelve weeks and withdrawn for the final four weeks. Fitbit Flex 2 provided for the duration of the study.
45716|NCT03826381|Diagnostic Test|Magnetic resonance (MR) spectroscopy of the liver|Magnetic resonance (MR) spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD
45717|NCT03826381|Diagnostic Test|Fibroscan|Transient Elastography for Measurement of liver fibrosis.
45718|NCT03826381|Device|Continuous glucose monitoring (CGM) for four days.|CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.
45719|NCT03826381|Radiation|Dual Energy X-ray Absorptiometry (DEXA) scan|DEXA-scan of the body composition.
45720|NCT03826381|Biological|Blood samples|Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
45721|NCT03826381|Other|Clinical and demographic data|Measurements of blood pressure, pulse, height, weight.
45722|NCT03826368|Dietary Supplement|Hemp-derived botanical dietary supplement|Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
45723|NCT03826355|Procedure|CO2 (carbon dioxide) laser vaporisation|CO2 (carbon dioxide) laser is used to vaporise the inner wall of the endometrioma
45724|NCT03826355|Procedure|Stripping technique|Identification of a cleavage plane and perform the cystectomy removing all the wall of the endometrioma from the healthy ovarian tissue
45725|NCT03826342|Behavioral|Health Check-up for Expectant Moms|A brief intervention (one session plus two booster sessions)
45726|NCT03826342|Behavioral|Information-matched control|We will include facts about alcohol/drug use and risky sex during pregnancy, along with informational brochures that provide face validity.
45727|NCT03826329|Other|observational study|this is an observational study, there is no intervention in this study
45728|NCT03826316|Drug|Nalbuphine|Pharmacokinetic study under fasting conditions
45729|NCT03826303|Other|E-cigarette liquid with ethanol, 1 puff|E-cigarette liquid with ethanol, 1 puff
45730|NCT03826303|Other|E-cigarette liquid without ethanol, 1 puff|E-cigarette liquid without ethanol, 1 puff
45731|NCT03826303|Other|E-cigarette liquid with ethanol, 10 puffs|E-cigarette liquid with ethanol, 10 puffs
45732|NCT03826303|Other|E-cigarette liquid without ethanol, 10 puffs|E-cigarette liquid without ethanol, 10 puffs
45733|NCT03826290|Other|EHR-integrated diabetes dashboard|The diabetes dashboard is available as a tab in the electronic health record (EHR) system and enables clinicians to confirm relevant patient parameters, select treatment goals, and review likely outcomes from alternative treatment strategies through an interactive graphical user interface.
45734|NCT03826277|Other|Melanostop peel|"Melanostop peel treatments containing 20% azelaic acid, 10% resorcinol, 6% phytic acid, 3% tranexamic acid. (4 treatments, performed at 2-week intervals), in combination with home care products (twice daily):~a facial tonic and cream containing brightening ingredients: vitamin C, niacinamide, alpha arbutin, kojic acid,~sunscreen protection cream with SPF 50, protecting against UVA, UVB, HEV and IR"
45735|NCT03826264|Procedure|TAVR|transcatheter aortic valve replacement (TAVR)
45736|NCT03826251|Procedure|Nasogastric tube removal|Nasogastric tube was removed immediately after surgery
45737|NCT03826238|Diagnostic Test|Validation Gate task|"The task is to observe several moving unfilled white circles on a dark background. The circles move in straight paths. Every so often, a randomly selected circle will displace to a point inconsistent with its trajectory, which will look like a jump. The subjects' task is to press the space bar every time they detect a displacement (e.g. jump). A session consists of 30 minutes, it starts with 2 training blocks which are followed by 2 no-cognitive load blocks and 6 blocks with increasing cognitive load conditions. During the assessment the eye movement as well as the key presses are registered in order to calculate early and late saccades as well as conscious reporting. Resting-state EEG will also be recorded and compared to the ones of age-matched healthy controls. Task-dependent EEG data will be recorded during the Validation Gate task."
45738|NCT03826212|Dietary Supplement|Soybean Germ Extract|Soybean Germ Extract 1,600 mg/day for 12 weeks.
45739|NCT03826212|Dietary Supplement|Placebo|Placebo 1,600 mg/day for 12 weeks.
45740|NCT03826199|Drug|TDF-FTC|We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
45741|NCT03826199|Behavioral|Counselling on PrEP in antenatal and postnatal care|Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.
45742|NCT03826186|Device|Traditional (loss-of-resistance technique) thoracic epidural placement|Thoracic epidurals will be administered using the traditional loss-of resistance technique.
45743|NCT03826186|Device|CompuFlo thoracic epidural placement|Pressure sensing technology to consistently and accurately identify the thoracic epidural space.
45744|NCT03826173|Behavioral|PPPA|The intervention will focus on a) health benefits of PA, b) individualized PA intensity prescriptions and instruction on gauging PA intensity, c) goal-setting and self-monitoring, and d) tips on overcoming barriers to PA. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period. The intervention includes activities that focus on identifying each individual's strengths, identifying/savoring positive experiences, engaging in constructive conversation, expressing gratitude, and strategies to maintain increased positive affect after the intervention has completed.
45745|NCT03826173|Behavioral|PA|The intervention will focus on (a) health benefits of PA, (b) individualized PA intensity prescriptions and instruction on how to gauge PA intensity, (c) goal-setting and self-monitoring, and (d) tips on overcoming barriers to PA, including time-management. Participants will be instructed to target 30-60 min/day 5 days/week of MVPA consistent with national guidelines. PA content will be concentrated in sessions 1 and 2, but content on goal-setting, self-monitoring, and overcoming barriers will continue throughout the 6-week period.
45746|NCT03826147|Dietary Supplement|Nitrate-rich beetroot juice|Daily supplementation with ~100 kcal of nitrate-rich beetroot juice containing 400 mg of dietary nitrate (James White Drinks, UK).
45747|NCT03826147|Dietary Supplement|Nitrate-depleted beetroot juice|Daily supplementation with ~100 kcal of nitrate-depleted beetroot juice (James White Drinks, UK).
45748|NCT03826134|Drug|[11C]PXT012253|Single intravenous bolus injection. The injected amount will be less than 5 μg. The radioactive dose is approximately 400 MBq per 70 kg body weight.
45749|NCT03826121|Dietary Supplement|Sesame Oil Cake Extract|Sesame Oil Cake Extract 1.5 g/day for 12 weeks.
45750|NCT03826121|Dietary Supplement|placebo|placebo for 12 weeks.
45751|NCT03826069|Other|Augmented reality-based curriculum|Participants in the Augmented Reality Group will be taught principles in augmented reality and training sessions will be enhanced by an augmented reality platform. This involves training on virtual reality simulators with superimposed videos and guides demonstrating correct procedure. In this study, the videos and guides will be on identifying and removing polyps.
45752|NCT03826069|Other|Conventional Simulation Curriculum|Participants in this group will will train from low- to high-fidelity colonoscopy simulation. During training, the participants will receive guidance and feedback from expert endoscopists. In addition, there will be didactic sessions covering theory of colonoscopy.
45753|NCT03826056|Behavioral|Current standard discharge educational intervention|The patients will receive the current hospital standard discharge educational material which explains the diagnosis, new medications, follow up and any activity/diet restrictions. A member of the study team will explain this material to the patient and answer any questions.
45754|NCT03826056|Behavioral|Personalized discharge educational intervention|The patients will receive a new personalized discharge educational material which will explain the specifics of their disorder, the treatment, and prognosis. The materials will contain simple, organized explanations and graphics. A member of the study team will explain this material to the patient and answer any questions.
45755|NCT03826043|Diagnostic Test|Blood sample analysis|Thrombophilia, blood count and coagulation count
46700|NCT03818932|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
45760|NCT03826017|Dietary Supplement|Catechin high contain greentea extract|Catechin high contain greentea extract 260 mg/day for 12 weeks.
45761|NCT03826017|Dietary Supplement|Placebo|Placebo for 12 weeks.
45762|NCT03826004|Drug|Clemastine|Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle
45763|NCT03826004|Drug|Saline Solution|Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
45764|NCT03825978|Behavioral|Prenatal Genetic Counseling|In this study prenatal genetic screening counseling was provided from the begining of the pregnancy, different from the other studies in the literature. In the literature, most of the study evaluated pregnant women's anxiety, information status about the test and decisional conflicts, only prenatal screening process or prenatal diagnosis process. In this study pregnant women were evaluated both in prenatal screening test and prenatal diagnosis procedures.
45765|NCT03825965|Drug|Cannabidiol (CBD)|Oral cannabidiol capsules
45766|NCT03825965|Drug|Placebo oral capsule|Visually identical placebo oral capsule (medium chain triglyceride oil)
45767|NCT03825952|Device|MERM - medication event reminder monitor|The MERM will help measure adherence to ART in routine clinical care.
45768|NCT03825939|Drug|Topical Tranexamic Acid|Topical TXA (1g/10mL in 0.9% sterile saline)
45769|NCT03825939|Drug|Intravenous Placebo|IV 0.9% sterile saline
45770|NCT03825939|Drug|Intravenous Tranexamic Acid|1g TXA IVPB
45771|NCT03825939|Drug|Topical Placebo|Topical 0.9% sterile saline
45772|NCT03825913|Behavioral|Exercise Intervention|"Training sessions will include a split routine based on the day of the week.~Session 1 (e.g. Tuesday) - aerobic exercise (20-30 min) followed by resistance training (10 stacked-weight machines: leg press, leg extension, leg curl, chest press, latissimus pull, shoulder press, seated row, triceps press, biceps curl, and chest fly) for 1-2 sets of 8-12 repetitions.~Session 2 (e.g. Thursday) - resistance bands and body weight exercises (4-6 exercises, 2 sets of 10-20 repetitions) followed by core exercises (2-3 sets of 10-20 repetitions) and aerobic training (20-30 min) at the end.~The starting training intensities will be at 50-55% of each individual's estimated maximum heart rate for aerobic exercise and one-repetition maximum for resistance training (assessed at baseline only for chest press and leg press). We plan a 5% monthly increase in the intensity to reach 65-70%% of one's maximum efforts by the end of the intervention."
45773|NCT03825913|Behavioral|Wellness Intervention|In our setting, ten lectures in nutrition, exercise and various complementary and integrative medicine topics (e.g. acupuncture and Chinese medicine, mindfulness, quality sleep, etc.) were implemented among non-cancer individuals and modified based on their feedback.
45774|NCT03825900|Device|Sham OR active Transcranial direct current stimulation|Sham OR active transcranial direct current stimulation over the motor cortex
45775|NCT03825887|Drug|Nalbuphine|"Nalbuphine (Group B): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
45776|NCT03825887|Drug|Morphine|"morphine (Group A): Patients will be started on the same dose of 10 mcg / kg / hour as a background and 10mcg bolus dose with lock-out 20 minutes having the maximum allowed dose up to 40mcg /kg/ hour.~Any patient will continue to complain of pain rating 4-6 on VAS after reaching the maximum designated dose (which is 40 mcg/kg/hour) will be transferred to the ICU for close monitoring according to the internal hospital guidelines and getting him/her out of the study.~There is no drug shifting at any part of the study."
45777|NCT03825874|Other|Amikacin|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
45778|NCT03825874|Other|usual antibiotic treatment|A first anorectal swab will be performed before starting any antibiotic treatment Three to four days after the start of antibiotic treatment, patients will be seen again and a new anorectal swab will be performed.
45779|NCT03825861|Drug|FOLFIRINOX|Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
45780|NCT03825848|Procedure|trans jugular intrahepatic portal systemic shunt|Shunting left or right PV branch in the TIPS procedure
45781|NCT03825835|Drug|30% oxygen group|"Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
45782|NCT03825835|Drug|60% oxygen group|"Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.~Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed."
45816|NCT03825549|Behavioral|Individual audit feedback|Practice sites randomly assigned to have individual audit feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. The email will inform the clinician that the health system is doing monthly audits and provide them the number of patients in the last month for whom they prescribed 30 opioid pills per prescription or higher.
45783|NCT03825822|Behavioral|ImPaC Resource Intervention (INT)|"A Change Team will lead the implementation process of the ImPaC Resource using the steps:~Step 1: Complete a checklist to ensure its members can commit to responsibilities.~Step 2: Reflect on the unit's readiness for change.~Step 3: Perform an audit on 10 to 15 medical charts.~Step 4: Identify a practice change based on audit results (pain assessment or pain treatment). Develop an aim statement for the practice change.~Step 5: Select the KT strategies and plan the implementation.~Step 6: Perform an audit on 10 to 15 medical charts.~Step 7: Examine the effectiveness of the implementation and decide on the aim and KT strategies for the next cycle of change."
45784|NCT03825822|Other|Standard Practice (SP)|The SP arm will continue as usual with their standard pain practices and will be offered the intervention 6 months after randomization and completion of data collection.
45785|NCT03825809|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
45786|NCT03825809|Drug|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
45787|NCT03825809|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
45788|NCT03825809|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
45789|NCT03825809|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
45790|NCT03825809|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
45791|NCT03825796|Drug|Enasidenib Mesylate|Given PO
45792|NCT03825796|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
45793|NCT03825783|Biological|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
45794|NCT03825770|Behavioral|"The PEP (Personal Energy Planning) Program"|The PEP program is designed to teach people on dialysis with fatigue how to conserve energy during day-to-day tasks, and how to use energy conservation to accomplish their goals. The program is delivered over 7-9 weekly sessions. It consists of 2 educational web modules about energy conservation, and 5-7 goal-focused training sessions with a study clinician that utilize a problem-solving training approach known as the Cognitive Orientation to Occupational Performance (CO-OP) approach. Each program session lasts ~20-30 mins. Sessions are completed either in person during hemodialysis, or via telephone (based on patient preference). The program is administered by a trained study clinician (occupational therapist or nurse).
45795|NCT03825770|Behavioral|General Education about Kidney Disease|"General education about kidney disease involves a review of information from the Kidney Foundation of Canada's patient handbooks Living with Reduced Kidney Function and Living with Kidney Failure (www.kidney.ca/manual) during 6-8 brief individual sessions with a trained study clinician (occupational therapist or nurse).The handbooks contains general information about managing kidney disease, addressing topics such as medication management, diet, and emotional well-being on dialysis. Sessions will take place either in person during hemodialysis, or via telephone (based on patient preference)."
45796|NCT03825757|Drug|Placebo Oral Tablet|Placebo Oral Tablet
45797|NCT03825757|Drug|Acetyl Salicylic Acid|Primaspan 250 mg tablet Acetyl Salicylic Acid
45798|NCT03825744|Drug|Hetrombopag Olamine+Standard Therapy|once daily
45799|NCT03825744|Drug|Placebo+Standard Therapy|once daily
45800|NCT03825731|Biological|GC022|GC022 is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The subjects will receive one dose of GC022 infusion. The dosage ranges from 3×10^5 to 1×10^7 CAR+T/Kg.
45801|NCT03825718|Biological|GC007F|GC007F is the CAR-T cell immunotherapy targeted CD19. The subjects will receive GC007F as one dose. The dosage ranges from 6×10^4 to 2×10^6 CAR+T/Kg.
45802|NCT03825705|Drug|TQB2450 injection|TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
45803|NCT03825705|Drug|Anlotinib|A multi-target receptor tyrosine kinase inhibitor
45804|NCT03825692|Drug|Zhizhu Kuanzhong Capsule|Zhizhu Kuanzhong Capsule, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
45805|NCT03825692|Drug|Zhizhu Kuanzhong Placebo Capsule|Placebo, 3 capsules at a time, 3 times a day, taken orally 10-15 min before meals. an 8-week intervention period
45806|NCT03825666|Other|ProvideXtra® Fresenius Kabi|Improving wellbeeing
45807|NCT03825640|Behavioral|CARE|Hybrid in-person and telephone-based adjunctive intervention for bipolar disorder across the transition from prison to the community.
45808|NCT03825627|Device|Transcranial Direct Current Stimulation|"Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp at F3 (active electrode, 4.4×4.4cm) and on the contralateral supraorbital area (reference electrode, 5.1×10.2cm).~Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton, Alberta, Canada). For each stimulation, the direct current is initially increased in a ramp-like fashion over 10 s until reaching 2 milliampere (mA) and will be similarly decreased at the end of stimulation.~In the active tDCS condition, stimulation will be maintained for 20 min; in the sham condition, it will be turned off after 15 s of stimulation, with a ramp-up/down of 10 s (i.e., 35 s total)."
45809|NCT03825614|Behavioral|training|plates and therapeutic exercises applied on young adults
45810|NCT03825601|Diagnostic Test|PET with [11C]Flumazenil|7T MRI sequences : TSE, T2w FLAIR GRE-T2* and DIR 3T MRI sequences: T1, T2, T1 with gadolinium, magnetization transfer, diffusion weighted, resting state fMRI.
45811|NCT03825588|Behavioral|ASAP (As Safe As Possible)|ASAP (As Safe As Possible) is a brief intervention for adolescents hospitalized for suicide risk that focuses on the development of a safety plan, teaching emotion regulation and distress tolerance skills, along with 1-2 post-discharge follow-up calls to encourage adherence to use of the safety plan and to outpatient treatment.
45812|NCT03825588|Behavioral|BRITE smart phone app|BRITE is a smart phone app that aims to support daily emotion regulation and a safety plan that is personalized to the needs and preferences of each adolescent.
45813|NCT03825588|Behavioral|TAU (treatment as usual)|TAU (treatment as usual) is the standard treatment that all adolescents admitted to their respective Inpatient Psychiatry Program receive.
45814|NCT03825575|Device|Low level laser therapy (LLLT)|A 3 week treatment period with a total of 8 treatments of 1 hour over the sacral spinal cord
45815|NCT03825562|Behavioral|acceptance and commitment therapy, ACT|
45991|NCT03824171|Drug|AD-102|AD-102 Raloxefene 45mg/Cholecalciferol 800IU tablet
45817|NCT03825549|Behavioral|Peer comparison feedback|"Practice sites randomly assigned to have peer comparison feedback will be sent information by email to each clinician at the site each month for the duration of the intervention period. Data on the mean number of opioid pills per prescription and the proportion of visits with an opioid prescription will be delivered using a 3-month rolling average as follows: a) If clinician is above median: informed how their data compares to the median; b) If clinician is below median but above 10th percentile: informed how their data compares to the 10th percentile; c) If clinician is 10th percentile or below: informed of their data and commended for being a low prescriber."
45818|NCT03825536|Drug|Oral Methamphetamine|In this phase IV open label double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For the oral methamphetamine treatment arm, an initial 10 mg of oral methamphetamine (over-encapsulated to look similar to placebo capsule) study drug will be administered to assess tolerability, followed by a subsequent 15 mg oral dose (over-encapsulated to look similar to placebo capsule) two hours later.
45819|NCT03825536|Other|Placebo oral capsule|In this phase IV open label double-blind randomized crossover study, participants will be randomized to either of two treatment arms, oral methamphetamine or placebo, using a crossover design with a 31-day washout period in between treatment arms. For placebo treatment phase, one placebo capsule will be administered orally on treatment day, followed by a second oral placebo capsule two hours later.
45820|NCT03825523|Other|iART|After group assignment, ART will be started within the first 48 hours after admission to the hospital. ART regimen will be decided according to each subject´s the clinical characteristics
45821|NCT03825523|Other|cART|After group assignment, ART is started at the discretion of the attending physician. ART regimen will be decided according to each subject´s the clinical characteristics
45822|NCT03825510|Radiation|Stereotactic Body Radiotherapy|"All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to <=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy."
45823|NCT03825497|Other|Promotion of activity during and after hospitalization|1) a welcome folder encouraging physical activity; 2) encouragement to use a walk path established in the ward; 3) encouragement to use posters containing exercise suggestions;4) prescription of a walk-plan for in-hospital use; 5) encouragement to pick up clothes and beverages by oneself; 6) prescription of a walk-plan at discharge for at home use 7) follow-up on walk plan after discharge by municipality
45824|NCT03825484|Drug|Erdafitinib|Participants will start erdafitinib 8 milligram (mg) (formulated as tablets with 3 mg, 4 mg and 5 mg dosages) orally once daily until disease progression, intolerable toxicity, withdrawal of consent or decision by the doctor to discontinue treatment. Dose will be up-titrated to 9 mg based on serum phosphate levels and if there is no drug-related toxicity.
45825|NCT03825471|Procedure|electrotherapy|Cranial electrotherapy stimulation
45826|NCT03825471|Drug|Opioid Anesthetics|consumption of opioids during general anesthesia
45827|NCT03825471|Procedure|colon cancer surgery|laparoscopic colon cancer surgery
45828|NCT03825458|Other|Blood sampling|Blood sampling at each clinical follow-up visit.
45829|NCT03825445|Drug|GnRHa (Fertipeptil 0.1mg)|Two doses of GnRH-a (Fertipeptil 0.1mg x 2 vial) for ovulation trigger after ovarian stimulation for IUI.
45830|NCT03825445|Drug|hCG (Pregnyl 5000IU)|hCG (Pregnyl 5000IU) for ovulation trigger after ovarian stimulation for IUI.
45831|NCT03825380|Drug|Bimatoprost|Eyedrops
45832|NCT03825380|Drug|Lumigan®|Eyedrops
45833|NCT03825367|Drug|Nivolumab|"The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg."
45834|NCT03825367|Drug|5-azacytidine|75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
45835|NCT03825354|Behavioral|BIC|World Health Organization, WHO, Brief Intervention and Contact (BIC)
45836|NCT03825341|Drug|Hydroxyurea|Drug: Hydroxyurea oral liquid dose administered will be 20mg/kg/day or infants's usual daily dose.
45837|NCT03825341|Drug|Hydroxyurea Oral Capsule|Drug: Hydroxyurea both a sprinkle formulation and capsules (Droxia 200mg) administered on 2 separate occasions.
45838|NCT03825328|Drug|Albumin-bound paclitaxel|Albumin-bound paclitaxel is paclitaxel formulated as albumin-bound nanoparticles with a mean particle size of approximately 130 nanometers.
45839|NCT03825328|Drug|S-1|a combination preparation of tegafur, gimeracil, and oteracil potassium
45840|NCT03825328|Drug|Oxaliplatin|The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
45841|NCT03825328|Drug|Gemcitabine|Gemcitabine is a synthetic pyrimidine nucleoside prodrug—a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms.
45842|NCT03825315|Biological|DAXI for Injection: LOW Dose|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
45843|NCT03825315|Other|DAXI for Injection: HIGH Dose|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
45844|NCT03825315|Other|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
45845|NCT03825302|Diagnostic Test|Methacholine challenge|Methacholine inhalation challenge will be administered to both male and females with asthma
45846|NCT03825302|Diagnostic Test|Mannitol challenge|Mannitol inhalation challenge will be administered to both male and females with asthma
45847|NCT03825289|Drug|Hydroxychloroquine|Given PO
45848|NCT03825289|Drug|Trametinib|Given PO
45849|NCT03825276|Dietary Supplement|Mango consumption|Daily consumption of 280 g of frozen mangos during 8 weeks. The daily dose in equivalent to a 2-cups serving.
45850|NCT03825263|Device|Intermittent Pressure Compression|The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
45851|NCT03825250|Drug|Sodium Valproate|Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
45852|NCT03825237|Diagnostic Test|Polysomnography|The polysomnography (referred to as type I) allows assessing several sleep physiologic parameters (eg, EEG, electrooculogram, electromyogram, electrocardiogram, airflow, respiratory effort, oxygen saturation), whereas audio-video recording enables documenting tooth-grinding sounds and distinguishing between rhythmic masticatory muscle activity (RMMA) and orofacial (eg, swallowing) and other muscular activity (eg, head movements) during sleep. Based on the RMMA index (number of episodes per hour of sleep), sleep bruxism is diagnosed when RMMA episodes are greater than or equal to 2 (low-frequency SB, mild bruxism) or RMMA episodes are greater than or equal to 4 (high-frequency SB, severe bruxism)
45853|NCT03825224|Procedure|Diagnostic Test: Myostrain|This test measures the contraction of the heart muscle in one to three heartbeats per plane. It's a pulse sequence that produces images that reveal the underlying contraction fo the muscle of a healthy heart and associated weaknesses in case of disease.
45854|NCT03825211|Procedure|Continuous suture in the perineals lesions|A continuous suture of the vagina, muscle and skin is performed continuously, without knotting or cutting the suture thread.
45855|NCT03825211|Procedure|Discontinuous suture in the perineals lesions|Suture the muscle independently of the vagina and independently of the skin
45856|NCT03825198|Procedure|Erector spinae plane block|Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
45857|NCT03825198|Drug|Levobupivacaine 0,25%|20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
45858|NCT03825198|Procedure|spine fusion|fusion of lumbar vertebral body on 1 or two levels
45859|NCT03825198|Drug|NaCL 0,9%|20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
45860|NCT03825198|Drug|Sufentanil|opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
45861|NCT03825198|Drug|propofol|induction agent for general anaesthesia ( 2-3 mg/kg)
45862|NCT03825198|Drug|Rocuronium Bromide|muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
45863|NCT03825198|Drug|sevoflurane|inhalation aesthetic used for the maintenance of general anaesthesia
45864|NCT03825198|Drug|paracetamol|postoperative drug for analgesia ( 1 gram 4/day)
45865|NCT03825198|Drug|Ketorolac|non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
45866|NCT03825198|Drug|morphine pca|postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
45867|NCT03825198|Drug|Dexamethasone|drug given during general anaesthesia to prevent postoperative nausea
45868|NCT03825198|Drug|Morphine|loading dose morhine 0,1 mg/kg at the end of surgery
45869|NCT03825185|Procedure|Transcervical Thymectomy|Transcervical Thymectomy. All transcervical thymectomies were performed with an 8 cm transversal cervicotomy was performed approximately 2 cm above the sternal notch. Musculocutaneous flaps were developed up to the thyroid cartilage and the suprasternal notch. Strap muscles were split in the middle and retracted laterally. The upper horns of the thymus were exposed and were freed up to the level of the innominate vein. All tributary veins were suture ligated. A sternal retractor was then placed to retract the sternum upward until the patient was nearly lifted off the table. The rest of the Thymus was dissected, from the pericardium and the pleura. Care was specially taken to remove as much fatty tissue adjacent to the thymus as possible preserving the phrenic nerves.
45870|NCT03825185|Procedure|Transsternal Thymectomy|Transsternal Thymectomy. A standard formal median sternotomy was carried out. The sternum was retracted laterally using an automatic retractor. All thymic tissue with the adjacent adipose tissue was removed starting with the inferior horns of the thymus. Thymic vessels were ligated and dissection was continued until the upper horns could be separated from the thyroid. A mediastinal tube was placed before closing the sternum and was kept in close suction for 2 to 3 days.
45871|NCT03825172|Diagnostic Test|Caudal Epidural Ultrasonography|Ultrasonographic Measurement
45872|NCT03825159|Device|Spinal Orthosis with an Integrated System of Electric Surface Stimulation and Heat Sensing|The electrical stimulation technology integrated with the total contact spinal orthosis combines the external correction forces on the spinal skeleton from the passive orthosis with the muscle forces at the lateral trunk from the stimulation process.
45873|NCT03825159|Device|spinal orthosis|The ventrally opened total contact spinal orthosis will be designed and made of Copolymer and Aliplast. Correcting pressure points have to use the pressure pads at relevant points.
45874|NCT03825146|Biological|Autologous Multi-lineage Potential Cells (AMPC)|"Multi-lineage potential cells which were induced to de-differentiate from somatic leukocytes from peripheral blood. Cells are autologous with respect to the patient, and are prepared in a suspension and administered via intravenous infusion.~An estimated average of 1 x 10^8 (0.5 to 5.0 x 10^8) cells/per suspension(275 to 450mL) will be infused into the patient via intravenous infusion on day 5. Cell counts depend on yield of initial leukocyte harvest on day 0."
45875|NCT03825133|Procedure|Bone Marrow Aspirate Concentrate|Bone marrow ( 100 ml) is aspirated from proximal tibia, concentrated in Arthrex Angel Centrifuge, and after concentration 6 ml of BMAC is injected in the knee
45876|NCT03825133|Procedure|Leukocyte Rich Platelet Rich Plasma|Blood sample is taken ( 100 ml), centrifuged in Arthrex Angel Centrifuge and after double spinning process about 6 ml of PRP is injected in the knee
45877|NCT03825133|Drug|Hyaluronic Acid|Three injections of Cartinorm (1% Sodium Hyaluronat (20mg/2 ml) by Goodwill Pharma) is injected in the knee weekly
45878|NCT03825107|Other|patching|covering the fellow eye with an eyepatch to force use of the amblyopic eye
45879|NCT03825107|Other|Dichoptic videos|watching contrast-rebalanced dichoptic videos to allow the two eyes to work together
45880|NCT03825094|Device|DyeVert™ Contrast Reduction Systems|Osprey Medical DyeVert™ Contrast Reduction Systems (DyeVert Systems) provide fluid pathway resistance modulation such that excess contrast media (CM) (i.e. CM that is not needed for diagnostic or therapeutic purposes) is minimized in the patient's vasculature and total contrast media volume (CMV) reduction occurs, while maintaining adequate image quality.
45881|NCT03825081|Drug|Brimonidine, pilocarpine|"1 drop of pilocarpine (0.5%)~1 drop of brimonidine (0.2%)"
45882|NCT03825068|Procedure|ESP Block|20 ml of lacal anaesthetics will be placed below the erector spinae muscle under ultrasound guide
45883|NCT03825068|Drug|general anesthetic|patient receive general anaesthetic only
45884|NCT03825042|Dietary Supplement|A mix of bioactive natural compounds|A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
45885|NCT03825042|Dietary Supplement|Placebo|Inactive compound in oral tablets
45886|NCT03825029|Procedure|Pillow|A pillow to lessen the angle differences between hips so that the acetabular component can be placed in an optimal position.
45887|NCT03825016|Drug|Lidocaine Hydrochloride|Lidocaine infusion on hystroscopic media during office hystroscopy
45888|NCT03825016|Drug|Diclofenac Sodium|Oral Diclofenac Sodium
45889|NCT03824990|Behavioral|Quality improvement of management of neonatal jaundice|During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
45890|NCT03824977|Diagnostic Test|Six minutes stepper test|The patient carries out the two tests before surgery then we observe the occurrence of postoperative complications
45891|NCT03824964|Biological|Anti-CD19/CD22 CAR NK Cells|Total dose of 50-600 thousand /kg Anti-CD19/CD22 CAR NK cells will be administered at day0
45892|NCT03824951|Biological|Anti-CD19 iCAR NK Cells|Anti-CD19 iCAR NK Cells injection
45893|NCT03824938|Drug|Aspirin 650mg Oral Capsule|A 650mg dose of aspirin is administered in the laboratory one hour before participant completes a maximal exercise test.
45894|NCT03824938|Drug|Acetaminophen Tab 650mg|A 650mg dose of acetaminophen is administered in the laboratory one hour before participant completes a maximal exercise test.
45895|NCT03824938|Other|Placebo|A placebo pill is administered in the laboratory one hour before participant completes a maximal exercise test.
45896|NCT03824925|Drug|Placebo oral Zinc capsule|Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
45897|NCT03824925|Drug|Zinc Sulfate 220 MG|Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
45898|NCT03824912|Drug|Ketoconazole Cream 2%|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
45899|NCT03824912|Drug|Ketoconazole Cream 2% (G&W Laboratories Inc.)|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
45900|NCT03824912|Drug|Placebo|Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
45901|NCT03824899|Diagnostic Test|Blood concentration check|Blood concentration check：the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion
45902|NCT03824886|Other|Implementation of skin care algorithm|Implementation of structured and standardized skin care regimen
45903|NCT03824873|Procedure|Internal iliac artery ligation|Internal iliac artery ligation and cesarean hysterectomy
45904|NCT03824873|Procedure|cesarean hysterectomy|cesarean hysterectomy
45905|NCT03824860|Behavioral|Yoga|"Participants will attend at least one class per week at the Zakim Center and practice one online yoga video class at home on their own per week, over eight weeks~Participants may choose to attend Flow Yoga and/or Chair Flow Yoga classes at the Zakim Center. These classes will be videotaped and made available to participants electronically.~Classes consist of:~guided breathing exercises,~upper and lower extremity stretching~structured postures and movements to improve balance and strength"
45906|NCT03824847|Drug|Clarithromycin 250 MG|Clarithromycin 1 tablet (250mg) twice daily for three days
45907|NCT03824847|Drug|Placebos|Placebo group: (identical-looking) placebo 1 tablet twice daily for three days
45908|NCT03824834|Drug|Exercise training with morphine|Immediate-release oral morphine (syrup, 0.1 mg/kg body mass to a maximum dose of 10 mg) prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions (three times per week for five weeks) on an electronically braked bike, supervised by a trained exercise specialist. Exercise sessions will be individualized based on participants' peak power output (60% PPO) determined from incremental exercise testing, and progressed to ensure the participant is exercising at a breathlessness intensity rating of between 3-5 Borg CR10 scale units and can complete at least 20-min of continuous cycling. Exercise duration will be increased in 5-min intervals up to 40-min. Thereafter, exercise intensity will be increased by 5-15% of baseline PPO.
45909|NCT03824834|Other|Exercise training with placebo|Diluted simple syrup prepared in 250 mL of orange juice 30-min prior to each exercise session. Participants will complete exercise training sessions as per the experimental group.
45910|NCT03824821|Other|No intervention|No intervention
45911|NCT03824808|Drug|Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution|Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
45912|NCT03824808|Drug|0.9% Sodium Chloride Injection|Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
45913|NCT03824795|Drug|MGB-BP-3|MGB-BP-3
45914|NCT03824782|Device|Phototherapy Mask|A standard phototherapy mask (Biliband, Natus, Pleasanton, California, USA) applied over the eyes after instillation of mydriatic drops. The masks will be removed 4 hours after the eye examination, when the pharmacologic effect of the mydriatic agents would have subsided.
46055|NCT03823742|Other|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT): Study treatments for the child will be conducted by a psychologist or master's level therapist. Therapists will be provided with a standardized protocol for each session . CBT treatment will be given over 1 hour, once a week, for three weeks .
45915|NCT03824769|Behavioral|Weight Loss Maintenance + Healthy Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will be asked to read short passages related to nutrition and a healthy lifestyle through our study website twice a day for the duration of treatment.
45916|NCT03824769|Behavioral|Weight Loss Maintenance Treatment + Future Thinking|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive a 4-month behavioral weight maintenance intervention consisting of 7 sessions that focus on evidence-based weight management strategies focused on diet, exercise, and behavioral skills. In this treatment, participants will create descriptions of upcoming positive events and will be asked to read short passages through our study website at least twice a day for the duration of treatment.
45917|NCT03824756|Other|NGO supported GMP program|An International NGO has signed a contract with Government to support in implementing the growth Monitoring and Promotion (GMP) program. This program will be implemented at Community clinics. It will ensure the sustainability of community clinics in the selected areas through capacity building and follow up with community groups, community support groups, and Government Health and Family Planning service providers.
45918|NCT03824756|Other|Non-supported GMP program|This is control arm of the study. In this arm, there will be Government's usual GMP program implemented at community clinics without any NGO support.
45919|NCT03824743|Drug|Lactate Ringer|Patients managed with Lactate Ringer and obstetric hemorrhage
45920|NCT03824743|Drug|Plasma-lyte|Patients managed with Plasma-Lyte and obstetric hemorrhage
45921|NCT03824730|Device|Stenting of the Common and/or External Iliac Arteries|"Stenting of the Common and/or External Iliac Arteries was performed in the angiographic suite. Under local anesthesia, arterial access was obtained through standard percutaneous puncture of the common femoral artery, brachial approach, or simultaneous brachial and femoral approach.~Iliac lesion crossing was achieved through intraluminal or subintimal manner depending on the behavior of the lesion intraoperatively.~Predilatation of the occlusion before stent deployment was performed at the discretion of the operator.~Balloon-expandable stents were used for proximal, ostial lesions, whereas self-expanding stents were deployed in all other lesions.~Both stents were used in long lesions involving heavily calcified common iliac arteries."
45922|NCT03824717|Drug|Dose of ropivacaine|Biased coin design up and down dose finding study of 0.5% ropivacaine to achieve a successful infraclavicular brachial plexus block
45923|NCT03824704|Drug|Rucaparib|Oral rucaparib will be administered twice daily
45924|NCT03824704|Drug|Nivolumab|IV nivolumab will be administered once every 4 weeks
45925|NCT03824691|Drug|Cabozantinib|cabozantinib 40 mg orally once daily
45926|NCT03824691|Drug|Durvalumab|1500 mg durvalumab (MEDI4736) IV infusion every 28 days
45927|NCT03824678|Drug|CC-220|CC-220
45928|NCT03824665|Drug|Nalbuphine Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group N:(Nalbuphine group)1 ml saline containing 4mg nalbuphine used instead of normal saline"
45929|NCT03824665|Drug|Fentanyl Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline"
45930|NCT03824665|Drug|Control Group|"All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline."
45931|NCT03824652|Other|walnuts|2 ounces of walnuts daily for 4-10 weeks
45932|NCT03824652|Other|usual diet|Subject continues usual diet
45933|NCT03824652|Other|phone counseling with dietitian|Weekly calls with dietitian
45934|NCT03824639|Behavioral|Structured exercise|Exercise instruction and encouragement
45935|NCT03824639|Behavioral|Health Education|Provision of general information about a variety of health topics
45936|NCT03824626|Diagnostic Test|TEVAR patients|Computed Tomography Angiography (CTA) will be performed using a 16-slice unit before and after intravenous administration of 100 mL of iodinated contrast material. Phase contrast-Magnetic Resonance (pc-MRI) will be performed using a 1.5-T unit with 40-mT/m gradient power and a four-channel cardio-thoracic coil. ECG-triggered, free-breathing through plane, and in-plane pc-MRI sequences will be performed for phase-velocity mapping of aortic and branches flow. Ad hoc processing of preoperative CTAs, based on 3D multiplanar reconstruction, will be performed with 3Mensio Vascular software 8.0® (3Mensio Medical Imaging B.V.), which provides specific functions for automatic measurements.
45937|NCT03824613|Diagnostic Test|Urinary miRNA|MiRNA detection in urine
45938|NCT03824600|Diagnostic Test|Fractional Flow Reserve Motorized Pullback|A pullback device (Volcano R 100, San Diego CA, USA), adapted to grip the coronary pressure wire (PressureWire X, St Jude Medical, Minneapolis, USA), set at a speed of 1 mm/sec to pullback the pressure-wire until the tip of the guiding catheter during continued pressure recording.
45939|NCT03824587|Drug|Tenapanor|Active Drug
45940|NCT03824587|Drug|Placebo|Inactive Drug
45941|NCT03824574|Device|Clear Mandibular Advancement Appliance|Clear Mandibular Advancement Appliance for treatment of skeletal class II patients with retrognathic mandible
45942|NCT03824561|Drug|Vedolizumab|Vedolizumab IV infusion
45943|NCT03824548|Other|this is non-intervention study, there is no intervention drug or device in this study.|this is exactly a non-interventional study, no intervention during the whole study.
45944|NCT03824535|Procedure|Computed Tomography|Undergo PET/CT
45945|NCT03824535|Drug|Fludeoxyglucose F-18|Given IV
45946|NCT03824535|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
45947|NCT03824535|Procedure|Positron Emission Tomography|Undergo PET/CT
45948|NCT03824522|Biological|ADYNOVATE|Pegylated recombinant human factor VIII
46701|NCT03818919|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
45949|NCT03824509|Other|Chart Review|"Study staff at PBMC (Cardiologist and two clinical researchers) will be responsible for maintaining all data related to this study in REDCap. Patient data to be included in this secondary data analysis will originate from MMC and PBMC.~Case-patient data to be included from MMC will be identified by an EPIC data request from Enterprise Reporting. The elements of the data request will be patients who have had a stroke or TIA, atrial fibrillation, and a transthoracic echocardiogram at MMC from 2014-2017."
45950|NCT03824496|Diagnostic Test|Cranial Accelerometry Measurement|Measuring the HeadPulse using cranial accelerometry
45951|NCT03824483|Drug|Zanubrutinib|zanubrutinib (160mg by mouth BID)
45952|NCT03824483|Drug|Obinutuzumab|"obinutuzumab (1000mg IVPB on Days 1*, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 through 8) starting on Cycle 1 (28-day cycles). * On Cycle 1, obinituzumab will be administered in split dose at 100mg IVPB on Day 1 and 900mg IVPB on Day 2 in patients at increased risk for IRR (ALC >25,000 cells/ul or baseline lymph nodes >5 cm diameter)."
45953|NCT03824483|Drug|Venetoclax|Venetoclax will be added to the regimen starting on Cycle 3, and will be incorporated into the regimen using the 5-week ramp-up schedule to mitigate the risk of tumor lysis syndrome (beginning at 20mg and gradually increasing to 400mg), and venetoclax will be administered a ta fixed dose level of 400mg by mouth daily of 28-day cycles thereafter.
45954|NCT03824457|Drug|Rheosorbilact®|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
45955|NCT03824457|Drug|Ringer lactate|Rheosorbilact® is administered as a part of the infusion therapy intravenously (with speed 40-60 drip per minute) at a dose of not more than 400 ml (6 to 7 ml/kg body weight per 24 hours) for 3 days.
45956|NCT03824444|Device|PODS|Percutaneous Osseointegrated device for transhumeral patients
45957|NCT03824431|Diagnostic Test|Endoscopic esophageal biopsies|
45958|NCT03824418|Procedure|Surveillance colonoscopy with chromoendoscopy|Surveillance colonoscopy with chromoendoscopy
45959|NCT03824405|Drug|BTX 1204|BTX 1204 liquid formulation
45960|NCT03824405|Drug|Vehicle|Vehicle liquid formulation
45961|NCT03824392|Biological|ATYR1923 1.0 mg/kg or placebo|ATYR1923 participants to receive ATYR1923 1.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks
45962|NCT03824392|Biological|ATYR1923 3.0 mg/kg or placebo|ATYR1923 participants to receive ATYR1923 3.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks
45963|NCT03824392|Biological|ATYR1923 5.0 mg/kg or placebo|ATYR1923 participants to receive ATYR1923 5.0 mg/kg IV every 4 weeks; Placebo participants to receive placebo IV every 4 weeks
45964|NCT03824379|Dietary Supplement|Magnesium citrate|magnesium citrate equivalent 20-30 mmol elemental magnesium
45965|NCT03824379|Drug|Antidiabetic|insulin or oral hypoglycemics
45966|NCT03824366|Device|Volumetric MR imaging|This will most frequently be supine with arms positioned so not in the way of treatment beams.
45967|NCT03824366|Radiation|Radiation therapy|-Standard of care
45968|NCT03824353|Behavioral|Social Intelligence Training|The social intelligence training consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that social intelligence training is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
45969|NCT03824353|Behavioral|The Healthy Living Program|A placebo condition delivered online which presents health-related information only.
45970|NCT03824340|Drug|Doxycycline before ICSI|Extra medication (Doxycycline ) group before ICSI :,women who will receive more medications (Doxycycline ) before starting the ICSI process
45971|NCT03824327|Procedure|Blood Oxygen Level Dependent Imaging|Undergo BOLD fMRI
45972|NCT03824327|Drug|Papaverine Hydrochloride|Given IV
45973|NCT03824327|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
45974|NCT03824314|Drug|Midazolam|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml midazolam (2 mg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
45975|NCT03824314|Drug|Fentanyl|2 ml of 0.5% isobaric levobupivacaine (10 mg) plus 0.5 ml fentanyl (25 μg)will be given intrathecally in L3 and L4 space with 25 gauge Quincke spinal needle via midline approach in sitting position. On free flow of cerebrospinal fluid, study drug will be injected intrathecally . Patients will immediately turn to supine position
45976|NCT03824301|Device|Volume controlled ventilation|Changing modes of ventilation during cardiopulmonary bypass
45977|NCT03824301|Device|Pressure controlled ventilation|Applying pressure controlled ventilation during cardiopulmonary bypass Period
45978|NCT03824288|Diagnostic Test|Intraoral ultrasound|The ultrasound transducer (either Hockey Stick or Burr-Hole N11C5s transducer from BK Ultrasound) is placed on the palatoglossal arch on the affected side and sweeped from the cranial to caudal end of the tonsil to look for an abscess cavity identified as a hypoechoic area with ill-defined margins.
45979|NCT03824288|Procedure|The landmark technique|A 14G needle aspiration is inserted blindly in the superior tonsil pol where pus aspiration is attempted.
45980|NCT03824275|Drug|18F- DCFPyL PET/CT|A CT scan using a radioactive marker to better image tumors
45981|NCT03824262|Device|HICO-VARIOTHERM 550|Warming during perioperative period.
45982|NCT03824262|Device|Mistral-Air Plus forced air warming device|Warming during perioperative period.
45983|NCT03824249|Diagnostic Test|Indirect Calorimetry|Performance of indirect calorimetry in Canopy mode.
45984|NCT03824236|Biological|RTS,S/AS01E (SB257049)|Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.
45985|NCT03824223|Diagnostic Test|Hypoxic challenge test|Physiological response to 15% ambient oxygen monitored.
45986|NCT03824210|Other|App|Mobile phone app
45987|NCT03824197|Other|EVOO|Extra-virgin olive oil that is rich with oleocanthal and other phenols.
45988|NCT03824197|Other|OO|Olive oil low in oleocanthal and other phenols.
45989|NCT03824184|Procedure|manipulation of endometrium|Manipulation of endometrium with saline
45990|NCT03824171|Drug|Raloxifene 60mg/Cholecalciferol 800IU|Raloxifene 60mg/Cholecalciferol 800IU tablet
45992|NCT03824158|Behavioral|In-person, facilitated advance care planning|The facilitator will contact the patient to schedule the ACP discussion. ACP discussions will be led by a nurse or social worker with supportive oncology experience who has been trained as a Respecting Choices facilitator, include the patient's caregiver when available, last 45-60 minutes, and be held in a private location at or near the patient's oncology clinic. Facilitators will use a structured interview tool as a discussion roadmap and provide guidance in choosing a medical decision maker, exploring serious illness understanding and experiences, identifying goals and values, and making future treatment decisions. Facilitators will provide a copy of a written advance directive, assist with completion when appropriate, and make recommendations for communicating goals and sharing written preferences.
45993|NCT03824158|Behavioral|Web-based advance care planning|Instructions for accessing and using the PREPARE website will be shared with participants upon randomization. Patients and their caregivers review the 5 steps of PREPARE (approximately 10 minutes per step) and create an action plan for each step. The PREPARE website includes a link to a written advance directive that participants are able to complete. The PREPARE website can be reviewed on a home computer or on a tablet in the oncology practice.
45994|NCT03824145|Behavioral|Lifestyle Intervention|The lifestyle intervention is a 12-week cognitive-behavioral intervention that addresses key changes in diet and PA behaviors to promote positive body composition changes.
45995|NCT03824132|Behavioral|Improvisational comedy classes|6 consecutive improvisational comedy classes
45996|NCT03824132|Behavioral|Waitlist control|After 10 week waitlist control, subjects will complete 6 consecutive improvisational comedy classes.
45997|NCT03824119|Drug|Ibuprofen 600 mg|Standard postpartum care (including administration of NSAIDs)
45998|NCT03824119|Other|Standard Postpartum Care without NSAIDs|NSAID administration will be withheld from this group.
45999|NCT03824106|Behavioral|Socialization|Social interaction is associated with better mental and physical health, and evidence suggests that group versus individual engagement may offer unique cognitive benefits for older adults as well as peer reinforcement and encouragement.
46000|NCT03824106|Behavioral|Group Exercise|A recent meta-analysis suggests 180 min/week of exercise (with a high challenge to balance) is most effective for fall prevention. Combined strength and endurance training performed at a moderate weekly frequency (i.e., two times per week) may promote marked gains on muscle hypertrophy, strength and power gains in frail older adults. Balance training is a key component of successful exercise programs for vulnerable older adults.
46001|NCT03824106|Combination Product|Nutrition and Medication review|"Nutrition review: Conduct nutritional screening flow and review any questions, provide some additional counseling/coaching at follow-up visits. Protein supplements will be provided to all participants unless contraindicated.~Medication review: Review/update current medication list and forward the list and medical history to the consultant study pharmacist. The study pharmacist will utilize TAPER and Start /STOPP criteria (based on a medication review process we have piloted in our Fit Joints study) and provide recommendations to the participant's family physician. Study geriatricians will be listed as contacts on the primary care provider recommendations and available for consultation."
46002|NCT03824106|Dietary Supplement|Protein Supplement|As piloted in our Fit Joints Study, the protein supplement (each serving) contains 350 kcal, 20-gram protein, 1.5 g β-Hydroxy β-Methylbutyrate (HMB), and participants are advised to take this with a meal or within 3 hours of exercise on activity days. A study nurse (trained in geriatrics) will schedule Arm 3 participants for an initial assessment appointment with two more follow-up appointments (over the first couple of months, as required). Working in consultation with the study geriatricians and pharmacist, as required, the multi-modal arm nurse assessment will include: 1) Review the participants' relevant medical history building on the screening intake form completed by primary care provider.
46003|NCT03824106|Dietary Supplement|Vitamin D|1000 IU of oral vitamin D
46004|NCT03824093|Behavioral|AFIX Only|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates.
46005|NCT03824093|Behavioral|AFIX+ Provider Communication Training|The intervention will include an in-person AFIX assessment of the practice's adolescent vaccination rates along with communication training for providers and poster and brochure displays.
46006|NCT03824080|Drug|Bemcentinib|"Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total)."
46007|NCT03824067|Diagnostic Test|Point of Care Early Infant Diagnosis|HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
46008|NCT03824067|Diagnostic Test|Standard of Care Early Infant Diagnosis|Conventional laboratory based EID testing
46009|NCT03824054|Procedure|colorectal resection|Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
46010|NCT03824041|Dietary Supplement|Aronia full spectrum - half dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
46011|NCT03824041|Dietary Supplement|Aronia full spectrum - full dose|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
46012|NCT03824041|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
46013|NCT03824028|Device|Clareon® IOL AutonoMe™ automated preloaded delivery system|Disposable injector preloaded with the Clareon IOL for precise IOL insertion during cataract surgery
46014|NCT03824015|Behavioral|Keeping Adults Physically Active (KAPA) intervention|The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.
46087|NCT03823495|Other|12-week PAP|It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
46702|NCT03818919|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
46015|NCT03824015|Other|Usual Care|Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
46016|NCT03824002|Drug|Dulaglutide|Diabetes therapy with dulaglutide and various combinations of insulin, metformin, glinides
46017|NCT03824002|Drug|Aspart insulin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
46018|NCT03824002|Drug|Glargine|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
46019|NCT03824002|Drug|Metformin|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
46020|NCT03824002|Drug|Repaglinide|Diabetes therapy with various combinations of insulin, metformin, glinides but without dulaglutide
46021|NCT03823989|Drug|Promitil|The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL.Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third confirmatory cohort (n=6) will be recruited and will be treated with the same dose as that administered to Cohort 2.
46022|NCT03823989|Radiation|EBR|A 10-fraction course of EBR (3 Gy/fraction), initiated 1-3 days after the first PROMITIL dose and completed within a 2-week period.
46023|NCT03823976|Other|Types of the dental procedures in general anaesthesia|Analysis of the mean number of preventive, prophylactic, therapeutic and rehabilitation procedures
46024|NCT03823963|Combination Product|Mepilex® Border dressing|Soft silicone self-adherent dressing (5-layers)
46025|NCT03823963|Other|Standard care|The control group will receive pressure ulcer prevention standard care
46026|NCT03823950|Drug|Granulocyte Colony-Stimulating Factor|Begin G-CSF 72 hours following chemotherapy
46027|NCT03823937|Other|Sniffin' Sticks test and Taste strips|"Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth."
46028|NCT03823924|Procedure|Bone mineral density (BMD)|"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."
46029|NCT03823911|Drug|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|All approved direct-acting antivirals for hepatitis C will be used as the intervention.
46030|NCT03823911|Procedure|Cardiac MRI|Cardiac MRI to assess for myocardial function and fibrosis
46031|NCT03823898|Behavioral|Supervised exercise|Two supervised exercise sessions per week from months 4 to 16
46032|NCT03823898|Behavioral|Lifestyle intervention from baseline to 4 months|Lifestyle intervention from baseline to 4 months
46033|NCT03823898|Behavioral|Monthly behavioral sessions|Monthly behavioral sessions consisted of lifestyle interactive sessions will take place monthly and covered and followed contents that were addressed during the first 4 months of the study
46034|NCT03823885|Other|e-cigarette|use e-cig for 30 minutes
46035|NCT03823885|Other|empty (-cigarette sham control)|use empty e-cig (sham control)
46036|NCT03823872|Other|Time restricted feeding|Time restricted feeding= consume food only from 12:00pm-8:00pm
46037|NCT03823872|Other|Normal feeding|Normal feeding= consume food per normal schedule
46038|NCT03823859|Diagnostic Test|Indirect calorimetry|Resting energy expenditure
46039|NCT03823859|Diagnostic Test|Dual energy X-ray Absorptiometry (DXA)|Body composition
46040|NCT03823859|Diagnostic Test|Blood sampling|fT4, fT3, TSH, HDL, LDL, triglycerides, cholesterol, HbA1c, Glucose Thyroid panel
46041|NCT03823846|Drug|Routine Dezocine injection|Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
46042|NCT03823846|Drug|Adjusted Dezocine injection|Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
46043|NCT03823846|Drug|Routine Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.
46044|NCT03823846|Drug|Adjusted Dynastat or Flurbiprofen Axetil jinjection|Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.
46045|NCT03823846|Other|postoperative rehabilitation|Rehabilitation was conducted at 8:00am and 2:00pm.
46046|NCT03823846|Drug|normal analgesia pump administration|Dose of analgesia pump was added if needed.
46047|NCT03823846|Drug|adjusted analgesia pump administration|Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
46048|NCT03823820|Other|Bioimpedance Analyser|Bio-electrical impedance analysis (BIA) measures whole body (or regional) impedance by means of an electric current transmitted at different frequencies.
46049|NCT03823807|Drug|SH-1028|Oral,100mg or 200mg ,QD, fasted
46050|NCT03823794|Other|No intervention|Observational analysis of usual care only
46051|NCT03823781|Drug|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo.
46052|NCT03823781|Drug|Normal saline|The study intervention is an intravenous infusion of milrinone or placebo.
46053|NCT03823768|Drug|Envarsus|Subjects in this group will take Envarsus daily for 6 months of treatment (goal 24 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
46054|NCT03823768|Drug|Tacrolimus Immediate release|Subjects in this group will take Tacrolimus immediate release for 6 months of treatment (goal 12 hour trough: 3-10 ng/mL) +/- adjunctive agent and prednisone.
46703|NCT03818919|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
46056|NCT03823742|Other|Low FODMAP Diet|Low FODMAP Diet Condition: Subjects will receive detailed education by a dietitian about following a low FODMAP diet including a definition of FODMAPs, how to select low FODMAP foods, and how to read food labels to identify FODMAPS. The dietitian will contact the family for 1 hour, once a week, for three weeks.
46057|NCT03823729|Device|Elosan Cabin|The Elosan Cabin is a closed, electrically insulated, biocompatible cabin for the short-term application of electrostatic high voltage. Patients assigned to the Group A will have 8 sessions in the Elosan cabin, with an interval of 3 to 4 days between sessions.
46058|NCT03823703|Drug|CORT118335|CORT118335 600mg, and Placebo tablets for oral dosing
46059|NCT03823690|Device|EUS-guided gastrojejunstomy|As listed in the arms description
46060|NCT03823690|Device|The pyloro-duodenal stent|As listed in the arms description
46061|NCT03823677|Procedure|Hypoxia|hypoxia
46062|NCT03823664|Diagnostic Test|Cardiorespiratory Fitness|Maximal symptom limited cardiopulmonary exercise test used assessment of cardiorespiratory fitness. For pulmonary function spirometry test and maximal respiratory pressures assessed.
46063|NCT03823651|Behavioral|Interval training|Patients will be asked to complete up to 3 x 30-minute structured high intensity interval training aerobic exercise sessions/week. For the first session, patients will come to the Duke Center for Living for in person evaluation and training. After the initial training session in person, a subsequent training session will take place at the patient's home via iPad/iPhone videoconference using a device provided to the patient to provide additional support and the opportunity to answer questions. Subsequent sessions will be done independently by patients, but study staff will be available via iPad/iPhone if questions arise.
46064|NCT03823651|Behavioral|Psychiatric consult|Subjects who score below threshold on the PHQ2/PHQ9, PC-PTSD/PCL-5, PROMIS-Depression and/or PROMIS-Anxiety assessments will be referred to a psychiatrist for follow up.
46065|NCT03823651|Behavioral|Nutrition/diet evaluation|PG-SGA, ASA24, food group tracking Assessments and Vit D, Vit A, albumin, prealbumin, lipids, A1c levels will be used to provide weekly feedback for one month
46066|NCT03823651|Behavioral|Referral to Social Worker|Subjects who score below threshold on the PROMIS-Emotional Support and/or PROMIS-Social Isolation assessments will be referred to a social worker for follow up
46067|NCT03823638|Dietary Supplement|Oral D-Mannitol of Placebo|Gradually increased doses of oral D-Mannitol of Placebo (Dextrose monohydrate)
46068|NCT03823625|Drug|Nivolumab plus Ipilimumab|Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.
46069|NCT03823625|Drug|Platinum-based chemotherapy plus Nivolumab|"Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days."
46070|NCT03823612|Drug|Clinpro Tooth Creme|The participant will be instructed to Place a pea-sized amount of Clinpro Tooth Crème on a soft bristled toothbrush and brush teeth for at least two minutes then after brushing the patient will rinse out his mouth with water and spit out. It will be used twice daily at first in the morning and before sleep.
46071|NCT03823612|Drug|GC tooth mousse|The participant will be instructed to squeeze a small amount of GC Tooth Mousse out onto a clean finger. A cotton tip, swab or custom tray are suitable application methods as it will Applied directly onto his tooth surfaces and leave undisturbed for three minutes then he will be instructed to Spread any residual crème around the mouth with his tongue and hold for a further one to two minutes then the participant will expectorate thoroughly and if possible he should avoid rinsing. Any GC Tooth Mousse remaining in the mouth can be left to gradually dissipate. The participant will be instructed to avoid eating or drinking for 30 minutes following application.
46072|NCT03823599|Behavioral|Mobile chat-based instant messages|Subjects in the active arm study will receive 5-minute face-to-face ABI, alcohol leaflet from Department of Health (DH) plus continuous interactive chat-based intervention for 1 month as an extension of alcohol brief intervention at baseline
46073|NCT03823599|Behavioral|Alcohol brief intervention|The Control group will receive face-to-face ABI plus an alcohol leaflet from DH.
46074|NCT03823586|Diagnostic Test|Questionnaire AQUA©, pediatric version|A version of AQUA© recently adapted and pretested in young athletes. It is a self-administered questionnaire composed of 25 items includes items about type, duration and intensity of training sessions, allergic status, habits of children (supplements and drugs intake) and their parents (smoking), presence and burden of infections.
46075|NCT03823573|Behavioral|Walk within 24 hours|Patients will start walking on different timings. Patients on the rapid recovery protocol won't be using drains.
46076|NCT03823560|Device|Celegyn®|Medical device Celegyn® present itself as a cream
46077|NCT03823534|Drug|Ketorolac|IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
46078|NCT03823534|Drug|Normal saline|An IV normal saline placebo prepared by the hospital pharmacy.
46079|NCT03823534|Drug|Acetaminophen|acetaminophen 500 mg PO Q4 hours PRN for mild pain
46080|NCT03823534|Drug|Oxycodone Acetaminophen|oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
46081|NCT03823534|Drug|Morphine|morphine IV PRN (or other opioid) for severe breakthrough pain
46082|NCT03823534|Drug|Hydrocodone/Acetaminophen|At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
46083|NCT03823534|Drug|Oxycodone|Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
46084|NCT03823521|Drug|Cardioplegia Solution|Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
46085|NCT03823508|Device|anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and a high density EEG. The anode will be placed over F3 in order to stimulate the left dorsolateral prefrontal cortex and the cathode over the right supraorbital area.
46086|NCT03823508|Device|sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
46088|NCT03823482|Drug|Lidocaine|Administration of lidocaine 2% 4 mg/kg administered as regional anesthesia of the scalp prior to Mayfield frame placement and lidocaine 1% 40 mg topically to the throat prior to direct laryngoscopy and endotracheal intubation.
46089|NCT03823469|Behavioral|CCTP|Twelve weekly one-on-one 30-minute tele-sessions through video conference. At the first session, subjects identify their vision regarding home cooking and 3-month goals. During each subsequent meeting, subjects will review their progress towards reaching the prior week's culinary goals and identify goals for the coming week, using a self-discovery process. When patients detect a new culinary skill that is necessary for their progress, s/he will either be taught through discussions or referred to active learning from a Culinary Resource Center.
46090|NCT03823469|Behavioral|Nutritional counseling|Two 30-minute nutritional counseling sessions
46091|NCT03823456|Other|Self-acupressure|We teach participants how to using self-acupressure to manage insomnia, depression, and anxiety. Six acupoints are included in our acupressure protocol which are Baihui, Yintang, Fengchi, Neiguan, Shenmen, and Taichong. Participants are requested to stimulate each acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from Anxiety and Depression Association of American.
46092|NCT03823456|Other|Sham Self-acupressure|We using a sham acupressure protocol to teach participants in this group. Six sham acupoints are included in the protocol. The sham acupoints are located 2-5cm away from the true acupoints. Participants are requested to stimulate each sham acupoint in 3 minutes once a day (at night time before going to bed) in 28 days (4 weeks). During the four weeks treatment, participants will receive a weekly phone call follow up to remind them practice self-acupressure at home. Participant also receives a patient leaflet with 10 tips heil to manage insomnia, depression, and anxiety. These tips include some basic sleep hygiene rules and tips to manage anxiety and depression adapted from the Anxiety and Depression Association of American.
46093|NCT03823430|Diagnostic Test|Pupillometry|Pupillar diameter variation measurement
46094|NCT03823417|Drug|Tranexamic Acid|Intravenous TXA given as a loading dose over 15 minutes of 30 mg/kg bolus (within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery
46095|NCT03823417|Drug|Normal saline|Normal saline infusion
46096|NCT03823404|Drug|COR388 capsule|bid
46097|NCT03823404|Drug|Placebo capsule|bid
46098|NCT03823391|Drug|ABBV-3373|ABBV-3373 is administered as intravenous (IV) injection
46099|NCT03823391|Drug|Placebo for ABBV-3373|Placebo for ABBV-3373 is administered as intravenous (IV) injection
46100|NCT03823391|Drug|Adalimumab|Adalimumab is administered as subcutaneous (SC) injection
46101|NCT03823391|Drug|Placebo for adalimumab|Placebo for adalimumab is administered as subcutaneous (SC) injection
46102|NCT03823378|Drug|Upadacitinib|Upadacitinib tablet will be administered orally.
46103|NCT03823378|Drug|Upadacitinib placebo|Upadacitinib placebo tablet will be administered orally.
46104|NCT03823378|Drug|ABBV-105 placebo|ABBV-105 placebo tablet will be administered orally.
46105|NCT03823378|Drug|ABBV-105|ABBV-105 tablet will be administered orally.
46106|NCT03823365|Biological|Blinatumomab Expanded T-cells (BET)|"Two to five days after the last chemotherapy infusion, BET will be administered. An accelerated titration dose escalation design will be used. During dose escalation, up to four dose levels (see table) will be evaluated or until (Maximum Tolerated Dose) MTD is reached.~Dose level BET dose(Counted on CD3+ cells)~(starting dose) 3.0 x 109~6.0 x 109~9.0 x 109~12.0 x 109"
46107|NCT03823352|Drug|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
46108|NCT03823339|Drug|Insulin degludec/liraglutide|Patients will be treated with Insulin degludec/liraglutide (Xultophy®) at the treating physician's discretion and independent from the decision to include the patient in the study.
46109|NCT03823313|Behavioral|SCAI (Spiritual Care Assessment and Intervention)|4 sessions completed with an IU Health chaplain using a framework of questions called the Spiritual Care Assessment And Intervention tool. The weekly sessions will focus on one of the 4 areas of spiritual experience (meaning and purpose, relationships, transcendence and peace, self-worth and identity)
46113|NCT03823287|Drug|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
46114|NCT03823287|Drug|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
46115|NCT03823287|Drug|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
46116|NCT03823274|Drug|Aspirin, Clopidogrel|to evaluate the relationship of stroke recurrence and anti-platelet resistance in ischemic stroke patients receiving aspirin and clopidogrel
46152|NCT03823053|Other|Home Based Traditional Scoliosis Exercise|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. Exercises will be applied 1 sets of 10 repetitions and once a day.
46187|NCT03822793|Drug|Group 2: perfusion of 1000 mg Exacyl|Patient will receive a perfusion of 1000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
46117|NCT03823261|Behavioral|Cognitive Behavioral Therapy|HIV(+) Koreans with depressive symptoms or poor adherence are our target population. This study is a hospital based implementation research. Most PLWH in South Korea regularly visit ID clinics in tertiary hospitals. The ID clinic of study site can reach the target population. In the clinic, the levels of adherence are routinely measured, and depressive symptoms will be asked with key questions We plan to enroll 50 subjects for CBT-AD intervention. In addition, 2 nurses who providing CBT service, and 6 health care workers will be enrolled for survey for providers and healthcare workers.
46118|NCT03823248|Drug|MoLuoDan|oral administration of Moluodan concentrated pills with warm water before meal for 8 pills each time for three times a day
46119|NCT03823248|Drug|Sanchi powder|oral administration of Sanchi powder mixing with warm water before meal for 3g each time for twice a day
46120|NCT03823248|Drug|Folic Acid Tablet|oral administration of folic acid tablets half an hour after meal for 5 mg each time for 3 times a day.
46121|NCT03823248|Drug|MoLuoDan simulation|oral administration of Moluodan simulation medicine with warm water before meal for 8 pills each time for three times a day
46122|NCT03823248|Drug|Sanchi powder simulation|oral administration of Sanchi powder simulation medicine mixing with warm water before meal for 3g each time for twice a day
46123|NCT03823248|Drug|Folic Acid Tablet simulation|oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
46124|NCT03823235|Other|Human embryo culture|humidifed or dry incubator
46125|NCT03823222|Dietary Supplement|Duckweed protein|20 grams isolated protein
46126|NCT03823222|Dietary Supplement|Whey protein|20 grams isolated protein
46127|NCT03823209|Behavioral|Social Network|Leaders of social networks will be statistically determined. Over 5 small-group training sessions, these leaders will be trained to communicate to their social network members accurate information about PrEP and its availability; correct PrEP misconceptions and negative stereotypes; endorse PrEP use and its benefits; and strengthen friends' attitudes, intentions, perceived peer norms, and self-efficacy regarding PrEP as a personal HIV protective strategy.
46128|NCT03823209|Behavioral|Brief HIV Prevention Counseling|Participants will receive brief (15-minute) counseling on how to prevent HIV infection.
46129|NCT03823196|Dietary Supplement|Verum900|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 900 mg for 16 weeks
46130|NCT03823196|Dietary Supplement|Verum1800|Sinetrol® Xpur is a blend of polyphenol-rich extracts from grapefruit, guarana seed, sweet orange and blood orange. Daily dosage is 1800 mg for 16 weeks
46131|NCT03823183|Behavioral|Cognitive training|Group-based cognitive training on iPads with commercially available video games (Lumosity) designed to enhance executive control, memory functions and processing speed. Difficulty will be automatically adjusted to the performance level of the participant. Participants will train for 40 min 2 days/wk over 3 months.
46132|NCT03823183|Behavioral|Physical training|Group-based fitness program (senior-friendly adaption of BodyAttack) that combines aerobic, strength and coordination training to a music soundtrack. Participants will train for 40 min, 2 days/wk over 3 months.
46133|NCT03823183|Behavioral|Cognitive control|Group-based cognitive control activity consisting of playing on iPads non-cognitively demanding video games during 40 min 2 days/wk over 3 months and exercises based on relaxation and stretching for 40 min, 2 days/wk over 3 months.
46134|NCT03823183|Behavioral|Physical control|Group-based exercises program (based on relaxation and stretching) for 40 min, 2 days/wk over 3 months.
46135|NCT03823170|Radiation|Laser therapy|The low-power, infrared (808nm wavelength) diode laser with a power of 100mW will be used. The mode of irradiation is punctual, in contact and perpendicular to the dental surface. Three points on the crown of multiradicular teeth (mesial and distal of the cervical region and central part of the tooth lesion) and two points on the crown of unirradicular teeth (central point of the cervical region and central part of the tooth lesion) will be irradiated for 10s per point , 1J per point, with a 72-hour interval between treatment sessions. The distance between the irradiation points will be about 2 mm. The tip of the laser equipment will be positioned perpendicular to the application site.
46136|NCT03823170|Procedure|Fluorotherapy|The treatment will be carried out with the application of fluoride varnish, with the aid of a microbrush. After the application, water will be dripped onto the applied varnish in order to promote its drying. Fluorotherapy will be performed once a week, totaling 4 sessions.
46137|NCT03823170|Combination Product|Laser therapy and Fluorotherapy|This group will be treated first with the laser (same specifications as Laser therapy), followed by application of fluoride varnish (same specifications as Fluorotherapy).
46138|NCT03823157|Behavioral|Tai Chi|mind-body exercise
46139|NCT03823144|Device|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
46140|NCT03823131|Device|Electroporation|Intratumoral
46141|NCT03823131|Drug|Epacadostat|Given PO
46142|NCT03823131|Drug|Pembrolizumab|Given IV
46143|NCT03823118|Drug|S1/Anlotinib|Anlotinib 12mg qd, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until maximum 6 cycles； S1 60mg bid, day 1 to day 14 followed by 7 days off treatment in a 21-day cycle until it can not tolerate, or disease progression.
46144|NCT03823105|Device|OHR Tracker and PulseWatch|Category A (ClinO). Medical study with CE-marked medical devices to photoplethysmographic measure heart rate, heart rate variability, and pulse wave and accelometric data
46145|NCT03823092|Diagnostic Test|polarization sensitivity|test of polarization vision as described in Study Description
46146|NCT03823079|Drug|rhTPO|rhTPO 300u/kg, subcutaneous injection, qd
46147|NCT03823079|Drug|irinotecan|80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
46148|NCT03823079|Drug|Raltitrexed|3mg/m2 q3w
46149|NCT03823079|Radiation|radiotherapy|in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
46150|NCT03823079|Drug|rhIL-11|rhIL-11 50ug/kg, subcutaneous injection, qd
46151|NCT03823066|Device|Coach Pepper|Robot Peppers's height is 1.20 meters and it weighs 28 kilograms. Pepper will be called Coach Pepper, because it is connected, via web interfaces, with a theratainment app including cognitive and physical training
83121|NCT03535727|Drug|Capecitabine|PO BID; Days 1- 14
46153|NCT03823053|Other|Home Based Core Stabilization Training|Program will include posture exercises, strengthening exercises of interscapular muscle and limb, diaphragmatic breathing exercises and stretching exercises for lumbar extensor, hip flexor, hamstring, pectoral muscles. In addition, the training group received core stabilization exercises for multifidus, transversus abdominis, diaphragm,erector spines, rectus abdominis, internal and external obliques, quadratus lumborum, gluteus maximus, and pelvic floor muscles.Exercises will be applied 1 sets of 10 repetitions and once a day.
46154|NCT03823040|Drug|Oxiconazole Nitrate Cream 1%|Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
46155|NCT03823040|Drug|Oxiconazole nitrate SLNs loaded gel.|Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
46156|NCT03823027|Device|SiPore15™|SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
46157|NCT03823014|Device|Elator|Measurement for device, use of device
46158|NCT03823001|Diagnostic Test|virtual biopsy (VB) monitoring protocol|"PSA bi-annually or more often according to the discretion of the urologist.~Annual DRE.~Visit with the urologist bi-annually.~Multi-parametric MRI (mpMRI) every year for 3 years.~Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year."
46159|NCT03822988|Other|no intervention, only complete a survey|we will ask patients to answer to a survey
46160|NCT03822975|Drug|Bivalirudin|Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 2-4 hours after PCI. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is <225 s (Hemotec method), intravenous injection of 0.35 mg/kg of bivalirudin should be administered, and the ACT re-checked to ensure it is >225 seconds.
46161|NCT03822975|Drug|unfractionated Heparin|Heparin 70 U/kg is started before coronary angiography. ACT is monitored 5 min after the first administration, and if the ACT <225 s (Hemotec method), an intravenous injection of 1000 U of heparin is administered, and the ACT re-checked to ensure it is >225 seconds.
46162|NCT03822962|Drug|Ibuprofen 600Mg Tablet|ibuprofen 600 mg by mouth every 8 hours scheduled in addition to standard tylenol regimen.
46163|NCT03822962|Other|"Standard Regimen | Tylenol"|Tylenol 1000 mg by mouth every 6 hours scheduled and a rescue prescription of oxycodone 5 mg tablets by mouth every 6 hours as needed for pain. Ten total oxycodone tablets will be prescribed.
46164|NCT03822949|Device|Day Light|Patients are exposed to daylight for up to 10 days prior to surgery
46165|NCT03822949|Device|Placebo light|Patients are exposed to placebo light for up to 10 days prior to surgery
46166|NCT03822936|Drug|Preoperative chemotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
46167|NCT03822936|Radiation|Preoperative radiotherapy|Preoperative chemotherapy, carbon ion therapy, surgery
46168|NCT03822923|Other|Experimental group|Neurodynamics with conventional treatment. Intervention will be applied for 6 weeks (10 reps per set, 1 set per day, 3 days per week) for 30 minutes
46169|NCT03822923|Other|Control group|Conventional treatment
46170|NCT03822910|Diagnostic Test|Pattern Separation Paradigm|Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
46171|NCT03822910|Diagnostic Test|Sequential Associative Mismatch Paradigm|used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).
46172|NCT03822910|Diagnostic Test|Encoding Plasticity Paradigm|Used to evaluate plasticity of hippocampal Intrinsic Functional Connectivity (IFC) in response to memory consolidation in FEP subjects before and after antipsychotic treatment and in matched HC.
46173|NCT03822897|Radiation|Radiation|"35 fractions, 5/wk, 7 wks 70Gy/56Gy, or~35 fractions, 6/wk, 6 wks, 70Gy/56Gy, or~35 fractions, 5/wk, 7 wks OR 6/wk, 6 wks 70Gy/56Gy"
46174|NCT03822897|Drug|Cisplatin|100 mg/m2 on day 1, 22, and 43 or 40 mg/m2 /wk for 7 wks
46175|NCT03822884|Drug|Epoetin Alfa 40000 UNT/ML|40.000 UI subcutaneous single dose
46176|NCT03822871|Drug|CTT1403|Escalating doses of 0.75 GBq - 6.0 GBq will be administered in an accelerated to traditional 3+3 dose escalation design. After escalation, 10 additional patients will be enrolled into a dose expansion cohort. Patients meeting eligibility criteria with demonstrated cessation of disease progression will be offered a second dose of the study drug, CTT1403.
46177|NCT03822871|Drug|CTT1057|Patients will be screened with CTT1057 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-6 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 to assess potential efficacy of CTT1403.
46178|NCT03822858|Drug|Intrathecal MSC-NP injection|"Between 5 to 10 million MSC-NPs will be administered intrathecally in each dose.~10 million cells is the maximum dose. Treatment will consist of 3-5 doses spaced 3 months apart."
46179|NCT03822845|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
46180|NCT03822832|Drug|Spesolimab|Solution for infusion
46181|NCT03822832|Drug|Placebo|Solution for infusion
46182|NCT03822819|Dietary Supplement|probiotic cocktail capsules|Daily uptake of probiotic cocktail for three weeks
46183|NCT03822819|Dietary Supplement|placebo capsules|Daily uptake of placebo capsule for three weeks
46184|NCT03822806|Other|Physical Exercise in addition to Patching|Patch for 2 hours a day, and exercise for the first 30 minutes of those 2 hours using the video game
46185|NCT03822793|Drug|Placebo|Patient will receive a perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 10 minutes just before surgery.
46186|NCT03822793|Drug|Group 1: perfusion of 500 mg Exacyl|Patient will receive a perfusion of 500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
83122|NCT03535727|Drug|Cisplatin|IV over 60 minutes; Days 4 and 11
46188|NCT03822793|Drug|Group 3: perfusion of 1500 mg Exacyl|Patient will receive a perfusion of 1500mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
46189|NCT03822793|Drug|Group 4: perfusion of 3000 mg Exacyl|Patient will receive a perfusion of 3000mg Exacyl (tranexamic acid) intravenous (IV) over 10 minutes just before surgery.
46190|NCT03822780|Drug|Hydroxychloroquin|Hydroxychloroquine Sulfate (HCQ, Quensyl) in a loading dose of 10 mg/kg*d, p.o., bid. After the illness gradually alleviate to maintain dose between 5mg/kg*d to 10mg/kg*d, p.o., bid ; the maximum daily dose is 400mg.
46191|NCT03822767|Biological|sIPV-sIPV-bOPV vaccination schedule|Two intramuscular injections of the investigational vaccine (0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Biotech Co., Ltd . The poliovirus (Live) vaccine type I & type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
46192|NCT03822767|Biological|wIPV-wIPV-bOPV vaccination schedule|Two intramuscular injections of the control vaccine(0.5 ml) on Day 0 and Day 30 respectively; Single dose of bOPV (0.1 ml) on Day 60. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I & type III (Human Diploid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
46193|NCT03822754|Biological|sIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the experimental sIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively. The investigational Sabin strain inactivated poliovirus vaccine (Vero cell)(sIPV) was manufactured by Sinovac Vaccine Technology Co., Ltd. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
46194|NCT03822754|Biological|wIPV-bOPV-bOPV vaccination schedule|Single intramuscular injection of the control wIPV (0.5 ml) on Day 0, following two doses of bOPV (0.1 ml) on Day 30 and Day 60 respectively.The control wild strain inactivated poliovirus vaccine (wIPV) was manufactured by SANOFI PASTEUR S.A. The poliovirus (Live) vaccine type I & type III (Human Dipoid cell) ( bOPV) was manufactured by Beijing Bio-institute Biological Products Co., Ltd.
46195|NCT03822728|Diagnostic Test|3D-DESS MRI (3 dimensional double echo steady state MRI)|3D-DESS MRI has been reported useful for the intra-parotid facial nerve imaging. It can provide information about the anatomical relationship between the tumor and the facial nerve in the parotid gland.
46196|NCT03822715|Other|Carbohydrate restricted dietary intervention|Carbohydrate restricted dietary intervention (<20 g carbohydrates/day)
46197|NCT03822715|Drug|standard of care aromatase inhibitors|standard of care aromatase inhibitors
46198|NCT03822702|Other|Biofeedback Training|Biofeedback training targeted to goals that are relevant to the handwriting skills for children by using a force acquisitional pen.
46199|NCT03822702|Other|Motor Training|Motor training targeted to goals that are relevant to the handwriting skills for children by using a personal designed motor training program.
46200|NCT03822689|Device|Ventilator breathing tube F2220|M: Folding D: 22mm; L: 2.0M
46201|NCT03822689|Device|Ventilator breathing tube F2216|M: Folding; D: 22mm; L:1.6M
46202|NCT03822689|Device|Ventilator breathing tube F1520|M: Folding; D: 15mm; L:2.0M
46203|NCT03822689|Device|Ventilator breathing tube F1516|M: Folding; D: 15mm; L:1.6M
46204|NCT03822689|Device|Ventilator breathing tube U1016|M: Unfolding; D: 10mm; L:1.6M
46205|NCT03822689|Device|Ventilator breathing tube U1516|M: Unfolding; D: 15mm; L:1.6M
46206|NCT03822689|Device|Ventilator breathing tube CA20|M: Co-axis; L:2.0M
46207|NCT03822689|Device|Ventilator breathing tube CA16|M: Co-axis; L:1.6M
46208|NCT03822676|Device|Prophylactic pancreatic stent|Prophylactic pancreatic stent before segmental pancreatic surgery
46209|NCT03822663|Dietary Supplement|Caffeine supplementation|The experimental procedure for each athlete includes an acute CAF supplementation in a different-dose crossover regimen in order to assess whether the dose affects the actual physical capacity and discipline-specific exercise performance (doses: 3.0-, 6.0- and 9.0 mg/kg of body mass, respectively). CAF (pure pharmaceutical caffeine) will be administered in the dissolved form. On testing days, the supplements will be taken 45 min before physical and exercise capacity test session. Between the CAF and PLA or a PLA and CAF treatments, a minimum 7-day washout period will be introduced.
46210|NCT03822663|Dietary Supplement|Placebo treatment|The experimental procedure for each athlete will include PLA supplementation. Placebo will be administered in the dissolved form. On testing days, the PLA will be taken 45 min before physical and exercise capacity test session. Between the PLA and CAF or a CAF and PLA treatments, a minimum 7-day washout period will be introduced.
46211|NCT03822637|Drug|n-acetylcystine + albuterol|NAC is a mucolytic drug and Albuterol is a bronchodilator.
46212|NCT03822637|Drug|0.9% saline + albuterol|Normal saline is a placebo agent and Albuterol is a bronchodilator.
46213|NCT03822624|Dietary Supplement|Probiotic|Probiotic mixture with three bacterial strains with maltodextrin as a carrier.
46214|NCT03822624|Other|Placebo|Placebo comparator with maltodextrin as a carrier.
46215|NCT03822611|Behavioral|Targeted Subsidy|Voucher
46216|NCT03822598|Behavioral|Teaching Recovery Techniques, TRT|TRT is a , low-threshold, group based, manual driven short term intervention to reduce trauma-related mental health problems. The program is based on principles from trauma-focused cognitive-behavioral therapy
46217|NCT03822585|Diagnostic Test|CBC, Iron Study, Serum Ferrittin, HPLC,Genitic Study|"high performance liquid chromatography (HPLC) has become the preferred technique, as it can detect most of the clinically significant variants. polymerase chain reaction (PCR)-based procedures detect Commonly occurring mutations of the HBB gene .~If targeted mutation analysis fails to detect the mutation, scanning or sequence analysis can be used. Sensitivity of both mutation scanning and sequence analysis is 99%."
46218|NCT03822572|Other|endurance exercise|defined exercise program
46219|NCT03822572|Other|control|habitual physical activity before the diagnosis
46220|NCT03822559|Drug|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL|One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.
46265|NCT03822299|Dietary Supplement|healthy feces microbiota|Suspension of healthy feces microbiota in sterile saline solution
46221|NCT03822559|Drug|A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL|One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.
46222|NCT03822546|Other|Conventional cigarette|Subject's own conventional cigarette brand smoked with puffs taken at 30 seconds intervals
46223|NCT03822546|Other|myblu 25 mg freebase|E-cigarette used for 10 inhalations every 30 seconds
46224|NCT03822546|Other|myblu 16 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
46225|NCT03822546|Other|myblu 25 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
46226|NCT03822546|Other|myblu 40 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
46227|NCT03822546|Other|blu PRO 48 mg nicotine salt|E-cigarette used for 10 inhalations every 30 seconds
46228|NCT03822533|Other|Physiotherapist as primary assessor|Physiotherapist diagnose and treat the patient.
46229|NCT03822533|Other|Physician as primary assessor|Physician diagnose and treat the patient.
46230|NCT03822520|Drug|Celecoxib|Celecoxib 400mg capsule
46231|NCT03822520|Drug|Moxifloxacin|Moxifloxacin 400mg tablet
46232|NCT03822520|Other|Water|Pure water 150ml
46233|NCT03822507|Drug|KHK7580|oral administration
46234|NCT03822507|Drug|Cinacalcet Hydrochloride|oral administration
46235|NCT03822494|Radiation|CyberKnife SBRT|Radiation Therapy
46236|NCT03822481|Behavioral|Mindful Construal Diary|A Mindful Eating Intervention
46237|NCT03822468|Drug|Ribociclib|Ribociclib will be supplied as 200 mg tablets as individual patient supply packaged bottles taken by mouth.
46238|NCT03822468|Drug|Letrozole or Anastrozole|Letrozole 2.5 mg by mouth QD continuously or anastrozole 1 mg by mouth QD continuously (investigator choice)
46239|NCT03822468|Drug|Goserelin|Goserelin 3.6 mg subcutaneously once every 4 weeks (pre-menopausal women only)
46240|NCT03822455|Drug|OligoG DPI|OligoG Dry Powder for Inhalation
46241|NCT03822429|Drug|Controlled ovarian stimulation|Hormonal therapy to induce ovulation by multiple ovarian follicles
46242|NCT03822416|Drug|Nicotine patch|Nicotine patch (dose based on number of cigarettes per day) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
46243|NCT03822416|Drug|Nicotine lozenge|Nicotine lozenge (2 or 4 mg if less or greater than 30 minutes to first cigarette in the morning respectively) (4-week, 8-week, or 12-week supply) depending on participant preference and how much they are smoking based on FDA guidelines for use
46244|NCT03822416|Behavioral|Therapy|In-person meeting at baseline, 6 phone counseling sessions with participants over 8 weeks after initial in-person meeting, possible additional phone counseling (3 phone calls) from 8 weeks to 6 months after initial in-person meeting, and possible text messages when agreed to by participants during the 8 week to 6 month phase
46245|NCT03822416|Other|Information|Information about smoking and mental illness and referrals to both the QUITPLAN helpline and additional resources in the community
46246|NCT03822403|Device|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
46247|NCT03822403|Device|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
46248|NCT03822390|Device|CAD-CNN system|The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
46249|NCT03822377|Drug|Ticagrelor orodispersible tablets|Ticagrelor loading dose (180 mg) given as two orodispersible tablets (each of 90 mg), to be dispersed in saliva.
46250|NCT03822377|Drug|Ticagrelor pills|Ticagrelor loading dose (180 mg) given as two standard coated tablets (each of 90 mg) to be swallowed with water.
46251|NCT03822364|Drug|009-1|Inhaled apomorphine via Staccato aerosol, Dose 1
46252|NCT03822364|Drug|active comparator|commercially available apomorphine injector
46253|NCT03822364|Drug|009-0|Inhaled placebo via Staccato device
46254|NCT03822364|Drug|009-2|Inhaled apomorphine via Staccato aerosol, Dose 2
46255|NCT03822364|Drug|009-3|Inhaled apomorphine via Staccato aerosol, Dose 3
46256|NCT03822364|Drug|009-4|Inhaled apomorphine via Staccato aerosol, Dose 4
46257|NCT03822364|Drug|009-5|Inhaled apomorphine via Staccato aerosol, Dose 5
46258|NCT03822351|Drug|Durvalumab + Oleclumab|Durvalumab + Oleclumab
46259|NCT03822351|Drug|Durvalumab|Durvalumab
46260|NCT03822351|Drug|Durvalumab + Monalizumab|Durvalumab + Monalizumab
46261|NCT03822338|Procedure|Pneumoperitoneum preconditioning|Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
46262|NCT03822338|Procedure|Sham-Pneumoperitoneum preconditioning|Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
46263|NCT03822312|Device|DBT-TOBI|The DBT-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through
46264|NCT03822312|Device|MRI-TOBI|The MRI-TOBI scan system is designed to deliver low power laser lights through a person's body tissue and collect data about the light that is transmitted through. The MRI scan is completed at the same time as the TOBI scan. Participation in this part of the intervention is optional.
46266|NCT03822286|Other|e-training course|Home care staff received mainly self-study, you can download e-books on your lithography or personal mobile phone reading and learning, with lively animation, sound and video guide home staff Learn the knowledge of demented care. The e-book course sets out the themes of the eight demented care training courses.
46267|NCT03822286|Other|Support group|A counseling master mix 8~10 resident staff members, through the counselor to lead the symposium to the case home to implement technical guidance and through the set of social network groups to immediately discuss the care and solutions of dementia cases, and hold once a month in gathering, about 40~60 minutes each time.
46268|NCT03822286|Other|traditional classroom teaching course programs|Home care staff received the traditional demented care traditional classroom teaching course and did not accept any e-training and gathering.
46269|NCT03822273|Procedure|Traditional acupuncture (TA)|"Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min."
46270|NCT03822273|Procedure|Laser acupuncture (LA)|"Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies [B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz]; RJ-Laser, Reimers & Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2)."
46271|NCT03822273|Procedure|Sham laser acupuncture (SLA)|"Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group."
46272|NCT03822260|Diagnostic Test|Bezmialem VAkif Unv. Ethical board|If ıs any trials not convenient to Helsinki Agrement about Human research rules
46273|NCT03822247|Procedure|Multidisciplinary Recovery Program|"Preoperative care:~Patient's education~Providing respiratory training~Assessment of nutritional status~Application of compression stockings~Thromboembolism prophylaxis by low molecular weighted heparin~Induction of hemodynamic support 12 hours before the surgery~Oral carbohydrate solution loading until 2 hours before the surgery~Intraoperative care:~Maintaining normothermia~Multimodal prevention of postoperative nausea and vomiting~Use of spinal anesthesia~Prevention of excessive blood loss~Local anesthetic infiltration~Postoperative care:~Active pain control~Early mobilization~Early onset of oral nutrition~Early delirium detection~Application of compression stockings"
46274|NCT03822234|Procedure|Modified ileal conduit|Modified ileal conduit (Extraperitonealization)
46275|NCT03822221|Other|MVIC and NMES with hip at 85º and knee at 20º|With hip joint at 85º (seated) and knee at 20º (SK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
46276|NCT03822221|Other|MVIC and NMES with hip at 85º and knee at 60º|With hip joint at 85º (seated) and knee at 60º (SK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
46277|NCT03822221|Other|MVIC and NMES with hip at 0º and knee at 20º|With hip joint at 0º (lying) and knee at 20º (LK20º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
46278|NCT03822221|Other|MVIC and NMES with hip at 0º and knee at 60º|With hip joint at 0º (lying down) and knee at 60º (LK60º), subjects will be submitted to maximal isometric voluntary contractions (15-18 per session) and to contractions evoked by neuromuscular electrical stimulation (15-18 per session).
46279|NCT03822208|Biological|AL003|Single-doses of AL003 in up to 7 dose-escalating cohorts
46280|NCT03822208|Other|Saline Solution|Saline Solution will be administered as a single infusion for each cohort in a ration of 6 active and 2 placebo subjects for healthy adults and 10 active and 2 placebo for patients
46281|NCT03822195|Procedure|Carotid endoarterectomy|Surgical removal of carotid bifurcation plaque and arterial repair (direct suture or patch)
46282|NCT03822182|Drug|liposomal bupivicaine|"The medication administered in the interscalene block is the intervention in this study. There are three different types of interscalene blocks that will be administered in order to compare the independent effectiveness of LB with the effectiveness of LB plus dexamethasone. Study participants will be randomized into one of three groups. The treatment groups are listed below:~Group 1 (Control): 30 ml of 0.5% bupivacaine and 0.4ml (4 mg) of dexamethasone Group 2: 15ml 0.5% bupivacaine and 10ml (133mg) of LB (Exparel) and 5.4ml normal saline Group 3: 5ml 0.5% bupivacaine and 10ml LB (Exparel) and 0.4ml (4 mg) dexamethasone and 5ml normal saline"
46283|NCT03822182|Drug|Dexamethasone|steroid that will be used in control as well as in group 3 to see if effect with liposomal bupivicaine is prolonged as has been shown with standard bupivicaine.
46284|NCT03822169|Dietary Supplement|Choline added as a phospholipid|A shake with 3000 mg choline added as a phospholipid
46285|NCT03822169|Dietary Supplement|Choline added as a salt|A shake with 3000 mg choline added as a salt
46286|NCT03822156|Other|Observation of AFB smear/culture|Observation of the patients from group for their AFB smear/culture results
46287|NCT03822143|Diagnostic Test|Ultrasound|Use of ultrasound device to diagnosis anemia in a fetus
46288|NCT03822130|Drug|Arterial catheter infusion chemotherapy|Arterial catheter infusion chemotherapy
46289|NCT03822130|Drug|Sodium Bicarbonate|Arterial catheter infusion Sodium Bicarbonate
46290|NCT03822130|Drug|Systemic Chemotherapy|Systemic Chemotherapy
46291|NCT03822130|Drug|Oral Chemotherapy|Oral Chemotherapy
46292|NCT03822117|Drug|Pemigatinib|Pemigatinib administered orally once daily (QD).
46324|NCT03821792|Drug|Abiraterone Acetate|Given PO
46325|NCT03821792|Drug|Apalutamide|Given PO
46326|NCT03821792|Drug|Prednisone|Given PO
46293|NCT03822104|Dietary Supplement|Bovine Colostrum|Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants start with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5 if the infants only receive DM. The intervention lasts until the infants reach postmenstrual age (PMA) 35+6 weeks or in no-need of fortification due to sufficient growth, whichever comes first.
46294|NCT03822104|Dietary Supplement|FM85|Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 80-100 ml/kg/d. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed until discharge.
46295|NCT03822091|Drug|Terlipressin|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, and randomised into group A and B. Group A patients will receive further higher doses of Terlipressin. The dose of Terlipressin will be increased by 1mg after 24 hrs if:~the creatinine values decrease by <12.5%~MAP increase of <10 mmHg~urine output of <200 ml in 4 hours.~Maximum terlipressin dose will be given upto 12 mg/day.Albumin will be administered in both arms according to standard protocol at the following dose :~1st day - Albumin at 1 gram/kg - a maximum dose of 100grams can be given.~A dose of 20gram/day to 60gram/day in the following days."
46296|NCT03822091|Drug|Terlipressin and Noradrenaline|"Patients with Type 1 HRS will be given Terlipressin at the dose of 2mg/24 hrs as infusion. After 48 hours of initial monitoring, patients who do not respond to the initial dose of Terlipressin, will be randomised into group A and B. Group B patients will be treated with~Terlipressin(2mg/24hr infusion- fixed dose) and Noradrenaline, which would be given as a continuous infusion at a starting dose of 0.5 mg/hr. The dose od noradrenaline will be increased every 24 hours in steps of 0.5 mg/hr, the maximum dose being 3 mg/hr IF:~the creatinine values decrease by <12.5%~MAP increase of <10 mmHg~urine output of <200 ml in 4 hours."
46297|NCT03822078|Drug|Placebo|Administered by subcutaneous injection
46298|NCT03822078|Biological|Denosumab|Administered by subcutaneous injection
46299|NCT03822065|Drug|LY03005|80 mg oral tablet single dose
46300|NCT03822052|Other|Lactated ringers|IV fluid
46301|NCT03822052|Other|5% dextrose lactated ringers|IV fluid
46302|NCT03822026|Other|Hyperventilation test|Increase of the alveolar ventilation by a stepwise increase in tidal volumes and respiratory rate until a reduction of end-tidal CO2 of 0.7 kPa is achieved
46303|NCT03822013|Drug|Miglustat|Treatment with Zavesca regimen based on body surface area as follows: SQRT [Height (cm) × Weight (kg)] / 3600 <1.25 : 200mg TDS 0.88- 1.25: 200mg BID 0.73- 0.88: 100 mg TDS 0.47- 0.73: 100 mg BID <0.47: 100 mg Daily
46304|NCT03822000|Other|Survival|Elderly patients with fall-induced femoral fracture who were survived.
46305|NCT03822000|Other|Death|Elderly patients with fall-induced femoral fracture who were dead.
46306|NCT03821987|Drug|Fludarabine|Patients enrolled in this study would receive Bu (IV)0.8mg/kg Q6hx2d,Fludarabine 30mg/m2x5d ,CTX (cyclophosphamide) 25mg/kg/dx4d,rATG (thymoglobulin,Sang Stat,France) 2.5mg/kg/dx4d.
46307|NCT03821974|Procedure|wet suction technique|"For the wet suction technique, after removing the stylet, the needle was flushed with 2 mL of saline solution to replace the column of air with saline solution. A 10-mL suction syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle after flushing the needle with saline solution. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
46308|NCT03821974|Procedure|dry suction technique|"For the dry suction technique, after locating by EUS, the stylet was removed from the needle before performing FNA. A 10-mL syringe, loaded to 5ml negative pressure, was attached in a locked position to the needle. Suction was applied after the lesion was punctured. The needle is moved back and forth 20-30 times by applying negative pressure suction within the lesion. Afterwards, the needle is withdrawn from the lesion."
46309|NCT03821961|Procedure|Metabolic Surgery|Roux-en-Y gastric bypass, Sleeve gastrectomy
46310|NCT03821935|Drug|ABBV-151|liquid for intravenous infusion
46311|NCT03821935|Drug|ABBV-181|lyophilized powder for solution for intravenous infusion
46312|NCT03821909|Procedure|Endoscopic ultrasound-guided protal venous blood sampling|We wil obtain portal venous blood samples via endoscopic ultrasound(EUS) in patients with suspected pancreatic masses.
46313|NCT03821896|Behavioral|Conversation Cards for Adolescents and Goal-Setting|The intervention includes using an adolescent-tailored tool (a deck of cards) created by researchers at the University of Alberta and adolescents with obesity seeking weight management care. It contains a list of factors that make it easy or hard for teens to make and maintain healthy lifestyle changes. Its use will be paired with a S.M.A.R.T. goal-setting activity using principles of shared decision-making.
46314|NCT03821896|Behavioral|Goal-Setting|Collaborative setting of S.M.A.R.T. goals using principles of shared decision-making.
46315|NCT03821883|Drug|Termination of aspirin|Discontinuation of aspirin therapy in the experimental group and continuance of aspirin therapy in the active comparator group
46316|NCT03821870|Diagnostic Test|Inditreat|Tumoroid formation and drug sensitivity analysis
46317|NCT03821870|Drug|Experimental drug|Second line treatment based on drug sensitivity analysis
46318|NCT03821857|Diagnostic Test|18-F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
46319|NCT03821844|Behavioral|Music and Memory|Music and Memory is a personalized music program in which caregivers (nursing home staff, family, or others) provide people with dementia with music playlists tailored to their personal history of music preferences.
46320|NCT03821831|Device|Continuous Positive Airway Pressure|CPAP machine
46321|NCT03821831|Device|Orthodontic intervention|Mandibular advancement or Rapid maxillary expansion devices
46322|NCT03821818|Behavioral|Food Allergy Elimination + Willis Exercise|Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise > 75% max heart rate, 5/day)
46323|NCT03821805|Other|Foot reflexology massage|Foot reflexology technique of Father Josef was used as massage intervention
46327|NCT03821779|Behavioral|In vivo social exposure|Subjects will be invited to give a 5 minutes oral presentation on the topic of their choice to five examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is prompt to elicit anticipation-type of social anxiety.
46328|NCT03821779|Behavioral|Social exposure in a virtual reality setting|Subjects will give a 5 minutes oral presentation on the subject of their choice to a virtual reality panel composed of 5 examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is expected to elicit anticipation-type of social anxiety.
46329|NCT03821779|Other|EEG recording|EEG will be recorded with a standard 16-electrodes cap. Recordings will start before the 5 minutes waiting period and continue throughout oral presentation and recovery. The recovery period will be used as a baseline control
46330|NCT03821779|Diagnostic Test|Psychometric evaluation|"Subjects will be evaluated prior to inclusion using the following assessment tools~Anamnestic Association for Methodology and Documentation in Psychiatry (AMDP) questionnaire~Mini International Neuropsychiatric Interview (MINI 6.0, for psychiatric diagnoses)~Liebowitz Social Anxiety Scale (LSAS)~Montgomery Asberg Depression Rating Scale (MADRS)~Brief Anxiety Scale of Tyrer (BAS)~State-Trait Anxiety Inventory (STAI A-B)~Global Assessment of Functioning (GAF)"
46331|NCT03821779|Diagnostic Test|Visual Analogue Scale of anxiety|"Subjects will be asked to rate their anxiety levels~immediately before (5 minutes of silent waiting),~during~and after the 5-minute oral presentation (recovery)"
46332|NCT03821766|Device|Ballistocardiography and seismocardiography|SCG and BCG signals will be recorded by the mean of an unobtrusive and friendly device consisting of two houses, the first one placed on the sternum and the second one place on the lumbar region near the subject's center of mass. The signal will be transferred to a tablet by Bluetooth and tracings will be analysed automatically with Matlab. The SCG+BCG signals are synchronized to the intracardiac pressure tracings in order to allow a comparative interpretation between the two tracings.
46333|NCT03821753|Other|Case|"OCT~OCT-Angiography,~Retinophotography~Neuropsychological tests"
46334|NCT03821753|Other|Control|"OCT~OCT-Angiography,~Retinophotography~Neuropsychological tests"
46335|NCT03821740|Other|Kinesiotaping|Mc Connel taping and another kinesiotaping technique
46336|NCT03821727|Procedure|Hematopoietic Stem Cell Transplantation|Hematopoietic Stem Cell Transplantation in Acute Leukemia Ph positive
46337|NCT03821714|Drug|Glucocorticoid combination therapy|Glucocorticoid combination therapy is defined as the combination of hydrocortisone, vitamin C and vitamin B1.
46338|NCT03821714|Drug|Glucocorticoid|The glucocorticoid group was defined as the use of hydrocortisone alone.
46339|NCT03821701|Drug|Entresto|Sacubitril Valsartan Sodium Tablets, 100mg bid, among whole study
46340|NCT03821701|Drug|ACEI/ARB|Choose one of ACEI/ARB according to the clinical condition among the whole study.
46341|NCT03821688|Procedure|SAS-GB|
46342|NCT03821688|Procedure|MBG|
46343|NCT03821688|Procedure|LSG|
46344|NCT03821675|Device|Electrical Stimulation|Subjects will receive an active electrical stimulation device to wear for 1 hour daily for 4 weeks.
46345|NCT03821675|Device|Electrical Stimulation - Sham|Subjects will receive a sham electrical stimulation device to wear for 1 hour daily for 4 weeks.
46346|NCT03821662|Behavioral|OT Diabetes Self-Management Intervention|Occupational therapy chronic disease self-management intervention.
46347|NCT03821649|Behavioral|SOONER Training and Naloxone Kit Kit|Participants are shown our unique overdose response education video and given the associated kit to take home.
46348|NCT03821649|Behavioral|Community or Hospital-Based Training|Referral to standard of care for Naloxone training
46349|NCT03821636|Procedure|Standard Roux-en-Y gastric bypass|Standard Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 25 % of total length of the intestine (150 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 65 % of total length of the intestine (400 cm).
46350|NCT03821636|Procedure|Long alimentary limb Roux-en-Y gastric bypass|Long alimentary limb Roux-en-Y gastric bypass is performed with a 30 ml gastric pouch, a stapled gastrojejunal anastomosis with an alimentary limb of 45 % of total length of the intestine (280 cm), connected to the biliary limb of 10 % of total length of the intestine (60 cm) below the duodeno-jejunal junction with a side-to-side jejuno-jejunal anastomosis and a common limb of 45 % of total length of the intestine (280 cm
46351|NCT03821623|Drug|Nicotinamide riboside|Nicotinamide riboside, a dietary supplement available over the counter under the name NIAGEN®, (ChromaDex Inc) is an exogenous NAD+ precursor that reverses age-related arterial dysfunction in aged mice, suggesting that declining NAD+ may play a key role in cardiovascular aging.
46352|NCT03821623|Other|Placebo|Subjects will take placebo pills twice a day for 3 months
46353|NCT03821610|Drug|Fludarabine|IV
46354|NCT03821610|Drug|Melphalan|IV
46355|NCT03821610|Drug|Alemtuzumab|IV
46356|NCT03821610|Drug|Cyclophosphamide|IV
46357|NCT03821610|Drug|Mesna|IV
46358|NCT03821610|Radiation|Total Body Irradiation (8Gy)|TBI (8Gy)
46359|NCT03821597|Procedure|Sequential compression devices (SCDs)|Application of sequential compression devices in surgery.
46360|NCT03821597|Procedure|No sequential compression.|No sequential compression devices are applied.
46361|NCT03821584|Other|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest|the difference of care management and prognosis, an early distinction of migraine aura based on imaging techniques will have a particular interest
46362|NCT03821571|Diagnostic Test|Brain MRI|Brain MRI with blood sensitive sequence (SWI) will be performed to all enrolled patients.
46363|NCT03821558|Other|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions with different intensity levels.
46364|NCT03821545|Other|Lidocaine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.
46365|NCT03821545|Other|Ketamine|Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
46366|NCT03821545|Other|Lidocaine and Ketamine|Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
46367|NCT03821545|Other|Placebo (0.9% NaCl)|Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
46368|NCT03821532|Other|Constipation Action Plan|Action plan, adapted from Autism Speaks Network, demonstrating Red, Yellow, and Green levels of symptoms with corresponding steps for treatment or action by parent/guardian, tailored by care provider to the child's condition.
46369|NCT03821519|Biological|donor-derived CIK cells|Treatment plan will be based on three infusions of donor derived CIK cells given by 3 weeks intervals at increasing dose levels. No dose changes are allowed and the following planned dose levels will be administered to each patient enrolled: 5x106, 5x106 and 10x106 cells/Kg according to the dose escalating program
46370|NCT03821506|Device|Dynamic Light|Dynamic Lighting system
46371|NCT03821506|Device|Usual care|Standard lighting system
46372|NCT03821493|Drug|PF-06651600 10 mg tablets|"On Day 1 in Period 1, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered.~On Day 4 of Period 2, a single oral dose of 30 mg (3 x 10 mg tablets) will be administered after itraconazole."
46373|NCT03821493|Drug|Itraconazole Solution 200 mg|"Itraconazole 200 mg will be administered as 20 mL (10 mg/mL) oral solution once daily on Days 1-5 in Period 2.~On Day 4 of Period 2, co-administration of itraconazole 200 mg and PF-06651600 30 mg will occur. Itraconazole will be administered first followed by PF-06651600 tablets."
46374|NCT03821480|Drug|Test drug|Fluconazole capsule 50 mg Manufacturer: West Ryde
46375|NCT03821480|Drug|Reference drug|Fluconazole capsule 50 mg Manufacturer: Amboise
46376|NCT03821467|Device|Dual beam Doppler Fourier-domain OCT (DOCT)|Retinal blood flow will be assessed using DOCT.
46377|NCT03821467|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
46378|NCT03821467|Device|Optical coherence tomography (OCT)|Retinal morphology will be imaged using OCT.
46379|NCT03821454|Drug|Capecitabine|Oral capecitabine (at a dose of 1250 mg per square meter of body-surface area, twice per day, on days 1 to 14) every 3 weeks for eight cycles.
46380|NCT03821454|Drug|Placebos|Oral Placebos (twice per day, on days 1 to 14) every 3 weeks for eight cycles.
46381|NCT03821441|Biological|bOPV(Candy)|"A single dose of 1 pill orally of bOPV to subjects aged 48 months who recieved bOPV (candy) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available ,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
46382|NCT03821441|Biological|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who recieved bOPV (liquid) produced by institute of Medical Biology, Chinese Academy of Medical Sciences in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
46383|NCT03821441|Biological|bOPV(Liquid)|"A single dose of 2 drops (0.1 ml) orally of bOPV to subjects aged 48 months who received tOPV (liquid) produced by Beijing Tiantan Biological Products Co., Ltd. in primary immunization.~If bOPV(candy/liquid) is not available,in order to protect the rights and interests of subjects ,the investigator can adjust other poliovirus vaccine such as IPV replace bOPV."
46384|NCT03821428|Procedure|Acupuncture|Needling of P6 and CV24 points
46385|NCT03821428|Procedure|Placebo|Application of placebo acupuncture needles to the areas, where the acupoints are situated
46386|NCT03821415|Drug|RP101|17β-oestradiol-3-phosphate ophthalmic sterile solution
46387|NCT03821402|Biological|DAXI for injection dose LOW DOSE|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
46388|NCT03821402|Biological|DAXI for injection dose MEDIUM DOSE|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
46389|NCT03821402|Biological|DAXI for injection Dose HIGH DOSE|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline
46390|NCT03821402|Other|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
46391|NCT03821389|Device|NIOD Frequencer|NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
46392|NCT03821376|Drug|Contrast enhanced ultrasound with Lumason|Following consent, they will undergo contrast enhanced ultrasound of their known renal mass(es). This will be performed at University hospital following intravenous administration of Lumason (2.5 mL per injection, maximum of 2 injections per mass).
46393|NCT03821363|Biological|SCT-I10A|Experimental: Anti- PD-1 monoclonal antibody（SCT-I10A）
46394|NCT03821350|Other|Information leaflet|The written and visual information form prepared specifically for the patients was aimed to provide detailed information by clearly expressing the procedure, the suggestions that will be needed before and after injection (what to bring next, what circumstances may not be done, the control visit day after the procedure etc.) to be applied on before the injection day.
46456|NCT03820804|Drug|Sapropterin|A pharmacological treatment for patients with Phenylketonuria, used alone or in combination with dietary treatment.
46395|NCT03821337|Device|repetitive Trans Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that is able to alter cortical excitability and is FDA-approved to treat Major Depressive Disorder. Magnetic fields pass unimpeded through the scalp, skull and meninges, and can directly excite cortical areas.
46396|NCT03821337|Device|Sham TMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real rTMS. This type of sham has been demonstrated to be indistinguishable from real rTMS, has been well tolerated (George et al., 2010; George et al., 2014) and successfully used in other clinical trials (Borckardt et al., 2008; Arana et al., 2008). During each session of rTMS the investigators will present a series of opioid related images, including those utilized in previous studies (Garland et al., 2015; Garland & Howard, 2014).
46397|NCT03821324|Device|Venus Viva|The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
46398|NCT03821311|Radiation|Computed tomography|End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
46399|NCT03821298|Other|Standard of Care Hand Therapy|8 sessions 2 times a week for 4 weeks
46400|NCT03821285|Procedure|Pulmonary Rehabilitation|Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training
46401|NCT03821272|Biological|PepCan|Vaccine regimen consisting of seven injections of PepCan
46402|NCT03821259|Other|Psychological measures|Participants will be asked to provide basic demographic information and to complete six measures, screening for cognitive impermanent and measuring symptoms of anxiety, depression and PTSD as well as lifetime trauma exposure, emotion regulation and group identification.
46403|NCT03821246|Drug|Atezolizumab|Given IV
46404|NCT03821246|Drug|Enzalutamide|Given PO
46405|NCT03821233|Drug|ZW49|"Dose Escalation: ZW49 administration IV every 2 weeks (Q2W) and dose levels determined by the SMC~Expansion: MTD or RD identified in the dose-escalation part of the study"
46406|NCT03821220|Behavioral|Motivational Interview support and Dietitian support|Three sessions of a structured motivational support intervention. Each patient will be required to set a SMART physical activity personal objective. The sessions will cover possible barriers and facilitators, enhancing self-efficacy, and feedback. In addition two sessions with a dietitian to discuss ways to improve current health habits.
46407|NCT03821220|Behavioral|Activity tracker plus usual care|Each patient will receive their own activity tracker (vivofit 3) with instructions on use, in addition to usual care, and written handouts for pre-diabetic patients.
46408|NCT03821220|Behavioral|Personalized physical activity prescription|Each patient will receive a personalized prescription of recommended physical activity including type of activity, duration and frequency.
46409|NCT03821207|Behavioral|The exercise group|The students will make exercise during the first three days of the menstrual period
46410|NCT03821207|Behavioral|The abdominal massage group|The students will make abdominal massage during the first three days of the menstrual period
46411|NCT03821207|Behavioral|Control Group|The students will nor massage or exercise
46412|NCT03821194|Other|Gua sha|Scrape the skin around the knee joint
46413|NCT03821194|Other|hot pack|hot pack
46414|NCT03821181|Device|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
46415|NCT03821181|Device|Sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
46416|NCT03821168|Drug|injection of bevacizumab and erythropoietin|injection of bevacizumab and erythropoietin
46417|NCT03821168|Drug|injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness
46418|NCT03821155|Other|Vestibular rehabilitation|Specialized physical therapy aimed at restoring balance
46419|NCT03821155|Drug|Corticosteroid|Prednisolone
46420|NCT03821142|Device|Pelvic organ prolapse surgical treatment|Surgical treatment with mesh for pelvic organ prolapse
46421|NCT03821129|Device|PFO closure with GORE® CARDIOFORM Septal Occluder|PFO closure with GORE® CARDIOFORM Septal Occluder in patients with ischemic stroke
46422|NCT03821116|Other|Milk|Swedish milk from cow.
46423|NCT03821116|Other|Soured milk (filmjölk)|Swedish soured milk (from cow milk).
46424|NCT03821103|Behavioral|Training|The training includes of (1) in-person training with pre- and post-session knowledge and attitude assessment, (2) three month post-session knowledge and attitude assessment and (3) self-report of first-time buprenorphine-naloxone ED administration within 3 month study period
46425|NCT03821103|Behavioral|Behavioral economic enhanced arm|Behavioral economic enhancement includes an opt-out invitation, loss-framed incentivization, weekly tailored text based reminders
46426|NCT03821077|Biological|Allergen Immunotherapy (AIT)|Immunotherapy vaccine with 2 allergenic extracts mixtures (pollens or mites)in polimerized-depot formulation
46454|NCT03820817|Drug|Rifaximin|Given PO
46455|NCT03820804|Other|Diet|A specific dietary treatment for patients with Phenylketonuria.
46427|NCT03821064|Other|Patient Navigation|NDURE is a theory-based, multi-level patient navigation (PN) intervention consisting of clinic-based sessions of manualized PN to reduce barriers to care, increase HNC care delivery, and improve clinical outcomes (timely, equitable PORT). NDURE will be delivered from surgical consultation to PORT initiation (~3 months). The three in-person NDURE sessions, which are expected to take 30-60 minutes each, will coincide with the presurgical consult, hospital discharge, and 1st postoperative clinic visit. During the first session, the navigator will 1) elicit barriers and facilitators to timely PORT, 2) develop the personalized barrier reduction plan (BRP), review the BRP with the patient, caregiver, and provider, and 3) implement the BRP. At the two subsequent sessions, the navigator will review and update the BRP in an iterative, dynamic fashion, identifying new barriers and systematically tracking resolution of prior barriers until the start of PORT.
46428|NCT03821038|Biological|CYT107|IV twice a week at 10µg/kg for 3 weeks
46429|NCT03821038|Drug|Placebos|IV twice a week at the same volume for 3 weeks
46430|NCT03821025|Device|Biliary stent|Palliation of malignant biliary obstruction
46431|NCT03821012|Other|in-hospital process optimization|
46432|NCT03821012|Other|PPCI hospital-based regional STEMI transfer network construction|
46433|NCT03821012|Other|the whole-city STEMI care network construction|
46434|NCT03820999|Other|Oral and written information on tick-bites and Lyme disease|See under study arm descriptions
46435|NCT03820986|Biological|Pembrolizumab|IV infusion
46436|NCT03820986|Drug|Lenvatinib|Oral capsule
46437|NCT03820986|Drug|Placebo for lenvatinib|Oral capsule
46438|NCT03820973|Behavioral|Brief CBT for Anxiety|All participants will receive psychoeducation on anxiety and bCBT treatment approach, work on setting goals, begin self-monitoring, and select skill sessions that fit his/her most pressing needs. Available skills: Relaxation-Diaphragmatic breathing is a simple relaxation technique that increases oxygen flow and reduces the unpleasant physiological sensations associated with anxiety; Exposure - designed to educate Veterans about the role of avoidance in maintaining anxiety problems, as well as information about how to reduce avoidance through exposure exercises; Cognitive - Veterans may opt to address anxiety and worry through modifying negative thinking patterns. Two available options - Increasing Helpful Thoughts and Managing Unhelpful Thoughts.
46439|NCT03820947|Device|VenaSeal™ Closure System|The VenaSeal™ closure system is the non-tumescent, non-thermal, non-sclerosant device that uses a proprietary medical adhesive delivered endovenously to close the vein.
46440|NCT03820934|Diagnostic Test|Fibroscan and Fibrosure|Patient's will undergo fibroscan and fibrosure to test their liver for the level of liver fibrosis as measured by these tests. Fibroscan uses vibrations sent through the liver to measure its stiffness and the fibrosure uses laboratory and demographic parameters to create a score associated with a certain level of fibrosis. The scores from these tests will then be compared to the amount of fibrosis noted on a standard of care liver biopsy.
46441|NCT03820921|Diagnostic Test|EUS-FNB|"EUS WITH EUS-FNB will be performed for confirmation of diagnosis and analysis of MMR status and PD-L1 expression~Protocol of EUS with EUS-FNB should include linear EUS instruments with complete examinations of the pancreas. Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNB will be performed in all pancreatic masses with at least three passes in the absence of an onsite cytopathologist using a fanning technique with a 22-gauge needle (SharkCore FNB needle Medtronic Corp. or Acquire FNB needle Boston, MA)."
46442|NCT03820921|Other|Immunohistochemistry|IHC will be performed on treatment-naïve formalin-fixed paraffin-embedded EUS-FNB pancreatic specimens. Briefly, 4-μm-thick tissue sections will be stained using the Ventana BenchMark XT automated slide-staining system using the following antibodies: Anti-PD-L1 (clone SP263, VENTANA, Tucson, AZ), MLH1 (clone G168-728, Cell Marque, Rocklin, California, United States), MSH2 (clone FE11, Biocare Medical, Concord, Massachusetts, United States), MSH6 (clone BC/44, Biocare Medical, Concord, Massachusetts, United States), and PMS2 (clone A16-4, Biocare Medical, Concord, M Massachusetts, United States). Antigen-antibody reactions will be visualized using UltraView detection with diaminobenzidine as the chromogen. The specimen will be considered to have PD-L1 expression if PD-L1 is expressed in ≥ 1 % of tumor cells and a high level of expression if ≥ 50 %. Tumors will be classified as dMMR if they exhibit absent nuclear staining of DNA mismatch repair proteins (MLH1, MSH2, MSH6, or PMS2).
46443|NCT03820908|Drug|Bisantrene|The patients will receive bisantrene 250mg/m2/d for 7 days in conjunction with the conventional supportive care.
46444|NCT03820895|Diagnostic Test|Blood test|Serum 25-hydroxyvitamin D 25(OH) D levels were measured for Vitamin D status, by electrochemiluminescence immunoassay (Roche, USA). Cobb's angle measurement was done by measuring the major spinal curve and was taken from the upper end vertebra to the lower end vertebra through an x-ray for all the patients included in the study.
46445|NCT03820882|Device|Catfish|Patients will be treated for mechanical recanalization with Catfish within 8 hours after stroke onset plus standard medical management.
46446|NCT03820882|Device|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
46447|NCT03820869|Other|Family Training|Family Training
46448|NCT03820869|Other|Occupational Therapy|Occupational Therapy
46449|NCT03820856|Procedure|acupuncture plus fire needle therapy|The protocol used in this group was the same as that used in the acupuncture alone group except that fire needle therapy was added. The treatments were administered twice weekly for 6 weeks. Fire needle therapy was performed as follows: an acupuncture needle made of tungsten was heated until red-hot over a lighter and then inserted into the two Ah shi points (the tender points on the common extensor tendon, specifically extensor carpi radialis). The red-hot needle was inserted rapidly into the Ah shi point (approximately 5-8 fen deep, 1 cun = 10 fen) for approximately half a second and then removed. Pressure was then applied to the needle hole using a sterilized dry cotton ball.
46450|NCT03820856|Procedure|acupuncture|We selected acupoints that have often been recommended for the treatment of lateral epicondylitis. Triple needling was performed at the Ah shi point, i.e., the 1-2-cm area encompassing the most painful spot on the humeral epicondyle. We also manipulated acupuncture needles in the following areas: LI10 (Shousanli), LI11 (Quchi), LI12 (Zhouliao) and LU5 (Chize). The treatments were administered twice weekly for 6 weeks.
46451|NCT03820843|Other|Art therapy and standard orthophonic rehabilitation|In addition to standard orthophonic rehabilitation, the patient will receive 12 sessions of art therapy
46457|NCT03820791|Device|Placement of a poster in patients' rooms|Patients and their caregivers will be exposed to the poster for one month
46458|NCT03820778|Diagnostic Test|Whole Body MRI|WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)
46459|NCT03820739|Other|Follow-up|No investigational vaccine will be administered during this study
46460|NCT03820739|Other|Blood sample collection|Blood sampling to assess vaccine-induced immune responses will be conducted only in cohort 1 in a subsample consisting of approximately 102 adults and 165 children (55 from each of the three paediatric age groups that were enrolled in EBOVAC-Salone: 12-17 year olds, 4-11 year olds, and 1-3 year olds).
46461|NCT03820726|Drug|Nintedanib|Bid
46462|NCT03820713|Procedure|Concentrate of plasma coagulation factors|The plasma concentrate of coagulation factors is applied to the surgical site.
46463|NCT03820713|Procedure|0.9% saline|Control group receives an identical syringe and applicator generated by processing normal saline 0.9% instead of plasma.
46464|NCT03820700|Behavioral|Hypnosis (Hypn)|The hypnosis session will consist of a 20-minute hypnosis recording created by Marie-Elisabeth Faymonville and recorded by Anne-Sophie Nyssen, both professionals in hypnosis from University of Liège. The recording includes suggestions about relaxation, corporal sensations, respiratory techniques and visual imaginative stimuli about a beautiful landscape. With this tool, the hypnosis session is standardized for all patients and there is no need of a psychotherapist to deliver hypnosis.
46465|NCT03820700|Behavioral|Virtual reality (VR)|VR sessions. This session will consist in using a head-mounted 3D graphical display with goggles. With this tool, participants will be able to visualize a 3D immersive landscape for 20 minutes consisting of a shed near a lake at sunrise followed by a relaxing moment in the clouds. The session ends on the lake's edge.
46466|NCT03820700|Behavioral|Virtual reality hypnosis (VRH)|The combined tool sessions. Participants will be simultaneously subjected to the same hypnosis recording and 3D visual stimuli used in the Hypn and VR conditions.
46467|NCT03820700|Behavioral|Music (M)|Music sessions consists in a 20 minutes relaxing song made by a music therapist. This tool is standardized for all patients. This group is an additional group to the study.
46468|NCT03820700|Behavioral|Live Hypnosis|Live hypnosis is an additional non randomized group to the initial study. Hypnosis will be made by a therapist for each patient. Hypnosis would consist in a standardized induction and suggestions during 20 minutes but the story will be adapted to the patient.
46473|NCT03820674|Other|Energy Conservation plus Problem Solving Therapy|EC-PST is a client-centered intervention aiming to guide people with chronic fatigue to create their own solutions so that they can generalize those learned solutions and strategies to other fatigue-related problems even after completing the study participation. Some of the topics covered during the first two introductory sessions are facts regarding fatigue, budgeting and banking energy, and the introduction of EC+PST Intervention.
46474|NCT03820674|Other|Health Education Intervention|The interventionist will be the PI, an occupational therapist (co-I), or OT graduate student who will be trained in the health education topics. During the Health Education sessions, participants will be educated on health-related topics relevant to CHF and EC strategies, although they will not learn how to apply the information to their daily life. Health Education Workbook containing information on the topics taught during the sessions will be provided during the Pretest visit and used throughout the Health Education sessions.
46475|NCT03820661|Device|Ultrasound|High resolution ultrasound pre-operatively and intra-operatively
46476|NCT03820648|Device|Alexis|The Alexis® (Applied Medical) is a surgical device indicated for use in retracting and protecting an incision during laparoscopic or open surgery. It is intended to allow the surgeon to access through an atraumatic circumferentially 360 degrees retracted wound that provides maximum exposure with minimum incision size. Further, once positioned, the Alexis Wound Retractor is intended to protect against wound contamination.The device will be manufactured in five sizes, extra-small, small, medium, medium-large and large. The Alexis Wound Retractor has been found non-toxic and non-irritant when tested in accordance with ISO 10993, Part 1: Biological Evaluation of Medical Devices. The materials used in the manufacturing of the Alexis Wound Retractor have been tested in accordance with applicable standards and was determined to pass tensile strength, elongation, (ASTM D 412) and Tear Strength (ASTM D 624). Functional performance testing has been completed and has passed the required testing.
46477|NCT03820648|Device|Standard 3M™ Steri-Drape 2|Standard 3M™ Steri-Drape 2 is a standard drape applicated on the skin of the patient before the surgical incision.
46478|NCT03820635|Diagnostic Test|Osteopontin (OPN)|the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
46479|NCT03820622|Device|Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)|patients in the study group will be treated by the Paclitaxel-Eluting Coronary Balloon Dilation Catheter (DIOR)
46480|NCT03820622|Device|Paclitaxel-Eluting Balloon (Bingo)|patients in the study group will be treated by the Paclitaxel-Eluting Balloon (Bingo)
46481|NCT03820609|Behavioral|Digital Intervention|This digital application for sexual assault prevention can be completed on a tablet computer.
46482|NCT03820596|Drug|Sintilimab|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
46483|NCT03820596|Drug|Chidamide|"To evaluate the short-term objective efficacy of sintilimab combined with chidamide in the treatment of refractory and relapsed ENKTCL patients, and to determine the MTD, DLT/RP2D of chidamide.~To evaluate the long-term efficacy and safety of sintilimab combined with chidmide in the treatment of refractory and relapsed ENKTCL patients. Exploring biomarkers that may have predictive effects."
46484|NCT03820583|Procedure|Whipple Procedure|Patients underwent Whipple procedure for pancreatic tumors. The procedure commenced with rooftop incision. then layers of abdomen dissected to reach the peritoneum. Then Duodenum dissected out along with pancreas and common bile duct. After rescetion of these structures the anatomy of the tract restored with three anastomosis namely pancreaticojejunostomy, gastrojejunostomy and choledochojejunostomy/hepaticojejunostomy.
46485|NCT03820570|Procedure|hernia repair|inguinal hernia repair
46486|NCT03820557|Other|Educational Intervention|Undergo Decision Counseling Program
46487|NCT03820544|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo ERCP with SEMS placement
46488|NCT03820544|Other|Standard of care|Undergo standard of care surgical resection
46489|NCT03820531|Diagnostic Test|Next Generation Sequencing|DNA Mutational Analysis in pancreas cyst fluid concerning KRAS/GNAS-mutations and mutations in tumor supressor genes
46490|NCT03820531|Diagnostic Test|CEA and lipase|"Measuring CEA and lipase level in pancreas cyst fluid:~CEA > 192 ng/ml and lipase > 200 U/l = mucinous cyst"
46491|NCT03820531|Diagnostic Test|Cytology|"Cytology in pancreas cyst fluid:~mucinous versus non-mucinous cyst; LGD versus HGD/Carcinoma"
46492|NCT03820531|Diagnostic Test|Histology of resected pancreas cyst|Histology of resected pancreas cyst concerning mucinous versus non-mucinous cyst, IPMN versus non-IPMN and LGD versus HGD/Carcinoma
46493|NCT03820518|Drug|Calcitriol|
46494|NCT03820492|Diagnostic Test|OCT, FFR, CTA and FFRCT|Multimodality assessment of intermediate left main stenosis: Comparison of optical coherence tomography-derived minimal lumen area, invasive fractional flow reserve and FFRCT
46495|NCT03820479|Other|Protocol|Best practice of protocol
46496|NCT03820466|Drug|Aspirin|Once daily application of platelet inhibiting medication
46497|NCT03820466|Drug|Atorvastatin|Once daily application of lipid lowering medication
46498|NCT03820466|Drug|Placebo Aspirin|Once daily application of placebo
46499|NCT03820466|Drug|Placebo Atorvastatin|Once daily application of placebo
46500|NCT03820453|Dietary Supplement|Tribulus Terrestris|The experimental arm will receive a dietary supplement to increase the libido and sexual function
46501|NCT03820453|Other|Placebo treatment|The control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics
46502|NCT03820440|Diagnostic Test|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
46503|NCT03820440|Diagnostic Test|Lung recruitment manovre (LRM)|The LRM is performed by using a single act of mechanical ventilation in pressure-controlled mode at 30 cmH20 for 30 seconds
46504|NCT03820427|Diagnostic Test|impulse oscillometry|impulse oscillometry
46505|NCT03820427|Diagnostic Test|multiple breath washout test|multiple breath washout test
46506|NCT03820427|Diagnostic Test|body plethysmography|body plethysmography
46507|NCT03820414|Biological|CRV 101|(Different formulations)
46508|NCT03820414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
46509|NCT03820401|Device|choice of dialyzer|Fiber blocking is calculated in different commercially available dialyzers
46510|NCT03820401|Other|choice of dialysis mode|Fiber blocking is calculated in different commercially available dialyzers used in different dialysis stategies
46511|NCT03820401|Other|choice of anticoagulation strategy|Fiber blocking is calculated in different commercially available dialyzers using different anticoagulation strategies
46512|NCT03820401|Other|preparation of dialyzer|Fiber blocking is calculated in different commercially available dialyzers either preprimed with Albumin or not
46513|NCT03820388|Drug|Propofol 2mg/kg|2 mg/kg
46514|NCT03820388|Drug|Etomidate 0.3 mg/kg|0.3 mg/kg
46515|NCT03820388|Drug|Propofol 1 mg/kg|1 mg/kg Propofol
46516|NCT03820388|Drug|Etomidate 0.15 mg/kg|0.15 mg/kg Etomidate
46517|NCT03820336|Dietary Supplement|Extra Virgin Olive Oil|Subjects will consume 45 ml (40 g) of EVOO daily for 8 weeks.
46518|NCT03820336|Dietary Supplement|Control Oil|Subjects will consume 45 ml (40 g) of a control sunflower seed oil daily for 8 weeks.
46519|NCT03820323|Diagnostic Test|POC VL and targeted DRM testing.|Point-of-care Viral Load Testing will be done to ensure that providers and caregivers receive the results with in 24 hours study. Targeted DRM testing will be performed during the initiation of ART and when viremia (VL>1000 copies/mL) is detected.
46520|NCT03820310|Biological|autologous Tcm cellular immunotherapy|autologous cellular immunotherapy plus traditional therapy. • cells will be infused in 3-5×109 cells/100 ml 1 month after radical resection, then cells will be infused as the same dose followed by a 1 month rest period, Each subject in experimental group will receive a total of 5 cell infusions.
46521|NCT03820297|Behavioral|10 sessions of ASGI|10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination
46522|NCT03820271|Other|SuperMELD|"The population of this arm will consist of patients newly enrolled in the National Liver Transplantation Waiting List for decompensated cirrhosis, whose liver function and MELD score are assessed at enrollment and then routinely reassessed at least quarterly during the waiting phase.~Patients will be followed from their listing to transplantation or discharge or death."
46523|NCT03820258|Drug|SOF/VEL/VOX|Administered once daily with food.
46524|NCT03820245|Dietary Supplement|Bixin|Volunteers consumed bixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
46704|NCT03818919|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
46525|NCT03820245|Dietary Supplement|Norbixin|Volunteers consumed norbixin capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
46526|NCT03820245|Dietary Supplement|Lycopene|Volunteers consumed lycopene capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
46527|NCT03820245|Dietary Supplement|Placebo|Volunteers consumed placebo capsules during 1 week , maintaining their usal lifestyle (avoiding excessive/unusual of fat and carotenoid-containing food, alcohol)
46528|NCT03820232|Device|temperature monitoring|In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
46529|NCT03820219|Device|Prevena™ system|The Prevena™ System acts by removing exudate from a clean, closed incision. It helps hold the edges of the incision together, protecting the surgical site from external contamination in a clean, protected postoperative wound environment.
46530|NCT03820219|Other|Standard sterile wound dressing|Standard wound care involves the application of an occlusive dressing in the operating room.
46531|NCT03820206|Drug|Tranexamic Acid|1 g (10 mL) tranexamic acid stored in a dry container at 15 °C-30 °C) diluted in 20 mL of 5% glucose slowly administered intravenously 15 minutes before skin incision over a 5-minute period.
46532|NCT03820206|Procedure|Cesarean section|Lower segement transverse cesarean section
46533|NCT03820193|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
46534|NCT03820193|Drug|Hydrocodon/Acetaminophen|Traditionally used narcotic pain control
46535|NCT03820193|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
46536|NCT03820193|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
46537|NCT03820193|Drug|Acetaminophen|Post-Operative Non Opioid Pain Protocol
46538|NCT03820193|Drug|Diazepam|Post-Operative Non Opioid Pain Protocol
46539|NCT03820180|Drug|Test Product|2 inhalations of Test and Reference product in each study period
46540|NCT03820180|Drug|Reference Product|2 inhalations of Test and Reference product in each study period
46541|NCT03820154|Diagnostic Test|Skin Prick Test|Skin Prick Testing with inhalant allergens
46542|NCT03820154|Diagnostic Test|Skin Prick Test TAPE|Skin Prick Testing with a Tape, integrating the allergens and needles
46543|NCT03820141|Drug|Durvalumab|programmed cell death-ligand 1 inhibitor
46544|NCT03820141|Drug|Trastuzumab|anti-HER2 monoclonal antibody
46545|NCT03820141|Drug|Pertuzumab|anti-HER2 monoclonal antibody
46546|NCT03820128|Other|Early diet intervention|Participant's diet includes several low-fiber and low-fat commonly available meals and products. Patients will choose what they want to eat with no amount or calories restriction.
46547|NCT03820115|Device|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
46548|NCT03820089|Diagnostic Test|Ultrasonography TP|TP us will be made to the included women
46549|NCT03820076|Other|AZT-04|Staphylococcus epidermidis
46550|NCT03820063|Drug|PTC-Pz|"Paclitaxel 80mg/m2 administered intravenously on day 1 and day 8~Herceptin® 6mg/kg administered intravenously on day 1 (loading dose 8mg/kg) or Herceptin® administered subcutaneously 600mg on day 1~Carboplatin AUC 6mg•ml/min administered intravenously on day 1~Pertuzumab 420mg administered intravenously on day 1 (loading dose 840mg)~Treatment cycles are repeated on day 22"
46551|NCT03820050|Device|Freestyle LIbre Flash Glucose Monitoring System|System Performance will be characterized with respect to YSI reference venous plasma measurements
46552|NCT03820037|Drug|Ongentys|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
46553|NCT03820037|Drug|BIA 9-1067 (test)|single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
46554|NCT03820024|Behavioral|Tailored Feedback Messages|Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period.
46555|NCT03820011|Other|PEM+|PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
46556|NCT03819998|Diagnostic Test|measurement of Fetuin-A level in serum|Fetuin A level will be measured in blood of the PCOS women
46557|NCT03819985|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
46558|NCT03819985|Other|Quality-of-Life Assessment|Ancillary studies
46559|NCT03819985|Other|Questionnaire Administration|Ancillary studies
46560|NCT03819972|Dietary Supplement|Dose response of Capolac®|Capolac® (milk minerals high in calcium) dose is manipulated
46561|NCT03819946|Device|esophageal cooling device (Attune Medical, Chicago, IL)|The esophageal cooling device is a silicone soft tubing that is designed to be inserted into the esophagus. It is currently used clinically to provide whole body cooling or temperature control for intensive care patients (in medically induced coma or general anesthesia). The tubing is established but not been used in the clinical setting of catheter ablation for AF (which is performed under general anesthesia). During application of ablation energy to the posterior left atrial wall, the tubing is cooled to medium-low levels (25 degrees) and this is controlled by the operator.
46628|NCT03819413|Diagnostic Test|serum MOG antibody (anti-MOG)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum myelin oligodendrocyte glycoprotein antibody (anti-MOG) if they tested negative for serum aquaporin 4 antibody (AQP-4-Ab)
46629|NCT03819413|Diagnostic Test|MRI brain, spine and orbit|All patients suspected to have NMOSD according to the recent diagnostic criteria will have MRI brain, spine and orbit with Gadolinium
46562|NCT03819946|Other|Standard esophageal temperature probe|If the participant is randomized to the control group, then a standard esophageal protection method will be used during their catheter ablation procedure. This comprises of an esophageal temperature probe, inserted whilst the patient is under general anesthesia. If during application of ablation treatment to the posterior left atrial wall causes the esophageal temperature to rise above 38 degrees the ablation treatment is halted in this region. If ablation treatment is incomplete, re-application can be applied again cautiously if temperatures fall back to 37 degrees. Further temperature rise of over 38 degrees at the same region is a contra-indication to further ablation work here.
46563|NCT03819933|Behavioral|Educational intervention|Investigators will first determine preferred language and approaches by families, then redefine current training for prenatal counseling at extreme prematurity by developing and implementing two novel, interdisciplinary simulation-based educational programs for MFM and Neonatology (a workshop and an online module), focusing on eliciting values and building partnerships through advanced communication and relational skills, to improve counseling practices and outcomes
46564|NCT03819920|Behavioral|Risk Assessment (CCRAT)|Patient receive personalized colorectal cancer risk assessment over the telephone by answering the questions as outlined in the National Cancer Institute Colorectal Cancer Risk Assessment Tool (https://ccrisktool.cancer.gov/calculator.html)
46565|NCT03819920|Behavioral|Usual Care (UC)|Patients receive standardized general information about colorectal cancer screening over the telephone.
46566|NCT03819907|Combination Product|Audiovisual Guided Relaxation|Five-minute guided relaxation delivered via a computer screen and speakers
46567|NCT03819907|Combination Product|Virtual Reality Guided Relaxation|Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
46568|NCT03819894|Diagnostic Test|Introduction of a lower female hs-cTn cut-point|The new female hs-cTn cut-point will be baed on current recommendations for each of the assays used (hs-cTn T and I). The hospitals are the unit of randomization. At 6-month intervals, randomly selected hospitals will be advised that they are to transition to the intervention phase. For all men, the standard of care, overall population cut-point will be used throughout the entire study.
46569|NCT03819881|Biological|STMC-103H|Live bacterial product
46570|NCT03819881|Biological|Placebo|Inactive placebo substance
46571|NCT03819868|Procedure|High cost|Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.
46572|NCT03819868|Procedure|Low Cost|Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
46573|NCT03819842|Diagnostic Test|Pseudophakic Measurement|standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
46574|NCT03819829|Other|Blood sample|Blood sample
46575|NCT03819816|Other|DEA-App|"The intervention (DEA) group will receive the newly developed app. DEA will consist of three simultaneous modules that provide multidimensional support for informal caregivers aiming to reduce the caregiver burden:~Information module~The information module consists of general information on the disease and the care of people suffering from dementia.~Activity module~The activity module suggests individualized activities and physical fitness exercises by a self-learning algorithm, which supports the caregiver to deliver more targeted and easier care.~Communication module~If two or more persons are caring for one person with dementia, the communication module provides a networking possibility."
46576|NCT03819816|Other|Standard Information group|The control group will receive a leaflet on some general principles for promoting health and well-being in older adults with dementia.
46577|NCT03819803|Biological|Fecal microbiota transplantation|200 ml of a tested stool suspension of a healthy donor is instilled into the patient´s caecum or terminal ileum
46578|NCT03819790|Drug|Basal insulin glargine and lixisenatide|Soliqua (insulin glargine and lixisenatide): a titratable combination of long-acting basal insulin glargine and lixisenatide (Glucagon-like peptide-1 receptor agonist)
46579|NCT03819790|Drug|Basal insulin Basaglar/Lantus + gliclazide MR|basal long-acting insulin Basaglar/Lantus with gliclazide MR 60 mg OD
46580|NCT03819790|Drug|Metformin|Patients can be administered with most tolerant dose of metformin
46581|NCT03819764|Behavioral|Aerobic Exercise|Cycling on a recumbent stationary bike with a specialized motor that forces the individual to cycle approximately 30-35% faster than your self-selected speed
46582|NCT03819764|Behavioral|Upper Extremity Repetitive Task Practice|Repetitive arm exercises
46583|NCT03819751|Procedure|MRI-targeted prostate biopsy|All participants receive traditional cognitive/visual registration biopsy and the above mentioned MRI/TRUS fusion biopsy (also known as software registration biopsy)
46584|NCT03819738|Diagnostic Test|fMRI|Functional MRI will be performed in 1 scan, which will take 1.5 h. (scanning time = 30 min)
46585|NCT03819725|Device|Glucose monitoring|FreeStyle® Libre Pro Interstitial Glucose Meter will be applied after skin preparation with anesthetic cream (Emla®) . Interstitial glucose measurements will be recorded during 2-5 days and during meals.
46586|NCT03819712|Procedure|Collection of blood samples|23 mL of blood will be collected during the inclusion visit
46587|NCT03819712|Other|Collection of fecal samples|Fecal sample self-collected after the inclusion visit
46588|NCT03819712|Other|Collection of urine samples|10 mL of urine will be collected during the inclusion visit
46589|NCT03819712|Other|Collection of vaginal swaps|Sample of vaginal microbiota collected during the inclusion visit
46590|NCT03819699|Drug|Lu AF20513|Lu AF20513 suspension for injection
46591|NCT03819699|Biological|booster vaccine|booster vaccine (Cohort 2) - to be administered as per national recommendations
46592|NCT03819686|Behavioral|Living ACTS website|Living ACTS: About Choices in Transplantation and Sharing video that draws from the Information-Motivation-Behavioral Skills Model of individual level behavior change. A patient will watch the Living ACTS video (embedded in the Living ACTS website) along with any family members or friends who are accompanying a patient. Plus minimum of 5 minutes navigating the website (aside from watching ~20-minutes of videos from the website)
46630|NCT03819387|Drug|NBF-006|Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks
46593|NCT03819686|Behavioral|Standard transplant education procedures|Review of a packet of information with the pre-transplant coordinator. The packet serves to inform transplant candidates and their families about the option living donor kidney transplantation (LDKT). In addition, participants will be provided an iPad/tablet to watch two ~10-minute National Kidney Foundation videos about kidney disease and transplantation in their private room during their regularly scheduled KT evaluation. This video discusses information about transplant, but does not specifically address LDKT and is not culturally-sensitive to African American population.
46594|NCT03819673|Behavioral|Intervention Group Care|children's assessment, setting weight management goals, provision of personalised meal plans, personalised diet and lifestyle optimization advice recommendations to children and their families, periodic re-evaluation every 3 or 6 months
46595|NCT03819660|Drug|Amifampridine Phosphate 10 MG Oral Tablet|Oral tablets
46596|NCT03819647|Drug|stiripentol (Diacomit)|Administration of stiripentol per os
46597|NCT03819634|Device|Inset II with Lantern Technology|Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
46598|NCT03819621|Device|IRISS Medical Technologies mediGrid app|IRISS mediGrid is standalone software, loaded on a mobile electronic platform, which is intended to record and document ophthalmic and other bodily characteristics and to aid in the diagnosis of abnormalities.
46599|NCT03819608|Device|real iTBS|Intermittent Theta Burst Stimulation (iTBS) is a form of repetitive transcranial magnetic stimulation (rTMS), which uses short magnetic field pulses applied to the scalp to induce currents in the underlying brain. iTBS will be delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
46600|NCT03819608|Behavioral|real APT|APT-III is an attention processing training program
46601|NCT03819608|Behavioral|placebo APT|computerized cognitive training
46602|NCT03819608|Device|placebo iTBS|delivered with the Magventure MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P. The Magpro Cool Coil B65 A/P can be switched to active or placebo (A/P).
46603|NCT03819595|Other|Supervised exercise|a free 12-week, small-group (~10 people) exercise program supervised by specially trained instructors, combining two weekly 1h sessions of moderate to high intensity aerobic and strength exercise. Participants are encouraged to undertake an additional group-based walking exercise guided by target heart rates.
46604|NCT03819595|Other|Personalized Program PVS|"a standardized promotion prescription of physical activity, balanced diet and smoking cessation, using the computer tool Promote Healthy Living integrated into the electronic medical record."
46605|NCT03819582|Device|EyeCee One intraocular lens|Hydrophobic aspheric monofocal intraocular lens
46606|NCT03819569|Procedure|Small Renal Mass Biopsy|Subjects will receive a small renal mass biopsy prior to making a treatment decision
46607|NCT03819569|Other|No Small Renal Mass Biopsy|Subjects will not receive a small renal mass biopsy prior to making a treatment decision
46608|NCT03819556|Other|Milk protein in fresh milk|Milk protein in increasing doses.
46609|NCT03819543|Device|Transcranial Direct Current Stimulation|Application of transcranial direct current stimulation via scalp electrodes over presumed epileptogenic focus for 20 minutes at 2.0 mA.
46610|NCT03819530|Dietary Supplement|Vitamin and Mineral Powder|Vitamin and mineral nutritional supplement. Each packet is 1g of powder, to be taken with food.
46611|NCT03819517|Dietary Supplement|Resveratrol|Over the counter supplementation
46612|NCT03819517|Other|Placebo|Empty white colored soft vegetarian capsule
46613|NCT03819504|Procedure|4-D navigated stereotactic radio surgical ablation|4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
46614|NCT03819491|Dietary Supplement|COQUN ORAL FORMULATION|COQUN ORAL FORMULATION is a food supplement based on Coenzyme Q10 MINIACTIVES®
46615|NCT03819465|Drug|Durvalumab|Durvalumab IV Cohort A: Every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w)
46616|NCT03819465|Drug|Danvatirsen|Danvatirsen IV Loading dose C1D1, C1D3, and C1D5 then once a week (q1w) starting at C1D8
46617|NCT03819465|Drug|Oleclumab|Oleclumab IV Cohort A: Every 2 weeks (q2w) for first 2 cycles, then every 4 weeks (q4w) Cohort B: Every 3 weeks (q3w) for the first 4 cycles, then every 4 weeks (q4w)
46618|NCT03819465|Drug|Pemetrexed|Pemetrexed IV Arm B1: Day 1 of each 21-day cycle for the first 4 cycles then either q3w or q4w (per investigator discretion) thereafter Arm B2 and B3: Day 1 of each 21-day cycle for the first 4 cycles then Day 1 of each 28-day cycle (q4w) thereafter
46619|NCT03819465|Drug|Carboplatin|Carboplatin IV Day 1 of each 21-day cycle
46620|NCT03819465|Drug|Gemcitabine|Gemcitabine IV Days 1 and 8 of each 21-day cycle
46621|NCT03819465|Drug|Cisplatin|Cisplatin IV Day 1 of each 21-day cycle
46622|NCT03819465|Drug|Nab-paclitaxel|Nab-paclitaxel IV Days 1, 8, and 15 of each 21-day cycle
46623|NCT03819452|Diagnostic Test|Vitamin D Level|Vitamin D level is measured upon the presentation of the case with ischemic stroke
46624|NCT03819439|Other|Microbiome and Autism Questionnaire|The questionnaire will be administered to collect demographic data (i.e. sex, age, race, and ethnicity) of the volunteers. Additionally, it will ask for the volunteers to identify whether or not they have autism spectrum disorder and what other medical conditions they have and what medications (e.g. prescribed, over the counter, herbal; etc.) that they take.
46625|NCT03819426|Behavioral|Low Intensity Exercise Intervention|Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
46626|NCT03819426|Behavioral|High Intensity Intervention|Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
46627|NCT03819413|Diagnostic Test|serum aquaporin 4 antibody (AQP-4-Ab)|All patients suspected to have NMOSD according to the recent diagnostic criteria will be examined for serum aquaporin 4 antibody (AQP-4-Ab) and serum myelin oligodendrocyte glycoprotein antibody (anti-MOG)
46631|NCT03819361|Diagnostic Test|pulse-oximetry|Patients with suspected OSA will be monitored with 14 nights of pulse-oximetry prior to the already planned in-hospital single-night sleep study at the University Hospital Zurich
46632|NCT03819348|Other|the multiple programs of antifungal therapy for HIV-negative host|the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
46633|NCT03819335|Device|mySugr app|mySugr is a mobile medical app for diabetes management. It has been developed by Roche Diabetes Care and it has two versions, free and Pro. It allows to carry out the diary of diabetes, including the collection and analysis of data on glycaemia, food, physical activity or insulin dose. In addition, it is compatible with continuous glucose measurement systems. It has the possibility to add functionalities such as estimation of HbA1c levels, more detailed data analysis or integration with Google Fit type motion sensors, as well as a bolus calculator, reminders for measuring blood glucose or photo gallery in the Pro version, which is the one that will be provided to the patients for the study.
46634|NCT03819335|Other|Standard care|Face-to-face visits
46635|NCT03819322|Drug|sofosbuvir/velpatasvir|12 week, oral, fixed dose
46636|NCT03819309|Procedure|Ultrasound-guided transvaginal drainage|evacuation of the TOA will be done by ultrasound-guided transvaginal puncture under simple sedation or under general anesthesia if necessary
46637|NCT03819309|Procedure|Laparoscopy|TOA will be evacuated by coelioscopy under general anesthesia
46638|NCT03819296|Other|Best Practice|Receive standard of care
46639|NCT03819296|Other|Biospecimen Collection|Undergo collection of stool, blood, and tissue samples
46640|NCT03819296|Procedure|Endoscopic Procedure|Undergo endoscopy
46641|NCT03819296|Procedure|Fecal Microbiota Transplantation|Undergo FMT
46642|NCT03819296|Biological|Infliximab|Given intravenously (IV)
46643|NCT03819296|Other|Laboratory Biomarker Analysis|Ancillary studies
46644|NCT03819296|Drug|Prednisone|Given orally
46645|NCT03819296|Biological|Vedolizumab|Given IV
46646|NCT03819283|Diagnostic Test|Hepatic evaluation|Evaluation of hepatic steatosis and fibrosis by non invasive tests, either serum markers (steatotest, Fibrotest) or imaging methods (CAP, FibroScan)
46647|NCT03819270|Drug|LY3372689|Administered orally
46648|NCT03819270|Drug|Placebo|Administered orally
46649|NCT03819244|Device|940 nm Gallium Aluminum Arsenide Diode Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.
46650|NCT03819244|Device|2780 nm Er,Cr:YSGG Laser|Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
46651|NCT03819231|Drug|Oxytocin|A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant. Each 40 IU dose will be transferred into four, 1 ml intranasal atomizers and will be administered in four sprays to each nostril over the course of 15 minutes.
46652|NCT03819231|Behavioral|Mindfulness|Participants will be instructed to listen to and practice a 20-minute guided mediation each day for 7 days prior to the experimental session. The guided mindfulness practices will include body scan and seated stillness meditations.
46653|NCT03819231|Drug|Saline Solution|A single 40mL doses of sterile saline (0.9% provided by USC pharmacy) will be transferred into four, 1 ml intranasal atomizers and will be self-administered in four sprays to each nostril over the course of 15 minutes.
46654|NCT03819231|Behavioral|Sham mindfulness|The mindfulness sham group will be required to listen to 20-minutes of Tedtalk podcasts each day that match the attention and time of the mindfulness group. Participants will be instructed to listen to two 10-minutes segments per day in succession between lab visits while in a seated posture.
46655|NCT03819218|Drug|MC2-01 cream|MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)
46656|NCT03819205|Other|kinesiotaping|The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
46657|NCT03819192|Diagnostic Test|microbiome analysis|"From all full age pregnant women with PPROM enrolled in this study vaginal smear samples will be taken at three time points:~directly after hospitalization~5-7 days after beginning of antibiotic treatment~24 h before birth~The microbiome of the neonates of these women will be analysed out of pharyngeal and rectal swabs and umbilical cord blood taken directly after birth and additionally out of the first Meconium."
46658|NCT03819192|Diagnostic Test|Conventional cultures|For every sample taken for microbiome analysis, a conventional culture is taken as control.
46659|NCT03819192|Diagnostic Test|CAAP48 measurment|CAAP48 is an identified sepsis marker in adult patients. The samples are taken dependent on clinical monitoring to compare CAAP48 with established inflammation markers (CRP, IL-6, White blood cell count, Procalcitonin).
46660|NCT03819179|Other|Burt's Bees Serum|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol.
46661|NCT03819179|Other|Burt's Bees Serum with Biulin|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, PreBIULIN FOS (GOVA).
46662|NCT03819179|Other|Burt's Bees Serum with Bonicell|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, Bonicel (Ganaden).
46663|NCT03819179|Other|Burt's Bees Serum with Berenew Complex|This is a commercially available over-the-counter product. Ingredients: Caprylic/ Capric Trigylceride, Isopropyl Palmitate, Sweet Almond Oil, Lanette O, Water, Cetearyl Glucoside, Gluconolactone ans Sodium Benzoate, Water, Glycerin, Xanthan GUM, Tocopherol, BeRenew CLR Complex (CLR).
46664|NCT03819179|Other|Burt's Bees Serum with Ecoskin|This is a commercially available over-the-counter product. Ingredients: Caprylic/Capric Triglyceride, Dimer Dilinoleyl Dimer Dilionoleatem, Silica, Citronellyl Methylcrotonate, Tocopheryl Acetate, Xymenynic Acid, Alpha-glucan Oligosaccharide, Fragrance, Slareolide, Polymnia sonshifolia root juice, Helianthus annuus (sunflower) seed oil, Maltodextrin, Tocopherol, Beta-sitosterol, Lactobacillus, Squalene.
46665|NCT03819166|Device|with deep touch pressure application|The deep touch pressure is applied by the weight loading devices, including but not limited to, weight blanket and weight vest.
46666|NCT03819166|Device|without deep touch pressure application|The deep touch pressure will not be applied.
46669|NCT03819140|Drug|Yasmin|Participants in each treatment arm will receive the medication Yasmin. However only the Cyclical OCP Therapy arm will take the sugar pills designated each month in the pill packs and the Continuous OCP Therapy arm will not.
46670|NCT03819127|Drug|Vildagliptin 50 MG Oral Tablet|
46671|NCT03819127|Drug|Metformin Pill|
46672|NCT03819114|Drug|Levonorgestrel Emergency Contraception (LNG EC)|LNG EC tablet(s) will be administered by mouth in a directly observed manner.
46673|NCT03819101|Drug|Acetylsalicylic acid|100mg
46674|NCT03819101|Drug|Atorvastatin|80 mg
46675|NCT03819088|Dietary Supplement|Zinc|Given PO
46676|NCT03819075|Device|Lightwalker Laser (Fotona)|For the laser group we will use a Lightwalker Laser (Fotona) with a Er:YAG 2940 nm and Nd:YAG 1064 nm wavelengths units. The laser protocol will follow the instructions of the manufacturer (TwinLight protocol) and consists of degranulation of necrotic soft tissue and bone, implant surface disinfection and creating spot bleeding in bone with Er:YAG and deep disinfection and biomodulation with Nd:YAG.
46677|NCT03819075|Other|standard|Granulation tissue elimination, mechanical instrumentation of the implant surface and curettage of intraosseous or supracrestally bone defects will be accomplished using plastic curets, under irrigation with sterile saline solution. Cotton pellets soaked in sterile saline solution will be use to clean debris and remains of removed tissue.
46678|NCT03819062|Device|Low Level Laser Therapy|A 3 week treatment period with 8 treatment sessions in total.
46679|NCT03819049|Biological|ExPEC10V|Participants will receive a single IM injection of ExPEC10V (1 of 3 doses [low or medium or high]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.
46680|NCT03819049|Biological|ExPEC4V|Participants will receive a single IM injection of ExPEC4V on Day 1.
46681|NCT03819049|Biological|Prevnar 13|Participants will receive a single IM injection of Prevnar 13 on Day 1.
46682|NCT03819049|Biological|Placebo|Participants will receive single IM injection of matching placebo on Day 1.
46683|NCT03819036|Other|Questionnaires|Day 0 : Satisfaction questionnaire immediately after consultation Day 1, Day 3 and Day 7 : Telephone follow-up
46684|NCT03819023|Diagnostic Test|Respilife monitor|Respilife monitor
46685|NCT03819010|Drug|Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 18-25
46686|NCT03819010|Drug|Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib|Letrozole(2,5 mg/day during 28 days of each Cycle) + Palbociclib(125mg/day during 21 days of each cycle of 28 days) as neoadjuvant treatment during 6 cycles before surgery of Breast Cancer for patients with pre-treatment recurrence Score of 26-100
46687|NCT03818997|Drug|DKN-01|Patient will receive DKN-01 300 mg IV every 2 weeks
46688|NCT03818997|Drug|Atezolizumab|Patient will receive Atezolizumab 840 mg IV every 2 weeks until PD
46689|NCT03818997|Drug|Paclitaxel|Patient will receive Paclitaxel 80 mg/m2 IV on day 1, 8 and 15 of a 28 day cycle until PD
46690|NCT03818984|Behavioral|Safer Conception for Men with At Risk Partners|CBT based safer conception counseling with longitudinal follow-up and booster sessions. The primary outcome will be HIV RNA suppression at 6 months. Secondary outcomes include early ART uptake, adherence, serostatus disclosure, couples HIV counseling and testing uptake, and limiting unprotected sex to peak fertility.
46691|NCT03818971|Other|electroretinogram (flash, pattern and multifocal)|we measured the waves a, b, oscillatory potentials, back ground noise and i for the flash ERG, the waves P50 and N95 for the pattern ERG and the P1, N1 and N2 for the multifocal ERG
46692|NCT03818958|Other|blood sampling|blood sampling
46693|NCT03818945|Drug|shofu PRG barrier coat|Trilaminar structure which forms a type of stable glass ionomer allowing ion release and recharge, while protecting the glass core from the damaging effects of moisture, greatly improving long-term durability.(Na, BO3, Al, SiO3, F,Sr)
46694|NCT03818945|Drug|Sodium fluoride varnish|5% sodium fluoride [22,600 ppm F-]
46695|NCT03818932|Drug|Celecoxib|Post-Operative Non Opioid Pain Protocol
46696|NCT03818932|Drug|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
46697|NCT03818932|Drug|Ketorolac|Post-Operative Non Opioid Pain Protocol
46698|NCT03818932|Drug|Gabapentin|Post-Operative Non Opioid Pain Protocol
46706|NCT03818919|Drug|Hydrocodone-Acetaminophen|Traditionally used narcotic pain protocol
46707|NCT03818906|Procedure|Molar extraction - Control Group|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
46708|NCT03818906|Procedure|aPDT + Molar Extraction - Test Group 1|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
46709|NCT03818906|Procedure|Infrared + Molar Extraction - Test Group 2|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
46710|NCT03818906|Procedure|aPDT + Infrared + Molar Extraction - Test Group 3|The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
46711|NCT03818893|Drug|Combination of GEN0101 and Pembrolizmub|New Combination immunotherapy GEN0101 and Pembrolizmub
46712|NCT03818880|Device|Novel spectacle lens design|Spectacle lens to control progression of myopia
46713|NCT03818867|Procedure|Insertion of cervical cerclage|insertion of a stitch around the neck of the womb in order to provide extra support.
46714|NCT03818854|Biological|Human Mesenchymal Stromal Cells|Immediately prior to administration, the study product will be thawed and diluted 1:1 with reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40). Additional reconstitution media is added to a final product volume of 300 mL.
46715|NCT03818854|Biological|Cell Reconstitution Media|300 mL of reconstitution media (1:1 mix of 5% human serum albumin and 10% Dextran 40)
46716|NCT03818841|Device|High-flow nasal cannula device|Patients will be randomly allocated to this treatment
46717|NCT03818841|Device|Non-rebreathing oxygen mask group|Patients will be randomly allocated to this treatment
46718|NCT03818828|Biological|TTAX01|TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B.
46719|NCT03818815|Drug|OP0201 20mg per day+Amoxicillin-clavulanate|OP0201 20mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
46720|NCT03818815|Drug|Placebo 0mg per day+Amoxicillin-clavulanate|Placebo 0mg per day+oral Amoxicillin-clavulanate in two divided doses for 10 days
46721|NCT03818802|Dietary Supplement|Nicotinamide Riboside|It will be administered a total of 1000 mg/day of NR in a regimen of 500mg every 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of 1000mg/day (500mg every 12 hours) for 6 weeks more, completing total of 6 months.
46722|NCT03818802|Dietary Supplement|Placebo|It will be administered a correspondent placebo with the same shape and color as the active pill 12 hours by mouth for 4.5 months. After 4.5 months, an advanced individual training (AIT) will be implemented in addition to administration of correspondent placebo every 12 hours for 6 weeks more, completing total of 6 months.
46723|NCT03818789|Behavioral|Mindfulness and acceptance training|A breathing mediation, body scan, talking about acceptance, and presence activity are used. All are low-impact and expected to cause no distress
46724|NCT03818789|Behavioral|Study skills video|A YouTube video describing study skills and suggested habits is used as a control condition.
46725|NCT03818776|Drug|Durvalumab|Durvalumab (MEDI4736) is an anti-PD-L1 monoclonal antibody immunotherapy for lung cancer. Participants will receive 1500mg durvalumab via intravenous (IV) infusion Q4W for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48 unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. (N.b. If a participant's weight falls to 30kg (≤30 kg)), then the participant should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W after consultation between Investigator and Study Physician, until the weight improves to above 30 kg >30 kg, at which point the participant should start receiving the fixed dosing of durvalumab 1500 mg Q4W).
46726|NCT03818776|Radiation|Proton beam therapy RT|Proton beam therapy is a type of RT where the proton stops at a specific depth according to its energy which allows for a sufficient tumor dose that may improve local control and survival while sparing normal organs at risk, such as the heart, lung, and spinal cord.
46727|NCT03818763|Biological|Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII|"Reduced intensity conditioning with melphalan and fludarabine, followed by a single infusion of autologous CD34+PBSC, transduced with a lentiviral vector (-889ITGA2B-BDDFVIII-WPTS(MUT6)(VSVg)) also known as (Pleightlet(MUT6)) encoding the B domain deleted from of human coagulation factor VIII (BDDFVIII) in up to five hemophilia A patients with inhibitors to FVIII~The infusion volume of transduced cells will not exceed 20 ml/kg body weight."
46728|NCT03818750|Device|MRI|"Subjects review alcohol ads in different contexts (neutral context vs positive context such as parties and sport) and answer with buttons lever while being in the MRI to express their desire to consume alcohol or not.~Subjects will be exposed to 288 ads set up."
46729|NCT03818750|Behavioral|Alcohol Use Disorders Identification Test|Questionnaire
46760|NCT03818490|Other|Bergamot Aromatherapy|Patients in this group inhaled bergamot essential oil for 15 minutes.
46761|NCT03818451|Dietary Supplement|Co-ultraPEALut (Glialia)|Co-ultraPEALut is administered to moderate traumatic brain injured patients for 180 days
46730|NCT03818737|Biological|Autologous Bone Marrow Concentrate (BMAC)|Bone Marrow Concentrate (BMAC) is a standard Orthobiologic injection for knee osteoarthritis.The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
46731|NCT03818737|Biological|Adipose-derived Stromal Vascular Fraction (SVF)|Adipose-derived Stromal Vascular Fraction will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a stromal vascular fraction (SVF) that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
46732|NCT03818737|Biological|Umbilical Cord Tissue (UCT)|Cryopreserved doses of cord tissue MSCswill be used. These MSCs were cyopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
46733|NCT03818737|Drug|Depomedrol and Normal saline (Corticosteroid injection)|7cc of the corticosteroid injection prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
46734|NCT03818724|Device|CoolLoop® cryoablation system|Cryoablation of Atrial Fibrillation using the CoolLoop® Cryoablation System
46735|NCT03818711|Behavioral|Communication & Coping Intervention|Mothers receive a treatment manual and participate in individual phone calls aimed at reducing depressive symptoms and improving the quality of parental involvement. A concurrent secret Facebook group will have daily posts to reinforce concepts.
46736|NCT03818711|Behavioral|Education & Check Ins|Mothers receive educational materials and participate in individual phone calls related to these materials. A concurrent secret Facebook group will have daily educational posts.
46737|NCT03818698|Other|Eplets mismatching numbers|In this study, the HLA high-resolution typing data of kidney transplant recipients from 2014 to the end of 2017 were analyzed with HLA Matchmaker for eplets mismatching number. To analyze the incidence of dnDSA and AMR after kidney transplant recipients with different eplets mismatching number posttransplant, and to elucidate the important role of tissue configuration patterns based on HLA eplets matching in long-term graft survival.
46738|NCT03818685|Drug|Nivolumab|Radiotherapy will be maintained in each Arm.
46739|NCT03818685|Drug|Ipilimumab|Radiotherapy will be maintained in each Arm.
46740|NCT03818685|Drug|Capecitabine|Radiotherapy will be maintained in each Arm.
46741|NCT03818672|Drug|Rifaximin|Rifaximin 550 MG BID
46742|NCT03818659|Other|Self-Guided M.A.P. BP Improvement Program|Active Clinics randomized to the Self-Guided Arm will receive access to an AHA/AMA web platform that includes the posted M.A.P. materials and limited access to AMA Staff who are available to answer questions. The study team will facilitate access to staff by hosting a kick-off webinar for program participants that will include an orientation to the materials on the website, general advice and practical tips about what works for implementation, and time for answering questions and discussion with the group.
46743|NCT03818659|Other|Full Support M.A.P. BP Improvement Program|"Active Clinics randomized to the Full Support Arm will receive online access to M.A.P. materials and orientation webinar and also a Practice Change Facilitator who will lead the health center clinical staff, site champions and physician leads at each clinic over the course of 6 months to support the implementation of the MAP Program. With support from an AMA Improvement Advisor, the Practice Change Facilitators will perform a baseline assessment of current workflows and assess each domain of M.A.P. The goal of the Full Support program is to help care teams develop skills and sustainable workflows that are effective at attaining and maintaining high levels of BP control."
46744|NCT03818646|Diagnostic Test|Functional Respiratory Imaging|Functional Respiratory Imaging (FRI) is a novel image based functional diagnostic tool that combines high-resolution CT scans (HRCT) at TLC and FRC with flow simulations (computational fluid dynamics - CFD) providing a 3D visualization and quantification of lung structure and function.
46745|NCT03818633|Device|Elastic abdominal binder|Each woman in the intervention group is fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder is placed snuggly tight (keeping in mind patient's comfort) on top of the hospital gown with the incision positioned at the middle part of the binder. The patients are encouraged to wear binders at all time. However, periods of break from wearing the binder are allowed at their convenience.
46746|NCT03818620|Device|Barco digital dermatoscope device images|Images of skin lesion taken with the Barco dermatoscope by site team member
46747|NCT03818620|Device|Reference standard dermatoscope device images|Images of skin lesion taken with a standard dermatoscope device (as part of standard care)
46750|NCT03818581|Drug|Suvorexant|10-mg or 20-mg Suvorexant capsules
46751|NCT03818581|Other|Placebo|Matching placebo capsules
46752|NCT03818568|Dietary Supplement|ketoanalogues of essential amino acids|Patients will receive conventional treatment according to the institution's clinical guidelines, with moderate restriction of proteins 0.6 g protein/kg/day, as recommended to slow renal damage progression), plus ketoanalogues in the established dosage (1 tablet/5 kg weight divided into 3 doses per day).
46753|NCT03818555|Other|Sebacia Microparticles Treatment|Sebacia Microparticles procedure involving microparticles and 1064 nm laser. Three treatment procedures over a two-week period.
46754|NCT03818542|Drug|ABBV-181|intravenous infusion
46755|NCT03818542|Drug|ABBV-368|intravenous infusion
46756|NCT03818542|Drug|ABBV-927|intravenous infusion
46757|NCT03818542|Drug|ABBV-927|intratumoral injection
46758|NCT03818516|Drug|Infliximab|Participants in this arm will receive one time intravenous infusion of infliximab (5 mg/kg body weight) over a 2 to 2½ hour period while participants rest in an infusion chair.
46759|NCT03818516|Other|Saline|Participants in this arm will receive one time intravenous infusion of saline (0.9% Sodium Chloride) over a 2 to 2½ hour period while participants rest in an infusion chair
46762|NCT03818412|Procedure|Archival tumor tissue collection and blood draws|Archival tumor tissue will be collected for testing of circulating tumor DNA. Blood draws will be taken for testing of circulating tumor DNA.
46763|NCT03818399|Drug|SUBLOCADE|SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
46764|NCT03818386|Drug|AGuIX®|"3 intravenous injection at 100mg/kg~D0: AGuIX® injection followed by MRI (within 7 days before commencement of WBRT)~S1: AGuIX® injection before the first radiation session~S6: AGuIX® injection before the sixth radiation session"
46765|NCT03818386|Radiation|Whole Brain Radiation Therapy|30 Gy in 10 fractions of 3 Gy over 2-3 weeks
46766|NCT03818373|Procedure|polysomnography|Sleep examination strictly non-invasive with skin sensors. This exploration would allow for the detection of respiratory sleep disorders and consider of appropriate management for patients.
46767|NCT03818360|Behavioral|an evidence-based smoking cessation intervention comprising brief advice plus active referrals|The trained healthcare professionals will be encouraged to deliver brief smoking cessation advice based on the AWARD model to smokers who attend emergency departments and are triaged as semi-urgent or non-urgent. The trained healthcare professionals will ask the smokers their smoking history, then deliver the warning message to the smokers. If the smokers refuse to quit immediately, the trained healthcare professionals will advise them to reduce the number of cigarettes smoked per day, with the goal of complete cessation within 6 months. The healthcare professionals will then actively refer smokers to the chosen service provider within 1 week of recruitment. Smokers will receive proactive telephone calls from the service providers, receive a leaflet about the health-related hazards of smoking and benefits of quitting, and a pocket-sized information card containing brief information about the existing smoking cessation services in Hong Kong.
46768|NCT03818347|Device|oxyhydrogen generator (AMS-H-03)|Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term
46769|NCT03818347|Device|analogue machine|This machine has the same apperance and gas condition
46770|NCT03818334|Drug|Cyclophosphamide|Cyclophosphamide 1000 mg/flask
46771|NCT03818334|Drug|ATG|Antihuman T-Lymphocyte Immune Globulin 25 mg/flask
46772|NCT03818321|Drug|Methenamine Hippurate 1 g tablet|Methenamine Hippurate (study drug) is an FDA approved medication in the prevention of UTI. Methenamine Hippurate 1g contains Hippuric acid salt of Methenamine (hexamethylene tetramine), Magnesium Stearate, Povidone, Saccharin Sodium, FD&C Yellow No. 5 (tartrazine) (www.iodine.com/drug/hiprex/fda-package-insert).
46773|NCT03818321|Drug|Placebo tablet|Placebo is a tablet that will be provided to you that looks like the study drug but does not contain any medication. These pills are comprised of gelatin and minimal amounts of lactose powder. The pills are designed to have no effect on the patient.
46775|NCT03818295|Drug|[14C]-praliciguat|10 mg praliciguat containing approximately 500 μCi of [14C]-praliciguat
46776|NCT03818282|Drug|Paclitaxel for injection (albumin-bound)|Paclitaxel for injection (albumin-bound) 260 mg/m2, i.v., d1; AUC = 5 for carboplatin injection, i.v., infusion completed on day 1-3; Repeated every 3-4 weeks for 6-8 cycles.
46777|NCT03818269|Procedure|Subcutaneous pressure measurement|Subcutaneous interstitial measurement at D1, D2, D3 and D7
46778|NCT03818256|Drug|Miricorilant|Miricorilant 600mg
46779|NCT03818256|Drug|Miricorilant|Placebo tablets for once daily oral dosing
46780|NCT03818243|Behavioral|Diary (for reporting all impulse control disorders especially compulsive eating disorders)|During 7 days, at home, patients must report in their diary all their impulse control disorders especially their compulsive eating disorders. They will detailed each food intake and drink intake and the time.
46781|NCT03818230|Other|None (observational study)|None (observational study)
46782|NCT03818217|Device|Coach Pepper group|"Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training ."
46783|NCT03818217|Device|Tablet group|The Tablet provides a theratainment app including cognitive and physical training.
46784|NCT03818204|Device|Magnetic Levator Prosthesis (MLP)|Neodymium magnet embedded in a glasses frame and a polymer embedded (PDMS) micro-magnet array fitted externally to the upper lid with IV 3000 securement film. The IV 3000 is FDA approved for extended wear on the skin. Tegaderm, which is essentially the same adhesive, is even FDA approved as an eye covering (we used Tegaderm in early studies but switched to IV 3000 for its superior ease of handling based on packaging technique).
46785|NCT03818191|Drug|Acamprosate|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
46786|NCT03818191|Other|Placebo|The research pharmacy contracted for this study will randomize the study participants for all sites with placebo or acamprosate.
46787|NCT03818178|Dietary Supplement|Intralipid|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
46788|NCT03818178|Dietary Supplement|Palm Oil Emulsion|Half of the participants will receive either naso-duodenal infusion of intralipid or palm oil each participant will serve as their own saline control on the second study day.
46789|NCT03818178|Other|Saline|All participants will serve as their own controls with a saline infusion study day.
46790|NCT03818165|Biological|CAR2 Anti-CEA CAR-T cells|doses will be delivered by hepatic arterial infusions using pressure enhanced delivery device (PEDD)
46791|NCT03818152|Other|Functional strength assessment|Functional strength exercises to assess strength in lower limbs.
46792|NCT03818139|Other|radiography thorax|The ultrasound of the thorax will be performed while waiting for the X-ray thorax
46827|NCT03817879|Procedure|Conventional double-lument tube for single-lung ventilation|Procedure using a tube without a camera
46896|NCT03817372|Device|Anterior-posterior electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-posterior electrode position
83123|NCT03535727|Drug|Irinotecan|IV over 30 minutes; Days 4 and 11
46793|NCT03818126|Drug|del Nido cardioplegia|"The del Nido components are: Plasma-Lyte A (1000ml), Mannitol 20% (16.3ml), MgSO4 50% (4ml) , NaHCO3 8.4% (13ml) , KCl 2mEq/mL (13ml), Lidocaine 1% (13ml). This solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 4:1 ratio (crystalloid:blood).~The dosage is 20ml/kg. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius. Additional dose of the cardioplegia is given only if the cross-clamp time exceeds 90 minutes. Due to high volume given in a single delivery, 40 milligrams of furosemide are injected into cardiopulmonary circuit."
46794|NCT03818126|Drug|cold blood cardioplegia|"The cold blood cardioplegia components are: Plasma-Lyte A (435ml), Mannitol 15% (20ml), NaHCO3 8.4% (20ml), KCl 2mEq/mL (25ml). The solution is mixed with autologous patient blood from the cardiopulmonary circuit in a 1:4 ratio (crystalloid:blood).~The initial dose is 15ml/kg and a dose of 5ml/kg is added every 20-30 minutes or whenever cardiac activity is observed. The target administration pressure is 100-200mmHg and the target administration flow is 200-300ml/min. The solution temperature is 4 degrees Celsius."
46795|NCT03818113|Other|cardioplegia with HTK-Bretschneider cardioplegic solution|cardioplegia with HTK-Bretschneider cardioplegic solution
46796|NCT03818113|Other|cardioplegia with St. Thomas cardioplegic solution|cardioplegia with St. Thomas cardioplegic solution
46797|NCT03818100|Radiation|Intensity modulated radiotherapy (IMRT)|Simultaneous integrated boost technique using IMRT: 48 Gray (Gy) and 40 Gy will treat tumour and breast tissue respectively, in 15 fractions over 3 weeks.
46798|NCT03818100|Drug|Endocrine therapy|Endocrine therapy will commence following completion of radiotherapy, and will continue for 20 weeks.
46799|NCT03818100|Procedure|Breast conserving surgery|Surgery carried out using local protocol following completion of endocrine therapy.
46800|NCT03818087|Behavioral|Observational cohort|Patients will be followed by collecting clinical data, biospecimens, and quality of life assessments over a period of five years from registration.
46801|NCT03818074|Device|Boston Wavewriter 1000Hz Spinal cord Stimulation|High frequency spinal cord stimulation.
46802|NCT03818061|Drug|Atezolizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
46803|NCT03818061|Drug|Bevacizumab|Patients will receive the combination of Atezolizumab 1200 mg and Bevacizumab 15 mg/kg by IV infusion every 3 weeks.
46804|NCT03818048|Drug|Propofol|after inicial bolus of propofol, remained sedated with propofol infusion (1-2 mg/kg/min)
46805|NCT03818048|Drug|Sevoflurane|after inicial bolus of propofol, remained sedated by inhalation with sevoflurane at a concentration of 2 vol% through a nasal cannula with an oxygen flow.
46808|NCT03818022|Procedure|Cryoneurolysis (Iovera)|Cryoneurolysis performed by radiology department 1 week prior to total knee arthroplasty
46809|NCT03818009|Other|Assessment document|The anesthesiologist will evaluate through his sheet women's cognitive functions.
46810|NCT03817996|Other|Fluid challenge|250ml of saline in Responders (those who increased >10% their cardiac output after a passive leg raising maneuver).
46811|NCT03817983|Diagnostic Test|MRE review for axSpA|Screening for evidence of axSpA on the MRE scan of patients with Crohn's disease followed by clinical and MRI assessment
46812|NCT03817970|Drug|Granisetron|An antiemetic regimen containing granisetron 2 mg oral or IV.
46813|NCT03817970|Drug|Ondansetron|An antiemetic regimen containing ondansetron 8 mg oral or IV.
46814|NCT03817970|Drug|Palonosetron|An antiemetic regimen containing palonosetron 0.25 mg IV.
46815|NCT03817957|Drug|Polyglucoferron|intravenous administration
46816|NCT03817957|Drug|Ferric carboxymaltose|intravenous administration
46817|NCT03817957|Drug|Ferrous Sulfate|oral administration
46818|NCT03817931|Drug|Anticholinergic|Tablet taken once daily.
46819|NCT03817931|Drug|Beta-3 Agonists, Adrenergic|Tablet taken once daily.
46820|NCT03817931|Diagnostic Test|Functional magnetic resonance imaging (fMRI)|All subjects have fMRI at baseline and again after 30 days
46821|NCT03817931|Diagnostic Test|Rey Auditory Verbal Learning Test (RAVLT)|All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
46822|NCT03817918|Procedure|Lung ultrasonography|Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
46823|NCT03817905|Other|Patient navigator|Intervention will utilize staff at the Seidman Cancer Center who are trained in patient navigation and have experience in navigating patients for breast cancer screening as well as sickle cell disease. The staff will undergo training for this study by study principal investigators which will include the target participant population, necessary steps in the navigation process and data that will be collected. In addition, they will receive brief training in supportive, listening technique. They will also be furnished with a telephone script for the initial participant contact.
46824|NCT03817892|Other|Guidance of the External Chest Compression|The CPRmeter® device is positioned on the patient's chest with a disposable adhesive. In the situation of guidance of the External Chest Compression the rescuers have access in real time on the screen to visual feedback on the quality of the External Chest Compression performed and indications of possible corrections to improve the quality of the External Chest Compression . In the case of non-guidance of the External Chest Compression , a mask is position on the screen in order to hide the feedback information.
46825|NCT03817892|Other|Rhythm of a relay 4 minutes|The duration or rhythm of a relay is the time during which a rescuer performs External Chest Compression before being relayed by another rescuer. This time is 2 minutes in non intervention group according to the current guidelines and 4 minutes in experimental group.
46826|NCT03817879|Procedure|VivaSight double-lumen tube for single-lung ventilation|Procedure using a tube with a camera
46828|NCT03817866|Diagnostic Test|BRAHMS CgA II KRYPTOR|"The BRAHMS CgA II KRYPTOR kit is an automated immunofluorescent assay for the quantitative determination of the concentration of CgA in human serum.~The assay is to be used as an aid in monitoring disease progression during the course of disease and treatment in patients with GEP-NETs (grade 1 and grade 2).~Serial testing for patient BRAHMS CgA II KRYPTOR assay values should be used in conjunction with other clinical methods for monitoring GEP-NETs (grade 1 and grade 2)."
46829|NCT03817853|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).
46830|NCT03817853|Drug|Bendamustine|Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.
46831|NCT03817853|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
46832|NCT03817853|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.
46833|NCT03817853|Drug|Prednisone/Prednisolone/Methylprednisolone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
46834|NCT03817853|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
46835|NCT03817840|Procedure|Treatment of Cushing's|Surgical resection of ACTH-secreting tumor to achieve cure of hypercortisolism
46836|NCT03817827|Other|Acupuncture|this group will receive Acupuncture for 30 minutes three times per week
46837|NCT03817827|Dietary Supplement|Diet supplementary|Diet supplementary with soy product
46838|NCT03817814|Behavioral|web-based questionnaire|Participants will complete a web-based questionnaire examining the decisions patients made about fertility preservation before and after treatment, the factors that influenced their decisions, and the ways in which patients pursue family building after treatment.
46839|NCT03817801|Device|NSE balloon|NSE (Goodman®) predilation + DCB (Sequent® Please) treatment
46840|NCT03817801|Device|NC balloon|NC balloon predilation + DCB (Sequent® Please) treatment
46841|NCT03817788|Drug|polyethylene glycol|All patients should receive dietary guidance, and eat a dregless diet three days before colonoscopy. For polyethylene glycol group (group P): the day before colonoscopy, 750 mL (1 box) of polyethylene glycol solution should be drunk 2 hours after dinner; the other 1500 ml (2 boxes) of polyethylene glycol solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same juniar clinician, and related indicators were recorded.
46842|NCT03817788|Drug|sodium phosphate|All patients should receive dietary guidance, and eat a dregless diet three days before colonoscopy. For sodium phosphate group (group S), 750 mL (1 box) of sodium phosphate solution should be drunk 2 hours after dinner; and the other 750 mL (1 box) of sodium phosphate solution should be taken 4-6 hours before the examination. After oral laxatives were finished, 20 ml dimethicone would be taken orally as defoamer. All the enteroscopy should by performed by the same clinician, and related indicators were recorded.
46843|NCT03817775|Other|Music therapy|"The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end."
46844|NCT03817749|Dietary Supplement|Exogenous ketone monoester|Participants will consume 20g of the oral ketone monoester supplement 15 minutes prior to each meal of the day for 14 days. All meals will be provided throughout the 14-day supplementation period.
46845|NCT03817736|Procedure|TACE|Procedure of TACE will be standardized.
46846|NCT03817736|Radiation|SBRT|SBRT screening and planning will be performed by radiation therapists, medical physicists, and oncologists.
46847|NCT03817736|Drug|Immune Checkpoint Inhibitor|An immune checkpoint inhibitor may be administered up to 3 days before or after the scheduled day of administration of each cycle due to administrative reasons.
46848|NCT03817723|Radiation|c-arm cholangiography|
46849|NCT03817697|Other|Questionnaire|The socio-demographic characteristics of patients, their current and past drug use as well as their knowledge of hepatitis B and vaccination, will be collected via a questionnaire, conducted by the service's addictologists at the beginning of the consultation.
46850|NCT03817684|Drug|BPN14770|Drug BPN14770
46851|NCT03817684|Drug|Placebo|Placebo
46852|NCT03817671|Other|5% O2|Culturing embryos in 5% O2 just after thawing and till embryo transfer
46853|NCT03817671|Other|2% O2|Culturing embryos in 2% O2 just after thawing and till embryo transfer
46854|NCT03817658|Drug|SHR-1210|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~SHR-1210 was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
46855|NCT03817658|Drug|Placebo|"First stage：~Concurrent chemoradiotherapy:~Cisplatin：25-30mg/m2 ivgtt d1;Capecitabine：800mg/m2, bid d1-5，qw，5weeks；Synchronous radiotherapy：1.8-2Gy/d，5d/W，45-50Gy。 Consolidation treatment： Cisplatin： 60-75mg/m2 ivgtt d1 Capecitabine：1000mg/m2, bid d1-14，q3w 6weeks。~Second stage:~Placebo was administered intravenously (no prophylactic use), a fixed dose of 200 mg, and 3 mg/kg for subjects with a baseline weight <50 kg. Each infusion for 30 min (not less than 20 min, no more than 60 min), once every 2 weeks, 1 cycle every 4 weeks, the cumulative longest medication period is 12 months."
46891|NCT03817398|Other|Quality-of-Life Assessment|Ancillary studies
46892|NCT03817398|Other|Questionnaire Administration|Ancillary studies
46893|NCT03817398|Drug|Tyrosine Kinase Inhibitor|Re-start TKI medicaiton
46894|NCT03817385|Device|repetitive TMS|rTMS x 10 times
46895|NCT03817385|Device|robotic GT|robotic gait training for 20 times
46856|NCT03817645|Other|Zeolite|The natural zeolite clinoptilolite is of volcanic origin. The mineral belongs to the group of zeolite minerals. Zeolites are silicates with a microporous structure. This results in a stable structure with nanometer-sized cavities that pass through the natural zeolite clinoptilolite - comparable to a mineral sponge. Due to the numerous pores and channels, the mineral has a large internal surface and it can absorb molecules that are smaller in diameter than the pore openings. Since zeolite clinoptilolite has an anionic charge, there are cations such as Na +, K +, Ca 2+, Mg 2+ which can be exchanged for other ions (e.g., Pb^2+) in the cavities for electrical charge balance. In particular, the ion exchange capacity is essential for the effect and is used in many areas.
46857|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot FS101 navigation system and Software 5.1|Computer Assisted Total Knee Replacement with the OrthoPilot FS101 and the software TKA 5.1
46858|NCT03817632|Device|Computer assisted primary total knee replacement with OrthoPilot Elite navigation system and Software 6.0|Computer Assisted Total Knee Replacement with the with the OrthoPilot Elite and the software TKA 6.0
46859|NCT03817619|Drug|Zepatier whole tablet|Single-dose ELB/GZR as a whole tablet in a fasted state.
46860|NCT03817619|Drug|Zepatier crushed tablet|Single-dose crushed ELB/GZR in a fasted state.
46861|NCT03817606|Device|Tritanium Posterior Lumbar Cage|Placement of Tritanium Posterior Lumbar Cage via TLIF procedure
46862|NCT03817606|Device|AVS UniLIF PEEK Posterior Lumbar Cage|Placement of AVS UniLIF PEEK Posterior Lumbar Cage via TLIF procedure.
46863|NCT03817593|Other|Transcendental Meditation (TM)|Each participant will have an individual instruction for 1 hour, followed by a course of 3 weekly group meetings (1-1.5 hours) The students shall meditate in a group for 10 minutes, twice a day, during 3 months, under the supervision of school teachers who will be instructed in TM technique.
46864|NCT03817580|Drug|Project X 26ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
46865|NCT03817580|Drug|Project X 5.1ml|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
46866|NCT03817580|Drug|Prevantics Maxi Swabstick|Application of antiseptic drug to the inguinal and abdomen areas of the subjects
46867|NCT03817567|Drug|recombinant anti-EGFR monoclonal antibody|Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
46868|NCT03817554|Drug|Pramipexole|Pramipexole will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of pramipexole is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
46869|NCT03817554|Other|placebo|Placebo will be taken once daily in the evening 2 to 3 hours before bedtime. The starting dose of placebo is 0.125 mg/day. During the first 4 weeks, the daily dose could be increased by the treating physician in weekly intervals to 0.25, 0.50, or 0.75 mg/day, according to the Patient Global Impression scale (PGI) rating and overall tolerability of the drug. In the case of adverse events (AEs), the dose could be reduced to the previous dose step. During 5 to 12 weeks, the dose will keep constant.
46870|NCT03817541|Device|Edmon (reg), BBraun|exhaled propofol will be compared With plasma propofol values
46871|NCT03817528|Drug|ITI-007|ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
46872|NCT03817515|Drug|ABI-009|Sirolimus Albumin-bound Nanoparticles
46873|NCT03817502|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily.
46874|NCT03817502|Drug|Placebo|Matching placebo capsules, oral administration, once daily.
46875|NCT03817489|Behavioral|Baduanjin qigong|The intervention consists of eight sequential forms of movements which is practiced with guidance on rhythmic breathing and mindful awareness. Each cycle of the eight movements requires 10 to 15 minutes for completion. Four cycles will be practiced in each session with short breaks arranged between them.
46876|NCT03817489|Behavioral|Mindfulness meditation|The intervention is developed based on the core components of the established Mindfulness-Based Stress Reduction and the Mindful Self-Compassion program with adaptation for local practice. The focus of the group is to nurture mindful awareness, acceptance, and self-compassion. The group sessions are composed of a combination of mindfulness-based practice, relaxation, and yoga exercise. The basic philosophy of this intervention is the emphasis of the nurturing of self-kindness attitude, and non-attachment attitude towards inter-personal connectedness and letting go of self-criticism, need for control, and defensive separation in times of adversity. Short breaks will be arranged between each practice.
46877|NCT03817476|Drug|BI 425809 (Treatment T1)|Intended commercial formulation tablet from batch 1 (iCF1)
46878|NCT03817476|Drug|BI 425809 (Treatment T2)|Intended commercial formulation tablet from batch 2 (iCF2)
46879|NCT03817476|Drug|BI 425809 (Treatment R)|Trial formulation 2 tablet (TF2)
46882|NCT03817450|Behavioral|Daily Mouth Care|Nursing assistants will be trained to provide daily mouth care to all residents in nursing homes. Mouth care supplies will also be provided to intervention nursing homes.
46883|NCT03817424|Drug|VIB7734|Participants will receive VIB7734 via injection.
46884|NCT03817424|Drug|Placebo|Participants will receive placebo matching to VIB7734 via injection.
46885|NCT03817411|Drug|Telatinib|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
46886|NCT03817411|Drug|Capecitabine|1000 mg/m²,twice daily for 14 days followed by a 7-day rest period (14 days on/7 days off schedule).
46887|NCT03817411|Drug|Oxaliplatin|130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
46888|NCT03817411|Drug|Placebos|300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
46889|NCT03817398|Procedure|Biospecimen Collection|Undergo blood collection
46890|NCT03817398|Other|Drug Withdrawn|Stop taking TKI medication
46897|NCT03817372|Device|Anterior-lateral electrode position|Escalating energy shocks (100 J, 150 J, 200 J, 360 J) using anterior-lateral electrode position
46898|NCT03817359|Combination Product|Remifentanil-propofol mixture|Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
46899|NCT03817346|Drug|GT-002|Single ascending dose
46900|NCT03817346|Drug|Placebo oral capsule|Comparator single ascending dose
46901|NCT03817320|Drug|Ixazomib|"Days 1, 4, 8, and 11. Note: at least 72 hours must have elapsed between doses~Dose Phase 1 - Assigned upon study entry.~Phase 2 - PO formulation at RP2D"
46902|NCT03817320|Drug|Vincristine|"IV push over 1 minute or infusion via minibag as per institutional policy~Days 1, 8, 15 and 22~Dose: ≥ 1 year: 1.5mg/m2/dose (maximum dose 2mg)~≥ 6 months and < 1 year: 1.2mg/m2/dose~< 6 months: 1mg/m2/dose"
46903|NCT03817320|Drug|Dexamethasone|"Days 1-14~Dose: ≥ 1 year: 10mg/m2/day, divided BID (i.e., 5mg/m2/dose, BID)~≥ 6 months and < 1 year: 8mg/m2/day, divided BID (i.e., 4 mg/m2/dose, BID)~< 6 months: 7mg/m2/day, divided BID (i.e., 3.5 mg/m2/dose, BID)"
46904|NCT03817320|Drug|Asparaginase|"Days 2, 15~Dose ≥ 1 year: 2,500 International units (IU)/m2/dose~≥ 6 months and < 1 year: 2,000 IU/m2/dose~< 6 months: 1,750 IU/m2/dose~Patient with allergic reaction to Pegaspargase can be given Erwinase IM/IV on Mon/Wed/Fri (or every other day per institutional standard) x 6 doses for each dose of Pegaspargase.~Dosing guideline for Erwinase:~1 year: 25,000 IU/m2/dose~6 months and < 1 year: 20,000 IU/m2/dose~< 6 months: 17,500 IU/m2/dose"
46905|NCT03817320|Drug|Doxorubicin|"Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and < 1 year: 48 mg/m2/dose~< 6 months: 42mg/m2/dose"
46906|NCT03817307|Diagnostic Test|USPIO-enhanced MRI|The USPIO contrast agent will be administered intravenously to the subjects. An MRI scan of the neck region is performed 24-36 hours later to detect lymph node metastases.
46907|NCT03817294|Other|Comparison of exercise training modalities|As above
46908|NCT03817281|Device|Accuryn Monitoring System|The Accuryn Monitoring System is a novel Foley catheter and monitoring device capable of detecting physiologic changes in vital signs via sensors within the catheter system. These data are captured non-invasively, continuously, and at a high frequency.
46909|NCT03817268|Drug|Capecitabine monotherapy|Capecitabine is administered within 6 weeks after resection and after adequate recovery. To reduce the side effects and improve patient compliance, the administered dose is half of the recommendation: 625 mg/m2, bis in die (BID) (1250 mg/m2 per day). A 2-week therapy is followed by a 1-week pause, and a cycle includes 3 weeks. A total of 8 cycles is planned for each patient.
46910|NCT03817255|Other|Substance use questionnaire|Questions about substance use based on the Detection of Alcohol and Drug Problems in Adolescents (DEP-ADO) survey.
46911|NCT03817255|Other|Physical activity|Questions about physical activity, based on the short version of the International Physical Activity Questionnaire (IPAQ).
46912|NCT03817242|Procedure|Tympanoplasty using tragal cartilage graft|tympanoplasty type I is performed using tragal cartilage in arm 1
46913|NCT03817242|Procedure|Tympanoplasty using temporalis fascia graft|tympanoplasty type I is performed using temporalis fascia in arm 2
46914|NCT03817229|Behavioral|Education microlearning sessions|mHealth education microlearning sessions
46915|NCT03817229|Behavioral|Automated digital reminders|reminders from electronic monitors based on texts or lights/chimes
46916|NCT03817229|Behavioral|Problem-solving mHealth module|mhealht problem solving module with 2 telehealth sessions with a therapist
46917|NCT03817229|Behavioral|Individualized Adherence Feedback Report|Individual Adherence Feedback reports sent to parents weekly
46918|NCT03817216|Device|Prostatic Urethral Lift (PUL)|PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
46919|NCT03817203|Other|Kinesio tape application|Kinesio tape application combined with pelvic floor exercises will be performed.Taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
46920|NCT03817203|Other|Sham tape application|Sham tape application combined with pelvic floor exercises will be performed.Sham taping is carried out for 2 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
46921|NCT03817190|Drug|DS107|DS107 Capsule
46922|NCT03817190|Drug|Placebo|Placebo capsule
46923|NCT03817177|Procedure|high flow nasal cannula oxygenation|high flow nasal cannula application in PACU
46924|NCT03817177|Procedure|nasal prong|conventional nasal prong application in PACU
46925|NCT03817164|Device|Autonomic Nerve Modulation - Active|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
46926|NCT03817164|Device|Autonomic Nerve Modulation - Control|Thync ANM is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck.
46927|NCT03817151|Procedure|posterior chamber intraocular lens implantation|patients who underwent transscleral sutured posterior chamber intraocular lens implantation
46928|NCT03817138|Other|Exposures: Markers of disease progression|From early phases of the study, it is expected that six main domains will be assessed which will include over N=100 potential markers reflecting different markers of dementia disease progression identifiable from patients' primary care EHR.
46929|NCT03817125|Drug|Placebo for antibiotic|Placebo for antibiotic will be administered orally four times a day for 4 days, followed by a 2-3 day washout.
46930|NCT03817125|Drug|Vancomycin pretreatment|Vancomycin (125mg) will be administered orally four times a day, followed by a 2-3 day washout.
46931|NCT03817125|Drug|Nivolumab|Nivolumab (480 mg) will be administered intravenously (IV) according to institutional guidelines every 4 weeks for up to 12 cycles. A cycle is defined as 4 calendar weeks.
46932|NCT03817125|Drug|Matching Placebo for SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
46933|NCT03817125|Drug|SER-401|Administered once a day for 7 days during the lead-in phase, followed by once a day for 8 weeks during the microbiome/anti-PD-1 treatment phase.
46934|NCT03817112|Drug|Dexmedetomidine Hydrochloride 0.1 MG/ML|Dexmedetomidine Hydrochloride 0.1 MG/ML infusion at 0.2-0.7 mcg/kg/min
46935|NCT03817112|Drug|Propofol 10 MG/ML|Propofol 10 MG/ML infusion at 0.3 -4 mg/kg/h
46936|NCT03817099|Other|Nutrition Intervention based on My Dia-RNP|Subjects in this group will be advised to follow My Dia-RNP and to incorporate diabetes-specific formula (Nutren®Untuk Diabetik)
46937|NCT03817099|Other|Usual Care|Subjects in the group continue with the usual care
46938|NCT03817086|Behavioral|Hand coordination and mental practice|"20 chronic (>1year) moderate to severe TBI patients, with upper extremity movement deficits, will be randomly and equally assigned to two groups.~In the experimental group, participants undergo 5 weeks (3 hrs/week) of physical practice training combined with mental practice (MP group)."
46939|NCT03817086|Behavioral|Hand coordination and action observation|In the control group 2, participants undergo 5 weeks (3 hrs/week) of physical training (PP group).
46940|NCT03817073|Device|Iowa Oral Performance Instrument (IOPI)|Using biofeedback to attain repetitions of 80% of baseline MIP.
46941|NCT03817060|Procedure|cryopreservation of embryos at cleavage stage|cryopreservation of embryos at cleavage stage (day 3) of embryo development
46942|NCT03817060|Procedure|cryopreservation of embryos at blastocyst stage|cryopreservation of embryos at blastocyst stage (day 5 or 6) of embryo development
46943|NCT03817047|Behavioral|Physical education|"Physical education (60 minutes): In addition to the ordinary PE-lessons. The pedagogical activities taught in this lesson should be in line with the curriculum of 9th grade and led by the PE-teacher. In the Don't worry - be happy intervention this class was also organized by the students. The students practiced their Be Happy-activities, or they introduced their class peers to their Be Happy-activity. A PE-teacher was present to support the students if necessary."
46944|NCT03817047|Behavioral|Physical active learning|The curriculum of the subjects (i.e. maths, English, Norwegian) were taught in a physically active manner. The lesson should last 30 minutes and be led by the teacher of the current subject.
46945|NCT03817047|Behavioral|Physical activity|"Without a connection to any specific subject Physical activity should be performed as 30 minutes a week. There are no specific aims to be taught in this lesson, but physical activities that stimulates mastery, joy and well-being should be in focus."
46946|NCT03817047|Behavioral|Be happy|The Be Happy classes were self-organized activity groups of at least three students, developed according to activity preferences across regular classes. The Be Happy groups practiced traditional sports and physical activities, lifestyle sports, dancing, out-door recreation, drama etc. - inside or outside school.
46947|NCT03817034|Drug|Multimodal analgesia|Subjects will be given a rectus sheath block containing dexmedetomidine, ropivacaine, and ketorolac
46948|NCT03817021|Behavioral|CORE NAP SACC|Modify the food environment following a self-assessment of current food conditions
46949|NCT03817021|Behavioral|Early Childhood Education|Provide online training for Head Start educators
46950|NCT03817021|Behavioral|Parent Responsive Feeding|Visit parents in their homes to educate them on responsive feeding
46951|NCT03817021|Behavioral|Child regulation|Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
46952|NCT03817008|Procedure|Ascending aorta replacement with graft|Patient with planned Ascending aorta replacement with graft
46953|NCT03816995|Device|CleanCision Wound Retraction and Protection System|wound retraction and irrigation
46954|NCT03816995|Device|Alexis O Wound Protector|wound retraction
46955|NCT03816982|Procedure|Single-injection bupivacaine HCl plus liposomal bupivacaine|Patients in the liposomal bupivacaine with added bupivacaine HCl ISB group will be given a single injection LB ISB in the preoperative area only by faculty who are part of the regional anesthesia division. The injectate will include liposomal bupivacaine 10ml (133mg) mixed with bupivacaine HCl 0.5% 10 ml.
46956|NCT03816982|Procedure|Single-injection bupivacaine HCl plus a subsequent bupivacaine CISB|Patients in the bupivacaine CISB group will undergo catheter placement with ultrasound guidance only by faculty who are part of the regional anesthesia division. A 20 mL single bolus ISB with 0.25% bupivacaine will be administered followed by catheter infusion of 0.125% bupivacaine at a rate of 5mL/hour postoperatively by the ON-Q pump
46957|NCT03816969|Device|Self-pressurized air-Q with blocker|"It has a drain tube through which a suction tube is passed like the Air-QILA blocker, and Instead of the pilot balloon and inflating cuff, the air-Q SP with blocker incorporates a self-regulating periglottic cuff at the end of this tube , a communication orifice at the junction of the peri-glottic cuff and the airway tube.~This communication between two spaces enables the cuff to dynamically regulate intra-cuff pressure depending on airway pressure. This distinguishing feature of the air-Q SP may result in reduced risk for airway morbidities related to cuff hyperinflation"
46958|NCT03816969|Device|Air-Q ILA blocker|A good seal will provide good ventilation, will guarantee the desired depth of anesthesia at lower gas flows and with lesser leaks to the esophagus, it will not cause rise in intragastric pressure thus preventing regurgitation However, When the cuff pressure is more than the mucosal perfusion pressure, it is likely to either cause postoperative pharyngo-laryngeal symptoms (sore throat, dysphagia, dysphonia) or cause local mucosal trauma and nerve injuries
46959|NCT03816956|Drug|AR-301|AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
46960|NCT03816956|Other|Placebo|Placebo comparator
46961|NCT03816943|Behavioral|Whatsapp|a WhatsApp message with encouraging words will be sent after bond up
46962|NCT03816943|Behavioral|Call|a telephone call will be made after bond up to provide encoring words
46963|NCT03816930|Procedure|mechanical cord usage|Due to the retraction procedures, same preparation conditions will be obtained.
46964|NCT03816917|Other|cutaneous parameters of psoriasis (exposure)|characteristic of the cutaneous domains of the psoriasis: age at start, disease duration, current and previous treatment PASI, BSA, nail involvement
46965|NCT03816917|Other|comorbidity (exposure)|medical and medication history, current and previous comorbidity
46966|NCT03816917|Other|family history (exposure)|Family history of PsC, PsA, IBD, AS, and uveitis
46967|NCT03816917|Other|lifestyle (exposure)|"Intoxications~Lifestyle: occupation and injuries, sport and physical hobbies"
46968|NCT03816917|Other|patient reported outcomes (exposure)|VAS-score on fatigue, PsC severity, joint pain and general well-being
46969|NCT03816917|Other|inflammatory markers (exposure)|Measurements of inflammatory and bone remodeling markers in serum and plasma
46970|NCT03816917|Other|genetic (exposure)|Assessment of known HLA- and SNP-associations with PsA or PsA
46971|NCT03816904|Other|Blood samples|Blood samples before the introduction of chemotherapy
46972|NCT03816891|Drug|KPL-716|solution for injection
46973|NCT03816891|Drug|Placebo|solution for injection
46974|NCT03816878|Biological|H5N1 pISV|Administered as an intramuscular (IM) injection
46975|NCT03816852|Biological|hucMSCs|Human umbilical cord mesenchymal stem cells were transplanted by intravenous infusion
46976|NCT03816839|Drug|SAR439859|"Pharmaceutical form: Capsules~Route of administration: Oral"
46977|NCT03816826|Other|physical therapy|both are physical therapy intervention technique used to treat the soft tissue acute injuries
46978|NCT03816813|Other|blood and saliva sampling|blood and saliva sampling
46979|NCT03816800|Dietary Supplement|ImmunoBon|The dietary agent contains vitamin A, Zn, chelated iron and whey proteins.
46980|NCT03816800|Dietary Supplement|Placebo|the dietary agent does not contain vitamin A, Zn, chelated iron and whey proteins
46981|NCT03816787|Procedure|Negative pressure therapy|Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
46982|NCT03816774|Drug|PEG split-dose and simethicone|Patients in active comparator arm are instructed to take 250mg simethicone pill 15 minutes before PEG dose on the previous evening plus 250mg simethicone pill 15 minutes before PEG dose ending 3 hours before colonoscopy
46983|NCT03816761|Drug|Fast-acting insulin aspart|In each cohort, participants will receive fast-acting insulin aspart using the iLet™ in a cross-over manner for 14 days (7days per period). Dose modification will be handled autonomously by the iLet™ based on the CGM sensor readings and the user interaction with the iLet™ e.g. meal announcements.
46984|NCT03816761|Device|iLet™|The bionic pancreas including pigtail adapters, used in insulin-only configuration
46985|NCT03816748|Device|High flow nasal cannula, HFNC|The HFNC used in this study can supply more than 40-60 L/min of oxygen flow, which is many times higher than the traditional nasal cannula. In addition, HFNC provides heating and moisturizing functions, so the patients 'nasal and oropharyngeal cavities do not dry out. This way, the patients can wear HFNC continuously for many days. Furthermore, when the patients close their mouths, HFNC can create a PEEP of 6-8 cmH2O, which helps with lung expansion after chest surgeries and lowers the risk of pneumonia related to lung collapses.
46986|NCT03816735|Device|Cikatridina|Women are asked to insert the suppositories according to the manufacturer's protocol.
46987|NCT03816735|Device|Juliet Feminine Laser|Women will receive the laser treatment twice during the study period.
46988|NCT03816722|Device|Airvo2|Treatment with HighFlow through the Airvo2 device, 8 hours per day
46989|NCT03816722|Other|Usual care|"High flow treatment is investigated as an add on treatment to the personalized care already prescribed to the patients. As patients with interstitial lung disease very often demand very different treatment set ups treatment will vary in the individual patients. All will, however, be treated with ambulatory oxygen. Usual care will be unaltered a month before inclusion in the study in each of the individual patients"
46990|NCT03816709|Device|Therapeutic Ultrasound|A therapeutic ultrasound treatment was applied to the left medial gastrocnemius muscle with the following parameters: 3 MHz, 1.0 W/cm2 for 15 minutes.
46991|NCT03816696|Drug|GSK3640254|GSK3640254 will be available as 100 mg capsules. Subjects will be administered GSK3640254 200 mg QD via the oral route.
46992|NCT03816696|Drug|DTG|DTG will be available as 50 mg tablets. Subjects will be administered DTG 50 mg QD via the oral route.
46993|NCT03816670|Drug|Corifollitropin Alfa|late start (day 4) vs. corifollitropin-alfa standard start (day 2)
46994|NCT03816644|Other|5-Cog|The 5-Cog is a 5 minute cognitive screen which will identify patients with 'cognitive impairment' from those with 'no cognitive impairment'.
46995|NCT03816644|Other|Health Literacy & Grip Assessment|The health literacy and grip assessment will take approximately 5 minutes, and will test the patient's comprehension and pronunciation of health-related terms as well as strength in their dominant hand. The screen will sort out patients with 'low health literacy' and 'frail (low grip strength)' from those with normal health literacy and normal grip strength.
46996|NCT03816631|Drug|Pimodivir|Participants will receive single oral dose of Pimodivir 600 mg (2*300 mg tablets) under fasted condition on Day 1.
46997|NCT03816618|Drug|Medihoney Gel in A Tube|TREATMENT1
46998|NCT03816618|Drug|Hydrogel|PURLOIN GEL
46999|NCT03816618|Drug|Fucidin Ointment|FUCIDIN ANTIBIOTIC OINTMENT 10%
47000|NCT03816592|Procedure|Opioid free anaesthesia|patient anesthtesized with lidocaine, ketamine and dexamethasone
47001|NCT03816592|Procedure|Opioid anaesthesia|patients anesthetized with sufentanil ketamine and dexamethasone
47002|NCT03816579|Other|PRO-A|30 g of beef protein will be consumed at each meal
47003|NCT03816579|Other|PRO-B|30 g of complementary proteins will be consumed at each meal
47004|NCT03816579|Other|PRO-C|30 g of complementary proteins will be consumed over 24 hours
47005|NCT03816566|Device|patch|A standalone wearable device (the patch), that can record tracheal sounds with a microphone attached just above the suprasternal notch of the subject. The patch also has a 3-dimensional accelerometer to record body position. Furthermore, the patch records oxygen saturation using an FDA cleared pulse oximeter, Nonin 3150 WristOx2® with Bluetooth Low Energy.
47006|NCT03816553|Drug|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg (3mg/kg for underweight patients).
47007|NCT03816553|Drug|Apatinib|Apatinib will be administered 250mg orally, once daily until progression.
47008|NCT03816540|Device|HRV and respiratory coherence biofeedback|Biofeedback treatment to support self-regulatory processes on the physiological level: heart rate variability (HRV) and respiratory coherence.
47009|NCT03816514|Procedure|SpHb monitoring|Noninvasive, continuous pulse oximetry-based hemoglobin (SpHb) monitoring
47010|NCT03816514|Procedure|Conventional management|Conventional management without SpHb monitoring
47011|NCT03816501|Other|music|The preference of the patients will be listened to preoperatively through the headphones
47012|NCT03816501|Other|no music|the patients will not be listened
47013|NCT03816488|Drug|Metformin|Metformin (usual dose) administered 2 h before surgery
47014|NCT03816488|Drug|Salsalate|Salsalate 1.5 g administered 2 h before surgery
47015|NCT03816475|Radiation|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance.
47016|NCT03816449|Other|exercises|"Aerobic exercise will be conducted as a dose walk, 3-5 km / h, lasting 50 minutes per day, least five days per week, for 12 weeks. The intensity of the training will be around 70% of the maximal heart rate.~Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased on weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions and load straps. Progression and maintenance load tapes will be carried out depending on the capacity of individualized persons. Frequency of training will be 3 times a week,will last 70 minutes per day for 12 weeks."
47017|NCT03816436|Other|Follow- up (FU) assessment|Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
47018|NCT03816423|Other|video|"After providing consent, participants will be randomized to video education or traditional care during routine prenatal visit. Randomization will be completed using a random number table. Participants randomized to the intervention group (video education) will view the prenatal screening video made by the Genetic Support Foundation and the Washington Department of Health, the 4.5 minute video How to Decide About Prenatal Genetic Testing, available at: https://www.geneticsupportfoundation.org/genetics-and-you/pregnancy-and-genetics/prenatal-genetictesting-videos"
47019|NCT03816410|Procedure|LAA amputation|complete surgical amputation of the left atrial appendage
47020|NCT03816397|Biological|Adalimumab|Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8mL and 40mg/0.8mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.
47021|NCT03816397|Other|Placebo|The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The placebo is designed to match the characteristics of the citrate-free adalimumab during injection.
47022|NCT03816384|Device|Standard of Care|Standard of care urinary drainage system.
47023|NCT03816384|Device|DLC Group|Urinary drainage system with active drain line clearance and plain silicone catheter.
47024|NCT03816384|Device|DLCS Group|Urinary drainage system with active drain line clearance and silver-doped silicone catheter.
47025|NCT03816371|Other|Head-of-bed elevation|Respiratory pattern including respiratory rate, peripheral oxygen saturation and dyspnea, and drainage including amount of drainage and hematoma formation of all patients were evaluated at 1st, 2nd, 3rd, and 4th hours after positions.
47026|NCT03816358|Biological|Anetumab Ravtansine|Given IV
47027|NCT03816358|Drug|Gemcitabine|Given IV
47028|NCT03816358|Drug|Gemcitabine Hydrochloride|Given IV
47029|NCT03816358|Biological|Ipilimumab|Given IV
47030|NCT03816358|Biological|Nivolumab|Given IV
47031|NCT03816345|Biological|Nivolumab|Given IV
47032|NCT03816332|Biological|Ipilimumab|Given IV
47033|NCT03816332|Biological|Nivolumab|Given IV
47034|NCT03816332|Drug|Prednisone|Given PO
47035|NCT03816332|Drug|Tacrolimus|Given PO
47036|NCT03816319|Drug|UAE Inhibitor TAK-243|Given IV
47037|NCT03816306|Drug|LCZ 696|LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
47038|NCT03816293|Device|Negative Pressure Wound Therapy|Occlusive dressing with attached Prevena incision management with 125mmHg of negative pressure and cartridge to manage secretions
47039|NCT03816280|Procedure|Elective cardiopulmonary bypass (CPB)|All groups undergo elective cardiopulmonary bypass (CPB)
47040|NCT03816280|Procedure|Alpha-stat acid-base management|Acid-base status during CPB will be maintained using the alpha-stat regime
47041|NCT03816280|Procedure|pH-stat acid-base management|Acid-base status during CPB will be maintained using the pH-stat regime
47042|NCT03816267|Device|Nebulizer|Nebulization via mask
47043|NCT03816267|Drug|Salbutamol|Delivery of appropriate dose according to weight
47044|NCT03816267|Device|Metered dose inhaler and spacer|Medication will be delivered through inhaler and spacer
47045|NCT03816241|Other|Frame|Vignette is framed in a way that nudges participant to leave a legacy
47046|NCT03816241|Other|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
47047|NCT03816228|Drug|F 18 T807 Flortaucipir|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
47048|NCT03816215|Behavioral|Volunteer experience|Participants will be assigned to a meaningful volunteer experience from a menu of local options (e.g., volunteering at an animal shelter or in a library) for 30 hours.
47049|NCT03816202|Device|Sundt carotid shunt|The Integra Sundt™ carotid shunts are indicated for temporary carotid artery bypass during carotid endarterectomy procedures to help protect the cerebral hemispheres from ischemia during the period of carotid artery occlusion.
47050|NCT03816189|Diagnostic Test|Blood test|Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing
47051|NCT03816189|Diagnostic Test|Skin biopsies|In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)
47052|NCT03816176|Drug|Isavuconazonium sulfate|Intravenous (IV) infusion
47053|NCT03816176|Drug|Isavuconazonium sulfate|Oral capsule
47057|NCT03816137|Biological|ConM SOSIP|Recombinant HIV-1 trimeric gp140 Env protein: ConM SOSIP gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
47058|NCT03816137|Biological|EDC ConM SOSIP|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env: EDC-ConM SOSIP. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
47059|NCT03816137|Biological|ConS UFO|Recombinant HIV-1 trimeric gp140 Env protein: ConS UFO gp140. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle
47060|NCT03816137|Biological|EDC ConS UFO|Chemically fixed version of recombinant HIV-1 trimeric gp140 Env : EDC-ConS UFO. Model immunogens will be used at the dosage of 100 ug and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle.
47061|NCT03816137|Biological|Mosaic SOSIPs|"Mosaic gp140 Env trimers designed to overcome the immunodominance of hypervariable regions of Env~The immunogen will be used at the dosage of 100 ug (3x33ug) and will be admixed with 500 ug MPLA formulated in liposomes and administered by intramuscular injection into the left or right deltoid muscle."
47062|NCT03816124|Procedure|radiofrequency ablation|radiofrequency ablation of the genicular nerves
47063|NCT03816111|Behavioral|TEACH-PD Training Curriculum|The TEACH-PD training modules have been developed by a core group of renal nurses from the HOME Network in conjunction with senior medical clinicians from the Australasian Kidney Trials Network, eLearning curriculum developers, consumer representatives, and education experts, in line with the International Society for Peritoneal Dialysis guidelines, utilizing modern adult learning principles and best practice eLearning techniques.
47064|NCT03816111|Behavioral|Current standard PD training|Current PD training materials and plan
47065|NCT03816085|Other|Shoes|Shoes with different heel heights
47066|NCT03816072|Drug|Phenylephrine infusion|Correction of anesthesia induced hypotension with phenylephrine to obtain sCA and dCA measurements at 60, 70, 80, 90 and 100 mmHg mean blood pressure. This is achieved by stepwise increases in phenylephrine infusion dose.
47067|NCT03816072|Other|Mechanical ventilation|Patientes are mechanically ventilated at 6 bpm to obtain low frequency blood pressure oscillations (~0.1 Hz).
47068|NCT03816072|Drug|Propofol|Propofol
47069|NCT03816072|Drug|Sevoflurane|Sevoflurane
47070|NCT03816059|Diagnostic Test|Respiratory virus testing|All patients will be tested for respiratory viruses
47071|NCT03816046|Drug|botulinum toxin A|injection in hair bearing area of armpits
47072|NCT03816033|Procedure|Cryotherapy|Catheter ablation treatment for the treatment of the studied arrhythmias
47073|NCT03816033|Procedure|radiofrequency catheter ablation|Catheter ablation treatment for the treatment of the studied arrhythmias
47074|NCT03816020|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside capsules 250mg x 2 BID
47075|NCT03816020|Other|Placebo|Placebo capsules BID
47076|NCT03816007|Behavioral|Yoga and Mantram Repetition|An existing yoga intervention designed for persons with chronic pain will be augmented with training in mantram repetition. The intervention meets 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
47077|NCT03816007|Behavioral|Veteran Calm|A relaxation intervention used previously as a comparator intervention will be delivered by a health educator 1x weekly for 75 minutes for 12 weeks, and includes a home practice component.
47078|NCT03815994|Device|Neuromuscular Electrical Stimulation|This device produces a muscle contraction in response to a externally generated low-voltage electric impulse, which is conducted through electrodes placed on the skin over the muscle group to be stimulated.
47079|NCT03815968|Other|low sodium diet|included in the diet mostly low sodium food. avoid tinned or smoked, food. avoid adding salt to the food.
47080|NCT03815955|Behavioral|Non-Sedentary Behaviour Modelling|Consistent with social learning theory, the primary care provider and the DIGMA support team will model, demonstrate, and verbalize aspects of increased confidence to perform the 1-hour appointment in a standing position and offer a variety of strategies to cope and overcome any feelings of discomfort. Emphasis will be placed on the strategies the primary care team uses to break sitting with standing and light, incidental movements. It will be anticipated that the participant will observe cues and relevant information specific to their behaviour change and engage in minimal sedentary behaviour.
47081|NCT03815942|Biological|ChAdOx1-MVA 5T4 vaccine|ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10^8 plaque forming units
47082|NCT03815942|Drug|Nivolumab Infusion [Opdivo]|Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
47083|NCT03815929|Drug|Estradiol 100 Micrograms Patch|Standard
47084|NCT03815929|Drug|Estradiol Patch|Individualized
47085|NCT03815916|Drug|Gold Nanocrystals|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
47086|NCT03815903|Drug|Induction chemotherapy|3 cycles, each 21 days, of Cisplatin 80mg/m2 plus Paclitaxel 175mg/m2
47087|NCT03815903|Combination Product|Chemoradiotherapy|Radiotherapy 70Gy convencional fractionation concomitant to 3 cycles, each 21 days, of Cisplatin 100mg/m2
47088|NCT03815890|Drug|Nivolumab|2 courses 3mg/kg
47089|NCT03815890|Drug|Doxorubicin|Doxorubicin; weekly low dose doxorubicin 15mg iv
47090|NCT03815877|Dietary Supplement|Nescafe Gold ® coffee|"Nescafe Gold ® coffee (5gm per 100cc water containing 170 mg of caffeine) will be used for all the women in the intervention group.~- patients will drink 100cc coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
47091|NCT03815877|Dietary Supplement|Nescafe Gold DECAF® coffee|"Nescafe Gold DECAF coffee (5 gm per 100cc water containing 5-10 mg of caffeine) will be used for all the women in the control group.~the control group will drink 100cc decaffeinated coffee with 1 tea spoon added sugar at 3, 6 and 9 hours after the surgery."
47092|NCT03815864|Diagnostic Test|Luminex-based solid phase assay of banked sera for anti-HLA antibodies directed against the donor of a second liver transplantation|Anti-AT1R antibodies were tested on pre-transplantation sera using ELISA kit (Lot #30, One Lambda, Canoga Park, CA)
47093|NCT03815851|Device|prophylactic drainage|leave prophylactic drainage after surgery
47094|NCT03815838|Diagnostic Test|PET imaging|Positron emission tomography imaging using 18F-Fallypride and 18F-FDOPA
47095|NCT03815825|Drug|IONIS-FB-LRx|IONIS-FB-LRx at multiple ascending doses, administered subcutaneously every 4 weeks
47096|NCT03815825|Drug|Placebo|Placebo matching solution, administered subcutaneously every 4 weeks
47097|NCT03815812|Drug|IBI306|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
47098|NCT03815812|Drug|placebo|Cohort 1: 75mg Q2W Cohort 2: 140mg Q2W Cohort 3: 300mg Q4W Cohort 4: 420mg Q4W Cohort 5: 450mg Q6W Cohort 6: 600mg Q6W
47099|NCT03815799|Procedure|Bilateral Erector Spinae Block|A linear ultrasound transducer will be place in a longitudinal parasagittal orientation about 3 cm lateral to spinous process. 40 ml bupivacaine/lidocaine mixture will be injected into the fascial plane on the deep aspect of erector spinae muscle. Standard perioperative and postoperative analgesia protocol will be given and postoperative pain levels will be determined by Numerical rating scale (NRS).
47100|NCT03815799|Other|Control|Standard perioperative and postoperative analgesia protocol will be given consisting of paracetamol 1 gr IV and tenoxicam 20 mg IV initiated after induction of anesthesia. At the end of the operation patients will receive meperidine 0.5 mg/kg IV before extubation. Postoperative pain levels will be determined by Numeric Rating Scale (NRS) system, 20 minutes intervals in the first hour and at 2th, 6th, 12th and 24 th hour. For the first hour in the postoperative care unit, tramadol 50 mg IV will be given for rescue analgesia with minimum 20 minutes between doses, in patients showing a NRS ≥ 4. Paracetamol 1 g / 12 hour will be given during ward follow-up. In the ward in patients showing a NRS ≥ 4 tramadol 50 mg IV will be given for analgesia.
47101|NCT03815786|Dietary Supplement|Symbiotic|2-months oral administration of the symbiotic supplement (2 bags/day) + 1 month washout
47102|NCT03815786|Dietary Supplement|Placebo|2-months oral administration of the placebo (2 bags/day) + 1 month washout
47103|NCT03815760|Device|Blood Flow Restriction|Subjects will perform sidelying external rotation exercise
47104|NCT03815747|Device|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
47105|NCT03815734|Procedure|motor imagery|motor imagery during the postoperative immobilization period
47106|NCT03815721|Device|Stimulette r2x+|device for repetitive transcutaneous spinal cord stimulation
47110|NCT03815682|Biological|TRQ15-01|Escalating dose levels
47111|NCT03815669|Procedure|Arthroscopic subacromial decompression|Arthroscopic subacromial decompression
47112|NCT03815656|Device|STN alone|DBS stimulation of STN alone
47113|NCT03815656|Device|GPi alone|DBS stimulation of GPi alone
47114|NCT03815656|Device|STN + GPi|cooperative DBS stimulation of STN and GPi sites
47115|NCT03815656|Device|Closed-loop stimulation|adaptive DBS stimulation of STN and/or GPi sites
47116|NCT03815643|Drug|Avelumab|Participants entering this roll over study will receive avelumab as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2 weeks until progressive disease, according to respective parent studies (EMR100070-001, EMR100070-002, EMR100070-004 and EMR100070-008).
47117|NCT03815630|Drug|pd-1 and dc-cik cells|Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
47118|NCT03815617|Dietary Supplement|Zircombi|Twenty-five IBS patients (Rome IV criteria) (M:F= 8:17; age 48 yrs ± 11 SD) were enrolled and randomized to treatment or placebo in a a crossover randomized double-blind two-block placebo-controlled trial. Abdominal pain and bloating, intestinal habits, severity of disease, intestinal permeability, and intestinal microbiota were performed at the different time points.
47119|NCT03815617|Dietary Supplement|Placebo|Given as comparable packets. Same duration.
47120|NCT03815604|Behavioral|Independent Housing and Support (IHS)|Direct placement of people with SMI in an independent accommodation in the community, usually in a flat rented by the service user. Support is provided by a coach according to individual needs in a permanent housing situation without time limit.
47121|NCT03815604|Behavioral|Residential Care Settings (RCS)|Placement in a common residential home or supportive housing setting with the aim to gain psycho-social stability before being able to maintain independent housing.
47122|NCT03815591|Device|smokeSCREEN web-based game|smokeSCREEN tobacco use reduction/prevention web-based game. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
47123|NCT03815578|Other|Clinical examination|"Number of painful joints,~Number of swollen joints,~Patient Global assessment VAS (0 - 100)~and Physician Global assessment VAS (0 - 100)"
47124|NCT03815578|Other|Pain assessment|"Pressure Pain Thresholds (PPTs),~Mechanical Temporal Summation (MTS)~and Diffuse Noxious Inhibitory Control (DNIC)"
47125|NCT03815578|Other|blood sample|18 ml whole blood for ELISA analysis and miRNAs detection
47249|NCT03814616|Drug|Pyronaridine tetraphosphate 180mg:artesunate 60mg|ACT
47126|NCT03815578|Other|Patient Reported Outcomes|"Health Assessment Questionnaire (HAQ),~Rheumatoid Arthritis Impact of Disease score (RAID),~Daily joint pain intensity VAS (0-100),~Hospital Anxiety and Depression scale~and Coping Strategy Questionnaire."
47127|NCT03815565|Procedure|continuous femoral block|infusion of anesthetic by PCA pump
47128|NCT03815552|Device|Eversense Continuous Glucose Monitoring|The Eversense Continuous Glucose Monitoring System is a glucose monitoring device intended to continually measure interstitial fluid glucose levels in individuals with diabetes for the operating life of the sensor.The System comprises a sensor and a transmitter. The small sensor will be subcutaneously inserted in the arm.The transmitter reads glucose data from the subcutaneous sensor.
47129|NCT03815539|Device|0.1% sodium hyaluronate|In dry eye group, part of the subjects will be instilled with one drop of 0.1% sodium hyaluronate in one of their eyes, then they will be tested with the devices of Oculus Keratograph 5M and Optical Quality Analysis SystemⅡ at different time points (10min, 30min, 60min, 90min and 120min).
47130|NCT03815526|Other|Dynamic tape|Dynamic tape apply 1 time
47131|NCT03815526|Other|Kinesio tape|Dynamic tape apply 1 time
47132|NCT03815526|Other|Sport tape|Dynamic tape apply 1 time
47133|NCT03815513|Other|brain MRI|both case and control groups received brain MRI to evaluate cerebrovascular reactivity
47134|NCT03815500|Behavioral|Enhanced Education|Enhanced educational curriculum will involve learning modalities including 3D modeling, video, and visual-aid enhanced text for references to improve caregiver and patient understanding of wound packing techniques.
47135|NCT03815487|Device|Medtronic MiniMed 670G Insulin Pump in Auto Mode|This kind of intervention will be part of the intensified insulin therapy for type 1 diabetic patients. The system will help to keep blood glucose in a defined range by automatic assisted adaption of insulin dosing.the HCL provides a lot more automatic functions to keep glucose in target compared to SAP.
47136|NCT03815487|Device|Medtronic MiniMed 670G Insulin Pump without Auto Mode|Sensor augmented pump therapy means the addition of alerts according to high or low glucose values as well as trend arrows showing actual glucose trends to pump therapy. There is no automatic adaption of insulin dosing. The patients must respond manually after alarm or according to the trend arrows.
47137|NCT03815474|Drug|anlotinib|Anlotinib 12 mg once daily for 14 days tablet by mouth ; epirubicin 30mg/m2 intravenous injection from 1 day to 2 , ifosfamide 1.8g/m2 intravenous injection from 1day to 5day with 6 cycles. Anlotinib 12 mg once daily for 14 days tablet by mouth to progressive disease
47138|NCT03815461|Drug|Nab-paclitaxel and S-1|Nab-paclitaxel was administered at 125mg/m2 intravenously on day 1 and 8, S-1 （80, 100, or 120 mg/d according to body-surface area on days 1 through 14 of a 21-day cycle for 4-6 cycles.
47139|NCT03815448|Drug|Methotrexate|Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
47140|NCT03815448|Other|Placebo|Participants randomized to placebo group will receive placebo tablets. Starting from 5 mg/week for 2 weeks, the dosage will be adjusted to 10 mg/week; after 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study.
47141|NCT03815435|Procedure|Total intravenous anaesthesia|Induction of anaesthesia: Sufentanil ( 0.2ug/kg) + Propofol (2 -3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: continuous administration of Propofol 6-12 mg /kg/h + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60 Hypotensives: Nitro Pohl 1mg/ml 0-10 ml/h
47142|NCT03815435|Procedure|Balanced anaesthesia group|Induction of anaesthesia: Sufentanil ( 0.2ug/ kg) + Propofol (2-3 mg /kg) + Rocuronium (0.6 mg/kg) Management of anaesthesia: Desflurane 0.8-1.2 MAC + Sufentanil boluses of 10 ug as needed. The target BIS value: 40-60
47143|NCT03815422|Procedure|Regional anesthesia|Short lasting sciatic nerve block and long lasting plantar block with distal deep peroneal block
47144|NCT03815409|Other|Treadmill with partial weight unload|10-minute treadmill walk with a support corresponding to 20% of his/her own weight, followed by a 5-minute rest and a second 10-minute session on the treadmill with a support corresponding to 10% of his/her own weight. In the initial treadmill session, the starting speed of the treadmill was set to 0.5 km/h, subsequent increments of 0.5 km/h per minute were added to reach the maximum speed that was comfortably tolerated by the patient. This latter was used for the entire training period.
47145|NCT03815409|Other|Traditional PT rehabilitation treatment|Every 40-minute treatment session consisted in isotonic and isometric exercises for the major muscles of the limbs and trunk including cardiovascular warm-up exercises (5 minutes), muscle stretching exercises (10 minutes), muscle stretching exercises for functional purposes (10 minutes), balance training exercises (10 minutes), relaxation exercises (5 minutes)
47146|NCT03815396|Drug|INBRX-101/rhAAT-Fc|INBRX-101 is a recombinant human alpha-1 antitrypsin (AAT) Fc fusion protein (rhAAT-Fc).
47147|NCT03815383|Biological|C-CAR088|Autologous BCMA-directed CAR-T cells by a single infusion intravenously will be given in escalating doses.
47148|NCT03815370|Device|Experimental: ABRO™ Binder Arm|ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.
47149|NCT03815370|Device|Placebo Comparator: Usual Care|"The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site."
47150|NCT03815357|Other|Referral to Immunology|Screening for primary immunodeficiency and splenic dysfunction
47151|NCT03815344|Drug|Standard|20 units diluted in 100mL of Normal Saline injected laparoscopic needle
47152|NCT03815344|Drug|Standard-vaginal misoprostol|20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
47244|NCT03814655|Procedure|Partially digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be partially digital.
47245|NCT03814642|Drug|Clopidogrel 75 mg|Clopidogrel 75 mg tablet
47246|NCT03814642|Drug|Tegoprazan 50 mg|Tegoprazan 50 mg tablet
47153|NCT03815331|Drug|Xiaflex®|medication indicated for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiaflex belongs to a family of enzymes called collagenases. Collagenases are proteinases that hydrolyze collagen in its native triple helical conformation under physiological conditions, resulting in lysis of collagen deposits. The signs and symptoms of Peyronie's disease are caused by a collagen plaque. Injection of XIAFLEX into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque. Following this disruption of the plaque, penile curvature deformity and patient bother caused by Peyronie's disease are reduced
47154|NCT03815331|Drug|Aveed|Aveed® is an FDA-approved medication for treatment of hypogonadism (low testosterone). It is not approved for the treatment of Peyronie's Disease. Aveed® 750 mg/3mL injection will be placed intramuscularly at the beginning of study, at four weeks, at 10 weeks thereafter.
47155|NCT03815318|Drug|Recombinant Human Coagulation FVIII|Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
47156|NCT03815305|Drug|Centella Asiatica Extract|centlla asiatica oral drug at 1100 mg dose
47157|NCT03815305|Drug|Topical CA|1% centella asiatica ointment
47158|NCT03815305|Drug|Petroleum jelly|vaseline album
47159|NCT03815292|Drug|MMH-MAP|MMH-MAP: oral administration, per 1 intake - 2 tablet (keep in the mouth until complete dissolution), twice times daily
47160|NCT03815292|Drug|Placebo|Placebo: oral administration, per 1 intake - 2 tablet (keep in the mouth until complete dissolution), twice times daily
47161|NCT03815279|Drug|Carfilzomib|Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
47162|NCT03815279|Drug|Lenalidomide|Lenalidomide PO once daily on days 1-21 of a 28 day cycle
47163|NCT03815279|Drug|Dexamethasone|Dexamethasone will be administered weekly
47164|NCT03815266|Diagnostic Test|transcranial Direct Current Stimulation (tDCS)|"transcranial Direct Current Stimulation (tDCS) is device which consist in setting up an electrode on the skull of the patient to deliver the low intensity current.~Patient will have transcranial Direct Current Stimulation (tDCS) at each session and at the same time of Computerized Mirror Therapy (CMT)."
47165|NCT03815266|Diagnostic Test|Computerized Mirror Therapy (CMT)|Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3). Patient will have Computerized Mirror Therapy (CMT) at each session and at the same time of transcranial Direct Current Stimulation (tDCS).
47166|NCT03815266|Diagnostic Test|Tolerance Assessment Questionnaire|The Tolerance Assessment Questionnaire will be completed at the end of each session.
47167|NCT03815266|Diagnostic Test|Ashworth's scale|Ashworth's scale evaluates the resistance to stretching. This test will be completed before the start of the program, at the end of the program and one month after.
47168|NCT03815266|Diagnostic Test|Frenchay arm test|"Frenchay arm test evaluates your abilities with the affected hand to perform several actions.~This test will be completed before the start of the program, at the end of the program and one month after."
47169|NCT03815266|Diagnostic Test|Abilhand questionnaire|"Abilhand questionnaire evaluates your abilities to perform several activities in the daily life with your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
47170|NCT03815266|Diagnostic Test|Fugl-Meyer test|"Fugl-Meyer test evaluates your ability to perform different movements with all the joints of your arm affected.~This test will be completed before the start of the program, at the end of the program and one month after."
47171|NCT03815266|Diagnostic Test|Goal Attainment Scaling (GAS)|"Goal Attainment Scaling (GAS) sets therapeutic goals with the patient before the start of the program.~These goals will be checked at the end of the program and one month after."
47172|NCT03815253|Other|acupuncture|"Body electro-acupuncture will choose eight acupoints as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), Sanyinjiao(SP-6).Disposable acupuncture needles (verum acupuncture needles asia-med Special No. 16 with 0.30 x 0.30mm matching the Streitberger sham-needles) will be inserted at a depth of 10-25 mm into the points.~We will also deliver electrical stimulation with dense-disperse waves with 50Hz at 10 volts through electrical acupuncture stimulation instrument (ES-160 6-Channel Programmable Electro-acupuncture) to the abdominal points. The bodily needles will be retained for 30 minutes."
47173|NCT03815240|Other|No dressing|no dressing at sacrum
47174|NCT03815240|Other|Mepilex® Border Sacrum|adhesive sacrum dressing
47175|NCT03815240|Other|ALLEVYN Life Sacrum|adhesive sacrum dressing
47176|NCT03815240|Other|Optifoam® Gentle Sacrum|adhesive sacrum dressing
47177|NCT03815227|Other|Outpatient birth|Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
47178|NCT03815214|Behavioral|Partial meal replacement program|Four meals consist of meal replacements made by OPTAVIA, such as shakes, soups, bars, biscuits, hot drinks, and puddings. Meal replacements will be provided to subjects without charge. For two other daily meals, subjects or their caregivers will be taught how to prepare meals consisting of 5-7 ounces (cooked) of a low-fat protein, 3 servings of non-starchy vegetables, and up to 2 servings of healthy fats.
47179|NCT03815214|Behavioral|Dietary Counseling|Participants will receive one 45-minute counseling session on a healthy diet
47180|NCT03815201|Dietary Supplement|Group 2|leucine-enriched protein supplementation during the first 1/2 hour post-training
47181|NCT03815201|Other|Group 1|placebo, an energy-matched mixture, during the first 1/2 hour post-training
47182|NCT03815175|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
47183|NCT03815175|Drug|DAPT (aspirin and/or P2Y12 receptor inhibitor)|"1-month clear subjects will receive 1 month of DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days and will discontinue P2Y12 receptor inhibitor as early as 28 days and will continue with aspirin monotherapy through 12-month follow-up."
47184|NCT03815162|Dietary Supplement|High Flavanol Cocoa extract|Experimental group
47185|NCT03815162|Dietary Supplement|Alkalised cocoa|Control group
47247|NCT03814642|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg tablet
47250|NCT03814603|Procedure|PET-MR Scan|Participants will undergo PET-MR scans at baseline and two-year follow up to examine brain amyloid deposition longitudinally.
47186|NCT03815149|Device|Pipeline™ Flex Embolization Device with Shield Technology™|Neurointerventional procedures to treat intracranial (cerebral) aneurysms are minimally-invasive procedures performed by Interventional Neuroradiologists. The physician accesses the arterial system through a blood vessel in the groin followed by the insertion of a catheter. Pipeline™ Flex Embolization Device(s) with Shield Technology™,a flow diversion device, is implanted under high-magnification subtraction fluoroscopy, requiring the use of ancillary devices, such as micro-catheters and guidewires to complete the procedure under general anaesthetic. Procedural heparinisation and preloading with dual antiplatelet therapy (DAPT) using acetyl-salicylic acid and P2Y12 inhibitors such as clopidogrel or prasugrel are required.
47187|NCT03815136|Other|Chewing Gum|Patients of CG group chewed one piece of sugarless gum for approximately 15 min every 30 min at the first hour of the examination.
47188|NCT03815136|Other|Control|The control group will not chew chewing gum while undergoing capsule endoscopy
47189|NCT03815123|Diagnostic Test|CT|
47190|NCT03815097|Procedure|Mapleson circuit and nasal trumpet|The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
47191|NCT03815084|Drug|pd-1 and DC-NK cells|total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
47192|NCT03815071|Drug|Ips-nsc cells|Total dose of ips-nsc cells will be administered at day0.
47193|NCT03815058|Biological|RO7198457|Participants will receive a recommended dose of RO7198457 administered by IV infusion at protocol-defined intervals.
47194|NCT03815058|Drug|Pembrolizumab|Participants will receive 200 mg pembrolizumab administered by IV infusion Q3W.
47195|NCT03815045|Procedure|Landmark-based lumbar puncture|Traditional landmark based lumbar puncture involves palpating spinous processes on the back and finding the inter-spinous space which is the site of needle entry to gain access to the thecal sac. Finding this space may be difficult by palpation, especially when subjects undergoing the procedure are obese, elderly, have had prior back surgery, or if the patient is positioned incorrectly.
47196|NCT03815045|Procedure|Ultrasound-guided lumbar puncture|Ultrasound guided lumbar puncture is a novel technique being increasingly utilized by emergency physicians, pediatricians and anesthesiologists. In this technique, an ultrasound probe is used to visualize the inter-spinous space. This space can be marked on the skin as the potential point of entry. This could potentially make it easier when patient factors make it difficult to palpate and find the site of entry.
47197|NCT03815032|Device|Drift assessment of OptoWire Deux FFR wire (1)|Simultaneous data of two different OptoWire DeuxTM guidewires (group 1) to assess a single coronary stenosis and detect any difference if any.
47198|NCT03815032|Device|Drift assessment of OptoWire Deux FFR wire (2)|Simultaneous data of one Optowire Deux TM guide wires and one VERRATA-TM FFR wire (group 2) to assess a single coronary stenosis and detect any difference if any.
47199|NCT03815019|Drug|Megestrol Acetate|The proposed study will use megestrol 6 mg/kg/day in two doses because this dose has been effective and safe in two previous studies using megestrol to stimulate appetite in children transitioning from tube to oral feedings. The megestrol will be dosed at full dose weeks 10-11, at 66% dose week 12, at 33% dose week 14, and fully tapered at the end of week 14. Megestrol is absorbed from the small bowel, so feeding it through the tube will be acceptable.
47200|NCT03815019|Behavioral|iKanEat Behavioral Intervention|"The 24 week iKanEat intervention is composed of 4 clinic visits and a series of 12 tele-visits. All visits (clinic and tele-visits) will focus directly on the oral-motor and behavioral skills necessary for oral eating.~Tele-visits will begin by building rapport and asking for a summary of all relevant information since the last point of contact, including parent perception of changes in weight, feeding habits, progress, stress of parent/child, and illness. The majority of the time left in the 30 minute session will be spent dealing with parent concerns, which our previous project indicates may include questions about measures, questions about implementation of the iKanEat protocol, and ensuring that children/families adhere to the oral-motor and behavioral guidelines for feeding."
47201|NCT03815006|Device|Free Style Libre|FreeStyle Libre (FSL) is a novel glucose monitoring device (Flash glucose monitoring) in the form of a disc worn on the arm for 14 days and a hand-held reader which is designed to largely replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of type 1 diabetes (T1D).
47202|NCT03814980|Behavioral|mindful breathing application|Participants will use a mindful breathing application on a computer tablet.
47203|NCT03814980|Device|application on a computer tablet|a computer tablet
47204|NCT03814967|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
47205|NCT03814954|Drug|Salbutamol|At first day of admission, patients will receive 3 doses of nebulized salbutamol every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
47206|NCT03814954|Drug|Epinephrine|At first day of admission, patients will receive 3 doses of nebulized epinephrine every 20 minutes. Then after 24 hours patients will receive standing dose according to clinical status
47207|NCT03814941|Other|paper-based anesthesia record|to evaluate the incidence of artifacts in the AIMS database by paper-based anesthesia record
47208|NCT03814941|Other|electronic documents|to evaluate the incidence of artifacts in the AIMS database by electronic documents anesthesia record
47209|NCT03814928|Behavioral|Caregivers e-Learning Course|Investigators will request that family/caregivers watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
47248|NCT03814629|Drug|Weifuchun|The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
47210|NCT03814902|Device|Electronic Tracking Device|This commercially-available electronic tracking device uses Global Positioning System (GPS) technology to display the wearer's location on a mobile phone, tablet, or computer. The device may be securely attached to clothing and is designed to be worn by children with developmental disabilities. Parents may use the associated application to view the child's location when the device is turned on and active.
47211|NCT03814889|Device|Vibration pattern|"There are four phases of the study. PHASE 1 and PHASE 2 are pilot studies not included in the clinical trial, and thus are not described here.~PHASE 3: VIBRATION EFFECTIVENESS (24 patients, 2 weeks each) Patients will be given a wearable device to take home. The patient will wear the device while feeling vibrations for 3 hours during the day while awake. At the beginning and end of the phase, each patient will be tested using one or more of the following metrics: Fugl-Meyer, strength, Ashworth, and range of motion.~PHASE 4: DEMONSTRATION (20 test patients and 10 control patients, 8 weeks each) Same as in PHASE 3, but for 8 weeks and both sets of patients will come to the clinic for outcome measures each week."
47212|NCT03814889|Device|No vibration|In PHASE 4, 10 patients will wear a glove with a blinking light instead of feeling vibrations.
47213|NCT03814876|Behavioral|Group session psycho-education|Active comparator - control group
47214|NCT03814876|Behavioral|FITS|Manualized family intervention
47215|NCT03814850|Device|Standard Manual Aneroid Sphygmomanometer|Use of a standard manual blood pressure cuff and manometer for the conditioning intervention.
47216|NCT03814824|Diagnostic Test|IRIS (Intelligent real-time image segmentation)|IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.
47217|NCT03814824|Diagnostic Test|VLE (Volumetric laser endomicroscopy)|VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
47218|NCT03814811|Diagnostic Test|Circulating Osteocalcin-positive (cOC) cells|Quantitative measurement of osteocalcin-positive cells in the peripheral blood mononuclear cells by flow cytometry
47219|NCT03814798|Biological|IGSC 20% daily push versus every 2 weeks pump|IGSC 20% syringe daily push dosing for 16 weeks followed by every 2 weeks pump dosing for 16 weeks or the reverse sequence
47220|NCT03814798|Biological|IGSC 20% daily push versus once a week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by once weekly ambulatory pump administration dosing for 16 weeks or the reverse sequence
47221|NCT03814798|Biological|IGSC 20% daily push versus 2 times per week pump|IGSC 20% syringe daily push dosing for 16 weeks followed by 2 times/week ambulatory pump administration on preselected days (eg, Monday and Thursday) not less than 3 days apart for 16 weeks or the reverse sequence
47222|NCT03814798|Biological|IGSC 20% 150 mg/kg|loading dose of IGSC 20% consisting of 5 consecutive daily doses of 150 mg/kg/day (Week 0, Days 1-5) followed by weekly infusions of IGSC 20% 150 mg/kg starting Week 1 (Day 8) through Week 32 using an infusion SC pump
47223|NCT03814772|Procedure|Liver transplant|blood transfusion
47224|NCT03814759|Drug|TS-1 + cisplatin|S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)
47225|NCT03814759|Radiation|radiation|radiation 45Gy per 5 weeks
47226|NCT03814746|Drug|Crizanlizumab (SEG101)|Crizanlizumab will be supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for infusion IV.
47227|NCT03814746|Drug|Placebo|Placebo will be supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of placebo. This is a concentrate for solution for infusion IV.
47228|NCT03814733|Drug|Rapastinel|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
47229|NCT03814733|Drug|Alprazolam|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
47230|NCT03814733|Drug|Ketamine|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
47231|NCT03814733|Drug|Rapastinel Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
47232|NCT03814733|Drug|Alprazolam Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
47233|NCT03814733|Drug|Ketamine Matched Placebo|Participants will be administered single IV doses of rapastinel, ketamine, rapastinel matched placebo, and ketamine matched placebo, and single oral doses of alprazolam and alprazolam matched placebo in a randomized crossover manner.
47234|NCT03814720|Biological|VRC-FLUNPF099-00-VP (H1ssF_3928)|The vaccine is composed of the HA stem domain from Influenza A/New Caledonia/20/l999 (HlNl) genetically fused to the ferritin protein from H. pylori. Purified HlssF_3928 displays eight well-formed HA trimers that antigenically resemble the native Hl stem viral spikes.
47235|NCT03814707|Drug|Topical application of 0.2% hyaluronic acid gel|Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting
47236|NCT03814707|Biological|Platelet rich fibrin|Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
47237|NCT03814694|Dietary Supplement|CRHP Diet|Dietary macronutrient composition of 30 E% from carbohydrate, 30 E% from protein and 40 E% from fat
47238|NCT03814694|Dietary Supplement|CD Diet|Dietary macronutrient composition of 50 E% from carbohydrate, 17 E% from protein and 33 E% from fat
47239|NCT03814681|Other|Colorectal Surgery|elective Colorectal Surgery
47240|NCT03814668|Dietary Supplement|Probiotic|Intake of probiotic
47241|NCT03814668|Dietary Supplement|Lactase|Intake of lactase
47242|NCT03814668|Other|Placebo|Intake of placebo
47243|NCT03814655|Procedure|Full digital workflow|Dental implants will be inserted usig a surgical guide performed after prosthetically driven treatment planning. The workflow will be full digital.
47251|NCT03814603|Drug|PiB|Subjects will receive a single dose of 555 MBq of PiB and perform a dynamic 30 min PiB PET-MR scan 60 min after injection.
47252|NCT03814590|Biological|RSV Vaccine (GSK3844766A) unadjuvanted low dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
47253|NCT03814590|Biological|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
47254|NCT03814590|Biological|RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
47255|NCT03814590|Biological|RSV Vaccine (GSK3844766A) unadjuvanted medium dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
47256|NCT03814590|Biological|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
47257|NCT03814590|Biological|RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
47258|NCT03814590|Biological|RSV Vaccine (GSK3844766A) unadjuvanted high dose|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
47259|NCT03814590|Biological|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm
47260|NCT03814590|Biological|RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
47261|NCT03814590|Drug|Placebo (Saline solution)|Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
47262|NCT03814577|Diagnostic Test|Total Antioxidant Status|Total Antioxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
47263|NCT03814577|Diagnostic Test|Total Oxidant Status|Total Oxidant Status values will be determined using a novel automated measurement method. The colour intensity, which can be measured spectrophotometrically, is related to the total amount of oxidant molecules present in the sample. The assay is calibrated with hydrogen peroxide) and the results are expressed in terms of micromolar hydrogen peroxide equivalent per litre.
47264|NCT03814577|Device|Bispectral Index|Bispectral Index is a method for depth of anesthesia and assessment of sedation. The values of bispectral index decreases with the deepening of anesthesia. The values of 40-60 characterize the appropriate depth of anesthesia.
47265|NCT03814577|Other|Invasive arterial monitorization|Invasive arterial monitorization will be performed to right radial artery under local anesthesia to follow up hemodynamic changes and take the blood samples.
47266|NCT03814564|Device|NIRS monitoring|Cerebral and peripheral NIRS monitoring of brain and tissue oxygenation. Of the 400 patients, a subpopulation of the first 250 adult critically ill patients (≥18 years) requiring ICU care, including both surgical and medical ICU patients with circulatory shock will be included in the NIRS-substudy. All 400 patients will be analyzed for endotheliopathy incidence, metabolomics, genetic data Representation of the study population will be ensured by enrolment of all consecutive patients at the study sites who meet the study enrollment criteria
47267|NCT03814551|Behavioral|Signage|Placement of signage discouraging consumption of beverages with added sugar
47268|NCT03814525|Radiation|Photobiomodulation|PBM will be applied with extra and intraoral LED devices. The LED plates speed up the treatment as they deliver all the energy at once, having the advantage of radiating several points at the same time. The applications of both will occur in the following experimental periods after the end of the surgeries: immediate postoperative, 1, 2, 7, 14, 30, 60 and 90 days.
47269|NCT03814525|Radiation|Placebo Photobiomodulation|The person responsible for applying the PBM will simulate the irradiation by positioning the devices in the same locations described for the PBM group, but the equipment will be kept off
47270|NCT03814512|Behavioral|Extended Sleep Intervention|Participants will receive an Extended Sleep Intervention (ES). Participants will be prescribed a sleep schedule that allows them to obtain approximately 1.5 h more time in bed compared to their typical sleep. Prescribed bedtimes and wake times will be determined collaboratively through discussion with participants and parents.
47271|NCT03814486|Other|descriptive|evaluate in number and efficacy platelet transfusion at the end of life, demographic characteristic are also noted
47272|NCT03814473|Other|Diet|"Participants provided with a brochure providing a thorough description of the diet, ~8 example recipes for each meal (i.e. breakfast, lunch, dinner, and snacks) included as a sample menu, and guidance to assist in shopping and self-preparation of food for the prescribed diet and to improve adherence. Diet consisted of following the popular paleolithic diet"
47273|NCT03814460|Diagnostic Test|Assessment of Tone, Pain and Thickness|Evaluation of Muscle state of tension, self-reported response to mechanical pressure pain and muscle thickness. The evaluation process of muscle tone and pressure pain sensitivity will be carried out following a topographical mapping covering myotendinous and muscle belly sites in the biceps brachii and the gastrocnemius muscles
47274|NCT03814447|Drug|anti- MESO CAR-T cells|Autologous genetically modified anti- MESO CAR transduced T cells
47275|NCT03814447|Drug|Fludarabine|Dose: 30mg/m2/d
47276|NCT03814447|Drug|Cyclophosphamide|Dose: 300mg/m2/d
47277|NCT03814434|Procedure|Non-Surgical treatment|Implant and teeth surfaces decontamination through scaling and planning, Curettage, profilaxys and Oral Hygiene orientation
47278|NCT03814434|Procedure|Surgical Treatment|Anaesthesia, Incision, curettage, Treatment of the contaminated implant surface, Irrigation with saline, Guided Bone Regeneration and suture
47312|NCT03814148|Drug|LENINGRADO 5 association|1 coated sustained-release tablet, oral, once a day.
47313|NCT03814148|Drug|Natrilix® SR|1 coated sustained-release tablet, oral, once a day.
47314|NCT03814148|Other|Natrilix SR Placebo|1 coated sustained-release tablet, oral, once a day.
47315|NCT03814148|Other|Leningrado 5 association Placebo|1 coated sustained-release tablet, oral, once a day.
47316|NCT03814135|Drug|Hipnos 3|1 tablet, oral, once a day.
47317|NCT03814135|Drug|Hipnos 5|1 tablet, oral, once a day.
47318|NCT03814135|Other|Hipnos 5 Placebo|1 tablet, oral, once a day.
47279|NCT03814421|Drug|intermittent (40mg as a bolus injection daily for 72hours)|Current guidelines recommend an intravenous bolus dose of a proton pump inhibitor(PPI) followed by continuous PPI infusion after endoscopic therapy in patients with high-risk bleeding peptic ulcers. However, recent many studies suggests intermittent low dose PPI infusion might have equal efficacy at preventing peptic ulcer hemorrhage recurrence. So, the present investigator assumed that intermittent administration of proton pump inhibitor will not be different from administration of continuous proton pump inhibitor for the prevention of rebleeding in patients with peptic ulcer bleeding. Also, intermittent proton pump inhibitor administration in patients with high risk of rebleeding (Rockall score 6 points or more) will not be different from prevention of rebleeding compared with continuous proton pump inhibitor administration.
47280|NCT03814408|Biological|RP-L102|CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
47281|NCT03814395|Other|No intervention|This is an observational study without any intervention
47282|NCT03814382|Device|Acupuncture needle|Acupuncture needle
47283|NCT03814369|Device|AmplifEYE|AmplifEYE colonoscopy
47284|NCT03814356|Drug|Methylphenidate|IV MPH
47285|NCT03814343|Drug|amphotericin B in 30% DMSO|amphotericin B in 30% DMSO was given to patients in active comparators group for continuous 12 weeks.
47286|NCT03814343|Drug|30% DMSO|30% DMSO was given to patients in placebo comparators group for continuous 12 weeks.
47287|NCT03814330|Diagnostic Test|State-Trait Anxiety Inventory|State-Trait Anxiety Inventory measures state anxiety levels and is an easy-to-implement inventory that the individual can answer on his/her own. State-Trait Anxiety Inventory determines how the individual feels himself / herself at a given moment and under certain conditions. It is widely used in preoperative anxiety measurement
47288|NCT03814330|Diagnostic Test|Quality of Recovery Score|Recovery Quality Score-40 (Quality of Recovery Score) and is used to measure the quality of postoperative recovery. This form consists 40 items and is divided into 5 subgroups according to various aspects of the improvement. There are a total of 40 items, 9 related to emotional state, 12 related to physical comfort, 7 related to psychological support, 5 related to physical independence and 7 items related to pain. The questionnaire is scored as a minimum of 40 to a maximum of 200.
47289|NCT03814330|Other|Sedation/Analgesia|Patients will be performed the procedure with sedation/analgesia under the condition of spontaneous breathing.
47290|NCT03814330|Device|Laryngeal Mask Airway|Patients will be performed the procedure with Laryngeal Mask Airway during the procedure. Laryngeal Mask Airway is a supraglottic airway device to ventilate the patients during anesthetic procedure.
47291|NCT03814317|Drug|Inhaled Treprostinil|"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
47292|NCT03814304|Other|Personalized tDCS|The participant will receive 20, 20-minute sessions of personalized tDCS on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
47293|NCT03814304|Other|Active-Sham|The participant will receive 20, 20-minute sessions of active-sham stimulation on Monday-Friday, at approximately the same time of day, over four consecutive weeks.
47294|NCT03814291|Drug|IBI302|0.05mg/eye;Intraocular injection
47295|NCT03814291|Drug|IBI302|0.15mg/eye;Intraocular injection
47296|NCT03814291|Drug|IBI302|0.5mg/eye;Intraocular injection
47297|NCT03814291|Drug|IBI302|1mg/eye;Intraocular injection
47298|NCT03814291|Drug|IBI302|2mg/eye;Intraocular injection
47299|NCT03814291|Drug|IBI302|4mg/eye;Intraocular injection
47300|NCT03814278|Behavioral|complete bed rest|Patients in this group received standard care for PPROM according to the institution protocol, including antepartum confinement to bed.
47301|NCT03814278|Behavioral|activity restriction|Patients in this group received standard care for PPROM according to the institution protocol but to had bathroom privileges and walks to the ward canteen four times per day.
47302|NCT03814265|Behavioral|Laughter yoga|440/5000 Laughter yoga; It is an exercise program that combines breathing techniques with unconditional laughter. During the sessions, laughter is simulated by hand clapping and warm-up exercises and by eye contact with other members in the group and by playing childish games with group members. Most of the time this simulation turns into genuine and contagious laughter. Laughter yoga is based on the argument that the brain cannot distinguish between real and unreal laugh.
47303|NCT03814252|Device|MRI-TULSA|"The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)"
47304|NCT03814239|Other|protocol|In patients of Group Protocol , basal crystalloid infusion was started at 4 ml/kg/h right after general anesthesia induction and intubation. ClearSight System (Edwards Lifesciences Cop, Irvine, CA, USA) was used to measure stroke volume variation and cardiac output, continuously and noninvasively through finger- cuffed technology. If SVV was >15% rapid crystalloid bolus of 10ml/kg or 4ml/kg colloid bolus were administered until it reached a value of ≤15%. After two consecutive fluid boluses SVV remained >15%, administration of noradrenaline infusion was considered.
47305|NCT03814226|Other|Evaluation of headache inducing capabilities of PACAP38|We wish to investigate the headache inducing capabilities of PACAP-38, a vasoactive peptide, over a 20 minute infusion. As PACAP-38 casues visible vasodilation, another vasoactive peptide, called VIP will be used as an active comparator.
47306|NCT03814213|Other|CGA|Multi-level Health assessment
47307|NCT03814213|Other|tailored care|Tailored care based on problems identified by CGA
47308|NCT03814200|Drug|Saline|Single i.v. infusion of 100 mL saline 0.9% for 30 min
47309|NCT03814200|Drug|ACT-246475|Single s.c. dose of 4 mg ACT-246475 in the thigh under fasting conditions
47310|NCT03814200|Drug|rifampicin|Single i.v. infusion of 600 mg rifampicin (100 mL) for 30 min
47311|NCT03814187|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
47320|NCT03814122|Behavioral|Action-based cognitive remediation|Action-Based Cognitive Remediation (ABCR) is a new program that was developed to address the challenges of transferring cognitive gains to improved quality of life and reduced disability. ABCR combines traditional cognitive training with an added behavioural component (e.g., role-plays, simulations of real world tasks) to foster learning through rehearsal and procedural memory which increases the likelihood of participants bridging cognitive strategies into real-world activities. ABCR also includes goal setting and behavioural activation procedures to stimulate transfer of in-session gains to everyday life changes.
47321|NCT03814122|Other|Waitlist Control Group|Receive treatment-as-usual through regular early psychosis programming.
47322|NCT03814109|Drug|LENINGRADO association|1 coated sustained-release tablet, oral, once a day.
47323|NCT03814109|Drug|Natrilix® SR|1 coated sustained-release tablet, oral, once a day.
47324|NCT03814109|Other|Natrilix SR Placebo|1 coated sustained-release tablet, oral, once a day.
47325|NCT03814109|Other|Leningrado association Placebo|1 coated sustained-release tablet, oral, once a day.
47326|NCT03814096|Diagnostic Test|Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)|Syphilis Health Check (SHC) POC-test is a treponemal POC-test based on 3d generation enzyme immunoassay (EIA) method detecting both Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies.
47327|NCT03814083|Device|Active-tDCS|Active-tDCS over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive active tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
47328|NCT03814083|Device|Sham-tDCS|Sham-tDCS stimulation over 10 sessions in 2 weeks (once per day, for 10 consecutive working days), while performing the executive function training tasks. Also, participants will complete an online cognitive training program while they receive sham-tDCS stimulation for 10 training sessions. The training session will last for 20 minutes and the online cognitive training program is comprised of 5 exercises targeting at information processing speed and executive function capacities. Each exercise lasts for approximately 4 minutes, totaling approximately 20 minutes.
47329|NCT03814083|Other|Wait-list|No intervention
47330|NCT03814070|Procedure|Fiber-reinforced framework|Glass fiber- reinforced framework is to be picked up over the implant abutments to strengthen the full arch acrylic restorations
47331|NCT03814070|Procedure|No framework|Non-reinforced acrylic full arch prosthesis is to be picked up directly over the implant abutments.
47332|NCT03814057|Diagnostic Test|24 hour urine creatinine excretion|two age corrected calculations of creatinine height index were obtained
47333|NCT03814044|Device|PEEK Suture Anchors|Subjects who have undergone hip joint repair using PEEK Suture Anchors: Bioraptor Knotless Suture Anchor and SpeedLock Hip
47334|NCT03814031|Other|NO internvention|NO internvention
47335|NCT03814005|Drug|Azacitidine|Azacitidine subcutaneous injection.
47336|NCT03814005|Drug|Pevonedistat|Pevonedistat intravenous infusion.
47337|NCT03813992|Drug|MED2005|Topical Product
47338|NCT03813979|Drug|Dolutegravir|Intake of a single-dose dolutegravir 50 mg tablet on an empty stomach
47339|NCT03813966|Diagnostic Test|Sofia Influenza A+B FIA|The Nasal Swab Home Collection Kit (NSHC Kit) provides the materials and training needed for you to safely collect a nasal swab at home. The sample can then be delivered to a designated test site for influenza testing.
47340|NCT03813953|Procedure|Liver resection|Resection of diseased liver
47341|NCT03813940|Biological|HPV Vaccine,135μg/0.5ml|HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
47342|NCT03813940|Biological|HPV Vaccine,270μg/1.0ml|HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
47343|NCT03813927|Dietary Supplement|Vitamin D|Supplementation with tablet 170 μg Vitamin each day.
47344|NCT03813927|Dietary Supplement|Placebo|Placebo with tablet 20 μg Vitamin each day.
47345|NCT03813914|Dietary Supplement|Sineos|glycyrrhizic acid 38 mg + Cinnamomum Zeylanicum 150 mg + corosolic acid 480 mcg 2 pills per day
47346|NCT03813901|Other|Samalochana Counselling|Counselling program was individual, based on advaita vedanta and traditional philosophical grounds to answer individual fears, concerns,conflicts and difficulties in order to cope and recover.
47347|NCT03813901|Other|Wait list control|Wait list had no intervention offered during the study period. Afterwards, they were offered the counselling for the same duration.
47348|NCT03813888|Other|Arsha Vidya chldren's Group|Yoga, Vedic chants, Vedant sessions, Gita sessions and group activities within the Gurukulam (centre)
47349|NCT03813888|Other|Usual Activity group|Usual after school activities at home.
47350|NCT03813875|Drug|Fentanyl|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical fentanyl ranged from 0~200mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery, the patient is observed in the operation room until return of consciousness before sending them to the recovery unit.
47351|NCT03813875|Other|Bispectral index (BIS) and analgesia nociception index (ANI)|After giving routine anesthetic medications, the investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S). BIS is maintained between 40 - 60 and MOAA/S less than 2. The vital signs, BIS, analgesia nociception index (ANI) are recorded automatically and continuously through computerized software. ANI is used to observational purposes only and do not guide anesthetic management in our protocol. Upon conclusion of the surgery or examination, the patient is observed until return of consciousness (MOAA/S = 5) before sending them to the recovery unit.
47378|NCT03813680|Other|Passive Vertebral Mobilization|Posteroanterior glides was given to cervical spine using Maitland method along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
47352|NCT03813875|Drug|alfentanil|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical alfentanil ranged from 0~1000mcg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
47353|NCT03813875|Drug|Propofol|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical propofol ranged from 0~200mg according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the surgery or examination, the patient is observed in the surgery or examination room until return of consciousness before sending them to the recovery unit.
47354|NCT03813875|Drug|sevoflurane|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine triple drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 1. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical sevoflurane concentration ranged from 0~3% according to patient condition. The timing and concentrations data are acquired for backend analysis. At the conclusion of the surgery, the patient is observed in the surgery room until return of consciousness before sending them to the recovery unit.
47355|NCT03813875|Drug|midazolam|The investigators assess the depth of anesthesia based on bispectral index (BIS) and modified observer's assessment/alertness scale (MOAA/S) after routine drug regimen is given. BIS is maintained between 40 and 60 and MOAA/S less than 2. The drug doses are given as a part of routine anesthesia practice and is identical regardless of study participation. Typical midazolam ranged from 0~5mg in boluses according to patient condition. The timing and doses are recorded for backend analysis. At the conclusion of the examination, the patient is observed in the examination room until return of consciousness before sending them to the recovery unit.
47356|NCT03813862|Other|Non-interventional (observational only)|
47357|NCT03813849|Diagnostic Test|Sonographic examination of uterus after surgical evacuation|
47358|NCT03813836|Drug|Pembrolizumab|Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
47359|NCT03813823|Behavioral|Fear tasks|All participants will be exposed to 5 fear tasks involving spiders, with increasing fear intensity.
47360|NCT03813810|Other|Non|There would be no interventions. Only measurements will be performed.
47361|NCT03813797|Device|Airseal®|Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
47362|NCT03813797|Device|Standard Insufflation|"Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg"
47363|NCT03813784|Drug|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
47364|NCT03813784|Drug|Capecitabine|1000 mg/m^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
47365|NCT03813784|Drug|Oxaliplatin|130 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle.
47366|NCT03813784|Drug|Apatinib|250 mg administered as continuous oral once daily (QD) of each 3-week cycle.
47367|NCT03813771|Drug|Benepali|Benepali will be adminstered subcutaneously at a dose of 50mg weekly and discontinued at the primary endpoint (24 weeks).
47368|NCT03813771|Drug|Sulfasalazine|Sulfasalazine will be added at follow up visits (T2T care) if the subject fails to achieve low disease activity,administered orally at a dose of 1g twice daily.
47369|NCT03813771|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15mg weekly. It may be increased in line with T2T care (to a maximum of 25mg) over the 24 weeks.
47370|NCT03813771|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at follow up visits (T2T care) if the subject fails to achieve low diseaseactivity, administered at a dose of 200mg daily.
47371|NCT03813758|Diagnostic Test|wrinkle test|soaking in 40 deg water for 40 min. every 10 min the hand will be photo
47372|NCT03813745|Other|early denudation|COCs will be denudated in 30 min after oocyte retrieval
47373|NCT03813745|Other|late denudation|COCs will be denudated 2 hr after oocyte retrieval
47374|NCT03813732|Procedure|orbital fracture|using the trans-conjunctival approach alone in restoring the esthetics compared with using it along in addition to lateral canthotomy which is important in providing wider surgical area
47375|NCT03813706|Procedure|lymph node dissection|The right cervical central compartment VI is subdivided into right cervical central VI-1 subzone and VI-2 subzone. Right central VI-1 subzone lies anterior to the RLN bounded by the hyoid bone superiorly, the suprasternal notch inferiorly, the inner edge of the common carotid artery laterally, and the midline of the trachea medially. Right central VI-2 subzone lies posterior to the right RLN. The superior, inferior, lateral, and medial borders are the laryngeal entry points of RLN, the intersection of the RLN with the innominate artery (near the right apical pleura), the inner edge of the common carotid artery, and esophagus, respectively. The floor of right central VI-2 is the prevertebral fascia.
47376|NCT03813693|Other|towels impregnated with 2% chlorhexidine gluconate|"The first TICHG should be used on the neck, chest and abdomen; The second TICHG should be used on the right upper limb, start at the shoulder; The third TICHG was intended for the upper left limb; The fourth TICHG should be used on the neck and chest; The fifth TICHG was for the right lower limb; The sixth TICHG should be used on the lower left limb.~2) Time of application: use six TICHGs the night before surgery and the six remaining on the morning of surgery.~3) After the hygiene of each member, discard the TICHG. After use of TICHG, allow the product to dry on the skin. Do not use bath towels to dry yourself and wear clean clothes."
47377|NCT03813693|Other|chlorhexidine gluconate 2% liquid|Spread the product on the skin during the bath and massage for 3 minutes, so that it is distributed equally to all parts of the body (except the face, hair and intimate area). Then rinse with water and dry with a clean, dry towel, and wear clean clothes.
47417|NCT03813368|Procedure|Whipples pancreatico-duodenectomy|Classic whipples and pylorus preserving
47457|NCT03813121|Drug|placebo intravenous infusion|Participants will receive a single placebo infusion
47379|NCT03813680|Other|PNF exercise|The subjects was given PNF exercises comprising PNF diagonal patterns for neck along with routine physiotherapy comprising thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
47380|NCT03813680|Other|Routine Physiotherapy|Thermotherapy with Hot Packs 15 minutes, Transcutaneous Electrical Nerve Stimulation (TENS) 15 minutes,Isometric neck exercises,Education on precautions and postural care
47381|NCT03813667|Behavioral|Intervention FamPALcare|"The FamPALcare intervention includes all standard care information on R-ALD home care plus 2 weeks of EOLPC coaching by community nurses experienced in EOLPC. The nurse uses the Conversation Ready pamphlet to guide discussion of EOL preferences. The nurse will: (1) support the patient and family in making decisions about EOL care options based on their preferences; (2) discuss options for EOL care when the patient's R-ALD symptoms become severe; (3) encourage completion of the advance directive forms at next physician appointment. The nurse will use teach-back processes to ensure that FamPALcare discussions are clear."
47382|NCT03813654|Behavioral|8-h Afternoon-Evening Sleep|8 consecutive hours time in bed during the afternoon/evening.
47383|NCT03813654|Behavioral|8-h Free Sleep|8 consecutive hours time in bed at any time.
47384|NCT03813641|Drug|Raltitrexed|Experimental: Oxaliplatin + Raltitrexed + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Raltitrexed (3mg/m2, intravenous drip for 15 minutes, d1)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
47385|NCT03813641|Drug|Capecitabine|Other: Oxaliplatin + Capecitabine + Bevacizumab The above schemes are repeated every three weeks. After 8 cycles, such as CR, PR or SD, the regimen is changed to Capecitabine (1000mg/m2 po. d1-14)+bevacizumab (7.5mg/kg, intravenous drip, d1). The regimen is repeated every 3 weeks until the disease progresses.
47386|NCT03813628|Other|polished celtra press full coverage crown|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by just polishing
47387|NCT03813628|Other|glazed celtra press full coverage crowns|a full coverage crown in esthetic area made from celtra press ceramic( zirconia reinforced lithium silicate) and finished by glazing
47388|NCT03813628|Other|contralateral natural teeth|the polished and glazed all ceramic crowns will be compared by the contralateral natural teeth
47389|NCT03813615|Behavioral|treadmill walking (Proof-of-Concept)|Individualized, progressive aerobic training consisting of treadmill walking for a total of 150 mins/wk delivered over 5 sessions/wk following a linear dosing schedule for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx. Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
47390|NCT03813615|Behavioral|treadmill walking Dose-Finding / Escalation|Three doses of aerobic training (150 mins/wk, 225 mins/wk & 300 mins/wk) delivered following either a standard linear (i.e., each dose of exercise is performed at the same intensity & duration) or non-linear (i.e., exercise dose is continually altered & progressed in conjunction with appropriate rest/recovery sessions across the entire intervention period) dosing schedule 5 times weekly (over a 7-day period) for a minimum 2 weeks. Aerobic training treatment will be implemented & may be monitored using TeleEx. Pts may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form & Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
47391|NCT03813615|Behavioral|treadmill walking Phase 1b: Dose-Expansion|Individualized, progressive aerobic training consisting of treadmill walking delivered to achieve the recommended phase 2 dose (RP2D) identified in the phase 1a trial for a minimum of 2 weeks. All aerobic training treatment will be implemented and may be monitored using TeleEx Participants may also perform up to two aerobic training sessions per week in an unsupervised home-based setting. Patients will be provided with Appendix J - Unsupervised Home-Based Exercise Recording Form and Appendix K - Unsupervised Home-Based Exercise Instructions to record their sessions.. General physical activity as well as exercise performed outside of the structured treatment sessions will be evaluated via continuous monitoring using MSK approved telemedicine / wireless technology.
47392|NCT03813602|Drug|Cannabis Sativa|750 mg cannabis cigarette with 12.5% THC
47393|NCT03813576|Diagnostic Test|Self-collected HPV vaginal swab|Patients will be instructed on how to collect a vaginal swab on themselves which will then be processed for presence of HPV DNA.
47394|NCT03813563|Drug|RL|lactated Ringer's
47395|NCT03813563|Drug|PLA|PlasmaLyte
47396|NCT03813550|Diagnostic Test|Fecal and blood samples|Fecal samples for intestinal microbiota analysis; Blood and fecal samples for assessment of various forms of vitamin K
47397|NCT03813537|Other|Phone Call|The experimental group will receive a phone call 3-days post procedure and asked questions based on the most frequent indications for readmission after colorectal surgery.
47398|NCT03813524|Device|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
47399|NCT03813498|Behavioral|HCV articles|The intervention group receive a targeted short article on HCV from WeChat weekly.
47400|NCT03813498|Behavioral|general health articles|The control group receive a general health article with no mention of HCV from WeChat weekly.
47418|NCT03813355|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) during 20 sessions
47419|NCT03813342|Behavioral|Gait training with visual feedback of joint kinematics|Gait training will be accomplished using a Woodway treadmill. The visual feedback will contain information about the real-time lower-limb joint angles. We will instruct participants to use the feedback to reach a target walking pattern.
47401|NCT03813485|Other|Dry Needling in upper trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the upper trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in upper trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
47402|NCT03813485|Other|Dry Needling in lower trapezius|"The following criteria are required for a patient to have latent TrPs: the presence of a palpable taut band in the lower trapezius muscle, the presence of a hypersensitive spot in the taut band, a palpable or visible local twitch on snapping palpation, and a no familiar reproduction of referred pain elicited by palpation of the sensitive spot.~Dry needling is performed with solid filiform needles (0.30x 30 mm), these needles are sterile and separately packaged. Needles are not reused and are immediately deposited in a needle container after usage. Patients receive dry needling in latent myofascial trigger point (LTRs) in lower trapezius. The needle is penetrated into the muscle fibers of the taut band and was moved upward and downward (fast in, fast out) in different directions with the aim to elicit LTRs"
47403|NCT03813472|Device|Hydration Sensor|This device includes a hydration sensor embedded within silicone and applied to the skin with a medical grade adhesive.
47404|NCT03813446|Device|Device: RhythmPadBP|"Detection of heart rhythm and measurement of blood pressure~Intervention:~Patients will start by wearing a consumer SmartWatch (Huwaei SmartWatch 2, which has a CE mark) and a 60 second reading of their wrist Photoplethysmyograph (PPG) will be recorded. This will enable us to compare the PPG from the wrist with the fingertip data collected from the RhythmPadBP.~The watch will be cleaned with alcohol wipe in the same manner that the RhythmPadBP is cleaned between subjects use.~Patients will be asked to place their palms of both hands on RhythmPadBP and then the underlying heart rhythm and BP will be recorded. 12-lead ECG and BP reading will be obtained by standard devices for comparison."
47405|NCT03813433|Other|Revascularization|a procedure used to regenerate pulp dentin complex that restores the functional properties of this immature anterior teeth, prevent and resolves apical periodontitis
47406|NCT03813420|Behavioral|Pittsburgh Sleep Quality Index (PSQI)|"The sleep quality was evaluated through the Turkish version of the PSQI containing 19 self-rated questions searching the sleep quality during the previous month. It has seven components as subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications, and daytime dysfunction.~Each component is scored from 0 to 3, and the Global Pittsburgh Quality of Sleep (PQS) score is the sum of the scores of the seven components that is between 0 and 21. The higher Global PQS scores indicate poor sleep quality and the cut off score for poor sleep is 5 and over."
47407|NCT03813420|Behavioral|International Physical Activity Questionnaire (IPAQ)|The physical activity of the participants was assessed through the Turkish version of the International Physical Activity Questionnaire -Short Form (IPAQ-SF), which includes 6 questions searching the frequency (days per week) and duration (hours) of walking, as well as low, moderate and vigorous physical activity that they engaged in during the last seven days prior to survey. Vigorous physical activity, defined by the questionnaire, referred to intense exercise that resulted in very rapid breathing and an elevated heart rate (e.g. intense weight lifting, aerobics, running, and cycling). Moderate physical activity was defined as less intense exercise that slightly heightened breathing and heart rate (e.g. less exertive cycling, fast walking, and light weight lifting).
47408|NCT03813420|Behavioral|The Short Form 36 Health Survey (SF-36)|The Turkish version of SF-36 was used to understand the health related quality-of -life (HRQOL) of the participants over the past four weeks in eight health concepts: limitations in physical activities because of health problems; limitations in social activities because of physical or emotional problems; limitations in usual role activities because of physical health problems; bodily pain; general mental health (psychological distress and well-being); limitations in usual role activities because of emotional problems; vitality (energy and fatigue); and general health perceptions. Additionally, the psychometric evaluation of the SF-36 generated two summary scores as the Mental Health Component Score and the Physical Health Component Score that the higher scores indicate better HRQOL.
47409|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level|"Sodium Zirconium Cyclosilicate (SZC) Dose:~To be considered by the iDMC in consultation with the Sponsor, if de-escalation is indicated by evaluation of safety/tolerability data"
47410|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)|Sodium Zirconium Cyclosilicate (SZC)Paediatric dose based on body weight equivalent to an adult 5 g TID (CP) or QD (MP/LTMP) dose
47411|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)|Sodium Zirconium Cyclosilicate (SZC) Paediatric dose based on body weight equivalent to an adult 10 g TID (CP) or QD (MP/LTMP) dose
47412|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)|Sodium Zirconium Cyclosilicate (SZC) To be considered by the iDMC in consultation with the Sponsor if further dose escalation is indicated by evaluation of safety/tolerability and efficacy data
47413|NCT03813407|Drug|Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase|A 28-day MP during which Sodium Zirconium Cyclosilicate ( SZC) or placebo is administered in randomised, double-blind manner orally once daily (QD) to maintain normokalaemia in subjects from 2 to <18 years. Subjects will be randomised in a 1:1 ratio to either SZC or placebo treatment.
47414|NCT03813394|Drug|pembrolizumab|-Pembrolizumab in Solution for Injection
47415|NCT03813394|Drug|bevacizumab|"Bevacizumab in Concentrate for Solution~Bevacizumab in Concentrate for Solution"
47416|NCT03813381|Behavioral|Calorie and protein restriction diet|"Patient in intervention arm will be given individualized dietary advice on the basis of WCRF/AICR recommendations. The aim of healthy dietary advice will be the reduction of patient's total daily calorie intake up to 600 kcal below their energy requirements and 0.8g of protein/Kg body weight mostly form plant-origin food.~Patients, periodically, will meet the dietitian for a 45-minute nutritional counselling session and a trained nurse for a 15-minute health coaching session.~Each patient in the IA will be involved in at least three 4-hour cooking classes.~Patients in the IA, after a medical/cardiac evaluation to assure their physical ability for exercise, will attend Nordic walking sessions of moderate intensity two times per month during the 24 months of intervention."
47420|NCT03813329|Dietary Supplement|Modified Sodium Bicarbonate|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of sodium bicarbonate
47421|NCT03813329|Dietary Supplement|Acute Sodium Bicarbonate|3 progressively larger doses of calcium carbonate followed by one acute dose of sodium bicarbonate (300 mg/kg)
47422|NCT03813329|Dietary Supplement|Calcium carbonate (placebo)|4 progressively larger doses (110 mg·kg-1 - 200 mg·kg-1) of calcium carbonate
47423|NCT03813316|Drug|DPP-4 inhibitor|Adding sitagliptin (DPP-4i) add-on using a fixed-dose combination with metformin (Janumet® 50/1000 mg BID).
47424|NCT03813316|Drug|SGLT2 inhibitor|Adding ertugliflozin (SGLT2i) add-on using a fixed-dose combination with metformin(Segluromet® 2.5/1000 mg BID)
47425|NCT03813316|Drug|SGLT2 inhibitor and DPP-4 inhibitor|Adding both a DPP-4i as Fixed dose combination (Janumet) plus SGLT2i ertugliflozin (steglatro) as add-on to metformin.
47426|NCT03813303|Drug|Midazolam|Administration of midazolam by anesthesiologist for sedation.
47427|NCT03813303|Drug|Fentanyl|Administration of fentanyl by anesthesiologist for sedation.
47428|NCT03813303|Drug|Propofol|Administration of propofol by anesthesiologist for sedation.
47429|NCT03813290|Device|Neuro-technological Intervention|During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
47430|NCT03813277|Drug|Dexmedetomidine|infusion
47431|NCT03813264|Other|Routine outcome measures (ROM)|The proposed study consists of two complementary processes: the first is the routine collection of clinical data using ROM; The second process is MATRIX-based intervention that is expected to improve the course of treatment.
47432|NCT03813251|Device|ForConti Contix Fecal Incontinence Management System (FIMS)|Use the device for up to 12 hours per use for 4 weeks
47433|NCT03813238|Drug|Deutetrabenazine|Dosage ranging from 6 mg to 48 mg.
47434|NCT03813238|Drug|Placebo|Dosage ranging from 6 mg to 48 mg.
47435|NCT03813225|Other|Bilateral serratus Intercostal plane Block|Will be performed by echo guided one puncture in the fifth costal arch with anterior axilary line, where the tip of the needle will be guided until it reaches a point above the external intercostal muscle, below the anterior serratus above the costal arch where they will be administered 21 ml of anesthesic mass, (20 ml of levobupivacaine 0.375 and 1 mg (2mg) of dexamethasone.)
47436|NCT03813212|Device|MRI|Magnetic resonance imaging. Trans-abdominal sonography (TAS) and transvaginal sonography (TVS) will be performed using a 3.5 or 5 MHz transabdominal convex transducer and a 7 MHz trans-vaginal transducer.
47437|NCT03813199|Drug|ABX464 50mg|ABX464 is a new anti-inflammatory drug
47438|NCT03813199|Drug|Matching Placebo|placebo matching with ABX464
47439|NCT03813199|Drug|ABX464 100mg|ABX464 is a new anti-inflammatory drug
47440|NCT03813199|Drug|Methotrexate|MTX ≥ 10 mg/week will be given at previous dose regimen kept stable throughout the study
47441|NCT03813186|Drug|ASTX727 + Day 2 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 2.
47442|NCT03813186|Drug|ASTX727 + Day 4 Food|ASTX727 is an oral drug product composed of a fixed-dose combination of cedazuridine (E7727), a CDA inhibitor, and decitabine. Food is a high-calorie, high-fat breakfast meal of 800-1000 calories given on Day 4.
47443|NCT03813173|Procedure|lymph node dissection|The patient was operated under general anesthesia with cervical hyper extension. The affected side or bilateral glandular lobes were resected routinely, which was confirmed as PTC by frozen section. Then one or both central lymph node dissection were separately packed and sent for examination. Scope of lymph node dissection in central carotid region: hyoid bone at the upper border, anonymous artery at the lower border, bilateral common carotid artery at the inner edge, shallow from the superficial layer of deep cervical fascia, deep to the deep layer of deep cervical fascia (anterior fascia). The right recurrent laryngeal nerve (RLN) passes through the central area of the right neck and should be specially protected.
47444|NCT03813160|Drug|Lenabasum 20 mg|oral capsule
47445|NCT03813160|Drug|Lenabasum 5 mg|oral capsule
47446|NCT03813160|Drug|Placebo|oral capsule
47447|NCT03813147|Drug|Azacitidine|Given IV
47448|NCT03813147|Drug|Cytarabine|Given intrathecally and IV
47449|NCT03813147|Drug|Fludarabine Phosphate|Given IV
47450|NCT03813147|Drug|Methotrexate|Given intrathecally
47451|NCT03813147|Drug|Pevonedistat|Given IV
47452|NCT03813147|Drug|Therapeutic Hydrocortisone|Given intrathecally
47453|NCT03813134|Procedure|Percutaneous coronary intervention (PCI)|Primary PCI or early/immediate PCI for NSTEMI will be undertaken according to recommended Guideline standards of care. This will include appropriate pre-loading with dual anti-platelet therapy, a preferred radial approach, intra-procedural anti-coagulation (with measure of ACT if considered appropriate every 30 minutes) and the use of drug eluting stents. Treatment will be delivered essentially to the culprit vessel only. A successful procedure will be one considered to have achieved TIMI 2-3 flow and residual stenosis < 50%. PCI failure will not be an exclusion itself from the trial.
47454|NCT03813134|Other|Pharmacological Support|Use of pharmacological agents (Norepinephrine, Dobutamine, Levosimendan) according to ESC Guidelines to maintain mean arterial pressure >75 mmHg in accordance with recognised standards of care. Changes in pharmacotherapy will NOT be regarded as escalation therapy. However the number of and dose of inotropes will be documented in the CRF.
47455|NCT03813134|Device|VA-ECMO|"Following PCI of the culprit lesion, patients will have ECMO initiated as soon as echocardiography (to exclude mechanical causes) has been completed, once they have been assessed as having failed to improve (with the aim to start ECMO as early as possible from 30 mins after completed P-PCI procedure ad fully established within 6 hours after randomisation).~Peripheral Veno-arterial ECMO will be employed with a flow rate according to individual patient needs. Other methods of LV unloading, distal limb perfusion, maintenance of ejection/aortic valve opening and anti-coagulation will be instituted as per sites' usual care.~A minimum 24 hours be allocated to the randomised therapy in order that strategy failure is demonstrated but this will be at the physicians' discretion."
47456|NCT03813121|Drug|midazolam intravenous infusion|Participants will receive a single drug infusion
47458|NCT03813121|Drug|ketamine intravenous infusion|Participants will receive a single drug infusion
47459|NCT03813108|Biological|CPS-immunization|Subjects will be immunized 3 times by exposure to the bites of P. falciparum NF135.C10 infected mosquitoes while taking mefloquine profylaxis.
47460|NCT03813108|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
47461|NCT03813108|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
47462|NCT03813108|Biological|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
47463|NCT03813108|Drug|Atovaquone / Proguanil Oral Tablet [Malarone]|All participants will be treated with atovaquone/proguanil (1000/400 mg (= 4 tablets) 1×/day during 3 consecutive days) when they develop a malaria infection or on day 28 after malaria challenge infection.
47464|NCT03813095|Drug|APH-1501|The investigational drug product APH-1501 is CBD encapsulated in biodegradable polymer nanospheres, is a lyophilized powder intended for oral administration.
47465|NCT03813095|Drug|Placebo|The placebo is a sterile pyrogen free lyophilized powder identical in appearance to the experimental drug product.
47466|NCT03813082|Behavioral|Prolonged wakefulness|40 hours of prolonged wakefulness
47467|NCT03813069|Other|IR3535|The topical repellent IR3535 (3-[N-butyl-N-acetyl]-aminopropionic acid ethyl ester) only
47468|NCT03813069|Other|Permethrin lower dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children of 10-20 kg.
47469|NCT03813069|Other|Permethrin higher dose|A fabric scarf, impregnated with the insecticide permethrin (m-Phenoxybenzyl)-cis,trans-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate) that has contact irritancy/spatial repellency. Dose appropriate to children more than 20 kg.
47470|NCT03813056|Drug|Glanatec|Rho kinase Inhibitor
47471|NCT03813056|Drug|Optive, Ophthalmic Solution|artificial tears (placebo)
47472|NCT03813056|Procedure|Descemet Membrane Endothelial Keratoplasty|Partial thickness corneal transplant that replaces only the diseased corneal endothelium and descemet membrane of the recipient.
47473|NCT03813043|Drug|Midazolam injection|Midazolam 2mg iv to be used as starting dose using Biased coins up and down method (BCM)
47474|NCT03813030|Procedure|Intravenous infusion of lidocaine|Lidocaine is intravenously administered in clearance visit and blood samples are taken to calculate individual clearance of each participant.
47475|NCT03813030|Drug|"Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)"|Topical application in dermal-sampling visit
47476|NCT03813030|Drug|"Lidocorit 2%-Ampullen (Gebro Pharma Gesellschaft mit beschränkter Haftung, Austria)"|Intravenous infusion in clearance visit
47477|NCT03813030|Device|Dermal open flow microperfusion|"Dermal open flow microperfusion will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentration in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
47478|NCT03813030|Device|Dermal Microdialysis|"Dermal microdialysis will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations in the dermis.~Interstitial fluid (ISF) sampling: 1 hour pre-dose and 12 hours post-dose"
47479|NCT03813030|Procedure|Blood sampling in dermal sampling visit|1 sample is taken pre-dose and 12 samples are taken post-dose.
47480|NCT03813030|Procedure|Blood sampling in clearance visit|1 sample is taken pre-dose, 3 samples during intravenous infusion and 13 samples post-dose.
47481|NCT03813004|Diagnostic Test|Reaction for gait perturbation|"Participants were subjected to four different perturbation types while walking on the treadmill:~left treadmill belt deceleration for right leg toe off~right treadmill belt deceleration for left leg toe off~left treadmill belt acceleration for right leg heel strike~right treadmill belt acceleration for left leg heel strike~Motion analysis was conducted to analyze effect of the intervention on gait."
47482|NCT03812991|Drug|Miacalcin Calcitonin Salmon Nasal Spray|Miacalcin nasal spray is 1 spray (200 International Units) per day administered intranasally, alternating nostrils daily
47483|NCT03812978|Other|Smart phone application|Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
47484|NCT03812965|Drug|Botulinum toxin type A|2 units/point of botulinum toxin type A
47485|NCT03812939|Drug|Octreotide|Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
47486|NCT03812926|Device|Compuflo assited procedure|number of needle entry required to identify the ligamentum flavum
47487|NCT03812913|Behavioral|psychological evaluation|"Neuropsychological and experimental tasks will assess cognitive and socio-cognitive functions.~Questionnaires will assess psychoaffective aspects (depression, anxiety, self-esteem), and social and behavioral functioning."
47488|NCT03812900|Drug|Echinacea purpurea alcoholic extract|Different galenic forms with Echinacea purpurea alcoholic extract from herb and roots (95:5%)
47489|NCT03812887|Diagnostic Test|Photopatchtesting|Photopatchtesting to the sunscreen series and extended series, irradiated at both 24 and 48 hours
47490|NCT03812874|Drug|PTX-9908 Injection|"Proposed dose cohorts:1 mg/kg, 2 mg/kg, 4 mg/kg, 8 mg/kg, and 16 mg/kg.~Frequency: one dose per day for 5 days in week 1, and one dose per week in the following treatment period.~Duration: 4 weeks (Phase I) and 12 weeks (Phase II)."
47491|NCT03812874|Drug|Placebo|"water for injection~Frequency: one dose per day for 5 days in week 1, and one dose per week in the following treatment period.~Duration: 12 weeks (Phase II)"
47492|NCT03812861|Other|CAMDS bundle|Cognitive aids for the assessment and management of deteriorating surgical patients (CAMDS). This bundle contains instructions for doctors and nursing staff to assess, manage and escalate care of deteriorating surgical patients. These management instructions will be derived from best practices that are linked with improved mortality and morbidity in surgical patients.
47524|NCT03812588|Drug|Placebo|A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
47525|NCT03812562|Biological|Nivolumab|Given IV
47526|NCT03812562|Radiation|Yttrium Y 90 Glass Microspheres|Given IV
47493|NCT03812848|Other|Anticoagulation Stewardship Program|"A clinical-pharmacist led anticoagulation stewardship program that includes:~Warfarin monitoring and dosing protocol. 1a.Warfarin initial dosing algorithm. 1b.Recommended International normalized ration (INR) target and duration of Warfarin therapy by indication.~1c.Warfarin dosage adjustment algorithms.~1d.Management of high INR values. 2-Heparin weight-based protocol. 3-Perioperative anticoagulation use protocol. 4-Policies that address baseline and ongoing laboratory monitoring for anticoagulants.~5-Protocol for Heparin Induced Thrombocytopenia(HIT) management. 6-Anticoagulation reversal protocol. 7-Booklet for anticoagulant drugs and all of previously prepared protocols. 8-Education programs regarding anticoagulation's therapy for health care team dealing with anticoagulation and patients."
47494|NCT03812822|Device|Insole|Custom-made insoles which support the foot at subtalar neutral position
47495|NCT03812809|Drug|BPI-7711|BPI-7711: 180mg, QD, oral
47496|NCT03812796|Drug|Domatinostat|"Domatinostat is an oral tablet which will be given at a variable dose during the Phase IIA safety run in phase of the trial.~During the Phase IIB efficacy phase of the trial patients will be treated with domatinostat at the safe and tolerated combination dose identified during the Phase IIA safety run in phase."
47497|NCT03812796|Drug|Avelumab|Avelumab is a monoclonal antibody which is given via an intravenous infusion at a dose of 10mg/kg every two weeks on the first day of a two week cycle. (Day 1 q 14d) from Cycle 2 onwards.
47498|NCT03812783|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
47499|NCT03812783|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
47500|NCT03812783|Drug|Sorafenib|administration of Sorafenib
47501|NCT03812783|Procedure|Hepatic arterial infusion chemotherapy|administration of Irinotecan, Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
47502|NCT03812783|Drug|FOLFIRINOX|Irinotecan, Oxaliplatin , fluorouracil, and leucovorin
47503|NCT03812770|Drug|Sorafenib|Oral Sorafenib, 400mg, Bid
47504|NCT03812770|Drug|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
47505|NCT03812770|Drug|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
47506|NCT03812757|Diagnostic Test|Supraclavicular fossa US scanning|As previously stated.
47507|NCT03812744|Drug|Whole coffee cherry extract (WCCE)|100mg WCCE
47508|NCT03812744|Drug|Placebo Oral Capsule [CEBOCAP]|Silica Oxide
47509|NCT03812731|Drug|Ropivacaine|Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg
47510|NCT03812731|Drug|Fentanyl Citrate|Intraoperatively after induction of anaesthesia fentanyl 1-mcg/kg/hour will be administered
47511|NCT03812718|Device|Endotracheal tube (ETT)|After induction of anaesthesia patient will be intubated with polyvinyl chloride (PVC) ETT for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
47512|NCT03812718|Device|ProSeal Laryngeal Mask Airway (PLMA)|After induction of anaesthesia ProSeal Laryngeal Mask Airway (PLMA) will be inserted for maintaining intraoperative ventilation. Anaesthesia will be maintained with propofol and the administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of GA.
47513|NCT03812705|Biological|fecal microbiome transplantation|"Stop antibiotics treatment 1 day before fecal microbiome transplantation;~Fasting food 6 hours before fecal microbiome transplantation;~Give Ondansetron intravenously 1 hour before fecal microbiome transplantation for vomiting prevention;~Perform fecal microbiome transplantation under colonoscopy or gastroscopy;~Perform up to 4 times if patient response;~Stop if no response after twice fecal microbiome transplantation."
47514|NCT03812692|Device|MATRx plus|The MATRx plus device is a feedback-controlled mandibular positioner that uses data collected during sleep to control movement of the mandible in real-time using a mandibular positioner. The test provides a prediction of the individual's response to oral appliance therapy; i.e., if the individual can treat his or her obstructive sleep apnea using a mandibular advancing oral appliance. For individuals predicted to respond to the therapy, the test also provides a mandibular position at which the appliance will be effective.
47515|NCT03812653|Device|CPAP|Automatically-adjusting continuous positive airway pressure (CPAP) delivered using a study supplied device.
47516|NCT03812640|Device|Vicryl suture|Corneal suture with Vicryl suture
47517|NCT03812640|Device|Nylon suture|Corneal suture with Nylon suture
47518|NCT03812627|Other|Blood, urine, hair, synovial fluid and peri-prosthetic tissue collections|"All inpatient subjects: following samples will be collected during hospitalization:~Twice blood and urine collections:~at the beginning of hospitalization: 10 ml of blood + 5 ml of urine;~at the end of hospitalization: 5 ml of blood + 5 ml of urine. Synovial fluid collection: 1 ml Peri-prosthetic tissue collection: about 1 cm3 Hair collection: a single hair of 0.5 cm diameter"
47519|NCT03812627|Other|Autopsy|Dead patients will be autopsied: hair, urine, blood, peri-prosthetic tissue and viscera (liver, kidney, spleen, brain, heart, lung) sampling for each autopsy.
47520|NCT03812614|Behavioral|FAM ACT|Patient and Support Person (dyad) will receive a Diabetes Complications Risk Assessment profile and introduction session, Support Person-focused information/skills training through 4-6 extended DSMES sessions, case management contacts with CHW for the remainder of a 12-month period, and guidance on how to prepare for and participate in healthcare appointments.
47521|NCT03812614|Behavioral|I-DSMES+CM|Patient only will receive a Diabetes Complications Risk Assessment profile and introduction session, 4-6 group DSMES sessions, case management contacts with CHW for the remainder of a 12-month period, and guidance on how to prepare for and participate in healthcare appointments.
47522|NCT03812601|Procedure|Simultaneous bi-atrial electroanatomic mapping and ablation|Simultaneous bi-atrial electroanatomic mapping during atrial fibrillation and during pacing from 3 different vectors at varying cycle lengths followed by pulmonary vein isolation and AcQMap guided ablation of non-pulmonary vein mechanisms.
47523|NCT03812588|Drug|Escitalopram|Escitalopram is a Selective Serotonin Reuptake Inhibitor (SSRI) medication that appears to help with symptoms of depression by increasing the availability of specific chemicals in the brain.
47527|NCT03812549|Drug|Sintilimab|Patients will receive treatment with Sintilimab 200mg every 3 weeks for a maximum of 24 months.
47528|NCT03812549|Radiation|stereotactic body radiation therapy|Radiation treatment utilized in this trial consists of SBRT with a standard doses to 30 Gy/3f
47529|NCT03812549|Radiation|Low Dose Radiotherapy|LDRT at dose escalation levels: 2 Gy/1f, 4 Gy/2f, 10 Gy/5f with conventional external beam radiation.
47530|NCT03812536|Other|No Void|Currently the protocol at The Ohio State University Hospital requires voiding spontaneously prior to discharge from the PACU. Our intervention group will be discharged home without having to void spontaneously as a discharge criteria.
47531|NCT03812523|Drug|Duloxetine 60 mg qd|60 mg tablet Taken by mouth, Once Daily for 180 Days
47532|NCT03812523|Drug|Lorcaserin|10 mg tablet Taken by mouth Twice Daily for 180 Days
47533|NCT03812510|Drug|A-101|hydrogen peroxide topical solution 45%
47534|NCT03812497|Behavioral|Individualized Education Program|The every participants will have individualized education program about a way of dietary control and exercise in their usual life.
47535|NCT03812484|Behavioral|SCF Supervision|SCF Supervision entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). SCF Supervision includes regular random drug testing.
47536|NCT03812484|Behavioral|Parole-as-Usual|Parolees are supervised under standard parole supervision practice in New Jersey
47537|NCT03812471|Device|3D volume acquisitions|2 abdominal volumes 2 thigh volumes 2 head volumes
47538|NCT03812471|Device|2D standard measurements and 3D volumes acquisitions|"1 abdomen circumference measurement~1 femur length measurement~1 head circumference measurement~1 bi-parietal diameter measurement~1 abdominal volume~1 thigh volume~1 head volume"
47539|NCT03812458|Behavioral|website and brochure|website and brochure
47540|NCT03812445|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus,Bifidobacterium lactobacillus,Lactobacillus paracasei,Lactobacillus rhamnosus and Lactobacillus fermentium with does of 8*10^9 Colony-Forming Units(CFU) *2/d for 3 months.
47541|NCT03812432|Device|Near-infrared fluorescence cholecystocholangiography|Device: Real-Time Fluorescence Imaging (VISERA ELITE II Imaging System). These device is used to identify anatomy, using infrared light that causes the indocianine green to fluoresce.
47542|NCT03812419|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
47543|NCT03812419|Drug|Pantoprazole 40mg|Pantoprazole 40 mg In addition, the immunosuppressant combination of CsA (Sandimmune; Novartis, East Hanover, NJ, USA), MMF (Cellcept; Roche, Basel, Switzerland) and the corticosteroid prednisolone (Solupred; Sanofi Aventis, Tours, France).
47544|NCT03812406|Procedure|French Abulatory Cesrean Section|A cesarean section performed according to the FAUCS technique
47545|NCT03812406|Procedure|Misgav-Ladach|A cesarean section performed according to the Misgav Ladach technique
47546|NCT03812393|Drug|Neratinib|For cycle 1 subjects will receive Neratinib 240mg daily for 21 days. For cycle 2-5, subjects will receive carboplatin AUC of 1.5 and Paclitaxel 80mg/m2 on day one in combination with Neratinib 240mg daily for 21 day.
47547|NCT03812380|Drug|EffCaMgCit|Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
47548|NCT03812380|Other|Placebo|Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
47549|NCT03812354|Other|THRIVE 4L/kg/min|High-flow nasal cannula therapy with 4L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
47550|NCT03812354|Other|THRIVE 2L/kg/min|High-flow nasal cannula therapy with 2L/kg/min with 100% oxygen via OptiFlow by Fisher&Paykel, Auckland, New Zealand.
47551|NCT03812341|Other|Experimental|KeraKlear Non-Penetrating Keratoprosthesis The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity
47552|NCT03812328|Drug|SelK2|I.V., single-dose
47553|NCT03812328|Biological|Enoxaparin|SC, QD for up to 10 ± 2 days
47554|NCT03812315|Combination Product|Propolis chewing gum|Children who will use chewing gum will be instructed to chew a gum for 20 minutes once after breakfast and another before bed time for two weeks.
47555|NCT03812315|Combination Product|Propolis mouthwash|Children who will use mouthwash will be instructed to rinse with 10 ml for 60 seconds twice daily once after breakfast and another before bedtime for two weeks.
47556|NCT03812302|Diagnostic Test|68-Ga HA-DOTATATE PET/CT|See arm description.
47557|NCT03812289|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
47558|NCT03812289|Other|Quality-of-Life Assessment|Ancillary studies
47559|NCT03812289|Other|Questionnaire Administration|Ancillary studies
47560|NCT03812276|Device|Dental Implants|Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).
47561|NCT03812263|Biological|RP-L201|CD34+ enriched hematopoietic stem cells from subjects with severe LAD-I transduced ex vivo with lentiviral vector carrying the ITGB2 gene, Chim-CD18-WPRE.
47562|NCT03812250|Procedure|ERCP assisted trans-papillary drainage for malignant biliary obstruction|ERCP assisted trans-papillary drainage for malignant biliary obstruction
47563|NCT03812250|Procedure|EUS-guide biliary drainage for malignant biliary obstruction|EUS-guide biliary drainage for malignant biliary obstruction
47564|NCT03812237|Other|(EWB) Early Weight Bearing (2 Weeks Post-op)|Patient were permitted to progressively weightbear on their heel at 2 week post-op.
47565|NCT03812224|Drug|Erenumab|Dose 1 erenumab or placebo will be dosed every 4 weeks, subcutaneously during the 24-week double blind treatment period.
47566|NCT03812224|Drug|Erenumab|Dose 1 erenumab will be dosed every 4 weeks, subcutaneously during the 28-week open label treatment period.
47596|NCT03811990|Behavioral|Cleveland Clinic Stress Free Now Meditations For Healers|Phone-based meditation application
47567|NCT03812211|Dietary Supplement|Active Supplement|Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women
47568|NCT03812211|Dietary Supplement|Placebo supplement|Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement
47569|NCT03812198|Drug|LEO 32731 modified release tablet|At each dosing, subjects will swallow the appropriate number of tablets with approximately 240 mL of water at room temperature.
47570|NCT03812198|Drug|LEO 32731 blend, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
47571|NCT03812198|Drug|LEO 32731 API, hard capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
47572|NCT03812198|Drug|LEO 32731 soft capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
47573|NCT03812198|Drug|LEO 32731 gastro-resistant capsule|At each dosing, subjects will swallow the appropriate number of capsules with approximately 240 mL of water at room temperature.
47574|NCT03812198|Drug|LEO 32731|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
47575|NCT03812198|Other|Placebo|At each dosing, subjects will swallow the appropriate number of tablets or capsules with approximately 240 mL of water at room temperature.
47576|NCT03812185|Device|Suctioning orogastric tube which is attached to TEE probe cover|Suctioning orogastric tube which is atttached to TEE probe cover.
47577|NCT03812172|Drug|99mTc-PYP|10 mCi of 99mTc-PYP will be administered intravenously and imaging will be performed after 1 hour.
47578|NCT03812159|Device|iCSPlan|"The Investigator will acquire a routine pre-operative CT-scan to help assess the synostosis severity. A week before the surgery a routine preoperative visit will be done. If the potential subject agrees to participate in the study, a presurgical plan will be built, and based on the CT scan, it will (1) quantify shape differences between pathological and healthy cranial shapes; (2) compensates for brain and cranial growth during the months between diagnosis, treatment and recovery; and (3) guides bone-cuts and bone-placement for the simplest and optimal surgical procedure.~Finally this plan will be recorded in a software, iCSPlan, which will be reviewed by the surgeon. If it is accepted, it will be available during the surgery as a rely-on tool which may or may not be followed."
47579|NCT03812146|Behavioral|PC-TIME|PC-TIME consists of five, 30-minute sessions delivered over 8 weeks. Intervention will be delivered by a behavioral health provider and will consist of brief Prolonged Exposure for PTSD integrated with aspects of the Motivational Interviewing counseling approach.
47580|NCT03812146|Behavioral|PC-TAU|PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
47581|NCT03812120|Procedure|Dural closure with L-PRF|Evaluation of the safety and effectiveness of autologous blood-derived products (L-PRF) as an adjunct for dural repair
47582|NCT03812120|Procedure|Dural closure with classical fibrin sealants|Evaluation of the safety and effectiveness of classical fibrin sealants as an adjunct for dural repair
47583|NCT03812107|Other|Moderate Treatment Approach|The frequency of visits will be organized similarly as the intensive treatment arm (weekly, every 2 weeks, and every 4 weeks) but participants in this arm will be able to move more freely between these steps and are hypothesized to require fewer provider visits than the intensive treatment arm.
47584|NCT03812107|Other|Intensive Treatment Approach|After stabilization on a MOUD, participants who relapse will be asked to return weekly until 2 consecutive urine drug tests are negative for opioids or other illicit drugs. Participants will then be asked to return every other week until 2 consecutive urine drug tests are negative for opioids or other illicit drugs, before being asked to return every 4 weeks. If the participant tests positive for illicit drugs while returning every other week, they will return to the beginning of the treatment plan (2 consecutive negative tests before going to every other week).
47585|NCT03812094|Device|Enurad 400|Alarm treatment
47586|NCT03812094|Behavioral|Basic Bladder advice|Pre-specified Basic bladder advice
47587|NCT03812081|Device|Group A : Baska Mask Airway|Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment. The Baska Mask is available in four sizes: size three (30 to 50 kg), size four (50 to 70 kg), size five (70 to 100 kg),The membranous cuff of the Baska Mask appears bulkier than the equivalent inflatable cuff on cuffed laryngeal masks. The mask can easily be decreased in size during insertion by compressing the proximal, firmer part of the mask below the airway tube, between the thumb and two fingers
47588|NCT03812081|Device|Group B: Proseal Laryngeal Mask Airway|Proseal LMA (size 3,4,5) was used for ventilation according of patient body weight.Size selection is based on the manufacturer's recommendation of weight-based estimate plus clinical judgment.
47589|NCT03812068|Behavioral|Long-distance developmental behavioral intervention|Long-distance learning program combined parent-mediated developmental behavioral intervention
47590|NCT03812068|Behavioral|Developmental behavioral intervention|Parent-mediated developmental behavioral intervention
47591|NCT03812042|Diagnostic Test|Enzyme assay and molecular sequencing|Enzyme assay and molecular sequencing on relevant samples conducted from left over blood samples
47592|NCT03812029|Drug|EYP001a|Oral tablets
47593|NCT03812029|Other|Placebo|Oral tablets
47594|NCT03812016|Device|Magnetic device prototype|The device prototype comprises 1 or 2 matched pairs of one near-infrared light-emitting diode (SMT910, Epitex Inc, Kyoto, Japan) and one sensor (PD15-22C TR8, Everlight Electronics Corporation, New Taipei City, Taiwan), a permanent electromagnetic actuator (JNP-12/12, Joint Magnetic Technology Corporation, Shenzhen, China), an iron sheet, and a biosignal acquisition module. The efficacy and safety of the device prototype were assessed using the device prototype.
47595|NCT03812003|Drug|Remifentanil|remifentanil 1mcg/kg added in 0.9% saline and diluted to 50ml
47597|NCT03811977|Dietary Supplement|Lutein syrup|12- week dietary supplementation with lutein syrup (20 mg lutein/day)
47598|NCT03811977|Dietary Supplement|Placebo syrup|12- week dietary supplementation with placebo syrup (0 mg lutein/day)
47599|NCT03811964|Other|Specific light exposures|Specific light exposures using light in a wide range of intensities or different light/dark regimens
47600|NCT03811951|Drug|Novolin R|Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
47601|NCT03811938|Procedure|Low voltage ablation|Catheter ablation of low voltage areas in the left atrium and catheter ablation aiming for the electrical isolation of the pulmonary veins.
47602|NCT03811938|Procedure|Pulmonary Vein Isolation|Catheter ablation aiming for the electrical isolation of the pulmonary veins.
47603|NCT03811925|Procedure|Angioplasty and drug coated balloon of the superficial femoral artery (SFA)|In case of drug coated balloon (DCB) there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). Thus, no direct DCB will be conducted. All DCB lengths (40mm to 200 mm) and Diameters (3mm to 7mm) are eligible for the Trial as long as used in the superficial femoral artery (SFA)
47604|NCT03811925|Procedure|Angioplasty and stenting of the superficial femoral artery (SFA)|In case of stent application there should be always a predilation of the lesion with a predefined ballon (180 sec, Passeo-18). In case of stenting there should be a strong effect on vasomotion of the treated vessel area. All Stent lengths (40mm to 200 mm) and Diameters (5mm to 7mm) are eligible for the trial as long as used in the superficial femoral artery (SFA)
47605|NCT03811912|Drug|CTP-543 QD Dose Regimen|16 mg once-daily (QD)
47606|NCT03811912|Drug|CTP-543 BID Dose Regimen|8 mg twice-daily (BID)
47607|NCT03811899|Diagnostic Test|18F-DCFPyL|The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
47608|NCT03811886|Drug|Natalizumab|"Natalizumab is an FDA approved monotherapy for treatment of relapsing forms of MS. It is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active CD who have had an inadequate response to, or intolerance of, conventional therapies and TNF-α inhibitors.~Traditional 3+3 escalation of Natalizumab at a weight-based dosing 2mg/kg not to exceed 300mg. If no subjects experience a dose limiting toxicity (DLT), 3 more subjects are enrolled at the next dose of 3mg/kg, not to exceed 300mg. If no subjects experience a DLT, 3 more subjects will be enrolled at the next and final dose of 4mg/kg, not to exceed 300mg.~Phase II will continue if the subject has Complete Response (CR), Partial Response (PR) or Stable Disease (SD) of pOS, defined by RECIST 1.1 criteria after every 3 cycles after the first 6 cycles but not beyond 24 cycles. If subject has progressive disease after cycle 6, they will be removed from the study."
47609|NCT03811873|Radiation|Thoracic spine X-Ray|All participants will receive above interventions, in addition to their standard of care. Additionally, 15 patients will undergo CT scan of the lumbar spine at baseline and 1 year follow.
47610|NCT03811860|Diagnostic Test|Lithium level|The level of lithium in the serum
47611|NCT03811860|Diagnostic Test|Serum Creatinine|The level of creatinine (as an indicator of kidney function, to approximate GFR) in the serum
47612|NCT03811847|Drug|Methylphenidate Extended Release Oral Capsule|Stimulant It can treat ADHD and narcolepsy.
47613|NCT03811847|Other|Placebo|Placebo Comparitive
47614|NCT03811834|Drug|TAK-788|TAK-788 capsule, [14C]-TAK-788 IV infusion, [14C]-TAK-788 oral solution.
47615|NCT03811821|Behavioral|Biofeedback|The participant will learn how to improve strength and rectal sensation during five (5) - six (6) visits each lasting 60 minutes.
47616|NCT03811821|Procedure|Sacral Nerve Stimulation|The participant will have a wire electrode inserted to S3 or S4, connected to stimulator. This involves two surgical procedures and a clinic visit of 45 minutes duration at weeks 0, 2 and 6 weeks respectively.
47617|NCT03811821|Device|Injection|The participant will have a bulking agent injected into rectal wall to narrow opening. Two visits each lasting 45 minutes at weeks 0 and 6 respectively.
47618|NCT03811795|Other|ECG monitoring with a Kardia Mobile monitor|The participants in the study will undergo a total of two follow-up visits after ablation (approximately 3 and 6 months) with a 12-lead electrocardiogram at each visit. An assessment of rhythm will be performed with daily transmissions as well as subject-activated event recordings for symptoms with the Kardia Mobile smartphone based monitor. The Kardia Mobile System is an FDA-cleared, clinical grade mobile ECG monitor coupled with a smartphone app that is able to record a single-lead ECG and securely transmit the tracings to the study investigators via the Kardia Pro commercial (HIPPA compliant) remote monitoring service for clinicians.
47619|NCT03811782|Behavioral|Single-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Single-task Training instructions (20 minutes) and cool down (5 minutes).
47620|NCT03811782|Behavioral|Dual-task Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Dual-task Training instructions (20 minutes) and cool down (5 minutes).
47621|NCT03811782|Behavioral|Analogy Training|In each training session, all groups will have warm-up (5 minutes), balance training (5 minutes), body transport training (5 minutes), body transport with hand manipulation training (5 minutes), walking training with various difficulties in a 10 meters walkway with Analogy Training instructions (20 minutes) and cool down (5 minutes).
47622|NCT03811769|Other|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies.
47623|NCT03811769|Procedure|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus BMT arm start of treatment is defined as the date and time of groin puncture (arterial access).
47624|NCT03811756|Dietary Supplement|Test syrup containing CoQ10 and collagen|Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
47625|NCT03811756|Dietary Supplement|Placebo syrup|Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
47626|NCT03811743|Behavioral|Brenner FIT|Brenner FIT pediatric weight management program enrollment. an interdisciplinary, family-based pediatric weight management clinic based upon the Familial Approach to Treatment of Childhood Obesity. Patients are referred by a physician for obesity or overweight with a weight-related comorbidity. Treatment teams are comprised of a pediatrician, counselor, dietitian, and physical activity specialist, with others (e.g., social workers, physical therapists) as needed. The entire family is encouraged to attend all aspects of the treatment program, although only one attending caregiver is required.
47627|NCT03811743|Behavioral|By Design|Weight loss program for adults/caregivers of those enrolled in Brenner FIT. Participants in the By Design condition (adult caregivers) will be prescribed the Essentials lifestyle intervention which includes tailored dietary and physical activity goals designed to achieve 1-2 lbs./week of weight loss, provided by a multidisciplinary team of medical providers, dietitians, behaviorists, and exercise specialists. A daily calorie restriction of 500 kcal/day is prescribed based on estimates of total energy expenditure (TEE) obtained from a measured resting metabolic rate (RMR) prior to enrollment.
47628|NCT03811743|Behavioral|Coordination|"This component adds four additional strategies: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment. This innovative approach will seek to employ components of motivation and communication theories to increase self-monitoring, positive communication, problem solving, and social support to increase healthy physical activity and eating behaviors to increase the effectiveness of the weight loss programs beyond gains observed in matched controls.~Essentials (adults), with four additional components: dyad group sessions, one-on-one parent/child communication sessions, joint goal setting/tracking, and home environment assessment"
47629|NCT03811730|Diagnostic Test|Transesophageal echocardiography|Eligible patients would be conducted both Transesophageal echocardiography and Transthoracic echocardiography to offer independent results
47630|NCT03811717|Other|FAST+EX|Participants will perform 2-hours of low-intensity arm exercise (8 x 15 min bouts of arm ergometer exercise separated by 10 min of rest) during an 8-hour fast.
47631|NCT03811717|Other|FAST|Participants will complete an 8-hour fast.
47632|NCT03811704|Device|Laparoscopic surgical navigation system|We will use this navigation system to guide de liver resection.
47633|NCT03811704|Drug|Indocyanine Green|ICG was administered 24 hours before the operation or intravenously after clamping the Glissonian sheaths flowing in the cancer-bearing hepatic segment, or directly into the portal branches supplying blood flow to the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
47634|NCT03811691|Diagnostic Test|MRI exam|Pacing system safety and stability under MRI scan environment
47635|NCT03811678|Drug|Kangdaprevir Sodium Tablet|Tablet，administered orally once daily
47636|NCT03811678|Drug|placebo|Tablet，administered orally once daily
47637|NCT03811665|Procedure|Radiofrequency Ablation|RFA probe will create an ablation zone of a 1.0 cm diameter beyond the maximum CT-measured tumor diameter. The generator will modulate power up to 150 W in reach average ablative temperature of 105oC. Tumors will be treated for two cycles of 8 minutes duration each upon reaching target temperatures.
47638|NCT03811665|Radiation|Stereotactive body radiation therapy|The Gross Tumour Volume (GTV) is defined as the visible tumour seen on the planning CT simulation. No clinical target volume (CTV) for microscopic disease is necessary. The internal target volume (ITV) accounts for changes in tumour position due to respiration, and is assessed on 4DCT. The planning target volume (PTV) will be a standard 0.5 cm around the ITV.
47639|NCT03811652|Drug|MEDI7247|Subjects with advanced solid tumors will enroll into the respective arms to receive Medi7247 IV at prescribed dose and schedule
47640|NCT03811639|Procedure|Radio-frequency ablation|Ablation for atrial fibrillation
47641|NCT03811639|Procedure|Cryoballoon ablation|Ablation for atrial fibrillation
47642|NCT03811626|Procedure|cognitive-behavioral rehabilitation|Combination of clinical examination and neuropsychological and psychological tests
47643|NCT03811613|Other|Transcranial photobiomodulation|Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)
47644|NCT03811600|Diagnostic Test|PD1/PD-L1 exosomal expression|exosomal PD1/PD-L1 expression
47645|NCT03811587|Other|Fasting Mimicking diet|The fasting mimicking diet is though to activate the metabolism as fasting would do, although the diet does include several meals a day and more calories than conventional fasting diets.
47646|NCT03811574|Drug|Semaglutide|Semaglutide injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
47647|NCT03811574|Drug|Placebo (semaglutide)|Placebo (semaglutide) injections will be administered once-weekly by a pre-filled pen-injector at the same day of the week (to the extent possible). Injections may be administered in the thigh, abdomen or upper arm, at any time of day irrespective of meals.
47648|NCT03811561|Drug|Semaglutide|Participants will get one dose of semaglutide once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
47682|NCT03811275|Behavioral|Task (B) then Virtual Reality (A)|Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
47683|NCT03811262|Procedure|ESP BLOCK|local anesthetic will be injected between transverous process and erector spinae muscle
47649|NCT03811561|Drug|Placebo (semaglutide)|Participants will get one dose of placebo (semaglutide) once weekly in addition to their diabetes medicines - which treatment they get is decided by chance. Participants will inject the study medicine using a pre-filled PDS290 pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. Participants will start with once-weekly doses of 0.25 mg for 4 weeks, then the dose will be gradually increased to 0.5 mg once weekly for 4 weeks, and finally to 1.0 mg once weekly (maximum dose) up to 260 weeks (5 years).
47650|NCT03811548|Drug|Janagliflozin 25mg|Tablets, Oral, 25 mg, Tablets, Oral, 50 mg
47651|NCT03811548|Drug|Janagliflozin 50mg|Tablets, Oral, 25 mg, Once daily, 52 weeks
47652|NCT03811548|Drug|Placebo/Janagliflozin|Tablets, Oral, 25 mg, Once daily, 52 weeks
47655|NCT03811522|Other|carbon dioxide insufflation|Receives CO2 insufflation
47656|NCT03811522|Other|Air insufflation|Receives air insufflation
47657|NCT03811509|Drug|bisphosphonate|antiresorptives
47658|NCT03811470|Other|Standard diabetes management model in each MMC center|Standard diabetes management model in each MMC center
47659|NCT03811457|Genetic|Welgenaleucel|Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19.
47660|NCT03811444|Device|Haemolance Plus safety lancet|Haemolance Plus safety lancet type 420 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients
47661|NCT03811444|Device|Prolance safety lancet|Prolance safety lancet type 430 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
47662|NCT03811444|Device|MediSafe Solo safety lancet|MediSafe Solo safety lancet type 520 is a sterile, single use medical device designed for the sampling of capillary blood from the fingertip of patients.
47663|NCT03811431|Procedure|Contrast enhanced ultrasound guided liver biopsy|Conventional liver biopsy
47664|NCT03811418|Drug|Trastuzumab|"administered as combined therapy with pertuzumab and vinorelbine or docetaxel.~Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) on day 1 of cycle 1 (1 cycle length = 21 days), and 6 mg/kg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
47665|NCT03811418|Drug|Pertuzumab|"administered as combined therapy with Kanjinti® and vinorelbine or docetaxel.~Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
47666|NCT03811418|Drug|Vinorelbine|"administered as combined therapy with Kanjinti® and pertuzumab.~Vinorelbine will be administered as an IV dose of 25 milligrams per kilogram (mg/kg) on days 1 and 8 of cycle 1 (1 cycle length = 21 days), and 25mg/kg up to 30 mg/kg (as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
47667|NCT03811418|Drug|Docetaxel|"administered as combined therapy with Kanjinti® and pertuzumab.~Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m^2) on day 1 of cycle 1 (1 cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) Q3W on day 1 of subsequent cycles until progressive disease, intolerable toxicity, or death."
47668|NCT03811405|Device|Active biphasic pulse stimulation---Home Settings|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
47669|NCT03811405|Device|Active biphasic pulse stimulation---VIN Biphasic|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
47670|NCT03811405|Device|Active biphasic pulse stimulation---Stimulator Off|During this visit, the DBS implantable pulse generator (IPG) will be loaded with a temporary custom firmware to allow implementation of active biphasic pulse stimulation.
47671|NCT03811392|Procedure|Hernioraphy/Caudal block|30 patients will receive a caudal block after induction of general anaesthesia
47672|NCT03811392|Procedure|Hernioraphy/Quadratus Lumborum block|30 patients will receive ultrasound guided quadrates lumborum block
47673|NCT03811379|Drug|Toripalimab|Drug: Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
47674|NCT03811366|Drug|Meticorten|All patients were treated with 3-day methylprednisolone pulse therapy followed by 1mg/day oral prednisone with slow tapper over a median 13 months
47675|NCT03811353|Diagnostic Test|T-MOE|Chewing performance will be evaluated with T-MOE and the Karaduman Chewing Performance Scale.
47676|NCT03811327|Behavioral|Zero-time Exercise|A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
47677|NCT03811314|Device|Strength training|Using dumbbells, butterfly machine and vertical leg press machine for strength training, 12 repetition maximum weight for 12 repetition, three times a day, five days a week, for a total of four weeks
47678|NCT03811314|Device|Aerobic training|Using stationary bicycle to perform cardiopulmonary endurance training in 50-70 heart rate reserve for 20 minutes, five days per week, for a total of four weeks
47679|NCT03811301|Device|BrainConnexion|A 4.4mm by 4.2mm electrode array is placed onto the surface of the motor cortex which is then connected to a miniaturized neural recording microsystem that transmits signals wirelessly to control an external assistive device. Neural signals are recorded at least once every week for 12 months or longer.
47680|NCT03811288|Other|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
47681|NCT03811275|Behavioral|Virtual Reality (A) then Task (B)|Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.
47725|NCT03811002|Other|Quality-of-Life Assessment|Ancillary studies
47684|NCT03811262|Procedure|PECS BLOCK|local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
47685|NCT03811249|Device|VisAbility™ Micro Insert|No (new) intervention will be administered during the course of this long term follow-up study. Subjects that previously participated in the VIS-2014 clinical trial that had VisAbility™ Micro Inserts surgically implanted in the eye(s) will be followed prospectively.
47686|NCT03811236|Other|Cold exposure|Two hours of mild cold exposure using a water-perfused vest
47687|NCT03811223|Drug|Evolocumab Auto-Injector [Repatha]|Evolocumab 140 mg every 2 weeks for 12 weeks
47688|NCT03811223|Drug|Placebos|Placebo subcutaneous injection every 2 weeks for 12 weeks
47689|NCT03811210|Behavioral|portion size|"Smaller than normal portion size - the intervention is the main meal component size perceived as 'smaller than normal' that participants are provided with during lunch and dinner in the laboratory.~Small-normal portion size - the intervention is the main meal component size perceived as 'small-normal' that participants are provided with during lunch and dinner in the laboratory.~Large-normal portion size - the intervention is the main meal component size perceived as 'large-normal' that participants are provided with during lunch and dinner in the laboratory."
47690|NCT03811197|Behavioral|Dietary counseling via face to face meeting|All subjects received individual MNT and individual dietary recommendations based on DASH (Dietary Approaches to Stop Hypertension) diet plan for 6 months (Part A). Dietary counseling is provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
47691|NCT03811197|Behavioral|Telemedicine|All subjects received an additional dietary counseling for 6 months (via internet, messenger or telephone) two weeks after each standard visit will be added to the counseling (Part A). Standard and additional dietary counseling (T) are provided by a trained dietitian. Months 9 and 12 - follow up (Part B).
47692|NCT03811197|Behavioral|Hypnotic Suggestions|"All subjects received individual hypnotic suggestion (HS) for 6 months as a supplementary method for dietary counseling. HS will be adapted to the small steps method used in the management of obesity. During the visit, HS will be recorded and the individual will listen to it every day (Part A). HS will be provided by a physician, qualified in the field of hypnotherapy. Months 9 and 12 - follow up (Part B)."
47693|NCT03811184|Diagnostic Test|MemScreen|Neuropsychological test on smartphone or digital tablet, on self assesment.
47694|NCT03811171|Device|Break Wave extracorporeal lithotripsy|The Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.
47695|NCT03811158|Device|HHHFNC|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
47696|NCT03811158|Device|UHFOM|Prospective, randomized crossover control trial, single ICU. Patents with COPD exacerbation who were intubated for respiratory failure will all enrolled to this study. Participants will be studied on 2 consecutive days and random assigned with crossover.
47697|NCT03811145|Biological|Tendoncel|Platelet lysate gel
47698|NCT03811145|Other|Placebo control gel|Placebo control gel
47699|NCT03811119|Device|MANTA vascular closure device|Collagen based vascular closure device
47700|NCT03811119|Device|Suture based vascular closure device|Suture based vascular closure device (ProGlide)
47701|NCT03811106|Device|NeuromuscularElectricalStimulation+ConventionalPhysiotherapy|Sırt ekstansör kaslarına nöromusküler elektrik stimülasyonu uygulanacaktır
47702|NCT03811106|Other|Conventional physiotherapy and rehabilitation|Konvansiyonel fizyoterapi ve rehabilitasyon uygulamaları yapılacaktır.
47703|NCT03811093|Device|Care as Usual Group|"Each participant randomly assigned to the Care As Usual Group will undergo nine therapy sessions over three weeks using a fully functioning invisa-RED Technology Elite device."
47704|NCT03811093|Device|Sham Group|"Each participant randomly assigned to the Sham Group will undergo nine therapy sessions over three weeks using a non functioning invisa-RED Technology Elite device."
47705|NCT03811080|Drug|DWP14012 A mg|The participants will receive treatment of DWP14012 A mg, tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
47706|NCT03811080|Drug|DWP14012 B mg|The participants will receive treatment of DWP14012 B mg, tablet, orally, once daily and DWP14012 A mg placebo-matching tablet, orally, once daily for up to 4 weeks.
47707|NCT03811080|Drug|Placebo|The participants will receive treatment of DWP14012 A mg placebo-matching tablet, orally, once daily and DWP14012 B mg placebo-matching tablet, orally, once daily for up to 4 weeks.
47708|NCT03811067|Procedure|Transversus abdominis plane block|Transversus abdominis plane block will be performed bilaterally after the surgery.
47709|NCT03811067|Procedure|Rectus sheath block|Rectus sheath block will be performed bilaterally after the surgery.
47710|NCT03811054|Drug|Apatinib（250mg/d） combined with EGFR-TKI|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
47711|NCT03811041|Other|MDA|Depressed adolescents of depressed parents will be oriented to the MDA of Brest for depression cares.
47712|NCT03811041|Other|Routine Cares|Depressed adolescents of depressed parents will be oriented to routine cares for depression cares.
47713|NCT03811041|Other|Parental depression|Parents of depressed adolescents will be met for a screening test of depression.
47714|NCT03811028|Drug|SOBI003|weekly i.v. infusion
47715|NCT03811015|Drug|Cisplatin|Given IV
47716|NCT03811015|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
47717|NCT03811015|Biological|Nivolumab|Given IV
47718|NCT03811015|Other|Patient Observation|Undergo observation
47719|NCT03811002|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
47720|NCT03811002|Drug|Atezolizumab|Given IV
47721|NCT03811002|Drug|Carboplatin|Given IV
47722|NCT03811002|Drug|Cisplatin|Given IV
47723|NCT03811002|Drug|Etoposide|Given IV
47724|NCT03811002|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
47727|NCT03810989|Device|infra-red sauna|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna of 15 minutes duration separated by ten minutes rest outside the sauna.
47728|NCT03810989|Device|argometer and treadmill|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of physical exercise (by treadmill and argometer) of 20-30 minutes duration separated by 10 minutes rest.
47729|NCT03810989|Device|combination of sauna and hot bath|During the intervention phase, the ESRD patients twill be subjected to a method of stimulation of sweating as the following :- three session of infra-red sauna as the first group then the patients will be immersed up to neck for one hour in water at 37-43 C.
47730|NCT03810976|Drug|Eribulin, gemcitabine|Elibulin 1.4mg/m2 Intravenous for 5minutes. Day 1& Day 8 every 3 weeks Gemcitabine 1000mg/m2 intraveoust for 30 minutes, Day 1& Day 8 every 3 weeks
47731|NCT03810963|Combination Product|HIIT-FES Cycling combined with Nutritional Counseling|High intensity interval training functional electrical stimulation cycling for 30 minutes, three days per week for eight weeks, Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
47732|NCT03810963|Other|Nutritional Counseling Only|Nutritional counseling over the telephone for 30 minutes once per week for eight weeks.
47733|NCT03810950|Behavioral|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
47734|NCT03810950|Behavioral|Reading Newspaper|Participants read newspaper
47735|NCT03810950|Behavioral|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
47736|NCT03810937|Other|head position|head positioning in sniffing or flat position
47737|NCT03810924|Behavioral|Trier Social Stress Test|Test to induce high levels of acute social stress, including actors and a faked exam situation
47738|NCT03810924|Behavioral|Ergometer|Riding ergometer
47739|NCT03810924|Behavioral|Barlab-Exposure|Participants are exposed to a bar situation with different sorts of alcohol available. They sniff at water and at one alcoholic drink.
47740|NCT03810924|Behavioral|Reading Newspaper|Participants read newspaper
47741|NCT03810911|Drug|Darbepoetin|Used to treat anemia. In the group labeled no intervention, the intervention is simply delayed 12 weeks after randomization as noted in the description.
47742|NCT03810898|Radiation|Radioligand [¹¹C]CHDI-00485180-R|Intravenous injection of radioligand in the arm with PET imaging of the brain.
47743|NCT03810898|Radiation|Radioligand [¹¹C]CHDI-00485626|Intravenous injection of radioligand in the arm with PET imaging of the brain.
47744|NCT03810885|Other|Bread with reduced salt content|Bread with gradually lowered salt content
47745|NCT03810885|Behavioral|Dietary advice|Participants will receive information on how to lower salt and increase potassium intake
47746|NCT03810885|Other|Bread with standard salt content|Bread with normal salt content
47747|NCT03810872|Drug|Afatinib|Open label
47748|NCT03810872|Drug|Paclitaxel|Paclitaxel
47749|NCT03810859|Biological|Blood sample|Adults : 7 to 10 mL Childs : 2 to 4 mL
47750|NCT03810846|Behavioral|Walking football exercise program|Participants will be organized in two teams of 20 players. Each team will have 60-min walking football exercise sessions three times per week (non-consecutive days), during three months (36 sessions). Different walking football exercise strategies will be developed according to participants' motor skills and tested with dose-escalated intensity for its safety and enjoyment. Exercise intensity will range between light to vigorous. No submaximal or maximal exercises will be tested. Exercise sessions will be conducted on a sports hall (indoor court) by a football coach and supervised by an exercise physiologist and a nurse.
47751|NCT03810833|Device|Brilliance device sensor|Two separate sensors will be attached via standard, single-use adhesive pads to the left and right pectoralis major on each participant.
47752|NCT03810820|Device|mobile Cardiac Arrhythmia Diagnostics Service (m-CARDS)|A wearable cardiac monitoring device is provided to patients pre- and post-TAVI. The monitor transmits cardiac data in real time to the m-CARDs team. Cardiac abnormalities are reported to the clinical team who then assess the abnormality and intervene as clinically necessary.
47753|NCT03810807|Drug|Dacomitinib|Dose level 1 Dacomitinib, Dose level 2 Dacomitinib, Dose level 3 Dacomitinib, Dose level 4 Dacomitinib. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
47754|NCT03810807|Drug|Osimertinib|Dose level 1, 2 and 3 Osimertinib 40mg daily, Dose level 4 80mg BID. Three patients will need to be enrolled at each dose level and assessed for DLT for 1 full cycle (28 days for cycle 1) before dose escalation decision is made.
47755|NCT03810794|Other|Acupuncture|The main acupoints are DU 24, EX-HN 3, DU 20, EX-HN 1, GB 12, HT 7, KI 6, GB39, and then selecting other acupoints according to TCM syndrome. The electric stimulator will be applied to DU 24, GB 12, HT 7, and LR 3 or SP 6 with a disperse-dense wave of 2/50 Hz, 0.5-1.0 mA. There are three sessions per week with each session lasting for 30 min. There will be 12 weeks of treatment for each participant in total.
47756|NCT03810794|Drug|Donepezil|Donepezil 5 mg will be given once daily before bed-time for 12 weeks. After the clinical trial, participants will be given conventional treatment clinically.
47757|NCT03810755|Other|Personalized Supervised physical activity|personalized exercise program for patients, supervised during 3 months by nursing in primary and autonomous care afterwards, with support from community resources
47758|NCT03810742|Drug|Nanoliposomal Irinotecan|Nanoliposomal Irinotecan (nal-IRI, ONIVYDE®) in Combination with TAS-102 (LONSURF®)
47759|NCT03810729|Diagnostic Test|Smartphone assessment|The smartphone app will be performed on participants randomly assigned to receive this test.
47760|NCT03810729|Diagnostic Test|Modified Allen's Test|The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
47761|NCT03810716|Device|Interactive Platform|The participants will see the interactive platform.
47762|NCT03810703|Drug|Placebo oral capsule|Placebo oral capsule
47763|NCT03810703|Drug|d-amphetamine 10 mg oral capsule|d-amphetamine 10 mg oral capsule
47764|NCT03810703|Drug|d-amphetamine 20 mg oral capsule|d-amphetamine 20 mg oral capsule
47765|NCT03810690|Biological|mRNA-3704|mRNA-3704 dispersion for intravenous (IV) infusion
47766|NCT03810677|Device|ELVeS® Radial® 2ring slim fiber|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
47767|NCT03810664|Drug|Somatrogon|A single dose of 12 mg of somatrogon will be injected as one sc injection to the arm on each dosing day (Day 0 and Day 14).
47768|NCT03810651|Other|Proton beam radiation using pencil beam scanning|Proton beam radiation using pencil beam scanning, characterized by Bragg peak dose deposition and high conformality of dose to target regions
47769|NCT03810625|Drug|D-0502|D-0502 oral tablets
47770|NCT03810599|Other|Early cardiac rehabilitation|"This is an early cardiac rehabilitation programme starting 1-2 weeks after hospital discharge (Phase 2A rehabilitation). The programme provided by a multidisciplinary team includes individual counseling, educational sessions and discussion in groups, and exercise training sessions three days a week for five weeks.~For additional analysis there will be a comparison group that did not receive the intervention for practical reasons."
47771|NCT03810586|Device|Non-invasive measurement of blood pressure|Comparing non-invasive measurement of blood pressure using the PPG-based BB-613 device to a blood pressure manomtry holter device (HUGECARE NIBP Monitor)
47772|NCT03810573|Device|NB1|rhNELL-1/DBX
47773|NCT03810560|Device|laser device Er,Cr:YSGG laser|laser device with open flap debridement
47774|NCT03810547|Drug|Propofol 10 Mg/mL Intravenous Emulsion|when spinal anesthesia is not satisfactory intervention drugs are used
47775|NCT03810534|Behavioral|Connect-Home|Connect-Home will introduce organizational structure to support delivery of transitional care processes. New elements of structure include:electronic health record (EHR) template, Connect-Home Toolkit, and Staff Training. After structural elements are added, SNF staff will use Connect-Home care processes to deliver the 2-step transitional care intervention.In Step 1, SNF nurses, therapists, and social workers will develop a Transition Plan of Care and prepare the patient and caregiver to manage the patient's serious illness and functional needs. In Step 2, the Connect-Home Activation RN will visit the patient's home within 24 hours of discharge; the nurse will activate the Transition Plan of Care at home. Both intervention steps focus on 6 key care needs to optimize patient and caregiver outcomes: 1) home safety and level of assistance; 2) advance care planning; 3) symptom management; 4) medication reconciliation; 5) function and activity; and 6) coordination of follow-up medical care.
47776|NCT03810521|Biological|umbilical cord derived-mesenchymal stromal cells|Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
47777|NCT03810495|Drug|naltrexone implant|1.8 g implant containing 60% naltrexone
47778|NCT03810482|Device|Pedometer|A pedometer will be worn by the patient at home for days 1 to 14 and 60 to 74.
47779|NCT03810482|Other|6 minute walking test|Performed according to current recommendations during routine visits (baseline and ~90 days for the purposes of this study).
47780|NCT03810456|Behavioral|Intensive Cognitive Behavior Therapy (iCBT)|Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
47781|NCT03810456|Behavioral|Standard Cognitive Behavior Therapy (sCBT)|Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
47782|NCT03810443|Diagnostic Test|Hyperventilation test|The elements of the research consist of the Nijmegen questionnaire response, two dyspnea questionnaires (Dyspnea 12, MDP), a quality of life questionnaire (SF36), a psychological disorder screening questionnaire (HAD) and a diagnostic test: the hyperventilation test.
47783|NCT03810430|Behavioral|health promotion|health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
47784|NCT03810417|Drug|Digoxin Antibodies Fab Fragments|Digoxin antibodies
47785|NCT03810417|Other|Placebo|Saline
47786|NCT03810404|Dietary Supplement|Sodium bicarbonate supplementation|"Interventions:~The experimental procedure for each athlete included an acute SB supplementation in a different-dose regimen in order to assess whether the dose affects the actual physical and exercise capacity (doses: 0,15-, 0,25- and 0,35 g/kgFFM, respectively). SB (Alkala T, SANUM, Poland) will be administered as dissolved form in a 600 ml of fluid (water + fruit juice). On testing days the supplements will be taken 2 hours before physical and exercise capacity tests session.~Between the SB and PLA or a PLA and SB treatments, a minimum 7-day washout period will be introduced."
47787|NCT03810404|Dietary Supplement|Placebo treatment|"Interventions:~The experimental procedure for each athlete will be included an PLA supplementation. Placebo will be administered in a form of 600 ml of fluid (water + fruit juice). On testing days the PLA will be taken 2 hours before physical and exercise capacity tests session.~Between the PLA and SB or a SB and PLA treatments, a minimum 7-day washout period will be introduced."
47788|NCT03810391|Drug|Butorphanol|intravenous loading dose of 15ug/kg butorphanol,and followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion until the Ramsay sedation score reached 4 points
47789|NCT03810391|Other|physiological saline|intravenous infusion of the same volume of physiological saline
47790|NCT03810378|Behavioral|Mediterranean Diet (Med-Plus)|Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
47791|NCT03810378|Behavioral|Well-Formulated Ketogenic Diet (WFKD)|Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
47792|NCT03810365|Behavioral|Brief behavioral treatment for insomnia|Healthy eating control involves healthy eating content with 1 month 3 month 12 month follow-up visits.
47793|NCT03810339|Drug|Toripalimab|Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
47794|NCT03810326|Device|CTR device (tradename named Xtend)|Non invasive active splint
47795|NCT03810313|Drug|Brolucizumab 6 mg|Solution for injection (intravitreal use)
47796|NCT03810313|Drug|Aflibercept 2 mg|Solution for injection (Intravitreal use)
47797|NCT03810313|Other|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking
47798|NCT03810300|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
47799|NCT03810300|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
47800|NCT03810300|Other|Food and cash transfer|15 kg of rice, 1 kg of lentils, and 1 kg of micronutrient-fortified cooking oil, and 750 taka cash per household, distributed monthly
47801|NCT03810300|Behavioral|Nutrition behavior Communication Change (BCC)|Weekly, group-based, one-hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice; twice-a-month home visits; monthly community meetings
47802|NCT03810300|Other|Control|No transfer, no behavior change communication
47803|NCT03810287|Drug|Domperidone|Domperidone will be prescribed for patients with upper GI symptoms at an initial dose of 10 mg up to 4 times a day (prior to each meal and at bedtime). It is possible that the dose of domperidone may be increased to 20 mg if symptoms are not adequately controlled on the initial dose.
47804|NCT03810274|Device|3DV+TPS；VARIAN TPS；FonicsPlan|
47805|NCT03810261|Dietary Supplement|Oil-based vitamin D|Participants will receive oil-based VALENS vitamin D, 1000 IU/day for 8 weeks.
47806|NCT03810261|Dietary Supplement|Water-based vitamin D|Participants will receive water-based VALENS vitamin D, 1000 IU/day for 8 weeks.
47807|NCT03810261|Dietary Supplement|Vitamin D capsules|Participants will receive vitamin D capsules with starch-adsorbed vitamin D (powder), 1000 IU/day for 8 weeks.
47808|NCT03810235|Drug|Transdermal Lidocaine Patch|Transdermal Lidocaine Patch
47809|NCT03810235|Drug|Transdermal Hydrocolloid Placebo Patch|hydrocolloid placebo patches
47810|NCT03810222|Other|N/A (Observational Study)|This is an observational study and does not include interventions. Exposure is TBI.
47811|NCT03810209|Drug|Magnesium Sulphate|adding magnesium sulphate to local anaesthetic in SAP Block
47812|NCT03810209|Drug|Normal saline|adding normal saline to local anaesthetic in SAP block
47813|NCT03810196|Device|CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback|Peripheral stem cell (PSC) product will be processed using the CliniMACS device for TCRαβ and T cell depletion. Approximately 10% of the PSCs will undergo CD45RA depletion and cryopreservation. Patients who exhibit no GVHD at Day 21 will receive CD45RA depleted infusion.
47814|NCT03810183|Drug|QAW039|QAW039 450 mg
47815|NCT03810183|Drug|Placebo|Placebo
47816|NCT03810170|Behavioral|safe sex and HIV/STD prevention education via a website|website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.
47817|NCT03810170|Other|written materials on safe sex|2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics
47818|NCT03810157|Device|Laser-assisted hatching system|The ZP was thinned or drilled with the Laser-assisted hatching system. The laser pulse was 0.296 ms. Laser aperture was 8μm.
47819|NCT03810144|Genetic|Vectra DA MBDA Test|Vectra Guided versus Usual Care
47820|NCT03810131|Other|'A Bite of ACT' (BOA)|An online Acceptance and Commitment Therapy transdiagnostic psychoeducational intervention called 'A Bite of ACT' (BOA)
47821|NCT03810118|Diagnostic Test|fluid challenge|A first aliquot of a of 100ml mini FC infused over 1 minute, followed by a the rest aliquot of a 4 ml/kg fluid challenge infused over in either 10 or 20 minutes
47822|NCT03810105|Drug|Olaparib|Olaparib 300mg twice daily (600mg total daily dose)
47823|NCT03810105|Drug|Durvalumab|Durvalumab 1500mg IV monthly
47824|NCT03810079|Device|Anodal transcranial direct current stimulation|Neuromodulation of bilateral prefrontal areas using 2 mA tDCS delivered during 20 minutes via sponge electrodes on the scalp
47825|NCT03810079|Device|Sham transcranial direct current stimulation|Identical to anodal tDCS, except that the stimulation is stopped after 15 seconds.
47826|NCT03810066|Drug|Osimertinib|All patients will be treated with osimertinib 80 mg/d for one cycle (28 days).
47827|NCT03810053|Behavioral|Mobile App/Online Module|Short didactic explainer video that will provide information about cancers and benefits of uptake of cancer prevention and early detection measures.
47828|NCT03810040|Device|140 microns denuding pipette|the degranulated needle size was 140 microns
47829|NCT03810040|Device|150 microns denuding pipette|the degranulated needle size was 150 microns
47830|NCT03810027|Diagnostic Test|Bladder diary|3-day bladder diary
47831|NCT03810014|Other|Conditional ACT subsidy, Arm 1 levels|The subsidy levels for participants randomly assigned to Arm 1 are: No subsidy for RDT (price to consumer=$0.40); 100% ACT subsidy (price to consumer=0).
47832|NCT03810014|Other|Conditional ACT subsidy, Arm 2 levels|The subsidy levels for participants randomly assigned to Arm 2 are: No subsidy for RDT (price to consumer=$0.40); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age).
47833|NCT03810014|Other|Conditional ACT subsidy, Arm 3 levels|The subsidy levels for participants randomly assigned to Arm 3 are: 50% subsidy for RDT (price to consumer=$0.20); 100% ACT subsidy (price to consumer=0).
47834|NCT03810014|Other|Conditional ACT subsidy, Arm 4 levels|The subsidy levels for participants randomly assigned to Arm 4 are: 50% subsidy for RDT (price to consumer=$0.20); 67% ACT subsidy (price to consumer=$0.10-0.40, dependent upon patient age)
47835|NCT03810001|Behavioral|Mechanical Stimulation|micromanipulation technique before insertion of the microinjection needle into the oocyte and expulsion of the spermatozoon
47836|NCT03809988|Drug|Palbociclib|Palbociclib capsules orally once daily (QD) (at 100mg or 125mg depending on previous treatment dose) for 21 days every four weeks
47837|NCT03809988|Drug|Endocrine therapy|Endocrine therapy alone (letrozole or fulvestrant)
47838|NCT03809975|Other|Multidisciplinary Community Program|"Patient will undergoes 12 weeks of structured and personalized multidisciplinary community-based program, which consists of Physiotherapy, Dietetics and Psychology sessions. Patients will also attend 2 educational sessions. Physiotherapy and educational sessions are mandatory for all participants, while the need for dietetics and psychological interventions are determine using individual's BMI measurements and psychological questionnaires.~Inclusion criteria:~Dietetics: 23.5 < BMI <32.5; Psychology: PEG > 4 or PHQ-4 > 5 or PAM level < 3"
47873|NCT03809793|Diagnostic Test|VO2 Max|Assessment of maximum aerobic capacity.
47874|NCT03809793|Diagnostic Test|Continuous Glucose Monitor|CGM sensor will be inserted to measure insulin sensitivity over a 24hr period.
47839|NCT03809975|Other|Current model of care|No controlled set of treatment assigned to patient. It is based totally on the discretion of the attending clinicians. It will generally contain an unspecific number of physiotherapy sessions. Other allied health involvement such as dietetics and psychological interventions will be on an ad hoc basis. In some cases, the orthopaedic surgeon may recommend for surgery.
47840|NCT03809962|Device|Ostenil® Plus|Ostenil® Plus is a CE-certified viscoelastic solution for injection into the Joint cavity, containing 2.0 % Sodium hyaluronate from fermentation
47841|NCT03809949|Drug|Fentanyl Opioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
47842|NCT03809949|Drug|Saline Nonopioid anesthesia|To compare between opioid and opioid free anaesthesia on post-operative nausea and vomiting in middle ear surgery
47843|NCT03809936|Device|real tDCS|Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode positioned over the left dorsolateral prefrontal cortex (F3 according to the 10-20 international system for EEG placement) and the cathode placed over the right supraorbital region. During real tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes.
47844|NCT03809936|Device|sham tDCS|For the sham condition(sham tDCS), the same electrode placement was used as in the stimulation condition, but the current was applied for only 5 seconds, and was then ramped down.
47845|NCT03809923|Drug|lidocaine and dexmedetomidine infusion|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
47846|NCT03809923|Drug|Saline infusion|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
47847|NCT03809910|Device|Reference MTB|Participants will brush their teeth with manual toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 1-timed minute under supervision of study staff.
47848|NCT03809910|Device|Reference PTB|Participants will brush their teeth with power toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute under supervision of study staff.
47849|NCT03809910|Device|Prototype PTB (Gum line mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode under supervision of study staff."
47850|NCT03809910|Device|Prototype PTB (Combined mode)|"Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff."
47851|NCT03809897|Drug|Varenicline|All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
47852|NCT03809897|Drug|Nicotine patch|Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
47853|NCT03809884|Behavioral|Dietary Counselling|Individually tailored strategy to increase potassium in the diet.
47854|NCT03809884|Drug|Potassium Citrate|Dosing of 50 to 100 mmol of potassium citrate per day (as 25 to 50 ml of the liquid solution).
47855|NCT03809871|Biological|Cardiometabolic biomarkers|This is for measures of cholesterol (HDL, LDL and total cholesterol), blood glucose and HbA1c, vitamin D, vitamin B12 and iron levels.
47856|NCT03809858|Other|Klue App|The Klue App utilizes an Apple Watch to detect eating or drinking behavior. The App can initiate a sequence of questions when eating/drinking is detected to determine if a subject has administered a bolus for the meal or if they need to do so.
47857|NCT03809845|Device|High-density surface electromyography|High-density surface electromyography
47858|NCT03809832|Diagnostic Test|Microbiological sampling|An microbiological sampling of the ventilator humidifier will be performed.
47859|NCT03809819|Procedure|laparoscopic Vecchietti vaginoplasty|Patients who underwent laparoscopic Vecchietti vaginoplasty
47860|NCT03809819|Diagnostic Test|FSFI questionnaire|Completion of FSFI questionnaire
47861|NCT03809819|Diagnostic Test|UDI-6 questionnaire|Completion of UDI-6 questionnaire
47862|NCT03809819|Diagnostic Test|IIQ-7 questionnaire|Completion of IIQ-7 questionnaire
47863|NCT03809806|Procedure|4-arm polypropylene mesh surgery|Pelvic reconstructive procedures were performed with the use of 4-arm mesh:upper arms through- anterior part of obturator foramens, lower arms-ischiorectal fossas and sacrospinal ligaments.
47864|NCT03809806|Diagnostic Test|The Female Sexual Function Index (FSFI) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
47865|NCT03809806|Diagnostic Test|King Health Questionnaire (KHQ)|patients fulfilled questionnaire before and 1 year after procedure
47866|NCT03809806|Diagnostic Test|Pelvic Organ Prolapse Quantification (POPQ) staging|Pelvic Organ Prolapse staging before and 1 year after the procedure
47867|NCT03809806|Diagnostic Test|Postoperative questionnaire|Postoperative questionnaire assessing quality of life fulfilled by patients 1 year after procedure
47868|NCT03809806|Diagnostic Test|The Short Form Health Survey (SF 36) questionnaire|patients fulfilled questionnaire before and 1 year after procedure
47869|NCT03809793|Other|Exercise Program|12-week walking based intervention (3 sessions per week)
47870|NCT03809793|Diagnostic Test|DXA|Participants will undergo an assessment of body composition (DXA)
47871|NCT03809793|Diagnostic Test|MRI|used to measure fat stored in the liver
47872|NCT03809793|Diagnostic Test|Hyperinsulinaemic Euglycaemic Clamp|Participants will arrive at the laboratory after an overnight fast (>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.
47875|NCT03809793|Procedure|Muscle Biopsies|Participants will undergo muscle biopsies pre and post the hyperinsulinemic euglyceamic clamp from the vastus lateralis.
47876|NCT03809793|Drug|Acipimox 250 MG|Participants will be randomised into two groups. One group will be prescribed Acipimox that will be taken 1 hour prior to each exercise session. The other group will take no drug.
47877|NCT03809780|Drug|Lenalidomide|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
47878|NCT03809780|Drug|Dexamethasone|-high dose: [lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly] -Low dose: [lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly]
47879|NCT03809767|Drug|CS1003 monoclonal antibody|CS1003 will be administered intravenously every 3 weeks.
47880|NCT03809754|Procedure|Percutaneous Coronary Intervention under OCT|After randomization, subjects receive primary PCI under the guiding of OCT
47881|NCT03809754|Procedure|Percutaneous Coronary Intervention under Angiography|After randomization, subjects receive primary PCI under the guiding of angiography
47882|NCT03809741|Other|Bundled L&D Infection Prevention Interventions|"The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy"
47883|NCT03809728|Procedure|endoscopic biopsy|Per-endoscopic biopsies
47884|NCT03809728|Procedure|samples of the oral cavity|7 samples of the oral cavity with a swab
47885|NCT03809728|Procedure|Samples of the resected specimen|if patient has to undergo a digestive resection as part of his standard management, samples of the pathological area and samples at the end of the resection will be realised
47886|NCT03809715|Device|Coroflex® ISAR NEO coronary stent system|"treatment of coronary artery disease with Coroflex® ISAR NEO of real world de-novo and restenotic lesions in native coronary arteries and coronary bypass grafts"
47887|NCT03809702|Drug|Pregabalin|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
47888|NCT03809702|Drug|Placebo|Pain score in group 1 (intervention group) will be compared with pain score in group 2 (placebo group)
47889|NCT03809689|Other|68Ga-NODAGA-RGD PET/CT|intravenous injection of 200 Megabecquerel (MBq) 68Ga-NODAGA-RGD followed by a whole-body acquisition after injection and one hour after injection
47890|NCT03809689|Diagnostic Test|82-Rb PET/CT as part of standard care, not a comparator|2 intravenous injections of standard dose of 82-Rb : the first followed by an at-rest acquisition, the second followed by a pharmacological myocardial stress acquisition
47891|NCT03809676|Other|periodontal examination|clinical measurements were recorded
47892|NCT03809663|Drug|Tezepelumab|Solution for injection
47893|NCT03809663|Other|Placebo|Placebo solution for injection
47894|NCT03809650|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
47895|NCT03809637|Drug|Pemetrexed, cisplatin|Pemetrexed 500mg/m2, Intravenous, Q 3weeks. Cisplatin 75mg/m2, Intravenous, Q 3weeks. Combination administration : up to 6cycles After 6 cycle, pemetrexed alone is administered.
47896|NCT03809624|Drug|INBRX-105 - PDL1x41BB antibody|The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
47897|NCT03809611|Drug|UNR844-Cl|1.5% solution
47898|NCT03809611|Drug|Placebo|placebo
47899|NCT03809598|Behavioral|Mindfulness Based Cognitive Therapy|"See Mindfulness Based Cognitive Therapy (MBCT) Arm description"
47900|NCT03809572|Behavioral|Mindfulness Based Cognitive Therapy|See Arm description
47901|NCT03809559|Device|MRCP+|Participants will undergo an initial abdominal MRI scan in a fasted state. They will then be asked to drink 400ml pineapple juice before undergoing four further abdominal MRI scans with short breaks in between each scan.
47902|NCT03809546|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
47903|NCT03809546|Drug|dextrose|We are administering dextrose to health volunteers for our placebo group
47904|NCT03809533|Drug|sofosbuvir/velpatasvir|12-week, oral, fixed-dose
47905|NCT03809520|Radiation|pedCAT|Weight-bearing CT scan (pedCAT) of ankles to measure 3D joint space width following ankle fracture.
47906|NCT03809507|Other|Qualtrics survey questions|"Qualtrics Survey:~For each of the scenarios, practitioners will be asked whether opioids are prescribed or not, and the type(s) of other analgesic medications that would be prescribed, the strength in mg, and the number of doses for each medication"
47907|NCT03809494|Device|HemaTrate™ Blood Filtration system|Anticoagulated whole blood is loaded into the filtration system. During gravity filtration, the majority of platelets, plasma, and red blood cells pass through the filter into a filtrate bag. The TNCs are captured in the filter material and recovered via a back-flush with 0.9 % saline into a syringe.
47908|NCT03809494|Other|Saline|Normal (0.9%) saline
47909|NCT03809481|Drug|Danaparoid Sodium|inhibits thrombin generation by indirect anti-Xa inhibition and direct inhibition of factor IX activation
47910|NCT03809481|Drug|Argatroban|Synthetic direct thrombin inhibitor
47911|NCT03809468|Other|phone call follow up|instead of a clinic visit, patients will be randomized to a phone call
47947|NCT03809221|Drug|Triptorelin acetate|Achieve pituitary down regulation with triptorelin acetate and start controlled ovarian stimulation after complete pituitary down regulation
47948|NCT03809195|Behavioral|Clinical Hypnosis|See information in arm/group description. Four different audio recordings are provided electronically, each approximately 20 minutes in length. Participants are encouraged to listen to one daily.
48022|NCT03808688|Drug|Netarsudil Ophthalmic Solution 0.02%|1 drop in each eye once daily in the evening
47912|NCT03809455|Drug|Fentanyl citrate|"Fentanyl citrate arm (FAR Arm): one intake of fentanyl citrate 100 µg (intranasal or buccal).~Placebo Arm: one intake of placebo (intranasal or buccal) The administration route will be left to the discretion of the investigator taking into account the patient's profile (capable of maintaining the sublingual tablet without swallowing, absence of nasal discharge…), and/or the patient's choice.~Medication Commercial name Formulation Administration route Dose Fentanyl citrate Pecfent® Nasal spray Intranasal 100 µg Fentanyl citrate Abstral® Sublingual tablet Buccal 100 µg For the cohort the choice of treatment by FAR is at the centres discretion, according to standard of practice.~Treatment duration: 1 day"
47913|NCT03809455|Drug|Placebo|one intake of placebo (intranasal or buccal)
47914|NCT03809442|Drug|Ropivacaine + Ketamine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 1mg/kg ketamine (8 mL per incision) (ketamine group).
47915|NCT03809442|Drug|Ropivacaine + Tramadol|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 2mg/kg tramadol (8 mL per incision) (Tramadol group).
47916|NCT03809442|Drug|Ropivacaine + Midazolam|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine + 50 μg/kg midazolam (8 mL per incision) (Midazolam group).
47917|NCT03809442|Drug|Ropivacaine + Dexmedetomidine|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% Ropivacaine + 0.5μg/kg dexmedetomidine (8mL per incision) (Dexmedetomidine group).
47918|NCT03809442|Drug|Ropivacaine + Dexamethasone|Patients will receive subcutaneous wound infiltration with total volume of 24 mL of 0.25% ropivacaine+ 8mg dexamethasone (8 mL per incision) (Dexamethasone group).
47919|NCT03809442|Drug|Ropivacaine|Patients will receive subcutaneous wound infiltration with 24ml of 0.25% Ropivacaine in three divided doses (i.e. 8 mL per incision) (control group). Total dose of Ropivacaine will be 60 mg.
47920|NCT03809429|Drug|FE 999049 + GnRH agonist (GONAPEPTYL)|FE 999049 + GnRH agonist (GONAPEPTYL)
47921|NCT03809429|Drug|FE 999049 + GnRH antagonist (CETROTIDE)|FE 999049 + GnRH antagonist (CETROTIDE)
47925|NCT03809390|Procedure|Vaginal seeding|The same as that stated in arm descriptions.
47926|NCT03809377|Procedure|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points during and after radiotherapy
47927|NCT03809364|Behavioral|START Together|Behavioral intervention using a cognitive behavioral couple therapy (CBCT) framework designed to improve the couple's communication and problem-solving behavior.
47928|NCT03809351|Drug|[F-18]AV-1451-PET|All study participants will undergo brain imaging with [F-18]AV-1451-PET/MRI. [F-18]AV-1451 is a PET imaging agent used primarily to measure the amount of abnormal tau protein deposition the brain.
47929|NCT03809338|Diagnostic Test|amh test|Antral follicle count with ultrasound on the 3rd day of menstruation
47930|NCT03809325|Drug|Paliperidone Palmitate 3-Month Formulation (PP3M)|No intervention will be administered as a part of this study. Participants who have been treated with PP3M in clinical practice will be enrolled.
47931|NCT03809312|Drug|Amoxicillin / Clavulanic acid 875mg / 125mg|Amoxicillin / Clavulanic acid 875 mg / 125 mg BID x 10 days
47932|NCT03809312|Drug|Placebos|Placebos BID x 10 days
47933|NCT03809299|Other|Ad libitum meal timing|Research participants will eat meals provided by the study throughout the day, ad libitum
47934|NCT03809299|Other|Twice a day meals|Research participants will eat meals provided by the study at two intervals during the day, and fast in between.
47935|NCT03809286|Device|active rTMS|rTMS delivers magnetic stimulation to the brain by using an electromagnet to generate a current that can penetrate the scalp and skull.
47936|NCT03809286|Behavioral|Inpatient admission|All subjects will be admitted to the hospital for a brief detoxification period followed by 3 weeks of abstinence.
47937|NCT03809286|Device|sham rTMS|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
47938|NCT03809273|Drug|Yangxinshi|Yangxinshi pill 3 pills /tid
47939|NCT03809273|Drug|Trimetazidine|Trimetazidine 20mg/tid
47940|NCT03809273|Drug|Yangxinshi mimic|Yangxinshi mimic tablets 3 pills /tid
47941|NCT03809273|Drug|Trimetazidine mimic|Trimetazidine mimic tablets 20mg/tid
47942|NCT03809260|Drug|Metformin (part 1)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).
47943|NCT03809260|Drug|Vancomycin|11d: Vancomycin 250 mg bid, 12~17d: Vancomycin 500 mg bid
47944|NCT03809260|Drug|Metformin (part 2)|1~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
47945|NCT03809234|Drug|Ondansetron 8mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
47946|NCT03809234|Drug|Ondansetron 16mg with Saline & Tariquidar|Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
47949|NCT03809182|Drug|Dexmedetomidine|A bolus of 1ug/kg in 10 minutes, followed by an infusion of 0.5ug/kg/h until the end of surgery.
47950|NCT03809182|Drug|0.9% Sodium-chloride|The same dose used in the dexmedetomidine group (bolus and infusion).
47951|NCT03809182|Drug|Fentanyl|Intraoperative fentanyl was given in case of 25% increment in the blood pressure and/or heart rate in comparison to baseline (previous anesthesia induction).
47952|NCT03809182|Drug|Morphine Sulfate|Boluses of 3mg of intravenous morphine were given in the postoperative acute care unit. Once the pain score was equal or less than 3/10 a patient-controlled analgesia pumps were installed and the patients were discharged to their room.
47953|NCT03809169|Procedure|Rapid on-site evaluation (ROSE)|Pathologist on site for direct evaluation of specimen adequacy
47954|NCT03809169|Procedure|Slim bronchoscope without a guide sheath|peripheral endobronchial ultrasound performed with a slim bronchoscope (3.0 mm outer diameter with a 1.7mm channel) combined with a radial ultrasound probe but without the use of a guide sheath.
47955|NCT03809169|Procedure|Standard pEBUS with guide sheath|Using a flexible bronchoscope with minimal outer diameter of 4.2mm.
47956|NCT03809156|Drug|Riociguat Oral Product|Dual therapy of Riociguat and Ambrisentan at initiation of treatment.
47957|NCT03809143|Drug|RBP-6000|All study participants are scheduled to receive monthly subcutaneous injections of depot BPN, RBP-6000. RBP-6000 (BPN in the ATRIGEL® Delivery System) contains buprenorphine (200mg/mL) in the ATRIGEL® Delivery System, which provides sustained plasma level of BPN over a minimum of 28 days.
47958|NCT03809130|Other|Internet-Based Intervention|Use Untire application after baseline up to 6 months
47959|NCT03809130|Other|Internet-Based Intervention|Use Untire application after 3 months up to 6 months
47960|NCT03809130|Other|Quality-of-Life Assessment|Ancillary studies
47961|NCT03809130|Other|Questionnaire Administration|Ancillary studies
47962|NCT03809117|Diagnostic Test|Biofire Film Array Gastrointestinal Panel|The 22-target FilmArray® GI Panel allows a syndromic approach to the diagnosis of infectious diarrhea as it includes bacteria, viruses and parasites in one test. Results are typically available within two hours of collection.
47963|NCT03809104|Other|Virtual reality-based rehabilitation programs|A virtual reality (VR)-based rehabilitation program that lasts for 12 weeks, twice per week, 30 minutes per time. The program was combined with progressive resistant training and functional movement of dominant upper (UE) limb. The device of the VR including one computer, one oculus headset, and one hand-hold sensor. The rehabilitation secession contains 4 different VR games in total, including (1) Leap Motion Blocks (2) Slum Ball VR Tournament (3) VR Super Sports 10th Edition- Basketball (4) VR Super Sports 10th Edition- Soccer.
47964|NCT03809091|Diagnostic Test|Whole genome sequencing|Whole genome sequencing of patients and their family will be performed. Among the variants detected by WGS, disease-causing variants will be analyzed by using segregation analysis.
47965|NCT03809078|Drug|68Ga RM2|PET radiopharmaceutical
47966|NCT03809078|Drug|68Ga-PSMA-11|PET radiopharmaceutical
47967|NCT03809078|Device|Investigational PET scanner coils and software|GE Healthcare non-approved PET scanner coils and software
47968|NCT03809065|Drug|Nitroglycerin|Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) <3}.
47969|NCT03809065|Drug|Labetalol|Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) <3}.
47970|NCT03809052|Drug|GB1211|Hard capsules for oral use
47971|NCT03809052|Drug|Placebo|Hard capsules for oral use
47972|NCT03809039|Drug|MT-6345|MT-6345
47973|NCT03809039|Drug|MT-6345 Placebo|MT-6345 Placebo
47974|NCT03809013|Drug|RC48-ADC|2.0mg/kg IV every 2 weeks
47975|NCT03809000|Radiation|Radiation Therapy|Radiation Therapy
47976|NCT03809000|Drug|Enzalutamide|Anti-androgen
47977|NCT03809000|Drug|Bicalutamide|Anti-androgen
47978|NCT03809000|Drug|GnRH analog|Anti-androgen
47979|NCT03808987|Behavioral|Child-Parent Psychotherapy (CPP)|Child-Parent Psychotherapy (CPP) focuses on parent-infant relationships, increases efficacy for improved mother-child relationships, more sensitive parenting, healthier child development, and maltreatment prevention. A primary goal is to strengthen the parent-child relationship to improve family functioning and child security of attachment. Through respect, empathic concern, and positive regard, the therapeutic relationship provides mothers with corrective emotional experiences, through which they are able to differentiate current from past relationships, form positive internal representations of themselves and of themselves in relationship to others, particularly their children. Parents are encouraged to process their experiences of trauma and restore parental roles as protective shields, improve affective regulation capacities, enhance understanding of the meaning of behavior, acknowledge the impact of trauma, and support children in a more positive developmental trajectory.
47980|NCT03808987|Behavioral|Community Health Worker (CHW) home visitation|Community Health Worker (CHW) home visitation includes assistance with concrete support needs, such as transportation to medical appointments, referrals for food, housing, and employment services, and attention to developmental needs of young children.
47981|NCT03808974|Other|Educational video|Short educational video describing the mid-urethral sling procedure
47982|NCT03808974|Other|Educational leaflet|Standard educational leaflet describing the mid-urethral sling procedure
47983|NCT03808961|Dietary Supplement|Niacin|100mg tablets twice daily
47984|NCT03808961|Dietary Supplement|Niacinamide|100mg tablets twice daily
47985|NCT03808961|Other|Placebo|Placebo tablet
47986|NCT03808948|Device|VFI|The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
48020|NCT03808714|Behavioral|Control Group|Alabama Quitline
47987|NCT03808935|Drug|Medical Cannabis|The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
47988|NCT03808935|Drug|Placebo|The placebo intervention will begin with two weeks of titration, followed by four weeks of treatment. Participants will then be unblinded to their study group and begin two weeks of titration, four weeks of treatment, and two weeks of washout with medical cannabis, following the same dosing and schedule as the experimental group. All daily doses are equally divided into a morning and evening dose.
47989|NCT03808922|Drug|DAS181|DAS181 4.5mg nebulized qd x 7 OR 10 days
47990|NCT03808922|Drug|Placebo|Placebo nebulized qd x 7 OR 10 days
47991|NCT03808909|Other|Continuous Labor Support|Participants in the intervention condition will be assigned a doula who is a lay person trained to provide emotional and practical support to individuals throughout labor and delivery.
47992|NCT03808896|Procedure|stylet-assisted epiglottic lifting|use stylet-equipped enodtracheal tube to lift the epiglottis and pass the endotracheal tube
47993|NCT03808896|Device|bougie-assisted intubation|use bougie as a introducer. Pass the bougie to the trachea and pass the tube via bougie guide.
47994|NCT03808883|Behavioral|TGNC Directed Advocacy Meetings|Series of community meetings with TGNC individuals to include meeting with health professionals to articulate barriers to access and to enter into dialogue with medical providers and staff
47995|NCT03808870|Drug|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
47996|NCT03808857|Biological|GB226|GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.
47997|NCT03808844|Drug|HSK3486|Initial dose of 0.4 mg/kg followed by 0.2 mg/kg if needed.
47998|NCT03808844|Drug|Propofol|Initial dose of 2.0 mg/kg followed by 1.0 mg/kg if needed
47999|NCT03808831|Device|Fall detection and prevention system|The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.
48000|NCT03808831|Device|Sham fall detection and prevention system|The sham system with record but no alert function
48001|NCT03808818|Other|Behavioral, Psychological or Informational Intervention|Receive information about tobacco cessation
48002|NCT03808818|Drug|Nicotine Replacement|Given NRT patch or lozenge (or both)
48003|NCT03808818|Other|Quality-of-Life Assessment|Ancillary studies
48004|NCT03808818|Other|Survey Administration|Ancillary studies
48005|NCT03808818|Other|Tobacco Cessation Counseling|Receive virtual tobacco cessation counseling
48006|NCT03808805|Drug|Aprepitant 80 mg|oral therapy - daily dose - 14 days
48007|NCT03808805|Drug|Hydroxyzine 25mg|oral therapy - daily dose - 14 days
48008|NCT03808805|Drug|Placebo of Hydroxyzine|oral therapy - daily dose - 14 days
48009|NCT03808805|Drug|Placebo of Aprepitant|oral therapy - daily dose - 14 days
48010|NCT03808792|Diagnostic Test|Ultrasound, CT and WB-DWI/MRI|Preoperative assessment with Ultrasound, CT and WB-DWI/MRI
48011|NCT03808779|Procedure|Radiofrequency Ablation|Patients were supine with the neck exposure completely during the procedure. Local anesthesia with 1% lidocaine was injected at the subcutaneous puncture site and the thyroid anterior capsule. If the distance between the tumor and critical cervical structures was less than 5 mm, normal saline was injected to form at least 1 cm distance between the tumor and the critical structure to prevent the unwilling thermal injury. RFA was performed using the moving-shot technique and RFA power was 5 W, if a transient hyperechoic zone did not form at the electrode tip within 5-10 seconds. The RFA extent exceeded the tumor edge to prevent marginal residue and recurrence. The ablation was terminated when all portions of the target ablation area had changed to hyperechoic zones.
48012|NCT03808779|Procedure|Conventional Surgery|Patient is performed total thyroidectomy or thyroid lobectomy depending on the intraoperative situation, disease condition and comprehensive judge by surgeon. Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat and placenta muscle are incised and separated successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process.
48013|NCT03808766|Other|embolization|Patient with a diagnosis of HCC and a treatment plan to receive partial hepatectomy will receive transarterial embolization under local anesthesia 2 weeks before the surgery. Angiographic examinations of the tumor before and after embolization of the tumor will be performed. Histological examination of the tumor in the surgical specimens will be performed.
48014|NCT03808753|Diagnostic Test|End-expiratory occlusion test (EEOT)|The EEOT is performed by interrupting the mechanical ventilation for 30 seconds, by using and end-expiratory hold on the ventilator.
48015|NCT03808753|Other|mini fluid challenge (mFC)|The mFC is performed by injecting a first aliquot of 100 ml of crystalloid over 1 minute before completing the 4 ml/kg-FC over the residual 9 minutes.
48016|NCT03808740|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day.
48017|NCT03808740|Drug|Placebo|atomoxetine 0.5 mg/kg/day.
48018|NCT03808727|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
48019|NCT03808714|Behavioral|TOUCHDOWN|We expect the intervention to consist of 3 to 4 group sessions and at least one individual session plus pharmacological consultation(s) via Skype, but this will be determined during pretesting. CHWs will have IPads with cellular connectivity and will be present when the pharmacological approach is discussed with the participant so that they can reinforce the message with the participant and be the liaisons between the participant and physician.
48023|NCT03808675|Behavioral|Aerobic walking|The investigators will use self-administered continuous walking exercise at a moderate intensity level, defined as 40-59% of heart rate reserve or 64-77% of heart rate at gas exchange threshold (HRGET) by ACSM as in the investigators' preliminary study (PMID: 24991037 PMCID: PMC4132568). The HRGET will be determined as the heart rate at VO2max during graded cycle ergometry. The total duration of the exercises will be 150 min/week per 2008 Physical Activity Guidelines for Americans and American Heart Association recommendations, conducted in three 50 min sessions. The aerobic walking intervention will take place outdoors (e.g., trails, sidewalks, parks) or indoors (e.g., track in a local gym or a mall) depending on the preferences of the subject and weather. Session duration will be 20 min the first week and will be advanced by 5 min per week over 6 weeks.
48024|NCT03808675|Behavioral|Usual care with PD specific health education|"In this study, patients will receive their usual medical treatment for motor and non-motor symptoms from their~primary neurologist. The investigators will use a streamlined form of PD specific health education prepared by the VA: My Parkinson's Story, which consists of a series of short videos prepared by the VA PADRECCs addressing various aspects of PD. These 6-12 minutes long videos are freely available on YouTube. The investigators can also provide them on a CD if subjects desire. They start with a patient testimony about the topic of the episode, followed by comments of experts in the field. The title of the episodes are: Early Parkinson's, Medications, Exercise, Memory, Visual Disturbances, Depression, Sleep, Speech and Swallowing, Impulsive Behaviors, Driving, Pain, Dyskinesias, Deep Brain Stimulation, Advanced Parkinson's Disease, Falls, The Caregiver, Hospitalization, Genetics, Environmental Exposure, Atypical Parkinsonism"
48025|NCT03808662|Radiation|Sterotactic Body Radiotherapy/SBRT|In general, it is recommended using 9-10 Gy x 3 or 10 Gy x 5 fractions given every other day. Physicians should try to give the highest BED whenever possible while respecting normal tissue tolerance. All lesions are recommended to receive a biologically effective dose (BED) of 60 Gy or higher (BED10≥70), assuming α/β ratio of 10 and using the linear-quadratic model: BED = nd x [1 + d/(α/β)] where n is number of fractions and d is dose per fraction. Sometimes BED ≥80 Gy is preferred, with lower doses ≥50 Gy allowed at the discretion of the treating physician for concerns about normal tissue toxicity.
48026|NCT03808662|Drug|Standard of care|Standard of care per physician discretion
48027|NCT03808649|Drug|1500ml of 2.5% mannitol|1500ml of 2.5% mannitol was used in experimental group
48028|NCT03808649|Drug|different volume of 2.5% mannitol|different volume of 2.5% mannitol based on BMI was used in active comparator group
48029|NCT03808623|Device|AMIC with NOVOCART Basic|NOVOCART® Basic is a biphasic, collagen-based matrix to support the biological reconstruction of localized and full-thickness cartilage damages after treatment with bone marrow stimulation techniques (microfracture). The procedure is called autologous matrix-induced chondrogenesis (AMIC). It is a single-step procedure. NOVOCART® Basic is tailored to fit the prepared defect size and is inserted in the defect area after microfracture. The NOVOCART® Basic device component is fully resorbed over a period of a few months as new reparative cartilage tissue is generated and integrated with the surrounding host tissue.
48030|NCT03808610|Drug|Cyclophosphamide|Given IV
48031|NCT03808610|Drug|Cytarabine|Given IV
48032|NCT03808610|Drug|Dexamethasone|Given IV or PO
48033|NCT03808610|Drug|Methotrexate|Given IV
48034|NCT03808610|Drug|Nelarabine|Given IV
48035|NCT03808610|Drug|Pegaspargase|Given IV
48036|NCT03808610|Drug|Prednisone|Given PO
48037|NCT03808610|Biological|Rituximab|Given IV
48038|NCT03808610|Drug|Venetoclax|Given PO
48039|NCT03808610|Drug|Vincristine|Given IV
48040|NCT03808597|Other|Digital health promotion intervention|Digital health promition related to HIV, Tuberculosis and TSCT in a digital format.
48041|NCT03808584|Other|Physiotherapy|4 specific core muscle exercises, targeting abdominal muscles, to be performed daily from postoperative day one to 2 months postsurgery.
48042|NCT03808571|Other|cord blood specimen during the delivery|The cord blood will be taken during the delivery of baby.
48043|NCT03808558|Drug|TVB-2640|TVB-2640 will be administered 100mg/m2 orally once a day for 8 weeks.
48044|NCT03808545|Behavioral|Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS)|This is a newly developed Internet website that delivered a Social Cognitive Theory-based behavioral intervention using e-learning and one-on-one video chats approaches for increasing physical activity and improving symptoms, walking impairment, and neurological disability. The intervention will last 16 weeks and will include physical activity information.
48045|NCT03808545|Behavioral|BIPAMS + Diet|For 8 weeks a participant will complete the standard BIPAMS intervention. For the subsequent 8 weeks, in addition to the BIPAMS website, participants will receive a diet prescription with instructions and guidance on their one-on-one video calls and will utilize the HealthWatch360 app and/or desktop website to track their dietary intake. The total intervention will last 16 weeks and will include physical activity information and dietary information.
48046|NCT03808532|Other|Moisturizing Cream|Parents of at-risk infants in the intervention arm will be instructed to apply moisturizer to the infant's entire body once daily.
48047|NCT03808532|Other|Best care skin practice instructions|Parents will be instructed by the dermatologist as to best care skin practices at the time of study enrollment.
48048|NCT03808519|Dietary Supplement|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
48049|NCT03808519|Dietary Supplement|Placebo|Organic Sunflower Oil 5000mg per day
48050|NCT03808506|Diagnostic Test|Fecal calprotectin|Stool test to look at baseline burden of inflammation
48051|NCT03808493|Drug|TAK-438 OD|TAK-438 OD tablet
48052|NCT03808493|Drug|TAK-438|TAK-438 tablet
48053|NCT03808480|Drug|CA and Nivolumab|Cyclophosphamide 500mg/m2 IV on D1 (C1-4), 1cycle=21days) Doxorubicin 50mg/m2 IV on D1 (C1~4, 1cycle=21days) Nivolumab 360 mg/IV C2~4 D1 (1cycle=21days) Nivolumab 400mg/IV on D1 from Cycle 5 every 4 weeks.
48080|NCT03808298|Drug|Moxifloxacin Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule.
48081|NCT03808298|Drug|Placebo for moxifloxacin Treatment C|Day 15: A single oral dose of a matching placebo capsule for moxifloxacin.
48082|NCT03808298|Drug|Placebo for moxifloxacin Treatment D|Day 2: A single oral dose of a matching placebo capsule for moxifloxacin.
48211|NCT03807297|Drug|Injection, Propofol, 10 Mg|non barbiturate type of intravenous anaesthetic drug
48054|NCT03808467|Behavioral|Cognitive Remediation Therapy|Nine individual transdiagnostic CRT sessions will be delivered once per week, each session lasting approximately 45 minutes. Building on previously published CRT manuals for anorexia nervosa and obesity, a transdiagnostic CRT manual developed for this project will be used during the course of CRT treatment. The manual comprises an introduction to CRT for eating disorders, and a detailed nine-session structure incorporating cognitive and behavioral tasks in the following domains; (1) planning-impulsivity, (2) flexibility-rigidity and (3) central coherence-attention to details. A certain set of guiding questions will accompany each task with the aim of stimulating metacognition (i.e. thinking about thinking).
48055|NCT03808467|Other|Treatment as usual|According to Norwegian guidelines established by the Norwegian Directorate of Health, the patients are likely to receive treatment focusing directly on the ED symptomatology, i.e normalization of weight in the case of underweight, reduction of binging and purging and normalization of other ED related thoughts and behaviors. Since both in-patients, patients in day treatment and out-patients will be included in the study, the number of hours with therapeutic interventions will vary. Records of the participants` received number of therapeutic hours will be logged weekly during the intervention for participants in both arms of the study.
48056|NCT03808454|Drug|PRP|The investigators draw 10cc of blood and concentrate the blood to get the platelet rich plasma
48057|NCT03808454|Other|Rehabilitation|strengthening ex, posture training,...
48058|NCT03808454|Combination Product|PRP+Rehabilitation|combine PRP and Rehabilitation
48059|NCT03808441|Other|ctDNA analysis|Regular ctDNA analysis, which upon a decrease in mutant BRAF VAF (variant allele frequency) level of ≥80% the switch to N+I is triggered.
48060|NCT03808428|Device|Ankle Group|Provide sensory feedback to help subjects relearn how to walk in correct gait pattern.
48061|NCT03808415|Device|EMG-driven|The EMG signals are processed and can be visualized with visual feedback to make sure the user actively engaging throughout a therapy session.
48062|NCT03808389|Other|Donor FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from healthy donors and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the treatment group.
48063|NCT03808389|Other|Autologous FMT|Fecal microbiota transplantation through nasojejunal administration. Fecal matter will be collected prior to the start of the study from each patient and will be frozen at -80°C after thorough screening for infectious diseases. At the time of transplantation, samples will be thawed and administrated to the patients in the control group.
48064|NCT03808376|Device|Continuous Glucose Monitoring System|The Eversense® 180 CGM System
48065|NCT03808363|Other|High Intensity Interval Training|Participants assigned to this group will perform a very mild 5-minute warm-up (0 resistance, and 60 rpm), followed by 5 one-minute bouts of high intensity exercise, with 90 seconds between each bout. These bouts will be followed by a 3-minute cool down (0 resistance, and 60 rpm). The high-intensity exercise will be performed at an intensity of 17 on the BORG RPE scale (very hard), and the 90 second active rest intervals will be performed at an intensity of 7-9 (very, very light - very light). The exercise will be performed on the NuStep machine 3 times a week for 6 weeks.
48066|NCT03808350|Procedure|Families Invited to Be Present at Procedures|Family members will be invited (but not required) to remain in the ICU room during procedures, if patients agree
48067|NCT03808350|Other|Placebo/Control|Family members will not be invited to remain in the ICU room
48068|NCT03808337|Radiation|Stereotactic Body Radiotherapy/SBRT|Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.
48069|NCT03808337|Drug|Systemic Therapy/Standard of Care|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
48070|NCT03808324|Diagnostic Test|Diagnostic investigations|Participants will undergo tests and diagnostics investigations to identify signs of chronic rejection after heart transplantation.
48071|NCT03808311|Other|Treatment strategy regarding different systolic BP goals|The trial will test a treatment strategy question regarding different systolic BP goals and not test specific medications. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of anti-hypertensive medications as long as systolic BP levels are within targets (<120 mmHg in the intensive arm and <140 mmHg in the standard arm).
48072|NCT03808298|Drug|Balovaptan therapeutic dose Treatment A|Days 1-14: A single once daily dose at dose level A of balovaptan for 14 days.
48073|NCT03808298|Drug|Balovaptan supra-therapeutic dose Treatment B|Days 1-14: A single once daily oral dose at dose level B of balovaptan for 14 days.
48074|NCT03808298|Drug|Active control [moxifloxacin] on Day 2 Treatment C|Day 2: A single oral dose of 400 mg moxifloxacin capsule
48075|NCT03808298|Drug|Active control [moxifloxacin] on Day 15 Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
48076|NCT03808298|Drug|Placebo for Balovaptan Treatment C|Days 1-14: Matching placebo for balovaptan for 14 days.
48077|NCT03808298|Drug|Placebo for Balovaptan Treatment D|Days 1-14: Matching placebo for balovaptan for 14 days.
48078|NCT03808298|Drug|Placebo for Moxifloxacin Treatment A|Day 2 and 15: A single oral dose of a matching placebo capsule for moxifloxacin.
48079|NCT03808298|Drug|Placebo for moxifloxacin Treatment B|Days 2 and 15: Single oral dose of a matching placebo capsule of moxifloxacin.
48083|NCT03808298|Drug|Moxifloxacin Treatment D|Day 15: A single oral dose of 400 mg moxifloxacin capsule.
48084|NCT03808285|Other|mandibular osteomylitis|
48085|NCT03808272|Device|HOT AXIOS Stent and Electrocautery- Enhanced Delivery System|The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
48086|NCT03808259|Drug|(S)-ketamine Oral Thin Film|(S)-ketamine OTF sublingual formulation at a dose of 7 mg, 14 mg, and 28 mg will be administered in sequential cohorts.
48087|NCT03808259|Drug|(S)-ketamine IV Infusion|(S)-ketamine IV solution will be infused at a dose of less than or equal to 14mg.
48088|NCT03808259|Drug|Placebo|Participants will receive matching placebo.
48089|NCT03808246|Other|using the demo version of a self-injector pen|Participants, whatever the arm they are included in, will have to use the demo version of the auto-injector pen during a simulation of an anaphylactic shock.
48090|NCT03808233|Other|ACTIVE mini|the ACTIVE-mini, is a non-invasive method of recording movement in an infant using a KINECT camera system. This camera is positioned over a resting infant and measures natural movement over a two minute time period.
48091|NCT03808220|Behavioral|postoperative pain intensity|estimate the postoperative pain intensity by using a scaling system via questionnaire
48092|NCT03808220|Behavioral|preoperative pain frequency|estimate the preoperative pain intensity by using a scaling system via questionnaire
48093|NCT03808220|Behavioral|Side effect|investigate the presence of any side effect
48094|NCT03808207|Other|Dietary counseling and DHA dietary increase in breastfeeding mothers|Specific dietary advices in order to increase the daily/weekly intake of docosahexaenoic acid of breastfeeding mothers for the first 3 months after delivery
48095|NCT03808194|Other|Conditional lottery incentive|Participants in the lottery incentive arm must fulfill the following criteria to be entered into the lottery. Participants must visit the clinic by month 1, initiate ART by month 3 and achieve viral suppression by month 6. Participants in this arm will be eligible to win the lottery.
48096|NCT03808194|Other|Optimized ART linkage package|Optimized ART linkage package
48097|NCT03808181|Device|ChloraSolv|Weekly application of ChloraSolv for 6 weeks
48098|NCT03808168|Drug|Nivolumab|Protocol dose: 3mg/kg mg as a 30-minute IV infusion on Day 1 (Arm I) or Days 1, 15, 29 (Arm II).
48099|NCT03808155|Drug|Tamsulosin|The drug ist taken once a day per os five days prior to the operation and two days after the operation.
48100|NCT03808155|Drug|Placebo Oral Tablet|The placebo ist taken once a day per os five days prior to the operation and two days after the operation.
48101|NCT03808142|Other|myBETAapp|Patients choosing to use the myBETAapp will be required to insert the Mixject number from their prescribed Betaferon box, which serves as an opening key for the app. Obtaining a new Betaferon box and obtaining a new Mixject number will not interfere with the process of continuously allocating data to a single patient; each patient has a unique personal identifier in the database. All data recorded in the myBETAapp including demographic and injection-related data will be stored in the database once the mobile device is connected to the internet.
48102|NCT03808142|Other|PEAK|Peak is an application that aims at helping its users to challenge their brains and keep them sharp.
48103|NCT03808142|Drug|Betaferon, BAY 86-5046|Injection
48104|NCT03808142|Device|BETACONNECT|BETACONNECT automatically records and stores injection-related details including injection time, speed, and depth upon every injection.
48105|NCT03808129|Drug|Bupivacaine and Lidocaine|ESP block was administered under general anesthesia before the surgery. Patients with ESP block, 1: 1 ratio of 0.25% bupivacaine and 0.4 ml / kg of 1% lidocaine
48106|NCT03808116|Device|SmartBx|"he SmartBx device is intended for the retention of a biopsy specimen and for preservation of the specimen's in-needle location and orientation.~The SmartBx is used as an aiding tool in biopsy procedures. When operated in conjunction with the standard equipment in a prostate biopsy procedure, the SmartBx may be used for the following:~To preserve sample unity, including core fragments in their original location along the needle notch.~Avoid sample damaging during sample removal from the needle and the following pathology process."
48107|NCT03808103|Biological|Placebo|Orally, twice a day, for a period of fifteen days
48108|NCT03808103|Biological|Bacteriophage preparation|Orally, twice a day, for a period of fifteen days
48109|NCT03808090|Other|Normal Individuals|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
48110|NCT03808090|Other|Calcium Oxalate Kidney Stone Formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
48111|NCT03808090|Other|Type 2 Diabetes|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
48112|NCT03808090|Other|Type 2 diabetic kidney stone formers|Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver
48113|NCT03808077|Drug|Rocuronium 0.3mg/kg/hr|The Moderate NMB group (Control ) will have rocuronium infusion titrated to moderate paralysis defined as TOF of 1-2 (infusion start rate 0.005mg/kg/min or 0.3mg/kg/hr).
48114|NCT03808077|Drug|Rocuronium 1.5mg/kg/hr|The Deep NMB group (Intervention) will have rocuronium infusion titrated to deep paralysis defined as PTC of 1-2 (infusion start rate 0.025mg/kg/min or 1.5mg/kg/hr).
48115|NCT03808064|Behavioral|FCHV home visit|Behavioral: FCHV visit Female Community Health Volunteer will visit selected households 4 times a year for providing health promotion messages Other Name: FCHV Home Visit
48116|NCT03808051|Procedure|Physiological-based cord clamping|See Arm description.
48117|NCT03808051|Procedure|Time-based cord clamping|See Arm description.
48118|NCT03808038|Other|None- Observational Study|None- Observational Study
48119|NCT03808025|Behavioral|opioid education|see arm/group descriptions
48120|NCT03808012|Other|Braking performance in a brake simulator|Braking performance is tested in a real middle size car cabin to simulate ergonomic conditions of driving a car. This testing cabin has been equipped with customised equipment to allow measurement of reaction time, foot transfer time, brake response time and brake force.
48121|NCT03807999|Drug|Nab-paclitaxel|
48122|NCT03807999|Drug|Gemcitabine|
48123|NCT03807986|Procedure|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
48124|NCT03807986|Procedure|Microfat grafting|Microfat grafting will be applied once every three months for 2 times.
48125|NCT03807986|Procedure|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
48126|NCT03807973|Drug|[Zr-89]Oxine-labeled leukocytes PET/MR|All study participants will undergo an investigational imaging study using autologous [Zr-89]-lableled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocutes in the blood sample will be isolated for labeling using [Zr-89]oxine. The labeled leukocutes (7.4- 18.5 MBq, 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
48127|NCT03807960|Other|written form|The written form which include PCA usage information.
48128|NCT03807960|Other|video|The video about PCA usage
48129|NCT03807960|Other|routine care|The routine description about PCA usage
48130|NCT03807947|Procedure|Radial TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via left transradial access
48131|NCT03807947|Procedure|Transfemoral TAE - Bland embolization with 40-100 Microparticles|TAE - Bland embolization with 40-100 Microparticles performed via right transfemoral access
48132|NCT03807934|Other|Stimulation via Soterix Medical or Neuroelectrics noninvasive brain stimulation systems|Active (at or below 2mA) versus sham (at or below 0.5mA) stimulation targeting brain regions engaged during verbal and/or spatial perceptual and cognitive processing. Brain stimulation devices are not currently regulated by the United States Food and Drug Administration. Local IRB has determined the devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
48133|NCT03807921|Drug|Warfarin|Oral anticoagulation
48134|NCT03807921|Drug|Aspirin|Antiplatelet treatment
48135|NCT03807908|Other|Tape|"The patient will be placed into maximal flexion of the lumbar spine prior to the tape being applied. The vertical strips will be applied on either side of spine, on the erector muscle group; from the lower PSIS with and end around the twelfth rib. The third strip of tape will be applied horizontally to superior to the posterior superior iliac spines (PSIS) and extend over the 2 vertical strips of tape. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
48136|NCT03807908|Other|Sham Tape|"One strip of tape will be applied horizontally to the thoracolumbar junction (at the level of the lower rib cage over the T12-L1 spinous processes) with no tape-tension. The tape will be gently rubbed to activate the adhesive.~Five to 7 days later, one of the investigators will follow up with the subjects over the phone and administer a questionnaire that will assess their experience with the tape as well as the outcome measures (numeric rating scale and Oswestry Disability Index)."
48137|NCT03807895|Behavioral|REBT Career Intervention|Eight sessions of regular career intervention with rational emotive behavioral therapy (REBT) methods.
48138|NCT03807895|Behavioral|Regular Career Intervention|Eight sessions of regular career intervention.
48139|NCT03807882|Other|Unilateral M-ECT|Unilateral M-ECT will be administered at a frequency of 1 session every 15 days. The seizure threshold of the patient will be calculated, and 1.5 times supra-threshold, unilateral, non-dominant hemispheric, brief pulse electrical stimulus will be applied under anesthesia
48140|NCT03807882|Drug|Clozapine|Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
48141|NCT03807869|Procedure|combined glaucoma surgery|phacoemulsification of cataract and I-stent by-pass implantation
48142|NCT03807856|Drug|Dabigatran Etexilate Mesylate|Dabigatran 150mg BID for 3 days
48143|NCT03807856|Other|Standard of Care|Daily vital signs, lab work and one outpatient clinic visit
48144|NCT03807843|Biological|MV-CHIK|Liquid frozen, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose.
48145|NCT03807843|Other|Placebo|Sterile physiological saline for injection
48146|NCT03807830|Procedure|Electrocochlography|Intra-operative ECochG recording via the implant, post operative ECochG measurements. Impedances measured over time.
48147|NCT03807817|Other|Alcohol administration|Amount of alcohol to be administered.
48148|NCT03807817|Other|Placebo|Placebo Alcohol
48149|NCT03807817|Other|No Alcohol|No Alcohol
48150|NCT03807804|Biological|HLCM051|HLCM051 is the stem cell product that can be mass-produced, being derived from adult adhesive stem cells that were taken from bone marrow of healthy unrelated donors from whom the informed consent was obtained, and proliferated ex vivo.
48151|NCT03807791|Procedure|Blood sample|"A blood sample will be taken by the nurse of our unit within a week after their consent. It consists as a simple blood sample and it will be taken during the normal analysis planed by the chief of the service in order to avoid to collect two different samples.~The measurement method will use equipment from the Lyon Sud hospital laboratory. The samples need a pre-treatment in the 3 hours after taking the blood to avoid the oxidation of vitamin C and a result lower than expected."
48152|NCT03807778|Drug|TAK-788|TAK-788 capsule
48153|NCT03807765|Drug|Nivolumab|480 mg intravenous Nivolumab administered every 4 weeks.
48154|NCT03807765|Radiation|Stereotactic Radiosurgery|"Patients will receive single session SRS to intact brain metastases and post-operative cavities.~A linear accelerator (LINAC)-based frameless delivery system will be used to deliver the stereotactic radiation. The lesion will be defined using gadolinium enhanced MRI with 1 mm slices for treatment planning purposes prior to the delivery of radiation. The MRI image will be co-registered and fused with CT imaging. Doses will be prescribed to ensure coverage of at least 95% of the planning target volume (PTV) with the prescription dose. Treatments will be delivered using dynamic conformal arcs or intensity modulated radiotherapy."
48212|NCT03807297|Other|sevoflurane|inhalational anaesthetic agent
48213|NCT03807297|Other|nitrous oxide|inhalational anaesthetic agent
48155|NCT03807752|Dietary Supplement|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
48156|NCT03807752|Dietary Supplement|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of X mg, duration 8 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
48157|NCT03807739|Drug|GDC-0134 F09 Formulation|Participants will receive a single oral dose of GDC-0134 reference capsule F09.
48158|NCT03807739|Drug|GDC-0134 F15 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F15.
48159|NCT03807739|Drug|GDC-0134 F16 Formulation|Participants will receive a single oral dose of GDC-0134 prototype capsule F16.
48160|NCT03807726|Behavioral|Simulation breastfeeding education|The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
48161|NCT03807713|Device|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implants in patients indicated and counselled for Bone Anchored Hearing Systems.
48162|NCT03807700|Drug|Experimental Denture Adhesive|In this arm, participants will apply the experimental adhesive on their dentures once per day when the denture is placed in mouth.
48163|NCT03807674|Procedure|Coronal pulpotomy|Coronal pulpotomy was performed with a sterile high-speed round bur under water coolant. Pulp vitality was confirmed by the presence of bleeding pulp tissue from all of the canal orifices. Hemostasis was achieved through the application of a pellet moistened with 2.5% NaOCl for two minutes and was repeated as needed. Calcium-silicate based material was prepared ac-cording to the manufacturer's instructions and gently placed over the pulp to fill the entire cavity.
48164|NCT03807661|Procedure|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
48165|NCT03807661|Device|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
48166|NCT03807648|Other|Data Inclusion|Patients in this group will be included in the project
48167|NCT03807635|Device|ergoLance safety lancet|The ergoLance contact activated safety lancets type 450 are sterile, single-use safety lancets designed for the sampling of capillary blood from the fingertip of patients.
48168|NCT03807635|Device|Acti-Lance safety lancet|The Acti-Lance safety lancet type 610 is a sterile, single use device used to carry out skin punctures for the purpose of collecting capillary blood samples.
48169|NCT03807622|Device|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System|EV1000NI Clinical Platform: Noninvasive Hemodynamic Monitoring utilizing ClearSight System
48170|NCT03807609|Other|CON . control condition without exercise / rest condition|Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48171|NCT03807609|Other|EX -30. Condition with an acute exercise set 30 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48172|NCT03807609|Other|EX-180. condition with an acute exercise set 180 minutes before lunch|The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling), 30 minutes before lunch. Lunch will be served ad libitum as well as diner. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
48173|NCT03807596|Procedure|Periodontal treatment with Hyaluronic acid associated with SRP|In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
48174|NCT03807596|Procedure|Scaling & root planning alone|Patients received full-mouth supra- & sub-gingival SRP with the use of ultrasonic device & periodontal universal & Gracey curettes under local anesthesia.
48175|NCT03807583|Drug|Aminoven 10%|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~group A: RENORAL® product~group B: AMINOVEN® 10% product~group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month (Day 90, Day 120, Day 150). Protocol visits are included in the patient's course of care."
48176|NCT03807583|Dietary Supplement|RENORAL|"After randomization to the visit Day 60, two months after patients inclusion (Visit Day 0) and one month after clinical examination (Visit Day 30), patients will be assigned to a group:~group A: RENORAL® product~group B: AMINOVEN® 10% product~group C: control group (without intradialytic supplementation)~Patients will consume the products and will be followed for 3 months, one visit per month ( V3, V4, V5). Protocol visits are included in the patient's course of care."
48177|NCT03807570|Dietary Supplement|Morus Alba L. Extract|Morus Alba L. Extract 30 ml/day for 12 weeks.
48178|NCT03807570|Dietary Supplement|Placebo|Placebo 30 ml/day for 12 weeks.
48206|NCT03807323|Behavioral|Lifestyle counselling and exercise|"The program consists of:~Instructor-led training twice a week,~One individual nutritionist counselling session of followed by three group based two-hour nutritionist counselling focusing on practical food purchase and preparation and~Three two-hour psychologist-led group counselling sessions based on implementation intentions theory and practical help to make if-then plans focusing on changing food and activity habits."
48207|NCT03807310|Dietary Supplement|Targeted nutrient supplementation (Long-drink)|Once daily for at least 12 months
48208|NCT03807310|Dietary Supplement|Placebo supplement|Once daily for at least 12 months
48209|NCT03807310|Behavioral|Counselling|Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
48179|NCT03807557|Other|Robotic Constraint-induced movement therapy|"i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic."
48180|NCT03807557|Other|conventional UE rehabilitation training|focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
48181|NCT03807544|Device|TENS|Transcutaneous electrical nerve stimulation
48182|NCT03807531|Device|Temporary Spur Stent System|Participating subjects that meet inclusion and exclusion criteria will undergo treatment of infrapopliteal occlusions and stenoses with the Temporary Spur Stent System according to protocol guidelines
48183|NCT03807518|Behavioral|Standard Exercise Program|Standard Exercise Program- Participants will be invited to take part in a structured home, supervised, or both, exercise program while undergoing neo adjuvant therapy and for a six week period when deemed fit post surgery.
48184|NCT03807505|Procedure|Interscalene brachial plexus nerve block|An interscalene brachial plexus nerve block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
48185|NCT03807505|Procedure|Erector spinae plane block|An erector spinae plane block (single shot or catheter, depending on surgical procedure) will be placed under ultrasound guidance and all patients will receive 10cc 0.5% ropivacaine during block placement. Patients with a nerve catheter will receive a bolus of 5cc 0.5% ropivicaine postoperatively, on arrival to the recovery unit.
48186|NCT03807479|Drug|Ponatinib|2 film-coated tablets à 15mg for oral administration on a daily basis
48187|NCT03807466|Behavioral|Dynamic/Interactive vs. Static/Paginated Report|Evaluate whether a stand-alone interactive audit-and-feedback report highlighting antibiotic prescribing can lead to greater reductions in antibiotic use, than a report embedded in a broader static feedback system
48188|NCT03807466|Behavioral|LTC Physicians Enrolled vs. Not Enrolled in Reports|Evaluate whether being provided an audit-and-feedback report (regardless of dynamic or static) can lead to greater reductions in antibiotic use, than those who do not receive either report
48189|NCT03807453|Other|Microbiome|The scalp microbiome
48194|NCT03807427|Behavioral|READY-Nepal|Regulating Emotions through Adapted Dialectical behavior skills for Youth in Nepal (READY-Nepal) is a brief (10-session), emotion-focused intervention targeting prevention and reduction of trans diagnostic problems related to emotion regulation. The culturally adapted program is divided into 5 modules, and includes both didactic and experiential instruction in skills related to mindfulness, stress tolerance, emotional awareness and regulation, validation of self and others, and mastery of interpersonal relationships.
48195|NCT03807414|Device|oXiris|Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
48196|NCT03807401|Behavioral|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to perform pointing movement toward visual target.
48197|NCT03807401|Behavioral|Virtual reality device|The lateral displacement will be simulated thanks to a virtual reality environment. Participants will wear an Oculus Rift instead of the prismatic goggles and will perform pointing movement as well.
48198|NCT03807401|Behavioral|Prismatic goggles|Goggles inducing a lateral displacement of the virtual field of ten degrees. Participants will be asked to wear those goggles during adaptation session and to mentally perform pointing movement toward visual target. There will be no concurrent movement execution.
48199|NCT03807388|Device|ReMindCare Intervention Group|Daily and weekly assessments of patient´s health status, and generation of alarms related to these answers. Moreover, patients can contact clinicians by an urgent consultation tab.
48200|NCT03807388|Other|Treatment as Usual|Psychiatric usual treatment at First Episode of Psychosis Unit at Clinical Hospital of Valencia, Spain.
48201|NCT03807375|Other|CPAP preoxygenation|During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O.
48202|NCT03807362|Drug|CC-11050|CC-11050 is a novel anti-inflammatory compound with potential to treat a variety of chronic inflammatory conditions.
48203|NCT03807349|Device|N-Force Screws Augmented with N-Force Blue|N-Force Fixation System 7.3 mm (Non-fenestrated/fenestrated) applied with washers; N-Force Blue (Bone Substitute Material)
48204|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Experiential|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
48205|NCT03807336|Behavioral|Emotion-Focused Skills Training for Parents - Psychoeducational|The intervention consists of a 2-day work shop given in a group format, in addition to 6 hours of parent supervision within 6 weeks after the work shop.
48210|NCT03807297|Drug|Injection dexmedetomidine|alpha 2 a agonist used for sedation, analgesia
83124|NCT03535714|Behavioral|MANTR-a treatment|MANTR-a treatment
48214|NCT03807284|Behavioral|A group psychosocial course|A 2 hour, weekly group psychosocial therapy RCAS course that aims to improve confidence and help adjustment after a stroke.
48215|NCT03807271|Device|Calculated and graphically produced depth of anesthesia (Smart Pilot® View)|Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
48216|NCT03807258|Other|Transcranial magnetic stimulation (TMS)|Evaluations by TMS
48217|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48218|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 25|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48219|NCT03807245|Biological|Placebo GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48220|NCT03807245|Biological|GBS-NN/NN2 with Alhydrogel® 50|GBS-NN/NN2 with Alhydrogel® vaccine will administered to subjects intramuscular 2 times with 4 weeks apart
48221|NCT03807219|Dietary Supplement|Magnox Comfort|Magnox Comfort (Magnesium (226 mg in equivalent), Vitamin E - 45 mg, Vitamin B6 - 2 mg.).
48222|NCT03807219|Other|Placebo|placebo
48223|NCT03807206|Behavioral|Questionnaire|Patient questionnaire
48224|NCT03807193|Behavioral|Self-selected treatment|The participants will select their own treatment material with the help of a written manual. The interventions possible to choose are all interventions used in standard cognitive behavior therapy for anxiety and depression.
48225|NCT03807193|Behavioral|Predetermined treatment|The participants will be given a treatment program designed to address worry and generalized anxiety disorder. The program are based on newer forms of cognitive behavior therapy and include mindfulness and acceptance.
48226|NCT03807193|Behavioral|Weekly support|The participants will have scheduled weekly support, once a week, during the treatment. The support till be delivered by students in clinical psychology.
48227|NCT03807193|Behavioral|Support on demand|The participants will have support if and when they ask for it by themselves. If asked for the support will be delivered by students in clinical psychology.
48228|NCT03807180|Other|Tai Chi (exercise)|Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
48229|NCT03807167|Other|Mattis Dementia Rating Scale|This scale was developed to assess the cognitive status of patients with neurodegenerative diseases. There are 37 items that are presented in a fixed order and grouped into five sub-scales: attention, initiation, construction, conceptualization and memory. Patients and healthy subjects with a score below 125 are not included because of major cognitive impairment.
48230|NCT03807167|Other|Unified Parkinson 's Disease Rating Scale-III|This scale is used to rate the severity of extra-pyramidal symptoms (akinesia, rigidity and tremors). These symptoms may be the cause of reduction of motor activity apart from any reduction in motivation, they onstitute a confounding factor that it should be controlled.
48231|NCT03807167|Other|Mini Neuropsychiatric Investigation|This is a structured interview that allows rapid screening in about 20 minutes of troubles Psychiatric. It is based on short questions to which the patient must answer yes or no and on a decision tree. Patients must validate clinical diagnoses of depression.
48232|NCT03807167|Other|Montgomery and Asberg depression Rating Scale|This scale is composed of 10 items from 0 to 6 from a semi-structured interview, to obtain a total depression score of 0 to 60 (0 no depression, 60 maximum intensity of depression).
48233|NCT03807167|Other|Clinical Global Impression|heterosexual assessment that rates the severity of symptoms suicidal and changes in suicidal symptoms. Any subject with a score greater than 4 is not included.
48234|NCT03807167|Other|Apathy diagnostic criteria|The clinical criteria make it possible to make a diagnosis of apathy with a functional repercussion. It is based on a lack of motivation felt by the patient, causing a functional or social impact that is not the consequence of a disturbance of consciousness or a disability engine. The cognitive, emotional and behavioral dimensions are affected.
48235|NCT03807167|Other|walking speed test|The patient is timed to walk 10m. A speed <1m / sec is a criterion exclusion because it shows severe sarcopenia and constitutes a bias.
48236|NCT03807167|Other|accelerometer presentation|accelerometer presentation and pose
48237|NCT03807167|Other|data acquisition from the accelerometer|withdrawal of the accelerometer and data acquisition from the accelerometer
48238|NCT03807167|Other|Apathy Evaluation Scale,|clinician version and near-helping version. It's a hetero rating scale from an interview semi structured by a trained clinician. It assesses cognitive, emotional and behavioral apathy than three items of various apathy. The total score ranges from 18 (total absence of apathy) to 72.
48239|NCT03807167|Other|fatigue Visual Analog Scale|To date, there is no valid fatigue scale in the depression of the elderly subject, a fortiori in French. The fatigue scale in adult depression includes has been validated with an EVA (Visual Analogue Scale) (38). We therefore propose to use this type of evaluation to control this aspect.
48240|NCT03807167|Other|executive function|"Modified Card Sorting Test MCST(Modified Card Sorting Test) (Wisconsin Test): This test assesses conceptualization, attention and mental flexibility using a deck of cards.~Trail Making Test (TMT): This test is used to assess mental flexibility.~Fluences verbal: This test tests the capacities of setting up search strategies in memory semantics and oral language.~Stroop Paradigm: This test is used to evaluate the resistance to interference, ie the patient's ability to inhibit some over-learned and automated responses."
48241|NCT03807167|Other|MRI|An MRI lasting 30 minutes is programmed
48242|NCT03807167|Other|Apathy Motivation Index|"This is a self-questionnaire of 18 items, each side on a 5-level Likert scale (0: not everything at 4: very often). It differentiates between behavioral apathy and social apathy.~Emotional."
48243|NCT03807154|Behavioral|ICBT|A nine week long ICBT-programme with therapist guidance. Based on cognitive and behavioral techniques that have been tailored to address loneliness.
48372|NCT03806166|Other|Standard treatment|Standard duration of systemic antibiotic treatment
83825|NCT03530514|Drug|Placebo|Placebo-matching REGN4461
48244|NCT03807154|Behavioral|IPT|A nine week long internet-based IPT-programme with therapist guidance. Contains three distinct phases: assessment phase (three weeks), focus phase (five weeks, during which the participants will choose from one of four primary problem areas during the three latter weeks), and end phase (one week).
48245|NCT03807141|Other|Modified Atkins diet|This is a modified version of the ketogenic diet where-in carbohydrates are restricted without any protein or calorie restriction.
48246|NCT03807128|Other|No interventional study|No interventional study
48247|NCT03807115|Other|Implementation of stroke mobility guidelines|Delivery of weekly online educational capsules on 4 evidence-based stroke recommendations (motor imagery/mental practice, rhythmic auditory stimulation gait therapy, task-oriented training including fitness and mobility exercises, and aerobic training) plus feedback on participant's awareness, agreement, satisfaction with, and perceived value of the content, perceived implementation success and facilitators and barriers encountered.
48248|NCT03807102|Biological|Tumor Vaccine|NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
48249|NCT03807089|Device|Conventional Pediatric Colonoscope|
48250|NCT03807089|Device|Short-Turn Radius Colonoscope|
48251|NCT03807076|Other|GIP-A|GIP-A
48252|NCT03807076|Other|Placebo|Placebo
48253|NCT03807063|Biological|Rivogenlecleucel|Given IV
48254|NCT03807063|Drug|Rimiducid|Given IV
48255|NCT03807050|Dietary Supplement|Astaxanthin|Capsules containing astaxanthin derived from the yeast Phaffia rhodozyma .
48256|NCT03807037|Dietary Supplement|Tocotrienols|Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day
48257|NCT03807037|Drug|Placebo oral capsule|Matching placebo to be administered orally at 1 capsule, twice daily
48258|NCT03807024|Diagnostic Test|Bladder diary|3-day bladder diary: The classification of OAB-wet or OAB-dry is based on the record of the three-day bladder diary of each patient. The diagnosis of OAB in each patient was based on the presence of at least one episode of urgency in her three-day bladder diary and with the absence of stress urinary incontinence. The presence of at least one episode of urgency associated incontinence was defined to be OAB-wet, otherwise, OAB-dry
48259|NCT03807011|Drug|fentanyl group|fentanyl 2 μg/kg
48260|NCT03807011|Drug|remifentanil group|remifentanil 0.2 μg/kg/min
48261|NCT03806998|Dietary Supplement|Ketoacids|Provision of 1 Tablet containing 630 mg of ketoacids every 5 kg of body weight during 16 weeks
48262|NCT03806998|Dietary Supplement|Placebo|Provision of placebo capsules similar to active supplement
48263|NCT03806985|Drug|Placebo oral capsule|microcrystalline cellulose capsule
48264|NCT03806985|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
48265|NCT03806985|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
48266|NCT03806959|Other|Pan Capsule and colonoscopy in patients with IBS|Every patient will have both Pan Capsule and colonoscopy examinations Descriptive study only Usual biological tests (CBC, CRP, TSH, anti-transglutaminase antibodies) and measurement of fecal calprotectin.
48267|NCT03806946|Diagnostic Test|electroencephalography|diagnosis epileptic discharge
48268|NCT03806946|Diagnostic Test|psychometric scales to diagnosis psychiatric disorders|to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
48269|NCT03806946|Other|psychometric scales for assesment socioeconomic and behaviour problems|to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
48270|NCT03806933|Drug|NT 201|Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
48271|NCT03806920|Dietary Supplement|Intervention A|
48272|NCT03806920|Dietary Supplement|Intervention B|
48273|NCT03806920|Dietary Supplement|Intervention C|
48274|NCT03806920|Dietary Supplement|Intervention D|
48275|NCT03806907|Radiation|Computed tomography lung subtraction iodine mapping|Subtraction of the non-contrast CT from the contrast-enhance CTPA produces the CT-LSIM
48276|NCT03806894|Diagnostic Test|Quantification of platelet aggregation|Platelet aggregation will be determined by vasodilator-stimulated phosphoprotein (VASP) assay
48277|NCT03806881|Device|reversed glenoid prothesis|All patients will undergo a primary or revision arthroplasty with Glenius according to the routine practice at the investigation site and will be followed at specified visiting moments, during which radiological and clinical data will be gathered.
48278|NCT03806868|Other|voucher for ordering foods (ONLY omega-3 rich foods)|A voucher will be provided weekly (4 times) for ordering only omega-3 rich foods. Groceries will be delivered to participants' home weekly.
48279|NCT03806868|Other|voucher for ordering foods in general (any type of foods)|A voucher will be provided weekly (4 times) for ordering any type of food. Groceries will be delivered to participants' home weekly.
48280|NCT03806855|Diagnostic Test|Bladder diary|3-day bladder diary
48281|NCT03806842|Device|Easytech group|total shoulder replacement
48282|NCT03806829|Other|Water|250 ml
48283|NCT03806829|Other|Red Wine|250 ml
48284|NCT03806829|Other|Green Tea|250 ml
48285|NCT03806829|Other|Orange Juice|250 ml
48286|NCT03806816|Dietary Supplement|Melatonin|5 daily enteral doses of melatonin 10 mg/kg. (=2 ml/kg)
48287|NCT03806816|Other|PLACEBO group|5 daily enteral doses of placebo 2 ml/kg
48288|NCT03806803|Biological|Lyophilized fecal microbiota transplant|15 capsules
48289|NCT03806803|Biological|Lyophilized sterile fecal filtrate|15 capsules
48290|NCT03806790|Drug|LEO 90100 foam|Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.
48291|NCT03806790|Drug|Dovobet® ointment|Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
48292|NCT03806777|Drug|Dexmedetomidine|Highly selective alpha-2 adrenergic agonist with sedative properties.
48293|NCT03806764|Diagnostic Test|Blood sampling|Blood sampling from prospective study participants will be taken for immune functions measurements
83901|NCT03530124|Biological|Hib|ACIP Recommended vaccine
48294|NCT03806751|Drug|[O-15]Water|All study participants with undergo brain imaging with [O-15]water-PET/MRI without and with administration of the carbonic anhydrase inhibitor acetazolamide. The PET tracer will be used to measure regional cerebral perfusion, and the administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
48295|NCT03806751|Drug|Acetazolamide|The administration of acetazolamide will lead to increased cerebral perfusion compared to baseline cerebral perfusion.
48296|NCT03806738|Other|Intervention-specific Carevive questionnaire|includes standard of care questions with additional decision-making questions
48297|NCT03806738|Other|Standard of Care questionnaire|includes the standard of care questions that are already in place for Carevive questionnaires
48298|NCT03806725|Diagnostic Test|Intravenous administration of iodinated contrast medium for coronary CT angiography|Administration of iodinated contrast medium for coronary CT angiography
48299|NCT03806712|Other|multi method questionary (developped by De Rosa, in 1995 and 2014)|questions from an association network according to the subject and the grounded theorise (Glasser and Strauss)
48300|NCT03806699|Biological|Placebo|Sterile normal saline
48301|NCT03806699|Biological|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
48302|NCT03806686|Biological|Placebo|Sterile normal saline
48303|NCT03806686|Biological|ID93+GLA-SE|ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). The adjuvant GLA-SE is a TLR4 agonist in a stable oil-in-water emulsion.
48304|NCT03806673|Drug|marcaine|epidural block
48305|NCT03806621|Procedure|Rotational Atherectomy|Patients with severe calcified lesions will receive rotational atherectomy during index PCI
48306|NCT03806608|Procedure|Crestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
48307|NCT03806608|Procedure|Subcrestal|Subjects will be included with the absence of 2-4 teeth in the posterior region of the maxilla or mandibular. Twenty patients will be recruited. Two implant placement depths, equicrestal and subcrestal, were randomly assigned to two sites of each patient with a predefined randomization tables (one crestal implant and one subcrestal implant).
48308|NCT03806595|Drug|Lidocaine 2% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of lidocaine 2% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
48309|NCT03806595|Drug|Normal Saline Flush, 0.9% Injectable Solution|The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
48310|NCT03806582|Drug|Norepinephrine|intervention with norepinephrine to reach a MAP of 85 mmHg
48311|NCT03806569|Behavioral|MAC-cbt group treatment for adult ADHD|Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
48312|NCT03806569|Behavioral|Jacobson|Relaxation treatment in technique of Jacobson in 8 sessions
48313|NCT03806556|Drug|Tranexamic Acid|IV medication administered after patient meets inclusion/exclusion criteria
48314|NCT03806556|Drug|Normal saline|IV medication administered after patient meets inclusion/exclusion criteria
48315|NCT03806543|Drug|Vancomycin|adult patients treated with intravenous vancomycin in intensive care unit
48320|NCT03806504|Other|PEEP|performing 35 cm/H2O PEEP and 2-3 ml/kg tidal volume
48321|NCT03806504|Other|control group|performing 6 cm/H2O PEEP and 6-8 ml/kg tidal volume
48325|NCT03806478|Drug|APH-1105|The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
48326|NCT03806478|Other|Placebo|The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
48327|NCT03806465|Biological|RTS,S/AS01E|The malaria vaccine, RTS,S/AS01E (Mosquirix) will be provided in a 0,1,2 and 18-21 month schedule as has been adapted by the evaluating countries.
48328|NCT03806452|Drug|Hydroxycarbamide|Hydroxycarbamide tablets of 100 and 1000 mg
48329|NCT03806452|Drug|Placebo Oral Tablet|Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
48330|NCT03806439|Other|Radical cystectomy.|Adult patients undergoing radical cystectomy.
48331|NCT03806426|Drug|Eicosapentaenoic acid free fatty acid (EPA-FFA)|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
48332|NCT03806426|Drug|Placebo|500mg capsule, two 500mg capsules to be taken twice daily for 24 months
48333|NCT03806413|Other|Open heart surgery|The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
48334|NCT03806387|Drug|Alemtuzumab|Alemtuzumab will be given two times, separated by 1 year.
48335|NCT03806374|Drug|Ketamine|ketamine
48336|NCT03806374|Drug|Propofol|propofol
48337|NCT03806374|Drug|Fentanyl|fentanyl
48338|NCT03806374|Drug|Cisatracurium|cisatracurium
48339|NCT03806374|Drug|Lidocaine|lidocaine
48340|NCT03806361|Procedure|Supplementation of fat grafts with ADRC|Isolation of ADRC from fat aspirates and its use for supplementation of fat grafts.
48341|NCT03806361|Procedure|Structural fat grafting|Fat grafts without supplementation of ADRC
48342|NCT03806348|Procedure|Resuturing|Early reconstruction of the perineal body after wound dehiscence within two weeks of delivery.
48343|NCT03806335|Other|Infiltration|The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
48344|NCT03806335|Other|Placebo|Patients will receive 2.5 ml normal saline in each tonsil
48345|NCT03806335|Other|General anesthesia|All patients will receive general anesthesia prior to infiltration
48346|NCT03806322|Other|Intermittent Pneumatic Compression|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.
48347|NCT03806322|Other|Cold-pack|The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
48348|NCT03806309|Drug|FOLFIRI|Intravenous (IV); folinic acid 400 mg/m2, irinotecan 180mg/m2, 5-FU bolus 400 mg/m2 and continuous infusion 2,400 mg/m2
48349|NCT03806309|Drug|OSE2101|subcutaneous injection on day 1, every 3 weeks for 6 doses then every 8 weeks for the remainder of year one and then every 3 months during year 2 as monotherapy, for a maximum treatment duration of 24 months,
48350|NCT03806309|Drug|Nivolumab|360 mg IV infusion on day 1 every 3 weeks for 6 doses, then 480 mg every 4 weeks, f or a maximum treatment duration of 24 months
48351|NCT03806296|Other|Increase morning bright light|Participants will wear Re-Timer bright glasses for 30 minutes each morning
48352|NCT03806296|Other|Decrease evening blue light|Participants will wear tinted glasses that block blue wavelength light for 2 hours before bed
48353|NCT03806296|Behavioral|Sleep scheduling|Participants will advance their weekday bedtime and maintain their weekday risetime on weekends
48354|NCT03806296|Behavioral|Monitor sleep, mood, and substance use|Participants will monitor sleep, mood, and substance use via smartphone-based platform and wrist actigraphy
48355|NCT03806283|Procedure|Omental Biopsy|The surgeon and clinical care team will conduct the c-section to deliver the baby and the placenta as clinically indicated. During the closing procedures, the surgeon will indicate a time for a participating Ob/Gyn physician on the study team to collect the omental bio-specimen. Omentum is frequently excised or removed for clinical reasons during surgical procedures. Omentum has small blood vessels within it that have been used for evaluation of vascular functional changes in research. The investigators wish to isolate one to three vessels of 5 to 7 cm length. The surgeon will then close and the clinical care team will resume their standard of care activities.
48356|NCT03806270|Drug|Midazolam|Demizolam 15mg/ml ampules, given orally with cherry juice
48357|NCT03806270|Drug|Hydroxyzine Dihydrochloride|Atarax 2mg/ml syrup, given orally
48358|NCT03806257|Other|Enhanced Physical Therapy Protocol|A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
48359|NCT03806244|Other|Intraoperative acquisition (robotic c-Arm) of images|"Conventional laparoscopic colorectal oncologic resection is performed. During the procedure, the operator will identify previously defined anatomical landmarks, point them with an instrument tracked by the navigation system and the accuracy of the stereotactic navigation system will be calculated by comparing the surgical anatomical point and its correspondent on the images of the navigation platform."
48360|NCT03806231|Drug|Outpatient Dinoprostone 10mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
48361|NCT03806231|Drug|Inpatient Dinoprostone 10 mg|Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
48362|NCT03806218|Device|Bipolar RFA|Bipolar RFA in which RF currents flow between two electrodes
48363|NCT03806218|Device|SM-RFA|Monopolar RFA using multiple electrodes with switching mode
48364|NCT03806218|Device|Dual internally cooled-wet electrodes|Saline-enhanced dual internally cooled electrodes allow intratumoral injection of a saline solution during the application of the RF current that alters the tissue conductivity
48365|NCT03806218|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
48366|NCT03806205|Other|regular follow-up|we give a regular follow-up and supervision on the study group
48367|NCT03806192|Behavioral|Telephone-Based Intervention|Attend psychoeducational counseling sessions via telephone
48368|NCT03806192|Other|Behavioral, Psychological or Informational Intervention|Attend psychoeducational counseling sessions in person
48369|NCT03806192|Other|Questionnaire Administration|Ancillary studies
48370|NCT03806179|Drug|Betalutin|Betalutin 10, 15 MBq/kg; lilotomab 40mg, rituximab 375 mg/m2
48371|NCT03806166|Other|Shorter Systemic Antibiotics|Reduced duration of post-operative systemic antibiotic therapy
48373|NCT03806153|Other|Morphokinetic|The embryos will be observed at a fixed time and according to morphological criteria (Alpha Specialist Group in Reproductive Medicine and ESHRE, 2011). and all the films obtained will be analyzed. Embryos will be classified according to morphokinetic criteria (Ciray et al., 2014).
48374|NCT03806140|Behavioral|text messages|receive about one health-related text message a day for 16 weeks
48375|NCT03806127|Drug|Vibegron|oral administration
48376|NCT03806127|Drug|Placebo|oral administration
48377|NCT03806114|Procedure|Posterior Approach Precautions|These patients will be advised not to bend their leg or trunk more than 90 degrees, avoid crossing the leg or crossing midline, and rotating the leg inwards. Patients will also be instructed to put a pillow in between their legs while sleeping for 6 weeks and to avoid bathing for 6 weeks.
48378|NCT03806114|Procedure|Anterior Approach Precautions|These patients will be advised to avoid extending the leg back, rotating the leg outwards, and lifting their bottom when lying down after their surgery for 6 weeks.
48379|NCT03806114|Procedure|No Precautions|For the non-precautions group, there will be no mention of precautions by any providers before, during, and after surgery. No equipment will be given, but a list of self-care equipment will be available for 'comfort' purposes. Patients will be instructed to avoid bathing for 4 weeks. All groups will have instructions to use a walking aid and a toilet seat if needed, to weight-bear as tolerated, and to avoid driving for 3 weeks.
48380|NCT03806101|Drug|PF-04965842|200 mg dose of PF-04965842 once daily (QD) for 3 days
48381|NCT03806101|Drug|Rosuvastatin|Single 10 mg dose of rosuvastatin
48382|NCT03806075|Behavioral|Second generation sequencing|Firstly, all Peutz-Jeghers patients accept second generation gene sequencing with their blood specimen
48383|NCT03806075|Behavioral|16s rRNA gene sequencing|Secondly, All patients and Health persons accepted 16s rRNA gene sequencing with their feces specimen
48384|NCT03806062|Drug|domperidone|10 mg domperidone 3 times a day after meals
48385|NCT03806062|Device|He-Ne laser (Bravo TrezaSerie) device|The laser scan beam was adjusted to the size of the treated breast for 10 minutes with wave length 632.8 nm and power output 25 mw after the end of treatment session
48386|NCT03806062|Device|faradic current|faradic stimulation (Body shaping System, model B-333, made in China) , at the following acupuncture points on both sides: Spleen 6 (Sanyinjiao), Liver 3 (Taichong) and Small Intestine 1 (Shaoze)
48387|NCT03806049|Drug|Niraparib|given orally once daily
48388|NCT03806049|Drug|Bevacizumab|given as iv infusion every three weeks
48389|NCT03806049|Drug|TSR042|Given as IV infusion every three weeks
48390|NCT03806049|Drug|Carboplatin|given as iv infusion every three weeks
48391|NCT03806049|Drug|Paclitaxel|given as iv infusion every three weeks
48392|NCT03806036|Drug|Vitamin D|300.000 I.U single dose of VIT D IM injection
48393|NCT03806036|Drug|Clomiphene Citrate|100mg daily for 5 days starting from third day of menstruation
48394|NCT03806023|Device|hand movements (signals from thumb muscle) triggered PNS and TMS|"PNS, TMS or PNS+TMS will be delivered while the participant performs specific finger tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
48395|NCT03806010|Procedure|Quantitative sensory testing|Quantitative sensory testing
48396|NCT03805997|Device|Dietary consultation|participants will benefit from a consultation 30-minute dietary program carried out by a dietitian at the University Hospital of Rennes, in order to provide nutritional advice adapted to pregnant women.
48397|NCT03805997|Other|Consumption of Bleu-Blanc-Coeur products|consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day
48398|NCT03805997|Other|No consumption of Bleu-Blanc-Coeur products|no consumption of Bleu-Blanc-Cœur products from the 29th week of amenorrhea to the 45th postpartum day. This group will receive Système U vouchers.
48399|NCT03805997|Biological|Blood sample|the fatty acid profile of the women red blood cells of the woman wil be test at the inclusion and at 21 days post-partum
48400|NCT03805997|Other|Phone contact|Participants of the group A will be contacted by phone by a technician every 15 days from 7th month of pregnancy to the 8th month of pregnancy and then every week from the 9th month of pregnancy to the 45th postpartum day (except the week of childbirth), in order to collect their consumption data of the delivered food products.
48401|NCT03805997|Other|food questionnaire|Participants will have to complete a food questionnaire at the inclusion and at 21 days post-partum
48402|NCT03805997|Other|newborn faeces sample|Newborn faeces sample will be collected at 21 Days post partum
48403|NCT03805997|Other|breast milk sample|Breast milk sample will be collected at 21 days and 45 days post partum
48404|NCT03805984|Drug|INO-4500|INO-4500 will be administered ID on Day 0 and Week 4.
48405|NCT03805984|Drug|Placebo|Placebo will be administered ID on Day 0 and Week 4.
48406|NCT03805984|Device|CELLECTRA® 2000|EP using the CELLECTRA® 2000 device will be administered following ID drug administration.
48407|NCT03805971|Device|Study of the pleural cavity with a confocal laser endomicroscope.|Probe based confocal laser endomicroscope can be introduced through the working chanel of the thoracoscope. this allows the study of the pleural cavity with this new tool.
48408|NCT03805958|Procedure|realtime ultrasonography|Applying realtime ultrasound during the combined anesthesia
48409|NCT03805958|Procedure|prescan ultrasonography|Applying realtime ultrasound before the combined anesthesia
48410|NCT03805945|Drug|dexmedetomidine group|After the fetus was delivered, low-dose dexmedetomidine intraoperative infusion, postoperative low-dose dexmedetomidine patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min).
48411|NCT03805945|Drug|control group|After the fetus was delivered, saline intraoperative infusion, postoperative patient-controlled intravenous analgesia pump(the background infusion is 2 ml/h, the bolus dose is 0.5 ml, the lock time is 15 min) without dexmedetomidine.
48412|NCT03805932|Drug|Moxetumomab Pasudotox-tdfk|Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg iv over 30 min given on days 1, 3, 5 of each cycle.
48413|NCT03805932|Biological|Rituximab|Rituximab will be administered at 375mg/m(2) iv, 50- 400 mg/hr. On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.
48414|NCT03805906|Procedure|L5 Dorsal ramus block|Ultrasound-guided L5 dorsal ramus block
48415|NCT03805893|Procedure|Moderate heat pain|To apply a sensory challenge that can be applied over longer periods required for PET imaging and that is also compatible with high magnetic fields during MRI scanning, we will use a well-established thermal challenge of the lower extremity. To apply mildly painful heat to the patient, the right leg (from the foot up to the knee) will be wrapped in a blanket that incorporates a network of small-diameter plastic tubing through which hot water (45 - 55 oC) is circulated from a temperature-controlled reservoir.
48416|NCT03805880|Diagnostic Test|cerebral desaturation monitoring and cognitive examination|Before general anesthesia, continuous monitoring of cerebral oxygenation(rSO2) was started using an INVOS 5100 (Somaneic, Tro, MI) .Patient cognitive function was assessed using Mini-Mental State Examination (MMSE) on the day before surgery (baseline) and then after 1 day after surgery.
48417|NCT03805854|Device|10 Hz tACS of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
48418|NCT03805854|Device|10 Hz tACS of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
48419|NCT03805854|Device|80 Hz tACS of the bilateral somatosensory cortex|80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
48420|NCT03805854|Device|80 Hz tACS of the prefrontal cortex|80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.
48421|NCT03805854|Device|Sham stimulation of the bilateral somatosensory cortex|10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.
48422|NCT03805854|Device|Sham stimulation of the prefrontal cortex|10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
48423|NCT03805841|Drug|tarloxotinib bromide|weekly intravenous infusion
48424|NCT03805828|Other|Educational program on parenting stress and coping mechanism|The educational program will deliver as a one-day event in four sessions: (1)background of autism spectrum disorder(ASD) and coping mechanism,(2) targeting communication and social difficulties among ASD children using coping mechanism,(3) targeting behavior problems among ASD children using coping mechanism, and (4) stress management as coping mechanism. The contents of the educational program deliver through the use of PowerPoint slides, Whiteboard and marker, practical exercise, video clips followed by group discussion and provision a hard copy booklet containing all items which were supposed to discuss. As well as each session will approximately be taken one hour. Each group will consist of 10 participants.
48425|NCT03805815|Device|tunable crack sensor|blood pressure monitoring via crack sensor
48426|NCT03805802|Other|active product|Once daily consumption over the period of the study
48427|NCT03805802|Other|reference product|Once daily consumption over the period of the study
48428|NCT03805789|Biological|Alpha-1 antitrypsin (AAT)|Alpha-1 antitrypsin is a lyophilized product for intravenous administration.
48429|NCT03805789|Biological|Placebo|Albumin solution administered intravenously
48430|NCT03805776|Other|Fasting (diet restruction for specific period)|12-14 hours fasting
48431|NCT03805763|Procedure|Large extent of ILM Peeling|The extent of ILM peeling is 4DD
48432|NCT03805763|Procedure|Small extent of ILM Peeling|The extent of ILM peeling is 2DD
48433|NCT03805750|Drug|CBD/THC|Oral formulation of CBD and THC.
48434|NCT03805750|Drug|Placebo oral capsule|Placebo
48435|NCT03805737|Other|Amulez and sunlight|Amulez and sun exposure for 2 hours
48436|NCT03805737|Other|Amulez and red light treatment|Amulez and red light treatment for 10 minutes
48437|NCT03805724|Other|Plaque Samples|After carefully drying of the selected site and isolation by cotton roll, plaque samples will be collected by sweeping movement of the probe at gingival crevices of the tooth aspect with pervious inclusion criteria for obtaining of the plaque sample. Samples will be immediately dipped in sterile Eppendorf tubes containing PVA.
48438|NCT03805711|Device|HLT® Transcatheter System|Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
48439|NCT03805698|Device|Platelet-rich Plasma (PRP) group|The CASCADE Autologous Platelet System is a product made commercially available by the Musculoskeletal Transplant Foundation (MTF) for PRP processing. Once processed, the PRP is injected into the debrided wrist.
48440|NCT03805698|Other|Normal saline|Once the arthroscopic debridement is complete, the patient is randomized to receive wrist injection(s) of normal saline (placebo).
48441|NCT03805685|Procedure|Non-Cardiac Surgery|Non-cardiac surgery
48442|NCT03805672|Drug|Low Dose Enoxaparin|
48443|NCT03805672|Drug|High Dose Enoxaparin|
48444|NCT03805659|Device|HD-tDCS|High-Dose transcranial Direct Current Stimulation
48445|NCT03805659|Device|Sham|Sham sessions (no electric current)
48446|NCT03805646|Other|Mobile Phone-based Triage Tool|The proposed intervention is a mobile phone-administered survey. Participants that have been admitted to participating hospitals for treatment of injury will be contacted by mobile phone approximately two weeks after discharge. A seven-question survey will be administered over the phone to each participant. Cross-validation with a separately administered in-person physical exam will be performed to assess the survey tool's prediction of who needs further care for treatment of their injury.
48447|NCT03805633|Diagnostic Test|Venous blood sample|Venous blood samples will be obtained for hemoglobin A1c, C peptide, insulin level, and 2-hour fasting glucose tolerance test.
48448|NCT03805633|Diagnostic Test|Ultrasound of pancreas|Ultrasound of pancreas will be obtained on all study participants.
48449|NCT03805620|Other|Combined physical-cognitive training|combined physical-cognitive training
48450|NCT03805620|Other|Physical training|Multi-component physical exercise
48451|NCT03805620|Other|Cognitive training|cognitive training
48452|NCT03805607|Drug|Ketorolac Tromethamine 30 MG/ML|Ketorolac 30 mg
48453|NCT03805607|Drug|Placebos|Normal Saline
48454|NCT03805594|Drug|Lutetium Lu 177-PSMA-617|Given IV
48455|NCT03805594|Biological|Pembrolizumab|Given IV
48456|NCT03805581|Drug|Defibrotide|Defibrotide 6.25 mg/kg IV q6h up to 7 days
48457|NCT03805568|Drug|dexmedetomidine infusion group|dexmedetomidine as anaesthetic adjuvant
48458|NCT03805568|Drug|remifentanil infusion group|remifentanil as anaesthetic adjuvant
48459|NCT03805555|Procedure|Radiofrequency ablation|Pulmonary vein isolation by radiofrequency ablation
48460|NCT03805555|Procedure|Cryoballoon ablation|Pulmonary vein isolation by cryoballoon ablation
48461|NCT03805542|Combination Product|0.5% Iodophors|Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
48462|NCT03805516|Behavioral|SCOPP-CW|The proposed intervention integrates the Social Cognitive Theory, use of everyday technology (WeChat), and an adaptation of an evidence-based program that is tailored to the behavior patterns, preferences, and cultures of premenopausal Chinese American women. The intervention includes three components: (1) daily tracking of physical activities, (2) 12 weekly educational modules on healthy lifestyle, physical activity, and breast cancer prevention, and (3) 6 bi-weekly tailored messages to include tips for lifestyle modification, stress management, and healthy weight maintenance based on the user's personal characteristics and behavior patterns.
48463|NCT03805516|Behavioral|Control|This is the comparative/control group for the intervention. The control group receives daily tracking of physical activity and 12 weekly non-tailored educational information on general health topics.
48464|NCT03805503|Drug|Chloroprocaine 1% Injectable Solution|"standard CSE procedure in outpatients for inguinal hernia. The first spinal dose of chloroprocaine 1% to start with is 50mg. This dose has been successfully used for spinal anesthesia in hernia repair outpatients to reach an adequate analgesia. 2,5 microgram of sufentanil will be added for prolongation of the analgesia. The testing interval is 2 mg.~Efficacy of the analgesia will be evaluated:~Successful : sensory block at or above T6 dermatome bilateral at the beginning of surgery without additional analgesia during surgery. Unsuccessful: sensory block under T6 dermatome bilateral and/or VAPS is more than 10 mm at the beginning of surgery what necessitates additional epidurals analgesia.~Patients who indicate an ineffective result will receive a rescue treatment by the administration of 5 ml chloroprocaine 3% epidural every 5 minutes with maximum of 30ml. When CSE fails, general anesthesia will be performed."
48465|NCT03805477|Drug|Nintedanib|Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily
48466|NCT03805464|Other|Knee Joint Effusion|60mL saline injection into the supra-patellar region of the knee
48467|NCT03805451|Behavioral|Life Steps for PrEP for Youth|Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
48468|NCT03805438|Drug|Chloroprocaine Hcl 3% Inj|"Initial Patient (A#X) 45mg (1.5mL) of Chloroprocaine 3% (Nesacaine — Fresenius Kabi), will be drawn up into a 3 ml syringe (a 1 ml 'TB syringe' will be used to aspirate the drug in aliquots to ensure accuracy). The following additive will be added: 10 mcg (0.2ml) of fentanyl (50 mcg/ml) 0.3 ml of sterile 0.9% sodium chloride Thus the total volume in the syringe will be 2 ml. Study drugs will be prepared by one anesthesiologist (un-blinded) and administered by another anesthesiologist (blinded).~Subsequent Patient (A#X+1) The dose of Chloroprocaine 3% based on outcome from prior subject and calculations mentioned previously will be added to 10 mcg (0.2ml) of fentanyl (50 mcg/ml). Sterile 0.9% sodium chloride will be added until the total volume in the syringe is 2 ml."
48469|NCT03805425|Radiation|PiXL|The system is set to deliver 30 mW/cm2 UVA irradiance in pulsed intervals of 1 second on and 1 second off to 5 to 9 mm diameter corneal annulus. Total energy delivered is 15J.
48470|NCT03805412|Device|DEXCOM G6 RT-CGM|CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.
48471|NCT03805399|Drug|Pyrotinib with Capecitabine|If patients were LAR subtype and had HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid(d1-d14)
48472|NCT03805399|Drug|AR inhibitor with CDK4/6 inhibitor|If patients were LAR subtype and had a wildtype RB gene,withCCDN1 amplification or CDKN2A copy number loss, she would receive AR inhibitor SHR3680 240mg qd combined with CDK4/6 inhibitor SHR6390 150 mg qd(three week on one week off)
48473|NCT03805399|Drug|anti PD-1 with nab-paclitaxel|If patients were IM subtype,she will receive PD-1 antibody SHR1210 200mg q2w and nab-paclitaxel 100mg qw(three week on one week off).
48474|NCT03805399|Drug|PARP inhibitor|If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid po.
48475|NCT03805399|Drug|BLIS with Apatinib|If patients were BLIS subtype and didn't have a BRCA gene pathogenic mutation , she will receive VEGFR inhibitor apatinib 500mg qd.
48476|NCT03805399|Drug|MES with Apatinib|If patients were MES subtype and without PI3K/AKT pathway activation,she will receive VEGFR inhibitor apatinib 500mg qd.
48477|NCT03805399|Drug|mTOR inhibitor with nab-paclitaxel|If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd combined with nab-paclitaxel100mg qw(three week on one week off).
48478|NCT03805386|Drug|Physician directed opioid prescribing|Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.
48479|NCT03805386|Drug|Patient directed opioid prescribing|Oxycodone 5mg amount ranging from 0 tablets to as much as 30 tablets as described in the standard of care.
48480|NCT03805373|Other|Diet Assessment Survey|Participants will complete 2 different diet assessment tools separated by at least 1 week.
48481|NCT03805360|Drug|Ropivacaine|Ropivacaine is a local anesthetic that is expected to provide numbness to the chest wall when injected into the erector spinae plane.
48482|NCT03805360|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline Flush, 0.9% Injectable Solution is not expected to provide numbness to the chest wall when injected into the erector spinae plane.
48483|NCT03805347|Drug|Helminthostachys zeylanica(L.)Hook|Extract of Helminthostachys zeylanica(L.)Hook, 1gm/time, 3 times daily
48484|NCT03805347|Drug|Starch|Starch in capsule, 1gm/time, 3 times daily
48485|NCT03805334|Other|Touchpoints|Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
48486|NCT03805308|Procedure|Intra-arterial Therapy|Mechanical Thrombectomy is a treatment for stroke that removes clots that block large blood vessels.
48487|NCT03805295|Other|BOKS Program|12-week physical activity program, occurring 3x/week, lasting 30-60 minutes per session.
48488|NCT03805282|Drug|Lidocaine|Continuous infusion, variable dose of lidocaine.
48489|NCT03805269|Drug|TAP block|TAP block: local anesthetics infiltration at trans abdominis plane
48490|NCT03805269|Drug|wound infiltration|wound infiltration: local anesthetics infiltration at surgical incision
48491|NCT03805243|Device|test of sensors for somnonaute device|test of sensors
48492|NCT03805243|Device|test of sensors for uronaute device|test of sensors
48493|NCT03805243|Device|test of sensors for toconaute device|test of sensors
48494|NCT03805243|Device|test of sensors for neuronaute device|test of sensors
48495|NCT03805243|Device|test of sensors for cardioskin device|test of sensors
48497|NCT03805204|Procedure|Open reduction and internal fixation (ORIF)|ORIF with a forearm plate
48498|NCT03805178|Drug|Belatacept|"Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen."
48499|NCT03805178|Drug|Carfilzomib|20mg/m2 Plasmapheresis
48502|NCT03805139|Dietary Supplement|Ajwa Date (phoenix dactylifera)|Effect of Ajwa on Dyslipidemia
48503|NCT03805126|Behavioral|Medical Legal Partnership|With the medical legal partnership, lawyers are embedded in clinics, and lawyers consult with patients who are identified as having health-harming legal needs (HHLNs). This arm will also receive usual care, which includes consultation with a social worker and a community health worker.
48504|NCT03805126|Behavioral|Usual Care|Usual care includes consultation with a social worker and a community health worker.
48505|NCT03805113|Device|Magnetotherapy device|Use of magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
48506|NCT03805113|Device|Placebo|Use of unplugged magnetotherapy device 15 consecutive working days in elegible patients with erosive hand osteoarthritis.
48507|NCT03805100|Biological|Ranibizumab|Intravitreal injection
48508|NCT03805087|Procedure|Transarterial coil embolization|Transarterial coil embolization of the superior rectal arteries via a transradial left arterial access.
48509|NCT03805061|Other|'aerobic exercise'|The aerobic exercise group by using treadmill their walking speeds were adjusted according to the maximum speed at which the person could walk was performed a period of; 8 weeks, 3 days a week, 30-45 minutes each patient.
48510|NCT03805061|Device|'isokinetic exercise'|Patients in the isokinetic exercise group pedaled a bicycle ergometer for warming with low exercise and exercise was applied for 5-10 minutes to cool down at the end of the study. were included in a rehabilitation program that they would apply for 3 days per week for 8 weeks.The measuring of isokinetic muscle strength, CSMI Humac Norm isokinetic dynamometer's commonly used angular velocities of 60 ° and 180 ° / sec was used.
48511|NCT03805048|Procedure|Percutaneous coronary intervention|PCI of the bypass graft will be performed by current standards and at the discretion of the operator. Only commercially available second generation DES - XIENCE Sierra will be used. In case of a CTO lesion, the aforementioned hybrid approach will be applied.This approach uses several angiographic characteristics to guide strategical planning of the procedure, using 4 complementary techniques to cross a CTO: antegrade wire escalation, antegrade dissection reentry, retrograde wire escalation, retrograde dissection reentry. In case of PCI failure, a second attempt can be performed within 1 month. Patients will be hospitalized for a min. of 6-8 hours after PCI and receive DAPT prior to the procedure or triple therapy in case of indication for oral anticoagulation, their duration according to the current guidelines of the ESC for stable coronary disease or ACS.
48512|NCT03805035|Device|electroacupuncture|Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
48513|NCT03805035|Drug|antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 3 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 1 tab);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
48514|NCT03805035|Drug|antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate)|Group 4 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate2mg/tab, 2 tabs);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)
48515|NCT03805035|Device|acupuncture|Minimal needling at ST36 and GB34
48516|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60-75mg/m² day or 20-25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
48577|NCT03804619|Device|Accelerated intermittent theta-burst stimulation (aiTBS)|aiTBS is an effective form of non-invasive brain stimulation which has been FDA-approved for the treatment of Major Depressive Disorder (MDD)
48517|NCT03805022|Drug|Ifosfamide|A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF), repeated every 3 weeks, up to 3 cycles.
48518|NCT03805022|Drug|Doxorubicin|A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60-75mg/m² day or 20-25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
48519|NCT03805022|Drug|Ifosfamide|A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF), repeated every 3 weeks, up to 6 cycles.
48520|NCT03805022|Drug|At the discretion of the investigator|Drug at the discretion of the investigator.
48521|NCT03805009|Device|Robot-Assisted Gait Training (RAGT)|The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
48522|NCT03804996|Drug|TG-1801|Intravenous infusion over 1 hour every 4 weeks
48523|NCT03804983|Device|Hybrid Closed Loop (HCL)|Participants will use Control-IQ with Hybrid Closed Loop (HCL) with their own insulin parameters during the entire two-week study, including the 72-hour ski admission and the at-home study collection times. Parameters will be reduced 20% during the ski admission to adjust for the increased activity.
48524|NCT03804983|Device|Control-IQ with MyTDI|Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
48525|NCT03804970|Behavioral|cash rewards for the fellow up|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
48526|NCT03804970|Behavioral|Showing retinal photos to participants|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
48527|NCT03804970|Behavioral|SMS reminders for participants and their family|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
48528|NCT03804970|Behavioral|Watching brief video and basic explanation for disease|This basic explanation will be offered by professional doctors or nurses.
48529|NCT03804970|Behavioral|Having the Diabetic Club|This is a multiple stimulus intervention study, and there are two intervention groups. One is the normal intervention group, and the other is the adjusted intervention group. The intensity of intervention in the latter group is based on the severity of diabetic disease.
48530|NCT03804957|Other|Autologous blood patch injection (ABPI)|Autologous blood patch injection (ABPI) through a coaxial needle at the site of biopsy
48531|NCT03804957|Other|CT-guided core needle biopsy (CNB)|Standard 18g lung core biopsy
48532|NCT03804944|Radiation|Focal Radiation therapy|Focal hypo-fractionated radiation therapy 8 Gy x 3 fractions, starting day 8, every other day (M/W/F or W/F/M or F/M/W).
48533|NCT03804944|Drug|Pembrolizumab (200mg IV for 30 minutes|Pembrolizumab, on day 12 (last day of radiotherapy), infused over 200mg IV over 30 minutes and then repeated every 3 weeks until disease progression or unacceptable toxicity.
48534|NCT03804944|Biological|CDX-301|Ftl-3 ligand, self-administered by subcutaneous injections at week 1, daily, for 5 consecutive days.
48535|NCT03804931|Procedure|Fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine
48536|NCT03804931|Procedure|Infusion of Saline|Infusion of Saline
48537|NCT03804931|Drug|5-Aminosalicylic acid(5-ASA) and/or Prednisone|Mesalazine and/or Prednisone
48538|NCT03804918|Other|VitalTips mobile application|VitalTips is a mobile learning application with learning on breaking bad news. Participants will be expected to spend at least three hours using the mobile learning resource, ensuring that this time does not impact on their clinical and academic commitments.
48539|NCT03804905|Other|Drug cards|Patients will be given a drug card and an information sheet that describes how the cards can be used. The patients can then use the cards when filling prescriptions at any pharmacy to get free access to diabetes, blood pressure and cholesterol medications, and for glucose test strips.
48540|NCT03804892|Diagnostic Test|Body Composition|Participants undergo a 5 minute body scan to determine their body composition.
48541|NCT03804892|Diagnostic Test|Maximal aerobic fitness test|Participants will complete a walking fitness text until exhaustion to determine maximal aerobic capacity.
48542|NCT03804892|Diagnostic Test|Oral glucose tolerance test|Participants will undergo an OGTT to determine insulin sensitivity.
48543|NCT03804892|Other|Muscle biopsy|Participants will give a small muscle sample pre-, immediately post and 3 hours post- the exercise trial to be assessed for lipid metabolites.
48544|NCT03804892|Other|Blood samples|Participants will give 16 blood samples, to be assessed for fatty acids in the blood.
48545|NCT03804879|Drug|LMB763|LMB763 capsule
48546|NCT03804879|Other|Placebo|Placebo capsule
48547|NCT03804866|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
48548|NCT03804866|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
48549|NCT03804866|Drug|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
48578|NCT03804606|Other|Referral to MTM Pharmacist|Patients will be referred for an encounter with a medication therapy management pharmacist.
48579|NCT03804580|Drug|osimertinib|Non-randomized trial, all patients receive therapy
48580|NCT03804567|Other|Oldpain2go®|This is a concept of dealing with a client in a way that uses their conscious mind to alter their unconscious automated programs such as chronic pain that are troubling them.
48581|NCT03804567|Other|Routine low back pain management|Standard low back persistent physiotherapy management as recommended by national guidelines.
48582|NCT03804554|Other|Non-Interventional|Non-Interventional
48550|NCT03804853|Other|Rehabilitiation|This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
48551|NCT03804840|Drug|Dronabinol|THC (Marinol® [dronabinol]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication (Broyd et al, 2016; Hartman and Huestis, 2013).
48552|NCT03804840|Drug|Placebo|Placebo
48553|NCT03804814|Behavioral|Motivational Interviewing Training|"Motivational Interviewing is a directive, client-centered counselling style intended to elicit behavior change by helping patients reach health goals through their own desires and actions.~A certified and experienced Motivational Interviewing trainer will develop and deliver the curriculum to healthcare providers."
48554|NCT03804801|Dietary Supplement|Hibiscus Sabdariffa|The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
48557|NCT03804775|Diagnostic Test|Serum lipid profile|Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
48558|NCT03804762|Procedure|the third space robotic and endoscopic cooperative surgery|This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
48559|NCT03804749|Drug|suramin sodium|The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
48560|NCT03804749|Other|placebo|Placebo is 0.9% sodium chloride injection.
48561|NCT03804736|Biological|FMT-c|Patients in the FMT-c receive FMT-c (15 capsules every 12 h for 2 days)
48562|NCT03804736|Biological|FMT-c Lactobacillus|Patients in the FMT-c Lactobacillus receive FMT-c Lactobacillus (15 capsules every 12 h for 2 days)
48563|NCT03804723|Drug|oral Prednisone 5mg|patients randomized to this arm will stop prednisone 5 mg
48564|NCT03804710|Drug|Developmental moisturizing cream 1|Participants will topically apply developmental moisturizing cream 1
48565|NCT03804710|Drug|Developmental moisturizing cream 2|Participants will topically apply developmental moisturizing cream 2
48566|NCT03804710|Other|Standard cleanser soap|Participants will cleanse the entire face and both lower legs (between the knees and the ankles)with simple pure soap
48567|NCT03804697|Drug|selective anticoagulation|Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
48568|NCT03804684|Diagnostic Test|Standard Automatic Perimetry Humphrey Field Analyzer|Standard Automatic Perimetry (SAP) Humphrey Field Analyzer (HFA) 24-2, Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures peripheral and central vision in an ophthalmic setting.
48569|NCT03804684|Diagnostic Test|visuALL Field Analyzer|visuALL Field Analyzer a new portable hardware and software virtual reality system measures peripheral and central vision to improve early detection of glaucoma damage in a non ophthalmic setting.
48570|NCT03804671|Drug|BI 730357|Oral dose
48571|NCT03804671|Drug|BI 730357 mixed with [C-14] BI 730357 BS|Intravenous dose
48572|NCT03804658|Device|Continue glucose monitor system|The cardiovascular risks and data from continue glucose monitor system
48573|NCT03804645|Drug|Treatment A|Each subject will receive single dose of AZD9977 capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
48574|NCT03804645|Drug|Treatment B|Each subject will receive single dose of AZD9977 HDL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
48575|NCT03804645|Drug|Treatment C|Each subject will receive single dose of AZD9977 ODL capsule under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and other dose under fasted condition.
48576|NCT03804645|Drug|Treatment D|Each subject will receive single dose of AZD9977 tablet under fasting condition in Part A. If the formulation chosen for Part B, each subject will receive one dose under fed condition and another dose under fasted condition.
85642|NCT03516604|Drug|Citalopram|Citalopram capsule
48583|NCT03804541|Drug|Ensartinib|A novel, potent ALK inhibitor.The ALK inhibitor ensartinib has been validated in potency and selectivity assays indicating that it is more selective and up to 10 times more potent than competitive ALK inhibitors. Ensartinib has been active in animal models of non-small cell lung cancer (NSCLC) and neuroblastoma, a childhood cancer. Importantly, ensartinib has shown activity in models with ALK mutations that confer resistance to other small molecule ALK inhibitors.
48584|NCT03804528|Behavioral|Aerobic Exercise|Participants will be fitted with a heart rate monitor and will be instructed to walk (or trot) to maintain 55-64% of maximal heart rate (determined by exercise test) for the first 4-weeks of exercise or to maintain 65-90% of maximal heart rate (determined by exercise test) for the second 4-weeks of exercise during each session.
48585|NCT03804515|Drug|14C-labeled poziotinib|a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
48586|NCT03804502|Device|TearCare|The TearCare System warms the eyelids to melt the meibum by applying heat to the external surface of the eyelids for 15 minutes. Following completion of the thermal portion of the procedure, the clinician performs manual expression of each of the eyelids.
48587|NCT03804489|Other|Decision aids|Decision aids in helping the infant family to decide whether the infant will or will not receive the oral rotavirus vaccine.
48588|NCT03804476|Drug|AER-271|AER-271, the test article for this study.
48589|NCT03804476|Drug|Placebo|Placebo control for this study.
48590|NCT03804463|Procedure|endometrial cancer radical surgery|Take hysterectomy and bilateral adnexectomy.
48591|NCT03804463|Procedure|fertility-sparing surgery|Take endometrectomy , preserve uterus and bilateral ovaries.
48592|NCT03804463|Procedure|ovarian preservation surgery|Take hysterectomy,preserve bilateral ovaries.
48593|NCT03804450|Procedure|Regenerative endodontic procedures (REPs)|Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
48594|NCT03804424|Drug|64Cu-LLP2A|-64Cu-LLP2A, will be manufactured following batch production record at the cyclotron GMP facility (Washington University School of Medicine GMP radiochemistry/cyclotron facility)
48595|NCT03804424|Device|PET/MR|-All PET imaging will be performed with a Siemens mMR PET/MR scanner
48596|NCT03804424|Procedure|Blood samples for serum stability|-3 venous samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (2 mL each) will be obtained at the following time points: Cohort 1: prior to injection, at completion of dynamic scanning in those who undergo dynamic imaging and at completion of one of the body imaging time points. In those who do not undergo dynamic imaging, prior to injection, and after completing body imaging at 2 of the 3 time points. Cohort 2: subjects will have samples drawn prior to injection, at completion of dynamic scanning, and at completion of body imaging.
48597|NCT03804424|Procedure|Blood samples for metabolite analysis|-Typically, 2 blood samples obtained from an IV site separate from the site of 64Cu-LLP2A injection (preferably 1 within the first 5 min and 1 at the completion of the first hour of imaging) will be obtained.
48598|NCT03804424|Procedure|Urine sample|-Cohort 1 only
48599|NCT03804424|Procedure|Tumor biopsy|-Cohort 2 only and only if there hasn't been a recent biopsy of disease
48600|NCT03804424|Procedure|Electrocardiogram|-A standard 12-lead ECG will be obtained on all subjects at baseline (within 30 mins prior to injection of 64Cu-LLP2A), and at least 60 minutes post injection or prior to study discharge
48601|NCT03804411|Drug|Automatic system guided treatment|Addition of: 1A -vildagliptin 100 mg/day 2A - sitagliptin 100 mg/day, 3A- dapagliflozin 10 mg/day 4A- empagliflozin 10 mg/day 5A- liraglutide 1,2-1,8 mg/day 6A- exenatide 20 μg/day 7A - glimepiride 8A - gliclazide
48602|NCT03804411|Drug|Standard treatment|"Addition of:~B -vildagliptin 100 mg/day~B - sitagliptin 100 mg/day,~B- dapagliflozin 10 mg/day~B- empagliflozin 10 mg/day~B- liraglutide 1,2-1,8 mg/day~B- exenatide 20 μg/day~B - glimepiride~B - gliclazide"
48603|NCT03804398|Device|compliance guided an optimal Positive End-Expiratory Pressure|The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
48604|NCT03804398|Device|PEEP level of 5 cmH2O|In the control group at PEEP level of 5 cmH2O was established and maintained during the study period
48605|NCT03804385|Procedure|intercostal tube|surgical operation
48606|NCT03804372|Drug|Rituximab|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
48607|NCT03804372|Drug|Chemotherapy|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
48608|NCT03804372|Drug|Tenofovir alafenamide|Patients will receive Rituximab+Chemotherapy+TAF for 6 months, followed by TAF as monotherapy for further 12 months. All subjects will receive TAF 1-3 weeks before Rituximab+Chemotherapy and withdrawn 12 months after the completion of chemotherapy.
48609|NCT03804359|Drug|Rituximab|"In the personalized arm, the patient will be treated in function of the CysR activity result during the inclusion visit."
48610|NCT03804346|Diagnostic Test|Acceleromyography|At the End of Surgery, shortly before Extubation, the TOF-Ratio is measured by an independent investigator using Acceleromyography.
48611|NCT03804333|Radiation|standard treatment|3000 cGy in 10 daily fractions
48612|NCT03804333|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
48613|NCT03804320|Other|Active Surveillance|
48614|NCT03804307|Radiation|standard treatment|3000 cGy in 10 daily fractions
48615|NCT03804307|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
48616|NCT03804281|Procedure|Test group|The surgery will be done with the use of 4x magnification loop, the knives are micro blades and micro-sutures 7//0 used with the microsurgical instruments kit
48743|NCT03803254|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48617|NCT03804281|Procedure|Control group|esthetic crown lengthening with conventional approach with an internal bevel incision, following CEJ anatomy, this will be followed by an intra-sulcular incision, removal of the strip of outlined marginal gingiva and elevation of a mucoperiosteal ﬂap to the level of the alveolar bone crest.
48618|NCT03804268|Drug|AGN-190584|One drop bilaterally, once daily for 30 days
48619|NCT03804268|Drug|Vehicle|One drop bilaterally, once daily for 30 days
48620|NCT03804255|Other|Survey Administration|Complete surveys
48621|NCT03804242|Behavioral|Black Youth M.A.T.T.E.R.: Molding Young Advocates While Transforming the School to Prison Pipeline Through Psychological Services Education and Resilience|This is a group psychoeducational and positive youth development intervention for students who have been expelled from school and are now enrolled in a specialized school at Youth Justice Coalition.
48622|NCT03804229|Drug|Butylphthalide soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills(100mg each) of Butylphthalide soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
48623|NCT03804229|Drug|Placebo soft capsule|700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
48624|NCT03804216|Other|Multimodal Imaging Analysis|The patients are seen in consultation ophthalmological before and the 1 hour after their session of dialysis. THE OCT angiography and other not invasive ophthalmological examinations will be realized during the follow-up
48625|NCT03804203|Radiation|standard treatment|3000 cGy in 10 daily fractions
48626|NCT03804203|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
48627|NCT03804190|Other|questionaire|dutch musculoskeletal questionaire
48628|NCT03804177|Procedure|immediate implant placement with melatonin hyaluronic acid vit C|immediate implant placement with melatonin and hyaluronic acid and systemic administration vitamin C
48629|NCT03804177|Procedure|immediate implant placement without melatonin hyaluronic acid vit C|immediate implant placement without melatonin and hyaluronic acid and systemic administration vitamin C
48630|NCT03804164|Other|Educational Intervention|Attend Emerging from the Haze psychoeducational sessions
48631|NCT03804164|Other|Quality-of-Life Assessment|Ancillary studies
48632|NCT03804164|Other|Survey Administration|Ancillary studies
48633|NCT03804151|Behavioral|FitSpirit intervention|The study evaluates the effects of the FitSpirit intervention on divers health markers of adolescents. Participants freely register to the intervention via their school. Physical activities and event are organized by the schools with the help of the FitSpirit organization.
48634|NCT03804138|Other|Anti-influenza and DTp pertussis vaccinations|Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).
48635|NCT03804112|Diagnostic Test|Ultrasound exam with Doppler|Ultrasound exam of the neck to search a perivascular inflammation at the level of the carotid bifurcation.
48636|NCT03804112|Biological|Blood samples|blood count , CRP and viral serologies (herpes virus, chlamydia, mycoplasma),
48637|NCT03804099|Drug|Aflibercept Injection [Eylea]|After instillation of topical anesthetic, sterilization of the eyelid, and instillation of 1.25% povidone-iodine drops, 2.0 mg/0.05 mL of aflibercept (Eylea) is injected into the vitreous cavity through a standard pars plana approach (3.5 mm posterior to the limbus) under sterile conditions
48638|NCT03804086|Procedure|Advanced PRF (A-PRF) + nano-crystalline hydroxyapatite bone substitute combined with open flap debridement|"will treated with OFD +A- PRF+ nano-crystalline hydroxyapatite bone substitute,10 mL of blood will be drawn from only patient assigned to the intervention group by vein puncture of the antecubital vein and is collected in sterile glass test tube, without any anticoagulant.~The blood will be quickly collected, and the tube will immediately centrifuge at 1500 rpm for14 min at room temperature.~After centrifugation, the A-PRF clot will be removed from the tube using sterile tweezers and placed on sterile woven gauze. Membrane will prepared by compressing clots between two pieces of woven gauze."
48639|NCT03804086|Procedure|Open flap debridement|a periodontal access flap will be initiated by intrasulcular incisions on the buccal and lingual aspects. The incisions will be carried as far interproximally as possible to preserve the entire Interdental papillae and to achieve primary wound closure.
48640|NCT03804073|Radiation|standard treatment|3000 cGy in 10 daily fractions
48641|NCT03804073|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
48642|NCT03804060|Device|Proteus IVTM|Cooling with the ZOLL® Circulation Proteus® catheter and the ZOLL® Intravascular Temperature Management system to initiate and maintain hypothermia for 6 hours as an adjunct to endovascular Recanalization.
48643|NCT03804060|Procedure|Recanalization only|Standard of Care for recanalization
48644|NCT03804047|Other|kinesio tape|kinesio tape is a therapeutic method used in the treatment of various musculoskeletal and neuromuscular deficits to provide support for muscles and increase or inhibit muscle recruitment, to correct joint malalignment, decrease swelling, and pain relieve
48645|NCT03804034|Device|Block of resin|
48646|NCT03804034|Device|Buccal tube, Bracket and 0.0017 × 0.025 in titanium molybdenum alloy wire|
48647|NCT03804021|Genetic|ADVM-043|Long term follow- up of subjects that received ADVM-043
48648|NCT03804008|Drug|Ultrasound-guided corticosteroid injection|A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml. The skin is cleansed with Chlorhexidine alcohol 0.5 %. The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness. Participants are asked to start performing the exercise as soon as they feel ready but not before 24 hours after the injection. Furthermore, they are asked not to progress the method used to achieve 8RM when they start to do the exercise after the injection until Week 3 of the exercise programme. If standing on both feet was sufficient to achieve 8RM at baseline, the participant must not perform the exercise single-legged or to wear a backpack with weights after the injection regardless of any pain reduction afforded by the injection.
48744|NCT03803254|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
48649|NCT03804008|Other|Heavy-slow resistance training|Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. Participants are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day.
48650|NCT03804008|Other|Fundamental advice and a silicone heel cup|Participants receive brief information about pathology, risk factors and advice on how to decrease activities that lead to symptom flares and slowly increase their activity level based on their symptoms. They also receive a leaflet that includes the same information as the research assistants will deliver orally after inclusion and a silicone heel cup.
48651|NCT03803995|Procedure|Mapping and Pacing the His Bundle|During the device implant procedure, 3D electro-anatomical mapping of the His Bundle region will be performed using EnSite™ Precision™ mapping system and Advisor™ HD Grid mapping catheter. This procedure might be part of the standard-of-care at the participating centers.
48652|NCT03803995|Procedure|Placing a guidewire in Coronary sinus for measurement of Q-LV during His Bundle pacing or, if needed, for LV pacing|During the device implant procedure, a VisionWire coronary guidewire will also be placed into a branch of coronary sinus (CS), targeting a lateral branch. This guidewire could be used for collecting local left ventricle (LV) activation time (Q-LV) or pacing the LV. This guidewire could also be used to deliver a LV lead at physician's discretion. This procedure might be part of the standard-of-care at the participating centers.
48653|NCT03803982|Procedure|Deep Neuromuscular Blockade|The proposed intervention in this study is delivery of an anesthetic with Deep Neuromuscular Blockage (NMB), which will be defined as a TOF of 0 and 2-3 twitches in the post-tetanic count.
48654|NCT03803982|Drug|Sugammadex|Sugammadex will be used to reverse the deep neuromuscular blockade in the experimental group.
48655|NCT03803969|Device|ConfirmRx (Insertable Cardiac Monitor)|This study is designed to characterise the safety and performance of the ConfirmRx device by assessing quality of signal attained from the device with changes in posture and physical activity at implant and 30days post procedure. The study is also intended to assess gross migrations of the device at 30days post implant.
48656|NCT03803956|Device|Active PBMT|The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.
48657|NCT03803956|Device|Placebo PBMT|The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
48658|NCT03803943|Behavioral|Parent-Implemented Communication Intervention (PICT)|Weekly hour long intervention sessions for 6 months
48659|NCT03803943|Other|No Intervention - Business-as-usual control|Does not receive PICT internvention
48660|NCT03803930|Device|Using 22G FNB, the first pass is SP|Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
48661|NCT03803930|Device|Using 22G FNB, the first pass is MWST|Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.
48662|NCT03803930|Device|Using 20G FNB, the first pass is SP|Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.
48663|NCT03803930|Device|Using 20G FNB, the first pass is MWST|Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
48664|NCT03803917|Procedure|Injection with freshly collected autologous adipose tissue|
48665|NCT03803904|Other|Spin|The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
48666|NCT03803891|Procedure|Endoscopic full-thickness resection|Endoscopic full-thickness resection (EFTR) with Over-The-Scope-Clip in colorectal lesions
48667|NCT03803865|Behavioral|Mindfulness Training|Guided mindfulness meditation and stress management training
48668|NCT03803865|Behavioral|Reflection and Problem Solving|Guided reflection,problem solving,and analytical thinking training
48669|NCT03803852|Device|Intraocular Lens Implantation|Implantation of an intraocular lens Rayner RayOne or Alcon Clareon into the capsular bag using an injector, after removing of the human cristalline lens.
48670|NCT03803839|Drug|Clodronate|
48671|NCT03803839|Drug|Saline|
48672|NCT03803826|Device|CRT-D re-programming|"The previously implanted, ineffective CRT-D is reprogrammed under supervision of Trans-Thoracic Echocardiography (TTE) to:~adjust the atrioventricular interval so that E and A waves do not overlap~the interventricular interval is subsequently optimized to yield maximum improvement of the sum of longitudinal+radial+circumferential strains."
48673|NCT03803826|Diagnostic Test|Trans-Thoracic Echocardiography|"This intervention relates to the determination of strains and atrioventricular interval and supplies data for reprogramming the ineffective CRT-D~Transthoracic echocardiography performed to determine the left ventricular ejection fraction as an outcome measure is not considered intervention here (as it is also performed in the control group and that would cause an error cross-referencing."
48745|NCT03803241|Drug|CD133+ infusion|
48746|NCT03803241|Other|portal vein embolization|
48747|NCT03803228|Drug|DUOSTIM|2 consecutive stimulations by Fertistartkit® on the same cycle
48674|NCT03803800|Other|Classic, progressive endurance training|Moderate intensity endurance training will be performed following a sequence of 5 training sessions every 2 weeks throughout the 12-week intervention. Sessions will include 60min of cycling on a stationary bicycle. Exercise intensity will match 60-80% of the maximal heart rate (HRmax)
48675|NCT03803800|Other|Periodized exercise training|Throughout the 12-week periodized intervention, subjects will perform four recurrent 3-week cycles of moderate endurance training (week 1,three sessions, 60min/session, 60-80% HRmax), high intensity interval training (week 2, three sessions, 10min/session, 3x20sec supramaximal sprint interspersed with recovery intervals of 2min), and recovery weeks (week 3, one high intense interval session as described above)
48676|NCT03803800|Dietary Supplement|beta-alanine|Some subjects will receive the ergogenic supplement beta-alanine.
48677|NCT03803787|Drug|Inhaled budesonide|Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.
48678|NCT03803774|Drug|Birinapant|Given IV
48679|NCT03803774|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRRT
48680|NCT03803761|Drug|Copanlisib|Given IV
48681|NCT03803761|Drug|Fulvestrant|Given IM
48682|NCT03803748|Device|Eyestil Plus®|• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis
48683|NCT03803722|Device|Eyestil Protection® unidose|to demonstrate the non-inferiority of Eyestil Protection® in terms of performance and safety, when compared to Vismed® in treatment of dry eye disease.
48684|NCT03803709|Dietary Supplement|inulin|inulin given at different dosis from day 3 to day 20
48685|NCT03803709|Dietary Supplement|placebo|maltodextrine given at different dosis from day 3 to day 20
48686|NCT03803696|Behavioral|Enhanced Standard Care|"Baseline data collection, registration and randomization~Inform primary transplant clinician of sexual dysfunction causing distress~Receive American Cancer Society sexual educational material"
48687|NCT03803696|Behavioral|Multimodal Intervention to Address Sexual Dysfunction|"Baseline data collection, registration and randomization~- 3 Monthly visits with trained study nurse practitioners~Referral to specialist if~Psychological etiology~Sexual Trauma~Relationship Discord~Concern for Malignancy or anatomic scarring requiring surgery"
48688|NCT03803683|Device|mLab App|The mLab App is a web application that uses an image processing algorithm to interpret the results of the OraQuick® In-Home HIV Test.
48689|NCT03803683|Behavioral|HIV Prevention Information|Youth randomized to the standard of care will be sent an email with links to mobile-optimized online prevention information, including PrEP and HIV testing information that is found on the Centers for Disease Control and Prevention (CDC) website.
48690|NCT03803670|Diagnostic Test|evaluation of cerebrospinal fluid of ALL|We evaluated cerebrospinal fluids of patients with ALL by conventional cytology and by flow cytometry
48691|NCT03803657|Device|Monitoring of energy expenditure|Continuous monitoring of energy expenditure.
48692|NCT03803644|Drug|CC-92480|Part 1 dose escalation
48693|NCT03803644|Drug|CC-92480|CC-92480
48694|NCT03803605|Biological|VRC07-523LS|VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
48695|NCT03803605|Drug|Vorinostat (VOR)|Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
48696|NCT03803592|Behavioral|Dyadic MCS program|"In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period."
48697|NCT03803566|Other|Pegboard practice|Practice of the grooved pegboard test
48698|NCT03803566|Other|Force control practice|Practice performing steady muscle contractions
48699|NCT03803553|Drug|FOLFIRI Protocol|FOLFIRI, a cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
48700|NCT03803553|Other|ACTIVE SURVEILLANCE|Will be followed with observation and monitoring with imaging, tumor markers, and ctDNA collections
48701|NCT03803540|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via duodenal infusion
48702|NCT03803527|Procedure|Esophageal String Test|An EST will be performed for a 1hour sampling period on the same day as the scheduled clinic visit. Subjects will be asked to swallow a capsule and the attached EST string will be taped to the cheek with tegaderm tape. At the completion of the 1-hour sampling period, the EST will be removed and it will immediately be processed and cryopreserved for metabolomics profiling.
48703|NCT03803514|Drug|Recombinant EPO|Beta-epoetin (Recormon, Roche) used according to current guidelines
48704|NCT03803501|Other|condensed functional restoration program|The condensed functional restoration program (CFRP) is a complex multidisciplinary intervention proposed as usual care according to international guidelines. The program takes place in our department of rheumatology, 6 hours per day, 1 day a week, for 4 weeks. Patients are included during consultation or Hospitalisation and are in groups of 6 maximum per FRP. The CRFP was developed on the basis of therapeutic patient education programs and physical exercises (Van Wambeke 2017, Desthieux 2014). Three hours per day are devoted to physical exercises which were divided into three periods: warming, stretching, and muscular strengthening. Specific exercises adapted to work circumstances (like manutention) are taught. Muscular strengthening is based on isotonic contraction on fitness devices. Education is based on 1 hour long educative session adapted from back school programs once a week. Educative booklets are also given to the patients.
48705|NCT03803488|Device|DropSafe safety pen needle|
48748|NCT03803228|Drug|Conventional stimuli|2 stimulations by Fertistartkit® performed on 2 different cycles
48706|NCT03803475|Drug|Ga-68 labeled PSMA-11|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if there is presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
48707|NCT03803475|Device|Positron emission tomography-computed tomography (PET/CT)|Positron emission tomography-computed tomography (PET/CT) is a nuclear medicine technique which combines, in a single gantry, a positron emission tomography (PET) scanner and an x-ray computed tomography (CT) scanner, to acquire sequential images from both devices in the same session
48708|NCT03803475|Device|Positron emission tomography-magnetic resonance imaging (PET/MRI)|A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan in a single session
48709|NCT03803462|Other|Behçet's disease Overall Damage Index (BODI)|BODI is a tool to document any organ damage that has occurred in patients since the onset of BD. It includes a form and an associated glossary with the definition of the items.
48710|NCT03803449|Drug|50-200mg propofol|participants in both groups are given standard regimen including 50-200mg propofol.
48711|NCT03803449|Drug|50ug fentanyl|participants in fentanyl group are given intervention regimen: 50ug fentanyl.
48712|NCT03803449|Drug|1 mg midazolam|participants in both groups are given standard regimen including 1 mg midazolam.
48713|NCT03803436|Procedure|Liver transplant|Liver transplant from cadaveric donors
48714|NCT03803436|Drug|Chemotherapy|mFOLFOX
48715|NCT03803436|Drug|Chemotherapy|Panitumumab
48716|NCT03803423|Other|The Donor App|The Donor app is a web-based application that helps transplant candidates tell the candidate's story via social media in the hopes of identifying an appropriate living donor. Sample stories created using the Donor App can be found at www.thedonorapp.com.
48717|NCT03803410|Procedure|blood test, noninvasive test for liver fibrosis|blood test of HCV serology and virology.noninvasive test including M2BPGi and fibroscan for liver fibrosis
48718|NCT03803397|Biological|PV-001-DC|Patient-specific cellular therapeutic for cancer immunotherapy
48720|NCT03803371|Drug|Ultracet Tablets|Ultracet tablet (Janssen Cilag Farmacêutica Ltda) equivalent to Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg
48721|NCT03803371|Drug|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets - tablet (Pfizer)|Tramadol hydrochloride 37.5 mg/Paracetamol 325 mg tablets (Pfizer)
48722|NCT03803358|Other|exercise training with non-invasive ventilation|In the intervention group (exercise training with non-invasive ventilation) exercise NIV pressures will be optimally adjusted to each individual patient to decrease TcPCO2 values. An IPAP of at least 15 cmH20 will be used to provide sufficient pressure to relief patients breathing muscles. Nocturnal NIV will be continued.
48723|NCT03803358|Other|standard exercise training without NIV|In the control Group (standard exercise training without NIV ), patients will be execute cycle exercise without additional NIV (usual care). Nocturnal NIV will be continued.
48724|NCT03803332|Behavioral|Exposure Therapy|Psychotherapy including imaginal and in vivo exposure for PTSD.
48725|NCT03803332|Behavioral|Interpersonal Psychotherapy|Psychotherapy that focuses on the effects of PTSD on current interpersonal functioning.
48726|NCT03803319|Dietary Supplement|Fibre 1 (combined fibres)|Dietary fibre supplement
48727|NCT03803319|Dietary Supplement|Fibre 2 (natural fibres)|Dietary fibre supplement
48728|NCT03803319|Dietary Supplement|Dietary Supplement: placebo|Dietary supplement
48729|NCT03803306|Combination Product|Vedic Medical Astrology|Individualised astrological based interventions were given including vedic counselling, diet, colors, gems, mantras and the worship deities as an adjuvent to ongoing conventional treatments
48730|NCT03803306|Other|Placebo vedic medical astrology (PMA)|Conventional treatments were followed with counselling and diet suggestions. astrological interventions were not incorporated during the study phase.
48731|NCT03803293|Diagnostic Test|Pharmacogenomic testing|A comprehensive PGx interpretive report created by OneOme (www.oneome.com) provides information on how an individual patient's genes may affect medication response. OneOme utilizes algorithms and curated clinical PGx knowledge to generate a highly intuitive personalized report based on a patient's genomic results.
48732|NCT03803280|Procedure|ERAS program|ERAS pathway according to the Spanish Via RICA
48733|NCT03803267|Other|Erector spinae plane block|For each side, the eighth thoracic transverse process will be identified by a linear US transducer (HFL38_10-5 MHz), puncture will be performed in the plane in the craniocaudal direction until the needle contacts the transverse process, and 20 ml of bupivacaine 0.25% and 4 mg dexamethasone will be injected visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesirable motor weakness will be recorded as a side effect.
48734|NCT03803267|Other|Quadratus lumborum block|For each side, shamrock sign with three leaves (psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process of the L4 vertebral body) will be identified by a curved array US transducer (6-2MHz), puncture will be performed in-plane, the needle will be advanced through the quadratus lumborum muscle penetrating the ventral proper fascia of the quadratus lumborum muscle, and 20 mL of bupivacaine 0.25% and 4 mg dexamethasone will be injected in that space visualizing the hydrodissection. After 30 minutes, the degree of sensory block in the trunk will be assessed by the pinprick test and any undesired motor weakness will be recorded as a side effect
48735|NCT03803267|Drug|Propofol|Propofol (2 mg/kg)
48736|NCT03803267|Drug|Fentanyl NCS|Fentanyl (1µg/Kg)
48737|NCT03803267|Drug|Atracurium Injectable Product|atracurium (0.5mg/kg)
48738|NCT03803267|Other|Endotracheal intubation|endotracheal intubation
48739|NCT03803267|Drug|Anesthesia Maintenance|Inhalational isoflurane in oxygen/air mixture
48740|NCT03803267|Drug|Muscle Relaxation|atracurium boluses (0.2 mg/Kg/20 minutes) will be used for maintenance of general anesthesia
48741|NCT03803254|Procedure|Hepatic arterial infusion chemotherapy|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
48742|NCT03803254|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
48749|NCT03803215|Drug|Theophylline|Oral theophylline initially 600 mg bid and then titrated at the maximum tolerated dose
48750|NCT03803202|Biological|ASP3772|Intramuscular Injection
48751|NCT03803202|Biological|PCV13|Intramuscular Injection
48752|NCT03803202|Biological|PPSV23|Intramuscular Injection
48753|NCT03803189|Behavioral|Usual care plus eToolkit|The intervention arm will receive repeated e-surveys via email to collect the Edinburgh Postpartum Depression Scale (EPDS) score at baseline and 2, 4, 6, 8, and 12 weeks. Those with EPDS<10 will be triaged as low risk. Those with EPDS 10-18 (without suicidality) will be triaged as symptomatic for non-urgent clinical assessment with a message delivered via the EMR. Those with EPDS≥19 or suicidality will be triaged as requiring immediate follow-up, with an urgent message to their PCP via EMR, phone (if suicidal) and fax. Prompts in the EMR will enable evidence-based clinical care for PPD and PPA, highlight treatment preferences to support shared decision making, and identify appropriate referrals. Intervention arm participants will receive a personalized eToolkit after the completion of each survey. Patients in the intervention group with symptoms will be invited to a telephone interview at 12 weeks postpartum to describe their experience with the intervention.
48754|NCT03803176|Procedure|Open Flap Debridement|Full thickness flaps are elevated to fully expose the periodontaldefects. Defects are then fully debrided and the roots are carefully planned. Flaps are repositioned and sutured to obtain primary closure of the interdental space. This will be done for chronic periodontitis patients
48755|NCT03803163|Drug|TransCon Treprostinil|
48756|NCT03803150|Procedure|PRA approach|A preauricular incision will be made that extends downwards in a curvilinear fashion in the cervicomastoid skin crease, though any variation in this incision will suffice. The great auricular nerve will be preserved and the flap raised in the subdermal fat plane, superficial to the superficial musculoaponeurotic layer to allow access to the masseter adjacent to the anteroinferior edge of the parotid gland, just below the parotid duct. Branches of the facial nerve will be readily identified and avoided with or without loupe magnification, on the surface of the masseter muscle.
48757|NCT03803150|Procedure|RT approach|The incision for the retromandibular approach begins 5mm below ear lobe and continues 3 to 3.5cm inferiorly. Initial incision begins through skin and subcutaneous tissues,platysma muscle ,(SMAS), parotid capsule Dissection is continued until the only tissue remaining on the posterior border of the mandible will be the periosteum of pterygomassetric sling,then the fracture site will exposed and reduced.
48758|NCT03803137|Other|VOC analysis|VOC analysis in exhaled air with e-noses and mass spectrometry
48759|NCT03803124|Drug|Tolvaptan|1 tablet before renography
48760|NCT03803124|Drug|Placebo|1 tablet before renography
48761|NCT03803111|Behavioral|Initial exercise training|Initial exercise training program
48762|NCT03803111|Drug|Initial FCM|Initial intravenous iron supplementation (FCM)
48763|NCT03803111|Drug|Subsequent FCM|Subsequent intravenous iron Supplementation (FCM) after 2 months
48764|NCT03803111|Behavioral|Subsequent exercise training|Subsequent exercise training program after 2 months
48765|NCT03803098|Device|reference measure|measure of a physiological parameter performed with the gold standard medical device
48766|NCT03803098|Device|alternative measure|measure of a physiological parameter performed with the connected device under evaluation
48767|NCT03803085|Behavioral|Control condition|Participants in the control group will only see their own daily walking steps using the WeChat. They will not use WeChat to see other group members' daily steps and will not compete with others in their number of steps. The participants will be asked to use the app every day. A message (through WeChat) will be sent to remind them to use the application if they have not done so within three days.
48768|NCT03803085|Behavioral|Experimental condition|Participants in the experiment condition will use the WeChat for 4 weeks to see their own and other's walking steps and also compete in their number of steps with group members. The participants will be asked to use the application every day. A message (through the group chat) will be sent to remind them to use the application if they have not done so within three days.
48769|NCT03803072|Behavioral|time restricted eating (TRE)|Participants will attend a face-to-face meeting with the researchers at the last day of the first week of data collection (habitual diet and physical activity period) where they will be counselled to consume all food and fluid within a 8-10 h time window of their choice starting no later than 09.00 h for five weeks. During the intervention period, they will be counselled by weekly phone calls to provide encouragement, support and monitoring to improve adherence to the TRE window.
48770|NCT03803059|Device|SkinPen Precision|Surgical instrument motors and accessories/attachments/Hydrogel
48771|NCT03803033|Other|Clinical pharmacy-based home medication management review service|A baseline interview by the clinical pharmacist was conducted with patients at their homes to assess their use of treatment and to collect all relevant information needed to identify TRPs. Upon TRP identification at baseline, the clinical pharmacist generated a written report of findings and recommendations, which was delivered directly to the patient's physician in a sealed envelope. Patients were asked to refer back to their physicians if they required confirmation of any changes in treatment. Physicians maintained the blinding of patients with regard to whether changes were based on recommendations by the pharmacist. In both the intervention and the control groups, the clinical pharmacist performed a follow-up interview with patients 3 months after the initial interview, during a regular follow-up visit to their physician at the hospital. Assessments in the follow-up interview, regardless of the study group, involved changes in treatment and number of TRPs.
48772|NCT03803020|Other|fractional flow reserve and SPECT detection|fractional flow reserve and SPECT detection
48773|NCT03803007|Drug|Intravenous ACT017 125 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
48774|NCT03803007|Drug|Intravenous ACT017 250 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
48775|NCT03803007|Drug|Intravenous ACT017 500 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
48776|NCT03803007|Drug|Intravenous ACT017 1000 mg|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
48777|NCT03803007|Other|Intravenous Placebo|Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
48806|NCT03802721|Drug|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
85750|NCT03515707|Other|Laboratory Biomarker Analysis|Correlative studies
48778|NCT03802994|Drug|23 valent pneumococcal polysaccharide vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.
48779|NCT03802994|Biological|13 valent conjugated pneumococcal vaccine|FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.
48780|NCT03802994|Other|Peripheral blood sample|Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.
48781|NCT03802955|Drug|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 3.0 mg/kg, 5.0 mg/kg, 7.5 mg/kg, or 10 mg/kg depending on cohort at enrollment.
48782|NCT03802942|Dietary Supplement|Glucerna|1 bottle in the morning with breakfast and 1 bottle in the evening with dinner
48783|NCT03802916|Drug|Deferiprone DR tablets 1000 mg (Low dosage)|Deferiprone DR tablets 1000 mg
48784|NCT03802916|Drug|Deferiprone DR tablets 1000 mg (High dosage)|Deferiprone DR tablets 1000 mg
48785|NCT03802903|Device|Remo-Wax|topical treatment
48786|NCT03802877|Behavioral|Resource bank|See intervention arm descriptions
48787|NCT03802877|Behavioral|ePlatform|See intervention arm descriptions
48788|NCT03802877|Behavioral|Health coach|See intervention arm descriptions
48789|NCT03802864|Drug|Liposomal Bupivacaine|After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.
48790|NCT03802864|Drug|Standard Bupivacaine|After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.
48791|NCT03802851|Procedure|Holmium Laser Enucleation of Prostate (HoLEP)|Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment use for men with bothersome lower urinary tract symptoms (LUTS) to improve their LUTS. During the procedure a thin telescope-like instrument is inserted into the urethra. The high-powered laser is then inserted through this instrument and used to carefully remove the excess prostate tissue that is causing obstruction of the urethra and contributing to the patient's lower urinary tract symptoms.
48792|NCT03802838|Device|acupuncture|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks. These patients were combined with acupuncture. Acupuncture points include:'Yintang', 'Shenting', 'Taiyang', 'Jingming', 'Zanzhu', 'Yuyao', 'Jiaosun', 'Baihui', 'Fengchi', 'Anmian'.
48793|NCT03802838|Drug|Amisulpride|Schizophrenia with negative symptoms were treated with Amisulpride, and the patients still remained negative symptoms and cognitive impairment.Amisulpride is allowed in a dose range of 50-1200 mg / d, once or twice a day for at least 12 weeks.
48794|NCT03802825|Behavioral|Diabetes Self-Management Training|The Decision-making Education for Choices in Diabetes Everyday (DECIDE) program is a nine-module, literacy adapted diabetes and cardiovascular disease education and problem-solving training program. Participants are taught the five steps of problem solving with each module going in depth on a single step: 1) identify the problem; 2) brainstorm possible strategies for problem resolution; 3) select the most appropriate strategy; 4) apply the strategy; 5) evaluate the effectiveness of the strategy. During the six months, CHWs will have weekly or bi-weekly contract with participants in-person or by phone to deliver the DECIDE modules and address social and economic needs.
48795|NCT03802825|Other|Standard Patient Navigation|Once the participant has completed the YCLS assessment with study staff, the navigator will receive the referral and follow-up with the participant to address the social and economic needs identified. The patient navigator will follow-up with the participant 2-3 times over the 6 months by phone or in-person about progress with the referral and help address additional needs that may develop during the 6-month intervention.
48796|NCT03802812|Device|Thin bronchoscope and VBN|targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system
48797|NCT03802799|Drug|ZYN002 - CBD Transdermal Gel|Pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery)
48798|NCT03802786|Drug|Imeglimin|Single administration dose of imeglimin
48799|NCT03802773|Procedure|CB transplantation|Myeloablative conditioning with post-transplant cyclophosphamide in patients receiving a matched CB transplant for hematological malignancies.
48800|NCT03802760|Device|Transcranial Doppler (TCD) ultrasound measurement|Non-invasive measurement of cerebral embolic load and blood flow using TCD
48801|NCT03802747|Drug|Durvalumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
48802|NCT03802747|Drug|Durvalumab and Tremelimumab|Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
48803|NCT03802747|Drug|Y-90 Selective Internal Radiation Therapy (SIRT)|Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
48804|NCT03802747|Drug|Stereotactic Body Radiation Therapy (SBRT)|High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
48805|NCT03802734|Device|Mindful meditation phone app|Participants in the intervention group will be given a free 6-month subscription to a mindful meditation phone app (Headspace). They will also be given an actigraph and a general pregnancy and sleep information leaflet.
48807|NCT03802721|Drug|Brussels sprouts before 50 ng dose|Brussels sprouts for 7 days before 50 ng (5.4 nCi) dose of BaP
48808|NCT03802721|Drug|DIM supplement before 50 ng dose|DIM supplement for 7 days before 50 ng (5.4 nCi) dose of BaP and coadministration with DIM supplement
48809|NCT03802708|Diagnostic Test|Metabolomic analysis urine sample|a urine sample will be anlayzed for metabolic pathways involving Nitric Oxide Nitric Oxide level will be measured at the exhaled air sample
48810|NCT03802695|Biological|OrcaGraft|engineered donor allograft
48811|NCT03802682|Drug|Apalutamide|Participants will receive apalutamide 240 mg as a whole tablets administered orally (Treatment A) or as a dispersed mixture in applesauce (Treatment B) under fasted condition.
48812|NCT03802669|Other|oral mutans streptococcus|quantitative assessment of mutans streptococcus of each group by using PCR and protein pattern
48813|NCT03802656|Device|Anterior Vertebral Body Tethering|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
48814|NCT03802630|Drug|Brolucizumab 6 mg|Solution for injection (intravitreal use)
48815|NCT03802630|Drug|Aflibercept 2 mg|Solution for injection (Intravitreal use)
48816|NCT03802630|Other|Sham injection|Empty sterile syringe without a needle administered as a sham injection for masking purposes
48817|NCT03802617|Drug|MR13A9|Intravenous administration
48818|NCT03802617|Drug|Placebo|Intravenous administration
48819|NCT03802604|Biological|Talimogene laherparepvec|Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10^6 PFU/mL. On week 3 (i.e. 21 days [± 2] days), a second talimogene laherparepvec injection will be administered at a dose of 10^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 [± 2] days). The maximum volume for each injection will be 4.0 mL.
48820|NCT03802604|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 [± 2] days), for a total of 4 treatment courses.
48821|NCT03802591|Drug|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
48822|NCT03802591|Drug|CS1001 placebo|Participant will receive CS1001 placebo antibody by intravenous infusion every 3 weeks(Q3W), for up to 24 months
48823|NCT03802591|Drug|Oxaliplatin|Administered as an IV infusion on Day 1 Q3W
48824|NCT03802591|Drug|Capecitabine|Administered as an IV infusion on Day 1 Q3W
48825|NCT03802578|Behavioral|HAND EXERCISE|
48826|NCT03802565|Drug|Tolperisone|TID
48827|NCT03802565|Drug|Placebo|Placebo
48828|NCT03802552|Drug|Cefadroxil|oral one-time dose of cefadroxil
48829|NCT03802552|Drug|Cephalexin|oral one-time dose of cephalexin
48830|NCT03802539|Device|Glass Liner|restoration of root caries according to two different protocols
48834|NCT03802513|Other|Physical Therapy|Individualized physiotherapy including exercises to be performed by the Veteran at home.
48835|NCT03802500|Diagnostic Test|Nerve conduction study|"Physical examination of muscle strength is conducted using the Medical Research Council (MRC) scale in 6 muscles bilaterally.~Patients with an MRC score of less than 48 of 60 are diagnosed with critical illness polyneuromyopathy (CIPNM).~The evaluation is completed by a routine neurological examination. In patients meeting the inclusion criteria, the screening Peroneal nerve test (PENT test) is performed on the day of study enrollment and subsequently in 1 week intervals until pathologic findings are detected or patient is discharged from the ICU.~PENT measures the peroneal nerve Compound muscle action potential (CMAP) amplitude in one leg. If the PENT is normal, the contra-lateral peroneal nerve is measured. An abnormal condition is identified if the peroneal nerve CMAP amplitude is reduced below the normal limits of the participating centre in at least one leg. In Lausanne, the abnormal response is < 2,5 mV."
48836|NCT03802487|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
48837|NCT03802487|Drug|14C-microtracer|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
48838|NCT03802487|Drug|Charcoal|"Pharmaceutical form: Granules for suspension~Route of administration: Oral"
48839|NCT03802461|Biological|Fecal Microbiota Transplantation (FMT)|Feces from healthy donor
48840|NCT03802448|Combination Product|Study group|"Each pregnant woman in the study group received myofascial release technique, 3 sessions/week for 4 weeks. a myofascial release in addition to wearing a natural wrist splint during sleeping for 4 weeks.~Myofascial wrist retinaculum (Transverse carpal ligament) release.~• Second part; Interosseous membrane and forearm muscles myofascial release (Bilateral thumb pressure technique)."
48841|NCT03802448|Device|Control group|A neutral wrist splint was worn by all pregnant women in both groups daily at night, only all through the study time (4 weeks). This neutral wrist splint was used to keep the wrist in a straight position (neutral position) and to prevent the extreme wrist motion (flexion and extension) while sleeping.
48842|NCT03802435|Procedure|two-sessions of ultrasound-guided PIT|two-sessions of ultrasound-guided PIT with 5cc D5W (3 months interval)
48843|NCT03802435|Procedure|One-sessions of ultrasound-guided PIT|One-session of ultrasound-guided PIT with 5cc D5W and 5cc normal saline separately (3 months interval)
48844|NCT03802435|Procedure|Placebo ultrasound-guided injection with nerve hydrodissection|Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 5cc normal saline (3 months interval).
48845|NCT03802422|Drug|Vitamin B12|Ultrasound-guided hydrodissection with 3cc Vitamin B12 (methycobal, 500μg/ml) between carpal tunnel and median nerve.
48846|NCT03802422|Drug|Normal saline|Ultrasound-guided hydrodissection with 3cc 0.9% normal saline between carpal tunnel and median nerve.
48847|NCT03802396|Drug|CN-105|"Three doses of CN-105 will be used in three successive cohorts of 67 patients each (50 receiving drug and 17 receiving placebo) 0.1 mg/kg (cohort 1) 0.5 mg/kg (cohort 2)~1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses."
48889|NCT03802058|Drug|Nab-paclitaxel|Nab-paclitaxel 40mg/m2 for Injection weekly
48848|NCT03802396|Drug|Placebo|Patients will receive placebo by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
48849|NCT03802370|Procedure|connective tissue grafting by Dome Technique|The dome technique addresses the placement of the CT, as it is layered over the implant and takes the shape of an inverted dome
48850|NCT03802357|Procedure|Exercise training|Patients perform an exercise Training program of 3 weeks Duration including endurance Training, resistance Training and squat Training. This program is part of an inpatient pulmonary Rehabilitation.
48851|NCT03802344|Drug|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
48852|NCT03802344|Drug|Cal/BDP combination|Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
48853|NCT03802344|Drug|Vehicle|Vehicle cream
48854|NCT03802331|Drug|BI 1323495,|single oral doses
48855|NCT03802318|Drug|Rabeprazole|Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
48856|NCT03802305|Device|computerized intraosseous technique (Quicksleeper™)|"The anesthetic solution is administered with a specific equipment allowing the injection step by step:~anesthesia of the interdental papilla,~positioning of the needle and perforating of the interdental space,~Injection of the solution. All of these steps are based on an adjustment of the different part of this equipment."
48857|NCT03802305|Device|loco-regional anesthesia (IANB technique)|The anesthetic solution is delivered by a needle near to the inferior alveolar nerve before it enters the mandibular foramen.
48858|NCT03802292|Biological|YQ23|Single dose of YQ23 delivered via intravenous route. Ascending dose levels will be evaluated
48859|NCT03802292|Biological|Matching Placebo|Single dose of the matching placebo delivered via intravenous route.
48860|NCT03802279|Other|Effort test|"Cardiac function:~Echocardiography: left ventricular ejection fraction and global longitudinal strain will be measured.~Cardiopulmonary exercise test (CPET): left ventricular stroke volume was assessed noninvasively using a thoracic bioelectrical impedance device : maximal stroke volume at the peak of effort will be considered.~Peripheral muscle function:~CPET: Oxygen uptake (VO2) (and carbon dioxide) output are measured. The slope of the relationship (dQ/dVO2) will be calculated between cardiac output (Q) and VO2 using measurements of Q (using measure of the stroke volume by thoracic bioelectrical impedance device) and VO2 at rest as well as during submaximal and maximal exercise~Muscle oxygenation is measured using a near-infrared spectroscopy device.~VO2 et Q will be measured : dQ/dVO2 is high in case of oxydation defect; If Q is low because of a concommittant cardiac impairement, the DAV = VO2/Q, and DO = (Q x DAV) / (200 - DAV) will be calculated."
48861|NCT03802279|Other|Functional tests on fibroblasts|Functional tests performed on fibroblasts in primary culture, using as tracers of stable isotope-labeled substrates. The metabolites of interest are assayed in mass spectrometry.
48862|NCT03802266|Device|Electromagnetic Navigation guided transthoracic needle aspiration|Patients in this group will receive electromagnetic navigation guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
48863|NCT03802266|Device|CT-guided Transthoracic Needle Aspiration|Patients in this group will receive CT guided transthoracic needle aspiration for the diagnosis of pulmonary peripheral nodule
48864|NCT03802253|Behavioral|Time Restricted Feeding(TRF)|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm) in the first 6 months. 6 months later,Participants will receive a diet of 1200-1500kcal/d without a restriction of feeding time.
48865|NCT03802253|Behavioral|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
48866|NCT03802240|Drug|Sintilimab|200mg IV Q3W
48867|NCT03802240|Drug|IBI305|15mg/kg IV Q3W
48868|NCT03802240|Drug|Pemetrexed|500mg/m2 IV Q3W
48869|NCT03802240|Drug|Cisplatin|75mg/m2 IV Q3W
48870|NCT03802240|Drug|Placebo1|Placebo1 IV Q3W
48871|NCT03802240|Drug|Placebo2|Placebo2 IV Q3W
48872|NCT03802227|Drug|NKTR-181|A combination of NKTR-181 and oxycodone IR placebo
48873|NCT03802227|Drug|Oxycodone IR|A combination of oxycodone IR and NKTR-181 placebo
48874|NCT03802214|Drug|Vedolizumab|standard vedolizumab induction (300mg IV at week 0, 2, 6)
48875|NCT03802201|Drug|PTG-300- 3 mg|subcutaneous (SC) weekly
48876|NCT03802201|Drug|PTG-300- 10 mg|SC weekly
48877|NCT03802201|Drug|PTG-300- 20 mg|SC weekly
48878|NCT03802201|Drug|PTG-300- 40 mg|SC weekly
48879|NCT03802162|Drug|CKD-355A (D797/Memantine HCl 20mg)|once a day
48880|NCT03802162|Drug|CKD-355B (D797/Memantine HCl 20mg)|once a day
48881|NCT03802162|Drug|D797|once a day
48882|NCT03802162|Drug|D324 (Memantine HCl 10mg)|twice a day
48883|NCT03802149|Drug|Ulipristal Acetate|90mg Ulipristal Acetate 18-24-hours prior to dilation and evacuation
48884|NCT03802123|Drug|⁸⁹Zr-Df-IAB22M2C|A dose of 3 mCi (±20%) of ⁸⁹Zr-Df-IAB22M2C between 0.5mg to 1.5mg of API will be administered intravenously over 5-10 minutes, within one week prior to the onset of immunotherapy, and 4 to 5 weeks after start of cancer immunotherapy.
48885|NCT03802110|Device|commercially released subcutaneous implantable cardioverter defibrillator (S-ICD) and the Investigational S-ICD Adapter.|The S-ICD System is a Subcutaneous (under the skin) Implantable Cardioverter Defibrillator for people who are at risk of Sudden Cardiac Arrest. A new electrode configuration will be tested for Defibrillation testing ( DFT). The unit of measure will be in Joules. VF will be induced and the device will deliver a shock at a certain defined energy level as described in the protocol
48886|NCT03802097|Drug|No antimicrobial prophylaxis|Do not use of prophylactic antimicrobial for the patients with undergoing totally laparoscopic distal gastrectomy with D1 or D1+ lymphadenectomy for the gastric cancer
48887|NCT03802084|Drug|vactosertib/imatinib combination|"Phase 1 : Imatinib 400mg QD P q28days Vactosertib 1 cohort 200mg bid (D1-5, 8-12, 15-19, 22-26)~1 cohort 100mg bid Phase 2 : Imatinib 400mg QD PO q28days. Vactosertib RP2D, bid (D1-5, 8-12, 15-19, 22-26)"
48888|NCT03802071|Drug|Durvalumab+olaratumab+doxorubicin cobination|Dervalumab 1500mg IV Olaratumab 15mg/kg IV D1, D8 Q3weeks Doxorubicin 75mg/m2 IV D1 Q3weeks (up to 8cycles)
48891|NCT03802058|Radiation|Thoracic radiation therapy|Thoracic radiation therapy 60-66Gy/30-33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
48892|NCT03802045|Procedure|Electroacupuncture|"The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3."
48893|NCT03802045|Device|Needle|Sterile and disposable 0.25mm x 30mm stainless steel needles (Dong Bang Acupuncture Inc., Seoul, Korea) will be used.
48894|NCT03802045|Device|Adhesive Moxa|In the placebo group an adhesive moxa will be placed on each acupoint and the needle will be inserted over it.
48895|NCT03802032|Drug|Lidocaine Gel|topical lidocaine gel
48896|NCT03802032|Drug|KY jelly|topical KY jelly
48897|NCT03802019|Other|LNC Cigarettes + Colored Packaging|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive low nicotine content cigarettes in one of four types of packaging: gray, red, blue, or plain.
48898|NCT03802019|Other|Own Brand|After completing a 5-day baseline period of smoking their own brand, participants will be randomized to a 30-day experimental period when they will receive their own preferred brand of cigarette (i.e., control).
48899|NCT03802006|Diagnostic Test|Ultrasound assessment of gastric content|Ultrasound assessment of gastric body is performed
48900|NCT03801980|Drug|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
48901|NCT03801980|Drug|Placebo|Patients receive Placebo three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (24 weeks), with individual dose adjustment.
48902|NCT03801967|Drug|AZD9977|Randomized participants will receive oral dose of AZD9977.
48903|NCT03801967|Drug|Placebo|Randomized participants will receive oral dose of matching placebo.
48904|NCT03801954|Behavioral|Educational Videos|15 videos that are about 3 minutes long each and cover nutritional advice for patients with bladder cancer undergoing RC and/or chemotherapy.
48905|NCT03801941|Device|wearing ATLAS device during evaluation at 4th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities with or without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
48906|NCT03801941|Other|wearing ATLAS device during evaluation at 5th day|Wearing the ATLAS device 60 min per day during 5 days and evaluation of pain during standardized activities without ATLAS Device at the 4th or 5th day of a 4 weeks rehabilitation program.
48907|NCT03801928|Drug|Inflectra|The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
48908|NCT03801915|Drug|MVT-5873|1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period
48909|NCT03801915|Procedure|pancreatectomy or hepatectomy|Pancreatectomy or hepatectomy
48910|NCT03801902|Biological|Durvalumab|Given IV
48911|NCT03801902|Radiation|Fractionated Stereotactic Radiation Therapy|Undergo conventionally fractionated radiation therapy
48912|NCT03801902|Radiation|Hypofractionated Radiation Therapy|Undergo ACRT
48913|NCT03801889|Drug|SP-420|Self-administered by mouth
48914|NCT03801876|Drug|Carboplatin|Given IV
48915|NCT03801876|Procedure|Esophagectomy|Undergo esophagectomy
48916|NCT03801876|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
48917|NCT03801876|Drug|Paclitaxel|Given IV
48918|NCT03801876|Radiation|Proton Beam Radiation Therapy|Undergo PBT
48919|NCT03801876|Other|Quality-of-Life Assessment|Ancillary studies
48920|NCT03801876|Other|Questionnaire Administration|Ancillary studies
48921|NCT03801863|Procedure|Ultrasound-guided Erector Spinae Plane Block with Ropivacaine 0.375%|Ultrasound-guided Erector Spinae Plane Block will be done at L4 interspace. Ropivacaine 0.375% will be used.
48922|NCT03801863|Drug|Ropivacaine|Using 0.375% Ropivacaine in the nerve block
48923|NCT03801850|Device|3D surface scan|measurement of inter fractional deformations by surface scanning
48924|NCT03801837|Dietary Supplement|Macadamia Nut|Participants will be provided with the appropriate portion of macadamia nuts [15% of daily calories or 30-45 grams based on kcal requirement of the individual]
48925|NCT03801837|Dietary Supplement|Control Diet|Participants will continue with their Habitual Diet during this part of the intervention
48926|NCT03801824|Other|Standard Nutrition Therapy|Subjects will be advised on standard diet appropriate for the management of Gestational Diabetes Mellitus (GDM) designed to be high in fiber and have moderate to high dietary glycemic index
48927|NCT03801824|Other|Low Glycemic Index|Subjects will be advised to eat low glycemic index foods
48928|NCT03801811|Procedure|Study of the efficacy of using skin glue in the application of Port a cath|The use of glue as a device in the implantation of central venous catheters has recently been introduced into European clinical practice. It is possible that the surgical incision created for the insertion of the PORT may be subject to complications such as: local bleeding, which if not properly treated may last even a few days, infections or surgical wound outbreaks. This possibility of bleeding occurs more easily in patients suffering from coagulation problems or when appropriate preventive measures have not been taken at the time of implantation of the device. A solution to this problem could be the application of the cyanoacrylate dermal glue on the edges of the surgical wound, after intradermal suture. The glue would have the purpose of sealing the surgical wound so as to immediately seal the skin incision with hemostatic effect and create a potential barrier against bacterial infections.
48931|NCT03801785|Other|Pacifier|The pacifiers used in this clinical trial have the same shape and material. They are produced by Artsana S.P.A. for soothing children. As such, the FDA has no jurisdictions over pacifiers (US FDA regulations May 15, 2012 https://www.fdaimports.com/blog/pacifiers-fda-change-abi-system/) because they are not medical devices intended for teething.
48932|NCT03801772|Device|Metronome|Pacing aquatic exercises to the beats per minute of a metronome. The metronome will be adjusted to each patient's pain free exertion level. Patients will start with 10-20 repetitions of the exercises depending on their physical ability. The repetitions will be progressed as the patient's strength and endurance improve and noted in the chart and the flow sheet. The metronome will be synchronized during their second aquatic therapy treatment. The beats per minute (BPM) will be increased on the metronome during the series of treatments until the patient can no longer maintain proper technique with the exercises. The exercises will continue at this BPM during future visits. The patient will be instructed to keep pace with the beat of the metronome for the duration of the exercise.
48933|NCT03801759|Drug|Vadadustat|Oral dose 600 mg
48934|NCT03801759|Drug|Furosemide|Oral Furosemide
48935|NCT03801759|Drug|Adefovir|Oral Adefovir
48936|NCT03801759|Drug|Digoxin|Oral Digoxin
48937|NCT03801746|Drug|vadadustat|Oral dose 300 mg
48938|NCT03801746|Drug|Rifampin|IV Rifampin
48939|NCT03801746|Drug|Probenecid|Oral Probenecid
48940|NCT03801746|Drug|Cyclosporins|Oral Cyclosporine
48941|NCT03801733|Drug|Vadadustat|Oral dose of 600 mg QD
48942|NCT03801733|Drug|Simvastatin|Oral Simvastatin
48943|NCT03801733|Drug|Rosuvastatin|Oral Rosuvastatin
48944|NCT03801733|Drug|Atorvastatin|Oral Atorvastatin
48945|NCT03801733|Drug|Pravastatin|Oral Pravastatin
48946|NCT03801733|Drug|Sulfasalazine|Oral Sulfasalazine
48947|NCT03801720|Other|Ultrasound|Using ultrasound stimulation to induce micturition.
48948|NCT03801707|Drug|Sofosbuvir/Velpatasvir|fixed dose combination medication for the treatment of hepatitis C
48949|NCT03801681|Diagnostic Test|ECG holter monitoring|patients will be monitored using ECG-holter
48950|NCT03801668|Drug|Albumin-bound Paclitaxel plus S-1|Albumin-bound Paclitaxel 260mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
48951|NCT03801668|Drug|Oxaliplatin plus S-1|Oxaliplatin 130mg/m2 IV on D1 plus S-1 80mg/m2 PO (Bid) on D1-14 every 21 days.
48952|NCT03801655|Dietary Supplement|Bio-Kult|4 capsules/day
48953|NCT03801655|Other|Placebo|4 capsules/day
48954|NCT03801642|Drug|Dapagliflozin|10 mg oral tablets taken once daily for 12 weeks
48955|NCT03801642|Other|Placebo|Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks
48956|NCT03801629|Drug|Intramuscular Morphine|See arm description.
48957|NCT03801616|Device|Virtual Reality|Virtual Reality in controlling pain
48958|NCT03801603|Behavioral|HPV vaccination training and education|1) Training of providers and clinic staff on the importance of providing a strong HPV vaccination program and 2) HPV vaccination education for parents and the community.
48959|NCT03801590|Device|Crosslinking with Riboflavin and UV-A|the procedure of cross linking(CXL) :combined riboflavin-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 for a 30-minute exposure irradiation of the cornea.
48960|NCT03801577|Dietary Supplement|Hepaxa|High concentrate EPA and DHA
48961|NCT03801564|Device|Platelet Rich Plasma Treatment Group (PRP)|EASY PRP is in category IIa and manufactured by Neotec Biotechnology Industry and Foreign Trade Company. (Item No. 8680976403603; UNSPSC 42295470; GMDN 46923; certificate no: M.2016.106.7294).
48962|NCT03801564|Device|Hyaluronic Acid Treatment Group (HA)|REGENFLEX STARTER is a class III intraarticular viscosupplementation device (Art. No. 8681065100076; UNSPSC 42295509). Sodium hyaluronate is obtained by bacterial fermentation (STREPTOCOCCUS EQUI) method. The product is in disposable packages, sterile and contained in a 2 ml pyrogen-free syringe.
48963|NCT03801551|Diagnostic Test|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).|Validate according to psychometric criteria, a dimensional measure of apathy in a population suffering from schizophrenia spectrum disorder and other psychotic disorders (according to DSM-5 criteria).
48964|NCT03801538|Drug|Peginterferon Alfa|Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.
48965|NCT03801538|Drug|Nucleoside Analog (Substance)|Patients do not need to change their NAs treatment.
48966|NCT03801525|Drug|Ublituximab|"recombinant chimeric anti-CD20 monoclonal antibody~administered as an IV infusion~to be administered on Cycle 1 Days 1, 2, 8, and 15; then Day 1 of Cycles 2-6"
48967|NCT03801525|Drug|Umbralisib|"PI3K delta inhibitor~Tablet form, to taken orally on a daily basis"
48968|NCT03801525|Drug|Venetoclax|"BCL-2 inhibitor~Tablet form, to be taken orally~Will begin treatment at Cycle 4 (follow dose ramp up schedule); then continue at 400 mg from cycles 5-24."
48969|NCT03801512|Other|Steroid|Triamcinolone 1pc + lidocaine 1% 1cc inject at neuritis nerve roots
48970|NCT03801512|Other|Acupuncture|1.5 inch acupuncture needles insert at acupoints BL23, BL24, BL25 and BL26
48971|NCT03801512|Other|Platelet Rich Plasma|Inject investigators Platelet Rich Plasma at neuritis nerve roots
48972|NCT03801499|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
48973|NCT03801486|Other|Experimental: Sprouted Chickpea Flour|255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.
48974|NCT03801486|Other|Control: Semolina Flour|255g of pasta with 100% semolina flour (SEM100) with butter.
48975|NCT03801473|Other|robot assisted gait therapy|The Robogait is a fixed lower body hip-knee exoskeleton. The user's weight is supported by a combination of an overhead attached harness and the support from the exoskeleton.
48976|NCT03801473|Other|Conventional rehabilitation|Conventional rehabilitation program. Exercise and walking education is performed by the physiotherapists.
48977|NCT03801460|Other|Remotely administered physiological reconditioning program|Patients assigned to intervention arm will be provided a personalized, tailored and graduated exercise program to improve physical strength and conditioning.
48978|NCT03801434|Drug|Ruxolitinib|Given PO
48979|NCT03801421|Procedure|Mass continous suture with PDS|The surgical incision will be treated by mass continous suture with PDS.
48980|NCT03801421|Procedure|Interrupted suture with thread|The surgical incision will be treated by interrupted suture with thread.
48981|NCT03801395|Other|There is no intervention|No intervention
48982|NCT03801382|Device|IntelliSpace Cognition (ISC)|Philips ISC is a Class-II Medical Device in the US and provides objective data regarding cognition via scoring algorithms that HCPs can use to inform diagnostic decision making and treatment planning. It enables tracking cognition over time and offers the possibility of new outcome measures. ISC can be used in a variety of healthcare environments such as neurology and neuropsychology practices.
48983|NCT03801382|Diagnostic Test|Paper-Pencil Tests|The same cognitive tests that are on the ISC platform are performed using paper and pencil (rather than digitally) as is the case in standard clinical practice.
48984|NCT03801369|Drug|Olaparib|Given PO (Orally) 300 mg twice daily, for 4 weeks (induction) then every 28 days for up to 12 cycles
48985|NCT03801369|Biological|Durvalumib|Given IV (infusion), 1500 mg over 1 hr starting at 4 weeks (following induction) and repeating every 4 weeks for up to 12 cycles.
48986|NCT03801356|Diagnostic Test|Selective Nerve Root Block|Prior to single level foraminotomy for lumbar foraminal stenosis, patients will undergo SNRB of the suspected nerve root. Patients will undergo surgery despite the response to injection. Patients will complete an ambulation assessment immediately before and after the injection. Distance and time will be noted. Patients will be called within 48 hours of injection to determine response to injection, and recorded as Pre-and Post-injection VAS leg as well as duration of the response. Patients will be seen at 6 weeks, 3,6, and 12 months post-surgery and outcome measured by VAS-leg, ODI, PDQ and EQ-5D scores. Data will be used to determine the ideal improvement in leg pain and duration of improvement, predicting a statistical and meaningful improvement in leg pain following foramintomy.
48987|NCT03801343|Dietary Supplement|Nutrakos®|"Nutrakos® Amino Acid Food Supplement supplies a specific mixture of amino acids that has been proven to induce synthesis of collagen and elastin, the main proteins of derma structure in fibroblasts and keratocytes."
48988|NCT03801330|Other|Pulmonary Rehabilitation Paper-Based Home Program|Participants in the Pulmonary Rehabilitation Paper-Based Home Program group will complete a Pulmonary Rehabilitation Home Program using a paper-based exercise program for two months (usual care).
48989|NCT03801330|Other|Pulmonary Rehabilitation Software-Based Home Program|Participants in the Pulmonary Rehabilitation Software-Based Home Program group will complete a Pulmonary Rehabilitation Home Program using a software app for two months (software)
48990|NCT03801317|Dietary Supplement|PTM1001|4.3 egg powder + 5.7 g bovine colostrum
48991|NCT03801317|Dietary Supplement|Control|15 grams corn-soya blend
48992|NCT03801317|Dietary Supplement|multiple micronutrient|multiple micronutrient sprinkle powder
48993|NCT03801304|Drug|Atezolizumab|Atezolizumab in IV infusions
48994|NCT03801304|Drug|Vinorelbine|Vinorelbine capsules
48995|NCT03801291|Procedure|Transvaginal repair|Vaginal incision through which plication of the rectovaginal septum is done
48996|NCT03801291|Procedure|Transperineal repair|Perineal incision through which plication of the rectovaginal septum is done
48997|NCT03801278|Drug|FPA144|Bemarituzumab administration every two weeks
48998|NCT03801265|Procedure|Lumbar plexus block|Patient will be positioned in lateral decubitus position with side to be blocked facing upwards. Midline will be identified by palpating the spinous process. Intercristal line will be drawn connecting iliac crests. The point of needle insertion will be 4 cm lateral to the intersection of both lines. The transverse process will first contact with a finder needle. Subsequently an 18 gauge 10 cm insulated needle will be used and advanced until it contacted the transverse process. Needle will then be redirected cephalad or caudad and advanced 2 cm, until the quadriceps femoris twitch is obtained. Local anesthetic will then be injected after confirming a motor response between 0.3-0.5 milli amperes.
48999|NCT03801265|Procedure|Quadratus lumborum type 3 block|Patient will be placed in a lateral position with the side to be blocked facing up. A low frequency transducer will be used to identify three layers of abdominal musculature, probe will be then moved posteriorly till the transverse abdominus aponeurosis is visualized, the QL muscle is then identified by tracing the aponeurosis posteriorly. The transducer is then moved more posteriorly to visualize the shadow of transverse process and the origin of QL muscle. Psoas muscle is then identified lying anterior to the QL muscle. A 22 gauge 8 cm is inserted in plane posterior to the probe and advanced intramuscularly through the QL to interfacial plane between QL and psoas major and local anesthetic is deposited.
49000|NCT03801265|Drug|Ropivacaine injection|0.5% ropivacaine 20 ml (100 mg) will be injected for both groups.
49001|NCT03801252|Drug|Cefazolin|intravenous drugs used as prophylactic antibiotics
49002|NCT03801252|Drug|Placebo|Intravenous saline
49003|NCT03801252|Drug|Azithromycin|prophylactic antibiotic
49004|NCT03801239|Diagnostic Test|Urodynamic Study|during visit Week 0 patients had urodynamic study
49005|NCT03801239|Diagnostic Test|OABSS questionnaire fulfilment|during visit Week 0 and Week 2 patients fulfilled OABSS
49006|NCT03801239|Diagnostic Test|UDI-6 questionnaire fulfilment|during visit Week 2 patients fulfilled UDI-6 questionnaire
49007|NCT03801239|Diagnostic Test|IIQ-7 questionnaire fulfilment|during visit Week 2 patients fulfilled IIQ-7 questionnaire
49008|NCT03801226|Drug|Two-hour dwell with 10% dextrose in sterile water|Patients will be randomized to undergo a two-hour dwell with 10% dextrose in sterile water at their first or second study visit and will receive the alternate intervention at the other study visit.
49009|NCT03801226|Drug|Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose|Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
49010|NCT03801213|Device|urinary catheterization|Urinary catheterization with pain controlled
49011|NCT03801213|Procedure|manual bladder stimulation technique|manual gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
49012|NCT03801200|Drug|Apatinib|radiotherapy with Apatinib
49013|NCT03801187|Procedure|chlorhexidine|Inflammatory tissue, excess cement or plaque deposits will be removed using titanium curettes and the implant surface will be cleaned by copious irrigation with sterile saline and surgical gauze soaked in chlorhexidine.
49014|NCT03801187|Procedure|Er:YAG laser|Er.YAg laser treatment will be provided on the implant surface.
49015|NCT03801187|Procedure|Air-Powder|An air powder device will be treatment will be provided on the implant surface.
49016|NCT03801174|Behavioral|Partner-assisted intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
49017|NCT03801174|Behavioral|Patient-only intervention|All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
49018|NCT03801161|Biological|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).|Pentavalent vaccine is being recommended to provide infants at 6wk, 10wk and 14wk of age. This vaccine also induces plasma CRP >5 mg/L in infants within 24 hours of immunization.
49019|NCT03801148|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
49020|NCT03801148|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
49021|NCT03801148|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release capsules.
49022|NCT03801148|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release capsules.
49023|NCT03801135|Drug|Fibrinogen concentrate|Haemocomplettan will be infused after plasma exchange procedure
49024|NCT03801135|Other|Fresh Frozen Plasma|Fresh frozen plasma will be part of replacement fluid
49025|NCT03801122|Drug|Tranexamic acid|Administration of tranexamic acid, with 3 injections/8 hours.
49026|NCT03801109|Other|Hyperbaric group|Participants in this group performed 5 sessions per week for 8 weeks (40 sessions in total) . The time of each session is 90 minutes and the chamber pressure is 1.4 ATA with a 100% oxygen mask.
49027|NCT03801109|Other|Magnetic group|There will be 5 sessions per week for 2 consecutive weeks (10 sessions in total), stimulating the left motor cortex at high frequencies, 10 Hz, for 30 minutes.
49028|NCT03801109|Other|Physical group|A protocol of low-impact physical exercise will be performed twice a week for 8 weeks, with a total of 16 sessions.
49029|NCT03801109|Other|Baseline group|This group will be the control group that did not take any action, perform the activities of daily life
49030|NCT03801096|Behavioral|Narrative Based Therapuetic Assessment (NbTa)|The NbTa interventiom will guide participants through an exploration of their human experience through stories and narratives. The interventionist will facilitate a collaborative process by which participants will explore the unique themes and meanings of their personal narrative (Parry & Doan, 1994) with respect to alcohol and drug use. In addition, participants will also be guided towards considering the re-authorship of personal narratives. The techniques utilized in NbTa aim to dislodge problem saturated narratives and derive more complete personal narratives and meanings (White & Epston, 1990).
49031|NCT03801096|Behavioral|Health Education Control Condition (HE)|The Health Education session is a didactic 45-minute session that focusses on three health-related topics: 1) Sleep, 2) Physical Activity, and 3) Nutrition. The goal of the session is to present health-related information to participants through videos and dydadic presentation.
49032|NCT03801083|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL are to be infused intravenously through a central vein catheter over 20-30 minutes followed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to a maximum of 6 doses.
49033|NCT03801070|Procedure|endoscopic drainage of walled off pancreatic necrosis|transmural drainage and mechanical debridement of solid debris (necrosectomy)
49034|NCT03801057|Dietary Supplement|MPH_active|One daily intake at breakfast of supplementary marine protein hydrolysate (MPH), a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water. Random sequence of arms.
49035|NCT03801057|Dietary Supplement|MPH_placebo|One daily intake at breakfast of supplementary placebo, a dosage of 2400 mg, duration 6 weeks. The form is powder, flavored with lemon, and to be mixed with 100 ml water.
49036|NCT03801044|Diagnostic Test|NT-BNP, VEGF|VEGF-C levels were measured in the serum samples. R&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).
49037|NCT03801044|Diagnostic Test|Echocardiography|Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography
49038|NCT03801044|Radiation|Chest Radiography|All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.
49118|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 2 multiple ascending oral doses (O, P).
49039|NCT03801044|Diagnostic Test|Lung Ultrasound|It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.
49040|NCT03801044|Diagnostic Test|Bioelectrical Impedence Analysis|The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG & Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
49041|NCT03801031|Drug|Lidocaine Topical|Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.
49042|NCT03801031|Drug|Placebo|Placebo solution intervention used to validate the effects of the lidocaine solution usage.
49043|NCT03801018|Other|Questionnary and Interviews|"An internet platform dedicated to the anonymous survey will be set up by the communication department and the digital System Department of the promoter Public assistance hospitals in Marseille, the data Processing manager. It would deplore anonymous questionnaires accessible from a dedicated web page. People will therefore respond to a national survey on the basis of volunteering and anonymity.~Interviews, lasting one to two hours, will be fully transcribed and processed anonymously.~The interviews will seek to collect data on the modalities, conditions and effects of the circulation (or retention) of information on the use of donation, throughout the lives of individuals and families, in a cross-analysis of Viewpoints of parents and people born of donation."
49044|NCT03801005|Biological|Blood and Marrow sample|"Twenty patients will be included in a prospective way over a period of nine months. No additional medullary or serum samples will be carried out in addition to those required for the clinical routine. Only an additional blood sample taken during a routine blood test will be recovered as part of the research. Just as some leftover bone marrow, taken as part of a usual unused follow-up will be recovered as part of this trial.~The persons concerned will be recruited on the occasion of their hospitalisation in one of the hematology services participating in the research, or during their consultation with one of the hematologists of the corresponding service (or services). On this occasion, detailed information on their pathology and research will be given, as well as the information document on the proposed research protocol."
49045|NCT03800992|Other|assessment of perception and evaluation of physicians advisory skills per questionnaire|questionnaire according to SPIKES - a Six-Step Protocol for Delivering Bad News to be completed by parents and children (older than eleven)
49046|NCT03800979|Drug|Tofacitinib|Tofacitinib is an oral medicine in Janus kinase inhibitor 3 group which has been approved by FDA in treating Rheumatoid Arthritis. It has ability to inhibit nerve signal Interferon-ɣ and Interleukin-15 between white blood cell(WBC) and the nucleus of hair follicle cell causing the production of WBC type CD8+NKG2D+ T cell to slow down which this type of WBC is one of the cause of hair loss.
49047|NCT03800966|Other|Leaflet|Leaflets for both groups will be printed in colour. Leaflet in each group contains 8 pictures and 8 statement, whose sequences will be scrambled. Primary school students need to do the matching, to ensure they read the statements.
49048|NCT03800953|Drug|Avelumab|The study treatment comprises two phases, the concurrent immune-chemoradiotherapy (Ave-PF-CRT) phase and the immune-chemotherapy (Ave-PF) phase. All the subjects will receive Avelumab at both phases.
49049|NCT03800940|Procedure|Fistulography and trans-drain occlusion|"Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed."
49050|NCT03800940|Procedure|Fistulography|Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
49051|NCT03800927|Device|Long duration ultrasound|Low-intensity long duration ultrasound treatment
49052|NCT03800914|Other|High intensity interval training|36 minutes of interval exercise on cycle ergometer alternating every 30 seconds between 100% peak work rate achieved on cardiopulmonary exercise test and unloaded cycling
49053|NCT03800914|Other|Traditional pulmonary rehabilitation|30 minutes of continuous exercise on cycle ergometer at 60% peak work rate achieved on cardiopulmonary exercise test.
49054|NCT03800901|Other|Continuing Medical Education|CME or ABIM MOC credits
49055|NCT03800901|Other|Quality IQ Patient Simulations|"Online patient cases designed to simulate typical patients seen in a primary care practice. In each case, providers will answer multiple-choice questions about their preferred course of action to work-up, diagnose and treat patients in the primary care setting. After each question, providers will receive evidence-based feedback, including references, on the appropriateness of each of their care decisions. Feedback will be supported with relevant reference to evidence-based guidelines, including national MIPS quality measures.~Cases will cover clinical conditions aligned with MIPS measures that are commonly seen in the primary care setting including: diabetes, hypertension, depression, osteoarthritis, asthma and pain control."
49056|NCT03800888|Other|Daily SMS reminders for TB patients|Daily SMS Medication reminders will be sent to TB patients to remind them take their medications.
49057|NCT03800888|Other|SMS Notifications for social supporters|SMS Notifications will be sent to social supporters to assit TB patients take their medication
49058|NCT03800888|Other|Weekly SMS remiders|Weekly SMS reminders sent to TB patients to remind them take medication
49119|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR optimized film-coated tablets, up to 3 multiple ascending oral doses (Q, R, S).
49120|NCT03800472|Drug|Placebo|Placebo optimized tablets
49309|NCT03798938|Other|plant-based diet|subjects will be placed in plant-based diet and the effect of plant-based diet to the endothelial function will be monitored
49059|NCT03800875|Drug|27-hour inpatient intervention|Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin, pramlintide and glucagon will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
49060|NCT03800862|Device|CT-FFR and CTP|Those who agree to participate will be scheduled to have the CT-FFR and CTP performed within sixty days of the initial Coronary CTA procedure. A CTA will be performed at rest for FFR. The patient will then take approximately a 30 min break. Regadenoson will then be administered and the dynamic CT procedure will be done for perfusion.
49061|NCT03800836|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28 day cycle.
49062|NCT03800836|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion on Days 1, 8, and 15 of each 28 day cycle.
49063|NCT03800836|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 840 mg on Days 1 and 15 of each 28 day cycle.
49064|NCT03800836|Drug|Nab-Paclitaxel|Nab-paclitaxel will be administered by IV infusion at a dose of 100 mg/m^2 on Days 1, 8, and 15 of each 28 day cycle.
49065|NCT03800823|Behavioral|Parent group|In group sessions parents will learn how to use positive parenting practices (e.g., encouragement and limit setting) instead of ineffective practices (e.g., coercive behaviour, negative reciprocity). Using a parent group approach, each of the 10 sessions consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments.
49066|NCT03800823|Behavioral|mHealth component|After the group sessions, parents will receive a 6-month mHealth program (MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet/physical activity behaviours. The program includes information, advice, and strategies to change unhealthy behaviours and the possibility to register the child's intake of fruit, vegetables, candy, sweetened beverages, and sedentary time.
49067|NCT03800823|Behavioral|Standard care|Standard care for overweight and obesity.
49068|NCT03800810|Drug|Hyaluronic Acid|
49069|NCT03800810|Biological|Umbilical Cord Mesenchymal Stem Cell|
49070|NCT03800810|Biological|Recombinant Human Somatropin|
49071|NCT03800797|Drug|Loxoprofen sodium hydrogel patch|100 mg per day
49072|NCT03800797|Drug|Loxoprofen sodium tablet|60 mg t.i.d.
49073|NCT03800784|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
49074|NCT03800771|Device|Cycléo BRAU|Practice dual-task tests.
49075|NCT03800771|Device|GAITRITE®|Routine practice dual-task tests.
49076|NCT03800758|Behavioral|Expressive Helping|Expressive Helping (EH) is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using previously-tested EH instructions, adapted for this population.
49077|NCT03800758|Behavioral|Factual Writing|Factual Writing has been used with cancer patients and in the investigators' prior EH trial. It is completed in 4 brief structured writing sessions during and immediately after transplant, with instructions focused on having participants write about their transplant experience using standard Factual Writing instructions.
49078|NCT03800745|Drug|Colace 100Mg Capsule|Prescribed to Arm B
49079|NCT03800745|Drug|Miralax|Prescribed to Arm C
49080|NCT03800732|Other|With Meal during night work|Two nights of work with a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
49081|NCT03800732|Other|Without Meal during night work|Two nights of work without a meal during the shift and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
49082|NCT03800732|Other|Sleep night|Two sleep nights and after will go to the laboratory the morning for eating a test meal ad libitum, which will consist of foods of various compositions and food groups. Preprandial metabolic assessments will be conducted (ghrelin, GLP-1 - glucagon-like peptide 1, PYY-peptide YY). The following postprandial evaluations will be carried out and in the 24 hours following the experiment: food choices (record of all foods) and food perceptions (hunger, appetite, satiety and eating).
49083|NCT03800719|Behavioral|AWARD advice|"At baseline, brief smoking cessation advice following AWARD model will be delivered to subjects within about 2 to 5 minutes:~Ask about smoking history and habit~Warn about the risks of smoking using a leaflet~Advise to quit smoking as soon as possible and use nicotine replacement therapy (NRT) or SC services~Refer subjects to free smoking cessation services in Hong Kong if they agree~Do it again: smokers who have tried to quit but relapsed will be encouraged to quit again and those who have reduced smoking will be advised to further reduce or quit smoking"
49084|NCT03800719|Behavioral|Health warning leaflet|At baseline, an A5-sized leaflet will be given to subjects, which includes information about risks of smoking, pictures of smoking-related diseases, and smoking cessation services provided in Hong Kong.
49085|NCT03800719|Behavioral|Active referral to smoking cessation (SC) services|At baseline, subjects will be encouraged to seek smoking cessation services in Hong Kong. If subjects agree, their contact information will be sent to the preferred service providers for a quick appointment and follow-up.
49164|NCT03800134|Drug|Pemetrexed/Carboplatin|Pemetrexed/Carboplatin, as per standard of care
49232|NCT03799601|Drug|Anlotinib|Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit.
49310|NCT03798925|Other|None Intervention|It is observational study
49086|NCT03800719|Behavioral|Regular messages through Instant Messaging (IM)|A total of pre-set 26 messages will be sent to subjects through WhatsApp 12 weeks after baseline to remind the quit date and to encourage abstinence. Messages are tailored based on subjects' sociodemographic characteristics and smoking habit following Social Cognitive Theory and Transtheoretical Model. Messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. The schedule will be adjusted according to the quit date and also smokers' requests. The format of regular messages will mainly be text-based but also include pictures, animations and videos.
49087|NCT03800719|Behavioral|Psychosocial support and referral to SC services through IM|Personalized interactive text or voice conversation will be provided by trained smoking cessation advisors through WhatsApp for 3 months after baseline. Advisors will periodically proactively send messages to subjects to initiate the conversation (e.g. asking recent progress of smoking cessation) and deliver evidence-based advice. Advisors will also actively refer subjects, if they have expressed the need, to smoking cessation services providers. A standard operation algorithm for advisors used in the pilot feasibility trial will be modified for the use.
49088|NCT03800719|Behavioral|Message on general health delivered by short message service (SMS)|After baseline, regular messages using SMS will be sent to subjects with similar frequency to Intervention group. The messages include information on general health and reminders on follow-up surveys and biochemical validation for quitting.
49089|NCT03800706|Drug|TQB2450|TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
49090|NCT03800693|Drug|Fluorouracil|Given IV
49091|NCT03800693|Drug|Leucovorin|Given IV
49092|NCT03800693|Drug|Oxaliplatin|Given IV
49093|NCT03800680|Behavioral|Diabetes Management Package (DMP)|"M-POWER app: A one-stop portal to monitor diabetes self-management activities and progress. The app syncs and displays relevant data from study devices and apps.~GlycoLeap: A 24-week, digitally-delivered education and behavior change program for T2DM patients.~4 study devices with accompanying apps to aid in diabetes self-management: weighing scale, pedometer, glucometer, and pill tracker.~Recommended activities:~Complete all 24 GlycoLeap lessons and quizzes~Weight Monitoring: Weigh at least once a week.~Physical Activity: At least 150 minutes of moderate-to-vigorous activity per week, targeting at least 420 Fitbit active minutes per week.~Blood Glucose Monitoring: At least three post-meal measurements within 4.0-10.0 mmol/L per week, with each reading taken on different days.~Medication: Take medications as prescribed."
49094|NCT03800680|Behavioral|M-POWER Rewards|A financial incentive program were participants can earn up to 1,000 M-Points (1 M-Point is equivalent to S$1) over the 2-year study period for performing specific activities according to recommendations that are meant to improve glycemic control and for achieving HbA1c and weight loss goals. M-Points can be reimbursed in the form of financial rebates for approved non-inpatient healthcare-related expenses incurred during the study period.
49095|NCT03800667|Drug|Ascorbic Acid 1000 MG|1000 mg ascorbic acid (Vitamin C) for 1 month post-op after an elective gynecological surgery.
49096|NCT03800654|Behavioral|Mindful Action for Pain|MAP integrates formal mindfulness meditation with methods from Acceptance and Commitment Therapy and Dialectical Behavior Therapy.
49097|NCT03800654|Behavioral|Cognitive Behavioral Therapy for Chronic Pain|CBT-CP is the current gold standard psychosocial intervention for chronic pain and will be compared to MAP in the second arm of the study.
49098|NCT03800641|Drug|Dexmedetomidine|oral, intravenous and nasal administration of Dexmedetomidine
49099|NCT03800628|Other|qualitative study|semi-structured interviews
49100|NCT03800615|Procedure|Cut the sling|Cut the mid-urethral sling for stress urinary incontinence
49101|NCT03800602|Drug|Metformin|Given PO
49102|NCT03800602|Biological|Nivolumab|Given IV
49103|NCT03800589|Procedure|phacoemulsification with implantation of the Ex-Press|The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
49104|NCT03800589|Procedure|deep sclerectomy, phacoemulsification, ExPress implantation|The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
49105|NCT03800563|Device|LipoLife system|Abdominal/ Outer thighs Laser Assisted Liposuction. Five to twenty subjects out of the study group will also undergo facial fat grafting.
49106|NCT03800550|Drug|Bedaquiline|Bedaquiline tablet will be administered, orally.
49107|NCT03800550|Drug|Clarithromycin|Clarithromycin tablet will be administered, orally.
49108|NCT03800537|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
49109|NCT03800524|Drug|Tauroursodeoxycholic Acid|"Tauroursodeoxycholic acid (TUDCA) 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
49110|NCT03800524|Drug|Placebo|"Placebo 250 mg capsules~Doses: 4 capsules (1 g) twice daily 10-15 minutes after a meal~Mode of administration: orally~Duration: 18 months"
49111|NCT03800511|Diagnostic Test|sliding test|ultrasound detected sliding test before doing repeated caesarean section
49112|NCT03800498|Other|DASH Education|DASH health education about general knowledge of DASH diet Plan and lifestyle modification
49113|NCT03800485|Device|IMT|A training protocol of the inspiratory muscles that goes from the 15% of the maximal inspiratory muscle preassure until the 60% of the maximal inspiratory muscle preassure during 8 weeks
49114|NCT03800472|Drug|GLPG3312 IR|GLPG3312 IR tablets, up to 4 single ascending oral doses (A, B, C, D).
49115|NCT03800472|Drug|Placebo|Placebo tablets
49116|NCT03800472|Drug|GLPG3312 MR|GLPG3312 MR film-coated tablets, up to 4 single ascending oral doses (H, I, J, K).
49117|NCT03800472|Drug|GLPG3312 FE MR|GLPG3312 MR film-coated tablets, single oral dose (N) on 2 occasions, i.e. in fed state after a high-fat high-calorie breakfast, and in fasted state.
49121|NCT03800459|Behavioral|family empowerment program|The empowerment program-nursing interventions were given in 6 sessions in the experimental group Session 1: Individualized training: General information about CF, respiratory system involvement and treatment process, airway cleaning in CF, drug applications (45-50 min) Session 2:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min).Session 3:Phone calls:Motivational and reminder interviews were carried out in order to reinforce the content of the first individual training (15 min) Session 4:Individualized training:protection from infections, nutrition and psychosocial support (45 min) Session 5:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min) Session 6:Phone calls: Motivational and reminder interviews were carried out in order to reinforce the content of the second individual training. (10 min)
49122|NCT03800446|Diagnostic Test|Point of care ferritin test|Point of care test that uses capillary blood sample from finger to determine ferritin level
49123|NCT03800433|Drug|Trental 400 MG Extended Release Oral Tablet|oral tablets
49124|NCT03800420|Drug|Active group|BBT-401-1S 12 weeks + Placebo 4 weeks
49125|NCT03800420|Drug|Placebo group|Placebo 8 weeks + BBT-401-1S 8 weeks
49126|NCT03800407|Other|Observational study|Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART
49127|NCT03800394|Other|Observational PK study|Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
49128|NCT03800381|Other|Observational PK study|The study team will examine the PK and tolerability of the new HRZ 50/75/150 mg dispersible tablet in children with TB with and without HIV coinfection. Intensive PK testing will be performed after at least 4 weeks of treatment in children on first-line anti-TB therapy using the new pediatric HRZ FDC tablet.
49129|NCT03800368|Other|Exercise|Indoor cycling exercise intervention
49130|NCT03800368|Other|Non-exercise|Psycho-education
49131|NCT03800342|Other|Aerobic Exercise Training|see arm/group description
49132|NCT03800329|Device|Snap40 Monitor|Non-invasive, wearable armband device used to measure change in systolic blood pressure, respiratory rate, heart rate, body temperature, movement, and oxyhemoglobin saturation and streams this information to a cloud-based storage system. Patients will complete a questionnaire.
49133|NCT03800329|Other|No Monitor|Patients will be discharged in the ordinary manner, without the Snap40 monitor. Patients will complete a questionnaire.
49134|NCT03800316|Device|Video Consultation|Video consultation with emergency medicine physicians for patients that are critically ill prior to arrival in the ED
49135|NCT03800303|Behavioral|Family-based treatment|2-week family-based treatment
49136|NCT03800290|Drug|Clenbuterol Hydrochloride|Daily ingestion of clenbuterol hydrochloride capsules (40 microgram/day) for a total period of 14 days with a wash-out period of 4 weeks.
49137|NCT03800290|Drug|Placebos|Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
49138|NCT03800277|Dietary Supplement|Cranberry|Supplementation of polyphenols from cranberry extract
49139|NCT03800277|Dietary Supplement|Agaves|Supplementation of inulin from Agaves powder
49140|NCT03800277|Dietary Supplement|Placebo|Supplementation with placebo
49141|NCT03800264|Drug|Bisoprolol|PREVENTIVE DOUBLE BLINDED
49142|NCT03800251|Dietary Supplement|Nutricia PreOp - a clear, non-carbonated, lemon flavoured, carbohydrate drink that provides 0.5kcal/ml|Fasting parturients at term, admitted for elective cesarean section and consent to partake in the study, will be given the intervention drink
49143|NCT03800238|Behavioral|Telehealth Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered via telehealth.
49144|NCT03800238|Behavioral|Standard Delivery Format|Participants will engage in a 6-week Powerful Tools for Caregivers program delivered in the traditional in-person format.
49145|NCT03800225|Procedure|Repair|Anterior ligament repair with internal brace.
49146|NCT03800212|Drug|treatment for ampullary adenocarcinoma|all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).
49147|NCT03800199|Other|Perceptive rehabilitation|The first session will be an education session. Spinous processes will be reference line of the body and patient will lie down on cones. The therapist will ask the patient first to breathe normally and feel the pressure. This will lead the patient to relax and understand cones. Then, the patient will start with the diagrammatic breathing. After breath exercises patient will perform active exercises (include stretching, warming up and cooling down) on supervision. Exercises will include the whole body. Additional to this during the session therapist will ask about the pressure of cones and she will correct the patients' posture. At the end of all the session, the therapist will take a photo of the patients back with the aim of to document the pressure and hyperaemic areas.
49148|NCT03800186|Other|Proximal type A|Patients with fracture of proximal type A
49149|NCT03800186|Other|Proximal type B|Patients with fracture of proximal type B
49150|NCT03800186|Other|Proximal type C|Patients with fracture of proximal type C
49151|NCT03800186|Other|femoral shaft|Patients with fracture of femoral shaft
49152|NCT03800186|Other|distal femur|Patients with fracture of distal femur
49153|NCT03800173|Drug|galidesivir|galidesivir IV infusion
49154|NCT03800173|Drug|placebo|placebo IV infusion
49155|NCT03800147|Drug|"Mutaflor Suspension (E. coli Nissle 1917)"|"Inoculation of Mutaflor Suspension (E. coli Nissle 1917)"
49156|NCT03800147|Other|Blood samples|Blood samples will be collected and analyzed at different study time points
49157|NCT03800147|Other|Stool samples|Stool samples will be collected and analyzed at different study time points
49158|NCT03800147|Other|Clinical information|Clinical information will be collected at different study time points using questionnaires
49159|NCT03800134|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
49160|NCT03800134|Other|Placebo|Placebo IV (intravenous infusion)
49161|NCT03800134|Drug|Carboplatin/Paclitaxel|Carboplatin/Paclitaxel, as per standard of care
49162|NCT03800134|Drug|Cisplatin/Gemcitabine|Cisplatin/Gemcitabine, as per standard of care
49163|NCT03800134|Drug|Pemetrexed/Cisplatin|Pemetrexed/Cisplatin, as per standard of care
49165|NCT03800121|Biological|Blood samples|"Localized sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample before surgery (32 ml) + 1 blood sample 1 month after surgery (32 ml) + 1 blood sample 3 month after surgery (32 ml) + 1 blood sample 6 month after surgery (32 ml)~Metastatic sarcoma group : 1 blood sample during inclusion (7 ml) + 1 blood sample during chemotherapy cure 1 (32 ml) + 1 blood sample during chemotherapy cure 3 (32 ml) + 1 blood sample during chemotherapy cure 6 (32 ml)"
49166|NCT03800108|Procedure|Personalized DBS adjustments|Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
49167|NCT03800095|Drug|Early palliative care integration|The follow-up time for each patient is 12 months with evaluation of the main objective by a standardized questionnaire: The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale at 6 months. Throughout the study, patients included will receive conventional haematological care and the interventional arm will benefit in addition to a monthly consultation by a palliative care team.
49168|NCT03800082|Behavioral|HEARTPA♀N|An integrated smartphone and web-based intervention (HEARTPA♀N) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with cardiac pain. The intervention for participants randomized to the treatment group will consist of daily use of the HEARTPA♀N app, in addition to usual care, for a period of 3 months.
49169|NCT03800069|Device|Group K Diagnostic point of care device|Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
49170|NCT03800030|Device|Theta-gamma tACS|NeuroConn technologies, direct current-stimulator plus
49171|NCT03800030|Device|Delta-beta tACS|NeuroConn technologies, direct current-stimulator plus
49172|NCT03800030|Device|Sham tACS|NeuroConn technologies, direct current-stimulator plus
49173|NCT03800017|Biological|Hyperoxia|Participants breathe 60% oxygen during exercise
49174|NCT03799991|Behavioral|Vestibular physical therapy|Vestibular therapy is a set of exercises delivered by a physical therapist involving head movements. The therapy is delivered over a course of 8 weeks.
49175|NCT03799991|Behavioral|Active control|Strength and flexibility exercises that do not involve head movements.
49176|NCT03799978|Drug|ACT-541468|ACT-541468 50 mg film-coated tablets
49177|NCT03799965|Other|ERAS (Enhanced Recovery After Surgery ) are evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
49178|NCT03799965|Other|ERAS are not evaluated|In this arm ERAS( Enhanced Recovery After Surgery) protocol will not be inserted.The findings regarding the patients under ERAS protocol are evaluated based on evidence.
49179|NCT03799952|Behavioral|Zoomers on the Go Exercise Program|60 minute exercise class involving resistance and aerobic training activities, as well as flexibility and balance activities. An educational handout is offered at the end of every class, relating to health behaviour.
49180|NCT03799939|Device|Intervention group|Polyvinylidene fluoride mesh (Dynamesh IPST) is used on intraperitoneal onlay position to prevent parastomal hernia.
49181|NCT03799926|Drug|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
49182|NCT03799926|Drug|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
49183|NCT03799926|Drug|placebo|Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
49184|NCT03799926|Drug|placebo|Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
49185|NCT03799926|Drug|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
49186|NCT03799926|Drug|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 2)
49187|NCT03799926|Drug|patiromer|Patiromer starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
49188|NCT03799926|Drug|patiromer|Patiromer starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 3)
49189|NCT03799913|Biological|anti-MESO CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-MESO CARs
49190|NCT03799913|Drug|Fludarabine|30mg/m2/d
49191|NCT03799913|Drug|Cyclophosphamide|300mg/m2/d
49192|NCT03799900|Drug|Rapastinel|During the Treatment Phase in Part 2, participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner.
49193|NCT03799900|Drug|Ketamine|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
49194|NCT03799900|Drug|Placebo|"Part 1~Part 2, Qualification Phase:~Participants will be administered single IV doses of ketamine and placebo in a randomized crossover manner~Part 2, Treatment Phase:~Participants will be administered single IV doses of rapastinel, ketamine, and placebo in a randomized crossover manner."
49195|NCT03799887|Behavioral|0% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 0% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
49196|NCT03799887|Behavioral|10% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 10% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
49306|NCT03799003|Drug|pembrolizumab|Intravenously (IV)
49307|NCT03798964|Other|Placental analysis|Analysis of placenta to determine expression of heparanase
49197|NCT03799887|Behavioral|20% unweighed BWSTT|"30 minutes conventional rehabilitation program (CRP) including range of motion, stretching and strengthening exercises for upper and lower extremities, balance and mobility exercises.~After CRP, participants were provided 30 minutes 20% unweighed BWSTT sessions including a 5 minutes warm - up and cool - down period for each session, 5 days a week, for 6 weeks (totally, 30 sessions)."
49198|NCT03799874|Drug|Inhaled Carbon Monoxide at 200ppm|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days.
49199|NCT03799874|Other|Inhaled Medical air|Inhaled Medical Air for up to 90 minutes daily for 5 days.
49200|NCT03799861|Other|Epoch 2: HBB with NeoBeat|At the beginning of Epoch 2, all birth attendants in each of the 3 maternity units will participate in a 2 day workshop in Kinshasa in French that will include instructions regarding use of NeoBeat and training in HBB 2.0. Participants will be introduced to NeoBeat, which will include practice with NeoBeat using the NeoNatalie newborn simulator. This training will be conducted in French using typical adapted training materials for this program that incorporate placement of NeoBeat at appropriate times in the algorithm, including a flipchart and NeoNatalie. Participants will complete the pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs) with the incorporation of use of NeoBeat into the OSCEs.
49201|NCT03799861|Other|Epoch 3: HR-guided HBB|At the beginning of Epoch 3, all birth attendants in each of the 3 maternity units will participate in a 1 day workshop in Kinshasa in French that will instruct them in an adapted, HR-guided HBB algorithm. This training will include simulation with NeoNatalie and NeoBeat. Participants will complete a pre and post knowledge check questionnaire for the training as well as the Observed Standardized Clinical Exams (OSCEs).
49202|NCT03799848|Drug|Vadadustat|Oral tablet
49203|NCT03799835|Drug|BCG|Intravesical administration posology: 2.10⁸ - 3.10⁹ Units
49204|NCT03799835|Drug|Atezolizumab|IV perfusion
49205|NCT03799822|Drug|Rivaroxaban 10 MG Oral Tablet|replacement of warfarin by rivaroxaban
49206|NCT03799822|Dietary Supplement|MK-7 2000µg thrice weekly|dietary supplement of vitamin K2 MK-7 2000µg thrice weekly
49207|NCT03799822|Drug|Vitamin K Antagonist - Drug|treatment with a vitamin K antagonist
49208|NCT03799809|Drug|Intrabronchial Voriconazole instillation|Efficacy of intrabronchial voriconazole instillation for inoperable pulmonary aspergilloma
49209|NCT03799796|Behavioral|Flash Glucose Monitoring with Online Peer Support|Hispanic Adults who are Spanish-Speaking with type 2 diabetes who are not using insulin will be asked to use flash glucose monitoring and to sign up for an moderated online peer support group where they can ask questions and share progress.
49210|NCT03799783|Drug|dexmedetomidine|To administrater dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete
49211|NCT03799770|Diagnostic Test|measurment of optic nerve sheath diameter by ultrasound|Sonographic measurement of ONSD was performed with the same manner of previous studies. Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the ﬁnal ONSD value was calculated by averaging 4 measured values.
49212|NCT03799757|Drug|40ml of 0.25% bupivacaine|
49213|NCT03799757|Drug|40ml of 0.9% normal saline|
49214|NCT03799744|Genetic|VCN-01|Dose level 1: 3.3x10^12 viral particles/patient and Dose level 2: 1x10^13 viral particles/patient
49215|NCT03799744|Biological|Durvalumab|Dose: 1500 mg Q4W
49216|NCT03799731|Drug|GM102 antibody|GM102 7 mg/kg weekly
49217|NCT03799731|Drug|Trifluridine/Tipiracil|Lonsurf 35 mg/m² twice daily during 10 days per cycle
49218|NCT03799718|Biological|NurOwn (MSC-NTF cells)|Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors
49219|NCT03799692|Drug|Chemotherapy|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1, 8, 15.~Drug: Carboplatin AUC=2 iv, d1, 8, 15."
49220|NCT03799679|Drug|Chemotherapeutic Agent|"Drug: Nanoparticle Albumin-Bound Paclitaxel Nanoparticle Albumin-Bound Paclitaxel 125mg/m2, iv, d1. Patients will receive this as a single-agent for the first twelve weeks, then followed by epirubicin in combination with cyclophosphamide.~Drug: Epirubicin 90 mg/m² given IV~Drug: Cyclophosphamide 600 mg/m² given IV"
49221|NCT03799666|Other|Pulmonary Rehabilitation|Patients will be treated with daily medication prescribed by the physician. Additionally patients will participate in a 12-w.eek community-based pulmonary rehabilitation programme, with two exercise training sessions per week and six psycho-education sessions, managed by a multidisciplinary team, once every two weeks. Patient's families will be invited to participate in the psychoeducational component
49222|NCT03799666|Other|Daily medication|Patients will be treated with daily medication prescribed by the physician and will continue to receive the standard care from the primary care centre team.
49223|NCT03799653|Other|No intervention|This is a prospective observational study, and there is no intervention.
49224|NCT03799640|Other|Standard Yoga|Yoga using standard poses and linear movements
49225|NCT03799640|Other|Multi-directional Yoga|The multidirectional yoga training program will use both simple and complex movement sequences (asana or postures) that include a cognitive component. For example, participants will be taught a movement sequence that includes 16-20 yoga postures that increase in difficulty as the training progresses.
49226|NCT03799640|Other|Educational Control|Lectures on health and fitness
49227|NCT03799627|Drug|Vadadustat|Vadadustat Tablets 150 mg
49228|NCT03799627|Drug|Epoetin Alfa|Epoetin Alfa
49229|NCT03799627|Drug|Vadadustat TIW|Oral vadadustat
49230|NCT03799614|Device|RMBand lower dose|Light-weight portable device that delivers low dose vibration (frequency of 80 Hz) to the arm
49231|NCT03799614|Device|RMBand higher dose|Light-weight portable device that delivers higher dose (frequency of 160 Hz) vibration to the arm
49350|NCT03798626|Drug|Ramucirumab|10 mg/mL concentration; administered IV
49233|NCT03799601|Drug|Docetaxel|a chemotherapy medication used to treat a number of types of cancer.This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer.It may be used by itself or along with other chemotherapy medication.It is given by slow injection into a vein.
49234|NCT03799601|Drug|Carboplatin|Carboplatin is used to treat a number of forms of cancer. This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma. It may be used for some types of testicular cancer but cisplatin is generally more effective.
49235|NCT03799588|Device|Biphasic Chest Cuirass|Patients will have a esophageal manometer placed after intubation and before initiation of negative pressure ventilation.
49236|NCT03799575|Behavioral|Transmission Electron Microscopy analysis|Morphology of two vitreal side of Internal Limiting Membrane in contact
49237|NCT03799562|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial. Placebo will be identical to the pregnenolone arm, except placebo will be dispensed.
49238|NCT03799562|Drug|Placebo|Same as pregnenolone (active study medication), except placebo dispensed.
49239|NCT03799536|Drug|Sotalol|Sotalol, Tablets,160 mg, manufactured by Pharmtechnology LLC, Belarus
49240|NCT03799536|Drug|Sotalex|Sotalex, Tablets,160 mg, manufactured by Bristol-Myers Squibb GmbH & Co. KGaA, Germany
49243|NCT03799510|Biological|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50μg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
49244|NCT03799510|Drug|GLA-SE solution|The lot concentration 10μg/mL for injection of 2.5μg GLA-SE/injection.
49245|NCT03799484|Drug|Botulinum toxin type A|Botulinum toxin type A will be administered to both sides
49246|NCT03799484|Drug|2.5% lidocaine/2.5% prilocaine|2.5% lidocaine/2.5% prilocaine will be applied to one side of the forehead
49247|NCT03799484|Device|petrolatum ointment|petrolatum ointment will be applied to one side of the forehead
49248|NCT03799458|Device|Active High-definition transcranial direct current stimulation (HD-tDCS)|Active HD-tDCS delivers active current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates.
49249|NCT03799458|Device|Sham High-definition transcranial direct current stimulation (HD-tDCS)|Sham HD-tDCS delivers sham current through 2-10 electrodes held against the scalp with a lycra cap at specified 10-20 electroencephalography (EEG) coordinates
49250|NCT03799445|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
49251|NCT03799445|Biological|Ipilimumab|Given IV
49252|NCT03799445|Biological|Nivolumab|Given IV
49253|NCT03799445|Other|Quality-of-Life Assessment|Ancillary studies
49254|NCT03799445|Other|Questionnaire Administration|Ancillary studies
49255|NCT03799432|Other|COAST-IS|COAST-IS has been designed to equip organizations with the knowledge, motivation, and skill needed to thoughtfully match implementation strategies to identified determinants by applying intervention mapping. The COAST-IS intervention will include four different modes of delivery: 1) dissemination of educational materials; 2) five web-based interactive education sessions on the need for tailoring implementation strategies and the application of intervention mapping; 3) site visits to discuss change objectives necessary to successfully implement trauma-focused cognitive behavioral therapy; and 4) organizational coaching related to using an intervention mapping approach.
49256|NCT03799432|Other|TF-CBT Learning Collaborative|The learning collaborative model was adapted from the Breakthrough Series Collaborative model. Leadership of the collaboratives includes experts in evidence-based practices, implementation, and quality improvement. Main components include: 1) three face-to-face learning sessions (2-days each) that provide clinical training; 2) post-learning session action periods structured to facilitate therapists' application of learned skills; 3) a secure website to facilitate faculty-to-participant and peer-to-peer learning and document use of quality improvement methods; 4) fidelity monitoring and coaching; 5) a senior leader track supporting organizational change; 6) monthly outcomes monitoring; and 7) sustainability planning.
49257|NCT03799419|Behavioral|Cognitive bias modification for interpretation bias|Eight sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
49258|NCT03799419|Behavioral|Psychoeducation|Eight sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
49259|NCT03799419|Behavioral|Approach avoidance training|Eight sessions of this computerized training program will be used to train approach tendencies, following previously validated procedures (Najmi, Kuckertz, & Amir, 2010). During the training program, participants will view a series of these images and be prompted to push or pull a joystick according to prompts on the screen, instead of the content of the picture. Avoidance will be stimulated through both pushing away (images on the screen will decrease in size upon the joystick being pushed), and approach will be stimulated through pulling towards pictures (images will increase in size to simulate approach).
49260|NCT03799419|Behavioral|Inactive sham approach avoidance training|Eight sessions of the approach avoidance training will be administered, however the percentage of push vs pull trials will be altered in this sham version of the training.
49261|NCT03799406|Drug|Cholecalciferol|Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis
49262|NCT03799406|Other|Placebo|Placebo supplementation during acute episode of bronchiolitis
49349|NCT03798626|Drug|FOLFIRI|Irinotecan [20 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]
49263|NCT03799393|Behavioral|CIAS (Computer Intervention Authoring Software)|This is a digital application that allows families to interact with a tablet computer to receive educational information customized to the patient's age and size. allows authors to develop screening, assessment, and intervention tools for patients without requiring new programming. The CIAS intervention is programmed using tailored branching logic to allow a custom path through the intervention based on the respondent's answers. Delivery of the intervention uses a two-dimensional avatar narrator character that mimics the conversational structure of person-delivered brief interventions.
49264|NCT03799393|Behavioral|Standard Printed Discharge Instructions|Patients/families will receive standard, printed discharge instructions. This is a 5 page general document from our Injury Prevention Center that describes appropriate car restraint safety for all age groups, not specific to the child enrolled.
49265|NCT03799380|Dietary Supplement|Gatorade G2|Gatorade (G2), 20 oz. bottle, daily through the entire course of radiation therapy (approximately 5-7 weeks)
49266|NCT03799380|Dietary Supplement|Standard of care nutritional support|Standard of care nutritional support
49267|NCT03799367|Device|Drug delivery during breastfeeding|This study aims to give a vitamin B12 supplement to babies during breastfeeding. 30 mother-infant pairs will be recruited. The supplement will be placed into a nipple shield, both of which are commercially available, and the mother will breastfeed her baby as usual. Before and after the feed, we will 1) collect a small blood sample from the baby to see whether the vitamin levels in the infant have increased, 2) ask the mother to participate in two short interviews about her expectations and experiences using the Therapeutic Nipple Shield.
49268|NCT03799354|Other|Maximal strenght training (MST) plus endurance training (ET)|"Patients will perform an addictive out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions) consisting of:~MST- It will consist of four sets of five repetitions on a leg-press with a focus on the rate of force development during the concentric contraction of the quadriceps from a 90° to legs complete extension. The load will be 85-90% of 1RM. When a patient will be able to perform more than five repetitions in a set, the load will be increased. All strength training will be performed on a seated horizontal leg press.~ET - A cycling session will follow the MST and last 40 minutes at constant-load, starting from a load intensity corresponding to patient specific AT. The intensity will be gradually increased with a symptom-based progression."
49269|NCT03799354|Other|Endurance training (ET)|"Patients will perform a usual out-patients rehabilitative treatment of 8 weeks (3 times/week, ≥20 training sessions). They will perform ET by cycling sessions that will last 40 minutes/each at constant-load, starting from a load intensity corresponding to patient specific AT, assessed during the baseline incremental test. The intensity will be gradually increased during the sessions with a symptom-based progression, according to the protocol by Maltais and coworkers. A 3-min warm-up and cool-down will be provided. Heart rate (HR), blood pressure, oxygen pulsoxymetry, and symptoms by Borg CR10 scale will be monitored at the beginning and end of each session.~Out of the training-days, both groups will continue their normal daily living with modest regular activity, as recommended by their physician."
49270|NCT03799341|Behavioral|Prize-Based Contingency Management|"Participants assigned to Prize-based Contingency~Management (PBCM) conditions will receive PBCM as an adjunct to TAU. PBCM will involve twice weekly one-on-one sessions with a provider for 12-weeks. During each session, a urine specimen provided by the patient will be tested for cocaine using a point-of-care dip-test. Results of point-of-care testing will be shared with the patient and negative results will be reinforced with draws from a fish bowl containing 500 paper slips, 250 of which award small, large, or jumbo prizes (remaining slips deliver words of encouragement). Patients will be reinforced with a single prize draw for their first negative specimen; an additional prize draw will be added for each consecutive negative result (up to 8~prize draws per session). Abstinence-contingent prize draws will be reset to one upon either a positive test result or unexcused, missed appointment."
49271|NCT03799341|Behavioral|Treatment As Usual Outpatient Substance Use Treatment|All participants will receive treatment as usual outpatient substance use services during the 12-week treatment interval. TAU will specifically entail recommended participation in at least two outpatient group and/or individual psychotherapy encounters per week within the Center for Treatment of Addictive Disorders (CTAD) at VA Pittsburgh Healthcare System. Participants will additionally continue any previously prescribed pharmacotherapy for substance use and/or other mental health conditions, if applicable.
49272|NCT03799328|Other|multi-OIT|low dose OIT to multiple foods
49273|NCT03799315|Drug|Nicotine Replacement Therapy|All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
49274|NCT03799315|Behavioral|Counseling|All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
49275|NCT03799302|Behavioral|SIC Coaching|Sites receiving consultation to implement either TFCO or MDFT will also receive consultation on their implementation fidelity as measured and tracked by the SIC.
49276|NCT03799289|Behavioral|Behavioral weight loss followed by yoga instruction|12-week standard behavioral weight loss program followed by a 12-week yoga intervention
49277|NCT03799289|Behavioral|Behavioral weight loss followed by cooking/dietary education instruction|12-week standard behavioral weight loss program followed by a 12-week cooking/dietary education intervention
49278|NCT03799276|Other|Opticare study|"Each patient will be evaluated by~An HIV physician~A nurse~A social worker~A psychological therapist~A cultural mediator/member of patients community if needed for migrants~Following these interviews and visits, a multisciplinary team will define for each patient an individualized OPTICARE program based on the following items: clinical, psychological/psychiatric, social status and follow up visits will be planned with the patient.~Regular (Day 15 and monthly) phone calls will be set up during the first six months of the OPTICARE program, to assess the clinical status and ART adherence.~Patients will have their medical, biological and social status assessed through visits at W4, W12, W24, W36 (medical and social status only) and W 48 with all members of the OPTICARE team."
49308|NCT03798951|Other|Prehabilitation|"The patients included in the treatment group will follow a prehabilitation program, based on a physiotherapist, nutritionist and psychologist evaluation. All the treatments will be tailored according the characteristics of each single patient.~The program will have a duration of, at least, 4 weeks."
49279|NCT03799263|Procedure|evaluation group|Recordings Pneumologic assessment Severity grades (I-IV: old GOLD and A-D: new GOLD) Smoke History Drug therapy Comorbidities 6MWT performed within previous 10-14 months, if available. Measurements Standard exams usually performed at Rehab Center Lung Function tests and diffusing capacity of the lung for carbon monoxide Arterial Blood Gases Dyspnoea Health Status and Health Related Quality of Life Daily activity Lower limb muscle strength Exercise capacity
49280|NCT03799250|Drug|Ringer lactate|Comparison between fluid maintenance in PACU compared to a bolus based goal directed hemodynamic therapy in the PACU
49281|NCT03799250|Other|standard care|standard care
49282|NCT03799237|Other|GOS trap and dengue NS1 antigen kit|The GOS trap lure and sticky surfaces to trap gravid Aedes mosquitoes. Three GOS traps will be placed on every 3 floors of the residential blocks. The traps will be changed weekly. Trapped Aedes mosquitoes will be identified to species. The mosquitoes will then be dissected, to remove the abdomen from the thorax. Five to seven abdomens of the same mosquito species will be pooled and tested for dengue NS1 antigen using the SD Biosensor Standard Q dengue NS1 antigen test kit. If the pool is tested positive for dengue NS1, the head and thorax of the respective abdomens will be subjected to the same procedure for dengue NS1 antigen test, individually. This may allow us to identify a focus where there could be dengue-infected individuals. Flyers/Posters will be disseminated besides, house-to-house approach to inform the residents of the findings and apartment blocks where these mosquitoes were found. The apartment management will also make use of social media disseminate this information.
49283|NCT03799224|Drug|Decitabine|Decitabine 200mg.m-2.d-1 intravenously on days -12 and -11
49284|NCT03799224|Drug|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
49285|NCT03799224|Drug|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Semustine (Me-CCNU, 250 mg·m-2) orally once on day -3
49286|NCT03799211|Behavioral|Motivational Interviewing|Phone call using motivational interviewing technique
49287|NCT03799211|Behavioral|Treatment as Usual|will receive a regular study phone call after three months
49288|NCT03799198|Other|Weight Management Program (WMP)|As part of usual care, participants will: 1) Discuss and choose one of three diet options: protein-sparing modified fast, Mediterranean, or meal replacement. 2) Be referred to a nutritionist appointment. 3) Initiate a series of twelve monthly study visits in the context of shared medical appointments (SMAs) covering nutrition, physical activity, appetite control, sleep issues, and anxiety/depression/stress. 4) Be referred to an exercise physiologist for a personalized physical activity program. 5) If assessed relevant by the study clinician, be referred to a mental health specialist and/or sleep clinic.
49289|NCT03799198|Drug|Medication for chronic weight management (Rx)|"Following listed 5 drugs will be administered as prescribed by the study doctor:~1) Orlistat (Xenical® pills, per os [p.o.; by mouth]). 2) Lorcaserin or lorcaserin extended-release (Belviq®/Belviq XR® pills, p.o.). 3) Phentermine/topiramate extended-release (Qsymia® pills, p.o.). 4) Naltrexone/bupropion extended-release (Contrave® pills, p.o.). 5) Liraglutide 3.0 mg (Saxenda® injections, subcutaneously [under the skin])."
49290|NCT03799172|Drug|Echinocandin treatment|Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care
49291|NCT03799172|Drug|Triazole treatment|"Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida."
49292|NCT03799146|Behavioral|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
49293|NCT03799146|Other|Waiting List|Waiting List control group
49294|NCT03799133|Device|Florence device|The Florence catheter will be placed at the beginning of the surgery and up to 72 hours in ICU.
49295|NCT03799120|Drug|Tamsulosin BID|comparison of once daily versus twice daily tamsulosin
49296|NCT03799120|Other|Placebo|Placebo
49297|NCT03799094|Drug|Vitamin C|Participants will receive intravenous vitamin C therapy at the indicated dose.
49298|NCT03799094|Drug|Tyrosine kinase inhibitor|Participants will receive Tyrosine kinase inhibitor therapy in cycles: continuous treatment at the indicated dose.
49299|NCT03799081|Procedure|Fetoscopy|Fetoscopy is a procedure that enables viewing of the fetus through use of a hysteroscope
49300|NCT03799068|Other|suprazygomatic maxillary nerve block|bilateral Suprazygomatic maxillary nerve block is performed before surgery in anaesthetized children, after aseptic preparation of the skin. The patient is in supine position with the head in neutral position. The puncture site is at the frontozygomatic angle, at the junction of the upper edge of the zygomatic arch and the frontal process. A 24G needle is attached to a syringe containing the local anaesthetic. It is advanced to reach the greater wing of sphenoid at approximately 20 mm depth, then withdrawn a few millimetres and redirected toward the nasolabial fold in a 20° forward and 10° downward direction. The progression in the pterygopalatine fossa is 35 to 45 mm. Loss of resistance after passing through the temporalis muscle assisted in determining the puncture depth. After a negative blood aspiration test, the calculated dose of the local anaesthetic is injected on each side.
49301|NCT03799068|Other|surgical site infiltration|peri-incisional infiltration of bupivacaine around the incision site given by the surgeon on an anesthetized patient before the incision is done.
49302|NCT03799042|Device|Virtual Reality|Subjects will wear a 3D glass and watch 3D pictures (or video) of landscapes or tourist sites in Hong Kong.
49303|NCT03799042|Behavioral|Inter-generation interaction|Secondary school student will play games and chats with secondary school students. Games involve identifying famous landscapes or tourist sites in Hong Kong
49304|NCT03799029|Other|Cognitive training|Participants will train at home during 25 sessions (about 45 minutes each) over a maximum of 5 weeks. Investigators will verify compliance via Internet and call participants and their legal guardians once a week. A reward system will be established with participants. Five sessions of metacognition (1 hour each) are added.
49305|NCT03799003|Drug|ASP1951|Intravenously (IV)
49311|NCT03798912|Combination Product|Intravenous octreotide and RaniPill capsule|Intravenous injection of 100-mcg of octreotide on a first study day, and administration of a RaniPill capsule loaded with 100 mcg of octreotide on a second study day. Serial blood samples will be collected over the following 4 h for pharmacokinetic analysis of the bioavailability of octreotide a) injected intravenously and b) delivered directly into the jejunal wall by the RaniPill capsule.
49312|NCT03798899|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
49313|NCT03798899|Drug|Normal Saline|Placebo
49314|NCT03798886|Other|natural cycle|When follicle is ready for ovulation, we will use this injection by intra-dermal route
49315|NCT03798886|Other|modified natural cycle|we will use that drug in the natural modified transfer group after embryo transfer
49316|NCT03798886|Other|embryo transfer|we will do transfer when the endometrium is ready
49317|NCT03798873|Device|FeelWell™ Compression garment|"Registered FDA class I device:~The FeelWell™ Compression garment is a custom-made orthopedic abdominal binder with full or half-body support. The garments are made of 70% polyamide and 30% elastane and OEKO-TEX certified confirming human-ecological safety of textiles. The company uses a wrap knitting to ensure an optimal compression and durability. The garment has two 360 degrees whalebones in the front and two in the back to provide support for the posture, reinforcing compression on the abdomen and lower-back."
49318|NCT03798873|Behavioral|Increase Mobility|Subjects will work with exercise physiologist and physical therapist to increase mobility, strength and activity
49319|NCT03798860|Diagnostic Test|blood samples|For performing the Luminex SPA test, 7.5 ml of patient whole blood are collected from a peripheral vein.
49320|NCT03798847|Device|Journey II XR TKA|Journey II XR Total Knee System
49321|NCT03798834|Drug|Fascia iliaca block (FIB)|ultrasound-guided Fascia iliaca block
49322|NCT03798834|Other|Spinal anesthesia|Spinal anaesthesia using 2 ml hyperbaric bupivacaine 0.5%
49323|NCT03798821|Dietary Supplement|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (100MG)|six weeks of consumption
49324|NCT03798821|Dietary Supplement|Lactobacillus rhamnosus, Lactobacillus casei y Bifidobacterium longum (300MG)|six weeks of consumption
49325|NCT03798821|Dietary Supplement|maltodextrin and sucrose (PLACEBO)|six weeks of consumption
49326|NCT03798808|Other|Consumption of fruits, vegetables and dairy products|Family Nutriathlon was an eight-week, family-based nutrition program where children and their parents were encouraged to reach individual and team goals with respect to the quantity and variety of fruit, vegetable and dairy product consumption.
49327|NCT03798782|Procedure|Ross procedure|The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.
49328|NCT03798782|Procedure|Conventional aortic valve replacement|The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
49329|NCT03798769|Other|Supportive Oncology Care at Home|"Entails the following:~patient-reported symptoms, vital sign, and weight monitoring with appropriate triggers to phone calls and home visits by Medically Home based on a clinician-derived algorithm;~scheduled nursing visits for intravenous (IV) hydration during the course of chemotherapy;~regular communication with oncology clinicians regarding care delivered at home to ensure continuity of care."
49330|NCT03798743|Drug|Sintilimab Combined With Docetaxel|Sintilimab 200mgi.v q3w Docetaxel 75mg/m2 i.v q3w
49331|NCT03798730|Behavioral|Solid Model|"Cake and biscuit will be used, with the amount of protein varied to study the effect on perception of the products (using sensory methods of rating drying and discrimination tests which is the stronger in drying)"
49332|NCT03798730|Behavioral|Liquid Model|"Intervention Description: To study the effect of protein denaturation on perception of whey protein beverages using sensory methods (rating drying as well as discrimination tests which is the stronger in drying). Measuring mucoadhesion via protein content remaining in saliva following swallowing of whey protein beverages."
49333|NCT03798717|Diagnostic Test|Heating|Warm water immersion
49334|NCT03798704|Diagnostic Test|IFA, LIAISON|Comparison of two diagnostic serological tests - IFA and LIAISON.
49335|NCT03798691|Biological|Shingrix|"Biological: SHINGRIX~SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized glycoprotein e (ge) antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later.~Other Name: Recombinant zoster vaccine"
49336|NCT03798678|Drug|Carfilzomib|Given IV
49337|NCT03798678|Drug|Dexamethasone|Given PO
49338|NCT03798678|Drug|Glutaminase Inhibitor CB-839 Hydrochloride|Given PO
49339|NCT03798665|Drug|Pegfilgrastim（PEG-rhG-CSF）|From the first chemotherapy cycle using PEG-rhG-CSF (which can be any chemotherapy cycle of the patient), record the use of PEG-rhG-CSF in this cycle and each subsequent chemotherapy cycle, including dosage, administration time and dosing frequency
49340|NCT03798652|Device|Research CMR scan|CMR scanning at a 3Tesla scanner at King's College London
49341|NCT03798652|Device|Research 3D transthoracic echocardiogram|The scan is required to assess left ventricular systolic function
49342|NCT03798652|Other|6-minute walk test|Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
49343|NCT03798639|Biological|Ipilimumab|Given IV
49344|NCT03798639|Biological|Nivolumab|Given IV
49345|NCT03798639|Radiation|Radiation Therapy|Receive radiation therapy
49346|NCT03798626|Drug|Gevokizumab|60 mg/mL concentration; administered intravenously (IV)
49347|NCT03798626|Drug|Bevacizumab|25 mg/mL concentration; administered IV
49348|NCT03798626|Drug|Modified FOLFOX6|Oxaliplatin [5 mg/mL concentration; administered IV], leucovorin [10 mg/mL concentration; administered IV] (or levoleucovorin [10 mg/mL concentration; administered IV]), and 5-fluorouracil [50 mg/mL concentration; administered IV]
49353|NCT03798613|Device|Apple Watch 4 Series Device|tracings from the apple watch 4 series watch
49354|NCT03798613|Device|Continuous Telemetry Monitor|tracings from the continuous telemetry monitor
49355|NCT03798600|Drug|Caspofungin|In accordance with routine clinical practice, Caspofungin will be given at the loading dose of 70 mg followed by 50 mg daily (for people < 80 kg body weight). No dose reduction will be performed in Child-Pugh score A or B. Duration of therapy will be performed in accordance with ESCMID guidelines and clinical conditions.
49356|NCT03798561|Drug|ASN008 TG|ASN008 TG
49357|NCT03798561|Drug|Placebo TG|Placebo TG
49358|NCT03798548|Behavioral|Brief Bedside CBT|4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
49359|NCT03798522|Procedure|bilateral ultrasound guided erector spinae plane block|ESPB on both sides at T7 before GA
49360|NCT03798522|Drug|Nalbuphine|in nalbuphine for analgesia after GA
49361|NCT03798509|Drug|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
49362|NCT03798496|Procedure|Open reduction and internal fixation|Open reduction of the Galeazzi fracture dislocation with a plate.
49363|NCT03798483|Other|Individualised exercise|The intervention will be comprised of up to 6, one-to-one physiotherapy sessions, over a maximum duration of 3 months. 1 or 2 extra sessions are allowed if deemed essential by the participant's physiotherapist. Less than 6 physiotherapy sessions can be agreed with the participant if they have achieved their goals. Throughout this time participants will be required to perform an exercise programme a minimum of 3 times per week. The exercise programme aims to increase leg muscle strength and facilitate a return to the participant's usual activities. It may include hopping and change of direction tasks if these are activities the participant would normally do. Behavioural change techniques to increase participant adherence to the exercise programme will also be used.
49364|NCT03798470|Behavioral|Peer Addiction Counseling|After identification, a 24/7 on-call FRC was paged and met with the patient in the ED. The patients were offered recovery services at the bedside by the FRC. The research team members offered voluntary participation and obtained informed consent to enrolling a longitudinal study looking into the success of his intervention. Patients did not need to participate to be eligible for counseling and resources from AVOR. The FRCs counselled and engaged the patient along with the family to offer a variety of services including active recovery coaching, group treatment modalities, family support services and transportation. After he initial encounter in the ED, the FAVOR team re-engaged the participant by phone or in person the next day and gradually increasing intervals thereafter.
49365|NCT03798457|Other|No intervention|In this study there is no intervention
49366|NCT03798444|Radiation|dual energy X-ray absorptiometry|BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis
49367|NCT03798444|Radiation|lateral spine imaging from T4 to L4 on X-ray|VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio <0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
49368|NCT03798431|Behavioral|M-ROCC|"LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks & 120 minutes/wk.~MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness."
49369|NCT03798418|Behavioral|elastic band strengthening exercise|2-3days per week(150min per week)
49370|NCT03798418|Dietary Supplement|diet counseling|each patients in this group will receive4-5times diet counseling
49371|NCT03798405|Behavioral|Proactive Analgesic Inpatient Narcotic-Sparing|Medications suggested to the physician with enhanced ease of ordering.
49372|NCT03798392|Device|Self-pressurizing Air Q blocker mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
49373|NCT03798392|Device|Baska mask measuring airway seal pressure of studied supra-glottic airway devices 10 minutes after insertion|comparing the airway seal pressure 10 min after insertion of each devices .
49374|NCT03798379|Other|Exercise|Strengthening, balance and aerobic exercises were explained to the patients examined before chemotherapy sessions and demonstrated by applying on the patient.
49375|NCT03798366|Drug|GLPG1690|film-coated tablets of GLPG1690 for oral use
49376|NCT03798366|Drug|Placebo|film-coated tablets of matching placebo for oral use
49377|NCT03798353|Combination Product|PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|A matrix-cell construct (PeriCord) will be placed on the ischemic area of the non-candidate revascularization area during a surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization.
49378|NCT03798353|Procedure|Surgery by sternotomy|The patient will undergo surgery by sternotomy to perform the surgical revascularization of the arteries candidates for revascularization. No additional procedure will be performed only the by-pass.
49379|NCT03798340|Other|Vibratory perturbed task-specific movement training|The perturbation-based pinch task training was conducted with the affected hand placed on the pinch device. The horizontal vibratory perturbation was generated for a total of 20 minutes by two recoil-type actuators with a frequency of 30 Hz and an amplitude of 2 mm, and intermittent exposure (10 s per 30 s). Each training session was divided into eight cycles with a training interval of 2 min per 2.5 min.
49380|NCT03798340|Other|Traditional task-oriented facilitation|Reach-to-grasp training and hand release training
49381|NCT03798340|Other|Sensorimotor training|Targeted to goals that are relevant to the sensorimotor facilitation of the patient
49382|NCT03798327|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
49383|NCT03798314|Biological|Nivolumab|Given IV
49384|NCT03798314|Drug|Pomalidomide|Given PO
49385|NCT03798301|Biological|CMV-specific T-cells|Naturally occurring, allogeneic donor lymphocytes derived from a leukapheresis or a whole blood product, enriched for CMVspecific CD4+ and CD8+ T-cells
49386|NCT03798288|Behavioral|selfBACK|Participants will use the selfBACK system and app in addition to receiving usual care
49387|NCT03798288|Other|Usual care|Participants will receive usual care
49388|NCT03798275|Dietary Supplement|coffee|2 g Nescafe Clasico contains approximately 65 mg caffeine
49389|NCT03798262|Other|Gluten|Tereos
49390|NCT03798262|Other|Placebo|Whey protein from Nestlé Healthy Science
49391|NCT03798249|Other|Gluten|Tereos
49392|NCT03798249|Other|Placebo|Nestlé Health Science
49393|NCT03798236|Drug|PBF-1650 oral capsules|Adenosine A3 receptor (AA3R) antagonist
49394|NCT03798236|Drug|Placebo oral capsule|solid microcrystalline cellulose
49395|NCT03798223|Procedure|SLT|A drop of Pilocarpine 4% is administered to the eye 20 minutes before SLT. Immediately before SLT a drop of Tetracaine hydrochloride 1% is administered. Selective laser trabeculoplasty is conducted through a Latina lens, in a fashion determined by randomization to a study arm (see description).
49396|NCT03798210|Dietary Supplement|Lactobacillus reuteri|Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
49397|NCT03798210|Dietary Supplement|Placebo|Placebo
49398|NCT03798197|Drug|30 mg estetrol (E4)|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or at the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (sequence AB), or Treatment B followed by Treatment A (sequence BA).
49399|NCT03798184|Procedure|Non-carious cervical lesion restoration|Restoration of non-carious cervical lesions with Prime&Bond Active in self-etch or selective-etch mode with or without bioglass
49400|NCT03798158|Other|Multidisciplinary Dyspnea Profile questionnaire|Multidisciplinary Dyspnea Profile questionnaire at the beginning and the end of an hospitalization
49401|NCT03798145|Procedure|Surgical Retinotomy|Surgical removal of small areas of retinal to increase outflow through the posterior drainage pathway.
49402|NCT03798132|Diagnostic Test|laparoscopy|evaluation of peritoneal carcinomatosis by laparoscopy
49403|NCT03798119|Drug|Tenofovir Alafenamide|Subjects in this group will switch prior nucleot(s)ide analogs to Tenofovir Alafenamide 25 mg/day for 96 weeks
49404|NCT03798106|Drug|Durvalumab, pazopanib|Durvalumab 1500mg IV 1hr q3weeks Pazopanib 800mg QD PO q3wwks
49405|NCT03798093|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
49406|NCT03798093|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
49407|NCT03798080|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
49408|NCT03798080|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
49409|NCT03798080|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
49410|NCT03798054|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
49411|NCT03798054|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
49412|NCT03798054|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
49413|NCT03798054|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
49414|NCT03798041|Behavioral|Debridement Within 24 Hours After Surgery|Debrided within 24 hours after surgery
49415|NCT03798028|Biological|UC-MSCs|The UC-MSCs will be administrated by intravenous injection at the dose of 1×10^6 cells/kg.
49416|NCT03798015|Other|mitral valve surgery|assessment of ischemic or hemorrhagic stroke subsequent to mitral valve surgery
49417|NCT03798002|Other|Neuro-muscular exercise training Group|"Training takes place 3 days a week for 8 weeks follow up, under the supervision of physical therapist A training session lasts for 40 minutes, and consists of three parts.~PART 1:Warming up:~warm-up period consists of ergometer cycling for 10 minutes~PART 2: Circuit program:~comprises four exercises, core stability/postural function; postural orientation; lower extremity muscle strength; and functional exercises. Each exercise is performed 2-3 sets 10-15 repetitions.~PART 3:Cooling down:~The cooling down part consists of walking exercises forward and backwards, about 10 meters in each direction, in front of mirror (mobility exercises for the lower extremity muscles for a total of about 10 minutes. Changes in patient's symptom assessed by structural questionnaire"
49418|NCT03798002|Other|quadriceps training program|"Apply Tens (10min+ hot pack 7-10min) Before excercise ROM,Quadriceps and hamstring stretching exercise's and strengthening exercises.~4th-6th week (in addition): Straight leg raise, Quads over a roll, Hamstring curls. 7th and 8th week (in addition): Elastic band exercise, Hamstring curls, Quads chair, isometric strengthening All exercises are performed in set of 10 repetitions. 1 set of all exercises was twice a day for first 3 week, and 2 sets twice a day until 6th week and then 3 sets twice a day until 8th week"
49419|NCT03797989|Biological|P. vivax infected inoculum (parasitised red blood cells)|In the first controlled human malaria infection (CHMI, Phase A), inoculation of parasitised red blood cells will be at three different doses (1 vial, 1:5 dilution, 1:20 dilution). The optimal inoculation dose will then be selected and administered to all participants in each of the second and third CHMI.
49420|NCT03797976|Device|MIP and MEP|Pre-op, Post-op of, 1 month after surgery, 3 months after surgery
49421|NCT03797963|Device|PBM+ACB|Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
49422|NCT03797963|Device|ABB+ACB|Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
49423|NCT03797950|Behavioral|Voice Reminder (Group A)|Woman with a recent delivery will be contacted via mobile phone by a central study staff member to encourage them to vaccinate their newborn with OPV0 and BCG, and information on where and when vaccines are available in this community will be provided. Community volunteers will receive small incentives for documenting births in the community.
49424|NCT03797950|Behavioral|Cash Incentive (Group B)|Mobile phone based monetary incentives will be provided to community volunteers and to women with a recent delivery who vaccinate newborns with OPV0 and BCG on time. Community volunteers will receive small incentives for documenting births in the community.
49425|NCT03797937|Other|Magnetic resonance imaging (MRI)|MRI scanner
49426|NCT03797924|Drug|Receive ICBN with ropivacaine|ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
49427|NCT03797924|Behavioral|No ICBN block|The site of injection will be prepped with tinted chlorhexidine
49428|NCT03797911|Combination Product|Active resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Activated resistive capacitive monopolar radiofrequency is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
49429|NCT03797911|Combination Product|Inactive resistive capacitive monopolar radiofrequency with physiotherapeutic techniques and pain education|Disactivated resistive capacitive monopolar radiofrequency inactived is applied to the patient along with the conventional treatment of physiotherapeutic techniques and pain education.
49430|NCT03797898|Other|Parent Coach|The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
49431|NCT03797885|Other|No treatment given|No treatment is administered to the participants for this study
49432|NCT03797872|Drug|Methotrexate|Methotrexate up to 25mg/week as tolerated po or sc
49433|NCT03797872|Drug|Sulfasalazine|Sulfasalazine up to 3g daily po
49434|NCT03797872|Drug|Leflunomide|Leflunomide 10-20mg daily po
49435|NCT03797872|Drug|Methylprednisolone|For IA or IM injection 20-120mg
49436|NCT03797872|Drug|Triamcinolone|For IA or IM injection 20-120mg
49437|NCT03797859|Procedure|Apneic ventilation|Ventilation by THRIVE
49438|NCT03797846|Procedure|combined glaucoma surgery|combined procedure with trabeculectomy/ ExPress device implantation with simultaneous cataract removal
49439|NCT03797833|Procedure|Spinal Anaesthesia|Spinal anaesthesia with Bupivacain 2.5 mg and Sufentanil 5 µg
49440|NCT03797820|Other|Our study type is observational|Our study type is observational
49441|NCT03797807|Procedure|MINST|A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
49442|NCT03797807|Procedure|MIST|A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
49443|NCT03797807|Diagnostic Test|GTI subgroup (Geometrical/Thermal Imaging)|Geometrical/Thermal Imaging
49444|NCT03797794|Device|Pulsating Electrostatic Field|A pulsating electrostatic field is generated by the New Health 9000 (Akern). During the session the patients sits on a chair which contains the apparatus for 30 minutes.
49445|NCT03797794|Device|SHAM Pulsating Electrostatic Field|The same apparatus which produces the pulsating electrostatic field contains a 'sham-inlet'. This inlet will be used as placebo.
49446|NCT03797781|Other|Lower limb immobilisation (leg brace) with varying levels of protein intake|Single leg immobilisation via leg brace and crutches, the groups have different amounts of protein intake
49447|NCT03797768|Behavioral|Behavioural-FCHV Visit|Female Community Health Volunteer will visit selected households on average 3 times a year for providing health promotion messages on improving lung health status and avoiding risk factors to COPD.
49448|NCT03797755|Radiation|palliative radiotherapy|Radiotherapy for palliating symptoms in stage IV cancer patients
49449|NCT03797729|Drug|Tirofiban|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive Tirofiban(0.05mg/ml) intravenous drip in a dosage of 4ml/hour (patients weight<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
49450|NCT03797729|Drug|Normal saline|Upon being diagnosed as ST Elevation Myocardial Infarction, if informed consent is obtained, patients start to receive normal saline intravenous drip in a dosage of 4ml/hour (patients weight<50kg) or 6ml/hour (patients weight > 50kg) lasting for 24 hours.
49451|NCT03797716|Device|Little Journey app|"The Little Journey app allows children to explore 360-degree hospital environments familiarising and desensitising them to areas and staff they'll see on the day of surgery. Children can visit the day case ward, anaesthetic and recovery rooms where their operation will occur -all while feeling safe in their own home. As the child explores the three areas, they are introduced to animated characters of staff who explain what will happen, the equipment that will be used and how they might feel. Using head tracking technology, the child triggers the animated characters by looking at them; meaning they control the pace of learning and speed at which they progress. The preparatory tool follows a pre-set story-line reflecting what happens from admission to discharge on the day of surgery."
49452|NCT03797703|Drug|Lidocaine Hydrochloride 2% gel enema|Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
49453|NCT03797690|Procedure|Percutaneous needle aponeurotomy|It consists in cutting the fibrotic cord due to the disease and responsible for the flexion contracture, with a needle under local anesthesia. The procedure can be repeated as required during the same session. One to three sessions with at least one-week interval are usually sufficient and will be allowed. It will be performed in outpatient setting by a senior physician experienced in the procedure
49725|NCT03795402|Device|Microneedle Device|Microneedle device will be used for collecting skin samples as a non-invasive method.
49454|NCT03797690|Procedure|Open surgery with limited aponeurectomy|It consists in excision of the fibrotic aponeurosis.It will be performed by hand surgeons under loco-regional anaesthesia during a short hospitalization (1 day stay). Post-operative cares are necessary (analgesics, splint, nursing, physiotherapy)
49455|NCT03797677|Device|MN 4000|Patients who required regular home airway clearance therapy were enrolled in the study and were prescribed therapy with the MN4000. Adherence to the prescribed therapy regimen and patient/caregiver satisfaction with the therapy was assessed. Pulmonary function, was assessed for each subject at baseline, after 1 month and after 3 months of home therapy. Results from the therapy period was compared to the baseline period, during which the subject received their regular airway clearance regimen. Airway Clearance Satisfaction surveys were conducted at baseline, after 1 month, and after 3 months of therapy. Results from the MN4000 therapy period were compared to the baseline period, during which the subject received their regular regimen
49456|NCT03797664|Drug|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 7.5, 15.0 and 22.5g
49457|NCT03797664|Drug|Placebo|Phosphate Buffer Diluent oral solution
49458|NCT03797651|Drug|Standard DAPT|Patient will continue standard treatment (aspirin plus ticagrelor) for 1 year. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day.
49459|NCT03797651|Drug|Very-short DAPT less than 1 month after PCI|Patient will stop aspirin (ticagrelor monotherapy) after discharge or within 1 month. Dosage of ticagrelor would be 90 mg twice a day, and 100 mg of aspirin will be prescribed once a day (during hospitalization).
49460|NCT03797638|Device|Finger Force Manipuladum (FFM)|Tasks performed with the device Finger Force Manipuladum (FFM), to assess abilities such as finger individuation but also fine finger force control, finger movement regularity and speed.
49461|NCT03797625|Drug|Irinotecan|60mg/m2，D1，8
49462|NCT03797625|Drug|DDP|60mg/m2，D1
49463|NCT03797625|Drug|Endostar|15mg/d，d1-d7 civ
49464|NCT03797612|Drug|Brivoligide Injection 660 mg/6 mL|Single preoperative intrathecal injection
49465|NCT03797612|Drug|Placebo 6 mL|Single preoperative intrathecal injection
49466|NCT03797599|Behavioral|20 minutes of mindfulness practice|A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.
49467|NCT03797599|Behavioral|5 minutes of mindfulness practice|A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.
49468|NCT03797599|Other|5 minute audio book|5 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything') per session, for four sessions.
49469|NCT03797599|Other|20 minute audio book|20 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
49470|NCT03797599|Other|25 minute audio book|25 minutes from an audio book by Bill Bryson ('A Short History of Nearly Everything'), per session, for four sessions.
49471|NCT03797586|Other|Electroacupuncture group|Bilateral Tianshu (ST25), Fujie (SP14), Shangjuxu (ST37) will be used in the EA group. With the local skin of the patients was routinely sterilized in a prone position in relaxation, acupuncturists will insert needles into the acupuncture points. For ST25 and SP14, 0.30×50mm or 0.30×75mm needles will be vertically inserted to the muscle layer of the abdominal wall, where participants will feel sharp pain and acupuncturists will feel resistance from the needle tip. For ST37, 0.30×40mm needles will be vertically inserted approximately 15 mm. For all the acupuncture points, needle insertion will be followed by manipulation with an even lifting and twisting method three times to elicit the sensation of deqi. Then paired alligator clips of the EA apparatus will be attached to the needle holders of the bilateral ST25, SP14, and ST37. EA stimulation will be retained for 30 minutes with a continuous wave of 10 Hz and current intensity of 0.5 to 4 mA.
49472|NCT03797586|Other|Sham electroacupuncture group|Bilateral sham ST25, SP14, and ST37 will be used in the SA group. After sterilizing the skin, 0.30×40mm needles will be straightly inserted at the sham points about 2-3mm until they can be fixed on the skin when attached by the alligator clips. No manipulation will be used, and no deqi sensation are elicited for all sham points. The bilateral sham ST25, SP14, and ST37 will be attached by the same EA apparatus with a continuous wave of 10 Hz and current intensity of 0.1 to 0.2 mA for 30 minutes.
49473|NCT03797573|Device|tDCS|tDCS will be applied during 20 minutes with a current of 1 mA preceded and followed by a behavioral assessments (Modified Ashworth Scale and Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3 and F4 and the cathodes over C3 and C4.
49474|NCT03797573|Device|sham tDCS|Indentical to the active tDCS, except that the stimulation is terminated after 5 seconds.
49475|NCT03797560|Other|Ba-Duan-Jin|"Ba-Duan-Jin is a common form of self-health-care Qigong exercise that has been practiced by Chinese people for at least eight hundred years. It consists of eight sets of simple movements. By combining meditation with slow, graceful movements, deep breathing, and relaxation, Ba-Duan-Jin practitioners believe it has the ability to move vital energy (Qi) throughout the body. Ba-Duan-Jin is also considered to be a multicomponent intervention that integrates physical, psychosocial, emotional, spiritual, and behavioral elements. While the biological mechanisms remain unclear, previous clinical trials have demonstrated that Ba-Duan-Jin can improve sleep quality, physical health, and mental health in patients with various chronic diseases"
49476|NCT03797560|Drug|Pregabalin capsule|Pregabalin is one of the three medications (pregabalin, duloxetine, and milnacipran) that have been approved by the Food and Drug Administration (FDA) to treat fibromyalgia in US, and the only medicine that has been approved in China.
49477|NCT03797547|Other|AFLIBERCEPT|Patients will be treated following a real life protocol and according to the French recommendation
49478|NCT03797534|Other|dose regime|The initial dose of the experimental group will be calculated by the Bayesian model.
49479|NCT03797521|Drug|SXC-2023|SXC-2023 oral capsules
49480|NCT03797521|Drug|Placebo|Matching Placebo oral capsules
49481|NCT03797508|Diagnostic Test|ultrasound|To evaluate the accuracy of ultrasound findings in comparison to serum CA125and progesterone in predicting fetal demise in cases of first trimester threatened miscarriage.
49508|NCT03797235|Procedure|Dominant Arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
49726|NCT03795389|Drug|DM199|Single SC dose
49482|NCT03797482|Procedure|Intra-operative Tumor Tissue Biopsy|The changing pattern of gene expression during surgery has never been studied. This could be an effect of acute hypoxia that sets in the tumour during surgery or could be a surgical response. To study these changes happening in the tumour during surgery, we are taking serial biopsies during surgery, one at the beginning, one midway during surgery and one at the end of surgery. These samples will be snap frozen and stored at -80 deg celsius in biorepository for future analysis.
49483|NCT03797469|Dietary Supplement|Vitamin B3|3 tablets of 1000 mg each will be administered orally.
49484|NCT03797469|Dietary Supplement|Pyruvate|2 tablets of 1500 mg each will be administered orally.
49485|NCT03797469|Dietary Supplement|Placebo|Tablets will look identical to the supplements and the number of tablets will equal the amount of supplements provided.
49486|NCT03797456|Drug|ICP-022|ICP-022 (tablets, 50 mg) is given orally at the dose of 150 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression.
49487|NCT03797443|Drug|Ascorbic Acid|"Four escalating dose levels are planned in order to determine the MTD for Phase II~The dose level for Phase II patients will be determined following completion of the Phase 1b study based on response from 3-6 patients receiving the designated dose level of ascorbic acid."
49488|NCT03797443|Drug|nab paclitaxel|30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
49489|NCT03797443|Drug|Cisplatin|60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
49490|NCT03797443|Drug|Gemcitabine|30 minute IV infusion on days 1 and 8 repeated every 21 days
49491|NCT03797391|Drug|EMB-01|"In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered.~In part 2, participants will receive intravenous infusion of EMB-01 at RP2D~The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks). Participants may continue to receive study drug until discontinuation criteria are met."
49492|NCT03797378|Other|Movement-2-Music (M2M)|The M2M intervention involves three 60-minute sessions per week for 12 weeks. The intervention uses combinations of movement patterns that target range of motion, muscle strength, cardiorespiratory fitness, balance, and breathing. Each session consists of movement routines choreographed to music, and every routine can be adapted to participants' functional ability.
49493|NCT03797365|Other|Classical rehabilitation|"Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)"
49494|NCT03797365|Behavioral|Cognitive associated rehabilitation|The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on…
49495|NCT03797352|Other|Multicomponent exercise|To identify frailty and other potential health issues, and determine if Multicomponent exercise helps at-risk elderly to have better health outcomes.
49496|NCT03797339|Other|risk factors of adverse cardiovascular events|During the follow-up period,general information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters will be collected
49497|NCT03797339|Other|multi-omics target discovery|Genome-wide genotype , DNA methylation and metabolomes were determined using illumina high-density genotyping chips, high-throughput sequencing, and high-resolution mass spectrometry respectly. Blood exposure of statins and metoprolol and its metabolites was determined by UPLC-MS/MS.
49498|NCT03797339|Other|validation|The genome-wide genotype of patients with coronary heart disease was detected using the illumina chip. The methylation level of the functional region was detected by the target region enrichment methylation sequencing method. Intestinal flora differences were detected using 16SrDNA high-throughput sequencing.
49499|NCT03797339|Other|Predictive mathematical models|Machine learning algorithms such as multiple linear regression or Bayesian classification are used to optimize clinical factors and multi-group targets to establish predictive mathematical models.
49500|NCT03797326|Biological|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
49501|NCT03797326|Drug|Lenvatinib|Administered orally once a day during each 21-day cycle.
49502|NCT03797300|Device|Spry Loop Band|Loop band measures pulse oximetry and respiration rate
49503|NCT03797287|Device|Tensor Tunnler|Create the bone tunnels during the arthroscopic rotator cuff repair procedure
49504|NCT03797287|Procedure|Anchor Rotator Cuff Repair|The suture anchors (Smith and Nephew PEEK Helicoil Anchor) are inserted in bone and the sutures are then used to sew the tendons to bone arthroscopically.
49505|NCT03797261|Drug|Venetoclax|tablet, oral
49506|NCT03797261|Drug|AMG 176|solution, intravenous
49507|NCT03797248|Combination Product|Chinese herbal medicine|All Chinese herbal products prescribed from TCM physicians in our hospital during patients receiving adjuvant chemotherapy
49627|NCT03796260|Drug|Entrectinib Reference Formulation (F06)|Participants will receive a single oral dose of entrectinib F06 after completion of a standardized meal.
49509|NCT03797235|Procedure|Non-dominant arm|The volume of local anesthetic used for the block of the ulnar and median nerve will be 5 times the estimated 95% effective dose (ED 95 ) of LA needed to block the nerve relative to the nerve cross-sectional area. The ED 95 for the ulnar nerve has been elucidated to be 0,11ml/mm2. The same ED 95 will be used for the median nerve.
49510|NCT03797222|Dietary Supplement|Vitamin E|Subjects will take an oral Vitamin E (alpha-tocopherol) supplement once daily with a fat-containing meal for 2 weeks. The dose will be based on subject age (150 IU if 1-3 years old, 300 IU if 4-8 years old, 450 IU if 9-17 years old, 600 IU if >17 years old). Formulations include 50 IU/mL liquid and 200 IU capsules. The liquid formulation will be used for subjects who will receive <600 IU daily, or for any subjects who prefer liquid medication to capsules.
49511|NCT03797209|Device|EUS-guided fistulization AXIOS|By using a convex type ultrasonic endoscope to form a fistula by gastrointestinal puncture, to perform various drainage.
49512|NCT03797196|Drug|low dose tacrolimus in combination with everolimus|a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
49513|NCT03797196|Drug|standard dose tacrolimus with mycophenolate mofetil|A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
49514|NCT03797170|Other|Gut microbiota samples|Gut microbiota analysis from diagnosis to follow up after first line-chemo-immuntherapy
49515|NCT03797157|Dietary Supplement|H2MF|H2MF is a human milk-based breastmilk fortifier for preterm infants
49516|NCT03797157|Dietary Supplement|Bovine milk-based fortifier|Bovine milk-based fortifier is the standard breast milk fortifier in Sweden
49517|NCT03797144|Device|CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement|The CD HORIZON® Legacy™ and Solera™ Fenestrated Screw Spinal System consists of a variety of cannulated screws with a series of fenestrations to allow polymethylmethacrylate (PMMA) bone cement (Fenestrated Screw Cement) to be injected into the treated site. The Fenestrated Screw Cement is used to augment screw fixation in subjects with compromised bone quality.
49518|NCT03797131|Other|KB195 (a novel mixture of oligosaccharides)|KB195 (a novel mixture of oligosaccharides) for oral intake for 21 days.
49519|NCT03797118|Device|FFR|Fractional flow reserve measured during cardiac catheterization
49520|NCT03797105|Behavioral|School-Based Obesity Intervention (FLOW)|The intervention consisted of nutrition lessons based on the traffic light diet, circuit-based physical activity, behavior modification techniques (token economy system, goal setting, self-monitoring), and parental involvement (materials sent home and monthly parent meetings). 80% of time was spent on physical activity and 20% was spent on nutrition. Behavior modification was incorporated into both physical activity and nutrition time. Specifically, instruction and activity time during PE class lasted approximately 40 minutes.
49521|NCT03797092|Biological|Allogeneic adipose-derived stromal cells (CSCC_ASC)|Active group
49522|NCT03797092|Other|Control group|No treatment
49523|NCT03797079|Procedure|ESP block|A high‑frequency linear ultrasound probe will be placed superficial to erector spinae muscle (ESM) in a parasagittal plane 3 cm lateral to the midline at the level of fifth thoracic vertebra. Three muscles will be identified superficial to the hyperechoic transverse process shadow: trapezius (uppermost), rhomboids major (middle), and ESM (lowermost). After local infiltration of skin and using in‑plane approach, an 18 G Tuohy needle will be inserted, until the tip lay between the rhomboid major muscle and ESM.
49524|NCT03797079|Procedure|TEA|Skin will be locally infiltrated at the site of needle insertion, and 18 G Tuohy needle will be introduced until its tip lay in the epidural space of the T5-T6 thoracic intervertebral space.
49525|NCT03797079|Device|Catheter insertion|After obtaining loss of resistance, 20 G epidural catheter will be threaded for 5 cm and then fixed on the skin.
49526|NCT03797079|Drug|Bupivacaine|After the negative aspiration for blood, a bolus dose of 15 ml 0.125% plain bupivacaine will be injected in the catheter, followed by a continuous infusion of 0.25% plain bupivacaine at the rate of 0.1 ml/kg/h for 48 hours
49527|NCT03797066|Drug|ZEPATIER 50Mg-100Mg Tablet|Zepatier 50/100 OD , with addition of Ribavarin in patients with Genotype 1a and 4 with HCV RNA> 800,000 iu/ml or baseline NS5A resistance.
49528|NCT03797053|Procedure|Biological sample|"Biological sample performed :~before treatment~1 months after the beginning of treatment~every tumoral assessment"
49529|NCT03797040|Biological|Cell therapy|PLX-R18: Allogeneic ex vivo expanded placental stromal cells
49530|NCT03797027|Device|Percutaneous Nephrolithotomy without an abdominal cushion|patients undergo prone PNCL without an abdominal cushion
49531|NCT03797027|Device|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 5 cm abdominal cushion
49532|NCT03797027|Device|Percutaneous Nephrolithotomy with an 5 cm abdominal cushion|patients undergo prone PNCL with an 10 cm abdominal cushion
49533|NCT03797014|Drug|B/F/TAF|Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
49534|NCT03797001|Drug|Anakinra|100 mg subcutaneous injection, daily for 24 weeks
49535|NCT03797001|Drug|Placebo|subcutaneous injection, daily for 24 weeks
49536|NCT03796988|Device|Autologous Regeneration of Tissue (ART) device|This device will harvest hundreds of full-thickness columns of skin tissue (500 micrometer diameter) using single-needle, fluid-assisted harvesting technology.
49537|NCT03796975|Drug|Combination of Pioglitazone and Metformin Tablets|15mg/500mg, oral, 2/day
49538|NCT03796975|Drug|Metformin Hydrochloride Tablets|Oral metformin 850mg, 2/day in the control group
49539|NCT03796962|Drug|XEN1101|Oral dose
49540|NCT03796936|Behavioral|Motion-assisted, Multi-modular Memory Desensitization and Reconsolidation (3MDR) Therapy|a novel treatment for PTSD combining aspects of virtual reality exposure therapy (VRET) and Eye Movement Desensitization and Reprocessing (EMDR), within the Computer Assisted Rehabilitation Environment (CAREN)
49541|NCT03796923|Other|Early follow-up visit after discharge|Early follow-up visit and different degrees of specialized care after discharge
49542|NCT03796923|Other|Comprehensive geriatric assessment (CGA)|Comprehensive geriatric assessment (CGA) during admission
49543|NCT03796923|Other|Continued geriatric care|Continued specialized geriatric care after discharge
49544|NCT03796923|Other|Possible follow-up visit from GP|Usual care: follow up visit from GP within one week after discharge
49545|NCT03796910|Drug|SPR720 for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
49546|NCT03796910|Drug|Placebo for SAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally as a single dose.
49547|NCT03796910|Drug|SPR720 for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing.
49548|NCT03796910|Drug|Placebo for MAD|Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 3 cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered orally for a total of 7 (or 14) days of dosing
49549|NCT03796897|Dietary Supplement|Leucine-enriched protein|Supplement contains 16g of protein given twice per exercise session (4 total exercise sessions)
49550|NCT03796897|Behavioral|Habitual diet only|Habitual diet only (no supplementation) for 4 exercise sessions
49551|NCT03796884|Drug|Linaclotide|Given PO
49552|NCT03796884|Other|Placebo|Given PO
49553|NCT03796871|Device|Dermapol|Use of the experimental medical device before lesion excision : skin lesion lighting (4 wavelengths) for less than 1 minute and image recording
49554|NCT03796858|Drug|Guselkumab 100 mg|Participants will receive guselkumab 100mg as SC injection.
49555|NCT03796858|Drug|Placebo|Participants will receive placebo as SC injection.
49556|NCT03796845|Other|No limited movement after surgery|Participants should move their arms from the first postoperative day, with unrestricted movement, with an amplitude above 90º for flexion and abduction of shoulder.
49557|NCT03796832|Device|Flat Flexible Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height <15 mm, (ii) shoe pitch <10 mm, (iii) absent arch support/motion control, (iv) minimal sole rigidity, (v) weight <=200g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
49558|NCT03796832|Device|Stable Supportive Shoes|Off-the-shelf commercially available shoes will be used compliant with previously published criteria: (i) heel height >30 mm, (ii) shoe pitch >10 mm, (iii) present arch support/motion control, (iv) sole rigidity, (v) weight >300g (+/-10%). Participants will be instructed to wear the shoes at least 4 hours daily for the duration of the 9-month intervention and to avoid wearing other types of shoes, if possible.
49559|NCT03796832|Other|Exercise Therapy|The 3-month supervised exercise program will consist of one group session per week of approximately 30 minutes complemented with home-based exercises 3 times per week. Group sessions will consist of a 10-min warm-up followed by a circuit training of strengthening and/or neuromuscular exercises. Subsequently, during a 6-month unsupervised home exercise program, participants will perform strengthening exercises of the lower limb muscles 3 times weekly. Throughout the 9-month intervention, participants will be encouraged to maintain a daily routine of aerobic exercises, consisting of structured activity bouts of at least 10 minutes at a moderate intensity (grade 5-6 (out of 10, maximum exertion) on a Rate of Perceived Exertion scale), achieving at least 70 minutes of weekly physical activity at 3 months and 150 minutes at 9 months.
49560|NCT03796819|Procedure|lymphadenectomy|Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
49561|NCT03796793|Procedure|Debridement|Surgical wound debridement
49562|NCT03796780|Dietary Supplement|Extra-Virgin Olive Oil|Daily consumption of 25 mL Extra-Virgin Olive Oil in adjunct to medical treatment for 6 weeks
49563|NCT03796780|Dietary Supplement|Refined Olive Oil|Daily consumption of 25 mL Refined Olive Oil in adjunct to medical treatment for 6 weeks
49564|NCT03796767|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
49565|NCT03796767|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
49566|NCT03796767|Procedure|Metastasectomy|Undergo salvage oligometastasectomy
49567|NCT03796767|Other|Quality-of-Life Assessment|Ancillary studies
49568|NCT03796767|Other|Questionnaire Administration|Ancillary studies
49569|NCT03796767|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
49570|NCT03796754|Behavioral|YoBEKA|The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
49571|NCT03796741|Other|Data collection on Stable Ischemic heart disease|No intervention only description of management and treatment
49572|NCT03796728|Device|Juvéderm® VOLIFT™ with Lidocaine|Injectable gel that is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant (dermal filler).
49573|NCT03796715|Diagnostic Test|Red Cell Distribution Width (RDW)|A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.
49574|NCT03796715|Diagnostic Test|Presepsin (sCD14-ST)|: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.
49575|NCT03796702|Procedure|Deileostomy|Deileostomy
49576|NCT03796689|Device|Smartphone-linked HBPM and associated app|Participants in the Smartphone-linked arm of the study will receive an Omron 786N Home Blood Pressure Monitor (HBPM) that can be linked to the Omron Connect app via Bluetooth. They will also receive instructions about how to use their device and download the app and will be provided with publically available guidelines for HBPM. Participants will be instructed to use their device and app to take readings which they can track over time and share with their provider using the app.
49577|NCT03796689|Device|Standard HBPM|Participants in the Standard arm of the study will receive an Omron 785N Home Blood Pressure Monitor (HBPM), instructions about how to use their device and publically available guidelines for HBPM. They will be instructed to use their device to take readings which they can track over time and share with their provider.
49578|NCT03796676|Drug|Placebo|Placebo
49579|NCT03796676|Drug|PF-04965842|100 mg QD
49580|NCT03796676|Drug|PF04965842|200 mg QD
49581|NCT03796663|Behavioral|Mindful Parenting Program|"The Mindful Parenting Program consists of 7, 2.5 hour weekly group sessions. In the program, parents learn to apply the skills of mindfulness to themselves and to their experience of parenting their children. Parents are introduced to formal meditation practices, including the bodyscan; choiceless awareness; mindful walking; and yoga. They are also introduced to mindfulness of everyday activities from the beginning of the sessions, with an added focus on day-to-day parenting and family activities. Additionally, short self-compassion practices occur throughout the weekly sessions, culminating in the teaching of formal loving-kindness meditation.~Additionally, the program encourages parents to engage in home practice, where parents can experience and practice many of the new skills they are learning. This includes both formal, longer meditation practices, as well as shorter practices, which can occur throughout the day, such as mindfulness of daily routines."
49582|NCT03796663|Behavioral|MATCH BPT Program|The MATCH BPT Program consists of 8-12 weekly (depending on how long it takes for individual parents and their assigned trainer to get through the material), 60 minute individually-implemented sessions.The sessions will consist of the coach obtaining and reviewing weekly assignments completed by the parent, followed by activities and discussions that focus on a particular parenting skill (i.e. praise, active ignoring, giving effective instructions). The discussions will emphasize benefits and possible problems that the parent may encounter throughout the week while implementing the new skill. The coach will assign to the parent a practice assignment to further encourage use of the concept.
49583|NCT03796650|Other|Fecal microbiota transplantation|50 g donor feces suspended in saline with added glycerol, administered by a enema kit.
49584|NCT03796650|Drug|Vancomycin|Peroral vancomycin 125 mg q.i.d. for ten days.
49585|NCT03796637|Other|Dystrophin levels|Dystrophin levels of participants who have previously received at least 9 months of treatment with ataluren.
49586|NCT03796624|Device|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per patient will be implanted"
49587|NCT03796624|Device|PODEYE|"Implantation of intraocular lens (IOL). Name: PODEYE It is a monofocal intraocular lens consisting of hydrophobic acrylic material. The IOL will be implanted in the contralateral eye of the same patient already implanted with Micropure 1.2.3."
49588|NCT03796598|Drug|Fecal Microbial transplant Capsules|Oral capsules of FMT
49589|NCT03796598|Drug|Fecal Microbial Transplant Enema|FMT enema
49590|NCT03796598|Other|Placebo|Placebo
49591|NCT03796585|Behavioral|Immunization Registry Training|Education highlighting practical strategies to improve pharmacies' willingness to adopt the immunization registry and improve their ability to integrate the immunization registry into their pharmacy workflow.
49592|NCT03796585|Behavioral|Informational flyer|Informational flyer with ImmPRINT contact information
49593|NCT03796572|Drug|Ropivacaine|Regional anesthesia protocol of open reduction percutaneous pinning of lateral condyle humerus fracture Ropivacaine
49594|NCT03796572|Other|Puncture Wound and Dressing|No regional anesthesia is given for open reduction percutaneous pinning of lateral condyle humerus fracture
49595|NCT03796559|Device|Magseed Marker|Implantable Magseed marker for marking lesions in soft tissue, detected using the Sentimag handheld probe.
49596|NCT03796533|Drug|Posaconazole|"PCZ will be used as recommended in tablet formulation at an initial dosage of 300 mg twice a day on the first day and then once a day at a dose of 300 mg the following days.~PCZ prophylaxis will be started on the same day as the start of chemotherapy and will be continued until the end of aplasia.~The dosage of the PCZ can be adjusted according to the results of the PCZ assay. It may be interrupted if the transaminase level is greater than 3 times higher than normal (3N) or on medical decision."
49597|NCT03796520|Diagnostic Test|EpiPick simplified seizure classification algorithm|"EpiPick simplified seizure classification algorithm input:~Grey matter brain lesion Exclusively nocturnal seizures First seizure at age > 20 years Lip smacking or chewing during seizures Staring with impaired awareness, lasting less than 20s without postictal confusion Sudden irregular jerks, in isolation or brief series, if none of the following applies: Are the jerks consistently in the same limb? When resting in bed when falling asleep? Bilateral tonic-clonic seizures within 1h of awakening or immediately preceded by irregular jerks Any of the following is present: Skin turning pale pre-ictally; Loss of consciousness immediately after urination or defecation; Sudden slump with loss of awareness, lasting less than 10 seconds; Seizure lasting longer than 10 minutes, with eyes closed throughout the seizure; Severe pre-ictal headache; Episodes consisting of falls that occur always after change in posture to the upright position, or coughing or feeling pain."
49598|NCT03796507|Drug|Temozolomide|oral temozolomide at 75 mg per square meter of body surface area daily for 21 days
49599|NCT03796494|Procedure|Straight abutment|This is the classic abutment, straight and anti-rotational for dental implants which have been tested before
49600|NCT03796494|Procedure|Slim abutment|This is the new concept of the prostheses abutment, slim and anti-rotational to improve the width of biologic space
49601|NCT03796468|Other|Best Medical Therapy|The administration of medications is at the treating physician's discretion (for example intravenous fibrinolysis, anticoagulants or antiplatelet) according to local standards of care but may NOT include any intra-arterial therapies. The rescue MT may be performed in case of deterioration within the 24 hours
49602|NCT03796468|Procedure|Mechanical Thrombectomy|MT in the Experimental Arm can be performed with any thrombectomy (CE labeled) device usually used at study site. For the subjects randomized to the MT plus medical, the MT is performed immediately after the randomization
49628|NCT03796234|Other|Dietary and physiotherapy|3 group talks were carried out, in a period of 3 months, in which different topics related to healthy eating were treated. In addition, a 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
49873|NCT03794297|Other|Questionnaire Administration|Ancillary studies
49603|NCT03796455|Dietary Supplement|Capsule + Powder supplementation|For Fish oil and Placebo oil, treatment will be provided in capsules.Each group will receive dose distributed to 3 capsules per day. Participants will be instructed to take all capsules with morning meal. . For HMB and a placebo powder, product will be delivered as powder taken with water or non-carbonated beverage (like juice). Product will be provided in 2 sachets/day. One sachet should be consumed with breakfast and the other prior to bedtime (approx. 10pm).
49604|NCT03796455|Other|stable tracer infusion|labeled amino acids L-Phenylalanine (ring-13C6), L-Tyrosine (ring-D4), and tau-Methylhistidine will be infused as a single injection. Subsequently, the catheter will be used for arterialized venous blood samples (3 ml) drawn multiple through the day
49605|NCT03796442|Device|AVR with AVALUS|aortic valve replacement with AVALUS bioprosthesis
49606|NCT03796442|Device|AVR with CEPME|aortic valve replacement with Carpentier-Edwards Perimount Magna Ease bioprosthesis
49607|NCT03796429|Drug|GS+Toripalimab|"Patients will be given treatment as below once recruited: PD-1 antibody Toripalimab（240mg, iv, q3w），combined with GS regimen(gemcitabine 1000mg／m2 ，d1,d8 + S1 40-60mg bid*14d，Q21d).~The treatment will be continued until emerging of disease progression or intolerable adverse effects (The upper time limit for treatment is 2 years)."
49608|NCT03796416|Drug|Misoprostol|used at a rate of 25 mcg Q4hours for cervical ripening.
49609|NCT03796403|Other|Diclofenac|Twenty mL of bupivacaine was infiltrated into surgical-site peritoneum , divided in 10 sites before closure, and diclofenac 75 mg (3 mL) was intramuscularly injected immediately after complete the procedure and the operative field was covered with sterile adhesive wound dressing.
49610|NCT03796390|Biological|CD123 CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CD123 CAR-T cells will be infused.
49611|NCT03796377|Drug|St Johns Wort Extract|20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.
49612|NCT03796377|Drug|Rivaroxaban|20 mg rivaroxaban.
49613|NCT03796364|Drug|Endostar|Patients in the observation group were treated with routine radiation pneumonia and Endostar. Endostar usage: continuous intravenous pumping of Endostar(14 doses each time) over 5 days. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
49614|NCT03796364|Drug|standard SRILI treatment|Patients in the control group were treated with current routine radiation pneumonia. At week 2, 4, 6, 12, 24, 36, 52, lung functional and blood oxygen saturation was measured, chest CT and the St. George Respiratory Questionnaire (SGRQ) were assessed for quality of life at week 12, 24, 52 and before treatment; collecting the related observation indexes of patients; primary endpoint; recrudescence rate of RP; secondary endpoints; remission rate of RP and incidence rate of RF; incidence rate of RF; number of acute exacerbations and quality of life.
49615|NCT03796351|Drug|MT10107|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
49616|NCT03796351|Drug|Botox|"Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner."
49617|NCT03796338|Device|Sleep Profiler|Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
49618|NCT03796312|Behavioral|Tub Bathing|The infant's face was washed and dried while still wrapped before being immersed. The water level in the tub was set at approximately 9-12 cm or deep enough to cover the baby's shoulders. A folded cloth towel was placed into the tub before bathing. The temperature of the bath water was controlled using a special water thermometer and adjusted to 37-38°C. The infant was held securely; the head and neck were supported on the researcher's forearm, and the shoulder was grasped using the researcher's thumb and finger. Cleaning was performed using a soft cloth and baby skin cleaner. The front and back areas were cleaned without turning the infant. The newborn was safely removed from the water and wrapped in a clean towel.
49619|NCT03796312|Behavioral|Sponge Bathing|Sponge bathing is routine care of the clinic
49620|NCT03796299|Diagnostic Test|Assessment of expression of MCM5 in the urine (ADX Bladder)|Each participant will be asked to urinate in a plastic container. Urine will be centrifuged afterwards, then the expression of MCM5 protein will be examined in cells from urine sediment. For this purpose, it is planned to use the Arquer Diagnostics ADXBLADDER test. It is an enzyme linked immunosorbent assay (ELISA) using two monoclonal antibodies directed against two different epitopes. Both antibodies have high affinity and specificity for the MCM5 antigen.
49621|NCT03796286|Other|Medium-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
49622|NCT03796286|Other|High-fiber bar|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
49623|NCT03796286|Other|Control bar (0 g fiber)|Each subject will receive one control and two active treatments in a crossover design. The two active treatments are dietary fiber-containing bars at two doses of fiber. The control bar will not contain fiber.
49624|NCT03796273|Other|Best Practice|Undergo standard surgery
49625|NCT03796273|Drug|Ketoconazole|Given PO
49626|NCT03796260|Drug|Entrectinib Test Formulation (F1)|Participants will receive a single oral dose of entrectinib F1 after completion of a standardized meal.
49629|NCT03796234|Other|Physiotherapy|A 3-month high intensity interval training program was developed. Physiotherapy sessions were carried out twice a week for one hour and intensity was established based in effort tests.
49630|NCT03796221|Behavioral|Parenting videos|Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
49631|NCT03796221|Behavioral|Standard pediatric obesity treatment|Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
49632|NCT03796208|Behavioral|Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC)|Women enrolled in the intervention group will receive TAU plus B-EPIC, which includes four core components: 1) Individualized tobacco treatment plus supplemental counseling, 2) Biomarker validation and feedback, 3) Change in maternal thought process and adoption of healthy behavior (e.g. exercise, based on PI framework), and 4) Pharmacotherapy as needed (see Table 3 for a summary of the study design). The initial assessment for this intervention takes 60 minutes, with follow-up sessions typically lasting 15-20 minutes. All sessions occur prior to or after pre-scheduled perinatal appointments. The intervention will be led by a certified tobacco treatment specialist (CTTS).
49633|NCT03796208|Behavioral|Treatment As Usual|Women enrolled in the control group are informed of the risks of tobacco use and benefits of quitting using the ACOG 5'A's approach by their healthcare provider. This standard takes approximately 5-15 minutes, and is offered at each prenatal and postpartum appointment. The five steps of the ACOG recommendation are: 1.) Ask about tobacco use, 2.) Advise to quit, 3.) Assess willingness to make a quit attempt, 4.) Assist in quit attempt, and 5.) Arrange follow-up. The provider may also talk to the participant about nicotine replacement therapy.
49634|NCT03796195|Drug|.5% Bupivacaine|Ultrasound guided right sided stelate ganglion block using .5% bupivacaine (5mLs)
49635|NCT03796182|Drug|Metformin|Commercially available metformin (GLUCOPHAGE®) as 500 mg tablets.
49636|NCT03796182|Drug|PF-04965842|PF 04965842 100 mg tablets
49637|NCT03796169|Behavioral|Personal notification|Baseline quality indicators of each endoscopist were measured and those were notified individually.
49638|NCT03796169|Behavioral|Open notification|Quality indicators were measured for 3 months after 1st interventions and those were notified openly
49639|NCT03796169|Behavioral|Education|Quality indicators were measured for 3 months after 2nd interventions and educated the importance of colonoscopy quality by a GI faculty
49640|NCT03796156|Drug|Aspirin|75mg low dose non enteric coated
49641|NCT03796143|Behavioral|The Mindfulness and Acceptance Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
49642|NCT03796143|Behavioral|The Cognitive Behavioral Workbook for Depression|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
49643|NCT03796130|Procedure|Myomectomy|"This study will include women who have intramural myomas ranging from 3-5 cm~The participants will be randomly allocated into two groups.~In group (1): myomectomy will be performed before ART~In group (2):women will have their trial of ART without myomectomy~In group A, ART will be performed 3 months after myomectomy if the uterine cavity is not opened and 6 months after myomectomy upon inadvertent opening of the uterine cavity during surgery"
49644|NCT03796117|Device|Pulsed current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, evaluation of the discomfort level, current intensity, analysis of neuromuscular efficiency and clinical efficiency, 2 configurations (PC1 and PC2) will be used.~PC1, will be set at a frequency of 100 Hz, phase duration of 1000 microseconds, ON-OFF time of 5s:10s.~PC2, will be set at a frequency of 100 Hz, phase duration of 200 microseconds ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the PC1 configuration will be used."
49645|NCT03796117|Device|Russian Current|"For stage 1 of the study, which corresponds to analysis of the evoked torque, discomfort level, current intensity, neuromuscular efficiency and clinical efficiency, 2 configurations (RC1 and RC2) will be used.~RC1, will be set to a frequency of 100 Hz, burst duty cycle of 20%, ON-OFF time of 5s:10s.~RC2, will be set at a frequency of 100 Hz, burst duty cycle of 50%, ON-OFF time of 5s:10s.~For stage 2 of the study, which corresponds to the analysis of the fatigability level, only the RC2 configuration will be used."
49646|NCT03796104|Other|Delta-haemolysin|comparison of groups having infection with S. aureus with and without delta-haemolysin Production
49647|NCT03796091|Behavioral|Educational Brochure|Participants will read an educational brochure from the National Eating Disorders Association and will receive treatment referral resources.
49648|NCT03796091|Behavioral|Body Project Traditional|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Traditional group therapy program (see Stice & Shaw, 2001).
49649|NCT03796091|Behavioral|Body Project Expanded|Participants will complete a 1-hour per week group therapy program for 4 weeks consisting of the Body Project Expanded group therapy program (see Green et al., 2017).
49650|NCT03796078|Procedure|Maxillomandibular advancement|Treatment: Mono or Bimaxillary Orthognathic Surgery. The surgery of Reposition of the jaws is carried out under general anesthesia using minimally invasive techniques, the patient is extubated After surgery, antibiotics are prescribed during admission, anti-inflammatories, antiemetics and a local cold mask is applied of closed circuit at 17ºCelsius. The patient is discharged at 24 h.
49651|NCT03796065|Behavioral|FSI-R Treatment|The FSI-R involves a series of separate and joint meetings with parents and children to discuss challenges the family has faced and the strengths that helped them make it through past challenging times. Additional psychoeducation on mental health and promoting resilience along with coaching to enhance parenting skills is provided throughout and may be tailored to family needs. The FSI-R provides a shared space for refugee families both to recognize their strengths and to problem-solve in a more collective way on family challenges and shared hopes for the future. The FSI-R is delivered in the home, by a trained interventionist, over the course of 10-modules.
49874|NCT03794297|Drug|Trametinib Dimethyl Sulfoxide|Given PO
49652|NCT03796052|Other|Avena Sativa Skincare Regimen|Regimen consisting of 3 topical agents containing Avena Sativa (oat) kernel flour: a body wash (type = cosmetic), a body cream (type = cosmetic), and an anti-itch balm (type = OTC monograph drug with 0.5% Pramoxine HCl)
49653|NCT03796039|Behavioral|Standing|Standing for an additional 100 minutes per week. In 10 minute bouts, twice a day, Monday-Friday for 6 months
49654|NCT03796026|Drug|Seltorexant 40 mg|Seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
49655|NCT03796026|Drug|Placebo|Matching placebo to seltorexant 40 mg capsules (over-encapsulated tablets) will be administered orally.
49656|NCT03796013|Drug|Entrectinib Form A|Participants will receive a single oral dose of entrectinib form A under fasted conditions.
49657|NCT03796013|Drug|Entrectinib Form C|Participants will receive a single oral dose of entrectinib form C under fasted conditions.
49658|NCT03796000|Procedure|tissue samples, blood and stool sample|Tissue samples from gastroscopy/colonoscopy.
49659|NCT03795987|Device|NightWare Therapeutic System|A wearable digital therapeutic system that will measure physiologic data when worn during sleep to deliver a mild vibration via the watch to elicit arousal thereby disrupting nightmares. This detection and stimulation sequence will be performed according to NightWare's proprietary algorithm.
49660|NCT03795974|Biological|MNC|Hematopoietic stem cells derived from allogenic umbilical cord
49661|NCT03795974|Biological|MSC|Mesenchymal cells derived from allogenic umbilical cord
49662|NCT03795974|Procedure|Control|control group without injection and appearance simulating lumbar puncture without awareness of the patients and evaluators , but rehabilitation continued .
49663|NCT03795961|Device|transcranial direct current electrical stimulation|anodal tDCS of M1 for 20 minutes, at 2 mA for 5 sessions (day after day)
49664|NCT03795948|Other|PROMs|"Introduction and assessment of the ICHOM standard set consisting of demographic and medical data as well as questionnaires filled in by patients, shortly after admission to the stroke unit, at discharge, and at 90 and 360 days after stroke.~Specifically the intervention includes an assembly of clinical records, in particular records of complications, recurrence of disease and mortality. Further patients will be required to complete a questionnaire assessing their situation in terms of housing and symptom burden as well as their self-perceived autonomy and quality of life.~Telephone assessments will be administered to support patients if necessary and validate their responses."
49665|NCT03795935|Other|No side-effect stimulator settings with directional lead|Individuals in this arm will have their stimulator settings programmed to the point in which they have maximum tremor control with no side effects.
49666|NCT03795922|Drug|MT10109L|MT10109L will be injected into the GL.
49667|NCT03795922|Drug|Placebo|Placebo will be injected into the GL.
49668|NCT03795909|Drug|Ruxolitinib|Ruxolitinib （2.5 mg twice daily for patients if the age<14 years and the weight <25kg，5 mg twice daily for patients if the age<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and<18 years）
49669|NCT03795909|Drug|Dexamethasone|Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.
49670|NCT03795896|Diagnostic Test|Optic nerve sheath diameter|The intracranial pressure will be measured by the optic nerve sheath diameter and after giving the mannitol osmotherapy the intracranial pressure will be monitored by the optic nerve sheath diameter
49671|NCT03795870|Dietary Supplement|Polymeric Tube Feeds|Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds
49672|NCT03795870|Dietary Supplement|Blenderized Tube Feeds|Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds
49673|NCT03795857|Behavioral|Semi-structured interviews|The purpose of this study is to describe the experience of pregnancy by parents who have chosen to carry to term despite a lethal fetal diagnosis. Therefore, semi-structured interviews will be conducted to explore the links between context, feeling, involvement, decision and actions during pregnancy, whether within the couple or in its environment.
49674|NCT03795844|Procedure|liver retraction Nathanson retractor|liver retractor will be used for the retraction of left lobe of liver
49675|NCT03795844|Procedure|liver retraction snake retractor|liver retractor will be used for the retraction of left lobe of liver
49676|NCT03795844|Procedure|liver retraction fan retractor|liver retractor will be used for the retraction of left lobe of liver
49677|NCT03795844|Procedure|liver retraction laparoscopic grasper|laparoscopic grasper without any special tools
49678|NCT03795831|Device|ClearSight feasibility testing|A cuff is placed on a finger of the patient. The ClearSight system uses a volume clamp technology allowing measuring of continuous blood pressure waveform. Note: There will only be observational recordings, no interventions
49679|NCT03795818|Behavioral|Interpersonal Psychotherapy for Adolescents|IPT-A is a psychosocial intervention for adolescents that focuses on improving interpersonal relationships that seem to be associated with the psychiatric symptoms.
49680|NCT03795805|Procedure|total knee arthroplasty|Total knee arhroplasty
49681|NCT03795805|Procedure|Tourniquet limb cuff|Tourniquet limb cuff and regular anesthesia
49682|NCT03795805|Drug|Intaarticular lidocain|20 ml of 2% lidocain application intraarticular before surgery (intraarticular lidocain)
49683|NCT03795792|Dietary Supplement|Curcumin|Will be provided in capsules
49684|NCT03795792|Dietary Supplement|Hydrolyzed collagen|Will be provided in capsules.
49685|NCT03795779|Biological|CLL1-CD33 cCAR T cells|CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
49686|NCT03795766|Procedure|Surgeries for gynecologic disease|All patients accept surgeries for gynecologic disease.
49687|NCT03795753|Device|F2S Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will ENABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
86666|NCT03509012|Drug|Carboplatin (dose level 2)|IV
49688|NCT03795753|Other|Non-functioning Communicator|"The communicator will be attached to the BPAP/CPAP mask. The study coordinator will DISABLE the communicator. A list of single words and 5-word through 15-word sentences will be provided to the patient. Each single word may be read aloud up to two times. The partner must then select the read word out of a list of twelve possible words. Each sentence may be read aloud up to two times. The partner must transcribe each sentence on a standardized form. A survey will be provided to evaluate the mask on, communicator on period."
49689|NCT03795740|Diagnostic Test|3-D CT scanning|For patients in Group 1,precisely analyzed CT scanning and/or pulmonary angiography will be done,and the patients in Group 1 will receive PEA procedure with the guide of precise 3-D imaging techniques
49690|NCT03795727|Device|MD ring and precontoured sectional matrix by TOR VM|MD ring (separation ring) and precontoured sectional matrix (thickness 0.035mm hard) and a diamond wedge was used to secure matrix in place
49691|NCT03795727|Device|Circumferential matrix and tofflemire retainer by Kerr|Circumferential matrix (thickness 0.038mm) applied by tofflemire retainer and secured in place with diamond wedge
49692|NCT03795714|Diagnostic Test|IVUS or OCT and Invasive physiologic indices|IVUS or OCT measurement in order to evaluate the lesion morphology and stent optimization, and invasive physiologic measurement in order to functional significance of epicardial stenosis
49693|NCT03795701|Drug|Saxenda®|Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.
49694|NCT03795701|Other|Placebo|Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
49695|NCT03795688|Other|Pregnancy|Peripartum transition from pregnant to postpartum state
49696|NCT03795675|Device|Cochlear Implant|Cochlear implant device to be implanted at time of surgical intervention.
49697|NCT03795662|Other|No intervention|Obervational
49698|NCT03795649|Drug|Tranexamic Acid|Imunomodulatory effect
49699|NCT03795636|Other|Garlic extract|A 100 gram of garlic cloves has been cleaned, peeled and dried. Ethanol of 70% concentration was added for 60 seconds. The cloves were placed in a laminar airflow chamber for evaporation of residual ethanol. Using a sterile mortar and pestle, cloves were homogenized aseptically and filtered through a double layer paper. The fully concentrated extracted was diluted to the concentration of 25% with distilled water
49700|NCT03795636|Other|NaOCl (COLTENE®)|Sodium hypochlorite
49701|NCT03795623|Other|Voice-Weaning|Audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
49702|NCT03795623|Other|Sham control|Muted audio recordings of patients' relatives for 10 minutes x 3 daily from initiation of assisted mechanical ventilation to extubation or ICU discharge.
49703|NCT03795610|Drug|IPI-549|40mg by mouth (PO) every day (QD) for at least 21 days
49704|NCT03795597|Drug|Carfilzomib|Carfilzomib is an anti-cancer drug acting as a selective proteasome inhibitor that is used to treat Multiple Myeloma.
49705|NCT03795597|Drug|Busulfan IV|Busulfan is an anti-cancer drug acting as a bifunctional alkylating agent that is used to treat Multiple Myeloma.
49706|NCT03795597|Drug|Melphalan IV|Melphalan is an anti-cancer drug acting as alkylating agent that is used to treat Multiple Myeloma.
49707|NCT03795584|Procedure|sterile repositionable hemostasis clipping device close the large duodenal papilla incision|After the bile duct stent was placed, the investigators can use sterile repositionable hemostasis clipping device to close large duodenal papilla incision at 11 o'clock on the duodenal papilla.
49708|NCT03795571|Drug|Rituximab|Rituximab 375mg/m2，d0
49709|NCT03795571|Drug|Gemcitabine|Gemcitabine 1000mg/m2，d1，d5
49710|NCT03795571|Drug|Oxaliplatin|Oxaliplatin 75mg/m2，d1
49711|NCT03795571|Drug|Dexamethasone|Dexamethasone 40mg/d，d1~d4
49712|NCT03795571|Drug|Lenalidomide Oral Capsule|Lenalidomide 10mg/d、15mg/d、20mg/d、25mg/d d1~d10； 21days a cycle
49713|NCT03795558|Drug|Etelcalcetide|Up-Titration
49714|NCT03795545|Procedure|SWL|Shock wave lithotripsy
49715|NCT03795532|Procedure|SWL|Shock wave lithotripsy
49716|NCT03795519|Drug|[14C]-olinciguat|oral capsule
49717|NCT03795506|Device|Nocturnal Temperature controlled Laminar Airflow (TLA) Treatment|12 weeks of overnight treatment with active TLA device
49718|NCT03795506|Device|Placebo TLA Device|12 weeks of overnight use of placebo TLA device
49719|NCT03795493|Behavioral|Short-term diet and exercise intervention|Participants assigned to the intervention group will perform both the diet and acute exercise interventions. The interventions will be applied prior to up to six chemotherapy treatments of a consistent protocol. The total number of treatments of a given protocol received prior to treatment conclusion is dependent on patient condition and oncologic care preferences.
49720|NCT03795480|Behavioral|MOOD|MOOD is an online self-help program targeted on depressive symptoms. The program consists of nine modules, one of which is an introductory module. The other modules are called: ABC-Scheme, Positive Activities, Self-Worth, Social Competence, Mindfulness, Modifying Thoughts, Sleep, and Relapse Prevention. All modules are based on principles of cognitive behavioral therapy (CBT) and include elements of mindfulness-based and metacognitive techniques. The modules contain interactive exercises which are aimed at incorporating the participant's experiences into the program and increasing identification of the participant with the presented material. Participants are free to work through the different modules in their own speed and way, however, it is recommended to work on one to two modules per week.
49721|NCT03795454|Behavioral|Singing|Infant-directed singing and singing of self-invented songs, especially songs emerging from the interaction with the infant, are especially encouraged. The families will receive audio material of children's songs, lullabies, and lyrics of the lullabies to support them if they feel unable to accomplish the task otherwise.
49722|NCT03795441|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection on Day 1.
49723|NCT03795428|Drug|PB1046 Injection|Once-weekly subcutaneous injection
49724|NCT03795415|Behavioral|Gundo So|"Gundo-So was adapted from a program established in quebec. It has been implemented in Mali following 3 phases: 1) cultural adaptation; 2) validation using a pre-post intervention evaluation; 3) scale-up~The programm consists on 9 group meetings group spread over 9 weeks (for 8 WLHIV + 2 trained community-based leaders). Each meeting has some particular thematics with adapted tools."
49727|NCT03795363|Drug|Orkambi|Orkambi is a novel approved therapy for use in people homozygous for the F508del mutation in the CFTR gene. It is a combination of lumacaftor (VX-809) and ivacaftor( VX-770) that addresses both the processing and gating defects of the F508del mutation. The small-molecule corrector lumacaftor corrects the F508del processing defect and increases epithelial delivery of CFTR protein1. Ivacaftor is a CFTR potentiator that increases the channel open probability in F508del-mutant CFTRs that undergo epithelial delivery in vitro and has an additive effect with lumacaftor on chloride transport (2,3,4,5).
49728|NCT03795350|Drug|Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide|single inhalation of 99mTc radiolabelled TRIMBOW pMDI (4 puffs for a total dose of 400mcg BDP, 24mcg FF, 50 mcg GB)
49729|NCT03795337|Radiation|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
49730|NCT03795324|Other|Redlove Apple intervention|The bioactive compounds present in this product are anthocyanins (50mg per 80g of product).It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized redlove apple.
49731|NCT03795324|Other|Green Apple intervention|It was a 6 weeks nutritional intervention. Volunteers will eat 80g per day of lyophilized green apple.
49732|NCT03795324|Other|Aronia drink intervention|The bioactive compounds present in this extract are anthocyanins (50mg per 1L of water).It was a 6 weeks nutritional intervention. Volunteers will drink 1L per day of an aronia drink
49733|NCT03795311|Drug|FOLFIRINOX Bevacizumab|"In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles."
49734|NCT03795298|Device|WATCHMAN FLX Implant|Left atrial appendage closure with the WATCHMAN FLX device
49735|NCT03795298|Drug|Market-approved OAC|Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
49736|NCT03795285|Diagnostic Test|Expression of neutrophil CD64|Expression of neutrophil CD64 will be measured by Flow cytometry. In addition, sTREM-1 will be measured in the serum by ELISA
49737|NCT03795272|Drug|Rucaparib|2:1 randomization to receive rucaparib/placebo twice daily for 24 month
49738|NCT03795272|Drug|Placebo|placebo
49739|NCT03795259|Drug|Rocuronium|After induction, rocuronium 0.6 mg/kg will be given by intravenously and patients will be orotracheal intubated when TOF value reaches 0%.
49740|NCT03795259|Drug|Sugammadex|Continuous TOF measurement will continue until the value reaches %25. At this time, sugammadex 2 mg/kg will be given intravenously.
49741|NCT03795246|Procedure|Consultation|Consultation in oncology: collection of oncological data and ongoing cancer treatments, clinical exam Consultation in gynecology: collection of gynecological data, contraception and reproductive medicine
49742|NCT03795246|Biological|Biological Test|"Blood test:~FSH, LH, E2 and AMH~4 tubes of 7 mL"
49743|NCT03795246|Procedure|Pelvic Ultrasound|Antral Follicles Count
49744|NCT03795233|Biological|Fecal microbiota transplant G3 capsules|After standard of care therapy with oral vancomycin, frozen oral FMT capsules will be provided in a formulation designed to deliver the product to the large intestine. 30 FMT capsules will be administered over a 2 hour period under direct observation
49745|NCT03795233|Other|Oral Vancomycin alone|Standard of care will be provided with oral vancomycin therapy.
49746|NCT03795220|Drug|Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
49747|NCT03795220|Drug|Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
49748|NCT03795220|Drug|No Lutinus + transfer day 6|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
49749|NCT03795220|Drug|No Lutinus + transfer day 7|Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
49750|NCT03795207|Combination Product|SBRT + Durvalumab|"Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy"
49751|NCT03795207|Radiation|SBRT|SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
49752|NCT03795194|Drug|ampicillin/clavulanate|FDA-approved antibiotic
49753|NCT03795168|Device|Transcranial vibrating system|The transcranial vibrating system (TCVS) will be worn by participants performing vestibular physical therapy (PT) exercises. The TCVS vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises. The TCVS will be set at an optimal vibration frequency as determined in a previous study.
49754|NCT03795168|Device|Transcranial vibrating system sham|A transcranial vibrating system (TCVS) sham set at an irrelevant vibrating frequency will be worn by participants performing vestibular physical therapy (PT) exercises in arm 2. The TCVS sham vibrating element will be placed against the skull, preferably over the mastoid bone behind the ear and will be hold in place by a headband. The TCVS sham will be worn during the whole time of the vestibular PT exercise (30 minutes) or less if the participant is unable to complete its exercises.
49755|NCT03795142|Biological|BGB149|Single Ascending Dose
49756|NCT03795142|Biological|Placebo|Matching placebo
49757|NCT03795129|Behavioral|SleepLife Application w/FitBit|"Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application.~Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application."
49758|NCT03795129|Behavioral|FitBit w/Minimal to No SleepLife App.|"Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it).~Subjects will receive no training with regard to how to access SleepLife Application.~Subjects' physicians will receive no subject sleep data."
49759|NCT03795116|Device|LED-RL phototherapy|The LED-RL treatment device has a 4.7 cm x 6.1 cm rectangular array of LEDs and emits visible red light (633 nm) at a power density of 360.2 W/m2 at room temperature and a distance of 10 mm from the target surface.
49760|NCT03795116|Device|Mock irradiation|The mock therapy device is designed to sound, look, and feel identical to the LED-RL treatment device (i.e., has the same physical components and thermal output), except it does not emit visible red light.
49761|NCT03795103|Device|neuromuscular electrical stimulator|A 12-week program of neuromuscular electrical stimulation
49762|NCT03795103|Other|Walking sessions|A 12-week program of walking sessions performed outdoors and independently
49763|NCT03795103|Other|Advices|The usual practice associated with an information leaflet outlining tips for active living and walking.
49764|NCT03795090|Combination Product|Regular Patient privacy curtain|Laundered curtains, used in the hospital, coming from the hospital inventory.
49765|NCT03795090|Combination Product|Antimicrobial Coated curtains|Antimicrobial coating consist of active polymers that are approved by USFDA and USEPA.
49766|NCT03795077|Other|Experimental group|Experimental group followed the 3-months programme based in professional ethics. A specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six related activities were created: to solve situations related to real clinical practices. Face to face group sessions based on cooperative learning were planned. Students were divided in small groups, and active participation techniques were used.
49767|NCT03795064|Procedure|Foam sclerotherapy|Foam sclerotherapy is used to all patients for endovenous ablation of insufficient veins in subulcer plexus area.
49768|NCT03795064|Procedure|Endothermal ablation|Endothermal ablation is performed in early setting when truncal vein(s) anatomy is suitable.
49769|NCT03795051|Device|Navigated Transcranial Magnetic Stimulation|This study is a feasibility trial. Each participant will receive 30sessions of 10 Hz or 20 Hz rTMS over the left DLPFC. The rTMS interventions will be guided by a neuronavigation system (StimGuide TMS Navigation System, Magstim, Ltd. Carmarthenshire, UK) for navigation to the treatment location and to ensure consistent placement and orientation of the coil during and between each session. For the purpose of this protocol, these sessions are referred to as nTMS.
49770|NCT03795038|Device|Lipoprotein Apheresis MONET and DALI|Three apheresis treatments assigned to one type of apheresis system of MONETand DALI
49771|NCT03795038|Device|Lipoprotein Apheresis DIAMED and DALI|Three apheresis treatments assigned to one type of apheresis system of DIAMOND and DALI
49772|NCT03795025|Other|Strength training 3x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
49773|NCT03795025|Other|Strength training 6x10RM + no training|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
49774|NCT03795025|Other|3x10RM + 6x10RM|Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.
49775|NCT03795012|Drug|Eribulin|Patients will receive eribulin injections intravenously on days 1 and 8 of every 21-day cycle alone.
49776|NCT03794999|Drug|Benralizumab-exposure|Exposure is defined as any dose of benralizumab for any length of time from 8 weeks prior to Last Mentrual Period (LMP) through the end of pregnancy, as reported by the mother and validated through medical record review. The 8-week cut-off prior to LMP is based upon the terminal half-life of benralizumab of approximately 15 days (clearance of benralizumab is based on five half-lives).
49777|NCT03794999|Drug|Exposure to other asthma medications|Exposure to asthma medications for any number of days, at any dose, and at any time from LMP up to the date of enrollment, but no exposure to benralizumab during pregnancy or within 8 weeks prior to LMP.
49778|NCT03794986|Behavioral|Trauma-informed SGM affirmative care|"All SGM male survivors who meet inclusion criteria, including significant emotional distress, will complete pre-test measures and be randomized to 6-week Motivational Interviewing (MI) delivered by peers in online groups or 6-week MI with trauma-informed, SGM affirmative care delivered by peers in online groups.~Participants will complete pre-intervention (baseline), end of the 6-week intervention, 60- and 120-days follow-up assessments via an online survey platform, to determine if there was an increase in formal treatment engagement, and any significant changes in mental health symptomology (i.e., PTSD, depression, high-risk drinking, and illicit substance use)."
49779|NCT03794986|Behavioral|Motivational Interviewing|"Major principles and tenets of Motivational Interviewing (MI) group include: Non-confrontational nature of group; environment is one of respect, safety, and encouragement of all group members; purpose is to learn about members' personal thoughts and choices and not to push an agenda"
49780|NCT03794973|Biological|TOL-3021|TOL-3021 1 mg is a bacterial plasmid expression vector containing the coding sequences for the human proinsulin (hINS) gene.
49781|NCT03794973|Other|TOL-3021 Placebo|TOL-3021 Placebo
49782|NCT03794960|Biological|TOL-3021|A plasmid expression vector containing the coding sequences for full-length human proinsulin.
49783|NCT03794960|Other|TOL-3021 Placebo|TOL-3021 Placebo
49784|NCT03794947|Procedure|Remote Ischaemic Conditioning|Induced ischaemia to a limb by inflating pressure cuffs around arms or legs to above systolic pressures (mmHg).
49785|NCT03794947|Procedure|Sham Intervention|The sham intervention will inflate pressure cuffs to much lower levels for the same number of cycles.
49786|NCT03794934|Behavioral|Structured Education for new glucose management devices|Individualized professional education based on new glucose management devices in patients with type 1 diabetes mellitus
49787|NCT03794921|Other|Every Step Counts|Pedometer coupled to a website that provides step-count goals, feedback, education, motivation, and social support.
49788|NCT03794908|Device|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
49789|NCT03794908|Device|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home for one hour using Re-timer®.
49790|NCT03794895|Device|Doppler|Doing doppler for women having IUCD associated menorrhagia
49791|NCT03794882|Procedure|Quadratus Lumborum Block|30 mL of .25% bupivacaine with 2.5mcg/mL epinephrine will ne injected on both sides of the mid-abdomen posterior to the mid-axillary line.
49792|NCT03794882|Procedure|Standard Medical Management|Standard medical management typically includes perioperative multimodal analgesia utilizing acetaminophen, opioids, non-steroidal anti-inflammatory drugs, and dexamethasone
49793|NCT03794869|Other|Percutaneous electrostimulation treatment (EPS)|Apply dry needles in a tight band of some of the muscles that most affect the appearance of low back pain, such as: paravertebral, lumbar quadrate, gluteus medius and pyramidal, and administer analgesic microcurrents.
49794|NCT03794869|Other|Exercise program|It will be consist in a program of lumbo-pelvic stabilization exercises and strengthening of CORE.
49795|NCT03794856|Other|Functional and Structural Magnetic Resonance Imaging (research grade)|Brain structure and function will be compared in middle to late-age adults with asthma compared to healthy adults.
49796|NCT03794856|Other|Cognitive Function Testing (non-diagnostic)|Multiple domains of cognitive functioning will be investigated, including processing speed, executive functioning/working memory and episodic memory.
49797|NCT03794856|Other|Asthma and Psychological Questionnaires (non-diagnostic)|Participants will fill out asthma and psychological questionnaires (non-diagnostic)
49798|NCT03794843|Drug|Nimodipine Injection|Nimodipine injection (trade name: Nimotop) manufactured by Bayer Pharma AG was used as the reference preparation
49799|NCT03794843|Drug|Nimodipine Injection (II)|Nimodipine Injection (II) was supplied by Shenyang Dongxing Pharmaceutical Technology Co., Ltd
49800|NCT03794830|Other|manipulation group (MG)|Patients were treated with sacroiliac joint osteopathic semidirect manipulation twice a week every 3 to 4 days over a period of time of 3 weeks
49801|NCT03794830|Other|electrotheraphy group (EG)|Patients were treated with micro-waves (circular antenna in lumbar area, pulsating-mode 120W for 12 minutes) and later conventional analgesic TENS (80Hz frequency, 30 minutes) 5 days per week over a period of time of 3 weeks (15 sessions)
49802|NCT03794804|Device|ColdZyme|"ColdZyme® Mouth Spray, a CE -marked device with the following composition of the spray solution: glycerol, purified water, cod trypsin, ethanol (<1 %), calcium chloride, trometamol and menthol.~ColdZyme is a non-sterile mouth spray packaged in a primary container consisting of a 20 ml semi-transparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap."
49803|NCT03794804|Device|ColdZyme Placebo|The placebo mouth spray solution has the following composition: ethanol (<1 %), menthol and water. The placebo mouth spray is packaged in a primary container consisting of a 20 ml semitransparent plastic bottle, pump, actuator (spray nozzle) and an actuator terminal cap.
49804|NCT03794791|Behavioral|education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
49805|NCT03794791|Behavioral|no education|Education Methods including video playing of HCV Introduction (disease profile, risk factors for infection, outcomes, HBV/HCV coinfection, reinfection, etc) for 5 min, booklets of relative information distribution, physicians and nurses consulting in clinic.
49806|NCT03794778|Drug|pegylated liposomal doxorubicin|PLD 30 mg/m2, i.v.,d1; once every 21days
49807|NCT03794778|Drug|paclitaxel|paclitaxel 175 mg/m2, i.v.,d1; once every 21days
49808|NCT03794778|Drug|Carboplatin|carboplatin AUC 5, i.v.,d1; once every 21days,
49809|NCT03794765|Drug|Ceftriaxone|Injection ceftriaxone 1 gm will be prepared by reconstitution of the crystallised powder form in 100 ml of normal saline. This preparation will then be infused slowly over thirty minutes, after intradermal testing for hypersensitivity. Inj ceftriaxone 1gm IV will be given twelve hourly.
49810|NCT03794765|Drug|Metronidazole|Injection metronidazole 500 mg is available from pharmacies in solutions of 100 ml. It will be infused slowly over thirty minutes, three times per day
49811|NCT03794765|Other|Placebo infusion|Similar placebo infusion
49812|NCT03794752|Device|Head-Mounted Visual Enhancement Device|'Head-Mounted Visual Enhancement Device' has designed a head mounted electronic visual enhancement device that is compact and similar to glasses. It will be powered by a battery pack connected to the device. The electronic display will be affixed over only one of the user's eyes. The vision through the unobstructed eye will aid with the subject's balance and spatial orientation. The prototype display and camera will be connected to a battery pack/control box that will allow the user to quickly select one of 3 modes. Each mode will represent a combination of parameters (brightness of the display, focus lock, color/black & white, contrast, magnification) designed to optimize the image for different activities (e.g. reading, walking, computer use).
49815|NCT03794713|Device|Patient support tool|The patient support tool, a software app installed on the smart phones plus a wrist connected to the smart phones by Bluetooth. The wrist could monitor the pulse, which was recorded to the app in the smart phone. Meanwhile, the app could inform to patients about the importance of medication, remind on the medicine intake, share the patients' data with themselves, and warn the patients if the wrist don't wear.
49816|NCT03794700|Other|Hospice Decision Aids|Paper and video hospice decision aid
49817|NCT03794687|Procedure|Left heart catheterization|Catheterization via the distal radial artery
49818|NCT03794674|Other|No intervention.|No intervention, since this is a validation study
50412|NCT03790150|Other|Evidence-based practices|Implementation of evidence-based practices
49819|NCT03794661|Device|Clinician programmer electrode screening mode tool|Provides a standardized workflow to guide clinicians or trained healthcare providers through the deep brain stimulation monopolar review screening process
49820|NCT03794648|Behavioral|Mobile Interactive Supervised Therapy (MIST)|MIST system will send a reminder notification (via push or SMS) to participants 10 to 15 minutes before the scheduled time for taking their medication. Participants will then activate the recording function of the MIST app on their phone, and record themselves taking their medication.Participants will be asked to go through a series of steps for recording the video.
49821|NCT03794635|Behavioral|Weekly 45 minute Sessions|The current intervention consists of six, weekly,45-minute sessions conducted over the telephone using patient and caregiver workbook. Interventions will occur weekly with a plus three-week window.
49822|NCT03794622|Other|intramedullary nail fixation with bone marrow concentration|intramedullary nail fixation with bone marrow concentration
49823|NCT03794622|Other|intramedullary nail fixation|intramedullary nail fixation only
49824|NCT03794596|Drug|Avelumab|Colourless odourless aqueous solution for infusion at dose of 10mg/kg
49825|NCT03794596|Drug|Aspirin|300mg tablets
49826|NCT03794596|Drug|Lansoprazole (Proton Pump Inhibitor)|300mg capsule
49827|NCT03794583|Drug|Inhaled treprostinil solution|Inhaled treprostinil solution (6 mcg/breath), 4 times daily (QID) during waking hours.
49828|NCT03794570|Device|Blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to 80% limb occlusion pressure
49829|NCT03794570|Device|Sham blood flow restriction therapy - with Delfi Personalized Tourniquet System|Physical therapy performed with Blood flow restriction therapy tourniquet inflated to only minimal pressure
49830|NCT03794557|Drug|Sterile Water Injection|Inhaled Sterile Water Injection
49831|NCT03794557|Drug|PUL-042 Inhalation Solution|PUL-042 Inhalation Solution
49832|NCT03794544|Drug|Durvalumab|Durvalumab
49833|NCT03794544|Combination Product|Durvalumab + Oleclumab|Durvalumab + Oleclumab
49834|NCT03794544|Combination Product|Durvalumab + Monalizumab|Durvalumab + Monalizumab
49835|NCT03794544|Combination Product|Durvalumab + Danvatirsen|Durvalumab + Danvatirsen
49836|NCT03794518|Drug|Pioglitazone Plus dapaglifliozin|Pioglitazone Plus dapaglifliozin
49837|NCT03794518|Drug|Placebo|(Beta blockers, ACEI, ARB, and aldosterone )
49838|NCT03794505|Drug|Methylprednisolone Acetate|depo-medrol 40 mg
49839|NCT03794505|Drug|Lidocaine 2% Injectable Solution|2ml of 2% lidocaine
49840|NCT03794505|Drug|Ropivacaine HCl Inj 7.5 MG/ML|25 mg
49841|NCT03794492|Drug|Mycophenolate Mofetil 500Mg Tab. or 250Mg Cap.|Mycophenolate mofetil 1,000 ~ 2,000mg
49842|NCT03794492|Drug|Tacrolimus|Tacrolimus
49843|NCT03794492|Drug|Methylprednisolone/prednisone|Methylprednisolone/prednisone
49844|NCT03794492|Drug|Simulect® (Basiliximab)|Simulect® (Basiliximab)
49845|NCT03794440|Drug|Sintilimab|200mg IV d1， Q3W
49846|NCT03794440|Drug|IBI305|15mg/kg IV d1， Q3W
49847|NCT03794440|Drug|Sorafenib|400mg PO BID
49848|NCT03794427|Other|unilateral lumbosacral nerve block|Patients will receive unilateral lumbosacral nerve block (sciatic nerve block and paravertebral block at levels L3-L4 and L4-L5). The sciatic nerve will be injected by 20 ml of the anesthetic mixture whereas levels L3-L4 and L4-L5 will be injected by a total of 20 ml of the anesthetic mixture without exceeding the maximum injected volume of 1 ml/kg.
49849|NCT03794427|Other|Spinal anesthesia|Patients will receive spinal anesthesia (3 ml of 0.5% bupivacaine)
49850|NCT03794427|Other|Placebo at the spinal anesthesia level|Patients will receive 1 ml normal saline at the spinal anesthesia level (L3-L4 or L4-L5).
49851|NCT03794427|Other|Placebo at lumbosacral level|Patients will receive normal saline at the sciatic, L3-L4 and L4-L5 levels
49852|NCT03794414|Procedure|PEEP challenge|apply PEEP 10 mmHg in one-lung ventilating patients.
49853|NCT03794388|Drug|Capsaicin|Application of capsaicin patches at 8% on painful area
49854|NCT03794388|Drug|Pregabalin|Taking Pregabalin tablets
49855|NCT03794375|Other|Telehealth|After 45 days after the estimated date of the consultation (6 months after discharge), the Telehealth staff will contact the patient to check if the consultation was actually performed. When individuals report difficulty accessing the unit, contact will be made to the primary care teams and the Telehealth staff will schedule the appointment. A new contact will be made in 12 months to verify if the consultation was actually performed.
49856|NCT03794375|Other|Usual care|The patients will remain in care at the HCPA thyroid disease outpatient clinic during the study period. This follow-up will be done by endocrinologists, and the patients will undergo clinical, biochemical (TSH, thyroglobulin, and antithyroglobulin) and radiological (cervical ultrasound) tests to seek disease recurrence. The patient's consultation will be done one or twice a year.
49857|NCT03794349|Biological|Dinutuximab|Given IV
49858|NCT03794349|Drug|Eflornithine|Given PO or via NG or G tube
49859|NCT03794349|Drug|Irinotecan|Given IV
49860|NCT03794349|Biological|Sargramostim|Given SC or IV
49861|NCT03794349|Drug|Temozolomide|Given PO or via NG or G tube
49862|NCT03794336|Drug|Alogliptin|"Pharmaceutical form: tablet~Route of administration: oral administration"
49863|NCT03794336|Drug|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
49864|NCT03794336|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral administration"
49865|NCT03794336|Drug|Aspirin|"Pharmaceutical form: tablet~Route of administration: oral administration"
49866|NCT03794323|Drug|BI 764122|Tablet
49867|NCT03794323|Drug|Placebo|Tablet
49868|NCT03794310|Drug|NPF-08 （1-day treatment）|NPF-08 will be administered on the day of colonoscopy.
49869|NCT03794310|Drug|NPF-08 （2-day split dose）|NPF-08 will be administered at 2 days divided into the day before and on the day of colonoscopy.
49870|NCT03794310|Drug|Moviprep（1-day treatment）|Moviprep will be administered on the day of colonoscopy.
49871|NCT03794297|Drug|Dabrafenib Mesylate|Given PO
49872|NCT03794297|Other|Quality-of-Life Assessment|Ancillary studies
49875|NCT03794284|Diagnostic Test|VereMTB|At least 2 mL of patient's expectorated or induced sputum would be collected for VereMTB assay and their clinical data would be retrieved for analysis use.
49876|NCT03794271|Procedure|Pupilometer guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
49877|NCT03794271|Procedure|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
49878|NCT03794258|Drug|SOF+DCV+CDI-31244|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg administered orally once daily.
49879|NCT03794258|Drug|SOF+DCV+CDI-31244+ASV|Sofosbuvir (SOF) 400 mg administered orally once daily; Daclatasvir (DCV) 60 mg administered orally once daily; CDI-31244 400 mg orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
49880|NCT03794245|Behavioral|Men-Centered HIV Testing|The intervention involves bringing mobile HIV testing to venues where men congregate, talking to them as a group about HIV testing, and then providing testing at that venue.
49881|NCT03794245|Behavioral|Linkage to Care for HIV+ Men|Men diagnosed with HIV are accompanied to the clinic and registered there with the help of a community health worker.
49882|NCT03794245|Behavioral|Clinic-based HIV Testing|Individuals present to a clinic and request HIV counseling and testing
49883|NCT03794245|Behavioral|Clinic Referral for HIV+ Men|Individuals diagnosed with HIV are referred to the nearest clinic for treatment of HIV
49884|NCT03794232|Dietary Supplement|NIUCHANG|
49885|NCT03794232|Dietary Supplement|Placebo|
49886|NCT03794219|Other|Kinesio Tape|To all patients,750 mg/day oral naproxen is administered for 10 days. Additionally, in intervention group kinesio tape is applied 3 times a week for 2 weeks with a total of 6 sessions.
49887|NCT03794219|Drug|oral naproxen|750 mg/day oral naproxen is administered for 10 days.
49888|NCT03794206|Device|Vesair Balloon|Treatment with Vesair Balloon for one year
49889|NCT03794193|Procedure|Radical resection of colon cancer|The patients with colon cancer will receive radical surgery. Adjuvant chemotherapy will be given according to the results of postoperative histological results.
49890|NCT03794180|Drug|TJ003234|Brownish-yellow liquid containing TJ003234, a recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody diluted with normal saline
49891|NCT03794180|Drug|Placebo|Colorless to slightly brownish-yellow liquid without TJ003234 diluted with normal saline
49892|NCT03794167|Drug|Busulfan|busulfan 3.2 mg/kg/day i.v. on days -8,-7, and -6
49893|NCT03794167|Drug|Cyclophosphamide|cyclophosphamide 50mg/kg/day i.v. on days -3 and -2
49894|NCT03794167|Drug|Etoposide|etoposide 400mg/m2 day i.v. on days -5 and -4
49895|NCT03794167|Drug|Melphalan|melphalan 50mg/m2/day i.v. on days -3 and -2
49896|NCT03794154|Drug|Cymbalta capsule|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
49897|NCT03794154|Drug|Duloxetine hydrochloride capsule|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
49898|NCT03794141|Behavioral|information on the risk gene status|information on risk gene status (APOE4 allele or not) was given before intervention
49899|NCT03794141|Behavioral|life style advise|all test persons were given information on healthy diet and life style
49900|NCT03794128|Procedure|Blood collection for research (next-generation sequencing [NGS])|Participants will have whole blood collected for next-generation sequencing (NGS).
49901|NCT03794128|Procedure|Blood collection for research (HLA typing)|Participants will have whole blood collected for HLA typing.
49902|NCT03794115|Procedure|Treatment for ovarian cancer|The treatment for ovarian cancer includes the debulking surgery and platinum-based chemotherapy.
49903|NCT03794102|Other|Water|Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
49904|NCT03794102|Other|Saline|0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
49905|NCT03794089|Behavioral|Brief anxiety intervention|Modular anxiety intervention, tailored for Veterans, with emphasis on healthy active coping skills
49906|NCT03794089|Behavioral|Usual PC-MHI care|Anxiety treatment with mental health provider in local primary care clinic
49907|NCT03794076|Drug|Cromoglycate|Cromoglycate will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray
49908|NCT03794076|Drug|Placebo|Normal saline nasal spray will be administered intranasally (nasal spray) (1 spray each nostril 4 times a day, 5.2 mg/spray)
49909|NCT03794063|Other|Robson 10 group classification system|WHO proposed the Robson classification system as a global standard for assessing, monitoring and comparing caesarean section rates within healthcare facilities over time, and between facilities. It classifies women in 10 groups based on their obstetric characteristics (parity, previous CS, gestational age, onset of labour, fetal presentation and number of fetuses) without needing the indication for CS.
49910|NCT03794050|Other|Resistance training exercise|randomized complete crossover for acute resistance training exercise session
49911|NCT03794050|Other|Aerobic training exercise|randomized complete crossover for acute aerobic exercise training exercise session
49912|NCT03794037|Drug|dydrgesterone 10 mg( tab)/12hs/14 days|Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup
49913|NCT03794037|Combination Product|montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days|montelukast 10 mg(tab) once daily oral for 7 days & dydrgesterone 10 mg (tab) twice daily oral for 14 days &
49914|NCT03794024|Device|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator|The Nuvectra Algovita Dorsal Column Spinal Cord Stimulator is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
49915|NCT03794024|Device|The Axium Neurostimulator System|The Axium Neurostimulator System is indicated for spinal column stimulation via epidural and intra-spinal lead access to the dorsal root ganglion as an aid in the management of moderate to severe chronic intractable pain of the lower limbs in adult patients with Complex Regional Pain Syndrome Types I and II
49916|NCT03794011|Device|fetoscopy|The fetoscopic arm is described above. Patients who have an appropriate window (posterior placenta) and choose fetoscopic surgery will be offered the two fetoscopic options, (i) laparotomy assisted and, (ii) totally percutaneous expandable port assisted. Patients with an anterior placenta will only be offered the lapartotomy assisted approach. All patients will undergo a fetoscopic repair of the fetal open neural tube defect including a the use of a Durepair patch.
49917|NCT03793985|Drug|T|CKD-391 40/10mg
49918|NCT03793985|Drug|R|D086 and D337 co-administration
49919|NCT03793972|Other|Triage with referral to primary care|During intervention weekends(and holidays) a nurse will triage patients using a newly developped extended Manchester Triage System (eMTS). Patients appropriate for primary care will be referred to the general practitioner on call.We will inform patients about the nature of the intervention using leaflets and broadcasting in the waiting room of the Emergency Department.
49920|NCT03793972|Other|Usual care|During a control weekend (and holidays), all data registration and collection will be the same as during intervention weekends but patents will not be informed about their allocation advice. The emergency physician will see all patients deciding to stay at the ED, without influence of the triage advice. As in standard clinical care, patients will have the right to change their mind and go spontaneously to the general practitioner. . During control weekends, we will only inform about triage in general but no about the general practioner or the intervention.
49921|NCT03793959|Dietary Supplement|Synbiotic Supplement|
49922|NCT03793959|Dietary Supplement|Placebo|
49923|NCT03793946|Other|AB-assistant|The AB-assistant is an antimicrobial stewardship smartphone application that offers local antimicrobial guidelines to physicians currently assessed per website or paper/digital booklet.
49924|NCT03793933|Procedure|Liver resection|Surgery for the liver
49925|NCT03793920|Other|Facial Emotion Test|All tasks will be delivered using a laptop and E-Prime 2 software (Psychology Software Tools, Inc., Pittsburgh), which will also be used to collect behavioral responses.
49926|NCT03793907|Other|Control Group|To perform activities of daily living according to the discretion of an orthopedic or neurosurgeon.
49927|NCT03793907|Other|Questionnaire Administration|Ancillary studies
49928|NCT03793907|Other|Strenght Training|Twice a week strength training for 6 months
49929|NCT03793894|Behavioral|Smoking Cessation Counseling|All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.
49930|NCT03793894|Behavioral|Decision Aid|"The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)"
49931|NCT03793894|Behavioral|Shared decision making (SDM)|"During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare & Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context."
49932|NCT03793894|Behavioral|CHW Navigation|The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
49933|NCT03793881|Behavioral|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
49934|NCT03793881|Behavioral|Dietary Prescription|Dietary prescription according to guidelines.
49935|NCT03793868|Drug|Perampanel|Oral tablet
49936|NCT03793868|Other|Placebo|Placebo (not drug)
49937|NCT03793855|Behavioral|Nutritional Strategy|Counseling based on dietary goals and mindfulness techniques.
49938|NCT03793855|Behavioral|Dietary Prescription|Dietary prescription according to guidelines.
49939|NCT03793842|Other|Usual care|Intervention is the standard basic lung protective ventilation strategy used at the University Hospital Respiratory Care at Michigan Medicine.
49940|NCT03793842|Device|PEEP titration by EIT|PEEP Titration procedure involves two phases: a recruitment phase followed by a gradual reduction in the end-expiratory pressure phase (Decremental PEEP).
49941|NCT03793829|Biological|(H2NVAC)|"Intervention: Biological/Vaccine: (H2NVAC) Dose levels: In phase I, there are 3 dose levels of H2NVAC Nine patients will be treated in each dose level starting dose level 1. a total of 27 patients will be enrolled in this phase.~Dose Levels H2NVAC Dose 1.500 µg/peptide 2.1000 µg/peptide 3.1500 µg/peptide~The dose with acceptable safety and tolerability & maximum immune response will be used in the expansion cohort of this trial. A total of 16 additional patients will be enrolled in this portion of this trial.~Dose limiting toxicities (DLT) are defined to be any of the following criteria using the National Cancer Institute's Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events, version 4.0"
49942|NCT03793816|Device|BiZactTM Open Sealer/Divider|The BiZactTM Open Sealer/Divider creates a seal by application of radiofrequency (RF) electrosurgical energy to blood and lymphatic vessels or tissue bundles interposed between the jaws of the instrument. A cutting blade within the instrument is surgeon-activated to divide tissue. It is a single-use device and will not be reused in other patients.
49943|NCT03793803|Behavioral|Home Palliative Care|Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
49944|NCT03793790|Behavioral|Conditioning with partial reinforcement|Conditioning with partial reinforcement (PRF) provides an uncertain pairing of unconditioned high pain stimuli and conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device). During PRF only 70 percent of unconditioned stimuli are paired to conditioned stimuli. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device and are also used in the 30 percent of unreinforced trials.
49945|NCT03793790|Behavioral|Conditioning with continuous reinforcement|During conditioning with continuous reinforcement (CRF) unconditioned high pain stimuli are paired to conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) in 100 percent of conditioning trials. Pain of only moderate intensity is used for control stimuli that are paired to the deactivation of the mock device.
49946|NCT03793790|Behavioral|Counterconditioning|During counterconditioning, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) to thermal pain stimuli of low intensity.
49947|NCT03793790|Behavioral|Extinction|During extinction, the previously conditioned nocebo effects on pain are attenuated by pairing the same conditioned stimuli (i.e., on-screen messages signaling the activation of a mock medical device) only to control stimuli of moderate intensity (previously paired to the deactivation of the mock device).
49948|NCT03793790|Behavioral|Sham Conditioning|In the sham group, participants receive different instructions (namely, that the activation of the device is not expected to affect their pain sensitivity). Additionally, during sham conditioning unconditioned stimuli are not consistently paired to conditioned stimuli, thereby preventing the formation of an association between high pain stimuli and the activation of the mock medical device. In the attenuation phase participants undergo an extinction procedure.
49949|NCT03793777|Dietary Supplement|Aronia|daily supplementation
49950|NCT03793777|Combination Product|Combination of aronia and guarana|daily supplementation
49951|NCT03793777|Dietary Supplement|Placebo|daily supplementation
49952|NCT03793764|Procedure|TAP block|USG guided TAP block
49953|NCT03793764|Procedure|QL block|USG guided QL block
49954|NCT03793751|Drug|Dexmedetomidine Injection|Dexmedetomidine Injection at a dose of 1 mcg/kg over 10 min, after Spinal Anaesthesia and before start of surgery, followed by a continuous infusion at a rate of 0.4 mcg/kg/h until the end of surgery.
49955|NCT03793738|Procedure|Anterior component separation|
49956|NCT03793738|Procedure|Posterior component separation|
49957|NCT03793725|Drug|SHR1210|Anti-PD-1 Antibody
49958|NCT03793725|Drug|Apatinib|Anti-angiogenic drugs
49959|NCT03793712|Drug|Lu AF11167 (1-2 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
49960|NCT03793712|Drug|Lu AF11167 (3-4 mg/day)|Fixed-flexible oral dose, tablets. Once daily. 12 weeks.
49961|NCT03793712|Drug|Placebo|Placebo oral dose, tablets. Once daily. 12 weeks.
49962|NCT03793686|Drug|PBCLN-003|Investigational drug
49963|NCT03793686|Drug|Placebo|Placebo
49964|NCT03793673|Behavioral|CoYoT1 Care|Selected providers will be trained in the CoYoT1 Care protocol for completing medical appointments (both telehealth/standard appointments). There are three key components: (1) Shared decision making: Providers and YA will mutually agree on priorities for each medical visit using a shared decision making tool completed by both the provider and patient. (2) Autonomy supportive care: Providers will be trained in communication strategies, such as motivational interviewing, designed to support YA autonomy and intrinsic motivation. YA will also direct extent of eligible family involvement. (3) Goal setting and action planning: Providers will be trained to coach YA in setting SMART goals, developing action plans, and establishing a plan for follow-up between visits as appropriate.
49965|NCT03793673|Other|Standard Care|Providers selected for the Standard Care group will complete medical appointments in their usual manner, without specific training or guidelines regarding how to deliver care.
49966|NCT03793647|Device|Electrical muscle devise|evaluate two types of EMS stimulation of legs
49967|NCT03793634|Drug|topical chamomile|herbal medication which has antioxidant, anti-inflammatory and anticarcinogenesis effect
49968|NCT03793621|Drug|BI 730357|single rising oral dose
49969|NCT03793621|Drug|Placebo|single rising oral dose
49970|NCT03793608|Drug|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
49971|NCT03793608|Drug|placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
49972|NCT03793595|Device|Seated Battle Ropes Protocol|Participants will begin swinging the rope as previously described in the seated position using the double arm swing technique for 15 seconds at a cadence of 100 beats/ minutes with a 45 second rest break repeated 10 times.
49973|NCT03793595|Device|Seated Upper Extremity Arm Bike|A modified Young Men's Christian Association (YMCA) cycle test will be performed.
49974|NCT03793582|Diagnostic Test|ApneaLink Type III portable sleep study|Type III portable sleep study
49975|NCT03793569|Behavioral|Peer discussion group|Subjects in the intervention group will be asked to attend one peer group between four and eight weeks postpartum. Peer groups will be expected to last approximately one hour. Each peer group will include 5-10 new mothers. A facilitator will be present for these groups, but the hope is to have mothers discuss with each other their postpartum experience and activities of their newborn at home.
49976|NCT03793556|Device|GERDOFF®|GERDOFF® Hyaluronic acid + chondroitin sulphate + hydroxide aluminium Melt-in-mouth tablet 1100 mg
49977|NCT03793556|Drug|Omeprazole|Omeprazole, 2 tablets 20 mg, once a day before breakfast
49978|NCT03793543|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
86667|NCT03509012|Drug|Etoposide (dose level 1)|IV
49979|NCT03793530|Other|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration|Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
49980|NCT03793530|Other|Transforaminal lumbar interbody fusion with local bone graft|Transforaminal lumbar interbody fusion with local bone graft
49981|NCT03793517|Drug|Decitabine|Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
49982|NCT03793517|Drug|mBU/CY and ATG|Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
49983|NCT03793517|Drug|mBU/CY|hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
49984|NCT03793491|Other|TCI scale|TCI scale : Evaluation of the patient's personality with the TCI before that the treatment by continuous infusion started.
49985|NCT03793491|Other|PDQ-39 scale|PDQ-39 scale: Comparison of life quality before and after the starting of he treatment by continuous infusion.
49986|NCT03793478|Drug|Quizartinib|"60 mg powder for solution for oral administration once daily:~during dose escalation: at the dose assigned at study entry~during dose expansion and maintenance: at the RP2D dose for their age group"
49987|NCT03793478|Drug|Intrathecal (IT) triple chemotherapy prophylaxis|IT cytarabine, methotrexate, and either prednisolone or hydrocortisone at doses based on the subject's age and standard practice at each site
49988|NCT03793478|Drug|Fludarabine|As part of FLA, 30-minute intravenous (IV) infusion of fludarabine on Days 1 through 5 of re-induction Cycles 1 and 2, followed by cytarabine
49989|NCT03793478|Drug|Cytarabine|As part of FLA, 3-hour IV infusion starting 4 hours after start of fludarabine on Days 1-5 of re-induction Cycles 1 and 2
49990|NCT03793478|Drug|Etoposide|IV infusion over 3 hours only on Days 1-5 of optional high intensity consolidation with chemotherapy and quizartinib
49991|NCT03793478|Drug|Daunorubicin|120-minute IV infusion on Days 1, 3 and 5 of re-induction Cycle 1 (after FLA)
49992|NCT03793465|Dietary Supplement|tart cherry concentrate|Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery
49993|NCT03793439|Drug|Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial|Tofacitinib 5mg oral table twice daily for 16 weeks
49994|NCT03793439|Diagnostic Test|Spirometry|Spirometry testing at baseline, week 4, week 8, week 12, and week 16
49995|NCT03793439|Genetic|RNA Sequencing|RNA sequencing test at baseline and week 16
49996|NCT03793439|Diagnostic Test|Laboratory testing|Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16
49997|NCT03793439|Drug|Corticosteroid|Taper corticosteroids starting at week 4
49998|NCT03793439|Drug|Tofacitinib 5mg [Xeljanz] 1 year open-label extension|After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
49999|NCT03793426|Biological|Fibryga|Human plasma-derived fibrinogen concentrate
50000|NCT03793413|Procedure|Lingual frenotomy|A lingual frenotomy will be performed using a CO2 laser - using the NFANT bottle feeding system, the intervention arm will be compared against the observation arm to determine if there are changes in lingual mobility parameters during bottle feeding.
50001|NCT03793400|Drug|Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)
50002|NCT03793387|Procedure|AF-guided endobronchial marking|Bronchoscopic dye marking under CBCT-augmented fluoroscopic guidance
50003|NCT03793387|Device|ENB-guided endobronchial marking|Bronchoscopic dye marking with ENB system
50004|NCT03793374|Other|Subcutaneous apocrine glands shaving|A 0.5-cm long incision was made in the identified elliptical surgical area at each axilla for the access of arthroscopy to remove the apocrine glands. A suction-assisted cartilage shaver (E9005 System, Linvatec Corporation, Largo, Florida, USA) was introduced through the incisions to remove of the subcutaneous apocrine glands radially. After defatting, the incisions were closed primarily with 4-0 polyglactin. We anchored the defatting skin to the axillary fascia by 4-0 nylon sutures instead of the tie-over dressing or tissue glues, and we also made several drainage holes by inserting an 18G needle obliquely into the defatting skin. Therefore, draining tubes were no longer needed. We will remove the stiches at the 8th day after the operation.
50005|NCT03793361|Drug|Regorafenib|"Oral Drug in the form of 40 mg tablets - Regorafenib (120 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.~Provided by BAYER"
50006|NCT03793361|Drug|Placebo|"Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER"
50007|NCT03793348|Device|MCD|Micro coring skin removal with automated coring device
50008|NCT03793322|Drug|Indocyanine-Green(ICG)|ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
50009|NCT03793309|Drug|Vitamin D|Oral vitamin D
50010|NCT03793296|Device|Percutaneous Device Closure: Vascular plug|percutaneous transcatheter approach into cardiac valve
50011|NCT03793283|Device|CSII|Currently receiving CSII therapy during 6 or more months.
50012|NCT03793283|Drug|Multiple dose insulin injections|Currently receiving MDI therapy during 6 or more months.
50013|NCT03793270|Diagnostic Test|for patients and healthy donors|"Detection of (CD19, CD24, CD38 & CD27) markers in peripheral blood samples by Flow Cytometry~Determine the serum level of IL 10 using ELISA plate"
50014|NCT03793244|Dietary Supplement|TARGET protocol EN 1.5 kcal/mL|Enteral nutrition
50015|NCT03793231|Combination Product|fungalAi platform technology|Electronic surveillance and radiologic diagnosis of invasive fungal infections using fungalAi and associated methodologies.
50016|NCT03793218|Device|Latera Device|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
50017|NCT03793218|Procedure|Alar Batten Graft|"This study seeks to compare a gold standard functional rhinoplasty maneuver, the alar batten graft, to the LATERA implant"
50018|NCT03793205|Drug|Long-acting G-CSF|Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
50019|NCT03793205|Drug|Short-acting G-CSF|Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
50020|NCT03793192|Other|PACE2 Intervention|Written educational materials regarding physical activity, telephone-based coaching to integrate physical activity in daily life activities and address barriers to attending pulmonary rehabilitation.
50029|NCT03793153|Procedure|Uterine Cooling Technique|Standard LSCS will be done except immediatelyfollowing delivery of the fetus the uterus will beexternalized in the usual fashion and the body of theuterus cephalad to the hysterotomy incision will bewrapped in sterile surgical towels saturated in sterile,iced normal saline. These towels will come from asterile cooling pot set to 30 degrees Fahrenheit. Theskin of the abdomen will be draped to prevent contactwith the cold towels. Iced saline-soaked towels will bekept in place for a minimum of 5 minutes and replacedat the discretion of the attending obstetrician until thehysterotomy is closed and the uterus is replaced intothe patient's abdomen.
50030|NCT03793140|Drug|CPI-613|CPI-613 [2,500 mg/m2/day IV] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 [2,500 mg/m2/day IV] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
50031|NCT03793127|Other|Maximal oxygen consumption (V02 max)|Aerobic fitness will be determined by measuring V02 max during a stationary bicycle exercise test.
50032|NCT03793127|Other|Brown adipose tissue (BAT) imaging|Brown adipose tissue will be differentiated from white adipose tissue using fat fraction and T2* relaxation time maps generated from a commercially available modified 6-point Dixon (mDixon) water-fat separation method.
50033|NCT03793127|Other|Muscle function testing|This test will be done on a machine called a Biodex. We will measure the speed at which subjects move resistance at different percentages of their peak strength.
50034|NCT03793114|Diagnostic Test|Cosyntropin stimulation test|Blood samples are taken before (0 min), and 30 and 60 min after intravenously administration of 250 µg cosyntropin (tetracosactide acetate) with the patient placed in the recumbent position. The test will be performed non-fasting (but medication-fasting) between 08:00 and 10:00 a.m.
50035|NCT03793114|Diagnostic Test|Baseline blood tests|Medication-fasting morning levels of adrenocortical hormones.
50036|NCT03793114|Device|30-hour ambulatory sampling of intestinal fluid|30-hour ambulatory sampling of intestinal fluid for analysis of adrenocortical hormones.
50037|NCT03793101|Procedure|BiMICS|Biaxial microincision cataract surgery implies performing of 2 corneal incisions under 1.8mm, removal of the crystalline lens with the use of ultrasounds and implantation of the artificial intraocular lens.
50038|NCT03793075|Drug|Ketamine|ketamine 5 mcg/kg/min will be used as intravenous anesthetic infusion
50039|NCT03793075|Drug|Propofol|propofol 17 mcg /kg/min
50040|NCT03793062|Other|no interventions|Not applicable- no interventions
50041|NCT03793049|Device|CADence testing will be performed|CADence is a noninvasive, handheld device comprised of acoustic and ECG technology and software
50042|NCT03793036|Dietary Supplement|preoperative nutrition|The participants of experimental group received 400 mil of a clear carbohydrate drink (12,5 gr/100 mil carbohydrate, 50 kcal/100ml, pH 5.0) at 10:00 pm the evening before surgery and another 200 mil of the carbohydrate drink on the day of surgery, 2 hours before induction of anesthesia. After surgery the participants fasted until the recovery of function of the bowel.
50043|NCT03793023|Drug|Teneligliptin 20mg|
50044|NCT03793010|Drug|FX006|Single Intra-articular injection
50045|NCT03793010|Drug|Normal saline|Single Intra-articular injection
50046|NCT03792997|Combination Product|combination therapy for high peripheral NK cells|lipid emulsion & prednisolone & LMWH
50047|NCT03792984|Dietary Supplement|Vitamin D3|Vitamin D3 (Cholecalciferol) (6000 IU/daily). PO for 8 weeks.
50048|NCT03792984|Dietary Supplement|Calcium Carbonate|Calcium carbonate (1000 mg/daily). PO for 8 weeks.
50049|NCT03792984|Drug|Metformin|Metformin (1500 mg/daily; the metformin dose was increased stepwise, starting with 500 mg once daily for the 1st week, 500 mg twice daily in the 2nd week, followed by 500 mg 3 times daily from the 3rd week onward). PO for 8 weeks.
50050|NCT03792984|Drug|Placebo|PO for 8 weeks.
50051|NCT03792971|Drug|Dextromethorphan HBr|A single 60 mg dose of DM capsules liquid-filled on Day 1 and Day 3
50052|NCT03792971|Drug|GC4419|Daily 90 mg IV infusions over 60 minutes on Day 3 and Day 4
50053|NCT03792958|Drug|CM082|CM082 tablets taken orally 200、400、600 and 800 mg (QD or BID)
50054|NCT03792945|Drug|local injection|In addition to the local injection, carpal tunnel brace will be given.
50055|NCT03792945|Device|extracorporeal shock wave therapy|In addition to all ESWT participants, carpal tunnel brace will be given.
50056|NCT03792932|Procedure|Laparoscopic distal pancreatectomy|Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
50057|NCT03792932|Procedure|Open distal pancreatectomy|Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
50058|NCT03792919|Drug|Stop current treatment (anti-HBV neucleos(t)ides)|Stop the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
50059|NCT03792919|Drug|Keep current treatment (anti-HBV neucleos(t)ides)|Keep the current anti-HBV neucleos(t)ides treatment among the CHB patients who meet the criteria the stopping rule of long term treatment.
50060|NCT03792906|Drug|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
50061|NCT03792906|Drug|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
50062|NCT03792906|Drug|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block.
50063|NCT03792906|Drug|Bupivacaine hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg.
50064|NCT03792893|Other|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
50065|NCT03792893|Other|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~BOSO-TM-2430 blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
50066|NCT03792880|Behavioral|Telematic control and self-management program|"During 6 months with CPAP treatment, patients must complete some questionnaires about the presence of refreshing sleep and side effects with the frequency established, using a computing application. Patients can download this application on their own smartphone but, if they prefer, they can be provided with a tablet during the study with this application installed.~A set of variables will be collected using an automatic and wireless transmission from latest generation CPAP to control the CPAP compliance and tolerance. All data will be processed in a platform to generate alarms, which will be controled daily by a researcher, as well as solutions to the problems presented during the monitoring."
50067|NCT03792880|Behavioral|Habitual follow-up in Healthcare System|According to the SEPAR regulation, patients treated with CPAP should be evaluated by the pulmonologist one month after beginning treatment, every 3 months during the first year, every 6 months during the second year and annually from the third year.
50068|NCT03792867|Drug|Doxorubicin|Immediately after resection, 15mg/m2 doxorubicin will be administered by peritoneal perfusion for 60 minutes and then drained.
50069|NCT03792854|Other|EORTC QLQ C30|standardized questionaire
50070|NCT03792854|Other|EORTC QLQ CR29|standardized questionaire
50071|NCT03792841|Drug|AMG 160|Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer
50072|NCT03792828|Drug|Duloxetine HCl 30mg|In the duloxetine group, one capsule of Duloxetine HCl 30mg (Duroceptol) is taken orally and daily from the day before the first operation to seven days after the second operation. In the control group, the patients can take painkillers except duloxetine.
50073|NCT03792815|Drug|Busulfan|busulfan 3.2mg/kg iv on day -8, -7, and -6,
50074|NCT03792815|Drug|Melphalan|melphalan 50mg/m2/day i.v. on day -3 and -2
50075|NCT03792815|Drug|Etoposide|etoposide 400 mg/m2 i.v. on day -5 and -4
50076|NCT03792802|Procedure|laparoscopic appendectomy port sites|one group will have classic port sites ;.Port sites located 1 infraumbilical , 1 right lower quadrant and 1 left lower quadrent . one group will have same dermatome port sites ; One of the port will put in infraumbilical site and the other ones will put 10 cm right and left side from infraumbilical port
50077|NCT03792789|Device|mCIMT with real rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses)."
50078|NCT03792789|Device|mCIMT with sham rTMS|"Modified constraint induced movement therapy will be provided to all children according to predefined protocol.~Sham rTMS will be given using a sham coil."
50079|NCT03792776|Other|cuff inflation with air|Endotracheal tube cuff inflation with air
50080|NCT03792776|Drug|cuff inflation with lidocaine 1%|Endotracheal tube cuff inflation with lidocaine 1%
50081|NCT03792776|Drug|cuff inflation with lidocaine 2%|Endotracheal tube cuff inflation with lidocaine 2%
50082|NCT03792776|Other|Induction of anesthesia|The induction of anesthesia will be made following a preoxygenation with a facial mask with 100% Oxygen. It consists on the intravenous injection of Sufentanil 5 mcg or Fentanyl 50mcg, Lidocaine 1mg/Kg, Propofol 2.5mg/kg, Rocuronium 0.6mg/kg or Cisatracurium 0.15mg/kg.
50083|NCT03792776|Other|Maintenance of anesthesia|Maintenance of anesthesia will be done by sevoflurane + nitrous oxide, and reinjections of morphinomimetics and curare will be made as needed (the total doses will be noted at the end of the intervention).
50084|NCT03792776|Other|Endotracheal intubation|The intubation is made by a N° 7.5 tube in men and a N° 7 tube in women. Cuff inflation will be done upon placement of the endotracheal tube. The cuff's pressure will be monitored at several intervals of the intervention and kept < or = 20 centimeter of water (cmH2O).
50085|NCT03792776|Other|Systematic post-operative analgesia|All patients will receive Paracetamol every 6 hours for the first 24 hours after the end of surgery.
50086|NCT03792763|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
50087|NCT03792763|Drug|Placebo 1.7 ml Subcutaneous Solution|Administration every 4 weeks (Q4W) for 6 months then every 3 months (Q3M) for a total of 3 years or until progression to active, symptomatic MM
50088|NCT03792750|Drug|BMS-986205|Specified Dose on Specified Day
50089|NCT03792750|Biological|Nivolumab|Specified Dose on Specified Day
50090|NCT03792737|Device|Spiral PDS Plus|The Spiral PDS Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral PDS Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
50091|NCT03792737|Device|Spiral MONOCRYL Plus|The Spiral MONOCRYL Plus is an antibacterial monofilament, synthetic absorbable device. It contains triclosan, a broad spectrum antibacterial agent. The device consists of barbed suture material, armed with a surgical needle on one end and a fixation loop at the opposite end. The device is designed to anchor with a closed loop at one end and a unidirectional barbed section on the other end. Spiral MONOCRYL Plus barbs are oriented in one direction to allow tissue approximation without the need to tie surgical knots.
50092|NCT03792737|Device|PDS Plus|PDS Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
50093|NCT03792737|Device|MONOCRYL Plus|MONOCRYL Plus is a non-barbed antibacterial monofilament, synthetic absorbable suture. The suture contains triclosan, a broad spectrum antibacterial agent.
50094|NCT03792737|Device|VICRYL Plus|VICRYL Plus antibacterial suture is a non-barbed synthetic absorbable sterile, surgical suture. The suture contains triclosan, a broad spectrum antibacterial agent.
50095|NCT03792724|Drug|Urelumab + Nivolumab|Treatment with intratumoral urelumab after which Nivolumab will be given.
50096|NCT03792711|Dietary Supplement|Ensure® Plus Advance|"Previous studies suggest that protein supplementation is an effective dietary strategy to decrease frailty by positively influence the weight loss or sarcopenia in elderly.~Lean body mass includes all body tissue except fat and is well recognized to be associated with an increased risk of morbidity and mortality. Oral nutrition supplements have been shown to increase food intake and body weight, but not lean body mass. In previous studies, β-hydroxy-β-methylbutyrate, which is leucine metabolite, has been shown to enhance protein synthesis and decrease protein degradation leading to increase lean body mass. It showed that β-hydroxy-β-methylbutyrate supplement with exercise increased lean body mass in health elderly population and improved the physical performance in elderly women."
50097|NCT03792698|Other|Aidcube digital app-based platform|Use of customizable, patient-specific mHealth home rehabilitation plan
50098|NCT03792685|Other|Normo-carbohydrate meal intake|Subjects are going to receive the normo-carbohydrate meal.
50099|NCT03792685|Other|High-carbohydrate meal intake|Subjects are going to receive the high-carbohydrate meal.
50100|NCT03792685|Other|High-fat meal intake|Subjects are going to receive the high-fat meal.
50101|NCT03792685|Other|High-protein meal intake|Subjects are going to receive the high-protein meal.
50102|NCT03792672|Drug|TAK-653|TAK-653 tablets.
50103|NCT03792672|Drug|Placebo|TAK-653 placebo-matching tablets.
50104|NCT03792672|Drug|Ketamine|Ketamine intravenous infusion.
50105|NCT03792659|Other|Blood Sample Draw|Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.
50106|NCT03792646|Dietary Supplement|Whey protein|Exercise training + 20g whey protein
50107|NCT03792646|Other|Exercise training|Strength exercise
50108|NCT03792633|Biological|huCART19|huCART19 infusion
50109|NCT03792620|Combination Product|Cyclo Thal Dex Daratumumab|Cyclo Thal Dex Daratumumab
50110|NCT03792594|Other|arthroscopic repair with bone marrow concentration|arthroscopic repair with bone marrow concentration
50111|NCT03792594|Other|arthroscopic repair|arthroscopic repair only
50112|NCT03792581|Device|EV1000 and closed-loop system|This system will recommend when patients need fluid or not and adjust vasopressor administration automatically
50113|NCT03792568|Other|ALK Inhibitor|Any ALK inhibitor like crizotinib, alectinib and so on.
50114|NCT03792555|Drug|CRN00808|CRN00808, capsules, once daily by mouth
50115|NCT03792555|Drug|Placebo|Placebo, capsules, once daily by mouth
50116|NCT03792542|Drug|Anlotinib|Anlotinib Hydrochloride ( 12mg, quaque die（QD）, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from adverse events(AEs), they can get declined dosage.
50117|NCT03792529|Other|detect gene mutations of ctDNA and ctRNA|Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.
50118|NCT03792516|Drug|artesunate ointment 40%|artesunate formulated as an ointment to be applied topically to the vulva
50119|NCT03792503|Drug|Apatinib|Apatinib 500 mg Po qd
50120|NCT03792503|Drug|Pemetrexed|Pemetrexe 500 mg/m2 d1×q3w
50121|NCT03792490|Drug|Fasudil|Fasudil hydrochloride hydrate IV solution
50122|NCT03792490|Drug|Placebo|Placebo to Fasudil hydrochloride hydrate, NaCl 0,9%
50123|NCT03792477|Biological|Test formulation|A single testosterone cypionate solution for injection (new formulation) 200 mg dose administered IM deep in the gluteal muscle (Test formulation).
50124|NCT03792477|Biological|Reference formulation|A single testosterone cypionate solution for injection (currently marketed formulation) 200 mg dose administered IM deep in the gluteal muscle (Reference formulation).
50125|NCT03792451|Drug|Pegvaliase|Treated with pegvaliase for one or more years or followed an unrestricted diet for 6 or more months while being treated with pegvaliase.
50126|NCT03792438|Diagnostic Test|Transvaginal 3D Power Doppler Ultrasound|Samsung H60 ultrasound machine with 4-9 MHz volume transducer using VOCAL system and Histogram Facility
50127|NCT03792425|Procedure|Connective tissue graft and implant placement|Augmenting soft tissue with connective tissue graft
50128|NCT03792412|Other|Usability Questionnaire|Patients receive the usability questionnaire and a structured nutrition and lifestyle program for post-bariatric follow-up visits. Twice in six months the patients visit their family doctor and hand over the usability questionnaire to evaluate the structured follow-up program for postbariatric patients. Family doctors fill out the questionnaire and returns it to the investigator.
50129|NCT03792399|Behavioral|feedback counseling|Professoinal CGM in combination with diet and exercise record is used as teaching material to help patient realize their blood glucose pattern and to modify their behavior after counseling feedback.
50130|NCT03792386|Procedure|Ultrasound guidance with fluoroscopic confirmation|the cervical spine will be sonographically examined to determine the C7 transverse process then after lidocaine skin infiltration, a 22G spinal needle is directed towards the hypoechoic shadow of the nerve root using the in-plane technique. then 1ml of non-ionic contrast will be injected and AP and the oblique foraminal fluoroscopic view will be obtained. After confirmation of correct placement of the needle,(2ml, 8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
50131|NCT03792386|Procedure|Fluoroscopic guidance with ultrasonographic confirmation.|After AP view, alignment or squaring of the target lower end plate, an oblique foraminal view is obtained. Following lidocaine 1% skin infiltration, a 22G spinal needle is directed towards the target foramen then, the superficial ultrasound probe will be applied to delineate the foramen. The needle will be advanced ~3mm towards the dorsal root ganglia under fluoroscopic guidance. After contrast confirmation of needle placement, 2ml,8mg dexamethasone plus 1ml Lidocaine 1%) will be injected.
50132|NCT03792360|Drug|SVF (Stromal Vascular Fraction)|The stromal vascular fraction (SVF), isolated when fresh lipoaspirates are enzymatically digested with a collagenase, contains a heterogeneous cellular and extracellular milieu. SVF is an aqueous fraction, consisting of endothelial cells and their precursors, macrophages, smooth muscle cells, lymphocytes, pericytes, pre-adipocytes and actual AMSCs.
50133|NCT03792347|Drug|Pembrolizumab|Arm1：Pre-operative Pembrolizumab+chemoradiotherapy
50134|NCT03792334|Device|depth of anesthesia|monitoring of depth of anesthesia
50135|NCT03792321|Drug|Testosterone Undecanoate|1000 mg i.m. every 10 weeks
50136|NCT03792321|Drug|Placebo|
50137|NCT03792308|Drug|SPR206|"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
50138|NCT03792308|Drug|Placebo|0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
50139|NCT03792295|Drug|acetominophen, ibuprofen, oxycodone|Multimodal pain treatment group
50140|NCT03792295|Drug|Oxycodone|Classic opiod pain treatment group
50141|NCT03792282|Behavioral|Time Restricted Feeding|Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).
50142|NCT03792282|Behavioral|Reduced Calorie Diet (RCD)|Participants will receive a diet of 1200-1500kcal/d and keep their usual eating pattern.
50143|NCT03792269|Drug|Irinotecan|intraperitoneal
50144|NCT03792269|Drug|Oxaliplatin|intravenous
50145|NCT03792269|Drug|Capecitabine|
50146|NCT03792256|Drug|Palbociclib|Given PO (or via NG- tube)
50147|NCT03792256|Drug|Cytarabine|Given IT
50148|NCT03792256|Drug|Methotrexate|Given IT
50149|NCT03792256|Drug|Hydrocortisone|Given IT
50150|NCT03792256|Drug|Doxorubicin|Given IV
50151|NCT03792256|Drug|Prednisolone|Given PO
50152|NCT03792256|Drug|Vincristine|Given IV
50153|NCT03792256|Drug|Pegaspargase|Given IV
50154|NCT03792243|Procedure|Complication|Readmission, reoperation
50155|NCT03792230|Behavioral|Video|Video group receive body mechanic education via CD material,
50156|NCT03792230|Behavioral|Brochure|Brochure group receive body mechanic education via written material (brochure)
50157|NCT03792217|Other|1.3% NaOCl|Endodontic irrigant
50158|NCT03792217|Other|5.25% NaOCl|Endodontic irrigant
50159|NCT03792204|Diagnostic Test|Wearing-off 9 questionnaire|The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
50160|NCT03792191|Radiation|Lumbar Spinal Ultrasonography|Ultrasonography of the lumbar spines using an 8-2 MHz curved array transducer. Identification of the intervertebral space with the best image. Marking the patient`s skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
50161|NCT03792191|Radiation|Sham Ultrasound Procedure|Moving the ultrasound probe on the patient's back with the machine in the freeze position.
50162|NCT03792191|Procedure|Conventional Landmark Palpation|Conventional palpation of the anatomical landmarks. The line crossing the iliac crests (Tuffier line) is assumed to cross the spine at L4 spinous process or L3-L4 intervertebral space. Identification of the widest intervertebral space. Marking the patient`s skin with horizontal and vertical lines over the L3-L4 and L2-L3 intervertebral spaces.
50163|NCT03792191|Procedure|Spinal Anesthesia|Spinal anesthesia using a 25- or 22-gauge spinal needle
50164|NCT03792191|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
50165|NCT03792191|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
50166|NCT03792178|Other|Bulk fill composite|Composite resin dental material
50167|NCT03792178|Other|Nano resin composite|Dental composite material
50168|NCT03792165|Other|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
50169|NCT03792165|Other|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
50170|NCT03792152|Drug|Rivaroxaban|After diagnosis of left atrial appendage thrombus by transesophageal echocardiography, then start with rivaroxaba 20mg qd (15mg If creatinine clearance is between 30-49 ml/min).
50171|NCT03792152|Drug|Warfarin|After the diagnosis of left atrial appendage thrombus by transesophageal echocardiography, subcutaneous injection of low molecular weight heparin (4000iu q12h) and oral warfarin treatment were started, and low molecular weight heparin was stopped after INR reached 2.
50172|NCT03792139|Drug|LY3200882|Administered orally.
50173|NCT03792139|Drug|Itraconazole|Administered orally.
50526|NCT03789097|Drug|Poly ICLC|an immune cell activating factor. vials containing 1 ml of 2 mg/mL
50174|NCT03792126|Other|Implicit Learning Approach|"All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA."
50175|NCT03792113|Procedure|Periodontal Flap Surgery|Periodontal access flap surgery will be performed in both test site followed by control site in each subject
50176|NCT03792113|Other|Autologous fibrin glue|Autologous fibrin glue procured from the subject's own venous blood will be used to approximate periodontal flaps following access periodontal surgery
50177|NCT03792113|Other|4-0 silk suture|Conventional 4-0 black silk suture will be used to approximate periodontal flaps following access flap surgery
50178|NCT03792100|Drug|SmofKabiven emulsion for infusion|Total Parenteral Nutrition
50179|NCT03792100|Drug|"Hospital compounded All in one emulsion"|Total Parenteral Nutrition
50180|NCT03792087|Drug|SmofKabiven Peripheral|Total Parenteral Nutrition
50181|NCT03792087|Drug|Hospital compounded emulsion|Total Parenteral Nutrition
50182|NCT03792074|Drug|SCT510|SCT510 Injection
50183|NCT03792074|Drug|Bevacizumab|Bevacizumab Injection
50184|NCT03792074|Drug|Paclitaxel|Paclitaxel Injection
50185|NCT03792074|Drug|Carboplatin|Carboplatin injection
50186|NCT03792061|Behavioral|Strategy Training|This approach is different from traditional direct skill training, which emphasizes clinicians' responsibility on identifying their patients' challenges in performing activities and teaching patients task-specific problem-solving strategies. Strategy training, on the other hand, requires clinicians to take a role as a facilitator, guiding participants to learn through prompts and questions. In the training process, participants learn to develop their own problem-solving strategies and work through the problems they have, through which they can develop self-efficacy and confidence to manage participation challenges. Participants can also generalize the strategies they learn to other similar problems they encounter in daily life.
50187|NCT03792048|Procedure|Magnetic Compressive Anastomosis|A magnetic device will be used during bilioenteric anastomosis and pancreaticojejunostomy
50188|NCT03792035|Drug|Tongxinluo|tid, po.
50189|NCT03792035|Drug|Placebos|tid, po.
50190|NCT03792022|Behavioral|Adherence to timely vaccine uptake|Adherence to timely vaccine uptake
50191|NCT03792009|Device|Paracervical block|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine or normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
50192|NCT03792009|Drug|5% bupivacaine|The paracervical injection with 10 mL of 0.5% bupivacaine plus 1:200,000 epinephrine was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
50193|NCT03792009|Drug|Normal saline|The paracervical injection with 10 mL of normal saline was administrated by the second assistant surgeon into the cervicovaginal junction at 3 and 9 o'clock with a depth of 1 cm after intubation but before fixation of uterine manipulator onto the cervix.
50194|NCT03791996|Procedure|"Early cranioplasty"|Subjects undergoing cranioplasty beyond 3 months after craniectomy.
50195|NCT03791983|Other|Scalp Acupuncture|Scalp acupuncture is a form of alternative medicine in which thin needles are inserted into the scalp. It is a key component of traditional Chinese medicine (TCM).
50196|NCT03791983|Other|Body Acupenture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM).
50197|NCT03791970|Device|Orchid 035 DCB Catheter|Stents placement for femoropopliteal arterial occlusions following with Orchid 035 DCB Catheter for post-dilation
50198|NCT03791970|Device|POBA Catheter|Stents placement for femoropopliteal arterial occlusions following with POBA for post-dilation
50199|NCT03791957|Other|Blood Haemoglobin|Routine haemotological investigation of blood haemoglobin levels in gm/dL will be recorded from withdrawn venous blood
50200|NCT03791944|Device|3DV+TPS/VARIAN|Use imported 3DV+TPS to map targets and develop treatment plans
50201|NCT03791944|Device|TPS / VARIAN|Use imported TPS to map targets and develop treatment plans
50202|NCT03791944|Device|3DV + TPS / Domestic Accelerator|Use domestic 3DV+TPS to delineate target areas and develop treatment plans
50203|NCT03791944|Device|TPS / Domestic Accelerator|Use domestic TPS to map targets and develop treatment plans
50204|NCT03791931|Diagnostic Test|oxidative stress measurement|oxidative stress measurement
50205|NCT03791918|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
50206|NCT03791918|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
50207|NCT03791918|Procedure|TACE|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. TACE Drug Protocol were injected.
50208|NCT03791918|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
50209|NCT03791905|Drug|Paclitaxel|chemotherapy drug
50210|NCT03791905|Drug|Cisplatin|chemotherapy drug
50211|NCT03791905|Drug|Oxaliplatin|chemotherapy drug
50212|NCT03791905|Drug|5-FU|chemotherapy drug
50213|NCT03791905|Drug|Leucovorin|chemotherapy drug
50214|NCT03791905|Radiation|Intensity-modulated radiotherapy|radiotherapy technique
50215|NCT03791905|Device|PET|Using PET to evaluate response to induction chemotherapy
50216|NCT03791892|Other|Shoulder mobilization Group|Suprascapular nerve block administered every week to both groups. Joint mobilization (3 sets / 40 seconds hold / 30 seconds interval) Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Strengthening exercises ( 3 sets / 15 reps)
50821|NCT03786770|Biological|DaxibotulinumtoxinA for injection|Intramuscular injection
50217|NCT03791892|Other|Conventional Treatment Group|Suprascapular nerve block administered every week to both groups. Daily Stretching exercises (3 sets / 30 seconds hold / 10 seconds interval) Daily Strengthening exercises ( 3 sets / 15 reps)
50218|NCT03791879|Drug|Caudal dexamedatomidine analgesia|"Technique performance (Caudal block): classical technique; palpation, identification and puncture with the patients in the lateral position (permits easy access to the airway under general anesthesia) using a 22‐G short‐beveled needle under sterile conditions advancing needle pierces the sacrococcygeal ligament.~After needle insertion, pre-calculated volume of Levob plus DEXM bolus was injected as follow; Group A Caudal Levob 0.125%+ DEXM 0.5µg/kg. Group B Caudal Levob 0.125%+ DEXM 1µg/kg. Group C Caudal Levob 0.125%+ DEXM 1. 5 µg/kg. Group D Caudal Levob 0.125%+ DEXM 2µg/kg."
50219|NCT03791866|Other|Nutrition|Enteral nutrition
50220|NCT03791853|Diagnostic Test|Light-CT|Fresh specimen is trimmed into a block with a size not larger than 2.5 cm (Typically not larger than 1.5 cm). Prepared specimen is submitted to Light-CT tests. FF-OCT images are obtained to depict the structure information and DCI images are generated to collect the dynamic information of the cell and tissue. After the imaging detection, specimens are submitted for routine pathological diagnosis to obtain corresponding pathological images.
50221|NCT03791840|Diagnostic Test|Ultrasound evaluation|High-frequency ultrasound is used to detected the lymph node metastasis in vivo and vitro. The lymph node number, morphology and elastographic parameters are collected in the patients and in fresh lymph node specimens.
50222|NCT03791827|Drug|Corticosteroid|corticosteroid is given to patients orally or methylprednisone is given to patients through i.v.
50223|NCT03791827|Drug|Hydroxychloroquine|Hydroxychloroquine is recommended as the basic therapy for lupus nephritis
50224|NCT03791827|Drug|Cyclophosphamide|The typical therapy for cyclophosphamide is either 500 to 750mg/m2 once every month for 6 doses or 8 to 12 mg/kg/d for two consecutive days every two weeks for 6 to 8 doses through i.v.
50225|NCT03791827|Drug|Mycophenolate Mofetil|The recommended dose of mycophenolate mofetil is 20 to 30mg/kg/d
50226|NCT03791827|Drug|Azathioprine|The recommended dose of azathioprine is 1.5 to 2mg/kg/d
50227|NCT03791827|Drug|Tacrolimus|The recommended dose of tacrolimus is 0.05 to 0.15mg/kg/d, Q12h
50228|NCT03791827|Drug|Cyclosporine A|The recommended initial dose of cyclosporine A is 4 to 6mg/kg/d, Q12h
50229|NCT03791827|Drug|Rituximab|The recommended dose of rituximab is 375mg/m2 once a week for 2 to 4 doses
50230|NCT03791814|Drug|Zepatier|Patients screened as HCV positive will receive Zepatier for 12 weeks.
50231|NCT03791801|Drug|Sugammadex|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
50232|NCT03791801|Drug|Neostigmine|the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
50233|NCT03791801|Drug|Rocuronium|Both groups will receive rocuronium for paralysis during intubation
50234|NCT03791801|Drug|Glycopyrrolate|The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
50235|NCT03791788|Diagnostic Test|QFR assessment|QFR measurement in order to evaluate functional significance of epicardial stenosis and to compare the response of QFR for worsening stenosis severity, FFR value as reference standard
50236|NCT03791775|Drug|Polidocanol foam (Atossisclerol® 3%)|The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self‐lighting open‐ended anoscope and a 20‐G needle in order to reduce bleeding
50237|NCT03791762|Procedure|WaveOne Gold|"WaveOne Gold was operated by an endomotor (VDW Gold, Munich, Germany) at WaveOne ALL setting."
50238|NCT03791762|Procedure|Reciproc Blue|"Reciproc Blue was operated by an endomotor (VDW Gold, Munich, Germany) at Reciproc ALL setting."
50239|NCT03791762|Procedure|ProTaper Next|ProTaper Next was operated by an endomotor (VDW Gold, Munich, Germany) with 16:1 contra angle at the settings suggested by the manufacturer (350 rpm, 3 Ncm).
50240|NCT03791749|Other|Breastfeeding Support|12-minute simple technique
50241|NCT03791736|Procedure|Injection of sandostatine|Intramuscular injection of sandostatin 30 mg 3 days before surgery
50242|NCT03791723|Drug|Sacubitril-Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
50243|NCT03791723|Drug|Valsartan|After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
50244|NCT03791710|Procedure|autologous fat grafting|regular liposuction procedure at which sufficient amount of fat is extracted from the patient and then the fat is processed then grafted underneath the burn wound
50245|NCT03791710|Drug|Topical Cream|serial dressing with topical agents e.g Silver Sulphadiazine
50246|NCT03791710|Procedure|split thickness skin grafting|depridment and split thickness skin grafting
50247|NCT03791697|Other|Telehealth 2 week postoperative visit|"The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)"
50248|NCT03791684|Device|Cross linking|Cross linking strategy either standard or accelerated
50249|NCT03791671|Other|individual balance training|One physiotherapist trains one Patient nearby a bar. The tasks changes in gage, visual feedback, vestibular feedback and underground. The Positions will be hodl for 10-30 seconds.
50250|NCT03791671|Other|group balance training|Like the individual balance training
50251|NCT03791658|Other|The 12-question TAI|The 12-question TAI (Test for the Adherence to Inhalers) yields a score indicating level of adherence (high, intermediate or poor). The TAI also provides some indication about the possible mechanisms of non-adherence (sporadic, deliberate or unconscious).
50252|NCT03791658|Other|Information from patients file|Depending on which arm or group specific information will be gathered from the patients file after informed consent.
50253|NCT03791658|Other|The Asthma Control Test (ACT)|An international validated questionnaire on the symptoms an asthmatic experiences and the disease control in the patient. Only for the Asthmatics arm of the study
50254|NCT03791658|Other|The COPD Assessment Test (CAT)|An international validated questionnaire on the symptoms a COPD-patient experiences and the disease control in the patient. Only for the COPD arm of the study
50255|NCT03791645|Behavioral|Sky Intervention|SKY meditation has three sequential components of breathing interspersed with normal breathing. These include a) sound breath: breathing against airway resistance with slight tightening of the laryngeal muscles, (2-3 cycles/min) followed by b) bellows breath: rapid, forced expiration(20-30 cycles/min) and c) regulated, rhythmical breathing rotating through medium to fast cycles. Each session is focused upon proper breathing techniques, social interaction, and discussion of practical wisdom for everyday life to manage the mind and emotions. SKY will be administered over a 5 day period (~3 hours/day), followed by 4 weekly follow-ups (~90 min session/week) at Signature Health clinic situated in Ashtabula, Ohio.
50256|NCT03791632|Other|classical lecture style presentation|classical lecture style presentation
50257|NCT03791632|Other|an intervention in the form of fun workshops|an intervention in the form of fun workshops on different themes by small groups of schoolchildren (8-10 children per workshop)
50258|NCT03791632|Other|digital media intervention|digital media intervention
50259|NCT03791619|Device|Higher Cylinder Toric IOL|Symfony Toric models ZXT300 and ZXT375 IOL
50260|NCT03791619|Device|Lower Cylinder Toric IOL|Symfony Toric model ZXT150 IOL
50261|NCT03791593|Drug|Evolocumab|Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
50262|NCT03791580|Behavioral|Commitment nudge|"The commitment nudge will ask clinicians to commit to discussing high-risk polypharmacy at the next office visit with patients who have high-risk polypharmacy. Clinicians who commit will receive a reminder just before the next office visit begins. The patient will also receive notification of the commitment via EHR patient portal.~This nudge will be operationalized via two sequential clinician-facing EHR best practice alerts (BPAs): the first at time of opening any encounter (including encounters other than a face-to-face office visit, e.g., medication refills), and the second (contingent on making a commitment to discuss high-risk polypharmacy) at time of opening the subsequent encounter for a face-to-face office visit. Each of these BPAs will describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies."
50263|NCT03791580|Behavioral|Justification nudge|The justification nudge will ask clinicians who prescribe or renew a drug that meets high-risk polypharmacy criteria (in the context of the patient's other medications) to write a brief justification for prescribing this high-risk medication. This written justification will be recorded in the patient's medical record. The best practice alert requesting the justification will also describe the specific high-risk polypharmacy criterion (or criteria) the patient meets, the specific harms associated with the medication(s) triggering the criterion/criteria, and lower-risk alternative treatment strategies.
50264|NCT03791567|Biological|Donislecel (allogeneic islets of Langerhans for transplant)|Intervention Description: The drug product consists of allogeneic human islets of Langerhans (islets) in serum-free transplant medium (indicator-free CMRL 1066 medium with HEPES, without sodium bicarbonate and supplemented with human albumin).
50265|NCT03791554|Procedure|Group A (Lateral closed tunnel subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the adjacent teeth to treating gingival recession with edges of the recession sutured together after placing connective tissue graft
50266|NCT03791554|Procedure|Group B (Tunnel procedure with subepithelial CT graft)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
50267|NCT03791541|Behavioral|Pharmacist services|Additional pharmacist/pharmacy student follow-ups, counseling, and other services
50268|NCT03791528|Other|Kinesio-taping treatment group|In treatment group; Kinesio-taping 3 times at 5-day intervals, one of the fan-shaped cut bands, 2-3 inches above the SIJ, and the other below 2-3 inches below the SIJ, and crossed each other by 90 degrees. evaluated at baseline, the twentieth minute after application and on the 15th day by physical examination of the sacroiliac joint, visual analog scale, Modified Oswestry Low Back Pain Disability Questionnaire.
50269|NCT03791515|Drug|Calcitonin Gene-Related Peptide|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 1.5 µg/min CGRP over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
50270|NCT03791515|Drug|Placebo|"A randomized clinical trial with a double-blinded, randomized, placebo-controlled crossover design. 30 PPTH patients will be included. All participants will receive continuous intravenous infusion of 40 mL placebo (isotonic saline) over 20 min.~The following variables will be recorded before, during and after infusion (every 10 min over 60 min): headache intensity on a verbal rating scale from 0 to 10 and headache characteristics. At 90 min, participants will be discharged and instructed to fill out a headache diary for 24 hours from start of infusion."
50271|NCT03791502|Other|Pilates Method Exercises|Pilates Method exercises performed on the apparatus, on the ground and with accessories. They will always be performed by a physiotherapist with teaching certification in the Pilates methodology and will be supervised by two properly trained physiotherapy trainees. Participants will start the exercise program in small groups of up to 8 people, twice a week for 60 minutes, for 12 weeks, totaling 24 sessions. The first day of intervention for both groups will be devoted to explaining the six principles described by Joseph Pilates: centralization, concentration, control, precision, fluidity and breathing, and some fundamentals such as the neutral position of the spine. And in all sessions, these principles will be remembered by the physiotherapist.
50448|NCT03789812|Device|Superfloss|Superfloss (Oral B) will be used to clean interproximal teeth surfaces.
50272|NCT03791489|Device|ClariFix|The ClariFix™ device (K162608) is an FDA 510(k) cleared Class II cryosurgical tool indicated for the destruction of unwanted tissue during surgical procedures, including in adults with chronic rhinitis.
50273|NCT03791476|Drug|rhC1INH|C1 esterase inhibitor
50274|NCT03791476|Other|Saline Solution|saline solution
50275|NCT03791463|Drug|salvianolic acid A|Following an overnight fast of at least 10 hours, a single dose of 90 mg salvianolic acid A will be administered on 2 separate occasions (fasting and after meal) in a randomized crossover fashion with different food restrictions.
50276|NCT03791437|Device|Digital chest drainage system|patients who received Digital chest drainage system
50277|NCT03791437|Device|Not use Digital chest drainage system|patients who not received Digital chest drainage system( traditional drainage system)
50278|NCT03791424|Drug|Midazolam|Administering premedication with sedative drug to relieve anxiety
50279|NCT03791398|Drug|Dose level 1 ONC201 625mg|ONC201 625mg + Nivolumab 240mg IV flat dose
50280|NCT03791398|Drug|Dose level 2 ONC201 500mg|ONC201 500mg + Nivolumab 240mg IV flat dose
50281|NCT03791398|Drug|Dose level 3 ONC201 375mg|ONC201 375mg + Nivolumab 240mg IV flat dose
50282|NCT03791398|Drug|Dose level 4 ONC201 250mg|ONC201 250mg + Nivolumab 240mg IV flat dose
50283|NCT03791398|Drug|Dose level 5 ONC201 125mg|ONC201 125mg + Nivolumab 240mg IV flat dose
50284|NCT03791385|Behavioral|Picture Exchange Communication System (PECS)|A communication system frequently used with non-verbal children with autism spectrum disorders (ASD) that uses a series of pictures that describe how a certain activity is done, in our case showing a structured method and technique for teeth brushing.
50285|NCT03791372|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
50286|NCT03791372|Biological|Autologous Umbilical Cord Blood|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
50287|NCT03791359|Other|CardioPulmonary Resuscitation|Whether the victim received CPR as per standard protocol.
50288|NCT03791333|Other|injury severity score|injury severity score of multi trauma patients
50289|NCT03791320|Diagnostic Test|Vessel Fractional Flow Reserve|FFR measurement based on coronary angiography
50290|NCT03791307|Other|Traditional Pilates group|The participants will perform only exercises based on the traditional Pilates method, 2 times a week, for 50 minutes, for 16 weeks.
50291|NCT03791307|Other|Modified Pilates group|The participants will perform exercises based on the Pilates method alternated with active rest periods on treadmill ergometer, 2 times a week, for 50 minutes, for 16 weeks.
50292|NCT03791294|Drug|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
50293|NCT03791281|Behavioral|BASIS|
50294|NCT03791281|Behavioral|Attention Control|
50295|NCT03791268|Procedure|Gastric cancer surgery|Gastric cancer surgery is performed according to the Japanese Guidelines. Patients will intraoperative evaluate the edema, fibrosis and exudation.
50296|NCT03791255|Drug|Calcium silicate liner|new light-cured resin-modified calcium silicate-filled base/ liner material designed for direct and indirect pulp capping
50297|NCT03791255|Drug|Calcium hydroxide liner|Calcium hydroxide is the gold standard for pulp capping, allows for the formation of a reparative dentin bridge
50298|NCT03791242|Device|Cpap and ketogenic diet|Patients with severe OSAS who are BS candidates will be treated with CPAP only at night (Group 1), or CPAP at night + KMED daily (Group 2), for 4 weeks
50299|NCT03791216|Other|Fasting blood draw for lipid assessments|Fasting blood draw for lipid assessments
50300|NCT03791203|Behavioral|Calorie restriction (MACR)|This was a randomized, single-blind controlled trial with modified alternate-day calorie restriction (MACR) as the active intervention and normal habitual diet as control at Hospital University of Sains Malaysia.
50301|NCT03791190|Other|Regional citrate anticoagulation|Sodium citrate (4%) infusion before the filter in order to maintain post-filter ionCa2+ level between 0.25 to 0.35 mmol/L. Calcium gluconate supplementary after the filter to maintain serum ionCa2+ level between 1.0 to 1.2 mmol/L.
50302|NCT03791190|Other|No-anticoagulation|Patients accepted CRRT without anticoagulant.
50303|NCT03791177|Other|Music Therapy|"Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy"
50304|NCT03791164|Behavioral|The Pain Toolkit|the Pain Toolkit is a leaflet that encourages self management techniques for patients with chronic pain
50305|NCT03791164|Behavioral|the Back Book|The Back Book is a patient information leaflet that offers information and advice about back pain
50306|NCT03791138|Other|online patient decision aid|An online, interactive tool that can be used to prepare for consultation with a plastic surgeon which contains evidence-based information about breast reconstruction options, the pros and cons of the options, value clarification exercises and patient narratives. It results in a summary sheet with patients' personal values and questions that can be discussed during consultation with a plastic surgeon.
50307|NCT03791125|Drug|Salvianolic Acid A|4 anticipated doses are 30 mg, 90 mg, 180 mg and 270 mg, respectively. All of these are single-dose study.
50308|NCT03791125|Drug|Placebo Oral Tablet|Placebo tablets containing no salvianolic acid A will be given to healthy subjects.
50309|NCT03791112|Drug|BPI-16350|BPI-16350 capsules administered orally
50310|NCT03791099|Drug|Metronidazole|After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
50311|NCT03791060|Drug|Secukinumab|Secukinumab is selective for human IL-17A and potently neutralizes the bioactivity of this cytokine. IL-17A is the central cytokine in multiple autoimmune and inflammatory processes. It is being recognized as one of the principal pro-inflammatory cytokines in autoimmune diseases such as psoriasis, PsA and AS, uveitis and is thought to play a role in other inflammatory conditions.
50312|NCT03791047|Other|Balance Analysis|Balance analysis is assessment method to estimate fall of risk and deterioration of postural control.
50313|NCT03791021|Diagnostic Test|draw a person (DAP)|the subjects will be given a blank sheet of white paper and a pencil, and will be asked to draw themselves with no other additional instructions.
50314|NCT03791021|Diagnostic Test|Edinburgh Postnatal Depression Scale (EPDS)|measure of postpartum depression symptoms.
50315|NCT03791021|Diagnostic Test|Beck Depression Inventory- II (BDI-II)|BDI-II is based on clinical observations of behaviors associated with depression, and it retains the somatic items in accordance with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria related to loss of energy. ansd sleep disturbances.
50316|NCT03791021|Diagnostic Test|Traumatic Events Questionnaire (TEQ)|The TEQ assesses experiences with nine specific types of traumatic events (e.g., accidents, crime, adult abusive experiences) reported in the empirical literature as having the potential to elicit PTSD symptoms.
50317|NCT03791008|Other|Risk based screening|Breast cancer risk measurement, screening recommendations and shared decision making
50318|NCT03790995|Procedure|Robot assisted laparoscopic prostatectomy|
50319|NCT03790982|Drug|Placebo of AD-35 60mg /AD-35 30mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 30mg +Placebo of AD-35 30mg oral 2nd 26 weeks.
50320|NCT03790982|Drug|Placebo of AD-35 60mg /AD-35 60mg|Placebo 60mg, oral, 1st 26 weeks; AD-35 60mg oral, 2nd 26 weeks.
50321|NCT03790982|Drug|AD-35 30 mg + Placebo of AD-35 30 mg|AD-35 30 mg + Placebo of AD-35 30 mg AD-35 30 mg + Placebo of AD-35 30 mg, Oral, 52 weeks.
50322|NCT03790982|Drug|AD-35 60 mg|AD-35 60 mg AD-35 30 mg x two tablets, oral, 52 weeks.
50323|NCT03790969|Device|26 gauge needle|smaller gauge needle
50324|NCT03790969|Device|23 gauge needle|control group
50325|NCT03790956|Procedure|Silk Microparticle Filler Injection|A silk protein microparticle-based filler will be injected deep to the thyroarytenoid muscle of the paralyzed vocal fold to augment/medialize its position.
50326|NCT03790943|Diagnostic Test|cardiac assessment|Personal history, physical examination including anthropometry with hip/waist-ratio, electrocardiogram, echocardiography, 1-minute-sit-to-stand test, questionnaires on health-related quality of life (SF-36), diet, physical activity, and fatigue
50327|NCT03790930|Diagnostic Test|deep learning|manually labeled samples will be used to train, validate and test deep learning algorithm, and then realize automatic location ideal plane.
50328|NCT03790904|Other|Co.|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
50329|NCT03790904|Other|Kin|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
50330|NCT03790904|Other|Distilled water|15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min
50331|NCT03790891|Biological|CD19-TriCAR-T/SILK|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
50332|NCT03790878|Behavioral|Mindful Breathing|Training in a mindful breathing skill that reduces emotional distress
50333|NCT03790878|Behavioral|Habituation|An exposure procedure that reduces emotional distress through habituation
50334|NCT03790878|Behavioral|Control|No emotion regulation intervention, placebo
50335|NCT03790865|Drug|Livoletide|Daily subcutaneous injection
50336|NCT03790865|Drug|Placebo|Daily subcutaneous injection
50337|NCT03790852|Drug|KSI-301|Intravitreal injection
50338|NCT03790839|Drug|Sitagliptin|Sitagliptin (Januvia® 100 mg tablets for oral administration)
50339|NCT03790839|Drug|Dorzagliatin|Glucokinase activator currently under development
50340|NCT03790826|Device|cystoscopy|Comparison of bladder mucosa via cystoscopy.
50341|NCT03790813|Diagnostic Test|Intervention 1|Ki-67 and Oncotype DX® will be performed on the baseline core biopsy specimen prior to initiation of neoadjuvant systemic therapy.
50342|NCT03790813|Diagnostic Test|Intervention 2|MRI will be performed prior to initiation of neoadjuvant systemic therapy and at the end of treatment.
50343|NCT03790800|Drug|urapidil|A standard treatment regime based on intravenous (IV) bolus of 25mg urapidil administered over 1 minute. For those patients initial systolic blood pressure 180, another 25mg urapidil bolus will be given if the systolic blood pressure level persists >150 after 5 minutes.
50344|NCT03790787|Drug|Empagliflozin|Empagliflozin as Jardiance® 25 mg film-coated tablets for oral administration
50345|NCT03790787|Drug|Dorzagliatin|Glucokinase activator currently under development
50346|NCT03790774|Behavioral|Neurofeedback|Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
50347|NCT03790761|Behavioral|PREP 8.0 Curriculum|The PREP 8.0 curriculum is an experiential curriculum designed to be implemented in a workshop or educational setting. Using techniques of cognitive-behavioral marital therapy and communication-oriented marital enhancement, PREP aims to help couples achieve high levels of relationship functioning and prevent marital problems. The PREP approach is based on research in the field of relational and marital health and success conducted at the University of Denver.
50348|NCT03790748|Other|Touhy epidural needle(17 gauage) with Quincke spinal needle(27 gauage or 25 gauage), or touhy epidural needle (17 gauage) alone.|These are needles used for neuriaxial blockade at the level of epidural( touhy needle) and subarachnoid ( quincke spinal needle) spaces.
50349|NCT03790735|Diagnostic Test|FISH|Targeted chromosomal aberrations detection
50350|NCT03790722|Other|Ergometry H|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined higher systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined lower systolic blood pressure."
50449|NCT03789812|Device|Dental Water Jet|Dental water jet (Jetpik JP210) will be used to clean interproximal teeth surfaces.
50450|NCT03789799|Other|TIAB: microcrystalline titanium dioxide with covalently linked monovalent silver ions|TIAGIN vaginal capsule, composition: TIAB (microcrystalline titanium dioxide with covalently linked monovalent silver ions), Sodium Hyaluronate, Aloe Barbadensis Extract
50451|NCT03789799|Other|Placebo|Placebo vaginal capsule, composition: Sodium Hyaluronate, Aloe Barbadensis Extract
50351|NCT03790722|Other|Ergometry L|"After a pre-rest period of 12 minutes, the subjects are physically strained on the ergometer for 48 minutes (6 minutes loading phase followed by a 2-minute rest phase; 30 watts increase every 8 minutes up to a maximum load of 180 watts), followed by a 12-minute rest periodmaximum load of 180 watts), followed by a 15-minute post-rest period.~Mobil-O-Graph PWA blood pressure cuff is applied to the upper arm with the previously determined lower systolic blood pressure (reference parameter).~SOMNOtouchTM RESP and GeTeMed Vitaguard 3100 are accordingly applied to the arm with the previously determined higher systolic blood pressure."
50352|NCT03790709|Drug|High dose ANAVEX2-73|Oral capsule
50353|NCT03790709|Drug|Mid dose ANAVEX2-73|Oral capsule
50354|NCT03790709|Drug|Placebo oral capsule|Oral capsule
50355|NCT03790696|Device|Cognitive Training Program|"The cognitive training program has been designed by Dr. Sylvester. It is a simple computer game looking at some shapes and faces on a computer screen and pressing a button when a target shape appears.~This is the first study to use this exact computer training regimen for testing in its ability to reduce symptoms of anxiety in children with anxiety disorders. Each session of the computer game takes approximately 45-60 minutes and subjects complete 8 total sessions over one month. The computer game involves paying attention to parts of the screen while distracting square boxes appear at other locations. A target X appears at the location that participants are paying attention to and the subjects press a button when it appears."
50356|NCT03790683|Device|EnsoETM|Patients having major surgery will have the EnsoETM device placed after induction of general anesthesia in addition to standard of care surface warming.
50357|NCT03790683|Device|Surface Warming|Forced air warming device will be placed on the patient according to standard practice.
50358|NCT03790670|Drug|sargramostim|Recombinant human GM-CSF produced by recombinant DNA technology using a yeast (S. cerevisiae) expression system
50359|NCT03790657|Behavioral|practice of a complex walking task|walking over obstacles
50360|NCT03790657|Device|Dosage A: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
50361|NCT03790657|Device|Dosage B: transcranial direct current stimulation (tDCS)|mild electrical stimulation delivered to the frontal region of the brain
50362|NCT03790644|Device|exoskeleton assist|"A powered exoskeleton describes a wearable robot designed around the shape and function of the human body with segments and joints externally coupled to those of the user. The exoskeleton includes a rigid outer frame, sensors that detect a user's desired movements, a computerized controller, motors and actuators, and lightweight batteries.~The exoskeleton is designed to be worn in the community."
50363|NCT03790631|Other|The study is observational.|The study is observational.
50364|NCT03790618|Drug|3,4-Methylenedioxymethamphetamine|Participants will be given 0.75mg/kg of 1.5mg/kg MDMA
50365|NCT03790618|Drug|methamphetamine|Please see above.
50366|NCT03790605|Drug|1 % curcumin chip|CURCUMIN CHIP: 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle
50367|NCT03790605|Other|Placebo chip|PLACEBO CHIP: 4x5x0.5mm chip (identical to test chip except for the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle
50368|NCT03790605|Procedure|Scaling and root planing|Routine full mouth scaling and root planing within 48 hours will be performed at baseline prior to local placement of the chips
50369|NCT03790592|Device|trifocal IOL|intraocular lens
50370|NCT03790566|Drug|Bupivacaine|0.5 ml/kg 0.25% bupivacaine
50371|NCT03790553|Radiation|Radiotherapy|Different total radiotherapy dose between two arms.
50372|NCT03790540|Device|DentalVibe|It is a vibrotactile device that aids in reducing pain during local anesthesia injection in pediatric patients
50373|NCT03790540|Drug|Topical Benzocaine 20%|Topical benzocaine 20% gel on the mucosal injection site prior to injection
50374|NCT03790527|Procedure|CBM training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
50375|NCT03790527|Procedure|Sham training|participants will be random-assigned into one of training groups. Participants in the modification group will receive modified training of 400 trials for six sessions during six days, the same as the sham group.The difference between these two groups is the proportion of push/pull trials. The sequence of the interventions will be counterbalanced across participants, and the callback will be conduct after one week.
50376|NCT03790514|Other|Heat Wrap|Commercially heat tapes ( without drugs) will be applied to patients.
50377|NCT03790501|Other|No intervention|As an observational study, no intervention will be associated with the study group.
50378|NCT03790488|Drug|JTX-4014|Specified dose on specified days
50379|NCT03790475|Other|Offering a choice for colorectal cancer screening|Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.
50380|NCT03790475|Other|Offering an alternative colorectal cancer screening method|Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
50381|NCT03790462|Other|Music intervention|"A raga out of 3 select Indian classical ragas Puriya/Hindol/Todi will be played for 10 minutes & data collected."
50382|NCT03790449|Behavioral|PreLiFe-programme|The intervention group will receive a mobile preconception lifestyle programme (the PreLiFe-programme) in addition to standard care for 12 months or until an ongoing pregnancy is confirmed by ultrasound. The PreLiFe-programme includes a mobile application (PreLiFe-app) with the same treatment information as the attention control group in combination with a lifestyle programme. This new lifestyle programme includes tailored advice and skills training on diet and physical activity and mindfulness exercises. Additionally couples will be offered interaction with a health care provider through text messages and telephone interaction following the concept of blended care.
50452|NCT03789786|Diagnostic Test|Gait and Motion Analysis|Gait and motion analysis is comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
86668|NCT03509012|Drug|Etoposide (dose level 2)|IV
50383|NCT03790449|Behavioral|Attention Control Programme|The standard care serving as control for this intervention is fertility treatment i.e. IVF with or without ICSI according to local protocols for infertility patients. This implies no guidance on lifestyle. However, to have attention control the control group will receive an attention control programme. The attention control programme includes a mobile application (app) with treatment information including medication instructions, reminders of injection of human Chorionic Gonadotropin (hCG) and time of fertility treatment appointments for 12 months or until an ongoing pregnancy is confirmed by ultrasound.
50384|NCT03790436|Dietary Supplement|Betaquik|"Study dietitian will advise each participant on target volume of Betaquik (45g MCT, 225mL Betaquik). Consuming too much MCT too quickly may cause gastrointestinal discomfort such as abdominal pain or diarrhea, this is related to its assimilation to the body. Any symptoms that do occur normally resolve in the majority of patients, and with time and persistence, GI tolerance is usually established.~Therefore the study dietitian will advise on a gradual systematic introduction to minimize any adverse effects. The daily-tolerated amount will be divided into 3-4 equal portions, taken regularly throughout the day. subjects will be advised to always take Betaquik with food, as part of meals and snacks, to help promote gastrointestinal tolerance. The goal is within the first 4 weeks participants will have reached their tolerated target volume of Betaquik."
50385|NCT03790423|Drug|Injection of 18F-ASIS|Each patient will receive one injection of 18F-ASIS (approximately 200 Mbq)
50386|NCT03790423|Other|PET/CT scan|Following one injection of 18F-ASIS the patients will be PET/CT scanned at 1 hour, 2 hours and 4 hours post-injection
50387|NCT03790410|Other|Complex pulmonary rehabilitation|Complex pulmonary rehabilitation program containing breathing exercises, bicycle ergometer conditionings, relaxations, strength and endurance trainings.
50388|NCT03790410|Other|Inspiratory muscle training|The training program contains strengthening exercises on the diaphragm muscle.
50389|NCT03790397|Drug|Osimertinib|Patients treated with Osimertinib within the Special Use medication Program (SUMP).
50390|NCT03790384|Drug|Mitomycin|Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
50391|NCT03790371|Drug|Misoprostol|vaginal misoprostol prior IUD insertion
50392|NCT03790371|Drug|Placebos|vaginal placebo tablet prior IUD insertion
50393|NCT03790358|Drug|Lysergic Acid Diethylamide|Drug will be administered in solution form.
50394|NCT03790345|Drug|Pyridoxine|Adjuvant daily treatment with 200mg of pyridoxine
50395|NCT03790345|Drug|Cobalamin|Adjuvant daily treatment with 2mg of cobalamin
50396|NCT03790345|Drug|Placebo Oral Tablet|Adjuvant daily treatment with placebo
50397|NCT03790332|Drug|Ibrutinib|Ibrutinib capsule, tablet, or suspension administered orally once daily
50398|NCT03790319|Behavioral|The Power of Feelings|"Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
50399|NCT03790319|Behavioral|The Emotional Backpack|"One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion."
50400|NCT03790293|Drug|Rituximab|Patient was enrolled into the RITUXIMAB 3 study in the arm Rituximab in association with low corticosteroids'therapy
50401|NCT03790293|Drug|corticosteroids'therapy|Patient was enrolled into the RITUXIMAB 3 study in the arm Patient was enrolled into the RITUXIMAB 3 study in the arm standard corticosteroid
50402|NCT03790280|Diagnostic Test|HFO analysis|We hypothesize that the strategy of incorporating HFO data to a standard ECoG-guided resection in pediatric epilepsy surgery will result in improved postoperative seizure outcome than the traditional approach.
50403|NCT03790267|Other|Questionnaire administration|One questionnaire (Euro Quality 5 Dimensions, EQ-5D) for the general assessment of patient's health status will be administered to all the patients in the study. One joint-specific questionnaires will be administered to patients depending on the surgery procedure they will be undergoing. Hip disability and Osteoarthritis Outcome Score - Short Form (HOOS-PS) for patients undergoing hip replacement (6); Knee injury and Osteoarthritis Outcome Score - Short Form (KOOS-PS) for patients undergoing knee replacement (7); the American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES), for patients undergoing shoulder implants.
50404|NCT03790254|Other|systematic review|
50405|NCT03790241|Procedure|insertion of a catheter|Analysis the palpation and perforation motion performed by the practitioner during the insertion of a catheter while measuring the loads applied on the skin and the veins
50406|NCT03790228|Drug|Anlotinib Combined With Pemetrexed And Carboplatin|Anlotinib(12mg, QD, PO, d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2, IV, d15-21,21 days per cycle) and Carboplatin(AUC5,IV, d15-21,21 days per cycle,using 4 cycles)
50407|NCT03790215|Drug|Dydrogesterone|The investigators give participants oral dydrogesterone(as described in arm description).After 3 cycles of treatment, the investigators evaluate the treatment effects.
50408|NCT03790202|Device|VistaCare®|Controlled atmosphere wound healing device
50409|NCT03790189|Biological|Subchondral and intra-articular injection of BMC|Bone Marrow concentrate will be injected intra-articularly and at the bone-cartilage interface both in the tibia and femur of patients affected by unicompartmental knee osteoarthritis
50410|NCT03790176|Drug|Intravenous Infusion|see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
50411|NCT03790163|Drug|Levobupivacaine|Drug: levobupivacaine at room temperature ( 23˚C) and second group levobupivacaine warmed to the (30˚C) while the third group levobupivacaine warmed to the body temperature (37˚C)
50413|NCT03790137|Drug|Fenfluramine Hydrochloride|Fenfluramine Hydrochloride will be supplied to the treatment group as an oral solution in a concentration of 2.5 mg/mL. Subjects will receive their daily dose of Fenfluramine Hydrochloride in two doses (one in the morning and one in the evening). After a four week baseline, subjects that meet enrollment criteria will enter a titration period. The starting dose will be 0.2 mg/kg/day for the first 14 days. The dose will be increased every 2 weeks as tolerated by 0.2 mg/kg/day, to a maximum dose of 0.8 mg/kg/day, or a total maximum dose of 30 mg/day. The subject will remain on a dose of 0.8 mg/kg/day, 30 mg/day, or maximum tolerated daily dose for a 6 week maintenance period.
50414|NCT03790111|Drug|telotristat ethyl|XERMELO (telotristat ethyl) tablets administered as 250 mg (1 x 250-mg tablet) tid plus 1L therapy for 7 days, then XERMELO (telotristat ethyl) tablets administered as 500 mg (2 x 250-mg tablets) tid plus 1L therapy for the duration of the study
50415|NCT03790098|Behavioral|Restorative-Flow Yoga|Restorative yoga consists of a series of gentle poses, supported by props, with an emphasis on breathing and relaxing; as opposed to stretching or contracting muscles, it is designed to support muscles. Flow yoga consists of a series of linked poses synchronized with the breath.
50416|NCT03790085|Drug|Risperidone|Risperidone tablet
50417|NCT03790085|Drug|Olanzapine|Olanzapine tablet
50418|NCT03790085|Drug|Aripiprazole|Aripiprazole tablet
50419|NCT03790072|Biological|OmnImmune®|infusion of OmnImmune® (expanded gamma delta T lymphocytes)
50420|NCT03790059|Drug|H101|Intraoperative injection of H101 can improve the efficacy of RFA in hepatocellular carcinoma.
50421|NCT03790059|Procedure|RFA|Treat the samll HCC with the RFA.
50422|NCT03790033|Drug|Ucha-Shinki-Hwan|"Product name : Bosinji Granule Manufacturer : Tsumura & Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g Achyranthes Root 1.0g Cornus Fruit 1.0g Dioscorea Rhizome 1.0g Psyllium Husk 1.0g Alisma Rhizome 1.0g Hoelen 1.0g Moutan Root Bark 1.0g Cinnamon Bark 0.3g Pulvis Aconiti Tuberis Purificatum 0.3g"
50423|NCT03790033|Drug|Placebo|placebo granule
50424|NCT03790020|Drug|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
50425|NCT03790007|Drug|Bupivacaine|In our study this local anesthetic agent will be applied for postoperative pain relief
50426|NCT03789994|Behavioral|Affective touch|The affective touch comprises of two elements, namely the signal of care, love and acceptance, and stimulation of CT afferent of the skin. Caregivers will be trained to perform light stroking on stroke survivor's forearm while reviewing happy events with the use of photos.
50427|NCT03789994|Other|Fine motor exercise|Fine motor exercises that are commonly used for rehabilitation.
50428|NCT03789981|Genetic|Immunogenic profile|RNA sequencing (RNAseq), Whole exome sequencing (WES), NeoAntigens (NeoAg), Immune checkpoints analysis, Gene expression profiling
50429|NCT03789968|Drug|bictegravir/emtricitabine/tenofovir alafenamide|Treatment experienced patients with HIV infection that switched to a bictegravir/emtricitabine/tenofovir alafenamide-based ART regimen
50430|NCT03789955|Procedure|Fluoroscopic-guided TEB|When performing a fluoroscopic-guided thoracic epidural block (TEB), an 18-gauge Tuohy needle will be used for interlaminar epidural access. If the epidural space was accessed under fluoroscopic guidance and using the loss of resistance technique with air. All procedures will be performed with a paramedian approach under the true AP and lateral view at first, If the interlaminar space is not visible, the CLO view will be used. If the needle is deemed to be in the epidural space when the loss occurred, six fluoroscopic views will be obtained: true AP, CLO at 40 degrees, 50 degrees, 60 degrees, CLO measured, and lateral. The CLO measured angle will be determined by measuring the angle between the superior lamina and spinous process on the midsagittal plane on thoracic MRI or CT.
50431|NCT03789942|Procedure|Oral surgery|Oral surgery procedures
50432|NCT03789929|Behavioral|The Emotional Backpack|In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
50433|NCT03789929|Behavioral|Feelings as Powers|In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
50434|NCT03789916|Drug|Ticagrelor|90 mg bis in die
50435|NCT03789916|Drug|acetylsalicylic acid|100 mg die
50436|NCT03789903|Diagnostic Test|amniotic fluid lactate|AF lactate
50437|NCT03789890|Drug|BAY1902607|BAY1902607 is administered once orally as tablets on Day 2 of study period 1 and on Day 4 of study period 2.
50438|NCT03789890|Drug|Itraconazole|Itraconazole is administered at a dose of 200 mg once a day (oral solution of 10 mg mL-1) on Day 1 to Day 14 of study period 2.
50439|NCT03789877|Other|Physical Activity|Participate in home-based walking program
50440|NCT03789877|Other|Questionnaire Administration|Ancillary studies
50441|NCT03789877|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
50442|NCT03789877|Procedure|Sham Intervention|Undergo sham rTMS
50443|NCT03789864|Diagnostic Test|single-arm, non-randomized Biodynamic imaging (BDI)|Skin punch biopsy samples from cutaneous lesions will be profiled for sensitivity to gemcitabine using ex vivo Biodynamic imaging (BDI). The primary clinical outcome assessed will be objective response to chemotherapy after 2 cycles of treatment.
50444|NCT03789851|Device|core needle biopsy|Because the ultrasound was unable to accurately position the marker clip, I125 coud be placed at the position of the marker clip under the guidance of preoperative mammography. The gamma detector was used to locate the tumor bed to guide the ultrasound-guided multi-point CNB. Ultrasound-guided multipoint CNB was used directly after breast conserving surgery or mastectomy. Centering on the marker clip, the range of 0.5 cm was the first area, and then the range of 0.5 cm was the second area, and so on, until the extent of the expansion reached the long diameter of the original tumor, and 4 pieces were uniformly taken in each area.
50445|NCT03789838|Other|Sepsis rapid response team|Patients with suspected sepsis is managed by a sepsis rapid response team in a structured manner.
50446|NCT03789812|Device|Manual toothbrush|Soft manual toothbrush (Oral B) will be used to brush occlusal, buccal and lingual teeth surfaces.
50447|NCT03789812|Device|Electric Toothbrush|Electric toothbrush (Jetpik JP210) will be used to brush occlusal, buccal and lingual teeth surfaces.
50453|NCT03789786|Diagnostic Test|Gross Motor Function Measure (GMFM)|Gross Motor Function Measure (GMFM) is an assessment used to evaluate gross motor function over time in individuals with cerebral palsy. The assessment is comprised of movement activities like standing, walking, running, and jumping
50454|NCT03789786|Behavioral|Surveys|Six surveys are used to assess function, activity, participation, pain, quality of life, and treatment history
50455|NCT03789773|Device|Millimeter-Wave Holographic Imaging|Undergo mm-wave holographic imaging
50456|NCT03789760|Drug|SaiLuoTong capsule|500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
50457|NCT03789760|Drug|placebo|500 subjects are randomly divided into two groups by 3:1. 125 subjects in the control group take two pills(120mg) of placebo each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
50458|NCT03789747|Other|As a observational study, there is no intervention.|As a observational study, there is no intervention.
50459|NCT03789734|Biological|BLS-M22|BLS-M22 250mg/capsule
50460|NCT03789734|Other|Placebo|BLS-M22 placebo 250mg/capsule
50461|NCT03789721|Other|Medical Record Abstraction|Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
50462|NCT03789721|Other|Biospecimen Sample Collection|Collect research samples, when feasible for those diagnosed with ALD.
50463|NCT03789708|Dietary Supplement|Gum Arabic|Instantly soluble granules of Gum Arabic; 100% Acacia Senegal
50464|NCT03789708|Other|Placebo|Maltodextrin powder, easily soluble
50465|NCT03789695|Drug|Dabigatran Etexilate|study drug dabigatran etexilate. There are two dosage regimens of dabigatran used in the study: 150 mg BID and 110 mg BID. The dose of dabigatran will be chosen by the investigator in accordance with Russian PRADAXA SmpC
50466|NCT03789682|Drug|Adjuvant chemotherapy|adjuvant chemotherapy using Gemcitabine plus Cisplatin
50467|NCT03789656|Drug|CRN00808|CRN00808, capsules, once daily by mouth
50468|NCT03789643|Drug|JTT-251|Active drug tablets containing JTT-251
50469|NCT03789643|Drug|Placebo|Placebo tablets matching in appearance to the active drug tablets
50470|NCT03789630|Device|Continuous physiology monitoring in ambulatory setting pre and post surgery|This study will recruit 151 patients aged 21 to 80 years who will be undergoing total knee replacement surgery. All study participants undergoing total knee replacement surgery will be monitored using the wearable biosensor to continuously monitor physiology biomarkers. Participants will be followed for an estimated total of 39 days, beginning four days before surgery, the entire period during in-patient recovery (four to five days), and 30-days post-discharge at-home.
50471|NCT03789617|Biological|EBViNT Cell|"Dosage: 1 bag containing 1.4x10^9 cells/100mL~Administration: Inject intravenously over 30 minutes~Dosing schedule: Single dose"
50472|NCT03789604|Biological|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
50473|NCT03789604|Biological|CS1001 placebo|Participant will receive CS1001 placebo 1200 mg by intravenous infusion every 3 weeks, for up to 24 months; Drug Carboplatin on Day 1 of each 21-day cycle; Drug Pemetrexed on Day 1 of each 21-day cycle; Drug Paclitaxel on Day 1 of each 21-day cycle
50474|NCT03789591|Drug|Hydroxyurea|The alternative arm will use PK data to choose a starting hydroxyurea dose to achieve an AUC of 115 mg*h/L to approximate maximum tolerated dose. On the standard arm, participants will start at the traditional, weight-based dose of 20 mg/kg/day. Following selection of the starting dose, all participants will follow the same dose escalation and laboratory monitoring procedures.
50475|NCT03789578|Drug|NNC0148-0287sema|Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.
50476|NCT03789578|Drug|Semaglutide|Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
50477|NCT03789578|Drug|NNC0148-0287|Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.
50478|NCT03789565|Other|Biomarker test|Diagnostic biomarker study
50479|NCT03789552|Drug|T89 capsule|T89 capsules (75mg)
50480|NCT03789552|Drug|Placebo capsule|Placebo capsules (0mg)
50481|NCT03789539|Biological|LD Universal Influenza Vaccine Uniflu|low dose Universal Influenza Vaccine Uniflu
50482|NCT03789539|Biological|HD Universal Influenza Vaccine Uniflu|High dose Universal Influenza Vaccine Uniflu
50483|NCT03789539|Biological|Placebo|Placebo saline
50484|NCT03789526|Procedure|ultrasound guidance|ultrasound guidance of tendon injection
50485|NCT03789513|Diagnostic Test|HPV test with partial genotyping and VIA triage|HPV testing with the GenXpert platform VIA Biopsies of VIA+ lesions or random Treatment with thermal ablation of women with precancerous lesions
50486|NCT03789500|Drug|Hydromorphone|
50487|NCT03789487|Device|Device programming of CRT pacemaker or defibrillator|Stimulation vector optimization then AV delay optimization in order to obtain the highest systolic blood pressure (SBP) by using the Finapress® NOVA noninvasive device
50488|NCT03789474|Device|HUNTLEIGH FLOWTRON ACS900|
50489|NCT03789461|Procedure|Fecal Microbiota Transplantation|FMT infusion (100-200ml) and Mucosal Microbiota Assessment (To assess the fecal and mucosal microbiota before and after FMT)
50490|NCT03789448|Other|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines
50523|NCT03789097|Drug|Pembrolizumab|200 mg administered as an IV infusion over 30 minutes Q3W
50524|NCT03789097|Drug|Flt3L|an immune cell growth factor. CDX-301 drug product is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains a nominal 2.5 mg/mL CDX-301 protein in a 1 mL volume of buffered solution composed of sodium phosphate and sodium chloride, with a pH of 7.0.
50525|NCT03789097|Radiation|Radiation|The target site will get 2 small treatments of radiation.
86669|NCT03509012|Drug|Paclitaxel|IV
50491|NCT03789435|Diagnostic Test|Questionnaire|"A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)"
50492|NCT03789422|Drug|association of levocetirizine and tranexamic acid|levocetirizine 10 mg/day + tranexamic acid 2 g/day
50493|NCT03789422|Drug|Levocetirizine only|levocetirizine 20 mg/day
50494|NCT03789409|Dietary Supplement|Intermittent Fasting|The aforementioned intermittent fasting in arm/group descriptions.
50495|NCT03789396|Other|Targeted Normoxia (oxygen saturation 90-96%)|The intervention (post-implementation) group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation
50496|NCT03789396|Other|Usual Care Oxygenation|The control (pre-implementation) group will be trauma patients admitted to the ICU during the 12 months prior to the targeted normoxia implementation
50497|NCT03789370|Drug|Propofol|Maintanance of general anaesthesia with propofol
50498|NCT03789370|Drug|Sevoflurane|Maintainance of general anaesthesia with sevoflurane.
50499|NCT03789357|Diagnostic Test|Aldosterone renin ratio|Aldosterone Renin Ratio to screen for Primary Aldosteronism
50500|NCT03789344|Other|acupuncture|Acupuncturists apply the seven-days' electro-acupuncture treatment on the acupoints of Neiguan points and Daling points for 30min per day.
50501|NCT03789344|Other|Psychotherapy|Subjects in psychotherapy group would be accepted 20mins- psychotherapy per day.
50502|NCT03789344|Other|blank control|Blank control subjects would be observed only during this investigation.
50503|NCT03789331|Other|Anogenital distance measurement|"The women were kindly asked to lay down in the lithotomy position with their thighs at 45° to the examination table. A digital caliper (Mitutoyo 500-752-10 ABSOLUTE Digimatic Coolant Proof Caliper 0-150mm / 0-6, Mitutoyo Corporation, Japan) was used to measure anogenital distance.~Anogenital distance anus to clitoris: will be measured in centimeters from the anterior clitoral surface to the center of the anus.~Anogenital distance anus to fourchette: will be measured in centimeters from the posterior fourchette to the center of the anus.~Two investigators who were blind to the gynecological status of the women will measure each distance three times, and the mean value of the six measurements of each anogenital distance will be used."
50504|NCT03789318|Drug|CA-008|Each cohort will use 5, 10, or 15mg CA-008 reconstituted in saline.
50505|NCT03789318|Drug|Placebo|Each cohort will use placebo reconstituted in saline.
50506|NCT03789292|Biological|CT-P17 SC|Subcutaneous injection of Adalimumab 40mg every two weeks
50507|NCT03789292|Biological|Humira SC|Subcutaneous injection of Adalimumab 40mg every two weeks
50508|NCT03789266|Procedure|drain ablation|drain ablation will be done in Aspiration mode or in non Aspiration mode
50509|NCT03789240|Biological|Rituximab|Rituximab is administered at a dose of 375 mg/m^2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.
50510|NCT03789240|Drug|Copanlisib|Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)
50511|NCT03789227|Procedure|ganglion impar block|the patient will be in the prone position with a pillow under the abdomen The pre-injection planning images will be obtained using CT with 2 mm axial section thickness. Under aseptic technique, a skin wheal will be raised with 2 ml lignocaine 0.5% using 23 G needle either in midline or paramedian approach. After identifying the ganglion impar, usually at the level of the sacro-coccygeal disc, a 25 G, 9 cm long spinal needle will be introduced at approximately 6-9 cm from midline and a small amount of non-ionic contrast medium (0.5 ml iopamidol; 300 mg/ml) will be injected. The midline approach may be selected according to patient position and operative condition. In the midline approach the sacro-coccygeal disc is identified and needle will be introduced perpendicular through the disc and just encroaching upon presacro-coccygeal space. Thereafter, 3 ml lidocaine 2% will be injected, three minutes later 5 ml absolute alcohol 95%.
50512|NCT03789214|Drug|Placebo oral capsule|Placebo Sleep Medication
50513|NCT03789214|Drug|Low Dose Suvorexant|Low Dose Suvorexant
50514|NCT03789214|Drug|High Dose Suvorexant|High Dose Suvorexant
50515|NCT03789201|Device|TMS EEG|attempt to use TMS EEG to measure connectivity between cortical areas
50516|NCT03789201|Device|TMS fMRI|compare measurements to established functional connectivity measures; e.g., EEG coherence and fMRI
50517|NCT03789175|Dietary Supplement|Niagen|Niacin is a form of vitamin B3 and has been used to treat hypercholesterolemia for many years. There is growing evidence that nicotinamide adenine dinucleotide (NAD+ can maintain mitochondria through various mechanisms and that it is possible to improve mitochondrial function by dietary supplementation with the vitamin B3 analogue nicotinamide riboside (NR), an intermediate in the NAD+ salvage pathway. We have observed that culturing the fibroblasts of a LFS patient with mitochondrial deficiency in medium containing NR rescues the defect in mitochondrial respiration.
50518|NCT03789149|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy with a mobile device (Intrabeam, Carl Zeiss AG) consisting of a small source of low energy x-rays (30-50 kV) mounted on a mechanical arm with six degrees of freedom. The resulting dose distribution is isotropic around the tip of the X-ray source. A set of spherical applicators with diameters ranging from 1.5 to 5 cm is available to connect to the source. The treatment time may vary from 20-30 minutes with the suggested dose of 18 Gy to the resection cavity to a depth of 1 mm.
50519|NCT03789136|Other|Not applicable, observational study|Not applicable, observational study
50520|NCT03789123|Drug|Estradiol valerate/dienogest|The effects of drugs given for endometrioma and contraception will be observed on ovarian reserve, endometrioma size and pain score.
50521|NCT03789110|Drug|Nivolumab|Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors
50522|NCT03789110|Drug|Ipilimumab|Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer
50527|NCT03789084|Behavioral|Brief Cognitive-Behavioral Therapy for Health Anxiety|4-session in-person 45-minute psychotherapy sessions focused on building motivation for change, psychoeducation, cognitive restructuring, and situational and interoceptive exposure to health-related fear stimuli.
50528|NCT03789084|Behavioral|Referral to mental health provider|Provider makes a referral to a mental health provider in the outpatient psychiatry clinic or a community provider of the participant's choice.
50529|NCT03789071|Diagnostic Test|External ultrasound evaluation of the airway|Patients scheduled to have surgery under general anesthesia in whom tracheal intubation is planned, will have a clinical and ultrasound assessment of the airway before surgery. Information regarding laryngoscopy in the operating room will be recorded.
50530|NCT03789058|Drug|Ibuprofen 400 mg|Surgical removal of wisdom teethb with different regimen of Ibuprofen frequency ; three times versus two times .
50531|NCT03789045|Diagnostic Test|Metabolic thresholds and fat oxidation points relationship|Investigators aim to determine exercise intensity (expressed in ml/kg/min of VO2) at which metabolic thresholds and fat oxidation points occur by using non-invasive breath-by-breath gas analysis during either graded treadmill or cycle ergometry test (2min stages and 1km/h or 50 W load increase) till exhaustion to determine maximal oxygen uptake (VO2max), with gases being collected at the mouth level. The strength of the relationship between AeT and at FATmax will be assessed using the Pearson product moment (r) correlation coefficient with same being done for AnT and FATmin correlation. A coefficient of determination (R2) will be used to detect the proportion of existing variance. A paired t-test will be used to asses' differences between measured variables.
50532|NCT03789032|Drug|Vadadustat|Vadadustat 300 mg
50533|NCT03789032|Drug|Rabeprazole|Oral Rabeprazole
50534|NCT03789019|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
50535|NCT03789006|Drug|Antithymocyte Immunoglobulin (Rabbit)|Induction agent for living donor kidney transplantation
50536|NCT03789006|Drug|Interleukin 2 Receptor Antagonist|Induction agent for living donor kidney transplantation
50537|NCT03788993|Other|Blue-depleted evening light condition|"A 20-bedded ward with tunable light emitting diode (LED) lamps. At 18:00h the lighting undergoes a 30-minute transition during which the green and blue LEDs are dimmed to produce blue-depleted amber colored lighting. At 06:50h a new 10-minute transition changes the light color to ordinary indoor lighting. From 07:00h to 18:00h, there is ordinary indoor lighting (3000K colour temperature). The light intensity is dimmed to 20% of the maximum from 23:00h to 6:50h.~Blue-blocking window filters are deployed also in the evening. All TV sets have permanent blue-blocking filters and individuals are provided with blue-blocking screens that can be attached to the front of personal electronic devices. If the patients leave the blue-depleted unit after 18:30 they are offered blue-blocking glasses to wear. The light spectrum in the ward was assessed prior to commencing the RCT and is well-matched to what has been shown in laboratory settings to minimally suppress melatonin."
50538|NCT03788993|Other|Normal light condition|"The other half of the unit (20 patient rooms and their corresponding bathrooms and common areas) have ordinary indoor light installed (Glamox, Norway). This has a 3000K color temperature. The light is dimmed to 20% of max in the night, similar to the blue-depleted condition.~The light in the normal light condition and the blue-depleted light condition have similar levels of photopic lux throughout the 24h cycle, but different levels of melanopic lux between 1830h and 0700h."
50539|NCT03788980|Procedure|Carotid endarterectomy|Patients will undergo a surgery called carotid endarterectomy where a surgeon will remove material that causes carotid stenosis (i.e. plaque)
50540|NCT03788980|Diagnostic Test|Mini Mental Status Examination|Short questionnaire used to diagnose cognitive dysfunction
50541|NCT03788967|Drug|Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr)|Antibiotic Therapy for Complicated Urinary Tract Infection
50542|NCT03788967|Drug|Ertapenem|Antibiotic Therapy for Complicated Urinary Tract Infection
50543|NCT03788954|Other|Kinesiotaping|Kinesio tape (KT) is the original elastic adhesive tape for injury prevention, rehabilitation, and performance enhancement. Kinesio Tape is latex-free, hypoallergenic and wearable for days at a time. It has been shown to be clinically effective in joint range of motion promotion,increasing muscle activity and functional performance.
50544|NCT03788941|Procedure|left atrial appendage closure and catheter ablation|"Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).~Catheter ablation is a procedure used to remove or terminate a faulty electrical pathway or pathological sites from sections of the hearts of those who are prone to developing cardiac arrhythmias such as atrial fibrillation, atrial flutter, supraventricular tachycardias (SVT) and Wolff-Parkinson-White syndrome (WPW syndrome). The ablation procedure can be classified by energy source: radiofrequency ablation and cryoablation."
50545|NCT03788928|Diagnostic Test|serum mitochondrial DNA|serum mitochondrial DNA will be measured using RT-PCR within first 72 hours of symptoms of acute pancreatitis
50546|NCT03788915|Behavioral|Online dietetic lifestyle counseling|"The certified clinical dieticians provide individual therapy online and offline according to their patients' needs and based on information supplied via the website www.livalife.dk. The dietician generates a daily caloric reduction plan of approximately 1600-4800 KJ based on the patients' diet record. The dietary advice will be standardized and follow the dietary guidelines given at www.livalife.dk and the Danish Health Administration (Sundhedsstyrelsen)."
50547|NCT03788915|Behavioral|Usual care|Patients randomized to the control group will be offered to receive usual municipal secondary or tertiary preventive offers.
50548|NCT03788902|Drug|Ritalin|Single dose of Ritalin IR 0.3-0.5 mg/kg OR placebo
50549|NCT03788889|Drug|Ketamine|Ketamine infusion
50550|NCT03788889|Drug|Phenobarbital|Phenobarbital intravenous injection
50551|NCT03788889|Drug|Lorazepam|Standard of Care
50552|NCT03788889|Drug|Placebo A|Placebo injection
50553|NCT03788889|Drug|Placebo B|Placebo infusion
50554|NCT03788876|Other|Neuromuscular electrical stimulation|The NMES training will be applied once a day (30 minutes of application per session with an increase of one minute every two days and reduction in the OFF time), until the discharge from the ICU. The patient will continue with the application also in the Hospitalization Units of HCPA until discharge.
50678|NCT03787706|Other|Dry Needling|Patients will receive dry needling over active trigger points in the upper trapezius muscle
50555|NCT03788876|Other|Conventional care|Physiotherapy protocol will be performed by HCPA physiotherapists twice a day, which will consist of exercises for bronchial hygiene, exercises for pulmonary reexpansion, and passive mobilization exercises.
50556|NCT03788863|Drug|Diflucortolone valerate (BAY866146)|Follow clinical administration
50557|NCT03788837|Drug|Ilomedin|The patient will receive treatment with intravenous Ilomedin therapy at a dose of 0.5ng/kg/min with increments of 0.5 ng/kg/min every 30 minutes up to a maximum posology of 1,5 ng/kg/min for 48h.
50558|NCT03788837|Drug|NaCl|The patient will receive treatment with intravenous NaCl 0.9% (placebo-double blinded) with increments of infusion rate every 30 minutes for 48h
50559|NCT03788811|Device|ERG assessment (RSPA)|Processing and analysis of retinal signals
50560|NCT03788798|Device|Patient infotainment system|The patient infotainment system is a quasi-interactive computer program connected to a server that pushes messages and educational programs ordered from the caring physicians or on-demand by the patients. The server has parallel data exchange gateways to the Hospital Information System (HIS), Picture Archiving Communication System (PACS), and can record the patients' responses to surveys and questionnaires.
50561|NCT03788785|Behavioral|Experimental arm|The specific tobacco cessation intervention will be based on meeting with trained nurses : three 1/2 hour session of assessment of current addictive behaviors and motivation to change smoking habits occurring within five days tops.
50562|NCT03788785|Other|Control arm|In the control arm, patients will receive the current standard of care for these patients, namely referral to external care after general advice on tobacco cessation (self-help tools).
50563|NCT03788772|Other|Multiple blood sampling|ICU septic and non-septic patients will be subjected to repeated blood samples at the following time-points: ICU admission, day 4/5, ICU and hospital discharge, 3 months. Patients exhibiting ICU-acquired infection will also be sampled at the time of diagnosis (up to 6 additional blood samples of 20 mL within 3 months = 120mL)
50564|NCT03788772|Other|Simple blood sampling|Healthy controls (blood donors and patients undergoing elective cataract surgery) will be subjected to one single blood sample of 20 mL.
50565|NCT03788759|Drug|Alpha-lipoic acid|Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.
50566|NCT03788759|Drug|Placebo Oral Tablet|Administration of placebo, as an adjunct to antipsychotic medication.
50567|NCT03788733|Drug|Melatonin 3 mg|1 time a day for 8 weeks
50568|NCT03788733|Drug|Placebo Oral|1 time a day for 8 weeks
50569|NCT03788720|Procedure|Suture of the ovarian cortex|Suture of the ovarian cortex after laparoscopic enucleation of endometriomas, using one single monofilament suture material, continuous suture technique with maximum 5 transfixion of the ovarian cortex and intracorporeal knots only (no extracorporeal knots).
50570|NCT03788720|Procedure|No suture of the ovarian cortex|Laparoscopic enucleation of endometriomas without suture of the ovarian cortex
50571|NCT03788707|Other|Passive leg raising|After 30 seconds of lying flat, volunteers will have passive leg raising to 45 degrees. Expired CO2 will be measured via a face mask before and after leg raising.
50572|NCT03788694|Drug|Ketamine|8 doses of intranasal ketamine; 40 mg per dose.
50573|NCT03788681|Drug|Estradiol Valerate|"oral estradiol  estradiol valerate  (Cyclo-Progynova)"
50574|NCT03788681|Drug|Placebo Oral Tablet|placebo
50575|NCT03788668|Procedure|Hyoid suspension|Hyoid suspension will be done with barbed reposition pharyngoplasty
50576|NCT03788642|Procedure|Control LED shoe arm|Patients with DFU will wear LED shoe 30 minutes once daily
50577|NCT03788642|Procedure|Laser Shoe arm|Patients with DFU will wear Laser shoe 30 minutes once daily
50578|NCT03788629|Other|Talocrural joint MWM mobilization|There were three groups for this study. In addition to conventional treatment group (control group), one of the study groups was performed talocrural joint mobilization.
50579|NCT03788629|Other|Subtalar joint MWM mobilization|There were three groups for this study. In addition to conventional treatment group (control group), one of the study groups was performed subtalar joint mobilization
50580|NCT03788629|Other|Bobath Concept|There were three groups for this study. This group was control group.
50581|NCT03788616|Drug|Fuji IX EXTRA|High-viscosity glass ionomer (Fuji IX EXTRA)
50582|NCT03788616|Drug|ACTIVA KIDS bioactive restorative material|Modified composite (ACTIVA KIDS)
50583|NCT03788603|Drug|Rogaratinib (BAY1163877)|Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
50584|NCT03788590|Device|Jenscare TAVI|Jenscare TAVI and delivery system will implant a percutaneous bioprosthesis value, which is positioned in the native aortic valve, plays a role to control blood flow, and help your heart to work better. It may also shorten your recovery time to getting back to everyday activities.
50585|NCT03788577|Dietary Supplement|Oligonol intake|Major intervention of Oligonol component , as suggested Oligonol safe dose for adults is 200mg per day.
50586|NCT03788577|Dietary Supplement|Placebo|Placebo
50587|NCT03788538|Drug|dexmedetomidine|10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.
50588|NCT03788525|Behavioral|Reduced recreational screen time|Participants must remove all recreational screen-based media use beyond 3 hours/week. This includes all recreational screen-based media use inside and outside the household. As a tool to comply with the intervention the families will hand-over all portable screen-based media devices. In return, each participant who own a smartphone will receive a regular cell-phone which can only make phone calls and send text messages. For a maximum of ½ an hour a day, adult participants may use this device for necessary contact. The families are allowed a maximum of 3 hours/week of recreational screen time. If participants can not hand over their smartphones due to daily use for work purposes we will install an app tracking screen use on these devices.
50679|NCT03787706|Other|Manual Therapy|Patients will receive a manual compression for 30seconds over active trigger points in the upper trapezius muscle
50680|NCT03787693|Behavioral|VR - Virtual Reality|Subjects in the experimental group will perform the split-belt task in a VR environment
50589|NCT03788525|Behavioral|Timed recreational screen time|Participants must remove all recreational screen-based media use after 6 PM. There are no restrictions on the amount of screen-based media use before 6 PM. Thus, before 6 PM, the participants must continue their habitual screen-based media use completely. However, after 6 PM, both work-related and recreational screen-based media use must be removed completely.
50590|NCT03788512|Other|observational only- no intervention|observational only- no intervention
50591|NCT03788499|Other|Massage of Maxillofacial and Oral Cavity|Massage of Maxillofacial and Oral Cavity is performed five times a day, each part lasts 1-2 minutes, repeating 3 cycles. The maxillofacial and oral massage last from the first day of radiotherapy to three months after last radiotherapy.
50592|NCT03788486|Device|2-3 Joule LED blue light device|application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
50593|NCT03788460|Other|no intervention|no intervention
50594|NCT03788447|Other|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
50595|NCT03788447|Other|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
50596|NCT03788434|Drug|VE303|VE303 is a live biotherapeutic product containing 8 clonal human commensal bacterial strains manufactured under GMP conditions.
50597|NCT03788434|Drug|Placebo|Placebo capsules contain micro-crystalline cellulose. They are visually identical to VE303 capsules. They will be taken by mouth for 14 days. Placebo capsules will not contain any VE303 Drug Product.
50598|NCT03788421|Device|LIGASURE|Electricity based cautery tool used during both laparoscopic and open surgery for optimal hemostasis.
50599|NCT03788421|Procedure|Clamping and suturing|Step by step clamping and suturing of the mesosalpinx until achievement of total salpingectomy.
50600|NCT03788408|Behavioral|Intensive Psychotherapy and case management for refugee trauma|CVT's approach emphasized active interdisciplinary coordination and a relational focus anchored in cultural humilityX to address survivors' priorities, empower survivors as the primary architects of their healing, and work alongside each survivor to co-construct meaning and behavioral change.
50601|NCT03788395|Device|Symbicort Turbohaler plus Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) plus Turbo+ for three months.
50602|NCT03788395|Drug|Symbicort Turbohaler without Turbo+|Symbicort Turbohaler (Budesonide and Formoterol Fumarate Dihydrate) without Turbo+ for three months.
50603|NCT03788369|Procedure|Hybrid Coronary Revascularization|Hybrid coronary revascularization (HCR) combines minimally invasive surgical coronary artery bypass grafting of the left anterior descending artery with percutaneous coronary intervention (PCI) of non-left anterior descending vessels.
50604|NCT03788356|Device|Inspiratory muscle training|Inspiratory muscle training with a device
50605|NCT03788356|Other|Diaphragmatic breathing|Diaphragmatic breathing exercise
50606|NCT03788343|Dietary Supplement|Phenylalanine|The study product Phenylalanine, a dietary supplement, is authorized in Switzerland, but not designated for this patient group.
50607|NCT03788343|Drug|Placebo|Placebo capsules are indistinguishable in their appearance from Phe capsules
50608|NCT03788330|Device|Fresh air system with filtration|Using fresh air ventilation combined with PM2.5 filtration system to reduce the indoor PM2.5 concentration in primarty school classrooms
50609|NCT03788317|Drug|Botulinum toxin type A|Injections to hypertonic muscles
50610|NCT03788304|Device|non-invasive ventilation|conventional NIV
50611|NCT03788304|Device|high flow nasal cannula|HFNC ventilation
50612|NCT03788291|Drug|Acalabrutinib|100 mg by mouth twice a day starting on day 8 of cycle 1
50613|NCT03788291|Drug|Rituximab|Administered 2 times weekly for 6 cycles. Initial dose day 1: 50 mg IV, then 50 mg SQ thereafter.
50614|NCT03788278|Device|BioBeat|The watch incorporates sensors, a battery, a software system, memory components, and a communications component. the watch will be worn 24 hours a day, 7 days a week.
50615|NCT03788265|Device|Lipogems|harvest and inject micro-fragment adipose tissue
50616|NCT03788252|Drug|Renamezin|7 capsules once, three times a day, for 48 weeks
50617|NCT03788239|Other|Staples versus sutures|"Prolene suture: non-absorbable, sterile surgical suture composed of an isotactic crystalline steroisomer of polypropylene, a synthetic linear polyolefin. After completion of the procedure, deep tissues will closed with subcuticular prolene suture. Compared to the absorbable sutures, prolene is known to cause less infection since it is a monofilament material.~Staples: specialized staples used in surgery in place of sutures to close skin wounds. After completion of the procedure, deep tissues were closed with absorbable braided suture, then the skin will be closed by staples."
50618|NCT03788226|Drug|POF|A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
50619|NCT03788226|Drug|CAPOX/SOX/FOLFOX|"CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles."
50620|NCT03788213|Radiation|3 week RT|40 Gy in 15 fractions over 3 weeks to the whole breast or chest wall. Patients undergoing breast conservation therapy will receive additional boost radiotherapy to the tumor bed. The supraclavicular fossa will be treated in patient with node positive disease or those receiving neoadjuvant chemotherapy. IMC and Axillary radiotherapy will be given as per the institutional policy. Boost Dose schedule for BCS patients will be 8 Gy delivered in 15 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
50681|NCT03787680|Drug|Olaparib|300 mg by mouth twice a day for days 1-28 of a 28-day cycle.
50682|NCT03787680|Drug|AZD6738|160 mg by mouth daily for days 1-7 of a 28-day cycle.
50683|NCT03787667|Diagnostic Test|CT or MRI based Radiomics|Radiomic features were extracted from enhanced CT or MRI of colorectal cancer.
50621|NCT03788213|Radiation|1 week RT|26 Gy in 5 fractions over 1 week to the whole breast or chest wall. Treatment volumes will be same as the control arm. Additional boost will be delivered to patients who have undergone breast conservation. Boost Dose schedule for BCS patients will be 6 Gy delivered in 5 fractions simultaneously with tangential EBRT. In institutions planning for sequential boost, a dose of 12 Gy in 4 fractions will be delivered after whole breast EBRT.
50622|NCT03788200|Procedure|Bracing|Treatment arm #1 (8 weeks of post-injury bracing with rigid cervical collar): Participants randomized to this treatment arm will be treated with 8 weeks in a rigid cervical collar.
50623|NCT03788200|Procedure|posterior C1-C2 instrumented fusion|Treatment arm #2 (posterior C1-2 instrumented fusion): Participants randomized to this treatment arm will undergo posterior C1-2 instrumented fusion with either local bone grafting or autologous iliac crest bone grafting with or without allograft bone grafting. Bone grafting decision will be made by the treating surgeon. All remaining decisions surrounding medical and surgical care will be made by the attending spine surgeon involved in each case.
50624|NCT03788187|Other|Blood test sample|
50625|NCT03788187|Other|Peritumoral adipose tissue sample|
50626|NCT03788174|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
50627|NCT03788174|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
50628|NCT03788161|Other|Real Virtual Reality|Participants will receive a distraction by playing a game of virtual reality with a 3D application
50629|NCT03788161|Other|Placebo Virtual Reality|Participants will receive a placebo distraction with a game of virtual reality with a 3D application without functioning
50630|NCT03788148|Device|Stent, red blood cell transfusion|BMS (Bare Metal Stent) and DES (drug-eluting stent) transplants with periprocedural red blood cell transfusion
50631|NCT03788135|Behavioral|cooling|the participants in the experimental group will receive a cold pack (gel pack, temperature -6 degrees to -12 degrees Celsius) will be placed on the target muscles for 20 minutes.
50632|NCT03788122|Other|In-depth interview|The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
50633|NCT03788109|Procedure|device: combined solid state HRiM|The HRiM catheter (Medical Measurement Systems, Enschede, The Netherlands) incorporating 36 pressure sensors, spaced at 2 cm in the stomach and esophagus and at 1 cm in the LES and upper esophageal sphincter (UES), and 16 impedance channels throughout the esophagus, will be placed transnasally, after topical anesthesia. Manometry will be used to record pressures in the stomach, the esophagus, the LES and the UES. In this way, it is possible to detect and characterize TLESRs, and to measure GA. The impedance channels will be used to measure bolus movement, and thus to detect and characterize gastro-esophageal reflux.
50634|NCT03788096|Behavioral|Peer Support with Motivational Interviewing|Mentors will trained in motivational interviewing and will conduct weekly telephone calls with participants randomized to the PS-PICS peer support intervention arm.
50635|NCT03788096|Behavioral|Usual Care Group|Usual care.
50636|NCT03788083|Drug|Trimix|Intratumoral TriMix injection
50637|NCT03788083|Drug|Placebo|Intratumoral placebo injection
50638|NCT03788057|Other|ICS dose reduction|"If control of symptoms is maintained (evaluation based on clinical symptoms solely), every 3 months the dose of ICS is halved according to GINA guidelines, until the control is lost or the lowest daily dose is reached (200 mcg, calculated as budesonide equivalent).~In the case of loss of asthma control, beta-mimetic will be administered (temporarily) and return to the chronic administration of the previous, twice higher dose of ICS is restored (or further increase of treatment). In severe exacerbations, inclusion of oral steroids will be considered."
50639|NCT03788044|Other|Education|Education + Medication adherence monitoring + Feedback when low adherence
50640|NCT03788031|Other|Acuity training|The intervention will be a vision therapy. On each trial, a properly oriented stimulus will be presented randomly at one of the four locations on a flat monitor screen. The visual task is to identify the location of the stimulus.
50641|NCT03788031|Other|Occlusion therapy|Participants will be required to patch the good eye for 20 days, 1 hour per day.
50642|NCT03788018|Drug|lidocaine and dexmedetomidine IV|Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.
50643|NCT03788018|Drug|saline IV|Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
50644|NCT03788005|Procedure|Early mobilization|Early mobilization as soon as possible and within a maximum of 12 hours following burr hole craniostomy for chronic subdural hematomas.
50645|NCT03787992|Drug|Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo|"The initial dose of AST2818 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
50646|NCT03787992|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
50647|NCT03787992|Drug|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
50710|NCT03787368|Drug|0.9% sodium chloride solution|Single intravenous infusion of Placebo (0.9% sodium chloride solution)
50711|NCT03787355|Combination Product|Morse connection Implants|2 neighboring morse connection Implants of Zinedent - Strauman
50648|NCT03787992|Drug|Placebo AST2818 80mg//40 mg|The initial dose of Placebo AST2818 80 mg once daily can be reduced to Placebo AST2818 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
50649|NCT03787979|Other|Lumbopelvic stiffening technique|"Participants will stretch their hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense your back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
50650|NCT03787979|Other|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with their hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax your back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
50651|NCT03787966|Other|ATOPE-B|Patients will perform therapeutic exercise before medical treatment and will follow the usual care after medical treatment.
50652|NCT03787966|Other|ATOPE-I|Patients will follow usual care before medical treatment and will perform therapeutic exercise after medical treatment.
50653|NCT03787953|Drug|Anti-PD-1/PD-L1 antibodies|The study is a real-world study. According to the actual medical history of patients, the usage of anti-PD-1/PD-L1 antibodies was collected.
50654|NCT03787940|Drug|Isoniazid|standard dose isoniazid or high dose isoniazid for participants with rapid acetylators
50655|NCT03787927|Drug|Autologous Platelet Transfusion (room-temperature-stored)|The participant will receive an autologous platelet transfusion of their room-temperature-stored platelets after 5 days of storage.
50656|NCT03787927|Drug|Autologous Platelet Transfusion (cold-stored 5 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 5 days of storage.
50657|NCT03787927|Drug|Autologous Platelet Transfusion (cold-stored 10 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 10 days of storage.
50658|NCT03787927|Drug|Autologous Platelet Transfusion (cold-stored 15 days)|The participant will receive an autologous platelet transfusion of their cold-stored platelets after 15 days of storage.
50659|NCT03787927|Drug|Aspirin|Aspirin (325mg) will be administered the day before every transfusion.
50660|NCT03787927|Drug|Clopidogrel|Clopidogrel (600mg) will be administered the day before every transfusion.
50661|NCT03787914|Procedure|Mobile Outreach Approach|TB patients in intervention arm were served by outreach mobile teams for DOTS (i.e. administration of anti-TB medicines orally at the place and time of their choice and convenience under mobile teams direct supervision
50662|NCT03787901|Other|Morula Vitrification|Evaluating the ongoing pregnancy rate following Morula vitrification compared with Blastocyst Vitrification.
50663|NCT03787875|Procedure|periodontal treatment|In the study group, periodontal scaling and root planning treatment of the 4 quadrants was performed for two consecutive weeks without the use of antiseptics or antibiotics, and the patients were instructed in oral hygiene, including both brushing techniques and proximal hygiene.
50664|NCT03787849|Drug|Sevoflurane|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
50665|NCT03787849|Drug|Propofol|All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
50666|NCT03787836|Behavioral|Maintained Exercise|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 4.5 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
50667|NCT03787836|Behavioral|Increased Intensity|"Complete 28 weeks of aerobic exercise, with one week (following week 16) for testing.~Week 1 - 16 Intensity: 4.5 metabolic equivalents (METs).~Duration:~Week 1: 80 minutes Week 2: 100 minutes Week 3: 120 minutes Week 4: 135 minutes Week 5 - 16: 150 minutes/week~Week 17: Physiological Testing~Week 18 - 29 Intensity: 6.0 METs Duration: 150 minutes/week~All exercise must be completed across a minimum of two sessions per week. Sub-maximal exercise tests will be completed every 4 weeks to adjust intensity."
50668|NCT03787823|Procedure|robotic Prostatectomy (RARP)|Modification of robotic Prostatectomy Arm A classic technique/ anterior transperitoneal RARP Arm B Transdouglas Technique/retzius-sparing RARP
50669|NCT03787810|Diagnostic Test|Echocardiography|Echocardiography for assessment of left ventricular dysfunction
50670|NCT03787797|Diagnostic Test|Echocardiography|Assessment of epicardial adipose tissue thickness
50671|NCT03787784|Other|AI presentation|Automatic diagnosis information of AI is visible to endoscopist
50672|NCT03787758|Drug|SAGE-718|SAGE-718
50673|NCT03787745|Procedure|Ischemic postconditioning|After 60 seconds of reperfusion, ischemic postconditioning with an adequately sized balloon (60 reperfusion/60 seconds re-occlusion, four cycles) will be performed
50674|NCT03787745|Procedure|Conventional|State of the art primary PCI, however thrombectomy is not allowed
50677|NCT03787719|Other|Twice per week dialysis|Twice-weekly 4 hour dialysis treatment
50684|NCT03787654|Device|electroacupuncture|"BL33 and BL35 are inserted by needles of 0.30×75mm size till a depth of 60~70mm. SP6 is inserted by needle of 0.30×40mm size till a depth of 25-30mm. After manipulation and deqi sensation generation, the electrodes will be attached to the acupoints transversely with 20Hz continuous wave and an electricity current of 2mA-6.5mA at BL33 and BL35, and 1-3.5mA at SP6. The current is adjusted from zero to the degree where patients can tolerate.~Subjects receive 3 sessions per week（every other day ideally) for 12 weeks, 36 sessions in total."
50685|NCT03787654|Device|sham electroacupuncture|"In sham electroacupuncture group, sham acupoints 1 cun(≈15mm） horizontally outwardly lateral to BL33 and BL35, and 0.5 cun (≈10mm) horizontally behind SP6 are stimulated by needles of 0.30×40mm size. The needles are inserted to a depth of 2-3mm to stand still, without any manipulation and sensation of deqi. The electrodes will also be attached to needles with an electricity current of 0.1-0.3mA.~The sessions will be the same as the electroacupuncture group."
50686|NCT03787654|Drug|Solifenacin|Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
50687|NCT03787641|Drug|Protamine Sulfate|Protamine Sulfate will be administered via an infusion pump to administer a 50 mg test doze, then 100 mg after 5 min waiting period. Following blood samples, additional alliquots of 50 mg will be measured to a maximum of 300 mg.
50688|NCT03787628|Drug|Cannabidiol Oral Solution|"CBD Oral Solution (700 and 1400 mg/day) or matching placebo will be administered orally once daily in the morning. The concentration of the CBD Oral Solution is 100 mg/ml.~Insys Development Company, Inc. has successfully manufactured a pharmaceutical grade, synthetic CBD drug substance. It is manufactured in Insys' current Good Manufacturing Practices (cGMP) manufacturing facility. This facility is approved by the Drug Enforcement Administration (DEA) and has been inspected by the Food and Drug Administration (FDA). This active pharmaceutical ingredient is ≥ 99.5% pure and can be consistently produced without concern for contaminant."
50689|NCT03787628|Drug|Placebo|The reference therapy will be placebo, consisting of an oral solution that matches the active test medication in appearance. Different volumes of placebo will be administered to match that of the active compound, daily in the morning for each of 28 days.
50690|NCT03787615|Device|sipIT tools|Just in time drinking detection tools to promote increase fluid consumption
50691|NCT03787602|Drug|KRT-232|KRT-232, administered by mouth
50692|NCT03787589|Behavioral|Exercise Prescription|"Participants in the intervention group will be given an exercise prescription to increase their baseline steps by 1200 and 2000 steps per day at least 3 days a week over the first 3 months. If tolerated and accepted, the participants will increase their step counts by an additional 600 to 1000 steps per day at least 3 days a week for the next 3 months.This will be followed by a 6-month maintenance phase. The research coordinator will instruct the participants on the proper use of the Nordic walking poles which can be used to help participants achieve their prescribed number of steps.~All participants will be encouraged to wear the pedometer throughout the trial in order to follow the step-count prescription, monitor adherence and allow them to join a virtual exercise group that will include dialysis patients with similar levels of baseline activity."
50693|NCT03787576|Device|Cataract surgery|Evaluation of patient satisfaction after bilateral cataract surgery with multifocal intraocular lens implantation
50694|NCT03787563|Drug|Herbal Tea|All participants will be given the intervention in an infusion tea bag. Participant will be instructed to take one tea bag three times a day at before breakfast, lunch and dinner meals. At the time of randomization both active and placebo infusion bag will be provided.There will be one day of washout period after 2 days on treatment.
50695|NCT03787563|Drug|Placebo Tea|Similar looking inert placebo tea.
50696|NCT03787550|Drug|The Sedatives, analgesics and antibiotics|The sedatives (dexmedetomidine, midazolam, propofol), analgesics (butorphanol, remifentanil, sufentanil), and six antibiotics (linezolid, voriconazole, tigecycline, teicoplanin, caspofungin and meropenem) will be used according to the clinical need.
50697|NCT03787511|Other|Cough assessment|Cough assessment with cough visual analog scale (VAS), and Leicester Cough Questionnaire (LCQ) for Diabetic patients with chronic cough and Diabetic patients without chronic cough
50698|NCT03787511|Other|Neurological tests and cardiovascular tests|Neurological tests : electromyography, thermotest, QSAR + cardiovascular test for Diabetic patients with chronic cough and Diabetic patients without chronic cough
50699|NCT03787511|Other|Skin biopsy|Skin biopsy to evaluate small fiber neuropathy for Diabetic patients with chronic cough and Diabetic patients without chronic cough
50700|NCT03787498|Drug|PLX2853|Tablets
50701|NCT03787485|Behavioral|LINKS|The primary aim of LINKS is to create community-clinical linkages between three community health centers and their respective county health departments in southern Arizona. This study will also develop and evaluate a chronic disease and emotional well-being intervention that will connect clinic patients to community-centered, county-delivered, community health worker programs.
50702|NCT03787459|Drug|Arbidol|Oseltamivir plus Arbidol will be administrated from Days 1-7.
50703|NCT03787459|Drug|Placebos|Oseltamivir plus placebos will be administrated from Days 1-7.
50704|NCT03787433|Device|ARC - Assisted Rehabilitation Care|"ARC is a platform based on wearable inertial sensors and machine learning algorithms, designed to bring the rehabilitation at post-stroke patients' home, following hospital discharge.~The product has been created with the purpose to improve physical skills and patient independence accordingly, in the six months following the acute event. ARC aims to optimize, ease and make more accessible the path of post-stroke rehabilitation during post-acute phase, in real life settings."
50705|NCT03787420|Other|communication system|"We will use the questionnaire Amyotrophic Lateral Sclerosis Supportive Care Needs ,Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, Beck Depression Inventory and Caregiver Burden Scale."
50706|NCT03787407|Behavioral|stress management and meditation|mindfulness training using mobile application
50707|NCT03787394|Other|adding taste enhancer|Comparing sensory profiles of food products either enriched with FAAA-conjugates or plain
50708|NCT03787381|Device|Ultrasound|Vaginal ultrasound examination
50709|NCT03787368|Drug|BAY1213790|Single intravenous infusion of BAY1213790 (Two different doses)
86670|NCT03509012|Drug|Pemetrexed|IV
50712|NCT03787342|Procedure|Double Flap Incision|A full-thickness crestal incision will be made over the edentulous ridge, and then one partial-thickness vertical incision will be made on the buccal side. A partial-thickness flap will be raised first to separate the mucosal layer from the overlying periosteum. Subsequently, the periosteal layer will be elevated to expose the underlying alveolar process. Xenograft and Ti-mesh will be used to augment the defective site then periosteal flap will be sutured first, with periosteal sutures securing the regenerative site. Then the mucosal flap will be closed.
50713|NCT03787342|Procedure|Modified Periosteal Releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side (crestal incision and two vertical releasing incisions). Near the base of mucoperiosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The shallow incision helps in preventing damage to the submucosal layer. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade with sweeping motion to allow flap advancement."
50714|NCT03787342|Procedure|Coronally Advanced Lingual Flap|A full-thickness crestal incision will be performed in the keratinized tissue from the distal surface of the more distal tooth to the retromolar pad. The flap design will be continued intrasulcularly on both vestibular and lingual sides of the mesial portion of the flap, buccally, it will be finished with a vertical releasing incision. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. Then, using a blunt instrument it will be localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. The blunt instrument will be inserted below this connective band, and, with gentle traction in the coronal direction, this muscular insertion will be detached from the lingual flap.
50715|NCT03787342|Procedure|Periosteal releasing incision|
50716|NCT03787329|Other|Core decompression surgery with bone marrow concentration|Core decompression surgery with bone marrow concentration
50717|NCT03787329|Other|Core decompression surgery|Core decompression surgery only
50718|NCT03787316|Device|Study group|4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
50719|NCT03787303|Drug|Triiodothyronine (T3)|Participants will have their L-thyroxine (T4) discontinued and Triiodothyronine (T3)/liothyronine sodium initiated at 3: 1 and titrated.
50720|NCT03787290|Drug|Tocilizumab|participants will receive a single subcutaneous injection of tocilizumab (162 mg)
50721|NCT03787290|Drug|Placebo|participants will receive a single subcutaneous injection of saline
50722|NCT03787290|Device|Whole-Body Hyperthermia|subjects' core temperature will be increased to 38.5 degrees Celsius (typically 60-120 minutes) then they will begin a 60-minute cool-down phase
50723|NCT03787264|Drug|Bendamustine|Debulking: Cycles 1-2: d1+2 - 70mg/m² i.v.
50724|NCT03787264|Biological|Obinutuzumab|"Induction: Cycle 1: d1 - 100 mg, d1 (or d2) - 900 mg, d8 + d15 - 1000 mg i.v.; Cycle 2 - 6: 1000 mg, d1 i.v.~Maintenance: Cycle 1 - 8: 1000 mg, d1 i.v."
50725|NCT03787264|Biological|Acalabrutinib|"Induction: Cycle 1: --; Cycles 2 - 6: d1-28: 2 x 100mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 2 x 100mg p.o."
50726|NCT03787264|Biological|Venetoclax|"Induction: Cycles 1 + 2: --; Cycle 3: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg p.o.; Cycle 4 - 6: d1-28: 400 mg p.o.~Maintenance: Cycle 1 - 8: d1-84: 400 mg p.o."
50727|NCT03787251|Drug|Apatinib|It is recommended that the initial dose of apatinib is 500mg po qd. Adjust the dose to 750mg po qd or maintain the original dose according to the patient's medication response for about 2 weeks. If there is grade III or above, or grade II and above non-hematologic toxicity, allow the dose to be lowered 2 times.
50728|NCT03787251|Drug|The chemotherapeutic drug chosen by the investigator.|"The choice of chemotherapy regimen is based on the medication habits of the drug delivery doctor and the specific circumstances of the patient.~In addition, the following regimens may be selected as monotherapy or combination: docetaxel 60-75 mg/m2d1 q3w; irinotecan 150-180 mg/m2 d1 q2w until disease progression or patient death. If grade 3 and above or non-hematologic toxicity of grade II and above adverse event appeared, allowing the dose to be lowered twice."
50729|NCT03787238|Device|non-invasive vagus nerve stimulation|non-invasive vagus nerve stimulation using the gammaCore Sapphire device
50730|NCT03787225|Drug|NNC0174-0833|Participants will receive dose levels of 0.3, 0.9 or 1.8 mg of NNC0174-0833 subcutaneously. Each participant will receive only one dose.
50731|NCT03787225|Drug|Placebo (NNC0174-0833)|Participants will receive NNC0174-0833 matched placebo subcutaneously.
50732|NCT03787212|Device|MiBo ThermoFlo|Test Device
50733|NCT03787212|Device|Bruder Mask|Control Device
50734|NCT03787199|Device|Andago|The Andago is a body-weight supporting device with which a patient can walk overground
50735|NCT03787199|Other|Treadmill|Bodyweight supported treadmill walking
50736|NCT03787186|Drug|GLPG1690 film-coated tablets|a single oral dose of GLPG1690
50737|NCT03787186|Drug|[14C]-GLPG1690 solution for infusion|a 15-minute IV infusion [14C]-GLPG1690
50738|NCT03787186|Drug|[14C]-GLPG1690 capsules|single oral dose of [14C]-GLPG1690
50739|NCT03787173|Device|Optimized|Inspiratory trigger and Expiratory trigger settings optimized by investigator
50740|NCT03787173|Device|Automated|Inspiratory trigger and Expiratory trigger settings automatized
50741|NCT03787160|Diagnostic Test|initial VOC|Difference in VOC profile between patients with CDH and healthy controls (2 samples per patient will be obtained after obtaining informed consent).
50742|NCT03787160|Diagnostic Test|initial fecal microbiome|Difference of alpha and beta diversity and relative fecal bacterial abundance between patients with CDH and healthy controls (1 stool sample will be taken per patient after obtaining informed consent)
50743|NCT03787160|Diagnostic Test|initial pulmonary microbiome|Difference of alpha and beta diversity and relative pulmonary bacterial abundance between patients with CDH and healthy controls (1 deep induced sputum sample will be taken per patient after obtaining informed consent)
50744|NCT03787160|Diagnostic Test|Maximum oxygen uptake|Comparison of the maximum oxygen uptake (corrected for body weight and gender) as determined by bicycle spiroergometry between patients with CDH and healthy controls
50745|NCT03787160|Diagnostic Test|Functional residual capacity|FRC will be determined by spirometry, bodyplethysmography and N2-breath wash out method. FRC will be compared between patients after CDH and healthy controls.
50746|NCT03787160|Dietary Supplement|Probiotic treatment|CDH patients will receive OmniBiotic 6(R) (Allergosan, Graz, Austria) probiotic supplementation 1 sachet daily for 3 months.
50747|NCT03787160|Diagnostic Test|VOC probiotic|Determination of the VOC profile 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
50748|NCT03787160|Diagnostic Test|Fecal microbiome probiotic|Determination of the fecal microbiome from 1 sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
50749|NCT03787160|Diagnostic Test|Pulmonary microbiome probiotic|Determination of the fecal microbiome from 1 deep induced sputum sample per patient (alpha and beta diversity, relative bacterial abundance at the genus level) 3 months after discontinuing probiotic treatment. Comparison to the profiles before the treatment.
50750|NCT03787147|Device|Google Cardboard|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
50751|NCT03787147|Device|Oculus|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Adult Patients for Pain Control During Spinal Injections (SI). VRA is a the oculus or the google cardboard that helps decrease anxiety. The participant in the oculus or the Google cardboard arms are asked to watch VR videos during the spinal injection.
50752|NCT03787147|Drug|Lidocaine Hydrochloride|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
50753|NCT03787147|Drug|Bupivacaine|All groups will receive pharmaceutical analgesia, either lidocaine or bupivacaine, depending on the condition. Dosage and frequency of pharmaceutical analgesia will be tailored to each participant's condition.
50754|NCT03787134|Behavioral|working memory and attention|Behavioral tests of working memory and attention
50755|NCT03787121|Procedure|care management pathways|different care management pathways, including thyroidectomy, iode 131, hormonal treatment and type of follow up
50756|NCT03787108|Other|Magnetic resonance spectroscopy measurement|Magnetic resonance spectroscopy measurement will be performed to measure liver fat content.
50757|NCT03787095|Biological|Cemiplimab|Administered as an intravenous (IV) infusion
50758|NCT03787095|Biological|Placebo|Admixture of Diluent for REGN2810 and sodium chloride for injection, administered as an IV infusion
50759|NCT03787082|Drug|Nitrates|1,000 mg/11.18 mmol, oral
50760|NCT03787082|Drug|Chlorhexidine Gluconate Mouthwash|chlorhexidine gluconate 0.12% (15mL) mouth rinse for 1 minute
50761|NCT03787082|Drug|Placebo Mouthwash|sterile water (15mL) mouth rinse for 1 minute
50762|NCT03787069|Drug|iv Lignocaine vs placebo|Lignocaine is available in an ampule of 10 ml containing 20 mg/ml of lignocaine or 2%, Lignocaine will be given in dose of 1.5 mg/kg I/V
50763|NCT03787056|Other|Blood draws|Blood draws are realized at each steps of patient disease management. The volume of each blood drawn is 20 mL for progastrin measurements and additional 5 mL for the dosage of the other tumor markers (PSA, CA19-9, CA125…). The frequency of blood drawn is maximum every 3 weeks (i.e. in case of chemotherapy treatment) and minimum every 6 months (for patients in follow up)
50764|NCT03787043|Drug|FDC(MP-513 10mg/Metformin XR 750mg)|
50765|NCT03787030|Drug|Vitamin E Acetate ointment|Application of 1 ml of ointment to the distal anal canal, every 12 hours for an 8-week period.
50766|NCT03787030|Drug|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
50767|NCT03787017|Drug|FDC(MP-513 20mg/Metformin XR 1000mg)|
50768|NCT03787017|Drug|MP-513 20mg|
50769|NCT03787017|Drug|Metformin XR 1000mg|
50770|NCT03787004|Drug|CNTX-6970|Oral dose CNTX-6970
50771|NCT03787004|Other|Placebo|Oral dose placebo
50772|NCT03786991|Other|No intervention|No intervention
50773|NCT03786978|Behavioral|Structured pharmaceutical care|Patients receive a structured pharmaceutical care from one year after basal hospital discharge
50774|NCT03786978|Behavioral|Comparator|Patient received a single phone call 30 days after basal hospital discharge.
50775|NCT03786965|Other|On-pump CABG|On-pump CABG
50776|NCT03786965|Other|Off-pump CABG|Off-pump CABG
50777|NCT03786965|Other|Pump-assisted CABG|Pump-assisted CABG
50778|NCT03786965|Other|Valve Repair Procedure without CABG.|Valve Repair Procedure without CABG (open heart procedure).
50779|NCT03786965|Other|Valve Repair Procedure with CABG.|Valve Repair Procedure with CABG (open heart procedure).
50780|NCT03786952|Behavioral|Stress immediately before learning in males|Male participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
50781|NCT03786952|Behavioral|Sham control immediately before learning in males|Male participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
50782|NCT03786952|Behavioral|Stress 30 minutes before learning in males|Male participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
50783|NCT03786952|Behavioral|Sham control 30 minutes before learning in males|Male participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
50784|NCT03786952|Behavioral|Stress immediately before learning in females|Female participants will be exposed to the socially evaluated cold pressor test immediately prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Immediately following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
50785|NCT03786952|Behavioral|Sham control immediately before learning in females|Female participants will be exposed to the sham control condition (no stress) immediately prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Immediately following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
50786|NCT03786952|Behavioral|Stress 30 minutes before learning in females|Female participants will be exposed to the socially evaluated cold pressor test 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of ice cold water for up to 3 minutes. The participants will also be informed that they are being videotaped for analysis of facial expressions and be asked to stare at a camera throughout the manipulation. Thirty minutes following the acute stressor, participants will undergo the acquisition phase of fear conditioning.
50787|NCT03786952|Behavioral|Sham control 30 minutes before learning in females|Female participants will be exposed to the sham control condition (no stress) 30 minutes prior to fear learning. Participants will place their dominant hand in a bath of lukewarm water for up to 3 minutes. Thirty minutes following the sham control condition, participants will undergo the acquisition phase of fear conditioning.
50788|NCT03786939|Procedure|On-pump CABG.|On-pump coronary artery bypass grafting.
50789|NCT03786939|Procedure|Off-pump CABG.|Off-pump coronary artery bypass grafting.
50790|NCT03786939|Procedure|Pump-assisted CABG.|Pump-assisted CABG.
50791|NCT03786926|Drug|HMPL-689|HMPL-689 is a PI3Kδ inhibitor
50792|NCT03786913|Diagnostic Test|Quantitative muscle ultrasound measurements|Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.
50793|NCT03786900|Biological|Fecal Microbiota Transplantation (FMT) product PRIM-DJ2727|
50794|NCT03786887|Drug|Nalbuphine|dosage of nalbuphine
50795|NCT03786874|Other|Identify work interruptions|estimate baseline characteristics of the collaborative working model (proportion expressed as a percentage)
50796|NCT03786874|Other|Understand work interruptions|Team-review of the results of the task interruption and professional representations, identify activities to protect from task interruption
50797|NCT03786874|Other|Act to limited work interruptions|Adaptation of organizations; Awareness raising and Coaching for change
50798|NCT03786861|Procedure|corneal WFG group|TransPRK using ESIRIS flying spot excimer laser system (SCHWIND AMARIS®500E, SCHWIND eye-tech-solutions, Kleinhostheim, Germany), with 500 Hz repetition rate for faster treatments and scanning spots and with smart pulse technology. Eye-tracking during laser ablation was achieved using a 1050 Hz infrared eye tracker centered on the pupil. Static cyclotorsion control (SCC) compensation was obtained for all patients in corneal WFG group.
50799|NCT03786861|Procedure|aberration free group|TransPRK was performed to eligible myopic patients with or without astigmatism with corneal HOAs ≥ 0.35 µ utilizing aberration free patterns provided by ORKCAM software (SCHWIND eye-tech-solutions, Kleinostheim, Germany)
50800|NCT03786848|Other|MiniPDX Group|Mini patient derived xenograft (MiniPDX) is a drug sensitivity test model established by transplanting primary human tumor cells into immunodeficient mice by special methods. This test can provide sensitivities of single drug or drug combination within 7 days to screen out the optimal individualized regimens for each patient.
50801|NCT03786835|Other|Protein supplementation and regular physical activity|To determine if high protein diet and/or regular physical activity improves muscle and bone health
50802|NCT03786822|Procedure|Cryoballoon Pulmonary Vein Isolation - PVI|A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12 French steerable sheath (FlexCath, Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
50803|NCT03786809|Drug|Cimifuga Racemosa|Experimental group will use 160mg of Cimifuga Racemosa for 28 days
50804|NCT03786809|Drug|Placebo|patients of the placebo group will use placebo once a day for 28 days
50805|NCT03786796|Drug|Olaparib|Olaparib is a crystalline solid, is non-chiral and shows pH-independent solubility of approximately 0.1 mg/mL across the physiological range. Olaparib is presented for oral administration as a green, film-coated tablet containing 25 mg, 100 mg or 150 mg of drug substance. The 100 mg strength is also available as a yellow, film-coated tablet. The 25 mg, 100 mg and 150 mg strengths of olaparib tablets are composed of the same constituents. The tablet cores comprise: olaparib, copovidone, colloidal silicon dioxide, mannitol and sodium stearyl fumarate. The composition of the green tablet film coating is: hydroxypropyl methylcellulose (hypromellose), macrogol 400 (polyethylene glycol 400), titanium dioxide, iron oxide yellow and iron oxide black. The yellow tablet film coating only differs from the green film coating with the omission of iron oxide black.
50822|NCT03786757|Drug|Rivaroxaban|Rivaroxaban 2.5mg/BID will be applied for 24 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
50823|NCT03786744|Biological|ASD CB-MNC injection.|CB-MNC injection from different donors. One dose consist 20-50 mil MNC/kg.The protocol include 3 injection at monthly intervals.
50824|NCT03786744|Other|Standard therapy.|The standard therapy can include drugs, special psychology training etc.
50825|NCT03786731|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
50826|NCT03786718|Other|Patient-facing Diabetes Dashboard|The Patient-facing Diabetes Dashboard is embedded within a patient web portal and includes graphics to visualize and summarize patients' health data, incorporates motivational strategies (e.g., social comparisons and gamification), provides literacy level appropriate educational resources, and contains secure-messaging capability.
50827|NCT03786705|Other|Massive transfusion|Trauma patients who had received blood transfusion≥10 U
50828|NCT03786705|Other|Non-Massive Transfusion|Trauma patients who had received blood transfusion<10 U
50829|NCT03786692|Drug|Arm A|Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
50830|NCT03786692|Drug|Arm B|Carboplatin + Pemetrexed + Bevacizumab
50831|NCT03786679|Device|Ultrasling ER III orthosis|Application of orthosis and start of rehabilitation after four weeks.
50832|NCT03786666|Procedure|Carotid artery recanalization CEA or carotid artery stenting|Carotid artery recanalization CEA or carotid artery stenting
50833|NCT03786640|Radiation|3T MRI scan|A clinically indicated 3T MRI scan will be performed per standard procedures for the radiology department. Cardiac monitoring during the MRI scan is recommended to include Pulse Oximetry and/or ECG.
50834|NCT03786627|Other|Combined NMES and motor control|This group will receive the neuromuscular electrical stimulation using interferential mode (6000 Hz, beat frequency 20-50 Hz, scanning effect) on bilateral lumbar multifidus muscles. The intensity will be set at the subject's maximum tolerance. Stimulation will be set at 10 seconds on and 60 seconds off to minimize muscle fatigue. The total stimulation time is 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. It is believed to restore the motor units in individuals with arthrogenic muscle inhibition. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
50835|NCT03786627|Other|Motor control and placebo NMES|This group will the neuromuscular electrical stimulation without turning the electrical current for 15 minutes. After that, this group will receive 30 minutes motor control training. This motor control training will focus on the control of the lumbar multifidus muscle in various functional tasks. This motor control training will take approximately 30 minutes. This group will receive intervention twice a week for 8 weeks.
50836|NCT03786614|Other|Discontinuation of serotonergic antidepressants|Discontinuation of serotonergic antidepressants and possibly shift to other antidepressant categories that were proven to be effective in treating depression such as pramipexole, bupropion, quetiapine, lurasidone, brexpipazole. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
50837|NCT03786614|Other|Continuation of serotonergic medications|Continuation of serotonergic medications which is the standard care of treatment. Additionally, subjects will have access to other treatment measures of treating treatment resistant depression.
50838|NCT03786601|Other|Observation|The participants were assigned to different groups according to the results of HPV detection.
50839|NCT03786588|Other|Observation|The patients with the negative results of HPV infection, and assigned to different group according to the CPP manifestation.
50840|NCT03786575|Diagnostic Test|Next Generation Sequencing (NGS) detection|The NGS detection panel is designed by our team and covers genes that are clinically useful and have definite guiding significance for endocrine therapy
50841|NCT03786562|Drug|Intrathecal Morphine|Group 1
50842|NCT03786562|Drug|Intrathecal Morphine + Intravenous Nalbuphine|Group 2
50843|NCT03786549|Other|pediatric-adult care transition program|"Three structured axes of multidisciplinary interventions are added to the usual follow-up for the patients drawn in this interventional arm. Those axes integrate the bioclinical medical care and include the parents of the adolescent~Three axes are :~Educative, family (patient and parent), at home~Psychological, with the patient individually~Medico-social orientation, group of patients"
50844|NCT03786536|Device|MediSieve Magnetic Haemofiltration System|The MediSieve Magnetic Haemofiltration System is a medical device intended for use in extracorporeal clinical procedures to remove magnetic targets (e.g. malaria infected red blood cells) from a patient's bloodstream.
50845|NCT03786523|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
50846|NCT03786523|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without restriction on feeding time.
50847|NCT03786510|Behavioral|Active control|Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.
50848|NCT03786510|Behavioral|Intensive + Maintenance program|"Both intensive and maintenance program~Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook"
50909|NCT03785951|Dietary Supplement|Whey Protein Isolate|"Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
52039|NCT03777514|Drug|Ferumoxytol|treatment of iron deficiency anemia with IV iron.
50849|NCT03786510|Behavioral|Intensive program only|"Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching."
50850|NCT03786497|Other|Brain monitoring using PBSF protocol|Brain function and perfusion will be monitored with two channel aEEG and NIRS by PBSF protocol via telemedicine
50851|NCT03786484|Drug|PBF-999|Phosphodiesterase 10 inhibitor (PDE10i)
50852|NCT03786471|Other|Health System-based Dementia Care|Active comparator
50853|NCT03786471|Other|Community-based Dementia Care|Active comparator
50854|NCT03786471|Other|Enhanced Usual Care|Control
50855|NCT03786458|Behavioral|web-based decision aid|The decision aid is then developed further process of evidence synthesis and multidisciplinary external review.
50856|NCT03786432|Device|Spira-C Interbody Device|40 subjects undergoing anterior cervical discectomy and fusion surgery using Spira-C titanium interbody device
50857|NCT03786419|Drug|Atezolizumab|Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
50858|NCT03786406|Other|No treatment given|No specific intervention is studied. All anti-diabetic and CV medication will be prescribed at the physician's discretion under routine clinical practice conditions.
50859|NCT03786393|Diagnostic Test|ACR 1990 fibromyalgia critters|ACR 1990 fibromyalgia critters
50860|NCT03786380|Drug|Relamorelin 10 μg|Relamorelin 10 μg injected subcutaneously twice daily.
50861|NCT03786354|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3DCRT
50862|NCT03786354|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
50863|NCT03786341|Device|with auxiliary illuminator|Ambulation training with laser quad-cane for 15 minutes and typical physical therapy with strengthening and balance training for 15 minutes.
50864|NCT03786328|Behavioral|Standard Psychiatric Treatment|Standard psychiatric treatment is offered individuals identified with a clinical mental disorder. Treatment will follow golden standard treatment in the psychiatric clinic, meaning a combination of therapy and psychopharmacological treatment.
50865|NCT03786328|Behavioral|Preventive Psychological Treatment|Preventive Psychological Treatment is offered individuals identified with a sub-clinical mental condition. Treatment consists of 8 sessions of cognitive-behavioural therapy.
50866|NCT03786315|Other|VOLITION|"The intervention will incorporate a training workshop for GPs in the use of shared decision-making surrounding an index consultation, and a written involvement-facilitating tool for patients attending an index consultation with these GPs. Evaluation will focus around the index consultation between participating patients and GPs. The intervention outcomes will be compared with 'usual care' in the control group.~A written decision-support tool may include simple bullet points prompting the patient to ask to be involved in decision-making when visiting a GP, with examples of the phrases to use. The tool will be mailed to the 'flagged' potential patient participants along with their patient information pack, ahead of the index consultation, and it will also be available in the waiting room."
50867|NCT03786302|Drug|TAMP bioglass|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
50868|NCT03786302|Drug|Biodentine|TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
50869|NCT03786289|Biological|Recombinant human serum albumin/erythropoietin fusion protein|Recombinant human serum protein/erythropoietin fusion protein 150μg-1200μg single subcutaneous injection at Day1
50870|NCT03786289|Biological|Recombinant erythropoietin injection (CHO cells)|Recombinant erythropoietin injection (CHO cells) 10000IU single subcutaneous injection at Day1
50871|NCT03786276|Behavioral|VR-WMR-Only|Participants will spend up to 30 minutes in a VR-WMR environment during each training session.
50872|NCT03786276|Behavioral|Exercise-only|Participants will ride a stationary recumbent bicycle for up to 30 minutes during each training session.
50873|NCT03786276|Behavioral|Active VR-WMR|Participants will spend up to 30 minutes in a VR-WMR environment while riding a stationary, recumbent bicycle during each training session.
50874|NCT03786250|Procedure|Geriatric Assessment|Systematic screening of delirium, prevention of delirium, early treatment, pain management with scales adapted to chronicity, conciliation of medication to emergency discharge, among others.
50875|NCT03786237|Drug|Rigosertib Oral Capsules / Rigosertib Oral Liquid Solution / Rigosertib Intravenous|"Patients will take Rigosertib either as oral capsules or oral liquid solution or will get intravenous infusions depending on the needs of the patients.~Oral Capsules/ Liquid Solution:~Patients will take oral Rigosertib continuously for a total of three weeks, every four week cycle (three weeks on, one week off drug) for up to 13 cycles. Patients will take 560 mg of oral Rigosertib (ie, 2 capsules of 280 mg or 7,47mL of the concentrate in 30mL water) in the morning and 280 mg of oral Rigosertib (ie, 1 capsule of 280 mg or 3,73mL of the concentrate in 30mL water) in the afternoon, total of 840mg/day.~Intravenous Infusions:~For IV treatment Rigosertib 1800 mg/24 hr is diluted in 0.9% sodium chloride for injection just prior to dosing and is administered as a 72-hr CIV infusion on days 1, 2, and 3 of a 2-week cycle for the first eight 2-week cycles, then on days 1, 2, and 3 of a 4-week cycle thereafter."
50876|NCT03786224|Behavioral|Contingency Management|Six months of cannabis abstinence will be incentivized using a standard contingency management approach involving an escalating schedule of payment for abstinence and attendance.
50877|NCT03786211|Procedure|IANB by the guide of Panoramic|IANB will be injected by the guide of panoramic radiograph
50878|NCT03786211|Procedure|IANB without the guide of Panoramic|IANB will be injected without the guide of panoramic radiograph, in the routine way.
50879|NCT03786198|Behavioral|Activity program|Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
50880|NCT03786198|Behavioral|Control|Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
50979|NCT03785509|Drug|DAPT, Statin|Compliance of DATP, Compliance of Statin, Drug Eluting Stent, Bare Metal Stent
50881|NCT03786185|Behavioral|MusicPlast|"Each subject will receive 20 sessions of the computerized training based on a simplified music reading protocol. The training will be provided via a smartphone or a tablet. Each training session will last for 20 minutes and the log file will be directly available to the researcher, allowing him/her to follow subject's timely participation. The stimuli used in the training protocol will consist of a visual image showing a circle on top of a background of 5 horizontal lines. The auditory part of the stimulus will consist of piano melodies of known songs. The position of the circle within the five lines will either follow the rule the higher the pitch of the tone, the higher the position of the circle or it will violate the above rule. The task requires audiovisual integration."
50882|NCT03786185|Behavioral|MusicPlast Control|Each subject will receive 20 sessions of the computerized training within a period of 4 weeks, aiming to train visual search via spot-the-difference tasks and identification of dissonance in music. Auditory and visual stimuli are concurrently presented, but do not require audiovisual integration.
50883|NCT03786172|Behavioral|Smoking cessation Intervention|"A 10 to 15 minute standardised counseling session performed peri-operatively by an ENT resident, and based on the 5 As motivational interviewing model (Ask, Advise, Assess, Assist, Arrange)~A motivational gadget distributed to the patients~Nicotine replacement therapy (NRT), consisting of nicotine transdermal patches for 8 weeks, offered to the patients"
50884|NCT03786172|Behavioral|Usual care|A 10-second brief advice to quit smoking, performed peri-operatively by an ENT resident
50885|NCT03786159|Other|No intervention|No intervention
50886|NCT03786133|Diagnostic Test|Analysis of microbiological tests|Collection and comparison of microbiological data
50887|NCT03786120|Drug|Zolpidem|PO sleep aid in various doses
50888|NCT03786107|Diagnostic Test|Almac HER-Seq Assay Kit|whole blood sample analysis
50891|NCT03786081|Drug|Tisotumab Vedotin|i.v.
50892|NCT03786081|Drug|Bevacizumab|i.v.
50893|NCT03786081|Drug|Pembrolizumab|i.v.
50894|NCT03786081|Drug|Carboplatin|i.v.
50895|NCT03786055|Behavioral|Somatic Yoga and Meditation (SYM)|A Hanna somatics and somatic yoga and meditation (SYM) protocol was designed to address sensory-motor amnesia and reduce trauma which creates reflex patterns that lead to chronic muscular contractions. The movements use voluntary muscular contraction and slow controlled eccentric contraction, with the constant focus on sensation to increase the resting length of muscles. Movements are performed slowly and gently with the least possible effort and are never forced. The protocol is endorsed by the US Army Surgeon General as treatment for chronic pain. The meditations are trauma informed and evidence based supporting pain modulation, healing and well-being.
50896|NCT03786042|Behavioral|E-cigarette ad exposure|Participants view a series of e-cigarette TV commercials
50897|NCT03786042|Other|non e-cigarette TV commercials|Participants view a series of non e-cigarette TV commercials
50898|NCT03786029|Drug|Acetaminophen|"Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
50899|NCT03786029|Drug|Placebo|"Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
50900|NCT03786029|Drug|Ibuprofen|"Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale."
50901|NCT03786016|Behavioral|8-Days in an Isolation, Confinement Unit|"Subjects will spend 8 days/7 nights continuously in an isolated and confined unit with up to 3 other subjects. Subjects will participate in daily, timed activities such as space-relevant computer simulations, team tasks, and cognitive performance testing. Subjects will also experience altered environmental conditions (such as changes in lighting, sound and ambient temperature) while in the isolation unit. Subjects will receive orders from mission control who will monitor activity in the isolation unit and direct subjects throughout the 8-day study."
50902|NCT03786003|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
50903|NCT03786003|Procedure|Thoracotomy|Standard thoracotomy
50904|NCT03785990|Other|adipose tissue|taking a sample of the adipose tissue during operation
50905|NCT03785990|Other|blood|taking a blood sample when a peripheral venous catheter is inserted before operation
50906|NCT03785990|Diagnostic Test|PEAPOD|Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
50907|NCT03785964|Drug|Nirogacestat oral tablet|Nirogacestat tablet
50908|NCT03785964|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic nirogacestat 50 mg tablet
50947|NCT03785730|Procedure|UCT|In the experimental group, the treatment will be performed after prophylaxis and relative isolation. The cavitated caries lesion will be widened with the aid of a metal sandpaper to facilitate the removal of the biofilm.
50910|NCT03785951|Dietary Supplement|Wheat Protein|"Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat.~50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake."
50911|NCT03785951|Dietary Supplement|Wheat Protein with Leucine|"Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate.~50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks."
50912|NCT03785938|Dietary Supplement|Probiotic|Liquid probiotic supplied by the company Symprove
50913|NCT03785938|Other|Placebo|Placebo made of maltdextrin. Will be similar in taste and consistency
50916|NCT03785912|Behavioral|Internet-based self-help|Eight cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of adjustment problems after having an accident.
50917|NCT03785899|Device|SPOCnew|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on."
50918|NCT03785899|Device|8s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 8s.
50919|NCT03785899|Device|SPOCold|"SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on."
50920|NCT03785899|Device|2s SpO2 averaging|The arterial saturation (SPO2) will be averaged over 2s.
50921|NCT03785886|Behavioral|Walking group|Subjects in this group perform exercise consisting of walking for 30 - 60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months . Each training includes 5 min warm-up and 5 min cool-down, and the exercise should start after meals for 1 hour . Heart rate is monitored by sports bracelet . Subjects using β-blockers will not use heart rate to monitor exercise intensity , but RPE scores . And RPE( Borg scale) scores are ranged from 11-13.
50922|NCT03785886|Behavioral|Chinese square dancing group|"Chinese square dances have been selected from 24 sets of square dances jointly launched in 2015 and 2017. According to the age and physical health status of the subjects, six dance pieces of are selected as the repertoires of the intervention in this study.~Subjects in this group perform exercise consisting of Chinese square dances for 30-60 min at 40% - 60% HRR intensity 3-5 d•wk-1 for 3 months. Each training includes 5 min warm-up and 5 min cool-down , and the exercise should start after meals for 1 hour. Make the subjects step for 30 s to 1 min between each track to adjust the heart rate. Heart rate is monitored by sports bracelet. Subjects using β-blockers will not use heart rate to monitor exercise intensity, but RPE scores. And RPE( Borg scale) scores are ranged from 11-13."
50923|NCT03785886|Behavioral|Control group|Walking group , Chinese square dancing group and control group are given the same health education brochures or health education lectures once a month . Specific contents of the brochure or lecture include : type 2 diabetes , hypertension related medical knowledge and the significance of intervention treatment ; prevention of type 2 diabetes , hypertension nutrition and exercise recommendations ; basic knowledge of scientific exercise and its matters needing attention .
50924|NCT03785873|Drug|Nivolumab|Intravenous (IV) infusion
50925|NCT03785873|Drug|Nanoliposomal-Irinotecan|Intravenous (IV) infusion
50926|NCT03785873|Drug|5-Fluorouracil|Intravenous (IV) infusion
50927|NCT03785873|Drug|Leucovorin|Intravenous (IV) infusion
50928|NCT03785860|Other|Dietary Fiber|Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
50929|NCT03785860|Other|Placebo|Placebo will be given in a powder form to mix with a beverage of one's choice.
50930|NCT03785847|Diagnostic Test|Ventica|Impedance pneumography measurement
50931|NCT03785834|Procedure|Punch Biopsy|The patient will undergo two 6 mm punch biopsies into the affected extremity at the most proximal portion of the redness.
50932|NCT03785821|Dietary Supplement|BMSO|BMSO was extracted from Hualien No. 4 cultivate of bitter melon seed. BMSO were incorporated into capsules containing 0.5 g of oil. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily, resulting in daily consumption of 2.3 g alpha-ESA in the BMSO group.
50933|NCT03785821|Dietary Supplement|OO|Olive oil (extra virgin grade) was purchased from La Espanola (Acesur, Spain). OO were incorporated into capsules containing 0.5 g of oil, identical appearance to BMSO. All persons took 3 capsules after each meal, i.e. 9 capsules (4.5 g of oil) daily.
50934|NCT03785808|Behavioral|Special Diet Therapy (low-carb)|Receive dietary guidelines and recipes and consume a low-carbohydrate diet
50935|NCT03785808|Behavioral|Special Diet Therapy (low-fat)|Receive dietary guidelines and recipes and consume a low-fat diet
50936|NCT03785808|Behavioral|Special Diet Therapy (USDA control)|Receive dietary guidelines and recipes and consume USDA control diet
50937|NCT03785795|Device|Uncertain diagnosis of true labor|Multichannel EMG of uterine bioelectrical signals will be recorded using area sensors. The output of the synchronization calculations will be correlated with the time to delivery
50938|NCT03785782|Device|Ultrasound|Breast ultrasound
50939|NCT03785769|Procedure|HVGIC restoration with pre-etching|Pre-etching of the surface with polyacrylic acid for 10 s, followed by washing and drying the cavity with cotton balls; and fill with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
50940|NCT03785769|Procedure|HVGIC restoration with non pre-etching|Restoration with HVGIC, inserted into the cavity with the aid of an insertion spatula and adapted to the cavity by the digital pressure technique.
50941|NCT03785756|Drug|Ibuprofen 300 mg Oral Tablet|2 x 300 mg tablets twice in 24 hours
50942|NCT03785756|Drug|Ibuprofen 200 mg Oral Tablet|2 x 200 mg tablets three times in 24 hours
50943|NCT03785756|Other|Placebo of PR tablet|Up to 2 tablets four times in 24 hours
50944|NCT03785756|Other|Placebo of IR tablet|Up to 2 tablets four times in 24 hours
50945|NCT03785743|Procedure|TLPD Surgery|TLPD
50946|NCT03785743|Procedure|OPD Surgery|OPD
50948|NCT03785730|Procedure|Restoration with composite resin|In control group, the treatment will be performed after prophylaxis and relative isolation. The selective caries removal will be performed with appropriate dentin curettes, and then the application of the adhesive system and restoration of composite resin will be conducted.
50949|NCT03785717|Procedure|ROG|Bone width augmentation using bone grafting and membrane non cross linking.
50950|NCT03785717|Procedure|ROG & ESWT|Before the bone width augmentation using bone grafting and membrane non cross linking, the patient was received ESWT (Extracorporeal shockwave therapy).
50951|NCT03785704|Drug|Xinmailong Injection|Xinmailong injection is extracted, separated, purified and refined from Periplaneta americana. It is the second class of new drugs and the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China) for the prevention and treatment of heart failure. Its main constituents include complex nucleoside bases and binding amino acids.
50952|NCT03785691|Drug|Mirtazapine|"Mirtazapine 15 mg oral tablet (incapsulated in gelatine to provide blinding) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered once daily (morning).~On Day 7 dosage increase is optional. If desired, mirtazapine 30 mg oral tablet (incapsulated in gelatine) will be administered once daily (bedtime) for 7 days. Placebo (empty gelatine capsule) will be administered three times daily (morning, noon and late afternoon). In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
50953|NCT03785691|Drug|Ondansetron|"Ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, ondansetron 8 mg oral tablet (incapsulated in gelatine) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
50954|NCT03785691|Drug|Placebo|"Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days."
50955|NCT03785678|Biological|Tenecteplase|The investigational medicinal product (IMP) for this study is tenecteplase. The recommended total dose for this study is weight-based with 0.25 mg of tenecteplase per kg, not exceeding a maximum dose of 25 mg. A single bolus dose should be administered over 5 seconds based on patient weight.
50956|NCT03785678|Other|Placebo|Placebo is being used as the comparator since a thrombolytic is only FDA-approved in the United States for use out to 3 hours, and the standard of care guidelines support use out to 4.5 hours.
50957|NCT03785665|Device|MDI|Capsule MD1 (Motility dummy 1)
50958|NCT03785652|Drug|LY03005 extended-release tablets 40 mg|LY03005 extended-release tablets 40 mg group :40mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfas
50959|NCT03785652|Drug|LY03005 extended-release tablets 80 mg group|"LY03005 extended-release tablets 80 mg group :~80mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
50960|NCT03785652|Drug|LY03005 extended-release tablets 120 mg group|"LY03005 extended-release tablets 120 mg group :~120mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
50961|NCT03785652|Drug|LY03005 extended-release tablets 160 mg group|"LY03005 extended-release tablets 160 mg group :~160mg/day，orally once a day, at a regular morning time on an empty stomach or after breakfast"
50962|NCT03785652|Drug|Placebo group|"Placebo group :~Placebo ，orally once a day, at a regular morning time on an empty stomach or after breakfast"
50963|NCT03785626|Procedure|CEA surgery|patients with carotid artery severe (70-99%) stenosis or occlusion received CEA surgery
50964|NCT03785613|Drug|Test Product T1: Buprenorphine patch (9 mg)|Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.
50965|NCT03785613|Drug|Test Product T2: Buprenorphine patch (3.8 mg)|Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.
50966|NCT03785613|Drug|Reference Product R: Transtec patch (20 mg)|Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
50967|NCT03785613|Drug|Matching placebo patch to T1|Placebo patch to T1.
50968|NCT03785613|Drug|Matching placebo patch to T2|Placebo patch to T2.
50969|NCT03785613|Drug|Matching placebo patch to R|Placebo patch to R.
50970|NCT03785600|Device|Morning Bright Light Therapy|Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.
50971|NCT03785600|Device|Negative Ion Generator|Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
50972|NCT03785587|Drug|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
50973|NCT03785574|Other|Follow up|the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
50974|NCT03785574|Drug|chemotherapy|First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
50975|NCT03785561|Other|participation in a health research study|Patients diagnosed with a musculoskeletal disorder, who are currently participating in a health research study at the outpatient osteoarthritis clinic at Frederiksberg Hospital
50976|NCT03785548|Other|Usage of a mirror|using a mirror during the pelvic examination
50977|NCT03785535|Device|Vibrotactile stimulation|The active treatment will involve whole-body sensory stimulation with mechanical stimuli of vibrotactile (pallesthetic) type at a relatively high rate, low intensity and long duration administered at sleep time (a total daily duration of 3 h distributed within a period of 2 h at bedtime and 1 h prior to getting up). The intensity will be 30% of power at bedtime and 45% prior to getting up.
52040|NCT03777514|Drug|Ferrous sulfate|treatment of iron deficiency anemia with oral iron
50980|NCT03785496|Drug|PDR001+MCS110|MCS110 and PDR001 will be administered once every 3 weeks via i.v. infusions over 1 hour and30 minutes, respectively. The drugs will be administered separately with at least a 30 min break between the two antibodies. Infusions of each antibody can be extended to up to 2 hours if clinically indicated. Both study drugs may be infused using the same i.v. access site. The same administration sequence must be followed for all patients, i.e. PDR001 should be infused first. If an infusion reaction occurs after administration of PDR001, the subsequent MCS110 infusion must be delayed until it is safe for the patient to receive MCS110 based on the clinical discretion of the investigator. The delay between PDR001 and MCS110 infusions can be up to 4 hours if clinically indicated.
50981|NCT03785483|Behavioral|Motivation|8 weeks of either action planning or mindfulness in addition to a treatment as usual which is a physical activity program of 120 minutes per week.
50982|NCT03785470|Other|Fructose and physical inactivity|Subjects will drink 6 cans of regular sodas daily (divided throughout the day) and will decreased physical activity to less than 5000 steps daily for 10 days.
50983|NCT03785457|Other|Repetitive Trunk Extension|Subjects will be asked to perform standing repetitive trunk extension at a rate of 10 per 45 seconds (Figure 2), repeated five times with 15-second rest breaks.
50984|NCT03785457|Other|Sustained Trunk Extension|Subjects will be asked to perform standing sustained trunk extension for 5 x 45 seconds with 15-second rest breaks.
50985|NCT03785444|Other|WHODAS 2.0|WHO Disability Score
50986|NCT03785444|Other|EQ5D|Health related quality of life measured with European Quality of Life 5 Dimensions 5 Level
50987|NCT03785444|Other|IADL|The Lawton Instrumental Activities of Daily Living
50988|NCT03785444|Other|Barthel-Score|Barthel Score of the patient
50989|NCT03785444|Other|SF-36|Short Form Health 36
50990|NCT03785444|Other|MoCA Blind|Montreal Cognitive Assessment
50991|NCT03785431|Device|PCI with Phantom Bioresorbable Scaffold|Once baseline angiography is performed and all eligibility criteria are met, the patient is included in the study. The target lesion should be crossed with a standard coronary guidewire. Next, the NIRS/IVUS and OCT probe is inserted and a pullback is being performed to evaluate the lesion and vessel morphology. The predilatation with 1:1 non-compliant or semi-compliant balloon is mandatory. Thereafter the scaffold should be inserted and position across the target lesion. Lesions up to 14 mm should be covered with the 18 mm device, for lesions of 15-20 mm a 24 mm device should be used. The scaffold will be deployed with intent to achieve the inner diameter to the reference vessel ration of 1:1 using a single inflation. Post-dilatation using a non-compliant balloon should be performed to achieve complete scaffold apposition and reduce the residual angiographic stenosis below 20%. The final NIRS/IVUS and OCT of the target vessel should be performed.
50992|NCT03785418|Behavioral|Multicomponent Risk Factor Modification|Healthy eating, regular exercise and behavioural therapy.
50993|NCT03785405|Drug|sacubitril/valsartan|"Target dose 3.1 mg/kg bid~Formulations:~Tablets (50, 100, 200 mg) Granules [12.5 mg (4 granules), 31.25 mg (10 granules), in capsules] Liquid (1 mg/ml, 4 mg/ml, prepared from tablets)"
50994|NCT03785392|Procedure|Group 1 In-plane|"Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block."
50995|NCT03785392|Procedure|Group 2 out of plane|Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
50996|NCT03785379|Behavioral|Caloric restriction|A structured dietary training will be implemented to educate participants about recommended dietary habits.Patients will follow a caloric restriction (CR) diet, with an energy intake equal to the measured Resting Metabolic Rate (RMR) and with 45% carbohydrate, 20%protein, 35%fat, and 30 g/day fibers. At each follow-up, nutritionist will adjust CR to the latest measured RMR and assess the compliance to the diet.
50997|NCT03785379|Behavioral|Exercise training|Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
50998|NCT03785366|Drug|VeraCept|VeraCept Intrauterine Device (IUD)
50999|NCT03785366|Drug|ParaGard|ParaGard intrauterine copper contraceptive
51000|NCT03785353|Behavioral|PNE lecture|A translated (from English to Spanish) lecture on Pain Neuroscience Education
51001|NCT03785340|Drug|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops 0.20% given 2 times a day for 4 weeks.
51002|NCT03785340|Drug|Placebos|Ophthalmic buffered saline Eye Drops given 2 times a day for 4 weeks.
51003|NCT03785327|Device|tDCS|Participants either complete active and sham tDCS sessions one week apart or an autism training program.
51004|NCT03785327|Behavioral|Autism Training|Autism Information Presentation developed by Dr. Grace Iarocci's Autism & Developmental Disorders Lab at Simon Fraser University
51005|NCT03785314|Other|thoracic epidural catheterization|thoracic epidural catheterization with different posture
51006|NCT03785301|Device|Freestyle Libre Flash Glucose Monitoring|Freestyle Libre Flash Glucose Monitoring will be used in diabetic patients once a month for therr months to monitor glucose level. Patients could scan the sensor to get the glucose level at any time as they want. They could alter thier diet and exercise according to the glucose levels. Patients will be required to keep track of food and exercise during wearing FGM sensor. Physicians would adjust patients' medication according their glucose profile provided by FGM, A1c, and diet and exercise every month.
51007|NCT03785288|Radiation|HDR vaginal brachytherapy|Arm 1: HDR vaginal brachytherapy 7 Gy in 3 fractions ; Arm 2: HDR vaginal brachytherapy 4 Gy in 6 fractions
51008|NCT03785275|Radiation|gallium-68-exendin PET/CT|PET/CT scan after injection with gallium-68-exendin
51009|NCT03785262|Device|Uroshield|The Uroshield device sends out low-frequency ultrasound waves which run along the surface of the catheter.
51306|NCT03783208|Drug|G-CSF|Slow infusion of G-CSF into the endometrial cavity using a soft embryo transfer catheter.
51010|NCT03785262|Device|Sham Uroshield|The sham Uroshield device is identical to the active machine, but it does not send out low-frequency ultrasound waves along the surface of the catheter.
51011|NCT03785249|Drug|MRTX849|MRTX849 will be administered orally once daily in a continuous regimen
51012|NCT03785236|Radiation|68Ga-NODAGA-exendin PET/CT|68Ga-NODAGA-exendin PET/CT
51013|NCT03785223|Drug|Methylphenidate Hydrochloride Controlled-Release Capsules|"25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur."
51014|NCT03785223|Drug|Placebo Capsule|At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
51015|NCT03785210|Drug|nivolumab|480 mg IV every 4 weeks
51016|NCT03785210|Drug|tadalafil|10 mg PO daily
51017|NCT03785210|Drug|oral vancomycin|125 mg every 6-hour (500 mg total daily dose) PO from week 1 to week 3, week 4 off.
51018|NCT03785197|Other|Prolonged modified fasting|The prolonged modified fasting is a dietary intervention with abstinence from solid foods and a caloric intake of 100-400 kcal through juices and vegetable broths
51019|NCT03785184|Drug|venetoclax|tablet; oral
51020|NCT03785184|Drug|lenalidomide|capsule; oral
51021|NCT03785184|Drug|dexamethasone|tablet; oral
51022|NCT03785171|Procedure|surgical revascularization|Indirect revascularization procedure
51023|NCT03785158|Other|Liquid Melatonin|Melatonin is a natural supplement.
51024|NCT03785158|Other|Placebo|Similar looking/tasting placebo syrup
51025|NCT03785145|Drug|MT10109L|MT10109L will be injected into the LCL.
51026|NCT03785145|Drug|Placebo|Placebo will be injected into the LCL.
51027|NCT03785132|Procedure|Cardiac surgery|The relationship between performance measurement of blood pressure during cardiac surgery (before, during and after cardiopulmonary bypass) and postoperative mortality
51028|NCT03785106|Drug|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)
51029|NCT03785106|Drug|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)|Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)
51030|NCT03785080|Other|restart NOAC very early|withhold NOAC less than 24 hours Post OGD
51031|NCT03785080|Other|restart NOAC early|withhold NOAC for 72 to 84 hours Post OGD
51032|NCT03785067|Drug|telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg|1 capsule taken orally once daily for 36 months
51033|NCT03785067|Drug|Placebo oral capsule|1 capsule taken orally once daily for 36 months
51034|NCT03785054|Drug|HTL0014242|HTL0014242 is a selective negative allosteric modulator (NAM) for the metabotropic glutamate (mGlu) receptor 5 subtype (mGlu5)
51035|NCT03785054|Drug|Placebo oral capsule|Placebo treatment
51036|NCT03785041|Drug|Levobupivacaine Hydrochloride 2.5 MG/ML|Intrarticular injection of tramadol in addition to levobupivacaine in different doses preemptive and postoperative
51037|NCT03785028|Behavioral|working memory and attention|working memory and attention tasks
51038|NCT03785015|Other|Resume Aspirin within 12 hours|Resume the standard treatment within 12 hours after endoscopic haemostasis
51039|NCT03785015|Other|Resume Aspirin 72 - 84 hours|Resume the standard treatment between 72 and 84 hours after endoscopic haemostasis
51040|NCT03785002|Other|Strength training|24 strength training sessions, with approximately 1 hour duration, that will occur 2x/week
51041|NCT03785002|Other|Protein intake|Guidance on the adequacy of protein intake (at least 20g of protein in breakfast, lunch and dinner)
51042|NCT03784976|Other|Iyengar Yoga Therapy|2 weekly yoga class (1.25 hours each)
51043|NCT03784963|Drug|Omega 3 fatty acids|Patients will receive 4 grams fish oil once daily
51044|NCT03784963|Other|Placebo|Standard of care
51045|NCT03784950|Behavioral|Rating tool|eConsult Specialty Reviewers are asked to rate the quality of other specialists' recently completed eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
51046|NCT03784950|Behavioral|Feedback|eConsult Specialty Reviewers receive confidential feedback via email on their performance (top performer vs not a top performer) as compared to colleagues in their specialty. Feedback is based on other reviewers ratings of their eConsult exchanges on the following four dimensions: 1) efforts to elicit additional information from PCPs, when needed; 2) medical decision making; 3) inclusion of educational content for PCPs, when appropriate; 4) perceived effect on the PCP-specialist relationship (i.e., overall tone of the eConsult exchange)
51047|NCT03784937|Diagnostic Test|Doppler ultrasound|Each patient received Doppler ultrasound for research of DVT, no matter the risk stratification.
51048|NCT03784924|Diagnostic Test|MRI prostate|MRI and laboratory biomarkers
51049|NCT03784911|Device|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. SOZO measurements will be performed before the start of cancer treatment, at the 1/4, 1/2, and 3/4 time points of treatment, and after completion of treatment. Participants be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes.
51095|NCT03784612|Behavioral|App-technology for healthy eating habits|Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
51050|NCT03784911|Device|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
51051|NCT03784898|Other|Blood draw for future biomarker analysis|Each patient will be required to undergo blood draw for future genetic testing and biomarker analysis as mentioned in the informed consent form
51052|NCT03784885|Biological|AD07010|A protein based adjuvant
51053|NCT03784885|Biological|Inactivated trivalent influenza vaccine|Inactivated trivalent seasonal influenza vaccine
51054|NCT03784872|Procedure|Laparoscopic guided Ventrosuspension|Laparoscopy was done. Under vision the skin overlying the attachment of the round ligament to the anterior abdominal wall was incised followed by introduction of 30 curved needle attached to absorpable Vicryl 2/0 suture through the incision and withdrawn through grasper under laparoscopi vision. The needle was turned around the round ligament all through its length to plicate it then the needle was pushed again beside its entry side to appear at the skin incision. The same was repeated on the other side and both sutures were tied at the subcutaneous tissue simultaneously. then the laparoscopy was withdrawn followed by closure of the skin incision.
51055|NCT03784859|Device|Insertion of Tissue Expander with Fluid Reservoir|Use of unique expander type in first stage of a two-stage breast reconstruction, without prolonged drain placement.
51056|NCT03784846|Behavioral|Mindfulness-Based Resilience Training|MBRT is an 8-week program combining training in standardized mindfulness practices targeting factors that facilitate resilience, CBT, and psychoeducation. It contains experiential and didactic exercises including body scan, sitting and walking meditation, mindful movement and discussions.
51057|NCT03784846|Behavioral|Stress Management Education|SME was designed as an active control condition for other Mindfulness-Based Intervention trials. SME uses a group-based didactic approach with modules on physiological and dietary effects of stress, time management, sleep physiology and insomnia, nutrition, exercise, stress hardiness, and factors mitigating impacts of stress.
51058|NCT03784820|Behavioral|UNITE|UNITE includes three stages: early treatment (psychoeducation and understanding the couple's experience of BED within the relationship); mid-treatment (effective communication, interpersonal problem-solving, and emotion regulation skills), and late treatment (relapse prevention). Additional relevant topics may be covered including body image, weight stigma, weight and health concerns, and intimacy and sexuality issues.
51059|NCT03784820|Behavioral|CBT-E|CBT-E includes four stages: an introductory stage (psychoeducation, normalization of eating patterns, and symptom self-monitoring); a second, brief stage (review progress and formulate plans for the subsequent treatment phase); a third stage (elimination of dieting, reducing shape checking and avoidance behaviors, educating about mood tolerance, and targeting overevaluation of shape and weight); and the fourth stage (maintaining progress and minimizing relapse risk).
51060|NCT03784807|Diagnostic Test|synovial calprotectin, confocal laser microscopy|Calprotectin will be determined in synovial fluid of patients with septic and aseptic failure of their prosthesis. CLSM will be used to detect presence of microorganisms in synovial fluid. Susceptibility to antimicrobials of bacterial strains isolated from patients with prosthetic joint infections will be assessed using planktonic cells and biofilm associated bacteria
51061|NCT03784794|Diagnostic Test|Thromboelastometry|devices generate output by transducing changes in the viscoelastic strength of a small sample of clotting blood (300 µl) to which a constant rotational force is applied. These point of care devices allow visual assessment of blood coagulation from clot formation, through propagation, and stabilization, until clot dissolution. Computer analysis of the output allows sophisticated clot formation/dissolution kinetics and clot strength data to be generated
51062|NCT03784794|Diagnostic Test|Standard Coagulation Test|coagulation tests, such as the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT), to assess blood clotting function in patients. Clauss Fibrinogen.
51063|NCT03784794|Drug|Fibrinogen Concentrate Human|To treat acquired fribinogen deficiency investigators will treat with the following doses FIBTEM A5 = 9-11 MM a 2 G FIBRINOGEN CONC. (25 MG/KG); FIBTEM A5 = 4-8 MM a 4 G FIBRINOGEN CONC. (50 MG/KG); FIBTEM A5 < 4 MM a 6 G FIBRINOGEN CONC. (75 MG/KG)
51064|NCT03784794|Drug|Prothrombin Complex Concentrates|to treat acquired factor deficiency investigators will treat as follows PROTROMBIN COMPLEX CONCENTRATE EXTEM CT > 80 SEC AND FIBTEM A5 ≥ 8 MM 4F-PCC 20 IU/KG (F II, VII, IX and X) GOAL: EXTEM CT ≤ 80 SEC
51065|NCT03784794|Other|Platelets|PLATELETS EXTEM A5 < 40 MM AND FIBTEM A5 ≥ 12 MM EXTEM A5 < 40 MM → 1 PLATELET POOL OR APHERESIS; EXTEM A5 < 30 MM → 2 PLATELET POOL OR APHERESIS GOAL: EXTEM A5: 40-50 MM or PLATELET COUNT < 100/µL PLT < 100/µL → 1 PLATELET POOL OR APHERESIS; PLT > 50/µL → 2 PLATELET POOL OR APHERESIS GOAL: PLT COUNT > 100/µL
51066|NCT03784794|Other|Red Blood Cells|"Transfuce Red Blood Cells if Hemoglobine levels < 7 G/DL;~1 unit of FFP for every unit of RBC Transfused GOAL: Hb > 7.5 G/DL"
51067|NCT03784794|Other|Fresh Frozen Plasma|FRESH FROZEN PLASMA TP AND/OR TTP PATHOLOGICAL INR, 2.0-4.0 → FFP 20 ML/KG GOAL: TP AND TTP NORMAL AND INR < 2.0
51068|NCT03784794|Other|cryoprecipitates|FIBRINOGEN (CLAUSS) < 250 MG/DL FIB 200-250 MG/DL → CRYOS, PACK OF 10 (25 MG/KG); FIB 100-200 MG/DL → CRYOS, PACK OF 20 (50 MG/KG); FIB < 100 MG/DL → CRYOS, PACK OF 30 (75 MG/KG) GOAL: FIB > 250 MG/DL
51069|NCT03784781|Biological|Biopsy|Mucosal biopsies under general anesthesia of the segmental bronchi of the right or left lower lobe
51070|NCT03784781|Biological|Blood collection|Blood collection (+15mL/ current care)
51071|NCT03784781|Biological|Bronchoalveolar lavage|Bronchoalveolar lavage fluid (3mL/Kg)
51072|NCT03784768|Other|Plantar Vibration Group|Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition after 45-minute conventional physiotherapy session for 3-days in 5-days, while each patient in plantar vibration group is supine position, plantar vibration will be applied to both foot of each patient with a vibration device with a frequency of 15-100 Hz over 7.5-minute.
51096|NCT03784599|Drug|Trastuzumab emtansine|Infusion
51097|NCT03784599|Drug|Osimertinib|Tablet
51098|NCT03784573|Behavioral|Dog + handler|Dog + handler
51099|NCT03784573|Behavioral|No dog|No dog
51073|NCT03784768|Other|Control Group|Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
51074|NCT03784755|Radiation|Ablative Radiation Therapy|Undergo stereotactic radiotherapy and/or surgery to all sites of disease (oligometastases and primary prostate if previously untreated).
51075|NCT03784755|Other|Standard of care|Patients continue to receive their current planned systemic therapy at the discretion of the treating physician
51076|NCT03784742|Other|Nitrate rich beetroot juice|James White Drinks Limited beetroot juice (0.4-0.45 g nitrate/70 ml drink).
51077|NCT03784742|Other|Placebo beetroot juice|James White Drinks Limited Placebo beetroot juice (0 nitrate/70 ml drink).
51078|NCT03784729|Other|Acupuncture|"The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted. For the bilateral BL25, sterile disposable steel needles (Huatuo, Suzhou, China; 0.3 mm×75 mm) will be inserted to a depth of 50-70mm until until participates feel a sensation similar to electric shock radiating downward to the knees. For the other four acupoints (BL23, BL40, BL57 and KI3), the needles (Huatuo, Suzhou, China; 0.3 mm×40 mm) will be inserted to a depth of 15-25 mm, gently rotated three times and lifted to achieve de qi. It should be noted that the needle at KI3 will be inserted at an angle of 45°obliquely downward. There will be 18 treatment sessions with 3 times a week for continuous 6 weeks and a 30 min treatment per session."
51079|NCT03784729|Other|Sham acupuncture|The acupoints of Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57) and Taixi (KI3) will be inserted into a depth of 2-3mm .No manipulation of needles without deqi will be conducted. The treatment duration and frequency of sessions for participants in the SA group will be the same as in the acupuncture group.
51080|NCT03784716|Other|Ketogenic Diet|Ketogenic diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 70% fat, 25% protein, and 5% carbohydrate for the ketogenic diet.
51081|NCT03784716|Other|Standard Weight Loss Diet|Standard weight loss diet for 28 days. Meals will be provided to all study participants for 28 days by a prepared meal delivery service. Daily caloric needs for each participant will be determined based on height, weight, gender, age, and activity level. Meals will be prepared based on compliance with the following macronutrient guidelines: 30% fat, 20% protein, and 50% carbohydrate for the standard weight loss diet.
51082|NCT03784703|Drug|Atorvastatin (Atrostat®, Delta Pharmaceutical Industries, Cairo, Egypt) tablets.|either 20 mg per day atorvastatin (ATROVA group, n= 40) or 20 mg per day rosuvastatin (ROSUVA group, n= 35) for three months and twenty patients (Non-statin group, n=20) not treated with statin and served as control.
51083|NCT03784703|Drug|Rosuvastatin (Rosuvastatin Calcium®, Chemipharm Co.|20 mg per day rosuvastatin (ROSUVA group, n= 35) for three months
51084|NCT03784690|Other|Individualized intraoperative BP management|"In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status."
51085|NCT03784690|Other|Standard intraoperative BP management|Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
51086|NCT03784677|Drug|TRPV6 Calcium Channel Inhibitor SOR-C13|Given IV
51087|NCT03784664|Diagnostic Test|Arterial blood gas|arterial blood sample with puncture of the radial artery
51088|NCT03784664|Diagnostic Test|Veinous blood gas|veinous blood sample using peripheral venepuncture
51089|NCT03784638|Procedure|lingually-based triangle flap design|A mucoperiosteal lingually-based triangle flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
51090|NCT03784638|Other|buccally based triangular flap design|A mucoperiosteal buccally based triangular flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 4-0 silk sutures. The patients will be invited after one week for removing the sutures.
51091|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 1)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 800 MBq/m²"
51092|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 2)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 1600 MBq/m²"
51093|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 3)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 2700 MBq/m²"
51094|NCT03784625|Drug|[131I]ICF01012 (therapeutic dose level 4)|"1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~1 therapeutic injection (D11) at a dose of 4000 MBq/m²"
51307|NCT03783208|Other|Saline|Slow infusion of saline into the endometrial cavity using a soft embryo transfer catheter.
51100|NCT03784560|Other|The Psychomotor Vigilance Task (PVT)|PVT has emerged as one of the most widely used tools to assess vigilant attention. Vigilance can be defined as sustained attention and tonic alertness. In sleep deprived individuals, vigilance is the component of cognition that is most consistently and dramatically affected. The PVT is a reaction-time test that allows the collection of a large amount of data in a relatively short period of time. These characteristics increase the sensitivity of the test to detect even small changes in vigilant attention, which can wax and wane within seconds.
51101|NCT03784560|Other|Epworth Sleepiness Scale|"Epworth Sleepiness Scale a set of questions that assess excessive daytime sleepiness during professional activities and vacations.~This scale was designed to assess the efficiency of sleep apnea treatments. It is also used for the subjective sleepiness assessment based on the likelihood of falling asleep in different everyday life situations. This results in an overall score."
51102|NCT03784560|Other|Karolinska sleeping scale|"The KSS is assumed to be an ordinal scale with a unitary structure. KSS scores may require standardization to control for differences between subjects. The changes observed in the EEG/EOG with drowsiness do not usually appear until KSS scores reach 7 and higher. Lower KSS scores (<5) may reflect differences in the subjective awareness of fatigue as much, or more than, levels of drowsiness.~Higher KSS scores (7+) may refer more specifically to the state of drowsiness because the subject may then have experienced involuntary dozing behavior, with lapsing episodes and brief loss of awareness of the here-and-now, followed by arousal and the return of awareness, including some awareness of recently having dozed off"
51103|NCT03784560|Other|Trail making test|Most variants of this test, which was apparently introduced in 1938 by Partington (Partington & Leiter, 1949), have at least two conditions. In condition A the participant is to draw lines to connect circled numbers in a numerical sequence (i.e., 1-2-3, etc.) as rapidly as possible. In condition B the participant is to draw lines to connect circled numbers and letters in an alternating numeric and alphabetic sequence (i.e., 1-A-2-B, etc.) as rapidly as possible.
51104|NCT03784547|Drug|Ocrelizumab|already described
51105|NCT03784534|Other|Imaging|high= density (64 sensors) EEG and anatomical MRI (T1 and tensor imaging) scan
51106|NCT03784534|Behavioral|Clinical and behavioral testing : Motor recovery progress|NIHSS with motor subitems and Rankin and Barthel score, measure of functional independence and Hemispatial neglect, test of Ashworth
51107|NCT03784534|Behavioral|Clinical and behavioral testing : Motor skills|the ARAT or ACTION RESEARCH ARM TEST, hand grip strength, Fugl Meyer
51108|NCT03784521|Device|In-line filtration|In-line filtration is used during anesthesia and intensive care unit in study group to purify fluids administrations.
51109|NCT03784521|Device|Standard care|Patients are treated with standard intravenous solutions and vascular access management
51110|NCT03784495|Drug|Melatonin 1mg|1 mg/day 30 minutes before sleep
51111|NCT03784495|Dietary Supplement|Essential Aminoacids (eAA)|4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
51112|NCT03784495|Combination Product|Essential Aminoacids + melatonin|4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
51113|NCT03784495|Other|Placebo|an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
51114|NCT03784469|Other|Changing body position in bed|The first hour:Supine position. The second hour:lateral position (right or left). The third hour:Supine position. The fourth hour:lateral position (right or left).
51115|NCT03784456|Dietary Supplement|25% protein|Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
51116|NCT03784456|Dietary Supplement|15% protein|Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus. Protein may come from either egg, meat, fish, soy, or milk product.
51117|NCT03784443|Drug|Iluvien 0.19 MG Drug Implant|Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
51118|NCT03784443|Drug|Ranibizumab Injection [Lucentis]|Monthly PRN intravitreal injections
51119|NCT03784443|Procedure|Sham Intravitreal Injection|Sham injection without penetrating needle and without drug delivery at baseline visit.
51120|NCT03784430|Procedure|Immediate dental implant placement|Tooth will be extracted and a dental implant will be positioned at the same time.
51121|NCT03784430|Procedure|Immediate dental implant placement with CTG|Tooth will be extracted and a dental implant will be positioned at the same time with a connective tissue graft.
51122|NCT03784417|Device|EUS-guided laser ablation|EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
51123|NCT03784404|Procedure|Transvaginal aspiration|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material
51124|NCT03784404|Procedure|transvaginal aspiration and surgicel injection|under sedation transvaginal insertion of spinal needle through the cul de sac under ultrasonographic guidance to reach cyst cavity followed by aspiration of the chocolate material followed by irrigation of the cyst cavity with normal saline solution till complete elimination of the chocolate material follwed by insertion of 3-4 pieces of small surgicel inside the cyst cavity
51244|NCT03783598|Behavioral|Person centered, occupation based intervention support with problem solving therapy|This program that was developed from the occupational therapy perspective which is person centered and occupation based for T2D intervention was designed as 6 modules. The intervention group received person centered, occupation based intervention support with problem solving therapy as 6 modules. The control group had not any intervention, just had a education about effect of diabetes on life.
51125|NCT03784404|Drug|Intracytoplasmic sperm injection|"Candidates for the standard long protocol received triptorelin 0.1 mg Subcutanous daily starting from day 21 of the previous cycle. On the second day of the stimulation cycle, pituitary downregulation was confirmed. Controlled ovarian stimulation was then started on day 3 using Human Menopausal Gonadotropin (Menogon; Ferring). The dose of gonadotropin was individualized. The patients were monitored with serial ultrasound and serum E2. When at least 3 follicles reached 18 mm, ovulation was triggered using Human Chorionic Gonadotropin 10000 IU (Epifasi 10000 IU; Eipico, Tenth of Ramadan, Egypt) IM and ovum pickup was performed 35 hours later.~All cases received luteal support in the form of progesterone 400 mg twice daily. Embryo transfer was done on day 3 or 5 using Labotect semi-rigid catheter (Labotect GmbH, Kassel area, Germany) under abdominal ultrasound guidance."
51126|NCT03784391|Drug|Lampit (Nifurtimox, BAYA2502)|Nifurtimox is a drug already approved in some South American countries since more than 45 years
51127|NCT03784378|Drug|RXDX-105|RXDX-105 capsules will be administered orally on a continuous daily dosing regimen. Patients will be continue to be treated at the dose level they were previously treated on during participation on Study of RXDX-105.
51128|NCT03784365|Drug|3Rd Generation Cephalosporins|Antibiotic
51129|NCT03784352|Device|Virtual Reality|A calming virtual reality game will be played
51130|NCT03784339|Other|Physiotherapy + education|Participants will take part in a 30 minute education session surrounding fear of movement and catastrophizing thoughts. They will then receive standard care, which will involve strength exercises and taping if needed.
51131|NCT03784339|Other|Physiotherapy|Standard physiotherapy care
51132|NCT03784326|Drug|Atezolizumab|Given IV
51133|NCT03784326|Procedure|Conventional Surgery|Undergo surgical resection
51134|NCT03784326|Drug|Fluorouracil|Given IV
51135|NCT03784326|Drug|Oxaliplatin|Given IV
51136|NCT03784313|Procedure|skin repair by axillary perforator flaps|"Perforators flaps (PF) of the axillary region for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa.~Perforated flap surgery does not involve any procedure or manipulation that may alter the biological characteristics and/or structural properties of the tissue (use autologue pur). A usual dressing is performed daily until complete healing."
51137|NCT03784313|Procedure|skin repair by secondary wound healing|Secondary intention wound healing (SIWH) for the coverage the axillary defect left after radical excision for axillary Hidradenitis Suppurativa
51138|NCT03784300|Drug|50 mg PTI-125|PTI-125 50 mg Oral Solution
51139|NCT03784300|Drug|100 mg PTI-125|PTI-125 100 mg Oral Solution
51140|NCT03784300|Drug|200 mg PTI-125|PTI-125 200 mg Oral Solution
51141|NCT03784287|Drug|BMN 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
51142|NCT03784274|Behavioral|Stakeholder analysis|"• INCLUSION CRITERIA FOR NET MAPPING ACTIVITIES: Those respondents who are directly involved or knowledgeable about pneumonia related policy environment in the country/province.~Respondents who consent to participate in the study.~Respondents belonging to Sindh, Punjab, Baluchistan, KPK and Islamabad.~EXCLUSION CRITERIA:~• Respondents belonging to Gilgit-Baltistan (GB), Azad Jammu and Kashmir (AJK) and Federally Administered Tribal Area (FATA). Reasons of their exclusion are newly developed governance system (GB), separate governance (AJK) and security threat (FATA)."
51143|NCT03784261|Drug|"Drug: Salirumab"|To examine the effects of salirumab in RA patients
51144|NCT03784261|Drug|"Drug: Tocilizmab"|To examine the effects of tocilizmab in RA patients
51145|NCT03784261|Drug|"Drug: Abatacept"|To examine the effects of abatacept in RA patients
51146|NCT03784248|Other|blood donation and isolation of leuco-platelet layers|patients donating blood. Blood bags will be treated and leuco-platelet coatings will be sent to Nice
51147|NCT03784235|Other|18F NaF-PET/CT and cone beam CT scans|Cross sectional and prospective measures of 18F NaF-PET/CT and cone beam CT scans before and after a 12 weeks training period
51148|NCT03784222|Drug|Blonanserin|patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
51149|NCT03784222|Other|MRI and serum BDNF|60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test
51150|NCT03784209|Diagnostic Test|The diagnosis of Artificial Intelligence and endoscopist|When suspected lesion is observed using pCLE, endoscopist and AI will make a diagnosis independently. In addition, the endoscopist can not see the diagnosis of AI.
51151|NCT03784196|Other|Conservative rehabilitation|WAD participants underwent 2-weeks rehabilitation.
51152|NCT03784183|Other|Cognitive Stimulation (CS)|CS consists of a wide range of structured activities aimed at the general improvement of social functioning and the maintenance of different cognitive functions. It is a non-specific in-group approach that places particular emphasis on social interactions.
51153|NCT03784170|Device|FemPulse System|Device therapy with the FemPulse System
51154|NCT03784144|Diagnostic Test|Biering-Sorensen Test and Prone Plank Test|All patients will be encouraged to achieve the maximum time to task failure, stopped only by muscular fatigue or pain precluding to maintain the position.
51155|NCT03784131|Drug|P-TEV|Replacement of vein with failing valves with personalized tissue engineering vein containing functional valves
51156|NCT03784118|Diagnostic Test|Ultrasonography|Ultrasonography is used to evaluate the change in artery size after arterial catheterization and to assess the complication in children
51157|NCT03784105|Drug|Codeine Phosphate|30 mL of codeine phosphate 10mg/5mL
51158|NCT03784105|Drug|Siripus simplex|Sugar syrup
51159|NCT03784092|Other|feedback|feedback by electronic pedometers regarding patient mobility while undergoing labor induction
51160|NCT03784079|Drug|GSK3640254|GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
51161|NCT03784079|Drug|Placebo matching GSK3640254 Mesylate salt|Placebo to match GSK3640254 Mesylate salt will be given as an oral capsule along with 240 mL of water
51245|NCT03783585|Behavioral|Cognitive behavioral therapy for insomnia|The web-based CBT-I program is a 6-week interactive, online program that delivers typical CBT-I treatment techniques of stimulus control, sleep restriction, behavioral modifications, and cognitive restructuring.
52484|NCT03773991|Diagnostic Test|Fractional Exhaled Nitric Oxide|Fractional Exhaled Nitric Oxide testing
51162|NCT03784066|Drug|Durvalumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
51163|NCT03784066|Combination Product|Durvalumab + Tremelimumab|"All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative."
51164|NCT03784053|Other|Immersive virtual reality|At the start of every session, the participants' top five occupational problems will be reviewed, and a list of apps corresponding to the desired occupational problem will be offered through the immersive virtual reality device (Oculus Go). There will be eight 30-minute virtual reality sessions.
51165|NCT03784040|Drug|OTSGC-A24|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
51166|NCT03784040|Drug|Nivolumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
51167|NCT03784040|Drug|Ipilimumab|OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.
51168|NCT03784027|Device|CamAPS FX|"CamAPS FX closed loop system comprises:~Dana insulin pump (Diabecare, Sooil, Seoul, South Korea)~Dexcom G6 real-time CGM sensor (Dexcom, Northridge, CA, USA)~An Android smartphone hosting CamAPS FX app with the Cambridge model predictive control algorithm and communicating wirelessly with the insulin pump and glucose sensor~Cloud upload system to monitor CGM/insulin data"
51169|NCT03784027|Other|Sensor augmented therapy|Study insulin pump and study CGM.
51170|NCT03784014|Drug|Nilotinib|Target: KIT, PDGFRA, CSF1R Nilotinib will be administered orally, 400 mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
51171|NCT03784014|Drug|Ceritinib|Target: ALK, ROS. Ceritinib will be administered orally, 450mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
51172|NCT03784014|Drug|Capmatinib|Target: MET. Capmatinib will be administered orally, 400mg twice daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
51173|NCT03784014|Drug|Lapatinib|Target: ERBB2, EGFR. Lapatinib will be administered orally, 1500mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
51174|NCT03784014|Drug|Trametinib|Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K. Trametinib will be administered orally, 2 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
51175|NCT03784014|Combination Product|Trametinib and Dabrafenib|"Target: KRAS, NRAS, HRAS, PTPN11, NF1, MAP2K, BRAF. Trametinib will be administered orally, 2mg once daily on a continuous basis. Dabrafenib will be administered orally, 150mg twice daily, on a continuous basis.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
51176|NCT03784014|Combination Product|Olaparib and Durvalumab|Target: PDL1, PARP. Olaparib will be administered orally, 300mg twice daily on a continuous basis. Dabrafenib will be administered intraveinously, 1500mg on day 1 every 4 weeks. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
51177|NCT03784014|Drug|Palbociclib|"Target: CDK4, CDK6. Palbociclib will be administered orally, 125mg once daily, 3 weeks on/1 week off.~A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation."
51178|NCT03784014|Drug|Glasdegib|Target: SMO. Glasdegib will be administered orally, 300 mg once daily on a continuous basis. A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation.
51179|NCT03784014|Drug|TAS-120|Target: FGFR. TAS-120 will be administered orally, 20 mg once daily on a continuous basis. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
51180|NCT03784014|Other|Next Generation sequencing exome|Both archived tumor material and blood sample collection will be used for genetic profiling
51181|NCT03784001|Behavioral|Gratitude Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest
51344|NCT03782844|Device|Traditional CPAP+Simple CPAP|Patients used Traditional CPAP and simple CPAP during overnight polysomnography.
51182|NCT03784001|Behavioral|Gratitude + Expectations Intervention|"Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a short gratitude list of up to five items. Participants will have a statement at the top of their Google form about the benefits of gratitude. Examples of these statements are: Practicing gratitude may increase social connectedness and Cultivating gratitude was shown to improve school satisfaction in a UK sample of students. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest"
51183|NCT03784001|Behavioral|Events Control Intervention|Participants will be emailed six different times, once every two days, with a link to an anonymous Google form. Each Google form will instruct participants to type a list of up to five items about events from their day. Additionally, the first form will include a demographics questionnaire and the first and sixth forms will include questionnaires assessing all outcomes of interest.
51184|NCT03783988|Combination Product|DHEA and TRIAC|The new topical gel contains dehydroepiandrosterone (DHEA) and triiodothyroacetic acid (TRIAC)
51185|NCT03783975|Genetic|Simplified Cascade Screening|Screening of the KCNQ1 Thr224Met variant for family members of probands
51186|NCT03783962|Behavioral|Active Intervention - Cooking|"Key behavioral strategies to facilitate making sustained changes in dietary habits and activity patterns are introduced, promoted and reinforced throughout the program. In-person sessions facilitated by an interventionist provide the group meetings. The program provides 24 weekly facilitated group sessions over 6 months. In addition to attending weekly classes, participants will track food intake, exercise, and weight. Participants will share online tracking diaries with the group facilitator who will offer individualized feedback on individual progress.~Twelve cooking classes will be run every other week after the in-person weight loss meetings."
51187|NCT03783962|Behavioral|Demonstrations - Cooking|The Demonstrations group will receive the exact same behavioral weight loss intervention as the cooking group. The only difference is that this group will attend cooking demonstrations as opposed to actively cooking.
51188|NCT03783949|Drug|Ganetespib|Ganetespib dose during chemotherapy will be 150mg/m² (q3w) Ganetespib dose during maintenance treatment will be 100mg/m² (q1w)
51189|NCT03783949|Drug|Niraparib|Niraparib starting dose during maintenance treatment will be 200mg or 300mg depending on subject's body weight and subject neutrophil count (QD)
51190|NCT03783949|Drug|Carboplatin|In combination with Gemcitabine: Carboplatin dose will be AUC4 (q3w) In combination with Paclitaxel: Carboplatin dose will be AUC5 (q3w)
51191|NCT03783949|Drug|Paclitaxel|Paclitaxel dose will be 175mg/m² (q3w)
51192|NCT03783949|Drug|Gemcitabine|Gemcitabine dose will be 1000mg/m² (q3w, d1 & d8)
51193|NCT03783936|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2
51194|NCT03783936|Drug|Leucovorin|Leucovorin 400 mg/m2
51195|NCT03783936|Drug|5 fluorouracil|5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion
51196|NCT03783936|Drug|Trastuzumab|Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
51197|NCT03783936|Drug|Avelumab|Avelumab 10 mg/kg
51198|NCT03783923|Drug|Deflazacort|Deflazacort tablet will be administered as per the dose and schedule specified in the respective arms.
51199|NCT03783923|Drug|Placebo|Placebo matching deflazacort will be administered as per schedule specified in the respective arm.
51200|NCT03783910|Drug|GRT9906|One prolonged-release tablet containing 40 mg of GRT9906
51201|NCT03783910|Drug|Placebo|Placebo matching GRT9906 tablets
51202|NCT03783897|Drug|EDP-305|Subjects will receive EDP-305 on on Days 11 through 21 of cycle 3
51203|NCT03783897|Drug|Oral Contraceptive|Subjects will receive active Oral Contraceptive on Days 1-21 and inert OC on Days 22-28 of cycles 1, 2 and 3
51204|NCT03783884|Device|Diaphragm Pacing Therapy|Transvenous phrenic nerve stimulation to induce diaphragm contraction.
51205|NCT03783871|Device|Microwave ablation|Subjects will be treated with microwave ablation.
51206|NCT03783858|Device|P200TE|OCT images
51207|NCT03783845|Combination Product|amoxicillin 500mg and metronidazole 400mg|metronidazole 400mg and amoxicillin 500mg three times daily for two weeks
51208|NCT03783832|Other|OCT ANGIOGRAPHY DATA|Follow-up of diabetic macular edema treated by Aflibercept (EYLEA®) with OCT angiography
51209|NCT03783819|Other|Hypericum perforatum oil|Ointment containing Hypericum perforatum oil
51210|NCT03783819|Other|Placebo|Ointment containing plant oils used in Hypericum perforatum oil production and dye
51211|NCT03783819|Procedure|SLS induced irritation|60 uL of 1% w/v sodium lauryl sulphate (SLS) will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis. Procedure will be performed to specified skin sites, according to randomization protocol.
51212|NCT03783819|Procedure|Tape-stripping|Skin barrier disruption will be induced by tape-stripping. Procedure will be performed to specified skin sites, according to randomization protocol.
51213|NCT03783819|Procedure|UV radiation|UV radiation will be used to induce skin erythema and damage. Procedure will be performed to specified skin sites, according to randomization protocol.
51214|NCT03783819|Procedure|Intact skin|Healthy, intact skin. Procedure will be performed to specified skin sites, according to randomization protocol.
51215|NCT03783806|Diagnostic Test|Posturography measurements|Determination of functional status, Posturography measurements, postural tests
51216|NCT03783793|Behavioral|Mindfulness Training App|Mindfulness training in the study was performed using a new app called Wildflowers. With this app participants were able to choose and complete a variety of guided meditations over the 3 week training period. Wildflowers includes guided meditations such as breathing, body scans, and open monitoring practices and also provides didactic content in the form of lessons and information about the benefits of mindfulness training.
51246|NCT03783585|Behavioral|Cognitive behavioral therapy for insomnia + biweekly support|Individuals randomized into the CBT-I + biweekly support will participate in CBT-I as described as well as a biweekly phone call or video call with research personnel for motivational interviewing.
51247|NCT03783572|Other|Clinical evaluation|For the control group : only one clinical evaluation : search for non-inclusion criteria and manual laterality score
51497|NCT03781687|Procedure|Bilateral ESP Block|Bilateral ESP Block will be performed at T8
51217|NCT03783793|Behavioral|Cognitive Training With 2048|The training app for the control condition was based on an open source code for a popular cognitive training app called 2048 that is marketed as a fun and relaxing puzzle game. Within 2048, participants slide numbered tiles around a grid, matching tiles of the same value. Instead of tiles disappearing, as in Candy Crush or other similar grid-sliding games, matching 2 numbered tiles in 2048 combines them into 1 new tile displaying the sum of the previous 2 numbers. For example, two 2-tiles linked side-by-side become a 4-tile, whereas 2 matched 4-tiles become an 8-tile, and so on. The goal is to match tiles until the sum of 2048 is reached on a single tile. There is no time limit.
51218|NCT03783780|Device|INVSENSOR00031|Noninvasive pulse oximeter sensor
51219|NCT03783767|Behavioral|Leadership Intervention|Grade 6/7 teachers will take part in a workshop on developing transformational leadership among their Grade 6/7 students, and provide teachers with a 4-week training program. Teachers will implement a 4-week leadership development component to their Grade 6/7 students. Grade 6/7 students will then deliver a 10-week peer-led FMS program to Grade 3/4 students. The Grade 6/7 peer leaders will lead 2 x 30 min sessions per week during physical education classes, recess, or lunch times. In weeks two and three, peer leaders will be observed by members of the research team and provided with feedback using a structured checklist regarding their delivery in the session. Mid-way through the 10-week program teachers will deliver a booster leadership training component to the Grade 6/7 peer-leaders.
51220|NCT03783754|Drug|telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg|low-dose combination therapy
51221|NCT03783754|Drug|Placebo oral capsule|matched placebo
51222|NCT03783741|Behavioral|Questionnaire|Interview
51223|NCT03783728|Drug|Rifapentine 600 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
51224|NCT03783728|Drug|Isoniazid 900 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
51225|NCT03783728|Drug|Pyridoxine 50 mg orally|Once a week for 12 weeks using Video Directly Observed Therapy
51226|NCT03783715|Drug|Ketoprofen|Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
51227|NCT03783702|Drug|OxyCODONE 5 Mg Oral Tablet|Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
51228|NCT03783702|Drug|Ibuprofen 600 Mg Oral Tablet|Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
51229|NCT03783702|Drug|Acetaminophen 650 MG Oral Tablet|All patients will receive acetaminophen as the first-line analgesic.
51230|NCT03783689|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
51231|NCT03783676|Drug|Remifentanil|Receive remifentanil bolus and infusion guided by an algorithm.
51232|NCT03783676|Drug|Normal saline|Receive normal saline bolus and infusion guided by the remifentanil algorithm.
51233|NCT03783663|Behavioral|Misfit Shine 2|The intervention group was given a Misfit Shine 2 to monitor sleep throughout the 12-week intervention period. Participants were instructed to wear the device on the wrist, which is better for capturing sleep than the other wear locations. Participants were instructed on how to self-monitor total sleep time and select a goal for that behavior. Further, participants were asked to view feedback on their sleep time daily on the Misfit smartphone app, which they used to monitor their progress toward achieving their behavioral goals.
51234|NCT03783650|Behavioral|Control condition|Practices will submit control data and not receive centralized data feedback. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic.
51235|NCT03783650|Behavioral|QIC with PCP and without subspecialist|During this phase, practice will begin working on improving HTN practices within their clinic via a QIC, while the other cohort will act as a control (usual care) with data collection. They will attend an initial 1-day interactive video webinar learning session where they will learn QI methodology, enhance and practice QI skills, identify local 30-60 day aims to improve local HTN practices and increase their understanding of pediatric HTN. They will also begin tracking data on a HTN registry and learn how to ensure accurate BP measurement is completed in their clinic. They will participate in QI coaching, monthly video conferences, and monthly mini-root cause analyses (Mini-RCAs).
51236|NCT03783650|Behavioral|QIC with Subspecialist|Practices will integrate their HTN subspecialist into the QIC and focus on issues at the boundary of PCP and subspecialty care (e.g. pre-referral work-up, communication across providers, and time for next available appointment).
51237|NCT03783650|Behavioral|Hub and Spoke co-management|Practices will continue QIC components and implement a hub and spoke model, where the PCP diagnoses and provides definitive management for pediatric HTN with subspecialist support.
51238|NCT03783650|Behavioral|Sustainability of changes|Practices will sustain their changes, illustrating the durability of these system changes even after QIC completion and without central feedback and regular meetings.
51239|NCT03783637|Other|Whole grain oats|A meal containing whole grain oats
51240|NCT03783637|Other|Whole grain wheat|A meal containing whole grain wheat
51241|NCT03783624|Behavioral|Hypnosis|A 6 session course of individual hypnosis therapy will be offered.
51242|NCT03783624|Behavioral|Open label placebo|Ritual intake of 2 placebo capsules twice a day
51243|NCT03783611|Behavioral|MyPlan 2.0.|eHealth intervention to increase physical activity in older adults. MyPlan 2.0 consists of five website visits. The first website visit contains pre- and post-intentional processes. The following four website visits contains mainly post-intentional processes. During the first website, participants fill in a questionnaire about their physical activity levels, and receive feedback. Furthermore, they are asked to make an action plan and think about barriers to reach their activity goals and possible solutions to tackle these barriers. During the other four website visits, participants receive feedback about their behavior change process and their action plan (did they reach their goal)? During these website visits, they can adapt their action plans.
51304|NCT03783221|Other|High-fat diet|The high-fat diet (51% fat, 27% carbohydrates, 21% proteins and 4.7 g fiber) will be administered for two weeks..
51498|NCT03781687|Procedure|Unilateral ESP Block|Unilateral ESP Block will be performed at T8 (right side)
51248|NCT03783572|Other|Clinical evaluation and Instrumental evaluation|For the patient : The standard clinical examination to evaluate movement : pain, motive power, spasticity plus Edinburgh's laterality score and Sensitivity deficiency by the Erasmus Nottingham Sensory Assessment (EmNSA) score and the evaluation of the cognitive function An encephalic MRI An instrumental evaluation : with concomitant recording of 3D kinematic data, surface and intramuscular EMG of the flexor and elbow extensor muscles, and EEG during active elbow extension, paretic and non-paretic movements.
51249|NCT03783559|Drug|TACE|TACE
51250|NCT03783559|Drug|chemotherapy±target therapy|chemotherapy±target therapy
51251|NCT03783546|Device|Acupuncture|Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
51252|NCT03783546|Other|Usual Care|the current standard of care with non-hormonal pharmacotherapy of western medicine
51253|NCT03783533|Behavioral|Behavioral Activation|Intervention: Behavioral Activation (BA) therapy is based on a functional analytic model of depression that highlights the need for increased positive reinforcement (rewards) and decreased anhedonia, or diminished motivation to seek rewards, to maintain normal mood. BA is significantly more effective than Cognitive Behavioral Therapy and comparable to antidepressant medication in reducing depressive symptoms among depressed adults (Dimidjian et al., 2006). McCauley (senior mentor) et al. (2016) adapted BA for adolescents to target anhedonia, effective problem solving and avoidant behaviors with peers, family, and school. McCauley's findings and others show BA is a promising intervention for adolescent MDD (Chu et al., 2009; Cuijpers et al.,, 2007; McCauley et al., 2015; Ritschel et al., 2011). BA focuses on targeting ideographically identified avoidant behaviors and rewarding experiences that affect mood.
51254|NCT03783520|Device|Er,Cr:YSGG Laser|Er,Cr:YSGG Laser is used for disinfection of the root canals.
51255|NCT03783520|Other|Sodium hypochlorite|Sodium hypochlorite is used for disinfection of the root canals
51256|NCT03783507|Behavioral|Order 1|"Meal Order 1:~Meal Session 1 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 2 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 3 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 4 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED)"
51257|NCT03783507|Behavioral|Order 2|"Meal Order 2:~Meal Session 1 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 2 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 3 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 4 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED)"
51258|NCT03783507|Behavioral|Order 3|"Meal Order 3:~Meal Session 1 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED) Meal Session 2 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 3 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 4 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED)"
51259|NCT03783507|Behavioral|Order 4|"Meal Order 4:~Meal Session 1 participant receives meal 4 (1 low-ED, 3 medium-ED, 1 high-ED) Meal Session 2 participant receives meal 1 (3 low-ED, 0 medium-ED, 2 high-ED) Meal Session 3 participant receives meal 2 (3 low-ED, 1 medium-ED,1 high-ED) Meal Session 4 participant receives meal 3 (1 low-ED, 2-medium ED, 2 high-ED)"
51260|NCT03783494|Drug|Target control infusion with propofol|Target control infusion with propofol for patients with indications of sustaining very painful orthopedic emergency emergent procedures
51261|NCT03783481|Device|Mobile community|Install an application (app) on subjects' smartphone. Subject's will join the mobile community using the application through which they can check their own and other members daily steps and communicate with each other.
51262|NCT03783481|Other|No Mobile community|No Mobile community
51263|NCT03783468|Other|decrease of sedation doses and switch of ventilator settings|tapering sedation doses (propofol) switch from assisted ventilation to pressure support ventilation
51264|NCT03783455|Procedure|Non arthroscopic joint lavage|Instillation of 4 litters of cold physiological serum
51265|NCT03783455|Procedure|Non arthroscopic joint lavage plus corticosteroid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of triamcinolone
51266|NCT03783455|Procedure|Non arthroscopic joint lavage plus hyaluronic acid|Instillation of 4 litters of cold physiological serum followed by intraarticular injection of hyaluronic acid
51267|NCT03783455|Procedure|Intraarticular injection of corticosteroid|Intraarticular injection containing 40 mg of triamcinolone acetonide.
51268|NCT03783455|Procedure|Intraarticular injection of hyaluronic acid|Intraarticular injection containing 4 mL of a bioengineered hyaluronic acid.
51269|NCT03783442|Drug|Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU)|"Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W~5-FU 750 to 800 mg/m2 IV continuous infusion over 24 hours daily on Days 1 to 5 Q3W"
51270|NCT03783442|Drug|Platinum (cisplatin or oxaliplatin) + capecitabine|"Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W~Capecitabine 1000 mg/m2 orally (PO) twice daily (BID) on Days 1 to 14 Q3W"
51271|NCT03783442|Drug|Platinum (cisplatin or oxaliplatin) + paclitaxel|"Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 or 2 Q3W~Depending on local guidelines, cisplatin may be given in 3 divided doses on Days 1, 2, and 3. The total dose given must be between 60 to 80 mg/m2 per cycle.~Paclitaxel 175 mg/m2 IV on Day 1 Q3W"
51272|NCT03783429|Drug|Digoxin|Digoxin tablets will be given orally
51273|NCT03783429|Drug|Placebos|Placebo tablets will be given orally
51274|NCT03783416|Drug|Ixazomib (NINLARO®) capsules / Matching placebo capsules|Participants will be treated for a maximum of 24 months
51275|NCT03783403|Drug|CC-95251|CC-95251 administered by IV (intravenous) infusion.
51276|NCT03783403|Drug|Rituximab|Rituximab administered by IV (intravenous) infusion.
51277|NCT03783403|Drug|Cetuximab|Cetuximab administered by IV (intravenous) infusion.
51278|NCT03783390|Behavioral|Exercise Intervention|Youth randomized to the active condition will participate in an organized exercise program. During the exercise program, adolescents will participate in a supervised structured exercise (treadmill walking/cycling on stationary bike) on 3 days equivalent to approximately 180 min/week of moderate-intensity exercise. The rationale for this dose of structured exercise is based on national (ADA) and international physical activity recommendations for youth of 60 minutes/day.
51305|NCT03783221|Other|High-residue diet|The high-residue diet (19% fat, 62% carbohydrates, 16% proteins and 54.2 g fiber) will be administered for two weeks.
51279|NCT03783390|Behavioral|Newsletter|"Families will receive a monthly newsletter with parenting tips, sample praise statements, and child-appropriate activities and recipes identical to what has been used in the work of leaders in the field of pediatric obesity. Previous research suggests that newsletter/mail interventions are well received by participants and are frequently included in federally funded health intervention studies."
51280|NCT03783377|Drug|ARO-APOC3|single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections
51281|NCT03783377|Drug|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
51282|NCT03783364|Radiation|Radiotherapy|Pre- or postoperative acellerated irradition in 5 fractions
51283|NCT03783351|Genetic|CYP2C19 genotype testing|CYP2C19 genotype testing will be conducted in a designated central laboratory.
51284|NCT03783338|Combination Product|Aerobic exercises and Vitamin D supplementation|"Aerobic exercises:~Children in groups B and C will receive aerobic exercises in the form of bicycle ergometer and treadmill training for 15 min 3 days/week for 12 weeks. The procedure and goals of exercise will be explained to all children before starting the exercise program. The child will stop exercising immediately if he feels pain, fainting or shortness of breath.~Vitamin D supplementation:~Children in group C only will receive vitamin D supplementation in the form of an oral daily dose of vitamin D3 1000 IU (Cholecalciferol) for 12 weeks."
51288|NCT03783312|Drug|placebo|250 ml saline will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
51289|NCT03783312|Drug|paracetamol|1 g paracetamol will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
51290|NCT03783312|Drug|ibuprofen|800 mg ibuprofen will be administered 60 minutes before the onset of Electroconvulsive therapy procedure. All administrations will be applied through IV infusion over 60 minutes.
51291|NCT03783299|Diagnostic Test|Standard RDT and HS-RDT|All household members (residents and temporary visitors) aged 18 months and older will be invited to participate in an RDT and blood collection component. After consenting, the MTAT team will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Malaria Ag P.f High Sensitive Cat# 05FK140)
51292|NCT03783299|Diagnostic Test|Standard RDT and HS-RDT|All individuals will be invited to participate in an RDT and blood collection component. Informed consent will be obtained from all participants. After consenting, the PNs will capture axillary temperature, and test each individual using both a standard RDT (SD Bioline Pf/Pv RDT) and HS-RDT (SD Bioline Alere Malaria Ag Pf High Sensitive Cat #05FK140). Dried blood spots (DBS) will also be collected on all HRPs if deemed feasible.
51293|NCT03783299|Drug|Artemether-lumefantrine|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
51294|NCT03783299|Drug|Primaquine Phosphate|If found positive by standard RDT or HS-RDT, treatment will be administered, and women of reproductive age will be assessed as outlined in the protocol. All individuals who have provided informed consent, test positive by either HS-RDT or standard RDT, are ≥18 months old, are not pregnant or breastfeeding, and who do not have symptoms associated with severe malaria or another severe illness, will be offered an age-appropriate course of AL (age-specific blister packages) and SLD-PQ according to national treatment guidelines.
51295|NCT03783286|Drug|Ivacaftor|Ivacaftor (Kalydeco®, Vertex Pharmaceuticals Inc.) was the first of a new class of drugs that improved CFTR gating dysfunction (2, 3, 4). For such mutations (G551D, G178R, S549N, S549R, G551S, G970R, G1244E, S1251N, S1255P, G1349D) that permit CFTR expression at the cell membrane but compromise its activity.
51296|NCT03783273|Dietary Supplement|Vitamin D3|Single dose vitamin D3
51297|NCT03783273|Combination Product|Whey protein-complex|Whey protein complex-bound vitamin D3
51298|NCT03783273|Other|Water|500 mL water
51299|NCT03783273|Other|Milk|500 mL milk
51300|NCT03783273|Other|Juice|500 mL juice
51301|NCT03783260|Other|Mediterranean diet|During both Mediterranean diet periods, participants will be provided with meals and snacks representative of the Mediterranean nutritional habits. Participants will be required to eat only the meals provided.
51302|NCT03783247|Procedure|Pericapsular nerve group block|The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees (Figs. 2, 3). In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed. A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution (20ml of bupivacaine 0.25%) was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 30 mL
51303|NCT03783247|Procedure|Fascia Iliaca BLock|In supine position, a high frequency linear probe will be placed in the inguinal crease. Scan starting laterally from the femoral artery and nerve in inguinal crease to identify the sartorius muscle, tracing the muscle until it's origin to anterior superior iliac spine. The shadow of the bony of iliac crest & iliacus muscle will be seen, the end point of the injection is deep to the fascia iliaca and above the iliacus muscle in the lateral part of the iliacus muscle. After negative aspiration, 30 mL of 0.25 % of bupivacaine will be injected under the fascial plane incrementally, aspirating every 5 ml.
51308|NCT03783195|Other|Sugar drink|A sugar drink made with 1.2 g/kg body weight of added sugar( 0.75g/kg body weight of fructose + 0.45g/kg body weight of glucose) and 24oz water
51309|NCT03783182|Drug|Betamethason Sodium Phosphate|Glucocorticoid
51310|NCT03783182|Drug|10% glucose solution|Glucose solution that can be used for injection, but in this case it is used perorally (one ml)
51311|NCT03783169|Other|Cardiovascular Sonographic Assessment|Maternal sonographic vascular measurements assessing volume status, cardiac output, and systemic vascular resistance by means of inferior vena cava collapsibility/caval index (ICV CI), end-point septal separation (EPSS) for determining left ventricular ejection fraction (LVEF), cardiac output determination (stroke volume x heart rate), stroke volume variation, & radial artery resistance index) augments standard vital sign assessment (pulse pressure and systolic / diastolic predominance)
51312|NCT03783156|Procedure|hot snare|polypectomy with hot snare
51313|NCT03783156|Procedure|cold snare|polypectomy with cold snare
51314|NCT03783130|Biological|VRC-HIVRGP096-00-VP|Trimer 4571 drug product is a sterile, aqueous, buffered solution filled under aseptic conditions into single dose vials at a concentration of 500 mcg/mL. The formulation buffer is comprised of 10 mM Sodium Phosphate, 10 mM Sodium Chloride, 7.5% Sorbitol, 0.01% PF-68 at pH 7.2. The drug product is aseptically filled at a volume of 1.2 +/- 0.10 mL in 3 mL glass vials. Vials contain a clear, colorless solution; no turbidity, some small white or translucent particles may be visible.
51315|NCT03783117|Device|Magnetic field treatment|The MBPL device for clinical trials is made with modification of an electromagnet: A bore of 10cm diameter was made to go through the frame and poles. The device can produce a magnetic field close to 1.0 T inside the bore, which is along the axis direction. The trial for each subject takes about 20-30 minutes. To start with, the subject's blood pressure is measured first as the baseline. Afterwards, the subject places his/her right arm into the bore of the electromagnet for treatment while the blood pressure is monitored with the left arm. The magnetic treatment lasts about 15 minutes and will lower the subject's blood pressure. In order to see how long the effect lasts, the subject needs to return and measure the blood pressure again 24 hours after the treatment. The clinical trials are non-invasive. There is no medicine or surgery involved.
51316|NCT03783104|Dietary Supplement|B12 Supplement|Differential doses of vitamin B 12 supplementation in a two-armed randomised controlled trial
51317|NCT03783091|Drug|Hydroxocobalamin|Single IV administration of Vitamin B12
51318|NCT03783091|Drug|Placebo|Single IV administration of saline
51319|NCT03783078|Drug|Pembrolizumab (MK-3475)|200 mg (adult participants) or 2 mg/kg (up to 200 mg; pediatric participants) on Day 1 of each 3-week cycle (Q3W). IV, Up to 35 administrations (approximately 2 years)
51320|NCT03783065|Drug|Propranolol|Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
51321|NCT03783065|Procedure|Laparoscopic splenectomy and pericardial devascularization|Including splenectomy and pericardial devascularizaion under laparoscopy
51322|NCT03783065|Procedure|Endoscopic therapy|Either endoscopic variceal ligation (EVL) or cyanoacrylate injection was applied according to the condition of varices
51323|NCT03783052|Device|SmartPill|SmartPill administration in fasted and fed state
51324|NCT03783039|Device|SURGICEL Powder|Proportion of subjects achieving hemostatic success at 5 minutes following the application of SURGICEL Powder or SURGICEL Original with no re-bleeding requiring additional treatment at
51325|NCT03783039|Device|SURGICEL Original|Proportion of subjects achieving hemostatic success at 5 minutes following the application of SURGICEL Powder or SURGICEL Original with no re-bleeding requiring additional treatment at
51326|NCT03783026|Drug|CC-10004|CC-10004
51327|NCT03783013|Other|High Lycopene Tomato Juice With Soy Germ Extract|Tomato juice made from high lycopene tomatoes with soy germ extract added
51328|NCT03783013|Other|Low Lycopene Tomato Juice|Tomato juice made from low lycopene tomatoes with no soy germ extract added
51329|NCT03783000|Drug|BI 425809|Treatment T
51330|NCT03783000|Drug|BI 425809 mixed with [C-14]-BI 425809|Treatment R
51331|NCT03782987|Drug|BI 730357|Tablet
51332|NCT03782987|Drug|Itraconazole|Oral solution
51333|NCT03782974|Dietary Supplement|beta glucan|Following screening and enrollment, participants will be treated with 2 tablets (Proglucamune or placebo) per day for a total duration of 8 weeks. Each Proglucamune tablet contained ~100 mg ß-glucan derived from Baker's Yeast extract (Saccharomyces cerevisiae, cell wall), Reishi mushroom powder (Ganoderma lucidum), and Shitake mushroom powder (Lentinula edodes).
51334|NCT03782961|Device|sodium lactate and combination of polymers|sodium lactate and combination of polymers (polycarbophil, carbomer and PVM / MA copolymer)
51335|NCT03782948|Device|Standard gait training on BART without pelvic perturbations|The Balance Assisted Robot on Treadmill (BART) enables various types of gait training on treadmill with visual feedback. It interfaces to the pelvis of the walking subject in an actuated and admittance-controlled manner, thus providing transparent haptic interaction with negligible power transfer.
51336|NCT03782948|Device|Robotised gait training with BART with pelvic perturbations|In addition to the standard gait training, the BART will deliver perturbations in the forward/backward and left/right direction.
51337|NCT03782935|Dietary Supplement|Prenatal multivitamin mineral supplement|prenatal vitamin/mineral supplement with or without choline supplement
51338|NCT03782922|Other|Exercise Training Program|10min of coordination and strength training (2-3x per week) during 2-6 weeks
51339|NCT03782909|Behavioral|Behaviour change intervention|"The behaviour change intervention consists of;~Feedback via an app based food diary~Coaching with problem solving and implementation plans~The intensive phase consists of 2 home visits and 4 phone calls and the use of the app The maintenance phase consists of use of the app if the PWCF wishes to continue using it"
51340|NCT03782896|Other|acute postoperative pain|All patients assessed postoperative pain score in the recovery room and postoperative 2 month
51341|NCT03782870|Diagnostic Test|echocardiography, lab tests|
51342|NCT03782857|Behavioral|Intervention|Prevention of recurrent stroke, myocardial infarction and death Stepwise escalation of preventive medication Life style counselling including adherence to preventive treatment
51343|NCT03782844|Device|Simple CPAP+Traditional CPAP|Patients used simple CPAP and Traditional CPAP during overnight polysomnography.
52485|NCT03773991|Diagnostic Test|Pulmonary Function Tests|Spirometry and Plethysmography
51345|NCT03782831|Procedure|TACE|Hepatic intra-arterial infusion with lipiodol mixed with chemotherapy drugs (EADM, lobaplatin, and MMC), and embolization with polyvinyl alcohol particles (PVA).
51346|NCT03782831|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
51347|NCT03782831|Drug|Placebos|intravenous injection every 2 weeks
51348|NCT03782818|Drug|Olaparib|Olaparib up to 300 mg BID for 24 weeks
51349|NCT03782805|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
51350|NCT03782805|Dietary Supplement|Placebo tablet|The participants are randomly asked to take either a pill containing either a supplement of cholecalciferol or placebo for 3 times a week, within a period of 6 months
51351|NCT03782792|Drug|Spesolimab|Solution for infusion
51352|NCT03782792|Drug|Placebo|Solution for infusion
51353|NCT03782779|Other|Breathing program and regular exercise|This program will be supervised by a physical therapist and will include learning and performing a diaphragmatic-abdominal breathing, and incorporating the new breathing pattern to a upper and lower limbs regular exercises as well as to daily life activities.
51354|NCT03782779|Other|Regular Exercise|Regular upper and lower limbs exercises supervised by a physical therapist
51355|NCT03782766|Procedure|Piezocision|Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
51356|NCT03782740|Drug|Melatonin 10 mg|Melatonin capsule
51357|NCT03782740|Drug|Placebo|Sugar pill manufactured to mimic Melatonin capsule
51358|NCT03782740|Drug|Melatonin 20 mg|Melatonin capsule
51359|NCT03782714|Device|Low-level laser therapy|It is a diode laser device that has laser set at low level, used for pain relief and inflammation reduction to induce healing
51360|NCT03782701|Drug|brimonidine tartrate ophthalmic solution 0.025%|One time dosing of brimonidine tartrate ophthalmic solution 0.025% (1 drop applied to ocular surface)
51361|NCT03782701|Other|sterile balanced saline solution|One time dosing of sterile balanced saline solution (1 drop applied to ocular surface)
51362|NCT03782688|Diagnostic Test|FFRCT planner|Non-invasive post-PCI fractional flow reserve prediction
51363|NCT03782675|Device|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
51364|NCT03782675|Device|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
51365|NCT03782662|Drug|Itraconazole|Itraconazole capsules
51366|NCT03782662|Drug|Verapamil|Verapamil tablets
51367|NCT03782662|Drug|Rifampicin|Rifampicin capsules
51368|NCT03782662|Drug|Midazolam|Midazolam oromucosal solution
51369|NCT03782662|Drug|Placebo for RV521|Placebo for RV521 capsules
51370|NCT03782662|Drug|RV521|RV521 capsules
51371|NCT03782649|Device|Working Model 3.4NR|Investigational Medical Device collecting spectral Raman data from tissue
51372|NCT03782636|Drug|Aldesleukin|"PROLEUKIN® 18 x 106 IU~Powder for solution for injection or infusion"
51373|NCT03782636|Other|Placebo|sterile diluent used for the aldesleukin preparation and 5% glucose
51374|NCT03782623|Diagnostic Test|Analysis of eicosanoid profile prior to and after PRBC transfusion|Using liquid chromatography-mass spectrometry to analyze the eicosanoid profile in patient plasma and aliquoted of the PRBCs prior to and after PRBC transfusion.
51375|NCT03782597|Behavioral|Semi-structured interviews or focus groups to explore families representations and strategies about their teenagers involved in radicalisation process|A sample of representative French families (parents, siblings, and persons identified as attachment figures) of adolescents or young adults (12-25 years old) involved in the radicalisation process will be asked to participate in semi-structured interviews or focus groups to explore their representations and strategies about radicalisation. It will be supplemented by genogram draw sociodemographic data.
51376|NCT03782584|Other|modified pilates exercise|modified exercises from original pilates exercises.
51377|NCT03782584|Other|daily life advises|they will be given daily life advises to prevent neck pain
51378|NCT03782571|Device|etafilcon a Test 1|1-DAY ACUVUE® MOIST
51379|NCT03782571|Device|etafilcon A Test 2|1-DAY ACUVUE® MOIST for ASTIGMATISM
51380|NCT03782571|Device|etafilcon A Test 3|1-DAY ACUVUE® MOIST MULTIFOCAL
51381|NCT03782571|Other|Control|Bare Eye
51382|NCT03782558|Procedure|Surgical transection of transverse ligament|Standard therapy for CTS. An incision is made at the base of the palm of the hand. Then the transverse ligament is cut, which releases the compression of the median nerve and improves the symptoms.
51383|NCT03782545|Device|Cutera truSculpt Device|The Cutera truSculpt Device uses radio frequency (RF) energy to provide topical heating for the purpose of elevating tissue temperature for the treatment of selected medical conditions, such as temporary reduction in the appearance of cellulite.
51384|NCT03782532|Drug|Dupilumab SAR231893|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
51385|NCT03782532|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
51386|NCT03782532|Drug|Asthma Controller Therapies (include prednisone/prednisolone)|"Pharmaceutical form: Aerosol, capsules, tablets, oral solution~Route of administration: Inhalation, oral"
51387|NCT03782532|Drug|Asthma Reliever Therapies|"Pharmaceutical form: Nebulized, aerosol~Route of administration: Inhaled"
51388|NCT03782519|Other|Dialysis frequency reduction|At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
51389|NCT03782519|Other|Frailty diagnosis|Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
51390|NCT03782506|Behavioral|Interactive Music Therapy|Ten 45-minutes individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. Each session involves learning and practicing music-based techniques for the self-management of pain, anxiety, stress, mood, fatigue, and sleep disturbance as these are common opioid withdrawal symptoms. Psychoeducation about opioid tapering is provided and tapering challenges experienced by the patient will be actively addressed through music-based interventions.
51391|NCT03782506|Behavioral|Verbal-based support|Ten 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears. As in the IMT protocol, psychoeducation about opioid tapering will be included and will be considered the only active treatment factor for this intervention.
51392|NCT03782493|Behavioral|the Enhanced Milieu Teaching-Sentence Focus|Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
51393|NCT03782480|Drug|Intrarosa|Prasterone intravaginal inserts
51394|NCT03782480|Drug|Placebos|Placebo intravaginal inserts
51395|NCT03782467|Biological|ATOR-1015|Bispecific human monoclonal antibody targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and OX40 (also known as CD134)
51396|NCT03782454|Diagnostic Test|Blood sampling|Blood samples taken every third hour during the first 48 hours of intensive care
51397|NCT03782441|Device|Prototype 0.5|Investigational Medical Device collecting spectral Raman data from tissue
51398|NCT03782428|Dietary Supplement|Probiotic|30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
51399|NCT03782428|Other|Placebo|Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
51400|NCT03782415|Drug|MN-166|MN-166 (ibudilast) is an anti-inflammatory/neuroprotective agent. MN-166 (ibudilast) distributes well to the CNS (Sanftner et al. 2009) and it is a selective inhibitor of certain cyclic nucleotide phosphodiesterases (PDE) and the pro-inflammatory cytokine, macrophage migration inhibitory factor (MIF). At clinically-relevant plasma or CNS concentrations, MN-166 (ibudilast) selectively inhibits macrophage migration inhibitory factor (MIF) (Cho et al 2010) and, secondarily, PDE3, 4 and 10 (Gibson et al 2006).
51401|NCT03782415|Drug|Temozolomide|Temozolomide is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; and a first-line treatment for glioblastoma multiforme.
51402|NCT03782402|Drug|Cannabinoids|Cannabinoids with different concentrations of THC and CBD
51403|NCT03782389|Other|Preseason Periodic Health Examination Completion|all available players completed a mandatory PHE on one of three days during the first week of the season. Typically, the musculoskeletal and performance components of the PHE included: 1) anthropometric measurements; 2) medical history (i.e. previous injury history); 3) musculoskeletal examination tests; 4) functional movement and balance tests; 5) strength and power tests.
51409|NCT03782363|Biological|Autologous CIK Dose level 1|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 22
51410|NCT03782363|Biological|Autologous CIK Dose level 2|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 22
51411|NCT03782363|Biological|Autologous CIK Dose level 3|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 20.000.000 cell/kgs days 1 and 15
51412|NCT03782363|Biological|Autologous CIK Dose level 4|Lymphocytapheresis of the autologous ex-vivo CIK cell expanded in the Cell factory at first level of dose 25.000.000 cell/kgs days 1 and 15
51413|NCT03782350|Drug|Tranexamic Acid Dosage 1|Tranexamic Acid Dosage 1
51414|NCT03782350|Drug|Tranexamic Acid Dosage 2|Tranexamic Acid Dosage 2
51415|NCT03782337|Behavioral|multi-discipline disease management program|The multi-discipline disease management program consists of nursing lead education program, dietitian consultation, psychologist consultation and assessment, and cardiac rehabilitation program by physical therapist.The cardiovascular lead nurse will contact the patient by telephone within 3 days after discharge. An appointment at the outpatient clinic will be arranged within 1 to 2 weeks after discharge. The purposes of the telephone call are to reinforce self-management and recognition of HF symptoms and to screen post-discharge health status.
51416|NCT03782311|Behavioral|motivation and and oral hygiene instructions|Motivation and oral hygiene instructions were received OHSE-high and OHSE-low groups. After showing the modified-Bass tooth brushing technique and interdental cleaning on the model, patients were followed up while brushing and flossing their teeth to correct misapplications. It was advised to brush teeth twice a day and use the interdental cleaning devices once a day.
51417|NCT03782298|Device|Spyromite, Dynomite, Raptomite, Footprint Ultra PK SL|Observational, post-market, clinical follow-up study
51499|NCT03781687|Device|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
88976|NCT03491644|Drug|Liberal Oxygen|Liberal treatment with oxygen.
51418|NCT03782285|Procedure|sacrospinous Ligament Fixation|sacrospinous ligament suspension (SSLF) as a typical native tissue repair procedure is one of the most widely used vaginal procedures for correcting apical prolapse. Ischial spinous fascia fixation (ISFF) will be the replacement procedure if SSLF will not be accomplished by conventional surgical instruments due to unsatisfactory exposure of spinous fascia.
51419|NCT03782272|Dietary Supplement|Enterade|enterade® (an amino acid-based oral rehydration solution [AA-ORS]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
51420|NCT03782272|Dietary Supplement|Placebo|a placebo solution containing natural flavor, steviol (sweetener), and purified water.
51421|NCT03782259|Drug|dapagliflozin|Subjects will either receive 10mg tabs of dapagliflozin or identical looking placebo - inactive medication. Subjects have an equal chance of receiving dapagliflozin or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects nor the Study Site personnel will know which treatment subjects are assigned to. The study drug must be taken daily. The subject's other medications will not be changed by the study.
51422|NCT03782259|Other|Placebo|Placebo
51423|NCT03782246|Behavioral|MBCT|Mindfulness- based Cognitive Therapy
51424|NCT03782246|Behavioral|CBT|Cognitive Behavioral Therapy
51425|NCT03782233|Drug|Rocuronium Bromide, 50 Mg/5 mL Intravenous Solution|60 patients receiving laparoscopic gastrectomy surgery are randomized to two arms(30 patients per arm). The patients in deep NMB（PTC=1-2）receive high dose rocuronium ;the patients in moderate NMB(TOF=1-2) receive moderate dose rocuronium.
51426|NCT03782220|Other|Kinesio tape|The Kinesio taping ( Kinesio Tex Gold, 2in x103.3 ft) was applied to sternocleidomastoid, upper trapezium and levator scapulae muscles by the muscle inhibition technique ( from insertion to origin of a muscle) for experimental group.
51427|NCT03782220|Other|Shame tape|For the Shame taping group, a placebo taping method considered to be ineffective ( not from insertion to origin of muscles) with the same material without tension and with the neck in neutral position was used.
51428|NCT03782207|Drug|Atezolizumab|Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
51429|NCT03782194|Device|Low Intensity Focused Ultrasound Pulsation|A low intensity, focused ultrasound pulsation causes mechanical changed without causing heating or cavitation.
51430|NCT03782194|Device|Sham Ultrasound|Low Intensity Focused Ultrasound Pulsation Transducer is left in place on the participant's head but is not turned on during the sham procedure.
51431|NCT03782181|Device|Whole body vibration platform|A neuromuscular treatment using a rotational whole body vibration platform.
51432|NCT03782155|Drug|glutamine supplementation|powder 14g
51433|NCT03782155|Drug|HMB|powder 3g
51434|NCT03782155|Drug|Placebo|powder 17g
51435|NCT03782142|Drug|Tenofovir|TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
51436|NCT03782142|Drug|Rilpivirine|NNRTI
51437|NCT03782142|Drug|Prezcobix|PI
51438|NCT03782142|Drug|Dolutegravir|II
51439|NCT03782129|Biological|blood samples|Blood samples drawn during hospitalisations when needed
51440|NCT03782129|Other|Clinical exam and DFU medical cares|Clinical exam and DFU's medical cares at each visit (planned evry 1 to 3 months), during all the 5 years follow up, or until death.
51441|NCT03782103|Drug|Zurex Prep|Apply topically.
51442|NCT03782103|Drug|ChloraPrep|Apply topically.
51443|NCT03782103|Drug|Zurex Prep Vehicle|Apply topically.
51444|NCT03782090|Device|Endobronchial intubation|"In control group, endobronchial intubation is performed using conventional technique with left-sided double-lumen endobronchial tube(Shiley®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. The tube is advanced according to the depth(cm) of the tube calculated by the height of patient(12.5+0.1*height). Afterwards, the depth of the tube is adjusted by the compliance of both lung.~In experimental group, patients are intubated with novel double-lumen endobronchial tube(Ankor®). The tube is introduced into the glottis via direct laryngoscopy. After the tube tip passes the vocal cord, the tube is rotated 90º toward the left. Once the carinal cuff of the tube is passed through the vocal cord of patients, the carinal cuff is inflated with 5-8ml of air. The tube is advanced until the tube stops itself at some point along the tracheobronchial tree. And then the carinal cuff is deflated."
51445|NCT03782077|Procedure|Deflation of pneumatic tourniquet|Deflation of pneumatic tourniquet
51446|NCT03782064|Drug|Nivolumab|Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells.
51447|NCT03782064|Biological|DC/myeloma fusions/GM-CSF|The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
51448|NCT03782051|Procedure|combined phacoemulsification and viscocanalostomy|phacoemulsification with viscocanalostomy
51449|NCT03782051|Procedure|combined phacoemulsification and viscocanalostomy and ologen|phacoemulsification with viscocanalostomy with ologen
51450|NCT03782038|Device|MCD|Micro coring skin removal with automated coring device
51451|NCT03782025|Drug|Phytomenadione|Blood samples will be taken before and after intravenously prescribed phytomenadione is given. Phytomenadione will be given independently of this study.
51452|NCT03782012|Behavioral|Supported|Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility
51453|NCT03781999|Dietary Supplement|Actiful|supplement containing 500 mg orange extract and 200 mg pomegranate actives
51454|NCT03781999|Other|Placebo|Maltodextrin
51455|NCT03781986|Drug|APG115 mono-therapy|APG115 at 150mg is taken orally every other day within one hour after food. Cycle length 21 days
51456|NCT03781986|Drug|APG115 + Carboplatin|APG115 at 150mg is taken orally every other day within one hour after food. Carboplatin is given IV at AUC=4.5, Cycle length 21 days
51457|NCT03781986|Other|Part 2|expansion of arm A OR arm B depending on the outcome of Part 1
51458|NCT03781973|Behavioral|Data platform +Quality Performance feedback reports|Teams from each of the participating sites will attend the webinars. Each site will share an example of a QI initiative that they are executing and describe the success and challenges.
51459|NCT03781960|Drug|Abemaciclib|Abemaciclib will be given at a dose of 150mg by mouth twice daily continuously for the duration of trial therapy.
51460|NCT03781960|Drug|Nivolumab|Nivolumab will be administered at a dose of 480mg IV every 28 days. Treatment with nivolumab will begin after an initial 7-day treatment period with abemaciclib monotherapy.
51461|NCT03781947|Drug|teverelix TFA|A single s.c. or i.m. injection of teverelix TFA administered on Day 1
51462|NCT03781934|Drug|MIV-818|Oral Capsules
51463|NCT03781921|Other|No intervention|There is no intervention. Each group will conduct the same tasks and questionnaires and we will compare performances between groups.
51464|NCT03781908|Drug|Silver Nitrate|First, pleural fluid drainage will be done after administration of 5 cc of local anesthetic lidocain1% either by insertion of chest tube (26F or 28F ) or by using ultrasonography. Pleural fluid drainage will be terminated when the patient want to cough to make sure that the pleural cavity is empty, then the sclerosant material will be injected, patients will receive 0.5% silver nitrate diluted in 50 ml distilled water with 10 ml of local anaesthetic lidocaine 1%.
51465|NCT03781908|Device|Indwelling Pleural Catheter|"First , insert the wire into the pleural effusion at approximately the anterior axillary line. A 1-2 cm incision is made over the wire. A chest wall tunnel (5-8 cm in length) is created with a counter incision. The catheter is pulled through the tunnel and out next to the wire. After dilation of the wire tract with a Teflon peel-away sheath, the indwelling catheter is inserted into the chest. The counter incision is closed primarily, and the catheter is secured to the skin medially with a suture."
51466|NCT03781895|Drug|Cholecalciferol|"• Cholecalciferol (40,000IU),~,Microcrystalline Cellulose (58.1 gm), Butylated Hydroxy Toluene ( 0.2mg),Magnesium Stearate (3mg),Gelatin Capsule Shell (1mg)"
51467|NCT03781882|Procedure|Platelet rich plasma infiltration in the wound edges|platelet rich plasma will be injected in the wound edges
51468|NCT03781882|Procedure|Closure of wound without platelet rich plasma infiltration|No infiltration of platelet rich plasma is done
51469|NCT03781869|Drug|Anlotinib Hydrochloride; etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1 and Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle, repeated every 21 days
51470|NCT03781869|Drug|etoposide and cisplatin|etoposide 100mg/m2 from day 1 to day 3, cisplatin 80mg/m2 on day 1, repeated every 21 days
51471|NCT03781856|Behavioral|La Vida Buena Program|The intervention is series of interactive one hour weekly classes over the course of 8 weeks related to child healthy weight, exercise and nutrition. Facilitated by community health workers, the classes are interactive and play-based and designed to engage both the child and accompanying parent or guardian in activities.
51472|NCT03781856|Behavioral|Brief Educational Session|A one hour session about nutrition and physical activity to address obesity facilitated by a community health worker
51473|NCT03781843|Drug|Genicular nerve block with lidocaine|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
51474|NCT03781843|Drug|Genicular nerve block with saline|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
51475|NCT03781843|Drug|Genicular nerve block with dextrose|The color doppler ultrasound-guided genicular nerve block at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves.
51476|NCT03781830|Other|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
51477|NCT03781817|Drug|Intravenous Ketamine|Subject randomized to IV Ketamine arm will receive IN Normal Saline at induction. After 8 minutes subjects will receive IV Ketamine (10 mg/mL) at a dose of 1.5 mg/kg. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
51478|NCT03781817|Drug|Intranasal Ketamine|Subject randomized to IN Ketamine arm will receive IN Ketamine (100 mg/mL) at a dose of 9 mg/kg at induction. After 8 minutes subjects will receive IV Normal Saline. Level of sedation will be scored at the 15 minutes from induction to determine if adequate sedation has been achieved.
51479|NCT03781804|Drug|OPN-375|OPN-375, BID
51480|NCT03781791|Drug|Active Investigational Treatment ENT-01|ENT-01 will be administered in tablet form, once daily.
51481|NCT03781791|Drug|Placebo Treatment|Placebo will be administered in tablet form, once daily.
51482|NCT03781778|Other|Dietary Intervention (resistant starch)|Eat foods with resistant starch
51483|NCT03781778|Other|Dietary Intervention (regular starch)|Eat foods with regular corn starch
51484|NCT03781778|Other|Questionnaire Administration|Ancillary studies
51485|NCT03781765|Drug|Methylphenidate|stimulant medication
51486|NCT03781765|Drug|Atomoxetine|non-stimulant medication
51487|NCT03781752|Drug|Methylphenidate|study to determine dose
51488|NCT03781739|Drug|MANP|single subcutaneous injection of MANP and monitoring of metabolic, cardiovascular and renal parameters
51489|NCT03781726|Drug|glecaprevir/pibrentasvir treatment|combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
51490|NCT03781713|Other|KDIGO|Interventions to prevent renal replacement therapy
51491|NCT03781713|Other|Delta SOFA|interventions to improve SOFA score
51492|NCT03781713|Combination Product|Hypoglycemia|Interventions to prevent new episodes of hypoglycemia in the next 24 hours
51493|NCT03781713|Drug|Drug interaction risk D or X|Intervention in the therapeutic plan in order to avoid adverse drug reactions.
51494|NCT03781713|Drug|Antimicrobial stewardship|Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
51495|NCT03781700|Drug|Prednisolone|Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
51496|NCT03781700|Drug|Placebo Oral Tablet|Placebo tablets with identical appearance to the experimental drug
51500|NCT03781674|Drug|progesterone 400mg|Women received vaginal progesterone suppositories in a dose of 400 mg daily beginning at 18-22 weeks gestational age
51501|NCT03781674|Drug|progesterone 200mg|Women received vaginal progesterone suppositories in a dose of 200 mg daily beginning at 18-22 weeks gestational age
51502|NCT03781674|Drug|placebo to progesterone 200mg|Women received placebo to vaginal progesterone 200 mg suppositories in a dose of (2 tablets) daily beginning at 18-22 weeks gestational age
51503|NCT03781674|Drug|placebo to progesterone 400mg|Women received placebo to vaginal progesterone 400 mg suppositories in a dose of (4 tablets) daily beginning at 18-22 weeks gestational age
51504|NCT03781661|Other|Extended information|The extended information consists out of an information leaflet and a visual go-through of the participants calcium score images. The patients are then given the normal examination result.
51505|NCT03781648|Diagnostic Test|NBI withdrawal method|The newly available second generation of NBI using the 290 system (290-NBI) provides an at least twofold brighter image compared with the previous version
51506|NCT03781635|Drug|bolus of intravenous ketamine|low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.
51507|NCT03781635|Drug|continuous infusion of intravenous ketamine|An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
51508|NCT03781622|Device|WOLF Thrombectomy Device|Mechanical thrombectomy for the neurovasculature
51509|NCT03781609|Behavioral|Roller system group (RG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions on the roller system per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
51510|NCT03781609|Behavioral|Overground group (OG)|They will first receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented. In addition, they will execute 750-1250 wheelchair propulsion repetitions overground per each 1 hour session (2-3 x per week for 4-6 weeks) until they reach approximately 10,000 repetitions (10 sessions). Each session will focus on minimizing the force and frequency of pushes while using longer push strokes during propulsion.
51511|NCT03781609|Behavioral|Placebo - Wheelchair skills group (WSG)|They will receive the standard of care that is often used in rehabilitation: a 30 minute educational session about recommended propulsion techniques with no motor learning principles implemented.
51512|NCT03781596|Diagnostic Test|Retrospective evaluation of endoscopy prior to study drug|Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
51513|NCT03781596|Other|Symptom Survey|Patient will complete symptom survey prior to starting the study drugs.
51514|NCT03781596|Other|Medication Compliance Phone Call|The patient will receive a phone call at 4 weeks to evaluate medication compliance including the number on the inhaler and the number of pills remaining in the container.
51515|NCT03781596|Diagnostic Test|Endoscopy while on study drug|Endoscopy will be performed after 8 weeks of therapy. Endoscopic scoring will be assigned and the histology will be evaluated, including eotaxin 3 staining. The change in eosinophil count and eotaxin staining will be measured.
51516|NCT03781596|Other|Symptom Survey|The patient will complete a symptom survey after 8 weeks on the study drugs, and the change in survey score will be measured.
51517|NCT03781596|Drug|Fluticasone|Participants in the experimental and placebo arms will be given swallowed fluticasone for an 8 week course. Doses determined by age and weight.
51518|NCT03781596|Drug|Omeprazole|The participants in the experimental arm will be given oral omprazole capsules for an 8 week period (along with the swallowed fluticasone). Doses determined by age and weight.
51519|NCT03781596|Drug|Placebo oral capsule|The participants in the placebo arm will be given placebo capsules for an 8 week period (along with the swallowed fluticasone). Number of pills determined by age and weight (to match omeprazole dosing).
51520|NCT03781583|Device|No HMD used|Participants will use their existing mobility skills and strategies to navigate toward a goal. If the participant cannot perform this task, the participant will not be forced to.
51521|NCT03781583|Device|HMD worn but not active|Participants will wear the HMD, but the HMD will not be active. This will test whether or not the HMD physical components obscure the participants remaining vision and reduce the participants ability to navigate toward a goal.
51522|NCT03781583|Device|HMD worn and active|Participants will wear the HMD and the HMD will be active. This will test the HMD function for navigation toward a goal.
51523|NCT03781557|Dietary Supplement|Docosahexaenoic acid|High-concentrated DHA
51524|NCT03781557|Dietary Supplement|Eicosapentaenoic acid|High-concentrated EPA
51525|NCT03781557|Dietary Supplement|Olive oil|Olive Oil softgels
51526|NCT03781544|Drug|Tramadol|A single i.v. infusion of Tramadol (dose: 400mg/100ml) will be administered to the participants (treatment arm).
51527|NCT03781544|Drug|Paracetamol|A single i.v. infusion of Paracetamol (dose: 1g/100ml) will be administered to the participants (control arm).
51528|NCT03781544|Drug|Diclofenac|A single i.v. infusion of Diclofenac (dose: 75mg/100ml) will be administered to the participants (treatment arm).
51529|NCT03781518|Procedure|ridge splitting in group and khoury shell technique in the other group|Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
51530|NCT03781505|Drug|Paracetamol +caudal ropivacaine|Paracetamol + Ropivacaine
51531|NCT03781479|Drug|Amifampridine Phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
51532|NCT03781479|Drug|Placebo Oral Tablet|Placebo Oral Tablet
51533|NCT03781466|Procedure|Cervical cerclage|Cervical cerclage indicated by short cervix ≤25mm
51640|NCT03780634|Drug|PD-1 antibody|200mg intravenously every 3 weeks
51534|NCT03781466|Drug|vaginal progesterone|Daily vaginal progesterone 400mg from diagnosis of short cervix to 36 weeks
51535|NCT03781453|Behavioral|POWERPLAY|"Employees from participating worksites will be invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
51536|NCT03781440|Procedure|Bilateral ESP catheter with lidocaine|All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
51537|NCT03781440|Procedure|Bilateral ESP catheter with saline|All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
51538|NCT03781427|Device|Cardiac resynchronization therapy|Left ventricular pacing
51539|NCT03781414|Biological|CFZ533|Comparison with standard of care immunosuppression
51540|NCT03781414|Drug|Tacrolimus - MMF - corticosteroids|Standard of care immunosupprevive regimen
51541|NCT03781401|Device|Ambulatory blood pressure monitoring|
51542|NCT03781388|Drug|Bupivacaine|Determination of the dose will rely on the outcomes of the preceding 7 patients receiving the same dose, as the number of previous patients to consider is a function of the target dose. Among all patients who received a certain dose, a proportion of successful outcomes will be determined (P(d)); if P(d) <0.90, and at least one of the previous 7 patients who received the same dose had an unsatisfactory outcome, the next patient will receive a pre-determined increment of 0.75 mg of bupivacaine. Alternatively, if P(d) 0.90 and the previous 7 patients who received the same dose had successful outcomes, the next patient will receive a pre-determined decrement of 0.75mg of bupivacaine. Otherwise, the dose will remain the same.
51543|NCT03781375|Drug|Etanercept|Administered by subcutaneous injection twice a week
51544|NCT03781375|Drug|Placebo to Etanerceot|Administered by subcutaneous injection twice a week
51545|NCT03781375|Drug|Methotrexate|Administered orally or subcutaneously once a week at the same dose as prior to study entry
51546|NCT03781362|Drug|CPI-100|CPI-100 will be administered via intravenous infusion on Day 1 of a 14-Day cycle
51547|NCT03781349|Device|MENS|
51548|NCT03781349|Device|TENS|
51549|NCT03781336|Behavioral|Mindfulness-based self care|Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
51550|NCT03781323|Drug|FOLFOX|"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."
51551|NCT03781310|Drug|Tocilizumab|IV Tocilizumab once every 4 weeks at reduced dose according to algorithm.
51552|NCT03781297|Other|Narrative Exposure Therapy|Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
51553|NCT03781297|Other|Genealogical Services|At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
51554|NCT03781284|Diagnostic Test|[18F]-FDG PET/MRI|
51555|NCT03781284|Diagnostic Test|Colonoscopy|
51556|NCT03781271|Device|Electromagnetic Navigation|Electromagnetic navigation is a form of surgical navigation that can be incorporated into the cervical interstitial brachytherapy workflow to improve the current standards of guidance.
51557|NCT03781258|Drug|Warfarin|Anti-thrombotic monotherapy (ASA)—Warfarin withdrawal.
51558|NCT03781245|Other|All the Right Moves for Subcontractors|"All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change."
51559|NCT03781232|Device|Prototype 0.3|Prototype 0.3 is a non-invasive glucose monitoring device using Raman spectroscopy
51560|NCT03781219|Drug|HL-085|HL-085 ( Capsule) is one MEK inhibitor.
51561|NCT03781219|Drug|Vemurafenib|Vemurafenib ( Tablet) is BRAF inhibitor,
51562|NCT03781206|Device|PICO™ 7|PICO™ system (Smith&Nephew Healthcare, Hull, UK) is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips.
51563|NCT03781193|Other|Questionnaires administration|Psychological and quality of life questionnaires
51564|NCT03781193|Other|Five Facet Mindfulness Questionnaire (FFMQ)|FFMQ is a 39-item measure consisting of five subscales (observing, describing, acting with awareness, non-judging of inner experience, and non-reactivity to inner experience).
51565|NCT03781193|Other|Langer Mindfulness Scale (LMS)|The LMS Tis a 21-item questionnaire, assessing four domains associated with mindful thinking: novelty-seeking, engagement, novelty producing, and flexibility.
51566|NCT03781193|Other|Cognitive Flexibility Scale (CFS)|The CFS is 12-item self-report test assessing awareness.
51567|NCT03781193|Other|Life Orientation Test (LOT)|The LOT is a 10-item, self-administered scale assessing generalized expectancies for positive versus negative outcomes.
51568|NCT03781193|Other|Mini Locus of Control test (MLS)|The MLS is a 6-item questionnaire that includes 3 factors : chance, powerful others, and internality.
51569|NCT03781193|Other|Hospital Anxiety and Depression Scale (HADS)|The HADS is a 14-items rated on a four-point Likert scale. The questionnaire was designed to screen for the presence and severity of depression (HADS-D) and anxiety (HADS-A) in people with a physical symptomatology
51570|NCT03781193|Other|Perceived Stress Scale (PSS)|The PSS is 14-item self-report tool commonly used to provide a global measure of perceived stress in daily life.
51571|NCT03781193|Other|Toronto Alexithymia Scale (TAS)|The TSA is a 20-item scale that evaluates the three components of alexithymia: difficulty to identify feelings and distinguish between feelings and bodily sensations of emotional arousal difficulty, describing feelings to others, and a cognitive style that is literal, utilitarian, and externally oriented.
51572|NCT03781167|Drug|ABBV-951|solution for infusion
51573|NCT03781154|Behavioral|1:1 Training|Patients will exercise with a personal trainer for 60 minutes, twice a week. Four social-cognitive theory-based discussion sessions with their trainer will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
51574|NCT03781154|Behavioral|Group Exercise|Patients will exercise in a group of 5 to 15 for 60 minutes, twice a week. Four social-cognitive theory-based discussion sessions with the group, and group exercise instructor will be held throughout the course of the intervention, lasting 30 to 60 minutes. The goal of these sessions is to enhance long-term physical activity behavior change.
51575|NCT03781141|Procedure|Wound closure|Comparison of two wound closures
51576|NCT03781128|Drug|Lysergic Acid Diethylamide|100 µg, per os, 3 times within 3 weeks
51577|NCT03781128|Drug|Placebo|placebo in an identical-looking vial as LSD, per os, 3 times within 3 weeks
51578|NCT03781115|Drug|Ziprasidone|anti-psychotic drug proposed for use as rapid diagnostic tool
51579|NCT03781115|Drug|Olanzapine|anti-psychotic drug proposed for use as rapid diagnostic tool
51580|NCT03781115|Drug|Placebo Comparator|A non drug oral placebo capsule will be given as a control
51581|NCT03781102|Behavioral|16-Week Diabetes Prevention Program for Mothers and Children|The 16-week intervention is focused on ways to modify behaviors associated with the pathogenesis of Type 2 Diabetes in youth, while engaging participants in fun, active, and interactive food demonstrations, energy balance, and physical activities appropriate for all the family. Weekly sessions will consist of: (1) physical activity upon arrival; (2) small group discussions; (3) hands-on food preparation and tasting opportunities; (4) low- to no-cost fun family physical activities; (5) energy balance activities (e.g. label reading) to increase foundational knowledge; and, (6) opportunities to set new weekly goals.
51582|NCT03781089|Drug|Patiromer Oral Powder Product|Patients randomized to the patiromer arm will initiate on 8.4 g/day (one pack) given once a day with breakfast or lunch (in place of the full dose of phosphate binder), to start at the end of Week 0. The patiromer dose will be titrated based on serum potassium concentrations drawn on HD1 of Weeks 1, 2, and 3. Patiromer will be increased by 8.4 g/day if K ≥ 5.1 meq/L, decreased by 8.4 g/day if K < 4.0 mEq/L, and patiromer will be discontinued if K < 3.5 mEq/L. Patients randomized to the usual care arm will undergo monitoring with laboratory measurements as outlined in the study protocol
51583|NCT03781076|Behavioral|Sleep Intervention|The study therapist will outline the biopsychosocial model of mTBI recovery, highlighting the shift from biological injury to behavior (especially sleep behavior) as key driver of symptoms. The intervention will then apply well-established strategies from the pediatric psychology and insomnia literatures, encouraging conjoint problem-solving by parent and youth with the shared goal of maximizing nocturnal sleep. These include: pre-planning, problem-solving, development of a positive routine, commitment to sleep-promoting behaviors, self-monitoring, and positive reinforcement. The therapist will also teach a brief, self-guided pre-sleep relaxation exercise that has been used in insomnia treatment to maximize the benefit of additional sleep opportunity.
51584|NCT03781063|Drug|Lasofoxifene|Estrogen receptor antagonist antineoplastic agent
51585|NCT03781063|Drug|Fulvestrant|Estrogen receptor antagonist antineoplastic agent
51586|NCT03781050|Drug|Rapamycin|"For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months~For adults: rapamycin, 2 mg a day, orally, for at least 6 months"
51587|NCT03781037|Behavioral|GIVE Module|The GIVE Module is a brief cognitive behavioral intervention targeting youths' beliefs that they are a burden or drain on others. It consists of two sessions embedded within a larger CBT protocol for anxiety or depression.
51588|NCT03781024|Combination Product|Footwash|footbath/footwash can help cleanse the wound, remove dead tissue, increase circulation and puts the wound in direct contact with medication to promote faster healing.
51589|NCT03781011|Behavioral|Low carnitine/choline diet habit|Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.
51590|NCT03780998|Drug|Life7|Life7 will used on the perianal skin with finger tips
51591|NCT03780985|Procedure|Intrauterine device insertion|Post-placental insertion of intrauterine device during Cesarean section
51592|NCT03780985|Procedure|Cesarean section|to delivery of the fetus
51593|NCT03780985|Procedure|Suture|to fix the intrauterine device
51594|NCT03780972|Drug|ONL1204|Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
51595|NCT03780972|Procedure|Intravitreal Injection|Injection of study drug into the eye
51596|NCT03780972|Procedure|Collection of ocular fluids|vitreous and aqueous fluid collection by a tap and during vitrectomy
51597|NCT03780959|Drug|Etanercept|Administered twice weekly by subcutaneous injection
51598|NCT03780959|Drug|Placebo|Administered twice weekly by subcutaneous injection
51599|NCT03780946|Procedure|Magnetic anastomosis for pancreaticojejunostomy|Magnetic anastomosis for pancreaticojejunostomy
51600|NCT03780946|Procedure|Traditional hand-sewn anastomosis|Traditional manual anastomosis for pancreaticojejunostomy
51601|NCT03780933|Dietary Supplement|vitamin c|vitamin c IV 10 G
51641|NCT03780634|Drug|Sorafenib|400 mg Bid Po
89045|NCT03491189|Device|Lag screw fixation|surgical fixation
51602|NCT03780920|Procedure|manual therapy/osteopathy|"In this group, children will benefit from early osteopathic treatment over a period ranging from the third day to 4 months. The number of sessions will not be fixed, on average, 3 sessions will be carried out during this period at the University Hospital of Montpellier.~The duration of the session will be between 20 minutes to 30 or even 40 minutes"
51603|NCT03780907|Drug|E2007|1 mg of E2007 was administered by mouth once daily.
51604|NCT03780907|Drug|E2007|2 mg of E2007 was administered by mouth once daily.
51605|NCT03780907|Drug|Placebo|Placebo once daily of oral tablet formulation to be taken in the morning, one hour before breakfast, with a glass of water.
51606|NCT03780894|Drug|Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]|Administration of 2 mg of FC together with RBC and TXA
51607|NCT03780894|Biological|Red blood cells concentrate|Administration of 2 red blood cells concentrates together with FC and TXA
51608|NCT03780894|Drug|Tranexamic Acid|Administration of 1g of TXA together with FC and RBC
51609|NCT03780881|Behavioral|Expectation confirmation|Participants receive manipulated feedback indicating that their performance was above average in the test they had previously worked on. This feedback is intended to confirm the previously induced positive expectations of their own performance.
51610|NCT03780881|Behavioral|Expectation disconfirmation|Participants receive manipulated feedback indicating that their performance was below average in the test they had previously worked on. This feedback is intended to negatively disconfirm the previously induced positive expectations of their own performance.
51611|NCT03780868|Procedure|external dacryocystorhinostomy|external DCR under general anesthesia with standard sterilization procedures.
51612|NCT03780868|Procedure|canalicular silicone intubation with MMC|canalicular silicone intubation with MMC under general anesthesia with standard sterilization procedures.
51613|NCT03780855|Device|nerve scaffold|It is a new kind of nerve scaffold with the microstructure of longitudinally oriented microchannels. It's made of collagen as the main raw material.
51614|NCT03780842|Device|NAVA level|"A titration protocol will be used for changing NAVA levels. The NAVA level will be reduced to 0,5 cmH2O/µV for 3 minutes as a starting point. Limit peak pressure will be set to 35cmH2O (i.e. according to the standard manufacturer's settings) the maximum pressure that can be delivered to the patient is cut off at 30cmH2O). Other ventilator settings will be left unchanged and are as clinically indicated. Ventilator settings will be according to our standard of care and as following: PEEP between 4 and 7 mmHg, apnea time 2-5 sec, back-up ventilation with a pressure above PEEP between 5 and 15 mmHg and a frequency between 30 and 50 per minute.~Starting from a NAVA level of 0,5 cmH20/µV the level will be increased by 0,5 cmH2O/µV every 3 minutes until reaching a maximum NAVA level of 4,0 cmH2O/µV."
51615|NCT03780829|Behavioral|hypoxia|intermittent cycles of normoxia-hypoxia
51616|NCT03780829|Behavioral|sham hypoxia|intermittent cycles of sham hypoxia
51617|NCT03780829|Drug|D-cycloserine|NMDA agonist treatment
51618|NCT03780829|Drug|sham-NMDA agonist|sham-NMDA agonist treatment
51619|NCT03780829|Behavioral|exercise training|bimanual massed practice training
51620|NCT03780816|Other|Observation of clinician-patient interactions and interviews|Clinical interactions between cancer patients and clinicians will be observed and hand-written field notes recorded and later transcribed. Semi-structured interviews with clinicians, patients, caregivers, and other informants will take place following initial observation.
51621|NCT03780803|Other|home cardiac rehabilitation and respiratory rehabilitation|
51622|NCT03780790|Drug|Bupivacaine|% 0,25
51623|NCT03780777|Behavioral|Home Hazard Removal|Removal of home barriers or hazards
51624|NCT03780764|Other|"A Pre-adjusted edgewise brackets: 3M Gemini Unitek, 0.022 Roth prescription brackets"|"A pre-adjusted edgewise fixed appliance (3M Gemini Unitek, 0.022 Roth prescription brackets) on one side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and tied with elastomers (figure of 8)."
51625|NCT03780764|Other|"Self- ligating brackets: Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets"|"Self-ligating brackets (Unitek™ Gemini SL Self-Ligating Brackets, 0.022 Roth prescription brackets) on the other side of lower arch. The standardized bonding technique was applied according to the manufacturer's instructions. Teeth alignment was initiated using round 0.016 NiTi arch wire until 0.016X0.022 NiTi was reached. The NiTi arch wires were placed into brackets slots and held in place by bracket's gate in the self-ligating brackets side."
51626|NCT03780751|Behavioral|Cognitive-behavioral treatment|COPE-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and cognitive-behavioral interventions (e.g., thought diaries, challenging of maladaptive thought patterns, behavioral analysis). Participants are encouraged to practice exercises between sessions.
51627|NCT03780751|Behavioral|Mindfulness-based treatment|MIND-program of 8 sessions (+ 1 booster session) of guided Internet-based treatment including psychoeducation, sexual education, guided masturbation, sensate focus and mindfulness-based exercises (e.g., breathing meditation, body scan, sitting meditation).
51631|NCT03780712|Other|Non applicable|No intervention as it is an observational study
51632|NCT03780699|Procedure|Diagnostic hysteroscopic examination|The hysteroscopic criteria of the cesarean scar defect will be observed with comment on different niche features
51633|NCT03780686|Drug|Norepinephrine, dopamine|drugs to decrease bleeding
51634|NCT03780673|Drug|Simvastatin|Simvastatin 20 mg/day for 12 months
51635|NCT03780673|Drug|Rifaximin|Rifaximin 400/8 hours for 12 months
51636|NCT03780673|Drug|Placebo of Simvastatin|Placebo of Simvastatin once a day for 12 months
51637|NCT03780673|Drug|Placebo of Rifaximin|Placebo of Rifaximin/8 hours for 12 months
51638|NCT03780647|Other|questionnaire|Assessment of the impairment at work by a specific auto- questionnaire given after echo-Doppler that confirm the diagnosis
51639|NCT03780634|Procedure|HAIC|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks
51642|NCT03780621|Dietary Supplement|Andrographis and Withania|Combination of Andrographis paniculata and Withania somnifera
51643|NCT03780621|Dietary Supplement|Placebo|Visually identical placebo capsule
51644|NCT03780608|Drug|AZD6738|AZD6738 will be administered at 240 mg twice daily on days 1 to 7 in Cycle 0 (lead-in period) and therafter at 240 mg BD on days 22 to 28 in a 28-day cycle.
51645|NCT03780608|Drug|Durvalumab|. Durvalumab will be administered at 1500 mg every 4 weeks from cycle 1 day 1.
51646|NCT03780595|Drug|Passiflora incarnata|Passiflora pills administration up to 6 pills per day
51647|NCT03780595|Drug|Control|Control pills administration up to 6 pills per day
51648|NCT03780582|Behavioral|AI-human interaction|Exploring what kinds of AI-human interaction improve radiologists detection accuracy.
51649|NCT03780569|Device|NovoTTF-200A|Patients receive continuous TTFields treatment using the NovoTTF-200A device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the scalp. The treatment enables the patient to maintain regular daily routine.
51650|NCT03780569|Radiation|Radiotherapy|60Gy given in 30 2Gy fractions concomitant to temozolomide
51651|NCT03780569|Drug|Temozolomide|"Temozolomide(TMZ) will be administered at 75 mg/m^2 concomitant to radiotherapy(RT) and NovoTTF-200A.~Maintenance treatment is to begin about 4 weeks after the end of TMZ/RT/NovoTTF-200A. TMZ is administered at the conventional dosing regimen for 5 days, every 28 days (i.e. 5 days of therapy, 23 days of rest). Cycle 1 is to be given at a dose of 150 mg/m^2 p.o. daily x 5 days, dose to be escalated to 200 mg/m^2 in the absence of toxicity."
51652|NCT03780556|Drug|Lornoxicam and mepridine|compare the effect of each to control pain
51653|NCT03780543|Drug|ABI-H0731|Participants will receive 300 mg QD of ABI-H0731 tablets orally.
51654|NCT03780543|Drug|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet QD orally as per approved package insert.
51655|NCT03780530|Procedure|subcuticular suturing|Those undergoing Subcuticular suturing of perineal skin using 910 polyglactin vicryl No 2/0 (EGYCRYL®).
51656|NCT03780530|Procedure|Surgical glue|Those undergoing perineal skin closure using adhesive glue n-butyl-2-cyanoacrylate (Histoacryl®).
51657|NCT03780530|Procedure|adhesive steri-strip tape|Those undergoing closure of perineal skin via Adhesive surgical water-resistant tape application. (3M® Transpore™ Surgical Tapes).
51658|NCT03780517|Drug|BOS172738|Oral capsules
51659|NCT03780491|Other|Cost Discussion|The second group of 50 patients will be the intervention group where the providers will have a discussion of cost emphasizing five points: 1) Cancer care is expensive and it is normal to be concerned about cost. 2) We will recommend treatments for your cancer based on what we think gives you the best chance of doing well, not based on the cost of the treatment. 3) Because of how complex our healthcare system is, it is very hard for your doctors to know what your costs will be, but we will do our best to give you some general information. 4) We have resources available to help you get more specific information so that you can plan appropriately. 5) Do you have any specific concerns about cost that you'd like to share with me?
51660|NCT03780478|Drug|Nerve block|0.25% bupivacaine with epinephrine (1:100k), with total volume of 2mL
51661|NCT03780478|Drug|Placebo Saline Injection|Saline injection, total volume 2ml
51662|NCT03780465|Drug|Oral idronoxil suspension|Idronoxil powder up to 150 ml ORA-BLEND® flavoured syrup
51663|NCT03780465|Drug|NOX66 (A)|Idronoxil formulated in suppository base A
51664|NCT03780465|Drug|NOX66 (B)|Idronoxil formulated in suppository base B
51665|NCT03780452|Device|novel dynamic compression intramedullary nail|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
51666|NCT03780426|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability (Oliviero et al., 2011; Oliviero et al., 2015; Dileone et al., 2018). Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the left or right motor cortex, using a tSMS helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
51667|NCT03780426|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain) of motor cortex contralateral to the stimulated hemisphere.
51668|NCT03780413|Behavioral|CPS treatment|
51669|NCT03780413|Behavioral|Control (TAU)|
51670|NCT03780400|Behavioral|Osteoarthritis Physical Activity Care Pathway|The intervention includes brief physical activity (PA) counseling delivered via phone by a PA Counselor trained in relevant aspects of PA and motivational interviewing. During the initial call, the PA counselor will assess readiness for change in PA and will utilize appropriate PA counseling components to assess participant's PA preferences/needs, as well as referral to PA resources and goal setting. Approximately two weeks after the initial call, the PA counselor will contact participants to check in on whether they have successfully connected with PA programs or resources discussed, review progress toward PA goals and set new goals. Participants will be provided with linkage to PA programs and resources to include: self-directed, group classes/community, physical therapy and other clinical/supervised programs. Three months after the initial call, the PA counselor will call participants to assess PA and stage of change using appropriate PA counseling components and goal setting.
51671|NCT03780387|Biological|Felis Catus|Inhalation of Felis Catus allergen in subjects allergic to Felis Catus
51672|NCT03780374|Device|Phonak Audéo L2M with Sound Processing Principle 1|Compensation of a hearing loss with Sound Processing Principle 1.
51673|NCT03780374|Device|Phonak Audéo L2M with Sound Processing Principle 2|Compensation of a hearing loss with Sound Processing Principle 2.
51674|NCT03780374|Device|Phonak Audéo L2M with Sound Processing Principle 3|Compensation of a hearing loss with Sound Processing Principle 3.
51675|NCT03780361|Drug|Aflibercept Injection|Total 5 times of monthly intravitreal aflibercept injections will be done.
51676|NCT03780348|Diagnostic Test|New Method|A 'new' WHZ tool will be used to assess children.
51677|NCT03780348|Diagnostic Test|Existing Method|'Existing' WHZ tools will be used to assess children
89046|NCT03491189|Device|Helical blade fixation|surgical fixation
51678|NCT03780335|Diagnostic Test|Computation of quantitative flow ratio|Computation of QFR was performed offline, using a prototype software package (QAngio XA 3D prototype, Medis Medical Imaging System, Leiden, the Netherlands). In the first step, 2 diagnostic angiographic projections before PCI, at least 25° apart, were selected and 3D reconstruction of the interrogated vessel without its side branches was performed. Then, the software computed the QFR.
51679|NCT03780322|Device|Armeo Spring Pediatric|"Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions."
51680|NCT03780322|Other|Conventional physical and occupational therapy|"Conventional therapy will combine physical and occupational therapy, including the following activities:~Upper extremity weight bearing exercises.~Approximation techniques on wrist, elbow and shoulder.~Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~Scapulothoracic joint mobilization.~Stretching of shoulder abductors and external rotators.~Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions."
51681|NCT03780309|Behavioral|Exercise Self-Monitoring|Participants engaged in exercise self-monitoring utilizing a traditional calendar recording method and heart rate monitor.
51682|NCT03780309|Behavioral|Blood Pressure Self-Monitoring|Participants engaged in blood pressure self-monitoring by measuring blood pressure twice daily and before and after exercise.
51683|NCT03780296|Device|Real-time action observation with augmented Kinect|Participants will receive 30 minutes of the augmented kinect software in real-time undergoing an exercise protocol involving seated upper extremity exercises, seated lower extremity exercises and standing upper extremity exercises.
51684|NCT03780283|Drug|Anlotinib Hydrochloride|Participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity
51685|NCT03780270|Device|Fluoride Varnish|Fluor Protector S (Ivoclar, 7'700 ppm F-)
51686|NCT03780270|Device|Curodont Repair|P11-4 (monomeric peptide) - for professional use
51687|NCT03780270|Device|Curodont Protect|Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
51688|NCT03780257|Drug|QR-421a|RNA antisense oligonucleotide for intravitreal injection
51689|NCT03780257|Other|Sham-procedure|Sham-procedure (no experimental drug administered)
51690|NCT03780244|Device|Sculptra Aesthetic 8ml and Lidocaine|Treatment of nasolabial folds
51691|NCT03780244|Device|Sculptra Aesthetic 5ml|Treatment of nasolabial folds
51692|NCT03780231|Other|non-ischemic scar|"non-ischemic LGE with no underlying labelled cardiomyopathy is detected on CMR"
51693|NCT03780218|Other|Respiratory function|Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength
51694|NCT03780205|Other|Prescription glasses for bilateral amblyopia|Correction of refractive error with prescription glasses both eyes
51695|NCT03780205|Other|Prescription glasses for unilateral amblyopia|Correction of asymmetric refractive errors with lenses
51696|NCT03780192|Device|Inspiron Sirolimus Eluting Stent|Bifurcation treatment using provisional stent technique
51697|NCT03780179|Biological|MMRvaxpro|MMRvaxpro vaccine
51698|NCT03780179|Biological|Placebo|Placebo
51699|NCT03780166|Drug|Parsaclisib|Parsaclisib administered orally once daily at the cohort-specified dose level.
51700|NCT03780153|Other|No intervention|Observation study. No intervention
51701|NCT03780140|Drug|Cefiderocol|Cefiderocol for intravenous infusion
51702|NCT03780127|Drug|Fenfluramine Hydrochloride|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with KD.
51703|NCT03780101|Diagnostic Test|Multi-parametric renal MRI|Multi-parametric functional magnetic resonance imaging of a transplant kidney including sequences for T1, T2, diffusion-weighted imaging, diffusion tensor imaging and arterial spin labelling.
51704|NCT03780088|Behavioral|mTranS-C|mobile health
51705|NCT03780075|Drug|1.11GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.11GBq (30 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
51706|NCT03780075|Drug|1.85GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
51707|NCT03780075|Drug|3.70GBq of 177Lu-EB-PSMA-617|Patients were intravenous injected with the dose about 3.70GBq (100 mCi) of 177Lu-EB-PSMA-617 every 8 weeks (±1 week) for a maximum of 3 cycles.
51708|NCT03780062|Biological|S100B protein dosing|Patients under antiplatelet therapy and who have a minor traumatic brain injury will have a blood samples with protein S100B dosage on arrival to the emergency room and after they will have a brain scanner between 4 and 8 hours after the trauma to analyse the negative predictive value with a treshold of 0.105 μg/L
51709|NCT03780049|Procedure|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
51710|NCT03780049|Drug|H101|Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC
51711|NCT03780049|Drug|Placebos|Patients receive normal saline 10ml in each session of HAIC
51712|NCT03780036|Device|Megaprosthetic Implants the Next Generation (MING)|Use of either porous of porous+hydroxyapathite collars.
51713|NCT03780023|Other|Questionnaire|All patients will receive three questionnaires at four different time points during their radiation treatment. The time points are 1) before treatment, 2) during the first week of treatment, 3) at the end of treatment (6-8 weeks after treatment begins), and 4) one year after treatment ends.
51714|NCT03780010|Drug|TRC105|Dose-finding study of TRC105 in combination with standard dose bevacizumab and paclitaxel/carboplatin in treatment-naive patients with stage IV non-squamous NSCLC.
51715|NCT03779997|Behavioral|Video-based DOT Application|Participants will be asked to record daily videos of themselves confirming daily ingestion of their buprenorphine. Clinical staff (i.e. physicians, nurses and medical assistants) of patients enrolled in the intervention group will be given training and the opportunity to review medication taking videos.
52689|NCT03772392|Procedure|HPB resection|:Liver and Pancreas surgery - Compliance with ERAS protocol
51716|NCT03779971|Other|Control Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain no pulses, legumes, or beans.
51717|NCT03779971|Other|Lentil Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain lentils.
51718|NCT03779971|Other|Chickpea Containing Diet|Participants will consume a diet prepared and provided by the USDA Nutrition Center. The diet will contain chickpeas.
51719|NCT03779958|Other|Mobile App|a mobile app that demonstrates hand therapy exercises
51720|NCT03779945|Biological|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
51721|NCT03779945|Procedure|posteriolateral lumbar fusion only|performing posteriolateral lumbar fusion without using platelet rich plasma
51722|NCT03779919|Device|extracorporeal shock wave|Extracorporeal shock wave therapy uses acoustic waves to fragment calcific deposits. Variables of the settings include dose (low or high energy), duration (impulses), and the interval of administration.
51723|NCT03779906|Drug|Isovue|Isovue will be given to all subjects per the standard of clinical care.
51724|NCT03779893|Combination Product|BioCoat® by Premier®.|Bioactive pits and fissure sealant
51725|NCT03779893|Combination Product|3M™ Clinpro™ Sealant.|conventional pits and fissure sealant
51726|NCT03779867|Behavioral|Exercise Intervention|Undergo acute exercise
51727|NCT03779867|Other|Resting|Seated resting
51728|NCT03779867|Other|Biomarker Analysis|Correlative studies
51729|NCT03779867|Other|Questionnaire Administration|Ancillary studies
51730|NCT03779854|Radiation|Total-Body Irradiation|Undergo TBI
51731|NCT03779854|Drug|Thiotepa|Given IV
51732|NCT03779854|Drug|Fludarabine|Given IV
51733|NCT03779854|Drug|Cyclophosphamide|Given IV
51734|NCT03779854|Drug|Busulfan|Given IV
51735|NCT03779854|Biological|Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM)|Undergo transplantation with unmanipulated T cell replete BM
51736|NCT03779854|Drug|Tacrolimus|Given IV
51737|NCT03779854|Drug|Methotrexate|Given IV
51738|NCT03779854|Biological|Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)|Undergo transplantation with naïve T cell-depleted PBSC
51739|NCT03779841|Drug|AGN-151607|Injections will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
51740|NCT03779841|Drug|Placebo|Injections of placebo will be made into each 1 of 5 fat pads. The total injection volume into each fat pad will be 1 mL. One-time treatment.
51741|NCT03779828|Device|HOME LINK|Telemonitoring system which include web platform and connected devices.
51742|NCT03779815|Drug|[18F]Florbetaben|"Drug: [18F]Florbetaben~[18F]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~Other name: Neuraceq~Amount: 300 MBq ± 20% bolus, 10mL intravenously"
51743|NCT03779802|Other|Device programming of ABBOTT CRT pacemaker or defibrillator|Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session Comparison of the acute hemodynamic effect of three modes of stimulation in ABBOTT CRT devices (Biventricular, SyncAV and MPP modes) by using the Finapress® NOVA method to assess the highest systolic blood pressure (SBP) during the programming session.
51744|NCT03779789|Drug|Vortioxetine|"Antidepressant classified under the category other antidepressants according to the ATC/DDD index [ATC=Anatomical Therapeutic Chemical Classification System; DDD=Defined Daily Dose]. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-20 mg/day)."
51745|NCT03779789|Drug|Sertraline|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 50-200 mg/day)."
51746|NCT03779789|Drug|citalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 10-20 mg/day)."
51747|NCT03779789|Drug|Escitalopram|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 5-10 mg/day)."
51748|NCT03779789|Drug|Paroxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-40 mg/day)."
51749|NCT03779789|Drug|Fluoxetine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 20-60 mg/day)."
51750|NCT03779789|Drug|Fluvoxamine|"Antidepressant classified under the category Selective serotonin reuptake inhibitors according to the ATC/DDD index. The dose will be flexible according to the clinical evaluation and in accordance with doses reported for elderly in the Summaries of Product Characteristics (available: https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci/home) (namely: 100-300 mg/day)."
51751|NCT03779776|Other|Vitamin AD|In Vitamin AD group, the very preterm infants will receive the daily vitamin AD with vitamin A at2000 IU/day and vitamin D at 700 IU/day in drop form added to their enteral feeds when minimal feeding is introduced, and continue to 28 days or discharge. In this group ,the patient also will receive standard intravenous multivitamin preparation (1 mL/kg/d, containing VA 230 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
51752|NCT03779776|Other|Control|In this group ,the patient will only receive standard intravenous multivitamin preparation (1 mL/kg/d, containing VA 230 IU/kg/d) within daily on parenteral nutrition until fed 120ml/kg.
51753|NCT03779750|Diagnostic Test|s.creatinine|All ESRD patients on regular hemodialysis in dialysis unit of Assiut university Hospital duing one year. will be subjected to 3- Routine investigations including complete blood picture ,blood urea , s.creatinine,urine analysis , calcium, phosphorus, and parathyroid hormone.
51754|NCT03779737|Behavioral|Muscular Resistance training|
51755|NCT03779737|Behavioral|Cardiorespiratory training|
51756|NCT03779737|Behavioral|Habitual training|
51757|NCT03779724|Other|exercises|
51758|NCT03779711|Biological|Autologous (self) mononuclear cells derived from umbilical cord blood|The investigational product will be delivered into the right myocardium via sub-epicardial injections of 0.1 mL per kg body weight to achieve the target dose of 1-3 million TNC per kg body weight.at the time of Stage II surgical repair.
51759|NCT03779711|Procedure|Stage II Surgical repair|This operation usually is performed about six months after Stage I surgery to divert half of the blood to the lungs when circulation through the lungs no longer needs as much pressure from the ventricle. The shunt to the pulmonary arteries is disconnected and the right pulmonary artery is connected directly to the superior vena cava, the vein that brings deoxygenated blood from the upper part of the body to the heart. This sends half of the deoxygenated blood directly to the lungs without going through the ventricle.
51760|NCT03779698|Other|BiodentineTM|In the experimental group, BiodentineTM was used following the manufacturer's recommendations. The whole pulp chamber was entirely filled with BiodentineTM until the occlusal surface. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
51761|NCT03779698|Drug|Formocresol|In control group, a sterile cotton pellet moistened with 1:5 concentration formocresol then blotted to remove excess was placed for 5 minutes on the pulp stumps and then the pulps were covered with zinc oxide-eugenol (IRM; Dentsply, Milford, DE) dressing. Follow-up was done for all children clinically at 3, 6 and 12 months and radiographically at 6 and 12 months.
51762|NCT03779685|Procedure|General anesthesia|Sevoflurane and morphine
51763|NCT03779685|Procedure|Regional anesthesia|Paravertebral block
51764|NCT03779672|Drug|Memantine Hydrochloride 10 mg|"Week #1: 5 mg id (am), 1 caps~Week #2: 5 mg bid (am and pm), 2 caps~Weeks #3-6: 5 mg am & 2x 5 mg pm, 3 caps~Weeks #7-8: Washout~Placebo~Week #9: id (am), 1 caps~Week #10: bid (am and pm), 2 caps~Weeks #11-14: 1 caps am & 2 caps pm, 3 caps~OR Placebo~Week #1: id (am), 1 caps~Week #2: bid (am and pm), 2 caps~Weeks #3-6: 1 caps am & 2 caps pm, 3 caps~Weeks #7-8: Washout~Memantine~Week #9: 5 mg id (am), 1 caps~Week #10: 5 mg bid (am and pm), 2 caps~Weeks #11-14: 5 mg am & 2x 5 mg pm, 3 caps"
51765|NCT03779659|Device|TENS device|At the time of local anesthetic application the TENS device will be activated and placed on the buccal and lingual alveolar mucosa adjacent to the tooth receiving the restorative treatment using the pad applicator. The tip of the device with the electrodes are placed in a vertical up and down motion for approximately ten seconds. Following this, the level of pain and anxiety are measured using the Wong Baker Scale and Visual Analog Scale. The TENS device is used for achieving localized pain relief at the site of local anesthetic injection prior to injecting the anesthetic agent (such as lidocaine or articaine). Following this, once the clinician ensures that the patient is pain free then local anesthetic injection is given and following that the dental procedures are conducted.
51766|NCT03779659|Drug|Topical anesthetic gel|The local anesthetic gel is typically used for achieving localized pain relief at the site of local anesthetic injection and this is part of standard care that is followed prior to dental procedures. Following this, the level of pain and anxiety are measured using the Wong Baker Scale and Visual Analog Scale. Once the clinician ensures that the patient is pain free then local anesthetic injection is given and following that the dental procedures are conducted.
51767|NCT03779646|Drug|Bisoprolol Fumarate|Bisoprolol was initiated at a dose of 1.25 mg every 24hr. At subsequent biweekly visits, the bisoprolol dose was increased 1.25mg progressively until a daily dose of 0.2mg/kg or the maximum tolerated dose (The rest heart rate <75bpm and systolic blood pressure <90mmHg) is achieved. If the participant feel dizziness or the rest heart rate below 60 bpm or systolic blood pressure below 85mmHg or there is any new onset contraindication to bisoprolol, the doctor will decide to return back to the previous dose or stop bisoprolol. Each time the dose is increased, the medication is administered in an outpatient clinic setting, with assessment of the participant's heart rate, blood pressure, symptoms and ECG. Once reach the target dose, the patients will be followed up every 8 weeks in an face-to-face or video visit. After 12 months , the participants will repeat cardiac MR besides heart rate, blood pressure, symptoms, ECG and brain natriuretic peptide(BNP), echocardiography records.
51768|NCT03779633|Drug|Linoladiol Estradiol|"Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
51769|NCT03779633|Other|Placebo vaginal cream|"Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks"
51770|NCT03779620|Device|Ultrasound treatment of Calcified aortic valve|Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacement
51771|NCT03779607|Other|Celtra Press|"new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing."
51828|NCT03779087|Drug|10d TL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.
51772|NCT03779594|Drug|Acetazolamide|Patients will be assign and treated by acetazolamide from time of allocation until surgery (2-6 weeks after treatment initiation). The maximal dose of acetazolamide will be the same dose used to treat glaucoma, considering similarity of patients' characteristics, such as age and polypharmacy. We will start at a low dose of 250 mg once a day, and increase it slowly to a maximal dose of 500 mg twice a day. Dose will be individualized according to side-effects and tolerability. Renal and liver function tests will be performed before initiation of treatment, and will be examined again two weeks after treatment had begun.
51773|NCT03779581|Other|De-Rotation breathing Exercises|De-rotation Breathing Exercises are the group of spinal extension, lateral spinal flexion and rotational exercises performed in synchrony with deep breathing. Exercises are performed in a sitting position with feet firmly placed on the ground. The therapist will stand behind the patient with a medicine ball or a small Swiss ball for the patient to receive while the patient rotates and laterally bend the trunk towards the convexity of scoliosis curvature. The patient is instructed to breathe in deeply during lateral bend and rotation in order to maximally expand the chest wall. Expiration involves relaxation while returning to the neutral position. Later, patients are instructed to extend their back along with former maneuver.
51774|NCT03779568|Other|Dose adjustment of bupivacaine|Spinal bupivacaine dose will be adjusted according to previous patient experience.
51775|NCT03779555|Other|Medication Event Monitoring System|-Microchipped bottle cap
51776|NCT03779542|Procedure|cataract surgery|phacoemulsification and intraocular lens implantation
51777|NCT03779529|Dietary Supplement|Olive oil|Intervention includes dosage and amount of biophenols administered daily
51778|NCT03779516|Other|Saline|Effect of saline on postoperative sore throat
51779|NCT03779516|Other|Lidocaine|Effect of nebulized lidocaine on postoperative sore throat
51780|NCT03779503|Device|midafilcon A|midafilcon A 1 day daily disposable contact lens
51781|NCT03779503|Device|somofilcon A|somofilcon A 1 day daily disposable contact lens
51782|NCT03779490|Device|Transcatheter Tricuspid Valve Repair|Transcatheter Tricuspid Valve Repair with Edwards Cardioband TR
51783|NCT03779477|Behavioral|Coping with Stress Course|The Coping with Stress Program is a group program, which is developed by Clarke and Lewinson (1995) for the prevention of depression in high-risk adolescents. It is based on cognitive-behavioral therapy principles and contains psychoeducation and cognitive-behavioral therapy interventions. There are handbooks available for the group leader of the program and the participating adolescents. In the handbook developed for the group leader, there is detailed information about the objective of each session and the implemented interventions. The adolescents will find lists organized for the fulfillment of the tasks in the handbook prepared for them. The handbooks of the program were translated in Turkish and experts were consulted for their validity.
51784|NCT03779464|Drug|S1 or Gemcitabine|Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area < 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area >1.5 m²; D1-14, q3w)
51785|NCT03779451|Drug|17-OHPC|received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 26-28 week and up to 37-weeks' gestation or delivery.
51786|NCT03779451|Drug|vaginal progesterone|vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
51787|NCT03779438|Drug|17-OHPC|patients received weekly 250 mg 17 alpha-hydroxyprogesterone-caproate (cidolut depot) intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
51788|NCT03779438|Drug|placebo to 17-OHPC|patients received weekly placebo to17 alpha-hydroxyprogesterone-caproate intramuscular injections started at 24-26 week and up to 37-weeks' gestation or delivery
51789|NCT03779425|Other|Virtual Reality Physical Therapy|Participants will undergo a non-weight bearing knee range of motion virtual reality physical therapy session.
51790|NCT03779412|Behavioral|The Happiness Trap|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
51791|NCT03779412|Behavioral|A Mindfulness-Based Stress Reduction Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
51792|NCT03779399|Other|Assessment of percentage of Treg, Th17, NKT and serum level of HE4, CA125 and ROMA.|Treg, Th17, NKT cells in peripheral blood and ovarian tissue and serum level of HE4, CA125 and ROMA.
51793|NCT03779386|Other|music|music during labor and delivery
51794|NCT03779373|Other|Use of a decision support system on the EV1000 monitor (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical deicsion support system for fluid administration called AFM (assisted fluid management)
51795|NCT03779360|Drug|Erythromycin 4% topical gel formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.
51796|NCT03779360|Drug|Clindamycin 1% lotion formulation:|7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.
51797|NCT03779360|Drug|Prednisolone tablet (0.5mg/kg; parallel comparison):|2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.
51829|NCT03779087|Drug|10d AL quadruple therapy|esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.
51798|NCT03779360|Drug|Clobetasol propionate 0.05% topical formulation (crossover comparison):|"2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.~Clobetasol propionate 0.05% topical formulation (crossover comparison):~Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2."
51799|NCT03779360|Other|Lipopolysaccharide|As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
51800|NCT03779347|Drug|Praziquantel|Praziquantel to treat schistosomiasis during pregnancy
51801|NCT03779347|Diagnostic Test|UCP-LF CAA|UCP-LF CAA to diagnose Schistosomiasis during pregnancy
51802|NCT03779347|Diagnostic Test|composite diagnostic|composite diagnostic reference test based on extensive egg microscopy, serology, qPCR on egg DNA, and POC-CCA to diagnose Schistosomiasis during pregnancy
51803|NCT03779334|Drug|Risdiplam|Risdiplam will be administered orally.
51804|NCT03779321|Other|Acceptability|Food samples two formulations (low and high acceptability levels) of custard were used as experimental meals
51805|NCT03779308|Device|whole body vibration therapy|The study participants will receive the WBVT when standing still on a vibration platform independently or with own hand support on the platform rail. The vibration protocol is modified from the study by Gusso et al (2016). The WBVT training is of 20 Hertz, a peak-to-peak amplitude of 2 mm and peak acceleration of 15.79m/s or 1.61g. The sessions will be 18 minutes in length, 4 days per week for 4 weeks. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the desired parameters.
51806|NCT03779295|Device|Pulse laser dye therapy (Device name: Candela Family of Pulsed Dye Laser Systems. 501k Number: K050673.)|The face will be split and randomized, one half will receive pulsed laser dye therapy.
51807|NCT03779295|Drug|Clindamycin|The entire face (both halves) will receive clindamycin.
51808|NCT03779282|Drug|Dexmedetomidine|see descriptions
51809|NCT03779269|Other|meditation|meditation effect assessment using assessment tools.
51810|NCT03779256|Procedure|2D and 3D transvaginal ultrasound|Transvaginal ultrasound is part of routine pre-operative examination of the patient before surgery is scheduled. Described surgical treatment interventions is standard practice used to alleviate patient symptoms.
51811|NCT03779243|Dietary Supplement|Melatonin 5mg and Sleep Education|Melatonin 5mg daily and sleep education for 6 weeks following injury or surgery.
51812|NCT03779243|Other|Placebo|Daily placebo pills for 6 weeks following injury or surgery.
51813|NCT03779230|Drug|L19TNF|Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.
51814|NCT03779217|Other|screening mammography|As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
51815|NCT03779204|Behavioral|Mentorship|The mentors will be encouraged to incorporate the key relationship-based components of natural mentors (e.g., a 'coach' or 'cheerleader' role) to assist with mainstream integration. The mentors will have more flexibility than a typical formal mentorship program in the types of activities they pursue with their mentees. They will not be mandated to attend shelter-based social events, but rather engage in activities that direct their mentees away from the shelter system (and their old identities as homeless youth) and toward the mainstream (e.g., meeting for coffee at a local university campus). All of the mentors will meet monthly with their mentees for two years. In addition, the mentor will be encouraged to touch base with their mentee via phone or text message every week. If a mentor is unable to continue their role and there are at least six months left in the study, the study participant will be matched with a new mentor.
51816|NCT03779204|Behavioral|Rent Subsidies|Participants will receive rent subsidies ($500 for those living in Toronto, $400 for those living in Hamilton or St. Catherine's due to differences in cost of living) for 24 months.
51817|NCT03779191|Drug|Alectinib|Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
51818|NCT03779191|Drug|Bevacizumab|Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
51819|NCT03779178|Drug|Landiolol|Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes
51820|NCT03779178|Drug|Placebo|Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
51821|NCT03779139|Procedure|Intrahepatic islets and islets in the omental pouch|Patients with islet harvest of >5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to 4000 IEq/kg delivered via intraportal route and the remainder implanted into a constructed omental pouch.
51822|NCT03779139|Procedure|Intrahepatic islets alone|This is the standard of care procedure. Patients with islet harvest of >5000 islet equivalents per kg body weight will be randomized in a 1:1 ratio to all islets autotransplanted intrahepatically via the intraportal route.
51823|NCT03779139|Other|Normal Volunteers|These individuals will undergo metabolic testing as well as islet cell function testing.
51824|NCT03779126|Device|Electrical stimulation|1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
51825|NCT03779113|Drug|HMPL-523|Oral HMPL-523
51826|NCT03779100|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
51827|NCT03779100|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
51830|NCT03779074|Drug|10d bismuth quadruple therapy|rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days
51831|NCT03779074|Drug|14d hybrid therapy|a dual regimen with rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days followed by a quadruple regimen with rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days
51832|NCT03779074|Drug|14D high-dose dual therapy|rabeprazole 20 mg and amoxicillin 750 mg q.i.d. for 14 days
51833|NCT03779061|Drug|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
51834|NCT03779061|Drug|Propofol|Initial dose plus supplemental doses as necessary
51835|NCT03779048|Behavioral|Behavioral Treatment|Behavioral treatment (BT) for weight loss includes diet and physical activity recommendations and behavior therapy strategies. All participants will complete an initial 4-week BT run-in, delivered in individual, 20-30 minute weekly sessions. After the end of the run-in, participants will be offered an additional 24 weeks of 20-30 minute individual BT sessions, occurring weekly for the first 12 weeks and every other week for the last 12 weeks (total of 18 visits).
51836|NCT03779048|Drug|Placebo|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
51837|NCT03779048|Drug|Phentermine 15 MG|The study medication (placebo or phentermine 15.0 mg) is a once-daily self-administered pill.
51838|NCT03779035|Drug|Gemcitabine|1000mg/m2
51839|NCT03779035|Drug|Capecitabine|1250mg/m2
51840|NCT03779022|Genetic|microRNA|The level of microRNA in plasma will be detected by TaqMan in screening phase and by quantitative Real-time PCR (qRT-PCR) in validation phase.
51841|NCT03779009|Other|ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)|Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.
51842|NCT03778996|Drug|Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)|Daily oral combination therapy for cancer
51843|NCT03778970|Other|Pain Neuroscience Education|Pain neuroscience education (2 sessions during 40 minutes) administered by an interactive workshop
51844|NCT03778970|Other|Self-Management Education|A self-management education (2 sessions during 40 minutes) administered by an interactive workshop
51845|NCT03778970|Other|Movement Control Exercises|Eight sessions of movement control exercises (30 minutes each) + advice to perform the exercises at home twice a week.
51846|NCT03778957|Drug|Durvalumab|Durvalumab IV (intravenous)
51847|NCT03778957|Drug|Bevacizumab|Bevacizumab IV (intravenous)
51848|NCT03778957|Other|Placebo|Saline solution for Durvalumab and/or Bevacizumab masking (IV intravenous)
51849|NCT03778957|Procedure|Transarterial Chemoembolization (TACE)|TACE (chemo and embolic agent injection into the hepatic artery)
51850|NCT03778944|Procedure|Mannitol infusion|Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.
51851|NCT03778944|Procedure|Dopamine infusion|Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.
51852|NCT03778944|Procedure|Adequate hydration|Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.
51853|NCT03778931|Drug|Elacestrant|400 mg/day once daily oral dosing
51854|NCT03778931|Drug|Standard of Care|"Fulvestrant: 500 mg administered intramuscularly (IM) into the buttocks as two 5 mL injections on C1D1, C1D15 and C2D1 and Day 1 of every subsequent 28-day cycle~Anastrozole 1 mg/day on a continuous dosing schedule~Letrozole: 2.5 mg/day on a continuous dosing schedule~Exemestane: 25 mg/day on a continuous dosing schedule"
51855|NCT03778918|Other|inflammatory bowel disease|blood based biomarkers in IBD such as REG3 alpha, serum calprotectin and hs-CRP
51856|NCT03778918|Other|IBS or Normal Control|blood based biomarker compared normal control with IBD
51857|NCT03778905|Other|Rehabilitation|The stroke patients who admitted to post acute care(PAC) institution would undergo regular rehabilitation.
51858|NCT03778892|Behavioral|'Project Raincoat' Mobile Phone Application|Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
51859|NCT03778879|Drug|CCX872-B|CCX872-B concurrent with stereotactic body radiation therapy for pancreatic adenocarcinoma.
51860|NCT03778866|Other|Bicarbonate-buffered handling medium|The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
51861|NCT03778853|Drug|Anlotinib Hydrochloride|"Anlotinib Hydrochloride ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.~Other Name: AL3818"
51862|NCT03778827|Behavioral|Intensive Center-Based Pivotal Response Treatment (PRT-C)|Intensive Center-Based Pivotal Response Treatment (PRT-C) will consist of a combination of weekly individual parent training sessions and center-based therapy for a total of 13 weekly treatment hours.
51863|NCT03778814|Biological|TCR-T cells|Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
51864|NCT03778801|Diagnostic Test|fibromyalgia syndrome and chronic neck pain|We assessed pain intensity, kinesiophobia, fatigue, depression, physical activity level and disability in patients with fibromyalgia syndrome and chronic neck pain, and healthy individuals in this cross-sectional study.
51865|NCT03778788|Other|App group|Intervention group the participants will receive a Lifestyle Intervention Program (LIP) with the support of MetS mobile application (MetS app). The MetS app support include app installment and briefing by a research assistant after the educational talk. The participants can view the similar knowledge content related to metabolic syndrome in their own smart phone. In addition, a membership area provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.
51909|NCT03778463|Other|Synovectomy|Removal of the synovium during total knee arthroplasty
51866|NCT03778788|Other|Booklet group|The participants will additionally receive a Hong Kong version LIP booklet to take home and use for 24 weeks. The major component of the LIP booklet consists of fact of metabolic syndrome, advise of diet, exercise, medication, life style and stress management.
51867|NCT03778788|Other|control group|Participants will be advised to maintain their usual activities. They will additionally receive a placebo health leaflet. The health leaflets are produced by Department of Health and commonly distributed to the general public. For the ethical reason, those control group participants are freely to receive the LIP booklet after completion of the study at 24 weeks.
51868|NCT03778775|Diagnostic Test|Liver sitffness measurement|Liver sitffness measurement is performed by FibroTouch, a new-generation of transient elastography with the tesing interval between liver sitffness measurement and esophagogastroduodenoscopy less than one week.
51869|NCT03778762|Procedure|Blind tracheal intubation through AirQ|underwent blind intubation with correction manoeuvres
51870|NCT03778762|Procedure|Fiberscopic tracheal intubation through AirQ|: underwent fibreoptic guided intubation
51871|NCT03778749|Diagnostic Test|TOF measurements|The investigators will determine how the TOF% values vary in each individual patient, over time, in ICU.
51872|NCT03778736|Other|Cumulase denudation|Testing the effect of cumulase for women with poor oocyte yield due to poor ovarian reserve
51873|NCT03778723|Drug|Total intravenous anesthesia (TIVA)|Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
51874|NCT03778723|Drug|Inhalation Anesthesia|Sevoflurane at a concentration of 2-2.5%
51875|NCT03778723|Drug|Rescue fentanyl|Fentanyl in repeated doses (50 µg) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value) are used for maintenance of analgesia
51876|NCT03778697|Procedure|Endoscopic Sleeve Gastroplasty|Endoscopic full-thickness suture system to plicate the greater curvature of the stomach
51877|NCT03778684|Diagnostic Test|Visceral fat thickness|An initial longitudinal sweep will be done from the xiphoid process to the umbilicus to determine the area of maximum pre-peritoneal fat thickness.
51878|NCT03778684|Diagnostic Test|Body mass index|Weight and height will be measured with subjects in a standing position wearing light clothes and no shoes.
51879|NCT03778671|Drug|bupivacaine|Patients will receive 25 ml bupivacaine 0.25% on each side
51880|NCT03778671|Drug|Dexmedetomidine Injection [Precedex]|Patients will receive 25 ml bupivacaine 0.25% + 50 µg dexmedetomedine on each side .
51881|NCT03778671|Drug|fentanyl|Patients will receive 25 ml bupivacaine 0.25% + 50 µg fentanyl on each side
51882|NCT03778658|Behavioral|Physical Activity Intervention|Participants will engage in a multimodal aerobic and strength training intervention.
51883|NCT03778645|Procedure|Adrenal Venous Sampling|Adrenal Venous Sampling via an Antecubital Approach
51884|NCT03778632|Behavioral|individualized desensitization exercises|implementing individualized desensitization exercises in standard application of intensive stuttering group therapy for school-age children who stutter
51885|NCT03778619|Drug|Rituximab|weekly administration of Rituximab 375mg/m2 during cycle 1 and 2, monthly administration from cycle 3(up to cycle 6)
51886|NCT03778619|Drug|Fludarabine|administration of fludarabine 20mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
51887|NCT03778619|Drug|Cyclophosphamide|administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
51888|NCT03778619|Biological|MG4101(allogeneic Natural Killer cell)|administration every fortnight for each cycle, beginning with the 1st dose of rituximab for that cycle.
51889|NCT03778619|Drug|Interleukin-2|1 x 10^6 IU/m2, together with MG4101
51890|NCT03778606|Dietary Supplement|Potato starch|Potato starch will be given twice a day for up to 14 days, discharge, or death, whichever occurs first.
51891|NCT03778593|Drug|5-Fluorouracil|D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
51892|NCT03778593|Drug|Leucovorin|D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
51893|NCT03778593|Drug|Irinotecan|D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
51894|NCT03778593|Drug|Oxaliplatin|D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks
51895|NCT03778580|Dietary Supplement|Pyridoxamine Dihydrochloride|pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid
51896|NCT03778580|Drug|placebo|placebo
51897|NCT03778567|Drug|Telbivudine|CHB patients who are receiving adefovir or tenofovir disoproxil fumarate are recruited. At the time of recruitment (0 month, baseline), lamivudine is switched to telbivudine while adefovir or tenofovir disoproxil fumarate was continued. The patients are followed-up for 24 months.
51898|NCT03778554|Drug|Metoprolol Succinate|Eligible patients randomized to receive long-term therapy with oral beta-blockade
51899|NCT03778554|Drug|Bisoprolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
51900|NCT03778554|Drug|Carvedilol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
51901|NCT03778554|Drug|Nebivolol|Eligible patients randomized to receive long-term therapy with oral beta-blockade
51902|NCT03778541|Drug|Temozolomide|75mg/m2/d concurrent with radiotherapy, taken for at least 20 days.
51903|NCT03778541|Radiation|hypofractionated radiotherapy|the regular radiation dose prescription is 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
51904|NCT03778528|Procedure|cataract surgery|tissue collection.
51905|NCT03778515|Diagnostic Test|MRI|Observational Study of novel MR imaging and image processing techniques that will provide reliable and fully quantitative evaluation of inflammation, chronic structural changes and vascularity in patients with Ankylosing Spondylitis (AS).
51906|NCT03778502|Drug|Direct Oral Anticoagulants|Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry
51907|NCT03778489|Other|Training|10 weeks of high intensity exercise training. 2-3 trainings per week of approx. 40 min.
51908|NCT03778476|Other|Isometric Exercise|Participants will be asked to hold a submaximal voluntary contraction of the quadriceps muscle as long as they can (task failure).
51910|NCT03778450|Drug|Analgesics, Opioid|"Patients are included in the long-term opioid group if they started an opioid-therapy between 2013 and 2017 and received consecutive prescriptions for opioid medications over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The treatment will be assessed using the ATC codes of opioid~treatment N02AA01, N02AA05, N02AB03, N02AE01, N02AX02, N02AX01, N02AX06) reported in reimbursed medicines to patients."
51911|NCT03778450|Drug|Non-Opioid Analgesic|Patients with non-opioid pain medication are included, if they received a medication therapy with anticonvulsants (gabapentin, pregabalin, carbamazepine), antidepressants or non-opioid analgesics (NSAIDs, Metamizole) over a minimum of 3 quarters, over a 60-month period between January 1, 2013, and December 31, 2017. The non-opioid treatment will be assessed using the ATC codes (N03AX12, N03AX16, N03AF01) of treatment reported in reimbursed medicines to patients.
51912|NCT03778437|Procedure|subclavian vein catheterization|Here we introduced a new freehand method, named as Aiming Method, which facilitated the alignment of injection needles with ultrasound beams. During this aiming method, patient is still positioned in Tredelenburg with the arm abducted to 90° and no needle guidance will be used.
51913|NCT03778437|Procedure|landmark techniques|The patient is positioned in Tredelenburg with the arm abducted to 90°. Venipuncture should occur 1 cm lateral to the curvature of the middle third of the clavicle with the needle pointing horizontally directed at the sternal notch. If subclavian vein is missing at the first try, withdraw the needle and direct horizontally at the cricoid cartilage at the second try.
51914|NCT03778437|Procedure|Ultrasound-guided plus needle guide techniques|Subclavian vein catheterization is performed under ultrasound guidance with in-plane technique. The patient is positioned in Tredelenburg with the arm abducted to 90°. During the needle insertion, the needle is secured in the needle guidance device which keeps the alignment of needle and ultrasonic beam.
51915|NCT03778424|Drug|Rufinamide|Rufinamide up to 45 milligram per kilogram per day (mg/kg/day).
51916|NCT03778411|Device|VCTE with splenic stiffness measurement|Subjects will undergo vibration controlled transient elastography to measure liver stiffness (LSM) liver steatosis via controlled attenuation parameter (CAP) and splenic stiffness
51917|NCT03778398|Other|Neurologic music therapy|Customized piano training
51918|NCT03778385|Other|Exercise|Submaximal exercise is performed in randomized order with the participant seated and the arm supported in an adjustable hand-arm orthosis.
51919|NCT03778372|Drug|Methadone|see desc above
51920|NCT03778359|Drug|Leuprorelin|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Leuprorelin.
51921|NCT03778359|Device|Levonorgestrel|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Levonorgestrel.
51922|NCT03778359|Drug|Dienogest|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Dienogest.
51923|NCT03778359|Drug|Progestins|This study was designed to analyze the differences in prognosis and recurrence of patients with endometriosis and adenomyosis after receiving various surgical and medical treatments. This arm intervention is Progestins.
51924|NCT03778346|Biological|CAR-T therapy in Relapsed/Refractory multiple myeloma|Integrin β7, BCMA, CS1, CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells to treat Relapsed/Refractory multiple myeloma
51925|NCT03778333|Biological|Autologous mesenchymal stem cells|IV therapy with autologous bone-marrow derived mesenchymal stem cells
51926|NCT03778320|Drug|CTP-692|Single oral dose
51927|NCT03778320|Drug|D-Serine|Single oral dose
51928|NCT03778307|Behavioral|Psychophysiological fear conditioning and extinction task|Behavioral task to assess psychophysiological measures of fear
51929|NCT03778307|Behavioral|Eyetracking task|Behavioral task to assess dysphoria-relevant attention allocation
51930|NCT03778294|Procedure|Computed Tomography|Undergo PET/CT
51931|NCT03778294|Other|Fluorodopa F 18|Given IV
51932|NCT03778294|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
51933|NCT03778294|Procedure|Positron Emission Tomography|Undergo PET/CT or PET/MRI
51934|NCT03778294|Radiation|Proton Beam Radiation Therapy|Receive proton beam RT
51935|NCT03778294|Other|Quality-of-Life Assessment|Ancillary studies
51936|NCT03778294|Other|Questionnaire Administration|Ancillary studies
51937|NCT03778294|Drug|Temozolomide|will receive concurrent chemotherapy, temozolomide
51938|NCT03778281|Drug|Baclofen|Oral baclofen 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
51939|NCT03778281|Drug|Methoxyclopramide|Intramuscular injection of metoclopramide 10mg, 3 times a day for three days, then evaluate the efficacy and side effects
51940|NCT03778268|Procedure|sentinel lymph node biopsy|"Injecting carbon nanoparticles (CNP)[Not Equipped with near-infrared fluorescent vascular imager] or CNP combining Indocyanine Green(ICG)[Equipped with near-infrared fluorescent vascular imager].~Identifying and removing sentinel lymph nodes.~Staining all nodes using hematoxylin-eosin staining."
51941|NCT03778255|Procedure|Sentinel Lymph Node Biopsy|"Injecting carbon nanoparticles (CNP)[Not Equipped with near-infrared fluorescent vascular imager] or CNP combining Indocyanine Green(ICG)[Equipped with near-infrared fluorescent vascular imager].~Identifying and removing sentinel lymph nodes.~Staining all nodes using hematoxylin-eosin staining."
51942|NCT03778242|Drug|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
51943|NCT03778242|Drug|TA|1 gm tranexamic acid (TA) in 100 ml saline by slow infusion
51944|NCT03778242|Drug|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
51947|NCT03778216|Behavioral|Family Based Treatment|
51948|NCT03778203|Biological|Fluzone 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly
51949|NCT03778203|Biological|Fluzone 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.5 mL administered intramuscularly
51950|NCT03778203|Other|natural influenza infection|Children enrolled on presentation to their primary care provider or emergency department with a natural influenza infection
51951|NCT03778190|Procedure|Corneal Foreign Body Removal|An eye magnet will be brought close to the foreign body on the surface of the eye in an attempt to remove the foreign body.
51952|NCT03778177|Procedure|transcranial electrical brain stimulation|Pain ratings will be recorded before and after transcranial brain electrical stimulation procedures using a Visual Analog Scale (VAS).
51953|NCT03778164|Other|Fast Track Partner Services-Sexual Health Intervention|The Partner Services-Sexual Health Intervention enhances the current standard of care by introducing four service innovations to the DOHMH Partner Services program: (1) enhanced field-based combination HIV and STI testing; (2) immediate field-based ARV/PrEP start; (3) navigation to a sexual health clinic for test results and treatment; and (4) enhanced linkage support to facilitate ongoing PrEP or HIV care.
51954|NCT03778164|Other|Partner Services Standard of Care|Participants in neighborhoods that have not yet been assigned to the intervention condition in the stepped wedge trial will receive standard Partner Services components, including field-based HIV testing and referral to clinical sites for HIV prevention or treatment.
51955|NCT03778151|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|daily treatment session of REPETITIVE TRANSCRANIAL MAGNETIC STIMULATIO will be applied over precuneus for 20 minutes of consecutive blocks of 20Hz pulses for two seconds followed by 28 seconds of no stimulation.
51956|NCT03778138|Drug|Anlotinib plus Pemetrexed|Anlotinib(12mg QD PO d1-14, 21 days per cycle) plus Pemetrexed (500mg/m2 IV d1)
51957|NCT03778112|Radiation|SBRT to whole prostate|Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate
51958|NCT03778112|Radiation|IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions|Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions
51959|NCT03778099|Drug|Cinnamon Cap 500 MG|The Cinnamomum cassia (C. aromaticum) capsules will be purchase from Spring Valley company (distributed by Wal-Mart Stores, Inc. USA) by the investigator.
51960|NCT03778099|Drug|Placebo|450 mg of starch and 50 mg of cinnamon powder
51961|NCT03778086|Procedure|gonioscopy|gonioscopic observation and grading of iridocorneal angle
51962|NCT03778073|Drug|TG-1501|Intravenous infusion on Days 1 and 15 of every 28-day cycle or only on Day 1 of every 28-day cycle
51963|NCT03778060|Device|Cala TWO stimulator|Treatment intervention will consist of subjects undergoing 40 minute sessions of transcutaneous stimulation with the Cala TWO stimulator twice daily for 3 months to reduce hand tremors prior to their undergoing deep brain stimulation `surgery for treatment of essential tremor at Mayo Clinic.
51964|NCT03778047|Drug|Enzalutamide|oral
51965|NCT03778047|Drug|HC1119|oral
51966|NCT03778034|Other|female with Forward head posture|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
51967|NCT03778034|Other|healthy female without (FHP)|measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
51968|NCT03778021|Behavioral|Behavioral Gardening Exposure|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
51969|NCT03778021|Behavioral|Healthy Eating and Gardening Curriculum|Attend 12 lessons (about 45 minutes each) throughout the school year, during the normal school day, that are focused on healthy eating and gardening, coordinated with the growing season
51970|NCT03778021|Behavioral|Family Workshops|During Year 3, quarterly healthy eating and gardening workshops for family and community members to attend
51971|NCT03778008|Drug|Recombinant bovine basic fibroblast growth factor|Recombinant bovine basic fibroblast growth factor is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of recombinant bovine basic fibroblast growth factor at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade ＞ 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
51972|NCT03778008|Combination Product|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and lidocaine composition|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade ＞ 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
51973|NCT03777982|Drug|Prednisone|Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
51974|NCT03777982|Drug|Apalutamide|Apalutamide also prevents the androgens from working within the prostate cancer cells, and can ultimately lead to cancer cell death.
51975|NCT03777982|Drug|Abiraterone Acetate|Abiraterone acetate interferes with an enzyme that is expressed in testicular, adrenal, and prostatic tumor tissues and is required as part of the body's androgen producing process. Because of this interference the amount of androgens produced are decreased. Abiraterone acetate, blocks androgen production at three sources; the testes, the adrenal glands, as well as from the tumor itself
51976|NCT03777982|Drug|LHRH Agonist or Antagonist|Luteinizing hormone-releasing hormone (LHRH) agonists (also called LHRH analogs or GnRH agonists) are drugs that lower the amount of testosterone made by the testicles
51977|NCT03777956|Drug|Lacosamide|Lacosamide (50 mg) and identical placebo are given as capsules and taken orally twice a day, up to 200 mg b.i.d.
51978|NCT03777956|Drug|Placebo|Identical placebo are given as capsules and taken orally twice a day.
52015|NCT03777722|Device|Tailored Lighting Intervention|Lighting Intervention - active or placebo
53276|NCT03767920|Drug|dexamethasone|TAP block with 4 mg dexamethasone bilaterally
51979|NCT03777943|Procedure|Sampling peritoneal tissue|Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.
51980|NCT03777930|Drug|Chemotherapy drugs|According to the NCCN Guidelines
51981|NCT03777930|Drug|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
51982|NCT03777930|Other|optimal support treatment|Patients who cannot tolerate chemotherapy and other cancer treatments receive optimal support for 8 weeks
51983|NCT03777930|Drug|thalidomide and megestrol acetate|The thalidomide and megestrol acetate administration groups were administered with thalidomide 100 mg qn po and megestrol acetate 0.16 qd po for 8 weeks
51984|NCT03777917|Device|Belotero Balance®|Up to 1.0 mL Belotero® Balance per infraorbital hollow (plus up to 0-5 mL per infraorbital hollow during touch-up 1month after baseline injection, as required). Mode of application: subdermal injection.
51985|NCT03777904|Diagnostic Test|Serum Ferritin level|Serum ferritin level will be collected with other clinical labs and measured in the research lab
51986|NCT03777904|Diagnostic Test|Serum Ferritin iron content|Blood will be collected with other clinical labs and the iron content in the ferritin will be measured in the research lab
51987|NCT03777904|Diagnostic Test|Urine Ferritin level|Urine will be collected non-invasively and analyzed for ferritin level
51988|NCT03777904|Diagnostic Test|Urine ferritin iron content|Urine will be collected non-invasively and analyzed for iron content within the ferritin
51989|NCT03777891|Combination Product|phonophoresis with different material|phonophoresis with Silicone gel for group A, , Group B: 15 patients (8 males and 7 females) received phonophoresis with Contractubex gel and Group C: 15 patients (9 males and 6 females) received Corticosteroid phonophoresis.
51990|NCT03777878|Drug|Carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
51991|NCT03777878|Drug|oxytocin|20 IU oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
51992|NCT03777878|Drug|TA|2 ampoules of TA in 100 ml saline by slow infusion
51993|NCT03777878|Drug|placebo to carbetocin|placebo ampoule to carbetocin will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
51994|NCT03777878|Drug|placebo to TA|2 placebo ampoules to TA in 100 ml saline by slow infusion
51995|NCT03777878|Drug|placebo to oxytocin|two placebo ampoules to oxytocin in 500 mL of intravenous solution infusion over 15 min after delivery of the baby
51996|NCT03777865|Biological|13vPnC|All subjects receive a single dose (0.5mL) of 13vPnC
51997|NCT03777852|Diagnostic Test|First Questionnaire application|Women with breast cancer will respond to the First Breast Q questionnaire before treatment with breast cancer reconstruction surgery.
51998|NCT03777852|Diagnostic Test|Second Questionnaire application|Women with breast cancer will respond to the Second Breast Q questionnaire after treatment with breast cancer reconstruction surgery.
51999|NCT03777839|Diagnostic Test|FDG PET/CT|FDG PET CT imaging with rest perfusion imaging
52000|NCT03777826|Other|PKU Synergy|PKU Synergy is a citrus flavored, powdered amino-acid mixture (containing traces of Phe, 4,3mg per portion; and 20 gr. Protein Equivalent (PE)) with a tailored amino acid and micronutrient profile adapted for the special requirements of HPA/PKU (Hyperphenylalaninemia/Phenylketonuria) subjects over 10 years of age with an increased Phenylalanine-(Phe) tolerance/intake.
52001|NCT03777813|Drug|Durvalumab|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w) Immunotherapy in experimental arm only: Patients will received concomitantly a maximum of 12 infusions
52002|NCT03777813|Combination Product|IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)|Radiochemotherapy in standard arm and in experimental arm: 10 weeks (RT 50 Gy and FOLFOX q2w)
52003|NCT03777800|Behavioral|Body therapy|"Body therapy involving direct physical treatments, conversations, breathing exercises and relaxation in the sessions. Moreover, the participants are taught how to practice vipassana or awareness meditation every day at home.~The body therapist works directly with the muscle armour and the treatment sessions have focus on creating a safe environment and enabling cognitive realisation and awareness of symptoms.~Each participant is assigned a practitioner who acts as contact person and 'lifeline'. Furthermore, a coordinator is assigned in ManuVision who will also act as contact person when needed for the veterans. This provides peace of mind, trust, and ensures retention. The coordinator or the practitioner follows up on the veteran's progress prior to each session."
52004|NCT03777800|Behavioral|Treatment as usual|Standard treatment
52005|NCT03777787|Dietary Supplement|Denatonium Benzoate|A single intragastric administration of denatonium benzoate (1 µmol/kg)
52006|NCT03777787|Dietary Supplement|Water|A single intragastric administration of water
52007|NCT03777774|Procedure|Passive Redon subgaleal drains|Passive non-vacuum subgaleal drains will be placed during closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
52008|NCT03777774|Procedure|Vacuum Redon subgaleal drains|Active vacuum subgaleal drains will be placed during the closing stage of craniectomy. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
52009|NCT03777774|Procedure|No Redon subgaleal drains|A subgaleal drain will be placed during the closing stage of craniectomy but it will be clamped. The drain will be unclamped if necessary. Drain used is closed suction drain system (3.2 mm in outer diameter, 10 French, round and transparent polyvinyl chloride tube with a 400 mL Redon bottle spring evacuator chamber; Privac, Primed, Germany)
52010|NCT03777761|Drug|tucatinib|300mg oral dose
52011|NCT03777761|Drug|placebo|Matching placebo for tucatinib
52012|NCT03777761|Drug|moxifloxacin|400mg single oral dose
52013|NCT03777748|Device|dental implants and stud attachments|
52014|NCT03777735|Procedure|human bone graft screw|All patients undergo surgical treatment of osteochondral defects in the knee joint with human bone graft screws.
52016|NCT03777709|Behavioral|FAITH! App|Participants allocated to the intervention arm will complete a 10-week, individual-tailored intervention program utilizing the FAITH! App to promote the AHA LS7 through health education and to increase awareness and skill development while enhancing self-efficacy, self-regulation, and social support for healthy behavior change.
52017|NCT03777696|Drug|Misoprostol|400 μg of buccal misoprostol
52018|NCT03777696|Drug|TA|1 gm of tranexamic acid in 100 ml saline iv
52019|NCT03777696|Drug|placebo to misoprostol|placebo tablets to misoprostol buccal
52020|NCT03777696|Drug|placebo to TA|110 ml saline iv
52021|NCT03777683|Dietary Supplement|Dietary Supplement Pycnogenol (OLIGOPIN)|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and intervention group (n=30) will receive Pycnogenol supplement. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
52022|NCT03777683|Other|Placebo|investigators obtained ethical approval from the Research Ethics Committees of the Mashhad University of medical sciences. investigators enroll 60 patients who are admitted to ICU at hospitals of university. All eligible patients or their first degree relatives give informed consent before participating. Participants are randomly (block stratification) divided in two groups. At the first visit, baseline data are gathered and control group (n=30) will receive oral capsules containing 130 mg Microcrystalline Cellulose. In order to control the confounding effect of food intake, both the control and the intervention group receive the standard formulas based on their daily required energy via enteral root feeding.
52023|NCT03777670|Diagnostic Test|Blood test|Drop of blood for RNA and metabolic analysis
52024|NCT03777657|Drug|Tislelizumab (BGB-A317) combined with oxaliplatin and capecitabine or Tislelizumab (BGB-A317) combined with Cisplatin and 5-FU|Tislelizumab (BGB-A317) + Oxaliplatin + Capecitabine: Subjects will be treated with BGB A317 200 mg IV on Day 1, cisplatin 80 mg/m² IV on Day 1, and 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21- day cycle. Tislelizumab (BGB-A317) + Cisplatin + 5- FU: Subjects will be treated with BGB A317 200 mg IV on Day 1, oxaliplatin 130 mg/m² IV on Day 1, and capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle.
52025|NCT03777657|Drug|Placebo combined with oxaliplatin and capecitabine or Placebo combined with Cisplatin and 5-FU|Placebo + Oxaliplatin + Capecitabine: Subjects will be treated with Placebo 200 mg IV on Day 1, cisplatin 80 mg/m² IV on Day 1, and 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. Placebo + Cisplatin + 5-FU: Subjects will be treated with Placebo 200 mg IV on Day 1, oxaliplatin 130 mg/m² IV on Day 1, and capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle
52026|NCT03777644|Procedure|Continuous Paravertebral block with ropivacaine|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose ropivacaine 0.5%ropivacaine with 1:200,000 adrenaline, 25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of ropivacaine 0.2% ropivacaine, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg"
52027|NCT03777644|Procedure|Continuous Paravertebral Block with Saline|"Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.~Device: Philip CX50 Ultrasound Scanner The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning~Device: PAJUNK Contiplex S Catheter Drug: single dose saline,25ml in total given immediately after the correct position of the tip of the needle has been confirmed Drug: continuously infusion of saline 0.9% saline, infusion rate: 0.125ml/kg/pulse,1pulse/h given through the catheter inserted in the T8 paravertebral space following the single dose"
52028|NCT03777644|Drug|Patient-controlled analgesia with morphine|Drug: Morphine given as IPCA bolus: 2mg, lock time: 5min, 1h limitation: 8mg
52029|NCT03777631|Procedure|Catheter ablation|CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
52030|NCT03777618|Procedure|gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation
52031|NCT03777605|Drug|Nitroglycerin 0.4 MG|"The study evaluate absorption rate of nitroglycerine 0.4 milligrams as tablets or a quickly absorbable capsuel NTG1523 determined by T-max and area under the response curve in the blood of NTG as well as from clinical effects.~Data is entered on data sheet in anonymous form and processed. The results are presented in anonymous form by publication and lecture. Experts are given the supplement: The applicant's rights in a biomedical research project"
52032|NCT03777592|Procedure|erector spinae plane block|local anesthetic or saline is administered in to the interfascial plane between the transverse process of the vertebra and the erector spinae muscles, spreading to multiple paravertebral spaces
52033|NCT03777579|Drug|JS001，an engineered anti-PD-1 antibody|JS001 at a fixed dose of 240 milligrams via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
52034|NCT03777579|Drug|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
52035|NCT03777579|Drug|Placebo|Placebo administered via intravenous (IV) infusion on Days 1 of each 21-day cycle until disease progression or unacceptable toxicity.
52036|NCT03777566|Diagnostic Test|sonohysterography|sonohysterography with measuring the uterine cavity volume
52037|NCT03777553|Behavioral|Narrative Exposure Therapy for Justice-Involved Veterans|Behavioral intervention that uses narrative therapy and exposure to address repeated or complex trauma.
52038|NCT03777540|Procedure|Gastric resection|"Partial gastrectomy with jejunal anastomosis, total gastrectomy, gastroenterostomy without gastrectomy or other (palliative surgery)."
52041|NCT03777514|Other|Oral vitamin C|Oral vitamin C to be used as a placebo for participants receiving IV iron
52042|NCT03777514|Other|Intravenous normal saline|Intravenous normal saline will be used as placebo for participants receiving oral iron
52043|NCT03777501|Behavioral|non-random whole body vibration|Each participant will receive the treatment about one hour after the administration of medicine. For non-random whole body vibration group, participants will be required to maintain the erect standing position on the vibratory platform and the frequency and amplitude of vibratory stimuli will be 6Hz and 3mm respectively. Each treatment includes five sessions and each session is composed of one minute whole body vibration and one minute rest.
52044|NCT03777501|Behavioral|occupational therapy|Participants will receive the occupational therapy including dynamic balance training and functional ambulatory training.
52045|NCT03777488|Drug|Tranexamic Acid 1 gram intravenously|Intravenous tranexamic acid crossover to oral and intramuscular arms
52046|NCT03777488|Drug|Tranexamic acid 2 grams oral solution|Oral tranexamic acid crossover to intravenous and intramuscular arms
52047|NCT03777488|Drug|Tranexamic acid 1 gram intramuscular|Intramuscular tranexamic acid crossover to oral and intravenous arms
52048|NCT03777475|Procedure|transarterial infusion|transarterial infusion
52049|NCT03777462|Drug|Neoadjuvant gemcitabine plus nab-paclitaxel|Neoadjuvant gemcitabine plus nab-paclitaxel is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. Surgical resection will be performed after neoadjuvant chemotherapy.
52050|NCT03777462|Drug|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT|Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
52051|NCT03777462|Drug|Neoadjuvant S-1 plus nab-paclitaxel with SBRT|Neoadjuvant S-1 plus nab-paclitaxel with SBRT is used in the intervention group for 3 cycles. Standard doses of gemcitabine and nab-paclitaxel are adopted. The radiation dose of SBRT is 7.5-8Gy/f for 5 fractions. Surgical resection will be performed 3 weeks after SBRT.
52052|NCT03777449|Radiation|CBCT|Patients will be taken a CBCT as a diagnostic tool to monitor peri-implant bone loss. This is a tool used on the daily basis for the evaluation of peri-implant bone loss. Patient will not be exposed to further radiation but the regular one.
52053|NCT03777436|Drug|Apremilast|Oral
52054|NCT03777436|Other|Placebo|Oral
52055|NCT03777423|Device|PEEK framework partial dentures|Polymer-based framework recently introduced made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
52056|NCT03777423|Device|Cobalt- chromium framework partial dentures|It's a bio-compatible metal used in thin sections so less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and resistance to corrosion.Drawbacks of metal frameworks can include hypersensitivity, aesthetics because of metal metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production
52057|NCT03777397|Other|Questionnaire|Questionnaire on the level of awareness of this risk among health sector employees, and more specifically the Lyon Civilian Hospices, and on participation in breast cancer screening for HCL employees, particularly among night shift staff.
52058|NCT03777371|Other|Anti HIV Seropositive Pregnant Women|
52059|NCT03777358|Device|3D-TVS|The 3D-TVS will be done by an experienced gynecological sonographer. The uterine cavity will be assessed by obtaining a mid-coronal view. Then hysteroscopy will be performed
52060|NCT03777345|Device|cobalt-chromium framework partial dentures|It's a biocompatible metal alloy used in thin sections and are less bulky, provide high strength and stiffness ,conduct heat and cold for a more natural experience, enable designs that minimize the covering of the gingival margins, allow for a stable denture base, and is resistant to corrosion. Disadvantages include hypersensitivity, esthetic issues with metal display, oral galvanism, adverse tissue reactions, osteolysis of abutment teeth, and biofilm production .
52061|NCT03777345|Device|PEEK framework partial dentures|It's a promising polymer-based framework material has recently been introduced which is made of polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base.
52062|NCT03777332|Drug|APL-2|Complement (C3) Inhibitor
52063|NCT03777319|Drug|Spironolactone|Spironolactone will be prescribed for 6 months, after which the family and primary care physician will determine to either remain on spironolactone or transfer to prednisolone.
52064|NCT03777319|Drug|Prednisolone|Prednisolone will be prescribed for 6 months as the clinical standard of care.
52065|NCT03777306|Other|ARM A EARLY INTERVENTION GROUP|"Post randomization, all patients will take baseline survey to assess their level of stress prior to starting the educational program During the educational interventions they will receive~1 video/picture/worksheet per week covering the topic to be covered.~1 phone/week by the Health Advisor, to discuss the topic for the week s/as their disease, stress and anxiety management, life organization, adherence skills, healthy eating and sleeping). Participant and the health advisor will also set up a Tiny Step to serve as a goal for the week .~3 emails/texts through the week, to remind about the topic covered, or to encourage them on their Tiny Step goal.~After 12 weeks on the program participants will re-take the surveys to assess the level of stress."
52066|NCT03777306|Other|ARM B DELAYED INTERVENTION GROUP|The educational intervention is similar as in ARM A except that the participants will receive standard of care for the first 12 weeks post randomization and then begin the educational intervention
52067|NCT03777293|Device|ultrasound viscoelasticity|use these devices to do ultrasound examination in chronic liver disease patients
52068|NCT03777280|Device|peek framework RPD|it is a polyetheretherketone polymer frame combined with acrylic resin denture teeth and a conventional acrylic resin denture base made by injecting technique and have several advantages regarding strength and esthetics
52069|NCT03777280|Device|cobalt chromium framework RPD|standard framework device
52100|NCT03777020|Behavioral|Service Dog Training Program|Participate in 8 weekly dog training sessions using a positive reinforcement method and curriculum under the direct supervision of trainer at the Warrior Canine Connection facility in Boyds (Montgomery County) MD.
53277|NCT03767920|Drug|placebo to dexamethasone|TAP block with 4 mg placebo to dexamethasone bilaterally
52070|NCT03777267|Device|Active CR|The upgraded platform for medical research using the HIRREM technology has been rebranded as Cereset Research® (CR). This system uses the same core technology and algorithms to echo brainwaves in real-time using audible tones, as with HIRREM. The CR system also includes 64-bit processing architecture for faster feedback, the use of 4 sensors, and the use of standard protocols (with flexibility regarding the length and sequencing of the standard protocols), all done with eyes closed. Four sensors are applied to the scalp at a time. However, only two sensors are actively echoing feedback. The software automatically switches from one sensor pair to the other when needed. This reduces the number of sensor placement changes needed, resulting in shorter session time and fewer interruptions.
52071|NCT03777254|Biological|RC28-E|RC28-E intravitreous injection 50ul
52072|NCT03777241|Behavioral|Behavioral Intervention Team|Multidisciplinary team to assist with actively identifying and managing mental illness and substance abuse disorders at their earliest possible time during hospitalization.
52073|NCT03777241|Behavioral|Standard of care|Participants in this group will receive standard of care.
52074|NCT03777215|Drug|Angiotensin-(1-7)|This is a biologically active beneficial hormone of the renin-angiotensin system.
52075|NCT03777215|Drug|Saline|Saline will be used as the placebo comparator.
52076|NCT03777202|Device|Study of high-flow nasal oxygen in obstructive sleep apnea patients|High-flow nasal oxygen will be applied to the patients through nasal openings during sleep endoscopy. Pulse oximetry will be monitored continuously. Otorhinolaryngologist will observe the degree of upper airway obstruction during sleep endoscopy.
52077|NCT03777189|Behavioral|Cognitive-Behavioral Therapy|Cognitive-behavioral therapy will be delivered in line with recommendations (e.g., NICE 2017). Format will be guided self help with added content related to physical activity.
52080|NCT03777163|Biological|Butantan Institute Trivalent Seasonal Influenza Vaccine|Butantan Institute and Pasteur-Mérieux (present, Sanofi Pasteur) established a technology transfer in 1999 for the production of a trivalent influenza vaccine of inactivated split-virion using embryonated eggs. The technology transfer followed a progressive approach from importing the finished product, to packaging and quality control test for release (1999), and, finally, to the first batch of influenza vaccine entirely produced by Butantan (2011). In 2013, the Butantan vaccine was registered by the Brazilian National Agency of Sanitary Surveillance (ANVISA).
52081|NCT03777163|Biological|Sanofi Trivalent Seasonal Influenza Vaccine|VAXIGRIP® was launched in 1968 and since then has been licensed in more than 100 countries and prequalified by WHO in 2011. Several clinical studies by Sanofi Pasteur have examined the safety and immunogenicity of Vaxigrip® in older children (8-10 years), adults (18-59 years), elderly (> 60 years),11,12 children (six months to three years) 13 and pregnant women.
52082|NCT03777150|Other|Postoperative care in Intensive care unit (ICU)|Postoperative care in Intensive care unit (ICU)
52083|NCT03777150|Other|Postoperative care in standard ward|Postoperative care in standard ward
52084|NCT03777137|Behavioral|TMS (Rapid2, Magstim Corp)|Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
52085|NCT03777124|Drug|SHR-1210|Subjects receive SHR-1210 intravenous every 2 weeks
52086|NCT03777124|Drug|Apatinib|Subjects receive Apatinib orally every day
52087|NCT03777124|Drug|Pemetrexed|Subjects receive Pemetrexed intravenous every 3 weeks
52088|NCT03777124|Drug|Carboplatin|subjects receive carboplatin intravenous every 3 weeks
52089|NCT03777111|Other|Exercise|Single Task Training: Single task training includes exercises that require only one task or stimulation. For this study the task consists of motor tasks (walking or balance) Dual Task Training: Dual task training includes exercises simultaneous performance of two tasks that can be performed independently, measured separately and with different goals. In the study motor tasks will combine with cognitive tasks.
52090|NCT03777098|Device|Strepic® Device|The Strepic® device is a qualitative point-of-care diagnostic test for the detection of GAS pharyngitis. The test uses direct visualization of the pharynx with a light source of specified wavelengths, causing excitation of endogenous fluorophores that emit a characteristic colored light pattern. White light images may give additional diagnostic accuracy through use of an artificial intelligence analysis of a large set of images of GAS and non-GAS pharyngitis.
52091|NCT03777085|Drug|TQB2303|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
52092|NCT03777085|Drug|Rituximab|375mg/m2, iv q3w,6 cycles(each cycle is 3 weeks
52097|NCT03777046|Behavioral|Standard of Care (SOC)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.
52098|NCT03777046|Behavioral|SOC with Psychology Therapy (CBT)|Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
52099|NCT03777033|Drug|Prophylactic protocol with Ca and Vit D|"3g calcium /day for 5 days and then 2g/day for 10 days 2 Micrograms Alfacalcidol/day and then 1 microgram /day for 10 days~the Prophylactic protocol with Ca and Vit D will be given in the form of Alfacalcidol 0.5 Micrograms Capsule and CALCIUM CARBONATE + CALCIUM GALACTOGLUCONATE 1000mg tablet"
52101|NCT03777020|Other|Dog Training Education|Learn about training dogs by watching 8 weekly dog training online modules programs at the Warrior Canine Connection facility in Boyds (Montgomery County) MD. After completing this education the participants will participate in the service dog training program.
52102|NCT03777007|Device|SPARTA force plate|The Sparta Platform includes force plate hardware coupled with Sparta Scan software that enables quick assessment of an individual's movement and balance within minutes
52103|NCT03776994|Biological|Vaccinations on Day 0, Day 28, and Day 140|The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 [Day 28], and Week 20 [Day 140]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
52104|NCT03776981|Other|Core Activation|Volitional activation of the transversus abdominis muscle during self-selected paced ambulation for both groups.
52105|NCT03776981|Other|Core Stabilization|Six-week core stabilization program for the group of participants with knee osteoarthritis.
52106|NCT03776968|Drug|HC1119|oral
52107|NCT03776955|Drug|Carvedilol|Oral tablet
52108|NCT03776929|Behavioral|Dialectical Behavioral Therapy|Dialectical Behavior Therapy (DBT) is a cognitive behavioral therapy that focuses on the balance between change and acceptance. DBT skills include four modules: two that enforce acceptance-oriented skills, mindfulness and distress tolerance, and two that promote change-oriented skills, interpersonal effectiveness and emotional regulation.
52109|NCT03776916|Other|Simethicone administration 20-30 min before the procedure|Patients intake simethicone 20-30 min before the procedure
52110|NCT03776916|Other|Simethicone administration 31-60 min before the procedure|Patients intake simethicone administration 31-60 min before the procedure.
52111|NCT03776916|Other|Simethicone administration > 60 min before the procedure|Patients intake simethicone administration > 60 min before the procedure.
52112|NCT03776903|Other|ZIKV Detect™ 2.0 IgM Capture ELISA|De-identified archive specimens are tested by ELISA and compared to reference testing (RT-PCR and CDC MAC-ELISA)
52113|NCT03776890|Behavioral|DeStress for Health Program|The program will consist of 4 in person sessions that are based on empirically supported Positive Psychosocial Well-Being PPWB components including Optimism, Mindfulness, Positive Reprisal as well as Strengths-based Cognitive Behavioral Therapy (SBCBT) to improve behavioral self-regulation towards health-related goals. Research staff will conduct face-to-face surveys with participants at baseline and at end of program. Finally, we will conduct a phone-based survey 30 days after program completion to assess sustainability of intervention effects.
52114|NCT03776864|Biological|Pembrolizumab|Given IV
52115|NCT03776864|Drug|Umbralisib|Given PO
52116|NCT03776851|Drug|erythropoietin|erythropoietin 50 International Units (IU) per kilogram three times weekly by subcutaneous route
52117|NCT03776838|Drug|Intravenous Fentanyl guided by SoC+NOL|Predeterminated bolus of IV Fentanyl will be given at the induction of anesthesia (2 mcg/kg), at the time of incision (1 mcg/kg). During surgery, administration of 0.5 mcg/kg of IV Fentanyl will be administred following a pre determinated algorithm based on NOL index + heart rate + mean arterial blood pressure variations.
52118|NCT03776838|Drug|Intravenous Fentanyl guided by SoC|Bolus of IV Fentanyl at the discretion of a physician will be given at the induction of anesthesia, and at the time of incision. During surgery, administration of IV Fentanyl at the discretion of a physician will be administred following a pre determinated algorithm based on heart rate + mean arterial blood pressure variations.
52119|NCT03776825|Device|Permacol Paste|Permacol Paste Injection
52120|NCT03776812|Drug|Relacorilant, 100mg QD|Relacorilant is supplied as capsules for oral dosing
52121|NCT03776812|Drug|Nab-paclitaxel, 80mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
52122|NCT03776812|Drug|Nab-paclitaxel, 100mg/m^2|Nab-paclitaxel is administered as IV infusion over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle
52123|NCT03776812|Drug|Relacorilant, 150mg QD|Relacorilant is supplied as capsules for oral dosing
52124|NCT03776799|Device|Stent-avoiding|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
52125|NCT03776799|Device|Stent-based|Stenting, in which a stent is advanced and implanted in the obstructed artery, has become the standard endovascular treatment for peripheral arteries
52126|NCT03776786|Biological|TY014|TY014 Injection, (100 mg/5 mL/Vial), Yellow Fever Virus (YFV) Monoclonal Antibody (mAb)
52127|NCT03776786|Other|0.9% Saline|Placebo
52128|NCT03776773|Other|Pollution exposure|Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
52129|NCT03776760|Device|Fingerstick GeneXpert HCV RNA quantitative assay|All participants at risk of HCV infection will receive HCV RNA testing using the GeneXpert finger-stick point-of-care HCV quantitative assay 6 monthly
52130|NCT03776760|Drug|sofosbuvir/velpatesvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
52131|NCT03776760|Drug|glecaprevir/pibrentasvir|Participants with active HCV infection will be offered treatment with one of two pan-genotypic regimens available in Australia
52132|NCT03776747|Drug|Prone hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
52133|NCT03776747|Drug|Supine hyperpolarized 3 helium gas scan|Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
52134|NCT03776747|Diagnostic Test|Vitals|
52135|NCT03776747|Diagnostic Test|Pulmonary Function Tests|Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
52136|NCT03776747|Diagnostic Test|Initial protocol MRI scan|Initial scan to determine placement
52137|NCT03776734|Other|Cryotherapy application|Effects of 5-10- 20 minutes cold application on quadriceps muscle
52138|NCT03776721|Procedure|Liposuction|Liposuction is performed on the abdomen or thighs.
52139|NCT03776721|Procedure|Fat graft|30mL harvested lipoaspirate is injected at the affected axillary site.
52140|NCT03776721|Procedure|Sham graf (Saline injection)|30mL saline is injected at the affected axillary site.
52141|NCT03776721|Biological|Stem cell injection|4mL stem cell suspension injected at the affected axillary site.
52142|NCT03776721|Procedure|Saline injection|4mL saline injected at the affected axillary site.
52143|NCT03776708|Other|Spinal manipulation|Spinal manipulation is defined as a quick, passive and forced manoeuvre applied to spinal joints, and sometimes followed by a characteristic cracking sound. It can be compared to a mobilisation, which is a passive manual therapy as well, but is applied slower and repetitively on the joints. Spinal manipulation has been shown to have a significant clinical impact in the treatment of musculoskeletal pain
52144|NCT03776708|Other|Sham procedure|"The sham procedure is a manual contact on both inferior angles of the scapulae by the chiropractor. After a short tensioning, a slight movement with low velocity and low amplitude is done, respecting scapula-thoracic sliding plans laterally, without repercussion on the spine. It is considered by us to be a credible sham procedure, as it resembles an actual act of thoracic manipulation, and it has been validated, with questionnaires"
52145|NCT03776695|Biological|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
52146|NCT03776695|Other|Placebo|0.9% Saline
52147|NCT03776669|Procedure|Laparoscopic sleeve gastrectomy + Hiatal hernia repair|To evaluate the role of concomitant hiatal hernia repair in laparoscopic sleeve gastrectomy for morbidly obese patients.
52148|NCT03776669|Procedure|Laparoscopic sleeve gastrectomy alone|Current mainstay and standard surgical treatment for morbidly obese patients.
52149|NCT03776656|Drug|Allopurinol|Daily oral administration
52150|NCT03776643|Drug|ILT-101 ld-(IL2)|Subcutaneous injections of ILT-101 or Placebo starting with once-daily administration for 5 consecutive days followed by once every two weeks administration during five months
52151|NCT03776630|Other|Blood sample|"Two blood samples (2 tubes of 4 ml for each blood sample) will be collected per patient during the study period for EC and OC. One blood sample will be collected for control population. The first sample will be collected prior to any treatment for EC, OC, and control population.~For EC, the second collection will be done one month post-surgery. For OC, the second collection will be done 6 to 9 months after the initial diagnosis, in most cases at the completion of adjuvant chemotherapy. For control population, there will be no second sample."
52152|NCT03776617|Procedure|scalp block|Scalp block will be performed five minutes before head pinning for elective craniotomy by blocking supraorbital, auriculotemporal, occipital and postauricular branches of the greater auricular nerves.
52153|NCT03776604|Drug|PEG-rhG-CSF|"Subjects with newly diagnosed small cell lung cancer who met the inclusion/exclusion criteria were prophylactically administered the test drug PEG-rhG-CSF 48 h after chemotherapy.~Jin Youli（PEG-rhG-CSF）: The dose is determined according to the patient's weight. Those who weighed more than ≥45kg were given 6mg/time, and those who were <45kg or less were given 3mg/time. Administration method: Subcutaneous injection, the lower edge of the deltoid muscle of both arms is preferentially selected, and each injection is injected once every chemotherapy cycle.~Dosing time: 48 h after chemotherapy."
52154|NCT03776591|Procedure|Open surgery|
52155|NCT03776591|Procedure|Right colectomy|
52156|NCT03776591|Procedure|Laparoscopic surgery|
52157|NCT03776591|Procedure|Central lymphadenectomy and vascular ligation|
52158|NCT03776578|Procedure|swallow fuction and swallow training|nasogastric tube dependence rate
52159|NCT03776565|Other|Ultrasound|Ultrasound of antrum of stomach
52160|NCT03776552|Other|Low energy diet (LED)|LED for 8 weeks
52161|NCT03776552|Other|Gradual weight loss (GWL)|Moderate energy restriction
52162|NCT03776539|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug. All groups will get the same treatment.
52163|NCT03776526|Behavioral|Fitbit® Alta HR Sleep monitoring|Patients will be fitted with a Fitbit® Alta HR after surgery, which will monitor sleep quality (sleep duration and number of awakenings) for the duration of hospitalization.
52164|NCT03776513|Behavioral|an MRI examination|The MRI examination implies the realization of an emotional associative memory task
52165|NCT03776500|Drug|PBTZ169|PBTZ169 crystalline supplied as powder for oral solution
52166|NCT03776500|Drug|Placebo|matching placebo supplied as powder for oral solution
52167|NCT03776487|Drug|Fluorouracil|Given IV
52168|NCT03776487|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
52169|NCT03776487|Biological|Ipilimumab|Given IV
52170|NCT03776487|Biological|Nivolumab|Given IV
52171|NCT03776487|Drug|Oxaliplatin|Given IV
52172|NCT03776487|Procedure|Therapeutic Conventional Surgery|Undergo partial or total gastrectomy and lymphadenectomy
52173|NCT03776474|Biological|Blood collection|Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
52174|NCT03776461|Device|Venus Viva|The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
52175|NCT03776448|Dietary Supplement|Sativa Nigra oil Softgels|Nigella sativa, a flowering plant native to southwest Asia, is considered one of the most important healing medicinal plants in Islamic culture. The use of its richly colored black seeds has been recommended in the prophetic medicine. It's also known by various other names amongst different cultures. Importantly, its seed is known in Arabic as 'habat al Baraka' which translates literally to 'the seed of blessing'.The active ingredient is believed to be thymoquinone richly present in the oil extract of its seeds. Apart from mild occasional gastrointestinal disturbance, black seed oil has no side effects and is considered very safe. .
52176|NCT03776448|Dietary Supplement|Activated Charcoal Softgels|This supplement is manufactured by [Arkopharma Pharmaceutical Laboratories] and is available commercially. The use of activated charcoal softgels as a placebo is documented in several other clinical trials. The single most relevant characteristic of charcoal is its minimal if any gastrointestinal absorption. As a result, it does not undergo any metabolism and is excreted completely in feces. This makes charcoal an attractive placebo choice for small trials or when manufacturing a specific placebo is not feasible. Charcoal softgels are black in color and resemble black seed oil softgels to a great extent.
53375|NCT03767088|Device|WB-EMS|whole body electromyostimulation
52177|NCT03776435|Radiation|Abdomen CT|Patients are divided into CT-exposed or unexposed group according to the presence of claims codes of abdominopelvic CT conducted within seven days before and after appendectomy. The seven-day threshold is arbitrarily determined considering the delay in the diagnosis of appendicitis and the postoperative examination for surgical complication.
52178|NCT03776422|Behavioral|Mobile self-help intervention|Participants receive several apps on their phone including IntelliCare apps, which are based on principles of cognitive-behavioral therapy. Participants also receive the Pocket Helper app, which has been designed for this study. The tools within the Pocket Helper app include a crisis text line that is available 24/7, the Illinois Warm Line which is available Monday through Friday from 8am to 5pm, directions to call 911 in the case of an emergency, the Koko web app that provides crowdsourced emotional support, brief cognitive-behavioral interventions, daily tips, and daily surveys. Phones will also include the StreetLight Chicago app, which provides homeless individuals with up-to-date information on shelters, health clinics, emergency contacts, mental health services, and more.
52179|NCT03776409|Drug|vancomycin plus piperacillin/tazobactam|Patients in intensive care unit who received the combination of VAN(vancomycin) and PTZ (piperacillin/tazobactam) for at least 48 hours, had a serum creatinine level measured in the 24-hour of hospital admission.The dosage and frequency of VAN and PTZ was adjusted based on clinical practice and patient characteristics.
52180|NCT03776409|Drug|vancomycin plus other beta-lactams|Patients in intensive care unit who received the combination of VAN (vancomycin) and other beta-lactams (cefoperazone/sulbactam, meropenem, imipenem/siastatin, ceftriaxone, ceftazidime, et al) for at least 48 hours, had a baseline serum creatinine (Scr) concentration value within 24 hours of hospital admission.The dosage and frequency of VAN and other beta-lactams were adjusted based on clinical practice and patient characteristics.
52181|NCT03776383|Other|Antibiotic use feedback letter|Mailed letters indicating that the physician prescribes more antibiotics than 75% of their peers
52182|NCT03776370|Procedure|Preserve the left colonic artery|Preservation of left colonic artery in rectal cancer surgery.
52183|NCT03776370|Procedure|The left colonic artery is not preserved|The left colonic artery was dissected in rectal cancer surgery.
52184|NCT03776357|Device|VERA clinic|A software system used with the Microsoft Kinect intended to support the physical rehabilitation of adults in the clinic and at home.
52185|NCT03776344|Device|Virtual Reality intervention - Oculus Rift HD|During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
52186|NCT03776331|Diagnostic Test|Flow mediated dilation|Measurement of the change in the vasodilatative reserve of the brachial artery
52187|NCT03776318|Drug|Long-Term Safety Follow-up|STX-015-18-01 long-term safety follow-up
52188|NCT03776305|Drug|Imipenem|1-h infusion of 0.5 g of imipenem diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h. The imipenem PK studies were carried out during administration of the fourth dose of each regimen (18-24 h after the start of the regimen). Blood samples were obtained by direct venipuncture at the following times: before (time zero) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the fourth dose of each regimen.
52189|NCT03776292|Other|monitoring|Primary outcome; composite 1ry outcome [1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
52190|NCT03776279|Drug|Mitoxantrone Hydrochloride Liposome Injection|Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
52191|NCT03776266|Procedure|No intervention is required due to retrospective observational study|Red blood cell transfusion on or after percutaneous coronary intervention
52192|NCT03776253|Behavioral|Psychosocial Care Conquer Fear Support intervention (psychoeducation, attention training, worry management, and detached mindfulness components)|Attend CFS
52193|NCT03776253|Other|Questionnaire Administration|Ancillary studies
52194|NCT03776240|Drug|HD201|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
52195|NCT03776240|Drug|EU-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
52196|NCT03776240|Drug|US-Herceptin|Single-dose 6mg/kg body weight by 90 minute intravenous infusion
52197|NCT03776227|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
52198|NCT03776201|Other|Balance Training|We expect that a balance training intervention that utilizes an external focus of attention will lead to the adoption of balance strategies that are protective against falls. The mechanism for this behavioral change will be identified using a Dynamical Systems Theory framework (i.e., entropy) to quantify postural sway characteristics before, during and after the training. We will determine whether the balance intervention utilizing an external focus of attention will lead to positive benefits through the three specific aims.
52199|NCT03776175|Drug|PF-05221304 Monotherapy|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of Placebo for PF-06865571, each to be taken twice daily for 41 days and once on Day 42.
52200|NCT03776175|Drug|PF-06865571 Monotherapy|Participants enrolled in this Arm will receive 300 mg dose of PF-06865571 (3 tablets of 100 mg each) and 3 tablets of Placebo for PF-05221304, all to be taken twice daily for 41 days and once on Day 42.
52201|NCT03776175|Drug|Placebo|Participants enrolled in this Arm will receive 3 tablets for Placebo of PF-05221304 and 3 tablets of Placebo of PF-06865571, to be taken twice daily for 41 days and once on Day 42.
52202|NCT03776175|Drug|PF-05221304 and PF-06865571 Combination|Participants enrolled in this Arm will receive 15 mg dose of PF-05221304 (3 tablets of 5 mg each) and 3 tablets of PF-06865571 (3 tablets of 100 mg each), each to be taken twice daily for 41 days and once on Day 42.
52203|NCT03776162|Procedure|ACL Reconstruction (Bone Patellar Tendon Bone Graft)|Standard of care procedure Patellar Tendon Autograft ACL reconstruction, in which a bone-patellar tendon-bone graft from the front of the knee is taken to replace the torn ACL.
52204|NCT03776162|Device|Bridge Enhanced ACL Repair (BEAR)|The BEAR technique involves surgically placing a sponge (the BEAR scaffold) between the torn ends of the ACL, providing a scaffold for the ligament ends to group into.
52205|NCT03776149|Dietary Supplement|Beetroot juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
52206|NCT03776149|Dietary Supplement|Black currant juice|Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
52207|NCT03776136|Drug|lenvatinib|Administered orally once a day during each 21-day cycle.
52208|NCT03776136|Biological|pembrolizumab|Administered as an IV infusion on Day 1 Q3W.
52209|NCT03776110|Drug|GRT9906 PR tablet|40 mg GRT9906 PR tablet oral (minimal release of 80 percent after 480 minutes)
52210|NCT03776110|Drug|Placebo|Placebo tablet matching 40 mg GRT9906 PR tablet
52211|NCT03776097|Other|observational study|Observational study
52212|NCT03776084|Device|Continuous Positive Airway Pressure|CPAP indication
52213|NCT03776071|Drug|Enzastaurin Hydrochloride|mg
52214|NCT03776071|Other|Placebo|mg
52215|NCT03776071|Drug|Temozolomide|mg/m^2
52216|NCT03776071|Radiation|Radiotherapy|Gy
52217|NCT03776058|Drug|Cinacalcet|Tablets for oral administration
52218|NCT03776058|Drug|Placebo|Tablets for oral administration
52219|NCT03776045|Other|Standard care plus exercise|The exercise was supervised by exercise science staff in the exercise science facilities at the University of East Anglia, UK. Participants competed two weekly sessions for 12 weeks upon initiating ADT. Each session lasted ~60 min and included aerobic interval exercise on a cycle ergometer (Monark 824E; Varberg, Sweden) followed by resistance training. In addition to the supervised exercise sessions, patients were advised on how to increase their habitual physical activity levels and were encouraged to engage in 30 minutes of self-directed exercise on three days each week (e.g. brisk walking, cycling, home-based resistance training).
52220|NCT03776032|Drug|Darbepoetin alfa|Administered by subcutaneous injection once a week
52221|NCT03776032|Drug|Placebo|Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
52222|NCT03776019|Device|AVWF device|The AVWF method utilizes sound modulated music, which is thought to regulate the vagus nerve.
52223|NCT03776006|Procedure|Transperineal Laser Ablation|Transperineal Laser Ablation of the Prostate
52224|NCT03775993|Drug|Human growth hormone|Administration of growth hormone
52225|NCT03775993|Other|Placebo|Administration of placebo
52226|NCT03775980|Device|Emprint Microwave Ablation System|Microwave Ablation of colorectal liver metastases
52227|NCT03775967|Diagnostic Test|sialic acid|sialic acid level estimation in salivary samples
52228|NCT03775967|Diagnostic Test|IL10|IL10 estimation in salivary samples
52229|NCT03775954|Diagnostic Test|Fetal Magnetocardiogram and Neonatal Electrocardiogram|Fetal Magnetocardiography (fMCG) is a new non-invasive diagnostic procedure that records tiny fetal cardiac signals similar to an Electrocardiogram or Holter monitor. The magnetometer has FDA clearance, and does not emit magnetic, electric or other energies. This is not an MRI. Examples of fetal MCG's can be found in the Links. The American Heart Association Scientific Statement on Fetal Diagnosis and Treatment (Circulation, 2014) has declared fMCG to be Class IIa for fetal heart rhythm abnormalities, meaning that benefit far exceeds risk. As part of this study, a neonatal electrocardiogram (nECG) will be obtained for comparison after the baby is born.
52230|NCT03775928|Drug|Apatinib|apatinib 425mg qd po
52231|NCT03775928|Drug|capecitabine|capecitabine 1000mg/m2 bid d1-d14
52232|NCT03775915|Other|Neurofeedback|A visual representation of the participants brain activity during movement of their affected hand in the MRI scanner.
52233|NCT03775915|Other|Sham Neurofeedback|A visual representation of brain activity pre-recorded from a previous participant
52234|NCT03775902|Drug|Placebo, Nicorandil, Glimepiride|On three separate experimental days, one of the two drugs or placebo is administered in tablet form.
52235|NCT03775889|Behavioral|Gardening|Assist with planting and maintaining the school garden, as well as observe the school garden curriculum and dietary assessment protocols
52236|NCT03775876|Procedure|Shoulder Arthroscopy|patients in both groups are programmed for an elective shoulder arthroscopy surgery
52237|NCT03775876|Procedure|Regional Block|patients in both groups received regional block for anesthesia: brachial plexus blockade was performed using the interscalene approach under ultrasound combined to nerve stimulation. 20 ml ropivacaine 0.375% were injected.
52238|NCT03775876|Drug|Propofol|propofol 10mg/ml was used for sedation as described in the arms section
52239|NCT03775876|Drug|Dexmedetomidine|Dexmedetomidine was diluted to 4mcg/ml and used for sedation as described in the arms section
52240|NCT03775876|Diagnostic Test|BIS|sedation level was monitored using bispectral index to achieve values described in the arms group
52241|NCT03775863|Procedure|Liver transplantation|Liver transplantation for patients with hepatocellular carcinoma
52242|NCT03775850|Biological|EDP1503|4 capsules taken by mouth twice daily. Each capsule will contain ≥ 7.5x10^10 colony-forming units (CFU)
52243|NCT03775850|Biological|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks
52244|NCT03775837|Dietary Supplement|Panax Ginseng C.A. Mey Extract group|This group takes Panax Ginseng C.A. Mey Extract for 8 weeks
52245|NCT03775837|Dietary Supplement|Placebo group|This group takes placebo for 8 weeks
52246|NCT03775824|Drug|MTX start|Patient prescribed MTX s.c. or p.o. because of active rheumatoid arthritis
52247|NCT03775824|Drug|TNF start|Patient prescribed TNF-inhibitor because of active rheumatoid arthritis
52248|NCT03775811|Other|Computer-assisted histological prediction of colon polyps|The objective is to validate in real clinical practice an improved version of our computer histological prediction system
52249|NCT03775798|Drug|Direct antiviral agents for hepatitis C|Direct-acting antivirals for hepatitis C
89780|NCT03485157|Drug|Saline|Injection of 1 mL 0.9% Sodium Chloride, USP
52250|NCT03775785|Dietary Supplement|Tailored enteral nutrition|"The mean of three measurements per batch (3 x 2-3ml) will be used to calculate the required amount of extra fat, protein, and carbohydrate for the following 3 days of fortification using a predefined Excel spread sheet (Microsoft Inc, Redmond, Washington).~The intervention will consist of adding fat, protein, and/or carbohydrate to achieve target levels of macronutrients.~The defined macronutrient concentration in breast milk is 4.4 g/100 mL of fat, 3 g/100 mL of protein, and 8.8 g/ 100 mL of carbohydrate to meet the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) guidelines (6.6 g/kg/d of fat, 4.5 g/kg/d of protein, and 13.2 g/kg/d of carbohydrate) assuming an intake of 150 mL/kg/d."
52251|NCT03775772|Procedure|Oral Health|"test group will receive an dental hygiene program for one year~control group will remain with dental hygiene regime like done before study participation (maximum of two dental hygiene Treatments per year)"
52252|NCT03775772|Procedure|Bite Force|"test group will receive physiotherapy with the aim of increasing muscle strength in chewing muscles for 3 months~control group will remain without such training"
52253|NCT03775759|Procedure|Tricuspid valve repair or replacement|Available rings used at Duke include the Tri-Ad™ Adams Tricuspid Ring by Medtronic, the TAILOR™ FLEXIBLE ANNULOPLASTY RING by St. Jude Medical/Abbott, and the Carpentier-Edwards Physio II Ring by Edwards LifeSciences. Available valves used at Duke include the Mosaic™ Mitral Orbutrator by Medtronic, the Carpentier-Edwardes PERIMOUNT Magna Mitral Ease Pericardial Bioprosthesis by Edwards LifeSciences, the On-X Mitral Valve, by CryoLife, the Carbomedics Prosthetic Heart Valve by LivaNova, and the St. Jude Medical™ Mechanical Heart Valve by St. Jude Medical/Abbott.
52254|NCT03775759|Other|Medical management of tricuspid regurgitation|The medical therapy involved includes inotropic medications and diuretic medications, which are standard of care for patients in this population.
52255|NCT03775746|Drug|Clopidogrel 75Mg Tablet|Prevention of atherothrombotic events in percutaneous coronary intervention (adjunct with aspirin) in patients not already on clopidogrel
52256|NCT03775746|Drug|Rivaroxaban 2.5Mg Tablet|Prophylaxis of atherothrombotic events following an acute coronary syndrome with elevated cardiac biomarkers (in combination with aspirin alone or aspirin and clopidogrel)
52257|NCT03775746|Drug|Ticagrelor 90Mg Tablet|Prevention of atherothrombotic events in patients with acute coronary syndrome [in combination with aspirin]
52258|NCT03775733|Dietary Supplement|Hydrolysed Red Ginseng Extract|Hydrolysed Red Ginseng Extract 2.4g/day for 12 weeks.
52259|NCT03775733|Dietary Supplement|Placebo|Placebo for 12 weeks.
52260|NCT03775720|Behavioral|Dietary advice|Based on their genetic risk, participants are given advice to either adhere to general dietary guidelines related to salt intake or to reduce their salt intake to no more than 4 grams per day.
52261|NCT03775707|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
52262|NCT03775707|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
52263|NCT03775694|Device|dMRI Scan|Data will be collected from cases where dMRI scans were obtained as part of the subject's previous treatment.
52264|NCT03775681|Procedure|Endoscopic Retrograde Cholangiopancreatography|Undergo standard of care ERCP
52265|NCT03775681|Other|Interview|Ancillary studies
52266|NCT03775681|Device|Laryngeal Mask Airway|Wear LMA
52267|NCT03775668|Drug|1 µCi of 14C-AAI101 + 500 mg AAI101|Single dose open label
52268|NCT03775655|Drug|Dexmedetomidine|10μg dexmedetomidine will be added to the injectate to be injected intrathecally
52269|NCT03775642|Behavioral|Intervention video|The intervention video will employ the debiasing strategies. It will avoid directly articulating contraception-related myths, but instead will provide a limited number of alternative explanations related to IUD and implant safety.
52270|NCT03775642|Behavioral|Control video|The video for the control arm will consist of an existing, public-use video on a non-contraception topic of similar duration
52271|NCT03775629|Drug|Polmacoxib and Tramadol combination|Tramadol hydrochloride (HCl) 150mg, Polmacoxib 2mg
52272|NCT03775629|Drug|Polmacoxib|Polmacoxib 2mg
52273|NCT03775629|Drug|Tramadol hydrochloride|Tramadol hydrochloride (HCl) 150mg
52274|NCT03775616|Other|Educational Intervention|Receive financial navigation program intervention
52275|NCT03775616|Other|Questionnaire Administration|Ancillary studies
52276|NCT03775616|Other|Quality-of-Life Assessment|Ancillary studies
52277|NCT03775603|Device|TOFscan|comparison of TOFscan over TOF-Watch SX
52278|NCT03775590|Procedure|Water|To evaluate using water in the treatment of atopic dermatitis
52279|NCT03775590|Procedure|Bleach|To evaluate using water + dilute bleach in the treatment of atopic dermatitis
52280|NCT03775590|Procedure|Acetic acid|To evaluate using water + vinegar in the treatment of atopic dermatitis
52281|NCT03775564|Other|REMEDRUGBY PROGRAM|"1st Session presentation of the programme, its objectives and a common reflection on the concepts of stigmatization/destigmatization.~2nd to 4th session devoted to a group reflection on social conventions and their meaning followed by a practice by means of role-playing.~5th to 7th session devoted to writing comments about tournaments on the blog by working on the intentions of others and the emotional impact of comments on their recipients.~8th, 9th 11th sessions devoted to media relations with group reflection on the image of themselves and their pathology that participants wish to refer to the media, followed by a practice in role-playing games Interviewer-interviewed~10th session devoted to planning and organizing the day of matches with writing a program of the day and spreading on the blog~12th General Debriefing session Including : - 3 tournaments~8 hours of Touch Rugby"
52282|NCT03775564|Other|TOUCH RUGBY PROGRAM|Practical training Program at Touchrugby at the rate of 12 weekly sessions of 2 hours and 3 inter-institutional tournaments per day
52283|NCT03775564|Other|TAU|Treatment as usual
52284|NCT03775551|Behavioral|Improvement cycle|at least 6 workshops (sessions) will be held with the members of the care system, in order to identify opportunities for improvement oriented to the design and application of an innovative intervention based on best practices.
52285|NCT03775538|Drug|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
52286|NCT03775538|Device|Renishaw Drug Delivery System|Stereotactically implanted device
52287|NCT03775525|Drug|GZ17-6.02|Super enhancer Inhibition
52288|NCT03775512|Device|RF Ablation with QDOT Micro|Subjects will be ablated using QDOT Micro catheter
52289|NCT03775499|Dietary Supplement|Intervention 1 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
52290|NCT03775499|Other|Intervention 1 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
52291|NCT03775499|Dietary Supplement|Intervention 2 : BL NCC 2705 + Maltodextrin|2 capsules of BL NCC 2705/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of BL NCC 2705 in the morning of the 4th day
52292|NCT03775499|Other|Intervention 2 : Maltodextrin|2 capsules of Placebo/day (1 in the morning and 1 in the evening) for 3 days + 1 capsule of Placebo in the morning of the 4th day
52293|NCT03775486|Drug|Durvalumab|Initial therapy phase: IV infusion q3w for 4 cycles. Maintenance phase: IV infusion q4w.
52294|NCT03775486|Drug|Placebo for Olaparib|Matching tablet
52295|NCT03775486|Drug|Olaparib|150-mg tablets (2 × 150-mg tablets for 300-mg dose) 100-mg tablet available if dose reductions are required
52296|NCT03775486|Drug|Nab-paclitaxel+carboplatin|Standard of Care chemotherapy (squamous and non-squamous patients)
52297|NCT03775486|Drug|Gemcitabine+carboplatin|Standard of Care chemotherapy (squamous patients only)
52298|NCT03775486|Drug|Pemetrexed+carboplatin|Standard of Care chemotherapy (non-squamous patients only)
52299|NCT03775486|Drug|Gemcitabine+cisplatin|Standard of Care chemotherapy (squamous patients only)
52300|NCT03775486|Drug|Pemetrexed+cisplatin|Standard of Care chemotherapy (non-squamous patients only)
52301|NCT03775473|Diagnostic Test|progastrin|PROCODE is an interventional study of category 2 (non-medicinal product), with a minimal risks and restrictions, involving only one blood drawn at the screening of colon cancer.
52302|NCT03775460|Drug|Methotrexate|Participants in the intervention group will receive methotrexate along side prednisolone
52303|NCT03775460|Drug|Placebo|Participants in the control arm will receive placebo along side prednisolone
52304|NCT03775460|Drug|Prednisolone|Participants in both arm will receive prednisolone, which will be the same dosage: 40 mg (initial dose) decreasing dosage for 20 weeks
52305|NCT03775447|Procedure|Lumbar Puncture|Lumbar Puncture for collection of Cerebrospinal Fluids
52306|NCT03775434|Drug|Experimental: B244|B244 suspension in 30ml/bottle
52308|NCT03775408|Device|FAST|Orthopaedic surgeons will use the FAST device to facilitate entry point selection and alignment of a guidewire for intramedullary nailing of femoral shaft fractures.
52309|NCT03775395|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
52310|NCT03775395|Drug|Sorafenib|400mg BID daily oral dosing
52311|NCT03775395|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
52312|NCT03775382|Other|Ascorbic Acid|"Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline."
52313|NCT03775382|Other|Normal Saline|Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
52314|NCT03775369|Other|endurance training|physical activity and exercising (PAE)
52315|NCT03775369|Other|social support and counseling|social support and counseling
52316|NCT03775369|Other|resistance training|physical activity and exercising (PAE)
52317|NCT03775356|Other|Treatment of hypotension and/or reduction of anesthetics|The treatment of hypotension can be done by the responsible anesthetist according to the clinical standard operations including any accepted drug typically used in this hospital. The reduction of anesthetics can be done either by reducing the volatile end tidal anesthetics concentration (ETAC) or the infusion rate of propofol.
52318|NCT03775343|Diagnostic Test|Neurocognitive Test Battery|neurocognitive testing: preoperative(baseline), 6 and 24 hours postoperative.
52319|NCT03775343|Diagnostic Test|Blood sampling|Blood sampling before surgery (baseline), immediately postoperative, 6 and 24 hours after surgery, investigating plasma levels of S 100-B, CRP, vitamines, homocysteine and folic acid
52320|NCT03775330|Radiation|Stereotactic Radiosurgery (SRS)|"SRS or hypofractionated stereotactic radiation delivered via the Leksell Gammknife Perfexion/Icon radiosurgery system~Maximum diameter of metastasis (doses in single fraction):~≤ 2 cm: 15-20 Gy > 2 cm and ≤ 3 cm: 15-18 Gy > 3 cm and ≤ 4 cm: 15 Gy~Tumour location (doses in single fraction):~Brainstem: 15 Gy~Hypofractionated stereotactic radiotherapy 25-32.5 Gy in 5 fractions may be used for lesions > 2 cm at the discretion of the radiation oncologist~Note: SRS dosing reduced by 20% (for all prescriptions > 15 Gy) when patient is randomized to SRS + WBRT arm"
52321|NCT03775330|Radiation|Whole brain radiation (WBRT)|WBRT 20 Gy in 5 fractions or 30 Gy in 10 fractions at the discretion of the radiation oncologist
52322|NCT03775317|Procedure|Video Laryngoscopy|The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
52323|NCT03775317|Procedure|Direct Laryngoscopy|The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
52324|NCT03775291|Diagnostic Test|Simultaneous assessment of sleep apnea by polysomnogram and wearable device|Characterization of sleep apnea by lab-based polysomnogram
52325|NCT03775278|Drug|PHP-303|Investigational drug
52326|NCT03775278|Other|Placebo|Matching placebo
52335|NCT03775252|Dietary Supplement|Ketogenic diet|Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
90803|NCT03476928|Drug|Vilaprisan (BAY1002670)|2mg, once daily, oral
52336|NCT03775239|Behavioral|Mindfulness in Sex Therapy and Intimate Relationships (MSIR)|"Mindfulness is a mental discipline inviting intentional, non-judgmental attending of the stream of experience. Mindfulness can be seen as an adjunct to sexual therapy. Firstly, it is a way of teaching the patients and the couples to carry out sensate focus so that it can achieve its goals. Beyond this, Mindfulness may invite a stance to one's own and a partner's physical and emotional experience that is more widely beneficial. The MSIR intervention was originally developed from the Mindfulness Based Cognitive Therapy (MBCT) protocol and consists of:~Week 1: Moving into the Body Week 2: Sensing & Exploring Week 3: Avoidance & Intimacy- Midway individual session. Week 4: Recognising our automatic mind Week 5: Spacious Awareness Week 6: Expanding new learning"
52337|NCT03775239|Behavioral|Treatment-as-usual|"The current treatment in Sexological Clinic is an eclectic, synthetic therapy form conducted by psychiatrists, other medical doctors, psychologists and bodytherapists.~In order to implement the bio-psycho-social character of sexual dysfunctions, the current treatment takes advantage of different elements from different therapy forms combined with pharmacological treatment if necessary.~The integrated treatment combines elements from therapy's such as cognitive behavioural therapy (CBT), psychodynamic therapy and systemic therapy together with Master and Johnson's sensate focus training, body exercises training as pelvis floor exercises, introduction of sexual aids and if necessary pharmacological treatment. The therapy can be individual treatment, couple therapy (marital therapy) or group therapy."
52338|NCT03775226|Device|ChampioNIR® SFA Stent|The ChampioNIR® SFA Stent is composed of a Nitinol alloy structure with an elastomeric micro-fiber mesh and is designed specifically to be used in the peripheral vasculature. The stent is characterized by high flexibility, strong radial support and high resistance to fractures, as well as high deliverability and precise positioning.
52339|NCT03775213|Behavioral|Decision Aid|The decision aid will communicate trade-offs for different management strategies for DCIS, including active surveillance and active treatment.
52340|NCT03775200|Drug|Psilocybin|Dose-ranging
52341|NCT03775187|Biological|Burosumab|
52342|NCT03775174|Drug|Mepsevii|
52343|NCT03775161|Device|V-LAP™ System|Delivery of the V-LAP™ implant via a catheter-based approach in a trans-septal puncture procedure, deploying it in the inter-atrial septum.
52344|NCT03775148|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction (TranS-C)|TranS-C integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy.
52345|NCT03775135|Other|Questionnaires|Different questionnaires about identity development and psychosocial functioning will be administered
52346|NCT03775122|Device|TAES|TAES over acupuncture point neiguan (pericardium 6) for 20min, placebo group only stick the stimulate electrode but no frequency and intensity
52347|NCT03775109|Drug|Canakinumab 150mg/ml solution for injection|Canakinumab 150mg/ml solution for injection
52348|NCT03775109|Drug|Placebo|100ml 5% Dextrose
52349|NCT03775096|Drug|Carvedilol|At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
52350|NCT03775083|Drug|Currently approved medications|subjects will be treated according to current Department of Health and Human Services (DHHS) Center for Disease control and prevention (CDC), Society for Healthcare Epidemiology of American (SHEA guidelines for nPEP
52351|NCT03775070|Drug|Simvastatin|"Starting dosage: in adult, the dose of simvastatin is 10 mg once daily. In children, the dose is 0.25mg/Kg/day (maximum dose: 10 mg/d).~Target dosage: in adult, the dose of simvastatin is 20 mg once daily. In children, the dose is 0.5mg/Kg/day (maximum dose: 20 mg/d).~The basic anti-congestive medication will be kept as the same."
52352|NCT03775057|Other|MyDoseCoach app|The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
52353|NCT03775044|Device|Medherent Device|The Medherent Medication Management Device (MMD) is intended to enable patients to self-manage their medication at home when it may otherwise require assistance.
52354|NCT03775031|Device|Fractional Laser and Chemical Peel|Fractional 1927 nm Laser, Fractional 1550 nm Laser, and 25% TCA (trichloroacetic acid) peel
52355|NCT03775018|Procedure|Transversus abdominis plane blockade|Patients will undergo Transversus abdominis plane blockade with Bupivacaine 0.25% 30ml, applied in the plane between the internal oblique muscle and the trasnversus abdominis. The injection will be performed laterally to the port-sites, bilaterally at the same levels.
52356|NCT03775018|Drug|Intravenous analgesia|Acetaminophen 1g/6h iv will be administered
52357|NCT03775005|Radiation|standard treatment|3000 cGy in 10 daily fractions
52358|NCT03775005|Radiation|short course treatment|1800 cGy in 4 fractions administered twice a day
52359|NCT03774992|Device|Orthokeratology lenses|Custom fit, form stable contact lenses
52360|NCT03774979|Drug|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a pre-set dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the trial.
52361|NCT03774966|Procedure|Adductor Canal Block + Catheter & IPACK block|Adductor Canal Block + Catheter & IPACK block
52362|NCT03774966|Procedure|Adductor canal block + catheter|Adductor canal block + catheter
52363|NCT03774953|Dietary Supplement|Protein and vitamin supplementation|The intervention group will receive 1.5 g protein/kilo/day during hospitalization and a standard dose of 27 g protein/day in 60 days after discharged together with a daily dose of vitamin/mineral supplement
52364|NCT03774940|Diagnostic Test|peripheric blood count|preoperative peripheric blood count
52365|NCT03774927|Device|10 Hz treatment group|10 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 27-s intervals with 20s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
52366|NCT03774927|Device|20 Hz treatment group|20 Hz stimulations over left DLPFC occurred at a power of 110% of MT for 20 intervals with 28s inter-train interval. 20 minutes were administered each day (Monday-Friday) for 8 consecutive weeks.
52367|NCT03774927|Device|Control Group|all procedures were identical to 10Hz group except they were the non-magnetized steel cylinders, instead of cylindrical magnets, that were rotated.
52368|NCT03774914|Drug|Alemtuzumab (GZ402673)|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
52369|NCT03774901|Drug|Avelumab|intravenous 10 mg/kg every 2 weeks
52370|NCT03774888|Procedure|Connective tissue graft at time of bone graft|following the placement of the bone graft and the membrane, a CTG will be harvested and sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
52371|NCT03774888|Procedure|Acellular Demal Matrix at time of bone graft|following the placement of the bone graft and the membrane, an ADM will be sutured to the membrane and then the flaps passively sutured on top on the bone and soft tissue graft
52372|NCT03774888|Procedure|No soft tissue grafting at time of bone graft|Following the placement of the bone graft and the membrane, the flaps passively sutured on top on the bone. No soft tissue graft will be added.
52373|NCT03774875|Drug|Apremilast (CC-10004)|"This study will randomize subjects to either apremilast 30 mg BID or placebo comparator in a 2:1 ratio, respectively. Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk 16 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 20. Thereafter, IP will be dispensed in open-label bottles."
52374|NCT03774875|Other|Placebo|Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally twice daily for 16 weeks.
52375|NCT03774875|Drug|Apremilast (CC-10004)|Beginning at Week 16 and after a 5-day titration with apremilast, subjects initially randomized to placebo will be switched to receive apremilast 30 mg BID for 36 weeks (52 weeks total). Investigational product (IP) will be dispensed in blinded dose cards until Week 20. Thereafter, IP will be dispensed in open-label bottles
52376|NCT03774849|Device|PicoWay™ 532nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
52377|NCT03774849|Device|PicoWay™ 730nm wavelength|PicoWay™ Laser System is picosecond 532/1064/785 laser
52378|NCT03774849|Device|PicoWay™ 1064nm fractional handpiece|PicoWay™ Laser System is picosecond 532/1064/785 laser
52379|NCT03774836|Drug|Tramadol|IV Tramadol 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
52380|NCT03774836|Drug|Morphine|Morphine 4 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
52381|NCT03774836|Other|Placebo|Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
52382|NCT03774823|Device|RF and PEMF|RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
52383|NCT03774823|Device|Ultrasound|Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
52384|NCT03774810|Drug|Zolpidem tartrate|Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.
52385|NCT03774797|Other|Implementation Toolkit|Post-implementation patients and providers will be assessed after the implementation toolkit has been used to improve service delivery at the study site.
52386|NCT03774771|Drug|Cinacalcet|Capsule for oral administration
52387|NCT03774771|Drug|Placebo|Capsules for oral administration
52388|NCT03774758|Diagnostic Test|Guardant Health ct-DNA LUNAR assay|Guardant Health is focused on conquering cancer by using its breakthrough blood-based assays, vast data sets, and advanced analytics. In 2016, it announced Project LUNAR, an effort to apply Guardant Health's technology platform to early detection, recurrence monitoring, and assessing minimal residual disease.
52389|NCT03774745|Drug|Mifepristone 200 MG|All subjects receive mifepristone tablet on treatment day 1.
52390|NCT03774745|Drug|micronized Progesterone|Subjects randomized to progesterone receive treatment starting day 2.
52391|NCT03774745|Drug|Placebo oral capsule|Subjects randomized to placebo receive treatment starting day 2.
52392|NCT03774732|Radiation|Radiotherapy|Irradiation technique (3D-CRT or SABR) will be at physician discretion.
52393|NCT03774732|Drug|Anti-PD(L)-1|Anti-PD-(L)1: Nivolumab, atezolizumab or pembrolizumab will be administered as per standard of care
52394|NCT03774719|Device|Hand-carried ultrasound|Hand-carried ultrasound of both kidneys to detect the presence or absence of hydronephrosis. Device used will be the lumify portable ultrasound equipped with the C5-2 curved array transducer (Philips, USA).
52395|NCT03774706|Drug|Misoprostol|two tablets misoprostol 400 μg sublingual
52396|NCT03774706|Drug|Tranexamic Acid|two ampoules of tranexamic acid (1gm in 10 ml) in 100ml saline
52397|NCT03774706|Drug|placebo to tranexamic acid|placebo to tranexamic acid (110 ml saline)
52398|NCT03774693|Other|General anesthesia with fentanyl boluses|Patients will receive general anesthesia with Fentanyl boluses of 0.5 mcg.Kg-1 given to maintain MAP between 55-65 mmHg with a maximum dose of 3 mcg.Kg-1
52399|NCT03774693|Procedure|Regional block|Patients will receive trans-oral bilateral sphenopalatine ganglion block and trans-oral bilateral infraorbital nerve block.
52400|NCT03774680|Drug|Cetuximab nanoparticles|The active group will receive cetuximab in nanoparticles as an anti-microbial drug.
52401|NCT03774680|Drug|Oral approved anticancer drug|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
52402|NCT03774654|Genetic|CD19.CAR-aNKT cells|"Patients will be given the T-cell product by intravenous injection (into the vein through an IV line) at the assigned dose.~Dose Level 1: 1 x 10^7/m2. Dose Level 2: 3 x 10^7/m2. Dose Level 3: 1 x 10^8/m2. Dose Level 4: 3 x 10^8/m2."
52403|NCT03774654|Drug|Cyclophosphamide|Lymphodepletion chemotherapy. Patients will receive 3 daily doses of cyclophosphamide (500mg/m^2/day) finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle).
52404|NCT03774654|Drug|Fludarabine|Lymphodepletion chemotherapy. Patients will receive 3 daily doses of fludarabine (30mg/m^2/day) finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle).
52405|NCT03774641|Drug|Lamictal|Blood-serum levels will be checked monthly during pregnancy and reference concentration will be maintained
52406|NCT03774628|Biological|Chengdu Kanghua (one booster shot)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0
52407|NCT03774628|Biological|Chengdu Kanghua (two booster shots)|A rabies vaccine (human diploid cell) for human use, Freeze-dried produced by Chengdu Kanghua Biological Products Co.,Ltd. 1.0 ml experimental vaccine on day 0 and 3
52408|NCT03774615|Drug|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
52409|NCT03774602|Behavioral|Health promotion and provision of RMNCH services|Implementation of quality, high-impact interventions at institutional and community levels to increase access to and utilization of RMNCH services
52410|NCT03774589|Procedure|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis will be used to complete the anastomosis during bilioenteric anastomosis.
52411|NCT03774589|Procedure|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
52412|NCT03774576|Drug|RO7017773|Single doses of RO7017773
52413|NCT03774576|Drug|Itraconazole|Multiple doses of Itraconazole
52414|NCT03774537|Drug|Transplantation of hUC-MSCs|Preterm infants at high risk for BPD will receive transplantation of hUC-MSCs through intravenous infusion. Dose A - 1 million cells per kg; Dose B - 5 million cells per kg
52415|NCT03774537|Drug|No transplantation of hUC-MSCs|Preterm infants at high risk for BPD will not receive transplantation of hUC-MSCs
52416|NCT03774524|Drug|Misoprostol|400 μg of sublingual misoprostol
52417|NCT03774524|Drug|TA|1 gm of tranexamic acid in 100 ml saline iv
52418|NCT03774524|Drug|placebo to misoprostol|placebo tablets to misoprostol subligual
52419|NCT03774524|Drug|placebo to TA|110 ml saline iv
52420|NCT03774511|Other|High-Intensity Interval Exercise|High-Intensity Interval Exercise
52421|NCT03774498|Drug|Sensodyne repair and protect|NovaMin & fluoride toothpaste
52422|NCT03774485|Device|G-Tech Gutcheck Myoelectric recording device|Three G-Tech patches are placed on the abdomen of the patient to record myoelectric activity.
52423|NCT03774472|Drug|Hydroxychloroquine|Given PO
52424|NCT03774472|Drug|Letrozole|Given PO
52425|NCT03774472|Drug|Palbociclib|Given PO
52426|NCT03774459|Drug|High dose ANAVEX2-73|Active oral capsule
52427|NCT03774459|Drug|Mid dose ANAVEX2-73|Active oral capsule
52428|NCT03774459|Drug|Placebo oral capsule|Placebo oral capsule
52430|NCT03774433|Behavioral|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
52431|NCT03774407|Drug|vaginal estriol|Estriol vaginal cream will be formulated by Twin Oaks specialty pharmacy-by the same compound specialist. 30 mg estriol powder will be mixed with 5 mL of propylene glycol and 22 g of vaginal base cream. The product can be stored at room temperature and has a shelf life of up to 4 months. It comes with an applicator.
52432|NCT03774394|Drug|Clopidogrel|Both CKD and Non-CKD patients will be administered a 600-mg LD of clopidogrel followed by a single 75-mg MD administered after 24 hours.
52433|NCT03774394|Drug|Clopidogrel active metabolite|In both CKD and Non-CKD patients, blood samples collected at baseline only (before clopidogrel LD administration) will be incubated with escalating concentrations of clopidogrel active metabolite (1, 3 and 10 μM)
52434|NCT03774381|Dietary Supplement|Bifidobacterium breve B-3|160 mg of Bifidobacterium breve B-3 is orally administered per day for 12 weeks.
52435|NCT03774381|Dietary Supplement|Control group|160 mg of placebo is orally administered per day for 12 weeks.
52436|NCT03774368|Other|Emergency contraception website|Existing website with factual information about emergency contraception
52437|NCT03774368|Other|Emergency contraception video|Existing video with factual information about emergency contraception
52438|NCT03774355|Drug|CG1801|Administration CG1801 2mg single dose in phase 1 and Administration CGL1802 2mg single dose phase 2.
52439|NCT03774355|Drug|CGL1802|Administration CGL1802 2mg single dose in phase 1 and Administration CG1801 2mg single dose phase 2
52440|NCT03774342|Procedure|Coronary Artery Bypass Grafting|Patients undergoing coronary artery bypass grafting
52441|NCT03774329|Other|Usual care|Patients included in the control group will not benefit from the intervention in adapted physical activity. However, this will not affect their support. Patients will be seen by their specialist doctor as part of the usual management of their IBD.
52442|NCT03774329|Other|adapted physical activity|Patients in the experimental group will have, in addition to their usual follow-up with their specialist doctor, an intervention in adapted physical activity at home, at the rate of 3 sessions (of a duration of 10 to 20 minutes) per week during 9 consecutive months.
52443|NCT03774303|Other|Mobile application|A mobile application that will be used to prepare families for day surgery
52444|NCT03774303|Other|current practice|the current practice used to prepare families for day surgery
52445|NCT03774290|Drug|PBF-680|PBF-680 is an adenosine A1 receptor antagonist
52446|NCT03774290|Drug|Placebo oral capsule|Oral gelatine capsule
52447|NCT03774277|Behavioral|Packed Promise for a Healthy Heart|"Voucher for fresh vegetables and fruits (referred to as a fresh check); Home delivered food boxes that contain Dietary Approaches to Stop Hypertension (DASH)-approved ingredients for preparing low-salt, and traditional healthy Chickasaw meals; Heart-healthy recipes (available at getfreshcooking.com) that are tailored to traditional Chickasaw diet and culture; Educational materials; Personalized invitation to attend local cooking demonstrations; Assistance to link the Fitbit and AYA app"
52483|NCT03773991|Diagnostic Test|Echocardiography|Transthoracic 2D Speckle-Tracking Echocardiography
52448|NCT03774264|Drug|Xiaflex|"The plaque is injected transversely through the width of the plaque, towards the opposite side of the plaque without passing completely through it. For the second injection in a cycle, the site of injection is made approximately 2 to 3 mm apart from the first injection.~Approximately 24 to 72 hours after the second injection of each treatment cycle subjects will undergo investigator initiated penile plaque modeling. The procedure is repeated 3 times (a total of 4 cycles). Subjects are also advised to gently attempt to straighten the penis without pain during spontaneous erection. The treatment cycle is repeated after 6 weeks for up to 4 treatment cycles. Patients may drop out from the study at any time during the study. .~Post-treatment follow up data is collected at 26 weeks (6 months), 39 weeks (9 months) and 52 weeks (12 months) from baseline evaluation. Post treatment measurements will mirror that of baseline evaluation: symptoms, IIEF, PDQ, degree of curvature, penis length."
52449|NCT03774251|Biological|Platelet-Rich Plasma Injection|The patient will undergo a single platelet-rich plasma peritendinous injection
52450|NCT03774251|Device|Extracorporeal Shock Wave Therapy|The patient will undergo a series of three extracorporeal shock wave therapy treatments to the lateral hip
52451|NCT03774238|Other|FMD analysis|Blood sample and vascular exploration.
52452|NCT03774225|Other|Virtual Reality with Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions with a manually and verbally assisted by a experient physiotherapist.
52453|NCT03774225|Other|Virtual Reality with No Manual and Verbal Guidance|Participants will perform 4 balance games during 8 sessions in the presence of a experient physiotherapist that will ensure patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game.
52454|NCT03774225|Other|Physical Therapy|Patients of the control group will be trained with balance exercises by a experient physiotherapist.
52455|NCT03774212|Device|Active noise cancelling headphones|The white noise will play from an 'iPod touch' (Apple), through the active noise cancelling headphones.
52456|NCT03774199|Device|NightOwl|The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
52457|NCT03774186|Device|Hybrid closed-loop therapy|Hybrid closed-loop therapy with a proportional integral derivative (PID) algorithm
52458|NCT03774186|Device|Sensor-augmented pump therapy|Insulin pump + non-communicating CGM
52459|NCT03774173|Drug|Aramchol|One Aramchol tablet (300 mg) twice daily and 2 Aramchol tablets (300 mg each) once daily
52460|NCT03774160|Behavioral|Generacion Actual|See description in arm description.
52461|NCT03774147|Device|24-hour Ambulatory Blood Pressure Monitoring (ABPM)|
52462|NCT03774134|Procedure|Complete mesocolic excision|Based on the principles of CME. The inferior mesenteric artery (IMA) was divided at its origin from the aorta to perform central lymph nodes dissection along the IMA between the aorta and the branching of the left colic artery. Sigmoid resection included the complete sigmoid colon and resection of the upper part of the rectum to ensure sufficient perfusion of the colo-rectal anastomosis. To achieve sufficient distance at the proximal bowel resection margin, parts of the descending colon or even left hemicolectomy were performed at the surgeon's discretion.
52463|NCT03774134|Procedure|Conventional colon resection|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
52464|NCT03774121|Device|Cryoneurolysis|A cryoprobe will be inserted percutaneously and freeze the target nerves (infrapatellar branch of the saphenous nerve & anterior femoral cutaneous nerve) guided by ultrasound visualization.
52465|NCT03774121|Other|Neuromuscular exercise (GLA:D)|The GLA:D program, is a standard education and exercise program for patients with osteoarthritis in Denmark. The program is performed in groups and with the supervision of an experienced physiotherapist specialized in training of musculoskeletal disorders.
52466|NCT03774121|Device|Sham|The sham intervention includes a similar procedure but without freezing temperatures.
52467|NCT03774108|Drug|Metformin Hydrochloride 850 MG|8 weeks tratment with oral metformin
52468|NCT03774108|Other|Placebo|8 weeks tratment with oral placebo
52469|NCT03774095|Dietary Supplement|Hydrolyzed pine nut oil|Given 30 min prior to oral glucose tolerance test
52470|NCT03774095|Dietary Supplement|Hydrolyzed pine nut oil and olive oil|Given 30 min prior to oral glucose tolerance test
52471|NCT03774082|Drug|INC424|Ruxolitinib is taken orally either as 5mg tablets or as pediatric formulation (dosage based on age group)
52472|NCT03774069|Device|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro and sent directly to the patient
52473|NCT03774069|Other|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team according to standard of care
52474|NCT03774056|Drug|HC-1119|oral
52475|NCT03774043|Other|Acute Intermittent Hypoxia|Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
52476|NCT03774043|Other|Sham Acute Intermittent Hypoxia|Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
52477|NCT03774030|Procedure|several virtual 3-D complex audio environments|The focus is a comparison of 3 hearing aid algorithms in a virtual 3-D complex audio Environment.
52478|NCT03774017|Procedure|one-staged hybrid operation|An integrated procedure that consists of microsurgery, intraoperative DSA, endovascular intervention techniques and other assistance tools. All the procedures are performed in a one-staged operation without any intermission or any transfer of patients.
52479|NCT03774017|Procedure|Traditional microsurgical operation|The classical mode of operations in neurosurgery. The operation is performed with neurosurgical instruments and microscope. Some of assisting tools can be used in the operation, such as neuro-navigation, Doppler probe, neural electrophysiological monitoring and so on. But neither the intraoperative DSA nor endovascular intervention techniques is used in the operation
52480|NCT03773991|Diagnostic Test|Lung MRI|Proton Lung Magnetic Resonance Imaging
52481|NCT03773991|Diagnostic Test|Sodium MRI|Sodium Soft Tissue Magnetic Resonance Imaging
52482|NCT03773991|Diagnostic Test|Chest CT|High-resolution Quantitative Chest CT
94060|NCT03451032|Other|Non Interventional Study|Non Interventional Study
52486|NCT03773991|Diagnostic Test|Blood Sampling|Blood testing for: standard-of-care, inflammatory biomarkers, uremic toxins
52487|NCT03773991|Diagnostic Test|Six-Minute Walk Test|Six-Minute Walk Test
52488|NCT03773991|Diagnostic Test|Dyspnea Questionnaires|Modified Medical Research Council; University of California, San Diego Shortness of Breath Questionnaire; Borg Scale
52489|NCT03773978|Drug|Baricitinib|Administered orally.
52490|NCT03773978|Drug|Placebo|Administered orally.
52491|NCT03773965|Drug|Baricitinib|Administered orally.
52492|NCT03773952|Drug|PBF-677|oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
52493|NCT03773952|Drug|Placebo oral capsule|Oral capsules
52494|NCT03773926|Device|Neuro-feedback therapy|The therapy consists of 10 Neuro-feedback training sessions, 2 times per week over 5 weeks.
52495|NCT03773913|Other|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~Community engagement meetings and feedback;~Elimination of public sector facility user fees for children under five and pregnant women;~Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing & referrals;~Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~Basic infrastructure improvements and supply chain management training of pharmacy managers"
52496|NCT03773900|Dietary Supplement|Kiotransine (chitin-glucan from aspergillus niger)|The volunteers will take three times a day one bag of powder containing 1.5g of chitin-glucan fiber during three weeks. The powder will be diluted in water.
52497|NCT03773900|Dietary Supplement|Placebo|The volunteers will take three times a day one bag of powder containing placebo during three weeks. The powder will be diluted in water.
52498|NCT03773887|Other|collection of liver biopsies collection of blood samples|blood and ascites samples; extraction of explants, hepatic resection parts; hepatic parenchyma on liver biopsies
52499|NCT03773874|Other|Assessment|Evaluation
52500|NCT03773861|Other|errors made in one BLS session|BLS instructors have to oversee a standardized BLS training session, where standardized errors are made by trained volunteers.
52501|NCT03773848|Procedure|Open Reduction Internal Fixation (ORIF)|Open Reduction Internal Fixation (ORIF) of fracture lateral third clavicle by hook plate & tightrope
52502|NCT03773835|Drug|HSK3486|Mmanual IV bolus injection completed in 1 minute.
52503|NCT03773822|Combination Product|Hydrocortisone + Flucortac|Low dose steroids
52504|NCT03773822|Other|Placebo|Placebo
52505|NCT03773809|Other|Vitamin D capsule|The intervention was given by oral administration of vitamin D3 capsule each of which contains 40000 IU of vitamin D3. The capsule was manufactured and supplied by Beximco Pharmaceutical Limited, Bangladesh. The placebo was also be manufactured and supplied by the same pharmaceutical company and was similar in size shape & appearance to vitamin D3 capsule but contained all the ingredients of vitamin D capsule other than the vitamin D3
52506|NCT03773809|Other|placebo|oral administration of placebo
52507|NCT03773796|Drug|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
52508|NCT03773783|Device|Button and Bead appliance|Button and Bead appliance
52509|NCT03773783|Device|Twin Block appliance|Twin Block appliance
52510|NCT03773770|Drug|Triheptanoin|
52511|NCT03773757|Behavioral|IN-PEACE Dementia Care Coordination|Patient/Caregivers assigned to the intervention arm will have monthly phone calls with a Nurse or Social Worker, in the capacity of a Dementia care coordinator (DCC) to identify symptoms and behavior problems the person with memory problems is having, including: pain, sadness, or other symptoms. The Dementia Care Coordinator will consult with the project clinical team to develop a plan of care utilizing standardized protocols to reduce the burdens of disease associated symptoms and behaviors. In addition, education and support materials will be provided to the caregiver in the role caring and management of a patient with dementia.
52512|NCT03773744|Drug|Ad-MAGEA3|Adenovirus vaccine expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
52513|NCT03773744|Drug|MG1-MAGEA3|MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen
52514|NCT03773744|Drug|Pembrolizumab|monoclonal antibody; checkpoint inhibitor of PD1
52515|NCT03773744|Drug|Cyclophosphamide|low-dose chemotherapy
52516|NCT03773731|Behavioral|High intensity interval training (HIIT)|Exercise training on bicycle ergometer with high intensity bouts of 1 min interspersed by low intensity recovery intervals
52517|NCT03773731|Behavioral|Moderate intensity continuous training (MICT)|Exercise training on bicycle ergometer with moderate intensity (60 - 65 % of individual maximal power output)
52518|NCT03773705|Procedure|Electrocautery versus scalpel|Electrocautery versus scalpel in the elevation of nasoseptal flaps following endoscopic transsphenoidal pituitary surgery
52519|NCT03773692|Behavioral|Passive feedback and JITAI|"Second Phase - PA Level Feedback~A PA recommendation handout based on PA guidelines for individuals with SCI will be provided. Participants continue to use the same sensing equipment as in phase one (baseline). The equipment consists of a smartwatch, a smartphone, and a wheel rotation monitor. Participants can view their feedback whenever they want, but will not be prompted with the information.~Third Phase - PA Level Feedback and Just-in-time Adaptive Intervention (JITAI)~The third phase of the study will be similar to the second phase of the study, but with an additional JITAI component. The JITAI component of the study will include providing proactively-prompted, real-time feedback through the smartphone and smartwatch when the participant performs a bout of moderate PA."
52520|NCT03773679|Procedure|Daily Exercise|Daily Exercise Programme
52521|NCT03773666|Drug|Durvalumab|Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
52522|NCT03773666|Drug|Oleclumab|Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
52732|NCT03772067|Diagnostic Test|Plasma GLP-1|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma GLP-1 measured at meal test after 14 days of diet intervention
52523|NCT03773653|Behavioral|BMT to be combined with BAT|Specifically, the participants will first receive 40 to 45 minutes of bilateral robotic priming using the BMT. After the robotic priming, participants will receive another 40 to 45 minutes training in tasks focusing on bilateral symmetric movements of both ULs.
52524|NCT03773653|Behavioral|BMT to be combined with MT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of mirror therapy.
52525|NCT03773653|Behavioral|BMT to be combined with IOT|Similar to the RT+BAT group, the participants will first receive 40 to 45 minutes of bilateral robotic priming delivered by the BMT with the same priming protocol. After bilateral robotic priming, participants will receive 40 to 45 minutes of impairment-oriented training.
52526|NCT03773640|Device|Radio frequency currents|Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
52527|NCT03773640|Drug|Sonophoresis|The control group ( II) consisted of 20 patients treated with occlusion splints and sonophoresis procedures. For the area of mastication muscles 0.9 W/cm² treatments were applied, the duty factor was 80%, the treatment time was 10 minutes, and the medical substance was 25%Voltaren gel.
52528|NCT03773601|Other|Sleep Profiler|A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.
52529|NCT03773601|Other|PSQI|Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.
52530|NCT03773601|Other|TQR|Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
52531|NCT03773588|Device|Closed-Loop propofol Target controlled infusion by Entropy and SPI|Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index
52532|NCT03773588|Device|Open-loop propofol target controlled infusion|Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
52533|NCT03773575|Device|PREVENA™ PEEL & PLACE™ Dressing Kit|In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).
52534|NCT03773562|Drug|Erenumab|Erenumab will be used per label instructions.
52535|NCT03773549|Other|Virtual reality experience|Expose all participants (healthy and control) to virtual reality videos while collecting reactivity and self-report outcome measures.
52536|NCT03773536|Drug|Artesunate-amodiaquine given with single low dose primaquine|Three day treatment with ASAQ with SLD primaquine given with the first dose of ASAQ.
52537|NCT03773523|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS will be performed with Neuroelectrics Starstim Enobio 20, an approved research device without an investigational device exemption due to meeting criteria for non-significant risk. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
52538|NCT03773510|Drug|Trabectedin discontinuation|"Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin."
52539|NCT03773510|Drug|Trabectedin continuation|Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
52540|NCT03773497|Other|Common Snack Combination|Combination of Chips, Pretzels, and Popcorn.
52541|NCT03773497|Other|Cheesy Broccoli Snack|Oven-roasted, freeze-dried, cheese flavored broccoli
52542|NCT03773497|Other|Cheesy Broccoli with Daikon Radish Snack|Oven-roasted, freeze-dried, cheese flavored broccoli with Daikon radish powder
52543|NCT03773497|Other|Uncooked Broccoli Snack|Uncooked, freeze-dried broccoli with ranch-type dip
52544|NCT03773484|Behavioral|Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions.
52545|NCT03773484|Behavioral|Active Choice (SmartSet)|Active Choice (SmartSet) will be triggered within the EHR for patients with long-term opioid to encourage taper discussion, increase use of nonopioid alternatives, naloxone prescriptions and urine drug testing
52546|NCT03773484|Behavioral|Audit and Feedback|Clinicians will receive feedback on their performance during the prior quarter as well as how they compare to other clinicians on CDC measures of interest.
52547|NCT03773471|Behavioral|Mobile Health App|ArthritisPower App
52548|NCT03773458|Device|An artificial system for the screening of scoliosis|An artificial intelligence to make evaluation of scoliosis using back images
52549|NCT03773445|Diagnostic Test|Golimumab trough levels|Golimumab trough levels taken immediately before the administration of the next subcutaneous dose of golimumab
52550|NCT03773445|Diagnostic Test|Antibodies to golimumab|Antibodies to golimumab taken immediately before the administration of the next subcutaneous dose of golimumab
52551|NCT03773445|Diagnostic Test|Histology|Histology of colonic biopsies using the Geboes Index
52552|NCT03773445|Diagnostic Test|Colonoscopy|Colonoscopy to evaluate the endoscopic activity by a Mayo endoscopic subscore
52553|NCT03773432|Other|Probe meal|The probe meal will be administered either in the afternoon (conventional schedule) or in the morning (unconventional schedule).
52554|NCT03773419|Behavioral|Texting Intervention (T-WRITE)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using a cellular phone
52555|NCT03773419|Behavioral|HandWriting Intervention (ORLA+WTG)|Computer-based intervention, guided by a virtual therapist, that involves repeated listening, reading and writing sentences using pen and paper
52556|NCT03773406|Device|Offline tDCS-before therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
52557|NCT03773406|Device|Sham tDCS|Stimulation will be given for a total 30 seconds (including ramp-up and ramp-down of current) and then the tDCS device will be turned off. The brief stimulation will produce tDCS-induced sensation so that participants will not be aware when the tDCS was turned off .We will use standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
52558|NCT03773406|Device|Offline tDCS-after therapy|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
52559|NCT03773406|Device|Online tDCS|Direct current stimulation will be delivered using a battery-driven constant current stimulator. 2mA of direct current will be applied for 20 minutes to the angular gyrus region of the brain. We will use a standard-of-care treatment - script training - to provide speech-language therapy to our subjects. The scripting treatment will be delivered by a computer program that provides script training in an interactive conversational context.
52560|NCT03773393|Biological|CK0801|CK0801 (a Cord blood-derived T-regulatory cell product)
52561|NCT03773380|Combination Product|Breathe Anew Survivorship Program|The feasibility will be tested of the Breathe Anew Survivorship Program
52562|NCT03773367|Drug|Fluorouracil|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
52563|NCT03773367|Drug|Oxaliplatin|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
52564|NCT03773367|Drug|Irinotecan|Treatment with Fluorouracil, Oxaliplatin, and Irinotecan is given for 4 cycles pre- and postoperatively, in total 8 cycles.
52565|NCT03773354|Behavioral|Cognitive-behavioural therapy group for individuals with somatic symptom disorders|The intervention is a cognitive-behavioural therapy group for designed for individuals with a formal diagnosis of a somatic symptom disorder (i.e., Somatic Symptom and Related Disorders from the DSM-5) who are interested in learning self-management skills to cope with somatic symptoms and reduce emotional dysregulation, increasing their understanding of factors that contribute to somatic symptoms, and learning relaxation skills to help reduce stress.
52566|NCT03773341|Other|research questionnaire|Patient personal data History taking clinical knee examination
52567|NCT03773328|Biological|CK0801|CK0801 (Cord blood-derived T-regulatory cells)
52568|NCT03773315|Dietary Supplement|UMH extract|Schisandra chinensis extract 500 mg/day for 12 weeks
52569|NCT03773315|Dietary Supplement|Placebo|Starch placebo 500 mg/day for 12 weeks
52570|NCT03773302|Drug|BGJ398|Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off. Participants who experience disease progression while receiving gemcitabine + cisplatin will be allowed to cross over and receive infigratinib.
52571|NCT03773302|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV D1 and D8 for a 21-day cycle
52572|NCT03773302|Drug|Cisplatin|Cisplatin 25 mg/m2 IV D1 and D8 for a 21-day cycle
52573|NCT03773289|Other|No intervention|This is a retrospective, observational pharmacoepidemiological study using nationally collected data. There is no intervention.
52574|NCT03773276|Drug|Norepinephrine boluses|"On portal vein declamping, We will inject NE boluses in the C.V.P port of the pulmonary artery catheter with 5 ml saline flushing after each. After reperfusion, we will start bolus noradrenaline 20 µg if mean arterial blood pressure (mABP) decreases by 10 % or more of the basal reading (immediately before portal vein declamping after ensuring withholding of the surgical manipulation). Additional NE boluses will be given as follow;~If mABP rises to 65 mmHg (lowest target level), we will hold NE boluses.~If mABP remains constant or begins to rise but did not reach 65 mmHg, we will give 20 µg after 10 seconds from the previous bolus~If mABP continues to drop, we will add 10 µg to the previous dose after 10 seconds and can be repeated.~If mABP remains below 65 mmHg more than 1 minute, we will give the scheduled bolus NE with adding 20 µg adrenaline boluses."
52575|NCT03773263|Drug|sequential IVM system|The immature oocytes will be cultured in sequential oocyte IVM medium 1 for 6 hours (37℃, 5% CO2). After flushed 3 times, COCs were removed into sequential oocyte IVM medium 2 for further cultivation.
52576|NCT03773263|Procedure|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
52577|NCT03773263|Procedure|Thawed embryo transfer (TET)|Patients administrates oestrogen (Progynova) 3mg twice a day for 10 to 12 days. From the day when endometrium reach a thickness of 8 mm and above, luteal phase support will be given with 10 mg progesterone (Dydrogesterone Tablets,) triple per day and utrogestan (Laboratories Besins International, Paris, France) 0.2g triple per day, until 14 days after embryo transfer.
52578|NCT03773263|Drug|traditional IVM system|COCs were aspirated and the immature oocytes will be cultured in traditional standard oocyte IVM system (Sage). 30 and 44 hours after cultivation, the maturity of oocytes will be assessed.
52579|NCT03773250|Behavioral|Behavioral intervention|The intervention has an intensive phase and a maintenance phase.
52580|NCT03773237|Dietary Supplement|SMOFLipid|SMOFLipid will be given to HPN patients to assess the benefits or adverse effects compared to Intralipid.
52581|NCT03773237|Dietary Supplement|Intralipid|Intralipid will be given to HPN patients to assess the benefits or adverse effects compared to SMOFlipid
52582|NCT03773224|Procedure|Irrigation|upon closure of the peritoneum gentamicin-saline solution (160 mg of gentamicin in 400 ml of normal saline 0.9%) will be used for irrigation of every layer of the wound before its closure
52583|NCT03773211|Drug|Renaparin|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
52584|NCT03773211|Drug|Placebo|50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
94437|NCT03447990|Drug|MYK-491|Single Ascending Dose of MYK-491/placebo
52585|NCT03773198|Other|Energy Resonance through Cutaneous Stimulation|"The ERCS method involves listening to the body by applying fingers to the acupuncture skin points, developed according to the energy imbalance caused by illness, pain and emotional disorders."
52586|NCT03773198|Other|questionnaires|Measurement of anxiety-trait and state-anxiety (Spielberger), pain ( numerical scale) and satisfaction (numerical satisfaction scale)
52587|NCT03773172|Drug|MEDI6012|MEDI6012 is recombinant human lecithin-cholesterol acyltransferase (rhLCAT), an approximately 60 kilodalton, glycosylated, single-chain protein consisting of 416 amino acids produced via Chinese hamster ovary cell culture. It is being explored as an acute treatment to reduce the risk of recurrent cardiovascular events as an adjunct to the standard of care in patients with acute myocardial infarction (MI). MEDI6012 and ACP501 have the identical amino acid sequence and are therefore considered the same molecular entity.
52588|NCT03773172|Drug|Placebo|The placebo will mimic the active treatment.
52589|NCT03773159|Biological|Blood sampling|4 citrated/PPACK tubes and 1 EDTA tube maximum
52590|NCT03773146|Other|1X Airtime Incentive|An incentive given in the form of airtime
52591|NCT03773146|Other|Lottery Airtime Incentive|An incentive given in the form of airtime
52594|NCT03773120|Device|Using Neuromonitoring to find EBSLN|intraoperative neuromonitoring to preserving external branch of superior laryngeal nerve during thyroid surgery
52595|NCT03773107|Drug|Carfilzomib|Irreversible proteasome inhibitor
52596|NCT03773107|Drug|Ruxolitinib|Oral JAK inihibtor
52597|NCT03773107|Drug|Dexamethasone|glucocorticoid
52598|NCT03773094|Drug|Guava leaves extract|"Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•"
52599|NCT03773094|Drug|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
52600|NCT03773081|Device|Implantation of the Magmaris scaffold|Subjects will undergo a PCI for the implantation of the Magmaris scaffold in accordance with the standard of care and standard hospital practice. Maximum of one single ACS-causing de novo lesions in one separate major epicardial vessels is allowed.
52601|NCT03773068|Drug|BAY1817080 - Formulation A|Formulation A
52602|NCT03773068|Drug|BAY1817080 - Formulation B|Formulation B
52603|NCT03773068|Drug|[13C715N]-BAY 181708 stable isotope label (SIL)|0.1 mg [13C715N]-BAY181708, 15 minutes i.v. infusion at the estimated tmax after administration of Formulation B
52604|NCT03773055|Drug|NPC-06|Patients will receive once a day for 7 days.
52605|NCT03773042|Drug|HSK3486|For induction and maintenance of sedation.
52606|NCT03773042|Drug|Propofol|For induction and maintenance of sedation.
52607|NCT03773029|Dietary Supplement|soy isoflavone|100 mg soy isoflavone (as 2 capsules)
52608|NCT03773029|Other|placebo|2 capsules of placebo
52609|NCT03773016|Behavioral|Art apps|Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
52610|NCT03773003|Dietary Supplement|Probiotics|"The administered probiotics are readily available on the market and contain~Bifidobacterium breve, B. infantis, B. lactis, B. longum~Lactobacillus acidophilus, L. bulgaricus, L. casei, L. crispatus, L. fermentum, L. paracasei, L. plantarum, L. reuteri, L. rhamnosus, L. salivarius~Streptococcus thermophilus"
52611|NCT03773003|Dietary Supplement|Placebo|Identically looking to verum, containing corn starch.
52612|NCT03772990|Drug|Calcium Chloride|Calcium Chloride
52613|NCT03772990|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride
52614|NCT03772977|Behavioral|Brain Health Champion|A health coach embedded within an existing clinical care team
52615|NCT03772964|Drug|MetFORMIN Hydrochloride ER|Subjects will be exposed to 500mg, 1000mg, or 1500mg of daily ER Metformin, by mouth, for up to 90 days. Subjects will have their venous blood sampled and baseline, throughout the trial, and following completion of their metformin exposure.
52616|NCT03772951|Other|Cognitive Remediation Therapy|Through computer information technology, using error-free, procedural learning, speech enhancement and a series of targeted computer programmatic cognitive correction tasks, patients can gradually improve problem solving and information processing capabilities, thereby improving their recognition function.
52617|NCT03772951|Drug|Clozapine|the course of disease is more than 2 years, the condition is stable for more than one month
52618|NCT03772938|Biological|Stem/progenitor cells transplantation|Human autologous bone marrow-derived stem/progenitor cell transplantation administered as an intravitreal injection in patients with degenerative disease of retina.
52619|NCT03772925|Drug|Belinostat|Given IV
52620|NCT03772925|Drug|Pevonedistat|Given IV
52621|NCT03772912|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
52733|NCT03772067|Diagnostic Test|DPP4 plasma activity|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial DPP4 plasma activity measured at meal test after 14 days of diet intervention
52970|NCT03770208|Drug|Control: Standard Care + Placebo|Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
52622|NCT03772899|Drug|Fecal Microbial Transplantation|"All patients in this trial will receive FMT at least one week prior to treatment with approved immunotherapy (either pembrolizumab or nivolumab). Samples for FMT are sourced at and by the microbiology group under the supervision of Dr. Silverman at St Joseph's Hospital. Donor screening procedures are described in appendix 4. Transplant will be from one single donor for all participants unless Dr. Silverman's lab considers the need for more than one donor based on availability of donors. There will be no mixture of donor samples.~Donor samples are manufactured into capsules according to Kao et al, 2017."
52623|NCT03772886|Device|Peanut Ball|A peanut shaped exercise ball.
52624|NCT03772873|Procedure|minimally invasive pilonidal excision|MIPE procedure with trephine excision of pits and sinuses
52625|NCT03772860|Other|Pain stimulation|Pain will be simulated with an electric shock 25 mlAMP over the median nerve
52626|NCT03772860|Other|Visual stimulation|Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
52627|NCT03772860|Other|Auditory stimulation|Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
52628|NCT03772860|Other|Mental stress|A mathematical challenge will be displayed on a computer screen that must be quickly solved
52629|NCT03772847|Drug|ginkgolide|ginkgolide plus alteplase
52630|NCT03772834|Behavioral|Exercise Intervention|Undergo resistance training and walking
52631|NCT03772834|Drug|Methylphenidate|Given PO
52632|NCT03772834|Other|Placebo|Given PO
52633|NCT03772834|Other|Quality-of-Life Assessment|Ancillary studies
52634|NCT03772834|Other|Questionnaire Administration|Ancillary studies
52635|NCT03772834|Other|Stretching|Undergo stretching
52636|NCT03772821|Other|Data collection|Between D0 and D90: local and general complications, demographic, clinical, paraclinical and biological data
52637|NCT03772821|Other|Incision/scar measurement|Between D0 and D90
52638|NCT03772808|Dietary Supplement|Lycocomfort|Evaluate of the perceived efficacy of LycoComfort™ supplements in alleviating symptoms associated with lower urinary tract symptoms (LUTS) and general prostate discomfort over the duration of 12 weeks intervention
52639|NCT03772795|Other|Orthodontic Alignment|"Group 1:- Teeth alignment in this group started using round 0.014 NiTi arch wire. The 0.014 NiTi arch wire was placed into the slots of the brackets and tied with elastomers by figure of 8. During this stage, only tipping movement was applied."
52640|NCT03772795|Other|Orthodontic Alignment|Group 2: Teeth alignment using clear aligners.
52641|NCT03772769|Diagnostic Test|Target Enriched Multiplex PCR (TEM- PCR)|Target Enriched Multiplex PCR (TEM- PCR) assays will be performed and will probe for the typical array of advanced deep space odontogenic infections, as well as MRSA resistance, clindamycin resistance, and the presence of Panton-Valentine leukocidin (PVL) toxin, a toxin produced by some bacteria.
52642|NCT03772769|Diagnostic Test|Microbial culture|Standard diagnosis by microbial culture.
52643|NCT03772756|Procedure|Endoscopic ultrasound guided radiofrequency ablation|Endoscopic ultrasound guided radiofrequency ablation （EUS-RFA） will be done in 3 different sessions with 2 weeks interval between each session on Day 1, Day 15 and Day 30. Each session will involve multiple applications of EUS-RFA (up to 10) with RF setting of 25 Watts over 90 seconds for each application.
52644|NCT03772756|Radiation|chemoradiotherapy|Receive chemoradiotherapy
52645|NCT03772743|Other|Culprit-only revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI. Each patient should receive revascularization with Supraflex stent or its newer versions
52646|NCT03772743|Other|Complete functionally-guided revascularization|Implantation of drug eluting stents with biodegradable polymer with struts ≤65 μ in the culprit lesion of the MI and in all non culprit lesions with positive functional assessment. Each patient should receive revascularization with Supraflex stent or its newer versions
52647|NCT03772717|Device|Vital EMS+|The nVNS study intervention will be delivered using a handheld electrical neuromuscular stimulator device (Vital EMS+). Participants will deliver nVNS twice per day for 60 minutes each time at least 5 days per week, for 2 years. The two electrodes for the device are placed on the left cervical (neck) region or on the left ear. Parents will be trained on where to place electrodes, how to ensure that the electrodes make a good contact with the skin, and how to set the stimulation parameters. The stimulation frequency (number of pulses) and amplitude (amount of current) will be set during the initial baseline session in the clinic at a level that prevents discomfort and does not impact cardiorespiratory parameters.
52648|NCT03772717|Drug|Standard of Care|Patients will be asked to continue their standard medication regimens which include in most cases will involve 3 weekly infusions of intravenous immunoglobulin (IVIG) (1 gm/kg) and rarely plasma exchange (PLEX).
52649|NCT03772691|Procedure|lateral suspension|• The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
52650|NCT03772691|Procedure|sacropexy|• The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
52651|NCT03772678|Drug|LSALT peptide|novel 16 amino acid peptide
52652|NCT03772678|Other|0.9% Saline|saline
52653|NCT03772665|Drug|Emixustat|Once daily oral tablet taken for 24 months
52654|NCT03772665|Drug|Placebo|Once daily oral tablet taken for 24 months
52655|NCT03772652|Other|Observation|Soft tissue implant measurements
52656|NCT03772639|Other|Shared decision making|Decision-making processes focused on the knowledge of the disease for set up adjusted care management about their necessities and engaging in recommended health behaviors
52690|NCT03772379|Device|tooth borne hyrax expander|ready made four stainless steel bands will be supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax,.The appliance will be activated one quarter turn per day untill reaching maximum amount of lateral expansion of the jack screw. the patients will be recalled twice per week to evaluate the progress of treatment.
52774|NCT03771768|Radiation|Diode laser 980nm&100 mWatt|Diode laser 980 nm &100 milli Watt.
52657|NCT03772626|Device|Heated Humidified High-flow Nasal Cannula|Patients will receive heated high humidity air through the AIRVO(TM) device starting in hospital and continuing for 60 days after hospital discharge. Oxygen will be titrated to target SpO2 between 88-92%, patients not requiring oxygen will receive heated high humidity air without oxygen. Temperature and flow rate will titrated to patient comfort with a target temperature 37 degree Celsius and flow rate of ≥20 l/minute. Patients will be encouraged to use the device overnight and when needed during the day with a target duration of at least 6 hours per night
52658|NCT03772613|Drug|Unfractionated heparin|Administration of unfractionated heparin will be assessed using the activated clotting time
52659|NCT03772600|Device|Dexcom G6 CGM|Use of Dexcom G6
52660|NCT03772587|Drug|M281|M281 administered as IV infusion
52661|NCT03772587|Other|Placebo|Placebo administered as intravenous (IV) infusion
52662|NCT03772574|Device|Facemask preoxygenation|Standard facemask preoxygenation
52663|NCT03772574|Device|THRIVE preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
52664|NCT03772561|Drug|AZD5363+Olaparib+Durvalumab|Patients will receive AZD5363 orally twice a day 4 days-on/ 3 days-off starting 14 days prior to cycle 1 day 1 (C1D1). Olaparib continuously twice a day at 300mg and Durvalumab intravenously at 1500mg once every 4 weeks will commence at C1D1. Treatment will continue until disease progression or the development of unacceptable toxicities.
52665|NCT03772548|Diagnostic Test|MRI|We will examine chronic (>6 months post SCI) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.
52666|NCT03772548|Diagnostic Test|MRI|We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
52667|NCT03772535|Diagnostic Test|Pharmacogenomics Testing|The doctor will use genetic test results to prescribe medications that are a most effective for subject.
52668|NCT03772522|Behavioral|dk Leadership|Participants will attend two full-day workshops and four half-day group coaching sessions over the course of six weeks. The workshops and coaching sessions will be supplemented by on-line (e.g., podcasts) and print (e.g., workbooks) material. The full-day workshops will focus on identity-enhancing topics such as self-understanding, creating a life of meaning and purpose, and strategic career development. The half-day group coaching sessions will focus on workshop debriefing and on exploring solutions to transition-related challenges faced by study participants. The workshops and coaching sessions will be held at the dk Leadership office in Toronto and led by certified psychologists from dk Leadership.
52669|NCT03772509|Other|CATI|The participants in this arm were read the introduction and asked for consent by a call center employee using computer-assisted telephone interviewing and then were sent a noncommunicable disease risk factor survey via interactive voice response. This mode was used to motivate participants to complete the survey.
52670|NCT03772496|Diagnostic Test|circulating tumor cells test|10 ml Peripheral blood are drawn from patients enrolled before surgery/FNAB and centrifuged to collect the peripheral blood mononuclear cells. Then, negative and positive immunomagnetic selections are used to exclude white blood cells and enrich tumor cells. After isolating mRNA, RT-PCR array is used to measure expression of target genes.
52671|NCT03772496|Diagnostic Test|Fine needle aspiration biopsy|patients with potential malignant thyroid nodules are performed fine needle aspiration biopsy with the aid of ultrasound. The result of FNAB were classified by Bethesda rating system.
52672|NCT03772483|Procedure|Local anesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
52673|NCT03772483|Device|Local anesthesia with conventional syringe + VR device|"Virtual reality device (Noon VR, Gear FX) is placed on the face of the patient, playing a video of soothing and peaceful natural landscapes.~Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
52674|NCT03772470|Other|1X airtime incentive|An incentive given in the form of airtime
52675|NCT03772470|Other|2X airtime incentive|An incentive given in the form of airtime
52676|NCT03772470|Other|Lottery airtime incentive|An incentive given in the form of airtime
52677|NCT03772457|Drug|Rivaroxaban|new oral anticoagulant molecules which is the selective factor Xa inhibitor
52678|NCT03772444|Dietary Supplement|Beetroot juice|Patients will drink 70 ml of beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
52679|NCT03772444|Dietary Supplement|Nitrate-depleted beetroot juice|Patients will drink 70 ml of nitrate-depleted beetroot juice daily in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
52680|NCT03772444|Dietary Supplement|Water|Patients will drink 70 ml of water in the week prior to surgery; the last dose will be administered via the nasogastric tube just before the start of the procedure.
52681|NCT03772431|Other|Female Voice|The survey was narrated by a female voice
52682|NCT03772431|Other|Motivational Introduction|The survey introduction was worded to include motivational content
52683|NCT03772431|Other|Male Voice|The survey was narrated by a male voice
52684|NCT03772431|Other|Informational Introduction|The survey introduction was worded to include informational content
52685|NCT03772418|Drug|Cream Base|The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.
52686|NCT03772418|Drug|Pomegrante and Ginkgo biloba group|The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).
52687|NCT03772405|Drug|Nascum Plus|nasal application of nascum plus
52688|NCT03772405|Other|ACC|4 hours challenge to grass pollen in the allergen challenge chamber (ACC)
52775|NCT03771768|Drug|Triamcinolone Acetonide|0.1 &5gm paste 4 times/day
52691|NCT03772379|Procedure|microosteoperforation|"ready made four stainless steel bands supported on the first premolars and first permanent molars and to which the palatal expander will be soldered to form the Hyrax.No activation will be provided to the hyrax expander before the micro-osteoperforation is performed.~Microosteoperforation will applied bilaterally on the buccal surface between the roots of teeth at the level of mucoginival junction, starting from the distal of canine till the distal of the first permanent molar using a small sized surgical bur mounted on a hand piece ."
52692|NCT03772353|Drug|Letrozole|Letrozole, 2.5mg, PO daily (continuously)
52693|NCT03772353|Drug|Pyrotinib|Pyrotinib, 400mg, PO daily (continuously)
52694|NCT03772353|Drug|SHR6390|SHR6390 either 100mg,125mg, 150 mg PO daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
52695|NCT03772340|Drug|Tradipitant|Oral capsule
52696|NCT03772340|Drug|Placebo|Oral capsule
52697|NCT03772327|Device|"Adheretech smart bottle"|"A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message."
52698|NCT03772327|Behavioral|Routine adherence counseling|Participants will be provided with routine adherence counseling
52699|NCT03772314|Drug|Modafinil|Participants will received 100-400 milligrams (mg) per day of modafinil for 12 weeks.
52700|NCT03772314|Drug|Amphetamine-Dextroamphetamine|Participants will receive 10-40 mg/day of oral amphetamine salts for 12 weeks.
52701|NCT03772288|Drug|TAK-659|Tablets.
52702|NCT03772288|Drug|NKTR-214|Intravenous infusion.
52703|NCT03772275|Diagnostic Test|New york Heart Association Class II-IV|"New york Heart Association Class II-IV  study of markers"
52704|NCT03772275|Diagnostic Test|New york Heart Association Class I|New york Heart Association Class I
52705|NCT03772262|Dietary Supplement|goldenseal|Oral 500 mg capsules
52706|NCT03772262|Drug|Metformin|Oral solution
52707|NCT03772262|Drug|Furosemide|Oral solution
52708|NCT03772262|Drug|Midazolam oral solution|Oral syrup
52709|NCT03772262|Drug|Rosuvastatin Oral Tablet|Oral tablet
52710|NCT03772249|Drug|DCR-HBVS|DCR-HBVS is a synthetic ribonucleic acid interference (RNAi) drug that consists of double-stranded oligonucleotides conjugated to an N-acetyl-D-galactosamine (GalNAc) ligand. DCR-HBVS, sterile solution of the siRNA (DCR-S219) at a concentration of 185 mg/mL in water for injection (WFI).
52711|NCT03772249|Drug|Placebo for DCR-HBVS|Sterile 9% saline for injection.
52712|NCT03772223|Drug|Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
52713|NCT03772223|Drug|Treatment B (Budesonide metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 80 µg).
52714|NCT03772223|Drug|Treatment C (Albuterol Sulfate metered dose inhaler)|Randomized participants will receive a single-dose (2 inhalations, 2 x 90 µg).
52715|NCT03772210|Device|tDCS|Current will be administered to subject groups as specified in arm descriptions.
52716|NCT03772210|Other|Sham|Apparent Stimulation administered
52717|NCT03772184|Procedure|Cervical inversion|inverting the cervical lip after delivery
52718|NCT03772158|Drug|Cetirizine 10mg|Chewable tablet
52719|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
52720|NCT03772158|Drug|Cetirizine 10 mg|Immediate Release Tablet
52721|NCT03772132|Biological|mutation and signal pathway activation status analysis Drug: FORFIRINOX|Conventional chemotherapy:5FU plus irinote- can plus oxaliplatin combination therapy
52722|NCT03772119|Procedure|Surgical resection|Surgical resection of hemivertebra
52723|NCT03772106|Drug|Propofol Fresenius|Propolipid 1% : IV
52724|NCT03772106|Drug|sevorane|sevorane Quick fill (sevoflurane) : inhalation
52725|NCT03772093|Device|Trabert current|Trabert current is an interrupted direct current of low frequency (143 Hz) applied via medium sized electrodes supported on a thick moist viscose sponge. These electrodes are placed near the spinal column along the thoracolumbar region. The electrodes are separated from each other by a distance of 3-4 cms.The current is passed through electrodes placed on the body. The intensity of the current is gradually increased short of pain. The feeling should be a pronounced but a comfortable 'tingling' sensation ('comfortably strong'). By doing this, the optimum current strength specific to the patient is found. The intensity of the current is slowly increased in the first few minutes as patients get used to the sensation. It is thought that this current provides pain relief, reduces muscle spasm and increases blood flow.
52726|NCT03772093|Other|Manual massage|Therapeutic massage is the manipulation of the soft tissue of whole body areas to bring about generalised improvements in health.Massage is thought to work through a mechanical action and a reflex action. A mechanical action is created by moving the muscles and soft tissues of the body using pressure and stretching movement. This mechanical action is based on breaking up fibrous tissue and loosen stiff joints.It may help heal damaged muscle, stimulate circulation, clear waste products via the lymphatic system, boost the activity of the immune system, reduce pain and tension and induce a calming effect.
52727|NCT03772080|Other|Early counseling of prematurity in high-risk pregnancies.|Standardized information regarding prematurity, including associated complications and ways to decrease chances of preterm birth using web-based educational platform.
52728|NCT03772067|Device|Continuous glucose monitoring CGM|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the overall glucose levels measured with CGM installed in the arm during 14 days at baseline before diet intervention and after 14 days of the beginning of diet intervention
52729|NCT03772067|Diagnostic Test|Clock Genes m RNA expression|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the blood levels of Clock Genes measured at baseline and after 14 days of diet intervention
52730|NCT03772067|Diagnostic Test|Postprandial Glucose|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Glucose measured at meal test after 14 days of diet intervention
52731|NCT03772067|Diagnostic Test|Postprandial Insulin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Insulin measured at meal test after 14 days of diet intervention
52734|NCT03772067|Diagnostic Test|Ghrelin|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma Ghrelin measured at meal test after 14 days of diet intervention
52735|NCT03772067|Diagnostic Test|Plasma CCK|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma CCK measured at meal test after 14 days of diet intervention
52736|NCT03772067|Diagnostic Test|Plasma PYY|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the postprandial plasma PYY measured at meal test after 14 days of diet intervention
52737|NCT03772067|Other|Body Weight|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing the body weight at baseline and every weeks of diet intervention
52738|NCT03772067|Diagnostic Test|Blood levels of HbA1c|The effect of the two diets (MBdiet and OBdiet) will be compared on the efficacy on changing blood HbA1c measured at baseline and after 90 days of diet intervention diet intervention
52739|NCT03772054|Drug|Sevoflurane|Inhalation anesthetic agent
52740|NCT03772054|Drug|Propofol|Intravenous anesthetic agent
52741|NCT03772041|Drug|OPC-61815|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg
52742|NCT03772041|Drug|Tolvaptan Tab 15 MG|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo
52743|NCT03772028|Drug|cisplatin|HIPEC with cisplatin after cytoreductive surgery
52744|NCT03772015|Diagnostic Test|Magnetic resonance imaging|MRI will be performed using a standard body spiral in the supine position with 5 mm section thickness, on the axial, coronal and sagittal planes and the diffusion weighted images acquired will be evaluated by a specialised radiologist who will be blind to the participants.
52745|NCT03772002|Diagnostic Test|HCV screening|HCV antibody and HCV RNA surveillance, anti-HCV treatment assessment
52746|NCT03771989|Biological|autologous, micro-fragmented adipose tissue|"The active treatment is an intra-articular injection with autologous, microfragmented adipose tissue prepared using the Lipogems system.~Implantation of the graft is performed with the patient supine using two injections sites in order to reduce the risk of extra-articular injection."
52747|NCT03771989|Other|Saline|The placebo is an injection with saline
52748|NCT03771976|Procedure|Cesarean section|Risk of cesarean section between the cohorts
52749|NCT03771976|Procedure|No cesarean section|Vaginal birth rate between the cohorts
52750|NCT03771963|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
52751|NCT03771950|Behavioral|Early team based neuro-rehabilitation|A structured interview will be made by OT about activity level, and an examination of the patients bodily and neurological symptoms will be made by PT. Based on this result a rehabilitation plan is established consisting of the patient's goals, and the purpose that the patient shall be as active as possible without triggering symptoms. An individual exercise program is prescribed. Between each appointment the patient will have personal tasks to accomplish with the purpose of being active based on symptoms and the adaptation to the current level of energy. The perceived symptoms will be logged. A week-schedule will be created in the purpose of helping the patient to a balanced activity level in relation to their current capacity. The PT assesses physical activity level and reactions to physical strain. Adaptations are made to the exercise program and advice is given on physical activity and exercises. When appropriate OT advices about returning to work and adaptations concerning work.
52752|NCT03771937|Other|Education and telephone follow-up intervention|A telephone follow up and a pre-discharge education
52753|NCT03771924|Dietary Supplement|inorganic phosphate|Sodium phosphate
52754|NCT03771924|Dietary Supplement|placebo|Sodium chlorid
52755|NCT03771911|Device|AED|Instructions provided by an AED
52756|NCT03771911|Device|Telephone|Instructions provided by emergency Call Center (telephonically) with the help of an AED.
52757|NCT03771898|Drug|SHP611|Participants will receive 150 mg of SHP611 IT via IDDD or LP once weekly for 105 weeks.
52758|NCT03771885|Drug|BI 705564|Film-coated Tablet
52759|NCT03771885|Drug|Placebo|Film-coated Tablet
52760|NCT03771872|Device|Virtual Prism Adaptation Therapy|Hand trajectory will deviate to the right side in the virtual reality.
52761|NCT03771872|Device|Sham Therapy|The therapy is the same as the real virtual prism adaptation therapy, but there will be no deviation of the hand trajectory in the virtual reality.
52762|NCT03771859|Other|Non-Interventional|Non-Interventional
52763|NCT03771846|Drug|gemcitabine, oxaliplatin , fluorouracil, and leucovorin|administration of gemcitabine, oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
52764|NCT03771846|Drug|gemcitabine and oxaliplatin|administration of gemcitabine and oxaliplatin via vein
52765|NCT03771833|Device|MARIA scan|The MARIA breast imaging system comprises of a scanning unit, housed under a patient bed. The scanning unit houses a hemispherical array, into which varying sizes of insert are fitted to ensure a close fit to the breast. The patient lies prone on the bed with their breast pendulous through an aperture in the bed and the scanning unit is risen to meet the breast. The fit is non-compressing and the scanner does not use ionising radiation.
52766|NCT03771820|Drug|NC-6004|NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.
52767|NCT03771820|Drug|Pembrolizumab|The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
52768|NCT03771807|Dietary Supplement|Beauty From Within|one scoop of product mixed in 8-16 ounces of water consumed once daily
52769|NCT03771807|Other|Placebo|one scoop of product mixed in 8-16 ounces of water consumed once daily
52770|NCT03771807|Other|Facial cleansing|All subjects will use a cosmetic instrument to clean on one half of their face daily
52771|NCT03771794|Device|ReguRate neurostimulation|"Device: ReguRate neurostimulation Device:~Sham : ReguRate neurostimulation - mock sham stimulation mode"
52772|NCT03771781|Drug|Empagliflozin Tablets|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.
52773|NCT03771781|Drug|Empagliflozin Tab 25 MG|Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
52776|NCT03771755|Drug|Ibuprofen|800 mg IV - Ibuprofen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
52777|NCT03771755|Drug|Acetaminophen|1000mg IV Acetaminophen every 6 hours. In case required - followed with Morphine (PCA) 1-2 mg every 5 minutes
52778|NCT03771742|Procedure|transverse scan, in-plane, posterior-anterior TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the transverse scan, in-plain, posterior to anterior approach. 0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
52779|NCT03771742|Procedure|paramedian sagittal scan, in-plane, caudal-cranial TMQLB|The patients will receive the transmuscular quadratus lumborum block(TMQLB) before surgery using the paramedic sagittal scan, in-plain, caudal-cephalic approach.0.6ml/kg 0.375% ropivocaine is injected when the correct needle location is confirmed.
52780|NCT03771729|Drug|LCZ 696|LCZ696 200mg twice daily
52781|NCT03771716|Behavioral|African Dance|Basic principles and guidelines for exercise programming will be followed including adequate warm-up and cool-down, progressive and gradual increments in duration, and instruction regarding avoidance of physical activity (PA) related injury. The African dance group will receive moderate intensity dance 1 hour per day, twice per week, for 6 months. The prescribed intensity will begin at light to moderate and progress to a moderate to high intensity level. Frequent assessment of heart rate and ratings of perceived exertion will ensure appropriate levels of intensity during each dance session. Levels of exertion during the dance will be prescribed and monitored based on baseline assessments of heart rate and cardiorespiratory fitness.
52782|NCT03771716|Behavioral|African Cultural Immersion|The Culture group will participate in activities, including cooking, art and games, music, traditional crafts, and lectures and discussions about other aspects of Africana culture and customs. Topics will vary from session to session to maintain interest and engagement. The sessions will be held in a small group format and will be lead my personnel with training in each topic. Participants will meet 1 hour per day, 3 times per week, for 6 months.
52783|NCT03771690|Behavioral|Standardised meal|A standardised meal will be consumed at 10:00 which will provide 5025 kJ energy (47% carbohydrate, 9% protein, 44% fat).
52784|NCT03771677|Drug|Nucleotide Analog|such as Entecavir,entecavir 0.5mg per day
52785|NCT03771677|Drug|Interferon Alfa-2A|Peginterferon alfa-2a 180ug per week
52786|NCT03771664|Drug|SAGE-217|SAGE-217
52787|NCT03771664|Drug|Placebo|Placebo
52788|NCT03771651|Drug|Aspirin 81 mg|Subjects will take aspirin daily for 14 days leading up to surgery to determine whether it impacts inflammation of fallopian tubes.
52789|NCT03771638|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
52790|NCT03771638|Other|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
52791|NCT03771625|Radiation|radiotherapy|whole brain with/without spinal cord
52792|NCT03771612|Drug|Naproxen|Half of the participants will be randomly assigned to receive naproxen twice daily (400 mg total daily; 200 mg 2x a day)
52793|NCT03771612|Drug|Placebos|Half of the participants will be randomly assigned to receive a placebo pill twice daily
52794|NCT03771599|Other|Intervention Group|"Traditional massage of thirty minutes duration ( five minutes of massage was provided to all four limbs, front and back of trunk area) prior to routine physical therapy.~Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks."
52795|NCT03771599|Other|Control group|Routine physical therapy comprising stretching of tight muscles ( stretch each muscle for five times with hold time of twenty seconds), Strengthening of weak muscles (perform resisted exercises ten times for each weak muscle), positioning ( how to make sitting and standing postures at home). This whole regimen was to be practiced fives times a week for a period of twelve weeks.
52796|NCT03771586|Drug|SAGE-718|SAGE-718 in combination with Ketamine
52797|NCT03771586|Drug|Placebo|Placebo in combination with Ketamine
52798|NCT03771573|Other|Physical exercise|Participants will perform physical exercises with constant, or intermittent professional supervision or will interrupt the exercise after ambulatorial physical therapy
52799|NCT03771573|Other|monitoring|the patients will be under monitoring to investigate the evolution of the disease
52800|NCT03771560|Drug|folinic acid|subject will take folinic acid daily for 12 weeks
52801|NCT03771547|Diagnostic Test|ERCP|
52802|NCT03771534|Drug|Oxygen gas|Brief maternal administration of 65-70% O2 via a face mask during the last trimester
52803|NCT03771495|Other|Joint Mobilization|Manual Therapy Intervention, commonly used by physiotherapists
52804|NCT03771495|Other|Laying on of Hands|Sham Hip Joint Mobilization
52805|NCT03771482|Behavioral|Quiztime modules|Text Messaging or Email system
52806|NCT03771469|Diagnostic Test|Sleep study|Sleep study
52807|NCT03771456|Procedure|Colorectal resections|Colorectal resections
52808|NCT03771443|Drug|experimental gluten free toothpaste|we prepared gluten free toothpaste in the faculty of pharmacy -Cairo university because there is no gluten free toothpaste available in the Egyptian market .
52809|NCT03771430|Behavioral|Group osteoarthritis education, exercise and CBT|"Group Osteoarthritis Education~60-min session by AktivA trained PT)~Signs/symptoms, risk factors, weight control, treatment~Importance of physical activity~Appropriate activity & training modalities~Exercise and CBT Support~60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~Warm-up session~Strengthening exercises~Functional exercises~Stretching~Monitoring of CBT progress~Review of CBT lessons learned~Integration of CBT skills~Enhance motivation to continue~Online CBT (e-Therapy) (10 modules completed at home)~Pain causes & prevention~Pain management~Health promotion & stress reduction at home & work~Adapting for leisure & work~Controlling flare-ups~Maintaining & improving results"
52810|NCT03771430|Procedure|Total Knee Arthroplasty|Standard total knee arthroplasty will be performed.
52811|NCT03771417|Behavioral|Exercise Intervention|The use of exercise to improve muscle and cardiometabolic health in older adults.
52877|NCT03770806|Procedure|Femoral Nerve Block|Standard Ultrasound-guided peri-neural femoral nerve block with Ropivacaine 0.5% and Dexamethasone 6-8mg.
52812|NCT03771404|Other|blood sampling|Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
52813|NCT03771391|Dietary Supplement|PKU Sphere|PKU sphere is a powdered, low phenylalanine protein substitute containing a balanced mix of casein glycomacropeptide (GMP) isolate, essential and non-essential amino acids, carbohydrate, vitamins, minerals and docosahexaenoic acid (DHA). With sugar and sweetener.
52814|NCT03771378|Drug|rhTPO|After enrollment, all subjects receive TPO, the dose is 300 U / Kg, s.c. qd, blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will receive a mimetic (tablet), po, qd.
52815|NCT03771378|Drug|eltrombopag|After enrollment, all subjects receive eltrombopag, the dose is 25 mg/day, po, qd. blood routine examination is detected every 3 days during treatment. If the platelet count > 250 × 109 / L, the drug will stop until the platelet count ≤ 100 × 109 / L. Efficacy and safety will be evaluated on day 15. The evaluation criteria were based on the consensus of ITP. At the same time, all subjects will give a mimetic (injection), at a dose of 300 U/Kg, s.c. qd.
52816|NCT03771365|Procedure|Standard-PCNL|percutaneous nephrostolithotomy (PCNL) with ≥24 Fr access tract for the treatment of ≥2 cm renal stone
52817|NCT03771365|Procedure|Mini-PCNL|percutaneous nephrostolithotomy (PCNL) with 12-20 Fr access tract for the treatment of ≥2 cm renal stone
52818|NCT03771365|Procedure|SMP|percutaneous nephrostolithotomy (PCNL) with 10-14 Fr access tract for the treatment of ≥2 cm renal stone
52819|NCT03771339|Procedure|Continuous Epidural analgesia|Continuous Epidural catheter is inserted at the Thoracic 11-T12 level, using Ropivacaine 0.375% 3 mL bolus followed by Ropivacaine 0.2% with rate 6 mL/hour for 24 hours after laparoscopic nephrectomy
52820|NCT03771339|Procedure|Bilateral Quadratus Lumborum block|Bilateral anterior Quadratus Lumborum block using Ropivacaine 0.375% 20 mL each injection as postoperative analgesia treatment for 24 hours
52821|NCT03771326|Biological|Kisspeptin-10|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)
52822|NCT03771313|Drug|Ceftaroline|Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.
52823|NCT03771300|Behavioral|Mindfulness|This program is structured around two central elements, mindfulness and compassion. The sessions combine theory and practice components, using a methodology which priorities the reflection and debate among the students. Regarding theory component, mindfulness and compassion concepts will be set out over the length of the program, in addition to others related to time management, stress, anxiety and the balance between personal life and academic/work life. The practical component of the program consists of mindfulness and self-compassion formal and informal practices under the guidance of a specialized instructor.
52824|NCT03771300|Behavioral|Mindfulness condition complemented by VR|"The VR is comprised of a Samsung VR goggles, a Samsung Galaxy S6 phone and optional headphones.~In this condition, the instructor is the same as previously but the implementation of VR will be carried out by a psychologist specially trained for the application of these VR scenarios. Prior to the VR use, the psychologist will make sure about the participants´ health."
52825|NCT03771300|Behavioral|Relaxation|This condition is based on the Progressive Muscle Relaxation.The relaxation program include training 16 muscle groups during the initial sessions, 7 muscle groups during the intermediate sessions, 4 muscle groups later and a only recall relaxation in the final session.This program is complemented with visualizations, as it was originally proposed by Jacobson (1938).
52826|NCT03771287|Device|Oticon OpenSound Navigator speech enhancement algorithm|OpenSound Navigator (OSN) is a speech enhancement algorithm developed by Oticon. The feature is built in Oticon's current OPN™ hearing aid platform and can be adjusted and disabled in the programming. It is designed to automatically enhance speech while reducing unwanted background noise to improve communication for the user.
52827|NCT03771287|Device|Oticon omni-directional microphone algorithm|Omni-directional microphone setups come standard for all Oticon hearing aid models. The hearing microphones have equal sensitivity across all directions.
52828|NCT03771274|Device|Tecnis ZLB00 & Symfony IOL|The Symfony IOL will be implanted in the dominant eye while the Tecnis ZLB00 will be implanted in the non-dominant eye.
52829|NCT03771261|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet by a registered dietitian and attend weekly social support/nutrition education meetings.
52830|NCT03771261|Dietary Supplement|Egg Protein|Participants will be provided pre-packaged hard-boiled eggs (3/day, medium) and egg white protein powder.
52831|NCT03771248|Device|peek telescopic partial denture|removable partial denture
52832|NCT03771235|Behavioral|Mindfulness-based Intervention for Tics|Psychological intervention that focuses on cultivating awareness of urges to tic and developing a different relationship to those urges through meditation and other mindfulness practices.
52833|NCT03771235|Behavioral|Tic Information and Coping Strategies|Psychological Intervention that focuses on learning more about tics, practicing a range of strategies for coping with tics (e.g., relaxation, effective communication), and discussing challenges commonly experienced by individuals with tics.
52834|NCT03771222|Biological|Prophylactic DLI|The G-CSF-mobilized PBSCs from cryopreserved cells of the graft were infused to the recipient at a dose of 2X10^7 CD3+ cells/kg recipient body weight. Decitabine (10 mg/m2, days 1 to 5) followed by prophylactic DLI would be given to those patients carrying TET2, DNMT3a or TP53 gene mutations.
52835|NCT03771209|Diagnostic Test|ultrasound examination|ultrasound assessment
52836|NCT03771196|Other|Bioactive Restorative Material|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth
52837|NCT03771196|Other|Resin-modified glass ionomer|Enhanced glass ionomer with acceptable mechanical properties and esthtic properties
52838|NCT03771183|Other|Patients in long response during Halaven® treatment|Data collection
53019|NCT03769818|Drug|bupivacaine|Bilateral TAP block with 20 ml of 0.25% bupivacaine
52839|NCT03771170|Drug|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
52840|NCT03771170|Drug|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
52841|NCT03771157|Drug|Shingrix vaccine|On day one, patients will receive the first of two doses of the Shingrix vaccine will be administered as an injection into the muscle in their upper arm. The second dose of vaccine will be administered as an injection to their upper arm approximately 2 months after the first dose.
52842|NCT03771144|Procedure|arthrolysis|Surgery is performed under general anesthesia. The usual duration of this surgery is on average 1h30. This surgery requires an anterior approach and a posterior approach. The patient is placed in lateral decubitus. The arthroscope of 2.7 is introduced by a posterior route. An anterior instrumental track is made from inside out through the rotator interval.
52843|NCT03771131|Behavioral|Multi-domain cognitive training|Weekly sessions of multi-domain cognitive training, each lasting around one hour for an overall duration of the training of 3 months (13 sessions)
52844|NCT03771105|Drug|phosphate|The target daily phosphate (Pi) intake is 3,500 mg/day (dietary intake plus our supplementation) for this study. Subjects will take a supplement of Pi (as KPhos Neutral 250 mg/tablet) to reach this target. Subjects will receive treatment for 30 days.
52845|NCT03771092|Dietary Supplement|SunActive®Fe|SunActive® Fe is a colorless, odorless, tasteless iron fortifier in a powder form. This product is most commonly used to increase the amount of iron in food, beverage, and dietary supplement applications.
52846|NCT03771092|Dietary Supplement|Lipofer®|Lipofer® is a micronized and microencapsulated source of iron, enhances the bioavailability of iron and does not taste metallic or oxidize unsaturated fats.
52847|NCT03771092|Dietary Supplement|Intravenous ferric gluconate|Sodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 - 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate.
52848|NCT03771066|Behavioral|bisphenol A|Vanilla wafer cookie with bisphenol A administered
52849|NCT03771066|Behavioral|Placebo|Vanilla wafer cookie with no bisphenol A
52850|NCT03771053|Drug|Ezetimibe with simvastatin|ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
52851|NCT03771053|Drug|Simvastatin|simvastatin 40mg everyday for 12 months after PCI
52852|NCT03771040|Drug|Masitinib|
52853|NCT03771040|Drug|Placebo|
52854|NCT03771027|Other|The low FODMAP diet.|The low FODMAP group had reduced the intake of FODMAP. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
52855|NCT03771027|Other|The diet based on NICE guidelines.|The control group based on NICE guidelines received diet contained products with different FODMAP content. Children received 3 main meals and 2 snacks daily prepared by the catering company according to the Human Nutrition Recommendations for Polish Population. The dietary intervention lasted four weeks.
52856|NCT03771014|Other|Early mobility|This progressive mobility pathway commenced with passive cycling within 48 hours of intubation and ventilation and progressing through assisted cycling, active cycling, bed exercises, sitting, mobilising out of bed to walking
52857|NCT03771001|Other|Motivational Interviewing coaching and habit-building app|Coaches will use a manualized motivational interviewing approach and participants' wellness promoting changes will be supported via a habit building app that also delivers a micro-mindfulness program
52858|NCT03770988|Drug|Treatment with Poziotinib|Treatment with Poziotinib
52859|NCT03770975|Procedure|delayed implant with immediate provisionaliztion and soft tissue graft|delayed implant placement in the esthetic zone with immediate provisinalization and placement of a connective tissue graft buccal
52860|NCT03770975|Procedure|delayed implant placement with immediate provisionalization|delayed implant placement with immediate provisionalization
52861|NCT03770962|Behavioral|Two midwives|"Two midwives will be present during the active phase of the second stage and the birth of the baby. Midwife no 1 is the midwife who has been responsible for the care of the woman and midwife no 2 will assist her."
52862|NCT03770949|Device|3-D Printed Orthotic (Ankle Foot Orthosis)|Participants will receive a custom individual 3-D printed ankle foot orthosis (AFO).
52863|NCT03770936|Drug|Candesartan|Candesartan 8 mg/day
52864|NCT03770936|Drug|Ramipril|ramipril 1.25 mg/day
52865|NCT03770923|Drug|Rupatadine|Rupatadine 10 mg daily
52866|NCT03770923|Drug|Montelukast|Montelukast 10 mg daily
52867|NCT03770910|Other|GIP receptor antagonist|GIP receptor antagonist
52868|NCT03770910|Other|GIP receptor agonist|GIP(1-42)
52869|NCT03770910|Other|Saline|Placebo (vehicle for infusions)
52870|NCT03770897|Procedure|3D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 3D laparoscopic procedure
52871|NCT03770897|Procedure|2D Laparoscopic Appendectomy|surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
52872|NCT03770871|Drug|Indirect pulp treatment using Dycal (TM)|Partial caries removal and protection of the dental pulp with biocompatible material
52873|NCT03770871|Drug|Indirect pulp treatment using Vitrebond (TM )|Partial caries removal and protection of the dental pulp with biocompatible material
52874|NCT03770858|Drug|Crisaborole|Subject to apply topical crisaborole twice daily to the affected atopic dermatitis areas
52875|NCT03770858|Device|Scratch sensor|advanced, flexible and wearable skin sensor
52876|NCT03770819|Procedure|Photodynamic therapy|"Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam."
52878|NCT03770806|Procedure|Adductor Nerve Block|Standard Ultrasound-guided peri-neural adductor nerve block, mid-thigh, with Ropivacaine 0.5% and Dexamethasone 6-8mg
52879|NCT03770806|Other|No Block|routine iv and oral pain medication alone-observation only
52880|NCT03770793|Procedure|Lung-sono guided|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, alveolar recruitment is performed to the non-surgical side of lung under examination with ultrasound just after anesthesia induction.~During the gradual increment in the pressure of recruitment, the anesthesiologist can find the opening pressure that means the minimal pressure at which observed atelectasis starts to disappear.~Then, alveolar recruitment is performed with the opening pressure until the atelectasis is not visible."
52881|NCT03770780|Drug|SAGE-718|SAGE-718 in combination with Ketamine
52882|NCT03770780|Drug|Placebo|Placebo in combination with Ketamine
52883|NCT03770767|Drug|Faster-acting Aspart insulin Fiasp|Randomization to treatment with insulin Fiasp
52884|NCT03770767|Drug|Control (insulin Novorapid)|Randomization to standard treatment with insulin Novorapid
52885|NCT03770754|Procedure|Clean and shape Control group|"For the control group the root canals were prepared manually with K-files and step back technique up to size #35. For this group were administered Tylenol"
52886|NCT03770754|Procedure|Cleand and shape Group 1|For the Group 1, LightSpeed LSX rotary instruments (Discus Dental, Culver City, CA, USA) were used to complete the canal preparation to a size #50 for the anteriors and molars to size #40. After procedures were administered Tylenol
52887|NCT03770754|Procedure|Clean and shape Group 2|"For the group 2 the root canals were instrumented with ProTaper ﬁles using X1, X2 (21mm) to X3 (21mm). 0.5% NaOCl was used for irrigation, the original protocol suggested by ProTaper for permanent teeth was simplified for this study.~After clinical procedures Tylenol were administered"
52888|NCT03770741|Other|Modify cardio-respiratory support to avoid cerebral hypoxia|modification of cardio-respiratory support based on an evidence-based treatment guideline
52889|NCT03770741|Other|Treatment as usual|Monitoring and treatment according to local guidelines and practice
52890|NCT03770728|Drug|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
52891|NCT03770728|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
52892|NCT03770728|Drug|Metformin|Pharmaceutical form: tablet Route of administration: oral
52893|NCT03770728|Drug|Sulfonylurea|Pharmaceutical form: tablet Route of administration: oral
52894|NCT03770715|Device|Respiratory polygraphy|The respiratory polygraphy consisted of continuous polygraphical recordings for a whole night from 22:00 h to 07:00 h with standardised equipment
52895|NCT03770702|Drug|Angiotensin receptor blockers|Candesartan
52896|NCT03770702|Drug|Statins|Atorvastatin
52897|NCT03770689|Drug|Phase Ib: M3814|Participants will receive M3814 at an escalated dose starting from 50 mg once daily 5 days per week in first cohort up to week 6 and for the next cohorts M3814 dose will be determined by the Safety Monitoring Committee (SMC) guided by a Bayesian 2-parameter logistic regression model with overdose control.
52898|NCT03770689|Drug|Capecitabine|Participants will receive capecitabine at a dose of 825 milligram per square meter (mg/m^2) twice daily 5 days per week in Phase Ib and Phase II up to week 6.
52899|NCT03770689|Radiation|Radiotherapy (RT)|Participants will receive RT of approximately 50 Gray (Gy) to the tumor area and 45 Gy to the electively irradiated tissues in 25 to 28 fractions (corresponding to 5 to 5.5 weeks) Phase Ib and Phase II.
52900|NCT03770689|Drug|Phase II: M3814|Participants will receive M3814 50 mg or matching placebo at the RP2D once daily 5 days per week up to week 6.
52901|NCT03770689|Drug|Phase II: Placebo|Participants will receive Placebo matched to M3814 for 5 days per week up to week 6.
52902|NCT03770676|Dietary Supplement|Selenium-fortified biscuits|Selenium-fortified biscuits, fortified with selenium-enriched yeast (approx. 60 mcg selenium per day, for 14 days). One of three novel flavours.
52903|NCT03770663|Drug|Cyclophosphamide and azathioprine|European strategy 6 IV pulses of Cyclophosphamide (1000mg) followed from M5 to M12 by oral Azathioprine (2mg/kg/day), with a maximum of 150mg/day
52904|NCT03770663|Drug|Tacrolimus|American strategy Tacrolimus given orally from M0 to M12 (started at the initial dose of 2x2mg/day). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15ng/mL.
52905|NCT03770650|Procedure|Stenting|DK crush technique with SYNERGY (Boston Scientific) drug-eluting stent implantation.
52906|NCT03770637|Drug|Glucagon RTU|Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.
52907|NCT03770637|Other|Placebo|The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
52908|NCT03770624|Drug|QL-007 tablet|QL-007 will be administered orally daily over the 28 days under fasted state.
52909|NCT03770624|Drug|TDF|TDF will be administered orally daily over the 28 days e.
52910|NCT03770611|Dietary Supplement|Probiotic|The probiotic supplement is composed of the following bacterial strains: Bacillus coagulans, Bacillus subtilis, Bifidobacterium (B) bifidum, B. breve, B. longum, Lactobacillus (L) acidophilus, L. brevis, L. casei, L. helveticus, L. Paracasei, L plantarum, L. rhamnosus, L. salivarus, Lactococcus lactis, Pediococcus acidilactici, Pediococcus parvulus, Weisella confusa, Weisella paramesenteroides
52911|NCT03770611|Dietary Supplement|Prebiotic|The prebiotic fiber is Agave inulin
52912|NCT03770611|Dietary Supplement|Symbiotic|The supplement is a combination of the probiotic product + the prebiotic fiber
52913|NCT03770611|Dietary Supplement|Placebo|The supplement is a combination of probiotic placebo and prebiotic fiber placebo. Placebo will consist on maltodextrin for both cases.
52914|NCT03770598|Behavioral|Standard of Care Distressed in study Arm Distressed|Social worker evaluation and possible referral to Psychiatry/Psychology for evaluation and further treatment.
52915|NCT03770598|Behavioral|Psycho-Education|Mindfulness based stress reduction class, yoga and education material
52916|NCT03770598|Behavioral|Team Based Care|Psychiatrist, Oncologist, clinical social worker, study coordinator
52917|NCT03770598|Behavioral|Standard of Care Non-Distressed|No psycho-education about wellness promotion or health. These patients will be monitored only.
52918|NCT03770585|Procedure|Fluoroscopy guided Facet joint injection|Fluoroscopy guided Facet joint injection (The patient will be placed in the prone position with a pillow under the abdomen to correct the lumbar lordosis. The joint to be injected is located and marked, the x ray tube is then slowly rotated till the joint appear in profile as two parallel lines. After cleaning and drapping and administration of local anesthesia a22-g spinal needle is inserted in line with x-ray beam till bony contact is felt. All procedures will be performed under sterile conditions. Each facet joint is infiltrated with a mixture containing 0.5 ml of 0.25 % bupivacaine and 0.5 ml (20mg) methylprednisolone acetate injected into the joint.)
52919|NCT03770585|Procedure|Ultrsound guided Facet joint injection|Ultrsound guided Facet joint injection (Patients will be placed in a prone position. The needle is inserted 1-2 cm laterally from the midline at the lateral end of the transducer and precisely positioned in the US plane at an angle of approximately 45o with respect to the axial plane)
52920|NCT03770572|Genetic|AT-GTX-502|Subjects with diagnosis of CLN3 Batten disease will receive a single dose of AT-GTX-502 at low dose or high dose.
52921|NCT03770559|Procedure|Laparoscopic RAMPS|Patients with pancreatic cancer treated by laparoscopic RAMPS surgery
52922|NCT03770559|Procedure|Open RAMPS|Patients with pancreatic cancer treated by traditional open RAMPS surgery
52923|NCT03770546|Biological|Amnion Injection|Per the manufacturer, this is considered an injection of tissue/organic matter.
52924|NCT03770546|Drug|Betamethasone injection|Routine steroid injection for these pathologies. Betamethasone Sodium Phosphate and Betamethasone Acetate injection.
52925|NCT03770533|Other|MR-proADM guided|MR-proADM value together with routine clinical evaluation identifies patients with a low 14 day mortality risk who do not need to be hospitalized
52926|NCT03770520|Procedure|QFR-guided CABG|CABG surgery based on CAG and QFR
52927|NCT03770520|Procedure|Angio-guided CABG|CABG surgery based on heart team discussion of CAG
52928|NCT03770507|Other|Exercise Training|Comparison of stationary bike and treadmill exercise among adolescents and adults
52929|NCT03770494|Drug|LY3405105|Administered orally.
52930|NCT03770481|Behavioral|nurse-led communication strategy|Nurse-led communication strategy (NLCS) applies 'COMFORT' framework that research nurses use the framework to engage one communication session per day with surrogates and two discussions with bedside nurses or attending physician during the ICU stay.
52931|NCT03770468|Procedure|Blood drawl|
52932|NCT03770455|Drug|Avelumab|Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
52933|NCT03770455|Drug|2nd generation ADT (abiraterone or enzalutamide)|2nd generation ADT (abiraterone or enzalutamide)
52934|NCT03770442|Device|Cycling with FES|As described already
52935|NCT03770442|Other|Routine physiotherapy|As described already
52936|NCT03770429|Drug|AZD6738|MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
52937|NCT03770416|Drug|Ibrutinib|Given PO
52938|NCT03770416|Biological|Nivolumab|Given IV
52939|NCT03770403|Biological|ARGX-113|Intravenous administration of ARGX-113
52940|NCT03770390|Procedure|Surgical correction of pectus excavatum|Surgical correction of pectus excavatum
52941|NCT03770377|Device|Intermittent Perturbation to Continuous Perturbation|Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
52942|NCT03770377|Device|Continuous Perturbation to Intermittent Perturbation|Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
52943|NCT03770338|Drug|Teriparatide|20ug dosage daily injection, 1-month preoperative
52944|NCT03770325|Drug|Berberine|Purified berberine (500 mg orally twice a day) in tablets for 12 weeks
52945|NCT03770325|Drug|Placebo|Placebo tablets, prepared with the same appearance, for 12 weeks
52946|NCT03770312|Drug|Low intensity statin|Use of low intensity statin for primary prevention of cardiovascular disease.
52947|NCT03770312|Drug|Moderate intensity statin|Use of moderate intensity statin for primary prevention of cardiovascular disease.
52948|NCT03770299|Biological|Nivolumab|Specified dose on specified days
52949|NCT03770299|Drug|Vinorelbine|Specified dose on specified days
52950|NCT03770299|Drug|Gemcitabine|Specified dose on specified days
52951|NCT03770299|Drug|Docetaxel|Specified dose on specified days
52952|NCT03770299|Drug|Pemetrexed|Specified dose on specified days
52953|NCT03770299|Drug|Cisplatin|Specified dose on specified days
52954|NCT03770299|Drug|Carboplatin|Specified dose on specified days
52955|NCT03770299|Drug|Paclitaxel|Specified dose on specified days
52956|NCT03770299|Other|Observation|Observation by the investigator
52957|NCT03770286|Device|5% Fluoride Varnish|Topical varnish
52958|NCT03770286|Device|38% Silver diamine fluoride|Topical varnish
52959|NCT03770286|Device|Floss|Floss will be used as a delivery agent of SDF to target interproximal carious lesion.
52960|NCT03770273|Biological|Sarilumab|Sarilumab is a fully human anti-IL-6R-alpha monoclonal antibody that binds membrane-bound and soluble human IL-6R and has been shown to inhibit IL-6 signaling
52961|NCT03770273|Other|Placebo|Placebo
52962|NCT03770260|Drug|Ixazomib Citrate|Given PO
52963|NCT03770260|Drug|Pevonedistat|Given IV
52964|NCT03770247|Procedure|Intraoperative celiac plexus neurolysis|neurolysis of celiac plexus by intraoperative techniques
52965|NCT03770247|Procedure|CT guided celiac plexus neurolysis|Neurolysis of celiac plexus percutaneously by CT guidance
52966|NCT03770234|Drug|Transtec 35 µg/hour transdermal patch|Transdermal patch containing 20 mg buprenorphine in an active surface area of 25 squared centimeters. Buprenorphine release rate 35 µg/hour.
52967|NCT03770221|Behavioral|CATCH|Brief, intensive case management service.
52968|NCT03770221|Other|Financial Incentive|Financial incentive for maintaining contact with CATCH service providers.
52969|NCT03770208|Drug|Intervention: Lidocaine|IV Lidocaine bolus plus infusion. Weight based.
52971|NCT03770195|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
52972|NCT03770182|Device|NEUROLITH|transcranial pulse stimulation (TPS)
52973|NCT03770156|Behavioral|Questionnaires|Overall Impression of the current state and evolution since the attacks
52974|NCT03770143|Other|Feeding with palm olein formula|
52975|NCT03770130|Drug|Dexmedetomidine|Dexmedetomidine, a selective α2-adrenoceptor agonist which is widely used as an adjuvant to general anaesthesia
52976|NCT03770130|Drug|Saline|Saline, a kind of crystalloid widely used in clinical treatment
52977|NCT03770117|Procedure|Prehabilitation|Participants who underwent Prehabilitation will have their CT scans analysed.
52978|NCT03770117|Procedure|Standard Procedure|Patients who underwent a panctratoduodenectomy and did not receive any Prehabilitation will have their CT scans analysed and compared.
52979|NCT03770104|Procedure|ETT insertion depth using Spanish recommendations|Infants included in this assignment group will be intubated using the formula 5.5 plus weight, when requiring oral intubation in the delivery room.
52980|NCT03770104|Procedure|ETT insertion depth using international recommendations|Infants included in this assignment group will be intubated using the formula 6 plus weight, when requiring oral intubation in the delivery room.
52981|NCT03770091|Drug|Theraworx|Theraworx foam applied to skin and/or compression wrap
52982|NCT03770091|Drug|Placebo|Placebo foam
52983|NCT03770078|Device|Test Product A|The test product is a newly developed ostomy product
52984|NCT03770065|Device|VML-0001|Medical device
52985|NCT03770052|Drug|duvie|take the intervention drug once daily according to the randomized groups
52986|NCT03770039|Drug|Oral PF-06700841 containing 14C microtracer|Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
52987|NCT03770039|Drug|Oral unlabeled PF-06700841|60 mg unlabeled PF-06700841 oral dose in 2nd period
52988|NCT03770039|Drug|IV 14C-labeled PF-06700841|30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period
52989|NCT03770026|Drug|clomiphene citrate|Clomiphene citrate-only arm: Patients will receive Clomiphene citrate induction (in a dose of 100 mg/day starting from day 3 of the cycle for 5 days). Sonographic assessment of endometrial thickness together with Power Doppler evaluation endometrial and sub-endometrial blood flow a will be done in the Day of HCG injection.
52990|NCT03770026|Drug|Saline cervical flushing|Cervical irrigation with 1 ml of 0.9% normal saline will be done at cycle day 8 and 10 to convince patient-blinded procedure.
52991|NCT03770026|Biological|Intrauterine Autologous platelet-rich plasma|Under complete aseptic cares and ultrasound supervision, Autologous platelet-rich plasma (0.5 - 1 ml) was immediately injected into the uterine cavity using an intrauterine insemination catheter in the cycle days 8 and 10. The Autologous platelet-rich plasma is prepared in collaboration with the Department of Clinical Pathology, Faculty of Medicine, Benha University.
52992|NCT03770013|Drug|bupivacaine|bupivacaine 0.25% a total volume of 40 ml (20 ml each side
52993|NCT03770013|Drug|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg
52994|NCT03770013|Drug|clonidine|1ug/kg clonidine
52995|NCT03770013|Drug|placebo|add placebo 9normal saline)
52998|NCT03769987|Other|observation|observe patients every 6 months
52999|NCT03769974|Behavioral|Motor imagery|Two series of 30 seconds training of motor imagery in each manual engine gesture
53000|NCT03769974|Behavioral|Action observation|Two series of 30 seconds training of action observation training in video format in each manual engine gesture
53001|NCT03769974|Behavioral|Placebo intervention|Two series of 30 seconds of observation and imagination of a landscape during for each manual motor sequence
53002|NCT03769961|Other|No intervention|No interventions - Observational study
53003|NCT03769948|Other|risk factors for diabetic retinopathy|Demographic variables: gender, race, marital status, urban rural status. Co-morbidity variable: neuropathy, nephropathy, peripheral circulatory, ketoacidosis, hyperosmolarity Lab tests variables: alanine aminotransferase (ALT), albumin serum, anion gap, aspartate aminotransferase, blood urea nitrogen, calcium serum, chloride serum, creatinine serum, glucose serum plasma, hematocrit, hemoglobin, mean corpuscular hemoglobin concentration (MCHC), mean platelet volume (MPV), potassium serum, protein total serum, red blood cell (RBC) count, sodium serum, white blood cell (WBC) count
53004|NCT03769935|Drug|cis Platinum, etoposide, S1|"cisplatin 75 mg/m2, iv day1, Etoposide: 60 mg/m2 IV day 1-5, every 21 days for up to 4-6 cycles.~S1 25 mg/m2 oral, everyday until progression disease"
53005|NCT03769922|Procedure|Extensive mesenteric resection|The mesentery is resected avoiding the root region.
53006|NCT03769922|Procedure|Limited mesenteric excision|The mesentery is retained.
53007|NCT03769896|Drug|Nabilone 0.25 mg|capsules, 0.25 mg up to 2 mg of nabilone taken orally on a daily basis
53008|NCT03769896|Drug|Placebo|capsule, corn starch, daily basis
53009|NCT03769883|Behavioral|Exercise and diet|The participants will undergo diet or combined diet and exercise. The exercise will be provided at different volumes
53010|NCT03769883|Behavioral|Diet|Dietary intervention
53011|NCT03769870|Drug|Teneligliptin 20mg/day|cross-over
53012|NCT03769870|Drug|Atorvastatin 40mg/Day|cross-over
53013|NCT03769870|Drug|Teneligliptin 20mg/day + Atorvastatin 40mg/day|cross-over
53014|NCT03769857|Dietary Supplement|NEM® + BIOCURC®|Dietary supplement combination for the support of joint health.
53015|NCT03769857|Dietary Supplement|Placebo|Placebo
53016|NCT03769844|Drug|GM-CSF|Subjects demonstrating immunoparalysis (defined by a whole blood ex vivo LP-induced TNF-alpha production capacity < 200 pg/ml) will receive 7 days of GM-CSF treatment by either the IV or SQ route at a dose of either 125 or 250 mcg/m2/day for 7 days.
53017|NCT03769831|Drug|SHR2285|Ascending dose oral adminstration
53018|NCT03769831|Drug|Placebo|Ascending dose oral adminstration
53020|NCT03769818|Drug|dexamethasone|Bilateral TAP block with 4 mg/kg dexamethasone diluted with isotonic saline.
53021|NCT03769818|Drug|placebo to dexamethasone|Bilateral TAP block with placebo to dexamethasone.
53022|NCT03769818|Drug|placebo to bupivacaine|Bilateral TAP block with placebo to bupivacaine.
53023|NCT03769805|Drug|Anlotinib|Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week.
53024|NCT03769792|Diagnostic Test|Blood and faeces tests|During V0 - Laboratory tests, particularly for calprotectin concentration assessment
53025|NCT03769792|Device|Impedance spectroscopy test|During V1 - the electrical impedance of pelvic floor muscles will be measured
53026|NCT03769792|Diagnostic Test|Full gynecological and proctological examination|During V1 - Examination with a gynecological speculum, Two-handed examination, Rectal examination and Anoscopy
53027|NCT03769792|Diagnostic Test|Transanal ultrasonography|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
53028|NCT03769792|Diagnostic Test|Anorectal manometry|During V2 - reference diagnostic methods with documented effectiveness and safety; for comparison with impedance spectroscopy results.
53029|NCT03769779|Dietary Supplement|FloraGLO Lutein|Lutein (FloraGLO™) in safflower oil
53030|NCT03769779|Dietary Supplement|Safflower Oil|Safflower Oil
53031|NCT03769766|Drug|Curcumin|Take medication one 500 mg pill of BCM-95 taken twice daily
53032|NCT03769766|Drug|Placebo|Take medication one 500mg pill twice daily
53033|NCT03769753|Device|IRE Device|For use in ablating soft tissue
53034|NCT03769740|Device|Cerebral Oximetry|Non invasive, near infrared spectroscopy cerebral oximetry
53035|NCT03769727|Device|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
53036|NCT03769727|Procedure|Tube Thoracostomy|Traditional chest tube placement
53037|NCT03769714|Drug|Saline Solution for Injection|Injection of 20mL of 0.9%Normal Saline
53038|NCT03769714|Drug|Exparel|Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
53039|NCT03769701|Procedure|self-monitoring capillary glucose (SMCG)|To measure the capillary glucose with a glucometer according to the assigned group.
53040|NCT03769688|Drug|Cervicovaginal secretions|Same as arm descriptions
53041|NCT03769688|Drug|Metronidazole gel|5 day course of vaginal MetroGel will be used prior to VMT intervention.
53042|NCT03769688|Diagnostic Test|Screening tests|Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.
53043|NCT03769688|Behavioral|Activities restriction|Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
53044|NCT03769688|Other|Sterile Saline placebo|This will be administered as a placebo in place of cervicovaginal secretions
53045|NCT03769675|Device|High Frequency Spinal Cord Stimulator|The SCS implant will follow standard clinical practice for these FDA approved indications. Two percutaneous leads will be placed in the posterior spinal epidural space under radiographic guidance and attached to either an external stimulator (trial phase) or a subcutaneously implanted impulse generator (IPG). Intraoperative impedance testing will be performed to ensure electrical integrity. Patients with HF10 SCS will receive 30 µs pulses delivered at 10,000 Hz with amplitude adjusted to optimal analgesic response. Programming will occur postoperatively and as needed based on patient feedback in standard clinic visits. .
53046|NCT03769662|Biological|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
53047|NCT03769649|Device|CelluTite|CelluTite: Radiofrequency-assisted lipolysis (RFAL) Morpheus8: Fractional RF
53048|NCT03769636|Device|GaitUp Physilog 5|"The primary outcomes are measured by the Physilog 5 (physical activity) at four different periods (T1-T4). Physilog 5 is worn for 4 weeks in total.~The secondary outcomes are fatigue, measured by FSMC (fatigue scale for motor and cognitive functions questionnaire), self-rated health-related quality of life, measured by the EQ-5D (health-questionnaire) and self-rated walking capacity, measured by the MSWS-12 (Twelve Item MS Walking Scale)."
53049|NCT03769623|Device|Biolimus|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Biolimus
53050|NCT03769623|Device|Powerline|103 subjects with small coronary artery disease who met the inclusion/exclusion criteria were enrolled, subjects were assigned to the treatment group of Powerline
53051|NCT03769610|Other|Inpatient Foley catheter|
53052|NCT03769610|Other|Outpatient Foley catheter|
53053|NCT03769597|Drug|Iohexol Inj 300 MG/ML|After injecting a loading dose of 5ml of iohexol bolus, blood samples will be taken at given times for 24 hours. The urinary samples will be taken at each urination, with measurement of the exact volume and times
53054|NCT03769584|Other|Follow-up questionnaire|Online- Questionnaire investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
53055|NCT03769584|Other|Follow- up interview|Semi- structured Interview investigating Follow-up of Treatment Outcome, Quality of Life, Sexual Life and Partnership After Surgery of Endometriosis
53056|NCT03769571|Behavioral|Parental coaching program at ESDM (P-ESDM)|It will have a duration of 7 months (with an inclusion period of 1 year). Parents will come to the hospital with their child once every 15 days for one-hour parental coaching sessions on the ESDM method. Home video sessions will also be performed by parents once every 15 days. Each parent will have a Certified therapist referral to the practice of ESDM and the program is framed by a certified therapist and trained in ESDM parental coaching.
53057|NCT03769558|Other|Non-Interventional|Non-Interventional
53058|NCT03769532|Drug|Pembrolizumab|Pembrolizumab (IMP): 200mg i.v. (fixed dose), every 3 weeks (Q3W), 8 doses
53059|NCT03769532|Drug|Azacitidine|Azacitidine (SOC): 75 mg/m2 s.c., day 1-7 every 4 weeks (Q4W), 6 cycles
53060|NCT03769519|Behavioral|ARICA|Personalized ARICA (AdheRence to Inhaled Corticosteroids in Asthma) intervention package.
53063|NCT03769493|Behavioral|Mobile After-Care Support (MACS) app|The MACS app assesses and intervenes by fostering increased treatment adherence (medication/appointments) and self-coping with illness (active, planned, problem-solving focused) to reduce symptoms and improve functioning. Additionally, MACS encourages participants who are already reporting adherence and healthy coping by using positive reinforcement strategies to maintain efforts and promote additional goal setting. MACS app strategies are linked to participants' specific assessment responses, allowing for a highly personalized self-management intervention experience. The MACS app provides interactive exercises delivered by the device designed to teach patients coping skills that they can use now and in the future.
53064|NCT03769480|Other|Muscle strength evaluation and Respiratory function Tests|Muscle strength evaluation and Respiratory function Tests
53065|NCT03769467|Biological|tabelecleucel|Tabelecleucel is an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
53066|NCT03769467|Biological|pembrolizumab|pembrolizumab IV infusion
53067|NCT03769454|Drug|PP-001|PP-001 eye drops
53068|NCT03769454|Other|Placebo|Placebo eye drops
53069|NCT03769441|Drug|Ferric carboxymaltose|Four intravenous dosages of ferric(III) carboxymaltose
53070|NCT03769441|Drug|Sodium chloride|Four intravenous dosages of sodiumchloride
53071|NCT03769428|Procedure|erector spinae plane block|The ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Local anesthetic (LA) is injected between the erector spinae muscle and transverse process. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid. Then 40cc of Ropivacaine (3.75mg/cc) will be injected .The distribution will be observed in both cranial and caudal directions.
53072|NCT03769428|Procedure|sham erector spinae plane block|The sham ESPB will be done in a sitting position using linear ultrasound probe (L10) of MySonoU6 machine. The blocks will be performed at the T4-T5 level of the spine using an in-plane approach. A linear probe will be placed 2-3 cm laterally to the spine using a sagittal approach. Three muscles will be identified superficial to the transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. Following confirmation of the correct position of the needle tip with administration of 0.5-1 ml of the fluid a total of 40 mL of fluid will be injected next between the erector spinae muscle and transverse process. Then 40cc of normal saline will be injected.The distribution will be observed in both cranial and caudal directions.
53073|NCT03769415|Device|Intrinsic Subtyping of Primary Breast Cancer|Primary breast tissue will be sent for Nanostring PAM50 Testing to determine intrinsic subtype
53074|NCT03769402|Drug|Citric acid|Citric acid ph1, 50% concentration solution
53075|NCT03769402|Drug|Control Test|Control group, xenograft was used to fill infrabony defects without treating bone surface
53076|NCT03769389|Dietary Supplement|Birhi|"Birhi which contain the following:~43.6g of Freeze-dried date powder+ 150g of 0% fat yoghurt"
53077|NCT03769389|Dietary Supplement|Khassab|34.6g of freeze-dried date powder+ 150g of 0% fat yoghurt
53078|NCT03769389|Dietary Supplement|placebo|50g of pure glucose dissolved in 100ml of water
53079|NCT03769376|Device|Bio-Oss®|Bio-Oss® xenograft bone material will be placed into the socket following tooth extraction.
53080|NCT03769376|Device|Salvin-Oss®|Salvin-Oss® xenograft bone material will be placed into the socket following tooth extraction.
53081|NCT03769363|Device|Smartphone-delivered CBT for SAD|12-week Smartphone-delivered CBT for SAD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for SAD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
53082|NCT03769350|Device|Smartphone-delivered CBT for MDD|8-week Smartphone-delivered CBT for MDD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for MDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral activation, and perceptual retraining/mindfulness skills.
53083|NCT03769337|Diagnostic Test|serum biomarkers|Measurement of Serum concentrations of IL-6, TREM-1, CCL2, MMP-9, OPN, IL-1RA, GP-130, C5a, sRAGE, urokinase and presepsin before revision surgery and after 2 and 7 days after surgery
53084|NCT03769324|Diagnostic Test|Osmolarity Test|Osmolarity Test
53085|NCT03769311|Drug|Cetuximab|Monoclonal antibody against epidermal growth factor receptor (EGFR)
53086|NCT03769298|Drug|Envarsus XR|The Envarsus XR® drug will be administered to study participants once daily, orally. The dosage can be 0.75 mg, 1 mg or 4 mg. The tacrolimus whole blood trough concentrations will be monitored and titrate Envarsus XR® dosage to achieve target whole blood trough concentration.
53087|NCT03769285|Drug|Nicotinamide|Oral nicotinamide (500 mg) twice daily for at least 52 weeks
53088|NCT03769285|Drug|Placebo oral capsule|Matching placebo taken twice daily for at least 52 weeks
53089|NCT03769272|Procedure|Measurement of electrical delay during LV lead placement|Measurement of electrical signal in the heart during implantation of CRT, by positioning the lead in different places in the heart.
53090|NCT03769259|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|Participants in BCBT receive 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. BCBT was is delivered in three sequential phases. In phase I (5 sessions), the therapist identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase II (5 sessions), the therapist applies cognitive strategies to reduce beliefs and assumptions that serve as vulnerabilities to suicidal behavior. In phase III (2 sessions), a relapse prevention task is conducted.
53204|NCT03768427|Combination Product|EZ 10 mg/Ator 20 mg|FDC of EZ10 mg/Ator 20mg
53091|NCT03769259|Behavioral|Present-Centered Therapy (PCT)|Participants in PCT will receive will include 12 outpatient individual psychotherapy sessions scheduled on a weekly or biweekly basis, with the first session lasting 90 minutes and subsequent sessions lasting 60 minutes. PCT consists of (1) psychoeducation about the typical symptoms and features associated with suicidal thoughts and behaviors among military personnel; (2) normalization of symptoms; (3) experience of receipt of support and feedback from a licensed professional; and (4) positive interpersonal interactions.
53092|NCT03769259|Behavioral|Treatment as Usual (TAU)|"All participants will receive the following interventions or procedures, regardless of treatment assignment:~Suicide risk assessment using the Columbia Suicide Severity Rating Scale~VA's safety planning intervention, which include Military Crisis Line contact information and lethal means access reduction~Caring contacts and outreach via the Marine Intercept Program (MIP)~Psychotropic medication, group therapy, substance abuse counseling, and other mental health interventions provided routinely as a part of treatment as usual"
53093|NCT03769246|Device|Upright Go Device|Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
53094|NCT03769246|Other|Ergonomic Handout|Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
53095|NCT03769233|Behavioral|Mindfulness-based Intervention|MBI will be delivered in group format, 90 minutes per week, for 5 consecutive weeks with 6-15 participants per group.
53096|NCT03769207|Device|Ambulatory ECG|Eligible participants are asked to wear the ambulatory ECG monitor
53097|NCT03769194|Biological|VLA15|a multivalent Outer surface protein A (OspA) based vaccine candidate
53098|NCT03769194|Biological|Placebo|Placebo: PBS (Phosphate Buffered Saline)
53099|NCT03769181|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
53100|NCT03769181|Drug|cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
53101|NCT03769168|Drug|AIN457|Secukinumab (AIN457) is a high-affinity fully human monoclonal anti- human antibody that target IL-17A and neutralizes activity.
53102|NCT03769155|Biological|Ipilimumab|Given IV
53103|NCT03769155|Biological|Nivolumab|Given IV
53104|NCT03769155|Biological|VX15/2503|Given IV
53105|NCT03769155|Procedure|Surgery|Undergo therapeutic conventional surgery
53106|NCT03769142|Procedure|All monitoring|All monitoring (TCD, BIS, NIRS) are collected from the healthy side, contralateral to the interventional side
53107|NCT03769129|Drug|Pembrolizumab|Pembrolizumab
53108|NCT03769129|Procedure|microwave ablation|microwave ablation
53109|NCT03769116|Drug|SRP-9001|Single IV infusion of SRP-9001
53110|NCT03769116|Drug|Placebo|Single IV infusion of placebo
53111|NCT03769103|Drug|Osimertinib|Daily oral osimertinib
53112|NCT03769103|Radiation|Stereotactic radiotherapy|1-5 fractions of stereotactic radiotherapy
53116|NCT03769077|Device|Exergaming|This study involves the use of multiplayer exercise video games or 'exergames' that incorporate an avatar powered by pedaling a recumbent stationary bicycle. The Liberi suite of exergames contains six mini-games, including a combination of cooperative games, competitive games and individual games designed to be fast-paced, action-oriented, and enjoyable for youth with special needs.
53117|NCT03769064|Drug|Placebo|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
53118|NCT03769064|Drug|Methylphenidate 60 mg|Potential subjects will be screened to determine their eligibility for the study within 28 days of the first dose in the Qualification Phase (i.e., Days -28 to -2). Eligible subjects will be admitted to the clinical site on Day -1 of the Qualification Phase (Part 1) and randomized on Day 1 to receive placebo and MPH (60 mg) in 1 of 2 sequences with a 48-hour washout between dose administrations (i.e., dose administration on Days 1 and 3).
53119|NCT03769064|Drug|Treatment Phase Sequence 4213|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
53120|NCT03769064|Drug|Treatment Phase Sequence 2134|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
53121|NCT03769064|Drug|Treatment Phase Sequence 1342|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
53122|NCT03769064|Drug|Treatment Phase Sequence 3421|Subjects will be administered single doses on Days 1, 4, 7, and 10 of the Treatment Phase.
53123|NCT03769038|Device|chronic total occlusion|chronic total occlusion of coronary atery was opened and then stents were placed
53124|NCT03769025|Behavioral|Suboxone Remote Observed Dosing|The remote observed dosing group will use the provided smartphone to video record themselves taking their Suboxone dose each day
53125|NCT03769025|Other|Suboxone Attention Control|Attention control group will send a text message daily confirming that they have taken their Suboxone dose
53126|NCT03769012|Dietary Supplement|Beta-Glucan|95% beta-glucan sourced from whole cell Euglena Gracilis
53127|NCT03769012|Dietary Supplement|Placebo|microcrystalline cellulose
53128|NCT03768999|Diagnostic Test|Non-contrast magnetic resonance coronary angiography (MRCA)|Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
53129|NCT03768986|Behavioral|Standard referral for HIV testing|Participants receive standard referral for HIV testing in the community.
53130|NCT03768986|Behavioral|Online risk reduction training|Participants are encouraged to use the CDC's website to learn more about their individual risks for HIV and how to reduce them.
53131|NCT03768986|Behavioral|Reinforcement|Systematic reinforcement of desired behaviors Participants will receive a monetary incentive for getting tested for HIV
53132|NCT03768973|Procedure|Elective cardiac surgery|Both groups will undergo elective cardiac surgery as an intervention.
53133|NCT03768960|Drug|Daratumumab|Participants will receive 16 mg/kg of daratumumab as IV infusion QW in Cycles 1 and 2 (Days 1, 8, 15 and 22) and Q2W in Cycle 3 to 6 (Days 1 and 15).
53134|NCT03768947|Other|Heat therapy via hot water immersion|Participants will be asked to participate in a 4-week heat therapy intervention, which consists of ~12-15 visits (45 min each) of immersion in to a hot tub.
53135|NCT03768934|Other|1X airtime incentive|An incentive given in the form of airtime.
53136|NCT03768934|Other|2X airtime Incentive|An incentive given in the form of airtime.
53137|NCT03768934|Other|Lottery airtime incentive|An incentive given in the form of airtime.
53138|NCT03768921|Other|PEEP Titriation|The alveolar recruitment maneuver PEEP reaches a maximum of 25 cmH2O, with recruitment being performed progressively, where the pressure variation is maintained at 15 cmH2O and the PEEP increase progressively occurs at 2 cmH2O every 2 minutes and Ventilatory mode with Controlled Pressure Ventilation. After the alveolar recruitment maneuver, the PEEP titration or determination will be performed, where the PEEP of 2 cmH2O will be reduced every 2 minutes and the variables after the alveolar recruitment maneuver and PEEP maintenance will be checked in the TIMPEL brand equipment at the point where the patient has better alveolar recruitment, with fewer alveolar collapsing points and pulmonary hyperdistension.
53139|NCT03768908|Drug|Artemether-lumefantrine|Three day treatment with Artemether-lumefantrine, 2 doses a day under direct observation
53140|NCT03768908|Drug|Artesunate + Amodiaquine|Three day treatment with Artesunate + Amodiaquine, co-administered, a dose a day under direct observation
53141|NCT03768895|Radiation|MRI|"The technique used was coronal and axial T1 and T2*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2*WI."
53142|NCT03768882|Drug|paracetamol|1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
53143|NCT03768882|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
53144|NCT03768869|Drug|Low Risk: Oupatient Management|Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
53145|NCT03768869|Drug|Low Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
53146|NCT03768869|Drug|High Risk: Inpatient Management|Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
53147|NCT03768856|Radiation|Temporally Feathered Radiation Therapy (TFRT)|Up to 5 different plans are created and delivered on a daily basis Monday-Friday for 7 weeks. The treating physician designates up to 5 organs at risk (OARs) to be feathered based on the proximity to the target. The daily prescription dose delivered to the Planning Target Volumes (PTV) is not changed.
53148|NCT03768843|Procedure|Harms technique|Atlantoaxial fusion
53149|NCT03768830|Behavioral|Exercise training|Exercise program includes breathing and upper and lower limbs exercise.
53150|NCT03768817|Other|No Intervention|This is a non-interventional retrospective medical record review study. No study investigational product will be administered in this protocol.
53151|NCT03768804|Other|SyncAV algorithm on|"Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings"
53152|NCT03768804|Other|SyncAV algorithm off|ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
53153|NCT03768791|Other|SCS is switched off|Spinal cord stimulator is switched off for 12 hours
53154|NCT03768791|Other|SCS is switched on|Spinal cord stimulator is on
53155|NCT03768778|Procedure|Debridement and dural repair|
53156|NCT03768765|Procedure|Holmium Laser Prostate Surgery|Patients will undergo standard of care holmium laser prostate surgery
53157|NCT03768739|Procedure|Fiberoptic Endoscopic Evaluation of Swallowing|This procedure involves a flexible laryngoscope that contains a light source and video camera on the end through the open passages of your nose and to the back of the throat in order to visualize the swallowing mechanism.
53158|NCT03768739|Device|Peak Cough Flow|A peak cough flow meter will be used to assess voluntary cough strength and function.
53159|NCT03768739|Device|Reflex Cough Testing|A handheld nebulizer (device that transforms liquid in to breathable mist) will deliver a citric vapor for participants to breath in and out for up to 15 seconds.
53160|NCT03768739|Behavioral|3-ounce Water Swallow Test|Participant will drink 3 ounces (90 cc) of room temperature water continuously from a cup without stopping.
53161|NCT03768739|Behavioral|Secretion Management|Research clinician will subjectively assess the presence of saliva.
53162|NCT03768739|Behavioral|Dysphonia Status|A subjective rating of vocal quality
53163|NCT03768739|Procedure|Vitals|Respiratory status and vital signs to include: oxygen saturation levels, respiratory rate, blood pressure, and heart rate.
53164|NCT03768726|Drug|Ziprasidone|"All investigational products will be provided by Pfizer and will include oral ziprasidone capsules of 20, 40, 60, and 80 mg strength. Matching placebo capsules will also be supplied for the initial 1-14 day dose transition period.~During the transition period all subjects will receive both active ziprasidone and placebo capsules. The placebo capsules are used to maintain the blind to the treatment assignment of the subjects in A1281198 . All medication will be packaged in childproof blister cards with columns for AM and for PM capsules.~During the dose transition period (Weeks 1-2, Days 1-14), subjects will receive a study drug blister card for each week of transition dosing. Subjects weighing greater than 45 kg will receive 2 weeks of transition medication, while subjects weighing less than 45 kg will receive 1 week of transition medication."
53165|NCT03768713|Drug|Suvorexant|Insomnia subjects will take a nightly pill of 20 mg Suvorexant for eight weeks.
53166|NCT03768713|Drug|Placebo|Insomnia subjects will take a nightly pill of 20 mg placebo for eight weeks.
53167|NCT03768700|Other|Data gathering|Questionnaires and collection of medical data on patients during hospitalization, at D28, at 90 and at 1 year
53168|NCT03768674|Other|Assessment of diagnoses, functioning and health services|Systematic differential diagnostics, assessment of psychosocial and personality functioning and treatment/ health services
53169|NCT03768661|Procedure|Single-incision Laparoscopic cholecystectomy|laparoscopic cholecystectomy performed through a single device located at a unique umbilical incision
53170|NCT03768661|Procedure|Laparoscopic Cholecystectomy|laparoscopic cholecystectomy performed using three-trocars standard technique
53171|NCT03768648|Other|Clinical assessment|EDSS (Kurtzke JF; 1983) and the modified MS functional composite (MSFC) score. MS history and MS treatment will be recorded
53172|NCT03768648|Other|Ecological evaluation|Virtual reality task : Urban DailyCog© and Actual reality
53173|NCT03768648|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
53174|NCT03768648|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
53175|NCT03768648|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
53176|NCT03768635|Other|necrotizing external otitis|description of necrotizing external otitis
53177|NCT03768622|Procedure|surgery for pertrochanteric femoral fracture|surgical treatment for proximal femoral fracture with intramedullary nail type Gamma® Nail or similar in case of pertrochanteric fractures
53178|NCT03768622|Procedure|surgery for femoral neck fracture|surgical treatment for proximal femoral fracture with a partial hip arthroplasty in case of femoral neck fractures
53179|NCT03768609|Drug|Pimodivir|Participants will be administered pimodivir 600 mg orally as two tablets of 300 mg each.
53180|NCT03768609|Drug|Cyclosporine|Participants will be administered cyclosporine 400 mg orally as 4 capsules of 100 mg each.
53181|NCT03768596|Behavioral|Nudge|Influenza Vaccine Prescription Form accompanied on the back of telephone numbers of occupational health centers of different hospitals where interns are likely to be on probation.
53182|NCT03768596|Other|vaccination form|a form about vaccination
53183|NCT03768583|Other|Group TSM ICT sneakers|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
53184|NCT03768583|Other|Group TSM ICT barefoot|Sensory motor training without sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
53185|NCT03768583|Other|Group TSM health sneaker|Sensory motor training with sneakers for volunteers with Chronic ankle instability, for five weeks, twice a week.
53186|NCT03768583|Other|Group TSM health barefoot|Sensory motor training without sneaker for volunteers with Chronic ankle instability, for five weeks, twice a week.
53187|NCT03768570|Drug|Durvalumab|1500 mg IV on day 1 of 4 week cycle every 4 weeks for 12 months
53188|NCT03768557|Drug|Minocycline|Minocycline (200mg)
53189|NCT03768557|Other|placebo|Lactose (400mg)
53190|NCT03768544|Behavioral|Self-help guided by a lay provider|Self-help based on the principles of cognitive-behavioral therapy and guided by a lay provider. Treatment lasts 15 weeks, is based on a participant's manual, and consists of relaxation, differentiation of the main types of worries, learning to tolerate uncertainty, questioning false beliefs about worries, problem solving, cognitive exposure, and planning pleasant activities. Weekly telephone sessions with the lay provider serve to provide support.
53191|NCT03768544|Behavioral|Waiting list where participants wait for delayed treatment|Participants have a 15-week wait period during which they receive a 15-minute telephone call from the local professional research assistant on three occasions separated by four-week intervals. The purpose of these calls is to encourage the participant to persevere until the start of treatment and to identify potential negative effects that could be associated with the waiting period. Participants receive self-help guided by a lay provider after the waiting period.
53192|NCT03768531|Drug|Nivolumab|Nivolumab 3 mg/kg will be given intravenously (IV) through a vein in the arm over 30 minutes every 2 weeks. (Cycle length 2 weeks).
53193|NCT03768531|Drug|Cabrilizumab|Cabiralizumab 4 mg/kg given IV for 30 minutes, 30 minutes after Nivolumab infusion is completed, every 2 weeks. (Cycle length 2 weeks).
53194|NCT03768518|Diagnostic Test|68Ga-exendin-4 PET/CT|68Ga-exendin-4 PET/CT
53195|NCT03768505|Drug|ME-401|ME-401
53196|NCT03768492|Drug|Caffeine anhydrous 5% added to Lipoderm Cream Base.|Caffeine USP Anhydrous 5 gm Ethoxy Digylco Reagent 10 ml Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
53197|NCT03768492|Other|Lipoderm Cream Base|Professional Compounding Centers of America (PCCA) Lipoderm Base 85 gm
53198|NCT03768479|Device|18F-FES-PET|18F-FES-PET/CT imaging before and after cycle 1 treatment with the first line Fulvestrant
53199|NCT03768466|Drug|Brand Name: Targin®|Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
53200|NCT03768440|Procedure|continuous erector spinae block (ESB)|Erector spinae block: T4/5 transverse process is identified with the ultrasound transducer in a parasagittal orientation; the needle tip is advanced until it contacts the transverse process, just below the erector spinae muscle complex; the erector spinae muscle is visualized to be elevated up off of the transverse process with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
53201|NCT03768440|Procedure|continuous paravertebral block (PVB)|The paravertebral space (bound medially by the bodies of the vertebrae, intervertebral discs, and intervertebral foraminae; anterolaterally by the parietal pleura and the innermost intercostal membrane; posteriorly by the transverse processes of the thoracic vertebrae, heads of the ribs, and the superior costotransverse ligament) laying between T4/5 is identified using the ultrasound transducer in a transverse orientation; the needle tip is advanced until it is seen passing under the transverse process, immediately superior to the pleura; the pleura is seen to deflect downward with normal saline injection. Following a bolus injection of 2ml/kg of 0.2% ropivacaine, a catheter is threaded into the space occupied by the local anesthetic bolus.
53202|NCT03768440|Drug|Ropivacaine|Ropivacaine 0.2% will be the drug used for each group (ESB group and PVB group)
53203|NCT03768427|Combination Product|EZ 10 mg/Ator 10 mg|FDC of EZ10 mg/Ator 10mg
53205|NCT03768427|Drug|Atorvastatin|Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
53206|NCT03768427|Drug|Placebo for FDC EZ/Ator|A single placebo tablet administered orally QD for 84 days
53207|NCT03768427|Drug|Placebo for atorvastatin|Two placebo tablets matching atorvastatin administered orally QD for 84 days
53208|NCT03768414|Drug|Cisplatin|Given IV
53209|NCT03768414|Drug|Gemcitabine Hydrochloride|Given IV
53210|NCT03768414|Drug|Nab-paclitaxel|Given IV
53211|NCT03768401|Other|Education|Seminars about wellness and exercise, and resulting therapeutic programs, while living with a neurological physical disability.
53212|NCT03768401|Behavioral|Trial Exercise Modalities|Wellness/exercise clinics located at Mayo Clinic, Rochester will be offered to persons with neurological physical disabilities on a regular basis, at least monthly, during the last half of the trial period.
53213|NCT03768388|Drug|levoketoconazole|food effect
53214|NCT03768375|Biological|conventional chemotherapy(FORFIRINOX) combined with target agents|Drug: FORFIRINOX Conventional chemotherapy:gemcitabine and oxaliplatin Drug: Cetuximab Drug: Trastuzumab Drug: Gefitinib Drug: Lapatinib Drug: Everolimus Drug: Sorafenib Drug: Crizotinib
53215|NCT03768375|Biological|conventional chemotherapy(FORFIRINOX)|conventional chemotherapy(FORFIRINOX)
53216|NCT03768362|Procedure|Plication strabismus surgery|The technique was the same as resection up to muscle suturing, in the next step, the sutures were passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures. At the end, conjunctiva was repaired by vicryl 8/0.
53217|NCT03768362|Procedure|Resection strabismus surgery|resection strabismus surgery
53218|NCT03768349|Drug|Ga-68 PSMA11|Ga-68 PSMA11 PET/CT for detection of tumor location
53219|NCT03768336|Other|Waitlist control|The 3RP is a group program that—through a variety of mind-body approaches, such as imagery, relaxation, and yoga—seeks to buffer stress and promote psychological resiliency and physical well-being. Waitlist control receives the adapted 3RP program (3RP-AYA) approximately 2 months after study enrollment.
53220|NCT03768336|Other|3RP-AYA|The 3RP is a group program that—through a variety of mind-body approaches, such as imagery, relaxation, and yoga—seeks to buffer stress and promote psychological resiliency and physical well-being.
53221|NCT03768323|Other|1X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey
53222|NCT03768323|Other|2X airtime incentive|an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey
53223|NCT03768310|Biological|CD19.CAR-multiVST for Group A|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the transplant (between days 30 and 90). A time period of 6 weeks will constitute the time for clinical safety monitoring.
53224|NCT03768310|Biological|CD19.CAR-multiVST for Group B|Patients will be evaluated in the clinic and a single dose of CD19.CAR-multiVSTs will be given by intravenous injection on or after 30 days of the bone marrow transplant. A time period of 6 weeks will constitute the time for clinical safety monitoring. If patients with relapse after transplant or those with evidence of disease before bone marrow transplant have at least a partial response to the treatment or have stable disease, they will be eligible to receive up to 6 additional doses of T cells separated by a minimum of four weeks. Patients are eligible to receive additional doses only after they have completed the initial 6-week clinical safety monitoring period.
53225|NCT03768297|Procedure|dual zone concept|immediate implant with bone fill till soft tissue level
53226|NCT03768284|Other|Saliva or buccal sample|Saliva or buccal sample
53227|NCT03768258|Drug|Testosterone Implant|Testosterone implants or combination testosterone + anstrozole implants used to treat symptoms of hormone/androgen deficiency
53228|NCT03768245|Behavioral|Health Education and Physical activity program|Its objective is to empower children on healthy lifestyle, addressing four main topics: nutrition (i.e. healthy food, hydration), adequate quantities of food, physical activity, and self-monitoring. The program is implemented in the classroom through workshops planned and conducted by psychologists and nutritionists. A total of 12 workshops are planned, to be conducted once a week, and lasting 50 minutes each. The Physical activity program objective is to develop an active scholar environment, and consists of a moderate-vigorous activity, five days a week. The activities are divided into two types: (a) in the school backyard for 60 minutes, three times a week, and (b) in the classroom two days a week, for 15 minutes three times a day, adding up to 45 minutes daily.
53229|NCT03768245|Dietary Supplement|Nutrition Program|Its objective is to maintain lean mass, decrease fat mass and ensure mineral vitamins and fatty acids intake, maintain proper growth under National Specific Action Program: Food and Activity4. From total energy, a fat intake of 25-35%, carbohydrate intake of 45-65%, protein intake of 10-30%, and total calories are adjusted according to age. The Nutrition program consists of three meals: breakfast, a snack for a mid-morning playtime, and lunch at school. Food is prepared daily following sanitary and quality standards of Mexican official regulation. Breakfast is served 40 minutes before starting class time, lunch is served 40 minutes before leaving school.
53230|NCT03768232|Other|ultrasound asessment|US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
53231|NCT03768219|Biological|APVO210|APVO210
53232|NCT03768219|Biological|Placebo|Placebo is saline based IV infusion, and is identical in appearance to active study drug.
53233|NCT03768206|Behavioral|Standard Physical Therapy|Participants will receive standard outpatient physical therapy that is typical following knee replacement
53234|NCT03768206|Behavioral|Physical therapist discuss aerobic physical activity|Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.
53235|NCT03768206|Behavioral|Physical activity session|Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
53275|NCT03767920|Drug|bupivacaine|TAP block with 20 ml of 0.25% bupivacaine bilaterally
53236|NCT03768193|Procedure|Deep serratus anterior plane block|Deposition of local anaesthetic in the space between the serratus anterior muscle and the external intercostal muscle, at the level of the 4th-5th rib, in the midaxillary line. Procedure performed under ultrasound guidance. Catheter - based infusion of local anaesthetic into this space for 48 hours.
53237|NCT03768193|Procedure|Surgically-placed paravertebral block|Surgically-placed paravertebral block catheters for continuous local anaesthetic infusion of 0.125% levobupivacaine at 8-12mls/ hr for 48 hours.
53238|NCT03768167|Procedure|Posterolateral corpectomy|Investigators' goal in this study is to report clinical series of 26 patients in Sohag university hospital with dorsolumbar metastatic lesions from different primaries treated by single-stage posterolateral circumferential corpectomy with reconstruction by a pyramesh titanium cage and account the degree of improvement regarding the pain.
53239|NCT03768154|Procedure|Supine + spontaneous effort|without muscle paralysis in supine position
53240|NCT03768154|Procedure|Supine + paralysis|administer muscle paralysis in supine position
53241|NCT03768154|Procedure|Prone + paralysis|change the patient position from supine to prone with muscle paralysis
53242|NCT03768154|Procedure|Prone + spontaneous breathing|cease the paralysis in supine position
53243|NCT03768141|Procedure|Liver surgery|"All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)"
53244|NCT03768128|Device|Journey™ II UNI Unicompartmental Knee System|"Journey™ II UNI UKS is a CE Marked medical device. The device has been designed to treat both medial and lateral unicompartmental disease.~It is a comprehensive system designed to allow surgeons to perform UKA. It is comprised of the following anatomic components: Oxidized zirconium femoral components Titanium tibial components with a grit-blasted surface Polyethylene tibial insert components The device is asymmetric and is available in oxidized zirconium to reduce wear and increase implant longevity."
53245|NCT03768115|Drug|Autologous Plasma Eye Drop|Autologous plasma crimped segments
53246|NCT03768089|Drug|VX-121|VX-121 tablet or suspension for oral administration.
53247|NCT03768089|Drug|VX-121|VX-121 suspension for oral administration.
53248|NCT03768089|Drug|VX-121|VX-121 tablet for oral administration.
53249|NCT03768089|Drug|TEZ/IVA|100 milligram (mg) TEZ/150-mg IVA, fixed-dose combination (FDC) tablet for oral administration.
53250|NCT03768089|Drug|TEZ/IVA|100 mg TEZ/150-mg IVA, FDC tablet for oral administration.
53251|NCT03768089|Drug|IVA|150-mg film-coated tablet for oral administration.
53252|NCT03768089|Drug|Matched Placebo|Matched placebo.
53253|NCT03768063|Drug|Atezolizumab|Atezolizumab will be administered as a monotherapy or atezolizumab with other agent(s) or comparator agent(s) as per parent protocol. Dosing regimen will continue in accordance with the parent study or at equivalent dose (if applicable) and at the same schedule as the parent study, or switch to a fixed atezolizumab dose of 1200 mg every 3 weeks (Q3W).
53254|NCT03768050|Other|Advanced care for frail elderly|"Home-based case management group receives advanced nursing care meeting the health and social needs of patient and/or carer. It is carried out through a process of evaluation, planning&coordination, facilitating the provision, monitoring and evaluation of the options and resources necessary for the resolution of the case. It is person-centred. The service also provides palliative care.~Home hospitalisation/early discharge dispenses medical and nursing care at home on a transient basis after hospitalisation when patients still need surveillance and assistance. It is done in the acute, subacute or post-acute phase. In the last phase the focus is on functional recovery.~The geriatric residences group is assisted by health care teams with expertise in geriatrics. They coordinate with primary care and health professionals of the residences to improve the attention. They are highly accessible, have high-resolutive capacity and can activate the resources of the healthcare network."
53255|NCT03768037|Drug|Anlotinib plus Pemetrexed|"Anlotinib p.o, qd and it should be continued until disease progress or unacceptable toxic effects.~Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects"
53256|NCT03768037|Drug|Pemetrexed|Pemetrexed 500 mg/m2 every 21 days for 4-6 cycles or unacceptable toxic effects
53257|NCT03768024|Drug|GRT0151Y 50 mg capsule|GRT0151Y 50 mg capsule
53258|NCT03768024|Drug|Hydromorphone IR 4 mg|Hydromorphone IR 4 mg tablet (encapsulated)
53259|NCT03768024|Drug|Matching placebo|Matching placebo
53260|NCT03768011|Combination Product|transdermal cream and or patch|transdermal cream and/or transdermal patch(s) with or without oral medication
53261|NCT03767998|Other|Respiratory muscle training for IMST|2 sets of 30 breaths or 6 sets of 10 repetitions with one or two minute of rest between sets, once per day, 5 days per week, training with breathing trainer.
53262|NCT03767998|Other|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
53263|NCT03767998|Other|Respiratory muscle training for EMST|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
53264|NCT03767985|Other|Dichoptic video game therapy|Dichoptic video gaming for 1 hour per week, viewed through the Oculus Rift.
53265|NCT03767985|Other|Occlusion therapy|Occlusion therapy for 2 hours per day, 7 days a week
53266|NCT03767972|Device|Energy-based device|Patients will receive one treatment for rejuvenation using one or multiple energy-based devices based on investigator discretion.
53267|NCT03767959|Procedure|Chen's U-Suture|Chen's U-Suture is a new technique of the invaginated end-to-end pancreaticojejunostomy with transpancreatic transverse U-sutures
53268|NCT03767959|Procedure|Classic pancreatic duct to mucosa|A Classical anastomosis technique for Pancreaticojejunostomy
53269|NCT03767946|Diagnostic Test|Quantiferon Gold Plus Test|Small volume of whole blood incubated with specific TB antigen and then dosage of Interferon gamma production.
53278|NCT03767907|Behavioral|Computer-based Training for Cognitive Behavioural Therapy|Interactive content organized into seven modules, illustrating real-life scenarios associated with common risky situations, which illustrate the application of targeted skills and strategies
53279|NCT03767907|Behavioral|Treatment As Usual|Treatment as usual will include standard psychosocial care determined to be appropriate or necessary, on an individual patient basis.
53280|NCT03767894|Device|EMG Band|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.
53281|NCT03767894|Device|Shoulder harness|The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
53282|NCT03767881|Device|AXIOS(TM) Stent and Electrocautery Enhanced Delivery System|Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
53283|NCT03767868|Other|color change in nail polish|The determination of color change in nail polish will be based on differences in skin temperature before and after the block.
53284|NCT03767855|Drug|CK-3773274 - Granules in Capsule|CK-3773274 formulated as granules in capsule
53285|NCT03767855|Drug|Placebo - Granules in Capsule|Placebo formulated as granules in capsule
53286|NCT03767855|Drug|CK-3773274 - Tablets|CK-3773274 formulated as tablets
53287|NCT03767842|Device|Visor System|Subjects are monitored one time with the Visor System.
53288|NCT03767829|Drug|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC) at dose levels planned for Part A.
53289|NCT03767829|Drug|Placebo|Sterile normal saline (0.9% NaCl) matching volume of ALN-AAT02 doses will be administered SC.
53290|NCT03767829|Drug|ALN-AAT02|ALN-AAT02 will be administered subcutaneously (SC). Part B dose levels to be determined upon review of data from Part A.
53291|NCT03767816|Drug|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.2% ropivacaine (Fresenius Kabi) 30ml around umbilicus
53292|NCT03767816|Drug|Ultrasound erector spinae plane block|Ultrasound guided erector spinae plane block with 0.2% ropivacaine (Fresenius Kabi) 40ml at T7 level
53293|NCT03767803|Other|Non-interventional study|This is an observational, non-interventional study.
53294|NCT03767790|Device|iAPS|The AID system (iAPS) is comprised of an insulin pump, a Dexcom G6 continuous glucose monitoring sensor, and a smart phone that contains the algorithm and communicates with the other devices.
53295|NCT03767777|Device|Artery Stent Graft System|The Artery Stent Graft System consists of Ankura pro Aorta Stent Graft System along with Longuette Aortic Branch Stent Graft System for chimney technique in the aim of revascularization of aorta branches.The Ankura pro aorta stent graft and Longuette Aortic Branch Stent Graft System are pre-assembled within delivery system. During the operation, the stent graft was delivered to the target lesion location of the vascular real cavity through a delivery system, which was accurately positioned and released to isolate the ruptured opening of aortic dissection, block the continuous flow of blood into the false cavity of the dissection, and avoid further tearing or even rupture of the dissection.
53296|NCT03767764|Diagnostic Test|Test Yliver|Test Yliver is used to detect autoantibodies against alpha fetoprotein in serum by an ELISA technique
53297|NCT03767751|Biological|Dual Specificity CD38 and bcma CAR-T Cells|1) Biological: Dual Specificity CD38 and BCMA CAR-T Cells,2)1-5X10E6/Kg
53298|NCT03767738|Drug|Intravitreal Aflibercept Injection (IAI)|IAI prepared and administered with a pre-filled syringe (PFS)
53299|NCT03767725|Biological|Treatment|Phase 1 Clinical Study of The patients undergo leukapheresis. The patients then receive fludarabine and cyclophosphamide on days-5 to-3. Subjects will receive (0.6-60)x10E8 transduced CART cells as a split dose over three days as follows: Day 0, 10% fraction: (0.06-6)x10E8 CART19 cells, Day 1, 30% fraction: (0.18-18)x10E8 CART19 cells, Day 2, 60% fraction: (0.36-36)x10E8 CART cells.
53300|NCT03767712|Diagnostic Test|Comparison of the levels of antinuclear antibodies (ANA) by indirect immunofluorescence on a Hep-2 cell line.|To analyse whether patients with pertrochanteric femoral fracture with consecutive gamma-nailing develop any laboratory signs of transient autoimmunity (comparison of the levels of ANA; in order to overcome the problem of subjective semiquantitative evaluation, the novel method of automated digital fluorescence microscopy will be used)
53301|NCT03767699|Behavioral|Medical Nutrition Therapy|MNT was offered every 2-4 weeks to all pregnant women with T2DM and GDM. Women. MNT is offered as a mandatory part of their prenatal visit and/or hospital stay. The MNT provides an individual food plan with the following recommendations: total calories should be calculated as 30 kcal/kg based on pregestational BMI for an ideal weight. Of the total energy intake 40-45% is provided by carbohydrates, a maximum of 40% is provided by lipids and the remaining percentage by proteins providing moderate-to-low glycemic index foods and fiber consumption, glucose self-monitoring, participating in 15-30 min of daily physical activity after prior authorization of the treating physician, and meeting the minimal energy requirements of pregnancy (never < 1,500 kcal).
53302|NCT03767673|Diagnostic Test|Initial Spirometry|Determination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
53303|NCT03767673|Diagnostic Test|Final Spirometry|Determination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
53304|NCT03767673|Diagnostic Test|Pulmonary microbiome (16S rDNA profiling)|Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).
53305|NCT03767673|Diagnostic Test|Maximum oxygen uptake|Determination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
53306|NCT03767673|Diagnostic Test|Maximum performance|Determination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
53307|NCT03767673|Diagnostic Test|weight|Determined by Kilogram on a medical weight scale
53308|NCT03767673|Other|age|Determination of age by patient's Report and past medical history
53376|NCT03767088|Other|(synchronized) Training program without WB-EMS|20 min of pronounced eccentric movement patterns
53309|NCT03767660|Drug|Rapamycin|For children: rapamycin, 1 mg per square meter of body surface area a day, orally, for at least 6 months For adults: rapamycin, 2 mg a day, orally, for at least 6 months
53310|NCT03767647|Behavioral|Emotional Intelligence lessons|6 lessons were given to the students in separated weeks by the same investigator. Lessons were 45-60 minutes long and each one was dedicated to one of the main aspects of emotional intelligence.
53311|NCT03767634|Other|Parenteral nutrition|Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
53313|NCT03767595|Device|ProACT Adjustable Continence Therapy for Men|The ProACT therapy consists of two small, adjustable silicone balloons connected with tubing to a port. During a minimally invasive outpatient procedure, the balloons are surgically placed in the area where the prostate was removed or resected.
53314|NCT03767582|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be administered between 2 to 4 weeks after chemotherapy. (Prior to surgery)
53315|NCT03767582|Drug|Nivolumab|Nivolumab (480 mg) will be administered IV over 30 minutes, on day 1 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery Nivolumab will be given on Day 1 of cycles 2-5. Cycles are 4 weeks long.
53316|NCT03767582|Drug|CCR2/CCR5 dual antagonist|CCR2/CCR5 dual antagonist (150 mg capsules) will be administered orally twice a day, on days 1-28 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery CCR2/CCR5 dual antagonist will be given daily on cycles 2-5. Cycles are 4 weeks long.
53317|NCT03767582|Drug|GVAX|Vaccine (5x10^8 cells) will be administered on day 2 of cycle 1 (within 1 to 2 weeks after SBRT prior to surgery). Post - surgery GVAX will be given on Day 2 of cycles 2-5. Cycles are 4 weeks long. Six intradermal injections every 4 weeks.
53318|NCT03767569|Drug|Myo-inositol|Myo-inositol and Folic acid daily
53319|NCT03767569|Drug|Folic Acid|Folic Acid daily
53320|NCT03767556|Procedure|Inspiratory muscle training|Powerbreathe® K5
53321|NCT03767543|Drug|INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
53322|NCT03767530|Device|Mibo Thermoflo|Thermal therapy with Mibo Thermoflo for 11 minutes per eye, during each session.
53323|NCT03767530|Other|Warm compresses and eyelid massage|Warm compresses plus eyelid massage 2 times per day 11 minutes per eye.
53324|NCT03767517|Other|Active Intervention|Half of the patients will receive tele-consult program. Tele-consult intervention includes: initial consult and 2 follow up contacts. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
53325|NCT03767517|Other|Usual Care|Half of the patients will receive usual care. Usual care includes assessment and treatment by the admitting physician, along with any subspecialists that are consulted.
53326|NCT03767504|Dietary Supplement|Thymol|Musclin - a dietary supplement: 2 capsules (20 mg thymol per capsule) BID with a meal for 30 days increased to 4 capsules for an additional 30 days.
53327|NCT03767491|Device|Smartphone-delivered CBT for OCD|12-week Smartphone-delivered CBT for OCD. In-person cognitive-behavioral therapy (CBT) is an empirically supported treatment for OCD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
53328|NCT03767478|Device|Revitive Medic (Actegy Ltd)|Twice daily use (2 x 30 minute sessions) of the footplate neuromuscular stimulation device (Revitive Medic).
53329|NCT03767452|Drug|Xiaflex® 0.58 mg|0.25 mL injections.
53330|NCT03767439|Drug|Vismodegib|150 mg PO daily
53331|NCT03767439|Drug|Nivolumab|480 mg IV every 4 weeks
53332|NCT03767439|Drug|Ipilimumab|1 mg/kg IV every 6 weeks
53333|NCT03767426|Behavioral|Sleep Deprivation|Subjects are sleep deprived for an entire night
53334|NCT03767426|Behavioral|Daytime nap|After a night of sleep deprivation, participants will be given a 2 hour nap opportunity
53335|NCT03767413|Procedure|PNF|proprioceptive neuromuscular facilitation training
53336|NCT03767413|Procedure|PNFMP|proprioceptive neuromuscular facilitation training and mental practice technique
53337|NCT03767400|Device|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight D-OCT and the measurements will be acquired post-study utilizing VivoSight software.
53338|NCT03767400|Other|Facial Cleanser|Participants will be instructed to remove all makeup from the face and cleanse the face with SkinMedica Facial Cleanser at least 15 minutes prior to investigator assessments and photography, and at least 30 minutes prior to use of D-OCT. Particiapnts in the cellulite group will have the thigh area cleansed with Facial Cleanser at least 15 minutes prior to photography and at least 30 minutes prior to use of D-OCT. For standardization, this procedure will be performed with SkinMedica Facial Cleanser (to remove makeup and cleanse the face and thigh (if applicable)) for all the participants.
53339|NCT03767387|Other|Trimodal Prehabilitation|Prehabilitation before major surgery consisting of: i) motivational interview to assess patient's adherence profile and to co-design the characteristics of the physical activity program with the patient; ii) personalised program to promote daily physical activity; and iii) supervised high-intensity endurance exercise training program.
53340|NCT03767374|Procedure|Inguinal swab sample|Inguinal samples using swab at cross-sectional visit
53341|NCT03767374|Procedure|Anal swab sample|Anal samples using swab at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
53342|NCT03767374|Procedure|Fecal sample|Fecal sample at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization)
53343|NCT03767374|Other|Risk factor assessment|Patients will be asked questions on risk factors associated with MDR/XDR colonization at cross-sectional visit and at 6-month visit (for those with ESBL and/or CRE colonization
53344|NCT03767361|Biological|packed red blood cells transfusion|packed red blood cells transfusion
53345|NCT03767348|Biological|RP1|Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation
53346|NCT03767348|Biological|nivolumab|anti-PD-1 monoclonal antibody
53347|NCT03767335|Drug|MEN1611|MEN1611 oral dose administered twice daily for a continuous 28-day cycle
53348|NCT03767335|Drug|Trastuzumab|Trastuzumab solution for infusion administered weekly via IV
53349|NCT03767335|Drug|Fulvestrant|Fulvestrant solution for injection administered monthly via IM (only for HR-positive postmenopausal women)
53350|NCT03767322|Drug|Allopurinol|Eligible patients will receive allopurinol 300 mg before and after coronary intervention
53351|NCT03767322|Drug|Febuxostat|Eligible patients will receive febuxostat 80 mg before and after coronary intervention
53352|NCT03767322|Drug|Placebo|Eligible patients will receive before and after coronary intervention
53353|NCT03767309|Procedure|coronally advanced flap with abrasive de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
53354|NCT03767309|Procedure|coronally advanced flap with de-epithelized graft.|SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
53355|NCT03767296|Drug|Ephedrine Hydrochloride 3 MG/ML|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Ephedrine (E): 6 mg, 6mg, 9 mg, 9 mg, 12 mg, …..(max 24mg/bolus) A total amount of 140 mg Ephedrine will not be exceeded.~Titrated according to the desired effect (= MAP decrease < 20%)"
53356|NCT03767296|Drug|Phenylephrine|"Bolus group, according to the randomization. Multiple boluses with incremental doses might be needed, according to the MAP ('effect titration')~Incremental doses if needed:~Phenylephrine (PE): 50μg, 50μg, 100μg, 100μg, 150μg, 150μg,…(max 500µg/bolus) A total amount of 1500 μg will not be exceeded. Titrated according to the desired effect (= MAP decrease < 20%)"
53357|NCT03767270|Biological|MRT5201|Codon-optimized human ornithine transcarbamylase messenger ribonucleic acid with lipid-based nanoparticles
53358|NCT03767270|Other|Placebo|5% dextrose in water
53359|NCT03767257|Drug|Colesevelam Pill|For treatment with colesevelam, the starting dose will be 1250 mg (2 x 625 mg) with food which can be increased to 6 tablets max per day based on efficacy and tolerability. Coleveselam should not be taken within 4 hours before or after lenalidomide and other interacting medications. All participants will be given a pill diary to record intake of colesevelam. The effect of colesevelam on lenalidomide-associated diarrhea will be evaluated after 1, 2, 4, 12 weeks after start of treatment. If the diarrhea does not respond to the starting dose of colesevelam, the dose can be increased every 2 days to 2 tablets two times per day (2 x 625 mg BID) and later to 3 tablets two times per day (3 x 625 mg BID). The colesevelam dose can be decrease to 1 tablet per day if there has been improvement of diarrhea but emergence of side effects.
53360|NCT03767244|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 tablets of 60 mg each) orally once daily.
53361|NCT03767244|Drug|Androgen Deprivation Therapy (ADT)|Participants will receive a stable regimen of ADT - gonadotropin-releasing hormone analog agonist or antagonist (GnRHa). ADT is a kind of hormone therapy for prostate cancer. GnRHa will be administrated to achieve and maintain sub-castrate concentrations of testosterone (50 nanogram per deciliter [ng/dL]).
53362|NCT03767244|Drug|Placebo|Participants will receive matching placebo oral tablets daily.
53363|NCT03767231|Diagnostic Test|Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)|The investigators will randomly assign eligible and consented patients to either to HCV POC VL Group or Reference Group. All participants will take a short survey regarding HCV care and treatment. As part of the investigators' ED HCV Screening and Linkage to Care Program, all participants will receive the standard-of-care clinical laboratory-based HCV RNA viral load testing via whole blood (i.e. patient will receive blood drawn). This standard-of-care HCV viral load testing result will be provided to participant when it is available (usually 1-2 days later). Participants in the HCV POC VL Group will receive the novel POC HCV RNA viral load testing and the result of the novel test will be disclosed to the patients approximately within 1 to 1½ hours of the testing.
53364|NCT03767218|Combination Product|Late follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 12 of the menstrual cycle onwards. Start of GnRH antagonist (ganirelix 0.25mg/day) when serum LH > 10 IU/L, till day of trigger.
53365|NCT03767218|Combination Product|Early follicular phase stimulation with recombinant-human FSH|Start of ovarian stimulation with recombinant-human FSH (Bemfola 225 IU daily) from day 2 of follicular phase onwards. Initiation of GnRH antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger.
53366|NCT03767205|Device|Ankle Assist Robot|"overground walking in three conditions (with robot-torque on/with robot-torque off/without robot). During overground walking, gait function was measured using motion analysis, sEMG, and force plate~treadmill waking in three conditions (with robot-torque on/with robot-torque off/without robot). During treadmill walking, the metabolic energy expenditure was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy)."
53367|NCT03767192|Device|Active Stimulation|SPG stimulation and standard of care
53368|NCT03767192|Device|Sham Stimulation|Sham SPG stimulation and standard of care
53369|NCT03767179|Diagnostic Test|study|procalcitonin, sedimentation, CRP, leukocyte identification
53370|NCT03767166|Device|Biodegradable biliary and pancreatic stents placement|Biodegradable biliary and pancreatic stents placement
53371|NCT03767153|Device|Venus Viva|"The Venus Viva™ fractional RF applicator has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars.~Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits."
53372|NCT03767140|Procedure|acupuncture|The patients were randomized in two groups, one verum acupuncture, submitted to real acupuncture treatment, and the other sham acupuncture, treated with false acupuncture
53373|NCT03767114|Diagnostic Test|RT-PCR for ERAP1 detection|Reverse transcriptase -Polymerase Chain Reaction for ERAP1 detection
53374|NCT03767101|Behavioral|Cognitive behavioral therapy|In all three treatment arms, licensed therapists/trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. All treatments are based on individualized treatment plans for each patient. Therapists are supervized by an CBT expert therapist in the outpatient treatment center. On average every forth session is supervized. The total duration of treatment is variable, oriented on patients symptoms and treatment goals.
53377|NCT03767075|Drug|Arm 1 - atezolizumab|Module 1 - 1200mg, IV, every 3 weeks, until progression or unacceptable toxicity develops.
53378|NCT03767062|Drug|Topamax|An antiepileptic agent used for migraine prophylaxis.
53379|NCT03767062|Procedure|Greater Occipital Nerve Block + Supratrochlear Nerve Block|An injection to paralyze the occipital and supratrochlear nerves.
53380|NCT03767049|Other|Colection of clinical data|Colection of clinical data
53381|NCT03767036|Drug|Tramadol hydrochloride 25 mg capsule|Capsule with tramadol hydrochloride 25 mg; Product of Grünenthal de Mexico S.A. de C.V.
53382|NCT03767036|Drug|Ketorolac Tromethamine 10 mg tablet|Tablet with ketorolac tromethamine 10 mg; Product of Siegfried Rhein, S.A. de C.V., Mexico
53383|NCT03767023|Other|cross sectional|
53384|NCT03767010|Other|Control (no PLM)|Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
53385|NCT03767010|Other|PLM|PLM Participants will take the PLM on the location of the brachial plexus at the level of the interscalene groove on surface ultrasound images. They will also take a pretest, a post-test and a delayed test at 6 months. Pre, post, delayed test Participants will perform a pretest, a posttest and a delayed test at 6 months.
53386|NCT03766997|Drug|Compound Betamethasone Injection|local injection
53387|NCT03766997|Drug|Hydrocortisone Butyrate 0.1% Cream|topical use
53388|NCT03766984|Drug|Diclofenac sodium 25 mg|Diclofenac sodium 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
53389|NCT03766984|Drug|Tramadol hydrochloride 25 mg|Tramadol hydrochloride 25 mg Tablets (Laboratorios Tecnandina S.A., Ecuador)
53390|NCT03766984|Drug|Diclofenac sodium 25 mg/Tramadol hydrochloride 25 mg|Fixed-dose combination tablet containing diclofenac sodium 25 mg and tramadol hydrochloride 25 mg (Laboratorios Tecnandina S.A., Ecuador)
53391|NCT03766971|Behavioral|7 days of Tobacco Cessation|Participants will be randomly assigned to 7 days of tobacco cessation.
53392|NCT03766971|Behavioral|21 days of Tobacco Cessation|Participants will be randomly assigned to 21 days of tobacco cessation.
53393|NCT03766971|Drug|Cannabis|Participants will receive cannabis.
53394|NCT03766919|Device|Implant of the INVICTA lead|The implant or the attempt to implant an INVICTA lead
53395|NCT03766906|Behavioral|Talk STEM Familia app|The Talk STEM Familia app will be used to improve access to sound instruction in scientific academic vocabulary through the development of a technology-enhanced, culturally responsive smart-speaker tool that engages Latino families in culturally responsive academic language acquisition and practice in the home setting.
53396|NCT03766893|Drug|Buprenorphine / Naloxone Oral Product|To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly (buprenorphine/naloxone) basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
53397|NCT03766893|Drug|injectable naltrexone|To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
53398|NCT03766893|Other|Pharmacy maintenance addiction care|Patients on a stable dose of buprenorphine/naloxone or naltrexone will receive maintenance care at the pharmacy for one month. Patients will visit weekly for check-ins with a pharmacist. Patients on buprenorphine/naloxone will be dispensed their medication at study visits, whereas patients taking injectable naltrexone will be dispensed it once by the pharmacist during the pilot. All patients will visit the pharmacy at least weekly for addiction care (assessment, toxicological testing).
53399|NCT03766880|Procedure|Transjugular HVPG measurement|By means of catheterization of a hepatic vein with a balloon catheter.
53400|NCT03766880|Procedure|MR imaging|MR images for the post-processing analysis
53401|NCT03766867|Drug|Vortioxetine infusion 25 mg|1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days
53402|NCT03766867|Drug|Vortioxetine tablets 10 mg/day|10 mg, tablets, oral administration once daily
53403|NCT03766867|Drug|Placebo infusion|concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose
53404|NCT03766867|Drug|Placebo tablets|oral administration once daily
53405|NCT03766854|Drug|Insulin 287|Participants will receive subcutaneous (s.c.) injections of insulin 287 once weekly for 8 weeks
53406|NCT03766854|Drug|Insulin glargine U100|Participants will receive s.c. injections of insulin glargine once weekly for 2 weeks
53407|NCT03766841|Behavioral|Facilitated Enrollment|Research coordinator will assist patients in account creation and usage of the tool.
53408|NCT03766828|Procedure|inside-out-access technique with inside-out access device (Surfacer (R))|inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)
53409|NCT03766828|Procedure|access technique including Sharp recanalization|access technique with Sharp recanalization via interventional radiology
53410|NCT03766815|Dietary Supplement|BCAA 200mg/kg/day|BCAA supplement based on 200mg/kg/day for 18 days.
53411|NCT03766815|Dietary Supplement|Placebo|Fiber supplement jelly for 18 days.
53412|NCT03766815|Dietary Supplement|BCAA 400mg/kg/day|BCAA supplement based on 400mg/kg/day for 18 days.
53413|NCT03766815|Behavioral|Muscle damaging exercise|Participants will be asked to perform muscle damaging elbow eccentric contraction exercise at 120% of 1RM for three sets of 15 repetitions with the dominant arm at maximal effort on a Biodex machine with a 3 minute rest period between each set.
53414|NCT03766802|Behavioral|Wearable watch training group.|3 orientation session Watch notifies 3/week for exercise
53415|NCT03766802|Behavioral|Mobile application training group.|"3 orientation session App notifies 3/week for exercise~Benefits of app:~Cheaper Trackable and notifiable if patients don't exercise."
53416|NCT03766802|Behavioral|Supervised exercise training group|3/week training supervised by a physical therapist
53417|NCT03766789|Device|Cell phone application|cell phone to organize medications
53546|NCT03765658|Drug|GRT0151Y dose escalation|Single doses of 150, 200, 250, 300, 350 and 400 mg (3, 4, 5, 6, 7 or 8 capsules of 50 mg)
53418|NCT03766776|Drug|Anlotinib|Anlotinib capsules: dosage of 12 mg PO qd, 14 days, 7 days, 21 days for a cycle. The dosage was adjusted according to the adverse reactions of patients.
53419|NCT03766763|Drug|Venetoclax|"Venetoclax is administered according to the usual schedule an escalating dose from 20 milligram per day the first week, then 50 milligram per day the second week, 100 milligram per day the third week, 200 milligram per day the fourth week and then 400 milligram per day.~For patient achieving a Compete Response with Minimal Residual Disease inferior to 0,01 percent in bone marrow at month 12, treatment will be stopped at month18 (18 months for total duration of treatment ).~For responding patients at month12 (Complete Response or Partial Response) with bone marrow Minimal Residual Disease inferior to 0.01 percent, treatment will be continued until month 24 (24 months for total duration of treatment)."
53420|NCT03766750|Drug|LIMA association|1 coated tablet, oral, once a day.
53421|NCT03766750|Drug|Tradjenta|1 coated tablet, oral, once a day.
53422|NCT03766750|Drug|Forxiga|1 coated tablet, oral, once a day.
53423|NCT03766737|Device|An intelligent visual acuity diagnostic system for children|An artificial intelligence to make evaluation and of children's vision.
53424|NCT03766724|Drug|Evogliptin→Evogliptin+Empagliflozin→Empagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD, Empagliflozin : Empagliflozin 25mg QD
53425|NCT03766724|Drug|Empagliflozin→Evogliptin→Evogliptin+Empagliflozin|Empagliflozin : Empagliflozin 25mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Empagliflozin : Evogliptin 5mg QD + Empagliflozin 25mg QD
53426|NCT03766724|Drug|Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin|Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD, Dapagliflozin : Dapagliflozin 10mg QD
53427|NCT03766724|Drug|Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin|Dapagliflozin : Dapagliflozin 10mg QD, Evogliptin : Evogliptin 5mg QD, Evogliptin+Dapagliflozin : Evogliptin 5mg QD + Dapagliflozin 10mg QD
53428|NCT03766711|Other|Physical Therapy|Repetitive bimanual task training for upper limb motor function recovery.
53429|NCT03766685|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
53430|NCT03766672|Diagnostic Test|Intervention Arm|The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
53431|NCT03766659|Diagnostic Test|MOSE|EUS-FNB with MOSE
53432|NCT03766659|Diagnostic Test|ROSE|EUS-FNA with ROSE
53433|NCT03766646|Device|Optiflow|45l.min oxygen
53434|NCT03766633|Diagnostic Test|Liver volumetry of the graft on CT|Preoperative liver volumetry using the CT images of the potential living liver donors.
53435|NCT03766607|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
53436|NCT03766607|Drug|Ramucirumab|Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days
53437|NCT03766607|Drug|Paclitaxel|Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
53438|NCT03766594|Drug|Sildenafil Citrate|Respatio(R) 25mg tablets four times daily for 24 days preconceptionally starting first day of previous period
53439|NCT03766594|Drug|Folic Acid|Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
53440|NCT03766594|Drug|Placebo Oral Tablet|Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
53441|NCT03766581|Drug|BMS-986177|Oral administration
53442|NCT03766581|Other|Placebo|Oral Administration
53443|NCT03766581|Drug|Clopidogrel|Oral administration
53444|NCT03766581|Drug|Aspirin|Oral administration
53445|NCT03766568|Device|JGG endoscope(R)|The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
53446|NCT03766555|Procedure|Microwave ablation|Microwave ablation will be performed in operation theatre under general anesthesia via laparoscopic or open approach according to the tumors' locations. In case of open approach, it will be done via a right subcostal incision with possible upper midline extension was necessary. After diagnostic laparoscopy in laparoscopic approach and exploratory laparotomy in open approach to exclude the presence of extra-hepatic disease, operative ultrasound (Aloka, Tokyo, Japan) will be performed to exclude preoperatively undetected lesion; guide insertion of the microwave applicator; and monitor the whole ablation process. Surrounding organs were cooled by constant irrigation of ice-cold saline to prevent thermal injury. The ablation will be carried out according to the standard protocol with the aim to create a 1cm ablation margin around the tumor. The insertion track will be burnt after ablation in order to prevent bleeding and tumor seeding.
53447|NCT03766555|Procedure|Liver resection|Liver resection will be performed as described previously. Liver parenchymal transection would be performed with CUSA (cavitron ultrasonic surgical aspirator) and TissueLink (a radiofrequency saline-linked dissecting sealer) in both arms. Vascular staplers would be used to divide major vascular pedicles. Fibrin glue (Tisseel) spray would be applied to the parenchymal cut surface of the liver before closure of abdomen.
53448|NCT03766542|Device|Bi-level positive airway pressure with ventilatory support|Positive airway pressure will be applied in the experimental group through a oronasal interface, in ventilatory support mode (Bi-level) with a fixed backup rate.
53449|NCT03766542|Device|continuous positive airway pressure without ventilatory support|Continuous positive airway pressure (CPAP) will be applied in the active comparator group through a oronasal interface.
53450|NCT03766529|Procedure|loop isolation-based uploading preconditioning (LiuPhD)|declamping was not done until heart could resume normal mechanical activities and sustain well for three minutes in terms of heart rate, rhythm, and myocardial contractility via continuous antegrade warm blood delivery closely following TWBC reperfusion.
53487|NCT03766178|Drug|Nimotuzumab + SHR-1210|"SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle."
53451|NCT03766503|Other|Daily|The main study intervention is the daily witnessing of participants while they self-administer their medications by trained pharmacy staff to ensure compliance. The staff in question will be provided by Leila pharmacy and will in addition provide support so that individuals can transition back into living independently through reminders to attend regularly scheduled medical appointments and counseling on correct use of prescribed medications.
53452|NCT03766490|Drug|Anlotinib Hydrochloride|Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
53453|NCT03766490|Drug|Gefitinib|Tablet, P.O. 250mg qd
53454|NCT03766490|Drug|Icotinib|Tablet, P.O. 125mg tid
53455|NCT03766477|Diagnostic Test|Pittsburgh Sleep Quality Index (IQSP) and Johansson|All participants will to answer the Pittsburgh Sleep Quality Index (IQSP) and Johansson questionnaires before polysomnography examination and use of APP.
53456|NCT03766477|Diagnostic Test|Smartphone APP|All study participants will use a smartphone application (APP), which will be made available by the researchers, at the same time as the polysomnography exam.
53457|NCT03766477|Diagnostic Test|Polysomnography|All participants slept for one night in a sleep laboratory for PSG recording. The data will be confirmed by an otorhinolaryngology certified by the Brazilian Association of Sleep Disorders
53458|NCT03766464|Diagnostic Test|Evaluation of TMD and pain sensitivity|Extra and intraoral clinical examination will be performed and the Diagnostic Criteria for Temporomandibular Disorders (DC / TMD) questionnaire will be applied. Measurements shall be bilateral in the masseter, anterior temporal and tenar muscles and the arithmetic mean between three measurements will be considered the value for each side for pain sensitivity analysis with an dynamometer.
53459|NCT03766464|Diagnostic Test|Evaluation of SB|The presence or absence of SB will be diagnosed by Polysomnography
53460|NCT03766464|Diagnostic Test|Evaluation of AB|A smartphone will be used, which was developed for a momentary evaluation that allows a report of the exact moment of AB and its possible associated symptoms.
53461|NCT03766438|Behavioral|Digital Storytelling Intervention|12-minute digital storytelling intervention in Spanish, with four individuals explaining their personal Type 2 Diabetes stories.
53462|NCT03766425|Drug|Aflibercept|subconjunctival injection
53463|NCT03766425|Drug|Mitomycin|subconjunctival injection
53464|NCT03766412|Other|High School start time|The time that the school starts
53467|NCT03766373|Combination Product|Drug: OP0201 20mg|OP0201
53468|NCT03766373|Combination Product|Drug: Placebo 0mg|Placebo
53469|NCT03766360|Behavioral|Functional Analytical Psychotherapy (FAP)|The intervention itself is based on the procedures of Functional Analytic Psychotherapy, a behavioral intervention focusing on improving social functioning.
53470|NCT03766334|Dietary Supplement|Highland Barley Diet|Highland Barley Diet(20g, thrice-daily)
53471|NCT03766321|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation will be performed during two endoscopic procedures (baseline and at 6 months) by allogenic infusion of collected feces in the duodenum-jejunum.
53472|NCT03766321|Biological|Placebo|patients will undergo endoscopic procedure with biopsy during sedation but without any kind of intervention
53473|NCT03766308|Dietary Supplement|Highland Barley Diet|Highland Barley Diet
53474|NCT03766308|Dietary Supplement|ADA diet|ADA diet
53475|NCT03766295|Drug|Masitinib|
53476|NCT03766295|Drug|Gemcitabine|
53477|NCT03766295|Drug|Placebo|
53478|NCT03766282|Device|ECMO|Extracorporeal membrane oxygenation (ECMO) temporarily supports patients with severe cardio-respiratory failure
53479|NCT03766269|Drug|Dronabinol|Dronabinol coadministered with patient's existing Baseline Opioid.
53480|NCT03766256|Behavioral|Shared decision-making with pharmacists|Pharmacist will engage patient with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
53481|NCT03766243|Behavioral|Brochure and DVD plus nursing training|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD.~The experimental group was closely followed by the research nurse, an expert in Adult Education, who held 20-minute face to face meetings at baseline and at follow-up with the patients allocated to the experimental group. For both groups an information brochure and an audio-visual DVD were developed specifically for the study. The audio-visual DVD is available on the IDI-IRCCS institutional website."
53482|NCT03766243|Behavioral|Brochure and DVD only|"After recruitment for both groups of participants, in a 30-minute meeting, a clinical nurse measured the opening of the mouth. She gave each participant the information brochure, the audio-visual DVD for self-management of oral exercises, diary card, and the research questionnaires, and explained their content and use.~The intervention consisted of stretching exercises and movements involving the mimic muscles to perform in front of a mirror. The control group could learn the standardized exercises for the mouth-opening through information brochure and the audio-visual DVD."
53483|NCT03766217|Combination Product|Mesenchymal stem cells associated with biomaterials|Deciduous dental pulp mesenchymal stem cells associated with hydroxyapatita/collagen.
53484|NCT03766217|Combination Product|Iliac crest autogenous bone graft|Autogenous bone will be obtained from iliac crest.
53485|NCT03766191|Behavioral|Food Ads|Exposure to foods ads that are embedded in an age-appropriate TV program
53486|NCT03766191|Other|Non-food Ads|Exposure to non-food ads that are embedded in an age-appropriate TV program
53547|NCT03765658|Drug|Matching placebo|Matching placebo capsules (3, 4, 5, 6, 7 or 8 capsules)
53488|NCT03766165|Behavioral|Intervention|Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.
53489|NCT03766165|Behavioral|Control|Participants will receive job announcements only.
53490|NCT03766152|Device|Adhesive bone conduction hearing aid (ADHEAR - Med El)|Patients are asked to wear an adhesive bone conduction hearing device which is attached to the mastoid with an adhesive adapter
53491|NCT03766139|Biological|SUPERCELL GLUE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with supercell glue in test sites (randomly selected by computer generated tabulation method)
53492|NCT03766139|Biological|PRFM ALONE|Following optimum anaesthesia, reflection of full thickness mucoperiosteal flaps for defect access and thorough debridement will be done. Subsequently the defect will be filled with PRFM in control sites(randomly selected by computer generated tabulation method)
53493|NCT03766126|Biological|CART123 cells; cyclophosphamide; fludarabine|"CART123 cells following lymphodepleting chemotherapy in patients with relapsed/refractory AML. Subjects will be treated with IV administration of CART123 cells using a split dosing approach (10% Day 0, 30% Day 1; 60% Day 2).~The total dose administered to each subject will be based on body weight obtained at the time of apheresis. Thus, the target total transduced dose is 1-2x10^6/kg CART123 cells, preceded by lymphodepleting chemotherapy. The protocol-specified minimum acceptable dose for infusion is 1x10^5 CART cells/kg."
53494|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual|One visit : Neurofeedback coupling electroencephalogram and functional MRI in time actual
53495|NCT03766113|Other|Electroencephalogram-neurofeedback program or Neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (Electroencephalogram-neurofeedback program) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program.~Controle Group (Neurofeedback-free mental imaging) : 24 minutes, 3 times a week for 12 weeks in addition to the traditional rehabilitation program of reference."
53496|NCT03766113|Other|Neurofeedback coupling electroencephalogram and functional MRI in time actual or a neurofeedback-free mental imaging program with electroencephalogram recording|"Interventional group (5 weeks) : 5 sessions of neurofeedback coupling electroencephalogram and functional MRI in time actual and 9 sessions of electroencephalogram-neurofeedback program~Controle Group (5 weeks) : 14 sessions of neurofeedback-free mental imaging program"
53497|NCT03766100|Behavioral|Cognitive behavioural therapy (CBT-i)|CBT-i aims to alter behaviours that sustain or add to insomnia and correct cognitions that drive these behaviours. The behavioural components of CBT-i are stimulus control (SC) and Sleep Restriction Therapy (SRT). SC works through the extinction of a conditioned arousal that emerges when bed and bedroom have become associated with wakefulness. With SRT time in bed is reduced to build up sleep pressure. When wakefulness is decreased, time in bed is gradually increased until optimal sleep is attained. With the cognitive component, insomnia is treated by identifying and changing unhelpful or inaccurate thinking regarding sleep and distressing emotional responses to insomnia. The last component of CBT-i aims to reduce hyperarousal with relaxation techniques, scheduled worry time, creating a time to unwind, and employing cognitive therapy strategies.
53498|NCT03766087|Procedure|decompressive craniectomy|decompressive craniectomy is decompression at the supratentorial level that is achieved by removing part of the skull and by making an opening, in the dura mater (with or without plastic surgery), without compromising the venous sinus.
53499|NCT03766074|Dietary Supplement|vitamin D supplement|The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
53500|NCT03766074|Dietary Supplement|Placebo|placebo
53501|NCT03766061|Procedure|Onlay mesh Hernioplasty|Patients with paraumblical hernia are treated with onlay mesh hernioplasty in which mesh is placed on anterior rectus sheath
53502|NCT03766061|Procedure|Sublay Mesh Hernioplasty|Patients with paraumblical hernia are treated with sublay mesh hernioplasty in which mesh is placed in retromuscular space
53503|NCT03766048|Procedure|Single-Anterior-Mesh, SAM|laparoscopic sacropexy is only performed with the anterior mes
53504|NCT03766048|Procedure|Double-Mesh, DM|laparoscopic sacropexy is performed using two synthetic non-absorbable meshes, both sutured to the promontory (Double-Mesh, DM): one mesh is placed in the vesicovaginal space and sutured to the uterine cervix or vaginal apex, and one mesh is placed in the rectovaginal space
53505|NCT03766035|Device|SpyGlass DS I - II|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
53506|NCT03766022|Device|Neo dental implant Alpha Bio Tec. Ltd.|Neo dental implant is used to restore missing teeth
53507|NCT03766009|Other|Usual Care|Usual Care
53508|NCT03766009|Other|Web-based decision aid|Web-based decision aid received prior to the surgical consultation
53509|NCT03765996|Other|Decongestive Physiotherapy|This group received CDP, which include MLD, short-stretch bandages, lymph-reducing exercises, and skin care. MLD was applied to the anterior trunk, posterior trunk, and the base of the neck, progressing to the affected limb. Short-stretch bandages were applied in multiple layers after MLD. A low pH skin lotion was applied prior to bandaging and then stockinette was placed on the arm. The fingers and the hand were wrapped in gauze. A layer of cotton was wrapped around the arm. Bandages (6, 8 and/or 10cm) were sequentially applied in a spiral fashion around the limb with the smallest bandage starting at the hand. The most compression was at the most distal points and gradually decreased proximally. Exercises were done by patients to improve mobility and enhance lymphatic flow.
53510|NCT03765996|Other|Decongestive Physiotherapy plus taping|This group received CDP as same protocol of active comparator. In addition, Kinesiotaping was applied to anterior and posterior axillo-axillary anastomosis and axillo-inguinal anastomosis. The tape was started on the unaffected side and strips of tape were applied so as to reach the affected side regarding anterior and posterior axillo-axillary anastomosis. For axillo-inguinal anastomosis, the tape was started in the inguinal region of the affected side and strips of tape were applied so that they reached the axillary region.
53544|NCT03765697|Drug|Lidocaine 5% medicated plaster|Topical application at the site of skin affected by painful PHN for up to 12 hours per day (plaster-free interval at least 12 hours).
53545|NCT03765671|Drug|Elafibranor|120mg oral single dose
53511|NCT03765983|Drug|Trastuzumab|"Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When targeted therapies attach to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system"
53512|NCT03765983|Drug|GDC-0084|GDC-0084 has been shown to stop the activity of a protein called PI3-kinase. This action blocks a pathway in the body that cancer cells commonly use to grow and divide
53513|NCT03765957|Biological|Mesenchymal Stem Cells|The subjects will be injected intravenously with 1x10E6/kg （according to the weight of subject）Human Umbilical Cord-derived Mesenchymal Stem Cells at baseline and every 2 weeks until week 6. Besides MSC, conventional moisturizer such 10% boric acid ointment is given to all patients in the treatment and follow-up period.
53514|NCT03765957|Drug|Oral Methotrexate|The subjects will be treated with oral methotrexate 7.5-15mg every week (The dose will start from 7.5mg/w and increase to 15mg/w depending on the response of subjects). Besides methotrexate, conventional moisturizer such 10% boric acid ointment is given to all patients in the treatment and follow-up period.
53515|NCT03765944|Drug|sirolimus|SIngle administration under fasted condition
53516|NCT03765931|Drug|Doxycycline|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged > 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature > 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature < 37.5°C.
53517|NCT03765931|Drug|Amoxicillin|The investigators conducted a non-inferiority, open-label, randomized controlled trial in patients aged > 8 years recruited from dispensaries in the rural area of Niakhar, Senegal. Participants were enrolled based on a body temperature > 37.5°C, as assessed using an electronic axillary thermometer. Febrile patients with a positive malaria test were excluded from the study. Participants were randomly assigned (2:1) to receive either a single dose of doxycycline (30 mg/kg) or a five-day course of amoxicillin (20 mg/kg) by a computer-generated random number sequence. The investigators monitored participants at days 2 and 7 post-treatment. The primary outcome was cure after 7 days, defined as a body temperature < 37.5°C.
53518|NCT03765918|Biological|Pembrolizumab 200 mg|200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
53519|NCT03765918|Radiation|Radiotherapy 60 Gray/day|Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
53520|NCT03765918|Radiation|Radiotherapy 66 Gray/day|High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
53521|NCT03765918|Radiation|Radiotherapy 70 Gray/day|Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
53522|NCT03765918|Drug|Cisplatin 100 mg/m^2|100 mg/m^2 administered by IV infusion on Day 1 of each 21-day cycle
53523|NCT03765905|Diagnostic Test|study|Scube-1 scube-2 scube-3
53524|NCT03765892|Other|Questionnaire (Adult)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the distribution of socio-professional categories.~Answering the questionnaires will take 45 minutes."
53525|NCT03765892|Other|Questionnaire (Children)|"Patients and case control will have to respond to the study questionnaire on the online entry platform to compare the proportion of subjects having repeated grades.~Answering the questionnaires will take 45 minutes."
53526|NCT03765879|Other|Verum VGAIT (Video-Guided Acupuncture Imagery Treatment)|In VGAIT treatment sessions, participants will re-watch the video of themselves receiving acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
53527|NCT03765879|Other|Sham VGAIT (Video-Guided Acupuncture Imagery Treatment)|In sham VGAIT treatment sessions, participants will re-watch this video of themselves receiving the sham acupuncture treatment, and they will be asked to vividly imagine that the treatment is being concurrently applied.
53528|NCT03765866|Procedure|Thromboelastometry guided transfusion|Comparing resuscitation strategies with standard MTP v.s. ROTEM guided MTP
53529|NCT03765853|Other|Physiotherapy|Usual prevention methods (ergonomic education) and Stretching Postural® postures.
53530|NCT03765827|Drug|Vitamine E Acetate|Vitamin E acetate ointment will be applied over the staple lines and anastomoses in Roux-en-Y gastric bypass
53531|NCT03765827|Drug|No application of vitamin E acetate|Vitamin E acetate ointment will not be applied in this group
53532|NCT03765801|Drug|GRTA9906 60 mg PR tablet|GRTA9906 60 mg PR tablet
53533|NCT03765801|Drug|GRTA9906 60 mg IR capsule|GRTA9906 60 mg IR capsule
53534|NCT03765788|Biological|Secukinumab 300 mg, s.c.|Secukinumab will be administered at a dose of 300 mg as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to Week 48.
53535|NCT03765788|Drug|Prednisolone|Prednisolone will be administered at tapering oral doses as tablets daily for 26 weeks according to the protocol-defined schedule. Prednisolone will also be administered as escape therapy to treat disease flares in an open-label manner at a dose and duration selected by the investigator.
53536|NCT03765788|Drug|Placebo to match Secukinumab, s.c.|Placebo will be administered as s.c. injection at Baseline, Week 1,2,3,4 and then every 4 weeks thereafter through to Week 48.
53537|NCT03765775|Biological|Sintilimab|Participants receive Sintilimab(IBI 308) 200 mg, administered as intravenous (IV) infusion on Day 1 of each 21-day cycle
53538|NCT03765775|Drug|Anlotinib Hydrochloride|Participants receive Anlotinib 10 mg, administered as PO on Day 1-14 of each 21-day cycle
53539|NCT03765762|Drug|GRF6019|GRF6019 for IV infusion
53540|NCT03765762|Other|Placebo|Placebo for IV infusion
53541|NCT03765736|Other|Genetic Testing|Undergo genetic testing
53542|NCT03765710|Other|Recommended protein intake|Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
53543|NCT03765710|Other|Elevated protein intake|Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
53847|NCT03763188|Other|Use of daily urinary urea excretion|Weaning dialysis catheter
53548|NCT03765645|Drug|Piperacillin + Tazobactam|Antibiotic used will be Piperacillin + Tazobactam Dose: 4.5 g, thrice a day at regular intervals Route: Intra-venous
53549|NCT03765632|Drug|Lentiviral transduced CD34+ cells|Biological: Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells
53550|NCT03765619|Drug|Aspirin|250 patients will be randomized to receive postoperative Aspirin.
53551|NCT03765606|Dietary Supplement|Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
53552|NCT03765606|Dietary Supplement|De-xanthinated Cocoa Flavanol beverage mix|Acute consumption of single portion of cocoa powder dissolved in 310g 1% milk.
53553|NCT03765593|Procedure|Biopsy Salivary Gland|A minor salivary gland biopsy will be performed at lower lip, with the minimally invasive technique that is carried out in Rheumatology Unit as a routine procedure for the diagnosis of pSS, from there it will be taken between 2-3 glands for the study. RNAlater®(Ambion, Inc., Texas, United States of America) will be stored in solution for the stabilization and preservation of RNA at -80ºC.
53554|NCT03765580|Dietary Supplement|Fish|Lunch containing fish
53555|NCT03765580|Other|Control|Lunch containing no fish
53556|NCT03765567|Drug|Vancomycin|2 vials of Vancomycin 1g powder will be applied topically to the open fracture wound site.
53557|NCT03765554|Drug|PF-06700841 Immediate release tablets|Small molecule tablets in immediate release form
53558|NCT03765554|Drug|PF-06700841 Modified release tablets|Small molecule tablets in modified release form
53563|NCT03765515|Device|Twinfix Ti|The purpose is to evaluate the safety and efficacy of Q-Fix in patients requiring the repair of soft tissue of shoulder who receive the arthroscopic repair of soft tissue using Q-Fix, when compared with the patients receiving the treatment with Twinfix Ti Suture Anchor. The result of this trial will be used for the Q-Fix All-suture Anchor registration in China.
53564|NCT03765515|Device|Q-Fix|Q-Fix
53565|NCT03765502|Device|Nasal Glucagon Device|NG devices will be provided empty of drug product
53566|NCT03765502|Device|GEK|Used to administer glucagon intramuscularly (IM)
53567|NCT03765502|Drug|IM Glucagon|Administered IM via GEK
53568|NCT03765489|Device|electrical muscle stimulation|electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction
53569|NCT03765489|Procedure|conventional physical therapy|"conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al"
53570|NCT03765476|Behavioral|SALIENCE|"3 computer-based training sessions with program SALIENCE per week over 3 weeks (see study description)"
53571|NCT03765476|Behavioral|TAU|treatment as usual, , i.e. medically supervised detoxification treatment (i.e. medical management of withdrawal symptoms, associated physical discomfort and any co-existing disorders, etc.) as well as health education and supportive therapy sessions.
53572|NCT03765463|Behavioral|Habit Reversal Training|4 sessions of habit reversal training
53573|NCT03765450|Drug|Infliximab|Patients will receive infliximab at the discretion of their physician as part of standard of care.
53574|NCT03765437|Biological|Quadrivalent Influenza Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
53575|NCT03765424|Diagnostic Test|Ultrasound|Ultraosund of temporal, carotid and axillary arteries
53576|NCT03765411|Procedure|Proctectomy|Resection of the rectum
53577|NCT03765398|Behavioral|VR Cognitive-motor-balance training|The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
53578|NCT03765385|Other|High-intensity training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
53579|NCT03765385|Other|Moderate-intensity continuous training|Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
53580|NCT03765359|Drug|metforminhydrochloride|metformin 500 mg tablets and insulin
53581|NCT03765359|Drug|Placebo Oral Tablet|Placebo tablets mimic metformin 500 mg tablets and insulin
53582|NCT03765346|Drug|Oxycodone IR ADF|Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
53583|NCT03765346|Drug|Oxycodone API powder|Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
53584|NCT03765346|Drug|Placebo to match oxycodone API powder|Placebo to match oxycodone API powder (mass of 30 mg).
53585|NCT03765346|Drug|Placebo to match manipulated oxycodone IR ADF.|Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
53586|NCT03765320|Procedure|Peritoneal closure|Peritoneal closure after pelvic lymph node dissection for early gynecologic cancer
53587|NCT03765320|Procedure|Retroperitoneal drainage|Retroperitoneal drainage after pelvic lymph node dissection for early gynecologic cancer
53588|NCT03765307|Device|SyMap Bronchial Ablation System|The Bronchial Ablation is performed using SyMap Bronchial Ablation System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
53589|NCT03765307|Device|Boston Scientific Alair System|The Bronchial Thermoplasty is performed using Boston Scientific Alair System in three sessions at least three weeks apart between each session: Right Lung Lobe, Left Lung Lobe, Right Up Lobe and Left Up Lobe.
53592|NCT03765281|Other|Navigation|Service delivered by clinical Navigator who learns about youth and family's needs and matches to appropriate services.
53593|NCT03765281|Other|Resource List|Extensive list of mental health and addictions resources, information, and services. Contact information and web links provided for individuals to explore and contact resources of interest.
53594|NCT03765268|Procedure|Neurectomy in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with neurectomy of ilioinguinal and iliohypogastric nerve
53595|NCT03765268|Procedure|nerve sparing in inguinal hernia repair|Mesh hernioplasty of inguinal hernia with sparing of ilioinguinal and iliohypogastric nerve
53596|NCT03765255|Other|In the Know: sexual health education|The in-person sessions include modules on: sexual and reproductive health (2 hours - anatomy, gender and sexual orientation, pregnancy, contraception, sexually transmitted infections); healthy relationships and life skills (2 hours - communication and negotiation, consent, violence, online dating, goal setting, strengths); and educational and career success (2 hours - educational and career options, applying for scholarships and financial aid, job readiness, resume preparation, interview skills). The app includes: online referrals, personal life plans/goal setting, text message reminders, quizzes, and other resources.
53597|NCT03765242|Other|Non-Interventional|Non-Interventional
53598|NCT03765229|Drug|Entinostat|Oral drug 5 mg taken once weekly for up to nine 3-week (21 day) cycles. Take on an empty stomach i.e., at least 2 hours after a meal and at least 1 hour before the next meal. On days when entinostat is administered on the same day as pembrolizumab, entinostat should be taken before the pembrolizumab infusion.
53599|NCT03765229|Drug|Pembrolizumab|200 mg IV starting on Day 22 (cycle 2, Day 1) given every 3 weeks for up to 8 cycles.
53600|NCT03765216|Drug|2L Polyethylene Glycol (PEG)|Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
53601|NCT03765216|Drug|4L Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
53602|NCT03765203|Diagnostic Test|Natera KidneyScan|Online educational materials on Natera Kidneyscan (dd-cfDNA) and sample test results for simulated patients
53603|NCT03765203|Other|Clinical Performance and Value Vignettes|Online renal allograft simulated patients
53604|NCT03765190|Combination Product|Radiation: Proton Therapy+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
53605|NCT03765177|Biological|CLIC-1901|Participants will undergo (a) lymphodepletion with cyclophosphamide and fludarabine, followed by (b) infusion of autologous CLIC-1901 CAR-T cells. All treatments will be delivered intravenously.
53606|NCT03765164|Diagnostic Test|GlycoMark 1-5-AG|Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
53607|NCT03765164|Other|Clinical Performance and Value Vignettes|Simulated diabetic patients cared for online
53608|NCT03765151|Device|low-level laser therapy|LLLT will be performed by a diode gallium-aluminum-arsenide (Ga-Al-As) laser with a 940-nm wavelength (Ezlase; Biolase Technology Inc., Irvine, CA) and delivered by a quadrant-sized probe which cover the region from the central incisor to the first molar on the test side. The laser probe will be 1 cm from the soft tissue around the test tooth at the gingival margin and alveolar mucosa covering the root area using a setting of 800 milliwatt in a continuous wave. Each tooth will receive 30 seconds of exposure, with no more than 8.6 J/cm2 of energy delivered. In addition, a spot-size laser probe will be applied for 30 seconds 5 mm from the cervical dentin with an output power of 700 milliwatt to reduce tooth sensitivity.
53609|NCT03765151|Other|orthodontic retention|All participants included will wear fixed lingual retainer and removable retainers in the post-orthodontic retention period and their previous orthodontic treatment will be carried out by one operator using preadjusted appliances with bonded 0.022×0.028-inch2 brackets/buccal tubes and 0.014-inch Nickel Titanium (NiTi) archwires as the first archwires.
53610|NCT03765138|Combination Product|PE/Pramipexole|"Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events."
53611|NCT03765125|Dietary Supplement|collagen peptide test|Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
53612|NCT03765125|Dietary Supplement|collagen peptide placebo|collagen peptide placebo
53613|NCT03765112|Device|Optical coherence tomography angiography|Multiple scans of the retina will be recorded to evaluate microvascular changes.
53614|NCT03765099|Behavioral|Animal-Assisted Interactions|Child and caregivers randomly assigned to the intervention group will spend approximately 15 min with a registered canine and its owner during potentially anxiety-producing visits to the hospital.
53615|NCT03765086|Procedure|Karydakis procedure|Pilonidal sinus will be excised by Karydakis procedure
53616|NCT03765086|Procedure|Limberg Flap|Pilonidal sinus will be excised by Limberg Flap
53617|NCT03765073|Biological|Multivalent Group B streptococcus vaccine|Various formulations at three dose levels
53618|NCT03765073|Biological|Placebo|Saline control
53619|NCT03765060|Procedure|Monomax® 2/0 HR26|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
53620|NCT03765060|Procedure|Monomax® 1 HR48|"It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1."
53621|NCT03765047|Behavioral|Intervention Arm|"The physical activity intervention consists of:~School Engagement and Assessment - Based on the customized assessment, training is provided for school staff to develop the capacity to increase PA. A school PA team is established.~Training - School teams are provided with ongoing in-person and virtual training to learn strategies for increasing PA before and during the school day. A training summit meeting will occur each summer, starting with the summer prior to the intervention. Teams will create a weekly calendar of activities to increase PA time to a minimum of 40 mts/day.~PA Equipment and Resources - After training, schools are provided with PA equipment, resources and teaching aids to facilitate the integration of PA into the school day.~Ongoing Assessment and Technical Assistance - Student accelerometer data will allow for monitoring of PA levels, so that additional technical assistance for classroom teachers can be provided if needed"
53622|NCT03765034|Behavioral|Constrain-induced Movement Therapy|8-week therapy program utilizing constraint of the unaffected arm
53623|NCT03765034|Behavioral|Usual Occupational Therapy|8-week therapy program without constraint of the unaffected arm
53624|NCT03765021|Drug|Tranexamic Acid|One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
53625|NCT03765021|Device|Fractional CO2 laser|The other side of the face will be randomly assigned to low power fractional CO2 laser with a power of 12 watts, spacing 700 micrometers (low density), and dwell time 300 microsecond every four weeks for three months.
53626|NCT03765008|Other|Water intake manipulation|for 5 days prior to each experiment subjects will undergo manipulation of their water intake.
53627|NCT03764995|Other|Standard bowel management|Lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
53628|NCT03764995|Other|Abdominal massage|Abdominal massage will be performed three days a week for four weeks. Each session will last around 15-20 minutes.
53629|NCT03764995|Other|Placebo Ultrasound|Placebo ultrasound (US) will be applied to the abdominal region for four weeks, 2 days of the week and 15 minutes per day.
53630|NCT03764969|Behavioral|standard smoking cessation program (SCP)|Each subject will receive standard SCP as group treatment once a week (1 hour) over six weeks. This group therapy is based on behavioural therapy and a psycho-educational approach (for more details see Batra & Buchkremer 2004), and will be carried out by a qualified therapist.
53631|NCT03764969|Behavioral|Cognitive remediation treatment (CRT)|Cognitive remediation treatment (CRT) employing a chess-based battery of tasks two times per week over six weeks as a group treatment in our outpatient clinic (60 min duration per session).
53632|NCT03764969|Behavioral|Implicit computer-based habit-modifying training (ICHT)|Implicit computer-based habit-modifying training (ICHT), applied twice a week for six weeks. In this training, the participants perform a two-part training. First, a subliminal presentation (20 ms) of negative valenced primes before smoking-cues in context and secondly, a subliminal presentation of positive valenced primes before potentially reinforcing events.
53633|NCT03764956|Other|Low glycemic Index Therapy (LGIT)|Specific dietary therapy called Low glycemic Index Therapy (LGIT) which provides diet including food items with glycemic index less than 50 only. For this purpose, various dietary menus will be provided to the parents.
53634|NCT03764956|Other|Modified Atkins Diet (MAD)|Specific dietary therapy called Modified Atkins Diet (MAD) which provides diet with restricted carbohydrates upto 20 grams per day and increased fat and protein ratio. For this purpose, various dietary menus will be provided to the parents.
53635|NCT03764943|Dietary Supplement|Impact Advanced Recovery|immunonutrition shake; nutritional supplement containing amino acids, omega-3 fatty acids, and nucleotides
53636|NCT03764943|Dietary Supplement|Boost Breeze|nutritional supplement
53637|NCT03764930|Other|Unsuspected Retinoblastoma|To study the clinical characteristics and treatment outcomes of patients who experienced inadvertent trauma before diagnosis of retinoblastoma.
53638|NCT03764917|Other|Time|Different detecting time
53639|NCT03764904|Radiation|Airway Ultrasound|Laryngeal US will be performed with a 12 megahertz (MHz) linear probe attached to the ultrasound device. With the probe placed transversely on the midline of the anterior neck over the cricothyroid membrane.
53640|NCT03764891|Procedure|Uphold|Uphold system in treating women with cystocele
53641|NCT03764891|Procedure|Perigee|Perigee system in treating women with cystocele
53642|NCT03764878|Diagnostic Test|functional MRI|Participants will undergo a functional MRI using multiple imaging modalities.
53643|NCT03764865|Procedure|day 3 uterine transfer|uterine transfer of embryo on day 3 after fertilization (cleavage stage)
53644|NCT03764865|Procedure|day 5 uterine transfer|uterine transfer of embryo on day 5 after fertilization (blastocyst stage)
53645|NCT03764852|Procedure|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.
53646|NCT03764852|Procedure|outpatient laparoscopic|The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
53647|NCT03764839|Behavioral|"Perioperative Digital Behavioral Pian Medicine My Surgical Success"|"The My Surgical Success website include 45 minutes of psychoeducation material developed and delivered by Beth Darnall, PhD. Viewers learn basic skills to improve regulation of pain-related distress. Treatment includes an app and a personalized plan for surgical success."
53648|NCT03764826|Device|CAABT|The sound generators with CAABT will be used 15 min each session, three times a day
53649|NCT03764826|Device|TMT|The sound generators with TMT will be used 15 min each session, three times a day
53650|NCT03764787|Combination Product|Radiation+PD-1 Ab|combination of proton radiotherapy with PD-1 antibody
53651|NCT03764774|Drug|LY3463251|Administered SC
53652|NCT03764774|Drug|Placebo|Administered SC
53653|NCT03764761|Device|AAC Technology - Standard of Care|Story Book is separate from AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and non-integrated presentation
53654|NCT03764761|Device|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is non-optimal arrangement and but integrated presentation
53655|NCT03764761|Device|AAC Technology - non-optimal integrated arrangement|Story Book is integrated on to the AAC display together with the AAC symbols, AAC symbols are arranged on a grid with color backgrounds. This is optimal arrangement and but integrated presentation
53656|NCT03764748|Drug|mini-FMT|200ml selective microbiota suspension (namely mini-FMT, mixed species of cultured bacteria) will be delivered daily through the nasojejunal transendoscopic enteral tubing (TET) tube for 3 days.
53657|NCT03764735|Drug|Low Dose - SkQ1|SkQ1 Low dose ophthalmic solution
53658|NCT03764735|Drug|High dose - SkQ1|SkQ1 High Dose ophthalmic solution
53659|NCT03764735|Drug|SkQ1 (Vehicle)|Vehicle for SkQ1 ophthalmic solution
53660|NCT03764722|Drug|Levosimendan|"The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP <90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months."
53661|NCT03764709|Device|Vital signs wireless monitoring system|WIN@Hospital wireless remote monitoring is a modern light monitoring medical device with no need for continuous presence of a dedicated person. WIN@Hospital is based on an innovative modular and wearable device laid out for remote monitoring of several vital parameters 24/7. Dexcom G6 is a continuous glucose monitoring system which measures interstitial fluid glucose levels in people with diabetes from a sensor applied to the skin as an alternative to routine finger-prick blood glucose testing, and can produce a -continuous record of measurements which can be checked using an App. It can also indicate glucose level trends over time. Monitoring devices will be applied to all patients randomly assigned to the wireless monitoring arm, with a continuous monitoring setting over the first 5 days after the initiation of monitoring, corresponding to the starting of the observation (i.e. transition to subacute unit for GROUP A, discharge for GROUP B).
53662|NCT03764696|Device|High flow facemask|Oxygen will be administered by facemask at 50% oxygen. The therapy will continue until after delivery
53663|NCT03764696|Device|Sham facemask oxygen|Room air will be administered by facemask at 21% oxygen. The therapy will continue until after delivery
53664|NCT03764683|Drug|Suvorexant (Belsomra)|Suvorexant (Belsomra) is approved by the U.S. Food and Drug Administration (FDA) to treat insomnia. It has not yet been studied in people with bipolar disorder who have problems sleeping.
53665|NCT03764683|Drug|Placebo|Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
53666|NCT03764657|Procedure|"In hot group 16 patients were treated by diathermy in Cold"|"In all interventions, the patients were placed in prone position on operating table with the gluteal line opened wide by adhesive patches; after skin disinfection, dimension and extension of cystic disease was studied by injection of hydrogen peroxide through superficial skin orifice. The same procedure was performed: an elliptical incision on midline around the sinus was made and the sinus was excided laterally and in depth on healthy tissue, down till the pre-sacral fascia: this common approach was made both using scalpel and electrosurgery in the two groups. During dissection and excision, in each group were measured and recorded the temperatures developing, both on the section surface using an infrared thermometer and thermal imaging camera, and deeper until 1 cm from the section frontline using a immersion thermometer sealed by a steri-drape to guarantee the sterility on surgical field. In this group excision was carried out with diatermocoagulation"
53667|NCT03764657|Procedure|"in Cold group 13 patients were treated by scalpel."|"the position and preparation of the patient on the operating table were the same as in the hot group, while the excision procedure performed with knife"
53668|NCT03764644|Behavioral|Combined ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Each session, participants see 160 trials of which 128 trials include one neutral and one threatening stimulus. The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
53669|NCT03764644|Behavioral|Combined Sham ABMT and CBT|ABMT: A trial begins with a fixation cross (+) for 500 ms, immediately followed by a stimuli pair consisting of a neutral and threatening stimulus that is centred horizontally. Stimuli pairs consist of two faces, pictures or words. After presentation of the stimuli pair, a probe (: or ..) always appears on the location of the neutral stimulus. The probe remains on the screen until the participant presses the corresponding key (: or ..), after which the next trial begins. Of the 160 trials, the probe appears with equal frequency on the location of the neutral and threatening stimulus (128 trials). The remaining 32 trials include a neutral-neutral stimuli pair. CBT: FRIENDS program individual
53670|NCT03764631|Drug|Empagliflozin|Drug
53671|NCT03764631|Drug|Dipeptidyl-peptidase 4 (DPP-4) inhibitors|Dipeptidyl-peptidase 4 - Drug
53672|NCT03764618|Drug|Fostamatinib disodium|"Fostamatinib (100mg PO bid or 150 mg PO bid)~The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed."
53673|NCT03764618|Drug|Placebo|Placebo
53674|NCT03764605|Drug|Metformin|Patieny will be treated by using Metformin from 500 mg a day to 500 mg thrice a day.
53675|NCT03764605|Drug|Tolvaptan|Patients will be treated with tolvaptan from 45 mg + 15 mg a day to 90 mg + 30 mg a day
53676|NCT03764592|Other|radiofrequency ablation|Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
53677|NCT03764579|Behavioral|sleep and diet intervention vs diet intervention|lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
53678|NCT03764566|Behavioral|Questionnaires|The intervention will include the implication of related questionnaires, followed by a lab experiment for social belonging with multiple modalities. Participants will be shown pictures of different faces and asked to judge their feelings towards them. Further, a VR task will include finding the way through a virtual maze with the help of two virtual characters.
53679|NCT03764553|Drug|Liposomal Irinotecan|Iv liposomal irinotecan
53680|NCT03764553|Drug|Carboplatin|IV Carboplatin
53681|NCT03764553|Drug|Capecitabine|PO Capecitabine
53682|NCT03764553|Drug|Oxaliplatin|IV Oxaliplatin
53683|NCT03764553|Drug|5-fluorouracil|IV 5-fluorouracil
53684|NCT03764553|Drug|Leucovorin|IV Leucovorin
53685|NCT03764540|Drug|Cabazitaxel plus prednisone|"Cabazitaxel 25 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
53686|NCT03764540|Drug|Docetaxel plus prednisone|"Docetaxel 75 mg/m² intravenously on day 1 of each cycle, plus prednisone 10 mg orally given daily.~A cycle is defined as a 3-weeks period for a maximum of 10 cycles."
53687|NCT03764527|Drug|Artemether-lumefantrine|Two doses a day for 3 days, under supervision
53688|NCT03764527|Drug|Coadministered Artesunate plus Amodiaquine|One dose a day for 3 days, under supervision
53689|NCT03764514|Device|Spinal Cord Stimulator|Permanent Implantation
53690|NCT03764501|Device|Image fusion system|Image fusion system for the 3D preoperative planning
53691|NCT03764488|Drug|BIIB067|Administered as specified in the treatment arm.
53692|NCT03764488|Drug|99mTc-MAG3-BIIB067|Administered as specified in the treatment arm.
53693|NCT03764475|Drug|ARQ-151|ARQ-151 cream 0.3% applied once daily for 52 weeks
53694|NCT03764462|Drug|AD-101 45mg|Raloxifene 45mg tablet
53695|NCT03764462|Drug|Raloxifene 60mg|Raloxifene 60mg tablet
53696|NCT03764449|Drug|Oral Balovaptan|"In Period 1, balovaptan will be administered as a single oral dose.~In Period 2, balovaptan will be administered as an oral dose once daily on Day 1 to Day 14."
53697|NCT03764449|Drug|IV Balovaptan|"In Period 1, IV infusion of balovaptan will be administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan will be administered after the final oral dose of balovaptan."
53698|NCT03764436|Behavioral|LEAPS-NCHD Program|The LEAPS-NCHD program trains young women aged 18 - 24 years with a minimum of 10 years of basic education to be preschool teachers, or Community Youth Leaders (CYLs) in community-based preschools in rural Sindh. CYLs will receive two weeks of classroom-based basic-training and 6 months of on-the-job coaching and support. A maximum of 20 children aged 3.5 -5 years old will be enrolled in each preschool. One preschool will be opened per cluster (village). Children will receive a minimum of 6 months of program exposure between assessment rounds.
53699|NCT03764423|Dietary Supplement|Salmon fishmeal|Salmon fishmeal with high protein content
53700|NCT03764423|Dietary Supplement|Microcrystalline cellulose|Microcrystalline cellulose contain no energy and is less fermented in the gut than other dietary fibers.
53701|NCT03764410|Procedure|Non-surgical periodontal treatment|all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
53702|NCT03764397|Behavioral|Prehabilitation for behavioural change|The 4-week prehabilitation educational programme will consist of a meeting for one session (approximately 1 - 1.5 hours) per week. This behavioural change programme will involve a mixture of interactive and didactic sessions, facilitated by a physiotherapist, psychologists, and other health professionals. The purpose of the initial prehabilitation programme is to gain participant 'buy-in' to the programme, to assist participants engage with exercise, to help participants overcome barriers to exercise and improve self-efficacy for exercise. The prehabilitation phase will also enable participants to understand why and how to perform gentle self-paced exercise. After the prehabilitation programme, participants will be advised to engage in a 6-week gentle self-paced walking programme; i.e., a simple pedometer-driven walking programme with weekly telephone support.
53703|NCT03764371|Diagnostic Test|KAPA Hyper Prep Kit + Agilent SureSelectQXT|We initiated this prospective clinical study to detect lung cancer related genes in tumor tissues and patients with at least 2 tumors that were confirmed as invasive adenocarcinoma by pathology after sMPLC resection (residual non-resectable or non-qualitative pulmonary nodules). At the same time, application of KAPA Hyper Prep Kit + Agilent SureSelectQXT technology to test lung cancer related genes in patients' tumor tissues and blood, patients with lung cancer drive genes were followed up to explore whether different drive genes had an impact on patients' disease progression. In order to investigate the type of gene that causes disease recurrence in patients, tissue or blood test was performed again when disease recurrence occur.
53704|NCT03764358|Device|Arteriovenous Fistula|Surgical implantation of an arteriovenous fistula for hemodialysis
53705|NCT03764358|Device|Tunneled Cuffed Catheter|Placement of a tunneled cuffed catheter in surgical theatre
53706|NCT03764345|Drug|Sofosbovir/Lepipasvir (200/45mg) tablet (Heterosofir)|Patients receive oral daily dose of Sofosbovir/Ledipasvir (200/45mg) daily for 8 weeks
53707|NCT03764332|Device|Stabilometry|To evaluate the static balance of subjects when barefoot and when using three types of footwear with their eyes closed or open.
53708|NCT03764319|Other|Ultra-protective ventilator settings|4-5 Breaths per minute; 14-16 cmH2O Positive endexpiratory pressure (PEEP) (adjust PEEP to 23 < Plateau pressure < 25 cmH2O); 23-25 cmH2O Plateau pressure (adjust to not exceed Tidal volume > 4 mL/kg Predicted body weight (PBW)); < 4mL/kg PBW Tidal volume; 1:5 Inspiration:Expiration (I:E)
53709|NCT03764319|Other|Standard ventilator settings|12-25 Breaths per minute; 8-12 cmH2O PEEP; max. 35 cmH2O Plateau pressure
94438|NCT03447990|Drug|MYK-491|Multiple Ascending Dose of MYK-491/placebo
53710|NCT03764306|Procedure|Carotid Artery Stenting|Carotid artery stenting was considered successful if there was no residual stenosis greater than 20%, and there was no dissection of target artery following the procedure.
53711|NCT03764306|Procedure|Endarterectomy carotid artery|Surgical endarterectomy was considered successful if there was no residual stenosis after procedure, without symptoms.
53712|NCT03764293|Drug|SHR-1210|Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
53713|NCT03764293|Drug|Apatinib|Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
53714|NCT03764293|Drug|Sorafenib|Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
53715|NCT03764280|Other|Multiple Daily Injections: Slow acting insulin and Rapid acting insulin|Multiple daily injections (MDI) therapy involves four or more daily insulin injections. Once or twice daily, a long acting insulin is injected as a basal dose. These long acting insulins are designed to dissipate slowly and evenly into the bloodstream for 24 to 36 hours following injection. This basal injection aims to mimic the physiological healthy basal insulin released from a healthy pancreas all day. Furthermore, multiple insulin bolus doses are injected at every meal each day using rapid or short acting insulin. These injections are administered before meals and are calculated using patients' ICRs and meal carbohydrate quantities.
53716|NCT03764267|Drug|Remifentanil|"Five minutes before infiltration of the local anesthestic by the surgeon, patients received an initial maintenance infusion of remifentanil 0.1 µg/kg/min and ketofol mixture 0.3 ml/kg (propofol 25 µg /kg/min and ketamine 10 µg/kg/min). ketofol mixture was prepared in a ratio of 1:2.5 (100 mg ketamine 2 mL (100 mg), propofol 1% 25 mL (250 mg), and glucose 5% 23 ml, total volume of 50 ml, each ml contain 2 mg ketamine + 5 mg propofol).~Throughout the surgery, titration of the infusion rate of the remifentanil and ketofol were indicated by vital signs and expression of pain"
53717|NCT03764267|Drug|general anesthetic|general anesthetic was induced with a bolus dose of remifentanil (1 ug/kg over 30 second) and propofol (2 mg/kg) followed by insertion of a laryngeal mask airway (LMA). After the induction of anaesthesia and securing the airway, patient' lungs were ventilated with volume controlled ventilation, 50% oxygen/air mixtures in a circle system. .Anesthesia was maintained with remifentanil (0.5 ug/ kg/ min) and propofol (5 mg/kg/h). Remifentanil and propofol titrated to keep heart rate and the blood pressure within 20% of the baseline values and maintain BIS between 40 and 60, respectively. Patient movements were treated with additional i.v. bolus doses of remifentanil 0.5 ug/kg
53718|NCT03764241|Drug|Rivaroxaban|Rivaroxaban 15mg/QD will be applied for 12 weeks unless severe safety outcome occurs. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
53719|NCT03764241|Drug|Vitamin K Antagonist|warfarin (INR 2.0-2.5) will be applied for 12 weeks unless severe safety outcome occur. All patients in both group will take aspirin 100mg/QD, clopidogrel 75mg/QD and proton pump inhibitor during the intervention.
53720|NCT03764228|Biological|hAECs|Human amniotic epithelial cells（hAECs）
53721|NCT03764215|Drug|Nilotinib 150 MG|10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
53722|NCT03764202|Other|Detection of sufentanil concentration|"Concentration of sufentanil in human breast milk was determined by LC-MS /MS method~The volume of human breast milk was detected at each fixed time point"
53723|NCT03764189|Procedure|microosteoperforation|small holes made using large round bur
53724|NCT03764176|Procedure|Conventional impressions|"In the conventional group, a polyether impression (ImpregumTM, 3M ESPE, Seefeld, Germany) will be taken with a customized tray (Diatray Top, Dental Kontor, Stockelsdorf, Germany). The impression will be poured with Gypsum IV Class Scale 5° (T6, Techim, Techim Group s.r.l., Arese, Italy) and then, the models mounted in a fully adjustable articulator (Protar Evo 7, KaVo Dental, Biberach, Germany). Afterwards, a dental wax-up will be made accordingly to the functional and esthetic requirements. Finally, master model and wax-up will be digitalized by using a lab scanner.~A surgical template will be derived from the mounted casts (conventional group) and used to place the implants using guided surgery."
53725|NCT03764176|Procedure|Digital impressions|"Patients will be randomly assigned to undergo intraoral digital impression (digital group) or conventional impression (conventional group). In the digital group, a digital impression will be taken using CS 3600 intraoral scanner (Carestream Dental LLC, Atlanta, GA, USA). The digital data (STL, STereo Lithography interface format) will be imported in a 3D design software to realize a virtual wax-up according to the functional and esthetic requirements.~A surgical template will be derived from the virtual plane (digital group) and used to place the implants using guided surgery."
53726|NCT03764163|Diagnostic Test|Pulmonary Function Test|Spirometry, Diffusing Capacity of the Lungs (DLCO), Lung Volumes
53727|NCT03764163|Diagnostic Test|CT Scans|volume scans, perfusion scan, ventilation scan
53728|NCT03764163|Behavioral|Questionnaires|Human Subjects Questionnaire, Baseline Dyspnea Index, Chronic Respiratory Questionnaire
53729|NCT03764163|Diagnostic Test|MRI|proton scans, hyperpolarized 3-Helium scan
53730|NCT03764163|Biological|Xenon gas|ventilation CT scans
53731|NCT03764137|Drug|[89Zr]Panitumumab PET-MRI|All patients entered into the study will have [89Zr]Panitumumab-PET/MRI imaging.
53732|NCT03764124|Diagnostic Test|PET/CT imaging|The PET/CT procedure was performed using cross-calibrated Philips Gemini TF Big Bore or TF 16 PET/CT systems (Philips Medical Systems, Cleveland, OH) at 201 18 minutes following intravenous injection of a mean dose of 3.2 0.2 MBq/kg of body weight of 18 F-FDG. A low-dose helical CT (5-mm slice thickness, 120-kV tube voltage, and 40-mAs tube current-time product) centered to the renal transplant was performed, followed by PET scanning with two bed positions, each lasting 240 seconds. Images were reconstructed using iterative list mode time-of-flight algorithms. Corrections for attenuation, dead time and random and scatter events were applied.
53733|NCT03764111|Device|Large Mobile Ultrasound System|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the large mobile ultrasound system.
53734|NCT03764111|Device|Handheld Ultrasound Machine|30 spine images, 15 Transverse abdominis muscle and 30 Obstetric images (i.e placenta, uterine blood flow, etc) images will be obtained using the handheld device.
53735|NCT03764098|Drug|Guanfacine ER|Guanfacine Extended Release (6mg/day ER)
53736|NCT03764098|Other|Placebo|Placebo
53737|NCT03764085|Drug|Rheosorbilact®|Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
53738|NCT03764085|Drug|Ringer lactate|Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
53739|NCT03764072|Drug|VX-150|Multiple doses for VX-150 will be administrated orally.
53740|NCT03764072|Drug|Placebo|Subjects will receive placebo matched to VX-150 orally.
53741|NCT03764059|Device|Filtek bulk fill posterior restoration|"The subjects will be assigned to either the investigational product (Filtek Bulk ) or the control product (Z350XT) per web-based randomization system.~Immediately after restoration placement, at 1 week and 1 year postoperative, two evaluators from each site will perform an independent clinical assessment."
53742|NCT03764059|Device|Filtek™ Z350XT Universal Restorative|Filtek™ Z350XT Universal Restorative (Z350 XT) will serve as the control in this study.
53743|NCT03764033|Behavioral|Impact of Killing (IOK)|Participants in this arm will receive 10 sessions (60-90 minutes) of a cognitive-behavioral moral injury treatment called IOK .
53744|NCT03764033|Behavioral|Present Centered Therapy|Participants in this arm will receive 10 sessions (60-90 minutes) of a PTSD treatment that does not focus on trauma or cognitive restructuring, but rather the functional impact of trauma called Present Center Therapy (PCT)
53745|NCT03764020|Drug|Placebo oral capsule/placebo comparator|3 mg placebo capsule one hour before bedtime for three weeks along with life style modification according to ACC/AHA 2013 guideline
53746|NCT03764020|Drug|Melatonin/experimental|Melatonin ,capsule, 3 mg, one dose one hour before bedtime, for three weeks along with life style modification according to ACC/AHA 2013 guideline.
53747|NCT03764007|Drug|Fluorocholine PET|Imaging study using PET after the injection of the fluorocholine radio tracer
53748|NCT03763981|Procedure|prolene seton treatment|patients with perianal fistulas will treated with seton placement by prolene thread
53749|NCT03763981|Procedure|silk seton treatment|patients with perianal fistulas will treated with seton placement by silk thread
53750|NCT03763968|Other|treatment and outcome|
53751|NCT03763955|Behavioral|MIRT|"4 week MIRT provide:~front to front treatment (1 hour/day for 5 days/week)~treatment with robotic devices (1 hour/day for 5 days/week)~occupational therapy (1 hour/day for 5 days/week)"
53752|NCT03763942|Behavioral|HealthMindr App|Participants in the intervention arm will receive access to the HealthMindr app with basic prevention services (HIV test planning and test locators; risk assessment; HIV treatment locators; and condom, HIV test kit, and at-home STI specimen collection kit distribution) plus monthly PrEP eligibility assessments, PrEP provider locator, enhanced information about PrEP, and referrals to local PrEP navigators. The app also provides information about obtaining health insurance coverage and paying for PrEP.
53753|NCT03763942|Behavioral|Control App|Men in the control arm will have access to an app with information pertinent to their participation in the study, including a study events timeline. The app will also allow participants and study staff to communicate via a messaging feature. The control arm app will not contain HIV prevention information.
53754|NCT03763929|Drug|Trans-Sodium Crocetinate|In the study drug kit containing the experimental drug (TSC), TSC will be reconstituted with the Sterile Water for Injection (USP) supplied in the same kit. There will be an unblinded paramedic who will reconstitute and inject the TSC on the ambulance.
53755|NCT03763929|Other|Placebo|The study drug kit containing placebo (sterile saline for Injection) will be prepared and injected by the unblinded paramedic on the ambulance.
53756|NCT03763916|Procedure|Ureteric dissection|clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
53757|NCT03763916|Procedure|Preoperative ureteric stenting|preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy [Karl storz] is done to identify the ureteric orifices. ureteric catheters [Roche] are inserted followed by the insertion of Foley's urethral catheter
53758|NCT03763916|Procedure|Cesarean hysterectomy|lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains
53759|NCT03763903|Other|3D training|Skills (FLS tasks) training using 3D visualization
53760|NCT03763903|Other|2D training|Skills (FLS tasks) training using 2D visualization
53761|NCT03763890|Device|Post-end-Expiratory pressure|Titrate the PEEP from 24 cmH2O to 6 cmH2O, 2 cmH2O/step and record EIT, trans-pulmonary pressure, hemodynamic parameter and Blood-gas analysis.
53762|NCT03763877|Drug|PXL770|Oral capsule
53763|NCT03763877|Drug|Placebo oral capsule|Oral capsule
53764|NCT03763864|Other|Skin Biopsy|Skin Biopsy
53765|NCT03763851|Radiation|Active PPP005|Group assigned to active PPP005 in the randomized placebo-controlled trial
53766|NCT03763851|Radiation|Radiotherapy|Palliative RadioTherapy to the symptomatic site
53770|NCT03763825|Behavioral|Mini-AFTERc|Structured 30-45 minute telephone discussion based on health psychology theory and CBT principles.
53969|NCT03762148|Dietary Supplement|ferrous fumarate|nutritional iron (14 mg) supplement in form of ferrous fumarate
53771|NCT03763812|Procedure|Endovascular Aneurysm Repair (EVAR)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~Before induction of anesthesia~At wound closure~24 hours after surgery~48 hours after surgery~1 month after surgery~6 months after surgery~12 months after surgery"
53772|NCT03763812|Procedure|Endovascular Aneurysm Sealing (EVAS)|"The following blood samples will be taken: WBC and circulating cytokines (TNF-α, Interleukin (IL)-1, 1RA, 6, 10, 18, CRP), Troponin T, HsTnT, NT-pro-BNP at these time points:~Before induction of anesthesia~At wound closure~24 hours after surgery~48 hours after surgery~1 month after surgery~6 months after surgery~12 months after surgery"
53773|NCT03763799|Procedure|PCR-based microbiological diagnosis strategy|Unyvero®, a multiplex PCR-based testing, will be used in addition to standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
53774|NCT03763799|Procedure|Standard microbiological diagnosis strategy|Standard strategy will be based on with standard microbiological culture of the tracheal aspirate to diagnose bacterial pneumonia after inhalation
53775|NCT03763786|Drug|Cetrorelix Acetate|Used a standard
53776|NCT03763760|Drug|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
53777|NCT03763747|Device|Scoreflex NC Scoring PTCA catheter|To dilate coronary arteries during the subject's index procedure with Scoreflex NC Scoring PTCA catheters
53778|NCT03763734|Drug|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
53779|NCT03763721|Device|intraoperative optical coherence tomography (iOCT)|"The OCT technology is fully integrated in a conventional ophthalmic surgical microscope (Zeiss LUMERA 700 platform). The OCT consists of A-scans (length/thickness) and B-scans (X-Y plane) to create the three dimensional image. Alternatively C-scans (3D cube scans) are available. All scans are non-invasive. The surgeon can continue surgery whilst using the iOCT and view a live image projected in the binocular or on the external screen and the video stream can be recorded as well.~The iOCT features are controlled using the foot paddle and the images are recorded on device. Investigations will be performed in a standardized matter: iOCT imagery and cube-scans after graft insertion, air injection, and the end of surgery."
53780|NCT03763708|Device|Spinal Cord Stimulation|Programming
53781|NCT03763695|Other|Measures for the VAP prevention in the PICU|Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.
53782|NCT03763695|Other|Evaluation of VAP incidence before the protocol introduction|evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
53783|NCT03763682|Device|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Six (6) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4, 5 and 6 month(s) after implantation
53784|NCT03763669|Dietary Supplement|Myoinositol|myo-inositol (2 g. twice a day)
53785|NCT03763669|Dietary Supplement|Placebo (for myoinositol)|(twice a day)
53786|NCT03763656|Drug|Hydroxy Urea|Oral Hydroxy urea
53787|NCT03763643|Drug|Rituximab|Rituximab 375mg/m2 intravenous on day 0 or -1 prior to kidney transplant
53788|NCT03763643|Drug|Placebo|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
53789|NCT03763643|Procedure|Plasmapheresis|1.5 volume exchange plasmapheresis with fresh frozen plasma replacement
53790|NCT03763630|Drug|House dust-mite SLIT|received 2000 standard treatment units of glycerinated HDM allergen extract (ALK-AbellÓ) per day. Normal saline was administered to the placebo group. 11 µg of HDM allergen (equal parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae) administered twice daily as oral drops.
53791|NCT03763630|Drug|Normal saline|Normal saline administered in same frequency and manner as intervention
53792|NCT03763617|Device|d-ptfe membrane|Socket preservation using d-ptfe membrane to inhibit the formation of osteoclasts
53793|NCT03763604|Drug|Abemaciclib|Administered orally.
53794|NCT03763591|Behavioral|Trauma Systems Therapy for Refugees Group Intervention|Psychological skills group for youth of refugee and immigrant backgrounds.
53795|NCT03763578|Other|Licorice|Natural herbal product
53796|NCT03763565|Biological|Bivalent or Quadrivalent HPV vaccines|Vaccination with at least one dose of Bivalent or Quadrivalent HPV vaccines at least 5 years ago at the ages of 20-45 years
53797|NCT03763552|Other|arthroscopic wrist arthrodesis|Cases of midcarpal wrist arthritis treated surgically with arthroscopic partial wrist fusion with cannulated screws
53798|NCT03763539|Procedure|SWL|Shock wave lithotripsy
53799|NCT03763513|Device|ESWT|Extracorporeal Shock Wave Therapy=ESWT
53800|NCT03763513|Other|Kinesiotaping Application|Kinesiotaping=KT (CT)
53801|NCT03763500|Other|Internet-based education|A six-step Internet-based patient education.
53802|NCT03763487|Diagnostic Test|venous blood sampling|Venous blood samples to determine memory B lymphocytes.
53803|NCT03763487|Procedure|spleen volumetry|Ultrasound examination of spleen to scaled the size.
53804|NCT03763474|Combination Product|Euglyca application|'Euglyca' is a mobile application developed by two of the authors (CC and DF). The application has a data base of 7000 foods and food products met in greek eating habits as well as the corresponding amount of carbohydrates and lipids for each of them. Subsequently, the amount of carbohydrates and lipids contained in a meal are calculated automatically by the application. By taking into consideration the amount of carbohydrates and lipids to be consumed, the preprandial and target post-prandial glycemia concentrations, the insulin correction factor for the patient, the carbohydrates and lipids factors and the active insulin (in case of CSII), 'Euglyca' calculates the required bolus dose of insulin.
53805|NCT03763461|Device|HFNC|High flow nasal humidified oxygen HFNC is an air-oxygen blender, which provides high flow (up to 60 L/min) of warmed (36°C) and humidified gas through nasal cannula, allowing tighter control of FiO2 from 0.2 to 1.0.
53806|NCT03763461|Device|Oxygen Mask|Application of oxygen during conscious sedation
53807|NCT03763448|Procedure|Infrapatellar Fat Pad preservation|In the IPFP preservation group, IPFP (more than 80%) will be preserved by retracting out of the operative field.
54363|NCT03759041|Drug|Vancomycin Pre-Treatment|Four times per day dosing of vancomycin pre-treatment
53808|NCT03763448|Procedure|Infrapatellar Fat Pad resection|In the IPFP resection group, more than 80% IPFP will be resected during the total knee arthroplasty.
53809|NCT03763435|Behavioral|Antenatal pregnancy classes|At least three comprehensive full-day educational program covering all the stages of pregnancy.
53810|NCT03763422|Drug|Temozolomide|Oral Administration of Temozolomide
53811|NCT03763422|Radiation|Radiotherapy|50.4 Gy in 28 fractions over 6 weeks
53812|NCT03763422|Procedure|Surgery|Surgery
53813|NCT03763409|Drug|Losartan Potassium|active drug
53814|NCT03763409|Other|placebo|placebo
53815|NCT03763396|Drug|Ketoconazole (KCZ)|Oral Tablet
53816|NCT03763396|Drug|Posaconazole (PCZ)|Delayed Release Oral Tablet
53817|NCT03763383|Procedure|Lateral Arm Flap|Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
53818|NCT03763370|Drug|GSK2857916 anti-BCMA-immunoconjugate|Dose and schedule: belantamab mafodotin 2.5 mg/kg IV Q3weeks
53819|NCT03763357|Device|Control/Sham Treatment|Thermoneutral water (33 degrees C) will be circulated though the water-circulating trousers to maintain skin temperature at baseline levels followed by PET/CT imaging of generator-based 62Cu-ETS.
53820|NCT03763357|Device|Heat Therapy (HT)|Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
53821|NCT03763344|Behavioral|Perceptual Cognitive Training (PCT)|Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery & cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
53822|NCT03763331|Device|Control/Sham Treatment|Thermoneutral water will be circulated through water-circulating trousers to maintain skin temperature at baselines levels daily for 90 minutes for 8 weeks.
53823|NCT03763331|Device|Heat Therapy|Water at 110 degrees F will be circulated through water-circulating trousers daily for 90 minutes for 8 weeks.
53824|NCT03763318|Biological|EQ001|Itolizumab [Bmab 600])
53825|NCT03763318|Biological|EQ001 Placebo|EQ001 Placebo
53826|NCT03763305|Drug|Propofol continuous infusion|Propofol intravenous continuous infusion for anesthetic induction and maintenance
53827|NCT03763305|Drug|Remifentanil|Remifentanil intravenous continuous infusion for anesthetic induction and maintenance
53828|NCT03763305|Drug|Sevoflurane|Study participants receive fentanyl 1mcg/kg and propofol 1.5~2mg/kg for induction of general anesthesia. For maintenance of anesthesia, desflurane is used to maintain 1 age-related minimum alveolar concentration (MAC).
53829|NCT03763305|Drug|Desflurane|1 age-related minimum alveolar concentration (MAC) of desflurane inhalation for anesthetic maintenance
53830|NCT03763305|Drug|Propofol bolus injection|Propofol intravenous injection for anesthetic induction
53831|NCT03763305|Drug|Fentanyl|Fentanyl intravenous injection for anesthetic induction
53832|NCT03763292|Behavioral|Specific information brochure|A purpose-designed brochure about anesthesia and surgery in the ear in children is developed by the investigators. This brochure has photos and describes the procedures the child is going through.
53833|NCT03763279|Combination Product|Triclosan-coated barbed suture|Use of Triclosan-coated Polydioxanone barbed suture
53834|NCT03763279|Combination Product|Triclosan-coated monofilament suture|Use of Triclosan-coated Polydioxanone monofilament suture
53835|NCT03763279|Device|Monofilament suture|Use of Polydioxanone monofilament suture
53836|NCT03763266|Other|1 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
53837|NCT03763266|Other|3 day low residue diet|Patients are interviewed and instructed by a nurse prior the colonoscopy. They receive oral and written dietary information. In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
53838|NCT03763253|Combination Product|Standard of Care|Androgen deprivation with or without docetaxel chemotherapy, Abiraterone, Enzalutamide or any other proven agent) treatment as determined by treating physician (positive control).
53839|NCT03763253|Procedure|Minimally Invasive Ablative Therapy (MIAT)|"MIAT includes High intensity focused ultrasound (HIFU) or Cryotherapy to the prostate.~Metastatic Directed Therapy available for use."
53840|NCT03763253|Procedure|Radical Therapy (Prostatectomy or Radiotherapy)|"Radical therapy includes: Prostatectomy (any surgical approach) or External beam radiotherapy (High dose).~Metastatic Directed Therapy available for use."
53841|NCT03763240|Dietary Supplement|BSE|"BSE powder will be provided as dry mixtures in sealed, non-transparent portion size bags. Each BSE bag contains 150 μmole, equal to 0.26 g, sulforaphane at a minimum. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning. BSE should be stored at room temperature in dry conditions.~The doses of sulforaphane contained in the BSE is not possible to get by eating fresh broccoli, thus it has to be given as an extract."
53842|NCT03763240|Dietary Supplement|Placebo|Placebo powder will be provided as dry mixtures in sealed, non-transparent portion size bags. The mixtures are suspended with appr. 1 dl water and are ingested once daily in the morning.
53843|NCT03763227|Drug|Intravitreal ranibizumab (IVR) injection|Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors
53844|NCT03763227|Drug|Carbonic Anhydrase Inhibitor (CAI) therapy|Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts
53845|NCT03763214|Device|Stenting with PTFE-coated stent (HILZO)|Placing a metal stent in the biliary tract by duodenoscopy
53846|NCT03763201|Diagnostic Test|measurement of GITR|serum and synovial fluid measurement of glucocorticoid-induced tumour necrosis factor receptor related protein
53848|NCT03763175|Drug|SYN-010 21 mg|21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
53849|NCT03763175|Drug|SYN-010 42 mg|42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
53850|NCT03763175|Drug|Placebo|A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
53851|NCT03763162|Drug|Bortezomib|Given SC
53852|NCT03763162|Biological|Daratumumab|Given IV
53853|NCT03763162|Drug|Dexamethasone|Given IV or PO
53854|NCT03763162|Drug|Ixazomib|Given PO
53855|NCT03763162|Other|Quality-of-Life Assessment|Ancillary studies
53856|NCT03763149|Biological|IBI188|"The study is composed of two stages: Part 1 Accelerated Titration Phase and Part 2 Dose Escalation Phase with initial fixed priming dose.~The starting dose for part 1 is 0.1 mg/kg QW, followed by 2 dose cohorts (0.3 mg/kg QW and 1 mg/kg QW). Duration of dose limiting toxicity (DLT) observation is 28 days.~Part 2 will have 4 dose cohorts(3mg/kg QW、10mg/kg QW、20mg/kg QW and 30mg/kg QW). Conventional 3+3 Dose Escalation will be adopted. DLT observation period is 28 days."
53857|NCT03763136|Biological|hPSC-CM therapy|Injection of allogenic human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) at time of coronary artery bypass grafting surgery, 100 million hiPSC-CMs in 2.5-5mL medium suspension will be injected into the myocardium.
53858|NCT03763123|Drug|Sevacizumab|Drug: Sevacizumab escalating doses of Sevacizumab : 0.5mg/kg，1mg/kg，1.5mg/kg and 2mg/kg
53859|NCT03763123|Drug|Paclitaxel|paclitaxel 80mg/m2 as a > 3-hour IV infusion on days 1, 8,15, and 22 every 4 weeks;
53860|NCT03763123|Drug|Topotecan|topotecan 4 mg/m2 as a >30 minute IV infusion on days 1, 8, and 15 every 4 weeks ;
53861|NCT03763110|Device|Photo Activated Disinfection|Photoactivated disinfection (PAD) is based on the interaction of a photosensitive antibacterial agent and a light source. It uses a nontoxic dye [named photosensitizer PS] and low-intensity visible light. In oxygen presentation, these combine to produce some cytotoxic species. The PS molecules attach to bacteria membrane
53862|NCT03763110|Drug|antibiotic paste|"An antibiotic mixture composed of ciproﬂoxacin, metronidazole, and minocycline, known as triple antibiotic paste (TAP) or 3mix, has been the most widely used medicament, This goes back to the studies by Hoshino et al.1996"
53863|NCT03763097|Diagnostic Test|Pelvic floor ultrasound|Pelvic floor ultrasound will include transperineal and introital ultrasound
53864|NCT03763084|Drug|Acetaminophen|For patients in the acetaminophen group, oral acetaminophen supplemented dexmedetomidine sedation will be provided after surgery.
53865|NCT03763084|Drug|Sufentanil|For patients in the control group, sufentanil supplemented dexmedetomidine sedation will be provided after surgery.
53866|NCT03763071|Other|Patient-reported scales to measure sleep disorders|"Patient-reported scales to measure sleep disorders include below mentioned scales:~Pittsburgh Sleep Quality Index; measures the quality of sleep Berlin Questionnaire; measures the obstructive sleep apnea Stop-Bang questionnaire; measures the obstructive sleep apnea Insomnia Severity Index; measures the insomnia and related parameters"
53867|NCT03763058|Other|Music Therapy|"The music intervention is administered via a smartphone- (and computer-) based application called Music Care. The Music Care app is a receptive music intervention, allowing the patient to freely adjust the length of and choose the preferred style between different sequences of instrumental music. All musical pieces were recorded in high-quality recording studios with professional musicians. Music Care utilizes the U technique designed to gradually relax the listener. The U technique is implemented using a musical sequence of 20 minutes that was divided into 5 different musical pieces at 3 to 4 minutes each.~Participants will complete 1-2 sessions of listening to music per day, with a minimum of 15 sessions per month."
53868|NCT03763045|Drug|Sildenafil|Sildenafil 25 mg: Phosphodiesterase inhibitor to be taken once daily
53869|NCT03763045|Drug|Sildenafil|Sildenafil 50 mg: Phosphodiesterase inhibitor to be taken once daily
53870|NCT03763045|Other|Placebo|Placebo tablet.
53871|NCT03763032|Behavioral|Counseling|The patient navigator will provide educational materials, assessments, and counseling to the patients
53872|NCT03763019|Procedure|Conventional rehabilitation|Static and dynamic control of position, balance skills, weight shift, and activities of daily living.
53873|NCT03763019|Procedure|Respiratory rehabilitation|Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
53874|NCT03763006|Procedure|Eyelid cleaning|This is a pure hypochlorous acid that kills many microbes, but remain very friendly and non-toxic for the ocular surface.
53875|NCT03762993|Behavioral|Vocal rest and Controlled Phonation|Voice rest and semi occluded vocal tract voice exercises
53876|NCT03762980|Other|Bilateral training (BAT)|Each group received bilateral training) for upper extremities for 3 days per week for 01 hour/day for up to 6 weeks. Tasks included functional tasks such as stacking cones and cups, positioning the cup upright, throw a ball into basket, carrying a wooden block and buttoning and unbuttoning of shirt with counting. Each task was performed for 10 minutes and had a rest break of 1 minute.
53877|NCT03762967|Biological|Lipoaspiration and SVF introduction.|Lipoaspiration, isolation of SVF and introduction into testis Interstitium.
54498|NCT03758118|Dietary Supplement|Citicoline|Citicoline administered in oral solution
53878|NCT03762967|Drug|Standard therapy.|Standard therapy include to give up bad habits, to establish a healthy diet, to eliminate excessive physical exertion. eliminate. In the case of endocrine disorders, hormone therapy is prescribed.
53879|NCT03762954|Other|Neurocognitive function assessment|Neurocognitive function will be assessed via a phone battery derived from standard cognitive tests proven feasible and valid to assess memory, attention, reasoning, and executive functioning. Functional status will also be assessed via phone. The duration of time required for the patient to complete telephone interview for neurocognitive and functional assessment will be approximately 45 minutes per time point.
53880|NCT03762928|Drug|PF-06651600|200 milligram (mg) PF-06651600 once daily (QD) orally for 11 days
53881|NCT03762928|Drug|midazolam|single administration of midazolam 2 mg oral solution
53882|NCT03762928|Drug|efavirenz|single administration of efavirenz 50 mg capsule
53883|NCT03762915|Drug|minocycline HCl microspheres|Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
53884|NCT03762889|Device|Eyeprotx™ General Anesthesia Protective Goggles|Eyeprotx™ Protective Goggles have been designed specifically for use in the operating room or in any scenario where general anesthesia must be used, such as intubation in an emergency. The integral function is to reduce intraocular pressure while in place, prevent operating room bright light penetration, facilitate a swift placement preventative measure with straps, form a barrier against bacterial invasion and mechanical damage. This study would seek to examine this goggles' effectiveness as a preventative measure as vs. other measures.
53885|NCT03762889|Device|Eyelid Tape|Taping the eyelids during intubation is one of the standard techniques used perioperatively under general anesthesia. This intervention would be used for the Eyelid Tape Group.
53886|NCT03762889|Device|Eye Ointment|Another standard technique used perioperatively under general anesthesia is to apply an ointment to the eye for lubrication. This intervention would be applied to the Eye Ointment Group.
53887|NCT03762863|Device|Tourniquet application skill retention|Tourniquet application following the procedure as learned in the Stop the Bleed curriculum.
53888|NCT03762850|Drug|sparsentan|Target dose of 400 mg daily
53889|NCT03762850|Drug|irbesartan|Target dose of 300 mg daily
53890|NCT03762837|Other|Benigh gallbladder diseases|We aim to observe the relationship between the benigh gallbladder diseases and gallbladder cancer, and we will not take any actions to interrupt.
53891|NCT03762824|Biological|13-valent pneumococcal conjugate vaccine|Pneumococcal conjugate vaccination during antirheumatic treatment
53892|NCT03762824|Biological|23-valent pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccination during antirheumatic treatment
53893|NCT03762811|Device|NanoFUSE® Bioactive Matrix|NanoFUSE® is placed into bony voids or gaps of the skeletal system that are not intrinsic to the stability of the bony structure.
53894|NCT03762798|Device|The Bridge|The Bridge (Also known as NSS-2) is a percutaneous, auricular field stimulator developed to alleviate pain through stimulation of peripheral cranial neurovascular bundles in the external ear that could potentially gain access to brain areas involved in fear, pain and nociception. After five days, the subject will return to the clinic for device removal and disposal.
53895|NCT03762785|Drug|nebulized Dexmedetomidine|inhalation of dexmedetomidine by nebulizer. the study drug will be prepared in 3 ml of 0.9% saline and will be administered by standard hospital jet nebulizer via face-mask with continuous flow of 100%oxygen at 6 l/m for 10 to 15 min
53896|NCT03762772|Drug|TAF/EVG Vaginal Insert|1 combination vaginal insert (20mg TAF/16mg EVG)
53897|NCT03762759|Procedure|Computed Tomography|Undergo PET/CT
53898|NCT03762759|Drug|Fluciclovine F18|Given IV
53899|NCT03762759|Radiation|Gallium Ga68-labeled PSMA-11|Given IV
53900|NCT03762759|Procedure|Positron Emission Tomography|Undergo PET/CT
53901|NCT03762746|Device|Transcranial Magnetic Stimulation|A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
53902|NCT03762746|Drug|Control|The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
53903|NCT03762720|Device|Physium treatment|patients will receive five sessions of physium therapy at 80 millibars in 30 minutes for one month in muscle injury and diagnosed by ultrasound and Shear Wave Elastography.
53904|NCT03762694|Device|Acupuncture|Electroacupuncture (EA) and Auricular Acupuncture (AA)
53905|NCT03762681|Drug|RO7239958|Subcutaneous (SC) dose administration as per the schedule specified in the respective arm.
53906|NCT03762681|Other|Placebo|Subcutaneous (SC) dose administration as per the schedule specified in the respective arm.
53907|NCT03762668|Device|Modified Delefilcon A Contact Lenses|Spherical soft daily disposable contact lens
53908|NCT03762668|Device|Delefilcon A Contact Lenses|Spherical soft daily disposable contact lens
53909|NCT03762655|Device|Neuro-Spinal Scaffold|"The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks."
53910|NCT03762642|Procedure|Mastectomy|Removal of the whole breast
53911|NCT03762642|Procedure|Breast-Conserving Surgery|Removal of the cancerous tissue only
53912|NCT03762629|Behavioral|Exercise|Subjects were provided with energy-restricted diets of 1300-2200 kcal/day based on weight. The energy percentages provided by protein, fat and carbohydrate were 20%, 20% and 60%, respectively, while energy distributions at breakfast, lunch and dinner were 30%, 40% and 30%, respectively. Subjects performed a series of endurance exercise such as bicycling, walking, running, dancing and ball games for 5 hour/day, supplemented with resistance exercise. Training interventions were performed 5-6 day/week for 6 weeks. The exercise program was designed to result in an energy expenditure of 1500-2500 kcal/day.
53913|NCT03762616|Diagnostic Test|Micro-ultrasound targeted biopsy|Micro-ultrasound targeted biopsy using the ExactVu micro-ultrasound system
53914|NCT03762616|Diagnostic Test|mpMRI targeted biopsy|Multiparametric MRI targeted biopsy using software assisted MRI/US fusion
53915|NCT03762603|Device|Robotic exoskeleton device|It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
53916|NCT03762590|Other|Doxy.me genetic education +/- Color Genomics genetic education|"Doxy.me is a HIPAA compliant telemedicine platform that allows clinicians to provide education to remote patients.~Genetic education via Doxy.me will consist of a pre-recorded genetic education video and a live interactive video conferencing session with a GENERATE genetic counselor.~Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website."
53917|NCT03762590|Other|Color Genomics genetic education|Genetic education via Color Genomics will consist of both written information and an educational video on the Color Genomics website.
53918|NCT03762577|Other|Ground-based walking training|Patients will attend a 2-day 30-minute ground-based walking training under the supervision of a physiotherapist. Patients will walk for 1-2 days in a week without supervision. According to the Modified Borg Scale, the dyspnea intensity will be 3-4 (medium to slightly difficult) and the heart rate will be completed to not exceed 120 min / pulse. Heart rate of patients will be followed by finger type pulse oximeter
53919|NCT03762564|Drug|Ramucirumab|Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
53920|NCT03762564|Drug|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, 8, 15
53921|NCT03762551|Other|skin biopsy|Two (4 mm) punch skin biopsies were taken from the 20 patients; one prior to the initiation of phototherapy and the other after the last session (from the same site). One skin biopsy was taken from the skin of each of the 10 control healthy participants. Skin biopsy specimens were preserved in Radio-Immunoprecipitation Assay (RIBA) buffer.
53922|NCT03762538|Drug|Propofol|Patients will be induced to unconsciousness using propofol intravenously.
53923|NCT03762525|Radiation|ECG gated CTA|"Routine care consists of a preoperative and several postoperative CTA scans. In A. The preoperative and first postoperative CTA will be replaced by ECG-gated CTA imaging and in B. the scheduled imaging will be replaced by an ECG-gated CTA.~General information: The protocol is based on the ECG gated cardiac protocol using abdominal parameter settings."
53924|NCT03762499|Diagnostic Test|Echocardiography scan|Non-invasive ultrasound imaging of the heart.
53925|NCT03762486|Other|TENS|4 electrodes were placed 2-3 cm lateral to the incision of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
53926|NCT03762486|Other|TAES|4 electrodes were placed at the ST25, P6, ST36, and LI4 acupuncture points of the patients at the 30th minute and 2, 18, 22, 42, and 46th hours after the surgery and electrical stimulation was implemented at varying frequencies of 2-100 Hz for 30 minutes, at a maximum current intensity of 12 milliamperes that would not bother the patient or create muscle contractions, with a pulse duration of 0.25 min
53927|NCT03762473|Drug|Study Group|Patients will convert from current tacrolimus dose to an Envarsus dose that is 80% of the total tacrolimus dose. They will take envarsus once daily in the morning and have 24 hour trough levels monitored at the standard of care interval for tacrolimus. Dosing will be titrated to achieve goal levels.
53928|NCT03762473|Drug|Control Group|Post transplant patients (kidney transplant alone) performed between 10-2016 and time of enrollment with standard of care immunosuppression, no prior rejection, prior BK or opportunistic infection, whom had a negative BK screening at month 1 and concentration/dose of < 1 at month 1, and BK data available and month 2,3, 6,9,12.
53929|NCT03762460|Other|Enhanced Measurement-Based Care (eMBC)|MBC utilizes validated rating scales to assess symptom severity, functional impairments, treatment adherence, and side-effect burden to personalize clinical decision-making based on measured outcomes and clinical algorithms. This study incorporates a technology-enabled platform of MBC (eMBC) that participants access using a personally-owned smartphone, tablet, or laptop computer.
53930|NCT03762447|Drug|INCB086550|Part 1: INCB086550 once or twice daily with dose modifications based on tolerability criteria. Part 2: Recommended doses from Part 1.
53931|NCT03762434|Other|mobile application|"Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management."
53932|NCT03762421|Behavioral|Psycho-social skills development workshops based on PM plus|5 weekly, psycho-social skills development workshops will be conducted for newly inducted civil servants in groups, based on the problem management plus intervention. These workshops will be integrated into routine induction sessions of trainee civil servants. Workshop 1 orients participants to the intervention with motivational interviewing techniques to improve engagement, teaches the difference between technical and adaptive challenges, and trains participants in a basic stress management strategy. Workshop 2 addresses a participant-selected problem using problem-solving techniques and introduces behavioral activation. Workshops 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks whenever required. In Workshop 5, education about retaining intervention gains are provided and all learned strategies are reviewed.
53933|NCT03762421|Behavioral|Routine training induction sessions|The control group will receive 5 routine training induction sessions. These orientation sessions include lectures introduction to governance, public sector management, basic information technology, economics and public finance and official rules of procedure of the government of Pakistan. These lectures are held in a friendly and supportive environment.
53934|NCT03762408|Device|ENKO 1|50 mg of HA/ 50 mg of CS in 5 ml
53935|NCT03762408|Device|Durolane|60 mg HA crosslinked in 3 ml
53936|NCT03762395|Drug|CXA-10|12 weeks of treatment with 150 mg/day of orally administered CXA-10
53937|NCT03762395|Drug|Matching Placebo|12 weeks of treatment with orally administered matching placebo (to 150 mg/day of CXA-10)
53938|NCT03762382|Drug|TFV/LNG IVR|TFV/LNG IVR is an intravaginal ring that releases approximately 8-10 mg/day of TFV and approximately 20ug/day of LNG to be used for 90 continuous days.
53939|NCT03762382|Drug|TFV IVR|TFV IVR is an intravaginal ring that releases approximately 8-10mg/day of TFV to be used for 90 continuous days.
53940|NCT03762382|Drug|Placebo IVR|Placebo IVR is an intravaginal ring containing no active experimental ingredients to be used for 90 continuous days.
53941|NCT03762369|Drug|CKD-351|twice a day
53942|NCT03762369|Drug|Latanoprost|once a day
53943|NCT03762369|Drug|D930|three times a day
53944|NCT03762369|Drug|Placebo of CKD-351|once a day
53945|NCT03762369|Drug|Placebo of CKD-351|twice a day
53946|NCT03762369|Drug|Placebo of D930|three times a day
53947|NCT03762343|Drug|ultrasound guided Greater occipital nerve block|ultrasound guided Greater occipital nerve block with 2 ml of bupivacaine 0.5% (up to a maximum of 2 mg/kg) subcutaneous under ultrasound guidance in the greater occipital nerve region bilaterally.
53948|NCT03762343|Drug|control group C|Patient in this group will receive the intraoperative standard of care(intraoperative intravenous fentanyl and paracetamol)
53949|NCT03762330|Behavioral|COPD structured self-management plan.|Education plan , including knowledge of the disease, healthy life habits, correct use of inhalers, skills to control symptoms and strategies to face the disease and exacerbations
53950|NCT03762317|Drug|Clonidine|clonidine will be given at 12 mcg/kg/d to the experimental arm in addition to oral morphine
53951|NCT03762317|Drug|Placebo|Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
53952|NCT03762304|Other|Household blood pressure screening with care encouragement|"During the household survey visit, survey enumerators collected two measurements of the respondent's blood pressure. If either of the measurements exceeded 140 mmHg systolic or 90 mmHg diastolic, enumerators told participants: Your blood pressure readings are higher than normal. High blood pressure is dangerous because it makes the heart work too hard. High blood pressure increases the risk of heart disease and stroke. High blood pressure can also cause other problems, such as heart failure, kidney disease, and blindness. You can control high blood pressure by taking action. Then the enumerators recommend that an individual seek medical care within 2 months."
53953|NCT03762291|Biological|CVD908ssb-TXSVN|"TXSVN may activate the immune system which is the participants body's ability to fight disease, and help develop a response against cancer cells that express Survivin. Survivin has been safely targeted using immune cells, drugs or direct inhibitors in over 50 patients with cancers in published reports.~Survivin belongs to the group of proteins known as tumor-associated antigens (TAAs). These are cell proteins that are specific to the cancer cell. They either are not found or are found in low levels normal cells in the human body. More than 90% of myeloma cancer cells have been shown to possess large quantities of Survivin."
53954|NCT03762278|Dietary Supplement|Leucine|Participants will ingest 15g of leucine supplementation/day during the immobilisation period. Leucine supplementation will be administered in powdered form (Infinit Nutrition, Canada) and participants will be required to consume 5g of leucine mixed with 250-300 ml of water during each meal. Leucine is a dietary supplement according to the US FDA. This supplementation protocol has been demonstrated in humans (Murphy et al., 2016, AJCN) with no reported side effects. The quantity of leucine supplementation falls well within the safe limits outlined by Rasmussen et al. (2016). Infinit Nutrition Leucine is in compliance with banned substances requirements as espoused by the World Anti-Doping Agency. Infinit Nutrition Leucine is not a medicinal product.
53955|NCT03762278|Dietary Supplement|Placebo|"Participants will ingest 15g of placebo supplementation/day during the immobilisation period. Placebo supplementation will be administered in powdered form and participants will be required to consume 5g of placebo supplementation mixed with 250-300 ml of water during each meal (3x/day).~Placebo supplementation will contain 5g of non-essential amino acids (Infinit Nutrition, Canada) and will be calorically matched to the leucine supplementation.This supplementation protocol has been demonstrated previously in humans, with no reported side effects (Murphy et al., 2016, AJCN)."
53956|NCT03762265|Drug|PRN1008 Oral Tablet|Bruton's agammaglobulinemia tyrosine kinase (BTK) inhibitor
53957|NCT03762265|Drug|Placebo Oral Tablet|Placebo
53958|NCT03762252|Other|Dry needling|A solid filiform needle will be inserted over active trigger points in the scalene muscles for 30 seconds. The aim will be to elicit local twitch responses or the referred pain pattern of the scalene muscles.
53959|NCT03762252|Other|Manual Therapy|The therapist will apply manual compression over active trigger points in the scalene muscles for 30 seconds
53960|NCT03762239|Other|Purifying the air with a Pure Airbox device (Zonair 3D)|Purifying the air of the classroom where the experiment is conducted using a Pure Airbox device (Zonair 3D)
53961|NCT03762239|Other|Using a sham air purifier (same device without filters)|Use the air purifier (Pure Airbox, Zonair 3D) without filters in the classroom where the experiment is conducted
53962|NCT03762226|Drug|Anti-VEGF|Patients will undergo as part of the routine care 4 monthly anti-VEGF injections.
53963|NCT03762213|Device|Oculus GO VR HMD, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
53964|NCT03762213|Device|iPad, application Happy Place (© Mimerse)|The Entertainment Software Rating Board (ESRB) has rated Happy Place as 'E' ('Everyone' or content suitable for all ages).
53965|NCT03762200|Device|SURGICEL Powder|SURGICEL Powder is a topical absorbable hemostatic treatment made of oxidized regenerated cellulose (ORC) - plant material
53966|NCT03762187|Behavioral|Self-affirmation|Individuals select important values and then write about why that value is important to them.
53967|NCT03762187|Behavioral|Positive living counseling|Each of the clinics from which participants were recruited conducts positive living counseling as part of their treatment programs. This counseling is conducted by counselors who are trained and monitored by the Lesotho Network of AIDS Support Organizations (LENASO) and consistent with the positive prevention framework (see Bunnell et al., 2005 for description). Each counseling session focused on addressing positive living goals such as the importance of taking one's medications on time and every day, using protection with every partner, and the importance of maintaining a healthy lifestyle.
53968|NCT03762161|Drug|TAS 102|Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
53970|NCT03762148|Dietary Supplement|ferrous sulphate|nutritional iron (14 mg) supplement in form of ferrous sulphate
53971|NCT03762148|Dietary Supplement|ferric pyrophosphate|nutritional iron (14 mg) supplement in form of ferric pyrophosphate
53972|NCT03762148|Dietary Supplement|ferrous fumarate + 3.5 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (3.5 g GOS)
53973|NCT03762148|Dietary Supplement|ferrous fumarate + 7 g GOS|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS)
53974|NCT03762148|Dietary Supplement|ferrous sulphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferrous sulphate with addition of prebiotics (15 g GOS)
53975|NCT03762148|Dietary Supplement|ferrous fumarate + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of Vitamin C
53976|NCT03762148|Dietary Supplement|ferric pyrophosphate + 15 g GOS|nutritional iron (14 mg) supplement in form of ferric pyrophosphate with addition of prebiotics (15 g GOS)
53977|NCT03762148|Dietary Supplement|ferrous fumarate + 7 g GOS + Vitamin C|nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (7 g GOS) and Vitamin C
53978|NCT03762135|Other|Full version of the LIITah App.|Participants will download the LIITAH app. For the first 2 weeks the app. will only record presence in a restaurant and ask users to submit photos of their food. in week 3 all of the program features will be activated.
53979|NCT03762135|Other|Partial App. (ELI and SNAP only)|Participants will download the LIITAH app. It will detect their presence in a restaurant and users will submit annotated photos of their purchases
53980|NCT03762122|Drug|Rogaratinib|Rogaratinib (BAY 1163877; Bayer) is an oral pan-kinase inhibitor, which selectively inhibits FGFR1, FGFR2, FGFR3, and FGFR4.
53981|NCT03762109|Drug|Dantrolene|muscle relaxant
53982|NCT03762109|Drug|Placebo Oral Tablet|inactive pill
53983|NCT03762096|Dietary Supplement|Trans-resveratrol|1 gram, twice a day by mouth Transmax (Biotivia)
53984|NCT03762096|Dietary Supplement|Placebo|Placebo
53985|NCT03762083|Device|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of BV.
53986|NCT03762070|Device|CL Detect™ Rapid Test|Observational study of a FDA cleared device, the CL Detect™ Rapid Test.
53987|NCT03762057|Diagnostic Test|Intraabdominal pressure monitoring|Classic manometry technique measurement once daily
53988|NCT03762044|Other|Activity-oriented Proprioceptive Antiedema Therapy (TAPA)|"Health education / patient empowerment.~Neurodynamic activities oriented to ADL.~Proprioceptive neuromuscular facilitation exercises oriented to ADL.~Self-adherent self-adhesive antiedema of low compression."
53989|NCT03762044|Other|Complete Decongestive Therapy (CDT)|"Skin care.~Kinesitherapy~Manual lymphatic drainage (MLD)~Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments."
53990|NCT03762031|Drug|GC4711 30mg|single dose given via a 15 minute intravenous infusion
53991|NCT03762031|Drug|GC4711 60mg|single dose given via a 15 minute intravenous infusion
53992|NCT03762031|Drug|GC4711 90mg|single dose given via a 15 minute intravenous infusion
53993|NCT03762031|Drug|GC4711 120mg|single dose given via a 15 minute intravenous infusion
53994|NCT03762031|Drug|Placebo|single dose of normal saline given via a 15 minute intravenous infusion
53995|NCT03762031|Drug|GC4711 75mg|single dose given via a 15 minute intravenous infusion
53996|NCT03762031|Drug|GC4711 105mg|single dose given via a 15 minute intravenous infusion
54001|NCT03762005|Other|CRT guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to capillary refill time (CRT)
54002|NCT03762005|Other|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), according to lactate levels
54003|NCT03761992|Dietary Supplement|Gingko Baloba|Tablets
54004|NCT03761992|Other|Placebo|Tablets
54005|NCT03761979|Dietary Supplement|Strontium L-lactate|The Study Product was a highly pure form of SrLac, the strontium salt of L-lactic acid. SrLac was manufactured in compliance with current Good Manufacturing Practices. SrLac was thoroughly tested and met rigorous purity specifications. It was free from contamination by D-lactic acid and trace metals known to harm human health.
54006|NCT03761966|Other|Pregnant women|
54007|NCT03761953|Drug|Oritavancin Injection|single 1200mg infusion of IV oritavancin.
54008|NCT03761940|Other|EQ5D questionnaire and a demographic questionnaire|questionnaires
54009|NCT03761927|Device|Hearing Aid without NR enabled|Each participant will be fitted with noise reduction disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
54010|NCT03761927|Device|Hearing Aid with NR(1)|Each participant will be fitted with the noise reduction program on the same hearing aid. The principle of the noise reduction algorithm is to remove noise from a speech signal with the aim of improving the speech intelligibility and comfort.
54011|NCT03761927|Device|Hearing Aid with NR(2)|Each participant will be fitted with a second noise reduction program on the same hearing aid. The parameterization of this NR algorithm differs from that in NR(1).
54012|NCT03761914|Biological|galinpepimut-S|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
54013|NCT03761914|Drug|Pembrolizumab|Galinpepimut-S will be administered as monotherapy, then galinpepimut-S will be co-administered with pembrolizumab. After that, there will be un-paired administration of pembrolizumab and galinpepimut-S according to the schedule described in the protocol and described in the arm/group descriptions on ClinicalTrials.gov.
54014|NCT03761901|Drug|1L treatment|chemotherapy, EGFR TKI, immunotherapy, other
54015|NCT03761901|Drug|2L Treatment|Chemotherapy, EGFR TKI, immunotherapy, other
54016|NCT03761901|Drug|3L treatment|chemotherapy, EGFR TKI, immunotherapy, other
54017|NCT03761888|Diagnostic Test|optic nerve sheath measurement and transcranial doppler|evaluation of cerebral hemodynamics through measurement of systolic and diastolic velocities and PI in middle cerebral artery. Intracranial pressure will be appreciate by optic nerve sheath value
54018|NCT03761875|Other|blood sample CHB patients|"During a boold sample at only one follow up visit:~3 tubes EDTA 10 ml per patient~1 tube Paxgene 1ml~1 dry tube per patient"
54019|NCT03761875|Other|boold sample Control group|"2 tubes EDTA ideally age and sex matched to CHB patient.~1 tube Paxgene 1ml~1 dry tube"
54020|NCT03761862|Procedure|Neural Therapy|Neural therapy is a form of alternative medicine in which local anesthetic is injected into certain locations of the body in an attempt to treat chronic pain and illness.
54021|NCT03761849|Drug|RO7234292|Intrathecal injection
54022|NCT03761849|Drug|Placebo|Intrathecal injection
54023|NCT03761836|Device|ShangRing|The ShangRing™ is a device for male circumcision that was invented by Jian Zhong Shang and has been on the Chinese market since 2005. It consists of a sterile device with two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. It currently holds a European Conformity (CE) mark, an EN ISO certificate, and is FDA approved. Clinical data from ShangRing studies in Africa were reviewed by the WHO Technical Advisory Group (TAG) on Innovations in Male Circumcision in January 2013 and were found to meet its clinical requirements. The ShangRing manufacturer was accepted by the WHO Prequalification Programme for Male Circumcision Devices in 2015.
54024|NCT03761810|Drug|S6G5T-3|once a day topical cream
54025|NCT03761810|Drug|S6G5T-8|once a day topical cream
54026|NCT03761797|Drug|TRADIANCE® Combination Tablets AP|Fixed dose combination
54027|NCT03761797|Drug|TRADIANCE® Combination Tablets BP|Fixed dose combination
54028|NCT03761784|Drug|S6G5T-3|once a day topical cream
54029|NCT03761784|Drug|S6G5T-8|once a day topical cream
54030|NCT03761771|Device|colonoscopy withdrawal with the ADS monitoring|During the testing of trained ADS, when the system doubts colonic lesions from the input data of the test images, a rectangular frame was displayed in the endoscopic image to surround the lesion. If the system confirmed it as the colonic lesions, a sound of reminder will be played and the types of lesions (non-adenomatous polyps, adenomatous polyps and colorectal cancers) will be classified by the system. We adopted several standards to define the identification and classification of colonic lesions: 1) when the system identified and confirmed any lesion in the images of no polyps or cancers, the results were judged to be false-positive. 2) when the system both confirmed and correctly localized the lesions in images (IoU > 0.3), the results were judged to be true-positive. 3) when the system did not confirm or correctly localize the lesions, the results were judged as false-negative. 4) when system confirmed no lesions in the normal images, the results were judged to be true-negative.
54031|NCT03761758|Device|Spectacle lenses|Spectacle lenses with clear central apertures
54032|NCT03761732|Behavioral|Islamic Trauma Healing|6 session behavioral intervention program designed to reduce PTSD and related symptomatology
54033|NCT03761719|Other|No intervention|No intervention
54034|NCT03761706|Behavioral|Engagement in Physical Activity|Study participants will be asked to wear a FitBit provided by the research team and agree to FitBit data downloads during regularly scheduled chemotherapy clinic visits. Participants will also complete a daily exercise log to record the total number of minutes walked and the total number of steps from the FitBit.
54035|NCT03761706|Other|Questionnaires|Study participants will complete the following questionnaires: Health Behavior Questionnaire (HBQ), Short Physical Performance Battery (SPPB), Functional Assessment of Cancer Therapy-General (FACT-G), 4.4.5 Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), PROMIS Cognitive Function (Short Form 8a), Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12) Version 4, Nutrition Survey, Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM),
54036|NCT03761693|Other|Fasting test|"The included infants will be fasted according to local standardized procedures at the University Medical Centre Groningen. Fasting will take place under hourly blood glucose monitoring and bedside supervision by an experienced, dedicated pediatric nurse, in collaboration with a metabolic pediatrician, who will be available to attend the patient instantly. Furthermore, on request of parent(s) or guardian(s), a continuous blood glucose monitoring device can be used during the study visits.~During study visit 1, at two months of life, fasting will be continued for maximally eight hours.~During study visit 2, at six months of life, fasting will be continued for maximally twelve hours.~Fasting will be ended prematurely in the following events:~blood glucose concentration drops < 3.6 mmol/L;~the child shows symptoms/signs of a low blood glucose concentration;~patients parent(s) or guardian(s) request end of fast."
54037|NCT03761680|Dietary Supplement|MEDPass mode of administration|Allocation of 50 ml of ONS four times per day distributed with the medication rounds
54038|NCT03761680|Dietary Supplement|Control Intervention|Patients receive ONS between meals or at their request as usual
54039|NCT03761667|Other|Endoscopy using Narrow band imaging|Inspection of resection margin of SSA/P for the evaluation of complete resection or the presence of remnant lesion using NBI method
54040|NCT03761654|Diagnostic Test|Global Longitudinal Strain measure|Global Longitudinal Strain measure on day 1 of hospitalization
54074|NCT03761381|Device|Optical Coherence Tomography Angiography (OCTA) Imaging|Optical coherence tomography is a non-invasive imaging technology that provides cross-sectional images of tissues in micron-scale resolution. The angiography component of this device allows for evaluation of blood vessel and blood flow changes in the eye. The RTVue-XR device with AngioVue software will be used to detect these blood vessel and flow changes as well as protein deposits in the retinal layers. Subjects will take oral curcumin supplements to hyperfluoresce and improve detection of the amyloid proteins within the retinal layers.
94439|NCT03447977|Other|cervical|cervical spine manual therapy
54041|NCT03761641|Other|Neurotriage|NeuroTriage binocular handset monitors pupil dynamics & eye position with infrared cameras. Rubber non-allergenic ocular spacers contoured to eye sockets come in contact with the face &cushion between the skin & eyepiece. During pupil dilation tests, an LED briefly illuminates the pupil. The NeuroTriage system measures neurological pupil index, constriction velocity, & dilation velocity. Total pupil dilation testing time is < 1 minute. During saccade-tracking tests, patients direct their gaze towards dim LED targets selectable across the range of view. Visual targets involve center-out ocular motion or smooth pursuit following of illusory movement. The NeuroTriage system measures eye position & movement velocity during these tests. Total saccade-tracking testing takes < 3 minutes. Ocular measures are non-invasive, are done quickly and commonly used to measure neurological function.
54042|NCT03761628|Device|pHyph, Gedea pessary|pHyph is a vaginal tablet for the treatment of VVC
54043|NCT03761615|Device|Dexcom G6 CGM|All women in the study will be given Dexcom G6 CGM and a study glucometer.
54044|NCT03761602|Other|Not applicable (for observational studies)|This study is an observational study. No intervention will be administered for research purposes.
54045|NCT03761589|Behavioral|AFL Intervention|The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.
54046|NCT03761589|Behavioral|Wait-List Control|Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
54047|NCT03761563|Device|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
54048|NCT03761550|Combination Product|pMDT(Process Implementation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
54049|NCT03761537|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
54050|NCT03761537|Other|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
54051|NCT03761524|Procedure|Customized V plate fixation|(CT) scan is taken for the patients and a customized V pattern plate will be designed .Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position guided by the CAD/CAM plate. MMF will be done.Fracture fragments will be fixed using CAD/CAM plate .
54052|NCT03761524|Procedure|Conventional miniplates fixation|Intraoral approach will be done to expose the angle fracture.Fracture site will be exposed and reduced in normal anatomic position. MMF will be done.Fracture fragments will be fixed using conventional miniplates fixation of angle fracture.
54053|NCT03761511|Drug|Nicotinamide|Nicotinamide 4 g (capsules) or highest tolerated dose with a minimum of 2 g/d per os once daily
54054|NCT03761511|Drug|Placebo|Matching Placebo (capsules) once daily
54055|NCT03761498|Other|Caloric Requirement|Infants will be provided standard of care and given calories required to maintain appropriate growth per unit policies already in place.
54056|NCT03761485|Other|Use of Dentifrice Fluoride|Use of few of dentifrice on brushing during a year
54057|NCT03761472|Biological|Hyaluronic acid injection|Hyaluronic acid 48 mg 2.0% in 2.4 ml solution
54058|NCT03761472|Biological|Platelet-rich plasma injection|Platelet-rich plasma injection 5ml
54059|NCT03761446|Other|Bed rest intervention|The participant will remain in bed rest for 10 complete days (240 hours).
54060|NCT03761446|Other|Oral Glucose Tolerance Test (OGTT)|For nondiabetics ONLY. This test will be done to measure participant body's response to glucose (sugar)
54061|NCT03761446|Other|VO2max Test|Aerobic fitness level will be assessed while participants pedals on a stationary bicycle.
54062|NCT03761446|Other|Activity Monitor|An activity monitor placed around your left upper arm and will be asked to wear the monitor for 7 days, except while showering/bathing. It is a tri-axial accelerometer that measures participant activity and uses those values to estimate the number of calories participants burn based on height, weight, age and gender.
54063|NCT03761446|Other|Magnetic Resonance Imaging- IMAT|Intermuscular adipose tissue (IMAT) is the fat that exists between muscle. This test will determine the amount of this type of fat inside thigh muscle.
54064|NCT03761446|Other|Biodex Strength Testing|Leg strength will be measured using a Biodex machine. This testing is completed in a seated position on the machine and participants will extend and flex their leg against different resistance levels.
54065|NCT03761433|Device|SPI group|All patients applied surgical pleth index at the time of surgical incision, under End tidal Sevoflurane 3%
54066|NCT03761407|Drug|100 mg GRT0151Y|100 mg capsule (1 x 100 mg capsule)
54067|NCT03761407|Drug|125 mg GRT0151Y|125 mg (1 x 100 mg capsule and 1 x 25 mg capsule)
54068|NCT03761407|Drug|150 mg GRT0151Y|150 mg (1 x 100 mg capsule and 1 x 50 mg capsule)
54069|NCT03761407|Drug|225 mg GRT0151Y|Day 1: 150 mg (1 x 100 mg capsule and 1 x 50 mg capsule) Day 2 - 5: 225 mg (2 x 100 mg capsules and 1 x 25 mg capsule)
54070|NCT03761407|Drug|Matching placebo|Matching placebo capsules using the same dosing regimen as defined in the treatment groups.
54071|NCT03761394|Device|Testing Devices|Pulsewatch system testing application on smartphone with smartwatch.
54072|NCT03761394|Device|Cardea Solo by Cardiac Insight|Gold-standard cardiac monitor for comparison of testing devices.
54073|NCT03761394|Device|Kardia Mobile by AliveCor|Mobile ECG device for comparison of testing devices during the extended use period.
54101|NCT03761173|Device|FlowTriever System|Thrombectomy
54075|NCT03761381|Device|Noninvasive Retinal Amyloid Imaging (NRAI)|The Spectralis will be used for NRAI. This system uses a special light source and optical filters to detect fluorescence of amyloid proteins in the eye.Subjects will take oral curcumin supplements to hyperfluoresce and improve detection of the amyloid proteins within the retinal layers.
54076|NCT03761368|Procedure|Remote Ischemic Preconditioning|four cycles of 5-min inflation to 200 mmHg followed by 5-min deflation of left upper - arm cuff
54077|NCT03761368|Procedure|Sham Remote Ischemic Preconditioning|deflated cuff placed on the left arm for 40 min
54078|NCT03761342|Behavioral|Multiple Traffic Light Label|The United Kingdom's Multiple Traffic Light label has repeatedly demonstrated effectiveness and has been widely implemented in Europe. The label shows how much calories, fats, saturated fats, sugar and salt are present in a product, with associated traffic light signals for high (red), medium (amber) and low (green) percentages for each attribute.
54079|NCT03761342|Behavioral|Nutri-Score Label|In late 2017, France began voluntary implementation of one FOP label, termed Nutri-Score, adapted from its predecessor, the 5-colour Nutrition Label. Consumer acceptability and understanding of the NS label has been demonstrated in several studies. It provides a letter score as a composite grade of a product's nutrition quality from A (best) to E (worst).
54080|NCT03761329|Procedure|mini-Bier's block with lidocaine 0.5% 25ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the forearm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (25ml lidocaine 0.5%). The tourniquet remains inflated for 10 minutes to reduce systemic toxicity reactions postoperatively.
54081|NCT03761329|Procedure|Conventional Bier's block with lidocaine 0.5% 40ml|An intravenous catheter will be placed in the dorsal vein of the hand that will undergo surgery. Afterwards, a tourniquet will be placed on the upper arm and inflated, after which the anesthetic can be administered via the dorsal vein catheter (40ml Lidocaine 0.5%). The tourniquet remains inflated for 25 minutes to reduce systemic toxicity reactions postoperatively.
54082|NCT03761316|Other|interview regarding goals|interview regarding goals
54083|NCT03761303|Device|active rTMS|The rTMS coil is applied tangentially to the head surface above the left DLPF (corresponding to position F3 of the international 10-20 system). For the stimulation intensity, the motor rest threshold of the patient is determined. The motor rest threshold is defined as the minimum intensity that triggers an EMG response with an amplitude> 50 μV in the first right interosseus dorsalis muscle in at least 5 out of 10 cases. The stimulation intensity within the rTMS therapy is 80 percent of the motor rest threshold. In one session, 1,000 pulses are applied in 10 trains at a frequency of 10 Hz (1 train = 100 pulses in 10 s). Between the individual trains there is an inter-train interval of 28 seconds. The total duration of a session is 5:52 minutes. In total, the patient recieve 20 sessions.
54084|NCT03761303|Device|sham rTMS|Patients in the intervetion group (active rTMS stimulation) receive active 10 Hz rTMS stimulation over the left dorsolateral prefrontal cortex (DLPFC) over a period of 20 days, seven days a week (20 sessions).
54085|NCT03761277|Device|Medtronic SynchroMed™ II infusion system|Implanted infusion system consisting of a pump and catheter, as well as external components of a clinician programmer, refill and catheter access port kits, and the Personal Therapy Manager (myPTM™).
54086|NCT03761277|Drug|Preservative-free morphine sulfate (PFMS)|The pharmacological agent used in the pump for this study is limited to a preservative-free morphine sulfate (PFMS).
54087|NCT03761264|Drug|Odontopaste®|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Odontopaste® will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
54088|NCT03761264|Drug|Pulpdent|Teeth with abscess will be opened from the crown to allow cleaning of the canals following which the Pulpdent paste will be placed in the canals and the pulp chamber. Cavity will be sealed with capsulated Glass ionomer cement.
54089|NCT03761264|Drug|Amoxicillin|Teeth with abscess will be opened from the crown to allow cleaning of the canals . A sterile cotton pellet will be placed in the pulp chamber and cavity sealed with capsulated Glass ionomer cement. The patient will be prescribed oral amoxicillin at 15mg/kg body weight tds for 5 days
54090|NCT03761251|Behavioral|Pet Fish|"Participants will be provided a fish tank with supplies to care for the fish and access to a fish (Betta splendens) from a local pet store. All participants will receive specific instructions for coupling the fish care and diabetes care:~feed fish one pellet in the morning after waking; check and record BG reading at that time~feed fish one pellet in the evening before dinner; check and record BG reading at that time~feed fish one pellet at night before bedtime; check and record BG reading at that time~every week clean the tank alternating with test the water quality in partnership with caregiver; review blood glucose readings with caregiver with each weekly fish care activity and problem solve any issues related to the blood glucose pattern.~Each child will also receive two books intended to supplement and enrich their pet fish experience."
54091|NCT03761238|Device|Molecular Adsorbent Recirculating System|MARS therapy will start within 24-48 h after randomization and be given on 3 consecutive days in sessions of 8-12 h. The patients are observed for 2 days following the last session, with focus on bilirubin INR and signs of encephalopathy, and can thereafter receive 3 additional sessions in case of no or partial response to treatment.
54092|NCT03761238|Other|Standard medical treatment (SMT)|Patient management and standard medical treatment (SMT) as specified in the study protocol.
54093|NCT03761225|Drug|Masitinib|
54094|NCT03761225|Drug|Docetaxel|
54095|NCT03761225|Drug|Prednisone|
54096|NCT03761225|Drug|Placebo|
54097|NCT03761199|Other|whole body cryostimulation|In this research project will be performed 15 treatments in cryogenic chamber (1 once a day, every day, with a break on Saturdays and Sundays). Cryostimulation will be conducted in a cryochamber located in the Małopolska Cryotherapy Centre in Kraków, Poland (Polish: Małopolskie Centrum Krioterapii). The whole body cryostimulation (WBC) exposure will be administered in a special temperature-controlled unit which consists of two rooms (-60° and -120°C). Throughout the session, the participants will be under direct supervision of qualified doctor.
54098|NCT03761186|Behavioral|traditional diabetes diet|Diet with carbohydrate content 50-60% of total energy intake
54099|NCT03761186|Behavioral|moderately low carbohydrate diet|Diet with carbohydrate content 30-40% of total energy intake
54100|NCT03761186|Behavioral|strictly low carbohydrate diet|Diet with carbohydrate content 15-20% of total energy intake
54102|NCT03761160|Other|Mobile Health App|mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit
54103|NCT03761160|Other|Usual care|Usual care per hospital guidelines
54104|NCT03761147|Other|Paula exercises|structured exercises aimed to stimulate ring muscles
54105|NCT03761134|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
54106|NCT03761134|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
54107|NCT03761134|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
54108|NCT03761134|Drug|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
54109|NCT03761121|Other|Wave-CAIPI|"wave-CAIPI technology, a data acquisition / reconstruction scheme designed to optimally exploit available information in modern multi-channel receivers and in multi-contrast/time-series data for improved image encoding"
54110|NCT03761108|Drug|REGN5458|Administered by intravenous (IV) infusion
54113|NCT03761082|Other|NA(observation study)|NA(observation study)
54114|NCT03761069|Drug|PTC299|PTC299 will be administered per the treatment arm description
54115|NCT03761056|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
54116|NCT03761056|Drug|Fludarabine|Administered according to package insert
54117|NCT03761056|Drug|Cyclophosphamide|Administered according to package insert
54118|NCT03761043|Behavioral|Professional Behavior Change Intervention|IV to PO antimicrobial conversion guidelines for nurses, nurse in-services and internet education sessions, IV to PO antimicrobial conversion health record reminder, endorsement from antimicrobial stewardship program, prescribers, and nurse educators.
54119|NCT03761030|Drug|L-Dopa|We will be using generic sinemet 25/100 tablets in this study.
54120|NCT03761030|Drug|Placebo Oral Tablet|25/100 placebo tablets
54121|NCT03761017|Biological|MGD019|Bispecific DART protein binding PD-1 and CTLA-4
54122|NCT03761004|Drug|carbidopa-levodopa|single dose of WD-1603, BID dose of WD-1603 and Sinemet IR
54123|NCT03760991|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous"
54124|NCT03760978|Drug|Dexmedetomidine|
54125|NCT03760965|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
54126|NCT03760965|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
54127|NCT03760939|Other|Clinical and economical evaluation|Evaluation of the clinical and the economical impact of a colorectal surgery
54128|NCT03760926|Device|AblaCare Kit|The intervention consists in the realisation of the AblaCare Procedure using the AblaCare Kit, which comprises two elements: a disposable device (AblaCare Device) and a radiofrequency (RF) energy generator (AblaCare System). The AblaCare Device is a short-term invasive device delivered and positioned through the vagina to deliver RF energy inside the ovary in order to ablate ovarian tissue.
54129|NCT03760913|Drug|OLP-1002 (Test): Part A, Single Ascending Dose|Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
54130|NCT03760913|Drug|OLP-1002 (Test): Part B, Multiple Ascending Dose|Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg
54131|NCT03760913|Other|Placebo: Placebo Part A, Single Ascending Dose|Subcutaneous Injection: Placebo
54132|NCT03760913|Other|Placebo: Placebo Part B, Multiple Ascending Dose|Subcutaneous Injection: Placebo x 5
54133|NCT03760900|Drug|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
54134|NCT03760900|Other|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 2.5×107cells/kg, 6 hours after birth
54135|NCT03760900|Other|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, 6 hours after birth
54136|NCT03760900|Other|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, 24 hours after birth
54137|NCT03760900|Other|Autologous Umbilical Cord Blood Stem Cells Therapy|Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, 6 and 24 hours after birth
54138|NCT03760887|Other|Home exercise program only|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program only
54139|NCT03760887|Other|Home exercise program and home program of sensory discrimination|After 5 minutes of sensory discrimination (using a 9 point grid) in the clinic patients will perform a home exercise program and two 5 minutes sessions of sensory training at home each day.
54140|NCT03760861|Device|Prototype Microcapsule Treatment|The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
54141|NCT03760848|Drug|Aramchol|Aramchol 600 mg
54142|NCT03760848|Drug|Midazolam|Midazolam 2 mg
54143|NCT03760848|Drug|Atorvastatin|atorvastatin 40 mg
54144|NCT03760835|Drug|Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone)|Treatment of congenital adrenal hyperplasia
54145|NCT03760835|Drug|Dual release hydrocortisone (plenadren)|Treatment of congenital adrenal hyperplasia
54146|NCT03760822|Drug|Ramucirumab|IV ramucirumab at 8 mg/kg on D1 and D15
54147|NCT03760822|Drug|Paclitaxel|IV paclitaxel at 80 mg/m² on D1, D8 and D15
54148|NCT03760809|Drug|Dexmedetomidine 0.5μg／kg|Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
54682|NCT03756805|Device|continuous positive airway pressure|One group of patients with CPAP
54149|NCT03760809|Drug|Dexmedetomidine 1μg／kg|Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
54150|NCT03760796|Device|Corrie Digital Health platform|The Corrie Digital Health platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure cuff.
54151|NCT03760783|Other|Parabolic flight|Sperm analysis (total motility M/ml; grade a+b sperm M/ml, vitality, DNA Frag and apoptosis) will be measured on ground at 1g before the flight and after flight were sperm samples have been exposed to simulated microgravity
54152|NCT03760770|Procedure|corneal collagen crosslinking|Crosslinking in patients with progressive keratoconus.
54153|NCT03760757|Dietary Supplement|ESPO-572®|ESPO-572® is the same as PCSO-524®, except it has krill oil added to it.
54154|NCT03760757|Dietary Supplement|PCSO-524®|PCSO-524® (Lyprinol®/Omega XL®) is a nutritional supplement containing a patented extract of highly condensed form of stabilized marine lipids from the New Zealand green lipped mussel (Perna canaliculus) that is combined with olive oil and vitamin E. This marine oil lipid and omega-3 polyunsaturated fatty acid (PUFA) blend is a diverse mixture of sterol esters, sterols, polar lipids, triglycerides, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (split between the triacylglycerol and polar lipid classes), and free fatty acids.
54155|NCT03760744|Procedure|CDT with Negative Pressure|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) in conjunction with manual intervention of graded negative pressure application for lymphatic stimulation/ tissue clearance
54156|NCT03760744|Procedure|CDT alone|Complete decongestive therapy (physical therapy conservative intervention of compression, manual lymphatic drainage, skin care and exercises) for lymphatic stimulation/ tissue clearance
54157|NCT03760731|Behavioral|Acceptance and Commitment Therapy for Moral Injury (ACT-MI)|Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
54158|NCT03760731|Behavioral|Present Centered Therapy (PCT)|Present Centered Therapy (PCT) will include 12 group sessions, but will focus on problem solving daily life difficulties related to moral injury rather than the experiential focus on moral emotions presented in ACT-MI. Because PCT has been established as an evidence-based active control condition, it is likely to serve as a beneficial transdiagnostic intervention in its own right.
54159|NCT03760718|Drug|Preservative free 1% Chloroprocaine|40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
54160|NCT03760718|Drug|Preservative free 2% Chloroprocaine|40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
54161|NCT03760718|Drug|Preservative free 3% Chloroprocaine|40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
54162|NCT03760705|Other|Data Collection|"Collection of data as detailed below:~Clinical data collected by SCDB~Clinical, administrative, pharmacy, financial data collected by each participating hospital~Administrative data collected by MOH~Data will be extracted and anonymized on a secure healthcare analytics platform~Collaboration with the MOH for collection of administrative and financial data~Analysis on how healthcare behavior is affected by education, socioeconomic level and other social or cultural factors.~Statistical Analysis by the bio statistical team. This team will be responsible for collecting and merging the collected data and will also ensure the quality of the data."
54163|NCT03760692|Device|i-gel|Evaluation of clinical performance in terms of insertion, ventilation and complications
54164|NCT03760692|Device|Ambu AuroGain|Evaluation of clinical performance in terms of insertion, ventilation and complications
54165|NCT03760679|Device|Laryngeal mask Supreme evaluation|Device: Laryngeal mask Supreme evaluation
54166|NCT03760679|Device|i-gel evaluation|Device: i-gel evaluation
54167|NCT03760666|Drug|Brequinar|Oral brequinar will be administered twice-weekly. After the first cohort of 6 subjects, dose adjustments can occur every 14-day cycle both at the intra-subject and the inter-cohort level depending on safety, efficacy, and biomarker levels.
54168|NCT03760653|Other|Physical Exercise and probiotic group|The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of ~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
54169|NCT03760653|Dietary Supplement|Probiotic group|Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
54170|NCT03760653|Dietary Supplement|Placebo group|Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
54171|NCT03760640|Drug|LY900014|Administered SC
54172|NCT03760640|Drug|Insulin Lispro|Administered SC
54173|NCT03760627|Behavioral|Refugees Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
54174|NCT03760627|Behavioral|Mindfulness Resiliency Training|The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
54175|NCT03760614|Drug|Entinostat|Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.
55598|NCT03750110|Other|Usual Care|Smoking cessation support in line with NICE PH48 guidelines
54176|NCT03760614|Drug|FOLFOX regimen|FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
54177|NCT03760601|Behavioral|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
54178|NCT03760588|Drug|LCZ696|Target dose 200 (97/103) mg b.i.d .
54179|NCT03760575|Drug|Pembrolizumab|Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
54180|NCT03760575|Procedure|Indocyanine Green (ICG) Image-Guided Surgery|Standard surgery with image guided resection.
54181|NCT03760575|Drug|Cisplatin|75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
54182|NCT03760575|Drug|Pemetrexed|500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
54183|NCT03760562|Drug|Glucocorticoids|Oral Glucocorticoids.
54184|NCT03760549|Drug|Subjects were administered NasoVAX high dose|NasoVAX administered by intranasal spray at a single dose of 1×10(11th) viral particles (vp) versus placebo
54185|NCT03760536|Behavioral|16-week Exercise Rehabilitation Program for Breast Cancer Survivors|Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
54186|NCT03760523|Drug|Minnelide|Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.
54187|NCT03760510|Device|Tube Fastener|Endotrachel tube secured with tube fastener
54188|NCT03760510|Device|Adhesive Tape|Endotracheal tube secured with adhesive tape.
54189|NCT03760497|Procedure|Restorative treatment|For all groups, first the patients will be submitted to the anesthetic technique indicated with Lidocaine + Epinephrine 1: 100,000 (New DFL, Rio de Janeiro, Brazil), followed by absolute isolation with rubber sheet and metal clamp; then prophylaxis of the selected tooth will be performed with Robson's brush and pumice stone and water, surface washing and drying with cotton balls, removal of carious tissue or affected enamel without dentin support with sharp curettes or low-speed spherical drills. Subsequently, each group will follow the treatment protocols suggested by the manufacturer of restorative materials.
54190|NCT03760484|Drug|Fidaxomicin 200 mg|Each cycle consists of fidaxomicin 200 mg PO bid x 7-10 days till clinical efficacy is achieved, to a max of 4 cycles.
54191|NCT03760484|Biological|fecal microbiota transplantation (FMT)|Each cycle consists of FMT per rectum daily x 3 days till clinical efficacy is achieved to a max of 4 cycles
54192|NCT03760471|Other|Evidenced-based symptom management and coping intervention|The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
54193|NCT03760458|Drug|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Fixed-dose combination dispersible tablets containing 60 mg ABC, 5 mg DTG, and 30 mg 3TC; administered orally once daily with or without food
54194|NCT03760458|Drug|Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)|Fixed-dose combination immediate release tablets containing 600 mg ABC, 50 mg DTG, and 300 mg 3TC; administered orally once daily with or without food
54195|NCT03760445|Drug|HDM201|2.5 mg and 10mg capsules, given orally
54196|NCT03760445|Drug|cytarabine|20mg or 1000 mg or other strengths as locally available given intravenously
54197|NCT03760445|Drug|anthracycline|20mg or other strength as locally available given intravenously
54198|NCT03760445|Drug|midostaurin|25mg capsules given orally
54199|NCT03760445|Drug|liposomal cytarabine/daunorubicin|100mg/44mg or other strength as locally available given intravenously
54200|NCT03760445|Drug|posaconazole|100mg delayed release tablet or other strength as locally available given orally
54201|NCT03760445|Drug|midazolam|2mg/mL oral solution or in other strength as locally available
54202|NCT03760432|Procedure|Laser Custom Corneal Collagen Cross-Linking|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for smoothing the anterior corneal surface and removing any present opacities. The surgeon uses the OCT data to plan treatment parameters while preserving at least 360 microns of residual corneal stroma using a phototherapeutic keratectomy procedure. After the laser procedure, adjunctive MMC or saline solution will be applied to the cornea in accordance with the group to which the treated eye is randomized. The CXL procedure is then performed following the FDA-approved CXL regimen by Avedro, Inc.
54203|NCT03760419|Behavioral|Decision Support|For enrolled subjects assigned to the decision support arm, providers will receive antibiotic recommendations in accordance with the 2011 PIDS/IDSA guideline, tailored to site of care and illness severity. The tool will offer treatment recommendations only and will not proscribe a specific treatment plan. Providers will receive prognostic information derived from the previously validated and best performing model. The application will calculate predicted risk for moderate (intensive care) and severe (respiratory failure or shock) outcomes using the parameters derived from the prognostic tool's regression equation. The tool will offer prognostic information only and will not proscribe a specific site of care or management plan.
54204|NCT03760406|Procedure|Opti-VIM targeting in DBS surgery|DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.
54239|NCT03760107|Behavioral|Connect Smokers to Treatment 2|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
56042|NCT03746522|Drug|Setmelanotide|Setmelanotide is a peptide that binds to the human MC4 receptor.
54205|NCT03760393|Behavioral|(SB-related planning + daily text messages)|"Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions plans specifying when, where, how, and for how long they would reduce occupational (student) sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will explicitly focus on the ultimate objective of increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing time spent standing and engaged in light-intensity PA, in the occupational domain (i.e. as a student; during school-related activities).~Participants will also receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions."
54206|NCT03760380|Device|Sole 1 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.
54207|NCT03760380|Device|Sole 1 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
54208|NCT03760380|Device|Sole 2 - Neutral|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.
54209|NCT03760380|Device|Sole 2 - Offset|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.
54210|NCT03760367|Other|Blue covarine toothpaste|2 min toothbrushing with 1 g of Pepsodent White Now Gold
54211|NCT03760367|Other|Control toothpaste|2 min toothbrushing with 1 g of Colgate Advanced Whitening
54212|NCT03760354|Drug|Methylprednisolone|Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
54213|NCT03760354|Other|Placebo|NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
54214|NCT03760341|Procedure|adenoidectomy - cold method|a surgery for adenoid removal or reduction under general anesthesia using surgical curretes
54215|NCT03760341|Procedure|adenoidectomy - hot method|a surgery for adenoid removal or reduction under general anesthesia using suction diathermy
54216|NCT03760328|Device|Upper Airway Stimulation|hypoglossal nerve stimulation by using a breathing cycle depended stimulation system of the upper airway
54217|NCT03760315|Diagnostic Test|mNGS (Next-Generation Sequencing Technology); Culture|mNGS and Culture of microbe in sepsis patients
54218|NCT03760302|Other|analgesics|analgesics given to a patient treated from HEMS
54219|NCT03760302|Other|hypnotics|hypnotics given to a patient treated from HEMS
54220|NCT03760276|Drug|Voriconazole Oral Product (Vfend®)|To be determined mg of Voriconazole (Vfend®, anti-fungal agent)
54221|NCT03760263|Drug|Tacrolimus|Immunosuppressive drug that can prevent organ rejection after transplant in its oral form.
54222|NCT03760250|Drug|Imiquimod 5% cream|Imiquimod 5% Cream application to keloid skin area 5-times per week for 6 weeks, starting 1-week before keloid excision
54223|NCT03760237|Other|observation only|No intervention, observational study only
54224|NCT03760224|Other|WhatsApp group|WhatsApp group will allow real-time group discussion for 8 weeks
54225|NCT03760224|Other|SMS group|SMS group for 8 weeks
54226|NCT03760211|Behavioral|Multilevel Gaming Adherence Intervention|Combination of electronic medication monitoring device with Information-Motivation-Behavior based mobile gaming application tailored for those living with HIV and adherence-based text messages
54227|NCT03760211|Behavioral|Treatment as Usual +|Combination of electronic medication monitoring device and non-HIV related mobile gaming application
54228|NCT03760198|Drug|Meditoxin|50U of MEDITOXIN is injected intradermally to each axilla
54229|NCT03760198|Other|Placebo|normal saline is injected intradermally to each axilla
54230|NCT03760185|Drug|Brimonidine Tartrate|All subjects will apply brimonidine tartrate to one eye only for the duration of study participation.
54231|NCT03760159|Device|Kinocardiography unintrusive recording|"The Kinocardiography (Kino) is a device which records the electric and mechanic function of the heart. The device comprises a combination of ECG recording, (6 degrees of freedom), accelerometer and gyroscope sensors. The Kino device consists of a back and a chest housing in contact with the patient. The back housing is placed in the middle of the lower back of the patient, and the chest housing is placed on the chest (either on the sternum or on the costal grill at the apex of the heart). The housings are connected by two cables. Data obtained from the device are visualized on a digital application via a Bluetooth connection.~For the group A, the KCG records the cardiac signals while the patient performs specific respiratory manoevres, as describe above.~For group B, C, D, the KCG records the cardiac contraction during sleep along with the PSG recording."
54232|NCT03760146|Biological|20vPnC|20vPnC
54233|NCT03760146|Biological|13vPnC|Pneumococcal conjugate vaccine
54234|NCT03760146|Biological|PPSV23|Pneumococcal polysaccharide vaccine
54235|NCT03760146|Other|Saline|Placebo
54236|NCT03760133|Drug|Duolac|Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
54237|NCT03760120|Device|PEP-MASK|
54238|NCT03760107|Behavioral|Connect Smokers to Treatment 1|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
54240|NCT03760107|Behavioral|Connect Smokers to Treatment 3|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
54241|NCT03760107|Behavioral|Connect Smokers to Treatment 4|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
54242|NCT03760107|Behavioral|Connect Smokers to Treatment 5|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
54243|NCT03760107|Behavioral|Connect Smokers to Treatment 6|Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
54244|NCT03760094|Device|Colour Doppler|evaluation of lymph nodes by Doppler
54245|NCT03760081|Drug|ASP1650|intravenously (IV)
54246|NCT03760068|Drug|MYL-1601D Product|(100 U/mL)
54247|NCT03760068|Drug|FlexPen NovoLog®|(100 U/mL)
54248|NCT03760055|Device|nGoggle|The nGoggle is a portable visual evoked potential system that uses an EEG to acquire visual evoked potentials in response to visual stimuli presented on a virtual reality goggle. The investigators will assess the ability of the nGoggle to detect visual field loss in patients with glaucoma, as well as to discriminate among the different stages of the disease, its repeatability and reliability for patient self-testing and patient satisfaction compared to standard automated perimetry (SAP), optical coherence tomography (OCT) metrics and Diopsys NOVA (Diopsys, Inc.). In addition, patients with other diseases affecting the visual system will also be tested in order to assess whether the nGoggle can differentiate glaucoma from them.
54249|NCT03760042|Drug|Within-Subject Active vs Placebo Topical Applications|Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
54250|NCT03760042|Drug|Within-Subject Active vs. Placebo Topical Applications|Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
54251|NCT03760029|Other|Visit frequency|All subjects need to visit sites more frequently than in routine clinical practice.
54252|NCT03760016|Behavioral|Moderate-Intensity Aerobic Training|Overground and treadmill walking with speed continuously adjusted to maintain a target heart rate of 40 +/- 5% heart rate reserve, progressing up to 55 +/- 5% heart rate reserve.
54253|NCT03760016|Behavioral|High-Intensity Interval Training|Overground and treadmill walking with 30 second bursts at maximum speed alternated with 30-60 second passive recovery periods. Intended to achieve a target average heart rate above 60% heart rate reserve.
54254|NCT03760003|Drug|ABX464 25mg|ABX464 25mg (One capsule of ABX464 25 mg + One capsule of placebo) once daily for 16 weeks
54255|NCT03760003|Drug|ABX464 50mg|ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
54256|NCT03760003|Drug|ABX464 100mg|ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
54257|NCT03760003|Drug|Placebo|Two capsules of placebo once daily for 16 weeks
54258|NCT03759990|Device|lean|Videolaryngoscope used in intubation
54259|NCT03759990|Device|obese|Videolaryngoscope used in intubation
54260|NCT03759977|Other|Adapted Physical Activity|The sessions of Adapted Physical Activity will be focus around the theme of balance, with a small part of resistance training.
54261|NCT03759964|Drug|Ferric carboxymaltose|1g of Ferric carboxymaltose diluted in 100 mL of IV isotonic serum saline at day 1 following surgery
54262|NCT03759964|Drug|Placebo|100 mL of IV isotonic serum saline at day 1 following surgery
54263|NCT03759951|Behavioral|DoIT-1|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.
54264|NCT03759951|Behavioral|DoIT-2|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.
54265|NCT03759951|Behavioral|DoIT-3|A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.
54266|NCT03759951|Behavioral|Control|No training will be performed during a 1-year period. Participation only in measurements.
54267|NCT03759938|Drug|Direct oral anticoagulant (DOAC)|Any of the DOACs listed above may be used for treatment in either study arm. The DOAC will be supplied from normal hospital stock, using local hospital prescriptions.
54268|NCT03759925|Other|Nutritional Support|Weekly nutritional components: Month 1: equivalent of 3 meals/day in the form of 14 frozen meals, and breakfast bag with items to prepare 7 breakfast meals. Month 2: equivalent of 3 meals a day in the form of 7 frozen meals, grocery bags, and breakfast bags with items to prepare 7 breakfast meals. Month 3: the equivalent of 2 meals a day in the form of 7 frozen meals and grocery bags. Month 4: Participant choice to receive either 7 frozen meals or grocery bag with equivalent food for 1 meal a day. Month 5: Grocery bag with equivalent food for 1 meal a day Nutritional counseling component: Individual counseling with Registered Dietician monthly
54269|NCT03759886|Drug|Paromomycin Sulfate Powder|The patients receive Paromomycin and Metronidazole the day prior to colorectal surgery after mechanical bowel preparation
54270|NCT03759873|Behavioral|Incentives|Patient earns financial incentives (gift cards) on an escalating schedule for completing cardiac rehabilitation sessions.
54359|NCT03759080|Procedure|proprioceptive neuromuscular facilitation|upper limb Pattern: Flexion -Abduction- External rotation
54271|NCT03759873|Behavioral|Case Management|A case manager is available by phone to assist patient with attending cardiac rehabilitation sessions as well as to provide advice about cardiac symptoms and healthy behavior change.
54272|NCT03759860|Combination Product|R:GEN laser treatment (Selective Retina Therapy) and Lucentis (ranibizumab) combination therapy|Lucentis (ranibizumab) injection into the vitreous cavity after R:GEN laser treatment (Selective Retina Therapy)
54273|NCT03759847|Other|Fluid intake app|Use of fluid app to monitor intake of fluids
54274|NCT03759847|Other|Survey|A survey will be used to assess the usability of the app (ease of use in general, ease of capturing fluid intake data, including the choice of pre-selected volumes for fluid containers, reasons for not using the app more frequently, the usefulness of the app notifications, ease of sending data to the study coordinator for review) as well as to collect recommendations for changes to the app itself.
54275|NCT03759834|Device|Cochlear promontory stimulation|Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
54276|NCT03759821|Behavioral|Nutrition, mothers|Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
54277|NCT03759821|Behavioral|Nutrition, mothers and fathers|Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
54278|NCT03759821|Behavioral|Nutrition+parenting, mothers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
54279|NCT03759821|Behavioral|Nutrition+parenting, mothers and fathers|Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
54280|NCT03759808|Behavioral|Psychological Intervention|Psychological treatment protocol designed to treat anxiety and avoidance in an adolescent/young adult population. The focus of treatment will be to address cognitive and behavioral factors associated with prolonged symptoms. Cognitive factors that may be addressed include, but are not limited to, catastrophizing, black or white thinking, and false expectations. Behavior factors that may be addressed include, but are not limited to, avoidance, relaxation, and behavioral activation. The psychological intervention is also designed to help reduce psychophysiological arousal associated with anxiety and stress. Participants will also be taught controlled shallow breathing exercises designed to normalize the ratio of sympathetic/parasympathetic activity.
54281|NCT03759795|Behavioral|ACTr (Acceptance and Commitment Training)|The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
54282|NCT03759782|Drug|Ribavirin|Ribavirin will be added to the standard of care treatment (tenofovir) regime for 24 weeks.
54283|NCT03759782|Drug|Tenofovir|Tenofovir as per standard of care
54284|NCT03759769|Other|Wheelchair simulator|Computer application providing 3D first person view of a wheelchair, with six different activities: street crossing, entering an elevator, entering an adapted van, bathroom, shopping mall and supermarket
54285|NCT03759769|Other|Video game|'Kart' driving video game
54286|NCT03759756|Other|AI presentation|AI presentation means the automatic diagnosis information of AI and AI presentation means it is visible in the group.
54287|NCT03759756|Other|no AI presentation|AI presentation means the automatic diagnosis information of AI and no AI presentation means it is invisible in the group.
54288|NCT03759743|Dietary Supplement|LMT1-48|capsules containing Probiotics
54289|NCT03759743|Dietary Supplement|Placebo|capsules that did not contain any probiotics
54290|NCT03759717|Other|Observation|Understanding the biology of skull base tumors will teach the investigators about the genesis and/or mechanisms of treatment resistance. The investigators hope to ultimately identify new targets which will add to the armamentarium by which to treat these tumors.
54291|NCT03759704|Drug|Hyperpolarized 13CPyruvate|Bolus injection of study drug during MRSI.
54292|NCT03759691|Behavioral|Structured interview|Interview contains questions about stroke knowledge and help-seeking behaviour on the day the stroke occured.
54293|NCT03759678|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
54294|NCT03759665|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
54295|NCT03759652|Behavioral|before-after study|The data analysed involve the time when the targeted, active surveillance of infections was establised, initially: 2003-2017, using tools (definitions, protocols) in accordance with the National Healthcare Safety Network (NHSN), then from 2012, HAI recognition methodology and HAI record-keeping has followed the Surveillance Network (HAI-Net), European Centre for Disease Prevention and Control (ECDC).
54296|NCT03759639|Drug|IB1001|IB1001 (N-Acetyl-L-Leucine) is a modified amino-acid ester that is orally administered.
54326|NCT03759314|Other|Observation|to use a simple screening tool to find out the risk of falling, the nutritional status and the level of cognitive functioning activity
54297|NCT03759626|Behavioral|Impulsive intervention|"As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions."
54298|NCT03759626|Behavioral|Reflective Intervention|"This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study."
54299|NCT03759613|Other|Gait Analysis|"Gait Analysis: Gait analysis is not a routine assessment tool for upper extremity burn injuries. This analysis is an assessment method to estimate gait symmetry.~Restriction arm swing: Participants in group will be restricted for arm swing using a bandage. Thus, the reciprocal arm swing will be prevented."
54300|NCT03759600|Drug|Niraparib|Niraparib capsule
54301|NCT03759587|Drug|Niraparib|Niraparib capsule
54302|NCT03759561|Procedure|intubation with videolaryngoscope vs fiberoptic bronchoscope|Tracheal intubation was performed using either videolaryngoscope or fiberoptic bronchoscope under cervical collar application according to the group allocations
54303|NCT03759548|Other|Assessment of nutritional status|Observational study. Assessment of nutritional status.
54304|NCT03759535|Diagnostic Test|Acute rejection|Donor derived cell free DNA
54305|NCT03759522|Drug|DPA-714 PET/MRI|DPA-714 PET/MRI
54306|NCT03759509|Behavioral|aerobic exercise|the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
54307|NCT03759496|Biological|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass
54308|NCT03759483|Diagnostic Test|AI diagnostic algorithm|The visual fields collected would be assessed by the algorithm and ophthalmologists independently. The performance of the algorithm and the ophthalmologists would be compared, including accuracy, AUC, sensitivity and specificity.
54309|NCT03759470|Diagnostic Test|CSF examination|"The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with ~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit."
54310|NCT03759457|Device|High Flow Nasal Cannula (AIRVO2)|High-flow nasal cannula (HFNC) delivers oxygen flows of up to 60 L/min. The gas source (air/oxygen blender, ventilator, or turbine flow-generator) is connected via an active heated humidifier to a nasal cannula and allows FiO2 adjustment independently from the flow
54311|NCT03759444|Other|Questionnaires|The three questionnaires applied were: the Time Metaphors Questionnaire by Sobol-Kwapinska, the Time Perspective Inventory by Zimbardo, and the UWIST Mood Adjective Checklist (UMACL) by Matthews et al.
54312|NCT03759431|Radiation|Vocal-cord Radiotherapy|Focal radiotherapy limited to the involved vocal cord(s) plus additional margins accounting for respiration and set-up errors.
54313|NCT03759431|Radiation|Complete Larynx Radiotherapy|Radiotherapy to the entire larynx, with target volumes defined to lead to traditional volumes from conventional complete larynx radiotherapy.
54314|NCT03759418|Device|exclusion of the left atrial appendage|A trans esophageal echocardiogram will be performed to assess the Atriclip device in the closure of the left atrial appendage in patients that had surgery at least 12 months ago.
54315|NCT03759405|Biological|iPS differentiated cardiomyocytes|Repair of injured myocardium by vein transplantation with autologous iPS differentiated cardiomyocytes
54316|NCT03759392|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 20 weeks with dose level determined by periodic blood testing
54317|NCT03759392|Drug|Placebo|Oral placebo twice daily for up to 20 weeks
54318|NCT03759379|Drug|Patisiran|Patisiran will be administered by intravenous (IV) infusion.
54319|NCT03759379|Drug|Vutrisiran (ALN-TTRSC02)|Vutrisiran will be administered by subcutaneous (SC) injection.
54320|NCT03759366|Drug|Eculizumab|Eculizumab will be administered by IV infusion.
54321|NCT03759353|Diagnostic Test|Baseline ferritin level|At enrollment, baseline serum ferritin level will be assessed to quantify iron deficiency.
54322|NCT03759353|Drug|Lactoferrin|lactoferrin 100 mg one sachet twice daily for 30 days to be dissolved in 1/4 glass of water before meals (Pravotin, Hygint pharmaceuticals).
54323|NCT03759353|Drug|Ferrous Sulfate|200 mg of dried ferrous sulphate tablet once daily for 30 days on empty stomach but may be taken with meals to avoid stomach upset.
54324|NCT03759353|Diagnostic Test|Follow up ferritin level|Four weeks after treatment, serum ferritin level will be assessed to quantify effect if treatment on iron status.
54325|NCT03759340|Drug|ATI 502 0.46% Topical Solution|apply ATI-502 Topical Solution, 0.46% Twice a day (BID) to the entire scalp and if applicable, the eyebrow(s)
54358|NCT03759080|Procedure|mental practice|training of mental practice to do the pattern of proprioceptive neuromuscular facilitation
54327|NCT03759301|Drug|Growth Hormones Somatropin Recombinant|Growth Hormones Somatropin Recombinant 4 IU/day subcutaneous from the 2nd day of the cycle and stopped 1 day before ovum pickup
54328|NCT03759301|Drug|Placebo saline solution|same volume as growth hormone ampule used
54329|NCT03759288|Drug|Brazikumab low dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous brazikumab on Day 85 and every 4 weeks through Week 48
54330|NCT03759288|Drug|Brazikumab high dose|Intravenous Brazikumab on Days 1, 29, and 57, followed by subcutaneous brazikumab on Day 85 and every 4 weeks through Week 48
54331|NCT03759288|Drug|Humira®|Administered subcutaneously on Day 1, Day 15, and Day 29 and every 2 weeks through Week 50.
54332|NCT03759288|Drug|Placebo|Intravenous placebo on Days 1, 29, 57 followed by subcutaneous placebo on Day 85 and every 2 weeks through Week 50
54333|NCT03759275|Other|pMDT(Baseline Investigation)|The pMDT(Baseline Investigation) takes multi-model analgesia as the main technical means. Multimodal perioperative analgesia refers to the combination of analgesics, adjuvant drugs and analgesic techniques with different effects throughout the perioperative period to achieve the best curative effect of reducing postoperative acute and chronic pain.
54334|NCT03759262|Drug|Cholecalciferol|A single dose of ultra-high-dose vitamin D (cholecalciferol) will be given prior to hematopoietic stem cell transplant. Research labs including inflammatory biomarker panels will be obtained prior to and after the dose is given.
54335|NCT03759249|Other|Sleep medical treatment|"The participant ungo Standard Sleep medical diagnostics. If a sleep disorder is diagnosed in the interventional Group the applicable therapy is conducted.~If the participant is randomized in the waiting Group the applicable Therapy is initiated after study completion."
54336|NCT03759236|Behavioral|Health Messaging via SMS|This intervention aims to provide health education on topics including HPV Vaccination, Cervical Cancer screening, contraceptive methods, menstrual problems, diet and exercise geared towards women with children of vaccination age.
54337|NCT03759236|Behavioral|CDC Health Pamphlets|This intervention aims to provide health education on the HPV Vaccination to women with children of vaccination age.
54338|NCT03759223|Behavioral|Enhanced Problem-Solving Training|E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training.
54339|NCT03759223|Behavioral|Healthy Living Messages|Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care.
54340|NCT03759197|Drug|188-0551 Spray|Topical Spray containing active drug
54341|NCT03759197|Drug|Vehicle Spray|Topical Spray containing no active drug
54342|NCT03759184|Drug|rhIL-15|civ IL-15 at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6
54343|NCT03759184|Biological|obinutuzumab|intravenous (IV) obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1; then 1,000 mg on day 4 of each subsequent cycle
54344|NCT03759171|Other|Guitars for Vets Intervention|This was an active intervention providing veterans with an acoustic guitar, guitar pick, tuning instruments, a music book, practice CDs, and individual and group sessions of music instruction during a 6-week intervention period. Six tailored 1-hour individual guitar instruction sessions were scheduled (1 session per week). In addition to the 6 tailored individual lessons, the intervention provided 3 group sessions. Veterans were given a guitar that they could keep upon completion of the program. The same instructor was assigned to a subject for the duration of the study, and group sessions were supervised by the Education Director of Guitars for Vets.
54345|NCT03759158|Drug|N-Acetyl Cysteine|NAC 1200 mg twice daily one day prior to the procedure and on the day of the procedure.
54346|NCT03759158|Drug|Placebo Oral Tablet|Placebo Oral Tablet twice daily.
54347|NCT03759145|Other|Exergame|Participants use exergame with the therapist in the rehabilitation center. Several games are available, the therapist adjusts the choice of game and level of difficulty according to the participant's abilities and interests.
54348|NCT03759145|Other|usual care|participants continued their planned rehabilitation sessions
54349|NCT03759132|Procedure|Transcranial direct current stimulation|Transcranial direct current stimulation is a noninvasive technique of neuronal modulation that has been used in different chronic neurological conditions, including Parkinson's disease.
54350|NCT03759119|Behavioral|Tummy time and parent education|Participants will receive tummy time positioning while awake for 10 minutes two times a day. Physiological monitoring will be maintained throughout the entire intervention and the intervention will be adjusted if needed to maintain stability. Participants will also receive parent education on tummy time prior to the tummy time intervention. The primary investigator will perform the tummy time intervention. Participants will be encouraged to continue performing tummy time on their own and record their adherence via the PT Pal application.
54351|NCT03759119|Behavioral|Parent education only|"Participants will receive the same tummy time education as those in the intervention group and will be asked to continue the intervention on their own and record their adherence via the PT Pal application.~Steps of the intervention for group 2 (standard care).~Complete educational session with primary investigator.~Adherence during the four-week intervention period will be measured remotely through the PT Pal® application."
54352|NCT03759106|Other|home written exercise program|exercises such as picking up objects, placing objects, frequently prescribed at discharge
54353|NCT03759106|Other|telerehabilitation/exergame system|Video games using the Kinect camera that are carried out using the impaired arm and monitored by a therapist by videoconferencing
54354|NCT03759093|Drug|Velcade|0.7,1.0,1.3 or 1.5 mg/m2 subcutaneous (SC) injection on Day 1, 8, 15 ,22 for cycles 1 to 4 , as determined and guided by the clinical care team and/or CURATE.AI. Standard of care is 1.3 mg/m2 SC on Day 1, 8, 15, 22 for cycles 1 to 4.
54355|NCT03759093|Drug|Cyclophosphamide|100, 150, 200, 250 ,300, 350 ,400 ,450 or 500 mg PO on Day 1, 8, 15, 22 for cycles 1 to 4 as determined and guided by the clinical care team and/or CURATE.AI. Standard of care is 500 mg PO on Day 1 ,8, 15, 22 for cycles 1 to 4.
54356|NCT03759093|Drug|Dexamethasone|8, 12 , 16, 20, 24, 28, 32 , 36 or 40 mg PO on Day 1 ,8 , 15, 22 for cycles 1 to 4, as determined and guided by the clinical care team. Standard of care is 40mg PO on Day 1, 8, 15, 22 for cycles 1 to 4.
54357|NCT03759093|Other|CURATE.AI-Guided dosage modulation|CURATE.AI-guided modulation of Velcade and Cyclophosphamide dosages
54360|NCT03759067|Drug|clopidogrel 75mg|clopidogrel once daily 75mg
54364|NCT03759041|Drug|Placebo for Vancomycin Pre-Treatment|Four times per day dosing of placebo pre-treatment
54365|NCT03759041|Drug|SER-287|Once-daily dosing of SER-287
54366|NCT03759041|Drug|Placebo for SER-287|Once-daily dosing of Placebo for SER-287
54367|NCT03759028|Drug|Ibuprofen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
54368|NCT03759028|Drug|Oxycodone|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
54369|NCT03759028|Drug|Acetaminophen|Post-operative pain control protocol of closed reduction percutaneous pinning of supracondylar humerus fracture.
54370|NCT03759015|Behavioral|Health education|All subjects are tasked to create an original 10-minute theater about physical activity and diet/nutrition.
54371|NCT03759002|Diagnostic Test|Imaging|Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
54372|NCT03759002|Other|Blood sampling|Blood sampling will performed on all participants for measuring hematological parameters including MPV.
54373|NCT03758989|Drug|Rituximab Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
54374|NCT03758989|Drug|Cyclophosphamide|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
54375|NCT03758989|Drug|Doxorubicin|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
54376|NCT03758989|Drug|Vincristine|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
54377|NCT03758989|Drug|Prednisone|A Phase II Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
54378|NCT03758976|Diagnostic Test|Biopsies, blood|We will perform targeted exon sequencing on paraffin embedded tissues from metastatic breast cancer
54379|NCT03758963|Device|R:GEN Selective Retina Therapy|Selective Retina Therapy (SRT) is the treatment method using innovative laser technology with the wavelength absorbed by melanosomes such as laser photocoagulation, but due to short pulse width (1.7 µs) with 100 Hz repetition rate, Retinal Pigment Epithelium (RPE) cells may be destroyed only through the generation of microbubble around melanosomes (photomechanical action), and no thermal damage of normal cells or tissues may occur in the surrounding tissues. SRT influences the RPE wound healing, including migration and proliferation of RPE cells, which treats CSC in the mechanism of recovering RPE. Once RPE is recovered, the sub-retinal fluid may be pumped out and retinal function again recovered. Moreover, previous studies showed that SRT may stimulate a moderate increase of activated metalloproteinase (MMP), leading to the improvement of Bruch's membrane's transport property.
54380|NCT03758950|Drug|Placebo|Once daily inhaled placebo for 48 weeks
54381|NCT03758950|Drug|Mometasone|Inhaled Mometasone for 48 weeks (with 4-week washout at study completion)
54382|NCT03758937|Procedure|volume-controlled ventilation|
54383|NCT03758937|Procedure|pressure-controlled ventilation|
54384|NCT03758924|Drug|ANAVEX2-73|Liquid oral solution
54385|NCT03758924|Drug|Placebo|Liquid oral solution
54386|NCT03758911|Other|Semi-structured Interview|
54387|NCT03758898|Other|Treatment|Chest physiotherapy and mobilization were applied twice a day, 8 times in total.
54388|NCT03758898|Other|Group 2|Only mobilization was applied twice a day, 8 times in total.
54389|NCT03758885|Drug|Nolasiban|Nolasiban single oral administration
54390|NCT03758885|Drug|Placebo|Placebo single oral administration
54391|NCT03758872|Diagnostic Test|cuff assisted colonoscopy(with cuff use of endocuff vision second generation)|this is a cohort prospective comparative, a group without cuff in 2017, 517 patient included in the retrospective phase, and in 2018, 517 patient will be included in the prospective phase with CUFF for detecting polyps
54392|NCT03758859|Other|sodium hyaluronate eyedrops|sodium hyaluronate eyedrops administered - route ocular -topical
54393|NCT03758846|Behavioral|Cognitive-motor exergaming|Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
54394|NCT03758846|Behavioral|Conventional balance Training|Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.
54395|NCT03758846|Behavioral|Dance Therapy for Stroke|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists."
54396|NCT03758846|Behavioral|Dance Therapy for Older adults|"Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists."
54397|NCT03758846|Behavioral|Home education for Older adults|Participants will receive a one-hour education on conventional physical exercises.
54428|NCT03758625|Biological|pgDC + no antigen|Control vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) but without an antigen
54429|NCT03758612|Drug|TBI-223 50mg|TBI-223 50 mg supplied for oral administration.
54398|NCT03758833|Diagnostic Test|preimplantation genetic test of embryo by new generation sequencing (NGS)|This is a genetic test to evaluate 24 chromosomes by the new generation sequencing platform. For that is necessary a embryo biopsy in the blastocyst stage and evaluation of a greater number of cells extracted from the trophectoderm
54399|NCT03758833|Procedure|Single embryo transfer|Transfer of single embryo
54400|NCT03758833|Procedure|Double embryo tranfer|Transfer of two embryos
54401|NCT03758820|Behavioral|Behavorial Cognitive Therapy (BCT)|"Check-in : review of the homewok Talk : Presentation of the aim of the session Group Activity : Relaxation and Execises Refreshment break Homework : exercises to practice at home and explanation about the forms to fill in.~Passout : session handbook and supports for exercises."
54402|NCT03758807|Other|Manual Therapy with Traditional Biomechanical Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (AP) Pressure with a traditional biomechanical or anatomic explanation of the technique..
54403|NCT03758807|Other|Manual Therapy with Neuroplastiicity Explanation|Patients will lie prone and receive lumbar Posterior to Anterior (PA) Pressure with a neuroplastic explanation of the technique.
54404|NCT03758794|Other|interactive lecture|an interactive lecture will be given to a group of dental interns students on child abuse recognition and reporting
54405|NCT03758794|Other|online education|an online educational module will be sent to a group of dental interns students on child abuse recognition and reporting
54406|NCT03758781|Drug|IRX 2|IRX-2 Regimen: 21 day regimen of cyclophosphamide on Day 1 and subcutaneous IRX-2 injections for 10 days between Days 4 and 18. This 21 day regimen will be given every 12 weeks.
54407|NCT03758781|Drug|Nivolumab|Nivolumab 240 mg will be given via IV infusion once every 2 weeks.
54408|NCT03758768|Other|Blue light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
54409|NCT03758768|Other|Full spectrum light exposure|Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
54410|NCT03758755|Device|Blood Flow Restriction Therapy|A wide pressure cuff will be applied to the upper thigh prior to starting strengthening exercises. The cuff is inflated to 80% of resting systolic blood pressure. The cuff remains inflated for the entirety of the exercise (4 sets of a specific movement). Once teh exercises are completed, it is deflated for a minimum of one minute before the next type of exercises are started.
54411|NCT03758755|Other|ACL Reconstruction rehabilitation|post-operative rehabilitation according to current standards of care
54412|NCT03758742|Behavioral|High-Fruit Diet|Participants will consume a diet rich in whole fruit. During Phase I (Weeks 1-4; supervised controlled feeding), participants will gradually increase the amount of whole fruit they consume, eventually reaching 50% of calories from whole fruit. In Phase II (Week 5-12; supervised controlled feeding), participants will consume a whole fruit-rich, eucaloric diet that provides 50% of calories in the form of whole fruit. The non-fruit portion of the diet will be styled as a Mediterranean Diet. Participants will be required to approximately keep their weight stable during Phases I and II. In the Follow-Up Phase (Months 4-12; free-living), participants will be instructed to continue consuming at least one-third of their diet as whole fruit and to make healthy food choices.
54413|NCT03758729|Drug|Nivolumab|Nivolumab 3mg/kg + NS 100mL MIV over 1hr every 2 weeks
54414|NCT03758729|Radiation|Radiation Therapy|Radiation Therapy
54415|NCT03758716|Drug|FB825, FB825-15D11, Anti-CemX|Pharmaceutical form: 20mg/ml solution Route of administration: IV
54416|NCT03758703|Other|Pre-recorded music intervention group|Refer to the arm/group descriptions.
54417|NCT03758703|Other|Pre-recorded soothing poetry group|Refer to the arm/group descriptions.
54418|NCT03758690|Device|High-Intensity Focused Electromagnetic (HIFEM) Field Device|The High-Intensity Focused Electromagnetic (HIFEM) Field device will be applied.
54419|NCT03758677|Drug|Apatinib|30 patients who progressed after EGFR-TKI treatment without T790M mutation will receive apatinib 250mg qd orally combine with chemotherapy , if the patient has a grade 3/4 adverse reaction during such treatment, apatinib should be reduced to 250mg orally once per two days. Chemotherapeutic agents are limited to platinum-based double drugs(Pemetrexed,Gemcitabine,Docetaxel).
54420|NCT03758664|Drug|ICP-192|Drug: ICP-192 Dose levels will be escalated following a modified 3+3 dose escalation scheme
54421|NCT03758638|Behavioral|Healthy Eating & Active Living Taught at Home|PAT National Center will train educators affiliated with PAT sites in HEALTH; among these, using the HEALTH training curriculum, which includes training materials, an ~8 hour training delivered through a synchronous web-based experience, and ongoing consultation. Participants at HEALTH sites receive usual care PAT+evidence-based life-style change strategies to prevent weight gain and promote weight loss embedded within and delivered as part of home visits. In addition to the usual care PAT curriculum content, goal setting related to healthy weight, and the importance of parental modeling of healthy eating and physical activity are incorporated throughout the discussion and visit. HEALTH will be delivered over 24 months via a (1) core and (2) maintenance phase. The visits begin with greater frequency, and taper. Consistent with PAT practice, the frequency and number of visits are determined by the family's needs and preferences.
54422|NCT03758638|Behavioral|Usual Care|The Foundational (usual care) curriculum uses a strength-based, solution-focused model to provide parents with child development knowledge and parenting support, empowering parents as their child's first and most influential teacher.
54423|NCT03758625|Biological|a1DC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with autologous -inactivated HIV
54424|NCT03758625|Biological|a1DC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) and loaded with a conserved HIV gag and pol peptide pool
54425|NCT03758625|Biological|a1DC + no antigen|Control vaccine composed of autologous dendritic cells matured with an optimized cocktail (a1DC) but without an antigen
54426|NCT03758625|Biological|pgDC + inactivated whole autologous HIV|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with autologous -inactivated HIV
54427|NCT03758625|Biological|pgDC + conserved HIV peptides|Investigational vaccine composed of autologous dendritic cells matured with a standard prostaglandin E2 cocktail (pgDC) and loaded with a conserved HIV gag and pol peptide pool
94440|NCT03447977|Other|thoracic|thoracic spine manual therapy
54430|NCT03758612|Drug|Placebo for TBI-223 50mg|Matching placebo for TBI-223 50mg supplied for oral administration.
54431|NCT03758612|Drug|TBI-223 100, 300, 600, 1200, 1400 mg|TBI-223 100, 300, 600, 1200, 1400 mg supplied for oral administration.
54432|NCT03758612|Drug|Placebo for TBI-223 100, 300, 600, 1200, 1400 mg|Matching placebo for 100, 300, 600, 1200, 1400 mg TBI-223 supplied for oral administration.
54433|NCT03758599|Procedure|Climbing|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
54434|NCT03758599|Procedure|Nordic Walking|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
54435|NCT03758599|Procedure|Social Contact|All interventions are identical in their duration. To fulfill the WHO guidelines of health enhancing activity (minimum 150 minutes of moderate exercise per week), two 75 minutes exercise sessions per week will take place. After meeting the inclusion criteria and after allocation to one of the three groups, patients will receive their timetable with the exercise or group session dates.
54436|NCT03758586|Other|Computerized spatial skill training|The spatial skills training session consisted of six practice trials that were run in a sequence. The objective of each practice was to manipulate the simulated robotic arm to grab the cubes and move them to a desired location using keyboard keys. The participant was required to reach a decision based on the visual-spatial information, before initiating subsequent movements of the simulated robotic arm. Each practice trial presented an initial state of the cubes in front of the robotic arm, and a target position of the cubes.
54437|NCT03758586|Other|Watching a presentation regarding robotic surgery|Watching a 20-35 minute long power-point presentation regarding the history of robotic surgery.
54438|NCT03758573|Other|Inspiratory Muscle Training (IMT)|Inspiratory Muscle Training (IMT)
54439|NCT03758573|Other|Intensive Physiotherapy (IPT)|Intensive Physiotherapy (IPT)
54440|NCT03758560|Other|Pre-operative Nepali version of pain catastrophizing scale (PCS) questionnaire|Patients will be asked to complete the scores based Nepali version of pain catastrophizing scale (PCS) questionnaire preoperatively
54441|NCT03758547|Device|in-exufflator technique|application through a device of 10 cycles using positive pressure (30 cmH20) during inspiration and negative pressure (-30 cmH20) during exhalation
54442|NCT03758547|Device|percussion technique|sliding venturi system (phasitron), powered by compressed gas that can be changed from 0.8 up to 3.5 bar and that generates the oscillations in the range of 80-650 cycles/min
54443|NCT03758534|Other|No intervention|This is a retrospective chart review study.
54444|NCT03758521|Device|Transcranial magnetic stimulation (TMS)|Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
54445|NCT03758521|Device|Magnetic resonance imaging (MRI)|These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
54446|NCT03758521|Device|Electroencephalogram (EEG)|These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
54447|NCT03758521|Procedure|Bio-specimen Collection|Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
54448|NCT03758508|Device|High Flow Oxygen nasal cannula|High Flow Oxygen nasal cannula
54449|NCT03758508|Device|Noninvasive ventilation|In this arm, participants receive noninvasive ventilation through an interface (such as full face mask or oro-nasal mask) alternated with continuous high flow oxygen though humidified nasal cannula
54450|NCT03758495|Other|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, and healthy controls.
54451|NCT03758482|Other|Probe meal|The probe meal (total caloric content 750 Kcal) will be ingested at a standard rate in 10 min.
54452|NCT03758469|Drug|HSK3486|Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.
54453|NCT03758469|Drug|rifampin , HSK3486|Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
54454|NCT03758456|Biological|HAL-MRE1|HAL-MRE1 is a liquid suspension for subcutaneous administration containing aluminum hydroxide adsorbed modified allergens extracted from ragweed pollen.
54455|NCT03758443|Drug|TD-1473 Dose A|See Arm description
54456|NCT03758443|Drug|TD-1473 Dose B|See Arm description
54457|NCT03758443|Drug|TD-1473 Dose C|See Arm description
54458|NCT03758443|Drug|Placebo|See Arm description
54459|NCT03758430|Other|Meal-Tagging App|Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
54460|NCT03758430|Device|Fitness Tracker|Fitness tracker will be worn around the clock for 16 weeks.
54461|NCT03758417|Biological|LCAR-B38M CAR-T Cell|Participants will receive LCAR-B38M CAR-T cells as a single infusion which consists of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
54462|NCT03758404|Biological|AAV- CNGA3|AAV gene therapy for defects in CNGA3 gene
94441|NCT03447977|Other|exercises|exercises for pain
54463|NCT03758391|Other|Flipped Classroom education|Fellows will receive GI/Bilirubin education in a flipped classroom format.
54464|NCT03758378|Other|Dietary intervention|Limiting dietary exposure to high intensity sweeteners and sugar alcohols; limiting eating out to a maximum of 2 days per week.
54465|NCT03758365|Drug|MC2-01 Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
54466|NCT03758365|Drug|Clobetasol Propionate 0.05% Lotion|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
54467|NCT03758365|Drug|Betamethasone Dipropionate 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
54468|NCT03758365|Drug|Triamcinolone Acetonide 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
54469|NCT03758365|Drug|Hydrocortisone Butyrate 0.1% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
54470|NCT03758365|Drug|Desonide 0.05% Cream|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
54471|NCT03758365|Drug|Vehicle|Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
54472|NCT03758352|Procedure|remote ischemic preconditioning (rIC)|Short intermittent peripheral occlusions and reperfusions of the blood flow in the right lower extremity with the help of a tourniquet.
54473|NCT03758352|Other|non remote ischemic preconditioning (non-rIC)|Retrospective group who have not undergone intervention.
54474|NCT03758339|Drug|tucatinib|Single dose of 300 mg of [¹⁴C]-tucatinib containing approximately 150 μCi of [¹⁴C] radioactivity
54475|NCT03758326|Other|Body App|Participants will indicate areas of concern on a virtual manikin using an electronic online interface. Body measurements will also be collected.
54476|NCT03758313|Other|CO2 measurements|Distal etCO2, tcCO2 and paCO2 values will be recorded simultaneously in ventilated preterm infants. We will measure etCO2 in a distal position using a double lumen tube connected to an external side-stream capnometer.
54477|NCT03758300|Other|Radiofrequency|See previous page
54478|NCT03758287|Drug|CT053PTSA|
54479|NCT03758287|Drug|Gefitinib|
54480|NCT03758274|Behavioral|CBT by Phone to Promote Treatment|Structured phone intervention to identify concerns about getting alcohol use disorder treatment and to work through those concerns using cognitive behavioral principles.
54481|NCT03758274|Other|Reading the Subject a Pamphlet on Obtaining Alcohol Use Disorder Treatment|The pamphlet was created by the National Institute on Alcohol Abuse and Alcoholism to describe evidence based treatments available for alcohol use disorder and how to obtain such treatment.
54482|NCT03758261|Drug|Paravertebral nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound Paravertebral Nerve Block will be performed.
54483|NCT03758261|Drug|Erector Spinae nerve block|The patient will be placed in a sitting position and the level of needle insertion will be marked corresponding to the level of surgical incision. With sterile technique an ultrasound erector spinae nerve block will be performed.
54484|NCT03758248|Genetic|CYP2C19|The CYP2C19 enzyme plays a vital role in the two bioactivation steps of clopidogrel leading to lower (CYP2C19*17 carriers) or higher (CYP2C19*2 carriers) risk of major adverse cardiovascular events.
54485|NCT03758235|Drug|Intradetrusor injections of botulin toxin A|Injections are performe in an outpatient basis, under local anesthesia in the endoscopic room.
54486|NCT03758222|Device|Mercury Expander System|Implantation and retrieval of the Mercury Expander System in the prostatic urethra to treat benign prostatic hyperplasia (BPH)
54487|NCT03758209|Procedure|Prehabilitation + ERAS|Prehabilitation will cover a range preoperative education and exercises (weekly) on diet, physical activity (daily walking), respiratory training (forced deep inspiration with spirometer device), as well as anxiolytic group psychotherapy.
54488|NCT03758209|Procedure|ERAS|Enhanced Recovery Program, including preoperative 4 weeks nutritional supplementation.
54489|NCT03758196|Device|Radiofrequency ablation instruments|Renal Sympathetic Denervation from the adventitia of renal artery
54490|NCT03758183|Procedure|total knee arthroplasty|
54491|NCT03758170|Drug|Dexamethasone|An intravenous bolus dose of dexamethasone given prior to surgery.
54492|NCT03758157|Diagnostic Test|welloStationX|welloStationX is an automated electronic thermometer using an infrared sensor of the surface of the forehead to measure human body skin temperature to screen for fever.
54493|NCT03758157|Diagnostic Test|SureTemp|SureTemp is an oral thermometer to measure human body skin temperature.
54494|NCT03758144|Drug|Rifaximin 200 MG|patients with type 2 diabetes and gut dysbiosis will be given rifaximin
54495|NCT03758131|Behavioral|Peer-enhanced Motivational Interviewing|"In the Peer-Enhanced Motivational Interviewing (PMI) condition, target clients and peers will receive separate one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change. With the peer of each PMI dyad, the therapist presents peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication skills they can use to influence the target client's substance use."
54496|NCT03758131|Behavioral|Motivational Interviewing|In the Motivational Interviewing (PMI) condition, target clients only will receive one-hour sessions of Motivational Interviewing (MI), an empirically-supported treatment that helps individuals work through ambivalence about making changes in substance use. MI is thought to work because it is a non-confrontational intervention where a therapist empathetically reviews substance use behaviors, listens empathetically, and reinforces any client statements indicating a desire to change.
54497|NCT03758131|Other|Waitlist Control|Dyads randomized to this intervention will have no contact with study personnel until 2 months after the PMI group has completed the PMI intervention. Then those in the Waitlist Control condition will receive the full PMI protocol.
54499|NCT03758105|Other|tDCS associated with usual care|"A tDCS cure will be given to the group tDCS, one week after their randomization.~This will be done in association with usual care: medication and psychotherapy Parameters: Anodal stimulation on dorso-lateral prefrontal cortex left, 2mA current.~Treatment will consist of 15 days with 30 minutes stimulation per day, 5 days a week for 3 weeks."
54500|NCT03758105|Other|Usual care|Medication and psychotherapy as prescribed in usual care
54501|NCT03758079|Drug|Doxepin|10 mg Doxepin for 4 weeks
54502|NCT03758079|Drug|Gabapentin|dose of 100mg after each hemodialysis session (increased as tolerated) for 4 weeks
54503|NCT03758066|Device|PlusCare|PlusCare is a mobile application designed to be used by youth and young adults with HIV and case managers.
54504|NCT03758053|Other|No intervention|No intervention
54505|NCT03758040|Other|Slips on Turns|Subjects will be administered a slip at 3 different times in the gait cycle for each of 3 different patch curvatures and 2 different legs for a total of 18 slip episodes. Slips will be delivered while walking along a straight path (infinite radius), or curved paths with radii 2, or 1 meters.
54506|NCT03758040|Other|Slips on Slopes|Slips will be administered at 3 different times in the gait cycle over sloped ground surface of no slope, ±5.0 and ±10.0 degrees slopes in the direction of walking, and 5.0 and 10.0 degrees perpendicular to the direction of walking. On slopes perpendicular to the direction of walking, slips will be administered to the uphill or downhill foot. A total of 27 slip episodes will be administered. Sloped walking surfaces will be generated with the CAREN system treadmill.
54507|NCT03758027|Behavioral|CARESS|"The goals of each component are as follows:~Communicate alternatively - a method to bring the brain back and remove the individual from his/her limbic system;~Release endorphins - a release for the internal stress created by the emotion; and~Self-soothe - a method of quelling and containing."
54508|NCT03758027|Behavioral|Isometric Exercise|5-minute protocol for cravings management and affect regulation
54509|NCT03758014|Drug|Chlorogenic acid for Injection|Chlorogenic acid (CHA) is a class 1 innovative small molecular natural drug, developed by Sichuan Jiuzhang Biological Science and Technology Co., Ltd. The mechanism of broad-spectrum antitumor activity is immunoregulation.
54510|NCT03758014|Drug|Lomustine|Lomustine (INN), abbreviated as CCNU (original brand name (formerly available) is CeeNU, now marketed as Gleostine), is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood-brain barrier. This property makes it ideal for treating brain tumors, which is its primary use.
54511|NCT03758001|Drug|IBI101|0.01 mg/kg; 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg; 15 mg/kg iv infusion day 1 of every 21 days
54512|NCT03758001|Drug|IBI101|1 mg/kg; 3 mg/kg; 6 mg/kg; 10 mg/kg iv infusion day 1 of every 21 days
54513|NCT03758001|Drug|Sintilimab|200mg iv infusion day 1 of every 21 days
54514|NCT03757988|Behavioral|Exercise Intervention- PACE-Life|Subjects will be provided with a Fitbit wristband and instructed how to use it. During the first group session, subjects will be taught how to use their heart rate (on the Fitbit) to determine how fast subjects should walk (to achieve the appropriate exercise dosage). Information on proper care, usage, and how to determine the appropriate heart rate from the watch, which will be used to guide the intensity of the walk will be provided to subjects and reviewed at each group session. For all clinic based group sessions, subjects will arrive at the STEP clinic to meet the entire group and leaders and be reminded of the HR that corresponds with the intensity of that group session. Next, the group will go outside and walk for 30 minutes.
54515|NCT03757975|Procedure|urethral length measure|measure of urethral length, distribution of questionnaires before and after operation
54516|NCT03757962|Other|Dietary intervention|Limiting dietary exposure to benzoic acid, sorbic acid, polysorbates and related food additives; limiting eating out to a maximum of 2 days per week.
54517|NCT03757949|Other|Laboratory Biomarker Analysis|Correlative studies
54518|NCT03757949|Dietary Supplement|Nutritional Intervention|Receive SIM PO
54519|NCT03757949|Other|Placebo|Given PO
54520|NCT03757949|Other|Quality-of-Life Assessment|Ancillary studies
54521|NCT03757949|Other|Questionnaire Administration|Ancillary studies
54522|NCT03757936|Drug|HLX04|Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
54523|NCT03757936|Drug|HLX10|Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
54524|NCT03757923|Drug|TAB METFORMIN|INSULIN SENSITIZING AGENTS
54525|NCT03757923|Drug|TAB PIOGLITAZONE|INSULIN SENSITIZING AGENT
54526|NCT03757910|Drug|18F-MK-6240|This radiotracer will be used to detect Tau.The injected activity will equal 5 millicuries (mCi).
54527|NCT03757910|Drug|11C-PIB|This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
54528|NCT03757897|Drug|Dexmedetomidine|The standard dosing of 1mcg/kg will be implemented over 10 minutes followed by a maintenance infusion of 0.2-1.0 titrated to a the target BIS (60-70) during the 20 minutes prior to MRI.
54529|NCT03757884|Behavioral|Mindfulness breathing exercise|Spire monitor instructed mindfulness breathing
54530|NCT03757884|Behavioral|Diagnostic Checklist|Checklist reminder for diagnosis
54531|NCT03757884|Behavioral|Noise cancelling headphones|Noise cancelling headphones
54532|NCT03757884|Behavioral|Privacy tablescreen|Privacy Tablescreen
54533|NCT03757884|Behavioral|Diagnostic assistance application|Diagnostic assistance application
54534|NCT03757871|Device|Laser stimulation|an acupuncture or placebo session will be performed 30 minutes before the fundus examination. This session will last 5 minutes.
54535|NCT03757858|Device|Thermotron RF-8|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week for a total of 10 times.
54536|NCT03757858|Biological|Adoptive cellular Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured cytokine-induced killer cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of CIK Immunotherapy . If the evaluation of the treatment is complete response, partial response or stable disease, additional cycles were eligible.
54537|NCT03757858|Drug|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks and assess the clinical outcome every 2 dosage of anti-PD-1 antibody treatment.
54538|NCT03757858|Drug|Chemotherapy|Patients will receive standard chemotherapy until disease progression, unacceptable toxicity or patient refusal.
54539|NCT03757845|Other|Mediterranean Diet|subjects will be asked to eat from a sub-menu items compliant with Mediterranean Diet
54540|NCT03757832|Device|Liver Imaging|The device will acquire thermoacoustic data while the ultrasound probe acquires ultrasound images, and an MR of the liver is acquired as a comparative modality.
54541|NCT03757819|Device|tDCS|Brain Stimulation
54542|NCT03757819|Device|SHAM|Placebo device
54543|NCT03757806|Other|Experimental group|"LiFE4D is an individualised programme, adapted to the participant's needs/preferences.~People with Dementia will receive assistance to increase their physical activity multiple times/day in their everyday tasks with the support/supervision of their caregivers.~The programme last for 12 weeks, with a lower face tracking over time with the health professional but replaced by caregivers. The intervention includes face-to-face sessions and phone calls. Face-to-face sessions aim to adapt physical activity to everyday tasks, increase tasks frequency and intensity, monitor progress, clarify doubts, motivate and manage expectations. Phone calls aim to monitor motivation/evolution and clarify doubts."
54544|NCT03757793|Device|FORE-SIGHT ELITE monitor|At end of surgery, one sensor of the FORE-SIGHT Elite monitor is placed on the DIEP flap or two sensors in case of bilateral DIEP flaps for monitoring perfusion and oxygen consumption in the free flap. A control sensor of the FORE-SIGHT Elite monitor placed on the abdomen where tissue is taken to perform the DIEP flap. This sensor reflects normal tissue oxygenation. Data obtained from the FORE-SIGHT Elite monitor will be compared to data obtained from physical examination, which is standard of care for flap monitoring.
54545|NCT03757780|Other|Questionaire|A questionaire will be made to pregnant ladies who take caffeine during pregnancy
54546|NCT03757767|Other|Fasting for 26-hours|"All research subjects will have to fast for 26 hours in total.~All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points."
54547|NCT03757754|Drug|HPPH 2.5 mg/m2|HPPH was administered as a single, 2.5 mg/m2, slow intravenous infusion over 1 hour , and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
54548|NCT03757754|Drug|HPPH 3 mg/m2|HPPH was administered as a single, 3 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
54549|NCT03757754|Drug|HPPH 3.5 mg/m2|HPPH was administered as a single, 3.5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
54550|NCT03757754|Drug|HPPH 4 mg/m2|HPPH was administered as a single, 4 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
54551|NCT03757754|Drug|HPPH 5 mg/m2|HPPH was administered as a single, 5 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
54552|NCT03757754|Drug|HPPH 6 mg/m2|HPPH was administered as a single, 6 mg/m2, slow intravenous infusion over 1 hour, and a fixed light dose of 150 J/cm delivered 48 hours after infusion of HPPH.
54553|NCT03757741|Diagnostic Test|Cardiac imaging tests|2D transthoracic echocardiography; Late gadolinium-enhancement cardiac magnetic resonance with the evaluation of pulmonary veins anatomy, atrial fibrosis, atrial volumes and the amount of epicardial fat will
54554|NCT03757741|Diagnostic Test|Venous blood samle collection|Venous blood sample collection 1 day prior to the ablation procedure: Serum levels of high sensitive C Reactive Protein, Matrix metalloproteases, Interleukin-6, and N-Terminal Pro-B-Type Natriuretic Peptide.
54555|NCT03757728|Procedure|Haemorrhoidectomy operations|for treatment of symptomatic 2 to 3 degree haemorrhoids
54556|NCT03757715|Drug|Bupivacaine|20 mL of 1.3% bupivacaine
54557|NCT03757715|Drug|Dexamethasone|2 mg dexamethasone
54558|NCT03757702|Other|Evaluation|Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
54559|NCT03757689|Drug|Pembrolizumab|Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
54560|NCT03757689|Procedure|Wide Excision and Sentinel Lymph Node (SLN) Biopsy|Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
54561|NCT03757676|Behavioral|No Play|Participants in this group were asked not to download or play Pokémon Go during the study period and were asked to simply continue with their normal daily activities. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
54562|NCT03757676|Behavioral|At Will Play|Participants in this group were asked to download Pokémon Go and play for at least 30 minutes initially, then play as much or as little as desired during the 4 week intervention period, with no specific instruction or goals for play. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
54563|NCT03757676|Behavioral|Goal Oriented Play|Participants in this group were asked to download and play Pokémon Go and achieve a minimum player level of 20 within the game during the study period. They were given materials that described game features and functions to show them how to play the game. There were no restrictions on which features to pursue within the game to achieve this goal nor on how long or how frequent their play sessions should be. Upon reaching their goal (Level 20), participants were encouraged to continue to play as much or as little as they desired. Participants were asked to wear the Fitbit device and use the GPS app on their mobile phones during the 6-week study period. Starting the fifth week, participants were prompted to complete five (5) brief daily surveys on their phones via the EMA app.
54863|NCT03755570|Diagnostic Test|Test of Premorbid Functioning|Cognitive Function Test (Questionnaire-based)
54564|NCT03757663|Behavioral|UV Counseling|Participants will self-report their knowledge and attitudes related to UV exposure. They will then wear a dosimeter for 3 weeks. After, the study team will counsel the participants on their UV levels and exposure, creating a personal plan and advice for avoiding sun exposure before letting the participants wear the dosimeter for an additional 3 weeks.
54565|NCT03757650|Drug|Bismuth Subsalicylate|omeprazole 2x1) + clarithromycin 2x500 mg + amoxicilline 2x1000 mg + Bismuth Subsalicylate 2x1
54566|NCT03757637|Other|NLSCP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in this groups will further receive either NLSCP (Exp-1). Patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). This group will receive a face-to-face education or counseling by trained research nurse.
54567|NCT03757637|Other|ICT supported HAP|Phase II is a 6-month three-group randomized controlled trial with 12 month follow-up of its effects. In addition to receive hospital routine case manager care, patients in the groups will further receive ICT supported HAP (Exp-2) intervention. For this groups, patients will be provided the same major education and counseling contents for the first two section of interventions through face-by-face by trained research nurses at time of (1) first intervention: one day before hospital discharge in post-operation, and (2) second intervention: first OPD visit (first week after hospital discharge). The group will receive the interactive mobile phone App.
54568|NCT03757624|Procedure|shrinkage|shrinkage of gastric specimen in %10 formol solution after Laparoscopic Sleeve Gastrectomy
54569|NCT03757611|Dietary Supplement|Tabetri capsule|1,000 mg/capsule (Taheebo extract 600 mg/day)
54570|NCT03757611|Dietary Supplement|Placebo capsule|1,000 mg/capsule
54571|NCT03757598|Other|ePartogram use|Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
54572|NCT03757585|Drug|Open-label Treatment with Omega-3 Fatty Acids + Inositol|Open-label Treatment with Omega-3 Fatty Acids + Inositol
54573|NCT03757585|Drug|Open-label Treatment with N-acetylcysteine|Open-label Treatment with acetylcysteine
54574|NCT03757572|Other|Alginate dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Alginate dressings with silver and high-G cellulose will be applied to the wound. The size of the dressings will be 3cm X 45cm and 1 cm cord will be used for filling the wound cavity. Dressings with perimetric adhesive layer from natural materials, will be also placed.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
54575|NCT03757572|Other|Simple gauze dressings|"The pilonidal cyst will be resected, with the use of a scalpel and then haemostasis will be performed with diathermy. Simple gauze dressings will be applied to the wound.~During wound care the wound will be irrigated with normal saline and betadine solution and finally without pressure the trauma will be dried."
54576|NCT03757559|Drug|Cebranopadol 100 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
54577|NCT03757559|Drug|Cebranopadol 400 micrograms|Tablets were taken under fasted conditions with non-carbonated water.
54578|NCT03757559|Drug|Hydromorphone hydrochloride 4 milligrams|Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
54579|NCT03757559|Drug|Placebo matching hydromorphone|Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
54580|NCT03757559|Drug|Placebo matching cebranopadol|Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
54581|NCT03757546|Other|observational|The aim of the study is to describe extra-pulmonary complications due to influenza virus and RSV in hospitalized patients from November 2018 to April 2019 and November 2019 to April 2020 in a French university hospital.
54582|NCT03757533|Behavioral|Health Coaching|10 phone calls with a trained health coach
54583|NCT03757533|Other|Surveys|Surveys to assess Behavioural and Psychosocial measures
54584|NCT03757520|Diagnostic Test|Pain Pressure Threshold|The pain pressure thresholds (PPTs) will be measured using an pressure algometer commander over potential trigger points (TrPs) on the body for upper fiber of trapezius, and sternocleidomastoid muscle.
54585|NCT03757520|Diagnostic Test|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected."
54586|NCT03757507|Device|MultiSpectral Optoacoustic Tomography|Multispectral Optoacoustic Tomography is a new emerging imaging technique which uses laser light to heat up molecules with a high pulsed laser. The molecules undergo thermal expansion and produces sound waves, which can be detected by special transducers. The device can pick up different signals in different wavelength to produce images with anatomic and biological information.
54587|NCT03757494|Device|Alpha Stim|Use of Alpha Stim Device
54588|NCT03757481|Other|no intervention|SF-36 questionnaire , veines QoL, Villalta score ,PembQoL
54589|NCT03757468|Device|orthodontic - maxillary expansion|After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
54590|NCT03757455|Procedure|ERAS protocol preoperative actions|"First appointment:~- Enlightenment on the benefits and objectives of the ERAS protocol~Call to the patient day before the surgery:~Discussing the course, benefits and goals of care in ERAS 4 dl PreOp drink before bedtime~Operation day:~Fluid intake allowed 2 hours before surgery 2 dl PreOP drink 2 h before cutting"
54591|NCT03757455|Procedure|ERAS protocol intraoperative actions|"Intraoperative:~Drains in the peripancreatic or perihepatic regions are not set unless the surgeon sees this particular reason The nasogastric tube is removed at the end of the surgery"
54864|NCT03755557|Drug|Rhinocort|Application of a nasal spray
54592|NCT03757455|Procedure|ERAS protocol postoperative actions|"Postoperatively:~Mobilization with nurses assisted Drinks allowed after 4h surgery~POP 1:~Drinking and normal food Removal of urinary catheter Intravenous liquids only if needed Mobilization Pain management by epidural cannula Discussion of the ERAS protocol Pancreatin capsules per os before eating~Postoperative day 2:~- Mobilization: As much as possible, autonomous movement~Postoperative day 3:~Ending epidural infusion cannula removal Mobilization as independently as possible~Pain relief: oxycodone/naloxone p.o. to keep mobilization possible:~Postoperative day 4:~Support and encouragement continues Pain management at a level that allows mobility"
54593|NCT03757429|Other|RS-virus infection|The intervention consists of lower respiratory tract infection due to RS-virus
54594|NCT03757416|Other|Data collection|If it has been determined that the patient will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome, the patient will be asked to participate in this data collection study.
54595|NCT03757403|Drug|RDD1609|RDD1609 to be applied on the perianal area BID
54596|NCT03757403|Drug|Mebendazole 100 MG|Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)
54597|NCT03757390|Drug|Exforge® tab 5/160mg, Crestor® tab 10mg|co-administration of Amlodipine 5mg/Valsartan 160mg(combination drug) and Rosuvastation 10mg
54598|NCT03757390|Drug|CJ-30060 5/160/10mg|Fixed-dose combination drug containing Amlodipine 5mg and Valsartan 160mg and Rosuvastatin 10mg
54599|NCT03757377|Device|BackBeat Moderato System|Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
54600|NCT03757377|Device|BackBeat Moderato Sytsem|Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
54601|NCT03757364|Drug|Methotrexate|Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
54602|NCT03757351|Drug|DNL747|DNL747
54603|NCT03757351|Drug|Placebo|Placebo
54604|NCT03757338|Drug|Fingolimod Reference Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the reference product produced by Novartis Pharmaceutical with the proposed test product manufactured by Asofarma S.A.I. y C. in healthy volunteers, under fasted conditions.
54605|NCT03757338|Drug|Fingolimod Test Formulation|To compare the rate and extent of absorption for Fingolimod when administered as a single oral dose of 3 x 0.5 mg capsules of the proposed test product manufactured by Asofarma S.A.I. y C. with the reference product produced by Novartis Pharmaceutical in healthy volunteers, under fasted conditions.
54606|NCT03757325|Drug|DNL747|DNL747
54607|NCT03757325|Drug|Placebo|Placebo
54608|NCT03757312|Diagnostic Test|Ultrasound|Ocular ultrasound to measure optic nerve sheath diameter (ONSD).
54609|NCT03757299|Diagnostic Test|HPV Test|Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
54610|NCT03757286|Procedure|FSF with CAD\CAM customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla and scapula. The CT scan will be sent to the modeling company that produce 3D autoclavable models and cutting guides to be used during resection and scapular harvesting as well as a model of the final reconstructed maxilla.~surgery will performed by two surgical teams one for tumor resection and the other harvesting the flap.~access to the maxilla was obtained and the cutting guides were secured in the planned position; the cuts were completed. The scapular guides were secured to the harvested scapula to replicate the cuts that were planned previously.~The scapula and plate will be fixed and pedicle anastomosis is performed. the operation then completed with soft tissue reconstruction."
54611|NCT03757286|Procedure|FSF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the patient's maxilla .~The C.T scan will be sent to the modeling company for planning three-dimensional model of the maxilla. autoclavable model will be prepared to be used during the workflow for plate reshaping to conforme the prices position of the maxilla.~surgery will performed in a single step by two surgical teams, one for cervicofacial resection and the other for harvesting the flap.~Resection-reconstruction then performed in aconventional surgical manner with microvascular anastomosis. finally the operation will be completed with soft tissue reconstruction as needed."
54612|NCT03757273|Procedure|FFF with CAD/CAM customized cutting guide|This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton and lower legs. the CT scan will be sent to the modeling company for producing autoclavable 3D models and cutting guides of the mandible and fibula to be used during the workflow as well as a model of the final reconstructed mandible. Surgery will be performed by two surgical teams, one for cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, osteotomy guides secured; cuts then accomplished as planned virtually. fibular flap is harvested and cutting guides secured to replicate osteotomies and reshaping as planned to conform with remaining mandible. fixation and pedicle anastomosis is performed. Finally, the operation completed with soft tissue reconstruction.
54613|NCT03757273|Procedure|FFF without customized cutting guide|"This began with the acquisition of a high-resolution CT scan of the craniofacial skeleton. the C.T scan will be sent to the modeling company for planning three-dimensional model of the mandible. autoclavable model will be prepared for mandible to be used during the workflow for plate reshaping and positioning to conform with the remaining mandible.~Surgery will be performed by two surgical teams, one in charge of cervicofacial resection and the other harvesting the flap. access to the mandible is obtained, and resection/ reconstruction then performed in conventional surgical manner with microvascular anastomosis. Finally, the operation will be completed with soft tissue reconstruction."
54614|NCT03757260|Device|Antimicrobial photodynamic therapy|Antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is methylene blue. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is illuminated for 60 seconds to activate the agent using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
54615|NCT03757260|Device|Placebo of photodynamic therapy|The placebo of the antimicrobial photodynamic therapy is carried out in the residual pockets using the Periowave system. The photosensitizing agent is saline solution. Approximately 0.2 mL of the solution is applied over 60 seconds to each pocket with a blunt-ended side-port irrigator. The site is not illuminated (falsely activated) for 60 seconds using a disposable, light-diffusing tip that is introduced into the pocket via a diode laser (wavelength = 675 nm, 160 mW of output power).
54616|NCT03757234|Drug|Omadacycline|iv solution/po tablets
54617|NCT03757234|Drug|Levofloxacin|iv solution/po tablets
54618|NCT03757221|Combination Product|Ixazomib and Daratumumab|"Daratumumab will be administrated every week for the first 2 cycles. For cycle 3 to 6, it will be administrated every two weeks at day 1 and day 15. From cycle 7 until progression Daratumumab will be administrated every 4 weeks.~Ixazomib will be administrated every week three weeks on one week off at D1, D8 and D15 on a 28-d cycle basis.~Dexamethasone will not be given except one series of 4 days of dexamethasone, 20 mg/day or a maximum of 80 mg, for emergencies and complications at initiation of treatment."
54619|NCT03757208|Dietary Supplement|carbohydrate rich drink|The carbohydrate rich drink (CHD) group received oral carbohydrate (200 ml) 2-3 h before surgery,
54620|NCT03757195|Procedure|Augmentation|combination product
54621|NCT03757182|Other|Wearable activity monitor|Continuous monitoring of physical activity including step counts, sleep, heart rate, with consumer-based wearable activity monitor (Fitbit Charge HR)
54622|NCT03757169|Other|Hand grip isometric contraction|The patients at the Hand Grip group will perform 12 weeks of hand grip exercises, three times/week for 16 minutes with time to rest.
54623|NCT03757169|Other|Control|The patients will receive verbal orientations about the OSA and the arterial hypertension.
54624|NCT03757156|Other|Withdrawal of aspirin|People who are taking aspirin stop to taking aspirin.
54625|NCT03757143|Drug|Povidone-Iodine-Alcohol|Povidone-Iodine-Alcohol will be used to disinfect the skin
54626|NCT03757143|Drug|Chlorhexidine-Alcohol|Chlorhexidine-Alcohol will be used to disinfect the skin
54627|NCT03757143|Device|Insyte Autoguard BC Winged|Pose of Insyte Autoguard BC Winged
54628|NCT03757143|Device|Nexiva single port catheter, MaxZero needless connector, PureHub Deinfecting Caps and Posiflush prefilled saline syringes|Pose of Nexiva single port catheter
54629|NCT03757130|Drug|AMG 598|AMG 598 dose
54630|NCT03757130|Drug|Placebo|Calculated volume to match experimental drug.
54631|NCT03757130|Drug|Liraglutide|Daily SC injection of liraglutide
54632|NCT03757117|Drug|Feminizing hormone therapy|"Estradiol valerate was initiated at 2 mg PO daily and increased to 4 mg after 4 to 12 weeks~Antiandrogen therapy with spironolactone started at a dose of 50 mg PO daily and increased every 4 weeks to 200 mg daily"
54633|NCT03757117|Behavioral|Peer navigation|Transgender women community peer navigation
54634|NCT03757104|Behavioral|micro-incentive|Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test
54635|NCT03757104|Behavioral|EPIC-HIV|Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
54636|NCT03757104|Behavioral|micro-incentive and EPIC-HIV|"micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.~EPIC-HIV 1:~Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care."
54637|NCT03757091|Device|Laryngoscopy|Undergo video laryngoscopy
54638|NCT03757091|Procedure|Tracheal Intubation|Undergo flexible scope intubation
54639|NCT03757078|Drug|Relief Pro cream|Relief Pro cream:1.0 mg/gm Fluocortolone + 20 mg/gm Lidocaine; Administration according to clinical practice.
54640|NCT03757078|Drug|Relief Pro rectal suppositories|Relief Pro rectal suppositories: 1.0 mg Fluocortolone + 40 mg Lidocaine; Administration according to clinical practice
54641|NCT03757052|Diagnostic Test|Penicillin Skin Testing|Skin test protocol: prick skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 100 mg/mL, amoxicillin 71 mg/mL, histamine/positive control, diluent/negative control), then intradermal skin tests (penicilloyl-polylysine 0.000012 mol/0.05 mL, penicillin G 10,000 U/mL, penoate 10,000 U/mL, ampicillin 1 mg/mL, diluent/negative control), administered as an intradermal injection of a standardized volume of 0.02 mL. Graded oral challenge with amoxicillin : a first dose of 50 mg of amoxicillin; 20-minute observation period; in the absence of any objective symptom of an allergic reaction, a second dose of amoxicillin of 450 mg; final observation period of 60 minutes, under nurse and medical supervision.
54642|NCT03757039|Device|Multifocal soft contact lenses|Commercially available contact lenses
54643|NCT03757039|Other|Progressive addition lens spectacles|Per subject's habitual prescription
54644|NCT03757026|Other|Conventional Physical Therapy|"20-22 participants randomly assigned to receive 10 sessions of balance training. Conventional balance training group (PT) will receive individualized standard of care physical therapy with the goal of improving balance and mobility during sessions 3 through 12. The only instructions to the PT are that the focus of the course of care should be on balance and mobility and that there should be 10 sessions total. The first visit will include an initial evaluation and limited treatment. While the remaining 9 sessions will consist of 45 minutes of PT treatment."
54685|NCT03756779|Other|Dietary intervention|Dietary intervention with dietary modification of fat intake.
54686|NCT03756766|Diagnostic Test|RSV point of care testing|Patients will have 2 nasopharyngeal swabs, a nasal swab, a stool and urine taken at baseline/ enrolment and the RSV positive ARTI group will have samples repeated at 6-8weeks.
54687|NCT03756753|Diagnostic Test|Results available to provider|Results of point of care testing are given to provider
54645|NCT03757026|Other|Slip Training|20-22 participants randomly assigned to 1 session of slip training and 9 sessions of accompanied walking. Reactive slip training group (Slip) will complete a standing slip session using the current protocol of scaling slip distance and force to each individual and modulating the slip intensity across the session based on subject responses. Initial perturbation intensity (percent body weight and slip distance) will be based on the participant's miniBEST score and each subsequent perturbation intensity will be determined based on their response to the previous perturbations. The remaining nine interventional sessions will consist of accompanied walking for up to 45 minutes. Participants will walk at a comfortable pace while accompanied by a researcher around Cleveland State.
54646|NCT03757026|Other|Harnessed gaming|20-22 participants randomly assigned to 10 sessions of harnessed gaming. Multidirectional harness group (MHG) will use a harness with the multidirectional OASUS frame and play selected Kinect™ active video games with varied balance demands, while standing on multiple balance training surfaces (e.g., solid floor, rocker board, foam, slider platform). Participants will wear the fall-arresting harness in the OASUS system for all game play. Motion data will be collected during gaming for Sessions 2, 6, and 10. Each game/surface will be played for about 5 to 6 minutes for 4 game/surface conditions per session. All participants will progress with the prescribed sequence of games and surfaces, progressing based on their rating of the previous three bouts of play.
54647|NCT03757013|Drug|Apremilast|Apremilast
54648|NCT03757000|Drug|YY-20394|YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.
54649|NCT03756987|Drug|Ropivacaine Injection|Ropivacaine will be injected in the erector spinae plane
54650|NCT03756987|Drug|Normal saline|Normal saline will be injected in the erector spinae plane.
54651|NCT03756974|Drug|BX-1|BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.
54652|NCT03756974|Drug|Placebo|Placebo of BX-1, oral solution
54653|NCT03756961|Drug|Dexmedetomidine|The intervention group will obtain the pharmacological treatment during both perioperative. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
54654|NCT03756961|Behavioral|Person-centred care (PCC)|The intervention tests non-pharmacological interventions compared to conventional treatment, supplemented by an evidenced-based Person-centred care PCC approach throughout the continuum of the perioperative and until 4 weeks after discharge
54655|NCT03756961|Drug|Esketamine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment:
54656|NCT03756961|Drug|Lidocaine|The intervention group will obtain the pharmacological treatment perioperatively. Pharmacological treatment in the intervention group differs solely from the patients in the control group by replacing opioids with the following non-opioid treatment.
54657|NCT03756961|Device|Transcutaneous Nerve Stimulation (TENS)|The intervention group will obtain non-pharmacological treatment by TENS during the entire hospital stay (both perioperative and post-operative) until discharge.
54658|NCT03756961|Drug|Remifentanil|The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
54659|NCT03756961|Drug|Desflurane|The patient receives general anesthesia with Desflurane as the routine volatile anesthetic during general anesthesia
54660|NCT03756961|Drug|Propofol|The patient receives general anesthesia with Propofol as the routine induction anaesthetic during general anesthesia
54661|NCT03756961|Drug|Oxycodone|The control group receives Oxycodone as the routine pain management drug post-operative.
54662|NCT03756948|Other|Usual Care|Treatment of Coagulation Disorders Using Standard Coagulation Tests and Blood Components
54663|NCT03756948|Other|Thromboelastometry-Guided Therapy with Synthetic Factor Concentrates|Thromboelastometry-Guided Treatment of Coagulation Disorders Using Synthetic Factor Concentrates
54664|NCT03756935|Procedure|All monitoring|Dicpleth and PI are obtained a posteriori from the PPG waveform reconstruction and blindly from ABP values. Dicpleth is defined as the ratio of the height of the dicrotic notch (from nadir point of the complex to the notch) to the height of the systolic peak (from nadir point of the complex to the pic), measured at end-expiratory time (average of 3 consecutive complex). PI is calculated as the ratio of the pulsatile component of the PPG signal and the continuous component.
54665|NCT03756922|Drug|FDL169|CFTR corrector
54666|NCT03756922|Drug|FDL176|CFTR potentiator
54667|NCT03756896|Drug|Carfilzomib|Given IV
54668|NCT03756896|Drug|Dexamethasone|Given PO
54669|NCT03756896|Drug|Pomalidomide|Given PO
54670|NCT03756883|Drug|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
54671|NCT03756883|Drug|Fluticasone Propionate and Salmeterol Inhalation Powder|100/50 mcg per actuation
54672|NCT03756883|Drug|Placebo Inhalation Powder|No active content
54673|NCT03756870|Procedure|Percutaneous coronary intervention (PCI)|A percutaneous coronary intervention of the chronic total occlusion with a drug-eluting stent.
54674|NCT03756857|Procedure|Afterload Transfer|"Embryo transfer is done by using afterload transfer method"
54675|NCT03756857|Procedure|Trial followed by transfer|"Embryo transfer is done by using afterload transfer method"
54676|NCT03756844|Behavioral|Just Right Challenge Food Club|Systematic desensitization, positive reinforcement and escape extinction at a level of just right challenge.
54677|NCT03756831|Diagnostic Test|Core Stability Assessment|Core Stability Assessment will be consisted of bilateral static balance with open and close eye, right foot balance test, and dynamic balance test.
54678|NCT03756818|Drug|Paclitaxel|Given IV
54679|NCT03756818|Other|Pharmacokinetic Study|Correlative studies
54680|NCT03756818|Drug|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
54681|NCT03756805|Device|upper airway stimulation|One group of patients with UAS
54688|NCT03756740|Other|telerehabilitation and physical therapy|subject will receive the LBP exercises as a video to his/her mobile or e-mail
54689|NCT03756740|Other|control|subjects will receive the LBP exercises as printed pictures on paper
54690|NCT03756727|Drug|Ascorbic Acid|Patients in Ascorbic acid group received 2g of intravenous Ascorbic acid at the night before surgery, during the surgery and five days after surgery (once a day).
54691|NCT03756727|Drug|Saline|Patients in Control Comparator group received saline 10ml at the night before surgery, during the surgery and five days after surgery (once a day).
54692|NCT03756701|Behavioral|Mind body skills|"2 hour skill sessions that focus on mindfulness: The topics for each session is based upon the Centers for Mind Body Medicine model. Both groups will follow this same weekly topic schedule.~Introduction and Drawings~Autogenic Training and Biofeedback~Guided Imagery~Meditation~Mobilizing, Transforming, and Celebrating Emotion~Genograms part 1~Genograms part 2~Mindful Eating and Healthy Nutrition~Spirituality~Closing Drawings and Ritual"
54693|NCT03756688|Device|RestoreX PTT - 6 months|Penile traction therapy in straight position for all 6 months.
54694|NCT03756688|Device|RestoreX PTT - 3 months|Penile traction therapy in straight position for first phase (3 months)
54695|NCT03756675|Other|haplotype PBSCT|"haplotype peripheral blood stem cell transplantation (PBSCT) of GIAC system"
54696|NCT03756662|Device|ARGOS-SC suprachoroidal pressure sensor|The sensor device is intended to be permanently implanted suprachoroidal in the human eye during non-penetrating glaucoma surgery.
54697|NCT03756649|Procedure|Blood Draw|50 ml will be collected
54698|NCT03756649|Procedure|Urine Collection|50 ml will be collected
54699|NCT03756649|Procedure|Stool Collection|Three 25 ml tubes will be collected
54700|NCT03756636|Procedure|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"|"Underwater mucosectomy with submucosal injection of viscous solution -SIC 8000 (EleviewTM)"
54701|NCT03756623|Drug|Metformin powder|0.5g of Metformin powder administered three times a day orally before meal
54702|NCT03756623|Drug|Probiotics powder|0.5g of Probiotics powder administered three times a day orally before meal
54703|NCT03756623|Other|Placebo powder|0.5g of Placebo powder administered three times a day orally before meal
54704|NCT03756610|Device|Active tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.
54705|NCT03756610|Device|Sham tACS|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
54706|NCT03756610|Device|Active boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.
54707|NCT03756610|Device|Sham boosting|Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
54708|NCT03756597|Device|ReCIVA|The ReCIVA breath sampler contains a CO2 and pressure sensor, which allows the operator to monitor the breath sampling procedure and patient comfort. Both the operator and the patient can pause or abort the breath sampling procedure within seconds by removing the mask. The time investment required from patients is approximately 15 minutes for consenting and medical history and 10 minutes per breath collection.
54709|NCT03756597|Device|CASPER|Minimizes contamination of breath samples by external VOCs Removes need for clean air supply line
54710|NCT03756584|Device|Theta-burst stimulation|iTBS comprises 3-pulse 50-Hz bursts, applied every 200 ms (at 5 Hz) as described previously (Huang, Edwards et al. 2005) and consists of 2-second trains with an inter-train-interval of 8 seconds. We will repeat trains (30 pulses; 10 bursts) for 20 times to reach a total number of 600 pulses per session (3x10x20)
54711|NCT03756571|Other|Ankle Foot Orthoses-Footwear Combination|This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
54712|NCT03756571|Other|Traditional Solid Ankle AFO (TSAFO)|This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
54713|NCT03756558|Device|Cross-Seal System|Use of the Cross-Seal system to close the femoral arteriotomy
54714|NCT03756519|Behavioral|Exercise|A standardized exercise program tailored to the individual based on their directional preferences and current functional abilities.
54715|NCT03756519|Behavioral|Advice to stay active and engaged in usual activities.|Participants will be advised that staying physically active and continuing to participate in usual activities improves recovery. This verbal advice will be reinforced with a written handout.
54716|NCT03756519|Behavioral|Advice on use of ice or heat|Participants will be advised on the appropriate use of ice or heat to manage pain. This verbal advice will be reinforced with a written handout.
54717|NCT03756519|Other|Advise regarding use of medications|Participants will receive education regarding the use of non-steroidal anti-inflammatory medications (NSAIDs) for pain relief, if needed and if the patient is appropriate for NSAIDs. Information regarding specific recommended doses, potential benefit and risk will be discussed.
54816|NCT03755804|Drug|Vinblastine|Given intravenously (IV)
54817|NCT03755804|Drug|Prednisone|Given orally (PO)
54718|NCT03756506|Device|DuraDerm|DuraDerm® is a 510K FDA cleared medical device indicated for providing a covering over minor wounds and scrapes that are clean and dry. The microbicidal liquid solution consists of organic polymers . The unique formulation eradicates any organisms (bacteria, fungi, viruses) it comes in contact with. This is a result of the solvent's activity against an infinite number of organisms After eradication is complete, the solvent then transitions into a clear, elastomeric, non-odorous film for covering disrupted tissue. The film protects the wound against entry of water, dirt, and germs. The film is elastomeric and protects in difficult regions where flexing, bending and creasing skin occurs. The clear film forms in less than a minute.6 DuraDerm® should not be used to the treat deep infected wounds. DuraDerm® can be used to protect disrupted skin surface of wounds that are clean and dry.
54719|NCT03756493|Procedure|Periodontal Surgery with PRF+ABG|Patients will be treated by periodontal surgical flaps with the addition of PRF+ Autologous Bone Graft filling material.
54720|NCT03756493|Procedure|Periodontal Surgery with ABG|Patients will be treated by periodontal surgical flaps with the addition of Autologous Bone Graft filling material.
54721|NCT03756493|Procedure|Periodontal Surgery OFD|Patients will be treated by Open Flap Debridement without use of filling material.
54722|NCT03756467|Behavioral|Girl Empower Program|Girl Empower (GE) encourages adolescent girls living in rural areas of Nimba County, Liberia to partake in weekly mentored community-based workshops on life skills, selfcare, and financial literacy.
54723|NCT03756454|Biological|Bezlotoxumab|Patients receiving Bezlotoxumab post-operatively.
54724|NCT03756454|Other|Normal Saline|Placebo
54725|NCT03756441|Behavioral|Mindfulness meditation|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
54726|NCT03756441|Behavioral|Psychotherapy group|Caregivers will learn the technique of group problem solving
54727|NCT03756428|Procedure|Deep dry needling in tibialis posterior|The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
54728|NCT03756428|Procedure|Sham technique in tibialis posterior|The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
54729|NCT03756415|Device|"DiMax Zero Total face mask R,"|a non-CO2 rebreathing device included directly in the full face mask
54730|NCT03756415|Device|traditional face mask|a traditional mask without a non-CO2 rebreathing device included directly in the full face mask
54731|NCT03756389|Drug|BMX-010|Safety and efficacy of BMX-010 in topical treatment of rosacea.
54732|NCT03756363|Procedure|Non-solvent|Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
54733|NCT03756363|Procedure|Solvent|Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
54734|NCT03756350|Device|1060nm diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
54735|NCT03756337|Device|Neuro 1 & Neuro 2|participant common fitting map used for tests
54736|NCT03756337|Device|Neuro 2 & Neuro 1|participant common fitting map used for tests
54737|NCT03756324|Drug|CHPM (Chinese Herbal Patent Medicine )|Pugongying (Herba Taraxaci) granules is named as Pugongying Granules in China and produced by Kunming pharmaceutical factory co. LTD. The form is granules, and the participants will take the medicine after dissolved as 15g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
54738|NCT03756324|Drug|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 3 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
54739|NCT03756324|Behavioral|Education|Doctors will give suggestions and the medical orders to all participants, including dietary, emotional regulation and the knowledge of breast-feeding.
54740|NCT03756324|Drug|Antibiotics Cefdinir Capsules|Cefdinir Capsules is also named as Cefdinir and produced by Astellas Pharma Inc. The form is capsule, and participants will take orally the capsules with water as 0.1g/tid for 2 days, and the investigators will follow them up for 7 days when the participants are stopped administrating.
54741|NCT03756311|Drug|NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension|
54742|NCT03756298|Drug|Atezolizumab|Atezolizumab and capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with Residual Invasive Cancer after Neoadjuvant Chemotherapy.
54743|NCT03756298|Drug|Capecitabine|Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with Residual Invasive Cancer after Neoadjuvant Chemotherapy.
54744|NCT03756285|Drug|AZD4831|AZD4831 tablet taken orally for 90 days.
54745|NCT03756285|Drug|Placebo|Placebo tablet taken orally for 90 days.
54746|NCT03756272|Procedure|Bupivacaine block|stellate ganglion bupivacaine injection
54747|NCT03756272|Procedure|Placebo ganglion block|stellate ganglion sodium chloride injection
54818|NCT03755804|Drug|Filgrastim|Given subcutaneously (SQ) or IV
54819|NCT03755804|Drug|Brentuximab Vedotin|Given intravenously (IV)
54820|NCT03755804|Drug|Cyclophosphamide|Given intravenously (IV)
54821|NCT03755804|Drug|DTIC|Given intravenously (IV)
54748|NCT03756259|Behavioral|Mobile Health (mHealth) for Pneumonia|Audiovisual mobile based application will be used to counsel caregivers of children under five on pneumonia and its prevention. This will be coupled with text and voice message dissemination to the cell phones of caregivers and active pneumonia case finding by the LHWs which will be managed according to severity.
54749|NCT03756246|Biological|Influenza Vaccine|The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.
54750|NCT03756233|Drug|Remifentanil|Remifentanil is a potent, short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anesthetic.
54751|NCT03756220|Drug|Combination therapy of vitamin C and thiamine|Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days
54752|NCT03756220|Drug|Normal saline solution|Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days
54753|NCT03756207|Procedure|multidisciplinary bladder-preservation therapy|Maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy
54754|NCT03756194|Device|Socially-assistive Pepper robot with a CARESSES cultural competence solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. The robot will be culturally aware i.e., it will be aware of the participants' cultural background prior to the testing commencing. As such, it will pre-load the appropriate CKB and apply this during its time with the participants. During the next two sessions, the robot will interact and provide culturally-competent assistance, however, it will not learn and adjust to the participants' individual cultural values and preferences.~Week 2. The participants will again utilize the robot for three days, but it now will learn from the responses it receives from them, consequently interacting in a culture-specific personalised way."
54755|NCT03756194|Device|Socially-assistive control Pepper robot with an alternative CARESSES solution|"Week 1. On the first day, training will be provided to the participants enabling them to familiarise themselves with the robot's functionalities. During the next two sessions, the CARESSES control robot will not be culturally aware: it will pre-load a generic and more limited CKB that is not tailored for anyone's cultural profile. It will also not learn and adjust to the participants' values and preferences.~Week 2. Participants will again utilize the robot for three days, but the CARESSES control robot will now be configured to be able to learn and adapt to the individual's particular profile. This robot's learning will not include propagation: improving its cultural knowledge base in one area will not also automatically lead to knowledge improvements in other related areas. This robot will possess the same full suite of functions as the CARESSES robot although will be less likely to offer these in a culturally appropriate way."
54756|NCT03756181|Behavioral|Five-week MSC program (MSC5wk)|This program adaptation will consist of conducted meditative practices, discussions, and background information within a group setting of no more than 25 students per group. The facilitator may discuss the student's experience and encourage group sharing within the course of the session. These discussions will reinforce the guiding principles of mindfulness meditation. There will also be sessions dedicated to incorporating or mindfulness in daily life, with more detailed instructions, as well as encouraging a 30- minute daily home practice.
54757|NCT03756168|Device|1060nm Diode laser|Non-invasive medical aesthetic device designed for body contouring. The device is comprised of a console, four 1060nm diode laser applicators which are 60x60 mm in size. There is a belt included with the system to allow for the secure application of the applicators to the treatment area.
54758|NCT03756155|Procedure|isometric intervention|The research participants will perform isometric repetitions against the hand held dynamometer
54759|NCT03756142|Diagnostic Test|Motion Analysis|Analysis of orthostatic posture, initiation of walking and walking by a motion analysis system
54760|NCT03756129|Drug|MIJ821|Different dosages and different regimen for MIJ821
54761|NCT03756129|Drug|Placebo|Infusion
54762|NCT03756129|Drug|Ketamine|Infusion
54763|NCT03756116|Procedure|Epinephrine sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla before the withdrawal of endoscope.
54764|NCT03756116|Procedure|Saline sprayed on the papilla|Patients received sublingual Nitroglycerin will receive 20 ml of normal saline sprayed on the duodenal papilla before the withdrawal of endoscope.
54765|NCT03756103|Drug|SPH3127 tablet Dose 1|Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
54766|NCT03756103|Drug|SPH3127 tablet Dose 2|Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
54767|NCT03756103|Drug|SPH3127 tablet Dose 3|Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
54768|NCT03756103|Drug|SPH3127 tablet Placebo|Oral SPH3127 tablet placebo, once daily for 8 weeks.
54769|NCT03756090|Drug|Palbociclib|Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week [28 days] cycle.
54770|NCT03756090|Drug|Placebo oral capsule|Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week [28 days] cycle.
54771|NCT03756090|Drug|Epirubicin|Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
54772|NCT03756090|Drug|Cyclophosphamide|Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
54773|NCT03756090|Drug|Paclitaxel|Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
54774|NCT03756077|Diagnostic Test|68Ga-PSMA-11 and/or 18F-FDG PET/MR, PET/CT|0.05-0.06 mCi per kilogram bodyweight of 68Ga-PSMA, 0.1-0.15 mCi per kilogram bodyweight of 18F-FDG will be injected intravenously prior to imaging
54775|NCT03756064|Drug|Pyrotinib|Pyrotinib: 400mg orally daily
54776|NCT03756064|Drug|Trastuzumab|Trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles;
54777|NCT03756064|Drug|Docetaxel|Docetaxel: 75mg/m2 for a total of 6 cycles
54778|NCT03756064|Drug|Carboplatin|Carboplatin: AUC=5 for a total of 6 cycles
54779|NCT03756064|Drug|Placebo Oral Tablet|Placebo Oral Tablet: 400mg orally daily
54862|NCT03755570|Diagnostic Test|Trail Making Test Part A and B|Cognitive Function Test (Questionnaire-based)
54865|NCT03755557|Drug|Budesolv|Application of a nasal spray
54780|NCT03756051|Other|Prospective Longitudinal Data|We will prospectively follow the cohort using electronic medical record to document the hepatocellular carcinoma screening process and characterize physical and financial harms related to positive or indeterminate screening results and burden of inappropriate screening. Patients are anticipated to undergo hepatocellular carcinoma screening every 6-12 months, so each patient will have ~4-8 screening encounters over the study duration. We will use manual chart review to determine intent of ultrasound exams (screening vs. diagnostic) and test results. Receipt of follow-up tests after positive or indeterminate screening results will be identified through electronic medical record extraction using Current Procedural Terminology (CPT) codes for CT, MRI, and biopsy.
54781|NCT03756051|Other|Surveys and Semi-structured Interviews|"We will use surveys and semi-structured interviews to characterize psychological harms after positive or indeterminate screening tests. Patient surveys will include patient-reported scales to measure psychosocial factors at three times points: baseline, 1 month after screening result, and 4 months after screening result. Semi-structured interviews will be conducted via telephone to explore patient attitudes toward risk perception, test follow-up, competing demands, and downstream harms, particularly financial issues (e.g., out-of-pocket costs, access to insurance, and juggling hepatocellular carcinoma screening process completion with competing demands-work and family)."
54782|NCT03756038|Drug|Placebos|In this study, patients will receive oral placebo, an inactive solution that looks like the study drug, but contains no active ingredients
54783|NCT03756038|Drug|Lorazepam|The purpose of this study is to determine whether a single low dose of Lorazepam/Ativan (1mg) can relieve pain and reduce negative mood in the emergency department and for 2 weeks after emergency department treatment.
54784|NCT03756025|Procedure|Atraumatic Restorative Treatment (ART)|The atraumatic restorations were performed in the dental office by a single operator trained in the ART Technique [20], who received the restorative material already prepared by a trained auxiliary, ensuring blinding of the study. The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin spoons, with subsequent conditioning of the cavity with a polyacrylic acid solution at 11.5% (DFL) applied with a microbrush for 10 seconds. Immediately after, the cavity was washed and dried with cotton balls. In this step, according to the randomization, the respective GIC was inserted and subsequent digital compression was performed for 30 seconds. After occlusal adjustment, the ARTs were protected with finish gloss Alfa Bond® (DFL).
54785|NCT03756012|Device|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
54786|NCT03755999|Other|The premature infant oral motor intervention (PIOMI)|The premature infant oral motor intervention (PIOMI) is an oral motor program that provides assisted movement to activate muscle contraction and provides movement against resistance to build strength in the areas of the mouth necessary for feeding. It is designed to increase the maturation of neural structures, improving their ability to suck and swallow.
54787|NCT03755986|Device|ATOMO Diagnostic Test|The ATOMO diagnostic test device is the only intervention used in this study.
54788|NCT03755973|Drug|CFA|Long-acting exogenous ovarian stimulation
54789|NCT03755973|Drug|rFSH|Daily rFSH
54790|NCT03755973|Procedure|Fixed daily rFSH dosing protocol of 200 IU|The dose of daily rFSH is fixed at 200 IU
54791|NCT03755973|Procedure|Step-down daily rFSH dose|The dose of daily rFSH is progressively reduced
54792|NCT03755960|Procedure|acupuncture|semistandardized selection of acupuncture points according to the clinical presentation of diabetic peripheral neuropathy (DPN) symptoms; 12 treatments over 8 weeks
54793|NCT03755960|Drug|routine care|pharmacological routine care (antidepressants, anticonvulsants, opioids, nonsteroidal antiinflammatory drugs)
54794|NCT03755947|Drug|Ibrutinib|Ibrutinib Oral Capsule [Imbruvica] Tablets 120 mg. Oral. 420mg/day, day 1 to 28, every 28 days. 3 cycles.
54795|NCT03755947|Drug|Obinutuzumab|Obinutuzumab Injection. Intravenous Solution [Gazyva] Parenteral. 1000 mg, day 1 of every cycle, every 28 days. 6 cycles.
54796|NCT03755947|Drug|Venetoclax|Venetoclax Oral Tablets [Venclexta] Tablets 100 mg. Oral. 400 mg/day. Day 1 to 28, every 28 days. 12 cycles.
54797|NCT03755934|Biological|MEDI7352|MEDI7352
54798|NCT03755934|Other|Placebo|Placebo
54799|NCT03755921|Other|bried and intensive therapy|Speech Therapy Exercises
54800|NCT03755908|Device|Forced oscillation technique (FOT)|FOT will be measured using the TremoFlo C-100 Airwave Oscillometry System (Thorasys , Montreal, Quebec, Canada). R5, R20, R5-20 (resistances in the reported frequency), X5 (reactance in 5hz) and Ax5 (reactance area in 5hz) will be reported.
54801|NCT03755895|Other|formal hypnosis|patients will have brachytherapy detachment under Kalinox and formal hypnosis
54802|NCT03755895|Drug|Kalinox|patients will have brachytherapy detachment under Kalinox
54803|NCT03755882|Device|ACUVUE® DEFINE™ Vivid Style|TEST Lens
54804|NCT03755882|Device|LACELLE™ Sparkling Brown|CONTROL Lens
54805|NCT03755869|Drug|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
54806|NCT03755856|Other|Questionnaire|Health-related quality of life
54807|NCT03755843|Diagnostic Test|PASSIVE LEG RISING|"Pasive Leg Rising: In the supine method, the legs are lifted passively from the horizontal position to a 30° to 45° elevation while the head of the bed is flat.~Fluid Challenge: Fluid responsiveness is generally defined as an increase in SV or CO of 10% to 15% in response to a 250 mL crystalloid fluid bolus"
54808|NCT03755830|Other|Skin biopsy|Two skin biopsies (lesional and non-lesional) will be taken from every patient. Also a skin biopsy will be taken from each control subject.
54809|NCT03755817|Device|SCENAR application|Active SCENAR application on the painful area
54810|NCT03755817|Device|SCENAR application with the device off|Placebo SCENAR application on the painful area
54811|NCT03755804|Drug|bendamustine|Given intravenously (IV)
54812|NCT03755804|Drug|Etoposide|Given intravenously (IV)
54813|NCT03755804|Drug|Doxorubicin|Given intravenously (IV)
54814|NCT03755804|Drug|Bleomycin|Given intravenously (IV)
54815|NCT03755804|Drug|Vincristine|Given intravenously (IV)
54822|NCT03755804|Other|Quality of Life Measurements|Quality of Life measurements will be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL will be done at year 1, 2 and 5 for all risk groups.
54823|NCT03755804|Radiation|Radiotherapy|Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
54824|NCT03755791|Drug|Cabozantinib|Supplied as 20-mg tablets; administered orally daily at 40 mg
54825|NCT03755791|Drug|Cabozantinib|Supplied as 60-mg tablets; administered orally once daily at 60 mg
54826|NCT03755791|Drug|Sorafenib|Supplied as 200-mg tablets; administered orally twice daily at 400 mg
54827|NCT03755791|Drug|Atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
54828|NCT03755778|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 1)
54829|NCT03755778|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 14 (Part 2)
54830|NCT03755778|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and 8 (Part 3)
54831|NCT03755778|Drug|Itraconazole|Subjects will receive itraconazole once daily from Day 5 to Day 18
54832|NCT03755778|Drug|Rifampin|Subjects will receive rifampin once daily from Day 5 to Day 16
54833|NCT03755778|Drug|Quinidine|Subjects will receive quinidine once daily from Day 5 to Day 12
54834|NCT03755765|Drug|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet|Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
54835|NCT03755765|Biological|BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
54836|NCT03755765|Other|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
54837|NCT03755752|Procedure|Phacoemulsification with and without Trypan Blue capsule staining|Phacoemulsification for patients with diabetic retinopathy having cataract in both eyes. One eye underwent phacoemulsification with trypan blue capsule staining and the other eye underwent phacoemulsification without trypan blue.
54838|NCT03755739|Drug|Pembrolizumab|Hepatic artery infusion of immunotherapy agent
54839|NCT03755713|Drug|ASP0892|Intradermal
54840|NCT03755713|Drug|Placebo|Intradermal; normal saline solution
54841|NCT03755700|Drug|Vitamin E|As a gel capsule of vitamin E 800 IU orally 2 hours before intervention and 400 IU orally 4 hours after intervention
54842|NCT03755700|Drug|N-acetyl cysteine|As an effervescent tablets of NAC 1200 mg orally 2 hours before intervention and 1200 mg orally 4 hours after intervention
54843|NCT03755700|Drug|Placebo oral capsule|The placebo of vitamin E as a soft gel capsule with the consumption order similar to vitamin e group
54844|NCT03755700|Drug|Placebos|The placebo of n-acetylcysteine as a tablet with the consumption order similar to n-acetylcysteine group
54845|NCT03755700|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal saline 0.9% infusions (1 mL/kg) for 12 hours prior to and after coronary catheterization
54846|NCT03755687|Other|Art Therapy Intervention|Standardized mixed media art directives.
54847|NCT03755674|Procedure|CHRONOTYPE-ADJUSTED DIET|Those patients followed a daily caloric distribution attending to their chronotype. In this regards, 'morning' subjects ate a higher quantity of calories at the first part of the day, while 'evening' subjects ate a higher amount of calories at the second half of the day.
54848|NCT03755661|Behavioral|MI&TXT4MSM|brief in-person intervention followed by text messaging
54849|NCT03755648|Other|Treadmill training|The motorized treadmill treatment parameters considered will be 50 Hertz, 10 Ampere and 220 Volts. The speed of treadmill will be controlled with a single finger tip allowing an individual to exercise in safe environment with sufficient space.The treadmill training will be provided by giving instructions first and then warm up will be given for 5 minutes prior to the training. The children will be upright with the feet flat on treadmill platform. The height of handrails will be adjustable according to every child thus keeping their gaze forward. The training will be ended at cool down period of 5 minutes.The treatment session will be thirty minutes for each group, six times a week for three months.
54850|NCT03755648|Other|traditional physical therapy|Traditional therapy includes hot pack for 15 minutes and stretching for 20 minutes
54851|NCT03755648|Other|Delorme resistance exercise|Delorme Resistance Training was also initiated with 5 minute warm up period. It was started with 10 Repetition Maximum and was gradually increased. The treatment session was thirty minutes for each group, six times a week for three months.
54852|NCT03755635|Combination Product|The WHO multimodal hand hygiene strategy|Comprises five essential elements; system change-availability of alcohol-based hand rub at the point of care and/ or access to safe continuous water supply and soap and towels; training and education of healthcare professionals; monitoring of hand hygiene practices and performance feedback; reminders in the workplace; and the creation of a hand hygiene safety culture with the participation of both individual healthcare workers and senior hospital managers.
54853|NCT03755622|Device|Conventional Transpalatal Arch (TPA)|In Group C, upper molar bands selection will be carried out by direct intra oral procedure. The conventional TPA is made on the stone working models.
54854|NCT03755622|Device|Transpalatal Arch (TPA) fabricated from 3D reconstructed model|In Group 3D, upper molar bands selection will be carried out on the 3D printed model instead of direct intra oral procedure. The 3D TPA will be fabricated on the 3D reconstructed model while the conventional TPA is made on the stone models.
54855|NCT03755609|Drug|Oxycodone|0.1 mg/kg intravenously
54856|NCT03755609|Drug|fentanyl|1ug/kg intravenously
54857|NCT03755596|Drug|Z. officinale extract|Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.
54858|NCT03755583|Dietary Supplement|Exclusive Enteral Nutrition|a complete liquid diet of formula for 8 weeks were adminstered in Crohn's Diseas patients ,Nutritional intake was based on the child's estimated energy requirements, no regular table food during 8 weeks treament.
54859|NCT03755570|Diagnostic Test|Repeatable Assessment of Neuropsychological Status|Cognitive Function Test (Questionnaire-based)
54860|NCT03755570|Diagnostic Test|Hospital Anxiety and Depression Scale|Cognitive Function Test (Questionnaire-based)
54861|NCT03755570|Diagnostic Test|Frontal Assessment Battery|Cognitive Function Test (Questionnaire-based)
54866|NCT03755557|Other|Placebo|Application of a nasal spray
54867|NCT03755531|Drug|Carbetocin|"Heat stable Carbetocin, a clear colourless solution. Oxytocic activity: approximately 50 IU of oxytocin/vial. One ml of Carbitocin (100 mcg), was given as a bolus intravenous injection, slowly over 1 minute after labor of the baby at once. It was used once and no further doses were given.~Drug was kept in cold storage (2 to 8°C)."
54868|NCT03755531|Drug|Oxytocin|"Oxytocin, a clear colourless solution. One ml of oxytocin (10 IU), was given as a bolus intravenous injection over 1 minute, after labor of the baby at once. Further doses can be given accordingly.~Drug was kept in cold storage (2 to 8°C)."
54869|NCT03755518|Drug|FEDRATINIB|A potent and selective inhibitor of JAK2 kinase activity
54870|NCT03755505|Diagnostic Test|obtain samples from sputum, feces and urine|Samples are obtained from participants. No further intervention is required. Obtained samples will be further analyzed.
54871|NCT03755492|Drug|Tadalafil Oral Tablet|to be taken every other day for 6 months after radical prostatectomy
54872|NCT03755492|Other|Placebo|to be taken every other day for 6 months after radical prostatectomy (in pill form), provided by same distributor of Tadalafil
54873|NCT03755492|Other|Absorbent pads|6 month supply provided to patients after radical prostatectomy
54874|NCT03755479|Device|Hybrid Closed Loop Insulin Pump Minimed 670G|Five Day Group Education on Minimed 670G
54875|NCT03755466|Drug|"Baricitinib, olumiant®"|To examine the effects of baricitinib in RA patients
54876|NCT03755466|Drug|"Biologics"|To examine the effects of biologics in RA patients
54877|NCT03755466|Drug|Tofacitinib 5 MG [Xeljanz]|To examine the effects of tofacitinib in RA patients
54878|NCT03755453|Device|Hearing aid: Phonak Audéo B90-Direct|Hearing aids will be fitted to the participants individual hearing loss.
54879|NCT03755440|Drug|PD-1 antibody (SHR-1210)|PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
54880|NCT03755427|Biological|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
54881|NCT03755427|Biological|Aluminum Hydroxide Adjuvant|The seasonal influenza vaccine was a inactivated, split virion preparation of the influenza virus, propagated in embryonated chicken eggs. The aluminum hydroxide adjuvant was 0.5ml aluminum hydroxide adjuvant.
54882|NCT03755414|Procedure|Stem cell transplantation|Standard of care
54883|NCT03755414|Drug|Itacitinib|Itacitinib may be taken without regard to food.
54884|NCT03755414|Other|Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)|-Screening, day 14, day 28, day 42, day 100, taper period, and follow-up period
54885|NCT03755414|Other|Human Activity Profile|-Screening, day 14, day 28, day 42, day 100, taper period, and follow-up period
54886|NCT03755401|Other|TFPP|Trauma-Focused Psychodynamic Psychotherapy
54887|NCT03755401|Other|TAU|treatment as usual at the VA for PTSD
54888|NCT03755388|Device|Episealer|Placing Episealer device
54889|NCT03755375|Device|E-stim|SEMG Biofeedback applied for relaxation, trigger points release and E-stim to decrease pelvic pain
54890|NCT03755375|Behavioral|Postural exercises|SEMG Biofeedback applied for relaxation, trigger points release and postural exercises to improve pelvic mobility to decrease the pelvic pain
54891|NCT03755362|Procedure|Standard Treatment|Dental evaluation at baseline, 3, 6, and 9 months.
54892|NCT03755362|Procedure|Intensive Treatment|Dental evaluation at baseline, 3, 6, and 9 months. Plus one or more sessions as needed at baseline of full mouth supra- and sub-gingival scaling and root planing, plus oral hygiene instruction. Additional sessions as necessary to remove remaining local factors and treat inflammation and bacteria overgrowth. Additional evaluations and therapy at 2 months or as needed based on therapeutic response. If bleeding on probing levels do not decrease to <20% of sites following initial therapy or at subsequent visits, intermediate treatment visits will be scheduled. Each participant will be instructed to use half of a capful of 0.12% chlorhexidine twice a day during active treatment including two weeks beyond the treatment visit.
54893|NCT03755349|Device|Placement of burr-hole covers|Placement of a burr-hole cover (Stryker® UN3 BURR HOLE COVER, 20mm, W/TAB, Item code 53-34520) fixed with 2 screws (Stryker® UNIII AXS SCREWS, SELF-DRILLING, 1.5 x 4MM, Item code 56-15934) on each of two burr-holes
54894|NCT03755349|Other|No placement of burr-hole covers|In the control group, none of the burr-holes is covered, representing our current standard of care. In patients with bilateral cSDH, none of the burr-holes on the control side are covered with burr-hole covers.
54895|NCT03755336|Other|Administered Slip Perturbations|Slips will be administered in early, middle or late phases of stance during overground walking.
54896|NCT03755310|Drug|Suvorexant|First week: 10 mg tabs; Second week: 10-20 mg tabs
54897|NCT03755310|Drug|Placebo|Equivalent dosage, route of administration and dose regimen
54898|NCT03755297|Other|Blood sample analysis of patients treated as standard care|Blood sample to analyse percentage of blood cells (regulatory B cells et T cells)
54899|NCT03755284|Other|Sacral Massage|● In addition to providing them with routine nursing/midwifery care, the women in the experimental group were administered a massage to the sacral region under the supervision of a doctor for 30 minutes using the effleurage (patting) ( 15 minutes) and vibration technique ( 15 minutes) in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour. To achieve this, the patients were placed in the left lateral position in the latent (3-4 cm), active (5-7 cm) and transition (8-10 cm) phases of labour.
54900|NCT03755258|Drug|GCK 100 mg + Placebo 200 mg|GCK 100 mg + Placebo 200 mg, oral, 12 weeks
54901|NCT03755258|Drug|GCK 200 mg + Placebo 100 mg|GCK 200 mg + Placebo 100 mg, oral, 12 weeks
54902|NCT03755258|Drug|GCK 300 mg|GCK 300 mg, oral, 12 weeks
54903|NCT03755258|Drug|Placebo 300mg|Placebo 300mg, oral, 12 weeks
54904|NCT03755245|Other|[68Ga]Ga-DOTA-Siglec-9|Vascular Adhesion Protein 1 (VAP-1) targeted radiopharmaceutical
54905|NCT03755232|Dietary Supplement|scFOS|Fossence™ (short chain Fructo-oligosaccharides (scFOS)
54906|NCT03755232|Other|Control|water or dextrose or white bread
54907|NCT03755219|Procedure|TEP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
54908|NCT03755219|Procedure|TAPP|By laparoscopic (keyhole) approach, the hernia is repaired with a plastic mesh which the surgeon may or may not anchor with some sort of fixation device
54909|NCT03755206|Other|Sustainability strategies|The investigators will work with each site to determine strategies that are relevant locally to help promote sustainability of the suicide prevention program.
54910|NCT03755193|Drug|"SERM Viviant®Tablet 20mg and ELD Edirol®Tablet 0.75ug"|To examine the effects of SERM and ELD in osteoporosis patients
54911|NCT03755193|Drug|"Bisphosphonates and ELD Edirol®Tablet 0.75ug"|To examine the effects of BP and ELD in osteoporosis patients
54912|NCT03755193|Drug|"ELD Edirol®Tablet 0.75ug"|To examine the effects of ELD in osteoporosis patients
54913|NCT03755180|Other|Exercise Training|In exercise training, aerobic exercise and strengthening exercises, especially for gastrocnemius and tibialis anterior muscles, will be applied to the patients. In addition the exercise training, Compression Therapy is applied to patients.
54914|NCT03755180|Other|Compression Therapy|Compression therapy is a treatment applied to patients in the form of Four Layer Compression Bandage and Compression Stocking. Four Layer Compression Bandage is a treatment that requires four different types of bandages. The compression stocking is an elastic stock with various tension and length.
54915|NCT03755167|Drug|IPL344|IPL344 will be administered by intravenously (IV) infusion once a day (every 24±6 hours), using a Peripherally Inserted Central Catheter (PICC) line or a permanent port. IPL344 will be administered using an electronic pump at a flow rate that will be determined in protocol 101/2. The dose will be fixed as MTD as established in protocol 101/2 (up to 3.2 mg/kg).
54916|NCT03755154|Drug|S65487|S65487 is administered as single agent via i.v. infusion on a 3-week cycle.
54917|NCT03755141|Drug|Herzuma|Herzuma + Treatment of Physician's Choice
54918|NCT03755128|Other|No intervention|No investigational drugs will be administered as part of the study
54919|NCT03755115|Drug|Epirubicin plus SHR1210|First intravenous injection of epirubicin injection, D1,30mg/m^2 Then intravenous administration with SHR-1210,D1, a fixed dose of 200mg, 30min per infusion, Q2W. The total dose of epirubicin is 360 mg/m^2.next SHR-1210 single drug maintenance .Until to secdonary disease progression or intolerance side effects.Evaluate efficacy every 3 cycles.
54920|NCT03755102|Drug|Dacomitinib|Dacomitinib (45mg) administered as a once daily dose (irrespective of food intake). Concomitant use of proton pump inhibitors with dacomitinib should be avoided if possible, and if necessary, dosing timing should be spaced apart (morning and evening).
54921|NCT03755089|Drug|Phenazopyridine|200mg PO Phenazopyridine taken 1-2 hours prior to the Botox® injection procedure
54922|NCT03755089|Drug|Lidocaine 2% Injectable Solution|30mL 2% lidocaine instilled into the bladder lumen 20 via a urinary catheter 20 minutes prior to the Botox® injection procedure
54923|NCT03755076|Behavioral|Perceptual cuing|The two perceptual cues are: (a) feedback about the time-lag between the two arms presented as a horizontal tilt of the common goal, and (b) different movement weighting coefficients to each arm to force greater movement contribution of the paretic arm in a bimanual context.
54924|NCT03755063|Other|Speech therapy apps|Speech therapy apps loaded on tablets
54925|NCT03755050|Other|general and specific data|General and specific data collected
54926|NCT03755037|Drug|Clomid, Respatio and Ethinyl estradiol|Drugs were received during the menstrual cycle.
54927|NCT03755024|Device|ultrasound|"The compulsory ultrasound measurements to be obtained at all visits include the following biometrical parameters:~Biparietal diameter~Head circumference~Abdominal circumference~Femur length~Humerus length"
54928|NCT03755011|Device|white noise|Patients in the interventional arm will have white noise (through in-room workstations- on-wheels and publicly-available white noise websites) playing overnight at a standardized volume to be determined.
54929|NCT03755011|Behavioral|usual care|normal ICU activity noise
54930|NCT03754998|Behavioral|Intervention Group|The participating dyads in intervention communities were invited to consume veo soup/meal (HSM) three times a week and provided weekly supply of iodized salt (450 g) for the household usage as well as being engaged in dry season container gardening. The veo soup/meal is a local Ghanaian soup/meal mainly made of Hibiscus Sabdarifa leaves. It is a soup when prepared a bit watery and consumed with 'tou zaafi' (millet or corn based cooked paste). It is also a meal when prepared thick and eaten by itself. The Hibiscus Sabdariffa leaves meal (HSM) used in the present study was made of 18 kg Hibiscus Sabdariffa leaves, 8 kg groundnut, 1.1 kg dawadawa (fermented African locust beans), 3 kg dried fish plus 0.045 kg iodized salt, cooked with about 23 L (23 kg) water to yield 52.5 kg HSM. In each community, groups of ten women took turns to share the cooking activities, washing of bowls, and making water available for cooking. No treatment provided in our control communities.
54931|NCT03754985|Device|Hyperbaric oxygen therapy|"The study included participants 18 years or older, scheduled for 60 HBOT sessions for any indication.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session.~After signing an informed consent form, the participants underwent a pulmonary function baseline evaluation. Participants were treated in a multiplace chamber (HAUX-Life-Support GmbH) for 60 daily sessions, 5 days a week. Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minute air breaks every 20 minutes. Participants repeated their pulmonary function evaluation after the last HBOT session."
54932|NCT03754972|Diagnostic Test|Sagittal plane shear index (SPSI)|Report SPSI to surgeon after surgeon records an initial surgical plan, and determine whether the objective spinal stability metric influences a change in the surgical plan.
54933|NCT03754959|Drug|BI 1358894|Film-coated tablet
54934|NCT03754959|Drug|Placebo|Film-coated tablet
54935|NCT03754959|Drug|Midazolam|Solution for injection
54936|NCT03754933|Biological|Ad/PNP|Ad/PNP is a replication defective adenoviral vector expressing E. coli Purine Nucleoside Phosphorylase
54937|NCT03754933|Drug|Fludarabine Phosphate|Fludarabine phosphate is an anticancer agent currently used to treatment patients with chronic lymphocytic leukemia.
54938|NCT03754920|Behavioral|prolonged fasting|"Fasting for 5 days: Fasting with some fitness regimen, such as meditation and mild physical exercise;~Feeding for 3 days: Gradually distribute participants with rice flour, porridge and juice."
55116|NCT03753425|Procedure|Low volume bowel preparation in inflammatory bowel diseases|Low volume bowel preparation in inflammatory bowel diseases
54939|NCT03754907|Procedure|Endocutter stapler|Endocutter ETS 35, ETS Flex 45 stapler, and the Echelon Flex Powered ENDOPATH Stapler with 2.5- or 3.5-mm staples (Johnson & Johnson K.K., Tokyo, Japan)
54940|NCT03754907|Procedure|suture material|absorbable suture material is used to perform hand-sewn anastomosis in an end-to-end manner.
54941|NCT03754894|Device|ready made plastic stent application|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement covered by ready-made plastic stent.
54942|NCT03754894|Procedure|simple interrupted sutures|full / partial thickness apically repositioned flap with paracrestal lingual incision will be performed for implant placement followed by healing abutment placement and securing the flap with simple interrupted sutures
54943|NCT03754881|Behavioral|Pulmonary rehabilitation|"In this study, we'll educate pulmonary rehabilitation to patients and make reservation for re-visiting outpatients clinics with PR diary after 8 weeks.~we want to confirm whether patients, who perform home based PR during more than 30 minutes in 3 days per week, present improved dyspnea score or quality of life compared with non-compliance group."
54944|NCT03754868|Diagnostic Test|Detailed coagulation monitoring|Monitoring of coagulation using activity of coagulation factors, rotational thrombelastometry and multiple electrode aggregometry
54945|NCT03754855|Behavioral|Questionnaire|Questionnaire
54946|NCT03754842|Other|Placebo (twice daily)|Matching placebo
54947|NCT03754842|Other|Nicotinamide Riboside/Pterostilbene (500 mg/100 mg twice daily)|Elysium Basis TM, Elysium Health, Inc., NY, USA
54948|NCT03754829|Behavioral|Her Sey Kontrol Altinda (HSKA)|HSKA consists of 5 sessions over 5 weeks and is based on Problem-Solving therapy. Participants receive feedback on their homework assignments in brief weekly online messages from a clinical psychologist.
54949|NCT03754816|Procedure|PECS II and parasternal block|10 ml of Levobupivacaine 0.375% injected between minor and major pectoralis muscles. 20 ml of Levobupivacaine 0.375% injected between minor and serratus muscles. 10 ml of Levobupivacaine 0.375% injected between major and intercostal muscles at II and IV intercostal space.
54950|NCT03754816|Drug|Levobupivacaine|Levobupivacaine
54951|NCT03754803|Other|HIV Symptom Distress Module Questionnaire|The Symptom Distress Module is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment.
54952|NCT03754803|Other|HIV treatment satisfaction questionnaire|The HIV TSQ is a 10-item-self-reported scale that measures overall satisfaction with treatment and by specific domains e.g., convenience and flexibility.
54953|NCT03754790|Drug|Fitusiran|Pharmaceutical form:solution for injection Route of administration: subcutaneous
54954|NCT03754777|Procedure|Laparoscopic appendectomy|"Preoperative care in both arms. Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~Surgery. General anesthesia with strict control of fluid therapy and hemodynamic changes during surgery. Appendectomy with the use of monopolar coagulation by experienced surgeons following appendix stump ligation by two Roeder knots.~Postoperative care. Antibiotics for 3-5 days for patients with complicated appendicitis (Gomez ≥ 3A). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 2, 6, 12 and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery."
54955|NCT03754764|Biological|Specificity CD38 CAR-T Cells|1) Biological: Specificity CD38 CAR-T Cells 2) Day 0: 1-5x10e6/kg total dose .3) Other: Laboratory Biomarker Analysis
54956|NCT03754751|Procedure|Laparoscopic cholecystectomy with the implementation of modified ERAS program|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient informing and brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~Low-pressure pneumoperitoneum (8-9 mmHg)~Trocar wound and intraabdominal anesthesia with 0.25% ropivacaine~PONV prophylaxis in patients of risk~Postoperative care~Early mobilization (2 h after surgery)~Early fluid intake (2 h after surgery)~Early liquid food (6 h after surgery) Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
54957|NCT03754751|Procedure|Laparoscopic cholecystectomy with standard perioperative treatment|"Preoperative Crystalloid isotonic solutions and antibiotic prophylaxis 30 min prior to surgery.~1) Patient oral informing. No brochure~Surgery Cholecystectomy using monopolar by experienced surgeons under general anesthesia~Standard CO2 pressure (12-14 mmHg)~No additional anesthesia~Postoperative care~Mobilization in 4-6 h after surgery~Fluid intake in 6 hours~Liquid food intake in 12 hours Antibiotics for 3-5 d for patients with complicated cholecystitis (TG13 2). The postoperative pain level evaluation in rest by VAS in 0 h (immediately after awakening), 6 h and 24 h postop. The postoperative analgesic modality on demand: Ketorolac 30 mg for patients with VAS pain level ≥ 5 cm. Antiemetics in dyspepsia. No iv infusions postoperatively. Intestinal peristalsis evaluation by auscultation every 2 h after surgery"
54958|NCT03754738|Device|Balloon guide catheter|Use a balloon guide catheter in the mechanical thrombectomy
54959|NCT03754738|Device|Non-balloon guide catheter|Use a non-balloon guide catheter in the mechanical thrombectomy
54960|NCT03754725|Drug|Deferiprone pill|1000 mg of deferiprone (oral) BID
54961|NCT03754725|Drug|placebo|patients will receive placebo orally
54962|NCT03754712|Dietary Supplement|Vitamin D3|Dietary supplement : Vitamin D3 one tablet of vitamin D3 (2000IU) per day for 8 weeks
54963|NCT03754699|Behavioral|Educational intervention|"During the usual pre-anesthesia assessment (performed between D-30 and D-2 of the intervention), the anesthesiologist will deliver to the intervention group patient oral and visual information on:~the numerical scale of pain ranging from 0 to 10 with examples of perceptions corresponding to each level of the scale (calibration)~nature of postoperative pain (inflammatory character, dynamic over time)~average pain level incurred by the intervention~the difference between anti-inflammatory and opioid analgesics~principles of systematic treatment and pain anticipation~principles of overdose and side effects prevention This information is standardized and delivered orally, accompanied by a visual support (patient diary), which will be given to the patient upon discharge from the hospital"
54964|NCT03754699|Behavioral|Standard information|Standard information on pain For patients in the control group the standardized information is based on the SG/DGM/DSS 1/41-2010 scheme of the AFSSAPS-CFETD repository.
54965|NCT03754686|Drug|Oseltamivir|Best medical care and oral oseltamivir 75 mg twice daily for five days. Dose adjustments of oseltamivir will be made according to manufacturer's instructions.
54966|NCT03754686|Drug|Paracetamol|Best medical care and oral paracetamol twice daily for five days
54967|NCT03754673|Device|MRI|MRI pulmonary with no contrast administration
54968|NCT03754660|Drug|BAY1237592|Oral inhalation with dry powder inhaler, single dose.
54969|NCT03754660|Drug|PH-monotherapy|Any kind of monotherapy for PAH/CTEPH with the exception of inhaled Iloprost. Known vasoresponders are excluded.
54970|NCT03754660|Drug|PH-combination therapy|Any kind of double or triple combination treatment for PAH/CTEPH with the exception of inhaled Iloprost. Known vasoresponders are excluded.
54971|NCT03754660|Procedure|NO gas|Inhaled NO (nitric oxide) given for vasoreagibility testing as part of the standard right heart catheterization diagnostic procedure.
54972|NCT03754647|Dietary Supplement|Vitamin C|One tablet of Vitamin C (500 mg) twice daily with SSRIs for 8 weeks
54973|NCT03754634|Drug|Eltrombopag and Diacerein|The initial dose of eltrombopag administration is 25 mg orally once daily, which could be transited to 50 mg/d in a 2-week cycle according to the need, and the maximum dose was not more than 75 mg/d. The dose of diacerein administration is 50 mg orally twice daily. The treatment was discontinued after 6 weeks without blood index reaction.
54974|NCT03754621|Diagnostic Test|Serum thyroid functions tests|Serum TSH, fT3, fT4 and anti-TPO
54975|NCT03754608|Diagnostic Test|MRI including cf-MRI, DTI, ASL and CVR.|A paradigm developed at Yale University called Cognitive Predictive Modelling which takes connectivity data and reduces it to two smaller network which predict higher and lower performance in a particular task for which these networks have been optimized. This will be supplemented by MRI vascular measures.
54976|NCT03754595|Procedure|3D Laparoscopic pancreatoduodenectomy|Patients with pancreatic cancer treated by 3D Laparoscopic pancreatoduodenectomy
54977|NCT03754595|Procedure|2D Laparoscopic pancreatoduodenectomy|2D Laparoscopic pancreatoduodenectomy
54979|NCT03754569|Procedure|Peritoneal biopsies after complete macroscopic cytoreduction|We will perform at the end of complete macroscopic cytoreductive surgery (CC-0) for epithelial ovarian cancer random peritoneal biopsies in apparently healthy peritoneum in order to assess the presence of microscopic peritoneal metastases
54980|NCT03754556|Device|Intrauterine device|Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
54981|NCT03754543|Other|Labeled iron salt Fe54|Ferrous fumarate enriched with Fe 54 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
54982|NCT03754543|Other|Labeled iron salt Fe57|Ferrous fumarate enriched with Fe 57 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
54983|NCT03754543|Other|Labeled iron salt Fe58|Ferrous bisglycinate enriched with Fe 58 isotopes contains 2.25 mg of iron source and 13.5 mg of Vitamin C per serving
54984|NCT03754530|Drug|Icotinib|orally three times per day
54985|NCT03754530|Radiation|WBRT or SRS|>3 with WBRT;<=3 with SRS
54986|NCT03754517|Diagnostic Test|RPR Titer|RPR titer; TPPA/FTA-ABS; Next-Generation Sequencing
54987|NCT03754504|Dietary Supplement|Cranberry powder|3 capsules /day of whole cranberry powder (500mg/each)
54988|NCT03754504|Dietary Supplement|Placebo|3 capsules/day of a placebo comparator
54989|NCT03754491|Behavioral|One stage treatment for mild and moderate cholangitis with choledocholithiasis|one stage of stone removal in mild or moderate cholangitis.
54990|NCT03754478|Other|Physical activity training|subjects will enter a 3-month supervised physical activity program during which they will take part to supervised and unsupervised physical activity sessions. Type of physical activity will be selected among a number of available activities (aquagym, aerobics, resistance training, outdoors activities) based on individual needs and preferences); it will consist in 2 weekly supervised activity sessions during which participants will be instructed by a specialist in adapted physical activity, and 2-3 weekly session of unsupervised physical activity which will be performed according to detailed instructions regarding intensity and duration.
54991|NCT03754465|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
54992|NCT03754465|Procedure|Hydrogel SHEET(Vehicle control)|Application of Hydrogel SHEET to diabetic foot ulcer
54993|NCT03754439|Behavioral|Physiological changes to noise and vibration exposure|Physiological parameters (HR, RR, Sats, NIRS) will be observed during a period of stay on the neonatal unit (Inborn group) or during ambulance transportation (Transported group) whilst simultaneous measurement of noise and vibration exposure. Urine will be collected during the first 24, 48 and 72 hours post exposure for biochemical markers of brain injury (S100B) and stress (Cortisol)
54994|NCT03754426|Device|Fluorescence Imaging Device|Hand-held, real-time fluorescence imaging device
54995|NCT03754413|Device|experimental|Neuramis® Deep Lidocaine
54996|NCT03754413|Drug|comparator|No-treatment
54997|NCT03754400|Biological|Albumin|All patients will receive a daily intravenous infusion of 20% Human Albumin Solution (HAS) 40 gram at day 0 (loading dose), Day-1 to day 7, 20 gm daily, then from day 8 to day 28, 20 gm every alternate day.
54998|NCT03754400|Other|Standard Medical Treatment|Antibiotics, nutrition and supportive treatment
54999|NCT03754387|Drug|Ceftazidime|Patients choosing AT group were admitted to the hospital for observation and to receive intravenous antibiotics Intravenous Ceftazidime sodium (50mg/kg/dose every 12 hours) was administered for 3 days.
55000|NCT03754387|Procedure|appendectomy|APPT group consisted of admission to the hospital with promptinitiation of intravenous antibiotics and appendectomy
55001|NCT03754374|Other|access to healthcare|use or non-use of dedicated health facilities
55002|NCT03754361|Procedure|automated peritoneal dialysis|peritoneal dialysis administered by a cycler
55003|NCT03754361|Procedure|IHD|HD 4hour 2-3times per week
55004|NCT03754348|Radiation|PET scan with tracer injection [18F] DPA-714|the subject will receive a dose of 3.5MBq / kg intravenous (in bolus) more or less 20%, knowing that the minimum dose injected is unchanged at 150MBq and the maximum dose at 370 MBq. Irradiation will remain below 10 mSv
55005|NCT03754335|Procedure|Lumbar puncture|"Patient will be managed according to the current international recommendations in the Toulouse acute stroke center.~In the absence of clear recommendation in the literature headache will be treated according to our local predefined analgesic protocol: paracetamol 1g/6 h, and if the numerical scale ≥ 4 : continuous intravenous morphine starting at 1mg/h and increased per 0.5 mg/h every hour if numerical scale remains ≥ 4.~Lumbar puncture will be performed between day 3 and day 5 after subarachnoid hemorrhage onset by an independent scientist from our clinical investigator center. 30-mL CSF will be removed by LP.~Sham LP consisting in superficial skin puncture by a subcutaneous needle (27 gauge needle) during the usual procedure will be performed at the same time point."
55006|NCT03754322|Diagnostic Test|LAMP|LAMP testing involves taking a blood specimen, extracting DNA and running it in an illumigene malaria assay manufactured by meridian bioscience to obtain a malaria result
55007|NCT03754322|Diagnostic Test|Microscopy|Thick and thin microscopy to look for evidence of malaria
55008|NCT03754309|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
55009|NCT03754309|Drug|Placebo|Matched placebo
55010|NCT03754296|Device|CATCHVIEW|Revascularization device
55011|NCT03754283|Device|Indirect bonding|Indirect bonding is the technique where orthodontic appliances are first placed on a model of the patient and then transferred to the patient using some kinf of trays
55012|NCT03754270|Other|Advice in lifestyle|Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive instructions and advice on lifestyle according to current clinical practice. Life style advice is quite subjective and it means that the patients are encouraged to stop smoking, to avoid alcohol, to lose weight, to be more physically active and to avoid sleeping on supine position.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed.
55013|NCT03754270|Device|Cervical collar|"Patients with moderate OSA according to a baseline nocturnal respiratory registration (NRR). Patients receive the same instructions and advice as in Arm lifestyle advice and also get a CC and instructions on how to sleep with it. CC is marketed for indications of various diseases such as traumatic cervical injury, cervical disc herniation and other neck problems and allows adjustment of the elevation level to achieve sufficient effect, i.e., extending the neck.Patients fill in questionnaire 1 that includes questions about nocturnal respiratory disturbances, daytime sleepiness, insomnia, use of tobacco and alcohol, comorbidity and medication. After 6+/-2 weeks of treatment, patients fill in Questionnaire 2 which contains the same questions as Questionnaire 1 and also questions about any side effects, evaluation of treatment. In conjunction with visit 2 another NRR will be performed."
55014|NCT03754257|Procedure|High-frequency Electrical Stimulation|High Electrical Stimulation (75Hz) during 40 minutes
55015|NCT03754257|Procedure|Sham Electrical Stimulation|Sham Electrical Stimulation (5Hz) during 40 minutes
55016|NCT03754257|Other|Conventional Physiotherapy|Active and passive exercises, and walking.
55017|NCT03754244|Drug|TQB3456|Observe the safety and pk when the subjects take TQB3456 p.o. qd
55018|NCT03754231|Other|Heart rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
55019|NCT03754231|Other|Respiratory rate monitoring|"The heart rate of recruited patients will be monitored for 15 minutes over 2 phases:~i) 10 minutes at rest ii) 5 minutes during physical activity in the form of walking or playing"
55020|NCT03754218|Drug|Amnion Membrane Powder|This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.
55021|NCT03754218|Procedure|SOC Wound Covering|Institutional standard of care wound covering.
55022|NCT03754205|Device|Microablative Fractional CO2 laser|3 therapies intravaginally administered will be applied at monthly intervals
55023|NCT03754192|Radiation|perfusion Computed Tomography|Will be carried before liver surgery
55024|NCT03754179|Drug|Dabrafenib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
55025|NCT03754179|Drug|Trametinib|"Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2.~Upfront treatment with dabrafenib and trametinib in Arm B phase 2 with add-on of hydroxychloroquine at progression of disease"
55026|NCT03754179|Drug|Hydroxychloroquine|Upfront treatment with dabrafenib, trametinib and hydroxychloroquine in phase 1 and Arm A phase 2. Add-on at progression of disease in Arm B phase 2
55027|NCT03754166|Other|Constraint-induced movement therapy|"Patient's unaffected arm is restrained, by a glove including thumb, during activities of daily life (bathing, grooming, dressing and feeding = approx. 4h/day).~Visual spatial cueing is displayed in the bedroom and the bathroom."
55028|NCT03754153|Device|Balanced Binocular Viewing (BBV)|The dose of BBV therapy will be one hour a day or 2x30 min/day (depending on child's attention span and/or need to implement the treatment around the family daily routine).
55029|NCT03754153|Other|Standard Therapy - Occlusion (patching) or blurring (atropine)|The prescribed dose of occlusion treatment / patching (parental choice) will depend on the severity of amblyopia, as by current clinical practice based on PEDIG studies
55030|NCT03754140|Drug|Polidocanol Injection|Sclerotic agent
55031|NCT03754127|Device|tDCS|Transcranial direct current stimulation
55032|NCT03754127|Device|sham tDCS|Sham transcranial direct current stimulation
55055|NCT03753919|Drug|Durvalumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
55085|NCT03753659|Procedure|Radio Frequency Ablation (RFA)|Local ablation via RFA or MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
55033|NCT03754114|Other|ICP + PbtO2 guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg and to avoid PbtO2 dropping below 20 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada for patients with severe TBI. The devices are used in standard care at hospitals participating in this research study. Doctors adjust their treatment choices to try to achieve these ICP and PbtO2 goals. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
55034|NCT03754114|Other|ICP guided management strategy|In this management strategy, the physiological goal is to avoid ICP from exceeding 22 mm Hg. ICP and PbtO2 are monitored using devices inserted into the brain through a hole in the skull, but PbtO2 is not used to guide care. These devices are approved by the US Food and Drug Administration (FDA) and Health Canada, and are routinely used in patients with severe TBI. Doctors adjust their treatment choices to try to achieve this ICP goal. Treatments include kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. This management strategy is used to guide care for 5 days in this research study.
55035|NCT03754075|Procedure|Complete mesocolic excision|The resection was based on the principles of CME. The superior mesenteric vein was exposed to perform central vessel ligation and lymph nodes dissection. Extended right hemicolectomies for tumors located from the ascending colon close to the hepatic flexure and distally were performed openly as standard during the study period. These resections included the prepyloric and gastroepiploic lymph nodes dissection.
55036|NCT03754075|Procedure|Conventional colon resections|The patients underwent what was considered standard colon cancer resections in Denmark during the study period.
55037|NCT03754062|Drug|Placebo - Cap|Administration of Placebo by pill.
55038|NCT03754062|Drug|L-dopa|Administration of L-dopa by pill.
55039|NCT03754062|Drug|Haloperidol|Administration of Haloperidol by pill.
55040|NCT03754049|Drug|TLC599|TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
55041|NCT03754049|Drug|DSP|Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
55042|NCT03754036|Behavioral|Sleep manipulation|Participants will sleep their typical amount at home for 1 week and will then be randomized to either increase or decrease their time in bed by 1.5 hours per night for 1 week, completing the alternate schedule on the fourth week (washout period of 1 week between sleep conditions). This procedure will result in a targeted 3-hour time in bed difference between conditions. Sleep will be objectively measured using actigraphy (Actiwatch) and sleep schedule adherence will be promoted by providing fixed bedtimes and wake times during the experimental weeks, and will be monitored through phone calls to the research center.
55043|NCT03754023|Diagnostic Test|Urine-TIMP-IGFBP7 biomarker for AKI|Urine-TIMP-IGFBP7 biomarker for AKI
55044|NCT03754010|Procedure|Scaling and root planning|Under local anesthesia, full-mouth SRP will be performed by a single investigator. Immediately after the SRP, HA gel or mouthrinse will perform according to the groups' procedure. In Group 1, the periodontal sulcus will be irrigated with saline solution after SRP.
55045|NCT03754010|Drug|Hyaluronic acid gel (HA) and SRP|In Group 2, after SRP will be performed and irrigated with saline the area was dried with a soft air and, then, a gel containing HA will be applied intrasulcular.
55046|NCT03754010|Drug|HA mouthrinse and SRP|In Group 3, HA hydrogel mouthrinse will be used as an irrigator after SRP.
55047|NCT03754010|Drug|HA mouthrinse+gel and SRP|In Group 4, after SRP will be performed, the sulcus was irrigated with HA hydrogel mouthrinse and, then, intrasulculary HA gingival gel will be applied.
55048|NCT03753997|Behavioral|Treatment by a diabetes educated psychologist|Patients will meet a diabetes educated psychologist. There will be a minimum of 5 meetings during the first 3 months and then in the following 6 months there will be a minimum of 2 meetings. More meetings will be scheduled if needed.
55049|NCT03753984|Other|Low-level laser therapy|In both arms will be applied Low-level laser therapy and induced muscle fatigue.
55050|NCT03753971|Other|Sound stimulation|Short sound stimulations will be emitted through a head band during sleep apneas
55051|NCT03753958|Procedure|Conventional treatment|The treatment will consist of oral hygiene orientation, with brushing technique instructions and daily flossing recommendation. All patients will receive a demonstration of oral hygiene techniques. The calculus deposits on the teeth will be removed with an ultrasound equipment and curettes for root scaling and straightening13. In implants, calculus will be removed with specific curettes for use on the implant surface. Treatment will be performed in 2 to 4 sessions under local anesthesia. Other biofilm-retaining factors, such as carious lesions, condemned teeth and maladaptive restorations, will be removed during these periodontal treatment sessions.
55052|NCT03753958|Radiation|aPDT|aPDT will be performed after conventional treatment, in sites with pockets greater than or equal to 5 mm. The PapaMblue® photosensitizer with 100 μM methylene blue will be deposited in the pockets with a syringe, with the bottom of the pouch in the coronal direction, and a pre-irradiation time of 1 min will be adopted, so that the PS may stain the entire bacterial biofilm. Then, the laser emitting an wavelength of 660 nm, with power of 100 mW, will be applied. The laser will be applied to the mucosa on the oral epithelium with an optical fiber (apparatus of DMC Therapy EC, São Carlos, Brazil). Irradiation will be performed until the entire peri-implanted pouch is illuminated for 2 minutes at each point. The 6 points around the implant will be irradiated and each irradiation point will present an area of 0.4 cm2, which will result in radiant exposure of 30 J/cm2 following 2 min of irradiation per point. The irradiation will have a constant power density of 250 mW/cm2.
55053|NCT03753945|Diagnostic Test|MRI of the spine|Perform a clinically indicated MRI of the spine in DBS patients
55054|NCT03753932|Device|Fixed prosthodontics|The intervention takes place six months after finishing radiotherapy.
55083|NCT03753672|Diagnostic Test|preload responsiveness|We investigated whether an increase in CVP ≥ 5 mmHg during PLR predict preload unresponsiveness diagnosed by the absence of increase in velocity-time integral (VTI) of the flow in the left ventricular outflow tract by more than 10%
55084|NCT03753659|Drug|Pembrolizumab|IV infusion
55056|NCT03753919|Drug|Tremelimumab|Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.
55057|NCT03753906|Device|Osmed® hydrogel expander implantation|Under local anaesthesia, a small vertical incision, adapted to the diameter of the Osmed® sself-inflating hydrogel expander, was made with #15 scalpel blade at the mesial line angle of the adjacent tooth which started below the gingival margin extending from the keratinized tissue above the MGJ to the non-keratinized tissue beyond the MGJ. A minimally invasive preparation of a subperiosteal pouch was performed with KPA tunnelling knife. Size of the pouch was controlled with the specific surgical template to ensure the device easily fits into the prepared pouch without tension. Expanders were secured in the correct position with a bone fixation screw, at the flat end, which does not possess an expansion capability. The wound was closed with 3-0 silk suture using simple interrupted sutures.
55058|NCT03753893|Other|No intervention used|no intervention used
55059|NCT03753880|Device|HEMOPATCH Sealing Hemostat|Hemopatch sealing hemostat used after LR to cover the resection surface
55060|NCT03753867|Drug|Acitretin|Acitretin will be provided to participants in the formulation Soriatane. Soriatane doses are oral tablets taken daily by the participant. Participants will then receive 35mg of oral acitretin (Soriatane) daily for 8 weeks during the intervention phase. Participants will be asked to return two months after completion of the acitretin course for clinical follow-up and additional phlebotomy for laboratory testing.
55061|NCT03753854|Diagnostic Test|polysomnography and oxygen saturation exam|Measurement of the Apnea/hypopnea index (AHI) and oxygen saturation
55062|NCT03753854|Biological|calculation of VOC frequency between the first polysomnography and the end of the first year of continuous positive airway pressure treatment|calculation of VOC rate within the two previous years or between first polysomnography and one year of continuous positive airway pressure treatment
55063|NCT03753854|Biological|Blood samples|Blood samples with measurements of hematological, hemorheological, inflammatory and blood coagulation markers
55064|NCT03753854|Other|Physiological measurements|Evaluation of microvascular reactivity and autonomic nervous system activity
55065|NCT03753854|Other|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure during 1 year
55066|NCT03753841|Other|Adjustment of oral diet|Adjustment of oral diet based on findings in fiberendoscopic evaluation of swallowing (FEES)
55067|NCT03753815|Device|19G FNA needle|Puncture of AIP under Endoscopic Ultrasonography, with a 19-gauge FNA needle
55068|NCT03753815|Device|20G FNB needle|Puncture of AIP under Endoscopic Ultrasonography, with a 20-gauge FNB needle
55069|NCT03753802|Other|Chest Physiotherapy|During sessions, the child is lying on the back, he should not have eaten within two hours prior to the sessions. An extended slow expiration handling is performed on 3 respiratory cycles consecutive, this session is repeated for 10 minutes. Breaks are made regularly during the treatment to have approximately 5 to 6 minutes of handling and 4-5 minutes of rest on the total 10 minutes of treatment. Induced cough handlings will be conducted at five minutes and at ten minutes if the child has not coughed during the movements of chest physiotherapy. These are performed by a brief pressure above the jugular (suprasternal) notch of the patient. Only two consecutive trials of the induced cough handling are allowed, even if the handlings are unsuccessful the physiotherapist does not insist. The following 5 minutes of the session are 5 minutes of rest. During the sessions the physiotherapist wears a mask and respects the usual rules of hygiene.
55070|NCT03753802|Other|Surveillance|The session is only a surveillance session with the physiotherapist. The physiotherapist is only watching over the child. The parents of the child wait in the waiting room during the physiotherapy session. They don't know which treatment (chest physiotherapy or no treatment) is applied to their child.
55071|NCT03753789|Device|Microwave Ablation|NEUWAVE microwave ablation of soft tissue liver lesions will be performed percutaneously by an interventional radiologist while the patient is under general anesthesia or deep conscious sedation.
55072|NCT03753776|Drug|Placebo pills of Radium bromatum|Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
55073|NCT03753776|Drug|Radium bromatum pills|Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition
55074|NCT03753776|Drug|Radium bromatum/Apis mellifica/Belladonna placebo pills|Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
55075|NCT03753776|Drug|Radium bromatum/Apis mellifica/Belladonna pills|Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
55076|NCT03753763|Drug|Safinamide Methanesulfonate|100 mg (free base)
55077|NCT03753763|Drug|Safinamide Methanesulfonate matching placebo|100 mg placebo
55078|NCT03753750|Device|Noninvasive spinal cord stimulation|Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
55079|NCT03753737|Other|Questionnaires and semi-structured interview|"Questionnaires : PDQ-4+ (personality disorders), HAD (Anxiety and Depression), AUDIT-c (Alcohol consumption), CTQ-SF (Childhood Trauma Questionnaire).~Semi-structured interview : Evaluation of socio-demographic characteristics, psychiatric and addiction comorbidities, sexually transmitted infections, sexual practices, sexual dysfunction, hypersexual disorder."
55080|NCT03753711|Procedure|Multifidus muscle biopsy during minimally invasive back surgery|Bilateral biopsy of the multifidus muscle in patient with a unilateral disc hernia.
55081|NCT03753698|Device|eCoin|"Implantation of device electrodes subcutaneous in lower tibia area;~Stimulation of posterior tibial nerves:~Regimen 1 (months 0-3): Six stimulation treatments per week, one stimulation per day, for duration of 30 minutes each Regimen 2 (months 3-6): Three stimulation treatments per week, one stimulation per day, for duration of 30 minutes each. Stimulation is activated by the patient."
55082|NCT03753685|Drug|X-396(Ensartinib) Capsule|All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
55086|NCT03753659|Procedure|Microwave Ablation (MWA)|Local ablation via RFA or MWA will be performed via ultrasound- or CT-guided placement of a needle electrode / probe penetrating into the lesion center
55087|NCT03753646|Other|Lactating allowance and psycho social stimulation|Mothers will receive lactating allowance and psycho social stimulation
55088|NCT03753633|Other|Speech therapy|Oropharyngeal exercises will be performed under the supervision of a speech therapist.
55089|NCT03753633|Other|Control|Inspiratory and expiratory exercises recruiting diaphragmatic muscles
55090|NCT03753620|Device|simultaneous fMRI and EEG + peripheral measures|Hemodynamic activity recorded with fMRI, cerebral electric activity recorded with EEG as well as peripheral physiological parameters will be recorded during music listening.
55091|NCT03753620|Device|EEG and peripheral measures|cerebral electric( with EEG) as well as peripheral physiological parameters will be recorded during music listening.
55092|NCT03753607|Other|No intervention|No intervention
55093|NCT03753594|Device|tissue oxygenation saturation|tissue oxygenation saturation
55094|NCT03753581|Device|Care protocol plus microcurrents|"CARE NURSING PROTOCOL: postural treatment every 4 hours more standardized cure according to the guide of recommendations based on evidence in prevention and treatment of pressure ulcers in adults of Osakidetza health service.~MICROCURRENTS: the electrodes will be placed on the edge of the dressing on the sides of the ulcer's longer length during 12 hours a day until the ulcer is completely healed or for a maximum of 25 days.~Characteristics of microcurrents: pulsed monophasic rectangular wave with a pulse of 1.5 s and pause of 300 ms, voltage 21 mV and intensity 42μA with a current density of 4.2 μA."
55095|NCT03753581|Device|Care protocol plus placebo microcurrents|The same nursing care protocol described for the experimental group will be applied more 12 hours per day of 2 electrodes of microcurrents around the ulcer, which will be previously manipulated and tested with an oscilloscope so that they do not emit electrical currents
55096|NCT03753568|Device|Electronic medicine reminder system|Electronic surveillance device is attached to the participants push through pill sheet and the smart phone application reminds the participants to take their medicine if they are about to take their daily dosage.
55097|NCT03753555|Drug|Atorvastatin Calcium|20mg Qd for 12 months
55098|NCT03753555|Drug|Atorvastatin Calcium|40-80mg Qd for 6 months
55099|NCT03753555|Drug|Probucol|0.5g Bid for 6 months
55100|NCT03753542|Other|Multimedia education, booklet Providence and tele-nursing follow-up|Multimedia education, booklet and weekly tele-nursing follow-up is about chemotherapy and side effects management
55101|NCT03753529|Other|Deep friction massage|Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
55102|NCT03753529|Other|Pressure release|First, using a pincer grasp moved throughout the fibers of the pterygoid, masseter, digastric and temporalis muscles to palpate the muscle aiming to locate a trigger point . A common location is detected according to Simon and Travell book. Once located on the trigger point, apply an IC by gradually applying pressure to the trigger point with your thumb. Keep in communication with the patient, checking to ensure that in staying within the limits of his pain tolerance. Hold this technique for approximately 20 seconds to 1 minute, patient tells you that pain has diminished, or until feels the muscle fibers begin to relax under your pressure. Once feel this release, gradually release pressure. All identified trigger points were treated. Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.
55103|NCT03753529|Other|control group|Stretching and transcutaneous electrical nerve stimulation
55104|NCT03753516|Procedure|Laparoscopic - Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close laparoscopically using an 0-Barbed suture.
55105|NCT03753516|Procedure|Vaginal- Vaginal Cuff Closure|All participants are scheduled for either laparoscopic or robotic assisted total hysterectomy. At the end of the hysterectomy the vaginal cuff is closed. In this arm the vaginal cuff will be close vaginally using an 0-Vicryl suture in a vertical fashion.
55106|NCT03753503|Behavioral|exercise|exercised three times a week in the 8-week HIIT program
55107|NCT03753503|Behavioral|conventional physical therapy|
55108|NCT03753490|Other|ABC score guided therapy|In the ABC arm, individual treatment recommendations based on the ABC-scores for stroke and bleeding including non-vitamin K oral anticoagulant or no anticoagulant treatment, and other drugs and interventions, to improve stroke free survival.
55109|NCT03753490|Other|Standard care|In the standard care arm, management according to local practice, national and international guidelines, including the potential use of traditional clinical risk scores for stroke and/or bleeding, anticoagulant treatment and other treatments and interventions.
55110|NCT03753477|Drug|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin)|DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin) X 1 tablet followed by Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet (after washout period)
55111|NCT03753477|Drug|Sevikar and Crestor|Sevikar(Amlodipine/Olmesartan) X 1 tablet and Crestor(Rosuvastatin) X 1 tablet followed by FDC Amlodipine/Olmesartan/Rosuvastatin X 1 tablet (after washout period)
55112|NCT03753464|Procedure|Gingival biopsy and blood sample collection|Gingival and blood samples will be collected.
55113|NCT03753451|Procedure|treatment of periodontal disease|Patients with periodontal disease received treatment of periodontal disease through ultrasound or manual scaling of dental calculations. In addition to receiving instructions to improve oral health, such as the correct use of dental floss, adequate time and the correct way to brush.
55114|NCT03753438|Procedure|Intragstric Ballooning|Intragstric Ballooning will be put.
55115|NCT03753438|Dietary Supplement|Standard of Care|Standard of Care
55117|NCT03753399|Procedure|acupuncture|Acupuncture at back-shu points according to heat-pain threshold measurement at 24 well-points, combining with electro-acupuncture at fixted acupoints.
55118|NCT03753386|Other|Oxygen therapy simulation|"The intervention consists of reproducing oxygen therapy situations in healthy individuals by replacing oxygen bottles with bottles of air. A TeleOx® device will be placed on the circuit between the source and the nasal cannula for respiratory signals recording.~The intervention will last 30 minutes, containing the following activities in the given order:~rest (9 minutes);~drinking water (1 minute);~rest (1 minute);~coughing (1 minute);~rest (1 minute);~reading aloud (1 minute);~rest (1 minute);~breathing by the mouth (1 minute);~rest (1 minute);~exercising (running) (3 minutes) and~rest (10 minutes)~Recordings will be retrieved after each test."
55119|NCT03753373|Other|Acupuncture|Acupuncture treatments will be utilizing the KB-2 points with manual manipulation accomplished by vigorously running the acupuncturists thumb nail up and down the handle until a perceived sensation change is noted in the subject's posteromedial tibia. A single, sterile 100mm needle will be inserted into the upper third of the medial tibiofibular ligament, followed by a second needle approximately 2-4 cm below the second needle. The needles will be manipulated as detailed above to achieve the sensation change along the posteromedial tibia. The needles will then be irregularly stimulated over the course of 5-7 minutes. The needles will be removed after the treatment is complete, which will last approximately 5-10 minutes (standard care).
55120|NCT03753373|Other|Home Exercise Program|Subjects will be given a study diary to document the number of times they performed the standard of care prescribed home exercise program. Subjects will be advised to complete the stretching exercises daily and the strengthening exercises every other day.
55121|NCT03753360|Behavioral|Internet-Based Mindfulness Program - Stress Free Now for Healers|Stress Free Now for Healers is an online stress management program developed at Cleveland. It's delivered in 4 components:1Weekly introductions to the concepts and meditation theme are delivered via Web page views or a 5to10-min audio clip2Weekly guided meditations 5-20 min ea.available as embedded/downloadable mp3 on the website or via the Stress Free Now for Healers phone app,which participants are invited to practice at least 4 times each week and to record those practices3Daily articles provide the scientific underpinnings and merits of each week's theme or discuss various cognitive and behavioral strategies,activities,and concepts supporting or related to mindfulness4Daily tips suggesting how to manage stress or incorporate mindfulness in daily activities,including motivational quotes.Participants will have access to a smartphone app with recordings of the 11 guided meditations.Ea. participant will be assigned an e-coach that will communicate with the participant at least weekly.
55122|NCT03753360|Behavioral|Active Control Group - Relaxing Music|The control group will be given a flash drive and a link to a website where they can download several digital recordings of relaxing music and will be instructed to quietly listen to one or more of the recordings for at least 5 minutes every day for 6 weeks.
55123|NCT03753347|Biological|2018-19 quadrivalent inactivated influenza vaccine|A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
55124|NCT03753334|Dietary Supplement|MAG-EPA|5g/day of omega-3-rich fish oil including 4g of purified monoglycerides EPA, capsules, taken once daily, for 12 months
55125|NCT03753334|Dietary Supplement|Placebo group|5g/day of placebo (high oleic sunflower oil), capsules, taken once daily, for 12 months
55126|NCT03753321|Dietary Supplement|Whey protein|Whey protein isolate, 0.25 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2
55127|NCT03753321|Dietary Supplement|Soy protein|Soy protein isolate, 0.25 g/kg body weight/day for 10 days (7 days pre-loading and 3 days during trials 1 and 2
55128|NCT03753321|Dietary Supplement|Placebo (maltodextrin)|Isoenergetic placebo (maltodextrin) for 10 days (7 days pre-loading and 3 days during trials 1 and 2
55129|NCT03753308|Biological|Blood Sampling|5 x Lithium Heparin Tubes WITHOUT DARK GREEN GEL, 5 ml- v. 4 ml Blood volumes collected as part of the usual care and this research comply with the recommendations of Jarde's law for an observational study (less than 80 ml in one day and less than 160 ml over 30 consecutive days for a subject over 40kg).
55130|NCT03753308|Biological|Liver biopsy|"The liver biopsy is part of the usual care and it follows the usual procedure of CHUGA:~The patient is placed in a supine position and received a transitory sedation, MEOPA gas (Kalinox®). Also, an ultrasound scan is performed. Local disinfection followed by local anesthesia with Xylocaine® are performed. The biopsy is performed with the Hepafix 17 gauge needle. 1 passage is carried out to obtain a biopsy fragment of at least 20 mm for the diagnosis (if the passage is unsuccessful, a second passage can be performed strictly as part of the usual care and not as part of research). If the biopsy is> 20 mm, a fragment of the excess biopsy specimen (10% or 2 mm) will be cut and used for research in groups 1b and 2. This division is performed by the clinician directly on the fresh specimen"
55131|NCT03753295|Diagnostic Test|Hand Grip Force|"For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation.~The test will be performed twice, and the higher value between the two measurements will be selected.~The subjects will be allowed a rest time of more than 5 minutes after the first measurement to avoid examiner bias and to decrease physical stress"
55132|NCT03753282|Other|questionnaires for patient reported outcome|"questionnaires with respect to outcomes:~Reoperations~Short term complications~Long term complications~EQ-5D (current)~HOOS (current)~disease related change of occupation~use of walking aids~comorbidities~medication"
55133|NCT03753282|Other|questionnaire for course of the disease|"questionnaires to assess course of the disease:~from initial diagnosis of AVN to joint replacement as total hip arthroplasty (THA)~therapeutic interventions"
55134|NCT03753269|Drug|Fasudil Hydrochloride|2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
55135|NCT03753269|Drug|Placebo saline|15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
55136|NCT03753256|Device|Transbond XT|"Application of~• Transbond XT (activator comparator) to labial surfaces of teeth of randomized quadrants."
55137|NCT03753256|Device|Protecto®CaF2Nano|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
55437|NCT03751176|Drug|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
55138|NCT03753256|Device|Pro Seal®|"Application of~• Protecto®CaF2Nano (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
55139|NCT03753256|Device|Opal®Seal|"Application of~• Opal®Seal (orthodontic surface sealant) to labial surfaces of teeth of randomized quadrants."
55140|NCT03753243|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
55141|NCT03753243|Drug|Enzalutamide|Patients will receive daily oral doses of study drug (enzalutamide 160 mg/day), which will be administered as four capsules/day to be taken at or near the same time each day.
55142|NCT03753230|Device|Electroencephalography|Cerebral measurements from electroencephalography devices while music is presented to the participant
55143|NCT03753217|Device|qCON Monitor|supervision by qCON monitor of the depth of anesthesia
55144|NCT03753204|Drug|Furosemide 40 mg|Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive.
55145|NCT03753191|Device|transcranial direct current stimulation|Each subject will undergo one tDCS stimulation session lasting for 20 minutes. A constant current of 2 mA will be applied with a linear fade in, fade out of 10 seconds to prevent electrical transients.
55146|NCT03753165|Other|High intensity interval exercise|High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
55147|NCT03753152|Device|experimental|Neuramis® Deep Lidocaine
55148|NCT03753152|Device|comparator|YVOIRE® Volume Plus
55149|NCT03753139|Device|Heart rhythm monitoring with portable device|"The study compares the ability of lightweight measurement methods to detect different heart rhythms compared to the Holter registration.~Faros 360 ECG sensor with wet electrodes. Faros 360 Holter is CE and FDA 510 cleared class 2a medical device, which is attached to the patient's chest with five single-use wet electrodes.~Suunto Movesense one-time ECG device (Suunto Oy, http://www.suunto.com Vantaa Finland). Movesense is CE cleared consumer device, which is used with two dry electrodes to the ECG measurement.~Empatica E4 activity bracelet (Empatica Ltd http://www.empatica.com Milan, Italy), which is CE cleared consumer device. Empatica E4 is a photopletysmogram which measures optically the amount of blood circulating in the blood vessel.~Samsung Gear S3 wearable (Samsung Electronics, Co., Soul, South Korea) which is CE cleared consumer device. Gear S3 is a photopletysmogram, which measures optically the amount of blood circulating in the blood vessel."
55150|NCT03753126|Radiation|4-dimensional volume-rendered computed tomography|
55151|NCT03753113|Other|Topical Herbal Solution|Use Topical Herbal Solution every day in scalp hair loss areas for 3-6 months
55152|NCT03753113|Drug|Topical Minoxidil 5%|Use Minoxidil 5% solution every day in scalp hair loss areas for 3-6 months
55153|NCT03753100|Other|Dual-energy X-ray absorbtiometry to evaluate periprosthetic bone mineral density around an uncemented stem implanted using either lateral or anterolateral approach to the hip joint|The measurement will start in the area about 2 cm proximal to the greater trochanter and will stop slightly below the tip of the prosthesis. This is the baseline scan and will be carried out twice with the patient lying on the table, but with movement between each scan. This is done to calculate the CV, Coefficient of Variation. We will use the formula from Wilkinson and associates, where delta is standard deviations (SD) of the difference between the two BMD measurements for each patient. BMD has been measured at baseline, 3 and 12 months. A DXA scan is now planned at 60 months. Changes in BMD related to the 7 Gruen zones will be registered.
55154|NCT03753087|Drug|Empagliflozin|10 mg tablet
55155|NCT03753087|Other|Standard care|Standard care with no SGLT-2 inhibitors
55156|NCT03753074|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg, Tablet, Oral, Daily
55157|NCT03753061|Device|Aspiration Catheter|Patients will be treated for mechanical recanalization with Aspiration Catheter within 8 hours after stroke onset plus standard medical management.
55158|NCT03753061|Device|Solitaire FR|Patients will be treated for mechanical recanalization with Solitaire FR within 8 hours after stroke onset plus standard medical management.
55159|NCT03753048|Procedure|Y-Graft|Y-Graft Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, the left internal thoracic artery is cut off distally and the right internal thoracic artery is cut off proximally and distally. Then they anastomose the following way. Left internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, distal part of the right internal thoracic artery should be anastomosed to the obtuse marginal artery. Finally, proximal part of the right internal thoracic artery is anastomosed to the left internal thoracic artery as Y-graft in the end to side fashion. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
55160|NCT03753048|Procedure|In-Situ|In-Situ Configuration Using BITA. Surgery can be performed off-pump or on the CPB. Both internal thoracic arteries should be harvested in semi-sceletonized fashion. After the administration of 3 mg/kg i/v UFH, both internal thoracic arteries are cut off distally. Then they anastomose the following way. Right internal thoracic artery should be anastomosed to the left anterior descending artery (LAD) at first. Secondly, left internal thoracic artery should be anastomosed to the obtuse marginal artery. If it is nessesary, the right coronary artery system can be bypassed by separate autoarterial (eg. radial artery) or autovenous graft with proximal anastomose to the aorta.
55161|NCT03753022|Other|Group G5|Submitted to peep 5
55162|NCT03753022|Other|Group G10|Submitted to peep 10
55163|NCT03753022|Other|Group G15|Submitted to peep 15
55192|NCT03752762|Behavioral|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits and group sessions.
55193|NCT03752749|Other|Prednisolone + Acute Intermittent Hypoxia|Administration of oral prednisolone followed by 15, 60-second bouts of mild hypoxia
55164|NCT03753009|Procedure|corneal cross-linking|"Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes."
55165|NCT03752996|Device|ACURATE TF™ Aortic Valve System|Transcatheter Aortic Valve Implantation
55166|NCT03752983|Diagnostic Test|blood samples|blood samples
55167|NCT03752970|Drug|Spesolimab|Solution for infusion
55168|NCT03752970|Drug|Placebo|Solution for infusion
55169|NCT03752944|Procedure|lefort I osteotomy for maxillary advancement|fixation of lefort I osteotomy in patients with retruded maxilla with two prebent plates versus four miniplates.
55170|NCT03752931|Drug|Celiprolol|receiving 1 tablet per day of Celiprolol 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
55171|NCT03752931|Drug|Diltiazem|receiving 1 tablet per day of Diltiazem 200 mg in the morning from the first postoperative day after pneumonectomy or bi lobecomty for 2 weeks.
55172|NCT03752918|Drug|MDMA|A single dose of 1.5mg/kg will be administered once orally.
55173|NCT03752918|Drug|Niacin|A single dose of 250mg will be administered once orally.
55174|NCT03752905|Drug|PTR-01|Recombinant human collagen 7 (rC7)
55175|NCT03752905|Drug|Normal saline|Saline control
55176|NCT03752892|Other|intervention -1-leg cycle training|partitioned aerobic exercise training
55177|NCT03752892|Other|usual care - 2-leg cycle training|conventional aerobic exercise training
55178|NCT03752879|Procedure|Fundal Pressure|Fundal Pressure to assist the vaginal delivery to shorten the second stage of labor
55179|NCT03752866|Device|Portico™ Valve, Delivery System(s) and Loading Systems(s)|Subjects will undergo implantation of a commercially available Portico transcatheter aortic heart valve
55180|NCT03752853|Behavioral|internet-based intervention for mild to moderate depression|The six-weeks, therapist-guided, internet-based intervention for depression includes expressive writing tasks and further consists of key elements of cognitive behavioral therapy (CBT) for depression. In seven consecutive modules, patients receive psychoeducation and instructions for weekly tasks, and an individualized feedback letter of their therapist after each module. The intervention is effective in reducing depressive symptoms (Zagorscak et al., 2018). In the current study, patients will be randomly assigned to two different conditions with varying orders of modules: 1. patients will receive two modules (module 3 and 4) of behavioral activation, followed by two modules (modules 5 and 6) of cognitive restructuring; 2. patients will receive two modules (module 3 and 4) of cognitive restructuring, followed by two modules (modules 5 and 6) of behavioral activation. All other modules (1, 2 and 7) will be identical across conditions.
55181|NCT03752840|Other|Visual acuity (presenting and pinhole)|Presenting and pinhole visual acuity will be assessed using the Peek Acuity mobile application. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
55182|NCT03752840|Other|Optical coherence tomography (OCT)|OCT will be used to image the anterior segment, the macula, and the retinal nerve fiber layer. The images will be assessed for abnormalities and participants meeting referral criteria will be referred to the local eye hospital.
55183|NCT03752840|Other|Intraocular pressure|Intraocular pressure will be measured using an iCare tonometer. Participants meeting referral criteria will be referred to the nearest eye care center or eye hospital.
55184|NCT03752840|Other|Active linkage to care|Referred participants will be followed closely by study staff to ensure completion of follow-up visits.
55185|NCT03752827|Device|Adipose Derived Regenerative Cells|Adipose-derived regenerative cells isolated with the Transpose Ultra system
55186|NCT03752827|Drug|Corticosteroid|Corticosteroid injection into subacrominal space
55187|NCT03752814|Device|SYNOSTE Nitinail System|Mode of application: 1. Implantation surgery: osteotomy and antegrade implantation of SNS in femur for distraction osteogenesis (callotasis), 2. distraction osteogenesis (implant lengthening phase), 3. Bone healing (implant as stabilizing element during consolidation phase), 4. Explantation after consolidation.
55188|NCT03752788|Behavioral|Dual-task Training Fixed Priority|"Dual-task training fixed priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~Attention was focused on both postural and cognitive tasks throughout this session. In postural tasks, subjects were instructed to perform the following: walk narrow base of support with a cognitive task of counting backward by three walk narrow base of support with cognitive task of count forward by three, walk narrow base of support, step, sideways, backward avoiding the obstacles (holding a basket) with cognitive task to remember words."
55189|NCT03752788|Behavioral|Dual-task Training Variable Priority|"Dual-task training variable priority instructional set for four weeks. Balance training sessions of 45 minutes per day, 3 times a week for four weeks, so as to complete 9-12 hours of training warm-up improve the balance performance. This included 12 repetitions in each session for 30 minutes after a 10-minutes warm up.~During the first half of the training session, attention was focused on postural tasks, while during the remaining half of the session, attention was focused on cognitive tasks."
55190|NCT03752775|Device|Robot assisted upper limb rehabilitation|The patients in the experimental and the other arms will receive 20 session device assisted upper limb rehabilitation. In each session, a subject will conduct multi-joint coordinated upper limb motions for 1 hour.
55191|NCT03752762|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study will not include sugar.
55194|NCT03752749|Other|Placebo + Acute Intermittent Hypoxia|Administration of oral matching placebo followed by 15, 60-second bouts of mild hypoxia
55195|NCT03752736|Behavioral|"I wear sunscreen everyday song-based video"|"All four classes (arms) will be shown (sitting on carpet, not participating) a 2-3 minute song-based video titled I wear sunscreen everyday in which they observe elementary age children applying sunscreen in a systematic fashion. Following the viewing, classes will be administered this video guided, song- based intervention while their teacher documents their independent participation using our classroom map data collection sheet."
55196|NCT03752723|Drug|GX-I7|i.m.
55197|NCT03752723|Drug|Pembrolizumab|i.v.
55198|NCT03752723|Drug|cyclophosphamide|i.v.
55199|NCT03752697|Behavioral|metacognitive performance|Paper and pencil/computerized tests of metacognition
55200|NCT03752684|Other|Low Oxalate Diet|Subjects will be instructed to ingest a controlled diet low in oxalate
55201|NCT03752684|Other|Moderately high oxalate/low calcium diet|Subjects will be instructed to ingest a controlled diet moderately high in oxalate
55202|NCT03752684|Other|Oxalobacter formigenes|Subjects will ingest liver preparation of O. formigenes
55203|NCT03752671|Device|Insertion of INTRASPINE device|"The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying on his/her back or front or in the knee to chest position) the approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed by the surgeon's usual practice.~IntraSPINE® is positioned once surgery for the disc hernia has been performed. The implant bed is prepared with the assistance of the distractor provided. The choice of implant size is made after positioning the trial device corresponding to the anatomical bed. Once the size has been established the corresponding implant is placed in a cup of physiological saline prior to implantation. Implantation is performed using the appropriate implant holder."
55204|NCT03752671|Procedure|Discectomy|The surgical technique for excision of the disc hernia is the surgeon's usual technique: patient positioning (lying prone or supine or in the knee to chest position). The approach to the lumbar disc hernia (interlaminar or interspinous), closure and drainage of the operation site are performed using the surgeon's normal practice.
55205|NCT03752658|Drug|Tenofovir Alafenamide|The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
55206|NCT03752645|Device|Transverse Many Channels Laser Instrument|The device consists of a control box and 4 sets of two light-emitting nasal probes. Prior to treatment, each patient put on a pair of black tinted glasses, and had the nasal probes gently placed into both nostrils. A turn-on switch on the control box activated the probe and the timer was set at 15 minutes during which time 36 J of light energy was delivered to each nostril.
55207|NCT03752632|Device|Veinplicity with tourniquet|Veinplicity will be used with a tourniquet
55208|NCT03752632|Device|Tourniquet|A tourniquet alone will be used.
55209|NCT03752619|Device|Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
55210|NCT03752619|Device|Non Contracting Producing Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
55211|NCT03752619|Other|Physical Therapy|All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
55212|NCT03752606|Biological|TACHOSIL GROUP|
55213|NCT03752593|Other|ET Tube|Patients with a BMI of greater than 30 or less than who are presenting to the hospital for any surgical procedure requiring general anesthesia
55214|NCT03752580|Device|User Instructions of novel nasal mask|User Unstructions interpretation of novel nasal mask for the treatment of obstructive sleep apnea (OSA).
55215|NCT03752567|Other|Follow up|like group descriptions
55216|NCT03752554|Procedure|segmental resection|All cases will undergo surgery under general anesthesia. The mandibular lesion will be segmentally resected. The cuts will be performed with the aid of the prefabricated digital template. The neurovascular bundle will be separated and protected. Then reconstruction will be performed
55217|NCT03752541|Biological|BCMA-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted for subjects before CART therapy.
55218|NCT03752528|Diagnostic Test|Blood sample collection|Determination of buprenorphine and norbuprenorphine plasma concentrations
55219|NCT03752528|Diagnostic Test|Urine sample collection|Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration
55347|NCT03751839|Diagnostic Test|Biochemical Tests|The investigators will perform blood tests in every participant.
55348|NCT03751839|Diagnostic Test|Osteodensitometry|The investigators will perform an osteodensitometry in every participant.
55220|NCT03752502|Procedure|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
55221|NCT03752502|Procedure|Peripheral electrical stimulation (PES)|Peripheral electrical stimulation (PES) activates a complex neural network involving a series of neurotransmitters and receptors capable of promoting segmental and extrasegmental analgesia.
55222|NCT03752502|Procedure|Sham tDCS|Transcranial direct current stimulation (tDCS) is a noninvasive brain stimulation (NIBS) technique that has been investigated for the management of various chronic pain conditions. However, as a monotherapy for pain relief, this therapy still has controversial results.
55223|NCT03752489|Diagnostic Test|Treatment-specific InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between clusters of patients who respond similarly to fluids treatment according to the nature of their disease progression.
55224|NCT03752489|Diagnostic Test|InSight|The non-customized InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis.
55225|NCT03752476|Procedure|number of Beta lactam class prescription for the same infection|Each number of Beta lactam prescription without interruption are compared
55226|NCT03752463|Drug|DAOI-A group|DAOI with A dose
55227|NCT03752463|Drug|DAOI-B group|DAOI with B dose
55228|NCT03752463|Drug|DAOI-C group|DAOI with C dose
55229|NCT03752463|Drug|Placebo oral capsule|Placebo
55230|NCT03752437|Diagnostic Test|ACT (Activated Clotting Time)|Measure of ACT in the two arms in order to determine if injection of heparin based on ideal weight is better or not than those one on real weight.
55231|NCT03752437|Drug|Heparin|300 IU of heparin
55232|NCT03752424|Drug|Silver nanoparticles|The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
55233|NCT03752424|Drug|Topical approved anti-microbial gel|The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
55234|NCT03752411|Other|Research Bottle|The purpose of the study is to test a research prescription bottle that will monitor the physical environment inside the bottle.
55235|NCT03752411|Other|Regular prescription Bottle|This will test if the research bottle changes behavior relative to the research bottle
55236|NCT03752398|Biological|XmAb®23104|Monoclonal bispecific antibody
55237|NCT03752385|Behavioral|reducing smartphone screen time|"Cutting average smartphone screen time in half. Sleeping without smartphone in bedroom. Establishing a bedtime to stop smartphone screen time."
55238|NCT03752372|Procedure|hematopoietic stem cell transplantation|"Reduced intensity conditioning(RIC) chemotherapy regimen before transplantation~All patients were cared for in single rooms ventilated with a highly effective particulate air filtration system. All patients received intravenous immunoglobulin and antimicrobial prophylaxis, which included antiviral, antifungal, and Pneumocystis jirovecii prophylaxis with ganciclovir and micafungin, as per routine clinical practice before transplantation.~Umbilical cord blood transplantation"
55239|NCT03752359|Dietary Supplement|whey protein|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
55240|NCT03752359|Dietary Supplement|placebo|This two-arm randomized, double-blind, placebo-controlled design was carried out over a period of 16 weeks. At the beginning and end of the experiment, two weeks were allocated for evaluations consisting of anthropometric (weeks 2 and 16), body composition (weeks 2 and 16), one repetition maximum tests (weeks 1 and 15), functional capacity tests (weeks 1 and 15), blood samples (weeks 2 and 16) and dietary intake measurements (weeks 1 and 15). The anthropometric, body composition, blood samples and dietary intake measurements were carried out in a temperature-controlled room (22-24 °C), and the RT sessions were conducted at the university training facility.
55241|NCT03752346|Other|exercise group|"A step aerobics exercise lasted a total 30 minutes, including:~a warm-up with 10 minutes of stretching exercises.~A step aerobics exercise (step aerobics for 30 minutes; step by step, step exercise, or stepping the ground repetitively)23,24 a total of 30 minutes then cool down (5 minutes).~Resistance training (10 minutes), stretching and relaxation for 10-15 minutes."
55242|NCT03752333|Drug|Pembrolizumab|"Pembrolizumab has high affinity and potent receptor blocking activity for PD-1, based on preclinical in vitro data. Pembrolizumab has an acceptable preclinical and clinical safety profile and is in clinical development as an IV immunotherapy for advanced malignancies.~The PD-1 pathway represents a major immune control switch, which may be engaged by tumour cells to overcome active T-cell immune surveillance. Pembrolizumab is a potent and highly selective humanized mAb of the Immunoglobulin (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection."
55243|NCT03752307|Drug|Isoxsuprine Hydrochloride|Compounded Isoxsuprine hydrochloride capsules
55244|NCT03752307|Drug|Placebo|Identical microcrystalline cellulose placebo manufactured to mimic Isoxsuprine Hydrochloride 10 MG capsules
55245|NCT03752307|Drug|Corticosteroid|This can be any accepted regimen, including daily iv methylprednisolone 1000 mg/day or 600mg oral prednisone two times a day at approximately 8AM and noon
55246|NCT03752294|Drug|Dabigatran|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up.
55247|NCT03752294|Drug|Placebo - Cap|At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
55351|NCT03751839|Diagnostic Test|HR-pQCT|The investigators will perform HR-pQCT measurements of the distal radius and distal tibia in every participant.
55248|NCT03752281|Other|Investigation of health and activity|During a six months multidisciplinary investigation of health status, activity and working ability for individuals receiving long-term social assistance, the health and activity status as well as function will be described using established questionnaires and the International Classification of Functioning
55249|NCT03752268|Behavioral|Enhancing Cancer Pain Management|Patients will learn and practice an enduring framework of cognitive-behavioral strategies, to enhance adherence behavior, reduce intentional and unintentional deviations from the prescribed regimen.
55250|NCT03752255|Other|Anxiety measurement method|Two different techniques (video or verbal information) will be examined about impacted third molar surgery.
55251|NCT03752242|Drug|BMX-010|Safety and efficacy of BMX-010 in topical treatment of acne.
55252|NCT03752229|Device|Acti-Lance Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55253|NCT03752229|Device|Acti-Lance Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55254|NCT03752229|Device|Acti-Lance Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55255|NCT03752229|Device|Medlance Plus Super Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55256|NCT03752229|Device|Medlance Plus Lite|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55257|NCT03752229|Device|Medlance Plus Universal|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55258|NCT03752229|Device|Medlance Plus Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55259|NCT03752229|Device|Medlance Plus Special|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55260|NCT03752229|Device|Prolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55261|NCT03752229|Device|Prolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55262|NCT03752229|Device|Prolance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55263|NCT03752229|Device|Prolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55264|NCT03752229|Device|Prolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55265|NCT03752229|Device|Prolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55266|NCT03752229|Device|Haemolance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55267|NCT03752229|Device|Haemolance Low Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55268|NCT03752229|Device|Haemolnace Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55269|NCT03752229|Device|Haemolance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55270|NCT03752229|Device|Haemolance Max Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55408|NCT03751423|Drug|IV Ketamine|200-500mcg/kg IV over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached
55271|NCT03752229|Device|Haemolance Pediatric|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55272|NCT03752229|Device|MediSafe Solo 29 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55273|NCT03752229|Device|MediSafe Solo 23 Gauge|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55274|NCT03752229|Device|ergoLance Micro Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55275|NCT03752229|Device|ergoLance Normal Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55276|NCT03752229|Device|ergoLance High Flow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55277|NCT03752229|Device|Medlance (light blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55278|NCT03752229|Device|Medlance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55279|NCT03752229|Device|Medlance (dark blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55280|NCT03752229|Device|Medlance (yellow)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55281|NCT03752229|Device|Medlance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55282|NCT03752229|Device|Medlance (red)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55283|NCT03752229|Device|Unistik 3 Extra|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55284|NCT03752229|Device|Unistik 3 Comfort|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55285|NCT03752229|Device|Unistik Touch|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55286|NCT03752229|Device|ReadyLance (blue)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55287|NCT03752229|Device|ReadyLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55288|NCT03752229|Device|AssureLance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55289|NCT03752229|Device|AssureLance MicroFlow|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55290|NCT03752229|Device|Surgilance|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55291|NCT03752229|Device|Surgilance Lite (grey)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55292|NCT03752229|Device|Surgilance Lite (purple)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55436|NCT03751176|Drug|Irinotecan|Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
55293|NCT03752229|Device|SteriLance Lite2|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55294|NCT03752229|Device|SensiLance (pink)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55295|NCT03752229|Device|SteriLance Press|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55296|NCT03752229|Device|SensiLance (orange)|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55297|NCT03752229|Device|mylife|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55298|NCT03752229|Device|VeriFine|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55299|NCT03752229|Device|Microdot|"Finger lancing was undertaken in a standardized way and was performed by medical staff trained from lancing procedure described in the Protocol.~Total blood collection time was recorded in the source documentation and then volume of the blood was measured using a calibrated ruler."
55301|NCT03752203|Drug|Sodium Fluorescein|Patients enrolled in this study will receive 3 mg/kg sodium fluorescein following induction of anesthesia by administration into a peripheral venous line over 10 seconds
55302|NCT03752203|Device|Microscopic Resection|Resection will proceed with the use of a surgical microscope equipped with excitation and barrier filters for monitoring with sufficient fluorescent enhancement and contrast.
55303|NCT03752190|Drug|Cosyntropin|intramuscular and intravenous administration
55304|NCT03752177|Drug|LY3415244|Administered IV
55305|NCT03752164|Behavioral|Yoga and Mindfulness Skills|Single brief session in which children are taught yoga and skills in mindfulness
55306|NCT03752151|Device|MARVEL 2 Algorithm Adaptive Mode Pacing|Software download into implanted Micra device and programmed to MARVEL 2 adaptive mode.
55307|NCT03752151|Device|MARVEL 2 Algorithm Monitor Mode Pacing|Software download into implanted Micra device and programmed to MARVEL 2 monitor mode.
55308|NCT03752138|Drug|Group 1: TK216|Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
55309|NCT03752138|Drug|Group 2: TK216|Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
55310|NCT03752138|Drug|Part 2: Decitabine 10mg/m2|10mg/m2 by vein on Days 1-10 of a 28 day cycle.
55311|NCT03752138|Drug|Part 2: Decitabine 20 mg/m2|20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
55312|NCT03752138|Drug|Expansion Phase TK216|Expansion cohort will receive the RP2D of TK216
55313|NCT03752138|Drug|Expansion Phase Decitabine|Expansion cohort will receive the RP2D of Decitabine
55314|NCT03752138|Drug|Part 2: TK216|Recommended dose from Part 1.
55315|NCT03752125|Dietary Supplement|Flavonoid, caffeine|2 flavonoid/caffeine capsules before breakfast, 2 capsules before lunch
55316|NCT03752125|Dietary Supplement|Placebo|2 placebo capsules before breakfast, 2 capsules before lunch
55317|NCT03752112|Drug|Cefixime|Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection
55318|NCT03752112|Drug|Benzathine penicillin 2.4 million units|Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
55319|NCT03752099|Drug|VERU-111|VERU-111
55320|NCT03752086|Procedure|greater omentum binding|Bind pancreatic stump using greater omentum after distal pancreatectomy
55321|NCT03752086|Procedure|Pancreatic stump exposed without omentum binding|Pancreatic stump exposed without greater omentum binding after distal pancreatectomy
55322|NCT03752073|Device|Trans-cervical cervical balloon|Insertion of Foley Catheter
55323|NCT03752073|Device|Hygroscopic cervical dilator|Insertion of Dilapan-s
55324|NCT03752060|Behavioral|Resistance Exercise|Women assigned to the resistance exercise training group will complete progressive, full-body resistance exercise 3 times per week for 16 weeks.
55325|NCT03752060|Behavioral|Aerobic Exercise|Women assigned to the aerobic exercise training group will complete progressive, aerobic exercise 5 times per week for 16 weeks. The aerobic training will progress first in duration, and then in intensity.
55349|NCT03751839|Diagnostic Test|Clinical Tests|The investigators perform the following clinical tests: vibration threshold test, monofilament test, chair rise test and timed up and go test in every participant.
55350|NCT03751839|Diagnostic Test|HR-QCT|The investigators will perform HR-QCT measurements of the proximal femur and tibia in every participant.
55326|NCT03752034|Other|Muscle Fiber Fragments (MFFs)|During the rotator cuff repair procedure, a biopsy of muscle will be taken from the pectoralis major and processed under sterile conditions in the operating room to obtain MFFs. The final product, composed of autologous MFFs in suspension, will be delivered via targeted injection into the muscle belly of the supraspinatus through the Naviaser Portal with visual guidance after rotator cuff repair is complete.
55327|NCT03752021|Procedure|Myometrial Sampling|"A myometrial sample will be obtained at the time of cesarean delivery. Sample will be obtained from the superior edge of the existing lower uterine segment incision and will be 2 inches in length and 0.5 inches in width. The uterine incision will be repaired in a standard two-layer closure. If a classical cesarean (vertical) uterine incision is deemed necessary and is performed by the surgical team, a sample of the same size will be taken parallel to the incision at the existing edge. The classical uterine incision will be closed utilizing the standard layered technique.~Placenta and gestational membrane tissue will be obtained after placental delivery. The entire placenta and attached gestational membranes will be collected if not being sent for pathologic review"
55328|NCT03752008|Behavioral|Active Play (AP)|This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.
55329|NCT03752008|Behavioral|Outdoor Play (OP)|This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
55330|NCT03751995|Behavioral|Mindfulness meditation|"Participants in the intervention group will have their choice of two commercially available mindfulness programs, HeadspaceTM and eMindful for 6 weeks.~The Headspace program provides progressive guided mindfulness meditation instruction via a website and mobile app to help users learn the skills of mindfulness for use in everyday life. Sessions last 3-20 minutes. Videos encourage the integration of mindfulness into daily life.~eMindful offers an online virtual classroom where participants can participate in synchronous, 1-hour mindfulness classes 1-2 times per week. The program is modeled after the mindfulness-based stress reduction (MBSR) program. eMindful also offers a cancer-specific meditation course that participants may choose to participate in."
55331|NCT03751982|Device|Transcranial Electrical Neuromodulation (TES)|TES phase-aligned with slow waves or not
55332|NCT03751969|Drug|HSK3486|The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing [14C] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
55333|NCT03751956|Drug|HSK3486|The subjects will receive an intravenous injection of 0.8 μCi/0.4 mg/kg of [14C]HSK3486 emulsion injection (i.e., a subject with the body weight of 60 kg is administered with a radiation dose of 48 μCi).
55334|NCT03751943|Device|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)|NanoFUSE® Bioactive Matrix (75%) w/autograft (25%)within one posterolateral gutter
55335|NCT03751930|Other|Samples|Urinary and faecal samples
55336|NCT03751917|Drug|Arsenic Trioxide|This is an observational study. Patients who have received or are receiving all trans retinoic acid (ATRA) + Arsenic Trioxide will be followed and analyzed.
55337|NCT03751904|Device|AcoustiCare|Electronic stethoscope
55338|NCT03751891|Device|Phonak Audéo B90-Direct|The Phonak Audéo B90-Direct is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
55339|NCT03751891|Device|HearingAid_A|HearingAid_A is the most recent Receiver-in-the-canal Hearing aid from manufacturer_A which will be fitted to the participants individual Hearing loss.
55340|NCT03751891|Device|HearingAid_B|HearingAid_B is the most recent Receiver-in-the-canal Hearing aid from manufacturer_B which will be fitted to the participants individual Hearing loss.
55341|NCT03751878|Behavioral|Evaluation of reporting inconsistencies|"The completed CONSORT checklist submitted by authors of manuscripts randomised to the intervention group will be assessed by the lead investigator (DB) as to whether it is consistent with the information that was actually reported in the manuscript. This evaluation will be focused on 8 core CONSORT items.~DB will produce a standardised report containing precise requests for authors in order to improve the completeness of reporting of the items where reporting inconsistencies were found. This report will consist of a brief introduction followed by a point by point description of the inconsistencies found together with precise requests related to the information missing and examples extracted from CONSORT. DB will upload this report to the submission on the managing system of the journal (Scholar One) to make it accessible to the handling editor of the manuscript.~This editor will include the report in the letter to authors alongside the standard peer review reports."
55342|NCT03751878|Behavioral|Standard Peer Review.|Manuscripts will undergo the usual peer review process.
55343|NCT03751865|Behavioral|CBT|A total of 8 CBT sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
55344|NCT03751865|Behavioral|Psychoeducation|A total of 8 psychoeducation sessions will be provided to the participants, each session lasts for approximately 1.5 hour.
55345|NCT03751852|Behavioral|Exercise Coaching|28 classes in 16 weeks
55346|NCT03751852|Behavioral|Psychoeducation|28 classes in 16 weeks
55528|NCT03750565|Drug|TD-1473 - Dose B|oral capsule/tablet, QD
55352|NCT03751826|Other|Incentivised network delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the first intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV themselves and in their peers and friends. They will be counselled to receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
55353|NCT03751826|Other|Peer navigator delivery of HIV-ST|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the second intervention arm will encourage females aged 18-24 to use the HIV-ST to test for HIV and then receive sexual and reproductive health services, contraception and condoms, HIV confirmatory testing and linkage to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
55354|NCT03751826|Other|standard of care|Peer navigators are area based young community care givers, who support young people in their area in the uptake of multi-level HIV prevention provided through the department of health, social welfare and basic education, e.g. parenting support, gender-based violence interventions, safe spaces, mentoring, life-skills, and support around knowing and getting social entitlements and financial literacy. The peer navigators in the standard of care arm encourage females aged 18-24 to test for HIV, receive sexual and reproductive health services, contraception and condoms, and link to HIV care and prevention, including HIV Pre-Exposure Prophylaxis (PrEP), through referral slips to the study mobile clinical services.
55355|NCT03751813|Dietary Supplement|Supplement|Supplement will be given to this group to take daily for 8 weeks
55356|NCT03751800|Drug|Chronic hormonal treatment|Drugs used in this study are described by the physicians during routine gynecological visits
55357|NCT03751787|Other|cranial osteopathy|two sessions at three weeks intervals
55358|NCT03751787|Other|comfort massage|manipulation, comfort massage, standardized and not affecting the skull
55359|NCT03751774|Behavioral|MAMAACT|Post graduate training and health education materials
55360|NCT03751761|Drug|durvalumab, tremelimumab, paclitaxel|Durvalumab, 1500 mg Q4W for 12 months Tremelimumab 75 mg Q4W for up to 4 doses/cycles Paclitaxel iv D1, D8, D15 Q4W (from 60mg/m2 to 80mg/m2)
55361|NCT03751748|Device|AFR implantation|Implantation of atrial flow regulator (AFR) device
55362|NCT03751748|Device|Sham procedure|Sham procedure to include cardiac catheterization and hemodynamic. Ongoing management at the discretion of the treating physician. Patient to undergo
55363|NCT03751735|Biological|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
55364|NCT03751709|Drug|Blinatumomab|Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.
55365|NCT03751709|Other|Haplo-Mismatched Cell Therapy (HMCT)|HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 & Day 15
55366|NCT03751696|Behavioral|Group Coaching|4 sessions of 2.5-hour group coaching intervention within 8 weeks
55367|NCT03751696|Behavioral|'General wellbeing' class (GMWP)|4 sessions of 2.5-hour 'general wellbeing' class within 8 weeks
55368|NCT03751670|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation programmes will include breathing retraining and chest clearance techniques, exercises for thoracic mobility, muscle strength, cardiorespiratory exercise training and education about the disease.
55369|NCT03751670|Drug|Daily medical treatment|Patients will be treated with daily medication prescribed by the physician.
55376|NCT03751644|Other|Electrical stimulation|Patients with systemic autoimmune myopathies will receive peripheral electrical stimulation in thigh muscles
55377|NCT03751631|Drug|Phenylephrine 2.5%-tropicamide 1% ophthalmic solution|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered with a microdose dispenser
55378|NCT03751631|Drug|Phenylephrine 2.5% ophthalmic solution|Phenylephrine 2.5% ophthalmic solution administered with a microdose dispenser
55379|NCT03751631|Drug|Tropicamide 1% ophthalmic solution|Tropicamide 1% ophthalmic solution administered with a microdose dispenser
55380|NCT03751618|Procedure|Hip arthroscopy|"Suture will be realized with two simple suture knots (non resorbable suture material). These suture knots will be performed at the end of hip arthroscopy. Correct capsular suture will be controlled under arthroscopy video.~Patients randomized in control arm will not received capsular suture at the end of the procedure."
55381|NCT03751605|Procedure|unipulmonary ventilation|observational study based on the computation of respiratory quotient in patient cohort treated by unipulmonary ventilation in routine thoracic surgery
55382|NCT03751592|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
55383|NCT03751579|Procedure|coelioscopic surgery|observational study based on the computation of respiratory quotient in patient cohort treated by routine coelioscopic surgery
55384|NCT03751566|Other|Acupuncture|"Schedule of the acupuncture:~Acupuncture may be done ambulant or during hospitalisation . Acupuncture will be administered 1-3 times a week ( in case of severe toxicity and problems caused by the radiotherapy, it may continue also after the termination of the radiotherapy.) Acupuncture needles will be left for 5- 30 minutes, as per individual need of the patients.~Acupuncture will be performed by a physician trained in acupuncture."
55385|NCT03751566|Drug|Standard supportive therapy|Standard supportive therapy
55386|NCT03751553|Drug|obsteric gel(k-Y jelly)|A sterile obstetric gel( K-Y Jelly 82GM; manufactured by Johnson&amp; Johnson) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membrane since the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping
55387|NCT03751540|Procedure|ostap|this block is performed under general anesthesia in this patients for postoperative analgesia.
55388|NCT03751540|Procedure|SIPB plus rectus sheath block|this block is performed under general anesthesia in this patients for postoperative analgesia.
55389|NCT03751527|Device|ZENFLEX peripheral stent system|The ZENFLEX Peripheral Stent System is designed to deliver a self-expanding stent to the iliac artery, superficial femoral arteries and / or proximal popliteal arteries to improve luminal diameter. The self-expanding stent is composed of nickel titanium alloy (nitinol); contains a total of 12 tantalum / gold radiopaque markers and imparts an outward radial force on the luminal surface of the vessel to establish patency.
55390|NCT03751514|Biological|Bordetella Pertussis B1917|"The B. pertussis isolate to be used in this human colonisation model is strain B1917, which is representative of current isolates in Europe. The strain, isolated in 2000 from a Dutch patient with B. pertussis disease, expresses Prn, PT and Filamentous Haemagglutinin (FHA). This strain has been extensively characterised in the mouse model as well as by proteomics and transcriptomics and has a closed genome available. It is fully sensitive to azithromycin in vitro.~Providing there are no safety concerns the standard inoculum (SI) will be identified in a dose escalating or de-escalating experiment commencing at 103 colony forming units administered intranasally."
55391|NCT03751514|Drug|Azithromycin 500 mg|To ameliorate risk of transmission of B. pertussis B1917 to the environment and household contacts, Azithromycin 500 mg once a day for 3 days will be given to eradicate colonisation with B. pertussis. The inoculum strain is fully sensitive to this antibiotic. Previous studies show that azithromycin eradicates colonisation in 97% of people in 48 hours.
55392|NCT03751514|Other|Sterile Saline|To compare against B. pertussis, some volunteers will be enrolled onto the Sham arm. These volunteers will not receive B. pertussis but instead be given sterile saline
55393|NCT03751501|Procedure|Indocyanine green-Guided Targeted Laser photocoagulation|Detection of macro-aneurysms by ICG angiography, laser photocoagulation and optional post-laser verification of the effectiveness of the photothrombosis by OCT.
55394|NCT03751501|Procedure|Sham laser|Therapeutic procedure used in ophthalmology
55395|NCT03751488|Drug|LY03010|Single Dose of LY03010 at 351 mg or 156 mg or 117mg
55396|NCT03751488|Drug|Invega Sustenna 156 MG in 1 ML Prefilled Syringe|Single Dose at 156mg
55397|NCT03751475|Other|Nutritional Strategy - OptiMA|"All children with a MUAC<125mm or oedema will be treated with the same RUTF, according to a new dosage table based on the evolution of MUAC and weight during recovery (RUTF dosage prescribed is gradually reduced as weight and MUAC increase).~All children will be followed-up for 6 months following randomization. They will have weekly outpatient visit in the health facility until they meet discharge criteria, and then a bimonthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated)."
55398|NCT03751475|Other|Effective nutritional standard strategy|"Children presenting with MUAC<115 or WHZ<-3 or nutritional oedema, will be treated with RUTF, according to the usual dosage table based on weight at each visit.~All children (whether eligible for RUTF or not) will be followed-up for 6 months following randomization. Children eligible for RUTF at randomization will have a weekly outpatient visit in the health facility until they meet discharge criteria, and then a bi-monthly community-based follow-up in their villages (vital & anthropometric status and referral to the health facility for appropriate nutritional/medical care if indicated). Children not eligible for RUTF at randomization will benefit from this same monthly community-based follow-up."
55399|NCT03751462|Device|Purkinjemeter|The Purkinjemeter will be used for assessment of IOL wobbling, tilt and decentration in patients with pseudoexfoliation syndrome or traumatic cataract
55400|NCT03751449|Other|Educational Intervention|Receive nutrition education
55401|NCT03751449|Behavioral|Exercise Intervention|Complete home-based aerobic and resistance exercise program
55402|NCT03751449|Other|Quality-of-Life Assessment|Ancillary studies
55403|NCT03751449|Other|Questionnaire Administration|Ancillary studies
55404|NCT03751436|Drug|Enzalutamide|Given PO
55405|NCT03751436|Drug|Venetoclax|Given PO
55406|NCT03751423|Drug|PO Morphine|10-20mg oral morphine depending on such factors as weight (100-200mcg/kg), previous opiate exposure (opiate naïve vs opiate sensitized), and participant's previous experiences with opiate medications for painful procedures. Dosing will be determined at the discretion of the surgical provider in clinic that day, as per standard of care.
55407|NCT03751423|Drug|IV Fentanyl|0.5-1mcg/kg IV fentanyl over 2 minutes repeated every 5 minutes as needed until appropriate analgesia is reached.
55409|NCT03751423|Drug|PO Placebo|A standard placebo pill, the same size, shape and colour of the oral morphine. The placebo will be administered to the participants randomized to the IV ketamine and IV fentanyl during pre-op in the same manner the oral morphine would be administered.
55410|NCT03751423|Drug|IV Placebo|This normal saline will be administered to the participants randomized to the oral morphine group during the procedure in the same manner that IV fentanyl or IV ketamine would be administered.
55411|NCT03751397|Other|blood test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein, beta-2 microglobulin, uromodulin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
55412|NCT03751397|Other|urine test for renal biomarkers (creatinine, cystatin C, Neutrophil gelatinase-associated lipocalin, beta-trace protein beta-2 microglobulin, uromodulin, albumin)|relationship between the different biomarkers by linear regression analysis is assessed; influence of demographic variables (age, body weight, body surface area) is investigated by multivariate regression.
55413|NCT03751384|Dietary Supplement|Möllers Omega-3 Ekstra Sterk|
55414|NCT03751384|Dietary Supplement|Nutrifriend Cachexia|
55415|NCT03751371|Device|Training with HWA device|Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
55416|NCT03751371|Other|Usual Care|The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
55417|NCT03751358|Procedure|Unilateral Erector spinae plane block|Magnetic résonance imaging
55418|NCT03751345|Behavioral|Parenting Wisely|PW is a self-administered, interactive, multimedia online program. Parents will complete computer-administered sessions during in-person appointments.The program comes with a parent workbook so that parents can gain additional exposure to and practice with the skills. The complete PW program takes from 3 to 5 hours to complete depending on the users' speed and depth of use. Parents will be given a login at enrollment so that they have the option to practice sessions or view any additional sessions at home. Individual coaching sessions will take place in-person with parents. Coaching sessions are designed to tailor the PW skills to each parent's presenting concerns.
55419|NCT03751332|Drug|Tacrolimus|Conversion from either cyclosporin or tacrolimus to tacrolimus modified release
55420|NCT03751319|Other|CGA|Comprehensive Geriatric Assessment
55421|NCT03751306|Procedure|Transcranial Photobiomodulation|"Photobiomodulation Rehabilitation:~Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) ."
55422|NCT03751306|Procedure|Transcranial Photobiomodulation (Placebo)|"Photobiomodulation Placebo Therapy:~The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off."
55423|NCT03751306|Procedure|Cardiorespiratory Rehabilitation|"Cardiorespiratory Rehabilitation:~Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives."
55424|NCT03751293|Biological|C-CAR088|Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10^6 anti-BCMA CAR+ T cells/kg
55425|NCT03751280|Device|PEAR-004|PEAR-004 is an investigational digital therapeutic, currently available on a mobile device (iOS and Android based). It is designed to serve as an illness self-management tool. Subjects can Subjects will access PEAR-004 as needed to receive suggestions about coping strategies to overcome difficulties in daily life.
55426|NCT03751280|Device|Sham|A control sham will be available to the control group. The sham will be downloaded to the subject's phone, but will not deliver the active therapeutic content of PEAR-004. It will deliver notifications prompting the subject to open the sham app, and will then display a prescription timer for the remaining duration of app availability.
55427|NCT03751267|Procedure|Tuina (massage)|Tuina is massage based on Traditional Chinese Medicine (TCM) principles.
55428|NCT03751254|Device|Stellaris Elite|The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length > 25.0 mm) during cataract surgery
55429|NCT03751241|Device|EyeTracker|The EyeTracker is used to determine reading quality of patients with different intraocular lens types (EROV, monofocal, minimonovision)
55430|NCT03751228|Drug|BMS-986165|Swish and expectorate after tasting
55431|NCT03751228|Drug|Active Pharmaceutical Ingredient|Swish and expectorate after tasting
55432|NCT03751215|Procedure|Cataract surgery|During cataract surgery the patient is implanted with the monofocal IOL Clareon in one eye and the monofocal IOL AcrySof in the contralateral eye
55433|NCT03751202|Drug|Fluticasone propionate 500 mcg and salmeterol xinafoate 50 mcg|2 inhalations of Test and Reference product in each study period
55434|NCT03751202|Drug|ADVAIR DISKUS|2 inhalations of Test and Reference product in each study period
55435|NCT03751176|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
55438|NCT03751176|Drug|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
55439|NCT03751163|Drug|Tranexamic Acid Oral Product|Encapsulated tranexamic acid 250 mg
55440|NCT03751163|Drug|Hydroquinone 4% Cream|Hydroquinone 4% Cream
55441|NCT03751163|Other|Sunscreen|Sunscreen SPF 30
55442|NCT03751163|Device|Placebo|Encapsulated placebo
55443|NCT03751150|Other|Exercise program|The runners will be asked to perform their specific training program- depending on the intervention to which they have been allocated- three times a week. The interventions consist of either strength and foam rolling exercises for the lower extremities or only foam rolling for the lower extremities.
55444|NCT03751124|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
55445|NCT03751124|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
55446|NCT03751124|Drug|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
55447|NCT03751124|Drug|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the E2/NETA capsule in size, shape, color, and odor
55448|NCT03751111|Drug|Naloxone|Naloxone at an sublingual dose of 40 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
55449|NCT03751111|Drug|Placebo|Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
55450|NCT03751098|Drug|Phenylephrine 2.5%-tropicamide 1% ophthalmic solution|Fixed combination phenylephrine 2.5%-tropicamide 1% ophthalmic solution administered with a microdose dispenser
55451|NCT03751098|Drug|Placebo|Eyewash administered with a microdose dispenser
55452|NCT03751085|Device|AW frame|AW stereotactic frame for intracranial lesion biopsy
55453|NCT03751059|Drug|Bromfenac 0.07% Oph Susp|Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.
55454|NCT03751059|Drug|Dexamethasone|Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.
55455|NCT03751046|Behavioral|Trial-Based Cognitive Therapy|Participants in the TBCT intervention arm will have 14 (fourteen) psychotherapy sessions over a period of 7 (seven) months. The frequency of the intervention is biweekly with a duration of approximately 90 minutes per session. We will have10 groups with 5 participants each. All participants will practice the learned techniques during the meetings, have a manual with a description summary of the sessions and the activities to practice at home. The main TBCT techniques that will be used are case conceptualization, intrapersonal thought record, consensual role-play, action plan, trial-based thought record and trial-based metacognitive awareness.
55456|NCT03751046|Other|Control group. Standard healthcare.|"Participants with therapeutic failure, receiving the standard healthcare in the HIV / AIDS Program, which includes at least a half-yearly psychology and pharmaceutical chemist consultations (approximately half an hour each).~The purpose of these consultations is to approach the importance of adherence and psychoeducation on HIV"
55457|NCT03751033|Device|BSS|Intraoperative aberrometry measurements for BSS will be performed.
55458|NCT03751033|Device|DiscoVisc|Intraoperative aberrometry measurements for DiscoVisc will be performed.
55459|NCT03751020|Behavioral|Expressive Writing (EW) Intervention|The EW intervention will utilize the procedures piloted earlier with gay and bisexual male college students in urban and rural regions of the US. In this condition, participants will be instructed to write for 20 minutes across three consecutive days in a free-form manner about the most stressful or traumatic LGB-related event that they have encountered.
55460|NCT03751020|Behavioral|Self-Affirmation (SA) Intervention|The SA intervention will ask participants to read a brief description, over the course of 3 consecutive days, of a (hypothetical) LGB youth who is facing minority stress. Each day's description will contain a different LGB youth facing a different stigma-related stressor derived from Phase 1 and 2 interviews. Participants will then be asked to write a letter for 20 minutes to advise the LGB youth how best to cope with minority stress drawing on their personal experiences.
55461|NCT03751020|Other|Control|Participants randomly assigned to the control condition will be asked to write about what they have done since waking up that morning for 20 minutes across 3 consecutive days. This control matches the time and activity of the EW and SA arms and has been implemented across dozens of EW and SA studies.
55462|NCT03751007|Biological|AG019 - Low Dose|Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
55463|NCT03751007|Drug|Teplizumab|Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).
55464|NCT03751007|Drug|Placebo-AG019|Formulated identically to AG019 with the active ingredient removed.
55465|NCT03751007|Drug|Placebo-Teplizumab|Formulated identically to teplizumab with the active ingredient removed.
55466|NCT03751007|Biological|AG019 - High Dose|Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)
55467|NCT03751007|Biological|AG019 - Low or High Dose|Solid, orally administered capsule - 2 or 6 capsules per day for 8 weeks (repeat dose).
55468|NCT03750981|Behavioral|13 week pilot intervention study.|Participants will begin a 13-week high-intensity functional training program conducted at CrossFit Detroit located in downtown Detroit.
55469|NCT03750968|Drug|Carotenoid Group|DHA Softgel active ingredients: DHA 200 mg, d-Alpha Tocopherol 30 IU, Lutein 6mg
55470|NCT03750968|Dietary Supplement|Control Group|DHA Softgel active ingredients: DHA 200 mg, d-Alpha Tocopherol 30 IU
55471|NCT03750955|Device|Plaque induced gingivitis|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene cessation utilizing localized stent-induced biofilm overgrowth model (SIBO), will manipulate the participants' oral environment by leading to reversible inflammation of the gingival tissues.
55472|NCT03750955|Device|Oral hygiene maintenance|Non-invasive microimaging (OTC device) of gingival tissue where oral hygiene has been maintained by tooth brushing with fluoride toothpaste and flossing twice daily.
55529|NCT03750565|Drug|TD-1473 - Dose C|oral capsule/tablet, QD
55473|NCT03750942|Device|Adhesix® monofilament polypropylene mesh (Bard Davol)|The intervention group will receive preventive mesh placement and in the control group no mesh is placed, the stoma is closed according to standard practise.
55474|NCT03750929|Other|Combined acute physical exercises (strength and aerobic)|Patients will be submmitted to combined acute physical exercises (strength and aerobic)
55475|NCT03750916|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
55476|NCT03750903|Behavioral|Aerobic Exercise|Participants will engage in an aerobic exercise program meeting thrice weekly for a period of 12 weeks.
55477|NCT03750903|Behavioral|Stretching and Balance Training|Participants will engage in a balance and stretching comparator condition meeting thrice weekly for 12 weeks.
55478|NCT03750877|Procedure|median approach|spinal anesthesia with median approach; is the known classical method and it is aimed to reach the spinal area from the middle line.
55479|NCT03750877|Procedure|paramedian approach|In spinal anesthesia with a paramedian approach, 1 cm lateral and 1 cm caudal to reach the spinal area.
55480|NCT03750864|Behavioral|ACT-LCS Therapy|All participants in Stage 1, and those randomized to the intervention condition in Stage 2, will receive the Acceptance & Commitment Therapy for Lung Cancer Stigma (ACT-LCS) intervention. The ACT-LC intervention is designed to be delivered as 6 sessions of individual psychotherapy with a trained psychotherapist at a weekly or bimonthly rate, delivered either in person or over the phone. The treatment manual is based in Acceptance and Commitment Therapy (ACT). Therapists are instructed to begin treatment with Module 1. Modules 2-5 can then be administered in any order at the discretion of the therapist, based upon what the therapist thinks is most likely to be helpful to the patient. Module 6 is the final session of treatment.
55481|NCT03750851|Other|Placebo|In this group, a water soluble gel without addition any desensitizing agent (K-Y®, Johnson & Johnson, Brazil) was applied to hypersensitive dentin. The GPlacebo volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) was used to scrub the placebo gel for 20 seconds on each tooth.
55482|NCT03750851|Other|CPPACPF|In this group, a toothpaste MI Paste Plus™ (Recaldent™, GC América, USA) was applied to hypersensitive dentin. The GCPPACPF volunteers were submitted to the application of the paste dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a microbrush applicator (Microbrush, 3M ESPE, Brazil) and left undisturbed on the surface during 05 minutes. Then, a rubber cup (Unid Microdont, Brazil) mounted on a low speed handpiece (500, Kavo, Germany) were used to scrub the desensitizing gel for 20 seconds on each tooth.
55483|NCT03750851|Other|Laser|In this group, the diode laser with an active medium of Asauxa bauxite (Photon Lase III, DMC Equipamentos Ltda, Brazil) was applied in hypersensitive dentin. GLaser received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 3 sessions with a time interval of 24 hours between them.
55484|NCT03750851|Other|LaserCPPACPF|In this group the laser + CPP-ACPF was applied. The laser was used with light intensity medium Asauxa (Photon Lase III, DMC Equipamentos Ltda, Brazil) and a toothpaste containing CPP-ACPF MI Paste Plus™ (Recaldent™, GC América, USA) was applied in hypersensitive dentin. GLaserCPPacpf first named a toothpaste application and them the laser application, according to the manufacturer's recommendations.
55485|NCT03750838|Behavioral|Text Messaging Intervention|The content for the TM Intervention will be designed to be non-confrontational in tone, seek to increase motivation to drink lightly or not at all, and based both on general information about light and non-drinking as well as information provided during the baseline assessment.
55486|NCT03750838|Behavioral|Active Control|Participants will receive a series of TM based on nutritional data on the same schedule as those in the TM intervention and will complete a 6 week post-intervention assessment as well as all follow-ups.
55487|NCT03750825|Device|NIDA Standard Research E-cigarette (SREC)|Smokers will switch to NIDA Standard Research E-cigarette (SREC).
55488|NCT03750812|Behavioral|Aerobic Exercise|Medium-intense 60% heart rate reserve (HRR) aerobic exercise on a treadmill for 30 minutes
55489|NCT03750812|Behavioral|Watching television|Sitting and watching television for 30 minutes
55490|NCT03750799|Device|Whole body vibration|Whole body vibration was applied on the right lower extremity in the experimental group.
55491|NCT03750799|Device|Sham vibration|Sham vibration was applied on the right lower extremity in the Control sham group
55492|NCT03750786|Drug|Arfolitixorin|Arfolitixorin and 5-FU and Oxaliplatin and Bevacizumab
55493|NCT03750786|Drug|Leucovorin|Leucovorin and 5-FU and Oxaliplatin and Bevacizumab
55494|NCT03750773|Drug|Gabapentin 600mg|Subject is given Gabapentin 600mg every 8 hours x 48 hours postoperatively for pain control.
55495|NCT03750773|Drug|Placebo oral capsule|Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
55496|NCT03750760|Drug|Alirocumab|PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) inhibitor antibody
55497|NCT03750760|Drug|Atorvastatin 80mg|3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statin)
55498|NCT03750760|Drug|Ezetimibe 10mg|Cholesterol absorption inhibitor
55499|NCT03750747|Device|Pulse Oximeter|SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing <10 kg, the sensor will be placed on the big toe. For patients weighing >10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
55500|NCT03750734|Diagnostic Test|Bronchoscopy|Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.
55501|NCT03750734|Diagnostic Test|Blood test|Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
55502|NCT03750721|Other|Role of rifampin in staphylococcal PJI|the aim is to determine if the dose and the duration of rifampin influenced the prognosis
55503|NCT03750708|Device|Ara® KOLIBREE tooth brush|"Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data."
55504|NCT03750695|Behavioral|Resistance exercise|One acute exercise session of resistance exercise (40 minutes including 3 sets of 8-10 repetitions at the participant's 10 repetition maximum load of upper and lower extremity exercise
55505|NCT03750695|Behavioral|Aerobic Exercise|One acute session of aerobic exercise (40 minutes of cycle ergometry exercise at 70% of VO2peak)
55506|NCT03750695|Behavioral|Rest|40 minutes of quiet rest in semi-recumbent position
55507|NCT03750682|Other|Physical Activity (PA) Intervention|The PA intervention will consist of a twice per week group- based moderate-intensity multimodal program that includes aerobic, strength, flexibility, and balance training, as previously described. The Community Health Promoter will be trained and certified by Dr. Reid to deliver the PA intervention. PA will be conducted at the Holland Street Senior Center in Somerville, MA. The center is equipped with a large dining hall and corridors which will be utilized to perform the various components of the PA intervention for ENGAGE-B. This real-world approach was shown to be safe, feasible and effective in the initial ENGAGE study among older adults with severe mobility-limitations. Throughout PA, walking will be the primary mode of exercise, given its widespread applicabilityThe study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all PA subjects.
55508|NCT03750682|Other|Healthy Aging Education (HE) Intervention|"The HE intervention will also be conducted at the Holland Street Senior Center in Somerville, MA. Participants will receive bimonthly lifestyle counseling workshops in a group setting. Participants will receive information on a variety of topics of relevance to older adults (e.g., nutrition for brain health, effective negotiation of the health care system, dietary guidelines for older adults, safe travel, age-appropriate preventive services and screenings, resources for reliable health information, etc.). All intervention materials will be submitted for IRB approval prior to the presentation. In addition to educational offerings, an instructor led program (5-10 minutes) of gentle upper extremity stretching exercises and relaxation techniques are to be performed during each class.~The study staff will administer an Adverse Event/Concomitant Medication Questionnaire biweekly to all HE subjects."
55509|NCT03750669|Drug|AG regimen|Combination of Nab-paclitaxel 125 mg/m^2 and Gemcitabine 1000 mg/m^2
55510|NCT03750669|Drug|mFolfirinox|Folic acid 400mg/m^2, 5- fluorouracil 2400mg/m^2 for 46h, irinotecan 135mg/m^2 and oxaliplatin 68mg/m^2
55511|NCT03750656|Drug|Hyoscyamine|Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
55512|NCT03750656|Drug|Tamsulosin|Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
55513|NCT03750643|Drug|LY3454738|Administered IV
55514|NCT03750643|Drug|LY3454738|Administered SC
55515|NCT03750643|Drug|Placebo|Administered IV
55516|NCT03750617|Diagnostic Test|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
55517|NCT03750604|Diagnostic Test|visceral fat obesity (surface area and function)|"WC is evaluated at the midpoint between the lower border of the rib cage and the iliac crest. The surface area of subcutaneous fat (S) and visceral (V) is calculated using slices between L4-L5 and umbilicus according to ct detection fat methods Also bladder wall thickness was calculated by measuring average bladder wall thickness at three different levels.~Subcutaneous fat to visceral fat ratio was calculated. Assays for serum total and high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels were performed in the hospital's chemistry laboratory with an autoanalyzer. VAI was calculated for females as this formula like the previous study.~VAI: WC/ [36.58 + (1.89 × BMI)] × TG/0.81 × 1.52/HDL.~And in males:~VAI: WC / [39.68 + (1.88 x BMI)] x TG/ 1.03 x 1.31/ HDL WC: waist circumference, BMI: body mass index, TG: triglyceride, HDL: high-density lipoprotein"
55518|NCT03750591|Drug|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
55519|NCT03750591|Procedure|Chuna manual therapy|"Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving highvelocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.~Chuna manipulation will be administered at the physician's discretion."
55520|NCT03750591|Procedure|Bee venom pharmacopuncture|"Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test.~Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea)."
55521|NCT03750591|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26gauze(G) x 1.5 syringe, Shinchang medical co., Korea).
55522|NCT03750591|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
55523|NCT03750591|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
55524|NCT03750591|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
55525|NCT03750591|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
55526|NCT03750578|Behavioral|Virtual Reality goggle (Oculus Rift ® Helmet)|as described
55527|NCT03750565|Drug|TD-1473 - Dose A|oral capsule/tablet, QD
55533|NCT03750539|Radiation|Standard radiotherapy|External Bean Pelvic Radiation: 50 Gy in 15 fractions, with weekly cisplatin.
55534|NCT03750539|Radiation|hypofractionated radiotherapy|External Bean Pelvic Radiation: 37.5 Gy in 15 fractions, with weekly cisplatin.
55535|NCT03750539|Procedure|Radical hysterectomy|Radical hysterectomy and pelvic and paraaortic lymph node resection
55536|NCT03750526|Behavioral|rTMS and AR|rTMS performs 1Hz,15 minutes real rTMS. AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
55537|NCT03750526|Behavioral|Sham rTMS and AR|Sham rTMS applies 1Hz, 15 minutes sham rTMS. AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
55538|NCT03750526|Behavioral|AR|AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
55539|NCT03750526|Behavioral|Conventional physiotherapy|Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
55540|NCT03750513|Radiation|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Given LET optimized IMPT
55541|NCT03750513|Other|Quality-of-Life Assessment|Ancillary studies
55542|NCT03750513|Other|Questionnaire Administration|Ancillary studies
55543|NCT03750500|Device|Biofeedback device|12-week exercise program performed through the device
55544|NCT03750500|Behavioral|Education on falls risk|Education on falls risk factors and how to minimize them
55545|NCT03750500|Other|Medication review|Medication will be reviewed to reduce sedative drugs and minimize interactions
55546|NCT03750500|Diagnostic Test|Visual and auditory screening|Patients will go through visual and auditory screening as part of their regular care
55547|NCT03750487|Behavioral|e-screening & brief intervention (e-SBI)|Computer-delivered screening and brief motivational intervention targeting alcohol and drug use + goal-setting and content reinforcement
55548|NCT03750474|Diagnostic Test|magnetic resonance elastography and shear wave elastography|magnetic resonance elastography and shear wave elastography of the back muscles
55549|NCT03750461|Device|Mesh Implantation|Implantation of permanent mesh (BARD Soft Mesh) into the abdominal wall for reinforcement to prevent hernia formation
55550|NCT03750448|Other|Telerehabilitation|The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
55551|NCT03750448|Other|No intervention|Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
55552|NCT03750448|Other|Unsupervised rehabilitation|The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
55553|NCT03750435|Procedure|AF ablation or left-sided AT ablation|According to the type of AF/AT, single or double transseptal and subsequent catheter ablation in the left atrium using radiofrequency will be performed.
55554|NCT03750422|Device|Picoway|1064/532nm picosecond laser
55555|NCT03750422|Other|Stratacel|a self-drying, bacteriostatic, transparent silicone gel with anti-inflammatory properties
55556|NCT03750422|Other|Aquasonic|clear ultrasound gel
55557|NCT03750409|Device|Helmet|The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
55558|NCT03750396|Procedure|Surgical resection|Surgical resection for their metastatic lesions will be performed. Achievement of tumor-free margin is not mandatory.
55559|NCT03750396|Radiation|Stereotactic body radiotherapy|Deliver appropriate metastasis directed radiotherapy while minimizing exposure of surrounding normal tissues. Total radiation dose and fractions are various according to metastatic lesions (57~97.5Gy/6~10 Fraction).
55560|NCT03750396|Procedure|Radiofrequency ablation|RFA is a localized thermal treatment technique designed to induce tumor destruction by heating the tumor tissue to temperatures that exceed 60℃. The alternating current of radiofrequency waves passing down from an uninsulated electrode tip into the surrounding tissues generates changes in the direction of ions and creates ionic agitation and frictional heating. This tissue heating then drives extracellular and intracellular water out of the tissue, resulting in tissue destruction by coagulative necrosis.
55561|NCT03750383|Drug|EDP-938|Subjects will receive EDP-938 once daily on Day 1 and Day 5 (Part 1)
55562|NCT03750383|Drug|EDP-938|Subjects will receive one dose of EDP-938 on Day 1 and Day 8 (Part 2)
55563|NCT03750383|Drug|Cyclosporine|Subjects will receive one dose of cyclosporine on Day 5
55564|NCT03750383|Drug|Prednisone|Subjects will receive prednisone once daily from Day 5 to Day 14
55565|NCT03750370|Device|Doppler ultrasound|Colored Doppler Sonography is well established to illustrate microvascularity and therefore perfusion of the testis. The arterial flow velocities (peak systolic velocity [PSV] and end diastolic velocity [EDV]) and the resistance indices against this flow (resistive index [RI] and pulsatility index [PI]) in the testis can be measured with this technique.
55566|NCT03750357|Device|Primary Relief v 2.0|To prove the effectiveness of Post Operative Pain Solution using Primary relief v 2.0 by Percutaneous Electrical Nerve Stimulation in the auricle.
94924|NCT03444285|Other|Hot Pack|20 minutes of hot-pack on both hamstring
55567|NCT03750344|Device|Diagnostic test|Comparison of respiratory rates in normal subjects as observational with end tidal CO2. No treatment or interventions will be performed
55568|NCT03750331|Other|Ap'Telecare|an internet application on a computer, tablet or smartphone
55569|NCT03750331|Other|traditional schedule|a group of renal transplant outpatients consulting their Transplant Centre following a traditional schedule
55570|NCT03750318|Device|Vital sign monitoring|Each patient will be set up for monitoring on admission. Duration of opioid therapy for post-operative in-patients may range from 1-3 days. Once opioid therapy is no longer required, Aingeal monitoring will be ended and each patient would be encouraged to have at least 1 day Aingeal monitoring to be recorded during the study. De-identified log files will be extracted from the Surveillance Station and reprocessed to produce counts of the number of alarms raised during monitoring. A sample of the data will be reviewed to determine whether cardiac and respiratory alarms are defined as True or False, with an overall Alarm Rate per patient per day and False Positive Alarm Rate per patient per day derived. Vital sign trend graphs for each patient will be produced.
55571|NCT03750305|Other|imagery-focused Cognitive Therapy|"In depth identification phase: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus.~Imagery interventions: The imagery intervention consists of metacognitive imagery rescripting or promoting positive imagery or competing tasks (or a combination of these).~Consolidation: Consist of fine tuning the strategies, relapse prevention using a video diary."
55572|NCT03750305|Other|TAU|Psycho-education is offered in groups, using the format described by Honig (Postma, Honig, & van Gent, 2008).
55573|NCT03750292|Device|HEPAirX air filter|It is a trademarked, patented (U.S. Patent # 7,802,443), U.S. FDA approved Class II medical re-circulating air cleaner, built by Air Innovations, Inc. (North Syracuse, NY) to provide improved indoor air quality in the bedrooms of asthmatic children. Units to be used in the proposed study have a 99.97% efficient filter for particles 0.3 µm in size. The device provides a clean air delivery rate (CADR) of 9 per hour with 1.8 of them being outdoor air.
55574|NCT03750292|Device|control air filter|A placebo mode was added to the HEPAirX to provide only recirculation (without filtration or ventilation using outdoor air) and temperature control of the room air. The placebo filter is made of metal.
55575|NCT03750279|Other|Exercise therapy|"5 min. warm up with light exercises for the lower limb prior to strength/endurance exercise therapy.~Strength/endurance exercise therapy including level 1 or 2 per session:~Level 1: Pelvic lifts (2x15 rep.), one-legged knee bends (2x10 rep. per leg), hip abductions (2x10 rep. per leg). The participants may progress from level 1 to level 2.~Level 2: Pelvic lifts (3x15 rep.), one-legged knee bends (3x10 rep. per leg), hip abductions (2x10 rep. per leg), sideways slide (2x10 rep. per leg), and backwards slide (2x10 rep. per leg). The participants may regress from level 2 to level 1."
55576|NCT03750279|Other|LLLT|- LLLT (60 mW mean output per probe, 904 nm wavelength) applied to the knee in adherence with the recommendations by World Association for Laser Therapy, in terms of dosage per treatment spot.
55577|NCT03750279|Other|Sham LLLT|- Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
55578|NCT03750266|Other|No intervention data collected through routine scans|No intervention, we wish to use the images a mother would have done as part of her normal medical care and make both 3D animations and 3D models of the baby and it's CDH.
55579|NCT03750253|Other|Extracorporeal Shock Wave Therapy|Extracorporeal Shock Wave Therapy will be used for pain-relief after arthroscopy for osteochondral lesions of the talus
55580|NCT03750240|Diagnostic Test|Sodium (Na) Magnetic Resonance Imaging (MRI)|"Two Na data will be acquired:~FLORET without Inversion Recovery (IR), and~FLORET with IR"
55581|NCT03750240|Diagnostic Test|Dynamic Contrast- Enhanced (DCE) MRI|DCE MRI will be acquired subsequent to Na MRI to prevent influence of the contrast agent on 23 Na data
55582|NCT03750227|Procedure|Conventional Surgery|Undergo surgery
55583|NCT03750227|Other|Quality-of-Life Assessment|Ancillary studies
55584|NCT03750227|Other|Questionnaire Administration|Ancillary studies
55585|NCT03750227|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
55586|NCT03750214|Device|Biop Colposcopy System|"The procedure stages:~Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~A questionnaire completed by the user after the Biop procedure, with regards to system usage~Image Registration analysis"
55587|NCT03750201|Device|Direct Selective Trabeculoplasty|Laser surgery by automated direct automated SLT device to lower intraocular pressure
55588|NCT03750201|Device|Selective Trabeculoplasty|Laser surgery by standard SLT device to lower intraocular pressure
55589|NCT03750188|Drug|ProHance|0.1 mmol/kg ProHance intravenous injection
55590|NCT03750175|Other|Plasma circulating DNA analysis|Clinical utility of ctDNA analysis for treatment decision
55591|NCT03750162|Device|VDW Ultra|supplementary disinfection technique
55592|NCT03750162|Device|AMD picasso|supplementary disinfection technique
55593|NCT03750162|Device|ProtaperNext X3 gutta-percha|supplementary disinfection technique
55594|NCT03750149|Device|EyeTracker|Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
55595|NCT03750136|Drug|Hypertonic saline|high dose furosemide with hypertonic saline 3x daily
55596|NCT03750136|Drug|Furosemide Injection|high dose furosemide
55597|NCT03750110|Other|Intervention|"In addition to usual care, personalised feedback from the participants screening appointment will be provided;~For participants with emphysema, an image of their own emphysematous lung compared to a library image of normal lung, or a section of their own non-emphysematous lung. Where emphysema is not present, library pictures showing normal and emphysematous lung will be used.~For participants with coronary artery calcification, a cross sectional segment from their chest scan (either horizontal or vertical) showing the calcium compared to a library image of coronary arteries without calcification and/or a healthy section of the participant's own heart scan. Where coronary artery calcification is not present, library pictures showing normal and calcified coronary arteries will be provided."
94926|NCT03444259|Procedure|Cardiac surgery|Open heart surgery
55599|NCT03750097|Behavioral|Comfortable walking velocity (CWV)|Walking for 250 Steps with self-selected comfortable walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT)
55600|NCT03750097|Behavioral|Slow walking velocity (SWV: CWV - 20%)|Walking for 250 Steps with slow walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Slow walking consists of walking with 20% slower than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
55601|NCT03750097|Behavioral|Fast walking velocity (FWV: CWV + 20%)|Walking for 250 Steps with fast walking velocity while wearing the two accelerometers (Polar M600 and ActiGraph wGT3X-BT). Fast walking consists of walking with 20% faster than the self-selected comfortable walking velocity by following a researcher who controls the walking velocity with a measuring wheel.
55602|NCT03750084|Other|questionary|The intervention consists of a digitally distributed questionary.
55603|NCT03750071|Biological|VXM01|Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid
55604|NCT03750071|Biological|Avelumab|Monoclonal anti-PD-L1 Antibody
55605|NCT03750058|Device|Implant test procedure|Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
55606|NCT03750045|Diagnostic Test|Jamar|The grip strength was evaluated through a dynamometer JAMAR 5030-J, formed by two parallel steel bars, one stationary and a mobile one, which can be adjusted in five different positions. The volunteer was sitting with a neutrally rotated abducted shoulder, elbow flexed at 90°, the forearm in neutral position, and the wrist between 0° and 30° of extension, 0° to 15° of ulnar variance and it was requested that he or she made the grip movement. This test was performed three times with a one-minute-break between each one.
55607|NCT03750045|Diagnostic Test|Wooden box|The motor coordination evaluation was made through the measurement of the time spent to perform the task of fitting. To do so, a wooden box was built. In its upper part, there is a circular orifice with 6 cm of diameter.
55608|NCT03750045|Other|Virtual environment|The system proposed is composed by a virtual environment and an access device. The Leap Motion was used as the access device, making it possible to capture the movements performed by the hands.
55609|NCT03750032|Procedure|Stapler appendectomy|The patients randomised for this intervention will undergo stapler appendectomy.
55610|NCT03750032|Procedure|Endoloop|The patients randomised for this intervention will undergo appendicular stump closure using Endoloop.
55611|NCT03750032|Procedure|Hem-O-Lock|The patients randomised for this intervention will undergo appendicular stump closure using Hem-O-Lock.
55612|NCT03750019|Behavioral|Satisfying rehearsal task|Participants rehearsed satisfying aspects of the lunchtime meal they just ate.
55613|NCT03750019|Behavioral|Dissatisfying rehearsal task|Participants rehearsed dissatisfying aspects of the lunchtime meal they just ate.
55614|NCT03750019|Behavioral|Neutral rehearsal|Participants rehearsed their journey to campus that day.
55615|NCT03750006|Behavioral|Short session HIIT|Individually tailored short session high intensity interval training session 3 times per week for 12 weeks on a recumbent exercise cycle.
55616|NCT03749993|Other|Screening|Use of bpMRI for opportunistic prostate cancer screening.
55617|NCT03749967|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
55618|NCT03749954|Diagnostic Test|Magnetically controlled capsule endoscopy|Esophagogastroduodenoscopy is performed 2 hours after the magnetically controlled capsule endoscopy (Ankon Medical Technologies Co. Ltd.).
55619|NCT03749928|Device|OstiSense biosensor - active|The activated biofeedback back night guard will be used to reduce sleep bruxism
55620|NCT03749928|Device|OstiSensor biosensor - not activated|A not-activated night guard will be used as control device
55621|NCT03749915|Device|Pain Ease Cold Spray|Pain Ease is a spray containing 1,1,1,3,3-Pentafluoropropane (HFC-245fa) and 1,1,1,2-Tetrafluoroethane (HFC-134a). It is a vapocoolant for use as a topical anesthetic.
55622|NCT03749915|Drug|Ametop|Tetracaine Hydrochloride Gel 4%
55623|NCT03749902|Drug|Oral misoprostol|"An initial dose of misoprostol 25mcg will be given orally after randomisation (this must be a minimum of 2 hours after the previous misoprostol dose).~The next dose of oral misoprostol will be omitted if moderate or strong contractions are occurring at 3 in 10 minutes or more (i.e. 9 or more in the preceding 30 minutes)~If contractions subsequently reduce to less than 3 in 10 (under 9 in 30 minutes), or become irregular or mild, then the oral misoprostol 25mcg can be restarted~In the event of inadequate progress, clinicians will be advised to give further misoprostol if there are any concerns about contractions strength or frequency."
55624|NCT03749902|Drug|Oxytocin|"Oxytocin infusion will be given through an electronic infusion pump. One unit of oxytocin will be injected in 500 mL of Ringer's lactate, started at a rate of 2 mU/min, and increased every 30 min by 2 mU/min until there are three to four contractions every 10 min. The rate will be titrated to maintain that contraction frequency. The maximum dose will be 20mU/min as oxytocin summary product characteristics.~The oxytocin group will not receive misoprostol after the membranes have ruptured."
55625|NCT03749889|Other|100 g carbs|Participants will be assigned a diet of 100g carbs max for the day
55626|NCT03749889|Other|MyPlate|40-65% of daily intake is from carbohydrates
55627|NCT03749876|Other|Unfiltered Cigarettes|Participants will be given unfiltered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
55628|NCT03749876|Other|Filtered Cigarettes|Participants will be given filtered Pall Mall or Camel cigarettes to smoke for two weeks according to the brand they smoked prior to the start of the study. They will agree to smoke the cigarettes using a monitoring device (CReSS) that measures puffing behavior on five (5) days during each of the two weeks. They will also collect their cigarette butts on all days as a measure of smoking behaviors.
55629|NCT03749863|Procedure|Serial PRP injections|Autologous platelet-rich plasma will be injected just deep to the thyroarytenoid muscle of the vocal fold in a serial fashion, once per month for a total of 4 injections.
55654|NCT03749642|Drug|trazodone/gabapentin 10/100|The total daily doses administered will be trazodone 30 mg and gabapentin 300 mg.
55630|NCT03749850|Drug|LTLD|"Patients will receive up to six cycles at three-weeks intervals of:~Intravenous LTLD dosed at 50mg/m2 administered during the MR-HIFU treatment~60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour~Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, LTLD, cyclophosphamide and/or hyperthermia dosages will be adjusted as specified in the study protocol."
55631|NCT03749850|Procedure|MR-HIFU induced hyperthermia|"Patients will receive up to six cycles at three-weeks intervals of:~- 60 minutes of MR-HIFU mild local hyperthermia at 40 °C - 42 °C to the primary breast tumour.~In case of toxicity, hyperthermia dosages will be adjusted as specified in the study protocol."
55632|NCT03749850|Drug|Cyclophosphamide|"Patients will receive up to six cycles at three-weeks intervals of:~- Intravenous Cyclophosphamide 600 mg/m2 after MR-HIFU treatment~In case of toxicity, cyclophosphamide dosages will be adjusted as specified in the study protocol."
55633|NCT03749837|Device|C- MAC VS|The C-MAC VS is a new device on the airway management aid market. It will be used according to the instructions of the distributor. Before the study starts on humans, each study participants will do at least 5 intubations on an airway manikin or more until he or she feels confident to use the device.
55634|NCT03749837|Device|Video Endoscope|Fiberoptic video endoscopic devices are standard aids to facilitate intubation on all study sites and are used according to the instructions to use. To facilitate fiberoptic intubation a macintosh blade to raise the root of tongue will be used. Also with these devices the study participants need at least 5 trials to intubate a manikin (or more to feel confident) before they are going to use the study device in patients.
55635|NCT03749824|Dietary Supplement|Omega-3|Omega-3 supplement is a highly concentrated fish oil brain booster supplement that helps compensate for the neurocognitive and brain dysfunction which acts as a predisposition to antisocial and violent behaviour. Individuals with antisocial personality disorder have been found to show an 11% reduction in gray matter in the prefrontal cortex (Raine et al. 2001), and structural prefrontal impairments are hypothesised to result in disinhibition of limbic subcortical structures that give rise to aggressive behaviour. Omega-3 (specifically DHA) is known to play a key role in neuronal structure and function.
55636|NCT03749824|Dietary Supplement|Placebo Capsules|Children in this group will be given two placebo capsules twice daily; at breakfast and at the evening meal for a total period of 6 months.
55637|NCT03749811|Device|Pupillometry|After induction of anesthesia and determination of the loss of consciousness of the participant, baseline diameter of pupil is measured by electronic pupillometry device. During anesthesia, participant's pupil diameter is repeatedly measured with 5-minute interval. Pupil dilation of 30% or more compared to baseline is indicative of insufficient analgesia.
55638|NCT03749798|Procedure|Cataract surgery|Intraoperative wavefront measurements will be carried out during cataract surgery
55639|NCT03749785|Other|Regular carbohydrate feeding|60 ml of water with 5 g sucrose given every 5 minutes 14 times up until 70 minutes followed by 5 g sucrose after 75 minutes in a 250 ml solution
55640|NCT03749785|Other|Single carbohydrate bolus|60 ml of water given every 5 minutes 14 times up until 70 minutes followed by 75 g sucrose after 75 minutes in a 250 ml solution
55641|NCT03749772|Behavioral|Cognitive Training|The intervention was carried out with the PC game Brain Exercise TM (Bandai Namco Games Ltd.). Participants held the training sessions on an HP 250 G3 Notebook PC (Windows 10), with a 15-inch screen, and a resolution of 1366x768x40 Hz. The performance achieved by each participant in each session was recorded to analyze the evolution of the subjects. The participants made a total of 12 practice exercises, which implies approximately 30 minutes of duration per session.
55642|NCT03749759|Procedure|Cataract surgery|A biofeedback measurement will be carried out during cataract surgery of both eyes
55643|NCT03749746|Behavioral|Home Blood Pressure Monitoring|Each participant will receive 1:1 training by the project staff in all aspects of home blood pressure monitoring (HBPM). Throughout the study, they will be asked to monitor home blood pressures for the first week of each month with Bluetooth-enabled blood pressure cuffs.
55644|NCT03749746|Behavioral|Heart Health 4 New Moms|The intervention is comprised of four key components: (1) The online curriculum consists of 12 modules on healthy eating and physical activity adapted from the Diabetes Prevention Program and specifically targeting postpartum women. (2) Self-monitoring and tracking program, in which participants will be provided with a Bluetooth-enabled blood pressure cuff and digital scale and will be provided real-time feedback on their blood pressure and weight trends. (3) A registered dietitian will act as a lifestyle coach for participants with regular review of progress and provision of coaching notes, support and suggestions. (4) Finally participants will have access to a customized online toolbox, including dietary tracking sheets and recipes from the American Heart Association (AHA).
55645|NCT03749746|Other|Usual care|Participants will be counseled on routine postpartum care and will receive additional information on cardiovascular risk following preeclampsia as well as information on support groups and registries as well as online resources for lifestyle modification.
55646|NCT03749733|Drug|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Reference Product)|Marketed Drug
55647|NCT03749733|Drug|Estradiol 1.5 mg/nomegestrol acetate 2.5 mg (Test Product)|Investigational Medicinal Product
55648|NCT03749720|Other|Blood sample|Blood sample taken from cervical cancer patients at time of diagnosis (baseline) and follow-up visits.
55649|NCT03749707|Diagnostic Test|HPV analysis|HPV analysis of SLNs
55650|NCT03749668|Other|non applicable|no intervention in this observational study
55651|NCT03749655|Behavioral|Physical Activity Promotion|The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
55652|NCT03749642|Drug|trazodone/gabapentin 2.5/25 mg|The total daily doses administered will be trazodone 7,5 mg and gabapentin 75 mg.
55653|NCT03749642|Drug|trazodone/gabapentin 5/50 mg|The total daily doses administered will be trazodone 15 mg and gabapentin 150 mg.
94994|NCT03443778|Drug|Nacl 0,9 %|Injectable Solution
55655|NCT03749642|Drug|Gabapentin|"The total daily doses administered will be:~600 mg from day 0 to day 6 (±1)~900 mg from day 7 (±1) to day 13 (±1)~1200 mg from day 14 (±1) to day 20 (±1)~1800 mg from day 21 (±1) to day 56 (±2)"
55656|NCT03749642|Drug|Placebo oral capsule|Two capsules, three times a day, for 8 weeks.
55657|NCT03749629|Other|GeneSight Psychotropic test|GeneSight® Psychotropic powered by CPGx® technology, the only test for depression reimbursable by Medicaid and Medicare. GeneSight® is a neuropsychiatric, combinatorial, PGx test that provides recommendations for psychotropic medications (antidepressants, mood stabilizers, hypnotics for insomnia, and antipsychotics) based on a patient's individual genetic profile.
55658|NCT03749629|Other|Canadian Network for Mood and Anxiety Treatment (CANMAT) Best Practice Guidelines|Guidelines for treatment
55659|NCT03749616|Drug|Ibuprofen|NSAID Group - will be administered ibuprofen 400-800 mg, up to three times a day as needed for pain control
55660|NCT03749616|Drug|Acetaminophen|Control Group - will be administered acetaminophen for pain control with dose and frequency of 325mg 1-2 tablets q4-6h hours as needed, Maximum dose 1000mg. Maximum amount per day: 3g/day.
55661|NCT03749603|Device|TIBAY Meter|fluorescence probe will be applied for 3-5 minutes onto the wet vermillion of the lower lip.
55662|NCT03749590|Drug|Magnesium Sulfate|Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
55663|NCT03749590|Drug|Placebo (NaCl 0,9%)|Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
55664|NCT03749577|Dietary Supplement|L-citrulline|L-citrulline 9g per day (capsule, per os) during 14 days;
55665|NCT03749577|Dietary Supplement|Beetroot juice|Concentrated 70 ml beetroot juice bottles containing 6.45 mmol of nitrates
55666|NCT03749577|Dietary Supplement|L-citrulline placebo|L-citrulline placebo (maltodextrin) 9g per day (capsule, per os) during 14 days
55667|NCT03749577|Dietary Supplement|Denitrated beetroot juice|Concentrated 70 ml nitrate-depleted beetroot juice
55668|NCT03749564|Behavioral|SMT|"The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
55669|NCT03749564|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
55670|NCT03749564|Behavioral|Mobilizing Exercises|Mobilizing exercises include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
55671|NCT03749564|Behavioral|Extended SMT|Additional 6 SMT sessions provided
55672|NCT03749551|Diagnostic Test|cardiac magnetic resonance (CMR) post haemodialysis|patients will undergo a second CMR scan immediately after receiving haemodialysis (native CMR study)
55673|NCT03749538|Other|Transcranial current stimulation session.|Patients with systemic autoimmune myopathies will receive or not a transcranial current stimulation session.
55674|NCT03749525|Drug|shenfu injection|we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
55675|NCT03749512|Diagnostic Test|Complete blood count|During routine preoperative blood test complete blood count is taken.
55676|NCT03749512|Other|Histopathological examination|Routine postoperative histopathological examination of lung tumor.
55677|NCT03749499|Other|HTN Educational Video|The video will educate participants in arm 2 about high BP, how it is diagnosed, and the importance of treating it to prevent secondary complications.
55678|NCT03749499|Other|Visual Echocardiogram Image Clips|Visual clips of age/gender-matched echocardiograms will be used to educate and motivate patients to change their behavior and improve their BP. We have found that real time visualization of cardiac ultrasound images with active discussion of findings is a significant patient motivator and empowerment tool, and was a significant factor in the success of our previous pilot study.
55679|NCT03749499|Other|Mobile Health and Remote BP monitoring|All participants randomized to the intervention group will receive an FDA-approved HBPM kit that includes the Nokia wireless (self-inflating) BPM+ monitor and Health Mate mobile app. The app automatically launches when the patient slips on the cuff and turns on the monitor to measure his/her BP. Synced data are automatically uploaded from the mobile app to the iCardia server of our study.
55706|NCT03749278|Behavioral|Latina Friends Motivating the Soul (ALMA)|In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed
55680|NCT03749499|Other|Post-Acute Care HTN Transition consultation (PACHT-c)|All participants randomized to the E2 intervention will have a focused consultation with either a clinical pharmacist or an APN. During this consultation, the pharmacist/APN repeats the BP measurement; reviews the screening assessments; and reviews general principles of BP control including nutrition, exercise, and smoking cessation. BP will be managed according to the current published guidelines available at the time of funding regarding initiation of first-line antihypertensive medications. Patients with BP ≥160/100 mmHg may be started on antihypertensive medications by the provider during the consultation if appropriate.
55681|NCT03749486|Procedure|Cataract surgery|Cataract surgery will be done following ArcScan measurement
55682|NCT03749473|Behavioral|Choice + Immediate|Participants in the choice + immediate goal arm will choose a step goal and must attempt to achieve this new step goal immediately at the start of the study.
55683|NCT03749473|Behavioral|Choice + Gradual|Participants in the choice + gradual goal arm will choose a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
55684|NCT03749473|Behavioral|Assigned + Immediate|Participants in the assigned + immediate goal arm will be assigned a step goal and must attempt to achieve this new step goal immediately at the start of the study.
55685|NCT03749473|Behavioral|Assigned + Gradual|Participants in the assigned + gradual goal arm will be assigned a step goal and will gradually work towards the chosen step goal over the first 8-weeks of the study.
55686|NCT03749473|Behavioral|Daily performance feedback|Participants will receive daily performance feedback on their daily step count.
55687|NCT03749473|Behavioral|Gamification|All participants in the intervention arms will be entered into a gamification platform that has points and levels designed to incorporate insights from behavioral economics.
55688|NCT03749460|Biological|Nivolumab|Given IV
55689|NCT03749460|Biological|Ipilimumab|Given IV
55690|NCT03749460|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
55691|NCT03749447|Drug|Bardoxolone methyl|Bardoxolone methyl capsules
55692|NCT03749421|Other|Prosigna PAM-50 assay|Looks at the gene activity of a person's cancer cells to determine the likely outcome or course of a disease (prognosis) and predict the benefit of chemotherapy or endocrine therapy after breast surgery
55693|NCT03749408|Drug|bupivacaine plus mannitol|local anesthesia
55694|NCT03749408|Drug|bupivacaine alone|local anesthesia
55695|NCT03749395|Procedure|Erector Spinae Plane Block|The patient will be placed in a sitting position and the ultrasound probe will be placed in a longitudinal orientation 3 cm lateral to the T5 spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae . the needle will be inserted in a cephalad-to-caudad direction until the tip lay deep to erector spinae muscles, as evidenced by visible linear spread of fluid beneath muscle upon injection . A total of 20 mL of 0.25% bupivacaine will be injected here.
55696|NCT03749382|Other|AprilAge- facial morphing appearance based intervention for smoking|"Appearance-based intervention: The intervention is a software that ages an individual's face with and without the effects of smoking. Participants have their photo taken on a laptop webcam, they are then asked to report their age and ethnicity in order to calibrate the software, the participants picture is then matched to a stock image. The participants will see two images on the screen, on the left is there face aged without the effects of smoking and one the right aged with the effects of smoking. Participants will be led through a series of morphing sequences (1-5). In-between each of the morphing sequences (Morph1 to Morph5) the participant will be asked to comment on the differences they can see between the two images.~General stop smoking intervention: The General stop smoking intervention comes in the form of a NHS stop smoking information leaflet. The participants will be given the leaflet on a laptop screen and asked to read through the whole document."
55697|NCT03749369|Drug|Salvadora Persica Root|Salvadora Persica Gel
55698|NCT03749369|Procedure|Scaling and root planing|Thorough scaling and root planing (SRP) will be performed by a single clinician. The SRP procedure will be carried out in two sittings, comprising of ultrasonic scaling in the first, and manual instrumentation and root debridement in the second.
55699|NCT03749356|Drug|TacroBell SR cap.|"Orally, once-daily in the morning~After first dose 0.2mg/kg, check the blood concentration of tacrolimus at each visit and adjust the dose to acheive the blood concentration maintaining at 3~12ng/ml for 0 to 3months and then at 3~8ng/ml for 3 to 6months of study treatment."
55700|NCT03749330|Behavioral|CICU Team And Loved Ones Communicating (CICU TALC)|When the necessary pre-intervention clinical encounters are completed, clinicians will go through the interprofessional team training to improve communication skills and teamwork in developing care plans and communicating with families in family meetings. The first step in the study is co-design of the intervention, so it will evolve as the study continues.
55701|NCT03749317|Drug|IVIEW-1201|IVIEW-1201; QID; one drop per eye, four times per day (QID) for 7 days
55702|NCT03749317|Drug|Placebo|Placebo drug; QID; one drop per eye, four times per day (QID) for 7 days
55703|NCT03749304|Device|ANI monitor|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index
55704|NCT03749291|Other|Obemat2.0 therapy|"Lifestyle (diet & physical activity) structured recommendations through a motivational interview.~Duration: 12(+3) months Description: 1 visit/month & 3 Workshops in primary care centers Providers: pediatricians and nurses trained to perform motivational interview The interviews are structured as follows: First, checking the accomplishment of objectives to motivate the participant. Second, a specific topic per visit is explained to the participant. Third, a task related to the topic (i.e. to plan a weekly menu for the family) is given to be brought back at the next visit. 4th. Objectives about diet, weight & physical activity are defined to be accomplished until the next visit."
55705|NCT03749291|Other|Usual Clinical Practice|Lifestyle (diet and physical activity) Duration: 12 (+3) months Description: 1visit/month to the primary care centers. Providers: pediatricians & nurses. Children assigned to the control group receive the usual treatment conducted in primary care centers based on the Clinical Practice Guidelines on the Prevention and Treatment of Child and Adolescent Obesity [Spanish Ministry of Science and Innovation], 2009). At visits, the family receive recommendations to carry out a balanced diet, to provide a moderate energy reduction from the previous intake. An increase in physical activity, both in terms of leisure activity, as sports is advised.
95904|NCT03436615|Drug|Placebo|Once or twice daily
55707|NCT03749265|Other|Ultrasound test|patients need to undergo an ultrasound test for detecting the presence or abscence of peroneus tertius tendon
55708|NCT03749252|Drug|P03277|A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.
55709|NCT03749239|Dietary Supplement|Collagen protein|Collagen protein
55710|NCT03749226|Drug|Aztreonam lysine|nebulization
55711|NCT03749226|Device|Aerogen Solo|Aerogen's vibrating mesh technology, available within the Aerogen® Solo has been adopted for use of conventional mechanical ventilation. Aerogen Solo utilizes active vibrating mesh technology, where energy applied to the vibrational element, causes vibration of each of the 1000 funnel shaped apertures within the mesh. The mesh acts as a micropump drawing liquid through the holes producing a low velocity aerosol optimized for targeted drug delivery to the lungs. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) Aeroneb Solo showed an excellent aerosol delivery profile for Aztreonam lysine (AZLI) in an in vitro model of MV with short drug delivery time.
55712|NCT03749226|Device|CombiHaler|The inhalation chamber CombiHaler™ spacer for mechanical ventilation and critical care (ICU) allows using both a vibrating mesh nebulizer such as Aeroneb ™, and a pMDI. It saves 50% of the nebulized drug when used in invasive ventilation. The inhalation chamber CombiHaler® is integrated on a circuit of a breathing device in invasive ventilation in particular for connexion of an Aeroneb® Pro or an Aeroneb® Solo. According our study (Rodriguez A et al , Expert Opin Drug Deliv. 2017 Dec;14(12):1447-1453) a better aerosol delivery performance (30%) was obtained using the Conbihaler spacer.
55713|NCT03749213|Drug|Icotinib|Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
55714|NCT03749200|Other|Obemat2.0 therapy|
55715|NCT03749200|Other|Regular practise in primary care|
55716|NCT03749187|Drug|PARP Inhibitor BGB-290|Given PO
55717|NCT03749187|Drug|Temozolomide|Given PO
55718|NCT03749174|Procedure|Short or long-acting local anesthetic vs. general anesthesia|Patients are randomized to receive either plaster or orthotic in this group
55719|NCT03749161|Device|Low-add multifocal IOL|Lentis comfort, low-add multifocal, IOL
55720|NCT03749161|Device|Monofocal IOL|Lentis L-313, monofocal IOL
55721|NCT03749148|Drug|Dupilumab|anti-IL4-Receptor alpha
55722|NCT03749148|Drug|Placebo|Placebo
55723|NCT03749135|Drug|Dupilumab|anti-IL4-Receptor alpha
55724|NCT03749135|Drug|Placebo|Placebo
55725|NCT03749122|Procedure|Waiting time for hip fracture surgery|Time from hospital admission to start of hip fracture surgery
55726|NCT03749109|Drug|Quinagolide 1080 µg|Vaginal ring containing Quinagolide 1080 µg for daily releases
55727|NCT03749109|Drug|Placebo|Matching placebo
55728|NCT03749096|Drug|Intravenous Immunoglobulins, Human|Immunoglobulins are fractionated blood products made from pooled human plasma.
55729|NCT03749096|Drug|Placebos|Normal Saline
55730|NCT03749083|Other|The Functional Assessment of Cancer Therapy- Colorectal|The Functional Assessment of Cancer Therapy- Colorectal (FACT-C) questionnaire measures health-related quality of life for people with chronic illnesses.
55731|NCT03749070|Dietary Supplement|Silymarin|It is a randomized, double-blind, controlled clinical trial to be performed at outpatient level. The intervention will last 12 weeks and the invited participants will be patients attended at the outpatient clinic of the Edgard Santos Hospital, which will be randomized into two groups: control and intervention. Data on laboratory and clinical markers, imaging, nutritional and dietary assessment, and physical activity level will be collected at the beginning and end of the trial for comparison purposes.
55732|NCT03749057|Drug|Rivaroxaban|Rivaroxaban 15-20 mg daily
55733|NCT03749044|Other|Patient Educational Tool|This tool is a modified version of the patient educational sheet elaborated and validated by You et al in collaboration with the Preeclampsia Foundation. This patient educational sheet graphically defines preeclampsia and its. A licensing agreement has been obtained from the Preeclampsia Foundation, with the rights to modify the educational tool for this RCT. The SLE-specific educational tool will consist in a sheet displaying the previously developed patient educational form on the recto. However, on the verso of the sheet, SLE-specific information related to the risk of preeclampsia in SLE pregnancies and the estimated efficacy of ASA in reducing preeclampsia risk in women at high risk are displayed.
55734|NCT03749031|Other|Orange juice + Orange Pomace|16 oz. orange juice + orange Pomace per day for 4 weeks
55735|NCT03749031|Other|Orange Juice|16 oz. orange juice per day for 4 weeks
55736|NCT03749031|Other|Apple Juice and Apple Pomace|16 oz. apple juice and apple Pomace per day for 4 weeks
55737|NCT03749031|Other|Apple Juice|16 oz. apple juice per day for 4 weeks
55738|NCT03749018|Drug|Cyclophosphamide|Given IV
55739|NCT03749018|Drug|Doxorubicin Hydrochloride|Given IV
55740|NCT03749018|Drug|Etoposide|Given IV
55741|NCT03749018|Biological|Nivolumab|Given IV
55742|NCT03749018|Drug|Prednisone|Given PO
55743|NCT03749018|Biological|Rituximab|Given IV
55744|NCT03749018|Drug|Vincristine Sulfate|Give IV
55745|NCT03748992|Drug|gNO|This is a proof-of-concept study in which all subjects will be treated with gNO (i.e. no control) to see if there can be a microbiological effect by conversion to negative sputum cultures and how long that effect can be sustained following treatment.
55746|NCT03748979|Drug|TAK-925|TAK-925
55747|NCT03748979|Drug|Placebo|TAK-925 Placebo
55748|NCT03748966|Drug|Calcitriol|Adults and children (age 6-17) with X-linked hypophosphatemia will be treated with calcitriol therapy without phosphate supplementation. Doses of calcitriol will be escalated and optimized in the first three months of the study. Calcitriol is an oral medication taken once a day.
55749|NCT03748953|Drug|Ixazomib|Ixazomib Capsules
55750|NCT03748953|Drug|Ixazomib Placebo|Ixazomib placebo-matching capsules
55751|NCT03748940|Drug|LY3074828|Administered SC
55752|NCT03748940|Drug|Placebo|Administered SC
55753|NCT03748940|Drug|LY900021|Administered SC
96771|NCT03430037|Dietary Supplement|Fisetin|Flavonoid Family
55754|NCT03748914|Other|Intervention Group|After delivery of the neonate via caesarean section the umbilical cord will be clamped within 30 seconds and cut long at least 30 cm by the obstetrician. The neonate is then placed under an overhead heater by the midwife. There, the umbilical cord must be untwisted and held in a vertical position. It is milked once by the neonatologist towards the baby at a speed of approximately 10 cm/s and then clamped 3 cm from the umbilicus by one member of the clinical team.
55755|NCT03748914|Other|Control Group|The umbilical cord is cut according to the standard procedure and no C-UCM is performed.
55756|NCT03748888|Behavioral|Exercise group|"An antenatal physical activity (APA) programme will be designed for participants in the exercise group.~The APA will last for 20-24 weeks. Participants in the EG must enrol in the APA between their 12-16 weeks of gestation.~The APA programme has a frequency of three times a week, which involves aerobic, strength and stretching exercises. The intensity of the APA programme is individually calculated for each participant based on their pre-pregnancy fitness level. Single sessions of the APA programme last 50-60min."
55757|NCT03748875|Behavioral|mindfulness-based relapse prevention|mindfulness-based relapse prevention, 8 weeks
55758|NCT03748862|Other|Taper Plan|Occurrence of a taper plan defined by a primary care provider during the follow-up period. Evidence of a taper plan will be obtained by searching prescriptions (SIGs) and medical encounter notes using natural language processing (NLP).
55759|NCT03748849|Procedure|Physiotherapy|
55760|NCT03748836|Drug|ALPN-101|Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
55761|NCT03748836|Drug|Placebo|Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
55762|NCT03748810|Drug|Empagliflozin|Empagliflozin 25 mg once daily add on the background OADs for 52 weeks
55763|NCT03748810|Drug|Dapagliflozin|Dapagliflozin 25 mg once daily add on the background OADs for 52 weeks
55764|NCT03748797|Other|Moderate intensity exercise training under supervision|Upper and lower limbs cycling, treadmill walking, multi-gym strengthening, stepper exercise, dumb bell and squatting exercise
55765|NCT03748784|Biological|ADVM-022|ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
55766|NCT03748758|Combination Product|Drug: OP0201|Drug OP0201
55767|NCT03748758|Combination Product|Drug: Placebo|Placebo
55768|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 1 to day 14
55769|NCT03748745|Drug|SH229|tablet, oral, 600 mg once daily for day 8 to day 14
55770|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 8 to day 14
55771|NCT03748745|Drug|Daclatasvir dihydrochloride|tablet, oral, 60 mg once daily for day 1 to day 14
55772|NCT03748732|Procedure|sclerectomy|scleral flap
55773|NCT03748719|Device|Stereotactic Body Radiation Therapy (SBRT)|SBRT treatment
55774|NCT03748706|Drug|PTI-125, 100 mg tablets|PTI-125, 100 mg tablets taken twice a day for 28 days
55775|NCT03748693|Procedure|Hysterectomy|Surgery performed on women with a variety of gynecological indications
55776|NCT03748693|Procedure|Colporrhaphy|Surgery performed on women with POP
55777|NCT03748680|Drug|Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy|"Six months of adjuvant combination chemotherapy with Capox (or FOLFOX) Patients will receive adjuvant chemotherapy with eight cycles of CAPOX (oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.~(Patients with an ileostomy are only eligible for FOLFOX and will be treated with 12 cycles of FOLFOX (oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every second weeks)"
55778|NCT03748680|Other|Intensified Follow-up Schedule|Close monitoring with Imaging during follow-up Patients included in this trial will undergo intensified follow-up with CT-chest and abdomen every four months after surgery for the first 2 years, then every 6 months for 1 years and finally once yearly for the last 2 years up to 5 years follow-up is completed.
55779|NCT03748667|Diagnostic Test|White light endoscopy (WLE)|Subjective endoscopic assessment of deep submucosal invasion based on the presence of gross morphological malignant features, morphology and size.
55780|NCT03748667|Diagnostic Test|NBI/BLI +/- chromoendoscopy (NBIBLI +/- CE)|Endoscopic assessment of deep submucosal invasion with NBI and dual focus/magnification or BLI and magnification. In the case of demarcated areas or JNET 2B, Kudo pit pattern assessment with crystal violet will be performed.
55781|NCT03748654|Diagnostic Test|Visual Field Testing|Visual field test using the protocol 24-2 Threshold Test
55786|NCT03748628|Drug|EDP-305|[14C]EDP-305
55787|NCT03748615|Device|Computer Guided ridge splitting in posterior mandible|"The computer guided ridge splitting for patients with atrophic posterior mandible and with residual bone width at least 3 to 5mm of residual ridge.~The selected patients will be informed of the nature of the research work and informed consent will be signed.~Radiographic examination included preoperative digital panoramic radiograph with 1:1 magnification for each patient as a primary survey to obtain an approximation of the available bone height and detect the presence of remaining roots and localized pathosis.~Computer surgical guides are fabricated for partially edentulous patients using teeth and tissue as support for the guide.~The same surgeon performed all surgeries. All surgical procedures were performed under strict aseptic conditions, all patients received nerve block local anesthesia (Articaine 4% 1:100 000 epinephrine).~A crestal incision is made using No. 15 blade extending over the posterior mandible using computer guided surgical stent.~no flap elevation ."
55788|NCT03748602|Procedure|Thoracic outlet decompression|TOD consists out of first rib resection with partial scalenectomy and neurolysis. If there are also complaints below the pectoral minor tendon insertion, a pectoral minor tenotomy is performed.
56043|NCT03746522|Drug|Placebos|Matching placebo at equivalent volume to 3 mg setmelanotide.
55789|NCT03748589|Device|laryngeal mask airway|i-gel laryngeal mask airway is a supraglottic airway device made from a medical grade thermoplastic elastomer , is a non-inflatable device to create anatomical seal of the pharyngeal, laryngeal and perilaryngeal structures and avoid compression trauma.
55790|NCT03748576|Behavioral|Mobile technologies|intervent diet and exercise during pregancy by mobile technologies
55791|NCT03748563|Device|DS-MCE and EGD|"Procedure of DS-MCE:~The DS-MCE system mainly consists of two parts: the NaviCam magnetic capsule guidance system and the detachable string part. In the esophagus, the movement of capsule can be controlled by the hollow string as the latex sleeve tightly wrapped around the end of the capsule. If attached from the hollow string, the capsule can be controlled manually by a magnet robot in the stomach or automatically using a default mode in the small bowel.~Procedure of EGD:~Subjects will undergo standard esophagogastroduodenoscopy(EGD) procedure within 48 hours after DS-MCE procedure. The EGD will be performed using conventional standard forward viewing upper gastrointestinal video endoscopes."
55792|NCT03748550|Behavioral|Aerobic exercise|All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.
55793|NCT03748537|Drug|Hydrocortisone|After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP <65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP < 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
55794|NCT03748524|Drug|Influenza Vaccine|Influenza Vaccine,Quadrivalent SIngle vaccination all participants at day 0
55795|NCT03748511|Other|fibroscan and stool sample|patients undergo ultrasaound (fibroscan) in order to stage the liver disease.
55796|NCT03748498|Device|laser|Application of the laser was performed through root canal and to the buccal mucosa over the apices of the target tooth
55797|NCT03748485|Behavioral|wait and watch|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),without(wait and watch) adjuvant chemotherapy
55798|NCT03748485|Drug|adjuvant chemotherapy|clinical local advanced colorectal cancer (cTxN1/2M0) following preoperational adjuvant therapies and pathologically proved stageⅡ(pT0-3N0M0),with adjuvant chemotherapy
55799|NCT03748472|Procedure|Continuous gavage feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 2 hours and the next feed will be given over 30 min and then over 2 hours again.
55800|NCT03748472|Procedure|Bolus feeding|Each subject will serve as his or her own control. In this arm infants will receive their feed over 30 min and the next feed will be given over 2 hours and then over 30 minutes again.
55803|NCT03748446|Drug|Xenon|The investigators have chosen to use as a maximum concentration about half the general anesthetic partial pressure of xenon (35%=70%/2) to achieve a dose that is sub-anesthetic. This concentration of xenon is very close to that at which subjects emerging from xenon anesthesia first respond to verbal commands, commonly referred to as MAC awake.
55804|NCT03748446|Drug|Nitrogen gas|nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual
55805|NCT03748433|Device|Dexcom G6 CGM|Commercially available Dexcom G6 Continuous Glucose Monitoring
55806|NCT03748433|Device|Tandem t:slim X2 Insulin Pump|sensor augmented insulin pump with predictive low glucose suspend
55807|NCT03748420|Other|Adherence-enhanced clinical decision support|Clinical decision support system integrating electronic medication data with claims data on prescription fills
55808|NCT03748420|Behavioral|ReachOut Adherence intervention|The pharmacist outreach intervention is based on the theoretically grounded and evidence-based Information-Motivation-Behavioral framework endorsed by the World Health Organization to improve adherence
55809|NCT03748407|Other|Dosages of Thyroid parameters|Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody)
55810|NCT03748394|Behavioral|Work-directed rehabilitation|Each participant starts with a meeting together with an occupational therapist or a physical therapist, focusing on the participant's resources and obstacles for functioning well at work. A plan is designed and carried out over 8 weeks, including 1-4 different treatment modules of occupational and physical therapy, to support the person's ability to function at work
55811|NCT03748394|Behavioral|Physical activity|In a meeting with a physical therapist, each participant receives advice on physical activity to support mental health, according to national recommendations. The participant is offered to train at a local gym during 8 weeks.
55812|NCT03748381|Procedure|Cataract surgery|During cataract surgery patients will be implanted with the AT Zeiss Lisa tri in one eye and the Rayner trifocal in the contralateral eye
55813|NCT03748368|Other|Cataract presentation|Presentation about cataract surgery
55814|NCT03748368|Other|Placebo presentation|Presentation about the history of the hospital
55815|NCT03748355|Genetic|Pharmacogentic Analysis|Participant will complete a buccal swab and it will be sent off to OneOme for analysis. When the results are available, the study investigators will review the medications for potential drug-drug and drug-genotype interactions. The risk for interactions will be classified as low, medium or high. The investigators will then communicate to the clinical team taking care of the patient these results and whether medication changes are recommended to minimize the drug-drug and drug-genotype interactions.
55816|NCT03748342|Device|Second-Generation Laryngeal Mask Airway|A second-generation LMA will be used for airway management (instead of ETT).
56110|NCT03745937|Drug|MEDI0382|MEDI0382 administered subcutaneously
55817|NCT03748329|Device|Ultrasound|Will deposit local anaesthetic intra-orally with the aid of ultrasound to guide the location of the final deposition.
55818|NCT03748303|Drug|Allopregnanolone|Administration of weekly IM injections of Allopregnanolone.
55819|NCT03748290|Drug|Pregabalin|Pregabalin 75 mg for 12 weeks
55820|NCT03748290|Drug|Placebo Oral Tablet|Placebo Oral Tablet
55821|NCT03748277|Procedure|Decompression|Bilateral decompression
55822|NCT03748277|Procedure|PLIF|Traditional open surgery
55823|NCT03748277|Procedure|MIS TLIF|On the one side - Wiltse approach, on the other side - percutaneous
55824|NCT03748277|Procedure|Screw Fixation|Transpedicular Screw Fixation
55825|NCT03748251|Other|the patients ate a pizza that fermented for 8 hours|Patients eat pizza prepared with controlled ingredients but fermented 8 hours
55826|NCT03748251|Other|the patients ate a pizza that fermented for 24 hours|Patients eat pizza prepared with controlled ingredients but fermented 24 hours
55827|NCT03748238|Procedure|Endometrial Injury with Hysteroscopy|All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
55828|NCT03748212|Drug|D935 Cap. 1T|single oral administration under fed condition
55829|NCT03748212|Drug|CKD-385 Tab. 1T|single oral administration under fed condition
55830|NCT03748199|Drug|POL6014|"DL1 80 mg cohorts 1A and 1B (QD and BID) DL2 160 mg cohorts 2A and 2B (QD and BID) DL3 320 mg cohorts 3A and 3B (QD and BID)~DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)"
55831|NCT03748199|Drug|Placebo|Placebo will be administered orally at a dose and frequency matched to POL6014
55832|NCT03748186|Drug|STRO-002|intravenous antibody drug conjugate
55833|NCT03748173|Combination Product|Aerosolized Infasurf|Infants randomized to aerosol treatment will receive Infasurf® aerosol at a rate of 12 ml/hour (the maximal rate using the Solaris CAG). The initial treatment will be for 60 minutes, with reevaluation every 30 minutes thereafter, with a maximum dose of 6 mL/Kg body weight or 2 hours of aerosolization. Treatment will be stopped after 60 minutes (and subsequently at 30-minute intervals) if a 2 point reduction in bronchiolitis score or a score ≤ 4 is achieved. Treatment will also be stopped at any time should there be evidence of other-than-transient deterioration in oxygenation or clinical status or for any serious adverse effect deemed by the infant's clinician to be possibly related to the drug administration.
55834|NCT03748160|Other|Letter|Intervention consists of two different types of postal letters reminding elderly citizens (65 years and above) about influenza vaccines that are available free of charge from the local health centers
55835|NCT03748147|Drug|Misoprostol|prostaglandin e1
55836|NCT03748134|Biological|Sintilimab|For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
55837|NCT03748134|Drug|Paclitaxel|87.5 mg/m^2 IV Q3W day 1, day 8 for first cycle and 175mg/m^2 IV Q3W day 1 after first cycle
55838|NCT03748134|Drug|Cisplatin|75mg/m^2 IV Q3W day 1
55839|NCT03748134|Biological|Placebo|For weight <60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
55840|NCT03748121|Behavioral|Pranayama|The pranayama intervention is placed directly before the respective CBT unit and will be repeated for 10 subsequent CBTS units. Pranayama containes the performance of Kapalabhati, Ujjayi, and/or Nadi Shodhana (for overall 1 minute) as well as following Kumbhaka (intentional respiratory reflex inhibition). Pranayama will be repeated 3 times before each CBT unit.
55841|NCT03748121|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy (CBT)
55842|NCT03748108|Drug|lidocaine|a bolus intravenous dose of 1.5 mg/kg lidocaine 2% over 15 s just before the induction of general anesthesia.
55843|NCT03748108|Drug|Placebo|a bolus intravenous dose of 1.5 mg/ kg a saline placebo over 15 s just before the induction of general anesthesia.
55844|NCT03748095|Drug|pipéracilline/tazobactam|There is not intervention description
55845|NCT03748082|Drug|Nitric Oxide|Inhaled nitric oxide (iNO) will be administered via the CPB machine and after CPB via the inspiratory limb of the anesthetic or ventilator circuit, and thereafter via the mechanical ventilator in the ICU. Test gas administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, iNO will be weaned and discontinued.
55846|NCT03748082|Diagnostic Test|Reactive Hyperemia Index|Vascular responsiveness will be assessed with peripheral arterial tonometry which measures the transient increase in forearm blood flow (Reactive Hyperemia Index, RHI) in response to a five-minute occlusion of the brachial artery with a pressure cuff.
55847|NCT03748082|Procedure|Endothelial Cells Collection|Endothelial cells are collected before and after surgery from a peripheral vessel using a soft J-shaped wire inserted through an intravascular catheter.
55848|NCT03748056|Behavioral|Targeted incentives|Participants receiving individually-targeted incentives will receive weekly coupons for healthier foods that are informed by their purchase history, responses to behavioral and health questions, food preferences, and need for improvement in different categories
55849|NCT03748056|Behavioral|Nominal loyalty card discount and nutrition education|All participants will receive a nominal discount on all groceries for using their loyalty card and nutrition education through weekly emails.
55850|NCT03748043|Drug|Lactoferrin|lactoferrin 100 mg per day plus ferric hydroxide polymaltose 6 mg /kilogram of Elemental iron
55851|NCT03748043|Drug|Ferric Hydroxide Polymaltose|group 2 will receive ferric hydroxide polymaltose 6 mg /kilogram of elemental iron
55852|NCT03748030|Radiation|Confirmed Left-Sided Breast Cancer|Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
55853|NCT03748017|Dietary Supplement|Placebo-Control Supplement|A once-daily oral dose of the placebo-control supplement will be consumed by adults for 14 consecutive days.
56111|NCT03745937|Drug|Placebo|Placebo administered subcutaneously
96772|NCT03430037|Drug|Placebo oral capsule|Placebo
55854|NCT03748017|Dietary Supplement|Streptococcus-Containing Probiotic Supplement|A once-daily oral dose of the streptococcus-containing probiotic supplement will be consumed by adults for 14 consecutive days.
55855|NCT03748004|Behavioral|IPS/SP|The 72 recruited clients receiving primary care services from one DTES clinical site who are employment ready will be randomly assigned to IPS and Peer Support (experimental group) or WorkBC control group
55856|NCT03748004|Behavioral|WorkBC|36 out of the 72 participants who live in the DTES will be randomly assigned to the control group (WorkBC). Participants will be provided with WorkBC employment services.
55857|NCT03747978|Drug|Perindopril and Amlodipine|Fixed combination of Perindopril 5mg and Amlodipine 5mg
55858|NCT03747978|Drug|Perindopril-indapamide|Perindopril 5mg and Indapamide 1.25mg
55859|NCT03747965|Biological|Mesothelin-directed CAR-T cells|Cells will be infused one day after the completion of conditioning regimen of paclitaxel and cyclophosphamide
55860|NCT03747952|Procedure|Tibiotalocalcaneal arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
55861|NCT03747952|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
55862|NCT03747939|Drug|Apremilast (CC-10004)|"Subjects randomized to apremilast will receive dose-titration for the initial 5 days. Apremilast subjects will receive dummy titration at wk. 16 (for early escape subjects) and again at week 24 to maintain the blinding of the original treatment assignments. Investigational product (IP) will be dispensed in blinded dose cards until Week 28. Thereafter, IP will be dispensed in open-label bottles."
55863|NCT03747939|Other|Apremilast (CC-10004) Placebo|"Subjects randomized to placebo will receive dummy dose-titration for the initial 5 days. Placebo subjects who meet the criteria for early escape at wk. 16 may receive apremilast beginning at wk. 16 and will receive active titration. Remaining placebo subjects will receive active dose titration at week 24. Beginning at wk 24 all subjects will be dispensed active apremilast. Investigational product will be dispensed in blinded dose cards until Week 28. to maintain the blinding of the original treatment assignments. Thereafter, IP will be dispensed in open-label bottles"
55864|NCT03747926|Drug|BI 705564|single-rising oral dose
55865|NCT03747926|Drug|Placebo|single-rising oral dose
55866|NCT03747913|Dietary Supplement|Antioxidative supplementation|Each participant conducts two identical cycling tests, first without and a week later with antioxidative supplementation
55867|NCT03747900|Drug|Botulinum Toxin Type A|200 U Botulinum toxin type A injection in the spastic biceps brachii muscle.
55868|NCT03747900|Combination Product|Botulinum Toxin Type A and dry needling.|Dry needling for 4 times in total in the spastic biceps brachii muscle after the Botulinum toxin type A injection.
55869|NCT03747887|Behavioral|Daily Report Card|Students assigned to the DRC group will have a consultant assigned to the student for the duration of the school year. The consultant will work with the child's primary special education teacher (or regular education teacher if the child spends the majority of his or her day mainstreamed) to establish a DRC over the course of three consultation visits. The How to Establish a Daily Report Card manual contains a standard DRC instruction packet that is provided to teachers to explain the rationale of the DRC, procedures for creating, modifying, and evaluating the DRC, procedures for parents to create home-based rewards for DRC performance, and information on trouble-shooting.
55870|NCT03747887|Other|School as Usual|The Individualized Education Program will be implemented as usual, with no additional study-related supports.
55871|NCT03747874|Diagnostic Test|ventilatory polygraphy|we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
55872|NCT03747861|Device|SenceBand|Wristband for registration of ECG RR intervals for one hand, SenceBand will collect data from 5-minutes intervals each 30 minute within 24 hours
55873|NCT03747848|Behavioral|CBT group|Each interested individual will complete eligibility screening, consent form, and pre-intervention assessment. Demographic information such as gender, age, and number of years since diagnosis of PD will be collected. This investigator will implement the treatment program by meeting with the participants in groups, once a week, for six weeks. Group meetings will encourage interaction and support among group participants. Program content includes encouraging physical exercise with higher intensity, changing poor sleeping hygiene habits, stress management, and encouraging utilization of social support.
55874|NCT03747835|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
55875|NCT03747835|Behavioral|Motivational Interviewing|"Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions."
55876|NCT03747822|Procedure|fat filler,PEEK,sliding genioplasty|The procedure will be done under general anesthesia; the donor site lower abdomen, flank, lateral thigh, or inner thigh will be infused using a solution that consisted of 100 ml of normal saline with 50 mg (0.05%) of lidocaine and 0.1 ml of epinephrine. Liposuction will be performed using a 2-mm blunt cannula. A 20-cc syringe will be used to collect the fat. The fat will be injected into the chin in a supraperiosteal (subcutaneous) plane with a blunt 2-mm cannula using a fanning technique.
55877|NCT03747809|Device|CIEDs Remote Monitoring System|Cardiac device remote monitoring system
55878|NCT03747796|Other|Supine position|The children will be placed in the supine position after ingestion of a standard volume of clear fluid
55879|NCT03747796|Other|Semi-sitting position|The children will be placed in the semi-sitting position after ingestion of a standard volume of clear fluid
55880|NCT03747783|Procedure|Radical Operation|The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
56112|NCT03745924|Drug|Nonacog beta pegol|Participants are treated with commercially available nonacog beta pegol (N9-GP) according to local clinical practice at the discretion of the treating physician
55881|NCT03747770|Biological|Bivalent HPV vaccine CERVARIX®|Bivalent HPV vaccine(Glaxo Smith Kline, GSK, Rixensart, Belgium) presented as a suspension for intramuscular injection containing purified viral L1 protein for HPV types 16 and 18. Each 0.5 mL dose of the bivalent vaccine contains 20μg of HPV-16 L1 protein and 20 μg of HPV-18 L1 protein adsorbed onto a proprietary adjuvant system containing 500 μg of aluminum hydroxide and 50 μg of 3-O-desacyl-4-monophosphoryl lipid A (AS04)
55882|NCT03747757|Behavioral|Cognitive Behavior Therapy|Undergo CBT
55883|NCT03747757|Other|Quality-of-Life Assessment|Ancillary studies
55884|NCT03747757|Other|Questionnaire Administration|Ancillary studies
55885|NCT03747744|Other|CD1c (BDCA-1)+ myDC|Intratumoral injection in subcutaneous, cutaneous, soft tissue metastases
55886|NCT03747718|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
55887|NCT03747718|Other|Placebo|Fecal Microbiota Transplantation via colonoscopy for the first transplant in all subjects. This will be followed by 2 fecal enema transplants for all subjects 7 days (+/- 3 days) after colonoscopy. All subjects will be assessed 1.5 months (+/- 2 weeks) after colonoscopy. The subjects who are deemed responders based on a drop in PCDAI=12.5 or higher will be randomized to receive fecal or placebo enemas at 1 monthly (+/- 2 weeks) enemas at 1.5, 2.5 and 3.5 months after colonoscopy. All subjects will be assessed at 4.5 and 6 months (+/- 2 weeks) following colonoscopy. The study will be completed at 6 months (+/- 2 weeks) following colonoscopy.
55888|NCT03747705|Other|An App for reminding patients to take their medication|Open-label, single-center study, up to 20 adults (>18) male and female with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs), will participate in a 4-week observation period during which no change in the drugs is permitted. The patients will then begin 10-week treatment by taking their medications according to a semi-random schedule that is pre-set for them by the physician using the same drugs the patient is taking and only changing the dose and times of taking them each day while keeping the drugs within their therapeutic window. Between 6:00-22:00 During the study, patients will fill a seizure diary daily.
55889|NCT03747692|Procedure|study group|local anesthesia by mepicaine hydrochloride by intracervical local injection using 10 mm syringe.
55890|NCT03747692|Procedure|control group|each patient receives one tablet of NSAIDs (diclofenac sodium 50 mg) and 5ml of a placebo in form of normal saline are injected intracervical 5 minutes before the procedure using 10 mm syringe.
55891|NCT03747679|Drug|200 Mg capsules of bosutinib in Water solution|200 mg (4X50) Capsules in water
55892|NCT03747679|Drug|bosunitib sorbitol|200 Mg of bosutinib sorbitol solution
55893|NCT03747679|Drug|Bosutinib Mannitol|Bosutinib mannitol solution
55894|NCT03747679|Drug|bosutinib in mannitol low sweet|bosutinib in mannitol solution low sweet
55895|NCT03747679|Drug|bosutinib in mannitol high sweet|bosutinib in mannitol high sweet
55896|NCT03747679|Drug|bosutinib taste low flavour|bosutinib solution low flavour
55897|NCT03747679|Drug|bosutinib high flavour|bosutinib solution high flavour
55898|NCT03747679|Drug|bosutinib capsules in applesauce|Bosutinib capsules in applesauce
55899|NCT03747679|Drug|Bosutinib capsules in yogurt|bosutinib capsules in yogurt
55900|NCT03747679|Drug|bosutinib capsules in water|sham comparator, bosutinb in water retest
55901|NCT03747679|Drug|Bosutinib capsules in low sweet|bosutinib capsules in low sweet
55902|NCT03747679|Drug|bosutinib capsules high sweet|Bosutinib capsules high sweet
55903|NCT03747679|Drug|bosutinib capsules low flavour|Bosutinib capsules low flavour
55904|NCT03747679|Drug|bosutinib capsules high flavour|bosutinib capsules in high flavour
55905|NCT03747666|Procedure|2.0 single locking miniplates|The fractured segments in the parasymphyseal region will be fixed using 2.0 single locking miniplates placed on the inferior border of the mandible.
55906|NCT03747653|Drug|ADVATE|Patients will be administered a single dose of ADVATE.
55907|NCT03747653|Drug|FRSW107|Patients will be administered a single dose of FRSW107 for Injection.
55908|NCT03747640|Device|Self Transcranial Direct Current Stimulation (tDCS)|tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., NY; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.
55909|NCT03747640|Behavioral|mindfulness-based meditation|The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.
55910|NCT03747640|Device|Sham Self Transcranial Direct Current Stimulation (tDCS)|For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.
55911|NCT03747640|Behavioral|sham meditation|For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
55912|NCT03747627|Diagnostic Test|Genetic profiling|All participating subjects will undergo detailed genetic analysis, with the aim of detecting novel genetic drivers for the development of interstitial lung disease in the context of known sensitising agent (pigeon antigen)
55913|NCT03747614|Drug|Fluorometholone|"Fluorometh010neEyeDrops:~Brand names: Allergan Pharmaceuticals Ireland, Serial number: J20130061, NDC 60758-880-05. Tacrolimus Brand names: Senju Pharmaceutical Co., Ltd. Fukusaki Plant Serial number: H20130452"
56010|NCT03746847|Drug|Gallium-68 DOTATATE|Gallium-68 DOTATATE is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the U.S. Food and Drug Administration (FDA) to diagnose certain tumors.
56011|NCT03746834|Device|NASHA/Dx (Solesta®)|Perianal submucosal injection of 3-4 ml of NASHA/Dx
55914|NCT03747614|Device|Functional Slit-Lamp Biomicroscopy|A traditional slit lamp (HAAG-STREIT SWISS MADE 900.7.2.34925) was used, and a digital camera (Canon 60D. Canon Inc, Melville, NY) was attached via an inherent camera port. Custom software was used to measure the conjunctival microvascular BFV and vessel diameter using a protocol that has been previously described in detail. At baseline, video clips were recorded on six fields of the bulbar conjunctiva, which was approximately 1 mm from the limbus. During the follow-up visits, attention was given to relocating the vessel segments for these 6 fields.
55915|NCT03747601|Device|Temporal Interference (TI) Stimulation|2-4 Temporal Interference stimulation sessions. The device is an experimental non-invasive electrical brain stimulator that functions similar to existing non-significant risk devices for electrical stimulation, including human non-invasive brain stimulation. Briefly, the device produces alternating current electrical stimulation in a kilohertz (kHz) range and results in less net charge applied within the brain. The device is powered by rechargeable 20 volt (V) battery (i.e. there is no connection to building power supply). The current is hardwired and limited to 5 milliamp (mA) via internal resistors. It includes extra safety features such as onboard fuses to limit any abrupt high current, and an emergency stop button which effectively insulates the subject and resets the device. The device was tested and characterized at all the required load conditions.
55916|NCT03747588|Other|Laparoscopic pancreaticoduodenectomy|Laparoscopic resection of pancreatic tumor
55917|NCT03747588|Other|Open pancreaticoduodenectomy|open resection of pancreatic tumor
55918|NCT03747575|Drug|MSTT1041A|Participants will receive subcutaneous (SC) MSTT1041A
55919|NCT03747575|Drug|Placebo|Participants will receive SC placebo
55920|NCT03747562|Drug|Gabapentin|Gabapentin will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, gabapentin capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, gabapentin powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
55921|NCT03747562|Other|Placebo|Placebo will be administrated orally, with or without food, and should be swallowed with sufficient fluid intake (e.g. a glass of water). Since head and neck cancer patients frequently experience swallowing difficulties, placebo capsules will be provided to enable opening of the capsule and use of the contents for mixture with food or liquids. Moreover, placebo powder can be dissolved in water to enable injection of the drug into a percutaneous endoscopic gastrostomy tube.
55922|NCT03747549|Other|Acupuncture and Home Exercise|Acupuncture (needles will be placed at BL 60, BL 61, KI 3, KI 4 with needles directed into the Achilles tendon. Needles inserted until a firm catch of the needle entering the tendon was appreciated. Energy (a small electrical current) is placed from KI 3(-) KI 4(+) and BL 61 (-) BL 60(+) at 30 Hz for 15min) plus the prescribed home exercise program
55923|NCT03747549|Other|Home Exercise Alone|The prescribed home exercise program alone.
55924|NCT03747536|Drug|Ipratropium bromide|ipratropium bromide via metered dose spray (21 micrograms per spray)
55925|NCT03747536|Other|Placebo|normal saline delivered via metered dose spray
55926|NCT03747523|Drug|Ergocalciferol|Investigational drug will be administered to eligible participants in a single dose of 200,000 USP units vitamin D
55927|NCT03747510|Device|CarpX Device|Transverse carpal ligament release with CarpX Device
55928|NCT03747497|Drug|contezolid acefosamil|IV and oral contezolid acefosamil given twice a day for 10 to 14 days
55929|NCT03747497|Drug|linezolid 600 mg|IV and oral linezolid given twice a day for 10 to 14 days
55930|NCT03747484|Biological|Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR|Given IV
55931|NCT03747484|Drug|Avelumab|Given IV
55932|NCT03747484|Radiation|Radiation Therapy|Undergo radiotherapy
55933|NCT03747484|Biological|Pembrolizumab|Given IV
55934|NCT03747471|Behavioral|Diabetic Conversation Map|"Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions."
55935|NCT03747458|Drug|OPN-375|OPN-375, BID
55936|NCT03747445|Procedure|Roux-en-Y gastric bypass|laparoscopic surgical procedure
55937|NCT03747432|Drug|Propofol|Conscious sedation during TAVR procedure using propofol
55938|NCT03747432|Drug|Dexmedetomidine|Conscious sedation during TAVR procedure using dexmedetomidine
55939|NCT03747419|Drug|Avelumab|Avelumab is a form of immunotherapy, which means it is designed to help the patient's immune system kill cancer cells.
55940|NCT03747419|Radiation|Radiation|Cancer treatment that uses ionizing radiation to kill cancer cells.
55941|NCT03747406|Procedure|Erector spinae plane block|the level between T9 and T10 will be identified using ultrasound as well as transverse processes depth. An array probe will be applied longitudinal orientation 3 cm lateral midline. The erector spinae and the psoas muscle will be identified. A skin wheal will be made using lidocaine 1% at each level and then a 22-gauge Tuohy needle will be advanced inplane until it made contact with the transverse process. The needle will be withdrawn slightly and 30cc of bupivacaine 0.25 % (15ml for each side) will be injected slowly after negative aspiration was confirmed. The same procedure will be repeated in the contralateral side.
55942|NCT03747406|Procedure|TAP block|a linear array transducer 5-12 MHz will be positioned inferior and parallel to the costal margin in a medio-lateral orientation. The external oblique, internal oblique and transverse abdominis muscles will be identified immediately lateral to the linea semilunaris. A a 22-gauge needle will be advanced medially and in-plane to the US beam until the tip lies between the fascia of the internal oblique muscle and the transverse abdominis muscle layers. 30 ml of 0.25 % bupivacaine will be injected in each side and the spread will be observed between the two muscles layers.
56012|NCT03746821|Dietary Supplement|Biotin|Biotin supplements (2) to be taken daily
56113|NCT03745911|Combination Product|Paclitaxel and TAK-228|Treatment with TAK-228 oral (D2, 3 and 4 of each week) and paclitaxel (D1 of each week) on Days 1, 8 and 15 for each 28-days cycle until disease progression or unacceptable toxicity. If paclitaxel is stopped, TAK-228 may be continued
55943|NCT03747393|Behavioral|DoD/VA CPG Core Set + PT|Participants randomized to receive the core set management class and physical therapy will be scheduled for their initial physical therapy evaluation approximately 1 week from their enrollment date. The purpose of the evaluation will be to identify relevant impairments that can be addressed during the physical therapy treatments. After this initial evaluation, the goal is for the patient to receive approximately 4 weeks of physical therapy (about 8-10 sessions in the clinic 2-3 times per week). Consistent with a pragmatic study we will not use placebos to blind patients or attempt to balance provider contact.
55944|NCT03747393|Behavioral|DoD/VA CPG Core Set|The published clinical practice guideline recommends early use of a core set of management strategies to include patient education about their condition and the role of obesity in disease progression, activity and lifestyle modification focusing on physical activity, and a therapeutic exercise program. Implementation of the core set is recommended prior to any referral for consultation about invasive procedures such as intra-articular injections or TKA surgery. All patients with knee pain will be scheduled to receive the core set management strategy class as a part of the usual care route.
55945|NCT03747380|Other|inspiratory muscle program|pre-operative inspiratory muscular training program
55946|NCT03747367|Behavioral|Insufficient Sleep|
55947|NCT03747354|Diagnostic Test|blood samples|blood samples
55948|NCT03747341|Drug|Buprenorphine Injectable Solution|0.3 mg/mL for intravenous injection
55949|NCT03747341|Drug|Placebo|0.9% normal saline for intravenous injection
55950|NCT03747341|Drug|Fentanyl|0.05 mg/mL for intravenous injection
55951|NCT03747328|Drug|ABI-009|nanoparticle albumin bound sirolimus
55952|NCT03747315|Other|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.
55953|NCT03747315|Other|In vitro functional test|Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.
55954|NCT03747302|Other|Social Media Message about HPV and HPV vaccine|Messages educate parents with facts about HPV vaccination.
55955|NCT03747302|Other|Social media message about risk of electronic cigarettes.|Messages educate parents with facts about electronic cigarettes. This is an attention control group without outcomes obtained.
55956|NCT03747289|Other|performing exercises in a weight bearing posture|20 participants will perform exercises in a weight bearing posture
55957|NCT03747289|Other|performing exercises in a non weight bearing posture|20 participants will perform exercises in a non weight bearing posture
55958|NCT03747276|Other|Clinical Trial Kiosk|Kiosk will consist of a patient facilitator and a computer with access to general information about clinical trials and information specific to active clinical trials at the facility. Patients will be made aware of the kiosk via a large banner visible in the clinic above the kiosk.
55959|NCT03747263|Procedure|Catheter ablation|Electrophysiology studies are performed during conscious sedation using boluses of midazolam and fentanyl and a continuous infusion of propofol. Vital parameters are continuously monitored. One 7F standard diagnostic catheter is positioned inside the coronary sinus (CS) via the femoral vein. One 8,5-F sheath is advanced to the left atrium (LA). After transseptal catheterization, intravenous heparin is administered to target an activated clotting time of ≥300 seconds. PV angiographies are obtained for each PV and PV recordings are registered at baseline in SR. The 8.5F transseptal sheath (TS) is changed over the wire for a 12F steerable TS.
55960|NCT03747250|Device|Videolaryngoscopy|In experimental group (interventional group), patients will be intubated with the videolaryngoscope
55961|NCT03747250|Device|Direct laryngoscopy|In control group (active comparator group), patients will be intubated with the direct laryngoscope
55962|NCT03747237|Other|Edema measurement methods|A correlation between the results of the first and second methods will be examined.
55963|NCT03747224|Drug|ARO-ANG3|single or multiple doses of ARO-ANG3 by subcutaneous (sc) injections
55964|NCT03747224|Drug|sterile normal saline (0.9% NaCl)|calculated volume to match active treatment
55965|NCT03747211|Behavioral|Aerobic exercise|High Intensity Interval Training (HIIT)
55966|NCT03747198|Dietary Supplement|methylsulfonylmethane|Subjects will be given 2 g/day methylsulfonylmethane.
55967|NCT03747198|Other|Placebo|Subjects will be given 2 g/day placebo (rice flour).
55968|NCT03747185|Other|Lumbopelvic stiffening technique|"Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
55969|NCT03747185|Other|Lumbopelvic relaxing technique|"Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions."
55970|NCT03747172|Dietary Supplement|complementary and alternative therapy|complementary and alternative therapies were grouped into five main categories: (1) biologically based therapies , (2) mind/body therapies, (3) manipulative and body-based therapies, (4) Energy therapies and (5) alternative medical systems.
55971|NCT03747159|Drug|Belimumab Injection|Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
55972|NCT03747146|Device|Continuous Adductor Canal Catheter (ACC)|At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
55973|NCT03747146|Device|Adductor Canal block with sham catheter|Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
55975|NCT03747120|Drug|Paclitaxel|All subjects will receive Paclitaxel weekly for 12 weeks
55976|NCT03747120|Drug|Trastuzumab|All subjects will receive Trastuzumab every 3 weeks
55977|NCT03747120|Drug|Pertuzumab|Arm A and Arm B subjects will receive Pertuzumab every 3 weeks
55978|NCT03747120|Drug|Pembrolizumab|Arm B and Arm C subjects will receive Pembrolizumab every 3 weeks
55979|NCT03747107|Behavioral|P-DQIP|The 'intervention' is a health board quality improvement programme to be implemented across all practices in one Scottish NHS health board and comprises the following components: (i) Case finding via the P-DQIP informatics tool to identify patients with drug therapy risks for review; (ii) Decision support via the P-DQIP informatics tool to facilitate medication reviews; (iii) Practice pharmacists will be trained on the use of the P-DQIP informatics tool and instructed to target patients at risk of bleeding and hypoglycaemia first (iv) Ongoing performance feedback. Practices and locality pharmacists will be able to access reports on review activity and targeted prescribing; (v) promotion of the P-DQIP tool and intervention among GP practices. The P-DQIP intervention will be evaluated in all NHS Tayside practices who agree to share their data for monitoring and evaluation purposes.
55980|NCT03747094|Drug|Fentanyl|0.5 mic/kg fentanyl will be given immediately before the procedure
55981|NCT03747094|Drug|Ketamine|0.25 mg ketamine will be administered immediately before the procedure
55982|NCT03747081|Drug|Rivaroxaban|Rivaroxaban will administrate to patient with CVT. In first day, enoxaparin is injected to patients and the next day, patients will receive Rivaroxaban and enoxaparin discontinue. Then, patients receive Rivaroxaban for 3 months daily.
55983|NCT03747081|Drug|Warfarin|Warfarin as a antocoagolant drug will administrate to patient with CVT. In first day, Warfarin plus enoxaparin until adjusting INR index to 2-3. Then, patients receive warfarin for 3 months daily.
55984|NCT03747068|Drug|Anti-TNF Drug|
55985|NCT03747055|Behavioral|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
55986|NCT03747055|Behavioral|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
55987|NCT03747042|Drug|Letrozole|Patients will receive a prescription for letrozole to be taken orally for 7-56 days to allow for variations in surgical scheduling. Patients are to undergo surgical resection of their tumor the day after the last dose of letrozole. Post-treatment tumor biopsies (a goal of 4-6 cores) will be obtained following 7-56 days of letrozole treatment on the day of surgery.
55988|NCT03747029|Other|No intervention is provided|No intervention is provided
55989|NCT03747016|Dietary Supplement|high-energy digestible food E2|The women undergoing Cesarean section are given high energy digestible food 300ml before surgery
55990|NCT03747016|Dietary Supplement|glucose injection G2|The women undergoing Cesarean section are given glucose injection 300ml before surgery
55991|NCT03747016|Dietary Supplement|normal saline N2|The women undergoing Cesarean section are given normal saline 300ml before surgery
55992|NCT03747016|Dietary Supplement|high-energy digestible food E1|The women in delivery room are given high energy digestible food 300ml.
55993|NCT03747016|Dietary Supplement|glucose injection G1|The women in delivery room are given glucose injection 300ml.
55994|NCT03747016|Dietary Supplement|normal saline N1|The women in delivery room are given normal saline 300ml.
55995|NCT03747003|Other|No intervention is provided|No intervention is provided
55996|NCT03746977|Dietary Supplement|Protein|Protein supplementation 1.2 or 1.5 g/kg body mass/d
55997|NCT03746977|Behavioral|Walking|Walking with a volume corresponding to 250 kcal/d
55998|NCT03746977|Behavioral|WB-EMS application|WB-EMS application 1.5x 20 min/week
55999|NCT03746964|Procedure|Cardiac MRI|Preoperative cardiac MRI
56000|NCT03746964|Other|in-vitro elasticity tests|in-vitro elasticity tests performed on a segment of ascending aorta collected during surgery
56001|NCT03746951|Drug|Ropivacaine Hcl 0.5% Inj Vil 20Ml|Anesthetic agent used in peripheral nerve block
56002|NCT03746938|Device|VB-C01|Surgical implant of VB-C01 (Collagen membrane seeded with allogeneic stem cells isolated from adipose tissue, ADSC).
56003|NCT03746925|Procedure|Direct Anterior Approach (DAA)|Direct Anterior Approach surgery to replace the hip.
56004|NCT03746925|Procedure|SuperPATH|SuperPATH approach surgery to replace the hip.
56005|NCT03746912|Drug|Quizartinib Dihydrochloride|Tablets for once daily oral administration at doctor-recommended dose in continuous 28-day cycles
56006|NCT03746899|Biological|PLX-PAD|PLX-PAD cell therapy to be administered via 30 IM injections (0.5 mL each) to the index leg leg per treatment, in each of two treatments, 8 weeks apart
56007|NCT03746886|Other|Breast-milk|A single breast-milk sample will be collected from 20 women. Milk samples will be pooled for analysis.
56008|NCT03746873|Behavioral|COPD Web|"The COPD Web will be introduced to the participant randomized to intervention by a letter containing a code to get access to the web site and how to create an account and login. At the web site there will be an instruction movie showing/ discussing specific content on the COPD Web. The web site will be self-managed. To secure that there is no technical or user problems participants will be contacted by a researcher the first week of intervention.~Participants will receive push notifications (email) with targeted information containing links to the COPD Web and reminder to register the number of steps walked during that week. The push notifications will come every week (week 1-12), every other week (week 12 to 24) and every fourth week (week 24-52)."
56009|NCT03746860|Drug|Tablet, Dispersible|1 tablet/day with 12 SQ-HDM per lyo-tablet
56041|NCT03746535|Drug|Ganirelix Acetate|Ganirelix acetate alone, 250 μg/day in 0.5 ml normal saline,
56114|NCT03745898|Drug|Oxygen|Active nocturnal oxygen concentrator
56013|NCT03746808|Behavioral|EMA + App/Treatment Messages|"This study will develop and test a just-in-time adaptive intervention to reduce alcohol use among homeless adults. Phase I will use smartphones and passive sensing to monitor geolocation, psychosocial variables (e.g., stress, urge to drink), and alcohol use in a group of 80 homeless adults enrolled in shelter-based treatment. Phase II will use this information to create a risk algorithm and tailored treatment messages that anticipate and intervene to prevent alcohol use."
56014|NCT03746795|Device|Spirometric examinations realized using the EIT|Spirometric examinations will be realized using the EIT alone.
56015|NCT03746795|Device|Simultaneous measurement by spirometer and EIT|Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
56016|NCT03746782|Diagnostic Test|Flow Cytrometry; Thrombin Generation Assay|Apixaban combined with blood specimens (in vitro) of study participants
56017|NCT03746769|Biological|Allogenic Human Islet Cells|islet cells transplanted into the portal vein in the liver
56018|NCT03746769|Drug|Gastrin 17|"Gastrin-17 (or GAST-17) - a gut hormone injected under the skin twice daily for 30 days soon after islet transplant and again 6 months later.~Also, anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets."
56019|NCT03746756|Behavioral|SBIRT|"As part of regular practice FQHC screen patients at least once a year with the Alcohol Use Disorders Identification Test (AUDIT) to identify alcohol problems and Drug Abuse Screening Test (DAST) to identify drug problems. Those who are the most severed and referred to treatment are approached about participating in the study."
56020|NCT03746756|Behavioral|SBIRT+RMC-PC|In addition to SBIRT, those randomly assigned to the experimental condition will also receive Recovery Management Checkups for Primary Care (RMC-PC) at the time of referral/study enrollment and quarterly for 12 months. RMC-PC involves a linkage manager reviewing the assessment data and using motivational interviewing to encourage the person to go to treatment and identify barriers to entering or staying in treatment. It also involves problem solving on how to address common issues (e.g., transportation, scheduling), staying in regular contact for the first two weeks to make sure they stay in treatment, and checking in on continuing care compliance at later checkups.
56021|NCT03746743|Diagnostic Test|score for neonatal sepsis|score for neonatal sepsis to predict morbidity
56022|NCT03746730|Device|ultrasound|gray scale and doppler ultrasound
56023|NCT03746717|Device|occlusive wound closure|skin closure with a commercially available wound closure product consisting of a synthetic adhesive mesh and cyanoacrylate based skin glue
56024|NCT03746717|Device|conventional wound closure|wound closure with surgical staples
56025|NCT03746704|Drug|89Zr˗DFO˗REGN3504|89Zr˗DFO˗REGN3504
56026|NCT03746691|Drug|Citalopram HCl|Citalopram HCl IV 20 mg in 100 ml saline will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
56027|NCT03746691|Drug|Placebos|Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
56028|NCT03746678|Other|C-Care Mobile Application|C-care is a mobile application developed based on previous research at the IWK Health Centre. It contains topics relevant to Cesarean delivery and the recovery process, which the patient could access at anytime. Patient engagement with the application will be monitored anonymously for 30 days after delivery. On days one to five after delivery, patients will receive a short self-monitoring questionnaire (approximately 1 minute). At the end of two weeks (14 days), patients will complete an online survey regarding overall satisfaction, potential impact on care, usability and feasibility problems. At any point during the study, patients can email us to report any problems with the application.
56029|NCT03746665|Biological|meningococcal serogroup A conjugate vaccine|Once final eligibility has been confirmed by a study clinician on the day, expectant mothers will be administered a single intramuscular dose of MenAfriVac™.
56030|NCT03746652|Drug|Daratumumab, Ixazomib, Dexamethasone|Daratumumab 16 mg/kg, Ixazomib 4 mg, Dexamethasone 40 mg
56031|NCT03746639|Other|physiotherapy modalities|"The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 ."
56032|NCT03746626|Behavioral|Chaplain visit|The patients will all see a chaplain routinely during 8-week stay according to their personal preference. The chaplain records the 'depth' and frequency of these encounters.
56033|NCT03746613|Device|HEARO|Robotic system for otological procedures
56034|NCT03746600|Behavioral|Project TRAC: Tracking and Reducing Alcohol Consumption|The TRAC intervention for people living with HIV/AIDS focuses on increasing motivation and building skills for avoiding triggers and managing situations that encourage alcohol consumption. It requires eight 30-minute sessions with a counselor using videoconferencing and mobile phones. In addition to receiving the eight sessions of intervention content, participants will complete smart phone-based self-monitoring of medication adherence and alcohol consumption, which will be discussed during intervention sessions.
56035|NCT03746587|Drug|Arimoclomol|Arimoclomol in 3 different dosages
56036|NCT03746587|Drug|Placebo oral capsule|Matching placebo capsule
56037|NCT03746574|Behavioral|Compassion Curriculum|12 session curriculum offered every other week for six months. Each session lasted 80 minutes and all staff at the intervention clinics were expected to participate. A total of 16 hours of experiences were provided.
56038|NCT03746561|Diagnostic Test|deep learning|detect and classify spinal stenosis by deep learning
56039|NCT03746548|Device|Adhear|Patients are wearing the Adhesive bone conduction hearing device (Adhear) for 2 weeks
56040|NCT03746548|Device|Contact Mini (CM)|Patients are wearing the Conventional bone conduction hearing device (Contact Mini) for 2 weeks
97830|NCT03421600|Device|White light imaging|White light imaging
56044|NCT03746509|Device|Laryngeal Vibration (Treatment)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
56045|NCT03746509|Device|Laryngeal Vibration (Comparator)|The strength of the vibration is similar to the vibration experienced from vibrating cell phones or gaming joysticks. Vibro-tactile stimulation at the applied frequency and amplitude is not known to cause pain or tissue damage. The participant may feel a mild tingling or vibrating sensation. Preliminary testing on healthy human subjects showed that at the given vibration parameters no adverse reactions occur.
56046|NCT03746496|Diagnostic Test|point-of-care laboratory analysis|POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
56047|NCT03746483|Drug|MS1819-SD|MS1819-SD, an oral, non-systemic, that is non-enterically-coated. It is a yeast-derived (non-porcine) lipase pancreatic enzyme replacement.
56048|NCT03746483|Drug|Porcine PERT|Porcine PERT is being used as a comparator to MS1819-SD as a second drug/intervention
56049|NCT03746470|Procedure|ACL reconstruction preserving insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis, preserving their insertion at the level of the hamstring.
56050|NCT03746470|Procedure|ACL reconstruction detaching insertion|Anterior cruciate ligament reconstruction with semitendinosus and gracilis tendons completely detached from their insertion at the hamstring.
56051|NCT03746457|Behavioral|Behavioral intervention|Individual counseling, group intervention, collective advocacy
56052|NCT03746444|Other|General Anesthesia|The patients in general anesthesia group will undergo general anesthesia
56053|NCT03746444|Other|Regional Anesthesia|The patients in Group R will be given combined spinoepidural anesthesia
56054|NCT03746431|Drug|[111In]-FPI-1547 Injection|[111In]-FPI-1547is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate (FPI-1397), and Indium-111.
56055|NCT03746431|Drug|[225Ac]-FPI-1434 Injection|[225Ac]-FPI-1434 is a targeted alpha radioimmuno-therapeutic agent that consists of FPI-1175, an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody, a bifunctional chelate (FPI-1397), and actinium-225 (225Ac or Ac-225).
56056|NCT03746418|Drug|Ultrasound Guided Bilateral single shot Erector Spinae Plane Block|Under aseptic technique and after skin infiltration with 3 ml of 2% lidocaine, a 22G, 50-mm, insulated facet type needle (visioplex® - vygon - France) was introduced in plane in a cephalad to caudad direction until (L3) transverse process was hit [figure1(A)(B)(C)] and the needle was slightly withdrawn. The confirmation of the correct position of the needle tip was done by injecting 0.5-1 ml of LA. Once confirmed, 20 ml of the drug was administered under vision after confirming negative aspiration of blood. LA distribution was observed in both cranial and caudal directions. This was repeated on the other side also. Twenty minutes later, sensory loss to cold was evident between (T10-T 12) and (L5-S1) vertebral level of the posterior dermatomes and dermatomes of the anterior roots of the spinal nerves (lumbar plexus, upper leg) on both sides without hemodynamic changes. Motor function of the legs was evaluated with a Bromage (0-3) score.
56057|NCT03746405|Device|repetitive transcranial magnetic stimulation|excitatory 5Hz rTMS will be used
56058|NCT03746405|Device|Sham repetitive transcranial magnetic stimulation|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
56059|NCT03746392|Behavioral|Jumpstart Intervention|"The intervention has 4 steps: use electronic medical record (EHR) to identify seriously ill, hospitalized patients with no documentation of a goals-of-care (GOC) discussion during their current admission; the enrolled patient or his/her surrogate completes a survey assessing preferences for discussions about GOC, barriers to having such discussions, and current GOC which is used to create a Jumpstart form designed to prompt and guide a GOC discussion between the patient or surrogate and the clinicians caring for the patient; use natural language processing/machine learning (NLP/ML) approach to identify GOC discussions or advance directives in the EHR that occurred prior to admission and include this information on the Jumpstart form; and, deliver the Jumpstart form to the primary clinician team. The patient or surrogate is also provided with a version of the form."
56060|NCT03746366|Radiation|[C-11]|Radiolabel
56061|NCT03746366|Drug|Pittsburgh Compound B|Tracer
56062|NCT03746353|Procedure|early ileostomy closure|Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
56063|NCT03746340|Drug|Propofol|Propofol group: intravenous Propofol (2.0mg / kg) for general anesthesia induction, maintained for 30~60s. Continuous intravenous infusion of Propofol (7~8 mg·kg-1·h-1) with a syringe pump maintains a smooth general anesthetic sedative effect.
56064|NCT03746340|Drug|Sevoflurane|Sevoflurane group: Inhalation of 1-8% sevoflurane for induction.Then Inhalation of sevoflurane (2.0~2.5Vol%) was maintained
56065|NCT03746327|Drug|Sivextro 200 milligrams Oral Tablet|200 mg milligram per day during 4 weeks
56066|NCT03746301|Drug|Rivaroxaban(Xarelto,BAY 59-7939)|10mg, 15mg and 20 mg film-coated tablets
56067|NCT03746288|Drug|CAN008|CAN008 400 mg weekly over no less than 30 minutes via intravenous drip, followed by rRT that same day
56068|NCT03746275|Drug|Rivaroxaban (BAY59-7939, Xarelto)|2.5 mg twice daily
56069|NCT03746275|Drug|Acetylsalicylic acid|75 - 100 mg once daily according to local label
56070|NCT03746249|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
56071|NCT03746249|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
56072|NCT03746223|Drug|Methotrexate|400ug intravitreal injection every week for 4 doses in the induction phase, every 2 weeks for 2 doses as consolidation, then every month for 10 doses as maintenance
56073|NCT03746223|Drug|Rituximab|Rituximab：375mg/m2 intravenous infusion d1, every 28 days for 1 cycle. 6 cycles will be prescribed as protocol
56074|NCT03746223|Drug|Lenalidomide|25mg Qd, oral , d1-21 in 28-day cycle in the induction phase and maintenance phase.
56075|NCT03746210|Diagnostic Test|Standard diagnostic procedures|B-Mode ultrasound, Duplex sonography, contrast-enhanced ultrasound, elastography, CT, MRI, anthropometrics
56115|NCT03745898|Other|Room Air|Sham nocturnal oxygen concentrator (room air)
56076|NCT03746197|Device|Project EVO Multi- Treatment|The EVO platform assesses perceptual discrimination while single-and multi-tasking. Visuomotor tracking involves navigating a character through a dynamically moving environment while avoiding obstacles. EVO uses adaptive algorithms to change game difficulty on a trial by trial and patient by patient basis for the tracking task and discrimination task with real-time feedback.
56077|NCT03746184|Other|Treatment course|Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
56078|NCT03746171|Diagnostic Test|Colonic polyp characterization by BLI|"All rectosigmoid <5 mm polyps, regardless of the presence of larger polyps, will be characterized by BLI-assisted optical diagnosis by using BASIC criteria (neoplastic vs. non neoplastic) and will be included in polyp-level assessment.~The polyp characterization will be always performed and recorded without zoom magnification. In patients in which colonoscopy will be performed with endoscopes equipped with zoom magnification, the zoom will be eventually systematically applied and the characterization with zoom will be also recorded. The post-polypectomy surveillance intervals based on BLI will be calculated by using histology estimation performed without zoom for all patients. Only polyps characterized with high confidence will be included in the analysis; the high-confidence characterization rate will be calculated."
56079|NCT03746158|Dietary Supplement|curcumin|subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
56080|NCT03746145|Dietary Supplement|Bifidobacterium longum 1714|This is a double-blind randomized placebo-controlled pilot study. Participants under extreme conditions of hypoxia, confinement and isolation receive Bifidobacterium longum 1714 on a daily basis over one year in order to test improvements on stress resilience and immune functions.
56081|NCT03746145|Dietary Supplement|placebo sachet containing maltodextrin and magnesium stearate.|placebo sachet containing maltodextrin and magnesium stearate.
56082|NCT03746132|Device|EPIFLO|EPIFLO is a 3 ounce oxygen generator that continuously delivers 3 ml/hr of pure oxygen to the wound site, to enable tissue regenerative processes, thus driving closure of delayed-healing acute or chronic wounds.
56083|NCT03746119|Other|E-cigarette vapor containing nicotine|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed e-solution containing nicotine.
56084|NCT03746119|Other|E-cigarette vapor, nicotine free|A fourth generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings, and pre-mixed nicotine free e-solution.
56085|NCT03746106|Drug|Trimethoprim|300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only
56086|NCT03746106|Drug|Metformin|1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only
56087|NCT03746106|Dietary Supplement|Vitamin B1|5mg of thiamine will be given alone and in combination
56088|NCT03746093|Dietary Supplement|Water|Participants will consume a bottle of water (330 ml) every day for 12 weeks.
56089|NCT03746093|Dietary Supplement|Non-alcoholic beer|Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
56090|NCT03746080|Drug|Plerixafor|Plerixafor will be administered via infusion at 400 micrograms per kilogram per day for four weeks beginning one week before the end of radiation
56091|NCT03746080|Drug|Temozolomide|Temozolomide (TMZ) will be administered concurrently with the radiation for 42 days and 6-12 cycles of monthly adjuvant Temozolomide (TMZ) after completion of Plerixafor infusion.
56092|NCT03746080|Radiation|Whole-Brain Radiotherapy (WBRT)|Undergo Whole brain radiotherapy (WBRT) - Radiotherapy consists of 30 Gy in 15 fractions of whole brain radiations
56093|NCT03746080|Radiation|Radiation Therapy|Radiotherapy consists of 30 Gy in 15 fractions
56094|NCT03746067|Drug|TS-134|5 mg, 10 mg, or 20 mg oral solution
56095|NCT03746067|Drug|Placebo|Matched Placebo oral solution
56096|NCT03746054|Combination Product|Optimal medical treatment|Life style modifications, Monitoring of the risk factors and Optimal medical treatment Lipid-lowering treatment, anti-platelet treatment and ACEi or AT2 antagonists treatment for a total duration of 24 months
56097|NCT03746054|Combination Product|usual clinical practice|usual clinical practice in each center
56098|NCT03746041|Drug|abaloparatide|In cycle 1, patients will be treated with single-agent, subcutaneous (SQ) abaloparatide at a dose of 80 mcg/day for 28 days.
56099|NCT03746041|Drug|bevacizumab|In cycles 2-4 (each cycle is 28 days), patients will be treated with SQ abaloparatide at a dose of 80 mcg/day and intravenous (IV) bevacizumab 5 mg/kg on days 1 and 15.
56100|NCT03746015|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|Tetravalent Dengue Vaccine (TDV) subcutaneous injection
56101|NCT03746002|Drug|Metolazone 60 minutes prior to furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
56102|NCT03746002|Drug|Metolazone concurrently with furosemide|All patients will receive furosemide background therapy (furosemide 120 - 160 mg IV bolus dosed twice within a twenty four hour period. Patients will be randomized 1:1 to either metolazone 5 mg tablet dosed 60 minutes prior to first dose of furosemide or metolazone dosed concurrently (within ten minute time frame) with the first dose of furosemide.
56103|NCT03745989|Drug|MK-8353|Starting Dose (Dose Level [DL] 1): MK-8353
56104|NCT03745989|Drug|Selumetinib|Starting Dose (Dose Level [DL] 1): selumetinib
56105|NCT03745976|Procedure|questionnaire and Xray for all patients|questionnaire and Xray for all patients
56106|NCT03745963|Behavioral|Skin-to-skin contact|Infants allocated to the SSC arm will be placed in upright, ventral SSC position (holding of a diaper clad baby on the bare chest of a mother) for a minimum of 15 minutes prior to data collection.
56107|NCT03745963|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance.
56108|NCT03745950|Drug|Olaparib Oral Capsule|- Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
56109|NCT03745950|Drug|Placebo oral capsule|- Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
56116|NCT03745885|Drug|Supaglutide injection|Administered SC in the Supaglutide arms.
56117|NCT03745885|Drug|Placebo|Administered SC in the placebo arms and to maintain the blind in the Supaglutide injection arms.
56118|NCT03745872|Behavioral|Knowledge Assessment|Students participating in this study will receive a pre test, instruction regarding sun safety, and a post test.
56120|NCT03745846|Biological|Composite Gel Containing Black Raspberry|Composite Gel Containing Black Raspberry 3,000/preparation
56121|NCT03745846|Biological|placebo|Composite Gel Containing Black Raspberry-placebo
56122|NCT03745833|Device|Virtual Reality Mindfulness|Participating patients will be provided with a VR headset (pre-programmed with mindfulness content) after lunch for 15 minutes with supervision while on strict bedrest. The headset will be collected following the intervention. Patients are currently provided with a post-meal survey following all meals as part of the standard of care, and will complete the survey following the lunchtime intervention.
56123|NCT03745820|Drug|BIIB104|Administered as specified in the treatment arm
56124|NCT03745820|Other|Placebo|Administered as specified in the treatment arm
56125|NCT03745807|Biological|NKTR-214|Specified dose on specified days
56126|NCT03745807|Biological|Nivolumab|Specified dose on specified days
56127|NCT03745794|Other|Best Practice|Given standard of care
56128|NCT03745794|Drug|Quadratus Lumborum Block|Undergo QL block
56129|NCT03745794|Other|Quality-of-Life Assessment|Ancillary studies
56130|NCT03745794|Other|Questionnaire Administration|Ancillary studies
56131|NCT03745781|Drug|Placebos|placebo pills
56132|NCT03745768|Device|Intermittent Theta Burst Stimulation|Intermittent theta burst stimulation delivered to the dorsolateral prefrontal cortex on the left and right sides of the brain.
56133|NCT03745742|Other|HRV measurement|"Patients in group A (control) will benefit from a standard re-training protocol based on initial functional abilities. The training is done at a target heart rate corresponding to the heart rate reached at the first ventilatory threshold (about 55% of VO2max).~Patients in group B (study strategy) will benefit from a re-training protocol based on HRV and initial functional abilities. Any increase in HRV compared to the previous day will result in an increase in workload of 10Watt. Any increase or decrease in HRV for 3 days in a row will cause the stagnation of the workload for 2 days.~HRV is measured every day in each group via a heart rate belt and a smartphone App."
56134|NCT03745729|Drug|allopurinol sustained-release capsules|allopurinol sustained-release capsules (0.3g), once a day, one pill at a time
56135|NCT03745729|Drug|placebo capsules|placebo sustained-release capsules, once a day, one pill at a time
56136|NCT03745716|Drug|APR-246 + azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
56137|NCT03745716|Drug|Azacitidine|"Patients will be randomized (1:1) to one of two arms: stratified by age (< 65 years versus ≥ 65):~Experimental arm: APR-246 + azacitidine; or Control arm: Azacitidine"
56138|NCT03745703|Behavioral|MOCHA|(see above)
56139|NCT03745690|Procedure|Image-Guided Surgery|Undergo near-infrared image guided surgical resection
56140|NCT03745690|Drug|Indocyanine Green Drug|Given IV
56141|NCT03745677|Behavioral|Advanced and Integrated MicroSystems (AIMS) interventions|Each of 4 sites will receive mentorship from nurse and physician with expertise in implementing similar interventions. The AIMS interventions consist of 1) unit-based physician teams, 2) unit nurse-physician co-leadership, 3) enhanced interprofessional rounds, 4) unit-level performance reports, and 5) patient engagement activities.
56142|NCT03745664|Drug|Methylprednisolone Sodium Succinate|During hospitalization, 40 mg of methylprednisolone (20 mg/ml) will be given intravenously twice a day (20 mg every 12 hours).
56143|NCT03745664|Drug|Saline Solution for Injection|During hospitalization, 2 ml of Saline Solution for Injection will be given intravenously twice a day (2 ml every 12 hours).
56144|NCT03745651|Drug|Ruxolitinib cream|Ruxolitinib cream 1.5% or 0.75% applied as a thin film twice daily (BID) (vehicle-controlled (VC) and long-term safety extension periods).
56145|NCT03745651|Drug|Vehicle cream|Matching vehicle cream applied as a thin film BID (VC period only).
56146|NCT03745638|Drug|Ruxolitinib cream|Ruxolitinib cream 1.5% or 0.75% applied as a thin film twice daily (BID) (vehicle-controlled (VC) and long-term safety extension periods).
56147|NCT03745638|Drug|Vehicle cream|Matching vehicle cream applied as a thin film BID (VC period only).
56148|NCT03745625|Drug|HSK3486|"First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h."
56149|NCT03745625|Drug|Propofol|"First-stage: after an initial dose of 5mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: loading dose of 1mg/kg given over 1 minute, then a continuous infusion of maintenance dose 1.75 mg/kg/h for a total infusion time of 12h."
56150|NCT03745612|Behavioral|Time restricted feeding|Participants will receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women during a window of 8 h/d (8 am to 4 pm).
56151|NCT03745612|Behavioral|Continuous Energy Restriction|Participants will follow receive a diet of 1500-1800kcal/d for men and 1200-1500kcal/d for women, without a restriction of feeding time.
56152|NCT03745599|Drug|Diclofenac|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
56153|NCT03745599|Drug|Flurbiprofen|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
56154|NCT03745599|Drug|Benzydamine|All patients were instructed to take one capsule orally every 8 h and apply the spray (4 puffs to the pericoronitis area) every 4 h for 7 days, commencing immediately after the clinical examination.
56323|NCT03744221|Dietary Supplement|Corn protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
56155|NCT03745586|Drug|Tocilizumab|Day 3: Tocilizumab infusion (8mg/kg body-weight) Day 10- week 52: Tocilizumab s.c. injections (162mg) in weekly intervals
56156|NCT03745586|Drug|Glucocorticoids|Day0-day2: methylprednisolone 500mg i.v.
56157|NCT03745573|Behavioral|Empateach|Empateach is a behavioural intervention for teachers.
56158|NCT03745547|Other|Adherence to wearing a Spire wearable health monitor|Participants will wear a Spire health monitor every day for 9 months and receive weekly emails with a short survey about the participant's condition and symptoms. If participants fail to respond to this email or Spire detects that a participant is not wearing the monitor, participants will be contacted by a nurse. While participants are wearing the monitor, Spire will make sure the sensors are collecting data but will not review the data in real time. If a participant's monitor stops sending data to Spire for more than 24 hours, the participant will be contacted. If the participant is unreachable for 10 days the participant's emergency contact will be contacted. If neither the participant nor the emergency contact is reachable over 24 days the participant will be removed from the study.
56159|NCT03745534|Other|eABR|eABR
56160|NCT03745521|Other|no intervention|no intervention
56161|NCT03745508|Other|Instant Coffee|Instant coffee prepared at different caffeine concentrations
56162|NCT03745482|Other|Lumbar Mobilisations|The intervention will consist of unilateral lumbar mobilisations at the L4 and L5 level in a Posterior Anterior direction. The side of the mobilisation will be determined by dominant leg - considered the kicking foot. The mobilisations will be administered by a physiotherapist with at least 10 years clinical experience. Teksan grip sensors will be worn by the physiotherapist to calculate the force applied to the participant. Grade three mobilisations will be applied for a one minute period three times at both L4 and L5 level. Each level will be determined by a passive physiological intervertebral movement. Participants will receive the mobilisations at L5 first for one minute followed by L4. This is an appropriate dose for mobilisation application (Maitland, 2013). This process will be carried out three times.
56163|NCT03745469|Device|Smartphone|A standard smartphone will be used for browsing the internet for two different durations (10 and 30 minutes)
56164|NCT03745456|Diagnostic Test|Blood samples for ROTEM and platelet function.|Thormoboelastometry is based on the measurement of elasticity of blood by continuous graphical logging of the firmness of a blood clot during clot formation and subsequent fibrinolysis
56165|NCT03745443|Procedure|increase and decrease positive end-expiratory pressure|20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
56166|NCT03745430|Drug|Ramucirumab|8 mg/kg (days 1 and 15, q4w) until disease progression
56167|NCT03745417|Biological|Umbilical cord mesenchymal stem cells|Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.
56168|NCT03745404|Drug|Lidocaine 5% medicated Plaster|
56169|NCT03745404|Drug|Placebo Plaster|
56170|NCT03745391|Diagnostic Test|MULTIMODAL MAGNETIC RESONANCE (Multimodal MR)|After randomization, a MULTIMODAL MR will be performed to select treatment patient
56171|NCT03745391|Diagnostic Test|MULTIMODAL COMPUTERIZED TOMOGRAPHY (Multimodal CT)|After randomization, a MULTIMODAL CT will be performed to select treatment patient
56172|NCT03745378|Other|JAK2V617F mutation|JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
56173|NCT03745365|Procedure|loop bipartition|A loop gastro-ileostomy 250-300 cm from the ileocecal valve or 200-250 cm from duodeno-jejunal junction was created at the dependent part of the antrum with 2 layers of handsewn suture but without division of the 1st part of duodenum. The resultant stomach tube has two outlets, one to the first part of duodenum through the pylorus and one to the terminal ileum through the gastroileostomy.
56174|NCT03745352|Drug|Azacitidine|Given IV or SC
56175|NCT03745352|Drug|Pevonedistat|Given IV
56176|NCT03745326|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
56177|NCT03745326|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m^2/day IVPB daily over 30 minutes for 5 days.
56178|NCT03745326|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
56179|NCT03745326|Biological|anti-KRAS G12D mTCR PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes.
56180|NCT03745313|Device|Transcatheter Tricuspid Valve Repair|Repair of the tricuspid valve through a transcatheter approach
56181|NCT03745300|Drug|ATORVASTATIN|Scaling and Root Planing (SRP) followed by placement of atorvastatin gel
56182|NCT03745300|Drug|SIMVASTATIN|Scaling and Root Planing (SRP) followed by placement of simvastatin gel
56183|NCT03745300|Drug|PLACEBO|Scaling and Root Planing (SRP) followed by placement of placebo gel
56184|NCT03745287|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan.
56185|NCT03745274|Biological|GHB04L1|Solution
56186|NCT03745274|Other|Placebo|Buffer solution
56187|NCT03745261|Drug|Salbutamol (Ventolin®)|According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
56188|NCT03745261|Drug|Tiotropium Bromide (Spiriva®)|Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
56189|NCT03745261|Drug|Salmeterol / fluticasone (Seretide®)|Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
56315|NCT03744286|Device|Slip Training|-On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
56316|NCT03744273|Procedure|breast capsule biopsy|
56190|NCT03745261|Drug|YCC capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
56191|NCT03745261|Drug|BL capsule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
56192|NCT03745248|Behavioral|Aerobic training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 1 month
56193|NCT03745248|Behavioral|Balance Training|Standard of care
56194|NCT03745235|Other|stress reduction program based on mindfulness|a two and a half hour session per week for 8 weeks
56195|NCT03745235|Biological|venipunctures|1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months
56196|NCT03745235|Other|psychometric questionnaires|"Cohen PSS' perceived stress scale~Beck's anxiety and depression questionnaires~Watson's affectivity questionnaire, positive affect and negative affect schedule~optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver~IN-OUT DASQ dispositional affective style questionnaire"
56197|NCT03745222|Drug|Tislelizumab|PD-1 inhibitor (monoclonal antibody against PD-1)
56198|NCT03745222|Drug|Concurrent chemoradiotherapy (cCRT)|Chemotherapy options include carboplatin/paclitaxel and cisplatin/etoposide per standard of care. Radiotherapy will also be given concurrently with chemotherapy.
56199|NCT03745222|Other|Placebo|Placebo
56200|NCT03745209|Device|Ultrasound|Use of real-time ultrasound in an attempt to establish intravenous peripheral catheter.
56201|NCT03745196|Drug|PC945|Study drug under investigation
56202|NCT03745196|Drug|Placebo|Placebo control
56203|NCT03745183|Other|Senna alata leaf decoction|"Preparation of the akapulko decoction~Remove the leaflets from the rachis of a mature leaf.~Wash the mature leaflets thoroughly to remove dust, dirt and debris.~In the clay, enamel, or stainless steel pot, place one glassful of closely packed chopped leaves (350 ml glass) and add 2 glasses (around 700ml) of clean water . Use the same glass for measuring the leaves and water.~Cook the leaves and bring to a rolling boil.~When the fluid is reduced to half, remove the decoction from the fire and cool slightly.~Strain the mixture using cheesecloth and press the cut leaves in the strainer to make sure to get as much liquid out of them.~Place the liquid in a clean container (bottle/jar with cover). Label the container clearly as Akapulko."
56204|NCT03745170|Drug|Sintilimab|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
56205|NCT03745170|Drug|Oxaliplatin|130 mg/m^2 Q3W on Day 1 by IV infusion
56206|NCT03745170|Drug|Capecitabine|1000 mg/m^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
56207|NCT03745170|Drug|placebo|Weight<60Kg: 3mg/kg Q3W Weignt>=60Kg:200 mg Q3W on Day 1 by IV infusion
56208|NCT03745157|Drug|Insulin Degludec/Insulin Aspart|Patients will be treated with commercially available Insulin Degludec/Insulin Aspart (Ryzodeg®) in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the treating physician in accordance with the Ryzodeg® label in Japan
56209|NCT03745144|Drug|Cladribine|Participants will receive cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
56210|NCT03745144|Drug|Placebo|Participants will receive placebo matched to cladribine once-daily for 5 consecutive days in treatment period 1 and 2.
56211|NCT03745144|Drug|Microgynon®|Participants will receive Microgynon® tablet once daily for 21 days in treatment period 1 and 2.
56212|NCT03745131|Other|Blood draw|Blood draw to obtain serum to determine anti-orthopox antibody titres.
56213|NCT03745118|Device|EpiTel EpiLog|Plastic pad that is about the size of a house key, and will be adhered to your scalp with gel
56214|NCT03745118|Device|Byte Flies Sensor Dots|Plastic pads that will be adhered to your chest area
56215|NCT03745118|Device|Empatica E4|wearable seizure detection wristband
56216|NCT03745118|Device|Biovotion Everion|wearable seizure detection device armband that is attached to upper arm
56217|NCT03745118|Device|GeneActiv|wearable seizure detection watch
56218|NCT03745105|Drug|Dexamethasone sodium phosphate|prophylactic intraligamentary supplemental injection of 0.4 ml of 8 mg/2 mL dexamethasone.
56219|NCT03745105|Drug|Piroxicam Injectable Solution|prophylactic intraligamentary supplemental injection of 0.4 mL of 20 mg mL-1 piroxicam
56220|NCT03745105|Drug|Mepivacaine HCL|prophylactic intraligamentary supplemental injection 0.4 mL of Mepivacaine HCl 36 mg /1.8 ml + Levonordefrin HCl 0.108 mg/ 1.8 ml
56221|NCT03745092|Device|normobaric oxygen|Normobaric oxygen (NBO) is a routine adjuvant hyperoxygenation intervention supplied by nasal cannula or facemask (such as Venturi mask), with one atmosphere pressure (1ATA=101.325kPa).
56222|NCT03745079|Other|Esophagus temperature monitoring|Measuring core temperature by esophageal stethoscope
56223|NCT03745079|Other|Spoton Temporal|Mesuring temperature on skin near to temporal artery using Spoton
56224|NCT03745079|Other|Spoton Carotid|Mesuring temperature on skin near to carotidl artery using Spoton
56225|NCT03745053|Device|Xlimus DES Implantation during coronary angioplasty|Xlimus DES Implantation during coronary angioplasty
56226|NCT03745053|Device|Synergy DES Implantation during coronary angioplasty|Synergy DES Implantation during coronary angioplasty
56227|NCT03745040|Drug|Liposomal bupivacaine|20ml bupivacaine liposome injectable suspension 1.3% (266mg) + 50ml 0.25% Bupivacaine (150mg) + 70ml preservative-free 0.9% neutral saline
56228|NCT03745027|Diagnostic Test|in vitro fertilization|All patients underwent gonadotropin-releasing hormone agonist (GnRHa) treatment for in vitro fertilization and Follicular fluid sialic acid levels are measured.
56229|NCT03745014|Diagnostic Test|Accelerate Pheno|The Accelerate Pheno™ system and PhenoTest™ BC Kit is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture.
56230|NCT03745014|Diagnostic Test|Standard of Care|Standard blood culture work up as determined by the site's microbiology lab.
56317|NCT03744260|Diagnostic Test|Patients undergo ultrasound and lumbar MRI|Patients undergo ultrasound, physical therapy exam and MRI before and after the radiofrequency ablation procedure that they are getting as part of their regular care.
56231|NCT03745001|Drug|EHP-101 Liquid single dose|One single oral administration with EHP-101 liquid formulation. The doses will be ascending per cohort from 0.91 mg to 200 mg. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day).
56232|NCT03745001|Drug|EHP-101 Liquid multiple doses|One single daily administration with EHP-101 liquid formulation during 7 consecutive days. The doses will be ascending per cohort. Each ascending level will not exceed the tested dose levels in the single dose part of the study. The initially planned once daily dose regimen may be modified by the Safety Review Committee based on emerging PK data, eg, assigned dose levels may be divided into 2 doses administered 12 hours apart (twice a day)
56233|NCT03745001|Drug|Matching placebo|Oral liquid administration daily
56234|NCT03744988|Diagnostic Test|serum androgen levels|measurement of serum free and total testosterone
56235|NCT03744975|Drug|Nesiritide Injection|Participants will receive 1 subcutaneous injection of Neseritide (10 µg/Kg) and 1 oral placebo capsule
56236|NCT03744975|Drug|LCZ 696|Participants will receive Oral LCZ 696 (Entresto 97/103 mg) and 1 subcutaneous Placebo injection of normal saline
56237|NCT03744975|Drug|Placebos|Participants will receive 1oral Placebo capsule and receive 1 subcutaneous Placebo injection of normal saline
56238|NCT03744949|Drug|Remifentanil dose 0.5 ug/kg|Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
56239|NCT03744949|Drug|Remifentanil dose 1 ug/kg|Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
56240|NCT03744949|Drug|Remifentanil dose 1.5 ug/kg|Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
56241|NCT03744949|Drug|Remifentanil dose 2 ug/kg|Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
56242|NCT03744936|Other|DA4Afib Prototyping|We will develop a prototype from patients with atrial fibrillation
56243|NCT03744923|Procedure|transmuscular QL block|"Ultrasound device will be used; The probe is placed in the mid-axillary line cranially to the iliac crest to identify the three muscles of the anterior abdominal wall. Then, scan dorsally keeping the transverse orientation until observing that the transversusabdominus muscle becomes aponeurotic, and this aponeurosis is followed until the QL muscle is clearly visualized with its attachment to the lateral edge of the transverse process of the L2 vertebral body and visualize the thoracolumbar fascia at the lateral edge of the QL muscle.~The view of the psoas major muscle (PM) anteriorly, the erector spinae muscle (ESM) posteriorly and the QL muscle adherent to the apex of the transverse process result in a well recognizable pattern of a Shamrock with three leaves (trifoliate)."
56244|NCT03744923|Procedure|Transversus Abdominus Plane block|"Posterior TAP block will be performed on the same side of surgery (unilateral) under ultrasonographic guidance with a with broadband (7-13MHz) linear probe covered with a sterile plastic sheath. Probe will positioned transversely midway between the iliac crest and the costal margin at level of mid axillary line.~Once the external oblique muscle (EOM), internal oblique muscle (IOM) and transversus abdominis muscle (TAM) are visualized at the level of the mid axillary line between the 12th rib and the iliac crest, the puncture area and the ultrasound probe were prepared in a sterile manner. After identification of the neuro-facial plane between IOM and TAM, block was performed with 20G spinal needle. The needle will be directed to approach the TAP with in-plane USG-guided technique. Once the tip of the needle placed in the space between the IOM and TAM, Inject a 1 ml test dose of lidocaine 2% for hydrovisualization of needle-tip position and confirming its correct postioning."
56245|NCT03744910|Biological|Clazakizumab|Clazakizumab is a genetically engineered humanized immunoglobulin G1 (IgG1) mAb that binds to human IL-6
56246|NCT03744910|Drug|Normal saline|Normal saline
56247|NCT03744897|Behavioral|Hypnotic analgesia|Subjects will receive hypnotic analgesia during 20 minutes
56248|NCT03744897|Device|a-tDCS|Subjects will receive transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
56249|NCT03744897|Other|Hypnotic analgesia + a-tDCS|Subjects will receive hypnotic analgesia associated to transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 2mA, 20 minutes
56250|NCT03744897|Device|s-tDCS|Subjects will receive sham transcranial direct stimulation over bilateral DLPFC left/anode right/cathodal, 0mA, 20 minutes
56251|NCT03744884|Behavioral|Force efforts with haptic feedback in virtual reality.|A virtual reality game-based intervention incorporating fully-automated robotic haptic feedback. The study consists of face-to-face assessments of movement before, after, and one-month following the completion of the six-session game-based intervention. Children with spastic/dystonic cerebral palsy between the ages of 7 and 17 will be recruited for this study along with a group of typically developing children in the same age range. Both groups of children will be randomly allocated into an intervention or control group using a blocked randomization method.
56252|NCT03744871|Device|Respirator Use|SiTi N95 respirator with microventilator (change twice weekly and earlier as needed). SiTi disposable nasal cyclone (change daily).
56253|NCT03744858|Procedure|Peripheral blood draw|Peripheral vein blood draw will be performed to all participants in order to collect blood samples to be evaluated.
56254|NCT03744845|Other|Virtual Reality Distraction|This RCT will utilize an Oculus Go VR headset that delivers VR images and sound. Users will wear the VR headset. A research coordinator will familiarize patients with hardware before use. The VR will be used preoperatively and intraoperatively to distracts patients, and aid with the treatment of pain and anxiety.
56255|NCT03744832|Diagnostic Test|Alere i™ Strep A assay|Point of care (POC) molecular-based, nucleic acid amplification test (NAAT). This isothermal molecular assay is CLIA waived (Clinical Laboratory Improvement Amendments) and Health Canada licensed for POC use, and is anticipated to have approval for use without need for back up culture testing.
56256|NCT03744832|Diagnostic Test|Throat culture|Standard bacterial throat culture.
56257|NCT03744806|Drug|Bevacizumab Injection|
56258|NCT03744793|Drug|Avelumab|Given IV
56259|NCT03744793|Drug|Pemetrexed|Given IV
56318|NCT03744247|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
56319|NCT03744247|Drug|PD-1 antibody|3mg/kg intravenously every 2 weeks
56320|NCT03744247|Drug|Placebo|Intravenously every 2 weeks
56260|NCT03744780|Behavioral|ACT Workshop for Emotional Eating|"This is a one-day intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's (2016) brief emotional eating intervention, which was derived from Forman et al.'s (2013) Mind Your Health program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness."
56261|NCT03744767|Drug|Spironolactone 50 MG|oral administration of Spironolactone, 25mg daily for 1 week, then 50mg daily until visit Month 3, followed by 25mg daily from visit Month 3 to visit Month 4
56262|NCT03744741|Diagnostic Test|HostDx Sepsis|Blood collection for mRNA analysis, Procalcitonin and CRP determination, molecular analysis of nasopharyngeal swab collection
56263|NCT03744728|Diagnostic Test|Accelerate PhenoTest™ BC kit|The Accelerate PhenoTest™ BC kit with the Accelerate Pheno™ System is a fully-integrated in vitro diagnostic system. It is FDA-cleared to perform ID of bacteria and yeast in less than 90 minutes and AST in less than 7 hours, on average, directly from positive blood culture
56264|NCT03744728|Diagnostic Test|Standard of Care|Standard culture and AST of positive blood culture bottles plus the Verigene® BC-GP/GN
56265|NCT03744715|Drug|Poziotinib|Poziotinib will be taken by the patient orally, once daily with food and a glass of water at approximately the same time. The dose will be the same as the dose at the end of the Original Study unless modified. If a dose is missed, it may be taken any time during the day preferably with food, at least 8 hours prior to the next scheduled dose.
56266|NCT03744702|Drug|Ascorbic Acid|Patients will receive IV ascorbic acid.
56267|NCT03744689|Procedure|Erector Spinae Plane block|Erector Spinae plane block will be done according to hernia level using bupivacaine hydrochloride
56268|NCT03744689|Procedure|Sham block|Sham block will be done with serum physiologic.
56269|NCT03744689|Drug|Bupivacaine Hydrochloride|20 ml 0,25% Bupivacaine will be used for block performances
56270|NCT03744689|Device|PCA|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
56271|NCT03744676|Biological|lisocabtagene maraleucel|lisocabtagene maraleucel (JCAR017) will be administered as single dose intravenous (IV) injection
56272|NCT03744663|Drug|Suboxone® SL|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized to two groups one of which will be Suboxone® SL.
56273|NCT03744663|Drug|Sublocade®|Subjects will be started and titrated to optimal Suboxone® SL dose for 14 days. After the 14 day induction phase, the subject will be started on the treatment to which they were randomized, either Suboxone® SL or Sublocade®. Subjects with significant opioid craving (> 20 mm on the Opioid Craving Visual Analog Scale) or withdrawal (a score of > 12 on the Clinical Opiate Withdrawal Scale) after 14 days of treatment will be started on Sublocade® only at the consensus of the research team. Otherwise they will undergo an additional 7 day titration period. Study drug with Sublocade® group: Patients assigned to this group will receive the study drug (300 mg subcutaneously) every 4 weeks for a total of 6 doses along with weekly therapy. The location and specifications of its application will follow the recommendations by the FDA previously published.
56274|NCT03744650|Behavioral|"Care4Heart programme"|"A 4-week mHealth programme in the form of a smartphone app, named Care4Heart, has been developed. The content and scope of the design are developed by a thorough literature review and an extensive analysis of existing education leaflets and brochures used to prevent CHD. The contents are specified and tailored to the working population.~The app is developed by a team of software engineers from Computing School of NUS. Several functions include: (1) app using instructional video; (2) easy-to-read information on healthy lifestyle toward heart health, including information about the disease, CHD risk factors (e.g. diet, smoking cessation), stress, physical exercises and relaxation techniques; and (3) scheduled reminders for doing exercise and relaxation"
56275|NCT03744637|Drug|MK-5475|Single inhaled dose of MK-5475 120, 165, 240, 300 or 360 µg
56276|NCT03744637|Drug|Placebo|Single inhaled dose of placebo to match MK-5475
56277|NCT03744624|Procedure|Laparoscopic liver resection|Laparoscopic liver resection for oncological purposes
56278|NCT03744624|Device|3D printing model|Use of 3D printed liver model in decision-making: preoperative planning and intraoperative guidance.
56279|NCT03744611|Dietary Supplement|CE|550mg capsule (Eucommia ulmoides Oliver extract)
56280|NCT03744611|Dietary Supplement|Placebo|550mg capsule (Placebo)
56281|NCT03744559|Behavioral|Retrieval Extinction Training (RET)|Retrieval extinction training (RET) is a behavioral intervention that involves cue-elicited retrieval followed by extinction training (i.e., massed unreinforced exposure to drug-associated cues). The first element of RET involves briefly presenting drug-associated cues to retrieve drug use memories. The second element, occurring after a brief interval, involves extinction training. It is argued that the initial retrieval of the memories prior to extinction training initiates a period of instability, which is followed by reconsolidation of the memories back into long-term storage. Extinction training during the period of instability is presumed to overwrite the original drug-associated cue with a non-drug-associated cue, to attenuate expression of drug-seeking behavior.
56282|NCT03744559|Behavioral|Control Retrieval Extinction Training (RET)|The control retrieval extinction training (RET) for the NR-E arms serves as the control intervention to the RET behavioral intervention. The first element of the control RET involves briefly presenting retrieval cues that contain neutral, non-smoking content. The second element, occurring after a brief interval, involves extinction training. Based on findings from the previous NIDA-funded R21, the R-E arm reported a significant 25 percent reduction in cigarettes smoked per day during the follow-up period versus the control NR-E arm.
56312|NCT03744312|Drug|11C-ER176|11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
56313|NCT03744312|Drug|Florbetaben|Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.
56314|NCT03744299|Other|Questionnaire|Patients and caregivers are asked to complete a questionnaire
56321|NCT03744234|Procedure|PRP|Autologous platelet-rich plasma
56322|NCT03744234|Procedure|Steroid Injection|Steroid injection
56283|NCT03744559|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI) will identify patterns of brain activity associated with RET and potentially predictive of treatment outcomes. The fMRI is used during the baseline and 24-hour follow-up test sessions while participants complete a cue-reactivity task. The collection of fMRI data is based on findings from human fear conditioning fMRI studies, in which groups receiving RET in the reconsolidation window exhibited less fear that was associated with attenuated BOLD response in the amygdala, relative to the control. We propose that the R-E arm will evidence attenuated cue reactivity in medial prefrontal cortex, limbic regions and ventral striatum, and that greater reduction in BOLD response in regions of interest will predict decreased smoking.
56284|NCT03744559|Other|No functional magnetic resonance imaging (fMRI)|No functional magnetic resonance imaging (fMRI) serves as the control intervention to the fMRI intervention. Participants who are randomized to the no fMRI intervention or who have a contraindication to MRI will complete an identical cue-reactivity task in a cue-reactivity lab during the baseline and 24-hour follow-up test sessions.
56285|NCT03744546|Drug|ABBV-8E12|Solution for infusion
56286|NCT03744533|Other|head-down position treatment|the head position of subjects is lowered to 20 degrees in a supine position between 8:00-22:00 within 24h post-randomization as long as possible. During the procedure, when subjects feel intolerable, the head position will be elevated to lying flat (0 degree) for 5-10min, and then the above procedure is repeated. After 24h post-randomization, the head down procedures with -20 degrees in a supine position with duration of 1-1.5 hour will be performed three times daily at 9:00-11:00, 15:00-17:00 and 20:00-22:00, respectively.
56287|NCT03744533|Other|guideline-based treatment|guideline-based treatment
56288|NCT03744520|Procedure|Erector spinae plane block|Local anesthetic infiltration is applied between the erector spinae muscle fascia and transverse process.
56289|NCT03744494|Procedure|Bilateral simple orchidectomy (BSO)|
56290|NCT03744494|Procedure|Bilateral Subcapsular Orchidectomy|
56291|NCT03744494|Procedure|Bilateral Epididymal-sparing Orchidectomy|
56292|NCT03744481|Other|Questionaire|"Evaluation of psychomotor development in children with mild EAI without indication of therapeutic hypothermia.~Precise analysis of the type (motor, sensory, language, epilepsy) and the severity of sequelae by sending a questionnaire to parents.~Investigation of early, clinical and paraclinical prognostic factors of good or bad neurodevelopmental outcome.~Evaluation of the height-weight growth and the cranial perimeter"
56293|NCT03744468|Drug|BGB-A425|Humanized IgG1-variant monoclonal antibody against TIM-3
56294|NCT03744468|Drug|tislelizumab|Humanized, IgG4-variant monoclonal antibody against PD-1
56295|NCT03744455|Biological|Axillary Plexus|Axillary plexus anesthesia technique for hand surgery
56296|NCT03744442|Procedure|Dignity Therapy (DT) module|psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
56297|NCT03744442|Procedure|CALM Therapy module|supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist
56298|NCT03744442|Procedure|Mindfulness-based interventions module|Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
56299|NCT03744429|Other|Mediterranean Diet|Participants will be provided with meals that follow a Mediterranean meal plan.
56300|NCT03744416|Other|Counseling based on Epstein's active decision making|"Birth information leaflet. Based on the best evidence practice. Midwives' training on share decision making based on Epstein model. Pregnant intervention. The pregnant women will receive from the midwives the birth plan (BP) in the prenatal check at the health center, between the 24-28 weeks, to be completed at home. Later, on the visit between 29-33 weeks, the midwives will provide the birth information leaflet and carry out the counseling intervention based on shared decision making to the pregnant women. As well, midwives will deliver a second BP that pregnant woman will fill at home. On the prenatal check between 34 to 40 weeks, the midwife will save a copy of the latest BP. The midwife will instruct the woman to deliver the BP when she arrives to the hospital for birth."
56301|NCT03744403|Drug|CS1001|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, the RP2D cohort will be expanded.
56302|NCT03744390|Drug|AG-221|Subjects enrolled will receive continuous 28-day cycles of AG-221 -100 mg.
56303|NCT03744377|Other|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
56304|NCT03744364|Drug|Misoprostol 25 mcg|To determine efficacy and safety of vaginal 'Misoprostol 25 mcg' every 4 hours with a maximum of 6 doses for induction of labor.
56305|NCT03744364|Drug|Dinoprostone 10mg|To determine efficacy and safety of 'Dinoprostone 10mg' vaginal insert for induction of labor.
56306|NCT03744351|Other|Biological Samples|Venous sampling that is performed solely for the purpose of research. The total blood volume taken is 80 ml maximum (8 tubes of 10 ml).
56307|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood and an additional 5 ml CSF tube will be taken from the patient during a sample taken for the patient's usual check-up /follow-up.~Inpatients will also be offered stool removal."
56308|NCT03744351|Other|Biological Samples|The patient will be taken 8 additional tubes of 10 ml of blood (during a blood test performed for the usual assessment of the patient) and an additional 5 ml of CSF in a sample taken for the assessment of the patient.
56309|NCT03744351|Other|Biological Samples|"Eight additional 10 ml tubes of blood will be taken from the patient during a sample taken for the patient's usual check-up / follow-up.~Inpatients will also be offered stool removal"
56310|NCT03744338|Other|questionnaire|"The questionnaire is composed of two parts:~The first part let know the characteristics of the patients as age, the BMI, the socio-professional category, the current treatments, the medical-surgical antecedents of interest."
56311|NCT03744325|Dietary Supplement|Hen's egg OIT|Increasing doses of egg white protein administered orally
101261|NCT03394872|Procedure|Drainage of the pleural effusion|
56324|NCT03744221|Dietary Supplement|Bovine plasma protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
56325|NCT03744221|Dietary Supplement|Whey protein powder|40g/d ( 2 times 20 grams per day for a period of 1 week)
56326|NCT03744208|Drug|Anti-EGFR monoclonal antibody|DDP(75mg/m2),d1; 5-FU(750mg/m2),d1-5, every 21d; PF chemothrapy up to 6 cycles. 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression
56327|NCT03744195|Other|Group I Experimental Kinesotaping|"For application of kinesotaping following procedure will be adopted:~The skin will be cleaned properly with alcohol~The first strip will be applied in Y-shape (15-20% stretch) surrounding the deltoid muscle to provide inhibition and muscle relaxation~A second strip (I-shape) will be applied for functional correction (50-75% stretch), passing over the supraspinatus, trapezius, glenohumeral joint and middle deltoid Daily Strengthening Exercises (3 sets / 10~30 reps) Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval"
56328|NCT03744195|Other|Group II conventional training group|Joint mobilization (3 sets / 60 seconds hold / 30 seconds interval) Stretching Exercises (3 sets / 30 seconds hold / 30 seconds interval) Strengthening Exercises (3 sets / 10~30 reps)
56329|NCT03744182|Drug|HM15211|A sterile solution of HM15211 contained in pre-filled syringes
56330|NCT03744182|Drug|Placebo of HM15211|A sterile, matching solution in pre-filled syringes
56331|NCT03744169|Diagnostic Test|Lung ultrasound|A point-of-care lung ultrasound exam will be performed on admission (no later than 14 hours following admission, allowing for patient stabilization and care) to the PICU and within 6 hours of any escalation in mechanical ventilatory support without interrupting clinical care, by study investigators blinded to patient history, physical examination, and diagnostic testing/imaging and who are not involved in the clinical management of the patient. Investigators will use a six-zone standardized scanning protocol with pattern analysis to form a diagnosis for the cause of the patient's respiratory failure. Images will be acquired by pediatric critical care trainness and saved online; accuracy of diagnoses based on the ultrasound exam will be evaluated by a expert sonographer offline.
56332|NCT03744169|Diagnostic Test|Clinical exam|Following morning ICU rounds, the PICU fellow or attending physician caring for the patient will be asked for his/her interpretation of the most recent chest radiograph and his/her diagnosis concerning the etiology of the patient's acute respiratory failure. This clinical diagnosis will be compared to ultrasound findings.
56333|NCT03744169|Diagnostic Test|Chest x-ray|Results of chest x-ray will be collected for comparison with ultrasound findings.
56334|NCT03744156|Behavioral|Cognitive Behavioral Treatment-Insomnia|8 session Cognitive Behavioral Therapy for Insomnia. Individualized sessions with a therapist.
56335|NCT03744156|Behavioral|Sleep Hygiene Education|8 Session Sleep Hygiene Education. Individualized sessions with a therapist.
56336|NCT03744143|Procedure|longitudinal suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a longitudinal suture
56337|NCT03744143|Procedure|transverse suture|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, and closure of the vagina with a transverse suture
56338|NCT03744143|Procedure|Removal of vaginal endometriotic nodule|Surgical eradication of deep infiltrating endometriosis of the vagina using laparoscopic technique, performing 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm, or vaginal technique, isolating the nodule through the vagina.
56339|NCT03744130|Diagnostic Test|Contrast-enhanced Ultrasound|"administration of drotaverine hydrochloride (No-Spa ®) to reduse excessive peristaltic movement~visualization of the previously chosen affected bowel segment with the use of DCE-US (Dynamic Contrast-Enhanced Ultrasound) technology~administration of 2.4 ml SonoVue® intravenously with a bolus injection through a peripheric venous line (left antecubital vein), followed by a 10ml 0.9% Natrium Chloride bolus~the video-loop is acquired during contrast agent administration and wash-out (preferable loop duration - 3 min)~the original DICOM loop is sent to a work station"
56340|NCT03744117|Other|Palliative care consultation|A palliative care consultation will occur via telemedicine with patients receiving maintenance dialysis.
56341|NCT03744104|Biological|Quadrivalent influenza vaccine|0.5 mL, intramuscular, one dose
56342|NCT03744104|Biological|Trivalent influenza vaccine A|0.5 mL, intramuscular, one dose
56343|NCT03744104|Biological|Trivalent influenza vaccine B|0.5 mL, intramuscular, one dose
56344|NCT03744091|Drug|P1|10 mg or 20 mg of THC:THCa
56345|NCT03744078|Device|Foley balloon catheter|18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
56346|NCT03744065|Procedure|lumbar plexus block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, in the posteromedial quadrant of psoas muscle
56347|NCT03744065|Procedure|suprainguinal fascia iliaca block|Injection with ultrasound guidance of 40 mL of levobupivacaine 0.25% with 5 micrograms of epinephrine per mL and dexamethasone 4 milligrams, underneath the fascia iliaca at the suprainguinal level
56348|NCT03744052|Other|Motivational Messages|Messages regarding physical activity will be texted to participants.
56349|NCT03744026|Device|SonoCloud-9|Escalating numbers of ultrasound beams at constant acoustic pressure
56350|NCT03744026|Drug|Carboplatin|Dose of carboplatin infusion is AUC4-6
56351|NCT03744013|Device|Fortiva® 1mm|Post mastectomy immediate reconstruction
56352|NCT03744000|Procedure|Immediate stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
56384|NCT03743727|Drug|Combined therapy LDV and SOF|All patients will receive ledipasvir/sofosbuvir fixed dose combination for 12 weeks. Patients weighing 35 kg or more will receive the adult dose: ledipasvir (90 mg)/sofosbuvir (400 mg). Patients weighing below 35 kg will receive half the adult dose: ledipasvir (45 mg)/sofosbuvir (200 mg).
56353|NCT03744000|Procedure|Deferred stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 3 to 7 days after TIMI Ⅲ flow has achieved.
56354|NCT03743987|Procedure|control group|a procedure used to prevent or resolves apical periodontitis.
56355|NCT03743987|Procedure|MTA group|a procedure used to prevent or resolves apical periodontitis.
56356|NCT03743987|Procedure|PRF group|a procedure that is used for wound healing
56357|NCT03743987|Procedure|MTA + PRF group|a procedure used to prevent or resolves apical periodontitis in combination with a procedure that is used for wound healing.
56358|NCT03743974|Procedure|arthroscopic shoulder surgery of rotary cuff (ISB)|ISB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
56359|NCT03743974|Procedure|arthroscopic shoulder surgery of rotary cuff (CSB)|SCB were performed in the same manner by one of the two anesthesiologists in our team: (i) patients were monitored, after sedation with sublingual midazolam (0.1 mg/kg) + a single bolus of intravenous (IV) ketamine (0.2 mg/kg); (ii) ultrasound-guidance was carried out using a Kontron® or General Electric® ultrasound machine; (iii) neurostimulation was performed with a Stimuplex HNS® 12 set at 0.1 ms, 1 Hz and 1 mA stimulation, in sentinel mode, with the aim of securing the approach of the needle; (iv) a single perineural injection was performed with a 50 mm Vygon® needle containing a mixture of 100 mg levobupivacaine (20 mL, 0.5%) and clonidine (1 µg/kg patient) as is the local common protocol and in the absence of contraindications.
56360|NCT03743961|Other|geriatric intervention|Geriatric intervention
56361|NCT03743948|Genetic|Non invasive prenatal diagnosis|15 pregnant women and their spouses Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
56362|NCT03743935|Other|Gadolinium-enhanced cardiac MRI|Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
56363|NCT03743922|Drug|Calciferol|calciferol capsule
56364|NCT03743922|Drug|Placebo|placebo capsule
56365|NCT03743896|Drug|Transdermal Glucosamine Cream|
56366|NCT03743883|Drug|Acetylsalicylic Acid(BAYE4465, Aspirin )|Administration according to clinical practice
56367|NCT03743870|Drug|Levobupivacaine|Levobupivacaine will be spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
56368|NCT03743870|Drug|Bupivacaine|Bupivacaine has been spinally administered, as required by normal clinical practice, at the dose of 12 mg 0,5% in combination with fentanyl 25γ.
56369|NCT03743857|Procedure|Manual Therapy|AP ankle mobilization
56371|NCT03743831|Device|orotracheal intubation by direct laryngoscopy|Orotracheal intubation by direct laryngoscopy by metal blade type Macintosch
56372|NCT03743831|Device|orotracheal intubation by indirect laryngoscopy|orotracheal intubation by indirect laryngoscopy by Airtraq
56373|NCT03743818|Device|dry needling|dry needling on the trigger point of the vastus medialis of the quadriceps
56374|NCT03743805|Drug|Flumazenil|0.2 mg IV push, which may be repeated every 20 minutes for up to a total of 1 mg
56375|NCT03743805|Drug|Naloxone|0.4 mg IV push, which may be repeated every 2 minutes for up to a total of 2 mg
56376|NCT03743792|Dietary Supplement|Active breakfast|freeze-dried red raspberry powder (12.5 g) in drink+ freeze-dried red raspberry powder (12.5 g) in buttermilk biscuit sandwich
56377|NCT03743792|Dietary Supplement|Control breakfast|Control drink + buttermilk biscuit sandwich
56378|NCT03743779|Behavioral|Mastering Diabetes|"The Mastering Diabetes provides a step-by-step program to transition to a low-fat, plant-based, whole-food lifestyle and reduce overwhelm. The program also provides direct access to expert coaches in the online community, which contains others living with all forms of diabetes. I includes access to live Q&A videoconferences twice per month to interact with coaches and personalize the experience.~The program is designed with seven core modules. Many participants continue in the program after completion of the modules for ongoing support.~The cost was $29/month or $249/year, but as of July 2018, only the $249/year option is offered."
56379|NCT03743766|Drug|Relatlimab|Relatlimab (BMS-986016) - 10mg/mL formulation to be administered as an intravenous (IV) infusion at 160 mg IV.
56380|NCT03743766|Drug|Nivolumab|Nivolumab (BMS-936558) - 10-mg/mL formulation to be administered as an IV infusion at 480 mg IV.
56381|NCT03743766|Drug|Relatlimab + Nivolumab|Combination (Relatlimab + Nivolumab) therapy will be administered by sequential infusion. Nivolumab administered at 480 mg IV followed by infusion of relatlimab at 160 mg IV.
56382|NCT03743753|Other|Experimental|The intervention is the educational session, which is a one-on-one session delivered by a research assistant using a visual aide on an iPad (power point presentation). The session is specifically tailored to the method of breast reconstruction (autologous or alloplastic) the patient will undergo and reviews the basics of their reconstruction, explains the normal in-hospital course and post-operative recovery, reviews potential complications and provides advice from previous breast reconstruction patients.
56383|NCT03743740|Other|Spinal stabilization exercise|The effects of spinal stabilization exercise in patients with myasthenia gravis will be investigated.There is no study in the literature that previously applied spinal stabilization exercises in patients with myasthenia gravis. The benefits of spinal stabilization exercises in other diseases are shown.
56447|NCT03743311|Procedure|Hemorrhoidectomy, Thrombectomy , Operation on Longo method|Surgical procedures for treatment of Hemorhoid
56385|NCT03743714|Other|yoga treatment; flexibility, balance and strength exercises.|yoga treatment including flexibility exercises, balance exercises, and strength exercises.
56386|NCT03743701|Diagnostic Test|The method of transrectal ultrasound in В-mode|A linear transrectal ultrasonic sensor with a frequency of 9 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. In real time, the rectal wall and anatomical structures of the anal canal are evaluated using linear sections. The localization of the internal fistula opening, the course of the fistula relative to the fibers of the external sphincter and the presence or absence of cellular and wall plug is determined.
56387|NCT03743701|Diagnostic Test|The method of transrectal ultrasound examination using three-dimensional image reconstruction.|A mechanical circular transrectal ultrasonic sensor with a frequency of 13 MHz is inserted into the rectum lumen to a depth of 10 cm from the edge of the anus. Within 30 seconds with a scan interval of 2 mm with a length of 10 cm, a circular recording of the anatomical structures of the rectum, surrounding tissue and anal canal takes place, obtaining an array of images in the form of a cube. The study was completed. After, at a convenient time for the researcher is working with a three-dimensional array of images. The resulting cube can be rotated 360 degrees in a circle of its axis, work with the sagittal, frontal and axial plane. To obtain a more visual representation of the exact localization of the internal fistula orifice, the course of the fistula relative to the fibers of the outer sphincter and to design volumetric cellular and wall plug.
56388|NCT03743688|Biological|Influenza Vaccine Recipients|0.5 mL intramuscular injection
56389|NCT03743675|Behavioral|Diet-Induced Weight Loss|Diet-Induced Weight Loss: The goal of the diet intervention is to produce a weight loss of approximately 5-10% of body weight over the six-month period, which is consistent with the goals for obesity treatment outlined by the Academy of Nutrition and Dietetics (AND). According to the 2016 AND position paper for obesity-related interventions, this level of weight loss produces clinically significant reductions in biometrics (biochemical and anthropometrics measurements) and associated risk factors for chronic disease. Additionally, obese older adults who achieve weight loss intentionally through lifestyle changes experience improved physical function. This intervention will last for 6-months with bi-weekly face-to-face counseling sessions with a registered dietitian.
56390|NCT03743675|Behavioral|Aerobic Exercise Training|"Exercise Intervention: Subjects will exercise on a cycle ergometer during the training sessions. Each session will consist of 1) a 5-10 minute warm up at light intensity; 2) a 20 to 30-minute training phase at moderate-to-vigorous intensity; and 3) a 5-minute cool down phase at light. The training will be conducted 3 days per week for 6 months."
56391|NCT03743662|Radiation|Re-irradiation (RT)|Re-RT will start on day 28 +/- 5 days for 5 fractions of 600cGy every other day over a 2-week period.
56392|NCT03743662|Drug|Bevacizumab|Bevacizumab if deemed beneficial by the investigator, will be started at the initiation of re-RT and continued for three doses in the medical arm. Patients in the surgical arm will omit the first bevacizumab dose to assure adequate wound healing after surgery and receive two doses. Bevacizumab will be dosed at 10mg/kg and given intravenously on day 28 (medical arm only), day 42 and day 56. Following day 56, further bevacizumab doses can be given every two weeks at the discretion of the treating physician.
56393|NCT03743662|Drug|Nivolumab|"Nivolumab will be started at enrollment and each patient will receive two doses of nivolumab prior to radiation.~Nivolumab will be dosed at 3mg/kg given intravenously before re-RT (day 1 +/- 5 and 14 +/- 5) and when given with bevacizumab if deemed beneficial by the investigator, (day 28 +/- 5 (medical arm only), day 42 +/- 5, and day 56 +/-5). Nivolumab will be dosed based on body weight while combined with re-radiation and bevacizumab for safety considerations to reduce adverse events. Single agent nivolumab will be given at 240mg flat dose every 2 weeks thereafter until disease progression, withdrawal, adverse event, or death."
56394|NCT03743662|Procedure|Re-resection|Re-resection will be performed in the surgical arm at day 14 (+/- 5 days).
56395|NCT03743649|Drug|Haloperidol|Given IV
56396|NCT03743649|Drug|Lorazepam|Given IV
56397|NCT03743649|Other|Placebo|Given IV
56398|NCT03743649|Other|Quality-of-Life Assessment|Ancillary studies
56399|NCT03743649|Other|Questionnaire Administration|Ancillary studies
56400|NCT03743636|Drug|Nicotinamide riboside|Participants randomized to the NR + resveratrol arm or the NR + placebo arm of the study will receive 1,000 mg of NR daily for six months.
56401|NCT03743636|Drug|Resveratrol|Participants randomized to the NR + resveratrol arm of the study will receive 125 mg of resveratrol daily for six months.
56402|NCT03743636|Other|Placebo|Participants randomized to the NR + placebo arm of the study will receiving placebo pills that are identical in appearance to resveratrol. Participants randomized to the placebo + placebo arm of the study will receive pills that are identical in appearance to NR and resveratrol. Participants will receive placebo pills daily for six months.
56403|NCT03743623|Device|Neurocytotron|Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.
56404|NCT03743623|Device|Placebo|Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field
56405|NCT03743610|Other|Simulated altitude|Participants will exercise in simulated altitude will range between 2100 feet and 16400 feet and will increase according to arm guidelines
56406|NCT03743610|Other|Placebo simulated altitude|Participants will exercise at sea level at similar percentage of intensities to the simulated altitude group.
56407|NCT03743597|Device|SOCKNLEG|"Innovative multilayer leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition understocking (polyamide, cotton, spandex), overstocking (polyamide, spandex)~In each participant all examinations will be performed with both study stockings, one after the other"
56408|NCT03743597|Device|Sigvaris COTTON|"Standard single leg compression stocking, compression strength CEN compression class II (European Compression Strength) with compression at the ankle of 23-32mmhg, product composition one stocking (polyamide, spandex, cotton)~In each participant all examinations will be performed with both study stockings, one after the other"
56409|NCT03743584|Procedure|Targeted temperature management|Target temperature management at 33°C
56410|NCT03743584|Procedure|Standard care, early treatment of fever|Standard of care with early treatment of fever
56448|NCT03743311|Drug|Detralex|Conservative treatment of Hemorhoid
56411|NCT03743571|Device|transcranial direct current stimulation|tDCS will be applied over EEG coordinate FpZ to target mPFC activation during exposure therapy
56412|NCT03743571|Behavioral|exposure therapy|participants will complete one session of exposure therapy for fear of public speaking, which will involve providing speeches to audiences in virtual reality
56413|NCT03743558|Behavioral|smartphone homemade video|value of a video recording of the child sleep on smartphone made by the parents
56414|NCT03743545|Other|low speed drilling without irrigation|comparing between conventional implant placement drilling speed with irrigation and experimental arm (low speed without irrigation)
56415|NCT03743532|Behavioral|financial incentives + NRT|Participants will receive nicotine replacement therapy (NRT) and the opportunity to earn weekly financial incentives, credited to a gift card with biochemical evidence of smoking abstinence during the first 4 weeks following a scheduled quit date.
56416|NCT03743532|Behavioral|JUUL/e-cigarette|Participants will receive a JUUL/e-cigarette device and JUUL pods. Each participant in this group will be yoked to a participant in the financial incentives group, thus receiving equal payments. Yoking will reduce or eliminate differential attendance rates between groups because participants have the opportunity to earn the same amount of money regardless of group assignment. Participants will be followed for the first 4 weeks following a scheduled quit attempt.
56417|NCT03743532|Behavioral|financial incentives + JUUL/e-cigarette|Participants will receive a JUUL/e-cigarette device and JUUL pods and the opportunity to earn financial incentives for biochemically-verified cigarette smoking abstinence, credited to a gift card with biochemical evidence of smoking abstinence during the first 4 weeks following a scheduled quit attempt.
56418|NCT03743519|Dietary Supplement|Cherry juice|30 mL of tart cherry juice concentrate, which will be diluted with 200 mL of water.
56419|NCT03743519|Dietary Supplement|Placebo|Identical in taste and colour to the Cherry juice, but with no anthocyanin content
56420|NCT03743506|Diagnostic Test|With feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.
56421|NCT03743506|Diagnostic Test|Without feedback|To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
56422|NCT03743480|Other|early palliative care|experimental arm. Patients in this arm will meet with the palliative care team soon after the decision on their last active treatment
56423|NCT03743467|Diagnostic Test|Clinical evaluation of vision and eye tests|"VFQ-25 Questionnaire~BCVA~Contrast sensitivity~Color sensitivity examination (Ishihara test 38 plates)~Complete evaluation of orthoptic features, eye movements, eyelid function, pupil function~Slit lamp examination~Shirmer test, Break up time test~Corneal pachymetry (optical pachymetry)~IOP~Quantitative and qualitative analysis of the macular area and of the optical disc by OCT: RPE, RNFL and Neuroretine Layer"
56424|NCT03743454|Other|No intervention|No intervention will be applied.
56425|NCT03743441|Other|Low-level Laser Therapy|LLLT, 904 nm wavelength, 3 Joules per treatment point in accordance with World Association for Laser Therapy (WALT) guidelines.
56426|NCT03743441|Other|Sham Low-level Laser Therapy|Same procedure as in the LLLT group with the exception of laser irradiation (0 mW mean output power).
56427|NCT03743441|Other|Exercise therapy|Concentric and eccentric exercises with a total duration of approximately 20 minutes.
56428|NCT03743441|Other|Cryotherapy|Twenty minutes of cryotherapy applied to the Achilles tendon.
56429|NCT03743428|Drug|Apatinib Mesylate Tablets|Apatinib combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
56430|NCT03743428|Drug|Bevacizumab Injection|Bevacizumab combinated with FOLFIRI regimen as the second-line chemotherapy for mCRC
56431|NCT03743415|Behavioral|Handbook|see arm/group descriptions
56432|NCT03743415|Behavioral|TIP-C plus Handbook|see arm/group descriptions
56433|NCT03743402|Behavioral|Pain self-management training|"This intervention will have 4 components:~telephone-delivered evidence-based pain self-management training,~web-based video of successfully tapered patients with motivational interviewing debriefing,~a voluntary, self-paced opioid taper~opioid and non-opioid prescribing guidance for the patient's primary care provider."
56434|NCT03743402|Behavioral|video education, motivational interviewing|web-based video of successfully tapered patients with motivational interviewing debriefing
56435|NCT03743402|Drug|voluntary self-paced opioid taper|Voluntary self-paced opioid taper where patient chooses whether, when and how much to taper opioids. Taper schedule and strategy will be proposed to patients, but they may modify it as wished.
56436|NCT03743402|Drug|prescribing guidance for primary care provider|Based upon review of medications and diagnoses in the electronic medical record, the principal investigator will offer guidance on opioid taper rate and strategy. He will also offer suggestions to adjust or initiate other psychotropic medications to treat pain or psychiatric comorbid illness that may be unmasked through opioid taper
56437|NCT03743402|Other|usual care|Usual care will consist of any and all regular care that may be offered by primary care for chronic pain and related illnesses, excluding only use of buprenorphine.
56438|NCT03743389|Device|12G pigtail catheter|12G pigtail catheter would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with the traditional 16F chest tube.
56439|NCT03743389|Device|16F chest tube|16F chest tube would be used for post-operative chest drainage after uniportal-VATS for mediastinal nodes resection when comparing with 12G pigtail catheter.
56440|NCT03743376|Biological|UB-421(25 mg/kg) Q2W|Monoclonal antibody by IV infusion plus standard ART
56441|NCT03743376|Biological|UB-421(25 mg/kg) Q4W|Monoclonal antibody by IV infusion plus standard ART
56442|NCT03743363|Other|Exergame 2/week|virtual training 2 times a week(8 week-long)
56443|NCT03743363|Other|Exergaming 3/week|virtual training 3 times a week(8 week-long)
56444|NCT03743324|Procedure|Immediate Breast reconstruction|Immediate Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
56445|NCT03743324|Procedure|Delayed Breast Reconstruction|Delayed Autologous/prosthetic-based breast reconstruction is performed after mastectomy on the breast that is diagnosed with breast cancer
56446|NCT03743324|Radiation|Radiation|Radiation is performed to the surgical site and complies with the ASCO guidelines on post-mastectomy radiotherapy
56449|NCT03743311|Other|Combined therapy|Surgical + conservative treatment of Hemorhoid
56450|NCT03743298|Drug|AV-MEL-1|AV-MEL-1: Autologous dendritic cells loaded with autologous tumor antigens (ATA) from a short-term cell culture of autologous tumor cells. AV-MEL-1 is admixed with granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, prior to injection.
56451|NCT03743285|Device|AID System|AID system
56452|NCT03743285|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
56453|NCT03743272|Device|LiverMultiScan|Up to 6 separate 5-10 minute abdominal MRI scans. Each scan requires a short breath hold.
56454|NCT03743259|Drug|LuminoMark inj. 0.1mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
56455|NCT03743259|Drug|LuminoMark inj. 0.2mL|Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
56456|NCT03743259|Drug|Charcotrace Inj.|Injection Charcotrace Inj. about 0.3~1mL once in this study.
56457|NCT03743246|Drug|JCAR017|JCAR017
56458|NCT03743246|Drug|Lymphodepleting|Lymphodepleting
56459|NCT03743246|Drug|Fludarabine|Fludarabine
56460|NCT03743246|Drug|Cyclophosphamide|Cyclophosphamide
56461|NCT03743233|Device|Hand file|A crown-down technique will be performed until reaching the provisory WL. The root canals will be initially deobstructed with size #3 and #2 Gates-Glidden burs (Dentsply-Maillefer) at the coronal and middle root thirds. Then, hand stainless steel K-files (Dentsply-Maillefer) with decreasing sizes will be used (#40, #35, #30, #25). The WL will be determined by an electronic apex locator (Novapex; Forum Technologies, Rishon Le-Zion, Israel). A radiograph will be taken to confirm the WL, which should be 1 mm short of the root apex. Apical patency will be reached and maintained with a size #15 K-file (Dentsply-Maillefer). The root canals will be reinstrumented and a size #50 K-file will be standardized as the master apical instrument. A step-back procedure in 1-mm increments followed until merging with the crown-down rotary enlargement (size #70) will be achieved.
56462|NCT03743233|Device|Reciprocating|Reciproc R25 file will be used for gutta-percha removal, until reaching the WL. The instrument will be introduced into the canal applying slight movements of 3-mm amplitude. Apical patency will be maintained with a size #15 K-file. The root canals will be reinstrumented using the Reciproc R50 file. For both groups, after the root canal filling removal and reinstrumentation protocol, a new radiograph will be taken, without any intracanal instrument, for posterior analysis of the percentage of remaining filling material in the root canal. If the radiograph demonstrates the persistence of filling material, the technique will be repeated with the last instrument used in the chemomechanical preparation (hand or reciprocating file), also using H-files with circumferential movements against the dentinal walls in order to remove these residual material, followed by abundant irrigation with NaOCl.
56463|NCT03743207|Other|Room temperature|These infants were fed with room temperature (22-24 °C) so that hypothesizing that they will have more feeding tolerance and therefore more co-existing morbidities.
56464|NCT03743207|Other|Warmer temperature|Fifteen NICU mothers volunteered and expressed their milk for rapid measurement of freshly expressed breast milk. The mean (± SD) temperature of freshly expressed breast milk was found to be 33±1.5 °C in these preliminary measurements. Confirming this finding, the investigators decided to feed these infants with milk at 32 - 34 °C to examine the effects of feeding temperature and the possible comorbidities with a hypothesis that warmer feeding at the temperature of freshly expressed breast milk may be better physiologically.
56465|NCT03743194|Drug|Exparel 266 MG Per 20 ML Injection|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
56466|NCT03743194|Drug|Placebo|Patients randomized to standard analgesia technique will be given pain medications.
56467|NCT03743181|Other|pharmaceutical care services|detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life
56468|NCT03743168|Other|Intermittent stretching protocol|Intermittent stretching protocol of five sets of 1 minute and15 second rest
56469|NCT03743168|Other|Continuous stretch|2 minutes continuous stretch
56470|NCT03743155|Biological|mesenchymal cells|Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out. The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration
56471|NCT03743142|Procedure|endovascular repair of the AAA|The Investigator will ensure that investigational devices are used only in subjects properly enrolled in the clinical study in accordance with the protocol. Subjects will undergo endovascular repair of their AAA. Procedural details may vary between sites, but will follow standard hospital protocol for EVAR and patient care management.
56472|NCT03743129|Drug|Anlotinib|Anlotinib 12mg p.o, qd
56473|NCT03743103|Drug|Brevibloc, 10 Mg/mL Intravenous Solution|10 mL/h every 5 minutes until reaching the pressure target
56474|NCT03743103|Drug|Nitroprusside, Sodium|0.5 ug/kg/min every 3 minutes until reaching the pressure target
56475|NCT03743090|Diagnostic Test|Polysomnography.|A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
56511|NCT03742791|Drug|Placebo|Matched Placebo oral solution
56512|NCT03742778|Behavioral|Incentivizing reflection|Participants receive bonus incentives for reflecting on their workouts
56513|NCT03742778|Behavioral|Incentivizing exercise|Participants receive bonus incentives for exercising
56514|NCT03742765|Behavioral|Incentivizing planning|Participants receive bonus incentives for planning their workouts
56515|NCT03742765|Behavioral|Incentivizing exercise|Participants receive bonus incentives for exercising
56516|NCT03742752|Other|Enteral nutrition|administration of enteral nutrition
56476|NCT03743077|Behavioral|Exercise training including inspiratory muscle training|Volunteers will participate in the the spinal mobility fitness training program for a frequency of one to 3 times a week with pre and post tests including four objective measures of function (timed t-shirt test, timed transfer test, four direction reach test and trunk test of strength) and a pre and post subjective interview. In addition to the program consenting volunteers will perform inspiratory muscle training as a home program and submit weekly diaries tracking their training. The inspiratory muscle trainer by Respironics provides specific pressure for inspiratory muscle strength and endurance, regardless of how quickly or slowly patients breathe. It exercises respiratory muscles and improves breathing. It Improves muscle strength and is easy to use.
56477|NCT03743064|Drug|anamorelin HCl|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
56478|NCT03743064|Drug|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
56479|NCT03743051|Drug|Anamorelin Hydrochloride|100 mg anamorelin HCl (administered as 100 mg tablets in the fasted condition)
56480|NCT03743051|Drug|Placebo Oral Tablet|Placebo (administered as matching placebo tablets in the fasted condition)
56481|NCT03743038|Drug|FMX101 vehicle|FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
56482|NCT03743038|Other|Hydro-alcohol solution|Hydro-alcohol solution based vehicle (Test Article B)
56483|NCT03743025|Drug|Dulaglutide Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Dulaglutide injection: 0.75 mg/0.5 mL solution in a single-dose pen 48-72 hours prior to surgery
56484|NCT03743025|Other|Saline Injection|Participants randomized at pre-surgery/anesthesia visit and without a history of DM will receive a single injection of Saline injection/0.5 mL pre-drawn solution 48-72 hours prior to surgery
56487|NCT03742999|Procedure|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip. Children were trained for 60 minutes per session, three times a week for three consecutive months.
56488|NCT03742999|Device|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months
56489|NCT03742999|Combination Product|physical therapy program and ELink Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months
56490|NCT03742986|Drug|Nivolumab 360 mg+ paclitaxel 80 mg/m2|Nivolumab 360 mg IV Day 1 x 4 cycles and paclitaxel 80 mg/m2 IV Day 1, 8, and 15 x 4 cycles
56491|NCT03742986|Drug|Doxorubicin 60 mg/m2+Cyclophosphamide 600 mg/m2|Doxorubicin 60 mg/m2 IV Day 1 x 4 cycles and Cyclophosphamide 600 mg/m2 IV Day 1 x 4 cycles
56492|NCT03742986|Drug|Nivolumab 360 mg+ Docetaxel* 75 mg/m2 +Trastuzumab 8 mg/kg +Pertuzumab 840 mg|• Nivolumab 360 mg IV Day 1 x 4 cycles, + Docetaxel* 75 mg/m2 IV Day 1 x 4 cycles, + Trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg IV on Day 1 of Cycle 2-4, + Pertuzumab 840 mg IV on Day 1 of Cycle 1 and then 420 mg IV on Day 1 of Cycle 2-4, followed by
56493|NCT03742986|Drug|Doxorubicin 60 mg/m2 +Cyclophosphamide 600 mg/m2|Doxorubicin 60 mg/m2 IV Day 1 x 4 cycles and Cyclophosphamide 600 mg/m2 IV Day 1 x 4 cycles
56494|NCT03742973|Drug|Baricitinib|Administered orally.
56495|NCT03742973|Drug|Placebo|Administered orally.
56496|NCT03742960|Behavioral|Behavioral Sleep Restriction|Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
56497|NCT03742947|Diagnostic Test|peripartum haemostasis|Three blood samples of 20 ml each at T0 after the anaesthesia for the caesarean section and before the administration of the product (TXA or placebo), T15 fifteen minutes after the administration of the product and T120, 2 hours after the administration of the product.
56498|NCT03742934|Other|Short peptide|Short peptide formula during bowel preparation
56499|NCT03742934|Other|Liquid diet|Liquid diet during bowel preparation
56500|NCT03742921|Drug|Istodax|Istodax
56501|NCT03742908|Drug|Cefazolin/clindamycin|Local implant immersion and/or breast pocket irrigation
56502|NCT03742895|Drug|Olaparib|Olaparib 300 mg administered BID as two, 150 mg oral tablets.
56503|NCT03742882|Drug|CC-90001|CC-90001
56504|NCT03742869|Combination Product|A multi-omics analysis|A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
56505|NCT03742856|Combination Product|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics.
56506|NCT03742843|Combination Product|A multi-omics analysis|A multi-omics analysis including whole exome sequencing, transcriptomics and metabolomics for eutopic and ectopic endometrium
56507|NCT03742830|Device|C-MAC VS|C-MAC VS, Karl Storz AG, 78532 Tuttlingen, Germany It has a flexible tip and a distal angular offset, in which the camera and light sources are integrated. It can be aligned (up to 60°) to the patient's anatomical structures to facilitate intubation.
56508|NCT03742817|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
56509|NCT03742804|Biological|Intratumoral G100|G100 agent is a potent Toll-like receptor (TLR)4 agonist. G100 is composed of glucopyranosyl lipid A (GLA) formulated in a stable emulsion (SE). GLA is a fully synthetic TLR4 agonist that is a potent stimulator of innate immune responses.
56510|NCT03742791|Drug|TS-134|5 mg to 80 mg oral solution
56517|NCT03742752|Other|Parenteral nutrition|administration of parenteral nutrition
56518|NCT03742726|Device|Smart Matrix scaffold|Smart Matrix dermal replacement scaffold
56519|NCT03742713|Drug|CPC634 (CriPec® docetaxel)|Docetaxel containing CriPec® nanoparticles
56520|NCT03742700|Behavioral|Cigarette smoking|T-smokers were asked to smoke a cigarette of one of the popular brands (0.6mg nicotine per one cigarette) according to their everyday habits.
56521|NCT03742700|Behavioral|E-cigarette use|E-smokers and dual users were instructed to use e-cigarettes (12 mg/ml nicotine) in accordance with everyday habits for 5 minutes.
56522|NCT03742700|Behavioral|Simulation of the use of e-cigarette|The control subjects were asked to simulate the use of e-cigarettes (a device without e-liquid where aerosol was not created or inhaled).
56523|NCT03742687|Radiation|Heterogeneously Hypofractionated Radiotherapy|A heterogeneous hypofractionated schedule for the treatment of high-risk locally advanced NSCLC patients in which the central idea is to decrease dose to normal tissue by ascribing a heterogeneous dose to the PTV. The dose to the periphery of the PTV as well as to the majority of lymph node targets is decreased compared to a standard treatment. The gross volume of the primary tumour and bulky lymph nodes receive mean doses of up to 66 Gy in 24 fractions, and thus receive a hypofractionated higher biological effective dose than standard 66 Gy in 33 fractions.
56524|NCT03742674|Other|Follow up|No intervention
56525|NCT03742661|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
56526|NCT03742648|Other|Physiotherapy|Chest physiotherapy in burn patients in order to treat and prevent post burn respiratory complications like pneumonia etc
56527|NCT03742635|Other|General Movements Assessment|Prechtl's Assessment of General Movements (GMA) is a tool used in early infancy to identify infants at high risk of cerebral palsy and neurodevelopmental impairment. General movements are complex motor patterns that involve the entire body, moving fluidly in different directions through the arms, legs, and trunk with variable speed, amplitude, force and intensity. During fetal development, spontaneously generated motor patterns, including general movements, can already be observed. The GMA is a functional assessment of the maturing nervous system that takes advantage of the fact that typically developing infants will have a progression in their general movements. This pattern is characterized by a writhing pattern in the early weeks post-term, followed by the emergence of fidgety movements at 3-5 months of age.
56528|NCT03742622|Behavioral|CON . control condition without exercise / rest condition|CON . Control condition without exercise / rest condition. The adolescents will be asked to remain quiet and at rest during the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
56529|NCT03742622|Behavioral|EX. Condition with an acute exercise set in the middle of the morning|EX. Condition with an acute exercise set in the middle of the morning The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning and will receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals
56530|NCT03742622|Behavioral|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack|EX+R. condition with an acute exercise set in the morning and followed by a energy replacement snack The adolescents will be asked to complete a 30 minutes exercise set at 65% of their capacities (cycling) in the morning followed by a snack that will cover the whole exercise-induced energy expenditure. They will then receive an ad libitum meal at lunch and dinner times. Their food reward will be assessed before and after lunch. Their appetite feelings will be assessed at regular intervals.
56531|NCT03742609|Other|ii) the reminder|Participants assigned to the prompt group were received instruction to use their hearing aid box as a physical prompt to remind participants to use their hearing aid(s)
56532|NCT03742609|Other|ii) written behavioural plan|Participants assigned to this group were received instruction to create at least one written plan for hearing aid use. Specifically, participants were asked to plan where and when to use their hearing aid(s).
56533|NCT03742609|Other|iv) all materials|i) provision of written information regarding consequences of using a hearing aid and not using a hearing aid, ii) the provision of a physical prompt for the purpose of prompting or cueing the behavior (hearing aid use) development, and iii) creation of a written behavioural plan for hearing aid use.
56534|NCT03742596|Drug|Probiotic Formula Capsule|The Probiotic will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
56535|NCT03742596|Drug|Placebos|The Placebos will be coded in a specific label by a researcher who will not be in contact with the participants and administrated randomly based on gender in a double-blind manner. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
56536|NCT03742583|Other|Square Knot|Standard square knot
56537|NCT03742583|Other|RHAP Knot|Reversing half-hitch alternating post knot
56538|NCT03742570|Behavioral|CBBDQ|a questionnaire for childood bladder and bowel dysfunctions
56539|NCT03742557|Drug|Ketamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV|Ketamine 0.5 mg/kg IV
56540|NCT03742531|Drug|oxytocin|one group will be treated with low dose oxytocin and the other group will be treated with high dose oxytocin for augmentation of labor induction.
56541|NCT03742518|Drug|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
56542|NCT03742518|Drug|Topical SM04554 solution|Study medication application will be performed by the individual subject at approximately the same time each day.
56543|NCT03742518|Drug|Topical vehicle solution|Vehicle solution application will be performed by the individual subject at approximately the same time each day.
56544|NCT03742505|Drug|Cholecalciferol|Single enteral cholecalciferol load at a dose of 10,000 IU/kg (maximum 400,000 IU)
56545|NCT03742505|Other|Placebo|Single enteral placebo dose equivalent in volume to the appropriate weight-based dose of cholecalciferol
56546|NCT03742492|Dietary Supplement|Meal containing canned tuna + fish oil (5 g EPA + DHA)|Meal containing canned tuna + fish oil (5 g EPA + DHA)
56547|NCT03742492|Dietary Supplement|Meal containing canned tuna + soybean oil|Meal containing canned tuna + soybean oil
56549|NCT03742466|Drug|Ozone|After prepping and draping the area, intracarpal injection of ozone/oxygen mixture (20 ml, 25μg/ml) will be performed under sonographic guidance
56550|NCT03742466|Drug|methylprednisolone acetate|After prepping and draping the area, intracarpal injection of methylprednisolone acetate 40mg, and 40 mg lidocaine (20 ml, volume) will be performed under sonographic guidance
56551|NCT03742453|Diagnostic Test|contrast-enhanced ultrasound|CEUS is performed using SonoVue (Bracco, Milan, Italy) intravenous administration in eligible participants within a month before/after EOB-MRI.
56552|NCT03742453|Diagnostic Test|EOB-MRI|EOB-MRI is performed using standard dose of hepatocyte specific contrast media (primovist or eovist) according to standard protocol of our institution.
56553|NCT03742440|Biological|GrafixPL PRIME|GrafixPL PRIME
56554|NCT03742427|Diagnostic Test|ultrasonography|optic nerve sheath diameter measurement will be done by ultrasonograhy on both eyes
56555|NCT03742414|Combination Product|Tri-lipid skin barrier cream (Epiceram)|The aim is to compare the effect of proactive sequential skin care, including the twice daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone proprionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
56556|NCT03742414|Combination Product|Fluticasone propionate Cream 0.05%|Atopic dermatitis flares detected during a study visit will be treated as indicated (e.g. with a petrolatum-based skin moisturizer and topical steroids such as 1% hydrocortisone or a more potent topical steroid where appropriate), without any subsequent proactive treatment.
56557|NCT03742401|Procedure|Surgery|Traditional open excisional surgery
56558|NCT03742401|Device|HIFU (Echopulse)|High intensity focused ultrasound (HIFU) non invasive intervention
56559|NCT03742375|Diagnostic Test|HPV genotyping|Quantitative HPV genotyping on anal swab
56560|NCT03742362|Device|MRI scans of distal radius|MRI scans to monitor the fat fraction in the bone marrow of the distal radius
56561|NCT03742349|Biological|spartalizumab|LIVI (Liquid in vial) Concentrate for Solution for infusion
56562|NCT03742349|Biological|LAG525|LAG525 LIVI (Liquid in vial) Concentrate for Solution for infusion
56563|NCT03742349|Drug|NIR178|Capsule
56564|NCT03742349|Drug|capmatinib|Tablet
56565|NCT03742349|Biological|MCS110|LIVI (Liquid in vial) Concentrate for Solution for infusion
56566|NCT03742349|Biological|canakinumab|LIVI (Liquid in vial) Solution for injection
56567|NCT03742336|Drug|PF-04965842|Single oral 200 mg dose of PF-04965842
56568|NCT03742336|Drug|Dabigatran|Single 75 mg dose of dabigatran
56569|NCT03742323|Drug|Idelalisib|Idelalisib Dose: 100, 150, 200 or 300 mg (in four cohorts of six patients each).
56570|NCT03742310|Drug|Vitamin D|Vitamin D is essential for healthy bones, and to control the amount of calcium in our blood.It is important at every stage of life, but especially for rapidly growing infants and teenagers and for pregnant and breastfeeding women.
56571|NCT03742297|Drug|Lenalidomide.|Lenalidomide
56572|NCT03742297|Drug|Carfilzomib|Carfilzomib
56573|NCT03742297|Drug|Bortezomib|Bortezomib
56574|NCT03742297|Drug|Daratumumab|Daratumumab
56575|NCT03742297|Drug|Dexamethasone|Dexamethasone
56576|NCT03742297|Drug|Prednisone|Prednisone
56577|NCT03742297|Drug|Melphalan|Melphalan
56578|NCT03742284|Device|SoftOx Wound Irrigation Solution|"The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective."
56579|NCT03742271|Device|senofilcon A|TEST Lens
56580|NCT03742258|Drug|Cyclophosphamide|Given IV
56581|NCT03742258|Drug|Doxorubicin Hydrochloride|Given IV
56582|NCT03742258|Drug|Prednisone|Given PO
56583|NCT03742258|Biological|Rituximab|Given IV
56584|NCT03742258|Drug|Spleen Tyrosine Kinase Inhibitor TAK-659|Given PO
56585|NCT03742258|Drug|Vincristine Sulfate|Given IV
56586|NCT03742245|Drug|Olaparib|PARP inhibitor
56587|NCT03742245|Drug|Vorinostat|HDAC inhibitor
56588|NCT03742232|Drug|PEG3350|"PLENVU® supplied as two powder-for-oral-solution formulations. One formulation contains PEG3350, sodium sulphate and electrolytes, and the second formulation contains PEG3350, sodium ascorbate, ascorbic acid, and electrolytes.~PLENVU® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
56589|NCT03742232|Drug|Macrogol 4000|"SELG-ESSE® supplied as powder-for-oral-solution containing PEG4000, simethicone, sodium sulphate and sodium bicarbonate, and electrolytes.~SELG-ESSE® Administration: 2-Day Split-Dosing Regimen (to commence in the evening of the day before colonoscopy)."
56590|NCT03742219|Behavioral|Lifestyle Modification|"Community awareness: a) individuals will be made aware of their own chronic lifestyle diseases and risk factors b) communities will be made aware of their aggregated data concerning chronic lifestyle related diseases and risk factors.~Education for individuals and communities on the meaning of the lifestyle diseases and risk factors. a) individual and small group sessions explaining diseases and lifestyle measures that are helpful, b) community level education to tentatively include i) shopping guides and recipes, ii) urban gardening projects, iii) puppet shows and other community presentations, iv) literature and posters."
56591|NCT03742206|Device|Parasacral Transcutaneous Electrical Stimulation|Electrical stimulation with surface electrodes on the sacral roots of S3 that produce inferior urinary tract neuromodulation.
56592|NCT03742206|Device|Transcutaneous Posterior Tibial Nerve Stimulation|Electrical stimulation with surface electrodes through the activation of peripheral afferent nerves that produce inferior urinary tract neuromodulation
56593|NCT03742193|Drug|Apatinib|Apatinib 250mg tablet by mouth, bid. 48 hrs break before and 96 hrs after the surgical resection of the pulmonary metastases.
56594|NCT03742193|Drug|GD regimen|"One cycle: gemcitabine 900 mg/m^2 over 90 min on Day 1, and gemcitabine 900 mg/m^2 and docetaxel 75 mg/m^2 on Day 8. Every 21 days were eligible.~1~2 -week break before and 2-week break after the surgical resection of the pulmonary metastases is taken."
56630|NCT03741907|Procedure|FAUCS|extraperitoneal cesarean with a paramedian left section
56595|NCT03742180|Drug|intranasal dexmedetomidine|The patient will receive intranasal dexmedetomidine in a dose of 1ug.kg-1 in a volume of 1 ml was dripped into both nostrils using a 1-mL syringe, with the patients in the recumbent position plus 1ml sublingual 0.9% saline
56596|NCT03742180|Drug|sublingual ketorolac|The patient will receive sublingual ketorolac in a dose of 0.5 mg.kg-1 in a volume of 1 ml and 1 ml intranasal saline 0.9%
56597|NCT03742167|Other|Telemedicine|The mobile, HIPAA-compliant, video-conferencing platform, Zoom Pro, will be used on tablet computers as a low-cost telemedicine platform for the intervention group. This platform uses Wi-Fi or cellular data connection for video streaming. The investigators will use the telephone communication on this platform for control scenarios, to mimic the current standard for audio-only consultation. A web-based software platform (WireCast®) will capture video recordings over a secure wireless network.
56598|NCT03742154|Drug|Varenicline 0.5 MG|varenicline comes in bottles of 56 - 0.5 mg pills
56599|NCT03742141|Device|Intraoperative Video Laryngoscopy|The IOVL is a disposable, otherwise standard fiberoptic laryngoscope that is inserted alongside the endotracheal tube following intubation for surgical procedures.
56600|NCT03742141|Drug|Glycopyrrolate|0.004mg/kg as per routine prior to intubation
56601|NCT03742115|Drug|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
56602|NCT03742115|Drug|Dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
56603|NCT03742115|Drug|Etoposide|150 mg/m2 weekly
56604|NCT03742115|Drug|IVIG|0.5 g/kg, once every 4 weeks
56605|NCT03742102|Drug|Durvalumab|Durvalumab iv Every 4 weeks (q4w)
56606|NCT03742102|Drug|Capivasertib|Capivasertib po bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
56607|NCT03742102|Drug|Danvatirsen|Danvatirsen iv Loading doses on days 1, 3 and 5 in first cycle; Once weekly (q1w) starting at cycle 1 day 8
56608|NCT03742102|Drug|Oleclumab|Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
56609|NCT03742102|Drug|Paclitaxel|Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off
56610|NCT03742089|Device|Bone Anchored Hearing Surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected will be used to assess the implant stability development of the Ponto BHX implant during up to 24 months after implantation in a pediatric population undergoing BAHS. The study will also monitor the Ponto BHX implant safety and survival throughout the study period.
56611|NCT03742076|Dietary Supplement|High-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
56612|NCT03742076|Dietary Supplement|Low-dose prebiotic|This is a spray-dried powder, yellowish-white in color, that is dissolvable.
56613|NCT03742076|Dietary Supplement|Placebo|Powder fiber supplement, yellowish-white in color, that is dissolvable.
56614|NCT03742063|Drug|first-line chemotherapy|patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
56615|NCT03742050|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with drug-eluting stents aiming to achieve complete revascularisation
56616|NCT03742037|Drug|Cenerimod 0.5 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 0.5 mg
56617|NCT03742037|Drug|Cenerimod 1 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 1 mg
56618|NCT03742037|Drug|Cenerimod 2 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 2 mg
56619|NCT03742037|Drug|Cenerimod 4 mg|Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg
56620|NCT03742037|Drug|Placebo|Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod
56621|NCT03741998|Device|Nasopharyngeal airway|THRIVE with a regular nasopharyngeal airway.
56622|NCT03741985|Behavioral|The handgrip exercise|The control group was given routine dialysis treatment and daily handgrip exercise .Patients are asked to squeeze a rubber ring 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
56623|NCT03741985|Behavioral|The dumbbell exercise|The experimental group was given routine dialysis treatment and daily dumbbell exercise .Patients are asked to hold 6-pound dumbbells to exercise 30 times per min for altogether 20 minutes on non-dialysis days.The 20-minute exercise can be divided into 3 parts according to individual circumstances.
56624|NCT03741972|Drug|iSGTL2|Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results)
56625|NCT03741959|Procedure|Experimental group|"Active self-correction exercises (20 minutes) to achieve the best possible trunk alignment the patient can achieve in the three-dimensional planes using visual, proprioceptive and EMG feedbacks.~Passive and active trunk stabilization exercises (20 minutes) to improve trunk biomechanical constraint Functional tasks (20 minutes) defined as functional exercises to train the automatic response to maintain the best alignment through the broadest possible range of challenging activities (Romano2015)."
56626|NCT03741959|Procedure|Control group|Training consisted of passive and active trunk mobilization (10 minutes) followed by muscle stretching, and strengthening exercises, and gait training (50 minutes)(Bartolo et. al., 2010).
56627|NCT03741946|Procedure|Triangle of Sedillot identification using ultrasonography|Contralateral head rotation was done with protractor at angle 30°, 45°, and 60°. The distance and overlap ratio of IJV and CA was calculated in each angle.
56628|NCT03741933|Drug|Apremilast 30mg|Apremilast 30 mg tablet
56629|NCT03741920|Device|Personal KinetiGraph™ (PKG™)|"The Personal KinetiGraph™ (PKG™) Movement Recording System was developed by neurologists at the Melbourne-based Florey Institute of Neuroscience and Mental Health. The product is manufactured and marketed by Global Kinetics (GKC).~The Personal KinetiGraph™ (PKG™) Movement Recording System consists of the following:~A wrist-worn data logger designed to acquire data on the kinematics of movement disorder symptoms over a 6-10 day period.~An application to configure the data logger and transfer the acquired data at the end of a recording.~A series of algorithms that analyze the uploaded data, producing a report that is delivered to the clinician. The report contains objective data distinguishing the movement patterns consistent with tremor, bradykinesia, dyskinesia and immobility."
56632|NCT03741894|Drug|Iodoform|Patients get iodoform (1000 grams containing 350 grams of iodoform, 300 grams of glycerin and 350 grams of alcohol 96%) soaked gauze (steril selvedge gauze bandage 2 cm x 5 m in appropriate length) drainage during suture placements for a week.
56633|NCT03741894|Other|Wound closure using sutures|Routine primary wound closure with single interrupted sutures (Surgilon 3-0 non-absorbable) only.
56634|NCT03741894|Drug|Chlorhexidine|Extraction sockets are filled with 1% chlorhexidine gel (Curasept ADS310, Sager Pharma, Sager Dental Kft.,Budapest, Hungary) before suture (Surgilon 3-0 non-absorbable) placements.
56636|NCT03741855|Device|Cloud Dx Kit with self-monitoring|Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.
56637|NCT03741855|Device|Cloud Dx Kit with remote-monitoring|"Patients in this group will be recording their vitals and symptoms with the Cloud DX platform everyday and will be provided with an action-plan that instructs them on what to do in response to their readings.~A respiratory therapist (RT) will be monitoring asynchronously patient vitals and contacting them when their vitals exceed pre-determined thresholds.~The RT will also check on patients once a week irrespective of the value of the vitals."
56638|NCT03741842|Behavioral|COMBO-KEY|The intervention will last for eight weeks with four home visits and five phone coaching sessions. It will also consist of a 4-item resource package for stroke survivors (including a stroke self-management and self-discovery workbook, a health and life planning toolkit, and videos on sharing of experience by survivors who managed their post-stroke challenges successfully, and a stroke self-management quick reference guide). A telephone hotline for survivors and caregivers to seek information and support related to stroke self-management will also be established. A programme protocol will be developed to ensure the consistent delivery of the programme.
56639|NCT03741816|Drug|Indirect pulp capping|Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
56640|NCT03741803|Device|Delayed cord clamping|The umbilical cord will be clamped after 60 seconds after birth
56641|NCT03741803|Device|Early cord clamping|The umbilical cord will be clamped as soon as feasible after birth, usually within the initial 15 seconds after birth.
56642|NCT03741790|Procedure|Ventilation|The difficult mask ventilation is defined as A) It is not possible for unassisted anesthesiologist to maintain the SpO2 > 90% using 100% oxygen and positive pressure mask ventilation in a patient whose SpO2 > 90% before anesthetic intervention; and/or B) It is not possible for unassisted anesthesiologist to prevent or reverse signs of inadequate ventilation during positive mask ventilation.
56643|NCT03741790|Procedure|Intubation|"The difficult endotracheal intubation is defined as  It is not possible to visualize any portion of the vocal cords with conventional laryngoscopy or when proper insertion of the endotracheal tube with conventional laryngoscopy requires more than three attempts or more than ten minutes."
56644|NCT03741777|Other|Clear oral fluid|clear oral fluid including water, pulp-free juice and tea or coffee without milk.
56645|NCT03741764|Device|Vivosorb|Resorbable implant device
56646|NCT03741751|Device|rTMS|Participants will receive either active or sham bilateral rTMS over the dorsolateral prefrontal cortex (DLPFC) for 12.5 min per side.
56647|NCT03741751|Behavioral|Computerized cognitive training|All participants will receive computerized cognitive training for 40 min after each rTMS session.
56648|NCT03741725|Other|Pay-it-forward|Participants will be offered a gift of free gonorrhea and chlamydia testing made available by donations from previous testers, and asked whether they would like to donate money (pay-it-forward) for future men to receive the same option.
56649|NCT03741725|Other|Pay-what-you-want|Participants will be offered gonorrhoea and chlamydia testing and told that they can decide and pay any desired amount after receiving the test.
56650|NCT03741712|Drug|SHR3680|Tablet. Specifications of 80mg
56651|NCT03741712|Drug|SHR2554|Tablet. Specifications of 50mg and 200mg
56652|NCT03741699|Drug|Pre-treatment with rLH (Luveris 75 IU),|Treatment with 150 IU/day rLH (Luveris 75 IU), administered subcutaneously for 4 consecutive days prior to COS (Controlled ovarian stimulation)
56653|NCT03741686|Dietary Supplement|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.5 g/412KJ [100kcal] of glucommanan)
56654|NCT03741686|Dietary Supplement|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
56655|NCT03741673|Other|Quality-of-Life Assessment|Ancillary studies
56656|NCT03741673|Other|Questionnaire Administration|Ancillary studies
56657|NCT03741673|Radiation|Stereotactic Radiosurgery|Undergo SRS
56658|NCT03741660|Dietary Supplement|konjac glucomannan|Konjac-mannan fiber-enriched biscuits (0.7 g/412KJ [100kcal] of glucommanan)
56659|NCT03741660|Dietary Supplement|wheat bran|Wheat bran (hard red wheat bran) fiber enriched biscuits
56660|NCT03741647|Diagnostic Test|sleep study and blood sample|full night polysomnographic study and blood sample to detect some genetic issues
56661|NCT03741634|Other|Multi-sectoral agricultural intervention|Adult participants in the intervention arm receive a loan (~$175) from a well-established Kenyan bank used to get a human-powered water pump, seeds, fertilizers and, pesticides, and education in financial management and sustainable farming practices.
56662|NCT03741621|Dietary Supplement|Viscous Fibre Blend|High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
56663|NCT03741621|Dietary Supplement|Psyllium|Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
56664|NCT03741621|Dietary Supplement|Wheat Bran|All Bran cereal (All Bran®; Kellogg Company)
56665|NCT03741608|Behavioral|High blood pressure management education|The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
56666|NCT03741608|Behavioral|Home blood pressure measurement|Participants will be taught to use an automated blood pressure cuff and will be asked to provide monthly blood pressure readings to study staff.
56667|NCT03741595|Behavioral|Item spacing|Spatial proximity of items to one another
56668|NCT03741582|Other|TransMiCable|"TransMiCable will have one service line 3.43 km-long with four stations (El Tunal , Juan Pablo II , Manitas , and Paraiso, see highlighted stops in Figure 2). El Tunal is the station that connects to the city's bus rapid transit system. The planned capacity of TransMiCable is 3,600 persons per hour in 163 cabins or gondolas. Each cabin fits ten passengers, with space for wheelchairs and bicycles and will be equipped with free Wi-Fi. The expected travel time reductions from each station to portal El Tunal, through the shortest pathway, are: 26 minutes saved from Juan Pablo II station—from 32 to 6 minutes; 31 minutes saved from Manitas station—from 38 to 7 minutes and 49 minutes saved from Paraiso station—from 62 to 13 minutes 22. In conjunction with TransMiCable, urban projects will be implemented including the construction of parks, outdoor gyms, sport courts, community centers for children and older adults, a market, an administrative, and a tourism offices."
56669|NCT03741569|Device|Transabdominal Fetal Heart Rate|"Doppler, ECG and acoustic sensors will be placed on the mother's abdomen to capture the heart rate of the fetus and mother as well as uterine contractions.~For each of the participants, we will make two 15-minute recordings: one with conventional ECG electrodes and one with ECG textile electrodes"
56670|NCT03741556|Other|questionaire|a questionaire is sent to each participans
56671|NCT03741543|Other|A 12-week health promotion course|The Health Promotion intervention consists of 12 weekly 2-hour sessions with a group of up to six participants and two course facilitators. Teaching methods includes lecture, questions- and answer periods, and interactive hands-on learning. During the class sessions, the facilitators encourages the participants to ask questions and make comments about the lecture at any time. During the first class session, each participant receives a booklet with the course material.
56672|NCT03741530|Drug|Glibenclamide Tablets|Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
56673|NCT03741530|Other|Standard management for ICH|Usual care and drug in hospital
56674|NCT03741517|Radiation|18F-FDG-PET|Fludeoxyglucose F18
56675|NCT03741517|Radiation|68Ga-DOTATOC-PET|DOTA-tyr3-Octreotide Ga68
56676|NCT03741517|Radiation|Computed tomography|Computed tomography of thorax and abdomen with 3-phase contrast
56677|NCT03741517|Other|Core needle biopsy|Core needle biopsy of metastatic lesions
56678|NCT03741517|Other|Phlebotomy|Phlebotomy from peripheral vein
56679|NCT03741504|Procedure|micro-osteoperforations (MOPs)|three (3) micro-osteoperforations (MOPs) in the cortical and medullar bone, distal to the upper canine. These MOPs will be at the apical, medial and gingival zone of the bone located at the distal surface of the canine in the buccal and in the palatal side. The deep of the MOPs will be at 6 mm. It is going to be done with a PROPEL
56680|NCT03741478|Drug|OLANZapine 2.5 MG|"Olanzapine capsules (2.5mg) will be administered with the following dosing schedules for each arm:~Metabolic arm - 5mg on Day 0, 7.5mg on Day 1, and 10mg on Day 2~Cognitive arm - 5mg on Day 0, 10mg on Day 1"
56681|NCT03741478|Drug|Placebo|Placebo capsules visually identical to those containing olanzapine will be administered according to the same dosing schedule for each arm.
56682|NCT03741478|Drug|Insulin Lispro 100 UNT/ML|"Intranasal insulin spray (or placebo) will be administered on day 2 for each arm.~For the metabolic arm: 40 IU of intranasal insulin lispro will be administered at timepoint 0 during the pancreatic euglycemic clamp procedure.~For the cognitive arm: 160 IU of intranasal insulin lispro will be administered at about 11 am on day 2 prior to the MRI imaging and cognitive testing procedures."
56683|NCT03741478|Other|Saline|Placebo saline spray visually identical to the intranasal insulin spray will be administered on day 2 for each arm according the same dosing schedules.
56684|NCT03741465|Procedure|The SFP technique|The USG, and the 5-point NRS evaluation in the SFP
56685|NCT03741465|Procedure|The ASP technique|The USG, and the 5-point NRS evaluation in the ASP
56686|NCT03741452|Other|transversalis fascia plane block|patient controlled analgesia devices with tramadol
56687|NCT03741439|Device|Treatment|Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
56688|NCT03741439|Device|Sham|Sham treatment
56689|NCT03741426|Drug|Olaparib|Olaparib 300mg twice daily, oral medication administered for at least 2 weeks and up until the morning of nephrectomy. Arms 2, 3 and 5
56690|NCT03741426|Drug|Cediranib|Cediranib 20mg once daily, oral medication administered for at least 2 weeks until 36 hours prior to nephrectomy. Arms 1 and 3
56691|NCT03741426|Drug|Durvalumab|Durvalumab 1500mg intravenous infusion administered once, no greater than 4 weeks prior to nephrectomy
56692|NCT03741413|Other|Gain-frame SMS|Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.
56693|NCT03741413|Other|Loss-frame SMS|Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.
56694|NCT03741413|Other|Control SMS|Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
56695|NCT03741400|Device|Neofect RAPAEL Smart Glove|The Neofect Rapael Smart Glove is a biofeedback system designed for upper extremity rehabilitation in stroke survivors. It includes a glove-shaped sensor device and a software application.
56696|NCT03741387|Other|Gain-frame questionnaire|Questionnaires focusing on the attitude of saving patients' lives were given to Rh negative blood donors in this group.
56697|NCT03741387|Other|Loss-frame questionnaire|Questionnaires focusing on the attitude of preventing patients from death were given to Rh negative blood donors in this group.
56698|NCT03741374|Procedure|Minimally-invasive non-surgical therapy (MINST)|A non-surgical minimally-invasive treatment protocol, named MINST, has been proposed (Ribeiro et al. 2011) for the treatment of periodontitis, in order to minimise patient discomfort and maximise the healing potential. This technique usually involve the use of magnification lenses or microscopes and small instruments which would reduce the risk of tissue trauma compared with traditional instruments.
56699|NCT03741361|Other|anxiety and depression|Female patients who have a previous history of surgery or infertility, or a history of miscarriage or abortion are often susceptible to preoperative anxiety or depression. We will observe the effect of anxiety and depression on the dosage of propofol during induction.
56700|NCT03741348|Procedure|Erector Spinae Plane Block|In (ES) group After skin sterilization, ESPB was performed in sitting position at the level of T9 linear ultrasound (US) transducer (Phillips-Saronno Italy) was placed vertically 3cm lateral to midline to visualize the muscles of the back, transverse process and simmering pleura in between the two transverse processes. After local infiltration of needle insertion site with 2-3ml of 2% lidocaine, a 22‑gauge Short bevel needle (Spinocan, B.Braun Melsungen AG, Germany) was inserted in cranial-caudal direction towards transverse process (TP) in-plane to the US transducer until needle touched the TP crossing all the muscles. Then, up to 20 ml of bupivacaine 0.5% was injected. The procedure was repeated following the same steps on the other side of back.
56701|NCT03741348|Procedure|control|in control group, Erector Spinae Plane Block will not be done
56702|NCT03741335|Behavioral|Tai Ji Quan training|Participants attend a supervised, group-based tai ji quan program where they perform an integrated exercise routine consisting of 8 purposeful movement forms and a set of therapeutic movements 3 times per week for 60 minutes per session
56703|NCT03741335|Behavioral|Strength training|Participants attend supervised, group-based moderate-intensity strength training program 3 times per week for 60 minutes per session.
56704|NCT03741335|Behavioral|Stretching|Participants attend a supervised, group-based supervised flexibility program 3 times per week for 60 minutes per session.
56705|NCT03741309|Other|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks.
56706|NCT03741309|Other|Calcium sodium phosphosilicate|Calcium sodium phosphosilicatand VAS score assessed at Baseline, 2weeks, 6 weeks.
56707|NCT03741309|Other|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
56708|NCT03741296|Procedure|Single stage revision|One-stage exchange hip joint replacement surgery
56709|NCT03741296|Procedure|Two-stage revision|Two-stage exchange hip joint replacement surgery
56710|NCT03741283|Other|Optimisation of nutrition and medication|"Inter-professional optimisation of medication prescribing:~Study participants in the intervention group receives optimisation of medication prescribing at admission day (baseline) regardless of nutritional state. The intervention is performed in cooperation between a clinical pharmacist and a medical physician.~Nutritional intervention:~If positive screening for malnutrition or risk of malnutrition a dietetic intervention is initiated and if positive screening below interventions are initiated:~Dysphagia: occupational therapy intervention.~Oral cavity problems: odontological intervention.~Depression: geriatric intervention.~Low ADL: occupational therapy intervention and if positive screening for poor muscle strength: physiotherapeutic intervention."
56711|NCT03741270|Biological|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
56712|NCT03741257|Drug|Hypertonic saline|resuscitation fluid
56713|NCT03741244|Drug|apatinib|Apatinib is an oral small molecule antiangiogenic targeted drug developed in China. More and more studies found that antiangiogenic drugs have outstanding performance in treating glioma. From the perspective of clinical and molecular mechanism, the combination of Temozolomide and apatinib may have synergistic effect especially to TMZ insensitivity patients(MGMT gene promoter unmethylated) and poor prognosis (IDH1 wild type) population
56714|NCT03741244|Drug|Temozolomide|Temozolomide，alkylating agent， is the standard first-line chemotherapy of glioma.
56715|NCT03741218|Other|Freeze-dried grape (GRAP)/Placebo (PLA)|The subjects will receive, after overnight fasting, either a monodose of freeze-dried grapes (equivalent to 300 g of fresh grapes) or isocaloric placebo solved in water, together with a high-fat breakfast. Blood samples will be collected before the intake, up to 5 h after breakfast, then a medium-fat lunch will be provided and blood samples will be collected for three additional hours. A total of 10 samples will be collected: 0-30-60-120-180-240-300-330-360-420 min. Both interventions will be separated by two weeks. Subjects will be instructed not to modify their dietary habits during the development of the study, but during the 72 h before each visit they will have to restrict the intake of polyphenol-rich foods (a detailed list will be provided).
56716|NCT03741205|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
56717|NCT03741192|Device|SPEAC System|Surface Electromyography (sEMG) based seizure monitoring and alerting system
56718|NCT03741179|Drug|ASA-withdrawn group|Patients whith sFlt/PlGF ratio < 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
56719|NCT03741166|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
56720|NCT03741153|Device|slit lamp|"Presence of white grayish exfoliation material on the anterior lens capsule and / or the pupillary margin.~Poor pupillary dilatation due to atrophy of the dilator pupillae muscle.~The presence of pseudoexfoliative material (PXF)in cilliary processes and zonules.~presence of PXF material scattered on corneal endothelium.~Flecks of the exfoliative material on the anterior chamber which leads to glaucoma."
56721|NCT03741140|Diagnostic Test|Motivation tests|Motivation tests will characterize elementary deficits of motivation
56722|NCT03741127|Drug|Rimiducid may be administered as indicated|Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
56723|NCT03741114|Procedure|Foley's Catheter|patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.
56724|NCT03741114|Drug|TA|patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline
56725|NCT03741114|Drug|Placebo|patients received 100 ml saline just before skin incision
56726|NCT03741101|Drug|Trametinib|treatment
56727|NCT03741088|Device|VORTX Rx treatment|Cavitation-based cellular destruction using focused ultrasound
56728|NCT03741075|Procedure|BUA|bilateral uterine artery ligation (BUAL) after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
56729|NCT03741075|Drug|topical tranexamic acid|topical application of 200ml saline contains 2 gm tranexamic acid to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
56730|NCT03741075|Drug|placebo|topical application of 200ml saline to the placental bed after delivery of the fetus which not respond uterotonic and simple hemostatic maneuvers like placental bed hemostatic sutures
56731|NCT03741062|Device|J. Morita AdvErl Evo Er:YAG laser|"Er:YAG laser perimeters:~Fluence = 6.3 J/cm^2 Energy = 80 mJ Pulse Rate = 25 Hz Duration = 30 s"
56732|NCT03741062|Device|Control|Sham treatment with laser unit turned off
56733|NCT03741049|Device|Scalpel Bougie technique (plastic laryngeal model)|ScalpelBougie Set
56734|NCT03741049|Device|Seldinger technique (plastic laryngeal model)|Melker Set
56735|NCT03741049|Device|Surgical technique (plastic laryngeal model)|Scalpel and speculum
56736|NCT03741049|Device|Scalpel Bougie technique (porcine laryngeal model)|ScalpelCric Set
56737|NCT03741049|Device|Surgical technique (porcine laryngeal model)|Scalpel and speculum
56738|NCT03741036|Procedure|Autogenous bone graft as space filling in immidiate implant placment|"The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with autogenous bone graft)~Patients will be subjected to CBCT (diagnostic for upper arch).~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~The procedure will be carried out flapless.~In the study group: Atraumatic extraction~The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
56739|NCT03741036|Procedure|Deprotinized bovien as space filling in immidate implant placement|"The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with deprotinized bovien material)~Patients will be subjected to CBCT (diagnostic for upper arch).~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~The procedure will be carried out flapless.~In the study group: Atraumatic extraction~The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
56740|NCT03741036|Procedure|Nano-hydroxiapatite alloplast in immidiate implant placement|"The selected patients will be informed of the nature of the research work and informed consent will be obtained (immediate implant placement grafting with nano-hydroxiapatite alloplast material )~Patients will be subjected to CBCT (diagnostic for upper arch).~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~The procedure will be carried out flapless.~In the study group: Atraumatic extraction~The extraction socket will be evaluated for absence of any fenestration or granulation tissues"
56741|NCT03741023|Procedure|Blood draw (venipuncture or fingerstick)|Blood will be drawn from participants by venipuncture or by fingerstick.
56742|NCT03740997|Drug|Optison|Optison is administered intravenously
56743|NCT03740984|Other|Interventions are self controlled by the patient via a mp3 player and noise reduction headphones.|During premedication and during chemotherapy the patient is connected to a long term ECG recording and allowed to listen to the mp3 Player via noise reduction headphones.
56744|NCT03740971|Device|Remote Ischemic Conditioning treatment|Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.
56745|NCT03740971|Drug|Guideline-based therapy|Guideline-based therapy
56746|NCT03740958|Drug|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA
56747|NCT03740958|Drug|Argatroban|100 ug/kg bolus over 3 to 5 minutes was administered intravenously, followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%)
56748|NCT03740945|Drug|Placebo|Daily administration of one placebo vaginal ovule at bedtime
56749|NCT03740945|Drug|Prasterone (DHEA)|Daily administration of one prasterone vaginal ovule at bedtime
56750|NCT03740932|Diagnostic Test|Study group (group A)|"Maximal vertical mouth opening (MIO):~From sitting position, with the use of the calliper, the distance between the incisal edges along the midline of the upper and lower central incisors without pain was measured, by placing one end of the poley gauge against the incisal edge of one of the upper central incisors, and the other end against the incisal edge of the opposing lower incisor.~The distance recorded in millimetres, the subjects was instructed to open your mouth as wide as possible without causing pain or discomfort. The poley gauge was sterilized with antiseptic solution before and after each measure"
56751|NCT03740919|Drug|LY900014|Administered SC
56752|NCT03740919|Drug|Insulin Lispro|Administered SC
56753|NCT03740893|Drug|AZD6738|"PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle."
56754|NCT03740893|Drug|Olaparib|"PART 1: Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2: 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle."
56755|NCT03740893|Drug|Durvalumab|"PART 1: Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2: 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle."
56756|NCT03740880|Other|Dual trigger|dual trigger: 10.000 IU hCG i.m. and 0.3 mg Deca
56757|NCT03740867|Other|Pulmonary rehabilitation|Exercise program includes aerobic (walking band, bicycle, arm ergometer) and strengthening (with free weights) components.
56758|NCT03740854|Other|Pressure Controlled Ventilation|Patients will be ventilated with a pressure level which supplies a tidal volume corresponding 8ml/kg, 12 breaths per minute, 1/2 inspiration/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
56759|NCT03740854|Other|Volume Controlled Ventilation|Patients will be ventilated with a tidal volume which corresponds 8ml/kg, 12 breaths per minute, 1/2 inspirastion/expiration ratio and %40 Fraction of Inspired Oxygen . These ventilator settings can be changed in order to adjust end tidal carbon dioxide and oxygen saturation levels.
56760|NCT03740841|Behavioral|Interactive story teller LUNII|Use of the interactive story teller LUNII by the child from the pre-operative visit to the discharge.
56761|NCT03740828|Device|KIDScore D3|Embryos are scored using the KIDScore D3 algorithm based on annotated morphokinetic parameters.
56762|NCT03740815|Procedure|Serratus plane block|Ultrasound guided injection of local anesthetic between latissimus dorsi and serratus muscles at mid axillary line.
56763|NCT03740815|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises the axilla to identify, examine, or remove lymph nodes.
56764|NCT03740815|Procedure|Intravenous sedation|Administration of sedatives thru an intravenous access to achieve relaxion and improve operative conditions.
56765|NCT03740763|Device|Spinal Cord Stimulation (SCS)|SCS for treatment of neuropathic pain
56766|NCT03740763|Other|Physiotherapy|Physiotherapy 2 hours/week with physiotherapist and physical activity counseling for treatment of neuropathic pain
56767|NCT03740750|Device|Thermacare heat wraps|low level continuous heat wrap
56768|NCT03740750|Device|TENS|electrical stimulation
56769|NCT03740750|Device|sham heat|expended heat wrap
56770|NCT03740750|Device|sham Tens|tens applied but unit not turned on
56771|NCT03740737|Drug|Follitropin delta|Follitropin delta
56772|NCT03740737|Other|Placebo|Placebo
56773|NCT03740724|Genetic|FCX-013|FCX-013 is a genetically modified cell product obtained from the subject's own skin cells (autologous fibroblasts). The cells are expanded and genetically modified to express metalloproteinase-1 (MMP-1) under the control of a RheoSwitch (RTS®) system. FCX-013 cell suspension is injected intradermally.
56774|NCT03740724|Drug|veledimex|Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
56775|NCT03740711|Procedure|Left atrial venting|The contralateral femoral vein is assessed with an 7-French(Fr) sheath() and femoral artery is assessed with 5-Fr sheath( ) for fluoroscopic guidance using 5-Fr pig-tail catheter. In some cases trans-esophageal echo is used. The inter-atrial septum in punctured with a standard BRK™tran-septal needle(St. Jude Medical Inc., St. Paul, MN) under direct visualization via an 8-Fr Mullin sheath(St. Jude Medical Inc.). A SAFARI™(Boston Scientific, Galway, Ireland) guidewire is advanced into the LA. An 8-Fr Mullin-sheath is removed and atrial septostomy is performed using 21-Fr dilator. A 17-Fr or 21-Fr Biomedicus Percutaneous Femoral cannula(Medtronic Inc., Minneapolis, MN) is then placed in the LA and was attached to the ECMO circuit using a Y connector.
56776|NCT03740698|Device|BiAP|The bio-inspired artificial pancreas (BiAP) system uses a control algorithm based on a mathematical model of beta-cell behaviour derived from physiological experiments, carried out by other groups, which have demonstrated how the beta cells in the pancreas produce insulin in people without diabetes. Utilising the data from these experiments it has been possible to implement the behaviour of the beta cell in software and we have used a simulator with 200 virtual patients to demonstrate the safety and efficacy of the algorithm. The data from the simulator have previously been published. The BiAP algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas.
56777|NCT03740698|Device|ABC4D|The Advanced Bolus Calculator for Diabetes (ABC4D) is a novel, adaptive decision support algorithm based on case-based reasoning (CBR) providing real-time insulin advice through a smartphone application.
56778|NCT03740685|Diagnostic Test|High sesitive C reactive protien|High sesitive C reactive protien will be evaluated at admission time and after 36 hours
56779|NCT03740659|Drug|Levofloxacin + Dexamethasone|Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
56780|NCT03740659|Drug|Levofloxacin|Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
56781|NCT03740659|Drug|Dexamethasone|Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
56782|NCT03740633|Behavioral|passive ankle pump motions on the day of surgery|Passive ankle pump motions include flexion and extension, circumduction, which will be conducted by caregiver on the day of surgery.
56783|NCT03740633|Behavioral|active ankle pump motions and abdominal breathing training on the 1-3 day after the surgery|Active ankle pump motions include flexion and extension, circumduction, which will be conducted by patient on the 1-3 day after the surgery. On the same time, the patient is given abdominal breathing training.
56784|NCT03740633|Combination Product|Regular care|Regular post-operative care consists of compression stockings, anticoagulant and instructions of early mobilization
56785|NCT03740620|Procedure|Bevel facing the cephalad direction of the patient|The bevel of the nasotracheal tube facing cephalad direction of the patient
56786|NCT03740620|Procedure|Bevel facing leftward of the patient|The bevel of the nasotracheal tube facing the left side of the patient
56787|NCT03740607|Device|Virtual reality|Healthcare virtual reality software implemented during peripheral intravenous catheter placement
56788|NCT03740607|Procedure|Peripheral intravenous catheter placement|Peripheral intravenous catheters are placed in the peri-operative suites in preparation for anesthesia during surgery.
56789|NCT03740594|Behavioral|KMC|Neonates were subjected to either daily KMC for 60 minutes, daily KMC for 120 minutes or conventional care (controls) for at least 7 days.
56790|NCT03740581|Drug|Insulin|Basal Bolus regimen (Participant to receive, Insulin >= 3 times per day)
56791|NCT03740568|Drug|Low Progesterone|"Additional daily dosage of subcutaneous progesterone (Psc) 25 mg/day at night since D4 (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night) New Progesterone analysis on D5 before warming the embryo. Group 2a (Canceled Group, P on D5 <10.64 ng/mL): cancel PGT-FET. Scheduling a new procedure under different P supplementation.~Group 2b (Restored Progesterone Group, P on D5 >10.64 ng/mL): continue HRT as previously described (vaginal micronized P 200mg/200mg/200mg + Psc 25 mg/night). Warming and transfer the same day (D5)~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is >10.64 ng /mL: the same P supplementation is continued. If P is <10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
56865|NCT03739983|Device|Vaginal Renewal Program|Therapeutic vibrating wand.
56909|NCT03739632|Other|Placebo|Placebo tablets will be given orally, twice daily, for 6 weeks
56792|NCT03740568|Drug|Normal Progesterone|"Same Progesterone supplementation (vaginal micronized P 200mg/200mg/200mg) Warming and transfer on D5~Beta-hCG and P analysis is performed on the 14th day of P supplementation (D14). In case of positive Beta-hCG analysis:~If P is >10.64 ng /mL: the same P supplementation is continued. If P is <10.64 ng /mL: an additional dosage of vaginal micronized P (200 mg) is added at night"
56793|NCT03740555|Drug|HNC042 single dose|HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
56794|NCT03740555|Drug|Placebo single dose|Placebo single ascending doses , Intravenous route Single dose, matching placebo
56795|NCT03740555|Drug|HNC042 multiple ascending doses|HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg
56796|NCT03740555|Drug|Placebo multiple ascending doses|Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
56797|NCT03740542|Procedure|Esophagectomy|Surgical removal of part of esophagus
56798|NCT03740542|Procedure|Pyloroplasty|pyloric drainage procedure
56799|NCT03740529|Drug|LOXO-305|Oral LOXO-305
56800|NCT03740516|Drug|CC-10004|CC-10004 will be administered orally
56801|NCT03740490|Combination Product|Smart-T + NRT|Smart-Treatment App and Nicotine Replacement Therapy
56802|NCT03740490|Combination Product|QuitGuide + NRT|NCI QuitGuide Treatment App and Nicotine Replacement Therapy
56803|NCT03740477|Diagnostic Test|ECG|Eligible participants will receive a 30-second ECG recording during their visit at the Absentee Shawnee Tribal clinic
56804|NCT03740464|Drug|long-acting granulocyte colony stimulating factor|A 6 mg of polyethylene glycol granulocyte colony stimulating factor will be given to patients of study group
56805|NCT03740464|Drug|Short-term granulocyte colony stimulating factor|Short-term granulocyte colony stimulating factor will be given to all patients according to the severity of myelosuppression
56806|NCT03740451|Other|Active mobilization of soft tissues|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
56807|NCT03740451|Other|Passive mobilization|This study will compare the effects of joint passive mobilization with the effects of soft tissue active mobilization on heart rate variability (as an indicator of autonomous regulation), psychological well-being (measured by the Ryff scale) and pain in patients with fibromyalgia.
56808|NCT03740438|Diagnostic Test|Hemoglobin concentration|Perioperative hemogloin concentration
56809|NCT03740425|Procedure|Blood Transfusion|Blood Transfusion in patients who underwent transcatheter aortic valve implantation (TAVI)
56810|NCT03740412|Behavioral|Sedentary behaviour reduction using motivational interviewing, education, individualised feedback, goal-setting, self-monitoring, environmental modification, and supportive phone calls|The intervention has multiple components in order to reduce sedentary behaviour, namely: incorporating individualised feedback on sitting time, education about sedentary behaviour, individualised goal-setting and environmental modification according to each participant's own behavioural patterns and capabilities, motivational interviewing, and biweekly phone calls.
56811|NCT03740399|Procedure|spinal anesthesia|Investigators will perform spinal anesthesia for section
56812|NCT03740386|Drug|Phentolamine Mesylate 0.235 MG/ML [OraVerse]|compare effect of phentolamine mesylate in three arms
56813|NCT03740373|Drug|BGF MDI (budesonide, glycopyrronium and formoterol fumarate) with 10 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 10 s breath‐hold.
56814|NCT03740373|Drug|BGF MDI ((budesonide, glycopyrronium and formoterol fumarate) with 3 s breath hold|Participants will receive a single dose of BGF MDI; the dose will be administered with a 3 s breath‐hold.
56815|NCT03740347|Behavioral|Questionnaires|"Response to questionnaires evaluating chronic pain and its repercussion :~anxiety questionnaire (Revised Children's Manifest Anxiety Scale),~depression questionnaire (Children's Depression Inventory score),~sleepiness questionnaire (Pediatric Daytime Sleepiness Scale),~quality of life questionnaire (Pediatric Quality of Life inventory score)."
56816|NCT03740334|Drug|Ribociclib|Ribociclib, blocks a specific type of protein called a cyclin-dependent kinases (CDK)
56817|NCT03740334|Drug|Dexamethasone|Corticosteroids are commonly used to treat ALL.
56818|NCT03740334|Drug|Everolimus|Everolimus is an inhibitor of mTOR. mTOR inhibition blocks the translation of genes that regulate cancer cell proliferation
56819|NCT03740321|Device|Embolization with tri-acryl gelatin (Embosphere) particles|Left, right and posterior branches of superior rectal artery will be embolized with tri-acryl gelatin particles in 500-700 and 700-900 micrometers in size until homeostasis will be achieved.
56820|NCT03740308|Device|Locally Made Zirconia Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. Locally Made Zirconia Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
56821|NCT03740308|Device|ZR Zirconia Crwons NuSmile ® Crowns|Occlusal reduction by decreasing the occlusal surface to less than the natural occlusal profile by about 1-1.5 mm roughly. Proximal reduction by unfastening the interproximal contacts. The tooth should be trimmed down circumferentially by around 0.5-1.25 mm as needed. Subgingival reduction, leaving no undercuts or subgingival ridges, about 1-2 mm subgingivally on every area should be prepared. Completion of the preparation by eliminating sharp lines and pointed angles to allow all prepared areas to be marginally rounded and smoothed. ZR Zirconia Crwons NuSmile ® Crowns are fixed using Glass Ionomer cement (Fuji- Jaban).
56822|NCT03740295|Dietary Supplement|Coconut oil and epigallocatechin gallate|600 mg of epigallocatechin gallate (EGCG) and 60 ml of coconut oil (3600 mg of TGCM) per day, divided into two doses (one in the morning and one at noon)
56823|NCT03740295|Other|Placebo|Lactose
56824|NCT03740282|Device|Lapiplasty|Patients 14 years through 58 years with symptomatic hallux valgus who are treated with the Lapiplasty System will begin weight-bearing by 3 weeks and follow a defined post-operative protocol.
56825|NCT03740269|Other|oral health educational program|poster education about the important of oral health status, different brushing technique, different tooth paste, the balanced diet, changes occur to their mouth during the puberty period
56826|NCT03740256|Biological|CAdVEC|The administration of CAdVEC may create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred CAR AdVSTs via both CAR recognition of tumor antigen and TCR recognition of viral antigen. The CAR AdVSTs expanded at primary tumor sites may re-circulate and target metastasized tumors. The combination this study proposes to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cell/VST and testing each element separately would not be beneficial or informative.
56827|NCT03740243|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone tablet or film
56828|NCT03740243|Drug|Buprenorphine|Buprenorphine tablet
56829|NCT03740217|Drug|GKT137831|oral bioavailable small molecule that selectively inhibit NOX1 and NOX4
56830|NCT03740204|Drug|17-β estradiol transdermal patches with cyclic progesterone|17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
56831|NCT03740204|Drug|Placebo patch and pill|Placebo patch and pill
56832|NCT03740191|Other|EPIC questionnaire|The EPIC questionnaire is used to evaluated the Quality of life of the patients including the sexual function.
56833|NCT03740191|Radiation|kV x-ray images|After the applied daily fraction, x-ray imaging will be repeated daily to assess for intra-fraction motion of the prostate.
56834|NCT03740191|Radiation|Conebeam CT|For the assessment of interfraction target and organs at risk movement. Conebeam CT as soon as it becomes available will be performed 5 x/week or at each day of proton therapy before treatment application.
56835|NCT03740178|Drug|MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive MK-4334 capsules administered orally, QD on Days 1-14. Participants will receive an initial loading dose of 120 mg (Day 1), followed by a maintenance dose of 60 mg (Days 2-14). Open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
56836|NCT03740178|Drug|Placebo to MK-4334|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD)will receive placebo capsules matching MK-4334 administered orally, QD on Days 1-14. Participants will also receive open-label donepezil tablets (dose strength: 10 mg) administered orally, QD on Days 1-14.
56837|NCT03740178|Drug|Donepepzil|Participants with Alzheimer's clinical syndrome (MCI or mild/moderate AD) will receive open-label, oral donepezil 10 mg QD on Days 1-14.
56838|NCT03740165|Biological|Pembrolizumab|IV infusion
56839|NCT03740165|Drug|Placebo for pembrolizumab|IV infusion
56840|NCT03740165|Drug|Carboplatin|IV infusion
56841|NCT03740165|Drug|Paclitaxel|IV infusion
56842|NCT03740165|Drug|Olaparib|Oral tablet
56843|NCT03740165|Drug|Placebo for olaparib|Oral tablet
56844|NCT03740165|Biological|Bevacizumab|IV infusion
56845|NCT03740152|Device|Transcranial Light Therapy|Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)
56846|NCT03740139|Other|The Police-Mental Health Linkage System|When, during an encounter, the police officer decides to call the number provided in the notice, the Linkage Specialist (a licensed mental health provider from the mental health service where the subject was recruited, who has access to the clinic's EMR) can provide telephonic support to the officer.
56847|NCT03740126|Diagnostic Test|Whole body 18F-FDG PET/CT|In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.
56848|NCT03740113|Behavioral|Kids SipSmartER|Kids SIPsmartER is grounded by the Theory of Planned Behavior as well as health literacy, media literacy, numeracy, and public health literacy concepts
56849|NCT03740100|Drug|Bimiralisib|Bimiralisib capsules
56850|NCT03740087|Other|Omnivorous diet|Determine if the transfer of bovine miRNAs is carried out after a meal containing beef.
56851|NCT03740087|Other|Vegan diet|Used as a baseline for miRNA levels in blood
56852|NCT03740074|Behavioral|PAI|"Consenting subjects will be given a Mio Slice, along with instructions on how to utilize the device.~They will register on line with PAI Health, and will be asked to sync their device at least once every 7 days. They will be encouraged to look at the device app on their smart phone at least once daily.~After 1 week of obtaining baseline data, subjects will be encouraged to try to obtain a PAI score of at least 30 initially. Once they obtain a score of 30 consistently, they will be encouraged to increase the score toward 50. If they consistently obtain 50, they can increase their goal sequentially toward a maximum goal of 100. The duration of the study will be 12 weeks."
56853|NCT03740061|Diagnostic Test|Ultrasonographic assessment of muscle|Ultrasonographic assessment of quadriceps muscle
56854|NCT03740048|Other|Hemodialysis|Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.
56855|NCT03740048|Drug|Patiromer Oral Product|Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.
56856|NCT03740035|Behavioral|eHealth for Sedentary Behavior|Prostate cancer patients will be testing the usability and acceptability of the eHealth web app for sedentary behavior
56857|NCT03740022|Procedure|ACL plasty|standard ligamentoplasty by Kenneth Jones
56858|NCT03740022|Procedure|ACL + ALL plasty|standard ligamentoplasty and anterolateral plasty
56859|NCT03740009|Drug|Bazedoxifene/Conjugated Estrogen|20 mg bazedoxifene/0.45mg conjugated estrogens tablets
56860|NCT03739996|Drug|Oral Cabotegravir (CAB)|30 mg tablets administered orally
56861|NCT03739996|Drug|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|NRTIs will not be provided by the study. Participants will obtain NRTIs outside of the study through routine care.
56862|NCT03739996|Drug|Long-Acting Injectable Cabotegravir (CAB LA)|600 mg loading dose followed by 400 mg maintenance doses administered by intramuscular (IM) injection
56863|NCT03739996|Biological|VRC07-523LS|40 mg/kg administered as an intravenous (IV) infusion
56864|NCT03739996|Drug|Standard of Care (SOC) Oral ART|SOC ART will not be provided by the study. Participants will obtain SOC ART outside of the study through routine care.
56866|NCT03739970|Dietary Supplement|Investigational Product (Silk Peptide)|"Ingredient: Silk Peptide~Type: Yellow granule stick~Storage: Room temperature~Weight: Silk Peptide 9g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
56867|NCT03739970|Dietary Supplement|Control Group - Placebo Product|"Ingredient: Microcrystalline Cellulose~Type: Yellow granule stick~Storage: Room temperature~Weight: Silk Peptide 0g/day~Directions: with water before breakfast and dinner, 9g/day (4.5g×2times/day)~Duration of use: 8 weeks"
56868|NCT03739957|Device|BPCO Media Kit|Telemonitoring system for patients with COPD
56869|NCT03739944|Procedure|Laparotomic radical hysterectomy|Laparotomic radical hysterectomy for patients without fertility requirement
56870|NCT03739944|Procedure|Laparotomic radical trachelectomy|Laparotomic radical hysterectomy for patients with fertility requirement
56871|NCT03739944|Procedure|Laparoscopic radical hysterectomy|Laparoscopic radical hysterectomy for patients without fertility requirement
56872|NCT03739944|Procedure|Laparoscopic radical trachelectomy|Laparoscopic radical hysterectomy for patients with fertility requirement
56873|NCT03739931|Biological|mRNA-2752|mRNA-2752 dose escalation and expansion
56874|NCT03739931|Biological|mRNA-2752 + durvalumab|mRNA-2752 + durvalumab dose escalation and expansion
56875|NCT03739905|Device|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
56876|NCT03739892|Behavioral|standard stroke rehabilitation|standard rehabilitation according to the french standard care and to the severity of the patient
56877|NCT03739879|Device|Inspiratory Muscle Trainer Philips Respironics|Subjects exercised using inspiratory muscle trainer (Philips Respironic®) for 8 weeks. Training dose with IMT was determined by inspiratory muscle strength result and adjusted in every evaluation visit. The subject was expected to do exercise twice daily for 15 minutes each session with 30-70% intensity from determined MIP score. Exercise is monitored and noted in a logbook.
56882|NCT03739853|Drug|Methotrexate|Used in all three arms of study
56883|NCT03739853|Drug|Sulfasalazine|Used in arm 2 of study
56884|NCT03739853|Drug|Leflunomide|Used in arm 2 of study
56885|NCT03739853|Drug|Adalimumab|Used in arm 3 of the study only
56886|NCT03739840|Drug|Padsevonil|Padsevonil in different dosages.
56887|NCT03739840|Drug|Placebo|Placebo will be provided matching padsevonil.
56888|NCT03739814|Biological|Blinatumomab|Given IV
56889|NCT03739814|Biological|Inotuzumab Ozogamicin|Given IV
56890|NCT03739801|Drug|Liposomal Irinotecan|Given IV
56891|NCT03739801|Other|Quality-of-Life Assessment|Ancillary studies
56892|NCT03739801|Other|Questionnaire Administration|Ancillary studies
56893|NCT03739801|Biological|Ramucirumab|Given IV
56894|NCT03739788|Drug|BMS-986165|Oral administration of tablet and 15-minute intravenous BMS-986165 solution for infusion
56895|NCT03739775|Procedure|Blood sampling|Patients will have a blood draw at each visit to the hospital and at least 6 months (+/- 1 month) intervals.
56896|NCT03739762|Behavioral|i-STAND|Via in-person and phone coaching sessions, participants randomized to this arm will be coached to find ways to sit less and stand more, and look for ways to change their home environment to encourage this, as well as look at how their lifestyle may contribute to their sitting time. Participants in this arm may be re-randomized at the half-way point to continue with additional phone coaching sessions.
56897|NCT03739762|Other|Healthy Living control|In this arm, participants will have phone coaching sessions focused on a variety of topics aimed at improving healthy habits. There is no focus on standing more or sitting less.
56898|NCT03739749|Procedure|Arthroscopic superior capsular reconstruction|The superior capsule of patients with irreparable rotator cuff tears will be reconstructed using an autograft or an allograft
56899|NCT03739736|Other|Combination of TB/HIV prevention activities|The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)
56900|NCT03739723|Other|Resource allocation to improve general surgery residency program culture|If a hospital/program is assigned to the intervention arm, they will receive numerous resources including a program-specific cultural outcomes report, a surgical culture toolkit, coaching calls, and in-person meetings to help improve their general surgery residency program culture.
56901|NCT03739710|Drug|Docetaxel|Docetaxel will be administered as an intravenous (IV) infusion at a dose of 75 milligram per meter squared (mg/m^2) once every three weeks.
56902|NCT03739710|Drug|GSK3359609 (ICOS Agonist)|GSK3359609 will be administered as an IV infusion at a dose of 80 mg once every 3 weeks.
56903|NCT03739697|Other|spontaneous breathing|spontaneous breathing during induction of anesthesia in infants
56904|NCT03739684|Drug|18F-DCFPyL|A single dose of 9 mCi (333 MBq) IV injection of 18F-DCFPyL
56905|NCT03739671|Drug|Vitamin D|Group will receive 5000 units of vitamin D daily
56906|NCT03739658|Other|Education|Cognitive-Based Neuromuscular Training has the content of focusing on different tasks at the same time and coordinating on neuromuscular functions as well as football-specific movements. Game-Based Training (OTE), which includes football, tennis, bowling, shooting, racing and climbing games, consists of active video games of game consoles, which are frequently used among young people.
56907|NCT03739645|Behavioral|conditioned fear|Subjects will be involved in a protocol producing fear conditioning protocol with colored lights as conditioned stimuli and laser pulses (duration 1`ms visual analog scale of pain 5/10) as the US and rating scales and questionnaires are administered. Networks will be defined parts of the brain which are activated (ERSP) and interact with each other as measured by event related causality (ERC).
56908|NCT03739632|Drug|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets will be given orally, twice daily, for 6 weeks
56910|NCT03739619|Drug|Bendamustine|Given IV
56913|NCT03739606|Biological|Anti-CD123/CD3 Monoclonal Antibody MGD006|Given IV
56914|NCT03739593|Drug|AR-1105-CF1|AR-1105 clinical formulation 1 (AR-1105-CF1)
56915|NCT03739593|Drug|AR-1105-CF2|AR-1105 clinical formulation 2 (AR-1105-CF2)
56916|NCT03739580|Device|DCB angioplasty (Orchid, Acotec Scientific Co. Ltd.)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
56917|NCT03739580|Device|Stent (Maris,Medtronic.USA or Sinus/Supera, Germany)|for popliteal stenosis/occlusive lesions, randomised received DCB or Stent deployment.
56918|NCT03739554|Drug|CYC065|intravenous infusion
56919|NCT03739554|Drug|Venetoclax|oral capsule
56920|NCT03739541|Drug|[14C]-Benznidazole|A single dose level of 100 mg; 200 μCi (7.4 MBq)
56921|NCT03739528|Drug|Levofloxacin + dexamethasone followed by dexamethasone|Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
56922|NCT03739528|Drug|Tobramycin + Dexamethasone|Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
56923|NCT03739515|Other|HSCP intervention|A team of HSCPs (physiotherapist, occupational therapist, medical social worker) will provide comprehensive functional assessment to older patients
56924|NCT03739515|Other|ED routine care|ED staff including consultants and nurses will provide patients with routine ED medical care.
56925|NCT03739502|Drug|Hyperbaric oxygen|"The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).~However, UCB as a graft source for a bone marrow transplant has drawbacks related to the limited cell dose available for transplant and defects in homing. Homing is the process of UCB stem cell lodging in the bone marrow. If the homing is not efficient it could delay the re-population of the stem cells (or engraftment), possibly lead to engraftment failure, and delay the rebuilding of the immune system after transplant. This could, in turn, provide a higher risk to infection after the UCB transplant."
56926|NCT03739489|Procedure|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation was a technique able to modulate the brain circuit restoring the function.
56927|NCT03739476|Drug|Quetiapine 25 milligrams capsule|Compare the incidence of postoperator delirium.
56928|NCT03739476|Drug|Placebo oral capsule|Compare the incidence of postoperator delirium.
56929|NCT03739463|Dietary Supplement|MAG-DHA|375 MG of MAG-DHA per capsules, two capsules BID
56930|NCT03739463|Dietary Supplement|Oleic acid|375 MG of sunflower oil (oleic acid) per capsules, two capsules BID
56931|NCT03739450|Behavioral|Problem Solving Training (PST)|The PST intervention consists of six sessions that will follow a structured format based on the PST manual. In these sessions, the interventionist will first provide the TBI-specific education, introduce the participant to the PST steps, then help the care partner generate and select a problem to address first. Interventionist will facilitate the care partner's use of the ABCDEF steps of PST to develop a specific action plan to solve the problem. As problems are attempted or solved, the care partner will learn how to perform the steps on his/her own, thus acquiring self-management problem solving skills that will be applicable to future problems. The final session will include a review and generalization of the PST steps and progress made.
56932|NCT03739450|Behavioral|Education|Participants will receive TBI-specific education alone through a workbook. It consists of educational modules for self-study, common sequelae of TBI, issues encountered by care partners, work and school concerns for those with TBI, and on navigating the rehab system and accessing resources. The modules consist of a brief introduction, key definitions, examples, resources, and a summary. Some chapters also include self-directed activities, such as worksheets or checklists. The investigators will provide a brief orientation to the workbook and include open-ended questions about the participants' need for clarification or questions of the education material. The last session will consist of an open discussion about expected problems that may arise post-discharge.
56933|NCT03739437|Behavioral|Mobile Contingency Management|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
56934|NCT03739437|Behavioral|Standard Care|Participants will be offered six tobacco cessation telephone counseling sessions, 12 weeks of nicotine replacement therapy, and incentives that are not contingent on smoking abstinence (incentives are yoked to participants in the contingency management group).
56935|NCT03739424|Other|Whole egg powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
56936|NCT03739424|Other|Whole milk powder|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
56937|NCT03739424|Other|Gelatin food product|Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
56938|NCT03739411|Radiation|Hyperpolarized Carbon C 13 Pyruvate|Given IV
56939|NCT03739411|Procedure|Magnetic Resonance Imaging|Undergo MRI
56940|NCT03739411|Radiation|Radiation Therapy|Undergo radiation therapy
56941|NCT03739411|Drug|Temozolomide|
56997|NCT03738930|Behavioral|AI based mHealth system|AI based mHealth system is used to deliver self-management contral message and health education message to make patients take notice of bleeding events after PCI.
57075|NCT03738397|Drug|Upadacitinib (ABT-494)|Upadacitinib is administered orally
56942|NCT03739398|Device|LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR))|1. LUTRONIC GENUS laser(Fractional Microneedle Radiofrequency(FMR)) : Fractional Microneedle Radiofrequency (FMR) equipment is a device that penetrates the epidermis and irradiates the high frequency by entering the dermis. The generated radiofrequency transfers heat energy and induces thermal denaturation in the surrounding tissue. Using this principle, FMR equipment is being used as a very effective treatment for scarring, enlarged pores, hyperhidrosis as well as wrinkles. Unlike conventional treatments, FMR equipment has the advantage of a short recovery time after treatment because it minimizes damage to the epidermis because the insulated microspheres penetrate the skin and generate high frequency only at the end of the microspheres.
56943|NCT03739398|Device|LASEMED laser(The Thulium laser with 1,927nm wavelength)|"2. LASEMD laser(The Thulium laser with 1,927nm wavelength) The Thulium laser with 1,927nm wavelength is a device that effectively removes various skin diseases present in the epidermis while minimizing the side effects such as scarring and pigmentation because it induces thermal damage to the only skin surface compared to conventional laser equipment. In recent years, not only skin lesions on the epidermis but also pigment disease and wrinkles have been reported to have a good effect.~In this study, we investigated the effect and stability of combined treatment of Thulium laser with 1,927nm wavelength in addition to FMR equipment which has already proven to be effective in improving skin aging."
56944|NCT03739385|Other|Exercise Intervention|The training interventions of all three groups (intergenerational group, peer group seniors, peer group children) will occur under professional supervision twice a week lasting over a 25-week period with training sessions lasting 45 minutes each. Control groups (control group seniors, control group children) receive no intervention.
56945|NCT03739372|Other|Specialized tumor board recommendation|Based on the molecular profile, the specialized tumor board will determine an individualized treatment recommendation for each patient using up to four FDA approved drugs. In special circumstances, Investigational new drug (IND) study agents may be used.
56946|NCT03739359|Other|nasal cannula gas flow|High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.
56947|NCT03739346|Behavioral|Hypnosis|Therapeutic technique in which clinicians make suggestions to individuals who have undergone a procedure designed to relax them and focus their minds.
56948|NCT03739346|Behavioral|Tell, show, do technique|The technique involves verbal explanations of procedures in phrases appropriate to the developmental level of the patient (tell); demonstrations for the patient of the visual, auditory, olfactory, and tactile aspects of the procedure in a carefully defined, nonthreatening setting (show); and then, without deviating from the explanation and demonstration, completion of the procedure (do). Tell-show-do technique is used with communication skills (verbal and nonverbal) and positive reinforcement.
56949|NCT03739333|Other|11C-Methionine PET-MRI|Implementation 11C-Methionine PET-MRI performed for each patient in one place (department of nuclear medicine of Hospices Civils de Lyon). The 11C-Methionine PET-MRI will be performed after radiochemotherapy in patients with MRI suspicious of pseudoprogression.
56950|NCT03739320|Drug|Mepolizumab 100 MG Injection [Nucala]|100 milligrams subcutaneously once every 4 weeks
56951|NCT03739294|Drug|Fluticasone Furoate/ Vilanterol Trifenatate|Asthma inhalation medication
56952|NCT03739281|Diagnostic Test|PET/MR|The included patients are imaged with PET/MR as part of the research protocol.
56953|NCT03739281|Diagnostic Test|PET/CT|The included patients are imaged with PET/CT as part of normal clinical routine.
56954|NCT03739268|Drug|Sevelamer|Sevelamer powder dissolved in water 1,600 mg three times a day for 17 days
56955|NCT03739268|Drug|Placebo|placebo powder dissolved in water 1,600 mg three times a day for 17 days
56956|NCT03739255|Device|Cacicol20|Cacicol20 is supplied as a sterile single-dose solution of alpha 1-6 poly-carboxymethyl glucose sulfate One drop is instilled at each application to impregnate cornea.
56957|NCT03739255|Device|Placebo|Ocluac is artificial tear which contains Hydroxypropylmethyl Cellulose and Sodium Chloride, It is presented in a 0.4 mL vial. One drop is delivered at each application.
56958|NCT03739242|Dietary Supplement|Nutraceutical combination|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
56959|NCT03739242|Other|Placebo|One tablet per os per day to be taken in the evening from randomization (day 0) to the end of the trial (day 56 +/- 3)
56960|NCT03739229|Biological|Placebo|2 intranasal administrations of lyophilized purified allantoic fluid of chicken embryos with stabilizers
56961|NCT03739229|Biological|H7N9 LAIV|2 intranasal administrations of H7N9 live influenza vaccine
56962|NCT03739216|Device|ClariFix|The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.
56963|NCT03739203|Drug|Cariprazine|Cariprazine supplied in capsules
56964|NCT03739203|Drug|Placebo|Placebo supplied in capsules
56965|NCT03739190|Device|NRL Condom|A minimum of 5 condoms (maximum 7 condoms) of each condom type will be provided to Subjects to be used during vaginal intercourse over a 4 week period, the assessment period. Couples will repeat the assessment period each of the 3 condom types.
56966|NCT03739177|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
56998|NCT03738917|Drug|Dextromethorphan 15 milligrams|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
56999|NCT03738917|Drug|Ipratropium Bromide 20Micrograms Inhaler|This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
57000|NCT03738917|Dietary Supplement|Honey 30 g (full tablespoon)|This study product will be provided free to the participants by the sponsor.
57076|NCT03738397|Drug|Dupilumab|Dupilumab is administered as a subcutaneous (SC) injection
56967|NCT03739151|Behavioral|Behavioral Obesity Treatment|"Self-monitoring. Participants will be taught to record their weight, the calories of each food item, and physical activity using a method of their choice (e.g., commercial smartphone app, paper diary). The clinician will review dietary intake and provide personalized feedback at the outset of session.~Diet. Per national guidelines for weight loss, a daily goal of 1200-1800 kcal/day will be prescribed depending on baseline weight. A Mediterranean diet will be prescribed to meet the recommended calorie goal and be consistent with dietary recommendations for CVD patients.~Exercise. Participants will be encouraged to achieve 250 minutes/week of moderate intensity activity in accordance with current national recommendations for physical activity among individuals attempting weight loss. Participants will be encouraged to gradually increase activity level to achieve approximately 50 minutes of activity over five days per week."
56968|NCT03739138|Biological|MK-4621/JetPEI™|"For Arm 1: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle.~For Arm 2: administered intratumorally Q1W, on Days 1, 8, and 15 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data.~For Arm 3: administered intratumorally Q3W, on Day 1 of each 21-day cycle. Range administered will depend upon allocation and be based on emerging safety data."
56969|NCT03739138|Biological|Pembrolizumab|200 mg administered intravenously (IV) on Day 1 of each 21-day cycle beginning with Cycle 1 (Arm 2) or Cycle 2 (Arm 3).
56970|NCT03739125|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
56971|NCT03739125|Drug|Placebo|orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
56972|NCT03739112|Biological|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
56973|NCT03739112|Biological|Quadrivalent Comparator Vaccine|Single dose of a 15 ug/strain of Quadrivalent Comparator Vaccine
56974|NCT03739099|Device|Closed-loop insulin infusion driven by continuous glucose monitoring through an algorithm, in free-life conditions|Continuous subcutaneous insulin infusion according to an automated algorithm from continuous glucose monitoring data
56975|NCT03739086|Procedure|erector spinae plane block|unilateral or bilateral or bilevel erector spinae plane block performance for postoperative pain or acute pain
56976|NCT03739073|Other|OCTA (angiography by tomography in optical coherence)|The study concerns patients with intermediate stenosis of the left anterior descending artery (LDA). A fundus oculi and an OCTA (angiography by tomography in optical coherence) examination will be performed; it's a non-invasive imaging test. OCT uses light waves to take cross-section pictures of your retina and then ophthalmological examination data will correlate with coronary angiography.
56977|NCT03739060|Device|Transcutaneous electric nerve stimulation|Conventional transcutaneous electric nerve stimulation
56978|NCT03739047|Behavioral|Desensitization with flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by desensitization. Desensitization will be conducted for 3, 45-minute treatment meals. Puree will be presented on a flipped EZ spoon after the desensitization sessions are completed. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
56979|NCT03739047|Behavioral|flipped spoon|Both groups will begin with a baseline phase: escape extinction (non-removal of an upright small maroon spoon) plus continuous access to reinforcement. The baseline phase will take place for 3, 5-bite sessions or until the data become stable. The baseline phase will be followed by puree being presented from a flipped EZ spoon. Bite size will be gradually increased. Acceptance of an upright EZ spoon and eventually an upright maroon spoon will be probed based on stability of the data.
56980|NCT03739034|Behavioral|Lifestyle Medicine|Treatment modalities consist of encouraging a plant based, whole food diet, physical activity, stress management, healthy sleep, control of unhealthy habits.
56981|NCT03739021|Drug|Exparel|Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
56982|NCT03739021|Drug|Ropivacaine|Continuous infusion of Ropivacaine via catheter, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
56983|NCT03738995|Biological|Red cell or whole blood transfusion during pregnancy and up to 6 weeks postpartum|Administration of red cell or whole blood transfusion to parturients during pregnancy and up to 6 weeks postpartum
56984|NCT03738982|Device|PEPPER|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
56985|NCT03738969|Procedure|Laparotomic radical hysterectomy|Radical hysterectomy applied by laparotomy
56986|NCT03738969|Procedure|Laparoscopic radical hysterectomy|Radical hysterectomy applied by laparoscopic
56987|NCT03738956|Drug|Tofacitinib|"The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment."
56988|NCT03738943|Drug|Adenosine Triphosphate|See arm/group descriptions
56989|NCT03738943|Drug|Acetylcholine|See arm/group descriptions
56990|NCT03738943|Drug|Sodium Nitroprusside|See arm/group descriptions
56991|NCT03738943|Drug|Adenosine Diphosphate|See arm/group descriptions
56992|NCT03738943|Drug|Adenosine Monophosphate|See arm/group descriptions
56993|NCT03738943|Drug|Uridine Triphosphate|See arm/group descriptions
56994|NCT03738943|Drug|Adenosine|See arm/group descriptions
56995|NCT03738943|Drug|Vitamin B 6|See arm/group descriptions
56996|NCT03738943|Drug|Pyridoxal 5'-Phosphate|See arm/group descriptions
57073|NCT03738410|Behavioral|Mobile Health Messaging application|Mobile messaging sent to participants over a 12-month period.
57001|NCT03738917|Other|Usual clinical practice|Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
57002|NCT03738904|Combination Product|ERAS|Gabapentin Acetaminophen Ketoroloac IV (intraop) and PO Dexamethasone (included with benzocaine in local anesthesia) Oxycodone PO Polyethylene glycol
57003|NCT03738904|Combination Product|Standard of care|Oxcodone PO Ketorolac IV only (intraop)
57004|NCT03738891|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
57005|NCT03738878|Drug|Valsartan|oral valsartan
57006|NCT03738878|Drug|LCZ696|oral LCZ696
57007|NCT03738878|Drug|Bradykinin|Intra-arterial bradykinin at three graded doses
57008|NCT03738878|Drug|Substance P|Intra-arterial substance P at three graded doses
57009|NCT03738878|Drug|BNP|Intra-arterial BNP at three graded doses
57010|NCT03738878|Drug|Sitagliptin|oral sitagliptin
57011|NCT03738865|Drug|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
57012|NCT03738865|Drug|Novo Glucagon|1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
57013|NCT03738852|Device|insulin pump closed loop|MiniMed 670G Insulin Pump in Closed Loop/Auto Mode
57014|NCT03738852|Drug|Insulin|standard insulin regimen
57015|NCT03738839|Device|Quantitative Light-Induced Fluorescence|White spot lesion on the tooth surfaces detected with Quantitative Light-Induced Fluorescence Orthodontic Bonding.
57016|NCT03738839|Procedure|Direct bonding|The patients in the direct bonding group received a bonding procedure with a conventional composite adhesive.
57017|NCT03738839|Procedure|Indirect bonding|For the patients in the indirect bonding group, bonding was performed with a flowable composite adhesive.
57018|NCT03738826|Behavioral|Behavioral Intervention|The intervention will be developed based on quantitative and qualitative data that is currently being collected. After data collection and analysis, an intervention will be designed with input from stake holders including lupus clinic providers, staff, and patients.
57019|NCT03738813|Device|Gloreha Aria|Device offers specific programs that help patients to move arm, wrist and fingers
57020|NCT03738813|Other|Usual care|Conventional occupational therapy
57021|NCT03738800|Drug|CD5789 Cream 200 µg/g|A fixed dose (determined at Visit 1) of 200 µg/g applied topically twice weekly to up to 90% BSA
57022|NCT03738800|Drug|CD5789 Cream 100 µg/g|A fixed dose (determined at Visit 1) of 100 µg/g applied topically twice weekly to up to 90% BSA
57023|NCT03738800|Drug|CD5789 Cream Vehicle|A fixed dose (determined at Visit 1) applied topically twice weekly, up to 36 g per dose up to 90% BSA
57024|NCT03738787|Procedure|Pancreatic duct occlusion with Neoprene|Pancreatic duct occlusion of the pancreatic stump with Neoprene-based glue after Pancreatoduodenectomy.
57025|NCT03738787|Procedure|Pancreato-Jejunal anastomosis|Standardized pancreato-jejunal anastomosis after Pancreatoduodenectomy
57026|NCT03738761|Drug|Amlessa®|Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.
57027|NCT03738761|Drug|Co-Amlessa®|Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
57028|NCT03738748|Other|Ultrasound- guided Percutaneous Neuromulation|The experimental group will be treated with percutaneous neuromodulation using a needle with Physio Invasive® device, in its modality of percutaneous electrostimulation for 15 minutes, and guided by ultrasound equipment in the multifidus muscles of L-3, once a week for 4 weeks.
57029|NCT03738748|Other|TENS Therapy|The control group will apply a transcutaneous treatment with surface electrodes with TENS current at 170 Hz for 15 minutes in the L-3 region, once a week for 4 weeks.
57030|NCT03738735|Drug|Hypertonic saline|For the intervention group, the surgical staff will add 120 mL of 23.4% saline to the 3L bags of lactated Ringer's solution, and this new solution will be used for arthroscopic irrigation purposes throughout the rotator cuff repair surgery.
57031|NCT03738722|Drug|Oxygen|HFNCT (high flow nasal cannula therapy) will be provided using OptiFlow by Fisher&Paykel.
57032|NCT03738709|Behavioral|Falls prevention and education giving a demonstration of the usage of technical assistance.|"Ecological trail to work on balance and walking.~Technical assistance presentation and try-outs within the therapeutic apartment.~Discussion on the perceived feelings over the exercises and the technical assistance submitted.~Falls Education and prevention, screening of the dangerous activities and education on the safe behaviours."
57033|NCT03738696|Drug|Exparel|A long-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
57034|NCT03738696|Drug|Ropivacaine|A short-acting injectable sodium channel blocker bound to lipid that is indicated in controlling postoperative pain
57035|NCT03738683|Drug|Piperacillin/tazobactam|Dose according to summary of product characteristics (SPC) or local protocols
57036|NCT03738670|Procedure|Percutaneous RFA|Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
57037|NCT03738657|Other|Olfactory screening|Therefore prior to gustatory testing, patients will be screened and assessed as having either normal or abnormal olfactory function using the Sniffin' Sticks (Burghart; Wedel, Germany). The test consists of 12 odour pens which represent every-day odours (peppermint, fish, coffee, banana, orange, rose, lemon, pineapple, cinnamon, cloves, leather and liquorice). Patients are presented with an odour and select the perceived smell using a multiple-forced-choice method.
57038|NCT03738657|Other|Quantative Gustatory Testing using Taste Strips|"Following screening for olfactory function, whole mouth gustatory function will be assessed using validated taste strips (Burghart; Wedel, Germany). Filter paper test strips are impregnated at one end with 2cm2 of either sweet, sour, salty or bitter taste solutions in four concentrations. In a pseudo-randomised sequence, individual strips will be placed on the tongue and patients will be asked to close their mouth in order to assess whole mouth function. Through a forced-choice procedure patients will be asked to identify the taste stimuli. Scores for individual taste qualities will range from 0-4 and an overall taste score will range from 0-16.~Patients will rinse their mouth with tap water prior the application of each taste strip."
57074|NCT03738410|Other|Standard of Care Treatment|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat HIV/AIDS. SOC associated procedures and policies may vary across clinical settings.
57039|NCT03738644|Other|Monitoring with near-infrared spectroscopy|"No interventions are used. Stroke patients are examined with near-infrared spectroscopy (NIRS). NIRS examinations are done with Octamon system (Artinis Medical Systems, Elst, The Netherlands) consisting of 8 transmitters emitting infrared light of 760 and 850 nm and 2 receivers measuring oxygenated and deoxygenated hemoglobin in the frontal cortex.~Examination protocol can be found in detailed description."
57040|NCT03738618|Drug|Follitropin delta|Follitropin delta
57041|NCT03738618|Drug|Placebo|Placebo
57042|NCT03738605|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
57043|NCT03738592|Other|behavioral exploration of spatial hearing performances|"Normal hearing children and cochlear implant children will have to localize a sound source in three dimensional space by using a virtual reality system (Neuro immersion platform). The experiment will last thirty minutes.~For normal hearing children, this experience will be performed at the inclusion visit.~For cochlear implant children, this experience will be performed 28 days (+/- 2 days) after inclusion."
57044|NCT03738592|Other|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for cochlear implant children and their parents)|"For cochlear implant children and their parents, a SSQ questionnaire will be given and completed during the first visit (at the inclusion).~This questionnaire offers a version for parents of children with hearing loss (SSQ Parents CI) and a version for the children themselves (SSQ Children CI)."
57045|NCT03738592|Other|The Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire (for parents of CI children)|"The SSQ questionnaire for Parents of CI children is composed of three distinct sections (A, B and C).~Each section will be filled separately by parents of CI children with one of the study collaborators during 3 telephone calls spaced 1 week apart. Thus, section A will be completed 7 days (+/- 2 days) after inclusion , section B 14 days (+/- 2 days) after inclusion, and section C 21 days (+/- 2 days) after inclusion."
57046|NCT03738579|Device|Next Science Group|TorrentX Wound Wash will be used for irrigation and then BlastX Wound Gel will be applied to the wound after debridement/irrigation during in-clinic visits. BlastX Wound Gel will be re-applied again during mid-week dressing change. Dressing used will be plain foam dressing from control group arm.
57047|NCT03738579|Device|Control Group|Foam Dressing will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
57048|NCT03738579|Device|Antibacterial Control Group|Foam Dressing AG will be used in conjunction with standard of care for chronic wound management, such as debridement and irrigation.
57049|NCT03738566|Device|Esophageal self dilation|Esophageal self dilation therapy (ESDT), where the patient learns to pass a polyvinyl dilator orally on a routine basis teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation twice a day. If dysphagia is adequately controlled, and there was no resistance with passing the dilator, patients will be asked to decrease the frequency of ESDT to daily, weekly, and monthly over an average period of 6 months as directed by the esophageal care team.
57050|NCT03738566|Procedure|Upper Endoscopy with Dilation|Patients will undergo repeat endoscopy and dilation as needed if their dysphagia relapse which is the current standard of care.
57051|NCT03738553|Device|MRI|Diffusion Weighted Imaging and Dynamic Contrast enhanced MRI
57052|NCT03738553|Drug|Trastuzumab|Single dose of Trastuzumab prior to surgery
57053|NCT03738540|Behavioral|TALK study group|Telephone Delivered Intervention
57054|NCT03738540|Behavioral|TALK control group|Telephone Delivered Intervention
57055|NCT03738527|Drug|Tranexamic Acid 100Mg/Ml Inj Vil 10Ml|Two 10 mL syringes each with 1g TXA (100mg/mL injection solution) to be applied topically to the mastectomy cavity (total 2g TXA)
57056|NCT03738527|Drug|Normal saline|Two 10 mL syringes containing 10 mL of normal saline to be applied topically to the mastectomy cavity (total 20 mL NS) for 5 minutes before wound closure
57057|NCT03738514|Other|5% fluorocalcium phosphosilicate dentifrice|dentifrice containing 5% fluorocalcium phosphosilicate and VAS score assessed at Baseline, 2 weeks, 6 weeks
57058|NCT03738514|Other|5% potassium nitrate dentifrice|5% potassium nitrate dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks.
57059|NCT03738514|Other|Placebo dentrifice|placebo dentifrice and VAS score assessed at Baseline, 2weeks, 6 weeks
57060|NCT03738501|Other|Chest physiotherapy with SET|Chest physiotherapy with SET, and standard treatment (medical treatment, health education, nasopharyngeal clearance, advice)
57061|NCT03738501|Other|Standard Treatment|Standard pharmacological and non-pharmacological treatments (medical treatment, health education, rhinopharyngeal clearance, advices)
57062|NCT03738488|Device|3D printing + images|To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials
57063|NCT03738488|Other|Images|To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
57064|NCT03738475|Drug|TIMP-GLIA|8 mg/kg up to a maximum of 650 mg administered intravenously on days 1 and 8
57065|NCT03738475|Drug|Placebo|Administered intravenously on days 1 and 8
57066|NCT03738462|Device|Conformis Hip System|The Conformis Hip System is an FDA cleared, uncemented, primary total hip replacement device composed of femoral and acetabular components. The system incorporates the use of a pre-operative CT scan to design patient-specific implants and instruments. Using patient imaging (CT scan), a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient.
57067|NCT03738449|Drug|CKD-387|Test drug
57068|NCT03738449|Drug|D484|reference drug
57069|NCT03738436|Other|Physical therapy traditional neuromuscular training, NMT|The NMT program includes re-position exercise using Swiss ball roll squat, strengthening and stretching exercises in various positions or combined using Swiss ball, Thera-Band or suspension system (Redcord), balance exercise on wobble board, proper landing strategy practices, and etc.
57070|NCT03738436|Other|Physical therapy modified visual feedback, MVF|traditional neuromuscular training (as in NMT group), but with modified visual feedback by eyes closed, reduced lighting or wearing strobe goggles
57071|NCT03738423|Drug|REGN3500|Administered subcutaneous (SC)
57072|NCT03738423|Drug|REGN3500-Matching Placebo|Administered subcutaneous (SC)
57077|NCT03738397|Drug|Placebo|Placebo pre-filled syringe is as administered subcutaneous (SC) injections
57078|NCT03738397|Drug|Placebo|Placebo tablets are administered orally
57079|NCT03738384|Device|Knee Connect + Visual Feedback System|A device to measure knee angle. It sends data a smartphone or tablet to be displayed as part of a visual feedback system.
57080|NCT03738371|Other|In situ simulation|Team involved in thrombectomy procedures will be trained by in situ simulation. Simulation will reproduce the initial step of a thrombectomy procedure, i.e from from the installation of the patient to the percutaneous punch by the neuroradiologist. Simulation will be followed by a debriefing focused on the team performance. Three in situ simulation sessions will be realized by each team.
57081|NCT03738358|Dietary Supplement|Trehalose|80 mL pouch/day for 12 weeks, containing trehalose 5 g, water 74.92 g and scent additive 0.08 g
57082|NCT03738358|Other|Placebo|80 mL pouch/day for 12 weeks, containing water 79.92 g and scent additive 0.08 g
57083|NCT03738345|Other|HFNC flow|HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
57084|NCT03738332|Device|Low-Level Laser|Low-level laser therapy
57085|NCT03738319|Genetic|Sequencing of miRNA/lncRNA|Next generation sequencing of micro-RNA (miRNA) and long non-coding RNA (lncRNA)
57086|NCT03738306|Other|Mezieres Method|"The Mézières treatment have 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain: the paravertebral muscles and latissimus dorsi."
57087|NCT03738306|Other|Conventional Physiotherapy|therapeutic exercise; physical agents
57088|NCT03738280|Diagnostic Test|Endoscopic ultrasound-fine needle biopsy|Patients with non-hypovascular solid pancreatic lesion undergo endoscopic ultrasound-fine needle biopsy
57089|NCT03738254|Other|The Guardians: A smartphone game|"The Guardians is a mix of two popular game genres: idle games (a game that doesn't require constant player input in order to progress in the game, but often progresses exponentially in response to a few user inputs, e.g., Cookie Clicker and Adventure Capitalist) and pet collection games (a game where the player seeks to collect all of the pets in a set, e.g., Pokemon or Neko Atsume). The game gives the player an in-game reward for completing a survey."
57090|NCT03738254|Other|Paper Survey|Paper version of daily survey
57091|NCT03738254|Other|Electronic Survey|Electronic version of daily survey administered via a smartphone app.
57095|NCT03738228|Drug|Atezolizumab|Given IV
57096|NCT03738228|Drug|Cisplatin|Given IV
57097|NCT03738228|Radiation|Internal Radiation Therapy|Undergo standard of care image guided brachytherapy
57098|NCT03738228|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
57099|NCT03738215|Drug|Cariprazine|Cariprazine supplied in capsules
57100|NCT03738215|Drug|Placebo|Placebo supplied in capsules
57101|NCT03738202|Behavioral|Multifaceted intervention package|"Multifaceted intervention package will comprise following strategies:~Initial training for all workers and managers on occupational health and safety (OHS)~Follow-up refresher sessions every three months~Formation of workplace committees (including worker representatives) to draw up, agree and promote a health and safety plan that includes wet mopping, safe disposal of cotton dust, and the use of simple face masks, as well as further publicity about the risks from cotton dust.~Provision of adequate supplies of face masks to support the health and safety plan"
57102|NCT03738189|Other|Augmented Reality Video|Augmented Reality selfies will place a selection of denture teeth in pictures of the participants in order to enable the selection of their preferred teeth on their new denture.
57103|NCT03738176|Drug|Sesame Oil|Sesame oil(80 gm NaCMC-20 gmSesame oil)
57104|NCT03738176|Drug|triamcinolone in orabase|triamcinolone 140 gm-Na CMC 50 gm
57105|NCT03738163|Device|Epaderm Cream|The treatment with the investigational device will be according to the prescription by the investigator together with the instruction stated on the investigational device.
57106|NCT03738150|Biological|Sotatercept|Sotatercept injection
57107|NCT03738137|Device|Narotrend|Narcotrend motoring
57108|NCT03738137|Device|BIS|Bispectral index monitoring
57109|NCT03738137|Drug|Sufentanil|sufentanil is applied.
57110|NCT03738137|Drug|Lidocaine|Topical Anesthesia
57111|NCT03738137|Drug|Midazolam|midazolam is applied.
57112|NCT03738124|Device|Valiant Mona LSA Thoracic Stent Graft System|The Valiant Mona LSA device is a modular two-component system consisting of a main stent graft (MSG) and a branch stent graft (BSG), delivered separately, designed to maintain LSA perfusion. Briefly, under general anesthesia and after heparin injection, a MSG access is achieved via a femoral artery. A Through-and-through wire access for delivery of the BSG is achieved via a brachial artery. After the placement of the main aortic stent graft in the arch with the cuff at the level of the ostium of the LSA, the BSG is placed through a femoral access.
57113|NCT03738111|Drug|TG02 Citrate|TG02 citrate capsules
57114|NCT03738098|Behavioral|Standard of Care|Participants will receive traditional genetic counseling (GC) for the Baseline and Return of Results (ROR1) visits.
57115|NCT03738098|Behavioral|GUÍA|GUÍA for the ROR1 visit.
57116|NCT03738072|Diagnostic Test|StiMiC stimulation condition|This new condition of stimulation of electrical Brain Stimulation will be evaluate to determine if this stimulation is more efficient that standard stimulation condition
57117|NCT03738059|Drug|Dexmedetomidine Injection [Precedex]|will receive intravenous Dexmedetomidine
102252|NCT03387111|Procedure|SBRT|Stereotactic Body Radiation Therapy
57118|NCT03738059|Other|normal saline 0.9%|will receive intravenous normal saline 0.9%
57119|NCT03738046|Behavioral|Cognitive Behavioral Therapy|Group therapy will occur once weekly (60-90-minute sessions) at the HOPE TEAM offices for 24 weeks. The group sessions with consist of 4 skill modules, each of which last 6 sessions. Three of these--the Cognitive, Social Skills, and Problem-Solving Modules—will be modules taken from Cognitive and Behavioral Social Skills Training (CBSST; Granholm McQuaid, & Holden, 2016) and modified for use with CHR adolescents. The fourth module—Stress Coping—will be adapted for this sample from an established group CBT treatment for psychosis (Lecomte, Leclerc, & Wykes, 2016).
57120|NCT03738033|Other|educational platform|The platform would be opened before they entered the study.
57121|NCT03738020|Device|HA IDF (YVOIRE classic)|Treatment with HA IDF
57122|NCT03738020|Device|Restylane|Treatment with Restylane
57123|NCT03738007|Device|HA IDF II|Treatment with HA IDF II (YVOIRE volume)
57124|NCT03738007|Device|Perlane|Treatment with Perlane
57125|NCT03737994|Drug|Alectinib|Given PO
57126|NCT03737994|Drug|Brigatinib|Given PO
57127|NCT03737994|Drug|Carboplatin|Given IV
57128|NCT03737994|Drug|Ceritinib|Given PO
57129|NCT03737994|Drug|Cisplatin|Given IV
57130|NCT03737994|Drug|Crizotinib|Given PO
57131|NCT03737994|Drug|Ensartinib|Given PO
57132|NCT03737994|Drug|Lorlatinib|Given PO
57133|NCT03737994|Drug|Pemetrexed|Given IV
57138|NCT03737968|Drug|Durvalumab|Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
57139|NCT03737968|Drug|durvalumab + tremelimumab|Patients in the durvalumab (MEDI4736) + tremelimumab combination therapy treatment group will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) once prior to surgery in this study. After surgical resection, these patients will receive the post op adjuvant treatment including RTx with/without cisplatin based on the pathologic findings and physician's discretion. After completion of adjuvant treatment, durvalumab (MEDI4736) 1500mg Q4W as maintenance treatment for up to a maximum of 12 months
57140|NCT03737955|Drug|Gemtuzumab Ozogamicin|Receive IV
57141|NCT03737955|Other|Quality-of-Life Assessment|Ancillary studies
57142|NCT03737942|Device|monitoring of neuromuscular function|started by percutaneous stimulation of the cubital nerve at the wrist level
57143|NCT03737929|Procedure|Hybrid ablation|In the hybrid ablation arm, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure (same operative time). During the endocardial approach, the isolation of the pulmonary veins and the posterior box will be checked and completed if necessary. Then additional ablation will be performed for atrial tachycardia or ongoing persisting atrial fibrillation (AF) according the same lesions setup or stepwise protocol than the conventional arm
57144|NCT03737929|Procedure|Percutaneous catheter ablation|In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint. Any atrial tachycardia will be mapped and ablated as well (DC shock performed otherwise).
57145|NCT03737916|Other|5 cc 5% Dextrose solution|Ultrasound-guided perineural injection with 5% Dextrose (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
57146|NCT03737916|Other|5 cc salin|Ultrasound-guided perineural injection with salin (1cc) to ulnar nerve into the elbow, 2 and 4 cm before and after the elbow (total 5 cc).
57147|NCT03737890|Other|Inspiratory Muscle Training|"Participants in the experimental group were given Inspiratory Muscle Training by using an IMT device. For this training, the inspiratory load for each participant was set at 30 cmH2O.~In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
57148|NCT03737890|Other|Hold Relax Pectoral Stretch|"In control group, the participants received 3 sets of passive hold- relax pectoral stretch for each session. Each stretch was maintained for 10 seconds with a rest period of 30 seconds given between the sets.~Each participant was supposed to complete a total of 12 sessions of exercises, 3 sessions per week for 4 weeks."
57149|NCT03737877|Other|Diet modification|"The parents will have four group sessions with a nutritional therapist, where in depth advice and information about the diet will be provided. Ongoing support will also be provided throughout the study by use of a closed Facebook or WhatsApp group (whichever the parents choose as most appropriate). The diet is based on five main principles:~Eat at least seven portions of different varieties of fruit and vegetables each day.~Have a 12 hour overnight break from food (water only during this time).~Drink a Kefir drink each day - provided free of charge.~Eat a microbiome friendly, protein rich, breakfast from our menu.~Reduce sugar and artificial sweeteners."
57150|NCT03737864|Behavioral|Patient navigation|The patient navigator will provide support to patients upon discharge and will maintain regular contact either in person or by phone at a minimum of once per week for 30 days, or until the patient successfully enrolled in substance abuse treatment, or readmission to detoxification occurs, whichever occurs first.
57151|NCT03737864|Behavioral|Motivational interviewing (MI)|A single 45-60 minute 1:1 session of MI provided by patient navigators at discharged focused on transitioning patients to treatment after detoxification.
57152|NCT03737851|Drug|elezanumab|solution for infusion
57153|NCT03737851|Drug|placebo|solution for infusion
57154|NCT03737838|Device|Atrial fibrillation ablation|High density mapping of left atrium using Rhythmia mapping system to identify gaps in conduction and wavefront discontinuities (deceleration zones)
57155|NCT03737825|Device|Computerized gaming rehabilitation Program 1|Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
57156|NCT03737825|Device|Computerized gaming rehabilitation Program 2|Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
57157|NCT03737812|Drug|elezanumab|solution for infusion
57158|NCT03737812|Drug|placebo|solution for infusion
57159|NCT03737786|Other|Tight control of end-tidal CO2 levels|The desired end-tidal PCO2 levels will be achieved by endotracheal intubation and controlled ventilation
57160|NCT03737773|Other|glasses (prismatic lenses)|
57161|NCT03737773|Other|glasses (neutral)|
57162|NCT03737747|Procedure|induced hypothermia|
57163|NCT03737734|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
57164|NCT03737721|Combination Product|Avelumab and Radical radiotherapy|A single-arm, interventional study combining Avelumab with radical radiotherapy. Avelumab will be delivered on a 14-day cycle, with the first cycle administered 14 days in advance of the radiation therapy start date; 63-66 Gy radiation will be delivered over 30 daily fractions concurrent with an additional 4 cycles of Avelumab
57165|NCT03737708|Drug|tacrolimus|Administered orally
57166|NCT03737708|Drug|methotrexate|Administered orally
57167|NCT03737708|Biological|adalimumab|Administered as subcutaneous injection
57168|NCT03737708|Biological|tocilizumab|Administered by intravenous injection
57169|NCT03737708|Biological|abatacept|Administered by intravenous injection
57170|NCT03737695|Procedure|Biospecimen Collection|Undergo biospecimen collection
57171|NCT03737695|Other|Medical Chart Review|Undergo clinical information collection
57172|NCT03737682|Diagnostic Test|ENzyme linked immunity-sorbet assays|Hemostasis achievement reflecting inflammatory status of the pulp based on cytokine levels
57173|NCT03737669|Biological|Mirasol-treated Fresh Whole Blood|Standard issue FWB, which gave negative serological assay results for HIV, HBV, HCV, and syphilis will subsequently be treated with Mirasol PRT, then stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
57174|NCT03737669|Biological|Standard Fresh Whole Blood|Fresh whole blood that gave negative serological assay results for HIV, HBV, HCV, and syphilis will be stored at 1 - 6 degrees Celsius and transfused within 21 days of collection.
57175|NCT03737656|Drug|Progesterone vaginal ring|Vaginal ring with 2.0 g progesterone (sustained-release over 90-days)
57176|NCT03737643|Drug|Bevacizumab|Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
57177|NCT03737643|Drug|Durvalumab|Durvalumab by intravenous infusion
57178|NCT03737643|Drug|Olaparib|Olaparib tablets
57179|NCT03737643|Drug|Placebo olaparib|Placebo tablets to match olaparib
57180|NCT03737643|Drug|Durvalumab placebo|Matching placebo for intravenous infusion
57181|NCT03737643|Drug|Carboplatin+Paclitaxel|Standard of care chemotherapy
57182|NCT03737630|Device|Inspiratory muscle training|This group will initiate inspiratory muscle training with 40% of the MIP load and each week will have a load increase of 10% of the initial MIP up to 4 weeks of training
57183|NCT03737617|Drug|Cuvitru 20 % Injectable Solution|Active
57184|NCT03737604|Drug|Ropivacaine Continuous Infusion Catheter|For those randomized to the TAP catheter group, ultrasound guidance will be used for TAP block and 5mls 1% lidocaine will be used for skin infiltration. A peripheral nerve catheter will be placed approximately 3-5 cm into the TAP space after injection of the ropivacaine solution. A bolus dose of 2.5 mg/kg of ropivacaine will be administered in a volume of 30 ml up to a maximum of 150 mg. An infusion with a programmable pump will be initiated at a rate of 8 ml/hr of 0.2% ropivacaine on the inpatient floor.
57185|NCT03737604|Drug|Single Dose Liposomal Bupivicaine|TAP block will be performed using ultrasound guidance. 12ml of 0,25% plain bupivacaine will be used for skin infiltration and to open up the TAP. Liposomal bupivacaine 266 mg (1.3% in 20 ml) will be diluted to 40 ml volume with 20 ml of preservative free normal saline. 20 ml (133mg) of liposomal bupivicaine will then be injected into the TAP.
57186|NCT03737591|Diagnostic Test|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers prior to endoscopy
57187|NCT03737578|Other|Delivery of a connected pedometer / accelerometer|"Delivery of a connected pedometer / accelerometer that the patient will be asked to wear at least 7 consecutive days / month.~Quality of life and leg restless syndrome questionnaires (auto questionnaire) completed by the patients every 3 months"
57188|NCT03737565|Device|Optimax stent®|Percutaneous coronary intervention with Optimax stent®
57189|NCT03737552|Other|Polysomnography|Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
57190|NCT03737539|Diagnostic Test|Next-generation sequencing (NGS)|NGS test for colorectal tumor-specific plasma ctDNA methylation markers
57191|NCT03737500|Device|B-Lite® light weight breast implant|Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant
57192|NCT03737500|Device|Standard silicone-based breast implant|Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution
57224|NCT03737253|Drug|Follitropin alpha|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
57225|NCT03737253|Drug|Menotropin|The objective is to measure the effect of the drug according to gonadotropin receptor genotype.
57226|NCT03737240|Drug|IDegLira|Participants in this study arm will discontinue all other diabetes medications, except for metformin which will be continued at prescribed dose (unless contraindicated). IDegLira will be given once daily, at the same time of the day with or without food for 26 weeks. IDegLira will be titrated until the maximum dose is reached, up to the target fasting blood glucose of 70 to 100 milligrams per deciliter (mg/dL).
57260|NCT03736967|Drug|REGN3500|Administered subcutaneous (SC) every 2 weeks (q2w)
57193|NCT03737487|Procedure|Multidisciplinary fall risk and geriatric comprehensive assessment|"Complete blood count, serum electrolytes, C-Reactive Protein, transaminases and gamma-glutamyl transferase, thyroid-stimulating hormone, and 25OH vitamin D.~Calculation of BMI~A 40-min assessment of balance, walking speed, muscle strength, activity, and functional status by a physiotherapist~A 40-min assessment by an occupational therapist, including a detailed questionnaire on social support, living situation and home environment, fear of falling, and cognitive function~A 20-min assessment by a podiatrist including an examination of the patient's feet and footwear.~A 60-min assessment by a geriatrician including assessment of circumstances of the previous fall(s), review of current medications and medical history, and an in-depth examination of the patient to detect possible contributors or risk factors for falling~A 20-min review meeting with the 4 healthcare professionals in order to prioritize recommendations to be provided."
57194|NCT03737474|Drug|Brexpiprazole|2 mg/day (starting dose 1mg/day) of Brexpiprazole will be orally administered once daily
57195|NCT03737461|Drug|Allogenic BM-MSCs Injection|Cell dose will be 20±5 million cells suspended in 2 ml of HypoThermosol isotonic transport solution
57196|NCT03737461|Other|Sham Procedure|sham-maneuver as in the cell-treated patients are added, consisting in anesthetic infiltration with 2 ml of 1% xylocaine in the paravertebral muscles close to the affected segment.
57197|NCT03737448|Drug|Trimetazidine|Subjects with receive up to 60 mg daily
57198|NCT03737422|Dietary Supplement|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
57199|NCT03737422|Other|control|no supplementation
57200|NCT03737409|Other|Ambulatory Oxygen Therapy|Supplemental oxygen delivered during exercise and activities of daily living via a portable oxygen concentrator
57201|NCT03737409|Other|Sham Ambulatory Oxygen Therapy|Air delivered during exercise and activities of daily living via a portable oxygen concentrator that has been modified to deliver air
57202|NCT03737396|Procedure|Self-administered electronic health screening|Health assessment using an electronic device
57203|NCT03737383|Behavioral|Narrative Exposure Therapy|brief, trauma-focused treatment.
57204|NCT03737370|Drug|Docetaxel|Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
57205|NCT03737370|Radiation|Radium 223|Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
57206|NCT03737357|Device|SLActive® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
57207|NCT03737357|Device|SLA® implant|One study test (SLActive® surface) (and simultaneously, in a split-mouth design one study control (SLA® surface) implant (Bone Level Tapered, Roxolid®)) will be placed in two different quadrants of partially edentulous patients. The implants will be placed at premolars, molars and canine positions in the mandible and maxilla (healed extraction sites). Implants will be restored with a single crown or splinted restorations 8 weeks after implant placement.
57208|NCT03737344|Drug|IL-1Ra Kineret®|Kineret® 100 mg in 0.67 ml Prefilled Syringe
57209|NCT03737344|Other|IL-1Ra Placebo|Placebo identical to Kineret® 100 mg in 0.67 ml Prefilled Syringe
57210|NCT03737331|Behavioral|Fractal visual cueing|Walking to an external visual fractal (i.e., pink noise) stimulus.
57211|NCT03737331|Behavioral|Periodic visual cueing|Walking to an external visual periodic (i.e., invariant) stimulus.
57212|NCT03737331|Behavioral|Random visual cueing|Walking to an external visual random (i.e., white noise) stimulus.
57213|NCT03737318|Behavioral|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
57214|NCT03737318|Behavioral|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional treatment (auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
57215|NCT03737318|Behavioral|Traditional articulation treatment|Traditional articulation treatment involves providing auditory models and verbal descriptions of correct articulator placement, then cueing repetitive motor practice. Images and diagrams of the vocal tract will be used as visual aids; however, no real-time visual display of articulatory or acoustic information will be made available.
57216|NCT03737305|Device|TMJ Condilar Distraction Device|The patients will perform condylar distraction with the condylar distraction device in an ambulatory basis.
57217|NCT03737305|Device|Conventional Physical Therapy|Conventional Physical Therapy, performed in office by a experienced physical therapist for the TMJ condition.
57218|NCT03737292|Drug|Exparel|The intercostal blocks will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions. On average, 5-6 intercostal spaces will be injected with 4-5 ml of local anesthetic at each level.
57219|NCT03737292|Drug|Bupivacaine|The intercostal injections of 0.5% Bupivacaine 2 mg/kg dose diluted to 30 ml total will be performed at several levels corresponding to the incisions and chest tube insertion sites + two levels above and two levels below the incisions.
57220|NCT03737279|Behavioral|Meditation|Routine care + twice daily meditation per schedule, to start on the day of randomization
57221|NCT03737279|Behavioral|Routine Care|"Routine care including ACOG educational pamphlets:~Day 1: Nutrition in Pregnancy~Day 2: Heart Health for Women~Day 3: Exercise after Pregnancy"
57222|NCT03737266|Procedure|Sonographically assisted breast surgery|Sonography
57223|NCT03737266|Procedure|Conventional breast surgery|Conventional
57227|NCT03737240|Drug|Insulin Degludec (U-100)|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
57228|NCT03737240|Drug|Insulin Aspart|Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
57229|NCT03737227|Radiation|Cinematographic recording|Cinematographic recording during flexion and extension of the lumbar spine.
57230|NCT03737214|Drug|Lucerastat|Administered in hard gelatin capsules containing 250 mg of lucerastat.
57231|NCT03737201|Other|ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
57232|NCT03737201|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
57233|NCT03737201|Other|Control|without any cavity disinfectant
57234|NCT03737188|Device|Blood glucose monitoring systems for self-testing|Capillary blood samples will be used for the evaluation of system accuracy.
57235|NCT03737175|Procedure|Carotid Artery Stenting|Carotid Artery Stenting
57236|NCT03737175|Procedure|Carotid Endarterectomy|Carotid Endarterectomy
57237|NCT03737162|Procedure|Stent implantation of subclavian artery|Stent implantation of subclavian artery
57238|NCT03737149|Other|mymobility with Apple Watch|The mymobility mobile application is a mobile software platform designed to facilitate remote episode of care management and asynchronous communication between the provider care team and their patient via provider-approved care plans and engagement communications. Current care pathways have been developed for: Total Hip Replacement, Total Knee Replacement and Partial Knee Replacement. Designed for the orthopedic population, mymobility also integrates wearable data from the Apple Watch into provider dashboards, providing enhanced understanding and monitoring of patients throughout the episode of care.
57239|NCT03737136|Drug|Bortezomib|one cycle of bortezomib (each cycle: 1.3mg/m2 intravenously on days 1, 4, 8, and 11)
57240|NCT03737123|Drug|Carboplatin|Carboplatin AUC 4 IV Day 1 of each 21 day cycle
57241|NCT03737123|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
57242|NCT03737123|Drug|Atezolizumab|Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
57243|NCT03737123|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
57244|NCT03737110|Drug|Rilonacept|Rilonacept 320 mg (or 4.4 mg/kg in pediatric subjects ≥12 and <18 years old) SC , followed by 160 mg (or 2.2 mg/kg in pediatric subjects ≥12 and <18 years old) injections once weekly
57245|NCT03737110|Drug|Placebo|Placebo SC injections once weekly
57246|NCT03737097|Other|Online Spaced Education|Investigators created a set of fall prevention strategies for multiple sclerosis patients into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), spaced education has been shown in randomized trials to improve knowledge acquisition, boosts learning retention for up to two years, and durably improves changes in behavior.
57247|NCT03737097|Other|Brochure Education|The investigators translated and validated the Minimizing Your Risk of Falls A GUIDE FOR PEOPLE WITH MS brochure developed by the National Multiple Sclerosis Society. The control cohort will receive the main education model for patients that has been used in the past few years.
57248|NCT03737084|Behavioral|CBCT Intervention|The training consists of six weekly sessions. The participant will receive six guided meditation audio, relative to each session, to practice during the week.
57249|NCT03737071|Behavioral|Low Carbohydrate Diet|Ketogenic dietary intervention
57250|NCT03737058|Behavioral|Program participants|The intervention is a 12-month telephonic program in which a lay health worker (LHW), supervised on-site by a registered nurse practitioner (RNP), assessed patient symptoms after diagnosis using the validated Edmonton Symptom Assessment Scale (ESAS) (cite) with the frequency of symptom assessment varying based on patient risk.
57251|NCT03737045|Other|Decision Aid|Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
57252|NCT03737032|Device|Intermittent Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered without interruption for a total duration of 40 seconds.
57253|NCT03737032|Device|Continuous Theta Burst Stimulation|Theta Burst Stimulation, a form of Transcranial Magnetic Stimulation, will be applied to the dorsomedial prefrontal cortex. will include 600 pulses delivered in brief bursts of three pulses with a frequency of 50 Hz, at an intensity of 110% of resting motor threshold, and administered every 200 ms (5 Hz). Bursts will be delivered during 2 second periods (10 bursts/period) interleaved with 8-second stimulation-free intervals, for a total duration of 190 seconds.
57254|NCT03737032|Device|Sham Theta Burst Stimulation|For the sham of theta burst stimulation, the device providing Theta Burst Stimulation can be placed in the same position and turned on, creating a similar experience for the participant, without providing any neural stimulation. Sham TBS will be delivered with a Cool-B65 Active/Placebo Coil, which includes a sham setting, and MagLink research software.
57255|NCT03737019|Behavioral|Education with Acceptance and Commitment Therapy|Group education with Acceptance and Commitment Therapy of the personnel at each center.
57256|NCT03737019|Other|Control, no intervention|Control, no interventions.
57257|NCT03736993|Other|Additional blood sampling|Establish predictive markers for early disease progression after complete surgical resection in patients with stage I to IIIA NSCLC.
57258|NCT03736980|Drug|Placebo|100% lactose
57259|NCT03736980|Drug|Psilocybine|Study Group 1: 0.250 mg/Kg weight Study Group 2: 0.200 mg/Kg body weight Study Group 3: 0.215 mg/Kg body weight Study Group 4: 0.315 mg/Kg body weight
57264|NCT03736954|Behavioral|positive suggestion|humanization of critical care experience with positive reframing of hospital course on daily basis to eligible participants
57265|NCT03736941|Other|Patients with venous leg|The medical device Venotrain® Ulcertec will be prescribed according to the indications supported by the Health Insurance and used according to the recommendations of the manufacturer. It will be dispensed in town pharmacies. After inclusion, follow-up visits are scheduled at 4, and 16 weeks (± 1 week) as well as an end-of-study visit, not later than 20 weeks after enrollment or in case of premature termination. follow-up.
57266|NCT03736928|Biological|AbobotulinumtoxinA dose 1/2|treatment of glabellar facial lines
57267|NCT03736928|Other|placebo|treatment of glabellar facial lines
57268|NCT03736928|Biological|AbobotulinumtoxinA dose 3|treatment of glabellar facial lines
57269|NCT03736928|Biological|AbobotulinumtoxinA dose 4|treatment of glabellar facial lines
57270|NCT03736915|Procedure|Injection using 1 cc of NaCl 0.9%|The injection will be using SIMPLE block technique using 1 cc of NaCl 0.9% solution under the injection speed of 30 seconds/cc.
57271|NCT03736915|Other|Patient Preference Question|Patient is asked at the end of each injection which injection they prefer
57272|NCT03736915|Other|Questionnaires|Patient is asked to answer questionairres at the end of each injection
57273|NCT03736902|Other|Qualitative semi structured interview|One-to-one semi structured interviews, guided by the Physical Activity for people with a Disability Framework (van der Ploeg et al, 2004) which is a model for understanding the different factors that influence whether people with a disability engage in physical activity. Participants that agree to take part in the study, will be offered an interview either in a private clinic room at the hospital, at their home (if they live within a 40-mile radius of the hospital) or via a web-based video link. The interviews are expected to last one hour and will be conducted by the primary researcher.
57274|NCT03736889|Drug|Tislelizumab (BGB-A317)|Anti-PD-1 Antibody
57275|NCT03736876|Behavioral|About Us|Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
57276|NCT03736863|Drug|Apatinib+SHR-1210|Apatinib 250mg, q.d.po+SHR-1210 200 mg，Intravenous injection， q2W continuous medication，A course of treatment need 28 days.
57277|NCT03736850|Drug|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
57278|NCT03736837|Drug|Anlotinib Plus Icotinib|"Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent."
57279|NCT03736824|Procedure|endoscopy|All endoscopy was performed by qualified gastroenterologists or endoscopic physicians in Renji hospital,Shanghai Jiaotong University School of Medicine.
57280|NCT03736811|Device|Polyglactin 910 or polydioxanone|Vicryl or PDS II
57281|NCT03736811|Device|Polyester or polypropylene|Ethibond Excel or prolene
57282|NCT03736785|Drug|LY3209590|Administered SC
57283|NCT03736785|Drug|Insulin Degludec|Administered SC
57284|NCT03736772|Drug|LY3090106|Administered SC
57285|NCT03736772|Drug|Placebo|Administered SC
57286|NCT03736759|Behavioral|Exercise|10 sets of 5 repetitions of 80% of calculated one-repetition maximum weight of lateral side arm raise and biceps curls, alternating
57287|NCT03736746|Behavioral|Motivational Interviewing|An investigator-led discussion about the participant's pain experience which is focused on the participant reporting of functional pain goals (FPGs)
57288|NCT03736733|Other|physical activity program|"Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months."
57289|NCT03736733|Other|Advice and recommendations of physical activity at home|Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
57290|NCT03736720|Drug|Fluorouracil|Given IV
57291|NCT03736720|Drug|Leucovorin|Given IV
57292|NCT03736720|Drug|Liposomal Irinotecan|Given IV
57293|NCT03736720|Procedure|Quality-of-Life Assessment|Correlative studies
57294|NCT03736707|Device|Selective HFOV|Selective HFOV will only be provided with piston/membrane oscillators able to provide a real oscillatory pressure with active expiratory phase
57295|NCT03736707|Device|CMV|CMV was delivered by time-cycled, pressure-limited ventilators
57296|NCT03736694|Behavioral|Cognitive behavioural therapy for insomnia|CBTI involves habitual, belief and attitude alterations so as to eliminate factors preventing sleep (Morin, Savard, Ouellet, & Daley, 2003). It is recommended by the American College of Physicians as the first-line therapy for insomnia (Qaseem, Kansagara, Forciea, Cooke, & Denberg, 2016). CBTI workshops are a relatively novel and emerging way of delivery which involves a greater number of patients than group CBTI, increases availability and accessibility by concentrating the content into half or whole day and taking place in the community settings, and reduces diagnostic labeling and cost (Bonin, Beecham, Swift, Raikundalia, & Brown, 2014; Swift, Stewart, Andiappan, Smith, Espie, & Brown, 2012). Self-help CBTI involves independent learning of the provided materials via the Internet, video or audio recording, books and pamphlets (Bruin, Bogels, Oort, & Meijer, 2015).
57297|NCT03736694|Behavioral|Sleep hygiene education|SHE, is commonly provided verbally or through leaflets during consultations (Espie, 2009), and is also included as a part of CBTI (Morin, Savard, Ouellet, & Daley, 2003).
57332|NCT03736447|Biological|AR101 powder|AR101 powder provided in capsules and sachets (peanut allergen formulation)
57333|NCT03736447|Biological|Placebo powder|Placebo powder provided in capsules and sachets
57298|NCT03736681|Drug|40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will receive 40cc buffered 0.5% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
57299|NCT03736681|Drug|20cc 1% lidocaine with 2 units of vasopressin paracervical block|Women undergoing D&C in the first trimester for either surgical abortion or miscarriage management will be randomly assigned to receive 20cc 1% lidocaine with 2 units of vasopressin paracervical block before cervical dilation.
57300|NCT03736668|Diagnostic Test|echocardiography|One year after patient's inclusion, an echocardiography / doppler will be performed to evaluate any changes.Two years after the patient's inclusion, an investigating cardiologist will contact the physician, cardiologist and / or diabetologist treating the patient by telephone to find out if any cardiovascular events have occurred.
57301|NCT03736655|Device|Interposition supraciliary implant|Surgical placement of an interposition supraciliary implant in the supraciliary space
57302|NCT03736642|Biological|blood sampling|12 ml sample
57303|NCT03736642|Other|stool sampling|20 g sample
57304|NCT03736642|Other|urine sampling|18 ml sample
57305|NCT03736642|Diagnostic Test|neuropsychological tests|"Go-nogo~flexibility~food stroop~implicit and explicit evaluation~Child Depression Inventory~Hamilton Depression Rating Scale"
57306|NCT03736629|Drug|Azithromycin|8 weeks of Azithromycin (250 mg) once daily by mouth
57307|NCT03736629|Drug|Placebo|Placebo
57308|NCT03736616|Drug|Carboplatin|Chemotherapy
57309|NCT03736616|Drug|Ifosfamide|Chemotherapy
57310|NCT03736616|Drug|Etoposide|Chemotherapy
57311|NCT03736616|Biological|Rituximab|Anti-CD20 mAb
57312|NCT03736616|Drug|Carmustine|Chemotherapy
57313|NCT03736616|Drug|Cytarabine|Chemotherapy
57314|NCT03736616|Drug|Melphalan|Chemotherapy
57315|NCT03736616|Other|Autologous HSCT|Cellular Therapy
57316|NCT03736616|Drug|Acalabrutinib|Bruton's Tyrosine Kinase Inhibitor
57317|NCT03736603|Behavioral|PIPA Intervention Bundle 1|"The PIPA intervention bundle 1 includes:~Pathway Implementation Toolkit~Local Multidisciplinary Champions~Audit and Feedback~Educational Seminars/Webinars~Practice Facilitation"
57318|NCT03736603|Behavioral|PIPA Intervention Bundle 2|"The PIPA intervention bundle 2 includes:~Pathway Implementation Toolkit~Local Multidisciplinary Champions~Audit and Feedback~Educational Seminars/Webinars~Practice Facilitation~Mobile App"
57319|NCT03736590|Behavioral|Financial coaching and services|The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
57320|NCT03736577|Other|Drug reviews with NorGeP-NH|Physicians in the intervention group will attend a 1-2 hours lecture about psychopharmacology and drug review. They will learn how to do drug reviews with the Norwegian general practice criteria - Nursing homes (NorGeP-NH). The nursing home physicians will do the drug review on the participants` drug charts
57321|NCT03736564|Combination Product|68Ga-DOTATATE PET/CT|Gallium-68 Dotatate, a radioactive imaging agent, is injected into a vein. Subjects will rest for approximately 50 minutes, after which approximately a 30 minute image of subjects body will be completed via PET/CT scan.
57322|NCT03736551|Behavioral|5:2 diet|very low energy diet (600 kcal/day) on 2 consecutive days of the week, and 5 days each week on an energy restricted diet to maintain a similar overall energy deficit of 600 kcal/day across the week (5:2 diet)
57323|NCT03736551|Behavioral|Renal Weight Management Programme|Dietary intervention includes a standard continuous energy restricted diet aimed at reducing daily energy intake by 600 kcal/day relative to their estimated total energy expenditure. In addition to the dietary intervention, the programme also includes personal exercise plans, optional pharmacotherapy (orlistat at standard dose), and development of personalised dietary and exercise goals using behavioural therapy techniques and motivational interviewing.
57324|NCT03736538|Drug|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
57325|NCT03736538|Drug|Placebo gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
57326|NCT03736525|Behavioral|Design For Wellness (DWELL)|Design for wellness is an online Facebook intervention. During 3 months intervention period, participants in the intervention group will be exposed to contents on their newsfeed (posts on Facebook wall), and also be expected and encouraged to create new content themselves. The contents will be interactive and involve different modes of delivery, as audio and video, to reinforce active learning. Participants will be part of DWELL Facebook group community and will be empowered to read and control cues in the environment, by developing skills to enhance their self-efficacy.
57327|NCT03736525|Behavioral|Wait list control group|Wait list control group will get no intervention during the study period. Participants will answer questionnaires pre, mid and post intervention. A delayed form of the intervention will be available to them after the close of the study.
57328|NCT03736512|Device|GreenLight XPS™ 532 nm Laser System with MoXy™ laser fiber|observational registry
57329|NCT03736473|Drug|MEDI9447 (oleclumab)|MEDI9447 administered intravenously
57330|NCT03736460|Behavioral|Mindfulness|The mindfulness-based intervention adheres to a standardized protocol developed from the MBSR curriculum (Kabat-Zinn, 1990). The program consists of four 3h group sessions spread over 8 weeks. Each session consists of guided experiential mindfulness exercises (e.g. focus on the breath, body scan, breathing space, mindful movement, sitting meditation), sharing of experiences of these exercises, reflection in small groups, psycho-education (e.g. stress, depression, fear of cancer recurrence, self-care) and review of home practices.
57331|NCT03736460|Behavioral|Physical training|This intervention is based on the recommended levels of physical activity for adults aged 18 - 64 year from the World Health Organization. These recommendations are the same for women after a breast cancer treatment (Schmitz et al., 2010). Just as the mindfulness intervention this will consist of four 2h group sessions spread over 8 weeks. Each session will consist of psycho-education (e.g. basics of movement, advantages of physical activity, training-principles), endurance and resistance training, stretching, balance and relaxation exercises, sharing of experiences of these exercises and review of home practices.
58277|NCT03728842|Other|Blood collection for laboratory studies|Peripheral whole blood will be collected
57334|NCT03736434|Behavioral|Mindfulness and DASH Diet Education|"Mindfulness and DASH diet education will include a didactic presentation on stress, theoretical material related to mindfulness, the somatic mind/body connection, relaxation, yoga, meditation, self-awareness, and bodily cues relating to emotional reactivity. Practices will include the body scan, gentle yoga movement, walking/sitting meditation, breathing, relaxation. Additionally, daily 20 min individual practices are done at least 5x/week delivered via a compact disc player or on a preloaded device. Each participant is asked to track his/her daily meditation practice and given a diary for adherence records. A combination of didactic, experiential, and hands-on activities will be done to deliver DASH diet guidelines."
57335|NCT03736434|Behavioral|Education group|The attention control group will attend eight, 2.5 hours sessions on non-health topics such as personal safety, fire prevention, cold weather protection, disaster preparation, internet safety, aging in place, how to know when it's time to move and managing your money.
57336|NCT03736421|Procedure|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral intravenous waveform analysis (PIVA) obtained by connecting an Edwards standard transducer to a universal adaptor or stopcock on a peripheral IV
57337|NCT03736421|Procedure|Non-invasive fluid response measure|To measure the stroke volume and changes in stroke volume in response to a passive leg raise (PLR) maneuver and fluid administration.
57338|NCT03736421|Diagnostic Test|Passive leg raise (PLR)|Test to predict cardiac output and fluid responsiveness
57339|NCT03736395|Behavioral|Idaho Rural Implementation Model|The Idaho Rural Implementation Model (I-RIM) includes several aspects to support implementation of schoolwide positive behavioral interventions and supports (SWPBIS). In the first year, schools will send a staff member to a coaching institute to build internal capacity. Schools will also receive technical assistance (on-site twice per year and virtual support as needed). Schools will also receive statewide professional learning opportunities, through one group meeting per year, and through access to an invitation-only professional learning community.
57340|NCT03736395|Behavioral|Control|Schools in this condition will receive a four-day training session about SWPBIS.
57341|NCT03736382|Other|Mild intermittent hypoxia|Participants will be exposed to twelve two minute episodes of mild intermittent hypoxia 5 days a week for 3 weeks.
57342|NCT03736382|Other|Sham protocol|Participants will be exposed to twelve two minute episodes of sham mild intermittent hypoxia (i.e. room air) 5 days a week for 3 weeks.
57343|NCT03736382|Other|Continuous positive airway pressure (CPAP)|All participants will be treated with CPAP each night for a duration of 3 weeks.
57344|NCT03736369|Drug|DWP14012 Xmg|DWP14012 X mg, tablet, orally, once daily for up to 8 weeks
57345|NCT03736369|Drug|DWP14012 Xmg placebo|DWP14012 Xmg placebo-matching tablet, orally, once daily for up to 8 weeks
57346|NCT03736369|Drug|Esomeprazole 40mg|Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks
57347|NCT03736369|Drug|Esomeprazole 40mg placebo|Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
57348|NCT03736343|Drug|Alcohol|Participants will complete two drinking sessions.
57349|NCT03736330|Biological|Combinations treatment|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with low dose anti-PD-1 antibody（pembrolizumab, Merck & Co., Inc.） and were transferred to participants via intravenous infusion .
57350|NCT03736317|Device|sham TBS|Stimulate the dorsal lateral prefrontal cortex and medial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
57351|NCT03736317|Device|real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the sham TBS pattern and coil, stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 4 weeks and five times for a week.
57352|NCT03736317|Device|real dlPFC iTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the sham TBS pattern. The therapy will be conducted for 4 weeks and five times for a week.
57353|NCT03736317|Device|real dlPFC iTBS + real mPFC cTBS|Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 4 weeks and five times for a week.
57354|NCT03736304|Device|AKI alert|An AKI alert will send to the doctor in charge. The team of nephrologists would give suggestions if the doctor in charge need a renal consultation.
57355|NCT03736304|Other|Usual care|Patients will receive standard clinical care by the doctor in charge.
57356|NCT03736291|Device|Repetitive transcranial magnetic stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a widely used non-invasive neuromodulation technique that induces excitatory changes in the cerebral cortex stimulated by repeated pulsed magnetic fields on the scalp.
57357|NCT03736278|Other|No intervention|We group the patients according to the outcome (survival vs mortality)
57358|NCT03736265|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day. Target dose of 12.5 mg twice daily per day will be started after 2 weeks if systolic blood pressure does not fall below 90 mm Hg and HR 55/min.
57359|NCT03736252|Device|Orthosis provision|Hely and Weber CMC controller
57360|NCT03736226|Device|SYNERGYTM Stent System|no intervention design in the study
57361|NCT03736213|Behavioral|Biofeedback--visual-acoustic|In visual-acoustic biofeedback treatment, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a dynamic display of the speech signal in the form of the real-time LPC (Linear Predictive Coding) spectrum. Because correct vs incorrect productions of /r/ contrast acoustically in the frequency of the third formant (F3), participants will be cued to make their real-time LPC spectrum match a visual target characterized by a low F3 frequency. They will be encouraged to attend to the visual display while adjusting the placement of their articulators and observing how those adjustments impact F3.
57362|NCT03736213|Behavioral|Biofeedback-ultrasound|In ultrasound biofeedback, the elements of traditional articulatory treatment (i.e., auditory models and verbal descriptions of articulator placement) are enhanced with a real-time ultrasound display of the shape and movements of the tongue. One or two target tongue shapes will be selected for each participant, and a trace of the selected target will be superimposed over the ultrasound screen. Participants will be cued to reshape the tongue to match this target during /r/ production.
57557|NCT03734627|Drug|Sulfasalazine|1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
57363|NCT03736200|Other|Exergaming group|Neurorehabilitation - 4-week-long intervention, targeted postural instability and mobility using at-limit intensity sensori and visuomotor agility training.
57364|NCT03736200|Other|Physiotherapy|Physiotherapy 4-week-long.
57365|NCT03736187|Drug|Cephalexin|Giving cephalexin and metronidazole in one group &cephalexin alone in another group
57366|NCT03736161|Drug|Group A- Tofacitinib|Group A patients will receive Tofacitinib 5mg BD. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to Tofacitinib 5 mg BD at the end of 3 months will be put on Tofacitinib 10 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
57367|NCT03736161|Drug|Group B- Methotrexate|Group B patients will receive Methotrexate in increasing dose weekly with maximum dose up to 25 mg/week. Patients will be followed up at 1, 3 and 6 months. Patients with inadequate response to highest dose of MTX at the end of 3 months will be put on Tofacitinib 5 mg BD. Primary endpoint for efficacy will be determined by ACR 20 response.
57368|NCT03736148|Other|Manual Manipulation|Subject was in supine position, and the therapist applied a manual manipulation with right side bending and left rotation of the neck.
57369|NCT03736148|Other|Instrument-assisted Manipulation|The instrument-assisted manipulation was applied using a handheld Activator IV Adjusting Instrument. Contacts were made firm enough to prevent slipping of the rubber tip but not so firm as to load the spring, in consistence with customary clinical use of the instrument. The spring was then loaded by means of the instrument's trigger mechanism, and the impulse was delivered in an anterosuperior direction, over the posterolateral aspect of the vertebra on the right lamina-pedicle junction of C3.
57370|NCT03736148|Other|Placebo|Subject was in supine position, and the therapist placed ths subject's cervical with right side bending and left rotation but no manual manipulation was applied.
57371|NCT03736122|Drug|BSG-001|"BSG-001 is in solution form, 4mg per vial (2mg/mL) with Inhalation as route of administration using nebulizer.~BSG-001 will be administrated as an approximately 5 - 30 minutes inhalation session daily for 3 cycles (in repeated 28 days cycle)."
57372|NCT03736109|Genetic|Soluble and genetic biomarkers measurements|Insulin-Like Growth Factor-1 and Coll2-1 gene expression will be measured by real time PCR. In addition, syndecan 4, hyaluronic acid, substance P and nitric oxide will be measured in plasma by ELISA
57373|NCT03736083|Device|Freestyle Libre Blood Glucose Monitor|The intervention arm of this study will begin using the Freestyle Libre glucose monitor within 2 weeks of their diabetes diagnosis
57374|NCT03736057|Other|Delayed results of pharmacogenomic results|"1:1 randomization schedule for delayed knowledge of pharmacogenomic results to clinician and patient. Results are released to prescriber at <1 week (unblinded) or 12 weeks (blinded). When genomic results are available upon receipt, unblinded clinicians select an FDA-approved drug from the recommended drugs when possible. Blinded prescribers provide the intended prescription when notified of blinded status. At 4 weeks, 1° outcome measures, NPI-Q and side effects ratings are collected. Clinicians make a GO/NO-GO decision for continuation based on those measures. A NO-GO decision is unblinding and an alternative drug may be prescribed. At 12 weeks, 1° outcomes are collected again. Previously blinded clinicians will be unblinded and may decide to continue or revise the treatment plan based on the clinical outcomes and the genetic results. After the 12 week visit, results of the genetic tests will be entered in the EHR. Further clinical follow-up is based on need."
57375|NCT03736044|Drug|TNF-blockers suspension in patients with rheumatoid arthritis|in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
57376|NCT03736031|Behavioral|Intervention (Promotora)|If the patient is in the intervention group, the promotora will call the patient in order to invite them to a meeting. Meetings will be arranged by the promotora and the patients. A total of 2 group meetings will be required by all participants and 1 family meeting.
57377|NCT03736018|Diagnostic Test|CTCA|Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
57378|NCT03736005|Other|Exposure of significant critical illness|Exposure. Observational study with all patients invited to follow-up clinic for kidney, muscle and functional assessments.
57379|NCT03735992|Behavioral|Mind-body medicine group program|The group program is mainly based on MBSR. It further integrates elements of the mind-body medicine cancer program of the Benson-Henry Mind/Body Medical Institute at Harvard Medical School which is rooted in psychoneuroendocrinology and focuses on relaxation techniques, exercise, cognitive restructuring, diet, and social support. In addition, naturopathic methods of selfregulation and self-care are incorporated.
57380|NCT03735979|Drug|Argatroban|Direct Thrombin Inhibitor - Argatroban is a derivative of arginine that competitively binds to the active site of thrombin thereby preventing fibrin deposition. With a half-life of 30 minutes, argatroban has an immediate anticoagulant effect after IV administration which is rapidly reversed with discontinuation of the drug.
57381|NCT03735979|Drug|Eptifibatide|GP 2b/3a Receptor Inhibitor - The final step of platelet aggregation is mediated via the GP2b/3a receptor. Eptifibatide was specifically developed to ensure rapid inhibition of platelet aggregation (within 15 minutes), a short half-life (~2 hours) and rapid dissociation from platelets with 50% restoration of platelet function within 2-4 hours of discontinuation.
57382|NCT03735979|Drug|Placebo|IV placebo solution
57383|NCT03735966|Drug|Pyrotinib plus trastuzumab and docetaxel|pyrotinib: 400mg orally daily; trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles; docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
57384|NCT03735953|Diagnostic Test|Retroflexion in the total colon|retroflexion in the cecum or proximal ascending colon and slow withdrawal to the rectum
57385|NCT03735940|Other|Spot monitoring device, excl. Sham|o During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. o During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
57386|NCT03735927|Other|Spot monitoring device, excl. Sham|During the control phase the 'care as usual' regarding delirium screening is studied. During the intervention phase the DeltaScan will be studied as screening method for delirium. During the intervention phase the DeltaScan will be used on the exact same moments, i.e. same time and same amount of measures per day, as the screening methods used in the 'care as usual'.
57387|NCT03735914|Other|MRI|Neuralgic patients for which a cryoneurolysis has been indicated, will passed an MRI befor and after the cryoneurolysis to check the presence of the nerve.
57388|NCT03735901|Drug|IMP Levodopa 100mg/Carbidopa 25mg|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive IMP solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive IMP in the morning and at lunch time; on day 38 and 39 solely in the morning."
57389|NCT03735901|Drug|Matching placebo|"Study treatment will comprise 3 phases:~Dose escalation phase: On day 1-3, patients will receive Placebo solely in the morning; on day 4-6 in the morning and at lunch time;~full study treatment phase: from day 7 to day 34, Placebo capsules 3 times per day (tid).~Treatment will stop with a tapering phase: On day 35-37, patients will receive Placebo in the morning and at lunch time; on day 38 and 39 solely in the morning."
57390|NCT03735875|Drug|Quizartinib|Given PO
57391|NCT03735875|Drug|Venetoclax|Given PO
57392|NCT03735862|Biological|Hepatic derived surgical matrix|Hiatal hernia repair with MIROMESH
57393|NCT03735849|Biological|VRC07-523LS|Administered by intravenous (IV) infusion
57394|NCT03735836|Other|MAG-EPA/MAG-DHA omega-3 oils|The monoglyceride (MAG) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are chemically modified fish oils that fall into the Natural Health products category in Canada.
57395|NCT03735823|Other|No intervention, just collect blood samples and CSF samples|No intervention
57396|NCT03735810|Drug|LBS-008|LBS-008 oral capsules
57397|NCT03735810|Drug|Placebos|Oral capsules
57398|NCT03735797|Diagnostic Test|Bone marrow aspirate or peripheral blood sample collection|Collection of specimen samples only
57399|NCT03735784|Behavioral|AWARE|AWARE consists of four group sessions. The AWARE curriculum involves sharing basic information on sexually transmitted diseases; providing condom use skills training; providing normative feedback on substance use and sexual risk behavior among young adults; discussing unrealistic beliefs about substance use and sexual risk; discussing potential benefits of both cutting down and stopping risky behaviors; and discussing risky situations and coping strategies.
57400|NCT03735771|Drug|Bupivacaine|0.25% bupivacaine plus fentanyl 8 mcg/ml
57401|NCT03735758|Drug|pazopanib or guideline conform chemotherapy|Pazopanib (800mg/each day) or guideline conform chemotherapy
57402|NCT03735745|Other|Blood collection|30cc of blood will be collected.
57403|NCT03735745|Other|Saliva collection|5cc of saliva will be collected.
57404|NCT03735745|Other|Tissue collection|Up to 10mg of tissue will be collected.
57405|NCT03735745|Other|Surveys|The Behavioral Risk Factor Surveillance System (BRFSS), Functional Assessment of Cancer Therapy - Head and Neck module (FACT-HN) the Chicago Priority Scale, Cancer Survivor Unmet Needs surveys will be administered at baseline and 3 months post-surgery.
57407|NCT03735706|Radiation|Radiation dose reduction|The radiation dose is is different between groups
57408|NCT03735706|Other|Contrast media volume reduction|Contrast media volume is different between groups
57409|NCT03735706|Radiation|Unenhanced slice|One unenhanced slice at the level of the portal vein will be added to the protocol before administration of contrast media. It will only take a minute to perform this extra slice. The patient does not have to visit the department a second time and no (extra) contrast is needed for this slice.
57410|NCT03735706|Diagnostic Test|Weight|A weighing scale is used to measure a patients body weight right before the scan.
57411|NCT03735693|Diagnostic Test|Ulstrasound|measurement of right femoral cross-section
57412|NCT03735680|Drug|ONM-100|A polymer micelle covalently conjugated to indocyanine green, an FDA-approved fluorophore
57416|NCT03735641|Procedure|Expanded Pedicled Deltopectoral Flap|Expanded Pedicled Deltopectoral Flap is a type of surgical flap
57419|NCT03735615|Behavioral|sprint interval training|Each training session will be performed 3 times per week for 3 weeks. Each session consists of 3-5x20 sec all-out cycling efforts against a load corresponding to 0.05-0.07 kg/kg body mass, separated by 3-5 min of low intensity cycling (20-50 W), on a lode bicycle ergometer (Excalibur Sport V2.0, Groningen, the Netherlands). All training sessions includes a 5 min warm-up and 3 min cool-down.
57420|NCT03735602|Behavioral|perceptual training|orientation discrimination task
57421|NCT03735589|Biological|Alpha-type-1 Polarized Dendritic Cells|Given ID
57422|NCT03735589|Biological|Autologous Natural Killer Cell-like CTLs|Given IP
57423|NCT03735576|Behavioral|Psychotherapy|15-session individually-delivered CBT specific for LLD in comparison with a supportive unspecific intervention (SUI) of the same quantity
57447|NCT03735394|Diagnostic Test|ultrasonic probe|apply the head of the ultrasonic probe on the keratinized tissue of the most protruded upper and lower central incisor in order to measure tissue thickness.
57668|NCT03733756|Procedure|POEM preserving longitudinal muscle|participants are operated POEM only involving circular muscle, leaving longitudinal muscle intact
57424|NCT03735576|Diagnostic Test|Questionnaires|There will be a total of four assessments (see primary & secondary endpoints). The first visit of the study will be a screening and baseline (T0) visit. After the baseline assessment, the subjects will be randomized to either of the two treatment arms. Within one week, the first of the successive bi-weekly 50-minute individual face-to-face treatment sessions will be performed by a study therapist. After 7 therapy sessions, the primary and secondary outcomes will be obtained in week 5 (T1) by the blinded rater. This will be followed by the treatment sessions 8 to 15 which will be carried out by the therapist. End-of-treatment primary and secondary outcomes will be obtained in week 10 (T2). The final follow-up assessment (T3) will be performed 6 months after randomization by the blinded rater.
57425|NCT03735576|Other|Magnetic Resonance Imaging|Underlying mechanisms are examined using neuroimaging. MRI data are acquired at four scanning sites and will be performed at baseline, end-of-treatment and follow-up to obtain a high-resolution structural T1-weighted image, a T2-weighted FLAIR image, a resting state fMRI, and diffusion tensor imaging (DTI) of the subjects' brain.
57426|NCT03735576|Other|Blood analysis|Blood sampling will be acquired in order to investigate the underlying mechanisms in LLD and the specific effects of psychotherapy. Blood samples are acquired at five sites at baseline (T0), T1, T2 and T3 for genetic and epigenetic analyses, measurement of Amyloid-β, Neurofilament light chain (NFL), Peripheral Blood Mononuclear Cells (PBMCs), Metabolomics, Proteomics and miRNA analyses.
57427|NCT03735563|Drug|Ketamine|Individuals will receive randomly either ketamine or fentanyl as a premedication
57428|NCT03735563|Drug|Fentanyl|Individuals will receive randomly either ketamine or fentanyl as a premedication
57429|NCT03735550|Device|Contact thermographic breast examination device|A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.
57430|NCT03735537|Drug|Teriparatide Pen Injector|
57431|NCT03735537|Drug|Zoledronic Acid|Any brand or preparation may be used to deliver the required dose of 5mg
57432|NCT03735524|Other|Exercise|Different exercises will be adopted including: repetition of different movements for ambulation and stair climbing, repetition of crossed patterns of movements for coordination, postural reactions while standing with eyes open and closed and oscillatory boards for balance, strengthening lower limb muscles, and low-intensity and long-duration static stretching of iliopsoas, rectus femoris, hamstrings, triceps surae, and lumbar spinal muscles for muscular flexibility and range of motion. In addition, advanced robotic therapy will be used to standardize rehabilitative treatment and to obtain more objective indexes of motor function. The Lokomat exoskeleton and the Biodex stability system will be used.
57433|NCT03735498|Other|Psychological Intervention|Promote effective coping and reduce caregiving burden
57434|NCT03735485|Other|Conventional Physiotherapy|"The conventional physiotherapy program consisted of electrotherapy and exercise approaches. The electrotherapy program consisted of infrared (for 15 minutes, from 70 cm distance), conventional Transcutaneous Electrical Nerve Stimulation (TENS) in an encircled region (for 20 minutes; with 4 electrodes, 100 Hz, 100 msec), and therapeutic Ultrasound (for 3 minutes; 1 megahertz (MHz), power: 1,5 W/cm²).~A physiotherapist supervised exercise program was performed following the electrotherapy program. Elastic resistive exercises were added at the week three. While, the first set of wand exercises and elastic resistive exercises was performed under supervision, two sets of the showed exercises were given as the home exercise program."
57435|NCT03735485|Other|Shoulder Mobilization|In shoulder mobilization technique while the shoulder joint was placed in the traction, anterior, posterior, and inferior gliding and circumduction were applied to the humerus for 2-3 minutes. All mobilization applications were performed in painless range of motion (ROM) limits. The degree of traction and gliding were increased as the relaxing obtained in the tissues.
57436|NCT03735485|Other|Proprioceptive Neuromuscular Facilitation|"In the Proprioceptive Neuromuscular Facilitation (PNF) program participants received PNF exercises with contract-relax technique, in the patterns of flexion-abduction-external rotation, extension-adduction-internal rotation, flexion-adduction-external rotation and extension-abduction-internal rotation along with the verbal and manual facilitation of the physiotherapist."
57437|NCT03735472|Device|Thoraflex™ Hybrid|"The Thoraflex™ Hybrid device is particularly suited to the treatment of extended lesions of the ascending aorta, the aortic arch and the descending aorta, which constitute a major challenge in cardiovascular surgery.~It enables, during a single surgical operation, combination of the Frozen Elephant Trunk technique and a 4-branch prosthesis of the aortic arch, thus enhancing the arsenal of the surgeon in the treatment of complex diseases of the aortic arch."
57438|NCT03735459|Behavioral|Patient reminders and accountability questionnaires|Participants who are assigned to the patient reminder arm will receive text messages 1, 2, and 4 weeks after enrollment. These text messages will encourage participants to adhere to the provided treatment plan, and ask participants to complete questionnaires to assess their adherence to treatment (in-house Adherence Questionnaire) and severity of eczema (PO-SCORAD) for that week.
57439|NCT03735446|Drug|Prexasertib|Checkpoint kinase 1 (CHK1) inhibitor
57440|NCT03735446|Drug|Mitoxantrone|Standard chemotherapy (topoisomerase inhibitor)
57441|NCT03735446|Drug|Etoposide|Standard chemotherapy (topoisomerase II inhibitor)
57442|NCT03735446|Drug|Cytarabine|Standard chemotherapy (anti-metabolite)
57443|NCT03735433|Drug|162mg aspirin dose|2 pills of 81mg aspirin
57444|NCT03735420|Drug|Xanthohumol|The xanthohumol supplement will be administered in a capsule. Participants in the experimental arm will consume the capsule once per day, with the first meal. The intervention will extend for 8 weeks.
57445|NCT03735420|Drug|Placebo oral capsule|The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
57446|NCT03735407|Device|C-Scan procedure|"The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.~o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,"
57556|NCT03734627|Drug|Paracetamol|Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
57448|NCT03735381|Device|Pedometer watch 'Xiomi mi band2'|"They receive information on the use of the pedometer.~Carry the pedometer (Xiaomi Mi Band 2 ™) from 12 to 32GW.~Prescription of benefits of walking in pregnancy:~Receive information about the goal of steps / day to be reached: 10,000-11,000 steps / day (Only the intervention 2 group).~Receive information on the adequacy of walking with moderate intensity.~They will receive messages on the mobile phone remembering the goal to achieve and a notification that the researching staff will proceed to collect the average count of steps / day of the week prior to 20 and 32 gestation weeks (only for the intervention 2 group)."
57449|NCT03735368|Drug|Dexmedetomidine Injection|Dexmedetomidine Injection 1 μg/kg then 0.5-1 μg/kg/h infusion
57450|NCT03735368|Drug|Placebo oral capsule|placebo oral capsules
57451|NCT03735368|Drug|Pregabalin Oral Capsule|150 mg pregabalin Oral Capsule
57452|NCT03735368|Drug|topical anesthesia|topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
57453|NCT03735355|Procedure|Surgery|Surgical resection of fibrostenotic area
57454|NCT03735355|Procedure|TTS balloon dilation|Dilation of a stricture using TTS balloon
57455|NCT03735342|Other|Audio Recording|All participants will be provided with a re-playable audio recording of the discharge discussion on a portable electronic device. In addition, participants will have the option to record the discharge discussion on a personally-owned smartphone or receive access to the recording online, via the Open Recording Automated Logging System (ORALS).
57456|NCT03735329|Device|Diagnostic test of SPO2|The SpO2 accuracy of the test devices will be evaluated over the oxygen saturation range between 70-100%.
57457|NCT03735316|Drug|Hydroxocobalamin|5g, IV, Infused once over 15 minutes. The drug comes in a 250ml glass vial with 5g of lyophilized hydroxocobalamin to be reconstituted in 200ml of Normal Saline, Dextrose or Lactated Ringers.
57458|NCT03735316|Procedure|Cardiopulmonary Bypass|Technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the patient's body.
57459|NCT03735316|Drug|Placebos|Placebo is a Normal Saline, 5g, IV, Infused once over 15 minutes. The placebo comes in a 250ml glass vial.
57460|NCT03735303|Dietary Supplement|VD3 group|VD3 50000 IU/ week for 8 weeks
57461|NCT03735303|Dietary Supplement|omega 3 FA group|omega 3 FA group 300 mg once daily for 8 weeks
57462|NCT03735303|Dietary Supplement|VD3 and omega- 3FA group|50000 IU VD3/week for 8 weeks and 300 mg of omega- 3 FA once daily for 8 weeks
57463|NCT03735303|Other|control group|no intervention was given
57466|NCT03735277|Biological|HPC, Cord Blood|HPC, Cord Blood is supplied as a cryopreserved cell suspension in a sealed bag containing a minimum of 5 × 10^8 total nucleated cells with a minimum of 1.25 × 10^6 viable CD34+ cells in a volume of 25 milliliters. The exact precryopreservation nucleated cell content is provided on the container label and accompanying records.
57467|NCT03735264|Drug|Anlotinib Hydrochloride plus Docetaxel|Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
57468|NCT03735251|Other|Diuretic，Betaloc，antiplatelet drugs|According to international guidelines,we treated patinets who suffered from different disease
57469|NCT03735238|Other|SMILE Computerized Decision-Aid|SMILE is a computerized decision-aid designed to give lupus patients information about lupus, treatments for lupus available to them, as well as side effects. This will be administered at every lupus clinic session. Every patient will see the SMILE Computerized Decision-Aid at their index baseline clinic visit.
57470|NCT03735225|Drug|Dasiglucagon|Dasiglucagon injection
57471|NCT03735225|Drug|Placebo|Placebo for Dasiglucagon injection
57472|NCT03735212|Behavioral|Enhanced Services|Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
57473|NCT03735199|Device|PCL-TCP scaffold|During the surgery, the scaffold will be shaped by cutting and shaving with a scalpel so as to fit the extraction socket snugly at the crestal half to two-thirds aspect. A collagen membrane will be placed over the scaffold at the crestal aspect of the socket. The periosteum of the buccal flap will then be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
57474|NCT03735199|Device|Geistlich Bio-Gide collagen membrane|A collagen membrane will be placed over the crestal aspect of the socket and the periosteum of the buccal flap will be incised to allow a tension-free primary closure with 4/0 Vicryl® suture.
57475|NCT03735186|Behavioral|Exercise|60 min treadmill exercise performed at 60% of maximum oxygen uptake.
57476|NCT03735173|Device|ReUnion TSA, pegged design|ReUnion total shoulder arthroplasty system, pegged design
57477|NCT03735173|Device|ReUnion TSA, keeled design|ReUnion total shoulder arthroplasty system, keeled design
57478|NCT03735160|Device|pressure sensor|Pressure sensor at the angle of intratracheal tube and nasal alar
57479|NCT03735147|Biological|Live attenuated influenza vaccine (LAIV)|Single dose of LAIV
57480|NCT03735134|Drug|Colchicine Loading Dose|Two milligrams of colchicine will be administrated in addition to the standard of care treatment
57481|NCT03735134|Drug|Standard of care treatment prior to elective PCI|All medications normally given to patients prior to elective PCI
57482|NCT03735121|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in arm or cohort.
57483|NCT03735121|Drug|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the arm.
57484|NCT03735121|Drug|Carboplatin|Carboplatin will be administered as per the schedule specified in the arm.
57485|NCT03735121|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the arm.
57486|NCT03735121|Drug|rHuPH20|rHuPH20 will be administered as per the scheduled specified in the cohort for Part 1.
57487|NCT03735095|Drug|Porfimer Sodium|Given IV
57488|NCT03735095|Procedure|Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy|Undergo EBUS-TBN guided I-PDT
57489|NCT03735082|Drug|Apatinib|apatinib 250mg,qd,d1-14,14day/cycle
57490|NCT03735082|Drug|Paclitaxel|paclitaxel 175mg/m2,d1,14day/cycle+carboplatin AUC=4,d1,14day/cycle
57491|NCT03735082|Drug|Carboplatin|carboplatin AUC=4,d1,14day/cycle;
57492|NCT03735069|Procedure|IPT (Indirect pulp treatment)|Indirect pulp treatment involves complete caries excavation from the dentin-enamel junction using a round bur. Caries near the pulp is removed with caution using spoon excavator until the remaining dentine shows increased resistance to manual instrumentation. A layer of resin-modified glass ionomer (RMGI) dressing material is placed, followed by resin-modified glass ionomer (RMGI) build-up material, and the final restoration; a preformed Stainless Steel Crown (SSC).
57493|NCT03735069|Procedure|Cvek/partial pulpotomy|Cvek/partial pulpotomy involves removal of inflamed pulp tissue to depth until healthy pulp tissue is reached (depth of 2-4 mm), as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 2-5 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber in 2-3 mm thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
57494|NCT03735069|Procedure|Cervical pulpotomy|Cervical pulpotomy involves removal of inflamed pulp tissue from all pulp chamber as indicated by healthy bleeding and arrest of hemorrhage upon pressure with a cotton pellet moistened with 2.5% NaOCl for 6 minutes and repeated for two times if required. Gray MTA will be placed in the pulp chamber (2-3mm) thickness, moist cotton pellet will be placed to ensure setting and the tooth will be temporized with IRM, the patient will be reviewed after 1 week. If the tooth is asymptomatic, final restoration with RMGIC and stainless steel crown will be placed , and a post-operative radiograph will be taken.
57495|NCT03735056|Other|MS Nurse Support|MS Nurse Support intervention is multi-faceted, involving various components (i.e. information provision and emotional support), and a range of strategies and techniques (e.g. psychoeducation, acceptance and commitment), delivered by MS Nurse Specialists, to provide standardised support and advice to patients at diagnosis, to establish and sustain coping strategies. MS Nurse Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
57496|NCT03735056|Other|Peer Support|Peer Support will be delivered by Peer Support Workers using information provision and supportive listening to provide support and advice to patients at diagnosis, and to provide patients the opportunity to talk freely, extensively and confidentially about their experiences, thoughts and feelings about MS diagnosis and its effects on their lives in a non-judgmental and safe environment. Peer Support intervention is person-centred and tailored to the needs and lifestyle of each participant.
57497|NCT03735043|Device|cardiac output by ccNexfin ©|Measurement of cardiac output by ccNexfin © comparatively to transthoracic echocardiography Subjects participating to the study will be simultaneously measured for cardiac output by ccNexfin © and transthoracic echocardiography. Echocardiographic measurements of cardiac output will be blinded to values measured by ccNexfin ©. For each participant, a first measurement of cardiac output will be performed in the supine position and then after 1 minute of strict left lateral position.
57498|NCT03735030|Drug|Human hCG 10'000 IU|A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.
57499|NCT03735030|Drug|Recombinant hCG 6'500 IU|A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.
57500|NCT03735017|Other|Non-Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
57501|NCT03735017|Other|Interactive Virtual Reality Walking|"Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart."
57502|NCT03735004|Device|Transcranial electrostimulation (TES)|Transcranial electrostimulation (TES) with combined direct (DC) and alternating (AC) current, or TES with DC only will be administered through the skin electrodes positioned on the patient's head
57503|NCT03734991|Drug|Ibrexafungerp|Ibrexafungerp 300 mg BID for 1 day
57504|NCT03734991|Drug|Placebo|Matching placebo
57505|NCT03734978|Diagnostic Test|Diagnosis|biochemistry
57506|NCT03734965|Device|AWAKEN INTUBATION|Intubation
57507|NCT03734952|Radiation|Neoadjuvant Radiotherapy Program:|Gross tumor volume (GTV) should include the primary tumor and involved regional lymph nodes as identified on pre-treatment diagnostic studies. Clinical target volume (CTV) is defined as the primary tumor plus 3cm expansion superiorly and inferiorly along the length of the esophagus and a 1cm radial expansion.The nodal CTV should be defined by a 0.5cm expansion from the nodal GTV.CTV should also include coverage the nodal region(s) in which the involved lymph node(s). A total dose of 45 Gy in 25 fractions is delivered 5 days per week on workdays with intensity modulated radiotherapy (IMRT).
57508|NCT03734952|Drug|Neoadjuvant chemotherapy Program|Chemotherapy is delivered concomitantly and composed of two cycles of paclitaxel 135-200mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 21 days at the intervals of neoadjuvant radiotherapy.
57509|NCT03734952|Procedure|Esophagectomy program:|Patients receive esophagectomy in 4-6 weeks after neoadjuvant neoadjuvant chemotherapy
57510|NCT03734952|Radiation|Postoperative radiotherapy program|A total dose of 18 Gy in10 fractions is delivered 5 days per week on workdays with IMRT.
57511|NCT03734939|Other|None intervention is planned.|None intervention is planned, just a survey.
57512|NCT03734926|Drug|ZSP1241|ZSP1241 tablets for oral administration.
57513|NCT03734913|Drug|ZSP1602|ZSP1602 capsules for oral administration
57514|NCT03734900|Other|Saline injection|5ml Placebo infusion of 0.9% Sodium Chloride
57515|NCT03734900|Biological|PRP injection|"Device: Aeon Acti-PRP~5ml autologous platelet rich plasma injection"
57516|NCT03734900|Biological|PL injection|"Device: Aeon Acti-PRP~5ml autologous platelet lysate injection"
57517|NCT03734887|Behavioral|Social Network Feedback|Social networks are cost-free and highly influential social relationships and interactions that influence behavior and conversely are influenced by a patient's behavior. In addition to receiving a private text message regarding their medication adherence rate, participant's feedback will also be shared to a loved-one or friend that the participant is willing to share medical information with.
57518|NCT03734887|Behavioral|Private Feedback|Participant will receive medication adherence feedback from a pharmacist at the start of the study.
57519|NCT03734874|Dietary Supplement|hesperidin|500 mg hesperidin as two capsuls
57520|NCT03734874|Other|control|no supplementation
57521|NCT03734861|Device|BreatheSmart System|"BreatheSmart System: a mobile application that tracks medication usage and sends real time reminders~HeroTracker sensor that counts dosage and monitors real-time medication adherence~CoheroConnect provider portal that allows the Investigator to monitor adherence"
57522|NCT03734861|Other|Standard of Care|These patients are reminded to adhere to the prescribed standard of care therapy provided by their clinician during their clinical encounters and when the family calls to report an illness.
57523|NCT03734848|Drug|Bilateral Ultrasound Guided Pectoralis Nerve Block.|Using a 20‑gauge 5 cm needle. Injection bupivacaine 0.25% used as a local anesthetic. The block was performed in a supine position with the arm slightly abducted. The ultrasound probe was placed at the midclavicular level infero-laterally to locate the axillary artery and vein and then moved laterally toward the axilla until pectoralis major, pectoralis minor, and serratus anterior muscles were identified at the level of the fourth rib. The needle was inserted in‑plane with respect to the ultrasound probe. A volume of 20 ml of local anesthetic solution was deposited in the fascial plane between pectoralis minor and serratus anterior muscle, followed by withdrawal of the needle to the fascial plane between the pectoralis major and pectoralis minor muscle, where a volume of 10 ml was deposited. The block was performed similarly on the opposite side. Care was taken not to cross the toxic dose of bupivacaine (3 mg/kg).
57524|NCT03734835|Dietary Supplement|hesperidin|1000 mg hesperidin as two capsules
57525|NCT03734835|Dietary Supplement|hesperidin and flaxseed|1000 mg hesperidin as two capsules and 30 grams flaxseed
57526|NCT03734835|Dietary Supplement|flaxseed|30 grams flaxseed
57527|NCT03734835|Other|control|no supplementation
57528|NCT03734822|Other|End tidal CO2 (EtCO2)|End tidal CO2 (EtCO2) is monitored through the endotracheal tube during general anesthesia.
57529|NCT03734822|Device|Transcutaneous CO2 (TCO2)|Continuous and noninvasive real-time monitoring of transcutaneous CO2.
57530|NCT03734822|Diagnostic Test|Capillary CO2 (CapCO2)|Capillary CO2 collected by finger stick and run on the i-STAT handheld blood analyzer.
57531|NCT03734822|Diagnostic Test|Arterial blood gas (ABG)|Arterial blood gas collected from the radial artery and run on the i-STAT handheld blood analyzer.
57532|NCT03734809|Drug|Pembrolizumab|200mg every 3 weeks infusion
57533|NCT03734770|Drug|Subcutaneous Progesterone|Subcutaneous progesterone (Pleyris, IBSA Farmaceutici, Italia) 25 mg one time per day (every day at the same time, according to patient's availability and preference).
57534|NCT03734770|Drug|Vaginal progesterone|Micronized vaginal progesterone (Progeffik, EFFIK Spa, Italia) 200 mg three times per day (every 8 hours).
57535|NCT03734757|Procedure|imaging in trimodality|PET-CT and MRI
57536|NCT03734744|Dietary Supplement|Vitamin D3|Vitamin D is a fat-soluble vitamin that plays an important role in immune modulation in addition to its classical roles in regulation of calcium homeostasis and bone health
57537|NCT03734731|Device|Monochromatic Infrared Photo Energy (MIRE)|Apply Monochromatic Infrared Photo Energy (MIRE) to the affected nerve
57538|NCT03734731|Device|Transcutaneous Electrical Nerve Stimulation|Apply Transcutaneous Electrical Nerve Stimulation (TENS) to the affected nerve
57539|NCT03734731|Drug|Opioids|Prescribe Opioids to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator
57540|NCT03734731|Drug|Cannabis|Prescribe Cannabis to treat for pain or circulatory disorders, dosage to be determined by Principal Investigator. Comparing Opioid results to Cannabis results with objective nerve testing
57541|NCT03734718|Drug|GIP|Infusion of Glucose-dependent insulinotropic peptide
57542|NCT03734705|Behavioral|Imaginal Exposure Writing|Imaginal exposure is a psychotherapy strategy that has been studied and shown to be helpful in the improvement of symptoms (e.g., anxiety, worry) for other psychiatric conditions, including excessive worry and obsessive-compulsive disorder symptoms.
57543|NCT03734705|Other|Neutral Writing|Used in prior research as a control condition for imaginal exposure. Neutral writing will involve writing about what one would do on a day off work or school.
57544|NCT03734692|Drug|Rintatolimod|200 mg by IP administration over 1-2 hours
57545|NCT03734692|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion
57546|NCT03734692|Drug|Cisplatin|50mg/m^2 solution
57547|NCT03734679|Device|SurVeil Drug Coated Balloon|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.
57548|NCT03734666|Behavioral|Mindfulness Based Relapse Prevention - Smoking and Alcohol|Mindfulness Based Relapse Prevention (MBRP) is a treatment for preventing relapse in addictive disorders that integrates mindfulness meditation with standard relapse prevention practices.
57549|NCT03734666|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a form of therapy that aims to help individuals modify problematic emotions, behaviors, and thoughts.
57550|NCT03734653|Drug|Transdermal Testosterone|Patients will be prescribed 2 packets of testosterone gel 1% containing 50mg per packet to apply transdermally daily.
57551|NCT03734653|Drug|Standard of Care, Enzalutamide|Patients will take four 40mg capsules of enzalutamide for a total daily dose of 160mg.
57552|NCT03734640|Other|Low-intensity monitoring strategy|Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment
57553|NCT03734640|Other|Guideline recommended standard monitoring|Post-tpa patients will be monitored in the usual care monitoring environment
57554|NCT03734627|Drug|Octreotide Acetate|50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
57555|NCT03734627|Drug|Saline Solution|Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
57558|NCT03734627|Diagnostic Test|Duodenal biopsy|Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
57559|NCT03734614|Drug|Low dose of aspirin|Low dose of aspirin, 100 mg daily for longer than one year
57560|NCT03734601|Radiation|Total body irradiation (TBI)|Administer Total body irradiation (TBI) 80 cGy on Day 1 of standard TLI ATG conditioning
57561|NCT03734601|Drug|Anti-thymocyte globulin (ATG)|Given intravenous (IV), Dose 1.5 mg/kg x 5 days
57562|NCT03734601|Drug|Tacrolimus|Oral, Dose 0.05 mg/kg twice daily, can be given intravenous (IV)
57563|NCT03734601|Drug|Mycophenolate mofetil (MMF)|Given Oral, 15 mg/k every 2 hours for peripheral blood stem cells (PBSC) from matched related donors; 15 mg/kg every 8 hours for PBSC from unrelated donors (URDs) or mismatched related donors.
57564|NCT03734601|Radiation|Total lymphoid irradiation (TLI)|9 x 120 cGy over 11 days
57565|NCT03734588|Genetic|SPK-8016|adeno-associated viral vector
57566|NCT03734575|Device|ClariCore System|The user will perform a standard trans-perineal biopsy and collect a number of biopsy cores as per standard practice.
57567|NCT03734562|Procedure|Ablation|Substrate-based radiofrequency catheter ablation
57568|NCT03734562|Drug|Antiarrhythmic drug|Amiodarone or sotalol therapy
57569|NCT03734536|Device|REGENETEN™ Bioinductive Implant|The REGENETEN™ Bioinductive Implant is a bioabsorbable device that provides a layer of collagen over injured tendons.
57570|NCT03734536|Device|Arthroscopic repair of the high-grade (>50%) partialthickness|Surgical treatment of partial-thickness rotator cuff tears using standard techniques.
57571|NCT03734523|Drug|oral metronidazole|If BV is confirmed at the one week visit, they will be treated with a 7 day course of oral metronidazole (standard of care). Those that are diagnosed and those that are not diagnosed with BV, will continue to use Balance every day, Restore every other day, and BiopHresh every third day until the completion of the study.
57572|NCT03734523|Device|BV Diary|"Once enrolled, each subject will be assigned a study number and receive a packet of study materials from their physician/clinician as well as a Guide to Completing the BV Trial. This is a booklet containing detailed instructions for each day of the study as well as a diary in which participants will record daily symptoms."
57573|NCT03734510|Dietary Supplement|Dietary Supplement: hesperidin and flaxseed|2 capsules hesperidin and 30 g flaxseed
57574|NCT03734510|Dietary Supplement|Dietary Supplement: hesperidin|2 capsules hesperidin
57575|NCT03734510|Dietary Supplement|Dietary Supplement: flaxseed|30 g flaxseed
57576|NCT03734510|Other|control|no supplementation
57577|NCT03734497|Other|"Group Carotis FTc 500 ml Ringer's lactate Lafleks®"|"will receive 500 ml Ringer's lactate Lafleks® if the patient is fluid responder"
57578|NCT03734497|Other|"Group Preloading 10 ml/kg Ringer's lactate Lafleks®"|"will receive 10 ml/kg Ringer's lactate Lafleks® fluid preloading"
57579|NCT03734497|Other|"Group Control 2 ml/kg Ringer's lactate Lafleks®"|"will receive 2 ml/kg Ringer's lactate Lafleks® during anesthesia"
57580|NCT03734484|Diagnostic Test|InSight|The InSight algorithm which draws information from a patient's electronic health record (EHR) to predict the onset of severe sepsis, and in this study will be customized to differentiate between various Gram-type infections.
57581|NCT03734471|Device|Reactor Device|The Reactor is a Class II FDA medical device to facilitate the insertion of chest tubes into the thoracic cavity.
57582|NCT03734471|Procedure|Tube thoracostomy|Traditional chest tube placement
57583|NCT03734458|Other|Group A - PRF plus AFG with a CAF|Group A - PRF plus AFG with a CAF will be used surgically to cover the exposed roots.
57584|NCT03734458|Other|Group B - PRF only with a CAF|Group B - PRF only with a CAF will be used surgically to cover the exposed roots.
57585|NCT03734458|Other|Group C - CTG with a CAF|Group C - CTG with a CAF will be used surgically to cover the exposed roots.
57586|NCT03734445|Dietary Supplement|Vitamin Supplement|Subjects will be randomly allocated to a supplementation of vitamin C 1000mg, vitamin D 400 IU and zinc 10 mg or an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
57587|NCT03734445|Other|Placebo|Subjects will be randomly allocated to a supplementation of an identical placebo. Subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding
57588|NCT03734432|Device|IGAR-Breast TeleOp|Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.
57589|NCT03734406|Other|Videoclips|The images contained in the videoclips show the pathophysiological process underlying the two diseases under study, namely deep vein thrombosis and atrial fibrillation.
57590|NCT03734393|Other|HIVD+/R+|Liver from an HIV-infected deceased donor
57591|NCT03734380|Behavioral|Laboratory-based gait retraining (LGR)|Subjects in the LGR group will be encouraged to modify the gait pattern (e.g. adjusting foot progression angle, performing medial knee thrust, and/or lateral trunk lean) to lower their KAM to 80% of respective average baseline KAM obtained during normal unmodified gait. Real-time auditory feedback will be delivered using stereo speakers from both sides of the staircase. A middle C (261.6 Hz) tone and a high-pitched C (4186.0 Hz) of equal intensity will be generated at a footfall below and above the targeted 80% value, respectively. They will be advised to maintain their new gait pattern during their daily living after training.
57592|NCT03734380|Behavioral|Sensor-based gait retraining (SGR)|Subjects in the SGR group will receive training similar to LGR, except the KAM measurement is based solely on inputs from IMUs embedded in the shoes. In addition, the auditory feedback will be delivered through a pair of earphones connected to a smartphone, which has been pre-installed with an app for KAM measurement. They will be advised to maintain their new gait pattern during their daily living after training.
57593|NCT03734380|Behavioral|Walking exercise control (Ctrl)|Subjects in the Ctrl group will walk on the same instrumented staircase at a self-selected pace without any guidance on gait modification. The training period and training time per session will be identical to the other two groups. They will not be given any instructions for out-of-lab activities.
57669|NCT03733756|Procedure|POEM involving longitudinal muscle|participants are operated POEM involving both circular and longitudinal muscle
57945|NCT03731650|Procedure|maxillary sinus lift|non grafted maxillary sinus floor augmentation with simultaneous implant placement
57594|NCT03734367|Behavioral|Emotional abilities training program|A randomized controlled trial that evaluates the effectiveness of a program of emotional skills on metabolic control to be assessed through the glycosylated hemoglobin (HbA1c), healthy lifestyle habits and wellbeing in adolescents with type 1, Diabetes Mellitus
57595|NCT03734354|Drug|Brexpiprazole|Brexpiprazole , single/oral/with fasting
57596|NCT03734341|Device|EZ START Titration|"The auto CPAP device gradually increases air pressure night-by-night until the preset therapeutic pressure is reached.~Pressure range: from 5 to 14 cmH2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: fixed pressure that reduces rAHI below 10, mask leak below 10% of the session, time session above 4 hours."
57597|NCT03734341|Device|APAP Titration|"The auto CPAP device continuously adjusts the pressure in real time to the minimum pressure needed to maintain upper airway patency at any moment. Pressure range: 5 to 14 cm H2O. Ramp: 4cmH2O, 20 minutes. Mask: nasal (if no contraindication).~Titration pressure: visual analysis pressure that reduces rAHI below 10 during 90% of the session, mask leak below 10% of the session, therapeutic session above 4 hours."
57598|NCT03734328|Procedure|connective tissue graft|"anesthesia of the palatal mucosa~subepithelial connective tissue graft harvesting~suturing (5/0 silk suture)"
57599|NCT03734328|Procedure|connective tissue graft&PRF|"anesthesia of the palatal mucosa subepithelial connective tissue graft harvesting~-suturing (5/0 silk suture)"
57600|NCT03734328|Other|connective tissue graft&PRF|"taking blood from patient~centrifuging blood~obtain PRF"
57601|NCT03734315|Device|Ostenil®|Ostenil® is a CE-certified viscoelastic solution for injection into the joint cavity, containing 1.0 % sodium hyaluronate from fermentation.
57602|NCT03734302|Drug|Brexpiprazole|Brexpiprazole , mutiple dose /oral/empty stomach
57604|NCT03734276|Other|High intensity activity|Cyclo-ergometer session in high intensity setting
57605|NCT03734276|Other|control arm|Usual care
57606|NCT03734263|Drug|sodium phenylbutyrate|Enrolled subjects will receive a four-week period of treatment with sodium phenylbutyrate (oral use)
57607|NCT03734237|Biological|Egg based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
57608|NCT03734237|Biological|Recombinant influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
57609|NCT03734237|Biological|Cell-culture based influenza vaccines|Participants will be randomly allocated to one of three vaccine types in accordance with standard clinical practices for those in the US military. All vaccines are FDA licensed for use in the United States.
57610|NCT03734224|Procedure|Adhesix mesh|Adhesix mesh
57611|NCT03734224|Procedure|Progrip mesh|Progrip mesh
57612|NCT03734211|Drug|Evolocumab|420 mg evolocumab will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
57613|NCT03734211|Drug|Placebo|Placebo will be administered subcutaneously by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector.
57614|NCT03734198|Drug|Ibrutinib|Ibrutinib will be given at the fixed dose of 420 mg daily for the duration of treatment.
57615|NCT03734198|Drug|Daratumumab|Daratumumab will be started 28 days after beginning of ibrutinib and will be administered at the standard dose of 16 mg/kg (divided over two days for the first infusion), then 16 mg/kg for the following infusions, weekly for 2 months, then every other week for 4 months and then once a month until progression or intolerance.
57616|NCT03734185|Other|Learning and Coping|'Experienced patients' plan, teach and evaluate, in cooperation with health professionals.
57617|NCT03734172|Diagnostic Test|Sample collection|Specimen collection
57618|NCT03734159|Drug|Ropivacaine|Injection of 60 ml of ropivacaine 0.25% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
57619|NCT03734159|Drug|sodium chloride 0.9%|Injection of 60 ml of sodium chloride 0.9% divided into 4 injections of 15 ml (2 per side, between ribs 2 and 3 and between ribs 4 and 5)
57620|NCT03734146|Behavioral|Aerobic Exercise|180 minutes of moderate-vigorous intensity aerobic exercise per week
57621|NCT03734146|Behavioral|Resistance Exercise|180 minutes of resistance exercise per week
57622|NCT03734146|Behavioral|Combined aerobic and resistance exercise|180 minutes of exercise per week with 90 minutes per week coming from moderate-vigorous intensity aerobic exercise and 90 minutes per week coming from resistance exercise
57623|NCT03734133|Other|Foot insoles|Different foot insoles of different hardness
57624|NCT03734120|Other|cryopreservation|Samples were frozen with a programmable freezing unit. Each semen sample was divided into two aliquots. One aliquot was plunged into liquid nitrogen and the other was stored in dry-phase nitrogen for 3 or 6 month. Thawing was performed at room temperature
57625|NCT03734107|Behavioral|Plan, Reflect, and Engage with Providers for Diabetes Care|Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care
57626|NCT03734094|Device|Ceramic barrier|The use of a ceramic barrier to induce bone formation during GBR
57627|NCT03734094|Device|Titanium Mesh|The use of a titanium mesh to induce bone formation during GBR
57628|NCT03734081|Device|ODC system (type 1 capsule)|ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
57811|NCT03732716|Diagnostic Test|blood pressure measurement|Intervention: Each patient's supine and standing blood pressure measurements will be recorded
57629|NCT03734081|Device|ODC system (type 2 capsule)|ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
57630|NCT03734068|Device|Chemoembolization Using LifePearl|Chemoembolization Using LifePearl
57631|NCT03734068|Drug|Doxorubicin|Doxorubicin is loaded to LIfePearl
57632|NCT03734055|Behavioral|Peer Mentoring|Manualized peer mentorship program designed to provide modeling and reinforcement by peers (mentors) to other African American women with SLE (mentees) to encourage them to engage in activities that promote disease self-management.
57633|NCT03734055|Behavioral|Social Support Group|Social support controls will participate in a lupus support group created for this project, on the same schedule as peer mentoring sessions.
57634|NCT03734042|Biological|Platelet rich plasma intrauterine infusion|platelet rich plasma will be prepared, activated then infused by Intrauterine insemination catheter intrauterine at day 11
57635|NCT03734042|Biological|Normal saline|Intrauterine infusion of normal saline at day 11
57636|NCT03734029|Drug|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
57637|NCT03734029|Drug|Capecitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
57638|NCT03734029|Drug|Eribulin|Administered according to label, as one option for Physician's Choice (determined before randomization)
57639|NCT03734029|Drug|Gemcitabine|Administered according to label, as one option for Physician's Choice (determined before randomization)
57640|NCT03734029|Drug|Paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
57641|NCT03734029|Drug|Nab-paclitaxel|Administered according to label, as one option for Physician's Choice (determined before randomization)
57642|NCT03734016|Drug|BGB-3111|160 mg orally twice daily
57643|NCT03734016|Drug|Ibrutinib|Ibrutinib 420 mg orally once daily
57644|NCT03734003|Device|liquid nitrogen|As an active comparator, for patients with cutaneous warts, liquid nitrogen crytherapy is applied
57645|NCT03734003|Device|controllable infrared bioeffect system|As an experimental arm, for patients with cutaneous warts
57646|NCT03733990|Biological|FP-1305|The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
57647|NCT03733964|Procedure|Manual therapy|Manual therapy - the mobilisation of joint segments L4-L5 and L5-S1 and mobilisation techniques for soft tissues (functional massage of soft tissues and skin relaxation using the methods of stretching).
57648|NCT03733964|Procedure|PNF|The PNF method - the movement patterns of the scapulae and the pelvis were used (anterior and posterior elevations and depression) along with the patterns of upper extremities (e.g. bending, abduction, outward rotation) and lower extremities (e.g. bending, abduction, inward rotation with bending of the knee joint).
57649|NCT03733964|Procedure|Manual therapy + PNF|Combination therapy - Manual therapy and Proprioceptive Neuromuscular Facilitation
57650|NCT03733964|Procedure|Kinesiotherapy|Traditional kinesiotherapy in the form of active slow exercises of back muscles, abdominal and gluteal muscles on a mat. The patients participated in a uniform treatment programme consisting of ten exercises. Each of the exercises was performed in a number of 20 repetitions.
57651|NCT03733951|Drug|KN046|"Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.~Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia."
57652|NCT03733938|Other|endodontic microsurgery|teeth with failed root canal treatment will be treated by endodontic microsurgery
57653|NCT03733925|Drug|Golimumab|Participants will receive golimumab 50 mg SC injections at Week 0 and q4w thereafter through Week 24.
57654|NCT03733912|Other|Phthalate metabolites measurement|To measure phthalate metabolites of urine and house dust in Pregnancy and Non-pregnancy groups
57655|NCT03733899|Diagnostic Test|Local Anesthesia|Minims Proxymetacaine hydrochloride Eye Drops
57656|NCT03733899|Diagnostic Test|Placebo|Sodium Chloride Solution
57657|NCT03733886|Device|Burst SCS|Burst SCS implies high frequency SCS treatment in intermittent packets with stimulation below detection level.
57658|NCT03733873|Drug|Desmopressin|take desmopressin for 3 months
57659|NCT03733873|Drug|Suoquan|take Suoquan mixture for 3 months
57660|NCT03733860|Procedure|Cavernous tissue sparing penile prosthesis implantation|Beginning penile prosthesis implantation (Coloplast Titan USA) procedure after intracavenosal injection of PGE1 prostine.
57661|NCT03733860|Procedure|Conventional penile prosthesis implantation|Beginning penile implant procedure (Coloplast Titan USA) without prior intracavernosal injection of PGE1 prostine
57662|NCT03733860|Procedure|Intracavernosal injection of alprostadil|Intraoperative intracavernosal injection of alprostadil in the cavernous sparing group
57663|NCT03733821|Device|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation tool
57664|NCT03733808|Device|Repetitive Transcranial Magnetic Stimulation|Non-invasive brain stimulation technique
57665|NCT03733795|Other|TCD|Transcranial Doppler will be used to measure brain blood flow in the middle cerebral artery.
57666|NCT03733782|Dietary Supplement|Modular enteral protein - Prosource|Supplemental protein (2 gm/kg/day of Prosource; Medtrition, Lancaster, PA) was administered via the nasal/oral feeding tube in 60 - 180 ml bolus infusions 2 - 4 times per day, independently of the enteral formula received. That is, the daily target amount of protein was initially administered as the supplement boluses and only after the enteral formula infusion approached the target rate was the amount of supplement decreased. Supplemental protein was reduced by 50% once the patient received 75% of targeted caloric intake over the previous day (0700 - 0700). Once the patient reached the target caloric intake for 48 hours, the amount of supplemental protein was decreased in order that the total protein prescribed equaled 2 gm/kg/day.
57667|NCT03733769|Procedure|transmuscular quadratus lumborum block|transmuscular quadratus lumborum block as an alternative to lumbar plexus block for peri-operative analgesia in hip Surgery
57670|NCT03733743|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
57671|NCT03733730|Device|ACRYSOF IQ RESTOR +3.0 D Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence
57672|NCT03733730|Device|ACRYSOF IQ RESTOR +2.5 D Toric IOL|Intraocular lens (IOL) intended for visual correction of aphakia in adult patients with and without presbyopia, who desire near, intermediate and distance vision, reduction of residual cylinder and increased spectacle independence
57673|NCT03733717|Drug|Isatuximab SAR650984|"Pharmaceutical form: Concentrate for solution~Route of administration: Intravenous"
57674|NCT03733704|Diagnostic Test|Heart rate variability analysis|Heart rate variability analysis extracted from ECG during normal and obstructed breathing
57675|NCT03733691|Drug|Ixazomib|3 mg oral capsule, Days 1, 8 and 15 of 28-day cycles
57676|NCT03733691|Drug|Lenalidomide|Same dose as in the front-line treatment in the last treatment cycle, taken orally, on days 1-28 of a 28-day cycle.
57677|NCT03733678|Behavioral|Price discounts for SARCs|SARCs are offered free to the client
57678|NCT03733678|Behavioral|Price discounts for LARCs|LARCs are offered at lower prices to the client
57679|NCT03733678|Behavioral|Sequential vs. simultaneous recommendations|Top ranked methods are presented to the client sequentially or simultaneously
57680|NCT03733665|Other|Patients admitted to hospital|Data is captured in HES for all patient interactions with the NHS (each episode) in England. All patients admitted for heart failure have data captured in the National Heart Failure Audit.
57681|NCT03733652|Drug|Interferon Alfa 2a|Patents are treated with interferon alfa 2a 180μg hypodermic injection once per week for 48 weeks. Then, interferon alfa 2a will be stopped if there is HBsAg clearance. Else, oral tenofovir 300mg once per day will be used if HBsAg is positive.
57682|NCT03733639|Drug|Tisseel®|Reinforcement of esophagojejunal anastomoses after total gastrectomy with the product.
57683|NCT03733626|Combination Product|ViviGen® Cellular Bone Matrix|ViviGen® is manufactured by DePuy Synthes, Inc. (West Chester, Pennsylvania). ViviGen® Cellular Bone Matrix is comprised of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen® Cellular Bone Matrix is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 1271.3 and will be used with the DePuy Synthes pedicle screw system for fusion.
57684|NCT03733626|Combination Product|Local Bone Autograft|Patient's own bone harvested during spinal surgery will be used with the DePuy Synthes pedicle screw system to create the fusion.
57685|NCT03733613|Other|no intervention|no intervention
57686|NCT03733587|Drug|GX-I7|GX-I7 25mg/ml/vial
57687|NCT03733587|Drug|Cyclophosphamide|Cyclophosphamide 500mg/vial
57688|NCT03733574|Drug|LY03005|Drug: LY03005 80 mg, oral tablets, single dose
57689|NCT03733574|Drug|Pristiq|Drug: Pristiq 50 mg, oral tablets, single dose
57690|NCT03733561|Drug|LY03003|LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)
57691|NCT03733561|Drug|Neupro 4Mg/24Hr Transdermal Patch|neupro patch
57692|NCT03733548|Behavioral|RELAX|Regulating Emotions Like An eXpert (RELAX) consists of 8 weekly, 90-minute sessions delivered (60 minutes of parents and adolescents meeting separately, 30 minutes of a combined meeting) in a group format. RELAX equips adolescents with emotion regulation and conflict management skills. This program includes a parent involvement component designed to help parents support adolescents' use of these skills. Each week skills will be discussed and practiced in group, and a skills rehearsal homework activity will be assigned. Following the program, an 8-week follow-up review session will be offered. Additionally, a single 60 minute focus group will be held following the review session to solicit parent and adolescent feedback on the intervention.
57693|NCT03733535|Drug|Benralizumab|Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody
57694|NCT03733535|Drug|129 Xenon|1.0 L of 129-Xenon/4-Helium mixture to acquire MRI images
57695|NCT03733522|Procedure|Rubber dam isolation|Local anesthesia, use of dental clamp and rubber dam, followed by restoration using universal adhesive system and bulkfill composite restoration
57696|NCT03733522|Procedure|Relative isolation|No local anesthesia, use of cotton rollers and saliva ejector, followed by restoration using universal adhesive system and bulkfill composite restoration
57697|NCT03733509|Procedure|Intraoperative Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision
57698|NCT03733509|Procedure|Ultrasound Block|One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh
57699|NCT03733509|Procedure|Intraoperative Placebo|One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision
57700|NCT03733509|Procedure|Ultrasound Placebo|One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
57701|NCT03733483|Behavioral|Sleep Deprivation|Participants in this arm will sleep for 8 hours at their habitual time for 1 week outpatient. Food will be provided for the outpatient week by the study. After the outpatient week participants will check into our inpatient Clinical Translational Research Center (CTRC) for a 9 day inpatient stay. During their inpatient stay participants will be sleep restricted to a 5 hour/night sleep opportunity for nights 2-7 of their inpatient stay. Outcome measures include a 24-hour serum draw (urine and blood) which will occur on night 1 (pre) and night 8 (post). Patients will be given a 10 + hour recovery sleep period on night 8 of their inpatient stay.
57702|NCT03733470|Drug|Sildenafil study group|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
57703|NCT03733457|Behavioral|Technology-assisted Stepped-care|Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
57704|NCT03733444|Drug|GLPG1690|GLPG1690, film-coated tablets for oral use.
57705|NCT03733444|Drug|Placebo|Matching placebo, film-coated tablets for oral use.
58739|NCT03725059|Drug|Endocrine therapy|Variable endocrine therapy for up 10 years
57706|NCT03733431|Device|Gammacore device|Transcutaneous stimulation of vagus nerve with the device positioned below the mandibular angle, medial to the sternocleidomastoid muscle and lateral to the larynx.
57707|NCT03733431|Device|Gammacore sham device|Sham device which does not deliver electrical stimulation, but instead, produces a buzzing sound will be placed along the lateral border of the sternocleidomastoid muscle in order to avoid mechanical stimulation of the vagus nerve in the carotid triangle.
57708|NCT03733418|Drug|540,000 IU vitamin D3|This intervention was administered as part of VIOLET parent study. A single dose of 540,000 IU vitamin D3 was administered within 2 hours of randomization time.
57709|NCT03733418|Drug|Placebo|Placebo was administered by the VIOLET parent study. A single, liquid enteral dose of placebo was administered.
57710|NCT03733405|Behavioral|Postpartum Visit at 6 Weeks|The patient will be scheduled for a routine postpartum visit at the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
57711|NCT03733405|Behavioral|Postpartum Visit at 2 Weeks|The patient will be scheduled for an earlier postpartum visit in addition to the standard time interval. Each postpartum visit will consist of the standard interview and physical examination. The purpose of this visit is for routine postpartum care. If she has a medical complication during delivery, she may be recommended to schedule an additional earlier visit.
57712|NCT03733392|Device|Advisor HD Grid Mapping Catheter, Sensor Enabled|The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, is indicated for multiple electrode electrophysiological mapping of cardiac structures in the heart, i.e., recording or stimulation only. This catheter is intended to obtain electrograms in the atrial and ventricular regions of the heart.
57713|NCT03733379|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
57714|NCT03733379|Drug|Metronidazole and Amoxicillin placebos|Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).
57715|NCT03733379|Drug|Metronidazole|Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).
57716|NCT03733379|Drug|Amoxicillin|Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).
57717|NCT03733379|Dietary Supplement|Probiotic|The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.
57718|NCT03733379|Dietary Supplement|Probiotic placebo|The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.
57719|NCT03733366|Other|Desk surface|The participants will test all 10 desk surfaces and will be randomly allocated to one of the desks each time.
57720|NCT03733353|Drug|EDP1815|EDP1815 is an orally administered monoclonal microbial
57721|NCT03733353|Drug|Placebo oral capsule|Placebo
57722|NCT03733340|Drug|Imipenem|Imipenem: A wide-spectre antibiotic from the carbapenem group Other name: Imipenem-cilastatin
57723|NCT03733327|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days−7 to −4.
57724|NCT03733327|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
57725|NCT03733327|Drug|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days −3 to −2.
57726|NCT03733314|Drug|E6011|E6011, infusion, intravenously.
57727|NCT03733314|Drug|Placebo|Placebo, infusion, intravenously.
57728|NCT03733301|Drug|Baricitinib|Administered orally.
57729|NCT03733301|Drug|Topical corticosteroid|Administered as standard-of-care.
57730|NCT03733301|Drug|Placebo|Administered orally.
57731|NCT03733288|Behavioral|Education and training sessions|Agents will be invited to attend sessions in intervention week 1, 3, 9, and month 6. Sessions will introduce (week 1) and reinforce (week 3, 9, month 6) the intervention aims, benefits of and ways to move more and sit less, with emphasis on active breaks. Feedback from baseline assessment will be provided and discussed in week 3 (health data) and 9 (activity data) and month 6 (health and activity data from the 12-week assessment). Each session will include discussion of daily standing/walking goals set by the research team, with timers and a goal log provided to participants in week 1 to enable self-monitoring. The Stand Up champions, and their role to encourage daily movement and sitting reduction through modelling and verbal support, will be communicated and reinforced in each session.
57732|NCT03733288|Behavioral|Support emails|Agents will receive support emails weekly (weeks 1-12) then monthly (months 4-9) across the intervention. Each email includes an infographic that encourages moving more and sitting less at work.
57733|NCT03733288|Behavioral|Team leader training|Team leaders in the participating organisation will be invited to attend a training session before the intervention starts. The training aims to enhance team leader's capabilities to demonstrate positive movement and sitting behaviours at work and promote call agents to sit less and move more at work. Team leaders will be asked to include the intervention as an agenda item in their weekly team meetings with their call agents and their 1:1 sessions with call agents. Team leaders will be encouraged to incorporate walking into their 1:1 meetings with call agents.
57734|NCT03733288|Device|Height-adjustable workstation|After baseline, agents in the SLAMM+ arm will have a height-adjustable workstation installed on their existing workplace desk. This will enable work in a seated or standing position, with flexibility to alternate between postures. Desk installation will occur with support from the onsite organisation health and safety team. The research team will brief participants on safe and effective workstation use. A laminated sheet will be fixed to each workstation to remind participants of safe and effective use.
57735|NCT03733275|Drug|Lidocaine|for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
57812|NCT03732703|Drug|Abemaciclib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57736|NCT03733262|Other|De-prescribing Trial|Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
57737|NCT03733249|Drug|Rimiducid|Rimiducid is administered to treat chronic graft versus host disease
57738|NCT03733249|Biological|rivogenlecleucel|donor T-cells modified with iCasp safety switch
57739|NCT03733236|Device|ISS Active Stimulation|ISS SPG stimulation and standard of care
57740|NCT03733223|Drug|Ateptidase|Treatment of ischemic stroke with Ateptidase
57741|NCT03733210|Drug|Panitumumab-IRDye800|50 mg administered intravenously (IV)
57742|NCT03733210|Drug|Zirconium Zr-89 Panitumumab|0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
57743|NCT03733210|Device|Pinpoint IR IR9000 flourescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
57744|NCT03733210|Device|SPY-PHI IR9000 flourescence imaging system (FIS)|Handheld fluorescence-imaging endoscope manufactured by Novadaq
57745|NCT03733210|Device|Explorer Air camera|Fluorescence camera manufactured by SurgVision
57746|NCT03733210|Device|PDE-NEO II camera|Medical infrared camera manufactured by Hamamatsu Photonics KK
57747|NCT03733210|Device|FIS-00 fluorescence imaging system (FIS)|Fluorescence imaging system (FIS) manufactured by Hamamatsu Photonics KK
57748|NCT03733210|Device|Da Vinci Firefly Imaging System|Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
57749|NCT03733210|Device|IGP-ELVIS-v4 Macroscopic Specimen Imager|Macroscopic specimen imager manufactured by LI-COR Biosciences
57750|NCT03733210|Device|Vevo 3100 LAZR-X|Photoacoustic ultrasound imaging system manufactured by VisualSonics
57751|NCT03733210|Device|Pearl Triology Imaging System|Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
57752|NCT03733210|Device|Odyssey CLx Imaging System|Infrared fluorescent imaging system manufactured by LI-COR Biosciences
57753|NCT03733210|Device|Leica fluorescence microscope|Fluorescence microscope manufactured by Leica
57754|NCT03733197|Behavioral|Culture Specific|We anticipate the culture-specific arm developed minimally will include two core components: barbers as motivational interviewers, and (2) fecal immunochemical test (FIT) kits distributed by barbers. If we choose this route for the culture-specific arm, preliminary data from our barbers suggest I teach the barbers the MI technique using content that stems from Aim 1 findings. Additional components for this arm may be developed during the APEASE process.
57755|NCT03733197|Behavioral|Control|the (control) arm will include an informational CRC screening brochure developed by the American Cancer Society74 plus a FIT kit distributed by the barbers.
57756|NCT03733184|Procedure|Cytoreduction and Heated Intraperitoneal Surgery|Cytoreductive Surgery is a procedure that aims for the complete removal of all visible tumours affecting the protective lining of the abdomen. After the surgical procedure is completed, the surgeon introduces a heated, sterile solution mixed with chemotherapy drugs into the abdominal cavity (the HIPEC).
57757|NCT03733171|Drug|PLATELET RICH PLASMA|PRP was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
57758|NCT03733171|Drug|diluted epinephrine|diluted epinephrine was injected in 1-2 ml by multiple injections into and circumferentially around the ulcer until bleeding stopped using a 25-G retractable, standard sclerotherapy needle
57759|NCT03733171|Device|hemoclips|diluted epinephrine was injected followed by application of hemoclips
57760|NCT03733158|Device|the standard Bougie stylet for difficult intubation|intubation with the standard Bougie stylet for difficult intubation and endotracheal tube 7.0 internal diameter
57761|NCT03733158|Device|The new Flexible Tip Bougie catheter|intubation with The new Flexible Tip Bougie catheter and endotracheal tube 7.0 internal diameter
57762|NCT03733145|Drug|Angiotensin II|Participants in the ACE inhibitors, ARBs, and Other Classes of Antihypertensive Agents who's systolic blood pressure (SBP) is less than 80% of the baseline reading is detected, will have Ang II initiated at 2 ng/kg/min through a peripheral IV. The infusion will be increased at the discretion of the clinical team based on the response of the patient until a SBP within 5% of the baseline SBP.
57763|NCT03733132|Drug|Metformin Hydrochloride|Metformin treatment of 2500mg for 10 months in the Metformin group
57764|NCT03733132|Drug|Placebo Oral Tablet|Placebo treatment of identical tablets to metformin group
57765|NCT03733119|Drug|Akt/ERK Inhibitor ONC201|Given PO
57766|NCT03733119|Dietary Supplement|Methionine-Restricted Diet|Given PO
57767|NCT03733106|Diagnostic Test|digital breast tomosynthesis|pseudo three dimension mammography
57768|NCT03733106|Diagnostic Test|standard two dimension digital mammogram|standard two dimension mammogram
57771|NCT03733041|Device|rTMS|This group will receive rTMS treatment
57772|NCT03733041|Device|Sham|This group will receive sham treatment
57773|NCT03733041|Other|No intervention|This group will receive no intervention
57774|NCT03733028|Behavioral|Mobile Intervention for Reducing Anger (MIRA)|This is a mobile intervention that uses interpretation bias modification (IBM) techniques to reduce the hostile interpretation bias. Participants will be given a mobile device with the MIRA app and instructed to complete 5 treatment sessions each week for a period of 4 weeks. Each session takes approximately 10 minutes. The app also includes a Nightly Diary to track symptoms, a calendar to program session reminders, and a My Progress feature to track use and performance.
58034|NCT03730896|Procedure|Dry needling|Dryneedling of the sternocleidomastoid muscles within a standard treatment approach of physical therapy
57775|NCT03733028|Behavioral|Mindfulness Intervention|"This is a mobile intervention that uses the Mindful Breathing and Body Scan exercises from the Mindfulness Coach app. These audio-guided exercises take approximately 10 minutes each. Participants will be given a mobile device with the Mindfulness app and instructed to complete 5 exercises (i.e., Body Scan or Mindful Breathing) each week for a period of 4 weeks. The app also includes a Nightly Diary to track symptoms, a calendar to program reminders, and a My Progress feature to track use and performance."
57776|NCT03733015|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
57777|NCT03733002|Drug|AngongNiuhuang pill|This group will receive AngongNiuhuang pill 1 pill 1 times/day for 5-day.
57778|NCT03733002|Drug|Placebo of AngongNiuhuang pill|This group will receive Placebo of AngongNiuhuang pill 1 pill 1 times/day for 5-day.
57779|NCT03733002|Other|Standard treatment|The other treatments according to guidelines for standard treatment of acute ischemic stroke.
57780|NCT03732989|Device|Interactive toy prototype|The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).
57781|NCT03732989|Device|Non-interactive toy prototype|This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
57782|NCT03732976|Other|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
57783|NCT03732976|Other|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
57784|NCT03732963|Drug|Placebo (Group P)|Group P: 20 patients will receive a placebo tablet preoperatively.
57785|NCT03732963|Drug|Melatonin (Group M)|Group M: 20 patients will receive an oral melatonin tablet 10 mg preoperatively.
57786|NCT03732950|Biological|Pembrolizumab|Given IV
57787|NCT03732937|Diagnostic Test|Ultrasonography|Ultrasonography with biometry and TCD measurement
57788|NCT03732924|Diagnostic Test|Zero to Five Automated Oscillometric Office Blood Pressure (AOBP) Measurement|To compare the difference between the daytime ABPM and AOBP with zero or five minutes wait time.
57789|NCT03732911|Behavioral|Intervention|Participants will receive the following intervention bundle (1) educational materials about child development and developmental monitoring checklists; (2) age and language appropriate picture books; and (3) two tailored text messages per week for a 6-month period.
57790|NCT03732898|Device|New Programming Paradigm|A new programming paradigm will be evaluated.
57791|NCT03732885|Device|densah burs osseo densification drills|maxillary sinus floor elevation during implant placement using Densah burs
57792|NCT03732885|Device|Summer's Osteotomes|maxillary sinus floor elevation during implant placement using Summer's Osteotomes
57793|NCT03732872|Diagnostic Test|Biopsy tissue analysis|biopsy samples for IHC staining and PCR
57794|NCT03732872|Diagnostic Test|Saliva analysis|Saliva samples for miRNA 21 expression analysis
57795|NCT03732846|Drug|Anlotinib|Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression
57796|NCT03732833|Drug|MT10109L|MT10109L will be injected into either the LCL, or both the LCL and GL.
57797|NCT03732833|Drug|Placebo|Placebo will be injected into either the GL, or both the LCL and GL.
57798|NCT03732820|Drug|olaparib|300 mg (2 x 150 milligrams (mg) tablets) twice daily
57799|NCT03732820|Drug|abiraterone acetate|1000 milligrams (mg) once daily
57800|NCT03732807|Drug|PF-06651600 Induction Dose|Oral tablets taken once daily (QD)
57801|NCT03732807|Drug|PF-06651600 Maintenance Dose #1|Oral tablets taken QD
57802|NCT03732807|Drug|PF-06651600 Maintenance Dose #2|Oral tablets taken QD
57803|NCT03732807|Drug|PF-06651600 Maintenance Dose #3|Oral tablets taken QD
57804|NCT03732807|Drug|Placebo|Oral tablets taken QD
57805|NCT03732794|Device|AtriCure CryoICE & AtriClip LAA Exclusion|AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
57806|NCT03732781|Drug|Radspherin|"Radspherin® suspension consists of degradable calcium carbonate micro particles with the α- emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R20 vial filled with 20 mL suspension which consists of approximately 5 g calcium carbonate particles with 1-7 MBq 224Ra. The injected dose will consist of 3-5 g calcium carbonate particles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."
57807|NCT03732768|Drug|Radspherin|Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days. The Sponsor will provide Radspherin® in single dose glass vial and the dose for each subject will be prepared at the site.
57808|NCT03732755|Device|PoNS Treatment|"PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.~Daily Training Program: The same daily training program will be performed during all stages with the exception of the morning BAT session, which is not performed during stage 2 or 3:~Morning:~Warm Up Exercises without the PoNS Balance Training with PoNS Gait Training with PoNS Breathing and Awareness Training (BAT) with PoNS 3- to 4-hour break between morning and afternoon sessions~Afternoon:~Balance Training with PoNS Movement Control Training without PoNS Gait Training with PoNS~Evening:~Breathing and Awareness Training with PoNS To be performed at home during all stages"
57809|NCT03732742|Procedure|TOF repair with trans-annular patch VS preservation of PV|One group study
57810|NCT03732729|Device|massage chair|Patient should use massage chair, twice per day, for 30minutes
57813|NCT03732703|Drug|Enasidenib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57814|NCT03732703|Drug|Cobimetinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57815|NCT03732703|Drug|Erdafitinib, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.
57816|NCT03732703|Drug|Venetoclax, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
57817|NCT03732703|Drug|Daratumumab, dexamethasone, ixazomib, pomalidomide|Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.
57818|NCT03732690|Other|Diet HP|"2000kcal for men 1800 kcal for women. Food boxes (HP pre-cooked meals and meat/chicken/fish portions, HP breads and snacks) will be provided to the participants throughout the study reaching 40-50% of their prescribed daily energy intake for 6 days per week. In total 932 kcal are provided through this food boxes (54g of carbohydrate, 101g of protein, 34,6g of fat). The rest of the daily food intake will be guided by a dietician with a list of recommended high protein foods.~Subjects are required to keep food diaries three days a week and will also have weekly contact with a dietician."
57819|NCT03732690|Other|Diet LP|2000kcal for men 1800 kcal for women. Food boxes (LP pre-cooked meals, LP breads and snacks) will be provided to the participants throughout the study
57820|NCT03732677|Drug|Durvalumab|Anti- PD-L1 Antibody
57821|NCT03732677|Drug|Cisplatin|Chemotherapy Agent
57822|NCT03732677|Drug|Gemcitabine|Chemotherapy agent
57823|NCT03732664|Drug|Nivolumab|Three doses of nivolumab will be administered to enrolled patients on Day -42, Day -28, and Day-14 (+/- two days) prior to planned surgery on Day 0 or up to +10 days.
57824|NCT03732651|Procedure|alteration of PaCO2 level|step changes between 30, 40 and 50 mmHg
57825|NCT03732638|Drug|Rimegepant|BHV-3000 (rimegepant) 75 mg tablet
57826|NCT03732638|Drug|Placebo|75mg matching placebo
57827|NCT03732625|Drug|Raltegravir|DTG will be replaced by Raltegravir (RAL) 1200 QD, maintaining the other two drugs that constituted the triple therapy established before the inclusion of the patient in the study.
57828|NCT03732599|Procedure|Standard Deep Anterior Keratoplasty (S-DALK)|Standard (with the use of a blade) deep anterior lamellar keratoplasty (DALK), which is a partial thickness corneal transplant, which has been shown to be a safe and effective procedure.
57829|NCT03732599|Procedure|IE-DALK (femtosecond)|Femtosecond deep anterior lamellar keratoplasty (DALK). The femotosecond laser technology allows for the creation of precise and reproducible corneal incisions.
57830|NCT03732586|Dietary Supplement|Omega 5 fatty acid supplement|Patients will be randomized to receive traditional treatment (prednisone 40 mg per day) plus omega 5 fatty acid ( 2 capsules of 0.64g per day) for 28 days.
57831|NCT03732586|Other|PLACEBO|Patients will be randomized to receive the traditional treatment (prednisone 40 mg per day) plus placebo (2 capsules of placebo with identical appereance and size like omega 5 supplement) for 28 days.
57832|NCT03732573|Behavioral|Text messages|Text messages conveying 3 specific behaviour change techniques
57833|NCT03732560|Other|Non-Interventional|Non-Interventional
57834|NCT03732547|Drug|PD-1 mAb|Intravenous infusion of PD-1 mAb, 200mg, once a time, every three weeks.
57835|NCT03732547|Drug|PolyIC|Intramuscular injection of polyIC, 2mg, every other day, for three weeks.
57836|NCT03732534|Drug|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
57837|NCT03732521|Other|Educational therapy|educational intervention to the caregiver and individualization according to their family and social context
57838|NCT03732508|Drug|Irinotecan liposome|Irinotecan liposome intravenous infusion will be administered during the first day of treatment.
57839|NCT03732508|Drug|SHR-1316|SHR-1316 intravenous infusion will be administered during the first day of treatment.
57840|NCT03732508|Drug|Fluorouracil|Fluorouracil intravenous infusion will be administered during the first day of treatment.
57841|NCT03732495|Drug|Lenvatinib + Denosumab|"Lenvatinib and Denosumab will be used in the indication of their respective SmPCs.~Study treatments will be divided in fictitious cycles of 28 days. Lenvatinib and Denosumab will be administered as per investigator's decision, based on the data from their SmPC, at starting doses of 24mg once daily and 120mg once every 4 weeks, respectively. Dose modification guidelines of their respective SmPCs will apply.~Lenvatinib should be started the day after the inclusion. It will be taken every day at the same time, preferentially in the morning.~As in routine practice, all patients will be supplemented with daily doses of at least 500mg Calcium and 400IU Vitamin D, unless hypercalcemia is present.~Patients will be encouraged to maintain good oral hygiene during treatment with Denosumab.~Study drugs will be continued until a treatment discontinuation criterion is met"
57842|NCT03732482|Drug|Temozolomide capsules|Temozolomide capsules(Jiangsu tasly diyi pharmaceutical Co.,Ltd) Oral Temozolomide capsules 75mg/m2 begins on day 1 and continues until completion of radiotherapy.
57843|NCT03732482|Device|radiotherapy|Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost
57844|NCT03732469|Drug|Acetaminophen|Rectal acetaminophen will be administered to the intervention group at the conclusion of the oocyte retrieval.
57845|NCT03732469|Drug|Fentanyl|Weight-based IV Fentanyl as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
57846|NCT03732469|Drug|Propofol|Weight-based IV Propofol as a part of the standard anesthesia/analgesia induction protocol at Tampa General Hospital
57847|NCT03732456|Procedure|Shoulder surgery and post-op pharmacological treatment|Usual care surgery (shoulder arthroscopy) and post-operative pain management protocol
57848|NCT03732443|Diagnostic Test|FAM-CAM|Family Confusion Assessment Method
57849|NCT03732430|Drug|IBI308|A humanized anti-PD-1 monoclonal antibody
57850|NCT03732417|Other|Secondary prevention of cardiovascular risk factors|Intervention group (n=35) Control group (n=35)
57851|NCT03732404|Drug|preoperative carbohydrate loading|Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
57852|NCT03732404|Drug|Placebo|The control group will receive plain water with the same volume and timing of treatment.
57853|NCT03732391|Drug|Pembrolizumab 25 MG(milligram)/ML|Carboplatin AUC6 EV will be given every 3 weeks in combination with Pembrolizumab 200 mg EV every 3 weeks for 6 cycles. Afterwards, the Pembrolizumab will be continued with the same schedule until unacceptable toxicity or disease progression
57854|NCT03732378|Dietary Supplement|Omega-3 capsule|Daily one capsule of omega-3 (EPA 300mg, and 200mg DHA) were given anti depressent( citalopram, escitalopram, paroxetine 1 tablet at night time)
57855|NCT03732365|Combination Product|Ultrasonic Drug Delivery|A maximum dose of 2 grams cefazolin in a solution of 1 gram/100 mL sterile saline will be injected into the affected area, followed by a 3-minute application of external ultrasound delivered at an acoustic intensity equal to 3 watts/square centimeter of surface area.
57856|NCT03732365|Drug|Standard of Care Antibiotic Treatment|Antibiotic treatment according to the antibiotic package insert instructions for the particular gram-positive pathogen over a period of no more than 14 days.
57857|NCT03732352|Other|Fludeoxyglucose F-18|Given IV
57858|NCT03732352|Drug|Osimertinib|Given PO
57859|NCT03732352|Procedure|Positron Emission Tomography|Undergo fludeoxyglucose F-18 PET scan
57860|NCT03732339|Device|GILUPI CellCollector®|Use of GILUPI CellCollector® to detect CTC
57861|NCT03732326|Procedure|bariatric surgery|Bariatric surgery for enrolled patients who fulfill the including criteria
57862|NCT03732313|Procedure|Central toenail resection|Using local aneasthesia, resection of central part of toenail with germinal matrix.
57863|NCT03732313|Procedure|Wedge toenail resection|Using local anaesthesia,we remove lateral part of toenail .
57864|NCT03732300|Other|ASSIP|Three PSychotherapy Sessions plus after 3/6/9/12 months individualized letters
57865|NCT03732287|Device|Cooling Anesthesia|Application of cooling anesthesia device prior to intravitreal injection
57866|NCT03732274|Drug|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart. Durvalumab will be administered as a dose of 1500 mg every 4weeks.
57867|NCT03732261|Other|Exercise and dietary|The 12-week study invention will take place between 6 to 8-weeks postpartum and 18 to 20-weeks postpartum, with a follow-up at one year postpartum. The six-week postpartum time point is to allow for exercise clearance from the participant's obstetrician. The exercise clearance is needed prior to the baseline laboratory measurement. Women will be randomized to an intervention group or minimal care group after all baseline measurements (anthropometrics, cardiovascular fitness test, human milk and blood samples and DXA) at six-weeks postpartum. A random numbers table will be used to stratify by parity and determine groups.
57868|NCT03732248|Drug|Rapamycin|Immunosuppressive drug
57869|NCT03732248|Drug|Placebo|Inert drug
57870|NCT03732235|Device|TACE+ systemic Bevacizumab|PEG embolics
57871|NCT03732235|Drug|FOLFIRI+Bevacizumab|antiangiogenic factor
57872|NCT03732235|Device|TACE|PEG embolics
57873|NCT03732222|Procedure|Stretching the diaphragm muscle|Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.
57874|NCT03732222|Procedure|Impulse technique in rotation of cervical level 3 and 4|head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.
57875|NCT03732222|Procedure|Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4|"The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group."
57876|NCT03732209|Behavioral|Episodic future thinking|Participants will engage in episodic future thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
57877|NCT03732209|Behavioral|Control Thinking|Participants will engage in non-future-oriented control thinking, prompted via text-based cues, when making decisions about dietary, exercise, and medication adherence choices.
57878|NCT03732183|Behavioral|Podcast SMART-3RP|28 daily podcasts, each 15 minutes.
57879|NCT03732170|Device|TotalFill® Bioceramic sealer|The participant will be treated with TotalFill® Bioceramic sealer.
57880|NCT03732170|Device|AH plus® sealer|The participant will be treated with AH plus® sealer.
57881|NCT03732157|Procedure|outpatient management of parathyroidectomy|The patient is discharged from hospital the same day of the parathyroidectomy intervention instead of conventional management (stay overnight in hospital)
57882|NCT03732157|Procedure|conventional management of parathyroidectomy|The patient stays overnight in hospital after intervention
57883|NCT03732144|Behavioral|Connect Staff-based PA intervention|After school program sites receiving the Connect intervention will receive a 16 week program that includes three related components - a staff health promotion initiative that helps staff pursue personally-tailored health goals and involves weekly 'check-ins', a tailored social PA curriculum to implement within the program's enrichment hour at least 3 times per week, and a comprehensive staff training program that provides strategies and tools for improving social connections within the program and guided support for implementing the social PA curriculum. Compared to control ASPs, ASPs receiving the `Connect' program are expected to show greater improvements from baseline to post- and 6 mo follow-up in PA-related social mechanisms, youth PA, and staff PA.
57884|NCT03732144|Other|Connect Health Curriculum Control|After school program sites receiving the general ASP health curriculum control will address the prevention of several negative health behaviors (e.g., substance use, stress, etc) and also involve three related components- a comprehensive health program curriculum that includes activities that are interactive and fun and where students will learn about a variety of health behaviors (nutrition, stress reduction, etc.) and life skills through group activities, a staff training program that provides strategies and tools for implementing program curriculum, and on-going support from the Connect staff. This arm will serve as the comparison group to the Connect Staff-based PA intervention
57885|NCT03732118|Device|Eye-tracker Mobile EBT|Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
57886|NCT03732105|Radiation|Radiotherapy|Patients in radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
57887|NCT03732105|Drug|Apatinib|Patients in apatinib group will receive oral apatinib at an initial dose of 500mg daily until recurrence, death,patient withdrawal or unacceptable toxic effects. At the first occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2 or below, and then treatment was resumed with a reduction to 500 mg and 250 mg taken on alternate days. At the second occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2, and then treatment was resumed with a reduction to 250 mg once daily.
57888|NCT03732105|Drug|Radiotherapy+apatinib|Patients in radiotherapy+apatinib group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50 Gy/25 fraction after randomization and after radiotherapy they will receive oral apatinib at an initial dose of 500mg daily until recurrence, death, patient withdrawal or unacceptable toxic effects. Two dose reductions were permitted for apatinib (500 mg and 250 mg taken on alternate days, and 250 mg once daily). At the first occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2 or below, and then treatment was resumed with a reduction to 500 mg and 250 mg taken on alternate days. At the second occurrence of grade 3 or 4 toxicities, apatinib was delayed until recovery to grade 2, and then treatment was resumed with a reduction to 250 mg once daily.
57889|NCT03732092|Diagnostic Test|Coma Recovery Scale-Revised|Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected three stimuli: 1) 1-octene-3-ol, 2) pyridine, 3) water. We presented these three stimuli in front of the patients nose for 3 seconds.
57890|NCT03732079|Diagnostic Test|Ultrasound|Ultrasound to measure the IVC diameter. The IVC diameter will be measured in the inspirium and the expirium, and the collapsibility index will be recorded.
57891|NCT03732066|Behavioral|Usual Text Messages|Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.
57892|NCT03732066|Behavioral|Personalized Reminders|"The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of >180 mmHg or <90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days."
57893|NCT03732066|Behavioral|Interactive Responses|"Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~The researchers will communicate with the patients every month."
57894|NCT03732053|Other|GPR Intervention Research group|The research intervention consisted in the reappointment of three GPR therapeutic postures.
57895|NCT03732040|Other|miswak stick|miswak stick use as preventive hygiene measures
57896|NCT03732040|Other|Miswak plus tooth brushing and tooth paste|use of miswak stick with tooth brushing and fluoride toothpaste for oral hygiene measures
57897|NCT03732040|Other|Standard preventive measures (tooth brushing , interdental cleaning and mouth rinse use containing CHX and Fluoride)|use toothbrush with fluoride toothpaste and interdental cleaning by dental flossing and use mouth wash containing chlorohexadine
57898|NCT03732027|Procedure|Surgical Transversus Abdominis Plane Block|At the end of operation and after hemostasis, 20 ml of 0.25% bupivacaine will be injected intra-abdominally into the Transversus Abdominis plane at the midpoint of the line connecting the crista iliaca and inferior costal margin and at two locations in the lateral abdominal wall at 3-4 cm inferior to the previous midline injection. The same procedure will be repeated on the opposite side using an identical amount of local anesthetic.
57899|NCT03732027|Procedure|Surgical Rectus Sheath Block|At the end of operation and after hemostasis,20 ml 0.25% bupivacaine will be administered slowly under direct vision after careful aspiration to the rectus sheath space which is present inbetween rectus abdominis muscle and the posterior layer of its sheath at the upper pole of the midline incision by time of closure of the anterior abdominal wall. The procedure will be repeated on the opposite side.
57900|NCT03732001|Drug|Anlotinib combined Docetaxel|Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
57901|NCT03732001|Drug|Docetaxel|Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
57902|NCT03731988|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
57903|NCT03731988|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 5.5% or 11% or 22% laser density with 350 µm ablation depth, level 1 coagulation and a single pulse
57904|NCT03731988|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
57905|NCT03731988|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
57944|NCT03731663|Behavioral|Exposure to neutral pictures|Participants allocated to the control group will watch a 3 minute video presenting a series of control pictures of tourist attractions in London. An audio of a young adult describing herself visiting these sites during a trip will be played.
57906|NCT03731988|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
57907|NCT03731975|Procedure|CTZ Paste|Tooth allocated to this group will be treated with CTZ paste, according to the Cappielo's protocol (1964), updated by Moura et al. (2016).
57908|NCT03731975|Procedure|GP Paste|Tooth allocated to this group will be treated with Guedes-Pinto paste, according to the Guedes-Pinto's protocol (1981), updated by Mello-Moura et al. (2011).
57909|NCT03731962|Procedure|Coronary Angiography|All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
57910|NCT03731949|Diagnostic Test|Ultrasonography|Ultrasonography to assess placental volume
57911|NCT03731936|Other|No intervention|No intervention
57912|NCT03731923|Diagnostic Test|Biannual ultrasonography|Biannual liver ultrasonography for HCC surveillance, without contrast agent.
57913|NCT03731923|Diagnostic Test|Annual abbreviated liver MRI|Abbreviated liver MRI using standard dose of extracellular contrast agent (Dotarem, Guerbet, France) on weight-based dosing. Table time targets 10 minutes.
57914|NCT03731910|Diagnostic Test|MRI|liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.
57915|NCT03731897|Other|5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
57916|NCT03731897|Other|9 cc salin + 1cc 2% lidocaine.|Plantar fascia will be injected to the places where it adheres to the bone.
57917|NCT03731884|Other|Time from the onset of symptoms to PCI|Patients will be divided in two groups according to the time from the onset of symptoms to PCI
57918|NCT03731871|Diagnostic Test|Ultrasonography|ultrasound to evaluate parameters of fetal maturity during pregnancy
57919|NCT03731845|Genetic|Blood sample for genetic test|Patients will be genotyped for single nucleotide polymorphism previously found to be associated with age at natural menopause
57920|NCT03731845|Biological|Blood sample for hormonal measurement|at each visit : 2x7ml. At the end of the study hormonal measurements (AMH, P4, LH, FSH, E25)
57921|NCT03731845|Other|Ovarian ultrasound scan|Ovarian ultrasound scan at follow up visits (Y1,Y1.5, Y2.5 Y3.5 Y4.5 Y5.5)
57922|NCT03731832|Drug|MLN9708|Study drug will be given as a single, oral dose of 4.0 mg weekly (day 1, 8 and 15) for 3 weeks, followed by 1 week without study drug in a 28-day cycle
57923|NCT03731832|Drug|Pomalidomide 4 MG Oral Capsule|Study drug will be given as an oral dose of 4.0 mg on day 1 until day 21, followed by 1 week without study drug in a 28-day cycle.
57924|NCT03731832|Drug|Dexamethasone|Dexamethasone will be administered as a single, oral dose of 40 mg/day weekly on day 1, 8, 15 and 22 in patients from 18 to 74 years old. For patients ≥ 75 years old dose has to be reduced to 20 mg/day with the same treatment schedule.
57925|NCT03731832|Drug|Cyclophosphamide|Cyclophosphamide will be administered once daily as an oral dose of 50 mg on cycle days 1 to 21, followed by one week without drug in a 28-day cycle.
57926|NCT03731819|Diagnostic Test|Abbreviated PB MRI|Abbreviated PB MRI which targets table time of 10 minutes. For MRI acquisition, standard dose of commercially available MR contrast agent (Gadovist, Bayer, Germany) is used on weight-based dosing (0.1mmol/kg).
57927|NCT03731793|Biological|Non-Animal Chondroitin Sulphate|Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
57928|NCT03731793|Other|Placebo|Placebo
57929|NCT03731780|Other|Personalized Treatment|Targeting individual caries risk factors
57930|NCT03731780|Other|Chlorhexidine and Remineralization|chlorhexidine mouth wash and remineralizing agent
57931|NCT03731780|Other|Control|Control is standard preventive measures (tooth brushing, fluoride tooth paste, interdental cleaning)
57932|NCT03731767|Procedure|Distraction thrust manipulation|Distraction thrust manipulation of the talocural joint in supine position
57933|NCT03731754|Procedure|Traditional Closure|Primary closure discontinuously the perineal wound of APR
57934|NCT03731754|Procedure|"Cross closure"|Two triangles of skin in the horizontal direction are excised to enlarge the skin incision, and the tumor resected. Then circumferential subcuticular suture of wound, and with tightening of the circumferential suture, the wound resembles a cross.
57935|NCT03731741|Drug|Pentoxifylline|a known drug of xanthine derivatives used in intermittent claudication
57936|NCT03731728|Behavioral|Group CBT|"All therapists will use a manualized Cognitive-Behavior Therapy (CBT) protocol with the same handouts and schedule developed based on the book Mind Over Mood. Group CBT will be provided to a group of maximum 10 participants. Each session will be 2 hours long and will be provided by certified therapists with special training to deliver group CBT. The structure of the session will be agenda setting, check-in, review of homework, new concepts/skills, homework assignment, and feedback."
57937|NCT03731728|Behavioral|Group exercise|Participants enrolled in the group exercise plus TAU arm of the study will be wait-listed for TAU and will receive 50 minutes of scheduled and facilitated exercises three times a week for 14 weeks.
57938|NCT03731715|Drug|Carisbamate|An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
57939|NCT03731689|Drug|Intrauterine lavage therapy|Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
57940|NCT03731689|Drug|Intrauterine gel-injection therapy|Intrauterine gel-injection treatment was performed within 3 to 7 days after the first menstrual period after surgery.
57941|NCT03731676|Device|Fixed bearing total knee arthroplasty|Fixed bearing total knee arthroplasty
57942|NCT03731676|Device|Rotating platform total knee arthroplasty|Rotating platform total knee arthroplasty
57943|NCT03731663|Behavioral|Exposure to pictures of appetizing food (known as Foodporn)|- Participants allocated to the experimental group will watch a 3 minute video presenting a series of pictures of appetizing foods. An audio of a young adult describing herself eating these foods during a trip to London will be played.
103776|NCT03375307|Drug|Olaparib|Given PO
57946|NCT03731611|Procedure|Umbilical Cord Milking|Umbilical cord milking (UCM) is typically performed by placing the infant below the level of the placenta. The cord is held at 20-25 cm distance from the baby and milked vigorously towards the umbilicus for 3 times at a speed of 10 cm/sec. After completion, the cord is clamped, and the neonate is handed to the resuscitation team.
57947|NCT03731598|Procedure|bed rest|Volunteers will be physically inactive on bed rest at the clinical research center
57948|NCT03731585|Behavioral|Behavioral Intervention|Participate in psychological sessions
57949|NCT03731585|Other|Educational Intervention|Participate in educational sessions
57950|NCT03731585|Other|Questionnaire Administration|Ancillary studies
57951|NCT03731585|Procedure|Support Group Therapy|Participate in group sessions
57952|NCT03731572|Other|Power Training|Hip abductor-adductor resistance exercises at maximum execution speed
57953|NCT03731572|Other|Strength Training|Hip abductor-adductor resistance exercises at reduced execution speed
57954|NCT03731559|Drug|DTG 50 mg OD with food|Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
57955|NCT03731559|Drug|DTG 50 mg BID|Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
57956|NCT03731546|Procedure|Delayed cord clamping|Cord clamping 60 seconds after delivery of fetus in preterm infants
57957|NCT03731533|Behavioral|WellStart|"Five weekly automated text messages linked to an online article on health and wellness.~Five weekly automated health coach motivational text message to smart phone. Optional back and forth text with their health coach is available.~Daily Option to participate and post comments or questions in online discussion forum moderated by health coaches.~Three group (up to 20 participants) health coach online visits (60 minutes).~Two online group visits with a dietitian in groups of 10-12 participants.~Three one-on-one online visits with a Physician Advisor to review progress, review any changes in medications by the primary medical provider (PCP), review biometrics and lab results, review safety guidelines and symptoms (30 minutes)."
57958|NCT03731520|Diagnostic Test|Assessing exercise behavior|11-point Numeric Analogue Scale (NRS) for satisfaction of exercising, Exercise Stages of Change Scale-Short Form (ESCS), Exercise Self-Efficacy Scale (ESES), and Decisional Balance Scale (DBS) for exercise behaviour will be inquired for the patients with JIA.
57959|NCT03731507|Device|Assessment of Range of Motion with Kinect Controller|A ROM measurement method called as KinectROM by us has been developed with Kinect Controller
57960|NCT03731494|Biological|Nickel oral hyposensitization treatment|Nickel oral hyposensitization treatment (NiOHT) was performed with hard gelatin capsules containing Nickel sulphate (NiSO4) at different dosages (0.1 ng, 1 ng, 10 ng, 0.1 μg, 0.5 μg) and microcrystalline cellulose as excipient (TIO Nickel, Lofarma SpA, Milan, Italy). Treatment was given 3 times a week increasing progressively the dose from 0.1 ng to 3 μg in 10 weeks with a maintenance phase of 1,5 μg a week for a period of 12 months. After 6 months, patients were allowed to gradually reintroduce nickel-rich foods, starting with those with a maximum of 100 mcg of nickel content. For all the treatment period, information on the appearance of side effects or more severe adverse reactions and the need for antiallergic drugs (corticosteroids, antihistamine drugs) were collected.
57961|NCT03731481|Behavioral|Lifestyle Medicine|Lifestyle Medicine programs provide instruction in plant-based nutrition, food preparation, methods of stress reduction and incorporation of physical activity into daily routine.
57962|NCT03731468|Drug|local anesthetic|ultrasound guided superficial cervical block in thyroid surgery
57963|NCT03731468|Drug|Dexmedetomidine|dexmedetomidine will be added to ultrasound guided superficial cervical block in thyroid surgery
57964|NCT03731455|Device|Wise Cortical Strip|The Wise Cortical Strip is a medical device composed by a strip, to be positioned on the exposed surface of the brain, and by a cable, that allows the transmission of the electrical signals to and from a commercial connecting cable.
57965|NCT03731442|Radiation|Involved field irradiation|Involved field irradiation; intensity-modulated radiation therapy
57966|NCT03731442|Radiation|Elective field irradiation|Elective field irradiation; intensity-modulated radiation therapy
57967|NCT03731442|Drug|Paclitaxel|Paclitaxel 135-150mg/m2, d1, every 3 weeks
57968|NCT03731442|Drug|Platinum|for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;
57969|NCT03731442|Drug|PEG-rhG-CSF|PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy
57970|NCT03731429|Drug|Lidocaine|prior to extubation
57971|NCT03731429|Drug|Saline Solution|Prior to extubation
57972|NCT03731416|Procedure|GBR by xenograft and autogenous bone|Ridge augmentation by native collagen membrane and mix of anorganic bovine bone derived mineral with particulated autogenous bone chips (ratio 1:1).
57973|NCT03731403|Other|MI varnish|CPP- ACP with 5 % sodium fluoride GC
57974|NCT03731390|Drug|GR1405 injection|Intravenous administration according to the patient's weight. All dose groups were administered once every 2 weeks.
57975|NCT03731377|Drug|Crystalloid Solutions|Mini-fluid challenge with crystalloid 250 ml will be given to patients first. After observation of hemodynamic parameters, further fluid challenge will be given for response observation.
57976|NCT03731364|Drug|CA-008|5 mg in 100 mL 10 mg in 100 mL 15 mg in 100 mL
57977|NCT03731364|Drug|Placebo|Placebo in 100 mL
57978|NCT03731351|Procedure|Mechanical Thrombectomy|Acute Ischemic Stroke patient with Large Vessel Occlusion and NIHSS less than or equal to 5 will have a standard of care mechanical thrombectomy. Mechanical thrombectomy is a treatment for stroke that removes clots that block large blood vessels. Some patients may be candidates for this procedure using an angiogram or a catheterization and a device that grabs clots and removes them, to reestablish blood flow to the brain.
57979|NCT03731325|Behavioral|Episodic Future Thinking Group|"Participants in the Episodic Future Thinking (EFT) Group will train with EFT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are descriptions of future events the participant can vividly imagine as happening right now.~Participants will be instructed to think about the EFT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their EFT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
58740|NCT03725059|Radiation|Radiation therapy|Variable radiation therapy per local standard of care
57980|NCT03731325|Behavioral|Healthy Thinking Group|"Participants in the Healthy (HT) Group will train with HT throughout the entire study. As part of the training, research staff will help participants create cues. Cues are statements about the nutrition of food and the health benefits of physical activity.~Participants will be instructed to think about the HT cues they created to help them focus on the future and importance of reaching their weight-loss goals. Participants will be instructed to use their HT cues at least once per day, but will be encouraged to use their cues with every eating and physical activity decision."
57981|NCT03731312|Other|No intervention|This is an observational study and no interventions will be administered.
57982|NCT03731286|Dietary Supplement|EnXtra|2 capsules
57983|NCT03731286|Dietary Supplement|EnXtra|2 capsules
57984|NCT03731286|Dietary Supplement|Microcellulose crystalline|2 capsules
57985|NCT03731273|Behavioral|portion size|"Smaller than normal portion size - the intervention is the meal size perceived as 'smaller than normal' that participants are provided with during a lunchtime session in the laboratory.~'Small-normal' portion size - the intervention is the meal size perceived as 'small normal' that participants are provided with during a lunchtime session in the laboratory.~'Large normal' portion size - the intervention is the meal size perceived as 'large normal' that participants are provided with during a lunchtime session in the laboratory."
57986|NCT03731260|Drug|Avapritinib|Avapritinib tablet
57987|NCT03731260|Drug|Placebo|Placebo tablet
57988|NCT03731247|Device|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
57989|NCT03731247|Device|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
57990|NCT03731234|Drug|Ibrutinib|Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance
57991|NCT03731221|Drug|Bupi HCI and lipo bupi|The local anesthetic (LA) used for the PECS II or serratus plane blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Treatment patients will also be given liposomal bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc. San Diego, CA) in a dose of 266 mg in 20 ml can be safely combined with bupivacaine HCL at a ratio not exceeding 2:1, but cannot be combined with other local anesthetics due to the concern of rapid release of encapsulated bupivacaine and subsequent local anesthetic toxicity.
57992|NCT03731221|Drug|Bupi HCI|The LA used for the blocks will be a 0.5% bupivacaine HCL, not to exceed 2.5mg/kg or up to 150mg. The LA solution can be diluted with preservative free normal saline for smaller patients to allow for appropriate volume of injection. Control patients will have preservative free normal saline mixed with 0.5% bupivacaine HCL and all patients will have a total block solution volume of 60 ml.
57993|NCT03731208|Device|Telerehabilitation|"The telerehabilitation program equipment consists of the following devices:~a tablet with a keyboard and a fingerprint sensor~two wearable sensors~a wireless modem~measuring tape"
57994|NCT03731182|Biological|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
57995|NCT03731182|Biological|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
57996|NCT03731169|Genetic|Voriconazole genotype-specific dosing|"Those in the intervention arm will receive an experimental dosage regimen of voriconazole based on their genetic status.~URM: 6 mg/kg voriconazole twice on the first day followed by 5 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~EM: 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy.~HEM and PM: 6 mg/kg voriconazole twice on the first day followed by 2 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy."
57997|NCT03731169|Drug|Standard of Care|Participants are given 6 mg/kg voriconazole twice on the first day followed by 4 mg/kg twice daily, rounded to the nearest 50mg for oral formulations up to day 4 post-start of voriconazole therapy. After TDM is conducted on day 4 for all patients, dosing in both trial arms will adhere to the following in order to reach the target therapeutic window: 1.0-5.5 mg/L.
57998|NCT03731143|Procedure|insertion of self retaining bicanalicular stent|"The pigtail probe was passed through the canalicular system from the normal punctum to the occluded aspect. When the tip of the pigtail probe was positioned near the occluded punctal area, the surgeon pushed the area to be tented with the pigtail probe. After they advanced the pigtail probe back and forth several times until they could locate the correct position of the occluded punctum, the authors incised the tented area with a scalpel No. 11 to make a new punctal opening.~To ensure punctal and canalicular patency, syringing was repeated through the perforated punctum. To prevent re-occlusion of punctal opening, a self retaining bicanalicular tube (FCI®; Paris, France) was inserted through the normal and perforated puncti"
57999|NCT03731130|Other|EORTC QLQ C30|standardized questionaire
58000|NCT03731130|Other|EORTC QLQ CR29|standardized questionaire
58001|NCT03731117|Drug|Furosemide|"Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period"
58002|NCT03731104|Device|Near InfraRed Spectroscopy assessment|"Regional Cerebral Oxygen saturation (rScO2 ) values will be collected for all patients during the procedure using a 2-wavelength (730-810 nm) cerebral oxymeter (monitor INVOS 5100C®, Medtronics). Two transducers will be placed on both fronto-parietal sides of the patient's head.~To assess the balance between oxygen delivery and consumption, the Fractional cerebral Tissue Oxygen Extraction (FTOE) will be calculated as this ratio: FTOE=[SpO2-rScO2]/SpO2.~Data will be collected for a period of 3 hours starting from the beginning of catecholamine treatment."
58035|NCT03730883|Procedure|Central line removal at 100ml/kg/day.|In this group central line will be removed at the time the infant reaches 100 ml/kg/day of enteral intake if well tolerated.
58036|NCT03730883|Procedure|Central line removal at 140ml/kg/day.|In this group central line will be removed at the time the infant reaches 140 ml/kg/day of enteral intake if well tolerated.
58741|NCT03725059|Procedure|Surgery|Definitive surgery for breast cancer
58003|NCT03731104|Device|Transcranial Doppler Ultrasound assessment|"Transcranial Doppler ultrasound will be performed for all patients during the procedure using a VIVID S-5 (General Electric®) echograph. All examinations will be performed by a single trained operator. A 3 MHz probe will be placed on left and right temporal window to detect signal from the middle cerebral artery. 2 measures will be performed for each side to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
58004|NCT03731104|Device|Cardiac output assessment|"Transthoracic echocardiography will be realized for all patients during the procedure using a transthoracic ultrasound device (VIVID S-5, General Electric®) with a 3 to 6 MHz probe. All examinations will be performed by a single trained operator.~Two echocardiographic views will be examined to assess cardiac output : the two-chamber long-axis view to measure sub-aortic diameter (d), and the four-chamber view to measure the Left ventricular outflow tract velocity time integral (LVOT VTI). Cardiac output (Qc) will then be calculated taking account these parameters and heart rate with this formula : Qc = [π x d2 x VTI x HR] / 4 2 measures will be performed to have the mean of the two measures; In case of difference in measures of more than 20%, a third measure will be performed.~Measures will be performed for a period of 3 hours starting from the beginning of catecholamine treatment."
58005|NCT03731091|Drug|Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064%|Once daily for 4 weeks (28 days)
58006|NCT03731091|Drug|Enstilar® foam (LEO Pharma Inc.)|Once daily for 4 weeks (28 days)
58007|NCT03731091|Other|Placebo of Calcipotriene/ betamethasone dipropionate topical foam|Once daily for 4 weeks (28 days)
58008|NCT03731078|Other|CBT Informed physical therapy Intervention|The 12 physical therapy sessions delivered in Massachusetts General Hospital outpatient physical therapy sites sessions include:1) evaluation and education; 2) strategy identification and goal setting; 3) functional strengthening part one; 4) functional strengthening part two; 5) pre-gait activities with distraction; 6) gait training with distraction and use of strategies; 7) minimizing tremor with use of strategies; 8) higher level balance training; 9) functional reintegration part one; 10) functional reintegration part two; 11) identification of strategies to limit recurrence; 12) education for relapse prevention.Patients will also be given and asked to complete the self-guided CBT workbookL Overcoming Functional Neurological Symptoms: A Five Area Approach. They will be asked to complete the first two chapters over the first 4 weeks and the remaining 8 chapters over the following 8 weeks.
58009|NCT03731065|Dietary Supplement|Fructose-maltodextrin|Fructose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
58010|NCT03731065|Dietary Supplement|Fructose-maltodextrin hydrogel|Fructose plus maltodextrin in a ratio of 1:1.4, encapsulated in an alginate-pectin hydrogel diluted in water to produce a 16% carbohydrate solution.
58011|NCT03731065|Dietary Supplement|Glucose-maltodextrin|Glucose plus maltodextrin in a ratio of 1:1.4, diluted in water to produce a 16% carbohydrate solution.
58012|NCT03731052|Drug|188-0551 Spray|Topical Spray containing active drug
58013|NCT03731052|Drug|Vehicle Spray|Topical Spray containing no active drug
58014|NCT03731039|Other|Observational study|Pain assessment, Anxiety assessment, Depression assessment
58015|NCT03731026|Combination Product|LightPath® Imaging System and 68Ga-RM2|"Imaging System:The LightPath® Imaging System is an in vitro diagnostic device which has CE mark in Europe, in line with In Vitro Diagnostic Medical Devices 98/79/EC (post-marketing study).~Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical."
58016|NCT03731026|Drug|68Ga-RM2|Radiopharmaceutical: 68Ga-RM2 is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
58017|NCT03731013|Behavioral|Mediterranean diet (MedDiet)|Participants randomized in the Mediterranean diet group without physical activity will be instructed and supported towards adhering to principles of the Mediterranean diet, without changes in physical activity habits.
58018|NCT03731013|Behavioral|Physical activity (PA)|Participants randomized in the group physical activity without Mediterranean diet will participate in a structured, supervised PA program to achieve 150 min of moderate PA per week, without changes in dietary habits.
58019|NCT03731013|Behavioral|Mediterranean diet and physical activity|The combination group (MedDiet + PA) will receive the combination of both interventions.
58020|NCT03731000|Device|PHIL® device|Using PHIL® device for treatment of intracranial dural arteriovenous fistulas
58021|NCT03730987|Behavioral|HoMBReS intervention|The experimental group (group A) will receive an intervention based on social cognitive theory and empowerment education that aims to reduce risky sexual behaviors among recently migrated rural men.
58022|NCT03730987|Behavioral|Families Talking Together|The brief intervention, is a parent-based intervention to teach parents effective strategies proven to reduce adolescent sexual risk behavior. The intervention specifically targets the parent (not the adolescent) to: promote communication skills, build parent-adolescent relationships, develop effective monitoring strategies, and prepare them to teach adolescents assertiveness and substance abuse refusal skills.
58023|NCT03730987|Behavioral|Diabetes Prevention Intervention|Session content will focus on the importance of physical activity, healthy eating and maintaining a healthy weight.
58024|NCT03730974|Device|Protac Ball BlanketTM (7kg Flexible)|All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
58025|NCT03730961|Drug|BMS-986231|Intravenous administration
58026|NCT03730961|Drug|Furosemide|Intravenous administration
58027|NCT03730961|Drug|Placebo|Intravenous administration
58028|NCT03730948|Biological|DC vaccine|DC vaccine for colorectal cancer
58029|NCT03730935|Device|Respiratory muscle endurance training|Respiratory muscle endurance training performed over the duration of 4 weeks
58030|NCT03730922|Procedure|Delayed-immediate reconstruction|Skin sparing mastectomy and reconstruction with silicone implant or expander covered by pectoral muscle and mesh or matrix. Final reconstruction with any reconstructive procedure 6-12 months after completion of chemotherapy and RT.
58031|NCT03730922|Procedure|Delayed reconstruction|Total mastectomy and delayed reconstruction:with any reconstructive procedure 6-12 months after completion of PMRT
58032|NCT03730909|Drug|Sodium Lactate|IV infusion
58033|NCT03730909|Drug|Sodium chloride|IV infusion
58037|NCT03730870|Diagnostic Test|Pharmacogenomics report|Intervention is the performance of a pharmacogenomics laboratory-developed test (LDT) performed by high-throughput sequencing of 38 genes involved in drug pharmacokinetics or pharmacodynamics. The clinician reviews the report results for each subject.
58038|NCT03730857|Drug|Olanzapine|olanzapine tablet
58039|NCT03730857|Drug|risperidone|risperidone tablet
58040|NCT03730857|Drug|Paliperidone|paliperidone tablet
58041|NCT03730831|Behavioral|Narrative Exposure Therapy|8-10 sessions: 1 lifeline session, 6-10 sessions narrative exposure, 1-2 sessions of future-oriented counselling
58042|NCT03730818|Other|Water-based Exercise Group|The intervention consist will of a water-based exercise protocol
58043|NCT03730818|Other|Land-based Exercise Group|The intervention will consist of a land-based exercise protocol
58044|NCT03730805|Behavioral|ASSIST-linked Brief Intervention|The intervention follows the WHO's ASSIST-linked Brief Intervention (Humenik et al., 2012; Humeniuk et al., 2010), a manualized one-session intervention that can be categorised as belonging to the Screening and Brief Intervention approach. It follows the FRAMES model (Bien et al., 1993) and contains techniques from Motivational Interviewing (Miller & Rollnick, 1991).
58045|NCT03730805|Behavioral|Induction of Deliberative Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down pros and cons for an unresolved personal problem of the participant's own choice) is used to induce a specific psychological state in which the individual is cognitively open to process new information.
58046|NCT03730805|Behavioral|Induction of Implemental Mindset|Based on the Mindset Theory of Action Phases (Gollwitzer & Keller, 2016), a brief writing task (writing down steps necessary to implement a personal decision of the participant's choice that has not yet been put into practice) is used to induce a specific psychological state in which the individual is cognitively not open to process new information.
58047|NCT03730792|Behavioral|SHIFT Onboard Intervention|A 12-month onboarding process and social challenge supported with goal setting, computer-based training, self-monitoring, and group motivational interviewing.
58048|NCT03730779|Drug|Hyperoxia|Patients will receive nocturnal normobaric hyperoxia therapy
58049|NCT03730766|Drug|Esomeprazole|Proton pump inhibitor
58050|NCT03730766|Drug|Amoxicillin|Antibiotics for H. pylori eradication
58051|NCT03730766|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
58052|NCT03730753|Device|Programmed intermittent epidural bolus|Programmed intermittent epidural bolus added to patient controlled epidural analgesia
58053|NCT03730753|Device|Continuous infusion|Continuous infusion added to patient controlled epidural analgesia
58054|NCT03730740|Drug|Lenalidomide 25mg|Lenalidomide 25mg, day 1 - day 21 (1cycle=28days) for 2yeas
58055|NCT03730727|Behavioral|Physical activity|Physical activity will consist of either 30-mins of standing still, 30-mins of walking at a self-selected brisk pace on a treadmill, or 3-sets of circuit-exercises (10 squats, 10 push-ups, 10 lunges, 10 sit-ups).
58056|NCT03730727|Dietary Supplement|Meal|Liquid meal replacement shake containing 500 kcal, with 55% kcals from carb, 30% from fat, and 15% from protein.
58060|NCT03730701|Behavioral|Prevention program for stroke|The prevention program include individual and group intervention sessions supported by a digital platform. The program will be personally tailored in relation to what the person needs and what to change and the individuals rediness for change. The digital platform will support the person during and in between sessions by prompting goals and goal-fulfilment, logging activities, step counts and provide a forum for sharing and reflection.
58061|NCT03730688|Device|Conventional compartment pressure measurement|Compartment pressure will be measured using the conventional compartment pressure measurement system.
58062|NCT03730688|Device|Experimental compartment pressure measurement|Compartment pressure will be measured using the newly-developed compartment pressure measurement system.
58063|NCT03730675|Procedure|Portal irradiation stent placement|The irradiation portal vein stent was designed as two separate parts that consisted of an outer seeds-loaded-stent and an inner self-expandable metallic stent
58064|NCT03730675|Procedure|TACE|TACE is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply.
58065|NCT03730675|Drug|Sorafenib|Sorafenib is a kinase inhibitor drug approved for the treatment of advanced hepatocellular carcinoma.
58066|NCT03730662|Drug|Tirzepatide|Administered SC.
58067|NCT03730662|Drug|Insulin Glargine|Administered SC
58068|NCT03730649|Drug|Sulforaphane (broccoli sprout extract)|Participants will topically apply Sulforaphane for a period of time
58069|NCT03730649|Radiation|UV or visible light|Participants will have 2 test areas irradiated with up to 5 UV or visible light treatments
58070|NCT03730636|Procedure|PCT dosage|Measurement of PCT concentration will be performed every two days and the ATB therapy will be stopped when PCT level reaches a value equal or below 0.5ng/mL.
58071|NCT03730623|Behavioral|Supervised exercise training|Supervised exercise training as a conservative management of intermittent claudication in a community setting based on cardiac rehabilitation program
58072|NCT03730610|Behavioral|Exercise training|Subjects are required to exercise four times a week during six months. Exercise training consists of endurance training, resistance training and high-intensity interval training adjusted to subject's fitness level.
58073|NCT03730597|Device|reverse shoulder arthroplasty|prosthesis implantation
58074|NCT03730584|Drug|Ropivacaine|"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."
104204|NCT03371979|Drug|Pegzilarginase|Administered IV
58075|NCT03730584|Biological|Blood test|Blood test during the first bath with Ropivacaine for Titration of Ropivacaine
58076|NCT03730571|Device|AbsorbaSeal 6Fr Vascular Closure Device|Patients whose access site will be closed with the AbsorbaSeal 6Fr Vascular Closure Device
58077|NCT03730558|Combination Product|aflibercept + FOLFIRI|aflibercept + FOLFIRI
58078|NCT03730545|Dietary Supplement|enteral immunonutrition|Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
58079|NCT03730532|Other|Cognitive Behavioural Therapy Guided Self Help|6-week manualised Cognitive Behavioural Therapy Guided Self Help
58080|NCT03730532|Other|Cognitive Analytic Therapy Guided Self Help|6-week manualised Cognitive Analytic Therapy Guided Self Help
58081|NCT03730519|Device|Baroreflex Activation Therapy with Barostim Neo|Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.
58082|NCT03730506|Device|Intra oral scanner|computer guided implant
58083|NCT03730493|Behavioral|Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.|In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
58084|NCT03730467|Behavioral|Phone call to the patient|Phone call to the patient
58085|NCT03730454|Device|Transanastomotic Tube (5FR)|5FR tube left in place for 5 days after completion of esophageal anastomosis.
58086|NCT03730454|Other|No Transanastomotic Tube|No transanastomotic tube used during repair
58087|NCT03730441|Device|Colonoscopy|Endoscopic examination of large bowel
58088|NCT03730415|Procedure|Viscoelastic (VE) Guided Transfusion|A viscoelastic analyzer (ROTEM) will be used to guide the transfusion algorithm during the burn wound excision of subjects enrolled into this arm
58089|NCT03730402|Drug|Bupivacaine|utilizing local anesthetic to perform a regional block under laparoscopic guidance
58090|NCT03730402|Drug|Exparel 266 milligram Per 20 ML Injection|utilizing local anesthetic to perform a regional block under laparoscopic guidance
58091|NCT03730402|Drug|Saline|placebo injection of saline
58092|NCT03730389|Device|External Physical Vibration Lithecbole (EPVL)|Using the the way of external physical vibration to promote separation of stones from ureteral mucosa and promoting the excretion of ureteral stones
58093|NCT03730376|Other|Cost Information|participants will be given information on the personal and societal costs
58094|NCT03730363|Drug|Pentamidine|Pentamidine will be administered as an IV infusion on treatment day 1-3 of a 21-day cycle 3 cycles using 2, 3, and 4 mg/kg dose escalation schedules. Non-investigational agents will be administered as follows: Ifosfamide 5000 mg/m2, Carboplatin 5 area under curve (AUC), and Etoposide 100 mg/mg2.
58095|NCT03730350|Behavioral|Clinical Hypnosis|Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
58096|NCT03730337|Drug|ONO-7475|ONO-7475 specified dose on specified days
58097|NCT03730337|Drug|ONO-7475 + ONO-4538|ONO-7475+ONO-4538 specified dose on specified days
58098|NCT03730324|Diagnostic Test|mpMRI|Study subjects will undergo urine and plasma biomarker testing and mpMRI prior to biopsy
58099|NCT03730324|Diagnostic Test|Urine and plasma biomarkes.|Study subjects will undergo urine and plasma biomarker testing prior to standard biopsy
58100|NCT03730311|Drug|Elpida|elsulfavirine, capsules
58101|NCT03730311|Drug|placebo|placebo
58102|NCT03730298|Dietary Supplement|American Ginseng|cpr
58103|NCT03730298|Other|Placebo|cpr
58104|NCT03730285|Device|Telemedicine|Installation of videotelephone with broadband in patient's home
58105|NCT03730272|Drug|analgesic drugs and methods|the patient will receive analgesic treatment at the discretion of the physician in charge
58106|NCT03730259|Other|Web-based Tailored Intervention Preparation for Surgery|A Tailored Internet-based Preparation Program for Perioperative Anxiety and Pain (WebTIPS) is developed using the conceptual framework of the Triple Aim that evaluates the intervention within the context of clinical efficacy, improved child and parent experience, and reduced resource utilization during the surgical episode. WebTIPS aims at reducing perioperative anxiety and pain in children via an internet-based platform with short message service (SMS) two-way communication between a healthcare provider and patient.
58107|NCT03730246|Procedure|cesarean sectio|consecutive parturients due for cesarean sectio
58108|NCT03730233|Procedure|Hiatal hernia repair by tension-free mesh closure|
58109|NCT03730233|Procedure|Hiatal hernia repair by simple suturing|
58110|NCT03730207|Device|Xpede™ Bone Cement|Xpede™ Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
58111|NCT03730207|Device|Mendec Spine Bone Cement|Mendec Spine Bone Cement will be injected into vertebral body via percutaneous Vertebroplasty or Kyphoplasty to stabilize the fractured vertebral body by filling the bony trabeculae.
58112|NCT03730194|Dietary Supplement|Melatonin|Melatonin (liquid, immediate release, 3 mg) 30 minutes before bedtime
58113|NCT03730194|Behavioral|Bedtime Bank|The Bedtime Bank a novel behavioral sleep intervention, which is based upon contingency contracting and relies on a credit or debt-based system to hold adolescents accountable for maintaining a consistent bedtime and improve total sleep time.
58114|NCT03730181|Drug|Rifapentine|Rifapentine. Initial dose will be 25mg/kg. Based on interim analysis, this may be adjusted throughout the study to achieve target exposures. The standalone water-dispersible rifapentine tablet may be used to adjust the rifapentine doses, if needed.
58115|NCT03730181|Drug|Isoniazid|Isoniazid. 25mg/kg
58116|NCT03730168|Other|circuit weight training program|30 male diabetic patients performed circuit weight training for 12 weeks
58117|NCT03730155|Other|CCT intervention.|8-week course with 2 hours sessions weekly. Participants should meditate 25 min. pr. day during the 8 weeks.
58118|NCT03730142|Drug|WXFL10030390|WXFL10030390 is a tablet in the form of 0.1mg and 0.5mg, oral, once a day.
58119|NCT03730129|Drug|Hizentra|Subjects will receive Hizentra 0.4 mg/kg qweekly subcutaneously for 6 months (24 weeks)
58120|NCT03730116|Drug|bisoprolol/perindopril FDC|the first and only single-pill combination of beta-blocker and ACE inhibitor
58121|NCT03730103|Other|Same day discharge|Patients will be discharged home from the hospital on the day of her surgery.
58122|NCT03730090|Device|zero flux skin termometer|Core temperature is monitored continously, non-invasively
58123|NCT03730077|Drug|18F-FMISO|18F-FMISO PET/CT
58124|NCT03730064|Drug|N-acetyl cysteine (NAC)|Experimental medication with N-acetyl cysteine (NAC) for six weeks
58125|NCT03730051|Drug|Gadoterate meglumine|Participants randomized into this arm will receive gadoterate meglumine contrast for their scheduled breast MRI.
58126|NCT03730051|Drug|Gadobutrol|Participants randomized into this arm will receive gadobutrol contrast for their scheduled breast MRI.
58127|NCT03730038|Drug|Treatment of pitavastatin 4 mg qd for 12 weeks|Treatment of pitavastatin 4 mg qd for 12 weeks
58128|NCT03730038|Behavioral|Life-style modification|Nutritional support with the meal less than 65% of carbohydrate, less than 30% of fat. Exercise 3-4 times, 30 min
58129|NCT03730025|Other|Auscultation plus NeoTapAS|Pediatric resident responsible for HR assessment will estimate the HR by listening to the praecordium with a stethoscope. When using NeoTapAS, he/she will simultaneously tap the same pace on the screen of an iPad with the NeoTapAS app installed and will verbally communicate the HR displayed on the screen.
58130|NCT03730025|Other|Auscultation without NeoTapAS|Auscultation without NeoTapAS
58131|NCT03730012|Drug|gilteritinib|Gilteritinib is administered orally
58132|NCT03730012|Drug|atezolizumab|Atezolizumab is administered by intravenous infusion
58133|NCT03729999|Device|Portable, Point-of-Care Ultrasound|Portable ultrasonography done at the bedside.
58134|NCT03729986|Other|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% of maximal inspiratory pressure in sitting and supine positions. The orders of the two loaded test conditions will be conducted in random order with at least 20 minute separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
58135|NCT03729973|Drug|Ketamine|Patients nebulized ketamine by compressor nebulizing for 15 minutes.
58136|NCT03729973|Drug|Magnesium Sulfate|Patients nebulized magnesium sulfate 250mg (3ml)plus 2ml normal saline by compressor nebulizing for 15 minutes.
58137|NCT03729973|Drug|Lidocaine|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized lidocaine 5ml by compressor nebulizing for 15 minutes."
58138|NCT03729973|Drug|Normal saline|"In preparation room an I.V line was secured ,and standard monitoring was connected to patient.~Patients nebulized by compressor nebulizing 5ml normal saline for 15 minutes."
58139|NCT03729960|Other|LENA recorder|The LENA recorder model# 0121 is a lightweight, pocket-size, rechargeable electronic recorder together with a mobile application to view the data and answer questionnaires
58140|NCT03729947|Device|Subfascial closed suction drain|Ch 14 closed suction drain
58141|NCT03729934|Dietary Supplement|Ketone Ester|This arm receives 25 g ketone ester.
58142|NCT03729934|Dietary Supplement|Ketone Salt|This arm receives 25 g ketone salt.
58143|NCT03729921|Procedure|gastric variceal ligation|The highest point of the variceal vein was used as the primary ligation site. If the input vein was not obvious, the edge of the variceal vein was ligated. The variceal veins were ligated with a 6-ring ligation device, and more than 18 rings rubber bands could be applied in one session. GVL was performed regularly until varices were obliterated or reduced to residual small varices, which could not be ligated. The residual small varices was treated by cyanoacrylate injection.
58144|NCT03729921|Procedure|gastric variceal obturation|Gastric varices were uniformly treated via the sandwich technique, which starts with an injection of lauromacrogol, followed by N-butyl cyanoacrylate, then finished with flush of lauromacrogol. The number of injection sites and volume of lauromacrogol and cyanoacrylate used, directly correlated with the size of the varix. Multiple injection sites were chosen in attempt to obliterate the varix or varices in one session. Volume of lauromacrogol used ranged from 2-10ml, while that of cyanoacrylate ranged from 0.5-2ml, per injection site.
58145|NCT03729908|Behavioral|Animal asisted mindfulness based intervention|A mindfulness based intervention in the presence of an animal
58146|NCT03729908|Behavioral|Anti-stress program|A mindfulness based intervention with no reference to animals
58147|NCT03729895|Device|Adjustable Oral Appliance|Adjustable Oral Appliance consist of plastic maxillary occlusal splint，mandible occlusal splint and adjustable connecting rod.It could offer a non-invasive form of treatment but also achieve a good therapeutic effect
58148|NCT03729882|Procedure|EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. A prophylaxis gallbladder drainage will be done using a 3.8 mm working-channel linear-array therapeutic echoendoscope (EG3870UTK;Pentax, Hamburg, Germany) attached to an ultrasound console (Avius Hitachi, Tokyo, Japan) within a transgastric and/or transduodenal approaches to the gallbladder puncture followed by placement of a lumen apposing stent (LAMS) (AXIOS; Xlumena Inc, CA, USA) with a 10 mm luminal diameter and a dumbbell-shaped flanges to bring together the 2 walls in apposition. These feature of the Axios decrease the risk for bile leak, stent migration, and stent occlusion.
58177|NCT03729635|Procedure|Pectoral-intercostal fascial plane block (PIFB)|Local anesthetic is infiltrated into the fascial plane between pectoralis major and the intercostal muscles lateral to the sternum to anesthetize the anterior cutaneous branches of the intercostal nerves.
58149|NCT03729882|Procedure|Non EUS-guided gallbladder drainage|During ERCP evaluation a self-expandable metallic stent will be deployed in the common biliary duct of the patients enrolled in both arms of the present study. If the patient had an acute cholecystitis will be sent to surgery and be considered as a Non EUS-guided gallbladder drainage
58150|NCT03729869|Drug|Progesterone|200 mg of exogenous progesterone twice a day
58151|NCT03729869|Drug|Placebo|One dose of matched placebo twice a day.
58152|NCT03729856|Behavioral|intervention|The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
58153|NCT03729856|Other|B|Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
58154|NCT03729856|Other|Follow-up|Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
58155|NCT03729843|Radiation|CBCT and intraoral digital radiography|Simulated periodontal bone defects will be measured by 2 techniques: group I detected and measured using CBCT and group II intraoral digital radiography and all the measurements will be compared with the gold standard real measurements on the dry jaws
58156|NCT03729830|Device|Boston Scientific Open Irrigated Ablation Catheters|The BSC Open-Irrigated catheters are designed to deliver RF energy to catheter tip electrode for cardiac ablation. The BSC OI catheters incorporate an open-irrigated cooling mechanism through a tip that is partitioned into two chambers. The proximal chamber circulates normal saline (0.9 %) within the tip to cool the proximal electrode and mitigate overheating while the distal chamber allows the fluid to flow through six irrigation holes into the patient's vasculature, thereby cooling the tip/tissue interface.
58157|NCT03729817|Device|Submaximal ballon angioplasty|Submaximal angioplasty involves use of a endovascular balloon to perform angioplasty for vessel stenosis with the aim of reducing, but not fully correcting, the stenosis.
58158|NCT03729804|Drug|Carfilzomib|"Carfilzomib will be given by IV on Days 1, 2, 15 and 16 of each cycle during cycles 1-8.~Carfilzomib will be given by IV on days 1, 2, 15 and 16 of each cycle during cycles 9-24."
58159|NCT03729804|Drug|Lenalidomide|"Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle during cycles 1-8.~Lenalidomide will be taken by mouth once a day for days 1-21 of each cycle for cycles 9-24."
58160|NCT03729804|Drug|Dexamethasone|"Dexamethasone will be taken by mouth on days 1, 8, 15 and 22 of each cycle during cycles 1-8.~Dexamethasone will be taken by mouth on Days 1, 8, 15 and 22 of each cycle during cycles 9-24."
58161|NCT03729804|Drug|Bortezomib|Bortezomib will be give by IV on days 1, 4, 8 and 11 of each cycle during cycles 1-8.
58162|NCT03729791|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation that uses constant, low direct current delivered via electrodes on the head. It can be contrasted with cranial electrotherapy stimulation, which generally uses alternating current the same way
58163|NCT03729778|Biological|Prevnar-13|One time administration of prevnar-13 vaccine
58164|NCT03729765|Device|hemoperfusion|The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.
58165|NCT03729752|Drug|[89]Zr-DFO-VRC-HIVMAB060-00-AB|Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.
58166|NCT03729739|Diagnostic Test|QFR-based diagnostic strategy|Novel computer based calculation of lesion severity. Pressure wire-free and adenosine-free
58167|NCT03729739|Diagnostic Test|FFR-based diagnostic strategy|Standard FFR based diagnostic method. Pressure drop across the stenosis is measured with a pressure wire during medical induced hyperaemic conditions
58168|NCT03729726|Behavioral|Future Foundation 2.0 PREIS Program|The Future Foundation 2.0 PREIS intervention model uses a placed-based collective impact framework to provide a comprehensive intervention model, including: academic support and college and career readiness services, evidence-based social emotional learning instruction to strengthen protective factors and promote healthy transitions to adulthood, and trauma-informed, medically accurate, and age appropriate sexual health education. Moreover, the 2.0 PREIS program model features a unique student advocacy component designed to ensure that youth and their families receive the wraparound supports necessary for their students to remain on track for school success.
58169|NCT03729713|Other|Computerized cognitive rehabilitation|6 week course of cognitive rehabilitation focused on attention, learning, and memory
58170|NCT03729713|Other|Sham placebo|an alternative home-based computer program not designed for cognitive remediation but of the same duration
58171|NCT03729700|Other|Almond|The almond dose will be provided as 20% of total energy (20% E) in the diet.
58172|NCT03729687|Combination Product|radiotherapy, capecitabine, oxaliplatin|5x5 Gy radiotherapy in 1 week, 4 cycles of CAPOX (capecitabine 1000 mg/m2 x2 d 1-14, oxaliplatin 130 mg/m2 d 1 every third week), surgery
58173|NCT03729674|Drug|Biosimilar|Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
58174|NCT03729674|Drug|Originator (legacy) drug|Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
58175|NCT03729661|Behavioral|Nasal High Flow Therapy|Use of Nasal High Flow Therapy during CT and treatment
58176|NCT03729648|Behavioral|Expressive Arts Therapy|The intervention brings together the strengths of different art modalities, such as visual art, music, movement, dance, drama and writing to assist reflect and response in individuals to their personal issues. Such variety of art forms multiplies the avenues by which a person in therapy may seek meaning, clarity, insight and healing.
58178|NCT03729622|Other|Low FODMAP Diet|Both arms will receive the intervention but at different time points.
58179|NCT03729609|Drug|Brentuximab vedotin (Genetical Recombination)|Brentuximab vedotin Intravenous Infusion
58180|NCT03729596|Biological|MGC018|Anti-B7-H3 antibody drug conjugate
58181|NCT03729596|Biological|MGA012|Anti-PD-1 antibody
58182|NCT03729583|Behavioral|Pulmonary Rehabilitation|A 12 week high intensity PR programme was delivered to both groups. The active group had additional breathing control interventions and exercises
58183|NCT03729570|Other|ePrEP|Participants will have a baseline teleconsultation with a site study clinician who will be responsible for prescribing PrEP as indicated. They will be offered a 1-month check-in and telemedicine consultations at 3, 6, 9 and 12 months. Participants will complete home specimen collection for laboratory tests for each consultation. The virtual study visit (visit) consists of surveys, specimen collection, and telemedicine consultation.
58184|NCT03729557|Procedure|Nephrectomy|Unilateral nephrectomy
58185|NCT03729544|Behavioral|On-screen computerized decision support alert|On-screen electronic alert during the outpatient clinical encounter that notifies him or her that the patient should be screened for CTEPH
58186|NCT03729531|Procedure|Conventional vein harvesting technique|Long incision will be used to expose the vein, the perivascular tissue will be dissected carefully by scissors, to check for leakage, the vein will be distended by injecting saline.
58187|NCT03729531|Procedure|no-touch vein harvesting technique|The vein will be harvested by low-frequency electrotome, about 5mm surrounding tissue will be preserved with the vein, distention should be avoided, the vein will not be cut off until being anastomosed.
58188|NCT03729518|Radiation|Radiation Therapy (IMRT or IMPT)|"Treatment of the primary tumor bed will be omitted in appropriate patients, as per the initial TORS de-intensification protocol. In those patients requiring treatment of the primary site, reduced dose (50 Gy) will be delivered.~Receipt of concurrent chemotherapy per current guidelines. Chemotherapy may be omitted in patients with focal or microscopic ENE (defined as ≤ 1 mm ENE), at the discretion of the treating Medical Oncologist.~Blood samples will be obtained at time of enrollment, and at two time points during RT, to quantify circulating HPV DNA and perform immune profiling."
58189|NCT03729505|Procedure|Pyloric injection of magnesium sulfate and lidocaine mixture|100 mg / 2 ml of magnesium sulphate (Magnesium Sulfate®) is mixed with 5 ml of 2% lidocaine and injected in the pylorus
58190|NCT03729505|Procedure|Pyloric injection of saline|5 ml of normal saline is injected in the pylorus
58191|NCT03729492|Diagnostic Test|CTEPH/CTED work-up|Patients diagnosed with acute pulmonary embolism (PE) in Region Midt (approx. 350 per year) will be screened for non-recovery or persistent PE related symptoms during their 3-6 months follow up at their local outpatient clinic. If the patient has persistent symptoms they will be referred to a V/Q-scan. If a V/Q mismatch is present, the patient will be referred to a full work-up for CTEPH/CTED.
58192|NCT03729479|Behavioral|DASH diet|Participants will be taught to follow a DASH diet (low-sodium and low-fat meal plan, which includes whole grains, fat-free or low-fat dairy products, vegetables, fruits, poultry, fish, and nuts, with processed, high-sodium, regular-fat, and sugar-added foods restricted).
58193|NCT03729479|Behavioral|Very low carbohydrate, ketogenic diet|Participants will be taught to follow a very low-carbohydrate diet (non-starchy vegetables, nuts, seeds, meat, fish, and natural fats such as avocado, olive oil, and butter, with starchy and sugary foods restricted).
58194|NCT03729479|Behavioral|Extras|Participants will be given training in positive affect, mindfulness, health information seeking and sharing, and cooking practices and behavior.
58195|NCT03729466|Other|clinical pilates|The intervention group will be performed in clinical pilates 45 to 60 minutes twice a week for 8 weeks.
58196|NCT03729453|Device|SpyGlass|Visualization of main pancreatic duct with SpyGlass catheter.
58197|NCT03729440|Behavioral|development of complications or not|assessment of development of complications
58198|NCT03729427|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block for patents undergoing rib cartilage grafting surgeries
58199|NCT03729414|Procedure|mucopexy with Doppler artery ligation|Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants
58200|NCT03729414|Procedure|mucopexy without Doppler artery ligation|Hemorrhoids will be treated by mucopexy alone performed in all quadrants
58201|NCT03729401|Drug|Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily|DAPT with aspirin and ticagrelor
58202|NCT03729401|Drug|Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily|Ticagrelor monotherapy
58203|NCT03729401|Drug|Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily|Personalized therapy based on risk score and genotyping
58204|NCT03729388|Other|Prognosis factor associated with good outcome.|Implementation of a systematic assessment of patient with OMT initiation. Patients included in the TOPAZE study will receive standardized clinical interviews, electrocardiograms, urinary and blood tests during a 12 months follow-up.
58205|NCT03729375|Drug|10cc injection of bupivacaine|10cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
58206|NCT03729375|Drug|20cc injection of bupivacaine|20cc intra-operative injection of bupivacaine into the carpal tunnel of the operative hand/wrist
58207|NCT03729362|Drug|AT2221|Participants received ATB200 co-administered with AT2221 (Miglustat)
58208|NCT03729362|Biological|alglucosidase alfa|alglucosidase alfa via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
58209|NCT03729362|Biological|ATB200|Enzyme Replacement Therapy via intravenous infusion
58210|NCT03729349|Biological|Golimumab|Participants will receive golimumab as a part of clinical practice.
58211|NCT03729336|Device|Midstream urine collection device|Non-invasive midstream urine collection device
58212|NCT03729336|Device|Catheter for urine collection|In-and-out catheter obtains urine through the urethra.
58244|NCT03729115|Other|Anxiety Self-management Techniques|Participants will be given a workbook with tools and techniques to help manage anxiety and stress related to getting the MRI scans and their overall healthcare.
104205|NCT03371979|Drug|Pembrolizumab|Administered IV
58213|NCT03729323|Behavioral|Motivational interviewing|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be addressed based on the principles and techniques of the Motivational Interviewing.
58214|NCT03729323|Behavioral|Nursing Consultation|In Diabetes and hypertension, nursing consultations to support the care should be focused on their educational component the orientation of measures that prove to reduce blood pressure, improve the glycemic indices, the lipid profile and the Cardiovascular risk classification, among them: adherence to drug therapy, proper diet, body weight maintenance, stimulating active life and regular physical exercise, reducing alcoholic beverage consumption, reducing stress and abandoning Smoking. In this group, these care will be approached in a conventional manner, as routine of the services, based on the recommendations of the Primary Care Strategy Notebooks for the care of chronic conditions in DM2 and SAH and the SSC-GHC Institutional Protocol for SAH and DM2 Patient Care.
58218|NCT03729297|Drug|Cabozantinib|cabozantinib tablets (Cabometyx®) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw for a maximum duration of 2 years.
58219|NCT03729284|Drug|Cymbalta Capsules|Active Comparator: Cymbalta®- hard gelatinous capsule with delayed release microgranules ( Eli Lilly do Brasil Ltda) equivalent to 60 mg of duloxetine.
58220|NCT03729284|Drug|Duloxetine Hydrochloride Capsules|Experimental Drug: Duloxetine hydrochloride - hard gelatinous capsule with delayed release microgranules (Pfizer S.R.L - Argentina.) equivalent to 60 mg of duloxetine.
58221|NCT03729271|Drug|Rifaximin|Rifaximin will be given during weeks 2-4
58222|NCT03729271|Device|Glucose and lactulose hydrogen breath testing|Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
58223|NCT03729258|Drug|Infex 400 MR|Infex (cefpodoxime) 400mg once a day (QD) for 10 days
58224|NCT03729258|Drug|Infex 200 IR|Infex (cefpodoxime) 200mg twice a day (BID) for 10 days
58225|NCT03729245|Biological|Bempegaldesleukin|Specified dose on specified days
58226|NCT03729245|Drug|Sunitinib|Specified dose on specified days
58227|NCT03729245|Biological|Nivolumab|Specified dose on specified days
58228|NCT03729245|Drug|Cabozantinib|Specified dose on specified days
58229|NCT03729219|Biological|E. coli ETVAX|Oral suspension Sterile water is added to dmLT . Vaccine is poured to the effervescent solution and needed amount of dmLT is added.
58230|NCT03729219|Other|Placebo|Oral suspension
58231|NCT03729206|Diagnostic Test|intravital microscopy|intravital microscopy with sidestream dark-field imaging
58232|NCT03729193|Behavioral|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer for identifying their pain threshold, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
58233|NCT03729180|Procedure|Routine Elective Surgery- In patient or out patient elective surgery|Participants will be undergoing routine planned surgeries.
58234|NCT03729180|Diagnostic Test|Blood test for genetic testing|Blood test to determine differences in genes which may affect how certain medications affect the participant. All patients will consent to collection of a blood sample for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk.
58235|NCT03729180|Other|Drug-genetic Profile|Profile describing drugs that may be high-risk, those that should be used with caution, or drugs that are favorable to use based on the participants genes.
58236|NCT03729167|Procedure|Scaling and root planing|Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
58237|NCT03729154|Behavioral|First Step|First Step is a comprehensive early intervention that is delivered by a behavioral coach who works in collaboration with the classroom teacher and parents. First Step addresses moderate to severe behavior problems of young children and includes both classroom and home components. The program takes about three months from start to finish and requires approximately 60 hours of the coach's time for implementation over this three month period.
58238|NCT03729141|Dietary Supplement|Added Cholesterol|Participants assigned to the added cholesterol group will receive snacks containing added cholesterol (1g/day) for 3 weeks prior to surgery.
58239|NCT03729141|Other|No Added Cholesterol|Participants assigned to the no added cholesterol group will receive snacks containing no added cholesterol for 3 weeks prior to surgery.
58240|NCT03729128|Drug|dextromethorphan and memantine (DM+MM)|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.
58241|NCT03729128|Drug|Placebos|Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
58242|NCT03729115|Procedure|Magnetic Resonance Imaging (MRI)|Patients will have MRI scans every 6 months.
58243|NCT03729115|Other|Clinical Hypnosis|Patients will provided with an audio recording which includes the technique of Clinical Hypnosis to help manage anxiety during MRI scans.
58245|NCT03729102|Biological|Blood drawn after rabies vaccine booster vaccination|All participants would be given one dose of rabies vaccine and monitor the immunological cells i.e., regulatory T cell, regulatory B cell, T follicular helper cells, cytokines i.e., IL-10, TGF-Beta, and Rabies neutralizing antibody titers, before and after the booster injection
58246|NCT03729089|Other|Modified Biophysical Profile scan|Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
58247|NCT03729076|Other|Crystalloid|Patients will receive the rapid co-loading with plasma solution A (PSA) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
58248|NCT03729076|Other|Colloid|Patients will receive the rapid co-loading with 6% volulyte (HES in acetated electrolyte) 10ml/kg, from the initiation of spinal anesthesia, within 10 minutes.
58249|NCT03729063|Other|Twice-daily expired carbon monoxide (CO) measurements|Patients included in this arm will have expired CO measurements every morning and evening during their initial hospitalization.
58250|NCT03729063|Other|Minimal control|Patients included in this arm will have one expired CO measurement on the morning just after initial hospital admission and a second expired CO measurement one the morning prior to discharge.
58251|NCT03729050|Behavioral|Rehabilitation Coordinator in Specialist Psychiatry|Rehabilitation Coordinator service in Specialist Psychiatry
58252|NCT03729037|Other|CPR self-training|
58253|NCT03729011|Drug|Volatile agent|Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.
58254|NCT03729011|Drug|Propofol|Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
58255|NCT03728998|Other|Passive leg raise (PLR)|"A PLR will simulate an autotransfusion of 250-300 cc.~1. Starting in semi-succumbed position (45 degree head-up)~2. PLR is performed by lowering head-end and putting a for this purpose designed device of 45 degrees under the patients legs. The PLR is non-invasive."
58256|NCT03728998|Other|Clearsight non-invasive hemodynamic monitoring system|3 baseline readings will be done for CO, CI, SV and SVR, separated by one minute intervals. Subsequently, the standardized passive leg-raise test will be performed and measurements of CO, CI, SV and SVR will be repeated at 30, 60, 90 and 120 seconds. Then the patient is repositioned to his original position, and after two minutes another reading of CO, CI, SV and SVR is done. Then all patients will receive a fluid challenge of 500cc natriumchloride 0.9% IV, considered as normal treatment/ common practice in our ED. 120 seconds after finishing the fluid challenge the final reading of CO, CI, SV and SVR is done.
58257|NCT03728985|Device|GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis|Endovascular Aortic Stent-Graft
58258|NCT03728972|Drug|Pembrolizumab|200mg IVPB every 3 weeks
58259|NCT03728959|Other|Liquid meal (Nutridrink)|Liquid meal ingested over 1 minute.
58260|NCT03728959|Other|GIP|Subcutaneous injected GIP
58261|NCT03728959|Other|GLP-2|Subcutaneous injected GLP-2
58262|NCT03728959|Other|Placebo (saline)|Subcutaneous injected Placebo (saline)
58263|NCT03728946|Drug|Liposomal Bupivacaine|Addition of 15mL of liposomal bupivacaine to 15mL of standard nerve block anesthetic solution containing 0.5% bupivacaine and 4mg of decadron
58264|NCT03728933|Drug|Rotigotine 1 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 1 milligram (mg)/24 hours (h) (5 square centimeter (cm^2) patch size).
58265|NCT03728933|Drug|Rotigotine 2 milligram/24 hours|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: Application of rotigotine transdermal patch with 2 milligram (mg)/24 hours (h) (10 square centimeter (cm^2) patch size).
58266|NCT03728933|Drug|Placebo|Pharmaceutical Form: transdermal patch Route of administration: transdermal use Concentration: not applicable
58267|NCT03728920|Other|Muscle strength measurement|Patients awaiting hip arthroscopy will undergo muscle strength testing pre- and post-operatively. There will be no deviation of treatment from their NHS care. Validated outcome measure questionnaires will be completed at five months post-operatively. Magnetic resonance imaging and electromyography tests will be performed on a subset of patients post-operatively.
58268|NCT03728907|Device|Hearing aid fitting technique- audiologist or user-adjusted|See information under 'arm' description
58269|NCT03728894|Drug|Midazolam-hydroxyzine with 100% O2|Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
58270|NCT03728894|Drug|Midazolam-hydroxyzine with 50% N2O/O2|Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
58271|NCT03728881|Biological|Cervarix|Vaccine indicated in females 9 through 25 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16 and 18. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 months (second dose between 5 and 13 months after first dose). Intervention will be one dose at 0 months in 520 girls ages 9-14 years.
58272|NCT03728881|Biological|Gardasil|Vaccine indicated in females 9 through 26 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18; and Genital warts (condyloma acuminata) caused by HPV types 6 and 11. In Costa Rica, in women 16 years old and older, it is approved for three doses (0.5- mL each) intramuscular injection at 0, 2 months, and 6 months. Intervention will be three doses at 0, 2, and 6 months, in 520 women ages 18-25 years.
58273|NCT03728868|Dietary Supplement|Placebo|Dietary supplementation with placebo once a day for 8 consecutive weeks
58274|NCT03728868|Dietary Supplement|High dose F. prausnitzii and D. piger|Dietary supplementation with high dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
58275|NCT03728868|Dietary Supplement|Low dose F. prausnitzii and D. piger|Dietary supplementation with low dose F. prausnitzii and D. piger once a day for 8 consecutive weeks
58276|NCT03728855|Behavioral|Self-administration of medication (SAM)|Patients use medication from their own stock, self-administered.
58278|NCT03728842|Other|Data collection from medical record|Clinical data such as demographics and cancer characteristics, history and treatment will be collected
58279|NCT03728829|Drug|Trastuzumab+TP|Trastuzumab (4 mg/kg loading dose, then 2 mg/kg I.V., every week, totally 17 weeks (6 cycles)) combined with TC neoadjuvant chemotherapy (Docetaxel 75 mg/m2 I.V., day 1, Carboplatin 400 mg/kg, I.V., day 2, every 3 weeks, totally 6 cycles).
58280|NCT03728803|Device|Threshold IMT, Philips Respironics, Murrysville, PA, USA|Active inspiratory muscle training (IMT) by the threshold IMT provides consistent and specific pressure for inspiratory muscle strength and endurance training, regardless of how quickly or slowly patients breathe. This device incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting (in cmH20) to be set. When patients inhale through the Threshold IMT, a spring-loaded valve provides a resistance that exercises respiratory muscles through conditioning.
58281|NCT03728790|Device|Remote Patient Monitoring|Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
58283|NCT03728764|Other|Preterm infant formula|Preterm infants will receive Stage 1 investigative product as soon as possible after birth until when 1.8 kg of body weight is achieved. Preterm infants will receive stage 2 preterm formula from when 1.8 kg of body weight is achieved until 1 month after hospital discharge.
58284|NCT03728751|Procedure|Dry needling|Paravertebral dry needling C7-T4. Total of 8 needles.
58285|NCT03728738|Procedure|Head of Bed Positioning|The head of bed (HOB) position will be selected through computerized randomization, and will include either zero degree positioning or thirty degree HOB elevation
58286|NCT03728725|Device|Cepheid Gene Xpert MTB/XDR|The Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA) is an integrated, automated, cartridge-based system for MDR-TB diagnosis that uses the GeneXpert instrument platform. WHO confirmed evidence to support the widespread use of the Xpert MTB/RIF assay in 2010 and the assay has since been widely used in TB programs, but it is only capable of identifying Mycobacterium tuberculosis (Mtb) and detecting RIF resistance. The Xpert MTB/XDR assay will be evaluated for INH and second-line resistance detection, and to recommend its use in diverse clinical settings. The focus of this protocol is the multicentre clinical evaluation.
58287|NCT03728712|Diagnostic Test|SPECT/CT|"Technegas-Tc99m is approved by Health Canada for the evaluation of ventilation. Technegas will be prepared with a Technegas Generator (Cyclomedica) according to the manufacturer recommendations with a simmer phase and a burning phase. 95% ethanol will be used to wet the carbon crucible. The crucible will be loaded with 20-30 mCi of Tc99m. Tc99m has a physical half-life of 6 hours.~Technegas will be administered to the patient within 10 minutes of its preparation, in a separate room than the scanning room. The inhalation technique will be rehearsed with the patient prior to the actual inhalation. The patient will be in supine position. A mouth piece and a nose clip will be used. The patient will be instructed to take 3 breaths of Technegas, starting after normal exhalation. A survey meter will be used to monitor the quality of the inhalation."
58288|NCT03728699|Diagnostic Test|Sample Collection Blood|Collected from each patient twice weekly.
58289|NCT03728699|Diagnostic Test|Stool Sample|Collected from each patient twice weekly.
58290|NCT03728686|Other|Different given time|Fentanyl 2mcg/kg (F) was given at either 1,2,3 minutes before intubation
58291|NCT03728673|Drug|Escitalopram Oral Tablet|Active capsules will contain 10 mg escitalopram oxalate.
58292|NCT03728660|Device|Virtual bioptic magnification with large field of view|The intervention device will have a larger field of vision than the legacy device and the intervention device will also have a virtual bioptic telescope mode not found on the legacy device. The user will be able to adjust the size of the virtual bioptic telescope and the amount of magnification with a touch pad on the side of the head-mounted display (HMD).
58293|NCT03728660|Device|Full field magnification with small field of view|Comparison intervention with user-controlled full field magnification with a smaller field size shared by legacy head-mounted devices. User can control amount of magnification
58294|NCT03728647|Behavioral|multimedia health education|The program (flat touch computer) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, complications, and experience sharing of insulin injection by a patient group. Technology: steps of insulin injection skills and complete technology demonstration . The program contents were organized using a unit-based piecemeal teaching approach. Participants could adjust their learning pace according to individual situations and could practice injection skills using an injection mold during hospitalization. A diabetes educator has assessed the learning outcome of each participant after intervention. At the day of discharge from hospital, each participant would acquire a copy of the multimedia health education compact disc.
58295|NCT03728647|Behavioral|regular health education|The traditional education program (a diabetes educator) consisted of knowledge and technology levels. Knowledge: diabetic introduction, treatment, management of hyper- and hypoglycemia, and complications. Technology: steps of insulin injection skills and complete technology demonstration.
58296|NCT03728634|Drug|AKCEA-TTR-LRx|Single and multiple doses of AKCEA-TTR-LRx administered subcutaneously
58297|NCT03728634|Drug|Placebo|Placebo comparator calculated volume to match active comparator administered subcutaneously
58298|NCT03728621|Behavioral|Normocaloric and balanced diet, physical activity|Promotion of normocaloric & balanced diet and physical activity
58299|NCT03728608|Device|Feeding tube dwell time of 48 hours|Feeding tube dwell time of 48 hours for first 4 weeks of life.
58300|NCT03728608|Device|Feeding tube dwell time of 7 day|Feeding tube dwell time of 7 days for first 4 weeks of life.
58301|NCT03728595|Diagnostic Test|Venepuncture|A blood sample will be taken for serum bicarbonate
58302|NCT03728595|Diagnostic Test|Spirometry|All patients who have not had a spirometry in the 12 months prior to the HAST will undergo one on the day of the HAST.
58303|NCT03728595|Diagnostic Test|Hypoxic altitude simulation test (HAST)|HAST will be performed as per clinical team request. No changes to this intervention will be made for research purposes.
58353|NCT03728140|Procedure|Self-spent Culture Medium|Replace embryo transfer solution with Self-spent culture medium in IVF-ET.
58354|NCT03728127|Dietary Supplement|Brazilian cardioprotective diet|Brazilian cardioprotective diet prescription
58304|NCT03728582|Device|Active tDCS plus Speech-Language Therapy|1 milliamp (mA) of Anodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge is placed on the left inferior frontal gyrus (IFG). The stimulation will be delivered at an intensity of 1 mA in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be verb naming therapy in a sentence context.
58305|NCT03728582|Device|Sham tDCS plus Speech-Language Therapy|Sham tDCS stimulation is provided to the left inferior frontal gyrus (IFG) using a tDCS device. Speech-language therapy will be verb naming therapy in a sentence context.
58306|NCT03728569|Other|Vanicream Moisturizing Skin Cream|Vanicream Moisturizing Skin Cream daily application
58307|NCT03728569|Other|Vanicream Cleansing Soap|Vanicream Cleansing Soap daily use
58308|NCT03728556|Biological|CS1001 monoclonal antibody|Participant will receive CS1001 monoclonal antibody 1200 mg by intravenous infusion every 3 weeks, for up to 24 months
58309|NCT03728556|Biological|CS1001 placebo|Participant will receive CS1001 placebo by intravenous infusion every 3 weeks, for up to 24 months
58310|NCT03728543|Drug|Sugammadex|"Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.~Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.~At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection"
58311|NCT03728530|Other|Deep Breathing exercises|"In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable."
58312|NCT03728504|Drug|ASN002|Daily dose of ASN002 for 32 weeks
58313|NCT03728504|Drug|Placebo Oral Tablet|Daily dose of Placebo Oral Tablet for 16 weeks
58314|NCT03728491|Device|Simulator|US Mentor simulator, lung module, provided by 3D Healthcare Systems
58315|NCT03728491|Device|Healthy figurants|Medical students or volunteers without any pathology in thorax
58316|NCT03728478|Drug|Etanercept|Patients will receive etanercept subcutaneously at a dose of 0.8 mg/kg weekly (up to a maximum dose of 50 mg weekly).
58317|NCT03728478|Drug|Methotrexate|Methotrexate will be administered subcutaneously, in a single weekly dose of 15 mg/m2 (max 20 mg).
58318|NCT03728478|Drug|Intra-articular corticosteroid injections|Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.
58319|NCT03728465|Biological|Nivolumab|In the induction phase of this study nivolumab is administered as a IV infusion in combination with ipilimumab at a dose of 1 mg/kg for 4 cycles at three weeks interval and in a maintenance phase alone at a dose of 3 mg/kg every two weeks.
58320|NCT03728465|Biological|Ipilimumab|In the induction phase of this study ipilimumab is administered as a IV infusion in combination with nivolumab at a dose of 3 mg/kg for 4 cycles at three weeks interval.
58321|NCT03728452|Procedure|Trophic Nutrition|"According to previously published studies of Trophic Nutritions in critically ill patients, an energy goal of 20-30% estimated caloric needs of 20-30 kcal / kg and a protein intake of 1.2 to 2.0 g / kg / day of proteins will be established. at most 72 hours after the start of nutritional therapy.~The rhythm of initiation and increase of enteral contributions will be at the discretion of each participating ICU. Prokinetic or parenteral nutrition (PN) complementary will not be used routinely, leaving its indication at the discretion of the responsible physician.~A hyperproteic nutritional formula (10 g / 100 ml) will be used, with a caloric intake of 1.2 kcal / ml and a non-protein kcal / nitrogen ratio of 52: 1. TN will be administered over 23 hours each day by continuous infusion pump. The head of the patient's bed will rise above 30° as much as possible to reduce the risk of aspiration. The Gastric Residue Volume (GRV) will be measured every 24 hours."
58322|NCT03728439|Device|LED therapy before exercise|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules (J) per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
58323|NCT03728439|Device|LED therapy applied on exercise interval|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
58324|NCT03728439|Device|LED therapy after exercise|Phototherapy will be applied through LED therapy equipment, with 15 light emitting diodes that produce 8 joules per diode and 120 joules in total. The muscular regions irradiated will be the quadriceps, hamstrings and triceps sural, with two points of application in each muscle group.
58325|NCT03728426|Drug|Letermovir|"Patients will receive intravenous or oral letermovir at a dose of 480mg/day.~Patients weighing 40 or more kilograms will receive a second, loading, dose 12 hours after the first dose of letermovir treatment.~For patients receiving concomitant cyclosporine treatment, the letermovir dose will be 240mg/day."
58326|NCT03728413|Biological|RSV A Memphis 37|"Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment."
58355|NCT03728127|Dietary Supplement|Brazilian cardioprotective diet plus 30g/day of mixed nuts|Brazilian cardioprotective diet plus 30g/day of nuts (10g of peanuts, 10g of cashew nuts and 10g of Brazil nuts)
59675|NCT03717701|Drug|esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day
58327|NCT03728387|Other|Clinical Pilates Exercise|All evaluations of the individuals included in the study will be done by the physiotherapist.. For the second evaluation the same individuals will be visited by the same physiotherapist at least 7 days after the first evaluation and only the FAB-T scale will be applied. 34 volunteer individuals who will be randomly choosen among 84 individuals will be given a 6-week exercise training program. According to this 6 week program, individuals will be admitted to the exercise training program for 45-60 minutes with a physiotherapist for 3 days in a week. The exercise program will consist of a warm-up, a strength training and a cool-down section. Various exercise methods (clinical pilates exercises) and tools will be utilized to improve balance and mobility. Third assessment of FAB-T will be applied only to individuals participating in the 6-week exercise training program.
58328|NCT03728374|Drug|Anlotinib|Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle)
58329|NCT03728361|Biological|Nivolumab|Given IV
58330|NCT03728361|Drug|Temozolomide|Given PO
58331|NCT03728348|Diagnostic Test|mt-sDNA screening test|Stool samples will be collected by the subject for the mt-sDNA screening test.
58332|NCT03728348|Procedure|Colonoscopy|Subjects will undergo a screening colonoscopy.
58333|NCT03728335|Drug|Enasidenib|Given PO
58334|NCT03728335|Drug|Enasidenib Mesylate|Given PO
58335|NCT03728322|Biological|iHSCs treatment group|iHSCs intravenous injection
58336|NCT03728296|Biological|islet body|Transplanting islet bodies under the diaphragm
58337|NCT03728283|Procedure|implant placement in combination with connective tissue grafting|A connective tissue graft of standardised dimensions was harvested from the palate under local anaesthesia and was stabilised over the implant's neck
58338|NCT03728283|Other|Implant placement|Implants were placed following teh manufacturer's instructions
58339|NCT03728270|Device|Patient Specific Titanium Eminoplasty|"The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~A multilayer closure of the incisions will be accomplished using Vicryl"
58340|NCT03728270|Procedure|Inlay Autogenous Bone Graft|"* Steps to harvest the bone graft:~Down-fracture of the articular eminence to be augmented with Inlay bone graft to increase the vertical height of the articular eminence. A green-stick fracture will be created avoiding a possible complete fracture of the lower segment of the eminence~To obtain Inlay bone graft from the chin, anterior mandibular vestibule incision will provide good access to the mandibular symphysis."
58341|NCT03728257|Behavioral|LTGO-Home Based Exercise|The LTGO intervention consists of two phases: Phase 1. Intensive home-based exercise training and behavioral coaching via a telerehabilitation platform, VISYTER (Versatile and Integrated System for Tele-Rehabilitation). Interactive intervention sessions will be delivered to the home via real time video conferencing (10 sessions within 12 weeks); and Phase 2. Transition to selfmanagement. Four telephone sessions (1 behavioral contract + 3 monthly counseling sessions) will be delivered over 12 weeks to provide behavioral coaching and exercise reinforcement
58342|NCT03728257|Behavioral|Enhanced Usual Care|EUC will involve delivery of monthly newsletters (6 newsletters) on the topics of post-lung transplant management, including general health topics, and provision of self-monitoring device.
58343|NCT03728244|Drug|MEBO ointment|The pharmacological effects of MEBO are attributable to beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensi, Beeswax and sesame oil (Zhang et al., 2005).
58344|NCT03728244|Drug|Hyaluronic Acid gel|Hyaluronic acid is a substance that is naturally present in the human body. It is found in the highest concentrations in fluids in the eyes and joints. The hyaluronic acid that is used as medicine is extracted from rooster combs or made by bacteria in the laboratory.
58345|NCT03728231|Other|Complete blood count|taking blood sample from venous blood
58346|NCT03728218|Device|Contact lenses (Orthokeratology)|Contact lenses
58347|NCT03728218|Device|Contact lenses (Soft Multifocal)|Contact lenses
58348|NCT03728205|Behavioral|Yoga|Twice weekly yoga sessions for 12 weeks
58349|NCT03728192|Other|mangosteen extract|For Mangosteen group :DNA fragmentation assay is used to identify apoptosis.1×106 cells were harvested and treated with mangosteen pericarp extract for 48 h For Camptothecin group : Cells were also treated with standard anticancer drug Camptothecin to act as a positive control.
58350|NCT03728179|Combination Product|Low dose irradiation + Nivolumab + Ipilimumab + Aspirin|"Low Dose Radiation (RT): RT will be administered as single fractions every 2 weeks (Q2W) from cycle C0 to cycle C4. RT will be delivered to a maximum of 10 metastatic deposits visible by PET/CT.~Cyclophosphamide: 200mg/m2 will be administered as intravenous infusion (IV) Q2W from cycle C0 to C4.~Nivolumab: 240 mg will be administered as IV Q2W from cycle C1 to C4.~Ipilimumab: 1mg/kg will be administered as IV every 6 weeks (Q6W) from cycle C1 to C4~Aspirin: 300mg will be administered orally daily from cycle C1 to C4. All subjects will receive mandatory gastric prophylaxis with an oral H2 antagonist.~At the end of cycle C4, patients eligible for maintenance will be treated with nivolumab at 240mg Q2W until progression or excessive toxicity; aspirin with prophylactic H2 antagonist will be maintained according to tolerability."
58351|NCT03728166|Behavioral|Electronic alert|"On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a Extended-Duration VTE Prevention order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis."
58352|NCT03728153|Drug|Fluoxetine 20 MG Oral Tablet|Once-daily dosing for 90 days
58356|NCT03728114|Device|RIC|Adults allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 200 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
58357|NCT03728114|Device|sham RIC|Adults allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
58358|NCT03728101|Drug|Simvastatin, Dabigatran Etexilate|The subjects receive dabigatran etexilate with and without simvastatin administration
58359|NCT03728088|Other|Rating scales concerning non-technical attributes|
58360|NCT03728075|Device|Neuromuscular electrical stimulation (NMES)|NMES was placed on the quadriceps muscle of both legs
58361|NCT03728062|Behavioral|Mindfulness meditation|Guided mindfulness meditation focused on breath sensations, thoughts and emotions.
58362|NCT03728062|Behavioral|Physical exercise|Cardio exercise at gym like rowing, eliptical, cycling, or running outside.
58363|NCT03728049|Diagnostic Test|CT-ADP performed during TAVI procedure|The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
58364|NCT03728049|Other|No CT-ADP performed during TAVI procedure|PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
58365|NCT03728036|Behavioral|conventional rehabilitation|The investigated cohort will be exposed to 'standard care' including conventional rehabilitation therapy.
58366|NCT03728023|Drug|AZD4205|SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
58367|NCT03728023|Drug|Placebo|Single dose in SAD and once daily for 14 days
58368|NCT03728010|Diagnostic Test|Electrical impedance tomography. Pulmonary mechanics measurement.Arterial gas measurement. Esophageal pressure measurement|After general anesthesia, patients will be ventilated with three tidal volume level (4, 6 and 8 cc / Kg / IBW), in two levels of PEEP, 6 cm2 H20, and best PEEP, the latter obtained after a recruitment maneuver and decremental titration.
58369|NCT03727971|Drug|Omalizumab Injection|The treatment is initiated with one injection with weight and serum-immunoglobulin E balanced omalizumab. After omalizumab treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
58370|NCT03727971|Drug|NaCl|The treatment is initiated with one injection with placebo. After placebo injection treatment at ovulation it will again be collected material (blood samples, sputum, secretion of the vagina, secretion of the rectum, secretion of the uterus, microbiota). If no pregnancy has occurred after first IVF cycle, this will be repeated for 3 consecutive IVF cycles in total or until pregnancy has occurred.
58371|NCT03727958|Diagnostic Test|Lung and coronary CT assessment|Subjects will undergo simultaneous coronary arteries and thoracic CT assessment
58372|NCT03727958|Diagnostic Test|Coronary CT assessment|Subjects will undergo coronary arteries CT assessment only
58373|NCT03727945|Other|abdominopelvic exercise and posture|n=21 women received supervised abdominopelvic exercise with previous postural correction. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises, previous explain postural correction pelvis, cervical and dorsal zone.
58374|NCT03727945|Other|abdominopelvic exercise|n=21 women received supervised abdominopelvic exercise. During 12 sessions a specialized physiotherapist supervised to realization of progressive abdominopelvic exercises.
58375|NCT03727932|Device|VioOne HIV Profile Supplemental Assay|The VioOne™ HIV Profile™ Supplemental Assay is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of Human Immunodeficiency Virus Type 1 (HIV-1 Group M & Group O) and Type 2 (HIV-2) in human serum or plasma. The HIV Profile™ is intended as an aid in the diagnosis of infection with HIV-1 and/or HIV-2.
58376|NCT03727919|Behavioral|Exoskeleton-assisted gait training|In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
58377|NCT03727906|Other|No pre-sleep arousal manipulation|As with the pre-sleep arousal up- and down-regulation nights, the participant will sleep in comfortable sound-proof and temperature-controlled bedroom and will go to bed and wake up at his/her self-reported usual school-week times. On this night, pre-sleep activities include watching television or reading a book.
58378|NCT03727906|Other|pre-sleep arousal down-regulation|"On the low pre-sleep arousal night, about 30 min before lights-out, a 20 min session of relaxation-driven Virtual Reality (VR) + slow breathing will be conducted. Adolescents will be instructed to perform slow diaphragmatic breathing and to let the VR immersion guide them through this relaxation process."
58379|NCT03727906|Other|pre-sleep arousal up-regulation|"On the high pre-sleep arousal night, an anticipatory stress procedure from the Trier Social Stress Test (TSST) will be used to elicit stress-induced ANS activation in the pre-sleep period. About 30 min before lights-out participants will be told that the following morning they will need to prepare and give a 5-min speech in front of a panel of assessors who will judge their performance and ask questions. Participants will be shown the testing room (set up with chairs, video camera, microphone)."
58380|NCT03727893|Behavioral|Roller-based Intervention Group (IG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education and a 12-week (3 sessions per week) evidence-based high-intensity interval training (HIIT) program using the roller-based WheelMill (WMS) system.
58381|NCT03727893|Behavioral|Control Group (CG)|A group of manual wheelchair users (MWUs) with spinal cord injury (SCI) that will complete an initial exercise education session and enroll in a 12-week (3 sessions per week) independent workout program at an accessible community-based fitness facility.
58382|NCT03727880|Drug|Pembrolizumab|Following standard of care neoadjuvant chemotherapy, subjects will receive two doses of pembrolizumab (200mg) IV 3 weeks apart prior to surgery. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 8 doses of pembrolizumab (200mg) IV 3 weeks apart.
58383|NCT03727880|Drug|Defactinib|Following 2 cycles of standard of care neoadjuvant chemotherapy, subjects will receive 100 mg defactinib twice a day up until 2 days preceding their surgery (approximately 6 weeks) during the immunotherapy cycles with pembrolizumab. After surgery, subjects will receive adjuvant standard of care chemotherapy. Following adjuvant chemotherapy, subjects will receive 100mg defactinib twice a day for 24 weeks.
58384|NCT03727867|Drug|Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor|Oral EGFR TKI begins on day 1 and continues until disease progresses.
58385|NCT03727867|Device|Stereotactic Body Radiation Therapy|Participants were given Stereotactic Body Radiation Therapy in a dose of 60 Gy/8 fraction for the central tumor or 50 Gy/5 fraction for the peripheral lung cancer, respectively.
58386|NCT03727854|Dietary Supplement|Premeal protein enriched bar|Subjects in the intervention group will intake protein enriched bar 15 minutes before each meals (at least twice a day).
58387|NCT03727854|Behavioral|Dietary modification|Subjects in this group will follow diabetes diet education.
58389|NCT03727828|Diagnostic Test|Patients with heart failure|Participants will have serial blood collection on medical therapy for heart failure
58390|NCT03727815|Other|Mindfulness Pain Management Arm|Mindfulness Pain Management intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the pain management mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
58391|NCT03727815|Other|Mindfulness Self Esteem Arm|Mindfulness Self Esteem intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for 2 weeks prior to participant's scheduled procedure and continue with the self esteem mindfulness module for 4 weeks postoperatively with periodic survey assessments using validated psychometric tools.
58392|NCT03727802|Drug|TRK-250|single and multiple doses (4 weeks)
58393|NCT03727802|Drug|Placebo|single and multiple doses (4 weeks)
58394|NCT03727789|Drug|FACT Complex-targeting Curaxin CBL0137|Given IA
58395|NCT03727776|Drug|Adrenocorticotropic Hormone|Adrenocorticotropic hormone (ACTH) is a melanocortin peptide hormone that is normally produced in the pituitary gland and acts as a major regulator of adrenal cortex function. It stimulates the adrenal cortex to produce and secrete glucocorticoids. ACTH is available for clinical usage as an injectable gel (H.P. Acthar®).
58396|NCT03727763|Drug|Vemurafenib|960mg po bid
58397|NCT03727763|Drug|Cetuximab|500mg/m2 iv gtt (14 days per course)
58398|NCT03727750|Drug|Gemtuzumab Ozogamicin|Three doses of GO 3 mg/m2 (up to one vial) as a 2 hour intravenous infusion on Cycle 1 Days 1, 4, and 7. A second cycle of GO 3mg/m² (up to one vial) on Cycle 2 Days 1, 4, and 7 will be allowed at the investigator's discretion for patients who meet the criteria
58399|NCT03727737|Device|Repetitive Transcranial magnetic Stimulation|RTMS will be delivered via magventure machine, on an approved FDA IDE protocol to DLPFC region to improve memory in older adults (veterans and non-veterans) with mild and moderate TBI.
58400|NCT03727724|Drug|Afatinib|Tablet
58401|NCT03727724|Drug|Cetuximab|Injection
58402|NCT03727711|Other|TPTNS|We will be comparing hospital treatment to TPTNS at home
58403|NCT03727698|Device|MR Linac|MR guided radiotherapy treatment
58404|NCT03727685|Behavioral|Our Care Wishes|A flyer describing the Our Care Wishes platform will be added to the back pocket of admission packets for patients being admitted via the Silverstein 1 Admission Office and the Emergency Department and for patients being seen in the Pre Admission Testing office. Registration reps in these locations will inform all patients seen that Penn has created a free, online resource called Our Care Wishes to help patients with Advance Care Planning and ask if they would like to be sent a link to Our Care Wishes by email or text. For those patients who respond affirmatively, the rep will then complete the necessary fields to refer on www.ourcarewishes.org/refer.
58405|NCT03727659|Behavioral|SHADE therapy + CONNECT FaceBook support|"See study arms description."
58406|NCT03727646|Dietary Supplement|Nicotinamide riboside|nicotinamide riboside supplied as 250mg capsules
58407|NCT03727633|Drug|Idarubicin and Lipiodol|Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
58408|NCT03727620|Drug|amoxicillin plus metronidazole|patients were administered 250 mg of Flagyl and 500 mg of Dyspamox, three times a day for 7 days
58409|NCT03727620|Drug|Doxycycline|patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
58410|NCT03727607|Drug|Desflurane|Desflurane vs TIVA, bariatric surgery. Postoperative nausea and pain
58411|NCT03727581|Diagnostic Test|Ultrasound guidance|Jugular vein is punctured with ultrasound guidance and guidewire is advanced. Right atrium and inferior vena cava junction is visualized by ultrasound using substernal view. Presence of guidewire in inferior vena cava or right atrium is confirmed. The procedure of catheter insertion is continued.
58412|NCT03727568|Procedure|Cryobiopsy|"In this study the investigators want to evaluate the diagnostic yield comparing 2 different techniques of performing cryobiopsy. A shorter freezing time and more number of biopsies vs a longer freezing time and less number of biopsies would be compared. Patients are randomised to the groups 1 or 2 immediate before the bronchoscopy.~Group 1: a total of 3 samples with a freezing time of 7 seconds at least for the first biopsy and freezing time for 5 seconds or more for the followings biopsies Group 2: a total of 8 samples with a freezing time of 3 seconds at least for the first biopsy and freezing time for less than 5 seconds for the followings biopsies"
58413|NCT03727555|Genetic|Intracerebral LV gene therapy|Intracerebral LV gene therapy to deliver high levels lenvirus which carry normal ABCD1 gene at 1-2×10^9 multiplicity of infection/ml per site in multiple sites.
58414|NCT03727542|Device|adjustment of atrioventricular delay in DDD packers|Atrioventricular delays are going to be adjusted as 60 milisecond shorter than the patients' native PR intervals in patients with already implanted permanent pacemakers.
58415|NCT03727529|Other|Treadmill + VR|Patients will walk on the tredmill with the virtual reality headset. Patients will walk in a straight line in a coherent, immersive and simple virtual environment. Before the first session, a 15-minute session will focus on patient familiarization with iVR
58416|NCT03727529|Other|Treadmill|Patients will walk on the treadmill without iVR. Patients will also receive a short familiarization to the treadmill before strating the experimentation.
58417|NCT03727503|Other|PPV from the capstesia|we will challenge the application by doing 2 maneuvers: the first one is to increase the PEEP level from 5 to 15 cmH2O and the second one is the infusion of a mini-fluid challenge (100 ml) followed by the other 400 ml.
58418|NCT03727490|Other|Repair|The subscapularis will be repaired.
58419|NCT03727490|Other|Standard Treatment|No repair will be performed
58420|NCT03727464|Behavioral|Abstract priming|Patients were primed with a list of abstract during their general anesthesia
58421|NCT03727464|Behavioral|Concrete priming|Patients were primed with a list of concrete during their general anesthesia
58422|NCT03727464|Behavioral|Controls|Patients did not receive any specific stimulation with words during their general anesthesia
58423|NCT03727464|Drug|Propofol|Propofol general anesthesia
58424|NCT03727464|Drug|Sevoflurane|Sevoflurane general anesthesia
58425|NCT03727451|Combination Product|iNO|inhaled nitric oxide
58426|NCT03727438|Behavioral|Tele-Self CBTI|The tele-self intervention is comprised of two treatment components: 1) self-management via a workbook with weekly readings, and 2) weekly telephone-based nurse support over 6 weeks
58427|NCT03727438|Other|Health Education Control|6 weekly phone calls from a study nurse on a range of health topics (non-sleep), similar call duration to intervention phone calls. At the end of the study, participants will be offered assistance through the Durham Behavioral Sleep Medicine clinic.
58428|NCT03727425|Device|Robotic assisted bronchoscopy|Robotic assisted bronchoscopy of peripheral airways in human subjects for the purpose of biopsying peripheral lung lesions.
58429|NCT03727412|Drug|Drugs, Generic (Naprosyn)|naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
58430|NCT03727412|Drug|Placebo Oral Tablet|placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
58431|NCT03727399|Other|blood withdrawal|Blood withdrawal
58432|NCT03727386|Other|Coconut oil|Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
58433|NCT03727386|Other|Sunflower oil|Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
58434|NCT03727360|Other|Exercise Training|Supervised exercise conducted four days per week for six months.
58435|NCT03727360|Other|Flexibility Control|Supervised exercise conducted four days per week for six months.
58436|NCT03727347|Device|InSeca Stylus|Low power radiofrequency energy delivery to the portion of the nasal cavity mucosa overlying the region of the posterior nasal nerve (the posterior middle meatus and posterior inferior meatus).
58437|NCT03727334|Behavioral|Online Spatial Navigation Training|Participants complete training tasks that test their spatial navigational abilities, cognitive map formation, and pattern separation. These training tasks involve map drawing, vector mapping, proximity judgments, and navigating with blocked routes.
58438|NCT03727321|Combination Product|Fecal Microbial Transplant|Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
58439|NCT03727321|Dietary Supplement|Fiber|A combination of soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)
58440|NCT03727321|Dietary Supplement|Cellulose|Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
58441|NCT03727308|Behavioral|Medical abortion pills sourced from pharmacies|One cohort using medical abortion pills sourced from pharmacies
58442|NCT03727308|Behavioral|Medical abortion pills sourced from health clinics|One cohort using medical abortion pills sourced from health clinics
58443|NCT03727295|Drug|Idebenone/placebo|The two control group will be given Idebenone in two different doses，and the placebo group will be given placebo
58444|NCT03727282|Procedure|adjust dobutamine according to the ejection volume index|adjust dobutamine dose
58445|NCT03727282|Procedure|adjust dobutamine according to the attending physician|adjust dobutamine dose
58446|NCT03727269|Other|Wii Fit Training Experimental Group|Experimental group receiving wii fit game based abdomino-pelvic training. A specific protocol was developed by the researchers. Wii fit games which promote exercises focusing on the abdominopelvic cavity strengthening, using as a therapeutic means a Wii™ console with a Wii Fit Plus™ CD game. The protocol was design that which playing games participant perform different pelvic movements such as anteversion, retroversion, lateral tilt and circumduction that maintain trunk control and stabilization with mild abdomino-pelvic muscle activation. Duration of each game is 5 minutes with 90 seconds interval between them twice a week. After performing the sequence of virtual games, a series of abdominopelvic and lower limb muscle stretching exercises will done.
58447|NCT03727269|Other|Conventional Training|"Control group (n=20) receiving conventional pelvic floor exercises. Conventional exercises includes:~Knack Maneuver (Ashton -Miller 1998, 2008)~Pelvic floor strengthening: kegel Exercise.~-Lumbo-Pelvic Stabilization Exercise.~Functional Training/ PFM Contraction during ADL~Correction of biomechanical/structural deformities"
58448|NCT03727256|Other|ultrasound therapy|Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes
58449|NCT03727256|Other|neuromuscular electrical stimulation application|Group 2, neuromuscular electrical stimulation application;20 mins/session
58450|NCT03727230|Other|Blood transfusion|"Transfusion with D+ blood rather than the rare D negative blood to Asia type DEL recipients"
58451|NCT03727217|Diagnostic Test|Pre and postoperative ultrasound|An ultrasound is performed in preoperative and in postoperative
58452|NCT03727204|Procedure|On-pump cardiac surgery|All participants will undergo on-pump cardiac surgery
58453|NCT03727191|Other|Control Group (education, guidelines, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet and recommendations for physical activity for one month.
58454|NCT03727191|Other|Experimental Group (education, guidelines, 2 pckts diet, recommendations)|Nutritional education and guidelines for the consumption of a completed shreded diet including 2 packets of 90 grams every day and recommendations for physical activity for one month.
58455|NCT03727165|Other|Continuous enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 24 hours per day
58456|NCT03727165|Other|Cyclic enteral nutrition infusion|Enteral nutrition administration in continuous infusion during 16 hours per day
58457|NCT03727152|Drug|generic single tablet TAF/FTC/DTG|HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir
58458|NCT03727139|Drug|Rasagiline|Rasagiline Tablets
58459|NCT03727126|Procedure|Robotic esophagectomy|Removal of the esophagus and its draining lymph nodes using robotic surgical instruments
58460|NCT03727126|Procedure|Thoracolaparoscopic esophagectomy|Removal of the esophagus and its draining lymph nodes using conventional thoracoscopic and laparoscopic techniques
58461|NCT03727113|Procedure|Optimization cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using an optimization/antibiotic strategy.
58462|NCT03727113|Procedure|Control cohort|Recipients of an allogeneic hemopoietic stem cell transplant in Centers using a classical strategy of administration of antibiotics.
58463|NCT03727100|Combination Product|Clonidine Micropellets|Injection
58464|NCT03727100|Other|Sham|Injection
58465|NCT03727087|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
58466|NCT03727074|Drug|5-FU Cream|topical cream twice a day
58467|NCT03727074|Drug|Efudex®|topical cream twice a day
58468|NCT03727074|Drug|Vehicle|topical cream twice a day
58469|NCT03727061|Biological|Nivolumab|Immunotherapy - Standard of care
58470|NCT03727061|Drug|Porfimer Sodium|Given IV
58471|NCT03727061|Procedure|Interstitial Illumination Photodynamic Therapy|Undergo I-PDT
58472|NCT03727061|Biological|Pembrolizumab|Immunotherapy - Standard of care
58473|NCT03727061|Drug|Cisplatin|Standard of Care
58474|NCT03727061|Drug|Carboplatin|Standard of Care
58475|NCT03727061|Biological|Cetuximab|Standard of Care
58476|NCT03727061|Other|Quality of Life Assessment|Ancillary Studies
58477|NCT03727061|Drug|Fluorouracil|Standard of Care
58478|NCT03727048|Drug|Ketorolac|the investigators aimed to evaluate the effect of postoperative ketorolac after ankle fracture surgery on postoperative opioid consumption, pain control, an patient satisfaction.
58479|NCT03727048|Other|No ketorolac|standard of care post operative pain management protocol
58480|NCT03727022|Drug|Placebo|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24
58481|NCT03727022|Drug|SM04690|Healthcare professional-administered intra-articular injections; first performed on Day 1 and second at Week 24
58482|NCT03727009|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
58483|NCT03726996|Drug|Desipramine|Study drug (desipramine) provided in tablet form to be taken daily.
58484|NCT03726983|Other|Experimental group|Pregnant women who agree to take part will be assigned to a group: experimental group and control group. The experimental group will received health management support and counseling that were conducted by the researchers through the e-health management platform.
58485|NCT03726970|Radiation|CBCT radiation|CBCT scanning
58486|NCT03726957|Behavioral|Improved Cookstoves|Villages were randomized to have participating households assigned to either a traditional biomass burning cookstove or to an improved cookstove. Once the participating villages had been selected, the investigators used their list of eligible households within each village to randomly order these households. Within each village, the investigators then approached the eligible households in the order that had been randomly chosen and continued that process until four households within each village had agreed to participate. The selection of villages and households preceded randomization and was pursued with the clear understanding that group assignment would be random, and that participation reflected a willingness to be randomized to either study group.
58487|NCT03726944|Behavioral|Calm App Meditation|The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
58488|NCT03726944|Behavioral|Unnamed Consumer-Based App Meditation|The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
58489|NCT03726944|Other|Educational Control|The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
58490|NCT03726931|Diagnostic Test|18F-Fluorestradiol PET/CT scan|[18F]FES PET/CT scan will be performed after administration of radioactive labelled estrogen.
58491|NCT03726918|Procedure|Surgery for implantation of a prosthesis|Analysis of micro Ribo Nucleic Acid (RNA) expressed by the synoviocytes, osteoblasts and chondrocytes
58492|NCT03726905|Other|respiratory muscles training|4 weeks respiratory muscles training aimed on respiratory muscles endurance and lengthening expiration time
58493|NCT03726905|Other|sham respiratory muscles training|4 weeks sham respiratory muscles training with the help of breathing simulators, with a breathing resistance level set at 0
58494|NCT03726905|Other|aerobic training|12 weeks treadmill walking
58495|NCT03726892|Device|PCI|Coronary Intervention
58496|NCT03726879|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
58497|NCT03726879|Drug|Placebo|Placebo matched to atezolizumab will be administered as per the schedule specified in the respective arm.
58498|NCT03726879|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
58499|NCT03726879|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
58500|NCT03726879|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
58501|NCT03726879|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
58502|NCT03726879|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
58503|NCT03726879|Drug|Trastuzumab Emtansine|Participants without pCR have the option of receiving adjuvant atezolizumab/placebo combined with Trastuzumab Emtansine 3.6 mg/kg IV Q3W.
58504|NCT03726866|Drug|Sequence 1|D326, D337 or CKD-828 for 9 days
58505|NCT03726866|Drug|Sequence 2|D326, D337 or CKD-828 for 9 days
58506|NCT03726866|Drug|Sequence 3|D326, D337 or CKD-828 for 9 days
58507|NCT03726866|Drug|Sequence 4|D326, D337 or CKD-828 for 9 days
58508|NCT03726866|Drug|Sequence 5|D326, D337 or CKD-828 for 9 days
58509|NCT03726866|Drug|Sequence 6|D326, D337 or CKD-828 for 9 days
58510|NCT03726853|Drug|CKD-497 200mg|CKD-497 200mg
58511|NCT03726853|Drug|CKD-497 300mg|CKD-497 300mg
58512|NCT03726853|Drug|CKD-497 placebo|Placebo of CKD-497
58513|NCT03726853|Drug|Comparator|Comparator
58514|NCT03726853|Drug|Comparator placebo|Comparator placebo
58515|NCT03726840|Other|Fragrance|peppermint, rosemary, and zest/pulp will increase memory recall for navigation and improve reaction times for braking, compared to performance during unscented conditions
58516|NCT03726827|Other|Fibroscan screening|A single Fibroscan screening for fat content and liver stiffness
58517|NCT03726814|Biological|EPC treatment group|Brain injection EPC
58518|NCT03726801|Other|HEALTH EDUCATION|"The nursing intervention prior to surgery: (breast and colon cancer):~First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort."
58519|NCT03726788|Drug|Botulinum Toxin Type A 100U|one intra-articular injection of 100 U of botulinum toxin type A, diluted in 2 ml of 0.9% SSI
58520|NCT03726788|Drug|Botulinum Toxin Type A 200U|one intra-articular injection of 200 U of botulinum toxin type A, diluted in 4 ml of 0.9% SSI
58521|NCT03726788|Drug|Triamcinolone Hexacetonide Inj Susp 20 MG/ML|one intra-articular injection of 2 ml Triamcinolone Hexacetonide
58522|NCT03726775|Drug|Durvalumab|Infusion of durvalumab during RT and after RT during 6 months
58523|NCT03726762|Behavioral|DBs at the end of the main meal + weight control program|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
58524|NCT03726762|Behavioral|Water at the end of the main meal+ weight control program|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan.
58525|NCT03726749|Drug|Tocilizumab|Tocilizumab is an interleukin-6 (IL-6) receptor inhibitor
58526|NCT03726749|Drug|Prednisone|Prednisone is an anti-inflammatory medication
58527|NCT03726736|Drug|Anlotinib combined Docetaxel|Anlotinib ( dose base on phase I study, QD PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
58528|NCT03726736|Drug|Docetaxel|Docetaxel (60mg/m2 IV, d1, 21 days per cycle)
58529|NCT03726710|Behavioral|Blood Pressure measurement and pharmacy|Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
58530|NCT03726697|Other|Tahneek|A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
58531|NCT03726684|Device|Coding strategy for cochlear implants|Comparison of two variations of a coding strategy based on electrophysiological objective measures with standard reference coding strategy
58532|NCT03726671|Other|25% Cho diet|Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus
58533|NCT03726671|Other|50% Cho diet|Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus
58534|NCT03726671|Other|100% Cho diet|Subjects will consume meals containing 100% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus
58535|NCT03726658|Drug|AGN-241751|AGN-241751 is supplied in tablet form
58536|NCT03726658|Drug|Placebo|Placebo is supplied in tablet form
58537|NCT03726645|Other|Fecal microbiota transplantation|Fecal microbiota transplantation
58538|NCT03726619|Behavioral|e-CHEC-uP|One time online-based education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
58539|NCT03726619|Behavioral|CHEC-uP|One time face-to-face education about breast and cervical cancer screening procedures followed by phone counseling by trained community health worker over 6 months
58540|NCT03726606|Device|Intraocular lens|Bilateral implantation of the same intraocular lens.
58541|NCT03726593|Drug|Artesunate and Pyronaridine|Standard weight based dosing
58542|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Pyronaridine|Both drugs (AP) and (ASPY) are administered once a day, on days 0, 1, and 2.
58543|NCT03726593|Drug|Atovaquone Proguanil and Artesunate Mefloquine|Sequential treatment with ASMQ (on days 0, 1, and 2) followed by the treatment with AP for 3 more days (total 6 days treatment)
58544|NCT03726580|Drug|Sevoflurane|Assess the effect of isoflurane, sevoflurane, propofol and regional anesthesia on the olfactory threshold, olfactory identification and endocrine regulation of associative memory in the postoperative period in old age group.
58545|NCT03726567|Procedure|Bariatric surgery|Roux-en-Y surgery
58546|NCT03726554|Device|Comprehensive Reverse Porous Augmented Glenoid|Three glenoid baseplate options designed for various severities of glenoid erosion and deformity, the device promotes bony ingrowth while restoring natural human anatomy.
58609|NCT03726151|Behavioral|Combined Condition|Parent reminders and multicomponent clinic-system strategies
58547|NCT03726554|Device|Comprehensive Mini Humeral Tray|The mini humeral tray offers additional sizing options to the Comprehensive Shoulder line. The mini tray is designed to fit smaller anatomies.
58548|NCT03726541|Other|physiotherapy|Physiotherapy program includes breathing exercises, incisive spirometer study, grade ambulation. Oxygen saturation, heart rate and blood pressure values will be recorded before and after the session. Changes in the follow-up parameters will be discussed.
58549|NCT03726528|Diagnostic Test|Measurements of left ventricular pressure and volume|Patients with suspected Takotsubo syndrome (typical ballooning in left ventriculography without significant obstructive coronary artery disease that sufficiently explains the contraction abnormalities) will undergo continuous online measurements of left ventricular pressure and volume using conductance catheters. Cardiac magnetic resonance (CMR) imaging will be performed in patients without contraindications for optimized morphological characterization and exclusion of important differential diagnoses.
58550|NCT03726515|Biological|CART-EGFRvIII T cells|autologous T cells that have been engineered to express an extracellular Humanized single chain antibody (scFv) with specificity for EGFRvIII linked to an intracellular signaling molecule comprised of a tandem signaling domain of the 4-1BB and TCRζ signaling modules.
58551|NCT03726515|Biological|Pembrolizumab|humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
58552|NCT03726502|Procedure|ureteroscopy with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
58553|NCT03726502|Procedure|ureteroscopy alone|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
58554|NCT03726502|Procedure|without safety guide-wire|ureteroscopy without use of safety guide-wire in treatment of ureteral stone
58555|NCT03726502|Procedure|with safety guide-wire|ureteroscopy with use of safety guide-wire in treatment of ureteral stone
58556|NCT03726489|Device|Daavlin 7 series 3 panel narrow band phototherapy home units|"Daavlin 7 series 3 panel narrow band phototherapy home units (with 8-12 bulbs and a smaller, flat surface with door, measuring 21 wide, 74.5 tall, and 23.5). This unit is a class II device with a FDA 510K indication for psoriasis, vitiligo and atopic dermatitis/eczema. The unit will have a dosimetry controller, a UV sensor built in that measures the intensity of the light. This sensor will adjust the treatment time to compensate for any variation in output due to aging of the lamps or other factors"
58557|NCT03726489|Device|narrow band phototherapy clinic units|Office based narrow band phototherapy unit (units typically have at least 24 bulbs in a surround structure
58558|NCT03726476|Behavioral|Patient centered pre-op education|To implement a patient centered education intervention to evaluate post-op narcotic use.
58559|NCT03726476|Behavioral|routine preop education|To implement routine patient education intervention to evaluate post-op narcotic use.
58560|NCT03726463|Procedure|Kidney transplantation|Bilateral nephrectomy of polycystic kidneys are routinely performed during kidney transplantation in ADPKD patients
58561|NCT03726450|Dietary Supplement|Andrositol Plus|Myo-inositol
58562|NCT03726450|Dietary Supplement|Andrositol Plus|N-Acetyl-Cysteine
58563|NCT03726450|Dietary Supplement|Andrositol Plus|Folic Acid
58564|NCT03726450|Dietary Supplement|Andrositol Plus|Selenium
58565|NCT03726450|Dietary Supplement|Andrositol Plus|L-arginine
58566|NCT03726450|Dietary Supplement|Andrositol Plus|L-carnitine
58567|NCT03726450|Dietary Supplement|Andrositol Plus|Vitamin E
58570|NCT03726411|Procedure|non-surgical periodontal therapy|scaling and root planing
58571|NCT03726398|Drug|Opsumit 10 Mg Tablet|Oral tablet taken once daily
58572|NCT03726372|Drug|Rocuronium|rocuronium is a neuromuscular blocking agent with a duration of 40 minutes
58573|NCT03726372|Other|continuous infusion|rocuronium is continuously infused
58574|NCT03726372|Other|intermittent injection|rocuronium is intermittently given
58575|NCT03726359|Radiation|Fractionated Stereotactic Radiation Therapy|Initial starting dose will be 7 Gy x5= 35 Gy delivered to the planning target volume (PTV). Radiotherapy will be delivered every other day so that the SBRT schedule is completed within 1.5-2 weeks.
58576|NCT03726346|Device|Trial Mask|Experimental Trial Mask
58577|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg lorlatinib
58578|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
58579|NCT03726333|Drug|lorlatinib|continued daily administration of 100 mg QD lorlatinib
58580|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
58581|NCT03726333|Drug|lorlatinib|continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
58582|NCT03726320|Behavioral|Education Counseling Session for PSA Screening|counseling from extensively trained CHW
58583|NCT03726320|Behavioral|General Health Counseling Coaching|coaching using an educational tool focused on dietary and lifestyle modification
58610|NCT03726125|Drug|LY3374849 - SC|Administered SC
58611|NCT03726125|Drug|Insulin Degludec - SC|Administered SC
58612|NCT03726125|Drug|LY3374849 - IV|Administered IV
58584|NCT03726307|Biological|DCreg: 0.5 million cells/kg+SOC|"DCreg 0.5 (±0.1) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
58585|NCT03726307|Biological|DCreg: 1.2 million cells/kg+SOC|"DCreg 1.2 (±02) million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
58586|NCT03726307|Biological|DCreg:2.5 to 5.0 million cells/kg+SOC|"DCreg 2.5 to 5.0 million cells/kilogram body weight infused as a single dose.~Standard of Care (SOC) immunosuppressive agents (ISA): Participants will receive combination ISA according to the site's SOC regimen, with two exceptions:~mycophenolic acid (MPA) will be initiated 7 days before transplant, at the time of donor DCreg infusion, instead of on the day of transplant; and~the pre-transplant dose of MPA will be half the standard post-transplant dose due to increased drug bioavailability in recipients with low glomerular filtration rate (GFR).~Participants will be maintained on triple IS therapy with MPA, tacrolimus, and prednisone after transplant, a combination regimen widely applied as SOC at many transplant centers in North America and worldwide."
58587|NCT03726294|Drug|NBM-BMX softgel capsules|Patients will initially receive NBM-BMX orally once a day at 100 mg per day.
58588|NCT03726281|Drug|Nivolumab|Nivolumab 240 mg, IV
58589|NCT03726268|Drug|Methadone|"Dose is 0.15-0.3 mg/kg IV methadone HCl given intraoperatively and in the immediate post-operative period. Intraoperative methadone doses are 15 mg in short-stay, anticipated next-day discharge patients and 10 mg in same-day surgery patients."
58590|NCT03726268|Drug|Fentanyl|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
58591|NCT03726268|Drug|Hydromorphone|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
58592|NCT03726268|Drug|Morphine|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
58593|NCT03726268|Drug|Sufentanil|Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
58594|NCT03726255|Procedure|Mesenchymal Stem Cell injection|curettage, closure of the internal opening (IO) and cell injection in IO (50%) and fistula tract (50%)
58595|NCT03726242|Drug|Levcromakalim|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
58596|NCT03726242|Drug|Saline|To investigate the role of levcromakalim compared with placebo after intradermal and intramuscular injection.
58597|NCT03726229|Device|Cholate assay|Labeled oral and IV cholate will be administered once to the Fontan cohort and blood specimens will be collected at baseline and timepoints thereafter.
58598|NCT03726216|Drug|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration [e.g. hospital, ICU]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
58599|NCT03726203|Device|laparoscopic gynecologic surgery with the MiniLap System.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care, but using the MiniLap System instead of the conventional single-use trocars used usually.
58600|NCT03726203|Device|laparoscopic gynecologic surgery with the conventional single-use trocars.|Subjects participating in the study will undergo laparoscopic gynecologic surgery as planned in the routine care using the conventional single-use trocars used usually.
58601|NCT03726190|Procedure|Oblique Lateral Lumbar Fusion|Oblique lateral lumbar interbody fusion (OLLIF) is a lumbar spinal fusion. OLLIF is performed with the patient in the prone position and employs an oblique lateral approach that enables the instrumentation to pass through Kambin's triangle which is defined as the space between the exiting nerve, the superior border of the caudal vertebra, and the superior articulating process of the inferior facet. This approach may be performed without direct visualization, guided by electrophysiological monitoring and biplanar fluoroscopy. During the approach, a blunt probe is used to make contact with the disc, followed by a series of gentle dilations. Discectomy is performed through a 10-mm access portal. The cage is inserted under continued electrophysiological monitoring and fluoroscopy.
58602|NCT03726177|Drug|aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
58603|NCT03726177|Drug|aspirin 81 mg|Aspirin 81mg one tablet once a day from recruitment until 37 weeks or labor whichever comes first
58604|NCT03726177|Drug|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
58605|NCT03726164|Device|Remote Conditioning|A Blood pressure cuff will be placed on the arm and inflated to 200mm hg for 5 minutes, and then deflated for 5 minutes, a cycle repeated 3 times.
58606|NCT03726164|Device|Sham protocol|An un-inflated blood pressure cuff will be placed on the arm for 20 minutes.
58607|NCT03726151|Behavioral|Parent Reminders|Automated, system-generated mailed or text message reminders
58608|NCT03726151|Behavioral|Multicomponent clinic-system strategies|"Workflow modifications to reduce missed opportunities for vaccination~Provider- and clinic-level audit and feedback~Provider & staff training on workflow modifications and communication strategies"
58613|NCT03726125|Drug|Insulin Degludec - IV|Administered IV
58614|NCT03726112|Device|SpotOn Specs|SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field
58615|NCT03726112|Device|Sham Specs|Sham device
58616|NCT03726099|Drug|rabeprazole, amoxicillin, furazolidone，tetracycline|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day concomitant therapy containing rabeprazole 10mg bid, amoxicillin 1000mg bid , furazolidone 100mg bid and tetracycline 500mg qid.
58617|NCT03726086|Diagnostic Test|laryngoscopy|A flexible camera (fiberoptic endoscope) is placed in the patient's nose to view the nose, throat, and airway.
58618|NCT03726073|Device|electrodes|electrodes are attached to acupoints Zusanli (ST36), Neiguan (PC6) and Hegu (LI4)
58619|NCT03726073|Device|electrical stimulation|electrodes are ligated to a stimulator and electrical stimulation is given
58620|NCT03726060|Other|control group|In the control group the patient will undergo gnathologic therapy for 6 months with neuromuscural splint every night for 3 months
58621|NCT03726060|Other|test group|In the test group the patient will undergo gnathologic therapy with neuromuscural splint every night for 3 months in association with physical therapy
58622|NCT03726047|Behavioral|Exercise|Subjects will complete 5 minutes of exercise on an ergometer to examine the effects of exercise on retention of a newly learned walking pattern.
58623|NCT03726034|Behavioral|Life Story Book|The protocol of life story book creation is validated in Hong Kong. The life story book would contain two elements: (1) the development of the older adults over the course of his/her lifetime (i.e. from childhood to old age); and (2) the psychosocial development and ways of life of the older adults (e.g. education, marriage, career, and hobbies). The product of the intervention will be a written story with pictures or other memorabilia that are meaningful to the older adults. There is no limitation on the number of words, pages, and pictures. Four to six 60-minute scheduled sessions will be needed for the older adult and the live-in migrant caregivers to discuss and produce the lifestory book at home.
58624|NCT03726034|Behavioral|Self-selected social activities|To control the possible social interaction effects on the dyadic relationship and wellbeing, the caregivers of the control group will conduct self-selected social activities with older adult at home individually for four times weekly.
58625|NCT03726021|Drug|Irinotecan,Oxaliplatin, and S1|"Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells"
58626|NCT03726008|Behavioral|Perinatal health promotion program and regular prenatal care|Regular prenatal care and perinatal health promotion program including health promotion during pregnant period, health promotion during the ritual of Tso-Yueh-Tzu, health promotion during postpartum period, newborn care
58627|NCT03725995|Drug|Midazolam|Patients received 0.5 mg/kg midazolam, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
58628|NCT03725995|Drug|Lidocaine-Midazolam|Patients received a puff of lidocaine 2% in each nostril, after 60 seconds, they received 0.5 mg/kg midazolam, with a maximum dose of 10 mg. , Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
58629|NCT03725995|Drug|Placebo|Patients received saline 9% (placebo), 0.5 mg/kg, with a maximum dose of 10 mg, Immediately following the administration, the child was asked to record the score of pain on the self reporting pain scale, WBFS.
58630|NCT03725982|Device|Laevo®|A passive exoskeleton supporting the lower back during bending and lifting tasks (for more information, visit the manufacturer's website: http://en.laevo.nl/).
58631|NCT03725969|Dietary Supplement|Camel milk|Camel Milk administered 10 minutes before a mixed meal of carbohydrate and protein; 2-week washout between interventions
58632|NCT03725969|Dietary Supplement|Cow milk|Cow milk administered 10 minutes before a mixed meal of carbohydrate and protein;2-week washout between interventions
58633|NCT03725956|Procedure|Endoscopic sinus surgery|"Surgical procedure under general anaesthesia:~Consists of the removal of bone boundaries between sinus cavities (ethmoidectomy) with nasal polyps resection in order to retrieve nasal patency and sinus drainage Polysomnographic assessment as routinely applied in clinical practice"
58634|NCT03725943|Diagnostic Test|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG.
58635|NCT03725930|Drug|Clonidine|clonidine intranasal premedication in preschool infants
58636|NCT03725930|Other|Placebo|Placebo intranasal premedication
58637|NCT03725917|Other|Physiotherapy protocol|The intervention will consist of a physiotherapy protocol twice a week for twelve weeks. The protocol will be done in three phases, constituting each month, a phase of the protocol. The first two phases will include therapeutic exercise of progressive difficulty and manual therapy, while the last phase will include only one week of manual therapy and therapeutic exercise, the last three weeks being composed only of therapeutic exercise
58638|NCT03725904|Diagnostic Test|Progesterone analysis in saliva|Analysis of salava progesterone
58639|NCT03725891|Drug|Aspirin 162 mg|Aspirin 81mg two tablet once a day from recruitment until 37 weeks or labor whichever comes first
58640|NCT03725891|Drug|Aspirin 81 mg|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
58641|NCT03725891|Drug|placebo|placebo one tablet once a day from recruitment until 37 weeks or labor whichever comes first
58642|NCT03725878|Procedure|Standard tertiary interventions of birth defects|Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.
58669|NCT03725605|Combination Product|LTX-315 and TILs|intratumoural injection of LTX-315 and infusion of TILs
58951|NCT03723447|Drug|Liposomal bupivacaine|Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
58643|NCT03725878|Procedure|Additional preconception health care|Various studies have revealed that folate is essential in early embryo development, whereas folate level evaluation in periconception women is not included in routine health cares. Therefore, we evaluate subject's folate level by serum and red blood cell folate examination. By combination of folate supplement obtained by questionnaire,folate level evaluated by examinations and folate metabolism ability evaluated by genotyping key enzymes in folate metabolism, an individualized folic acid supplementary guide is given to subjects. Red blood cell folate concentration >400 ng/ml before pregnancy is recommended.
58644|NCT03725878|Procedure|Additional health care procedures during and after pregnancy|Fetus with birth defect will be referred to a tertiary hospital to receive genetic assessments and prenatal diagnosis to reduce unnecessary abortions. A 6-months follow up will be conducted to follow children's birth outcomes. It also helps clinical team to give early diagnosis and treatment for children with birth defect to reduce disability and improve life quality of defect children.
58645|NCT03725865|Biological|Induction of neural stem cells|Brain injection iNSC
58646|NCT03725852|Drug|GLPG1205|GLPG1205 will be provided as an oral hard gelatin capsule.
58647|NCT03725852|Drug|Placebo|matching placebo will be provided as an oral hard gelatin capsule.
58648|NCT03725839|Device|F&P Interface|F&P Interface to be used for OSA therapy
58649|NCT03725813|Other|Person-centred inpatient care|"The intervention comprises three sequential steps in the care process. The first two steps follow one after the other in conjunction with admission to the ward: 1) person-centred assessment, and 2) creation of a person-centred health plan. Persistent person-centred inpatient care, the third step, is practiced throughout the hospital stay, and is a component of the quality and patient safety program.~The model is systematically applied to all patients admitted to the unit. All staff are trained in PCC before implementation of the intervention."
58650|NCT03725787|Device|CuroCell S.A.M. ® pro mattress|During 30 days, participants will use the static air mattress.
58651|NCT03725774|Other|GRIP (Getting Research into Practice) model|"The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.~The GRIP model is a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying the obstacles to improvements in clinical practice, and drawing up and implementing a plan of action for the purpose of improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the obstacles that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles."
58652|NCT03725761|Drug|IMMU-132|IMMU-132 is a novel Antibody Drug Conjugate (ADC) based on a humanized anti-Trop-2 antibody (hRS7) conjugated to SN-38 payload.
58653|NCT03725748|Other|irrigation|irrigation the edges of the cs scar before closure
58654|NCT03725735|Behavioral|CBT for problem gambling with emotion regulation|CBT group treatment for problem gambling with emotion regulation focus, with 8 sessions.
58655|NCT03725722|Drug|Delgocitinib cream|Cream for topical application
58656|NCT03725722|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
58657|NCT03725709|Procedure|spinal anesthesia|Plan to enroll 120 Type 2 diabetes and 120 non-diabetes patients with received spinal anesthesia.Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
58658|NCT03725696|Diagnostic Test|Semen Analysis|Sperm counts will be determined by semen analysis.
58659|NCT03725696|Diagnostic Test|Hormonal panel|Blood test for LH, FSH, testosterone, and estradiol
58660|NCT03725696|Procedure|RYGB Gastric Bypass|Roux-en-Y Gastric Bypass
58661|NCT03725696|Diagnostic Test|IIEF Survey|International Index of Erectile Function is a validated 5-question survey examining sexual health in men
58662|NCT03725683|Device|Increased caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI(ankle-brachial pressure index);Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
58663|NCT03725683|Device|matched caliber balloon|"Imaging of target lesions was performed before surgery to evaluate the characteristics of target lesions.~Postoperative to discharge Laboratory examination: blood routine, renal function, biochemical, coagulation functionTo determine and record the ABI index;Records Rutherford classification; record the application of anticoagulant and antiplatelet agents; Records of adverse events."
58664|NCT03725670|Biological|Lentivirus-mediated delivery of ARSA to the CNS.|Intracerebral LV gene therapy to deliver high level lenviral vectors which carry normal ARSA gene at 1-2×10^9 multiplicity of infection (moi)/ml per site.
58665|NCT03725644|Behavioral|parent-training program|Parents in the treatment group received the training program from the registered pediatric occupational therapist in six hours over three weeks. The occupational therapist provided suggestions and gave feedback. The parents were encouraged to interact with their children for at least 15 hours per week. Between the fourth and 14th weeks, the parents implemented the intervention programs at home and recorded the daily intensity. The occupational therapist met with the parents and children at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered and to practice the child-initiated activities.
58666|NCT03725644|Behavioral|traditional program|Parents in the control group also conducted a 14-week program. They received six hours of training over three weeks.Between the fourth and 14th weeks, the parents implemented parent-led activities at home and recorded the daily intensity. The parents were encouraged to do activities with their children for at least 15 hours per week. The occupational therapist met with the parents at monthly intervals (the seventh and 11th weeks) at the laboratory to discuss any difficulties they encountered while practicing the parent-led activities.
58667|NCT03725631|Diagnostic Test|Imaging and serologic evaluation of fibrosis and steatosis|Imaging evaluation: Fibroscan, MRI scan for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients Serologic evaluation: serologic test for evaluation of fibrosis and steatosis in biopsy proven NAFLD patients
58668|NCT03725618|Biological|Yellow Fever 17DD Vaccine|live attenuated vaccine based on the 17DD strain
58670|NCT03725592|Other|Standard Treatment|Participant households receive a point of use arsenic removal device and a replacement filter. Households are also provided with an instruction manual on how to use the device.
58671|NCT03725592|Behavioral|Intensive Education|Participant households receive up to five additional in-person visits and phone calls to provide support regarding the health implications of arsenic and the proper use and maintenance of the arsenic removal device.
58672|NCT03725579|Drug|mepivicane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
58673|NCT03725579|Drug|articane hydrochloride|Pain will be assessed during access cavity preparation and instrumentation
58674|NCT03725566|Drug|Experimental|Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
58675|NCT03725553|Drug|Intramyometrial Vasopressin|a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30‐seconds) immediately after delivery, as soon as the umbilical cord was clamped.
58676|NCT03725553|Drug|Placebo|the group received a 10‐mL bolus injection of saline into the myometrium during slow (30‐seconds)as soon as the umbilical cord was clamped.
58677|NCT03725540|Device|I‑gel|Patients will be anesthetized using an appropriate sized I‑gel mask according to the manufacturer's recommendations after lubrication with a water-soluble lubricant.
58678|NCT03725540|Device|Baska_mask|Patients will be anesthetized using BASKA mask after lubrication with a water-soluble lubricant.
58679|NCT03725527|Procedure|Rectus Sheath Catheter Block|Sonar guided RSC will be performed using a 16-G, 8-cm TuohyUpon reaching this potential space, after careful aspiration.
58680|NCT03725527|Procedure|Epidural Catheter Block|Sonar-guided epidurals will be performed with a 17-gauge Tuohy needle and 19 G flex-tip catheter. Using an LOR (loss of resistance) to saline technique, catheters will be inserted 4 cm into the epidural space and a suitable test dose will be administered to exclude intravascular or sub-arachnoid injection.
58681|NCT03725514|Procedure|Conventional|Conventional Blood Clot Technique
58682|NCT03725514|Procedure|PRF|Platelet Rich Fibrin Technique
58683|NCT03725501|Drug|ALS-L1023|ALS-L1023 is an active fraction extracted from Melissa officinalis L. (Labiatae; lemon balm) leaves.
58684|NCT03725501|Drug|Ranibizumab|LUCENTIS® (an anti-neovascular VEGF-A inhibitor) 0.5 mg, intravitreal injection
58685|NCT03725501|Other|Placebo|Control group for comparison with oral administration of ALS-L1023
58686|NCT03725488|Other|Questionnaire|"students were involved in the pre-clinical prosthodontic lab. Participation in these labs were mandatory and it involved crown and bridge preparations on typodont models. There were 2 sessions of these labs per week, one for each gender. Each session lasted for 3 hours.~The study was conducted in 2 phases. At the beginning of the first phase of the study, the labs were conducted without any BM for 4 weeks. PSS(perceived stress scale), a standardized and validated, self-reporting international test was used for measuring the level of psychological stress were administered to all participants."
58687|NCT03725462|Device|Cardioskin|Subjects have a monitoring with cardioskin and comparator
58688|NCT03725462|Device|Neuronaute|Subjects have a monitoring with Neuronaute and comparator
58689|NCT03725449|Other|Best Practice|Receive standard of care
58690|NCT03725449|Behavioral|mySmartCheck|Receive access to mySmartcheck program
58691|NCT03725449|Other|Survey Administration|Ancillary studies
58692|NCT03725436|Drug|MDM2/MDMX Inhibitor ALRN-6924|Given IV
58693|NCT03725436|Drug|Paclitaxel|Given IV
58694|NCT03725423|Drug|Apatinib|250mg, qd once a day, take it half an hour after meal (the time for taking the medicine should be the same as possible), and take it with warm water. 28 days is a drug delivery cycle.
58695|NCT03725410|Device|Venus Fiore Study Treatment|Study treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (50 - 70% for up to 15 minutes), externally to the labia (10 - 35% for up to 10 minutes) and externally to the mons pubis (10 - 35% for up to 15 minutes).
58696|NCT03725410|Device|Venus Fiore Sham Treatment|Sham treatment consists of delivering radiofrequency (RF) and pulsed electromagnetic fields (PEMF) internally to the vagina (1% for up to 15 minutes), externally to the labia (1% for up to 10 minutes) and externally to the mons pubis (1% for up to 15 minutes).
58697|NCT03725397|Behavioral|Outpatient|The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.
58698|NCT03725397|Behavioral|Inpatient|"Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care."
58699|NCT03725384|Drug|Ferrous Sulfate 300Mg Tablet|oral dose of Ferrous Sulfate (300 mg) every day versus every other day along with vitamin C
58700|NCT03725384|Drug|Vitamin C 500Mg tablet|Vitamin C 500 Mg tablet every day versus every other day along with ferrous sulfate
58701|NCT03725371|Other|No intervention was administered for the purpose of this study.|No intervention was administered for the purpose of this study. Observations were carried out for all participants.
58702|NCT03725358|Behavioral|Training|Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
58703|NCT03725358|Behavioral|App|"Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.)."
58983|NCT03723252|Drug|Placebo|Participants will receive placebo po qd
58704|NCT03725358|Behavioral|Control|The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
58705|NCT03725345|Behavioral|MRI Scanner|Participants will enter the MRI scanner and complete a series of computer tasks that include noise blasts while undergoing brain scans that measure the structure and function of the brain
58706|NCT03725332|Behavioral|Telemedicine|Patients enrolled at sites randomized to telemedicine will receive a standardized, rotating patient education curriculum through consultations with a clinician with specialty training and expertise in substance abuse counseling, maternal fetal medicine, addiction medicine, and neonatal medicine. Consultations will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1)Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
58707|NCT03725332|Behavioral|Group Care|Patients enrolled at sites randomized to group care will receive a standardized, rotating patient education curriculum delivered in small groups led by a perinatal nurse facilitator and community-based peer support specialist. Small group care meetings will occur every two weeks until 8 weeks post-partum and will then continue monthly until 6 months post-partum. Rotating topics include: 1)Treatment Options for Opioid Use Disorder, 2) Smoking Cessation, 3) Relapse Prevention Education, 4) NAS Reduction Education, 5) Breast Feeding Support/Education, 6) Domestic Violence Education, 7) Postpartum Depression, and 8) Birth Control/Family Planning.
58708|NCT03725306|Device|Librata|Hyperthermic endomyometrial treatment via Librata catheter and balloon device
58709|NCT03725293|Device|Angiodynamics BioFlo Midline Catheter|Placement of Angiodynamics BioFlo Midline Catheter.
58710|NCT03725293|Device|Teleflex Arrowg+ard Blue Advanced Midline Catheter|Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
58711|NCT03725280|Procedure|IVF|None interventional study (Collection of ovarian follicular fluid during IVF treatment)
58712|NCT03725267|Drug|Melatonin Pill|Patients will receive 1 pill of melatonin each day during polymyxin B therapy for a maximum of 14 days.
58713|NCT03725267|Drug|Placebo oral capsule|Patients will receive 1 pill of placebo each day during polymyxin B therapy for a maximum of 14 days.
58714|NCT03725254|Procedure|lymphadenectomy|The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.
58715|NCT03725254|Radiation|chemoradiotherapy|Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
58716|NCT03725241|Dietary Supplement|Glutathione Supplement|1000 mg/day Glutathione
58717|NCT03725241|Dietary Supplement|Placebo Supplement|Crystalline cellulose
58718|NCT03725228|Drug|Magnesium Sulfate|Magnesium Sulfate 15mg/kg/h
58719|NCT03725228|Drug|Lidocaine|Lidocaine 1,5mg/kg/h
58720|NCT03725215|Behavioral|Split-Belt Treadmill Training|One session of 6 x 5 min with 1 min intervals.
58721|NCT03725202|Drug|Upadacitinib|It will be administered orally.
58722|NCT03725202|Drug|Corticosteroid (CS)|It will be administered orally.
58723|NCT03725202|Other|Placebo|It will be administered orally.
58724|NCT03725189|Device|PPG during exercise|PPG use for pulse waveform evaluation of healthy exercise group
58725|NCT03725163|Behavioral|Acceptance and Commitment Therapy Enhanced Behavior Therapy (AEBT)|This treatment approach blends traditional behavior therapy elements of habit reversal training and stimulus control techniques with the more contemporary behavioral elements of Acceptance and Commitment Therapy (ACT). The first phase of the treatment, clients are taught skills for stopping and preventing their unconscious pulling episodes. The second phase, clients are introduced to ACT. Unlike interventions that aim to change the type or frequency of pulling-related cognitions, this treatment uses strategies to change the function of these cognitions. Clients are taught to see urges for what they really are and to accept their pulling-related thoughts, feelings, and urges without fighting against them. Over the course of 10 session clients will learn to be aware of their pulling and warning signals, use self-management strategies for stopping and preventing pulling, stop fighting against their pulling-related urges and thoughts, and work toward increasing their quality of life.
58726|NCT03725137|Other|Analysis of T-lymphocytes|Analysis of T-lymphocytes regarding: post-stroke t-cell priming (activation marker, polarization), activation state of microglia, , cerebrospinal fluid (glucose, t-tau, phospho tau, Aβ1-40; Aβ1-42; further neurodegenerative/ Glia associated marker, cytokines); cognitive tests; structural and functional MRI
58727|NCT03725124|Other|Interview|Participants will be interviewed on their experience of family planning and inflammatory bowel disease.
58728|NCT03725111|Device|venous compression|venous compression
58729|NCT03725098|Device|HEMOBLAST Bellows|The HEMOBLAST™ Bellows hemostatic agent consists of a bellows pre-loaded with 1.65g of powder composed of collagen, chondroitin sulfate, and thrombin (1500 IU). HEMOBLAST™ Bellows is indicated in surgical procedures as an adjunct to hemostasis when control of minimal, mild, and moderate bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, and urological procedures.
58730|NCT03725098|Device|FLOSEAL|The FLOSEAL Matrix consists of a bovine-derived Gelatin Matrix component, a human-derived Thrombin component, applicator tips, and several mixing accessories. FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.
58731|NCT03725085|Drug|Mucinex™ extended-release (SE)|2 tablets of Mucinex™ (GGE, 600 mg extended-release bi-layer tablets)
58732|NCT03725072|Drug|Evobrutinib|Participants will receive a single, oral dose of evobrutinib under fasting conditions as a solution, which will contain [14C]-evobrutinib.
58733|NCT03725059|Biological|Pembrolizumab (K)|IV infusion Q3W
58734|NCT03725059|Drug|Placebo (P)|Normal saline or dextrose IV infusion Q3W
58735|NCT03725059|Drug|Paclitaxel (X)|IV infusion QW
58736|NCT03725059|Drug|Doxorubicin hydrochloride (A)|IV infusion Q3W
58737|NCT03725059|Drug|Epirubicin (E)|IV infusion Q3W
58738|NCT03725059|Drug|Cyclophosphamide (C)|IV infusion Q3W
58742|NCT03725046|Other|Optimized information transmission|Sending to the community referring physician by the emergency department an discharge report containing the reason for emergency consultations (report currently made as part of the treatment). Within 72 hours (working hours), the Emergency Clinical Pharmacist contacts the referring physician and the patient's community pharmacist to discuss how to manage the ADE. In parallel, a second report, summary of the ADE (ADE-report), is sent to them. The ADE-report, written and validated by the investigators (emergency physician and clinical pharmacist), includes the type of ADE, the suspected drug(s) and other recommendations: therapeutic modification, referral to specialized consultations (geriatrics ...).
58745|NCT03725020|Other|Fluoride varnish|The study will employ a double-blind, randomized placebo-controlled design with two parallel groups. The intervention will start at onset of the fixed appliances and will be finalized one year after debond. The primary outcome will be incidence of white spot lesions on the labial surfaces of the maxillary incisors, canines and premolars, as assessed from high-resolution digital photos. The secondary outcome is the prevalence of WSLs at debonding.
58746|NCT03725007|Drug|Upadacitinib|Upadacitinib is administered as an oral solution or tablet as described in protocol.
58747|NCT03724994|Drug|Gemcitabine|Adjuvant or palliative chemotherapy according to national guidelines
58748|NCT03724981|Drug|Dulaglutide Pen|Injected on a practice pad.
58749|NCT03724981|Drug|Semaglutide Pen|Injected on a practice pad.
58750|NCT03724968|Drug|Nivolumab|Nivolumab will be given by vein on day 1 of each cycle.
58751|NCT03724968|Drug|Relatlimab|Relatlimab will be given by vein on day 1 of each 28-day cycle
58752|NCT03724968|Drug|Ipilimumab|Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days).
58753|NCT03724955|Drug|Estradiol 2 mg|Participants in this arm will receive Estradiol 2 mg oral daily for 6 months
58754|NCT03724955|Other|Placebo|The placebo group will receive placebo oral daily for 6 months
58755|NCT03724942|Drug|Brexpiprazole|Brexpiprazole 1mg or 2mg will be orally once daily for 14 weeks
58756|NCT03724929|Procedure|Blood sample|Blood samples will be systematically collected at W0, W2, W6, W14 and W52 for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-vedolizumab antibody. A supplementary blood sample will be collected at W10 which is the point where a significant greater number of patients were in remission.
58757|NCT03724929|Device|Rectosigmoidoscopy|Rectosigmoidoscopy will be performed in each center at time points W0, W10 and W52.
58758|NCT03724916|Drug|TAK-079|TAK-079 Subcutaneous injection.
58759|NCT03724916|Drug|TAK-079 Placebo|TAK-079 placebo-matching subcutaneous injection.
58760|NCT03724903|Procedure|Ductal lavage|The patients received ductal lavage and breast massage every other day for two weeks. We used lidocaine (1%) for local anesthesia around the nipple. We used a lacrimal probe to identify 4-5 openings in the lactiferous ducts on the nipple and inserted the infusion cannula (21-23G). A total of 25ml of irrigation solution (5 ml of 2% lidocaine, 40 mg of triamcinolone acetonide, 20 ml of 0.9% saline and 1.0 g of ceftriaxone) was pumped into the ducts over 20-25 minutes. The patient returned to the clinic the next day for breast massage, and the cycle was repeated for two weeks.
58761|NCT03724903|Drug|Corticosteroid therapy|Meprednisone or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
58766|NCT03724877|Drug|Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)|(LABA-LAMA-ICS)
58767|NCT03724877|Drug|Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)|(LABA-LAMA)
58768|NCT03724864|Dietary Supplement|delivery of snacks|Subjects were randomly assigned to three groups (blue, green and yellow), receiving a single type of snack for 42 days. Block randomization ensured similar proportions of participants in each group. All subjects received snack packets (six cookies each) on a weekly basis. Children were instructed to use the snack twice a day, one in the morning and one in the afternoon during lesson breaks. Both participants and investigators were blinded to the treatment assignment.
58769|NCT03724851|Drug|TEW-7197|TEW-7197 will be administered orally for 5 days per week (5D/W) at the same time in the morning and evening (BID) approximately 12 hours apart.Pembrolizumab will be administered as a dose of 200 mg every 3weeks.
58770|NCT03724838|Drug|Esomeprazole with Sildenafil Citrate|Patients will take esomeprazole single dose of 40 mg orally once a day
58771|NCT03724838|Drug|Sildenafil Citrate|Patients will take Sildenafil Citrate 40mg every 8 hours
58772|NCT03724838|Drug|Placebo to Esomeprazole|Patients will take inert tablets similar in appearance, color, and consistency to esomeprazole single dose of 40 mg orally once a day
58773|NCT03724838|Drug|Placebo to Sildenafil Citrate|Patients will take inert tablets similar in appearance, color, and consistency to Sildenafil Citrate 40mg every 8 hours
58774|NCT03724825|Diagnostic Test|lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL))|blood samples will be collected after 10 hours fasting
58775|NCT03724825|Diagnostic Test|Total testosterone|blood samples will be collected after 10 hours fasting
58776|NCT03724825|Diagnostic Test|Adropin|blood samples will be collected after 10 hours fasting
58777|NCT03724825|Diagnostic Test|Adiponectin|blood samples will be collected after 10 hours fasting
60776|NCT03709485|Other|rectal swab for microbial culture.|Rectal swab and culture.
58778|NCT03724812|Device|Portico Valve and FlexNav™ Delivery System|Subjects will undergo transcatheter aortic valve replacement (TAVR) with the Portico valve and second-generation FlexNav Delivery system via a transfemoral access approach
58779|NCT03724799|Device|Intravascular laser irradiation of blood for the patients with cerebral infarction|Intravenous low level therapy has been a variety of applications in many different areas of medicine with a growing interest. It possesses laser specific biomodulation, analgesic, spasmolytic and even sedative effects among many other.
58780|NCT03724786|Diagnostic Test|Six-hour urine protein collection|This intervention includes the analysis of a 6-hour urine collection for protein, to serve for a calculated 24-hour result, according to which pregnancy will be managed.
58781|NCT03724773|Device|Long-Arm Cast|A long-arm cast is a circumferential wrapping of the arm from the fingers to above the elbow with casting material.
58782|NCT03724773|Device|Sugar-Tong Splint|A sugar-tong splint is the application of hard splinting material on the front and back of the arm.
58783|NCT03724760|Other|personalized repeated feedback approach|Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
58784|NCT03724747|Drug|BAY 2315497 Injection|BAY 2315497 Injection comprises 3 components: the PSMA-specific monoclonal antibody (mAb), the mAb-chelator conjugate, and the thorium-227 labeled mAb-chelator conjugate. BAY 2315497 Injection will be administered on Day 1 of each treatment cycle.
58785|NCT03724734|Device|Adaptive DBS|We will use our custom-built externalized research system (ERS) to allow recordings and stimulation. The device is small and lightweight and communicates wirelessly with a personal computer. The electrical connections to the DBS leads will be through temporary extensions with appropriate mechanical slack. To allow for stimulation return, a conductive clip to the ERS case will be connected to a conducting (ECG) pad placed over chest. Periodic impedance checks will ensure this connection is robust through the course of the experiment. The patient can be ambulant whilst wearing the device.
58786|NCT03724734|Device|Conventional DBS|We will use our custom-built externalized research system (ERS) to deliver continuous conventional stimulation.
58787|NCT03724721|Procedure|vacuum bottle|using vacuum bottle plus catheter for drainage of pneumothorax
58788|NCT03724708|Device|IUD|IUD insertion
58789|NCT03724695|Other|Clinician nudge or opt out approach for AHCAH liaison visit|"This study is a nudge or opt-out approach of an AHCAH liaison visit to eligible seriously ill HF patients prior to hospital discharge to discuss the AHCAH program and to subsequently facilitate enrolling them in the AHCAH program if they are amenable, compared to the opt-in approach (usual care)."
58790|NCT03724682|Device|Carry Life UF device|Treatment with the Carry Life UF device compared to standard PD therapy
58791|NCT03724669|Behavioral|psychiatric related knowledge intervention|participants receiving psychiatric related knowledge push through the electronic interventions App, once a week, last for six months
58792|NCT03724669|Behavioral|benzodiazepines related knowledge intervention|participants receiving benzodiazepines related knowledge push through the electronic interventions App, once a week, last for six months
58793|NCT03724656|Device|acupuncture treatment|"TAES treatment 30 minutes before induction of anesthesia. Bilateral Neiguan（PC6）, bilateral Zusanli（ST36）and bilateral Hegu （LI4）point were selected by electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China).After Deqi, electroacupuncture stimulation apparatus is connected and maintained until the end of operation."
58794|NCT03724656|Device|sham acupuncture treatment|"Participants in the sham acupuncture group received shallow needling (0.30mm×25mm) at bilateral sham points(nonacupoints located 5cm beside acupoints, about 20mm). The control group was treated with non-acupoint shallow acupuncture method and the needling depth was less than 2 mm. At the same time, the manual stimulation and Deqi was avoided."
58795|NCT03724643|Other|Protocolized wean|Respiratory therapist determined extubation readiness based on: patent and protected airway; adequate secretion clearance; suction requirement ≤ every 2 hours; FiO2 < 50% and PEEP = 5; and hemodynamic stability without circulatory support. The SBT included CPAP = 5 mmHg at FiO2 ≤ 0.4. Patients were assessed after 3-minutes for appropriateness to continue (SaO2 ≥ 92%; no arrhythmia; RSBI < 105 breaths/min/L). Respiratory distress signs included RR > 30 breaths/min, SaO2< 90%, HR > 140 beats/min, or a sustained change in HR of >20%, systolic BP >200 mmHg or <80 mmHg, or agitation, anxiety, or diaphoresis without other cause. The SBT lasted 120 min in accordance with prior studies. Upon SBT completion, the RSBI was re-measured and an ABG was obtained.
58796|NCT03724617|Drug|umbilical cord mesenchymal stem cells combined with collagen scaffold|3-7 days after the end of menstruation, we underwent hysteroscopic exploration and separation if there was intrauterine adhesions. Intraoperative endometrial biopsy, recording biopsy location, endometrial specimens sent to HE examination and immunohistochemistry (vwf detection of microvessel density). The umbilical cord mesenchymal stem cell combined with collagen scaffold was spread on the balloon scaffold and placed in the uterine cavity. 5 ml of saline was filled into the balloon, and B-ultrasound confirmed that the scaffold was attached to the uterine wall. The patient was hospitalized for 2 hours and the patient's vital signs were recorded.
58797|NCT03724604|Diagnostic Test|Neuron-Specific Enolase to Albumin Ratio|Previous studies have shown that inflammation and nutrition-related factors such as CRP/Alb (C-reactive protein-albumin ratio), PLR (platelet-to-lymphocyte ratio), NLR (neutrophil-to-lymphocyte ratio) can help to assess the prognosis of malignant tumors. This study is the first time to combine NSCLC tumor marker NSE and patient nutrition-related indicators Alb to predict the prognosis of patients, trying to find high sensitivity and specificity for NSCLC prognostic indicators to guide clinical work.
58798|NCT03724591|Procedure|a high ligation of IMA|total mesorectal excision (TME) for rectal cancer by a high ligation of IMA without preservation of left colic artery
58799|NCT03724591|Procedure|a low ligation of IMA|total mesorectal excision (TME) for rectal cancer by a low ligation of IMA with preservation of left colic artery
58800|NCT03724578|Drug|Grape Seed Extract mouth wash|participants will use grape seeds extract mouth wash in addition to standard preventive measures
58801|NCT03724578|Drug|standard preventive measures|twice daily brushing with fluoride tooth pate and daily flossing
58802|NCT03724578|Drug|antimicrobial and fluoride mouth wash|using chlorhexidine and fluoride containing mouth wash
58926|NCT03723642|Diagnostic Test|Initial c-reactive protein serum level|"C-reactive protein levels will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
58803|NCT03724565|Procedure|Method of endoscopic procedure|Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
58804|NCT03724552|Device|Transcranial LED Therapy|Transcranial Laser Emitting Diode (LED) Therapy (TLT) is a noninvasive intervention in which near-infrared light (830nm) is applied to forebrain.
58805|NCT03724539|Device|STRIPA intervention|"STRIPA is a Dutch software-based tool for the support of the pharmaceutical analysis by 1) taking into account the predictable adverse medication effects, 2) advising safe and appropriate therapy using established STOPP/START criteria, 3) interaction monitoring, and 4) appropriate dosing in accordance with renal function. It represents a highly efficient and user-friendly software engine, which is capable of individually screening the clinical status and pharmacological therapy of older patients with multimorbidity, which can define optimal drug therapy, and which can highlight the adverse drug reaction risk. A summary of these outputs will be used as STRIPA recommendations, which will, if applicable, be implemented by GPs and patients.~Prior to the STRIPA medication review, the necessary patient information will be loaded from the FIRE database that contains data from more than 300 Swiss GP practices."
58806|NCT03724539|Other|Sham intervention|Patients being assigned to the control arm will be treated in accordance with standard care. They will receive a sham intervention, which consists of a usual medication review by their GP and a shared decision making between patient and GP.
58807|NCT03724526|Behavioral|Text messaging|"Intervention-Text messaging: Participants will receive regular text messages for 12 months. Each participant will receive 6 text messages per week. They will receive one general education about diabetes and CVD messages, one glucose control message, one blood pressure control message, one healthy eating message, one medication adherence message and one physical activity message per week.~Control: The control group will receive the usual care."
58808|NCT03724487|Behavioral|Coachman|Coachman is comprised of: TBI and nurse counseling. TBI is comprised of: 1) web-based education modules on hypertension knowledge and skills as well as behavioral lifestyle guidance, (2) Medisafe, a smartphone medication management app to support medication adherence to antihypertensives, and (3) self-monitoring blood pressure. Participants will be exposed to nurse counseling, by registered nurses from the community, affiliated with a local nurse organization that will serve as community health workers (CHWs). The CHWs will provide informal counseling, social support, as well as follow-up phone sessions on medication adherence and monitoring blood pressure.
58809|NCT03724487|Behavioral|Enhanced Usual Care (EUC)|Standard printed education materials on hypertension management, including content on lifestyle modification and medication-taking will be provided; plus access to one web-based education (video) with information on how to self-monitoring blood pressure.
58810|NCT03724474|Behavioral|Be SMART|The behavioral intervention will examine 12-week changes in sleep metrics and physical activity, compared to baseline measures, between subjects randomly assigned to a treatment (Be SMART) and an active control (Fitbit Only) condition (n=30, respectively).
58811|NCT03724461|Behavioral|High Intensity resistance training (12 weeks)|High intensity resistance training (80% of 1 repetition maximum), 2 d/wk (Longitudinal)
58812|NCT03724461|Behavioral|Light-moderate intensity resistance training (12 weeks)|Light-moderate intensity resistance training (40% of 1 repetition maximum), 2 d/wk (Longitudinal)
58813|NCT03724461|Behavioral|Control (12 weeks)|No resistance training during the intervention period.
58814|NCT03724461|Behavioral|One High Intensity resistance training session|High intensity resistance training, 1 training session
58815|NCT03724461|Behavioral|One Light-moderate intensity resistance training session|Light-moderate intensity resistance training, 1 training session
58816|NCT03724448|Drug|aleozen|treatment with herbal medicine
58817|NCT03724448|Drug|Placebo Oral Tablet|No aleozen treatment
58818|NCT03724422|Radiation|Radiation|A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
58819|NCT03724409|Drug|[90]Y-DOTATOC|Intra-arterial infusion to the liver of [90]Y-DOTATOC. The administered dose is determined by cohort and is dependent upon the results of the previous cohort.
58820|NCT03724396|Behavioral|Behavioral Weight Loss - BWL|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
58821|NCT03724396|Behavioral|Novel Executive Function Training - NEXT|Modifies programs like CogSMART and cognitive remediation training to help participants improve executive functioning to adhere to recommendations from BWL.
58822|NCT03724383|Behavioral|Risk Factor Management Consult|Participants may be referred to an Internist to control risk factor management - this may require monthly visits until risk factor targets have been met.
58823|NCT03724383|Behavioral|Diet Classes|Group nutrition sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention) delivered by a registered dietitian.
58824|NCT03724383|Behavioral|Stress Management Classes|Group sessions delivered two times per week (1 hr each), over a 3 month period (months 0 to 3 of intervention). Techniques taught will include awareness, coping, and relaxation strategies.
58825|NCT03724383|Other|Exercise Classes|Group sessions delivered two times per week (1 hr each), over 3 month period (months 3-6). Classes will include high intensity interval training, resistance training.
58826|NCT03724383|Other|Home based exercise program|The interval and resistance training program will mirror the supervised exercise.
58827|NCT03724370|Behavioral|Telehealth Monitoring System|TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.
58828|NCT03724370|Other|VHA-SRM|Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
59076|NCT03722498|Drug|HAIC of FOLFOX|administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
58829|NCT03724357|Drug|Vaxchora|One dose. Approximately 100 mL of cold or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
58830|NCT03724344|Other|Cross section resaerch|Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
58831|NCT03724331|Behavioral|Light Physical Activity 1|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately within the first week post-discharge from the hospital."
58832|NCT03724331|Behavioral|Light Physical Activity 2|"Light (mild) physical activity program that corresponds with normal every day activities of daily living (< 3.0 metabolic equivalents, METs), with a time commitment starting at 5 minutes a day 5 days a week gradually increasing to 30 minutes a day 5 days a week as you are able by week 6 as guided by your Registered Nurse researcher.~The program begins approximately within one week after discharge from the hospital with the physical activity program starting approximately 7 weeks post-discharge from the hospital."
58833|NCT03724331|Behavioral|Support Education Activity|"Participate in a supportive cancer-related education activity including a direct 10 - 15 minute phone conversation with a Registered Nurse researcher each week for 6-weeks after returning home from the hospital. Wear a pedometer each day of the study.~Recording pedometer steps in the daily diary each day."
58834|NCT03724318|Procedure|closure of the left atrium appendage|closure of the left atrium appendage in addition to the planned Heart operation
58835|NCT03724305|Behavioral|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
58836|NCT03724305|Behavioral|Sleep Hygiene Education|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine.
58837|NCT03724305|Behavioral|mindfulness-augmented telemedicine Cognitive Behavioral Therapy for Insomnia|Mindfulness-augmented tCBT-I will use mindfulness-based stress reduction techniques to specifically target cognitive-emotional arousal associated with non-refractory insomnia while increasing the dose of and personalizing CBT-I to target insomnia.
58838|NCT03724292|Drug|Placebo|Dose-matched placebo administered as oral capsule(s) once daily
58839|NCT03724292|Drug|VTP-43742|VTP-43742 administered as oral capsule(s) once daily
58840|NCT03724279|Device|ByCross Atherectomy and Thrombectomy|"After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening."
58841|NCT03724266|Drug|Chitosan|chitosan will be used as intracanal medication
58842|NCT03724266|Drug|Calcium Hydroxide|intracanal medication
58843|NCT03724253|Drug|[68Ga]-NeoBOMB1|[68Ga]-radiolabeled bombesin peptide targeting Gastrin Releasing Peptide Receptors
58844|NCT03724240|Biological|Placebo solution|4 x 2 injection over 21 days the dosage is100 µg/ml
58845|NCT03724240|Biological|gpASIT+TM|4 x 2 injection over 21 days the dosage is100 µg/ml
58846|NCT03724227|Drug|ACE-011|ACE-011 will be administered subcutaneous injection
58847|NCT03724214|Combination Product|Pre-hospital interventional care bundle|"The interventional care bundle will include pre-hospital and in-hospital components and core and adaptable components. All seven centres will implement the core pre-hospital and in-hospital components. Implementation of the adaptable components will be decided by the local team to optimise the interventional care bundle to the local environment.~Pre-hospital core components: 1) covering the bowel in clear plastic, 2) administering intravenous fluids, 3) keeping the neonate warm, 4) transferring to a study centre as soon as possible. This will be implemented as a pre-hospital gastroschisis care protocol to district and secondary level hospitals who refer patients with gastroschisis to the study centres.~Pre-hospital adaptable components: 1) the strategy for disseminating the pre-hospital gastroschisis care protocol."
58848|NCT03724214|Combination Product|In-hospital interventional care bundle|"In-hospital core components: 1) use of a standardised care protocol, 2) neonatal resuscitation and ward care including intravenous access, intravenous fluids, maintenance of normothermia, appropriate antibiotics, regular monitoring and infection control, 3) gastroschisis reduction and sutureless closure using a preformed silo and avoidance of neonatal anaesthesia and surgery, 4) early establishment of breastfeeding and an enhanced enteral feeding programme.~In-hospital adaptable components: 1) administration of parenteral nutrition for neonates who have survived for 1-week in hospital, 2) maternal involvement in monitoring and basic management, 3) management of neonates with gastroschisis on the neonatal intensive care unit if available."
58849|NCT03724188|Procedure|surgical parathyroidectomy|total parathyroidectomy, subtotal parathyroidectomy, total parathyroidectomy with autotransplantation
58850|NCT03724175|Drug|ursodiol (ursodeoxycholic acid, UDCA)|ursodiol (ursodeoxycholic acid, UDCA) 300 mg two times daily for 10 weeks for UC pouchitis patients
58851|NCT03724149|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
59077|NCT03722498|Drug|Sorafenib|administration of Sorafenib
58852|NCT03724149|Drug|Epclusa|Epclusa (sofosbuvir 400mg and velpatasvir 100mg once daily) is taken by mouth for 12 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
58853|NCT03724136|Procedure|Intravenous Bone Marrow Stem Cell (BMSC) Fraction|14 cc of BMSC fraction separated from bone marrow aspirate and filtered with 150 micron filter and administered intravenously.
58854|NCT03724136|Procedure|Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction|Approximately 1 cc of BMSC fraction separated from bone marrow aspirate and administered to the nasal mucosa topically.
58855|NCT03724136|Procedure|Near Infrared Light|Near Infrared Light will be administered using an FDA cleared medical device on the preoperative day and the first postoperative day as tolerated to the general area of the frontal bone.
58856|NCT03724110|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST-TIA, inpatient telestroke rounding will be used to oversee the urgent diagnostic TIA evaluation, secondary stroke prevention, and stroke education in patients admitted with TIA.
58857|NCT03724097|Other|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
58858|NCT03724097|Other|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
58859|NCT03724097|Drug|target drug with the score above 0,1|target drug with the score above 0,1
58860|NCT03724097|Drug|target drug with the score equal or below 0,1|target drug with the score equal or below 0,1
58861|NCT03724097|Drug|non-target drug|non-target drug
58862|NCT03724097|Drug|palliative care|palliative care
58863|NCT03724084|Drug|Cytarabine|Given IV
58864|NCT03724084|Drug|Daunorubicin|Given IV
58865|NCT03724084|Drug|Daunorubicin Hydrochloride|Given IV
58866|NCT03724084|Drug|Pinometostat|Given IV
58867|NCT03724071|Biological|TG6002|"Phase I: Dose escalation from 1 x 10E6 PFU to 1 x 10E9 PFU Phase II: Established recommended Phase II dose (RP2D)~Administration intravenously on Days 1, 8 and 15. An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
58868|NCT03724071|Drug|Flucytosine (5-FC, Ancotil)|"Administered orally at a dose of 200 mg/kg/day from Day 5 to 7, Day 12 to 14 and Day 19 to 28.~An extension of the 28-day cycle of TG6002/5-FC combination can be repeated in case of evidence of patient benefit, defined as an objective radiological response or disease stabilization, and/or a clinically significant relief in patient's symptoms. Additional cycle(s) will start from 2 to 4 weeks following the last 5-FC intake."
58869|NCT03724058|Device|Trident® II Clusterhole HA Acetabular Shell|Hip arthroplasty
58870|NCT03724058|Device|Trident® Hemispherical Acetabular Shell|Hip arthroplasty
58871|NCT03724045|Dietary Supplement|Back Side of the Moon|The procedures are: several measurements will be performed, including some which are not part of the Standard Operating Procedure, hence causing it to be considered interventional.
58872|NCT03724032|Device|HD-tDCS*|Non-invasive brain stimulation (active protocol)
58873|NCT03724032|Device|Sham HD-tDCS*|Non-invasive brain stimulation (sham protocol)
58874|NCT03724019|Drug|Ketamine|Administration of 0.5mg / kg ideal body weight of ketamine at induction of anesthesia in laparoscopic surgery.
58875|NCT03724006|Behavioral|Psychoeducational intervention|"The intervention, prepared by a multidisciplinary team, will consist of two 90 minutes collective sessions (max. 8 families). Sessions will consist of lectures, group discussion and relaxation. The program includes content on the effects of a diagnosis of a congenital anomaly on a child in the parents and in the family, stages of mourning, adaptation process, coping strategies, legislative framework and social protection. This is a non-specific intervention for CHD, where the main focus is the diagnosis of a congenital anomaly.~In second session, written support material will be distributed. Participants will be asked to practice relaxation in the next 4 weeks."
58876|NCT03723993|Device|Inflated cuff|After patient being draped, applying cuff inflation will be done to the upper arm not having the arterial line inserted of about 200 mmHg or 15 mmHg above patient's systolic pressure 3 cycles 5 minutes each followed by 5 minutes of pressure relieve
58877|NCT03723993|Device|Non inflated cuff|non inflated cuff around the arm for the control group
58878|NCT03723980|Drug|Propolis|it is a natural product obtained from beehive. it has been evaluated for biocompatibility and toxicity; and it is found that it is extremely biocompatible material. In our study, propolis powder will be mixed with saline in a ratio of 1 : 1.5 (propolis powder(wt) / saline(vol)) to form paste; and inserted into the root canals. it will be inserted once and will remain in root canals for 4 days.
58879|NCT03723980|Drug|Calcium Hydroxide|it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
58880|NCT03723967|Drug|Durvalumab with Carboplatin/Paclitaxel|Durvalumab associated with Carboplatin / Paclitaxel as first line treatment in patients with recurrent/metastatic SCCHN not eligible to standard chemotherapy
58881|NCT03723954|Device|ECG Holter SpiderFlash-t|"Record at visit V0 (day without match) and the competition days (Visit V1, V2 et V3) during the matches the heart rate of the golf fans.~SpiderFlash-t™ from MicroPort is a long-lasting event recorder set in walking position by the investigator the day of the record and it is activated by detecting rhythm anomalies. This recorder is a Class IIA medical device (according to European Economic Community Directive 93/42). It benefits from European Economic marking."
58882|NCT03723954|Device|Actigraph GT3Xp|"Record the study participant's physical activity while we record his heart rate.~The GT3Xp based activity monitors provide objective measurements of human activity and are used in many research and clinical applications. It includes a micro-electro-mechanical system (MEMS) based accelerometer and an ambient light sensor. It benefits from CE marking and FDA agreement (Class II medical device)."
58950|NCT03723460|Other|Passive Dietary Monitoring|Passive dietary monitoring devices will be used to monitor dietary intake in household in communities in Ghana and Kenya
58883|NCT03723941|Drug|Cisplatin plus Etoposide|"Etoposide 100 mg/m2 will be administered IV on days 1, 2, 3 diluted in 500 mL of isotonic NaCl or 5% dextrose.~Cisplatin, 80 mg/m2 will be administered IV on day 1, diluted in 500 mL of isotonic NaCl."
58884|NCT03723941|Other|Observation or Mitotane|Observation or mitotane alone according to the investigator's preference
58885|NCT03723928|Other|Usual care disease monitoring|Imaging and serum tumor markers are at the discretion of the treating physician (however imaging must be performed at least every 12 weeks).
58886|NCT03723928|Other|Serum Tumor Marker directed disease monitoring|Serum tumor markers every 6 weeks without imaging
58887|NCT03723928|Other|Quality-of-Life Assessment|Ancillary studies
58888|NCT03723928|Other|Anxiety Questionnaire Administration|Ancillary studies
58889|NCT03723915|Biological|Pembrolizumab|Given IV
58890|NCT03723915|Biological|Wild-type Reovirus|Given pelareorep IV
58891|NCT03723902|Other|Heavy-load strength training|Three weekly sessions of heavy-load strength training for 10 weeks
58892|NCT03723902|Dietary Supplement|Protein supplementation|Daily supplementation of 2 x 17 grams of milk protein
58893|NCT03723876|Behavioral|Body awareness therapy|"The physiotherapist uses body awareness techniques, i.e. guiding the participant in movement qualities such as stability, breathing, flow and grounding. Conscious awareness focused on bodily experiences is a key component to be able to reflect on what your body signals.~As a baseline a standardized observation of the movement quality of the individual is performed. The physiotherapist needs special education in the body awareness technique used, to rightly perform and analyse the observation and administer the intervention.~The aim of the body awareness therapy is to raise physical and mental awareness by strengthening the interplay between sensory impressions and motor ability and to gain knowledge of own movement patterns that are not functional and to form alternatives to these."
58894|NCT03723863|Behavioral|Occupational Therapy|Receive in-person occupational therapist-led work consultation
58895|NCT03723850|Device|Active tDCS|The brain is stimulated for 20 minutes with mild electrical current (maximum 2 mA) with two 7 cm x 5 cm electrodes placed on the scalp, using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
58896|NCT03723850|Device|Sham tDCS|The brain is not stimulated for 20 minutes with mild electrical current, but instead a sham procedure is administered using a standard 1x1 tDCS Clinical Trials device (Soterix Medica, NY), specialized for double-blinding.
58897|NCT03723837|Biological|Inactivated Polio Vaccine (IPV)|Children receive one or two doses of IPV based on study arm they fall in
58898|NCT03723824|Drug|grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®|grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
58899|NCT03723811|Drug|SJP002 BID|1 drop b.i.d for 12 weeks
58900|NCT03723811|Drug|SJP002 QID|1 drop q.i.d for 12 weeks
58901|NCT03723811|Drug|SJP002 Placebo 1|1 drop q.i.d for 12 weeks
58902|NCT03723811|Drug|SJP002 Placebo 2|1 drop q.i.d for 12 weeks
58903|NCT03723798|Drug|SA001 Low dose|3 tablets b.i.d for 12 weeks
58904|NCT03723798|Drug|SA001 Mid dose|3 tablets b.i.d for 12 weeks
58905|NCT03723798|Drug|SA001 High dose|3 tablets b.i.d for 12 weeks
58906|NCT03723798|Drug|SA001 Placebo|3 tablets b.i.d for 12 weeks
58907|NCT03723785|Drug|Insulin 287|Participants will receive single dose of Insulin 287 subcutaneously (under the skin) on Day 1
58908|NCT03723772|Drug|Insulin 287|Participants will receive subcutaneous injections of insulin 287 once weekly for 8 weeks
58909|NCT03723772|Drug|IGlar U100|Participants will receive subcutaneous injections of insulin glargine once weekly for 2 weeks.
58910|NCT03723759|Drug|Faster Aspart 200 U/mL|A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection.
58911|NCT03723759|Drug|Faster aspart 100 U/mL|A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection.
58912|NCT03723746|Biological|JNJ-67670187|Participants in Cohorts 1, 3 and 4 will receive Dose 1 and participants in Cohorts 2, 5, 6, 7, 8 and 9 will receive Dose 2.
58913|NCT03723746|Biological|Placebo|Participants will receive matching placebo in all cohorts.
58914|NCT03723733|Behavioral|screen high and low triat subjects|use a range of questionniares to screen screen high and low triat subjects (eg. Autism, Anxiety, Depression traits and social network size)
58915|NCT03723720|Device|Colonoscopy|Endoscopic examination of large bowel
58916|NCT03723707|Behavioral|EQUIPED-ADRD Intervention|(10 clinic sites and ~500 patients) which includes practice guidelines for clinicians, provider education, electronic health record support for quality DM-ADRD care, information about community/clinical resources, ongoing targeted provider feedback, and a panel manager (PM)
58917|NCT03723707|Behavioral|Control (CON)|Will use current guidelines for primary care treatment with Diabetes and Dementia
58918|NCT03723694|Dietary Supplement|650 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.
58919|NCT03723694|Dietary Supplement|0 mg of Cocoapro flavanols|12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.
58920|NCT03723681|Drug|Quizartinib|Quizartinib is provided as 20 mg tablets for oral administration
58921|NCT03723655|Drug|mavacamten|mavacamten capsules
58922|NCT03723642|Diagnostic Test|Initial serum malondialdehyde level|"Blood sample (0.4ml) will be obtained within 5 minutes before induction of general anaesthesia.~Samples will be obtained in both groups (LAE and OAE)"
58923|NCT03723642|Diagnostic Test|Final serum malondialdehyde level|Blood sample (0.4ml) will be obtained within 5 minutes after wound closure. Samples will be obtained in both groups (LAE and OAE)
58924|NCT03723642|Diagnostic Test|Initial differential white blood cell count|"Differential blood counts (microscopic) will be obtained during pre-operative routine work-up.~Samples will be obtained in both groups (LAE and OAE)."
58925|NCT03723642|Diagnostic Test|Final differential white blood cell count|"Differential blood counts (microscopic) will be obtained 24h after the first sample (Initial differential blood count).~Samples will be obtained in both groups (LAE and OAE)."
59676|NCT03717701|Drug|Placebo|Patients will take inert tablets similar in appearance, color, and consistency
58927|NCT03723642|Diagnostic Test|Final c-reactive protein serum level|"C-reactive protein levels will be obtained 24h after the first sample (initial c-reactive protein level).~Samples will be obtained in both groups (LAE and OAE)."
58928|NCT03723642|Diagnostic Test|Initial VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 10 minutes before induction of general anesthesia
58929|NCT03723642|Diagnostic Test|VOC 5min|Volatile organic compound sampling (2 samples within5 minutes) within 5 minutes after endotracheal intubation before skin incision.
58930|NCT03723642|Diagnostic Test|VOC 15min|Volatile organic compound sampling (2 samples within 5 minutes) 15 minutes after skin incision.
58931|NCT03723642|Diagnostic Test|VOC 30min|Volatile organic compound sampling (2 samples within 5 minutes) 30 minutes after skin incision.
58932|NCT03723642|Diagnostic Test|VOC 45min|Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
58933|NCT03723642|Diagnostic Test|Final VOC|Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
58934|NCT03723629|Other|No intercention|No intercention
58935|NCT03723616|Behavioral|Control|Participants will view 24 ads with and without health warnings. Additionally, 16 control non-tobacco ads matched for graphical content, presence of text, people, and other factors will be randomly distributed among these ads.
58936|NCT03723616|Behavioral|Text Only|Participants will view at random 24 ads twice, each ad will have a different health warning chosen at random with the caveat that each health warning will be seen 3 times. The 16 control ads will have text disclaimers to control for physical features of the ads.
58937|NCT03723616|Behavioral|Text + Graphic|This arm is identical to the text only intervention except a graphic will be added to the health warning. Thus, each ad will be seen twice; the text + graphic warnings will be seen three times. The 16 control ads will have text disclaimers and logos or other images to control for physical features of ads.
58938|NCT03723603|Device|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
58939|NCT03723590|Device|Esterified Hyaluronic Acid Matrix|A non-woven pad composed of esterified hyaluronic acid, covered with a semipermeable silicone layer to protect the wound and control water vapor loss
58940|NCT03723577|Device|Fibrillar collagen powder dressing|A powder-like fibrillar collagen microsponge composed of Type I porcine dermis collagen. The dressing is a currently marketed, cleared device in the United States, indicated for the management of full and partial thickness wounds: pressure ulcers, diabetic ulcers, caused by mixed vascular origin, venous ulcers, and several other wound types.
58941|NCT03723564|Drug|Lactated Ringers Solution for Injection|Using ultrasound guidance, a 22 gauge needle will be introduced into amniotic cavity. Warmed Lactated Ringers solution will be injected into the amniotic cavity until an AFI of 8.0 cm is achieved
58944|NCT03723538|Drug|Dexmedetomidine|patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
58945|NCT03723525|Combination Product|Package of HIV care|"A. Screening and management (Preventive / Pre-emptive therapies dosages) of different opportunistic infections (OI). Detail information mentioned in the manual (refer to uploaded protocol).~B. Rapid ART Initiation~PLHIV without suspicion or active OI: Initiate ART within seven days or same day after HIV serology disclosure~PLHIV with suspicion or active OI: Defer initiation if clinical symptoms suggest tuberculosis or cryptococcal meningitis. Detail information mentioned in the manual (refer to uploaded protocol).~C. Enhanced Adherence/Retention Support: mHealth: Receive text messages in mobile regarding appointment reminder (pill pick up, CD4 test, viral load test, early infant diagnosis (EID) test etc.) and general awareness messages (positive prevention, the importance of regular health check-up etc.). PLHIV with advanced HIV disease will also receive weekly/biweekly home-based adherence/ retention support linked to community care centre and community home-based care."
58946|NCT03723525|Combination Product|Standard HIV care|Standard of HIV care includes screening and management of OI (OI- tuberculosis (TB), bacterial pneumonia, herpes, and candidiasis), baseline assessment (CD4 and other blood tests- complete blood count, hemoglobin, platelets, liver function test, renal function test, urine for albumin, chest x-ray), at 6 months CD4 test, viral load (twice a year) and then on a yearly basis, additional lab test at 3 months, 6 months, antiretroviral (ARV) toxicity monitoring like hemoglobin (Zidovudine), Serum Glutamic-Pyruvic Transaminase (Nevirapine/Efavirenz), Creatinine (Tenofovir), prophylaxis (Co-trimoxazole preventive therapy CD4<350 and WHO stage III and IV and Isoniazid preventive therapy if eligible) and ART / follow up (generally monthly/ bimonthly).
58947|NCT03723512|Device|Non contrast-enhanced magnetic resonance imaging|Non contrast-enhanced magnetic resonance imaging
58948|NCT03723499|Other|Medical data collection|Medical data collection by medical record will be collected: demographics data, medical history, clinical symptoms, smoking, type of endoscopic method, complete treatment or not, type of surgeries if yes, anatomopathology of the injury and recurrence if yes
58949|NCT03723473|Device|Magnetic Resonance Imaging (MRI)|MRI (muscular volume and composition) and gated-P-31 magnetic resonance spectroscopy (MRS) with low-intensity ergometric exercise.
59143|NCT03721978|Biological|VGX-3100|1 milliLiter (mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
58952|NCT03723447|Drug|Bupivacaine/epinephrine/dexamethasone|Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
58953|NCT03723434|Device|Single-pulse transcranial magnetic stimulation (spTMS)|Single-pulse TMS (spTMS) will be delivered with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 80 spTMS will be repeated at 0.2 Hz. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
58954|NCT03723434|Device|Paired associative stimulation (PAS)|Paired associative stimulation (PAS) will be applied with two TMS stimulators (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and two TMS coils. The pulses from each stimulator/coil will be repeated at 0.2 Hz, duration of run 15 minutes (180 pulses for each stimulator/coil). In different sessions, we will deliver PAS with different asynchrony values to examine their effects on effective connectivity. Coils will be navigated using an MRI-based TMS navigation system (Localite, St Augustin, Germany).
58955|NCT03723434|Device|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) will be applied at 1 and 20 Hz with a TMS stimulator (MagPro X100 w/ MagOption, MagVenture, Farum, Denmark) and a figure-of-eight TMS coil. 300 rTMS pulses will be delivered during 1 and 20 Hz stimulation. An MRI-based TMS navigation system will be used to navigate the TMS coil (Localite, St Augustin, Germany).
58956|NCT03723421|Other|Rapid Injection Group Without Aspiration|After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
58957|NCT03723421|Other|Control|After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
58958|NCT03723408|Device|ClearLine IV (formerly, AirPurge)|Patient safety device that automatically and continuously detects and actively removes air from IV lines - protecting patients from dangerous air burden, air embolism, air infusions.
58959|NCT03723395|Drug|tucatinib|300mg dose, orally administered
58960|NCT03723395|Drug|itraconazole|200mg dose
58961|NCT03723395|Drug|rifampin|600mg dose
58962|NCT03723395|Drug|gemfibrozil|600mg tablets
58963|NCT03723395|Drug|repaglinide|1mg dose
58964|NCT03723395|Drug|tolbutamide|500mg dose
58965|NCT03723395|Drug|midazolam|2mg dose
58966|NCT03723395|Drug|digoxin|0.5 mg dose
58967|NCT03723382|Other|SECRET structured 5 bundles of standard healthcare services|THE 5 BUNDLES OF Stroke SERVICE They the mix of the services for stroke patient which are available at the SS EVT bundle: is the availability of the Endovascular services Telemedicine core bundle : is the ability to guide or guided via tele-medicine for decision making for stoke patients tPA core bundle : the availability of all infrastructure to administer tPA in the first 3 hours of onset (NNT=8) DISMAST bundle : which refer to the availability of Dysphagia detection and management ,Aspirin in hyper acute phase , The Mobilization plans and programs for the patients, anticoagulant and statin prescription for selected patients for secondary prophylaxis programs Process of care bundle : like registering patients and morphology of the disease, screening programs for risk factors , following primary prevention plans all bundles should be judged by the 8M approach
58968|NCT03723369|Device|accupuncture|accupuncture
58969|NCT03723356|Diagnostic Test|Siemens Biograph mMR (molecular MR)|5mCi of the radiotracer FDG administered intravenously as a bolus over 30s. After injection, emission data will be collected for 60 min,
58970|NCT03723356|Diagnostic Test|fMRI|High-resolution T1-weighted structural image will be acquired using an MP2RAGE sequence. Subject will beasked to look at the cross hair on a screen andnot fixate on any one thought.
58971|NCT03723356|Diagnostic Test|Diffusion Spectrum Imaging (DSI)|DSI allows for more accurate characterization of diffusion,overcomes traditional dMRI artifacts, and is capable of more precise and detailedcharacterization of white matter fibers
58972|NCT03723343|Drug|GP+IMRT|Gemcitabine 1000 mg/m2 intravenously, d1&d8 +Cisplatin 80 mg/m2 intravenously, d1 21~28 days/cycle, 4 patients with oligometastasis, 6 cycles with multiple metastases
58973|NCT03723343|Drug|TPF+IMRT|Docetaxel: 75mg/m2 intravenous drip, d1+Cisplatin75mg/m2 intravenous drip, d1~d5+5-fluorouracil 750mg/m2/d intravenous drip, d1~d521~28 days/cycle, patients with oligometastasis take 4 cycles, moreTransfer patients for 6 cycles
58974|NCT03723330|Dietary Supplement|plant sterols|Consumption a healthy eating pattern diet with a plant sterols-enriched food product
58975|NCT03723330|Other|healthy diet|Compliance with a healthy diet in accordance to the recommendation by the Singapore Health Promotion Board.
58976|NCT03723317|Procedure|Liver transplantation|First deceased-donor liver transplantation
58977|NCT03723304|Procedure|Bridging followed by transplant|Trans-arterial chemoembolization or percutaneous alcohol injection or radio-frequency ablation during the waiting time followed by liver transplant
58978|NCT03723304|Procedure|Direct liver transplant|Direct liver transplant (no neoadjuvant approaches during the waiting time period)
58979|NCT03723291|Combination Product|Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months|• Arm B: A combination of pentoxifylline 800 mg/d in two 400-mg tablets and 1,000 IU/d of tocopherol acetate in two 500-IU aliquots in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months
58980|NCT03723291|Procedure|• Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months|Prophylactic swallowing exercises consist of strap muscle exercises, airway protection exercises and base of tongue exercises
58981|NCT03723265|Device|Cardiac Resynchronization Therapy|
58982|NCT03723252|Drug|Dapagliflozin|Participants will receive dapagliflozin 10mg po qd
58984|NCT03723239|Device|TricValve® System|The TricValve® Delivery System is inserted from the femoral vein to access the inferior vena cava (IVC) and superior vena cava (SVC) of the heart under fluoroscopy guidance. The appropriately sized TricValve® is unsheathed at the implantation site and positions itself as per the anatomy - self expanding frame.
58985|NCT03723226|Behavioral|Low Load Resistance Exercise|Subjects allocated to Low Load Resistance Exercise will undergo 5 weeks of single-legged low load (25%) resistance exercise. Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
58986|NCT03723226|Behavioral|Low Load Resistance Exercise + BFR|Subjects allocated to Low Load Resistance Exercise + BFR will undergo 5 weeks of single-legged low load (25%) resistance exercise with blood flow restriction (60% occlusion pressure). Subjects will then perform 4 sets of 30, 15, 15 and 15 repetitions at 25% of their 1RM for the single-legged leg press and single-legged knee extensions. Their contralateral leg will serve as within subject control.
58987|NCT03723200|Other|Fibrinogen and blood products|Fibrinogen and blood products
58988|NCT03723187|Other|normal saline|experimental group use normal saline sealing tube
58989|NCT03723187|Other|normal saline+heparin|normal saline+heparin(Currently, Regular used in hospital)
58990|NCT03723174|Behavioral|Oral Health Educational Program|proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
58991|NCT03723161|Device|Bone Achored Hearing surgery|This is a observational study of pediatric patients undergoing bone anchored hearing surgery. The collected data will be used to assess the implant stability development of the Ponto BHX implant during up tp 24 months after implantation in a pediatric population undergoing bone anchored hearing surgery.
58992|NCT03723148|Drug|Oral Fedratinib|Oral fedratinib administered as directed by treating physician.
58993|NCT03723135|Drug|CC-486|Oral azacitidine administered as directed by treating physician.
58994|NCT03723122|Behavioral|Dyadic Communication Reinforcement Intervention|Psycho-educative and behavioral intervention centered on cancer-related dyadic communication
58995|NCT03723109|Procedure|Induction of anesthesia|Standardized TCI and RSI anesthesia induction
58996|NCT03723096|Drug|CC-4047|CC-4047 will be administered orally
58997|NCT03723083|Drug|CC-2001|CC-2001 will be administered orally
58999|NCT03723057|Drug|AG-221|Oral AG-221 administered as directed by treating physician.
59000|NCT03723044|Other|EEG and occulometry|Each participants will spend two sessions of EEG and occulometry during a visual cognitive task where she/her will be presented with multi-stable visual stimuli to gaze at for one or two minutes. Depending on the experimental conditions, the participant will provide or not her/his perceptual state (i.e. which stimulus has been perceived ).
59001|NCT03723031|Drug|Misoprostol|400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
59002|NCT03723018|Behavioral|Meditation|10 minutes a day of meditation, done on your own time.
59003|NCT03723005|Device|Neolight Phototherapy Mattress|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
59004|NCT03723005|Device|Standard-of-Care|Once a qualified patient is enrolled, he/she will be randomized to Neolight phototherapy or standard-of-care phototherapy, which is ordered by physician as part of routine. Duration of phototherapy exposure will be recorded as entered by RN in patient medical progress notes.
59005|NCT03722992|Other|MBSR|Guided yoga and meditation practices
59006|NCT03722979|Procedure|Cardiac surgery|The study will enroll patients having a planned cardiac surgery under extracorporeal circulation (CEC)
59007|NCT03722966|Drug|Varenicline|All participants will be offered a 13-week course of varenicline (including a 1 week titration period). Dosage and administration per manufacturer: 0.5mg once daily for days 1-3 and 0.5mg twice daily for days 4-7 encompass the titration period, then 1mg twice daily for 12 weeks. An additional 12 weeks of treatment is recommended for long-term abstinence.
59008|NCT03722966|Drug|Oral Nicotine Replacement Therapy (NRT)|Half of study participants will be randomly assigned to receive oral nicotine replacement therapy (4mg gum or 4mg lozenge, depending on preference; to be used every 1-2 hours as urges occur) in addition to varenicline.
59009|NCT03722966|Behavioral|Medication Reminders|Half of study participants will be randomly assigned to receive automated medication reminders via their smartphones.
59010|NCT03722966|Behavioral|Tobacco Cessation Counseling|All participants will be offered 6 weekly tobacco cessation counseling sessions with a Tobacco Treatment Specialist.
59011|NCT03722953|Other|Control|"Ultrasound~Blood Pressure~Heart Rate~Oxygen Saturation"
59012|NCT03722953|Other|Aerobic Exercise|"Ultrasound~Blood Pressure~Heart Rate~Oxygen Saturation"
59013|NCT03722940|Drug|Magnesium sulphate|Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
59014|NCT03722940|Other|Na CL 0.9%|Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
59015|NCT03722927|Drug|Bupivacaine|While in the operating room,if subject is randomized to bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
59016|NCT03722927|Drug|Liposomal Bupivacaine|While in the operating room,if subject is randomized to Liposomal Bupivacaine, it will be injected into the surgical site. After surgery, oral and IV pain medications will be available to control pain. During the hospital stay, subject will rate pain on pain scales and monitor how much pain medications needed. Once discharged, PI/staff will provide a pain diary to record pain medication use and pain rating (0-10). Subjects will follow up with clinic at regularly scheduled appointment times at 1 week, 3 weeks and 5 weeks postoperatively. At those appointments, PI/staff will have subjects bring pain medication diary and fill out a pain assessment and a disability assessment related to recent surgery.
59017|NCT03722914|Drug|Benzonatate 200 mg|200 mg/pellet, 1pellet/time, 3times/day
59018|NCT03722914|Drug|blank control 0mg|0 mg/pellet, 1pellet/time, 3times/day
59019|NCT03722888|Device|smokeSCREEN video game|smokeSCREEN video game is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
59020|NCT03722875|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
59021|NCT03722875|Drug|apatinib|Apatinib is a selective VEGFR2 inhibitor
59022|NCT03722862|Dietary Supplement|Low fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 3 gram doses
59023|NCT03722862|Dietary Supplement|Placebo|Participants will receive the placebo/dextrose.
59024|NCT03722862|Dietary Supplement|High fiber|Partially hydrolyzed guar gum (PHGG) commercially available as Sunfiber in 6 gram doses
59025|NCT03722849|Drug|Adenosine Triphosphate|Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
59026|NCT03722849|Drug|Capsaicin|Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
59027|NCT03722849|Other|Functional Brain Imaging|Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
59028|NCT03722823|Drug|Tucatinib|300mg oral single dose
59029|NCT03722810|Other|Intervention|"The intervention will be a structured in-depth interview with a patient with a chronic illness that has been chosen by the student's allocated GP teacher. These chronic diseases are the four conditions at the top of a list of diseases with high disability-adjusted life years (DALY) scores in Switzerland: ischaemic heart disease, low back pain, major depressive disorder and COPD.~GP teachers and students will be told that the students' intervention interviews need to be unaccompanied and at patients' own homes. The interview will be followed by a structured interview with the practice nurse and then a structured debriefing interview with the GP teacher."
59030|NCT03722810|Other|Sham comparator|In the sham comparator, the student's allocated GP teacher will be give the student time to read a document that gives information about consultation skills, and asks questions that the student will need to discuss with the GP teacher. The document is designed to have real educational value, and to complement BIHAM's department-based consultation skills teaching.
59031|NCT03722797|Procedure|Metabolic Cost Testing Procedures|"The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3."
59032|NCT03722771|Behavioral|Inhalation|lavender oil inhalation in a separate room for 3 minutes prior to surgery
59033|NCT03722771|Other|Anxiety Questionnaires 1|Modified Dental Anxiety Scale was used to describe the level of the dental anxiety.
59034|NCT03722771|Other|Anxiety Questionnaires 2|State-Trait Anxiety Inventory-State Scale was used to distinguish the true anxiety level of the patients from the anxiety level for a particular situation.
59035|NCT03722771|Diagnostic Test|Vital Signs 1|Changes in vital signs 1 - blood pressure - before, during and after the procedure were noted.
59036|NCT03722771|Diagnostic Test|Vital Signs 2|Changes in vital signs 2 - respiratory rate - before, during and after the procedure were noted.
59037|NCT03722771|Diagnostic Test|Vital Signs 3|Changes in vital signs 3 - heart rate - before, during and after the procedure were noted.
59038|NCT03722771|Diagnostic Test|Vital Signs 4|Changes in vital signs 4 - saturation - before, during and after the procedure were noted.
59039|NCT03722758|Device|Spectrum TPH3|tooth restoration with two different restorative materials
59040|NCT03722758|Device|Riva LC|tooth restoration with two different restorative materials
59041|NCT03722745|Behavioral|TARGET|TARGET is manualized cognitive-behavioral treatment designed to help adolescents and adults with symptoms of posttraumatic stress
59042|NCT03722745|Behavioral|TAU|It involves referral to an offsite community mental health provider with no attempt to control the treatment modality-type-quality (i.e., evidence-based-treatment or not).
59043|NCT03722732|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy either laparoscopically or open will be done
59044|NCT03722719|Other|the Knack|The Knack consists of voluntary PFM contractions before and during activities that increase abdominal pressure. Such contraction elevates the pelvic floor cranially, with consequent closure of the urethra, vagina and rectum, stabilization of the pelvic floor and avoidance of urine leakage.
59045|NCT03722719|Other|PFMT|The rationale underlying intensive PFM strength training is that it might develop the structural support of the pelvis by raising the levator plate to a permanent, higher position within the pelvis and promoting PFM and connective tissue hypertrophy and stiffness. These conditions facilitate automatic and more efficacious activation of motor units (neural adaptation), which impedes descent during activities that increase abdominal pressure.
59046|NCT03722719|Other|The Knack + PFMT|These participants will perform the exercises described for both the Knack and PFMT groups at the outpatient clinic and at home.
59047|NCT03722706|Other|Educational handbook|The intervention being evaluated in this study is an educational handbook for parents of children with atopic dermatitis (AD). The handbook was developed and written by the interdisciplinary study team (psychologist, allergist, nurse practitioner, dermatologists, primary care physician, dietitian). Content was based on practice guidelines for AD management, consensus recommendations for therapeutic patient education for AD, and clinical experience of our study team. Content includes topics central to effective AD management, such as pathophysiology/course, elements of treatment plans, and strategies to improve quality of life, such as breaking the itch-scratch cycle, improving sleep, and coping with social-emotional issues.
59048|NCT03722693|Device|Functional electrical stimulation based treatment|Two types of multi-pad electrodes will be used during this study. Both were designed for covering the extrinsic muscles of the hand. Electrodes are comprised of 8 pads that act as anodes and 32 pads that acted as cathodes. The shape and distribution of the conductive pads within the electrodes were designed considering the motor points for achieving different movement primitives (wrist extension, wrist flexion, fingers extension, fingers flexion, index extension, index flexion, thumb extension, and thumb flexion). Each participant will receive 5 assessment sessions:1. before starting the interventions, 2. after the 7 days of standard care, 3. after 7 days of first FES based protocol, 4.after another 7 days of standard care and 5. after seven days of the other FES based intervention
59049|NCT03722680|Drug|Riluzole|Riluzole during chemotherapy (oxaliplatin)
59050|NCT03722680|Drug|Placebo Oral Tablet|placebo
59051|NCT03722667|Behavioral|Technology-based Component|This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.
59052|NCT03722667|Behavioral|TechSupport|"The TechSupport intervention is the combination of both an behavioral and emotional intervention.~Technology-based Components: This intervention is comprised of three technology components: a) six weekly web-based modules focused on improving knowledge and skills to manage hypertension; (b) personalized medication adherence support (SMS reminder messages, adherence feedback, health and lifestyle tips) through Medisafe app; and (c) self-monitoring blood pressure to support self-managing hypertension.~Positive Psychological Training (PPT): This intervention will include a structured online training and skill building for PPT accessible by smartphone on techniques to promote optimism, resilience, well-being, and self-confidence."
59053|NCT03722654|Behavioral|MTFS-I Installation|MTFS-I Installation will focus on introducing MTFS-I components including weekly training modules and mock video segments to be coded, as well as monthly feedback reports summarizing therapist self-reported FT and CBT implementation in active cases. Facilitation will also be included to review progress and provide regular support.
59054|NCT03722641|Other|Bread reference|Commercially available white wheat bread
59055|NCT03722641|Other|Product 1: Milk|Developed reference product based on milk
59056|NCT03722641|Other|Product 2: Full fat milk + oat|Developed product based on full fat milk with addition of oat
59057|NCT03722641|Other|Product 3: Skim milk + oat, high fibre|Developed product based on skim milk with addition of oat giving a high fiber content to the product
59058|NCT03722641|Other|Product 4: Skim milk + oat, low fibre|Developed product based on skim milk with addition of oat giving a lower fiber content to the product
59059|NCT03722628|Diagnostic Test|MMP1 genotypes polymorphism|Determination of MMP-1 gene polymorphism By PCR amplification followed by restriction Fragment length polymorphism (RFLP) and gel electrophoresis
59060|NCT03722602|Other|Standard rehabilitation after stroke|The program of the rehabilitation was designed specifically for each patient. It was prepared to match the patient's functional status and the defined goals. The subjects participated in exercise five days per week, for five weeks. During their stay at the Clinic, the patients took part in morning exercise and received individual practice, based on neuro-developmental treatment (Bobath concept), and proprioceptive neuromuscular facilitation (PNF) method, addressing the impaired motor abilities; if it was needed they also performed exercise based on equipment using biological feedback: Balance Trainer (static and dynamic parapodium) and Pablo system designed for upper limb training.
59061|NCT03722589|Biological|Flublok|0.5 mL intramuscular dose of Flublok
59062|NCT03722589|Biological|Flucelvax|0.5 mL intramuscular dose of Flucelvax
59063|NCT03722589|Biological|Fluarix|0.5 mL intramuscular dose of Fluarix
59064|NCT03722589|Biological|Fluzone|0.5 mL intramuscular dose of Fluzone
59065|NCT03722589|Biological|Fluzone High-Dose|0.5 mL intramuscular dose of Fluzone
59066|NCT03722576|Drug|Vidofludimus calcium|30 mg VC orally once daily
59067|NCT03722563|Procedure|total laparoscopic hysterectomy with sacrocolpopexy|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
59068|NCT03722563|Procedure|total laparoscopic hysterectomy with lateral suspension|Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
59069|NCT03722550|Other|Starter Infant Formula, Follow-up Formula, and Growing-up Milk Supplemented With a Blend of Five Human Milk Oligosaccharides|Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
59070|NCT03722550|Other|Breast-feeding|Exclusive Breast-feeding up to 4 months of age
59071|NCT03722550|Other|Standard Starter Infant Formula, Follow-up Formula, and Growing-up Milk|Standard Study formulas are administered orally, ad libitum, from enrollment until 15 months of age
59072|NCT03722537|Procedure|Osteochondral Allograft|The arthritic bone that the thumb rests on (the trapezium) is removed and replaced with femoral trochlear osteochondral allograft that is designed to be similar in morphology to the human trapezium articular surface.
59073|NCT03722537|Procedure|Ligament Reconstruction Tendon Interposition|During the LRTI, the arthritic bone that the thumb rests on (the trapezium) is removed. A small cut is made in the forearm to release a tendon, which is moved to the base of the thumb to fill in the area from which the trapezium bone was removed. A small suture anchor is then placed into a thumb bone which holds everything together.
59074|NCT03722524|Drug|amlodipine / indapamide / perindopril arginine FDC|CCB / diuretic / ACE inhibitor
59075|NCT03722511|Dietary Supplement|Amino Acid Based Medical Food/Drink|Study Compound Enterade® is a medical food drink/beverage composed of a proprietary blend of electrolytes and amino acids.
59078|NCT03722485|Device|Negative Pressure Therapy w/ instillation and dwell (NPWTi-d)|Negative Pressure Therapy at -125mmHg for 3.5 hours followed by 10 minute dwell of saline solution for 6-9 days.
59079|NCT03722485|Biological|Collagenase Ointment|Collagenase ointment applied daily to the wound and covered with secondary dressing for 6-9 days.
59080|NCT03722472|Biological|ID93 + GLA-SE|The single-vial lyophilized vaccine will be reconstituted with WFI. For the two-vial presentation, the lyophilized ID93 will be reconstituted with WFI and mixed with liquid GLA-SE.
59081|NCT03722459|Device|MR Fingerprinting|The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
59084|NCT03722433|Drug|Vigiis 101-LAB and sequential therapy|Vigiis 101-LAB is the probiotic containing Lactobacillus paracasei subsp. Paracasei, which is the isolate from Taiwanese by Prof. Pan. This strain is resistant to gastric acid and bile acid. Therefore, its survival rate in the gastrointestinal tract could be as high as 95%. Previous studies showed that Vigiis 101-LAB can modulate the gut microbiota, with 10% increase in Bifidobacterium species and 20% reduction in Clostridium difficile.
59085|NCT03722433|Drug|Placebo and sequential therapy|Placebo without Vigiis 101-LAB component
59086|NCT03722420|Drug|Radotinib|Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).
59087|NCT03722420|Drug|Imatinib|Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
59088|NCT03722407|Drug|Ruxolitinib|Ruxolitinib 5 mg tablets, 4 per dose
59089|NCT03722394|Behavioral|Pain Neuroscience Education|15 minute verbal one-on-one education session
59090|NCT03722381|Drug|Amlodipine Besylate|Pharmacokinetics
59091|NCT03722368|Behavioral|RCHC|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills.
59092|NCT03722368|Behavioral|RCHC+|The RCHC group will receive a three hour psychoeducational intervention on common stress responses among healthcare providers and coping skills. They will also receive a booster session one month later which will reinforce these skills. This intervention group will also receive on-going support groups and one on one counseling as needed.
59093|NCT03722368|Other|Waitlist control|This group will served as the control group and will receive treatment as usual until the end of the study. At the end of the study they will have the opportunity to take part in the RCHC or RCHC+
59094|NCT03722355|Radiation|Conventional RT|Radiation therapy
59095|NCT03722355|Radiation|Hyperfractionated RT|Radiation therapy
59096|NCT03722355|Drug|Carmustine|Chemotherapy
59097|NCT03722342|Drug|TTAC-0001 and pembrolizumab combination|"Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~Treatment groups: 3 dose levels~Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Cycle: 3 weeks (21 days per cycle)"
59098|NCT03722329|Drug|Eculizumab|Eculizumab Injection. 300 mg, single dose
59099|NCT03722316|Other|Immersive Nature Video|"An approximately 15-minute digital nature experience using work by filmmaker Louie Schwartzberg—Visual Healing by Moving Art. Time-lapse, high-speed, and macro cinematography are incorporated within each video. Audiovisual content include vivid imagery of a variety of ecosystems and climates accompanied by calming instrumental music.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
59100|NCT03722316|Other|Neutral Video|"This video will include clips from relatively non-arousing educational documentaries. Fifteen minutes of documentary content will be selected from a longer video, ensuring that the content remains as neutral as possible. Video selections were modeled after the work from Eryilmaz, Van De Ville, Schwartz, and Vuilleumier (2011) who identified very brief movie clips (i.e., <1 minute) that were rated as neutral as opposed to frightful or enjoyable.~Both the MCI/Mild dementia arm and the healthy older adult arm will experience this intervention."
59101|NCT03722303|Other|Fat Injection|Used by plastic surgeons, lipografting injects autologous fat to correct contour deformities. Plastic surgeons have witnessed the regenerative properties of fat transfer, and these clinical manifestations have fostered numerous studies defining fat as a rich source of pluripotent stem cells with the potential for reducing scar formation, bringing neo-angiogenesis, and providing a barrier against scar adhesions. This study applies the regenerative properties of autologous fat transfer to treat mild to moderate carpal tunnel syndrome in comparison to the current standard of care, corticosteroid treatment. Ideally, fat transfer would prevent scar formation and aid in nerve excursion along the canal, while the neoangiogenic and regenerative growth factors stimulate nerve regeneration.
59102|NCT03722303|Drug|Steroid Injection|Standard of care non-operative treatment for the treatment of Carpal Tunnel Syndrome
59103|NCT03722290|Drug|Metformin|Oral administration of metformin 250mg (twice a day) for the 1st week followed by metformin 500mg (twice a day) for the next 8 weeks.
59104|NCT03722277|Other|Variable load training|Based on symptoms/strength measured in an isometric maximum strength test at five different angles of knee flexion- and extension, participants will be training with variable load during both concentric and excentric phase of the dynamic movement. Initially participants will start at 40% of symptom limited isometric strength, this will increase to 50% during the training period.
59105|NCT03722277|Other|Conventional strength training|Conventional strength training with rubber bands in knee flexion- and extension, additionally hip abduction- and adduction.
59106|NCT03722264|Device|OpalSeal|OpalSeal is a fluoride releasing orthodontic primer that is FDA approved for use during bonding of orthodontic brackets
59107|NCT03722264|Device|TransbondXT|Transbond is a primer used to bond orthodontic brackets that does not contain fluoride
59108|NCT03722251|Behavioral|Glucose beverage, control beverage, glucose beverage and active video game playing, control beverage and active video game playing|
59144|NCT03721978|Biological|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
59109|NCT03722238|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Tablet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
59110|NCT03722225|Other|Carbohydrate loading and high intermittent carbohydrate intake during physical exercise|The intervention consisted of carbohydrate loading prior to and intermittent high carbohydrate intake during PE and a proactive use of Real-Time Continuous Glucose Monitoring (rtCGM) to achieve and maintain glucose control
59111|NCT03722212|Diagnostic Test|METAglut1|A blood draw is performed on each patient for the METAglut1 test, and sent to Laboratoire CERBA, Saint-Ouen l'Aumône, France, for sample analysis.
59112|NCT03722199|Dietary Supplement|flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)|single intake of capsules with flavanols (subgroup of polyphenols, subgroup of phenolics, natural substances)
59113|NCT03722199|Other|Placebo|single intake of capsules with a placebo
59114|NCT03722186|Drug|SHR-1603|SHR-1603 monotherapy
59115|NCT03722173|Drug|Itraconazole|Oral solution
59116|NCT03722173|Drug|BI 894416|Tablet
59117|NCT03722160|Device|Solo TympanostomyTube Device|The Solo Tympanostomy Tube Device is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
59118|NCT03722147|Biological|AK105|AK105 200 mg intravenously (IV) every-2-weeks (Q2W)
59119|NCT03722134|Procedure|MOCA|Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
59120|NCT03722134|Procedure|EVLA|Great saphenous vein occlusion with a thermal laser chateter
59121|NCT03722134|Procedure|RFA|Great saphenous vein occlusion with a thermal radiofrequency chateter
59122|NCT03722108|Combination Product|Regorafenib and Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
59123|NCT03722108|Drug|Irinotecan|Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
59124|NCT03722095|Device|active tDCS|A current of 2 milliampère (mA) through electrodes of 5x5cm.
59125|NCT03722095|Device|sham tDCS|Similar set-up as in the active tDCS, but stimulation is too short to cause any effects.
59126|NCT03722095|Device|iTBS|54 cycles with 10 bursts of 3 pulses, train duration of 2 seconds and intertrain intervals of 6 seconds, results in 1620 pulses at 110% resting motor threshold.
59127|NCT03722082|Behavioral|Enhancing Cognitive Reserve|The intervention is aimed at improving cognitive reserve in offsprings of patients diagnosed with schizophrenia or bipolar disorder. The program is composed of 12 sessions of 60 minutes and will be adapted according the three different age groups (6-12) (13-18) (18-25). Each group will include between 6-to-8 offsprings and conducted by 4 experienced neuropsychologists in both children and adults. The sessions are the following:
59128|NCT03722082|Behavioral|Support intervention|The support group will schedule meetings with the participants in order to talk about their daily life with the possibility to talk about the difficulties they encounter.
59129|NCT03722069|Other|Low sodium diet|Patients received low sodium diet (3g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
59130|NCT03722069|Other|Normal sodium diet|Patients received normal sodium diet (7g of sodium chloride/day) and a limit of fluid intake of 1000 ml/day.
59131|NCT03722056|Procedure|Laparoscopic resection|all patients with suspected Gastric GIST undergoes laparoscopic resection. Tumour location decides the approach used for resection. Therefore, a variety of options such as local resections, wedge resections, transgastric resections, intragastric resection and partial gastrectomies were performed.
59132|NCT03722043|Behavioral|Parenting Program|Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
59133|NCT03722030|Other|Baseline Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
59134|NCT03722030|Behavioral|Strength-Training|2 sessions per week (20-40 min), home-based resistance training
59135|NCT03722030|Other|Mid-point Measures|Accelerometer (steps)
59136|NCT03722030|Other|Post-Study Measures|Accelerometer (steps), Biomarkers (finger prick for hemoglobin A1c and c-reactive protein), Anthropometrics (height, weight, waist and hip circumference), Body composition (dual-energy absorptiometry for measuring fat mass, lean mass, % body fat, visceral fat), Functional fitness test.
59137|NCT03722017|Other|Deprescribing intervention|"In addition to a medication history, a study Pharmacist or Nurse Practitioner will review the reconciled total enrollment medication list. The following information will be ascertained for each medication: (1) Medication Indication; and, (2) Deprescribing rationale: Rationales for deprescribing (i.e., stopping or reducing dose) will be assessed for each medication.~Deprescribing Recommendations: For each medication recommended for deprescribing, the deprescribing action will be specified as: (1) Stop prior to hospital discharge without need for monitoring; (2) Stop prior to hospital discharge with symptoms/physiologic monitoring; (3) Stop at specified time point following hospital discharge; (4) Reduce over time with monitoring until medication is stopped; (5) Reduce to lower dose without need for monitoring; (6) Reduce to lower dose with symptoms/physiologic monitoring."
59138|NCT03722004|Biological|mOPV1|Monovalent oral poliovirus vaccine type 1 is a type-specific, live, attenuated oral poliovirus vaccine that protects against poliovirus type 1.
59139|NCT03722004|Biological|bOPV|Bivalent oral poliovirus vaccine is a live, attenuated oral poliovirus vaccine that protects against poliovirus types 1 and 3.
59140|NCT03722004|Biological|fIPV|Fractional dose of inactivated poliovirus vaccine that protects against types 1, 2, and 3 (all polio serotypes). Given as a 0.1 milliliter (mL) dose (fractional) by intradermal injection in lieu of the full 0.5mL dose that is given intramuscularly.
59141|NCT03721991|Dietary Supplement|Gama amino butyric acid (GABA)|food supplement Gama amino butyric acid (GABA) as capsules
59142|NCT03721991|Dietary Supplement|placebo|matching placebo
59331|NCT03720366|Drug|Arm 2 Probes|digoxin and rosuvastatin
59145|NCT03721978|Device|CELLECTRA™-5PSP|CELLECTRA™-5PSP is used for EP following IM injection of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
59146|NCT03721965|Drug|Itacitinib|Phase 1: Itacitinib administered orally once daily at the protocol-defined dose according to age cohort, with dose reductions or modifications based on safety assessments. Phase 2: Itacitinib administered orally once daily at the recommended dose from Phase 1.
59147|NCT03721965|Drug|Corticosteroids|Phase 1 and 2: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose that is appropriate for the severity of disease as outlined per local treatment guidelines as background treatment.
59149|NCT03721939|Device|FLEX Scoring Catheter|Vessel preparation with the FLEX Scoring Catheter® with a 30° rotation between each passage is performed, followed by a DEB angioplasty.
59150|NCT03721926|Other|Usual Care|Participants assigned to receive usual oncology care will not meet with the study nurses, though they may receive geriatric or palliative care consults at their request or at the discretion of their treating oncologist.
59151|NCT03721926|Other|Geriatric Oncology Collaborative Care|Patients receive three visits with a trained study nurse. At each visit, the study nurse will assess the patient's symptom burden, functional status, comorbid conditions, psychosocial issues, and medication use. The nurses can refer patients to specialists as needed. The study nurses will meet with a supervising support team, consisting of clinicians from geriatrics, palliative care, social work, and pharmacy to discuss each patient and review documentation. Following the team meetings, the nurses will document recommendations in the medical record and communicate with the primary oncology team, either in person or via phone, as appropriate. The study nurses will contact the supervising team in between meetings for any urgent issues or questions that arise.
59152|NCT03721913|Other|participation-based intervention|The participation-based intervention is a goal-orientated, family-centered, and self-determined approach that emphasize on solution strategies based on child and family-selected goals. Intervention strategies will be formed by analyzing the strength and needs of child, family, and environment, and implemented by collaboration between family and interventionists.
59153|NCT03721900|Drug|SHX-001 Active low dose|ketamine transdermal patch
59154|NCT03721900|Drug|Placebo|transdermal patch
59155|NCT03721900|Drug|SHX-001 Active High dose|ketamine transdermal patch
59156|NCT03721887|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
59157|NCT03721874|Drug|Dapagliflozin 10mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered dapagliflozin 10 mg during Period 1 or Period 2."
59158|NCT03721874|Drug|Placebo matching to Dapagliflozin 10 mg|"The study consist of 2 weeks treatment period 1, 6-8 weeks wash-out period and 2 weeks treatment period 2.~The subject may be administered placebo during Period 1 or Period 2."
59159|NCT03721861|Device|Intra-operative neural cuff stimulation|A feasibility study consists of placing 2 electrodes around the radial or medial nerves intraoperatively. The movements caused by the electrical stimulation of these nerves are observed.
59160|NCT03721848|Behavioral|Healthy community clinic NCD+MH|"NCD+MH Awareness Intervention Overview:~i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 28 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, Smoking, Emotional Wellness, Stress Relief and Positive Coping.~iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
59161|NCT03721848|Behavioral|Healthy community clinic NCD|"i. Patients are assigned, at minimum, one health awareness lecture per month with a total of 24 lectures possible ii. Patients attend lectures on specific topics given by MoH staff, mainly nurses.~iii. Topics tackled include: Diabetes, Hypertension, Asthma, Cardiovascular Disease, Reproductive Health, Healthy Nutrition, and Smoking iv. Group nutrition and physical fitness counselling are incorporated into most health awareness lectures"
59162|NCT03721835|Device|CONQUEST FN Femoral Neck Fracture System|Fracture fixation device consisting of a single plate and three screws
59163|NCT03721822|Drug|[18F]NOS|[18F]NOS is an investigational radiotracer which each subject will have one [18F]NOS positron emission tomography/computed tomography (PET/CT) scan performed.
59164|NCT03721809|Biological|Blood samples|"There are 3 specific blood sampling times for each patient, on D1, D2 and D5 (D1 being the day of inclusion): cytokine samples (IL-1β, IL-6, IL-10, TNF-α, IFN-gamma) on 5ml dry tube.~On D1, a 2.5ml PAXgene tube will also be taken for each patient."
59165|NCT03721796|Other|Audio recording of initial consultation and debriefing interviews.|Semi-structured debriefing interviews with participating oncologists and HIV-infected newly diagnosed cancer patients will follow the initial encounter. Interviews will be conducted over 45-60 minutes and will be semi-structured with open-ended questions to allow the interviewee to direct the flow of the conversation.
59166|NCT03721783|Procedure|Cryoablation|Image guided cryoablation therapy of soft tissue lesions
59167|NCT03721757|Biological|Nivolumab, Surgery, Radiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
59168|NCT03721757|Biological|Nivolumab, Surgery, Chemoradiotherapy|A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
59332|NCT03720366|Drug|Arm 3 probes|pioglitazone
59169|NCT03721744|Drug|Napabucasin|Napabucasin will be administered twice daily, at 240 mg bid (480 mg total daily dose), one hour prior or two hours after meals
59170|NCT03721744|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle
59171|NCT03721744|Drug|Gemcitabine|Gemcitabine 600 mg/m^2 will be administered intravenously following paclitaxel infusion on Days 1, 8 and 15 of every 28-day cycle
59172|NCT03721744|Other|Standard of care treatment options|Patient will receive standard of care treatment options, including Fluorouracil /Leucovorin, Gemcitabine, Onivyde plus Fluorouracil /Leucovorin (if Onivyde has been approved to treat pancreatic cancer in the country/region) or best supportive care (BSC) alone, one of which will be assigned by the investigator, per Investigator decision
59173|NCT03721731|Device|Obesity treatment with a Plication device|Plicating the stomach to treat obesity
59174|NCT03721718|Biological|GLS-5300|[Part A] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) [Part B] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
59175|NCT03721718|Device|Cellectra 2000 Electroporation|GLS-5300 administered ID followed by Cellectra 2000 Electroporation
59176|NCT03721705|Device|Renew NCP-5|Treatment will be given 3-5 times a week for a total of 35 treatments over 12 weeks.
59177|NCT03721692|Device|RIC|The patients will use RIC everyday for three months, 5 cycles 5min ischemic-5min reperfusion each day.
59178|NCT03721679|Biological|Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months|Same as above
59179|NCT03721666|Other|CCTV footage to the medical dispatcher in OHCA|The medical dispatchers' perception of bystanders' responses and dispatchers' reflections about the added value of visual information in out-of-hospital cardiac arrests (OHCA) situations.
59180|NCT03721653|Drug|Bevacizumab|5 mg/kg iv over 30 minutes day 1
59181|NCT03721653|Drug|Irinotecan|165 mg/sqm iv over 60 minutes day 1
59182|NCT03721653|Drug|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
59183|NCT03721653|Drug|L-Leucovorin|200 mg/sqm iv over 2 hours day 1
59184|NCT03721653|Drug|5-fluorouracil|3200 mg/sqm 48 h-continuous infusion
59185|NCT03721653|Drug|Atezolizumab|840 mg iv over 30 minutes (60 minutes at the first infusion) day 1
59186|NCT03721640|Other|electrocardiogram|Autonomic and hemodynamic evaluation with different indices (LF, heart rate, Systolic, diastolic and mean arterial blood pressure, SaO2) during a sedation protocol for intubation and surfactant administration according the INSURE or LISA technique.
59187|NCT03721627|Drug|Ledipasvir/Sofosbuvir|Direct acting anti HCV drugs
59188|NCT03721614|Device|BioMime™ Morph - Sirolimus Eluting Coronary Stent System|Study Device :- BioMime™ Morph - Sirolimus Eluting Coronary Stent System Approximately 200 patients will be randomly enrolled in a 2:1 ratio [BioMime™ Morph (n=133) vs. XIENCE family (n=67)].
59189|NCT03721614|Device|Xience family Everolimus Coronary Stent Systems|Active Control Device :- Xience family Everolimus Coronary Stent Systems Approximately 200 patients will be randomly enrolled in a 2:1 ratio [BioMime™ Morph (n=133) vs. XIENCE family (n=67)].
59190|NCT03721601|Device|Heart rate monitor chest strap|Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
59191|NCT03721601|Device|Wrist band photoplethysmography|Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
59192|NCT03721588|Other|Clinical interviews, psychometric scales were applied.|
59193|NCT03721575|Procedure|Scarpa's preserving hernio-abdominoplasty|Scarpa's fascia is preserved during hernio-abdominoplasty
59194|NCT03721575|Procedure|Classical hernio-abdominoplasty|Scarpa's fascia is removed during hernio-abdominoplasty
59195|NCT03721549|Biological|Norwalk GI.1 Virus|Norwalk virus causes viral gastroenteritis, which is also known as acute nonbacterial gastroenteritis, food poisoning, food infection, or stomach flu.
59196|NCT03721536|Diagnostic Test|hemodynamic parameters|vital signs on the monitor including heart rate, mean arterial pressure, peripheral oxygen saturation and End-tidal Carbon Dioxide
59197|NCT03721536|Diagnostic Test|arterial blood gase|Arterial blood gas including partial oxygen pressure and partial carbon dioxide pressure is an important routine investigation to monitor the acid-base balance of patients, effectiveness of gas exchange, and the state of their voluntary respiratory control.
59198|NCT03721523|Diagnostic Test|3 Dimensional tomographic Ultrasound|3-D tUS at five timepoints following acute ipsilateral stroke or Transient Ischaemic attack (TIA) to document carotid plaque volume and presence or absence of adverse plaque features.
59199|NCT03721523|Diagnostic Test|Platelet Aggregometry|Blood test to test for platelet resistance to aspirin or clopidogrel and to measure effect of acute inflammatory response post event.
59200|NCT03721510|Biological|PGT121 + VRC07-523LS|PGT121 + VRC07-523LS, dose 30 mg/kg each, given intravenously
59201|NCT03721510|Biological|PGT121 + VRC07-523LS + PGDM1400|PGT121 + VRC07-523LS + PGDM1400, dose 20 mg/kg each, given intravenously
59202|NCT03721497|Drug|Testosterone Undecanoate|The patients will be randomly assigned to either testosterone or placebo.
59203|NCT03721484|Diagnostic Test|CINtec PLUS|CINtec PLUS testing will be used to triage HPV positive women to colposcopy
59204|NCT03721471|Other|Scoring of frailty|"Patients will be scored by the Clinical frailty Scale~Patients` hand-grip-strength will be measured by a dynamometer."
59205|NCT03721458|Other|Sequence|Potentially identifying genetic defects that could have clinical significance
59206|NCT03721445|Device|continuous positive airway pressure|Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
59207|NCT03721432|Drug|Pregabalin 150mg|pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia
59208|NCT03721432|Drug|Placebo oral capsule|Placebo oral capsule given 60 minutes prior to epidural anesthesia
59209|NCT03721419|Device|High Flow High Humidity device|High Flow High Humidity device has a flow generator built into the body of unit and can deliver flows between 10 to 60 Liters per minute (LPM) with oxygen bled in as needed in order to deliver specified Fraction of inspired Oxygen (FiO2)
59210|NCT03721419|Device|Low Flow High Humidity device|Standard high humidity trach collar utilizing venturi device bleed in
59211|NCT03721406|Drug|Ropivacaine|ropivacaine administerd via thoracic paraveretebral catheter
59212|NCT03721393|Device|Wearable heart monitor|Participants will be fitted with a wearable heart monitor placed on the skin that measures physiologic signals. There is no intervention or treatment.
59213|NCT03721380|Behavioral|Treatment as usual|Patients receive some HIV risk education for the enrollment; after that, health education is delivered irregularly (1-2 times a month or none), based on the patient's needs. During MMT treatment, the participant receives monthly random urine testing for opiate use and HIV testing as needed. Monthly meetings between the patient and physician are expected to occur however, there is no structure to these sessions and content is considered to be quite variable.
59214|NCT03721367|Other|Diagnostic Ultrasound|All individuals will undergo a blood draw for measurement of biomarkers of liver disease and an ultrasound with shear-wave elastography.
59215|NCT03721354|Other|NAVA vs PSV - TCCD|"Patients will be submitted to 3 different 30 minutes ventilation trials: the first one in PSV mode, the second one in NAVA mode and the third one in PSV mode again. PSV will have PEEP setted by clinician and pressure support set in order to obtain Vt 6-8 ml/kg. NAVA will have the same PEEP as PSV and NAVA level will be set to obtain the same Peak of Inspiratory Pressure) of PSV.~Trans cranial doppler technique will be performed to evaluate the blood cerebral flow speed (average/systolic speed) at the end of every ventilation trial. At the end of each trial, ABGs will be performed. Traces of flow, airways pressure (Paw) and electric diaphragmatic activity (EAdi) will be recorded and acquired through a dedicated ventilator software called NAVA tracker."
59216|NCT03721341|Radiation|Palliative Radiation|Investigators should follow the principles of palliative radiotherapy as per the individual institution in order to alleviate symptoms or prevent complications. If radiotherapy is indicated, recommended doses are 8 Gy in 1 fraction, 20 Gy in 5 fractions, and 30 Gy in 10 fractions.
59217|NCT03721341|Drug|Chemotherapy|Chemotherapy may be given as indicated.
59218|NCT03721341|Drug|Immunotherapy|Immunotherapy may be given as indicated.
59219|NCT03721341|Drug|Hormones|Hormones may be given as indicated.
59220|NCT03721341|Other|Observation|Observation only is acceptable if this is the standard practice.
59221|NCT03721341|Radiation|Stereotactic Ablative Radiotherapy|Total dose of radiation and number of fractions will depend on the site of disease. Doses are 20 Gy in 1 fraction, 30 Gy in 3 fractions (every 2 days), or 35 Gy in 5 fractions (daily).
59222|NCT03721328|Combination Product|vancomycin hydrochloride and tobramycin sulfate|vancomycin hydrochloride and tobramycin sulfate via local irrigation
59223|NCT03721315|Behavioral|Intervention|"The health literacy enhancement will comprise of the following:~Practical day to day information to help manage the disease~Benefits of medication and adherence~Tips to improve managing shortness of breath~Proper use of inhalers (if applicable)~Managing daily activities"
59224|NCT03721302|Other|Main study clinical sepsis|No intervention-Observational study
59225|NCT03721302|Other|Microbiology sub study|Analysis of Bacterial isolates
59227|NCT03721263|Biological|ASLAN004|Single Dose
59228|NCT03721250|Other|epidural|thoracic epidural analgesia
59229|NCT03721237|Other|EBC-assisted|"After definitive catheter positioning, esophageal balloon calibration will be performed in:~volume-controlled mode with tidal volume set to obtain 6-8 lm/kg of ideal body weight (reference),~pressure support ventilation (PSV) with support set to obtain a tidal volume ranging between 6-8 ml/kg of ideal body weight at equal PEEP of volume control mode (PSV baseline);~PSV + sigh ventilation (sigh setting: total inspiratory pressure equal to 35 cmH2O at a rate of 1/ minute; inspiratory time equal to 4 seconds)."
59230|NCT03721224|Diagnostic Test|Kiddie Schedule for Affective Disorders and Schizophrenia|Both of the clinical and control group will be evaluated via Psychiatric semi-structured interview
59231|NCT03721211|Drug|[11C]Martinostat|a type of dye used for radiographic imaging of the HDAC protein
59232|NCT03721211|Device|MR-PET scanner|PET, or positron emission tomography, is a type of imaging test that uses a tracer, or dye, to make detailed pictures showing the activities of the cells that make up tissues and organs
59233|NCT03721198|Combination Product|Acidulated phosphorous flouride|Acidulated phosphorous flouride is used to prevent white spot lesions
59234|NCT03721198|Other|Resin modified glass ionomer varnish|Resin modified glass ionomer varnish is used to prevent white spot lesions
59235|NCT03721185|Combination Product|Dr.K. Treatment|Overweight and obesity treatment response
59236|NCT03721172|Drug|Apremilast|Apremilast, oral, twice daily
59237|NCT03721172|Other|Placebo|Placebo, oral, twice daily
59238|NCT03721133|Diagnostic Test|Blood sampling|"20 ml blood that withdrawal from peripheral vein. Blood sampling time: less than 3 minutes.~Sample examination: Purification circulating tumor cell by high sensitive tumor cell marker. Combine the medical record to analyze the relationship between circulating tumor cell and disease relapse"
59239|NCT03721120|Diagnostic Test|InvisionFirst® molecular panel|"During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS- and LKB1- mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis."
59240|NCT03721107|Biological|MRx1234 [Blautia Hydrogenotrophica]|MRx1234 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is two capsules two times per day for the duration of the treatment period.
59241|NCT03721107|Other|Placebo|Placebo control
59333|NCT03720353|Drug|SAS2094AH and SAS2094BH|SAS2094AH and SAS2094BH for 7 days, preceded by SAS2094AL and SAS2094BH for 3 days.
59334|NCT03720353|Drug|SAS2094AL and SAS2094BL|SAS2094AL and SAS2094BL for 10 days
59335|NCT03720353|Drug|Placebo|Placebo for 10 days. Capsules will mimic active treatments.
59242|NCT03721094|Other|Immersive virtual reality|In the IVR environment, four different 360-degrees videos were in sequence played as backdrop during the procedure. The videos reflected real life situations in the operating room with two videos representing calm periods, one video representing a light stressor and one video representing a severe stressor with a bleeding (2 ml/s) being triggered in the simulation. Participants complete the procedures while wearing the head mounted device.
59243|NCT03721081|Drug|Lidocaine 1%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Lidocaine 1%/Epi 1:200000 Inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
59244|NCT03721081|Other|Na Cl 0.9%/Epi 1:200000|Five minutes before skin incision, subcutaneous infiltration of 0.5 ml/kg of Na CI 0.9%/Epi 1:200000 inj along a 3 cm extended endaural incision with a 23 G hypodermic needle administered was performed by the surgeon, who was blinded to the applied drug solution.
59245|NCT03721068|Biological|iC9.GD2.CAR.IL-15 T-cells|Three dose levels are being evaluated: 0.5 x 10^6, 1.0 x 10^6, 1.5 x 10^6
59246|NCT03721068|Drug|Cyclophosphamide|500 mg/m^2 IV dose on days 1-2 for lymphodepletion prior to cell infusion
59247|NCT03721068|Drug|Fludarabine|30 mg/m^2 IV dose on days 1-4 for lymphodepletion prior to cell infusion
59248|NCT03721055|Radiation|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
59249|NCT03721042|Device|olfactory measuring device|Patients blowing into bags then analysis by olfadiag system
59250|NCT03721029|Device|Intraoperative nerve monitoring,|Intraoperative nerve monitoring, via electromyography, enables real-time identification of the location of the somatic fibers in the pelvic nerves that seem crucial for urinary continence control and erectile function.
59251|NCT03721029|Procedure|standard of care robotic-assisted radical prostatectomy|With out the usage of intraoperative nerve monitoring
59252|NCT03721016|Drug|MT10109L|MT10109Lwill be injected into either the GL, LCL, or both.
59253|NCT03721016|Drug|Placebo|Placebo will be injected into either the GL, LCL, or both.
59254|NCT03721003|Device|ICP monitoring|"4- Use the Touhy needle to tunnel under the scalp from the Burr Hole site to the desired MICROSENSOR exit site.~5- Place the tip of the MICROSENSOR in the Parenchyma through the puncture in the Dura"
59255|NCT03720990|Drug|Cholic Acid|Participants will be treated with cholic acid for 8 weeks
59256|NCT03720951|Radiation|pudendal nerve|Fluoroscopic-guided pulsed R.F. to pudendal nerve bilaterally under image guidance
59257|NCT03720951|Radiation|sacral n roots|Fluoroscopic-guided pulsed R.F. to nerve roots S 2, 3, 4 bilaterally under image guidance
59258|NCT03720938|Other|Active Video Games|Nintendo Wii® AVGs from sports, balance, aerobics, resort and training categories.
59259|NCT03720925|Procedure|TDI treatment|The TDI treatment was performed according to its complexity. Uncomplicated TDI received minimally invasive treatment (simple restorations and clinical and radiographic follow-up). Complicated TDI received invasive treatment (more complex restorations, endodontic treatment, confection of aesthetic devices, restraints).
59260|NCT03720912|Behavioral|Online Learning Modules|The modules will include information about common family management skills: social support, problem solving, communication, and supportive behavior change strategies.
59261|NCT03720899|Drug|NicoBloc|For Session 1, participants will use one drop of NicoBloc (which will block 33% of tar and nicotine) on their conventional cigarette and then will smoke this cigarette in session. Following smoking, they will discuss the effects of the NicoBloc on their withdrawal, cravings, and overall enjoyment of their cigarette. To bolster their in vivo NicoBloc experience, participants will be provided with NicoBloc to use between sessions to acclimate to the NicoBloc and to make practice quit attempts (PQAs). Sessions 2 and 3 are similar to Session 1 except they will use more NicoBloc product during the session and will be instructed to use the product between sessions.
59262|NCT03720899|Drug|Nicotine Lozenge|Participants who receive nicotine lozenge (mini lozenge) will be given either a 2 or 4 mg lozenge to use in session, depending on how soon they smoke after waking. If a participant smokes within 30 minutes of waking, they start with the 4 mg lozenge; more than 30 minutes, they start with the 2 mg lozenge. They will be given lozenges between sessions to make PQAs.
59263|NCT03720886|Biological|rhPTH（1-34） 28.2μg|Administered by subcutaneous injection
59264|NCT03720886|Biological|rhPTH（1-34） 56.5μg|Administered by subcutaneous injection
59265|NCT03720886|Biological|teriparatide acetate(Teribone™)|Administered by subcutaneous injection
59266|NCT03720873|Drug|erlotinib or gefitinib or icotinib|Patients will be treated with erlotinib 150mgQD or gefitinib250mgQD or icotinib 125 mg TID
59267|NCT03720873|Drug|Anlotinib|Patients will be treated with Anlotinib 12mg po d1-14 Q21d
59268|NCT03720847|Drug|Estradiol Transdermal Patch 0.1 mg/24 hrs|Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation
59269|NCT03720847|Drug|Oral Micronized Progesterone|100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation
59270|NCT03720847|Drug|Inactive Clear Patch|Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation
59271|NCT03720847|Drug|Placebo capsule|Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
59272|NCT03720821|Behavioral|Cognitive Training + fMRI|"Consented subjects will be asked to participate in the study for up to five months. Patients will be consented at the Washington University Department of Anesthesiology and will be asked to complete baseline resilience, pain, and anxiety and depression questionnaires, along with cognitive tests by pencil and paper that will be administered by a member of the research team. The participants will also be required to complete a computer-based Trails-making test, Color Match test, and NCPT (Neurocognitive Performance Test) battery at baseline, and undergo a functional magnetic resonance imaging (fMRI) session.~All subjects will be asked to complete the three paper-pencil and computer-based measurements along with repeat pain questionnaire again 1-3 days after completion of training, undergo a second fMRI scan at that time, and complete the questionnaires again 3 months after the completion of training."
59336|NCT03720340|Drug|Recombinant Human Interleukin-11|Recombinant Human Interleukin-11 was administed through respiratory tract.
59337|NCT03720340|Drug|Saline|saline was administed through respiratory tract
104263|NCT03371589|Drug|Dexamethasone|Solution for otic injection
59273|NCT03720808|Other|Balloon Blowing|The parents of the children in this group were asked whether their children had the latex allergy or not and the children without the allergy were included in the group. The children's skills of blowing balloon were observed before the procedure. Before starting the venous blood sampling procedure, the children were asked to choose a balloon in the color they preferred and to start blowing the balloon at least 20 seconds before the procedure. Venous blood sampling started as the children exhaled to blow up the balloon. Until the venous blood procedure ended, they continued to blow up the balloons.
59274|NCT03720808|Other|Ball Squeezing|Before the venous blood collecting procedure, a soft ball was given to the right hands of the children and they were asked to squeeze and release this ball during the procedure.
59275|NCT03720808|Other|Coughing|The children included in this group were asked to cough after taking a deep breath during the venous blood sampling procedure. Before the procedure, the researcher showed the children how they should cough and asked them to imitate. The venous blood sampling was not performed until the child successfully completed coughing. The child was directed by the researcher during the procedure. Just before the entrance of the needle, the child was asked to take a deep breath and the venous blood sampling procedure was started during coughing.
59276|NCT03720808|Other|Control|No intervention was performed to reduce pain and fear in the control group.
59277|NCT03720795|Behavioral|Stepped Care CBT|"Stepped Care CBT is a multi-method, parent-led approach, consisting of two main steps. Step one involves a low-intensity delivery of CBT, consisting of more flexible, parent-led, at-home treatment. Participants who do not show improvement in symptom severity at the end of Step One, are then stepped up to receive Step Two. Step two involves a high intensity delivery of CBT, consisting of therapist-led, parent-assisted weekly treatment sessions."
59278|NCT03720782|Device|LEGION Porous HA Tibial Baseplate and/or the LEGION Porous HA CR Femoral Component|LEGION Porous HA Tibial Baseplate (with and without holes) and/or the LEGION Porous HA CR Femoral Component
59279|NCT03720769|Behavioral|Step-by-Step|Guided self-help programme delivered through an app/website for the treatment of depression
59280|NCT03720769|Behavioral|Enhanced care as usual|Psychoeducation and information about where to get help (i.e., mhGAP trained primary health care centres)
59281|NCT03720756|Other|Nickel-free diet|Subjects follow a nickel-free diet. Lists of acceptable foods will be provided to subjects.
59282|NCT03720743|Other|Biodanza|Intervention group received a total of 10 sessions, once a week, over the course of two months. Each session lasted 60 minutes. All sessions began with a 10-minute warm-up period combining music and low-intensity movements as a welcome round, followed individual exercises, in pairs and/or groups, which included dance combined with exercises based on the five lines of Biodanza (vitality, sexuality, creativity, affectivity and transcendence). Finally, a celebration and farewell round of 10 minutes was held. At the end of each session, the participants were asked to share their experiences with the rest of the group.
59283|NCT03720730|Other|EMA|"The mobile application (EMA) combines an explicit data collection with an implicit one.~For the explicit data collection with Memind application, patients will have to answer specific questionnaires about sleep, appetite and social factors. Some of the questions will be asked on regular basis, at the same time everyday, while others will be asked randomly during the day (between 9 a.m and 9 p.m).~The implicit data collecting will be carried out using smartphone sensors (application eB2)."
59284|NCT03720717|Drug|Baclofen 10mg|Baclofen administration pre-operatively
59285|NCT03720717|Other|Placebo|Placebo administration
59286|NCT03720704|Device|GORE VIABAHN VBX Balloon Expandable Endoprosthesis|GORE VIABAHN VBX Balloon Expandable Endoprosthesis will be implanted in peripheral vessels in patients who require interventional treatment.
59287|NCT03720691|Device|Real rTMS Supplementary motor area|There will be a series of four rTMS blocks separated by 10 minutes. Each block will consist of 15 to 25 pulse trains of 1-second duration at 25 Hz, with an intertrain interval of 10 seconds.
59288|NCT03720691|Device|Sham rTMS Supplementary motor area|There will be no real brain stimulation in Sham rTMS, and participant will be blinded.
59289|NCT03720678|Drug|AB928|AB928 is an A2aR and A2bR antagonist.
59290|NCT03720678|Drug|mFOLFOX|Oxaliplatin, Leucovorin and 5-fluorouracil given as part of standard mFOLFOX chemotherapy regimen
59292|NCT03720652|Behavioral|8-Week Mindful Self-Compassion (MSC)|"The 8-week MSC is a course of eight 2.5 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 8-session program that integrates SC and mindfulness.~It includes the following components:~Discovering Mindful Self-Compassion~Practicing Mindfulness~Practicing Lovingkindness~Discovering your Compassionate Voice~Living Deeply~Meeting Difficult Emotions~Exploring Challenging Relationships~Embracing Your Life"
59293|NCT03720652|Behavioral|6-Week Mindful Self-Compassion (MSC)|"The 6-week MSC is a course of six 1 hour weekly sessions that is based off self-compassion, a construct closely related to mindfulness. Self-compassion (SC) has three main interrelated components: self-kindness, common humanity, and mindfulness. MSC is an 6-session program that integrates SC and mindfulness.~It includes the following components:~What is Self-Compassion~Practicing Self-Compassion~Discovering your Compassionate Voice~Self-Compassion and Resilience~Self-Compassion and Burnout~Going Forward This program is a shortened version of the 8-week program, specifically created for the needs of health care staff."
59294|NCT03720639|Device|Abbott, Inc Confirm Rx™ versus Medtronic, Inc Reveal LINQTM|Comparing reliability and timeliness in data transmission between two implantable cardiac monitors.
59295|NCT03720626|Drug|crizanlizumab|IV formulation with 30 min infusion, 5mg/kg dosage
59296|NCT03720613|Drug|Naldemedine|0.2 mg tablet once a day at any time with or without food
59297|NCT03720613|Drug|Lubiprostone|0.024 mg twice a day [adjust dose based on liver function]
59298|NCT03720613|Drug|Naloxegol|25 mg tablet once a day in morning, 1 hour before or 2 hours after food
59435|NCT03719560|Drug|Methotrexate|Systemic methotrexate
59299|NCT03720600|Behavioral|MAB Intervention|The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, & Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
59300|NCT03720587|Other|Semi-structured interviews|Semi-struuctured telephone interviews
59301|NCT03720574|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
59302|NCT03720574|Drug|Matching Placebo BID|Matching Placebo tablet each morning and evening for a duration of 48 weeks
59303|NCT03720561|Drug|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 3 years.
59304|NCT03720548|Drug|LY3372993|Administered IV.
59305|NCT03720548|Drug|Placebo|Administered IV.
59306|NCT03720535|Device|Cordio Medical|App used for recording, no medical intervention in the patient regular care
59307|NCT03720522|Procedure|Short cardiovascular MRI (CMR)|A short CMR without additional contrast administration will be performed immediately after the routine brain MRI (at admission or after 24h).
59308|NCT03720522|Procedure|Adenosine-perfusion cardiovascular MRI (CMR)|An adenosine-perfusion CMR using contrast medium (gadolinium) will be performed in all patients (except group 1) between 48h and 6 days after admission.
59309|NCT03720522|Procedure|Blood draw|"The following study-specific parameters will be tested: neuropeptide Y 1-36, neuropeptide Y 3-36, total plasma metanephrines, metabolomics analysis~Time points for blood draw: at admission (routine), 3h (routine), 24h (routine), 48h, 72h and 3 months."
59310|NCT03720522|Procedure|Urine (collection over 24h)|"The following study-specific parameters will be tested: catecholamines.~Time points for collection: at 24h, 72h, and 3 months"
59311|NCT03720509|Device|Cordio Medical|All patients are recorded using the Cordio Medical app, no further intervention
59312|NCT03720496|Biological|CD19-TriCAR-T|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.1-1 x 10^6 CAR+ T cells/kg body weight.
59313|NCT03720483|Drug|N-acetyl cysteine then Placebo|Subject will receive N-acetyl cysteine first followed by Placebo
59314|NCT03720483|Drug|Placebo then N-acetyl cysteine|Subject will receive Placebo first followed by N-acetyl cysteine
59315|NCT03720470|Drug|PF-04965842 100 mg|"PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows:~In the arm PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~In the arm Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 subjects take PF-04965842 100 mg from Week 16 to Week 20."
59316|NCT03720470|Drug|PF-04965842 200 mg|"PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows:~In the arm PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg, PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20;~In the arm Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842 subjects take PF-04965842 200 mg from Week 16 to Week 20."
59317|NCT03720470|Drug|Dupilumab|Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.
59318|NCT03720470|Drug|Oral Placebo|"Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows:~In the arm Dupilumab Injection + Oral Placebo followed by Oral Placebo, the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20;~In the arms Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842 and Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842, subjects, take Oral Placebo from Day 1 until Week 16."
59319|NCT03720470|Drug|Injectable Placebo|Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
59320|NCT03720457|Drug|Human CD19 targeted T Cells Injection|Autologous genetically modified anti-CD19 CAR transduced T cells
59321|NCT03720444|Other|MDT (mechanical diagnosis and therapy) method|The intervention consists of a first session to carry out an assessment, followed by 4 reassessment sessions
59322|NCT03720431|Drug|TTAC-0001 and pembrolizumab combination|"Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~Treatment groups: 3 dose levels~Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~Cycle: 3 weeks (21 days per cycle)"
59323|NCT03720418|Drug|OXB-102|Neurosurgical delivery of OXB-102 (gene therapy) to the striatum
59324|NCT03720418|Other|Imitation Surgical Procedure (ISP)|Patients randomized to the control group in Part B will receive an ISP
59325|NCT03720392|Drug|FMT|FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
59326|NCT03720392|Drug|Placebo|a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
59327|NCT03720379|Device|Fluor Protector S|. All of the elements of a clinical trial and the varnish applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
59328|NCT03720379|Device|Placebo|All of the elements of a clinical trial and the placebo applications will be performed every three-month during one year: Changes in The Simplified Oral Hygiene Index (OHl-S), white spot carious lesion discovered at the initial assessment as invisible, visible and inactive, active, cavities), dmft and dmfs and their components, bite-wings and Diagnodent assessment will be scored at follow-up examinations.
59329|NCT03720366|Drug|enasidenib|enasidenib
59330|NCT03720366|Drug|Arm 1 probes|caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
59338|NCT03720327|Behavioral|Get FIT|The Get FIT arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; and one 45 minute behavioral counseling session to set personal goals and provide education by a health coach.
59339|NCT03720327|Behavioral|Get FIT+|The Get FIT+ arm includes use of a free commercially available smartphone application to track daily food intake for 3 months; use of a Fitbit activity tracker for 3 months; one 45 minute behavioral counseling session to set personal goals and provide education by a health coach; and personalized text messaging for 3 months by a health coach. The health coach will have access to these participants' daily food and activity data through the smartphone application, and will monitor progress and send push-only text messages to participants in this group based on the participant's goals and progress in the areas of physical activity, nutrition, and weight loss.
59340|NCT03720314|Other|NA observational study|observational study
59341|NCT03720301|Procedure|Osteopathic Manipulation Treatment|"All techniques with patient supine and physician at head of the bed:~Soft tissue massage to the posterior cervical musculature for approximately 1 minute~Muscle energy to the muscles of neck extension approximately 1 minute~Muscle energy to the Occipital Atlanto (OA) joint 1 minute~Muscle energy to the jaw. Approximately 1 minute~Occipital decompression approximately 1 minute~With time remaining complete another round of soft tissue massage.~Intraoperative techniques:~Myofascial Steering wheel Technique~Sibson's Fascia Release~Occipital decompression"
59342|NCT03720301|Procedure|Sham|"Sham protocol:~Patients randomized into the sham arm of the study will undergo a controlled trial tested sham treatment that was shown to induce no statistical improvement in cervical pain or mobility with zero adverse effects with the subjects unable to tell the difference between sham and actual protocol treatment."
59343|NCT03720288|Drug|Acetazolamide|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
59344|NCT03720288|Drug|Placebo|Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
59345|NCT03720275|Genetic|Systematic screening of TTR mutations|The diagnosis of TTR-FAP requires genetic analysis using direct sequencing of TTR gene.The diagnosis of TTR-FAP will be performed using standard procedures following international recommendations, requiring genetic analysis of the TTR gene.
59346|NCT03720262|Combination Product|Mesh reinforcement|Reinforcement of the abdominal wall with Ultrapro Advanced.
59347|NCT03720262|Other|No reinforcement|Suturing the abdominal wall without mesh reinforcement
59348|NCT03720249|Dietary Supplement|supplementation of compound nutrients|Betaine、 (6S)-5-methyltetrahydrofolic acid、vitamin B6、vitamin B12 and zinc per day orally for 12 weeks.
59349|NCT03720249|Dietary Supplement|placebo control|The placebo is an excipient and the color, flavor, shape, taste and weight are same with the tablet of supplement.
59350|NCT03720236|Procedure|Implant bed preparation protocol|This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
59351|NCT03720236|Procedure|Implant loading|This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
59352|NCT03720223|Drug|Liposomal Bupivacaine|20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)
59353|NCT03720210|Device|RFA|Radiofrequency ablation of a portion of thyroid parenchyma to treat amiodarone-induced thyrotoxicosis
59354|NCT03720197|Other|Online questionnaire - Phase 1|Draw an overall picture of the population with type 1 diabetes in Quebec in terms of demographics, diabetes treatment, hypoglycemia frequency and diabetes complications.
59355|NCT03720197|Other|Online questionnaire - Phase 2|Characterize the causes, experience and consequences of hypoglycemia.
59356|NCT03720197|Other|Online questionnaire - Phase 3|Collect information on diabetes and hypoglycemia treatment, hyperglycemia management, sleep habits, depression, physical activity and the benefits of technologies to reduce the frequency of hypoglycemia.
59357|NCT03720197|Other|Food questionnaire|24-hour food recall questionnaire
59358|NCT03720197|Other|Podometer|Participants will wear a podometer for 14 consecutives days
59359|NCT03720197|Other|Waist circumference|Participants will be asked to measure their waist circumference
59360|NCT03720197|Other|Blood and urine tests|Participants will be invited to send us their latests blood and urine test results.
59361|NCT03720197|Other|List of medications|Participants will be invited to send us their list of medications
59362|NCT03720184|Procedure|HAR|"HAR is a procedure that can be performed before the circuit is primed and deaired. The remaining volume in the reservoir as well as the venous line content are displaced to a collector bag that is connected to the oxygenator´s recirculation line.~When the arterial cannula is connected to the patient and the circuit, patient´s blood is used to reprime the arterial line to the oxygenator´s edge, via retrograde, displacing the crystalloid to the collector bag.~Once the arterial line is fully primed with blood, an amount of 300-400ml of patients blood is sequestered to the reservoir preserving a median arterial pressure of 60 mm Hg.~Finally, sequestered blood is used to reprime the arterial pump head and oxygenator-filter pushing the rest of the crystalloid to the collector bag, reducing haemodilution to 300ml.~CPB is established normally, using the vacuum assisted venous drainage not higher than -30 mmHg."
59363|NCT03720184|Device|Self-venting Technology|An oxygenator with self-venting technology is used
59364|NCT03720171|Device|e-OPRA Implant System|Implantation of e-OPRA Implant System in lower limb to be used with amputation limb prosthesis
59365|NCT03720158|Dietary Supplement|Omega 3 Group|Five mL of an Omega-3 highly concentrated substance (containing 2.25 g of EPA and 1.08 g of DHA) will be added daily to the standard enteral diet during the entire radiotherapy
59366|NCT03720158|Dietary Supplement|Placebo or Control Group|Five mL of pigmented and flavored corn oil will be added daily to the standard enteral diet during the entire radiotherapy treatment period (from 5-7 weeks)
59367|NCT03720145|Behavioral|Lifestyle Medicine|Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
59368|NCT03720132|Procedure|Extensive flushing of the port catheter|The port catheter will be flushed extensively with sodium chloride 0.9% before blood sampling. Blood sampling will occur through the central catheter and peripherally simultaneously.
59369|NCT03720119|Drug|Lidocaine Hydrochloride|As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.
59370|NCT03720106|Other|GOAL therapy plan|The GOAL algorithm designs a therapy plan based on the LIMOS assessment, patient goals and subject-specific treatment pathways. The adherence of this therapy plan is examined.
59371|NCT03720080|Device|OpenAPS|A self-constructed OpenAPS system will be worn contemporaneously to a Medtronic Minimed 670G hybrid closed loop system. Both systems will calculate recommended basal rate insulin adjustments but only the Minimed 670G system will inject insulin. The maximum treatment period will be 2 weeks per patient
59372|NCT03720067|Drug|Propranolol|40mg to 320mg / day
59373|NCT03720067|Drug|Carvedilol|6.25mg to 25mg / day
59374|NCT03720067|Drug|Rosuvastatin|20mg / day
59375|NCT03720067|Drug|Placebo|Placebo of rosuvastatin
59376|NCT03720054|Behavioral|MapTrek|Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.
59377|NCT03720054|Behavioral|Fitbit|Fitbit Only
59378|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm|"In the reactive arm at Randomisation 1, participants will receive IRD induction therapy with standard up-front dosing, with toxicity assessed at each cycle and doses adjusted in accordance with the guidelines given in the trial protocol. All participants will be given the following starting doses:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally~Lenalidomide: 25mg/day on days 1-21, taken orally~Dexamethasone: 40mg on days 1, 8, 15 and 22 for participants aged ≤75 years, or 20mg on days 1, 8, 15 and 22 for participants aged > 75 years; taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
59379|NCT03720041|Drug|R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm|"In the adaptive arm at Randomisation 1, participants will receive IRD induction therapy with up-front dose reductions adjusted according to their frailty score: fit, unfit, or frail. The starting doses for each frailty category are described below:~Fit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 25mg on days 1-21, taken orally Dexamethasone: 40mg on days 1, 8, 15 and 22, taken orally~Unfit category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 15mg on days 1-21, taken orally Dexamethasone: 20mg on days 1, 8, 15 and 22, taken orally~Frail category:~Ixazomib: 4mg/day on days 1, 8 and 15, taken orally Lenalidomide: 10mg on days 1-21, taken orally Dexamethasone: 10mg on days 1, 8, 15 and 22, taken orally~Participants will receive this dosing regimen for 12 cycles of induction treatment, in the absence of disease progression or unacceptable toxicity. Each cycle is 28 days."
59380|NCT03720041|Drug|R2: Lenalidomide plus placebo maintenance|"Participants randomised to receive lenalidomide plus placebo maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Placebo: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
59381|NCT03720041|Drug|R2: Lenalidomide + ixazomib maintenance|"Participants randomised to receive lenalidomide plus ixazomib maintenance at Randomisation 2 will receive the following starting doses:~Lenalidomide: 10mg*/day on days 1-21, taken orally Ixazomib: 4mg*/day on days 1, 8 and 15~* or final dose administered at the end of induction treatment if lower.~This dosing regimen is continued for every maintenance cycle. Participants will continue maintenance treatment until disease progression or intolerance/unacceptable toxicity. Each maintenance cycle is 28 days.~Randomisation 2 is double-blind - participants and their treating clinicians will be blinded to maintenance allocation."
59382|NCT03720028|Behavioral|Observation|Describe communication and sensory profile using standardized tests and observations.
59383|NCT03720028|Behavioral|Parental experiences|Survey parents' experiences with parent-child interaction and augmentative and alternative communication.
59384|NCT03720015|Behavioral|Physical exercise|Physical exercise controlled program supervised by an accredited exercise specialist
59385|NCT03720015|Dietary Supplement|Nutritional management|Nutritional management controlled by a PhD clinical and sport nutrition specialist
59386|NCT03720002|Dietary Supplement|HF2|placebo
59387|NCT03719989|Drug|azacitidine plus R-GDP|azacitidine S.C 25 mg/m2 D1,2,3,4,5 rituximab I.V. 375 mg/m2 D8 gemcitabine I.V. 1,000 mg/m2, D8,15 dexamethasone I.V. or P.O. 40 mg D8,9,10,11 every 21 days, up to 6 cycles
59388|NCT03719976|Other|Group-based educational intervention|The group-based educational intervention will use a bilingual Community Health Worker (CHW) who will teach parents key skills needed to access health care for children. Parents will be invited to attend 6 small, closed-group sessions held over 12 weeks and lasting no more than 75 minutes. Sessions will be interactive, culturally-appropriate, and held in parents' preferred language.
59389|NCT03719963|Device|Cochlear implant|Cochlear implant for hearing process by surgical intervention
59390|NCT03719937|Device|weight on the anterior chest of the patient|The investigators aim at assessing whether and to what extent an artificial increase in chest wall elastance, while the patient is in the supine position, may yield a significant benefit to oxygenation. The increase in chest wall elastance will be will be achieved placing a 100 g/kg weight on the anterior chest wall of the patient while he/she is in the supine/semirecumbant position. The weights will be placed on the patients' chest for 120 minutes, and then removed. A number of measurements will be recorded before and after the procedure.
59391|NCT03719924|Drug|Onivyde|onivyde will be administered first, followed by folinic acid or L-folinic acid and then 5-FU at D1 and D14.
59392|NCT03719924|Drug|Paclitaxel|Paclitaxel : 80 mg/m2 IV during 60 minutes at D1, D8 and D15
59393|NCT03719911|Behavioral|Live diabetes coaching program|Live diabetes coaching program
59394|NCT03719898|Drug|Brigatinib|Brigatininb is administered in tablet form. It is to be taken until disease progression, unacceptable toxicity or completion of 24 cycles. patients may continue to take brigatininb beyond 24 cycles if they are benefiting from the drug
59395|NCT03719885|Device|TrueTear Intranasal Tear Neurostimulator|This study will evaluate the immediate tear production resulting from use of intranasal tear neurostimulation in patients with Sjogren's disease
59436|NCT03719560|Drug|Cytarabine|Systemic cytarabine
59396|NCT03719872|Diagnostic Test|Pre-Operative Transabdominal Ultrasound|Pre-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
59397|NCT03719872|Diagnostic Test|Post-Operative Transabdominal Ultrasound|Post-Operative Transabdominal Ultrasound evaluation of the right upper quadrant of the abdomen. Examination with be performed with low frequency curvilinear transducer and high frequency linear transducer at 5 standardized locations along the right costal margin followed by a 10 second sweep along the costal margin from the xyphoid process to the mid-axillary line
59398|NCT03719859|Other|Physical Therapy|"Subjects who will participate in the physical therapy intervention group will attend therapy 4-6 days after discharge from the hospital, and continue in therapy approximately once a week for three months. The physical therapy progression will follow the standard of care developed at Duke Sports Medicine Physical Therapy for rehabilitation following RSA. Some of the patients in the PT intervention cohort may have physical therapy at an institution outside of Midwest Orthopaedics at Rush. All patients, whether in the Rush system or outside, will be given a prescription with the identical instructions for physical therapy, status post (R/L) reverse total shoulder arthroplasty, 1-2 x per week x 12 weeks."
59399|NCT03719859|Other|Home Therapy|The surgeon/Nurse Practitioner/Physician Assistant will advance rehabilitation exercises and activity guidelines at customary scheduled postoperative appointments for this surgical procedure: 2 weeks (+/- 5 days), 6 weeks (+/- 1 week), 3 months and 6 months (+/- 1 month), and 1 and 2 years (+/- 2 months).
59400|NCT03719820|Drug|aggressive medical management|Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg daily) for at least 6 months as well as traditional risk factors management
59401|NCT03719807|Other|Rehabilitation protocol|A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
59402|NCT03719807|Other|Usual Care|No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
59403|NCT03719794|Dietary Supplement|Probiotic supplement|Probiotic supplement once daily (xyz) for 12 weeks
59404|NCT03719794|Dietary Supplement|Placebo supplement|Placebo supplement once daily for 12 weeks
59405|NCT03719781|Diagnostic Test|standardized minimental testing|To diagnose postoperative cognitive dysfunction
59406|NCT03719768|Drug|Avelumab|Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.
59407|NCT03719768|Radiation|Whole Brain Radiotherapy|Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks
59408|NCT03719755|Procedure|50% dextrose|maximum injection of 40 cc of 50% dextrose plus 300 cc of normal saline washout versus normal saline after hysterectomy for benign indications.
59409|NCT03719755|Procedure|Normal Saline|Cystoscopic distention media of normal saline
59410|NCT03719742|Other|Sponsor Test Products|Baby Bee Foaming Cleanser(at least once daily but not more than twice daily), BB Baby Ultra Gentle Lotion (Once immediately after cleansing and again approximately 10-12 hours after cleansing)
59411|NCT03719729|Drug|Rifaximin|Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.
59412|NCT03719716|Other|Anticipatory care planning letter|Patient letter to take to GP and GP literature
59413|NCT03719690|Drug|Tipifarnib|Tablet for oral administration
59414|NCT03719690|Device|HRAS Detection Assay|In Vitro Assay to detect HRAS mutations
59415|NCT03719677|Behavioral|Habit development intervention|Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning
59416|NCT03719664|Drug|Albuvirtide|Intravenous infusion of Albuvirtide
59417|NCT03719664|Drug|3BNC117|Intravenous infusion of 3BNC117
59418|NCT03719664|Drug|Baseline ART|Subjects continuing on baseline ART
59419|NCT03719651|Behavioral|LOCI|LOCI includes training of leaders in general leadership, implementation leadership, and implementation climate.
59420|NCT03719651|Behavioral|EMDR|EMDR (Eye Movement and Desensitization Reprocessing), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
59421|NCT03719651|Behavioral|CT-PTSD|CT-PTSD (Cognitive Therapy for PTSD), treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
59422|NCT03719651|Behavioral|TF-CBT|TF-CBT (Trauma-Focused Cognitive-Behavioral Treatment) treatment method developed for treating patients with Post-Traumatic Stress Symptoms (PTSD).
59423|NCT03719638|Device|D-blade of videolaryngoscope|intubation will be done using d-blade of videolaryngoscope
59424|NCT03719638|Other|simulated difficult airway|extension of head will be limited by using collar.
59425|NCT03719638|Device|Macintosh videolaryngoscope|intubation will be done using macintosh videolaryngoscope
59426|NCT03719625|Drug|Ephedrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
59427|NCT03719625|Drug|Norepinephrine|Comparaison of Norepinephrin and Ephedrin for prevention of the post spinal anesthesia in cesarean section
59428|NCT03719612|Drug|DEFINITY®|All subjects will receive a single dose of DEFINITY®
59429|NCT03719612|Diagnostic Test|Ultrasound|All subjects will undergo an unenhanced and DEFINITY®-enhanced ultrasound.
59430|NCT03719586|Drug|ZMapp|Three doses of 50 mg/kg of body weight administered intravenously every third day beginning on Day 1
59431|NCT03719586|Drug|Remdesivir|Administered intravenously with a loading dose on Day 1 (200 mg for adults and pediatric patients with body weight >= 40 kg and for pediatric patients weighing < 40 kg one loading dose of remdesivir 5 mg/kg) followed by 9 to 13 days of once-daily maintenance dosing starting on Day 2 and extending through Day 10 to 14 (100 mg for adults and pediatric patients with body weight >= 40 kg and for pediatric patients weighing < 40 kg remdesivir 2.5 mg/kg)
59432|NCT03719586|Drug|MAb114|50 mg/kg of body weight administered intravenously on Day 1 as a single infusion
59433|NCT03719586|Drug|REGN-EB3|150 mg/kg of body weight administered intravenously on Day 1 as a single infusion
59434|NCT03719573|Other|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
59437|NCT03719547|Procedure|Abdominal radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu&Morrow classification) with pelvic lymphadenectomy
59438|NCT03719547|Procedure|Robot-assisted radical hysterectomy|Radical hysterectomy (type B or C according to the Querleu&Morrow classification) with pelvic lymphadenectomy
59439|NCT03719547|Diagnostic Test|Sentinel lymph node biopsy|Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
59440|NCT03719534|Procedure|haplo-SCT|SCT will be performed with a haplo-identical donor
59441|NCT03719534|Procedure|haplo-cord SCT|Haplo-identical donor SCT will be performed with co-infusion of unrelated cord blood unit
59442|NCT03719521|Other|Community-based package of integrated HIV, SRH and general health services|HIV Testing and Counselling, SRH and HIV prevention Services and General Health Counselling for all 16-24 year olds and ART initiation and ongoing treatment and adherence support for those who test HIV positive
59443|NCT03719482|Drug|[18F]MNI-1054|Healthy Volunteers recruited for the study will undergo a single [18F]MNI-1054 injection and PET scan.
59444|NCT03719469|Dietary Supplement|Green tea group|
59445|NCT03719456|Procedure|Retrograde Intrarenal Surgery|
59446|NCT03719443|Biological|VIS649|Single IV dose of study product on Day 1 of study
59447|NCT03719443|Biological|Placebo|Singe IV dose of placebo administered via IV on Day 1 of study
59448|NCT03719430|Drug|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity 75 mg/m2 IV day 1 (21 day cycles)
59449|NCT03719430|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
59450|NCT03719417|Procedure|Unicompartmental Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery.
59451|NCT03719417|Procedure|Extensive Biologic Arthroplasty|Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently
59452|NCT03719404|Procedure|sodium hypochlorite|sodium hypochlorite is used as primary irrigant and edta is used as secondary irrigant in endodontic retreatment cases
59453|NCT03719404|Procedure|chlorhexidine|Chlorhexidine is used as primary irrigant and citric acid is used as secondary irrigant in endodontic retreatment cases
59454|NCT03719391|Device|Virginia Tobacco flavored JUUL 5% ENDS|Treatment with Virginia Tobacco flavored JUUL 5% ENDS (10 puffs).
59455|NCT03719391|Device|Cool Mint flavored JUUL 5% ENDS|Treatment with Cool Mint flavored JUUL 5% ENDS (10 puffs).
59456|NCT03719391|Device|Mango flavored JUUL 5% ENDS|Treatment with Mango flavored JUUL 5% ENDS (10 puffs).
59457|NCT03719391|Device|Creme Brulee flavored JUUL 5% ENDS|Treatment with Creme Brulee flavored JUUL 5% ENDS (10 puffs).
59458|NCT03719391|Device|VUSE Solo e-cigarette|Treatment with VUSE Solo Original with 4.8% nicotine e-cigarette (10 puffs).
59459|NCT03719391|Other|Nicorette White Ice Mint 4mg nicotine polacrilex gum|Treatment with Nicorette White Ice Mint 4mg Nicotine polacrilex gum (30 minutes Chew and Park method)
59460|NCT03719391|Device|Usual Brand combustible cigarette|Treatment with usual brand cigarette (10 puffs).
59461|NCT03719378|Other|Pre Operative Oral Fluids|Patients will be self hydrating prior to their total knee replacement.
59462|NCT03719365|Device|NAVAPSV|During the first trial, PSV will be set in order to obtain a Vt between 6 and 8 ml/kg; this support level will be defined as PSV100. Subsequently, the corresponding NAVA level (NAVA 100) will be determined using a dedicated ventilator function (NAVA Preview) which is able to estimate NAVA level in order to deliver an equivalent inspiratory peak pressure (Paw peak) compared to that obtained during PSV mode. Afterwards, PSV100 and NAVA100 will be first increased (PSV150 and NAVA150) during the second trial and then decreased during the third trial (PSV50 and NAVA150) by 50% from basal value. During the study period, PEEP and FiO2 will be kept equal to the values in use before patient enrollment.
59463|NCT03719352|Procedure|Experimental: Deep dry needling|Deep dry needling until achieving twitch response of the muscle
59464|NCT03719352|Procedure|Experimental: Superficial dry needling|Superficial dry needling to achieve sensitive pain with needle rotation
59465|NCT03719352|Procedure|Placebo Comparator: Placebo Gastrocnemius dry needling|Simulate pain with de plastic needle guard in the gastrocnemius muscle
59466|NCT03719326|Drug|AB928|AB928 is an A2aR and A2bR antagonist
59467|NCT03719326|Drug|IPI-549|IPI-549 is a phosphoinositide-3kinase-gamma inhibitor
59468|NCT03719326|Drug|Pegylated liposomal doxorubicin (PLD)|Doxil is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use
59469|NCT03719326|Drug|nanoparticle albumin-bound paclitaxel (NP)|NP is a microtubule inhibitor
59475|NCT03719300|Drug|inodiftagene vixteplasmid|"BC-819 at 20 mg/50 mL, instilled intravesically into the bladder, with a retention time of at least 30 minutes (up to 2 hours).~Induction Phase (weekly treatments): 10 weekly treatments; Maintenance Phase: treatment every 3 weeks for up to 84 additional weeks"
59476|NCT03719274|Dietary Supplement|vitamin c depigementation|locally injected vitamin c depigementation
59477|NCT03719261|Drug|chitosan nanoparticles|Chitosan is a bioactive polymer obtained from deacetylation of chitin and is used in biomedical application due to its antimicrobial properties and biocompatibility and ability to resist aging for longer periods provide antibacterial effect in root canal disinfection.10ml of cs-np will be used during instrumentation in intervention group
59478|NCT03719261|Drug|Sodium Hypochlorite|Sodium hypochlorite (NaOCL) is the most recommended irrigant due to its broad antibacterial effect, necrotic tissues and dentin collagen dissolving capability and inactivation of endotoxins.10ml of 2.5%NaOCL will be used during instrumentation in control group
59479|NCT03719248|Device|thoracic epidural|high thoracic epidural anesthesia (HTEA) combined with GA, transesophageal, transthoracic echocardiography and Holter ECG
59480|NCT03719235|Other|CBCT|ultra-low dose CBCT
59481|NCT03719222|Other|non intervention|It is an non-interventional retrospective observational study by using archived paraffin-embedded tumor specimens
59677|NCT03717688|Drug|Entresto|Single dose administration of Entrestro 194 mg sacubitril / 206 mg valstartan
59482|NCT03719209|Other|HealthVoyager|HealthVoyager is a virtual reality application that allows providers to create customized representations for patients and share the results of endoscopic procedures via an interactive platform. The app can show both normal and abnormal endoscopic findings and anatomy. Families will also receive a web link so that they may access the procedure results via the app at home on their smartphone or tablet.
59483|NCT03719209|Other|Standard Practice|Patients and families will receive handouts with printed images of their endoscopic findings, as per standard practice at Boston Children's Hospital.
59484|NCT03719196|Other|Reading glass|Participants from the experimental group have received reading glasses free of cost. Investigators hypothesize that a simple pair of eyeglasses could improve the lives of these people by enabling continued participation in the workforce, restoring productivity levels in both paid and unpaid work, and enhancing the ability to perform everyday tasks. Investigators also hypothesize that reading glasses will improve quality of life.
59485|NCT03719183|Diagnostic Test|Conventional Cytogenetics Studies|Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
59486|NCT03719183|Diagnostic Test|Fluorescent in Situ Hybridization (FISH) Panels|"AML Panel includes:~t(8;21) (RUNX1-RUNX1T1).~inv(16), t(16;16) (CBFB-MYH11).~t(9;22) (BCR-ABL).~11q23 KMT2A rearrangements.~inv(3) MECOM rearrangements.~NUP214 rearrangements.~Acute Promyelocytic Leukemia panel includes:~t(15;17) (PML-RARA).~17q RARA rearrangements~CML Panel includes:~t(9;22) (BCR-ABL).~Isochromosome (17) by FISH."
59487|NCT03719170|Behavioral|PPI De-prescribing Program|The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
59488|NCT03719157|Procedure|Unilateral ESP Block|USG guided ESP block will perform unilateral with Bupivacaine and Lidocain mixture
59489|NCT03719157|Procedure|Unilateral OSTAP Block|USG guided OSTAP block will perform unilateral with Bupivacaine and Lidocain mixture
59490|NCT03719157|Procedure|Injection of Local Anesthetic to Trocar Insertion|Bupivacaine infiltration will be performed at the end of the surgical procedure to trocar insertion sites.
59491|NCT03719157|Drug|intravenous patient controlled analgesia|All patients were followed using a standardized postoperative analgesia protocol which includes tramadol PCA. Tramadol at a concentration of 5 mg/mL is included in our PCA protocol (total volume 100 mL.) PCAs were set to no basal infusion and 10 mg bolus doses with a 20 min lock time.
59492|NCT03719131|Drug|Nivolumab|Receive standard of care nivolumab therapy
59493|NCT03719131|Biological|Rituximab and Hyaluronidase Human|Given IV or SC
59494|NCT03719131|Drug|Ipilimumab|Receive standard of care ipilimumab therapy
59495|NCT03719118|Genetic|genotyping for three genes (TPMT, NUDT15 and FTO)|Patients who carry any heterozygotic variants receive 50 mg AZA or 25 mg 6-mercaptopurine (6-MP), while those who have any homozygotic variants are recommended to take other alternative drugs instead of thiopurines
59496|NCT03719118|Other|non-genotyping|Patients receive standard doses of thiopurines based on the conventional regimen without pretreatment genotyping. Conventional regimen starts with 50 mg of AZA, then the dose is increased by 25 mg in every 1-2 weeks to 2.0-2.5 mg/kg along with regular monitoring of general blood tests including WBC counts.
59497|NCT03719105|Drug|Methotrexate|Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
59498|NCT03719105|Drug|pralatraxate,|Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59499|NCT03719105|Drug|Ifosfamide|Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59500|NCT03719105|Drug|Dexamethasone|Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59501|NCT03719105|Drug|Etoposide|Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59502|NCT03719105|Drug|Pegaspargase|Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59503|NCT03719105|Drug|cyclophosphamide|Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59504|NCT03719105|Drug|Doxorubicin|Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59505|NCT03719105|Drug|Prednisone|Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59506|NCT03719105|Drug|Brentuximab Vedotin|Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
59507|NCT03719092|Dietary Supplement|Vitamin A Compound|Given PO or enterally
59508|NCT03719079|Device|SimpleSENSE|The Nanosense study is observational only. No interventions will be triggered by the SimpleSense device
59509|NCT03719066|Biological|killed whole cell oral cholera vaccine|two week interval
59510|NCT03719053|Drug|Tenofovir|pre- and post-dosing measurements of TFV and TFV-DP in plasma and PBMCs.
59511|NCT03719040|Device|His bundle pacing (HBP) device implant|"Patients with cardiac disease may exhibit symptoms associated with electrical conduction abnormalities requiring implantation of a permanent cardiac pacing device. However, pacing is often associated with alteration of the normal electrical conduction system.~An alternative and potentially more physiologic pacing strategy for patients with electrical conduction abnormalities is HBP - this is achieved by delivering pacing stimuli at the His bundle region with a permanent lead. HBP activates the heart through the native His-Purkinje conduction system, thus offering the most physiologic pacing approach to correct electrical dyssynchrony."
59512|NCT03719027|Diagnostic Test|Study population|Dyspnea assessment (NYHA functional class) EKG Echocardiography
59513|NCT03719014|Device|NovaCross|The NovaCross micro-catheter will be used during a standard of care Percutanous Coronary Intervention (PCI) on subjects diagnosed with at least one coronary chronic total occlusion (CTO), in order to assist the operator in guidewire stability and centralization.
59678|NCT03717688|Drug|Sitagliptin 100mg|2 x 100mg sitagliptin as single dose.
59514|NCT03719001|Drug|Phenylephrine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure
59515|NCT03719001|Drug|Dexmedetomidine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
59516|NCT03719001|Drug|Clevidipine|blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca
59517|NCT03719001|Other|tetanic stimulus|A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)
59518|NCT03719001|Other|Increased venous pressure|A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.
59519|NCT03719001|Drug|Calcium Chloride|CaCl will be administered to increase blood pressure and plasma calcium concentration
59520|NCT03718988|Behavioral|Meat products|Traditional meat products (beef burger patties, pork sausage, etc.)
59521|NCT03718988|Behavioral|Plant Alternative products|Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
59522|NCT03718975|Device|Successor of Phonak Audéo B90|Successor of the most recent Receiver in the canal (RIC) Hearing aid form Phonak which will be fitted to the participants individual Hearing loss.
59523|NCT03718975|Device|Phonak Audéo B90|The Phonak Audéo B90 is the most recent Receiver-in-the-canal Hearing aid from Phonak which will be fitted to the participants individual Hearing loss.
59524|NCT03718962|Device|accupuncture|needling
59525|NCT03718897|Diagnostic Test|Endoscopic retrograde cholangiopancreatogram|Biopsy specimens are attained via endoscopic retrograde cholangiopancreatogram in patients with suspicious biliary tract cancer.
59526|NCT03718884|Drug|Drug Cocktail|Drug cocktail consists of caffeine, warfarin plus vitamin K, omeprazole, dextromethorphan, and midazolam, administered orally
59527|NCT03718884|Drug|Mirikizumab|Administered SC
59528|NCT03718871|Behavioral|HIV testing at traditional healer practices|HIV 1/2 antigen-antibody POC test (Alere Determine©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for Western Blot confirmation, and linkage to care.
59529|NCT03718858|Procedure|Interscalene Block|15 mL ropivacaine 0.5% will be injected in 5 mL aliquots in order to achieve spread adjacent to C5 and C6 nerve roots.
59530|NCT03718858|Procedure|Placebo Block|0.5 ml of 1% lidocaine will be administered subcutaneously as a placebo injection.
59531|NCT03718845|Behavioral|Mind-Body Medicine Curriculum|The Mind-Body Medicine curriculum consists of presentations on different mind-body techniques as well as the research supporting the use of these techniques.The mind-body technique is then practiced in a supportive small group setting. Mind-body techniques will include guided imagery, relaxation techniques, several forms of meditation, autogenic training and biofeedback.
59532|NCT03718832|Other|Fresh Food Farmacy|Patients are prescribed fresh food by a dietician, fill the prescription each week at the FFF clinic, receive training on how to use the food, and training in diabetes self management.
59533|NCT03718819|Other|exercise|Pilates and aquaplyometric exercises will be done combinedly.
59534|NCT03718806|Drug|Zoliflodacin|oral suspension; oral administration
59535|NCT03718806|Other|high calorie, high fat breakfast|fasted/fed conditions
59536|NCT03718793|Diagnostic Test|Peripheral exhaled nitric oxide|Small airway inflammation and dysfunction will be measured using the above mentioned tests.
59537|NCT03718780|Other|simultaneous determination of PaCO2 and PtCO2|"Patients in intensive care, equipped, for their routine clinical management, with an arterial catheter blood line, will have a simultaneous determination of PaCO2 and PtCO2:~1) at rest; 2 arterial CO2/PtCO2 determinations will be carried out, 10 minutes apart~2) During the muscular exercise part of their routine rehabilitation program (whatever it might be, limbs active mobilization, walking, etc...) : several arterial /PtCO2 samples will be collected during the first minutes of their muscular routine: 30 sec, 1 minute, 1 ½ minute, 2, 2 ½ , 3, 4, 5 minutes, 10 minutes (end of exercise). This will generate several couples of blood/transcutaneous CO2 determinations"
59538|NCT03718780|Other|Hyperventilation test|Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest (0), then 30 sec post beginning of hyperventilation (breathing with accelerated frequency e.g. 30/min), 1 minute, 1 ½ minute 2, 2 ½ , 3, , 4, 5 minutes; recovery of this hyperventilation will be followed, for 5 minutes, with the PtCO2, during 3 minutes
59539|NCT03718780|Other|Exercise test|an exercise test, according to the routine protocol used in the clinic: initial phase of 3 minutes gentle pedaling (10 to 50 watts, according to subject capabilities), then stepwise increase in the workload, by increments of 20-40 watts every minute, until maximum tolerated workload (VO2max). Repeated pairs of PtCO2 and PaCO2 (through arterialized capillary sampling), will be measured at the following timing: rest -10 minutes, 0, then 30 sec post beginning of exercise, 1 minute, 1 ½ minute 2, 2 ½, 3 minutes, then 3 ½ minutes, then at mid-point of every step increase in workload, until maximum tolerated workload. Recovery will be followed with the PtCO2, for 5 minutes
59541|NCT03718754|Device|En-Bloc TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. Laser resection, hydrodissection with HybridKnife® or electric resection are allowed. All procedures, including cTURB, must be performed with an imaging enhancing technique (PDD / NBI at surgeon's discretion). After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
59542|NCT03718754|Device|Conventional TURB|En-bloc resection will be performed at each center based on local clinical practice and available instruments. After resection, a single intravesical instillation of 40mg Mitomycin-C will be performed if clinically feasible.
59543|NCT03718741|Radiation|Radiotherapy +/- CT|Adiuvant Radiotherapy +/- weekly cisplatin
59544|NCT03718728|Behavioral|Mind&Life|Acceptance and mindfulness-based group intervention program.
59545|NCT03718728|Behavioral|Standard|Personalized diet and physical exercise recommendations.
59546|NCT03718715|Drug|Metformin|Receiving Metformin is no study intervention. The investigators have no influence on the Metformin treatment. All participants receive Metformin provided by the health care system. The individual case determine dose and frequency of the treatment as part of the usual therapy guidelines.
59547|NCT03718702|Other|ePain|Electronic pain management programme (ePain)
59548|NCT03718689|Device|Laser etching|Acid etching
59549|NCT03718676|Procedure|Ferric sulphate|Teeth were pulpotomized with ferric sulphate in this group.
59550|NCT03718676|Procedure|Ortho-MTA|Teeth were pulpotomized with Ortho-MTA in this group.
59551|NCT03718676|Procedure|Retro-MTA|Teeth were pulpotomized with Retro-MTA in this group.
59552|NCT03718663|Other|Physiotherapy-guided Evidence-based Exercise Therapy|Standardized supervised exercise therapy for 6-8 weeks (two times per week).
59553|NCT03718663|Other|Part 2: Military training|Part 2: standardized military training for 6-8 weeks in Defence Command Denmark
59556|NCT03718637|Biological|Smith & Nephew Bioinductive Implant|A bioinductive implant that is supposed to foster healthy tendon regrowth after surgery.
59557|NCT03718637|Procedure|Lateral Epicondylectomy|This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.
59558|NCT03718637|Radiation|Ultrasound Imaging|An ultrasound will be performed on each patient both preoperatively and at 6 months.
59559|NCT03718624|Drug|apatinib|apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.
59560|NCT03718624|Drug|paclitaxel|Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.
59561|NCT03718624|Drug|S-1|S-1： According to the body surface area, BSA <1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.
59562|NCT03718611|Drug|BR9001|BR9001 is a test drug as generic
59563|NCT03718611|Drug|BR900A|BR900A is a reference drug
59564|NCT03718598|Behavioral|Tendon and Nerve Gliding Exercises|Tendon and Nerve Gliding Exercises: The tendon slip exercises used in this study were performed in five different positions, namely flexion, flat, hook, punch, table top and flat punch positions. Nerve-gliding exercises were performed by moving the fingers and wrists in six different positions, focusing on the median nerve consisting of all the disease grip, finger lengthening, wrist extension, thumb extension, forearm supination and gentle gentle gait. Instructions were given to make 10 sets of exercises in 3 sets, written and verbal, in order to have e exercises for all patient's tendons and nerves shifting exercises. Brochures were also provided explaining the exercises.
59565|NCT03718585|Other|whole exome sequencing analysis|Collecting peripheral blood samples (2 ml) from subjects for whole exome sequencing
59566|NCT03718572|Procedure|Laparoscopic cholecystectomy|Surgical removal of Gall bladder using laparoscopy
59567|NCT03718559|Drug|Edoxaban|Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
59568|NCT03718559|Drug|Single Antiplatelet Agents|Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily is recommended.
59569|NCT03718533|Drug|Eltrombopag|50mg Film-coated tablet and 25mg Film-coated tablet for oral use administration
59570|NCT03718520|Other|no intervention, this is a purely observational study|No intervention
59571|NCT03718507|Drug|Fentanyl|atropine (0.01-0.02 mg/kg i.v. bolus) and fentanyl (0.5-2 mcg/kg i.v. in 5 minutes)
59572|NCT03718507|Drug|Sucrose 24% Oral Solution|0.5 ml given orally 2 minutes before LISA procedure
59573|NCT03718494|Combination Product|F-18 AV-1451 PET|Participants will receive an intravenous bolus injection of approximately 370 MBq (10 mCi) of 18F- AV-1451. PET/CT image acquisition will include a low dose CT and then a 20-minute PET acquisition starting at 80 minutes after injection of 18F-T807 and will be performed as 4, 5-minute frames that will then be summed into one static frame. Serial frames will allow for adjustment in the case of patient motion.
59574|NCT03718494|Combination Product|F-18 Florbetapir|Each participant will be injected with 10 mCi of 18F-Florbetapir (target dose 370 MBq, range 296 - 444 MBq). After a 25-minute uptake period, the patient will be positioned on the scanner bed with instructions to remain motionless. A helical CT image will be obtained at 50 minutes after injection of 18F-Florbetapir, followed by a 10-minute PET acquisition consisting of two 5-minute dynamic frames.
59575|NCT03718481|Other|ARCP Process|One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training [1]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
59576|NCT03718468|Biological|GC FLU Quadrivalent|A single dose administration of GC FLU Quadrivalent will be through intramuscular injection.
59577|NCT03718468|Biological|Fluarix Tetra|A single dose administration of Fluarix Tetra will be through intramuscular injection.
59578|NCT03718455|Device|Axillary Magseed|The Magseed will replace the investigators' current clinical practice of using radioactive seeds in women receiving neoadjuvant chemotherapy.
59638|NCT03718013|Device|accelerated deep TMS|subjects treated with deep TMS twice a day (6-8 hours between two applications), during 2 weeks
59639|NCT03718013|Device|standard deep TMS|standard deep TMS treatment: once a day, during 4 weeks
59673|NCT03717714|Dietary Supplement|Polycan 50mg + Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
59579|NCT03718442|Device|PhotonBlade vs Bovie for lumpectomy shaved surgical margins|For each enrolled patient, six shaved margins will be obtained (superior, inferior, medial, lateral, anterior, and posterior). For each patient, electrocautery will be used to obtain 3 of the shaved margins, and PhotonBlade to obtain the other 3 shaved margins. Once the lumpectomy site shaved margins have been obtained, the shaved surgical margins will be evaluated by a pathologist whom is blinded in regards to the dissection device that was used for each margin. The pathologist will be evaluating each shaved margin and reporting the outcomes (qualitative severity and depth of thermal artifact)
59580|NCT03718429|Drug|Rivaroxaban 2.5Mg Tablet|PD assessments will be conducted at 3 time points: i) baseline (while on standard of care antiplatelet therapy), ii) 7-10 days after adjunctive treatment with low dose rivaroxaban, and iii) 7-10 days after dropping aspirin.
59581|NCT03718403|Drug|Theophylline|Theophylline will be given to maintain a peak level between 10-15 mcg/mL
59582|NCT03718390|Drug|Formulation A|Formulation A (37/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
59583|NCT03718390|Drug|Formulation B|Formulation B (46/40A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
59584|NCT03718390|Drug|Formulation C|Formulation C (37/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
59585|NCT03718390|Drug|Formulation D|Formulation D (46/50A) of LYN-PLT containing less than 300 mg sucrose within the extended release formulation
59586|NCT03718390|Drug|Formulation E|Placebo Capsule containing microcrystalline cellulose
59587|NCT03718390|Procedure|Endoscopy|Endoscopy at 2 hours post dosing
59588|NCT03718390|Procedure|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
59589|NCT03718377|Procedure|Serratus plane block|The subjects were received serratus plane block in the regional-anesthesia unit out of operation room before induction of general anesthesia. And, video-assisted thoracic surgery was performed under balanced general anesthesia.
59590|NCT03718377|Procedure|General anesthesia only|Video-assisted thoracic surgery was performed under balanced general anesthesia without serratus plane block
59591|NCT03718364|Procedure|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)|catheter-based ablation of atrial fibrillation (pulmonary vein isolation)
59592|NCT03718351|Procedure|transanal endoscopic microsurgery|a TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
59593|NCT03718351|Procedure|endoscopic submucosal dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
59594|NCT03718338|Procedure|Evaluation|Undergo clinical evaluations
59595|NCT03718338|Other|Quality-of-Life Assessment|Ancillary studies
59596|NCT03718325|Device|Burst-SCS|The treatment arm used in the study is clinically-effective burst spinal cord stimulation (Burst-SCS). The device used to deliver Burst-SCS is the St. Jude Medical Invisible Trial System.
59597|NCT03718325|Device|Sham SCS|The placebo control arm used in the study is sham spinal cord stimulation (sham SCS). The device used to deliver sham SCS is the St. Jude Medical Invisible Trial System.
59598|NCT03718312|Procedure|clamping with pre-conditioning (PCl)|"PCI procedure: clamping of the supracellular thoracic aorta for 5 minutes followed by a 5-minutes de-clamping period.~PCI procedure is repeated twice."
59599|NCT03718299|Drug|Injections of tildrakizumab|given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52
59600|NCT03718286|Drug|Alirocumab|150 mg alirocumab administered prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
59601|NCT03718286|Other|Sham Control|Sham injection prior to revascularization procedure, 2 weeks post-procedure and 4 weeks post-procedure.
59602|NCT03718273|Drug|Ivabradine|"Ivabradine 5 mg, twice a day the first month administered by mouth. If the tolerance is good, the dose will be increased to 7.5 mg on month 2 and will continue until the third month.~Patients with 75 or more years of age will receive an initial dose of 2.5 mg / twice a day, which can be increased to 5 mg / twice a day in week 7 and to 7.5 mg in month 1 if the tolerance has been good"
59603|NCT03718273|Drug|Digoxin|The initial dose will be based on whether there are factors such as age over 80 years, weight less than 60 kg and creatinine clearance <60ml / min, if there is no factor, the oral dose will be 0.25mg / 24h. If there are 2 factors, the dose will be 0.15 mg / 24 h. and if there are 2 or 3 factors, the dose will be 0.10 mg / 24 h.
59604|NCT03718260|Diagnostic Test|[18F]-DCFPyL PET/ CT scan (PSMA PET)|Participants will undergo re-staging with [18F]-DCFPyL PET/CT Scan (PSMA PET).
59605|NCT03718247|Other|Modified Atkins diet|High fat low carbohydrate diet.
59606|NCT03718234|Drug|Subcutaneous hydrocortisone|Patients will be monitored and receive an interval bolus SQHC dosing regimen that more closely mimics cortisol, 17OHP and D4A circadian and ultradian rhythms than conventional oral HC dosing.
59607|NCT03718234|Drug|Standard glucocorticoid therapy|Subjects in this arm will continue on standard oral hydrocortisone therapy
59608|NCT03718221|Other|Usual Care FIT Screening Strategy|Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
59609|NCT03718221|Other|GeoMail FIT Screening Strategy|Patients in treated neighborhoods will receive kits at the same time.
59610|NCT03718208|Dietary Supplement|Paediatric Formula|Children will switch over to the low calorie paediatric feed. Intake diaries and tolerance diaries will be completed for one week.
59611|NCT03718195|Other|Pediatric Formula|One week intake diary, one week tolerance diary, product intake
59612|NCT03718182|Dietary Supplement|Cholecalciferol|vitamin D3 daily oral supplement
59613|NCT03718169|Behavioral|questionnaires|Female smokers will be asked to complete a structured questionnaire at smoking hotspots. In addition, the smokers will respond to the same questionnaire at 6 months via telephone. The structured questionnaire will collect information related to their demographic characteristics and quitting behaviors, i.e. self-reported abstinence, smoking reduction and quit attempts.
59674|NCT03717701|Drug|metformin|Patients will take metformin single dose of 1000 mg orally once a day
59614|NCT03718156|Other|PREPARED Trial Intervention|Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
59615|NCT03718143|Drug|Combination AZD1775 with AraC|AZD1775 days 1-5 & 8-12 AraC days 1-5 & 8-12
59616|NCT03718143|Drug|AZD1775 only|AZD1775 days 1-5 & 8-12
59617|NCT03718130|Combination Product|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
59618|NCT03718130|Combination Product|Hantann virus vaccine (HTNV) - Using TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The HTNV vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
59619|NCT03718130|Combination Product|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The PUUV vaccine will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
59620|NCT03718130|Combination Product|Puumala virus vaccine (PUUV) - Using the TriGrid Delivery System (TDS) for Intramuscular Delivery (IM)|The PUUV DNA vaccine will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
59621|NCT03718130|Combination Product|Hantaan/Puumala (HTNV/PUUV) virus vaccines - Using the TriGrid Delivery System (TDS) for Intradermal Delivery (ID)|The HTNV and PUUV vaccines will be administered using the ID TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
59622|NCT03718130|Combination Product|Hantaan/Puumala (HTNV/PUUV virus vaccines - Using the TriGrid Delivery System (TDS) for Intramusular Delivery (IM)|The HTNV and PUUV vaccines will be administered using the IM TriGrid™ Delivery System (TDS), which utilizes the in vivo application of electrical fields (electroportation) to enhance the intracellular delivery of agents of interest in a targeted region of tissue.
59623|NCT03718104|Other|Pharmacokinetic analysis|Pharmacokinetic analysis of maternal blood, maternal urine, cord blood, infant blood and urine for dyads in the naltrexone group at various time points in the pregnancy, at delivery, and 4 weeks postpartum.
59624|NCT03718104|Other|Safety and Efficacy|Examination of the safety and efficacy of naltrexone and comparison of outcomes with the buprenorphine/naloxone cohort. Outcomes examined will include: 1) maternal outcomes (relapse, retention in care, preterm labor); 2) fetal outcomes (growth, fetal anomalies, fetal distress, cortisol levels); and 3) infant outcomes (NAS, growth, neurodevelopment via NNNS exam at 4 weeks and Bayley exam at 12 months of age).
59625|NCT03718104|Genetic|Genetic and epigenetic analysis|Maternal blood and saliva DNA samples will be genotyped for single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) to look for associations with effectiveness of NTX and BPH. In addition, DNA methylation levels in the OPRM1 promoter within maternal and infant saliva and placenta at delivery and 4 weeks postpartum will be examined. Lastly, we will compare genome-wide DNA methylation levels at delivery and 4 weeks postpartum in mother-infant dyads.
59626|NCT03718104|Other|Breast milk analysis|Mothers in the naltrexone group will have their breast milk analyzed at 4 weeks post-delivery for naltrexone levels, with corresponding maternal and infant plasma levels.
59627|NCT03718091|Drug|M6620|M6620 is a drug designed to inhibit the ATR enzyme. Inhibiting ATR may block how cancers repair their naturally damaged DNA, handle cancer cell stress, and maintain cancer cell life and health.
59628|NCT03718078|Device|Confocal Laser Endomicroscopy|"The study is divided in two parts. For the two parts, patients will receive an intravenous injection of indocyanine green:~Ex vivo study~- Images/sequences of normal and abnormal hepatic tissues and surgical margins will be acquired on surgical specimens~In vivo study - Intra-operative pCLE imaging will be performed on hepatic masses and surgical margins"
59629|NCT03718065|Drug|Lofexidine|Lofexidine, sold under the brand name Lucemyra among others, is a medication historically used to treat high blood pressure, but more commonly used to help with the physical symptoms of opioid withdrawal. It is taken by mouth. It is an α2A adrenergic receptor agonist.
59630|NCT03718065|Drug|Placebo|Placebo comparator.
59631|NCT03718052|Procedure|Early valve surgery (EVS)|Early valve surgery (EVS) within 72 hours of randomization
59632|NCT03718052|Procedure|Conventional Care|Conventional care according to the 2015 European guidelines.
59633|NCT03718039|Drug|HTX-011|HTX-011; up to but not to exceed 2.1 mL, via instillation into the surgical site.
59634|NCT03718039|Device|Luer Lock applicator|Applicator for instillation.
59635|NCT03718039|Device|Vial access device|Device for withdrawal of drug product.
59636|NCT03718039|Drug|aprepitant|Aprepitant; Three single doses of aprepitant will be administered orally presurgery, Day 2, and Day 3.
59637|NCT03718026|Other|The timed 360° turn test|"The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~One-leg stance test: Individuals were asked to stand on either their left or right leg.~Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways."
59640|NCT03718000|Device|Daily self-weighing (DSW)|DSW was conducted using digital WiFi scales during the holiday season. Participants received electronic graphic feedback of their weight fluctuations immediately after weight measurement.
59641|NCT03717987|Drug|Botulinum toxin type A|"Botulinum toxin type A will be injected in all patients at both sides into the Yonsei point, (3Units) the point that would target 3 muscles responsible for upper lip elevation during smiling, including the LLSAN, in a single injection. This landmark was identified as the center of a triangle formed by the convergence of the LLSAN, the LLS, and the Zminor muscles and is located 1 cm lateral to the ala horizontally and 3 cm above the lip line vertically in both men and women (Hwang et al. 2009) and (Nasr et al. 2015)."
59642|NCT03717987|Dietary Supplement|Zinc supplementation|zinc supplementation will be given to patients in the intervention arm 4 days prior to Botulinum toxin type A injection
59643|NCT03717974|Other|Telemedecine follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by telemedicine. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
59644|NCT03717974|Other|Mobile team follow-up after an intervention at home of the mobile team|"After a first visit of the mobile team at home, patients are followed by mobile team. Moreover, in case of pain, a specialized consultation by an algologist of La Sagesse will be realized."
59645|NCT03717961|Drug|BOTOX® solution|Botox solution + Saline serum + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
59646|NCT03717961|Drug|Placebo group|Placebo + lidocaine/prilocaine cream + Nitrous oxide/oxygen (50%/50%)
59647|NCT03717948|Other|BFR Exercise|Participants will exercise on a recumbent bike placed on a 45 degree incline (BFR).
59648|NCT03717948|Other|CTL Exercise|Participants will exercise on a recumbent bike placed on flat ground (CTL).
59649|NCT03717935|Dietary Supplement|Essential Amino Acid (EAA) Supplement|Powder supplement
59650|NCT03717935|Other|Placebo|Powder that will be similar to the essential amino acid supplement
59651|NCT03717922|Device|Low Intensity Focused Ultrasound Pulsation|BOLD fMRI will be collected during two conditions (given that the timecourse of LIFUP related changes is unknown, sham will always precede the LIFUP condition). LIFUP (previously used in primary sensory cortices will be administered in 75 sonifications at 210 KHz frequency with pulse repetition frequency of 500Hz, 35mW/cm2, sonification duration 0.5s with 7s inter-stimulation intervals. Sham LIFUP will involve the same procedures (e.g. participant provided the same instructions) except the sonification will not occur.
59652|NCT03717922|Device|SHAM Ultrasound|BOLD fMRI will be collected while the ultrasound trandsducer is not turned on. Participants are unable to tell whether the transducer is on or off.
59653|NCT03717909|Drug|Sodium Valproate 200Mg E/C Tablet|Treatment with twice-daily oral tablet(s)
59654|NCT03717909|Drug|Sodium Valproate matched placebo|Treatment with twice-daily oral 200mg tablet(s)
59655|NCT03717896|Drug|200mg IV thiamine in 50mL 0.9% saline|Thiamine 200mg IV every 12 hours for 2 days
59656|NCT03717896|Drug|Placebo|50mL 0.9% saline
59657|NCT03717870|Procedure|Laparoscopic enucleation of ovarian endometrioma.|Laparoscopic enucleation of ovarian endometrioma (stripping of the peripheral capsule and coagulation using the lowest energy source available).
59658|NCT03717870|Procedure|Prolonged pituitary downregulation|Treatment with GnRH-a (triptorelin, goserelin, and leuprolide), with add-back therapy (combined oral contraceptive) for 3-6 months.
59659|NCT03717870|Procedure|Assisted Reproductive Technology (ART)|Fresh ART cycle: ovarian stimulation, oocyte retrieval, in vitro fertilization and embryo transfer.
59660|NCT03717818|Behavioral|Good Psychiatric Management - Brief|specific interventions as defined by Gunderson and Links (2014)
59661|NCT03717818|Behavioral|treatment as usual|non-specific intervention
59662|NCT03717805|Other|POAM|The new 5 minutes preparatory information movie on oocyte aspiration (POAM) details what couples can expect to happen on the day of oocyte aspiration. More specifically, it describes the patient journey detailing which procedures will happen when and how, in which room, in the presence of their partner or not, and in the presence of which healthcare professionals.
59663|NCT03717792|Other|no intervention|no intervention
59664|NCT03717779|Diagnostic Test|lung ultrasound|we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
59665|NCT03717766|Device|intraoperative neuronavigation ultrasound, intraoperative tractography, intraoperative fluorescence, advanced neuronavigation and intraoperative neurophysiology|"5-aminolevulinic acid (5-ALA) is a pro-drug that causes fluorescent protoporphyrins that accumulate in malignant gliomas. Fluorescence can be visualized during surgery by the use of a modified microscope, which helps the surgeon define the margins of the tumor.~Neuro-navigated intraoperative ultrasound is an imaging technique that allows us to visualize intracranial lesions during surgery and correlate them with the image provided by the neuronavigator, obtaining a real-time view of the lesion and possible tumor remains.~To achieve greater tumor resections without increasing the incidence of neurological deficits, the use of intraoperative neuromonitoring has been progressively implemented. This technology and specifically the brain mapping allows us to locate the functional areas of the brain and perform more aggressive resections with lower morbidity"
59666|NCT03717753|Other|Pathway|The study team emphasizes that all components of the pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the pathway will receive these standard of care components.
59667|NCT03717740|Drug|Esomeprazole|Patients will take esomeprazole single dose of 40 mg orally once a day from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
59668|NCT03717740|Drug|Placebo|Patients will take an inert tablet similar in appearance, color, and consistency from 12+ and 17 weeks of pregnancy until 34 weeks of pregnancy
59669|NCT03717727|Other|Exergame|16-week home-based exercise intervention with exergaming system and usual treatment.
59670|NCT03717727|Other|Control|16-week home-based exercise by standard protocol and usual treatment.
59671|NCT03717714|Dietary Supplement|Glucosamine 1500 mg|Patients in this group take 3 capsules, each capsule contains Placebo 16.7mg and Glucosamine 500 mg, once a day for 12 weeks
59672|NCT03717714|Dietary Supplement|Polycan 50mg + Glucosamine 750 mg|Patients in this group take 3 capsules, each capsule contains Polycan 16.7mg and Glucosamine 250 mg, once a day for 12 weeks
59679|NCT03717688|Drug|Placebos|No treatment
59680|NCT03717675|Device|NovaCross™ Chronic Total Occlusion micro-catheter|The NovaCross™ micro catheter is a guidewire positioning and support micro catheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment. Investigators will use the NovaCross Micro catheter during a standard of care catheterization of patients diagnosed with coronary total occlusion.
59681|NCT03717662|Drug|nicotine gum or nicotine patch|The project will provide intensive counseling at the Centre for Health Promotion (CHP) of HKU Department of Nursing Studies, female smokers who require more intensive counseling or advice on nicotine replacement therapy, upon referral from the women's organizations and trained women counselors. The smokers will receive face-to-face (or telephone) counseling and a 1 week supply of Nicotine replacement therapy (NRT) (4 mg nicotine gum or 10 mg/ 15 mg nicotine patch) from the nurse counselor, and follow up calls at 1 week, 1-, 3-, 6-, 36- and 72-month post-intervention.
59682|NCT03717649|Device|Conventional 2-stage venous cannula|venous cannula
59683|NCT03717649|Device|Conventional 3-stage venous cannula|venous cannula
59684|NCT03717649|Device|Fenestrated 3-stage venous cannula|venous cannula
59685|NCT03717636|Other|medical evaluation|return of medical evaluation after discharge
59686|NCT03717623|Drug|Posaconazole pharmacokinetics|Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
59687|NCT03717610|Procedure|radical surgery with HIPEC|Straight after macroscopic radical cytoreductive surgery, an intraperitoneal hyperthermic perfusion using the open-abdomen technique will be performed with a single dose of cisplatin 100 mg/m2 administered for 90 minutes in the hyperthermic phase (41°C-43°C).
59688|NCT03717597|Behavioral|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
59689|NCT03717571|Diagnostic Test|Glenohumeral translation assessment|amount of glenohumeral translation under load
59690|NCT03717558|Drug|ivermectin T1|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
59691|NCT03717558|Drug|ivermectin T2|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
59692|NCT03717558|Drug|ivermectin T3|Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol
59693|NCT03717545|Other|second allogeneic stem cell transplantation|"Change another donor~conditioning regimen: FLU/CY/anti-CD25 moAb"
59694|NCT03717532|Procedure|Placebo|Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.
59695|NCT03717532|Procedure|Personalized Tourniquet System for Blood Flow Restriction|Patients will be receiving blood flow restriction therapy with a pressure cuff
59696|NCT03717519|Diagnostic Test|Measurement of platelet count at diagnosis|Blood samples were drawn by expert phlebotomists in vacuum blood tubes containing K2-EDTA (Terumo Europe NV, Leuven, Belgium). The complete blood cell count (CBC) was performed using Advia 2120 (Siemens Healthcare Diagnostics, Tarrytown NY, USA). The local reference range for platelets was 150-400 x 109/L. The same analyser was used throughout the study period, and the quality and reproducibility of test results was validated by data of both internal quality control and external quality assessment
59697|NCT03717506|Drug|GDC 268 Lotion|GDC 268 is a topical lotion
59698|NCT03717506|Drug|Clindamycin Phosphate Lotion 1%|Clindamycin Phosphate Lotion is an FDA-approved drug
59699|NCT03717506|Drug|GDC Vehicle Lotion|GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs
59700|NCT03717493|Behavioral|Affect Regulation Training|Following the guidelines for the 6-week intensive ART format, we scheduled one 180-minutes session per week (each consisting of two modules à 90min) for a period of six subsequent weeks. Training groups included four to eight participants. The implementation of ART followed standardized treatment protocols (Berking & Whitley, 2014). ART was delivered by doctoral candidates (DCs) in clinical psychology who had completed or were in advanced stages of their clinical training. All therapists had been intensely trained and received weekly supervision from experienced ART trainers. To control adherence a random sample of 5% of all sessions was be videotaped and will be rated with regard to adherence.
59701|NCT03717480|Device|ClinicMACs|The Reagent System will remove certain cells (called T-Cell Receptor (TCR) α/β positive T-cells) that are thought to cause GVHD from donor product before it is given to participants
59702|NCT03717467|Drug|isotonic saline|100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
59703|NCT03717467|Drug|Magnesium Sulfate|40 mg/kg of magnesium sulfate in 100 ml of isotonic saline over 15 min immediately before induction of anesthesia and then 15 mg/kg/h by continuous I.V. infusion until the end of operation.
59704|NCT03717454|Other|Surgery|The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .
59705|NCT03717454|Drug|Drug treatment|The medication will continue if DA causes tumors to shrink.
59706|NCT03717441|Diagnostic Test|chromosome numeration of embryos|Use genomic technologies to analyze the discarded media drop for chromosome counting
59707|NCT03717428|Device|Daily Weighing Group|The Experimental group will weigh themselves everyday
59708|NCT03717428|Device|Control group|This group will be weighed and measured at the beginning and end of the study and will not be weighing themselves daily
59709|NCT03717415|Drug|rebastinib|25 mg tablets or 75 mg tablets
59710|NCT03717415|Drug|Carboplatin|Carboplatin administered by IV infusion at AUC5 or AUC6
59848|NCT03716401|Diagnostic Test|US (ultrasound)|An ultrasound scan is a medical test that uses high-frequency sound waves to capture live images from the inside of the body.
59711|NCT03717402|Other|STAMP App|STAMP--A patient-facing mobile phone app with a clinician web-based portal aimed to help advanced cancer patients and providers better co-manage cancer pain with opioids.
59712|NCT03717402|Other|No access to STAMP App|Patients in this group will not have access to the STAMP app and will take part in a qualitative interview describing their experiences with chronic cancer pain management.
59713|NCT03717389|Other|presence of soft tissue calcification in head and neck|soft tissue calcifications of the head and neck region in the Egyptian population
59714|NCT03717376|Other|Self-questionnaire YSQ-S3 (Young Schema Questionnaire)|All participants will fill the YSQ-S3 at home and send it back to the main investigator.
59715|NCT03717363|Procedure|Training programme|Training program in the primary care center supervised by a physiotherapist. The duration is two months and the frequency of sessions 3 times / week. Each session lasts 60 minutes.(30 minutes of aerobic exercise and 15 minutes of strength exercise).
59716|NCT03717363|Behavioral|Educational talk|An educational talk given by the nurse and the physiotherapist about the components of a cardiosaluble lifestyle.
59717|NCT03717350|Drug|Meropenem|2g of meropenem diluted in 100ml of sodium chloride 0.9% within 15 minutes intravenously administered once
59718|NCT03717350|Drug|Placebo|100ml of sodium chloride 0.9% within 15 minutes intravenously once
59719|NCT03717337|Procedure|Single visit pulp regeneration|Access cavity, disinfection, preparing and injecting platelet rich plasma, and restoring the tooth all done in one visit.
59720|NCT03717337|Procedure|Two visit pulp regeneration|first visit : access, disinfection and placing calcium hydroxide as intracanal medicament second visit: re opening of tooth, preparing and injecting platelet rich plasma and restoring the tooth.
59721|NCT03717324|Other|Procedure created in co-creation group|Interventions will be those obtained from the co-creation workshop with patients
59722|NCT03717311|Other|Nutritional Intervention|The intervention will be done on 1 day, time during which, each subject will stay at the CRNH. A breakfast containing the fibers will be given to them, then during 24h a following will be done to get fecal, urinary, plasmatic and expiratory samples. Standardized lunch, dinner and collation will be served during the day.
59723|NCT03717298|Dietary Supplement|Ocoxin-Viusid®|"An oral solution of Ocoxin-Viusid® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT.~The treatment with Ocoxin-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously from the inclusion of the patient in the study, up to one year."
59724|NCT03717285|Procedure|Insert the UAS under direct vision|Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.
59725|NCT03717285|Procedure|Insert the UAS under non direct vision|Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
59726|NCT03717272|Drug|AEF0117|AEF0117 capsules
59727|NCT03717272|Drug|Placebo oral capsule|Corn oil capsule manufactured to mimic AEF0117 capsule
59728|NCT03717259|Procedure|Open nephrectomy|The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.
59729|NCT03717259|Procedure|Hand-assisted laparoscopic nephrectomy|The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.
59730|NCT03717259|Procedure|Laparoscopic nephrectomy|In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
59731|NCT03717246|Behavioral|Sleep Smart Latino|A culturally tailored group intervention aimed at improving sleep duration and quality for Latino middle school students.
59732|NCT03717246|Behavioral|Basic Sleep Hygiene and Child Health|A group intervention providing sleep hygiene and child health topics education to Latino middle school students.
59733|NCT03717233|Device|Exoskeleton|Ankle-foot exoskeleton - device to help reduce load on the bottom of the front of the foot
59734|NCT03717220|Procedure|flap transferring|we use regional dorsal digital flaps for simultaneous reconstruction of multiple-digit soft-tissue defects
59735|NCT03717207|Other|ecg Holter|all patients before to perform an head up tilt test for syncope evaluation will be steadied by ecg Holter to assess heart rate, heart rate variability.
59736|NCT03717194|Drug|Ertugliflozin|Ertugliflozin as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
59737|NCT03717194|Drug|Placebo|Placebo as add-on to Metformin and/or DPP4 inhibitors in patients with inadequately controlled type 2 diabetes
59738|NCT03717181|Drug|Lixivaptan|Daily dose of lixivaptan optimized using a predetermined titration protocol.
59739|NCT03717168|Drug|Recombinant human growth hormone|All the patients received subcutaneous rHGH (0.3 IU/kg/ twice daily) for 10 days in addition to intensive care standard management.
59740|NCT03717168|Other|Control|All patients will not receive growth hormone.
59954|NCT03715751|Other|Lung Protective Ventilation|Targeted tidal volume of 6cc/Kg, Positive Inspiratory Pressure titrated per ARDS guidelines.
59745|NCT03717142|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and tissue will be imaged in vivo and ex vivo with the LUM imaging device.
59746|NCT03717129|Drug|Genvoya Oral dose|Single Genvoya oral dose directly observed
59747|NCT03717129|Drug|Genvoya Crushed Dose|Single Genvoya crushed tablet in water directly observed
59748|NCT03717116|Diagnostic Test|parathormone level|From the patients, blood will be taken preoperatively and postoperatively.
59749|NCT03717103|Drug|IBI188|"0.1 mg/kg IV QW 0.3 mg/kg IV QW~1 mg/kg IV QW"
59750|NCT03717103|Drug|IBI188|3 mg/kg IV QW 10 mg/kg IV QW 20 mg/kg IV QW 30 mg/kg IV QW
59751|NCT03717103|Drug|IBI188, Rituximab|Recommended dose from Ia
59752|NCT03717090|Other|No intervention|Sample collection study Sample collection and collection of laboratory values
59753|NCT03717077|Procedure|learned resourcefulness intervention|The LR program includes: 1) Solving problem strategy, 2) Organizing daily actions, 3) Using self-regulation, 4) Reframing positive situations, 5) Changing negative self-thinking, 6) Exploring new thinking and skills. It is conducted one time per week.
59754|NCT03717064|Drug|RO7049389|RO7049389 will be taken orally, in tablet form, BID on Days 1-6 of Period 2.
59755|NCT03717064|Drug|Pitavastatin|Pitavastatin will be taken orally, in tablet form, once on Day 1 of Period 1, and once on Day 4 of Period 2.
59758|NCT03717038|Drug|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
59759|NCT03717038|Drug|TAS-102|TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
59760|NCT03717025|Procedure|SUCTION BLISTER EPIDERMAL GRAFTING|"Preferred donor sites for making blister is lateral aspect of upper thigh. The area is shaved and cleansed with surgical spirit.~Blister formation is induced by using suction apparatus.~Recipient site is surgically prepared by doing dermabrasion.~After formation of blisters, each blister is gently cleansed with normal saline and cut all along its border with curved iris scissors parallel to the skin surface. The roof is everted over the thumb with dermal surface facing upwards and then with the help of blunt end of forceps it is placed on the recipient area.~The graft is firmly pressed with sterile moist gauze to remove any underneath serous collection.~The pressure dressing is done with double layer framycetin tulle, moist gauze and bandage.~Donor area is dressed with dry sterile pads.~The part is immobilized and Antibiotics and Analgesic are given till dressing are removed (after 5-7 days)."
59761|NCT03717025|Procedure|MINI PUNCH GRAFTING|"Recipient area is prepared first after shaving and cleaning with surgical spirit. 2 % lignocaine with or without adrenalin will be infiltrated as local aneasthetic.~The punched out chambers are spaced at a gap of less than 5 mm (preferably 2 - 2.5 mm) from each other.~The donor area is either upper lateral portion of thigh or gluteal region.~Grafts are placed directly from donor to the recipient area. Care is taken, so that graft edges are not folded, the tissue is not crushed or placed upside down.~Hemostasis is achieved by pressing a saline soaked gauze piece over the area.~For the recipient area 3 layers of dressing from inside out are : paraffin embedded non adherent sterile gauze, sterile surgipad, and micropore.~For the donor area only surgipad and micropore are used.~Immobilisation of recipient area is advised along with antibiotics and analgesics till removal of dressing (after 4-7 days)."
59762|NCT03717025|Procedure|NON CULTURED EPIDERMAL CELL SUSPENSION|"About one-tenth the size of recipient area is selected as the donor site.~Split thickness skin graft is taken under aseptic precautions with the help of a shaving blade held firmly by a straight artery forceps.~The area is dressed with Bactigras gauze.~Split thickness skin specimen is transferred under aseptic conditions to a container with Normal Saline and transferred to laboratory for preparing suspension.~Recipient site is dermabraded under aseptic precautions until tiny pinpoint bleeding spots are seen.~Epidermal cell suspension is carefully transferred to a tuberculin syringe.~With 18 gauge needle attached to this syringe, suspension is spread evenly on dermabraded recipient site.~This is then covered with Collagen dressing, followed by bactigras, guaze and tegaderm dressings from inside to outside.~The patient is observed for 2 hours after performing the procedure and given antibiotics and analgesics for 5-7 days till dressing removal."
59763|NCT03717012|Drug|Nintedanib|stable dose
59764|NCT03717012|Other|Pulmonary rehabilitation program|12 weeks
59765|NCT03716999|Other|Starlight Therapy|Starlight Projector will be placed in patients' rooms and project starlight on the ceilings and walls in an effort to reduce unpleasant symptoms
59766|NCT03716986|Diagnostic Test|MRI Oxygen Saturation Map|Calculation of the oxygen saturation map of gliomas cases
59767|NCT03716973|Device|High Density Programming|Patients implanted with Medtronic spinal cord stimulator will have high density programming.
59768|NCT03716960|Other|Pumpkin Seed Oil|This intervention consisted of 6 weeks of PSO consumption. Subject were supplemented with 3 g/day of PSO which was ingested in the form of 1g capsules with each main meal of the day (breakfast, lunch and dinner).
59769|NCT03716960|Other|Placebo|This intervention consisted of 6 weeks of placebo consumption. Subject consumed 1 capsule of maltodextrin with each main meal of the day to match the dose and number of capsules ingested daily by the PSO group.
59770|NCT03716947|Procedure|Device: ZACK|Surgical procedure with total disc replacement using ZACK disc prostheses
59771|NCT03716947|Procedure|Device: ORBIT|Surgical procedure with total disc replacement using ORBIT disc prostheses
59772|NCT03716947|Procedure|Device: SASCA|Surgical procedure with anterior intracorporal fusion (ALIF) combined with adjacent level total disc replacement (TDR) (using either ORBIT mechanical disc prosthesis or ZACK viscoelastic disc prosthesis)
59773|NCT03716934|Device|Arctic Front Advance® balloon catheter|Cryoablation of bidirectional block of all pulmonary veins
59774|NCT03716934|Drug|Antiarrhythmic drug|The drug will be chosen based on the preference of the researcher / responsible physician and current clinical practice guidelines.
59775|NCT03716934|Device|Confirm RX heart monitor® (Abbott)|Is a subcutaneous implantable device that provides continuous monitoring of the heart rate for more than 3 years without any effect on cardiac function
59776|NCT03716921|Other|Short antibiotics treatment|Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
59777|NCT03716882|Device|Song Meter (SM)4|Their cries will be longitudinally registered using an automatic record device: Song Meter (SM)4 during 3 consecutive days and nights. This record will take place at 15 days of life, 1 and half months, 2 and half months and 3 and half months.
59778|NCT03716869|Other|Universal Screening Arm|"Students with PHQ-9 score >10, corresponding to a positive MDD screen, will proceed through the same SAP triage process as students referred by traditional means.~SAP triage will determine MDD identification. As SAP triage is not diagnostic, MDD identification is based on SAP recommendations for MDD related school or community services.~Treatment engagement will be tracked per current SAP processes.~To immediately identify and address suicidal intent, the survey will flag a positive response to PHQ-9 question 9 in real time. A suicidal student would proceed directly to management through the school crisis plan.~Students in the intervention arm will also be tracked for behavior concerning for MDD at any point in the school year prompting SAP triage referral."
59779|NCT03716856|Genetic|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
59780|NCT03716856|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
59781|NCT03716856|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion
59782|NCT03716843|Other|Pressure monitoring system|"The pressure measurement undergarment will be given to all consenting AIS patients who have received their own thoraco-lumbo-sacral orthosis (TLSO) rigid brace. Each patient will wear the undergarment first and the TLSO brace on top. FBG sensors embedded in the undergarment will measure each pressure signal at approximately 2 minutes. The average force reading will be calculated.~Then, the experiment will be repeated once, but the anisotropic textile brace will replace the TLSO brace. The pressure measurement system will be used to obtain an accurate and adequate comparison of the forces applied to the patients. The effectiveness of the anisotropic textile brace will be evaluated through X-ray radiography, and its correction effect with be compared with that of the TLSO brace."
59783|NCT03716830|Device|verum acupuncture|Participants will receive real acupuncture treatment.
59784|NCT03716830|Device|sham acupuncture|Participants will receive acupuncture treatment with retractable needles (sham).
59785|NCT03716830|Device|real tDCS|Participants will receive real transcranial direct current stimulation.
59786|NCT03716830|Device|sham tDCS|Participants will receive sham transcranial direct current stimulation.
59787|NCT03716817|Device|Tetric CAD|Resilient ceramic crowns (Tetric CAD by Ivoclar Vivadent) are placed using an adhesive bonding process including a total etch process with a universal adhesive (Adhese by Ivoclar Vivadent) and dual cured resin cement (Variolink Esthetic by Ivoclar Vivadent).
59788|NCT03716804|Drug|Tablet Nitrofurantoin|Tablet Nitrofurantoin (100 mg), two times daily in 12 hours interval for 7 days
59789|NCT03716804|Drug|Tablet Ciprofloxacin/ Tablet Cefixime/ Tablet Cefuroxime|Tablet Ciprofloxacin (500 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefixime (200 mg), two times daily in 12 hours interval for 7 days or, Tablet Cefuroxime (250 mg), two times daily in 12 hours interval for 7 days
59790|NCT03716791|Dietary Supplement|methylsulfonylmethane|3g per day
59791|NCT03716791|Dietary Supplement|placebo|white rice flour
59792|NCT03716778|Other|Eccentric rehabilitation sessions|"ECC cycling will be conducted using a commercially available ECC motor-driven ergometer. Intensity and duration are progressively increased during the first five sessions in order to minimize the extent of exercise-induced muscle soreness.~The subjects will perform five sessions of endurance training on cycle ergometer per week. Each session lasting 30 minutes will be achieved at an intensity corresponding to the pre-determined CON ventilatory threshold. In the ECC group, 3 sessions of ECC (Monday, Wednesday and Friday) and two session of concentric (Tuesday and Thursday) cycling will be carried out each week. In the control group CON all sessions will be achieved using the traditional pedaling mode."
59793|NCT03716765|Dietary Supplement|locally injected vitamin D|locally injected vitamin d as non surgical method for periodontal regeneration of vertical bony defects
59794|NCT03716752|Procedure|Modified connective tissue graft wall with wing technique|the usage of bone graft and collagen barrier to treat recession defects accompanied vertical bony defcets in posterior teeth
59795|NCT03716739|Drug|Testosterone Cypionate 100 MG/ML|100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
59796|NCT03716739|Drug|Placebo|Placebo administered by intramuscular injection weekly for 12 weeks.
59800|NCT03716713|Device|CeraShield Endotracheal Tube|Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
59801|NCT03716700|Biological|CUVITRU|CUVITRU
59802|NCT03716687|Device|Prophylactic negative pressure wound dressing after laparotomy|Five days of -90 Hgmm continuous negative pressure wound dressing left on primary closed laparotomy wound.
59847|NCT03716401|Diagnostic Test|MRI (magnetic resonance imaging)|An MRI (or magnetic resonance imaging) scan is a radiology technique that uses magnetism, radio waves, and a computer to produce images of body structures. The MRI scanner is a tube surrounded by a circular magnet.
59803|NCT03716674|Device|Metronome|Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
59804|NCT03716661|Procedure|ORIF|Open Reduction Internal Fixation
59805|NCT03716648|Diagnostic Test|DISE-assisted titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
59806|NCT03716648|Diagnostic Test|PSG-guided titration|Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
59807|NCT03716648|Device|subjective titration|Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
59808|NCT03716635|Procedure|cryotherapy|2.5c cold saline is used as a final flush after chemomechanical preparation
59809|NCT03716635|Procedure|normal saline|a room temperature saline is used as a final flush after mechanical preparation
59810|NCT03716622|Drug|Furazolidone|bismuth-furazolidone-containing quadruple regimens
59811|NCT03716622|Drug|Clarithromycin|bismuth-clarithromycin-containing quadruple regimens
59812|NCT03716609|Dietary Supplement|Magnesium Citrate|Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)
59813|NCT03716609|Other|Food grade citrate acid|Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)
59814|NCT03716609|Other|Splenda(Sucralose)|Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
59815|NCT03716596|Radiation|SBRT|SBRT radiation dose is 40-50 Gy in total.
59816|NCT03716596|Drug|anti-PD-1 antibody|Intravenous drug of anti-PD-1 antibody, 200mg, once a time, every three weeks.
59817|NCT03716583|Drug|Melatonin|25 mg
59818|NCT03716583|Drug|Dimethyl Sulfoxide|150 mg
59819|NCT03716583|Drug|Placebos|1 g
59820|NCT03716570|Drug|BIIB054|Administered as specified in the treatment arm.
59821|NCT03716570|Drug|Placebo|Administered as specified in the treatment arm.
59822|NCT03716557|Device|Spinal Cord Stimulation 4000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
59823|NCT03716557|Device|Spinal Cord Stimulation 10000Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
59824|NCT03716557|Device|Spinal Cord Stimulation 40Hz|Differential programming of the Boston Scientific Precision™ Plus Spinal Cord Stimulator System
59825|NCT03716544|Device|Amplification with hearing aid|Use of hearing aids
59826|NCT03716544|Device|Customized music|Customized music delivered via an iPod
59827|NCT03716531|Radiation|IORT|IORT works by delivering radiation therapy to the tumor while reducing the amount of healthy tissue exposed to the radiation therapy
59832|NCT03716479|Other|Low Fiber|20 g of acacia gum will be added to orange juice
59833|NCT03716479|Other|High Fiber|40 g of acacia gum will be added to orange juice
59834|NCT03716479|Other|Placebo/Control|No acacia gum will be added to orange juice.
59835|NCT03716466|Other|Endotracheal intubation|Subjects will receive prophylactic endotracheal intubation for upper gastrointestinal endoscopy procedure
59836|NCT03716466|Other|No airway intervention|Subjects without prophylactic endotracheal intubation during upper gastrointestinal endoscopy procedure
59839|NCT03716440|Other|Nature exposure|Participants will view images of nature.
59840|NCT03716440|Other|Non-nature exposure|Participants will view non-nature images.
59841|NCT03716427|Drug|CT1812|
59842|NCT03716427|Drug|tolbutamide|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of tolbutamide
59843|NCT03716427|Drug|dextromethorphan|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of dextromethorphan
59844|NCT03716427|Drug|Omeprazole|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of omeprazole
59845|NCT03716427|Drug|midazolam|Single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of midazolam
59846|NCT03716414|Procedure|SLN mapping|"Intra-operative SLN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and Arms Assigned Interventions another 1ml will be injected superficially (2mm-depth).~The time between the injection and the search for SLN must be as soon as possible."
59849|NCT03716401|Procedure|Renal Biopsy|A kidney biopsy involves taking one or more tiny pieces (samples) of the kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail.
59850|NCT03716401|Diagnostic Test|Positron Emission Tomography (PET)|Positron emission tomography (PET) uses small amounts of radioactive materials called radiotracers, a special camera and a computer to help evaluate organ and tissue functions. By identifying body changes at the cellular level, PET may detect the early onset of disease before it is evident on other imaging tests.
59851|NCT03716401|Diagnostic Test|Microvascular Assessment|Glycocalyx (a network of membrane proteoglycans and glycoproteins lining all blood vessels) thickness is non-invasively estimated from video clips of sublingual vessels captured using a hand held microscope. Glycocalyx is vital for vascular health; perturbations in the glycocalyx are thought to contribute to numerous vascular health complications including DKD.
59852|NCT03716388|Biological|Fecal Microbiota Transplantation|Freshly passed stools (80 g) will be diluted with normal saline (200 ml) and homogenized using a blender, filtered, filled into 4 syringes (50 ml each) and used within 1 hour of preparation or 6 hours of passage of stools. Polyethylene glycol lavage will be done for bowel preparation and the slurry administered into the ileum and/or caecum by colonoscopy. Post FMT, recipients will be encouraged to retain the slurry for 4-6 hours. FMT sessions will be scheduled at weeks 0,2,6,10,14.
59853|NCT03716388|Drug|Mesalamine Granules|Mesalamine granules 4 grams a day
59854|NCT03716388|Other|Placebo infusion|Water with food grade colour to resemble fecal slurry
59855|NCT03716388|Other|Placebo granules|Granules resembling mesalamine granules, 4 grams a day
59856|NCT03716375|Drug|Intrapleural Medications|urokinase
59857|NCT03716362|Device|Otoacoustic emissions device|as a screening tool for Auditory brainstem response
59858|NCT03716349|Diagnostic Test|Pulp vitality testing|each tooth will be tested to determine if the pulp of the tooth responds to cold
59859|NCT03716349|Other|Photos|Photos of teeth (Photos will be taken with a DSLR camera settings will be determined with optimal settings) and captured periodically throughout the study. Photographs will be made of the cavity preparation. Photographs will be made post-operatively
59860|NCT03716349|Drug|local and/or topical anesthetic|Local and/or topical anesthetic will be applied as necessary to the teeth or gingiva
59861|NCT03716349|Device|rubber dam|The area will be isolated with rubber dam isolation
59862|NCT03716349|Other|tooth surface cleaned|The tooth surface will be cleaned with flour of pumice on a prophy cup only, cavity preparation will be performed as usual for caries removal.
59863|NCT03716349|Procedure|enamel margins|Enamel margins will be beveled with a long flame diamond bur (8863.314.012 Komet) at 45 degrees to the external tooth surface to achieve the desired bevel length. Along with the use of the diamond bur, infinite invisible margins will be created by contouring and smoothing with a dark orange Sof-LexTM extra-thin contouring and polishing disc (3M).
59864|NCT03716349|Procedure|Adhesive Systems|Adhesive systems will be applied according to manufacturer's instructions and selective etching of the enamel will be performed. The dental composite will be incrementally placed using a two- layer or one-layer technique based on the cavity size and light-cured (detailed adhesive instruction sheet will be chairside for reference)
59865|NCT03716349|Procedure|cavity preparation|The technique to be used will be determined by the size of the final cavity preparation. For small preparations a one-layer technique will be used. No backing material is necessary for the Tokuyama system, Filtek Supreme Ultra will be determined by manufacturer's wheel. A two-layer technique will be used for a large cavity preparation. Large cavity preparation is defined as being 4mm in length or more and/or at least 2mm in depth.
59866|NCT03716349|Other|Shade selection using Easy Shade 5|A1 (shade determined by Easy Shade 5), ECM-001/Backing material, A1E/A2D (shade will be selected by shade wheel) A4 (shade determined by Easy shade5), ECM-001/Backing material, A3E/A6D (shade will be selected by shade wheel
59867|NCT03716349|Procedure|Light Curing|A Valo Grand curing unit (Ultradent) with an exitant irradiance with no less than 500 and no greater than 1500 mW/cm2 as measured with MARC Light Collector will be used in standard mode to deliver the required radiant exposure J/cm2 for adhesive and dental composite increments.
59868|NCT03716349|Procedure|Contoured and polished|The restoration will be contoured and polished with - Long flame diamond bur (8863.314.012 Komet), Sof-Lex Medium (orange) Contouring and Polishing Discs (3M), Green Jiffy cup pre-polisher (Ultradent Products, Inc.), Blue and grey silicone points composite polisher gloss plus finisher (Kerr Hawe)
59869|NCT03716349|Other|Consent|The consent form will be signed, copy will be provided to the patient
59870|NCT03716349|Other|Health Questionnaire|The health questionnaire will be completed at initial visit and updated at each follow-up visit
59871|NCT03716349|Radiation|xray|When necessary a radiograph (xray) will be obtained
59872|NCT03716349|Other|Release of medical information signed|The release of medical information form will be signed
59873|NCT03716349|Other|Oral Exam|An Oral Exam will be completed
59874|NCT03716349|Other|Teeth Assessment|The teeth assessment by subject will be completed using the Visual Analog Scale (VAS) and Verbal Rating Scale (VRS) at the follow-up visits 1 month after restoration, 1 year, 2 years and 3 years post restoration.
59875|NCT03716349|Other|Clinical Assessment|A clinical assessment will be completed by the evaluators
59876|NCT03716349|Device|Tokuyama Universal Bond|Tokuyama Universal Bond (TUB) single component self-etching 1-step adhesive system with Tokyuama supra-nanofilled dental composite (ECM) (Tokuyama Dental Corp., Japan)
59877|NCT03716349|Device|ScotchBond|Scotch Bond Universal one-step adhesive system with Filtek Supreme Ultra™, nanofilled dental composite (3M)
59878|NCT03716336|Other|Resistance exercise|Resistance exercise were performed for all participants in group (A) included 9 exercise for big muscles of upper limbs (shoulder flexors muscles, shoulder extensors and shoulder abductors), lower limbs (hip flexors, hip extensors and knee flexors and knee extensors) and abdominal muscle using moderate work load (60 - 75% of IRM) 1set of 10 repetitions, progressing to 2 sets of 10 repetitions after four weeks for 20 minutes
59879|NCT03716336|Other|Aerobic exercise|aerobic exercise were performed on treadmill. For 20 minutes. All patients in the (group A) had attended the program of a resistance exercises and followed by aerobic exercise for 8 weeks in form of 20 minutes walking on the treadmill without inclination.
60052|NCT03715023|Drug|SOC|Standard treatment for RSV infection at study site
59880|NCT03716323|Device|immediate premolar implant with xenograft and allograft|"A peritome will be used for atraumatic extraction of remaining roots.~The extraction socket will be evaluated for absence of any fenestration or granulation tissues.~Copious normal saline irrigation and curettage will be performed.~In the study group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with cortico-cancellous allograft (MinerOss®, BioHorizons, USA)~In the control group: Immediate implant insertion following standard manufacturer's recommended surgical protocol followed by grafting the jumping gap with anorganic bovine bone mineral xenograft (Bio-Oss®, Geistlich, USA)"
59881|NCT03716310|Diagnostic Test|platelet responsiveness evaluation|Blood samples were anticoagulated with 0.129 mmol/L of sodium citrate and then centrifugated for 10 min at 200 rpm; platelets aggregation was assessed with an AggRAM Advanced Modular System light transmittance aggregometer (Helena Laboratories, Beaumont, Texas, USA). Low-molecular-weight heparin (LMWH) was given at least 8 hours before any blood aggregation sample. Agonist used to initiate aggregation test were: -Adenosine diphosphate (ADP) to assess P2Y12-dependent platelet aggregation; (20 ng) - Arachidonic acid (AA) to assess cyclooxygenase-dependent platelet Adenosine diphosphate aggregation (1 mcg) - thrombin receptor-activating peptide-6 (TRAP-6) to assess protease-activated receptor 1-dependent platelet aggregation. Max aggregation reached (Aggmax), the slope of the curve (slope) and the latency time (lat) were analyzed for each agonist.
59882|NCT03716284|Procedure|Electromagnetic navigation bronchoscopy (ENB)|ENB is carried out by a ENB system（LungCare, China) with/without other guided bronchoscopy techniques and/or ROSE, which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
59883|NCT03716271|Device|Visual Acuity Examination with a novel lens|Visual Acuity Examination with a novel lens set in an ophthalmic trial frame
59884|NCT03716245|Procedure|supraclavicular lymph node dissection|people with supraclavicular lymph node metastasis before surgery should receive dissection of supraclavicular lymph node and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
59885|NCT03716245|Radiation|supraclavicular area radiotherapy|people with supraclavicular lymph node metastasis before surgery should receive radiotherapy of supraclavicular area and the supraclavicular lymph node metastasis should be confirmed either by core needle biopsy or fine needle aspiration biopsy
59886|NCT03716232|Device|Metallic stent|"All procedures will be performed under propofol sedation. Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 4-6cm fully covered expandable metallic stent (Kaffes stent, Taewoong medical, Seoul, Korea) will then be deployed at the level of the stricture. In cases close to the hepatic hilum where the deployment of the stent is expected to reach one duct and possibly block another duct, a 7 Fr stent will be inserted prior to deployment of the metallic stent in the contralateral duct..~- Stent will be extracted endoscopically after 6 months."
59887|NCT03716232|Device|Multiple plastic stents|"Strictures will be identified by cholangiography and then dilated by a dilating balloon (diameter 6-10mm). A 10 French plastic stent will be inserted bypassing the level of the stricture.~Stent replacement and the addition of further stents will be planned after 3 months from the initial procedure and every 3 months until stricture resolution occurs with a maximum of four procedures. Balloon dilatation with a 6-10 mm balloon will be used in each session before stent insertion."
59888|NCT03716219|Other|Exercise Training|Physical activity in children and adults with asthma.
59889|NCT03716206|Device|Exergame|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
59890|NCT03716206|Other|Physical therapy|This intervention included upper limb task-orientation training, upper limb coordination training, shoulder range of motion and upper limb activity training.
59891|NCT03716193|Other|Oxygen|Patients will be given oxygen via a facemask during the measurement session
59892|NCT03716180|Drug|Paclitaxel|"Paclitaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug"
59893|NCT03716180|Drug|Trastuzumab|Trastuzumab works by targeting the HER2/neu receptor on cancer cells
59894|NCT03716180|Drug|Pertuzumab|Pertuzumab is a monoclonal antibody which targets the surface of the cells human epidermal growth factor receptor 2 protein (HER2) on the cancer cell, interfering with HER2 causing cancer cell death
59895|NCT03716167|Device|K-Laser|infrared laser treatment
59896|NCT03716167|Device|K-Laser Sham|non-infrared light
59897|NCT03716154|Radiation|Diode laser|Diode laser 810nm, 2W, 20sec, 20 HZ
59898|NCT03716141|Other|Autologous Platelets Rich Plasma Treatment|For PRP preparation 10 mL of the patient blood was collected. The blood was centrifuged at 2000 rpm for 5 min to obtain plasma. Then, this plasma was centrifuged at 3000 rpm for another 5 min to collect platelets. Platelets were diluted in 5 mL plasma to form PRP.
59899|NCT03716141|Other|Conventional Saline dressing|saline dressing of diabetic wounds will be done
59900|NCT03716128|Diagnostic Test|18F-PET|Bone biopsy and 18F-PET
59901|NCT03716115|Dietary Supplement|Colostrum high protein powder (Neovite)|Bovine colostrum provided as powder will be reconstituted and administered orally or via NG tube.
59902|NCT03716115|Drug|N-Acetyl Glucosamine (GInNAC)|N-Acetyl glucosamine provided as powder will be reconstituted and administered orally or via NG tube.
59903|NCT03716115|Drug|Teduglutide|Teduglutide will be administered daily as subcutaneous injection
59904|NCT03716115|Drug|Budesonide|Budesonide liquid (as marketed for nebulisation) will be administered orally or bia NG tube daily.
59905|NCT03716102|Device|PCI with implantation with DES|PCI with implantation with DES
59906|NCT03716089|Procedure|Laparoscopic resection|Laparoscopic surgery under general anesthesia
59907|NCT03716076|Drug|Carbetocin|50 mcg or 100 mcg bolus of carbetocin
59908|NCT03716063|Drug|Jianpi Huatan dispensing granule|once a day in the morning and evening, every month for a course of treatment, a total of three courses
59909|NCT03716050|Drug|Nitroglycerin|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
59910|NCT03716050|Device|Negative Pressure Wound Therapy/ Wound VAC|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
104264|NCT03371576|Device|intraocular lenses|
59911|NCT03716050|Other|Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
59912|NCT03716050|Other|No treatment|Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.
59913|NCT03716037|Other|Physical Activity for Life (PAL)|The eight-week exercise program (The PAL Study) will incorporate balance, strength, endurance, and flexibility training. The duration of each exercise session, which will be offered three times a week, will be one hour. The supervised exercise session will include 30 minutes of moderate-intensity aerobic exercise, 15 minutes of resistance training, and 15 minutes of stretching and balance training
59914|NCT03716024|Drug|PTK0796|PTK 0796 100mg for injection; PTK 0796 tablet 100mg
59915|NCT03716024|Drug|Linezolid|Pre-mixed 600 mg IV infusion solution; Linezolid 600 mg tablets
59916|NCT03716011|Device|EXCROSSAL|a Second Generation Biodegradable Polymer Sirolimus-Eluting Stent
59917|NCT03715998|Drug|Ramipril|1 or 2 capsules administered orally, twice daily
59918|NCT03715998|Drug|Firibastat|1 or 2 capsules administered orally, twice daily
59919|NCT03715985|Drug|EVAX-01-CAF09b|The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
59920|NCT03715972|Drug|Hydroxyurea|info included in arm group
59921|NCT03715972|Drug|Acetazolamide|Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.
59922|NCT03715959|Procedure|Aspiration of Breast|Undergo NAF
59923|NCT03715959|Procedure|Biospecimen Collection|Undergo NAF
59924|NCT03715946|Drug|Nivolumab Injection|A fully human anti-programmed death 1 (PD-1) monoclonal antibody
59925|NCT03715946|Radiation|Radiotherapy (RT)|45-50 Gy accelerated fractionation in 25 daily fractions, 6 fractions per week
59926|NCT03715933|Drug|INBRX-109 - multivalent DR5 agonist antibody|The active ingredient of INBRX-109 is a recombinant, humanized, multivalent antibody that targets the human death receptor 5 (DR5).
59927|NCT03715920|Device|Electrical currents|The training was planned as HVPG current for the the first group (n = 16), as Russian current for the second group (n = 15) and as isometric strengthening for the third group (n = 15). All treatments were performed under physiotherapist supervision for a total of 15 sessions for 3 days a week for 5 weeks.
59928|NCT03715907|Behavioral|Financial Incentives|Incentives for gap closure.
59929|NCT03715907|Behavioral|Information|Information on care gap and closure process.
59930|NCT03715894|Procedure|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
59931|NCT03715881|Drug|Oral prednisolone administration 50 mg|50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
59932|NCT03715881|Drug|Intravenous Erythropoietin injection|1000 units of erythropoietin every 12 hours for three days
59933|NCT03715868|Other|Non-milked derived protein source formula diet|Formula diet based on a non-milked derived protein source
59934|NCT03715855|Device|olfactory measuring device|"Patients blowing into bags then analysis by olfadiag system~Patients blowing into sachets then analysis by olfadiag system"
59935|NCT03715842|Other|Tub shaped design|The tub-shaped inlay preparation design this consists of an occlusal proximal reduction featuring a 3.5-4 mm width bucco-lingually, 3-3.5mm depth occluso-gingivally and 7-7.5 mm length mesio distally for molars and 2.3-2.8mm width buccolingually, 3-3.5 mm depth occluso gingivally and 3.5-4mm length mesiodistally for premolars. when necessary, superficial extensions may also be made on the preparations so that the occlusal fossa included in the preparation area and then the susceptibility for plaque accumulation will be diminished.
59936|NCT03715842|Other|Inlay shaped design|The occlusal inlay had a preparation depth that allowed a thickness of 2.0 mm for the ceramic. The occlusal preparation was 4 mm wide and extended 4 or 6 mm mesio-distally for the premolar or molar models, respectively. The proximal box was 1 mm wide and had approximately 5˚ divergence, extending 2 mm apical to the isthmus floor . The preparations corresponded to a proximal connector area of 3 mm × 3 mm for molars and premolars.
59945|NCT03715816|Behavioral|Work break schedule|Participants will receive 2.5-min breaks during a 90-min simulated laparoscopic surgery in the laboratory. The breaks will be either passive (simple rest) or active (selected mobilization exercises).
59946|NCT03715803|Device|Calistar A mesh to treat anterior and apical POP|Single incision surgery using Calistar A mesh to treat anterior and apical pelvic prolapses
59947|NCT03715803|Device|Calistar S mesh to treat anterior and apical POP|Single incision surgery using Calistar S to treat anterior and apical pelvic prolapses
59948|NCT03715790|Behavioral|EP referred group|Referred for sudden cardiac death (SCD) risk stratification and management
59949|NCT03715790|Behavioral|Non-Referred group|Not referred for sudden cardiac death (SCD) risk stratification and management.
59950|NCT03715777|Drug|Clostridium botulinum type A (BoNTA)|"Powder and solution for solution for injection Specify total dose: 80 U~Route of administration:"
59951|NCT03715764|Other|Physical therapy assessment|Primary assessment, diagnose and treatment by a physical therapist for patients with knee pain in primary care.
59952|NCT03715764|Other|Physician assessment|Primary assessment, diagnose and treatment by a physician for patients with knee pain in primary care.
59953|NCT03715751|Other|ASV|Adaptive Support Ventilation
106093|NCT03357133|Drug|Alteplase|Only alteplase intravenous thrombolysis
59955|NCT03715738|Other|arm 1 : Creaform3D + MyotonPRO|"After inclusion,are carried out:~estimation of the volume of the breast to be reduced with the 3D digital camera~measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete."
59956|NCT03715725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Administration according to clinical practice
59957|NCT03715725|Drug|Apixaban (Eliquis)|Administration according to clinical practice
59958|NCT03715725|Drug|Dabigatran etexilate (Pradaxa)|Administration according to clinical practice
59959|NCT03715725|Drug|Warfarin (Marevan)|Administration according to clinical practice
59960|NCT03715712|Other|standardized blood pressure management|Standardized blood pressure management of a mean blood pressure > 65mmHg and a systolic blood pressure of < 160mmHg using norepinephrine continuous infusion
59961|NCT03715712|Other|Individualized blood pressure management|Individualized blood pressure management of 20% within the preoperative ward blood pressure using norepinephrine continuous infusion
59962|NCT03715699|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 7.5mg to 10mg/d to 12 months.
59963|NCT03715699|Drug|Prednisone and Leflunomide|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Leflunomide: 20mg qd for 6 months and 10mg qd for 6 months."
59964|NCT03715686|Procedure|wire localization|Pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. ALND will be performed in all participants.
59965|NCT03715673|Diagnostic Test|von willebrand antigen and activity|Measuring von Willebrand antigen and activity (VWF: RCo and VWF: CB)
59966|NCT03715660|Diagnostic Test|Xpert bladder cancer monitor|Xpert Bladder Cancer Monitor, is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.The test utilizes a voided urine specimen and measures the levels of five targetmRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR). The Xpert Bladder Cancer Monitor is indicated as an aid to standard clinical evaluation in monitoring for bladder cancer recurrence in patients previously diagnosed with bladder cancer and should be used in conjunction with other clinical measures to assess disease recurrence.
59967|NCT03715647|Other|Sepsis|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
59968|NCT03715647|Other|HELLP Syndrome|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
59969|NCT03715647|Other|Respiratory Distress Syndrome Adult|Evaluation and monitoring with Electrical Impedance Tomography in order to conduct ventilatory therapy.
59970|NCT03715634|Drug|INDV-6200|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
59971|NCT03715634|Drug|Placebo|Subjects will be randomized in a 3:1 ratio to receive either depot buprenorphine or volume-matched placebo
59972|NCT03715634|Drug|SL Buprenorphine|All subjects will receive SL buprenorphine as non-investigational IMP to confirm tolerability
59973|NCT03715634|Drug|Nalorex|Both Periods will include series of nalorex administrations to antagonize potential opioid effects from buprenorphine
59974|NCT03715608|Other|Psychological Intervention|The patients in the intervention group received psychological counseling and corresponding medication after the operation. Psychotherapy was based on the clinical expertise of the psychosocial specialist from Peking University Sixth Hospital, who selected the most appropriate plan for each patient.
59975|NCT03715595|Other|SSDM group|The patients can perform self-evaluation, including DAS28, morning stiffness duration (MSD) and HAQ, and input medical records (including medication and laboratory test results) every month.
59976|NCT03715582|Drug|trimetazidine|Pills of masking drug - trimetazidine
59977|NCT03715582|Drug|Placebo Oral Tablet|Pills of masking drug - placebo
59978|NCT03715569|Diagnostic Test|Vestibular function|Vhit, Caloric test
59979|NCT03715569|Diagnostic Test|OAE/WBT|Oto acoustic emissions Wide Band Tympanometry
59980|NCT03715569|Diagnostic Test|Biomarker|Biomarker examination
59981|NCT03715569|Diagnostic Test|MOCA, eGOS|Cognitive tests
59982|NCT03715569|Diagnostic Test|Audiometry|Hearing test
59983|NCT03715556|Drug|Amiodarone|Administration of the drug will be blinded within the first 48 hours for the principal investigator. Amiodarone (5 mg / kg EV in 30 minutes) will be the drug of choice in the Restricted group blinded to the principal investigator. If there is no reversal / control and there is no adverse event, a further dose of the same previously administered medicinal product will be performed within 30 minutes, amiodarone 3 mg / kg. After the second dose, continuous infusion of amiodarone at a dose of 900 mg in 24 hours will be initiated.
59984|NCT03715556|Drug|0.9% physiological solution|Administration of 0.9% physiological solution.
59985|NCT03715543|Procedure|Surgical Resection of the Greater Splanchnic Nerve|"Video-Assisted Thoracoscopic Surgery (VATS) is performed under general anesthesia using existing, CE marked instrumentation. Two or more 5 mm incisions are used to pass a tiny video camera and a single dissecting instrument into the chest. These small ports are advantageous because the chance for infection and wound dehiscence are drastically reduced. This allows for a faster recovery by the patient and a greater chance for the wound to heal.~In the procedure the GSN will be identified visually or through stimulation-induced hemodynamic reflex. The GSN will then be ablated using standard techniques. If there are multiple branches of the GSN, each branch will be systematically identified and ablated."
60990|NCT03707925|Procedure|Conventional Surgery|Undergo standard resection
59986|NCT03715530|Device|PAMG-1 immunoassay|The procedure includes the insertion of a PAMG-1 swab into the subject's vaginal vault without a speculum for one minute. Once the swab is obtained, the treating physician will place the swab in a solvent vial for one minute. A developing strip is then placed in a vial and allowed to develop for five minutes. The results are read from the developing strip.
59987|NCT03715517|Procedure|Continuous thoracic epidural analgesia|"Needle/catheter: 17 Ga. × 80 mm Tuohy epidural needle (Perican®, B. Braun Medical Inc., Bethlehem, PA, USA); Arrow FlexTip Plus® 19 Ga. epidural catheter (Arrow International Inc., Reading, PA, USA)~Level of insertion and patient positioning: T6-T8, upright sitting position for insertion of needle and catheter (to 5 cm beyond loss-of-resistance point) and for injection of test dose (3 mL 2% lidocaine with epinephrine 1:200,000); supine for injection of bolus dose~Confirmation of correct placement: Loss of resistance to air or saline; negative aspiration of the epidural catheter; negative test dose; and ease of injection of an initial bolus dose"
59988|NCT03715517|Procedure|Spinal anesthesia with intrathecal morphine|"Needle/catheter: 25 Ga. × 90 mm high-flow Whitacre spinal needle (Becton-Dickinson, Franklin Lakes, NJ, USA)~Level of insertion and patient positioning: L2-L3, lateral decubitus position during injection; immediately post-injection, patient is placed supine in <5% degree of Trendelenburg~Confirmation of correct placement: Aspiration of cerebrospinal fluid"
59989|NCT03715517|Drug|Bupivacaine 0.75% in Dextrose Inj 8.25%|0.25 mg⋅kg⁻¹ hyperbaric bupivacaine 0.75%
59990|NCT03715517|Drug|Morphine|3 mcg⋅kg⁻¹ intrathecal morphine (preservative-free)
59991|NCT03715517|Drug|Bupivacaine 0.25% Preservative-Free Injectable Solution|0.25 mg⋅kg⁻¹ bupivacaine 0.25%
59992|NCT03715517|Drug|Bupicavaine 0.125% epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL⁻¹, infusion range 0.075-0.125 mL⋅kg⁻¹⋅h⁻¹
59993|NCT03715517|Drug|Hydromorphone 10 mcg/mL epidural solution|Epidural solution, bupivacaine 0.125% with hydromorphone 10 mcg·mL⁻¹, infusion range 0.075-0.125 mL⋅kg⁻¹⋅h⁻¹
59994|NCT03715504|Drug|TP-3654|oral PIM inhibitor
59995|NCT03715478|Drug|GSK2857916 with Pomalidomide and Dexamethasone|Recommended phase 2 dose (RP2D) of GSK2857916 determined by the phase 1 portion of study will be administered in combination with pomalidomide (approved dose and schedule) and dexamethasone until progression of disease.
59996|NCT03715465|Drug|Melatonin 0.5 MG|Melatonin tablet
59997|NCT03715465|Other|Dim Light Melatonin Onset (salivary)|Test to determine the time of melatonin onset in saliva under dim light conditions
59998|NCT03715452|Device|DyeVert Plus Contrast Reduction System|The DyeVert Plus System interfaces with standard manifold systems to provide real-time contrast monitoring and reduce the amount of contrast used in catheterization procedures while maintaining fluoroscopic image quality. System components include a disposable, single-use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe and DyeVert Plus Module, which is connected to a standard manifold and provides fluid pathway resistance modulation via a dedicated diversion valve. The diversion valve self-adjusts to the manual injection pressure to divert some of the contrast media into the reservoir chamber within the module. This diverted volume of contrast media does not enter the patient.
59999|NCT03715439|Device|Dental implant|A single dental implant was inserted 3 months after tooth extraction
60000|NCT03715426|Behavioral|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
60001|NCT03715413|Other|pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia.|Patients were lying prone. Firstly, T2, 3, 4 disc level was detected then the target 2nd, 3rd and 4th thoracic nerve roots were identified. After marking the entry points, adequate sterilization of the skin was achieved using bovidone iodine then the skin was anasthesied by 2 ml lidocaine 2% at each entry point. The Baileys radio frequency (RF) 22G, 10 cm, sharp needles with 10 mm active tip was introduced to face the 2nd, 3rd and 4th thoracic nerve roots.The PRF course was carried out at 42°C for 120 s twice at each level followed by injection of 1 ml lidocaine 2% and 1 ml dexamethasone 4 mg at each level.
60002|NCT03715413|Drug|Tamoxifen|received Tamoxifen 10 mg daily
60003|NCT03715400|Behavioral|Positive Virtual Reality Training|Participants will undergo 13 one-hour sessions of positive virtual reality training over the course of eight weeks. All assessments will be completed online at home following initial orientation to the program.
60004|NCT03715387|Drug|Tacrolimus Topical 0.1% Topical Ointment|Topical tacrolimus ointment
60005|NCT03715387|Drug|Polysporin Ointment|Polysporin ointment
60006|NCT03715374|Procedure|Periodontal Surgery with PRF+ABB|Patients will be treated by periodontal surgical flaps with the addition of PRF+ Anorganic Bovine Bone filling material
60007|NCT03715374|Procedure|Periodontal Surgery with Collagen Membrane +ABB|Patients will be treated by periodontal surgical flaps with the addition of Collagen Membrane + Anorganic Bovine Bone filling material
60008|NCT03715361|Diagnostic Test|SL-ECG|additional SL-ECG measurement
60009|NCT03715348|Drug|Prothrombin Complex Concentrate (PCC)|PCC is a blood product produced through pooling of thousands of human plasmas, which is then treated to inactivate enveloped viruses. From the pooled plasma, vitamin K dependent clotting factors (factors II, VII, IX and X, and protein C and protein S), are selected to produce the concentrated form called PCC.
60010|NCT03715348|Biological|Fresh Frozen Plasma|Fresh Frozen Plasma a blood component manufactured from whole blood collection.
60011|NCT03715335|Other|Targeted STI Screening|GC/CT screening will be offered to those who screen at risk or at high risk for STIs.
60012|NCT03715335|Other|Universally Offered STI Screening|GC/CT screening will be offered to all patients who meet the age eligibility criteria.
60013|NCT03715322|Drug|Tobramycin Inhalant Product|Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
60014|NCT03715322|Other|usual care|ambroxool (30mg thrice daily), or N-acetylcysteine (0.2g thrice daily) plus chest physiotherapy (5 min, once daily)
60015|NCT03715322|Drug|Natural saline inhalation|Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
60016|NCT03715309|Drug|Revlimid|Revlimid 25mg PO d1-10 Plus Rituximab 375 mg/m2 IV d0
60085|NCT03714763|Other|Surgery|Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .
60017|NCT03715296|Drug|Lenalidomide 25mg|Lenalidomide 25mg/d PO d1-10 Plus Rituximab 375 mg/m2 IV d1, Cyclophosphamide 750mg/m2 IV d2, Doxorubicin 50mg/m2 IV d2, Vincristine 1.4 mg/m2 IV d2, Prednisone 60 mg/m2 PO d2－6 OR Ifosfamide 1500mg/m2/d iv d1-3, Carboplatin 5*[GFR(ml/min)+25]mg/d iv d2, Etoposide 100mg/m2/d iv d1-3,
60018|NCT03715283|Other|Home Ankle Strengthing Program|Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
60019|NCT03715283|Other|Standard of Care|Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
60020|NCT03715270|Device|Image surgical area|Image surgical area
60021|NCT03715257|Device|14F staged extubation set guidewire|"14F staged extubation set guidewire is a single use supraglottic airway device. This airway device provides access and functional separation of the respiratory and digestive tracts.~Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
60022|NCT03715257|Device|Tube changing catheter|"Tube changing catheter Tube changing catheter is an alternative extubation device. Cough, straining, hemodynamic parameters and occurrance of hypoxemia (SpO2<94%) are recorded for the first 20 postoperative minutes. Blood gas analyses are done before extubation and 15 minutes after placement of the extubation catheter.~The patients are randomly distributed into two groups; one with 14F staged extubation set guidewire (n=50)"
60023|NCT03715244|Procedure|Spinal anesthesia with short-acting local anesthetics|Spinal anesthesia in patients with duration of surgery < 90 minutes
60024|NCT03715244|Procedure|General anesthesia (current standard)|General anesthesia in patients with duration of surgery < 90 minutes
60025|NCT03715231|Diagnostic Test|NIDEK Gonioscope GS-1|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
60026|NCT03715231|Diagnostic Test|Standard Digital Gonioscopic Images|To determine inter-observer repeatability when using this device, two observers will examine each image obtained from NIDEK Gonioscope GS-1 and separately determine the iridocorneal angle. Inter-observer repeatability will be tested using Pearson correlation.
60027|NCT03715218|Other|Mothers Touch Program|Mothers Touch Program with bed rest, Relaxation program to reduce stress, massage for mother and infant, gently physical exercise and special dietary program each week.
60028|NCT03715218|Other|Usual Care Program|Usual care group had advice, support and educational program delivered by midwife, or physicians.
60029|NCT03715205|Drug|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
60030|NCT03715192|Biological|LY3462817 IV|Administered IV
60031|NCT03715192|Biological|LY3462817 SC|Administered SC
60032|NCT03715192|Drug|Placebo|Administered IV
60033|NCT03715179|Device|Ostomy Pouching System|An ostomy pouching system is a medical device that provides a means for the collection of effluent from a surgically diverted biological system (colon, ileum, bladder) and the creation of a stoma.
60034|NCT03715166|Drug|Bumetanide Oral Solution|Oral Solution dosed at 0.5mg/mL Taken twice daily
60035|NCT03715166|Drug|Placebo|Oral Solution Taken twice daily
60036|NCT03715153|Drug|BUMETANIDE/S95008|Oral solution dosed at 0.5 mg/mL Taken twice daily.
60037|NCT03715153|Drug|PLACEBO|Oral solution Taken twice daily.
60038|NCT03715140|Drug|Crucumin|Evaluation of the effect of Crucumin in patients with osteoarthritis
60039|NCT03715140|Drug|Placebo|Placebo
60040|NCT03715127|Drug|Psilocybine oral capsule|single dose of psilocybin (0.215mg / kg body weight)
60041|NCT03715127|Drug|Placebo oral capsule|single dose of placebo (100% mannitol)
60042|NCT03715114|Drug|GV-971|Oral GV-971
60043|NCT03715114|Drug|Placebo|Oral Placebo
60044|NCT03715101|Drug|Rosuvastatin|Open-label, one-sequence, multiple administration
60045|NCT03715088|Behavioral|Resistance Training Intervention|Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
60046|NCT03715075|Procedure|Caesarean Section|Caesarean Section
60047|NCT03715062|Other|Dialogue tool|The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
60048|NCT03715049|Procedure|Fraxel Laser Treatment|The device to be used in this study is a FDA approved device [510(k) approval] used for aesthetic dermatological procedures. The Fraxel Repair laser system utilizes a sealed off, all metal carbon dioxide gas tube that is radio frequency (RF) excited and air cooled, emitting light at a wavelength of 10.6 μm with programmable pulse duration and frequency. The Fraxel Repair laser has a continuous motion (rolling) optical tracking system. The Fraxel system consists of a treatment component and an internal control component. The treatment component consists of the laser delivery handpiece. A computer with a touch screen keyboard to enter subjects' information also provides controls for the fractionated delivery of the 10.6 μm beam.
60049|NCT03715036|Diagnostic Test|Point-of-care US|The intervention includes reassuring the AC and DVP
60050|NCT03715023|Drug|PC786|PC786 suspension for inhalation
60051|NCT03715023|Drug|Placebo|Placebo solution for inhalation
60053|NCT03715010|Dietary Supplement|BCAA|Subjects will be randomly assigned to take either the 25g supplement (containing 4g BCAA) daily for 4 weeks followed by the 20g BCAA supplement daily for 4 weeks, or vice versa
60054|NCT03714997|Procedure|Walking training|Practice of walking training in variable contexts, including multiple tasks and environments specific to the patients' deficits and community walking goals.
60055|NCT03714984|Other|Pre operative exercise|After randomization participants will be allocated in two groups. The educational pelvic floor intervention group will receive two months before surgery a physiotherapy visit were will be explain to patients and care giver the pelvic floor anatomy and biomechanics and how perform the exercises to be follow at home focusing on pelvic muscles awareness and contraction.
60056|NCT03714984|Other|Control Group|The control group will be just informed about the study protocol and will not receive any pre-operative intervention.
60057|NCT03714971|Behavioral|WhatsApp embedded in smoking cessation service|The routine service delivery was ongoing as the intervention was conducted. In addition to the routine procedures in service delivery described above, WhatsApp messages were sent according to the plan.
60058|NCT03714958|Drug|HDM201|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
60059|NCT03714958|Drug|Trametinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
60060|NCT03714945|Other|No intervention|No intervention is required as this study is observational.
60061|NCT03714932|Diagnostic Test|3shape ortho analyzer software|Arch analysis , manual analysis , digital analysis , Mixed dentition , Tanaka and Johnston
60062|NCT03714919|Drug|Dextromethorphan|Preoperative oral dextromethorphan 1 mg/kg
60063|NCT03714919|Drug|Acetaminophen|Preoperative oral acetaminophen 15 mg/kg
60064|NCT03714919|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine 0.5 μg/kg
60065|NCT03714919|Drug|Ketamine|Intraoperative intravenous ketamine 0.5 mg/kg
60066|NCT03714906|Procedure|Stellate ganglion block|Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
60067|NCT03714893|Device|Sensor wrist watch|Participants will wear a sensor wrist watch which will collect data
60068|NCT03714880|Drug|Mifepristone 200 MG|Ingestion of study medication vs placebo
60069|NCT03714880|Drug|Placebo Oral Tablet|Ingestion of study medication vs placebo
60070|NCT03714867|Drug|Pregabalin 150mg|150 mg concealed pregabalin capsule
60071|NCT03714867|Other|Placebo|Concealed placebo capsule
60072|NCT03714854|Device|transcranial magnetic stimulation|TMS will be delivered on the sensory-motor system and the inhibitory motor control network while patients are performing behavioral and motor tasks. Brain and muscle activity will be recorded concurrently using EEG and EMG respectively.
60073|NCT03714841|Other|CRP|Knowledge of CRP value
60074|NCT03714828|Drug|Injection of TVEC into target lesions - week 1-2|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with regional and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size - section 7.1, Table 5) Talimogene laherparepvec at nominal concentration of 106 plaque forming units (PFU)/mL with approximately 1.15 mL in a 2 mL vial for the initial dose. This will be administered intralesionally to 1-3 cSCC lesions per anatomical site with a maximum of 5 injectable lesions per patient."
60075|NCT03714828|Drug|Injection of TVEC into target lesions 3wks after 1st injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL withapproximately 1.15 mL in a 2 mL vial for the second and subsequent doses."
60076|NCT03714828|Drug|Injection of TVEC into target lesions 2wks after 2nd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected.Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
60077|NCT03714828|Drug|Injection of TVEC into target lesions 2wks after 3rd injection|"Target lesions are identified and documented with measurements and photographs. Photographs will be taken with global and close up view of the anatomical area and lesion.~Inject 0.5ml - 4ml (based on lesion size) and number of lesions selected. Talimogene laherparepvec at nominal concentration of 108 PFU/mL with approximately 1.15 mL in a 2 mL vial for the subsequent doses."
60079|NCT03714802|Procedure|Szabo T-Stenting Technique|2-stent strategy was performed using modified T-stenting with Szabo technique in bifurcation lesions. First, stent was implanted in the side branch with Szabo technique. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
60080|NCT03714802|Procedure|T-Stenting Technique|2-stent strategy was performed using traditional T-stenting technique in bifurcation lesions. First, stent was implanted in the side branch with angiographic guidance. Then, stent was implanted in the main branch. Finally, kissing balloon inflation was performed.
60081|NCT03714789|Other|Blood and spent dialysate collection|A certain amount of blood and spent dialysate are collected during and after dialysis for quantification of drug concentration.
60082|NCT03714776|Drug|IONIS-AGT-LRx|IONIS-AGT-LRx injected subcutaneously once-weekly
60083|NCT03714776|Drug|Placebo|Placebo matching solution injected subcutaneously once-weekly
60084|NCT03714763|Drug|Drug treatment|Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.
60086|NCT03714750|Procedure|DK crush|revascularization of true coronary bifurcation stenosis in DK crush technique
60087|NCT03714750|Procedure|Reverse TAP|revascularization of true coronary bifurcation stenosis in Reverse TAP technique
60088|NCT03714737|Biological|experimental vaccine|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(OLYMVAX Biological Co., LTD)
60089|NCT03714737|Biological|Positive control vaccine 1|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(WALVAX Biological Co., LTD)
60090|NCT03714737|Biological|Positive control vaccine 2|bivalent meningococcal serogroups A and C tetanus toxoid conjugate vaccine(Royal (Wuxi) Biological Co., LTD)
60091|NCT03714724|Diagnostic Test|Intraabdominal Pressure Measurement|In this method, a sterile set system (AbViser- Wolfe Tory Medical, Saik Lake City, Utah, USA) was used in normal conditions. Measurements will be made in 20 ml saline was given, Pressure transducer was used as a reset point pubic symphysis and intra-abdominal pressure was measured.
60092|NCT03714711|Procedure|total hip arthroplasty|Total hip replacement
60093|NCT03714711|Procedure|total knee arthroplasty|Total knee replacement
60094|NCT03714698|Other|Pilates exercise group|Pilates exercise group participated in supervised Pilates-based group training twice per week for six weeks
60095|NCT03714698|Other|Control Group|The control group participated in a routine non-specific activity program twice a week in Community Mental Health Center during study
60096|NCT03714685|Drug|Firibastat|Firibastat (QGC001) 500 mg
60097|NCT03714672|Drug|Tramadol/Diclofenac 50/50|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
60098|NCT03714672|Drug|Tramadol/Diclofenac 25/25|Each dose comprised 1 fixed-dose combination tablet and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
60099|NCT03714672|Drug|Tramadol 50|Each dose comprised 1 capsule containing 50 mg tramadol hydrochloride and 3 placebo tablets matching the other active treatment groups. Doses were taken 8 hours apart.
60100|NCT03714672|Drug|Diclofenac 50|Each dose comprised 1 tablet containing 50 mg diclofenac sodium and 3 placebo tablets or capsules matching the other active treatment groups. Doses were taken 8 hours apart.
60101|NCT03714659|Device|Lipogems|Lipogems is a closed-loop system designed to break up adipose tissue into micro-fragmented adipose tissue without additives; therefore, meeting FDA requirements for minimal manipulation. A small volume of adipose tissue is harvested from the abdomen, thigh, or other location. The lipoaspirate is fed into the device through a reduction filter, and is then cleansed of blood and oil residues using a sterile saline solution. This fat-saline solution is then shaken for 30 seconds in a device containing stainless steel ball bearings, which further fragments and washes the lipoaspirate. Once the tissue is purified and fragmented, it is collected in 10cc sterile syringes and subsequently injected into the meniscus and knee joint.
60102|NCT03714646|Dietary Supplement|beta glucan and resistant starch|12g per day the day before the CID Resistant starch 7.5 g
60103|NCT03714646|Dietary Supplement|Placebo|isocaloric maltodextrin before the CID
60104|NCT03714646|Dietary Supplement|beta gluten|12 g beta gluten there day before the CID
60105|NCT03714633|Behavioral|Stockholm Preterm Interaction-Based Intervention (SPIBI)|Post-discharge intervention to extreme premature infants and their parents
60106|NCT03714620|Drug|Ketamine|Ketamine 0.15 mg/kg vs. 0.3 mg/kg IVPB over 15 minutes
60107|NCT03714607|Device|Erbium Yttrium Aluminum Garnet (Er:YAG) laser|5 Er:YAG laser therapies vaginally administered at monthly intervals
60108|NCT03714594|Drug|Dapagliflozin 10mg|Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine.[
60109|NCT03714594|Drug|Saxagliptin 5mg|Inhibits DPP-4 and slows inactivation of incretin hormones, thereby increasing blood concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
60110|NCT03714594|Drug|Saxagliptin 5mg + Dapagliflozin 10 mg|Please see Intervention 1 and 2
60111|NCT03714581|Device|Microablative Fractional CO2 Laser Therapy|5 laser therapies intravaginally administered will be applied at monthly intervals.
60112|NCT03714568|Drug|TQ-A3326|TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
60113|NCT03714568|Drug|placebo|Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses)
60114|NCT03714555|Diagnostic Test|Safety Laboratories|CBC w Differential, CMP, PT/INR, aPTT, Urinalysis
60115|NCT03714555|Other|AE Assessment|Assessment of Adverse Events
60116|NCT03714555|Other|Physical Exam|Physical Exam, Weight, Vital Signs, ECOG Performance Status
60117|NCT03714555|Other|Concomitant Medication Review|Prior and Concomitant Medication Review
60118|NCT03714555|Diagnostic Test|Tumor Imaging|Tumor CT or MRI
60119|NCT03714555|Drug|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate|nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
60120|NCT03714555|Drug|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate|FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing
60121|NCT03714555|Drug|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate|Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
60122|NCT03714542|Other|Pre- and postoperative MRI|
60123|NCT03714529|Biological|PD-L1|IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.
60124|NCT03714516|Behavioral|Online psychological intervention|The intervention is a non-controlled unguided internet-based self-help intervention for adults who seek support for coping with prolonged grief symptoms after romantic bereavement or separation/ divorce. The self-help program consists of 10 text-based sessions based on cognitive-behavioral psychotherapy techniques.
60125|NCT03714503|Device|Retina re-attachment repair using C3F8 gas tamponade|Assigning a one day post-operative head positioning
60183|NCT03713996|Other|Health Education|Participants in this arm will receive education in sleep hygiene, foot care, causes and diagnosis of diabetes, healthy diet, and physical activity. The education will be provided in 6-session (1 session/week).
60184|NCT03713983|Other|Observational study|Observational study
60126|NCT03714490|Radiation|SCPRT plus neoadjuvant chemotherapy|Short-course preoperative radiotherapy(SCPRT) with neoadjuvant chemotherapy, which consists of SCPRT, 5 Gy x 5, 4Gy for boost on the GTV with MRI-simulation alone, then after 7-10 days of radiotherapy completed, patients will receive consolidation chemotherapy, given in 3 week cycle of capecitabine 1000 mg/m2 twice daily, day 1-14 combined with oxaliplatin 130 mg/m2 once. In total, 4 cycles of neoadjuvant chemotherapy are scheduled before surgery.
60127|NCT03714490|Radiation|long course chemoradiation|Long-term chemoradiotherapy(CRT), which consists of a long-term chemoradiation (2 Gy x 25 with capecitabine) preoperatively.
60128|NCT03714477|Procedure|Extracorporeal shock wave lithotripsy|A minimally invasive treatment for renal stone which was first introduced in early 1980's. It tries to fragment the renal stones by high-energy shockwave at the kidney from the outside.
60129|NCT03714464|Other|Whole apples|350 of whole apples containing 49g of available carbohydrate with 173ml water
60130|NCT03714464|Other|Apple puree|384g of apple puree containing 44g of available carbohydrates with 224 ml water
60131|NCT03714464|Other|Apple Juice|338g apple juice containing 46g of available carbohydrate with 260 ml water
60132|NCT03714451|Dietary Supplement|onyx sorghum|The diet intervention will last a total of 28 days. Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat. In the Onyx Group, 25% of carbohydrate will come from the onyx sorghum, and at least three foods per day (including cereals, bread, muffins, pasta, and smoothie boosters) will contain this.
60133|NCT03714451|Dietary Supplement|whole wheat flour|Per the American Heart Association (AHA) and American Diabetes Association (ADA) recommendations, the daily diet plan will consist of 50-55% carbohydrate, 15-20% protein, and 25-30% fat.
60134|NCT03714438|Drug|Medicago Sativa|Single oral doses of Medicago sativa (1,500 mg), 30 min before before the oral glucose tolerance test.
60135|NCT03714438|Dietary Supplement|Placebo|Single oral doses of placebo (1,500 mg), 30 min before before the oral glucose tolerance test.
60136|NCT03714425|Device|Quell|Quell is a Transcutaneous Electrical Nerve Stimulator Device (TENS). The device will use nerve stimulation to treat chronic pain by sending signals to the brain that cause it to release natural opioids.
60137|NCT03714412|Device|Implantation|Implantation of the Cardiovalve transfemoral mitral valve replacement system
60138|NCT03714386|Device|A synthetic high-flux dialyzer will be used for OL-HDF.|A synthetic high-flux dialyzer used for OL-HDF must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
60139|NCT03714386|Device|A medium cut-off dialyzer will be used for HDx.|A medium cut-off dialyzer used for HDx must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription
60140|NCT03714373|Drug|DCCR|Once daily oral administration
60141|NCT03714360|Drug|Tranexamic Acid|patients with ASA(American Society of Anesthesiologists grades) 1 to 2, scheduled to undergo lumbar decompressive surgery at Middelfart Hospital. Patients were randomized, in blocks of 10, to two groups: TXA or placebo. Anticoagulation therapy was discontinued 2-7 days preoperatively. Prior to the incision, patients received either a bolus of TXA (10mg/kg), or an equivalent volume of saline solution (placebo).
60142|NCT03714360|Drug|Sodium Chloride 0,9%|Sodium Chloride 0,9%
60143|NCT03714347|Device|cerebral oxygen monitoring|probes will be placed on eyebrows on forehead
60144|NCT03714347|Device|routine monitoring|We will use routine monitoring intervention such as hate rate, arterial pressure, BIS. cerebral oxygen monitoring will not be applied to this group
60145|NCT03714334|Drug|DNX-2440 injection|DNX-2440 virus will be injected stereotactically
60146|NCT03714321|Device|Mechanical insufflation-exsufflation (MIE)|Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
60148|NCT03714295|Other|Use of interdental brushes|No intervention they just use interdental brushes as it should be done routinely
60149|NCT03714282|Device|Noninvasive spinal stimulation with gait training|Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform locomotor activities.
60150|NCT03714282|Device|Conventional gait training|May receive up to 50 min of locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and overground training will depend on individual tolerance and progression.
60151|NCT03714282|Other|Healthy control group|Participant in the Healthy Control Group will participate in up to 3 assessment sessions in order to obtain comparative data for Spinal Motor Evoked Potentials (MEPs), lower extremity MVC's, sidelying EMG data and overground EMG data
60152|NCT03714269|Other|measurement evaluated with an isokinetic dynamometer|measurement of the maximum dorsiflexion angle in degrees evaluated on an isokinetic dynamometer
60153|NCT03714269|Other|measurement evaluated with an 2D ultrasound|"simultaneous recording of force torque, joint angle and myotendinous junction displacement in 2D ultrasound during 5 passive mobilization cycles of ankle flexion-extension at very low speed~recording of static images in 2D ultrasound representing the proximal insertion of the gastrocnemius muscle in the internal condyle of the femur, the myotendinous junction."
60154|NCT03714269|Other|assessment of the level of discomfort|visual analogue scale (0 = no discomfort and 10 = maximal discomfort)
60155|NCT03714256|Device|Device, patient mobility, powered|Pediatric mobility device
60156|NCT03714243|Device|ExAblate BBBD|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in patients with Her-2 positive breast cancer and brain metastases
60157|NCT03714217|Behavioral|Telenutrition Counseling|A registered dietitian nutritionist will contact each participant twice a month for 3 months to provide nutrition counseling via iPad FaceTime.
60185|NCT03713970|Procedure|celtra duo press|celtra duo press ingot
60186|NCT03713970|Procedure|IPS e.max press|IPS e.max press ingot
60187|NCT03713957|Drug|GRF6021|GRF6021 for IV infusion
60188|NCT03713957|Other|Placebo|Placebo for IV infusion
60189|NCT03713944|Drug|Carboplatin|Carboplatin, AUC 5
60158|NCT03714204|Behavioral|Transcendental Meditation technique|The TM technique is a simple mental procedure that is categorized in the automatic self-transcending category of meditation practices. It is automatic in that it does not involve any concentration or control. It allows the mental activity to settle down in a spontaneous and natural manner during a process called transcending, or going beyond, until it reaches a state beyond conscious thinking. Correspondingly, the body settles down to a deep state of rest which allows stress to dissolve and the nervous system to rejuvenate The effortless nature of the TM practice coupled with the vast research supporting its efficacy, its systematic standardized teaching program and the fact that it does not involve any belief or change in one's lifestyle made it the choice intervention for this research.
60159|NCT03714191|Other|Patient Outcomes|The intervention includes different versions of the BPA design and message.
60160|NCT03714191|Other|Billing documentation|The intervention includes different versions of the BPA design and message.
60161|NCT03714191|Other|Regulatory|The intervention includes different versions of the BPA design and message.
60162|NCT03714178|Device|FARAPULSE Endocardial Ablation System|Endocardial ablation using the FARAPULSE Endocardial Ablation System.
60163|NCT03714165|Diagnostic Test|Alpha defensin and 16SrRNA gene|Alpha defensin 16S rRNA gene CBC: Complete blood count CRP: C reactive protein ESR: Erythrocyte sedimentation rate Culture and antibiotic sensitivity of synovial fluid
60164|NCT03714152|Drug|ABI-H2158|5 mg or 25 mg tablets
60165|NCT03714152|Drug|Placebo for ABI-H2158|Sugar pill manufactured to mimic the ABI-H2158 5 mg or 25 mg tablets
60166|NCT03714139|Procedure|immediate loading|"The participants will be assigned to immediate or delayed functional loading groups. In each participant, edentulous areas with adequate thickness of the alveolar bone crest will be identified and at least two sites will be identified for implant installation. All implant recipient sites will be sub-prepared to allow good stability of the implants. Experimental mini-implants (Sweden & Martina, Due Carrare, Padova, Italy), 3.5 mm in diameter and with an intraosseous portion of 4 mm in length will be installed.~Immediate loading group - A prosthetic component will be applied over the trial implants. Impressions will be taken and a crown / bridge will be provided to patients in one day."
60167|NCT03714139|Procedure|non implant loading|Control implants will receive a healing screw and will remain unloaded
60168|NCT03714126|Device|Cordio Medical|Recording to an app, no interference to the regular care
60169|NCT03714113|Diagnostic Test|Anti-HLA donor-specific antibodies monitoring|Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
60170|NCT03714100|Behavioral|Tai Ji Quan: Moving for Better Balance|Participants will attend one-hour Tai Ji Quan: Moving for Better Balance classes twice a week for 16-weeks. Groups of participants will gather at a local community site that has videoconferencing capabilities. The instructor will be teaching the class from a different location via a live video feed.
60171|NCT03714087|Device|T1 before aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
60172|NCT03714087|Other|T2 after the aligner|The UDEA2 finishing protocol include: Training of the clinicians, evaluation of finishing records, checklist according OGS items, using of aligner with set-up)
60173|NCT03714087|Other|Historic control group|
60174|NCT03714074|Device|PEEK implant abutment|Implants will be restored with abutments made from polyetheretherketone (PEEK) abutments and a PEEK superstructure
60175|NCT03714074|Device|Zirconia abutment|Imolants will be restored with zirconia abutments and a PEEK superstructure
60176|NCT03714061|Other|Pain Neuroscience Education|"The PNE will be administered following Explaining Pain concepts, initially contextualizing the importance of the program, addressing concepts of neuroscience and pain, incorrect information about what is pain, how the brain responds to nociception in a variety of situations, and how an experience of danger can trigger or aggravate a state of pain, coexistence of several potential protection systems, central sensitization and how to promote behavioral change, abandoning incorrect beliefs, proposing graded activity exposure.~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
60177|NCT03714061|Other|Self-Management Education|"Concepts about pain, musculoskeletal pain, chronic pain and disability will be addressed. Participants will be guided on the process of chronic pain, associated suffering, conceptual model of fear-avoidance and clarified on avoidant and confronting profiles. In a third phase, strategies will be presented on how to deal with chronic pain, with advice on the harmful effects of restricting activities and the use of drug therapy in a careful way (Dupeyron et al, 2011).~In addition, participants were requested to perform a group of 7 exercises two times a week. In the day of the education session (second day), participants were again oriented on how to perform the exercises (reinforcement) and invited to show the way they were executing them at home. In the first session, participants were trained on how to perform the abdominal bracing and oriented to repeat the maneuver in all exercises during the following three weeks."
60178|NCT03714035|Other|no intervention|no intervention
60179|NCT03714022|Drug|Abatacept|Single intravenous dose
60180|NCT03714009|Behavioral|Fasting|"Periodic fasting last for 4weeks prior to the treatment cycle. The fasting method involves daily fasts of 14-16hours and restrict eating to an 8-10 hour eating window as 2-3 or more meals of balanced diet. Patients should take adequate water and non calorie beverages intake daily (2-3 liters)."
60181|NCT03714009|Behavioral|No fasting|Patients will not fast . But they will take balanced food and drink 2 to 3 liters of water and non caloric drinks all the day for 4 weeks
60182|NCT03713996|Behavioral|Cognitive behavioral therapy for insomnia|CBT-I is designed to change sleep habits as well as direct misconceptions about sleep and insomnia. Participants will receive several face-to-face interview techniques: sleep restriction therapy, stimulus control procedures, sleep hygiene, relaxation training and cognitive components. The intervention will be provided in 6-session (one session/week).
60190|NCT03713944|Drug|Pemetrexed|Pemetrexed 500mg/m2
60191|NCT03713944|Drug|Atezolizumab|Atezolizumab 1200mg
60192|NCT03713944|Drug|Bevacizumab|Bevacizumab 15mg/kg
60193|NCT03713931|Diagnostic Test|PUMA Score questionnaire|"Every patient who meet the criteria for active search (older than 40 years, smokers or ex-smokers of more than 10 pack-years who attend the usual care in the first level of care) will be scored with the PUMA´s questionnaire in an application and electronic database (RedCap) specially designed for the active search of cases.~Patients with PUMA´s score ≥ 5, and without exclusion criteria for spirometry will be referred to perform spirometry at the institution"
60194|NCT03713918|Other|Reinforced lithium silicate endocrowns|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with reinforced lithium silicate and cemented with self adhesive cement
60195|NCT03713918|Other|Post retained reinforced lith silicate crn|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and reinforced lithium silicate crown will be cemented with self adhesive cement.
60196|NCT03713905|Drug|GLS-010|Recombinant Human Anti-PD-1 Monoclonal Antibody
60197|NCT03713892|Drug|CKD-504|orally administered once with investigational drug assigned on 1d morning with 240 mL of water
60198|NCT03713892|Drug|Placebo|orally administered
60199|NCT03713879|Device|pancreatic stenting|"a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025 or .035 wire)"
60200|NCT03713879|Drug|Indomethacin|rectally administered indomethacin before or after ERCP
60201|NCT03713866|Diagnostic Test|EP Imaging and Testing|"Magnetic Resonance Imaging: pre-procedure imaging is standard care prior to catheter ablation procedures for VT to document anatomy of the heart.~120-Lead Body Surface Mapping: a 120-lead ECG will be recorded using a standardized mapping protocol. 120 disposable radiolucent silver chloride (Ag/AgCl) surface electrodes will be placed on the torso in 18 strips and connected via cables to an advanced acquisition system.~Noninvasive programmed stimulation (NIPS) study will be performed using the patient's implanted defibrillator, and is part of standard practice during a VT catheter ablation."
60202|NCT03713840|Behavioral|Healthy Beverages in Child Care|12-week intervention promoted consumption of healthy beverages (water, unsweetened low-fat milk) and discouraged consumption of unhealthy beverages (juice, sugar-sweetened beverages, high-fat or sweetened milk). The multi-pronged intervention was delivered via child care centers, targeted children, parents, and child care staff, and included education, environmental changes, and policies.
60203|NCT03713827|Device|tooth restoration|restoration of non carious cervical lesions with two different restorative materials
60204|NCT03713814|Other|Exercise|"8-week exercise program, three times a week, during 45 minutes each section. Exercises for strength, endurance and mobility of the spine using pilates´ball and mat.~The researcher will explain, demonstrate and supervise the participants. It will start with 10 minutes of warming-up using a ergometer bicycle, followed by the mat exercises. Some of these will require motor control with mobility, others will require isometry, or concentric and eccentric phases with progression of eccentric phase timing."
60205|NCT03713801|Drug|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 3 weeks and continued for a total exposure of 12 weeks.
60206|NCT03713801|Drug|Placebo|Placebo tablets titrated up to 3 tablets over the course of 3 weeks and then continued as 3 daily for a total exposure of 12 weeks
60207|NCT03713788|Other|Cold pressor test|Participants placed their non-dominant hand into cold water for 2 minutes
60208|NCT03713775|Other|Meal Replacement Weight Loss Programme|The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.
60209|NCT03713775|Other|Usual Care|Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (~15 min), together with supporting written information.
60210|NCT03713762|Drug|peribulbar block 1 lidocaine/bupivacaine|Peribulbar block: 100 mg of lidocaine 5% and 15 mg of bupivacaine 0.5% for a total volume of the anesthetic mixture of 5 ml.
60211|NCT03713762|Drug|peribulbar block 2 lidocaine/bupivacaine/fentanyl|Peribulbar block: 100 mg of lidocaine 5%, 15 mg of 0.5% bupivacaine and 50 mcg of fentanyl citrate for a total volume of the anesthetic mixture of 6 ml.
60212|NCT03713749|Device|Robot esophagectomy (RE)|Patients in RE group will receive Robotic-assisted surgery in thoracic phase.
60213|NCT03713736|Diagnostic Test|Cervical smear|Cervical smear will be obtained using an Ayre spatula and a cervical brush (Cervex-Brush®). HPV test will be performed using the CLART® HPV2 kit (Genomica).This kit enables the detection of 35 genotypes: HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 43,44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85 et 89.
60214|NCT03713736|Diagnostic Test|Pregnancy test|Urinary pregnancy test
60215|NCT03713736|Behavioral|Sexual activity questionnary|Sexual activity questionnary
60216|NCT03713723|Device|NICaS bioimpedance system|NICaS is a bioimpedance system focusing on noninvasive assessment and monitoring of cardiovascular, respiratory, and fluid parameters.Cardiovascular monitoring will be carried out using non-invasive NICAS cardiac impedance cardiography by the use of two electrodes stickers which are pasted on the wrists for 6 minutes
60217|NCT03713710|Behavioral|Pap testing|Women will be approached in the community by a Peer Health Educator and scheduled an appointment for a Pap testing at the local health department
60218|NCT03713710|Behavioral|Choice|Women will be approached in the community by a Peer Health Educator and they will be given a choice between scheduling an appointment for a Pap testing at the local health department or engage in self-sampling for HPV testing at home
60219|NCT03713697|Behavioral|Pap testing|Un/underscreened women received a home visit by a Community Health Worker and were scheduled an appointment for a Pap testing at the Basic Health Unit
60220|NCT03713697|Behavioral|Self-collection for HPV testing|Un/underscreened women received a home visit by a Community Health Worker and were given a kit to self-collect their own sampling for HPV testing at home
60291|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 1|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
60221|NCT03713697|Behavioral|Choice|Un/underscreened women received a home visit by a Community Health Worker and were given a choice between scheduling an appointment for a Pap testing at the Basic Health Unit or self-collect their own sampling for HPV testing at home
60222|NCT03713684|Drug|Efpeglenatide SAR439977|Pharmaceutical form: solution for injection Route of administration: subcutaneous
60223|NCT03713684|Drug|Placebo|Pharmaceutical form: solution for injection Route of administration: subcutaneous
60224|NCT03713684|Drug|Insulin glargine|Pharmaceutical form: solution for injection Route of administration: subcutaneous
60225|NCT03713671|Diagnostic Test|gait analysis|Computerized gait analysis system will use to evaluate spatio-temporal gait parameters
60226|NCT03713658|Drug|Risperidone 3 mg|Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
60227|NCT03713658|Drug|Paliperidone Palmitate 50 mg eq.|Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
60228|NCT03713658|Drug|Paliperidone Palmitate 75 mg eq.|Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
60229|NCT03713658|Drug|Paliperidone Palmitate 100 mg eq.|Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
60230|NCT03713658|Drug|Paliperidone Palmitate 150 mg eq.|Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
60231|NCT03713658|Drug|Paliperidone Palmitate 175 mg eq.|Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
60232|NCT03713658|Drug|Paliperidone Palmitate 263 mg eq.|Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
60233|NCT03713658|Drug|Paliperidone Palmitate 350 mg eq.|Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
60234|NCT03713658|Drug|Paliperidone Palmitate 525 mg eq.|Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
60235|NCT03713645|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus] 0.13mg/kg/day initiated within post-operative day 3 after kidney transplant|Study drug (tacrolimus extended-release) initiated at 0.13/mg/kg/day for all patients
60236|NCT03713632|Drug|Secukinumab|Secukinumab 300mg every 2 or every 4 weeks
60237|NCT03713619|Drug|secukinumab|Secukinumab 300mg every 2 or every 4 weeks
60238|NCT03713606|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
60239|NCT03713593|Drug|lenvatinib|Administered orally once a day during each 21-day cycle
60240|NCT03713593|Biological|pembrolizumab|Administered as an IV infusion on Day 1 Q3W
60241|NCT03713593|Drug|saline placebo|Administered as an IV infusion on Day 1 Q3W
60242|NCT03713580|Drug|Venetoclax|"Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor."
60243|NCT03713567|Behavioral|Experimentally induced plaque|Experimentally induced plaque by suspension of oral hygiene only in the tested areas (tooth / implant), protected by a personalized stent made of plastic, according to the experimental gingivitis and mucositis model of 21 days of duration
60244|NCT03713554|Procedure|FNIRS Observational|In addition to completing an Informed Consent and survey questions, fNIRS Imaging and Electroencephalography (EEG) will take place will take place:The fNIRS imaging is experimental technology that has not been approved by the FDA. EEG is a noninvasive way to record electrical activity of the brain. The recording device is made up of electrodes that are fixed to a snug-fitting elastic cap. An MRI and EEG will follow the fNIRS procedure. The MRI will be performed before participants undergo fNIRS or EEG. The MRI will be done to show there are no lesions in the inner ear and therefore is a recruitment clearance tool.
60245|NCT03713541|Other|No intervention|Survey during normal supply.
60246|NCT03713528|Drug|Intraoperative Intraosseous Vancomycin|After debridement and irrigation the interventional group will receive intraosseous vancomycin 500mg in 150ml of normal saline. This solution will be prepared by the hospital pharmacy and administered via an EZ-IO intraosseous cannula. 75ccs of the vancomycin solution will be injected as a bolus. Subsequent to this the remaining 75ccs will be placed in the distal femur just proximal to the femoral component evenly split between the medial and lateral femoral condyles in knees. In hips, the remaining 75ccs is placed into the supra acetabular region through the cannula.
60247|NCT03713515|Behavioral|Helping Hypertensive Latinos Improve Medication Adherance (ALMA)|intervention to help patients improve their ability to take their high blood pressure medications and control their blood pressure
60248|NCT03713489|Procedure|platelet|Participants in platelet transfusion group will receive one unit of apheresis platelets transfusion 3 times for the first week after enrollment, then 2 times a week in the following three weeks.
60249|NCT03713476|Other|Motor task specific training|Motor training targeted to goals that are relevant to the functional needs of the patient
60250|NCT03713463|Other|Oral Nutritional Supplement (ONS)|Per standard of care (SOC)
60251|NCT03713450|Device|Control with imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
60252|NCT03713450|Device|Control without imaging guidance|"Prospective randomized study during aorto-iliac revascularisation comparing patient and staff radiation exposure not using the automated overlay imaging guidance, in addition to the application of the ALARA principles.~The study includes only the per-operative period but no follow-up. The study will be performed in all imaging environment (Hybrid room or mobile)."
60253|NCT03713437|Diagnostic Test|Measurement of differentially methylated insulin DNA|A serum sample will be drawn to measure differentially methylated insulin DNA.
60254|NCT03713424|Drug|Clavulanic Acid|Beta lactamase inhibitor for smoking cessation
60255|NCT03713424|Drug|Placebo oral capsule|placebo
60256|NCT03713411|Procedure|urethral catheter placement|urethral catheter placement to provide low-pressure urinary bladder by providing active drainage of the bladder
60292|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 2|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
60293|NCT03713086|Biological|Rabies mRNA vaccine CV7202 Dose level 3|1 or 2 doses administered IM at Days 1 and 29 in the deltoid region of the arm
60257|NCT03713398|Behavioral|T4C-SMI|T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
60258|NCT03713372|Drug|Anti-EGFR monoclonal antibody|Initially, 6.0mg/kg of SCT200 will be administered once a week for a maximum of 6 cycles. After 6 cycles, 8.0mg/kg of SCT200 will be administered every two weeks until disease progression.
60259|NCT03713359|Biological|Trial arm (MRVAC)|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
60260|NCT03713359|Biological|Control arm|Volunteers from 1-45 years old will be injected only one dose of MRVAC vaccine
60261|NCT03713346|Other|Lactose free milk|Single dose of lactose free milk
60262|NCT03713346|Other|Jersey milk|Single dose of jersey milk
60263|NCT03713346|Other|High A1 β-casein milk|Single dose of high A1 β-casein milk (commercial milk)
60264|NCT03713346|Other|High A2 β-casein milk|Single dose of A2 β-casein milk
60265|NCT03713333|Diagnostic Test|Digital Health Device Diagnostics|"Technology-enabled visitations with digital health will include the following devices used at the time of a patient-physician encounter. These findings will be available to the treating physician at the time the visitation and to be used for clinical decisions.~Handheld imaging - focused echocardiographic examination (Butterfly IQ)~Smartphone iECG for cardiac rhythm assessments (Alivecor)~Blood Pressure (CloudDX)~Oxygen Saturation (CloudDX)~Weight (CloudDX)~Point-of-Care Genetic Testing (Phosphorous)"
60266|NCT03713320|Drug|Cobomarsen|At least weekly doses of cobomarsen (282 mg) throughout study treatment period
60267|NCT03713320|Drug|Vorinostat|Daily doses of vorinostat throughout study treatment period
60268|NCT03713294|Drug|Dexamethasone|Given intravenously (IV) and orally (PO)
60269|NCT03713294|Biological|Elotuzumab|Given intravenously (IV)
60270|NCT03713294|Drug|Pomalidomide|Given orally (PO)
60271|NCT03713268|Device|Microscope integrated optical coherence tomography|This is translational study in which subjects will either be imaged with a microscope integrated optical coherence tomography (MIOCT) system or they will use MIOCT during surgical procedures. OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, cornea, optic nerve head and retinal blood vessels. The MIOCT has been integrated into the surgical microscope used in retinal and anterior segment surgeries so it does not touch the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the patient is not disturbed by the light.
60272|NCT03713255|Procedure|PVB group|Patients in this group will receive preoperative ultrasound-guided thoracic paravertebral block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
60273|NCT03713255|Procedure|MTP block group|Patients in this group will receive preoperative ultrasound-guided mid-point transverse process to pleura block using ropivacaine 0.5% with epinephrine 2.5 mcg/mL, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
60274|NCT03713255|Procedure|Control Group|Patients in this group will receive preoperative ultrasound-guided sham block with subcutaneous local anesthetic injection using lidocaine 1%, and supplemental standardized anesthetic/analgesic regimen (Acetaminophen / NSAIDs / opioids for breakthrough pain).
60275|NCT03713242|Drug|ACT-541468 25 mg|Administered as a tablet.
60276|NCT03713242|Drug|ACT-541468 25 mg (or 10 mg depending on interim results)|Administered as a tablet.
60277|NCT03713229|Diagnostic Test|Screening for anal squamous intraepithelial lesions|digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
60278|NCT03713216|Drug|Naldebain|150 mg Nalbuphine sebacate
60279|NCT03713216|Drug|Morphine|Morphine
60280|NCT03713203|Device|pagetex PDT|2 to 4 sessions of PDT treatment during 2.5 hours after application of Metvixia and incubation under occlusive coat.
60281|NCT03713190|Combination Product|Empagliflozin|Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.
60282|NCT03713190|Drug|Placebo|A substance without specific pharmacology principles
60283|NCT03713164|Dietary Supplement|Pomegranate Juice|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
60284|NCT03713164|Dietary Supplement|Ellagic Acid|Volunteers will consume either one dose of pomegranate juice or pure ellagic acid, an ellagitannin naturally present in pomegranates.
60285|NCT03713151|Other|Dividat FIT|The study intervention is a blended therapy approach of face-to-face physiotherapy sessions with an interactive tablet-based home exercise program.
60286|NCT03713138|Dietary Supplement|flaxseed powder|Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
60287|NCT03713125|Behavioral|Reading Tutoring|20 hours of 1:1 reading tutoring intervention over 6 weeks
60288|NCT03713112|Other|Weekly MDT deprescribing rounds for certain drugs|"Weekly deprescribing round (from randomization to day of discharge)~Conducted by a multidisciplinary team (non-ward doctors, pharmacist, ward nurse)~Using the 5 steps of de-prescribing~De-prescribing targets:~Beer's list of potentially inappropriate medications (American Geriatric Society 2015 version)~Supplements of questionable benefits (glucosamine, chondroitin, vitamin B complex and multivitamins)~Symptomatic medications (laxatives, gastro-protectives, painkillers, anti-emetics and steroid creams) (Standardized verbal script to initiate de-prescribing by the team)~On top of usual care"
60289|NCT03713099|Device|Microwave ablation|Microwave ablations will be performed under general anesthesia via a transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound (EBUS) to confirm disease staging.
60290|NCT03713086|Biological|Rabipur®|3 doses administered IM at Days 1, 8 and 29 in the deltoid region of the arm
60294|NCT03713073|Device|Allogenic amnion chorion membrane|Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
60295|NCT03713073|Device|Collagen dressing|Collagen dressing is used to cover wounds in dental surgery.
60296|NCT03713060|Diagnostic Test|Mixed meal test|All women will have mixed meal test, continous glucose monitoring and antenatal ultrasounds performed. The children born of these women will have DXA-scans performed after birth.
60297|NCT03713034|Other|HTC game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
60298|NCT03713034|Other|Control game|"The research staff will orient the participants to the use of either the active or the control videogames. Players in both groups will play through an online tutorial demonstrating the mechanics of the game.~Each player will use a dedicated device to access their game on the web and a set of headphones that they will use during each gameplay session."
60299|NCT03713021|Device|TraceIT Tissue Marker|The maximum injection volume of TraceIT hydrogel, for a single location, is 1mL.
60300|NCT03713008|Diagnostic Test|Fluid bolus|All patients included in the study will receive 5 ml/kg fluid bolus of a balanced crystalloid solution.
60301|NCT03712995|Procedure|'Cutler-Beard modified with graft'|A tarsoconjunctival graft was harvested from the contralateral upper eyelid, with an extra 3 mm of conjunctiva from the superior edge of tarsus and was attached to the upper eyelid defect, differently than previously described.
60302|NCT03712982|Behavioral|Attention to Variability - Patient Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
60303|NCT03712982|Behavioral|Attention to Variability - Partner Only|In Attention to Variability we ask the participant to attend to the natural fluctuations in mood and physiology in their partner that occur throughout the day, to notice when a symptom is better or worse and to ask why it may be.
60304|NCT03712982|Behavioral|Attention to Variability - Patient & Partner|Same as patient and partner only conditions, just that in this condition both the patient and partner do their corresponding intervention rather than only one of them.
60305|NCT03712982|Other|Infertility Stories - Reading|Reading Stories About Others' Infertility Experiences
60306|NCT03712969|Drug|Shenlingcao Oral Liquid|Patients receive Shenlingcao oral liquid combined with conventional adjuvant chemotherapy, which take 4 courses, 30 days per course, one bottle per day.
60307|NCT03712956|Drug|Caelyx®|Caelyx® every two weeks for 8 courses
60308|NCT03712943|Drug|Regorafenib|Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
60309|NCT03712943|Drug|Nivolumab|Nivolumab 240 mg administered intravenously every 2 weeks.
60310|NCT03712930|Drug|Pamiparib 60 mg PO BID|Pamiparib 60 mg PO BID
60311|NCT03712917|Procedure|Greater Occipital Nerve Block|An enjection to paralyze the occipital nerve.
60312|NCT03712917|Drug|Topiramate|An antiepileptic agent used for migraine prophylaxis.
60313|NCT03712917|Drug|Flunarizine|A calcium overload blocker agent used for migraine prophylaxis.
60314|NCT03712904|Radiation|Stereotactic Body Radiation Therapy|Undergo radiation
60315|NCT03712904|Biological|Ziv-Aflibercept|Given IV
60316|NCT03712891|Dietary Supplement|Coffee|Patients will receive coffee in a Styrofoam cup at a temperature of 125 degree Fahrenheit or less. Coffee will be offered to the patient in the PACU once the patient's gag reflex has been restored following their procedure. Volume of estimated coffee consumption will be measured using a sample scale (with a maximum of 300mL of coffee offered)
60317|NCT03712878|Radiation|Total-Body Irradiation|Undergo TBI
60318|NCT03712878|Procedure|Donor Lymphocyte Infusion|Given IV
60319|NCT03712878|Drug|Cyclophosphamide|Given IV
60320|NCT03712878|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
60321|NCT03712878|Drug|Tacrolimus|Given IV
60322|NCT03712878|Drug|Mycophenolate Mofetil|Given IV
60323|NCT03712852|Procedure|PRF+CAF treated patients|Patients will be treated by coronally advanced flap with addition of PRF membrane
60324|NCT03712852|Procedure|SCTG+ CAF treated patients|Patients will be treated by coronally advanced flap with addition of SCTG graft
60325|NCT03712852|Procedure|CAF treated patients|Patients will be treated by coronally advanced flap
60326|NCT03712839|Other|Cognitive-functional evaluation|The participants will be evaluated with a set of tools within the context of meaningful ADL.
60327|NCT03712826|Drug|Anti-TNF Drug|Crohn patient with antiTNF treatment
60328|NCT03712826|Drug|Ustekinumab|Crohn disease with ustekinumab treatment
60329|NCT03712813|Device|Macrodyne LivMD plate|Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
60330|NCT03712800|Other|Rhythmical massage|Rhythmical Massage according to Dr Ita Wegman, derived from Swedish Massage in the 1920s. Applied for various indications in the context of Anthroposophic Medicine, aiming at a recovery of self-regulation and self-healing forces.
60331|NCT03712800|Behavioral|HRV biofeedback|One of various biofeedback types, HRV biofeedback gives a visual feedback of the participant's heart rate variability as an indicator for general health, physical and cognitive performance, self-regulation and a decreased risk of illness.
60332|NCT03712787|Drug|ABBV-8E12|ABBV-8E12 solution for IV infusion
60333|NCT03712774|Other|EORTC QLQ C30|standardized questionaire
60334|NCT03712774|Other|EORTC QLQ OES-18|standardized questionaire
60335|NCT03712774|Other|EORTC OG-25|standardized questionaire
60336|NCT03712761|Dietary Supplement|Enriched Protein®|This product contains high quality bovine milk proteins enriched with additional leucine.
60337|NCT03712748|Behavioral|Imaginal Exposure therapy|All participants will complete the same arm, which is four sessions of imaginal exposure across a one month time period. Each session is separated by 1 week.
60338|NCT03712735|Drug|Bupivacaine 0.08% - fentanyl 2mcg|In each arm, bupivacaine and fentanyl are being delivered at different intervals and rates for the maintenance of labor analgesia.
60339|NCT03712722|Other|Faecal microbiota transplantation (FMT)|FMT delivered by colonoscopy, nasojejunal tube, glycerol-based capsules, or freeze-dried encapsulated donor faeces
60340|NCT03712709|Diagnostic Test|Truenat MTB|The Truenat MTB (including both MTB and MTB Plus) and the MTB-RIF Dx reflex assays (Molbio Diagnostics; Bangalore, India) utilize chip-based real-time micro-PCR for detection of tuberculosis (TB) and rifampicin (RIF) resistance from DNA extracted (on a separate device) from sputum samples. The Truenat MTB assay targets a single copy gene while the MTB Plus assay combines detection of a single copy and multi-copy gene.
60341|NCT03712696|Device|DIGNICAP™|Scalp cooling to prevent chemotherapy-induced alopecia
60342|NCT03712683|Drug|Thyroxine|Thyroxine was prescribed with the diagnosis of SCH and continued when pregnancy was confirmed
60343|NCT03712670|Drug|Aflibercept|monthly intravitreal injections
60344|NCT03712670|Drug|Pranoprofen|0.1% pranoprofen 3 times a day topical eye drops administration
60345|NCT03712670|Dietary Supplement|Carotenoids|daily supplementation of nutraceutical tablets containing the AREDS2 formulation
60346|NCT03712657|Combination Product|ERAS|"preoperative pain control;~avoiding application of ureter;~avoiding application of gastric tube;~avoiding application of irrigation;~avoiding application of drainage;~early exercising postoperatively;~early oral feeding postoperatively;~early discharging."
60347|NCT03712644|Device|FFR-guided coronary revascularization|Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
60348|NCT03712631|Procedure|tunneling technique bone augmentation|horizontal ridge augmentation using mixture of xenograft,autogenous bone
60349|NCT03712618|Other|Platelet Transfusion - LONG Platelet Transfusion|Platelets Transfused over 4-HOURS
60350|NCT03712618|Other|Platelet Transfusion - SHORT Platelet Transfusion|Platelets Transfused within 60-minutes
60351|NCT03712605|Other|Best Practice|Receive standard of care observation
60352|NCT03712605|Biological|Pembrolizumab|Given IV
60353|NCT03712605|Radiation|Radiation Therapy|Undergo radiation therapy
60354|NCT03712592|Other|Pre and post running evaluations|"Each visit will include a series of neuromuscular, cardiovascular, blood glucose and body composition evaluations will be performed. The subjects will provide some information about their muscular pain and their food and water intake.~Finally, for the study of sleep that only concerns participants in the 4x40 km race, a home sleep registration banner will be given to each participant of the event step by step at the arrival of each stage in order to study sleep the next night as well as 2 nights after the arrival of the last stage."
60355|NCT03712579|Dietary Supplement|SFA-Rich Meal|Saturated fatty acid-rich test meal, containing 75g test fat
60356|NCT03712579|Dietary Supplement|MUFA-Rich Meal|Monounsaturated fatty acid-rich test meal, containing 75g test fat
60357|NCT03712553|Behavioral|Opt-Out|Opt-In messaging prompts participants to contact their primary care provider to receive Hepatitis C screening whereas Opt-Out messaging includes a signed laboratory order for Hepatitis C screening.
60358|NCT03712553|Behavioral|Letter|Participants receive messaging prompting them to contact their primary care provider to receive Hepatitis C screening, either as a letter or an electronic message on the MyPennMedicine patient portal.
60359|NCT03712553|Behavioral|Behavioral Economic Messaging|Participants receive standard messaging about HCV and ways to get screened and messaging that incorporates behavioral economic principles such as norms, reciprocity, anticipated regret, and pre-commitment to get screening.
60360|NCT03712553|Behavioral|Usual Care Messaging|Participants receive standard messaging about HCV and ways to get screening.
60361|NCT03712540|Drug|BMS-986278|Oral administration 30 mg
60362|NCT03712540|Drug|Rifampin|Oral administration 600 mg
60363|NCT03712527|Other|Injection of Platelet rich plasma|The blood of the PRP patients group will be centrifuged by the nurse using the dedicated device. A single centrifugation is required to separate the red and white blood platelets and plasma. This method of centrifugation is carried out using specific kits (Mini-GPS System III, Zimmer Biomet Company). The PRP is then collected by the nurse into a syringe that will be provided to the injector physician. Duration of preparation: 20 to 25 minutes. After a standardized sterile preparation, a local anaesthesia will be performed. Then, the injector will inject a volume of 2 mL of PRP into the median portion of the suspected disc under radiographic guidance.
60364|NCT03712527|Other|Injection of NaCl|The placebo will be a single-dose of saline solution which corresponds to NaCl 0,9% ProAmp 10 ml (Laboratoire Aguettant). The vials will be kept at room temperature (≤ 25°C) within the local pharmacy of each centre. 2 mL of this solution will be intra-discal injected.
60365|NCT03712514|Other|Destabilization of the upper cervical spine by Cervistab|Simulate a situation of destabilization of the cervical spine with Cervistab
60366|NCT03712501|Behavioral|Exercise|A 60 minute walk at 60% maximal oxygen uptake.
60367|NCT03712488|Device|flowcytometry|four colour flowcytometry
60368|NCT03712475|Drug|Pregabalin|pharmacokinetic study under fasting conditions
60369|NCT03712462|Behavioral|Acceptance-Based Behavioral Weight Loss Therapy for BED|ABBT group therapy incorporates standard behavioral and acceptance-based strategies and was adapted to meet suit the unique needs of BED.
60370|NCT03712462|Behavioral|Standard Behavior Therapy|SBT group therapy will be adapted from the gold-standard standard behavioral therapy manuals used from previous weight loss studies.
60371|NCT03712449|Device|JUVÉDERM®|Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)
60399|NCT03712228|Drug|Placebo|Buffer without active ingredient
60400|NCT03712215|Other|Rehabilitation|diaphragmatic electrical stimulation
60401|NCT03712202|Drug|Bleomycin|Given IV
60402|NCT03712202|Drug|Brentuximab Vedotin|Given IV
60372|NCT03712449|Drug|BOTOX Cosmetic®|Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)
60373|NCT03712449|Drug|BELKYRA®|Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)
60374|NCT03712449|Other|SkinMedica|Subjects may receive BELKYRA treatment from visit day 1 continuing on to visit day 6 then from V7 to V9 continue to Facial filter injection (JUVÉDERM VOLBELLA with Lidocaine, and/or JUVÉDERM VOLIFT with Lidocaine, and/or JUVÉDERM VOLUMA with Lidocaine, and/or JUVÉDERM VOLITE with Lidocaine) and SkinMedica products (Facial Cleanser, TNS Essential Serum®, Rejuvenative Moisturizer and Optional: Total Defence + Repair Broad Spectrum Sunscreen SPF34) to be applied daily through throughout the course of the study. At V10 and V11, Subjects will receive BOTOX Cosmetic, 20U to glabellar lines (GLs) and /or 2-6U injected bilaterally to crow's feet lines (CFL) and or 24 U injected to forehead lines (FHLs)
60375|NCT03712436|Combination Product|Palliative care|The Palliative Care Package is a protocol for Palliative Care delivery, derived from the African Palliative Care Association and adapted to the local environment in Addis Ababa.
60376|NCT03712436|Combination Product|Standard oncological care|Standard Oncological Care available in Addis Ababa, Ethiopia which includes chemotherapy, radiation oncology
60377|NCT03712423|Drug|Cripec Docetaxel|89 Zirconium Cripec Docetaxel PET
60378|NCT03712410|Behavioral|PISCES|The intervention is based on Problem Solving Therapy and is a coping skills intervention designed for family caregivers of hospice patients.
60379|NCT03712397|Drug|nanoliposomal irinotecan|combination therapy of nal-IRI , leucovorin and 5-FU in sequence at day 1, every 14 days counted as one cycle
60380|NCT03712384|Other|Semi structured face to face interview|Face-to-face semi-structured interview conducted in the hospital, where young adults were hospitalized 10 years before, in a quiet and isolated office. The topic guide was built according to literature review, without further change after pilot test. Interviews where audio-recorded and transcribed
60381|NCT03712371|Drug|Chitosan|The starting dose for Chitosan is 500mg twice a day, the second dose level is 1000mg twice a day, the third dose level is 1500mg twice a day, and the fourth dose level is 2000mg twice a day. Each dose level lasts for 28 days.
60382|NCT03712358|Biological|PVSRIPO|Intralesional injection of PVSRIPO.
60383|NCT03712345|Drug|IFX-1|Single IV infusions of IFX-1
60384|NCT03712345|Drug|IFX-1|Single IV infusions of IFX-1
60385|NCT03712345|Drug|Placebo|Placebo
60386|NCT03712332|Behavioral|Distress Tolerance Group|The intervention is a distress tolerance skills-based group informed by mindfulness and acceptance principles and dialectical behavioural therapy (DBT).
60387|NCT03712319|Behavioral|REM Volver a casa|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).
60388|NCT03712319|Behavioral|Mindfulness-Based Stress Reduction program|The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
60389|NCT03712306|Other|Dietary advice|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d
60390|NCT03712306|Other|Dietary advice and advice on timing|Dietary advice to increase protein intake to at least 1.2 g/kg adjusted body weight/d plus advice on consuming protein in close proximity of usual physical activity
60391|NCT03712293|Device|BBB Disruption with Chemotherapy Arm|The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.
60392|NCT03712280|Drug|MNK6106|1 gram tablet of MNK6106 for oral administration
60393|NCT03712280|Drug|Rifaximin|550 mg tablet of rifaximin for oral administration
60394|NCT03712267|Behavioral|Electronic Media Enhanced|Research assistants will provide participants' therapists with information from participants' electronic media, to see if that has any impact on their therapy.
60395|NCT03712254|Drug|Fosphenytoin|Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
60396|NCT03712241|Drug|K-285|Topical
60397|NCT03712241|Drug|Indomethacin|Capsule
60398|NCT03712228|Biological|Factor XIIa antagonist monoclonal antibody|Factor XIIa antagonist monoclonal antibody for intravenous and subcutaneous use
60408|NCT03712189|Device|LifeFlow|The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
60409|NCT03712176|Behavioral|Lifestyle alteration|Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
60410|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 1)|Single dose Norketotifen
60411|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 2)|Single dose Norketotifen
60412|NCT03712163|Drug|Norketotifen Oral Capsule (Cohort 3)|Single dose Norketotifen
60413|NCT03712163|Drug|Norketotifen Oral Capsule (Multiple Dose Cohort)|Multiple dose Norketotifen
60414|NCT03712163|Drug|Placebo Oral Capsule|Placebo
60415|NCT03712150|Device|tdcs|application of optimised parameters of tDCS (anodal stimulation, 1.5 mA, 10 min) over the unconditioned hemisphere reverses the brain and behavioural consequences of inhibitory pre-conditioning
60416|NCT03712137|Device|VOLUX XC|Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with an optional maintenance treatment at Month 12.
60417|NCT03712137|Other|No-treatment control|No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) during the Post-Control period.
60418|NCT03712124|Drug|CNSA-001|CNSA-001 Powder for Suspension
60419|NCT03712124|Drug|Placebos|Placebo Suspension
60420|NCT03712111|Drug|Norepinephrine 6 mcg|An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
60421|NCT03712111|Drug|Norepinephrine 10 mcg|An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
60422|NCT03712111|Drug|Bupivacaine Hydrochloride|Subarachnoid block will be performed using Bupivacaine hydrochloride (2.2 mL) in addition to fentanyl 25 mcg
60423|NCT03712111|Drug|Norepinephrine infusion|Prophylactic norepinephrine infusion will be started after subarachnoid block
60424|NCT03712098|Drug|Liraglutide|Liraglutide 3.0 mg is an injectable medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Liraglutide is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management when combined with a reduced-calorie meal plan and physical activity.
60425|NCT03712098|Drug|Placebo|The placebo is an inactive substance that is designed to look like liraglutide but contains no medication.
60426|NCT03712098|Behavioral|Smoking Cessation Counseling|All participants receive manual-based counseling from a trained smoking cessation counselor. The counseling sessions are designed to enhance awareness of the harmful effects of smoking, assist the participant in developing skills to quit, and avoid relapse.
60427|NCT03712085|Other|Abdominal acupuncture|Abdominal acupuncture treatment method: 1.Acupoints selection :Zhongwan,Xiawan,Shangqu,Qihai,Guanyuan,Huaroumen,Upper rheumatic and Upper rheumatic external points etc.(Acupoints selection referred to Abdominal Acupuncture Therapy written by Bo Zhiyun ,the founder of Abdominal Acupuncture. 2.Treatment Duration: 30 minutes a session, once a day, 5 times a week for 3 weeks.
60428|NCT03712085|Other|Sham abdominal acupuncture|Sham abdominal acupuncture Abdominal acupuncture treatment method: 1.Acupoints selection and treatment duration are the same as abdominal acupuncture. 3.Method：Using the sham abdominal acupuncture needles were produced by DONGBANG AcuPrime Acupuncture Instrument Co., Ltd. ( U.K.)The tip of the needle was exposed to 1mm of the cannula. The acupoint skin of patients was touched gently by the tip, and the tip of needle was lifted and removed from acupoint skin after 30s. Rest for 30 seconds ,then repeated 6 times, a total time of stimulation is 6min.
60429|NCT03712072|Device|Magnetoencephalography (MEG)|The purpose of the device is to measure magnetic fields produced by an individual's brain and provide information on the location of the source of the fields. Participants between the ages of 0-3 years of old whose head can fit in the MEG helmet will be the patient population used for the BabyMEG. The device will be used in this study to learn more about the somatosensory and motor networks of children who have cerebral palsy and compare their brain signals to healthy children.
60430|NCT03712072|Device|Electroencephalography (EEG)|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp.
60431|NCT03712072|Device|Transcranial Magnetic Stimulation (TMS)|The device will be used for motor mapping. Motor threshold is operationally defined as minimum machine output necessary to elicit a response from the abductor pollicis brevis right (APB), contralateral to the stimulated hemisphere, of 50 microvolts, on >50% of trials. Upper limb motor mapping is conducted at 110% abductor pollicis brevis motor threshold in each hemisphere, or at 100% machine output (MO). Lower limb motor mapping is conducted at a fixed machine output corresponding to the magnitude sufficient to elicit reliable tibialis anterior (TA) motor evoked potentials (MEPs). Single pulse TMS is performed while motor evoked potentials are recorded bilaterally from the APB, deltoid, and TA using surface electromyography (EMG).
60432|NCT03712059|Diagnostic Test|FIT test and colonoscopy|All included patients received FIT test and then colonoscopy, with the risk factors of CRC recorded. The diagnostic performance of predicting model (based on FIT and risk factors) and colonoscopy were compared.
60433|NCT03712059|Diagnostic Test|Polypectomy and biopsy|All included patients received polypectomy, and then biopsy is performed on the edge of resection for patients with ＜ 10 mm adenoma (confirmed by pathology or predicted by NBI images), with the complete resection rate of polyps being calculated.
60434|NCT03712059|Diagnostic Test|Classification|Pathology of polyps is classified by endoscopists through NICE principle and the performance of classification between endoscopists and computer is compared.
60435|NCT03712046|Diagnostic Test|18F-FDG PET-CT|Patient will receive one injection of 18F-FDG and then undergo PET-CT imaging
60436|NCT03712007|Device|MAMP therapy with MARPE expander|Twenty patients will be submitted to MAMP therapy with MARPE expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The maxillary and mandibular miniscrews will be placed in the same section. After a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks to the mandibular mini-implants.
60437|NCT03712007|Device|MAMP therapy with Hyrax expander|Fifteen patients will be submitted to MAMP therapy with Hyrax expander as anchorage in the maxillary arch. The appliance anchorage will be provided by bands adapted on the maxillary first permanent molars and circumferential clamps in the maxillary canines or premolars. The mandibular miniscrews will be placed and after a 24-hour period, parents will be oriented to activate the expander screw. Patients will be instructed to wear intermaxillary elastics connecting the maxillary first molar hooks and the mandibular mini-implants.
60438|NCT03711994|Other|Alkantis|cold therapy pack placed on the wound post operatively
60439|NCT03711981|Procedure|TAP Block|
60440|NCT03711968|Other|Rehabilitative treatment protocol|A combination of: postural exercise with visual spatial tasks, relaxation, balance exercise, motricity improvement and cognitive rehabilitation.
60441|NCT03711955|Other|Exercise|Two types of training exercises, AET and IRT, will be used as the interventions in this study. Participants will either be assigned to the AET group or the IRT group, where they will participate in the respective training intervention group for 8 consecutive weeks.
60442|NCT03711942|Procedure|Intra orifice barrier|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.3mm GP in the orifice was removed and intraorifice barrier and 2mm thick base was given of GIC.
60443|NCT03711942|Procedure|Base|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.2mm thick Base of GIC was applied over the orifice before composite restoration
60444|NCT03711942|Procedure|Control|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.coronal accees upto orifice was restored with composite resin
60445|NCT03711929|Drug|DE-109 Intravitreal Injections|440 ug of DE-109 Injectable Solution
60446|NCT03711929|Other|Sham Procedure|The sham procedure mimics an intravitreal injection without penetrating the eye.
60447|NCT03711929|Drug|DE-109 Intravitreal Injections|Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
60448|NCT03711916|Device|PlasmaBlade 3.0S|PlasmaBlade (Medtronic) is approved by United States Food and Drug Administration (FDA) as a low thermal dissection device that has shown to be associated with effective cutting, and significantly lower temperature than traditional electrosurgical dissection devices.
60449|NCT03711903|Drug|Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).|The study drug, CN-105 is supplied in amber glass vials containing 4 mL of a concentrated 12.5-mg/mL clear-to-slightly-yellow solution.
60450|NCT03711903|Drug|0.9% Sodium-chloride|normal saline
60451|NCT03711890|Procedure|Optical Coherence Tomography|Undergo OCT
60452|NCT03711890|Procedure|Therapeutic Conventional Surgery|Undergo resection will be undertaken
60453|NCT03711890|Diagnostic Test|Laboratory Evaluation|Labs will be obtained to test for cancer cell derived exosomes
60454|NCT03711877|Device|Scalp cooling system|Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward. Temperature of scalp cooling system can be controlled constantly, the effect of reducing scalp temperature maybe better and patient tolerance maybe better. Meanwhile, there is a higher likelihood of hair retention due to a tight fit in scalp cooling system.
60455|NCT03711877|Device|Cold cap|The operation of chemical cold cap is convenient and the price was low, and the economic burden of patients was not increased. But it is necessary to replace the cold cap periodically during chemotherapy, and the temperature during chemotherapy is difficult to keep constant.
60456|NCT03711864|Biological|IM21 CART|fludarabine and cyclophosphamide Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
60457|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (Web-based)|9 week program with minimal contact with therapist (predominantly self-help)
60458|NCT03711851|Behavioral|Self-help Acceptance and commitment therapy (bibliotherapy)|9 week program with contact with therapist (predominantly self-help)
60459|NCT03711851|Other|Self-help Education pamphlets on pain (active control group)|9 week program with contact with therapist (predominantly self-help)
60460|NCT03711838|Dietary Supplement|N-Acetylcysteine|N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
60461|NCT03711838|Dietary Supplement|Placebo|Placebo consisted of 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
60462|NCT03711825|Drug|LYN-057|Administration of single dose of LYN-057 presented as extended release capsule containing 50 mg of memantine hydrochloride (HCl)
60463|NCT03711825|Procedure|Imaging Assessment (MRI)|Imaging assessments [MRI] will be performed on specified days according to protocol
60464|NCT03711825|Procedure|Imaging Assessment (U/S)|Imaging assessments (abdominal U/S) will be performed on specified days according to protocol
60465|NCT03711812|Procedure|Serratus Anterior Plane Catheter|Insertion of a Serratus Anterior Plane Catheter to establish a continuous analgesic block with a local anaesthetic infusion
60466|NCT03711812|Procedure|Thoracic Epidural Catheter|Insertion of a Thoracic Epidural Catheter to establish a continuous analgesic block with a local anaesthetic infusion
60528|NCT03711279|Drug|SHR-1210 Plus Apatinib|SHR-1210 (200mg lyophilized powder in a single-dose vial for reconstitution) q3w+ Apatinib (250mg/375mg tablets) qd
60467|NCT03711799|Behavioral|Access to services via peer coaching|This intervention will allow for half of the participants, randomly selected, to get help navigating the system of acquiring services for their child. These participants will be assisted by a coach who are also parents of a child with autism and have already been through the process.
60468|NCT03711786|Other|Basic implementation package|The basic implementation package will involve identifying an internal coordinator who is one of the full-time on-site providers at the clinic. The internal coordinator provides mentoring to peers and support to leadership in implementing the treatment program and aligning it with clinic priorities.
60469|NCT03711786|Other|Enhanced implementation package|The enhanced implementation package will combine the internal coordinator with an external quality assurance committee. This committee will complete quarterly audits at the facility to evaluate compliance with the depression treatment protocol as well as providing high-level support in implementing the treatment program through clinical expertise and limited on-site presence.
60470|NCT03711773|Other|Group Physical Therapy Classes|Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
60471|NCT03711760|Behavioral|telepsychology|CBT delivered by telepsychology
60472|NCT03711747|Procedure|Osteochondral allograft ankle|Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
60473|NCT03711734|Other|Acupuncture + Standard of Care|Acupuncture is a nonpharmacologic pain management modality that has been shown to provide superior analgesia for acute pain. This will be combined with our facility's standard of care anesthesia and pain management plan.
60474|NCT03711721|Dietary Supplement|Food basket|
60475|NCT03711721|Dietary Supplement|Ready-to-Use Therapeutic Food|
60476|NCT03711708|Drug|Zoloft Oral Solution|Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water
60477|NCT03711708|Drug|Zoloft tablets|Reference Product: 50 mg sertraline administered as 1x Zoloft 50 mg tablet
60478|NCT03711695|Device|iBeat wristwatch device|The participant will be asked to wear one iBeat wristwatch device on each arm during the planned procedure.
60479|NCT03711682|Dietary Supplement|Cinnamon|Participants in this group will receive cinnamon capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of cinnamon powder (Cinnamomum verum), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
60480|NCT03711682|Dietary Supplement|Wheat Flour|Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
60481|NCT03711669|Behavioral|Immunosuppression withdrawal|IS will be tapered gradually over a period of 6 months. Azathioprine will be stopped during the first 3 months, reducing the dose 50% every month. Prednisone will be tapered 2.5mg monthly until total withdrawal. During withdrawal and the first year after stopping treatment patients will undergo laboratory tests on a monthly basis, afterwards follow-up will be done every 3 months until the end of the project.
60482|NCT03711656|Device|isCGM (intermittently scanned Continuous Glucose Monitoring)|Data collection
60483|NCT03711656|Device|Physical exercise tracker|Data collection
60484|NCT03711643|Procedure|Periprostatic nerve block|4 injections of 2 cc of lidocaine for a Periprostatic nerve block
60485|NCT03711643|Device|hypnosis mask|"The mask HYPNOS pro stimulates the imagination of the user by means of 6 diodes among 3 by eye.~Just before the introduction of ultrasound probe, the patient put the hypnotic mask and choose a session.Twenty minutes after the removal of the probe, an healthworker assess the painful patient with the visual analogue scale VAS, after this the patient fulfill the STATE- TRAIT Anxiety Inventory (STAI) form Y-A."
60486|NCT03711630|Behavioral|Meditation|Meditation practice will be through the InsightTimer smart device application. Participants will choose what types of meditation practices they will engage in and report their time spent meditating via REDCap.
60487|NCT03711604|Drug|Tenalisib|BID Orally
60488|NCT03711591|Device|Conventus Cage PH device|The Conventus CAGE™ PH (PH Cage) is a permanent implant comprised of an expandable scaffold, made from nitinol and titanium, which is deployed into the medullary canal and provides a structure to which fractured bone fragments are attached using fragment screws.
60489|NCT03711578|Drug|Tenalisib,|BID, Orally
60490|NCT03711565|Device|Regular Nasal CPAP using a conventional ventilator|The Nasal CPAP is connected to the patient via prongs in the nose. Pressure adjustments are made to improve lung inflation. The frequency and pressure can be adjusted as needed to improve the patient's oxygen and carbon dioxide levels
60491|NCT03711565|Device|High Frequency Nasal CPAP|High Frequency Nasal CPAP for management of respiratory distress Patient will be connected to the high frequency device through nasal prongs. The Bronchotron produces a pressure that is variable with an adjustable frequency that is equal or greater than 500 times per minute connecting to prongs in the patient's nose. The pressure, frequency and amplitude of the pulsations will be adjusted as needed to provide acceptable oxygenation and ventilation.
60492|NCT03711552|Other|ObsQoR-11|Quality of recovery questionnaire
60493|NCT03711552|Other|QoR-15|Quality of recovery questionnaire
60494|NCT03711513|Behavioral|Cognitive behavioral therapy|All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.
60495|NCT03711500|Drug|D-serine|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
60529|NCT03711279|Drug|ADM Plus IFO or IFO Alone|ADM 60mg/m2 D1 + IFO 2mg/m2 D1-D4 q3w；if the cumulative doses of ADM is beyond 450mg/m2, the monotherapy of IFO (2mg/m2 D1-D5 q3w) will be used.
60496|NCT03711500|Drug|Placebo|Subjects will receive three sessions of auditory remediation paired with either D-serine or Placebo in a 4:1 D-serine:placebo ratio. This will be conducted in 3 separate cohorts of D-serine dose 80, 100 and 120 mg/kg, which 15 subjects per cohort (12 active and 3 placebo) per cohort
60497|NCT03711487|Drug|Foeniculum Vulgare Seed Ironing|Stir-fry 500 grams of Foeniculum vulgare seeds until the aroma overflows. Put them into a cotton bag. Ironing therapy put the bag on abdomen after the temperature is suitable, 30 minutes per time, twice daily on postoperative days 2 to 3. The medicine bag can be heated and reused after it cool down.
60498|NCT03711474|Drug|Dexamethasone|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgery
60499|NCT03711474|Drug|Saline|Single dose of Dexamethasone IV or Saline IV given within the first hour of surgey
60500|NCT03711461|Device|endotracheal tube (double lumen)|patients routinely use double lumen endotracheal intubation while they have received thoracoscopy
60501|NCT03711461|Device|nonintubated|patients receiving nonintubated anesthetic plan while they have received thoracoscopy
60502|NCT03711448|Drug|prednisone treatment|tapering prednisone regimen
60503|NCT03711448|Drug|prednisone and ustekinumab treatment|Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
60504|NCT03711448|Other|questionnaires|HAQ ; SF-36 ; FACIT-fatigue
60505|NCT03711448|Biological|Blood samples|Additional blood samples for immunomonitoring
60506|NCT03711435|Diagnostic Test|Metabolomics|we test the two group with metabolomics for serum， urine，stool and saliva，the case group with TCM Syndrome，and other diagnostic tests
60507|NCT03711422|Drug|Afatinib|40mg daily
60508|NCT03711422|Drug|Afatinib|160mg for 3 days every 3 weeks
60509|NCT03711409|Other|Soft tissue biased manual therapy group|It includes hot pack and muscle release technique of pectoralis major, pectoralis minor, teres major, teres minor, infraspinatus and posterior deltoid muscles. Subjects are supine on the bed. The muscle release technique is applied at the end available range and the acceptable intensity. The time of muscle release intervention is about 30 min and hot-pack about 15 min.
60510|NCT03711409|Other|Conventional physical therapy group|It includes modality (electrotherapy, ultrasound and low-level laser therapy) and GH joint mobilization. GH joint mobilization includes anterior to posterior glide, caudal glide and distraction. The intensity of joint mobilization is grade III to IV. The time of joint mobilization is about 30 min and hot-pack for 15 min.
60511|NCT03711396|Behavioral|Advance Care Planning Group Visit|"Aim 1: The first part of this study will focus on refining and adapting the Advance Care Planning Group Visit intervention so that it meets the needs of persons with amnestic cognitive impairment and a study partner who participates with them.~Aim 2: The second part of the study will pilot test the Advance Care Planning Group Visit intervention adaptations, called ENgaging in Advance Care planning Talks Group Visit intervention (ENACT Memory Group Visits), to see if it is feasible, acceptable and improves the number of people with amnestic mild cognitive impairment who complete an advance directive (a legal form that describes someone's wishes for future medical care if they are unable to make their own decisions). It will also see how ready individuals are to participate in advance care planning. The overall goal is to improve opportunities for older adults with amnestic mild cognitive impairment to receive medical care that is consistent with their values, goals, and preferences."
60512|NCT03711383|Dietary Supplement|Inulin and Resistant Starch|12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g
60513|NCT03711383|Dietary Supplement|Inulin|12g per inulin in combination with maltodextrin per day the day before the CID
60514|NCT03711383|Dietary Supplement|Placebo|isocaloric maltodextrin before test day
60515|NCT03711370|Other|Clear Bottle|These mothers will receive usual care from their pediatric providers and each mother will be given 12 conventional, clear bottles of various sizes (4-12 ounces) that are compatible with a variety of different nipples manufactured by leading bottle companies. Mothers will also be given a handout about paced bottle-feeding, which includes messages about feeding in response to infant cues.
60516|NCT03711370|Other|Opaque Bottle|These mothers will receive everything provided to the clear group, but will instead receive 12 opaque, weighted bottles of various sizes (4-12 ounces). These bottles will be stainless steel and compatible with a variety of different nipples manufactured by leading bottle companies. Mothers in the intervention group will also receive a handout about how opaque bottles can help them attend to infant cues.
60517|NCT03711357|Radiation|980 nm diode laser|980 nm high power diode laser device.
60518|NCT03711357|Other|placebo|the diode laser fiber optic tip will be inserted in root canals, but will not be activated.
60519|NCT03711344|Behavioral|Cognitive Behavioral Therapy|The intervention will be administered by therapists working at community agencies who are experienced at providing Cognitive Behavioral Therapy.
60520|NCT03711331|Other|Unyvero®-based strategy|Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV.
60521|NCT03711331|Other|Standard care|Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results
60522|NCT03711318|Drug|Buprenorphine/naloxone|3 week treatment with buprenorphine/naloxone
60523|NCT03711305|Drug|SHR-1316|SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
60524|NCT03711305|Drug|Carboplatin|Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
60525|NCT03711305|Drug|Etoposide|Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
60526|NCT03711305|Drug|Placebo|Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
60527|NCT03711292|Behavioral|Antibiotic Stewardship|For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.
60582|NCT03710876|Drug|Celecoxib Oral Product|400 mg twice daily
60530|NCT03711266|Behavioral|PE-PC|PE-PC treatment will follow the PE-PC manual and patient workbook. Treatment content for PE-PC is drawn from the PE model and condensed so as to deliver the most efficacious components of PE. PE-PC consists of four, 30-minute appointments scheduled approximately once a week over 4-6 weeks
60531|NCT03711253|Drug|Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg|antiretroviral therapy
60532|NCT03711240|Drug|bevacizumab|5mg/kg iv day 1 every 2 weeks
60533|NCT03711240|Drug|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
60534|NCT03711240|Drug|Irinotecan|150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks
60535|NCT03711240|Drug|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
60536|NCT03711240|Drug|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
60537|NCT03711227|Diagnostic Test|Procalcitonin lab test|A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
60538|NCT03711214|Procedure|Periodontal scaling|Periodontal scaling and root planing
60539|NCT03711201|Behavioral|Group IORE|This group will undergo the IORE procedure before surgery (operation). On the day of surgery, the patient will be brought to the operating room by the anesthesiologist. Hemodynamic data (blood pressure, pulse rate, respiratory rate, SpO2) will be measured at the service, preop unit and operating room. The anxiety level in the operating room will be measured by the ST-STAI scale.
60540|NCT03711188|Drug|Nivolumab|Nivolumab is to be administered as a 3 mg/kg IV infusion every two weeks in accordance with the prescribing information.
60541|NCT03711188|Drug|Ipilimumab|Ipilimumab, when used as subsequent treatment for patients in cohort B, is to be administered as a 3 mg/kg IV infusion over 90 minutes every three weeks for a maximum of 4 doses, in accordance with the prescribing information.
60542|NCT03711188|Drug|IMM-101|A single 0.1 mL intradermal injection of IMM 101 (10 mg/mL) given every 2 weeks for the first 3 doses followed by a rest period of 4 weeks, then one dose every 2 weeks for the next 3 doses. This is followed by a dose every 4 weeks thereafter.
60543|NCT03711175|Procedure|Subscapularis repair|Utilizing fiberwire, high tensile strength suture
60544|NCT03711175|Device|Shoulder implant|Reverse shoulder arthroplasty device
60545|NCT03711162|Drug|GLPG1690|GLPG1690, film-coated tablets for oral use.
60546|NCT03711162|Drug|Placebo|Matching placebo, film-coated tablets for oral use.
60547|NCT03711149|Other|Activity monitor feedback loop|The intervention arm will test if the feedback system (i.e., activity monitor, real-time feedback, and art tours) increases daily step count, decreases length of stay, and improves patient and provider communication, patient awareness of step count goals, and patient confidence in accomplishment of daily goals.
60548|NCT03711136|Procedure|aortic prosthesis|ascending aortic and/or aortic arch prosthesis with linear vascular prosthesis or hybrid prosthesis
60549|NCT03711123|Behavioral|Group metacognitive therapy|10 weekly Group session of 90 minutes duration
60550|NCT03711123|Behavioral|Clinical management|10 weekly individual sessions With clinical management including guided self-help
60551|NCT03711110|Other|Intensive cardiovascular monitoring|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; EKG; Echocardiogram; Biomarkers (troponin and natriuretic peptide); Structured counselling on healthy cardiac practices; Treatment optimization of cardiovascular risk factors and heart diseases; Quality of life (ECOG Performance status and Minnesota questionnaires); Interaction and management of patient care by the cardio-onco-hematology team. Moreover, cardiac MRI in centers participating in the CARTIER-MR sub-study."
60552|NCT03711110|Other|No intervention|"Schedule of visits: Evaluation before starting chemotherapy, at three and six months and annually for five years (eight visits: baseline, 3rd and 6th month, 1st, 2nd, 3rd, 4th and 5th years).~Assessment protocol: Anamnesis and physical examination; ECOG Performance status; cardiac patient care based on the onco-hematologist criteria"
60553|NCT03711097|Drug|Vanish XT Dental Varnish|Varnish will be applied to the front surface of the intervention upper central and lateral incisors
60554|NCT03711084|Dietary Supplement|Natural high potency sweetener from leaf extract|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
60555|NCT03711084|Dietary Supplement|Glucose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
60556|NCT03711084|Dietary Supplement|Sucrose|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
60557|NCT03711084|Dietary Supplement|Maltodextrin|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
60558|NCT03711084|Dietary Supplement|Water|"Upon arrival, participant's blood will be collected at 0 (before the consumption of the test beverage), 15, 30 and 60 min after the consumption of the drink. Participants will rate their feelings of hunger, fullness etc using VAS at 0, 15, 30 and 60 min.~Fifteen min after the consumption of the drink, participants will complete a set of computer-based tasks designed to capture behaviour in response to food cue presentation. Thirty min after the consumption of the drink, a lunch buffet will be served and participants will be free to eat as much or as little as they like until feeling comfortably full."
60559|NCT03711071|Other|"Workshop ICE training"|The workshop includes training in communication skills in relation to evidence based medicine.
60560|NCT03711058|Drug|Copanlisib|"Copanlisib will be administered as a 60 minute IV infusion (-5min/+10min) at a dose of 45 mg - 60 mg IV. Copanlisib will be administered once a week (days 1, 8, and 15 or Day 1 and Day 15 of each 28 day cycle).~Drug: 45 or 60 mg IV"
60561|NCT03711058|Drug|Nivolumab|"Nivolumab 480 mg will be administered as a 60 minute IV infusion (-5min/+10min) on Day 1 of each 28 day cycle.~Drug: 480 mg IV"
60562|NCT03711045|Behavioral|eye-tracking|"After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded."
60563|NCT03711032|Biological|Pembrolizumab|Pembrolizumab IV infusion of 200 mg Q3W
60564|NCT03711032|Biological|BCG|BCG (intravesical instillation): powder for instillation fluid for intravesical use, administered during Induction and Maintenance therapy
60565|NCT03711019|Device|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
60566|NCT03711019|Device|RUL-UB ECT|"In the RUL-UB ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. Seizure threshold will have been determined during the first treatment session following a standard established protocol in the context of CREST-MST or CORRECT-BD. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
60567|NCT03711019|Device|Bitemporal ECT|"Bitemporal ECT treatments will be administered using the MECTA spECTrum 5000Q, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. Bitemporal ECT will be administered at 1.5 times seizure threshold according to standard clinical practice. Treatment in the continuation phase will be administered at the same stimulus dose as the last treatment in acute phase.~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
60568|NCT03711006|Other|Fecal Microbiota Transplantation Capsules|25 daily multi-donor FMT Capsules for 50 days
60569|NCT03710993|Device|oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding transfer standard and reference devices to assess oximeter calibration and accuracy.
60570|NCT03710980|Device|Oximeter|Participants breathe a controlled gas mixture to induce several reduced oxygen states while oximeter measurements are taken for comparison to corresponding arterial blood draw samples to assess oximeter accuracy.
60571|NCT03710967|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation of the primary motor cortex
60572|NCT03710954|Diagnostic Test|Experimental Group|All volunteers were evaluated by numerical pain scale and Fuzzy scale. This procedure was performed to compare the efficacy of the Fuzzy Scale demonstrating greater accuracy of quantification of skeletal muscle pain
60573|NCT03710941|Drug|REGN2477+REGN1033|Single, sequential, repeat-dose Intravenous (IV) or matching placebo
60574|NCT03710941|Drug|Matching placebo|Single, sequential, repeat-dose Intravenous (IV)
60575|NCT03710928|Other|very low carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement as needed with each meal to support digestive health, and a daily multi-vitamin, magnesium and omega-three supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 5% carbohydrate, 70% fat, 20% protein."
60576|NCT03710928|Other|standard carbohydrate diet|"All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance.~The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein."
60577|NCT03710915|Drug|HG146|HG146 will be administered every other day for 14 days, followed by 1 week off the drug with each treatment cycle of 21-days.
60578|NCT03710902|Diagnostic Test|ECG monitoring for 3 weeks|A 3-week continuous ECG monitoring to detect occult AF.
60579|NCT03710902|Other|Self-monitoring of BP and self-titration of antihypertensive medication|One-week monthly self-monitoring of BP and self-titration of antihypertensive medication according to a pre-specified protocol, assisted with a mobile device application.
60580|NCT03710889|Drug|Abaloparatide|Abaloparatide is an 34-amino acid analog of PTHrP that is chemically synthesized.
60581|NCT03710876|Biological|rAd-IFN|Adenovirus-Delivered Interferon Alpha-2b
60583|NCT03710876|Drug|Gemcitabine|1250 mg/m2 administered intravenously on Days 1 and 8 of a 21-day cycle and continued every 3 weeks until disease progression/ early termination
60584|NCT03710863|Drug|CM082|Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.
60585|NCT03710850|Dietary Supplement|Inulin|Inulin is a dietary fibre. Will be supplemented in a dose 10g/d for a period of 3 moths.
60586|NCT03710837|Other|Pain neuroscience education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
60587|NCT03710837|Other|Red flag education|Two different lectures covering essential clinical skills but one designed to explore the hypothesis
60588|NCT03710824|Drug|Nintedanib|diagnosed IPF patients initiating treatment with nintedanib
60589|NCT03710811|Drug|Insulin|Continuous Subcutaneous Insulin Infusion
60590|NCT03710798|Dietary Supplement|Low carbohydrate high fat diet|Energy balanced low carbohydrate high fat diet during 6 weeks. Then 6-week reintroduction of a healthy normal diet
60591|NCT03710785|Behavioral|cervical spine extension exercise|cervical spine extension exercise for 4 weeks
60592|NCT03710772|Drug|Cyclophosphamide|Given IV
60593|NCT03710772|Drug|Cytarabine|Given IV
60594|NCT03710772|Drug|Dexamethasone|Given PO or IV
60595|NCT03710772|Drug|Doxorubicin Hydrochloride|Given IV
60596|NCT03710772|Drug|Ibrutinib|Given PO
60597|NCT03710772|Drug|Methotrexate|Given IV
60598|NCT03710772|Biological|Rituximab|Given IV
60599|NCT03710772|Drug|Venetoclax|Given PO
60600|NCT03710772|Drug|Vincristine|Given IV
60601|NCT03710759|Other|Assitive autogenic Drainage|Assistive autogenic Drainge : All the 3 components of Autogenic drainage was given passively to the patients. By placing the hands on the child's chest, the therapist manually increases the expiratory flow to achieve the different lung volume breathing.
60602|NCT03710746|Behavioral|Project Health|A brief dissonance-based obesity prevention program delivered in six one-hour weekly sessions.
60603|NCT03710746|Behavioral|Response and Attention Training|Individualized, computerized response and attention training consisting of five separate tasks designed to increase inhibitory control to reduce overeating.
60604|NCT03710733|Radiation|Sequential boost|Boost (10 Gy/4 fx/1 week) is given after whole breast irradiation
60605|NCT03710733|Radiation|Concomitant boost|Boost (8 Gy/15 fx/3 weeks) is given with whole breast irradiation
60606|NCT03710720|Behavioral|TIPS app|Psycho-educational electronic application
60607|NCT03710720|Behavioral|Trauma Focused-Cognitive Behavioral Therapy|Effective form of trauma therapy for adolescents
60608|NCT03710707|Drug|DNL201 low dose|DNL201 low dose
60609|NCT03710707|Drug|DNL201 high dose|DNL201 high dose
60610|NCT03710707|Drug|Placebo|Placebo
60611|NCT03710694|Device|DAV132|"DAV132:~Dosage: 15 g/day activated charcoal (22.5 g/day DAV132)~Route: Oral~Duration: duration of fluoroquinolone treatment + 2 days~DAV132 is regulated as a medical device in Europe and as a drug in the United States of America."
60612|NCT03710681|Biological|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
60613|NCT03710668|Radiation|MRI if indicated|MRI brain if indicated
60614|NCT03710655|Drug|Apitox - pure honeybee toxin|Intradermal injection of 0.01 microliters
60615|NCT03710655|Drug|Placebo|Intradermal injection of 0.01 microliters
60616|NCT03710642|Drug|Prazosin|Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules
60617|NCT03710642|Drug|Placebo oral capsule|Placebo capsule matched to appearance of active drug.
60618|NCT03710629|Other|Patients with driver genes|Patients with driver genes
60619|NCT03710616|Procedure|Surgeries|Surgical operations plus systematic lymphadenectomies
60620|NCT03710603|Drug|Daratumumab|Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months & after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.
60621|NCT03710603|Drug|velcade|Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
60622|NCT03710603|Drug|Lenalidomide|Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
60623|NCT03710603|Drug|dexamethasone|Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
60624|NCT03710590|Other|ECIG Lab Session 15 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
60625|NCT03710590|Other|ECIG Lab Session 15 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.).
60626|NCT03710590|Other|ECIG Lab Session 15 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
106502|NCT03353805|Behavioral|questionnaire|questionnaire
60627|NCT03710590|Other|ECIG Lab Session 30 watts, 10 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
60628|NCT03710590|Other|ECIG Lab Session 30 watts, 15 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
60629|NCT03710590|Other|ECIG Lab Session 30 watts, 30 mg nicotine|During each session, participants will first complete a 10-puff product use bout, and then a 90-minute ad lib product use bout.
60630|NCT03710577|Behavioral|Yoga|1 session
60631|NCT03710577|Behavioral|Quiet Rest|1 session
60632|NCT03710564|Biological|Brolucizumab|6 mg/0.05mL solution for intravitreal injection
60633|NCT03710564|Biological|Aflibercept|2 mg/0.05mL solution for intravitreal injection
60634|NCT03710551|Other|Experimental Infant Formula|Standard bovine milk-based infant formula with a new fat blend plus L. reuteri, fed ad libitum
60635|NCT03710551|Other|Standard Infant Formula|Standard bovine milk-based infant formula, fed ad libitum
60636|NCT03710538|Dietary Supplement|Snack beverage|Consumption of a 200ml of soy beverage (100Kcal, 11g CHO, 6g proteins, 4g fat)
60637|NCT03710538|Behavioral|Exercise|3min walk at 60% VO2max every 30 minutes,(x5)
60638|NCT03710525|Other|Own-Price Elasticity|The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
60639|NCT03710525|Other|Cross-Price Elasticity|The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
60640|NCT03710512|Procedure|Bilateral sagittal split osteotomy|Bilateral sagittal split osteotomy of the mandible is a surgical procedure used to correct dentofacial discrepancies
60641|NCT03710499|Procedure|Physical activity|Activities included overall stretching and strengthening (flexion, extension, adduction and abduction movements) and muscular endurance exercises (exercises involving open and closed kinetic chains), along with aerobic conditioning using a functional circuit.
60642|NCT03710473|Diagnostic Test|Optical sensor, Pulse watch|Continuous blood pressure monitoring obtained by a Pulse watch
60643|NCT03710460|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
60644|NCT03710460|Drug|Dapagliflozin plus Metformin XR|10/1000 mg, one per day before breakfast during 12 weeks.
60645|NCT03710460|Drug|Metformin XR|1000 mg, one per day before breakfast during 12 weeks.
60646|NCT03710447|Other|HIIT + WB-EMS|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and whole-body electromyostimulation (WB-EMS).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~2 exercise sessions per week. Order of application: HIIT - WB-EMS. Additionally, participants receive individualized nutritional counseling."
60647|NCT03710447|Other|WB-EMS + HIIT|"12-week supervised exercise program consisting of whole-body electromyostimulation (WB-EMS) and ergometer-based high-intensity interval training (HIIT).~WB-EMS: Simulanteous stimulation of all major muscle groups with dedicated individual intensity.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: WB-EMS - HIIT. Additionally, participants receive individualized nutritional counseling."
60648|NCT03710447|Other|HIIT + CST|"12-week supervised exercise program consisting of ergometer-based high-intensity interval training (HIIT) and conventional low-volume strength training(CST).~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~2 exercise sessions per week. Order of application: HIIT - CST. Additionally, participants receive individualized nutritional counseling."
60649|NCT03710447|Other|CST + HIIT|"12-week supervised exercise program consisting of conventional low-volume strength training(CST) and ergometer-based high-intensity interval training (HIIT).~CST: Conventional 1-set strength training using weight machines to train all major muscle groups with an individual intensity corresponding to 70-80% of one repetition maximum.~HIIT: 5x1 min at 85-95% HRmax divided by low-intensity recovery periods. 2 exercise sessions per week. Order of application: CST - HIIT. Additionally, participants receive individualized nutritional counseling."
60650|NCT03710434|Drug|AZD4635 50 mg nano-suspension (reference)|Subjects will receive a single dose of AZD4635 50 mg nano-suspension (reference) in the fasted state.
60651|NCT03710434|Drug|AZD4635 solid oral formulation - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fasted state.
60652|NCT03710434|Drug|AZD4635 solid oral formulation - fed|Subjects will receive a single dose of AZD4635 solid oral formulation, in the fed state.
60653|NCT03710434|Drug|Lansoprazole and AZD4635 50 mg solid oral formulation|Subjects will receive lansoprazole 30 mg BID for 5 days followed by a single dose of AZD4635 50 mg solid oral formulation in the fasted state.
60654|NCT03710434|Drug|AZD4635 solid oral formulation variant 1 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 1 in the fasted state.
60655|NCT03710434|Drug|AZD4635 solid oral formulation variant 2 - fasted|Subjects will receive a single dose of AZD4635 solid oral formulation, variant 2 in the fasted state.
60656|NCT03710434|Drug|[14C] AZD4635 IV microtracer - fasted|Subjects will receive a single dose of [14C] AZD4635 IV microtracer. This intervention will be co-administered with AZD4635 solid oral formulation variant 1.
60657|NCT03710421|Procedure|CS1-CAR T Therapy|Undergo CS1-CAR T therapy
60658|NCT03710421|Drug|Cyclophosphamide|Given IV
60659|NCT03710421|Drug|Fludarabine|Given IV
60660|NCT03710421|Procedure|Leukapheresis|Undergo leukapheresis
60661|NCT03710408|Other|Intravenous hydration|"Participants assigned to the intravenous hydration arm will receive their hydration therapy through an intravenous access. This access will be achieved by inserting a BD VenflonTM Pro Safety - 22G in a vein in the dorsal side of the hand or further up the forearm. If the participants is suspected of becoming delirious and at risk of removing the cannula from the hand/forearm, it may be inserted at the dorsal side of the foot. The clinical staff judge this risk and decide site of placement.~Furthermore, a sham subcutaneous access device BD Saf-T-Intima™ Integrated Safety Catheter System will be placed on the abdomen without piercing the skin."
60701|NCT03710161|Drug|Vitamin D|Vitamin D taken in two different dosages daily for six months.
60662|NCT03710408|Other|Subcutaneous hydration|"Participants assigned to the subcutaneous hydration arm will receive their hydration therapy through a subcutaneous access. This access will be achieved by placing a BD Saf-T-Intima™ Integrated Safety Catheter System on the abdomen or, alternatively if the participants is suspected of becoming delirious and at risk of removing the needle, it will be placed on the back at the scapular region.~Furthermore, a sham IV access device BD VenflonTM Pro Safety - 22G will be placed on the dorsal side of the hand without piercing the skin."
60663|NCT03710395|Procedure|Blood and breast milk sampling|At least 15 days after starting treatment with 20 mg slow-release nifedipine every 12 hours. Blood and breast milk will be sampled before first dosing in the morning.
60664|NCT03710395|Drug|Nifedipine|Chronic hypertensive breastfeeding women will be treated with slow-release 20 mg nifedipine, twice a day.
60665|NCT03710382|Other|Walking epidural|Parturients in spontaneous or induced labor will receive combined spinal-epidural analgesia (CSE) using an infusion of bupivacaine 0.0625% and fentanyl 2 mcg/mL and will be encouraged to walk a minimum of 15 minutes every hour during the first stage of labor.
60666|NCT03710369|Drug|Placebo|The placebo pill was compounded by McDonalds Pharmacy.
60667|NCT03710369|Drug|Sildenafil|Sildenafil from Pfizer, compounded by McDonalds Pharmacy.
60668|NCT03710356|Drug|Danazol 200 MG|DANAZOL 200 mg as capsules 800 mg/d orally, in 2 doses Duration of treatment: 12 months
60669|NCT03710343|Drug|Metformin|Participants will be randomized to either the Metformin (Glucophage) or Placebo group at baseline. Participants in both groups will receive active physiotherapy twice weekly during the 16 week intervention. Participants will be followed-up until 40 weeks from baseline.
60670|NCT03710343|Drug|Placebo Oral Tablet|Participants will be randomized to either the Metformin (Glucophage) or Placebo group at baseline. Participants in both groups will receive active physiotherapy twice weekly during the 16 week intervention. Participants will be followed-up until 40 weeks from baseline.
60671|NCT03710330|Drug|normal saline|110 ml normal saline IV just before skin incision
60672|NCT03710330|Drug|1gm tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
60673|NCT03710330|Drug|0.5 gm tranexamic acid|0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
60674|NCT03710317|Drug|carbetocin|100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
60675|NCT03710317|Drug|Tranexamic Acid|1 gm tranexamic acid in 100 mL of intravenous solution infusion over 15 min.
60676|NCT03710317|Drug|misoprostol|Group 2 400 μg buccal misoprostol (2 tablets of 200 μg) will be given after spinal anesthesia and few minutes before skin incision
60677|NCT03710304|Drug|Oxytocin|20 IU oxytocin or placebo ampoules in 500 mL of intravenous solution infusion over 15 min after delivery of the baby.plus 2tab placebo buccal plus 110 ml saline by slow infusion
60678|NCT03710304|Drug|Tranexamic acid plus misoprostol|1 gm TA or separate placebo will be diluted in 100 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist before skin incision,
60679|NCT03710304|Drug|misoprostol|400 μg misoprostol (2 tablets of 200 μg) will be give buccally after spinal anesthesia and few minutes before skin incision;
60680|NCT03710291|Drug|TRC101|Oral, non-absorbed, polymeric hydrochloric acid binder
60681|NCT03710291|Drug|Placebo|Placebo comparator
60682|NCT03710278|Device|LPat Device|Performing Lumbar Puncture utilizing LPat device
60683|NCT03710265|Drug|SHR-1701|Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
60684|NCT03710252|Drug|paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin|OMB/PTV/r + DSV +/- RBV
60685|NCT03710239|Device|Dilapan-S|Synthetic osmotic dilator
60686|NCT03710239|Device|Laminaria|Seaweed-based osmotic dilator
60687|NCT03710213|Behavioral|Text Message-based Intervention|The intervention consists of a series of educational and reminder text messages that a patient will receive in the week prior to a scheduled colonoscopy, in addition to two text messages at the time of enrollment explaining the texting program.
60688|NCT03710200|Other|Bologna 00+S. cerevisiae yeast|Bologna 00 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL of water
60689|NCT03710200|Other|Bologna 1+S. cerevisiae yeast|Bologna 1 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
60690|NCT03710200|Other|Bio2+S. cerevisiae yeast|Bio2 bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
60691|NCT03710200|Other|ICARDA+S. cerevisiae yeast|Icarda bread made with yeast (portion corresponding to 50g available carbohydrates) +500 mL water
60692|NCT03710200|Other|Bologna 1+sourdough|Bologna 1 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
60693|NCT03710200|Other|Bio 2+sourdough|109g of Bio2 bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
60694|NCT03710200|Other|ICARDA+sourdough|Icarda bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
60695|NCT03710200|Other|Grossi+sourdough|Grossi bread made with sourdough (portion corresponding to 50g available carbohydrates) +500 mL water
60696|NCT03710187|Drug|Combination (Hydrocortisone and Fludrocortisone)|Hydrocortisone 50 mg IV Q6h and Fludrocortisone 50 mg PO/PFT Q24h
60697|NCT03710187|Drug|Hydrocortisone|Hydrocortisone 50 mg IV Q6h
60698|NCT03710174|Radiation|Infrared LED photobiomodulation|Infrared LED (3 X 6 cm) will be administered using a board with 6 LEDs with a wavelength of wavelength: 850 nm ± 20 nm, seven-minute operation time, optical spot of 5 ± 2 mm and optical output of 2~5 mW, with a dose of 2.675 J/cm2. Further analyses will be performed immediately after the photobiomodulation session and one week later.
60699|NCT03710174|Device|Occlusal splint|After the initial evaluation, molds will be made for the fabrication of the splints, which will be delivered one week later. Written and verbal instructions for use will be given. After one month of daily use, the volunteers will return for the final morphological and psychosocial evaluations.
60700|NCT03710174|Radiation|Placebo LED photobiomodulation|The same procedure as LED group with the device turned off.
60702|NCT03710148|Other|Natural exposure of deficient or excessive iodine|Natural exposure of deficient iodine from diet & drinking water, and of excessive iodine intake from drinking water
60703|NCT03710122|Drug|Vancomycin|Firvanq by Cutis Pharma
60704|NCT03710122|Other|Placebo|Placebo for Vancomycin
60705|NCT03710109|Other|EEG|non-invasive, non-interventional sensor
60706|NCT03710096|Device|macGrath|in the mac grath group we use the videolaryngoscope macGrath as first-line for the insertion of double lumen tube
60707|NCT03710096|Device|Macintosh's|in the macintosh group we use the laryngoscope with Macintosh's blade as first-line for the insertion of double lumen tube
60708|NCT03710083|Device|Guardian™ Sensor (3)|Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.
60709|NCT03710070|Device|Amplatzer vascular plug 4|See above
60710|NCT03710070|Other|Sham Control|Angiography of the IMA without occlusion
60711|NCT03710057|Drug|Ivabradine|A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.
60712|NCT03710044|Drug|Cyclosporine A|"Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks."
60713|NCT03710031|Other|PNS Tracking|Through blood and stool samples the study team will track the interplay among PNS as they relate to diminished QOL. Symptoms tracked include neurocognitive dysfunction, fatigue, anxiety, depression and pain, inflammation (cytokines and C-reactive protein), gut microbiota [(GM) richness and diversity] and diet (macronutrients: carbohydrates, fats and proteins).
60714|NCT03710005|Procedure|Ascent|Dehydrated Cell and Protein Concentrate injection
60715|NCT03710005|Procedure|Standard|Standard corticosteroid injection
60716|NCT03709992|Drug|Trospium Chloride|30 mg of Trospium chloride tablet twice daily
60717|NCT03709992|Drug|Tamsulosin|0.4 mg of Tamsulosin tablet once daily
60718|NCT03709979|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation will be performed by anesthesiologist with C-MAC videolaryngoscope
60719|NCT03709966|Device|Portable monitoring device|similar to a wrist-sport watch with many features including step calculations, distance traveled, calories burned, but also heart rate and sleep status
60720|NCT03709966|Behavioral|Routine|Physical activity promotion supported by a kinesiologist
60721|NCT03709953|Drug|Apatinib|500 mg，po，QD； 28 days every cycle
60722|NCT03709940|Drug|MPH|Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
60723|NCT03709927|Drug|ZTI-01|6g IV fosfomycin
60724|NCT03709927|Drug|Moxifloxacin 400mg|oral moxifloxacin (Avelox 400 mg) + IV normal saline (Placebo)
60725|NCT03709927|Other|Placebo IV|IV Placebo (0.9% Normal Saline)
60726|NCT03709914|Drug|ZTI-01 100 mg/kg|ZTI-01 intravenous (IV)
60727|NCT03709914|Drug|ZTI-01 75 mg/kg|ZTI-01 intravenous (IV)
60728|NCT03709901|Other|Active Allograft|Injection of viable allograft into the nucleus pulposus of the degenerated disc
60729|NCT03709901|Other|Placebo|Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
60730|NCT03709888|Drug|Memantine XR-pregabalin combination therapy|Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
60731|NCT03709875|Device|TR Treatment|A virtual reality based system, consisting of two PC-based workstations, located at the patient's home and at the rehabilitation center, will be used. For the motor treatments the patient has to move the real end effector, following the trajectory of the corresponding virtual task displayed on his computer screen. The speech (mainly lexical based) and cognitive (attention focused) exercises will be delivered from the two Research Institutes to the patient's home. During the treatment at home, the patients will use wearable monitoring devices to monitor their status (speed, heart rate, respiratory rate, training load and single-lead ECG in real-time) and to provide real-time feedback during exercises.
60732|NCT03709862|Diagnostic Test|Whole Genome Sequencing|Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
60733|NCT03709849|Drug|experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo|the same as group description including dosage, frequency and duration
60734|NCT03709849|Drug|control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo|the same as group description including dosage, frequency and duration
60735|NCT03709823|Drug|Cytisine|film coated tablet containing 1.5 mg cytisine in a single tablet
60736|NCT03709823|Drug|Placebo Comparator|1.5 mg cellulose powder to match final weight of the cytisine tablet
60737|NCT03709823|Behavioral|Behavioral support|12 behavioral support sessions by a qualified staff member plus supportive literature and online resources
60738|NCT03709810|Combination Product|Marketed Denture Adhesive (Super Poligrip Max Seal)|The denture adhesive will be applied directly from the tubes. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.1 g for the maxillary and 0.6±0.1g for the mandibular dentures.
60739|NCT03709810|Other|No Adhesive|No adhesive will be applied.
60740|NCT03709797|Procedure|Dry needling in infraspinatus muscle|Dry needling technique with multiple rapid needle insertion.
60741|NCT03709784|Other|Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care|This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
60774|NCT03709524|Device|Nasotracheal Airtraq + styletted tube|video laryngoscope with a monitor
60775|NCT03709511|Other|Cardiac rehabilitation|Cardiac rehabilitation consists of exercise rehabilitation, psychological counseling and Dietary guidance.
60742|NCT03709771|Diagnostic Test|Ambulatory Blood Pressure Measurement|"Baseline: Subjects will undergo an abbreviated physical exam, review changes in medical history since last oncology visit, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic digital velocity time interval (VTI) using pulse amplitude tonometry, cubital vein endothelial cell harvest, and ambulatory 24 blood pressure measurement.~30 day (± 2 days) Review changes in medications and any medical events that happened since the last visit, an abbreviated physical exam, blood collection, urine collection, blood pressure and heart rate in triplicate, baseline and hyperemic velocity time interval (VTI), digital pulse amplitude tonometry, endothelial cell harvest, and ambulatory 24 blood pressure."
60743|NCT03709758|Drug|Venetoclax|Venetoclax blocks an important pathway that promotes cell survival in tumor cells that overexpress BCL-2, so venetoclax causes cells to die
60744|NCT03709758|Drug|Daunorubicin|Chemotherapy is most effective at killing cells that are rapidly dividing.
60745|NCT03709758|Drug|Cytarabine|Chemotherapy is most effective at killing cells that are rapidly dividing.
60746|NCT03709745|Drug|Aflibercept Injection [Eylea]|Intravitreal injection is given as described in the arm description
60747|NCT03709745|Drug|Ranibizumab Injection [Lucentis]|Intravitreal injection is given as described in the arm description
60748|NCT03709732|Other|no intervention|observational study
60749|NCT03709719|Drug|Blinatumomab Injection|Blinatumomab 28 μg/day : D1 to D28
60750|NCT03709706|Drug|GSK3377794|GSK3377794 will be given as a single IV infusion of 1 to 6 x10^9 transduced cells.
60751|NCT03709706|Drug|Pembrolizumab|Pembrolizumab will be given as a dose of 200 mg using a 30-minute IV infusion
60752|NCT03709693|Device|SternaLock Blu|Sternal closure will be accomplished using SternaLock Blu plates and screws in combination with single-wire method of sternal reduction.
60753|NCT03709680|Drug|Palbociclib|Administered (oral) at 55 mg/m2, 75 mg/m2, or 40 mg/m2 on days 1-14 of a 21-day cycle
60754|NCT03709680|Drug|Temozolomide|Administered at 100 mg/m2 (oral or intravenous), on days 1-5 of a 21-day cycle
60755|NCT03709680|Drug|Irinotecan|Administered at 50 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
60756|NCT03709667|Behavioral|EX|An individualized aerobic and resistance-exercise program will be developed for each participant on the basis of a maximal incremental exercise test and strength assessments performed at baseline. This test will measure aerobic capacity (VO2 max) and the metabolic or lactate threshold (VO2θ) (i.e., the level of O2 uptake that defines one's ability to perform prolonged work), using indirect calorimetry with an automated metabolic-measurement system. The intervention will comprise 24 sessions over 8 wk (3x/wk), supervised by a credentialed exercise specialist. Each session will consist of a 5-min warm-up, 30-40 min of aerobic activity on a treadmill, 15-20 min of resistance training, and a 5-min cool-down.
60757|NCT03709667|Behavioral|CON|Participants attend 50-min sessions 3x/wk matched to EX for staff contact. A counselor will facilitate integrative group discussions, and will conduct a multimedia program addressing various health, wellness and lifestyle topics, such as nutrition, dental care, stress relief, sleep hygiene, relationships, immunizations, health screening, smoking, environmental health, and time management.
60758|NCT03709654|Biological|NB01|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of NB01
60759|NCT03709654|Other|Vehicle Control|5-7 day pretreatment of gold standard benzoyl peroxide therapy to kill resident facial bacterial followed by 11 weeks of daily topical application of vehicle control
60760|NCT03709641|Device|Restylane Defyne|Restylane is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL
60761|NCT03709628|Drug|EB8018 (First-in-class FimH blocker)|"Drug: EB8018 EB8018 is an orally administered, first-in-class, FimH blocker~• In Part 1, a single oral dose of EB8018 3000 mg will be administered to the 2 sentinel patients in the morning on Day 1. In the multi-dose treatment period (part 1 and 2), multiple oral doses of EB8018 1500 mg will be administered to 2 + 6 patients BID (in the morning and evening) on Days 1 through 13."
60762|NCT03709615|Behavioral|Internet delivered CBT for social anxiety disorder|"An internet-based CBT for social anxiety based on a protocol from Andersson et al., 2006:~Internet-based self-help with therapist feedback and in vivo group exposure for social phobia: a randomized controlled trial."
60763|NCT03709589|Other|Modified Early Warning Score|Modified Early Warning Score
60764|NCT03709576|Drug|Pevonedistat|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
60765|NCT03709576|Procedure|transplant|Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.
60766|NCT03709576|Drug|Azacitidine|To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
60767|NCT03709563|Dietary Supplement|Oral Nutraceutical Supplement|Standardized Botanicals. Take 4 capsules by mouth daily with a meal
60768|NCT03709563|Dietary Supplement|Placebo|Placebo. Take 4 capsules by mouth daily with a meal
60769|NCT03709550|Drug|Decitabine|Given IV
60770|NCT03709550|Drug|Enzalutamide|Given PO
60771|NCT03709537|Behavioral|Mental Health Peer Workforce Support|"Supervisors and peer workers will participate in trainings covering effective peer services, trauma-informed effective peer supervision, and responsibilities of peer workers in a supervising relationship. A monthly Supervisors of Peer Workers meeting will support site change efforts. Sites will create an implementation team to work within their site to implement the training received.~Peer Workers will enroll in a peer mentoring program, where they serve as peer mentors matched with fellow peer mentors. Recovery International and the Los Angeles Department of Mental Health will encourage peer workers to attend Recovery International meetings. Emotional Health Association will refer Peer Workers and their Supervisors in the intervention group to self-help support groups that reduce stress and increase resiliency."
60772|NCT03709524|Device|Airtraq + fiberoptic|video laryngoscope with a monitor
60773|NCT03709524|Device|Airtraq|video laryngoscope with a monitor
60777|NCT03709472|Behavioral|Computer Assisted CIFFTA|This is a hybrid intervention that includes individual work with the adolescent (e.g., Motivational Interviewing, diary card identification of triggers), computer assisted psychoeducational work, and intensive family therapy interventions.
60778|NCT03709472|Behavioral|Behavioral: Traditional face-to-face treatment-no technology|Community agencies provide mostly individual counseling but may add some family involvement in treatment planning.
60779|NCT03709459|Drug|Doxycycline|Participants will be asked to take Doxycycline 100mg/day for 12months duration
60780|NCT03709446|Drug|Leflunomide|Single agent leflunomide
60781|NCT03709433|Behavioral|ACT groups and mobile app|See arm description.
60782|NCT03709420|Drug|Placebo|Placebo capsule to match active drug
60783|NCT03709420|Drug|FOR-6219|FOR-6219 capsule
60784|NCT03709407|Other|cervical stimuli|Manouvres Godoy
60785|NCT03709407|Other|terminus|Manouvres Vodder
60786|NCT03709407|Other|Placebo|placebo manouvre
60787|NCT03709407|Other|Control group|lie down
60788|NCT03709394|Procedure|Full utrasound guidance|The target vein is directly identified by portable ultrasound device and the complete procedure of peripheral venous cathether insertion is controlled by ultrasound guidance in real time
60789|NCT03709394|Procedure|Partial ultrasound guidance|The target vein is directly identified by ultrasound but the procedure of peripheral venous cathether insertion is performed conventionally, without ultrasound guidance
60790|NCT03709394|Procedure|No ultrasound guidance|The target vein is identified and peripheral venous catheter is inserted by conventional approach without use of any guiding devices
60791|NCT03709381|Drug|Low Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 1 mcg IV given to subjects at t=0
60792|NCT03709381|Drug|High Dose Cosyntropin (ACTH) stimulation test|Cosyntropin 250 mcg IV given to subjects at t=60
60793|NCT03709368|Other|Hardware|Community sessions will be provided to each of the sub-villages (n=27) teaching participants how to build a tippy tap, how to build an improved latrine, and how to make liquid soap. In addition, an existing water gravity flow scheme will be rehabilitated and extended, 350 tippy taps and 350 pans for pour flush latrines will be distributed, and sanitation blocks will be built in four schools. Within these schools, SWASH school hygiene clubs will be organized.
60794|NCT03709368|Behavioral|CLTS|CLTS sanitation and HW sessions will be given. A first session will focus on sanitation, covering 7 exercises: 1) sanitation or social map, 2) transect walk, 3) shit calculation, 4) medical expenses, 5) shit flow diagram, and 6) water/shit demo, 7) community declaration. A second session will focus on HW, involving 10 exercises: 1) anal cleansing materials, 2) shit and shake, 3) cassava/egg demonstration, 4) charcoal smearing, 5) smelly hands, 6) feces on baby nappies, 7) scratch & smell, 8) wall contamination, 9) food sharing, 10) dirt under fingernails. These sessions will take approximately 3-5 hours each. Follow-up community meetings and household visits will take place to monitor improvement.
60795|NCT03709368|Behavioral|PHAST|PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
60796|NCT03709368|Behavioral|RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
60797|NCT03709368|Behavioral|mini-RANAS|Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
60798|NCT03709368|Other|Placebo poster|One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
60799|NCT03709355|Drug|Elpida®|Elpida® capsules, 20mg
60800|NCT03709355|Drug|Rifampin|Rifampin capsules, 150mg
60801|NCT03709355|Drug|Rifabutin|Rifabutin capsules, 150mg
60802|NCT03709355|Drug|Clarithromycin|Clarithromycin Film-coated tablets, 250mg
60803|NCT03709355|Drug|Omeprazole|Omeprazole Film-coated tablets 20mg
60804|NCT03709355|Drug|Atorvastatin|Atorvastatin Film-coated tablets, 80mg
60805|NCT03709355|Drug|Levonorgestrel+Ethinylestradiol|Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
60806|NCT03709342|Drug|CM4620-IE|single IV infusion on Day 1 over 4 hours
60807|NCT03709329|Device|Robot Assisted Gait Therapy|The robot-assisted gait treatment will receive 18 treatments per patient for 1 week, 3 times a week, and 6 weeks for 30 minutes a day.
60808|NCT03709329|Device|Conventional Gait Therapy|The conventional gait therapy group receives a total of 18 classical gait training sessions once a day for 30 minutes and three times a week for 6 weeks. Classical gait training consisted of exercise training based on neurophysiological theories such as Bobath, restraint of rigid and cooperative movements by therapists, exercise training in sitting or standing posture, Gait training and balance training, weight training of the paralyzed lower limb.
60809|NCT03709316|Drug|ZL-2306 (Nirapairb)|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
60991|NCT03707925|Procedure|Laser Ablation|Undergo bronchoscopic laser ablation
60810|NCT03709316|Drug|Placebo Comparator|The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
60811|NCT03709290|Radiation|mri|mri brain & spinal cord
60812|NCT03709277|Behavioral|Pharmacist-Driven Intervention|The pharmacist will investigate patient assistance options for patients who cannot afford their specialty medication, reach out to prescribers when needed to address intolerance/adverse effects, improve health literacy, recommend options for forgetfulness, make every effort to reach patient, address clinical and financial barriers to unresponsiveness (lack of lab completion, not returning to clinic, etc.)
60813|NCT03709264|Drug|Amino Acids|Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line
60814|NCT03709264|Drug|Placebos|Placebo: standard treatment
60815|NCT03709251|Behavioral|High Intensity Walking|Intense walking activity at an intensity of 70-80% of the maximum heart rate
60816|NCT03709251|Behavioral|Casual Speed Walking|Moderate intensity (50-60% of Heart Rate maximum)
60817|NCT03709238|Behavioral|Thermal stimulation|Thermal stimulation
60818|NCT03709225|Behavioral|Music-based meditation|The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
60819|NCT03709212|Other|interviews|20 participants will undergo individual semi-structured interviews, 60 will undergo one of 6 focus groups comprising of 10 participants of the same gender and ethnicity.
60820|NCT03709199|Diagnostic Test|Ventilation Inhomogeneity|Ventilation inhomogeneity will be measured using the Lung Clearance Index (LCI), derived from multiple breath Nitrogen washout during tidal breathing, measured by a mouthpiece or mask covering nose and mouth.
60821|NCT03709199|Diagnostic Test|Diaphragm Ultrasound|Diaphragm thickness and contractile activity measured during tidal breathing.
60822|NCT03709199|Diagnostic Test|Respiratory Inductance Plethysmography|Measure of thoraco-abdominal asynchrony during tidal breathing
60823|NCT03709199|Diagnostic Test|Spirometry|Measurement of Forced Expiratory Volume (FEV1), Forced Vital Capacity and other lung volumes using standard pulmonary function techniques
60824|NCT03709199|Diagnostic Test|Functional Residual Capacity|Measurement using body box plethysmography of functional residual capacity and other lung volumes using standard pulmonary function techniques
60825|NCT03709199|Diagnostic Test|MIP/MEP|Measurement of maximal inspiratory and expiratory pressures during airway occlusion
60826|NCT03709199|Diagnostic Test|6 minute walk test|Measurement of cardio-respiratory function and capabilities during treadmill walking for 6 minutes.
60827|NCT03709199|Diagnostic Test|Neurocognitive Testing|Detailed in person neuro-cognitive testing using standardized inventories using either the Battelle Developmental Inventory, second edition (Battelle-2) (age birth to 5 years 11 months) and the Wechsler Intelligence Scale for Children, fifth edition (WISC-5, for age 6 years to 19 years).
60828|NCT03709199|Diagnostic Test|Emotional Health Assessment|In person and written assessments of children and parents using the Behavioral Assessment System for Children, third edition (BASC-3) for children ≥ 2 years and the UCLA PTSD Reaction Index (UCLA RI) for children ≥ 8 years.
60829|NCT03709199|Diagnostic Test|Health Related Quality of Life|Standardized instruments to assess (in person, over the phone, or via mail) health related quality of life in children. Parent and child questionnaires.
60830|NCT03709199|Diagnostic Test|Functional Status|Survey of overall functional status, administrated by asking a series of questions to patient and families.
60831|NCT03709199|Diagnostic Test|Respiratory Status Questionnaire|Survey of respiratory health, administrated by asking a series of questions to patient and families.
60832|NCT03709173|Behavioral|FuRST 2.0|Round 2 of cognitive pre-testing for a new functional rating scale
60833|NCT03709160|Drug|Bumetanide 1 MG|all patients will be taking the treatment recommended by heart failure guidelines
60834|NCT03709147|Drug|Metformin Hydrochloride|Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)
60835|NCT03709147|Drug|Cisplatin|Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles
60836|NCT03709147|Drug|Carboplatin|Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles
60837|NCT03709147|Drug|Pemetrexed|Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
60838|NCT03709147|Dietary Supplement|Fasting-mimicking diet|5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles
60839|NCT03709134|Diagnostic Test|Genomic and CTC Markers|This is a non-interventional study.
60840|NCT03709121|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) dosed twice.
60841|NCT03709121|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) dosed twice.
60842|NCT03709121|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution dosed twice.
60843|NCT03709108|Other|SI-Informed Bolus Calculator|The SI-Informed Bolus Calculator will be used to dose the dinner meal insulin bolus during the Experimental Admission
60844|NCT03709095|Other|Sprint interval training|Participants utilized the arm ergometer for improving aerobic exercise capacity
60845|NCT03709095|Other|moderate intensity continuous training|Participants utilized the arm ergometer for improving aerobic exercise capacity
60846|NCT03709082|Drug|Palbociclib 75mg|Oral Administration
60847|NCT03709082|Drug|Letrozole 2.5mg|Oral Adminstration
60848|NCT03709082|Drug|T-DM1|Intravenous Administration
60849|NCT03709082|Drug|Palbociclib 100mg|Oral Administration
60850|NCT03709082|Drug|Palbociclib 125mg|Oral Administration
60851|NCT03709082|Drug|Palbociclib|Oral Administration
60852|NCT03709069|Dietary Supplement|Albumin supplementation|Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
60853|NCT03709056|Drug|HSK3486|HSK3486 intravenous (iv) 0.4(0.5) mg/kg for induction, and 0.2 (0.15)mg/kg top-ups for maintenance. 0.3(0.375) mg/kg for induction and 0.15 (0.113)mg/kg for maintenance in adults of 65-70 years old
60854|NCT03709056|Drug|Propofol|Propofol iv 2.0 mg/kg for induction, and 1.0 mg/kg top-ups for maintenance. 1.5 mg/kg for induction and 0.75mg/kg for maintenance in adults of 65-70 years old.
60855|NCT03709043|Drug|Standardized kudzu|Standardized kudzu
60856|NCT03709043|Other|Placebo|Placebo
60857|NCT03709030|Diagnostic Test|magnetic resonance cholangiopancreatography (MRCP)|magnetic resonance imaging of liver, gall bladder, pancreas
60858|NCT03709017|Drug|Ponatinib|Iclusig 45mg, 15mg
60859|NCT03709004|Other|Pacifier|Pacifier given to mom.
60860|NCT03708991|Diagnostic Test|IVF combined with PGT-A|trophectoderm biopsy to test the ploidy state of the IVF embryos
60861|NCT03708991|Diagnostic Test|ICSI combined with PGT-A|trophectoderm biopsy to test the ploidy state of the ICSI embryos
60862|NCT03708978|Diagnostic Test|mammography|When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
60863|NCT03708965|Drug|JR-141|IV infusion (lyophilized powder)
60864|NCT03708939|Dietary Supplement|artificial sweeteners|consumption of 5 mg of an artificial sweeteners for 14 days
60865|NCT03708926|Drug|Abaloparatide|abaloparatide injection pen
60866|NCT03708926|Drug|Placebo|placebo injection pen
60867|NCT03708913|Device|Hypothalamic Deep Brain Stimulation|One-year continuous hypothalamic deep brain stimulation
60868|NCT03708900|Drug|LCI699|osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
60869|NCT03708887|Drug|Low dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 1 g/d by mouth for 1 year
60870|NCT03708887|Drug|High dose omega-3 fatty acid supplementation|Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year
60871|NCT03708887|Drug|Control drug|Matching placebo capsules,1 g/d by mouth for 1 year
60872|NCT03708861|Drug|maraviroc (300 mg QD) + atazanavir/ritonavir (300 and 200 mg /100 mg QD)|"Phase 1: switch from tenofovir disoproxil fumarato/emtricitabine (200/245 mg QD)+ atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD).~Phase 2: switch from maraviroc (300 mg QD) + atazanavir/ritonavir (300 /100 mg QD) to maraviroc (300 mg QD) + atazanavir/ritonavir (200 /100 mg QD)"
60873|NCT03708848|Drug|Esomeprazole|Proton pump inhibitor
60874|NCT03708848|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
60875|NCT03708848|Drug|Clarithromycin|antibiotic for H. pylori eradication
60876|NCT03708848|Drug|Metronidazole|antibiotic for H. pylori eradication
60877|NCT03708848|Drug|Levofloxacin|antibiotic for H. pylori eradication
60878|NCT03708848|Drug|Tetracycline|antibiotic for H. pylori eradication
60879|NCT03708835|Other|Transitional care model|In this study, the feasibility and impact of a transitional care model from hospital to home for stroke patients and caregivers will be tested.
60880|NCT03708822|Drug|Docetaxel and Cisplatin and Nimotuzumab|All patients enrolled in the study will accept docetaxel combined with cisplatin and Nimotuzumab as their firstline chemotherapy
60881|NCT03708809|Device|Intrauterine system|13.5 mg levonorgestrel-releasing intrauterine system
60882|NCT03708809|Other|Alternative contraception to intrauterine system|Alternative contraception including contraception pills, hormonal patches, hormonal vaginal , condomsring,
60883|NCT03708796|Diagnostic Test|SIRS, qSOFA, NEWS, RETTS scores evaluation|Simple data collection from regular vital signs recordings during the initial phase of care management in the emergency department. Missing data is then possibly completed by the physician when made available during the regular medical management of the patient.
60884|NCT03708783|Procedure|laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection|For patients with locally advanced upper or middle third gastric cancer, laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-preserving No. 10 lymph node dissection is performed.
60885|NCT03708770|Device|everlinQ endoAVF System|
60886|NCT03708757|Other|Post isometric relaxation - Group I|Post isometric relaxation (PIR) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
60887|NCT03708757|Other|Eccentric Muscle contraction - Group II|and Eccentric muscle energy techniques(EME) techniques are used by orthopedic manual physical therapists to enhance the flexibility of muscles and to increase the joint range of motion
60888|NCT03708744|Drug|M207|M207 3.8 mg administered as two 1.9 mg patches applied to thigh or upper arm
60889|NCT03708744|Drug|Intranasal zolmitriptan|2.5 mg/0.1 mL intranasal zolmitriptan
60890|NCT03708718|Drug|Prednisolone 5 mg|5mg prednisolone, once a day for 6 months
60891|NCT03708718|Drug|Placebo oral capsule|Matched placebo capsule, once a day for 6 months
60892|NCT03708705|Other|Risk model of tumor relapse|High risk factor model of tumor relapse after liver transplantation
60893|NCT03708692|Behavioral|Group F|After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
60894|NCT03708666|Other|Telemonitoring of blood pressure|Blood pressure monitoring at least once a week.
60895|NCT03708640|Other|Digital Activity Tracker|Group wears physical activity tracker and receives physical activity feedback information informed by the tracker
106809|NCT03351101|Device|Acuvue Vita|contact lense
60896|NCT03708640|Other|Smart Text Messaging|"Group receives personalized, health coaching via smart text messages"
60897|NCT03708640|Other|Physical Activity Counseling|Group receives baseline counseling on physical activity
60898|NCT03708627|Drug|Bimatoprost Ophthalmic|Bimatoprost, aka Lumigan, one drop in one eye nightly
60899|NCT03708614|Other|Controlled energy diet with elevated protein intake|Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks. Protein intake will be increased in the range of 20-30% of total daily caloric intake. Each participant's diet will also be modified to implement controlled energy intake. Controlled energy intake will be defined as being isocaloric with the participant's current dietary intake.
60900|NCT03708588|Drug|Ticagrelor|Chewed
60901|NCT03708588|Drug|Ticagrelor|Integral
60902|NCT03708562|Device|everlinQ endoAVF System|The everlinQ device is a single-use disposable device. The everlinQ catheter system consists of two flexible, magnetic catheters. Once the catheters are properly inserted and aligned, the magnets contained in each catheter attract to one another, approximating the vessels while simultaneously aligning the electrode with the backstop. RF energy is delivered to the electrode whereby the arterio-venous fistula (AVF) is created.
60903|NCT03708549|Drug|Berberine|The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
60904|NCT03708549|Drug|Metformin|The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
60905|NCT03708536|Drug|S-1|S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
60906|NCT03708536|Drug|Bevacizumab|Bevacizumab (7.5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 3-week cycle.
60907|NCT03708536|Drug|Capecitabine|Capecitabine 2000mg/m2/d is administered orally on days 1 to 14 of a 21-day cycle.
60908|NCT03708510|Device|Restorative materials- Filtek Silorane|Filtek Silorane
60909|NCT03708510|Device|Restorative materials-Kalore|Kalore
60910|NCT03708510|Device|Preparation-Er,Cr:YSGG Laser|Er,Cr:YSGG Laser
60911|NCT03708510|Device|Preparation- Diamond Bur|Bur
60912|NCT03708497|Drug|carbetocin|Carbetocin 100 microgram will be applied intravenously in a short infusion over about a minute
60913|NCT03708497|Drug|Tranexamic acid plus misoprostol|1000mg oral TA at the end of the first stage of labor plus 600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
60914|NCT03708497|Drug|misoprostol|600 mg buccal misoprostol after delivery of the baby. A buccal route, in which the tablets are placed in the cheek for 30 min after which any remnants are swallowed.
60915|NCT03708484|Other|Aerobic Interval Training|"Aerobic Interval Training Patients in this group will perform 6 minutes of cycling followed by 3 minutes of pause and again 6 minutes of cycling followed by 3 minutes of pause and finally 6 minutes of treadmill followed by 3 minutes of rest.~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
60916|NCT03708484|Other|Aerobic + Resistive Interval Training|"Aerobic + Resistive Interval Training Patients in this group; first set will perform 3 minute of cycling ,1 set of hand grippers 1.5 to 2.5 lbs (10 to 12 reps) and 1 set of biceps resistive exercises 1 Kg to 3 kg (10 to 12 reps) followed by 3minute of pause. In second set patient will perform 3 minutes of stationary cycling , 1 set of quadriceps resistive exercises 1 to 3 Kg (10 to 12 reps) again followed by 3 minutes of pause and in third set patient will perform 3 minutes of treadmill walk at 1.5 to 4 speed, and 1 set of standing ankle pumps (10 to 12 reps).~both groups will perform cool down exercises that include again breathing exercises, stretching and active exercises."
60917|NCT03708471|Procedure|Hybrid ablation|This intervention including thoracoscopic surgical ablation, percutaneous catheter ablation and cardiovascular risk control.
60918|NCT03708471|Procedure|Thoracoscopic surgical ablation|This intervention including thoracoscopic surgical ablation and cardiovascular risk control.
60919|NCT03708458|Drug|indomethacin suppository|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
60920|NCT03708458|Drug|N-acetylcysteine (NAC)|the investigators aimed to perform a comparative study, evaluating the efficacy of three prophylactic approaches aiming to reduce the risk of PEP, using indomethacin and/or N-acetylcysteine -NAC, in different regimens
60921|NCT03708445|Diagnostic Test|Cytology staining|"Two staining will be performed in cytology specimens obtained from same patient. The cytology specimen will be obtained through brushing cytology using endoscopic retrograde cholangiopancreatography~conventional cytology staining method~new cytology staining method using antibody of aminoacyl-tRNA synthetases"
60922|NCT03708419|Other|Optimal diet|Based on a 7-points OGTT, participants will be classified as MIR or LIR. The hypothesized optimal diet for MIR has a moderate fat content which is high in mono- unsaturated fatty acids (HMUFA) with a macronutrient breakdown of 38 E% from fat (20% MUFA, 10% polyunsaturated fatty acids (PUFA), 8% saturated fatty acids (SFA)), 48 E% from carbohydrates (CHO, 35% complex), and 14 E% from protein (35-40% plant protein). The hypothesized optimal diet for LIR is low in fat, high in protein (LFHP) and increased fiber with a macronutrient breakdown of <28 E% from fat (10% MUFA, 10% PUFA, 8% SFA), 48 E% from CHO (35% complex), and 24 E% from protein (35-40% plant protein), and an additional supplement of 6g of soluble fiber per day. Participants wil be randomly allocated to one of the two diets.
60923|NCT03708419|Other|Suboptimal diet|"The optimal diet for the other metabolic phenotype will be considered as suboptimal/ control diet. For the MIR phenotype this is the high protein, high fiber, low fat diet; for the LIR phenotype this is the high monounsaturated fatty acid diet. See the description above."
60924|NCT03708380|Behavioral|Dietary intervention|Over a 60-day period, participants will receive healthy lunches that provide a hand-delivered healthy alterative to their current diets.
60925|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at preoperative visit for study group
106810|NCT03351101|Device|Ultra|contact lense
60926|NCT03708367|Device|LipiFlow Thermal Pulsation System|Treatment at 3 month visit as the cross-over group
60927|NCT03708354|Drug|placebo softgel|One 430 mg olive oil softgel daily for 24 weeks. Each placebo softgel of 430 mg olive oil will contain no tocotrienol or tocopherols at detectable levels.
60928|NCT03708354|Drug|DeltaGold® Tocotrienol 70%|Each TT softgel (DeltaGold® Tocotrienol 70%) contains 430 mg TT (90% δ-TT+10% γ-TT) with a 70% purity, representing 300 mg TT.
60929|NCT03708341|Drug|Melatonin 5 mg|Systematic daily administration of melatonin 5 mg during patient's ICU stay
60930|NCT03708341|Drug|Placebo Oral Tablet|Systematic daily administration of placebo during patient's ICU stay
60931|NCT03708328|Drug|RO7121661|RO7121661 will be administered intravenously (IV) with a flat dose on the schedule described for each study arm.
60932|NCT03708315|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride
60933|NCT03708315|Drug|Normal saline|Normal Saline (Placebo)
60934|NCT03708302|Procedure|Bilateral serratus plane block|Ultrasound guided bilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20mls of 0.2% ropivacaine will be injected in the plane in 5 mls aliquot after aspiration on each side. Ultrasound guided bilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20mls of 0.2% ropivacaine will be injected in the plane slowly in 5 ml aliquots after aspiration on each side.
60935|NCT03708302|Procedure|Bilateral parasternal infrapectoral block|"Ultrasound guided bilateral serratus plane block will be performed at the level of 4th rib in anterior axillary line. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the serratus muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane in 5 mls aliquot after aspiration on each side.~Ultrasound guided bilateral parasternal infrapectoral plane block will be performed at the level of 4th rib, lateral to the sterum. After skin infiltration with 1% lidocaine, 80mm 22G block needle will be inserted at the caudal aspect of the ultrasound probe and advanced in-plane to target the fascial plane directly below the pectoralis major muscle. Once the tip is verified in the correct position, 20 mls of 0.9% saline will be injected in the plane slowly in 5 ml aliquots after aspiration on each side."
60936|NCT03708289|Radiation|DXA scan|total and hip and spine dual energy x-ray absorptiometry
60937|NCT03708289|Other|Achilles bone US|
60938|NCT03708289|Other|Medical body composition measurements|
60939|NCT03708289|Other|Resting energy expenditure measurement|
60940|NCT03708276|Other|My MS Toolkit|My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
60941|NCT03708263|Device|Excel V 532nm (KTP) green Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
60942|NCT03708263|Device|PHOTOLASE PLV 585 nm yellow laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
60943|NCT03708237|Drug|Ropinirole|ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.
60944|NCT03708237|Drug|Gabapentin|GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.
60945|NCT03708237|Drug|Placebos|Opaque gel capsules filled with methylcellulose 1500 filler
60946|NCT03708224|Biological|Atezolizumab|Given IV
60947|NCT03708211|Drug|TAK-931 PIC|TAK-931 PICs.
60948|NCT03708211|Drug|TAK-931 Tablet|TAK-931 Tablets.
60949|NCT03708211|Drug|Esomeprazole|Esomeprazole Tablets.
60950|NCT03708198|Drug|Liposomal Bupivacaine|intercostal block
60951|NCT03708185|Dietary Supplement|Beta-alanine|N/A: see arm description
60952|NCT03708185|Dietary Supplement|Placebo|N/A: see arm description
60953|NCT03708172|Device|Repetitive Transcranial Magnetic Stimulation|Intermittent TBS (iTBS) rTMS applied to the left Dorsolateral Prefrontal Cortex (DLPFC) + continuous TBS (cTBS) rTMS applied to the right DLPFC. The order will be counterbalanced. Administration of this treatment takes roughly 10 minutes. This treatment will be applied daily, 5 days/week, for 4 weeks.
60954|NCT03708172|Other|Cognitive Training|Computer-based cognitive training designed to enhance executive function
60955|NCT03708172|Other|sham Cognitive Training|Computer-based inactive sham training
60956|NCT03708159|Device|active tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to active. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
60957|NCT03708159|Other|sham tDCS + mindfulness meditation|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). These devices will be set to sham. Each tDCS sessions will be delivered in combination with a guided mindfulness meditation that we have recorded.
61032|NCT03707574|Procedure|Biospecimen Collection|Undergo collection of blood and tissue
61033|NCT03707561|Diagnostic Test|Right Heart Catheterization (RHC)|RHC at the enrollment and every 12 months
60958|NCT03708146|Drug|BIA 5-1058|"25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
60959|NCT03708146|Drug|Placebo|"matching placebo tablet; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), placebo will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), placebo will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water."
60960|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Test|Orally intake of 1 *120mg new formulation tablet as test treatment
60961|NCT03708133|Drug|Nifurtimox (Lampit, BAYA2502)_Reference|Orally intake of 1 *120mg current clinical formulation tablet as reference treatment
60962|NCT03708120|Other|Citrepel (Insect Repellent) EPA Reg. No. 84878-2|Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
60963|NCT03708107|Device|MEP|MEP® will be applied with an acupuncture needle (0,30 x 25 mm). The needle will be introduced perpendicularly to the MTrP with 100 uA and then increased up to 600 uA. The current will be paused if the patient feels a burning sensation, pain or oppression, waiting up to the patient feels no discomfort. The procedure will be repeated as many times is necessary until the patient do not feel any discomfort for more than 1 minute.
60964|NCT03708107|Other|Ischemic compression|Ischemic compression will be applied perpendicularly to the MTrP, increasing gradually the pression until the patient refers the maximum tolerable pain. This pressure will be applied for 1 minute.
60965|NCT03708094|Diagnostic Test|molecular diagnosis|whole exome sequencing and data analysis to elucidating molecular diagnosis
60966|NCT03708081|Procedure|ProTaper Next|Root canal instrument
60967|NCT03708081|Procedure|TF Adaptive|Root canal instrument
60968|NCT03708068|Other|Early exclusive enteral nutrition|Infants will be fed at least 80% of reference daily fluid intake from day one. Feeds will be advanced by 20-30 ml/kg per day on second day onwards to meet reference daily fluid intake until infant reaches full enteral feed.
60969|NCT03708055|Behavioral|Exercise Intervention|Undergo weight bearing exercise program
60970|NCT03708042|Combination Product|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
60971|NCT03708042|Combination Product|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
60972|NCT03708029|Other|Revita Allograft|Human placental allograft
60973|NCT03708016|Device|Robot gait training|Lokomat robot training was applied to stroke patients.
60974|NCT03708016|Device|Brain stimulation|tDCS brain stimulation on leg motor areas was applied to stroke patients.
60975|NCT03708003|Drug|Ibrutinib|"Patients receive 6 cycles (cycle = 28 days) of ibrutinib monotherapy at the daily dose of 420 mg (3x 140 mg).~Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
60976|NCT03708003|Drug|Venetoclax|"Venetoclax is added on ibrutinib treatment starting from cycle 7 as weekly dose ramp-up (20 mg, C7 day 1-7; 50 mg, C7 day 8-14; 100 mg, C7 day 15-21; 200 mg, C7 day 22-28; 400 mg, C8-31 day 1-28).~Venetoclax (400 mg d1-28) and ibrutinib (420 mg d1-28) continue until cycle 31. Depending on MRD-neg CR/CRi patients will continue the combination treatment (maintenance) or stop treatment (observation) up to 5 years after cycle 31."
60977|NCT03707990|Drug|NNC0165-1875|Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
60978|NCT03707990|Drug|Placebo (NNC0165-1875)|Participants will receive a single dose of s.c. placebo injection.
60979|NCT03707990|Drug|Semaglutide|Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
60980|NCT03707977|Drug|ART|ART will not be provided by the study. Participants will continue to receive their ART regimen they were receiving prior to enrolling in the study.
60981|NCT03707977|Biological|VRC01LS|Administered by intravenous (IV) infusion
60982|NCT03707977|Biological|10-1074|Administered by intravenous (IV) infusion
60983|NCT03707964|Other|Crisis Resource Management Skill Training|Focused crisis resource management training which targets at the cognitive skills needed to monitor and challenge a superior's decision.
60984|NCT03707964|Other|Standard ACLS Training|Standard didactic interactive session on Advanced Cardiac Life Support (ACLS) principles.
60985|NCT03707951|Drug|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)
60986|NCT03707951|Drug|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
60987|NCT03707938|Drug|Brigatinib|Given PO
60988|NCT03707938|Procedure|Local Consolidation Therapy|Undergo local consolidative therapy
60989|NCT03707925|Procedure|Cone-Beam Computed Tomography|Undergo CBCT
60992|NCT03707912|Drug|Anaferon|1 tablet per 1 intake. On the first day of treatment: the first 2 hours of 1 tablet every 30 minutes, then, during the first day, 3 more times at regular intervals. From the second to the fifth day: 1 tablet 3 times a day. The drug is taken out of the reception of food (in the interval between meals or 15-30 minutes before eating), should be kept in your mouth, not swallowed, until it is dissolved completely.
60993|NCT03707912|Drug|Placebo|1 tablet per 1 intake. On the first day of treatment: the first 2 hours of 1 tablet every 30 minutes, then, during the first day, 3 more times at regular intervals. From the second to the fifth day: 1 tablet 3 times a day. The drug is taken out of the reception of food (in the interval between meals or 15-30 minutes before eating), should be kept in your mouth, not swallowed, until it is dissolved completely.
60994|NCT03707899|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
60995|NCT03707899|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
60996|NCT03707886|Behavioral|Pain SMART|Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.
60997|NCT03707886|Other|minimally enhanced usual care|The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
60998|NCT03707873|Other|Education|Education + Medication adherence monitoring + Feedback when low adherence
60999|NCT03707847|Drug|Crizotinib|250mg, BID, PO
61000|NCT03707847|Drug|Etoposide Capsule|50mg, QD, PO, d1-10，21days for one cycle
61001|NCT03707847|Procedure|Auto-HSCT|Auto-HSCT will be performed with patients who have achieved CR or VGPR.
61002|NCT03707834|Behavioral|Antenatal Obesity Treatment (AO)|Participants in the treatment (AO) arm will receive a 4-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; and 4)WIC provider counseling Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
61003|NCT03707821|Device|senofilcon A TEST Lens|JJVC Investigational Contact Lens
61004|NCT03707821|Device|senofilcon A CONTROL Lens|Acuvue Oasys
61005|NCT03707808|Drug|intratumoral injection of autologous CD1c (BDCA-1)+ myDC|intratumoral injections plus intravenous administration
61006|NCT03707795|Drug|Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days|Participants will be given four IM injections throughout the study
61007|NCT03707769|Device|TIPS microspheres|TIPS microspheres manufactured from GMP grade poly(lactide-co-glycolide) (PLGA) prepared as a paste with GranuGel.
61008|NCT03707730|Dietary Supplement|AGY|oral AGY taken prior to meals
61009|NCT03707730|Other|placebo|oral placebo taken prior to meals
61010|NCT03707717|Drug|Bimekizumab|Subjects will receive a pre-specified sequence of bimekzumab in the Treatment Period.
61011|NCT03707691|Behavioral|Listening tests. Pitch training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
61012|NCT03707691|Behavioral|visuo-spatial training protocol|The two training protocols consists of perceptual tasks (auditory or visual exercises) performed repetitively using a tablet. Each protocol consists in 30 sessions of ~20 minutes performed at home over a period of 15 weeks.
61013|NCT03707691|Behavioral|EEG/MEG/MRI recordings.|Listening tests. EEG/MEG/MRI recordings
61014|NCT03707678|Drug|GSK2245035|GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
61015|NCT03707678|Drug|Placebo|Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.
61016|NCT03707678|Drug|FP-DPI|FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.
61017|NCT03707678|Drug|Albuterol/Salbutamol|Albuterol/Salbutamol MDI will be administered for symptom relief from screening to the end of the study.
61018|NCT03707678|Other|eDairy|Subjects will record all the alerts indicative of worsening of asthma in eDairy.
61019|NCT03707678|Other|ACQ-6|ACQ-6 will include six questions which enquire about the frequency and/or severity of symptoms. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/limitation) scale.
61020|NCT03707665|Diagnostic Test|Compression ultrasound testing|Compression ultrasound testing, screening technique for diagnosing deep venous thrombosis
61021|NCT03707652|Dietary Supplement|Oral supplement A|1, 2 or 4 capsules daily of oral supplement A for 3 days
61022|NCT03707652|Dietary Supplement|Oral supplement B|4 capsules daily of oral supplement B for 3 days
61023|NCT03707652|Dietary Supplement|Oral supplement C|1,2 or 4 capsules daily of oral supplement C for 3 days
61024|NCT03707652|Dietary Supplement|Oral supplement D|1 or 2 tablets daily of oral supplement D for 3 days
61025|NCT03707652|Dietary Supplement|Oral Supplement D in combination with oral supplement C|1 or 2 tablets of oral supplement D in combination with 2 or 4 capsules of oral supplement C for 3 days
61026|NCT03707639|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
61027|NCT03707639|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
61028|NCT03707626|Other|Wellens Sign|presence or absence in presence of coronary collaterals to LAD
61029|NCT03707613|Procedure|DWT learning curve|trainees learn to perform DWT after unsuccessful initial cannulation
61031|NCT03707587|Drug|M7824|Patients will receive 1200 mg IV of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
61034|NCT03707548|Behavioral|BPT|BPT will consist of 6 weekly group sessions, based on a scientific approach, integrating body-oriented techniques to improve patients' awareness, perception, acceptance, and expression regarding their body.
61035|NCT03707548|Behavioral|Smartphone-triggered bodily interventions|Smartphone-triggered bodily interventions will consist of brief BPT exercises insuring the transfer from the group BPT sessions into patients' daily lives. Smartphone bodily interventions will be triggered by short audio-clips.
61036|NCT03707548|Behavioral|Smartphone triggered control intervention|The smartphone triggered control intervention will be selected fairy tales presented by audio-clips.
61037|NCT03707535|Biological|CT-P13|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
61038|NCT03707535|Biological|Remicade|3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
61039|NCT03707522|Behavioral|Growth mindset|10 minute interactive article describing neuroplasticity
61040|NCT03707522|Behavioral|Modifiable risk factor (MRF) information|10 minute interactive article describing modifiable risk factors for depression and anxiety
61041|NCT03707522|Behavioral|Control|10 minute interactive article describing activity scheduling
61042|NCT03707509|Drug|Camrelizumab|Maximum 6 cycles for combined therapy. Camrelizumab maintenance.
61043|NCT03707509|Drug|Placebos|Maximum 6 cycles for combined therapy.
61044|NCT03707509|Drug|Gemcitabine|Maximum 6 cycles for combined therapy.
61045|NCT03707509|Drug|Cisplatin|Maximum 6 cycles for combined therapy.
61046|NCT03707483|Combination Product|combination of vitamin C and platelet rich fibrin|combination of vitamin C and platelet rich fibrin
61047|NCT03707470|Device|Custom fitted compression garments (CF)|Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
61048|NCT03707470|Device|Standard-sized compression garments (SSG)|Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
61049|NCT03707470|Procedure|Sham ultrasound (CON)|Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
61050|NCT03707457|Drug|Nivolumab|Patients receive nivolumab intravenously (IV) over 30 minutes on Day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61051|NCT03707457|Drug|Anti-GITR Monoclonal Antibody MK-4166|Patients receive anti-GITR intravenously (IV) over 30 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61052|NCT03707457|Drug|IDO1 inhibitor INCB024360|Patients receive IDO1 inhibitor by mouth daily beginning on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
61053|NCT03707457|Drug|Ipilimumab|Patients receive ipilimumab intravenously (IV) over 90 minutes on Day 1 of the first cycle of nivolumab after arm assignment. Courses repeat every 21 days for up to 4 doses in the absence of disease progression or unacceptable toxicity.
61055|NCT03707431|Behavioral|Web-based CBT|The eight child modules include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) deep breathing and relaxation, 4) implementing coping skills at school, 5) cognitive skills (e.g., reducing negative thoughts), 6) lifestyle interventions, 7) staying active (e.g., pleasant activity scheduling), 8) relapse prevention. The eight parent modules are: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I (using attention and praise to increase coping), 4) operant strategies II (using rewards to increase positive coping and reach school goals), 5) modeling, 6) lifestyle, 7) communication, 8) relapse prevention.
61056|NCT03707431|Behavioral|Pain Education|The pain education website provides publically available educational information about chronic pancreatitis and abdominal pain. There is general information about pancreatitis from available web sources (e.g., National Pancreas Foundation) as well as information about chronic pain in childhood. The content does not include any instruction in the behavioral and cognitive skills taught within the WebMAP program.
61057|NCT03707418|Drug|Heparin Sodium|Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels
61058|NCT03707418|Drug|Bivalirudin Injection [Angiomax]|Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
61059|NCT03707405|Behavioral|Ride-On Cars Training with Different Postures|All programs will include 120 minutes/per session, 2 sessions/per week. All participants will continue their regular therapy during the whole study. The treatment strategy of ROC training with different postures will be based on the exploratory learning which focuses on providing opportunities to the participants to explore environmental properties with various motor patterns during the intervention.
61060|NCT03707392|Other|Ostomy Education Video|Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
61061|NCT03707392|Other|Control - Standard ostomy education|Standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
61062|NCT03707366|Behavioral|FHF-T|FHF-T employs mentoring, consisting of relationship development, advocating for and empowering youth, and skill-building activities to promote positive youth development. Mentors meet individually for 2-3 hours per week for 30 weeks with each teen they mentor, in order to engage teens in positive youth development activities and provide skills training in areas including emotion recognition, perspective-taking, problem solving, effective communication, managing anger, healthy coping and resisting peer pressure for deviant activities. Youth also attend group workshops over the course of the program, in which they engage with other participants and mentors in skill-building activities.
61063|NCT03707353|Biological|ChAd63 ME-TRAP and MVA ME-TRAP vaccination|vaccination with ChAd63 ME-TRAP 5x10^10 vp (intramuscularly and intravenously) vaccination with MVA METRAP 2x10^8 pfu (intramuscularly) and MVA METRAP 2x10^7 pfu (intravenously) Group 5 will be challenged with malaria by mosquito bite.
61064|NCT03707340|Drug|Flibanserin Pill|Eligible participants will begin treatment with flibanserin 100 mg orally daily at bedtime for 24 weeks.
61208|NCT03706209|Drug|Placebo|hard gelatin capsules containing no active ingredient
61065|NCT03707327|Other|Game Ready|the participants remained for 20 minutes with intermittent compression therapy + cryotherapy
61066|NCT03707327|Other|Ice pack|the participants remained for 20 minutes with cryotherapy with ice pack
61067|NCT03707314|Procedure|Angiography with follow-on revascularisation if indicated|Angiography with follow-on revascularisation (if indicated)
61068|NCT03707301|Other|Questionnaires|Questionnaires of satisfaction and the Hospital Anxiety and Depression scale.
61069|NCT03707288|Other|Spine Exercise Program|Spine exercises should be done 20 minutes/ 3 days per week Desk stretches should be done when exposed to prolonged sitting for greater than 60 mins
61070|NCT03707275|Device|Alexa+|Patients will receive the Amazon Echo Dot with Alexa voice technology (Alexa+) and will be asked to interact with the device for 3 months. Alexa+ will ask a series of questions. Based on the answers to these questions, it will either contact a study coordinator or will ask patients to take a specific action (such as weighing themselves). Data from this simple intervention will be merged with data extracted from the patient's health record and analyzed for clinical variables and demographics that are most predictive for success in use of these technologies.
61071|NCT03707275|Other|Standard of Care Arm|This group will receive standard of care (SOC) HF management, which will entail regular follow up from the HF nurse and data from all hospital or clinic visits will be captured from the EHR.
61072|NCT03707262|Biological|Donor CD34+ and CD3+ cells|Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
61073|NCT03707249|Drug|Ferric Carboxymaltose Injectable Product|iv iron infusion: 15 mg / kg up to a maximum 1g dose of Ferinject diluted in normal saline (0.9%) up to a total volume of 250 ml
61074|NCT03707249|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of normal (0.9%) saline given by intravenous infusion over 20 minutes. This constitutes the control for the iron infusion.
61075|NCT03707236|Behavioral|Teledermatology visits|Patients in the treatment arm will be taught by study staff how to take the standardized photos of themselves at treatment week 4 (prior to initiation of teledermatology visits). For patients in the treatment arm, the teledermatology visits will be managed by the study staff. A monthly teledermatology visit will consist of sending facial and truncal (if affected) clinical images to a the study staff using Patient Gateway. Once this is completed, the patient and a member of the study staff will have a scheduled telephone appointment during which the provider will screen for any adverse events and will provide counseling as outlined in iPledge guidelines. The patient will also be asked to verbally complete a monthly survey assessing acne severity, quality of life, cost attributable to the appointment, time missed from school/work, satisfaction with treatment. All photographs will be uploaded in LMR/EPIC in the patient's medical record.
61076|NCT03707223|Behavioral|The Interfaces Program|career development program
61077|NCT03707223|Behavioral|IPS|supported employment using the individual placement and support (IPS) model
61078|NCT03707210|Behavioral|VR training program|Use VR software to make a training education program.
61079|NCT03707197|Behavioral|Meditation|Ten minutes of meditation per day for 8 weeks using a mobile application
61080|NCT03707184|Procedure|Computed Tomography|Undergo PET/CT scan
61081|NCT03707184|Drug|Fluciclovine F18|Given IV
61082|NCT03707184|Procedure|Positron Emission Tomography|Undergo PET/CT scan
61083|NCT03707171|Drug|Liraglutide|Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. It has been proved that Liraglutide can improve insulin resistance and cognitive function in AD animals. Therefore, it is speculated that Liraglutide may interfere with the occurrence and development of cognitive dysfunction in patients with T2DM. In order to confirm the effects, the investigators conduct an open, prospective, positive controlled study in patients with T2DM.
61084|NCT03707171|Drug|placebo|Any hypoglycemic drugs except glucagon-like peptide type 1 (GLP-1) analogue.
61085|NCT03707158|Behavioral|Office-based Cognitive-Behavioral Therapy|Participants receiving office-based cognitive-behavioral therapy will participate in therapist-led, face-to-face CBT treatment for up to 16 weeks. Sessions focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
61086|NCT03707158|Behavioral|Digital Cognitive-Behavioral Therapy|Participants receiving digital cognitive-behavioral therapy will complete an online, largely self-administered CBT program for up to 16 weeks with 8 modules and adjunctive therapist phone support. Treatment modules focus on psychoeducation about anxiety, thought challenging and cognitive restructuring, somatic management skills training, youth exposure to feared stimuli, family patterns associated with the maintenance of youth anxiety, and contingent reinforcement.
61087|NCT03707145|Behavioral|Consultation|The consultation will provide advice (including a short written report) about promoting healthy lifestyles, tailored to the individual
61088|NCT03707145|Behavioral|Online Support|The participant will have access to an online platform 'FACET', to monitor themselves periodically, obtain feedback about their functional ability, receive recommended diet, exercise and physical activity interventions and record the adherence to any intervention.
61089|NCT03707145|Behavioral|Empowered|The participant will be actively encouraged to contribute to their own consultation and take co-ownership and responsibility for the action plan.
61090|NCT03707132|Procedure|Tourniquet: Folley catheter in the low segment of the uterus|
61091|NCT03707119|Other|Educational programme|the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
61092|NCT03707106|Behavioral|CBT smoking cessation|an established protocol for smoking cessation based on cognitive behavioral therapy
61093|NCT03707106|Behavioral|virtual reality based cue exposure|smoking cue exposure in virtual reality
61094|NCT03707106|Behavioral|progressive muscle relaxation|Progressive muscle relaxation for unspecific stress reduction
61095|NCT03707093|Drug|ADG106|IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg depending on cohort at enrollment.
61096|NCT03707067|Device|Compression garments|Made-to-measure compression garments providing high pressures (> 30 mmHg at the ankle and >20 mmHg at the thigh - equivalent to European class-2 stockings)
61097|NCT03707067|Other|Sham recovery drink|"Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving"
61098|NCT03707054|Diagnostic Test|Study Arm|Measurements of optic nerve diameter, serum and urine osmolarity, serum vasopressin
61099|NCT03707041|Drug|P218 (1000 mg) Oral Capsules|1000 mg P218 (4 x 250 mg capsules)
61100|NCT03707041|Drug|Placebo Oral Capsules|Placebo capsules matched to the P218 capsules with regard to appearance and taste
61101|NCT03707041|Drug|P218 (100 mg) Oral Capsules|100 mg P218 (2 x 50 mg capsules)
61102|NCT03707041|Biological|PfSPZ Challenge|3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
61103|NCT03707028|Drug|Rivoceranib|Oral daily doses of rivoceranib (as its mesylate salt)
61104|NCT03707028|Drug|Paclitaxel|Fixed dose of paclitaxel given intravenously on day 1, day 8, and day 15
61105|NCT03707002|Dietary Supplement|scFOS|daily intake for 6 weeks
61106|NCT03707002|Dietary Supplement|Maltodextrin|daily intake for 6 weeks
61107|NCT03706989|Procedure|EEG|EEG recordings will be performed before and during the cardiac surgery in order to detect signals of poor cognitive reserve
61108|NCT03706976|Device|Tissue Oxygenation Monitoring|The NIRS sensor will be applied to the abdomen of the study population. To ensure good skin contact the sensor will be placed underneath the diaper. If that should not provide enough measurement stability, additional fixation will be given by employing aforementioned flexible bandage routinely employed in neonatal care. Once good skin contact is ensured, the sensor will measure aStO2 for up to seventy-two hours. The presence of this sensor will not disturb daily clinical activities or medical treatment in any way. Should good skin contact be endangered by movements, clinical interactions or such, the sensor will be removed and re-attached to the infants' abdomen as a consequence.
61109|NCT03706963|Other|Phone Call|-phone call 7 days (+/- 2 days) into preoperative period
61110|NCT03706950|Drug|Elpida® + 2 NRTIs|Elpida® 20mg qd orally + 2 NRTIs standard prescribed ART therapy
61111|NCT03706937|Other|Semi directive interview|Semi directive interview will be performed to try to define the management of addictions in the oncology care course. Thus, an approach in terms of social representations among paramedical professional actors involved in the care of patients treated for cancer and with an unresolved addictive disorder sounds the best way for this research.
61112|NCT03706924|Drug|VM-1500FDC|A fixed-dose combination of three active substances: tenofovir 300 mg + elsulfavirine 20 mg + emtricitabine 200 mg, film-coated tablets
61113|NCT03706924|Drug|Elpida®|Elpida®, capsules, elsulfavirine 20 mg
61114|NCT03706924|Drug|Truvada®|Truvada® (tenofovir 300 mg / emtricitabine 200 mg), film-coated tablets
61115|NCT03706911|Drug|VM-1500A-LAI|VM1500A (parent drug of elsulfavirine) IM injection dosage form
61116|NCT03706898|Drug|Elpida®|Elpida® capsules, 20mg
61117|NCT03706898|Drug|Dolutegravir|Dolutegravir, film-coated tablets, 50mg
61118|NCT03706898|Drug|Sofosbuvir|Sofosbuvir, film-coated tablets, 400mg
61119|NCT03706898|Drug|Daclatasvir|Daclatasvir, film-coated tablets, 60mg
61120|NCT03706885|Drug|Sustiva Pill|One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
61121|NCT03706872|Other|Intervention group|The provision of an App for monitoring physical activity and weight with a smart watch and the administration of virtual advice through messages with mobile phone and the midwife's feedback, as well as the provision of usual prenatal care
61122|NCT03706859|Procedure|Pneumatic tourniquet inflation pressure|Pneumatic tourniquet inflation pressure estimation using two different mathematical equations
61123|NCT03706846|Procedure|fasting|fasting before gastrointestinal endoscopy
61124|NCT03706833|Device|Edwards PASCAL System|Transcatheter mitral valve repair with the Edwards PASCAL System
61125|NCT03706833|Device|Abbott Mitraclip System|Transcatheter mitral valve repair with the Abbott Mitraclip System
61126|NCT03706807|Other|Mindfulness-Based Intervention|This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol
61127|NCT03706807|Other|Cognitive Stimulation|A basic computer workshop in order to develop the psychomotricity involving the use of mouse, keyboard, MS paint, photo gallery and PowerPoint presentations to surf on the internet, learn how to play online games and use social networks
61128|NCT03706794|Behavioral|Clinical Decision Support Tool|Tailored education provided via a smartphone application.
61129|NCT03706794|Behavioral|Headache Education|Non-tailored education provided via a smartphone application.
61130|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15% + mucus adhesive polymer|Test product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
61131|NCT03706781|Drug|Cetylpyridinium Chloride 0.05% + Benzydamine HCl 0.15%|Reference Product will be applied twice a day (b.i.d) every 12 h once in the morning and once in the evening for 6 consecutive days (from Day 1 to Day 6) and once in the morning on Day 7 for a total of 13 dose
61132|NCT03706768|Other|Glycocalyx|Measure Degradation of the Glycocalyx
61133|NCT03706755|Drug|Norepinephrine: 1mcg/kg|intervention:Parturients will receive Norepinephrine: a bolus of 1 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.5 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
61134|NCT03706755|Drug|Norepinephrine 0,5mcg/kg|intervention: Parturients will receive Norepinephrine: a bolus of 0.5 mcg/Kg immediately after SA (preventive bolus) then they will receive complementary doses of Norepinephrine (half dose: 0.25 mcg/Kg) to maintain systolic blood pressure above 80 % of baseline
61135|NCT03706742|Behavioral|Mailed outreach|The investigators will randomize all baby boomer patients (~12,000 patients) using a centrally maintained computer-generated list. Patients will be randomly assigned to one of two HCV screening strategies including: visit-based screening as part of usual care (Group 1) or mailed screening invitation outreach and centralized patient navigation (Group 2).
61200|NCT03706287|Drug|anlotinib + AP/PC|anlotinib doses to be determined following the completion of Phase I of the study, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
61136|NCT03706729|Device|Spraino|"Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch developed with the purpose of minimizing lateral shoe-surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the study sponsor, Spraino® ApS. The participants will receive four pairs of Spraino® upon their enrollment to the study."
61137|NCT03706716|Other|decision aid developed for pelvic organ prolapse|Conversation based upon the inter face in the Electronic patient journal.
61138|NCT03706703|Drug|Endostar|continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
61139|NCT03706703|Drug|Docetaxel|docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
61140|NCT03706703|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
61141|NCT03706703|Drug|Pemetrexed|pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
61142|NCT03706690|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks [q4w] intravenously [iv] until clinical progression/ deterioration or confirmed radiological progression.
61143|NCT03706690|Other|Placebo|Matching placebo for infusion every 4 weeks iv until clinical progression/deterioration or confirmed radiological progression
61144|NCT03706677|Device|Cryoballoon (Arctic Front Advance Cryoballoon)|Ablation using a Cryoballoon catheter (Arctic Front Advance Cryoballoon Cardiac Ablation Catheter)
61145|NCT03706677|Device|Radiofrequency Catheter (ThermoCool Smarttouch)|Ablation using a Radiofrequency ablation catheter (ThermoCool Smarttouch catheter)
61146|NCT03706664|Other|Machine learning algorithm|Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
61147|NCT03706651|Device|Infants hospitalized in health facilities performing Tele-expertise|
61148|NCT03706638|Dietary Supplement|Ferrous Sulfate|Patients would be randomized to either taking ferrous sulfate daily or every other day (on non consecutive days).
61149|NCT03706599|Behavioral|Therapeutic education on fever|Session for therapeutique education on fever
61150|NCT03706599|Behavioral|Therapeutic education on household accidents|Session for therapeutic education on household accidents
61151|NCT03706586|Procedure|30% group|Infants in the 30 % group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
61152|NCT03706586|Procedure|60% group|Infants in the 60 % group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.
61153|NCT03706573|Drug|alpelisib|50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
61154|NCT03706547|Biological|anti-CD19/BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-CD19 and anti-BCMA CARs
61155|NCT03706547|Drug|Fludarabine|30mg/m2/d
61156|NCT03706547|Drug|Cyclophosphamide|300mg/m2/d
61157|NCT03706534|Device|Ultrasound Image review with CADe|This software is a computer-aided detection (CADe) software application, designed to assist radiologist to analyze breast ultrasound images. S-Detect automatically segments and classifies shape, orientation, margin, lesion boundary, echo pattern, and posterior feature characteristics of user-selected region of interest. The device uses deep learning methods to perform tissue segmentation and classification of images.
61158|NCT03706534|Device|Ultrasound Image review with CADx|This software is also a computer-assisted diagnostic(CADx) software application, designed to assist a medical doctor in determining diagnosis by presenting whether a lesion is malignant in a breast ultrasound image obtained from an ultrasound imaging device.
61159|NCT03706534|Device|Ultrasound Image manual review|The images will be reviewed by the radiologists using BIRADS scheme without any assistance of artificial assistance. This review will be done off-line using a separate program in entirely manual mode. During this review, BIRADS descriptor choices by each radiologist and the time it takes for the radiologist to make such decision will be stored.
61160|NCT03706534|Procedure|Biopsy|Suspicious lesions found on breast ultrasound are then followed either by ultrasound guided biopsy or ultrasound imaging every 6 months for two years. For those who undergo biopsy, ultrasound provides images which are used to localize the lesion and guide the placement of the biopsy needle. The sample is sent to pathology for diagnosis, while the ultrasound guidance images are stored. For those who have imaging follow-up, ultrasound images of the breast mass are obtained, digitally stored and interpreted by the radiologist typically using BIRADS scheme.
61161|NCT03706521|Drug|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
61162|NCT03706508|Procedure|Robot-assisted laparoscopic radical prostatectomy|Patients with localized prostate cancer underwent transperitoneal robot-assisted laparoscopic radical prostatectomy
61163|NCT03706495|Behavioral|The Group I Postural Exercise|Spine anatomy and daily life activities will be informed about proper posture. Strengthening of postural muscles, stretching (Pectoral Region, M. Psoas Major) and breathing exercise will be performed under the supervision of a physiotherapist. The Group I will receive postural exercise for 60 min/day 2 times/week for 8 weeks.
61201|NCT03706274|Drug|CX-188|CX-188
61202|NCT03706261|Drug|18F-MK-6240|Administration of 5 mCi of 18F-MK-6240 for tau PET.
61203|NCT03706261|Drug|18F-Florbetaben|Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.
61204|NCT03706248|Other|Blood Draw|20 ml of blood will be drawn from subjects via venipuncture
61205|NCT03706235|Other|Blood draw (venipuncture)|Draw 40 mls of blood from eligible subjects. Process and ship samples to sponsor.
106917|NCT03350165|Drug|Placebo|K-877 matching placebo tablet
61164|NCT03706495|Behavioral|The Group II Three-dimensional Exercise Therapy Program|The Group II Schroth method corrects the kyphotic posture, with the help of proprioceptive and exteroceptive stimulation and mirror control in the sagittal plane, using specific corrective breathing patterns. The Schroth method three-dimensional exercise therapy program adapted for the specific posture will be exercised in four specific positions (sitting, supine, standing, prone) under the supervision of a physiotherapist. Exercise include, trunk elongation, symmetrical sagittal straightening, shoulder traction, corrective breathing and muscle activation by increasing tension (isometric tension). The Group II will receive Schroth's three-dimensional exercise therapy program for 60 min/day 2 times/week for 8 weeks.
61165|NCT03706482|Biological|BOOST cells|Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.
61166|NCT03706469|Drug|TAK-831 T2|TAK-831 T2 Tablets.
61167|NCT03706469|Drug|TAK-831 T3|TAK-831 T3 Tablets.
61168|NCT03706456|Biological|Darvadstrocel|Darvadstrocel of cell suspension for intralesional injection
61169|NCT03706443|Other|Systane Complete|Lubricant eye drop which is based on propylene glycol 0.6%. Used for temporary relief of burning and irritation due to dryness of the eye.
61170|NCT03706443|Other|Systane Ultra|Lubricant eye drop which is based on polyethylene glycol 400 0.4% and propylene glycol 0.3%. Used for temporary relief of burning and irritation due to dryness of the eye.
61171|NCT03706417|Diagnostic Test|Telemedicine consult|Utilizing telemedicine in community hospital for earlier identification of symptoms of neonatal encephalopathy.
61172|NCT03706404|Diagnostic Test|Point-of-Care ultrasound and testing|Point-of-Care ultrasound + Point-of-Care blood gas testing
61173|NCT03706378|Other|Glucose Reference 1|Glucose contains 50g of available carbohydrates
61174|NCT03706378|Other|Glucose Reference 2|Glucose contains 50g of available carbohydrates
61175|NCT03706378|Other|Glucose Reference 3|Glucose contains 50g of available carbohydrates
61176|NCT03706378|Other|Wheat Yellow Noodle|Wheat Yellow Noodle will contain 50g of available carbohydrate
61177|NCT03706378|Other|Beta-glucan yellow Noodle|Beta-glucan yellow noodle will contain 50g of available carbohydrate
61178|NCT03706378|Other|Rice Roll|Rice Roll will contain 50g of available carbohydrate
61179|NCT03706378|Other|Rice Roll with resistant starch|Rice Roll fortified with resistant starch will contain 50g of available carbohydrate
61180|NCT03706378|Other|Sucrose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of sucrose
61181|NCT03706378|Other|Isomaltulose Jelly|Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of Isomaltulose
61182|NCT03706365|Drug|Abemaciclib|Administered orally.
61183|NCT03706365|Drug|Abiraterone Acetate|Administered orally.
61184|NCT03706365|Drug|Prednisone|Administered orally.
61185|NCT03706365|Drug|Placebo|Administered orally.
61186|NCT03706352|Procedure|tunneling epidural catheter|The epidural needle was used to horizontally tunnel the catheter for a length of five centimeters on either side of the insertion point.
61187|NCT03706339|Other|normal saline arm group|110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the placental bed during Cesarean section
61188|NCT03706339|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 120 ml normal saline applied on the pelvic bed during cesarean section
61189|NCT03706339|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 120 ml normal saline applied on the pelvic bed during cesarean section plus110 ml normal saline IV just before skin incision
61190|NCT03706326|Biological|Anti-MUC1 CAR-T cells|Using the T cells from the patients' blood to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
61191|NCT03706326|Biological|PD-1 knockout Engineered T cells|Using the T cells from the blood of the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients.
61192|NCT03706326|Combination Product|CAR-T combined with PD-1 Knockout T cells|Using the T cells from the blood of the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
61193|NCT03706313|Drug|15mL 0.25% bupivacaine|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
61194|NCT03706313|Procedure|Genicular nerve block|"The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml of 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described."
61195|NCT03706313|Drug|Saline|Patients will be randomly assigned to either a genicular nerve block with bupivacaine or saline
61196|NCT03706300|Drug|Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg|
61197|NCT03706287|Drug|anlotinib 8mg + AP/PC|anlotinib 8mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
61198|NCT03706287|Drug|anlotinib 10mg + AP/PC|anlotinib 10mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
61199|NCT03706287|Drug|anlotinib 12mg + AP/PC|anlotinib 12mg/d, q.d., p.o. 1-14days every 21 days Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
61206|NCT03706222|Drug|elbasvir/grazoprevir|Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.
61207|NCT03706209|Drug|MP1032|hard gelatin capsules containing 50mg MP1032 as active ingredient
61209|NCT03706183|Diagnostic Test|Ischemia-modified albumin|The biomarker was investigated in many studies and it was associated with the ischemia and tissue injury.
61210|NCT03706183|Diagnostic Test|Hearing thresholds|The hearing levels will be determined for each group.
61211|NCT03706170|Behavioral|Physiological recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
61212|NCT03706170|Behavioral|EEG recording in response to different types of stimuli|In order to answer these questions, the study is designed to record in a single session: (i) physiological vegetative reactions (electrodermal, pupillary responses and heart rate) to emotional stimuli ; (ii) a neurophysiological marker of consciousness; and (iii) physiological parameters during a trace conditioning experiment using auditory stimuli with and without emotional valence.
61213|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media
61214|NCT03706157|Drug|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline|Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
61215|NCT03706144|Other|Prodigy Math Training|https://www.prodigygame.com/
61216|NCT03706131|Other|cervical mobilisation|manual therapy
61217|NCT03706118|Other|Magnetic resonance imaging|At month 0, 12, 24 and 36 participants will be examined by quantitative magnetic resonance imaging of brain, cervical and part of thoracic spine.
61218|NCT03706105|Behavioral|Cardiac Rehabilitation|3 x week ~1 hour of exercise + education
61219|NCT03706079|Biological|Tezepelumab|Tezepelumab subcutaneous injection
61220|NCT03706079|Other|Placebo|Placebo subcutaneous injection
61221|NCT03706066|Device|Acrysof IQ PanOptix IOL|Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery
61222|NCT03706066|Procedure|Cataract surgery|Per investigator's standard of care
61223|NCT03706053|Drug|Midodrine Hydrochloride|Midodrine Hydrochloride, enteral, 10 or 20 mg
61224|NCT03706053|Other|placebo|investigational pharmacy formulated placebo comparator
61225|NCT03706040|Biological|placebo for rizankizumab|subcutaneous (SC) injection
61226|NCT03706040|Biological|risankizumab|subcutaneous (SC) injection
61227|NCT03706027|Device|radiation therapy-3 fractions|Radiation therapy given in a 3 fraction schedule (over 3 days). Total dose is 54 Grays.
61228|NCT03706027|Device|Radiation therapy-5 fractions|Radiation therapy given in 5 fractions (over 5 days). Total dose is 60 Grays.
61229|NCT03706014|Behavioral|SIBS Program|Universal prevention program promoting positive sibling and family relationships conducted in an afterschool setting
61230|NCT03706014|Behavioral|Control|Contact-equivalent attention control program in which students play educational games
61231|NCT03706001|Other|Psychotherapy|Psychotherapy has gained increasing acceptance as a major treatment option for mood disorders.
61232|NCT03705988|Device|Cranial Electrotherapy Stimulation(CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The current intensity could be adjusted continuously from 500 μA~2mA.
61233|NCT03705988|Device|sham Cranial Electrotherapy Stimulation( sham CES)|Cranial electrotherapy stimulation (CES) has been known as a kind of noninvasive treatment, which applies pulsed, weak electrical current to head through two electrodes that placed on the earlobes. The sham CES devices were identical to the active device, except the ear clip electrodes emit electricity intensity of lower than 100 μA.
61234|NCT03705975|Other|Manual treatment|Scapula mobilization, glenohumeral joint mobilization
61235|NCT03705962|Drug|Tobramycin|
61236|NCT03705962|Other|Placebo: normal saline|
61237|NCT03705949|Drug|Sodium Hyaluronate 0.1% drops|Patients will be administered Drops of Sodium Hyaluronate 0.1% quid
61238|NCT03705949|Drug|Sodium Hyaluronate 0.2% drops|Patients will be administered Drops of Sodium Hyaluronate 0.2% quid
61239|NCT03705936|Device|rTMS|rTMS is a non-invasive brain stimulation technique. It can regulate brain activities with electrical pulses sent to the brain through electromagnetic induction.
61240|NCT03705923|Procedure|Bariatric surgery|laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy
61243|NCT03705897|Other|Computerized Risk Stratification Tool|Implement a novel computerized risk stratification tool in Parkland community-oriented primary-care clinics that collects data directly from patients and uses a computerized algorithm system to generate their personalized guideline-based next steps in the screening regimen
108151|NCT03340662|Drug|Fluvoxamine|CYP1A2 Inhibitor
61244|NCT03705897|Other|Algorithmic Risk Stratification Tool|Implement a novel algorithmic risk stratification system in Parkland's endoscopy clinics that, based on test findings entered by colonoscopists, generates personalized guideline-based next steps in the screening regimen for patients with colorectal polyps removed at olonoscopy
61245|NCT03705897|Other|Step completion assessment|Assess completion of guideline-recommended steps in personalized screening regimens, under-screening, and over-screening
61246|NCT03705884|Other|18F-FDG|Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.
61247|NCT03705884|Drug|Prednisolone|Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
61248|NCT03705871|Device|Differential Expansion|Twenty-four patients will be treated with a rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm in the anterior screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
61249|NCT03705871|Device|Fan-Fype Expander|Twenty-four patients will be treated with a rapid maxillary expansion using the fan-type expander. Appliance anchorage will be performed by bands adapted in the second maxillary deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. The activation protocols will totalize an opening of 8mm screw of the expander. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
61250|NCT03705858|Drug|Ac-Lintuzumab|225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
61251|NCT03705845|Drug|placebo softgel|Each placebo softgel of 430 mg olive oil will contain no TT or tocopherols at detectable levels.
61252|NCT03705845|Drug|DeltaGold® Tocotrienol 70%|DeltaGold® Tocotrienol 70% contains 430 mg tocotrienol (90% δ-tocotrienol + 10% γ-tocotrienol) with a 70% purity, representing 300 mg tocotrienol.
61253|NCT03705832|Drug|Ginger Extract|2gm Capsule of Ginger extract
61254|NCT03705832|Drug|Placebo|Matching Placebo
61258|NCT03705793|Drug|Mometasone Furoate Nasal Irrigation|Participants will undergo an 8-week treatment course that includes nasal saline irrigation with mometasone powder and placebo nasal spray.
61259|NCT03705793|Drug|Mometasone Nasal Spray|Participants will undergo an 8-week treatment course that includes placebo saline irrigation with mometasone nasal spray.
61260|NCT03705780|Other|the short OSAS scale|Parents fill in the short OSAS screening scale in preoperative interview，calculate score of the scale.
61261|NCT03705780|Diagnostic Test|fentanyl test|In the operating room，giving 1 mcg/kg fentanyl when the End-tidal concentrations of sevoflurane were maintained at 3.0 and the spontaneous respiratory frequency was stable after eyelash reflex disappeared and pharyngeal airway insertion, observing the changes of respiratory rate
61262|NCT03705754|Device|carbon black suspension colonic tattoo injection|Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.
61263|NCT03705741|Behavioral|Resistance exercise|Resistance exercise twice a week during pregnancy week 23-34.
61264|NCT03705728|Drug|Propofol|"Propofol will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
61265|NCT03705728|Drug|Sevoflurane|Sevoflurane will be manually administered to maintain the BIS value within the 40-60 interval
61266|NCT03705728|Drug|Remifentanil automatic|"Remifentanil will be automatically administered according to the EasyTIVA device algorythm to maintain the BIS value within the 40-60 interval"
61267|NCT03705728|Drug|Remifentanil manual|Remifentanil will be manually administered to maintain the BIS value within the 40-60 interval
61268|NCT03705715|Drug|PET with radiotracer [11C]PBR-28|[11C]PBR-28 will be injected into subjects' veins during PET scanning.
61269|NCT03705715|Other|Affective challenge|Affective challenge is the induction of, for example, mood or affective pain.
61270|NCT03705702|Other|Education Program|The educational program will consist of 2 classes held once a week, each lasting 90 minutes. The classes will be based on an education videotape, presentations and group discussions. The first class will address the asthma education, which will include information about the pathophysiology of asthma, medication and peak flow meter instructions, self-monitoring techniques, environmental control techniques and avoidance strategies. The second class will be about the current international physical activity recommendations and the importance and benefits of being physically active and maintain a healthy lifestyle.
61295|NCT03705494|Other|Home-based peer counselling intervention|The intervention consists of 5-6 home based visits over 6 months by trained peer counsellors who will focus on breastfeeding among mothers who have already decided to breastfeed and are interested in this programme.
61717|NCT03702205|Dietary Supplement|Betaine supplementation|Group taking oral betaine supplementation
61271|NCT03705702|Behavioral|Behavioral intervention|The behavioural intervention will be performed in 8 weekly goal-setting consultation, face-to-face, each lasting 40 minutes. Patients will be offered a commercially-available activity tracker to wear during 3 days prior to each consultation. According to their own PA data and the behavioural change stage, an individual action plan will be established with realistic goals to increase PA. Each participant will receive individual counselling with the goal of increasing participation in PA and reducing their sedentary time. Techniques such as weekly goal-setting, motivational interviewing, activity tracker vibration instructions, self-management, positive reinforcement, relapse prevention and strategies to overcome barriers will be included.
61272|NCT03705689|Other|validation of Bitts|No intervention, observation of photographs of stool
61273|NCT03705676|Behavioral|Rapid Arm Movements|240 trials of RAM in either a forward (50%) or backward (50%) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
61274|NCT03705676|Device|Unpleasant stimulus|An unpleasant, but harmless, electrocutaneous stimulus is administered to the low back region in 25% of the threat trials during the fear condition. Due to a conditioning phase before testing, participants know to expect this stimulus after the presentation of a warning cue related to the fear trials (either pink or blue dot dependent on randomization).
61275|NCT03705676|Device|Vibrotactile stimulus|In all trials, during the presentation of the warning cue, a vibrotactile stimulus is administered to the low back region. This stimulus is used to evoke somatosensory evoked potentials (SEP) measured with EEG during the movement-preparation phase.
61276|NCT03705663|Behavioral|PrEP initiation|Women who are interested in or who initiate PrEP will be followed in a prospective cohort to identify and populate the PrEP cascade for cis-gender, high risk women
61277|NCT03705650|Diagnostic Test|Limited Echocardiogram|STUDY SOFTWARE non-significant risk (NSR) Bay Labs EchoGPS software interfaced with the Terason uSmart 3200t FDA 510(k)-cleared, commercially available ultrasound EchoGPS software communicates with the ultrasound image formation engine of the 510(k)-cleared Terason uSmart 3200t through an application programming interface (API). EchoGPS will be used to provide visual guidance, feedback and interpretation assistance to users during image acquisition. For this study, CMAs will use EchoGPS to perform point-of-care echocardiogram examinations.
61278|NCT03705637|Drug|Exparel|"Donor sites will receive up to 50mg of 0.25marcaine with epinephrine injected uniformly into the wound.~The donor site will also receive one bottle (266mg) of Exparel, diluted to be administered uniformly into the entire donor site, spaced out ever 3-4cm. The dilution will be as follows:~o 20ml Exparel + 10ml injectable 0.9% NS (30ml) for every 100cm2 of donor site.~Injection of local anesthesia will be performed after the donor site has been harvested and is hemostatic. The goal is to provide the maximum time possible for the local anesthetic to work while under anesthesia, so it can benefit the patient and not be administered at the end of the case just prior to extubation."
61279|NCT03705624|Other|Enhanced Community Case Management (CCM)|Enhanced Community Case Management for malaria (CCM) involving weekly active screening for fever using a research-grade thermometer by a trained health worker. A measured temperature ≥37.5°C or reported fever in the last 24 hours will prompt screening with a conventional rapid diagnostic test (RDT). RDT positive individuals will be treated with AL according to national guidelines
61280|NCT03705624|Other|Monthly Screening and Treatment (MSAT)|Monthly Screening and Treatment (MSAT) regardless of symptoms with a conventional RDT. Screening will be performed by research staff with 25-35 days between screening rounds; RDT positive individuals will be treated with AL according to national guidelines.
61281|NCT03705611|Diagnostic Test|HIV self-testing only|Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.
61282|NCT03705611|Behavioral|HIV self-testing secondary accuracy|A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
61283|NCT03705598|Behavioral|Light physical exercise|One hour each session, two sessions each week, for 24 weeks. Each session includes 10 minutes of warm up, 30 minutes of normal walking, light intensity resistance exercise and stretching, and 20 minutes of health education discussions, supervised by a certified exercise physiologist and a research assistant.
61284|NCT03705598|Behavioral|Tai Chi|One hour each session, two sessions each week, for 24 weeks. Each session includes 10 minutes of warm-up that included joint rotations and balance games, 45 minutes of Tai Chi practice that included Tai Chi walking drills and the 8 forms (with 12-15 minutes of breaks), and 5 minutes of cool down and breathing exercises, supervised by an experienced Tai Chi instructor and a research assistant.
61285|NCT03705585|Drug|Vivotif Typhoid Oral Vaccine|The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
61286|NCT03705585|Drug|Vaxchora|One dose. Approximately 100 mL of cool or room temperature purified bottled water is placed into a clean disposable cup. The contents of the buffer sachet are added to the water and stirred. Then the contents of the active (lyophilized vaccine) sachet are added to the water and stirred for approximately 30 seconds. The reconstituted mixture should be completely ingested within 15 minutes.
61287|NCT03705572|Dietary Supplement|Lacprodan PL20|Milk protein concentrate that is high in phospholipid content (min 16%).
61288|NCT03705572|Other|Placebo|Placebo milk drink.
61289|NCT03705559|Drug|Vaporized Marijuana|Active Marijuana or Placebo, administered through vaporizer
61290|NCT03705559|Drug|Opioid Agonist|Active Opioid Agonist or Placebo, administered intranasally
61291|NCT03705533|Drug|Telmisartan|Telmisartan is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 80 mg of telmisartan.
61292|NCT03705533|Drug|Micardis|Micardis is manufactured by Boehringer Ingelheim Ellas AE, Greece. Each tablet contains 80 mg of telmisartan.
61293|NCT03705507|Drug|Selumetinib|Selumetinib is a small molecule inhibitor of the MEK protein
61294|NCT03705507|Drug|Dexamethasone|Steroid used for the treatment and management of a number of conditions including cancers and leukaemias.
61335|NCT03705143|Behavioral|Treatment as usual|Treatment as Usual participants will receive the treatment typically provided to patients at the MMT clinic in Wuhan, China.
61296|NCT03705481|Device|Remote treatment of PCI.|To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
61297|NCT03705455|Behavioral|ISAP SMS|ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
61298|NCT03705442|Dietary Supplement|Omni-Biotic 10|All patients will have at their disposal current medications for diarrhea based on guidelines, and education regarding side effects and dietary recommendations will be undertaken. One cohort will also ingest a probiotic (OMNi-BiOTiC® 10AAD), while other cohort will take a placebo, same in colour, shape, taste and smell; both medications will be taken 2 per day, every 12 hours, over 84 days (6 chemotherapy cycles every 14 days).
61299|NCT03705442|Drug|"loperamide (Seldiar)"|All the patients will have access to standard drugs for diarrhoea
61300|NCT03705429|Drug|TC-H x Paclitaxel (P) + Trastuzumab(T)|chemotherapy
61301|NCT03705416|Procedure|Endoscopy|endoscopic suturing of stomach
61302|NCT03705416|Procedure|Surgery|Vertical sleeve gastrectomy (VSG) surgical reduction of stomach, or (RYGBP) , or gastric bypass procedure
61303|NCT03705403|Drug|Darleukin|The product name refers to the molecule structure, in fact, L19-IL2 is a recombinant fusion protein composed of two moieties: L19, a human monoclonal antibody fragment in the single chain Fv (scFv) format, bound via a flexible linker to IL2, the human cytokine Interleukin-2.
61304|NCT03705403|Radiation|Radiation|Radiotherapy
61305|NCT03705390|Drug|ILB|Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for 10 weeks
61306|NCT03705364|Other|Fall Management program|Comprehensive fall management program that develops strategies for non-ambulatory wheelchair users living with MS to develpo strategies to recover from a fall.
61310|NCT03705338|Device|Electroencephalography|Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.
61311|NCT03705338|Drug|Propofol|Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
61312|NCT03705325|Device|Spirobank Smart spirometer|The spirometer is a compact, portable, home-based spirometer that pairs with a smartphone app. Exhaled air flow causes the turbine to rotate, generating a voltage analogous to the rate of air flow across the turbine. The spirometer measures Forced expiratory volume in 1 second (FEV1), or the volume of air that is exhaled in the first second. The device prompts the user to perform a minimum of three expiratory maneuvers in and records the best of the three maneuvers. The information generated is then transmitted to the VitalFlo App (password protected) on the user's iPhone. The user is alerted, by the App, if their expiratory effort is inadequate (such as early termination of exhalation) and is provided coaching for proper technique.
61313|NCT03705312|Device|Transcatheter mitral valve repair|Transcatheter mitral valve repair performed using the MitraClip device
61314|NCT03705312|Other|Guideline-directed medical therapy|Standard medical therapy for heart failure as recommended by HF guidelines
61315|NCT03705299|Device|Non-Invasive CVP vs Standard CVP|
61316|NCT03705286|Device|EVAC-PU-ETT|Placement of a EVAC-PU-ETT in the setting of emergent intubation.
61317|NCT03705286|Device|PVC-ETT|Placement of a PVC-ETT in the setting of emergent intubation.
61318|NCT03705273|Drug|Dexamethasone IV for PO|Common pediatric emergency department practice
61319|NCT03705273|Drug|Dexamethasone crushed tablets|Alternative route of administration for patients unable to swallow tablet whole
61320|NCT03705260|Other|Usual Care|Usual care from Primary Care Physician and dietitian.
61321|NCT03705260|Behavioral|Intensive Behavioral Intervention|The intensive behavioral intervention which will incorporate lower carbohydrate diet, diet coaching, and more intensive glucose monitoring.
61322|NCT03705260|Other|Monthly Screening for Risk|Monthly screening of HbA1C to identify patents who have become poorly controlled in the interval.
61325|NCT03705221|Behavioral|Healthy Parent Carers group programme|Peer-led group-based weekly programme.
61326|NCT03705221|Behavioral|Healthy Parent Carers online resources|Online resources related to health and wellbeing
61327|NCT03705208|Other|Youth First Curriculum|A 25 session emotional resilience and health curriculum designed for 7th and 8th grade students.
61328|NCT03705195|Drug|Gliclazide|Low dose liquid gliclazide will be used with the second matched clamp (OGTT/IGII) in visits 4 & 5.
61329|NCT03705182|Device|Fluorescence visualization (feedback)|UVA-light will illuminate the skin of head, neck, arms and hands and the fluorescent areas will be recorded and quantified by a computer vision system each time the participant leaves a production area. The intervention group will be shown the fluorescent areas on their skin, the control group will not have this opportunity
61330|NCT03705169|Biological|SAR441236|Administered by intravenous (IV) infusion
61331|NCT03705169|Biological|Placebo|Administered by intravenous (IV) infusion
61332|NCT03705169|Drug|Antiretroviral treatment|Antiretroviral treatment will be prescribed by participants' primary HIV clinician. It is not provided by the study.
61333|NCT03705156|Drug|ZL-2306(nirapairb)|The starting dose is 300 mg or 200 mg based on patient's body weight.
61334|NCT03705156|Drug|Placebos|The starting dose is the matched dose of placebo (3 capsules or 2 capsules).
63158|NCT03690869|Drug|REGN2810 (monotherapy)|To be administered intravenously as monotherapy in Phase 1
61336|NCT03705143|Behavioral|Chinese translated LETS ACT|The Chinese translated Behavioral Activation (C-BA) will be provided in Mandarin. C-BA treatment includes psychoeducation regarding the link between mood and behavior, identification of values/goals/activities across life areas, planning and tracking of daily value driven activities.
61337|NCT03705130|Device|Single Vision Contact Lens|Spherical Contact Lens worn on non-dispensing basis
61338|NCT03705130|Device|Multifocal Contact Lens 1|Multifocal Contact Lens worn on non-dispensing basis
61339|NCT03705130|Device|Multifocal Contact Lens 2|Multifocal Contact Lens worn on non-dispensing basis
61340|NCT03705117|Biological|V565|Capsules for oral administration
61341|NCT03705104|Behavioral|EPIO|App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
61342|NCT03705091|Diagnostic Test|Magnetic resonance imaging|ASL and DWI MRI
61343|NCT03705078|Procedure|Transjugular Portosytemic Shunt (TIPS)|The TIPS is placed under radiologic guidance. A branch of the intrahepatic portal vein is punctured; afterwards, the splenic vein is catheterized so that a portal venography and pressure measurements can be performed. Then, the parenchymal track is dilated and a stent is placed. A final portography and pressure measurement in the main portal vein and the inferior caval vein are performed.
61344|NCT03705078|Procedure|glue obliteration|The standard protocol uses cyanoacrylate and lipiodol in 1:1 ratio injecting with no more than 1 mL at the varix each time. In most cases, cyanoacrylate is usually extruded into the stomach lumen within 1-3 months after injection. The French observational survey observed that a large majority (78%) of practitioners diluted glue with lipiodol and most (68%) proposed a proportion of glue to lipiodol of 1:1 the total volume injected per varix (from 1mL to 20 mL) varied substantially. Regarding the type of glue, although the majority of published data concern Histoacryl®, nearly half of practitioners used Glubran®. This lack of preference for one glue over the other may be explained by the fact that only Glubran® is approved in this indication in Europe.
61345|NCT03705065|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine 0.25%, 60 mL (30 mL per pectoral pocket)
61346|NCT03705052|Other|Questionnaire|Patients and caregivers were asked to complete a questionnaire
61347|NCT03705039|Other|Pulsed Ultrasound Treatment|Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
61348|NCT03705039|Other|Control group|Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
61349|NCT03705013|Other|Cologuard|Observational
61350|NCT03705000|Device|Slit Stent II|The Slit-Stent II device is created by modifying the BIKA for DCR lacrimal stent through the addition of a center slit, 12 ± 1.5 mm in length, and two lateral slits 32 ± 4.5 mm in length, each having identical depth measurements to facilitate the drainage of tears. The BIKA for DCR is a sterile, single-use device that is FDA cleared as part of the BIKA family of devices under K911109..There are no changes to the raw materials used in making the modifications to the BIKA for DCR during the manufacturing of the Slit Stent II.
61351|NCT03705000|Device|BIKA for DCR|The BIKA for DCR lacrimal stent is a bicanalicular intubation device used for intubation of the lacrimal drainage apparatus, especially in cases of dacryocystorhinostomy (conventional or laser). The silicone tube acts as a conformer during the healing process while facilitating drainage of tears through capillary action around the stent. In cases of canalicular lacerations, the silicone tube guides wound healing and prevents the onset of synechia. The BIKA for DCR is a sterile, single-use device, and is an FDA cleared device
61352|NCT03704987|Diagnostic Test|dual-energy X-ray absorptiometry|dual-energy X-ray absorptiometry
61353|NCT03704974|Behavioral|Video-Based Parent Training Program|An18-20 week evidence-based social cognitive theory-based parenting program where parents see brief video vignettes of effective and less effective parenting and develop concepts to modify their child's behavior.
61354|NCT03704961|Behavioral|music and audiobook listening|
61355|NCT03704948|Behavioral|Listening Visits|6 sessions, approximately one hour in length, delivered by a nurse who uses empathic listening and problem solving.
61356|NCT03704948|Behavioral|Standard Care (Social Work)|Mental health services provided by social workers to emotionally distressed mothers.
61357|NCT03704922|Biological|Transfusion|Red cell units for transfusion
61358|NCT03704909|Drug|Adrenaline|i.v bolus of adrenaline 0.15µg/Kg rescue boluses of adrenaline 0.15µg/Kg
61359|NCT03704909|Drug|Ephedrine|i.v bolus of Ephedrine 0.1mg/Kg rescue boluses of Ephedrine 0.1mg/Kg
61360|NCT03704896|Other|Lung function measurement|Spirometry-derived lung function measurements
61361|NCT03704870|Diagnostic Test|Chest Xray|Daily chest xray
61362|NCT03704870|Diagnostic Test|No daily chest xray|Chest xray will be done post chest tube removal only
61363|NCT03704857|Other|Foraminal Enlargement / Irrigating solutions / Filling materials|"Instrumentation with foraminal enlargement and various irrigation solutions and filling materials will be performed according to the allocated group.~The foraminal enlargement provides better results in the bacterial removal of the apical portion of the root canal. This instrumentation will be done with the Reciproc 40 or 50 system in the apical foramen, determined by the apical locator.~To contribute to disinfection of the root canal, sodium hypochlorite and chlorhexidine are the most widely used irrigators. Sodium hypochlorite has a broad antimicrobial spectrum and an effective ability to dissolve organic matter and necrotic tissue; while chlorhexidine shows substantivity and antimicrobial residual activity when used as an irrigating substance.~Besides that, MTA Fillapex or AH Plus will be used and the recommended filling technique will be lateral condensation."
61364|NCT03704857|Other|Photodynamic therapy|PDT will be performed with 0.01% methylene blue solution and it will be inserted into the root canal for 5 minutes. The excess will be removed and irradiation will be performed inside the root canal with the red laser of Índio Gálio Alumínio Fósforo (660nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) for 90 seconds. Laser therapy with Gallium-Aluminum-Arsenic infrared laser (808nm, Laser Duo, MMOptics, São Paulo, SP, Brazil) will be performed on the gingiva from the vestibular face and on the palatal / lingual face, both located in the periapical region for 40 seconds.
61397|NCT03704753|Drug|Ropivacaine|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients
61365|NCT03704857|Other|Passive ultrasonic irrigation|PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.
61366|NCT03704857|Other|OHIP-14|Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
61367|NCT03704857|Other|Assessment of pain and swelling|The analysis of the postoperative signs/symptoms will be performed by the visual analog pain scale at 1th, 2th, 3th, 4th, 5th, 6th, 7th, 14th and 30th days and by the subjective evaluation of swelling in 48 and 72 hours.
61368|NCT03704857|Other|Assessment of periapical lesion|The periapical lesion repair will be evaluated clinically and radiographically at 3, 6, 12, 18 and 24 months.
61369|NCT03704844|Other|non applicable|non applicable
61370|NCT03704831|Other|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block|Injection of local anesthetics during total knee arthroplasty by a locoregional anesthesia named IPACK block (Interspace between the Popliteal Artery and the Capsule of the posterior Knee)
61371|NCT03704831|Other|Injection of local anesthetics during total knee arthroplasty by surgical infiltration|Injection of local anesthetics during total knee arthroplasty by surgical infiltration.
61372|NCT03704818|Drug|Dapagliflozin 5mg|Dapagliflozin treatment taken daily for 4-weeks.
61373|NCT03704818|Drug|Placebo Oral Tablet|Placebo treatment taken daily for 4-weeks.
61374|NCT03704805|Behavioral|Friendship bench intervention|The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.
61375|NCT03704805|Other|Enhanced Standard of Care|Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
61376|NCT03704792|Device|FibroScan 530 Compact|The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
61377|NCT03704779|Behavioral|Multimodal mindfulness activity program|"This program will provide the opportunity for participants to engage in in-person and online activities. The in-person activities will be held from 12:00 pm to 12:45 pm in the Georgian Physical Therapy Lab (and offered twice per week). The online activities will be available at all times during the study at convenience. There are one 40-minute in-person and four 10-minute online mindfulness activities per week (combined time of 1 hour and 20 minutes per week).~In-person activities will consist of mindfulness activities including guided imagery meditation, yoga, Tai Chi, progressive muscle relaxation, creating a Zen garden, aromatherapy, journaling, self-massage, and pet therapy. Online materials will additionally include guided and unguided meditations."
61378|NCT03704766|Diagnostic Test|Synovial Alpha-defensin assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
61379|NCT03704766|Diagnostic Test|Synovial Neutrophil elastase assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
61380|NCT03704766|Diagnostic Test|Synovial lactate assay|Synovial Fluid (joint fluid) will be sent out to CD Diagnostics for this test.
61381|NCT03704766|Diagnostic Test|Synovial C-reactive Protein (CRP)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
61382|NCT03704766|Diagnostic Test|Synovial Staphylococcus spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
61383|NCT03704766|Diagnostic Test|Synovial Candida spp antigen panel|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
61384|NCT03704766|Diagnostic Test|Synovial Enterococcus faecalis assay|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
61385|NCT03704766|Diagnostic Test|Synovial bacterial culture by BacT/Alert|The synovial fluid (joint fluid) sent to CD Diagnostics for testing will also be cultured to see if any organisms grow.
61386|NCT03704766|Diagnostic Test|Synovial Cell count + differential (CBC)|One of the synovial fluid (joint fluid) tests that will be performed by the outside lab, CD Diagnostics.
61387|NCT03704766|Diagnostic Test|Synovial Gram Stain|This will be performed by CD Diagnostics if any organisms are present in the synovial fluid.
61388|NCT03704766|Diagnostic Test|Synovial Leukocyte Esterase Test Strips|These test strips will be tested at the hospital where the patient is being seen, a few drops of synovial fluid will be used on the strip.
61389|NCT03704766|Diagnostic Test|Synovial PCR for Kingella kingae|In participants < 8 years old, a sample of synovial fluid will be tested for Kingella kingae using PCR.
61390|NCT03704766|Diagnostic Test|Serum Cell count + differential (CBC)|A blood test performed at the hospital.
61391|NCT03704766|Diagnostic Test|Serum erythrocyte sedimentation rate (ESR)|A blood test performed at the hospital.
61392|NCT03704766|Diagnostic Test|Serum C-reactive Protein (CRP)|A blood test performed at the hospital.
61393|NCT03704766|Diagnostic Test|Serum D-dimer|A blood test performed at the hospital.
61394|NCT03704766|Diagnostic Test|Serum Procalcitonin|A blood test performed at the hospital.
61395|NCT03704766|Diagnostic Test|Blood Cultures|Blood will be cultured at the hospital to see if any organisms grow.
61396|NCT03704766|Diagnostic Test|Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )|In patients with suspected inflammation/infection, there are other blood tests which may be standard of care and used for diagnosis.
61486|NCT03704181|Drug|Placebo Oral Tablet|placebo twice day for one year
61398|NCT03704753|Drug|Sodium chloride 0.9%|Serratus anterior plane block for thoracic surgery patients and subpectoral interfascial nerve block for open heart surgery patients (placebo).
61399|NCT03704740|Biological|NBP607-QIV|Purified inactivated influenza virus surface antigens of four strains (quadrivalent)
61400|NCT03704740|Biological|Agrippal|Influenza virus surface antigens of three strains (trivalent)
61401|NCT03704727|Dietary Supplement|Probiotic|Probiotics (beneficial microorganisms) VSL#3 is a probiotic formula containing a mixture of 9x10^10 CFU/g Lactobacilli strains (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus bulgaricus), 8x10^10 CFU/g Bifidum strains (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis) and 20x10^10 CFU/g Streptococcus thermophilus
61402|NCT03704714|Drug|Cyclophosphamide|Given IV
61403|NCT03704714|Drug|Doxorubicin Hydrochloride|Given IV
61404|NCT03704714|Biological|Nivolumab|Given IV
61405|NCT03704714|Drug|Prednisone|Given PO
61406|NCT03704714|Other|Quality-of-Life Assessment|Ancillary studies
61407|NCT03704714|Biological|Rituximab|Given IV
61408|NCT03704714|Drug|Vincristine Sulfate|Given IV
61409|NCT03704701|Diagnostic Test|Cardiac MRI and contrast-enhanced cardiac CT|Cardiac MRI Contrast-enhanced cardiac CT
61410|NCT03704688|Drug|Trametinib 0.5 mg|0.5mg PO q daily
61411|NCT03704688|Drug|Trametinib 1 MG|1.0 mg PO q daily
61412|NCT03704688|Drug|Trametinib 1.5 MG|1.5mg PO q daily
61413|NCT03704688|Drug|Trametinib 2 mg|2 mg PO q daily
61414|NCT03704688|Drug|Ponatinib 15 MG|15mg PO q daily
61415|NCT03704688|Drug|Ponatinib 30 MG|30mg PO q daily
61416|NCT03704675|Drug|TEW-7197|Administered orally
61417|NCT03704662|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
61418|NCT03704662|Radiation|Preoperative Fractionated Radiation Therapy and Chemotherapy|Conventional concurrent chemotherapy and radiation therapy.
61419|NCT03704649|Behavioral|Participatory video|Participatory video education is an intervention model that gives communities the film-making skills necessary to make videos that can be used in nutrition promotion. For the purposes of this study, we will be using a participatory video model as an approach to educate participants in a school-based girls club on nutrition education topics. Participants are taught how to use film equipment and accompanied to draft scripts, create characters, video-record the shots, and act (if they wish) in the video. These videos will be used in the group as a means of sharing nutrition information with students and in stimulating discussion around the nutrition topic.
61420|NCT03704623|Drug|Paracetamol|Paracetamol 1g IV
61421|NCT03704623|Drug|Parecoxib|Parecoxib 40 mg IV
61422|NCT03704610|Drug|Infliximab|An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions
61423|NCT03704610|Drug|Placebo|An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
61424|NCT03704597|Other|cryotherapy|Cooling of oral mucosa
61425|NCT03704584|Drug|Treatment Group (corticosteroid injection plus lidocaine)|Subjects will receive (corticosteroid injection plus lidocaine) that is (40 mg/mL injection of Methylprednisolone or 40mg/mL injection of methylacetate injectable suspension or 40 mg/mL triamcinolone and 1% lidocaine HCl).
61426|NCT03704584|Drug|Control Group (corticosteroid alone)|Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
61427|NCT03704571|Drug|Polyethylene Glycol|"In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.~In the control group, all the patients are given routine regimens."
61428|NCT03704545|Other|Pharmaceutical consultation at the hospital|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
61429|NCT03704545|Other|Pharmaceutical consultation at the pharmacy|During 20 minutes, the patient will be educated about chronic obstructive pulmonary disease treatments and their use.
61430|NCT03704545|Other|Follow-up pharmaceutical consultation at the pharmacy|During 10 minutes, the patient will get more information about his chronic obstructive pulmonary disease treatments and their use.
61431|NCT03704532|Procedure|Operative treatment|Open surgical repair of tendon rupture
61432|NCT03704532|Procedure|Nonoperative treatment|Nonoperative treatment with lower leg orthosis and functional rehabilitation
61433|NCT03704519|Drug|Darolutamide (BAY1841788)|300 mg tablet darolutamide, once orally
61434|NCT03704519|Drug|Enzalutamide|4 x 40 mg capsules, once orally
61435|NCT03704519|Other|Placebo|4 placebo tablets, once orally
61436|NCT03704506|Drug|Reyanning mixture|Reyanning mixture , 20ml by mouth , 3 times per day for 7 days
61437|NCT03704506|Drug|amoxil capsule|amoxil capsule , 0.5g by mouth , 3 times per day for 7 days
61438|NCT03704506|Drug|Reyanning mixture simulator|Reyanning mixture simulator , 20ml by mouth , 3 times per day for 7 days
61439|NCT03704506|Drug|amoxil capsule simulator|amoxil capsule simulator , 0.5g by mouth , 3 times per day for 7 days
61440|NCT03704493|Diagnostic Test|Video Group|A video of a group of five amateur runners running along woods and fields. The group was filmed from behind to give the patient the impression of running within the group.
61441|NCT03704480|Drug|Durvalumab|1500mg by intravenous (IV) infusion on D1 until progression or unacceptable toxicity or withdrawal of consent
61442|NCT03704480|Drug|Tremelimumab|75mg by IV infusion on D1 for the first 4 cycles
61443|NCT03704480|Drug|Paclitaxel|80mg/m² every week for 3 weeks (D1-D8-D15), by IV infusion until progression or unacceptable toxicity or withdrawal of consent (at least 6 cycles at the discretion of the investigator)
61444|NCT03704467|Drug|M6620|Part A: Participants will be administered M6620 90 milligram per square meter (mg/m^2) intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m^2, or 40 mg/m^2. Part B: Participants will be administered M6620 at a dose as confirmed by the safety monitoring committee after the safety run-in (Part A).
63286|NCT03689855|Procedure|Peripheral blood draw|-Baseline and Cycle 2 Day 1
61445|NCT03704467|Drug|Avelumab|Part A and B: Participants will be administered IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620 followed by avelumab 800 mg IV on Day 1 of every two weeks (Q2W) cycle as maintenance monotherapy after the last dose of carboplatin and M6620 until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
61446|NCT03704467|Drug|Carboplatin|"Part A and B (Experimental): Participants will be administered carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.~Part B (SoC): Participants will be administered carboplatin intravenously (IV) area under the concentration-time curve (AUC) 5 (+ paclitaxel) or AUC 4 (+ gemcitabine) as a standard of care (SoC) treatment on Day 1 of each Q3W or every 4 weeks (Q4W) cycle for a maximum of 6 cycles, with or without bevacizumab."
61447|NCT03704467|Drug|Paclitaxel|Part B: Participants will be administered Paclitaxel 175 mg/m^2 IV on Day 1 Q3W in combination with carboplatin for 6 cycles, with or without bevacizumab.
61448|NCT03704467|Drug|Gemcitabine|Part B: Participants will be administered Gemcitabine 1000 mg/m^2 IV on Day 1 and 8 of each Q3W cycle in combination with carboplatin for a maximum of 6 cycles.
61449|NCT03704467|Drug|Bevacizumab|Part B: Participants will be administered bevacizumab 15 milligram per kilogram (mg/kg) IV on Day 1 of each Q3W cycle in combination with carboplatin/paclitaxel or carboplatin/gemcitabine followed by bevacizumab monotherapy until disease progression.
61450|NCT03704467|Drug|Pegylated Liposomal Doxorubicin (PLD)|Participants will be administered PLD 30 mg/m^2 Q4W in combination with carboplatin for a maximum of 6 cycles with or without bevacizumab.
61451|NCT03704454|Dietary Supplement|50 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
61452|NCT03704454|Dietary Supplement|100 mg PYC and then placebo|4 weeks on PYC, then 4 weeks on placebo
61453|NCT03704454|Dietary Supplement|Placebo and then 50 mg PYC|4 weeks on placebo, then 4 weeks on PYC
61454|NCT03704454|Dietary Supplement|Placebo and then 100 mg PYC|4 weeks on placebo, then 4 weeks of PYC
61455|NCT03704441|Drug|Bupivacaine|bupivacaine dose
61456|NCT03704428|Drug|SHR-1314|Pharmaceutical form: Injection solution. Route of administration: subcutaneous injection.
61457|NCT03704415|Procedure|Extended endoscopic sinus surgery|ESS of all sinuses
61458|NCT03704415|Procedure|Limited endoscopic sinus surgery|Partial ethmoidectomy
61459|NCT03704402|Other|Alcohol policy|Introduction of new mutual alcohol policy
61460|NCT03704389|Behavioral|Clinical decision support|Clinical decision support nudges within the electronic health record
61461|NCT03704376|Drug|30 ml of 0.2% ropivacaine|
61462|NCT03704376|Drug|15 ml of 0.2% ropivacaine|
61463|NCT03704376|Drug|100 mcg clonidine|
61464|NCT03704376|Device|High-frequency linear ultrasound transducer|
61465|NCT03704363|Drug|Biosimilar Infliximab|Intravenous infusion(5 mg/kg). Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98, unless unacceptable toxicity is encountered.
61466|NCT03704363|Other|Placebo|Intravenous infusion. Each participant will be given 4 infusions, at day 0, day 14, day 42 and day 98,
61467|NCT03704350|Dietary Supplement|controlled diet|Participants will consume a diet that is controlled in its daily contents of oxalate, calcium, vitamin C and sodium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements (vitamins, calcium or other minerals, herbal supplements, nutritional aids), to exercise strenuously, or to consume food or drink that is not provided to them as part of the controlled diet.
61468|NCT03704337|Dietary Supplement|Commercially Available Food Bar|Active
61469|NCT03704337|Dietary Supplement|Placebo|Placebo
61470|NCT03704311|Procedure|Muscle biopsy|Local anesthesia was applied to the superficial skin covering the MTrP of each participant. Percutaneous biopsy sampling optimized with a suction-enhancement technique was used to obtain muscle biopsies of the m. trapezius MTrP or the m. gluteus medius MTrP from each participant using small Bergstrom muscle biopsy needle, 8 swg (4.0mm) x 100 mm (Dixons Surgical Instruments, Essex, United Kingdom).
61471|NCT03704298|Drug|Cyclophosphamide|Administered according to package insert
61472|NCT03704298|Drug|Fludarabine|Administered according to package insert
61473|NCT03704298|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
61474|NCT03704298|Biological|Utomilumab|Administered as an IV infusion
61475|NCT03704285|Drug|Propofol|Patients undergoing general anesthesia using target controlled infusion of propofol. Initial bolus of 1-2 mg/kg and then a continuous infusion of 10 mg/kg/hr that will be adjusted adjusted to maintain a BIS between 40 and 60.
61476|NCT03704285|Device|BIS|GeneralAnesthesia maintenance with propofol+remifentanil guided by BIS monitoring.
61477|NCT03704272|Behavioral|SunBrite|SunBrite is a family-empowered injury risk mitigation intervention with 3 core components: screening for the risk of supervisory neglect associated with traumatic injury in very young children; a brief behavioral intervention using motivational interviewing designed to provide feedback to the caregiver on supervisory risk and traumatic injury; and a referral to treatment for ongoing risks such as substance abuse, trauma or mental illness, requiring specific clinical interventions.
61478|NCT03704259|Other|Ceramic coating|coating the laparoscope lens with commercial brand ceramic coating, bought from car service centers specialized in such applications
61479|NCT03704246|Drug|Anti-PD-1 monoclonal antibody|HX008 is a monoclonal antibody drug which is intravenous drip at a dose of 200mg.
61480|NCT03704233|Procedure|Transbronchial cryobiopsy|Transbronchial cryobiopsy procedure
61481|NCT03704220|Drug|Warfarin|Removal of anticoagulation with warfarin
61482|NCT03704207|Other|nNO testing|Collection of already performed clinical data and nNO testing
61483|NCT03704194|Behavioral|Adapted LiFE|The standardized components include presenting the Adapted LiFE user manual to participants, and teach participants to embed the exercise activities in their daily routine with the LiFE activity calendar.
61484|NCT03704194|Behavioral|Attention control|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
61485|NCT03704181|Drug|Colchicine 0.5 MG twice day for one year|placebo twice day for one year
61487|NCT03704168|Device|CRYOABLATION|The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.
61488|NCT03704155|Drug|Botulinum toxin type A|Botulinum Toxin type A The intervention with BoNT-A (Dysport®, Ipsen Biopharmaceutical, USA) was performed in the gastrocnemius and soleus muscles, bilaterally for diplegic children and unilaterally for hemiplegic children.
61489|NCT03704155|Other|Physical Therapy|"Physiotherapeutic intervention was performed twice a week, with duration of one hour per session for 4 weeks. To maintain standardization of treatment, physiotherapists received a booklet with instructions on what treatment they should do.~The intervention protocol consisted of:~Passive stretching of lower limbs,~Stretching associated with the functionality of the plantar flexor muscles, knee flexors, adductors and hip flexors;~Strengthening of the antagonist muscles with the application of BoNT-A;~Static and dynamic balance training;~Up and down stairs;~Functional walking training, prioritizing the initial contact of the heel and active and passive dorsiflexion."
61490|NCT03704142|Device|Sound World Solutions CS50+|Participants will be tested using the Sound World Solutions CS 50+ hearing devices.
61491|NCT03704142|Device|Tweak Focus|Participants will be tested using the Tweak Focus hearing devices.
61492|NCT03704142|Device|IQ Earbuds|Participants will be tested using the IQ Earbuds hearing devices.
61493|NCT03704142|Device|Bose Hearphones|Participants will be tested using the Bose Hearphones hearing devices.
61494|NCT03704129|Other|Tutor|The participants will access the practical training, during which each participant will be followed by a tutor who will interactively explain, using a healthy volunteer, how to perform the ultrasound scan of the diaphragm. The ultrasound will be performed on a healthy volunteer first by the tutor and then by the participants. During the exercise, each individual learner will be supervised by the tutor himself.
61495|NCT03704116|Behavioral|Expedition|On a laptop computer participants work on simulated daily life activities including packing for a trip, navigating a transit system, and learning at museum attractions. The intervention increases difficulty as participants accomplish goals. We are testing the effects of this performance challenge on executive function measures.
61496|NCT03704103|Other|iSage|The provider will choose a treatment algorithm within the iSage app and set the parameters to make insulin dose adjustments no less frequently than every 7 days. The patient is instructed to perform daily fasting glucose measurements and follow the app's recommendations for insulin adjustment.
61497|NCT03704090|Behavioral|Occupational therapy intervention|Prevention of postoperative delirium by occupational therapy intervention
61498|NCT03704090|Behavioral|Standard non-pharmacological prevention intervention|Prevention of postoperative delirium using standard non-pharmacological prevention measures
61499|NCT03704077|Biological|Relatlimab + Nivolumab|Specified dose on specified days
61500|NCT03704077|Biological|Nivolumab|Specified dose on specified days
61501|NCT03704077|Drug|Paclitaxel|Specified dose on specified days
61502|NCT03704077|Drug|Ramucirumab|Specified dose on specified days
61503|NCT03704064|Behavioral|Stigma-Reduction Intervention|Session topics will be based on those tested in a previous pilot study, including: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to physical activity. For example, they will be given strategies to cope with anticipated stigma while exercising in public spaces (e.g., while walking), as well as to challenge self-critical beliefs (e.g., that they are lazy) which may otherwise lead them to avoid exercising. These concrete strategies, along with reducing WBI and improving self-confidence, are intended to increase participants' self-efficacy for and engagement in physical activity.
61504|NCT03704064|Behavioral|Behavioral Weight Loss (BWL)|This intervention will be based on the Diabetes Prevention Program. A diet of 1200-1499 calories per day will be prescribed for participants < 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 20 weeks will include self-monitoring, stimulus control, social support, portion sizes, and goal-setting. Those during weeks 21-72 will focus on skills required for weight loss maintenance and relapse prevention. Physical activity will be begin with a prescription of 60 min/wk, and will gradually progress by 10 minutes over 2-4 week intervals until achieving 150 min/wk by week 20, 200 min/wk by week 46, and 250 min/wk by week 72. Participants will be instructed to spread the activity equally across at least 5 days in bouts that are >10 minutes in duration. Moderate intensity will be prescribed with an emphasis on walking; the vast majority of our research participants self-select this form of activity.
61505|NCT03704051|Behavioral|Mode of Feeding (breastfeeding versus bottle-feeding|Infants will be breastfed during one lab visit and bottle-fed (with expressed breast-milk) during the other.
61506|NCT03704038|Procedure|PEEP level|Patients will have variable PEEP levels and will be monitored
61507|NCT03704025|Behavioral|Current guidelines rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. All the patients will have a detailed and personalized training diary.
61508|NCT03704025|Behavioral|Mobile device guided rehabilitation|Exercise training intervention is six months and includes four to five aerobic and two strength training session a week according to American Heart Association guidelines for coronary artery disease patients. Study group will have virtual glasses or mobile device to motivate and control exercise training program.
61509|NCT03704012|Behavioral|Protocol of massage therapy and kinesiotherapy|Infants received massage and kinesiotherapy, applied by parents, twice a day; 15 minutes each.
61510|NCT03703999|Device|Type 1 diabetic patients freestyle libre|patients selected to use freestyle libre
61559|NCT03703583|Other|There is no intervention in this observational study.|There is no intervention in this observational study.
61511|NCT03703973|Diagnostic Test|Neuropsychology test|We do the neuropsychological tests, Mini-Mental score examination (MMSE) and olfaction test 1 day before (baseline) and 1 week,3 months,1 year and 3 years after surgery without safety issue.
61512|NCT03703960|Other|hypnotic analgesia|classic three-step hypnosis procedure (induction, trance and return to consciousness).
61513|NCT03703960|Other|music|calm music conducive to relaxation
61514|NCT03703908|Drug|CCX140-B|Orally administered tablet
61515|NCT03703895|Drug|Topical AFX5931|Active Comparator, Topical AFX5931, a medication combining a small, potent anti-inflammatory molecule.
61516|NCT03703895|Drug|Topical Placebo|Placebo Comparator, Topical Placebo.
61517|NCT03703882|Drug|Edasalonexent|100 mg/kg/day
61518|NCT03703882|Drug|Placebo|Placebo
61519|NCT03703869|Drug|Insulin glargine (U300)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
61520|NCT03703856|Drug|Memantine|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 88 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of early auditory information processing memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
61521|NCT03703856|Drug|Placebo|"Phase 1 will test the acute effects of memantine (20 mg po) vs. placebo (PBO) on early auditory information processing measures in 88 carefully characterized patients with mild-to-moderate severity AD who are not currently taking AD medications. From this challenge test, a set of Early auditory information processing P memantine sensitivity measures will be derived for each patient. In Phase 2, all patients will begin an open-label trial of memantine monotherapy, titrated to 10 mg bid, with outcome measures collected after 8, 16 and 24 weeks of treatment. Medication adjustments are not restricted, and response heterogeneity is anticipated."
61522|NCT03703843|Device|ARTUS MONO|Temporarily implant and activation of the medical device
61523|NCT03703830|Device|Cerebellar transcranial direct current stimulation|Cerebellar transcranial direct current stimulation (ctDCS) will be applied during 25 minutes at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle.
61524|NCT03703830|Other|Treadmill locomotor training|The Treadmill Locomotor Training (TLT) will be performed through speed and step length progression protocol for 25 minutes and combined to ctDCS
61525|NCT03703830|Device|Sham Cerebellar transcranial direct current stimulation|Sham Cerebellar transcranial direct current stimulation (ctDCS sham) will be applied during 30 seconds at 2 mA of intensity. Anodal electrode will be positioned 1 cm below inion and cathodal electrode at right deltoid muscle. However, subjects will keep the placement of electrodes for 25 minutes to ensure stimulation's masking.
61526|NCT03703791|Biological|AR101|AR101 powder
61527|NCT03703778|Procedure|Androgen deprivation therapy - bilateral orchidectomy|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
61528|NCT03703778|Drug|Androgen deprivation therapy - GnRH agonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
61529|NCT03703778|Drug|Androgen deprivation therapy - GnRH antagonist|Androgen deprivation therapy (ADT) is a kind of hormone therapy for prostate cancer. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. It can be surgical, i.e. bilateral orchidectomy, or medical, i.e. GnRH agonist or GnRH antagonist.
61530|NCT03703765|Device|lower limb volume estimation|"The 3D scanner system is a three-dimensional measurement system.~It allows to evaluate the volume of the lower limbs in order to quantify the evolution of the edema of the lower limbs in the venous pathology in pre and post therapeutic technique.~It is a non-invasive, easily accepted, non-invasive, non-invasive technique that minimizes discomfort."
61531|NCT03703752|Diagnostic Test|Multi-detector CT scan|This is a diagnostic radiological test to diagnose the IH and evaluate the clinical condition of IH
61532|NCT03703739|Dietary Supplement|Reference meal 1|1 ml Ferrous sulfate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g mixed vegetable Sauce and 300 ml nanopure water
61533|NCT03703739|Dietary Supplement|Reference 2|1 ml Ferrous sulphate solution (4mgFe/ml) was added in cooked comercial Rice Prior to served to participant. The meal served with 30 g bean Sauce and 300 ml nanopure water
61534|NCT03703739|Dietary Supplement|Test meal A|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc oxide and ethylenediaminetetraacetic acid"
61535|NCT03703739|Dietary Supplement|Test meal B|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and ethylenediaminetetraacetic acid"
61536|NCT03703739|Dietary Supplement|Test meal C|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
61537|NCT03703739|Dietary Supplement|Test meal D|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g vegetable Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate and sodium pyrophosphate."
61538|NCT03703739|Dietary Supplement|Test meal E|"Fortified extruded Rice was mixed with Commercial Rice (mixing Ratio: 1:100) The meal served with 30 g bean Sauce and 300 ml nanopure water.~** composition of extruded Rice: Ferric pyrophosphate, zinc sulfate, citric acid and trisodium Citrate."
61539|NCT03703726|Dietary Supplement|Reference meal|50 g of Commercial Rice (Jasmin Rice) (dry weight) was cooked and 4 mg iron from Ferrous sulphate was added Prior to give to participants. Rice meal consumed with mixed vegetable Sauce.
61540|NCT03703726|Dietary Supplement|Test meal A|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
61541|NCT03703726|Dietary Supplement|Test meal B|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Warm temperature extruding process (60-70 C°) was used to produce the extruded rice"
61542|NCT03703726|Dietary Supplement|Test meal C|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate, Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 °C) was used to produce the extruded rice."
61543|NCT03703726|Dietary Supplement|Test meal D|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Cold temperature extruding process (30-40 C°) was used to produce the extruded rice."
61544|NCT03703726|Dietary Supplement|Test meal E|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~warm temperature extruding process (60-70 C°) was used to produce the extruded rice."
61545|NCT03703726|Dietary Supplement|Test meal F|"Commercial Rice (Jasmin Rice) was mixed with iron fortified extruded rice co-fortified with zinc sulfate,citric acid and trisodium Citrate. Rice meal consumed with mixed vegetable Sauce.~Hot temperature extruding process (80-100 C°) was used to produce the extruded rice."
61546|NCT03703713|Drug|Sodium chloride|Treatment with Sodium chloride
61547|NCT03703700|Drug|Zishen Yutai Pill|Patients who undergo the long-term protocol will start taking Zishen Yutai Pill on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Zishen Yutai Pill on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
61548|NCT03703700|Drug|Placebo|Patients who undergo the long-term protocol will start taking Placebo on the day of pituitary suppression, 5g three times a day (Stopping on the first 1-4 days of menstruation), and patients who undergo the antagonist protocol will start taking Placebo on the 19th to 23rd day of the previous menstruation cycle, 5g three times a day (Stopping on the first 1-4 days of menstruation). The drug will be taken till 2 weeks after transplantation. If the test result is confirmed as biochemical pregnancy (HCG>50 IU/L), patients continue to take pills till 3 weeks after the clinical pregnancy determined by the ultrasound. If it is determined that the pregnancy test is negative, stop the drug.
61549|NCT03703687|Behavioral|Gratitude intervention|"The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence."
61550|NCT03703674|Drug|GCSF|Granulocyte-colony stimulating factors (G-CSF)
61551|NCT03703661|Procedure|Needle-Aspirated Negative Pressure Dressing|dressing consisting of Needle-Aspirated Negative Pressure dressing with gauze and adhesive/occlusive dressing, placed over wound after primary closure
61552|NCT03703661|Procedure|Control|dressing consisting of gauze and adhesive/occlusive dressing, placed over wound after primary closure
61553|NCT03703648|Radiation|Radiotherapy (curative) for head and neck cancer|Curative intent radiotherapy for head and neck cancer. Doses will be prescribed by an independent Clinical Oncology team. There will be no alteration or experimentation of radiotherapy dosage
61554|NCT03703635|Device|intracranial balloon angioplasty|This group will receive intracranial balloon angioplasty and aggressive medical care including Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20mg once/day as the situation requires and risk factors management including blood pressure to maintain 130-140/90-100 mmHg and LDL lower than 70 mg/dl.
61555|NCT03703622|Behavioral|Video-debriefing with standard HBB training compared with standard HBB training only|"We will use the AAP training curriculum for the HBB 2nd edition through out the training and course assessments pre-and post- training and during follow-up period.~Both intervention arms will a 2 days training consisting of: lectures, neonatal resuscitation demonstrations using NeoNatali mannequin, and practical skills s sessions. Pre- and post-tests knowledge (MCQs) and skills (bag mask ventilation, OSCE A, & OSCE B) will be given to all participants.~In the intervention arm, in addition to standard training, participants will work in teams of three (birth attendant, mother, and an assistant) to perform different HBB case scenarios. These will be filmed and used for subsequent debriefing after each case scenarios. After all participants in the intervention have had the opportunity to participate in the debriefing, then a post test is done to assess performance.~Analysis is done to compare the intervention and control arms performances."
61556|NCT03703609|Behavioral|Tele-yoga|Participants will get a 60 min tele-yoga session biweekly led by a certified medical yoga instructor via live videoconference link on the participants tablet. Each participant will perform a total of 20-24 yoga instructor-led sessions over a 12-week period. A session will contain 10 min breathing exercises, 40 min of yoga and 10 min relaxation/meditation. Before and at the end of each session, participants can discuss their experiences or ask questions to the instructor online. The tablet also includes an app with instructions (text, pictures, and sound files) for yoga positions, breathing and meditation. Participants are encouraged to practice yoga at home individually with one goal of one session a day for a minimum of 10 minutes.
61557|NCT03703596|Drug|Anlotinib Hydrochloride|Anlotinib (12mg QD PO d1-14, 21 days per cycle)
61558|NCT03703596|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1, 21 days per cycle)
63398|NCT03689114|Drug|Low dose lamotrigine|Lamotrigine 100 mg/die
61562|NCT03703557|Diagnostic Test|Sorbstar®|Thermodesorption method coupled with full two-dimensional gas chromatography and mass spectrometry.
61563|NCT03703557|Diagnostic Test|Odour sampling|Analyzed by the dogs of Curie Institute at the training centers
61564|NCT03703544|Other|High glycemic index|Wheat yellow noodle, glutinous rice, tea with sucrose, biscuits, jelly made with sucrose and teriyaki chicken rice.The foods provided have been tested as high glycemic index. Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
61565|NCT03703544|Other|Low glycemic index|Beta-glucan yellow noodle, basmati rice, tea with isomaltulose, biscuits, jelly made with isomaltulose and mung bean noodles.The foods provided have been tested as low glycemic index.Participants' blood glucose will be monitored using the Continuous Glucose Monitor.
61566|NCT03703531|Procedure|Cardiopulmonary resuscitation|CPR performed because of out-of-hospital cardiac arrest
61567|NCT03703518|Other|Mixed reality|"This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions, using the Microsoft Hololens Roboraid game. The duration of the sessions will be 10 minutes."
61568|NCT03703518|Other|Conventional exercise group|This group received 6 exercise sessions over 3 weeks, 2 days/week with an interval of 48 to 72 hours between sessions. This program will consist on stabilisation exercises of the cervical region, in neck deep flexors and neck deep extensors muscles to provide them with strength and resistance
61569|NCT03703505|Drug|AG-348|120 milligrams (mg) oral capsule, single dose, contains 100 microcuries (μCi) of radio labelled [14C]AG-348.
61570|NCT03703505|Drug|[13C6]AG-348|IV microdose of approximately 100 micrograms (mcg), single dose.
61571|NCT03703492|Drug|(18F)FES|"18F-FES is an investigational new drug which will be used for this study. For complete information, please refer to the Investigator's Brochure: [18F]Fluoroestradiol: An investigational positron emission tomography (PET) radiopharmaceutical for injection, intended for use as an in vivo diagnostic for imaging estrogen receptors in tumors"
61572|NCT03703492|Drug|Gadobenate dimeglumine|Gadolinium-based intravenous contrast agent used for the MRI portion of this study
61573|NCT03703479|Other|autologous blood clot made from the patient own clot without any additive|advanced Platelet-rich fibrin clot is made from venous blood withdrawn from the patient
61574|NCT03703466|Drug|Abemaciclib|Administered orally.
61575|NCT03703453|Device|ER-REBOA catheter|The ER-REBOA™ catheter is a device that has been gaining increased use in the setting of severe trauma for the purposes of stopping intra-abdominal hemorrhage. The catheter is advanced through a femoral artery sheath into the aorta, where a balloon at its tip is inflated, occluding all distal blood flow (and stopping any hemorrhage while the patient can be prepared for definitive operative intervention).
61576|NCT03703440|Other|Active arm|≥3 group education sessions in addition to usual diabetes care, every 3 months for 12 months
61577|NCT03703440|Other|Control arm|Usual diabetes care, every 3-month for 12 months
61578|NCT03703427|Drug|Capecitabine, Oral, 500 Mg|1250mg/m2，d1-d14，q3w
61579|NCT03703427|Drug|Vinorelbine Tartrate Oral|60mg/m2，d1；d8；q3w
61580|NCT03703414|Diagnostic Test|Fecal microbiota composition analysis and blood cytokine level analysis|Fecal microbiota composition analysis and blood cytokine level analysis
61581|NCT03703401|Diagnostic Test|Hysterosalpingo-contrast-sonogram|A contrast ultrasound scan to examine fallopian tube pathology and blockage
61582|NCT03703388|Dietary Supplement|Arctigenin|Arctigenin capsule
61583|NCT03703375|Drug|Azacitidine|Azacitidine
61584|NCT03703375|Drug|Romidepsin|Romidepsin
61585|NCT03703375|Drug|Gemcitabine|Gemcitabine
61586|NCT03703362|Other|Resistance training|30 supervised training-sessions over 12 weeks
61587|NCT03703349|Drug|Magnesium Sulfate|Magnesium sulfate will be prescribed by the surgeon / Anesthesiologist and will be taken orally by the patient for the 3 days preceding the surgery
61588|NCT03703349|Drug|Placebo Oral Tablet|Placebo for Magnesium
61589|NCT03703336|Biological|ROTAVIN (liquid formulation)|Two doses of the vaccine will be administered 8 weeks apart, with the first administration given at 2-3 months (60-91 days) of age.
61590|NCT03703336|Biological|ROTAVIN-M1 (frozen formulation)|Two doses of the vaccine will be administered 8 weeks apart, with the first administration given at 2-3 months (60-91 days) of age.
61591|NCT03703323|Other|Rotative thromboelastometry analysis|Obtaining blood sample (one tube of blood)
61592|NCT03703310|Drug|Patidegib Topical Gel, 2%|Patidegib Topical Gel, 2%
61593|NCT03703310|Drug|Patidegib Topical Gel, Vehicle|Patidegib Topical Gel, Vehicle
61594|NCT03703297|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
61595|NCT03703297|Drug|Tremelimumab|Tremelimumab IV (intravenous infusion)
61596|NCT03703297|Other|Placebo|Placebo IV (intravenous infusion)
61597|NCT03703284|Other|Treatments to reduce intracranial pressure|Drugs such as mannitol, glycerin fructose, etc and/or surgery
61598|NCT03703271|Drug|Methotrexate|single-agent 5-day methotrexate, two weeks a cycle
61599|NCT03703271|Procedure|hysteroscopic repeat curettage|Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia
61600|NCT03703258|Behavioral|Web-based intervention|A web-based cognitive-behavioral intervention to prevent the development of PTSD and high-risk drinking in recently-victimized adults
61601|NCT03703245|Other|Sodium bicarbonate|Experimental dentifrice containing 67% w/w sodium bicarbonate in 3 studies and additionally 62% w/w sodium bicarbonate in 3 studies.
61602|NCT03703245|Other|Control Dentifrice|Negative control dentifrice containing 0% w/w sodium bicarbonate
61603|NCT03703232|Device|Investigational prosthetic foot|Individuals will complete one week of community walking with the investigational foot and compare to their regular prosthetic foot.
61604|NCT03703219|Other|Mothers Touch Program|Combination of diet, massage, body binding methods along with 40 days of rest following the traditional way of delivering
61605|NCT03703206|Drug|ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)|nerve block for posterior knee pain after a TKA.
61606|NCT03703193|Other|Dry Needling|A single session of modulatory interventions combined with a single session of dry needling into the shoulder muscles which active trigger points will reproduce the shoulder pain symptoms.
61607|NCT03703193|Other|Physical Therapy|A single session of modulatory interventions targeting modulation of central nervous system.
61608|NCT03703167|Drug|Ibrutinib|Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).
61609|NCT03703167|Drug|Lenalidomide|Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 & 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).
61610|NCT03703167|Drug|Rituximab|Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
61611|NCT03703154|Drug|Envarsus|Patients will then be randomized in the ratio of 2:1 with 20 being in the study arm and 10 in the control arm. Envarsus will be prescribed by the transplant team per conversion guidelines. The transplant team will monitor drug levels, per the dosing guidelines.
61612|NCT03703154|Drug|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
61613|NCT03703141|Dietary Supplement|sucralose 48 mg (splenda)/day for ten weeks|volunteers will take sucralose or placebo daily for 70 days
61614|NCT03703115|Behavioral|Fasting|No food for 14 -16 hours with water intake and non caloric beverages then eating balanced meals over 8 to 10 hours
61615|NCT03703102|Drug|KHK4083|Anti-OX40 Monoclonal Antibody KHK4083
61616|NCT03703102|Drug|Placebo|Matching placebo
61617|NCT03703089|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
61618|NCT03703089|Drug|nab-paclitaxel|Administered by intravenous infusion over 30-40 minutes.
61619|NCT03703063|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
61620|NCT03703063|Drug|nab paclitaxel|Administered by intravenous infusion over 30-40 minutes.
61621|NCT03703063|Drug|Onivyde|Administered by intravenous infusion over 90 minutes.
61622|NCT03703063|Drug|Leucovorin|Administered by intravenous infusion over 30 minutes.
61623|NCT03703063|Drug|5-fu|Administered by intravenous infusion over 46 hours.
61624|NCT03703050|Drug|Nivolumab cohort 1|Induction: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) iv Q2W until CR Evaluation of response as defined below, including biopsy in case of residual masses at Week 24 Maintenance: nivolumab 3 mg/kg (maximal unitary dose: 240 mg) Q4W Total duration of treatment (induction + maintenance) = 24 months
61625|NCT03703050|Drug|Nivolumab cohort 2|Induction: nivolumab 3 mg/kg iv Q2W for 4 doses (Wk0, Wk2, Wk4 and Wk6) Maintenance: nivolumab 3 mg/kg Q4W, for 25 doses, starting at Week 8 (14 days after the last induction dose) Total duration of treatment (induction + maintenance) = 24 months
61626|NCT03703037|Diagnostic Test|Ultrasound and Doppler ultrasound|Assessment of fetal cerebral and maternal uterine pulsatility index using Doppler ultrasound. Measurement of amniotic fluid index according to four-quadrant technique.
61627|NCT03703024|Dietary Supplement|Raspberry Leaf Extract|Eligible subjects will be scheduled for an initial visit. The study will involve 3 visits over a 12 to 13-week period. One capsule to be taken every morning over a 12-13 week period.
61628|NCT03703024|Dietary Supplement|Placebo|Delivered in a capsule
61629|NCT03703011|Device|Accelerometers positioned at the wrinkle, the hip, and the ankle|Accelerometers are positioned at the wrinkle, the hip, and the ankle. The subject stands and walks 10 meters, followed up by a physiotherapist in the physiotherapy area. The accelerometers are triggered by a smartphone. The protocol is filmed (without the face), and 2 physicians will watch the film and count the steps blind to the results of the accelerometers (and blind to each-other steps counts)
61630|NCT03702985|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
61631|NCT03702985|Drug|Capecitabine|625mg/m2 bid Monday-Friday per week
61632|NCT03702985|Drug|Irinotecan|80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
61633|NCT03702985|Drug|Amifostine|400mg/m2 per week
61634|NCT03702959|Drug|Betamethasone|Corticosteroids
61635|NCT03702946|Other|oxytocin in abdominal myomectomy|Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
61636|NCT03702933|Dietary Supplement|D-serine|dosage
61637|NCT03702920|Biological|SMT + PE-A 5%|Plasma exchange treatment (PE-A 5%) will be performed using 5% albumin solution (Albutein 5%). Fresh frozen plasma will be given to prevent coagulopathy. IVIGs will be administered intravenously to prevent the development of hypogammaglobulinemia and infection.
61638|NCT03702920|Other|Standard Medical Treatment|Standard medical treatment according to the institution's standard practice
61639|NCT03702894|Drug|Clavamox|Clavamox, Film-coated Tablets, 875 mg + 125 mg, manufactured by Pharmtechnology LLC, Belarus
61640|NCT03702894|Drug|Augmentin®|Augmentin®, Film-coated Tablets, 875 mg + 125 mg, marketed by GlaxoSmithKline Trading CJSC, Russia
61641|NCT03702881|Device|Bonded Spurs associated with posterior build-ups|Twenty-five patients will be treated with bonded spurs associated with posterior build-ups. The cervical portion of the palatal surfaces of the maxillary incisors and the incisal portion of the lingual surfaces of the mandibular incisors will be pumiced, rinsed, dried, and acid etched with 37% phosphoric acid. The etched surfaces will be subsequently rinsed and carefully dried. Then, the spurs will be bonded using Transbond primer/adhesive. The positions for the spurs will be chose to prevent possible future occlusal interferences The spurs will be sharpened with a carborundum disk before bonding. In addition, posterior build-ups (resin blocks) will be cemented on the functional cusps of all maxillary posterior teeth. The treatment time will be 12 months. After this time, the posterior build ups will be removed and the bonded spurs will be maintained for 12 months more, as active retention.
61642|NCT03702881|Device|Conventional bonded spurs|Twenty-five patients will be treated only with bonded spurs. The bonding of the spurs will follow the same protocol described for the experimental group. The treatment time will be 12 months. After this time, the bonded spurs will be maintained for 12 months more, as active retention.
61643|NCT03702855|Drug|Tetrabenazine Tablets 25 mg|
61682|NCT03702530|Biological|3x 50 L3 larvae immunisation with albendazole treatment|Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
63399|NCT03689114|Drug|Standard dose lamotrigine|Lamotrigine 200 mg/die
61644|NCT03702842|Device|Soterix Medical tsDCS stimulator|tsDCS will be delivered to the lumbar region of the spinal cord with electrodes placed over the low back and abdomen. The electrodes will be secured with a large elastic bandage so that stimulation can be applied for up to 30 minutes during locomotor training with a harness attached to the ceiling for safety. A physical therapist will supervise the session.
61645|NCT03702842|Other|Locomotor training|Participants will complete 16 sessions of locomotor training (4 times per week for 4 weeks). This involves walking on a treadmill for up to 30 minutes with a harness attached to the ceiling for safety, followed by 10 minutes of overground walking training; with physical assistance as needed.
61646|NCT03702829|Drug|Inotersen|Open Label Study
61647|NCT03702816|Diagnostic Test|GE180 PET Scan|GE180 PET Scan
61648|NCT03702803|Dietary Supplement|Galphimia glauca standardized extract|Each patient will be administered with a capsule once a day (in the morning), for 10 weeks. A capsule contains the standardized extract of Galphimia glauca corresponding to 0.374 mg of Galphimine-B
61649|NCT03702803|Drug|alprazolam 1mg|Each patient will be administered once a day (in the morning) for 10 weeks. A capsule contains 1 mg Alprazolam
61650|NCT03702777|Drug|ASP8302|Oral
61651|NCT03702777|Drug|Placebo|Oral
61652|NCT03702764|Diagnostic Test|CCTA|128-multislice CT coronary angiography and complex atherosclerotic plaque analysis, with the use of CT imaging post-processing techniques.
61653|NCT03702751|Procedure|Adhesive tape|will be subjected to skin repair after episiotomy with skin adhesive tape.
61654|NCT03702751|Procedure|Continuous subcuticular skin suturing|will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
61655|NCT03702738|Drug|N-acetyl cysteine|NAC is listed by WHO as an essential medicine for its use in paracetamol (acetaminophen) poisoning, in which it protects against fatal liver injury. It also reduces the viscosity of sputum, thereby serving as an expectorant.
61656|NCT03702725|Drug|Ibrutinib|Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.
61657|NCT03702725|Drug|Lenalidomide|Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.
61658|NCT03702725|Drug|Dexamethasone|Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.
61659|NCT03702712|Behavioral|Aerobic Exercise and Relaxation|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of mindfulness training.
61660|NCT03702712|Behavioral|Aerobic Exercise Only|This intervention will combine 20 minutes of moderate aerobic exercise followed by 20 minutes of quiet rest.
61661|NCT03702712|Behavioral|Relaxation Only|This intervention will combine 20 minutes of mindfulness-based relaxation training followed by 20 minutes of quiet rest.
61662|NCT03702699|Device|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
61663|NCT03702686|Device|FEEDBACK System|Smart Nipple Shield and Monitor Unit
61664|NCT03702673|Drug|K-877 CR Tablet A|K-877 Controlled Release Tablet A
61665|NCT03702673|Drug|K-877 CR Tablet B|K-877 Controlled Release Tablet B
61666|NCT03702673|Drug|K-877 CR Tablet E|K-877 Controlled Release Tablet E
61667|NCT03702673|Drug|K-877 IR Tablet|K-877 Immediate Release Tablet
61668|NCT03702660|Other|GIP(3-30)NH2|Peptide derived from the naturally occuring gut hormone GIP
61669|NCT03702660|Other|Peripheral venous cannulation|Intravenous access for infusions
61670|NCT03702647|Drug|Ropivacaine|30mL of 0.2% Ropivacaine placed in the POEM tunnel
61671|NCT03702647|Drug|Normal saline|30mL of normal saline placed in the POEM tunnel
61672|NCT03702634|Behavioral|Spiritual Care Assessment and Intervention (SCAI) framework|The study chaplain will work with the surrogate, using questions in four domains of spiritual care, to assess them and tailor the visit to their specific needs. The study chaplain will then utilize a pre-determined list of spiritual care interventions, and also document observable outcomes that occur at each visit (which are also listed within the SCAI framework).
61673|NCT03702621|Procedure|Quadratus Lumborum (QL) Block with liposomal Bupivacaine|For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane.
61674|NCT03702621|Procedure|Quadratus Lumborum (QL) Block with Standard Bupivacaine|For the QL block, Shamrock sign consistent of the quadratus lumborum muscle, psoas major muscle, erector spinae muscles and the L4 transverse process will be identified. Under ultrasound guidance with an in-plane technique, the needle will be advanced into the fascial plane between the quadratus lumborum and psoas major muscles. Local anesthetic will be injected into the plane.
61675|NCT03702608|Combination Product|EluNIR Ridaforolimus Eluting Coronary Stent System|"The EluNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising of:~Stent - a mounted Cobalt Chromium (CoCr) alloy based stent - 38 mm length and 2.75mm, 3.0 mm, 3.5mm, 4.0mm diameter~Delivery System - Rapid Exchange (RX) Coronary System~Polymer matrix coating - (PBMA) and CarboSil®~Ridaforolimus drug"
61676|NCT03702595|Other|Hip flexors stretching protocol|Stretching protocol of rectus femoris, vastus lateralis and iliopsoas according to Kaltenborn- Evjenth Orthopaedic Manual Therapy Concept (OMT)
61677|NCT03702582|Drug|Rivaroxaban|Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation
61678|NCT03702582|Drug|Warfarin|Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation
61679|NCT03702569|Diagnostic Test|Left ventricular global longitudinal strain measure|Left ventricular global longitudinal strain value measured before and immediately after volume expansion (500mL crystalloid) using speckle tracking images with echocardiography
61680|NCT03702556|Device|MRI scan|7.0 tesla functional MRI scan
61681|NCT03702543|Behavioral|SymTrend, Inc.|Use of SymTrend and Apple Health apps with feedback and strategies provided.
61683|NCT03702530|Other|3x placebo immunisation with albendazole treatment|Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8
61684|NCT03702530|Biological|2x 50 L3 larvae infection|After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
61685|NCT03702517|Device|lateral stair walking exercise|15 minutes of lateral stair walking exercise
61686|NCT03702517|Device|traditional physiotherapy|strengthening exercise, balance training and gait training
61687|NCT03702491|Drug|Apatinib|Three to four weeks after surgery, the SOX regimen was given palliative adjuvant chemotherapy for 6-8 cycles, then followed by the second cycle combined with the treatment of apatinib mesylate and the monotherapy maintenance of apatinib mesylate
61688|NCT03702491|Drug|Tegafur|3-4 weeks after operation, 6-8 cycles of adjuvant chemotherapy with simple SOX protocol were given.
61689|NCT03702478|Other|Questionnaire|No intervention only observational
61690|NCT03702465|Other|DNA-based dietary intervention|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the intervention arm, will be provided with a hard-copy of a genetic report, which will explain how their SNPs influence their dietary habits.
61691|NCT03702465|Other|DNA-based dietary intervention using an app|The DNA for all arms of the study will be analysed for pre-determined single nucleotide polymorphisms (SNPs) relevant to metabolism. Participants in the exploratory arm, will be given personalised DNA-based dietary advice via the DnaNudge App.
61692|NCT03702465|Other|Control arm|Standard care for pre-diabetic individuals: dietary advice as per the NICE guidelines for individuals who have pre-diabetes.
61693|NCT03702452|Other|functional rehabilitation nursing program|According to the modified Barthel index score, the patients' function was divided into four parts Level,each level has different kinds of rehabilitation nursing.
61694|NCT03702452|Other|control group|The rehabilitation were given by the rehabilitation therapist based on the patient's condition, such as, bridge movement,limb passive motion, limb active motion,turn over,sit upw,walk, and so on.
61695|NCT03702426|Drug|GMCSF|GMCSF 1.5mcg/Kg
61696|NCT03702426|Drug|Norfloxacin|Tablet Norfloxacin 400 mg
61697|NCT03702413|Procedure|Endovascular treatment|Acute thrombectomy
61698|NCT03702400|Drug|Phenylephrine 100 mcg|Phenylephrine at a dose of 100 mcg bolus at a dilution containing 20 mcg / mL of the drug, 5 mL each bolus
61699|NCT03702400|Drug|Norepinephrine 5 mcg|Norepinephrine at a dose of 5 mcg at dilution containing 1 mcg / mL, 5 mL each bolus
61700|NCT03702387|Procedure|standard intravenous regional anesthesia (IVRA) with reapplication of esmach|his intervention simply adds one additional step to the standard IVRA procedure: reapplication of the Esmarch bandage after lidocaine has been injected intravenously. Everything else about this experimental procedure is standard of care.
61701|NCT03702374|Drug|Combined antioxidant therapy|It consists in a tablet with lutein (10 mg), astaxanthin (4 mg), Zeaxanthin (1mg), vitamin C (L-ascorbic acid 180mg), vitamin E (DL-alpha tocopherol 30mg), zinc (zinc oxide 20mg), copper (copper sulfate 1mg), taken once a day for 12 months
61702|NCT03702374|Other|Placebo|It consists in a capsule with 100mg of magnesium oxide.
61703|NCT03702361|Drug|VPRIV|VPRIV (Velaglucerase alfa) Long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.
61704|NCT03702348|Other|Resistance exercise|Protocol with 5min warm-up exercise and 8 exercises that progress in positioning and resistance based on maximum repetition test. The exercises strengthen both the lower and upper limbs and are intended to simulate activities such as sitting and standing up, climbing stairs, picking up weight ...
61705|NCT03702335|Behavioral|Dietary Counselling|Intervention group will be given a comprehensive dietary guidance on how to choose healthier options when eating out, as well as how to personally prepare a healthy meals.
61706|NCT03702322|Behavioral|Voice therapy: respiratory|Abdominal voice onset
61707|NCT03702322|Behavioral|Voice therapy: glottal closure|Pulling/pushing task
61708|NCT03702322|Behavioral|Voice therapy: loud|Assertive task
61709|NCT03702322|Behavioral|Voice therapy: Semiocclusion|Semi-occluded vocal tract
61710|NCT03702296|Other|Ear plugs and eye masks|Patients in the intervention arm will be provided with ear plugs and eye masks and instructed on the use of these during sleep
61711|NCT03702283|Other|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
61712|NCT03702270|Other|Penicillin Allergic Risk Stratification Best Practice Alert|Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
61713|NCT03702257|Procedure|bronchoscopy.|gDSAs are studied on cryopreserved biopsies obtained during bronchoscopy. The technique is the one described by Visentin J.
61714|NCT03702244|Diagnostic Test|cCTA with selective FFRct|PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall
61715|NCT03702231|Biological|Zoster VaccineRecombinant, Adjuvanted|Patients with CLL will enroll on the study for the purpose of determining the SHINGRIX vaccine efficacy in patients who are treatment naive or receiving BTK-I therapy. A series of 2 doses of SHINGRIX will be given on a 0- and 3-month schedule by intramuscular injection. Subjects will be followed for 6 months and receive assessment of serologic response 6- months following the first SHINGRIX vaccine dose. SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
61716|NCT03702218|Drug|Direct Acting Antivirals|"Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR>30~Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR>30~Kidney Transplant:~• Combinations of choice:~Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR>30"
63400|NCT03689114|Drug|Low dose gabapentin|Gabapentin 450 mg/die
61718|NCT03702205|Dietary Supplement|Placebo treatment|Group taking oral supplementation with placebo (starch) in a similar capsule form.
61719|NCT03702192|Device|novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR|novel antithrombotic management protocol
61720|NCT03702179|Drug|Durvalumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
61721|NCT03702179|Drug|Tremelimumab|All patients will receive durvalumab (MEDI4736) (1500mg Q4W) in combination with tremelimumab (75 mg IV Q4W) for up to 3 doses/cycles each, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30kg or below the patient should receive weight-based dosing equivalent to 20 mg/kg of durvalumab Q4W and 1mg/kg tremelimumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500mg plus tremelimumab 75 mg Q4W.
61722|NCT03702179|Radiation|Radiotherapy|Radiotherapy at doses of 46 Gy to the minor pelvis and 64-66 Gy to the bladder.
61723|NCT03702166|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, & Chard, 2017; Resick & Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging.
61724|NCT03702153|Procedure|Abdominal wall reconstruction|The repair of abdominal wall defects with polypropylene mesh
61725|NCT03702140|Drug|"Teriparatide, Forteo® or Teribon"|To examine the effects of terimaratide less than 6 months in osteoporosis
61726|NCT03702127|Device|Transcranial magnetic stimulation; transcranial direct current stimulation; multimodal stimulation|NIBS is applied to the brain.
61727|NCT03702114|Device|auricular point detection|This device is only for auricular detection. No additional intervention will be delivered.
61728|NCT03702101|Device|Auricular point detector|This device is only for auricular detection. No additional intervention will be delivered.
61729|NCT03702075|Other|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
61730|NCT03702062|Diagnostic Test|6 Minute Walk Test Smart phone Application|The intervention requests participants to user the smart phone application at prescribed frequencies during the follow-up period.
61731|NCT03702049|Behavioral|Nurse-led Community Health Worker TBI (RN/CHW TBI) program|Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.
61732|NCT03702036|Drug|molibresib|molibresib 20 mg will be supplied for compassionate use for the identified individual subject.
61733|NCT03702023|Drug|Acetaminophen|Intervention group will receive 1000 mg of acetaminophen
61734|NCT03702023|Drug|Placebo Oral Tablet|Control group will be given a placebo capsule.
61735|NCT03702010|Device|spinal cord stimulation conventional|If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
61736|NCT03702010|Device|spinal cord stimulation experimental|If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
61737|NCT03701997|Device|EXCOR Pediatric|Mechanical circulatory support using ventricular assist device
61738|NCT03701984|Drug|Lidocaine|The lidocaine group will be administered a 1,000 ml distention medium containing 5 ml lidocaine per 250 ml (DEBOCAINE (LIDOCAINE) 2% 1 VIAL 50 ML, Sigma-Tec pharmaceutical Industry. Co. Egypt) and oral placebo similar to tramadol(given 1 hour before the procedure).
61739|NCT03701984|Drug|Tramadol|an oral tramadol tablet (Tramal®, Memphis, Giza, Egypt) 1 h before the procedure and with a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml.
61740|NCT03701984|Drug|placebo|a 1,000 ml distention medium containing 5 ml serum physiologic per 250 ml and oral placebo(1 h before the procedure).
61741|NCT03701971|Other|evaluation of the intensity of pruritus|evaluation of the intensity of pruritus with various questionnaires
61742|NCT03701958|Device|Exalt Model D Single-Use Duodenoscope|Subjects will have a clinically indicated per standard of care ERCP procedure performed with the Exalt single use duodenoscope study device.
61743|NCT03701945|Other|Pulmonary rehabilitation|Pulmonary rehabilitation will be provided to patients presenting an acute exacerbation. The intervention will be composed of exercise training, education and psychosocial support.
61744|NCT03701932|Behavioral|TMS and Lumosity®cognitive retraining|The Lumosity® training includes exercises for speed, memory, attention, flexibility, and problem solving. Subjects will complete this battery while receiving TMS treatment.
61745|NCT03701932|Behavioral|TMS and non cognitive computer games|Subjects will play computer games while receiving TMS treatment.
61746|NCT03701919|Drug|Botulinum toxin pyloroplasty|Intraoperative laparoscopic injection of Botulinum toxin into the pylorus immediately following sleeve gastrectomy
61747|NCT03701919|Drug|Normal saline pyloric injection|Intraoperative laparoscopic injection of normal saline into the pylorus immediately following sleeve gastrectomy
61748|NCT03701906|Dietary Supplement|L.salivarius PS11603 & B.longum PS10402|Approximately 8 weeks intervention study: Participants with 0-5 days of age will start a period of 8 weeks of intervention. During this time the participants will intake one daily dose of the product that contains 1*10E9 CFU of L.salivarius PS11603 and 1*10E8 CFU of B.longum PS10402.
63401|NCT03689114|Drug|Standard dose gabapentin|Gabapentin 900 mg/die
61749|NCT03701906|Dietary Supplement|Placebo|8 weeks intervention study: A 8 weeks intervention period. During the 8 weeks of intervention the participants will intake one daily dose of placebo supplement.
61750|NCT03701893|Dietary Supplement|Lactobacillus PS11610|7 months and a half intervention study. A 6 months intervention period preceded by a period of sampling and analysis of vaginal, seminal and gland swabs of 6 weeks. During the 6 months of intervention the men participants will intake one capsule that contains 1*10E9 colony forming unit (CFU) of Lactobacillus PS11610 and the women participating will intake two capsules of the same product (each 12 hours). If the couple stay pregnant during the intervention the man will end the product intake and the woman will reduce the dose to one capsule with 1*10E9 CFU of Lactobacillus PS11610 per day during 12 additional weeks.
61751|NCT03701880|Drug|Ivabradine|Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential
61752|NCT03701880|Drug|Bisoprolol|Bisoprolol is beta-blocker
61753|NCT03701867|Other|Metabolic Flexibility Tests|Energy Metabolism, Oxygenation, Body Composition, Blood Samples
61754|NCT03701841|Drug|PEG-rhG-CSF|All patients need to receive PEG-rhG-CSF 6mg approximately 24h or 48h after chemotherapy administration once per cycle, at least 2 cycles
61755|NCT03701828|Procedure|Weight loss surgery|All surgery types will be included
61756|NCT03701815|Behavioral|Wellness in Rehabilitation program|The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
61757|NCT03701789|Drug|Baricitinib|Effect of Baricitinib on vBMD measured by HR-pQCT
61758|NCT03701776|Behavioral|Aerobic Training|Aerobic training on stationary bicycle for 30 minutes a day, 5 days a week for 6 months
61759|NCT03701776|Behavioral|Balance Training|Standard of care
61760|NCT03701763|Drug|Apremilast (CC-10004)|Apremilast (CC-10004)
61761|NCT03701763|Other|Placebo|Placebo
61762|NCT03701750|Drug|Low Molecular Weight Heparin (enoxaparin sodium)|enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
61763|NCT03701737|Other|questionnaires|"VAS on the feeling of hunger~Evaluation of food wanting by the Finlayson test~PREFQUEST Questionnaire~24-hour food recall~Stunkard Questionnaire~Measurement of daytime sleepiness by Epworth score"
61764|NCT03701737|Device|wrist actimeter|Actimeter delivery: it is worn on the wrist for 7 days, 24 hours a day.
61765|NCT03701737|Biological|Blood samples|2 dry tubes of 7 ml of blood collected at each visit for plasma assays (ghrelin, leptin, FGF 21, amino acids including tryptophan, insulin resistance)
61766|NCT03701724|Device|Systematic maintenance rTMS|Same parameters as the initial course (session of 8,5 minutes, at 1 Hz, on the right dorsolateral prefrontal cortex (DLPFC) targeting with either neuronavigation or the Beam). The frequency is : 2 sessions / week during 1 month, then 1 session / week during 2 months and finally 1 session every 2 weeks during 8 months.
61767|NCT03701724|Device|rTMS course in case of relapse|Same parameters as the initial course. The frequency is the same as the initial course: one daily session on 5 consecutive working days from Monday to Friday for at least 20 to 30 sessions over 4 to 6 weeks.
61768|NCT03701724|Device|sham rTMS|The sham stimulation consists of the identical rTMS procedure at the identical location using a commercial figure-eight sham coil. However, it does not produce the identical tactile sensation. A local electrical stimulation will be delivered with two disposable Electromyogram (EMG) electrodes using a transcutaneous electrical nerve stimulation (TENS) Stimulator.
61769|NCT03701711|Drug|Lenalidomide|"Dose Escalation~Patients in the dose escalation phase will receive oral treatment with:~Lenalidomide: 10, 15, or 25 mg on Days 1-21 of every 28-day cycle Dexamethasone: 20mg on Days 1,8,15 and 22~Starting doses of Lenalidomide will be assigned at the time of registration.~Dose Expansion~Once the MTD has been established or determined, 3 additional patients will be treated at the MTD of lenalidomide at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study."
61770|NCT03701698|Drug|Ruxolitinib Oral Tablet|Ruxolitinib Oral Tablet （Jakafi）, 5~10mg bid po for at least 28 days.
61771|NCT03701698|Drug|Methylprednisolone|Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.
61772|NCT03701685|Procedure|nerve flap|sensory reconstruction via a nerve graft included in the flap
61773|NCT03701672|Other|Opioid Analgesic Treatment|Opioid treatment is determined, prescribed, modified and discontinued at the sole discretion of the treating physician at each research site; regardless of generic name, manufacturer, constituent components, route of administration, and dosing schedule (including titration and run-in periods).
61774|NCT03701659|Procedure|Surgery combinate with Endocrine therapy|TUPKRP is abbreviation of transurethral plasma kinetic resection of prostate, which is an effective treatment of bladder outlet obstruction for benign prostate hyperplasia. MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrinotherapy for advanced prostate cancer.
61775|NCT03701659|Drug|Endocrine therapy|MAB is abbreviation of Maximal androgen blockade, which is a kind of endocrine therapy for advanced prostate cancer.
61776|NCT03701646|Device|Measurement by Clearsight device|Clearsight Device is used to obtain non-invasive measurements to be correlated to standard invasive measurements.
61777|NCT03701633|Diagnostic Test|Postpartum ultrasound|Measurements of the UtA doppler ultrasound will be carried out twice for each eligible woman on the second day postpartum. The first measurement will take place just prior to a planned breastfeeding. The second measurement will be followed immediately (within 10 min) after the breastfeeding session.
61778|NCT03701620|Diagnostic Test|HRV monitoring|HRV monitoring derived from electrocardiogram
61779|NCT03701607|Other|PD-L1 group|PD-L1 expression is evaluated using immunohistochemical assay
61818|NCT03701347|Device|Reeve's model|Reeves, K. O., Young, A. E., & Kaufman, R. H. (1999). A simple, inexpensive device for teaching the loop electrosurgical excision procedure. Obstetrics and Gynecology, 94(3), 474-5.
61862|NCT03701035|Behavioral|Aerobic Training & UL Motor Training|Aerobic training at 40%-59% Heart Rate Reserve (AT) increasing from personal maximum time (if < 40 mins) to 40 minutes followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
61783|NCT03701581|Drug|4-Aminopyridine|FDA-approved tablets.
61784|NCT03701581|Other|Placebo|Placebo will be tooled to look similar to the study drug.
61785|NCT03701568|Drug|dC/dT|Collection of retrospective data from TK2 patients previously treated with dC/dT
61786|NCT03701555|Other|PvP001 placebo|placebo
61787|NCT03701555|Drug|PvP001 100 mg|PvP001 100 mg
61788|NCT03701555|Drug|PvP001 300 mg|PvP001 300 mg
61789|NCT03701555|Drug|PvP001 900 mg|PvP001 900 mg
61790|NCT03701555|Drug|Maximum Feasible Dose (MFD) of PvP002|Maximum Feasible Dose (MFD) of PvP002
61791|NCT03701555|Drug|Maximum Tolerated Dose (MTD) of PvP001|Maximum Tolerated Dose (MTD) of PvP001
61792|NCT03701555|Drug|MTD of PvP001 following 7 days of PPI treatment|Maximum Tolerated Dose (MTD) of PvP001 following 7 days of PPI (Proton Pump Inhibitor) treatment
61793|NCT03701555|Other|PvP002 placebo|Placebo
61794|NCT03701555|Drug|PvP001 600 mg|PvP001 600 mg
61795|NCT03701542|Diagnostic Test|Microperymetry|Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality.
61796|NCT03701542|Diagnostic Test|M-charts|The M-chart (Inami Co., Tokyo, Japan) is a diagnostic tool developed by Matsumoto to quantify the degree of metamorphopsia in patients with macular diseases.
61797|NCT03701529|Drug|Sevoflurane|1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.
61798|NCT03701529|Drug|Propofol|2-5 mcg/ml of propofol is used for maintenance of anesthesia.
61799|NCT03701516|Device|etafilcon A with novel molding process|TEST Lens
61800|NCT03701516|Device|etafilcon A with current molding process|CONTROL Lens
61801|NCT03701503|Behavioral|Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women|
61802|NCT03701490|Drug|Progesterone subcutaneous|25 mg/twice a day.
61803|NCT03701490|Drug|Progesterone Vaginal Product|200 mg three times a day.
61804|NCT03701477|Behavioral|Trans-diagnostic cognitive-behavioral therapy|10 therapeutic sessions hold in groups of 5-10 individuals. Details about each session: Session 1: Establishing rapport, psychoeducation; Session 2: Relaxation, hierarchy development; Session 3: Identifying automatic negative thoughts, guided imaginary; Session 4: Cognitive restructuring; Session 5: Problem solving skills training, distraction; Session 6: Exposure-based procedures, cognitive restructuring; Session 7-9: Advanced cognitive restructuring, stress management, assertiveness skills training, preparation for termination phase; Session 10: Relapse prevention, termination
61805|NCT03701477|Behavioral|General relaxation/stress management therapeutic session|Patients will attend a 3-hour meeting in which basic techniques of relaxation and stress management will be discussed.
61806|NCT03701464|Procedure|Endoscopic naso-gallbladder drainage|Using ERCP technique insert a naso-gallbladder drainage tube through common bile duct and cystic duct.
61807|NCT03701464|Procedure|Percutaneous gallbladder drainage|Percutaneous transhepatic technique insert drainage tube into gallbladder
61808|NCT03701451|Drug|Demethylated drug decitabine|Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
61809|NCT03701438|Biological|Influenza Vaccine|Administered per standard of care using a vaccine licensed and recommended in the site's country
61810|NCT03701425|Dietary Supplement|Mediterranean diet and exercise plan|"Mediterranean diet:~Diet: according to the definition, with the following distribution of macro nutrients:~Protein contribution 0.8-1.2 Carbon Hydrates 45-50% Lipids 30%"
61811|NCT03701412|Radiation|MRI|MRI brain
61812|NCT03701399|Drug|troriluzole|200 mg PO
61813|NCT03701399|Drug|Placebos|200 mg PO
61814|NCT03701386|Procedure|cesarean hysterectomy|Elective cesarean hysterectomy will be planned at 37-38 weeks of gestation. An adequate amount of blood products was prepared to be available for transfusion. Delivery will be performed by the same multidisciplinary team, including two expert obstetricians, an assistant, an expert anesthesiologist, and a pediatrician.
61815|NCT03701386|Procedure|N&H sandwich technique|In the N&H group, after acceptable control of bleeding from the placental bed, the internal os of the cervix was identified a double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade will be performed
61816|NCT03701373|Drug|S-1 maintenance|S-1 maintenance till disease progression or untolerable toxicities, in oral doses of 40 mg (BSA<1.25 m2), 50 mg (1.25≤BSA<1.50 m2) and 60 mg (BSA≥1.50 m2) b.i.d. on days 1-14 for each 21-day cycle.
61817|NCT03701373|Other|Observation|Observation without anti-tumor treatment
62510|NCT03695900|Other|Targeting SpO2 at 90-92%|FiO2 adjusted to keep basal SpO2 at target range of 90-92% for 2 hours.
61819|NCT03701347|Device|Hefler's model|Hefler, L., Grimm, C., Kueronya, V., Tempfer, C., Reinthaller, A., & Polterauer, S. (2012). A novel training model for the loop electrosurgical excision procedure: An innovative replica helped workshop participants improve their LEEP. American Journal of Obstetrics and Gynecology, 206(6)
61820|NCT03701347|Device|Ida's model|Reusable, portable and modular 3D printed simulator
61823|NCT03701321|Drug|Bortezomib|Given SC
61824|NCT03701321|Biological|Daratumumab|Given IV
61825|NCT03701321|Drug|Dexamethasone|Given PO
61826|NCT03701321|Drug|Venetoclax|Given PO
61827|NCT03701308|Drug|Cytarabine|Given IV
61828|NCT03701308|Drug|Daunorubicin|Given IV
61829|NCT03701308|Drug|Uproleselan|Given IV
61830|NCT03701295|Drug|Azacitidine|Given IV or SC
61831|NCT03701295|Drug|Pinometostat|Given IV
61836|NCT03701256|Procedure|Bilateral ultrasound guided TAP bloc|In the TAP group: Bilateral ultrasound guided TAP bloc for laparoscopic gynecologic surgery
61837|NCT03701256|Drug|Neuromuscular blockade agent: Atracurium 01mg/kg per bolus|In the TRAC group: Neuromuscular blockade agent: Atracurium 01mg/kg per bolus for maintaining muscular relaxation and immobilization during laparoscopic gynecologic surgery
61838|NCT03701243|Procedure|mNT-BBAVF|Briefly, to construct an mNT-BBAVF, an incision is made on the ulnar side of the elbow. The brachial artery and basilic vein are then isolated, and a side-to-side anastomosis is performed without transposition of the basilic vein.
61839|NCT03701243|Procedure|RCAVF|Briefly, to construct a wrist RCAVF, an incision is made on the radial side of the wrist. The radial artery and cephalic vein are then isolated, and a end-to-side anastomosis is performed.
61840|NCT03701230|Other|low temperature rota-flush solution|Patients with severe calcified lesions undergoing RA were performed with low temperature rota-flush solution. The investigators used thermal insulation equipment to keep rota-flush solution at 0～5℃. The EKG and blood pressure were monitored during the RA procedure. After RA, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
61841|NCT03701217|Drug|Eltrombopag|Eltrombopag 25mg bid, starts from the day when platelet count decreases lower than 30×10`9/L, and the treatment lasts for at least 5 days, and stops until platelet count goes up to more than 30×10`9/L, after consolidation therapy in AML patents.
61842|NCT03701204|Behavioral|DynamiCare Rewards|"Participants assigned to the DynamiCare Rewards group will receive the following:~App on their smartphone~Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~Next Step debit card to receive financial incentives~Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~The amount of coins and funds are available on a progressive variable reward schedule."
61843|NCT03701191|Procedure|Inverted periosteal pedicle flap|The periosteum will be used as an autogenous graft after raising a partial thickness flap in group A
61844|NCT03701178|Other|BioHPP PEEK|milled BioHPP PEEK in a new material can be used as a dental restoration
61845|NCT03701165|Device|DryMouth Shield|The DryMouth Shield provides an elastomeric, one-piece design with breath-actuated, one-way valves configured to create an air-tight seal between the teeth and lips, which effectively reduces oral venting and air leakage while also allowing air flow into the mouth by generating a high-volume, low resistance airflow during inhalation while sealing when the user exhales.
61846|NCT03701152|Device|Negative pressure therapy|Negative pressure therapy at sub atmospheric level
61847|NCT03701139|Procedure|posterior capsulotomy|After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
61848|NCT03701139|Procedure|laser capsulotomy|A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
61849|NCT03701126|Procedure|Transversus Abdominis Plane Block|ultrasound (US) guided TAP block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
61850|NCT03701126|Procedure|Caudal Block|ultrasound (US) guided caudal block will be done to the patients using 0.25% bupivacaine, in a dose of (1 ml / kg).
61851|NCT03701126|Drug|Bupivacaine 0.25% Injectable Solution|Dose 1ml /kg of patient body weight
61852|NCT03701126|Device|Ultra-sound guidance|using superficial high frequency probe to guide regional anesthesia
61853|NCT03701113|Dietary Supplement|Milk-based protein matrix (MBPM)|Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention
61854|NCT03701113|Dietary Supplement|Habitual dietary behaviour|Subjects to maintain habitual dietary behaviour for the 24 week intervention
61855|NCT03701100|Device|tDCS|tDCS
61856|NCT03701087|Drug|Vitamin D|2800 IU daily till 26 weeks of pregnancy
61857|NCT03701074|Drug|Ibuprofen and acetaminophen|Intravenous ibuprofen given concomitantly with oral acetaminophen
61858|NCT03701074|Drug|Ibuprofen and placebo|Intravenous ibuprofen given concomitantly with oral placebo
61859|NCT03701061|Biological|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
61860|NCT03701061|Biological|Seasonal Influenza Vaccine|A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study
61861|NCT03701048|Procedure|Cesarean Section|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed.
61863|NCT03701035|Behavioral|Non-aerobic training & UL Motor Training|40 minutes non-aerobic gait & balance circuit training followed by UL motor training with the Armeo®Spring/Senso/Pablo X2®
61864|NCT03701022|Drug|SHR1210|SHR-1210 injection, 200 mg/dose, intravenous infusion within 20-60 minutes. Apatinib oral administration, 500mg per day.
61865|NCT03701009|Procedure|CBD stone removal via lithotripsy|Hold saline irrigation just after X-ray demonstrated no stone residue, a Spyglass explored.
61866|NCT03701009|Procedure|Saline 50ml|If not clean, intermittent saline irrigation 50ml, and Spyglass explored second time.
61867|NCT03701009|Procedure|Saline +50ml|If still have some stone fragments, intermittent saline irrigation another 50ml after the second Spyglass detection, Spyglass explored third time to evaluate stone clearance.
61868|NCT03700983|Dietary Supplement|Nutri-PEITC jelly|an edible, easily to swallow nutritious gel containing a bioactive compound PEITC
61869|NCT03700970|Drug|Liposomal bupivacaine|20mL of Exparel® 1.3% mixed with 20mL of 0.25% bupivacaine, for a total of 40mL of local anesthestic mixture, 20mL to be injected on each side.
61870|NCT03700970|Drug|Regular bupivacaine|20mL of 0.25% bupivacaine injected on each side.
61871|NCT03700957|Dietary Supplement|Docosahexaenoic Acid|100 milligrams of Docosahexaenoic Acid
61872|NCT03700957|Other|placebo|placebo
61873|NCT03700944|Other|Yoga training|Complete protocol with yoga training for a period of 8 weeks, 60 minutes, 3 times a week.
61874|NCT03700931|Behavioral|Eating recall condition|Recall of eating episodes would increase subsequent intake of fruit or vegetable items
61875|NCT03700931|Behavioral|Non-eating recall condition|Recall of non-eating episodes would not influence subsequent intake of fruit or vegetable items
61876|NCT03700918|Device|DaVingiTR System|DaVingiTR Tricuspid valve annuloplasty repair device
61877|NCT03700905|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor including neck dissection according to standard of care
61878|NCT03700905|Radiation|Adjuvant radio(-chemo)therapy|Risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy Cisplatin 100 mg/m2 on days 1, 22, 43, or Cisplatin once weekly (40mg/m2) for high risk patients only)
61879|NCT03700905|Drug|Neoadjuvant Nivolumab|Neoadjuvant dose with Nivolumab 3mg/kg after randomization within 2 weeks before surgery
61880|NCT03700905|Drug|Adjuvant Nivolumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
61881|NCT03700905|Drug|Adjuvant Nivolumab and Ipilimumab|Administration of Nivolumab 3mg/kg i.v. d1 every 2 weeks and Ipilimumab 1mg/kg i.v. d1 every 6 weeks within 6 weeks after end of radiotherapy until progression or up to 6 months
61882|NCT03700892|Other|Cinnamaldehyde e-liquid|Participants will inhale an e-liquid that contains cinnamaldehyde from Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
61883|NCT03700892|Other|PG/VG e-liquid|Participants will inhale an e-liquid that contains PG/VG from the Vapor Shark DNA 250™ e-cigarette device allowing manual control and vapor setting recordings (voltage, wattage, puff volume, and frequency).
61884|NCT03700879|Radiation|MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler|Patients presented with clinical picture and radiography suggestive of acute ischemic stroke will be subjected to a comprehensive evaluation with MRI,MRA,Carotid ,vertebrobasilar and Transcranial Doppler
61885|NCT03700866|Procedure|Functional splinting time|Functional splinting time is the time needed for the final healing and organization of Peridontal ligament of tooth with extrusive luxation injury to reattach to the alveolus and function normally in the oral cavity
61886|NCT03700853|Diagnostic Test|Dysphagia Trained Nurse Assessment (DTNAx)|Bedside swallowing assessment carried out by trained nurses
61887|NCT03700840|Device|Interdental brushes|interdental brush at 4 sites and PCR analysis
61888|NCT03700827|Other|Resistance Training|High-intensity Resistance Training Group
61889|NCT03700827|Other|Aerobic Training|Aerobic Interval Training Group
61890|NCT03700814|Drug|Co-amoxiclav|Patients in this group will receive single dose of intravenous co-amoxiclav (Dose: 25 mg/kg body weight) which was injected 30 minutes prior to the incision during surgery.
61891|NCT03700801|Drug|Triple combination therapy group|Triple oral hypoglycemic therapy based on metformin, dapagliflozin plus saxagliptin.
61892|NCT03700801|Drug|Premixed insulin therapy group|Subcutaneous injection therapy with insulin aspart 30 in patients with T2DM
61893|NCT03700788|Drug|Chlorhexidine|2% Chorhexidine (intracranial; remains in canal until removal at next visit)
61894|NCT03700788|Drug|Calcium Hydroxide|Calcium Hydroxide (intracranial; remains in canal until removal at next visit)
61895|NCT03700775|Other|Remote Telemonitoring|Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal <130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
61896|NCT03700762|Diagnostic Test|ultrasound gray-scale ratio|RADinfo radiograph reading system was used to measure the gray-scales of PTMC, NG, and thyroid tissues at the same gain level, the UGSR values of the PTMC, NG, and thyroid tissue were calculated.
61897|NCT03700749|Drug|2% chlorhexidine + non-coated suture|"Interventions:~2% alcoholic chlorhexidine non-coated suture"
61898|NCT03700749|Drug|2% chlorhexidine + coated suture|"Interventions:~2% alcoholic chlorhexidine triclosan coated suture"
61899|NCT03700749|Drug|10%povidone-iodine + non-coated suture|"Interventions:~10% povidone-iodine non-coated suture non-coated suture"
61900|NCT03700749|Drug|10%povidone-iodine + coated suture|"Interventions:~10% povidone-iodine triclosan coated suture"
61975|NCT03700138|Drug|Privigen® 100mg/ml at the dose of 2g/kg of body weight|The treatment (IV Ig, 100mg/ml at the dose of 2g/kg of body weight) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
61901|NCT03700736|Behavioral|Healthy Moms|The 6-month intervention will include dietary and exercise counseling and tips to help participants meet their healthy lifestyle goals. Participants will receive personalized calorie and physical activity goals to help them achieve a healthy weight loss of 1-2 pounds per week. Participants will be encouraged to increase physical activity to 150 minutes per week of moderate intensity activity. Counselors will encourage and support participants to make a plan for incorporating regular physical activity into their lives in a way (i.e., duration per session, frequency per week) that works for that individual woman. We will encourage participants to track their diet and exercise daily. We will encourage participants to use My Fitness Pal to track their diet and activity.
61902|NCT03700723|Biological|Resusix|spray-dried solvent/detergent treated plasma (blood product)
61903|NCT03700723|Biological|FP24 (Frozen Plasma)|plasma frozen within 24 hours of phlebotomy
61904|NCT03700710|Behavioral|Self-Guided Approach|For a 12-week period, patients will be asked to enter dietary information into the LoseIt mobile app.
61905|NCT03700710|Behavioral|Dietitian-led Approach|For a 12-week period, patients will be asked to enter dietary information into the LoseIt mobile app. Dietitians will access this information and provided personalized motivational interview phone calls on a weekly basis.
61906|NCT03700697|Behavioral|Family Stress Module Intervention|as above
61907|NCT03700684|Behavioral|Lee Silverman Voice Treatment|Persons with Parkinson's disease receive sixteen hours of voice treatment over a four week period. Participants will practice the vocal exercises at home for an additional four weeks.
61908|NCT03700684|Device|SpeechVive|Persons with Parkinson's disease wear the SpeechVive device several hours a day over an eight week period during opportunities for communication.
61909|NCT03700684|Behavioral|Control|Persons assigned to the non-treatment control group will not participate in voice treatment.
61910|NCT03700671|Other|High intensity interval training|Participants performed LV-HIIT twice a week for eight weeks. Findings were compared to moderate intensity continuous training which followed the same exercise frequency and duration
61911|NCT03700671|Other|Moderate intensity continuous training|The MICT group completed a practical seven-station mixed modality exercise circuit (cycle ergometer, rower, treadmill, sit to stand, knee to elbow and leg kickback with bicep curl) at an intensity of 60-80% HRmax twice per week for eight weeks. Participants initially performed 20 minutes of MICT with duration gradually increased to the desired 40 minutes as tolerated
61912|NCT03700658|Drug|TV-46046 - 1|120 mg/0.3 mL
61913|NCT03700658|Drug|TV-46046 - 2|60 mg/0.3 mL of 1:1 saline-diluted TV-46046
61914|NCT03700658|Drug|medroxyprogesterone acetate injectable suspension|104 mg/0.65 mL (injectable suspension)
61915|NCT03700658|Drug|TV-46046 Placebo|0.3 mL
61916|NCT03700645|Drug|Allopurinol|Allopurinol
61917|NCT03700632|Other|patch therapy|The eyes are alternatively patched for 2 hours a day in cases without a dominant eye while in cases with dominancy, the dominant eye is patched five days a week and the non-dominant eye is patched two days a week
61918|NCT03700619|Other|BRIEF parental survey|estimate incidence of executive functions disorders in preterm children in 11 to 12 year old, born less than 34 weeks of gestation, with the BRIEF parental questionnaire. Effects are potentially important because this study could objectify an increase of risk of executive functions disorders f in preterm children in 11 to 12 year old, and identify associated risk factors. This work could eventually alert pediatrician to be careful at the executive functions and to propose adapted supportive cares.
61919|NCT03700606|Procedure|High flow nasal cannula|8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.
61920|NCT03700606|Procedure|Nasal CPAP|Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.
61921|NCT03700593|Device|Single Port Robotic Colorectal Surgery|Single Port Robotic Colorectal Surgery
61922|NCT03700580|Drug|Hydrogel treatment|Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.
61923|NCT03700580|Drug|P1G10|P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
61924|NCT03700567|Other|low temperature contrast|UAP patients undergoing PCI were performed with low temperature contrast. The investigators used thermal insulation equipment to keep contrast at 5℃. The EKG and blood pressure were monitored during the PCI procedure. After PCI, the investigators monitored levels of myocardial injury biomarkers for 3 days every 8 hours.
61925|NCT03700554|Device|Pleuralvent™|Pneumothorax treatment with Pleuralvent™ device (Heimlich valve device)
61926|NCT03700554|Procedure|Chest tube|Chest tube insertion
61927|NCT03700541|Drug|Morphine|Morphine intravenous
61928|NCT03700541|Drug|Piritramid|Piritramid intravenous
61929|NCT03700528|Behavioral|Acceptance and Commitment Therapy (ACT)|The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
61930|NCT03700515|Drug|Erythropoietin|Subjects receive weekly infusions of EPO
61931|NCT03700515|Drug|Placebo|Subjects receive weekly infusions of saline
61932|NCT03700502|Diagnostic Test|resting-state functional Magnetic Resonance Imaging|The investigators used fraction Amplitude of Low Frequency Fluctuation (fALFF) and Regional Homogeneity (ReHo) of resting-state functional Magnetic Resonance Imaging (rs-fMRI) to explore the brain activity in patients with PDN in order to study the central mechanism. The investigators also evaluated the symptoms, signs and mental conditions of the patients.
62106|NCT03699176|Drug|Placebo|Once daily, oral
61933|NCT03700489|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover des
61934|NCT03700476|Drug|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 12 cycles, with 3 cycles before, 3 cycles concurrent with, and 6 cycles after IMRT
61935|NCT03700476|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
61936|NCT03700476|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
61937|NCT03700476|Radiation|intensity-modulated radiotherapy|Definitive IMRT of 70Gy will be given in six to seven weeks.
61938|NCT03700463|Other|BRIEF parental survey|Estimate incidence of executive functions disorders in preterm children in 3 to 4 year old, born less than 34 weeks of gestation
61939|NCT03700450|Drug|Cyclophosphamide|Patients will receive on day 3 and 4 after allogeneic stem cell transplantation 50 mg/kg BW cyclophosphamide
61940|NCT03700437|Other|Fasting-Mimicking Diet|Chemo-immunotherapy + FMD (fast-mimicking diet)
61941|NCT03700437|Other|Regular Diet|Chemo-immunotherapy + regular diet
61942|NCT03700424|Drug|Trehalose|"Trehalose is a natural disaccharide sugar found extensively among miscellaneous organisms including bacteria, plants, insects, yeast, fungi, and invertebrates. By preventing protein denaturation, it plays various protective roles against stress conditions such as heat, freeze, oxidation, desiccation and dehydration. Owing to this capacity, trehalose is an FDA-approved pharmaceutical excipient that is used as a stabilizer in numerous medicines including parenteral products.~In this study, all injections will be conducted by a trained nurse in the presence of a specialist physician at a duration of 45-90 minutes."
61943|NCT03700424|Drug|Normal saline|A solution of 0.90% w/v of sodium chloride (NaCl) in water
61944|NCT03700411|Drug|Morphine|Morphine intravenous
61945|NCT03700411|Drug|Piritramid|Piritramid intravenous
61946|NCT03700411|Drug|Epidural|Perioperative epidural analgesia
61947|NCT03700398|Device|first OE|optical enhancement(OE)，a kind of electron straining endoscopy
61948|NCT03700398|Device|first WLI|the routine in the clinical practice
61949|NCT03700385|Device|IOWA Approach Endocardial Ablation System|Endocardial ablation using the IOWA Approach Endocardial Ablation System
61953|NCT03700346|Device|microdialysis|Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
61954|NCT03700333|Drug|S-1 therapy|accept S-1(50mg, twice a day, morning and night, if<1.5m2; 75mg, twice a day, morning and night,if >1.5m2 )chemotherapy after finishing first-line therapy(>21 days).
61955|NCT03700333|Drug|Pemetrexed therapy|accept Pemetrexed (500mg/m2,d1)chemotherapy after finishing first-line therapy(>21 days).
61956|NCT03700320|Drug|Atogepant 60 mg|Tablets containing atogepant 60 mg
61957|NCT03700320|Drug|Standard of Care (SOC) Migraine Prevention Medication|Medication recognized as safe and effective for the prevention of migraine
61958|NCT03700307|Procedure|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice.
61959|NCT03700294|Drug|ADCT-601|Intravenous (IV)
61960|NCT03700281|Behavioral|Messaging|The participants will receive influenza promotion emails, text messages, and U.S. mail from Sendero Health Plans.
61961|NCT03700281|Behavioral|Incentive|Participants will be eligible for a gift card to a local grocery store chain as an incentive for obtaining an influenza vaccine
61962|NCT03700268|Other|Manual intervention to programme Cochlear Implant electrodes|The Clinician test the 22 electrodes so that the patient is able to hear the language
61963|NCT03700255|Procedure|PickUpSimTM simulation training program|"The residents will take part in simulation sessions of 30 minutes duration. There will be 4 training sessions with seven simulation scenarios available. During the sessions, the following data will be collected for each scenario success or failure, reason for failure, time needed for completion, and oocyte retrieval rate. All scenarios will be repeated in the same conditions in the second week and data collected again. In the following 15 days, residents will start performing OPU, under direct supervision from senior physicians. For each patient, the resident will puncture one ovary. During the retrieval, the operator will specify the number of follicles punctured for each collected tube. The identity of the operator and the number of follicles punctured (per tube and in total) are noted on a separate sheet entitled the retrieval sheet. After the first month, residents will start performing all the OPUs, including both ovaries, supervised by the senior physicians."
61964|NCT03700242|Biological|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
61965|NCT03700242|Biological|HDCV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
61966|NCT03700242|Biological|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intramuscular
61967|NCT03700242|Biological|PVRV|Pharmaceutical form:Solution for injection Route of administration: Intradermal
61968|NCT03700229|Drug|Bortezomib|Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses
61969|NCT03700229|Drug|Rituximab|rituximab intravenously 500 mg for one dose
61970|NCT03700177|Drug|Dexamethasone|modified pectoralis block for breast surgery with ropivacaine combined with dexamethasone 8mg.
61971|NCT03700177|Drug|Placebo|modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
61972|NCT03700177|Drug|Ropivacaine Injection [Naropin]|30ml (=60mg) for modified pectoralis block (thoracic regional fascial plane block)
61973|NCT03700164|Other|Temperature|Water-perfused suit.
61974|NCT03700151|Behavioral|Treatment for Children with Severe Speech Sound Disorders|The intervention has two tasks, including syllable repetition tasks which requires participants to repeat nonsense syllables, and training of vocabulary or phrase with the application of Principle of Motor Learning.
61976|NCT03700138|Drug|NaCl 0,9%|The treatment (NaCl 0,9% 20 ml/kg) will be administered by perfusion every 4 weeks, with a total of 3 perfusions administered (W0, W4, W8).
61977|NCT03700125|Procedure|ECMO resuscitation|Extracorporeal Cardio-Pulmonary Resuscitation (ECPR) using ECMO within 30 minutes of cardiac arrest
61978|NCT03700112|Device|JUUL Virginia Tobacco flavored 5.0% ENDS|Virginia Tobacco Flavored 5.0% ENDS product is administered using a controlled method and adlibitum
61979|NCT03700112|Device|PMI iQOS Heat sticks|PMI IQOS Heat sticks is administered using a controlled method and ad-libitum
61980|NCT03700112|Device|Reynolds VUSE Solo ENDS - Original|Reynolds VUSE solo ENDS - Original is administered using a controlled method and ad-libitum
61981|NCT03700112|Device|Imperial MyBlu ENDS - Original|Imperial MyBlu ENDS- original is administered using a controlled method and ad-libitum
61982|NCT03700112|Device|Altria MarkTen ENDS - Bold Classic|Altria MarkTen ENDS - Bold Classic is administered using a controlled method and ad-libitum
61983|NCT03700112|Device|MLV PHIX ENDS - Original Tobacco|MLV PHIX ENDS - Original Tobacco is administered using a controlled method and ad-libitum
61984|NCT03700112|Device|NJOY Daily EXTRA ENDS - Rich Tobacco|NJOY Daily EXTRA ENDS - Rich Tobacco is administered using a controlled method and ad-libitum
61985|NCT03700112|Device|Altria Marlboro combustible cigarette - Red|Altria Marlboro combustible cigarette - Red is administered using a controlled method and ad-libitum
61986|NCT03700099|Drug|Docetaxel|Docetaxel 75 mg/m2 IV every 3 weeks, for 6-10 cycles.
61987|NCT03700099|Drug|Enzalutamide|Upon disease progression after treatment with docetaxel, patients will receive Enzalutamide 160 mg P.O. daily until disease progression or limiting toxicity.
61988|NCT03700086|Device|Disposable negative wound pressure device (PICO)|Application of a disposable negative wound pressure device for surgical site infection prevention.
61989|NCT03700086|Device|OPsite post-op visible standard sterile dressing|Application of a standard sterile wound dressing.
61990|NCT03700073|Other|Experimental group (GTVR)|Gait training with a robotic system (CL1Walker) combined with immersion in a Virtual Reality program
61991|NCT03700073|Other|Control group (GT)|Gait training with a robotic system (CL1Walker) alone.
61992|NCT03700034|Other|mHealth Integrate Model of Antenatal Care|Non-physician front line health workers (FHWs) will screen, detect, and refer PIH and GDM cases. Physicians will be trained to manage PIH and GDM. In the intervention clusters, pregnant women will receive enhanced antenatal care via a FHW, supported by an electronic decision support system. This will integrate the screening, detection, and referral/management of GDM and PIH with existing antenatal care services, prompt FHWs to provide routine care, and help them record and report data upwards. Non-physician FHWs will not prescribe treatments, but they will carry out all other duties including diagnosis, referral to an appropriate physician to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans.
61993|NCT03700021|Drug|Abatacept + csDMARD|Abatacept Time 0, Week 2, Month1,2,3, 4, & 5 IV administration on Abatacept (7 infusions). Abatacept will be initiated in concert with methotrexate or pre-existing csDMARD.
61994|NCT03700008|Diagnostic Test|Speech analysis tool|Using the speech analysis tool with recording 120 seconds of free speech and analysis of 200 content-free parameters of the speech including factor analytic process to compress the data to 5-10 core parameters.
61995|NCT03700008|Diagnostic Test|Conventional psychological measurements|Using well known and validated psychological measurements to identify the mental state of the participants.
61996|NCT03699995|Other|Confocal Microscopy|Undergo confocal microscopy
61997|NCT03699995|Procedure|Imaging Technique|Undergo MoleMapper imaging with iPhone
61998|NCT03699995|Procedure|Imaging Technique|Undergo Visiomed imaging
61999|NCT03699995|Drug|Lidocaine|Given SC
62000|NCT03699995|Procedure|Punch Biopsy|Undergo punch biopsy
62001|NCT03699995|Procedure|Shave Biopsy|Undergo shave biopsy
62002|NCT03699982|Other|Daily calorie target based on resting energy expenditure|"Resting Energy Expenditure will be determined using the Harris-Benedict formula and indirect calorimetry testing. Additionally, a 48 Hour Dietary Recall will be completed to estimate approximate caloric intake at baseline.~Participants will be instructed to increase their daily calorie intake based on the highest REE/caloric intake, whether by indirect calorimetry, the Harris-Benedict formula, or patient's estimated current caloric intake."
62003|NCT03699969|Radiation|Hypofractionated dose escalated VMAT|measure the local control, progression free survival and overall survival
62004|NCT03699956|Combination Product|RRx-001 + eLOOP Device|RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
62005|NCT03699956|Drug|Cisplatin/carboplatin plus etoposide|Standard of care platinum doublet chemotherapy
62006|NCT03699943|Procedure|CaverStem|
62007|NCT03699930|Device|tDCS|Transcranial Direct Current Stimulation
62008|NCT03699904|Drug|Valaciclovir|Participants will self-administer Valaciclovir 1 gram three times daily for 8 weeks.
62009|NCT03699904|Drug|Placebo capsules (containing Avicel blend)|Participants will self-administer two matching placebo capsules (containing Avicel blend) three times daily for 8 weeks.
62010|NCT03699891|Device|Fortilink IBF System with TETRAfuse Technology|Cervical and lumbar fusion
62011|NCT03699865|Other|Nicotine content|Study-supplied cigarettes will contain either intermediate or very low nicotine content
62012|NCT03699852|Radiation|Membracel and LED photobiomodulation|The volunteer will be positioned so that the skin graft donor area is accessible. In addition to Membracel®, a porous regenerating membrane of crystalline cellulose (conventional treatment), LED photobiomodulation will be performed in this group. The LED board will be covered with waterproof and transparent film and re-covered with sterile, waterproof and transparent film to prevent contamination. The LED board will cover the entire skin donor area and will be irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. The LED board will be applied in contact with the operative wound in the immediate postoperative period and applied through the Membracel® in the 1st, 3rd, 5th and 7th postoperative days.
62013|NCT03699852|Other|Membracel|The volunteers will be in the same condition. The only difference between the groups is that no LED photobiomodulation will be applied to the control group; only Membracel®, a porous regenerating membrane of crystalline cellulose (conventional treatment).
62014|NCT03699839|Biological|High-dose influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
62015|NCT03699839|Biological|MF59-adjuvanted influenza vaccine|The experimental intervention consists in an intramuscular injection of a MF59-adjuvanted trivalent inactivated influenza vaccine containing 15 µg of antigen per strain (Fluad®) or an intramuscular injection of trivalent inactivated influenza vaccine containing 60 µg of antigen per strain (Fluzone-HD®) and will be performed at day 0.
62016|NCT03699839|Biological|Standard intramuscular influenza vaccine|The control intervention consists in an intramuscular injection of one dose of VaxigripTetra®, the standard non-adjuvanted intramuscular influenza vaccine (as routinely done).
62017|NCT03699826|Device|TMS for tinnitus|Targeted stimulation to decrease tinnitus symptom severity.
62018|NCT03699813|Other|Comparison of two approaches to bleeding management|
62019|NCT03699800|Other|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
62020|NCT03699787|Other|Graphomotor intervention program|The graphomotor intervention program aims to promote the development and reinforcement, different skills involved in the learning process of handwriting and has a preventive character. It follows a bodily, playful, multisensory, exploratory (sensory integration) and neuromotor task training approach and focuses on the following intervention domains: segmental awareness, passive relaxation, trunk-limb dissociation, interdigital coordination, attention, planning, spatial organization/orientation and perception.
62021|NCT03699774|Drug|DS-8500a|DS-8500a is provided as three 25-mg tablets for oral administration
62022|NCT03699774|Drug|Rosuvastatin|Rosuvastatin is provided as a 10-mg tablet for oral administration
62023|NCT03699761|Procedure|Closure of the pelvic peritoneum|Closure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
62024|NCT03699761|Procedure|Nonclosure of the pelvic peritoneum|Nonclosure of the pelvic peritoneum after anastomosis for middle-low rectal caner.
62025|NCT03699748|Behavioral|Lay Health Worker Intervention|Patients randomized into the intervention will be assigned a lay health worker who will contact the patient to begin the intervention. The intervention includes: education on early advance care planning, documenting goals of care, assessing symptoms, and coordinating community services (such as home health, home visits, and home hospice). The intervention is provided along with usual care as provided by Unite Here Health and local oncologists.
62026|NCT03699748|Other|Usual Care|Usual care as provided by Unite Here Health and local oncologists
62027|NCT03699735|Device|Bolero B90-SP|Behind the ear Hearing device fitted with an individual ear mold to compensate a Hearing loss
62028|NCT03699722|Behavioral|Education + Activities|Format:Video; discussion; information handouts; facilitated referral
62029|NCT03699722|Behavioral|Information|Format: Information handouts
62030|NCT03699709|Behavioral|Budgeting, purchasing and cooking educational intervention|Receive culturally-tailored healthy food budgeting, purchasing, and cooking skills curriculum
62031|NCT03699696|Drug|Propofol|Induction of anesthesia prior to surgery with propofol
62032|NCT03699683|Other|Combined aerobic and resistance training program|
62033|NCT03699657|Device|DSM|Monopolar RFA using dual switching mode (DSM)
62034|NCT03699657|Device|SSM|Monopolar RFA using single switching mode (SSM)
62035|NCT03699657|Device|Separable clustered electrodes|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
62036|NCT03699644|Device|Spectral-Domain Optical Coherence Tomography (SD-OCT)|Each participant in this study will undergo Optical coherence tomography (OCT), a non-invasive imaging test of the eye, one time. OCT uses light waves to take cross-section pictures of the retina, which are generated using scattered light waves.
62037|NCT03699644|Device|Magnetic Resonance Imaging (MRI)|Each participant in this study will undergo a single Magnetic resonance imaging (MRI) scan, a scanning technique for creating detailed images of the human body. The scan uses a magnetic field and radio waves to generate images of the brain.
62038|NCT03699644|Device|Positron Emission Tomography (PET)|Each participant in this study will undergo a single Positron emission tomography (PET) scan of the brain. PET is a nuclear medicine functional imaging technique that is used to observe metabolic processes in the brain as an aid to the diagnosis of disease using the combination of a radioactive tracer, camera, and a computer.
62039|NCT03699644|Diagnostic Test|Comprehensive Ophthalmic Examination|Each participant in this study will receive one comprehensive eye examination which will be performed by a licensed ophthalmologist at the University of Michigan. This examination will include the assessment of the participant's visual acuity, a slit lamp examination which will look at the anterior and posterior tissues of the eye including the retina using various lights and lenses, and intraocular pressures.
62040|NCT03699644|Device|Fundus Photography|Each participant in this study will undergo fundus photography of each eye. Fundus photography involves the use of a retinal camera coupled with a low power microscope to capture photographs of the retina.
62041|NCT03699631|Drug|Tacrolimus|Tacrolimus will be given intravenously at a dose of 0.03 mg/kg/day starting Day -3. Subsequent dosing will be based on blood levels.
62042|NCT03699631|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
62043|NCT03699631|Drug|Tocilizumab|Tocilizumab will be administered intravenously (IV) at a dose of 8 mg/kg (maximum dose of 800 mg) once on the Day -1 approximately 24 hours prior to the estimated time of the hematopoietic cell infusion, and subsequently, on Day +100 (+/- 14 days, i.e., Days +86 to +114) post-alloHCT. The infusion will be administered over 60 minutes through a dedicated IV line and must not be administered by IV bolus.
62044|NCT03699618|Drug|Anti-VEGF|Standard of care treatment with anti-VEGF only
62045|NCT03699618|Other|Hemorrhage displacement + Anti-VEGF|Standard of care treatment with hemorrhage displacement (at investigators' discretion) followed by anti-VEGF injections
62046|NCT03699605|Other|VESMP|. The application contains following seven domains: spontaneous speech, comprehension, naming, reading, writing, imitation and automated speech. The programme was developed in Urdu language which contains different daily functional words, phrases and sentences. Treatment stimuli consisted of images of objects along with auditory sounds of person and actions cues. The voice output can operate by pressing the selected picture with index finger. Participants received 1-16 weeks of therapy using software of two domains with different difficulty levels. Specifically the programme included seven domains within the software comprising of eight 30-45 minutes sessions (4 days per week for total 16weeks). The measurement will be taken at 0 week (baseline) after 16 weeks.
62047|NCT03699605|Other|Traditional Therapy|, All subjects participated in an traditional therapy group in routine and received MIT for 4 months of periods with three sessions per week to improve language skills.
62048|NCT03699592|Behavioral|Reach Home and Read Toolkit|The toolkit currently includes one age-appropriate book along with a set of educational pamphlets explaining the importance home literacy. These educational materials focus on appropriate literacy milestones and descriptions of how parents can engage with their children around books. In addition, we will create an information sheet outlining zipcode-specific community literacy resources, including location and information on how to access the library, where to obtain low-cost books, and a schedule of literacy promotion activities in their community (e.g. community reading sessions). All materials will also be translated into Spanish by a certified interpreter, and will be reviewed to ensure that they are written at a fifth grade reading level. Additionally, EDCI families receiving this intervention will also receive an additional new book at each home visit conducted during the study period.
62049|NCT03699566|Other|Assessment of Respiratory Muscle Strength|The maximal voluntary inspiratory (PImax) and expiratory (PEmax) pressure measurements of the subjects were performed using Cosmed Pony FX model (Italy 2001) while the subjects were in the sitting position with a nose clip.
62050|NCT03699566|Other|Spirometer|Spirometric measurements were conducted with Cosmed, Pony FX (descopt spirometer- Italy 2001) spirometer using a nose clips while the subjects were in 90 degree relaxed sitting position.
62051|NCT03699566|Other|Trunk Muscles Endurance Tests|Trunk muscle endurance of the subjects was measured using four different tests (Side Bridge Test- SBT, Prone Bridge Test- PBT, Flexor Endurance Test- FET, Sorenson Test- ST).
62052|NCT03699553|Behavioral|LARKSPUR; Online Positive Emotions Skills for Individuals with Chronic Musculoskeletal Pain|8 positive emotion skills taught over 5-6 weeks to help individuals cope with chronic pain and stress.
62053|NCT03699553|Behavioral|Emotion Reporting Control Group|Attention matched control condition, participants will report their daily emotions over 5-6 weeks online.
62054|NCT03699540|Drug|Marijuana|Experimental, non-therapeutic administration of active and inactive marijuana dose(s)
62055|NCT03699540|Drug|Alcohol|Experimental, non-therapeutic administration of active and inactive alcohol dose(s)
62056|NCT03699527|Behavioral|Multiple questionnaires administered|This is an observational trial
62057|NCT03699514|Device|Brain Network Activation (BNA™) technology|"The BNA™ technology was developed and is utilized by ElMindA Ltd. The BNA Analysis System is cleared for use by qualified medical professionals for the post hoc statistical analysis of the human electroencephalogram (EEG), utilizing evoked response potentials (ERP'). This device is indicated for use in individuals 14 to 24 years of age. The BNA Analysis System is to be used with the auditory oddball task only."
62058|NCT03699501|Other|Questionnaires|"A validated oral health-related quality of life self-assessment questionnaire: the GOHAI~A validated oral health-related quality of life self-assessment questionnaire to be validated: SOHP~A validated depression scale: the Beck scale~A self-assessment questionnaire for oral health coping to be validated: the SCOOHP~A validated self-assessment questionnaire for coping: The Brief cope)"
62059|NCT03699501|Procedure|Oral examination|"An evaluation of dental health using the CAO index~An evaluation of oral hygiene with the IHO-S index"
62060|NCT03699501|Other|questionnaires (test-retest)|SCOOHP and SOHP questionnaires
62061|NCT03699488|Behavioral|psychotherapy via asynchronous message|Behavioral psychotherapy delivered by asynchronous message using the Talkspace application
62062|NCT03699475|Biological|rivogenlecleucel & rimiducid|Biological: T cells transduced with caspase 9 safety switch
62063|NCT03699475|Drug|rimiducid|administered to inactivate rivogenlecleucel in the event of GVHD
62064|NCT03699475|Drug|Cyclophosphamide|GVHD prophylaxis
62065|NCT03699462|Drug|Plasma solution-A injection|The group receiving balanced crystalloid solution (Plasma solution-A injection, CJ Pharma, South Korea) during surgery
62066|NCT03699462|Drug|5% Albumin|The group receiving 5% albumin (Albumin 5% inj, Green cross, South Korea) during surgery
62067|NCT03699449|Drug|olaparib+cediranib combination therapy|Cediranib (30mg p.o. qd) + Olaparib (200mg p.o. bid) until disease progression
62068|NCT03699449|Drug|durvalumab + olaparib combination therapy|Durvalumab (1500mg i.v. every 4 weeks starting on week 5 day1 for up to 12 months) + Olaparib (300mg p.o. bid) until disease progression
62069|NCT03699449|Drug|durvalumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 12 months) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin(PLD) up to 6 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
62070|NCT03699449|Drug|durvalumab + tremelimumab + chemotherapy treatment|"Durvalumab (1500mg i.v. every 4 weeks for up to 12 months) + Tremelimumab (75mg i.v. every 4 weeks for up to 4 doses) + non-platinum-based standard of care chemotherapy (weekly paclitaxel, topotecan, or Pegylated liposomal doxorubicin (PLD) up to 4 cycles)~Chemotherapy regimen:~Weekly Paclitaxel 80mg/m2 (day 1,8,15,22 every 4 weeks), PLD (40mg/m2 on D1 every 4 weeks), topotecan (4mg/m2 on D1,8,15 every 4 weeks)"
62071|NCT03699436|Other|Electrotherapy with Galvanic Current|The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
62511|NCT03695887|Drug|Nitrous Oxide Inhalant Product|Nitrous Oxide Inhalant Product
62072|NCT03699436|Other|Control without Electric Stimulation Therapy|The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
62073|NCT03699423|Drug|0.01% atropine eye drops|0.01% atropine sulphate
62074|NCT03699423|Drug|0.02% atropine eye drops|0.02% atropine sulphate
62075|NCT03699423|Drug|0.03% atropine eye drops|0.03% atropine sulphate
62076|NCT03699410|Radiation|Neoadjuvant radiotherapy|Radiotherapy with total dose of at least 50 Gy on the tumor (cT) and the involved nodes (cN+) and with standard fractionation (1.8 Gy/fraction), 5 days/week.
62077|NCT03699410|Drug|Neoadjuvant chemotherapy|Oral Capecitabine, at the standard dose of 825 mg/m2 twice daily, concomitant to radiotherapy.
62078|NCT03699410|Procedure|Radical surgery|The time point of surgery is usually dependent on surgeon's and institutional habits and lies within 6 to 12 weeks after the end of nCRT. Surgeons participating in this study will be asked to operate patients on the 10th week after the end of nCRT.
62079|NCT03699397|Diagnostic Test|Dry electrode EEG|A single dry electrode electroencephalography (EEG) will be performed in each patient that is included in this study. To do this, the investigators will use the WaveguardTM dry electrode EEG cap and compatible eegoTM amplifier, developed by ANT Neuro B.V. Netherlands and both CE marked as medical devices in the European Union (see appendices 1 and 2). Both products will be used within the intended use as described in the user manuals. The dry electrode cap is put on the patients head and records the EEG signal for several minutes; the amplifier is used to amplify the EEG signal and reduce artefacts.
62080|NCT03699384|Drug|Azacitidine|AZA 75 mg/m^2 SC or IV D 1-7 28 day cycle x 1
62081|NCT03699384|Drug|Avelumab|Avelumab 10mg/kg IV D1, D15, 28d cycle Until progression or MRD If MRD-, tx x 1 yr or go to allo SCT
62082|NCT03699371|Procedure|Early Supplemental Parenteral Nutrition|Intervention group: would receive EN reaching up to 20 % of daily nutritional requirements and early (on first day of stay in ICU) provision (of up to 80%) of protein (2 g/kg/ day or in case of CRRT 2,5 g/kg/ day) and caloric (15-20 kcal/kg/day) needs in SPN that would be continued until 7th day of stay in ICU. Central venous catheter placement would not be assessed as a part of intervention due to the fact that it is a part of routine medical activities performed during admission to ICU.
62083|NCT03699345|Device|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
62084|NCT03699332|Drug|Indium-111-DOTA-Labetuzumab-IRDye800CW injection|Tracer injection
62085|NCT03699332|Radiation|SPECT/CT scan|Abdominal and thoracic SPECT/CT scan.
62086|NCT03699332|Procedure|CRS extended with dual-modality imaging|cytoreductive surgery will be performed extended with the use of dual-modality imaging.
62087|NCT03699319|Drug|CPI 613|CPI-613, 500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port on days 1 and 3, every 2 weeks.
62088|NCT03699306|Procedure|NG tube insertion method|a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
62089|NCT03699293|Drug|celecoxib 200mg capsule|celecoxib 200mg twice a day for 4 weeks
62090|NCT03699293|Drug|naproxen sodium 550mg tablet|naproxen sodium 550mg twice a day for 4 weeks
62091|NCT03699293|Drug|Aspirin 81mg tablet|81mg aspirin for 4 weeks in the run-in period, and for 8 weeks during treatment and crossover period
62092|NCT03699280|Other|Virtual Reality|Oculus Go VR device
62093|NCT03699267|Other|US-guided Bilateral TAP block|
62094|NCT03699254|Drug|Valganciclovir|"Valganciclovir is a L-valyl ester of ganciclovir that exists as a mix of 2 diastereomers. After administration, both are converted to ganciclovir by esterases. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
62095|NCT03699254|Drug|Ganciclovir|"Ganciclovir is a synthetic analogue of 2'-deoxyguanosine, it inhibits replication of cytomegalovirus.~In CMV-infected cells it's phosphorylated (phosphorylation is dependent on the viral kinase and occurs preferentially in virus-infected cells). Ganciclovir activity is due to inhibition of viral DNA synthesis by ganciclovir triphosphate."
62096|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 30ug, Intramuscular administration
62097|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 100ug, Intramuscular administration
62098|NCT03699241|Biological|BG505 SOSIP.664 gp140, adjuvanted|Dosage of 300ug, Intramuscular administration
62099|NCT03699241|Biological|Placebo|Tris-NaCl Diluent
62100|NCT03699215|Drug|Levosimendan|Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension <90 mmHg.
62101|NCT03699215|Drug|Placebos|continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
62104|NCT03699189|Behavioral|Immediate ANAIS|"ANAIS is a structured therapeutic education programme aimed at providing the patients with the necessary skills to manage their diabetes independently and confidently. The programme particularly promotes dietary freedom, in an intensive insulin regime, by enabling effective carbohydrate counting and accurate prandial insulin dose adjustment and avoiding hypoglycaemia.~ANAIS was organised as a five day (Monday to Friday), seven-hour, outpatient programme using principles of adult education, with explicit learning objectives, in a group setting."
62105|NCT03699176|Drug|Vilaprisan (BAY1002670)|2 mg, once daily, oral
62107|NCT03699163|Diagnostic Test|Breath sample|Patients will be asked to give a sample of their breath, using the ReCIVA breath testing device. This involves performing tidal breathing whilst wearing a face mask for approximately 5 minutes. Breath (500mls at a flow rate of 200mls/min) is passed over thermal desorption tubes which absorb compounds of interest.
62108|NCT03699137|Other|No interventions|No interventions
62110|NCT03699098|Diagnostic Test|TSH, T3, T4 and thyroid gland DVH|measuring thyroid functions and DVH parameters of thyroid gland
62111|NCT03699085|Behavioral|ED-LINC|ED-LINC will include 1) A brief negotiated interview at the bedside with an emphasis on motivation to link to services 2) Pharmacotherapy including a discussion of opioid safety, take-home naloxone and initiation of buprenorphine from the ED for participants that are interested and eligible; 3) Longitudinal care management which will proceed for 3-months; and 4) Care plan in the Emergency Department Information Exchange (EDIE) system. This will be coupled with a study cell phone and a weekly supervisory case conference which is consistent with collaborative care principles.
62112|NCT03699072|Device|DermaRep™ Wound Contact Device|Treatment of venous leg ulcers once weekly for 8 weeks along with standard of care dressings
62113|NCT03699059|Other|ExeRTiOn|REHAB-online is an online weight gain prevention tool comprising of physical activity advice, dietetic advice, self-monitoring and tracking and behavioural change techniques. This resource is specific to kidney transplant patients and has been created by the research steering group including patient representation. During this study participants (both HCPs and patients) will have a one-off study visit to test and evaluate the online intervention.
62114|NCT03699046|Procedure|Subchondroplasty and Knee Arthroscopy|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The bone marrow lesion(s) will be located using pre-operative MRI combined with fluoroscopy (intra-operative X-ray) and a small, drillable AccuPort® Delivery Cannula will be placed in the appropriate position. The cannula will then be drilled into the bone marrow lesion(s) and a flowable, synthetic, calcium phosphate bone substitute (AccuFill® Bone Substitute Material, Zimmer Biomet) will be injected into the lesion(s). The calcium phosphate bone substitute will then harden, improve the structural integrity of the damaged subchondral bone, and will gradually be resorbed and replaced with new bone.
62115|NCT03699046|Procedure|Knee Arthroscopy Alone|Knee arthroscopy is a surgical procedure that involves the orthopaedic surgeon making small incisions in the knee and then inserting a small camera into the joint. Following the insertion of the camera, multiple procedures can be completed to treat a number of different conditions such as repair or partial/complete removal of the meniscus, debridement, lavage, removal of a loose body among others.
62116|NCT03699046|Biological|Subchondroplasty|Subchondroplasty® (SCP®) is a procedure performed along with minimally-invasive arthroscopy. The specific biological component of the procedure involves the injection of the AccuFill® Bone Substitute Material (Zimmer Biomet), which is a a flowable, synthetic, calcium phosphate bone substitute, into the bone marrow lesion(s).
62117|NCT03699033|Radiation|2.5 Gy/fraction|Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel
62118|NCT03699033|Drug|Carboplatin|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
62119|NCT03699033|Drug|Paclitaxel|"The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively.~Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation."
62120|NCT03699020|Behavioral|Acceptance and Commitment Therapy (ACT)|Empirically based behavioral intervention that encourages acceptance of circumstances with commitment and behavioral change strategies to improve psychological flexibility.
62121|NCT03699020|Other|Chronic Pain Education|Education materials about living with chronic pain developed by Weill Cornell Universitys Translational Research Institute for Pain in Later Life
62122|NCT03699007|Behavioral|Graded Exposure Therapy (GET Living)|The protocol consists of 12 interdisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Phase I-III are conducted with the psychologist, physical therapist, adolescent, and parent (as developmentally appropriate). Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment.
62123|NCT03699007|Behavioral|Typical Pain Management (TPM)|The protocol consists of 12 multidisciplinary sessions, 1-hour each, delivered twice a week, for an average of 6 weeks. Sessions will alternate between psychological CBT sessions and Physical Therapy sessions. Patient and parent will complete daily diaries and patients will wear the Actigraph throughout the duration of treatment. The parent will also participate in 3 additional parent-only sessions with the psychologist to address parental coping skills.
62124|NCT03698994|Other|Pharmacokinetic Study|Ancillary studies
62125|NCT03698994|Drug|Ulixertinib|Given PO
62126|NCT03698981|Behavioral|Mothers Moving towards Empowerment (MME)|"MME integrates 3 components: 1) psychoeducation regarding causes, transmission, and treatment of HIV re how adherence to ART and antenatal care acts to promote health for HIV+ women and PMTCT82,83. We will emphasize ART adherence spanning into PP as a maternal duty to raise a healthy child; 2) challenging stereotypes of HIV+ women, such as promiscuity, that threaten core aspects of being a good woman and hinder treatment adherence; 3) coping skills for HIV-related discrimination, i.e., rejection or abandonment by male partners leading to discontinuing treatment adherence and impacts on raising children."
62127|NCT03698968|Device|Negative Pressure Wound Therapy|Single use disposable negative pressure system. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 1 week.
62128|NCT03698955|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following the vegan diet.
62129|NCT03698955|Other|Mediterranean Diet|Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
62512|NCT03695887|Drug|Placebo|Inactive comparator
62130|NCT03698942|Device|Reading of Automated Breast Ultrasound in conjunction with Screening Mammography|Reader performance when SoftVue automated breast ultrasound (SV) and digital screening mammography (DM) are combined, compared to screening mammography alone.
62131|NCT03698929|Other|Dietary Effect of Cholesterol - Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
62132|NCT03698929|Other|Dietary Effect of Cholesterol - Non-Egg Phase|After the study entry, you will be assigned by chance, like the flip of a coin, to one of two groups. You will have an equal chance of being assigned to either group. Each group will be asked to consume baked goods daily. The two groups will consume the same baked goods, but in a different order. Each week, you will be given a week's worth of baked goods.
62133|NCT03698916|Drug|Celecoxib cream 8%|transdermal delivery of 8% Celecoxib
62134|NCT03698903|Behavioral|Take a STAND 4 Health|The 4-week is comprised of several elements, including: (1) an in-person introductory session to acquaint the individuals with all intervention elements, customize to their preferences and describe the mHealth component of the intervention; (2) a website that will provide individualized feedback over time on the participant's scheduled breaks, sedentary time reduction, and sedentary patterns; (3) texts to serve as prompts and alert the participant to stand or move, with a goal of a 60 minute reduction per day, which are customized to the individual's schedule, personal preference and sedentary profile; and (4) two coaching phone calls to trouble shoot and problem solve implementation of the intervention.
62135|NCT03698890|Device|Network-based home blood pressure monitor|A network-based home blood pressure monitor will be loaned to patients in the intervention group, who will be asked to monitor their blood pressure at least once every week using the network based home blood pressure monitor, which automatically uploads measured blood pressure readings to the portal for care managers (CM) to review blood pressure readings and provide updates to the patient on blood pressure control. If a patient's blood pressure is elevated, the CM can titrate medications over the phone and provide follow up tele-consultation and necessary treatment.
62136|NCT03698877|Diagnostic Test|Brain Natriuretic Protein (BNP) and Procalcitonin (PCT) blood tests|"For patients with suspected infection, PCT levels will be drawn at the time of suspected infection and again at the start of the next HD treatment.~For patients with shortness of breath, PCT and BNP levels will be drawn at the time of the complaint and again at the start of the next HD treatment."
62137|NCT03698864|Drug|PCS499|PCS499 900mg twice a day with food
62138|NCT03698851|Device|Guidor® and Guidor easy-graft® CRYSTAL|A compound of biphasic calcium phosphate, 60 % hydroxyapatite and 40 % beta-tricalcium phosphate. The beta-tricalcium phosphate component completely resorbs via physiological dissolution in 5-15 months, while the interconnected hydroxyapatite remains embedded in the implantation site and forms an integrated long term osteoconductive scaffold with new bone.
62139|NCT03698851|Device|Guidor® and Guidor easy-graft® CLASSIC|Phase-pure beta-tricalcium phosphate that offers complete resorption via physiological dissolution in 5-15 months. This material has been used in oral surgery for more than 25 years and there are extensive research available on it.
62140|NCT03698838|Device|McDESPOT|MRI sequence, mcDESPOT (multicomponent driven equilibrium potential of T1 and T2) that utilizes a computer model that takes T1 and T2 sequences and derives a quantitative value for the myelin content in the myelin sheath
62141|NCT03698825|Drug|TEW-7197|TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
62142|NCT03698812|Combination Product|Colonoscope|take off specimen
62143|NCT03698786|Behavioral|Exercise|Participants will be required to complete two, 8-hours trials (exercise & control) in a randomised order, preceded by 2 hours of preliminary testing (baseline) with no more than 14 days between conditions.
62144|NCT03698773|Other|Access to routine information|Access to routine pain-control information
62145|NCT03698773|Other|Access to website|Access to informational website: thepainlesspush.com
62146|NCT03698760|Diagnostic Test|Olfactory test|"Olfactory test:~All fragrances tested are kept in an airtight case protected from cold and heat.~The test is done on a tablet and the data will be automatically saved. The first screen is about the administrative data, sex and age of the subject. Olfactory test: six odors among the fourteen are proposed in a randomized way."
62147|NCT03698747|Device|McDESPOT|myelin specific MRI sequence (mcDESPOT) added to standard MRI sequence
62148|NCT03698734|Drug|Evening primrose oil(EPO)|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of EPO( 1000mg) in addition to misopristol
62149|NCT03698734|Drug|Placebo - Cap|primiparous women with missed abortion between(13 to 24 weeks) will receive 1 capsule of placebo in addition to misopristol
62150|NCT03698721|Procedure|Transurethral Resection of Prostate|Transurethral resection of the prostate is a urological operation used to treat benign prostatic hyperplasia (BPH). It is performed by visualising the prostate through the urethra and removing tissue by electrocautery or sharp dissection with a resectoscope. This is considered the most effective treatment for BPH. This procedure is done with spinal or general anaesthetic. A triple lumen catheter is inserted through the urethra to irrigate and drain the bladder after the surgical procedure is complete. Outcome is considered excellent for 80-90% of BPH patients.
62151|NCT03698708|Behavioral|CARES Intervention|A 12-week group-based telemedicine intervention to treat depression in parents/caregivers of children with T1D using a cognitive-behavioral approach.
62152|NCT03698695|Drug|THN 201|THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
62153|NCT03698695|Drug|Donepezil|Donepezil 5 mg/d and Mefloquine placebo
62154|NCT03698695|Drug|Placebo|Donepezil placebo and Mefloquine placebo
62155|NCT03698682|Drug|Levofloxacin 500mg|One tablet per day for 7 days.
62189|NCT03698409|Other|Preserved saline in reconstitution of Botox|The intervention consists of using 4 ml of preserved saline for the reconstitution of OnabotuliniumtoxinA prior to its use in subjects with chronic migraine.
62190|NCT03698396|Biological|Allogenic Islet Cell Transplantation|Transplantation of allogenic islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
63079|NCT03691467|Device|immediate dental implant|immediate dental implant placement in freshly extracted socket.
62156|NCT03698669|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|TOPPS involves an initial face-to-face meeting followed by regular phone meetings. In preliminary research, patients found this format to be convenient. The initial meeting includes the patient, the BHS and the PCP; the PCP then regularly receives treatment notes from the BHS. Also, the PCP, who has a longitudinal relationship with the patient, is encouraged to further reinforce TOPPS goals. After each TOPPS session, the BHS also mails a copy of the clinical note to the patient. Additionally, each participant is provided with a workbook that reviews the key elements of each treatment session and provides exercises for at-home practice of skills.
62157|NCT03698669|Behavioral|Health Education (HE)|After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity. This control condition was accepted by our participants in preliminary studies; it does not directly target functional impairment, and participants do not set tailored goals relating to their own values. The BHS will communicate with the PCP only if a participant shows signs of clinical deterioration.
62158|NCT03698656|Behavioral|Spiritual Interview|Three patient interviews (45 to 60 minutes) will be conducted by the study nurse at the beginning of the study and approximately 2 and 4 month later, according to the program of the medical care. Each interview will be conducted according the active listening method of Carl Rogers.
62159|NCT03698630|Drug|Prednisolone Sodium Phosphate|Prednesol 5mg Tablets (Phoenix Labs Ltd). Pink, circular, flat, bevel-edged scored tablets containing 5 mg of prednisolone as prednisolone sodium phosphate.
62160|NCT03698630|Drug|Dexamethasone|"Dexamethasone 2 mg tablets (Organon Ireland Ltd). Round, 6 mm, flat, white tablet with the code XC/8 engraved on one surface and Organon* on the other containing 2 mg dexamethasone."
62161|NCT03698617|Drug|HSK3486|For induction of general anesthesia In dose escalation cohort: Starting from 0.4mg/kg, up-titration dose by 0.1mg/kg until 0.8mg//kg or down-titration dose by 0.1mg/kg until 0.1mg/kg based on the efficacy and safety results.
62162|NCT03698617|Drug|Propofol|For induction of general anesthesia
62163|NCT03698604|Procedure|Hysterectomy|Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
62164|NCT03698591|Device|Transcranial magnetic stimulation task|Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
62165|NCT03698591|Device|Sham transcranial magnetic stimulation task|A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
62166|NCT03698578|Other|combat fight|Jiu-jitsu heating with light intensity was used for 5 minutes. The simulated fight protocol occurred in accordance with the rules of the Brazilian Confederation of Sports Jiu-Jitsu, excluding any types of finalization. In these cases, the athletes were separated and oriented to return immediately. Thus, maximum effort was advocated as well as, similar time of activity for all
62167|NCT03698565|Other|Nerve stimulation of the ulnar nerve|"The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes."
62168|NCT03698552|Biological|ADCT-602|Starting dose of ADCT-602: 30 μg/kg given by vein.
62169|NCT03698539|Behavioral|hand gestures|We observe the use of spontaneous hand gestures in both groups.
62170|NCT03698526|Device|Samsung Gear VR, Galaxy S8, Applied VR App|Virtual Reality Experience
62171|NCT03698513|Drug|BMS-986177|BMS-986177 capsule
62172|NCT03698513|Drug|Aspirin|Aspirin tablet
62173|NCT03698513|Drug|Clopidogrel|Clopidogrel tablet
62174|NCT03698513|Drug|Placebo (for BMS-986177)|BMS-986177 placebo match capsule
62175|NCT03698500|Other|Removal of blood|10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw
62176|NCT03698487|Other|Intervention|Pharmacist-led medication optimization intervention using an electronic tool (DBI Calculator©). The DBI Calculator is an electronic tool which calculates a score from the medication reconciliation list (medications taken prior to admission). It also creates a 'DBI report' which includes their full medication list, their DBI score, an explanation of the risks associated with their DBI score and highlighted medications which are contributing to their DBI score (that is, high risk medications which may be suitable for deprescribing).
62177|NCT03698474|Drug|Natrium picosulfate / Magnesium citrate|bowel preparation formula
62178|NCT03698474|Drug|Polyethylene glycol / Ascorbic acid|bowel preparation formula
62179|NCT03698474|Drug|Natrium/ Kalium/ Magnesium sulfate|bowel preparation formula
62180|NCT03698461|Drug|Atezolizumab|"1200mg IV on day1 before start of cycle 'atezolizuamb, bevacizumab + FOLFOX(Oxaliplatin, Levoleucovorin, 5-FU')~840mg IV D1 of C1-12 (Cycle: every 2 weeks)"
62181|NCT03698461|Drug|Bevacizumab|5mg/kg IV D1 of C1-12 (Cycle: every 2 weeks) at least 5 minutes after completion of atezolizumab
62182|NCT03698461|Drug|Oxaliplatin|85mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
62183|NCT03698461|Drug|Levoleucovorin|200mg/m2 IV D1 of C1-12 (Cycle: every 2 weeks)
62184|NCT03698461|Drug|5-FU|"5-FU Bolus: 400mg/m2 IV bolus D1 of C1-12 (Cycle: every 2 weeks)~5-FU infusion: 2400mg/mg continuous IV infusion over 46hours D1-3 of C1-12 (Cycle: every 2 weeks)"
62185|NCT03698448|Drug|OligoG Dry powder for inhalation|10 capsules Dry Powder for Inhalation, BID
62186|NCT03698435|Drug|Ganciclovir|Intravenous ganciclovir + TDM
62187|NCT03698435|Drug|Valganciclovir|Oral valganciclovir + TDM
62188|NCT03698422|Diagnostic Test|Blood and urine samples|Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
62191|NCT03698383|Drug|Trastuzumab biosimilars(Herzuma), Gedatolisib|"Trastuzumab biosimilar: Intravenously administered on Day 1 of every 21 day cycle at a dose of 6mg/kg (loading dose 8mg/kg at 1C)~Gedatolisib: Intravenously administered on Day 1, 8 and 15 of every 21 day cycle at a dose of 180mg"
62192|NCT03698370|Drug|Gallium Ga 68 DOTA-NeoBOMB1|Administered intravenously (IV)
62193|NCT03698370|Device|Gallium Ga 68 PSMA-R2|Administered intravenously (IV)
62194|NCT03698357|Behavioral|interactive video balance-based exercise|Interactive video balance-based exercise :10 minutes of warm up exercise, 30 minutes of Interactive video balance-based exercise and 5 minutes of cool down exercise.
62195|NCT03698357|Behavioral|Conventional physiotherapy|conventional physiotherapy: 10 minutes of warm up exercise, 30 minutes conventional physiotherapy and 5 minutes of cool down exercise. Conventional physiotherapy contains rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on.
62196|NCT03698344|Other|Biodiesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute biodiesel exhaust via mask.
62197|NCT03698331|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
62198|NCT03698331|Drug|Placebo oral capsule|non-active dosage form
62199|NCT03698318|Dietary Supplement|Tested product n°1|1 capsule (26% of gingerol/shogaol in 100 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
62200|NCT03698318|Dietary Supplement|Tested product n°2|1 capsule (38.6% of gingerol/shogaol in 74.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
62201|NCT03698318|Dietary Supplement|Tested product n°3|2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
62202|NCT03698318|Dietary Supplement|Tested product n°4|1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
62203|NCT03698318|Dietary Supplement|Tested product n°5|6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
62204|NCT03698305|Drug|ASP5354|Intravenous
62205|NCT03698305|Drug|Placebo|Intravenous
62206|NCT03698292|Drug|Itopride|Prokinetic Drug
62207|NCT03698292|Drug|Metoclopramide 10mg|Prokinetic Drug
62208|NCT03698279|Biological|QIV-HD, 30 µg HA/strain/dose|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
62209|NCT03698279|Biological|QIV-HD, 45 µg µg HA/strain/dose|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
62210|NCT03698279|Biological|QIV-HD 60 µg HA/strain/dose|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
62211|NCT03698279|Biological|Unadjuvanted QIV-SD, 15 µg HA/strain/dose|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
62212|NCT03698279|Biological|Adjuvanted TIV, 7.5 µg HA/strain/dose|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
62213|NCT03698266|Procedure|Needle knife fistulotomy|A needle knife fistulotomy uses a tiny knife to cut directly into the ampulla to gain access to the biliary system in patients undergoing ERCP
62214|NCT03698253|Drug|Regorafenib|Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle
62215|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA6)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2
62216|NCT03698253|Genetic|UGT1A1 genotyping (TA6/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2
62217|NCT03698253|Genetic|UGT1A1 genotyping (TA7/TA7)|The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2
62218|NCT03698240|Behavioral|Mindfulness-based program|The program includes 9 mindfulness-based sessions for children and their parents.
62219|NCT03698227|Drug|Olaratumab|iv infusion
62220|NCT03698227|Drug|Dexrazoxane|iv infusion
62221|NCT03698227|Drug|Doxorubicin|iv infusion
62222|NCT03698214|Other|reversed shock index < 1|Among patients with isolated TBI, those with an RSI < 1 had higher mortality
62223|NCT03698214|Other|reversed shock index ≥ 1|Among patients with isolated TBI, those with an RSI ≥ 1 had lower mortality
62224|NCT03698201|Other|Non-interventional|Translational, observational study
62225|NCT03698188|Procedure|Injectable platelet-rich fibrin|A blood sample will be drawn from the patient, centrifuged at 700 rpm for 3 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
62226|NCT03698188|Procedure|Platelet-rich plasma|A blood sample will be drawn from the patient, centrifuged at 3000 rpm for 10 minutes and the upper yellow fluid will be collected by a plastic syringe, avoiding the inclusion of the red blood cells underneath, and will be introduced within the root canal.
62227|NCT03698175|Behavioral|Three good things exercise|Participants are asked to remember each evening three things that went well during their day and to write them down in a journal including a short explanation of why they think each of them has happened.
62228|NCT03698175|Behavioral|Placebo exercise|Participants are asked to briefly recall a childhood memory (no further specification) and to write it down including a short explanation why they think it has happened.
62229|NCT03698162|Device|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo STAR DCE-MRI
62230|NCT03698162|Drug|Bevacizumab Injection|Bevacizumab will be give to participants who have recurrent high-grade glioma as part of standard of care.
62231|NCT03698149|Device|PMT/Blackrock Combination Device|PMT Subdural Cortical Electrodes/Blackrock NeuroPort Array and NeuroPort System
62265|NCT03697837|Behavioral|Parent Management Training|The online digital parent training (DPT) program consists of 8 self-guided courses that take approximately 10 minutes to complete and include text and animated parent-child simulations. The courses are designed to closely parallel the content of existing evidence-based parent management training approaches that exist in numerous parenting books.
62232|NCT03698136|Other|Stimulation of denervated muscles|The study investigates the effect of electrical stimulation on denervated muscles in the forearm and hand regarding muscle structure and thickness. The study will be performed on tetraplegics who have either paralysed the wrist extensor, the short thumb spreader or the muscle between the thumb and index finger.The study lasts 12 weeks and consists of an ultrasound examination at the beginning and end of the study and an intermediate stimulation phase.The stimulation takes place either during an inpatient stay or at home for 12 weeks, 5 times a week 33 minutes.
62233|NCT03698123|Other|Dietary Modification|Participants will be provided with meals, snacks and drinks with specific macronutrient compositions and encouraged to only eat and drink study meals, snacks and drinks and to avoid eating after 10:00 hours.
62234|NCT03698110|Behavioral|Intervention Group|PUEDES program included eight hours in groups and activities to practice at home.
62235|NCT03698097|Other|patient satisfaction survey|Patient survey completed in a paper or survey monkey based internet version accessible via a QR code or link
62236|NCT03698084|Procedure|venepuncture|sample collection for analysis
62237|NCT03698084|Procedure|nasopharyngeal swab|sample collection for analysis
62238|NCT03698071|Biological|blood sample|30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
62239|NCT03698071|Biological|urine sample|6 ml
62240|NCT03698058|Dietary Supplement|Toddler milk|Commercially available toddler milk
62241|NCT03698045|Drug|PRO-143 Ophthalmic Solution|PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
62242|NCT03698032|Dietary Supplement|Water|Participants will consume water only
62243|NCT03698032|Dietary Supplement|1.5 oz Pistachios|Participants will consume water plus 1.5 oz of pistachios as the intervention
62244|NCT03698032|Dietary Supplement|3.0 oz Pistachios|Participants will consume water plus 3.0 oz of pistachios as the intervention
62245|NCT03698019|Biological|Pembrolizumab|Given IV
62246|NCT03698019|Procedure|Therapeutic Conventional Surgery|Undergo surgery
62247|NCT03698006|Drug|Ropivacaine 0.5% Injectable Solution|Tibial nerve block with 10ml of Ropivacaine 0.5%
62248|NCT03698006|Drug|Ropivacaine 0.2% Injectable Solution|Infiltration with 25ml of Ropivacaine 0.2% in the posterior knee capsule
62249|NCT03697993|Drug|Fosfomycin tromethamine|Administered orally as 3-gram single-dose sachet into 3-4 ounces (1 / 2 cup) of cool water; each dose must be taken immediately after dissolving in water. Hot water should not be used to dissolve fosfomycin. It may be taken either with or without food for normal kidney function. If Creatinine Clearance (CrCl) is less than 20 mL/min, fosfomycin should be taken as 3 grams every other day.
62250|NCT03697993|Drug|Levofloxacin|750 mg is administered orally as one tablet once daily with or without food for normal kidney function. If Creatinine Clearance (CrCl) is 20-49 mL/min, 750 mg should be taken every other day. If on subsequent testing post-randomization, the Creatinine Clearance (CrCl) is less than 20 mL/min, followed by the dose is 500 mg every other day.
62251|NCT03697980|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
62252|NCT03697967|Procedure|Delayed cord clamping|Umbilical cord clamped at 2 minutes
62253|NCT03697954|Device|full stage implantation of sacral neuromodulation|full stage implantation of sacral neuromodulation for overactive bladder and urge incontinence
62254|NCT03697941|Procedure|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device|Percutaneous arteriotomy closed using a plug-based arteriotomy closure device (MANTA, Essential Medical Inc., Malvern, Pennsylvania).
62255|NCT03697941|Procedure|Surgical cut-down and arterial puncture under direct vision|Surgical cut-down and arterial puncture under direct vision.
62256|NCT03697928|Other|Exercise metabolism|Participants will perform a series of exercises inside and outside the MRS/MRI scanner.
62257|NCT03697915|Device|Experimental|Conventional physical therapy was administered to the control group and was aimed at achieving sitting balance in the first phase; once sitting balance could be achieved, we aimed at achieving standing balance in the second phase. Once standing balance was also achieved, supported and unsupported ambulation was commenced in the final phase.
62258|NCT03697902|Diagnostic Test|Ultrasonographic Measurement on Fetal cisterna magna length|"The length measurement on the fetal cisterna magna (CM) with an angle of 0° between the transducer and the axial cerebellar plane of the fetal head (midline structures will be perpendicular to the ultrasound beam). After that, CM will be measured again after moving the transducer approximately 30° towards the fetal occiput.~Measurements will be performed on the axial cerebellar plane using internal landmarks including the cavum septi pellucidi, thalamus, third ventricle, cerebral peduncles and cerebellar hemispheres.The anteroposterior measurement will be made between the posterior border of the cerebellar vermis and the internal face of the occipital bone.~All the ultrasonography examinations were performed abdominally, using 3-5 megahertz (MHz) transducers."
62259|NCT03697889|Drug|Naproxen sodium (test product)|Participants will be administered single doses of 275 mg Naproxen sodium (test product) tablet orally.
62260|NCT03697889|Drug|Naproxen sodium (reference product)|Participants will be administered single doses of 275 mg Naproxen sodium (reference product - Nalgesin) tablet orally.
62261|NCT03697876|Drug|PRO-165|PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
62262|NCT03697876|Drug|Artelac|Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch & Lomb México, S.A. de C.V.
62263|NCT03697863|Procedure|Noninvasive Respiratory Support|Noninvasive Respiratory Support delivered by conventional flow triggered ventilation or neurally triggered ventilatory assist
62264|NCT03697850|Drug|Atezolizumab|Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
62266|NCT03697824|Drug|GSK3377794|GSK3377794 is genetically engineered NY-ESO-1 Specific (c259) T cells.
63472|NCT03688503|Dietary Supplement|placebo|placebo
62267|NCT03697824|Drug|Pembrolizumab|Pembrolizumab will be administered at a dose of 200 mg once every 3 weeks for adults and 2 mg/kg (up to 200 mg) once every 3 weeks for children.
62268|NCT03697824|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
62269|NCT03697824|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
62270|NCT03697811|Drug|DE-117 Ophthalmic Solution|Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
62271|NCT03697798|Biological|Boostrix®-IPV combination vaccine|A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
62272|NCT03697785|Device|Beacon Care System|Beacon has been developed by Mermaid Care in Denmark. BEACON is a critical care ventilation assist system (http://beaconcaresystem.com/beacon-5/), which potentially enables better ventilation strategies and a more efficient patient care workflow. As an add-on to standard ventilation systems it provides ventilation recommendations 24/7 based on non-stop, personalised monitoring/diagnostics of patients. Based on unique mathematical algorithms and physiological models, it recommends changes in ventilation settings, supporting the critical decision-making processes.
62273|NCT03697759|Other|Usual care + selfBACK|"The selfBACK intervention is a digital Decision Support System (DSS) for self-management of LBP provided to the participant via a smartphone app (selfBACK app). In addition, the participant is provided with a step-detecting wristband (Xiaomi Mi Band 2) that interacts with the selfBACK app.~The DSS provides individually tailored self-management plans including content from three categories; 1) information/education, 2) physical activity monitoring through wearing the step-detecting wristband, and 3) strength and flexibility exercises. The weekly plans are individually tailored to the specific patient, using the data available from the patient, and each week the patients report back their progress on physical activity (step count) and exercise (volume completed). These data are matched with the patients follow-up data to create a self-management plan that is up to date and adaptable to variation in health-status of the individual patient."
62274|NCT03697746|Drug|paracetamol|paracetamol 1000 mg vial
62275|NCT03697746|Drug|Dexketoprofen Trometamol|dexketoprofen trometamol 50 mg bulb
62276|NCT03697746|Drug|Ibuprofen|ıbuprofen 400 mg vial
62277|NCT03697733|Procedure|fractional curettage|Fractional curettage under TIVA by used oral Etoricoxib120 mg at 30 minutes before fractional curettage and then added intravenous Propofol 2 mg/kg when start the procedure or Intravenous Fentanyl 1 microgram/kg and Propofol 2 mg/kg when start the procedure
62278|NCT03697720|Drug|Naproxen|Participants will take naproxen 500mg BID before and for the first 3 days of their period.
62279|NCT03697707|Biological|DCP-001|allogeneic dendritic cell vaccine
62280|NCT03697694|Dietary Supplement|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
62281|NCT03697694|Other|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
62282|NCT03697681|Drug|Tranexamic acid|Intravenous infusion of Tranexamic acid(mixed with normal saline) at the dose of 10mg/kg(body weight) for 20 min after induction of anesthesia and then administration another 1mg/kg/hr(body weight) of Tranexamic acid(mixed with normal saline) until the end of the operation.
62283|NCT03697681|Drug|0.9% NaCl (normal saline)|The same amount of normal saline solution without the addition of tranexamic acid is administered in the same manner as the experimental group(Tranexamic acid intervention group).
62284|NCT03697668|Drug|Imatinib|triple combination for the treatment of malaria
62285|NCT03697668|Drug|Dihydroartemisinin-piperaquine|standard malaria treatment
62286|NCT03697655|Drug|Daratumumab 20 MG/ML [Darzalex]|Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
62287|NCT03697642|Procedure|With nasopharyngeal airway|Nasopharyngeal airway is previously inserted into selected nostril. NG tube is properly lubricated and placed through Nasopharyngeal airway.
62288|NCT03697642|Procedure|Without nasopharyngeal airway|NG tube is properly lubricated and placed into selected nostril
62289|NCT03697629|Drug|Daratumumab|"Patients will receive daratumumab, in the following schedule:~Daratumumab 8mg/kg in 500 mL over 4 hours Cycle 1 Day 1, Daratumumab 16mg/kg in 500 mL over 90 minutes (20% of dose given in first 30 minutes and remaining 80% of dose given over 60 minutes) Cycle 1 Days 8, 15 and 22; Cycle 2 Days 1, 8, 15, and 22, and on Days 1 and 15 for Cycles 3-6."
62290|NCT03697616|Device|Ridge augmentation with sticky bone and GBR|"Autogenous particulate bone will be harvested and a mixture of autogenous particulate and anorganic bovine bone mineral will be prepared at a ratio of 1:1~Venous blood will be drawn from patients' forearm and centrifuged at 2500 RPM/3 minutes and 4000 RPM/15 minutes to produce autologous fibrin glue and concentrated growth factors membrane, respectively~Sticky bone will be prepared by adding autologous fibrin glue to the particulate mixture, placed onto the defect and covered by the prepared concentrated growth factors membrane~For guided bone regeneration the particulate mixture will be placed onto the defect and covered by resorbable collagen membrane~Periosteal releasing incision will be done to provide flap advancement for tension free closure~Closure will be done using horizontal mattress and interrupted 4/0 polypropylene sutures"
62291|NCT03697603|Drug|Brexpiprazole|Tablets, Oral, once daily, 14 weeks
62292|NCT03697603|Drug|Placebo|Tablets, Oral, once daily, 14 weeks
62293|NCT03697590|Drug|No curettage|Standard PDT without curettage
62294|NCT03697590|Drug|Curettage|Standard PDT
62295|NCT03697577|Diagnostic Test|CT scans|Patients will undergo CT or PETCT as part of their standard of care
62296|NCT03697577|Diagnostic Test|DEXA scan|Patients will undergo DEXA scan to measure body fat mass. This is part of proposed study.
62297|NCT03697564|Drug|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 Q4W
62298|NCT03697564|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV on Day 1 Q4W
62300|NCT03697551|Drug|Satoreotide trizoxetan|Subjects will receive a single dose of Satoreotide trizoxetan consisting of a peptide mass up to 45 μg, with a radioactivity range of 150-200 MBq. Satoreotide trizoxetan is intended for diagnostic use as a Positron emission tomography/computed tomography (PET/CT) tracer for the imaging of tumours expressing SSTR2.
62301|NCT03697538|Procedure|Nerve Block for pain control post-revision total knee arthroplasty|A 20g catheter will be introduced and advanced 2-3 cm beyond the tip of the needle under ultrasound visualization. After needle withdrawal, catheter placement will be checked by visualizing local anesthetic spread under ultrasound. 0.5% ropivacaine will be used for catheter placement. At the conclusion of surgery, the catheters will be connected to a pump that will infuse ropivacaine 0.2% at 6 mL/hr with a patient controlled bolus of 5mL and a lockout of 30 minutes.
62302|NCT03697525|Device|Vibration|Low-amplitude rMV (frequency 100 Hz; amplitude range 0.2-0.5 mm) is applied over the flexor carpi radialis and the biceps brachii for the upper limb treatment, and/or over the quadriceps femoris for the lower limb treatment, by means of a specific commercial device (Cro®System, NEMOCOsrl).
62303|NCT03697512|Drug|Ibrutinib|capsules for oral intake in a dosage of 560 mg (four capsules) daily
62304|NCT03697512|Drug|Rituximab|Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.
62305|NCT03697499|Combination Product|fish oil and acute ozone exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
62306|NCT03697499|Combination Product|fish oil and sham exposure|The participants will take fish oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
62307|NCT03697499|Combination Product|soy oil and acute ozone exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour ozone exposure (200 ppb ozone) will be conducted in a chamber after four weeks of supplementation.
62308|NCT03697499|Combination Product|soy oil and sham exposure|The participants will take soy oil (2.2 g/day, two 1.1-g capsules daily) in divided doses. Two hour shame exposure (0 ppb ozone) will be conducted in a chamber after four weeks of supplementation
62309|NCT03697486|Behavioral|diet with different composition|"Participants should not eat within the last 10 hours. Participants could drink mineral water up to 2 hours before intervention. Breakfast given is a milk-based formula which has to be finished within 15 minutes, and subjects could only consume 600 mL of mineral water within the next 4 hours after intervention. Participants' blood was taken before intervention, and 15, 60, 120, and 180 minutes after intervention, then examined in laboratory to measure ghrelin and PYY level. Breakfast given is adjusted to participants' energy requirement. Energy requirement is calculated by adding basal metabolic rate (BMR) with additional energy from physical activity. Different composition of protein, carbohydrate and fat were given to each arm depends on their group.~After 4 hours, participants were given ad libitum meal. After the participants done eating, the calorie in meal taken by participants was measured."
62310|NCT03697473|Other|Nordic hamstring exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
62311|NCT03697473|Other|Hip extension exercise|The exercise protocol consisted of the following sets and repetitions Week 1 - 2 sessions with 2 sets of 6 repetitions. Week 2 - 2 sessions with 3 sets of 6 repetitions Week 3 - 2 sessions with 4 sets of 8 repetitions. Week 4 - 2 sessions with 4 sets of 10 repetitions.
62312|NCT03697460|Drug|INCB018424|Topical cream
62313|NCT03697447|Procedure|Endermotherapy|Endermotherapy massage (mechanic massage) of burn scar
62314|NCT03697434|Behavioral|Palliative Care referral|Individuals with Parkinson disease identified as having specific uncontrolled symptoms or critical events will undergo standardized referral to palliative care, who will provide supportive care. During the palliative care referral, participants and their care partners may discuss symptoms, disease burden (physical, emotion, financial, and psychological), quality of life, goals of care, and advance directive completion. Palliative care specialists may recommend interventions to manage bothersome symptoms or to improve disease burden for both participants and care partners.
62315|NCT03697421|Other|Relationship Education|"We will provide the following 4 activities: 1) marriage and relationship education [using a modified version of the empirically supported Loving Couples, Loving Children (LCLC); 2) pre-marital education and marriage skills; 3) marriage enhancement and marriage skills for married couples; and 4) divorce reduction and relationship skills.~All couples will be expected to participate in 24 hours of core relationship education workshops (including parenting education). Since parental financial support represents a core element of family stability, relationship education workshops will address motivation for providing financial support through employment for all couples (employed and unemployed) as well as how to manage conflicts over money. All couples will be invited to supplemental workshops (with couples from other cohorts) on topics of specialized interest, including employment services and financial literacy (i.e. budgeting, debt, etc.)."
62316|NCT03697421|Other|Employment Services|For couples in need of job search, job retention, and career advancement services, we will provide employment services.
62317|NCT03697408|Drug|Itacitinib|A JAK 1 selective small molecule inhibitor
62318|NCT03697408|Drug|Everolimus|A mammalian target of rapamycin (mTOR) inhibitor
62319|NCT03697395|Diagnostic Test|Lung transplant recipient without MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant, but without consenting to be evaluated by hyperbolized gas MRI. Bronchoscopy sampling will be performed per usual lung transplant team protocol.
62320|NCT03697395|Drug|Lung transplant recipient with MRI imaging|Patients who received lung transplant and undergoing surveillance follow-up at 1, 3, 6, 12, 24 months after the date of lung transplant and with consenting to be evaluated by hyperbolized has MRI. Bronchoscopy sampling will be guided by the results of the hyper polarized gas MRI, different from the usual lung transplant team protocol. Administration of hyper polarized gas MRI is under FDA regulation by IND #129769 (PI, Yun Michael Shim, MD)
62354|NCT03697135|Behavioral|Respondent Driven Sampling|Participants are asked to invite contacts that they previously injected with to take a test for hepatitis C
63080|NCT03691467|Drug|Hyaluronic Acid|topical application of hyaluronic acid
62321|NCT03697382|Behavioral|Very Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Very Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
62322|NCT03697382|Behavioral|Low Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Low Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
62323|NCT03697382|Behavioral|Moderate Steps|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trials. Following this 2-day period, they will undergo the Moderate Stepping trial with the acute bout of exercise on day 2. Day 3 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
62324|NCT03697356|Drug|Lenalidomide, Bortezomib, Rituximab, Dexamethasone|"step 1; R-VRD induction : rituximab, bortezomib, lenalidomide, and dexamethasone induction~Rituximab 375 mg/m2 intravenous on day 1~Bortezomib 1.3mg/m2 subcutaneous on day 1, 8, 15~Lenalidomide 15mg p.o on day 1-21~Dexamethasone 20 mg/m2 intravenous or p.o on day 1-4~Step 2 ; Maintenance Beginning 8 weeks after completion of induction therapy, patients receive lenalidomide 10mg once day 1-21 for 4 weeks. Treatment repeats every 1 months for 24 months."
62325|NCT03697343|Radiation|Radiosurgery|Radiosurgery with 1 x 18 Gy (2-3 cm) or 1 x 15 Gy (3-4 cm)
62326|NCT03697343|Radiation|Fractionated stereotactic radiotherapy|Fractionated stereotactic radiotherapy with 12 x 4 Gy and 2 mm
62327|NCT03697330|Drug|Ringer lactate|"Randomization will be done using computer generated table of random numbers in a 1:1 ratio and will be conducted using sequentially numbered, opaque and sealed envelope. The trial will be planned that neither the doctors (investigators) nor the patients will be aware of the group allocation and amount of fluid received. Intraoperative and postoperative data collections will be achieved by the same blinded anesthiologist.~Patients will be randomly allocated into two groups:~Group L: 40 patients who will be subjected to ''liberal approach of intraoperative 18-20 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Group R: 40 patients who will be subjected to ''restrictive approach of intraoperative 4-6 ml/kg/h of Ringer's lactate starting from conduction of spinal anesthesia.~Blood loss will be replaced if more than 500 ml in a ratio of 3 ml crystalloid: 1 ml blood."
62328|NCT03697317|Behavioral|Televideo Lifestyle Coaching|Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.
62329|NCT03697317|Behavioral|Enhanced Usual Care|Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
62330|NCT03697304|Drug|BI 754091|Solution for infusion
62331|NCT03697304|Drug|BI 754111|Solution for infusion
62332|NCT03697304|Drug|BI 891065|Tablet
62333|NCT03697291|Device|PS wire|The wiring connection used to convey ECG signal from inside the body
62334|NCT03697278|Device|Smith medical CADDsolis|This group will be monitoring from a network.
62335|NCT03697265|Drug|Sepranolone (UC1010) low dose|Subcutaneous (SC) administration
62336|NCT03697265|Drug|Sepranolone (UC1010) high dose|Subcutaneous (SC) administration
62337|NCT03697265|Drug|Placebo|Subcutaneous (SC) adminstration
62338|NCT03697252|Drug|Xanomeline and Trospium Chloride Capsules|Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
62339|NCT03697252|Drug|Placebo Capsules|Placebo Capsules
62340|NCT03697239|Drug|Ascorbic Acid|25, 37.5, 56.25 or 75 grams/m2
62341|NCT03697239|Drug|Paclitaxel protein-bound|125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days
62342|NCT03697239|Drug|Cisplatin|25mg/m2 in 500*mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days
62343|NCT03697239|Drug|Gemcitabine|1000mg/m2 in 500*mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
62344|NCT03697226|Drug|Topical ABI-1968|Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
62345|NCT03697213|Other|Online study|20 hypothetical patient summaries
62346|NCT03697200|Other|APA|Light touch using vaccaria seeds on specific points of the ear
62347|NCT03697200|Other|Sham APA control|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
62348|NCT03697200|Other|Education control|Participants in the Education Control will receive four, 15-minute weekly individual sessions in which the scheduling and duration of interaction with the study staff are identical to the APA and Sham interventions. Materials will be tailored so that they can be delivered within 15 minutes for each session
62349|NCT03697187|Drug|rhC1INH|Recombinant human C1 inhibitor
62350|NCT03697174|Other|200 ppb ozone group|The exposure group will be exposed to 200 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 to 27 L/min/m2 body surface area. The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
62351|NCT03697174|Other|0 ppb ozone group|The control group will be exposed to 0 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 to 27 L/min/m2 body surface area. The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
62352|NCT03697161|Drug|OV101 (gaboxadol)|OV101 (gaboxadol)
62353|NCT03697148|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
62415|NCT03696641|Other|glazed lithium disilicate crowns|glazing of IPS e.max crowns
62355|NCT03697122|Device|Heated Humidified Breathing Circuit and Forced Air Blanket|"Heated humidified breathing circuits (ANAPOD) will be set up and managed by respiratory therapist in standard fashion defined by the manufacturer. Temperate will be set at 41C.~Forced air warming blankets will be set at 42C for duration of rewarming."
62356|NCT03697109|Drug|Relacorilant|Relacorilant is supplied as 100 mg capsules for oral dosing.
62357|NCT03697109|Other|Placebo|Placebo matched to study drug
62358|NCT03697096|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
62359|NCT03697096|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
62360|NCT03697083|Other|Reminders Through Association|Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.
62361|NCT03697083|Other|Active Control|Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.
62362|NCT03697083|Other|Baseline Control|Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
62363|NCT03697070|Other|INSPIRE CPOE Smart Prompt|"Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having PNA due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards."
62364|NCT03697070|Other|Routine Care|Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
62365|NCT03697057|Procedure|General anaesthesia|Standard general anaesthesia for gynecologic surgery in patient group
62366|NCT03697044|Procedure|Irinotecan Drug-Eluting-Bead Trans Arterial ChemoEmbolisation|Patient Registry to assess the delivery of Irinotecan loaded drug eluting beads for the treatment of colorectal liver cancer metastases.
62367|NCT03697031|Drug|Follitropin Delta|"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH <15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."
62368|NCT03697018|Other|zirconia reinforced lithium silicate glass ceramic|It represent a new generation of glass ceramic material. Using an innovative manufacturing process the glass ceramic is enriched with zirconia (10% by weight) for dental CAD/CAM applications for the fabrication of inlays, onlays, crowns and anterior and posterior single tooth restorations on implant abutments.
62369|NCT03697005|Other|BioHPP PEEK single posterior crowns|BioHPP is a 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymeric material, used for fabrication of high strength fixed and removable prostheses. it has advantages of bio-compatibility, low density, light weight, shock absorption.
62370|NCT03697005|Other|zirconia-based single posterior crowns|ZrO2, a ceramic material used for medical devices, displays good esthetic appearance, high mechanical strength, and high biocompatibility and is used in a wide range of indications, such as frameworks, implants, and abutments. In addition, it's very good long-term stability and reliability was proven in a 10-year clinical study. These excellent material properties and the transformation behavior are explained by the yttrium oxide stabilization of ZrO2.
62371|NCT03696992|Procedure|Tandem colonoscopy|Tandem colonoscopy with different image modalities
62372|NCT03696979|Other|Myofascial induction therapy|Myofascial induction therapy is a therapy concept focused on optimizing function and balance within the fascial system. The approach aims at global recovery, local correction and painless body use.
62373|NCT03696979|Other|Therapeutic pain education|Therapeutic pain training is a training intervention that aims to reduce pain and disability by helping patients better understand the biological processes that support pain states. The neurobiology of pain and pain processed by the nervous system is explained to the patient in detail. Changes the patient's olab viewpoint to pain. For example, the patient believes that the cause of pain is caused by tissue damage. The patient who receives pain training understands that the cause of pain is the hypersensitive central nervous system. As a result, the patient's fear avoidance behavior decreases and he starts to move more easily. Because the sensitivity of the central nervous system will be alleviated, the perceived pain will decrease.
62374|NCT03696966|Dietary Supplement|Portion-Controlled Meals|Increase dietary structure using portion-controlled meals (PCM)
62375|NCT03696966|Behavioral|Low-Calorie Diet|Restrict calorie intake daily
62376|NCT03696966|Behavioral|Intermittent Very-Low Calorie Diet|Severely restrict calorie intake intermittently
62377|NCT03696953|Biological|Florajen3|Probiotic combination product One capsule daily by mouth.
62378|NCT03696940|Drug|L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg|Oral administration of 2 tablets of atorvastatin 10 mg (each one) every 24 hours for 6 months.
62379|NCT03696940|Drug|Atorvastatin 10mg|Oral administration of 2 tablets atorvastatin 10 mg (each one) every 24 hours for 6 months.
62380|NCT03696927|Device|Active Powered Prosthesis (APEX) for Spinal Cord Injury|The Active Powered Prosthesis (APEX) is a proof-of-concept shoulder-elbow-wrist device intended to provide non-invasive active powered robotic assistive movement to upper extremities. Focus group participants will control the APEX device on a test manikin and provide feedback on the device design and function.
62416|NCT03696641|Other|polished lithium disilicate crowns|polishing of IPS e.max crowns
62417|NCT03696628|Other|Electrocardiogram|heart testing
62418|NCT03696628|Other|physical examination|done by the investigator
62381|NCT03696901|Drug|Xydalba|Information will be recorded about Xydalba administration (e.g. dose(s), number of infusions, length of infusions, dates or schedule of administration, sites of administration [e.g. hospital, ICU]), and reason for discontinuation, including response to treatment to assess whether the patient was clinically improving when Xydalba was discontinued
62382|NCT03696888|Behavioral|Telecoach|A skills-training web-app teaching skills for reducing problematic alcohol use.
62383|NCT03696888|Behavioral|TeleCoach control|A web-app providing information about the health-related consequences of alcohol consumption.
62384|NCT03696875|Other|Multilevel Guided Discharge Planning|Clinical recommendations and resources activations + scheduling of early visit with the specialist + communication with primary care + written instruction sheet to the patient
62385|NCT03696875|Other|Standard of care|Standard of care
62386|NCT03696862|Procedure|free gingival graft|Use of free gingival graft to seal the socket after flapless atraumatic tooth extraction is performed, implant placement and filling the socket with bone graft.
62387|NCT03696849|Other|polished emax Press|lithium disilicate glass ceramic crowns subjected to polishing only
62388|NCT03696836|Device|Trammpolin® meniscus prosthesis|Trammpolin® meniscus prosthesis is an anatomically shaped, synthetic medial meniscus replacement
62389|NCT03696823|Procedure|laparoscopic cholecystectomy|treatment of chronic calcular cholecystitis laparoscopically
62390|NCT03696810|Diagnostic Test|Laboratory tests|• Laboratory tests (HbA1C levels and lipids)
62391|NCT03696797|Procedure|Phlebotomy|Participants in the TREATMENT GROUP will have a Unit of blood (two cups, the same amount you would donate at the Red Cross) drawn. This involves having a needle inserted into a vein in your arm. Prior to taking the blood, staff will measure blood count to be sure participants are not anemic, and blood pressure to be sure there is no dehydration. During or after donation, participants will be given a sports drink to replace the fluid loss. Participants in the CONTROL GROUP will not donate blood, but will have a needle inserted into a vein in your arm. Neither group will not know to which they have been assigned, all will have a sleep mask (like a blindfold, covering the eyes, held on with an elastic band) placed so they will not know whether blood was actually removed.
62392|NCT03696797|Procedure|Sham Phlebotomy|Participants will have a needle inserted their arm, however, no blood will be drawn.
62393|NCT03696784|Biological|iC9-CAR19 T cells|iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
62394|NCT03696784|Drug|Bendamustine|70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
62395|NCT03696784|Drug|Fludarabine|30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion
62396|NCT03696784|Drug|AP1903|Subjects who develop Grade 4 CRS or grade ≥3 CRS that is unresponsive to standard of care interventions (i.e., does not resolve to grade 0 - 1 within 24 hours after 2 doses of tocilizumab, with sum of doses ≥12mg/kg) and subjects who develop grade ≥3 CRES or grade 2 CRES that does not improve to grade ≤1 within 72 hours with standard of care interventions will receive 0.4 mg/kg of AP1903 as an IV infusion over 2 hrs.
62397|NCT03696771|Drug|NJH395|Immune stimulator antibody conjugate (ISAC), consisting of a monoclonal antibody which targets HER2 conjugated to an immune-stimulatory agent
62398|NCT03696758|Procedure|Pulmonary Function Testing|Subjects will undergo spirometry, Plethsymography, and diffusion capacity.
62399|NCT03696758|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
62400|NCT03696758|Procedure|Cardiac Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
62401|NCT03696758|Drug|Metoprolol|Subjects will receive intravenous metoprolol
62402|NCT03696758|Drug|Sildenafil|Subjects will receive a 50 milligram tablet of sildenafil (to be taken orally)
62403|NCT03696745|Other|autologous umbilical cord blood stem cells|autologous umbilical cord blood stem cells treatment for brain injury for safety and effect evaluation
62404|NCT03696745|Drug|0.9% Sodium-chloride|0.9% Sodium-chloride in control group
62405|NCT03696732|Other|Anxiety questionnaire|Spielberger. State-Trait Inventory questionnaire
62406|NCT03696732|Other|VAS questionnaire|verbal numerical scale (VNS) anxiety score
62407|NCT03696719|Device|BIS bispectral index monitoring device|In addition to the standard monitoring prescribed by the American society of Anesthesiologists, all study participants will be monitored with the BIS, a noninvasive monitoring device which measures the depth of anesthesia. The monitoring is performed using noninvasive electrodes placed on the forehead.
62408|NCT03696719|Biological|NSE cerebral biomarker testing|Venous blood will be collected from each participant in the surgery room prior to anesthesia induction, throughout anesthesia and one hour following surgery in the PACU in order to assess NSE cerebral biomarker according to the ELISA method requirements. At each one of the assessment points 9 cc of venous of blood will be taken from each of the study participants, while routine blood tests are taken.
62409|NCT03696706|Radiation|LED photobiomodulation|LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
62410|NCT03696706|Radiation|Placebo LED photobiomodulation|In this group, the same procedures as the LED group will be made, but the device will be turned off.
62411|NCT03696693|Device|acoustic vocal analysis|Computerized Speech Laboratory (model 4300; Kay Elemetrics Corporation)
62412|NCT03696680|Radiation|FSRT Stereotactic radiation therapy|For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days
62413|NCT03696667|Device|BCI|As participants listen to the music, the EEG waves of their affective states and their variations detected in real-time is converted into an auditory signal providing direct feedback to participants about their affective states and assisting participants to learn and practice emotion regulation.
62414|NCT03696654|Procedure|adenotonsillar surgery|when indicated, adenotonsillar surgery for SDB treatment
62420|NCT03696628|Biological|blood test|A sample of blood will be taken to each patient or healthy children in order to generate hiPSC-cardiomyocytes
62421|NCT03696615|Other|Tabata Kettlebell Swing Workout|See description of experimental arm.
62422|NCT03696615|Other|Control|see description of control arm
62423|NCT03696602|Diagnostic Test|bronchial provocation test|
62424|NCT03696589|Behavioral|Physical Activity Coaching|Based in the self-determination theory, participants will be coached on beneficial exercises, how to utilize supports and overcome barriers to PA engagement. Emphasis of exercise coaching will be on increasing aerobic exercise engagement and will include us of Fitbit devices to facilitate uptake and monitor aerobic exercise. Intervention will be delivered by a physical or occupational therapist, who will work with the participant to develop a plan, set goals and targets, and track changes. Additional resources that will support exercise engagement will be provided. Participants will have the choice to receive their face-to-face session either in person or remotely via secure video-based service.
62425|NCT03696576|Device|EMST|Training of the respiratory system muscles using the EMST device.
62426|NCT03696576|Behavioral|PhoRTE|Completing of PhoRTE voice therapy.
62427|NCT03696563|Device|Automated oxygen administration - FreeO2|The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
62428|NCT03696563|Other|Standard administration of oxygen flow|The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
62429|NCT03696550|Drug|Eravacycline (TP-434)|"Subjects will be stratified by age into 2 cohorts, as follows:~Cohort 1: from 12 to <18 years of age (N=8)~Cohort 2: from 8 to <12 years of age (N=12 or at least 60% of subjects)"
62430|NCT03696537|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV (total 5 doses) administered days -7 through -3 of conditioning regimen
62431|NCT03696537|Radiation|Total Marrow Irradiation (TMI)|TMI will be delivered twice a day, at least 6 hours apart, on days -7 through -3 (total of 10 fractions) of conditioning regimen
62432|NCT03696524|Device|tunneled pleural catheter|Placement of a tunneled pleural catheter through the chest wall into the pleural space to drain the patient's chronic pleural effusion. The catheter is an indwelling device that will be drained from home three times per week by nursing care, the patient, or patient's family.
62433|NCT03696511|Device|Orthodontic miniscrew insertion|orthodontic treatment using miniscrews as anchorage reinforcement
62434|NCT03696498|Procedure|Resin restoration (1 step)|Permanent resin restoration is placed on top of the partial removed caries.
62435|NCT03696498|Procedure|Resin restoration (2 steps)|A calcium hydroxide containing base material is used and a temporary glass-ionomer restoration is placed in the entire cavity. After 4-6 months the patients are recalled. The temporary restoration is removed and final excavation is carried out with hand excavators until firm but stained dentine remains. A permanent resin restoration is performed.
62436|NCT03696485|Biological|SCM-010|SCM-010 is comprised of adipose derived expanded mesenchymal cells (ADSC), suspended in Plasma-Lyte and intended for intrathecal (IT) administration.
62437|NCT03696472|Procedure|robotic assisted surgery|robotic assisted surgery was benefit to operation
62438|NCT03696472|Procedure|laparoscopic|conventional laparoscopic surgery
62439|NCT03696459|Drug|JNJ-53718678, 2000 mg|Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).
62440|NCT03696459|Drug|JNJ-53718678, 3000 mg|Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).
62441|NCT03696459|Drug|JNJ-53718678, 4500 mg or Dose to be decided|Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).
62442|NCT03696459|Drug|JNJ-53718678 500 mg|Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.
62443|NCT03696459|Drug|JNJ-53718678 Placebo|Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.
62444|NCT03696459|Drug|Moxifloxacin 400 mg|Participants will be administered moxifloxacin 400 mg as capsule in Part 2.
62445|NCT03696459|Drug|Moxifloxacin Placebo|Participants will be administered moxifloxacin matching placebo in Part 2.
62446|NCT03696446|Behavioral|Virtual Cardiac Rehabilitation Program|This group will receive their Rehab program primarily online through a secure web-based platform with a trained facilitator.
62447|NCT03696446|Behavioral|Case Managed Home Program|This group will receive their Rehab program over the phone with a trained facilitator
62448|NCT03696433|Dietary Supplement|Low-salt diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
62449|NCT03696433|Dietary Supplement|High-salt diet|The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
62450|NCT03696420|Other|Coordinates of active plots and VIM landmarks calculation|Stimulation efficacy will be assessed by comparing, according to usual care, the clinical evaluation (FTM scale) with and without stimulation, and the four contacts of each electrode will be tested clinically, with an accelerometer and an electromyography to determine which one is the most active on tremor. Coordinates of the anatomical landmarks will be calculated on the pre-operative MRI and those of the active plots on the fusion between post-operative CT-scan and pre-operative MRI.
62451|NCT03696394|Device|BioCartilage® Micronized Cartilage Matrix|BioCartilage® is a scaffold with Collagen Type II and cartilage matrix elements
62452|NCT03696381|Other|Real tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. During the first 20 minutes of each cognitive training session, patients will receive bi-frontal and bi-parietal tRNS. It has a start and end ramp of two seconds in each case to avoid the slight unpleasant sensation that occurs in the first moments of the introduction of direct current DC.
63113|NCT03691233|Drug|Clinical audit on diagnosis and management of neonatal shock|intervenous
62453|NCT03696381|Other|Sham tRNS|The treatment consists of a set of 1-h sessions, three sessions per week for 8 weeks. A series of cognitive exercises of attention, memory, and executive functions will be conducted in each session. We will apply a sham tRNS for the first 20 minutes of each cognitive training session. The subjects will receive sham tRNS and will perform the same type of cognitive training as the rest of patients and will receive the same type of adverse reaction questionnaire. Subjects receiving simulated stimulation will receive the same type of ramps at the beginning and end of the session to ensure triple-blind maintenance .
62454|NCT03696355|Drug|GDC-0084|Given PO
62455|NCT03696355|Radiation|radiation therapy|Both photon and proton therapy modalities will be allowed.
62456|NCT03696342|Drug|Pazufloxacin|"Pazufloxacin 0.6%. by Sophia Laboratories, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
62457|NCT03696342|Drug|Zymar|"Gatifloxacin 0.3%. by Allergan, topical ophthalmic~1 drop, 3 times a day during the waking period in both eyes (at approximate intervals of 6 hours), for 7 days."
62458|NCT03696329|Drug|Tetrabenazine Tablets 25 mg|
62459|NCT03696303|Other|Urinary antigen detection assay|Screening for Ag level in S. pneumoniae urinary antigen detection assay.
62460|NCT03696290|Drug|Aztreonam lysine|Nebulised aztreonam lysine 75mg
62461|NCT03696290|Other|Placebo|Nebulised lactose monohydrate 5mg
62462|NCT03696277|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
62463|NCT03696264|Dietary Supplement|Amino acid intake|Amino acid intake will range between 0.2-3.0g/kg/d
62464|NCT03696238|Dietary Supplement|500mg of Aronox® >40% polyphenol aronia extract|Name: Aronia PE 40% polyphenols Description: Powdered extract obtained from aronia berries (Aronia melanocarpa) Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg aronia extract Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX / Virage sante
62465|NCT03696238|Other|Placebo|Name: Placebo Description: Identical formulation as the treatment consisting of colored maltodextrin using artificial colors Dosage form: Capsule (opaque, beige, size 00) Strength: 500 mg placebo Regimen 1 capsule, once a day with breakfast (except on days when attending the laboratory) Batch number: As per label Expiry Date: As per label Manufacturer: NATUREX (Advance nutraceutical) / Virage sante
62466|NCT03696225|Behavioral|Compensatory Cognitive Training (CCT)|Compensatory Cognitive Training draws from the theoretical literature on compensatory strategy training for other cognitively impaired populations (e.g., Huckans et al., 2013; Twamley et al., 2010; Storzbach et al., 2016). It is a rehabilitation model that aims to teach individuals strategies that allow them to work around cognitive deficits. Consistent with this model and the expert recommendations for civilians and Service members with TBI (Cicerone, 2011), manualized CCT treatment provides training in compensatory attention and learning/memory skills, formal problem-solving strategies applied to daily problems, and the use of external aids such as calendar systems and assistive devices to promote completion of daily tasks (Storzbach et al., 2016).
62467|NCT03696225|Behavioral|Treatment as Usual (TAU)|All TAU participants have an ongoing VA mental health provider and received ongoing mental health care during the course of the study (generally weekly individual or group sessions focusing on evidence-based PTSD treatment).
62468|NCT03696212|Drug|grapiprant and pembrolizumab|Participants will be administered 21-day cycles of oral grapiprant in combination with IV pembrolizumab
62469|NCT03696199|Drug|Long-Acting Local Anesthesia|"The cocktail consists of:~0.5% Ropivicaine, 24.6 mL~Clonidine 100 mcg/mL, 0.4mL~Epinephrine 1mg/mL, 0.5mL~Saline to total volume of 50 mL (24.5mL of saline)~The total amount of solution prepared is 50mL, but typically 30mL is used based on the size of the incision. The total volume administered will be recorded."
62470|NCT03696199|Drug|Regional Anesthesia|0.5% ropivicaine - 30mL each sciatic and femoral/saphenous nerve, ultrasound guided
62471|NCT03696186|Drug|Luminal type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
62472|NCT03696186|Drug|Luminal type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+Prednisone (5 mg, twice daily)
62473|NCT03696186|Drug|Neuroendocrine type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
62474|NCT03696186|Drug|Neuroendocrine type-2|Goserelin (3.75mg, once every 4 weeks)+Carboplatin (area under the curve 5 on day 1 every 3 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
62475|NCT03696186|Drug|Atypical type-1|Goserelin (3.75mg, once every 4 weeks)+Docetaxel (75 mg/m2 on day 1 every 3 weeks)+Prednisone (5 mg, twice daily)
62476|NCT03696186|Drug|Atypical type-2|Goserelin (3.75mg, once every 4 weeks)+Abiraterone (1000 mg, once daily)+ targeted therapy according to next Generation Sequencing (NGS)+ Prednisone (5 mg, twice daily), or Goserelin (3.75mg, once every 4 weeks)+Abiraterone+ Prednisone (5 mg, twice daily) if no druggable gene mutation detected.
62477|NCT03696173|Other|Non-Interventional|Non-Interventional
62478|NCT03696173|Other|Non-Interventional|Non-Interventional
62479|NCT03696160|Drug|Biktarvy|Integrase inhibitor used to treat HIV-1 infection
62480|NCT03696160|Drug|Symtuza|Protease inhibitor used to treat HIV-1 infection
62481|NCT03696147|Device|Magnetic resonance imaging|Diffusion weighted sequence of MRI
62482|NCT03696134|Other|questionnaire|questionnaire
62483|NCT03696121|Drug|Desmopressin Injection|Single dose 20 micrograms in 50ml Normal Saline as intravenous injection infused over 20 minutes
62484|NCT03696121|Drug|Normal saline|Single dose 50ml Normal Saline as intravenous injection infused over 20 minutes
62485|NCT03696108|Drug|Gefapixant|Participants will receive a gefapixant 15 mg or 45 mg tablet administered orally BID
62486|NCT03696095|Drug|Ropivacaine Hcl 0.2% Inj Bag 200Ml (PIB mode)|programmed intermittent bolus 5ml each one hour.
62487|NCT03696095|Drug|Ropivacaine Hcl 0.2% Inj Bag 200Ml (CI mode)|continuous infusion 6ml/h
62548|NCT03695549|Procedure|CAF + (A-PRF)|advanced platelet rich fibrin prepared by low speed centrfugation concept(LSCC) together with coronally advanced flap .
62549|NCT03695549|Procedure|CAF+SCTG|cornally advanced flap plus subepithilial connective tissue graft harvested from the palate
62550|NCT03695536|Behavioral|ultrasound use during resuscitation|ultrasound use during resuscitation
62488|NCT03696082|Behavioral|Aerobic Activity|Moderate-intensity exercise aerobic exercise that involves participating in activities similar to brisk walking that increase heart rate and breathing rate, with activity progressing to 150 minutes per week. Activities other than brisk walking, such as dance, aerobics, swimming, cycling or other activities that increase heart rate and breathing rate to a moderate intensity that can be sustained for at least 10 minutes will also be encouraged. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62489|NCT03696082|Behavioral|Resistance Training|Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62490|NCT03696082|Behavioral|Yoga|Yoga involves a series of movements and poses that are performed in a specific sequence that are adapted to your ability, with activity progressing to 150 minutes per week. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62491|NCT03696082|Behavioral|Health Education|This involves the participant receiving information regarding aspects of health that are important for older adults, and also physical activity in the form of light stretching activities and movements. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
62492|NCT03696069|Other|Non-Interventional|Non-Interventional
62493|NCT03696056|Behavioral|Kirtan Kriya meditation|The program incorporates song with visualization and mudras, and is a multi-faceted, multisensory exercise that appears to engage several areas of the brain implicated in cognitive decline, yet is simple to learn and practice. The meditation includes a repeated Kirtan or song, a mudra or physical/motor component, and a visualization component. The meditation sound file will contain a user friendly introduction to the Kirtan Kriya meditation technique along with detailed instructions and meditation tracks. Three tracks will contain 12 minute guided meditations with the same female voice, and 2 with nature sounds, 2 without any additional sounds. Another 2 tracks will provide only the timing cues (1 with nature sounds, 1 without) so that the participant can conduct the meditation session without guidance if they chose.
62494|NCT03696056|Behavioral|Music listening program|"The participants will receive audio files and an instruction sheet to facilitate their practice.~The audio tracks are 12 minutes in length and contain relaxing instrumental music from Mozart, Bach, Beethoven, Debussy, and Pachebel. Participants are instructed to sit comfortably with their eyes closed and listen to a track of their choice for 12 min daily, for 8 weeks and to record each session on their practice log."
62495|NCT03696043|Other|Axium Steatlh Image Guidance|The Axiem Stealth imaging guidance system uses a probe (AxiEM Registration Probe) and a side mount emitter (AxiEM Side Mount Emitter) to register the patient's head in relation to the probe. A trajectory (entry point and target) is then planned. This registration process takes an estimated 5-15 minutes to perform. A separate stylet (StealthStation EM Stylet) is designed specifically for the catheter and slides down the center of the catheter. A burr-hole is created at the predefined precise location and the catheter is passed to the target under electromagnetic guidance.
62496|NCT03696043|Other|EVD placement|A sterile field is prepared about 10-12 centimeters posterior to the eye and about 2-3 cm lateral to the midline of the skull. An incision is made at this point and a burr hole is created using a hand drill. The catheter is advanced in a trajectory perpendicular to the skull, which results in a direction that is towards the ipsilateral medial canthus and ipsilateral tragus which are other landmarks that can be used.
62497|NCT03696030|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given HER2-CAR T cells via intraventricular administration
62498|NCT03696004|Drug|FEC-100|Patients will recieve six cycles of FEC-100 and Breast conservative surgery after 4-6 weeks
62499|NCT03695991|Procedure|percutaneous nephrostomy|The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
62500|NCT03695965|Procedure|magnetic resonance imaging.|1.5 Tesla magnet system is going to be utilized for ankle imaging. A dedicated extremity surface coil (Foot/Ankle 16-Channel Coil; Siemens Medical Solution) is used to enhance spatial resolution.
62501|NCT03695952|Drug|Nivolumab or pembrolizumab|Nivolumab 3 mg/kg intravenous every 2 weeks; Pembrolizumab 200 mg intravenous every 3 weeks
62502|NCT03695939|Biological|Xeno-Skin™|3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1 Trial
62503|NCT03695926|Drug|[18F]MNI-1054|Healthy volunteers recruited for the study will undergo a [18F]MNI-1054 PET scan.
62504|NCT03695913|Other|Normal Diet|"Phase I (regular diet):~all participants will eat their normal diet and will log their food."
62505|NCT03695913|Other|Low carb diet|"Phase II (low carb diet):~participants will be asked to eat a low carb diet and log their food"
62506|NCT03695913|Device|CGM with no real time feedback|Phase I will collect CGM without real time feedback
62507|NCT03695913|Device|CGM with real time feedback)|Phase II participants will be asked to scan their sensor at least every eight hours and document their blood sugar before and two hours after eating as well as before breakfast and before going to bed.
62508|NCT03695913|Behavioral|Education material|"Phase I: participants will be given the book Always Hungry and be asked to read chapters 1-5 after a health check phone call approximately 5 days after the sensor is placed.~Phase II: participants will be taught about carbohydrates and the benefits and side effects. Additionally, they will be given multiple resources to assist them regarding carbohydrates as well as a book entitled The Calorie King, Calories, Fat, and Carbohydrates. Groceries will also be delivered for 2 recipes that the participants choose from to make."
62509|NCT03695900|Other|Targeting SpO2 at 93-95%|FiO2 adjusted to keep basal SpO2 at target range of 93-95% for 2 hours
62713|NCT03694197|Drug|Praluent|Subcutaneous (SC) administration
62513|NCT03695874|Other|Phase 1 : fill out 1 scale|"Patients will be asked to complete questionnaires.~Group 1: the purpose is to simplify a 75 items scale by a statistical analysis of the data collected from 400 patients. The statistical purification will allow to finalize an abbreviated scale (20-25 items).~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
62514|NCT03695874|Other|Phase 2 : fill out 1 scale and 4 questionnaires|"Patients will be asked to complete questionnaires.~Group 2: the purpose is to validate the abbreviated scale by a statistical analysis of the data collected from 200 patients. The statistical validation will allow to check the consistency and correlation of the abbreviated scale with other scales: a general Quality Of Life scale (SF36), an anxiety and depression scale (HAD), a social support scale (SSQ6) and a scale of regulation emotional (CERQ) and to test and re-test to check fidelity of the abbreviated scale.~Doctors specialized in Hereditary Haemorrhagic Telangiectasia may suggest that patients enter the study. After submission of the information notice and collection of their non-opposition, patients will have the choice to fill out the paper version or the electronic version of the scale and questionnaires."
62515|NCT03695861|Diagnostic Test|Whole-body 18F-FDG PET-CT scan|A 18F-FDG PET-CT will be performed within 5 days of the beginning of the patients care with infectious endocarditis at the University Hospital center of Bordeaux.
62516|NCT03695848|Device|MRI scan|Before decompresssion surgery, DTI and fMRI will be recorded by a FDA approved 3T MRI scanner (Philips Achieva)
62517|NCT03695835|Drug|Immunotherapeutic Agents|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
62518|NCT03695835|Device|Ablation|Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
62519|NCT03695822|Drug|Mirabegron 25mg|The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
62520|NCT03695809|Biological|G9a protein|To assess G9a protein expression on vulvar cancer
62521|NCT03695796|Diagnostic Test|biopsy-proven NAFLD patients with non-invasive tests of liver fibrosis (blood tests, elastography devices) and biobank|To evaluate and improve the non-invasive diagnosis of liver fibrosis in NAFLD and to develop the non-invasive diagnosis of NASH
62522|NCT03695783|Other|Online decision aid called IBD&me|Patients randomized to IBD&me will be directed to go through the website at least 2 days before their clinic appointment, and will be asked to bring their personalized report with them to their upcoming visit.
62523|NCT03695783|Other|Standardized educational material|Patients randomized to the control arm will be sent a PDF file corresponding to the CCFA's online resource at least 2 days before their clinic appointment, and will be asked to bring it with them to their upcoming visit.
62524|NCT03695770|Other|kit for self-diagnosis and self-treatment|distribution of kits for malaria self-diagnosis and self-treatment after a training by health facilitators
62525|NCT03695757|Biological|Part A) Healthy subjects|Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).
62526|NCT03695757|Biological|Part B) Advanced solid tumor|Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).
62527|NCT03695744|Drug|Daratumumab|Daratumumab
62528|NCT03695744|Drug|Bortezomib|Bortezomib
62529|NCT03695744|Drug|Dexamethasone|Dexamethasone
62530|NCT03695731|Procedure|cold induced activation of brown adipose tissue|cold exposure wearing a cold life jacket
62531|NCT03695705|Drug|Rifaximin 550 mg twice a day and Norfloxacin 400 mg once a day|Patients on Rifaximin prophylaxis will be given 550 mg twice daily and on Norfloxacin prophylaxis will receive Norfloxacin 400 mg once daily for 6 months
62532|NCT03695692|Behavioral|pelvic floor exercise and connective tissue massage|Pelvic floor exercises with connective tissue massage will be performed.The massage program is carried out for 18 sessions, 3 days/week in 6 weeks. The exercise program is performed every day for 6 weeks
62533|NCT03695692|Behavioral|pelvic floor exercise|The exercise program is performed every day for 6 weeks
62534|NCT03695679|Behavioral|Interactive computer-based intervention|"There are 4 components of the Interactive computer-based intervention(ICBI) which will be delivered in 3 phases:~Perceived Susceptibility and Perceived Severity~Perceived Benefits and Perceived Barriers~Cue to Action~Self-Efficacy~In addition, a discussion forum will be created to handle questions from the participants. Also, there will be an email address for enquiries if the participants need any support or if they want to seek further enquiry/ clarification after reading the web-based information."
62535|NCT03695666|Other|Clerical policy|Clerical policy introduction
62536|NCT03695653|Behavioral|Drink Tracking (MA)|Weekly drink tracking for self-monitoring and assessment
62537|NCT03695653|Behavioral|Adaptive Tailored (TA)|Messages are sent more frequently and tailored to some baseline characteristics and adapt to progress
62538|NCT03695653|Behavioral|Tailored (TO)|Messages are sent more frequently and tailored to some baseline characteristics
62539|NCT03695640|Drug|Magnesium Sulfate|Addition of magnesium sulfate as an adjuvant to levobupivacaine
62540|NCT03695640|Procedure|continuous femoral nerve block|continuous nerve block with levobupivacaine for treatment postoperative pain
62541|NCT03695627|Behavioral|Meditation|10 minute a day, 8 week digital meditation
62542|NCT03695614|Other|Cognitive Remediation Therapy|Cognitive Remediation is a well-established psychotherapy that aims to improve neurocognitive abilities such as memory performance, executive functioning, processing speed, and attention.
62543|NCT03695601|Other|Standard of Care|Other Standard measures for monitoring rejection: Endomyocardial Biopsy, Echocardiogram, Angiography, Intravascular Ultrasound, Donor-specific HLA Antibody
62544|NCT03695588|Procedure|Quadratus lumborum block|Ultrasound guided Quadratus Lumborum block using a posterior approach. (QLB 2)
62545|NCT03695588|Procedure|Sham QLB|Sham QLB - Ultrasound identification of QLB followed by skin pressure with blunt needle.
62546|NCT03695575|Device|Bone-conduction headset|A bone-conduction headset paired with a microphone will be used.
62547|NCT03695562|Procedure|sequential drilling technique|Patient with vitamin D deficiency using sequential drilling technique
62551|NCT03695523|Behavioral|PLAY (PhysicaL ActivitY) Policy Intervention|An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
62552|NCT03695510|Drug|Afatinib Oral Tablet|40mg oral, daily, continuously
62553|NCT03695510|Drug|Pembrolizumab Injection|200mg, intra-venous injection, every 3 weeks, for 35 cycles
62554|NCT03695497|Procedure|Direct anterior approach|total hip arthroplasty with DDA
62555|NCT03695497|Procedure|Direct Lateral Approach|total hip arthroplasty with DLA
62556|NCT03695471|Biological|Pembrolizumab|Given IV
62557|NCT03695458|Device|Phototherapy|The Photobiomodulation Therapy will be applied 3 minutes after MVC test in 6 points of the quadriceps muscle (2 points in vastus lateralis, 2 in rectus femoris and 2 in vastus medialis).
62558|NCT03695445|Drug|Peripheral administration of Norepinephrine|Systematic follow-up of complications from peripheral administration of Norepinephrine
62559|NCT03695432|Biological|Flubio|Flubio (A/California/7/2009, A/Texas/50/2012 and B/Massachusetts/2/2012) Vaccine 0,5 ml for every subjects The vaccine will be given intramuscularly
62560|NCT03695432|Dietary Supplement|Lacidofil|Lacidofil (Lactobacillus acidophilus Rossel-52 and Lactobacillus rhamnosus Rosell-11 with maltodextrin 211 mg, magnesium stearat 8 mg and ascorbic acid 1 mg) antibiotic The antibiotic will be given 2 times each day for 6 months
62561|NCT03695432|Other|Placebo Vaccine|Nacl 0,9% 0,5 ml The placebo vaccine will be given intramuscularly
62562|NCT03695432|Other|Placebo probiotic|Capsul
62563|NCT03695406|Behavioral|Mind-Body Program for Fear of Recurrence|An adapted protocol of the Relaxation Response Resiliency Program, a manualized, group-based, multimodal mind body program. Protocol adaptation includes refinement of content and study procedures to target fear of cancer recurrence (FCR) among adult cancer survivors.
62564|NCT03695393|Behavioral|ACT Therapy|The ACT intervention will consist of four 2-hour group sessions of culturally adapted ACT (intervention) to reduce stigma and related manifestations, followed by a refresher session at 6 months. The first ACT session will be held at the civil society organization following randomization; the subsequent sessions will be scheduled to take place at the same location. The First St. Petersburg Pavlov State Medical University is an alternative location where sessions can be conducted. Sessions will be planned to occur in biweekly succession, with a goal of 4 sessions within the first two months of study participation and an additional refresher session at 6-months, for a total of 5 sessions.
62568|NCT03695367|Drug|HTX-011|HTX-011, 300 mg
62569|NCT03695367|Device|Luer lock applicator|Applicator for instillation
62570|NCT03695367|Device|Vial access device|Device for withdrawal of drug product
62571|NCT03695367|Drug|Ibuprofen|Ibuprofen, 600 mg
62572|NCT03695367|Drug|Acetaminophen|Acetaminophen, 1 g
62573|NCT03695354|Device|whole body vibration plus conventional therapy|"Subjects enrolled in whole body vibration training group are exposed to side-to-side alternating vertical sinusoidal vibration. Galileo system(Novotec Medical GmbH, Pforzheim, Germany) is used to training. Frequency of whole body vibration is 12Hz and amplitude is 4mm. After 10 minutes of vibration training, subjects rest 3 minutes. Then, additional 10 minutes of training will be given.~conventional physical therapy is consisted of passive range of motion exercise and walking exercise."
62574|NCT03695354|Procedure|conventional therapy|conventional physical therapy is consisted of passive range of motion exercise and walking exercise.
62575|NCT03695328|Behavioral|physical activity level|
62576|NCT03695328|Behavioral|Dietary Intake|
62577|NCT03695315|Device|Continuous Positive Airway Pressure|CPAP is a noninvasive treatment for sleep apnea
62578|NCT03695302|Behavioral|questionnaire|KAP questionnaire for fifth year undergraduate dental students.
62579|NCT03695289|Behavioral|iOTA SMI|Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
62580|NCT03695289|Behavioral|Health Education Control|Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
62581|NCT03695276|Behavioral|PushCon Model|Pulmonary specialist consultation facilitated by a trained health coach, who will gather information from the patient and medical record prior to the consultation and will using health coaching skills to support implementation of recommended care.
62582|NCT03695276|Behavioral|Usual care|Patients referred for pulmonary consultation will be scheduled for an in-person visit at the central hospital-based office. Recommendations will be provided to the primary care clinician. Implementation of those recommendations will rely on follow up of the primary care clinician.
62583|NCT03695263|Behavioral|Choice of one of five behavioral interventions|All participants will choose one of the five intervention options.
62584|NCT03695250|Drug|IDO1 Inhibitor BMS-986205|Given PO
62585|NCT03695250|Biological|Nivolumab|Given IV
62586|NCT03695237|Drug|Leuprolide Acetate (LA)|It is administered intramuscularly as an injection
62587|NCT03695224|Diagnostic Test|Topological perception test|Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.
62588|NCT03695211|Procedure|Conventional landmark technique|inject at the midpoint of the posterior border of the sternocleidomastoid muscle
62589|NCT03695211|Procedure|Precise block technique|inject at the point where the great auricular nerve emerges the posterior border of the sternocleidomastoid muscle
62590|NCT03695198|Drug|LY3361237 - SC|LY3361237 administered SC
62591|NCT03695198|Drug|LY3361237 - IV|LY3361237 administered IV
62592|NCT03695198|Drug|Placebo - SC|Placebo administered SC
62593|NCT03695198|Drug|Placebo - IV|Placebo administered IV
62594|NCT03695185|Drug|ABBV-323 Dose A|ABBV-323 Dose A is intravenously (IV) administered.
62595|NCT03695185|Drug|ABBV-323 Dose B|ABBV-323 Dose B is administered subcutaneously (SC).
62596|NCT03695172|Drug|Ropivacaine|Patients will be randomly assigned to receive one three blocks (TAP, QL, ESP)after delivery of baby with ropivicaine
62597|NCT03695172|Procedure|TAP block|Patient will receive bilateral TAP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
62598|NCT03695172|Biological|QL block|Patients will receive bilateral QL blocks after delivery and within one hour of skin closure with 25 mL of 0.2% ropivacaine with epinephrine 1:400,000 per side.
62599|NCT03695172|Procedure|ESP block|Patients will receive bilateral ESP blocks after delivery and within one hour of skin closure with 25 mL of 0.2% of ropivacaine with epinephrine 1:400,000 per side.
62600|NCT03695146|Behavioral|Paced breathing|Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group.
62601|NCT03695146|Behavioral|Active relaxation|Individuals will be provided with headphones while resting quietly listening to soft music or be provided with a hand-held device to monitor electrodermal activity.
62602|NCT03695133|Behavioral|Group-based interventions|"Group-based interventions Elderly women will have a walk for physical activity for 12 weeks, three days a week. It is planned that each of the sightseeing, picnic, theater and cinema activities will be done twice. The topics that elderly women need most for group educations will be determined. Group educations will be held once every four weeks approximately three hours.~Individual interventions After the pre-tests are applied to the women in the intervention group, the home environment and the individual's health problems will be assessed, interventions will be implemented and the results will be evaluated during home visits at online. During the home visit to the elderly women and twelve-week intervention period, each woman will meet four times and initiatives will be implemented."
62603|NCT03695120|Other|Change of treatment plan|Withholding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR. This treatment modification will also allow the option of aggressive diuresis in volume overloaded CHF patients which should result in a lesser decline of AKI, length of stay, readmission rates, and cost associated with CHF treatment.
62604|NCT03695107|Drug|Nifedipine controlled released tablets|lower blood pressure
62605|NCT03695094|Drug|Padsevonil|Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
62606|NCT03695094|Drug|Oxcarbazepine|Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
62607|NCT03695094|Drug|Levetiracetam|Concomitant administration of levetiracetam (LEV) at therapeutic dosage
62608|NCT03695094|Drug|Lamotrigine|Concomitant administration of lamotrigine (LTG) at therapeutic dosage
62609|NCT03695094|Drug|Brivaracetam|Concomitant administration of brivaracetam (BRV) at therapeutic dosage
62610|NCT03695081|Procedure|Patient Pathway Pharmacist intervention|"Medication reconciliation at admission to hospital~Medication review post surgery~Optimised list of drugs in the discharge summary, in accordance with hospital procedures~Medication reconciliation, six weeks after discharge~Medication review, six weeks after discharge"
62611|NCT03695068|Behavioral|RISE Intervention|Described in Arms description.
62612|NCT03695055|Drug|Maintenance therapy post-HSCT|Rituximab vs DPP/DCEP-G vs observation
62613|NCT03695042|Other|Blood Flow Restriction Training with Exercise|The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads
62614|NCT03695029|Drug|Tenofovir Alafenamide|Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
62615|NCT03695016|Behavioral|ActiveGOALs|13 week, online self-directed intervention. Once weekly sessions are based on social-cognitive theory models of behavior changes. Coaches will provide weekly feedback . Behavior tracking tools will be provided. Links to tools that support physical activity will also be provided.
62616|NCT03695003|Dietary Supplement|Cognivia|Cognivia is a trademarked sage/polyphenol combination dietary supplement from Nexira
62617|NCT03695003|Dietary Supplement|Placebo|Placebo control capsules were prepared by Nexira also and are aesthetically identical to the Cognivia capsules
62618|NCT03694990|Other|Follow-up schedule|Patients will be randomized into 1 of 3 follow-up schedules for post-operative clinic visits.
62619|NCT03694977|Drug|MCS110/PDR001 combination|MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
62620|NCT03694964|Drug|ProteoCIT®|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
62621|NCT03694964|Drug|Placebo Oral Tablet|30 patients will be randomized into the group that will receive 10 mg of citrulline and 30 patients will be randomized into the placebo group for 45 days
62622|NCT03694951|Behavioral|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (i.e., action planning and coping planning) to reduce sedentary behaviour.
62623|NCT03694938|Device|Magnetic resonance imaging|Annually magnetic resonance imaging
62624|NCT03694925|Diagnostic Test|Calprotectin test|Calprotectin will be measured both by ELISA and point of care test.
62625|NCT03694912|Procedure|Partial or radical nephrectomy|The investigators perform partial or radical nephrectomy those diagnosed as RCC.
62626|NCT03694899|Behavioral|phone contact|patients will be called prior to their outpatient appointment
62627|NCT03694886|Drug|Caffeine Anhydrous with small sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
62628|NCT03694886|Other|Placebo - large sucrose pill|sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
62629|NCT03694886|Drug|Caffeine Anhydrous with large sucrose pill|caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
62630|NCT03694886|Other|Placebo - small sucrose pill|sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
62631|NCT03694873|Drug|Tramadol Hydrochloride|one tablet of Tramadol 100 mg (Tramaw, Global Napi, Giza,Egypt) administered orally immediately, 12 h and 24 h after randomization.
62632|NCT03694873|Drug|Celecoxib 200mg|Celecoxib 200 mg (Celebrex® 200, Pﬁzer,USA) administered orally immediately, 12 h and 24 h after randomization.
62633|NCT03694860|Other|questionnaire|Members of European society of anaesthesiology care will obtain an electronic survey considering their clinical practice in RSI
62634|NCT03694834|Drug|Pembrolizumab|"A single dose of Pembrolizumab (200 mg) will be administered IV over 30 min (-5 /+10 min) approximately 3 weeks prior to the scheduled hysterectomy.~Pembrolizumab (200 mg) will be administered IV over 30 min (-5/+10 min) every three weeks in combination with paclitaxel and carboplatin as adjuvant therapy over 6 cycles. Pembrolizumab should be given on D1 of each cycle after the infusion of cytotoxics."
62635|NCT03694834|Procedure|Hysterectomy|Hysterectomy/Surgical Staging per institutional standard of care.
62636|NCT03694821|Drug|Ketorolac Tromethamine Injection|One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
62637|NCT03694821|Drug|Methylprednisolone Acetate Injection|One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine
62638|NCT03694821|Drug|Hylan G-F 20|One knee injection of Hylan G-F 20 (Synvisc-One)
62639|NCT03694808|Drug|Fluad Vaccine|single adjuvanted dose (AD) intramuscular injection
62640|NCT03694808|Drug|Fluzone HD Vaccine|single high dose (HD) intramuscular injection
62641|NCT03694782|Behavioral|Food diary supply|Each participant was issued with a food supply diary to record details of their household food supply and related trips over 1-mo period. Household food supply included food purchases, food gift/donation, and potential crops from the garden. Away-from-home food consumption was not recorded. For each food purchase, participants provided details of date, place of purchase, foods purchased (name, quantity and expense incurred), and trip made (origin/where the trip started, destination/where the trip ended, and mode of transportation). When till receipts were available in grocery stores or supermarkets, participants were asked to collect them in an envelope placed at the end of the food supply diary. To facilitate data entry, all family members were encouraged to help filling out the diary.
62642|NCT03694782|Behavioral|Actigraph|Participants were instructed to wear a triaxial accelerometer (wGT3X-BT or wActiSleep-BT, Actigraph, Pensacola, FL, USA) fitted with an elastic strap on right side of the hip for 9 consecutive days, except for bathing and performing activities in the water. The Actigraph was accompanied by an activity logbook in which participants were required to daily record time when awake and sleeping, and, if any, time and duration of workout or device removal
62643|NCT03694782|Behavioral|Questionnaire|Participants received by email a link to complete an online questionnaire about mental and social health, sensibility to food waste, and connection with nature
62644|NCT03694769|Other|Semi-structured interview|One-hour interview with researcher
62645|NCT03694769|Other|Drop attack diary|Diary of any drop attacks experienced within an 8 week period
62646|NCT03694756|Device|TMEM-MRI|TMEM MRI INFORMATION: Unilateral breast MRI will be obtained on a 3.0T whole body MRI scanner with a dedicated breast radiofrequency coil. The patient will be scanned in the prone position with an in-dwelling IV catheter for a single dose contrast agent injection.
62647|NCT03694756|Procedure|FNA|FNA: The patients who are recruited prior to biopsy (Cohort A) will have had TMEM-MRI performed prior to biopsy. They will then present to radiology for ultrasound-guided core biopsy of the breast mass. FNA will be performed during this procedure. The FNA will be performed after local anesthetic is administered but prior to insertion of the core biopsy needle. FNA will be performed by the radiologist under direct sonographic visualization of the mass. Five passes will be obtained with a 25 gauge needle. The FNA material will be expelled into 1.5 ml Eppendorf tube containing phosphate buffered saline with EDTA.
62648|NCT03694743|Device|2Shape rotary system|root canal preparation
62649|NCT03694730|Other|Exercise Treatment|Exercise treatment will consist of squatting and knee extension exercises, designed to progressively load the patellar tendon (Heavy-Slow Resistance protocol). A pain-monitoring model is used to guide exercise loads. As the protocol progresses, exercise load is increased while repetitions are decreased.
62650|NCT03694730|Other|Pain- Guided Activity Modification|Participants sports participation and physical activity will be guided by the Pain-Monitoring Model. Using the Pain-Monitoring Model, patients may participate in activities that cause patellar tendon pain, as long as pain does not exceed 5/10 on the numeric pain rating scale (NPRS) (0 = No pain, 10 = Worst pain imaginable) during or immediately after activity. Additionally, pain should return to pre-activity levels by the following morning and pain should not increase from week-to-week.
62651|NCT03694717|Drug|Saline Solution for Injection|The fluid expansion will consist in a less than 10 min infusion of 500 milliliters of saline through a central venous catheter (jugular). The duration of infusion will be controlled by an airbag pressurized at 300 mmHg.
62652|NCT03694704|Device|FineHearing strategy|Cochlear implant with FineHearing strategy
62653|NCT03694691|Diagnostic Test|Liver Biopsy|For measurement of tissue co-factor levels, we will take needle biopsies of transplanted livers immediately after procurement, immediately prior to implantation (at the end of preservation), 30 minutes after portal vein reperfusion, and 30 minutes after hepatic artery reperfusion. For those livers that have more than 60 minutes between portal vein and hepatic artery reperfusion, an additional biopsy will be performed at 60 minutes after portal vein reperfusion. Post-procurement biopsies will be collected regardless of where the liver was obtained.
62714|NCT03694158|Drug|Dupilumab|anti-IL4 receptor antagonist
62654|NCT03694678|Behavioral|Recovering Together|The intervention will teach resiliency skills (mindfulness, coping, interpersonal communication, etc) within 2 in person sessions at hospitalization and 4 live video sessions after discharge. Both patient and caregiver will participate in all sessions
62655|NCT03694665|Other|Lung recruitment maneuver|A Lung recruitment maneuver is aimed to resolve atelectasis during mechanical ventilation. It consists in a brief and controlled increment in airways pressure using pressure control ventilation. Positive end-expiratory pressure (PEEP) is increases every 5 centimeters of water (cmH2O), from 0 to 20 cmH2O keeping a fixed driving pressure of 20 cmH2O. A final step of 40 cmH2O of plateau pressure was maintained for 10 breaths, returning then to standard ventilatory settings.
62656|NCT03694652|Behavioral|PACE|Patient-centered Assessment and Counseling for Exercise [PACE] program
62657|NCT03694652|Behavioral|Diet|Motivating healthy dietary habits
62658|NCT03694652|Other|App|Using an app to deliver communication to the participant.
62659|NCT03694652|Other|Face-to-face|Using in person meetings and/or phone communication with the participant.
62660|NCT03694639|Other|ganglion impar block|CT sections were done in the axial plane 4 mm slice thickness to detect the site of sacrococcygeal disk. After a suitable section was confirmed, two distances were measured, one from patient's spine to the proper site of entry and the other from the site of entry to the target point.22 gauge spinal needle 12 cm was introduced until reach anterior to sacrococcygeal disk. When the needle tip location was ideal, 2 ml lidocaine mixed with1ml of radiopaque dye was injected. CT sagittal section was done to verify the retroperitoneal distribution of the dye. After good contrast spread confirmation, 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone was injected
62661|NCT03694626|Device|Pupillography|A hand-held pupillometer/electroretinogram device (RETeval, LKC) will be held in front of the subject's eye, but will not touch the eye. The device will provide a brief, a series of brief light stimuli and then record the pupil response and the elicited electrical response from the retina from a surface skin patch (electrode) placed below each eye, from the light as a measure of whether the inherent sensitivity of the eye in the retina is normal. The investigators will repeat this in the left eye. The visible light stimulus is safe and is given at an intensity experienced in normal daily light exposures. The test takes about 2 minutes per eye.
62662|NCT03694626|Device|Ocular Coherence Tomography (OCT)|The thickness of the optic nerve and macula will also be measured inside of the eye using a special camera that forms an image of the layers of the retina without pupil dilation. The imaging is harmless and measures the structural health of the optic nerve and retinal layers. This test takes 5-10 minutes per eye.
62663|NCT03694626|Device|Wrist-watch sensor device|A wrist-watch sensor device (E4, Empatica) will be place on each wrist to measure skin conductance, heart rate, skin temperature and arm movement during testing. These wrist-watch devices are being used to monitor changes in sympathetic nerve activity to light intensity, (the sympathetic nerves supply the blood vessels to the skin and heart).
62664|NCT03694626|Device|Videography|"The subject will sit comfortably in front of miniature combination infrared/visible light video cameras and infrared diode light source located within 1 meter to provide video recording of the face during testing with light and during darkness, described next.~After the 10 minutes of dark-adapting, the subject will put his/her chin on a chin rest in front of the video cameras and a light emitting diode (LED) array give diffuse red, blue, and white stimuli over a range of intensities. None of the stimuli are as bright as a flash from a camera and are in the range of intensities normally experienced during daily activities.~At the end of the test the investigators will add filters over the glasses: orange (blue-blocking) filters and neutral density filters. Subjects will grade independently, both the brightness and discomfort they feel from each light stimulus intensity."
62665|NCT03694626|Device|Electrophysiology|Next, electrodes will be placed above, below and to the side of the test eye to record the electromyogram (EMG) for measuring eyelid opening and blink rate.
62666|NCT03694613|Other|Plancental/Umbilical Cord Blood sample|After infant is delivered, placenta along with clamped umbilical cord Blood will be obtained from the ObGyn team. One umbilical clamp will be placed at the umbilical end, and the other clamp will be placed on the placental end of the umbilical cord. Then the umbilical cord will be cut between the clamps. The umbilical cord will be cleaned three times with 2% chlorhexidine, plus 70% isopropyl alcohol under sterile conditions (sterile gloves). Cord blood samples will be collected using vacutainer blood collecting system with a sterile 22-gauge needle. We will collect 3 - 4 ml of blood.
62667|NCT03694600|Diagnostic Test|IvyGene DX Liver Cancer Test|intended for the qualitative detection of DNA methylation profiles associated with hepatocellular carcinoma in cell-free DNA derived from patient whole blood specimens.
62668|NCT03694587|Drug|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200mg TEPI medicated plaster applied to the upper back daily for 24 hours for 5 days
62669|NCT03694587|Drug|Aktren® 200 mg überzogene Tabletten (Ibuprofen)|one dose of Aktren® 200 mg überzogene Tabletten (Ibuprofen tablet)
62670|NCT03694574|Behavioral|instruction to suppress|"It might happen that in some situations in which you try to do something and you fail or things don`t come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, try not to think of the situation that makes you angry, mad or irritated. Please try as much as you cannot to think about the situation, don`t think about how you feel or what had happened, and try to suppress your emotions and not to feel them. It`s very important to try as much as you cannot to think about the situation that makes you angry, mad or irritated. (Szasz, Szentagothai, & Hoffmann, 2011)"
62671|NCT03694574|Behavioral|instruction to reappraise|"It might happen that in some situations in which you try to do something and you fail or things don`t come up as you want, you could become angry, mad or irritated and feel some level of distress and discomfort. Next, please try to tell yourself that or would be preferable that the others are nice and/or fair to you, but if they are not, it does not mean that you or they are worthless human beings. It would be preferable that the others be nice and/or fair to you but if they are not, remember that it is only (very) bad), not catastrophic (the worst thing that could happen to you). It would be preferable that others are nice and/or fair to you, but if they are not, you can tolerate it, and go on enjoying life, even if it`s more difficult at the beginning. (Szasz et al., 2011)"
62672|NCT03694574|Behavioral|control|No instruction
62673|NCT03694561|Other|Observational|This study is a systematic investigation of the natural history of late-onset Pompe disease in infancy
62715|NCT03694158|Other|Placebo|Placebo for Dupilumab (packaged/administered the same as the active drug)
62674|NCT03694548|Other|Yoga program: Instructor-led group yoga sessions (Part B)|Participants enrolled in Part B will receive eight in-person instructor-led group yoga sessions. Proposed yoga session will comprise of poses, breathing exercises, and guided relaxation.
62675|NCT03694535|Drug|bladder wall thermotherapy with Mitomycin-c|application of intravesical mitomycin-C with hyperthermia
62676|NCT03694522|Drug|bemarituzumab (FPA144)|bemarituzumab (FPA144)
62677|NCT03694522|Drug|Placebo|Placebo
62678|NCT03694522|Drug|mFOLFOX6|mFOLFOX6
62679|NCT03694509|Other|Breakfast tea with full fat milk|Assessment of gastric emptying using ultrasound. Black breakfast tea (200ml) with full fat milk (50ml) - The volume of milk added to the tea is at the discretion of the patient but the remaining milk must be consumed afterwards.
62680|NCT03694509|Other|Water|Water 250ml.
62681|NCT03694496|Behavioral|peer-led theory-based intervention group|"We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader."
62682|NCT03694483|Diagnostic Test|Genetic analysis for the detection of prostasomes|"Whole blood will be collected and processed within 2 hours. Samples will be brought to Hackensack University Medical Center and will be centrifuged.~The plasma samples will be tested for presence of prostasomes using the ExoPLA (Exosome in situ Proximity Ligation Assay) assay and the prostasomes will be purified for further miRNA sequencing."
62683|NCT03694457|Procedure|Reversed total shoulder arthroplasty|Replacement of the proximal humeral head by a reversed prosthesis through an anterior approach
62684|NCT03694457|Procedure|lateral approach|Replacement of the proximal humeral head by a reversed prosthesis through a lateral approach
62685|NCT03694444|Drug|AMY-101|C3 complement inhibitor
62686|NCT03694444|Other|Water for injection|Placebo
62687|NCT03694431|Other|Tech-supported HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
62688|NCT03694431|Other|Standard HBPC|Palliative care provided consistent with recommendations from the National Consensus Project for Quality Palliative Care
62689|NCT03694418|Behavioral|We are here now: a multi-level, multi-component sexual and reproductive health intervention for American Indian youth|N/E will be implemented simultaneously over the 9-month school year. Components include: 1) Individual Level- Native Stand 2) Family Level - Native Voices; 3) Community Level - Cultural mentoring program; and 4) Systems Level. The fourth level of N/E mobilizes the existing Epi Team to enhance the coordination and implementation of SRH services at Fort Peck.
62690|NCT03694405|Biological|MenACWY-CRM|Booster vaccination with MenACWY-CRM
62691|NCT03694405|Biological|MenACWY-DT|Booster vaccination with MenACWY-DT
62692|NCT03694405|Biological|MenACWY-TT|Booster vaccination with MenACWY-TT
62693|NCT03694392|Biological|Flublok Quadrivalent|Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs.
62694|NCT03694392|Biological|Standard Dose Inactivated Influenza Vaccine (SD-IIV)|For the 2018-2019 flu season, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. The SD-IIV for the 2019-2020 flu season will be determined prior to the start of the season.
62695|NCT03694379|Other|Apneic oxygenation during endotracheal intubation|Providing oxygenation through nasal cannula during the apneic phase of endotracheal intubation.
62696|NCT03694366|Other|ICBHSS model|"Bundle of evidence-based interventions that include the following 5 components:~Community engagement meetings and feedback;~Elimination of public sector facility user fees for children under five and pregnant women;~Pro-active community based IMCI using trained, equipped, supervised, and salaried Community Health Workers (CHWs) with additional services including linkage to family planning and counseling, HIV testing & referrals;~Clinical mentoring and enhanced supervision by a trained peer coach at public sector facilities;~Basic infrastructure improvements and supply chain management training of pharmacy managers"
62697|NCT03694353|Drug|Pegvaliase|40-60mg/day
62698|NCT03694340|Other|Re-programming of cochlear implant|New MAP based on behavioral T- and C-levels
62699|NCT03694327|Device|Treatment A Digital Intervention|Mobile Application
62700|NCT03694327|Device|Treatment B Digital Intervention|Mobile Application
62701|NCT03694314|Dietary Supplement|Omega-3 fatty acids|200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).
62702|NCT03694314|Dietary Supplement|Placebo|200 mL placebo fruit juice with no effect on the hypothesized outcome.
62703|NCT03694288|Procedure|Implant removal|Surgical Implant removal
62704|NCT03694275|Drug|TAK-935|TAK-935 tablets or mini-tablets.
62705|NCT03694262|Drug|Rucaparib|Rucaparib 600mg orally twice daily by continuous dosing
62706|NCT03694262|Drug|Bevacizumab|15mg/kg IV on day 1 of every cycle
62707|NCT03694262|Drug|Atezolizumab|1,200mg IV on day 1 of every cycle
62708|NCT03694249|Drug|Ifetroban Sodium|Given by mouth
62709|NCT03694249|Other|Placebo|Given by mouth
62710|NCT03694236|Drug|durvalumab|"Neo-adjuvant chemoradiation period The treatment consisted of paclitaxel, carboplatin, duvalumab and radiation. The radiation treatment comprises 45Gy (total 25Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery Chest CT and/or PET CT with appropriate other diagnostic method (ex. Bronchoscopy) will be performed before surgery and type of surgery Follow-up period There is every 4 month visit with chest CT and abdominal CT is done at 1,2,5 post-op year. Other diagnostic method can be performed if indicated."
62711|NCT03694223|Other|Health education delivery methods|
62712|NCT03694210|Device|EndoRotor Therapy|To evaluate the EndoRotor's ability to safely remove non-viable/necrotic tissue for direct endoscopic necrosectomy in patients with walled off pancreatic necrosis.
62716|NCT03694145|Other|In-Person Eye Examination|Dilated in-person eye examination by a board-certified ophthalmologist or retinal fellow.
62717|NCT03694132|Device|functional MRI|conditioning brain activity with peripheral stimulations
62718|NCT03694132|Device|structural MRI|diffusion MRI and tractography for evaluating the brain structures
62719|NCT03694132|Device|EEG/MEG|conditioning brain activity with peripheral stimulations
62720|NCT03694119|Drug|Phenelzine|Phenelzine
62721|NCT03694119|Drug|Tyramine|Tyramine
62722|NCT03694119|Drug|Phenelzine placebo|Phenelzine placebo
62723|NCT03694119|Drug|ozanimod placebo|ozanimod placebo
62724|NCT03694119|Drug|ozanimod|ozanimod
62725|NCT03694106|Behavioral|TEAM PSYCHOTHERAPY|Patients data will be collected from the first to the final psychotherapy session as performed normally by TEAM trained clinicians. The treatment-as-usual includes therapy sessions of 50 to 110minutes long, typically once or twice per week for an average of 8-12 sessions. Treatment as usual by these clinicians includes the use of psychological symptoms survey immediately before and after each psychotherapy session. Typically patients will fill out these surveys in the clinic's waiting area before and after each session.
62726|NCT03694080|Combination Product|Calcium electroporation|Patients with potentially curable colorectal rectal cancer will be treated preoperatively
62727|NCT03694067|Other|Punch skin biopsy|One 1 mm punch biopsy will be taken from the patients from balding scalp. Another 1 mm punch biopsy will be taken from an area of occipital non-balding scalp of the same individual. Local anesthesia will be injected around the biopsy site beforehand.
62728|NCT03694054|Other|Care coordination tool|Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
62729|NCT03694041|Drug|SAD: APX-115|Drug: APX-115 SAD APX-115 SAD for 1day
62730|NCT03694041|Drug|SAD: Placebo|Drug: Placebo Placebo for 1day
62731|NCT03694041|Drug|MAD: APX-115|Drug: APX-115 MAD APX-115 MAD repeatedly administered.
62732|NCT03694041|Drug|MAD: Placebo|Matching study drug will be repeatedly administered.
62733|NCT03694041|Other|Food effect: fasted and fed|A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
62734|NCT03694041|Other|Metabolic probe with or without APX-115|A metabolic probe will be administered with and without APX-115.
62735|NCT03694028|Other|Limb Loading|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
62736|NCT03694028|Other|Conventional Training|Participants will be assigned to one of two interventions. The intervention will occur 3 times a week for six weeks (18 sessions) each session for one hour.
62737|NCT03694015|Radiation|SUPR|simple unplanned palliative radiotherapy-(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
62738|NCT03694015|Radiation|VMAT|volumetric modulated arc therapy--(either 8 Gy in 1 fraction or 20 Gy in 5 fractions), chosen pre-randomization at ROs or centres discretion
62739|NCT03694002|Drug|Carboplatin|Given IV
62740|NCT03694002|Drug|Paclitaxel|Given IV
62741|NCT03694002|Biological|Ramucirumab|Given IV
62742|NCT03693989|Drug|Difluprednate 0.05%|Dosage: 1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.
62743|NCT03693989|Drug|Prednefrin|"1 drop 4 times a day (every 4 hours) during the period of vigil in the operated eye, for 14 days. Dose reduction for 14 days at the discretion of the principal investigator.~- Route of administration: topical ophthalmic"
62744|NCT03693976|Drug|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
62745|NCT03693976|Device|Ectoin Rhinosinusitis Nasal Spray|Application of Ectoin Nasal Spray (SNS01) in accordance with the instructions for use
62746|NCT03693963|Device|Serranator|The Serranator® PTA Serration Balloon Catheter is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
62747|NCT03693950|Biological|BCD-066|BCD-066 will be administered once a week intravenously in a dose 1 µg/kg
62748|NCT03693950|Biological|Aranesp|Aranesp will be administered once a week intravenously in a dose 1 µg/kg
62749|NCT03693937|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
62750|NCT03693924|Radiation|SRT-100|The SRT-100™ is a simple painless non-invasive in-office procedure that is approved by the U.S. Food and Drug Administration (U.S. FDA) to treat keloids caused by surgery or injury by delivering a precise, calibrated dose of Superficial Radiation Therapy (SRT) that only goes skin deep.
62751|NCT03693911|Behavioral|Acceptance and Commitment Therapy|6 digital and gamified session prevention program based on Acceptance and Commitment Therapy
62752|NCT03693898|Other|Observeational|No intervention, observational
62753|NCT03693885|Other|Oxytocin challenge test (OCT)|Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.
62754|NCT03693872|Drug|Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient
62755|NCT03693872|Drug|Dopaminergic Agonist + Apomorphine|Apomorphine (5 mg/ml), supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate adjusted during the whole duration of the study to obtain the best effect in each patient and associated with dopaminergic agonists
62756|NCT03693859|Behavioral|Cognitive enhancement program|The cognitive enhancement condition (BWL+GAMING) will both teach the behavioral skills necessary for weight loss and strengthen the executive functions that underlie these skills.
63155|NCT03690908|Other|no intervention (descriptive study)|no intervention (descriptive study)
62757|NCT03693859|Behavioral|Behavioral Weight Loss + Health Segments|Control participants will be asked to spend 30 minutes watching health segments online, five days per week, for 8 weeks.
62758|NCT03693846|Drug|Nivolumab|IV infusion per institutional guidelines and the Package Insert
62759|NCT03693846|Drug|Ipilimumab|IV infusion per institutional guidelines and the Package Insert
62760|NCT03693833|Drug|Cannabidiol|Cannabidiol (CBD) tablets of 10mg each
62761|NCT03693833|Drug|Placebo Oral Tablet|Oral Placebo tablets of 10mg each
62762|NCT03693820|Drug|the infiltration group|"15-20 ml periportal,~50 ml in gallbladder bed,~The rest (about 150 ml in 70 Kg patient) will be intraperitoneal"
62763|NCT03693820|Drug|the control group|the 50 ml prepared for gallbladder bed infiltration will be replaced by saline.
62764|NCT03693807|Device|Medtronic pump and Codman catheter|All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.
62765|NCT03693807|Drug|Floxuridine (FUDR)|Please see Detailed Description.
62766|NCT03693807|Drug|Gemcitabine|Please see Detailed Description.
62767|NCT03693807|Drug|Oxaliplatin|Please see Detailed Description.
62768|NCT03693807|Drug|Irinotecan (CPT-11)|Please see Detailed Description.
62769|NCT03693807|Drug|Fluorouracil|Please see Detailed Description.
62770|NCT03693807|Drug|Anti-EGFR (Panitumumab or Cetuximab)|Please see Detailed Description.
62771|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
62772|NCT03693781|Drug|Colchicine 1 MG Oral Tablet|Colchicine tablets depending on arm (0.01 mg/kg/day, 0.005 mg/kg/day, placebo) and on weight (>70 kg or <71 kg) for 30 weeks of duration.
62773|NCT03693781|Drug|Placebo Oral Tablet|Corresponding tablets for 30 weeks
62774|NCT03693768|Behavioral|Health coaching|Health coaching
62775|NCT03693755|Procedure|In-plane Group|Placement of femoral nerve catheter under ultrasound control
62776|NCT03693755|Procedure|Out-of-plane Group|Placement of femoral nerve catheter under ultrasound control
62777|NCT03693742|Diagnostic Test|18F-DCFPyL PET/CT scan|"Participants will have their weight recorded and baseline vital signs (blood pressure, heart rate, and oxygen saturation level) measured prior to the tomato juice ingestion, immediately prior to 18F-DCFPyL injection and 5 to 15 minutes after injection.~The participant will receive a bolus intravenous dose of 18F-DCFPyL.~After 60 min, the vital signs will be recorded and again two hours after 18F-DCFPyL. Immediately before scanning, the participants will be taken to a designated washroom and asked to void.~The PET/CT image acquisition time will be approximately 30 minutes."
62778|NCT03693742|Other|Placebo drink|Participants will consume 300mL of tomato juice 30 minutes prior to 18F-DCFPyL injection.
62779|NCT03693742|Other|MSG drink|Participants will consume 300mL of tomato juice with MSG 30 minutes prior to 18F-DCFPyL injection.
62780|NCT03693729|Device|HD-tDCS|Participants will complete a metamemory and memory task
62781|NCT03693716|Procedure|Dynamic Anterior Stabilization|All-arthroscopic trans subscapular Long Head of the Biceps tenodesis in the anterior-inferior glenoid with all-suture anchors
62782|NCT03693703|Diagnostic Test|bi-parametric MRI|Axial T2-weighted and diffusion-weighted imaging with no endorectal coil nor intravenous contrast agent administration
62783|NCT03693703|Diagnostic Test|multi-parametric MRI|T2-weighted imaging in the three planes, diffusion-weighted and dynamic contrast-enhanced imaging using endorectal coil and intravenous contrast agent administration
62784|NCT03693690|Procedure|Vaginal laser thermotherapy|Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence.
62785|NCT03693677|Drug|Irinotecan Liposomal Injection|Nal-IRI at 80 mg/m2 IV over 90 minutes
62786|NCT03693677|Drug|5-FU/LV|5-FU 2400 mg/m2 IV over 46-hours, every 2 weeks.
62787|NCT03693677|Drug|Nab-Paclitaxel|Nab-Paclitaxel: 125 mg/m2 This treatment is administered at D1, D8, D15 and at D29, D36, D43.
62788|NCT03693677|Drug|Gemcitabine|1000 mg/m² in 500 ml normal saline infusion at a fixed dose rate of 10 mg/m²/min (i.e. 100 min). This treatment is administered at D1, D8, D15 and at D29, D36, D43.
62789|NCT03693638|Drug|Bupivacaine-fentanyl|2,5 ml total anesthetic drug dose were given with 0.2 ml/second rate, and subjects were asked to remain sitted for 90 seconds
62790|NCT03693638|Drug|Bupivacaine-fentanyl|1,5 ml of total anesthetic drug dose followed by 1 ml remaining dose after 90 s interval were given
62791|NCT03693625|Drug|Fenebrutinib|200 mg orally, twice daily
62792|NCT03693612|Drug|GSK3359609|GSK3359609 is humanized anti-ICOS agonist immunoglobulin G (IgG) 4 monoclonal antibody (mAb), which will be administered as an intravenous (IV) infusion once every 3 weeks.
62793|NCT03693612|Drug|Tremelimumab|Tremelimumab is humanized anti-CTLA-4 IgG2 mAb, which will be administered as an IV infusion once every 3 weeks for 6 doses, thereafter once every 12 weeks .
62794|NCT03693612|Drug|Docetaxel|Docetaxel is a microtubule stabilizer which will be administered as an IV infusion once every 3 weeks at a dose of 75 milligrams per meter square (mg/m^2).
62795|NCT03693612|Drug|Paclitaxel|Paclitaxel is a microtubule stabilizer which will be administered as an IV infusion once weekly at a dose of 80 mg/m^2.
62796|NCT03693612|Drug|Cetuximab|Cetuximab is a recombinant, human/mouse chimeric anti-estimated glomerular filtration rate (EGFR) mAb. Cetuximab will be administered at a loading dose of 400 mg/m^2 followed by 250 mg/m^2 once weekly.
62797|NCT03693599|Drug|carbetocin|single 100 µg IV dose of carbetocin diluted in 10 ml of Ringer's lactate solution (Pabal, Ferring Pharmaceuticals Ltd, West Drayton, UK).
62798|NCT03693599|Drug|Syntometrine|received combination of 5 IU oxytocin (Syntocinon®, Novartis, Basel, Switzerland) and 0.2 mg ergometrine (Methergin®,Novartis).
62799|NCT03693573|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
63156|NCT03690895|Other|Retrospective survival analysis|Kaplan-Meier model
62800|NCT03693573|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at 15 mg/kg on Day 1 of each 21-day cycle. Administration of study drugs will continue until unacceptable toxicity; loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status; investigator or patient decision to withdraw from therapy; or death (whichever occurs first).
62801|NCT03693560|Drug|Vildagliptin 50 mg Oral Tablet|Patients who the endocrinologist prescribed them Vildagliptin 50 mg Oral Tablet plus their Metformin 1000 mg Oral Tablet to control their blood sugar level.
62802|NCT03693560|Drug|Metformin 1000 mg Oral Tablet|Patients with Coronary artery diseases.and uncontrolled Diabetes Mellitus type 2 who's taking Metformin 1000 mg Oral Tablet only will be enrolled from endocrinology clinic.
62803|NCT03693560|Drug|Glimepiride upto 4 mg Oral Tablet|Patients who the endocrinologist prescribed them Glimepiride 4 mg oral tablet plus their Metformin 1000 mg Oral Tablet
62804|NCT03693547|Drug|utidelone injection|utidelone monotherapy in patients with advanced NSCLC by utidelone
62805|NCT03693534|Diagnostic Test|Clinical Pregnancy Rate|The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS
62806|NCT03693521|Device|Handgrip strength measurement|Measurement of handgrip strength with Jamar hand-held dynamometer as a complement to standard care of patients with diabetes type 2 by diabetes-nurses.
62807|NCT03693521|Other|Standard care|Standard care of patients with diabetes type 2 by diabetes-nurses.
62808|NCT03693508|Drug|Genvoya®|Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
62809|NCT03693495|Diagnostic Test|ellume·lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic participants. The sample type used is a throat swab.
62810|NCT03693495|Diagnostic Test|Bacterial Culture|Pharyngeal swab is collected from participant and this specimen is inoculated into 5% sheep blood agar plates. Beta-haemolytic colonies are isolated, followed by latex agglutination test.
62811|NCT03693495|Diagnostic Test|Polymerase Chain Reaction (PCR)|Polymerase Chain Reaction (PCR) is a molecular diagnostic technique for the detection and identification of Group A Streptococcus, both for clinical samples and isolates. Polymerase Chain Reaction (PCR) allows template bacterial RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
62812|NCT03693482|Diagnostic Test|the Four Square Step test|A square will be formed by using four 90 cm long canes placed on the ground. The sequence will be explained and demonstrated to the participants. They will be allowed one practice trial and subsequently two trials. Instructions will be given and encouraged to complete the sequence as fast as possible without touching the canes. The sequence of trial was 1,2,3,4,1,4,3,2,1. If a participant touch the canes, or perform the test sequence inaccurately, or both feet of the participant do not make contact with the floor in each square, the trial will be considered as unsuccessful and the test will be repeated. One unsuccessful trial will be allowed. The best time will be taken as the score of FSST which are completed successfully.
62813|NCT03693469|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
62814|NCT03693456|Other|Conjunctival Allergen Challenge|Food allergen dissolved in water will be instilled in an increasing titrated fashion into the subjects eye and response will be graded according to proprietary scales.
62815|NCT03693443|Behavioral|early childhood caries|a questionnaire evaluates the oral health beliefs, knowledge, and behaviors of a sample representing Egyptian mothers toward early childhood caries
62816|NCT03693430|Drug|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
62817|NCT03693430|Drug|Placebo (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
62818|NCT03693417|Device|Heated circuit on|Heated circuit will be turned on.
62819|NCT03693417|Device|Heated circuit off|Heated circuit will be turned off.
62820|NCT03693404|Drug|Marcaine, Duramorph , ketorolac|Subjects in the SSI group will receive an injection of 40cc 0.25% Marcaine, 5 mg Duramorph (1 mg/cc, 5 cc total), and 30 mg of ketorolac (30 mg/cc, 1 cc total) into the periosteum, and musculature surrounding the fracture site and 0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
62821|NCT03693404|Drug|Bupivacaine (Marcaine)|0.25% Bupivacaine (Marcaine) 10 mL into the subcutaneous tissue surrounding the surgical incision.
62822|NCT03693404|Drug|General Anesthetics|Placebo group will only receive standard of care general anesthesia
62823|NCT03693391|Drug|JNJ-64140284|Single dose of JNJ-64140284 up to 3 mg oral solution will be administered under fasted conditions.
62824|NCT03693391|Drug|Fluorine-18 Labeled [18F]-JNJ-64511070|An intravenous (IV) bolus injection of 185 MegaBecquerel (MBq) [18F]JNJ-64511070 will be administered.
62825|NCT03693365|Procedure|PEEP trial|Positive end-expiratory pressure (PEEP) is increased from 5 to 10 cmH2O during one minute.
62826|NCT03693339|Drug|Capmatinib|Capmatinib 400 mg twice oral administration and continuously dosing (28-day treatment schedule as one treatment cycle)
62827|NCT03693326|Drug|PDR001|PDR001 300 mg (fixed dose) intraveneously every 3 weeks
62828|NCT03693313|Behavioral|CrossFit Kids exercise program|Participants will be actively participating in a 14 week twice weekly CrossFit Kids exercise program.
62829|NCT03693300|Drug|Durvalumab|Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.
62830|NCT03693287|Drug|Standardized-parenteral nutrition (S-PN)|NUMETA G13%E 300 mL is a triple-chamber (lipid emulsion, amino acids solution with electrolytes, and glucose solution), ready-to-use parenteral nutrition product available to treat preterm infants (less than 37 weeks gestational age).
63044|NCT03691610|Biological|Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
62831|NCT03693287|Drug|Personalized-parenteral nutrition (P-PN)|"Intravenous glucose will preferably be dextrose 50%, amino acids (AA) will be Primene® and lipids (FAT) will be Clinoleic®.~Parenteral nutrition bags will be prepared by the hospital pharmacy according to the prescription of the attending neonatologist."
62832|NCT03693274|Behavioral|BreathAware for Pain Management|Patients will be given access to a BreathAware, a 16- week web-based mindfulness course, which will be initiated at their enrollment. BreathAware is a self-paced course comprised of 2-3 minute lessons delivered via video, audio and technology-based guided instruction, and is available on a phone or tablet.
62833|NCT03693261|Procedure|Coronary artery bypass grafting (CABG)|CABG, as part of the standard medical care
62834|NCT03693261|Procedure|Valve replacement|cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
62835|NCT03693248|Drug|Two cycles of neoadjuvant chemotherapy|Two and three cycles of neoadjuvant chemotherapy will be administered in experimental and control groups, respectively
62836|NCT03693235|Procedure|bending angle of a lightwand|For tracheal intubation, investigators will bend the tracheal tube combined a lightwand by assigned angles (70, 80, or 90 degrees) for each patient. Next a practitioner will perform tracheal intubation with the bent tube.
62837|NCT03693222|Drug|Tramadol Hydrochloride|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
62838|NCT03693222|Drug|Morphine Sulfate|The Wong-Baker facial pain scale was used to assess pain (1: no pain, 10: worst possible pain). During monitoring patients with pain score ≥3 had intravenous 1 mg/kg tramadol hydrochloride administered, After 15 minutes following tramadol injection, cases with pain score continuing ≥3 were to be assessed as insufficient analgesia and had 0.1 mg/kg morphine hydrochloride planned for intravenous administration.
62839|NCT03693209|Behavioral|Volitional Help Sheet (VHS)|VHS with a general anger trigger and 10 anger management strategies
62840|NCT03693209|Behavioral|Volitional Help Sheet (VHS)|VHS with 10 specific anger triggers and 10 anger management strategies
62841|NCT03693196|Other|PICF, Perio-paper®|PICF was collected from the mesio-buccal area of the implant by using paper tapes. Paper tapes were placed 1-2 mm inside the peri-implant sulcus by using a dental tweezer. After they were kept for 30 s, the paper tapes were placed in sterile microcentrifuge tubes which contained 200 µL phosphate-buffered saline (PBS). The tubes were kept at -80°C until the analysis day. TNF-α, PGE2, RANKL, RANK, and OPG, which are immunological markers of peri-implant disease were compared between groups.
62842|NCT03693196|Other|Subgingival Plaque, Hu-Friedy®|Subgingival plaque samples were collected about 15 min after PICF was collected. Supragingival plaque was carefully removed by using a sterile scale. Implants were isolated using cotton rolls and dried with an air spray. Subgingival plaque samples were collected from the mesio-buccal area of the implant by using sterile plastic Gracey curettes during 30 s (Hu-Friedy). The samples collected were transferred to sterile microcentrifuge tubes containing 200 µL PBS. The tubes were kept at -80°C until the analysis day. Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, Fusobacterium nucleatum, Prevotella intermedia, and Streptococcus oralis, which are microbiological agents of peri-implantitis were compared between groups.
62843|NCT03693196|Other|Williams probe, PCPNU-15 Hu-Friedy®|Clinical periodontal measurements were recorded using Williams probe. The plaque index, gingival index, pocket depth, bleeding on probing, clinical attachment level, and keratinised tissue width around the implant were recorded. The implants included were categorised into three groups, namely, healthy, peri-implant mucositis, and peri-implantitis. Panoramic radiographs were acquired to assess the interproximal bone levels around the implant.
62844|NCT03693196|Other|Demographic|Age, gender and state of smoking were compared between groups.
62845|NCT03693183|Drug|Ketorolac/HPMC|0.30% Ketorolac/0.80%HPMC Ophthalmic solution administered 4 times per day for 2 days
62846|NCT03693183|Drug|HPMC|0.80% Hydroxypropyl Methylcellulose solution 4 times per day for 2 days
62847|NCT03693183|Drug|Vehicle|Vehicle
62848|NCT03693170|Drug|encorafenib|Once daily, orally
62849|NCT03693170|Drug|Binimetinib|Twice daily, orally
62850|NCT03693170|Drug|Cetuximab|Standard of care for the 28 first weeks and then every 2 weeks
62851|NCT03693144|Other|Full LIITA3H App|This is the full version of the LIITA3H mobile app that will use the Enhanced Location Identification (ELI) technology to identify when a user is in an eating venue and then deliver culturally and individually tailored point of purchase prompts (POP) to encourage healthy choices and will allow participants to take pictures of the food they purchase using the Self-report of Nutrients with Annotated Photos (SNAP) function.
62852|NCT03693144|Other|Partial LIITA3H App|This is a version of the LIITA3H mobile app that will track participants' location and allow them to submit photos of their food.
62853|NCT03693144|Other|LIITA3H Location only|This is a version of the LIITA3H mobile app that will only track participants' location.
62854|NCT03693131|Drug|Icosapent (MND-2119)|Icosapent (MND-2119) capsules.
62855|NCT03693131|Drug|Icosapent (EPADEL CAPSULES 300)|Icosapent (EPADEL CAPSULES 300) capsules.
62856|NCT03693118|Behavioral|Reh1,Reh2|The initial group comprised 86 subjects including. The Nine Hole Peg Test (NHPT), administered to all of the patients, was used to evaluate the subjects' manual dexterity. The standardized scale enabled obtaining scores of high validity (right: r= 0.984, left: r = 0.993). Having been administered the NHPT test the initial 86-patient group was reduced to a cohort of 40 subjects qualified for the study, who were subsequently randomly divided into two groups - the study and the control - each consisting of 20 subjects. Three times a week the study group received the upper limb treatment by means of the cognitive function platform. They were expected to achieve 96 levels of visuo-motor coordination in 3 months or the treatment was to be terminated. Prior to the first session of the treatment the patients were provided with all relevant instructions and information about the test displayed on the monitor. They could also choose which hand they would start with.
62857|NCT03693105|Device|Accelerated theta burst stimulation|All participants will receive iTBS (intermittent theta burst stimulation), either to the left DLPFC or ACC. Stimulation intensity will be individualized according to the individual's resting motor threshold.
62858|NCT03693079|Procedure|Wet cupping therapy|"CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46). The cupping technique procedure was conducted in five phases:~Primary suction; cups are left attached to the skin for 5 minutes.~Area disinfection; areas are wiped with sterile gauze after disinfection with povidone iodine.~Scarification; Superficial incisions (20-30 gauge), 5 mm length and 1-2 mm depth, are made on the skin with a sterile, number 11 surgical blade.~Bloodletting and secondary suction; the cups which had been previously removed are placed again on the scarified areas Blood leaks from the capillary vessels of the skin and subcutaneous tissue and fills the cups, which are left in place for 15 minutes.~Removing and dressing; the cups full of blood are removed. The areas of application are wiped with sterile gauze and then a dressing is applied"
62859|NCT03693066|Other|Ozone|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.
62860|NCT03693066|Other|chlorhexidine digluconate|In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.
62861|NCT03693066|Other|Control|
62862|NCT03693040|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their PrEP medication. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their PrEP medication.
62863|NCT03693027|Dietary Supplement|PTx800 lozenges|PTX800 is a nutritional supplement containing generally recognized as safe designated active ingredients in a rapid melt oral lozenges.
62864|NCT03693027|Dietary Supplement|Placebo control|The placebo of PTX800 is a rapid melt oral lozenge without the active ingredients found in the PTX800 lozenges.
62865|NCT03693014|Radiation|Stereotactic Body Radiotherapy|(27 Gy over 3 fractions)
62866|NCT03693014|Biological|Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab|The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
62867|NCT03693001|Device|Intermittent Exposure to Oxygen via Oro-Nasal Mask|Patients were exposed to breathing 100% oxygen at 2 atmospheres absolute (ATA) in a multiplace pressure chamber for 90 minutes using an oro-nasal mask for 40 treatments over a 2 month period.
62868|NCT03692988|Behavioral|Dignity Therapy|Dignity Therapy (DT) invites individuals with life-limiting illnesses to reflect on matters of importance to them and compiles them in a narrative document for the patient to share.
62869|NCT03692975|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
62870|NCT03692975|Other|Neuropsychological evaluation|cognitive tests exploring episodic memories, information processing speed, attention/concentration and working memory.
62871|NCT03692975|Other|Psychological evaluation|included questionnaires for depression, anxiety, fatigue, cognitive complaint and reserve
62872|NCT03692975|Device|MRI Evaluation|Diffusion including NODDI, 3DT1 with and without gadolinium, 3D-FLAIR before and after gadolinium infusion, 3D White Matter nulled-MPRAGE, 3D Double-Inversion recovery sequences-weighted imaging and Resting state functional MRI
62873|NCT03692962|Behavioral|Sleep restriction|Time in bed will be restricted to 5 hours per night for 7 nights.
62874|NCT03692962|Other|Acoustic stimulation|Brief tones will be presented time-locked to ongoing slow waves during deep sleep.
62875|NCT03692949|Drug|LY3451838|One dose administered (IV)
62876|NCT03692949|Drug|Placebo|Administered IV
62877|NCT03692949|Drug|Placebo|Administered SC
62878|NCT03692949|Drug|LY3451838|One dose administered SC
62879|NCT03692923|Other|virtual community|
62880|NCT03692910|Drug|SAGE-217|SAGE-217
62881|NCT03692897|Other|TAF|Patients who have a medication history of TAF
62882|NCT03692871|Biological|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
62883|NCT03692871|Biological|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
62884|NCT03692858|Drug|Adductor Canal Block plus IPACK Block|Adductor Canal Block plus IPACK Block using Ropivacaine
62885|NCT03692858|Drug|Adductor Canal Block|Adductor Canal Block using Ropivacaine
62886|NCT03692845|Procedure|Transforaminal Lumbar Interbody Fusion either open or minimally invasive|Spinal fusion procedure through the intervertebral foramen
62887|NCT03692832|Procedure|LH|Laparoscopic hysterectomy (TLH or LHa)
62888|NCT03692832|Procedure|VH|Vaginal hysterectomy
62889|NCT03692819|Drug|Placebo Oral Tablet|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session.
62890|NCT03692819|Drug|Amoxicillin 500 Mg|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the antibiotic (Metronidazole 400mg + Amoxicillin 500mg) every 8 hours for 7 days
62891|NCT03692819|Drug|Lactobacillus reuteri Oral Drops|Non-surgical periodontal treatment will be performed by means of periodontal debridement in a single session after the therapy will be administered the probiotic (Lactobacillus reuteri oral drops ) twice a day for 21 days.
62892|NCT03692806|Dietary Supplement|Stablor|Stablor sachet
62893|NCT03692806|Dietary Supplement|placebo|placebo sachet
62926|NCT03692455|Procedure|Vertical Sleeve Gastrectomy|VSG surgery restricts food intake and decreases the amount of food used. Most of the stomach is removed during this surgery, which may decrease ghrelin, a hormone that prompts appetite. Lower amounts of ghrelin may reduce hunger more than other purely restrictive surgeries, such as AGB.
62894|NCT03692793|Other|Pulmonary rehabilitation|Patients will perform continuous aerobic training (treadmill walking) during 30min (60% of the 6MWT mean speed) and progression according to dyspnea (4-6 of the modified Borg scale). Upper limbs resistance training will be performed using the modified diagonals from the proprioceptive neuromuscular facilitation method (2 sets of 2min). Lower limbs strength training will be performed for quadriceps and triceps sural (2 sets of 10 repetitions), with progression when the patients report that the exercise are ´easy´. All the muscle exercised and the breathing accessory muscles will be stretched for 30s. Eleven educational sessions will be delivered addressing topics related to COPD self-management.
62895|NCT03692780|Drug|Careseng 1370|4,000mg granules in sachet
62896|NCT03692780|Drug|Placebo|4,000mg granules in sachet
62897|NCT03692767|Biological|Anti-CD22 CAR NK Cells|Anti-CD22 CAR NK Cells injection
62898|NCT03692754|Drug|Atorvastatin 20mg|Atorvastatin will be given in 20 mg po qn for 1 year
62899|NCT03692754|Drug|Atorvastatin 10mg|Atorvastatin will be given in 10 mg po qn for 1 year
62900|NCT03692728|Other|Psychological and Behavioral Problems|Differences in age and sex between the CC and NV groups were compared using the independent samples t test and Chi-square test, respectively. Comparisons of abnormal rates between the CC and NV groups were performed using the Chi-square test. Scores on all subscales recorded for the CC group were compared with those of the NV group and the Chinese urban norm using the independent samples t test and one-sample t test, respectively.
62901|NCT03692715|Drug|Ciprofloxacin|Oral or intravenous ciprofloxacin prior to shockwave lithotripsy.
62902|NCT03692715|Drug|Placebo|identical oral placebo if oral cipro was used, or intravenous saline alone in a blinded fashion if IV cipro was used prior to shockwave lithotripsy.
62903|NCT03692702|Behavioral|WE PLAY|WE PLAY is an online preschool teacher training that is based in theory and implementation science. It contains six components: (1) online training; (2) video library; (3) game sheets; (4) teacher self-assessment; (5) supervisor support; and (6) activity packs containing low cost physical activity equipment
62904|NCT03692689|Biological|SCT200|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）
62905|NCT03692676|Device|Spiriva Respimat|soft-mist inhaler
62906|NCT03692663|Biological|anti-PSMA CAR NK cells|Total dose of 500 thousand-3 million /kg anti-PSMA CAR NK cells will be administered at day0
62907|NCT03692637|Biological|anti-Mesothelin Car NK Cells|anti-Mesothelin Car NK Cells injection
62908|NCT03692624|Behavioral|Biofeedback|Heart Rate Variability Biofeedback
62909|NCT03692611|Behavioral|Skills TO Manage Pain (STOMP)|12 week pain self management (PSM) intervention incorporating social cognitive theory constructs.
62910|NCT03692611|Behavioral|comparison group|Participants in this arm will receive usual care as given by providers but no behavioral PSM intervention.
62911|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Surgical|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach
62912|NCT03692598|Device|MIA, Minimally Invasive Annuloplasty Device - Percutaneous|Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach
62913|NCT03692572|Dietary Supplement|Nitrate supplementation|Subjects will drink 70 ml of beet root juice twice a day for 2 weeks.
62914|NCT03692572|Dietary Supplement|placebo|Subjects will drink 70 ml of nitrate depleted placebo juice twice a day for 2 weeks.
62915|NCT03692559|Other|full aseptic dressing|Replacement of the central venous catheters in the dressing process
62916|NCT03692546|Drug|Liposomal bupivacaine (LB)|Addition of LB solution to soft tissue surgical field block to a standard interscalene block procedure
62917|NCT03692533|Diagnostic Test|Immunohistochemistry|"Histopathological study and evaluation:~For each case, the tissue samples will be evaluated by the pathologist for detecting the histopathology and in cases of malignant renal spicemens the pathologist will also assess the histologic type, Fuhrman nuclear grade, cellular invasion of perinephric fat, and the extent of any vascular invasion seen by microscopy.~Immunohistochemistry:~Immunohistochemical staining will be performed by using the following antibodies: Geminin and Minichromosome maintenance-2 (MCM-2).~Evaluation of the immunohistochemical staining will be performed by light microscopy. The interpretation of immuno-reactivity will be performed in a quantitative manner by analyzing the extent of the staining positivity of the tumor cells. Immuno-staining of greater than 10% of tumor cells is required for scoring as a positive case."
62918|NCT03692520|Biological|SCT200|Recombinant Anti-EGFR Monoclonal Antibody （SCT200）
62919|NCT03692507|Dietary Supplement|HMB|Patients in the first group (HMB only) will take 3 capsules of HMB by VitaMonk™ (1000mg/capsule) daily (morning, noon, and night) for 14 days prior to surgery.
62920|NCT03692507|Dietary Supplement|Protein and HMB|Patients in the second group (HMB + protein) will drink 2- 8oz bottles of Ensure Enlive daily (morning and night) for 14 days prior to surgery. Each bottle contains 1500mg of HMB and 20 g of protein.
62921|NCT03692494|Other|Standard of care voice therapy|Exercises will include improved breath coordination, sustained humming and vowels, vocal glides, resonant voice therapy, and relaxation techniques to the neck and shoulder
62922|NCT03692494|Device|Expiratory muscle strength training (EMST)|EMST150 used at 75% of their maximum expiratory pressure. Participants will be directed to perform 5 sets of 5 breaths, 5 days per week, for 5 weeks, at the pressure threshold established in therapy. Maximum expiratory pressure will then be determined at the beginning of each therapy session and recalibration of the device will be performed if indicated.
62923|NCT03692481|Radiation|18FDG-PET scan|18FDG PET scan will be performed in each patient before initiation of pirfenidone and after 12 weeks of treatment
62924|NCT03692468|Behavioral|Psychotherapy|Participants will complete 5, 60 minutes sessions. At each session, participants will learn strategies that have been shown to improve pain functioning and/or mood for patients who have chronic pain. The intervention will be delivered in the patient's primary care clinic.
62925|NCT03692455|Procedure|Roux-en-Y Gastric Bypass|The Roux-en-Y gastric bypass procedure involves creating a stomach pouch out of a small portion of the stomach and attaching it directly to the small intestine, bypassing a large part of the stomach and duodenum. Not only is the stomach pouch too small to hold large amounts of food, but by skipping the duodenum, fat absorption is substantially reduced.
63078|NCT03691480|Procedure|Fuhrman catheter and ambulatory care|Fuhrman catheter and ambulatory care
62927|NCT03692429|Drug|CYAD-101|CYAD-101 has the potential to treat many of distinct tumor-types (solid and hematological). This Phase I study will explore the hypothesis that targeting of NKG2D-ligands with an allogeneic CAR T-cells, CYAD-101, concurrently with standard chemotherapy in patients with metastatic colorectal cancer is safe and might potentially improve the patients' outcome.
62928|NCT03692416|Drug|Ibuprofen|"Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests & Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Ibuprofen for ANCA, C3, C4 &C5a levels done, measured By ELISA technique."
62929|NCT03692416|Drug|Prednisone|"Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests & Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Steroids for ANCA, C3, C4 &C5a levels done, measured By ELISA technique."
62930|NCT03692416|Drug|Methotrexate|"Infants and children with vasculitis attending AssiutU, aged > 1 mo. - 17 yr. of both genders will be included during 2 years of study.~Besides full clinical history and thorough examination, all cases will have: CBC, CRP, ESR, Renal function tests & Albumin / creatinine ratio.~All cases will have an initial estimation as well as follow up estimation after treatment by Methotrexate for ANCA, C3, C4 &C5a levels done, measured By ELISA technique."
62935|NCT03692390|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
62936|NCT03692377|Device|Virtual Reality|Stage 1 : Demonstration of the use of the VR headset by the research assistant (anticipated 1-2 min) Stage 2 : Child will choose the application they would like to see - they will be shown 3 pages of the three applications offered - see Fig 1 (anticipated 1-2 min) Stage 3 : Handling of the VR headset by the child (anticipated 1 min) Stage 4 : Applying the headset on the eyes of the child with software application (anticipated 1 min) Stage 5 : The child use the VR set and application (up to 10 minutes) Stage 6 : Removal of the headset (anticipated 1 min) Stage 7 : Questionnaire to child (interview - 2 minutes) Stage 8 : Questionnaire to parents/guardians (interview - 2 minutes)
62937|NCT03692364|Device|Ceramic-on-ceramic uncemented hip arthroplasty|
62938|NCT03692364|Device|Metal-on-polyethylene uncemented total hip arthroplasty|
62939|NCT03692351|Device|Uncemented acetabular cup with screw holes|
62940|NCT03692351|Device|Uncemented acetabular cup without screw holes|
62941|NCT03692338|Behavioral|Exercise|Patients will be asked to complete 3 x 30 minute exercise sessions each week.
62942|NCT03692325|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
62943|NCT03692312|Drug|Tideglusib|Tideglusib for oral suspension, weight-adjusted at 400mg, 600mg or 1000 mg dose levels, once daily
62944|NCT03692312|Drug|Placebo|Matching placebo formulation
62945|NCT03692299|Drug|Saccharomyces Boulardii Oral Tablet|Saccharomyces boulardii 200 mg b.i.d. during 2 weeks, followed by a 2-week rest period and then again 200 mg b.i.d. during 2 consecutive months.
62946|NCT03692299|Drug|Metronidazole|Metronidazole 500 mg b.i.d during 1 week, followed by a 3-week rest period and then again 500 mg b.i.d during 2 consecutive months
62947|NCT03692286|Combination Product|Silver nanoparticle/Calcium hydroxide|Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide
62948|NCT03692286|Drug|Silver Nanoparticles in gel form|Intracanal medication composed of silver nanoparticles in gel form
62949|NCT03692286|Drug|Calcium Hydroxide Intracanal medication|Calcium hydroxide intracanal medication
62950|NCT03692273|Procedure|Luminis ultrapulse fractional ablative carbon dioxide laser|This laser will target water molecules and ablate columns of tissue that are approximately 3mm deep.
62951|NCT03692273|Procedure|0.5mm punch biopsy|punch biopsies will be performed to remove approximately equivalent volumes of tissue compared to the laser
62952|NCT03692260|Procedure|3D stent in Herbert screw insertion vs titanium plate|benefit of 3d template in fracture gap
62953|NCT03692247|Other|Smartphone-based Music Intervention|The smartphone-based music intervention (Unwind) is a music protocol that gathers basic information from the patient including a 0-10 pain scale and 0-10 anxiety scale as well as recorded heart rate. Using these variables, a machine learning protocol pieces together a music intervention between 5-20 minutes long. The duration of the intervention can be controlled by the patient or experimenter. No identifying data is kept on the smartphone.
62954|NCT03692234|Dietary Supplement|125 mg L-homoarginine|capsules for oral supplementation
62955|NCT03692234|Other|placebo|capsules for oral supplementation
62956|NCT03692221|Drug|MSC Treatment group 1 (low dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
62957|NCT03692221|Drug|MSC Treatment group 2 (high dose)|Autologous Bone Marrow Derived Mesenchymal Stem Cells (MSC) - A one time injection of 1-2 ml of a 4 x 106/ml concentration solution
62958|NCT03692221|Other|Healthy Control (no treatment)|Comparative analysis of psychometric and morphometric based data
62959|NCT03692208|Behavioral|My Diabetes Goal Survey and Optional Care Management|The intervention is already described in the intervention arm description.
62960|NCT03692195|Device|WHOOP Strap 2.0|The WHOOP Strap 2.0 is worn on the wrist, continuously throughout the 7-day period of which participants will be assigned. It measures heart rate, sleep, strain, and recovery.
63036|NCT03691636|Device|Eyelash prostheses|Eyelash prostheses are essentially specialized eyelash extensions
63037|NCT03691636|Device|5.0% Lifitegrast Ophthalmic Solution|5.0% Lifitegrast Ophthalmic Solution
63038|NCT03691623|Drug|EDP-938 Dose 1|Oral suspension for 5 days
62961|NCT03692169|Procedure|Half-dose photodynamic therapy|Half-dose photodynamic therapy was achieved by administering 3mg/m² of Verteporfin (Visudyne; Novartis, Switzerland) intravenously over a period of 10 minutes. Fifteen minutes after commencing the verteporfin infusion the greatest linear dimension was exposed to a 689 nm laser light with a florescence of 600 mw/cm² for 83 seconds and a total energy of 50 J/cm². Optical coherence tomography angiography (OCTA) with the split-spectrum amplitude-decorrelation angiography algorithm (XR Optovue, Fremont, CA, USA) and spectral domain OCT (SD-OCT) were performed at baseline and each follow-up (one month and three months) visit after hd-PDT.
62962|NCT03692143|Drug|Teriparatide|subcutaneous injection of teriparatide(20 mg) once daily
62963|NCT03692143|Procedure|PVP|With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
62964|NCT03692143|Drug|Alendronate|Alendronate Sodium, oral, 70mg, once a week
62965|NCT03692130|Behavioral|Mindfulness, Acceptance and Commitment-Therapy|Psychotherapeutic intervention to treat depressive patients with special exercises and education to be mindful, to accept situations and behaviors and to commit with the situation or the possibility to change.
62966|NCT03692130|Behavioral|Jacobson|Relaxation treatment in technique of Jacobson
62967|NCT03692117|Device|Extracorporeal Carbon Dioxide Removal|Place a double lumen catheter in jugular vein, drainage the venous blood in vitro tube, after blood-gas exchange and remove CO2, then return back to the Superior vena cava
62968|NCT03692104|Diagnostic Test|transrectal ultrasound|Use of US for post implant quality assessment
62969|NCT03692091|Procedure|Subacromial Injection|Injection in to subacromial space in the shoulder from anterior portal
62970|NCT03692078|Other|OTDN product 1|Oral tobacco-derived nicotine product
62971|NCT03692078|Other|OTDN product 2|Oral tobacco-derived nicotine product
62972|NCT03692078|Other|Tobacco Cessation|Tobacco Cessation
62973|NCT03692065|Drug|Apixaban 5 MG|Subjects will be randomized (1:1 ratio) to apixaban 5 mg bid (full dose) or apixaban 2.5 mg bid (reduced-dose) using a centralized IWRS (double blind study).
62974|NCT03692052|Drug|AG-348|"Core period: Participants will receive an initial AG-348 dose of 50 mg BID, oral tablets, and may undergo one potential dose-level increase to 100 mg BID, based on an evaluation of the participant's safety profile and Hb concentrations.~Extension Period: Participants who achieve a Hb response with an acceptable safety profile will continue receiving treatment with AG-348 for up to 2 years at the same dose they were receiving at the Week 24 Visit."
62975|NCT03692039|Procedure|M-pro files in rotating motion|An endodontic file that has controlled memory properties
62976|NCT03692039|Procedure|ProTaper Next files in rotating motion|An endodontic file that has an off center mass of rotation
62977|NCT03692026|Procedure|Immediate implant placement|implants will be placed in freshly extraction sockets with or without application of Hyaluronic acid and Melatonin mixture.
62978|NCT03692026|Drug|Hyaluronic acid and Melatonin Mixture|a mixture of hyaluronic acid and melatonin will be prepared and added topically to the implant surface, extraction socket and peri-implant area for the study group
62979|NCT03692013|Drug|Losartan|Participants will be divided into 2 groups as daytime group and nighttime group The participants in daytime group will take 100-200mg Losartan in the morning between 6AM to 8AM. The participants in nighttime group will take 100-200mg Losartan at night between 9PM to 11PM .
62980|NCT03691987|Biological|Preprocessed thawed donor FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
62981|NCT03691987|Biological|Preprocessed thawed autologous FMT|Delivered as an enema using the same equipment and technique as X-ray of the colon
62984|NCT03691961|Other|Hair sampling|After 4 months of treatment, a strand of hair from the vertex posterior region of the scalp about the width of a thin pencil and with a length equal to or greater than 3 cm will be cut.
62985|NCT03691961|Diagnostic Test|Hair's drug concentrations|The hair's concentrations of budesonide/formoterol is analysed with mass spectrometry.
62988|NCT03691935|Drug|Ropivacaine|Erector Spinae Block with ropivacaine infusion with standard of care analgesics for perioperative pain control
62989|NCT03691935|Drug|Normal saline|Erector Spinae Block with saline infusion with standard of care analgesics for for perioperative pain control
62990|NCT03691922|Procedure|Erector Spinae Plane (ESP) Block|"Preoperative US guided ESP blockade using 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine, injected in 5-mL aliquots through the needle (maximum of 3 mg/kg)~PAI of 30 mL of saline at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
62991|NCT03691922|Procedure|Periarticular Infiltration (PAI)|"Preoperative US guided ESP blockade using 30 mL of saline, injected in 5-mL aliquots through the needle~PAI of 30 mL of 0.25% bupivacaine with 5 mcg/mL of epinephrine at the end of the surgical procedure on the operated side rotator cuff, injected in 5-mL aliquots through the needle"
62992|NCT03691909|Drug|HB-adMSC|Hope Biosciences autologous adipose-derived mesenchymal stem cells
62993|NCT03691896|Dietary Supplement|Cholecalciferol 400|dose 400 UNT/day for 12 months
62994|NCT03691896|Dietary Supplement|Cholecalciferol 800|dose 800 UNT/day for 12 months
62995|NCT03691896|Drug|Cholecalciferol 1200|dose 1200 UNT/day for 12 months
63039|NCT03691623|Drug|EDP-938 Dose 2|Oral suspension for 5 days
63040|NCT03691623|Drug|Placebo|Oral suspension for 5 days
63041|NCT03691623|Drug|EDP-938 Dose 3|Oral suspension for 5 days
63042|NCT03691623|Drug|EDP-938 Dose 4|Oral suspension for 5 days
62996|NCT03691870|Procedure|Standard Trans-Arterial Embolization (TAE)|"The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.~If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means."
62997|NCT03691870|Procedure|Trans-Venous Embolization (TVE)|"The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.~The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion."
62998|NCT03691857|Procedure|Ultrasound algorithm (EMERALD-US)|Ultrasound algorithm EMERALD-US is an dedicated to emergencies using lung, cardiac and vascular ultrasound for the 3 main dyspnea causes (heart failure, pneumonia and obstructive pulmonary disease exacerbation) in patients with acute non-traumatic dyspnea managed in the emergency department. The ultrasounds will be performed within first hour after first medical contact in emergency department by another emergency physician not in charge of the patient. The ultrasound results will be not shared with the emergency physician in charge of the patient.
62999|NCT03691844|Drug|AMZ001|diclofenac gel
63000|NCT03691844|Drug|Placebo|Placebo
63001|NCT03691844|Drug|Comparator|diclofenac gel
63002|NCT03691831|Drug|A-101|hydrogen peroxide 45% topical solution
63003|NCT03691831|Other|Vehicle|Vehicle solution containing isopropyl alcohol and water
63004|NCT03691818|Drug|X0002 Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
63005|NCT03691818|Drug|Ibuprofen Tablet|Ibuprofen Tab 400mg, tid.
63006|NCT03691818|Drug|Ibuprofen Placebo Tab|Ibuprofen Placebo Tab 400mg, tid.
63007|NCT03691818|Drug|X0002 Placebo Spray|According to the different dose groups assigned, each knee joint was sprayed with 1, 2 or 4 sprays.
63008|NCT03691805|Device|tDCS|The participants will receive anodal tDCS (transcranial direct current stimulation) of the right dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
63009|NCT03691805|Device|Sham tDCS|The participants will receive sham tDCS (transcranial direct current stimulation) of the dorsolateral prefrontal cortex for 20 minutes on five consecutive days.
63010|NCT03691792|Behavioral|Cognitive-Behavioral Therapy (CBT-SAD)|12 group sessions over 6 weeks
63011|NCT03691792|Other|Light Therapy|10,000-lux initiated at 30 min upon waking and adjusted per treatment algorithm, continuing for 6 weeks
63012|NCT03691779|Drug|VX-445|Fixed dose combination (FDC) tablet (VX-445/TEZ/IVA)
63013|NCT03691779|Drug|TEZ|FDC tablet (VX-445/TEZ/IVA)
63014|NCT03691779|Drug|IVA|FDC tablet (VX-445/TEZ/IVA) and IVA mono tablet
63015|NCT03691766|Other|Photobiomodulation Therapy|Photobiomodulation therapy, a mix of red lights thought to improve mitochondrial function will be applied in and acute and chronic manner to test whether muscle fatigue improves in persons with MS.
63016|NCT03691766|Other|Placebo|Device with sham light source
63017|NCT03691753|Device|Fitaya Vena Cava Filter System|After the implantation of Fitaya Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
63018|NCT03691753|Device|Aegisy Vena Cava Filter|After the implantation of Aegisy Vena Cava Filter, the filter can be withdrawn from the patient within the window period (60 days) by using the withdraw system in junction of the sheath.
63019|NCT03691740|Device|Ocular light|A light mask to which small light emitting diode(LED) lights emitting a blue or red color light will be used to deliver ocular light
63020|NCT03691727|Drug|tirofiban hydrochloride (AGGRASTAT®)|Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
63021|NCT03691727|Diagnostic Test|MRI|Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
63022|NCT03691727|Diagnostic Test|Neurological Exam|Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
63023|NCT03691727|Behavioral|Questionnaires|Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
63024|NCT03691727|Diagnostic Test|Vital Signs|Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
63025|NCT03691727|Other|Standard of Care Treatment|Participants will receive standard of care treatment and will not receive study drug.
63026|NCT03691714|Drug|Durvalumab|One hour infusion
63027|NCT03691714|Drug|Cetuximab|Two hour infusion for loading dose followed by weekly one hour infusion
63028|NCT03691701|Other|strict blood pressure control|Home SBP target < 120 mmHg or 90th percentile for age and height (whichever is lower)
63029|NCT03691688|Drug|Aspirin 100 mg|Aspirin 100mg will be prescribed for antiplatelet therapy at the physician`s discretion
63030|NCT03691688|Drug|Clopidogrel 75mg|Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician`s discretion
63031|NCT03691675|Device|Drug coated balloon|Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
63032|NCT03691662|Drug|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months
63033|NCT03691662|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months
63034|NCT03691649|Drug|DE-117 Ophthalmic Solution|Topical DE-117 Ophthalmic Solution once daily and Vehicle once daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
63035|NCT03691649|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Topical Timolol Maleate Ophthalmic Solution 0.5% twice daily for 3 months for all subjects, followed by DE-117 Ophthalmic Solution once daily for additional 9 month for adult subjects only
63045|NCT03691610|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
63046|NCT03691610|Biological|Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine|Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
63047|NCT03691610|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
63048|NCT03691610|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
63049|NCT03691610|Biological|Haemophilus b Conjugate Vaccine|Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
63050|NCT03691610|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
63051|NCT03691610|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
63052|NCT03691610|Biological|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
63053|NCT03691610|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
63054|NCT03691610|Biological|Varicella Virus Vaccine Live|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
63055|NCT03691597|Diagnostic Test|improved patient satisfaction ,marginal integrity, shade match and gingival health|"For both groups N.Awill make a recall visit after6 months and after 12 months:~Patient satisfaction will be performed according to questionnaire after One year.Questionnaire will contain several questions that evaluate patient satisfaction.~The color will be measured using spectrophotometer Vita easy shade in the same delivery visit ,after 6months and after one year .~Images will be captured using digital handheld light microscope (Celestron 5 Megapixel Resolution, USA) that is fixed on a film holder on a specific distance for the standardization of all the images will be captured by the microscope for all the patients.(22)~Images will be analyzed using imageJ software to measure marginal gap.~Gingival health will be measured using G"
63056|NCT03691584|Drug|TP-6076|The dose planned to be administered in this study is an iv infusion of 30 mg TP 6076 q24h for 4 consecutive days (starting on Day 1 and ending on Day 4).
63057|NCT03691584|Procedure|Bronchoalveolar lavage|Subjects will be randomized to undergo a BAL at a single time point: either 2, 4, 8, or 24 hours after the start of the final TP-6076 iv infusion on Day 4.
63058|NCT03691571|Device|Esophageal Cooling|The EnsoETM is a non-sterile multi-lumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while simultaneously allowing gastric decompression and drainage.
63059|NCT03691571|Device|Control|Standard of care involves standard temperature probe monitoring.
63060|NCT03691558|Other|Ketogenic diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, & Compher, 2005; Wang et al., 2000). Macronutrients percentage is 68% fat, 26% protein and 6% carbohydrate Paoli et al. 2013). Very low carbohydrate foods that simulate carbohydrates taste food like croissants, bread and cracked slices made by Le Gamberi Foods (Forlì, Italy), are used for a better compliance to the dietary intervention
63061|NCT03691558|Other|Western Diet|total daily caloric intake was divided into 5 meals. Individual daily caloric need is calculated referring to body composition and adjusted for daily activity (Frankenfield, Roth-Yousey, & Compher, 2005; Wang et al., 2000). The diet macronutrient percentage distribution is the following: protein is 25% of TDC (total daily calories), fat is 20% of TDC and carbohydrates represented the 55% of TDC
63062|NCT03691545|Behavioral|interactive sessions|This arm will receive personalized health coaching (behaviour change counseling)
63063|NCT03691532|Behavioral|Seated control (CON)|Seated rest
63064|NCT03691532|Behavioral|Arm cycle exercise (ACE)|Arm cycling at a continuous power output
63065|NCT03691532|Behavioral|Liquid meal|Liquid meal of 0.5 L volume containing 20 kcal/kg fat free mass (FFM) and 5 mg/kg FFM of uniformly 13-carbon labeled palmitate ([U-13C]palmitate) at a macronutrient distribution of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
63066|NCT03691519|Dietary Supplement|Omega-3 treatment|"Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day)."
63067|NCT03691519|Dietary Supplement|Placebo|"The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day).~For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day)."
63068|NCT03691506|Other|Classic CIMT group|Constraint Induced Movement Therapy (CIMT) is a new treatment technique that claims to improve the arm motor ability and the functional use of a paretic arm - hand. CIMT forces the use of the affected side by restraining the unaffected side. Child with hemiplegic cerebral palsy can learn to improve the motor ability of the more affected parts of their bodies and thus cease to rely exclusively or primarily on the less affected parts.
63069|NCT03691506|Other|Modified CIMT group|Modified CIMT protocol that was based on suggestions made by Dromerick, Edwards, and Hahn (2000) . Modifications were reductions in the duration of mitt wear and massed practice compared with the traditional protocol
63070|NCT03691493|Drug|Anastrozole|Given PO
63071|NCT03691493|Drug|Exemestane|Given PO
63072|NCT03691493|Drug|Fulvestrant|Given IM
63073|NCT03691493|Drug|Letrozole|Given PO
63074|NCT03691493|Drug|Palbociclib|Given PO
63075|NCT03691493|Radiation|Radiation Therapy|Undergo radiation therapy
63076|NCT03691493|Drug|Tamoxifen|Given PO
63077|NCT03691480|Procedure|simple exsufflation|simple exsufflation
63081|NCT03691454|Drug|Docetaxel|Docetaxel 50mg/m2, intravenous drip, D1, combined with Oxaliplatin 85mg/m2，intravenous drip 2h，D1 and S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-7；For patients with Her2 positive, add Herceptin 4mg/kg(6mg/kg first cycle) D1; every 14 days for a cycle.
63082|NCT03691454|Drug|Oxaliplatin|Oxaliplatin 130mg/m2，intravenous drip 2h，D1 combined with S-1 40-60mg bid(BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid)，D1-14；For patients with Her2 positive, add Herceptin 6mg/kg(8mg/kg first cycle) D1; every 21 days for a cycle.
63083|NCT03691441|Procedure|Resection|Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.
63084|NCT03691441|Radiation|Radiotherapy|6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible
63085|NCT03691441|Drug|Chemotherapy|The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.
63086|NCT03691441|Procedure|Salvage neck dissection|+/- Salvage neck dissection 12±2 weeks after treatment
63087|NCT03691428|Behavioral|Wish Outcome Obstacle Plan|"1. Wish or goal: A wish (e.g. responding calmly when the partner asks a question repeatedly). 2. Outcome: The most positive outcome of realizing the wish or goal (e.g. both partners feel respected and happy). Then the participant vividly imagines the outcome. 3. Obstacle: The most critical internal, controllable, obstacle (e.g., feeling impatient). Then the participant vividly imagines the internal obstacle occurring. 4. Plan: The participant answers the following question: What action can I take or what thought can I think to overcome the obstacle (e.g., take a deep breath, take my partner's perspective, and answer the question calmly); then he or she forms an if [specified obstacle - when I feel impatient], then I will [specified action or thought to overcome obstacle - take a deep breath, take my partner's perspective, and answer the question calmly] plan."
63088|NCT03691415|Drug|BELKYRA Inj.|Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
63089|NCT03691402|Behavioral|MCT-Silver|Metacognitive training for depression in later life (MCT-Silver) is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
63090|NCT03691402|Behavioral|Cognitive Remediation|mybraintraining© is a computer-based cognitive remediation program, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The program is administered individually on personal computers and each session lasts approximately 45-60 min. To match the MCT-Silver group, participants will complete up to eight sessions of cognitive remediation.
63091|NCT03691376|Biological|Aldesleukin|Given SC
63092|NCT03691376|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
63093|NCT03691376|Other|Cellular Therapy|Given autologous NY-ESO-1 CD4-TCR CD34+ HSC IV
63094|NCT03691376|Drug|Melphalan|Given IV
63095|NCT03691363|Behavioral|M-STEP|Youth will be assessed using actigraphy at baseline, and will then be asked to exercise for 1) a duration of 10 minutes > MVPA at baseline with 2) HR>120 while being monitored by a Fitbit. Youth will be asked to exercise daily, and intensity and duration will be increased every few days for a goal of 60 minutes per day at a HR>140 (low end of MVPA). The intervention will be 6 weeks in duration.
63096|NCT03691350|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
63097|NCT03691350|Drug|Cigarette|Smoke usual brand
63098|NCT03691350|Other|Electronic Cigarette|Smoke SREC with nicotine
63099|NCT03691350|Other|Electronic Cigarette|Smoke SREC without nictoine
63100|NCT03691350|Other|Laboratory Biomarker Analysis|Correlative studies
63101|NCT03691350|Drug|Nicotine Replacement|Receive NRT comprising patch, gum, or lozenge
63102|NCT03691350|Other|Questionnaire Administration|Ancillary studies
63103|NCT03691337|Drug|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.11 mL x subject height
63104|NCT03691337|Drug|Marcaine 0.25 % Injectable Solution|Fascia iliaca block with volume 0.22 mL x subject height
63105|NCT03691337|Drug|Sodium chloride|Fascia iliaca block with volume 0.11 mL x subject height
63106|NCT03691324|Other|Inhalation technique training and discharge service|Patient drug counselling one-to-one, focusing on inhalation drugs and technique
63107|NCT03691311|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Two injections on days 1 and 8 previous to surgery breast cancer excision
63108|NCT03691298|Device|Suturefix Ultra and Suturefix Curved Suture Anchor|Fixation device intended to provide secure fixation of soft tissue to bone to stabilize hip
63109|NCT03691285|Procedure|Mandibular Overdenture|Placement of 1 or 2 implants in the anterior region of the edentulous mandible.
63110|NCT03691272|Device|rTMS - Real Air Film Coil|70% resting motor threshold amplitude; Frequency 10 Hz; 10 trains of 60 pulses/train (total of 600 pulses); Inter-train interval 45s.
63111|NCT03691272|Device|rTMS - Sham Coil|A sham coil will be applied to the scalp after the resting motor threshold is determined. Patients will be able to hear the sound and feel the vibration of sham coil, but will not experience any effective stimulation.
63112|NCT03691259|Other|Ballet Classes|Ballet classes will consist of learn the basic positions and combinations used in ballet, including: Plié, Tendu, Degagé, Rond de Jambe, Frappé, Chassé, Sauté, Pas de Bourrée, Glissade, and Révérance. Additional ballet movements and patterns may be employed as well.
63114|NCT03691220|Behavioral|Telemetric Intervention|Calls, scripted by a manual; the frequency of the calls varies with patient's MLVI status and preferences.
63115|NCT03691207|Drug|AL101|"AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway by releasing the Notch intracellular domain (NICD) of all four Notch receptors from the membrane.~In patients with aberrant Notch signaling, AL101 may inhibit Notch signaling and potentially impede tumor growth.The drug is administered intravenous."
63116|NCT03691194|Dietary Supplement|fresh orange juice|The fresh oranges will be bought from Sysco. They will be squeezed at the kitchen of School of Allied Health Professional with a juicer. They will either be squeezed the night before or on the same day. The juice will not be treated with additional preservatives or sugar. The brand of the juicer is Kitchen Aid. Eight ounces of fresh orange juice needs approximately two and half oranges. They will be put into 32 oz water bottles that were bought from Sysco, and then store them in the refrigerator. They will be given to the subjects every three or four days.
63117|NCT03691194|Dietary Supplement|concentrated orange juice|The concentrated orange juice will be bought from Sysco then reconstituted. One part of concentrated orange juice needs four parts of water to reconstitute. Then, it will be measured and the reconstituted orange juice will be put into 32 oz water bottles that we bought from Sysco. They will be stored in the refrigerator. The subjects will need to get the reconstituted orange juice every three or four days.
63118|NCT03691181|Device|Ventilation|monitoring with the use of the Life2000 Ventilation System for a period of six months
63119|NCT03691155|Other|The Crohn's Diet|All recruited participants will be educated on the Crohn's Diet and instructed to adhere to the study diet for 14 days.
63120|NCT03691142|Other|Questionnaire|Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
63121|NCT03691129|Behavioral|Participation in the elderly yoga program|Yoga participant groups will practice elderly yoga for four months.
63122|NCT03691116|Behavioral|Digital Health Profile|Screening, health check-up and automatic feedback in the areas tobacco, alcohol, exercise and diet, used on a National digital platform (Stöd och Behandlingsplattformen, SoB)
63123|NCT03691116|Behavioral|Treatment as usual|Ordinary psychological assessment and counseling.
63124|NCT03691090|Drug|SHR-1210|SHR-1210 200mg
63125|NCT03691090|Drug|Placebo|Placebo
63126|NCT03691090|Drug|paclitaxel|paclitaxel 175mg/m2
63127|NCT03691090|Drug|cisplatin|cisplatin 75mg/m2
63128|NCT03691077|Drug|Ocrelizumab|The first dose of ocrelizumab will be administered as two 300-mg IV infusions (600 mg total) in 250 mL 0.9% sodium chloride each separated by 14 days (i.e., Days 1 and 15), followed by one 600-mg IV infusion in 500 mL 0.9% sodium chloride every subsequent doses (i.e., every 24 weeks) for 72 weeks.
63129|NCT03691064|Drug|LUTATHERA|Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 microCurie [mCi]) every 8 weeks for a total of 4 doses.
63130|NCT03691051|Drug|Pyrotinib plus Capecitabine|Pyrotinib:400mg/d,q.d.,p.o. A course of treatment need 21days. Capecitabine:1000mg/m2,bid,from day1-day14, A course of treatment need 21 days.
63131|NCT03691038|Drug|Pregabalin 75mg bid|Through the study period, Incremental protocol follows the conventional dose regimen starting pregabaline 75mg bid.
63132|NCT03691038|Drug|Pregabalin 25mg, 50mg|Through the study period, Incremental protocol follows the new dose regimen starting pregabalin 25mg, 50mg
63133|NCT03691012|Diagnostic Test|Circulating tumour DNA testing|Circulating tumour DNA testing
63134|NCT03690999|Dietary Supplement|Placebo|Placebo product
63135|NCT03690999|Dietary Supplement|Prebiotic supplement|Prebiotic supplement
63136|NCT03690986|Biological|VX15/2503|Given IV
63137|NCT03690986|Biological|Ipilimumab|Given IV
63138|NCT03690986|Biological|Nivolumab|Given IV
63139|NCT03690973|Procedure|Alveolar socket preservation with graft and flap surgery|Alveolar socket preservation with xenogenic bone graft and flap surgery
63140|NCT03690973|Procedure|Immediate implant placement with bone using flapless surgery|Immediate implant placement with xenogenic bone graft using flapless surgery
63141|NCT03690973|Procedure|Immediate implant placement with bone using flap surgery|Immediate implant placement with xenogenic bone graft using flap surgery
63142|NCT03690973|Procedure|Alveolar socket preservation with graft and flapless surgery|Alveolar socket preservation with xenogenic bone graft and flapless surgery
63143|NCT03690960|Procedure|electrospun TAP nanofibers|electrospun TAP loaded nanofibers containing modified triple antibiotic paste of clindamycin , ciprofloxacin and metronidazole by electrospinning process will be placed in the root canals. The access cavity will be sealed with temporary filling material
63144|NCT03690960|Procedure|modified TAP paste|modified TAP paste will be prepared by mixing equal proportions of CIP, MET and CLIN then placed inside the root canal, access cavity will be sealed with temporary filling
63145|NCT03690947|Drug|Intravitreal Ranibizumab|All subjections received 3 initial Ranibizumab injections
63146|NCT03690947|Procedure|Micropulse Laser|After 3 initial Ranibizumab injections, Micropulse Laser will be done as needed each month if macular edema persists
63147|NCT03690947|Drug|Intravitreal Ranibizumab as needed|After 3 initial Ranibizumab injections, Ranibizumab will be injected as needed till BCVA reaches stabilization
63148|NCT03690934|Procedure|Fistula-tract laser closure (FiLAC™)|The procedure was performed with a diode laser platform emitting laser energy of 15 W at a wavelength of 1470 nm by means of a radial ﬁber. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the laser ﬁbre withdrawn at a rate of approximately 1 cm per 2-3s.
63149|NCT03690934|Procedure|Monopolar coagulation of fistulous tract|The procedure was performed with a monopolar coagulator platform emitting monopolar coagulation. For obliteration, the ﬁstula track is treated with a continuous slow retraction of the monopolar energy with suturing the internal fistulas opening.
63150|NCT03690921|Drug|Cisplatin|Given IV
63151|NCT03690921|Drug|Fluorouracil|Given IV
63152|NCT03690921|Radiation|Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy|Undergo LET-IMPT
63153|NCT03690921|Procedure|Quality-of-Life Assessment|Ancillary studies
63154|NCT03690921|Other|Questionnaire Administration|Ancillary studies
63159|NCT03690869|Drug|REGN2810 (maintenance)|To be administered intravenously in combination with radiation and then used as maintenance therapy
63160|NCT03690869|Radiation|Conventional or hypofractionated|Combined with REGN2810 IV administration
63161|NCT03690869|Radiation|Re-irradiation|Combined with REGN2810 IV administration
63162|NCT03690856|Other|inflammatory, neuropsychological and neuroimaging assessment|"Acts add by research:~pregnancy test; Centralized: IL1, IL6, TNF~Neuropsychologic tests at M6 and M24:~Edinburgh Ladder Lateral Test, Direct and Inverse Verbal Empan, Matrices (WAIS IV), Similarities (WAIS IV), Vertebral fluences, STROOP test, TMT test (Delis Kaplan), WCST test, CPT III, WAIS IV (code)"
63163|NCT03690843|Other|Test Battery|All toddlers (DCD children + TD children) included in the study will be tested at three points in time, that is at the age of 3y, 4y and 5y with an extensive test battery. Questionnaires will be filled in by parents and teachers. Children will be tested using different instruments.
63164|NCT03690830|Other|metabolomics analysis|collect blood samples and endometrial cells
63165|NCT03690817|Behavioral|RBANS-H, virtual Morris Water Maze|Cognitive tasks for respectively: general cognition and spatial cognition
63166|NCT03690804|Device|Evaluation of Autonomic nervous system indices|The ECG signal, respiration rate, SpO2 and NIPΣ or ANI are recorded simultaneously on a computer with a capture card. The other indices of HRV will be analyzed offline: SDNN (standard deviation of all NN intervals), pNN30 (NN30 count divided by the total number of all NN intervals), pNN50 (NN50 count divided by the total number of all NN intervals), RMSSD (quadratic mean of successive R-R intervals), SD1 (standard deviation), SD2 (standard deviation), LF (low frequencies), HF (high frequencies), VLF (very low frequencies), SDANN (standard deviation of the averages of NN intervals in all 5 min segments of the entire recording), ratio LF/ HF, Ptot, Poincaré plot (plot points corresponding to each R-R space of a record).
63167|NCT03690791|Drug|CannTrust CBD Oil (capsule)|25 mg of CBD: <2mg of THC The cannabis oil will be extracted from a hybrid cannabis plant diluted into medium-chain-triglyceride (MCT) oil. It will be formulated in 25mg of CBD delayed release (DR) capsules.
63168|NCT03690791|Drug|Placebo (capsule)|Placebo will contain only MCT oil.
63169|NCT03690778|Drug|"Metformin and Rosuvastatin seperately"|"administration of Metformin and Rosuvastatin seperately"
63170|NCT03690778|Drug|JLP-1310|administration of JLP-1310
63171|NCT03690765|Drug|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day from the 5th to the 25th day of the menstrual period cycle. Description of routine practice only.
63172|NCT03690765|Drug|Duphaston® (Dydrogesterone)|No intervention. Duphaston® is prescribed according local labelling for treatment of endometriosis 10 mg 2-3 times a day continuously. Description of routine practice only.
63173|NCT03690752|Device|unweighting using Alter-G Anti-Gravity Treadmill|The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
63174|NCT03690752|Device|normal weight using Alter-G Anti-Gravity Treadmill|The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
63175|NCT03690739|Drug|Carboplatin|Administration according to investigator's discretion
63176|NCT03690739|Drug|Gemcitabine|Administration according to investigator's discretion
63177|NCT03690739|Drug|Bevacizumab|Administration according to investigator's discretion
63178|NCT03690739|Drug|PLD|Administration according to investigator's discretion
63179|NCT03690739|Drug|Paclitaxel|Administration according to investigator's discretion
63180|NCT03690739|Drug|PLD|Administration 30 mg/m² q21
63181|NCT03690739|Drug|Trabectedin|Administration 1.1 mg/m² q21
63182|NCT03690726|Device|repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
63183|NCT03690726|Other|Sham stimulation|Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
63184|NCT03690713|Diagnostic Test|Fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance|The pressure sensor was positioned at the distal segment of a target vessel, and intracoronary nitrate was administered before each physiologic measurement. To derive resting mean transit time (Tmn), a thermodilution curve was obtained by using 3 injections (3-4 mL each) of room-temperature saline. Hyperemic proximal aortic pressure (Pa), distal arterial pressure (Pd), and hyperemic Tmn were measured during sustained hyperemia. CFR was calculated as resting Tmn/hyperemic Tmn. FFR was calculated as the lowest average of 3 consecutive beats during hyperemia. The uncorrected IMR was calculated by Pd × Tmn during hyperaemia. All IMR values were corrected by Yong's formula (Pa × Tmn × ([1.35 × Pd/Pa] − 0.32).
63185|NCT03690700|Other|BFRE|"Blood pressure will be measured prior to each session. Active BFRE group train during inflation of the occlusion cuffs placed around the upper arm to 30 % above resting systolic BP. The occlusion pressure of the participants in sham BFRE group will be of 50mmHg.~Subjects from both groups will participate in 45 minutes of low-intensity BFRE (30-40% 1RM) of the upper extremities twice/week for 8 weeks, consisting of 5 minutes warm up using handcycling followed by 4 sets (30x15x15x15) of biceps curl and wrist extension with BFR. Individual contraction duration will be set to 4 seconds; 2-second flexion/2-second extension, measured by a metronome. To ensure no signs of autonomic dysreflexia, blood pressure will be measured immediately at the end of every training session."
63186|NCT03690687|Procedure|Primary anastomosis|
63187|NCT03690687|Procedure|Delayed anastomosis|
63188|NCT03690687|Procedure|Enterostomy|
63189|NCT03690674|Behavioral|Lifestyle Enhancement for ADHD Program|The LEAP intervention consists of 3 components: 1) an enhanced 8-week, group-based BMT curriculum, 2) parent and child use of the Garmin daily activity tracker accompanied by personalized goal setting, and 3) parent participation in a private Facebook group to encourage PA goal achievement and promote social support and positive parenting.
63256|NCT03690102|Other|T-CPR|Participants receive telephone instructions in cardiopulmonary resuscitation (T-CPR) from the Emergency Medical Services in Copenhagen during the cardiac arrest scenario test.
63190|NCT03690661|Behavioral|Intervention Video Game|"The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues."
63191|NCT03690661|Behavioral|Placebo Control Game|The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
63192|NCT03690648|Other|Quality of life survey|Administration of scales: SF-12v2, EQ-5D, QCD, DN4, EIMIR, MFIS-5 et EHAD
63193|NCT03690648|Genetic|Saliva collection|Collection of 20 ml of saliva with a kit of saliva collection
63194|NCT03690648|Genetic|Blood collection|Collection of 20 ml of blood with kit of blood collection
63195|NCT03690635|Procedure|VISTA (vestibular incision subperiosteal tunnel acess)|"A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity."
63196|NCT03690622|Drug|Dexmedetomidine|Instillation of eyedrops
63197|NCT03690622|Drug|Balanced salt solution|instillation of eyedrop
63198|NCT03690609|Dietary Supplement|CytoQuel|3 capsules daily.
63199|NCT03690609|Dietary Supplement|CytoQuel|2 capsules twice daily.
63200|NCT03690596|Other|NRT + QuitBuddy|QuitBuddy treatment app and 1 month supply of 4 mg nicotine lozenge
63201|NCT03690596|Other|NRT + QuitBuddy-Recall|QuitBuddy-Recall treatment app and 1 month supply of 4 mg nicotine lozenge
63202|NCT03690596|Other|Treatment as Usual|1 month supply of 4 mg nicotine lozenge
63203|NCT03690583|Drug|Zinc sulfate|Zinc sulfate 10 mg for children younger than 1 year old, 20 mg for children older than 1 year old, will be diluted in 1 ml of sterile water and administered orally every day in the morning during hospitalization
63204|NCT03690583|Other|Glucose|The placebo group will receive glucose diluted in 1 ml of sterile water orally every day during hospitalization
63205|NCT03690557|Behavioral|IncentaHealth|IncentaHealth is a comprehensive, behavioral weight management program designed to help individuals initiate and maintain weight loss. Individuals participate in the IncentaHealth program from their homes, receive program information electronically through daily emails and through a smartphone app for the duration of the study, and have the option to receive text messages and speak with health coaches over the telephone. Participants in this study will be enrolled in the IncentaHealth program for 12 months, and will engage with health coaching, tracking of body weight, and are provided a number of resources for healthy living throughout the 12 months.
63206|NCT03690544|Drug|Apremilast 30mg|Apremilast is an oral small-molecule inhibitor of phosphodiesterase (PDE) 4 that works intracellularly to modulate a network of pro-inflammatory and anti-inflammatory mediators. PDE 4 is a cyclic adenosine monophosphate (cAMP)-specific PDE and the dominant PDE in inflammatory cells. PDE4 inhibition elevates intracellular cAMP levels, which in turn down-regulates the inflammatory response by modulating the expression of TNF-alfa, IL-23, IL-17 and other inflammatory cytokines. Cyclic AMP also modulates levels of anti-inflammatory cytokines such as IL-10. Apremilast has immunomodulatory activity and, therefore, has the potential to be effective in the treatment of RAS.
63207|NCT03690531|Device|Take-Pause virtual reality|Take-Pause virtual reality simulation lasting 3 minutes shown through a virtual reality goggle, headset and iPhone.
63208|NCT03690531|Device|Passive Distraction|Standard or passive distraction technique, lasting 5 minutes.
63209|NCT03690518|Other|Cardiac rehabilitation|Educational/Counseling/Training : Rehabilitation, , cardiovascular rehabilitation in congenital heart disease
63210|NCT03690505|Behavioral|Interviews|informant-based questionnaire semi-structured individual interviews focus group interviews
63211|NCT03690492|Other|The Box 2.0|Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.
63212|NCT03690479|Device|Florida Probe Straight Tip Probe|Twenty (20) consecutive adult patients with a diagnosis of periodontal disease (varying degrees, from slight to severe) will be selected to undergo full-mouth periodontal probing. . One half (upper or lower jaw) of the mouth will be probed using the current, standard probe tip.
63213|NCT03690479|Device|Ball Tip Probe|Twenty (20) consecutive patients meeting the inclusion criteria will be selected to undergo full-mouth periodontal probing. The opposing jaw will be probed using the new trial tip. At a second visit, prior to treatment, the mouth will be probed once again, alternating the jaws from the first visit.
63214|NCT03690466|Device|Study device treatment|The ultrasound portable device comprises a tabletop control unit and a transducer connected to the control unit by a cord.
63215|NCT03690466|Device|Sham device treatment|A similar device as used for the study device treatment will be used, except that no energy will be delivered to the spleen.
63216|NCT03690453|Drug|Ivermectin|single dose of Ivermectin
63217|NCT03690427|Other|Traditional hookah smoking|Charcoal-heated hookah smoking
63218|NCT03690427|Other|Electronic hookah inhalation|Electronic hookah bowl
63219|NCT03690414|Drug|Experimental BHVI2|Experimental BHVI2 eye drops
63220|NCT03690414|Drug|Atropine sulfate 0.02% eye drops|Atropine eye drops
63221|NCT03690414|Combination Product|Combination eye drops|Combination eye drops with experimental BHVI2 plus 0.02% atropine
63253|NCT03690128|Behavioral|I-EWS with incorporated clinical assessment (Trigger Tool)|In relation to systematic measurement of vital parameters the nursing staff will perform an individual clinical assessment of the patient and adjust the I-EWS score accordingly.
63254|NCT03690128|Behavioral|Standard EWS - Control (Trigger Tool)|Standard EWS - Based on principles of National Early Warning Score (NEWS)
108152|NCT03340662|Drug|Rifampin|CYP3A Inducer
63222|NCT03690401|Device|SOZO Device|SOZO device will estimate fluid status, total body composition, metabolic report, skeletal muscle mass, phase angle, body mass index, weight, and hydration index analysis. Participants will be asked to fast for at least 8 hours before each visit, but water may be consumed to ensure they are well-hydrated. Participants will be asked to provide a urine sample at each visit and to report the color of your urine to the staff so they can determine how well hydrated the participants are. If not hydrated to the extent needed, participants will be asked to drink water and repeat the urine sample again after 30 minutes. A total of 5 SOZO measurements will be recorded over 12 weeks.
63223|NCT03690401|Device|DEXA Scan|DEXA scan bone density reading with hip and spine measurements as well as a whole body composition scan will be performed. Where DEXA cannot be collected on the same day as other study assessments, Weight/BMI, Urine Color, and SOZO should all be collected (or repeated if already done) to coincide with the DEXA scan if SOZO is available at DEXA location.
63224|NCT03690388|Drug|Cabozantinib|Tablets containing 60-mg or 20-mg cabozantinib or placebo equivalent) once daily orally.
63225|NCT03690388|Drug|Placebo|Tablets containing placebo equivalent of 60-mg or 20-mg cabozantinib once daily orally. once daily orally.
63226|NCT03690375|Device|Radiofrequency Microneedling|Cutera Secret Radiofrequency Microneedling Treatment
63227|NCT03690375|Device|Broad Band Light (BBL)|Sciton BBL treatment using a new protocol that utilizes a 590nm, 560nm, and skintyte filter
63228|NCT03690362|Drug|VNRX-5133 and VNRX-5022|intravenous infusion
63229|NCT03690349|Other|Skin test|Demographic data review, Disease severity evaluation, Treatment evaluation and Skin prick test for 16 common aeroallergens
63230|NCT03690336|Drug|Nonacog beta pegol|Treatment with commercially available nonacog beta pegol according to routine clinical practice at the discretion of the treating physician
63231|NCT03690323|Procedure|Radiofrequency ablation (RFA)|RFA involves the implantation of electrodes directly into the tumor, with the use of intra-operative ultrasound. The electrodes produce a high frequency alternating current, which leads to frictional heating and thus tissue destruction by thermal coagulation and protein denaturation.
63232|NCT03690323|Drug|FOLFIRINOX|Oxaliplatin 85mg/m2 given as 2-hour IV infusion, followed by leucovorin 400mg/m2 given as 2-hour IV infusion with addition of irinotecan 180mg/m2 given as 90-minute IV infusion. Followed by fluorouracil 400mg/m2 IV bolus, followed by continuous IV infusion of 2400mg/m2 during 46-hour. Every 2 weeks.
63233|NCT03690323|Drug|Nab-paclitaxel plus Gemcitabine|Nab-paclitaxel 125mg/m2 given as 30-40-minute IV infusion, followed by gemcitabine 1000mg/m2 IV infusion. On day 1, 8 and 15 every 4 weeks.
63234|NCT03690323|Drug|Gemcitabine|Gemcitabine 1000mg/m2 given as 30-minute IV infusion. On day 1, 8 and 15 every 4 weeks.
63235|NCT03690310|Biological|Anti-CD19 CAR NK Cells|Anti-CD19 CAR NK Cells injection
63236|NCT03690297|Device|Linked Color Imaging|Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
63237|NCT03690284|Device|Conventional Double Lumen Tube|Patient will be intubated with Mallinckrodt Double Lumen endotracheal tube for single lung ventilation during thoracic surgery
63238|NCT03690284|Device|VivaSight Double Lumen Tube|Patient will be intubated with the VivaSight double lumen endotracheal tube with an integrated camera for single lung ventilation during thoracic surgery
63239|NCT03690258|Device|Variable load exercise|This study is being conducted to determine whether variable load training approach (nHANCE™ squat - more data available at http://nhance.se/) is an effective countermeasure to attenuate for rapid declines in muscle power, function, that typically originate from aging and muscle disuse. Since age-related decline is accelerated already after short bouts of physical inactivity, with small recovery potential, any attempt to counteract age-related and disuse-related decline have high clinical significance. Based on the findings, safety guidelines and protocols could be developed aimed at reducing health risks in seniors. Importantly, in case present hypotheses are confirmed, this may offer important information to the healthcare system.
63240|NCT03690245|Procedure|Initiation of Resuscitation While Attached to the Cord|Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
63241|NCT03690232|Drug|glucose water|3 sessions of 6cc 25% glucose injection with a 2-week interval
63242|NCT03690232|Drug|hyaluronic aicd|intra-articular HA ((Hyruan Plus® , average MW 3000 kD; LG Life Sciences Ltd, Korea)) for sessions with a 1-week interval between each treatment
63243|NCT03690219|Other|no intervention|no intervention
63244|NCT03690206|Drug|glepaglutide|Glucagon-Like Peptide-2 (GLP-2) analog
63245|NCT03690206|Drug|Placebo|Placebo for glepaglutide
63246|NCT03690193|Behavioral|Ketogenic Diet|All participants will be assigned to the 3-month 1:1 ketogenic diet intervention (approximately 70% fat, <10% carbohydrate, and 20% protein).
63247|NCT03690180|Diagnostic Test|serum magnesium|assessment of serum magnesium in all patients
63248|NCT03690167|Other|Concentrated Growth Factor (CGF)|CGF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for CGF)
63249|NCT03690167|Other|Advanced Platelet Rich Fibrin (A-PRF)|A-PRF application (9 ml venous blood will harvested from the participants in the CGF group and centrifuged according to the protocol for A-PRF)
63250|NCT03690167|Other|Control|Nothing applied after extraction
63251|NCT03690154|Drug|FN-1501|Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until the pre-determined highest dose of 35 mg/day or MTD is reached. At least 3 patients will be enrolled in each cohort. Administration of FN- 1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
63252|NCT03690141|Drug|tomivosertib (eFT508)|This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
63255|NCT03690115|Drug|Ponatinib 30 MG|Administration of ponatinib after allo-SCT transplant in FLT3-ITD AML patient
63257|NCT03690102|Other|ERC standardized BLS course|Participants will receive and complete the standardized course in basic life support (BLS) from European Resuscitation Council (ERC).
63258|NCT03690089|Drug|Atropine Sulfate|Atropine sulfate 0.01% eye drops which consist of 10mls of a clear colourless solution of atropine sulfate 0.01% w/v and benzalkonium chloride 0.01% w/v in sterile water.
63259|NCT03690089|Other|Placebo|Placebo eye drops which consist of 10mls of a clear colourless solution of benzalkonium chloride 0.01% w/v in sterile water.
63260|NCT03690076|Other|Endocarditis|Comparison : Endocarditis vs. control
63261|NCT03690076|Other|Obese vs. control|Comparisons : Obese vs. control
63262|NCT03690063|Other|Follow up|Follow up of treatment, behavior, co-morbidity
63263|NCT03690050|Procedure|Diode 577 nm subthreshold micropulse laser|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The DSML surgery will be performed by an Ophthamologist
63264|NCT03690050|Procedure|Standard threshold laser (532 nm laser)|On the day the laser procedure is going to be performed, participants will be randomised 1:1 to receive DSML or standard laser using an automated randomisation system. The standard laser surgery will be performed by an Ophthamologist
63265|NCT03690037|Drug|Tranexamic Acid 100 MG/ML|Tranexamic Acid: 100 MG/ML Solution for injection
63266|NCT03690037|Drug|Tranexamic Acid 500 MG|Tranexamic Acid: Tranexamic Acid 500mg Tablets
63267|NCT03690011|Genetic|CD7.CAR/28zeta CAR T cells|Three dose levels will be evaluated: Dose level one: 1×10^7 cells/m^2, Dose level two: 3×10^7 cells/m^2, Dose level three: 1×10^8 cells/m^2
63268|NCT03690011|Drug|Fludarabine|Patients will receive 3 daily doses of fludarabine (30 mg/m^2) to induce lymphopenia, finishing at least 24 hours before T cell infusion. Infusions should be given following hospital/pharmacy recommendations (including dose adjustments as appropriate per institutional guidelines) however at a minimum the fludarabine should be infused over 30 minutes. Mesna, IV hydration and anti-emetics should also be provided following local institutional guidelines.
63269|NCT03690011|Drug|Cytoxan|Patients will receive 3 daily doses of cyclophosphamide (500 mg/m^2/day) to induce lymphopenia, finishing at least 24 hours before T cell infusion. Infusions should be given following hospital/pharmacy recommendations (including dose adjustments as appropriate per institutional guidelines); however at a minimum, the cyclophosphamide should be infused over 1 hour. Mesna, IV hydration and anti-emetics should also be provided following local institutional guidelines.
63270|NCT03689998|Procedure|immediate implant placement|immediate implant placement with and without melamine application
63271|NCT03689985|Device|smART Feeding Tube System|Replacing generic feeding tube with smART Feeding Tube System.
63272|NCT03689972|Drug|Natalizumab|Natalizumab 300 mg IV infusion
63273|NCT03689959|Procedure|Eight plate hemiepiphysiodesis|Patient is positioned in a classic supine position. Under fluoroscopic guidance and tourniquet hemostasis, the distal femoral physis is identified. Two 3-cm incisions are made, one on either side of the patella, centred at the level of the physis. The capsule and synovium are opened to visualize the sulcus and place the plates just outside the articular portion of the joint surface, medially and laterally. Care is taken not to damage the periosteum and a needle is inserted into the physis. The 8-plate, which has a central hole, is slipped over the needle and screws inserted. After wound closure, a soft dressing is used, and the patient is allowed to ambulate as tolerated.
63274|NCT03689946|Drug|Evolocumab|"Evolocumab: In patients without homozygous familial hypercholesterolemia (FH), evolocumab will be self-injected as follows: 140mg every 2 weeks or 420mg once a month subcutaneously.~Patients with homozygous FH will be instructed to administer 420mg subcutaneously once a month by giving 3 injections consecutively within 30 minutes using the single-use prefilled autoinjector."
63275|NCT03689946|Diagnostic Test|18F-NaF PET|18F-NaF PET: Baseline (pre-treatment) and follow-up dual cardiac and respiratory-gated PET- imaging of the thoracic aorta. Dose of 250 MBq 18F-NaF intravenously.
63276|NCT03689946|Diagnostic Test|CCTA|CCTA: Baseline (pre-treatment) and follow-up CCTA. Bolus injection of 80-100 ml contrast (Omnipaque or Visipaque). Possible beta blocker(metoprolol)administered to achieve a target heart ≤70 beats/min (bpm) and/or 0.4 or 0.8 mg of sublingual nitroglycerin administered, if medical safe.
63277|NCT03689933|Device|Root analog implant|a custom made root analogue implant made from milled titanium
63278|NCT03689920|Device|Boston Scientific Spectra WaveWriter™ Spinal Cord Stimulation (SCS) System|The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.
63279|NCT03689907|Other|Chimerism Evaluation|Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant.
63280|NCT03689894|Drug|Ibrutinib|"Subjects will receive oral (PO) Ibrutinib 140 mg once daily with Rituximab 375 mg per meter squared IV weekly x4 (with pre-medications and infusion procedure as per standard protocol) Rituximab Pre-medications:Acetaminophen 650 mg PO; Diphenhydramine 25 mg PO/IV; Dexamethasone 20 mg IV.~If no adverse events >Grade 3+ are noted after 1 week, the Ibrutinib dose schedule will be increased to 280 mg daily. If no adverse events >Gr3+ are noted after an additional 1 week, the Ibrutinib dose will be increased to 420 mg daily."
63281|NCT03689894|Drug|Rituximab|Subject will receive an intravenous infusion of 375mg per meter squared weekly for 4 weeks, which may be repeated 8 weeks after initial therapy if only a suboptimal response is achieved.
63282|NCT03689881|Device|Tomosynthesis of SI joints|"All patients will undergo additional tomosynthesis performed per study protocol along with Xray and CT performed as part of standard imaging evaluation of sacroillitis.~Tomosynthesis of SI joints will be performed on a digital Tomosynthesis system (PLATINUM dRF v2 DMS/APELEM), with a single acquisition followed by coronal image reconstruction."
63283|NCT03689868|Behavioral|Virtual Reality|Virtual Reality headset with calming scenery
63284|NCT03689855|Drug|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
63285|NCT03689855|Drug|Atezolizumab|The initial dose will be administered over 60 minutes (+/- 15 minutes). If the first infusion is tolerated without infusion-associated events, the second infusion may be delivered over 30 minutes (+/- 10 minutes).
63287|NCT03689855|Procedure|Biopsy|"If archival biopsy tissue not available, participant will undergo biopsy at baseline~When feasible, a repeated tumor biopsy will be obtained between Cycles 2 and 3 after the scheduled CT scan."
63288|NCT03689842|Procedure|Uterine transplantation|Uterine transplantation from living donor
63289|NCT03689829|Drug|MOR106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human interleukin-17C (IL-17C).
63290|NCT03689829|Drug|Placebo|Corresponding placebo s.c. injections.
63291|NCT03689816|Procedure|sleeve gastrectomy|sleeve gastrectomy
63292|NCT03689816|Procedure|gastric bypass|gastric bypass
63293|NCT03689803|Procedure|sleeve gastrectomy|sleeve gastrectomy.
63294|NCT03689803|Procedure|gastric bypass|gastric bypass
63295|NCT03689790|Procedure|sleeve gastrectomy|sleeve gastrectomy
63296|NCT03689790|Procedure|gastric bypass|gastric bypass
63297|NCT03689777|Procedure|sleeve gastrectomy|sleeve gastrectomy
63298|NCT03689777|Procedure|gastric bypass|gastric bypass
63299|NCT03689764|Other|interactive video game-based exercise|Twenty-four patients were randomly allocated to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
63300|NCT03689764|Other|no intervention|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no intervention in the subsequent 6 weeks. Group B had no intervention for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
63301|NCT03689751|Other|LSCS Video|LSCS video created depicting the patient journey for elective LSCS patients.
63302|NCT03689751|Other|TVT/TOT Video|TVT/TOT video created depicting the patient journey for elective TVT/TOT patients.
63303|NCT03689738|Other|Potato (Resistant Starch)|Potato lunch and dinner meals, and an evening snack containing 100 g potatoes and 5 g resistant starch (RS) per meal, providing a total of 300 g/d potatoes, equivalent to roughly two whole potatoes, and 15 g/d RS.
63304|NCT03689738|Other|CHO-matched (Low-fiber, RS-free)|Isocaloric, CHO-matched, low-fiber, RS-free lunch and dinner meals, and an evening snack.
63305|NCT03689725|Other|Music|Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
63306|NCT03689712|Drug|GC4419|60 minute IV infusion
63307|NCT03689712|Drug|Placebo|60 minute IV infusion
63308|NCT03689699|Drug|Nivolumab|A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
63309|NCT03689699|Drug|Degarelix|Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.
63310|NCT03689699|Drug|BMS-986253|BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
63311|NCT03689686|Device|Noninvasive Respiratory Support|"Physiological crossover prospective study comparing four study trials (20 mins) delivered in computer generated random order:~Standard Oxygen therapy with mask~HFNC flow 2l/Kg~HFNC flow 3l/Kg~Helmet CPAP"
63312|NCT03689673|Other|Data collection|
63313|NCT03689660|Other|Virtual Reality Training|Participants will be given a game-based workout program that includes balance and weight transfers using the XBOX Kinect ™ device in a low-to-medium intensity for 3 weeks, 3 days a week, 30 minutes per day.
63314|NCT03689660|Other|Biofeedback Training|biofeedback training will be applied to participants in 10-minute sessions with 10 seconds of voluntary contraction and 15 seconds of rest at each session. Training will last 12 weeks.
63315|NCT03689660|Other|Conventional rehabilitation|Participants will receive a 12-week conventional rehabilitation program.
63316|NCT03689647|Device|Arm Swing Driven Assistive Apparatus|The investigators are testing a simple, custom built apparatus to determine if it can facilitate the use of the arms to swing the legs during walking. More specifically, the investigators will measure how this assistive apparatus affects the metabolic cost and biomechanics of walking.
63317|NCT03689634|Device|Move For Surgery Preconditioning Program using a Wearable Activity Tracker (Fitbit) Intervention Group|Participants randomized to this group will be be provided with a wearable activity tracker (Fitbit) for the duration of the study and asked to reach daily step goals.
63318|NCT03689621|Device|Transcutaneous vagus nerve stimulation (tVNS)|
63319|NCT03689608|Other|Intermittent Fasting (IF)|Participants will fast 3 days per week. In fasting days, meal replacements at 30% of daily energy requirements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
63320|NCT03689608|Other|Daily Restriction (DR)|Participants are instructed to restrict energy intake by 30% of daily energy requirements. Meal replacements will be provided for the first 6 months. Participants will have fortnightly nutrition assessment.
63321|NCT03689608|Other|standard care (SC)|Participants will receive current practice guidelines in a static information format, will not take part in any counselling or receive meal replacements.
63322|NCT03689595|Other|Sample of Blood|Collection of blood sample from participants
63323|NCT03689582|Drug|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
63324|NCT03689569|Dietary Supplement|Resistant starch|Patients will receive 30 grams of resistant starch daily for 16 weeks or a placebo in a double blind fashion
63325|NCT03689569|Behavioral|Exercise|Patients randomized to the exercise group will train aerobically for 16 weeks at a moderate exercise intensity
63326|NCT03689569|Behavioral|Starch|Patients will be given 30 grams of corn starch
63327|NCT03689556|Diagnostic Test|FLT PET/CT|Patients will receive 3'-deoxy-3'-[18F]fluorothymidine (FLT) PET/CT scans before CIRT and after completion of CIRT.
63328|NCT03689543|Drug|ER beta agonist|Lilly Compound LY500307
63329|NCT03689543|Other|Placebo|Placebo
63330|NCT03689530|Behavioral|Peer Support|"Participants will be paired with a peer supporter. They will meet in person one time and then be in contact by phone or texting on a weekly basis for the first 6 months of a year.~During the final six months of the year, the peer supporter and participant will be in touch at least monthly. The peer supporter will help link participants to existing health system and community diabetes prevention programs, support their engagement in formal programs, maintain achieved gains, and support participants to initiate and sustain healthy behaviors to prevent diabetes."
63331|NCT03689530|Behavioral|Enhanced Usual Care|Participants will receive brief education and folder of information and resources.
63332|NCT03689517|Other|placebo|participants took placebos (pills made by starch) that were told to be an effective analgesic.
63333|NCT03689517|Device|orthodontic elastic separators|Orthodontic pain was introduced by placement of orthodontic elastic separators to the mesial and distal sides of the right mandibular first molar.
63334|NCT03689504|Dietary Supplement|Standard of care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder (Chispitas) or lipid-based nutrient supplement (Nutributter)
63335|NCT03689504|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
63336|NCT03689504|Behavioral|Home-based family gardening|Health promoters will facilitate the building and maintenance of a family home garden using a square foot or container gardening method.
63337|NCT03689491|Behavioral|rTMS|The EMG measured the MEPs of the anterior tibialis in response to the TMS delivered using a Magstim Rapid2 stimulator (Magstim Co, Ltd, Carmarthenshire, Wales, UK) with a 70-mm figure-8 coil (maximum power, 2.2 T) over the contralateral M1. The intensity was initially set at 100% of the machine output (MO) to determine the optimal stimulation site (hotspot). The hotspot was marked on the scalp with oil ink and recorded as x, y, in centimeters from the vertex (cz). The participants received real rTMS or sham rTMS, respectively (1 Hz, 10 min), which was before a 30-minute visual feedback training and/or traditional rehabilitation training.
63338|NCT03689491|Behavioral|visual feedback training|Game-based visual feedback training system and software.The system was designed to enable the subjects to perform ankle movements in multiple axes.
63339|NCT03689491|Behavioral|traditional rehabilitation|30 min traditional rehabilitation. The traditional rehabilitation programs included balance training, postural training, muscle strengthening, ambulation training and etc..
63340|NCT03689478|Other|Hyperthermic intravesical chemotherapy|Intravesical instillation of 40mg mitomycin C at 43 degrees for 60 minutes immediately after transurethral resection of bladder tumour
63341|NCT03689465|Drug|ATG|In PTCy-ATG group, ATG will be intravenously infused via a central venous catheter from day -3 until day -1 at a total dose of 4.5mg/kg. In ATG group, ATG will be intravenously infused via a central venous catheter from day -5 until day -2 at a total dose of 7.5mg/kg.
63342|NCT03689465|Drug|CTX|In PTCy-ATG group, CTX will be intravenously infused via a central venous catheter on day +4 at a dose of 50mg/kg/d.
63343|NCT03689465|Drug|Mycophenolate Mofetil|In PTCy-ATG group, Mycophenolate Mofetil will be taken orally from day +5 with the dosage of 0.5g twice a day. The dosage will be halved from day +30. In ATG group, Mycophenolate Mofetil will be taken orally from day -9 with the dosage of 0.5g twice a day. The dosage will be halved from day +30.
63344|NCT03689465|Drug|Ciclosporin A (CsA)|In PTCy-ATG group, Ciclosporin A (CsA) will be intravenously infused from day +5 at a dose of 2.5mg/kg/d. In ATG group, Ciclosporin A (CsA) will be intravenously infused from day -9 at a dose of 2.5mg/kg/d.
63345|NCT03689465|Drug|methotrexate (MTX)|In ATG group, methotrexate (MTX) will be intravenously on days +1, +3 and +6.
63346|NCT03689452|Device|Platelet Rich Plasma|Platelet Rich Plasma (PRP) is defined as an autologous concentration of human platelets that is 3 to 5 times greater than physiologic concentration of platelets in whole blood. Using the Eclipse PRP system, the participants PRP will be attained. The PRP will then be used as described in the arm/group description section.
63347|NCT03689452|Drug|Normal saline|Preservative-free normal saline will be used as described in arm/group description section.
63348|NCT03689439|Diagnostic Test|bone scintigraphy|bone scintigraphy
63349|NCT03689413|Drug|Sugammadex 200 MG in 2 ML Injection|1 mg/kg or 2 mg/kg intravenous injection for each group (1 mg/kg group, 2 mg/kg group) after tracheal intubation
63350|NCT03689387|Other|the Medical Program Information Systems (PMSI)|The selection of the files will be carried out using the Medical Program Information Systems (PMSI) and search convocations for post-stroke follow-up consultations conducted by the Secretariat of Neurological MPR Amiens University Hospital.
63351|NCT03689374|Drug|Semaglutide|Subjects will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly (OW) with a dose of 0.25 mg. The dose should be increased after four weeks to 0.5 mg semaglutide. After 4 more weeks the dose can be increased to 1.0 mg semaglutide if the study doctor decides and further dose adjusted throughout the study.
63352|NCT03689374|Drug|Insulin aspart|Subjects should initiate treatment with 4U of Insulin aspart (s.c. injections) before each main meal, three times daily (TID). The dose will be adjusted individually based on pre-prandial and bedtime self measured plasma glucose (SMPG) from the preceding 3 days
63353|NCT03689374|Drug|Insulin glargine U100|Run-in period: Subjects will receive s.c. injections of IGlar U100 OD in accordance with the approved local label of IGlar U100. The dose will be adjusted based on the mean of three pre-breakfast SMPG values (target SMPG: 4.0-6.9 mmol/L)
63354|NCT03689361|Combination Product|MRI|Routine MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion).
63355|NCT03689361|Diagnostic Test|MRI control|MRI with all the sequences performed for the management of acute neurological deficit in the Toulouse Neuro Vascular Unit (diffusion, FLAIR, T2 *, vascular sequences (AngioRM and TOF) and perfusion)
63356|NCT03689361|Other|telephone consultation|telephone consultation
63357|NCT03689348|Dietary Supplement|Avena sativa|A supplement derived from wild green oat
63358|NCT03689348|Dietary Supplement|Placebo|Maltodextrin
63359|NCT03689335|Procedure|Operative|Open reduction and internal fixation, using a plate and screws (the exact surgical approach and fixation technique utilised will be at the discretion of the treating surgeon)
63360|NCT03689335|Device|Humeral brace|Immobilisation in a U-slab or hanging cast, followed by application of a lightweight prefabricated humeral brace
63361|NCT03689322|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
63362|NCT03689322|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
63363|NCT03689322|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
63364|NCT03689309|Procedure|High Flow Oxygen SBT|The patient is disconnected from the ventilator and remains 30 minutes without support but high flow oxygen delivered through a dedicated piece that is usually connected on tracheotomy.
63365|NCT03689296|Other|Questionnaires|"CardioVascular Risk (CVR) questionnaire representation~SF12~Citizenship Measurement (CM) Scale~Recovery Assessment Scale~Score Ricci-Gagnon"
63366|NCT03689283|Other|Dry Needling|Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle
63367|NCT03689283|Other|Sham Dry Needlling|Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
63368|NCT03689270|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete.
63369|NCT03689270|Procedure|Divide and conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
63372|NCT03689231|Other|Volumetric measurements of liver metastases|"Depending on the available data and to be reproducible, patients will be divided into 2 sub-groups of follow-up imaging: CT only or MRI only, combined evaluation being not reliable for tumor detection~Patient follow-up at CT or MRI will be analyzed at baseline (date of discovery of hepatic metastatic disease), then 3-6 months after the start of the study, then annually.~At each assessment, a radiologist will analyze: the total volume of liver metastases (mm3), the estimated volume of the two target lesions chosen for RECIST follow-up (mm3), the number of liver lesions, and the evolution according to the RECIST criteria based on uni-dimensional measurements.~We will then correlate the following clinical data collected for patients: age, sex, presence of a carcinoid syndrome, Ki67 (%) and chromogranin A blood level (%) at diagnosis, number and location of other metastases, Octreoscan or Stereotactic Radio Surgery data if available."
63373|NCT03689218|Dietary Supplement|Maamta (Nutritious Food Supplement)|Pregnant women will receive 30 sachets of Maamta during pregnancy and first six months of lactation.
63374|NCT03689218|Dietary Supplement|Wawamum (Lipid-Based Nutrient Supplement)|Children 6-24 months will receive 30 sachets of Wawamum every month during the study.
63375|NCT03689192|Biological|ARG1-18,19,20|300 ug ARG1-18,19,20 peptide in water mixed with 500ul montanide
63376|NCT03689179|Behavioral|Time for Living and Caring (TLC)|"Time for Living & Caring (TLC) is an online, self-administered intervention. It includes three types of modules: a virtual coaching module (defined as a series or prompts, reminders, and suggestions delivered electronically through an interactive calendar website) that guides caregivers through assessment, goal setting, and goal review activities using an interactive calendar for each planned respite period they have. Supplementary modules provide education and resources such as What is Respite?, Why is Respite Important?, How do I Get (More) Respite?, How do I Use Respite?. Optional modules include interactive online forum, peer-to-peer chat functions, and videos or messages to provide daily affirmation, inspiration, and humor for caregivers."
63377|NCT03689166|Dietary Supplement|Probiotic|Reduce preterm birth with this dietary supplement
63378|NCT03689166|Other|Placebo|Placebo
63379|NCT03689153|Drug|JNJ-63733657|Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
63380|NCT03689153|Drug|Placebo|Participants will receive matching placebo intravenously.
63381|NCT03689140|Behavioral|Smoke Free Together - App-only|Pregnant smokers and their life partners will use a smoking cessation app.
63382|NCT03689140|Behavioral|Smoke Free Together - Telemedicine counseling only|Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
63383|NCT03689140|Behavioral|Smoke Free Together - app + telemedicine|Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
63384|NCT03689127|Device|Heated breathing circuit on|Heated breathing circuit will be turned on.
63385|NCT03689127|Device|Heated breathing circuit off|Heated breathing circuit will be turned off.
63386|NCT03689114|Drug|Low dose carbamazepine|Carbamazepine, 300 mg/die
63387|NCT03689114|Drug|Standard dose carbamazepine|Carbamazepine 600 mg/die
63388|NCT03689114|Drug|Low dose levetiracetam|Levetiracetam 500 mg/die
63389|NCT03689114|Drug|Standard dose levetiracetam|Levetiracetam 1000 mg/die
63390|NCT03689114|Drug|Low dose valproate|Valproate 300 mg/die
63391|NCT03689114|Drug|Standard dose valproate|Valproate 600 mg/die
63392|NCT03689114|Drug|Low dose zonisamide|Zonisamide 150 mg/die
63393|NCT03689114|Drug|Standard dose zonisamide|Zonisamide 300 mg/die
63394|NCT03689114|Drug|Low dose oxcarbazepine|Oxcarbazepine 600 mg/die
63395|NCT03689114|Drug|Standard dose oxcarbazepine|Oxcarbazepine 1200 mg/die
63396|NCT03689114|Drug|Low dose topiramate|Topiramate 100 mg/die
63397|NCT03689114|Drug|Standard dose topiramate|Topiramate 200 mg/die
63402|NCT03689101|Procedure|Endometrial biopsies|Endometrial biopsy was performed precisely 7 days after LH surge (LH+7)
63403|NCT03689088|Device|Goldfish|Goldfish will be placed in the eye for 24h monitoring
63404|NCT03689088|Device|Tonometry|Fellow eye will be measured by tonometry
63405|NCT03689075|Drug|Envarsus Oral Product|Patients will be randomised to receive either envarsus or to continue on an immediate release tacrolimus formulation
63406|NCT03689062|Procedure|induction of labor|oxytocin intravenous drip
63407|NCT03689062|Procedure|follow up|hospitalization and antibiotics
63408|NCT03689049|Procedure|SPIDER|The SPIDER intervention will include a family physician-led inter-professional practice team participating in 3-4 Learning Collaboratives over a period of 12 months, reviewing validated and comparable practice EMR data and working with a QI Coach to develop strategies and implement changes to improve care for elderly patients living with complex care needs and taking ten or more unique medications.
63409|NCT03689049|Procedure|Usual Care|Physicians and their teams enrolled in this arm will follow the best scientific evidence available to provide standard care that is in the best interest of their patients.
63410|NCT03689023|Other|A controlled multimodal intervention|The intervention is interdisciplinary, multimodal and patient activating and uses the existing setting and work flows at the Clinic as well as new interventions, ensuring that the patients receive education about cardiovascular risk factors, physical activity and healthy diet through a systematic approach including targeted patient education
63411|NCT03689010|Drug|Azelaic acid foam 15%|Azelaic acid foam 15%
63412|NCT03689010|Drug|Finacea® (Azelaic acid Foam) 15%|Azelaic acid foam 15%
63413|NCT03689010|Drug|Vehicle of the test product|Vehicle of the test product
63414|NCT03688997|Other|Simulator training|bench-top simulator with computer acquired assessments, designed to allow novices to acquire basic surgical skills in knot tying. The simulator measures the forces used and applied on the tissue while ligating a vessel. Simulator training was included in both arms (expert and novice groups).
63415|NCT03688984|Behavioral|Cognitive Behavioural Therapy for Insomnia|Cognitive Behavioural Therapy for Insomnia (CBT-I) consists of six individual therapy sessions that last approximately one hour each. The sessions include psychoeducation about insomnia, goal setting, relaxation training, stimulus control, sleep consolidation and medication review. Additional components include cognitive therapy, sleep hygiene and mindfulness and relapse prevention.
63416|NCT03688971|Drug|Omiganan|Omiganan Topical Gel
63417|NCT03688971|Drug|Ketoconazole|Ketoconazole Cream
63418|NCT03688971|Drug|Placebo|Vehicle
63419|NCT03688958|Drug|Placebo|Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
63420|NCT03688958|Drug|iodine|Selected patients with early breast cancer (stage II) non-pretreated received iodine solution (Experimental) within the time before the hospital assigned them to her surgery (7 to 35 days).
63421|NCT03688958|Drug|FEC/TE Placebo|The selected patients with advanced breast cancer (stage III) non-pretreated received colored water solution (placebo) within the time of oncology designed chemotherapy treatment FEC/TE (4 or 6 cycles/ every 21 days).
63422|NCT03688958|Drug|FEC/TE iodine|The selected patients with advanced breast cancer (stage III) non-pretreated received iodine solution (experimental) within the time of oncology designed chemotherapy treatment (4 or 6 cycles/ every 21 days).
63423|NCT03688945|Procedure|Art Therapy|Attend art viewing sessions
63424|NCT03688945|Other|Best Practice|Receive standard of care
63425|NCT03688945|Other|Questionnaire Administration|Ancillary studies
63426|NCT03688932|Other|WBV + IMT|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training will be performed through a device that provides inspiratory resistance.
63427|NCT03688932|Other|WBV + IMTsham|The whole body vibration training will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 02 to 04 mm.The inspiratory muscle training sham will be performed through a device without inspiratory resistance.
63428|NCT03688932|Other|WBVsham + IMTsham|Whole body vibration training will be performed through a vibrating platform coupled to a device that generates non-therapeutic low frequency vibration. The simulation of inspiratory muscle training will be performed through a device with no inspiratory resistance.
63429|NCT03688919|Behavioral|Self-Regulation Intervention|The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
63430|NCT03688893|Device|Laser Application for Dental Bleaching|The Laser used was the Whitening Lase II (DCM EQUIPMENTS).
63431|NCT03688880|Device|MAR-CUTIS|MAR-CUTIS will be applied in one 1 to 2 mm thick layer, ensuring that at least 1 cm of the glue is applied over the length of the wound on each side. The amount of the glue applied will be calculated such that one 5-mL syringe covers approximately 8 cm of wound length (giving a total of 10 cm per syringe). For wounds >8 cm, 2 syringes will be required. The wound will be held for approximately 30 seconds to allow for initial polymerization.
63432|NCT03688880|Device|Dermabond Advanced|Dermabond Advanced will be applied in 1 continuous layer onto a dry wound through painting motions, taking care not to apply adhesive between the wound edges. The wound will be held for 60 seconds to allow for complete polymerization.
63473|NCT03688477|Device|iovera°|iovera° is minimally-invasive procedure using cold to target sensory nerve tissue and provide temporary pain relief through cryoneurolysis. The iovera° device uses well-established principles of cryobiology to temporarily deactivate sensory nerves that contribute to pain
63565|NCT03687892|Device|intermittent Theta Burst Stimulation|Intermittent Theta Burst Stimulation will be applied in an intermittent manner resulting in cortical inhibition.
63433|NCT03688867|Behavioral|Prehabilitation regimen|"The intervention targets individual behavior, specifically a patient's proclivity to exercise prior to pancreatic resection. The prehabilitation program is tailored to the three most commonly used objective frailty metrics currently available and will be implemented during the initial consultation visit in the surgery outpatient clinic, where patients will undergo baseline testing and then provided with a fitness tracker and stress ball.~Additionally, they will be provided with an activity log to keep track of their daily activity. Shown below is the activity log."
63434|NCT03688854|Dietary Supplement|SCFA mixture|Intracolonic administration
63435|NCT03688841|Device|Bridged V.A.C.® with compression therapy|Patients randomised to receive Bridge VAC with compression dressings will be managed using ActiV.A.C. Therapy unit, with a continuous pressure of 125mmHg. A V.A.C.® Granufoam™ Bridge Dressing will be used instead of the tube connector. A Coban™ Lite compression dressing will be placed over the VAC dressing. The Bridge connector of the VAC will be used to tunnel underneath the Coban™ Lite till the upper edge of the dressing.
63436|NCT03688841|Device|Conventional Compression Therapy|Patients randomised to receive compression dressings will be managed using Coban™ Lite compression dressings with underlying non-adherent wound contact layer (WCL) dressings. Under the supervision of the investigating clinician, the dressings will be applied by a wound care specialist nurse and changed once to three times per week (depending on amount of exudate), until full ulcer healing or up to 12 weeks.
63437|NCT03688828|Drug|Saccharomyces boulardii|500mg bid
63438|NCT03688828|Drug|Esomeprazole|20mg bid
63439|NCT03688828|Drug|Amoxicillin|1.0g bid
63440|NCT03688828|Drug|Clarithromycin|0.5g bid
63441|NCT03688828|Drug|Bismuth potassium citrate|0.22g bid
63442|NCT03688815|Diagnostic Test|myocardial perfusion scintigraphy|Myocardial perfusion scintigraphy as it is described in the international literature.
63443|NCT03688802|Drug|OC-01|OC-01
63444|NCT03688802|Drug|Placebo|Placebo
63445|NCT03688789|Other|Hydrocortisone supplementation|"Cortisol at T0 and T30 mins less than 550 nmol / L after ACTH 250 μG achieved during the last chemotherapy session~Hydrocortisone supplementation in patients with biological adrenal insufficiency~scale of quality of life estimated by EORTC QLQ-C30"
63446|NCT03688776|Other|1805AA|A moist snuff product
63447|NCT03688776|Other|1805AB|A moist snuff product
63448|NCT03688763|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is an evidence-based treatment for insomnia. Participants will receive CBTi via website/mobile application (Sleepio).
63449|NCT03688750|Other|no intervention|
63450|NCT03688737|Other|low level laser|LLLT with wavelength (λ) of (600 nm to 700nm), The laser will be held 1 cm away from the surface of the target tissue, the irradiated area is 0,5 cm2.The area of impact is the surgical wound zone and the neighboring 0,5-1,0 cm of the adjacent oral mucosa for 1min and 22sec, at day of surgery, 1st day and 3rd day and come for follow up visits at 5th day ,2 weeks, month and 3 months postoperative
63451|NCT03688737|Other|placebo|placebo like device as it like low level laser device shape but with no effect to blind the intervention
63452|NCT03688711|Drug|dasiglucagon|Glucagon analogue
63453|NCT03688711|Drug|Placebo|Placebo for dasiglucagon
63454|NCT03688698|Radiation|PET/MRI|PET/MRI scans
63455|NCT03688685|Drug|CAD-1883|Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
63456|NCT03688672|Device|Apioc Contact Lens Design|Novel soft contact lens design.
63457|NCT03688659|Drug|Vancomycin and gentamycin|intravenous
63458|NCT03688646|Dietary Supplement|Intensive Nutrition Intervention|
63459|NCT03688633|Drug|Candesartan|Candesartan treatment with dose adjustments (8-16mg/day) during 6 months in accordance with adverse effects
63460|NCT03688633|Other|Usual care|patients will be followed as usual
63461|NCT03688620|Other|Passive enhanced safety surveillance|Prospective data collection starting at Visit 1 (Day 1) and ending at Visit 2 (Day 8 or when the ADR card is returned by mail) for all subjects who have previously been vaccinated against influenza in preceding seasons or aged ≥9 years at the time of vaccination, or ending at Visit 4 (Day 36 or when the last ADR card is returned by mail) for children aged <9 years who have not previously been vaccinated against influenza in preceding seasons). Subjects will have up to 14 days post vaccination to return their ADR card (at the next study visit or by mail)
63462|NCT03688607|Procedure|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.|There will not be an intervention, rather the investigators will deploy best practices and track POKEs within the healthcare system to evaluate clinical and operational outcomes.
63463|NCT03688594|Diagnostic Test|NIPT Test|This test is based onto capture and high throw put sequencing adapted to cell free plasmatic DNA of pregnant women in order to detect point mutation present in her fetus. This approach has been previously described for others clinical applications such as liquid biopsy in cancers but not for NIPT analysis.
63464|NCT03688568|Drug|Imatinib Mesylate|Imatinib given orally as dose escalation treatment.
63465|NCT03688555|Drug|ACT-774312|ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312
63466|NCT03688555|Drug|Placebo|Matching placebo capsules
63467|NCT03688542|Other|Quality Circle Deprescribing Module|The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..
63468|NCT03688516|Behavioral|Manipulation of valence and modality|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
63469|NCT03688516|Behavioral|Spatial and recognition memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
63470|NCT03688516|Behavioral|Source and content memory|mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
63471|NCT03688503|Dietary Supplement|magnesium glycinate supplement|magnesium glycinate (480 mg/day)
63474|NCT03688464|Drug|Melatonin|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
63475|NCT03688464|Drug|Diphenhydramine|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
63476|NCT03688464|Drug|Placebos|Drug to be administered for 4 weeks. Subjects will complete surveys prior to initiation and at the end of the study that will assess severity of eczema, quality of life, severity of itch, and sleep quality.
63477|NCT03688451|Drug|Rituximab|Intrathecal administration over 3-5 minutes
63478|NCT03688438|Device|Closed-Incision Negative-Pressure Therapy|A foam or gauze dressing is put directly on the wound. This foam acts as a filter to keep any large particles (such as blood clots or dead, sloughed off tissue) from clogging the vacuum system. A clear, occlusive, adhesive film covers and seals the dressing and wound, creating an airtight seal. A drainage tube leads from under the adhesive film and connects to a portable vacuum pump. This pump removes air pressure over the wound. The pump is programmed for strength of suction, amount of time it is to be applied and if it is to be intermittent or continuous. A chamber on the pump collects drainage and moisture is drawn away from the wound site.
63479|NCT03688425|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
63480|NCT03688425|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
63481|NCT03688412|Device|Cook lead extraction devices|The Cook lead extraction devices are mechanical devices that encompass a full variety of devices required for percutaneous removal of CIED leads, indwelling catheters and foreign objects.
63482|NCT03688399|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
63483|NCT03688399|Device|IOL implantation comparator|Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
63484|NCT03688386|Behavioral|Reading intervention|Written packet with 3 lessons. The first lesson includes how to begin to read and talk to their baby. The second lesson includes reading or talking about the day using parentese talk. The third lesson includes continuing to engage with the baby through interactive reading.
63485|NCT03688386|Behavioral|Infant bonding|Written packet with 3 lessons. The first lesson includes skin-to-skin and learning about their baby. The second lesson includes learning readiness cues and participation in feeding times. The third lesson includes developing routines and playing games.
63486|NCT03688386|Behavioral|LENA recording|The LENA device provide 16 hours of language recordings placed inside an infant vest. The recordings are uploaded to a computer which analyzes total adult word counts, infant vocalizations, conversational turns, background noise, and silence.
63487|NCT03688386|Behavioral|LENA linguistic feedback|LENA recordings of adult word counts, infant vocalizations, and conversational turns will be provided in printed form after each recording with review of each recording and progress over time.
63488|NCT03688386|Behavioral|LENA summary|All 3 LENA recording summaries of adult word counts, infant vocalizations, and conversational turns will be summarized in printed form and provided to mother at discharge.
63489|NCT03688373|Behavioral|Cognitive Behavioral Therapy|Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy (1 relating to least fearful and 10 indicating most fearful situation), formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises in either big or small steps.
63490|NCT03688360|Behavioral|Cognitive Behavioral Therapy|. Each intervention will contain a 60-minute psycho-education session (PE) and two 60-minute exposure sessions (EX), conducted by a mental health professional together with a master student in psychology, who are both weekly supervised by a CBT certified psychologist. In the first (PE) session, participants learn about anxiety, specific phobias and exposure. During this session they will create a fear hierarchy, formulate their cognition about the feared object or situation and determine what they want to achieve during treatment (e.g. goal situation). The next two sessions consist of exposure exercises.
63491|NCT03688347|Procedure|Nasal Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently inserted less than one inch into the anterior nare (nostril) until resistance is met at turbinate. Then it is rotated several times against nasal wall and repeated in other nostril using the same swab.
63492|NCT03688347|Procedure|Oral Swab|The swab is removed from packaging, moistened with sterile water if needed to prevent any discomfort to the participant. The swab is gently rubbed along the inside of the participant's cheek for 5-10 seconds.
63493|NCT03688347|Other|Stool Collection|A stool collection kit will be sent home with each participant. It will include instructions on how to collect the stool specimen and how to return the kit.
63494|NCT03688347|Genetic|Microbiome analysis|Study of microbial communities found in and on the human body.
63495|NCT03688347|Genetic|DNA Banking|Secure, long term storage of an individual's genetic material.
63496|NCT03688347|Procedure|Skin Swab|Gentle rubbing of the swab will be applied to the skin on the dorsal part of the hand.
63497|NCT03688334|Drug|Oxygen 40 %|Oxygen supplementation (40%) via Venturi mask
63498|NCT03688334|Drug|Medical air (sham O2)|Medical air supplementation via Venturi mask
63499|NCT03688321|Dietary Supplement|Probiotic capsule GR-1 and RC-14|Study Group will take 2 probiotics capsules containing 1 billion colony forming unit(CFU) of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each before sleep for 18 weeks starting at 28th week gestation
63500|NCT03688321|Dietary Supplement|Placebo capsule|Placebo Group will take 2 placebo capsules before sleep for 18 weeks starting at 28th week gestation
63564|NCT03687892|Device|continuous Theta Burst Stimulation|Continuous Theta Burst Simulation will be applied in a continuous manner resulting in cortical excitability.
63668|NCT03686917|Other|CHAT-P|Survey
63501|NCT03688308|Procedure|Arthroscopic rotator cuff repair with bone marrow aspirate concentrate|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique. Subjects will also be injected with bone marrow aspirate concentrate harvested from the pelvis and centrifuged prior to injection in the shoulder (produced using the Harvest/Terumo BCT system)
63502|NCT03688308|Procedure|Arthroscopic rotator cuff repair|Subjects will undergo shoulder arthroscopy for rotator cuff repair using a double row technique.
63503|NCT03688295|Other|No antibiotics|Patients will not receive antiobitherapy post surgery for CAA
63504|NCT03688295|Drug|Antibiotics|Patients will receive antiobitherapy post surgery for CAA
63505|NCT03688282|Device|Wearable vibration belt|The device is worn, a wearable vibration belt, for a specified time. This will provide vibration starting at the hips.
63506|NCT03688269|Drug|Intravenous dexamethasone|Intravenous injection of 8mg/2ml dexamethasone
63507|NCT03688269|Drug|Intravenous saline|Intravenous injection of 2ml Saline 0.9%
63508|NCT03688269|Drug|Perineural ropivacaine|Perineural injection of 20ml ropivacaine with adjustment of the concentration determined by sequential up and down method
63509|NCT03688256|Device|Obalon Balloon System|6 month Obalon Intragastric Balloons
63510|NCT03688243|Device|SS-OCT imaging|All subjects will undergo retinal imaging using the Zeiss PlexElite SS-OCT, a non-contact, non-invasive ocular imaging instrument
63511|NCT03688230|Drug|abituzumab|1000 mg IV
63512|NCT03688230|Combination Product|Placebo + Cetuximab + FOLFIRI|400 mg/m2 over 120 min followed by 250 mg/m2 weekly 60 min or 500 mg/m2 every two weeks, initially 120 min followed by 60 to 90 min
63513|NCT03688217|Behavioral|Philani Intervention Model+MOVIE (PIM+M)|The PIM+M intervention will involve the integration of the mobile video intervention into the standard perinatal counseling program offered by the intervention mentor-mothers. MOVIE intervention videos are narrated in English and isiXhosa, the languages spoken most widely among the study participants. Teaching videos are short (2-5 min.) and use simple language, avoiding medical jargon. The modularity of the videos facilitates delivery in any order and thus, they can be deployed at the discretion of each skilled mentor-mother, such that the health messages delivered are aligned with the individual needs of each participant at each perinatal stage. All videos will be administered at least once to each participant in the intervention group during the study period.
63514|NCT03688217|Behavioral|Philani Intervention Model (PIM)|The Philani Intervention Model (PIM) describes a structured program of antenatal and postnatal home-visits covering foundational health promotion topics including nutrition in pregnancy, infant feeding, newborn care and maternal mental health among others.
63515|NCT03688191|Drug|Sirolimus|Patients will receive oral sirolimus at a starting dose of 2 mg per day for 3 days and a sequential dose of 1mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL.
63516|NCT03688178|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 20 DC vaccines.
63517|NCT03688178|Drug|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 4 (+ 2) weeks for up to 12 cycles (patients with unmethylated MGMT gene promoter will receive only cycle 1)
63518|NCT03688178|Biological|Varlilumab|Varlilumab is an agonist anti-CD27 monoclonal antibody
63519|NCT03688178|Biological|Td|A single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally
63520|NCT03688178|Biological|111In-labeled DCs|111In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10^7 DCs) and given i.d. as fourth vaccine
63521|NCT03688178|Biological|Unpulsed DCs|Patients in Group I will receive 1 x 10^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
63522|NCT03688178|Biological|HIV-Gag mRNA-pulsed autologous DCs|2x10^7 HIV-Gag mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions) only with DC Vaccine #1
63523|NCT03688165|Device|Treadmill-based Robotic Gait Training|All the stroke survivors admitted to the participating centers and eligible for the study will follow a gait training protocol (treadmill-based or overground). The data will be registered at baseline (T0), end of treatment (T1) and at three months follow up (T2). All robotic systems used for the study (Lokomat Pro - Hocoma AG, Volketswil, Switzerland); G-EO System - Reha technologies, Italy) are treadmill-based and do not provide the over-ground gait training. They are characterized by the possibility of a programmable weight support, as well as speed and stride length. The data relating to the patients' training is always displayed and stored with a computerized control system.
63524|NCT03688152|Drug|INCB053914|"Dose Escalation: INCB053914 at the protocol-defined starting dose in combination with INCB050465, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
63525|NCT03688152|Drug|INCB050465|"Dose Escalation: INCB050465 at the protocol-defined starting dose in combination with INCB053914, with dose modifications based on tolerability criteria.~Dose Expansion: Recommended dose from the dose-escalation study."
63526|NCT03688139|Behavioral|Engage Therapy|"Engage therapy is designed to help individuals with depression become involved in activities they previously enjoyed but have not been participating in since developing depression. In Engage therapy, individuals with depression work with a therapist to develop action plans to pursue rewarding activities of their choice."
63527|NCT03688139|Behavioral|Supportive Therapy|Supportive therapy is designed to provide a warm and supportive environment in which individuals with depression can feel comfortable expressing their thoughts and feelings. In supportive therapy, therapists help patients identify themes in their thinking, provide reassurance, emphasize coping skills, and provide guidance as needed.
63528|NCT03688126|Behavioral|Self-Guided Lifestyle Intervention|Lifestyle intervention that involves providing participants with education, support, and tangible tools to assist them in developing and carrying out healthier lifestyle practices.
63529|NCT03688126|Behavioral|Structured Lifestyle Intervention|Lifestyle intervention that involves a structured program of diet, physical and cognitive exercise, and management of cardiometabolic risks.
63530|NCT03688113|Behavioral|Tinnitus application|Use of tinnitus application
63531|NCT03688100|Behavioral|Behavioral Activation Therapy|The therapy group will consist of an introductory in person 50-minute treatment session, followed by 12 weekly telephone 50-minute outpatient treatment sessions, then 3 monthly telephone 50-minute outpatient maintenance sessions. A typical BA session will last 50 minutes and include a review of the previous session and completed daily monitoring record forms, an in-depth discussion of life areas and value, and verbal reinforcement of activity engagement.
63532|NCT03688100|Drug|Medication Management|Collaborative care model will be used. The medication management group will meet with the patient in a one 50 minute in person introductory antidepressant medication treatment session to educate the patient about depression and medication options. Patients will get prescribed a standard of care anti-depressant medication by treating physician, followed by 12 weekly follow up telephone visits, then on a monthly basis for 3 months, and then as needed thereafter.
63533|NCT03688087|Device|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
63534|NCT03688087|Device|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
63535|NCT03688074|Biological|Tezepelumab|Tezepelumab subcutaneous injection
63536|NCT03688074|Other|Placebo|Placebo subcutaneous injection
63537|NCT03688061|Biological|ChAd3-hliNSmut|Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV
63538|NCT03688061|Biological|MVA-hliNSmut|Modified Vaccinia Ankara (MVA) vectored vaccine against HCV
63539|NCT03688048|Device|Bright light treatment lamp|Exposure to bright white light (1 hour, 10 000 lux)
63540|NCT03688048|Device|Sham negative ion generator|Placebo treatment with deactivated negative ion generator (1 hour, audible hum, no ions emitted)
63541|NCT03688022|Drug|MT-7117|MT-7117
63542|NCT03688022|Drug|PPI|Proton pump inhibitor
63543|NCT03688022|Dietary Supplement|Acidic beverage|Acidic beverage
63544|NCT03688009|Behavioral|Mindfulness-Based Family Psycho-Education (MBFBE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
63545|NCT03688009|Behavioral|Family Psycho-Education (FPE)|Six sessions includes: 1. Working with Caregiving Stress; 2. The Struggles of a Caregiver; 3. The Struggles of a Person in Recovery; 4. The Path of Recovery; 5. A Supportive Caregiving; and 6. Review of Learning.
63546|NCT03687983|Device|GoldenFlow Peripheral Stent System|Performing anaesthetic and pathological angiography according to the standard method, and select appropriate stent specifications according to the contrast results. After 1:1 pre-expansion, the stent system will be imparted into the lesion location, the stent will be distally positioned and released. The Tip head will be reset and the conveyor will be removed. If necessary, local re-expansion can be carried out. Remove the catheter and suture the wound. Postoperative treatment and anticoagulation.
63547|NCT03687970|Other|Brief Pain Inventory|-A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
63548|NCT03687970|Other|Hospital Anxiety and Depression Scale|"14 item scale with even of the items relating to anxiety and seven relating to depression~Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression"
63549|NCT03687970|Other|Neuropathic Pain Symptom Inventory|-The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia [pain provoked by light touch]). Each of the parameters includes recall of the past 24 hours
63550|NCT03687970|Procedure|Diode Laser fiber type Selective Stimulator|"-Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers"
63551|NCT03687970|Procedure|Quantitative sensory testing|"Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio"
63552|NCT03687970|Procedure|Conditioned pain modulation efficiency|-Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
63553|NCT03687970|Other|Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)|"-The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain."
63554|NCT03687957|Drug|rhIL-7-hyFc|-Given by intramuscular injection
63555|NCT03687957|Drug|Placebo|-Given by intramuscular injection
63556|NCT03687957|Drug|Temozolomide|-Standard of care
63557|NCT03687957|Radiation|Radiation therapy|-Standard of care
63558|NCT03687957|Procedure|Blood sample|"Week 1 (prior to the 1st dose of rhIL-7-hyFc)~Week 2 (one week after rhIL-7-hyFc)~Week 3 (two weeks after rhIL-7-hyFc)~Week 4 (three weeks after rhIL-7-hyFc)~Week 13 (prior to the 2nd dose of rhIL-7-hyFc)~Week 14 (one week after rhIL-7-hyFc )"
63559|NCT03687944|Other|Validity and reliability|Test-retest method and concurrent validity
63560|NCT03687931|Drug|Dexamethasone|Drop
63561|NCT03687918|Other|Assessment of the performances of QCAD/Lyon in characterizing Gleason ≥7 cancers among contoured lesions|"Principal Objective:~To assess the performances of QCAD/Lyon (AUC and its 95% confidence interval) in characterizing Gleason ≥7 cancers among the lesions delineated on mpMRI from the Dijon University Hospital.~Secondary Objectives:~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the Likert score~To compare the diagnostic performance (AUC) of QCAD/Lyon and of the PIRADS v2 score~To define the best combination of quantitative parameters in the Dijon cohort (if different from that defined in Lyon)"
63562|NCT03687905|Drug|Chloroquine|group1 received chloroquine .
63563|NCT03687905|Drug|Hydroxychloroquine|Group 2 received hydroxychloroquine
63669|NCT03686904|Drug|Benzalkonium Gel|antibiofilm solution (BlastX) topical wound gel
63566|NCT03687879|Other|Questionnaires|Reporting of medical gestures or acts, speech, embarrassing or hurtful attitudes during pregnancy follow-up or during hospitalization outside childbirth, or during childbirth or immediate after birth among women giving birth in one of the 26 maternity hospitals in the period of observation period.
63567|NCT03687866|Genetic|non invasive prenatal testing|
63568|NCT03687853|Device|Intrahepatic Arterial Infusion|Intrahepatic Arterial Infusion chemotherapy is one of the most widely used liver tumor treatments.
63569|NCT03687840|Diagnostic Test|gait analysis|Computerized gait analysis system was used to 3 times to evaluate the spatio-temporal parameters of gait.
63572|NCT03687814|Other|Low FODMAP diet/PEG 3350|Subjects will follow a low FODMAP diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
63573|NCT03687814|Other|sham diet/PEG 3350|Subjects will follow a sham diet and will take PEG 3350 (Miralax) at 17.7 g (single dose) daily for 4 weeks.
63574|NCT03687801|Behavioral|Online hearing support|The intervention group will follow an online hearing support for five weeks
63575|NCT03687801|Behavioral|Standard care|The control group will follow standard care during the time the intervention group receives online haring support
63576|NCT03687788|Behavioral|Laughter Therapy|Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
63577|NCT03687775|Other|Stability assessment|Qualitative and quantitative stability assessment
63578|NCT03687762|Behavioral|Cognitive Therapy (CT)|"The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts, recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs."
63579|NCT03687762|Behavioral|Mindfulness Meditation (MM)|Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
63580|NCT03687762|Behavioral|Activation Skills (AS)|Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
63581|NCT03687736|Biological|AbobotulinumtoxinA|AbobotulinumtoxinA treatment in the glabellar region
63582|NCT03687723|Device|OCS Heart System|The OCS™ Heart System is a portable organ perfusion and monitoring medical device intended to preserve donor hearts in a near physiologic and beating state prior to transplantation.
63583|NCT03687710|Behavioral|Multidomain precision medicine intervention|Participants will receive individualized evidence-based multidomain interventions (education, pharmacologic, non-pharmacologic) in the setting of routine outpatient clinical care.
63584|NCT03687697|Biological|Global vs. G-TL vs Cornell's C3 vs Cornell's C1/C2 media|A comparison between Global, G-TL, Cornell's C3, and Cornell's C1/C2 embryo culture media.
63585|NCT03687684|Drug|TAK-831|TAK-831 Tablets
63586|NCT03687684|Drug|Placebo|TAK-831 Matching Placebo Tablets
63587|NCT03687671|Other|Animal-assisted therapy|Animal-assisted occupational therapy, animal-assisted physiotherapy and animal assisted speech therapy with different animals. All animals are trained for the specific service with vulnerable patients. There are guinea pigs, rabbits, miniature pigs, sheeps, goats, chicken, dogs, cats and horses.
63588|NCT03687671|Other|Treatment as usual|Speech therapy, occupational therapy or physiotherapy
63589|NCT03687658|Behavioral|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
63590|NCT03687645|Diagnostic Test|Hyperpolarised MRI|Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
63591|NCT03687632|Biological|ST266|1X ST266 applied in a dose of one drop (30-50 µL) in the study eye for 28 days (112 doses total will be administered).
63592|NCT03687619|Other|CO-OP|Interventions (from top to down) related to the development of fine-motor skills
63593|NCT03687619|Other|Conductive Education|Interventions (from down to top) related to the development of fine-motor skills
63594|NCT03687606|Drug|Human Chorionic Gonadotropin|White freeze-dried cake or powder with specifications of 1000U, 2000U, 5000U.
63595|NCT03687606|Drug|human menopausal gonadotropin|White freeze-dried cake or powder with specification of 75IU.
63596|NCT03687593|Device|Legion™ CR Oxinium and CoCr Femoral Implants combined with Legion™/Genesis™ II XLPE High Flex Tibial Inserts|Single arm study, all subjects received the Legion™ CR Femoral Oxinium and CoCr Implant with Legion™/Genesis™ II XLPE Hi-flex Tibial Insert
63597|NCT03687580|Device|B-Cure Laser Pro|The B-Cure Laser Pro is a portal, non-invasive low-level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min
63598|NCT03687580|Device|Sham laser|The sham laser device is externally identical to the B-Cure Laser Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays
63599|NCT03687567|Procedure|Preimplantation genetic diagnosis|
63600|NCT03687554|Drug|Venglustat GZ/SAR402671|Pharmaceutical form: Hard Capsule Route of administration: Oral
63601|NCT03687528|Radiation|CT-scanner|After a clinical exam, patient have a CT-scanner to check any cerebral haemorrhage.
63602|NCT03687515|Drug|budesonide|1mg/2ml Pulmicort Respules BIS twice daily
63603|NCT03687515|Drug|budesonide|nasal spray 256μg BID
63604|NCT03687515|Drug|Prednisone|oral prednisone 24mg QD
63605|NCT03687502|Drug|Sulfur hexafluoride lipid-type A microspheres|Contrast Enhanced Ultrasound of the appendix
63606|NCT03687489|Device|Abdominal Aortic Aneurysm Stent Graft System|Abdominal aortic bifurcation stent and iliac artery extension stent were preloaded into abdominal aortic bifurcation stent transporter and iliac artery extension stent transporter, respectively. In the operation, the abdominal aorta bifurcation stent and the iliac artery extension stent will be delivered to the corresponding lesion position of the abdominal iliac artery and release. The abdominal aortic bifurcation stent and the iliac artery extension stent will form a whole through docking and thereby reducing the risk of rupture of an infrarenal abdominal aortic aneurysm due to the shock of blood flow.
63607|NCT03687476|Drug|VTS-270|VTS-270 200 mg/mL administered as described in the arm group description.
63608|NCT03687463|Drug|Decitabine|Decitabine for injection
63609|NCT03687450|Behavioral|RISE yoga-based program|The RISE program developed by Kripalu Center for Yoga and Health includes yoga postures, mindfulness practices, meditation, breathing techniques, and education sessions about mindful approaches to daily living. The RISE program will be delivered as a 6-week yoga-based program on-site at Brigham and Women's Hospital in Boston, MA. The program will consist of six 60-90-minute weekly yoga-based RISE classes. Sessions will be lead by experienced instructors from Kripalu Center for Yoga & Health. Subjects in this arm will also be asked to participate in 5-10 minutes of daily home practice with direction from the RISE curriculum.
63610|NCT03687437|Diagnostic Test|Blood sample|Complete blood count
63611|NCT03687424|Device|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
63612|NCT03687424|Device|low-flow nasal oxygenation (LFNO)|Active comparator (LFNO): O2 flow 5L/min, FiO2 40%
63613|NCT03687411|Procedure|Neuraxial ultrasonography|Ultrasound gel is applied to lower back lumbar spine of patient and placed with an ultrasound probe around the sacral region. The graphical interface of the software integrated with ultrasound machine will help identify the sacrum. The probe is moved in until the L3/4 interspinous space is identified for skin surface marking. Once the longitudinal scan is completed, the investigator will turn the probe 90° clockwise for transverse scan to identify ligamentum flavum.
63614|NCT03687398|Diagnostic Test|genetic testing with nanoclonal technique|endometrial sampling
63615|NCT03687385|Device|high-flow nasal oxygenation (HFNO)|Experimental HFNO: O2 flow 40L/min, FiO2 40%
63616|NCT03687385|Device|low-flow nasal oxygenation (LFNO)|Active comparator LFNO: O2 flow 5L/min, FiO2 40%
63617|NCT03687372|Drug|A-101|hydrogen peroxide topical solution 45%
63618|NCT03687372|Other|vehicle|vehicle as a topical solution
63619|NCT03687359|Other|Standard of care|Treatment as per standard practice
63620|NCT03687333|Drug|ALGLUCOSIDASE ALFA (MYOZYME)|"Pharmaceutical form: cake or powder for injection~Route of administration: intravenous infusion"
63621|NCT03687320|Device|B-Cure Pro|The B-Cure laser Pro is a portal, non-invasive, low level laser therapy device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 5J/min.
63622|NCT03687320|Device|Sham|The sham device is externally identical to the B-Cure Pro and emit the same guiding light, but does not emit the therapeutic near infrared rays.
63623|NCT03687294|Device|enzyme linked immunosorbent assay (ELISA)|ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
63624|NCT03687281|Other|Survey|"The questionnaire consists of three parts:~knowledge assessment;~socio-demographic, medical and lifestyle data;~use of Chemsex."
63625|NCT03687268|Drug|Naloxone HCl PR tablets|oral administration
63626|NCT03687268|Drug|Placebo Oral Tablet|Placebo
63627|NCT03687255|Drug|cefepime/AAI101 combination|cefepime 2 g / AAI101 500 mg
63628|NCT03687255|Drug|Piperacillin/tazobactam|piperacillin 4 GM / tazobactam 500 MG
63629|NCT03687242|Drug|SPR001|Open label SPR001
63630|NCT03687229|Diagnostic Test|A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)|measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction
63631|NCT03687229|Diagnostic Test|A)fasting serum glucose, B)Fasting serum insulin|measure level of insulin resistance
63632|NCT03687216|Procedure|HVPG-guided therapy|"The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails."
63633|NCT03687216|Procedure|Routing Therapy|Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
63634|NCT03687203|Diagnostic Test|Functional Activities Questionnaire|The FAQ is an economic and easy to apply activity of daily living scale. We aim to validate the prognostic value of novel FAQ scores, which differentiate cognitive- from motor-driven activity of daily living function.
63635|NCT03687190|Behavioral|Tai chi|participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 2 years
63636|NCT03687190|Drug|conventional medicine|participants without Tai chi training still received routine conventional medicine
63637|NCT03687177|Other|With visual cue and nurses informed|Using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
63638|NCT03687177|Other|Without visual cue and nurses informed|Not using visual cue or no visual cue with to estimate the angle of elevation of the head of intubated patients with prevention of nurse
63639|NCT03687164|Other|Group Medical Visits|Patients will attend group medical visits in groups of 6 -10. Groups will have a set curriculum and patients will meet with the provider one on one to assess individual needs at each session.
63640|NCT03687151|Other|non intervention / observationnal|non intervention / observationnal
63641|NCT03687138|Other|24h urin sample|The samples will analyzed by proteomic techniques
63642|NCT03687125|Drug|Treatment with TINOSTAMUSTINE|Conditioning treatment with TINOSTAMUSTINE
63643|NCT03687112|Other|non ontervention / observational study|non intervention
63644|NCT03687099|Other|no intervention|Histological samples from 10 GBM removed from patients with long-term survival and 10 GBM removed from patients with short-term survival
63645|NCT03687086|Other|Program A|Cognitive behavioral therapy type A plus medications prepared in packaging type A.
63646|NCT03687086|Other|Program B|Cognitive behavioral therapy type B plus medications in packaging type B.
63647|NCT03687073|Drug|Indole-3-Carbinol|Cohorts 2, 3, & 4: 400 mg PO BID
63648|NCT03687073|Drug|Silibinin|Cohorts 1 & 4: 720mg
63649|NCT03687073|Drug|Silibin|Cohort 3: 360mg
63650|NCT03687060|Behavioral|Knowledge assessment|Investigators will conduct semi-structured interviews with medical directors, clinical leadership and all participating physicians to gain insight on knowledge about and barriers to prescribing statins for people living with HIV. People living with HIV will participate in focus groups.
63651|NCT03687060|Behavioral|Education Intervention|"Education intervention will be adapted from the the findings of these interviews and focus groups.~Clinics will be randomized to receive the education intervention and feedback implementation strategies at different times.~Medical directors and providers will receive a brief educational intervention about cardiovascular disease risk in people living with HIV. Providers will additionally receive a web-based survey before and after the education intervention.~Patients will receive pamphlets tailored to the effects of cardiovascular disease treatment for people living with HIV."
63652|NCT03687060|Behavioral|Provider Feedback|Six months after the education intervention, providers will receive monthly emails with feedback regarding their rates of prescribing statins, with language targeted at increasing motivation to prescribe by leveraging social norms and self-image.
63653|NCT03687047|Device|New complete dentures|Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
63654|NCT03687034|Drug|Temozolomide|Standard-of-care chemotherapy for patients with glioblastoma includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body- surface area per day, seven days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for five days during each 28-day cycle).
63655|NCT03687034|Device|Optune|Standard-of-care treatment for glioblastoma includes alternating electric-field therapy, or Optune, as a Category 1 treatment in conjunction with temozolomide after maximal safe resection and completion of radiation therapy.
63656|NCT03687021|Drug|Progesterone|Different routes of administration of progesterone; Whether there is endometriosis
63657|NCT03687008|Behavioral|Cognitive Computer Based Intervention|25 sessions [each 30-45 minutes, 5 days a week / for 5 weeks], supervised by trained coaches
63658|NCT03686982|Other|Active Nitrate Bar|Bar containing Nitrate, L-citrulline; epicatechin; vitamin C and glutathione
63659|NCT03686982|Other|Placebo Bar|No active ingredients
63660|NCT03686969|Drug|Octanorm|Octanorm 0.5g/kg/week
63661|NCT03686969|Other|Placebo|Placebo
63662|NCT03686956|Other|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
63663|NCT03686943|Other|Family pharmacy|Observation of the family pharmacy in elderly group
63664|NCT03686930|Drug|Cohort 1 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
63665|NCT03686930|Drug|Cohort 2 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
63666|NCT03686930|Drug|Cohort 3 - FP-045 oral solution|FP-045 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Cohorts 2 and 3 doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration for cohorts 1-3 will be 7 consecutive days.
63667|NCT03686930|Drug|Placebo (for FP-045 oral solution)|Participants (cohorts 1-3) will receive FP-045 oral solution matching placebo.
63670|NCT03686904|Other|standard of care topical gel|standard of care topical gel (hydrocolloid topical gel)
63671|NCT03686904|Procedure|Debridement|Removing dead tissue from infected wound (in clinic)
63672|NCT03686904|Drug|benzalkonium irrigation|washing and lavaging in clinic with benzalkonium irrigation
63673|NCT03686904|Other|Saline Irrigation (SOC Irrigation)|Normal Saline Irrigation (SOC Irrigation)
63674|NCT03686891|Other|Skin prick tests with four native legumes|Skin prick tests with four native legumes
63675|NCT03686878|Drug|Lifitegrast|Lifitegrast used twice a day
63676|NCT03686865|Device|dental implants|extraction sockets regenerated with xenograft
63677|NCT03686852|Other|same medications but different dosages|The main difference between the groups is due to the different dose of r-FSH which will be given to pa-tients after the 7 days of CFA; namely that patients who need additional r-FSH following corifollitropin-alfa will be randomized on day 8 of the stimulation into 3 study groups. In group A, B and C, ovarian stimula-tion with Corifollitropin alfa (Elonva®, MSD) will be used for ovarian stimulation, followed by 50IU (Group A), 150IU (Group B) or 250IU (Group C) of recFSH (Puregon®, MSD)
63678|NCT03686839|Behavioral|SMR neurofeedback training to MCI|SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
63679|NCT03686826|Procedure|Acquisition of MEP und SSEP|Acquisition of MEP und SSEP at two different time points within 1 to 30 days
63680|NCT03686813|Drug|Sildenafil Citrate|Oral sildenafil, 50 mg
63681|NCT03686813|Drug|Placebo Oral Tablet|Placebo
63682|NCT03686800|Device|Rivelin® plain patches|The comfort and adherence of Rivelin® plain patches in Vulva Lichen Sclerosus patients
63683|NCT03686787|Drug|Tranexamic Acid|A split face study of oral tranexamic acid in combination with laser treatment
63684|NCT03686774|Drug|Memantine|"Women provide written informed consent prior to their participation in the study, during their Anesthesiology visit. After baseline assessments (15 days before surgery: Day 0 - 15) of pain intensity, cognitive, quality of life and quality of sleep questionnaires, participants will be randomized in two parallel groups: memantine (n=75) or usual care (n=75). Memantine will be given orally for four weeks starting two weeks before surgery. Endpoints will be assessed 15 days (Day 0 + 15), 3 months (Day 0 + 3 months), 6 months (Day 0 + 6 months) et 12 months (Day 0 + 12 months) post-mastectomy. In order to maintain a good compliance and to verify that women do not develop adverse events, patients will be called once a week by phone. A booklet for monitoring will be completed daily by the patient for 3 months from the day of surgery."
63685|NCT03686774|Other|no memantine|"Concerning the comparator group, patients will be followed in the same way as those in the memantine group except that they will not receive the study treatment"
63686|NCT03686761|Procedure|A Involvement with the osteotomy site of the surgery|A Involvement with the osteotomy site of the surgery
63687|NCT03686748|Behavioral|Two-point discrimination training|Patients will undergo multiple sessions of two-point discrimination training.
63688|NCT03686748|Behavioral|One-point discrimination training|Patients will undergo multiple sessions of one-point discrimination training.
63689|NCT03686735|Other|5 anchors and numbers|"How helpful was this visit? 0 This visit was not helpful at all~1 2-3 There were many ways it could have been better 4 5 Neither useless nor helpful visit 6 7-8 Exceptionally helpful visit 9 10 One of the most helpful doctor visits I have ever had"
63690|NCT03686735|Other|5 anchors and no numbers|How helpful was this visit? This visit was not helpful at all There were many ways it could have been better Neither useless nor helpful visit Exceptionally helpful visit One of the most helpful doctor visits I have ever had
63691|NCT03686735|Other|Visual analog scale with 3 anchors and numbers|How helpful was this visit? 0 neutral/50 100 Least helpful visit Most helpful visit
63692|NCT03686735|Other|Visual analog scale with 3 anchors and no numbers|"How helpful was this visit?~This visit was not Neither useless nor One of the most helpful doctor helpful at all helpful visit visits I have ever had"
63693|NCT03686722|Drug|Metformin|Metformin is used primarly in treatment of diabetes type II
63694|NCT03686722|Drug|Daclatasvir|Daclatsvir is a direct acting antiviral drug
63695|NCT03686709|Diagnostic Test|Post therapy PET/CT Imaging|whole-body PET/CT following Y90 radioembolization
63696|NCT03686696|Drug|Beta blocker|Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
63697|NCT03686696|Drug|ACEI|Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
63698|NCT03686696|Drug|ARB|Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
63699|NCT03686683|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
63700|NCT03686657|Drug|Metformin|1000 mg metformin-HCL XR once-a-day or maintenance dose of metformin for 26 weeks
63701|NCT03686657|Drug|Val, Cel and Met XR Low|500 mg metformin-HCL XR plus 100 mg celecoxib once-a-day in the morning and 160 mg valsartan 6 hours later once-a-day in the afternoon for 26 weeks.
63702|NCT03686657|Drug|Val, Cel and Met XR High|1000 mg metformin-HCL XR plus 200 mg celecoxib once-a-day in the morning and 320 mg valsartan once-a-day 6 hours later in the afternoon for 26 weeks.
63703|NCT03686644|Procedure|Wearing of night splint ankle foot orthoses (phase A)|"Children wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
63704|NCT03686644|Procedure|No wearing of night splint ankle foot orthoses (phase B)|"Children no wearing of night splint ankle foot orthoses during 6, 7 or 8 days according to the position of inclusion.~An ultrasound of the leg muscles will be realized every morning after removing night splint.~An isokinetic dynamometer will be realize at the beginning of the study and at the end of each phase.~measure of quality of night sleeping will be measured by Visual Analog Scale (VAS) results."
63705|NCT03686631|Behavioral|Smartphone Arm|"The smartphone arm will have an associated smartphone application, available in kiosk mode, that will remind and encourage patient to utilize the spirometer and provide a gamified application for that patient to do so."
63706|NCT03686618|Drug|Secretin|Drug to stimulate pancreatic secretion
63707|NCT03686605|Other|Thai version of the Edmontom Symptom Assessment System (ESAS)|Screening and diagnostic questionaire for depression
63708|NCT03686592|Other|Measurement of body awareness|Questionnaires+ interviews
63709|NCT03686579|Radiation|chest trauma|clinical and radiological study
63710|NCT03686566|Drug|13C-glucose|13C-glucose, glucose with every carbon labeled, is a naturally occurring, stable isotope of carbon and is not radioactive. 13C-glucose in sterile water will be mixed in the investigational pharmacy and brought to the patient area on the day of surgery. 13C-glucose will be administered over 3 hours with the total dose and volume based on patient weight. The duration of infusion may be prolonged if more time is required to remove the tumor sample during surgery. We will obtain serum glucose levels and blood samples during the infusion. When the tumor is biopsied, we will also obtain a piece of the tumor for research purposes. We will analyze the metabolism of the labeled glucose with use of mass spectrometry and metabolomics.
63711|NCT03686553|Other|laboratory-based data collection|laboratory-based surveillance of SSI
63712|NCT03686540|Procedure|ExtraCorporeal Membrane Oxygenation (ECMO)|The objective of this study is to determine the average cost of stay of a patient supported by ExtraCorporeal Membrane Oxygenation from the point of view of the hospital facility, during the hospitalization in which the ECMO was implanted.
63713|NCT03686527|Procedure|stenosis aortic valve|"The exams to be realized :~a clinical examination with blood pressure~a 12-lead surface electrocardiogram~a standard biological assessment including NTproBNP (Brain Natriuretic Peptide)~Transthoracic echocardiography at baseline and 12 months after the aortic valve intervention on the (according to recommendations)~a cardiac MRI looking for fibrosis myocardial"
63714|NCT03686514|Biological|Seasonal influenza vaccine|The FDA-approved, quadrivalent seasonal influenza vaccine that will be administered contains four distinct strains, two IAVs and two influenza B viruses (IBVs)
63715|NCT03686501|Drug|PF-06412562|Healthy Volunteers recruited for the study will undergo a single dose of PF-06412562 and will undergo two [18F]MNI-968 injections
63716|NCT03686488|Drug|TAS 102|TAS 102 35 mg will be administered orally twice daily every 2 weeks.
63717|NCT03686488|Drug|Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA]|Ramucirumab 8 miligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks.
63718|NCT03686475|Other|Biodentine|pulpotomy for primary molars , clinical and radiographic evaluation at 1,3,6 and 12month
63719|NCT03686475|Other|MTA pulpotomy|MTA pulpotomy
63720|NCT03686462|Device|Virtual reality-based interactive treadmill training|During the 30-min training session, VR based interaction and feedback will be provided; the foot location will be visualized in the VR screen (semi-immersive condition), the obstacles will be seen in the screen from which subjects has to avoid, gait speed will be visualized, slopes of the treadmill will be changed according to the slope changes in VR and distractors will be added. Dual tasks will also be provided. Subjects in this group will receive a 30min/session, 3 sessions/week for 4 weeks, the total of 12 sessions of VR-based training.
63721|NCT03686462|Device|Treadmill training without VR-based interaction|Treadmill training without VR-based interaction
63722|NCT03686449|Procedure|Non-cultured Autologous Keratinocyte Suspension|New method for treatment of post-burn raw area
63723|NCT03686449|Procedure|Adipose-Derived Stem cell-Keratinocyte Suspension|New method for treatment of post-burn raw area
63724|NCT03686449|Procedure|Split skin graft|Traditional method for treatment of post-burn raw area
63725|NCT03686436|Device|ocular coherence tomography|imaging by ocular coherence tomography
63726|NCT03686410|Behavioral|Web-based Therapeutic Educational Intervention|"The subjects assigned to this group will follow a web-based therapeutic educational intervention on pain and poor sleep quality.~All the subjects assigned to this intervention will have free access to the website from any device with internet access and will be able to consult it as many times as they wish during the intervention. The intervention will last for four weeks."
63727|NCT03686410|Other|Conventional Treatment|"The subjects assigned to this condition will continue with their usual treatment is based on the recommendations of the clinical practice guideline for the treatment of fibromyalgia Guide of Fibromyalgia developed by the Department of Health of the Generalitat de Catalunya and the Servei Català de Salut."
63728|NCT03686397|Drug|SVT-15652|1 vial twice daily
63729|NCT03686397|Drug|Placebo|1 vial twice daily
63730|NCT03686384|Drug|SVT-15652|1 vial twice daily
63731|NCT03686384|Drug|Placebo|1 vial twice daily
63732|NCT03686371|Procedure|posterior surgery for spinal arthrodesis|posterior surgery for spinal arthrodesis
63733|NCT03686358|Procedure|Renal artery angioplasty|"Patients meeting the inclusion criteria were selected from the medical records of renal angioplasty performed at the Rennes University Hospital between 01/01/2010 and 12/31/2013. Each selected patient will receive a notice by mail of information. In the absence of opposition from them within a two weeks, the processing of their data will begin :~Evaluation of the results at 3 years of renal angioplasty on atherosclerotic stenosis performed at Rennes University Hospital~Evaluation of indications of renal angioplasty on stenosis atherosclerosis performed after 2009 at Rennes University Hospital~Identification of prognostic factors"
63938|NCT03684811|Biological|Nivolumab|Nivolumab will be administered per site's standard of care
63734|NCT03686345|Drug|Midostaurin|Midostaurin associated with standard chemotherapy in patients with core-binding factor leukemia
63735|NCT03686332|Drug|Arm A: Atezolizumab and Radiotherapy|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion. Patients in group A will additionally receive 33 fractions of 1.5 (locoregional affected lymph nodes) and 1.8 Gy (tumor+margin) irradiation, concurrently with atezolizumab treatment.
63736|NCT03686332|Drug|Arm B: Atezolizumab|patients will receive atezolizumab, 1200 mg, every 3 weeks, by IV infusion.
63737|NCT03686319|Other|Reflexology|Reflexology: foot massage
63738|NCT03686306|Drug|Sildenafil|"Sildenafil 100 mg/day (single morning oral dose of 100 mg) + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
63739|NCT03686306|Drug|Placebo|"Placebo (single morning oral dose) + advice to walk for a total duration of 6 months.~Treatment will be proposed in addition to optimal treatment (Antiplatelet + Lipid Lowering Drugs + AT2 antagonists / ACE Inhibitors; unless contra-indicated) + advice to walk."
63740|NCT03686293|Other|Standardized breakfast|One tablet of paracetamol (500 mg) and a glass of water (150 mL) is consumed followed by a breakfast consisting of white bread, butter, jam, and juice (300 mL) and
63741|NCT03686280|Other|Clinical evaluation|A clinical evaluation of the balance and the walk: is carried out by one of the coordinating physiotherapists of the center where the patient realizes his rehabilitation. The latter performs, according to the functional level of the patient, the following tests: Berg balance scale, FAC, PASS, TUG, 10MWT, 6MWT, paretic lower limb traction index
63742|NCT03686280|Other|Intervention - with Robot|16 sessions of 45 minutes of reeducation with robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
63743|NCT03686280|Other|Intervention - without Robot|16 sessions of 45 minutes of reeducation without robot of the walk and the procedure to follow with the same patient for the same phase of rehabilitation of the balance and the walk or of several of them (Annex 3b), at the rate of 3 at 5 sessions per week, for 4 weeks and according to predefined exercises
63744|NCT03686280|Other|quality of life assessment|A quality of life assessment: SIS questionnaire completed by the patient, the results of which will be reported in the observation book by the coordinating physiotherapist who carried out the evaluations described above.
63745|NCT03686280|Other|assessment of the patient's satisfaction|An assessment of the patient's satisfaction with walking rehabilitation: Satisfaction index completed by the patient
63746|NCT03686267|Other|opaqued titanium abutments|masking metallic color of titanium abutments by opaque porcelain
63747|NCT03686267|Other|lithium disilicate coping (high opacity)|masking metallic color of titanium abutments using lithium disilicate copings
63748|NCT03686267|Other|titanium abutment with no color masking|color masking methods are avoided in this arm
63749|NCT03686254|Combination Product|RFA, bevacizumab and second-line chemotherapy|Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI [Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 [Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
63750|NCT03686254|Drug|Bevacizumab and second-line chemotherapy|Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI [Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 [Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
63751|NCT03686241|Procedure|Tibiotalocalcaneal (TTC) arthrodesis|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail.
63752|NCT03686241|Device|DynaNail|Utilization of a novel dynamic compression pseudoelastic intramedullary nail
63753|NCT03686228|Procedure|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and wound care and pain killer drug
63754|NCT03686228|Drug|No-PB-MNC therapy|Patients will receive ASA 81 mg once daily and wound care and pain killer drug
63756|NCT03686202|Biological|MET-4|Microbial Ecosystem Therapeutics (MET) is a new treatment approach developed as an alternative to fecal transplantation. Unlike donor stool used in fecal transplants, which are incompletely characterised complex communities of microbes and associated metabolites and fecal material, MET consists of a defined mixture of pure live cultures of intestinal bacteria isolated from a stool sample of a healthy donor.
63757|NCT03686189|Device|Iliac Bifurcation Stent Graft System|Device placement after preoperative preparation. For patients with the aortoiliac aneurysm, the placement of short-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft, or the placement of long-bodied iliac artery bifurcation stent graft combined with the placement of the abdominal aortic stent graft are recommended.
109076|NCT03333538|Other|Placebo|Placebo vaccination
63758|NCT03686176|Other|Virtual Reality|A child life specialist will fit the patient with the goggles, select a game, and initiate play once the medical procedure begins.
63759|NCT03686163|Drug|Nerve Growth Factors|the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
63760|NCT03686163|Drug|normal saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
63761|NCT03686150|Dietary Supplement|Vitamin D3 oral regimen|Vitamin D3 oral regimens supplementation
63762|NCT03686137|Other|Data collection|Colelction of pre-operative, surgical and post-surgical data
63763|NCT03686124|Biological|IMA203 Product|Four dose levels (DL) of IMA203 product will be evaluated. The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula
63764|NCT03686124|Device|IMADetect|IMADetect is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials. IMADetect is intended for investigational use only.
63765|NCT03686111|Diagnostic Test|oocytes collect|After stimulation, an echo-guided oocyte puncture is performed under anesthesia
63766|NCT03686098|Dietary Supplement|Dietary soy|Soy isoflavones delivered through diet, assisted by a detailed food guide for locally available soy-based foods.
63767|NCT03686098|Dietary Supplement|Soy Supplement|Soy isoflavones delivered in extracted form
63768|NCT03686085|Drug|Dinoprostone 3 mg|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
63769|NCT03686085|Drug|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
63770|NCT03686072|Procedure|Cataract surgery with endoscopic goniosynechialysis|Phacoemulsification was performed first. Immediately after implantation of the IOL, a 23G ophthalmic endoscope (OE) probe was inserted into the anterior chamber to visualize the PAS through the main incision and side incision. A viscoelastic agent and a blunt iris spatula were used to release the areas where where PAS existed.
63771|NCT03686059|Drug|Omega 3|daily intake of 250 mg
63772|NCT03686059|Device|punctal plug|punctal plug will be inserted in inferior punctum
63773|NCT03686046|Other|Exploratory use|Participants will be accompanied by a researcher while wearing the open-source speech processing platform as a hearing aid - adjusted to their needs using a widely accepted Fitting prescription. Using a hand-held controller, they will readjust to their liking as the acoustic conditions change. After returning to the laboratory, they will complete speech perception tests using under their self-selected amplification conditions and respond to a structured interview dealing with perceived performance of the device and its acceptability as a hearing aid during possible field studies.
63774|NCT03686033|Drug|Placebo|Participants will receive E2082-matched placebo tablets orally.
63775|NCT03686033|Drug|E2082|Participants will receive E2082 tablets orally.
63776|NCT03686020|Diagnostic Test|Enzyme Linked Immunosorbent assay (ELISA)|measure serum and salivary CYFRA21-1 levels in all included participants using Enzyme Linked Immunosorbent assay (ELISA)
63777|NCT03686007|Other|Informational Intervention|Receive MSM intervention handbook
63778|NCT03686007|Other|Informational Intervention|Receive MSM intervention research nurse coaching
63779|NCT03686007|Other|Informational Intervention|Receive ASCO print materials
63780|NCT03686007|Other|Informational Intervention|Receive CRA assistance
63781|NCT03686007|Other|Media Intervention|View the MSM intervention videos
63782|NCT03686007|Other|Media Intervention|View ASCO Cancer.net videos
63783|NCT03686007|Other|Quality-of-Life Assessment|Ancillary studies
63784|NCT03686007|Other|Questionnaire Administration|Ancillary studies
63785|NCT03685981|Other|Incentives mailer|Participants will receive a letter that describes the incentives provided by their health plan for following appropriate preventative care guidelines.
63786|NCT03685968|Device|Video laryngoscopes|Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
63787|NCT03685955|Biological|Amniotic membranes|Amniotic membranes will be employed during participant's genitourinary reconstruction
63788|NCT03685942|Device|active light therapy (LUMINETTE®)|light therapy on a portable light visor device
63789|NCT03685942|Device|placebo light therapy|placebo portable light visor device
63790|NCT03685929|Procedure|Punch skin biopsy|Two punch biopsies will be performed in each patient, one at the border of the skin lesion, and one at the adjacent healthy skin. A disposable biopsy punch of 4 mm will be used. A biopsy punch is a small circular blade (like an apple corer) which is rotated into the skin to obtain a cylindrical specimen. Local anaesthesia will be applied and the circular wound will be closed by a single suture. Sutures will be removed after one week.
63791|NCT03685916|Other|Control|Plain rice with plain water
63792|NCT03685916|Other|Cumin Rice|Cumin rice with plain water
63793|NCT03685916|Other|Cumin Drink|Cumin drink with plain rice
63794|NCT03685916|Other|Cornsilk Rice (Low dose)|Low dose cornsilk rice with plain water
63795|NCT03685916|Other|Cornsilk Rice (High dose)|High dose cornsilk rice with plain water
63796|NCT03685916|Other|Cornsilk Drink (Low dose)|Low dose cornsilk drink with plain rice
63797|NCT03685916|Other|Cornsilk Drink (High dose)|High dose cornsilk drink with plain rice
63798|NCT03685916|Other|Tamarind Rice|Tamarind rice with plain water
63799|NCT03685916|Other|Tamarind Drink|Tamarind drink with plain rice
63800|NCT03685903|Device|CapsoCam® Plus (SV-3) capsule endoscope|Endoscope Capsule
63801|NCT03685890|Drug|Nivolumab|One infusion of nivolumab (Opdivo®) 480mg (flat dose) in NaCl (Natriumklorid Baxter Viaflo, 9 mg/ml) during 60 minutes
63939|NCT03684811|Drug|Gemcitabine and Cisplatin|Gemcitabine and Cisplatin will be administered per site's standard of care
64386|NCT03681067|Drug|GSK1070806|GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion
63802|NCT03685890|Procedure|Isolated limb perfusion (ILP)|Patients will be treated with ILP according to clinical routine at each separate site. The procedure is performed under general anaesthesia. The major artery and vein of the limb is catheterized, and a tourniquet is placed proximally on the limb. Continuous leakage monitoring is performed. The perfusate is heated to 40C and after ensuring steady state, melphalan (Alkeran®) at a dose of 13 mg/L (upper limb) or 10 mg/L (lower limb) is infused into the circulation during 20 minutes for a total perfusion time of 60 minutes. According to local routine tasonermin (Beromun®) will be added to the perfusate 30 minutes before the melphalan as a bolus dose of 1-4 mg.
63803|NCT03685864|Other|Suture Embedding Acupuncture|Suture Embedding Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
63804|NCT03685864|Other|Sham Acupuncture|Sham Acupuncture at 8 acupoints (both sides of BL23, BL24, BL25, BL37). Receiving intervention 1 time in 2 weeks, and total receive 3 times.
63805|NCT03685851|Procedure|DSAEK type corneal transplant|All surgeries were performed by the same surgeon and according to the same protocol
63806|NCT03685838|Other|Compression Stockings|Class II above knee compression stockings
63807|NCT03685812|Diagnostic Test|Autocad software|The participants will be prepared for image-capture data collection by putting four squared markers on leg and thigh.Each subject will extend his/her leg and make two angles from the resting position (90º) to the full extension, photos will be taken. The tested leg passively moved by the researcher through 20° to 60° of knee extension, the participant will be instructed to actively move that leg to the target angle and hold it in this position another photograph will be taken. The angles will be measured using the AutoCAD software. Knee JPS measurements will also be collected using an IKD by same steps
63808|NCT03685799|Diagnostic Test|Pathological revision|Pathological revision
63809|NCT03685786|Biological|CART19 cell and auto-HSCT|Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10^7 CART19 cells, Day 1, 30% fraction: 1.5x10^7-1.2x10^8 CART19 cells, Day 2, 60% fraction: 3x10^7-2.4x10^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
63810|NCT03685773|Drug|Diazoxide|"MRI studies: Non-diabetic and T2D participants will receive diazoxide (up to 7 mg/kg) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive diazoxide (up to 7 mg/kg) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the pancreatic clamp study."
63811|NCT03685773|Drug|Placebo (for diazoxide)|"MRI studies: Non-diabetic and T2D participants will receive placebo (for diazoxide) between baseline MRI scan and second MRI scan.~Clamp studies: Non-diabetic participants will not require an overnight admission. They will receive a taste-matched placebo (for diazoxide) and undergo the pancreatic clamp study. Type 2 diabetic participants will be admitted the evening before the study day to normalize blood sugar levels. They will then receive a taste-matched placebo (for diazoxide) the next morning and undergo the pancreatic clamp study."
63812|NCT03685773|Drug|Nicotinic acid|Type 2 diabetic participants in this arm will receive a nicotinic acid infusion to lower free fatty acid levels. They will then receive diazoxide (up to 7 mg/kg) the next morning and undergo the MRI or pancreatic clamp study.
63813|NCT03685760|Other|Reiki therapy|Reiki, a complementary health approach where trained practitioners place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. Reiki therapists will administer the Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions).
63814|NCT03685760|Other|Sham Reiki|Sham (pretend) Reiki therapists will administer the sham Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions). Sham providers do not have Reiki training.
63815|NCT03685747|Drug|Vancomycin|Vancomycin one-time 20 mg/kg intraperitoneal dose.
63816|NCT03685708|Biological|HEPLISAV-B|HEPLISAV-B (Hepatitis B Vaccine [Recombinant ], adjuvanted) vaccine - A series of 2 doses (0.5 ml each) will be given on a 0- and 3- month schedule via intramuscular injection.
63817|NCT03685695|Other|Laboratory Biomarker Analysis|Correlative studies
63818|NCT03685695|Device|Monitoring Device|Wear Fitbit Charge 2
63819|NCT03685695|Other|Physical Activity|Complete aimed walking steps
63820|NCT03685695|Other|Quality-of-Life Assessment|Ancillary studies
63821|NCT03685695|Other|Questionnaire Administration|Ancillary studies
63822|NCT03685682|Biological|recombinant subunit Herpes zoster vaccine|Seronegative Solid Organ Transplant patients will receive two doses of the subunit Herpes zoster vaccine at 0 and 2-6 months
63823|NCT03685656|Other|Slimming gel|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
63824|NCT03685656|Other|Slimming gel placebo|On the morning, one application per day on each area under study (thighs and abdomen) during 8 weeks.
63825|NCT03685643|Behavioral|Intervention - Dating application topic|The intervention will consist of multimedia content to promote the safe usage of dating applications and raise awareness of the risks associated with dating application usage. The intervention will be delivered one-time in a classroom setting.
63826|NCT03685643|Behavioral|Control - Health and exercise topic|The placebo control will consist of multimedia content regarding exercise and healthy living. It will be delivered once-time in a classroom setting.
63827|NCT03685630|Drug|Brivaracetam|"Pharmaceutical form: Solution for injection~Concentration: 10 mg/ml~Route of administration: Intravenous injection"
63853|NCT03685422|Other|Virtual Reality|Before surgery, consented patients are given a Virtual Reality headset with pre-installed relaxation apps to choose a preferred scenario. Patient will be asked on their satisfaction on the VR experience after the intervention. Hospital Anxiety and Depression Scale (HADS), Spielberger State-Trait Anxiety Inventory (STAI) and EQ-5D-3L questionnaires will be conducted during this period.
63854|NCT03685409|Drug|Metformin Hydrochloride 500 MG|Metformin hydrochloride tablets 500 mg given orally once daily.
63828|NCT03685617|Device|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
63829|NCT03685617|Device|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
63830|NCT03685604|Drug|CHX disinfection|CHX (Softasept® Chlorhexidine solution 2% coloured, from B. Braun Medical AG) is applied three times on the patient's skin with the use of swabs. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
63831|NCT03685604|Drug|PI Disinfection|PI (Braunoderm® from B.Braun or Betaseptic® from Mundipharma) is applied prior to surgery on the patient's skin with the use of swabs. The product is applied three times. The cumulative residence time is a minimum of 3 minutes. The application is performed according to standard procedures of the participating centers and according to manufacturer's recommendations
63832|NCT03685591|Drug|PF-06952229|Oral 7 days on / 7 days off - 28 day cycles (Part 1)
63833|NCT03685591|Drug|Palbociclib|Breast Cancer (Part 2). 125mg, capsules, orally, once daily for 21 days followed by 7 days off.
63834|NCT03685591|Drug|Letrozole|Breast Cancer (Part 2). 2.5mg, tablets, orally, daily.
63835|NCT03685591|Drug|Enzalutamide|Prostate Cancer (Part 2). 160mg, capsules, orally, daily
63836|NCT03685578|Device|EmboTrap® Revascularization Device|EmboTrap® Revascularization Device
63837|NCT03685565|Procedure|Dermabond and steristrips|Laceration repaired with Dermabond with underlying steristrips
63838|NCT03685565|Procedure|Dermabond|Laceration repaired with Dermabond
63839|NCT03685552|Other|Prog: Purify-2|"Nutritional Supplements to be administered:~Protein Shakes: one protein shake twice a day~Probiotics (Bacillus Coagulans) once a day~Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day"
63840|NCT03685539|Procedure|Dual-Energy Computed Tomography|Undergo DECT
63841|NCT03685526|Device|Cinenses Lung Volume Reduction Reverser System|Lung Volume Reduction Reverser System is show as figure 1-4, consists of lung volume reduction reverser (short as: reverser), conveyor, measuring guide wire and transporting sheath. Matrix of reverser is nickel titanium alloy, its surface is coated by polymer flexible film, at the end of the connection segment is specially designed connector, which is easy for the reverser's transport and recycling. The silica gel part at the far end of reverser makes it softer.
63842|NCT03685513|Other|BioHPP PEEK-based single posterior crowns|BioHPP PEEK is 20% ceramic reinforced, semicrystalline, thermoplastic and radiolucent polymer for extreme durability especially for frameworks for fixed and removable dental prostheses. It has many advantages as low density, light weight, shock absorber, biocompatible and venerable with composite resin.
63843|NCT03685513|Other|Metal ceramic single posterior crowns|Standard metal coping veneered with glass ceramics
63844|NCT03685500|Drug|Symtuza® (TAF/FTC/DRV/c)|Treatment with TAF/FTC/DRV/c during 8 weeks since randomized
63845|NCT03685500|Drug|ABC/3TC/DTG + Symtuza® (TAF/FTC/DRV/c)|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to TAF/FTC/DRV/c for 8 weeks
63846|NCT03685487|Procedure|decolonization|current practice : V1 : consultation to the service : nasal sample for all 5 days before surgery : order sent with decolonization procedure : nasal mupirocin, shower and mouthwash V2 : admission to the service : nasal sample for all and urine sample for decolonized patients V3 : nasal sample for all
63847|NCT03685487|Other|compliance questionnaire|We asked if the patient has done the whole decolonization procedure
63848|NCT03685474|Behavioral|Facing Your Fears - School Based|Participants receiving FYF-SB will receive cognitive-behavioral treatment (CBT), which is an evidence-based practice (EBP) for treating anxiety in typical youth, within their school setting.
63849|NCT03685474|Behavioral|Usual Care|Participants receiving usual care will experience no different therapies, strategies, or recommendations other than what would typically be administered within the school setting in the absence of the proposed study.
63850|NCT03685461|Other|Electrocochleography|Electrocochleography is a noninvasive method of monitoring for acoustic evoked electrophysiologic responses from the cochlea. A speaker in the external auditory canal presents a tone burst stimulus and a nearby electrode, in this case from the apical electrode of the cochlear implant, records changes in the electrical activity within the cochlea. Different functional elements within the cochlea have signature electrophysiologic responses that can be isolated and studied individually. Through the use of intracochlear electrocochleography during cochlear implant electrode insertion valuable insight can be gained about structural or physiological changes that may be occurring.
63851|NCT03685448|Drug|Cabozantinib|The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
63852|NCT03685435|Other|Bedside ultrasound|Checking for gastric content using bedside ultrasound
63855|NCT03685409|Drug|Placebo Oral Tablet|Starch Placebo oral tablets will be given once daily to the control group
63995|NCT03684395|Drug|DOACs: Rivaroxaban, Dabigatran, Apixaban|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
63856|NCT03685396|Biological|Platelet rich fibrin ( PRF)|"Venous blood was collected with a butterfly needle in two 10 mL tubes without anticoagulants or other chemicals. The tubes were immediately centrifuged at 3000 rpm for 10 minutes.~At the end of centrifugation a fibrin clot (PRF) was obtained in the middle of the tube, just between the red corpuscles at the bottom and acellular plasma at the top. The PRF clot was taken from the tube and the red cells portion at the base of the clot was eliminated with sterile scissors Then the PRF was enveloped in sterile gauzes and positioned between two glass plates: the compression drove out the serum from the clot obtaining PRF membranes that were ready to be used in the surgical site."
63857|NCT03685396|Drug|hemostatic agents with oxidized and regenerated cellulosa|In the Control Group hemostatic agents with oxidized and regenerated cellulosa were sutured to the palatal wound with mattress suture ( silk 5/0).
63858|NCT03685383|Device|Cytosorb removal column in eCPR|In addition to standard treatment in eCPR in the study group a CytoSorb removal column is added to the va-ECMO system for the prevention of post-cardiac arrest syndrome.
63859|NCT03685383|Device|standard eCPR (va-ECMO)|Standard treatment in eCPR with a established va-ECMO system.
63860|NCT03685370|Procedure|LOS|placement of epidural catheters with LOS technique
63861|NCT03685370|Procedure|X-ray placement|placement of epidural catheters with x-ray guide
63862|NCT03685344|Drug|Loncastuximab Tesirine and Durvalumab|intravenous (IV)
63863|NCT03685331|Drug|Palbociclib|Combination of palbociclib, olaparib, and fulvestrant.
63864|NCT03685331|Drug|Olaparib|Combination of palbociclib, olaparib, and fulvestrant.
63865|NCT03685331|Drug|Fulvestrant|Combination of palbociclib, olaparib, and fulvestrant.
63866|NCT03685318|Device|Use of conventional mouthguard|Use of a conventional custom-made mouthguard while playing water polo
63867|NCT03685318|Device|Use of shortened mouthguard|Use of a shortened custom-made mouthguard while playing water polo
63868|NCT03685305|Behavioral|Hypocaloric diet with hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. Counseling will include specific instructions on a dietary manipulation which may reduce hunger, in order to facilitate dietary adherence.This will include tracking of the strategy. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
63869|NCT03685305|Behavioral|Hypocaloric diet without hunger reduction strategy|Participants will be counseled to consume a hypocaloric diet during the 4-week weight loss phase. They will also be provided a pedometer and instructed to attain 10,000 steps per day.
63870|NCT03685292|Behavioral|Behavioral Advisory System|Support and training to help increase throughput while promoting upstanding stature and reproducibility in behavioral testing using cutting edge methodologies.
63871|NCT03685292|Drug|Behavioral Treatment|This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
63872|NCT03685292|Device|Behavioral Division|This study is relative to minimal contact control (MCC).
63873|NCT03685279|Behavioral|Nurtured Heart Approach|Based on three stands designed to reduce negative reactivity from parents/guardians, increase positive interactions, and set firm, clear limits.
63874|NCT03685266|Other|Observation|There are no specific interventions in this study; it is observational only. One could argue that the act of observing the participants may change their behavior (the Hawthorne effect).
63875|NCT03685253|Drug|Niagen|Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
63876|NCT03685253|Drug|Placebo|Placebo capsules matched to the experimental drug and taken orally as 2 capsules twice daily for 6 months.
63877|NCT03685240|Behavioral|SafelyYou Fall Prevention System|Technology + Quality Assurance Services Provided by SafelyYou
63878|NCT03685227|Other|Yoga Nidra|This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
63879|NCT03685214|Drug|0.9% saline|we use 0.9% saline in ICU patients with sepsis for resuscitation fluid.
63880|NCT03685214|Drug|lactated Ringer's solution|we use balanced balanced crystalloids in ICU patients with sepsis for resuscitation fluid.
63881|NCT03685201|Dietary Supplement|Orange Juice1|100% Orange Juice
63882|NCT03685201|Dietary Supplement|Orange Juice2|100% Orange Juice with enzyme-treated orange pomace fiber
63883|NCT03685201|Dietary Supplement|Raw Orange|Raw Orange
63884|NCT03685188|Drug|Oxycodone Hydrochloride|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 0.4 mg/ml of oxycodone for postoperative analgesia.
63885|NCT03685188|Drug|Sufentanil Citrate|Subjects will receive patient' controlled intravenous analgesia in analgesic pump with 2 μg/ml of sufentanil for postoperative analgesia.
63886|NCT03685175|Drug|Formal study using hyperpolarized 13C-pyruvate injection|Administration at two visits: 1) baseline MRI before administration of doxorubicin and 2) within 2 weeks after completion of doxorubicin treatment
63887|NCT03685175|Drug|Feasible study using hyperpolarized 13C-pyruvate injection|Administration at two visits 1) after completion of doxorubicin treatment and 2) 1 to 6 months after the first scan following medical therapy, after standard of care medical therapy
63888|NCT03685149|Drug|Flecainide Pill|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
63889|NCT03685149|Drug|Placebo|Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
63890|NCT03685123|Behavioral|Physical activity recommendations|Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format
63891|NCT03685123|Behavioral|Weight maintenance recommendations|Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format
63892|NCT03685123|Behavioral|OPTIFAST weight loss|Participants will participant in an OPTIFAST medical weight loss program and exercise training
63893|NCT03685110|Device|CoreHip Total Hip Arthroplasty|Replacement of the Hip Joint
63894|NCT03685097|Diagnostic Test|Quantra System with the QPlus Cartridge|Point-of-care viscoelastic testing
63895|NCT03685084|Drug|AAI101 i.v.|600 mg, 1 g, 2 g, 4 g, 1 g (every 6h), 2 g (every 6h)
63896|NCT03685084|Drug|Saline 0.9% infusion|Vehicle infusion
63897|NCT03685084|Drug|Piperacillin i.v.|piperacillin 3 g i.v.
63898|NCT03685084|Drug|Cefepime i.v.|cefepime 1 g i.v.
63899|NCT03685071|Other|role of CBC as prognostic tool in sepsis.|"Our study will be conducted on children who admitted to PICU in Assuit University Hospital .CBC parameters as TLC , platelet count , and Hb will be evaluated at time of admission , another CBC will be done at 5th day and another one at day of discharge or last one before death.~patients will be classified into three groups according to the outcome(discharge, mortality and has morbidity sequel.)~correlation between the outcome and CBC will be done."
63900|NCT03685058|Device|Light curable resin modified glass ionomer varnish|Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
63901|NCT03685058|Other|standard-of-care preventive measures|Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
63902|NCT03685045|Procedure|Campaign days|Participants who consent will complete study procedures (Hep C test, fibroscan, questionnaire, clinical assessment) and followed up through medical record review.
63903|NCT03685032|Drug|Dexamethasone|The 4 mg of dexamethasone in 1 ml intravenous was administrated after patient received general anesthesia
63904|NCT03685032|Drug|Ondansetron|The 4 mg of ondansetron in 2 ml intravenous was administrated at the end of the operation.
63905|NCT03685032|Drug|0.9% Sodium Chloride Injection|The 0.9% sodium chloride in 1 ml intravenous was administrated after patient received general anesthesia. At the end of operation, the 0.9% sodium chloride in 2 ml intravenous was administrated.
63906|NCT03685019|Radiation|Valgus Stress|Valgus stress radiograph
63907|NCT03685019|Radiation|Varus stress|Varus stress radiograph
63908|NCT03685019|Radiation|0 degree flexion radiograph|0 degree flexion radiograph
63909|NCT03685019|Radiation|20 degree flexion radiograph|20 degree flexion radiograph
63910|NCT03685019|Radiation|45 degree flexion radiograph|45 degree flexion radiograph
63911|NCT03684993|Drug|Arabic, Gum|natural gum of acacia tree: Antimicrobial, anti-inflammatory medicinal plant used as a traditional oral hygiene substance (anticariogenic). It is used in treating sore throats, colds, bronchitis, toothache, gingival bleeding and mouth ulcers.
63912|NCT03684993|Drug|Licorice Root|natural licorice, herbal plant to relieve coughs, sore throats, and gastric inflammation. flavouring and sweetening agent. it's anti-caries, soothing anti-inflammatory and anticancer properties benefit against oral diseases and dental caries
63913|NCT03684993|Drug|Chlorhexidine|chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
63914|NCT03684980|Drug|Voraxaze|Dose of Voraxaze will be 2000 units during cycles 1-4, and 1000 units during cycles 5-8.
63915|NCT03684980|Drug|Methotrexate|(Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m^2
63916|NCT03684980|Drug|Rituximab|Patients will be treated with rituximab 500 mg/m^2.
63917|NCT03684980|Drug|leucovorin|Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
63918|NCT03684967|Drug|Fruquintinib|Fruquintinib treatment: 4mg in the Cycle 1,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days.5mg ,administration for 3 weeks followed by 1 week break, and administration every day for the first 21 days
63919|NCT03684954|Other|Prf|Take 10 cc blood from patient and gain prf
63920|NCT03684941|Device|Treatment Period One|LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
63921|NCT03684941|Device|Treatment Period Two|CE-marked LoFric Origo urinary catheter, 40-cm length, CH12/CH14 diameter, with Nelaton tip
63922|NCT03684928|Device|Comfilcon A (test)|Daily wear contact lenses
63923|NCT03684928|Device|Senofilcon C|Daily wear contact lenses
63924|NCT03684915|Device|Rotary files|using rotary files in cleaning root canals of infected primary molars
63925|NCT03684902|Procedure|emergency midline exploratory laparotomy|Once an adequate level of anesthesia has been reached, the initial incision into the skin may be made. A scalpel is first used to cut into the superficial layers of the skin.with the diathermy The incision is then continued through the subcutaneous fat, the abdominal muscles, and finally, the peritoneum. (Morris J ;2017) For all the patients, closure of midline laparotomy wound was en-mass closure done with non-absorbable No. 1 (Polypropylene) or slowly absorbable (PDS) (double loop). sutures in continuous single layer fashion with 1 cm interval. (Morris J ;2017) The operative details were recorded with special consideration to the operative diagnosis, presence and types of adhesions, duration of surgery, the need for diversion and stoma formation, the use of intraperitoneal drain and the suture material to close the rectus sheath.
63926|NCT03684889|Biological|SCRI-huCAR19v1|1:1 mixture of CD4:CD8 autologous T cells lentivirally transduced to express a second generation 4-1BB-ζ human CD19-specific CAR and Her2tG
63927|NCT03684876|Procedure|diuretic use|use of diuretic
63928|NCT03684863|Drug|Capecitabine|observation
63929|NCT03684850|Other|Home-based exercise|Home-based exercises three times per week.
63930|NCT03684850|Device|Knee brace|Progressive use of knee brace each day during activities of daily living.
63931|NCT03684850|Device|Biomechanical footwear device|Progressive use of footwear each day during activities of daily living.
63932|NCT03684837|Dietary Supplement|Vitamine D supplementation|a vitamine D dose for week
63933|NCT03684837|Other|chronic exercise in whole body vibration (WBV)|exercise in WBV during 03 months, e times per week
63934|NCT03684824|Drug|Long luteal phase GnRH agonist protocol|Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle
63935|NCT03684824|Drug|Gonadotropins|Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response
63936|NCT03684811|Drug|FT-2102|FT-2102 will be supplied as 150 mg capsule and will be administered per the protocol defined frequency and dose level.
63937|NCT03684811|Drug|Azacitidine|Azacitidine will be administered per site's standard of care
63940|NCT03684798|Other|MCII|In this study, the research staff will work through the MCII approach with the participant as an interactive, face-to-face training. The desired future consists of imaging an abstinent life and comparing it with personally relevant obstacles. Afterwards, the most relevant obstacle will be chosen and an if-then-plan will be formed, that refers to this obstacle.
63941|NCT03684798|Other|Treatment as usual|The patients in the control group will receive a 2 x 2 contingency table about the disadvantages and advantages of being abstinent and of drinking. In addition, abstinence intentions of patients in the control group will also be supported and risk situations and relapse events since the last trainings will be reappraised, but without the use of MCII.
63942|NCT03684785|Drug|AST-008|Intratumorally dosed AST-008.
63943|NCT03684785|Biological|Pembrolizumab|Pembrolizumab dosing as per the US prescribing information.
63944|NCT03684772|Drug|ICVT Topical Gel|Digoxin and Furosemide (0.125%)
63945|NCT03684772|Drug|Furosemide Topical Gel|Furosemide (0.125%)
63946|NCT03684772|Drug|Digoxin Topical Gel|Digoxin (0.125%)
63947|NCT03684772|Drug|Vehicle Topical Gel|Vehicle Gel
63948|NCT03684746|Other|No Intervention|It is an observational Study with staff
63949|NCT03684733|Diagnostic Test|MRI|Clinical MRI breast screening examination
63950|NCT03684720|Other|Discover followed by direct instruction [DD]|The intervention group will be taught suturing using the principles of guided-discovery-learning. In its simplest form, this means allowing the participants to practice placing a simple interrupted suture using the materials needed, as well as a picture of a finished suture. They must then draw from their own learning experiences, as well as discover for themselves how to do it. After a discovery period, an instructor will then teach them, how to place a simple interrupted suture, and will them guide them, as they begin to practice again.
63951|NCT03684707|Drug|Metformin Hcl 500Mg 24Hr Sa Tab|Glucophage 500 mg once daily
63952|NCT03684707|Other|starch tablet|starch tablets
63953|NCT03684694|Drug|Loncastuximab Tesirine and Ibrutinib|oral
63954|NCT03684681|Behavioral|Peer Navigator Intervention|A peer navigator delivers an intervention to current drug users and uses their own training and real- life experiences to help people meet their goals.
63955|NCT03684681|Behavioral|Social Work Intervention|A hospital social workers uses their own previous training to help people meet their goals.
63956|NCT03684668|Behavioral|Psychoeducational intervention|The intervention will be carried out every 24 hours with four participants in four computers and 3D lenses available in the computer labs of the University.
63957|NCT03684655|Drug|[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine)|[18F]F-AraG is a radiolabeled high affinity substrate for deoxyguanosine kinase (dGK) and a low affinity substrate for deoxycytidine kinase (dCK), which are over-expressed in activated T cells.
63958|NCT03684642|Drug|Efpeglenatide SAR439977|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
63959|NCT03684642|Drug|Dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
63960|NCT03684642|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
63961|NCT03684629|Behavioral|the response of KPI and corresponding suggestion|The KPI of the AIS patients who were admitted to a single hospital continuously at the time of hospitalization were studied. The hospital included in the study upload the medical records of all AIS patients by medical records scanning system since that month into the group. Quality control platform of Cerebral apoplexy in Zhejiang province extracts and analyze the data through the computer and calculates the corresponding monthly KPI. The hospitals will receive their own monthly KPI and the monthly highest KPI of all hospitals included in the study. Based on the compare of the monthly KPI of all hospitals, Quality control platform will give corresponding suggestions to all hospitals for the improve of next month.
63962|NCT03684616|Drug|Statin|continuous statin treatment for 3 months prior to cardiac arrest
63963|NCT03684603|Behavioral|melody during motor training and slow wave sleep|sequence of tones which are presented to the patient using earphones
63964|NCT03684603|Behavioral|melody only during motor training|sequence of tones which are presented to the patient using earphones
63965|NCT03684590|Device|ANI-guided opioid administration|Intraoperative opioid will be administered guided by analgesia nociceptive index (ANI) values measured by ANI monitor (MetroDoloris Medical Systems, Lille, France)
63966|NCT03684590|Other|Standard opioid administration|Intraoperative opioid will be administered according to standard practice during surgery.
63967|NCT03684577|Behavioral|Hypnotherapy for Agoraphobia|see description of the experimental arm
63968|NCT03684564|Drug|Rivaroxaban|rivaroxaban oral tablet twice daily for 24 months
63969|NCT03684564|Drug|Warfarin|warfarin (standard of care) to maintain a target INR of 3.5 (range 3.0 to 4.0)
63970|NCT03684551|Other|The CHW-led health system|During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
63971|NCT03684551|Other|The CHW Supervision model|CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
63996|NCT03684395|Drug|Standard of care (Warfarin)|Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
64118|NCT03683303|Behavioral|oral education|"the control group receiving the oral education, collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3)."
63972|NCT03684551|Other|The CHW Performance Dashboard|"The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month."
63973|NCT03684538|Other|Probiotics|Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
63974|NCT03684538|Other|Zinc|Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
63975|NCT03684538|Other|Probiotics & Zinc|Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
63976|NCT03684538|Other|Standard care|initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
63977|NCT03684525|Procedure|Extraction of primary canines|"At Baseline (T0): Clinical examinatiion + CBCT scan and then both primary canines will be extracted At 6 month follow-up (T1): Clinical examination only At 12 month follow-up: Clinical examination +/- CBCT scan~Treatment Plan :~If displaced canine is not erupted and no improvement in position radiographically is noticed, patient will be referred to orthodontic/oral surgery department~If Canine is emerged to oral cavity: No further CBCT scan will be taken~If Position of canine is improved radiographically: Follow up untill canine emerges, total observation time is 18 months"
63978|NCT03684512|Behavioral|Group Exercise Sessions|Remote exercise sessions delivered over group video conference
63979|NCT03684512|Behavioral|Individual Support Sessions|Individual education/support/feedback sessions delivered over video chat
63980|NCT03684512|Behavioral|Facebook Group|Facebook group for parents to provide additional support and education
63981|NCT03684499|Other|fluid supplementation|The subjects will be divided into two equal groups Study group and control group by randomization. The study group will be given IV fluid supplementation with 0.5% normal saline in dextrose 5%for period of 24hours . The volume of supplementation included a presumed deficit of 50 ml/kg (equivalent to mild dehydration), half of daily maintenance fluid for 24 hours in accordance to standard norms and extra 20 ml/kg per day as a phototherapy allowance. In addition, they will continue breastfeeding. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.
63982|NCT03684499|Other|breast feeding|The subjects will be divided into two equal groups Study group and control group by randomization . The control group will be continued on breast feeding , before the randomization procedure. All the infants will get phototherapy by standard method. Phototherapy will be discontinued when the bilirubin level will be <15 mg/dl.(Bandyopadhyay et al, 2017)
63983|NCT03684486|Behavioral|rehabilitation by effort|
63984|NCT03684473|Behavioral|Yoga Intervention|"Online video instruction of yoga postures combined with breath awareness and meditation form the foundation of the intervention. The trauma-informed component of the program uses specific language, movement cues, teacher qualities, and physical assists. The yoga intervention will emphasize full choice and control of the participant through invitational language such as, when you are ready, if you like before each body posture cue. Based on trauma-informed yoga best practices, a predictable foundation of yoga postures (with variations) will be followed in a consistent order each session to allow participants to anchor to the series."
63985|NCT03684460|Device|Daytime Bright Light|Daytime Bright Light (DBL) will be delivered by a free-standing apparatus set to deliver 10,000 lux. The device will be placed at the bedside within 36 inches of the patient's head and is expected to provide at least 1,250 lux at the angle of gaze. To remain in the study, the patient must be in the Intensive Care Unit (ICU) through 13:00 on day 2 (e.g., the first day of potential intervention). After day 2, DBL and other study activities will continue if the patient is transferred out of the ICU to the general medical floor.
63986|NCT03684460|Device|Usual Light|"Usual care lighting in ICU.~To remain in the study usual care patients must also remain in the MICU through 13:00 on day 2."
63987|NCT03684447|Drug|Propofol|Series of 9 treatments with propofol
63988|NCT03684447|Drug|Midazolam|Series of 9 treatments with midazolam
63989|NCT03684434|Behavioral|Online MI plus Online CBT|An online motivational interviewing (MI) lesson will first be delivered to clients. The MI lesson is expected to take one hour to complete. No therapist support will be provided during this component of treatment. An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be then delivered to clients following completion of online MI. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
63990|NCT03684434|Behavioral|Online CBT|An 8-week Internet-delivered cognitive behavioural therapy (ICBT) will be delivered to clients. Clients will receive weekly support in the form of emails and phone calls from registered social workers, psychologists or supervised graduate students, who have experience delivering ICBT. Therapist will spend approximately 15 minutes per week/per client.
63991|NCT03684421|Diagnostic Test|Pregnancy Rate|The clinical pregnancy and live birth rate according to the protocol of COS
63992|NCT03684408|Device|RFID Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
63993|NCT03684408|Device|Wire Localization|The RFID and wire localization devices used in this study are FDA approved for the image guided localization of breast tumors prior to surgical excision. The two techniques for localization will be compared in this trial.
63994|NCT03684408|Device|RFID and Wire Localization|Both RFID and the standard of care wire localization will be performed for physician training.
64059|NCT03683810|Dietary Supplement|Lactoferrin|Lactoferrin in tablets 4g/daily
63997|NCT03684382|Other|NeW-I group|A 5-week intervention offered to parents of children with chronic life-threatening illness using an internet-based narrative approach with life review elements. After completion of the first four weeks of the intervention, participants will receive a 'legacy' document which is a compiled and edited document of their narrative expression during the first four weeks. This legacy document is structured in a manner that enables participants to find a sense of spiritual well-being and hope in their experience of caring for their child through examination of past experiences and achievements as well as future aspirations.
63998|NCT03684369|Device|Transcutaneous electrical nerve stimulation|Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
63999|NCT03684356|Procedure|socket shield technique|immediate implant placement with buccal part of the root is retained
64000|NCT03684356|Procedure|xenograft|immediate implant placement with filling the buccal gap with xenograft
64001|NCT03684343|Other|Filmed consultation with a dermatologist|"Patient will be seen by a dermatologist for a consultation which will be filmed. During the consult, a laterality test and a tactile sensitivity test will be performed.~After the consult, videos will be analysed by scientists to identify the frequency of occurrence of each behavior and the percentage of time passed to express each behavior."
64002|NCT03684330|Dietary Supplement|Vitamin D|a dose once a week
64003|NCT03684330|Other|whole body vibration (WBV)|03 months of WBV training three times per week
64004|NCT03684304|Device|Abdominal binder|The abdominal binder is an elastic abdominal compression / support device that will be placed on the patient after surgery has been completed.
64005|NCT03684291|Procedure|Mode of Mechanical Ventilation|Adjustment of mechanical ventilation mode
64006|NCT03684278|Drug|Infusion of 5 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
64007|NCT03684278|Drug|Infusion of 10 mg/kg Infliximab|Infliximab is a prescription drug with marketing authorisation for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In the RAPID-I trial infliximab will be used outside the manufacturer's indication for the treatment of AP, and it is classed as an investigational medicinal product (IMP).
64008|NCT03684278|Other|0.9% Sodium Chloride (Placebo)|250 ml (500 ml if patient weighs over 100 kg) of 0.9% Sodium Chloride
64009|NCT03684265|Drug|Meloxicam Capsule (Test)|single dose
64010|NCT03684265|Drug|Meloxicam Tablet (Reference)|single dose
64011|NCT03684252|Behavioral|CBT-based intervention|Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
64012|NCT03684252|Other|Treatment as Usual|Participants' will receive treatment as usual.
64013|NCT03684239|Behavioral|G-CBT|CBT is based on the model that there is a interaction between cognition, emotion and behavior. The way people think affects the way they feel and the behavior they do. And then the feelings in turn affect how they think,So it is valid for AN patient.
64014|NCT03684239|Other|Conventional treatment|Conventional treatment including nutritional advice, encouragement, and routine treatment by a psychiatrist with work experience with eating disorders.
64015|NCT03684213|Drug|Control (Norepinephrine)|This intervention is aimed at assessing the vascular responsiveness to norepinephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
64016|NCT03684213|Drug|Norepinephrine + Ascorbic Acid|This intervention is meant to globally assess the impact of oxidative stress on vasoconstrictor responses by scavenging numerous oxidative molecules.
64017|NCT03684213|Drug|Norepinephrine + L-NAME|This intervention is meant to assess the impact of endothelium-derived nitric oxide on vasoconstrictor responses by inhibiting production of this source of nitric oxide.
64018|NCT03684213|Drug|Norepinephrine + L-NAME + Ascorbic Acid|This intervention is meant to assess the combined impact of scavenging oxidative stress and inhibiting endothelium-derived nitric oxide on vasoconstrictor responses.
64019|NCT03684200|Other|Copenhagen adductor exercise|The active player is supported on one forearm on the floor and the upper arm is resting along their side. The supporting partner places their hands at the ankle and the knee of the upper leg. The active partner raises their body from the floor and adducts both legs in a three second movement until the body reaches a straight line. The body is then lowered to the ground in a three second movement, the foot of the lower leg touches the ground before performing another repetition.
64020|NCT03684187|Behavioral|Mindfulness Based Intervention|"Mindfulness - Based Intervention (MBI) Course:~The 8-week MBI program is comprised of an orientation session, 8 separate weekly sessions of 2.5 hours and also a 7.5 hour retreat session on a weekend day. The orientation session will include an introductory session, description of the course and will include completion of stress surveys. During the orientation session, there will be explanation to the patients of objectively the basis of mindfulness teaching. The role of the stress surveys that are conducted are to assess an individual's degree of stress prior to the initiation of any mindfulness practice teaching.~Subjects will also be asked to wear a BodyGuard 2 (BG2) for parts of the study, on average of 7 days at baseline, end of the control phase, end of intervention phase, and end of 48 week follow up period. This will track subjects heart rate (HR), HR variability, VO2, energy expenditure and activity."
64021|NCT03684174|Device|Intraocular pressure measurement|Pressure tip or air puff is applied on eye
64022|NCT03684161|Diagnostic Test|Cardiopulmonary function|Body composition measurements; Pulmonary function tests; Cardiopulmonary exercise test; Force frequency releationship, ultrasound
64060|NCT03683810|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rHuEPO, epoetin alfa)
64061|NCT03683797|Other|Post-discharge call|Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.
64062|NCT03683771|Diagnostic Test|Transvaginal US with Doppler study|Transvaginal Ultrasound with doppler study on endometrium will be made
64119|NCT03683290|Other|Image acquisition and analysis|Oocyte image obtention and analysis prior to intracytoplasmic sperm injection
64023|NCT03684148|Other|Motor imagery practice|In detail, they were advised to imagine maximal voluntary isometric contractions (MViC). MViC imagery practice was planned in a progressive manner. Thus, it was performed in two sets of 25 repetitions with 2 minutes of inter-sets rest period, for two weeks, and 10 additional repetitions were added on week three and four, respectively. Each MViC repetition was sustained for 5 seconds, followed by 5 seconds of inter-repetition rest periods. Additionally, after every fifth contraction, participants had a 20 seconds of rest. Following 5 days of MI practice, the participants were advised to take a break from MI for two consecutive days. After hospital discharge, the participants in the MIp group were supplied with an audio description of the exercises to be performed.
64024|NCT03684135|Other|Cosmetics|"Tendre Caresse au cold cream body cream from Cosmétosource Crème de douche face and body cleanser from Cosmétosource"
64025|NCT03684122|Biological|Injection of Umbilical cord derived MSCs|Allogenic umbilical cord derived MSCs which are to be injected intrathecally and intravenously as a treatment option for consenting PD patients
64026|NCT03684109|Diagnostic Test|3T MRI Scanner|3T MRI image of the brain at Baseline, prior to standard-of-care surgery.
64027|NCT03684096|Dietary Supplement|non-estrogenic pollen extract PCC-100|non-estrogenic pollen extract PCC-100
64028|NCT03684096|Other|placebo|placebo -non-estrogenic pollen extract PCC-100
64029|NCT03684083|Procedure|bronchial biopsies|bronchial fibroscopy with bronchial biopsies
64030|NCT03684070|Behavioral|Self-Monitoring, peer support and motivational prompts|The intervention compares the effect of technologically delivered motivational messages, and peer support upon daily step counts.
64031|NCT03684070|Behavioral|Self-monitoring|Self-monitoring of data from wearable step count tracker
64032|NCT03684057|Behavioral|App-based mindfulness training|Unwinding Anxiety is an app-based mindfulness training program which includes a progression through 30+ daily modules. Each module's training is delivered via short video tutorials and animations (~10 min/day). Each training builds on the previous one; modules are 'locked' so that they can only be viewed at a pace of 1/day (previous modules can be reviewed at any time). A built-in self-assessment is taken after every seven modules to ensure key concepts are learned before moving on with automated suggestions on which modules to repeat based on the self-assessment results. User-initiated guided practices range from short exercises (30 seconds) to manage anxiety the moment it arises to formal guided meditations (up to 15 minutes), and can be accessed at any time
64033|NCT03684044|Drug|Baloxavir Marboxil|"Baloxavir marboxil will be administered as a weight-based dose on Days 1 and 4. A third dose of Baloxavir or its matching placebo will be given on Day 7 for participants who have not improved according to protocol defined criteria on Day 5~Treatment with a SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) will also be administered in accordance with local clinical practice."
64034|NCT03684044|Other|Placebo|Participants will receive Baloxavir marboxil or matching placebo in 2:1 ratio. Treatment with a SOC NAI (i.e., oseltamivir, zanamivir, or peramivir) will also be administered in accordance with local clinical practice.
64035|NCT03684031|Behavioral|Cognitive Control Training|A computer-based flanker task that aims to reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
64036|NCT03684031|Behavioral|Sham Cognitive Control Training Program|A placebo version of the computer-based cognitive control training. Designed to appear similar to the experimental task, but will not reinforce the recruitment of cognitive control in the presence of hostile/aggressive stimuli.
64037|NCT03684018|Biological|IgPro10|Normal human immunoglobulin G administered intravenously
64038|NCT03684005|Other|MyPatientPal smartphone app|All patients in this single-arm study will use a smartphone-based app, MyPatientPal, to enter symptoms and track medications related to their cancer treatment. No drugs will be administered for the purposes of this behavioral study.
64039|NCT03683992|Device|Triathlon total knee system|Implantable
64040|NCT03683979|Behavioral|Interpretation Bias Modification|A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.
64041|NCT03683979|Behavioral|Control Training Program|A sham training program that is similar in design and delivery to the experimental training condition.
64042|NCT03683953|Other|mesenchymal stem cells therapy|mesenchymal stem cells treatement of BPD for safety and effect evaluation0.9% sodium chloride incontrol group
64043|NCT03683953|Drug|0.9% sodium chloride|0.9% sodium chloride in control group
64044|NCT03683940|Diagnostic Test|Screening|Subjects will undergo a low dose non contrast CT chest for lung cancer screening. The test will be performed by the UCH Radiology Department and read by board-certified chest radiologists using Lung-RADS criteria.
64045|NCT03683927|Combination Product|Bacillus clausii|The probiotic (Bacillus clausii) will be administered 4 times a week to the infant
64046|NCT03683927|Other|Sterile water|The placebo group will receive sterile water 4 times a week
64047|NCT03683914|Drug|Dinoprostone 3Mg Vaginal Tablet|1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia & Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
64048|NCT03683914|Drug|placebo vaginal tablet|1 vaginal tablet of placebo inserted by the patient 12 hours before the scheduled office diagnostic hysteroscopy.
64049|NCT03683901|Device|TENS|Electrical Stimulation
64050|NCT03683901|Device|t-NMES|Electrical Stimulation
64051|NCT03683901|Other|No stimulation|No stimulation
64052|NCT03683888|Behavioral|HealthSnap|HealthSnap provides personalized lifestyle reports and track progress over time using an electronic lifestyle record (ELR). HealthSnap Assessment is a simple, quick and not invasive tool that uses an algorithm that includes a questionnaire, physical measurements, dietary data and body fat indices
64053|NCT03683888|Behavioral|dietary counseling|Dietary counseling by RD. Low Calorie and/or Low Carb dietary plans will be discussed and provided to the study participant
64054|NCT03683862|Other|orthodontic appliance|Orthodontic device for retention in the upper arch, after the end of orthodontic treatment
64055|NCT03683849|Other|Training|One hour of training, twice a week, for six months.
64056|NCT03683836|Diagnostic Test|No intervention|No intervention
64057|NCT03683823|Behavioral|Attention guidance|Explicitly guiding attention towards faces during public speaking exposures
64058|NCT03683823|Behavioral|Control intervention|Public speaking exposures
64063|NCT03683758|Other|FIFA11+|"The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential."
64064|NCT03683758|Other|'Usual' Soccer Warm-up|"This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement."
64065|NCT03683732|Behavioral|Individual semi-structured interviews|Individual semi-structured interviews were conducted using purposeful sampling of 15- to 18-year-olds, until data saturation, and were transcribed and analysed
64066|NCT03683719|Drug|Delgocitinib cream|Cream for topical application.
64067|NCT03683719|Drug|Delgocitinib cream vehicle|The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
64068|NCT03683706|Behavioral|LTP in My Own Way Plus|LTP in My Own Way Plus is a 12-session integrated intervention—Learning through Play in My Own Way Plus Cognitive Behaviour Therapy (CBT). LTP in My Own Way is the extension of the parent education program called 'Learning Through Play' developed by Toronto Public Health (1993) revised by The Hincks-Dellcrest Centre (2000). LTP aims for the healthy growth of young children (birth to 6 years) using the stages of development incorporating Piaget's theory of cognitive development and Bowlby's theory of attachment. The objective of this program is to strengthen parent-child attachment by encouraging parental involvement and teaching parents how to use play activities to enhance their children's development. Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.
64069|NCT03683693|Diagnostic Test|Procalcitonin group|"The ICU physician gets on regular base (day 0, d4, d7, d11, d15, d19, d23, d27) a PCT value and the according non-binding recommendation:~PCT < 0.5 microgram/L of 80% drop of the peak value : antibiotic stop recommended.~PCT < 0.25 microgram/L: antibiotic stop strongly recommended. The recommendation is not-binding and can be overruled by the ICU physician. The intervention is only set up for stopping antibiotics, not for initiating. PCT measurements only happens in case of still ongoing antibiotic course. In case of a second course of antibiotics, after interruption of the initial course, new PCT measurement will take place at this point followed by the continuation of the initial schedule of PCT measurement.~Intervention ends 28 days after inclusion."
64070|NCT03683680|Other|MPT Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
64071|NCT03683680|Other|CLDN15/VIM Test|molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms
64072|NCT03683667|Drug|Azithromycin Oral Product|Azithromycin oral suspension (10 mg/kg; 3 days) administered by study personnel at 6 and 9 months of age
64073|NCT03683667|Drug|Placebos|Contain inert excipients only
64074|NCT03683667|Dietary Supplement|Protein Supplement|Blended food providing 125 kcal and 10 g protein as egg white powder prepared as porridge and fed daily to infants from 6-12 months of age
64075|NCT03683667|Dietary Supplement|Isocaloric Supplement|Blended food providing 125 kcal and 1 g protein as rice powder prepared as porridge and fed daily to infants from 6-12 months of age
64076|NCT03683667|Dietary Supplement|Egg|Egg provided daily to infants from 6-12 months of age
64077|NCT03683667|Behavioral|Nutrition Education|Monthly messaging on infant and young child feeding
64078|NCT03683654|Other|Identify Biomarkers of Dietary Intake in Healthy Subjects|Observational study. No intervention.
64079|NCT03683641|Device|Extracorporeal Shock Wave Therapy|Use ESWT on chronic insertional Achilles tendinopathy
64080|NCT03683641|Device|Sham Control group|Use sham ESWT on chronic insertional Achilles tendinopathy
64081|NCT03683628|Procedure|PB-MNC therapy|The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
64082|NCT03683628|Drug|No PB-MNC therapy|Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
64083|NCT03683615|Procedure|repair of orbital floor fractures using resorbable plates|
64084|NCT03683602|Other|PNF group|PNF is used in treatment of musculoskeletal pain of cervical and lumbar spine. Proprioceptive neuromuscular facilitation is a rehabilitation concept widely used by physiotherapists in many countries, in which stimulation of central nervous system is to achieve the highest possible functional level
64085|NCT03683602|Other|manual therapy group|"Manual therapy is used for an assessment and treatment of joint and soft tissues.~The basic therapeutic tool is mobilisation. In the study joint mobilisation according to Kaltenborn-Evjenth Manual Therapy was used. The joint were mobilised with low velocity passive movements in the whole or end range. Spinal manipulation wasn`t used. Liter Exelby reports that manual therapy with joints mobilisation was quite effective in improvement of functional movements and decreasing of pain."
64086|NCT03683576|Drug|GB001|GB001 dose daily
64087|NCT03683576|Drug|Placebo Oral Tablet|Placebo dose daily
64088|NCT03683563|Other|4% sodium citrate|the catheter will be locked with 4% citrate solution after each dialysis session
64089|NCT03683563|Other|30% sodium citrate|the catheter will be locked with 30% citrate solution after each dialysis session
64090|NCT03683550|Procedure|SLNE with preoperative hybrid SPECT/CT|Single-photon emission computed tomography/computed tomography (SPECT/CT) provides complementary functional and anatomical information and has been shown to be superior to planar imaging in a number of indications. It can provide valuable information before sentinel lymph node biopsy and advocate its use in a range of tumors such as truncal and head and neck melanomas.
64091|NCT03683550|Procedure|Standard SLNE|"The current gold standard for detection and targeted extirpation of the sentinel lymph node (SLN) is preoperative lymphoscintigraphy.~Lymphoscintigraphy (sentinel lymph node mapping) is an imaging technique used to identify the lymph drainage basin, determine the number of sentinel nodes, differentiate sentinel nodes from subsequent nodes, locate the sentinel node in an unexpected location, and mark the sentinel node over the skin for biopsy."
64092|NCT03683537|Diagnostic Test|Glial fibrillary acidic protein|3 samples of serum are drawn from patients. The 1st Sample of patient serum is drawn before induction into anesthesia. The 2nd is drawn 24 hours after the 1st one. The 3rd sample is drawn on 3 or 4 postoperative day. All samples collected and preserved in the same temperature as required for ELISA.
64093|NCT03683524|Drug|Dolutegravir (DTG) plus Darunavir/cobicistat (DRV/cobi).|bitherapy based on DTG (50 mg QD) plus DRV/cobi (800/150 mg QD)
64094|NCT03683524|Drug|Current ART|To continue with their current ART
64095|NCT03683498|Biological|Regulatory T-cell enriched infusion|Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.
64096|NCT03683485|Procedure|long duration EPBD|An 8-mm dilatation balloon was used for EPBD. Balloons were gradually inflated to maximum pressure for 3 minute, and complete inflation was verified by fluoroscopy.
64097|NCT03683485|Procedure|EST|After deep cannulation was achieved, a complete sphincterotomy was performed with a 25-mm pull-type sphincterotome (Clever Cut 3; KD-V411M, Olympus, Tokyo, Japan) and the sphincter was divided up to the transverse duodenal fold.
64098|NCT03683472|Behavioral|Unwinding Anxiety Phone App|"The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety"
64099|NCT03683459|Device|FemFlow Drug-Eluting Peripheral Balloon Catheter|Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
64100|NCT03683446|Procedure|Laparoscopic rectal surgery|Minimally invasive surgery and specialized technique for performing surgery using smaller incisions (or ports) to enter into the abdomen or anus for a tubular instrument(trochar), and a special camera (laparoscope), which is passed through the trochars to visualize the colon.
64101|NCT03683446|Procedure|Open rectal surgery|Surgery performed through a single long incision (cut) in the abdomen (belly) to access the colon and/or the rectum.
64102|NCT03683433|Drug|Azacitidine|Given SC or IV
64103|NCT03683433|Drug|Enasidenib Mesylate|Given PO
64104|NCT03683420|Behavioral|Music Therapy|The intervention consists of using an iPod to listen to music for up to 60 minutes while patients are receiving chemo infusion. There are no on components to the study.
64105|NCT03683407|Other|Next-Genernation Sequence|Tumor Mutation burden will be evaluated using NGS after 2-cycle chemotherapy, 4-cycle chemotherapy, or at progressive disease
64106|NCT03683394|Behavioral|SMARRT Intervention|Interventionists will follow a standard protocol for delivering the SMARRT intervention that allows for personalization of the specific risk reduction action plan; these plans will evolve over time according to participant progress, motivation and preferences or newly identified risk factors. Staff will use a tracking database to record information for each participant, including session dates, identified risk factors, motivational barriers and important values, and the outcome of discussions around developing goals. For each participant, the exact number and mode (phone or in-person) of contacts will differ, but we will aim to have at least 1 contact per month with each participant. Best practice will include in-person meetings twice a year during the 2-year intervention period.
64107|NCT03683394|Behavioral|Health Education Intervention|Participants randomized to the Health Education (HE) group will receive mailed materials (typically 1-2 pages) every 3 months. This will include general information on Alzheimer's and dementia risk reduction using materials from sources such as the Alzheimer's Association and educational materials commonly provided as part of routine care at Kaiser Permanente Washington (KPWA).
64108|NCT03683381|Behavioral|Sleep Health|Participants in the intervention group will be provided with an application containing weekly instructions to improve sleep
64109|NCT03683381|Other|Patient education|Participants in the Patient education group will receive weekly information on insomnia symptoms
64110|NCT03683368|Device|YpsoPump Orbit soft|Insulin infusion sets will be used for up to 7 days or until failure
64111|NCT03683368|Device|YpsoPump Orbit micro|Insulin infusion sets will be used for up to 7 days or until failure
64112|NCT03683355|Radiation|18F-FDG PET/CT|18F-FDG PET/CT and blood cultures will be performed at 3-month follow-up after TAVR Patients with positive 18F-FDG PET/CT (moderate or intense radiolabeled tracer uptake) will be scheduled for a second 18F-FDG PET/CT at 6-month follow-up.
64113|NCT03683342|Procedure|Ankle Block|Ankle block will be performed prior to surgery under ultrasound guidance
64114|NCT03683342|Procedure|Sciatic nerve block|Sciatic nerve block will be performed prior to surgery under ultrasound guidance
64115|NCT03683329|Other|Antibiotic de-escalation|"All the therapeutic protocols made the object of a consensus between the different partners of the study.~Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation."
64116|NCT03683329|Other|Standard treatment|Antibiotic treatment will be delivered according to current practice, in agreement with the national and international recommendation.
64117|NCT03683303|Behavioral|mobile applications (APP)|"the experimental group receiving education using Mobile Application (APP), collected data using Wound Care Knowledge Scale, Wound Care Skills Scale, State Trait Anxiety Inventory and Heart Rate Variability at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3). The SPSS 22.0 for Windows was used for statistics analyses."
64202|NCT03682601|Drug|Sinecatechins Topical|Topical sinecatechins ointment will be applied daily.
64120|NCT03683277|Drug|Ixazomib/Pomalidomide/Dexamethasone|"Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged <75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21"
64121|NCT03683264|Other|Ultrasound diagnosis of avulsion of the levator ani muscle|In the multi-view ultrasound images, complete avulsion was defined as an abnormal insertion of LAM in the lower pubic branch identified in all three central slices, i.e. in the plane of minimal hiatal dimensions (PMD) and the 2.5 and 5.0mm slices cranial to this one. Levator hiatus measurements, transverse diameters, anteroposterior diameters and area were also determined in the same plane (PMD).
64122|NCT03683251|Drug|PDS Implant with Ranibizumab 100 mg/mL|Will be administered as per the schedule described in individual arm
64123|NCT03683238|Dietary Supplement|Mediterranean Diet|We aim to determine the effects of the traditional Mediterranean Diet on Hidradenitis suppurativa
64124|NCT03683225|Combination Product|CTC-413|pramipexole ER, given with aprepitant
64125|NCT03683212|Procedure|Early intensive care bundle|"The care bundle comprises a list of items to follow and tick on a handover checklist within 4 hours of ED management:~Treatment of the congestion: (international guidelines and recommendations)~Treatment of precipitating factors~NIV (non-invasive ventilation) if respiratory distress with hypercapnia and pH < 7.35 in absence of contra indication.~Preventive LMWH (low molecular weight heparin) if no pre-existing anticoagulation therapy."
64126|NCT03683199|Procedure|Rhinoplasty|"The cleft lip rhinoplasty will be performed under general anesthesia.~1: 100,000 epinephrine will be infiltrated in the columellar incision and in the septum.~Open approach rhinoplasty will be used. A step ladder incision placed at the patient's columella, and continued with infra-cartilaginous incision.~The columellar skin flap along with the nasal tip skin will be dissected from the lower lateral cartilages.~Harvesting of the septal cartilage, to be used as spreader graft and columellar graft. Correction of the septal deviation.~Lengthening of the columella on the expense of the ala. Correction of the nasal tip by suturing techniques and by cartilage grafts."
64127|NCT03683186|Drug|Ralinepag|Active
64128|NCT03683173|Behavioral|Intervention|Participants in the intervention arm may receive community events, partake in walking groups, and receive short messaging service.
64129|NCT03683160|Other|Cognitive Augmented Mobility Program|CAMP will combine education, one-on-one cognitive strategy training, and a cardiovascular and strength-training program conducted within a group setting. It will be run as a group of up to 6 participants, facilitated by a physiotherapist and a physiotherapy assistant or kinesiologist. It consists of 2 phases with a total of 19 sessions: Intervention Preparation (3 sessions), Active Intervention (16 sessions), and Follow-Up (1 session).
64130|NCT03683147|Other|Laboratory Biomarker Analysis|Correlative studies
64131|NCT03683147|Behavioral|Meditation-Based Stress Reduction Program|Participate in 6-week online program
64132|NCT03683147|Other|Quality-of-Life Assessment|Ancillary studies
64133|NCT03683147|Other|Questionnaire Administration|Ancillary studies
64134|NCT03683134|Behavioral|Mediterranean diet|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
64135|NCT03683134|Dietary Supplement|Olive oil and mixed nuts|Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.
64136|NCT03683134|Behavioral|American Heart Association|Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
64137|NCT03683108|Drug|Resveratrol and Carbossimetyl Beta Glucan|Medical device based on Resveratrol and Carbossimetyl Beta Glucan. 3 drops, 4 times a day for 1 week.
64138|NCT03683108|Other|Saline Solution|Medical device based on Saline Solution. 3 drops, 4 times a day for 1 week.
64139|NCT03683095|Procedure|Lymphovenous bypass|"Lymphovenous bypass will be performed under general anesthetic. Indocyanine green lymphangiography will be performed by injecting indocyanine green into each finger / toe web of the lymphedematous limb and mapping the lymphatic system with the NOVADAQ SPY Fluorescence Imaging (Mississauga, Canada).~Subdermal dissection of lymphatics and venules will be carried out under a surgical microscope. Lymphatic vessels will be anastomosed to adjacent recipient venules to create the bypass between the lymphatic and the venous systems. In total, 1-5 anastomoses will be performed. This will require 1-5 incisions, each with a length of 2-3 cm.~Postoperatively, the limb will be wrapped loosely with compression bandages. No special postoperative monitoring is required.~The surgery will be performed on an outpatient basis with no planned hospital stay."
64140|NCT03683082|Drug|Oxygen supplementation|40% FiO2 via Venturi mask
64141|NCT03683082|Drug|Sham O2 (medical air)|Medical air supplementation via Venturi mask
64142|NCT03683069|Drug|Eplerenone vs Amlodipine|We posit that decreases in striatin activity/levels increases aldosterone secretion resulting in hypertension and salt sensitive blood pressure. Thus, our mechanistic clinical study will assess whether hypertensive striatin risk allele carriers will show significantly greater reductions in blood pressure with a specific aldosterone mediated treatment approach (mineralocorticoid receptor blockade) than with a non-specific approach (amlodipine). To test this hypothesis, we will perform a randomized, double-blind, active controlled study in hypertensive carriers of the striatin risk allele using a novel two-limb, proof-of-principle study. Our primary outcome will be a liberal salt diet systolic blood pressure with a secondary outcome of salt sensitive blood pressure. Therefore, this mechanistic trial will provide support for using a genetic marker that identifies individuals who are uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine.
64203|NCT03682601|Other|Placebo|Aquaphor
64143|NCT03683056|Behavioral|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
64144|NCT03683043|Drug|Long GnRH agonist protocol|"8. The patients follow long protocol, which includes down regulation starting on day 21 of the previous cycle. The patient is seen after 14 days to confirm down regulation. Serum E2 ≤ 50 pg/ mL and no ovarian cysts observed in transvaginal US.~9. Induction is started on day 3 of the current cycle by gonadotrophins (FSH and LH) daily IM or SC injections provided that the different preparations at the market can be used."
64145|NCT03683043|Procedure|Embryo transfer|Cusco speculum was used to allow access to the cervix. The vagina was flushed by saline, and the cervical mucus is removed by Q-tips and/ or suction tubes. In few cases, where patients had long vaginae; two Sims' speculums were used to spread the vaginal anterior and posterior vaginal walls apart. In these cases, the attending nurse assisted the gynecologists during transfer The gynecologist asks the embryologist to load the embryos in the transfer catheter, and the gynecologist receives the loaded catheter from a window connecting the lab and operating room. In cases of trans-vaginal ultrasound guided embryo transfer the embryologist hands in the catheter to the gynecologists in the outer sheath and the gynecologist injects slowly the fluid containing the embryo/s. All patients are asked to rest for 30 minutes after the transfer
64146|NCT03683030|Device|Radiofrequency Ablation|RF ablation using the multi-electrode radiofrequency balloon catheter
64147|NCT03683017|Device|OrthoPulse 2.0|Patients are given OrthoPulse 2.0, an extended OrthoPulse device with no zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
64148|NCT03683017|Device|OrthoPulse 2.1|Patients are given OrthoPulse 2.1, an extended OrthoPulse device with zone control (ability for doctor to control treatment regions). Patients complete 10 minute treatments (5 minutes each arch) every day.
64149|NCT03683017|Device|Invisalign 3.5 Day Wear|Patients are are fitted with sets of clear orthodontic Aligners by a qualified Principal Investigator (PI) using a ClinCheck plan by Align Technology. Aligners are worn for approximately 22 hours a day, and switched every 3.5 days.
64150|NCT03683017|Device|Fixed Orthodontic Appliances (Braces)|Patients are fitted with a set of brackets and wires, as per standard orthodontic treatment by a qualified Principal Investigator (PI).
64151|NCT03682991|Other|Aggressive Risk Factor Control|"Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).~Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~Blood Pressure management to achieve a target systolic blood pressure (SBP) of <120/80 mm/Hg~Smoking cessation facilitated through local resources already established at each site"
64152|NCT03682991|Other|Standard of Care|Recommendations based on current guidelines
64153|NCT03682978|Drug|Arbaclofen|Arbaclofen tablet.
64154|NCT03682978|Drug|Placebo|Placebo tablet.
64155|NCT03682965|Biological|Intra-lymphatic allergenic extract|Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
64156|NCT03682965|Biological|Intra-lymphatic placebo|The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.
64157|NCT03682952|Drug|Alprostadil Injection|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks.
64158|NCT03682952|Drug|Beraprost sodium tablets|Participants are given alprostadil injection 10ug intravenously once a day for 2 weeks ,then they take beraprost sodium tablets 40ug orally three times perday for 3 months.
64159|NCT03682939|Biological|Bexsero® (meningitis B vaccine)|Bexsero® 0.5ml IM vaccine administered into non-dominant arm of participant
64160|NCT03682939|Biological|Menveo® (meningitis ACWY vaccine)|Menveo® 0.5ml IM vaccine administered into dominant arm of participant
64161|NCT03682926|Other|Electro-stimulation|Intracavitary electrostimulation with Quark medical vaginal electrode for perineal muscle strengthening protocol.
64162|NCT03682913|Behavioral|P-CIT protocol|Personalized inhibitory control training for one week.
64163|NCT03682913|Behavioral|Placebo|without personalized inhibitory control training for one week.
64164|NCT03682900|Other|Click City Tobacco Prevention Program|Fifth and sixth grade classroom tobacco prevention computer activities designed to postpone or prevent youth smoking, through changing theoretically-based risk factors predictive of subsequent use.
64165|NCT03682887|Procedure|Cryoballoon PV isolation group|"Pulmonary vein isolation will be performed using a cryoballoon catheter.~Esophageal temperature will be monitored to prevent esophageal injury.~A 28mm cryoballoon catheter will be used.~Cryoablation will be performed for 180 secs at -30 C or below on condition that the pulmonary vein is occluded with a cryoballoon.~CMAP (compound motor action potential) monitoring will be done to avoid phrenic nerve damage during the freezing of the right superior pulmonary vein.~The procedure and ablation times will be evaluated.~The procedure will be completed without checking any other trigger came from beyond pulmonary vein after the administration of isoproterenol~Rhythm follow-up will be performed after the procedure in accordance with the aforementioned study design."
64166|NCT03682887|Procedure|Cryoballoon PV isolation with Additional RA linear ablation group|It is a percutaneous catheter procedure to ablate the source of atrial fibrillation. By femoral vein access, the investigators conduct trans-septal puncture and introduce cryoballoon catheter into left atrium. Because the main foci of atrial fibrillation is pulmonary veins, the investigators isolate 4 pulmonary veins by freezing with cryoballoon catheters. However, in the discovery arm, the investigators conduct additional linear ablation on right atrial cavotricuspid isthmus and septum to reduce potential recurrence in patients with persistent atrial fibrillation.
64167|NCT03682861|Behavioral|20 km time trial performance|20 km time trial cycling test will be conducted to measure the effect of different drinks on time
64794|NCT03678051|Behavioral|Treatment as Usual (TAU)|Standard of care residential treatment
64168|NCT03682861|Behavioral|Glycogen lowering exercise|Glycogen will be lowered using a 10-min warm-up period at a workload of 50% max wattage power output (Wmax). Thereafter, participants will be instructed to cycle 2-min block periods at alternating workloads of 90% and 50% of Wmax, respectively. This will be continued until the participants are no longer able to complete the 2 min at 90% Wmax. That moment will be defined as the time at which the individual is unable to maintain cycling speed at 60 revolutions/min. At that moment the high-intensity block will be reduced to 80% Wmax. Again, athletes will cycle until they are unable to complete a 2-min block at 80% Wmax, after which the high-intensity block will be reduced to 70% Wmax. Finally, participants will be allowed to stop when pedalling speed could not be maintained at 70% Wmax.
64169|NCT03682848|Drug|DTG + 3TC FDC|DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.
64170|NCT03682835|Dietary Supplement|FDGard|capsule containing peppermint oil and caraway oil
64171|NCT03682835|Other|Placebo|Placebo capsule containing cellulose
64172|NCT03682822|Procedure|Early Artificial rupture of membranes|Women in this arm will undergo artificial rupture of membranes before 4 cm of cervical dilation is reached during induction of labor as long as the procedure is deemed clinically safe and feasible.
64173|NCT03682822|Procedure|Delayed Artificial rupture of membranes|Women in this arm may undergo artificial rupture of membranes performed only after 4 cm of cervical dilation is reached during induction of labor. Rupture may also be performed after 10 hours of oxytocin administration with no cervical change.
64174|NCT03682809|Drug|Systane Complete|Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
64175|NCT03682796|Drug|TRPH-222|administered by IV, 21-day Cycle
64176|NCT03682783|Diagnostic Test|Fundus Image|Fundus image of optic nerve
64177|NCT03682770|Drug|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)
64178|NCT03682770|Drug|Placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
64179|NCT03682770|Drug|AR101|AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase
64180|NCT03682744|Biological|anti-CEA CAR-T cells|Intraperitoneal delivery of anti-CEA CAR-T cells
64181|NCT03682718|Device|Transcervical Foley catheter|combined methods of induction of labor Floey Catheter with misoprstol
64182|NCT03682718|Drug|Misoprostol|Misoprstol inserted vaginally for induction of labor
64183|NCT03682705|Drug|Upadacitinib|Upadacitinib tablet will be administered orally.
64184|NCT03682705|Drug|ABBV-105|ABBV-105 capsule will be administered orally.
64185|NCT03682705|Drug|Upadacitinib placebo|Upadacitinib placebo tablet will be administered orally.
64186|NCT03682705|Drug|ABBV-105 placebo|ABBV-105 placebo capsule will be administered orally.
64187|NCT03682692|Drug|ACEI/CCB|benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination
64188|NCT03682692|Drug|ACEI/DIU|benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination
64189|NCT03682679|Diagnostic Test|Sonoelastography|"This diagnostic test would be executed by a physician who has experiences of using Siemens Acuson S2000 ultrasound system for more than three year. The examination includes two of four rotator cuff muscles, listed as follows, supraspinatus muscle and infraspinatus muscle. Linear transducer (4-9 MHz) would be used for the whole test. The probe would be positioned along the longitudinal axis of the muscle belly.~Compressive sonoelastography technique is used for semiquantitative analysis. In order to maintain the quality of images, quality factor needs to be over or equal to 60. The quantitative analysis was performed by shear wave sonoelastography. While assessing, the ROI would be divided into four quadrants. The physicians will measure the shear wave velocity for wight times at the center point of each quadrant."
64190|NCT03682666|Device|Kinesiotaping|Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.
64191|NCT03682666|Behavioral|modified Constraint Induced Movement Training|A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.
64192|NCT03682666|Device|Sham taping|A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
64193|NCT03682653|Drug|Azithromycin|a single dose of Azithromycin will be administered to infants between their 8-27th days of life
64194|NCT03682653|Drug|Placebo|a single dose of Placebo will be administered to infants between their 8-27th days of life
64195|NCT03682640|Drug|Azithromycin Monohydrate|Azithromycin Monohydrate tablet (Azithromycin Sandoz) or oral suspension (Azithromax).
64196|NCT03682640|Drug|Insulin Lispro|Solution for intravenous or subcutaneous use
64197|NCT03682640|Behavioral|Dietician support|Dietary advice
64198|NCT03682627|Procedure|Fenestration|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The peritoneal will not be sutured at the edges to keep the fenestration open. No interpositioning of the omentum will be performed.
64199|NCT03682627|Procedure|Fenestration and clipping|A standardized fenestration of the peritoneum will be performed. A 2 cm incision will be made in the peritoneum that is parallel to the skin incision after the transplant procedure. The window edges will be clipped after fenestration using 8 metal clips.
64200|NCT03682614|Drug|HCG|we will use the catheter to pass through the cervix, and after that, the experiment Group will accept 40 μl 500 IU HCG injection into the uterine cavity 2 days before the blastocyst transfer.
64201|NCT03682614|Other|culture medium|The placebo group will accept 40 μl of culture medium injection into the uterine cavity 2 days before the blastocyst transfer.
112292|NCT03308552|Radiation|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
64204|NCT03682588|Other|Physical activity|The Functional exercise group performed functional exercise training for 45 minutes twice a week for 14 weeks. The Stretching exercise group performed stretching exercises with the same duration and frequency.
64205|NCT03682575|Other|Enrollment|All infants whose families consent will be enrolled and will all receive the same treatment which included measurements of work of breathing.
64206|NCT03682562|Diagnostic Test|DNA Integrity Index|"This test will be performed for ALL three groups:~Sample collection:~Patients will be given a sterile cup containing 5mL saline solution with which they will vigorously rinse their mouth while rubbing their tongues against the oral mucosa for 30 seconds, then spit it back into the cup. The solution will then be used for DNA extraction.~DNA integrity analysis:~The DNA integrity will be done through measuring a housekeeping gene using competitive polymerase chain reaction where the isolated DNA will be combined with DNA capture probes for sequence-specific DNA fragments. The DNA integrity index will be calculated as the ratio of the concentration of longer DNA fragments to the ratio of shorter ones."
64207|NCT03682549|Diagnostic Test|Oral microbiome analysis|Oral swab from the buccal mucosa will be obtained and then analysed Oral Microbiome analysis:The microbial RNA will be sequenced using Next Generation Sequencer.
64208|NCT03682536|Drug|Luspatercept|Luspatercept
64209|NCT03682536|Drug|Epoetin alfa|Epoetin alfa
64210|NCT03682523|Behavioral|Sedentary behavior reduction intervention|Participants will be provided with a device to measure physical activity and sedentary behaviours. A tablet will be placed in the participants' hospital room and synced to the device to provide real-time feedback. The research team will deliver an upright time goal and will target a 20% increase in upright time from the previous hospital day. Physiotherapist research assistants will visit the participants every afternoon to monitor progress and safely mobilize participants to their maximum ability if they have not met their daily goal (including weekend). The maximum level of ability will be determined in consultation with the healthcare team. Participants who do not meet their goal will be mobilized in the afternoon and early evening.
64211|NCT03682510|Procedure|stepwise devascularization|stepwise devascularization begins with suture the placenta bed through uterine artery ligation, internal iliac artery ligation etc
64212|NCT03682510|Procedure|B-Lynch Transverse Compression Suture group|"After acceptable control of bleeding from the placental bed, uses the suture material 1 VICRYL with a 70mm ½ circle needle mounted on a 90 cms VICRYL suture. We use the needle blunt ended to puncture the uterus 3 cms above the upper margin of the incision posteriorly and behind the vascular bundle.~The needle is retrieved through the cavity of the uterus and pulled inferiorly with the suture material lying on the posterior wall of the uterine cavity. The needle then perforates the posterior wall of the uterus 3 cms below the inferior margin of the Caesarean incision and exists behind the vascular bundle of the same side of the uterus retrieved and runs on the surface of the lower segment below the incision margin parallel to it and taking a 1 cm bite of tissue for stabilization running to the other side. After encircling the para-uterine vasculature, the needle then perforates the posterior side of the uterus behind the vascular bundle entering the uterine cavity."
64213|NCT03682510|Procedure|N&H sandwich technique|In the N&H group, double uterine compression suture at the lower uterine segment with inflated Foley's catheter balloon tamponade.
64214|NCT03682497|Drug|AZD9977|AZD9977 capsules taken orally for 28 days.
64215|NCT03682497|Drug|Spironolactone|Spironolactone tablets taken orally for 28 days.
64216|NCT03682484|Drug|MA-0211|oral
64217|NCT03682484|Drug|Placebo|oral
64218|NCT03682471|Drug|Deoxycholic acid Injection|Solution for subcutaneous injection.
64219|NCT03682471|Drug|Placebo|Placebo, 10 mM sodium phosphate, 0.9% [w/v] sodium chloride in water for subcutaneous injection.
64220|NCT03682458|Genetic|Study of Neurodegenerative Diseases Induced Stem Cells|The aim of this study is to generate iPS-induced stem cell lines from patients with neurological and neurodegenerative diseases to differentiate into neurons and glial cells to study the pathological cellular and molecular processes of these diseases. These in vitro cultures will also be used to validate molecules or experimental therapeutic approaches. IPS cells will be generated by the reprogramming of isolated 10-mL cells of peripheral venous blood.
64221|NCT03682445|Other|exercise|Aerobic tyep of exercise will be made at different intensities in 2 groups.
64222|NCT03682419|Procedure|VKA Patients|Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy
64223|NCT03682419|Procedure|Non-VKA Patients|Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy
64224|NCT03682406|Behavioral|CAMS-G|Group-based suicide-specific intervention based upon the Collaborative Assessment and Management of Suicidality.
64225|NCT03682393|Drug|Hydrocortisone|100mg 1x3 hydrocortison intravenously for three days after mitral valve surgery or until atrial fibrillation onset
64226|NCT03682393|Drug|Placebos|100mg 1x3 intravenous fysiologic saline for three days after mitral valve surgery or until atrial fibrillation onset
64227|NCT03682380|Drug|Seltorexant High Dose|In Part 1, Part 2, and Part 3 (3A and 3C), Seltorexant high dose (either a high dose tablet or two low dose tablets) will be administered orally.
64228|NCT03682380|Drug|Seltorexant Low Dose|In Part 3 (3B and 3C), Seltorexant low dose will be administered orally.
64229|NCT03682367|Drug|Gabapentin|Use of Gabapentin peri- and post-operatively.
64230|NCT03682367|Drug|Placebo - Concentrate|Use of sugar-free Placebo peri- and post-operatively.
64231|NCT03682354|Drug|Intercostal Nerve Block with PCIA|Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.
64232|NCT03682354|Drug|Erector Spinae Plane Block (ESPB)|Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
64233|NCT03682341|Genetic|endometriosis|patients with or without ovarian endometriosis
64234|NCT03682328|Procedure|vertebroplasty|Cement augmentation of the vertebral body
64235|NCT03682328|Procedure|kyphoplaty|Cement augmentation of the vertebral body
64384|NCT03681093|Drug|Placebo|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 Dose 1 and one tablet blinded placebo to QAW039 Dose 2)
64236|NCT03682315|Device|Biphasic phycogenic biomaterial|Maxillary sinus floor elevation and bone grafting with the use of biphasic phycogenic biomaterial combined with autogenous cortical bone
64237|NCT03682315|Device|Xenograft bovine hydroxyapatite|Maxillary sinus floor elevation and bone grafting with the use of xenograft bovine hydroxyapatite combined with autogenous cortical bone
64238|NCT03682302|Drug|Exparel|EXPAREL 4mg/kg (maximum 266 mg)
64239|NCT03682302|Drug|0.5% Bupivacaine HCl|Bupivacaine HCl 2mg/kg
64240|NCT03682289|Drug|ATR Kinase Inhibitor AZD6738|Given by mouth
64241|NCT03682289|Drug|Olaparib|Given by mouth
64242|NCT03682276|Biological|Ipilimumab|Ipilimumab is a monoclonal antibody given as an immunotherapy
64243|NCT03682276|Biological|Nivolumab|Nivolumab is a monoclonal antibody given as an immunotherapy
64244|NCT03682263|Behavioral|Full Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, care management services, and Medication Management Support provided by a Nurse Care Coordinator (NCC).
64245|NCT03682263|Behavioral|Basic Service|Receive Individual Placement and Support (IPS) model of employment services, behavioral health services, and care management services.
64246|NCT03682250|Device|FreeStyle Libre Pro|A FreeStyle Libre Pro will be used to identify hypoglycemic episodes
64247|NCT03682250|Device|Holter monitor|A Holter monitor will be used to measure heart's activity
64248|NCT03682237|Device|Carbohydrate counting, automated bolus calculation|Group training in carbohydrate counting and bolus calculation. The app MySugr will be taught and downloaded on own smart phone and person specific parameters will be estimated and entered in the app with the patients. SMBG measures at least 4 times daily with patients own preferred glucose meter.
64249|NCT03682237|Device|Flash glucose monitoring (FGM)|Group training, patients will be instructed to use unblinded FGM for the whole study period. Patients are recommended to measure SMBG according to FGM manufactures guideline and handling of trend arrows etc.
64250|NCT03682224|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine 1.3% (Exparel), 20 ml vial for injection, administered subcutaneously at port site
64251|NCT03682224|Drug|Bupivacaine-Epinephrine|Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
64252|NCT03682211|Drug|Fentanyl Citrate|50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
64253|NCT03682211|Drug|Morphine sulphate|10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
64254|NCT03682198|Device|NIRS measurements on skin, skull and dura|During a neurosurgical procedure, we will measure the brain oxygenation with a NIRS-electrode, first on forehead skin, then on the skull and finally directly on dura.
64255|NCT03682198|Drug|Phenylephrine's effect on brain oxygenation|With a Clark-electrode (Licox(R)) in the white matter and a NIRS-electrode on the forehead skin, we will give a small dose (0.1 mg iv.) Phenylephrine.
64256|NCT03682198|Drug|Normal vs. high inspired oxygen|By the end of the neurosurgical procedure, still with a Clark-electrode in the white matter and a NIRS-electrode on forehead skin, we will change the inspired oxygen fraction from 0.3 to 0.8.
64257|NCT03682185|Behavioral|Attention-Control Condition|This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
64258|NCT03682185|Behavioral|Timed Activity Intervention|The timed activity group will involve 4 in-home visits and 4 brief telephone education sessions provided over 4 weeks. The timed activity intervention provides activities delivered at specific times in the daily cycle. The in-home sessions are spaced weekly so that the participants can have the opportunity to practice the activity with the interventionist and then on their own. During each session, the interventionist will reinforce activity use, review problem-solving approaches, and provide education.
64259|NCT03682172|Drug|GLP-2 (1pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 1pmol/kg/min
64260|NCT03682172|Drug|GLP-2 (10pmol/kg/min)|Four hour intravenous infusion with glucagon-like peptide 2 at a rate of 10 pmol/kg/min
64261|NCT03682172|Drug|Placebo|Four hour intravenous infusion with saline water
64262|NCT03682159|Other|manual lymphatic drainage|The intervention group received the same conventional postoperative cares as the control group, but also underwent 5 sessions of manual lymphatic drainage (MLD)
64263|NCT03682146|Procedure|Prostatectomy|Comparison of robot-assisted and conventional laparoscopic radical prostatectomy
64267|NCT03682107|Biological|Andes virus DNA vaccine|A vaccine targeting the hantavirus pulmonary syndrome (HPS) causative agent Andes Virus (ANDV), with potential pan-hantavirus effect. The plasmid backbone, pWRG7077, is modified to produce the active ingredient of the vaccine, plasmid pWRG/AND-M (opt2), and includes the ANDV M gene responsible for encoding viral GnGc envelope glycoproteins. ANDV DNA vaccine will be administered intramuscularly at 2 mg or 4 mg doses using the PharmaJet Stratis Needle-Free Injection System.
64268|NCT03682107|Other|Placebo|Normal saline injections will be administered intramuscularly as matching placebo using the PharmaJet Stratis Needle-Free Injection System
64346|NCT03681418|Procedure|Ultrasound-guided axillary lymph nodes FNAC and\or CNB.|Ultrasound-guided axillary lymph node fine needle aspiration and\or core needle biopsy of the most suspicious lymph node. If all the lymph nodes appeared similar or normal, the lymph node that is lowest in the axilla will be selected because it is considered to most likely be the sentinel node.
64347|NCT03681405|Other|Informational Intervention|Given information about mindful movement and breathing
64348|NCT03681405|Other|Questionnaire Administration|Ancillary studies
64269|NCT03682094|Drug|VSL#3|Probiotics are dietary supplements composed of live microorganisms that are normally found within the human microbiome. Probiotics, specifically Lactobacilli and Streptococcus salivarius, have been shown to alter oral microbial composition and to inhibit oral pathogens that contribute to dental caries and periodontal disease. The probiotic chosen for this study is VSL#3, a blend of 8 strains of bacteria, including Lactobacillus and Streptococcus salivarius. VSL#3 has been well tolerated, with minimal adverse effects. VLS#3 was chosen as the treatment substance for this project due to its successful use in trials examining an array of outcomes and its combination of several strains of bacteria.
64270|NCT03682081|Device|Isometric tongue strengthening|The tongue is the primary propulsive force for bolus movement into the esophagus during swallowing. Maximum isometric lingual pressures decline with age and in patients with dysphagia. Just as participation in progressive resistance training can strengthen striated limb musculature to improve mobility in healthy older adults, it also benefits bulbar-innervated striated muscles of the head and neck. Lingual strengthening therapy based on core principles of exercise physiology employs high intensity, repetitive, non-specific exercises for the tongue. Positive changes following lingual strengthening in lingual isometric and swallowing strength have been shown for healthy older adults.
64271|NCT03682081|Drug|Biotene|To alleviate dry mouth, older adults often use commercial saliva substitutes as a replacement for natural saliva. The most commercially successful products are Biotene® products, a hybrid between biopolymer plant mucilage and salivary enzyme-based substitutes. Salivary substitutes decrease mouth dryness and need to drink water to swallow in older adults.
64276|NCT03682055|Drug|VK-2019|EBNA1 inhibitor
64277|NCT03682042|Other|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
64278|NCT03682029|Dietary Supplement|Vitamin C (ascorbic acid)|Monotherapy with oral vitamin C supplementation to elevate plasma vitamin C level to the upper end of the physiological range.
64279|NCT03682029|Other|Placebo|Placebo
64280|NCT03682003|Diagnostic Test|blood diagnostic tests|blood tests are performed to determine hepcidin, IL-6, CRP, PCT, serum iron, ferritin, transferrin and transferrin saturation
64281|NCT03681990|Drug|3M CHG/IPA Prep|Apply topically to intact skin
64282|NCT03681977|Device|Zimmer MP Persona|The medial pivot Persona® knee implant with a Medial Congruent™ Bearing
64283|NCT03681977|Device|Zimmer Persona Knee-PS|Persona the personalized knee system
64284|NCT03681951|Drug|GSK3145095|GSK3145095 will be available as capsule (size 1 containing 5 to 25 mg GSK3145095 and size 0 containing 25 to 75 mg GSK3145095) or tablet (25, 50, 200 mg white to slightly covered round/oval shaped coated) for oral administration in the fasted stated with approximately 200 milliliters (mL) of water.
64285|NCT03681951|Drug|Pembrolizumab|Pembrolizumab will be available as solution for infusion (100 milligrams/ 4 milliliter) at a dose of 200 mg via IV infusion for 30 minutes (given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted i.e., infusion time is 25 to 40 minutes).
64286|NCT03681938|Procedure|Autograft|Autograft
64287|NCT03681925|Diagnostic Test|Nutrition Literacy Assessment Instrument (NLit)|The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
64288|NCT03681912|Behavioral|Competency: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS)|"Coaching feedback will be triggered by a provider falling below the competency threshold on the standardized patient interaction. Everyone will receive coaching for two assessments in the month following training. After that, if mean scores fall below competency, then the provider will receive a 5-minute coaching session by the external Motivational Interviewing Network of Trainers (MINT) facilitator.~Feedback on two highest and two lowest ratings, review of the audio recording and interactive coaching activities (e.g., fidelity assessments) targeting the lowest ratings. While many aspects of this implementation strategy are adaptable, organizational leadership will review data on completion of coaching feedback sessions and will determine corrective action for suboptimal adherence."
64289|NCT03681912|Behavioral|Randomized Guided Development of COPs with an internal facilitator after one year of implementation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity monitoring, and prevent drift. In addition to CoP, half the sites will be randomized to receive an internal facilitator who will be trained to continue quarterly fidelity monitoring and coaching feedback when scores fall below competency.
64290|NCT03681912|Behavioral|CoP development without internal facilitation.|Development of the CoP will be guided by scheduling and assisting in setting the agenda for the first three meetings to encourage MI practice, peer coaching and potentially fidelity
64291|NCT03681899|Other|Questionnaires|"Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~Medical and surgical history (Charlson Comorbidity Scale);~Assessment of oral/dental condition~Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~Autonomy evaluation (Lawton and Katz scales);~Mobility assessment (anamnestic evaluation);~Evaluation of Thyme (GDS 4 items);~Psycho-behavioral disorders,~Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data)."
64292|NCT03681873|Diagnostic Test|Extremely Low Dose CT|Patients undergoing a clinically indicated chest CT will also undergo the extremely low dose CT
64349|NCT03681405|Behavioral|Telephone-Based Intervention|Receive caring attention phone call
64385|NCT03681080|Procedure|leg crossing|As Counter maneuvre legs will be crossed and cognitive tests will be performed.
64293|NCT03681860|Biological|ChAdOx185A|ChAdOx1 85A is an adenoviral vaccine based on a vector that is a chimpanzee adenovirus isolate Y25 expressing the M.tb antigen 85A. Adenoviruses are attractive candidates for use as viral vectors and have been used as vaccine vectors for a number of conditions; however, the use has been limited by the high level of anti-vector immunity present in humans in whom adenovirus is a ubiquitous infection. This has led to the consideration of simian adenoviruses, which are not known to cause pathology or illness in humans and to which the prevalence of anti-vector antibodies is low. The ChAdOx1 vector has been developed by the University of Oxford and been used with different inserts for vaccination, for example the vaccine ChAdOx1 NP+M1 has demonstrated an excellent safety profile in the Influenza trial FLU004. A BCG - ChAdOx1 85A - MVA85A prime boost regime is more protective than BCG alone in mice.
64294|NCT03681860|Biological|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly-attenuated strain of vaccinia virus which cannot replicate in human cells. It is known to be highly immunogenic in UK adults but has been less immunogenic in African children and infants. It is suitable for use as a viral vector in a prime-boost regime in new vaccine development. It has an excellent safety record as it was administered intradermally to approximately 120,000 people during the smallpox eradication campaign, and has since been used in numerous clinical trials of candidate vaccines against viral, mycobacterial and protozoal infections.
64295|NCT03681860|Biological|BCG|BCG is the only vaccine currently approved for use against Tuberculosis.
64296|NCT03681847|Procedure|Normal saline|normal saline 0.9% 15 ml/kg over 15-20 minutes.
64297|NCT03681847|Procedure|hydroxyethyl starch|hydroxyethyl starch 130/0.4 in 0.9 % sodium chloride 5 ml/kg over 15-20 minutes.
64298|NCT03681847|Procedure|Hypertonic saline|hypertonic saline 3% (7ml/kg) over 15-20 minutes.
64299|NCT03681834|Other|Data collection|Data on the effectiveness and safety of the Cor-Knot® knotting device
64300|NCT03681821|Behavioral|Transtheoretical Model (TTM)-based Intervention|Patients in the intervention group had access to conventional care, in addition to receiving the follow-up TTM-based intervention sessions. The intervention was provided by trained nurses, including one researcher and one ET nurse. Sessions were held in the meeting room in the unit four times: at baseline (T0), 2 days before discharge (T1), and at 1-month (T2) and 3-months (T3) after discharge, according to the assessment of their current stage of change delivered by filling the Stages of Change Subscale. Each face-to-face group contact lasted about 1 hour, depending on the complexity of the patients' problems.
64301|NCT03681808|Device|Control|Contact Lens
64302|NCT03681808|Device|Test|Soft Contact Lens
64303|NCT03681795|Combination Product|Experimental MRI exam and PET scan exam|MRI exam and PET scan exam
64304|NCT03681769|Device|iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the Universal Serial Bus (USB) key).
64305|NCT03681769|Device|Sham iTBS to the left dlPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
64306|NCT03681769|Device|cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
64307|NCT03681769|Device|Sham cTBS to the mPFC|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
64308|NCT03681756|Behavioral|WALK|Walking program
64309|NCT03681743|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
64310|NCT03681730|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a VOX+ Z3 3D Virtual Reality Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
64311|NCT03681717|Device|Virtual Reality|Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
64312|NCT03681704|Drug|HuangQi Decoction|HuangQi Decoction 150ml twice a day for 24 weeks
64313|NCT03681704|Drug|HuangQi Decoction placebo|traditional Chinese medicine placebo mimic HuangQi Decoction 150ml twice a day for 24 weeks
64314|NCT03681691|Drug|Estradiol patch|transdermal 17β-estradiol patch
64315|NCT03681678|Device|fCO2 Laser Therapy Group|Women enrolled in the study will receive three treatments with the fractional carbon dioxide (fCO2) laser. The interval between treatments is approximately six weeks. Intra-vaginal laser treatments will be delivered at 8 points at each level of the vaginal wall.
64316|NCT03681665|Other|ultralow dose abdominopelvic CT|In the patient cohort with abdominal abscess, ultralow dose abdominopelvic CT will be performed as a follow-up protocol. Ultralow dose CT has approximately 80~90% reduced radiation dose compared to standard dose CT.
64317|NCT03681652|Drug|Azathioprine|Children with Crohn's disease who are treated with azathioprine for post-operative prophylaxis following ileo-cecal resection
64318|NCT03681652|Drug|Anti-TNF Drug|Children with Crohn's disease who are treated with anti-TNF monotherapy for post-operative prophylaxis following ileo-cecal resection
64319|NCT03681639|Diagnostic Test|Serum Metal ion levels determined to monitor changes in chromium and cobalt levels|Analyses will be performed pre-operatively, 6 months, 1 year, 2 years and 5 years postoperatively for all study subjects enrolled in this study, as well as, all revision study subjects receiving the Metasul® LDH™ total hip system. To prevent intra-observer variation the metal ion concentrations will be analysed by an approved Central Laboratory. The Central Laboratory will provide specimen collection kits for the transfer of blood specimens to the Laboratory for analysis. The Laboratory will provide the results to the Investigators. The cobalt and chromium will be measured by induced coupled plasma mass spectrometry (ICP-MS). BUN, creatinine and GFR will be determined locally.
64320|NCT03681626|Procedure|no tracheal suction|No tracheal suctioning during extubation
64321|NCT03681626|Procedure|tracheal suction|tracheal suctioning during extubation
64350|NCT03681392|Dietary Supplement|Dr. Pyke's Supplement for Stream (S4S)|Proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3
64322|NCT03681613|Other|NEMEX program combined with a CNS-focused protocol|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The CNS-targeted treatment will consist of 12-week individualized and supervised sessions applied once weekly. Each training session will last approximately 30 minutes and include three parts, which are further explained below: 1) discussion of the participant's knee pain experience from a pain neuroscience perspective, 2) graded SDT and 3) GMI training."
64323|NCT03681613|Other|NEMEX program combined with a sham intervention|"The NEMEX program will consist of 12-weeks of individualized and supervised exercise sessions applied twice weekly (n=24 sessions). Each exercise session will last approximately 60minutes and include three parts: warming up, a circuit program and cooling down.~The sham intervention will consist of detuned ultrasound and short-wave diathermy applied over the affected knee for the same duration and with the same number of sessions of the CNS-targeted treatment. In this way, the time spent with the therapist between both intervention groups will be the same."
64324|NCT03681587|Other|Control situation|"Standard breakfast usually offered monotonous control condition at the retirement home: the time of distribution, the duration of ingestion and the composition will be habitual. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone in the room or with others in the dining room."
64325|NCT03681587|Other|Experimental situation|"Salty/sweet breakfast varied experimental situation: the time of distribution and the duration of mealtime will be open and the composition will be varied with sweet/savory foods. This meal and subsequent meals will be measured over 3 consecutive days with observation periods at breakfast time in order to identify the variables of pleasure, feasibility, commensality and conviviality in 2 situations: alone or in the room or with others in the dining room."
64326|NCT03681574|Drug|Placebo Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive placebo concentrate.
64327|NCT03681574|Drug|GABA 15mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 15mg/kg.
64328|NCT03681574|Drug|GABA 30mg/kg Group|Patients will be submitted to either myelogram or lumbar puncture procedure. Before that they will receive gabapentin at 30mg/kg.
64329|NCT03681561|Drug|Ruxolitinib|"Ruxolitinib at assigned dose* twice daily by mouth begin Day 1 and continuing daily until study treatment stop.~Dose Levels:~1 (starting) : 10mg twice daily 2: 15mg twice daily 3: 20mg: twice daily"
64330|NCT03681561|Drug|Nivolumab|Nivolumab 480 mg IV every 4 weeks (Day 1) Until disease progression, unacceptable toxicity, patient refusal or a maximum of 2 years
64331|NCT03681548|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 1 patients will receive either reference or test product, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation
64332|NCT03681535|Radiation|Radiation Therapy|This phase II study will evaluate whether a reduction in the RT dose, concomitant with a decrease in the RT field size, in patients that achieve complete response and have a negative post-chemotherapy PET scan following 3 to 6 cycles of rituximab containing chemotherapy, will be associated with a low risk of in-field failure. The goal of this approach is to maintain excellent control rates while minimizing the risk of acute and late toxicity.
64333|NCT03681522|Procedure|Pelvic plexus block|Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
64334|NCT03681522|Procedure|Periprostatic nerve block|Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
64335|NCT03681509|Drug|Pramipexole|Pramipexole
64336|NCT03681509|Drug|Placebo|Lactose placebo capsule
64337|NCT03681483|Drug|RO5126766|RO5126766 (CH5126766) is given 4mg twice weekly (Day 1 and Day 4 of each week) and should be taken by mouth on an empty stomach, either one hour before or two hours after a meal.
64338|NCT03681470|Drug|Aczone Gel|Aczone Gel 7.5%
64339|NCT03681457|Drug|LJN452|Dose A single dose
64340|NCT03681444|Other|Regular diet|Patients will be provided with any type of food preferred at any time in any quantity
64341|NCT03681444|Other|Clear fluid diet|"Patients will be provided with~Plain water~Fruit juices without pulp, such as grape juice, filtered apple juice, and cranberry juice~Soup broth (bouillon or consommé)~Clear sodas, such as ginger ale and Sprite~Gelatin (Jell-O)~Tea or coffee with no cream or milk added~Sports drinks that don't have color"
64342|NCT03681444|Other|Low residue diet|"The Low Residue Diet is the same as the soft diet with the added limitation of milk to one pint. It provides foods that are easily digestible. It is often used as a transition diet from liquids to the general diet. Indigestible fiber is reduced by using tender cooked vegetables and ripe, canned or cooked fruits from which the tough skins and seeds have been removed. Tender meat or meat made tender in the cooking process is used, thus reducing the amount of connective tissue.~Adequacy: By following the recommended guidelines, the diet will be adequate according to the Recommended Daily Allowance.~Note: For patients with dentures this diet can be modified by the substitution of ground meat for whole meat and excluding all raw vegetables. Personal tolerances determine food choices; avoid foods that cause GI (gastrointestinal) distress prior to the admission even though that food may be on the foods included list."
64343|NCT03681444|Diagnostic Test|Colonoscopy|Colonoscopy will be performed under conscious sedation with intravenous midazolam and pethidine titrated as required
64344|NCT03681431|Drug|Ceftriaxone 4g/ 24h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
64345|NCT03681431|Drug|Ceftriaxone 2g/ 12h|Each individual will be administrated 2 doses of 2 g of ceftriaxone separated for 12 hours. After a wash-out period (5-7 days) the same individuals will receive a single dose 4 g of ceftriaxone. In both cycles, plasma drug concentrations will be measure during 24 hours.
64351|NCT03681366|Device|DISC3.5 plus|The Defocus Incorporated Soft 3.5 Plus Contact Lens (DISC3.5 Plus) is a soft contact lens that comprises of simultaneous distance optical prescription and myopic defocus areas.
64352|NCT03681353|Behavioral|Mobile Contingency Management, active|Participants are provided monetary reinforcement for providing oral fluid test results that suggest they have reduced cannabis use.
64353|NCT03681340|Other|Hydroxyapatite toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
64354|NCT03681340|Other|Fluoridated toothpaste|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
64355|NCT03681327|Other|Sensory stimulation during sleep|Sensory stimulation during sleep
64356|NCT03681314|Other|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
64357|NCT03681301|Other|virtual reality simulator|Additional self-directed learning and practice using virtual reality simulator
64358|NCT03681288|Behavioral|Mindful Self-Compassion|Mindful Self-Compassion Intervention
64359|NCT03681275|Drug|Tofacitinib 5 mg|administered twice daily for two days
64360|NCT03681275|Drug|Placebo to match Tofacitinib|administered twice daily for two days
64361|NCT03681262|Device|High frequency spinal cord stimulation|We will use Senza® (Nevro Corp., Palo Alto, CA) trial and implant systems to deliver high frequency spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. High frequency waveform will be delivered with following parameters: frequency of 10,000 hertz, pulse width of 20 microseconds, and amplitude of 0-15 milliamperes.
64362|NCT03681262|Device|Burst spinal cord stimulation|We will use BusrtDRTM (Abbott Saint Jude Medical, St. Paul, MN) trial and implant systems to deliver burst spinal cord stimulation. A trial system includes two trial leads, an external pulse generator, and a remote control. The permanent implant system includes two leads, an internal pulse generator, a remote control, and a charging device for internal pulse generator. We will use our routine process of trial and implant. The parameters of the stimulation are as below: each burst includes 5 pulses of electrical stimulation at intra-burst frequency of 500 hertz without time for discharge in between pulses. These bursts will be repeated at inter-burst frequency of 40-60 hertz. The amplitude will range between 0 and 15 milliamperes.
64363|NCT03681249|Drug|ShenqiDihuang Decoction|ShenqiDihuang Decoction 150ml twice a day for 24 weeks 150ml twice a day for 24 weeks
64364|NCT03681249|Drug|ShenqiDihuang Decoction placebo|traditional Chinese medicine placebo mimic ShenqiDihuang Decoction 150ml twice a day for 24 weeks
64365|NCT03681236|Procedure|Alveolar recruitment maneuver|Applying plateau pressure 30cmH₂O for 30 seconds to achieve alveolar inflation
64366|NCT03681223|Device|Vertessa® Lite Y mesh|Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.
64367|NCT03681223|Device|Restorelle® Y mesh|Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.
64368|NCT03681223|Procedure|Laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation
64369|NCT03681223|Procedure|Robotic assisted laparoscopic sacrocolpopexy|The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation
64371|NCT03681197|Drug|Metformin|Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
64372|NCT03681197|Drug|Placebo|In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
64373|NCT03681197|Drug|Clomiphene Citrate|50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
64374|NCT03681184|Drug|Lumasiran|Multiple doses of lumasiran by subcutaneous (SC) injection
64375|NCT03681184|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match experimental
64376|NCT03681171|Other|Therapeutic Dance|Participants attended therapeutic ballet sessions three times per week for six weeks.
64377|NCT03681158|Drug|sodium valproate|Pharmaceutical form:Powder for oral solution reconstituted with water Route of administration: Oral
64378|NCT03681145|Behavioral|Counselor delivered telehealth intervention|This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.
64379|NCT03681132|Other|Stop of therapy|The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.
64380|NCT03681119|Behavioral|Dementia symptom management at home hospice edition|quality assurance performance improvement program
64381|NCT03681106|Device|Kinesio Tex|Kinesio Tex tape on the operated limb
64382|NCT03681093|Drug|fevipiprant Dose 1|QAW039 Dose 1 once daily (one tablet of blinded QAW039 Dose 1 to be given together with one tablet of blinded placebo to QAW039 Dose 2)
64383|NCT03681093|Drug|fevipiprant Dose 2|QAW039 Dose 2 once daily (one tablet of blinded QAW039 Dose 2 to be given together with one tablet of blinded placebo to QAW039 Dose 1)
64387|NCT03681067|Drug|Placebo- sodium chloride|Placebo injectable solution will be delivered via intravenous infusion as a single infusion
64388|NCT03681054|Other|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
64389|NCT03681054|Other|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 50 E%; fat 30 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
64390|NCT03681041|Other|Standard treatment|Treatment according to guidelines for pancreatic trauma according to the Chinese Trauma Association and the American Association for the Surgery of Trauma
64391|NCT03681028|Drug|Individualized therapy|"For a given proposed individualized combination of drugs the first priority to establish doses will be to identify the same combination of drugs in a peer-reviewed journal article or presented as a reviewed abstract.~When a proposed individualized combination of drugs has not previously been reported, the process to establish doses will be to then identify individual members of the proposed combination that have been used in combination with other cytotoxic agents similar to those being considered for combination therapy.~When a proposed individualized combination of drugs has no available combination data, dosing guidelines will start with the FDA-approved package insert recommended dose."
64392|NCT03681002|Behavioral|structured lifestyle program|Intensive Lifestyle counseling during one year
64393|NCT03680989|Device|Bright Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver ~10,000 lux at 22."
64394|NCT03680989|Device|Natural Light Exposure|"For 10 consecutive days, participants will use an Ultralux(R) V HD-LED light therapy light for 30 minutes beginning 30 minutes after waking. The light will be preset to deliver ~500 lux at 22."
64395|NCT03680976|Drug|CXA-10|Liquid-filled capsule containing 150 mg CXA-10 in super refined olive oil.
64396|NCT03680976|Drug|Placebo|Liquid-filled capsule containing olive oil manufactured to mimic CXA-10 150 mg capsule
64397|NCT03680963|Procedure|Non-invasive strategy|"No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure)."
64398|NCT03680963|Procedure|Control strategy|An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
64399|NCT03680950|Device|Upper Gastrointestinal Monitoring System|Participants will wear a monitoring system consisting of a tiny endoscopy and a mobile device. The endoscopy is inserted to upper gastrointestinal tract via nasal cavity and the mobile device is set to take and send images from the endoscopy to a server for analyzing if the abnormal condition occurs.
64400|NCT03680937|Other|Gavi , Merck® (automated vitrification instrument)|Gavi, Merck ® permits semi-automated vitrification with closed system.
64401|NCT03680937|Other|Vitrification|Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
64402|NCT03680911|Drug|N Acetyl Cysteine|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
64403|NCT03680911|Drug|Placebo oral capsule|2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
64404|NCT03680898|Device|Rectal swab collection|Patient will provide a rectal swab by following hospital-provided instructions.
64405|NCT03680885|Drug|Lidocaine gel|Lidocaine gel 5%, PEG with FD&C Blue No.1 (Brilliant Blue FCF)
64406|NCT03680885|Drug|Placebo|PEG with FD&C Blue No.1 (Brilliant Blue FCF)
64407|NCT03680885|Drug|Injected lidocaine|Standard FDA-approved dental injectable lidocaine
64408|NCT03680872|Device|Bidirectional Neural Bypass System|These participants will receive the investigational device called the Bidirectional Neural Bypass System. The study intends to use this device to restore volitional movement and sensation to the hand and wrist of an individual during its use in the laboratory.
64409|NCT03680846|Device|HF10 Therapy|Senza 10 kHz Spinal Cord Stimulation
64410|NCT03680846|Other|CMM|Conventional Medical Management
64411|NCT03680833|Procedure|Sentinel node detection in cervical cancer|The study intervention is the injection of tracer followed by detection and removal of sentinel lymph nodes
64412|NCT03680807|Diagnostic Test|Muscle function test|Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
64413|NCT03680794|Other|sampling of ophthalmic liquid|aqueous sampling for patients with cataract surgery or vitreous sampling for patients with posterior segment surgery
64414|NCT03680781|Device|Intermittent theta-burst stimulation (iTBS)|"Participants will receive iTBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
65082|NCT03675776|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration).
64415|NCT03680768|Other|Health Assessment|The protocol includes measurements of body composition, strength test, functional and fitness test as well as biochemical measurements from blood samples and AGEreader
64416|NCT03680755|Behavioral|Internet-based intervention for dental anxiety|Participants will complete the experimental dental anxiety management program, which will be facilitated by a person trained in psychological treatments or by dental staff. This program consists of a series of videos which provide information about dental anxiety, educate about the details of three dental procedures which are anxiety-provoking for the participant, and teach them how to cope better with the dental experience. This program will take about 60 minutes to complete.
64417|NCT03680742|Device|Contour Neurovascular System|The Contour Neurovascular System™ is an intrasaccular, self-expanding, embolization device intended for the treatment of unruptured intracranial aneurysms.
64418|NCT03680729|Behavioral|Adapted Brothers Saving Brothers (aBSB)|This information is listed in the arm description.
64419|NCT03680729|Behavioral|Standard Street Outreach|This information is listed in the arm description.
64420|NCT03680716|Drug|Ropivacaine injection|Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).
64421|NCT03680716|Drug|Ropivacaine injection|Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
64422|NCT03680703|Behavioral|Guided Self-Help Behavioral Weight Loss|Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
64423|NCT03680690|Procedure|hysteroscopy|office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
64424|NCT03680677|Procedure|Bone Marrow or Peripheral Blood Graft (BMT)|Patient receives bone marrow or peripheral blood graft (BMT) on or off protocol.
64425|NCT03680677|Other|Cancer-directed Therapy or Best Supportive Care|"Cancer-directed therapy with intensive regimens (7+3, Vyxeos, clofarabine, or similar), clinical trial, hypomethylating agent (azacitidine or decitabine), hypomethylating agent combinations (i.e. with venetoclax, sorafenib, enasidenib, ivosidenib, midostaurin, gilteritinib, or other targeted agent), targeted agents alone (i.e. enasidenib, ivosidenib, gilteritinib, midostaurin, etc.), or supportive care."
64426|NCT03680677|Diagnostic Test|Frailty Assessment|Frailty is the vulnerability of older adults to adverse health outcomes in response to illness and iatrogenic stressors.
64427|NCT03680664|Device|Active tDCS|Excitatory bilateral stimulation to the frontal lobes, in particular the left and right DLPFC, will be applied. The anode will be placed at Fz and the cathode at Iz to achieve this bilateral frontal excitatory stimulation. Rubber electrodes will be inserted in 35-cm2 saline-soaked sponges and fixed with a headband. The direct current will be of 2 mA (current density = 0.57 A/m2) for 30 min per day.
64428|NCT03680664|Other|sham tDCS|The same tDCS parameters as as the active condition will be used; however, the device will be turned off after 1 minute of active stimulation.
64429|NCT03680664|Behavioral|MBSR|After a brief orientation session, the MBSR sessions will be conducted in 8 weekly 2.5 hour classes plus a half-day retreat. Content includes instruction and guidance to mindfulness meditation practices, gentle mindful movement, and various exercises to enhance mindfulness in everyday life. Participants will get daily at-home assignments with CDs of meditative practice.
64430|NCT03680638|Other|Control (Lactated Ringer's)|This intervention is meant to serve as a control by which the experimental sites are compared to, to assess effectiveness.
64431|NCT03680638|Drug|Tempol|This intervention is meant to assess the impact of superoxide on vasodilator responses by scavenging available superoxide.
64432|NCT03680638|Drug|Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme NADPH oxidase.
64433|NCT03680638|Drug|Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasodilator responses by inhibiting the enzyme xanthine oxidase.
64434|NCT03680625|Device|Passive Distraction|Patients in this group will be offered an iPad® showing a video while they will undergo their pins' removal. There will be videos appropriate for each age group. The child can choose from the videos presented on the iPad® and start watching 5 minutes before the beginning of the procedure to assure similar preparation for both groups.
64435|NCT03680625|Device|Virtual Reality Distraction|Patients in this group will be offered virtual reality distraction through the use of Oculus Rift® while they undergo their pin removal. VR produces a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness symptoms such as nausea, vomiting, headache. The videogame was developed by our team with three levels of difficulty, and approved by pediatric healthcare professionals. The game, oculus goggles and computer will be available in the procedure room and ready for immediate use. Goggles will be adjusted to the head of the child before any procedure and a period of 5 minutes will be allotted prior to pin removal in order for the child to get acquainted with the game and immersed in the virtual environment.
64436|NCT03680612|Drug|Cefepime 1G - 2G / AAI101 0.5G - 0.75G|Experimental drug
64437|NCT03680612|Drug|cefepime 1 g or cefepime 2 g|cefepime monotherapy
64438|NCT03680599|Behavioral|Connection to Health for Smokers|Connection to Health for Smokers includes 5 core components supported by online tools: (1) comprehensive electronic patient survey, (2) automated summary report to flag areas of difficulty (3) interactive priority setting, (4) interactive action planning, and (5) electronic text reminders and followup.
64439|NCT03680599|Behavioral|Enhanced Standard of Care|Participants will complete a survey and receive standard one-on-one smoking cessation according to a usual care protocol delivered by health educators
64440|NCT03680586|Radiation|Radiation Therapy|Undergo ultra low-dose radiation
64441|NCT03680573|Drug|Control: Lacated Ringers|This site will serve as the control site
64442|NCT03680573|Drug|Apocynin|This site will be used to inhibit NADPH oxidase and subsequent production of superoxide.
64443|NCT03680573|Drug|Allopurinol|This site will be use to inhibit xanthine oxidase and subsequent production of superoxide.
64444|NCT03680573|Drug|BH4|This site will be use to locally supplement BH4.
64445|NCT03680573|Drug|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
64446|NCT03680573|Drug|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
64447|NCT03680573|Drug|Acetyl-ß-methylcholine chloride|Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
64448|NCT03680560|Biological|ACTR T Cell Product|Autologous Antibody-Coupled T Cell Receptor (ACTR) T Cell Product (ACTR707 or ACTR087)
64449|NCT03680560|Drug|Trastuzumab|monoclonal antibody targeting HER2
64451|NCT03680534|Procedure|Root canal preparation|Root canals from lower premolars with extraction indicated were prepared previous to being extracted with either the Reciproc Blue, the WaveOne Gold or the XP EndoShaper single-file techniques.
64452|NCT03680521|Drug|Sitravatinib|Sitravatinib oral capsule administered daily for 6-8 weeks.
64453|NCT03680521|Drug|Nivolumab|Nivolumab administered as 240 mg IV every 2 weeks for 4-6 weeks.
64454|NCT03680508|Drug|TSR-022 and TSR-042|immunotherapy
64455|NCT03680495|Drug|Methylprednisolone|1. Methylprednisolone is a steroid (corticosteroid) similar to a product produced in the adrenal glands. It is used to help relieve inflammation (swelling, heat, redness, and pain) and is used to treat certain medical issues including COPD.
64456|NCT03680482|Other|Intervention ingest a 48 mg of sucralose|Intervention: Subjects with type 2 diabetes who ingest a 48 mg of sucralose. Sucralose is a non-caloric sweetener derived from sucrose and is 600 times more sweet than sucrose. Your allowable daily intake is 15 mg / kg of body weight per day. 85% is not absorbed and is excreted unchanged in the stool; the rest that is absorbed is excreted unchanged by the urine
64457|NCT03680482|Other|Intervention ingest a 96 mg of stevia|"Intervention: Subjects with type 2 diabetes who ingest a 96 mg of stevia (steviol glycosides). The word stevia refers to the whole plant of Stevia rebaudiana Bertoni (SRB), only some of the components of the stevia leaf are sweet. Steviol glycosides are up to 300 times sweeter than sucrose, do not provide calories and can be used as a substitute for sucrose or as a non-nutritive sweetener alternative. Your allowable daily intake is 4 mg / kg / body weight (expressed as steviol)"
64458|NCT03680469|Behavioral|standard early rehabilitation|The standard early rehabilitation program is an intervention regularly utilized in the stroke center of National Taiwan University Hospital. Activities performed in the standard early rehabilitation program within 24-72 hours of onset include(1) bed exercises including the joint range of motion exercise, bridge exercise, the straight leg raising exercise, stretching exercises, and facilitation techniques, and (2) functional training in which the patients are instructed to engage in the repetitive and systematic practice of tasks, such as rolling or sitting supported on the bed.
64459|NCT03680469|Behavioral|adding early out-of-bed mobilization|Early mobilization treatment involving out-of-bed, task-specific activities including rolling and sitting up, sitting unsupported out of bed, and standing within 24-72 hours of onset and accounting for more than two thirds of the treatment time in early rehabilitation .
64460|NCT03680456|Drug|Ferric carboxymaltose|maximum of 750mg in U.S. is given, maximum of 1000mg in EU
64461|NCT03680456|Drug|Crystalloid|an equivalent volume dose of Natriumchlorid is administered
64462|NCT03680443|Other|assembly in THA revision|A single-center continuous series of 62 patients receiving such an assembly in THA revision was assessed retrospectively at a minimum 5 years' follow-up. Failure due to aseptic loosening or instability and implant survival at last follow-up were analyzed.
64463|NCT03680430|Radiation|Adaptive radiation therapy|Patients will be treated by preoperative or definitive radiotherapy for a limb STS, using an intensity-modulated conformal irradiation (with a static or dynamic technic), over 5 to 7 consecutive weeks. The total dose delivered will be of 50 Gray (preoperative RadioTherapy), or 60 to 70 Gray (exclusive RadioTherapy).
64464|NCT03680417|Biological|Measles-Rubella (MR) Vaccine|Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
64465|NCT03680404|Drug|Control (Phenylephrine)|This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.
64466|NCT03680404|Drug|Phenylephrine + Apocynin|This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.
64467|NCT03680404|Drug|Phenylephrine + Allopurinol|This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.
64468|NCT03680404|Drug|Phenylephrine + Tempol|This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.
64469|NCT03680391|Procedure|Cesarean section|"Both groups cesarean section will be held with the same technique:~spinal anethesia~pfennenstiel imcision~lower segment cesarean section~suturing uterus in two layers while exterionezed~gentle manibulation~no towels in gutters will be used"
64470|NCT03680378|Drug|Cefepime 2 gram|Combination of cefepime 2 gram with AAI101 1 gram
64471|NCT03680352|Drug|cefepime/AAI101|Fixed dose combination of cefepime and AAI101
64472|NCT03680339|Procedure|cesarean section|CS will be done by pfannenstiel incision , transverse lower uterine segment incision ,immediate cord clamping after delivery of baby , closure of uterus by 2 layers , closure of abdomen in layers
64473|NCT03680339|Drug|Misoprostol|The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
64474|NCT03680339|Drug|Oxytocin|10 IU of oxytocin with fetal delivery
64475|NCT03680326|Device|OCT|only OCT
64476|NCT03680313|Procedure|Hypertension outpatient treatment|Patients who have been diagnosed with primary hypertension and meet the conditions of the study will receive outpatient treatment
64903|NCT03677206|Device|Exposure to green LED light|Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.
64477|NCT03680300|Other|Post Facilitation Stretch|"The Post Facilitating Stretch technique is performed as follows:~The hamstring muscle will be placed between a fully stretched and a fully relaxed state. The patient will be asked to contract the agonist using a maximum degree of effort for 5-10 seconds while the therapist resists the patients force. The patient will then be asked to relax and release the effort, whereas the therapist will apply the rapid stretch to a new barrier and will be held for 10 seconds. Then the patient will relaxes for approximately 20 seconds and the procedure will be repeated between three to five times and five times more. Instead of starting from a new barrier, the muscle will be placed between a fully stretched and a fully relaxed state before every repetition."
64478|NCT03680300|Other|Post Isometric Relaxation|"The Post Isometric Relaxation technique is performed as follows :~The hamstring muscle will be taken to a length just short of pain, or to the point where resistance to movement is first noted. A submaximal (10-20%) contraction of the hypertonic muscle will be performed away from the barrier for between 5 and 10 seconds and the therapist applies resistance in the opposite direction. The patient should inhale during this effort. After the isometric contraction the patient will be asked to relax and exhale while doing so. Following this a gentle stretch will be applied to take up the slack till the new barrier. Starting from this new barrier, the procedure is repeated two or three times."
64479|NCT03680300|Other|Friction Massage|Each patient in group C will receive hot pack along with Tens for 20 mins then the patients will receive frictional massage alone for about one months on daily basis. Friction massage on hamstrings will be given for 20 mins by thrive massager by a therapist.
64480|NCT03680287|Drug|Within-Subject test of blinded study medication|On the day after each sleep condition (Uninterrupted Sleep and Sleep Disruption), participants will undergo multiple injections of study medication or placebo. This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (saline). This study uses a within-subject design, such that participants serve as participants' own control.
64481|NCT03680274|Drug|Vitamin C|Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-mL solution of either dextrose 5% in water (D5W) or normal saline (0.9% NaCl), during 30 to 60 minutes, every 6 hours for 96 hours (i.e. 200 mg/kg/day and 16 doses in total).
64482|NCT03680274|Other|Control|Dextrose 5% in water (D5W) or normal saline (0.9% NaCl) in a volume to match the vitamin C.
64483|NCT03680261|Radiation|chemoradiotherapy|CRT (1 cycle CT: Xelox or SOX, Q21d×1, Followed by RT: 45 Gray (Gy), 5d/week×5 with capecitabine or S1, Followed by 3 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
64484|NCT03680261|Drug|chemotherapy|CT (6 cycles CT: Xelox or SOX, Q21d×3) will be applied to radical resected advanced gastric cancer patients with lymph node metastasis and lymphovascular Invasion.
64485|NCT03680248|Dietary Supplement|Fat|Subjects will consume dairy cream (150 g of fat) at time 0 hours.
64486|NCT03680248|Dietary Supplement|Fasting|Subjects will fast throughout the experiment.
64487|NCT03680248|Dietary Supplement|Fat+Glucose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of glucose.
64488|NCT03680248|Dietary Supplement|Glucose|Subjects will drink herbal tea containing 50 g of glucose at times 0, 2 and 4 hours.
64489|NCT03680248|Dietary Supplement|Fat+Fructose|Subjects will consume dairy cream (150 g of fat) at time 0 hours. At the same time and 2 and 4 hours later they will drink herbal tea containing 50 g of fructose.
64490|NCT03680248|Dietary Supplement|Fructose|Subjects will drink herbal tea containing 50 g of fructose at times 0, 2 and 4 hours.
64491|NCT03680235|Other|Informational Intervention|Receive standard information about breastfeeding and pregnancy
64492|NCT03680235|Other|Informational Intervention|Receive information about breastfeeding and cancer
64493|NCT03680235|Other|Interview|Participate in focus groups
64494|NCT03680235|Other|Survey Administration|Ancillary studies
64495|NCT03680222|Procedure|Reversed Tracking Method|Reversed Tracking Method
64496|NCT03680209|Other|Simulation|pre-training observation training post training observation
64497|NCT03680196|Drug|medication Botulinum A injection.|In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
64498|NCT03680183|Drug|Entecavir 1Mg Oral Tablet|The anti-HBV treatment includes a anti-HBV antibiotics and a drug of protecting liver cells or decrease alanine aminotransferase (ALT) or aspartate transaminase (AST)
64499|NCT03680170|Behavioral|Working memory updating training|Each training session includes four working memory updating tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
64500|NCT03680170|Behavioral|Placebo training|Each training session includes four short term memory tasks that is performed at the participants home on their computer via internet. Each training session takes about 20 minutes to perform.
64501|NCT03680144|Procedure|Dynamic Susceptibility Contrast-MRI (DSC-MRI)|Undergo DSC-MRI
64502|NCT03680144|Procedure|Magnetic Resonance Imaging (MRI)|Undergo diagnostic MRI
64503|NCT03680131|Drug|EB01 Cream Placebo|Vehicle Cream containing 0% EB w/w applied BID
64504|NCT03680131|Drug|EB01 Cream 0.2%|EB01 Cream containing 0.2% EB01 w/w applied BID
64505|NCT03680131|Drug|EB01 Cream 1.0%|EB01 Cream containing 1.0% EB01 w/w applied BID
64506|NCT03680131|Drug|EB01 Cream 2.0%|EB01 Cream containing 2.0% EB01 w/w applied BID
64541|NCT03679871|Other|Questionnaire validation|"Participants will fill in the questionnaire Spiritual Resources and Distressplus additional questionnaires required for validation purposes. Three weeks later, a sub-sample will fill in the questionnaire one more time for consistency testing (test-retest)"
64542|NCT03679858|Other|Platelet function test|Ex vivo platelet aggregation analysis by Multiplate aggregometer
64543|NCT03679845|Drug|Sarilumab|Sarilumab is an IL-6 monoclonal antibody that has shown to be potentially important in the creation of sclerosis in SSc.
64904|NCT03677206|Device|Exposure to white LED light|Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
64507|NCT03680118|Device|autogenous rings with GBR and autogenous graft with ti-mesh|"Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures."
64508|NCT03680105|Drug|RJX|RJX is a formulation of known vitamins and a mineral in a diluent suited for parenteral administration.The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
64509|NCT03680105|Drug|Placebo|Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
64510|NCT03680092|Drug|Cyclophosphamide|Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).
64511|NCT03680092|Drug|abatacept|Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168
64512|NCT03680092|Drug|Methotrexate|standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11
64513|NCT03680092|Drug|Tacrolimus|Tacrolimus per institutional guidelines
64514|NCT03680079|Other|Group education sessions|Peer support and interaction both in-person during group education sessions and online via social media platforms
64515|NCT03680066|Other|Oral food challenge to foods with traces|"Subjects will undergo an open food challenge to 3 processed foods labeled with may contain traces. The following foods (similar for all patients) will be given in one dose in the size of a regular serving:~cookies, max 30 g;~chocolate, max 30 g;~breakfast cereals, max 50 g.~Each meal will be administered with a 1 hour observation period in between and at the end."
64516|NCT03680053|Drug|Duphaston|Women will receive oral duphaston 20mg daily from Day 3 till the day of ovulation trigger.
64517|NCT03680053|Drug|Cetrorelix|Women will receive antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
64518|NCT03680040|Diagnostic Test|Subjects previously implanted with a RESILIA aortic tissue valve.|Subjects to undergo multi-slice computed tomography and echocardiogram to assess predictors of valve durability in previously implanted Edwards aortic valves with RESILIA tissue.
64519|NCT03680027|Dietary Supplement|Walnut-enriched Group|All subjects supplemented with 40 g/day of walnuts for 6 weeks.
64520|NCT03680014|Diagnostic Test|CUSH|Machine learning assisted remote monitoring/ telehealth platform to predict and prevent falls
64521|NCT03680001|Behavioral|Training in Rating Emotional Connection|Didactic education (video-supported educational module) on emotional connectivity will be offered to the subjects. Subjects will conference with PI to review ratings on modules.
64522|NCT03679975|Drug|Riluzole Oral Soluble film (ROSF) 50 mg|Enrolled subjects will undergo an instrumental evaluation of swallowing safety before and after administration of a single dose of the ROSF formulation containing 50 mg of riluzole.
64523|NCT03679962|Behavioral|Triple Chronotherapy|"Day 0: One night of total sleep deprivation. The first 24 hours are spent with 1:1 nursing care for provision of comfort measures to stimulate wakefulness and to encourage completion of the intervention.~Day 1-4: Sleep phase advancement Day 1: Sleep from 6 PM to 1 AM Day 2: Sleep from 8 PM to 3 AM Day 3: Sleep from 10 PM and 5 AM Day 4: Awaken at 5 AM; discharge following light therapy~On days 1-4 patients will receive bright light therapy at 7am to 7:30am using a 10,000 Verilux light box. At discharge patients will be given a light box, strongly advised to continue the maintenance sleep schedule and bright light therapy at 7am daily for 30 minutes. Patients will be scheduled for follow-up appointments at 1-week, 1-month and 2-month following discharge."
64524|NCT03679962|Behavioral|Treatment as Usual|Normal inpatient care, including pharmacotherapy, psychotherapy, milieu therapy and social work interventions
64525|NCT03679949|Drug|Oxycodone|Oxycodone, 2.5 mg
64526|NCT03679949|Drug|Cannabis (THC:CBD = ~ 1:0)|Cannabis with high THC concentration and negligible CBD concentrations
64527|NCT03679949|Drug|Cannabis (THC:CBD = ~ 0:1)|Cannabis with high CBD concentration and negligible THC concentrations
64528|NCT03679949|Drug|Cannabis (THC:CBD = ~ 1:1)|Cannabis with equivalent CBD and THC concentrations
64529|NCT03679949|Drug|Placebo|Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone
64530|NCT03679936|Diagnostic Test|PET/CT dynamic scan|This study is designed to evaluate the patients who are first diagnosed with non-small cell lung cancer (NSCLC)，for 18 F-FDG PET/CT dynamic scanning and primary tumors and/or metastases in biopsy, than find the inner link of the tumor imaging findings, genomics and histopathologic characteristics, discuss diagnostic value of 18 F-FDG PET/CT dynamic imaging in metastatic non-small cell lung cancer (NSCLC).
64531|NCT03679923|Dietary Supplement|NEM® brand eggshell membrane|Dietary supplement for the support of joint health.
64532|NCT03679923|Dietary Supplement|Placebo|Placebo
64533|NCT03679910|Diagnostic Test|CEMIP , CA19-9 ,CEA|CEMIP: Cell migration inducing protein CA19-9: Carbohydrate antigen 19-9 CEA: Carcinoembryonic antigen
64534|NCT03679910|Diagnostic Test|A) CBC . B) RBG. C)KFT. D) LFT.|A)CBC: Complete blood count. B)RBG: Random blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
64535|NCT03679897|Drug|Ropivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution
64536|NCT03679897|Drug|Levobupivacaine solution|ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution
64537|NCT03679884|Drug|ACT-541468 10 mg|ACT-541468 10 mg tablets
64538|NCT03679884|Drug|ACT-541468 25 mg|ACT-541468 25 mg tablets
64539|NCT03679884|Drug|ACT-541468 50 mg|ACT-541468 50 mg tablets
64540|NCT03679884|Drug|Placebo|ACT-541468 matching placebo tablets
64544|NCT03679819|Device|HR-TRUS|Medical procedures to be performed in the study consist of subject preparation and prostate imaging. The HR-TRUS exam will be done with a transrectal probe either the day before surgery, or in the OR right before surgery. The exam will be done in the same manner as during a regular transrectal ultrasound exam and no invasive procedures will be associated.
64545|NCT03679806|Other|Halliwick|The exercise program was progressed by increasing the speed and the range of motion of the movements. Patients were asked not to accelerate the exercise and to focus on their alignment. Mental adjustment, sagittal rotation, transverse rotation, and combined rotation controls, balances in stillness steps of the Halliwick concept were included.
64546|NCT03679806|Other|Aquatic Plyometric Exercises|The APE programme was progressed by increasing speed and the range of motion of the movements. Patients were carefully informed not to deform the exercise just to emulate the speed. The three phases of each exercise; eccentric (or loading) phase, the amortization phase, and the concentric (or unloading) phase explained thoroughly at the beginning of every exercise.
64547|NCT03679793|Procedure|Open Release Group|Open surgical release of the A1 pulley is the gold standard of treating symptomatic trigger finger
64548|NCT03679793|Procedure|Percutaneous Release Group|Percutaneous release is a minimal invasive alternative surgical procedure
64549|NCT03679780|Drug|BQ-788|This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
64550|NCT03679780|Drug|BQ-123|This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min
64551|NCT03679780|Drug|L-Arginine|A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
64552|NCT03679780|Drug|NG Nitro L Arginine Methyl Ester|L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
64553|NCT03679780|Drug|Sodium Nitroprusside|SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
64554|NCT03679780|Drug|Lactated Ringer's|Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
64555|NCT03679767|Drug|INCMGA00012|INCMGA00012 administered intravenously at the recommended Phase 2 dose every 4 weeks.
64556|NCT03679754|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection~intratumoral injection of Ad-RTS-hIL-12"
64557|NCT03679754|Drug|veledimex|"20mg/day~15 oral daily doses of veledimex"
64558|NCT03679741|Device|CONTROL Lens|Acuvue OASYS
64559|NCT03679741|Device|TEST Lens|senofilcon A
64560|NCT03679728|Behavioral|First trimester|Analysis of sensorimotor outcomes
64561|NCT03679728|Behavioral|Second trimester|Analysis of sensorimotor outcomes
64562|NCT03679715|Other|participatory art-based activity|"The intervention is a participatory art-based activity which consists in making art in group, involving the participants directly in the creative process, allowing them to become co-authors of the work. Participants will meet once per week for a 2h workshop from 2.00 PM to 4.00 PM at the MMFA in a dedicated room during a three month-period defining a session. Two successive sessions will be setup; a winter and a spring sessions. Each session will be composed of 12 consecutive workshops."
64563|NCT03679702|Device|Viveve System|Radiofrequency device utilized in general surgical procedures for electrocoagulation and hemostasis.
64564|NCT03679689|Dietary Supplement|artificially sweetened beverages|artificially sweetened beverages restriction
64565|NCT03679676|Drug|Omalizumab|To compare immunological responses after 24 weeks of treatment with omalizumab, dupilumab, omalizumab dupilumab combination, or placebo.
64566|NCT03679676|Drug|Dupilumab|To compare immunological responses after 24 weeks of treatment with omalizumab, dupilumab, omalizumab dupilumab combination, or placebo.
64567|NCT03679676|Other|Placebo|To compare immunological responses after 24 weeks of treatment with omalizumab, dupilumab, omalizumab dupilumab combination, or placebo.
64568|NCT03679663|Device|Ultrasound|Use of ultrasound to identify pre-puncture site
64569|NCT03679650|Drug|decitabine|Decitabine is thought to act as an anti-metabolite. It seems to work by having a toxic effect on the abnormal bone marrow cells.
64570|NCT03679650|Biological|DC/AML fusion cells|An investigational agent that tries to help the immune system to recognize and fight against cancer cells
64571|NCT03679637|Behavioral|Tablet-based aphasia therapy|patients will independently practice with a speech app during hospitalisation
64572|NCT03679624|Drug|Ibrutinib|Ibrutinib, 420mg orally, once daily
64573|NCT03679624|Drug|Daratumumab|Daratumumab, 16 mg/kg intravenously, weekly for 8 weeks, bi weekly for 16 weeks, then monthly for up to 19 months.
64574|NCT03679611|Drug|Sugammadex Sodium|Sugammadex is a FDA approved newer NMBD reversal agent. But does not use in standard of care in most of institutions This study is designed to compare the impact of reversal of neuromuscular blockade with sugammadex vs. neostigmine on discharge time from the operating room in obese patients with OSA undergoing bariatric surgery
64575|NCT03679611|Drug|Neostigmine|neostigmine is a FDA approved NMBD reversal drug, uses as standard care drug in most of the institutions. neostigmine use as active comparator to compare with investigational drug Sugammadex in the study.
64576|NCT03679598|Drug|Alvelestat (MPH996)|Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
64577|NCT03679598|Other|Placebo|Placebo is a pill or tablet that does not contain any study drug.
64578|NCT03679585|Other|Internet-Based Intervention|Undergo Talking Pictures social media intervention
64579|NCT03679585|Other|Quality-of-Life Assessment|Ancillary studies
64580|NCT03679585|Other|Questionnaire Administration|Ancillary studies
64581|NCT03679572|Procedure|Robot assisted partial nephrectomy super-selective clamping|The device used to performe the surgery is a Da Vinci robot. After injection of infracyanine, the super-selective clamping is possible. The surgery is performed using a specific clamping of the tumor arteries. Super-selective ischemia is checked using near infrared fluorescence.
64692|NCT03678870|Other|Opioid Education Handout|a single page handout with information about how to use medications for pain after discharge.
64582|NCT03679572|Procedure|Robot assisted partial nephrectomy with renal artery clamping|Partial nephrectomy is performed with the conventional method in wich a renal artery clamping is done.
64583|NCT03679559|Other|Best Practice|Continue usual physical activity
64584|NCT03679559|Behavioral|Exercise Intervention|Complete home-based walking program and resistance training
64585|NCT03679559|Behavioral|Exercise Intervention|Complete home-based Zumba program and resistance training
64586|NCT03679559|Behavioral|Exercise Intervention|Complete HIIT program and resistance training
64587|NCT03679559|Other|Informational Intervention|Watch video
64588|NCT03679559|Other|Laboratory Biomarker Analysis|Correlative studies
64589|NCT03679559|Device|Monitoring Device|Wear Fitbit
64590|NCT03679559|Other|Quality-of-Life Assessment|Ancillary studies
64591|NCT03679559|Other|Questionnaire Administration|Ancillary studies
64592|NCT03679546|Drug|Infliximab|Infliximab : The treatment is infused at a dose of 5 mg/kg at week 0, 2 and 6 and then every 8 weeks.
64593|NCT03679546|Drug|Vedolizumab Injection|Vedolizumab : The treatment is infused at a dose of 300 mg at week 0, 2 and 6 and then every 8 weeks.
64594|NCT03679533|Dietary Supplement|Freeze-Dried Cranberry Powder|Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
64595|NCT03679533|Dietary Supplement|Placebo|Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
64596|NCT03679520|Other|New programme|"Time for topics related to the time after birth and in reversed chronological order to give an early and joint focus on parenthood for both parents. Involving new parents to share their experiences of early parenthood with expectant parents. Introducing and using evidence-based websites in the sessions A breastfeeding preparation that gives tools to meet common challenges in the initial phase of breastfeeding. Based on principles for adult learning.~Sessions~Introduction, life-change of becoming a parent and co-parenting~Early parenthood~Breastfeeding, caring for the baby and early parenthood~and 5 Labour, birth and postnatal care"
64597|NCT03679520|Other|Regular programme|"Antenatal parental preparation as usual. As no guidelines exist the number of sessions may vary between 2 and 3 sessions and smaller variations in content may also occur.~Sessions~(or 1 and 2) Labour, birth and postnatal care~or 3 Breastfeeding, caring for the baby and early parenthood"
64598|NCT03679507|Procedure|Low Intensity Ultrasound Therapy|Subjects suffering from chronic pain due to osteoarthritis of the knee will be recruited for this study, and randomly assigned to two groups. One-half of these Subjects (Group A) will receive ultrasound therapy as detailed below on the affected joint; the other half (Group B) is a placebo group.
64599|NCT03679507|Other|Enhancing CBD oil penetration into joints by sonophresis|High CBD oil will be applied to the affected knee of one-half of the recruited subjects.
64600|NCT03679494|Other|Shared deicision making support tool|Health education materials containing treatments and questions about patient values to help patients make the most appropriate decisions
64601|NCT03679481|Drug|Tranexamic acid (TXA)|Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
64602|NCT03679481|Drug|Normal saline|Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
64603|NCT03679468|Other|Cognitive Rehabilitation|"RehaCom software~Information processing speed and attention modules"
64604|NCT03679468|Other|Sham Exercise|Sets of balance and stretching exercises
64605|NCT03679468|Other|Sham Cognitive Rehabilitation|"Kompozer software~24 session module consisting of basic internet searches"
64606|NCT03679468|Other|Aerobic Exercise|"Recumbent NuStep Bike~Aerobic cycling"
64607|NCT03679455|Drug|Obinutuzumab 25 MG/ML|Study treatment, obinutuzumab is a Type II humanized anti-CD20 monoclonal antibody of the IgG1 subclass derived by humanization of the parental B-Ly1 mouse antibody and produced in the Chinese Hamster Ovary cell line by recombinant DNA technology. The Study Treatment, obinutuzumab is a liquid concentrate for infusion. Obinutuzumab vials are type 1 glass vials with a butyl rubber stopper. Obinutuzumab is provided as a single 1000 mg dose liquid concentrate with a strength of 25 mg/mL. It is supplied in 50 mL glass vials containing 40 mL of the 25 mg/mL liquid concentrate.
64608|NCT03679442|Drug|N-acetylcysteine|Non-randomized exposure to N-acetylcysteine (NAC) of healthy individuals corresponding to the clinical treatment guidelines for paracetamol-overdosed patients
64609|NCT03679429|Device|NBI Function|In the intervention arm polyps will be optically characterized using the NBI function. The WASP (Workgroup serrAted polypS and Polyposis) classification will be used in order to determine the optical diagnosis.
64610|NCT03679403|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
64611|NCT03679390|Drug|Ketamine|With the Ketamine group, we add ketamine 0.5mg/kg for anesthesia.
64612|NCT03679377|Device|Mandibular slotplate|Mandibular slotplates are placed during the osteosynthesis phase of the BSSO surgery. After testing of the plates they are removed and the osteotomy is fixated with three bicortical screws.
64613|NCT03679338|Device|Ablation Therapy|Ablation Therapy With Bipolar Radio frequency
64614|NCT03679325|Dietary Supplement|vitamine D|a dose once a week
64615|NCT03679325|Other|whole body vibration (WBV)|03 months of WBV training three times per week
64616|NCT03679312|Drug|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
64617|NCT03679312|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
64618|NCT03679299|Other|Observational - No intervention|See outcomes
64619|NCT03679286|Device|PCM and ROTEM|Test of blood sample by both PCM and ROTEM
64620|NCT03679273|Dietary Supplement|Abound|Study Group will take the supplementation drink containing 79 kcal, 7 g L-arginine, 7 g L-glutamine and 1.5 g calcium β-hydroxy-β-methylbutyrate (Abound; Abbott Nutrition, Columbus, OH, USA). The subjects will be instructed to drink the entire packet dissolved in 250 ml of water twice per day for 21 days.
64621|NCT03679260|Other|Carbohydrate restricted diet|20 grams total carbs/day
64622|NCT03679260|Other|Non-restricted diet|Subject follows normal diet
64623|NCT03679260|Other|Phone counseling with dietitian|Weekly calls with dietitian
64624|NCT03679247|Other|Intervention Phase One|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) iterative improvement to maximize informativeness of the CDS, and 3) the use of three behavioral nudges (pre-checked default orders, in-person conference with study team to obtain commitment to following the CDS recommendations and requiring an accountable justification if the PCP does not follow the recommendations). This intervention will be administered during the first phase of the study."
64625|NCT03679247|Other|Intervention Phase Two|"The intervention will be a clinical decision support (CDS) system that contains three main features: 1) methods to synthesize electronic health record (EHR) data in order to identify under-diagnosed chronic conditions (synthesize existing medical data to increase recognition of CKD and uncontrolled HTN in CKD patients and deliver management recommendations based on this evidence), 2) iterative improvement to maximize informativeness of the CDS, and 3) the use of three behavioral nudges (pre-checked default orders, in-person conference with study team to obtain commitment to following the CDS recommendations and requiring an accountable justification if the PCP does not follow the recommendations). This intervention will be administered during the second phase of the study."
64626|NCT03679234|Other|Routine infant formula|Routine infant formula with probiotic
64627|NCT03679221|Other|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
64628|NCT03679208|Device|Investigational device coded KIO014|Innovative chitosan-based biomaterial intended for intraarticular injection.
64629|NCT03679208|Device|Durolane(r) as control device|Crosslinked hyaluronic acid-based biomaterial intended for intraarticular injection.
64630|NCT03679195|Dietary Supplement|NO Ultra|6-week supplementation period with 764 mg/day of cranberry and grape seed extracts (containing polyphenols) and 2 g/day of L-citrulline Participants will have to take daily 2 NO Ultra capsules (containing 382 mg cranberry and grape seed extracts / 1 g L-citrulline) between breakfast and lunch and 2 other NO Ultra capsules between lunch and dinner.
64631|NCT03679195|Dietary Supplement|Placebo|"6-week supplementation period with placebo capsules (the active ingredients will be replaced by cellulose)~Participants will have to take 2 capsules of cellulose between breakfast and lunch and 2 capsules between lunch and dinner to match the number of capsules ingested daily by the NO Ultra group."
64632|NCT03679182|Drug|Olanzapine|Olanzapine 5 mg Tab at 0, 12, 24, and 36 hours
64633|NCT03679169|Procedure|pancreatosplenectomy|standard or radical anterograde modularpancreatosplenectomy
64634|NCT03679156|Device|OCT|Patients were recruited, visual acuity and optical coherence tomography Pictures were taken
64635|NCT03679143|Drug|ZSP1273 100 mg|ZSP1273 tablet administered orally once daily under fasted condition
64636|NCT03679143|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.
64637|NCT03679143|Drug|ZSP1273 200 mg|ZSP1273 tablets administered orally once daily under fasted condition
64638|NCT03679143|Drug|Placebo 200 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
64639|NCT03679143|Drug|ZSP1273 400 mg|ZSP1273 tablets administered orally once daily in the fasting state
64640|NCT03679143|Drug|Placebo 400 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
64641|NCT03679143|Drug|ZSP1273 600 mg|ZSP1273 tablets administered orally once daily under fasted condition
64642|NCT03679143|Drug|Placebo 600 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
64643|NCT03679143|Drug|ZSP1273 900 mg|ZSP1273 tablets administered orally once daily in the fasting state
64644|NCT03679143|Drug|Placebo 900 mg|Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition
64645|NCT03679143|Drug|ZSP1273 1200 mg|ZSP1273 tablets administered orally once daily in the fasting state
64646|NCT03679143|Drug|Placebo 1200 mg|Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state
64647|NCT03679143|Drug|ZSP1273|ZSP1273 tablets administered orally once daily under fasted or fed condition
64648|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition
64649|NCT03679143|Drug|ZSP1273 Low Dose|ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
64650|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.
64651|NCT03679143|Drug|ZSP1273 Median Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
64652|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
64653|NCT03679143|Drug|ZSP1273 High Dose|ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
64654|NCT03679143|Drug|Placebo|Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
64655|NCT03679130|Behavioral|Structured supervised exercise training|EXE contains three weekly one-hour exercise sessions at moderate intensity, more specifically one water exercise session and two land exercise sessions. The training will be supervised, held in teams, and both water and land exercise sessions will consist of a combination of aerobic and resistance training.
64656|NCT03679130|Behavioral|Motivational counseling supported by health technology|MOT contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
64657|NCT03679117|Behavioral|Mindfulness Training|Phone-delivered mindfulness training. 8 weeks of 30 minute phone sessions with an instructor, plus 15 minutes of self-guided practice.
64755|NCT03678389|Other|ESC|USE OF ENDOSPHENOIDAL COIL (ESC) TO OBTAIN MRI IMAGING OF THE PITUITARY GLAND
64658|NCT03679104|Procedure|Closure of mucosotomy using endoscopic clips|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done using endoscopic clips. These are used in endoscopy to mechanically close two mucosal surfaces without the need for surgery and suturing. In this study, the following endoclips may be used: Resolution 360™ Clip (Boston Scientific), QuickClip Pro™(Olympus) or Instinct™ Endoscopic Hemoclip (Cook Medical).
64659|NCT03679104|Procedure|Closure of mucosotomy using OverStitch™ suturing device|Gastric per-oral endoscopic pyloromyotomy procedure requires the incision in the mucosa and submucosa. The closure of this incision at the end of the procedure will be done by OverStitch™ (Apollo Endosurgery Inc., Austin, Texas, USA), which is a suturing device that enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope.
64660|NCT03679091|Drug|low-dose ticagrelor|low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
64661|NCT03679091|Drug|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
64662|NCT03679078|Dietary Supplement|IDDSI nutritional supplement drink|ready-to-use nutritional supplement drink to be taken daily for 28 days
64663|NCT03679065|Drug|Paracetamol|Each patient received 1g paracetamol tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
64664|NCT03679065|Drug|Dexamethasone|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
64665|NCT03679065|Drug|Placebo|Each patient received a placebo tablet identical to paracetamol tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
64666|NCT03679052|Drug|Mirtazapine|Each patient received 30 mg mirtazapine tablet and a placebo tablet for clonidine orally with sips of water 2 h preoperatively.
64667|NCT03679052|Drug|Clonidine|Each patient received 150 µg clonidine tablet and a placebo tablet for mirtazapine orally with sips of water 2 h preoperatively.
64668|NCT03679052|Drug|Placebo|Each patient received two placebo tablets for mirtazapine and clonidine orally with sips of water 2 h preoperatively.
64669|NCT03679026|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|Participants' baseline characteristics will be summarized using means and standard deviations or frequencies and percentages, as appropriate.
64670|NCT03679013|Drug|Oral Gabapentin and Intravenous Acetaminophen (IV APAP)|Scheduled multimodal pain regimen consisting of oral Gabapentin paired with intravenous Acetaminophen following cardiopulmonary bypass surgery.
64671|NCT03679013|Drug|Opiate based pain regimen.|Standard of care opite based pain regimen.
64672|NCT03678987|Diagnostic Test|P-MPA concentration|We will calculate AUC_0-12 of MPA based on 4 measurements of P-MPA
64673|NCT03678987|Drug|mycophenolic acid|Patient will ingest mycophenolic acid as prescribed by their physician under the surveillance of an investigator.
64674|NCT03678974|Behavioral|Exercise Prescription|The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
64675|NCT03678961|Behavioral|external rotation of leg|external rotation of leg by 45 degrees
64676|NCT03678961|Behavioral|hip flexion and knee flexion|hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
64677|NCT03678948|Device|Radiofrequency-Based Debridement|In this process, radiofrequency energy is used to excite the water molecules in a conductive medium, such as an electrolyte (saline) solution, to generate excited radicals within precisely focused plasma. The energized particles in the plasma have sufficient energy to break molecular bonds (16-18), excising or dissolving (i.e. ablating) soft tissue at relatively low temperatures (typically 40ºC to 70ºC).
64678|NCT03678948|Device|Mechanical Debridement|Arthroscopic chondroplasty used to remove loose and damaged cartilage which minimizes synovial irritation and mechanical impingement
64679|NCT03678935|Other|Low FODMAP diet|The intervention group follows the low FODMAP diet for 4 weeks.
64680|NCT03678909|Procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure|Norwood Palliation / DKS / Damus-Kaye-Stansel procedure
64681|NCT03678896|Behavioral|CrewD Program|The CrewD Program - Creative reading and writing in Diabetes Program - is a Diabetes self-management education and support program to help people with Diabetes coping with the disease.
64682|NCT03678896|Behavioral|Classical structured education|The Classical educational approach consists in an educational method based on the presentation of relevant theoretical information to help people with Diabetes coping with the disease.
64683|NCT03678883|Drug|9-ING-41|Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.
64684|NCT03678883|Drug|Gemcitabine - 21 day cycle|Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle
64685|NCT03678883|Drug|Doxorubicin.|Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.
64686|NCT03678883|Drug|Lomustine|Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.
64687|NCT03678883|Drug|Carboplatin.|Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.
64688|NCT03678883|Drug|Nab paclitaxel.|Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle
64689|NCT03678883|Drug|Paclitaxel.|Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.
64690|NCT03678883|Drug|Gemcitabine - 28 day cycle|Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle
64691|NCT03678883|Drug|Irinotecan|Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle
64693|NCT03678857|Dietary Supplement|Creatine|"Participants will resistance train their left arm and left leg one day and their right arm and right leg the next day. Participants will supplement with creatine BEFORE one of the training days (randomized to either left or right side) and on the opposite training day (opposite side of the body to the previous training day) supplement with creatine AFTER training. Having the same person in both conditions will control for genetics, habitual diet, other daily activities, and so on, that may have confounded previous research. Muscle mass and strength changes will be measured in each limb prior to and following 8 weeks of training to determine whether creatine timing influenced muscle growth.~Research Question: To determine whether creatine supplementation timing (i.e., before versus after training) effects 8 weeks of resistance training adaptations (i.e., muscle growth and strength changes)."
64694|NCT03678844|Behavioral|Taekwondo practice|The Taekwondo intervention program consisted of the technical skill development aspect (e.g., blocking, punching and kicking) of the sport and poomse (forms) for 30-min.
64695|NCT03678844|Other|CONTROL|The participants of the control group engaged in physical activities, including athletics, handball and gymnastic, during two sessions of physical education per week at school.
64696|NCT03678831|Procedure|tissue|Adipocyte isolation from distal femoral epiphysis and subcutaneous adipose tissue at the surgery site; classical piece removal during prosthetic replacement of the knee
64697|NCT03678818|Other|Medium Supplemented with Latrunculin A|A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
64698|NCT03678805|Procedure|Corticotomy|Perforations in the areas close to the impacted canines will be performed in order to accelerate tooth movement.
64699|NCT03678805|Procedure|Traditional withdrawal techniques|The impacted canines will be withdrawn using elastic modules.
64700|NCT03678792|Drug|Buprenorphine/naloxone|Participants in this group will be tapered on buprenorphine-naloxone regimen, 2mg/day
64701|NCT03678792|Drug|Morphine|Participants in this group will be tapered on an oral morphine regimen, 30-60mg/day
64702|NCT03678792|Drug|Tramadol|Participants in this group will be tapered on an oral morphine regimen, 50-100mg/day
64703|NCT03678779|Behavioral|Incentive|$5 grocery gift card
64704|NCT03678779|Behavioral|Education|Video-based brief nutrition education
64705|NCT03678779|Behavioral|Combined|Both Incentive and Education interventions received
64706|NCT03678766|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger, satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
64707|NCT03678766|Behavioral|Cognitive Behavior Therapy (CBT)|"Participants are taught to identify problems in eating, thinking, and mood patterns that served to trigger binge episodes through self-monitoring and to gradually develop alternative patterns aimed at facilitating healthy, binge-free eating patterns. Participants are taught to eat a healthy variety of foods and reducing the avoidance of forbidden foods that are typically consumed during a binge."
64708|NCT03678753|Drug|Cenobamate|12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets
64709|NCT03678753|Drug|Placebo|Matching Placebo
64710|NCT03678740|Other|Odyssey 2 Survey|Odyssey2 will retain the strengths (simplicity, brevity, confidentiality, and data quality assurance measures) which made Odyssey1 successful. While Odyssey2 adds some refinements based on experience learned from Odyssey1, the basic questions are changed as little as possible to maximize comparability, and the additions are limited. Odyssey1 consisted of between 16 and 23 questions, depending on skip patterns, and took an estimated 15 minutes to complete. Odyssey2 consists of between 23 and 33 questions, depending on skip patterns and we estimate that it will take approximately 20 minutes to complete.
64711|NCT03678714|Behavioral|Exercise Intervention|2 sessions of supervised exercise training each week for 8 consecutive weeks and 3 sessions of supervised exercise training each week for the final 4 consecutive weeks, at 57-74% heart-rate max. Each session will last approximately 60 minutes.
64712|NCT03678714|Behavioral|Lifestyle Physical Activity|Advice and information on how to increase physical activity will be provided. Participants will be asked to monitor and track their daily physical activity using a smart-phone fitness application. The research team will gain permission to access their recorded activity.
64713|NCT03678701|Dietary Supplement|Pre-meal 100% whey protein intake|Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
64714|NCT03678688|Drug|10 mg OPC-167832|Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
64715|NCT03678688|Drug|30 mg OPC-167832|Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
64716|NCT03678688|Drug|90 mg OPC-167832|Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
64717|NCT03678688|Drug|270 mg OPC-167832|Once daily oral dose of 270 mg OPC-167832 from Day 1 through Day 14.
64718|NCT03678688|Drug|RHEZ|"RHEZ will be used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants will receive a single-dose from Day 1 through Day 20. The total number of tablets per day will be based on the pretreatment body weight:~Participants weighing 30 to 37 kg will receive 2 tablets per day~Participants weighing 38 to 54 kg will receive 3 tablets per day~Participants weighing 55 to 70 kg will receive 4 tablets per day~Participants weighing > 70 kg will receive 5 tablets per day"
64719|NCT03678688|Drug|Low dose OPC-167832 plus 200 mg delamanid|Once daily oral dose of low dose OPC-167832 plus 200 mg delamanid from Day 1 through Day 14. The OPC-167832 dose will be determined after review of the data from Stage 1.
64720|NCT03678688|Drug|High dose OPC-167832 plus 200 mg delamanid|Once daily oral dose of high dose OPC-167832 plus 200 mg delamanid from Day 1 through Day 14. The OPC-167832 dose will be determined after review of the data from Stage 1.
64721|NCT03678688|Drug|200 mg delamanid alone|Once daily oral dose of 200 mg delamanid from Day 1 through Day 14.
64722|NCT03678675|Drug|Ketorolac|The intervention is a protocol of scheduled IV Ketorolac administered postoperatively.
64723|NCT03678662|Other|Hypoalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information."
64724|NCT03678662|Other|Hyperalgesia expectation|"Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information."
64725|NCT03678662|Other|Neutral|"Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles."
64726|NCT03678649|Drug|Capecitabine|1000-1250 mg/m2 orally twice daily for 14 days followed by a 1-week rest period, given as 3- week cycles for a total of 6 cycles .
64727|NCT03678636|Device|Silver antimicrobial dressing|Silver dressing suitable for exudate level
64728|NCT03678636|Device|Standard care|Usual care for wound type and condition
64729|NCT03678610|Other|Doing ICSI I a medium supplemented with Ionomycin and Latrunculin A|Ionomycin and Latrunculin A would activate oocyte during ICSI along with cytoskeleton stabilization for a favourable outcomes
64730|NCT03678597|Other|Medium Supplemented with Latrunculin B|A medium with in-house supplementation of Latrunculin B to decrease oocyte degeneration after ICSI and improve the survival rate
64731|NCT03678584|Other|Medium Supplemented with Chaetoglobosin A|A medium with in-house supplementation of Chaetoglobosin A to decrease oocyte degeneration after ICSI and improve the survival rate
64732|NCT03678571|Other|Latrunculin A supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Latrunculin A
64733|NCT03678558|Other|Cytochalasin B supplemented vitrification medium|Vitrification of human oocyte in medium supplemented with Cytochalasin B
64734|NCT03678545|Drug|Dupilumab (blinded)|Subcutaneous injection every two weeks as follows: 600 mg initial dose, and 300 mg subsequent doses for a total of 6 injections.
64735|NCT03678545|Drug|Placebo (blinded)|Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
64736|NCT03678545|Drug|Dupilumab (open-label)|After completing 6 doses of blinded study drug (dupilumab or placebo), participants can continue into the open-label portion of the study, in which all subjects will receive 12 doses (every 2 weeks for 24 weeks) of dupilumab.
64737|NCT03678532|Drug|Midazolam|
64738|NCT03678519|Diagnostic Test|Pulmonary function test|Pulmonary Function tests using Spirometry. It will show following indices of ventilatory functions: Forced vital capacity (FVC), Forced expiratory volume in the 1st second (FEV1) and Forced expiratory volume in the 1st second as a percentage of the Forced vital capacity (FEV1/FVC %).
64739|NCT03678506|Drug|Apixaban|Apixaban 2.5 mg x 2 will be administered to patients with positive D-dimer results
64740|NCT03678493|Biological|Fecal Microbiota Transplant (FMT)|Oral Capsule
64741|NCT03678493|Other|Placebo|Oral Capsule
64742|NCT03678480|Drug|HTD1801|HTD1801 capsules, 250mg
64743|NCT03678480|Drug|Ursodeoxycholic Acid|UDCA capsules, 125mg
64744|NCT03678467|Combination Product|EB-CMF|Autologous, anatomically shaped bone graft
64745|NCT03678441|Behavioral|BrainCheck Cognitive Assessment|Receive BrainCheck cognitive assessment
64746|NCT03678441|Procedure|Cognitive Assessment|Receive pen and paper cognitive assessment
64747|NCT03678428|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.
64748|NCT03678428|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
64749|NCT03678428|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
64750|NCT03678428|Drug|Leucovorin|Leucovorin 200mg/m2 IV on Day 1 and 15.
64751|NCT03678428|Drug|5-FU|5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.
64752|NCT03678428|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
64753|NCT03678415|Behavioral|Community-Based Primary Mental Health Care (CBPMHC) package|According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
64754|NCT03678402|Device|PUP™ sock|The Palarum Fall Prevention System that includes the PUP™ (Patient is Up) System, is made upon of seven tangible elements: an inpatient room Android tablet (IRT), a nurse station Android monitor (HUC), a local server (PLS), a cloud server (PCS), a Bluetooth Low Energy beacon(s), an Android smart watch, and an e-textile sock connected sensor transmitter (PUP™ sock). The PUP™ sock monitors and transmits pressure, force, acceleration and motion data.
65083|NCT03675763|Other|Manual treatment|Craniosacral therapy protocol.
64756|NCT03678376|Other|complaint, cognitive and functional assessments|"The evaluation with their GP is composed of (1-) Clinical impression, (2-) GP-Cog part 2 with patient or their informal caregiver and (3-) 6-CIT test.~The identification of patients at risk of NCD with the new strategy applied by the GP will be compared to the gold standard for diagnosis of NCD at the Memory Clinic, established according to Diagnosis and Statistical Manual of mental disorders (DSM-5) criteria and based on a clinical, neuropsychological evaluation and functional abilities. If needed, a secondary etiological diagnosis procedure will be undertaken following the HAS 2011 recommendation including brain MRI and biology."
64757|NCT03678363|Other|Tai chi chuan|Tai chi sessions will consist of repetition of simple and basic movements focusing mainly on breating, relaxation and body diagram. This Chinese martial art also includes coordination exercises of body parts (legs, arms, pelvis and spine), looseness and limbering up of joints and muscles.
64758|NCT03678350|Procedure|Light Dosimetry|Undergo IO-PDT
64759|NCT03678350|Procedure|Photodynamic Therapy|Undergo IO-PDT
64760|NCT03678350|Drug|Porfimer Sodium|Given IV
64761|NCT03678337|Other|observational cohort with plasma samples|plasma samples
64762|NCT03678324|Other|Functional MRI and fast bound-pool fraction imaging|"Use a form of MRI called fast bound-pool fraction imaging (FBFI), which is a technique better suited to capture and quantify these lesions, to study these lesions in patients with FD. In parallel, we would like to use functional MRI (fMRI) to study how these lesions alter brain function and connectivity in FD.~Neuropsychological assessements will include Wechsler Adult Intelligence Scale, WAIS-III (Digit Span, Symbol-Digit/Coding, and Symbol Search), the Connors Continous Performance text (CPT-II). The Health Questionnaire form, the Center for Epidemiologic Studies Depression Scale (CES-D), the RAND 36-Item Health Survey."
64763|NCT03678311|Device|Continuous Positive Airway Pressure (CPAP)|If diagnosed with Long QT Syndrome and have Sleep Apnea index >5 pauses per hour then given CPAP to wear for approximately 3 months.
64764|NCT03678298|Other|Epidemiological/treatment profiles|All consecutively hospitalized adult patients (older than 18 years of age) undergoing surgery, interventional drainage or conservative treatment, with diagnosis of cIAIs (defined as abdominal infections originating in an organ cavity, extending into the peritoneal space, and forming an abscess or peritonitis, will be included in the study.
64765|NCT03678285|Other|HIFRT Workout|A single high intensity functional resistance training (HIFRT) exercise bout.
64766|NCT03678272|Procedure|HERNIOPLASTY WITH PANAVALE MESH|Polypropylene mesh fixed with 3 points. Preformed polypropylene mesh will be used by fixing it with one point to the pubis, another to the inguinal ligament and another to the joint tendon.
64767|NCT03678272|Procedure|HERNIOPLASTY WITH PARIETEX PROGRIP MESH|"Preformed polypropylene mesh will be used which presents a self adhesive system not based on glue, but on the arrangement of the fibers of the mesh as hooks, and to which we will give a single point to the pubis."
64768|NCT03678272|Procedure|HERNIOPLASTY WITH ADHESIX MESH|It will use a self-adhesive mesh without giving points to fix this one, since it is a mesh that integrates the glue.
64769|NCT03678272|Procedure|HERNIOPLASTY WITH TIMESH MESH|Titaniumized polypropylene mesh will be used without fixing points, since liquid cyanoacrylate (Ifabond) will be used to fix it.
64770|NCT03678259|Drug|124I-p5+14 Injection|124I-p5+14 Injection which is a formulation of a synthetic, all natural, 45 amino acid peptide (MW = 4766.4) with a net +12 positive charge
64771|NCT03678246|Procedure|Ramped position|LSFOI glottis view
64772|NCT03678246|Procedure|Supine position|LSFOI glottis view
64773|NCT03678233|Drug|AndroGel 16.2 mg/L|Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
64774|NCT03678220|Device|LapAR|LapAR system will be used for guidance during laparoscopic hepatectomy and laparoscopic liver thermal ablation
64775|NCT03678207|Other|Anesthesiologist phone call|Patients receiving ambulatory surgery with no prior diagnosis of hypertension but have elevated blood pressure prior to surgery. Patients will receive a phone call from a participating anesthesiologist 1-3 days after surgery notifying them of their high blood pressure and obtaining oral consent to participate in the study. Patients will receive reminders via mail about following up with their PCP.
64776|NCT03678194|Device|Smartphone Support System|6 weeks smartphone application with daily evaluations
64777|NCT03678181|Behavioral|Information Resources|The investigators will provide a HIV-related content as the attention-control condition.
64778|NCT03678181|Behavioral|Social Support|The investigators will provide evidence-based answers to users' health questions, including linkage to care.
64779|NCT03678181|Behavioral|HIV Testing|The investigators will provide opportunities for participants to get tested through HIV home test kits.
64780|NCT03678168|Other|Throat Pack|Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
64781|NCT03678168|Other|Pharyngeal Tampons|Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
64782|NCT03678155|Other|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
64783|NCT03678142|Diagnostic Test|analysis of last resort antibiotic drug (Flucloxacillin, Imipenem, Vancomycin or Cefepim) in sweat and blood|blood draw (4.7 ml EDTA) and sweat sample taken (Macroduct Sweat Collecting System)
64784|NCT03678129|Drug|AZD7325_10|Single oral dose (10mg)
64785|NCT03678129|Drug|AZD7325_20|Single oral dose (20mg)
64786|NCT03678129|Drug|Placebo|Single oral dose placebo (capsule)
64787|NCT03678116|Drug|Sugar Pill (placebo)|Taken orally in capsule form
64788|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine and Cayenne)|Taken orally in capsule form
64789|NCT03678116|Dietary Supplement|Caffeine (plus Teacrine)|Taken orally in capsule form
64790|NCT03678090|Drug|tPA standard dosage|Tissue plasminogen activator 25mg dosage
64791|NCT03678090|Drug|tPA low dosage|Tissue plasminogen activator 2.5mg
64792|NCT03678077|Other|Mild traumatic brain injury|This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
64793|NCT03678064|Device|Lokomat|16 sessions total. Provided by study PT twice weekly for a period of 8 weeks
64795|NCT03678051|Behavioral|TAU+CBT4CBT|45-minute web-based modules covering core concepts to substance use treatment. The information is presented via graphics and voiceovers and key concepts are illustrated with brief videos depicting the material. Participants will be scheduled for a minimum of two sessions/week over the 3.5 weeks post-randomization (7 modules). These seven sessions will provide protected time to access the interventions, but the women will be able to access the modules and complete homework as much as they wish.
64796|NCT03678038|Drug|triamcinolone, shincort|via rotator interval.
64797|NCT03678038|Drug|triamcinolone, shincort|via rotator interval posterior recess
64798|NCT03678025|Drug|Abiraterone|Given PO
64799|NCT03678025|Drug|Bicalutamide|Given PO
64800|NCT03678025|Drug|Degarelix|Given via injection
64801|NCT03678025|Drug|Docetaxel|intravenous
64802|NCT03678025|Drug|Flutamide|Given PO
64803|NCT03678025|Drug|Goserelin Acetate|Given SC
64804|NCT03678025|Drug|Histrelin Acetate|Receive SC
64805|NCT03678025|Drug|Leuprolide Acetate|Receive SC or IM
64806|NCT03678025|Drug|Nilutamide|Given PO
64807|NCT03678025|Procedure|Orchiectomy|Undergo bilateral orchiectomy
64808|NCT03678025|Drug|Prednisone|Given PO
64809|NCT03678025|Other|Quality-of-Life Assessment|Ancillary studies
64810|NCT03678025|Radiation|Radiation Therapy|Standard radiation
64811|NCT03678025|Procedure|Radical Prostatectomy|Standard surgery
64812|NCT03678025|Drug|Triptorelin|injection
64813|NCT03678012|Drug|Ferumoxytol/Hydrogen peroxide|1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
64814|NCT03678012|Drug|Hydrogen Peroxide|Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
64815|NCT03678012|Drug|Water|Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
64816|NCT03677999|Diagnostic Test|MEGA-PRESS sequence Magnetic Resonance Spectroscopy|MRS protocols and novel MRI methods that allow detection and quantification of 2 hydroxyglutarates (2HG) as well as the physiologic consequences of 2HG accumulation.
64817|NCT03677986|Behavioral|Video DOT+|Participants will receive financial incentives for recording and submitting videos of themselves taking their daily buprenorphine dose.
64818|NCT03677973|Drug|AB680|AB680 is a Cluster of Differentiation (CD)73 Inhibitor
64819|NCT03677973|Other|Placebo|Matching Placebo
64820|NCT03677960|Drug|Topical ABI-1968 cream|Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29
64821|NCT03677947|Behavioral|Exposure and response prevention|ERP is a treatment developed to help people confront their fears based on the rationale that exposure to feared objects, activities, or situations in a safe environment helps reduce fear and decrease avoidance. During the treatment, participants will engage in these exposures to feared stimuli within and between sessions according to hierarchies developed during the initial evaluation sessions, and refrain from engaging in compulsive behaviour until their anxiety subsides (i.e. ritual prevention). Exercises will consist of both exposure in vivo (i.e. exposure in real life situations) and/or imaginal exposure according to recommendations.
64822|NCT03677947|Other|Inference-based cognitive therapy|The treatment primarily targets the dysfunctional reasoning that gives rise to obsessional doubts and overvalued ideas. IBCT does not include exposure in vivo, but instead, aims to bring resolution to the initial obsessional doubt or overvalued idea by showing the participant that the obsession is the result of incorrect reasoning.
64825|NCT03677921|Dietary Supplement|Investigational Product (Bio-Germanium)|"Ingredient: Bio-Germanium~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day (1.2g/day of Bio-Germanium)~Storage: Room temperature (below 25℃)~Duration of use: 8 weeks"
64826|NCT03677921|Dietary Supplement|Control Group - Placebo Product|"Ingredient: Corn starch~Type: HPMC capsule~Weight: 300mg/capsule~Directions: 2 capsules, twice a day~Storage: Room temperature (below 25℃)~Duration of use: 8 weeks"
64827|NCT03677908|Other|ElectroEncephaloGraphy|Density ElectroEncephaloGraphy analysis
64828|NCT03677895|Drug|Hyaluronic Acid|Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
64829|NCT03677882|Behavioral|Mind Body Bridging Group Session|Participants assigned to TAU + MBB will will receive treatment from the Suicide Prevention Team and the Mental Health Service, AND will be asked to participate in four, 90-minute Mind Body Bridging group sessions that will occur for four weeks in a row. Each group will involve up to 15 participants and will be led by a trained MBB facilitator. Participants will receive a workbook at the beginning of the training that contains an explanation of all the major concepts involved in Mind Body Bridging. The workbook has homework assignments to be completed daily between group sessions.
64830|NCT03677869|Device|Intraocular gas (C3F8)|Intraocular gas (C3F8) injection
64831|NCT03677856|Procedure|Paravertebral blockade|Type of anaesthesia
64832|NCT03677856|Procedure|Thoracic epidural block|Type of anaesthesia
64833|NCT03677830|Drug|Acetaminophen|Scheduled intravenous acetaminophen for post-operative pain to minimize opiate exposure.
64834|NCT03677830|Drug|Saline|Intravenous saline will be administered at appropriate volume and schedule for control group as a placebo.
64835|NCT03677817|Drug|Lidocaine|regimen of lidocaine administration of 1,5 mg/kg, IV bolus, followed by continuous infusion at 3,0 mg/kg/h
64836|NCT03677817|Drug|NaCl 0,9%|IV bolus of NaCl 0,9%, followed by continuous infusion of NaCl 0,9%
64837|NCT03677791|Other|Virtual tour in coronary computed tomography - 360° counselling environment|Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients
64838|NCT03677791|Other|Current practice|counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
65035|NCT03676140|Drug|Azithromycin on Day 8|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 8
64839|NCT03677778|Procedure|Normal saline injected via interscalene nerve catheter|With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (three boluses of 10cc 0.9% NS, 10 minutes apart) via their interscalene nerve block catheter.
64840|NCT03677778|Other|Placebo|With the catheter covered, placebo group patients will go through the same steps as the treatment group (patient will be visited three times, 10 minutes apart), but no solution will be injected into the interscalene nerve block catheter.
64841|NCT03677765|Procedure|Supra- vs Infraclavicular approach using ultrasonography|In the supraclavicular group, subclavian venous catheterization using ultrasonography is performed beneath the clavicle. Meanwhile, in the infraclavicular group, subclavian venous catheterization using ultrasonography is performed over the clavicle.
64842|NCT03677752|Other|GP_Posit|Mother-infant dyads allocated to this arm will receive the GP_Posit intervention. The intervention consists of a guided participation intervention to positioning. Mothers will meet with the intervention nurse twice a week for the two first weeks after birth and then one a week until the infant will reach 35 weeks of gestational age. During these encounters, mothers will learn how to interpret their infant's stress and stability cues and participate in his/her care and positioning while being guided by the intervention nurse.
64843|NCT03677739|Other|Informational Intervention|Receive information focusing on skin cancer
64844|NCT03677739|Other|Informational Intervention|Receive information on healthy lifestyle
64845|NCT03677739|Other|Survey Administration|Ancillary studies
64846|NCT03677726|Behavioral|Mindfulness Based Therapy for Insomnia|The mindfulness-based intervention consists of eight 2-hour sessions covering various mindfulness techniques (e.g. mindfulness of breath, body and movement, senses and informal practice, and empathy and compassion) that pertain to people with sleep problems and insomnia. Participants will be provided handouts for the information covered during these talks and discussions.
64847|NCT03677726|Other|Sleep Hygiene Education Exercise Program|The Sleep Hygiene Education and Exercise Program has known relationships with good sleep quality. It will comprise 8 weekly 2-hour sessions. Each session will introduce a concept related to sleep and sleep hygiene. The facilitator will provide the theory and rationale behind the concept, and encourage participants to share and discuss their experiences related to the concept. The session will end with the participants evaluating how to implement the specific concept in their daily lives, and its potential implications for their sleep. Participants will be provided with a manual that outlines the concept and how they intend to apply it to their daily lives.
64848|NCT03677713|Procedure|No nasal packing.|No nasal packing at the end of the surgery
64849|NCT03677713|Procedure|Nasal Packing|Patients will have nasal packing at the end of the surgery
64850|NCT03677700|Other|Laser Flare Meter|Measurement of the inflammation of the operated eye and the fellow eye before the surgery and at each post-surgery visit: D7, M1, M2, M3, M6, M12
64851|NCT03677687|Behavioral|Mindfulness for Physical Activity|The Mindfulness for Physical Activity (MfPA) programme aims to change participants' relationship with physical activity by targeting psychological factors related to physical activity uptake and maintenance.
64852|NCT03677674|Other|Dehydration|Participants will be dehydrated (2% of their body weight) using sauna.
64853|NCT03677661|Other|Conventional approach|The intervention will consist of light cognitive and physical activity with no symptoms exacerbation followed by graded exertion. Participant will be evaluated by a neuropsychologist. The neuropsychological intervention will consist of advice relative to cognitive rest in line with the clinical evaluation results followed by an individualized step-by-step graded exposition to cognitive stimulus according to symptoms evolution. A kinesiologist will also evaluate the symptoms response to cardio-vascular exertion. According to the result of this clinical evaluation, a graded physical exercise program will be given to the participants. 8 in-clinic cardio-vascular exercise sessions in a 6-week period supervised by the kinesiologist (30 to 45 minutes each session) will be provided.
64854|NCT03677661|Other|Personalized rehabilitation program|The same advice and exercise program than the active comparator group will be provided. However, 2 physiotherapists will provide 8 treatment session ( 30 to 45 minutes). One physiotherapist will initially evaluate the physical dysfunctions associated to mTBI with a standardized evaluation to build the treatment plan. He will provide cervical manual therapy and therapeutic exercises based on the best current clinical approach and according to the impairment specifically found initially. A vestibular physiotherapist will provide treatment of canalith repositioning manoeuvre, vestibular adaptation, ocular motor exercises, balance and/or habituation exercises. This treatment will be adapted to the individual patient. No more than 8 sessions will be delivered.
64855|NCT03677648|Drug|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
64856|NCT03677648|Drug|Placebos|Placebos
64857|NCT03677635|Behavioral|Guided Autobiographical Memory Recall|Participants are asked to recall positive autobiographical memories with the assistance of prompts to promote specificity, generalisability and links to the future. The participants will also view a 5min psychoeducation video on the subject of memory specificity and motivation.
64858|NCT03677622|Drug|Voluven to near maximal stroke volume of the heart|Stroke volume guided fluid treatment with Voluven on the basis of restricted fluid therapy
64859|NCT03677609|Behavioral|Mindset & Communication Training|The mindset training is a two-hour, live training, with a one-hour follow-up one month later, that teaches care providers to recognize, shape, and leverage patient mindsets in healthcare.
64860|NCT03677596|Drug|inotuzumab ozogamicin-dose level 2|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose is 1.8mg/m2/cycle. This treatment arm evaluates a lower starting dose of 1.2mg/m2/cycle.
64861|NCT03677596|Drug|Inotuzumab ozogamicin-dose level 1|Inotuzumab ozogamicin (BESPONSA™) is a CD22 targeted antibody drug conjugate (ADC) approved by US FDA for treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL). The approved starting dose of 1.8mg/m2/cycle is administered in this treatment arm.
64862|NCT03677583|Other|Duckweed|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
64863|NCT03677583|Other|Spinach|various meal products such as meal soup, quiche, mashed potato, curry and pasta sauce
65081|NCT03675776|Drug|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration).
64864|NCT03677570|Diagnostic Test|postural stability|Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
64865|NCT03677557|Drug|16,5% Cutaquig|Participants with primary or secondary immunodefiiciney disease and who do not tolerate other immunoglobulin treatments will be asked to use 16.5% Cutaquig
64866|NCT03677544|Other|laparoscopic approach with an extended pelvic lymph|Surgery was performed through either open or laparoscopic approach with an extended pelvic lymph node dissection up to the common iliac bifurcation
64867|NCT03677531|Other|Questionnaire Administration|Ancillary studies
64868|NCT03677531|Radiation|Radiation Therapy|Undergo RT
64869|NCT03677531|Other|Video|Watch video of choice during RT
64870|NCT03677505|Device|KoMAC videolaryngoscope|Double lumen endotracheal intubation was performed with the KoMAC videolaryngoscope
64871|NCT03677505|Device|Macintosh Laryngoscope|Double lumen endotracheal intubation was performed with the Macintosh Laryngoscope
64872|NCT03677492|Other|Medium Supplemented with Cytochalasin D|A medium with in-house supplementation of Cytochalasin D to decrease oocyte degeneration after ICSI and improve the survival rate
64873|NCT03677479|Procedure|socket preservation procedure|socket preservation of post extraction site using bone xenografts
64874|NCT03677466|Drug|Pharmaco-invasive strategy|"Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography."
64875|NCT03677466|Procedure|Primary PCI|After primary PCI patients will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images and Global Longitudinal Strain measured with echocardiography.
64876|NCT03677453|Other|Interactive Perioperative Teaching Platform|An active video format will be used to provide instructions for navigating the hospital; describe induction of anesthesia and the surgical procedure; and provide post-surgery and post-discharge instructions for pain management.
64877|NCT03677440|Behavioral|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
64878|NCT03677440|Behavioral|Stretching-and-Toning Exercise Training|12-weeks of supervised, progressive stretching-and-toning exercise training
64879|NCT03677427|Radiation|Radiation|Radiation in breast cancer
64882|NCT03677375|Device|INVSENSOR00026|Noninvasive pulse oximeter sensor
64883|NCT03677362|Behavioral|Weight loss intervention|In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages. Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages. Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo. intervention. Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
64884|NCT03677349|Procedure|neurorrhaphy|"During the surgery, the flap is removed from its donor site, placed on the recipient site (instead of carcinological excision) and its survival is ensured by arterial and venous anastomosis (to the artery and facial vein or to the external carotid artery and thyro-linguofacial veinous trunk).~We then propose a reconstruction complement: nerve anastomosis (neurorrhaphy) to the lingual nerve for the antebrachioradial and anterolateral thigh flaps, and to the lower alveolar nerve for the fibular bone flaps. This supplement is performed during microsurgical time by a suture for the patient in group 1."
64885|NCT03677336|Drug|Dydrogesterone Oral Tablet|Tablet, oral, 10 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
64886|NCT03677336|Drug|Micronized progesterone|Capsule, vaginal, 200 mg, 3 times daily, starting on the day of oocyte retrieval in the morning and during 8 days
64887|NCT03677336|Drug|Placebo Dydrogesterone oral tablet|Tablet, indistinguishable from dydrogesterone oral tablet
64888|NCT03677336|Drug|Placebo Micronized progesterone|Capsule, indistinguishable from micronized vaginal progesterone capsules
64889|NCT03677323|Device|Virtual reality|"The patient will have the choice between different environments and the use of this device will remain under the control of the medical team.~The patient will wear the virtual reality device at the time of the completion of the ankle block and will remove it once the nerve puncture is complete."
64890|NCT03677323|Drug|Droleptan|Venous administration of 1.25 mg of Droleptan
64891|NCT03677323|Drug|Propofol|Venous administration of 20 mg of Propofol
64892|NCT03677323|Drug|Sufentanyl|Venous administration of 5 μg of Sufentanyl.
64893|NCT03677310|Drug|3% Sodium Chloride|3% sodium chloride will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
64894|NCT03677310|Drug|Normal Saline|Normal Saline will be given intravenously at a rate of 10 cc/hour over a period of 24 hours beginning immediately prior to incision.
64895|NCT03677297|Drug|Rosuvastatin|Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel
64896|NCT03677284|Other|Time assistive products|The decision on the specific time assistive product to be prescribed will be decided based on current knowledge and the personal goal of the PwD.
64897|NCT03677284|Other|Information brochure|The information brochure will provide information frequent problems about daily time management and suggest strategies to manage them.
64898|NCT03677271|Behavioral|Physical Activity|
64899|NCT03677258|Device|Collagen for injections 7%|Injection of medical device
64900|NCT03677258|Device|Hyaluronic acid for injections 2%|Injection of medical device
64901|NCT03677245|Other|Strider Balance Bike|Learning to ride a Strider balance bike
64902|NCT03677219|Other|Educational Video|The educational video is a 2 minute video depicting a live lumbar puncture on an infant interwoven with animations of the relevant anatomy.
112485|NCT03307031|Other|Control Group|Did not exercise, during 10 weeks.
64905|NCT03677193|Behavioral|Playing ICP game|Participants will play the ICP game from their home this is expected to be 30 min * 5 days / week for 4 weeks. Once per week, participants will play the ICP game with a researcher.
64906|NCT03677167|Other|walking on a treadmill|Patients will go on the treadmill (barefoot or with shoes) twice a week for a month, up to a medium-high level effort, and will receive ultrasound treatment for the painful heel spot
64909|NCT03677141|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
64910|NCT03677141|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV.
64911|NCT03677141|Drug|Rituxumab|Participants will receive rituxumab via IV.
64912|NCT03677141|Drug|Cyclophosphamide|Participants will receive cyclophosphamide via IV.
64913|NCT03677141|Drug|Doxorubicin|Participants will receive doxorubicin via IV.
64914|NCT03677141|Drug|Vincristine|Participants will receive vincristine via IV.
64915|NCT03677141|Drug|Prednisone|Participants will receive oral prednisone.
64916|NCT03677141|Drug|Tocilizumab|Participants will receive tocilizumab via IV.
64917|NCT03677128|Other|mNavigator|Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma or retinoblastoma.
64918|NCT03677115|Drug|Dexmedetomidine|combination of ropivacaine and dexmedetomidine 20 ug every time
64919|NCT03677102|Other|higher chloride crystalloid|Normal saline (chloride concentration 154 mmol/L)
64920|NCT03677102|Other|lower chloride crystalloid|Ringer's Lactate (chloride concentration 110 mmol/L)
64921|NCT03677089|Behavioral|12 ECHO Autism telehealth clinics|Twice-monthly 2-hour ECHO Autism Clinics will be provided during a 6-month period. Each Clinic will include a didactic presentation, 2 to 3 Primary Care Provider-generated case presentations, expert feedback, and group discussion. Although the ECHO Clinic will include discussion of specific cases, no identifiable personal health information will be shared, individual patients will not be identified, and no direct patient care will be provided.
64922|NCT03677076|Other|Ancillary/Correlative|Collection of research blood and urine
64923|NCT03677063|Other|No dressing|Then, care is the same and exit-site remains covered with an occlusive dressing to promote tunnel epithelialization and healing. The shower is forbidden during this period.
64924|NCT03677050|Other|Smart phone patient education application|Smart phone patient education application including a personalized colonoscopy preparation scheme and information about the procedure.
64925|NCT03677037|Other|Short-term MBT|Short-term mentalization-based therapy
64926|NCT03677037|Other|Long-term MBT|Long-term mentalization-based therapy
64927|NCT03677024|Procedure|SLN arm|Intra-operative SN mapping with indocyanin green: Intracervical injection will be performed by the surgeon. Sub-mucous injections will be performed with 50% diluted dye at 3 and 9 o'clock positions. 1ml injection contained infracyanine green will be injected deeply into the stroma of the cervix (1cm-depth), and another 1ml will be injected superficially (2mm-depth). The time between the injection and the search for SLN must be as soon as possible.
64928|NCT03677011|Diagnostic Test|Andrositol® Test|The intervention consists in the addiction of myo-inositol directly to the semen identifying the quality of sperm prior ICSI procedure
64929|NCT03676998|Device|Measurement of diaphragm function|A bilateral magnetic stimulation induces a non voluntary diaphragm contraction and a drop in airway pressure that is measured.
64930|NCT03676985|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
64931|NCT03676985|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
64932|NCT03676985|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
64933|NCT03676972|Device|LithoVue Ureteroscope System|The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
64934|NCT03676959|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
64935|NCT03676959|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
64936|NCT03676959|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
64937|NCT03676946|Drug|ZKAB001 5mg/kg|5mg/kg/times bi-week IV administration of ZKAB001
64938|NCT03676946|Drug|ZKAB001 10mg/kg|10mg/kg/times bi-week IV administration of ZKAB001
64939|NCT03676946|Drug|ZKAB001 15mg/kg|15mg/kg/times bi-week IV administration of ZKAB001
64940|NCT03676933|Drug|DS107E|
64941|NCT03676933|Drug|Vehicle|
64942|NCT03676933|Drug|Hydrocortisone Butyrate 0.1% Cream|Steroid taken topically once a day
64943|NCT03676920|Behavioral|Discussions of Cost App (DISCO App)|The DISCO App is an app-based and patient-focused intervention designed to improve the frequency and quality of patient-oncologist treatment cost discussions. The DISCO App allows patients to provide basic demographic information (e.g., employment status, insurance status, etc), and uses that information to provide patients with an individually-tailored list of treatment cost questions they can ask their provider.
64944|NCT03676907|Procedure|double layer suturation technique|in our clinic uterine incision is sutured by single layer suturation technique routinely. in this arm, we will use double layer suturation technique which is also accepted as valid suturation technique in obstetrics and gynecology textbooks
64945|NCT03676894|Device|Sham Fotona SP Dynamis|Female patients with SUI will be treated with non-ablative Er:YAG laser with Fotona SP Dynamis with sham handpiece.
64946|NCT03676894|Device|Intravaginal Fotona SP Dynamis|Female patients with SUI will be treated intravaginaly with non-ablative Er:YAG laser with Fotona SP Dynamis
64947|NCT03676894|Device|Intraurethral Fotona SP Dynamis|Female patients with SUI will be treated intraurethraly with non-ablative Er:YAG laser with Fotona SP Dynamis
64962|NCT03676764|Drug|Azithromycin|biannual azithromycin in eligible communities to children 1 to 59 months old Targeted azithromycin to children aged 5 to 8 weeks old at the vaccine visit
64963|NCT03676764|Drug|Placebos|biannual placebo in eligible communities to children 1 to 59 months old Targeted placebo to children aged 5 to 8 weeks old at the vaccine visit
64948|NCT03676881|Device|Computerized cognitive battery: Cognigram (CG)|is a validated, computerized battery of cognitive tasks based on card games, developed by Cogstate Ltd. This technology includes four tasks, with a total duration of 10-15 minutes. The subject is asked to answer each task by pressing either 'D' or 'K' keyboard buttons. The technology supports the measurement of attention/vigilance, processing speed, concentration, visual working memory and visual recognition memory. The software will run on a computer supplied by the Bruyère Research Institute, in a private test room. The RA will be present during the testing session, reading out loud the batteries standardized instructions and doing the practice trials with the participants. After the practice trials, the RA will not give any feedback or support.
64949|NCT03676881|Device|The NeuroCatch™ Platform (NCP)|the NCP includes 6 stimulus sequences specifically designed to elicit desired brain responses. Each sequence contains both the oddball task and semantic word-pair task, and lasts 6 minutes. In our protocol, two sequences will be used. For the setup, EEG electrodes are placed on the participant's scalp, and the EEG signal quality is ensured by gently abrading the skin beneath each of the electrodes. A conductive gel is then placed between the skin and the electrode. Most electrodes are contained in an elastic cap, which is worn by the participants, but some electrodes are attached to the skin with adhesive. This part of the session takes around 10 minutes. EEG scan will commence once the setup is completed. Two auditory scans of 6 minutes each, separated by a one-minute break, will be administered. The total time of EEG testing for participants, including setup, will be of ≈25 minutes.
64950|NCT03676855|Procedure|bladder dissection|Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
64951|NCT03676842|Combination Product|FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB|Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
64952|NCT03676829|Device|Arterial Embolization of the Shoulder|Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
64953|NCT03676816|Device|Xpert® NG/CT|This is a prospective, non-inferiority trial comparing two methods of collection using a US Food and Drug Administration- cleared 90-minute rapid nucleic acid amplification assay, the Xpert CT/NG assay. Any adult female patient admitted to the Emergency Department at Community Regional Medical Center felt by the provider to require gonorrhea/chlamydia endocervical testing may be entered in the study.
64954|NCT03676816|Device|provider-performed endocervical sampling|provider-performed endocervical sampling is the gold standard for both gonorrhea and chlamydia. The provider takes a endocervical sample which will get sent to the laboratory as the standard care in comparison to the device being studied.
64955|NCT03676803|Other|mixed spices|All spices in the spice mixture capsules contains 1g or 20% cinnamon, 1.5g or 30% oregano, 1.5g or 30% ginger, 0.85g or 17% black pepper, 0.15g or or 3% cayenne pepper for a total of 5.0g spice mixture. They are identical to herbs and spices sold in grocery stores for human consumption.
64956|NCT03676803|Other|placebo capsule containing 5 g of maltodextrin|placebo capsule containing 5 g of maltodextrin
64957|NCT03676790|Other|Group I|"Group I In the first month, continuous ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the ultrasound treatment, the following parameters were used: frequency of 1 MHz, intensity of 1.5 W/cm2 (temporal and spatial mean SATA), duty cycle of 100%, with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
64958|NCT03676790|Other|Group II|"Group II In the first month, pulsed ultrasound was applied three times a week. In the second month, patients performed only exercise sessions three times a week. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
64959|NCT03676790|Other|Group III|"Group III In the first month, the continuous ultrasound was applied 3 times a week. In the second month, 3 times a week, the continuous ultrasound was applied associated with exercises. The parameters were used: frequency of 1 MHz, intensity of 1.5 w / cm2 (temporal and spatial mean SATA), continuous mode (100%), with application time of 5 minutes on the medial side and 5 minutes on lateral side of knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
64960|NCT03676790|Other|Group IV|"Group IV In the first month, the pulsed ultrasound was applied three times a week. In the second month, three times a week, the pulsed ultrasound associated with exercises was applied. In the treatment with the US, the following parameters were used: 1 MHz frequency, 2.5 w / cm2 intensity (temporal and spatial mean SATA), pulsed mode (25%), 5 minutes on the medial side and 5 Minutes on the lateral side of the knee.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
64961|NCT03676790|Other|Group V|"Group V Patients received only exercise sessions three times a week for two months.~Exercises~The intervention was divided into three phases: P-1, P-2 and P-3 during eight weeks with three sessions a week. Each session lasted 45 minutes:~10 minutes warming-up (treadmill, ergometer bike or rowing machine);~30 minutes 2-3 sets with P-1, P-2 or P-3;~5 minutes stretching (hamstrings, quadriceps, adductors, and gastrocmenius)."
64964|NCT03676751|Drug|Azithromycin|Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
64965|NCT03676751|Drug|Placebo|Oral suspension of placebo for azithromycin
64966|NCT03676725|Drug|Lidocaine gel|Lidocaine gel 5%, PEG with FD&C Blue No.1 (Brilliant Blue FCF)
64967|NCT03676712|Device|scoliosis brace|Wear at least 18 hours a day
64968|NCT03676699|Diagnostic Test|Ultrasound chest|Ultrasound detection of extravascular lung water
64969|NCT03676686|Device|Nåva Foot Cream|Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
64970|NCT03676673|Other|Psychiatric diagnosis|Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
64971|NCT03676647|Other|Diagnostic DNA Methylation Signature|Undergo collection of tissue samples
64972|NCT03676634|Biological|rBV A/B|Recombinant Botulinum Vaccine A/B, rBV A/B
64973|NCT03676621|Drug|Misoprostol|buccal tablets
64974|NCT03676621|Drug|Oxytocin|intravenous drip
64975|NCT03676608|Biological|Bee Wax Mammary Areolae|The product to be valued are mammary areolae made by hand with organic beeswax. Despite its honey aroma, it does not contain honey. The wax used for the manufacture of the areolae is operculum. This wax is used and not another because it avoids possible residues and allergies that may contain other types of waxes. The operculum wax is used as a thickener in pharmacy and cosmetic products as a fat base in ointments and creams.
64976|NCT03676608|Other|Usual educational care|The WHO protocol for maternal lactation.
64977|NCT03676595|Other|interactive video game-based exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
64978|NCT03676595|Other|no exercise|Twenty-four patients were randomly assigned to two groups (12 participants per group). Group A received interactive video game-based exercise training for the first 6 weeks, with no exercise in the subsequent 6 weeks. Group B had no exercise for the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks.
64979|NCT03676582|Diagnostic Test|Acoustic analysis plus pulse oximetry|Acoustic analysis plus pulse oximetry
64980|NCT03676569|Biological|ADRC transplantation in autoimmune refractory epilepsy|
64981|NCT03676556|Drug|Lidocaine|Two sterile gauzes will be dampen with the content of the syringe (20ml lidocaine 0.5%) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
64982|NCT03676556|Drug|Saline Solution|Two sterile gauzes will be dampen with the content of the syringe (20ml saline serum) and apply on the wound. After 7-15minutes of waiting to the effect, the wound treatment will start.
64983|NCT03676543|Procedure|Timed repetitive sensory stimulation|Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
64984|NCT03676530|Device|Pro-Tec Shin Splint Compression Wrap|EVA Foam pad compression device with Velcro straps that is placed over tibial site of pain.
64985|NCT03676517|Radiation|preoperative short-course radiotherapy|1-week short-course radiation (5 Gy x 5) plus 6-week XELOX (capecitabine 1,000mg/m2 and oxaliplatin 130mg/m2 every 3 weeks) chemotherapy before total mesorectal excision (TME)
64986|NCT03676504|Biological|CD19.CAR T Cells|Dose Level 1: 1×10^6 transduced cells/m^2; Dose Level 2: 5×10^6 transduced cells/m^2; Dose level 3: 20×10^6 transduced cells/m^2
64987|NCT03676504|Drug|Fludarabine|3 days of fludarabine 30 mg/m^2/day
64988|NCT03676504|Drug|Cyclophosphamide|3 days of cyclophosphamide 500 mg/m^2/day
64989|NCT03676491|Other|Music Intervention|Music intervention
64990|NCT03676478|Other|delayed start enteral support @ POD5|instead of caloric suppletion, participants will receive 500mls of water over the jejunostomy feeding tube daily.
64991|NCT03676465|Other|CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. The participants will receive a weekly CloudConnect Report that is based on analysis of the data gathered from the downloads provided by the subject during that week. Participants will both receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
64992|NCT03676465|Other|Will not receive a CloudConnect Report|Subjects and their parents will be asked to download the data from the study devices as well as download their insulin pump/pen. Participants will receive weekly contact from the study team to discuss the communication that the subject & their parent had during the week about the participant's diabetes management.
64993|NCT03676452|Behavioral|Active@Home exergame training|The Active@Home exergame is a multicomponent, motor-cognitive training for fall prevention in elderly adults. It mainly consists of three components; strength training, balance training and cognitive training. For strength training, Tai Chi-based movements are included. For balance training, dancing is included in the Active@Home exergame. Moreover, the Active@Home exergame explicitly targets specific attentional and executive functions. The Active@Home system set up is easy and consists of an HDMI dongle (to run the application) which must be plugged into the TV and four wearable sensors (to measure the movements).
64994|NCT03676439|Device|Magnetic Spinal Stimulation|"Spinal Magnetic Stimulation (TMS) on Lateral Cord Stimulation (LCS), in the search of the improvement of the tone, motor function and speech, in patients with spastic cerebral Palsy.~Due to its non-invasiveness and possible efficacy, the use of Magnetic Spinal Stimulation is proposed to try to prove its therapeutic usefulness.~This is the phase 2/3 clinical test of the method, in the future, and as its use could be extended, if the results were positive, its indications could be extended to other pathological conditions, giving a greater spectrum of spastic patients, potentially benefited."
64995|NCT03676426|Other|Web platform for advance care planning/advance directive|Ourcarewishes (OCW) is a web-based platform to document advance care planning based at Penn. OCW contains more detailed content on preferences and values than a standard advance directive and allows electronic sharing with loved ones and transmission to the Penn EHR.
64996|NCT03676426|Other|Standard advance directive|Patients receive a paper copy of an advance directive used by social workers at Penn Medicine and are encouraged to complete on their own.
64997|NCT03676413|Drug|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals|new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study
64998|NCT03676413|Drug|ADVAIR DISKUS® 100/50 mcg inhalation powder pre-dispensed/GSK|twice daily inhalation throughout the study
64999|NCT03676413|Drug|Placebo|twice daily inhalation throughout the study
65000|NCT03676400|Other|conditioned media of umbilical cord blood-derived stem cells|Hair serum with 5% conditioned media of human umbilical cord blood-derived mesenchymal stem cells
65001|NCT03676400|Other|Placebo|Hair serum without conditioned media of human umbilical cord blood-derived mesenchymal stem cells
65002|NCT03676387|Other|ultrasound guided|"Ultrasonography technique:~The subglottic diameter was estimated with B-mode ultrasonography (Korean, Siemens, Acuson, x300) with a 10-13-MHz linear probe positioned on the midline of the anterior neck (figure1). The evaluation began by identifying the true vocal folds as paired hyperechoic linear structures that moved with respiration and swallowing before patients were paralyzed. The probe was then moved caudally to visualize the cricoid arch which appears as an arched, rounded and hypoechoic structure (figure2). The transverse air-column diameter was measured at the lower edge of the cricoid cartilage after patients were paralyzed (figure3).~The measurements of the subglottic diameter was used to select the outer diameter of endotracheal tube by the equation [ETT OD=0.55*(subglottic diameter)+1.16] (Shibasaki et al., 2010), since the outer diameter of endotracheal tube differs among different manufactures, we used uncuffed Mallinckrodt tracheal tube with a Murphy's eyes."
65003|NCT03676374|Drug|Prucalopride|Prucalopride 2mg taken once a day as add-on to PPI (2x/d)
65004|NCT03676374|Drug|Placebo Oral Tablet|Placebo tablet taken once a day as add-on to PPI (2x/d)
65005|NCT03676361|Drug|Desmopressin|Subjects will complete a water deprivation test using desmopressin to aid in the determination of maximum tubular concentration capacity before and six months after uni-nephrectomy.
65006|NCT03676335|Drug|CsA eye gel|The CsA eye gel of 0.3 g: 0.15 mg, 0.3 g: 0.3 mg
65007|NCT03676335|Drug|CsA for eye emulsion|The CsA for eye emulsion of 0.4 ml: 0.2 mg
65008|NCT03676335|Drug|Hypromellose Eye Drops|Hypromellose Eye Drops of 15ml：75mg, 3 times daily, 1-2 drop
65009|NCT03676322|Drug|M5049|Participants will receive single ascending oral dose of M5049 in Part A. Participants will receive multiple ascending oral dose of M5049 once daily for 14 days or twice daily for 13 days followed by a single dose on Day 14 in the morning in Part B. Participants will receive a single oral dose of M5049 under fed conditions in Part C.
65010|NCT03676322|Drug|Placebo|Participants will receive placebo matched to M5049.
65011|NCT03676309|Drug|Nutriceutical Oral Capsule,|nutraceutical 920 mg (Bergamot 450 mg, Gymnema (400 mg, Phaseolamine 30 mg, Olea Europaea 10 mg) twice day , 12 weeks
65012|NCT03676309|Drug|Placebo Oral Tablet|placebo tablet twice a day twenty minutes before main meals, for 12 weeks,
65013|NCT03676296|Drug|Puerarin|Puerarin (90.2 mg daily) in granules (as well as excipients) taken orally for 12 weeks
65014|NCT03676296|Drug|Placebo|Placebo in granules (with the same excipients as the puerarin supplement but without puerarin) taken orally for 12 weeks
65015|NCT03676283|Other|Web-based psycho-educational support for family caregivers|A website including potentially modifiable topics shown to be associated with preparedness. The topics cover areas such as knowledge about medical issues including symptoms and symptom relief, communication within the couple, how to spend the time before death, being partner or caregiver, planning of the moment of death and considerations of the partner's future, including psychological issues, logistical issues, economy, and the care for children.
65016|NCT03676270|Other|Phase I|Chemotherapy, ITK, Hormotherapy, Immunotherapy
65017|NCT03676257|Other|Endocrine therapies|No intervention
65018|NCT03676244|Device|immediate implant in defected anterior maxillary esthetic zone|"Patients indicated for immediate implant placement with presence of partial or complete loss (type 2 sockets) of labial bone plate.~Use of GBR (mix of autogenous bone graft and xenograft in combination to absorbable collagen membrane) and healing abutment at the same time of extraction then place implant palatally engaging the side walls of the socket, leaving a buccal gap.~construct custom two-piece screw retained healing abutment then remove custom healing abutment and fit and place the collagen membrane for GBR , the membrane should cover the defect 2 mm circumferentially and extend to the level of free gingival margin, Place bone graft material buccal to the implant surface ,replace custom healing abutment."
65019|NCT03676231|Drug|SGM-1019|Active
65020|NCT03676231|Drug|Placebo|Inactive
65021|NCT03676218|Other|Elderly cancer patients|No intervention: consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
65022|NCT03676205|Biological|PRP|Platelet-Rich Plasma
65023|NCT03676205|Other|Traumeel|Homeophatic Treatment
65024|NCT03676192|Drug|CT-16|15mg/kg IV of CT-P16 every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
65025|NCT03676192|Drug|Avastin|15mg/kg IV of Avastin every 3 weeks up to 6 cycles in the induction study period and every 3 weeks until PD occurs in the maintenance study period.
65026|NCT03676179|Procedure|patella denervation|patella denervation
65027|NCT03676179|Procedure|patella non-denervation|patella non-denervation
65028|NCT03676166|Drug|Cannabis|Inhaled cannabis
65029|NCT03676153|Other|Nurse-provided guidance|Nurse-provided guidance following an integrative medicine treatment program, for patient implementation of self-administered manual therapies, relaxation, lifestyle changes and traditional medicine.
65030|NCT03676153|Other|Integrative medicine treatment program|Integrative medicine treatment program
65031|NCT03676140|Drug|Albendazole on Day 1|Albendazole 400 mg oral tablet Single Dose Treatment on D1
65032|NCT03676140|Drug|Ivermectin on Day 1|Ivermectin 200 µg/kg oral tablet Single Dose Treatment on Day 1
65033|NCT03676140|Drug|Diethylcarbamazine on day 1|Diethylcarbamazine 6 mg/kg oral tablet Single Dose Treatment on Day 1
65034|NCT03676140|Drug|Azithromycin on Day 1|Azithromycin 30mg/Kg oral tablet Single Dose Treatment On Day 1
65036|NCT03676127|Other|ultrasonographic dermal thickness measurements|ultrasonographic dermal thickness measurements
65037|NCT03676114|Drug|ketamine|0.5mg/kg intravenous ketamine injection before incision followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
65038|NCT03676114|Drug|Normal saline|Same volume of normal saline will be administrated
65039|NCT03676101|Biological|9-valent HPV Recombinant Vaccine|Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.
65040|NCT03676101|Biological|Placebo|Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.
65041|NCT03676088|Procedure|root coverage|recession coverage is treated with modified coronally advanced tunnel with connective tissue graft with recombinant human platelet derived growth factor- BB for Experimental: Test group and without recombinant human platelet derived growth factor- BB for Active Comparator: Control group
65042|NCT03676062|Other|exercise|All exercises programs applied three sessions per week, totally six week.
65043|NCT03676049|Drug|Cannabidiol|CBD will be administered as an adjunct to all current antiepileptic drugs. A dosing titration period will start with 100 mg/day, with 50mg BID dosing, and will be titrated monthly as tolerated based on clinical response, up to 300mg/day. This is based on a targeted dosing of 2.5 ---5---7.5 mg/kg/d.
65044|NCT03676036|Drug|DS107E|
65045|NCT03676036|Drug|Vehicle|
65046|NCT03676023|Drug|Tranexamic Acid|Inhalation of Transexamic acid in age adjusted dosing
65047|NCT03676010|Other|Sarcoma and GIST|No Intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
65048|NCT03676010|Other|Breast cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
65049|NCT03676010|Other|Pancreatic cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
65050|NCT03676010|Other|Renal cell carcinoma|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
65051|NCT03676010|Other|Colon cancer|No intervention : Consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy (adjuvant setting).
65052|NCT03675997|Other|HAD (Hospital Anxiety and Depression) scale|HAD (Hospital Anxiety and Depression) scale will be completed and reported by patients the first day of conditioning and then weekly from day 0 corresponding to the autograft, until their last day in the hematological department.
65053|NCT03675984|Behavioral|asymmetrical stabilization exercise|Exercise is combined to form an appropriate combination of motion (Side-lying, Bird-dog, Prone arm lift, Prone leg lift) according to the curve pattern and muscle weakness of each patient's.
65054|NCT03675971|Drug|Cannabinol|Postoperative pain treatment
65055|NCT03675971|Drug|Placebo oral capsule|Placebo comparator
65056|NCT03675958|Other|Johnstone's Pressure Splint|the intervention consists in the application of two tools used for the treatment of spasticity post - CVD. Johnstone's Pressure Splint added Stretching
65057|NCT03675958|Other|Stretching|the intervention consists in the application of one tool used for the treatment of spasticity post - CVD. Just Stretching
65058|NCT03675932|Other|Rapid Cadence Cycling on a Solo-Rider Spin Bicycle|Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
65059|NCT03675919|Device|Scale|self-monitoring of body weight; with automatic data transfer into the personalized and secured online portal
65060|NCT03675919|Device|Step counter|self-monitoring of physical activity; with automatic data transfer into the personalized and secured online portal
65061|NCT03675919|Device|Blood glucose meter with test stripes|self-monitoring of blood glucose; with automatic data transfer into the personalized and secured online portal
65062|NCT03675919|Other|Access to the online portal|self-monitoring of health parameters
65063|NCT03675919|Other|Telemedical coaching|regular telephone calls providing information about T2DM, healthy lifestyle, low-carbohydrate diet and physical activity
65064|NCT03675906|Other|hypoalbuminemia|hypoalbuminemia and acute kidney injury
65065|NCT03675893|Drug|Letrozole|Letrozole is a hormonal therapy that works by lowering the production of estrogen in the body.
65066|NCT03675893|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor.
65067|NCT03675880|Drug|TAB014|TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)
65068|NCT03675867|Other|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise|Correlation between resting respiratory parameters and cardio-respiratory parameters at exercise
65069|NCT03675854|Drug|Cefazolin|3 weeks
65070|NCT03675841|Drug|Pazufloxacin Mesilate ear drops|Pazufloxacin Mesilate ear drops of 0.1%，0.3%，0.5%
65071|NCT03675828|Behavioral|Virtual Visit|The Cleveland Clinic Express Care Online application will be used in this intervention. The subjects will have a virtual consult with a clinician from the study team that will mirror an experience had at an outpatient post-discharge visit, including review of systems and medications.
65072|NCT03675815|Drug|Darunavir 800 MG Oral Tablet|800 milligrams (mg) orally once daily for 96 weeks
65073|NCT03675815|Drug|Ritonavir 100 MG Oral Tablet|100 mg orally once daily for 96 weeks
65074|NCT03675815|Drug|N(t)RTIs|Choice of N(t)RTIs determined by clinician guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection
65075|NCT03675815|Drug|Dolutegravir 50 MG Oral Tablet|50 mg orally once daily for 96 weeks
65076|NCT03675815|Drug|TDF 300 MG Oral Tablet|300 mg orally once daily for 96 weeks
65077|NCT03675815|Drug|3TC 300 MG Oral Tablet|300 mg orally once daily for 96 weeks. Choice of 3TC or FTC will be determined by clinician
65078|NCT03675815|Drug|FTC 200 MG Oral Cap|200 mg orally once daily for 96 weeks. Choice of emtricitabine or lamivudine will be determined by clinician
65079|NCT03675802|Drug|misoprostol|giving misoprostol to this group
65080|NCT03675802|Drug|dinoprostone|giving dinoprostine
65084|NCT03675737|Drug|Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
65085|NCT03675737|Drug|Cisplatin|Administered as an IV infusion on Day 1 Q3W
65086|NCT03675737|Drug|5-fluorouracil|Administered as a continuous IV infusion on Days 1-5 Q3W
65087|NCT03675737|Drug|oxaliplatin|Administered as an IV infusion on Day 1 Q3W
65088|NCT03675737|Drug|capecitabine|Administered orally BID on Days 1 to 14 Q3W
65089|NCT03675737|Drug|Placebo for Pembrolizumab|Administered as an IV infusion on Day 1 Q3W
65090|NCT03675724|Dietary Supplement|Fisetin|Flavonoid Family
65091|NCT03675724|Drug|Placebo oral capsule|Placebo
65092|NCT03675711|Device|Midline|Patient will receive a Midline catheter within 48h after disappearance of indication for CVC
65093|NCT03675711|Device|PVC|Patient will receive a standard PVC within 48h after disappearance of indication for CVC
65094|NCT03675698|Other|Nasotracheal Intubation|side of nostril and size of endotracheal tube estimation for nasotracheal intubation will be done based on radiological imaging ( CT/MRI head)
65095|NCT03675685|Biological|CCH (collagenase clostridium histolyticum)|A single dose of 3.36 mg of CCH will be administered as subcutaneous injections (CCH 0.84 mg) per quadrant concurrently in 4 quadrants. A quadrant is defined as one of the following: left buttock, right buttock, left posterolateral thigh, or right posterolateral thigh.
65096|NCT03675672|Drug|Misoprostol Oral Tablet|Misoprostol 200mcg
65097|NCT03675672|Drug|Placebo Oral Tablet|Placebo Tablet
65098|NCT03675659|Drug|intra-articular injection|intra-articular injection with magnesium sulfate with four injections at weekly intervals
65099|NCT03675646|Drug|Morphine|Intrathecal injection of 250 mcg preservative-free morphine before surgery
65100|NCT03675633|Diagnostic Test|FEUrea|FEUrea in decompansated liver cirrhosis
65101|NCT03675620|Device|BFR|Delfi's Personalized Tourniquet System for Blood Flow Restriction will be used with leg extension and leg press exercises. Bilateral thigh cuffs will be applied to the participants and occlusion pressure will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each participant will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between exercises. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
65102|NCT03675620|Other|Standard Rehabilitation|The control group will perform perform 4 sets of leg extensions and leg press (1 set of 30 repetitions followed by 3 sets of 15 repetitions) with resistance of 30% 1-repetition maximum. Sets and repetitions will remain constant for each participant; however, resistance will be incrementally increased.
65103|NCT03675607|Other|Complementary feeding behaviours|Any kind of complementary feeding practice
65104|NCT03675594|Device|CAD/CAM titanium denture base|metallic denture base made of titanium
65105|NCT03675594|Device|CAD/CAM cobalt/chromium denture bases|metallic denture bases made of cobalt/chromium
65106|NCT03675581|Drug|Microgynon|fixed sequence trial
65107|NCT03675581|Drug|Nintedanib|fixed sequence trial
65108|NCT03675568|Procedure|Non-cultured keratinocyte suspension|A new method for treatment of burn wounds
65109|NCT03675568|Procedure|Split skin Graft|A traditional method for treatment of burn wounds
65110|NCT03675555|Drug|Mirtazapine|Each patient received 30 mg Mirta tablet orally with sips of water and 100 ml 0.9% sodium chloride (normal saline [NS]) (IVI) over 15 minutes as a placebo for Dex solution 2 hours preoperatively.
65111|NCT03675555|Drug|Dexamethasone phosphate|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and Dex 8 mg ampoule diluted in 100 ml 0.9% NS IVI over 15 minutes, 2 hours preoperatively.
65112|NCT03675555|Drug|Placebo|Each patient received a placebo tablet identical to Mirta tablet orally with sips of water and 100 ml 0.9% NS IVI over 15 minutes as a placebo for Dex solution 2 h preoperatively.preoperatively.
65113|NCT03675542|Drug|CUDC-305|Dose-selection treatment with HSP90 inhibitor (CUDU-305)
65114|NCT03675529|Behavioral|High Intensity Interval Training bout|Patients randomized to the HIIT bout will perform one single supervised High Intensity Interval Training bout consisting firstly of a wattmax test on a stationary bike, in order to set the training intensity. This is followed by 10 minutes at low intensity at approximately 30% of wattmax. Subsequently patients will perform 16 min with 4 cycles with High and Low intensity. HI intervals consisting of 1 min with 100% of wattmax followed by 3 min recovery with the intensity load of 30% of wattmax.
65115|NCT03675516|Other|No specific intervention|Usual care
65116|NCT03675503|Other|Fall Prevention Decision Support|Decision support used by nurses to appropriately provide ambulatory aids to hospitalized patients in order to reduce hospital falls
65117|NCT03675490|Behavioral|ABLE - exercise with interactive technology|Multicomponent exercise with interactive technology - consists of wearable sensors and a screen displaying interaction. When the person does the exercises it produces an arts-based response on the screen (e.g., digital painting).,
65120|NCT03675451|Drug|89ZR-DF-IAB2M|injection of 10 milligrams of radioactive 89Zr-Df-IAB2M followed by PET/CT scan
65121|NCT03675451|Drug|68Ga-PSMA-HBED-CC|Optional but recommended 68Ga-PSMA-HBED-CC (5±2mCi) injection and PET/CT scan (1 to 3 hours after the injection) will also be performed prior to radical prostatectomy depending on subject's availability and compliance.
65122|NCT03675438|Other|Sub-epitheilal TCA Inlay|A TCA lenticule is placed at the sub-epithelial interface with the anterior surface of Bowmans layer
65123|NCT03675425|Other|Group 1: non chest shielding|non chest childin: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
65124|NCT03675425|Other|Group 2: chest shielding|chest childing: infants will be randomized into two different phototherapy groups eco with pad diameter will be measured in before and after phototherapy,
65125|NCT03675412|Dietary Supplement|Caffeine tablet|Each eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
65126|NCT03675399|Other|Supra-threshold isometric exercise|The supra-threshold intensity will be stablished at 120% of participant's PFIS pre-session measurement (20% above the individual's pain threshold).
65127|NCT03675399|Other|Infra-threshold isometric exercise|The infra-threshold intensity will be stablished at 80% of participant's PFIS pre-session measurement (20% bellow the individual's pain threshold).
65128|NCT03675386|Other|Interventional Group|The Transitional Pain Service Program enables targeted, mechanism-based, treatment innovations aimed at reducing the incidence and severity of chronic post-surgical pain, disability and enabling safe opioid prescribing/ weaning after major surgery. The investigator's TPSP intervention uses a variety of methods to support patients to manage pain and wean off opioids. This includes physician-guided opioid and non-opioid pharmacotherapy and tapering, and clinical psychology services specializing in pain education, Acceptance & Commitment Therapy (ACT) and e-mobile self-management tools.
65129|NCT03675386|Other|Control Intervention|Patients in the control group will receive standard care, which involves standard postoperative follow-up with their surgeon/primary care provider. Patients will also be sent with a link for an online multimedia tool during each follow-up time point that will provide information and education regarding non-pharmacologic techniques for managing pain. At the end, all patients in the control arm will be invited to join the TPSP after one year of follow-up if they are still taking opioids.
65130|NCT03675373|Behavioral|Mobile chat-based instant messages|"Subjects in the active arm study will receive continuous interactive chat-based intervention as an extension of alcohol brief intervention at baseline. The interactive mobile chat will be carried out on Friday night and Saturday before and during the period of happy hour and ask for drinking and giving personalized advises on drinking reduction using behavioral change techniques."
65131|NCT03675373|Behavioral|Alcohol brief intervention|Those in the control arm will be assigned to only receive the face-to-face ABI. The ABI consists of: (1) giving feedback and information about the screening result in phase I and hazard of drinking; (2) emphasizing the benefits of reduce drinking and informing about alcohol problems; (3) setting goal on reducing alcohol consumption; (4) reviewing advice and ;(5) giving encouragement.
65132|NCT03675360|Behavioral|Low-Carbohydrate Diet|"Behavioral modification to reduce carbohydrate consumption. Target <40 g net carbohydrates per day for first 3 months; <60 g net carbohydrates per day for months 4 onwards. The intervention will consist of 4 weekly individual counseling sessions, followed by 4 group sessions held every other week, with phone follow-ups in between group sessions. For the last 3 months of the study, there will be 3 monthly group sessions and 3 telephone follow-ups.~At baseline, participants will receive written information with standard physical activity recommendations."
65133|NCT03675347|Other|angioplasty|angioplasty
65134|NCT03675334|Procedure|Root coverage with collagen matrix graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
65135|NCT03675334|Procedure|Root coverage with subepithelial connective tissue graft|at one side, the root coverage have been done with a extended flap technique and collagen matrix graft. At the other side, the same technique was performed with connective graft.
65136|NCT03675334|Other|Basic periodontal treatment|profilaxis, coronary polishing and scaling and root planning
65137|NCT03675321|Device|Active Auricular Neurostimulation|Active auricular neurostimulation for 4 weeks. Subjects in Active group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy.
65138|NCT03675321|Device|Sham Auricular Neurostimulation|"Sham auricular neurostimulation for 4 weeks with identical device as the active but lacking the electrical charge.~Subjects in Sham group who do not have significant improvement after 4 weeks may receive an additional 4 weeks of active neurostimulation therapy."
65139|NCT03675308|Biological|placebo for rizankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
65140|NCT03675308|Biological|risankizumab|Risankizumab administered by subcutaneous (SC) injection
65141|NCT03675295|Drug|Hyalase|injection of Hyalase + 10 cc saline injection nearby median nerve as hydro-dissection
65142|NCT03675295|Drug|Saline|injection of 10 cc saline injection nearby median nerve as hydro-dissection
65143|NCT03675282|Drug|(11C)PE2I|Subjects will received (11C)PE2I PET Scans at Baseline and 24 Month Visits
65144|NCT03675269|Other|HBOT|Standard practice
65145|NCT03675269|Behavioral|Standard wound care|Standard wound care
65146|NCT03675256|Biological|immediate Gardasil 9, delayed MenVeo vaccine|Intervention is immediate administration of 9-valent HPV vaccine and delayed MenVeo vaccine
65147|NCT03675256|Biological|immediate MenVeo vaccine, delayed Gardasil 9|Intervention is immediate administration of MenVeo vaccine and delayed administration of Gardasil 9
65148|NCT03675256|Biological|immediate Cervarix, delayed MenVeo vaccine|Intervention is immediate administration of bivalent HPV vaccine and delayed MenVeo vaccine
65149|NCT03675243|Diagnostic Test|sphincterometry|Sphincterometry is a method of the spincter function examination, which allows to assess the state of the anal sphincter muscle and its function
65150|NCT03675230|Device|Tomotherapy HD|Patients with Medulloblastoma receiving Tomotherapy
65151|NCT03675230|Device|3DCRT|Patients with Medulloblastoma receiving Three-Dimensional Conformal Radiation Therapy
65152|NCT03675217|Other|PE|Physical exercise program for familiy caregivers. 36 session physical exercise (3 sessions/week) performed by physioterapist. It incluided exercices to improve coordination, aerobic capacity, control motor and strenght
65153|NCT03675217|Other|Usual Care|Usual Programe in primary care for family caregivers. 4 session (2 session/week). It incluides: ergonomy, postural hygiene, mobilitation of patients and self-care.
65154|NCT03675204|Other|No intervention|No intervention
65155|NCT03675191|Drug|Orlistat 120Mg Cap|Drug,Orlistat 120Mg Cap, three times a day, within 1hour after meal
65156|NCT03675191|Drug|Phentermine Pill|Drug,Phentermine Pill 37.5mg, both in two arms, one time a day, within 1hour after meal
65157|NCT03675178|Drug|Anerning particle|Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
65189|NCT03674905|Procedure|Peripheral nerve block|Pre-operative peripheral nerve block.
112588|NCT03306212|Other|Occupational Therapy|
65158|NCT03675178|Drug|control group|Anerning particle placebo ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured, stop the medicine at any time.
65159|NCT03675165|Behavioral|Best Possible Self|A writing exercise developed in 2001 by Laura King. The frequency of engagement with the exercise is down to the user's discretion though we recommend to them to write things down once every week for the duration of the study.
65160|NCT03675152|Other|Soft spinal brace|Soft thoracolumbar brace worn 23 hours a day.
65161|NCT03675152|Other|thoracolumbar orthosis|Hard thoracolumbar orthosis done individually molded, Worn 23 hours a day.
65162|NCT03675152|Other|Excersice restriction|Patients are only allowed to do isometrical excersices adviced by a physiotherapist.
65163|NCT03675139|Drug|Medroxyprogesterone Acetate|At a dosage of 10mg/day
65164|NCT03675139|Drug|Dydrogesterone 10 MG|At a dosage of 20 mg/day
65165|NCT03675126|Drug|SRP-5051|SRP-5051 administered as an IV infusion.
65166|NCT03675113|Other|Upper extremity aerobic exercise|"Range of maximal heart rate will be followed by a polar band during supervised session each week.~Aerobic exercise will be trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
65167|NCT03675113|Other|Control Group|Deep breathing exercises combinated with arm movements
65168|NCT03675100|Procedure|colonoscopic mucosal biopsy|colonoscopic mucosal biopsy was undertaken for every participant
65169|NCT03675074|Device|Neujia|Neujia devices endoscopically deployed for jejunoileal compression anastomosis
65170|NCT03675061|Other|Current care|Tocolysis and a complete corticosteroid treatment.
65171|NCT03675061|Device|PartoSure Test negative|Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
65172|NCT03675061|Device|PartoSure Test positive|Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
65173|NCT03675048|Dietary Supplement|BioGaia Protectis drops|food supplement containing the patented lactic acid bacterium Lactobacillus reuteri Protectis®/™ (L. reuteri DSM 17938).
65174|NCT03675048|Dietary Supplement|Placebo|Contains same excipients as study drug, without the active ingredient L. Reuteri.
65175|NCT03675035|Device|Endomina|Reduction of the gastro-jejunal anastomosis through sutures
65176|NCT03675022|Drug|Dupilumab|The investigational drug is dupilumab, 300mg in 2ml solution for subcutaneous application. All Patients will receive dupilumab, 300mg, every two weeks (8 subcutaneous injections total).
65177|NCT03675009|Other|Educational Programming|Green Cleaning educational programming to day care staff.
65178|NCT03674996|Other|Same day discharge|Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
65179|NCT03674996|Other|Next-day discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
65180|NCT03674996|Other|2-days discharge|Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
65181|NCT03674983|Behavioral|Conditional Economic Incentive (CEI)|"If hair testing shows that a participant has taken PrEP pills about 5-7 times in the previous week, he will receive a grade A; if he has taken PrEP pills about 3-4 times in the previous week he will receive a grade B; and if he has taken PrEP pills only 2 times or less, he will receive a grade C. For those in the CEI group, if participant gets an A, he receives two additional prizes; if he gets a B, he receives one additional prize; and if he gets a C, he receives no additional prizes."
65183|NCT03674944|Behavioral|Behavioral Weight Loss (BWL) + Emotion Regulation (ER)|The BWL + ER program will teach Dialectical Behavior Therapy (DBT) skills (dialectical abstinence, emotion regulation skills, mindfulness, and distress tolerance) to the adolescent and parent group sessions. Parents are expected to model skill usage and DBT language with their teen to reinforce the skills at home. Adolescents and parents will track emotions and DBT skills used in diary cards which will be provided. Emotion-Focused Parent Training (EFPT) will be provided to the parents at each session to train the parent to support the adolescent in processing emotions, increasing parental emotion self-efficacy, promoting positive parent-adolescent relationships, and reducing the need for dysfunctional emotion regulation behaviors.Behavior coaching will be provided to the adolescent and parent to encourage compliance and review skills after each session (DBT or BWL).
65184|NCT03674944|Behavioral|Behavioral Weight Loss (BWL)|All participants will be instructed to consume an energy restricted diet based on initial body weight. Participants will be instructed to record and self-monitor their food intake. The physical activity component will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations will include: self-monitoring, goal setting, managing high-risk situations, and relapse prevention. Parenting skills will be discussed during parent group sessions which will encourage parents to adopt authoritative parenting styles with regard to eating and exercise behaviors. Parents will also learn about behavioral modification principles, including modeling, reinforcement, and operant conditioning. Behavior coaching will be provided to the adolescent and parent after each session to encourage compliance, discuss completed homework, review habit books to praise efforts and give feedback for areas of improvement.
65185|NCT03674931|Behavioral|musical practice|Intensive weekly musical keyboard training over 12 months
65186|NCT03674931|Behavioral|music education|Recreative weekly musical courses without practice over 12 months
65187|NCT03674918|Diagnostic Test|24 h ambulatory blood pressure measurements|24 h ambulatory blood pressure measurements : an ambulatory 24 h blood pressure device that automatically measures blood pressure every 15 minutes is given to the patient for 24 h
65188|NCT03674905|Procedure|Intra-articular injection|Intra-articular injection at the completion of TAA procedure.
65190|NCT03674892|Device|TrueTear™ intranasal neurostimulator (ITN)|Subject will place the tips of the ITN into both nostrils simultaneously. Subject will be asked to apply it for 3 minutes [could be modified if need be], daily.
65191|NCT03674879|Other|Text Message|Patient contact attempted with text message.
65192|NCT03674866|Drug|Insulin degludec|Participants are treated with Tresiba® (insulin degludec) under conditions of routine care.
65193|NCT03674853|Drug|Wuling Capsule|take Wuling Capsule in experiment group for 2 months
65194|NCT03674853|Drug|Oryzanol|take oryzanol in active comparator group for 2 months
65195|NCT03674840|Procedure|angle kappa based SBL-3 implantation|SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
65196|NCT03674840|Procedure|0 to 180 degree SBL-3 implantation|SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
65197|NCT03674827|Biological|PF-06936308|PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
65198|NCT03674814|Drug|Enzalutamide|Enzalutamide will be taken by mouth at assigned dose. Enzalutamide will be obtained as standard of care prescription (not provided by study).
65199|NCT03674814|Drug|Relacorilant|Relacorilant will be taken by mouth at assigned dose. Relacorilant will be provided by the study.
65200|NCT03674788|Device|Transcatheter valve intervention|
65201|NCT03674775|Other|DART QI Program Participation|Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
65202|NCT03674762|Device|Microgrooved dental implants|Dental Implant placement
65203|NCT03674749|Other|Meditation and Hyperbaric Oxygen Treament|Meditation sessions will be combined with hyperbaric oxygen treatment
65204|NCT03674736|Dietary Supplement|Dietary Intakes|Four levels of methionine or lysine intakes will be provided by the reference protein drinks, 3 levels of methionine from rice and wheat bread and 3 levels of lysine from chickpeas and lentils
65205|NCT03674723|Other|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from Mung beans and 3 levels from Mung beans with rice or wheat.
65206|NCT03674710|Procedure|Standard suction, slow-pull, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, slow-pull, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
65207|NCT03674710|Procedure|Standard suction, wet suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of standard suction, wet suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
65208|NCT03674710|Procedure|Slow-pull, standard suction, wet suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, standard suction, and wet suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
65209|NCT03674710|Procedure|Slow-pull, wet suction, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of slow-pull, wet suction, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
65210|NCT03674710|Procedure|Wet suction, standard suction, slow-pull|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, standard suction, and slow-pull. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
65211|NCT03674710|Procedure|Wet suction, slow-pull, standard suction|"Patients will be sampled for a total of 3 consecutive FNA passes with a sequential method of wet suction, slow-pull, and standard suction. After completing all the passes, the obtained specimen will be packed individually and sent to pathologists who are blind to the method sequence."
65212|NCT03674697|Device|Green LED vs White LED light therapy|You will be asked to locate a dark room in your house three weeks prior to your surgery. You will place the provided LED strip near you on a flat surface and turn it on for 2 hours a day until the day of the surgery. You have the freedom to pick anytime during day or night to use the light. We will ask you to be as consistent as possible with the time you chose. You can engage in any activity to pass the time as long as it does not involve exposure to another light from an outside source (computers, TV, smart phones, tablets, etc…).
65213|NCT03674684|Other|hydroxyethyl starch|After induction to anaesthesia patients received either hydroxyethyl starch or gelatin or crystalloids
65214|NCT03674671|Drug|Intravenous Ketamine|Participants will receive 0.5mg/kg IV over 40 minutes, thrice weekly for 3 or 4 weeks. If participant responds, they will receive infusions weekly for one month, once every two weeks for two months, and once every month for three months. Should participant relapse during once monthly dosing, they may return to dosing once every two weeks for the remainder of the study.
65215|NCT03674671|Procedure|Electroconvulsive Therapy|Participants will receive ECT treatment thrice weekly for the 3 or 4 weeks. If participant responds, they will continue to receive ECT, with frequency at the discretion of the treating physician based on best practice guidelines for the remainder of the study.
65216|NCT03674658|Drug|Propafenone|oral, TID
65217|NCT03674645|Device|MRI acquisitions|Procedure of the study is an MRI exam without any injection or invasive procedure, that will be performed on the Siemens Magnetom Aera imager of Liryc institute (L'Institut de RYthmologie et modélisation Cardiaque) (Xavier Arnozan site - Bordeaux)
65218|NCT03674632|Behavioral|Relaxation meditation tape|The tape used in this study is based on a meditation CD designed for breastfeeding mother (Menelli, 2004). The recording will be transcribed and translated into Chinese language by a certified yoga therapist.
65219|NCT03674619|Procedure|Anterior discectomy|Anterior discectomy will be performed and a microscope is used. After separation of the platysma muscle the pre-vertebral space is reached by an approach medial to the sternocleido-mastoid muscle and the carotid artery and lateral to the trachea and oesophagus. Then the disc is incided and the corpora are distracted to perform discectomy. Usually the posterior ligament is cut and the spinal root is decompressed and if necessary the arthritic rims are removed. An inter-vertebral fusion device is inserted, two levels are allowed in the spondylosis study.
65220|NCT03674619|Behavioral|Conservative treatment|Patients will first attend an experienced specialist in physical medicine and rehabilitation who will answer concerns and questions and if necessary repeat the information given before inclusion. The aim of the brief intervention is to promote better understanding and coping of the condition. The intervention will include supervision by a physiotherapist (6 sessions in the disc herniation study and 6-12 sessions in the spondylosis study) and provide advice on how to handle secondary neck muscle pain and dysfunction, reduce eventual fear avoidance, and advice to stay active.
65221|NCT03674606|Drug|Low dose aspirin|One 75 mg aspirin dose taken daily
65222|NCT03674593|Procedure|Mitral valve chordae prosthesis|"The method consists of five stages:~Measure the required length of the chords~Forming loops~Fixation of the loop group to the papillary muscles~Fixation of chordal loops to the free edge of the valve~Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse"
65223|NCT03674593|Procedure|Mitral valve chordae translocation|"The method consists essentially of three stages:~Selection of the secondary chord.~Fixation of secondary chords to the free edge of the valve.~Annuloplasty support ring and hydraulic test to confirm the absence of prolapse."
65224|NCT03674580|Behavioral|Follow-up of the suicidal patients|No intervention. Follow-up of the suicidal patients
65227|NCT03674554|Procedure|titanium bases using intra oral luting cement technique|a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique
65228|NCT03674554|Procedure|transmucosal abutment|a full-arch screw-retained implant prosthesis with transmucosal abutment
65229|NCT03674541|Drug|Pyridostigmine|Pyridostigmine 60 mg by mouth as a one time dose
65230|NCT03674528|Other|Magnetic Resonance Elastography (MRE)|The MRE scan will several breath holds and will take approximately 30 minutes to complete.
65231|NCT03674528|Diagnostic Test|Liver biopsy|Subjects undergoing WLS will be asked to allow for liver biopsy samples to be collected during their surgical procedure. The collection of these samples will take approximately 5 minutes to complete.
65232|NCT03674515|Device|"Smartphone application placebo"|"Strategy based on smartphone application placebo"
65233|NCT03674515|Device|"Smartphone equipped with application bouge = Coach group"|"Strategy based on smartphone application bouge"
65234|NCT03674502|Drug|ADU-1604|anti-CTLA-4 monoclonal antibody
65235|NCT03674489|Other|Neurodynamic Slider Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULNT2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to slide the nerve proximally and distally in an alternating manner via providing wrist extension with concurrent shoulder girdle elevation and then providing wrist flexion with concurrent shoulder girdle depression. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
65236|NCT03674489|Other|Neurodynamic Tensioner Mobilization|"Subjects will be positioned in supine with the examiner supporting his/her arm and facing caudally. The arm will be taken into the ULND2a position as described in Butler's text - so as to bias the median nerve. Once passive resistance is felt or a feeling of mild tension is reported in the median nerve field, a series of mobilizations will be performed to tension the nerve in an alternating on/off manner via providing wrist extension with concurrent shoulder girdle depression and then providing wrist flexion with concurrent shoulder girdle elevation. This will be performed for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position) - not moving further into described tension or passive resistance."
65237|NCT03674489|Other|Sham Neurodynamic Mobilization|Subjects will be positioned in supine with the examiner supporting his/her arm and facing cranially - in a similar position as the UNLD1 test described previously. From here, the therapist will position the patient's arm in 45 deg. of shoulder abduction without scapular depression, 45 deg. of shoulder external rotation, 45 deg. of elbow flexion, and forearm pronation. From this position, a series of sham mobilizations will be performed by passively alternating flexion and extension of the wrist for 2 sets of 10 cycles at a rate of 6 seconds per cycle (3 sec in each position).
65238|NCT03674476|Drug|BMS-986036|Specified dose on specified days
65239|NCT03674463|Drug|LCAR-B4822M CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
65240|NCT03674450|Behavioral|Heart Rate Variability Biofeedback Training|The study will utilize the Physiolab GP8 heart rate variability and respiration system on a laptop computer used solely for the study with the proper security passwords to protect participant information. The equipment consists of two electrocardiogram sensors (one per wrist) attached by sports wrist bands, a respiration monitoring belt placed around the upper abdomen, two galvanic skin conductance sensors attached to the fingertips, and a thermistor sensor attached to one of the finger tips. Participants will perform a series of monitored breathing exercises.
65241|NCT03674437|Behavioral|Traditional Neurocognitive Assessments|Traditional Neurocognitive Assessments given with pen and paper
65242|NCT03674437|Behavioral|Online Cognitive Battery (Cogsuite)|Cognition (Cogsuite) for a battery that consists of seven measurements.
65243|NCT03674424|Drug|Avelumab|Chemotherapy with or without avelumab followed by surgery
65244|NCT03674424|Procedure|cystectomy|Cystectomy 3 to 6 weeks after last administration of chemotherapy
65245|NCT03674424|Combination Product|CG|Chemotherapy 4 cycles of 3 weeks
65246|NCT03674424|Combination Product|DD-MVAC|Chemotherapy 4 cycles of 2 weeks
65247|NCT03674424|Combination Product|PG|Chemotherapy 2 cycles of 4 weeks
65248|NCT03674411|Drug|Fludarabine (FLU)|25 mg/m2 IV over 1 hour (<10 kg: 0.83 mg/kg IV over 1 hour)
65249|NCT03674411|Drug|Cyclophosphamide (CY)|60 mg/kg IV over 2 hours
65250|NCT03674411|Drug|Total Body Irradiation (TBI)|165 cGy twice daily
65251|NCT03674411|Drug|Tacrolimus (Tac)|Tacrolimus will start day -3 and will be administered as a continuous IV infusion at a starting dose of 0.03 mg/kg/day. Goal trough levels will be 10-15 ng/mL for the first 14 days post-transplant and then decreased to a goal of 5-10 ng/ml thereafter.
65252|NCT03674411|Drug|Mycophenolate Mofetil (MMF)|MMF 3 gram/day IV/PO for adult patients divided in 2 or 3 doses. Pediatric patients will receive MMF at the dose of 15 mg/kg/dose (max 1 gram per dose) every 8 hours beginning day -3.
65253|NCT03674411|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5 ug/kg/d until the absolute neutrophil count (ANC) is >2500/uL for 2 consecutive days
65254|NCT03674411|Drug|Busulfan (BU)|BU IV once daily with dose based on Pharmacokinetics (PK) calculator over 3 hours
65255|NCT03674411|Drug|Melphalan|50 mg/m2/day (1.7 mg/kg/day if < 10 kg) IV over 30 min
65256|NCT03674411|Drug|MGTA 456 Infusion|The target cell dose is >10 x 106 CD34/kg with a maximum TNC 2.7 x 108/kg for children (<18 years) and 8.1 × 108 cells/kg [expanded product only] for adults based on the highest cell dose windows evaluated in prior studies.
65257|NCT03674398|Behavioral|Exercise+CT|The exercise+CT group is asked to participate in 30 minutes of aerobic exercise followed by a 20-minute cognitive training (CT) program that targets attention and memory. Training will take place following exercise due to elevated levels of brain-derived neurotrophic factor and increased arousal, which is theorized to benefit cognitive task performance. Computerized CT exercises will be delivered using participants' smartphone. Adherence to the computerized CT program is monitored using electronic data upload after each training session. Participants are asked to engage in three sessions per week with the first week taking place in a lab-setting. Participants are asked to continue the aerobic exercise and CT program at home for the subsequent three weeks.
65258|NCT03674398|Behavioral|Exercise only|The exercise only group will receive the same exercise prescription as the exercise+CT group. Participants in this group are asked to watch 20 minutes of health-related educational videos post-exercise. Videos are administered via participants' smartphones. After each video session, participants answer multiple-choice questions that assess engagement. Following the first week of treatment in-lab, participants are asked to continue watching health-related videos, post-exercise, for three weeks at home.
65259|NCT03674385|Dietary Supplement|vitamin E|Vitamin E is sold as a dietary supplement, either by itself or incorporated into a multivitamin product. it also has anti-oxidant effect
65260|NCT03674385|Drug|Metformin|Metformin is in the biguanide class. It works by decreasing glucose production by the liver and increasing the insulin sensitivity of body tissues. It is also used in the treatment of polycystic ovary syndrome (PCOS)
65261|NCT03674385|Drug|Clomiphene Citrate|is a medication used to treat infertility in women who do not ovulate
65262|NCT03674372|Device|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E < 25%; O/E LHR < 30 %) and right CDH (O/E LHR < 45%).
65263|NCT03674359|Diagnostic Test|BDG analysis|BDG analysis
65264|NCT03674346|Other|Hypnoanalgesia group|"The running of a hypnosis session is protocolized and is based on three times:~The hypnotic induction time that allows to move from the state of consciousness to a modified state of consciousness: it will be adapted according to the patient as specified by the procedure of Ericksonian hypnosis. It varies from a few seconds to 10 minutes. Induction time depends on the patient's level of stress, apprehension, subsequent experiences of hospitalization, history, and level of hypnotizability.~The dissociation time. It is the state of modified consciousness obtained at the end of the induction which is prolonged,~The time of return. It is time that allows the patient to regain his classic state of consciousness."
65265|NCT03674346|Other|Meopa Group|"The pain management will be done exclusively by a mask delivering the equimolecular mixture of oxygen and nitrous oxide (MEOPA) throughout the procedure.~For optimal use, the beginning of its administration by the radiological technologist is performed 3 minutes before the sclerosant injection (at the end of the locating ultrasound). The end of administration will correspond to the end of the injections of the sclerosing product. These sclerosing products are not considered experimental or ancillary products in this study."
65266|NCT03674333|Dietary Supplement|Folic Acid|Folic acid is a water soluble vitamin, required for various biological functions in human body, including metabolism of homocysteine.
65267|NCT03674333|Other|Placebo|Placebo - a sugar pill
65268|NCT03674320|Drug|Testosterone Enanthate|Testosterone Enanthate (25 mg women, 100mg men) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
65269|NCT03674320|Drug|Placebo|Placebo Injection (saline) will be given via intramuscular injection at study week 2, 3, 6, 7, 10 and 11.
65270|NCT03674307|Other|No screening|No further screening for asymptomatic coronary artery disease after wait-list entry
65271|NCT03674307|Other|Regular Screening|Annual or second-yearly screening for asymptomatic coronary artery disease after wait-list entry
65272|NCT03674294|Drug|Aprepitant|Aprepitant is manufactured by Merck & Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. It was approved by the FDA in 2003
65273|NCT03674294|Drug|Palonosetron|Palonosetron is a 5-HT3 antagonist used in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is used for the control of delayed CINV—nausea and vomiting and there are tentative data to suggest that it may be more effective than granisetron.
65274|NCT03674294|Drug|Dexamethasone|Dexamethasone is a type of corticosteroid medication. It is used in the treatment of many conditions, including rheumatic problems, a number of skin diseases, severe allergies, asthma, chronic obstructive lung disease, croup, brain swelling, and along with antibiotics in tuberculosis.
65275|NCT03674294|Drug|Placebo Oral Tablet|In the current clinical trial, placebo oral tablet is provided as a substance for Aprepitant with no active therapeutic effect.
65276|NCT03674281|Device|SAP|Subjects will wear their own personal insulin pump and will wear the study CGM (Dexcom G6).
65277|NCT03674281|Device|CLC|The Tandem t:slim X2 is an insulin pump with software (Control-IQ Technology) that helps regulate blood glucose more optimally, based on data received from the Dexcom G6 CGM.
65278|NCT03674268|Diagnostic Test|Management of the Contraversive Pushing Scale|Scale of evaluation of trunk control and pushing behavior in patients with stroke.
65279|NCT03674242|Drug|eryaspase (L-asparaginase encapsulated in red blood cells)|IV infusion 100 U/kg
65280|NCT03674242|Drug|Gemcitabine|IV infusion 1000 mg/m2
65281|NCT03674242|Drug|Carboplatin|IV infusion AUC2
65282|NCT03674229|Other|Informational Intervention|Receive information about weight management programs
65284|NCT03674229|Behavioral|Telephone-Based Intervention|Receive phone calls from an assigned patient navigator
65285|NCT03674203|Biological|Platelet-Rich Plasma|1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.
65286|NCT03674190|Procedure|Anterior Lumbar Interbody Fusion|Anterior Lumbar Fusion(ALIF)
65287|NCT03674190|Procedure|Total Disc Replacement|Total Disc Replacement
65288|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 1|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
65289|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 2|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
65290|NCT03674177|Biological|GSK3888550A RSV Maternal vaccine formulation 3|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
65291|NCT03674177|Drug|Placebo (Normal Saline)|Single dose administered intramuscularly at Day 1 in the deltoid region of the non-dominant arm
65292|NCT03674164|Other|Ovarian Cryopreservation|Surgical ovarian removal and vitrification
65293|NCT03674151|Device|Silver Nylon dressing|Non-staining Silver Nylon dressing with a permanently plated metallic surface on split-skin grafted third-degree burn wound
65294|NCT03674151|Device|Manuka-Honey|Manuka-Honey dressing on split-skin grafted third-degree burn wound
65295|NCT03674151|Device|Povidone-Iod (PVP-Iod)|Povidone-Iod (PVP-Iod) dressing on split-skin grafted third-degree burn wound
65296|NCT03674151|Device|Hydrogel|Hydrogel dressing on split-skin grafted third-degree burn wound
65297|NCT03674138|Diagnostic Test|DNA-guided choice of therapy|Buccal swab for DNA genotyping to identify best antidepressant therapy
65298|NCT03674138|Other|Clinical management|Clinical management to identify best antidepressant therapy
65299|NCT03674125|Biological|GLS-6150|Group 1: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, healthy volunteers); Group 2: GLS-6150 1.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 3: GLS-6150 2.0 mg at 0, 4, 12, and 24 weeks (N=8, previously treated for HCV infection); Group 4: GLS-6150 2.0 mg at 0, 8, and 24 weeks (N=8, previously treated for HCV infection)
65300|NCT03674112|Drug|Pertuzumab and Trastuzumab FDC SC|Pertuzumab and Trastuzumab FDC SC will be administered subcutaneously (SC) at a fixed non-weight-based dose. A loading dose of 1200 mg pertuzumab and 600 mg trastuzumab is then followed by a maintenance dose of 600 mg pertuzumab and 600 mg trastuzumab once every 3 weeks (Q3W).
65301|NCT03674112|Drug|Pertuzumab IV|Pertuzumab will be administered intravenously (IV) as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
65302|NCT03674112|Drug|Trastuzumab IV|Trastuzumab will be administered intravenously (IV) as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
65303|NCT03674099|Drug|Imatinib Mesylate|Tablets 400 mg
65304|NCT03674099|Drug|Methylprednisolone|1 g tablets or infusion
65305|NCT03674086|Device|eAdjust 0.2 hearing aid smartphone application (or app)|The app connects to the Audeo B-90 Direct hearing aids via Bluetooth. The intended use for the app to enable hearing aid users to fine-tune their hearing aids. The app contains a series of sound modifiers, factory presets, sound modifier presets.
65306|NCT03674073|Biological|Neoantigen Vaccines|HCC (3cm≤D ≤5 cm, fewer than three tumors) patients were treated with Microwave Ablation and 7 courses of neoantigen-based DC vaccines.The first neoantigen-based DC vaccine injection will take place up to 30 days following the completion of Microwave Ablation. The day of the first vaccine injection will be referred to as Day 1.The schedule of vaccination is Day 1, Day 8, Day 15, Day 22, Day 50, Day78, Day106.
65307|NCT03674073|Procedure|Microwave Ablation|ALL the HCC patients will be treated by Microwave Ablation.
65308|NCT03674060|Drug|SYO-1644|"100mg: SYO-1644 tablet, PO, 1 100mg tablet~150mg: SYO-1644 tablet, PO, 1 100mg tablet and 1 50mg tablet~200mg: SYO-1644 tablet, PO, 2 100mg tablet"
65309|NCT03674060|Drug|Nexavar tab|Nexavar 200mg/tablet, PO, 1 tablet
65310|NCT03674047|Drug|ruxolitinib|Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
65311|NCT03674034|Other|CTscan and MRI images|CTscan and MRI images segmented according to procedures previously developed by GRAMFC
65312|NCT03674021|Other|Chest Pain Choice visual aid|The Chest Pain Choice (CPC) decision aid is a visual aid that was developed to facilitate shared decision-making between physicians and patients who present to the emergency department with chest pain. The visual aid includes a brief description of what tests have been done thus far to assess the patient's risk of MACE, a graphic representation of the risk as calculated based on the HEART score, as well as the evaluation options available. The visual aid has been modified from its original form for the local context in terms of viable options for further evaluation.
65313|NCT03674008|Drug|HSK3486|HSK3486 intravenous (iv) 0.4 mg/kg for induction, and 0.2 mg/kg top-ups for maintenance.
65314|NCT03674008|Drug|Propofol|Propofol iv 1.5 mg/kg for induction, and 0.75 mg/kg top-ups for maintenance.
65315|NCT03673995|Dietary Supplement|Myo-inositol+L-tyrosine|PCOS patients were treated every day, with one sachet containing 2000 mg myo-inositol, 500 mg L-tyrosine, 40 mcg chromium picolinate, 55 mcg selenium, 200 mcg folic acid. All patients underwent, before starting the therapy, after 3 months and 6 months, hormonal, hirsutism and ovulation assesment.
65316|NCT03673982|Behavioral|iCASK|Materials and support to aid transitions
65317|NCT03673969|Procedure|Gastric bypass|Surgical method of gastric bypass
65318|NCT03673956|Drug|Topical Antibiotic Nasal Saline Irrigation|The topical antibiotics will prescribed to the patient in capsule form as compounded by the Mayo Clinic pharmacy, or suitable licensed 3rd party compounding pharmacy. One capsule will subsequently be added to a nasal saline irrigation bottle, and the patient will administer this irrigation to him or herself in the usual fashion twice per day. The antibiotic prescribed may be either Tobramycin, Mupirocin, Gentamicin or Levofloxacin.
65319|NCT03673943|Drug|64Cu-DOTATATE|Detection of somatostin positive lesions in NET
65320|NCT03673930|Dietary Supplement|Zanthozylum armatum|Zanthozylum armatum MCT oil extract
65321|NCT03673930|Dietary Supplement|Placebo|sunflower oil matched for appearance
65322|NCT03673917|Other|Educational video|The educational video on skin cancer for cosmetologists
65323|NCT03673917|Other|Control video|A publicly accessible healthy lifestyle video on YouTube, which does not contain any information on skin cancer
65324|NCT03673891|Device|Life Flow|LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
65325|NCT03673865|Device|office-based 3-dimensional printers (OB3DP)|In this treatment group subjects, using office-based 3-dimensional printers (OB3DP) a patient-specific pre-adjusted (pre-bend) orbital plates will be made using over-the-counter titanium plates that are manually adjusted according to the printed model. The plates are then send to sterilization for preparation.
65326|NCT03673865|Device|standard stock orbital plate|In this control group subjects will receive non-patient-specific orbital implants which is standard stock orbital plate that is adapted intraoperatively to the fractured orbit
65327|NCT03673852|Behavioral|WE Harambee|WE Harambee is a 6-month intervention, comprised of twice a week group meetings for 12 weeks, followed by a second 12 weeks of individual peer coaching/navigation. WE Harambee aims to enhance access to and engagement in primary care and behavioral health services, as well as improve overall health and well-being, including the 8 dimensions of wellness and social determinants of health.
65328|NCT03673852|Behavioral|Behavioral Health Home Enrollment|A BHH is a Center for Medicaid Services program supporting Medicaid beneficiaries with complex needs, typically multiple chronic conditions impacting both physical and behavioral health. Utilizing a team-based clinical approach that includes the patient, his/her providers, and possibly family members, BHH programs target service fragmentation by linking community supports and resources as well as by enhancing the integration of primary and behavioral health care. Care Coordinators oversee and facilitate access to all services an individual needs to stay as healthy as possible, aiming to promote continuous health management not mere resolution of repeated acute episodes.
65329|NCT03673839|Other|Animal Proteins (crossover)|Animal proteins mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
65330|NCT03673839|Other|Plant-based protein blends type 1 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
65331|NCT03673839|Other|Plant-based protein blends type 2 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
65332|NCT03673839|Other|Plant-based protein blends type 3 (crossover)|Plant-based protein blends mixed with water and consumed as a beverage once by the subject in a 4x4 Williams square crossover design
65333|NCT03673826|Drug|Carfilzomib|9 cycles 20/36mg/m2 days 1,2,8,9,15,16
65334|NCT03673826|Drug|Dexamethasone|4 cycles 20 mg days 1,2,8,9,15,16,22,23 followed by 5 cycles 10mg days 1,2,8,9,15,16,22,23
65335|NCT03673826|Drug|Lenalidomide|9 cycles 25mg days 1-21 followed by 24 extended dosing cycles 10mg days 1-21
65336|NCT03673800|Other|Experimental Group|Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
65337|NCT03673800|Other|Control Group|Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
65338|NCT03673787|Drug|ipatasertib|Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
65339|NCT03673787|Drug|Atezolizumab|Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
65340|NCT03673774|Device|cardiac impedancemetry|The cardiac output is measured by impedance measurement at rest and during the walking test.
65341|NCT03673761|Other|MRI, dual-energy, x-ray absorptiometry, muscle ultrasounds, blood testing|3.Dixon, T2 mapping MRI microRNAs
65342|NCT03673748|Drug|Mesenchymal stromal cells (MSC)|Endovenous injection of MSV in saline
65343|NCT03673748|Drug|Placebo|Endovenous injection of saline without cells
65344|NCT03673735|Drug|Durvalumab|Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
65345|NCT03673735|Radiation|radiotherapy|radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
65346|NCT03673735|Drug|Placebo|placebo (one dose) before CRT and for 6 months Q4W after CRT
65347|NCT03673735|Drug|Cisplatin|Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
65348|NCT03673722|Other|Foods consistent with a MDP|We aim to increase MDP by 3 points, according to a 14-point MEDAS score
65349|NCT03673722|Other|Physical Activity|We aim to increase PA to 150 minutes moderate activity per week.
65350|NCT03673722|Other|Control|Participants will be given generic healthy eating advice based
65351|NCT03673709|Behavioral|Antenatal Care|Women in group care bypass the waiting room and have a 2-hour visit with the same provider with a group of 8-12 women at a similar stage of pregnancy. Women assess their own blood pressure and weight, briefly consult the midwife in a corner of the room, and meet for 80-90 minutes of interactive health promotion, enlivened by games and role-plays.
65352|NCT03673696|Drug|HEC74647PA Capsule|Capsule administered orally once daily
65353|NCT03673696|Drug|placebo|Matching Placebo Capsule
65354|NCT03673683|Behavioral|SANDWICH protocol|A protocol based intervention incorporating co-ordinated care with greater nursing involvement; patient-relevant sedation plans linked to regular assessment using the COMFORT scale; regular assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test; a spontaneous breathing trial (SBT) on low levels of respiratory support to test extubation readiness
65355|NCT03673683|Behavioral|Usual care|Usual sedation and weaning management that is not protocol based
65358|NCT03673670|Drug|Tiotropium/olodaterol (Respimat)|An anticholinergic/β-agonist combination medication
65359|NCT03673657|Dietary Supplement|ONS from the start of radiotherapy|ONS from the start of radiotherapy
65360|NCT03673657|Dietary Supplement|ONS from the time of grade 2 radiation esophagitis|ONS from the time of grade 2 radiation esophagitis
65361|NCT03673657|Dietary Supplement|Energy goal-based ONS|Energy goal-based ONS
65362|NCT03673657|Dietary Supplement|Prealbumin goal-based ONS|Prealbumin goal-based ONS
65363|NCT03673657|Radiation|Thoracic radiotherapy|Definitive thoracic radiotherapy with total radiation doses of 60-70 Gy
65364|NCT03673657|Drug|Weekly DP chemotherapy concurrent with thoracic radiotherapy|Weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with thoracic radiotherapy
65365|NCT03673644|Other|Questionnaires|Two questionnaires will be administered, one focusing on life space and the other focusing on low luminance.
65366|NCT03673631|Device|NIV|NIV setting: minimal FiO2 0.3; tidal volume 6-8ml/kg (theoretical body weight)
65367|NCT03673631|Device|NFHC-O2|NFHC-O2 setting: minimal FiO2 0.3; minimal flow 40l/min
65368|NCT03673618|Drug|Soluble Corn Fiber|Fiber or placebo
65369|NCT03673605|Drug|Rivaroxaban 15 mg|Rivaroxiban in stroke prevention in patients with Mitral Stenosis and AF.
65370|NCT03673605|Drug|Warfarin|Warfarin in stroke prevention in patients with Mitral Stenosis and AF.
65371|NCT03673592|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
65372|NCT03673579|Device|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
65373|NCT03673566|Device|NICU Dashboard|The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
65374|NCT03673553|Other|Multimodal treatment of patients with FM|The intervention group took part in 2.5-hour sessions of MRT once a week for 10 weeks. This intervention combined physical exercise with stretching. Health education was geared towards pain management, the pathology itself, healthy habits, insomnia, postural correction and ergonomics. The psychological approaches used in the MRT were problem-solving therapy, cognitive behavioural therapy and sophrology. Given the diversity of the sessions, they were directed by a rheumatologist, a nurse, a psychologist, and a physiotherapist. If the patient needed their pharmacological treatment to be altered, they were offered an appointment with the rheumatologist.
65375|NCT03673553|Other|Association of people with fibromyalgia|The control group attended the activities organised by the association of people with FMS. These consisted of a weekly 1-hour session of group psychology and a weekly 2-hour session of handicrafts for 10 weeks.
65376|NCT03673540|Behavioral|CBT+ application|Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
65377|NCT03673527|Drug|topical formulation of tacrolimus|Topical application of tacrolimus twice daily for 14 days (one dose on Day 14).
65378|NCT03673514|Procedure|Total hip arthroplasty|Two fellowship-trained surgeons in two separate hospitals performed all procedures. Both surgeons had previously performed over 100 cases with each approach, before initiating this study
65379|NCT03673501|Drug|ripretinib|Oral KIT/PDGFRA kinase inhibitor
65380|NCT03673501|Drug|Sunitinib|Oral receptor tyrosine kinase (RTK) inhibitor
65381|NCT03673488|Device|TephaFlex™ mid-urethral sling|The sling is made from P4HB material. It is placed in a similar technique to standard retropubic sling procedures, but will resorb over 18-24 months post surgery.
65382|NCT03673475|Procedure|Assessment of fluid responsiveness|assessment of intravascular volume status using pleth variebility index and internal jugular vein distensibility in major abdominal surgery
65383|NCT03673462|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine)|Pharmaceutical form: liquid solution. Route of administration: Intramuscular
65384|NCT03673462|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)|Pharmaceutical form:Lyophilized powder combined with liquid components Route of administration: Intramuscular
65385|NCT03673462|Biological|Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine|Pharmaceutical form:Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
65386|NCT03673462|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
65387|NCT03673462|Biological|Rotavirus Vaccine|Pharmaceutical form:Oral solution Route of administration: Oral
65388|NCT03673462|Biological|Hepatitis B Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
65389|NCT03673462|Biological|Measles, Mumps, and Rubella Virus Vaccine|Pharmaceutical form:Lyophilized live virus vaccine Route of administration: Subcutaneous
65390|NCT03673462|Biological|Varicella Virus Vaccine|Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous
65391|NCT03673449|Device|SilkBridge|SilkBridge is a biocompatible silk fibroin-based scaffold, which recruits the patients' own cells to remodel or regenerate the nerve, without pre-seeding of the scaffold nor biological/chemical treatments.
65392|NCT03673436|Procedure|Lumbar spinal fusion|The patient got a instrumented fusion of a maximum of 3 adjacent vertebrae
65393|NCT03673410|Procedure|Robotic bariatric surgery - revisional|Using robotic techniques during any revesional bariatric surgery
65394|NCT03673410|Procedure|Laparoscopic bariatric surgery - revisional|Using laparoscopic techniques during any revesional bariatric surgery
65395|NCT03673397|Behavioral|Aerobic exercise, bicycle ergometer|Exercise performed below individual anaerobic threshold for 30 minutes
65396|NCT03673384|Device|infrared-C ray irradiation|Infrared-C irradiation by hot compress with a powered heating compress
65397|NCT03673384|Device|eye mask|infrared-C irradiation by hot compress with a powered heating eye mask
65398|NCT03673384|Drug|Xyzal Oral Product|used to relieve allergy symptoms, It works by blocking histamine that body secretes during an allergic reaction.
65399|NCT03673384|Drug|Fluticasone Furoate|used to treat seasonal and perennial allergic rhinitis. It also helps to reduce the symptoms of seasonal allergic rhinitis.
65400|NCT03673371|Other|Questionnaire|This is a questionnaire developed by DoD and VA researchers specifically for this study.
65401|NCT03673358|Behavioral|Cognitive Behavioural Therapy|"Participants who are randomized to the CBT intervention will be encouraged to begin CBT immediately following randomization. The CBT intervention will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses to baseline questionnaires. All other aspects of post-operative care will be at the discretion of participant's surgeon.~Other Name: CBT"
65402|NCT03673345|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
65403|NCT03673332|Drug|immune-checkpoint inhibitors therapies|All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.
65404|NCT03673319|Procedure|Dry needling with positives expectation|"DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain"
65405|NCT03673319|Procedure|Dry needling with neutral expectation|"DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain"
65406|NCT03673306|Other|Clinical outcomes|Clinical outcomes
65407|NCT03673280|Procedure|Quadratus Lumborum Block|Instead of using morphine in the classical spinal anaesthesia we will be performing in the experimental group the Quadratus Lumborum Block
65408|NCT03673267|Behavioral|Nutricity|Participants will use their smartphone or web-accessing device to access the Nutricity website to potentially increase nutrition literacy and set nutrition goals. Participants will have their own user name and password to access the site. Access to Nutricity will last approximately 3 months.
65409|NCT03673254|Device|rotational atherectomy device|angioplasty with rotational atherectomy device on a nonselected population
65410|NCT03673241|Device|Guardian System|The Study arm will have the Guardian system applied to their bed and recovery chair with the intent for the patient to have the inflatable surface utilized underneath them .
65411|NCT03673228|Behavioral|Comprehensive Relapse Prevention Intervention|"This intervention consists of 4 components:~Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling~Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit~Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit~Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations"
65412|NCT03673228|Behavioral|Standard Treatment Counseling|Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge
65413|NCT03673228|Drug|Nicotine Replacement Therapy (NRT)|Patients in both arms will be encouraged to receive NRT
65414|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class A
65415|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
65416|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class B.
65417|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 150 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
65418|NCT03673215|Drug|Placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
65419|NCT03673215|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 300 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
65420|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
65421|NCT03673215|Drug|Recombinant human thrombopoietin|Recombinant human thrombopoietin will be administered single dose 450 U/Kg subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C.
65422|NCT03673215|Drug|placebo|Placebo will be administered single dose subcutaneous injection in the patients with liver function impairment classified as Child-Pugh class C
65423|NCT03673202|Diagnostic Test|Cx bladder Monitor test|Cxbladder Monitor is a non-invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma and also two clinical variables (whether the previous tumor was primary or recurrent and the time since the previous tumor was resected).
65424|NCT03673189|Device|sensors|Acquisition and transmission of exploitable recordings in the public targeted by the DS, that is to say which allow to draw clinical information in relation to the objectives of the DS (detection of the cardiac rhythm): data without artefact (saturation), in a good signal to noise ratio.
65425|NCT03673176|Radiation|Stereotactic Ablative Radiotherapy (SABR)|The prescribed dose will be 45 Gy in three fractions of 15 Gy, on each side that is treated.
65426|NCT03673163|Drug|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h,prior to surgery and discontinued until 24 h after surgery.
65427|NCT03673163|Drug|Control|Infusion of normal saline at 4 mL/h, prior to surgery and discontinued until 24 h after surgery.
65428|NCT03673150|Other|non intervention|Observational study / non intervention
65429|NCT03673137|Device|Irreversible electroporation|During the IRE process, we employed a CT scanner and an ultrasound system to guide percutaneous insertion of the electrode probes (one main electrode and one to three standard electrodes were used per treatment). The electrode number, electrode-insertion mode and intraoperative parameters were decided upon during pretreatment planning. The IRE parameters were visually simulated in the pulse generator and set up as follows: energy was applied at 1500 V/cm for 90 ms/pulse for a total of 7-9 pulses. After an initial testing pulse train was discharged to establish the best voltage value, the remaining 80 pulses were completed in 1-2 minutes. After ablation, we confirmed completion of IRE by measuring real-time resistance or current changes, in addition to intraoperative ultrasound and CT.
65430|NCT03673137|Drug|Gemcitabine|Gemcitabine hydrochloride (Qilu pharmaceutical [Hainan] Co., Ltd. Haikou, China] was administered by intravenous infusion at a dose of 1000 mg/m2.
65431|NCT03673124|Drug|Ribociclib|600 mg by mouth daily for 21 days followed by 7 days off treatment
65432|NCT03673124|Drug|Letrozole|2.5 mg by mouth daily
65433|NCT03673111|Drug|Y14|Gut hormone analogue
65434|NCT03673111|Drug|Placebo|0.9% saline
65435|NCT03673098|Behavioral|Adapted 3RP|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The adapted 3RP intervention consists of 10, 90-minute weekly group sessions. Content specific to older women living with HIV, including self-compassion exercises, was added to the intervention in the first phase of this study (open pilot).
65436|NCT03673085|Drug|CN128|CN128
65437|NCT03673085|Other|placebo|The tablets without CN128
65438|NCT03673072|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) in 250-500 ml 0.9% saline every three weeks on days 1 and 8 intravenously
65439|NCT03673072|Drug|Cisplatin|Cisplatin (25 mg/m2) every three weeks on days 1 and 8 intravenously, in 1000 ml 0.9% saline with KCl 20 mmol and MgSO4 8 mmol during the one hour cisplatin infusion followed by 500 ml 0.9% saline over 30 minutes prior to gemcitabine; with adequate pre- and posthydration
65440|NCT03673072|Procedure|Oncologically radical margin-free (R0) resection|Oncologically radical margin-free (R0) resection
65441|NCT03673072|Drug|Adjuvant chemotherapy|Can be selected by Investigator's Choice
65442|NCT03673059|Drug|OTC Eczema Moisturizer Regimen|Subjects were assigned to use an OTC, oatmeal-containing eczema therapy moisturizing cream twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group B) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
65443|NCT03673059|Other|Cosmetic Moisturizer Regimen|Subjects were assigned to use a non-fragranced, dry skin daily moisturizer twice daily on their face and entire body for the 14-day treatment period of the study, in place of any other moisturizers/emollients. Subjects were also provided with a mild cleanser to use in place of their normal body wash and/or soap (same cleanser as used by Group A) per their usual cleansing routine. After the 14-day treatment period, subjects discontinued use of the moisturizer for the 7-day regression period.
65444|NCT03673046|Device|Smartphone-delivered CBT for BDD|12-week Smartphone-delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
65445|NCT03673033|Procedure|liver transplantation|calculation of hot and cold ischemia durations from donor artery cut-off time in liver transplantation
65446|NCT03673020|Biological|ASV™ AGEN2017 + QS-21 Stimulon® adjuvant|Neoantigen Vaccine
65447|NCT03673007|Behavioral|Gift card to be used for contraceptives|M-CARES will randomize allocation of vouchers (gift cards) for contraception.
65448|NCT03672981|Behavioral|Exercise Intervention|Undergo resistance training program and cardiovascular exercise
65449|NCT03672981|Other|Quality-of-Life Assessment|Ancillary studies
65450|NCT03672981|Other|Questionnaire Administration|Ancillary studies
65451|NCT03672981|Behavioral|Telephone-Based Intervention|Participate in phone calls with exercise physiologist
65452|NCT03672968|Genetic|GS010|
65453|NCT03672942|Behavioral|Communication Skills Training|Gentle start-up is one treatment technique in the Creating Healthy Relationship Program written by John Gottman, Ph.D.
65454|NCT03672942|Behavioral|Mindfulness|Acceptance/willingness of unwanted emotions is treatment technique of Achieving Change through Value-Based Behavior (ACTV) written by Amie Zarling, Ph.D.
65455|NCT03672942|Behavioral|Placebo|Couples randomly assigned to this condition listen to music on headphones. This may be considered an active placebo as it is similar to a Time Out technique taught in battering interventions.
65456|NCT03672929|Device|RSA|Roentgen Stereometric Analysis (RSA) is a very accurate measurement technique used to obtain micromotion of the implants relative to bone, by means of inserted tantalum markers in the surrounding acetabulum and femur. RSA provides data on the in-vivo stability of the Cup System within 2 years.
65457|NCT03672903|Device|Weight Vest|A vest with added weights up to a maximum of 15 kg.
65458|NCT03672890|Other|Telestroke|Telestroke is an audiovisual communication network that allows for coordination of stroke care from a distant 'hub' site (the telestroke provider location) to an originating 'spoke' site (patient location) in a HIPAA compliant fashion. In TELECAST, inpatient telestroke rounding will be used to oversee the urgent diagnostic stroke evaluation, secondary stroke prevention, health screening & evaluation, and stroke education in patients admitted with stroke.
65523|NCT03672383|Device|BAY987534|Form: cream; Route of Administration: topical; Frequency of Administration: twice daily ; Duration of Treatment: 4 weeks .
65524|NCT03672357|Procedure|Laparoscopic liver resection|Laparoscopic hepatectomy
65525|NCT03672357|Procedure|Open liver resection|Traditional open hepatectomy
65459|NCT03672877|Behavioral|Intensive exercise|Intensive, child-initiated activities of the lower extremities including walking (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. Sessions will be one hour long, 4 days a week. A physical therapist or designate will supervise sessions.
65461|NCT03672851|Drug|anti-CD123 CAR-T treatment|Patients receive fludarabine phosphate(300 mg/m^2) and cyclophosphamide (30 mg/m^2) IV on days -5 to -3, and then Patients receive autologous anti-CD123 CAR T cells IV over 20 minutes on day 0 (20% of total dose), day2 (30% of total dose) and day6 (50% of total dose, according to the side-effects occured). The total dose of CAR-T cells used in dose-escalation study is 0.5x10^6- 2.0x10^6 CAR-T cells/kg.
65462|NCT03672838|Behavioral|hand-held dynamometer|Strength of one weak muscle group and of the biceps of the dominant arm will be measured using a hand-held dynamometer. An average of three readings will be used as one observation. Three observations per patient will be obtained on one day with a minimum of 15 minute rest period between each observation.
65463|NCT03672825|Drug|REcycled CartiLage Auto/Allo IMplantation|Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
65464|NCT03672812|Drug|Liraglutide|liraglutide 3mg 6/6 hours
65465|NCT03672799|Behavioral|Rehabilitation Planning Consult (RPC)|"Participants allocated to RPC will receive a 1 hour consultation with the Rehabilitation Consult and second consultation over the next 12 weeks as needed.~Participants will be assessed at three time points, 1) Baseline assessment, 1 week prior to RPC, 2) post-intervention assessment, 1 week after RPC, and 3) follow-up assessment, 13 weeks after RPC."
65466|NCT03672799|Other|Wait list control (WLC)|"Participants who are allocated to WLC will complete a 12 week waiting period. At the end of the waiting period, participants will crossover to the RPC group.~Participants will be assessed at four time points, 1) Baseline assessment, 1 week prior to waiting period, 2) post-waiting period assessment, 1 week after waiting period, 3) post-intervention assessment, 1 week after RPC, and 4) follow-up assessment,13 weeks after RPC."
65467|NCT03672786|Dietary Supplement|Multicentrum|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 2 months
65468|NCT03672773|Drug|Talazoparib|Given PO
65469|NCT03672773|Drug|Temozolomide|Given PO
65470|NCT03672760|Device|CardioBreathApp|Respiratory exercises performed with CardioBreathApp prescription and voice and visual guidance
65471|NCT03672760|Device|IMT PowerBreath|Inspiratory Muscle Training (IMT) performed with 30% load based on Maximal Inspiratory Pressure
65472|NCT03672760|Device|IMT PowerBreath Placebo|Inspiratory Muscle Training (IMT) without load
65473|NCT03672747|Device|transcranial direct-current stimulation (tDCS)|20 minutes duration using high-definition system with center-surround configuration
65474|NCT03672721|Drug|IA Carbo+ Radiation|combination of intraarterial carboplatin + radiation in dose escalation
65475|NCT03672708|Diagnostic Test|Cresyl violet|cresyl violet is applicated at the concentration of 0.15% via a spraying catheter to visualize cellular and tissue architecture in the pCLE
65476|NCT03672695|Combination Product|S 64315 (also referred as MIK665) and venetoclax|"The treatment combination period should start the day after the planned dose of venetoclax is reached. The initial schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.~S64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 1000 mg once a week might be explored.~Venetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy."
65477|NCT03672669|Genetic|Advanced Platelet Rich Fibrin (A-PRF)|blood samples collected in 10 ml of vacuumed plain glass tubes were centrifuged for 14 minutes at 1500 rpm without anticoagulant agents in order to obtain A-PRF
65478|NCT03672669|Genetic|Leukocyte- and platelet-rich fibrin (L-PRF)|blood samples collected in 10 ml of glass coated plastic tubes were centrifuged without anticoagulant agents for 10 minutes in order to obtain L-PRF
65479|NCT03672656|Device|lasercoagulation by Pascal system|pattern scanning laser system Pascal given in a single-session
65480|NCT03672656|Device|conventional laser|conventional laser multiple-session treatment
65481|NCT03672643|Drug|Crizotinib|receive crizotinib orally
65482|NCT03672630|Drug|Azithromycin|Azithromycin 500 MG Oral Tablet [ZITHROMAX]
65483|NCT03672630|Drug|Ethambutol|Ethambutol 25 mg/kg [MYAMBUTOL]
65484|NCT03672630|Drug|Rifampin|Rifampin 600 MG [RIFADIN]
65485|NCT03672617|Other|No treatment given|"No treatment is given to study participants. Only evaluation of a questionnaire assessing reasons for non-adherence to growth hormone therapy (GHT) and to determine its validity and reliability.~The preliminary working title of the questionnaire GHCQ used in the outcome measures was renamed for simplicity reasons into BAR-GHT (abbreviation for barriers to growth hormone therapy) after study completion."
65486|NCT03672604|Drug|NLY01|NLY01, a PEGylated form of the anti-diabetic peptide exenatide
65487|NCT03672591|Other|Renal clearance examination|Evaluation of renal hemodynamic parameters by constant-infusion input clearance technique with p-aminohippuric acid and Iohexol
65488|NCT03672578|Other|loss-frame|loss frame label
65489|NCT03672578|Other|gain-frame|gain frame label
65490|NCT03672578|Other|text-only|text-only label
65491|NCT03672578|Other|icon|label with icon and text
65492|NCT03672578|Other|attribution|label with attribution
65493|NCT03672578|Other|no attribution|label with no attribution
65494|NCT03672578|Other|No label|No label
65526|NCT03672344|Device|BioStream Training|Gaze-controlled video game that leverages ABA principles of learning to target social skills deficits in children with autism spectrum disorder.
65527|NCT03672344|Device|Alternative Game|Alternative Control Group Game
65495|NCT03672565|Behavioral|Phase One: Standardized Brief Intensive ERP|Participants will be randomized to receive ERP sessions at the hospital or at relevant community locations. In the introductory session, participants will be provided with psychoeducation about OCD and the treatment model, will develop a list of potential exposures, and will attempt initial exposure and response prevention (ERP) exercises. The session will end with an assignment of ERP homework. In the seven days following the introductory session, youth and parents will receive two 3-hour sessions, separated by a three day break. The sessions will begin with a brief review of homework completion and success. Following this, with parent observation, the clinician will guide the youth through escalating ERP exercises. The session will end with ERP homework planning. Other evidence-based treatment strategies (e.g., addressing motivation, discussing parental accommodations) may be implemented as deemed necessary by the clinician in order to encourage effective engagement in ERP exercises.
65496|NCT03672565|Behavioral|Phase Two: Flexible Patient Driven Intensive ERP|"Families will have the opportunity to access up to four additional once/week 3-hour intensive ERP sessions.~Three days prior to each additional ERP session (sessions 3-6), families will be prompted to fill out online forms and decide how to proceed with treatment for that week with the following options:~They may select that they would like to receive and complete the next ERP session, and up to four 3-hour ERP sessions during Phase Two. Completion of all four ERP session will automatically end Phase Two.~They may opt to delay receiving a treatment session by one week for any reason. Families will be allowed to take a week off up to two times during Phase Two. If both weeks off are utilized, at the next decision point families must either opt to complete an ERP Session or end their participation in Phase Two.~They may select to end their participation in Phase Two at any decision point and for any reason (e.g., don't perceive it as helpful, have improved substantially)."
65497|NCT03672565|Behavioral|Follow-Up Phase: Booster Calls|Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
65498|NCT03672552|Other|FFWP and Improved Oral Care|The FFWP with dental hygiene participants will have assessments for swallowing and oral health then proceed to have a dental hygienist cleaning. This intervention group will have supervised and assisted tooth brushing by nursing staff before taking plain (thin) unmodified water and between meals.
65499|NCT03672539|Drug|Gemtuzumab Ozogamicin|Given IV
65500|NCT03672539|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
65501|NCT03672539|Other|Quality-of-Life Assessment|Ancillary studies
65502|NCT03672526|Device|measure of injection pressure by compuflo|injection pressure mesured by Compuflo
65503|NCT03672513|Dietary Supplement|Placebo Comparator|Oral administration of 1 daily capsule containing lactose
65504|NCT03672513|Dietary Supplement|Zinc Supplement|Oral administration of 1 daily capsule containing 50 mg/day of Zn
65505|NCT03672513|Dietary Supplement|Magnesium supplement|Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
65506|NCT03672500|Drug|Bupivacaine 0.5%+Epinephrine 50mc|Local infiltration of the perineum with Bupivacaine 0.5%+Epinephrine 50mc
65507|NCT03672500|Drug|NaCl 0.9%|Local infiltration of the perineum with NaCl 0.9%
65508|NCT03672500|Other|Sham injection|Sham injection of the perineum
65509|NCT03672487|Drug|Benznidazole|Benznidazole tablet
65510|NCT03672487|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Benznidazole
65511|NCT03672474|Device|Photobiomodulation REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
65512|NCT03672474|Device|SHAM REGEnLIFE RGn530 device|For the photobiomodulation group the device is set up and not activated. REGEnLIFE RGn530 medical device will follow EC labelling if proven to be safe and effective
65513|NCT03672461|Other|Yoga Practice Program|The 3-month yoga intervention will provide instruction and practice in a variety of yoga postures and techniques that have been selected by the study yoga expert consultants for their potential to improve bladder control and safety and feasibility for the target population.
65514|NCT03672461|Other|Physical Conditioning Program|"The 3-month muscle stretching/strengthening intervention program (also referred to as the physical conditioning program) has been designed by the study physical therapist consultants."
65515|NCT03672448|Other|Naturalistic observation|Naturalistic observation
65516|NCT03672435|Drug|Topical Solution|proparacaine 0.5% eye drop
65517|NCT03672422|Diagnostic Test|Blood sample|Six ml of blood will be collected from patients in an EDTA tube. 2 ml saliva samples in Oragene DNA collection kits
65518|NCT03672422|Behavioral|Patient questionnaires|Questionnaires will be completed at the baseline and annual follow-up visits to collect data that will define the demographics of the pediatric ARP and CP cohort, describe risk factors, presence of family history of acute and chronic pancreatitis, diabetes and pancreatic cancer and assess disease burden and sequelae.
65519|NCT03672422|Diagnostic Test|Saliva sample|2 ml saliva samples in Oragene DNA collection kits collected if no blood sample being collected.
65520|NCT03672422|Diagnostic Test|Urine sample|50 ml of urine in collection container.
65521|NCT03672409|Behavioral|Intervention in knowledge|"The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes."
65522|NCT03672396|Behavioral|Home-based exercise|The intervention consists of aerobic and strength training ~3 times per week for 12 weeks with each session lasting 1 hour. The progressive aerobic exercise will involve walking that varies from from 15 to 30 minutes done 2-4 times per week at an intensity from 40% to 65% of heart rate reserve. Therabands elastic bands will be used to perform 12 to 15 repetitions per exercise. Once a participant can comfortably complete 15 repetitions for all prescribed sets, they will increase resistance by moving up to the next band. The training volume increased from 1 set per exercise on week 1 to 3 sets by week 12.
65705|NCT03670966|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplantation
65528|NCT03672331|Other|Mammogram|Every 1-4 years according to the national/regional guidelines or personalised schedule according to risk assessment
65529|NCT03672331|Other|Ultrasound|As required according to the national/regional guidelines or personalised schedule according to risk assessment
65530|NCT03672331|Other|MRI|As required according to the national/regional guidelines or personalised schedule according to risk assessment
65531|NCT03672331|Other|Tomosynthesis|As required according to the national/regional guidelines or personalised schedule according to risk assessment
65532|NCT03672318|Drug|CAR138 T Cells|"The MTD is defined as the dose at which approximately 0.20 of patients experience DLT dose escalation guided by the continual reassessment method (CRM).~Six dose levels will be evaluated:~Dose level 1: 5X10^6 cells/m^2 Dose level 2: 1X10^7 cells/m^2 Dose level 3: 2.5X10^7 cells/m^2 Dose level 4: 5X10^7 cells/m^2 Dose level 5: 1x10^8 cells/m^2 Dose level 6: 2x10^8 cells/m^2~Six patients will be enrolled at the MTD to better characterize safety at that dose level.~Cell Administration: CAR138 T cells will be given by intravenous injection over through either a peripheral or a central line.~The lymphodepletion regimen will consist of intravenous cyclophosphamide 300 mg/m^2 and fludarabine 30 mg/m^2 given once daily for three days."
65533|NCT03672305|Biological|c-Met/PD-L1 CAR-T cell injection|injection content:c-Met/PD-L1 CAR-T cell Infusion way:Steady intravenous drip in 15 to 30 minutes
65534|NCT03672292|Drug|SCY-078|Oral tablets of SCY-078
65535|NCT03672292|Drug|Voriconazole|Voriconazole IV vials or oral tablets
65536|NCT03672292|Other|Oral Placebo Tablets|Oral Placebo Tablets matching SCY-078
65537|NCT03672279|Diagnostic Test|CogCheck|Novel self-administered cognitive assessment tool
65538|NCT03672253|Drug|CAR-T Re-treatment|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) or use their mononuclear cells that preserved in the laboratory for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the re-treatment of CAR-T therapy by intravenous injection.
65539|NCT03672240|Drug|APL-1202|To assess the safety and pharmacokinetics of APL-1202 alone and in combination with Bacillus Calmette Guerin
65540|NCT03672227|Behavioral|Mealtime Matters Training|This training will address common issues that Head Start teachers including how to deal with picky eaters, in addition to education about the nutritional needs of pre-school aged children.
65541|NCT03672214|Procedure|Without placement of indwelling catheter|No placement of indwelling catheter prior to Caesarean section
65542|NCT03672214|Procedure|With placement of indwelling catheter|Placement of indwelling catheter prior to Caesarean section
65543|NCT03672201|Behavioral|Non-Pharmacological Intervention|The behavioural intervention will be a structured implementation of individualized activities to be followed and customized as per the needs of the participant.
65544|NCT03672201|Other|Pharmacological Intervention|The medication algorithm provides recommendations to the treatment team about algorithmic treatment and assessments as per the ICP but ultimately the decision to prescribe any particular intervention will be the treatment team's decision and the recommendations of the research team for ICP arm will not be binding for the treatment team.
65545|NCT03672188|Drug|VIR-2218|VIR-2218 given by subcutaneous injection
65546|NCT03672188|Drug|Placebo|Sterile normal saline (0.9% NaCl) given by subcutaneous injection
65547|NCT03672175|Drug|SAGE-217|Sage-217
65548|NCT03672175|Drug|Placebo|Placebo
65549|NCT03672162|Procedure|Total abdominal hysterectomy|Each drug group undergo elective total abdominal hysterectomy with the same general anesthesia
65550|NCT03672149|Drug|Cefazolin|Mixing cefazolin into the CRRT solution(s) for delivery as a continuous infusion
65551|NCT03672136|Drug|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
65552|NCT03672136|Other|Concurrent Chemoradiotherapy|Concurrent chemoradiotherapy as the current standard of care for unresectable stage III non small cell lung cancer patients
65553|NCT03672110|Drug|Advagraf|intervention: different advagraf dosing in the study compared to the control arm, see above
65554|NCT03672097|Drug|Prasugrel|Prasugrel, oral tablets, containing 3.75 mg per tablet
65555|NCT03672071|Other|Ephedrine, Noradrenaline ,ephedrine+Noradrenaline)|If a 20% decrease in any hemodynamic parameter compared to their baseline levels is sustained, necessary interventions will be performed. In the case of hypotension, for all groups
65556|NCT03672058|Behavioral|Fitness tracker with goal setting and text message feedback|Participants provided with a Fitbit and this will also be linked to Fitabase. The physiotherapist will discuss the participants' baseline physical activity levels and individual patient centred short and long-term goals will be set with each participant. Every week participants will be contacted via text message by their CF physiotherapist. The physiotherapist will review their online data and will provide feedback and encouragement on their progress. Goals will be reviewed for each participant.
65557|NCT03672058|Behavioral|Fitness Tracker only|"Participants will be provided with the Fitbit and educated on how to use it. This will be linked to Fitabase, an online monitoring system for data collection purposes, with the consent of the participants. However no goal setting will be completed and no feedback will be provided to the participants on their physical activity levels"
65558|NCT03672045|Drug|Carbetocin|carbetocin administered IV, over 1 minute following delivery of the fetal head
65559|NCT03672032|Device|SharkCore Needle|SharkCore Needle will be used to obtain biopsy
65560|NCT03672032|Device|Acquire Needle|Acquire Needle will be used to obtain biopsy
65561|NCT03672019|Behavioral|FACT-Hep|Patient Reported Outcomes (PRO) assessments at baseline and at three time points post-procedure: 4 weeks (+/- 1 weeks), 12 weeks (+/- 2 weeks), and 6 months (+/- 2 weeks).
65562|NCT03672006|Biological|alteplase (recombinant t-PA)|Medication administered to dwell in central venous catheter
65563|NCT03672006|Drug|Heparin|Medication administered to dwell in central venous catheter
65602|NCT03671720|Biological|personalized DC vaccine|personalized vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous tumor cells, administered intranodally on day 1,8,15, with a combination of oral cyclophosphamide (50mg) every day except the day of vaccine administrations.Cycles are repeated every 21 days. Treatment is continued until disease progression or exhaustion of vaccine supply, whichever comes first.
65706|NCT03670966|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
65564|NCT03671993|Procedure|Electrical pudendal nerve stimulation|Four sacrococcygeal points were selected. Two 0.40Х100 mm needles were inserted perpendicularly to a depth of 80-90 mm 1 cm bilateral to the sacrococcygeal joint, to produce a sensation referred to the root of the penis (perineum) or the anus. Two needles of 0.40Х100 or 125mm were inserted obliquely toward the ischiorectal fossa to a depth of 90 to 110 mm about 1 cm bilateral to the tip of the coccyx, to produce a sensation referred to the root of the penis (or the perineum). Each two ipsilaterally needles were connected to one electrode from a G6805-2Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China), with a frequency of 2.5 Hz and an intensity (45~55 mA). EPNS was given for 60 min a time, 3 sessions per week for 6 weeks.
65565|NCT03671993|Procedure|Intravesical instillation|The patient should lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine should be drained. A mixture of the Cystistat (sodium hyaluronate, 50ml 40mg, Bioniche Teoranta, Ireland) solution and Lidocaine hydrochloride (40mg :20ml, Fangming Pharmacy company, Shangdong, China) is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the mixture solution inside the bladder, retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at 6 weeks.
65566|NCT03671980|Other|My Medical record website|Website comprising patient records, blood and other test results, useful information on IBD, and messaging service to communicate with IBD team, plus home smartphone faecal calprotectin monitoring.
65567|NCT03671967|Drug|Piperacillin/tazobactam|4.5 grams QID
65568|NCT03671967|Drug|Meropenem|1 gram TID
65569|NCT03671954|Behavioral|Home Strengthening Exercises|The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
65570|NCT03671954|Other|Standard Physical Therapy|Physician determined standard of care for individual TKA patients.
65571|NCT03671954|Other|Preoperative Assessments|"Assessments will include:~TUG (timed up and go test) >12 sec indicates increased fall risk~Tandem balance test < 10 sec indicates increased fall risk~Sit to Stand test (age based norms)~Knee Range Of Motion (ROM)~Quadriceps and hamstring strength (MMT or hand held dynamometer)~Lower Extremity Functional Score (LEFS questionnaire)"
65572|NCT03671941|Drug|D578|D578 Tab.1T single oral administration under fasting condition
65573|NCT03671941|Drug|CKD-357|CKD-357 Tab.1T single oral administration under fasting condition
65574|NCT03671928|Other|additional blood tube|sampling of an additional tube at the usual blood test to determine the glicentin level
65575|NCT03671928|Other|additional blood sample|for le group control, another blood sample is taken outside the usual care.
65576|NCT03671915|Device|Continuous Glucose Monitoring|collection of glucose data
65577|NCT03671915|Device|External Insulin Pump|Insulin delivery
65578|NCT03671915|Device|Diabeloop Software (Model predictive control)|Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
65579|NCT03671915|Other|Remote monitoring (Telemedicine)|Remote follow up by care health providers team
65580|NCT03671902|Device|Fluid shift|We are using lower body negative and positive pressure to create a fluid shift in the body. This study is investigating if there are changes in phonocardiographic parameters related to changes in blood volume caused by this fluid shift
65581|NCT03671889|Device|Blood Brain Barrier (BBB) Disruption|Focal Ultrasound (FUS) involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct targets to induce BBB disruption.
65582|NCT03671876|Device|Intervention plus therapy|Task oriented exercise plan to improve mobility for stroke patients
65583|NCT03671863|Other|Invasive analysis (caryotype, CGH array)|Invasive analysis (caryotype, CGH array)
65584|NCT03671863|Other|Prenatal management|Prenatal management
65585|NCT03671850|Biological|VT-EBV-N|Epstein-barr virus human cytotoxic T lymphocytes (EBV-CTL)
65586|NCT03671850|Other|Placebo|Peripheral blood mononuclear cell, PBMC
65587|NCT03671837|Other|Oxygen|15 L/min O2
65588|NCT03671837|Other|Air|15 L/min air
65589|NCT03671824|Other|Measurements|Physiologic measurements including but not limited to thyromental distance, sternomental distance, Mallampati score, mouth opening, interincisor distance, and mandibular protrusion will be measured and recorded. All measurements are non invasive.
65590|NCT03671811|Drug|Megestrol|Given PO
65591|NCT03671811|Drug|Megestrol Acetate|Given PO
65592|NCT03671811|Biological|Pterostilbene|Given PO
65593|NCT03671785|Drug|PRIM-DJ2727|Twice filtered fecal microbiota product from three screened healthy donors will be lyophilized and encapsulated in enteric-coated capsules. Each dose of enteric coated capsules consists of 60 grams of stool and will be administered orally twice-weekly for 12 consecutive weeks
65594|NCT03671785|Drug|Placebo oral capsule|Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria. The placebo will consist of Lactose (spray-dried United States Pharmacopeia (USP) 64.385gm), food color, powdered Black, Brown, and Yellow in the enteric capsules. Placebo will be administered orally twice-weekly for 12 consecutive weeks
65595|NCT03671759|Behavioral|Start: On Caffeine|In this two-day block, participants will be instructed to consume caffeine for one day and avoid caffeine the next day.
65596|NCT03671759|Behavioral|Start: Off Caffeine|In this two-day block, participants will be instructed to avoid caffeine for one day and consume caffeine the next day.
65597|NCT03671746|Drug|Ketorolac|Participants will receive Ketorolac at 30 mg IV every 6 hours for their first 5 days of hospitalization
65598|NCT03671746|Drug|Saline Solution|Participants will receive 10 ml of saline solution IV every 6 hours for their first 5 days of hospitalization
65599|NCT03671733|Drug|Liraglutide|The treatment of Liraglutide lasted three months,During the first week: 0.6mg per day, subcutaneous injection;During the second week: 1.2mg per day, subcutaneous injection; From third week onwards, 1.8mg per day, subcutaneous injection.
65600|NCT03671733|Drug|Exenatide|10mcg once a day for 4 weeks increased to 10mcg twice a day for 8 weeks.
65601|NCT03671733|Drug|Exenatide Microspheres for Injection|Exenatide 2 mg injection once weekly for 12 weeks.
65603|NCT03671707|Behavioral|Brief AWARD advice|"Subject will receive brief, face-to-face counselling following a structured AWARD model at baseline :~Ask: smokers will be asked about their smoking behaviour~Warn about the harms of smoking using a leaflet which contain information about harms of secondhand smoke to women, fetus and infant, motivational messages to quit and smoking cessation services.~Advise to quit or reduce their smoking and use the provided 1-week nicotine replace therapy sample as soon as possible~Refer smokers to smoking cessation services if they agree.~Do-it-again: repeat the AWARD advise through telephone boosters at 2-week and 4-week after baseline"
65604|NCT03671707|Drug|Nicotine replacement therapy sampling|Subjects will receive 1-week supply of free nicotine patch or gum with dosage based on participants' number of cigarette per day. An information card containing reminders of nicotine replacement therapy use and actions to handle potential side effects will be provided.
65605|NCT03671707|Behavioral|Active referral|Subjects will be encouraged to select and access a smoking cessation services in Hong Kong. If the subjects agree, their contact information will be sent to the smoking cessation service providers for further arrangement.
65606|NCT03671707|Behavioral|Very brief advice|Subjects will receive general advice to quit
65607|NCT03671707|Behavioral|Leaflet|Subjects will receive a standard leaflet on perinatal smoking by Department of Health
65608|NCT03671694|Procedure|Erbium-YAG laser vaginal treatment|Erbium-YAG laser vaginal treatment
65609|NCT03671681|Behavioral|Mindfulness|The experimental group will receive education, will be prescribed prophylaxis and will attend Mindfulness-based therapy sessions. The MINDFULNESS therapy consists in 6 weekly sessions, 45 minutes each. The main focus of the six mindfulness session will be the following: 1) introduction and meaning; 2) Focus on breath; 3) posture and body awareness; 4) meditation of sounds; 5) Guided imagery; 6) acceptance and awareness. During training, patients will be invited to close their eyes, assume a relaxed position, focus on their breathing and on the present to enhance awareness of current mind and body sensations. Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions.
65610|NCT03671681|Drug|Prophylactic|Control group will receive education on the use of pharmacological compounds for acute treatment and on healthy lifestyle habits (e.g. adequate sleep/wake pattern, eating and hydration, physical activity, avoidance of triggers) and will be prescribed prophylactic medications. The preventive compound will be chosen on the basis of clinical profile among the following categories: neuromodulators (e.g. topiramate or valproate), antidepressant (e.g. tricyclics or SSRIs) or others, e.g. beta-blockers.
65611|NCT03671668|Other|titanium bases using intra oral luting cement technique|comparing between screw retained prosthesis constructed on transmucosal abutments versus titanium bases in terms of crestal bone loss and patient satisfaction
65612|NCT03671655|Device|Drug-eluting stent|Drug eluting stent which are nitinol stent coated with Paclitaxel drug
65613|NCT03671655|Device|Bare metal stent|Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
65614|NCT03671642|Device|Q-ICG|Quantitative perfusion assessment with indocyanine green on a touch screen tablet
65615|NCT03671642|Procedure|White light perfusion assessment|Traditional visual perfusion assessment in white light
65616|NCT03671642|Procedure|Fluorescence angiography|Perfusion assessment with fluorescence angiography - without quantification
65617|NCT03671629|Other|Enhanced clinical pharmacist service|The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician.
65618|NCT03671616|Biological|IPV-Al SSI|IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral of the right thigh. A single dose of the IPV-Al SSI will be given to infants age 15-18 months.
65619|NCT03671603|Drug|Iodixanol|Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
65620|NCT03671590|Drug|TG-1701|Oral daily dose
65621|NCT03671590|Drug|Umbralisib|Oral Daily Dose
65622|NCT03671590|Biological|Ublituximab|Ublituximab at a fixed IV infusion on specific Days, followed by maintenance infusions
65623|NCT03671577|Behavioral|Building Closer Friendships|Intervention designed to build social support and reduce loneliness by giving participants skills to strengthen their relationships
65624|NCT03671564|Drug|Milademetan|Milademetan, an MDM2 inhibitor, is provided in capsules for oral administration
65625|NCT03671538|Drug|Anlotinib|Anlotinib 12mg qd on day 1 to 14 of a 21-day cycle
65626|NCT03671538|Drug|pemetrexed|pemetrexed 500mg/m2 on day 1 of a 21-day cycle ;
65627|NCT03671538|Drug|Cisplatin|Cisplatin 75mg/m2 on day 1 of a 21-day cycle ;
65628|NCT03671525|Drug|Nimodipine|Subject will receive two 30mg capsules of nimodipine during study visit.
65629|NCT03671525|Drug|Placebo oral capsule|Two coconut oil capsules that mimic the size and color of the nimodipine capsules
65630|NCT03671512|Device|Periodontal Structure Repair (PSR)|Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.
65631|NCT03671512|Device|Standard Root Planing|Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
65633|NCT03671473|Device|Extracorporeal shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis.
65704|NCT03670966|Radiation|Total-Body Irradiation|Undergo TBI
65634|NCT03671460|Biological|CD19 CAR-T cells|T cells purified from the PBMC of subjects, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
65635|NCT03671447|Other|ICU Usual Care|The control condition delivered at ICU is usual care.
65636|NCT03671447|Behavioral|Tele-ICU|The experimental complex intervention ERIC consists of daily tele-medicine based rounds at ICU. Tele-ICU is implemented after a blended learning program for ICU staff which will be completed prior to the site's crossover.
65637|NCT03671434|Behavioral|Research-to-Policy Collaboration|The RPC is a behavioral intervention through which RPC Researchers and RPC Congressional Offices are prepared and matched for collaboration. Specifically, congressional offices are asked to identify opportunities for researcher engagement in policy efforts, researchers with expertise related to policy opportunities are identified and prepared to collaborate with congressional offices, researchers and congressional staff are matched for ongoing collaborative partnerships, and both researchers and congressional staff receive ongoing support to facilitate research translation.
65638|NCT03671434|Behavioral|Light Touch Policy Training|Control Researchers are provided information on policy engagement via email.
65639|NCT03671421|Procedure|ACL reconstruction - graft choice|Use of 3 different ipsilateral autograft options
65640|NCT03671408|Other|clinical measurements|only clinical parameters were recorded
65641|NCT03671382|Behavioral|Communication Training Program and Patient Prompt Sheet|The intervention being delivered is a two-component intervent. First component is the Oncologist Communication Skills Training Program. This is an e-learning module teaching oncologists to recognize and respond to patient/caregiver distress, provide information including prognosis and discuss goals of care. The second component is a patient prompt sheet which will be administered to three patients of intervention arm oncologists in the waiting area at least 30 minutes before their consultation. The sheet includes structured questions for patients to ask the oncologist about diagnosis and prognosis and will prompt patients to label and express their emotions in a direct manner.
65642|NCT03671369|Other|Safety data collection (following routine vaccination) by a continuous surveillance method.|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine in terms of frequency and intensity of adverse events (AEs) and serious adverse events (SAEs) when administered routinely in male and female subjects aged between 9 and 25 years, according to the approved Prescribing Information in Korea.~All AEs reported during the 30-day post-vaccination follow-up period (Day 1 to Day 30) and all SAEs reported through the study period from dose 1 up to 30 days after the last dose administered during the post-marketing surveillance (PMS) will be collected as part of safety data in this PMS."
65643|NCT03671356|Other|risk score|risk score
65644|NCT03671343|Behavioral|Physical rehabilitation|It will benefit from an initial and final geriatric assessment, an initial dietary balance and a personalized treatment in physical activities adapted for 3 months by an Educator in Adapted Physical Activities.
65645|NCT03671330|Drug|Ribociclib Placebo|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
65646|NCT03671330|Drug|Ribociclib|Film-coated tablets for oral use (200 mg x 3) form Day 1 of 21 of each 28 day cycle.
65647|NCT03671330|Drug|NSAI: Letrozole or Anastrazole|"Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).~Anastrazole: Tablets for oral use, 1mg daily (all days of every cycle without interruption) For Premenopausal cohort, it is the investigators choice for NSAI based on patients past history.~For postmenopausal and PK cohorts, all patients will be on Letrozole."
65648|NCT03671330|Drug|Letrozole|Letrozole: Tablets for oral use, 2.5mg daily (all days of every cycle without interruption).
65649|NCT03671330|Drug|Goserelin|Subcutaneous implant, 3.6mg on Day 1 of each 28 day cycle
65650|NCT03671317|Behavioral|Medical Clowning|This arm will receive a medical clowning intervention in addition to pre and post surveys about the blood draw process.
65651|NCT03671304|Device|Fitbit Versa|"Participants will receive a Fitbit Versa and instructions on its use. Participants will be asked to wear the device for eight weeks, removing it only for charging and when engaging in activities in which the device could be submerged in water (bathing, swimming, etc.).~At enrollment, participants will indicate a preferred time to receive affective framing messages and EMA prompts (morning), and intention planning prompts (evenings). Participants will receive affective framing messages and intention planning prompts on a randomized schedule, such that participants will receive each message type on 50% of days."
65652|NCT03671291|Behavioral|self-administrated questionnaire|Persons who the biological parameters or past screening show that they were recently infected with HIV cf. eligibility criteria, will, after obtaining his consent, answer a series of questions through a self-administrated questionnaire that will take approximately 40 minutes.
65653|NCT03671278|Other|STarT Back Screening Tool Approach|Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
65654|NCT03671265|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
65655|NCT03671265|Radiation|IMRT or VMAT|The IMRT or VMAT technique was used in our study.
65656|NCT03671265|Drug|Apatinib|Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
65657|NCT03671252|Drug|FOLFOXIRI|Irinotecan165 mg/m2、Oxaliplatin85 mg/m2、Left-calcium leucovorin 200mg/㎡，Intravenous infusion，first day. Then, 5-FU 1600 mg/m2/d×2 continuous intravenous infusion（total 3200 mg/m2，infusion 46 hours）in the next two days. Repeat every 14 days.
65658|NCT03671252|Drug|XELOX|XELOX consisting of 130 mg/m2 oxaliplatin administered intravenously on day 1 and 1,000 mg/m2 capecitabine administered orally twice daily on days 1-14 for a 3-week cycle.
65659|NCT03671252|Other|Chemoradiotherapy|"Chemotherapy: oral capecitabine（1650 mg/m2）twice daily during radiotherapy without weekend breaks.~Radiation: Radiation therapy is administered via intensity-modulated radiation therapy (IMRT) with a linear accelerator, 6MV-X ray. The patients are scheduled to receive a GTV expanding 6mm to form PTV1 and CTV expanding 6mm to form PTV2. The dose of PTV1 is 50Gy/25 times for 35 days and the dose of PTV2 is 45Gy/25 times for 35 days. Patients were treated in consecutive days per week for a total of 5 weeks."
65660|NCT03671252|Procedure|TME operation|TME operation
65707|NCT03670966|Drug|Tacrolimus|Given IV or PO
65661|NCT03671252|Procedure|efficacy evaluation|chest/ abdominal CT、pelvic nuclear magnetic resonanceimaging、transrectal ultrasonography
65662|NCT03671239|Behavioral|Placebo rectal insert|Participants will be instructed to insert in the rectum a placebo insert prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
65663|NCT03671239|Behavioral|Placebo rectal suppository|Participants will be instructed to insert in the rectum a placebo suppository prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
65664|NCT03671239|Behavioral|Placebo rectal douche|Participants will be instructed to insert in the rectum a placebo douche (enema bottle with approximately 120 mL of clean tap water or bottled water) prior to RAI. If a dose is missed, participants will be instructed to wait to take a dose at the next occurrence of RAI, or if no other RAI activity occurs in that 7-day period, to take a dose in the absence of RAI. Furthermore, if no RAI activity occurs at all in a given 7-day period, participants will be instructed to take a dose on the seventh day in the absence of RAI.
65665|NCT03671226|Other|Questionnaire Administration|Given questionnaire
65666|NCT03671213|Device|Calypso Knee System|The Calypso Knee System is an extra-capsular knee implant designed to fill the therapeutic gap between conservative care and more invasive surgical interventions for knee osteoarthritis.
65667|NCT03671187|Other|Exercise|8 week exercise program
65668|NCT03671174|Drug|Prednisone|10mg once daily orally
65669|NCT03671174|Drug|Hydroxychloroquine|100mg to 200mg twice daily orally
65670|NCT03671174|Drug|Aspirin|50mg once daily orally
65671|NCT03671174|Drug|low molecular weight heparin|Enoxaparin 40mg once daily subcutaneous or dalteparin 5000IU once daily subcutaneous or nadroparin calcium 4100U once daily subcutaneous
65672|NCT03671161|Device|Insulin Pump and flash glucose monitoring|Adults with type 1 diabetes, HbA1c >9% (75 mmol/mol), multi daily insulin injections ( MDI) and who perform less than 2 SMBG /day. Patients will be switched to insulin pump and start a FGM system (Free Style Libre®) during 6 months.
65673|NCT03671148|Biological|placebo for rizankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
65674|NCT03671148|Biological|risankizumab|Risankizumab administered by subcutaneous (SC) injection
65675|NCT03671135|Other|TCA Intrastromal Inlay|Anterior surface of Bowmans Layer Corneal Optical Correction Inlay
65676|NCT03671122|Diagnostic Test|Cardiac imaging in the PREFERS and CABG PREFERS cohorts|performed at baseline and after 1 year
65677|NCT03671122|Other|Biomarker analysis in the PREFERS and CABG PREFERS chorts|blood samples will be taken for biomarker analysis at baseline and after 1 year
65678|NCT03671122|Procedure|Cardiac biopsies in the CABG PREFERS cohort|myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG
65679|NCT03671109|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-DHA-PPQ under supervision
65680|NCT03671109|Drug|Placebo Oral Tablet|Following physical examination, recruited women with more than 13 weeks of gestational age will receive IPTp-Placebo under supervision
65681|NCT03671096|Other|Intrastromal TCA Inlay|An intrastromal inlay that will be provided to correct the required hyperopic correction
65682|NCT03671083|Device|BrainScope Ahead 300iP|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT5), Electrophysiological Function; Neurocognitive Performance Assessment, Ocular Motor Assessment. BrainScope Ahead 300iP will be used to perform EEG and Cognitive assessments.
65683|NCT03671070|Drug|Epinephrine|IV Low dose Boluses
65684|NCT03671070|Drug|Traditional management of shock|"Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency."
65685|NCT03671057|Device|HospiAvontuur|To be included in the study children should play the game at least one time together with one parent
65686|NCT03671057|Drug|Midazolam|current practice in Jessa
65687|NCT03671044|Drug|Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
65688|NCT03671044|Drug|Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Each vial containing lyophilized Docetaxel lipid powder, equivalent to 20 mg or 80 mg of anhydrous Docetaxel.
65689|NCT03671044|Drug|Taxotere® (100 mg/m2)|Docetaxel Injection Concentrate; 20 mg/0.5 mL
65690|NCT03671031|Procedure|isolated roux loop|Isolated roux loop reconstruction following pancreaticoduodenectomy
65691|NCT03671031|Procedure|single loop|Conventional single loop reconstruction following pancreaticoduodenectomy
65697|NCT03671005|Behavioral|Mindfulness-based group therapy|see above
65698|NCT03671005|Other|Treatment as usual|see above
65699|NCT03670992|Procedure|duodenal-pancreatectomy|surgical removal of metastatic repetitions in pancreas and/or other distal sites
65700|NCT03670979|Procedure|bone swaging|osseous wall pedicle was placed to treat the infrabony defect by autogrnous bone
65701|NCT03670966|Biological|Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10|Given via infusion
65702|NCT03670966|Drug|Fludarabine|Given IV
65703|NCT03670966|Drug|Cyclophosphamide|Given IV
65710|NCT03670966|Biological|Granulocyte Colony-Stimulating Factor|Given IV or SC
65711|NCT03670953|Drug|IR CD-LD|Active comparator - IR CD-LD
65712|NCT03670953|Drug|IPX203 ER CD-LD|Investigational formulation - ER CD-LD
65713|NCT03670953|Other|IPX203 placebo|Double dummy placebo capsules
65714|NCT03670953|Other|IR CD-LD placebo|Double dummy placebo tablets
65715|NCT03670927|Other|Environmental, occupational and lifestyle-related exposures|A standardized questionnaire will be administered by a trained interviewer in order to gather information about occupational and residential history, demographic and socioeconomic characteristics and lifestyle factors. At the end of the interview, a saliva sample will be systematically proposed
65716|NCT03670914|Diagnostic Test|WatchPAT 200|The WatchPAT200 device has been approved by the Food and Drug Administration (FDA) for testing sleep related disorders in patients ages 17 and older. They are widely used with thousands of studies performed in the United States to validate the devices accuracy and efficacy. It is also routinely used in many other countries. The devices are not currently being used for patients who are currently taking narcotic medications at Kaiser Permanente. Therefore, we are asking patients to simultaneously wear this device during an in-lab study, so we can test how effective and accurate the WatchPAT 200 is in diagnosing sleep breathing disorders in patients on narcotic medications.
65717|NCT03670901|Biological|JHL1101|JHL1101, 100mg/10mL
65718|NCT03670901|Biological|MabThera|Rituximab, 100mg/10mL
65719|NCT03670888|Biological|JHL1101|100 mg/10 mL solution in a single-use vial
65720|NCT03670888|Biological|Rituximab|100 mg/10 mL solution in a single-use vial
65721|NCT03670875|Dietary Supplement|Agave inulin|Will be provided in dehydrated apple cubes
65722|NCT03670875|Dietary Supplement|Curcumin|Will be provided in capsules
65723|NCT03670875|Dietary Supplement|O3FA|Will be provided in capsules
65724|NCT03670875|Behavioral|Control|Dietary recommendations to ingest 1600 calories per day. Exercise: 30 minutes each day, al least 5 days a week (caloric consumption 150-200 kcal per day)
65725|NCT03670862|Other|CT|No enhancement computed tomography , computed tomography angiography, computed tomography perfusion imaging
65726|NCT03670849|Device|LapAR|LapAR system will be used for visualization of anatomy prior to surgery starts
65727|NCT03670836|Device|Dilapan|Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter. It is FDA approved for cervical ripening.
65728|NCT03670836|Drug|Misoprostol|"25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses)~Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose."
65729|NCT03670823|Device|SIEMENS PRISMA MRI|Collect data on brain activation from different methods
65730|NCT03670810|Drug|Lasmiditan|Administered orally.
65731|NCT03670810|Drug|Placebo|Administered orally.
65732|NCT03670784|Other|No intervention|No intervention, epidemiological investigation
65733|NCT03670771|Diagnostic Test|Harrahill method for measuring of intraabdominal pressure|IAP obtained by using patient own urine as the transducing medium. One clamps the Foley catheter just above the urine collection bag. The tubing is then held at a position of 30-40 cm above the symphysis pubis and the clamp is released. The IAP is indicated by the height (in cm) of the urine column from the pubic bone. The meniscus should show respiratory variations.
65734|NCT03670758|Diagnostic Test|Protein S activity|Intravenous blood sample
65735|NCT03670745|Behavioral|An electronic self-administered pre-visit planning tool.|An electronic self-administered pre-visit planning tool allowing adolescents to list areas of concern to support shared decision-making during an office visit.
65736|NCT03670745|Behavioral|Control group|No planning tool
65737|NCT03670732|Other|continuous positive airway pressure|Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
65738|NCT03670732|Other|nasal intermittent positive pressure ventilation|NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
65739|NCT03670719|Other|Manual Therapy and Exercise|Combination of physiotherapy (manual therapy) techniques and exercises for the cervical spine
65740|NCT03670719|Other|Exercise|Exercises for the cervical spine
65741|NCT03670706|Behavioral|Exercise|Package of care
65742|NCT03670706|Other|analgesic optimisation|optimisation
65743|NCT03670693|Diagnostic Test|Muscle strength and fatigue assessment|Measurement of maximum voluntary isometric contraction of the quadricep muscle on a cybex isokinetic dynomometer. This will be followed by a fatigue assessment where the torque decrement over 20 isokinetic knee extensions at a fixed angular velocity will be quantified to assess muscle fatigue
65744|NCT03670693|Diagnostic Test|Dual-energy X-ray absorptiometry (DEXA scan)|Body composition will be assessed via DEXA scan (Lunar Prodigy, GE Medical Systems, Bucks, UK)
65745|NCT03670693|Diagnostic Test|Supine cardiorespiratory fitness assessment|VO2 peak will be quantified during completion of a continuous, incremental exercise test performed in the supine position on an MR adapted stepper machine (Ergospect, Innsbruck Austria)
65746|NCT03670693|Diagnostic Test|fMRI Exercise assessment|Measurement of cardiac output and, cerebral and regional perfusion using Blood-Oxygen-level-dependent (BOLD) measures and arterial spin-labelling (ASL)-MRI as well as fractional oxygen extraction using TRUST-MRI during supine exercise of the quadriceps with the MR compatible cardiostepper (Ergospect, Innsbruck, Austria) at 50% of relative VO2 peak as measured during the supine cardiorespiratory fitness assessment.
65747|NCT03670693|Diagnostic Test|Muscle deconditioning assessment|Limb blood flow will be occluded with a cuff, whilst participants perform repeated plantar flexion exercise in a MRI scanner. This will drive PCr, (the available reserve of ATP) to zero. Once the cuff is removed, they will undergo non-invasive and well-established in vivo 31P magnetic resonance (31P MRS) measurements on the gastrocnemius to determine PCr re-synthesis rate during resting recovery.
65748|NCT03670680|Device|Use of the Lina LibrataTM|Use of the Lina LibrataTM
65749|NCT03670667|Other|Non-Interventional|Non-Interventional
65750|NCT03670667|Other|Non-Interventional|Non-Interventional
65752|NCT03670654|Other|Pilates|The Pilates exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. The first two weeks will be spent learning the technique and, in the third week, patients will receive an exercise booklet for in-home training. Will be used the classical solo Pilates exercises, adapted for non-trained individuals. Before and after each session, patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
65753|NCT03670654|Other|Muscle stretching|The muscle stretching exercises will be performed in 12 weeks with 40-minute sessions, three times a week: 2 at ambulatory and 1 at home. Ambulatory sessions will be supervised by a physical therapist in non-consecutive days. Patients could be grouped in classes with a maximum of 4 subjects. Patients will practice muscle stretching exercises for principal muscle groups, performed with 3 repetitions, 15 seconds sustain and 1 minute interval. Before and after each session, the patients will be evaluated in relation to expiratory peak flow, blood pressure, heart rate and asthma symptoms.
65754|NCT03670641|Drug|Glargine|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
65755|NCT03670641|Drug|Lispro|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
65756|NCT03670641|Device|Dexcom G6|Dexcom G6 CGM will be used to guide daily insulin glargine and lispro dose titrations in participants with newly diagnosed type 2 diabetes. After 4 weeks of CGM and insulin therapy, insulin will be discontinued and participant's labs monitored every 3 months to determine if diabetes remission achieved.
65757|NCT03670628|Device|Shockwave therapy|This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic ED patients. The patients are randomized in a 2:1 ratio of active to sham treatment groups. Patients randomized to the treatment group will be instructed to stop any use of PDE5i for 4 weeks prior to first treatment session and refrain from using any other ED therapy option during the study. They will be instructed to undergo a PDE5i washout period of 4 weeks prior to treatment. After the washout period and before the first treatment session, patients will answer the IIEF-EF, SEP and EHS questionnaires for baseline evaluation. Penile Doppler ultrasound will be performed by the time of enrollment, at 1,3, 6, 9 and 12 months and after treatment.
65758|NCT03670615|Other|tDCS|All study participants randomized to tDCS will receive active tDCS.
65759|NCT03670615|Other|Exercise|Participants will exercise at TRI according to an individualized exercise prescription.
65760|NCT03670615|Other|Exercise Education|Exercise education/ treatment as usual will include routine advice about physical activity for older adults.
65761|NCT03670615|Other|Sham tDCS|The same procedure for tDCS will be used for the sham condition, except without active current.
65762|NCT03670602|Behavioral|Episodic Future Thinking (EFT)|Participants will practice using these cues when making decisions about health choices. Participants will implement EFT while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
65763|NCT03670602|Behavioral|Control Thinking|Participants may see non-future cues that do not require prospection while using The Traffic Light Diet, The Traffic Light Activity Program, and a variety of behavioral techniques including stimulus control, self-monitoring, goal setting, problem solving, resetting rewarding mechanisms by reducing need for immediate gratification, finding behavioral substitutes for highly reinforcing food.
65764|NCT03670589|Radiation|Radiosurgery gammaknife|This procedure use intense gamma ray, which are concentrated to the precise volume of the tumor that used to stop the progression of the tumor
65765|NCT03670589|Procedure|Microsurgery resection|Classical surgical approach with oto-neurosurgery procedures
65766|NCT03670576|Procedure|Optional Bronchoscopy|Patients can decide to have an optional bronchoscopy so that samples can be taken for research up to three months from baseline.
65767|NCT03670576|Other|Quality of Life Questionnaires|MRC Dyspnoea, SPARC, KBILD and EQ-5D-5L will be administered at baseline, 3 months, 12 months and 24 months,
65768|NCT03670576|Other|Blood Samples for Biomarkers|a 40ml research blood sample to be taken at baseline, 3 months, 12 months and 24 months.
65769|NCT03670576|Other|Home Hand Held Spirometry|Patients possessing a smart phone can download an app and are given a small hand held device to record their own spirometry at home. This is for the first three months on study. this is optional.
65770|NCT03670563|Other|Short foot exercise protocol|Exercises that target intrinsic foot muscles
65771|NCT03670563|Other|Short foot exercise plus NMES|Exercises that target intrinsic foot muscles supplemented by NMES for muscle re-education
65772|NCT03670550|Device|Ossur Rebound ACL Brace|ACL-reconstruction patients will be issued an Ossur Rebound ACL Brace at the time of enrollment in the study, prior to surgery. They will use this brace throughout their rehab and physical therapy. The intervention (brace) will be applied only to the surgical limb.
65773|NCT03670537|Diagnostic Test|Iron parameters|Serum iron, total iron binding capacity, TSAT (Fe/TIBC), serum ferritin
65774|NCT03670524|Other|Greenness as a therapeutic intervention|Greenness to be used as a therapeutic intervention
65775|NCT03670511|Other|sit-to-stand test|to sit and stand from a chair
65776|NCT03670511|Other|six minute walking test|to walk for six minutes
65777|NCT03670498|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
65778|NCT03670498|Device|2 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
65779|NCT03670485|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
65780|NCT03670472|Other|smear of nasal fossae|1 smear of nasal fossae during a usual or scheduled visit
65781|NCT03670459|Other|Cawthorne Cooksey exercises|Eye movements and head movements
112589|NCT03306212|Other|Intermittent serial casting|
65782|NCT03670459|Other|Vestibular habituation exercises|Move from a sitting position to flat on the back
65783|NCT03670459|Other|Balance exercises|Weight Shift Forward and Back
65784|NCT03670446|Other|Pharmacists' intervention|"Medication education: When the patient is enrolled in the intervention group, pharmacists issue an education manual to give a medical education which contains the reasons for using NOACs, the characteristics of the drug, the precautions, and how to monitor the efficacy. Pharmacists re-educate through telephone or clinic during follow-up.~Establish a medical record and remind their follow-up by message, phone every 2 weeks.~Follow-up in the 4th week and 8th week : Pharmacists recommend patients for drug therapy optimization after conducting a full pharmacotherapy review of each patient's medication regimen and remind them to test urinary occult blood every 1-3 months, detect hemoglobin and liver/kidney function every 3-6 months."
65785|NCT03670433|Other|Cost analysis of medication reconciliation|"The MR at entry is performed by the pharmaceutical team as soon as possible after admission. The sequences of the medical conciliation are attributed to the health professionals according to the recommendations of the French National Authority for Health (HAS).~The MR at the discharge is carried out in collaboration between the pharmaceutical and medical teams. It associates the patient through pharmaceutical interview and relies on the sharing of informations related to the patient's medical treatments. These informations are synthesized in an output conciliation sheet transmitted in real time by secure messaging to the attending physician and the dispensing pharmacist. In parallel, the liaison letter and the patient discharge order are generated in order to guarantee a perfect homogeneity between all the documents transmitted at the patient's exit. MR sequences are attributed to health professionals according to the recommendations of the HAS."
65786|NCT03670420|Other|Medical honey|The investigators use Medihoney®, a medical honey released by the DermaSciences.
65787|NCT03670407|Procedure|Ovarian tissue fragmentation|Unilateral ovariectomy, ovarian tissue in vitro fragmentation and reimplantation.
65788|NCT03670394|Diagnostic Test|Capillary Refill|We are measuring capillary refill to assess it's correlation with dehydration in children
65789|NCT03670381|Other|Psychiatric diagnosis|
65790|NCT03670368|Behavioral|Mentoring|The intervention will include one-on-one mentoring sessions held after school, focusing on coping, social relationships, and healthy lifestyles.
65791|NCT03670368|Behavioral|Comparison group - written materials|Written materials from the mentoring sessions will be provided to those in the comparison group
65792|NCT03670355|Drug|Tenofovir (TFV) IVR|Contains 1.4 g TFV
65793|NCT03670355|Drug|Placebo IVR|Contains placebo
65794|NCT03670329|Device|URGO2875|Dressing
65795|NCT03670316|Drug|Algorithm Treatment|Varenicline was selected as the first line of treatment for patients willing to take a medication twice per day and wanting cessation. Following varenicline, bupropion and then NRT are subsequent options. In terms of preference for NRT, nicotine patches would be the first option followed by lozenge, gum, inhaler, and nasal spray. The order of NRT within the algorithm is based upon patient familiarity and number of clinical trials supporting their use. Combination NRT (e.g., patch and lozenge) or adding NRT to varenicline or bupropion is offered to participants who have made an unsuccessful quit attempt with these medications in the past. If none of these medications are appropriate, then the participant is offered counseling only.
65796|NCT03670316|Other|Quitline only|eTAU participants will complete the same algorithm questions but will not have this information sent to their provider, although their provider may elect to prescribe medication as part of standard of care. Participants will be referred to a quitline for behavioral support services for cessation.
65797|NCT03670303|Behavioral|Educational intervention|"Educational intervention will be given by trained optometrists to participants (requiring spectacles) their parents and teachers. Duration of Intervention will be about one hours and it includes:~Lectures on importance of spectacles use including visual materials such as pictures and videos.~An interactive classroom based demonstration carried out by trained optometrist. Children will be asked to read from blackboard, written to be visible with 6/6 vision, while seated at a distance of 6m. After this children will be given their glasses and asked to read again. The purpose of this demonstration is to make children aware of their poor vision and of the potential impact of corrected VA.~Posters~Brochures"
65798|NCT03670290|Procedure|Fascia iliaca compartment catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 30 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
65799|NCT03670290|Procedure|epidural catheter|Patient will evaluate and if VAS score >3, catheter will be inserted and 10 ml bupivacaine 0.25% will be applied after admission. Dose will be repeated VAS>3 or patient enounce pain.
65800|NCT03670290|Procedure|patient controlled analgesia|Patient will evaluate and if VAS score >3, patient controlled analgesia pump will be set 1mg morphine/15 min lockout.
65801|NCT03670264|Behavioral|Quitline Incentive|The incentive structure emphasizes engaging with the quitline, with an additional smaller payment for tobacco cessation. Each adolescent can receive compensation for enrolling in the quitline, for maintaining involvement in the quitline program (compensation per call for up to 5 calls), and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
65802|NCT03670264|Behavioral|Tobacco Cessation Incentive|The incentive payment structure emphasizes quitting regardless of engagement with the quitline (though the quitline will be presented as a helpful tool). Each adolescent will receive compensation for enrolling in the Quitline and, for those reporting abstinence, for submitting the cotinine swab and for confirmed quitting (negative cotinine swab).
65803|NCT03670264|Behavioral|Way to Health (WTH) Platform|The WTH platform is a web-based platform that sends reminder text messages to participants regarding study procedures and has has secure financial tracking and processing systems to manage participant payments, including the ability to track earnings and pay participants via a non-integrated payment system.
65804|NCT03670264|Behavioral|Quitline Delivered Treatment|The quitline provides tobacco cessation treatment to individuals who enroll in treatment. This treatment includes 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between proactive calls.
65805|NCT03670251|Procedure|Blood sampling|Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick
65836|NCT03669965|Drug|Ruxolitinib|Ruxolitinib per approved prescribing label
65806|NCT03670238|Device|Orogastric intubation|Patient was placed in Fowler position (45º) and intraoral infiltrative anesthesia was carried out with Lidocaine 2% (without vasoconstrictor) at gingival papilla in the vestibular-palatine direction. A polyurethane enteral tube (Medicone®, Cachoeirinha - Brazil) was inserted through the mouth and passed into de stomach, followed by fixation of the tube tip to a superior molar or premolar, in its palatine surface. For dental amarry it waas used a suture wire in stainless steel size 1.0
65807|NCT03670238|Device|Nasogastric intubation|After nostril anesthesia with xylocaine gel, a polyurethane enteral tube was inserted through the nose and its tip was positioned in the gastric lumen, according to the nose-ear-xiphoid method. The tube was attached to the face using antiallergic adhesive tape.
65808|NCT03670225|Device|Invia Motion Endure|NPWT Invia Motion Endure
65809|NCT03670212|Drug|Yohimbine Hydrochloride|54mg of yohimbine powder was encapsulated in a generic opaque capsule and swallowed with water.
65810|NCT03670212|Drug|Hydrocortisone|10mg hydrocortisone was encapsulated in a generic opaque capsule and swallowed with water.
65811|NCT03670212|Drug|Lactose Monohydrate Powder|Lactose powder was encapsulated in generic opaque capsules identical to those used during the acute stress session. Lactose doses weighed the same as the acute stress session doses (54mg and 10mg, respectively).
65812|NCT03670199|Other|Dietary advice|Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet
65813|NCT03670199|Other|Physiotherapist intervention|Respiratory capacity Functional capacity
65814|NCT03670199|Other|Dietary intervention|Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
65815|NCT03670199|Other|Intensify physiotherapist intervention|Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
65816|NCT03670186|Behavioral|High-Intensity Interval Training (HIIT)|Participants perform high-intensity interval training (HIIT) on a cycle ergometer. The HIIT protocol consists of a 3-minute warm-up at 50W, ten 60-second high-intensity cycling intervals interspersed with 90 seconds of active recovery at 30% of their peak power output and a 2-minute cool-down at 50W for a total of 17.5 minutes.
65817|NCT03670173|Drug|Osalmid|Participants are initially given oral capsules with 0.5g tid osalmid daily for two weeks. Thereafter, the dosage will be increased by 0.25g tid every two weeks as tolerated by participants to a maximum daily dosage of 1.0g tid for up to one year.
65818|NCT03670160|Drug|Phenobarbital|Phenobarbital loading dose 20 mg/kg in 2 divided doses, then 5 mg/kg/day divided every 12 hours. Phenobarbital dose will be adjusted to obtain desired trough of 25 to 30 mcg/mL. Levels will be obtained on Day 6 then weekly thereafter. Phenobarbital will be tapered over 4 weeks upon discharge from the hospital. The standardized taper is based the patient specific dose at the time of discharge.
65819|NCT03670160|Drug|Clonidine|Clonidine 5 mcg/kg/day divided every 3 hours. Clonidine will be increased by 1.5 mcg/kg/day to achieve control of NAS symptoms based upon standardized scoring for neonatal abstinence syndrome. Clonidine will be weaned by 25% every 24 hours after successful discontinuation of oral morphine sulfate. Infants will not be discharged on clonidine.
65820|NCT03670147|Device|PF-SCS programming|In a blinded fashion, the study physician will ask subjects to switch their PF-SCS to the LAP.
65821|NCT03670134|Device|The Nvision VLE Imaging System|Volumetric laser Endomicroscopy (VLE) will be performed by using the Nvision VLE Imaging System (Nine Point Medical, MA) consists of an imaging console, monitor and optical probe. The optical probe is centered by a balloon (diameter: 14 mm, 17 mm, 20 mm; length: 6 cm) that is deployed through a diagnostic gastroscope's instrument channel. Imaging is performed by automatic helical pullback of the probe from the distal to the proximal end of the balloon over 90 seconds.
65822|NCT03670121|Device|Bronchoscopic Thermal vapor ablation (BTVA)|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
65823|NCT03670095|Drug|Lactose-free memantine|Lactose-free memantine tablet, 10 mg; orally as a single dose
65824|NCT03670095|Drug|Memantine|Lactose-containing memantine tablet, 10 mg, orally as a single dose
65825|NCT03670082|Drug|Lu AF35700|20 mg Lu AF35700 single oral dose
65826|NCT03670082|Drug|Lu AF35700 iv|100 μg [14C]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
65827|NCT03670069|Drug|Itacitinib|Given PO
65828|NCT03670069|Other|Laboratory Biomarker Analysis|Correlative studies
65829|NCT03670056|Drug|Combination immunotherapy with Ipilimumab and Nivolumab|Patients will be treated with nivolumab 1 mg/kg and ipilimumab 3 mg/kg, starting on Day 1. Patients will receive 4 doses of each nivolumab and ipilimumab and then will receive nivolumab 240 mg starting week 13 (day 85) every 2 weeks until progression, unacceptable toxicity, withdrawal of consent, or the study ends, whichever occurs first.
65830|NCT03670043|Drug|Psyllium powder|To evaluate whether Psyllium will alleviate diarrhea
65831|NCT03670043|Drug|Metformin Extended Release Oral Tablet|Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin
65832|NCT03670030|Drug|ABI-009|rapamycin protein-bound nanoparticles for injectable suspension (albumin bound)
65833|NCT03670017|Device|OptiScanner® 5000 Glucose Monitoring System|The study population includes surgical critical care patients who require blood glucose monitoring. Subjects must have a vascular access device [i.e., Central Venous Catheters (CVC), Multi-lumen Access Catheters (MAC) either in place or to be placed with an expected usage of at least 48 hours. During Phase One of the trial, patients will be connected to the OptiScanner for up to 72 hours and the hospital's current standard of care for glucose management will be followed.
65834|NCT03669978|Procedure|Creation of a bone and arterial panorama using EndoNaut® software.|"The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software."
65835|NCT03669965|Drug|KRT-232|KRT-232, administered by mouth
65837|NCT03669952|Other|None intervention|No interventions are realized, only observational study
65838|NCT03669939|Other|Communication Strategy|Communication Strategy The intervention consists of a handbook that refers to the CDC Guidelines with tools and communication strategies that the PCP can use when assessing their patients who are on opioids. The Handbook will have a description of the Ohm-app and the information the PCP can retrieve from the dashboard in their medical record. They will also be provided a template to use when seeing the patient to use as guide and as documentation.
65839|NCT03669939|Other|Standard of Care|The standard information about the CDC Guidelines and no other information that is available through the study.
65840|NCT03669926|Radiation|Digital Breast Tomosynthesis+synthetic mammography|Two-view tomosynthesis performed with GE Senographe Pristina.
65841|NCT03669913|Other|Lessons on comprehensive sexuality education|Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
65842|NCT03669900|Procedure|a minimally invasive surgery (SERI)|The SERI technique (as abbreviated to stand for simple, effective, rapid and inexpensive) was presented by several authors to be a minimally invasive technique since it presents with the same advantages as the percutaneous techniques with less tissue dissection and a need for only temporary hardware, meaning no instrumentation and surgery is performed under direct vision without fluoroscopy
65843|NCT03669887|Behavioral|Lifestyle Modification Program|The intervention will consist of 5 individual face-to-face sessions at 2-weekly intervals with a dietitian with experience in lifestyle modification program, followed by monthly phone contact and smartphone text messages. All study participants in the intervention arm will also be arranged to meet with an exercise instructor at least once during the LMP on the same day as one of the dietitian appointment. Ongoing support from the exercise instructor will also be available by phone calls or emails.
65844|NCT03669874|Device|Endoscopic fundoplication|"Endoscopic fundoplication is a less invasive alternative to the traditional surgical fundoplication.~The MUSE device is similar to an endoscope, so the whole procedure can be done by a single operator. The device is composed of a shaft with a distal rigid part which is placed in the esophagus 3 cm proximal to the esophago-gastric junction containing a cartridge holding five B-shaped titanium surgical Staples and a tip which is retroflexed and contains an ultrasonic transducer which defines the correct tissue thickness for stapling the fundus against the esophagus. The device must be extracted to be reloaded with 5 more staples at a time for creation of a 180° anterior fundoplication."
65845|NCT03669861|Drug|Abatacept|Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
65846|NCT03669848|Other|Pulse CO-oximetry|Measuring blood Carbon Monoxide levels with Pulse CO-oximetry (SpCO)
65847|NCT03669835|Dietary Supplement|Mare milk supplement|Supplement consisting of sublimated mare's milk with single-dose 20 mg sachet. The supplement is dissolved in 36-27 degrees of Celsius water and taken 15-20 minutes before meal.
65848|NCT03669835|Drug|Standard therapy|For hepatitis virus C genotype 1: sofosbuvir 400 mg + lepidavir 90 mg for 12 weeks OR sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks; For hepatitis virus C genotypes 2 and 3: sofosbuvir 400 mg + daclatasvir 60 mg for 12 weeks.
65849|NCT03669822|Other|Standard of care|Care decisions driven by local physicians; this is an observational cohort.
65850|NCT03669796|Dietary Supplement|Marine protein hydrolysate (mph)|Marine (Cod) protein hydrolysate
65851|NCT03669796|Dietary Supplement|Control|Maltodextrin/Casein
65852|NCT03669783|Drug|treatment Vincristin|1 x Vincristin 1,5mg/m² iv bolus day 1 in week 1,2,3,4,5,6
65853|NCT03669783|Drug|treatment Actinomycin-D|1 x Actinomycin D 45µg/kg iv bolus day 1 in week 1, 3, 5
65854|NCT03669783|Drug|treatment Doxorubicin|1 x Doxorubicin 50mg/m² 6h Infusion day 1 in week 1,5
65855|NCT03669783|Drug|treatment Carboplatin|1 x Carboplatin 200 mg/m² 1h infusion day 1,2,3 in week 1,4
65856|NCT03669783|Drug|Etoposide|1 x Etoposide 100mg/m² 1h infusion day 1,2,3 in week 1,4
65857|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
65858|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
65859|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
65860|NCT03669757|Drug|LEO 134310|Active substance: LEO 134310 is a compound in development at LEO Pharma A/S
65861|NCT03669757|Drug|LEO 134310 vehicle|Active substance: none
65862|NCT03669757|Drug|0.1% betamethasone valerate ointment (class III steroid)|Active substance: betamethasone valerate
65863|NCT03669744|Other|telephone survey|a telephone survey will be conducted at 21 patients with trigeminal neuralgia resistant to usual treatments, according to the ICHD-3β criteria treating by one or more trigeminal nerve blocks at the peri operative pain management center of Limoges University Hospital between 2014 and 2018.
65864|NCT03669731|Other|food diary|This food diary is to be completed by the patient in the 3rd trimester of pregnancy, on 3 consecutive days and if possible including a weekend day. Finally, the investigator also prescribes a biological analysis: a urinary urea from a 24h diuresis to be collected in the 3rd trimester in a dedicated collector and given that same day.
65865|NCT03669718|Biological|ISA101b|Every 3 weeks for a total of 3 times
65866|NCT03669718|Drug|Cemiplimab|Every 3 weeks for up to 24 months
65867|NCT03669718|Other|Placebo|Every 3 weeks for a total of 3 times
65868|NCT03669705|Procedure|Omitting axillary surgery in early breast cancer|Before the Sentinel Node era all invasive breast cancer was recommended to have axillary dissection but after the introduction of national breast cancer screening this guideline statement was challenged by this national Swedish cohort.
65869|NCT03669692|Behavioral|Caloric Restriction|Subjects will be trained to perform intermittent caloric restriction, based on an early time restricted feeding, with a 16/8 hour fasting / feeding schedule, respectively.
65870|NCT03669692|Behavioral|Control|Subjects will receive diet and lifestyle recommendations from the Spanish Association of Urology, for symptoms secondary to HBP, without restriction in the meal schedule.
65871|NCT03669679|Procedure|Breast reduction|breast reduction surgery for breast hypertrophy using either superomedial or inferior pedicle technique
65912|NCT03669328|Procedure|locoregional anesthesia|Both groups received locoregional anesthesias
65913|NCT03669315|Device|Transcranial Magnetic stimulation|Neuromodulation tool
65872|NCT03669653|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
65873|NCT03669653|Procedure|Sham remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.
65874|NCT03669640|Drug|RO6889450|Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
65875|NCT03669640|Drug|Placebo|Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
65876|NCT03669627|Biological|aTIV Primer|MF59-adjuvanted trivalent influenza virus primer: 2 doses (0.25mL) one month apart
65877|NCT03669627|Biological|QIV Primer|Unadjuvanted quadrivalent influenza vaccine primer: 2 doses (0.5mL) one month apart
65878|NCT03669627|Biological|aTIV Booster|MF59-adjuvanted influenza virus vaccine booster: 1 dose (0.25mL), year 2
65879|NCT03669627|Biological|QIV Booster|Unadjuvanted quadrivalent influenza vaccine booster: 1 dose (0.5mL), year 2
65880|NCT03669614|Drug|inhaled AR-501|single and multiple ascending doses of inhaled AR-501
65881|NCT03669614|Drug|inhaled AR-501 placebo|single and multiple ascending doses of inhaled placebo
65882|NCT03669601|Drug|AZD6738|A potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members.
65883|NCT03669601|Drug|Gemcitabine|Nucleoside metabolic inhibitor.
65884|NCT03669588|Biological|ARGX-113|Intravenous administration of ARGX-113
65885|NCT03669588|Biological|Placebo|Intravenous administration of placebo
65886|NCT03669575|Dietary Supplement|omega 7|Three weeks omega 7 fatty acid nutritional supplement, approximately 900 mg/day
65887|NCT03669575|Dietary Supplement|Placebo|Three weeks placebo fatty acids approximately 900 mg/day which does not contain omega 7
65888|NCT03669562|Drug|Alprostadil Liposome for Injection|intravenous infusion Alprostadil Liposome
65889|NCT03669562|Drug|Placebo|intravenous infusion liposome control
65890|NCT03669549|Drug|Nevanimibe hydrochloride|During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
65891|NCT03669523|Drug|Denosumab-nivolumab combination|"Denosumab: 120 mg every 4 weeks subcutaneously~Nivolumab: 3 mg/kg intravenously on day 1 every 2 weeks"
65892|NCT03669510|Other|computer guided IAN lateralization surgical technique|Tthe neurosensory alterations with computer guided inferior alveolar nerve lateralization versus non guided classic technique
65893|NCT03669497|Radiation|Hypo fractionated whole breast radiotherapy|Hypo fractionated radiotherapy to the whole breast and SCF to a dose of 26 GY in 5 fractions with simultaneous integrated boost in advanced incurable breast cancer
65894|NCT03669484|Drug|Remimazolam|Lyophilisate for preparation of solution for intravenous administration, 50 mg. Required to prepare a 50 ml syringe with the infusion solution at a concentration of 1 mg/ml (in accordance with guidance given in protocol)
65895|NCT03669484|Drug|Propofol|Emulsion for infusion, 10 mg/mL in 20-mL glass vials
65896|NCT03669484|Drug|Fentanyl|Solution for intravenous administration, 50 mg/mL. Used for anesthesia induction (at a dose of 2 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
65897|NCT03669484|Drug|Rocuronium bromide|Solution for intravenous administration, 10 mg/mL. Used for anesthesia induction (at a dose of 0.6-0.9 mg/kg) and, if necessary, anesthesia maintenance (the dose was selected individually)
65898|NCT03669471|Other|Testing of performance|"The cross-sectional evaluation will involve assessment of:~Hip muscle function~Single leg jump performance~Self-reported hip and groin function~Evaluation of return to sport~Evaluation of satisfaction regarding usual-care post-operative rehabilitation~The exercise-based treatment will involve criteria-based physiotherapy aiming at improving muscle function around the hip and trunk."
65899|NCT03669445|Drug|Ixazomib|21-day cycles induction and 28-day cycles consolidation
65900|NCT03669445|Drug|Lenalidomide|21-day cycles induction and 28-day cycles consolidation and 28-day cycles maintenance therapy
65901|NCT03669445|Drug|Dexamethasone|21-day cycles induction and 28-day cycles consolidation
65902|NCT03669445|Drug|Daratumumab|21-day cycles induction and 28-day cycles consolidation
65903|NCT03669432|Radiation|Intensity Modulated Radiotherapy|"The patient will receive adjuvant radiation therapy about 8-10 weeks after completion of initial surgery. The duration of this radiation therapy will be approximately 45 days.~: The goal of the treatment plan would be to encompass the PTV subclinical disease with a dose of 54-60 Gy and the planned target volume (PTV) of the gross disease with 70-74 Gy while sparing as much of the aforesaid critical structures as possible.~The maximum permissible point doses to the spinal cord will be limited to 46 Gy. IMRT planning and delivery will be carried out on the Tomotherapy Hi Art System."
65904|NCT03669432|Procedure|Surgery alone|This intervention is of no interest
65905|NCT03669419|Diagnostic Test|QoR 9 Questionnaire|The QoR-9 as established patient-centred outcome measure, which is validated in German language, is surveyed preoperatively, as well as on postoperative day 1 and 3 after non-cardiac surgery. Postoperative complications are evaluated using the Clavien-Dindo Score. A follow-up is intended after 6 months. Preoperative risk is estimated using the ASA (American Society of Anesthesiologists) and the POSPOM (Preoperative Score to predict postoperative mortality) score.
65906|NCT03669406|Procedure|Autograft fat|autograft fat
65907|NCT03669393|Drug|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
65908|NCT03669367|Drug|Abatacept Injection|Abatacept subcutaneous in monotherapy 125 mg/week during the first year (12 months). Abtacept subcutaneus in monotherapy 125 mg/2weeks during the second year.
65909|NCT03669367|Drug|hydroxycloroquina|oral hydroxycloroquina 5 mg/Kg/day for 2 years (0-48 months)
65910|NCT03669341|Other|Deep Inspiration Breath Hold (DIBH)|human-based DIBH method with short-term breath-hold training
65911|NCT03669341|Other|High Frequency Percussive Ventilation (HFPV)|device-based HFPV technique
65914|NCT03669302|Other|Robotic gait training|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
65915|NCT03669302|Device|Robotic gait training and low-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a single pulse at 0.3 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
65916|NCT03669302|Device|Robotic gait training and high-frequency transspinal stimulation|Fifteen people with spinal cord injury will receive 20 daily sessions of robotic gait training. During assisted stepping, they will receive also non-invasive transspinal stimulation as a pulse train at 30 Hz during the stance phase of gait. Before and after training standardized clinical and neurophysiological tests will be used to assess recovery of sensorimotor function.
65917|NCT03669289|Other|enhanced model of primary care|The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
65918|NCT03669263|Drug|Fentanyl buccal soluble film (FBSF)|"After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed."
65919|NCT03669250|Drug|CVN058|3-way crossover
65920|NCT03669250|Drug|Placebos|Placebo
65921|NCT03669237|Procedure|different reconstruction methods|Different reconstruction methods should be performed after sphincter preservation surgery in two groups.The methods include end-to-end anastomosis or end-to-side anastomosis
65922|NCT03669224|Other|Nano Care Gold|Mixture of Gold and Silver nano particles suspended in 70 % Isopropyl alcohol. This group will be compared with no intervention group.
65923|NCT03669224|Other|No intervention|No intervention will be applied in this group. It will be the negative comparator. In this group only the standard of care will be applied, which means the steps will be cavity preparation followed by adhesive system then resin composite without any surface pre-treatment
65924|NCT03669224|Other|Chlorhexidine|2 % chlorhexidine gluconate. This group will be compared with no intervention group.
65925|NCT03669211|Diagnostic Test|Cardiac stress test|In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.
65926|NCT03669198|Diagnostic Test|NT-Pro BNP|. AHF patients who met inclusion and exclusion criteria were randomly assigned to 2 groups, NT-pro BNP group and control group. In the NT-pro BNP group, serial NT-pro BNP levels at admission and pre-discharge was measured, the latter with the target of decrease ≥ 30% NT-pro BNP level. Randomised patients were followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.
65927|NCT03669185|Drug|Pentalong|Pentalong, 2 x daily 1 tablet, intake max. 133 days
65928|NCT03669185|Drug|Placebos|Placebos, 2 x daily 1 tablet, intake max. 133 days
65929|NCT03669172|Biological|Donor IL-15 stimulated NK cells infusion|DONOR IL-15-STIMULATED NK CELLS POST TRANSPLANT INFUSION, IN ACUTE LEUKEMIA PATIENTS WITH POOR PROGNOSIS AND HAPLOIDENTICAL UNMANIPULATED TRANSPLANT
65930|NCT03669146|Device|Glasses|Partial refractive correction in a pair of glasses.
65931|NCT03669133|Drug|Vitamin E|Vitamin E 800 IU/daily
65932|NCT03669133|Drug|Placebos|Matching placebo daily
65933|NCT03669120|Other|Informational Intervention|Receive advice to quit smoking and materials to promote smoking cessation
65934|NCT03669120|Behavioral|Telephone-Based Intervention|Receive individualized text based messages
65935|NCT03669107|Drug|Gum|no gum
65936|NCT03669094|Dietary Supplement|Lactobacillus salivarius V4II-90|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the Lactobacillus salivarius V4II-90 (1*10E9 CFU) probiotic supplement over a 12 weeks period. A visit will then be completed one month after delivery.
65937|NCT03669094|Dietary Supplement|Placebo|7 months intervention study: with a screening period of 12 weeks after which participants GBS+ women will be randomized and start the orally intake of 1 capsule per day of the placebo supplement over a 12 weeks period. A visit will then be completed one month after delivery.
65938|NCT03669081|Drug|Ketorolac|Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
65939|NCT03669081|Drug|Pregabalin|Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
65940|NCT03669081|Drug|Placebo oral capsule|Placebo oral capsule was administered orally 30 minutes prior to operation.
65941|NCT03669081|Drug|Saline|Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
65942|NCT03669068|Procedure|Gastrointestinal endoscopy|"Two separated groups will be included in the registry:~Patients with oral anticoagulants-induced gastrointestinal bleeding unrelated to an endoscopic procedure.~Patients undergoing elective gastrointestinal endoscopy."
65943|NCT03669055|Other|Magnetic Resonance Imaging|Realization of a MRI before and after the endovascular treatment of the aortic dissection. Use of the 4D phase-contrast sequence during the MRI.
65944|NCT03669042|Device|PhotoFix|PhotoFix Patch Implantation
65945|NCT03669029|Drug|Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg|Clinical response at week 6,14, 30 and 54 will be correlated to serum golimumab levels and anti-golimumab antibody levels.
65946|NCT03669029|Drug|Golimumab treatment optimization.|Golimumab dosing will be optimized in patients without clinical response at week 6.
66012|NCT03668561|Device|Caligaloc|15 days of wearing of the Caligaloc orthosis
65947|NCT03669016|Behavioral|Face-to-face group-based mindfulness|"An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. An eight-week course, including 75-90 minutes once-a-week meeting. Participants are supposed to practice mindfulness skills in their spare time 10-30 minutes per day. This training is based on Jon Kabat-Zinn's course Mindfulness Based Stress Reduction and book Williams & Penman Mindfulness: a practical guide to finding peace in a frantic world and adapted for university students. In addition, a manual written in Cambridge University Mindfulness Skills for Students is utilized."
65948|NCT03669016|Behavioral|Internet-based mindfulness|An eight-week course, including 60 minutes starting and ending meeting. Participants are practicing mindfulness, doing other tasks (writing, reading, reflecting) on their own. This course is created in University of Jyväskylä, Finland. It is based on mindfulness and Acceptance and Commmitment Therapy.
65949|NCT03669003|Biological|Gelfoam slurry|Approximately 1-2cc of Gelfoam slurry will be used to lace the needle track.
65950|NCT03669003|Procedure|CT-guided percutaneous lung biopsy|Biopsy of a lung nodule under CT guidance.
65951|NCT03668990|Other|IMUs (Xsens, MVN Studio)|It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
65952|NCT03668977|Dietary Supplement|Fortified balanced protein-energy.|The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). We expect the calorie content to be between 300 and 400 Kcal/day.
65953|NCT03668964|Dietary Supplement|Vitamin B2|One capsule of 75 mg Vitamin B2 once a day for 4 weeks
65954|NCT03668964|Dietary Supplement|Vitamin C|One capsule of 500 mg Vitamin C once a day for 4 weeks
65955|NCT03668964|Dietary Supplement|Vitamin B2 + C|One capsule of of 75 mg Vitamin B2 plus 500 mg Vitamin C once a day for 4 weeks
65956|NCT03668964|Dietary Supplement|Vitamin A|One capsule of 250 µg Vitamin A once a day for 4 weeks
65957|NCT03668964|Dietary Supplement|Vitamin D3|One capsule of 60 µg Vitamin D3 once a day for 4 weeks
65958|NCT03668964|Dietary Supplement|Vitamin E|One capsule of 100 mg Vitamin E once a day for 4 weeks
65959|NCT03668964|Dietary Supplement|Placebo|One capsule of 575 mg microcrystalline cellulose once a day for 4 weeks
65960|NCT03668951|Drug|Dexmedetomidine buccal|DEX 2 mcg/kg buccal
65961|NCT03668951|Drug|Dexmedetomidine Intranasal|DEX 3 mcg/kg intranasal
65962|NCT03668951|Drug|Dexmedetomidine Intranasal|DEX 4 mcg/kg intranasal
65963|NCT03668938|Other|Occupational Therapy|The intervention in the hospitalization phase is mainly aimed at achieving the objectives related to the self-care area and, secondly, to the objectives in the areas of productivity and leisure time, identified in T0 and to the environmental assessment of the places of life of the patient; more an intervention in the patient's post-discharge home, mainly aimed at achieving the objectives related to social reintegration, the area of productivity and leisure time and, secondly, to possible objectives in the areas of self-care identified in T1.
65964|NCT03668938|Other|usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
65965|NCT03668925|Radiation|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement|magnetic resonance imaging (MRI) of the sacro-iliac region HLA B27 test C-reactive protein (CRP) measurement
65966|NCT03668912|Behavioral|Guided participation discharge programme|A nurse-led GP discharge intervention (3 structured 30- to 60-minute GP sessions and 1 follow-up phone call)
65967|NCT03668899|Procedure|irrigation|irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
65968|NCT03668886|Other|multimodal exercise program|warm-up, strengthening exercise, aerobic exercise, cool-down
65969|NCT03668873|Behavioral|Sleep Parent Training|SPT provides a comprehensive intervention that teaches parents the basic concepts and practical skills to address an array of sleep problems.
65970|NCT03668873|Behavioral|Sleep Parent Education|SPE is a structured program intended to mimic competent treatment as usual. Thus, SPE is an accepted treatment and serves as an active comparator that controls for time and attention.
65971|NCT03668860|Drug|Dexamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
65972|NCT03668860|Drug|Betamethasone 4 mg/ml|Intramuscular. Total dose: 1.5 mL (6 mg)
65973|NCT03668860|Drug|Celestone Soluspan 6Mg/Ml Suspension for Injection|Intramuscular. Total dose: 1 mL (6 mg)
65974|NCT03668860|Drug|Dexamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
65975|NCT03668860|Drug|Betamethasone Oral Tablet|Oral. Total dose: 12 Tablets (6 mg)
65976|NCT03668847|Drug|DM-CHOC-PEN|DM-CHOC-PEN administration by IV infusion
65977|NCT03668834|Procedure|Dermabrasion with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~Dermabrasion will be done using Manekshaw's dermabrader until tiny pinpoint bleeding spots are seen and extended 5mm beyond margins to prevent halo phenomenon.~The denuded area will be washed with PBS and covered with a PBS moistened gauze piece.~With 18 G needle attached to tuberculine syringe, few small drops of non cultured epidermal cell suspension will be placed over the denuded surface and spread evenly.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
65978|NCT03668834|Procedure|Dermaroller with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit.~Microneedling will be done with a device containing 540 microneedles in 8 rows, each 0.25 mm in length. Microneedling will be extended 5 mm beyond margins to prevent halo phenomenon.~The roller will be passed repeatedly over the skin in a star-shaped way for about 10 minutes~The noncultured epidermal cell suspension will be carefully transferred to a tuberculin syringe.~NCES will be applied to the skin surface with a tuberculin syringe with an 18G needle and spread evenly after dermarolling treatment.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
66013|NCT03668548|Dietary Supplement|Leucine|192 mg/kg body mass/day
66014|NCT03668548|Dietary Supplement|Placebo|A taste and calorie-matched placebo
66052|NCT03668314|Drug|RDN-929 TBD dose|Fed vs fast dose TBD based upon results of previous cohorts
66053|NCT03668314|Drug|RDN-929|Multiple dose based on results of previous cohorts
65979|NCT03668834|Procedure|Liquid nitrogen induced blister with NCES|"The recipient site will be shaved, cleaned with betadine and surgical spirit and anaesthetized with mixture of 2% lignocaine and NS (1:1).~The site to be grafted is outlined with a surgical marking pen.~To induce blisters on the achromic areas, freezing with liquid nitrogen spray was performed during 10 to 20 seconds inside round circles previously drawn on the skin.~The patient is asked to visit 24 hours later.~The blister fluid is aspirated and NCES taken in tuberculin syringe with 18 G needle is injected into it such that the blister roof is preserved.~Dressing is done in 4 layers in order-collagen(Neuskin F), bactigras, cutisoft(sterile gauze) and dynaplast (elastic plaster)."
65980|NCT03668821|Other|Questionnaire|Quality of life and frailty questionnaires
65981|NCT03668808|Drug|Insulin Degludec|Subjects will use Insulin Degludec (Tresiba) with TRESIBA® FLEXTOUCH® pens as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
65982|NCT03668808|Drug|Insulin Glargine|Subjects will use Insulin Glargine (Lantus) with LANTUS® SOLOSTAR® INSULIN PEN as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
65983|NCT03668808|Device|TRESIBA® FLEXTOUCH®|Subjects will use Tresiba FlexTouch pens when using Tresiba as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
65984|NCT03668808|Device|LANTUS® SOLOSTAR® INSULIN PEN|Subjects will use Lantus SoloStar insulin pens when using Lantus as their basal insulin during a 9-10 hour flight, at each destination, and then during a return flight.
65985|NCT03668795|Procedure|Bakrey balloon insertion within the uterus and caesarean hysterectomy|Creating an intrauterine tamponade to stop the uterine bleeding by inflating an intrauterine balloon with 600 cc of saline versus undergoing hysterectomy if conservative management failed
65986|NCT03668782|Procedure|Umbilical cord milking|The babies were held at the level of the placenta, while the umbilical cord was milked or cut and clamped.
65987|NCT03668769|Other|Internet Mobile Technology|Use Quitting Schedule mobile smartphone app
65988|NCT03668769|Other|Interview|Ancillary studies
65989|NCT03668769|Other|Questionnaire Administration|Ancillary studies
65990|NCT03668769|Behavioral|Smoking Cessation Intervention|Participate in individual smoking cessation program
65991|NCT03668756|Procedure|Computer-Assisted Navigation TKA|TKAs were performed using the image-free CAS navigation system VectorVision
65992|NCT03668730|Radiation|Intensity-modulated radiation therapy|Patients undergo low-dose OR standard dose IMRT based on their radiographic response to induction chemotherapy
65993|NCT03668730|Drug|Paclitaxel liposome|Patients receive Paclitaxel liposome by 135mg/m2 with a total of two cycles.
65994|NCT03668730|Drug|Cisplatin|Patients receive Cisplatin by 25mg/m2 on day1-day3 with a total of two cycles as induction chemotherapy ; patients receive cisplatin by 100mg/m2 with a total of three cycles as concurrent chemotherapy.
65995|NCT03668730|Drug|5-Fluorouracil|Patients receive 5-Fluorouracil by 3750mg/m2 civ120h with a total of three cycles.
65996|NCT03668717|Device|Robotic-arm assisted medical MCK implant|Robotic-arm assisted medical MCK implant system to replace the medial compartment of the knee.
65997|NCT03668691|Device|Robotic-arm assisted partial knee arthroplasty|Robotic-arm assisted medial unicompartmental knee arthroplasty, lateral unicompartmental knee arthroplasty, bicompartmental knee arthroplasty, patellofemoral knee arthroplasty implants. A robotic arm assisted unicompartmental or bicompartmental knee arthroplasty procedure to replace the medial or lateral and /or patellofemoral compartments of the knee.
65998|NCT03668678|Other|iGrow Readers Curriculum|As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
65999|NCT03668665|Drug|Ready Medical Post Treatment|"Treatment of half of the wound with the product ready medical post treatment in addition to conventional treatment with moist dressings (Mepilex and Fixomull); on the 1st, 4th and 7th day after surgery, the product is applied to the wound and the dressing is changed"
66000|NCT03668665|Device|Conventionell Treatment|Treatment of half of the wound with conventional moist dressings (Mepilex and Fixomull); a dressing change only takes place on the 7th day postoperatively
66001|NCT03668652|Device|Focal HIFU treatment using Focal One (EDAP TMS)|"HIFU arm:~Focal ablation of prostate cancer using HIFU Focal One"
66002|NCT03668652|Procedure|Radical prostatectomy|"Prostatectomy arm:~Robot assisted or open retropubic prostatectomy"
66003|NCT03668639|Drug|Akynzeo|Weekly administration of akynzeo for five weeks.
66004|NCT03668639|Drug|Dexamethasone|Weekly administration of dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 for five weeks.
66005|NCT03668626|Other|Family-centered intervention program (FCIP)|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education.
66006|NCT03668613|Drug|secukinumab low dose|dose depends on the weight group
66007|NCT03668613|Drug|secukinumab high dose|dose depends on the weight group
66008|NCT03668600|Drug|Rapastinel|Rapastinel 450 mg (prefilled syringe, weekly or biweekly or up to 4 weeks at the investigator's discretion intravenous IV administration)
66009|NCT03668587|Other|Troponin Protocol|Feasibility and security of a rapid rule-out and rule-in troponin protocol in the management of NSTEMI in an Emergency Departement.
66010|NCT03668574|Other|Aerobic exercise|Aerobic exercise that is defined as a form of exercise lasting 15 to 60 minutes continuous and intensity of 60% to 90% of maximal heart rate.
66011|NCT03668574|Other|Placebo Group|Will be treated with pulsed 5-minute ultrasound and pulsed short-wave diathermy for 25 minutes. The devices will be used with disconnected internal cables to obtain the placebo effect
66015|NCT03668535|Procedure|Bladder Filling|Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
66016|NCT03668535|Procedure|Bladder deflation|Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
66017|NCT03668522|Other|Genetic testing|To determine whether H3F3AK27M exist in spinal glioma
66018|NCT03668509|Drug|SHR1459|oral adminstration, single dose
66019|NCT03668496|Drug|SHR-1210|Drug delivery cycle is 3 weeks, and in the experimental group,200 mg shr-1210 was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
66020|NCT03668496|Drug|The placebo|in the control group,placebo was given with Carboplatin and Paclitaxel in the first day of each cycle, with intravenous drip.
66021|NCT03668483|Other|Pulmonary rehabilitation|A 6-min walk test, peripheral and respiratory muscle strength measurements, and a dyspnea rating scale Mmrc will be applied to the lung transplantation candidates who are trained in 3-month hospital-based preoperative exercise training in the Pulmonary Rehabilitation unit. The tests will be carried out at the beginning and end of rehabilitation.
66022|NCT03668470|Drug|Dulaglutide|Dulaglutide 1.5mg : One injection per week during 24 weeks
66023|NCT03668470|Drug|Placebo|Placebo: one injection per week during 24 weeks
66024|NCT03668457|Behavioral|Intervention to Patients|"Multifaceted intervention consisting of:~A collaborative care management intervention, including depression education, medication management and behavioral activation.~Use of a medication reminder mobile app."
66025|NCT03668457|Behavioral|Intervention to Psychiatrists|Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
66026|NCT03668457|Other|Control|Other: Usual care Usual care for depressive disorder received in mental health units
66027|NCT03668444|Behavioral|TXS- Supportive Text Group|TXS participants will receive one treatment supportive text message each day for 30 days.These messages will address three domains 1) Recovery oriented messages, 2) Avoiding relapse and sanctions,and 3) Commitment to family, community and the Drug Treatment Court program. After receiving each text message, participants will receive a second message asking them to reply with a rating of how helpful the original message was. Ratings will use a 5-point Likert scale,ranging from 1-not at all helpful to 5-extremely helpful. Participants will also be asked to describe, via text message, what they liked or did not like about the original message, and suggest a better message for those they did not like.
66028|NCT03668444|Behavioral|TAU- Treatment As Usual|Participants randomized to the TAU arm of the study will continue to participate in court-ordered treatments as usual with no additional intervention. Participants will receive one motivational text message for the 30-days.
66029|NCT03668431|Drug|Dabrafenib|"Dabrafenib will be taken twice a day for 28 consecutive days~."
66030|NCT03668431|Drug|Trametinib|Trametinib will be taken once a day for 28 consecutive days
66031|NCT03668431|Drug|PDR001|PDR001 will be administered IV every 28 days
66032|NCT03668418|Drug|Fluorouracil|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66033|NCT03668418|Drug|Lederfolin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66034|NCT03668418|Drug|Oxaliplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66035|NCT03668418|Drug|Irinotecan|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66036|NCT03668418|Drug|Docetaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66037|NCT03668418|Drug|Cisplatin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66038|NCT03668418|Drug|Epirubicin|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66039|NCT03668418|Drug|Gemcitabine|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66040|NCT03668418|Drug|Nab paclitaxel|The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
66041|NCT03668405|Drug|Lu AF20513|Injection
66042|NCT03668392|Drug|Asparaginase|Measurement of serum Asparaginase activities during therapy, in terms of intensity and duration, as surrogate parameter for asparaginase depletion.
66043|NCT03668379|Behavioral|Augment w/mHealth|"Non-responders to the first stage treatment of BAT alone may be re-randomized to this augmented intervention to receive text-message support in addition to the BAT intervention."
66044|NCT03668379|Behavioral|Maintenance|"Responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth will continue in maintenance mode. These participants will not receive any additional interventions during the 2nd-stage treatment."
66045|NCT03668379|Behavioral|Switch to CBT & mHealth|"Non-responders to the 1st-stage treatment of either 1. BAT or 2. BAT & mHealth may be re-randomized to switch interventions in the form of an intensified dose of Cognitive Behavioral Therapy (CBT). CBT is eight sessions long and covers five modules that can be re-arranged to fit patient needs. Sessions will be scheduled once a week to facilitate more contact with participants. An identical text-messaged tool will be used."
66046|NCT03668379|Behavioral|Augment w/BAT & mHealth|"Non-responders to the BAT & mHealth intervention may be re-randomized to receive an additional dose of BAT & mHealth in the form of an additional session of BAT."
66047|NCT03668366|Drug|S-1|The patients will receive IMRT combined with S-1 concurrent chemoradiotherapy. The specific treatment description is included in arm description.
66048|NCT03668353|Biological|Recombinant SeV-hFGF2/dF Injection|intramuscular injection of investigator drugs
66049|NCT03668340|Drug|AZD1775|AZD1775 blocks the activity of Wee1, a protein that helps to regulate how cells divide and grow. Certain cancer cells may be more vulnerable to having this process blocked
66050|NCT03668314|Drug|RDN-929|Single dose from 2 mg to TBD
66051|NCT03668314|Drug|Placebo oral capsule|Matching placebo Single dose
66054|NCT03668314|Drug|Placebo oral capsule|Matching placebo multiple dose
66055|NCT03668288|Other|Data record and questionnaires passation|Data record and questionnaires passation (SF36)
66056|NCT03668275|Procedure|(partial) oncological home-hospitalization|Patients assigned to oncological home-hospitalization will receive as many as possible parts of their oncological treatment at their homes. These include the required preparatory actions before treatment administration is possible and/or the treatment administration itself in case of subcutaneous cancer drugs.
66057|NCT03668262|Drug|Cis-atracurium|Different concentration of cis-atracurium
66058|NCT03668236|Drug|Isotonic crystalloids|"Types of fluid to be used in both intervention groups:~IV fluids given for circulatory impairment: Only isotonic crystalloids are to be used as per the Scandinavian guideline for fluid resuscitation~Fluids given to substitute overt loss: Isotonic crystalloids are to be used. If large amounts of ascites are tapped, then human albumin may be used~Fluids used for dehydration: Water or isotonic glucose should be used~Fluids used for electrolyte disturbances: Fluids should be chosen to substitute the specific deficiency, including water in the case of severe hypernatremia~Blood products are only to be used on specific indications including severe bleeding, severe anaemia and prophylactic in case of severe coagulopathy"
66059|NCT03668223|Behavioral|Promoting Resilience in Stress Management (PRISM)|Manualized skills training targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
66060|NCT03668210|Procedure|Isokinetic evaluation|Isokinetics is used to measure the peak of strength of quadriceps and hamstrings, in concentric or eccentric, at slow and fast speed to determine a hamstring / quadriceps ratio to highlight a deficit or imbalance.
66061|NCT03668197|Biological|microbiological analysis|microbiological analysis of the peritoneal fluid
66062|NCT03668184|Other|preeclampsia|occurrence of pre-eclampsia
66063|NCT03668171|Procedure|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
66064|NCT03668145|Procedure|mesenchymal stem cell transplantation or placebo infusion via peripheral vein|0.1-1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8 mesenchymal stem cell mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China For control group, placebo infusions will be given to the participants at the same time points
66065|NCT03668132|Other|ischemic brain damage|Have or not have the ischemic brain damage and the location of the damage
66066|NCT03668119|Biological|Nivolumab|Specified dose on specified days
66067|NCT03668119|Biological|Ipilimumab|Specified dose on specified days
66068|NCT03668106|Procedure|sperm processing method|different sperm processing method for selcting most proper sperm for ICSI
66069|NCT03668093|Other|ICCM|comprehensive system for caries management
66070|NCT03668093|Other|CAMBRA|Caries risk assessment model
66071|NCT03668067|Device|2WIN photoscreener|conventional infrared off-axis photoscreener
66072|NCT03668054|Drug|Bevacizumab (Lumiere®)|The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
66073|NCT03668041|Drug|Trazodone|Trazodone is approved by the Food and Drug Administration (FDA) for treating major depression in adults but not for PTSD. Although trazodone has not been approved by the FDA to treat insomnia or PTSD, some doctors have tried it for these purposes. The doses in this study will be lower than the doses used to treat depression.
66074|NCT03668041|Drug|Eszopiclone|Eszopiclone is approved by the FDA for treating insomnia, but it's unknown if eszopiclone can help treat insomnia when it's related to PTSD. Some doctors have tried it for this purpose. The doses in this study will be the same as the doses used to treat insomnia. A small study found it to be helpful for treating patients with PTSD.
66075|NCT03668041|Drug|Gabapentin|Gabapentin is an FDA approved medication for the treatment of seizures, a type of nerve pain and some forms of chronic pain. Some doctors have prescribed it for insomnia. While the total daily doses in this study are less than the usual total daily dose, the highest dose of gabapentin used in this study will be higher than the typical dose taken at a single time. Doses even higher than this have been taken and observed to be acceptable for treating patients with PTSD.
66076|NCT03668041|Other|Placebo|The active study medications listed above will be compared with a placebo, which is a pill that looks like a study medication but has no medication in it.
66077|NCT03668028|Biological|TPX-114|Subjects will be treated with autologous fibroblasts (TPX-114) during arthroscopic surgery.
66078|NCT03668028|Procedure|Arthroscopic surgery|Subjects undergo conventional arthroscopic surgery for rotator cuff repair.
66079|NCT03668015|Other|Xylitol then Sorbitol gum|Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax. Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included.
66080|NCT03668015|Other|Sorbitol then Xylitol gum|Sorbitol gum was similar except that xylitol was replaced by 63% sorbitol and 2% maltitol and aspartame was included. Xylitol gum contains 70% xylitol in addition to gum base, natural flavors, soy lecithin, gum arabic, titanium dioxide, carnuba wax.
66081|NCT03668002|Procedure|Arteriovenous Fistula (AVF)|If the participant is randomized to the AVF arm of the trial, the surgeon will connect an artery to a vein in the upper extremity, without using artificial material as conduit.
66082|NCT03668002|Procedure|Arteriovenous Graft (AVG)|If the participant is randomized to the AVG arm of the trial, the surgeon will place a synthetic graft connecting an artery and vein under the skin in an upper extremity.
66083|NCT03667989|Diagnostic Test|Assessment of cardiac sympathetic innervation by 123I-MIBG|Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
66084|NCT03667976|Behavioral|SATHI|see above
66085|NCT03667963|Other|Glucose|50g glucose dissolved in 250ml water
66086|NCT03667963|Other|Glucose plus lactulose|50g glucose plus 10g lactulose dissolved in 250ml water
115674|NCT03281902|Other|Laboratory Biomarker Analysis|Correlative studies
66087|NCT03667963|Other|Hot Rice|Freshly cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) and consumed hot.
66088|NCT03667963|Other|Cold Rice|Cooked polished rice containing 50g available carbohydrate (approximately 2/3 cup cooked rice) cooled overnight in a refrigerator and consumed cold.
66089|NCT03667950|Procedure|Hyperspectral Imaging|Photos were taken with the hyperspectral camera of the gastrointestinal anastomosis.
66090|NCT03667937|Combination Product|CUTIMED|Hydrophobic Dressing
66091|NCT03667937|Other|AQUACEL silver|Silver Dressing
66092|NCT03667924|Behavioral|PorchLight Project|Senior Companions (or other LSS-MN volunteers providing senior companionship services) who deliver the PorchLight Project will complete online CARES® Dementia Care Specialist training modules, additional trainings delivered by the research team (1. overview of the PorchLight Project, 2. review of the National Consensus Guidelines on Palliative Care, 3. review of the list of guided questions, and 4. review of journaling approach and LTSS resources), and participate in unstructured monthly check-ins (discussions and case review as applicable) with the research team.
66093|NCT03667911|Other|virtual reality videos|Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
66094|NCT03667898|Procedure|Lumbar plexus block using NTT|An lumbar plexus block is performed using ultrasound guidance with needle tip tracking.
66095|NCT03667898|Procedure|Lumbar plexus block without NTT|An lumbar plexus block is performed using ultrasound guidance without needle tip tracking.
66096|NCT03667885|Diagnostic Test|Blood sample|basic blood sample
66097|NCT03667885|Diagnostic Test|urine sample|basic urine sample
66098|NCT03667885|Diagnostic Test|Multi planar MRI|T1 (with reduced affinity for fatty tissue) +/- contrast, diffusion weighted sequences and wash in/wash out
66099|NCT03667872|Procedure|Bilateral implantation of DBS system to Habeluna|Bilateral implantation of MRI compatible and LFP recordable DBS system to Habeluna
66100|NCT03667859|Diagnostic Test|Vaginal Tactile Imaging|Vaginal elasticity measurements using the Vaginal Tactile Imaging system.
66101|NCT03667846|Drug|Topiramate|Generic topiramate, FDA-approve for clinical use, will be purchased in 25mg, 50mg, and 100mg strengths, and encapsulated.
66102|NCT03667846|Other|Placebo|Placebo tablets will be encapsulated in identical capsules.
66103|NCT03667833|Other|Shoulder brace|Shoulder brace is a designed elastic strap to correct scapula alignment in different characteristics such as tension and direction of force.
66104|NCT03667820|Drug|Osimertinib|Osimertinib 80mg tablet to be taken once daily.
66105|NCT03667820|Radiation|SABR|Stereotactic Ablative Radiation (SABR)
66106|NCT03667807|Device|Repetitive transcranial magnetic stimulation|Non invasive brain stimulation
66107|NCT03667794|Diagnostic Test|body plethysmography|measurement of conventional lung function parameters
66108|NCT03667794|Diagnostic Test|impulse oscillometry|measurement of central and peripheral airway resistance
66109|NCT03667794|Diagnostic Test|multiple breath washout|measurement of ventilation heterogeneity
66110|NCT03667781|Diagnostic Test|Therapeutic drug monitoring|Blood assay to evaluate for the presence of medications that the patient is prescribed. This is not being used for therapeutic purposes. It has already been validated in prior papers.
66111|NCT03667768|Procedure|Glass ionomer sealant|
66112|NCT03667768|Behavioral|Non-sealant (toothbrushing)|
66113|NCT03667755|Procedure|fast track recovery surgery with whey protein infused carbohydrate loading and early oral feeding|participants will be carbohydrate loaded with whey protein infused carbohydrate drink and started on early oral feeding post-operation
66114|NCT03667742|Diagnostic Test|analysis of sweat and serum samples for protein markers|collection of blood and sweat samples (with Macroduct Sweat Collecting System) in patients with suspected tuberculosis or proven acute tuberculosis or pulmonary diseases (pneumonia, bronchitis, COPD) and analyzing serum and sweat for protein markers (Early Secretory Antigenic Target (ESAT-6) and Culture Filtrate Protein 10 (CFP-10) and C-reactive protein (CRP) and Amyloid A2 and complement component 1q (C1q)) by mass spectrometry and enzyme-linked immunosorbent assay (ELISA)
66115|NCT03667729|Behavioral|progressive muscle relaxation|intervention group: The experimental group received muscle relaxation training once a week for 3 consecutive months. The results were measured and followed up after 3 months.
66116|NCT03667716|Drug|COM701|COM701 monotherapy.
66117|NCT03667716|Drug|COM701 with Opdivo (Nivolumab).|COM701 in combination with Opdivo (Nivolumab).
66118|NCT03667703|Drug|Ranitidine|Patients will be randomized to either receive a placebo or ranitidine (study drug).
66119|NCT03667703|Drug|Placebo|Patients will be randomized to either receive a placebo or ranitidine (study drug).
66125|NCT03667677|Drug|Tandospirone + Amlodipine|The first group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
66126|NCT03667677|Drug|Tandospirone placebo + Amlodipine|The second group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine one day(a 5 mg dose of amlodipine and one time a day).
66127|NCT03667677|Drug|Tandospirone + Amlodipine placebo|The third group will receive a 30 mg dose of tandospirone one day( a 10 mg dose of tandospirone and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
66128|NCT03667677|Drug|Tandospirone placebo + Amlodipine placebo|The fourth group will receive a 30 mg dose of tandospirone placebo one day( a 10 mg dose of tandospirone placebo each time and three times a day) and a 5 mg dose of amlodipine placebo one day(a 5 mg dose of amlodipine placebo and one time a day).
66196|NCT03667105|Procedure|CAF|Periodontal surgical technique to treat gingival recessions.
66129|NCT03667664|Behavioral|Physical exercises et nutritional counseling in elderly people at risks of loss of autonomy|"Pre-program : eligibility criteria, nutritional status (MNA score, BMI, recent loss of weight), previous history, comorbidities, clinical examination, number of loss in the previous year, Rapid Assessment of Physical Activity score, activities of daily living and Instrumental activities of daily living, Medical Outcome Study Short Form 36 score, physical tests (Hand grip, Short Physical Performance Battery, Knee extension, Neurocom platform physical tests, Dual X-Ray Absorptiometry and Bio-impedance for Body Mass measurement, Muscular echography.~Implementation of a one year multimodal program based on physical exercises and nutrition counseling as a way of preventing dependence and loss of autonomy in elderly people."
66130|NCT03667651|Drug|EpiCeram|Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
66131|NCT03667638|Combination Product|Platelet-Rich Plasma|Adding PRP to wound bed during surgical debridement
66132|NCT03667625|Other|Multidimensional Mobility Exercises|Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
66133|NCT03667625|Other|Control group|A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
66134|NCT03667599|Other|home care|This is the interventional arm where patients receive the transplant care in their homes.
66135|NCT03667586|Behavioral|Group cognitive behavioral therapy|Group sessions based on the principles of Cognitive Behavioral Therapy and adjusted for chronic disease patients
66136|NCT03667573|Device|tsDCS Dosage (A)|mild electrical stimulation delivered to lumbosacral spinal cord
66137|NCT03667573|Device|tsDCS Dosage (B)|mild electrical stimulation delivered to lumbosacral spinal cord
66138|NCT03667573|Other|textured shoe insoles|textured shoe insoles
66139|NCT03667560|Procedure|Dermacell ADM without basement membrane|Patient will be implanted with Dermacell ADM.
66140|NCT03667560|Procedure|FlexHD|Patient will be implanted with FlexHD.
66141|NCT03667547|Drug|Raltegravir|Raltegravir 600 mg tablet
66142|NCT03667534|Diagnostic Test|Dry blood spot screening|Dry blood spot measurement of biomarker for screening of cholestasis patients
66143|NCT03667521|Procedure|nerve-sparing laparaoscopic sacrocolpopexy|nerve-sparing laparaoscopic sacrocolpopexy implemented after 2010
66144|NCT03667508|Procedure|Rapid Maxillary Expanding Device|The expansion screw will be turned two times in the first day, and then daily until the correction is achieved.
66145|NCT03667508|Procedure|Slow Maxillary Expanding Device|The expansion screw will be activated every five days until correcting the crossbite.
66146|NCT03667482|Drug|Cabozantinib|Cabozantinib will be initiated at 40 mg PO daily, with subsequent 20 mg or 40 mg doses as tolerated per the study design.
66147|NCT03667482|Drug|Cetuximab|400 mg/m2 loading dose of cetuximab followed by 240 mg/m2 cetuximab IV weekly.
66148|NCT03667469|Procedure|gastric bypass|Laparoscopic surgical bariatric procedure with creation gastric pouch. A jejunal loop was created about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch.
66149|NCT03667469|Dietary Supplement|Hypocaloric diet therapy|Hypocaloric diet therapy with energy restriction (-500 kcal/d)
66150|NCT03667456|Procedure|Self-rehabilitation by digital support|Provision to patients selected by doctors or physiotherapists of an interactive digital tool (tablet + inertial sensor) to support self-rehabilitation home Parkinson's patients.
66151|NCT03667443|Dietary Supplement|Myo-inositol + folic a. + α-lactalbumin|3 months of treatment
66152|NCT03667443|Dietary Supplement|Myo-inositol + folic a.|3 months of treatment
66153|NCT03667430|Dietary Supplement|Porous silica|The particle is rod shaped and approximately 1-3 x 0.4-0.5 micrometers with pore sizes in the range of 70-130 Ångström or 7-13 nanometer.
66154|NCT03667430|Dietary Supplement|Placebo (microcrystalline cellulose)|All participants starts with five days placebo run in period
66155|NCT03667417|Other|Questionnaires|standardized data collection and 10-year prospective follow-up
66156|NCT03667404|Dietary Supplement|Resistant maltodextrin|Resistant maltodextrin powder
66157|NCT03667404|Dietary Supplement|maltodextrin|maltodextrin powder
66158|NCT03667378|Behavioral|Expectations Survey (CanCORS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
66159|NCT03667378|Behavioral|Values Survey (Serious Illness Care Program)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
66160|NCT03667378|Behavioral|Functional Assessment of Cancer Therapy-General (FACT-G)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
66161|NCT03667378|Behavioral|NCCN Distress Thermometer|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
66162|NCT03667378|Behavioral|Hospital Anxiety and Depression Scale (HADS)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
66197|NCT03667105|Other|MC|Xenogenous graft placed in the surgical site.
66198|NCT03667105|Other|XDM|Xenogenous dermal collagen graft placed in the surgical site.
66403|NCT03665259|Procedure|Lower oxygen group|Pre-oxygenation with 60% oxygen during induction of anesthesia
66163|NCT03667378|Behavioral|Quality of Communication (QOC)|Study assessments will be conducted at baseline (t0); at 3-6 weeks +/- 1 week from Day 1 of receiving investigational therapy, prior to sharing information on treatment response and before the first planned scan to evaluate extent of disease (t1); and at 8-12 weeks (the end of the 3 month total study time period) (t2).
66164|NCT03667378|Behavioral|visits with a supportive care clinician|Monthly visits with a supportive care clinician
66165|NCT03667365|Procedure|aortic valve replacement|aortic valve replacement surgical or transcatheter aortic valve replacement (will be decided by the heart team before randomization)
66166|NCT03667365|Other|strict clinical surveillance|strict clinical surveillance strategy
66167|NCT03667352|Procedure|Unilateral Scalp Block|Scalp block is provided by injecting local anaesthetic in the scalp at specific areas to block 6 nerves which are responsible for sensory innervation of the scalp - Supraorbital and supratrochlear nerves, Zygomaticotemporal nerve, Auriculotemporal nerve, Greater and lesser occipital nerves.
66168|NCT03667352|Procedure|Transversus abdominis plane block|The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). It is usually accomplished by a single bolus injection into the transversus abdominis plane through the lumbar triangle of Petit and can be accomplished either by blind landmark based technique or alternatively under ultrasound guidance (as in this study).
66169|NCT03667352|Drug|Intravenous Fentanyl|Fentanyl is a commonly used opioid drug administered for analgesia in the perioperative period. It may be used as either intermittent bolus administration or continuous infusion or a combination of the two. Usual infusion doses range from 1-2 microgram/kg/hr, which may be titrated based on intraoperative haemodynamics or postoperative patient reported pain scores.
66170|NCT03667339|Procedure|Direct Anterior Total Hip Arthroplasty|Direct Anterior Total Hip Arthroplasty
66171|NCT03667326|Drug|Aspirin|Low dose aspirin, 81mg tablets, PO
66172|NCT03667326|Drug|Placebo oral capsule|Placebo oral capsule, PO
66173|NCT03667313|Device|sirolimus-eluting balloon (SEB) MagicTouch|Patients with coronary in-stent restenosis treated with sirolimus-eluting balloon
66174|NCT03667313|Device|paclitaxel-eluting balloon (PEB) Sequent Please|Patients with coronary in-stent restenosis treated with paclitaxel-eluting balloon
66175|NCT03667300|Drug|Evogliptin|This group will take daily evogliptin 5mg per oral, not linagliptin.
66176|NCT03667300|Drug|Linagliptin|This group will take daily linagliptin 5mg per oral, not evogliptin
66177|NCT03667287|Procedure|Repair of parastomal hernia|Surgical repair of symptomatic parastomal hernia.
66178|NCT03667274|Procedure|cardiac valve surgery|cardiac double valve surgery (aortic and mitral valve)
66179|NCT03667261|Device|Sealing Socket Abutment|Sealing Socket Abutment (SSA) serves as a mechanical barrier to isolate the grafted area, stabilize the clot and contain the graft material, and seal the socket from foreign contaminants and also minimizing the risk of premature loading of the implant during healing. By preparing an SSA fabricated to follow the transmucosal contours of the natural tooth, the grafted area can be sealed and separated from the growth of soft tissue without the use of a membrane or releasing incisions
66180|NCT03667261|Device|cover screw|immediate implant placement in mandibular molar area will be covered with conventional cover screw
66181|NCT03667248|Device|Sorin Perceval ® Sutureless Valve (Sorin Group Italia Srl, 13040 Saluggia, Italy), available in different sizes (S 19-21mm, M 21-23mm, L 23-25mm, XL 25-27mm)|Sizing of the valve by preoperative CT scan of the heart and comparison of this measurement with the standard procedure (Sizing intraoperatively using the measuring devices provided by the product manufacturer)
66182|NCT03667235|Other|Treatment of human pericardium with glutaraldehyde in OZAKI procedure|10 versus 20 minutes treatment of human pericardium with 0.6% glutaraldehyde in OZAKI procedure
66183|NCT03667235|Other|Treatment of human aortic valve tissue with glutaraldehyde|10 versus 20 minutes treatment of human aortic valve tissue with 0.6%glutaraldehyde
66184|NCT03667222|Drug|minocycline topical gel|Once daily administration of BPX-04 minocycline gel for 12 weeks
66185|NCT03667222|Drug|topical gel vehicle|Once daily administration of BPX-04 gel vehicle for 12 weeks
66186|NCT03667209|Other|Pain neuroscience education (PNE) and traditional exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
66187|NCT03667209|Other|Pain neuroscience education (PNE) and suspension exercise|"PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour."
66188|NCT03667196|Procedure|antegrade and retrograde approach|This study intends to identify and compare the clinical, anatomical and periprocedural factors of the patients who used only the antergrade approach and the patients who needed the retrograde approach among the patients with coronary CTO
66189|NCT03667183|Other|Pilates|Specific postures in movement according to Pilates guidelines.
66190|NCT03667170|Biological|KN035|subcutaneous injection
66191|NCT03667157|Drug|every week IVMP therapy|12 pulses of intravenous methylprednisolone (IVMP) in every week schedule (for the first 6 weeks 0.5g IVMP per week, for the next 6 weeks 0.25g IVMP per week; cumulative dose 4.5g) according to EUGOGO recommendations
66192|NCT03667157|Drug|very high doses IVMP therapy|3 pulses of intravenous methylprednisolone (IVMP) (1.0g/day for 3 consecutive days; cumulative dose 3.0g) according to EUGOGO recommendations
66193|NCT03667131|Drug|Enalapril Maleate|Enalapril Maleate 5 mg tablet, every 12 hrs for 90 days.
66194|NCT03667131|Drug|Placebo|Placebo 5 mg tablet, every 12 hrs for 90 days.
66195|NCT03667118|Dietary Supplement|Food Supplement|A powder blend of 16 common allergenic proteins ([oat, milk, egg, sesame, wheat] [almond cashew, hazelnut, peanut, pecan, pistachios, soy, walnut] [cod, shrimp, salmon]) combined with 400 IU of Vitamin D3
66199|NCT03667092|Biological|non-drug intervention type|8 peripheral blood samples (8x5ml) will be obtained at different times ; before, during and after treatment
66200|NCT03667079|Other|integrated delivery of deworming and vaccination|integrated delivery of mass drug administrations, one targeting humans (deworming) and one targeting animals (rabies vaccination)
66201|NCT03667079|Other|Mass deworming only|Delivery of mass deworming to people only
66202|NCT03667079|Other|Mass vaccination of dogs|Delivery of mass vaccination of dogs only
66203|NCT03667066|Drug|Clopidogrel|Patients who were on long-term (more than 3 months) of clopidogrel or received a loading dose more than 4 hours prior to elective percutaneous coronary intervention.
66204|NCT03667053|Drug|dasiglucagon|glucagon analog
66205|NCT03667053|Drug|placebo|placebo for dasiglucagon
66206|NCT03667053|Drug|GlucaGen HypoKit|native glucagon
66207|NCT03667040|Behavioral|JOOL app|Participants will use the JOOL app for 30 days
66208|NCT03667027|Device|Respiratory support|Mechanical ventilation or extracorporeal life support
66209|NCT03667014|Drug|Dupilumab|Dupilumab treatment
66210|NCT03667001|Drug|Lidocaine Hydrochloride|The intervention to be studied will be the additional application of systemic lidocaine 1% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Patients, medical practitioner, nurses and investigators will be blinded by utilization of equal appearance and packing of IMPs, which will be fabricated individually for each patient and on request one to two days before surgery by the pharmacy. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
66211|NCT03667001|Drug|Saline Solution|The intervention to be studied will be the additional application of NaCl 0.9% dosed 1.5 ml/kg LBM to general anesthesia in bariatric surgery as a placebo. Patients, randomly assigned to one study group, will be surveyed for 48 hours after completion of surgery, experienced pain, occurrence of PONV, time to first defecation and length of hospitalization will be monitored. Each patient will self-evaluate his maximal experienced pain eight-hourly during a sequence of 48 hours after completion of surgery.
66212|NCT03666988|Drug|GSK3368715|GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.
66213|NCT03666975|Device|LIV 30 Hz|LivMD LIV platform
66214|NCT03666949|Drug|All General anesthesia|"Use of a hypnotic(propofol 2.5mg/kg), morphine(remifentanil1yg/kg) and curare(atracurium0.5mg/kg), with the support of orotracheal intubation and mechanical ventilation"
66215|NCT03666949|Drug|All Locoregional anesthesia|"Use of a local anesthetic( xylocaine 1%) for the realization of scalp nerve block"
66216|NCT03666936|Other|Social-health care intervention|Cancer survivors enrolled in the study could receive support from the Occupational Therapist and/or from the social care professionist to overcome the difficulties encounter at work or to facilitate work reintegration.
66217|NCT03666923|Drug|THR-687 dose level 1|single intravitreal injection of THR-687 dose level 1
66218|NCT03666923|Drug|THR-687 dose level 2|single intravitreal injection of THR-687 dose level 2
66219|NCT03666923|Drug|THR-687 dose level 3|single intravitreal injection of THR-687 dose level 3
66220|NCT03666910|Diagnostic Test|Audiometer|detection of hearing problems
66221|NCT03666897|Other|DTI Images and Plasma Biomarkers|Additional Images added from standard of care MRI, Bio-markers identified
66222|NCT03666884|Drug|COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
66223|NCT03666884|Biological|AS 50% eye drops 8*1|clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
66224|NCT03666871|Biological|SB-728-T|Autologous CD4+ T cells with ex vivo modification of the CCR5 gene by zinc finger nucleases
66225|NCT03666871|Biological|Expanded unmodified autologous CD4+ T cells|Autologous CD4+ T cells without ex vivo modification of the CCR5 gene by zinc finger nucleases
66226|NCT03666845|Procedure|Sciatic nerve block|Sciatic nerve block will be performed using ropivacaine (2.5mg/kg) under ultrasound-guidance with nerve stimulator.
66227|NCT03666832|Drug|TEW-7197|"TEW-7197 1cycle 14days~-intake 5days, rest 2days"
66228|NCT03666819|Device|Carbon Dioxide Fractional Laser|Undergo CO2RE laser therapy
66229|NCT03666819|Other|Questionnaire Administration|Ancillary studies
66230|NCT03666806|Biological|Influenza vaccine|The randomized FLUVACS trial demonstrated the benefits of influenza vaccination in the prevention of cardiovascular death. In the VIPS study the risk for acute ischaemic stroke (AIS) in children increased by 6-fold compared to the baseline population. It was postulated that infections and in particular upper respiratory tract infections acts as a stroke trigger in a child who is otherwise predisposed to stroke and why it would occur at a particular point in that child's life. It should be noted that major infections such as meningitis have been causes of stroke while this study has shown that minir infections can also act as a trigger for stroke in adults
66231|NCT03666793|Other|global care|Medication Reconciliation at admission, Multidisciplinary medication review, Medication Reconciliation at discharge
66232|NCT03666780|Device|LAmbre occluder|All patients are implanted with a LAmbre occluder device
66233|NCT03666767|Other|Comparisons will be made between LMICs and HICs|Countries will be defined as low, middle or high-income using the World Bank classification.
66234|NCT03666754|Procedure|Standard therapy arm|Multilayer elastic compression bandaging/ stockings with the deferred treatment of superficial reflux (usually once the ulcer has healed)
66235|NCT03666754|Procedure|Early endovenous glue embolization arm|Early endovenous glue embolization of superficial venous reflux within 2 weeks in addition to standard compression therapy
66236|NCT03666741|Device|AVR with or without CABG|Surgical aortic valve implantation with INSPIRIS RESILIA Aortic Valve™
66237|NCT03666728|Drug|SHR-1210|SHR-1210 was administered 200 mg iv every 3 weeks
66238|NCT03666728|Drug|BP102|BP102 was administered 15 mg/kg iv every 3 weeks
66338|NCT03665818|Device|oral appliance treatment|mandibular advancement device to enlarge pharyngeal airway space to get rid of apnea and hypopnea events
66239|NCT03666715|Drug|Oral Antipsychotics (OAPs)|No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
66240|NCT03666715|Drug|Paliperidone Palmitate 1-Month Formulation (PP1M)|No study treatment will be administered as a part of this study. Participants will receive PP1M as per their usual clinical practice.
66241|NCT03666702|Other|Upper limb physiotherapy programme|Web-based physio programme
66242|NCT03666702|Other|Usual care|Usual physiotherapy care
66243|NCT03666689|Procedure|surgical technique|surgical reconstruction
66244|NCT03666676|Other|Signal processing to improve intelligibility|Signal processing will be used to manipulate frequency and amplitude fluctuations in complex sounds.
66245|NCT03666663|Drug|Lidocaine|Nasal application using the Sphenocath device- cleared by FDA
66246|NCT03666663|Drug|Bupivacaine|Nasal application using the Sphenocath device- cleared by FDA
66247|NCT03666663|Drug|Ropivacaine|Nasal application using the Sphenocath device- cleared by FDA
66248|NCT03666663|Drug|Placebo|Placebo Saline using the Sphenocath device- cleared by FDA
66249|NCT03666650|Drug|Edoxaban 60 MG|Viscoelastic analysis and standard laboratory tests after edoxaban ingestion
66250|NCT03666637|Procedure|dynamic hip screw (DHS) and cannulated screw (CS)|A preformed case report form was used to collect the data which included the demographic profile of the patients (age, gender), comorbidities, smoking history, mode of injury (high or low energy), presence of multiple trauma, garden classification, side of injury, time to fixation (in hours), type of reduction, type of implant used, RUSH score (healing), start of weight bearing, development of AVN, and final outcome (whether varus, valgus, displaced or healed).
66251|NCT03666624|Behavioral|Personalized care network|The Personalized care network intervention includes exercise training for care receiver with dementia and surrogate caregiver and behavioral management training for surrogate caregiver.
66252|NCT03666598|Device|Tourniquet|In the patients randomized to the use of tourniquet, the tourniquet time starts before skin incision and terminates when the wound closure starts. The cuff pressure is set at 300mmHg.
66253|NCT03666585|Other|mobile application actuated rehabilitation exercise guidance|Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.
66254|NCT03666585|Other|routine rehabilitation exercise guidance|the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
66255|NCT03666572|Other|Bifidobacterium infantis|Bifidobacterium longum subsp. infantis (EVC001)
66256|NCT03666572|Other|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]|Bifidobacterium infantis with prebiotic Lacto-N-neotetraose [LNnT]
66257|NCT03666572|Other|Placebo (Lactose)|Placebo (Lactose)
66258|NCT03666559|Drug|Azacitidine|Chemotherapy
66259|NCT03666546|Drug|Lactulose crystals 20 g|White or almost white crystalline powder. The product will be provided in sachets to be dissolved in 250 mL water.
66260|NCT03666546|Drug|Lactulose crystals 30 g|White or almost white crystalline powder. The products will be provided in sachets to be dissolved in 250 mL water.
66261|NCT03666546|Drug|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
66262|NCT03666546|Drug|Lactulose liquid 30 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
66263|NCT03666546|Drug|Glucose|White crystalline powder. To standardise for 30 g glucose, 33 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
66264|NCT03666546|Drug|Still water|250 mL still water will be used. Water from the same source will be also used to dissolve investigational and control products
66265|NCT03666533|Other|Active transcranial Direct Current Stimulation|Active tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
66266|NCT03666533|Other|Sham transcranial Direct Current Stimulation|Sham tDCS is combined with gait therapy. Gait therapy includes gait task practice in Virtual Reality setting and overground gait therapy
66267|NCT03666520|Other|Clinical Decision Support prompted to the clinician to convert drug.|This study is designed to further research the conversion of Intravenous medications to oral medications in patients in an inpatient setting whenever it is appropriate and safe. We have chosen eight medications to research in this study. These medications were chosen because large difference in cost between an intravenous (IV) dose of this medication versus an oral (PO) dose of this medication exist. This study aims to further evaluate the appropriateness and safety of converting IV medications to PO medications for hospitalized patients through a pilot clinical trial.
66268|NCT03666507|Procedure|Intraoperative Monitoring during resection of brain tumor|Intraoperative Monitoring during resection of brain tumor
66269|NCT03666494|Drug|Ketamine Hydrochloride|As part of anesthetic induction, the addition of ketamine hydrochloride 0.5mg/kg.
66270|NCT03666494|Drug|Propofol|As part of the patient's anesthetic induction, they will receive propofol.
66271|NCT03666494|Drug|Fentanyl|As part of the patient's anesthetic induction, they will receive fentanyl.
66272|NCT03666481|Behavioral|Motivational Physical Activity Intervention (MPAI)|"MPAI was carried out during 6 consecutive months. The sessions were directed by sport sciences professionals, who were trained in the application of motivational strategies based on self-determination theory.~The frequency of training, as well as the duration of the sessions, was increasing throughout the 6 months. The contents of the sessions could be directed in two ways: sessions with activities to develop cardiorespiratory fitness and muscular strength, and playful sessions to enhance psychosocial aspects. Nevertheless, motivational strategies were implemented in both types of sessions."
66273|NCT03666468|Other|PlayMed|A highly immersive role-playing computer game focused on Paediatric Asthma and Seizure management
66274|NCT03666468|Other|Online Package|Online package (OP) of NSW Health Guidelines focused on Paediatric Asthma and Seizure management
66275|NCT03666468|Other|Paper Guidelines|Paper NSW Health Guideline focused on Paediatric Asthma and Seizure management
66276|NCT03666455|Behavioral|Acceptance and Commitment Therapy|Acceptance and commitment therapy (ACT) is a type of psychotherapy, or cognitive behavioral therapy, that aims to help patients focus on the present, accept their situation, and find positive coping skills.
66277|NCT03666442|Drug|XELOX|Xelox chemotherapy,that oxaliplatin 130mg/m2 d1,capecitabine 1000mg/m2 twice daily d1-14,every 3 weeks
66278|NCT03666429|Device|Bulb suction|Parents will use the bulb suction on their child in the emergency room then complete a 7 point likert survey.
66279|NCT03666429|Device|NoseFrida|Parents will use the NoseFrida in the emergency department and complete a 7 point likert survey.
66280|NCT03666416|Behavioral|Sprint Interval Training|Participants will attend two experimental appointments, during which they will complete two identical executive functioning tasks (i.e., sustained attention, working memory). During one appointment, participants will receive the sprint interval training manipulation prior to completing the tasks.
66281|NCT03666403|Procedure|NIV rate: 0/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
66282|NCT03666403|Procedure|NIV rate: 10-20/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
66283|NCT03666403|Procedure|NIV rate: 5-10/min|A basic PhO2 flow was routinely provided. A small pharyngeal catheter with warmed, humidified and fixed pure oxygen flow was inserted via one nostril to ensured catheter tip positioning in the oropharynx. The NIV was performed in the following steps. Firmly closed the mouth, then intermittently applied a) assisted inspiration by nose-closure accompanied with cricoid depression; and b) assisted expiration by the release of above nose and cricoid maneuver but with simultaneous abdomen-compression. The above assisted ventilation cycle was maintained at a rate of 0-20 cycles per minute. The scopist executed both the FB and the nose-closure and release, whereas an assistant delivered the abdomen compression.
66284|NCT03666390|Drug|Ketamine|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
66285|NCT03666390|Drug|Midazolam|We will elucidate the exact efficacy of a low dose of ketamine infusion for the rapid anti-depression and anti-suicidal ideations.
66286|NCT03666377|Other|Gum chewing|1 piece of sugarless gum to be chewed three times daily for 1 hour each.
66287|NCT03666364|Other|Sperm preparation for ICSI|A new protocol for sperm preparation for ICSI cycles with teratozoospermia in over 35 years old women
66288|NCT03666351|Drug|Amlodipine 5mg|Amlodipine 5 mg
66289|NCT03666351|Drug|Losartan|Losartan Potassium 50 mg
66290|NCT03666351|Drug|Losartan and Amlodipine|Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
66291|NCT03666351|Drug|Amlodipine/Losartan/Chlorthalidone|Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
66292|NCT03666351|Drug|current treatment|treatment is done by maintaining the current treatment
66293|NCT03666338|Other|Early, goal-directed mobilization|Early, goal directed mobilization using (1) the SOMS algorithm and (2) facilitator
66294|NCT03666325|Drug|Pembrolizumab|Pembrolizumab at 200 mg every 3 weeks for 9 weeks.
66295|NCT03666325|Drug|Cetuximab|In case of first progression or no response cetuximab will be added at a weekly dose of 250 mg.
66296|NCT03666299|Drug|Lidocaine|Infusion of 2% lidocaine hydrochloride at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
66297|NCT03666299|Drug|Control|Infusion of normal saline at 4 mL/h, started after tracheal intubation and discontinued until 24 h after surgery.
66300|NCT03666260|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with echography
66301|NCT03666260|Procedure|femoral block|femoral block with echography
66302|NCT03666247|Behavioral|HealthMindr Application|From baseline to 3-month post-test, participants in the intervention arm are granted access and instructed to interact regularly with the HealthMindr messaging platform. The HealthMindr messaging platform delivers messages relevant to both general audiences of sexually-active MSM, as well as messages relevant only to specific subgroups of HIV-positive men, and currently higher and lower risk HIV-negative men. Answers provided during the assessments determine which subset of messages are delivered to app users, with information such as HIV status, changes in self-reported risk behaviors, or other factors that influence the relevance of any given message. The HealthMindr application also offers free condoms, lube, and a HIV and STI testing kits.
66303|NCT03666247|Behavioral|Waitlist|Participants assigned to the waitlist-control arm will be given a welcome sheet orienting them to the study. The message they view will include the same resources links provided to the intervention arm. The information will cover the importance of testing, links to an online mapping tool about the HIV epidemic in the United States (AIDSVu) and resources to locate HIV testing services and prevention information in their area. No information recommending frequency of testing will be given in the welcome greeting.
66304|NCT03666221|Drug|Nimotuzumab|Drug: Nimotuzumab Radiation: Intensity Modulated Radiation Therapy
66401|NCT03665272|Procedure|deepithelialized gingival graft fixation|one group's deepithelialized gingival graft fixed by sutures and other one's by tissue adhesive.
66305|NCT03666208|Device|Sirolimus Coated Balloon|"Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution."
66306|NCT03666195|Combination Product|Titanium Dioxide Nanoparticles|incorporating titanium dioxide nanoparticles to PMMA, significantly decreases porosities in the denture resin, rendering titanium dioxide nanoparticles a suitable additive to denture base materials, as it also exhibits anti-microbial effects
66307|NCT03666182|Other|No Intervention|No Intervention
66308|NCT03666169|Other|Survey|Survey
66309|NCT03666156|Other|No intervention|No Intervention
66310|NCT03666143|Drug|Sitravatinib|Sitravatinib 120 mg orally once daily in combination with tislelizumab 200 mg IV once every 3 weeks
66311|NCT03666130|Procedure|endoscopic septoplasty|endoscopic septoplasty is the use of nasal endoscopy in the septoplasty surgery for treatment of deviated nasal septum . we aim to compare the outcome of using this method versus conventional septoplasty
66312|NCT03666104|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
66313|NCT03666078|Procedure|cesarean delivery|women delivered by cesarean section
66314|NCT03666065|Drug|Aspart insulin|Standard insulin
66315|NCT03666039|Behavioral|Trainings app|Sensorimotor trainings app for at home Training (tablet-based)
66316|NCT03666026|Behavioral|1 MyChart R/R|Up to 1 flu vaccine reminder recall notice sent via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
66317|NCT03666026|Behavioral|2 MyChart R/R|Up to 2 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
66318|NCT03666026|Behavioral|3 MyChart R/R|Up to 3 flu vaccine reminder recall notices sent every 3-4 weeks via MyChart to patients who are due for the flu vaccine, per the EMR records of the health system.
66319|NCT03666000|Genetic|PBCAR0191|Single dose of Allogeneic Anti-CD19 CAR T cells will be infused
66320|NCT03666000|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
66321|NCT03666000|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
66322|NCT03665987|Behavioral|consultation in preoperative assessment clinic|The treatment group will be seen in the preoperative clinic before hospitalization, while the control group will get anesthetic consultation after hospitalization without clinic service. No additional interventions will be given during and after surgery.
66323|NCT03665948|Other|Dietary Intervention - Ketogenic Diet (KD)|The experimental procedure for each randomly assigned participant included a 4-week of KD diet.
66324|NCT03665948|Other|Dietary Intervention - Low-Glycemic Index Diet (CHO-LGI)|The experimental procedure for each randomly assigned participant included a 4-week of CHO-LGI diet.
66325|NCT03665922|Dietary Supplement|BroccoMax®|Nutraceutical neoadjuvant
66326|NCT03665922|Other|Placebo|control
66327|NCT03665909|Other|Remote activity monitoring system|The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
66328|NCT03665896|Device|intubation with VivaSight double-lumen tube|
66329|NCT03665896|Device|intubation with standard double-lumen tube|
66330|NCT03665896|Procedure|fiberoptic bronchoscopy|
66331|NCT03665883|Procedure|Monopolar energy|Monopolar energy in TEP for inguinal hernia
66332|NCT03665883|Procedure|Blunt dissection|Blunt dissection in TEP for inguinal hernia
66333|NCT03665870|Behavioral|Hypoglycemia Education|Two in-person visits to the home of the participant and 4 phone calls will be conducted to provided education on prevention of hypoglycemia.
66334|NCT03665857|Behavioral|a multicomponent intervention|"School-level policies Students will not be allowed to drink sugar-sweetened beverage or eat unhealthy snacks in schools and drinking water will be advocated.~Monitoring of students' weight and height Students will be monitored their weight and height monthly.~Promotion of physical activity Students will be required to perform at least 60 minutes of moderate to vigorous physical activity each day in school and increase their physical activity outside school (reaching 30 minutes per weekday and one hour per weekend day).~Health education activities Health education activities will be provided for students (10 sessions, 40 minutes per session, 2-3 weeks once), parents and school teachers.~The mobile application The mobile application will disseminate health education knowledge among students, parents and teachers, monitor and provide feedback of students' BMI status and diet and physical activity behaviors."
66335|NCT03665844|Device|SmartSleep Boost On|"SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS)."
66336|NCT03665844|Device|SmartSleep Boost Off|SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
66337|NCT03665831|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered daily for 4 consecutive weeks.
66402|NCT03665259|Procedure|Pure oxygen group|pre-oxygenation with 100% oxygen during induction of anesthesia
66339|NCT03665805|Other|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of the TOFscan neuromuscular transmission monitor (iDMed, Marseille, France).
66340|NCT03665792|Device|nociception index qNOX|non-invasive, real time, monitoring for nociception stimulation
66341|NCT03665779|Drug|isosorbide mononitrate|70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times
66342|NCT03665779|Drug|Placebo|70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times
66343|NCT03665766|Drug|Cycloserine,Tacrolimus|
66344|NCT03665753|Drug|Ketorolac|Subject will receive 10, 20, and 30mg of Ketorolac.
66345|NCT03665740|Drug|Resveratrol|resveratrol is an OTC supplement
66346|NCT03665727|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
66347|NCT03665727|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
66348|NCT03665727|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
66349|NCT03665714|Other|Impact Oral|Impact Oral belongs to Food for Special Medical Purpose (FSMP) according to China registration regulation, including Omega-3 fatty acids, Arginine and Nucleotides immunonutrition.
66350|NCT03665714|Other|Enteral Nutrition Emulsion(TPF-T)|TPF-T
66351|NCT03665701|Procedure|Blood Sampling|Blood samples used within in vitro experiments to investigate the activation potency of Prostaglandin D2 metabolites to the DP2 receptor in comparison to Prostaglandin D2.
66352|NCT03665688|Device|Outpatient Dilapan-S|After Dilapan-S placement, subjects will be given the option to either return home or to stay in a hotel if transportation is an issue. Subjects will also be instructed to return to L&D unit 12 hours after insertion, or earlier if any excessive bleeding, rupture of membranes, pain or other concerns (contractions, decreased fetal movement) develop before the 12 hours. After the designated 12 hours' time or earlier, if indicated, subjects are to return and to be admitted to L&D unit for standard protocol of labor induction.
66353|NCT03665688|Device|Inpatient Dilapan-S|"After Dilapan-S placement, subjects will be admitted to L&D unit and standard clinical protocol will be initiated for cervical ripening and labor induction. During the period of 12 hours of cervical ripening subject is to remain nothing per os (NPO), nothing per vagina and undergo continuous fetal heart rate monitoring. No other interventions are to occur during this period of 12 hours, unless clinically indicated."
66354|NCT03665675|Biological|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given intravenously
66355|NCT03665662|Other|Music|Intra-procedure music through headphones
66356|NCT03665649|Procedure|CD133+ cells isolation|Hematopoietic precursors from human donors will be mobilized by administering Colony Stimulating Factors (G-CSF) for 5 days (according to the clinical standard administration) and subsequently CD133+ cells will be isolated and transferred in a murine model.
66357|NCT03665636|Drug|Triheptanoin|This is an open-label study. The UX007 (triheptanoin) starting dose will be 0.25 - 0.5 g/kg and titrated to a maximum of 2.5g/kg depending the on the subject's tolerance. The dose may be reduced if not tolerated. The compound will be administered 3-4 times per day, either at the end of a meal or with a snack. It should be given at least 2 hours apart from any cornstarch dose to allow each to act independent of one another, and to prevent the risk of increased gastrointestinal side effects. The doses may be held during episodes of gastroenteritis or diarrhea.
66358|NCT03665610|Drug|ozanimod|ozanimod
66359|NCT03665597|Biological|Pembrolizumab Dose C|SC injection
66360|NCT03665597|Biological|Pembrolizumab Dose A|SC injection
66361|NCT03665597|Biological|Pembrolizumab Dose B|IV infusion
66362|NCT03665597|Biological|Pembrolizumab Dose D|IV infusion
66363|NCT03665584|Device|FxCO2 Laser|The FxCO2 laser allows a microablative effect in soft tissue.
66364|NCT03665584|Device|Sham Laser|The Sham laser will be used on the participants who receive the sham treatment.
66365|NCT03665571|Diagnostic Test|Receptor specific activation method|NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
66366|NCT03665558|Device|Temporary DDD pacing|Measurements will be performed in patients otherwise undergoing invasive catheterization procedure. Baseline ventricular and aortic hemodynamic parameters (continuous pressure recordings) will be recorded. Thereafter, DDD pacing with stepwise changing of the AV delay will be performed. During each pacing steps left ventricular and aortic pressures at different aortic levels will be continuously recorded. From these hemodynamic data, left ventricular and aortic dP/dt values will be calculated off line.
66367|NCT03665545|Drug|IMA950/Poly-ICLC|IMA950 mixed with Poly-ICLC administered subcutaneously
66368|NCT03665545|Drug|IMA950/Poly-ICLC and pembrolizumab|IMA950 mixed with Poly-ICLC administered subcutaneously in combination with pembrolizumab
66369|NCT03665532|Behavioral|Youth Engagement in Services|Brief phone coaching to enhance engagement, retention, and sustain adherence to HIV and substance use services for younger people living with HIV.
66370|NCT03665519|Dietary Supplement|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh mare milk (few hours) through sublimation process.
66371|NCT03665519|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid treatment will be given for 3 months.
66372|NCT03665506|Drug|Trifluridin/Tipiracil|QoL assessment
66373|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
66399|NCT03665298|Behavioral|Smartphone Application|App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
66374|NCT03665493|Drug|PD patients H&Y=1.5-2 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
66375|NCT03665493|Behavioral|Healthy age-matched controls|Healthy controls will perform the stop signal task and the go-only task in the same day. The order of administration will be counterbalanced.
66376|NCT03665493|Drug|PD patients H&Y=3 Medications OFF|Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
66377|NCT03665493|Drug|PD patients H&Y=3 Medications ON|Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
66378|NCT03665480|Drug|G-SCF|In G-CSF treatment group, all patients are treated with G-CSF at the dose of 5ug/kg pre day until neutrophil higher than 0.5 g/L or 14 days from day three after induction therapy. MRD is monitored at day 14 and 28, respectively, with flow cytometry and quantity PCR if a fusion gene is available.
66379|NCT03665454|Drug|PF-06412562|PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
66380|NCT03665454|Drug|Standard of Care Placebo|25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
66381|NCT03665441|Drug|eryaspase|L-asparaginase encapsulated in erythrocytes (red blood cells)
66382|NCT03665441|Drug|Gemcitabine plus Abraxane|gemcitabine, Abraxane
66383|NCT03665441|Drug|Irinotecan plus 5-FU plus leucovorin|irinotecan, 5-FU, leucovorin
66384|NCT03665428|Drug|PAMB treatment (modified quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
66385|NCT03665428|Drug|PBMT treatment (bismuth-containing quadruple therapy)|Randomly assign either as PAMB or PBMT group treatment
66386|NCT03665415|Behavioral|NDGameSquad|The intervention will be delivered within participants' homes. Participants will be provided a gaming console and exergames. Participants will be encouraged to meet a goal of 60 minutes/day of MVPA for the duration of the intervention by playing the exergames at least three times per week and engaging in non-screen based physical activity on other days. Participants will receive a booklet that includes a curriculum for playing weekly challenges. Participants will wear a FitBit during their exergaming sessions. Participants and parents meet bi-weekly with a health coach via video-chat using the exergame console. Sessions will identify and encourage specific physical activity, healthy eating, and healthy sleep habits. At the school site, participants will receive additional check-ins, engagement support, and health curricula from classroom teachers during the first 10 weeks of the intervention.
66387|NCT03665402|Drug|Isoniazid|One of the first line anti-tubercolosis drug
66388|NCT03665389|Device|iFR / FFR measurement|At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
66389|NCT03665376|Dietary Supplement|Carbohydrate drink load|Administration of 5% Dextrose orally as a carbohydrate drink load two hours before surgery and as an oral sips eight hours after the surgery.
66390|NCT03665376|Combination Product|Enhanced Recovery After Surgery (ERAS)|The ERAS intervention consisted of exposing patients to ERAS protocol of care as described by the ERAS Society® for the entire perioperative period. However, some of these ERAS protocols were modified to our local resources and requirements.
66391|NCT03665363|Other|SCOPE|SCOPE is a internet-delivered, coach-guided, psychoeducational intervention, intended to serve as a first-line intervention for intellectually able adolescents and young adults with ASD. The SCOPE program is based on information comprising neuropsychology, pedagogy, and also interdisciplinary clinical experience regarding ASD. The content is aimed at providing information about typical and specific impairments of ASD, as well as the associated strengths.
66392|NCT03665363|Other|Self-study|Active control consisting of directed self-studies on internet.
66393|NCT03665350|Drug|Insulin|"Insulin as well as oral anti-diabetic drugs will be prescribed by the responsible physician and/or the diabetologist from each participating site, in conformity with the current guidelines, and the therapeutic target chosen according to patient characteristics.~The choice of anti-diabetic medications should be guided by medical needs of each patient and taking into consideration their general safety profile."
66394|NCT03665337|Behavioral|mTranS-C|MOBILE HEALTH
66395|NCT03665337|Behavioral|inJOY|MOBILE HEALTH
66396|NCT03665324|Other|Evaluation of the relationship between atrial remodeling evaluated by ECG and ETT with the occurrence of supraventricular arrhythmias|"Subjects will be retrospectively retrieved from the Sport Medicine Service of Rennes University Hospital database.~Medical data will then be collected from the athletes' medical records. The ECG present in the medical file will be reinterpreted to obtain the resting heart rate, the amplitude of the P wave, the morphology of the P wave and the duration of the PR space.~The data from the stress test will be found from reports in the medical records: resting heart rate, maximum heart rate, sustained peak load, arrhythmia during the test.~ETTs will be retrieved from the local server. They will be reinterpreted to collect anatomical and functional cardiac data necessary for the study."
66397|NCT03665311|Biological|25% Albumin fluid|25% Albumin fluid (100 mL)
66398|NCT03665311|Other|Normal Saline|9% Normal Saline (100 mL)
66400|NCT03665285|Drug|NC318|NC318 is an experimental antibody drug that may make the immune response more active against cancer.
66404|NCT03665246|Behavioral|Integrated Mothers and Babies Course|The Integrated Mothers and Babies Course/Early Childhood Development (iMBC/ECD) will be implemented along side normal C-PrES programming (key MNCHN behaviors). The iMBC curriculum is a prevention model based on cognitive behavioral therapy with the aim of supporting pregnant women and mothers with children under two years of age to become more resilient, decrease risk for future depression, and manage daily stressors effectively. In addition, the updated version of the iMBC is integrated with selected early childhood development (ECD) messages. The integration of these messages is intended to increase mothers' knowledge of the stressors associated with pregnancy and parenting young children and promote early stimulation behaviors and bonding to support child development.
66405|NCT03665233|Device|VR|People in the VR-group get a VRH session during the CPM physiotherapy , people in the sham group get a VR sham session, while they both can enjoy Standard Treatment
66406|NCT03665220|Other|Ergonomic adjustments|The ergonomic adjustments made were based on a prior assessment of the patient's needs in this respect, using a purpose-made home inspection form .
66407|NCT03665220|Other|Kinesiotherapy plus ergonomic adjustments|This group received, in addition to the ergonomic adjustments described above, sessions of postural orientation and kinesiotherapy (therapeutic exercises).
66408|NCT03665220|Other|Healthcare education|This group received health education information, based on an illustrated manual with advice for patients with chronic stroke.
66409|NCT03665207|Drug|Insulin|When blood glucose exceeds the preset target, insulin will be administered through continuous intravenous infusion. Insulin will be titrated according to frequent measurement of blood glucose and with use of the LOGIC-insulin algorithm in the experimental group. The intervention will be stopped upon ICU discharge, or until the patient is able to resume oral feeding, or until the patient no longer has a central venous catheter, whatever comes first.
66410|NCT03665194|Drug|Cortexolone 17α-propionate solution|Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.
66411|NCT03665194|Drug|Placebo|matching placebo
66412|NCT03665181|Other|use or non-use of dose modulator and bismuth mask|For each child for who the eligibility criteria are met, the CT exam is perfomed with or without dose modulator associated to with or without bismuth mask
66413|NCT03665155|Drug|89Zr-daratumumab|2 mCi of 89Zr-daratumumab will be administered on day 0.
66414|NCT03665155|Device|PET/CT scans|PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.
66415|NCT03665155|Other|Blood draws|Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
66416|NCT03665142|Other|Kinesio taping|Upper trapezius muscle stretching exercise with Kinesio taping (KT) was applied to the study group. KT was applied 8 times in total for 4 weeks with 2 sessions per week. Stretching exercise was done in the morning, afternoon and evening 3 times (repeated 10 times per set) every day for 4 weeks and 5 days of the week.
66417|NCT03665142|Other|Exercise|Upper trapezius muscle stretching exercise was applied to the control group.
66418|NCT03665129|Biological|IPH5401 and Durvalumab|IPH5401 and durvalumab
66419|NCT03665116|Dietary Supplement|L-arginine|L-arginine capsule
66420|NCT03665103|Other|Laser-assisted ICSI|Laser opening of the zona pellucida.
66421|NCT03665090|Behavioral|Diabetic eye disease screening|Community-based, prospective cohort study from three consecutive years (2016 to 2018) to determine the prevalence and impact of diabetic eye disease, especially diabetic retinopathy (DR), in adults with diabetes living in Shanghai.
66422|NCT03665077|Diagnostic Test|Initial blood draw|At baseline, patients will undergo a blood draw.
66423|NCT03665077|Diagnostic Test|Initial SWE ultrasound|At baseline, patients will undergo a sheer wave elastrography (SWE) ultrasound of their hands including wrists.
66424|NCT03665077|Diagnostic Test|Blood draw at three months|Blood drawn at three months to evaluate oxylipins.
66425|NCT03665077|Diagnostic Test|Blood draw at six months|Blood drawn at six months to evaluate oxylipins.
66426|NCT03665077|Diagnostic Test|SWE ultrasound at six months|SWE ultrasound at six months to evaluate tendon stiffness.
66427|NCT03665051|Procedure|Muscle Tissue Biopsy|A biopsy of the Vastus Lateralis muscle will be performed on the left leg using the Bergstrom technique.The skin will be incised (approximately 0.75 cm) with a #11 scalpel, and the Bergstrom needle will be inserted into the Vastus Lateralis. Approximately 150 mg of muscle tissue will be obtained under suction. After the biopsy, pressure will be applied to stop bleeding and the skin will be closed with Steri strips (suture(s) if allergy to steri strips and removal 7-10 days post biopsy). A sterile dressing will be applied. Ace bandage may also be used along with applied pressure and an ice pack for any swelling and pain relief.
66428|NCT03665051|Other|Maximal Oxygen Consumption (V02max)|Aerobic fitness will be determined by measuring maximal O2 consumption (VO2max) during a stationary bicycle exercise test. Heart rate, blood pressure and ECG will be recorded throughout this test. Subjects will breathe through a low resistance mouthpiece and wear a nose clip. Expired gases will be measured by indirect calorimetry and heart rate monitored by a portable heart rate monitor. Following a standardized warm up, subjects will begin exercising at a moderate intensity with the workload increased every minute until the subject can no longer continue. A leveling-off (plateau) or decline in oxygen uptake should be demonstrated in order to be reasonably sure that a subject has achieved the maximum capacity for aerobic metabolism.
66429|NCT03665038|Drug|Brexanolone|Brexanolone
66430|NCT03665038|Drug|Placebo|Placebo
66431|NCT03665025|Other|immediate implant using mixed allograft and xenograft|immediate implant using mixed allograft and xenograft in anterior area to fill jumping area
66432|NCT03665012|Other|Pediatric Development Clinic (PDC)|All children enrolled in PDC will be at screened for any medical condition they may have and be referred for treatment as required. Nutrition and development support are also provided to clinic enrollees, based on clinic protocols which include regular monitoring and intervention.
66433|NCT03664999|Diagnostic Test|Blood sampling|differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
66434|NCT03664986|Drug|Liposomal Bupivacaine|The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
66435|NCT03664973|Procedure|Serratus plane block|Local anesthetic infusion though a peripheral nerve catheter placed on the 5th rib under the serratus plane
66436|NCT03664960|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
66437|NCT03664947|Other|exercise|After the initial evaluations, a video-based gaming console exercise program will be implemented for 8 weeks, taking into account the possibility of accepting and participating in treatment with children. Exercises applied by a Nintendo Wii Fit Plus System. Evaluations will be repeated at the end of treatment.
66438|NCT03664934|Other|Exercises|Neck-specific exercises for chronic whiplash associated disorders
66439|NCT03664921|Drug|Omnitram Oral Tablet|Administered three times daily for 28 consecutive days.
66440|NCT03664921|Drug|Placebo Oral Tablet|Administered three times daily for 28 consecutive days.
66441|NCT03664908|Other|Detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method).|biological detection of circulating anti-GBM antibodies (using chemiluminescence method and indirect immunofluorescence (IIF) method) in three serum samples groups, coming from SLE patients (having Lupus Nephritis or not) and in a control group.
66442|NCT03664895|Drug|Leuplin or zoladex|OFS(Leuplin or zoladex) add on to TMX
66443|NCT03664882|Drug|Fexofenadine M016455|Pharmaceutical form: tablet Route of administration: oral
66444|NCT03664882|Drug|Placebo|Pharmaceutical form: tablet Route of administration: oral
66445|NCT03664869|Drug|BCG instillation therapy|Induction period of six weekly instillations of BCG followed by maintenance period of ten monthly instillations of BCG
66446|NCT03664869|Drug|Sequential BCG and EMDA mitomycin C|"Induction period includes nine weekly instillations of sequential BCG and EMDA-MMC instillations applied as three cycles of BCG, BCG and EMDA-MMC. Induction period is followed by maintenance period of nine monthly instillations of sequential EMDA-MMC and BCG applied with three cycles of EMDA-MMC, EMDA-MMC and BCG.~BCG instillation is performed as a standard instillation.~Mitomycin C is administered with electromotive drug administration (EMDA) device (Instillation: 40 mg mitomycin C with 960 mg of excipient sodium chloride dissolved in 100 ml sterile water, EMDA settings: current rise rate 30-50 microamperes per second, max 25 milliamperes, treatment duration 30 min)"
66447|NCT03664856|Other|interview|The patient will be asked to answer the questions that the interviewer will ask him.
66448|NCT03664830|Drug|Plerixafor|Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)
66449|NCT03664817|Behavioral|social capital intervention|The social capital intervention will focus on developing skills and group-work that culminate in participant-derived photovoice projects. Each group of YBMSM will be encouraged to complete a 30 day photovoice challenge. The 30 day challenge is based on a prior community action project done as a part of our Centers for AIDS Research (CFAR)-funded research, which was a Photovoice project conducted by Dr. Hussen. Photovoice is a participatory action research methodology in which groups of individuals from a population of interest are given cameras to document events, people and places of significance in their lives.
66450|NCT03664817|Behavioral|group-based health promotion intervention|"The control arm will participate in a health education intervention that will be delivered in a group, but without a specific goal of creating group cohesion or social capital. The intervention will be a modified version of Health for Life or H4L, which was used as a control arm intervention in a recently completed protocol of the Adolescent Trials Network which was co-chaired by Dr. Harper (University of Michigan)."
66451|NCT03664804|Other|No Study Drug was Administered in this Study|No study drug was administered in this study
66452|NCT03664791|Procedure|Vanguard Rocc|Patient operated with the Vanguard Rocc knee prosthesis
66453|NCT03664765|Other|UA and RMT|daily oropharyngeal and respiratory muscle exercises
66454|NCT03664765|Other|Sham exercise|Daily sham exercises
66455|NCT03664752|Drug|IDP-120 Gel|Component A
66456|NCT03664752|Drug|IDP-120 Vehicle Gel|Vehicle
66457|NCT03664739|Drug|IDP-120 Gel|Component A
66458|NCT03664739|Drug|IDp-120 Vehicle Gel|Vehicle
66459|NCT03664726|Behavioral|Episodic Future Thinking|Participants will be instructed to use their episodic cues as they engage in different decision making tasks
66460|NCT03664726|Behavioral|Episodic Recent Thinking|Participants will be instructed to use their episodic cues as they engage in different decision making tasks
66461|NCT03664713|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR) Therapy|EMDR is an 8-phase psychological treatment composed of protocols and standardized procedures applicable to both adults and children. The eight phases (patient history, patient preparation, evaluation of the main aspects of the memory, desensitization of the traumatic memory, installation of the positive cognition, body scan, close and re-evaluation) and the protocol of the time line of past-present-future, allow a holistic evaluation of the image of the traumatic memory, and allow for the patient to be well-prepared before processing past events which underlie current pathology, current situations which cause perturbation, and challenges and possible future stimuli which might lead to the appearance of symptoms. (Shapiro, 2014)
66462|NCT03664700|Device|LMA Protector|The LMA Protector will be inserted when a supraglottic device is needed
66463|NCT03664687|Drug|Zoledronate|Administered intravenously (IV)
66464|NCT03664674|Drug|OTO-104|Single intratympanic injection of 12 mg dexamethasone
66465|NCT03664674|Drug|Placebo|Single intratympanic injection of placebo
66497|NCT03664362|Behavioral|The BSHAPE Intervention|The BSHAPE intervention program key elements include strengths based assessments, individualized plans and support based on priorities and needs, motivational interviewing strategies, psychoeducation (education with skill building exercises), mindfulness activities, danger assessment, safety planning, behavioral activation and linkage to community resources
66498|NCT03664349|Device|SuperEar9000|Handheld hearing amplifier, not FDA regulated.
66466|NCT03664661|Drug|BCMA nanobody CAR-T cells|"step 1: Collect 50-100ml of peripheral blood for culture of BCMA nanobody CAR- T cells. step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days. step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 5x106 /kg for the first 3 patients, 1.5x107 /kg for the second 3 patients and 4.5x107 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
66467|NCT03664648|Biological|HEPLISAV-B|This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
66468|NCT03664635|Biological|MB-CART20.1|MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL
66469|NCT03664622|Drug|Ketamine|Ketamine group to whom intravenous ketamine was administered in a loading dose of 0.15 mg/kg over 5 min, 10 minutes pre incision, followed-by an infusion at 2 micg/kg/min until the end of surgery.
66470|NCT03664622|Drug|Morphine|a loading dose of 0.1 mg/kg over 20 min intravenously, 10 minutes pre incision, then infused with morphine an infusion rate of 5 - 40 microgram/kg/hour till the end of surgery.
66471|NCT03664609|Device|Deep Brain Stimulation|Deep Brain Stimulation in patients with Parkinson Disease, Dystonia and Essential Tremor.
66472|NCT03664596|Dietary Supplement|Sublimated mare's milk|Supplement obtained through sublimation of mare milk, packed into one-dosage sachet (20g), and dissolved in a warm water (36 degrees of Celcius).
66473|NCT03664596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid in the form of 250 mg capsule.
66474|NCT03664583|Behavioral|ACHRU-Community Partnership Program (CPP)|The intervention is a 6-month community navigation and self-management program for patients with diabetes and at least one additional chronic condition, and their caregivers, to improve health outcomes. The intervention will be provided by an interprofessional team of providers and consists of six core components.
66475|NCT03664570|Device|VIPUN Balloon Catheter|The VIPUN Balloon Catheter is a nasogastric balloon catheter consisting of a standard nasogastric double lumen Sump catheter and a balloon attached to this catheter. Once the catheter is advanced into the stomach, the balloon can be inflated. The inflated balloon dimensions and intraballoon pressure are such that intragastric motility can optimally be assessed without inducing epigastric symptoms.
66476|NCT03664557|Device|ER Reboa TM Catheter|During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
66477|NCT03664544|Drug|MCI-186|30 mg MCI-186 will be administered intravenously over 60 minutes.
66478|NCT03664531|Other|Purified gluten|1 low FODMAPs, vegan muesli bar containing purified gluten per day for 1 week, for a total of 10 g purified gluten per day.
66479|NCT03664531|Other|Non-purified gluten (containing ATIs)|1 low FODMAPs, vegan muesli bar containing whole wheat flour with non-purified gluten per day for 1 week, for a total of 10 g non-purified gluten per day.
66480|NCT03664531|Other|Nocebo|1 gluten-free, ATI-free, low FODMAPs, vegan muesli bar per day for 1 week. This is a nocebo because we expect that participants will feel worse even though there is no potential irritant.
66481|NCT03664518|Drug|Eltrombopag|subjects will initiate treatment with 25 mg eltrombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts. and maximum dose should not exceed 75 mg daily. Subjects whose platelet count between 50~150×109/L，the eltrombopag dose Maintain. platelet count between 150~250×109/L, need to reduce the dose of eltrombopag to the next lower dose or lower frequency. Subjects whose platelet count exceeds 250×109/L at any point during the treatment period, must have eltrombopag interrupted and increase the frequency of platelet monitoring to twice weekly, until platelet counts fall below 100×109/L.
66482|NCT03664505|Device|Compression garment (manual)|Garment based on manual measurement
66483|NCT03664505|Device|Compression garment (scan)|Garment based on scan measurement
66484|NCT03664492|Other|Educational whiteboard video|Participants will be prompted to complete pre-questionnaire, followed by access to the video, with a prompt to complete the post questionnaire after. If they agree, they will receive 4 to 6 months later, a third questionnaire to complete. For those without access to the internet, we will offer to them view the video at the SickKids at their convenience.
66485|NCT03664479|Device|4 channel Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
66486|NCT03664466|Dietary Supplement|astaxanthin|astaxanthin capsules 12 mg twice daily
66487|NCT03664466|Other|Placebo|placebo capsules twice daily
66488|NCT03664453|Drug|omaveloxolone|Omaveloxolone 50 mg capsules
66489|NCT03664440|Drug|Nevirapine|Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
66490|NCT03664440|Drug|Rilpivirine|Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
66491|NCT03664414|Drug|pentoxifylline|Pentoxifylline or placebo will be prescribed three times a day with meals. All the participants will continue with the usual treatment. Time frame: two years
66492|NCT03664401|Device|Kerecis Oral™|
66493|NCT03664401|Other|Free Gingival Graft|A free gingival autograft from patient palate placed and secured on wound bed
66494|NCT03664388|Drug|Dual antiplatelet therapy with ticagrelor/prasuglre|Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy
66495|NCT03664375|Other|Botulinum toxin type A|All patients in the experimental group received a BoNT-A injection. The injected total dose for individual patient in the experimental group was 100 units which is equivalent to approximately 300-500 Units of Dysport (the other type of BoNT-A available). The Botox was injected by the neurophysician intramuscularly using insulin U100 syringe and determination of muscles for injection was assessed clinically.
66496|NCT03664375|Other|Task Specific Training|Task specific training is the repetition of a specific task until expertise is reached. More challenging tasks are added as a means of progression
66594|NCT03663504|Other|No Preparation|No preparation before surgery
66595|NCT03663504|Drug|Neomycin and Flagyl|Oral antibiotic (Neomycin and Flagyl) taken the day before the surgery
66499|NCT03664323|Biological|Evaluate the improvement in response from the end of anti-PD-1 monotherapy|Evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2).
66500|NCT03664310|Other|FSET Anxiety and Sleep Treatment|Computerized anxiety and insomnia intervention.
66501|NCT03664310|Other|Control|Physical health control
66502|NCT03664297|Drug|SHR1459|SHR1459 will be administered continually till disease progression or unacceptable toxicity.
66503|NCT03664284|Procedure|subcutaneous disinfection|The investigators will randomize 105 patient on two arms. The control group receiving no disinfection of the subcutaneous tissue (A) and intervention group, receiving disinfection of the subcutaneous tissue (B).
66504|NCT03664271|Behavioral|in-clinic video intervention|Video with information about eczema and eczema treatment, to be watched in clinic and at home
66505|NCT03664271|Behavioral|at home video intervention|Video with information about eczema and eczema treatment, to be watched at home only
66506|NCT03664258|Diagnostic Test|Xpert Bladder Cancer Monitor|The Xpert Bladder Cancer Monitor Assay is a qualitative in vitro diagnostic test designed to monitor for the recurrence of bladder cancer in patients previously diagnosed with bladder cancer. It should be used in conjunction with other clinical measures to assess disease recurrence. The test provides a fast and accurate result, is non-invasive and easy to perform.The test utilizes a voided urine specimen and measures the level of five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) by means of real-time, reverse transcription-polymerase chain reaction (RT-PCR).
66507|NCT03664232|Drug|JNJ-42165279|Participants will receive 25 mg JNJ-42165279 orally once-daily for 12 weeks.
66508|NCT03664232|Drug|Placebo|Participants will receive a matching placebo orally once-daily for 12 weeks.
66509|NCT03664219|Other|isolation of IAN from implant with collagen membrane|comparing between the neurosensory disturbances with and without isolation of the inferior alveolar nerve from implant
66510|NCT03664206|Diagnostic Test|MRS, conventional TMS and treshold tracking TMS|"Using~two MagStim 200 magnetic stimulator and a figure-of-eightc double 70 mm coil~SPECIAL MR Spectroscopy sequence~In addition, each group will undergo neurological examination"
66511|NCT03664193|Radiation|SIBRT|Patients will receive 35 Gy in 5 fractions. In addition, patients will also receive 0.5-2 Gy per fx for a total dose 37.5, 40, 42.5 or 45 Gy. Patients will also have an option to have a rectal balloon or a rectal spacer prior to receiving radiation therapy.
66512|NCT03664180|Drug|Bivalirudin|IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
66513|NCT03664180|Drug|Enoxaparin|40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
66514|NCT03664180|Drug|Unfractionated heparin|IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
66515|NCT03664180|Drug|Bivalirudin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
66516|NCT03664180|Drug|Enoxaparin placebo syringe|Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
66517|NCT03664180|Drug|Unfractionated heparin placebo|Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
66518|NCT03664167|Dietary Supplement|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.|intensive weight loss diet, with Cambridge weightplan products, and visits to a dietician.
66519|NCT03664154|Behavioral|Stress and Feeding (SAFE)|"The Stress Management component of the intervention acknowledges the mind-body connection between stress and adverse outcomes and consists of four web-based modules based on Lazarus and Folkman's Transactional Model of Stress and Coping designed to improve health outcomes.~The Guided Feeding component of the intervention is based on the synactive theory of development. The synactive theory of development provides insight in to reading the physiological and behavioral cues of infants born preterm and involves weekly viewing of video clips of adaptive and maladaptive feeding behaviors of mothers and infants, practice opportunities, and follow-up phone calls."
66520|NCT03664141|Drug|Cannabis oil|Treatment with cannabis oil
66521|NCT03664141|Drug|Placebo/ Regular Oil|Treatment with placebo (Regular Oil)
66522|NCT03664128|Other|Coping with Anxiety through Living Mindfully (CALM) Pregnancy|Mindfulness-based Cognitive Behavioral Therapy (CBT) for perinatal anxiety on a subset (8 participants); no intervention for other participants
66523|NCT03664115|Drug|Itraconazole 200 mg|itraconazole 200 mg oral tablet daily, on a 21-day cycle.
66524|NCT03664115|Drug|Chemotherapy|"intravenous doses of cisplatin 80 mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8 every 3 weeks for a maximum of 6 cycles.~Alternatively, Carboplatin may be used instead of Cisplatin, Carbplatin AUC 5 DAY 1 only Dose = AUC x (GFR + 25) IV in 250 mL Normal Saline over 30 minutes"
66525|NCT03664102|Device|Cor Knot|Heart valve replacement with or without the use of automated fastener device Cor Knot
66526|NCT03664089|Behavioral|Ankle weights (2.5 pounds [1.1 kg]/ankle)|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds [1.1 kg]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.
66527|NCT03664089|Behavioral|Control|Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
66528|NCT03664076|Diagnostic Test|COMISS score|cow's milk protein symptoms score awareness tool to select cow's milk protein allergy in infants
66529|NCT03664063|Drug|Azithromycin|Treatment with Azithromycin single dose - weight based dosing max 2gm
66530|NCT03664063|Drug|Albendazole|"Single dose of Albendazole weight based dosing~- 400mg"
66531|NCT03664063|Drug|Ivermectin|Ivermectin weight based dosing - max 21mg
66532|NCT03664063|Drug|Diethylcarbamazine|Diethylcarbamazine weight based dosing - max 500mg
66533|NCT03664050|Drug|group A 2.5 mg letrozole oral tablets|2.5 mg letrozole oral tablets will be administered on the 2nd-3rd day of menses and then every day for 5 days. Treatment will be repeated for up to three cycles if the patient failed to conceive.
66534|NCT03664050|Procedure|laparoscopic ovarian drilling|Bilateral laparoscopic ovarian drilling, each ovary will be cauterized at 4 points, each for 4 sec at 40 W, at a depth of 7-8 mm and a diameter of 3-5 mm, using a monopolar electrosurgical needle according to the size of each ovary.
66535|NCT03664037|Drug|Dexamethasone phosphate|each patient received 8 mg of intravenous DEX diluted in 100 ml 0.9% sodium chloride (normal saline [NS]) intravenous infusion (IVI) over 15 min 2 hours preoperatively
66536|NCT03664037|Drug|Placebo|each patient received 100 mL 0.9% NS IVI over 15 min (Placebo) 2 hours preoperatively
66537|NCT03664024|Drug|Pembrolizumab|Pembrolizumab, 200 mg, Day 1 of each 21-day cycle (Q3W), intravenous infusion (IV), standard of care in most countries
66538|NCT03664024|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2 infusion, standard of care, Q3W, IV
66539|NCT03664024|Drug|Carboplatin|Carboplatin AUC 5 mg/mL/min, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
66540|NCT03664024|Drug|Cisplatin|Cisplatin, 75 mg/m^2, IV infusion, Day 1 of each 21-day cycle for 4 cycles (Cycles 1 - 4). Investigator's choice of either cisplatin or carboplatin.
66541|NCT03664011|Drug|BI 730357 mixed with [C-14]BI 730357 BS|Oral Solution
66542|NCT03663998|Biological|CN54ENV DNA|"CN54ENV DNA concentration 4 ± 0.7 mg/mL is formulated in 1 x PBS~All administrations of CN54ENV will be by in vivo electroporation using the Ichor Medical Systems TriGrid Delivery System for intramuscular (TDS-IM) or intradermal use (TDS-ID) and will be delivered into the upper thigh(s)."
66543|NCT03663998|Biological|GENEVAX® IL-12 DNA|"GENEVAX® IL-12 DNA, concentration 2 mg/mL with a fill volume of 1.0 mL (1.0 ± 0.1mL), is formulated in 30 mM citrate buffer.~GENEVAX® IL-12 DNA is mixed with the CN54ENV DNA immediately prior to administration."
66544|NCT03663985|Other|Groupe FALCOn|The objective of the study is to determine what are the anthropo-sociological factors in the surgeon, the oncologists and radiotherapists influencing decision making in ENT carcinology.
66545|NCT03663972|Behavioral|articulation therapy|children receive instruction in producing new sounds at the isolation, syllable and word level.
66546|NCT03663972|Behavioral|phonologic treatment|children receive instruction in producing new sounds at the word level
66547|NCT03663959|Procedure|vaginal sacrospinous fixation procedure with dr.Aksakal's desta suture carrier|A right sacrospinous fixation using Dr. Aksakal's Desta suture carrier with two permanent sutures that combined the sacrospinous ligament and vaginal cuff fascia was done. The Desta suture carrier was developed for deep pelvic surgery, and the suture depth can be easily adjusted. After the vaginal hysterectomy, under the vaginal cuff mucosa, we created a tunnel through the spinous process with a straight tool. After passing the rectovaginal pillars, the perirectal space was entered and the ischial spine was palpated. With the help of an index finger placed on the spinous process, we placed two permanent sutures 1.5-2 cm medial to the spinous process on the sacrospinous ligament and iliococcygeus muscle complex using the Desta suture carrier. Next, permanent sutures were combined with the pubocervicovaginal and rectovaginal fascia under the vaginal cuff mucosa.
66548|NCT03663959|Procedure|Laparoscopic Pectocolpopexy procedure|First, the peritoneal layer above and lateral to the bladder was opened parallel to the round ligament toward the pelvic side wall on the right side. Then, with the guidance of the obliterated umbilical artery, lateral to the obliterated umbilical artery and medial to the external iliac vein, the iliopectineal ligament was found . At this point, a segment of approximately 3-4 cm2 was formed, exposing the iliopectineal (Cooper's) ligament. In this area, behind the obliterated umbilical artery, the obturator nerve could be seen, and special care was given not to make contact with the nerve. The same area on the left side was prepared using the same steps. Then, anterior part of the vaginal cuff was prepared for mesh fixation. Bilaterally, the ends of a polypropylene monofilament mesh (1,5x15 cm) were fixed to the iliopectineal ligament with nonabsorbable polypropylene or polyester sutures . The vaginal cuff was elevated to POP-Q level 0-1.
66549|NCT03663946|Other|Non-Interventional|Non-Interventional
66550|NCT03663933|Drug|Immunosuppression Only Conditioning (IOC)|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2 /day IV on days -9 and -5, cyclophosphamide:5 mg/kg orally daily on days -9 through -2
66551|NCT03663933|Drug|Reduced Intensity Conditioning (RIC)|E-ATG 40 mg/kg IV once daily for days -14 and -13. Prednisone: Tapering doses, given orally daily, and given prior to each daily dose of e-ATG on days -14 and -13 Pentostatin:4 mg/m2 /day IV on days -11 and -7, cyclophosphamide:3 mg/kg orally daily on days -11 through -4 Busulfan IV, pharmokinetically dosed, on days -3 and -2.
66552|NCT03663933|Drug|GVHD Prophylaxis|High-dose, post- transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, Mesna: 25-50 mg/kg weight based dosing, Tacrolimus 0.02 mg /kg on days +5 through +90, and mycophenolate mofetil (MMF) 15 mg /kg on days +5 through +25
66553|NCT03663933|Procedure|Allogeneic HSC|Stem cell transplant
66554|NCT03663907|Procedure|Telemonitoring|"The system (the home tele-healthcare platform) designed jointly by engineers and clinical personal to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring. The system allow weekly follow up through videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses daily."
66555|NCT03663881|Drug|P2Et extract|P2Et extract daily doses. Dosage scaling will be performed according to the 3 + 3 standard design.
66556|NCT03663868|Diagnostic Test|CC-Test|Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells
66557|NCT03663855|Drug|7 Days Tiopronin|On day 7 of this period,patients will be asked to perform a 24-hour urine collection to measure the urinary cystine levels.
66558|NCT03663855|Drug|500 mg Tiopronin|5 tablets a day (200mg tab AM and 300mg tab PM). On day 7 of this period, you will perform a 24-hour urine collection.
66559|NCT03663855|Drug|1 grams per day of Tiopronin|5 tabs twice a day (100mg per tab). Patients will have another 24-hour urine collection on day 7 of this period.
66560|NCT03663855|Drug|2 grams per day of Tiopronin|10 tabs twice a day (100mg per tab). On day 7 of this period, patients will perform the final 24-hour urine collection.
66596|NCT03663491|Procedure|Nasal Gastroscopy|Use of transnasal endoscopes for routine gastroscopy in adults.
66597|NCT03663491|Procedure|Oral Gastroscopy, unsedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of local anesthesia.
66561|NCT03663842|Other|Physical therapy treatment|All patients underwent the same techniques, and there was no modification of the intervention protocol during the study: (1) Myofascial release technique - piriformis muscle and biceps femoral muscle; (2) Hip joint mobilization; (3) Cross-fiber friction over the sacroiliac joints; (4) Neural mobilization to improve sciatic nerve excursion.
66562|NCT03663829|Other|Non-Interventional|Non-Interventional
66563|NCT03663829|Other|Non-Interventional|Non-Interventional
66564|NCT03663816|Device|experimental foot device|Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in healthy people.
66565|NCT03663803|Behavioral|Brief theory-based health promotion intervention (group-based)|The intervention is depicted using a PaT Plot in the published paper: Juul, L et al. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting. Primary Care Diabetes 1 0 ( 2 0 1 6 ) 111-120.
66566|NCT03663790|Other|Foot Progression|The intervention will be a gait retraining biofeedback focused on foot angle during gait trials
66567|NCT03663790|Other|Trunk Lean|The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
66568|NCT03663777|Other|Isometric handgrip training|Intervention period will last 12 weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of eight sets of bilateral handgrip contraction of two minutes of isometric contraction, with 30% of maximum voluntary contraction, and two minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. The patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
66569|NCT03663777|Other|Control Group|Intervention period will last 12 weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
66570|NCT03663764|Drug|Thymosin a1|All patients received weekly thymosin a1(1.6mg) during and within 2 months after the end of chemoradiotherapy.
66571|NCT03663751|Drug|Decitabine|low-dose decitabine: 5mg/m2 daily for 5 days
66572|NCT03663738|Behavioral|mobile app NOVAME|The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
66573|NCT03663725|Drug|Intensified protocol|Early Temozolomide (TMZ) 1 cycle (150 mg/m²/ day X 5 days, per os) Started between day 2 and 15 after surgery/ biopsy RT (60 Gy, 2 Gy/fraction) + concomitant TMZ (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ Prolonged TMZ Until progression, intolerance, patient's or physician's decision (150-200 mg/m2 every 4 weeks, per os)
66574|NCT03663725|Drug|Stupp protocol|RT (60 Gy, 2 Gy/fraction) + concomitant Temozolomide (75 mg/m2/day X 42 days, per os) Started between W4 and W6 after surgery/ biopsy Adjuvant TMZ 6 cycles (150-200 mg/m2 X 5 days /month, per os) Started 1 month after the end of the concomitant TMZ
66575|NCT03663712|Biological|Talimogene Laherparepvec|TVEC is an oncolytic, genetically modified virus designed to reproduce in tumor tissue and stimulate your immune system to attack the tumor cells
66576|NCT03663699|Behavioral|Exergaming|free access to the exergaming platform PlayPulse for 24 weeks
66577|NCT03663686|Drug|Litapiprant Tablet|Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells
66578|NCT03663673|Drug|EpiCeram|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
66579|NCT03663673|Drug|Aveeno Daily Moisturising Sheer Hydration Lotion®|To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
66580|NCT03663660|Other|Organizational infrastructure pediatric plan (OIPP)|Restructuration of the hospital sectors with a stratification of health care into 4 levels.
66581|NCT03663634|Other|Cytochalasin B use in ICSI handling medium|A medium with in-house supplementation of Cytochalasin B to decrease oocyte degeneration after ICSI and improve survival rate
66582|NCT03663608|Procedure|WALANT Technique|pure local anaesthesia and without use of a tourniquet (WALANT Technique) for trigger finger release surger
66583|NCT03663595|Other|Model 1|Model 1 will be composed of exercises focusing on local (knee) and proximal (hip) factors.
66584|NCT03663595|Other|Model 2|Model 2 will be composed of exercises focused on the local (knee) and distal (ankle and foot) factors.
66585|NCT03663582|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
66586|NCT03663582|Device|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by Pharmaceuticals and Medical Devices Agency (PMDA).
66587|NCT03663582|Device|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
66588|NCT03663582|Device|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
66589|NCT03663569|Drug|Spiolto® Respimat®|Drug
66590|NCT03663556|Other|Infant-feeding|Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
66591|NCT03663543|Drug|Conjugated Estrogen|Dosing of conjugated estrogen will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
66592|NCT03663543|Drug|Normal saline|Dosing of normal saline will be given pre kidney transplant procedure and twice after reperfusion of the transplanted kidney.
66593|NCT03663530|Behavioral|Meal times|Meal times vary based on the arm: aligned or misaligned
66598|NCT03663491|Procedure|Oral Gastroscopy, sedated|Use of transoral endoscopes for routine gastroscopy in adults. Use of intravenous sedation.
66599|NCT03663491|Procedure|Oral Gastroscopy with transnasal endoscope, sedated|Use of transnasal endoscopes for routine gastroscopy in adults, following a failed attempt to perform transnasal gastroscopy
66600|NCT03663478|Drug|Ropivacaine|2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour
66601|NCT03663478|Drug|Saline|2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour
66602|NCT03663465|Other|Hawthorn|Hawthorn tablet
66603|NCT03663465|Drug|SGAs|SGAs tablet
66604|NCT03663452|Behavioral|Targeted Assessment and Context-Tailored Implementation of Change Strategies (TACTICS)|TACTICS begins with a mixed methods assessment (using data from medical records, staff surveys, and staff interviews) to identify barriers and facilitators of PE use in each clinic. From a menu of implementation strategies that can be matched to local conditions, an implementation plan is developed in collaboration with clinic personnel and deployed to address specific barriers and leverage strengths at each clinic site over a 5-month period.
66605|NCT03663452|Behavioral|Prolonged exposure training|Providers will receive a 2-day workshop training in the delivery of prolonged exposure, followed by weekly phone clinical consultation.
66606|NCT03663439|Procedure|modified shell technique|divided block of bone into two shells and grafting one shell in anterior maxilla
66607|NCT03663426|Procedure|study group|"High dose corticoids pre-operative and 24h postoperative~Opioid free general anesthesia~Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol."
66608|NCT03663426|Procedure|control|"No corticoids pre-operative.~Opioid anesthesia~Opioids post-operative after NSAID and paracetamol."
66609|NCT03663413|Device|non-invasive monitor|cutaneous EEG monitor
66610|NCT03663400|Diagnostic Test|GWAS analysis by Illumina BeadChip|will generate comprehensive genotype data for patients. Samples will be used for transcriptional profiling, microbiota profiling by 16S analysis and immunological profiling by flow cytometry
66611|NCT03663387|Device|18F--MK6240 PET-MRI|tau tracer predictive of: a) future amyloid lesions (PiB-PET); b) brain atrophy (MRI); and c) cognitive decline.
66612|NCT03663374|Drug|Odelepan|Tablets, 125 mg
66613|NCT03663374|Drug|Placebo|Contains the same excipients as Odelepran but it does not contain the active agent. Placebo is identical to Odelepran in terms of drug form and external characteristics (colour, smell, etc). Doses and route of administration are identical to those for Odelepran.
66614|NCT03663361|Other|SMART Intervention|Ankle rehabilitation with the addition of sensorimotor components
66615|NCT03663361|Other|Standard of Care Intervention|Ankle rehabilitation focused on restoring range of motion, strength and balance
66616|NCT03663335|Biological|CFZ533|Comparison with standard of care immunosuppression
66617|NCT03663335|Drug|Tacrolimus - MMF - +/- corticosteroids|Standard of care immunosupprevive regimen
66618|NCT03663322|Procedure|OMT Protocol|Selected hands-on OMT techniques intended to improve pancreatic function will be administered during the treatment sessions
66619|NCT03663322|Procedure|OMT-Sham Protocol|Selected hands-on Sham-OMT techniques that are not intended to affect pancreatic function will be administered during the treatment sessions
66620|NCT03663309|Diagnostic Test|detecting Gluten peptides in faecal and urine samples|"At each visit patient will:~Bring 4-day food diary (attached)~Fill symptoms and complaints questionnaire (attached)~Provide 24 h diet recall in case a food diary absents~Fill Biagi score questionnaire (attached)~Perform blood test of TTG~Provide stool and urine samples"
66621|NCT03663296|Other|Airway Ex App|30 minutes of self-directed learning and practice using the mobile application
66622|NCT03663283|Drug|Liposomal Bupivacaine|Interscalene Nerve Blocks
66623|NCT03663283|Drug|Bupivacaine Hydrochloride|Interscalene Nerve Blocks
66624|NCT03663270|Device|Hypotension probability index (HPI)|The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
66625|NCT03663257|Device|AneurysmFlow|AneurysmFlow R1.0 is an approved (CE labeled, cleared in US, Canada and Argentina), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It provides color coded and vector field representation of a digital subtraction angiography (DSA). It can quantify blood flow rates in the artery based on DSA and 3-D Rotational Angiogram (3DRA) data. It can visualize blood flow patterns in an aneurysm based on DSA data. Specifically, it calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. It is manufactured by Philips Medical Systems B.V., a Philips Healthcare company.
66626|NCT03663244|Behavioral|MBSR|Standardised stress reduction programme with established efficacy
66627|NCT03663244|Behavioral|LSR|Existing stress reduction programme in a Danish municipality
66628|NCT03663231|Device|Biotene|Biotène Dry Mouth Moisturizing Spray contains water, polyglycitol, propylene glycol, sunflower oil, xylitol, milk protein extract, potassium sorbate, acesulfame K, potassium thiocyanate, lysozyme, lactoferrin, lactoperoxidase. 3 sprays, approximately 15 mL.
66629|NCT03663231|Device|Placebo|IND/IDE exempt device primarily water
66630|NCT03663218|Radiation|Dose escalation|This is a modified dose escalation study. The first 3 patients will be given 5 Gy for five days. If all 3 patients do not have an unacceptable dose limiting toxicity, another 3 patients will be given 6 Gy for 5 days. If all 3 do not have an unacceptable dose limiting toxicity, another 3 will be given 7 Gy, and finally 8 Gy. If all 3 patients given 8 Gy do not have an unacceptable dose limiting toxicity, an additional 7 patients will be recruited at this dose. If at any point a patient develops an unacceptable dose limiting toxicity, recruitment at the current dose will immediately stop and an additional 7 patients will be recruited at a dose 1 Gy lower. If any of these additional patients develop an unacceptable dose limiting toxicity, an additional 7 will be recruited at an even lower dose.
66631|NCT03663205|Drug|Tislelizumab,Cisplatin or Carboplatin ,Pemetrexed|Treatment for advanced NSCLC
66632|NCT03663205|Drug|Cisplatin or Carboplatin,Pemetrexed|Treatment for advanced NSCLC
66633|NCT03663192|Device|strain echocardiography|strain echocardiography during septic shock
116743|NCT03273842|Biological|US-approved Neulasta|pre-filled syringe 6 mg
66634|NCT03663179|Device|Transcranial Magnetic Stimulation (TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
66635|NCT03663179|Device|Sham Transcranial Magnetic Stimulation (Sham TMS)|A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
66636|NCT03663166|Radiation|Thoracic Radiotherapy|2 Gy in 30 fractions directed at all sites of suspected disease
66637|NCT03663166|Drug|Platinum Based Chemotherapy|Platinum based chemotherapy including cisplatin and etoposide, carboplatin and paclitaxel or cisplatin and pemetrexed (for patients with non-squamous histology).
66638|NCT03663166|Drug|Ipilimumab|Iplimamab 1mg/kg delivered concurrently with initiation of chemoradiotherapy and in week 4 of chemoradiotherapy
66639|NCT03663166|Drug|Nivolumab|Nivolumab 480 mg (30 minute IV infusion) at least 7 days but no more than 21 days after completion of radiation and chemotherapy every 4 weeks for up to 12 cycles.
66640|NCT03663153|Other|SEMA4C high value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
66641|NCT03663153|Other|SEMA4C low value follow-up group|Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
66642|NCT03663140|Diagnostic Test|gingival crevicular fluid (GCF) and peri-implant sulcular fluid(PISF) collection|GCF/PISF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva.
66643|NCT03663127|Dietary Supplement|Beauty Drink|"Subjects receive two bottles Beauty Drink per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks."
66644|NCT03663127|Dietary Supplement|Placebo|Subjects receive two bottles placebo of similar appearance per day for 8 weeks of a stage. Anthropometric measurements such as blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), body weight, body fat, waistline, hipline and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every four weeks.
66645|NCT03663114|Drug|Lenvatinib|Lenvatinib capsule
66650|NCT03663088|Other|GPR-A|Standard Global postural re-education physiotherapy scoliosis specific exercises
66651|NCT03663088|Other|GPR-B|Experimental Global postural re-education physiotherapy scoliosis specific exercises combining individual and class exercises
66652|NCT03663075|Behavioral|Group information (GI)|The group education consists of four information sessions discussing myths and myths around menopause, physiology, local estrogen deficiency symptoms, women's cardiovascular health, stress-related ill health, mental health, relationships, sexuality, lust and possible treatment options. In addition, conversations about insight into obstacles and resources, coping strategies and behavioral changes will be included.
66653|NCT03663075|Behavioral|Structured person-centered support (PCS)|The individually structured person-centered support comprises of five meetings consisting of dialogue on symptoms of stress-related ill health, physiology and coping strategies.
66654|NCT03663062|Diagnostic Test|Colonoscopy|All patients would undergo colonoscopy as part of standard care. Patients recruited for this study would have their past medical history, family history, medication history, as well as waist circumference, BMI and blood pressure recorded. All patients would also have blood tests (described earlier) and a subset will undergo Fibroscan.
66655|NCT03663049|Drug|discontinue statin|Discontinue statin as prescribed for 12 weeks
66656|NCT03663036|Diagnostic Test|Magnetic Resonance Imaging of the shoulder|Clinical and radiological assessments of the shoulders and the donor sites
66657|NCT03663023|Procedure|Intestinal obstruction|
66658|NCT03662997|Device|Bordered Five-Layer Foam Dressing|Bordered, five-layer, flexible foam dressing with soft silicone adhesive technology
66659|NCT03662997|Device|Hydropolymer Foam Dressing|Hydropolymer, adhesive foam island dressing
66660|NCT03662997|Device|Hydrocellular Multi-Layer Foam Dressing|Multi-layered, hydrocellular foam dressing with silicone adhesive
66661|NCT03662984|Drug|Ciprofibrate 100Mg Tablet|Ciprofibrate is a PPARα ligand and is considered to be a major regulator of the lipid metabolism. PPARα regulates the genes involved in mitochondrial function and fat metabolism and is therefore abundantly expressed in tissues that require high rates of FFA oxidation, like for instance in the heart and activation of PPARα in the heart may have beneficial effects on mitochondrial function and fat oxidative capacity.
66662|NCT03662984|Drug|Placebo Oral Tablet|To compare ciprofibrate
66663|NCT03662971|Drug|Germinal peptide eye drops|Germinal peptide eye drops of 0.0005%, 0.001%, 0.002%, 0.004% and 0.008%
66664|NCT03662958|Drug|Lutrate|a novel leuprolide acetate 3.75mg depot
66665|NCT03662958|Drug|Enantone|market reference leuprolide acetate 3.75 mg depot
66666|NCT03662945|Other|Mobile Geriatric Team intervention|Person-centred intervention based on Comprehensive Geriatric Assessment
66667|NCT03662932|Other|Early intensive mobilization|"Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week."
66668|NCT03662919|Drug|Infliximab|Administered as specified in the treatment arm.
66669|NCT03662906|Other|Electroacupuncture|"Bilateral BL32 and BL 33 will be inserted to a depth of 70-95 mm with an angle of 20-30° inward and downward into the second and third sacral foramen. Bilateral BL35 will be inserted to a depth of 60-70 mm with a slightly superolateral direction using needles (0.30 mm in diameter, 75 mm in length). Bilateral BL23 and SP6 will be inserted vertically to a depth of 25-30 mm using needles (0.30 mm in diameter, 40 mm in length). The electric stimulators (6805-D electroacupuncture apparatus, Guangzhou Jiayu Medical Company, China) will connect the bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 5-10 mA for BL 32 and BL 33 and an intensity of 1-5 mA for SP 6 will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
66670|NCT03662906|Other|Sham electroacupuncture|"Sham BL 23, BL32 and BL33 which are 2 cm lateral to BL23, BL33 and BL35 will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. Sham SP 6 which is at the midpoint between the spleen meridian and the kidney meridian will be inserted by the needles (0.20 mm in diameter, 25 mm in length) to a depth of 2-3 mm. The electric stimulators (SDZ-V electroacupuncture apparatus, Suzhou Medical Appliance Factory, China) will connect bilateral BL32, BL33, BL35 and SP 6 and a continuous wave of 10 Hz frequency and an intensity of 0.1-0.3mA will be applied.~The needles will be retained for 60 mins for each treatment session. The participants will be treated three times a week, on alternate days, for 12 successive weeks; 18 sessions for each patient in total."
66671|NCT03662893|Behavioral|behavioural therapy with written checklist form to complete|Behavioural therapy for overactive bladder such as advice on fluid balance, bladder retraining, urgency suppression or normal voiding techniques, pelvic floor muscle training, caffeine reduction, dietary changes, weight loss and other life style changes
66672|NCT03662893|Drug|Antimuscarinic drugs used in overactive bladder|Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
66673|NCT03662893|Behavioral|behavioural therapy with written guideline|behavioural therapy with written guideline,which are the same as those in the checklist
66674|NCT03662880|Radiation|Cardiac Magnetic Resonance|Imaging modality used to detection thrombus in left atrium
66675|NCT03662880|Radiation|Trans-esophageal echo|a procedure in which the ultrasound probe is inserted into the esophagus and ultrasonographic images are obtained of the heart using echo and color Doppler images.
66676|NCT03662867|Behavioral|Family-based mindfulness intervention|"For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice."
66677|NCT03662867|Other|Wait-list|No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
66678|NCT03662854|Biological|Hair Stimulating Complex (HSC)|Patients will receive 2 mL of HSC separated by 6 weeks (total of 4 mL of HSC)
66679|NCT03662854|Other|Phosphate Buffered Saline|Patients will receive 2 mL of Phosphate Buffered Saline separated by 6 weeks (total of 4 mL of Phosphate Buffered Saline)
66680|NCT03662841|Procedure|Ablative chemoembolization (ACE)|Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin
66681|NCT03662815|Biological|iNeo-Vac-P01|Neoantigen peptides
66682|NCT03662815|Other|GM-CSF|immune adjuvant
66683|NCT03662802|Other|Neural Network Classifier|The convolutional neural network is configured to receive an electrocardiogram segment as an input and to generate an output indicative of whether the received electrocardiogram segment represents a cardiac arrhythmia. No specific features of the electrocardiogram are identified to the convolutional neural network, and the received electrocardiogram segment is not filtered, transformed, or processed prior to reception by the algorithm. The algorithm is trained in a similar manner - the electrocardiogram segments are the sole input to the convolutional neural network.
66684|NCT03662789|Drug|Iron Isomaltoside 1000|Intravenous infusion
66685|NCT03662789|Other|Placebo: NaCl 0,9%|Intravenous infusion
66686|NCT03662776|Behavioral|BASC-3 survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 5-17 and to participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
66724|NCT03662633|Diagnostic Test|Breast cancer group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
117299|NCT03269669|Drug|Vincristine Sulfate|Given IV
66687|NCT03662776|Behavioral|PROMIS survey|A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 5-17 and to participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.
66688|NCT03662763|Drug|Extended-release Guanfacine Hydrochloride (SPD503)|dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
66689|NCT03662763|Drug|Placebo oral capsule|
66690|NCT03662750|Diagnostic Test|Brain Imaging|"The study involves an initial screening visit and 2 study imaging visits at days 15 and 90 after the stroke episode.Patients will undergo:~Two 90-minute brain imaging sessions using Positron Emission Tomography (PET) (involves injection of safe radiotracers which attach to brain immune cell markers TSPOs and light up the inflamed areas in the brain),~Two 45-90 minute Magnetic Resonance Imaging (MRI) scanning sessions (include administration of safe chemical contrast agent Gadolinium),~Physical and neurological examinations (vital signs, assessments of mobility and cognitive functioning),~Blood testing (routine measurements, blood inflammation markers, and genetic testing for TSPO marker).~Venous cannula will be inserted into the forearm for the duration of the scans."
66691|NCT03662737|Diagnostic Test|Visuomotor adaptation task|We will measure performance of the subjects of each group on the visuomotor adaptation task, especially in the rotation condition, in which a perturbation will be induced between the anticipated location of the hand and the provided visual feedback, and in the washout condition, in which the rotation will be removed. We expect that subjects with cannabis use disorder will not show the expected implicit motor adaptation to the perturbation and consequently no deterioration of performance on the task, due to cannabis-induced cerebellar damage. In other words, we want to show that this visuomotor task is a cheap and quick biomarker of cerebellar dysfunction in chronic cannabis users.
66692|NCT03662724|Drug|Venetoclax|Registry study observing clinical and biological characteristics of patients with acute myeloid leukemia who are treated with Venetoclax.
66693|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/vilanterol
66694|NCT03662711|Drug|Bronchodilator Agents|Tiotropium
66695|NCT03662711|Drug|Bronchodilator Agents|Indacaterol
66696|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium/vilanterol
66697|NCT03662711|Drug|Bronchodilator Agents|Fluticasone propionate/salmeterol
66698|NCT03662711|Drug|Bronchodilator Agents|Beclometasone dipropionate/formoterol
66699|NCT03662711|Drug|Bronchodilator Agents|Budesonide formoterol
66700|NCT03662711|Drug|Bronchodilator Agents|Glycopyrronium
66701|NCT03662711|Drug|Bronchodilator Agents|Aclidinium
66702|NCT03662711|Drug|Bronchodilator Agents|Umeclidinium
66703|NCT03662711|Drug|Bronchodilator Agents|Formoterol
66704|NCT03662711|Drug|Bronchodilator Agents|Indacaterol glycopyrronium
66705|NCT03662711|Drug|Bronchodilator Agents|Salmeterol
66706|NCT03662711|Drug|Bronchodilator Agents|Tiotropium olodaterol
66707|NCT03662711|Drug|Bronchodilator Agents|Aclidinium/formoterol
66708|NCT03662711|Drug|Bronchodilator Agents|Olodaterol
66709|NCT03662711|Drug|Bronchodilator Agents|Formoterol/glycopyrronium bromide/beclometasone dipropionate
66710|NCT03662711|Drug|Bronchodilator Agents|Fluticasone furoate/umeclidinium bromide/vilanterol
66711|NCT03662698|Behavioral|Guided Imagery|GI is a relaxation technique involving the visualization of images and is considered an adjuvant cancer therapy.The GI intervention will include two hour-long meetings between the participant and a trained interventionist. The sessions will include direct, written, and audio delivery of one of three GI vignettes. The patient will be able to choose one of the three vignettes. The approximately twelve minute long vignettes included in the study will be: Taking a Walk, Healthy Cell Alliance for Treatment, and Daily Intention (32). Patients will also be given access to psychosocial support resources (i.e., clinical psychologists and social workers) at UCCC.
66712|NCT03662698|Other|Treatment as Usual|This will include a tour of the treatment room and education about RT. Patients will also receive educational materials about RT including the process of RT and CT simulation, treatment side effects, pain management, and swallowing exercises. Participants in this condition will also have access to psychosocial support resources (i.e., clinical psychologists and social workers) at UCCC.
66713|NCT03662685|Other|Goeckerman Therapy|The Goeckerman regimen consists of exposure to narrowband ultraviolet B (NB-UVB) light phototherapy and application of crude coal tar to the skin 5 days per week. The treatment will occur the UCSF outpatient skin treatment center for approximately 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions). The treatment is consistent with the standard of care Goeckerman treatment protocol at UCSF.
66714|NCT03662685|Drug|Crude Coal Tar Only|A topical medication consisting of crude coal tar will be applied to the psoriatic skin under plastic wrap occlusion for approximately up to 4-5 hours, 5 days a week for 6 weeks (total of 30 sessions), at the outpatient skin treatment center at UCSF.
66715|NCT03662685|Device|Phototherapy Only|Light treatment with narrowband ultraviolet B (NB-UVB) phototherapy three days per week for 12 weeks at the UCSF Phototherapy Center per the standard UCSF phototherapy protocol, in which starting dose is based on the subject's Fitzpatrick skin type and gradually increased as tolerated. Each phototherapy treatment will last approximately from under 1 minute to less than 15 minutes.
66716|NCT03662672|Procedure|Rib raising and lumbar release|Rib raising per protocol described in arm description.
66717|NCT03662672|Procedure|Sham procedure|Sham procedure per protocol described in arm description
66718|NCT03662659|Biological|BMS-986213|Relatlimab + Nivolumab specified dose on specified days
66719|NCT03662659|Biological|Nivolumab|Specified dose on specified days
66720|NCT03662659|Drug|XELOX|Oxaliplatin + capecitabine
66721|NCT03662659|Drug|FOLFOX|Oxaliplatin + leucovorin + fluorouracil
66722|NCT03662659|Drug|SOX|Oxaliplatin + tegafur/gimeracil/oteracil potassium
66723|NCT03662646|Other|no intervention performed- observational only|no intervention performed- observational only
66852|NCT03661619|Procedure|Sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the tuberosity for root coverage procedure
66725|NCT03662633|Diagnostic Test|Benign breast tumor group|All the serum samples are collected before any treatments and will be tested in single center in order to decrease bias. Serum SEMA4C levels were measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.
66726|NCT03662620|Drug|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White colored oval three-layer tablet
66727|NCT03662620|Drug|Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg|White and pink colored oval two-layer tablet
66728|NCT03662607|Behavioral|Virtual reality experience|"Baseline wellness self-assessment administered (reporting on absence or presence and degree of severity of headache, nausea, dizziness, fatigue and vision abnormalities)~Seated comfortably and free of direct obstruction~Shown individual components of the VR system (View-Master with smartphone; headphones); given instructions; encouraged to ask questions.~Begin the VR experience. Study personnel stay in the room & provide guidance and answer questions regarding the technology~When VR experience concluded, wellness self-assessment will be administered again."
66729|NCT03662594|Other|ECMO|In this project, the investigators will apply a new technique of atomic layer deposition (ALD) to coat biocompatible and hemocompatible ZrO2/Al2O3 nanolaminate thin films on the inner surface of ECMO tubing to suppress the device-induced coagulopathy. ALD is a thin-film deposition technique for preparing high-quality oxides with atomic-layer accuracy. It offers many benefits including accurate thickness control. These characteristic clear accounts of the high-quality hemocompatible oxide thin films on the whole surface of complex 3-D structures, such as the inner surface The newly-prepared ECMO circuit will then undergo in vitro tests and animal study to carefully examine the safety and effectiveness of improvement of hemocompatibility.
66730|NCT03662581|Behavioral|Mindfulness Group Program|"The mindfulness program has the following aims (Iacono, 2018): to teach mindfulness skills for stress reduction, self-compassion, and dealing with difficult thoughts and emotions, to promote an integrative concept of health, which treats the whole person, to promote community building and positive relationships, and to capitalize on the power of groups to:~Foster peer-to-peer learning and support when it comes to coping with life challenges~Combat isolation~Increase efficiency, quality, and timeliness of care"
66731|NCT03662568|Drug|GLS4|Administered GLS4 120 mg orally three times daily in fed state
66732|NCT03662568|Drug|RTV|Administered RTV 100 mg orally three times daily in fed state
66733|NCT03662568|Drug|ETV|Administered orally ETV 0.5 mg once daily in fasted state
66734|NCT03662568|Drug|TDF|Administered TDF 300 mg orally once daily in fasted state
66735|NCT03662555|Device|Neuromuscular electrical stimulation|"Neuromuscular electrical simulation (NMES) Two self-adhesive electrodes (2 mm thick) will be placed over the rectus femoris, vastus medialis and vastus lateralis muscles. The electrodes will be placed on the motor points of each muscle. The stimulator discharges biphasic rectangular pulses. The stimulation frequency and duty cycle will be 50 Hz and 5 s of stimulation followed by a 5 s pause for each rep. The intensity of electrical flow will be at each subject's maximum that they can tolerate. The stimulation will be for 5 x 5 min sets with 1 min rest between sets.~Blood flow restriction~A handheld Doppler probe (Hi-Dop) will detect their auscultatory and visual pulse using the doppler's screen. The cuff will be inflated initially up to their systolic blood pressure and then incrementally by 10 mmHg until no auscultatory or visual pulse is detected. A percentage of 40% or 80% of each subject's LOP will then be used during the BFR conditions."
66741|NCT03662529|Behavioral|Four-Session Mind Freedom Plan|Problem-solving-focused individualized cognitive behavioral therapy (CBT) that featured homework-worksheets to reinforce session-concepts.
66742|NCT03662529|Behavioral|Treatment as usual therapy|Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed.
66743|NCT03662516|Drug|PF-04965842|Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
66744|NCT03662516|Drug|Ethinyl estradiol (EE) and levonorgestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
66745|NCT03662490|Device|High resolution oesophageal manometry|High resolution oesophageal manometry (HRM) is the gold standard for the diagnosis of oesophageal motility disorder.
66746|NCT03662477|Biological|NK cells|"NK cells were generated in good manufacturing practice (GMP) condition. In brief, PBMCs were isolated from 50mL patient's blood with Ficoll-Hypaque(Morecell Biomedical Co. Ltd., Shenzhen, China). Then the Human NK Cell Culture Kit (Cat. No.~MCF-004, Morecell Biomedical Co. Ltd., Shenzhen, China) and Serum-free Medium for NK Cells (MCM-002, Morecell Biomedical Co. Ltd., Shenzhen, China) was used for induction of NK cells according to the manufacturer's instructions. Three days before NK cell transfusion, the NK cells were sampled and sent to detect the NK cell quality."
66747|NCT03662464|Other|No intervention|develop and validate a specific tool to score the risk of escaping in Nursing Homes residents
66748|NCT03662451|Procedure|Robotic assisted hysterectomy|Periumbilical single incision vs multiple abdominal incisions for hysterectomy
66749|NCT03662438|Other|Home-based physiotherapy program|The home-based physiotherapy program will consist of a total of 2 home visits by a physiotherapist which will be scheduled at the start and midpoint of the 10-week program. The visit will include activity education, goal setting and establishment of a home exercise regimen in patient's own home and community environment). Participants will be contacted weekly via telephone to provide encouragement for patient on the program, enquire about compliance to the exercise program and safety (e.g. falls and healthcare utilisation).
66750|NCT03662438|Device|Prescription of a Portable Oxygen Concentrator (POC) device|Participants will be prescribed a lightweight Portable Oxygen Concentrator (POC) device [Philips SimplyGo Mini] to be used during exercise and when going into the community setting. Familiarisation and training on the usage of the device will also be provided in conjunction with the home-based physiotherapy program.
66888|NCT03661346|Drug|Labetalol|"Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case"
66751|NCT03662425|Drug|Oxytocin|It's a two-week treatment trial.Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of OT
66752|NCT03662425|Drug|Saline|It's a two-week treatment trial. Subjects self-administer intranasal study drug twice daily; before breakfast and before dinner. Each dose consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
66753|NCT03662425|Drug|Oxytocin|Subjects self-administer a single dose of oxytocin ,it consists of six 0.1 ml insufflations (alternating between the left and right nostril) of OT spray containing approximately 24 international units of oxytocin
66754|NCT03662425|Drug|Saline|Subjects self-administer a single dose of saline ,it consists of six 0.1 ml insufflations (alternating between the left and right nostril) of saline spray containing approximately 24 international units of saline
66755|NCT03662412|Drug|Sirolimus|Oral solution of sirolimus, 2mg, once a day.
66756|NCT03662399|Device|Insoles|Orthotic Insoles
66757|NCT03662399|Other|Standard shoe|Standard shoe
66758|NCT03662386|Procedure|OCT-A|Optical coherence tomography angiography (OCT-A)
66759|NCT03662386|Procedure|Visual acuity (ETDRS)|Visual acuity tested with ETDRS score (Early Treatment Diabetic Retinopathy Study)
66760|NCT03662373|Radiation|carbon ions radiation therapy|Carbon ion radiation therapy to treat adenoid cystic carcinoma, skull base (clivus) chordoma.
66761|NCT03662373|Radiation|protons radiation therapy|Proton radiation therapy used to treat meningioma and squamocellular rhinopharynx carcinoma
66762|NCT03662360|Other|essential oils|Following a specific schema, the randomization will be perfomed. Patients enrolled in Group B will receive in environmental diffusion two essential oils, to define their possible effectiveness in the control of the psychological and behavioural disorders
66763|NCT03662334|Drug|Rapid Acting insulin with pre-treatment of rHuPH20|Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
66764|NCT03662334|Device|Sham injection|A sham injection will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
66767|NCT03662295|Behavioral|Language treatment|Individual speech-language therapy sessions totaling 1.5 to 2.5 hours five days per week. Intervention activities include performing oral and written confrontation and responsive naming, writing single words to dictation, reading single words and sentences aloud, and generating written and spoken picture descriptions.
66768|NCT03662282|Drug|Omegaven|Omegaven® fat emulsion will be used as a compassionate use treatment for critically ill infants with parenteral nutrition associated liver injury
66769|NCT03662269|Drug|indomethacin|indomethacin (75mg, bid, po, 14days)
66770|NCT03662269|Drug|Placebo|placebo (75mg, bid, po, 14days)
66771|NCT03662269|Drug|Omeprazole|placebo (20mg, qd, po, 14days)
66772|NCT03662256|Other|Current Primary Care Referral Process|Children who refer hearing screening will receive the same referral method each preschool had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
66773|NCT03662256|Other|Telemedicine Referral Process|In communities randomized to the expedited telemedicine intervention, parents of children who refer hearing screening will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children who refer screening will be transported to clinic for their appointment with adult chaperones. Parent participation will be required unless parents direct otherwise. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
66774|NCT03662243|Behavioral|Multicomponent reading and writing treatment|Intervention procedures incorporated into the program include drilling on sight words to improve immediate recognition of common words; engaging in Multiple Oral Reading procedures to increase reading fluency; practicing oral spelling of sight words to improve spelling accuracy; generating written sentences to improve accurate spelling and use of written conventions (e.g., punctuation, capitalization); and summarizing and subsequently writing sentences about read material to establish strategies to enhance reading comprehension and promote written expression.
66775|NCT03662217|Other|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria
66776|NCT03662217|Other|ADA- based diet|The American standard of care dietary guidelines for diabetes.
66777|NCT03662204|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
66778|NCT03662191|Drug|Tafamidis|bioavailability study
66779|NCT03662165|Behavioral|Intervention|"A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling."
66889|NCT03661346|Drug|Esmolol|"Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min"
67008|NCT03660345|Procedure|PPV/MP|23 gauge Pars Plana Vitrectomy with Internal Limiting Membrane Peeling
67009|NCT03660345|Drug|Intravitreal injection|Intravitreal ziv-Aflibercept
66780|NCT03662165|Behavioral|Enhanced Standard of Care|"Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test."
66781|NCT03662165|Behavioral|Traditional Standard of Care|"Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test."
66782|NCT03662152|Device|Foam roller|Foam roller massage after DOMS
66783|NCT03662152|Device|Vibration foam roller|Foam roller massage with vibration after DOMS
66784|NCT03662139|Other|Dynamic Gait Index|Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
66785|NCT03662126|Drug|KRT-232|KRT-232, administered by mouth
66786|NCT03662113|Drug|Domperidone|5ml Domperidone prior to VCE
66787|NCT03662113|Dietary Supplement|water|5ml water prior to VCE
66788|NCT03662100|Biological|LY3074828|Administered SC
66789|NCT03662100|Drug|LY3074828|Administered SC
66790|NCT03662100|Device|Auto-injector (AI)|AI to administer LY3074828
66791|NCT03662100|Device|Prefilled syringe (PFS)|PFS to administer LY3074828
66792|NCT03662087|Combination Product|HMA+DLI|HMA: Decitabine was administered at 20mg/m2/day for five consecutive days or Ara-C was administered at 75mg/m2/day for seven consecutive days. DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
66793|NCT03662087|Biological|DLI|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
66794|NCT03662074|Drug|Gemcitabine|Given IV
66795|NCT03662074|Biological|Nivolumab|Given IV
66796|NCT03662061|Other|Assessment of the follow-up of oncological and geriatric recommendations 4 months after the RCP|"After inclusion, patient's results are discussed at a weekly onco-geriatric multidisciplinary team meeting including surgeons, geriatrics, oncologists, radiotherapist, nurse, pharmacist. Oncological and geriatric recommendations are given.~A phone call is made to the patient to evaluate the follow-up of the oncological and geriatric recommendations defined during the RCP along with their survival, autonomy and quality of life."
66797|NCT03662048|Behavioral|Safe|Feedback, according to the 2016 national American Academy of Pediatrics (AAP) guidelines on Sudden Unexplained Infant Death (SUID) risk factors, will be generated by the study team and communicated with parents. Feedback will be given to parents in the intervention group at ages 1 and 2 months. The control group parents will only receive this feedback at age 2 months.
66798|NCT03662035|Drug|Apatinib|"Apatinib~Patients with advanced pancreatic cancer after failure of first-line chemotherapy will receive Apatinib (500mg/d, orally) 30 minutes after meal with warm water.Take 21 days as a cycle, patients will receive this treatment until they have got disease progressed. Dose adjustment: with 3/4 level of adverse reactions, the dose should be lowered to 250 mg/d."
66799|NCT03662035|Drug|S-1|"S-1~Patients will receive S-1 (60mg/d for BSA<1.25m2, 80mg/d for 1.25<BSA<1.5m2, and 100mg for BSA >1.5m2, orally) twice a day, once after breakfast and once after dinner, for 14 days, 7 days for suspension and 21 days as one cycle."
66800|NCT03662022|Drug|Rifampicin|Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
66801|NCT03662009|Other|multilimb dual task|control of arm and foot in two attentional contexts of simulated driving
66802|NCT03661996|Drug|CNTX-4975-05|Osteoarthritis (OA) intra-articular injection 1 mg CNTX-4975-05
66803|NCT03661996|Drug|Lidocaine without epinephrine|15 mL lidocaine intra-articular injection
66804|NCT03661996|Device|ElastoGel|Cooling Device
66805|NCT03661996|Device|Breg Ice Water Pump|Cooling Device
66806|NCT03661983|Drug|Aripiprazole (OPC-14597)|Once daily, tablets
66807|NCT03661983|Drug|Placebo|Once daily, tablets
66808|NCT03661970|Other|Cognate Speech Synthesizer sound percepts|The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
66809|NCT03661957|Procedure|Non grafted maxillary sinus floor elevation with simultaneous implant placement|lateral window for sinus elevation ,membrane elevation ,implant placement , membrane for window closure
66810|NCT03661957|Procedure|using short dental implants for posterior atrophic maxilla|placement of short dental implant with bone height below 8mm
66811|NCT03661944|Diagnostic Test|functional performance test|Functional performance test is to test the ability of the athletes in functional movements
66812|NCT03661931|Diagnostic Test|DQPN Validation|We are planning to recruit 150 individuals who are patients in the Boston Heart Lifestyle Program and are already having fatty acids measured as part of clinical care, and ask them to complete the DQPN, FFQ, and a brief User Experience Questionnaire for each dietary assessment method.
66813|NCT03661918|Behavioral|In-Person First Session|Conduct first session in person vs. over the phone
66814|NCT03661918|Behavioral|Second Caregiver|Have second caregiver participate in three coaching calls
66815|NCT03661918|Behavioral|WiFi-enabled Scale|Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
66816|NCT03661918|Behavioral|10 Core Coaching Calls Only|Participant will receive 10 core phone coaching sessions
66817|NCT03661905|Other|Cognitive therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
66927|NCT03660995|Behavioral|Evaluation of language skills and procedural learning of children with SLI and their controls. DNA sampling.|"Behavioral evaluation of language skills at the formal, semantic and pragmatic levels and of procedural learning for each child with SLI and each control child.~DNA sampling for each child."
66818|NCT03661905|Behavioral|Exposure and Response Prevention|Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
66819|NCT03661892|Drug|Syndros|"As noted in arm description. For patients who have side effects secondary to Sydnros, the dose will be decreased as below:~Dose subject is taking Reduction recommendation 8.4mg BID Decreased to 8.4mg AM , 4.2mg PM (or it can be 4.2g in AM and 8.4mg in PM- depending on their side effect timing) 8.4mg AM, 4.2mg PM (or vice versa) 4.2mg BID 4.2mg BID 4.2mg once a day 4.2mg once a day Stop and take off study"
66820|NCT03661879|Drug|NNC9204-1706|Participants will receive NNC9204-1706 subcutaneous (s.c., under the skin) injection(s) once daily (OD) for 10 weeks. They will either receive the same dose throughout the trial, or the dose will be escalated over a period of 1-3 weeks and continued for at least 7 weeks at the same dose.
66821|NCT03661879|Drug|Placebo (NNC9204-1706)|Participants will receive matching placebo (NNC9204-1706) s.c., injection(s) OD for 10 weeks.
66822|NCT03661853|Behavioral|Control|60 minute psycho-education on alcohol and drugs.
66823|NCT03661853|Behavioral|Functional Analysis|"Component of standard CBT that helps to break the chain of events (external and internal) that lead from cue (trigger) to alcohol use to consequences of use."
66824|NCT03661853|Behavioral|Cognitive Restructuring|CR is used to to help identify and change automatic, habituated thoughts that occur in response to alcohol triggers.
66825|NCT03661853|Behavioral|Dealing With Cravings|DC is used reduce cravings for alcohol by conjuring negative images associated with alcohol, teaching distraction techniques, and teaching breathing techniques to reduce physiological arousal.
66828|NCT03661827|Diagnostic Test|Stress Cardiac MRI|Dobutamine and adenosine stress MRI
66829|NCT03661814|Device|Prevena|The NPWT device is a wound dressing with a vacuum system that can be placed over abdominal wounds, placed in the immediate postoperative period over abdominal wounds after clean/contaminated colorectal surgical procedures.
66830|NCT03661788|Drug|Atomoxetine|14-day treatment interval: first week 40 mg atomoxetine (one pill), second week 80mg atomoxetine (two pills)
66831|NCT03661788|Drug|Placebos|14-day treatment interval: first week one placebo pill, second week two placebo pills
66832|NCT03661775|Drug|Magnesium sulfate administration|controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
66833|NCT03661762|Device|CAVA|prototype device for monitoring dizziness
66834|NCT03661749|Other|clean catch|clean catch technique applied to collect urine for PR/CR ratio
66835|NCT03661736|Other|Food for Specific Medical Purpose|Infants aged 1 to 8 months with moderate-to-severe cow's milk allergy fed an amino acid-based formula with two added human milk oligosaccharides
66836|NCT03661723|Drug|Pembrolizumab|Pembrolizumab is a drug (an antibody) that may treat cancer by working with the immune system
66837|NCT03661723|Drug|Bevacizumab|"Bevacizumab (also known as Avastin) is designed to prevent or slow down the growth of cancer cells by blocking the growth of blood vessels."
66838|NCT03661723|Radiation|Re-irradiation|Radiotherapy destroys cancer cells using radiation aimed at a cancer from a machine
66839|NCT03661710|Other|Investigating Adherence to Standard of Care Medication and Cardiac Rehabilitation|Information from health care insurance providers on how many patients adhered to prescribed medication and how many underwent cardiac rehabilitation and how adherence influenced cardiovascular outcome will be retrieved
66840|NCT03661697|Device|Skin Care Regimen plus Lytera 2.0 and Laser Therapy|Combined
66841|NCT03661697|Device|Basic Skin Care Regimen Only and Laser Therapy|Not Combined
66842|NCT03661697|Other|Lytera plus Laser|two arms of study- each with different topical cosmeceutical
66843|NCT03661684|Drug|Prednisone|40 mg po q day of Prednisone for 3 days
66844|NCT03661671|Diagnostic Test|LCI+white light|Firstly use white light to observe from cardia to duodenum and then switch LCI model to observe from antrum to cardia
66845|NCT03661658|Procedure|Using short dental implant|Using short dental implant for patients with atrophic posterior mandible.
66846|NCT03661658|Procedure|Inferior alveolar nerve lateralization with simultaneous implant placement|Inferior alveolar nerve lateralization with simultaneous implant placement in atrophic posterior mandible.
66847|NCT03661645|Drug|10 mg IV dexamethasone & 6 day oral methylprednisolone taper|"Drug: 6-day oral methylprednisolone (glucocorticoid) taper course The oral methylprednisolone taper course will begin on the day of surgery and will include 24mg on day 1, 20mg on day 2, 16mg on day 3, 12mg on day 4, 8mg on day 5, and 4mg on day.~Drug:10 mg intravenous (IV) dexamethasone"
66848|NCT03661645|Other|10 mg IV dexamethasone|Drug:10 mg intravenous (IV) dexamethasone
66849|NCT03661632|Drug|BMS-986310|Specified dose on specified days
66850|NCT03661632|Biological|Nivolumab|Specified dose on specified days
66851|NCT03661619|Procedure|Sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure|Envelope technique + sub-epithelial connective tissue graft harvested from the palatal for root coverage procedure
67006|NCT03660371|Procedure|PPV without MP|No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
66853|NCT03661606|Other|Simulated Altitude Chamber|"Subjects will wear one armband linked biosensor: the Everion® CD, to capture their HR, RR and activity levels, continuously for 4 days.~Measurements will be taken at sea level (baseline), during controlled rest and normal day-to-day activities without exercise for the first 3 days to establish an individual's physiological baseline. On Day 4 subjects will be monitored for another period of controlled rest followed by 2 hours in a simulated altitude (intervention) chamber with altitude change of 3000 meters. At the chamber site, subject will rest quietly for 1 hour outside the chamber prior to entering the chamber for 2 hours. In the chamber, subjects will be asked to remain seated. At the completion of the chamber run, subjects will hand back the device and smartphone and complete a user experience survey. A follow up phone call to check on subjects will then be done on day 5 before closing the study."
66854|NCT03661593|Other|Cataract guideline|The patients gets an IOL according to cataract guideline correcting the ametropia
66855|NCT03661580|Behavioral|Behavioural Activation|The BA intervention will be the outpatient version of the Life Enhancement Treatment for Substance Use (LETS ACT; Daughters et al., 2008). This brief, manualised BA intervention has been specifically developed to meet the needs of patients with comorbid substance misuse and depression in drugs and alcohol treatment settings. LETS ACT targets the link between mood, substance use and behaviour, and focuses on identifying and increasing rewarding, substance-free activities that are based on the patient's own personal values.
66856|NCT03661580|Behavioral|Treatment as Usual|The control intervention in this study is Treatment as Usual at the CDAT service. Treatment as Usual consists of planned key-working sessions every 2-4 weeks with an allocated caseworker plus monthly prescribing review appointments with a medical practitioner for patients who require drug treatment medication. Key-working sessions are primarily focused on addressing substance misuse issues using a range of intervention techniques such as motivational interviewing and brief solution-focused therapy.
66857|NCT03661567|Radiation|chest radiation|split-course chest radiation
66858|NCT03661567|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
66859|NCT03661567|Drug|Methylprednisolone|Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
66860|NCT03661554|Biological|BCMA CAR-T Cells|The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
66861|NCT03661541|Drug|Squaric Acid Dibutyl Ester|2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.
66862|NCT03661528|Drug|andexanet alfa|Andexanet is a recombinant version of human FXa
66863|NCT03661515|Drug|Selinexor|"According to escalation level:~Level -1: Selinexor 40 mg/day, once weekly~Level 1: Selinexor 60 mg/day, once weekly~Level 2: Selinexor 80 mg/day, once weekly~Level 3: Selinexor 100 mg/day, once weekly"
66864|NCT03661515|Drug|fludarabine|fludarabine 30 mg/m2/day intravenously on days 1 to 4
66865|NCT03661515|Drug|idarubicin|idarubicin 10 mg/m2/day intravenously on days 1 to 3
66866|NCT03661515|Drug|cytarabine|cytarabine 2 g/m2/day intravenously on days 1 to 4
66867|NCT03661515|Drug|G-CSF|G-CSF 300 mcg/m2/day subcutaneously from days -1 to 5
66868|NCT03661502|Device|VVV|ventilation mode with variable tidal volume is chosen. the average tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
66869|NCT03661502|Device|PCV|ventilation mode with constant tidal volume is chosen. the tidal volume is 6 ml/kg and respiratory rate adapted to reach end tidal con between 30 and 50 mmHg
66870|NCT03661489|Drug|Remimazolam|For induction and maintenance of general anesthesia
66871|NCT03661489|Drug|Propofol|For induction and maintenance of general anesthesia
66872|NCT03661476|Behavioral|Oculo-Motor Exercises (OME)|"Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
66873|NCT03661463|Drug|Aspirin|Drug
66874|NCT03661450|Diagnostic Test|Clinical Decision-Support System|Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
66875|NCT03661437|Device|Actigraph|Wear Actiwatch
66876|NCT03661437|Other|Questionnaire Administration|Ancillary studies
66877|NCT03661437|Procedure|Systematic Light Exposure|Undergo BWL treatment
66878|NCT03661437|Procedure|Systematic Light Exposure|Receive DWL treatment
66879|NCT03661424|Drug|HER2 BATs|A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.
66880|NCT03661411|Drug|Aspirin|100mg qd
66881|NCT03661411|Drug|Clopidogrel 75mg|75mg（after first dose of 300mg）qd
66882|NCT03661411|Drug|Alteplase|Iv at 0.9 milligrams per kilogram (mg/kg)
66883|NCT03661398|Device|Transcatheter Mitral Valve Replacement|All eligible patients will be in the treatment arm for treatment with the Caisson Transcatheter Mitral Valve Replacement (TMVR) System. There is no control (comparator) arm for this study.
66884|NCT03661385|Drug|Nitric Oxide|Addition of nitric oxide 20ppm into bypass circuit
66885|NCT03661372|Other|Robot|Use of a telesimulation robot using contextual interview format.
66886|NCT03661372|Other|Face-to-face|Use of face-to-face patient interview using contextual interview format.
66887|NCT03661359|Other|Social Determinants of Health Referrals|Patients who screen positive for any of the Social Determinants of Health will be given information for referral to any of the community resources that apply to their situation.
66890|NCT03661333|Behavioral|Dialectical behavioral therapy|DBT will be conducted over 1 year, and divided into two modalities: skills training, conducted in 60 minute biweekly family meetings and individual therapy conducted in 60 minute biweekly sessions. Family skills training proceeds as follows: psychoeducation about DBT and bipolar disorder, mindfulness skills, emotion regulation skills, distress tolerance skills, interpersonal skills, and walking the middle path skills. Individual therapy sessions aim to aid the adolescent in applying skills in their daily lives. We adopt the standard DBT hierarchy of treatment targets, whereby the individual therapist selects behaviors to focus on based on the following priorities: 1) decreasing life-threatening behaviors, 2) decreasing therapy-interfering behaviors, 3) decreasing quality-of-life interfering behaviors, and 4) increasing behavioral skills. Therapists will be available to participants and their participating family members by cell phone for in-vivo skills coaching between sessions.
66896|NCT03661307|Drug|Decitabine|Given IV
66897|NCT03661307|Drug|Quizartinib|Given PO
66898|NCT03661307|Drug|Venetoclax|Given PO
66899|NCT03661294|Diagnostic Test|GE Healthcare Metabolic Oxygenator|
66900|NCT03661281|Diagnostic Test|Jebsen Taylor Hand function test|consists of seven test items, which are felt to represent various hand activities. These test items include: writing a short sentence; turning over 365 inch cards; picking up small objects and placing in a container; stacking checkers; simulated eating; moving empty large cans; and moving weighted large cans.
66901|NCT03661281|Diagnostic Test|Pinch strength|Measured in every splint position using a standard dynamometer
66902|NCT03661281|Diagnostic Test|Grooved pegboard test|Time will be measured and compared between control, MP splint and IP splint
66903|NCT03661268|Other|fluid chanllenge|A bag of 500ml of normal saline is infused within 15 minutes using a bag pressurized to 300 mmHg.
66904|NCT03661255|Behavioral|PC CARES|PC CARES trains local residents to deliver the PC CARES curriculum in their own community. These facilitators will attend a 40 hour training, and then will deliver the 4 session PC CARES curriculum in their home village. To aid local facilitators, each session follows the same structure after a beginning ritual:(1) agreements/safe talk, (2)'small wins', (3)'what do we know?' (facilitator shares current research on suicide prevention or wellness) (4)'what do we think?' (participants have an opportunity to discuss their thoughts on the research presented), and (5)'what we want to do?' (participants identify what steps they can take in their village to make positive change).The content of learning circles (LCs) includes community-level conditions, evidence-based approaches, risk and protective factors that can prevent suicide and promote well-being.Each LC includes both primary and secondary prevention strategies.Teaching tools include charts, short films, and case studies.
66905|NCT03661242|Behavioral|Physical activity|Patients in shared care arm has regular combined visits with Oncologist and Clincal Exercise Physiologist (CEP). Individual physical activity plan developed by CEP for patients in shared care arm.
66906|NCT03661216|Dietary Supplement|Nephure Oxalate-reducing Enzyme|3g of Nephure is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
66907|NCT03661216|Other|Placebo|3g of non-GMO maltodextrin is mixed with 8oz of water and ingested with breakfast, lunch and dinner.
66908|NCT03661203|Behavioral|Focus group|Focus group for qualitative group only
66909|NCT03661203|Behavioral|Individual interview|Individual interview for qualitative group only
66910|NCT03661203|Behavioral|online self questionnaire|online self questionnaire
66911|NCT03661203|Behavioral|self questionnaire|online self questionnaire following focus group or individual interview For qualitative group only
66912|NCT03661190|Other|Grammatical Reasoning|START measures the ability to determine the relationships among different shape combinations which are assigned to grammatical statements about them which can be either correct or incorrect. It is a measure of attention, working memory and executive control.
66913|NCT03661190|Other|Card Pairs|A basic picture-matching task.
66914|NCT03661177|Other|Sovereign nation diet|We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
66915|NCT03661164|Procedure|corneal cross linking|Iontophoretic corneal cross linking
66916|NCT03661138|Drug|Upadacitinib|Upadacitinib is administered orally.
66917|NCT03661138|Drug|Placebo for upadacitinib|Placebo is administered orally.
66918|NCT03661138|Drug|Topical Corticosteroids (TCS)|It is administered concomitantly with upadacitinib or placebo.
66919|NCT03661125|Drug|Saracatinib|AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/49. Two tablets to be taken every morning for 14 days.
66920|NCT03661125|Drug|Placebo Oral Tablet|Placebo AZD0530 (Saracatinib) 50 mg Tablet Pink Round 7.0 mm ADM P/5406/37. Two tablets to be taken every morning for 14 days.
66921|NCT03661099|Diagnostic Test|colonoscopy|endoscopists' performance outcome
66922|NCT03661086|Device|O2matic|O2matic controls oxygen with the aim of maintaining SpO2 within a predefined target interval, e.g. 88-92 % with the lowest possible supplementation of oxygen by nasal cannula
66923|NCT03661073|Behavioral|Assessment of motor imagery ability|The intervention will last 3 hours ± 45 minutes, the assessment will be spread over 3 sessions of 1 hour ± 15 minutes on one week. The time between two sessions will depend on patient fatigability and availability. The VMIQ-2 and the KVIQ-20 will be realized during the first session. In the second session, patients will perform the hand laterality judgment task and the MIQ-RS. During the last session the Timed up and go and the box and block test will be realized.
66924|NCT03661073|Behavioral|Assessment of motor imagery ability of healthy subject|The intervention will last 2 hours ± 15 minutes. All the tests will be spread over 1 session. Assessment order will be VMIQ-2, KVIQ-20, the hand laterality judgment task, the after a break MIQ-RS, iTUG and iBBT.
66925|NCT03661047|Drug|AMR101 (VASCEPA, icosapent ethyl)|Oral administration, 4 grams per day
66926|NCT03661034|Device|GammaSense Stimulation System (non-invasive, non-significant risk)|Non-invasive, non-significant risk audio-visual sensory stimulation device
66928|NCT03660956|Behavioral|Exercise|Twelves-week exercise training sessions include a variety of strength, flexibility, and coordination exercises. Each exercise session lasts for one hour. Participants are expected to attend exercise session once a week and are encouraged to continue exercising at home.
66929|NCT03660956|Behavioral|Back counselling|Procedure of back counselling includes one session back counselling, lasting one hour. The topics of back counselling session are as follows: (1) Anatomy of lumbar; (2) Factors causing low back pain; (3) Problems of physical inactivity for the lumbar; (4) Risk of poor postures for developing persistent/chronic low back pain; (5) Maintaining right posture of the lumbar; (6) Avoiding harmful loading of the back during work and leisure time.
66930|NCT03660943|Drug|Placebo|Receiving Placebo Injection
66931|NCT03660943|Drug|CNTX-4975-05 (trans-capsaicin)|Receiving CNTX-4975-05 Injection
66932|NCT03660930|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
66933|NCT03660930|Drug|Pazopanib hydrochloride|Given PO
66934|NCT03660917|Drug|Riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
66935|NCT03660917|Drug|Placebo|Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
66936|NCT03660904|Biological|home made vitrification & thawing kit|home made vitrification was made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
66937|NCT03660904|Biological|commercially made vitrification & thawing kit|commercially available vitrification & thawing kit were made and prepared for vitrification of blastocysts then thawing with a prepared thawed media too
66938|NCT03660891|Diagnostic Test|measuring neuromuscular block|During anesthesia patients are monitored with two instead of one NMT monitor. the difference in measured TOF-PTC is compared
66939|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered four times a day and an additional four times a day on an as needed basis.
66940|NCT03660878|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered four times a day and an additional four times a day on an as needed basis.
66941|NCT03660878|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered four times a day and an additional four times a day on an as needed basis.
66942|NCT03660865|Device|Light Adjustable lens (LAL) and Light Delivery Device (LDD)|Primary eye will receive Light adjustable lens with Light delivery Device treatments
66943|NCT03660865|Device|Control monofocal IOL|Fellow eye will receive control monofocal IOL
66944|NCT03660839|Drug|Artefenomel OZ439|Pharmaceutical form:Granule for oral suspension Route of administration: Oral
66945|NCT03660839|Drug|Ferroquine SSR97193|Pharmaceutical form:Capsule Route of administration: Oral
66946|NCT03660826|Drug|Cediranib|Given PO
66947|NCT03660826|Drug|Cediranib Maleate|Given PO
66948|NCT03660826|Drug|Olaparib|Given PO
66949|NCT03660813|Diagnostic Test|Follicle measurment|Follicle will be measured before aspiration
66950|NCT03660813|Drug|Ovitrelle ( Hcg 250 mcg)|Drug used for triggering
66951|NCT03660813|Drug|Decapeptyl ( GnRH Agonist 0.1 mg*2 )|Drug used for triggering
66952|NCT03660800|Drug|CTAP101 Capsules|Calcifediol Extended-Release Capsules
66953|NCT03660787|Drug|Seroguard|Seroguard 0.41 g/L solution
66954|NCT03660787|Drug|Placebo|Saline
66955|NCT03660774|Other|No treatment given|The participants will undergo a brief physical examination focused on neurologic function (muscle function, sensation, coordination, walking). Parents will be asked by the study team or the psychologist about their children and will complete several commonly used standard surveys about brain development, thinking, behavior, and decision making. The participants will also engage with the psychologist to evaluate development or thinking (IQ), and depending on their age they may be asked to complete one or more commonly used standard surveys about behavior and decision making.
66956|NCT03660761|Drug|apatinib|The patient was given a daily dose of apatinib 500mg (or based on weight). For adult, the dose of apatinib was prescribed with 425 mg or 500 mg per day and four weeks for a cycle. The dosage was modified to 250 mg if patients experienced ≧grade 2 hematologic adverse events, hand and foot syndrome, proteinuria, fecal ocular blood, or grade 3/4 hypertension, or other grade 3/4 adverse events. Apatinib was administrated until disease progression, unacceptable toxicity or death.
66957|NCT03660761|Drug|temodar|dose-dense temozolomide (100 mg/m2 , 7 days on with 7 days off ) , 28d
66958|NCT03660748|Biological|MET-2|Ingestion of a novel human microbiome preparation
66959|NCT03660722|Other|blood and urinary samples|blood samples, rectal and urethral swabs , urine samples at inclusion, after 4 weeks then 12 weeks
66960|NCT03660709|Behavioral|Intervention|"Standard-of-care HIV testing and counseling~Watch a video clip while waiting for the HIV testing result on a tablet.~Receive a pamphlet and post-test counselling promoting HIV retesting.~Receive the e-health HIV risk calculator through e-mail, SMS or social media means 3 and 5 months afterwards.~Receive brief e-health reminder for retesting at Month 3 and 5."
66961|NCT03660709|Behavioral|Control|Standard-of-care HIV testing and counseling
66962|NCT03660683|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg PO QD
66963|NCT03660683|Drug|Saxagliptin 5mg|Saxagliptin 5 mg PO QD
66964|NCT03660683|Drug|Placebo Oral Tablet|Matching Placebo Tablets
66965|NCT03660670|Behavioral|ONCORAL therapeutic education|Multidisciplinary program that includes informative cessions with a hospital pharmacist about the anticancer drug: information is given to the patients on adverse events and their managements, optimizing drug dosage plans. Moreover, information is shared with town partners: doctor, pharmacists, and nurses.
66966|NCT03660670|Behavioral|Standard of care|In the group of standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessments.
66967|NCT03660657|Drug|Ozone|Ozone Group: Standard treatment + Ozone therapy (O3/O2) by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 µg/ml; 40 sessions in 16 weeks.
66968|NCT03660657|Drug|Oxygen|Control Group: Standard treatment + Oxygen (O2) by rectal insufflation. O3/O2 concentration = 0 µg/ml (only O2); 40 sessions in 16 weeks.
67007|NCT03660358|Device|kinesiotape application|kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
66969|NCT03660644|Behavioral|WhatsApp, Pedometer and Step Diary|"Participants will be provided with a daily step diary and added to a group chat on WhatsApp. The group chat will be populated by other members of pulmonary rehabilitation programme (cluster) and the WhatsApp group leader will encourage participants to keep active. Participants will be encouraged to record the number of steps walked in a paper diary at the end of each day (i.e. prior to bedtime). This diary will simply have three columns: day of the week; number of steps; comments (optional).~The intervention will last 52 weeks."
66970|NCT03660631|Behavioral|CVRS Intervention|"Evaluate gaps in therapy~Contact patients regularly by email, phone and/or text message~Assess and counsel for medication adherence, side effects, life-style behaviors~Develop an action plan and send recommendations to provider"
66971|NCT03660618|Device|laser speckle flowgraphy|blood flow state of the skin as real time two dimensional image
66972|NCT03660605|Other|Rhythmic Auditory Stimulation|Participants will complete 6 weeks of walking training (3x/week). During each session, participants will walk on a treadmill for up to 20 minutes (stepping to a metronome at 85% of typical cadence) followed by overground walking for up to 15 minutes (stepping to a metronome at 115% of typical cadence).
66973|NCT03660579|Other|HIIT-AB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer with 5.4% alcohol.
66974|NCT03660579|Other|HIIT-NAB Group|Group that performed HIIT and consumed 330 ml (women) or 2x300 ml (men) of beer without alcohol (0.0%).
66975|NCT03660579|Other|HIIT-SW Group|Group that performed HIIT and consumed the same amount of sparkling water (0.0%).
66976|NCT03660579|Other|HIIT-ASW Group|Group that performed HIIT and consumed sparkling water with the same amount of alcohol than the pre-established beer (5.4%).
66977|NCT03660566|Procedure|Test - Implant with L-PRF|The patient's blood will be collected and the tubes (4) will be inserted into a tabletop centrifuge (Kasvi). Using a 2500rpm for 12 minutes protocol, the leucocyte- and platelet-rich fibrin clot will be prepared using a kit consisting of a perforated metal box where the clots will be positioned and covered by a metal plaque. The pressure exerted on the clot will lead to the formation of L-PRF membranes, which will be used to cover the ridge after placement of the implant. Then, the flap will be sutured.
66978|NCT03660566|Procedure|Control - Implant without L-PRF|Single implant installation surgery in maxillary esthetic area.
66979|NCT03660553|Drug|Insulin Glargine|0.40 units/kg body weight
66980|NCT03660553|Drug|Insulin Glargine|0.20 units/kg body weight
66981|NCT03660553|Drug|Insulin Aspart|0.20 units/kg body weight
66982|NCT03660553|Drug|Insulin Lispro|0.20 units/kg body weight
66983|NCT03660540|Dietary Supplement|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations.
66984|NCT03660527|Other|Not refered|No intervention was refered.
66985|NCT03660514|Behavioral|Jovenes Sanos|FP counselors in intervention clinics will a) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPC (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
66986|NCT03660501|Device|Continuous monitoring system|Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.
66987|NCT03660488|Drug|Cefixime 400 milligram Oral Capsule [Suprax]|The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days
66988|NCT03660488|Drug|Benzathine Penicillin G|The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
66989|NCT03660475|Drug|Naltrexone|naltrexone formulated as ophthalmic solution
66990|NCT03660475|Drug|Placebos|Placebo ophthalmic solution
66991|NCT03660462|Dietary Supplement|FeSO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferrous sulfate (58FeSO4)
66992|NCT03660462|Dietary Supplement|FePO4 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg ferric phosphate (58FePO4)
66993|NCT03660462|Dietary Supplement|HiFePO4 1 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 1 (57FePO4)
66994|NCT03660462|Dietary Supplement|HiFePO4 2 fortified rice test meal|Rice test meal extrinsically labeled with 2 mg high surface ferric phosphate 2 (57FePO4)
66995|NCT03660449|Combination Product|Moderately hypofractionated conformal radiation combined With cisplatin|All patients will receive five cycles of weekly cisplatin (25mg/㎡), each of 1 day's duration, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.
66996|NCT03660436|Drug|BMS-986165|Specified dose on specified days
66997|NCT03660436|Drug|MMF|Specified dose on specified days
66998|NCT03660423|Other|Integrative Dance|Integrative dance may be defined as dance that encourages the participation of all individuals, regardless of ability, supporting and celebrating these differences as a community. In the intervention, adults with developmental disabilities will be dancing in a contemporary dance class alongside college students.
66999|NCT03660410|Other|Anamnesis|A detailed anamnesis should be carried out in order to know the habits, the presence of systemic pathologies, the use of medication
67000|NCT03660410|Other|Oral clinical examination|Clinical examination should be carried out evaluating the presence of caries, tooth loss, periodontal condition, occlusal factors
67001|NCT03660397|Procedure|Selective endovascular chemical ablation of adrenal gland|Intervention with selective endovascular chemical ablation of adrenal gland is performed after adrenal angiography in the group.
67002|NCT03660397|Drug|Traditional triple antihypertensive treatment|irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
67003|NCT03660384|Procedure|PPV/SO|Subjects receive 1,000 centistoke silicone oil tamponade during vitrectomy
67004|NCT03660384|Procedure|PPV/C3F8|Subjects receive 16% C3F8 gas tamponade during vitrectomy
67005|NCT03660371|Procedure|PPV/MP|Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
67010|NCT03660332|Procedure|Infusion of a liquid meal intraduodenally|Infusion of IL-6/NaCL before a liquid meal intraduodenally
67011|NCT03660319|Other|Environmental Music Therapy|Experiencing Environmental Music Therapy during wait time in radiation oncology waiting room.
67012|NCT03660306|Procedure|open lung|open lung means giving lung recruitment and PEEP when dynamic compliance drops
67013|NCT03660306|Procedure|opioid free anesthesia|opioid free anesthesia means giving no opioids during surgery
67014|NCT03660293|Drug|Atorvastatin|cardio-protective agents
67015|NCT03660293|Drug|Captopril|cardio-protective agents
67016|NCT03660293|Drug|L-carnitine|cardio-protective agents
67017|NCT03660280|Dietary Supplement|Probiotics|Specific probiotic lactobacilli (added to stabilized ongoing treatment)
67018|NCT03660280|Other|Placebo|Placebo
67019|NCT03660267|Other|caffeine coffee|"drank 3 cups of caffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
67020|NCT03660267|Other|decaffiene coffee|"drank 3 cups of decaffeinated coffee daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
67021|NCT03660267|Other|still water|"drank 3 cups of still water daily (100 mL at 05:00 AM, 10:00 PM, and 15:00 PM), beginning on the morning after surgery Patients were free to drink any amount of water but no more coffee, black tea, or other form of caffeine, such as soda.~Coffee was prepared with a conventional coffee machine"
67022|NCT03660254|Behavioral|tai chi|tai chi exercise intervention，two times a week and each time cost one hour
67023|NCT03660241|Drug|PF-04965842|PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).
67024|NCT03660228|Other|Peri-Transfusion QOL Assessment|Participants will undergo a peri-transfusion quality of life assessment (PTQA) using the Quality of Life in Myelodysplasia Scale (QUALMS)
67025|NCT03660215|Other|mediation|support throughout their care journey during the 90 days following an emergency visit. This support will be carried out by a specific staff trained in medico-social mediation
67026|NCT03660202|Device|Firesorb|Implantation of Sirolimus Target Eluting Bioresorbable Vascular Scaffold （Firesorb）
67027|NCT03660189|Other|Two bag system|The two IV fluid bags have identical fluids and electrolytes, except one has 10% dextrose and the other has no dextrose. The two fluid bags run simultaneously and their rates are adjusted according to the patient's blood sugar.
67028|NCT03660176|Drug|butyrate enemas + routine management|10ml/kg volume of butyrate enemas in addition to the colonic irrigations
67029|NCT03660176|Other|routine management|the colonic irrigations
67030|NCT03660150|Other|Evaluation of health-related quality of life|Short Form-36 Medical Outcomes Survey (SF-36), and Brief Version of Burn Speciﬁc Health Scale (BSHS-B) are used for the present evaluation.
67031|NCT03660137|Device|MOLLI Localization|All patients will also be implanted with an additional MOLLI seed using a specialized introducer needle. A specialized MOLLI probe will be used to find the magnetic seed during the lumpectomy surgery.
67032|NCT03660124|Device|Deep Brain Stimulation|DBS is a neurosurgical procedure that involves the administration of small amounts of electricity to disrupt abnormal activity of brain structures associated with disease symptoms. It involves inserting thin electrodes into deep brain structures and electrically stimulating them in a controllable and ultimately reversible manner. The electrodes are connected to an internal pulse generator that is implanted in the upper chest region, below the collarbone.
67033|NCT03660111|Diagnostic Test|spirometry|only measurement of spirometry
67034|NCT03660085|Behavioral|PC-PEP|"The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips."
67036|NCT03660059|Drug|Peficitinib|Oral
67037|NCT03660059|Drug|Plaebo|Oral
67038|NCT03660059|Drug|Disease-modifying antirheumatic drugs (DMARDs)|"As necessary concomitant medications, DMARDs listed below will be administered orally unless specified.~For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod."
67039|NCT03660046|Drug|Depot medroxyprogesterone acetate (DMPA)|Depot medroxyprogesterone acetate (DMPA) will be dispensed from the Grady Pharmacy Service and will be administered every 12 weeks at the standard dose of 150 mg Intramuscular injection, beginning from week 3 of study enrollment and repeated every 13 weeks
67040|NCT03660046|Drug|Etonogestrel implant (Eng-Implant)|A standard Nexplanon rod Implant that is a subdermal implant in the arm. This will be placed at study week 3 by Dr. Haddad or a trained clinician. It contains Etonogestrel 68mg.
67041|NCT03660046|Drug|Levonorgestrel IUD (Lng-IUD)|The Levonorgestrel Intrauterine Device (Lng-IUD) (Mirena or copper) will be placed at study week 3 by Dr. Haddad or a trained clinician.
67042|NCT03660033|Diagnostic Test|ECG in delivery room|See arm/group discussions
67043|NCT03660020|Drug|Local anesthetic|ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy with local anaesthetics only
67044|NCT03660020|Drug|Hyaluronidase|hyaluronidase will be added to ultrasound guided erector spine plane block (ESP) will be done in patients under going mastectomy
67045|NCT03660007|Procedure|Fresh or frozen embryo transfer IVF|
67046|NCT03659994|Dietary Supplement|Multivitamin|Vitabeard
67048|NCT03659981|Other|MRI 7T|The imaging parameters will come from the 7 Tesla Siemens MRI
67049|NCT03659968|Other|Physical activity training|brisk walking on treadmill and exercises of muscular strengthening with varying durations and intensities depending on physical capabilities of patients
67050|NCT03659955|Other|Autologous blood applied to dry eye|See previous description for the study arm.
67051|NCT03659942|Other|CAST questionnaire|the CAST questionnaire will be used to answer the main objective of the study and to identify consumers with problematic cannabis use. This is a validated self-questionnaire in France (Legleye et al., 2011), specific to the adolescent population, which is interpreted according to the score obtained (Bastiani et al., 2013, Legleye et al. 2007, Legleye et al., 2011). It includes 6 items with answer modes coded from 0 to 4. The total score obtained by summing these 6 items can therefore vary from 0 to 24. We define users without risk for a score of less than 3, users with low risk for a score greater than or equal to 3 and less than 7, and finally those with a risk of problematic use for a score greater than or equal to 7
67052|NCT03659929|Drug|Amphetamine Sulfate|2 arms of active experimental AR19 will be given, compared to 1 arm of placebo comparator
67053|NCT03659929|Drug|Placebo|Matching placebo
67054|NCT03659916|Drug|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of IBAT
67055|NCT03659903|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy
67056|NCT03659890|Dietary Supplement|Low nucleotide|2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose
67057|NCT03659890|Dietary Supplement|High nucleotide|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose
67058|NCT03659890|Dietary Supplement|High nucletide + Ribose|2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
67059|NCT03659877|Behavioral|Physical activity|Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
67060|NCT03659864|Other|diesel exhaust particulate|aerosolised diesel exhaust particulate
67061|NCT03659864|Other|carbon nanoparticles|aerosolised 'clean' carbon nanoparticles
67062|NCT03659864|Other|small graphene oxide|aerosolised 'small' graphene oxide
67063|NCT03659864|Other|ultrasmall graphene oxide|aerosolised 'ultrasmall' graphene oxide
67064|NCT03659864|Other|filtered air|control: filtered air
67065|NCT03659851|Drug|Levosimendan 2.5 MG/ML Injectable Solution|LVAD implantation
67066|NCT03659825|Dietary Supplement|Ketone Ester|Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
67067|NCT03659825|Dietary Supplement|Taste Matched Placebo|Placebo that tastes similar to active intervention
67068|NCT03659825|Other|Hypoxic exposure|Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
67069|NCT03659812|Other|MACS technique|MACS is a technique that allow us to tag and detect apoptotic spermatozoa. These apoptotic spermatozoa have phosphatidylserine in their membranes, so we add magnetic beads with Annexin V, which binds specifically to phosphatidylserine. The spermatozoa are then tagged and can be retained in a magnetic field, allowing us to collect just the non-apoptotic spermatozoa.
67070|NCT03659799|Drug|Insulin FiAsp|An insulin bolus of FiAsp will be given 5 minutes before breakfast
67071|NCT03659799|Drug|Insulin Aspart|An insulin bolus of Aspart will be given 5 minutes before breakfast
67072|NCT03659799|Other|60-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 60 minutes after breakfast
67073|NCT03659799|Other|120-minutes postprandial exercise|A 60-minute exercise at 60% of VO2 peak will be performed 120 minutes after breakfast
67074|NCT03659786|Other|CC-Test|Classification of the oocyte/embryo based on the expression pattern observed in the cumulus cells
67075|NCT03659773|Biological|immune biomarkers to evaluate vaccine response in HSCT recipients|a 24mL-blood sample will be collected before and at 3, 12 and 24 months after complete block vaccination.
67076|NCT03659760|Other|Group Isolated|Eyes closed with patch and ears plugged between 24:00-06:00
67077|NCT03659747|Dietary Supplement|Probiotic|- 6 g sachet containing probiotic powder (1.8 x 10^12 CFU Probiotic) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
67078|NCT03659747|Dietary Supplement|Lactrase|- 6 g sachet containing 4500 Food Chemical Codex (FCC) units of lactase (Lactrase, Oy Verman Ab, Kerava, Finland) and maltodextrin as a carrier - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat-free milk once in the beginning of a 6-hour challenge at a study visit.
67079|NCT03659747|Other|Placebo|- 6 g sachet containing placebo powder (maltodextrin) in sachet - One sachet of the investigational product will be consumed with 521 ml of Weihenstephan fat- free milk once in the beginning of a 6-hour challenge at a study visit.
67080|NCT03659734|Behavioral|Motivational Interviewing and Gradual Opioid Weaning|Following surgery, participants will undergo motivational interviewing with a trained member of the study staff. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
67081|NCT03659734|Behavioral|Enhanced Usual Care|Following surgery, participants will receive phone calls from a trained member of the study staff to discuss various aspects of surgical recovery and medication use. These calls will occur weekly for 6 weeks with a follow-up call at 10 weeks or until the participant completes the protocol.
67082|NCT03659721|Behavioral|FACAM|Support person
67083|NCT03659721|Behavioral|Care as Usual|Usual care
67084|NCT03659721|Behavioral|COS-P|Attachment based therapy
67085|NCT03659708|Procedure|Lyon-VTE score|follow-up at 3 months, 5 months, 7 months during pregnancy and 3 months and 12 months after delivery.
67086|NCT03659708|Procedure|recommendations currently available|follow-up at 7 months during pregnancy and 3 months and 12 months after delivery.
67087|NCT03659695|Dietary Supplement|Grape Powder|69 g/d freeze dried grape powder
67088|NCT03659695|Dietary Supplement|Placebo Powder|69 g/d placebo powder matched for taste and appearance
67089|NCT03659682|Drug|Semaglutide|subcutaneous, 1.0 mg, weekly, 48 months
117379|NCT03268941|Drug|TAK-906 Maleate|TAK-906 Maleate Capsules
67090|NCT03659656|Behavioral|Lifestyle coaching|Goal setting and behavior change barriers will be discussed through lifestyle behavioral change coaching. Personalized weekly physical activity achievement report will also be sending to participants in experimental group. The participants will also have a Fitbit to use for 3 months.
67091|NCT03659656|Device|Fitbit usage|The participants will have a Fitbit to use for 3 months.
67092|NCT03659643|Diagnostic Test|EEG with SPR analysis|qEEG with SPR analysis was performed in group 1 during 2011-2013 and in group 2, the same procedure is performed.
67093|NCT03659630|Behavioral|MyCompass|Self-help tools to change behaviours in various different domains including sleep deprivation, anxiety and depression.
67094|NCT03659630|Behavioral|Comparison group|An email containing a brief text on general tips regarding mental health was sent out once a week.
67095|NCT03659617|Device|xenograft (BioOss Collagen)|Alveolar ridge preservation using xenograft (BioOss Collagen) and implant placement at 3 different time intervals (3, 6 and 9 months)
67096|NCT03659604|Behavioral|'SmartLife' with tailored feedback|'SmartLife' game with tailored feedback: mobile exergame with tailored feedback. Feedback will be based on accelerometer data from a sensor that is integrated in a T-shirt. The sensor captures individually calibrated accelerometer data and is paired with the mobile exergame. Depending on the physical activity intensity of the player, the game challenge and feedback adapts individually in real-time.
67097|NCT03659604|Behavioral|'SmartLife' without tailored feedback|'SmartLife' without tailored feedback: mobile exergame without tailored feedback. The mobile exergame will not be paired to any sensor. The participant can play the mobile game, yet, will not receive any real-time feedback or adjustment in the game on physical activity intensity.
67098|NCT03659604|Behavioral|No game|Passive control: School classes will be asked to continue their daily life as usual.
67099|NCT03659591|Behavioral|Cognitive Behaviour Therapy|CBT will be delivered in group format, consisting of 10 weekly two-hour sessions, with 10 participants per group
67100|NCT03659591|Behavioral|Adaptive Psychological Training|APT will be delivered in group format, consisting of 5 weekly two-hour sessions, with 20 participants per group
67101|NCT03659578|Drug|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
67102|NCT03659578|Radiation|split-course radiotherapy|split-course chest radiation at 51Gy/17f and 15Gy/5f
67103|NCT03659578|Drug|thymosin alpha 1|subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
67104|NCT03659565|Behavioral|Enhanced Pre-Visit Consultation|The Intervention Group will be given access to the optimized personal health record and will use Zoom as part of the pre-visit consultation.
67105|NCT03659565|Behavioral|Usual Care Control|Caregivers and patients will participate in usual pre-visit process.
67106|NCT03659552|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left jugular vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
67107|NCT03659539|Drug|PROPOFOL|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
67108|NCT03659539|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
67109|NCT03659526|Diagnostic Test|Deformation imaging|Deformation parameters derived using myocardial velocity imaging or speckle tracking
67110|NCT03659500|Diagnostic Test|Four-week routine bloodwork|Routine hemodialysis bloodwork done every 4 weeks
67111|NCT03659500|Diagnostic Test|Six-week routine bloodwork|Routine hemodialysis bloodwork done every 6 weeks
67112|NCT03659487|Procedure|Nissen|Laparoscopic total (Nissen) fundoplication
67113|NCT03659487|Procedure|Toupét|Laparoscopic posterior 270 degrees partial fundoplication
67114|NCT03659474|Other|compression|compression by Game Ready
67115|NCT03659474|Other|ice pack|cryotherapy for ice pack
67116|NCT03659474|Other|immersion|immersion therapy
67117|NCT03659461|Drug|Sitagliptin|oral 100mg Sitagliptin daily will be given for 12 weeks. Subjects are required to undergo OGTT pre and post treatment.
67118|NCT03659448|Drug|SGM-101|A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
67119|NCT03659435|Drug|RID-TDS 9.5 mg/24 h|3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period
67120|NCT03659435|Drug|Exelon® 9.5 mg/24 h|11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
67121|NCT03659422|Other|Modified Paleolithic diet|The diet eliminates legumes, grains and nightshades (as opposed to the Paleolithic diet) and is higher in vegetable and fruit intake and in omega-3 fatty rich foods.
67122|NCT03659409|Behavioral|Mindfulness-Based Intervention|4 weekly 2-hour sessions. Participants will be introduced, taught and guided in practice of mindfulness-based interventions that are focused on their (1) breath, (2) senses, (3) body and bodily movements, (4) feelings of empathy and compassion.
67123|NCT03659409|Behavioral|Waitlist - Mindfulness-Based Intervention|Participants in this group will only receive the Mindfulness-Based Intervention 3-months after they have started the study and baseline measurements. While participants in the Intervention Arm are receiving the treatment, this group will receive No intervention for the first four weeks and will continue as treatment as usual until it is their turn to receive the Intervention.
67124|NCT03659396|Other|individualized Tai Chi|individualized Tai Chi training exercise
67125|NCT03659396|Other|Entire Tai Chi|the classical Yang style Tai Chi program
67126|NCT03659396|Other|home-based program|Home-based exercise
67127|NCT03659383|Combination Product|Optimal hypoglycemic treatment|Standardize oral hypoglycemic medication and adjust insulin dose according to blood glucose values obtained by self-monitoring
67128|NCT03659370|Other|Fumigation|use Fumigation to increase the improvement of osteoarthritis of knee
67129|NCT03659370|Other|Acupuncture|Acupuncture
67130|NCT03659344|Drug|Vicryl plus|Using vicryl sutures which coated with triclosan (antibiotic)
67257|NCT03658408|Drug|4-aminopyridine|Oral tablet of 2.5 mg given 4 times a day
67131|NCT03659331|Dietary Supplement|Zinc|blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
67132|NCT03659318|Procedure|Robotic-assisted TKA|Total knee arthroplasty is carried out with help of robotic surgery system, using a Robodoc system. CT-based preoperative planning using ORTHODOC (Integrated Surgical Technology Corp) performed in the first step before the day of surgery, and the robotic-assisted surgery using the ROBODOC surgical assistance in the second step. The bone markers are registered to the computer, and the computer arm does all the cutting and preparation of bones. This is in contrast to conventional jigs and cutting blocks. Actual implantation of the implants is done by a surgeon. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
67133|NCT03659318|Procedure|Conventional TKA|Total knee arthroplasty is carried out with classical, conventional, manual method. A surgeon measures the angle, length of the cuts with bone landmarks and specialized surgical instruments. After all the cuts actual implantation is done. A Duracon posterior cruciate-substituting total knee prosthesis (Stryker Orthopedics, Mahawh, NJ, USA) are used in all knees.
67134|NCT03659305|Biological|RPH-001|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
67135|NCT03659305|Biological|Avastin|Concentrate for preparation solution for infusion in ampules, 25 mg/mL
67136|NCT03659292|Other|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
67137|NCT03659292|Other|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine and 0.5ug/ml sufentanil infusion) will be provided after surgery.
67138|NCT03659292|Other|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
67139|NCT03659292|Other|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
67140|NCT03659279|Behavioral|Let's Get Organized|Group intervention aiming to enhance time-management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with a PowerPoint presentation and a course manual, and information from the group leaders is intermixed with discussion among the participants and tasks to complete.
67141|NCT03659266|Other|Robotic walking rehabilitation by Lokomat®|Lokomat sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of effective work of the march and 15 minutes of setting up.
67142|NCT03659266|Other|Conventional walking rehabilitation|5 physiotherapy sessions / week for 2 weeks. Each session lasts 45 minutes including 30 minutes of walking and 15 minutes of stretching
67143|NCT03659253|Diagnostic Test|Oral Fluid Based Self Testing|The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
67144|NCT03659253|Procedure|Simplified ART Initiation|In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
67145|NCT03659253|Procedure|CBO AND BROTHEL-BASED ART SERVICE|The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
67146|NCT03659253|Behavioral|SMS REMINDER|HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
67147|NCT03659253|Procedure|MOTIVATIONAL INTERVIEWING|"The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence"
67148|NCT03659240|Other|Cranberry beverage|During the intervention period, research participants will consume a cranberry beverage daily.
67149|NCT03659240|Other|Placebo beverage|During the intervention period, research participants will consume a placebo beverage daily.
67150|NCT03659214|Behavioral|Questionnaires|Answering 4 questionnaires : anxiety, depression, quality of life and adherence
67151|NCT03659201|Drug|Neosil complete|Oral, during 24 weeks.
67152|NCT03659201|Drug|Pantogar|Oral, placebo for 12 weeks and pantogar for 12 weeks.
67153|NCT03659201|Drug|Neosil|Oral, during only 12 weeks.
67154|NCT03659188|Procedure|Corticotomy with drills|Mechanical drills will be used on a handpiece
67155|NCT03659188|Procedure|Traditional Corticotomy|Piezo-surgery will be employed following flaps' elevation.
67156|NCT03659175|Other|SIBO|SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
67157|NCT03659162|Drug|Azole Antifungal|oral gel & injections
67158|NCT03659149|Drug|CKD-333 formulation I|1 tablet administered before the breakfast(single-dose)
67159|NCT03659149|Drug|CKD-333 formulation II|1 tablet administered before the breakfast(single-dose)
67160|NCT03659149|Drug|CKD-330+D086|2 tablet administered before the breakfast(single-dose)
67161|NCT03659136|Drug|Xentuzumab|Intravenous infusion
67162|NCT03659136|Drug|Placebo|Intravenous infusion
67163|NCT03659136|Drug|Everolimus|Tablet
67165|NCT03659123|Behavioral|standardized geriatric intervention|"Nutritional care is based on:~A personalized evaluation of nutritional balance and nutritional needs of the patient~A weekly follow-up of weight and nutritional intake~Total-body rehabilitation is based on:~2 to 3 times a week: strength exercise~2 to 3 times a week: endurance exercise, 20 to 45 min each sequence~2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results."
67166|NCT03659110|Biological|HPV 4|1000 subjects will be received the HPV 4 vaccine
67167|NCT03659097|Procedure|periodontally accelerated osteogenic orthodontics|Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
67168|NCT03659084|Drug|EXJADE|The patient having given his consent, will begin the Exjade at 10 mg / kg per day if the ferritin level reached 1000 ng / ml at 6 months after allograft, for a minimum duration of three months and up to 6 months. The iron parameters will be evaluated at 3, 6, 9, 12, 18 and 24 months after the beginning of the exjade treatment. The evaluation of the disease will be carried out according to the practices of the center. It is recommended to have a washout period of one week between stopping the ciclosporin and the beginning of treatment by exjade.
67169|NCT03659071|Other|questionnaire VSP-A|VSP-A (écu et Santé Perçue de l'Adolescent et de l'enfant): Lived and perceived health of the adolescent and child developed from the exclusive point of view of the child, for which reference values in French population are available. The self-questionnaire used is a questionnaire developed and validated in French for children and adolescents, according to the standards in force, apprehending 9 dimensions (vitality, psychological well-being, relations with friends, leisure, family relations, good physical, relationships with teachers, school work, self-esteem)
67170|NCT03659058|Drug|silymarin|silymarin 140 three times daily
67171|NCT03659058|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid 500
67172|NCT03659058|Drug|Antioxidants|Beta Carotene - 6Mg Vitamin C - 200Mg Vitamin E - 50Mg
67173|NCT03659058|Drug|Colchicine|Colchicine 0.6
67174|NCT03659058|Other|FOLLOW UP|follow up by abdominal ultrasound and fibroscan every 6 month for 1 year
67175|NCT03659045|Other|scale of pain|The measurement is simple, reproducible, performed using a scale of pain rated from 0 to 10 (0 absence of pain, 10 maximum of pain felt)
67176|NCT03659032|Procedure|Pediatric Manual Therapy|
67177|NCT03659032|Procedure|Educational Physical Therapy|
67178|NCT03659019|Other|Quality of life questionnaires|During 10 years, the study will be conduct to obtain the quality of life evolution and medical complications in patients candidates but not implanted, and in patients candidates then implanted with the phrenic nerve stimulator.
67179|NCT03659006|Biological|Biological Collection|Blood sampling on catheter and CSF sampling from VDE, multimodal MRI at D42 and D365, Neurological and neuropsychological evaluation at one year
67180|NCT03658993|Drug|Rifaximin 550 MG|Oral Rifaximin 550 mg TID for 4 weeks.
67181|NCT03658980|Behavioral|Health Education Intervention|Face-to-face health education intervention on Diabetic Retinopathy and available services at a tertiary hospital, followed by telephonic reminder at Day 7, 30 and 90.
67182|NCT03658967|Drug|Lymfactin® (1x10E11 vp)|Lymfactin® will be administered as a single dose via perinodal injection in a volume of 2 mL.
67183|NCT03658967|Drug|Placebo|Placebo will be administered as a single dose via perinodal injection in a volume of 2 mL.
67184|NCT03658954|Behavioral|Advice|Once per week for two weeks, participants will come to in-person visits to receive brief web-based sleep hygiene advice.
67185|NCT03658954|Behavioral|Self-monitoring|Participants will complete daily web-based sleep and alcohol diaries for two weeks.
67186|NCT03658954|Behavioral|Feedback|Participants will receive feedback once per week for two weeks on their sleep and alcohol consumption, using all possible data derived from Fitbit actigraphs and Milo Sensor blood-alcohol trackers.
67187|NCT03658941|Procedure|No dural tenting techniques|Not applying dural tenting sutures during closure of a craniotomy
67188|NCT03658941|Procedure|Dural tenting techniques|Applying at least 3 dural tenting sutures during closure of a craniotomy
67189|NCT03658915|Device|Smartphone application (Goniometer Pro )|Knee repositioning error will be measured simultaneously by smartphone and Biodex isokinetic dynamometer by a single blind assessor. All assessments will be done with eyes closed and repeated over two separate sessions, with one-week interval in-between. For active repositioning, the participant will actively extend the knee to reach a predetermined target position45° flexion at an angular velocity of 10°/sec. For passive knee repositioning, the isokinetic dynamometer will move the knee at 5°/s to a predetermined angle between 5° and 80° of flexion and the participant should stop the movement when the predetermined angle is reached.
67190|NCT03658876|Drug|Iron Sucrose Solution for Injection|200mg iron sucrose given on 5 successive haemodialysis sessions
67191|NCT03658876|Drug|Epoetin Beta|Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000
67192|NCT03658863|Procedure|endoscopic ultrasound|Evaluation of bile ducts with endoscope with special ultrasonographic function
67193|NCT03658863|Procedure|intraoperative cholangiography|evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy
67194|NCT03658863|Procedure|ERCP|evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum
67195|NCT03658863|Device|Ultrasound endoscope|Endoscope with built-in ultrasound function
67196|NCT03658850|Drug|Hydrochlorothiazide 50Mg|for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
67197|NCT03658850|Drug|Placebos|for the placebo group will receive one tablet or equivalent volume of enteral solution of inert substance, identical to the hydrochlorothiazide presentations, every 12 hours until day 3
67198|NCT03658837|Procedure|Ivor Lewis Oesophagectomy|Patients who underwent Ivor-Lewis Oesophagectomy for cancer of oesophagus
67258|NCT03658408|Drug|placebo|2.5 mg sugar pill given orally 4 times a day
67199|NCT03658824|Other|Behavioural Activation (BA)|"BA is based on the assumption that depression may be precipitated and is maintained by a reduction in healthy, adaptive behaviours and positive reinforcement of these, and an increase in avoidance behaviours. Together, these changes reduce the person's immediate distress, often at the expense of their medium and longer term goals. The therapy involves helping the individual to re-establish healthy patterns of activity, and replace avoidance behaviours with more adaptive behaviours that are constructive in the longer term.~The intervention consists of up to 20 individual therapy sessions of Behavioural Activation, with one booster session three months after the end of therapy. Each session lasts approximately 50 minutes and this is supplemented by home practice between sessions."
67200|NCT03658811|Device|intense pulsed light|Use of 6 mm SapphireCool light guide to treat upper lid margins from tragus to tragus including the nose
67201|NCT03658798|Procedure|Functional Electrical Stimulation|Study participants will receive 40 sessions of intervention, 3 to 5 times a week over 2 to 3 months. Each session will be one hour in duration and participant will receive functional electrical stimulation therapy with their customized shirt. During therapy participants will be expected to carry out functional movements with assistance from the FES Garment.Participants will be expected to don, activate, and doff the garment as independently as possible. The exercises conducted will be defined by the investigator based on the functional status of the participant and eventual progress.
67202|NCT03658785|Biological|TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)
67203|NCT03658785|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.)
67204|NCT03658785|Drug|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
67205|NCT03658785|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days
67206|NCT03658772|Drug|grapiprant|Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
67207|NCT03658772|Drug|grapiprant and pembrolizumab|Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
67208|NCT03658759|Procedure|Extracorporeal Cardiopulmonary Resuscitation|local ECPR clinical pathway, including transport with mechanical chest compression device and rapid response VA-ECMO
67209|NCT03658746|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day quadruple therapy for the H.pylori eradication. The regimen contains one proton pump inhibitor, colloidal bismuth pectin and two sensitive antibiotics determined by antimicrobial susceptibility test. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
67210|NCT03658746|Drug|one proton pump inhibitor, colloidal bismuth pectin|All patients need these two drugs.
67211|NCT03658746|Drug|two antibiotics based on personal medication history(amoxicillin,levofloxacin, furazolidone)|Patients will receive a 14-day quadruple therapy according to personal medication history for helicobacter pylori eradication. The regimen contains one proton pump inhibitor, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient hasn't been treated with levofloxacin previously, he will be treated with amoxicillin and levofloxacin. Otherwise, he will be treated with amoxicillin and furazolidone.
67212|NCT03658733|Drug|esomeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing esomeprazole for the Helicobacter pylori eradication. The regimen contains a double dose esomeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by esomeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
67213|NCT03658733|Drug|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy containing rabeprazole for the Helicobacter pylori eradication. The regimen contains a double-dose rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole, amoxicillin , tetracycline and colloidal bismuth pectin for the second 7 days.
67214|NCT03658720|Drug|200 mg Ibuprofen acid orodispersible tablet|orodispersible tablet
67215|NCT03658707|Other|questionnaire|Shoulder questionnaire
67216|NCT03658694|Procedure|rTMS high dose - stage 1|Patients will be undergoing to transcranial magnetic stimulation session with high dose 3000 pulses
67217|NCT03658694|Procedure|rTMS sham - stage 1|Patients will be undergoing to sham transcranial magnetic stimulation session with high dose 3000 pulses
67218|NCT03658694|Procedure|high dose rTMS - stage 2|Patients will be undergoing to transcranial magnetic stimulation session with high dose 3000 pulses
67219|NCT03658694|Procedure|low dose rTMS - stage 2|Patients will be undergoing to transcranial magnetic stimulation session with low dose 1500 pulses
67220|NCT03658681|Other|Saturated fat 14.9 E%|Dietary cross-over study with saturated fat
67221|NCT03658681|Other|Polyunsaturated fat 13.6 E%|Dietary cross-over study with polyunsaturated fat
67222|NCT03658668|Device|active tDCS|tDCS is a therapeutic treatment that utilizes low amplitude direct currents (<4 mA) to induce changes in cortical excitability.
67223|NCT03658668|Device|sham tDCS|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.5 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then againat the end of the session. These brief periods of stimulation serveto mimic the effects of a true stimulation session.
67224|NCT03658668|Other|Physical Activity (PA)|20 minutes of cycling on an ergonomic cross-trainer
67256|NCT03658421|Procedure|Continuous femoral nerve block|All the continuous femoral nerve block infusion regimes in the pump were connected to CFNB catheter, which contained only ropivacaine with different concentrations (ropivacaine 0.1% for L group and LD group; ropivacaine 0.2% for H group, 5 ml/h).
67225|NCT03658655|Biological|Stem Cells From Human Exfoliated Teeth|"Basic treatment:~The original treatment regimen will be maintained during the study period, insulin dose could be adjusted with the change of blood glucose, while the type and dose of oral hypoglycemic drugs remained unchanged (except when side effects of drugs or insulin preparations were stopped, but patients still had frequent hypoglycemia).~Stem cell therapy:~Usage: drip slowly, 50ml normal saline first, then Stem Cells From Human Exfoliated Teeth (during 60 min), then 50ml normal saline."
67226|NCT03658642|Behavioral|Clinical Decision Support (CDS)|This clinical decision support tool will improve the clinician's ability to identify those with OUD, initiate BUP and refer the patient to ongoing Medication Assisted Treatment (MAT)
67227|NCT03658629|Biological|2018-2019 Investigational Seasonal Influenza Vaccine|2018-2019 Investigational Seasonal Influenza Vaccine
67228|NCT03658629|Biological|2018-2019 Licensed Seasonal Influenza Vaccine|2018-2019 Licensed Seasonal Influenza Vaccine
67229|NCT03658629|Other|Placebo|Placebo
67230|NCT03658616|Drug|WO3970|Application of cream to each axilla
67231|NCT03658616|Drug|Placebo (WO3988)|Application of cream to each axilla
67232|NCT03658603|Procedure|thoracodorsal artery perforator flap|fascio-cutaneous flap used in cases of trauma or burns
67233|NCT03658603|Procedure|latissimus dorsi flap|musculo-cutaneous flap used in cases of trauma or burns
67234|NCT03658590|Drug|Dexamethasone|a prefilled syringe with two milliliters (8 mg) of dexamethasone intravenously
67235|NCT03658590|Drug|Distilled Water|a prefilled syringe with two milliliters of distilled water intravenously.
67236|NCT03658564|Dietary Supplement|Preoperative Oral Carbohydrate Drink|Patients in Oral carbohydrate group consumed 400 ml Preoperative Oral Carbohydrate Drink Nutricia preOp® (12.5% carbohydrates, 0.5kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, the Netherlands) 3 hours prior to induction of anesthesia and finished the ingestion within 20 minutes.
67237|NCT03658551|Diagnostic Test|Fluorescein|Measurement of intensity in the gastrointestinal mucosa after intravenous administration of fluorescein by confocal endoscopy
67238|NCT03658538|Device|Active HEPA Air Cleaner|The active treatment arm will receive two active air cleaners with HEPA and carbon filters to support a home smoking ban and SHS reduction.
67239|NCT03658538|Behavioral|Motivational interviewing|"The active treatment arm will receive 4 sessions of phone based motivational interviewing to support a home smoking ban and SHS reduction (in addition to the smoking cessation counseling received by all study participants).~The Control arm will receive only continued counseling for smoking cessation."
67240|NCT03658538|Device|Sham Air Cleaner|The Control arm will receive sham air cleaners
67241|NCT03658525|Device|MR LINAC|MR GUIDED PROSATE RADIOTHERAPY
67242|NCT03658499|Behavioral|two day skills group plus treatment adjuncts|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will be provided with the treatment adjuncts.
67243|NCT03658499|Behavioral|two day skills group control group|The modified dialectical behavior therapy protocol for victims of intimate partner violence dedicates additional time to address validation of self and others in order to mitigate the impact of punishing social relations, and increase the victims' access to positive reinforcement (Iverson et al., 2009). The modified protocol covers the same four major modules as the original DBT protocol in an abbreviated manner. Participants in this group will not be provided with the treatment adjuncts and will serve as the control group
67244|NCT03658486|Other|Exercise|Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be assigned a moderate intensity walking and strengthening program to complete at home. At baseline, 12 and 24 weeks patients will wear an accelerometer to determine activity levels. At these time points, patients will also complete a physical fitness assessment (timed sit-to-stand and six minute walking tests) and a range of quality of life questionnaires. At baseline, patients will receive a behaviour change consultation and continued support throughout the intervention. Each patient will receive a pedometer during the home-based, unsupervised regime to monitor step count and they are expected to complete a daily physical activity diary. Upon completion of the 24 week follow-up, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
67245|NCT03658473|Drug|550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
67246|NCT03658473|Drug|550 mg naproxen + placebo + 20 mg rabeprazole|Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
67247|NCT03658473|Drug|550 mg naproxen + 300 mg rebamipide + placebo|Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
67248|NCT03658473|Drug|550 mg naproxen + placebo + placebo|Oral administration of 550 mg naproxen 2x daily + placebo 2x daily + placebo of rabeprazole 1x daily over 7 days.
67249|NCT03658460|Other|DNA sequencing|Targeted next generation sequencing and gene expression analysis with focus on immuno-oncology signatures
67250|NCT03658447|Drug|Pembrolizumab|200mg Pembrolizumab given 3 weekly for upto 35 cycles
67251|NCT03658447|Drug|177Lu-PSMA|6-weekly 177Lu-PSMA treatments for upto 4 cycles starting at 8.5GBq with administered radioactivity reduced by 0.5GBq for each cycle.
67252|NCT03658434|Radiation|Palliative radiotherapy|Palliative Radiotherapy to Dominant Symptomatic Lesion in Patients With Hormone Refractory Prostate Cancer
67253|NCT03658421|Drug|Dexmedetomidine|Dexmedetomidine added to lower concentration of ropivacaine for postoperative analgesia in FNB
67254|NCT03658421|Procedure|ultrasound-guided femoral nerve block|ultrasound-guided femoral nerve block, a single bolous of 20 ml ropivacaine (concentration 0.2% for H group or 0.1% for L group) before surgery followed by continuous femoral nerve block using an infusion rate of ropivacaine 0.2% 5 ml/h for postoperative analgesia started right after surgery
67255|NCT03658421|Device|intravenous patient-controlled analgesia pump with morphine|All subjects received intravenous patient-controlled analgesia (IV-PCA) pumps to measure additional morphine consumption, which included 50 mg morphine in 50 ml saline: bolus 2 mg; lock out time, 15 minutes.
67259|NCT03658395|Procedure|Laparoscopic Sacrocolopopexy|The LSCP surgery involves pulling up the bladder, vagina, and rectum using a Y-shaped mesh attached to the lower back bone
67260|NCT03658395|Procedure|Posterior repair|The PR surgery involves tightening the tissue between the rectum and vagina to reduce vaginal bulging during bowel movements.
67261|NCT03658382|Other|Virtual Visit|Patients will receive the results of their genetic testing via a virtual visit.
67262|NCT03658369|Dietary Supplement|Lanconone®|2 capsules
67263|NCT03658369|Dietary Supplement|Methyl crystalline cellulose|2 Capsules
67264|NCT03658356|Other|Video instructions|Pregnant patient will watch her video explaining how to collect a urine sample for asymptomatic bacteriuria determination.
67265|NCT03658343|Diagnostic Test|T2* Imaging|T2* imaging sequences for MRI
67266|NCT03658330|Drug|Ketamine + Naltrexone|Subjects will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 1 injection).
67267|NCT03658317|Diagnostic Test|renal arterial resistive index|done by dupplex on renal arteries
67268|NCT03658317|Diagnostic Test|uric acid level|serum sample for doing the test
67269|NCT03658317|Diagnostic Test|serum urea and creatinine|serum samples for doing the test
67270|NCT03658317|Diagnostic Test|24 hours urinary proteins|urine collected over 24 hours for doing the test
67271|NCT03658317|Diagnostic Test|lipogram|serum sample for doing the test
67272|NCT03658317|Diagnostic Test|HbA1c level|serum sample for doing the test
67273|NCT03658317|Diagnostic Test|urine analysis|urine sample for doing the test
67274|NCT03658317|Diagnostic Test|abdominal ultrasonography|done by the ultrasonography device
67275|NCT03658304|Drug|Mitomycin c|All participants will receive a single 40 mg dose of mitomycin C intraoperatively during their scheduled nephroureterectomy. This single dose will be given through a catheter in the subject's bladder.
67276|NCT03658291|Drug|Sanjin tablets|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
67277|NCT03658291|Drug|Sanjin tablets simulants|levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
67278|NCT03658291|Drug|Levofloxacin|Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
67279|NCT03658278|Dietary Supplement|Juven|Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations
67280|NCT03658265|Other|7 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
67281|NCT03658265|Other|7 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
67282|NCT03658265|Other|3 days SIE plus 4 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
67283|NCT03658265|Other|3 days SIE plus 3 weeks PRE|"Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity."
67284|NCT03658252|Behavioral|Targeted education|Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
67285|NCT03658252|Behavioral|Online disease specific forum|An invitation to join an online moderated disease specific social forum
67286|NCT03658239|Other|Inversion|Inversions will be done while the subject is on the inversion table. The subject will be inverted to 135, 150 and 165 degrees. There inversion will not last longer than 3 minutes at a time. The inversion will be terminated if the subject's blood pressure drops below 50 mmHg diastolic or if the subject's blood pressure increases more than 50 mmHg systolic.
67287|NCT03658226|Behavioral|Psychodynamic Interpersonal Therapy (PIT)|PIT is conversational model of psychotherapy; participants will receive 8 sessions of this therapy once weekly. The first session will be 2 hours and all remaining sessions will be 50 minutes.
67288|NCT03658213|Drug|ZOLADEX 10.8 mg|10.8 mg depot for injection (equivalent to 10.8 mg goserelin)
67289|NCT03658213|Drug|ZOLADEX 3.6mg|3.6 mg depot for injection (equivalent to 3.6 mg goserelin)
67290|NCT03658200|Other|FAST start software delay|Scan delay will be determined by the FAST software bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold the FAST START software calculates the delay.
67291|NCT03658200|Other|Manual bolus tracking delay|Scan delay will be determined by the standard bolus tracking technique. Before the start of bolus tracking (the time between start injection and start bolus tracking), a delay of 8 s is chosen. Bolus tracking threshold is set at 100 HU with a cycle time of 1.13 s and scan time of 0.25 s. After reaching the 100 HU threshold a delay of 6 s is chosen (table movement and breath hold command) and the scan starts.
67292|NCT03658187|Dietary Supplement|Placebo|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
67293|NCT03658187|Dietary Supplement|IP|Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
67294|NCT03658174|Dietary Supplement|Nitrate-rich beetroot juice|70mls of concentrated beetroot juice containing approximately 5-6 mmol of inorganic nitrate
67295|NCT03658174|Dietary Supplement|Nitrate-free beetroot juice|70mls of concentrated beetroot juice that has been nitrate-depleted
67296|NCT03658161|Behavioral|Communicating About Sexual Concerns and Dysfunction Effectively|The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
67297|NCT03658148|Procedure|Cardiac Surgery with Cardiopulmonary Bypass|Cardiac Surgery with Cardiopulmonary Bypass
117380|NCT03268941|Drug|Metaclopramide|Metaclopramide Tablets
67298|NCT03658135|Drug|BIIB092|BIIB092 is an investigational monoclonal antibody directed at tau protein
67299|NCT03658135|Other|Placebo|Inactive ingredient
67300|NCT03658122|Behavioral|Parent-Child Care|Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
67301|NCT03658109|Drug|Lidocaine Bolus Infusion|Patients will undergo Lidocaine Bolus infusion.
67302|NCT03658109|Procedure|QL block|Patients will undergo a posterior QL block pre-operatively
67303|NCT03658109|Drug|Saline Bolus Infusion|Patients will undergo Saline Bolus infusion.
67304|NCT03658109|Procedure|Simulated QL block|Patients will undergo a simulated posterior QL block pre-operatively.
67305|NCT03658096|Device|pressure monitor ultrasound system|Patients and healthy volunteers will be tested sitting with the elbow flexed and the forearm pronated. The forearm of the examinee will be secured to the table. The hand will be positioned on an adjustable block such that the forearm will be in a horizontal position. At the distal radioulnar joint level, the transducer will be maintained perpendicular to the longitudinal axis of the ulna. The dorsal surface of the distal radius and the center of the ulnar head will be displayed on a monitor.To determine the same measurement level in each volunteer, the highest aspect of the ulnar head will be taken. The DRUJ motion during cyclic loading toward the palmar direction at the distal ulna will be recorded. The compression-release cycles will be applied with the pressure-monitor ultrasound system. The cycle will be set to 1.5Hz. The pressure in the palmar direction will be applied with different levels of transducer displacements, i.e. 1 mm, 2 mm, and 3 mm.
67306|NCT03658083|Procedure|Thoracotomy|Open surgery
67307|NCT03658083|Procedure|Robotic-assisted thoracic surgery|Minimally invasive surgery
67308|NCT03658070|Drug|XY0206|Dosage form:Tablet;Single dose treatment:Take the drug once on day 1,each time 1 tablet. Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the criteria for stopping treatment or determine the duration and interval of treatment according to the accumulated condition after multiple dose.
67309|NCT03658057|Drug|Rocuronium|whether neuromuscular blockade by administering rocuronium is performed or not.
67310|NCT03658044|Other|Participation in the internet forum|Active participation in the forum with encouragement to participate on a weekly basis
67311|NCT03658044|Other|Placebo|No intervention performed. Patients are offered to read the open pages on the website
67312|NCT03658031|Drug|Dapagliflozin 10mg|Dapagliflozin 10 mg administered each morning before breakfast
67313|NCT03658018|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
67314|NCT03658005|Other|Blood sample|3 blood samples, for a maximum of 60mL, will be taken at 0-3h, 3-6h and >6h, between two doses of ticagrelor (taken at 0 and 12 hours).
67315|NCT03657979|Drug|Ropivacaine|TAP-block Ropivacaine 0.2% during 48 hours
67316|NCT03657979|Drug|Placebo|TAP-block with placebo
67317|NCT03657966|Biological|DCVAC/OvCa|activated dendritic cells (DCVAC/OvCa) for immune maintenance after chemotherapy
67318|NCT03657966|Drug|Standard of Care Chemotherapy|either carboplatin and gemcitabine or carboplatin and paclitaxel followed by DCVAC/OvCa
67319|NCT03657953|Other|surgical approach|
67320|NCT03657940|Behavioral|VIVIFRAIL multicomponent exercise training program|The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using dumbbells aiming for 2-3 sets of 10-15 repetitions at an intensity of 30-50% of 1Repetition Maximum ( combined with balance-training, flexibility and gait exercises that progressed in difficulty.
67321|NCT03657927|Device|C-MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with C-MAC videolaryngoscope.
67322|NCT03657927|Device|McGrath MAC videolaryngoscope|An intubating device that is used for endotracheal intubation. Endotracheal intubation was applied by anesthesiologist with McGrath MAC videolaryngoscope.
67323|NCT03657914|Procedure|Single-hole inflatable mediastinal mirror|The radical resection of single-hole inflatable mediastinal mirror synchronization with laparoscopic esophageal carcinoma is new minimally invasive operation for esophageal carcinoma. All enrolled subjects will receive this operation for their ESCC.
67324|NCT03657901|Behavioral|Music listening|Guided music listening for 30 minutes before sleep onset
67325|NCT03657901|Behavioral|Slow breathing|Guided slow breathing for 30 minutes before sleep onset
67326|NCT03657888|Behavioral|Family Club Denmark (FCD)|Participation in Family Club Denmark
67327|NCT03657888|Other|Wait-list control|Participants on the waiting list
67328|NCT03657862|Device|application of 38% silver diamine fluoride solution|SDF solution was painted onto the surface of the carious lesion of the tooth
67329|NCT03657862|Other|application of a placebo (tonic water)|tonic water was painted onto the surface of the carious lesion of the tooth
67330|NCT03657849|Device|EBUS TBNA|All patients undergo EBUS TBNA with two needle sizes
67331|NCT03657836|Dietary Supplement|Sublimated mare milk supplement|The dietary supplement consisting of sublimated mare milk packed in single-dose sachet.
67332|NCT03657836|Drug|Standard antibiotic therapy|Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.
67333|NCT03657810|Drug|CL-108 5 mg|hydrocodone 5 mg/APAP 325 mg/promethazine 12.5 mg
67334|NCT03657810|Drug|Norco|hydrocodone 5 mg/APAP 325 mg
67335|NCT03657810|Drug|Placebo|Placebo matching CL-108
67336|NCT03657797|Drug|NCX 470|NCX 470 Ophthalmic Solution
67337|NCT03657797|Drug|Latanoprost 0.005%|Latanoprost 0.005% Ophthalmic Solution
67338|NCT03657784|Drug|P03277|Single intravenous bolus injection at 0.1 mmol/kg body weight at a rate of 2 mL/second
67339|NCT03657771|Other|DED|DED: Diet eliminating dairy
67340|NCT03657771|Other|FREE|FREE: Diet eliminating dairy and food additives
67341|NCT03657758|Drug|EPA and rosuvastatin|To take EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for ９ months.
117383|NCT03268928|Behavioral|Wait-list Control|Wait-list control
67342|NCT03657758|Drug|High dose rosuvastatin|To take high dose rosuvastatin (10mg/day) for ９ months.
67343|NCT03657745|Device|Combination of 40Hz light and cognitive therapy (ALZLIFE)|Combination of 40Hz light and cognitive therapy delivered by iPad application ALZLIFE
67344|NCT03657719|Biological|GC3114|High-dose Quadrivalent influenza vaccine
67345|NCT03657719|Biological|GCFLU Quadrivalent|Quadrivalent influenza vaccine
67346|NCT03657706|Procedure|group A (Tunnel procedure with subepithelial connective tissue graft (sCTG)|Subepithelial connective tissue graft (autogenous graft) will be harvested from the palate by Single incision technique to be used with the prepared tunnel to treating gingival recession
67347|NCT03657706|Procedure|group B (Tunnel procedure with modified free gingival graft (mFGG))|modified free gingival graft (autogenous graft) will be harvested from the palate and will be used with the prepared tunnel to be used in treating gingival recession
67348|NCT03657693|Diagnostic Test|NICU MRI|MRI device that is not FDA approved.
67349|NCT03657693|Diagnostic Test|Polysomnography|Polysomnography to better determine obstruction index in the airway.
67350|NCT03657680|Other|Evaluation|The volunteers were submitted to an evaluation of pain, range of motion, muscular strength and functional capacity.
67351|NCT03657667|Procedure|Ureteroscopy|Endoscopic removal of kidney stones
67352|NCT03657654|Other|No intervention: observational only|No intervention: observational only
67353|NCT03657641|Biological|Pembrolizumab|Given IV
67354|NCT03657641|Drug|Regorafenib|Given PO
67355|NCT03657628|Other|Exercise Intervention|Strength training and moderate-intensity, aerobic exercise
67356|NCT03657615|Device|hearing aid fitting|All patients were fitted bilaterally with hearing aids for hearing loss compensation. . Apart from different HAs used, device selection followed strict criteria to fit hearing loss demands, patient profile, resources and algorithms recommended for tinnitus patients.
67357|NCT03657602|Drug|Skyla Intrauterine System|Participant will be randomly allocated to this intervention
67358|NCT03657602|Drug|Mirena Intrauterine System|Participant will be randomly allocated to this intervention
67359|NCT03657576|Biological|C134|C134 is a virus that was created from an oncolytic Herpes Simplex Virus (oHSV) known to infect and kill tumor cells. The Investigators have made changes to the original virus to make C134. It efficiently infects tumor cells (not normal healthy cells) and induces an immune response to fight the cancer as well.
67360|NCT03657563|Other|Positive psychological intervention|"Participants in the intervention group are required to record three good things every night before sleeping for five days a week using WeChat. Such things could be ordinary, minor or important.~WeChat is a common communication tool used in China, just like Facebook, basic messages could be sent individually and posting pictures or texts is also available."
67361|NCT03657550|Drug|Levamlodipine Malate Tablets|5mg of Levamlodipine Malate Tablet
67362|NCT03657550|Drug|Amlodipine Besylate Tablets|5mg of Levamlodipine Malate Tablet
67363|NCT03657537|Drug|Ketone infusion|β-hydroxybutyrate is infused intravenously.
67364|NCT03657537|Drug|Saline infusion|saline is infused intravenously.
67365|NCT03657524|Other|echocardiography|Speckle tracking echocardiography
67366|NCT03657511|Behavioral|Educational Interventions to Promote Tobacco Cessation|"Women receiving a screening mammogram at KCI downtown and McLaren Macomb, will be given a self-administered questionnaire at check-in.~Women who indicate they are current smokers are eligible for the study. After the screening mammogram is complete, eligible women will be consented. Educational materials will be provided to the participant at that time. The materials provided outline evidence-based approaches to smoking cessation and include contact information for local resources including cessation support groups, Michigan Tobacco Quitline, American Cancer Society's Guide to Quitting Smoking, Quitnet, Smokfree.gov and Become An Ex. The participant will be contacted by telephone approximately 12 weeks later to determine if she is currently smoking or had quit in the last 12 weeks."
67367|NCT03657498|Procedure|Combined orthodontic-orthognathic treatment|combined treatment including orthodontics and orthognathic surgery
67368|NCT03657498|Procedure|Standard orthodontic treatment|treatment with standard orthodontic procedures
67369|NCT03657485|Dietary Supplement|containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A|we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
67370|NCT03657472|Drug|CJ-30061|Test: CJ-30061(Fixed-dose combination drug containing Amlodipine 5mg/Valsartan 160mg/Atorvastatin 20mg)
67371|NCT03657472|Drug|Exforge® 5/160mg & Lipitor® 20mg|Reference: Co-administration of Exforge® tab 5/160mg and Lipitor® tab 20mg
67372|NCT03657459|Other|Danger Signs of Heart Failure Videos|Short (under 3 minutes each) videos on (a) recognition of dyspnea, fatigue and edema and (b) self-management of each (based on diet, fluid management and activities)
67373|NCT03657446|Drug|Clazosentan|Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
67374|NCT03657446|Drug|Placebo|Matching placebo infusion
67375|NCT03657446|Drug|Moxifloxacin|Film-coated tablet containing 400 mg moxifloxacin
67376|NCT03657433|Dietary Supplement|Ferrous sulfate 325mg|Oral tablets supplied for home use
67377|NCT03657433|Drug|Ferumoxytol|Ferumoxytol will be administered in two infusions, one week apart
67378|NCT03657420|Drug|ABI-009|ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
67379|NCT03657420|Drug|Pomalidomide|Pomalidomide is an immunomodulatory agent and believed to work by affecting the growth signals that keep cancer cells alive.
67380|NCT03657420|Drug|Dexamethasone|Dexamethasone is a steroid which is believed to kill cancer cells
67381|NCT03657407|Drug|Belladonna Opium|Belladonna Opium 16.2-60mg rectal suppository
67382|NCT03657407|Drug|Glycerin Suppository|Glycerine rectal suppository
67383|NCT03657394|Other|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 1--15 seconds.
67534|NCT03656159|Behavioral|Non directive support Group|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The support group will be delivered by Ph.D. students having no experience with CBT.
67384|NCT03657381|Drug|Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection|Biological: F520 single-dose:0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 200mg/times, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 200mg/times, 10mg/kg, treat every 2 weeks; multiple dosing: 3mg/kg, 200mg/times, treat every 3 weeks.
67385|NCT03657368|Procedure|Low tidal Volume|Tidal volume = 6 ml/kg predicted body weight
67386|NCT03657368|Procedure|High tidal Volume|Tidal volume = 10 ml/kg predicted body weight
67387|NCT03657368|Procedure|Low PEEP|PEEP = 5 cm H2O
67388|NCT03657368|Procedure|High PEEP|PEEP = 8 cm H2O
67389|NCT03657355|Drug|ACT-541468|ACT-541468 will be administered as 50 mg tablets for oral use.
67390|NCT03657355|Drug|Suvorexant|Suvorexant will be administered as 15 mg over-encapsulated tablets for oral use.
67391|NCT03657355|Drug|Zolpidem|Zolpidem will be administered as 10 mg over-encapsulated tablets for oral use.
67392|NCT03657355|Drug|Placebo|Matching-placebo will be used.
67393|NCT03657342|Drug|Liposomal Cyclosporine A|delivered via the PARI eFlow® Device
67394|NCT03657329|Diagnostic Test|Dreem|Dreem Band to be worn by each participant while undergoing in-lab sleep study with PSG. Pursuant to the physician-ordered diagnostic study, clinical staff may determine a split-night study with CPAP to be appropriate for any participant, simultaneous with the PSG and Dreem.
67395|NCT03657316|Behavioral|nutrition education|"The content of the three days workshop:Healthy diet, Diet-related health risks and diseases, Physical activity The sustained multi-component program will be based on The three days nutritional and physical education workshop Enhanced physical education Involvement of the morning broadcast in provision of messages for students about nutrition and physical activity Brochure including key messages about diet and physical activity will be designed and sent to parents of the intervention classes of students A monthly telephone call or a text message will be sent to the parents to remind them about the commitment to the dietary health practices.~Message to school administration to prevent selling of soft drinks and to sell healthy food A monthly session for three months will be held to remind the students with the messages"
67396|NCT03657303|Device|Magnetic resonance imaging (MRI)|Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination.
67397|NCT03657290|Drug|vadadustat|Vadadustat Tablets
67398|NCT03657277|Device|Micropatch|Each micropatch contains 50 tiny projections (800 um in length)
67399|NCT03657264|Drug|P03277 0.1 mmol/kg|Single intravenous bolus injection at 2 mL/sec
67400|NCT03657264|Drug|Moxifloxacin 400mg|One tablet per os
67401|NCT03657264|Drug|NaCl 0.9%|Single intravenous bolus injection at 2 mL/sec
67402|NCT03657264|Drug|P03277 0.3 mmol/kg|Single intravenous bolus injection at 2 mL/sec
67403|NCT03657251|Genetic|liquid biopsy|Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
67404|NCT03657238|Drug|RD01|single S.C. dose of RD01 for subjects in test group
67405|NCT03657238|Drug|Placebo|single S.C. dose of placebo for subjects in placebo group
67406|NCT03657225|Device|Utilization of the mini CPB circuit|Comparison of the mini CPB circuit to conventional circuit
67407|NCT03657225|Drug|Utilization of the conventional circuit|Comparison of the mini CPB circuit to conventional circuit
67408|NCT03657212|Drug|Zolpidem|The research involves oral administration of zolpidem (ZOL) or placebo during sleep with EEG recording. This study will employ a within-subject, crossover design, in which every subject experiences each of the following study conditions: Nap/5mg, Nap/placebo, plus an adaptation nap to be scheduled one week prior to the first experimental day. One condition will be tested per week, with condition order counterbalanced. Each subject will have 2 visits (plus an adaptation nap), each separated by 5-7 days (although this may be extended based on participant availability) to ensure that the drug is completely eliminated from the body. The order of drug conditions will be randomized and counterbalanced.
67409|NCT03657199|Diagnostic Test|Cardiac computed tomography|Routine computed tomography of the heart before discharge
67410|NCT03657186|Dietary Supplement|ProbioSatys™|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
67411|NCT03657186|Other|Placebo|One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.
67412|NCT03657160|Drug|Vedolizumab|Vedolizumab intravenous infusion.
67413|NCT03657160|Drug|Vedolizumab Placebo|Vedolizumab placebo-matching intravenous infusion.
67414|NCT03657147|Behavioral|Educational Video and Question Prompt List|A short educational video will be presented on an iPad about the importance of encouraging patients to ask questions and to be involved during glaucoma visits to improve self-management skills. A question prompt list will also be completed where participants check questions of interest to ask the provider.
67415|NCT03657134|Diagnostic Test|CoVa 2 Sensor|Upon completion of EP procedure, CoVa 2 sensor will be applied until discharge. Data from the sensor will be sent to the Gateway and Cloudbased system and analyzed retrospectively.
67416|NCT03657108|Radiation|Civasheet 60 Gy|implantable proposed doses of Civasheet are 60 Gy
67417|NCT03657108|Radiation|Civasheet 75 Gy|implantable proposed doses of Civasheet are 75 Gy
67418|NCT03657108|Radiation|Adjuvant external beam radiation therapy|45 Gy in 25 fractions
67419|NCT03657095|Drug|Beraprost Sodium 314d Modified Release tablets|15 μg esuberaprost sodium tablets (Beraprost Sodium 314d Modified Release tablets) for oral administration as 1 or 2 tablets four times a day (QID)
67420|NCT03657082|Device|PEP-10|Bottle PEP with a water level of 10 cmH2O
67421|NCT03657082|Device|PEP-1|Bottle PEP with a water level of 1 cmH2O
67422|NCT03657069|Device|Blossom|Undergo Implant Breast Reconstruction (IBR) with the Blossom Smart Expander Technology
67423|NCT03657069|Other|Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire|Ancillary studies
67867|NCT03653546|Drug|AZD3759|Advanced Non-Small Cell Lung Cancer (NSCLC) with CNS metastases.
67424|NCT03657056|Device|BX Pulsar 1002|"LIFUP will be administered to the temporal region on the side to undergo surgery, within the focus producing seizures. The ultrasound will be focused on the highest activity area within the temporal lobe. Functional MRI of the brain will be obtained throughout the LIFUP session.~After the participant is fitted with the transducer they will be placed in the MRI machine and undergo a series of scans. After placing the transducer over the anterior tip of the temporal lobe the participant will undergo fMRI BOLD scans with LIFUP excitation (from (Lee et al., 2015): Tone Burst Duration = 2ms and Pulse Repetition Frequency = 250Hz) at four levels of intensity (720mW/cm2, 1440mW/cm2, 2880mW/cm2 and 5760mW/cm2). Before increasing the intensity, the transducer will be moved approximately 5mm posterior. After the last excitation scan the LIFUP parameters will be changed to inhibitory parameters (from (Yoo et al., 2011): Tone Burst Duration = 0.5ms and Pulse Repetition Frequency = 100Hz)."
67425|NCT03657043|Drug|tisotumab vedotin|Intravenous (IV) infusion
67426|NCT03657030|Drug|CVN424|SAD / MAD
67427|NCT03657030|Drug|Placebo|Placebo
67428|NCT03657017|Diagnostic Test|PET/MR|Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
67429|NCT03656991|Other|Bicycle intervention|
67430|NCT03656978|Behavioral|dynamic|Use the according methods in dynamic arm descriptions.
67431|NCT03656978|Behavioral|Regular-triangle|Use the according methods in regular-triangle arm descriptions.
67432|NCT03656965|Drug|Acyclovir 800 MG|Acyclovir tablets 800 mg per day during the whole course of treatment Or Placebo.
67433|NCT03656965|Combination Product|Radiotherapy and chemotherapy|Concurrent chemoradiotherapy which consisted of Cisplatin 40 mg/m2 weekly or 100mg/m2 every 3 weeks with IMRT 70Gy/35 fractions.
67434|NCT03656952|Drug|PF-06700841|a single oral dose of 200 mg PF-06700841
67435|NCT03656952|Drug|Placebo|Placebo matching PF-06700841
67436|NCT03656952|Drug|moxifloxacin|a single oral dose of 400 mg moxifloxacin
67437|NCT03656926|Drug|Liposomal Cyclosporine A|delivered via the PARI eFlow® Device
67438|NCT03656913|Diagnostic Test|Extremely low dose CT|Patients undergoing clinically indicated CT will also receive the extremely low dose CT
67439|NCT03656900|Device|rTMS BA9/BA46|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 9, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 46.
67440|NCT03656900|Device|rTMS BA46/BA9|10 sessions of low-frequency repeated transcranial magnetic stimulation over two weeks on cortical area 46, then 4 weeks wash-out, then 10 sessions of low-frequency repeated transcranial magnetic stimulation repeated low frequency over two weeks on cortical area 9.
67441|NCT03656900|Radiation|brain MRI|T1 weighted full-head high-resolution MRI with 1 mm seam cuts and sagittal orientation.
67442|NCT03656900|Other|Medical evaluation|complete evaluation with 6 scales (HDRS, MADRS, Beck, CGI, COVI, UKU)
67443|NCT03656900|Other|Psychological assessment|Subjective Life Profile Assessment (SLPA) and Helping Alliance Assessment
67444|NCT03656887|Device|Continuous interstitial glucose sensor|Installing and removing the sensor
67445|NCT03656887|Other|Sensor Scan|Scan of the sensor, using the Freestyle Pro free version reader, at installation then before removal after 14 days.
67446|NCT03656874|Other|Clinical Decision Support|The clinical decision support will provide clinical practice guideline-supported, evidence-based, and personalized scripts that are tailored based on patients' self-reported smoking attributes to deliver interventions consistent with the standard of care
67447|NCT03656861|Other|Physical load|The impact of training on cardiac structure and function depends on the type, intensity and duration of the activity, as well as previous physical activity engagement, genetics and gender type. More knowledge about cardiac pathophysiologic training adaptation is needed.
67450|NCT03656835|Procedure|Molecular Nanotechnology|Undergo ILN biochip testing
67451|NCT03656822|Diagnostic Test|Routine CT|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions.
67452|NCT03656822|Diagnostic Test|Routine imaging CT with a 3D printed model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + 3D Printed Model
67453|NCT03656822|Diagnostic Test|Routine imaging MRI with a 3D printed model|will measure post-operative lesion volume as visualized on the post-operative MRI + 3D Printed Model
67454|NCT03656822|Diagnostic Test|Routine MRI|will measure post-operative lesion volume as visualized on the post-operative MRI
67455|NCT03656822|Diagnostic Test|Routine imaging CT with a VR model|CAT (Computerized Axial Tomography) scan, is a noninvasive X-ray test that is used to diagnose a variety of medical conditions + VR Model
67456|NCT03656822|Diagnostic Test|Routine imaging MRI with a VR model|will measure post-operative lesion volume as visualized on the post-operative MRI + VR Model
67457|NCT03656796|Other|Treadmill training with auditory cues|Participants should walk on the treadmill according to the rhythmic auditory cues (110% step frequency) for 30 min
67458|NCT03656796|Other|Treadmill training without auditory cues|Participants should walk in comfortable speed on the treadmill for 30 min.
67459|NCT03656783|Drug|Biktarvy|Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
67460|NCT03656770|Other|Survey questionnaire|Each version of the questionnaire portrays a young Ugandan woman with different profiles of illness severity, treatment, and treatment response.
67461|NCT03656744|Drug|HTD1801|HTD1801 tablets, 250mg
67462|NCT03656744|Drug|Placebo|tablets manufactured to mimic HTD1801 tablets
67868|NCT03653546|Drug|Erlotinib|SoC EGFRTKI Erlotinib 150 mg PO Q.D
67463|NCT03656731|Other|Breast cancer exercise intervention|"The exercise-based intervention is comprised of:~Supervised and group-based exercise training at the hospital setting two times a week. Each session will last approximately 60 minutes.The program consists of warm-up, exercises for balance and flexibility, progressive resistance training (seven resistance training exercises targeting the large muscle groups), and stretching and relaxation.~Home-based walking with activity tracker assessment. Evaluation and goal-setting in relation to activity (step counts) will be conducted once weekly.~Serving of a protein supplement (protein drink or bar) after each supervised training session."
67464|NCT03656718|Biological|Nivolumab|Specified dose on specified days
67465|NCT03656718|Drug|rHuPH20|Specified dose on specified days Permeation enhancer
67466|NCT03656705|Biological|CCCR-NK92 cells|CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.
67467|NCT03656692|Drug|Acthar|See Arm Description
67468|NCT03656679|Procedure|Pectoralis Blockade (PECs)|Ten milliliters of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited between the pectoralis major and minor (PECs I) and 20 cc of 0.25% bupivacaine with 2.5mcg/ml epinephrine deposited between the pectoralis minor and serratus anterior muscle.
67469|NCT03656679|Procedure|Paravertebral Blockade|10cc of 0.25% bupivacaine with 2.5 mcg/ml epinephrine will be deposited at two levels (T3 and T5) per side while in the sitting position.
67470|NCT03656666|Drug|Apremilast|Apremilast oral tablets
67471|NCT03656666|Drug|Placebo|Placebo oral tablets
67472|NCT03656653|Behavioral|Mental Imagery for Craving Reduction|a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
67473|NCT03656640|Drug|Gammanorm|Patients already receiving Gammanorm will be observed over the course of 2 years every 3 months. Gammanorm will be given standard of care.
67474|NCT03656627|Drug|Nivolumab|"Nivolumab will be given as an IV infusion every two weeks, in an outpatient setting. One cycle is a 28-day period, with Nivolumab given on days 1 and 15 of a 28-day cycle.~For each cohort, all patients will be dosed at 240 mg IV. There will be no dose de-escalation or escalation from this dose level."
67475|NCT03656614|Drug|Sugammadex|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Sugammadex 0.125 mg/kg (sugammadex 0.125) Sugammadex 0.25 mg/kg (sugammadex 0.25) Sugammadex 0.5 mg/kg (sugammadex 0.5) Sugammadex 1.0 mg/kg (sugammadex 1.0) Sugammadex 2.0 mg/kg (sugammadex 2.0)"
67476|NCT03656614|Drug|Neostigmine|"At the end of surgical procedure at a depth of neuromuscular blockade at the reappearance of train-of-four 0.3, single intravenous injection of either :~Neostigmine 5 µg/kg (Neostigmine 5) Neostigmine 10 µg/kg (Neostigmine 10) Neostigmine 15 µg/kg (Neostigmine 15) Neostigmine 25 µg/kg (Neostigmine 25) Neostigmine 50 µg/kg (Neostigmine 50)~Atropine will be administered with Neostigmine at a half dose of Neostigmine administered through an intravenous line with brisk flow."
67477|NCT03656601|Diagnostic Test|3D pelvic ultrasound|3D pelvic ultrasound by transperineal route
67478|NCT03656588|Drug|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol|a. Standard iodine scrub, 3% hydrogen peroxide prep, follow by ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol
67479|NCT03656588|Drug|Iodine scrub and ChloraPrep alone|Iodine scrub and ChloraPrep alone
67480|NCT03656575|Biological|synovial fluid biomarker concentrations|Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
67481|NCT03656562|Drug|VAY736|Powder for solution for injection
67482|NCT03656562|Drug|VAY736 Placebo|Solution for injection
67483|NCT03656562|Drug|CFZ533|Concentrate for solution for infusion
67484|NCT03656562|Drug|CFZ533 Placebo|Solution for infusion
67485|NCT03656549|Drug|Pemetrexed|patients will be treated with pemetrexed, with dosing based on renal function. As a safety measure, the first dose will be calculated to 50% exposure. After administration, safety and pharmacokinetics are assessed. If tolerated well, dose escalation to reach 100% exposure is performed, including assessment of safety and pharmacokinetics.
67486|NCT03656536|Drug|Pemigatinib|Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
67487|NCT03656536|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
67488|NCT03656536|Drug|Cisplatin|Cisplatin 25 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
67489|NCT03656523|Other|Acute coronary syndrome and PCI and AF|Patient with ACS and ACS treated with PCI
67492|NCT03656497|Other|Observational|No intervention is conducted as the study aim is to explore the link between pheno- and genetype of trigeminal neuralgia
67493|NCT03656484|Drug|Tetracycline-Metronidazole (TM) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
67494|NCT03656484|Drug|TM-Melatonin-Hyaluronic acid (TM-MHa) group|Following mechanical debridement (scaling and root planning) the above-mentioned paste will be topically administrated in the periodontal pocket of affected teeth once a day, for 30 consecutive days.
67495|NCT03656471|Device|clear aligners or fixed appliances|Patients choose clear aligners or fixed appliances to treat their malocclusions
67496|NCT03656458|Other|Warm Up|10 low jumps 5 Illiopoase Stretches 5 L/L Abductor Stretches 10 Trunk rotations 10 Should Circumduction Clock wise/Counter clockwise 10 Cervical Rotations Clockwise/Counter Clockwise
67533|NCT03656159|Behavioral|Cognitive-Behavioral group therapy|Intervention will consist of eight weekly sessions of two hours each with a break of 15 minutes. The CBT will be delivered by a clinical psychologist and a clinical neuropsychologist previously trained in this therapeutic approach.
67869|NCT03653546|Drug|Gefitinib|SoC EGFRTKI Gefitinib 250 mg PO Q.D
67497|NCT03656458|Other|Conventional Balance Training|"Internal Protuberances:~Looking up/Looking down/looking over the shoulder (Rt. /Lt.) 10 Reps Each~Looking behind over the shoulder (Rt. /Lt.)10 Reps~Looking Up with overhead Upper Limb Flexion. 5 Reps~Reaching out of Base of support (Rt. /Lt. / midline Cross) 10 Reps Each~Side to Side weight Shifting 10 Reps~Standing on toes/Heels 10 Reps each~External Protuberance:~Tuck forward/ Backward/ Sideways(Rt. /Lt.) 10 reps Each~Bosu Ball Training"
67498|NCT03656458|Other|Biodex Balance Training|Biodex Balance Training Using Biodex Balance System SD
67499|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision, administered during the induction of the anesthesia
67500|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, 10 minutes before incision and an additional dose of IV TXA (15mg/kg) in 100-ml normal saline 3 hours after skin incision
67501|NCT03656445|Drug|Tranexamic Acid|1 dose of IV TXA (15mg/kg) in 100-ml normal saline, before incision and two additional doses of IV TXA (15mg/kg) in 100-ml normal saline 3 and 6 hours after skin incision respectivel
67502|NCT03656432|Drug|CPP-ACP paste|The complex CPP-ACP derived from a milk protein called casein. CPP-ACP represents an alternative remineralizing agent that prevents the early demineralization, it is capable of stabilizing calcium phosphate, maintaining the supersaturation of these ions in the oral environment by binding with them and transport them in the form of amorphous calcium phosphate. They can enhance remineralization, decrease demineralization or even both in an acid challenge to teeth surfaces.
67503|NCT03656419|Procedure|photodynamic therapy|aPDT with methylene blue and red led irradiation.
67504|NCT03656419|Procedure|Tongue scraper|Tongue scraper 10 times from de back to the top.
67505|NCT03656406|Behavioral|Lateral decubitus positioning|After the DLT intubation, the patient is placed in lateral decubitus position
67506|NCT03656406|Device|Cuff-manometer|The pressure of the bronchial cuff should be measured with cuff-manometer in supine position, and then measurement should be repeated after lateral positioning.
67507|NCT03656393|Drug|Gefitinib|Gefitinib (250 mg, orally, every day) for 56 days
67508|NCT03656393|Drug|Vinorelbine|Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
67509|NCT03656393|Drug|Carboplatin|Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
67510|NCT03656380|Drug|Mepolizumab 300 mg|Mepolizumab 300 mg subcutaneous injection
67511|NCT03656380|Drug|Mepolizumab 100 mg|Mepolizumab 100 mg subcutaneous injection
67512|NCT03656380|Other|Placebo|Saline subcutaneous injection
67513|NCT03656367|Dietary Supplement|Cheddar cheese|The reference product is a commercial matured cheddar cheese
67514|NCT03656367|Dietary Supplement|Blended and homogenized cheddar cheese|A blended and homogenized cheddar cheese (a spread) which, compared to the reference, has a minimal protein network and has smaller fat droplet
67515|NCT03656367|Dietary Supplement|An analog milk|An anolog milk (i.e. milk with a cheese-like nutritional composition) which, compared to the reference, does not contain a protein network
67516|NCT03656367|Dietary Supplement|An analog cheese|This analog cheese (a gel/yoghurt) is produced from the analog milk which, compared to the reference, has a protein network, however it is a network that differs from the reference
67517|NCT03656354|Device|Seismocardiography|Seismocardiography recording
67518|NCT03656341|Behavioral|2 Feet 4 Life|2 Feet 4 Life consists of four weekly group intervention sessions of one hour each. 2 Feet 4 Life includes self-management teaching, interactive lecture, and group activities, including instruction and demonstration of routine foot care. The program includes education regarding appropriate footwear and how to find it, evidenced based practices on hygiene, skin care and self-care of the lower extremities, nail trimming and filing, and care of common foot problems.
67519|NCT03656328|Dietary Supplement|Lactobacillus Reuteri 4659|supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy
67520|NCT03656328|Dietary Supplement|Placebo|supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
67521|NCT03656315|Other|Airway Assessment|All patients recruited to this study will have an ultrasound of their cricothyroid membrane
67522|NCT03656289|Drug|Etonogestrel 68Mg Implant|Participants will have an etonogestral contraceptive implant (NEXPLANON) placed sub-dermally just under the skin at the inner side of the non-dominant upper arm.
67523|NCT03656276|Behavioral|Tool to improve Participation In Clinical Trials (ToPIC)|The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
67524|NCT03656263|Diagnostic Test|Doppler assessment of portal vein flow|Doppler assessment of portal vein flow using peri-operative trans-esophageal echography before and after cardiopulmonary bypass.
67525|NCT03656250|Diagnostic Test|PET/CT scans|(approximately 18 mSv/scan) and perform maximum two additional PET/MR scans; one immediately after the first stage of treatment and another one immediately after the second stage if the 3-month chemotherapy is given).
67526|NCT03656237|Other|Usual Training|Training in a classroom setting of health care providers
67527|NCT03656237|Other|Audits + LDHF Training|Clinical audits followed by case-based low-dose high-frequency training
67528|NCT03656224|Other|Survey Administration|Ancillary studies
67529|NCT03656211|Other|Telephone interview|"Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility.~All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview."
67530|NCT03656198|Biological|Rabivax-S|Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg).
67531|NCT03656198|Drug|Sterile Water Injection|The vaccine diluent (sterile water for injection) is provided in a separate 1 mL ampoule.
67532|NCT03656172|Biological|Haemoglobin measure|Haemoglobin measure before and one month after standard iron treatment
67535|NCT03656146|Other|Food Insecurity Screening Tablet|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
67536|NCT03656146|Other|Food Insecurity Screening Verbal|The intervention is the type of screening modality used to identify food insecurity: verbal face-to-face, or tablet-based screening
67537|NCT03656133|Radiation|Radiotherapy fractionation|Standard fractionation at 2Gy once daily or Hyperfractionation at 1.2 Gy twice daily (≥ 6 hours apart)
67538|NCT03656120|Drug|0.2mg group|Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
67539|NCT03656120|Drug|0.5mg group|Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
67540|NCT03656120|Drug|placebo control group|Participants only take placebos for 12 weeks during the research.
67541|NCT03656107|Behavioral|Cognitive Training|Lumosity© is a commercially available software, developed by a group of neuropsychologists, which has been used across several studies of brain training and disciplines. The brain training software targets multiple brain areas, is based online, and is relatively easy to use and administer. It has been designed to adapt to the individual's memory performance to personalise the training program to their needs. Brain exercises will be selected with the support of Lumosity© to target the following brain areas; attention, memory, visuospatial, verbal fluency, and language.
67542|NCT03656094|Drug|Pembrolizumab plus chemotherapy|Pembrolizumab plus chemotherapy
67543|NCT03656094|Drug|Placebo plus chemotherapy|Placebo plus chemotherapy
67544|NCT03656081|Drug|inhaled Ambisome®|inhaled liposomal amphotericin B = inhaled LAmB
67545|NCT03656081|Drug|inhaled placebo|inhaled isotonic saline
67546|NCT03656081|Drug|Itraconazole|Itraconazole tablet
67547|NCT03656068|Drug|Nitazoxanide 500mg BID|Patients will receive 500mg of Nitazoxanide BID daily for 24 weeks
67548|NCT03656042|Drug|Filgrastim (75mcg/0.3ml)|"Subjects who meet all eligible requirements for entry into the study will be randomized into one of the two treatment groups in 1:1 ratio as shown below:~10 microgram/kg/day, by sc, for 5 continuous days for the first week, rest for 11 weeks; repeat dosing regimen every 12-weekly (12 weeks / cycle) for 2 cycles~Non-treatment"
67549|NCT03656029|Drug|Cannabis|Participants will smoke as much of the cigarette as they wish
67550|NCT03656029|Drug|Placebo|Participants will smoke a placebo cigarette
67551|NCT03656016|Device|Magnetic Resonance Imaging|Phase contrast magnetic resonance imaging technique
67552|NCT03656003|Device|Procore biopsy needle|EBUS-TBNA with the EchoTip ProCore needle (Cook Medical Inc., Bloomington, Ind., USA)
67553|NCT03656003|Device|Conventional biopsy needle|EBUS-TBNA with the conventional 22-gauge EBUS-TBNA needle (Vizishot, Olympus, Japan)
67554|NCT03655990|Device|Treatment with the JUVORA™ Dental Disc|treatment with the JUVORA™ Dental Disc
67555|NCT03655977|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before external beam radiation therapy (EBRT).
67556|NCT03655977|Device|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.
67557|NCT03655977|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before brachytherapy (BT).
67558|NCT03655977|Device|PET/MRI scan instead of only MRI|Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.
67559|NCT03655964|Drug|Olmesartan|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive olmesartan 20 mg once daily until Day 7 of stroke onset
67560|NCT03655964|Drug|Nebivolol|At Day 4 of stroke onset, patients with clinic BP >160/100 mmHg will receive nebivolol 5mg once daily until Day 7 of stroke onset
67561|NCT03655964|Other|No antihypertensive treatment|Patients will be left without treatment
67562|NCT03655951|Behavioral|Web-based resource on adolescent sexual health|Web-based resource on adolescent sexual health than the intervention.
67563|NCT03655951|Behavioral|Alternate web-based resource on adolescent sexual health|This is a different web-based resource on adolescent sexual health than the intervention.
67564|NCT03655938|Procedure|Piezocision combined minimally invasive alveolar bone regeneration|The piezocision surgery was performed two weeks after orthodontic appliance placement. The patients received local anesthesia in mandibular arch and vertical interproximal incisions were made below the interdental papillae in the midline, from the mesial aspect of each canine and in between each of the posterior lower teeth. The periostium was then released in order to create two subperiotal envelopes connecting the vertical incisions together. Thereafter, corticotomies were performed in the region of the incisions with a piezotome (Acteon, Merignac, France) and the envelopes were filled with a beta tricalcium phosphate, a resorbable biomaterial in order to thicken the buccal bone plate. Resorbable 5-0 sutures were used to close the flaps. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
67565|NCT03655925|Diagnostic Test|plasmatic HLA-G|plasmatic HLA-G by blood sample
67566|NCT03655912|Device|Red/green glasses|The use of red/green glasses and electronic devices for two hours a day during 4 months.
67567|NCT03655912|Device|Electronic Tablet|The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
67568|NCT03655912|Device|Eye patch|The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
67569|NCT03655886|Procedure|radical prostatectomy|can be performed either open, laparoscopic or robot-assisted, which is chosen by the discretion and expertise of the performing surgeon
67570|NCT03655886|Radiation|Whole pelvis radiotherapy|radiation of prostate bed and pelvis
67571|NCT03655873|Drug|HEC30654AcOH capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg HEC30654AcOH capsule in day1.~Multiple ascending-dose study:~15-、30-、60mgHEC30654AcOH capsule in day1-day7，2 times everyday."
67572|NCT03655873|Drug|Placebo capsule|"single ascending-dose study: 5-、10-、15-、30-、60-、90-、120mg placebo capsule in day1.~Multiple ascending-dose study:~15-、30-、60mg placebo capsule in day1-day7，2 times everyday."
67573|NCT03655860|Device|SIMEOX|SIMEOX is a device generating a succession of gentle depression at the mouth.
67628|NCT03655392|Diagnostic Test|Induced sputum collection|All participants performed induced sputum collection
67574|NCT03655847|Drug|Dexmedetomidine|Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
67575|NCT03655834|Drug|Pemetrexed|patients will be administered a microdose with subsequent pharmacokinetic assessment.
67576|NCT03655821|Drug|Pemetrexed|Dosing is either based on BSA or renal function
67577|NCT03655808|Biological|Bronchial basal cells|Bronchial basal cells transplantation
67578|NCT03655795|Biological|Bronchial basal cells|Autologous transplantation of bronchial basal cells
67579|NCT03655782|Behavioral|PATH neurotraining|Improve visual timing and sensitivity in the dorsal stream. The mTBI subject will sit 57 cm in front of a computer monitor. During the presentation, the bars in the 'fish-shaped' window in the center of the screen formed by a sinusoidal grating, move left or right very briefly. When the screen goes blank, the subject reports which way the center pattern moved by pushing the left or right arrow key. A brief tone is presented after incorrect responses. The program adaptively changes the contrast of the test pattern so that the subject detects motion at lowest contrast possible. A sequence of patterns in each training cycle that are designed to optimally activate magnocellular neurons are shown to the subject. There are two programs, the first measures the contrast needed to see one direction of movement, and the second program measures the contrast needed to see two directions of movement, requiring memory.
67580|NCT03655782|Behavioral|Orientation Discrimination|The sham treatment will be Orientation Discrimination training that is identical to PATH training except instead of low contrast sinewave gratings moving left or right, 100% contrast stationary test and background sinewave gratings are used, both red, green, and black and white gratings. These patterns are randomly oriented left or right, at decreasing tilt angles as the test grating's orientation is identified correctly. These patterns only activate parvocells in ventral pathways (Ungerleider & Mishkin, 1982; Kaplan & Shapley, 1986) instead of activating dorsal pathways, the key components of PATH neurotraining. Therefore, this task does not speed up the brain's visual timing, which is a function of the dorsal stream. For the Orientation Discrimination task, the subject pushes the left arrow key when the test pattern is tilted left and the right arrow key when pattern is tilted right. Otherwise the two training tasks use the same paradigm.
67581|NCT03655769|Device|transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
67582|NCT03655769|Device|sham transcranial direct current stimulation|transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
67583|NCT03655756|Biological|IFx-Hu2.0|"The product being tested in this clinical study, IFx-Hu2.0, is designed to exploit the inherent vulnerability of specific differences from patient to patient, lesion to lesion, and cell to cell. Regardless of the degree of complexity of an individual's antigenic signature, this truly patient-specific approach capitalizes on the antigenic differences to create the broadest immune response possible.~Surface expression of the Emm55 antigen through intralesional injection of pAc/emm55 engages the patient's immune system and thwarts the tumor's ability to evade surveillance by exposing multiple patient-specific tumor antigens and activating a wide array of naïve T cells."
67584|NCT03655743|Device|LASIK, PRK, Phacoemulsification|"Please see:~https://en.wikipedia.org/wiki/LASIK https://en.wikipedia.org/wiki/Photorefractive_keratectomy https://en.wikipedia.org/wiki/Phacoemulsification"
67585|NCT03655730|Other|weekly psychotherapeutic individual sessions|weekly psychotherapeutic individual sessions following the IPT method during one year
67586|NCT03655730|Other|Usual care|the standard follow-up provided by the Mission Locale, including periodic meetings with a referee
67587|NCT03655717|Drug|Dronabinol|THC (dronabinol) at physician determined doses of 10-50mg designed to produce intoxication.
67588|NCT03655717|Drug|Ethanol|Oral Ethanol, dosed to obtain a breath alcohol concentration (BrAC) of approximately 0.05 BrAC (equal to 1-2 standard drinks).
67589|NCT03655717|Drug|Placebo Dronabinol|Identical in appearance to active dronabinol (overencapsulation of both active and placebo dronabinol)
67590|NCT03655717|Drug|Placebo Ethanol|Placebo ethanol will consist of diet soda used in the active ethanol condition with 0.25ml ethanol floated on top to provide the odor of ethanol and blind the study drug.
67591|NCT03655704|Drug|Apabetalone|A 4-week pre-treatment phase will allow ensuring that patients are on stable doses of medication. Patients will be given doses of apabetalone 100mg BID for 16 weeks. Patients will be regularly followed (Fig.1). At baseline and week 16, a cardiac catheterization and MRI will assess changes in pulmonary hemodynamics and RV function.
67592|NCT03655691|Biological|Vehicle|Vehicle Formulation
67593|NCT03655691|Biological|Dose 1|botulinum toxin, Type A
67594|NCT03655691|Biological|Dose 2|botulinum toxin, Type A
67595|NCT03655678|Biological|CTX001|Administered by IV infusion following myeloablative conditioning with busulfan
67596|NCT03655665|Drug|Ofloxacin otic solution|Three drops of ofloxacin otic 0.3%. intra and post-operatively for 3 days post-surgery on one ear.
67597|NCT03655626|Other|Sepsis Watch|The operational intervention comprises of a sepsis machine learning model, custom dashboard to present risk scores, and a rapid response team to monitor patients at-risk of sepsis and deliver sepsis treatment. Sepsis Watch was developed under operational management. The rapid response team will utilize information presented on the dashboard and follow a protocol that will enable them to support the primary teams of hospitalized patients.
67598|NCT03655613|Biological|APL-501|Humanized IgG4 monoclonal antibody against programmed death receptor-1 (PD-1)
67599|NCT03655613|Drug|APL-101|Oral specific c-Met inhibitor
67600|NCT03655613|Biological|Nivolumab|Fully human IgG4 monoclonal antibody against PD-1
67601|NCT03655600|Other|Self-administered acupressure|Self-administered acupressure learned through app for reduction of need for opioids post-surgery in breast cancer patients
67602|NCT03655587|Device|Solid ankle foot orthotic|
67603|NCT03655587|Device|Resting night splint|
67660|NCT03655145|Other|HLA 10/10 MUD stem cell transplantation|HLA 10/10 matched unrelated donor myeloablative transplantation
67604|NCT03655574|Behavioral|Motivational + Family Check-up (MET+FCU)|In the MET session, motivational strategies of individualized normative feedback, examining decisional balance, and providing information/advice will be used to support goals for behavior change and to examine barriers to changes. There are four specific phases of the FCU session: (1) Self-assessment: Parents are asked if they learned anything about their family from participating in the assessment. (2) Support and clarification: The interviewer supports the parent's self-assessment efforts, assesses their level of understanding, and clarifies issues within the family. (3) Feedback: A summary form of the assessment is reviewed. (4) Action Plan: Throughout the session, the counselor works with the parent to develop a brief, written Action Plan about communication and monitoring.
67605|NCT03655574|Other|Psychoeducation|Psychoeducation about substances is provided to teens and parents.
67606|NCT03655561|Other|Non interventional research|Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
67607|NCT03655535|Drug|BTI320|Non-systemic galactomannan complex polysaccharide
67608|NCT03655535|Other|Placebo|Placebo
67609|NCT03655522|Drug|NAVX-010|Dose levels of NAVX-010 were 2, 8, 25, 50, and 75 mcg. Four patients per active group. Each subject participated in only 1 treatment period.
67610|NCT03655522|Drug|Placebo|There were two Placebos per group.
67611|NCT03655509|Procedure|Dynamic test ACTH stimulation|
67612|NCT03655496|Device|Home-based tool|The tool consists of a tablet computer and a Bluetooth connected weight scale. The patient is encouraged to use the tool daily. The weight is titrates the dose of diuretics and a short tip about how to improve living with heart failure, this is presented on the screen. Every five days the patient assess their self-perceived symptoms on the tablet computer. If the weight increases by 2kg or more in 3 days or less, the high dose is recommended for two days, after which the effect on the weight is assessed. If the weight increased was reverted, the dose is returned to normal and if it is still elevated, an alert on the table computer. If the self-assessed symptoms deteriorate, the same type of alert will appear on screen, urging the patient to contact the health care provider.
67613|NCT03655483|Drug|GLS-010|Full-human anti-pd-1 monoclonal antibodies
67614|NCT03655470|Behavioral|Safety Planning|Safety planning is an individual coping intervention to reduce suicidal risk in adolescents
67615|NCT03655470|Behavioral|Standard care|Standard care entails sending an adolescent for an emergency evaluation for suicidal risk in an Emergency Department
67616|NCT03655457|Device|group 1 Poractant alfa|Comparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
67617|NCT03655457|Device|group 2 beractant|lComparison of lung usg scores in infants treated with Poractant alfa and Beractant: 0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.
67618|NCT03655444|Drug|Abemaciclib|Abemaciclib is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient.
67619|NCT03655444|Drug|Nivolumab|Nivolumab is commercially available
67620|NCT03655444|Procedure|Tumor biopsy|"Phase II patients only~If the patient consents, fresh tumor tissue will be collected at baseline and then during Cycle 2 (between days 8-22) of abemaciclib and nivolumab."
67621|NCT03655444|Procedure|Peripheral blood|"Phase II patients only~Peripheral blood will be collected at baseline and during cycle 2 (between days 8-22)"
67622|NCT03655444|Other|EORTC QLQ-30|"Phase II patients only~Screening , Cycle 2 D1, Cycle 4 D1, and End of treatment (EOT)"
67623|NCT03655431|Other|Telerehabilitation|Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.
67624|NCT03655431|Other|Standard treatment|Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
67625|NCT03655418|Other|Resilience Curriculum (RESCUR)|"The method of the present project, developed by experts in Europe, concerns giving children their own self-empowerment, strengthening protective factors, and, in the long run, their resilience. In Sweden, the material has been named Jag vill, jag kan, jag törs!.~The methodology that will be further developed and evaluated in this project is called RESCUR (the resilience curriculum) aimed at increasing children's resilience, i.e., children's ability to cope with crises, changes and stressors without falling apart. The method is rooted in research on human resilience."
67626|NCT03655405|Other|Individual Deprescribing Intervention|The pharmacist responsible for the nursing home will perform a medication review (type 3). The results of this review will be discussed with the physician and nurse responsible for this participant, with the goal of creating a personalised deprescribing plan. Once validated by the physician, this plan will be submitted to the participant for approval.
67627|NCT03655392|Behavioral|Individualized educational program|IG patients were submitted to three 30-minutes intervention of a individualized shortterm educational program delivered by a nurse, were given explanations about general aspects of the disease, prevention methods and about the importance and correct use of inhaled corticosteroids, with an educational video showing the use of the device
67629|NCT03655392|Diagnostic Test|Spirometry|All participants performed spirometry test using a Koko spirometer. Pulmonary function was assessed by spirometry prebronchodilator, after withholding short-acting beta-agonists for ≥ 6 hours and long-acting beta-agonist for ≥ 24hours. Forced expiratory volume in one second (FEV1) % predicted was used as a proxy variable for overall lung function.
67630|NCT03655392|Diagnostic Test|Nitric oxide measure|All participants performed nitric oxide measure in three Mylar bags and measure was performed in a NOA280 Sievers equipment. For collection the patients blew in the balloons through a sterile nozzle in the equipment collector without prejudice or damage to the patient.
67631|NCT03655392|Other|Questionnaires ACT, ACQ, AQLQ, BDI|All participants answered standardized questionnaires about asthma symptoms and depression: Asthma Control Test (ACT), Asthma Control Questionnaire (ACQ), Asthma Quality Life Questionnaire (AQLQ), Beck Depression Inventory (BDI)
67632|NCT03655392|Other|Symptoms Diary|All participants were instructed to note in the morning and evening before the use of routine inhaled corticosteroids, asthma symptoms (coughing, wheezing, shortness of breath, use of emergency inhaled corticosteroids) and three measures of peak expiratory flow (individual, provided to patients) and to return this completed diary at each study visit
67633|NCT03655392|Diagnostic Test|Peak flow measure|All participants registered three peak flow measures in the symptoms diary by morning and night before the use of routine inhaled corticosteroids. Peak flow was measured by the electronic peak flow meter (Mini-Wright).
67634|NCT03655392|Diagnostic Test|Exhaled breath condensate air measurement|Exhaled breath condensate was collect during 15 to 20 minutes in a Turbo DECCS equipment (Medivac SRL, Italy) in a sterile buccal of the own apparatus with the aid of a nasal clip with the participant breathing normally without any effort or damage.
67635|NCT03655379|Device|Fetal nasal Doppler by ultrasonography|Pregnant patients who present with preterm labor will be evaluated with ultrasonography and fetal nasal Doppler will be used to detect specific fetal breathing patterns and measurements will be performed
67636|NCT03655366|Other|Questionnaire for Dog owners|Questionnaire directed to epileptic patients, parents of epileptic children and legal representatives of epileptic patients with intellectual disabilities. It includes questions about demographics, epilepsy diagnosis, seizures, the behavior of their dogs around the time they have a seizure and a validates scale to measure dog personality traits.
67637|NCT03655366|Other|Questionnaire for Dog trainers|Questionnaire for seizure response and seizure alert dog trainers including information on number of active working dogs, dog demographic information and selection criteria, the type of patient inclusion criteria they use, training methods used.
67638|NCT03655353|Diagnostic Test|ABY-PET|Diagnostic PET for HER2 expression
67639|NCT03655340|Drug|Alprolix|Extended half-life factor IX product
67640|NCT03655327|Other|reach to grasp a cup|reach to grasp a cup of different weights located at different heights of table
67641|NCT03655314|Other|NEWT|The Newborn Weight Tool (NEWT) is publicly available at www.newbornweight.org. For this intervention, NEWT will be embedded into the electronic medical record along with a flag for weight loss greater than or equal to the 75th centile of birth weight.
67642|NCT03655314|Other|Usual care|The electronic medical record will display the weight only as weight in grams and percent weight lost from birth weight.
67643|NCT03655301|Drug|Copanlisib (Aliqopa, BAY80-6946)|"The copanlisib dose for this study is the standard dose recently approved and also used in Phase 1, 2 and 3 studies across the copanlisib development program: 60 mg i.v. infusion administered intermittently on Days 1, 8 and 15 of a 28-day cycle.~In this study subjects will receive a single i.v. dose of 60 mg copanlisib on day 8."
67644|NCT03655301|Drug|Metformin|Single dose of 1000 mg is administered orally.
67645|NCT03655275|Biological|PRP prolotherapy|PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
67646|NCT03655275|Biological|Saline prolotherapy|Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
67647|NCT03655262|Behavioral|Unconscious Neuro-reinforcement|Individuals will be unconsciously exposed to feared stimuli, leading to effective fear extinction while eliminating a primary cause of attrition.
67648|NCT03655249|Other|Autogenic drainage|Autogenic drainage is an airway clearance technique that attempts to obtain the optimal airflow to evacuate the secretions. This technique uses modulation of inspiratory and expiratory airflow at different breathing level within the vital capacity.
67649|NCT03655249|Drug|Aerosoltherapy|Aerosolized drugs are individualized for each participants, in line with current standardized practice in our hospital. Those drugs will not be modified for the purpose of this study.
67650|NCT03655236|Drug|K0706|low dose, orally, once-daily
67651|NCT03655236|Drug|K0706|high dose, orally, once-daily
67652|NCT03655236|Other|placebo|placebo capsules, orally, once-daily
67653|NCT03655223|Diagnostic Test|Confirmatory Testing|If a newborn's screening test is positive, an experienced genetic counselor will contact the infant's mother by phone to explain the positive screening result and arrange for confirmatory testing and a follow-up appointment. If the confirmatory test is positive, then the child receives a diagnosis of the disease. Children identified with a disorder are referred for treatment, their parents receive information and counseling on what a positive diagnosis means for their child, and they are offered participation in follow-up and registry activities for the disorder.
67654|NCT03655210|Drug|HL151|HL151(1Tab) once a day for 4 weeks of treatments
67655|NCT03655210|Drug|placebo|HL151 placebo(1Tab, Placebo of Bepostatine salicylate) once a day for 4 weeks of treatments
67656|NCT03655197|Drug|Doxycycline|For those participating in the Doxycycline intervention, they will take 100 mg twice daily for 1 month.
67657|NCT03655171|Diagnostic Test|Video-based quantitative methods|The AI video analysis is used to automatically identify motion details and quantify motion features such as amplitude and angular velocity, then an algorithm will be applied to generate the degree of motor dysfunction.
67658|NCT03655158|Device|ozone device ( Ozonytron XL )|The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
67659|NCT03655145|Other|Haplo donor stem cell transplantation|The algorithm for selection of haploidentical donor has been defined by the french society for stem cell transplantation The stem cell source will be bone marrow for haploidentical transplantation.The bone marrow collection is carried out according to the practice of each centre with a minimal target dose of 3x108 TNC/kg.
67661|NCT03655132|Behavioral|Veteran Acceptance and Commitment Therapy for Chronic Pain|Eight online modules based on the theoretical framework of ACT for chronic pain, provided as weekly sessions that will feature an ECA (virtual therapist) as a treatment guide. The initial module is devoted to an explanation of the treatment rationale, initial psychoeducation on pain-related symptoms, pain interference, and focal concepts of ACT, and assessment of individual pain symptoms. Modules 2-4 will focus on values clarification, acceptance and willingness, mindfulness, with an emphasis on tolerance of pain-related experiences. Modules 5-7 will continue to this focus, and incorporate goal-creation and committed action exercises. Module 8 will consolidate and provide feedback on goal-related achievements, and will focus on planning for the future.
67662|NCT03655119|Behavioral|Parent toolkit|The parent tookit is a resource that reinforces evidence-based practices for crisis management such as safety planning and means restriction and encourages parents to increase their support, supervision, and monitoring of their at risk youth.
67663|NCT03655119|Behavioral|Enhanced Care|PES clinical staff will receive training on the best practices in brief crisis-focused interventions in emergency settings with parents and youth.
67664|NCT03655119|Behavioral|Caring Follow-Up Messages|Parents will receive caring contacts via phone, text, or email to provide support, additional education, and problem solving assistance in the days and weeks post-discharge.
67665|NCT03655106|Device|Standard Long IV 4.78 cm 20 g catheter|Standard Long IV 4.78 cm 20 g catheter
67666|NCT03655106|Device|Ultra-Long IV 6.35 cm 20 g catheter|Ultra-Long IV 6.35 cm 20 g catheter
67667|NCT03655093|Other|Validation of AMSQ questionnaire|"Participation in the study will be proposed to any patient meeting the inclusion criteria and consulting a neurologist from the SEP reference center of the University Hospital of Rennes.~The neurologist will explain the purpose of the study to the patient, give him the information form.~Without opposition from the patient, the neurologist will give him the self-questionnaire. The patient will fill it during the consultation. In case of disability to the upper limbs making it impossible to fill the questionnaire by the patient, it will be filled by the neurologist or the patient's companion, according to the answers given by the patient.~While the patient completes the questionnaire, a record of clinical information will be filled in by the neurologist.~No additional act will be performed except the questionnaire, which result will not change the patient's management."
67668|NCT03655080|Radiation|Radiation therapy|Using the View Ray System
67669|NCT03655080|Drug|nab-Paclitaxel|Should be administered by IV over 30 minutes
67670|NCT03655067|Behavioral|CATCH-IT|The CATCH-IT internet program consists of 14 modules and exercises and activities based on best practices components of depression prevention. They will be instructed to complete at least 2 modules a week, over a period of 6 weeks. This would require at least 40 minutes per week (approximately 20 minutes minimum per module).
67671|NCT03655041|Dietary Supplement|Beta-alanine|Beta-alanine in sustained-release tablets to increase muscle carnosine content
67672|NCT03655041|Dietary Supplement|Placebo|Maltodextrin is used as a placebo as it does not lead to any increases in muscle carnosine
67673|NCT03655028|Behavioral|rhythmically auditory stimulation enhanced music|Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program
67674|NCT03655028|Behavioral|control|Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
67675|NCT03655015|Procedure|Lung Tumor Resection|Lung Tumor Resection
67676|NCT03655002|Drug|Cyclophosphamide|Given IV
67677|NCT03655002|Biological|Cytokine-based Biologic Agent IRX-2|Given SC
67678|NCT03655002|Biological|Nivolumab|Given IV
67679|NCT03654989|Drug|Treprostinil iontophoresis|We will administer treprostinil at increasing doses by a iontophoresis.
67680|NCT03654989|Device|Remodulin® placebo iontophoresis|"Placebo iontophoresis will be performed using Remodulin® placebo (United Therapeutics) delivered with Axion GmbH electrodes connected to a PeriIont generator (Perimed).~Part 1: 1 administration/day, on separate days, with 72h between two doses. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm².~Part 2: 1 administration/day for 10 days. The intensity will be set at 120 µA during 60 minutes, i.e. a total current of 17.3 mC/cm²."
67681|NCT03654976|Biological|HDM SLIT-tablet|Sublingual allergy immunotherapy tablet, for daily administration (1 tablet per day)
67682|NCT03654976|Other|Placebo|Placebo sublingual tablet, for daily administration (1 tablet per day)
67683|NCT03654963|Procedure|Medication reconciliation|Medication reconciliation is the systematic process described above.
67684|NCT03654950|Other|No intervention|Interviews and questionnaires
67685|NCT03654937|Biological|Influenza Vaccination|"Influenza vaccination Influsplit Tetra 2016/2017, GlaxoSmithKline GmbH & Co. KG, Munich, Germany, batch: AFLBA 152AB."
67686|NCT03654924|Device|Laryngeal Mask|General anaesthesia using LMA will be performed as per standard procedure. A pressure gauge will be connected to the LMA using a small cable to measure the LMA cuff pressure continuously.
67687|NCT03654911|Diagnostic Test|EEG|EEG
67688|NCT03654911|Genetic|ApoE|ApoE
67689|NCT03654898|Behavioral|VITAL Start: Video-based pre-ART counseling|Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q & A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
67690|NCT03654898|Behavioral|Standard of Care|Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
67691|NCT03654885|Device|XEN group|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for XEN implantation
67692|NCT03654885|Procedure|Trabeculectomy|Subjects will undergo at least one preoperative visit (and more as needed), and then be scheduled for trabeculectomy.
67693|NCT03654859|Other|cardiopulmonary resuscitation|no pre-specified
67694|NCT03654846|Device|EmergencyEye|EmergencyEye Smartphone App
67695|NCT03654833|Drug|Rucaparib|PARP inhibitor
67696|NCT03654833|Drug|Abemaciclib|CDK4/6 inhibitor
67697|NCT03654833|Drug|pembrolizumab & bemcentinib|PD1 checkpoint inhibitor, AXL inhibitor
67698|NCT03654833|Drug|Atezolizumab & Bevacizumab|PDL1 checkpoint inhibitor, VEGF inhibitor
67699|NCT03654820|Device|PVP-I solution combined with NaF varnish|4-monthly application of 10% povidone-iodine solution and 5% sodium fluoride varnish
67700|NCT03654820|Device|SDF solution|Annual application of 38% SDF solution
67701|NCT03654807|Behavioral|High Intensity Walking|70-80% HRmax
67702|NCT03654807|Behavioral|Casual Speed Walking|Self selected pace
67703|NCT03654794|Biological|Cell pharmacokinetics of tacrolimus|"Three levels of tacrolimus will be tested. Each aliquot will be supplemented with an amount of tacrolimus to achieve one of these three levels of concentration.~At 0, 5, 15, 30, 60, 120, 240mn, the samples will be separated into 2 aliquots : one dedicated to the determination of tacrolimus in mononuclear cells, the other dedicated to the determination of calcineurin activity. in mononuclear cells."
67704|NCT03654781|Drug|Triple therapy|triple therapy:a 10-day course of a Lansoprazole (proton pump inhibitor )combined with amoxicillin (2 × 1 g daily) and clarithromycin (2 × 500 mg daily).(trio)
67705|NCT03654781|Procedure|professional periodontal treatment|periodontal treatment consisting of mechanical periodontal treatment (scaling and root planing) Oral hygiene insruction Periodontal treatment started concurrently with triple therapy
67706|NCT03654768|Drug|Dasatinib|Given PO
67707|NCT03654768|Other|Laboratory Biomarker Analysis|Correlative studies
67708|NCT03654768|Drug|Nilotinib|Given PO
67709|NCT03654768|Drug|Ruxolitinib Phosphate|Given PO
67710|NCT03654755|Drug|ASN002|Daily dose of ASN002 for up to 110 weeks
67711|NCT03654742|Procedure|tonsillectomy|removal of tonsil tissue as described in the study arms
67712|NCT03654729|Drug|Calmangafodipir (2 µmol/kg)|Bright yellow, clear solution in 20 mL colourless, single dose, glass vial
67713|NCT03654729|Drug|Calmangafodipir (5 µmol/kg)|Bright yellow, clear solution in 20 mL colourless, single dose, glass vial
67714|NCT03654729|Drug|Placebo|Bright yellow, clear solution in 20 mL amber, single dose, glass vial
67715|NCT03654716|Drug|ALRN-6924|ALRN-6924 is a drug that blocks certain proteins in tumor cells called MDM2 and MDMX. These proteins may be important in the growth of some cancers. Laboratory experiments and results from studies with adults show that ALRN-6924 may stop tumor growth and, in some cases, may cause tumor cells to die.
67716|NCT03654716|Drug|Cytarabine|Cytarabine belongs to the category of chemotherapy called antimetabolites. Antimetabolites are very similar to normal substances within the cell. When the cells incorporate these substances into the cellular metabolism, they are unable to divide
67717|NCT03654703|Drug|Cyclophosphamide|cyclophophamide
67718|NCT03654690|Diagnostic Test|HIV self-test|Home delivery of HIV self-test kits (OraSure OraQuick Rapid HIV test)
67719|NCT03654690|Behavioral|Counseling|Post-Test HIV Risk ReductionCounseling
67720|NCT03654677|Biological|inactivated hepatitis A vaccine|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
67721|NCT03654677|Biological|Havrix Inj|A single dose of the test vaccine or the control vaccine in the form of pre-filled syringe is injected intramuscularly into the deltoid muscle (not to be injected into the gluteal region), and additional vaccination is performed using the same vaccine and the same method at 6 months after the first vaccination.
67722|NCT03654664|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A virus antigen 250 U (Name of viral strain: TZ84)
67723|NCT03654664|Biological|Havrix Inj|720 ELISA/0.5 mL Junior (Inactivated hepatitis A virus antigen 160 U (Name of viral strain: HM175 Inj)
67724|NCT03654651|Drug|Peanut|Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.
67725|NCT03654651|Drug|High carbohydrate snack|Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).
67726|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices soy bread each day for 20 weeks while initiating hormone therapy
67727|NCT03654638|Combination Product|Dietary Intervention|The dietary intervention requires men to consume 2 slices wheat bread each day for 20 weeks while initiating hormone therapy
67728|NCT03654638|Other|Questionnaire Administration|Ancillary studies
67729|NCT03654625|Behavioral|Standard Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry.
67730|NCT03654625|Behavioral|Enhanced Written Exposure|Four spaced, 30-minute sessions occurring within a period of 2 weeks. Participants write a narrative about their worst worry and rescript it.
67731|NCT03654625|Behavioral|Control Condition|Four spaced, 30-minute sessions occurring within a period of 2 weeks. At each session, participants write a narrative about a neutral topic.
67732|NCT03654612|Drug|Apatinib|Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle
67733|NCT03654599|Behavioral|Baseline Surveys|Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
67734|NCT03654599|Behavioral|Digital Stories Intervention|Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
67735|NCT03654599|Behavioral|Information Control Intervention|Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
67736|NCT03654586|Behavioral|Sugary drink warning labels|The description of each intervention appears in the descriptions of the experimental arms.
67737|NCT03654573|Device|CorFlow Controlled Flow Infusion System - CoFI™|The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.
67738|NCT03654560|Device|HemoStyp|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Hemostyp applied in accordance to instructions for use.
67739|NCT03654560|Device|Surgicel|During elective surgical procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery) subject has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical will have Surgicel applied in accordance to instructions for use.
67740|NCT03654547|Drug|TT-00420|"TT-00420 is an investigational, oral, multi-target, dual mechanism kinase inhibitor targeting both mitosis and tumor microenvironment, for the treatment of triple negative breast cancer (TNBC) and other advanced solid tumors.~TT-00420 capsule will be administered once daily on a continuous schedule. A treatment cycle consists of 28 days.~The proposed dosage form for early clinical research is powder filled hard gelatin capsule (PIC) with dosage strengths as of 1 mg, 5 mg and 20 mg."
67741|NCT03654534|Dietary Supplement|NutrenOpimum|NutrenOpimum administration was recommended with a dosage of 400 kcal/400 ml per day within 7 days postoperatively and was continued for 3 months postoperatively.
67742|NCT03654521|Diagnostic Test|Fetal interventricular septum thickness|Two-dimensional ultrasound fetal cardiac imaging test
67743|NCT03654508|Genetic|ADRB2-genotype guided treatment|This intervention assesses whether ADRB2 genotype-guided treatment leads to better asthma control after 3 months compared to usual care in children who are uncontrolled despite adherent and adequate use of ICS.
67744|NCT03654508|Other|Randomisation|In the control arm, children will be randomised over double dose ICS or ICS+LABA instead of treatment according to their genotype.
67745|NCT03654495|Other|Exergame training|"Training on Medical Device (MD): Dividat Senso, DIV-SENSO-H, Dividat GmbH, Software development: ISO 62304:2016; designed to train aspects of executive functions (EFs; divided attention, working memory, inhibition, and shifting) and physical functions through Virtual Reality video game training.~FITT training principles are implemented; Frequency: three times per week, Intensity: individually adapted VG (allowing training progression), Type: combination of cognitive and motor training, and Time: 20 min training sessions. Training lasts 6 weeks (18 training sessions). Participants train 20 min, three times per week. Training includes one session of each VG (4 min) in a pre-defined order and short breaks (~1 min) for game change."
67746|NCT03654495|Other|Usual Care Training|Routine (standard) therapy given based on conventional current-best-evidence Rehabilitation. Preoperative Phase: Diminish inflammation, swelling, and pain; Restore normal range of motion (especially knee extension); Restore voluntary muscle activation Immediate Postoperative Phase (Day 1-7): Restore full passive knee extension; Diminish joint swelling and pain; Restore independent ambulation Early Rehabilitation Phase (Week 2-4): Maintain full passive knee extension; Gradually increase knee flexion; Muscle training Controlled Ambulation Phase (Week 4-10): Restore full knee ROM; Improve lower extremity strength; Enhance proprioception, balance, and neuromuscular control Advanced Activity Phase (Week 10-16): Normalize lower extremity strength; Enhance muscular power and endurance; Improve neuromuscular control; Perform selected sport-specific drills.
67747|NCT03654482|Device|SuperSeton|The SuperSeton will be placed at the outpatient clinic in patients that already have a seton in situ. This seton will then be exchanged by the SuperSeton. In case patients do not have a seton in situ, the SuperSeton can be placed at the operating theatre in day care setting instead of a regular seton.
67748|NCT03654469|Other|questionnaires and electronic mini-spirometry|prospective screening study based on questionnaires and electronic mini-spirometry (Néo-6(®)) that includes a representative sample of dairy farmers from the departments of Morbihan and Île-et-Vilaine in Brittany
67749|NCT03654456|Biological|OSA|The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
67750|NCT03654443|Diagnostic Test|Critical care pain observation tool|The CPOT tool is administered in a crossover manner by two study observers
67751|NCT03654430|Other|Echocardiography|Two echocardiographies will be performed in healthy newborns: The first between day 2 and day 5 of life, the second between day 60 and day 90 of life
67752|NCT03654417|Drug|EMLA|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
67753|NCT03654417|Drug|Lidocaine|Patients undergoing a vulvar biopsy will be randomized to receive EMLA cream or a lidocaine injection as their numbing agent prior to the procedure.
67754|NCT03654404|Behavioral|Positive Psychology Intervention|Weekly phone calls with the study interventionist and positive psychology exercises over an 8-week period. The positive psychology program exercises includes three modules: gratitude-based activities, strength-based activities, and meaning-based activities.
67755|NCT03654391|Dietary Supplement|InnoSlim|Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
67756|NCT03654391|Dietary Supplement|Placebo|Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.
67757|NCT03654365|Other|Bulk ordering and bulk messaging|Patients in the intervention group had the hepatitis screening test ordered for them in bulk and then a bulk message sent to them through the personal health record describing hepatitis C and how they could be tested.
67758|NCT03654365|Other|Routine alerting|Passive alerting to providers (during face-to-face encounters using the electronic health record) and to patient (when they review preventative screening recommendations through their personal health record).
67864|NCT03653572|Device|Ultrasound exam|Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
67759|NCT03654339|Procedure|root coverage|"Group A: After administration of local anaesthesia using ophthalmic microsurgical knives a V-shaped incision was made in the gingival recession area. the gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then secured with 6-0 absorbable sling suture without tension. the surgical procedure was done with seilar microscope 40X magnification.~Group B: After administration of local anaesthesia using 15 no blade a V-shaped incision was made in the gingival recession area . gingiva was removed .the adjacent partial thickness pedicle flap was reflected from the donor area .the pedicle flap was then covered over the recipient site. then carefully secured with 4-0 absorbable sling suture"
67760|NCT03654326|Drug|Gefapixant|Gefapixant tablet taken orally
67761|NCT03654326|Drug|Placebo|Placebo matching gefapixant tablet taken orally
67762|NCT03654326|Drug|Naproxen|Naproxen sodium tablets taken orally as needed.
67763|NCT03654313|Biological|MEDI6570|MEDI6570
67764|NCT03654313|Biological|Placebo|Placebo
67765|NCT03654313|Biological|Part B Placebo|Placebo
67766|NCT03654287|Other|Treatment|The CELS way to intervene severe sepsis and refractory shock
67767|NCT03654274|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
67768|NCT03654274|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
67769|NCT03654261|Behavioral|Cognitive Behavioural Therapy|The intervention is a 1-day Cognitive Behavioural Therapy based workshop.
67770|NCT03654248|Behavioral|Let's Get Organized group intervention|Group intervention aiming to enhance time management, targeted to persons with mental or neurodevelopment disorders. Each group has 6-8 participants and is lead by two trained group leaders. Goal-directed and other learning strategies are used to train effective time management habits such as maintaining a calendar and wearing a watch. Group sessions are structured with PowerPoint presentation and a course manual, an information from the group leaders is intermixed with discussion among the participants and tasks to complete.
67771|NCT03654248|Device|Individual Occupational Therapy|Individual meetings with Occupational Therapist (standard therapy) during a 10-week period. Number of meetings and exact nature of intervention depends on the client's needs and is decided by the treating occupational therapist. Interventions will include prescription or instruction regarding time assistive devices and instructions regarding structure and planning of everyday life.
67772|NCT03654235|Other|Health Education|6 pain neuroscience education sessions (10 hours) and delivery of printed reinforcement material.
67773|NCT03654235|Other|Physical exercise|Group physical exercise program (18 sessions; 3 sessions/week) leaded by a physiotherapist. It includes exercises to improve strength, coordination, balance and aerobic capacity. Work with double tasks, recreational activities to overcome kinesiophobia and activities to do at home are used in the program.
67774|NCT03654235|Other|Usual care in Primary Care Physiotherapy Units|"Treatment supported by the protocol of primary care of physiotherapy in the health service of Castilla y León that was in force at the time of the intervention.~Patients receive 15 sessions of analgesic electrotherapy, thermotherapy and standardized physical exercise"
67775|NCT03654209|Device|Argon Plasma Coagulation|APC will be applied to the perimeter of the resection site
67776|NCT03654209|Device|Snare Tip Soft Coagulation|STSC will be applied to the perimeter of the resection site
67777|NCT03654196|Drug|HL301(Experimental)|Total 7 days of treatment and The daily dose is as follows [Morning: HL301 1Tab + Placebo of Umkamin 1Tab] [Noon: Placebo of Umkamin 1Tab] [Evening: HL301 1Tab + Placebo of Umkamin 1Tab]
67778|NCT03654196|Drug|Umkamin(Active Comparator)|Total 7 days of treatment and The daily dose is as follows [Morning: Placebo of HL301 1Tab + Umkamin 1Tab] [Noon: Umkamin 1Tab] [Evening: Placebo of HL301 1Tab + Umkamin 1Tab]
67779|NCT03654183|Diagnostic Test|Indocynine green clearance test|Indocyanine green clearance was determined by non-invasive pulse spectrophotometry (NIHON KOHDEN™; Pulse Dye Densito-Graph Analyzer, Japan).
67780|NCT03654170|Drug|BI 425809 mixed with [C-14] BI425809|Oral Solution
67781|NCT03654144|Drug|Dienogest|oral tablets
67782|NCT03654144|Drug|Combined Oral Contraceptive|oral tablets
67783|NCT03654131|Device|MWA|Patients are allocated to one of the two arms in a 1:1 randomization
67784|NCT03654131|Radiation|SBRT|Patients are allocated to one of the two arms in a 1:1 randomization
67785|NCT03654118|Other|Phone follow-up|"Through a short phone interview :~Determination of a complication (Infection, capsulitis, recurrence)~Determination of the Rowe score~Determination of the Walch-Duplay score"
67786|NCT03654105|Drug|Cytisine|"Cytisine administration will be randomized 1:1 in standard (40 days)and prolonged treatment (84 days).~Subjects will be educated on how to take the product and informed about possible adverse effects."
67787|NCT03654105|Drug|Acetylsalicylic acid|The treatment will consist of Acetylsalicylic acid at 100mg once a day
67788|NCT03654105|Other|Diet Modification and Physical Activity Increase|"It will be proposed:~an optimal diet with the aim of favoring control of weight, abdominal fat and adequate nutritional status without increasing the levels of IGF-I and inflammatory factors or glycemic peaks, with periodic verification of the results~a regular and sustainable physical activity program with periodic verification of the results."
67789|NCT03654105|Diagnostic Test|early lung cancer detection|standard treatment for early lung cancer detection with ultra low dose CT
67790|NCT03654105|Diagnostic Test|spirometry with CO test|spirometry with CO test
67791|NCT03654105|Other|anthropometic data collection|anthropometic data collection
67792|NCT03654105|Other|blood test|blood test to assess the metabolic and inflammatory profile
67818|NCT03653936|Device|HITT device|Rebion has developed a noninvasive, handheld device that uses retinal polarization scanning (RPS) to rapidly assess eye fixation and retinal integrity in adults and children. RPS can automatically detect the fixation of the human eye with proprietary technology that uses a scanned annulus of polarized laser light to create a signature that confirms central fixation within seconds. RPS requires no calibration or imaging, and eye movement recordings are not required. The HITT device is a repurposed Pediatric Vision Scanner (PVS), Rebion's first commercial product which has passed all applicable safety and performance standards.
67865|NCT03653559|Behavioral|Home meals|"Adult participants with overweight or obesity are asked to consume home meals during 12 weeks."
67793|NCT03654092|Behavioral|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
67794|NCT03654079|Other|Simulation|Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
67795|NCT03654066|Drug|Botulinum toxin type A|Botox injection in the LES
67796|NCT03654066|Device|Endoscope balloon dilator|Distal esophageal dilation
67797|NCT03654066|Other|Patient reported outcomes|Subjects will complete two patient reported outcome measures (Eckardt and MADS).
67798|NCT03654066|Diagnostic Test|Barium esophagram|Assess for radiologic severity of achalasia with barium column height measured 1 minute and 5 minutes after upright ingestion of barium
67799|NCT03654053|Drug|Placebo Oral Tablet|Placebo taken once nightly at bed time.
67800|NCT03654053|Drug|Simvastatin 40mg|Simvastatin 40mg taken once nightly at bed time.
67801|NCT03654040|Biological|arTreg|"Eligible participants will receive a single dose of Treg product (arTreg). The target dose is 100 to 500 x 10^6 total cells. However, if a minimum arTreg dose of 30 to < 100 x 10^6 total cells is manufactured, the product will be infused. If the dose obtained after product manufacture is < 30 x 10^6 cells, the product will not be infused. When the dose obtained after product manufacture is > 500 x 10^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 500 x 10^6 cells, and ≥ 30 to 500 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes."
67802|NCT03654040|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion."
67803|NCT03654040|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 hours after completion of leukapheresis on Day -3 (-1 day) prior to Treg product (arTreg) infusion.
67804|NCT03654040|Drug|mesna|"Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide.~The first dose will be administered intravenously before cyclophosphamide administration and the subsequent 3 doses at 3, 6 and 9 hours after the cyclophosphamide infusion."
67805|NCT03654040|Drug|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 22 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
67806|NCT03654027|Drug|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
67807|NCT03654027|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1)
67808|NCT03654014|Device|SofPulse|SofPulse PEMF device treatment of the brain after traumatic injury
67809|NCT03654001|Biological|Albumin|Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination.
67810|NCT03654001|Other|Balanced|Balanced crystalloid solutions are traditionally crystalloid solutions containing a relatively low concentration of chloride as compared to 0.9% NaCl containing solutions (Normal Saline).
67811|NCT03653988|Procedure|PEC I/II blocks by anesthesiologist - pre-operative|PEC I/II blocks by anesthesiologist - pre-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II). Group I will have the PEC block administered by the anesthesiologist prior to surgical incision.
67812|NCT03653988|Procedure|PEC I/II blocks by surgeon - intra-operative|PEC I/II blocks by surgeon - intra-operative; PEC I/II block to anesthetize the pectoral, intercostobrachial, third to sixth intercostal and long thoracic nerves. The PEC I/II blocks are pectoralis field blocks where local anesthetic medication is injected under ultrasound guidance between the tissue planes of pectoralis major and minor muscles (PECS I) and in the plane of the serratus anterior muscle at the level of the third rib (PEC II).
67813|NCT03653975|Other|no intervention|no intervention
67814|NCT03653962|Behavioral|video assisted group|
67815|NCT03653962|Behavioral|non-video group|
67816|NCT03653949|Other|Educational intervention|It will be an interactive lecture, 60 minutes long. The class will cover physiopathology, complications, treatment and prevention of exacerbations. Audiovisual resources and practical demonstrations of usual care will be used. Individual questions will be answered during the class.
67817|NCT03653949|Other|Aerobic exercise|The aerobic exercise program will be performed at home, on a cycle ergometer for lower limbs between 24 and 35 minutes: 5 minutes of warm-up, 14 to 25 minutes of high-intensity interval exercise and 5 minutes of cool down.
67819|NCT03653923|Behavioral|Exposure Therapy|"Before the treatment, subjects will have one session of psychoeducation in which the rationale for the treatment is explained. In each therapy session subjects are exposed to 20 trials (each lasting 40s) of guided exposure by a psychotherapist. Further, 20 control trials of equal length are assessed in which subjects work with an earthworm. Each session lasts for approximately 90 minutes. During the therapy additional anxiety coping strategies (e.g., controlled breathing, attention refocusing, cognitive reappraisal) are trained.~Subjects of the waiting-list will be treated in the second study phase."
67820|NCT03653910|Device|Airtraq|Airtraq is a kind of videolaryngoscope for intubation
67821|NCT03653910|Device|Macintosh|Macintosh is a traditional laryngoscope for intubation
67822|NCT03653897|Device|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
67823|NCT03653897|Device|Wearable Sensor|Subjects will wear an ID-Reader
67824|NCT03653884|Diagnostic Test|Ultrasound monitoring|Ultrasound monitoring is recommended during the third trimester in search of an increase in dilation and especially the appearance of a thrombus. A particular clinical form, related to abnormal umbilical vein involvement in the infra-hepatic portal system, must be individualized because of a high risk of thrombosis. It justifies the realization of an abdominal ultrasound in the first days of life. This is an aneurysm of the umbilical vein when the umbilical vein has a diameter greater than 9 mm, or a diameter of the subhepatic segment of the umbilical vein greater than 50% of the diameter of its intrahepatic segment.
67825|NCT03653871|Behavioral|Performing Arts Instruction|Professionally delivered performing arts curriculum
67826|NCT03653858|Device|Vercise GEVIA deep brain stimulation (DBS) system|DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)
67827|NCT03653845|Procedure|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
67828|NCT03653845|Drug|Sequenced antihypertensvie drugs with titrated dosage|Patients will be treated with different antihypertensive drugs in two groups.
67829|NCT03653832|Drug|Dexmedetomidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
67830|NCT03653832|Drug|Clonidine|"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."
67831|NCT03653832|Drug|Propofol|Patients will continue to receive intravenous propofol according to current usual care.
67832|NCT03653819|Other|First exercise session + compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
67833|NCT03653819|Other|First exercise session - compression|The Interval Training consists of a 5 minute warm-up on the stationary bike followed by 7 intervals of cycling for 1 minute at level 15-16 on the Borg Scale of Perceived Exertion. Inbetween intervals, participants reduce resistance on the stationary bike and pedals for 1 minute at level 11-12 on the Borg Scale. The session ends with a 5-10 minute cool-down pedaling and stretching exercises for the lower limbs.
67834|NCT03653806|Other|computerized algorithm for automated analysis|"First: to develop a computerized algorithm for automated analysis of the electrical impedance tomography (EIT) data. The algorithm calculates the optimal positive end-expiratory pressure (PEEP) and inspiratory pressure defined as the optimal balance between stretch, ventilation distribution and collapse.~Second: to compare the results of the algorithm with the current standard of care clinical judgement of experienced EIT users"
67835|NCT03653793|Other|Natural Health Product: LivRelief Varicose Veins Cream|This product is intended to improve circulation and blood flow to minimize the appearance of varicose veins.
67836|NCT03653780|Device|Ekso GT|Walking in the Ekso GT with maximum bilateral assistance for 20 minutes
67837|NCT03653767|Device|Adjustable Furniture|The intervention will include adjustable school furniture.
67838|NCT03653754|Diagnostic Test|Measurement of growth and body composition|Growth (height and body weight), and body composition were measured. For the body composition, Inbody 770 and Inbody S10 were used.
67839|NCT03653741|Drug|Perampanel 6 MG|Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
67840|NCT03653728|Device|Near infrared spectroscopy|"All patients would be receiving the same treatment including application of non-invasive monitoring with near-infrared spectroscopy (NIRS) together with the standard of care with interval CT Brain scan for all patients.~Non-invasive monitoring with near-infrared spectroscopy (NIRS) is very safe and is in current daily routine clinical use for intraoperative patients."
67841|NCT03653715|Device|Clerio Vision LIRIC-modified Bifocal Contact Lens|Within this arm the investigational acofilcon B material bifocal contact lens, which has been modified with the laser and is the focus of the study, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
67842|NCT03653715|Device|Johnson & Johnson 1-Day Acuvue Moist Multifocal Contact Lens|Within this arm the control etafilcon A material bifocal contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
67843|NCT03653715|Device|Johnson & Johnson 1-Day Acuvue Moist Contact Lens|Within this arm the control etafilcon A material single vision contact lens, which is commercially available, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
67844|NCT03653715|Device|Clerio Vision Single Vision Contact Lens|Within this arm the control acofilcon B material single vision contact lens, the material of which is commercially available from Contamac Ltd, is tested. This lens is one of four (4) administered to each participant, tested on either visit 2 or 3 according to the randomization schedule, for a period of approximately 20 minutes.
67845|NCT03653702|Drug|Lumason|Lumason will be used as the contrast agent. Standard Lumason dose will be used: 0.03mL/kg up to a maximum dose of 2.4 milliliter (mL) per injection
67846|NCT03653689|Dietary Supplement|FODMAP|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
67847|NCT03653689|Dietary Supplement|Gluten|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
67848|NCT03653689|Dietary Supplement|Placebo|The intervention will run for seven weeks. During the whole intervention, the participants will hold a baseline diet with no gluten and low intake of FODMAPs. The first week, the participants will consume a one-time cocktail provocation consisting of gluten (17.3 gram) and FODMAPs (50 gram) Thereafter, study participants will receive three 1-week diets with additions of either FODMAPs, gluten or an inert control with 1-week washout in-between. The daily amount for gluten will be 17.3 gram and the daily amount for FODMAPs will be 50 gram. The order of the three weeks with extra diets (gluten/FODMAPs/control) will be randomized.
67849|NCT03653676|Other|Exercise Test (CIIT)|The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
67850|NCT03653663|Drug|Simvastatin 20 mg|Subjects are treated with 20 mg simvastatin for 8 weeks
67851|NCT03653663|Drug|Placebo Oral Tablet|Subjects are treated with placebo for 8 weeks
67852|NCT03653650|Combination Product|PRP plus BCL|Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
67853|NCT03653650|Combination Product|BCL plus PFL|Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
67854|NCT03653650|Combination Product|Eye patch plus ocular lubricant ointment|Eye patch plus ocular lubricant ointment every 24 hours.
67855|NCT03653637|Behavioral|Project Life Force|A novel, 10-session group intervention to enhance currently mandated VA suicide safety planning by involving Veterans who are at high-risk for suicidal. The PLF intervention augments the SSP in a group treatment with skills training, and psychoeducation, to maximize use and effectiveness of the plan. Overall, PLF aims to enhance suicide coping skills, safety planning and connection to others. The primary purpose is to enhance the safety plan with skills training in emotion regulation, building of support and distress tolerance, and enable even acutely-suicidal Veterans to be able to implement the steps of the safety plan.
67856|NCT03653637|Behavioral|Treatment as Usual|The comparison condition will be an assessment-only treatment-as-usual (TAU). Participants in the TAU condition will receive safety planning and specified clinical support, as mandated by their high-risk status.
67857|NCT03653624|Other|No intervention|No intervention is involved int his study. Fully anonymised blood pressure data will be collected from the vital signs monitors in the operating room.
67858|NCT03653611|Other|On-site Practice Assessment|The assessment takes place in three parts; the pre-observation practice overview (conducted with the 2 practice clinicians - 60 minutes), the ½ day practice workflow observation (observation by one member of the Aim 2 research team of common and testing areas used for the respiratory patient). There is no patient engagement and no collection of patient-specific identification or health information), and the post-observation practice summary (conducted with the same 2 practice clinicians - 30 minutes).
67859|NCT03653611|Other|Clinical Staff Questionnaires|"Written or on-line questionnaires are provided to participating and consented staff personnel at two practice levels -- Non-Prescribing clinical (also known as support) staff and Prescribing (PR) clinical (also known as provider) staff."
67860|NCT03653611|Other|Patient Opinion Surveys|200 Eligible participants will complete a one-time 5 to 10 minute CAPTURE opinion survey.
67861|NCT03653611|Other|Modular online COPD Education|Access to free, COPD on-line, continuing education is provided for all clinical staff at each practice. Each module will take 20 minutes or less. Aim 2 clinician participant access and completion of COPD education modules is assessed by clinician questionnaires and focus group item response over 12 months (between months 2 and 14 of Aim 2 timeline).
67862|NCT03653611|Other|COPD in Primary Care/CAPTURE Introduction Focus Groups|Two 45 to 60-minute focus group discussions occur at each Aim 2 practice. Focus groups are informed by practice demographics, practice assessment data, as well as patient opinion from CAPTURE surveys and past CAPTURE study. Focus group candidate themes and prompts are developed for non-prescribing clinical staff (NPR) and prescribing clinical staff (PR) and are presented at separate on-site focus group sessions to allow more detailed discussion of role responsibility in the context of daily practice workflow.
67863|NCT03653598|Other|Atrial Fibrillation|Data collection on Atrial Fibrillation
67866|NCT03653559|Behavioral|Healthy meals|"Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks."
67870|NCT03653533|Device|MiniMed™ 640G|The MiniMed™ 640G corresponds to the medical device = pump using for the delivery of insulin
67871|NCT03653533|Device|Captor CGM Enlite®|The Captor CGM Enlite® corresponds to the device added for the measurement of the glycemic level
67872|NCT03653533|Device|SmartGuard®|This SmartGuard® function is used to improve the glycemia stability in real condition
67873|NCT03653520|Drug|Diazepam|5 or 10mg
67874|NCT03653520|Drug|Tramadol|50mg or 100mg
67875|NCT03653520|Drug|Ondansetron|1 or two tabs
67876|NCT03653520|Drug|MKO melt|1 or 2 MKO melts
67881|NCT03653494|Procedure|phrenic block|phrenic block by 1% ropivacaine 5ml
67882|NCT03653494|Procedure|no phrenic block|no phrenic block
67883|NCT03653481|Dietary Supplement|Oligofructose-enriched Inulin OI|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
67884|NCT03653481|Dietary Supplement|Maltodextrin|Consumed as a powder, 8g/d for children <50kg and 16g/d for children ≥50kg, divided in 2 daily doses.
67885|NCT03653468|Behavioral|Concurrent training (CT)|The core part of each session included resistance training (RT) followed by aerobic training exercises (for 50 and 30 minutes, respectively) and was preceded and followed by a 5-minute warm-up and cool-down with callisthenic movements.
67886|NCT03653455|Behavioral|Email reminders|Patients will receive email reminders until their PROs are completed.
67887|NCT03653455|Behavioral|pre-operative discussion|Patients will discuss the importance of PROs with their provider pre-operatively.
67888|NCT03653455|Behavioral|Pre- and Post-operative discussion|Patients will discuss with their provider the importance of PROs pre-operatively, as well as their post-operative progression in comparison to established norms.
67889|NCT03653455|Behavioral|Incentive|Patients will receive up to $30 in amazon gift cards upon the completion of their PROs.
67890|NCT03653429|Drug|Tranexamic Acid|administered prior to surgical incision
67891|NCT03653429|Drug|Normal saline|administered prior to surgical incision
67892|NCT03653416|Device|Ipack|IPACK block - local anesthesia injected safely under ultrasound guidance in the interspace between the popliteal artery and capsule of the knee.
67893|NCT03653416|Drug|Bupivacaine|20 cc of bupivacaine(o.25%) injection
67894|NCT03653416|Procedure|Peri Articular Infiltration|Adductor Canal Catheter and Peri Articular Infiltration
67895|NCT03653403|Drug|IDP-126 Gel|Component A
67896|NCT03653403|Drug|Control Gel|gel
67897|NCT03653390|Behavioral|EnhanceWellness for Disability (EW-D)|Participants work one-on-one with the study Wellness Coach to identify health self-management problems, consider options, develop goals and an action plan, and make adjustments to that plan over time.
67898|NCT03653390|Behavioral|Wellness Education|Sessions will cover: (1) blood pressure management; (2) smoking cessation; (3) cancer screening; (4) regulation of blood glucose; (5) decreasing LDL cholesterol; (6) physical activity; (7) bone, joint, and muscle health; and (8) immunizations.
67899|NCT03653377|Other|Self administrated questionnaire|Questionnaires are distributed to patients with their parents during their visit to the CF center.
67900|NCT03653364|Drug|Baloxavir Marboxil|"Participants will receive single oral dose of baloxavir marboxil on Day 1 based on body weight and age.~Participants will be recruited in parallel to the following three cohorts:~Cohort I: ≥ 3 months to < 12 months old (minimum 8 participants): 2 mg/kg~Cohort II: ≥ 4 weeks to < 3 months old (minimum 4 patients): 1 mg/kg~Cohort III: birth to < 4 weeks old (minimum 4 patients): 1 mg/kg"
67901|NCT03653351|Device|Active Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 mA (current density = 0.57 A/m2) and will be applied for approximately 30 minutes per day during meditative practices of the MBSR protocol.
67902|NCT03653351|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a form of neurostimulation (also known as neuromodulation) where very low levels of direct electrical current are delivered to specifically targeted areas of the brain, in order to increase neuroplasticity. The direct current in active tDCS will be of 2 milliampere (mA) (current density = 0.57 A/m2), however, the device is pre-programmed to turn off after 1 minute of active stimulation (and then turn back on briefly at the end of the 30 minutes).
67903|NCT03653338|Biological|CD3/CD19 depleted leukocytes|Negative selection for CD3+/CD19+ cells will be performed on the CliniMACS® depletion device.
67904|NCT03653338|Biological|CD45RA depleted leukocytes|Negative selection for CD45RA will be performed on the CliniMACS® depletion device.
67905|NCT03653338|Drug|Hydroxyurea|Sickle Cell Disease Conditioning
67906|NCT03653338|Drug|Rituximab|Sickle Cell Disease Conditioning
67907|NCT03653338|Drug|Alemtuzumab|Sickle Cell Disease Conditioning
67908|NCT03653338|Drug|Fludarabine|Sickle Cell Disease Conditioning
67909|NCT03653338|Drug|Thiotepa|Sickle Cell Disease Conditioning
67910|NCT03653325|Device|ORI measurement|Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.
67911|NCT03653325|Device|oxygen saturation measurement|Oxygen (FiO2) will be titrated according to oxygen saturation
67912|NCT03653312|Device|NMES|Neuromuscular electrical stimulation of the paretic lower limb during exercise
67913|NCT03653299|Device|Placebo or Active Phototherapy (MR4)|Phototherapy, placebo or active, will applied in 9 different points of anterior muscle of the thigh, 6 different points of posterior muscle of the thigh and 2 different points of the gastrocnemius muscle, bilaterally. Once a week during for 4 weeks, before the tests, the phototherapy programs (1, 2, 3 and 4) order will depend of the group randomized. The 10 subjects will do the three-dimensional gait analysis, muscle activity during gait, evaluation of mobility, static and functional balance, and mobility tests.
67914|NCT03653286|Other|NMES and Run|"NMESIn this exercise protocol for quadriceps strengthening using NMES, the medium-frequency alternating current (1KHz with 10% of the work cycle) 4 will be used. The total daily training time is 900sec (15min), it is expected to perform 45 contractions per training, with three workouts per week for six weeks.~RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance."
67915|NCT03653286|Other|Only Run|RUN: It will be allowed to carry out training drills that comprise 15-40Km per week, being allowed a minimum of 2 and a maximum of 3 training sessions per week, not being able to carry out drills of explosion and during each training must be covered at least 5km and at most 15km. These limitations were based on the American College of Sports Medicine (ACSM) cardiorespiratory training guidelines to minimize confounders of cardiopulmonary performance.
67916|NCT03653273|Other|DMT withdrawal|Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
67917|NCT03653273|Drug|DMT continuation|Group 2 (DMT continuation) may undergo the DMT . The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
67918|NCT03653260|Drug|Lidocaine (Zingo)|0.5 mg lidocaine, 20 bar pressure
67919|NCT03653260|Drug|Placebo|Placebo injector, 20 Bar pressure, empty injector
67920|NCT03653247|Biological|Plerixafor|Plerixafor subcutaneous injection will be administered prior to apheresis.
67921|NCT03653247|Drug|Busulfan|Busulfan IV infusion will be administered as myeloablative conditioning therapy.
67922|NCT03653247|Genetic|BIVV003|BIVV003 will be administered as an IV infusion following myeloablative conditioning with busulfan.
67923|NCT03653234|Device|TV-based Assistive Integrated Service|"TV-AssistDem is an interactive platform which has been adapted specifically for people with MCI and mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal caregivers. The device consists of an Android software and hardware TV (a Digital TV STB with Android technology).~The core services of the platform are: 1) Calendar and reminders, 2) Health tracking and data transmission and 3) Videoconference; service-oriented applications are: 4) Cognitive stimulation (Stimulus© software); 5) Reminiscences; and 6) Patient and caregiver advice."
67924|NCT03653221|Other|Standard patients with VRNET|In group of standard patients with VRNET, the medical students examine the standard patient of neurologic deficits. When they examine, they get some information of neurologic signs via the VRNET which presents neurologic deficits directly by alternating facial expressions. The students should interpret that signs to have a diagnosis.
67925|NCT03653221|Other|standard patients|In group of standard patients, those neurological deficits are presented only by words or pictures which are not realistic.
67926|NCT03653208|Drug|hzVSF-v13|"Monoclonal Antibody IgG4~Product Formulation: 40 mg/mL hzVSF-v13 in 20 mM Histidine, 250 mM Sucrose, 0.02% Polysorbate 20, pH 5.8"
67927|NCT03653208|Drug|Placebo|Normal saline solution
67928|NCT03653195|Other|urine metabolomics|We aim to determine of a specific urine metabolomic biomarkers can diagnose concussion.
67929|NCT03653182|Diagnostic Test|Pulse, tongue image, and voice sound|They are four diagnosis methods of TCM
67930|NCT03653169|Device|Transcranial Magnetic Stimulation|TMS is a form of noninvasive brain stimulation. An external electromagnetic coil is placed on the head, and a large current is passed through an insulated wire coil held flat on the surface of a subject's scalp in a fraction of a millisecond. This pulse of current induces a weak electrical current within the surface brain cortex. Repetitive trains of TMS pulses (repetitive TMS or rTMS) can transiently modulate corticospinal excitability following the rTMS train. When current is delivered at high frequency (10 Hz), it may simultaneously increase the activity of the brain at this site.
67931|NCT03653143|Behavioral|JASPER|JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
67932|NCT03653130|Behavioral|Crossroads Orchestra Participatory Music Program|The intervention is a participatory music program where adults engage in music-making as members of a strings orchestra.
67933|NCT03653117|Device|Transperineal laser ablation|Minimal invasive coagulation of prostatic tissue by laser
67934|NCT03653104|Behavioral|Melodica Intervention|The melodica program will include education about pursed lip breathing, instruction in the melodica instrument, and participation in a melodica training group which meets twice-weekly for an 8-week period. Each session will include musical instruction, group music-making, and education about COPD and related health topics.
67935|NCT03653104|Behavioral|Pulmonary Health Education|A single session including education about COPD and related health topics.
67936|NCT03653091|Device|Duodenal Mucosal Resurfacing (DMR)|The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub‐mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
67937|NCT03653091|Device|Duodenal Mucosal Resurfacing Sham (Sham)|The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.
67938|NCT03653078|Device|Three dimensional printed digital guide|A CAD/CAM printed plate with a channel for mini-screw insertion
67939|NCT03653052|Drug|Durvalumab|Durvalumab will be administered via an infusion in the arm, over a duration of up to 1 hour.
67940|NCT03653039|Device|Tritube|The ultra thin tribute is used used for the ventilation of the patients in this arm
67941|NCT03653039|Device|Standard enditracheal tube|A standard endotracheal tube is used used for the ventilation of the patients in this arm
67942|NCT03653026|Drug|Upadacitinib (ABT-494)|Upadacitinib will be orally administered
67943|NCT03653026|Drug|Placebo|Placebo will be orally administered
67944|NCT03653013|Behavioral|Usual standard of care|Participants will receive treatment and diabetes management as usual standard of care from their diabetes care team. They will also complete as part of the study visit: a pediatric quality of life scale(PedsQL,GenericScale and Diabetes Module) and diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study.
67945|NCT03653013|Behavioral|Neuropsychological Consultation|Children and parents in Group 2 will also complete a pediatric quality of life scale (PedsQL,Generic Scale and Diabetes Module),diabetes related family conflict scale (DFCS-R) to assess quality of life and family stress at the start of the study, as well as the self-report form of the BRIEF-2 if they are over age 11. Parents will also undergo a brief literacy and numeracy screening using the Wide Range Achievement Test, complete a parent report assessing their children's executive functioning skills at the start of the study (BRIEF-2) and they will fill out the Family Impact Module.
67946|NCT03653000|Procedure|Ultrasound guided brachial plexus blockade|Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery
67947|NCT03652974|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
67948|NCT03652974|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
67949|NCT03652961|Drug|Abatacept|IV Abatacept
67950|NCT03652948|Behavioral|Meru Health Ascend Program|Cognitive-behavioral skills, mindfulness
67951|NCT03652935|Behavioral|Mindfulness Based Stress Reduction|
67952|NCT03652935|Other|Health Education Series|This is an active comparator condition that consists of 8 weekly classes related to health.
67953|NCT03652922|Drug|Reactivation Mismatch|"Ninety minutes prior to each of six weekly traumatic memory reactivation sessions, the subject will be given 0.67 mg/kg of short-acting propranolol (or placebo), rounded up to the nearest 10 mg (minimum 40 mg) and 1 mg/kg of oral long-acting propranolol or placebo (minimum 60 mg). rounded so as to achieve a dose of 60, 80, 120, or 160 mg. The subject will then read a narrative of their personal traumatic event aloud. During each weekly reading, a simple, different mismatch condition will be created by having the subject do such things as whisper the narrative, skip over every word that contains the letter e, pronounce the narrative in a different accent, or alter the tense and/or person of the narrative."
67954|NCT03652909|Device|Ascending Hearing Technologies device|Personal Sound Amplification Device
67955|NCT03652896|Procedure|anatomical liver resection|Liver resection is performed to achieve R0 resection for patients with appropriate BCLC staging, indocyanine green retention rate, Child-pugh grading and adequate liver remnant.
67956|NCT03652883|Other|ItFits-toolkit|The ItFits-toolkit provides evidence-informed methods, materials, knowledge on determinants and implementation strategies, and concrete guidance on tailoring implementation strategies to local determinants of practices, apply them and evaluate their impact. It applies a standardised four-step approach to iteratively develop evidence-informed implementation strategies. The ItFits-toolkit is based on the Normalisation Process Theory (NPT), which suggests that lasting changes in practice only happen through people working together. The ItFits toolkit functions as an online self-help toolkit with minimal support. The toolkit will provide instructions for the IL to establish a core team and to create a sounding board consisting to enable co-creation.
67957|NCT03652883|Other|Implementation as Usual|IAU refers to any existing efforts to embed and integrate iCBT within an organisation.
67958|NCT03652870|Drug|Nortriptyline|A medication used to treat conditions such as depression
67959|NCT03652870|Drug|Escitalopram|A medication used to treat conditions such as depression
67960|NCT03652870|Drug|Placebo|Lactose and magnesium stearate tablet to be used as a placebo.
67961|NCT03652857|Drug|Apatinib Combined With Vinorelbine|Vinorelbine 60mg/m2 d1qweek , Apatinib 500mg po Qd,evaluate every 2months
67962|NCT03652844|Procedure|AAM|Subcutaneous injection procedure
67963|NCT03652831|Other|Soft Tissue Mobilization with Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints~Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minute.~Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization.~Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 15minute. Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 50mints each session)"
67964|NCT03652831|Other|Soft Tissue Mobilization without Neural Mobilization|"Cervical Traction for 15mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints~Post isometric relaxation technique. The post-isometric relaxation technique begins by placing the muscle in a stretched position. Then an isometric contraction is exerted against minimal resistance. Relaxation and then gentle stretch follow as the muscle releases. Frequency for PIRs 3sets of 5 repetitions and duration of 10minutes Participant will be scheduled to attend 12 treatment session (3 sessions every week for 4 weeks, 35mints each session)"
67965|NCT03652818|Drug|Pre-Op pregabalin|Pre-op pregabalin will be administered 60 min prior to surgery.
67966|NCT03652818|Drug|Pre-Op Placebo 1|Placebo 1 will be administered 60 min prior to surgery.
67967|NCT03652818|Drug|Post-Op pregabalin|Post-op pregabalin will be administered Post-operatively.
67968|NCT03652818|Drug|Post-Op Placebo 1|Placebo 1 will be administered post-operatively.
67969|NCT03652818|Drug|Post-Op Placebo 2|Placebo 2 will be administered post-operatively.
67970|NCT03652818|Drug|Post-Op acetaminophen|Acetaminophen will be administered Post-operatively.
68001|NCT03652571|Drug|Nortriptyline|"Nortriptyline escalating dose regimen:~Week 1-2: 10mg Week 3-4: 25mg Week 5-12: 50mg"
68002|NCT03652571|Drug|Placebo|Placebo
68130|NCT03651557|Drug|Neu2000KWL High-dose group|1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
67971|NCT03652805|Drug|IPL344|"The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose."
67972|NCT03652792|Drug|Azilsartan (Zhaoke)|Azilsartan 20mg tablets from Zhaoke
67973|NCT03652792|Drug|Azilsartan (Takeda)|Azilva 20mg tablets from Takeda
67974|NCT03652779|Drug|Tecarfarin 10mg|Tecarfarin 10mg tablets
67975|NCT03652779|Drug|Tecarfarin 20mg|two tecarfarin 10mg tablets
67976|NCT03652779|Drug|Tecarfarin 30mg|three tecarfarin 10mg tablets
67977|NCT03652779|Drug|Tecarfarin 40mg|four tecarfarin 10mg tablets
67978|NCT03652766|Behavioral|Daily Weight Tracking|Daily weight tracking + weekly email or text message feedback
67979|NCT03652753|Drug|N-acetylcysteine|4 mL of a 20% solution of NAC will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
67980|NCT03652753|Drug|Saline|4 mL of a 20% solution of saline will be injected into the ankle of patients with pilon fractures at the time of their external fixator surgery
67981|NCT03652740|Drug|Effects of commonly used medications on mood and medication preference|"Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States."
67982|NCT03652727|Device|ECG-EM Guidance|"ECG-EM method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. The length of the PICC is estimated prior to its insertion using morphological landmarks. The placement of the PICC is done using SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) [CE marked device, C. R. Bard, Inc.].~At the end of procedure, a chest x-ray is performed to assess the PICC position"
67983|NCT03652727|Device|FX Guidance|"FX method consists on a puncture of an arm vein, under the ultrasound control and local anesthesia. Through the point of puncture, a long wire is then introduced and directed to the level of the target zone located in the superior vena cava under fluoroscopy control. The length of the guide inside the vessel is then measured to adjust the length of the PICC necessary for its optimal positioning.~At the end of procedure, a chest x-ray is performed to assess the PICC position"
67984|NCT03652714|Procedure|Ganglion sphenopalatine block with local anesthetic|Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.
67985|NCT03652714|Procedure|Ganglion sphenopalatine block with placebo|Block performed with bilaterally inserted q-tips with isotone NaCl
67986|NCT03652701|Other|Hair Up|Herbal topical
67987|NCT03652701|Other|Placebo|Placebo
67988|NCT03652688|Behavioral|Three 0's|A group approach to reducing unwanted outcomes was implemented prior to entering the nightclub. The focus was on peer-to-peer intervention.
67989|NCT03652688|Behavioral|Fire Safety|Groups were asked to read information about fire safety prior to entering the club and to answer some questions about fire safety
67990|NCT03652675|Behavioral|Intervention: (Clinician's Guide + HealthCall for HIV/HCV)|This intervention consists of an adaptation of the National Institutes of Health (NIH) Clinician's Guide (CG; NIAAA, 2007) in conjunction with the previously tested HealthCall smartphone app program (Hasin et al., 2013; Hasin et al., 2014). Participants will complete a brief baseline meeting (~20 minutes) with a counselor to discuss alcohol use, liver function, and HIV medication adherence. They will track their drinking using HealthCall for 60 days, with brief follow-up meetings with their counselor to check in about their drinking 30 and 60 days later.
67991|NCT03652662|Device|RESP-FIT|Inspiratory and Expiratory muscle strength training 5 times a week, plus Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
67992|NCT03652662|Behavioral|RESP-FIT Comparator|Fitbit activity monitoring (Daily) Daily symptom and training log entered into mobile application (SAMS)
67993|NCT03652649|Other|3:1 ratio Ketogenic diet|Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period
67994|NCT03652636|Other|Ultrasound of liver|From the MRI schedule at the performance site, a radiology investigator will prospectively identify patients who are to undergo abdominal MRI with hepatobiliary contrast and who otherwise meet entry criteria. Exclusion criteria will be evaluated by consulting the medical record. At the time of MRI scanning, an investigator will meet with the potential subject, confirm that exclusion criteria are not met, explain the study, answer any questions, and seek written informed consent. If consent is granted, CEUS of the liver will be scheduled on the same day or near the same day.
67995|NCT03652623|Drug|TDF/FTC|In Phase 1, a PK study will be conducted to evaluate the differential PK of TDF/FTC in a cohort of transgender youth on cs-HT by conducting a PK trial of daily TDF/FTC among transgender women taking estradiol and transgender men taking testosterone (ages 15-24 years) using video-based directly observed therapy (DOT) to insure daily TDF/FTC adherence and maximize drug exposure.
67996|NCT03652610|Biological|MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
67997|NCT03652610|Biological|Licensed GSK MenACWY vaccine (Menveo)|Single dose administered at Day 1, by intramuscular injection in the deltoid of the non-dominant arm
67998|NCT03652597|Device|Transcranial magnetic stimulation (TMS)|Subjects receive TMS on several cortical brain locations, while recording the heart rate.
67999|NCT03652584|Other|High Protein Diet|
68000|NCT03652584|Other|Control Diet|
68003|NCT03652558|Device|Ozone application with the Ozonytron XL device|An ozone generator (Ozonytron; Bionix, Munchen, Germany) with an KPX probe (CA Probe; Ozonytron, Bionix, Munchen, Germany) was used for OT. Topical gaseous ozone was applied into the periodontal pocket twice a week for 2 weeks based on the manufacturer's instructions. Ozone applications were at 75% power for 30 seconds (75 µg/ml). Ozone applications were performed by an experienced investigator. Ozone applications in the control side were simulated without starting the ozone generator
68004|NCT03652545|Biological|TAA-T|Patients with newly diagnosed diffuse intrinsic pontine gliomas DIPGs (Group A) or recurrent, progressive, or refractory non-brainstem CNS malignancies (Group B). The goal of this cell infusion will be to initiate an immune response against brain tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen)
68005|NCT03652532|Behavioral|Alternate Day Fasting|"During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week."
68006|NCT03652532|Behavioral|Exercise|During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
68007|NCT03652519|Behavioral|Exercise Training|Treatment in both arms consists of specific of aerobic exercise training modalities. Exercise has become an efficient strategy within rehabilitative programs and is part of a goal-orientated multidisciplinary approach to improve disability and participation in persons with MS. Recently, short and exhaustive bouts of exercise have gained much attention as a promising option in supportive care in MS.
68008|NCT03652506|Device|regional oxymetry probe|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
68009|NCT03652506|Procedure|Quadratus Lumborum block|Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
68010|NCT03652506|Procedure|Thoracic Epidural block|Thoracic Epidural block with 20 ml %0.25 bupivacaine+The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
68011|NCT03652493|Drug|Carboplatin|Tumoral evaluation every 3 cycles
68012|NCT03652480|Drug|MethylPREDNISolone Acetate 40 MG/ML|
68013|NCT03652467|Drug|Conventional TACE|Conventional chemoembolization drugs are injected through hepatic artery.
68014|NCT03652467|Drug|Deferoxamine and conventional TACE|Deferoxamine is injected before conventional transarterial chemoembolization.
68015|NCT03652454|Device|micro-osteoperforation|Propel device (ABD) using for regional acceleratory phenomenon
68016|NCT03652454|Other|conventional fixed appliance treatment|conventional fixed appliance treatment
68017|NCT03652441|Drug|Brentuximab Vedotin|BV will be administered i.v. at 1.8mg/kg at 3-weekly intervals for up to 16 infusions
68018|NCT03652428|Drug|Gemcitabine|see arm description
68019|NCT03652428|Radiation|Hypofractionated Ablative Proton Therapy|see arm description
68020|NCT03652415|Device|Artificial tears (classified by MHRA as a medical device)|Use of artificial tears
68021|NCT03652402|Procedure|kidney transplantation|samples additional to the standard of care' (SOC)will be taken at each visit (Day 0, Month 3, Month12, clinical indication)
68022|NCT03652389|Behavioral|MJS Diabetes|patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
68023|NCT03652389|Behavioral|Usual Care|Standard Diabetes Treatment
68024|NCT03652376|Drug|Benralizumab|Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
68025|NCT03652363|Drug|glial cell line-derived neurotrophic factor|Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administered via Convection Enhanced Delivery
68026|NCT03652350|Procedure|CT-guided microwave ablation|Using thermal ablation electrode ECO-100AL6 probe target the GGN zone with the guidance performed by CT (Bright Speed Scanner )
68027|NCT03652337|Device|BlephEx|Electronic lid margin debridement
68028|NCT03652337|Device|Manual debridement|Manual lid margin debridement
68029|NCT03652324|Other|method|to compare the use of general anesthesia and deep sedation
68030|NCT03652311|Device|ThermoNeuroModulation TNM Device|Study participants will undergo 10 sessions 15 minutes each of Caloric Vestibular Stimulation across 5 days with the FDA approved CVS device. This will be administered in home by study coordinators. Participants will be asked to fill out ODAS, GAD-7, and PHQ-9 on each of the five days during treatment; there is the possibility that other drug specific surveys will be used. Participants will receive two approximately 1 hour MRI scans at the beginning and at the end of the study period.
68031|NCT03652298|Other|Memory structuring intervention + Vagal breathing|"The MSI component will teach participants to chronologically organize the segments of their memory of the incurable diagnosis, to verbally label feelings or somatic sensations they had at that moment, and to provide causal links between the event's segments and causality to their feelings and sensations, following the protocol of Gidron et al. (2001).~In the MSI part, the patient will talk, and the therapist will note the different event parts and their real timing. Each time the patient says a feeling or sensation, the therapist will ask to verbally elaborate and provide the cause of these feelings and sensations. Then, the therapist will retell the story in a chronological manner, with verbal titles and causes for feelings and sensations. Finally, the patient will be asked to retell the story in this structured manner, after being explained how to do so.~vagal breathing (i.e., deep, paced breathing) is a way to increase HRV, and thus parasympathetic activation"
68032|NCT03652298|Other|support and attention (usual care)|support and attention (usual care)
68203|NCT03651011|Drug|Aflibercept Injection [Eylea]|Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
68033|NCT03652285|Device|Esophageal stent implantation|"An upper endoscopy will be performed with the use of fluoroscopy. Depending on the size of the stricture a dilation can be performed prior to the stent deployment. Otherwise, the stent will be deployed over a guidewire, under fluoroscopy.~After, the gastroscopy will go through the esophagus to check for the stent deployment, or any complications.~An injection of contrast agent will be done to be sure of the correct positioning and that no complications was happened.~The patient will be kept overnight, with liquid food for 3 days and under PPI until one month after the stent placement."
68034|NCT03652285|Device|Stent removal|Six months after implantation, the removal of the stent will be performed. Patient will undergo a first endoscopy under general anesthesia for the placement of a FCSEMS. Then, depending on the importance of the hyperplasia, removal of both stents, under general anesthesia, will be done after 7 to 10 days.
68035|NCT03652272|Behavioral|EMC2|"Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks~Patients will receive a Medication Guide + Summary with their After Visit Summary~Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)~Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols."
68036|NCT03652259|Drug|SRP-9003|Subjects with diagnosis of LGMD2E will receive SRP-9003 administered through a single systemic injection
68037|NCT03652233|Drug|Nivolumab|Given by vein every 14 days for up to 12 months
68038|NCT03652233|Drug|Afatinib|Taken by mouth daily for up to 12 months
68039|NCT03652220|Behavioral|Meditation Based Lifestyle Modification|8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation
68040|NCT03652220|Other|Minimal treatment|Drug continuation under medical supervision
68041|NCT03652220|Other|Multimodal specific treatment:|Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
68042|NCT03652207|Other|isomaltulose (Palatinose(TM)|isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
68043|NCT03652207|Other|Sucrose|sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
68044|NCT03652194|Other|in vitro evaluation of epithelial immune response during C. glabrata infection|"study of the expression of genes coding for different proteins involved in the RTqPCR activation cascade~study of protein expression by the Western-Blot method"
68045|NCT03652194|Other|study of the impact of resistance phenotype acquisition on the virulence of C. glabrata isolates|"in vitro evaluation by measuring cell invasion, cell adhesion and by determining epithelial cell cytotoxicity.~in vivo evaluation measured by a survival study on a CD-1 mouse model."
68046|NCT03652168|Behavioral|Meditation|10 minute a day, 8 week digital meditation
68047|NCT03652155|Procedure|Orthognathic surgery|Patient's pre and post operative hard and soft tissues will be evaluated retrospectively through the use of con-beam computed tomography imaging for hard tissue evaluation and 3DMd three dimensional photography for soft tissue imaging.
68048|NCT03652142|Other|Biomarker Research|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks. Patient samples will be collected with appropriate written informed consent and analyzed.
68049|NCT03652142|Drug|Nivolumab|The investigators will include recurrent/metastatic HNSCC patients who progressed after cisplatin-based chemotherapy and are to be treated with nivolumab 240mg IV q 2 weeks.
68050|NCT03652129|Procedure|Disinfection|Disinfection maneuver using LASER and nano irrigant
68051|NCT03652116|Drug|Wound infiltration by Bupivacaine|Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
68052|NCT03652116|Drug|Wound infiltration by Pethidine|Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
68053|NCT03652103|Procedure|Ultrasound Guided Erector Spinae Plane Block Catheterisation|After receiving general anesthesia, patients will positioned prone. Before operation begins, ESP block catheter will be applied with ultrasound guidance to the same level as surgeon's incision.
68054|NCT03652103|Drug|Bupivacaine 0.25% Injectable Solution|Perineural Injection
68055|NCT03652090|Procedure|cell sampling|nasal brushing to collect cells
68056|NCT03652077|Drug|INCAGN02390|Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation in 7 total cohorts to determine the maximum tolerated dose or PAD.
68057|NCT03652064|Drug|Daratumumab|Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.
68058|NCT03652064|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.
68059|NCT03652064|Drug|Lenalidomide|Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.
68060|NCT03652064|Drug|Dexamethasone|Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
68061|NCT03652051|Drug|AZR-MD-001 Low Dose|AZR-MD-001 is an ophthalmic ointment
68062|NCT03652051|Drug|AZR-MD-001 Mid Dose|AZR-MD-001 is an ophthalmic ointment
68063|NCT03652051|Drug|AZR-MD-001 High Dose|AZR-MD-001 is an ophthalmic ointment
68064|NCT03652051|Drug|AZR-MD-001 Vehicle|AZR-MD-001 is a vehicle ophthalmic ointment
68065|NCT03652038|Drug|TD-8236|Study drug to be administered via inhaler device
68066|NCT03652038|Drug|Placebo|Placebo to be administered via inhaler device
68067|NCT03652025|Procedure|embolotherapy of incompetent gonadal and iliac veins|minimally invasive
68204|NCT03651011|Procedure|Navigated laser photocoagulation|Navigated laser photocoagulation planned from flourscein angiography.
68068|NCT03652012|Device|Transcranial Magnetic Stimulation (TMS)|TMS in a non-invasive brain stimulation technique. In this study, we will use TMS to excite brain tissue in the motor cortex and measure the subsequent motor response in the hand. This 'intervention' will be the same in both cohorts, as we are interested in how this motor response to TMS may vary across two distinct cohorts.
68069|NCT03651999|Other|"participation in a workshop: dream workshop animated by a nurse anesthesist"|After consultation with the pediatric surgeon or the anesthesiologist, parents and children are invited to meet the nurse, in a room dedicated to this purpose and specially designed to accommodate children; they will find a playmobil model, photographs of the patient circuit as well as different games or activities that can be performed during induction; the nurse anesthetist will take care to explain to them the progress of the hospitalization and help them to choose a pleasant dream, a perfume adapted to their taste, a distraction adapted to their age (animated book, soap bubbles, favorite song ...) ; he can customize his mask and choose the blanket he wants to take; the most recalcitrant or special sites (autism, long-term hospitalization) will be able to be accompanied by a parent during sleep
68070|NCT03651986|Diagnostic Test|ctDNA methylation analysis by NGS|A blood-based assay for differentiating benign and malignant pulmonary nodules early using circulating tumor DNA (ctDNA) methylation analysis by next-generation sequencing (NGS)
68071|NCT03651973|Other|Standard follow-up|Patients enrolled into standard group will be followed in a standard way without any additional procedure except randomization that allocates to the standard group
68072|NCT03651973|Other|Learning workshops|Patients enrolled into experimental arm will participate to educative workshops before and after surgery for breast cancer. The aim of these workshop is to educate patient to self massages and self stretching.
68073|NCT03651960|Other|ROBOT PROTOTYPE|The intervention consists of 12 45-minute sessions of balance and gait training with a mobile and interactive robot prototype for 4 weeks.
68074|NCT03651947|Drug|QL1206|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
68075|NCT03651947|Drug|Xgeva®|subcutaneous injection of 120 mg (1.7 ml)only once,on the first day.
68076|NCT03651934|Dietary Supplement|Normal iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
68077|NCT03651934|Dietary Supplement|Weak iron|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (iron 20mg/d), and the middle stage of pregnancy (iron 24mg/d). The second stage lasts for 4 weeks. For subjects in iron deficiency, the maximum tolerable amount (iron 42mg/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
68078|NCT03651934|Dietary Supplement|Normal selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
68079|NCT03651934|Dietary Supplement|Weak selenium|The intervention was divided into two stages, the first stage lasted for 4 weeks, and the dosage used was the dietary nutrient recommendation amount, namely the dietary recommendation amount standard for early pregnancy (selenium 60ug/d), and the middle stage of pregnancy (selenium 65ug/d). The second stage lasts for 4 weeks. For subjects in selenium deficiency, the maximum tolerable amount (selenium 400ug/d) is used for intervention. For those with good nutritional status, the dietary recommendation amount is maintained.
68080|NCT03651921|Behavioral|CTS-BC-CH|"CTS-BC-CH is a standardized program with 7 weekly group sessions (2.5. to 3 hours). The CTS-BC-CH focuses on building skills, sharing experiences, and support among the participants.~Program elements are: Brainstorming, action plan formulation, action plan feedback, problem solving, and decision making."
68081|NCT03651908|Procedure|Conventional Flap Surgery|"After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back.~After administering local anaesthetic a full thickness flap will be raised and reflected to expose the intrabony defects.The intrabony defects would then the debrided and grafts secured in position.Later the flap would be sutured back."
68082|NCT03651895|Drug|Metformin|Drug
68083|NCT03651895|Drug|Placebo|Placebo
68084|NCT03651882|Drug|Oxytocin|Oxytocin given in a combined regimen: after delivery 10 IE of oxytocin are applied intramyometrially and 10 IE of oxytocin are given over an infusion of 1000ml of 0.9% NaCL over 12 hours intravenously.
68085|NCT03651882|Drug|Carbetocin|Carbetocin is given 0.1mg intravenously as a bolus after delivery.
68086|NCT03651869|Drug|Cigarette 1|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
68087|NCT03651869|Drug|Cigarette 2|Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)
68088|NCT03651869|Drug|Patch 1|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
68089|NCT03651869|Drug|Patch 2|A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
68090|NCT03651856|Drug|ATM FOG in PD|open label pilot study on atomoxetine 40mg BID on patients with Parkinson's disease and Freezing of Gait
68091|NCT03651843|Other|Questionnaire|Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
68092|NCT03651830|Device|Prosthetic Foot Emulator|Participants will walk in the laboratory with the Prosthetic Foot Emulator (PFE) in three foot modes corresponding to actual study feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.
68205|NCT03650998|Drug|Ropivacaine|See arm description
68206|NCT03650998|Drug|Saline|See arm description
68093|NCT03651830|Device|Commercially available prosthetic feet|"Participants will walk in the laboratory with three different commercially available prosthetic feet. Walking conditions will include self-selected speed, slow speed, fast speed, incline, and up stairs.~Additionally, participants will be fit with one of the actual feet and wear it at home and in the community for approximately two weeks. This will be followed by two-week periods in the community with each of the other two commercially available prosthetic feet."
68094|NCT03651817|Device|Mechanical ventilation|Patients will be ventilated with anesthesia machine according to the group they belong to
68095|NCT03651804|Procedure|Radiofrequency ablation of the medial branch nerves|A radiofrequency ablation (RFA) is a procedure in which a heat lesion via a needle is created on the nerve that transmits the pain signal in order to interrupt the brain to interrupt the painful signal to the brain. We will target the medial branch nerves.
68096|NCT03651804|Drug|Non-steroidal anti-inflammatory drugs|Some of the most commonly used pain medicines in adults. NSAIDs block proteins, called enzymes, in the body that play a role in pain and inflammation. They include aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), and many other generic and brand name drugs.
68097|NCT03651804|Drug|Bisphosphonates|A class of drugs that prevent the loss of bone density and are used to treat osteoporosis and similar diseases.
68098|NCT03651804|Drug|Acetaminophen|A medicine used to treat pain and fever. It is typically used for mild to moderate pain relief. Commonly known as Tylenol.
68099|NCT03651804|Behavioral|Physical therapy|Physical Therapy.
68100|NCT03651804|Drug|Opioids|Opioids are narcotics that act on opioid receptors to produce morphine-like effects and medically they are primarily used for pain relief.
68101|NCT03651791|Combination Product|USPIO labeled MSC injection|USPIO labeled MSC injection
68102|NCT03651765|Drug|Setmelanotide|Once daily subcutaneous injection
68103|NCT03651752|Drug|Diphenylcyclopropenone (DPCP) Ointment|All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
68104|NCT03651739|Device|Knee Connect|An electronic goniometer with smart phone application
68105|NCT03651726|Drug|THX-110 (dronabinol plus PEA)|2.5 mg dronabinol capsules and 400 mg PEA tablets
68106|NCT03651726|Drug|Placebo|Sesame oil pill manufactured to mimic 2.5 mg dronabinol capsules; cellulose pill manufactured to mimic 400 mg PEA tablets
68107|NCT03651713|Behavioral|GLU+EX|Subjects will complete 45 minutes of recumbent cycling at 60-65% of age-predicted maximal heart rate five times over seven days while ingesting a 75g glucose beverage three times daily.
68108|NCT03651713|Dietary Supplement|GLU|Subjects will consume a 75g glucose beverage three times daily over a seven-day period.
68109|NCT03651700|Device|Active TMS|Active TMS will be at 90% motor threshold
68110|NCT03651700|Device|Sham TMS|Sham TMS will be administered
68111|NCT03651700|Behavioral|CILT|60-90 minutes of CILT will be administered during each treatment session
68112|NCT03651674|Device|ECT treatment|Patients had bilateral temporal modified ECT four times a week for 3 consecutive weeks
68113|NCT03651674|Drug|Drug treatment|Patients only have antipsychotic drugs
68114|NCT03651661|Drug|human insulin|human insulin administered as nasal spray
68115|NCT03651661|Drug|placebo|placebo administered as nasal spray
68116|NCT03651661|Diagnostic Test|Pupillography|Autonomic tone will be adressed by pupillography using the F2D2 (Amtech Germany) device.
68117|NCT03651648|Device|SENSITACT System|the activated stimulation (ON period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
68118|NCT03651648|Device|SENSITACT System|the desactivated stimulation (OFF period of 6 hours) will be hidden from the care team, who will continue the care according to the usual procedures (blind treatment).
68119|NCT03651635|Diagnostic Test|Blood sampling for MR-proADM & CT-proET-1|Collection of at most 8 blood samples (3ml each) per Patient admitted to the study and sampling for MR-proADM & CT-proET-1
68120|NCT03651622|Behavioral|Hypocaloric, low carbohydrate diet|Participants will be advised on use of a hypocaloric, low carbohydrate diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
68121|NCT03651622|Behavioral|Hypocaloric, moderate low fat diet|Participants will be advised on use of a hypocaloric, moderate low fat diet using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
68122|NCT03651622|Behavioral|Mediterranean diet, no caloric restriction|Participants will be advised on use of a healthy Mediterranean-based eating plan using lifestyle counseling to include motivational interviewing and problem solving skills training strategies.
68123|NCT03651609|Procedure|Simple decompression of the ulnar nerve|Surgical HUA release 2-3 cm distal to medial epicondyle with minimal-incision technique .
68124|NCT03651609|Behavioral|Conservative treatment|Patients will be given pictured recommendations with descriptions, which limb positions should be avoided.
68125|NCT03651596|Behavioral|mHealth Messaging Intervention Group|The newly developed intervention messages will be sent to individuals assigned to the intervention group during the study.
68126|NCT03651596|Behavioral|Standard mHealth Messaging Group|Standard mHealth messages will be sent to individuals assigned to the active control group during the study.
68127|NCT03651583|Behavioral|Kiko exercises-combines breathing and movement|
68128|NCT03651570|Device|PTSD Coach|PTSD Coach is a mobile mental health app that addresses the issue of mental health and stigma which can be used as a stand-alone education and symptom management and contains 4 modules: 1) Learn- Module, 2) Self- Assessment-Module, 3) Manage Symptoms-Module and 4) Find Support-Module.
68129|NCT03651570|Behavioral|Game application|This control condition is important to control for distraction (attention on something pleasant or a task) and the human factor involved in usage prompting (i.e., same exposure time + contacts with personnel), since either distraction or the human contact with staff may, alone, lower anxiety
117437|NCT03268460|Diagnostic Test|Arterial blood gases|blood PH, HCO3
68131|NCT03651557|Drug|Neu2000KWL Low-dose group|1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)
68132|NCT03651557|Drug|Placebo|1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
68133|NCT03651544|Biological|GamFluVac|1 dose (0,5 ml)
68134|NCT03651531|Drug|Insulin|Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.
68135|NCT03651531|Drug|Metformin|Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
68136|NCT03651518|Drug|Kineret|100 mg, once/day sc 6 months
68137|NCT03651518|Drug|Humira|40 mg/15 days sc 6 months
68138|NCT03651518|Drug|Stelara|45 mg/12 weeks sc, 6 months
68139|NCT03651518|Drug|Cosentyx|300mg sc every week for 1 month, then 300 mg/month sc for 5 months
68140|NCT03651518|Drug|Roactemra|480 mg/perf/4 weeks 6 months
68141|NCT03651518|Drug|Rituximab|2 sessions of 1000 mg at inclusion and 15 days after inclusion
68142|NCT03651505|Other|No intervention|Access to any treatment is through authorized commercial use and not as a part of this DMP
68143|NCT03651492|Behavioral|questionnaire administration|All the patients will be administered the Pittsburgh Questionnaire after completion of ABPM.
68144|NCT03651479|Other|real boxing training|In the real boxing (RB) group in addition to the NDT program, real boxing training will be given. Accordingly, the physiotherapist and the patient will wear boxing gloves and the patients will punch the physiotherapist's glove with a pre-specified treatment protocol. Resistance and frequencies between levels will be increased by the physiotherapist as the sessions progress. The RB group will have 30 minutes of real boxing training for 3 sessions per week for 8 weeks.
68145|NCT03651479|Other|virtual boxing training|In the virtual boxing (VB) group, in addition to the NDT program, virtual boxing training will be given by using Kinect Xbox Boxing. For the VB group, virtual boxing training will be held for 3 weeks 30 minutes a week for 8 weeks.
68146|NCT03651466|Drug|Gx-G6|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
68147|NCT03651466|Drug|Placebo|Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
68148|NCT03651453|Behavioral|Decision aid|Participants in the experimental arm will receive the PrEP decision aid.
68149|NCT03651453|Behavioral|Standard care|Standard harm reduction information
68150|NCT03651440|Other|PNF|PNF
68151|NCT03651440|Other|lumbar stabilization training|lumbar stabilization training
68152|NCT03651440|Other|Physical Therapy|Physical Therapy
68153|NCT03651440|Other|Control|Control group
68154|NCT03651427|Drug|Estradiol|Induced hypogonadism and re-institution of CSHT
68155|NCT03651414|Other|Clinical data collection|There will not be any experimental intervention. The study will be conducted according with normal clinical practice.
68156|NCT03651401|Other|Scapular muscle endurance test, pain, Range of Motion, Strength, Upper Limp Functional Performance, outcome scores|
68157|NCT03651375|Drug|Sequential chemotherapy - 3 courses of AI|Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
68158|NCT03651375|Radiation|Hypofractionated radiotherapy|Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with a daily image guidance with cone beam-CT-based position verification.
68159|NCT03651349|Drug|HK-001|HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.
68160|NCT03651349|Drug|Placebo control|In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.
68161|NCT03651336|Device|ARGOS-IO Sensor Pressure System|The ARGOS-IO Pressure sensor have been additionally implanted during local routine working procedures for cataract surgery in Patients with Primary Open Angle Glaucoma (POAG) and indicated cataract surgery in previous studies ARGOS-01 and ARGOS-02
68162|NCT03651323|Device|Left atrial appendage closure with Watchman device|Percutaneous left atrial appendage closure using Watchman device
68163|NCT03651310|Other|Music Listening Group|Waiting in preoperative area with music listening.
68164|NCT03651297|Other|Balance training with Fall-Arrest harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a standard Fall-Arrest harness for safety throughout, but no other external support. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
68165|NCT03651297|Other|Balance training with Adjustable harness|This study will analyze the subjects' responses to balance training protocols with two types of harness support. The protocol will involve balance training, initially of low intensity and then advanced by an algorithm based on subjects' responses to the prior repetition of balance activity. For this intervention, the subjects will be using a motorized harness in which the support provided is adjustable. This will allow comparison of postural control, slip responses, motor learning, reliance on the harness and confidence with the system between the two harness types.
68207|NCT03650985|Procedure|Fetoscope technique|Intrauterine intervention with fetoscope technique will be applied to treat complex twin diseases with intention to improve the prognosis of patients.
68315|NCT03650036|Drug|Pulp Therapy ZOE Paste|The zinc oxide of the ZOE paste will be supplied in 250mg capsules and handled with 0.1ml eugenol in a sterile glass plate with metal spatula at the time of use.
68166|NCT03651284|Behavioral|Aim2Be app with Live Coach + Fitbit + BMI tracking tools|Participants will spend six months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. They will also complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Live Coach and the Virtual Coach. The Live Coach has specialized training in lifestyle and motivational interviewing and will support families in changing their health behaviours through in-app messaging and phone calls. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
68167|NCT03651284|Behavioral|Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools|Participants in this condition will be waitlisted for three months while they receive standard of care (Canadian Health Recommendations for physical activity, dietary habits, screen behaviours, and sleep). Participants will gain access to the Aim2Be app with Virtual Coach after the three month assessment. Participants will then spend three months using the Aim2Be app setting aims, completing tasks, accessing articles, doing self-assessments, and participating in the social wall. For the whole six months, participants will complete a series of questionnaires, dietary recalls, BMI tracking using scales and tape measures, and physical activity tracking using Fitbits. Participants in this condition will have access to the Virtual Coach only. The Virtual Coach gives guidance to families through an avatar that has been programmed using motivational interviewing theory.
68168|NCT03651271|Biological|Nivolumab|Single-agent nivolumab will be administered at 360 mg IV Q3W. Participants who continue to show clinical benefit after the first disease assessment will receive nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
68169|NCT03651271|Biological|Ipilimumab|For nivolumab and ipilimumab combination therapy, nivolumab will be administered at 360 mg IV Q3W, and ipilimumab will be administered at 1 mg/kg IV Q3W for the first 2 doses and then Q6W for the 3rd and 4th doses, followed by single-agent nivolumab 480 mg IV Q4W until PD or intolerable toxicity.
68170|NCT03651258|Behavioral|Implementation of ALIJEU|"The intervention concerns the passage from the passive feed (gastric tube) to the active feed (breast, feeding bottle).~We propose to set up a pleasant moment just before his meal. This is a practical exercise of a few minutes.~The aim of this special moment is to facilitate child-adult exchanges, improve active food intake and reduce the length of hospital stay."
68171|NCT03651232|Behavioral|yoga|once weekly group yoga class for 12 weeks
68172|NCT03651232|Behavioral|support group|once weekly group support class for 12 weeks
68173|NCT03651219|Drug|Apatinib|Apatinib Mmesylate tablets 250mg/d, po, there's totally 4-6 cycles(21days per cycle)
68174|NCT03651219|Drug|Irinotecan|Irinotecan 80mg/m2 d1, d8, vi, there's totally 4-6 cycles(21days per cycle)
68175|NCT03651206|Drug|Niraparib|PARP Inhibitor
68176|NCT03651206|Combination Product|Niraparib + TSR-042 (Dostarlimab)|Combination of 2 drugs, a PARP Inhibitor and an Anti-PD-1
68177|NCT03651206|Drug|Chemotherapy Drugs|Chemotherapies given in standard of care
68178|NCT03651193|Diagnostic Test|Exon sequencing and Methylated sequencing|Exon sequencing and Methylated sequencing
68179|NCT03651167|Other|Survey|Participants will complete a survey online
68180|NCT03651154|Procedure|Hypovolemic Phlebotomy|Removal of 7-10ml/kg of blood from participant, as tolerated after patient is under anesthesia, before liver resection start time
68181|NCT03651141|Other|Neurodynamic Sliding|Subjects in the neurodynamic sliding group perform 2 movements; 1) movement 1 involves sitting on the edge of the treatment table the bringing their neck to their chest along with bending their knee and pointing their ankle to the ground. Movement 2 is performed by facing their head towards the ceiling and straightening their knee while pointing their ankle towards their nose. Subjects will alternate these 2 active movements for 60s and repeated 5 times, with rest period of 15s between sets. A metronome will be set at 30 beats per minute for 15 full slides per minute to standardize the amount of slides per session.
68182|NCT03651141|Other|Myofascial Decompression|For the group receiving the cupping treatment, the subject will lay on their stomach and their affected hamstring will be exposed. Cocoa butter will be applied to the hamstring prior to the application of the cups. 5 cups will be placed along the hamstring and calf muscles. Using a handheld suction pump, each cup will be pumped so that skin fills up half of the cup. The cups will stay in place for five minutes and the clinician will instruct the subject to perform 5 repetitions of active quad sets and 5 repetitions of ankle pumps .
68183|NCT03651141|Other|Diathermy|The control group will receive a sham heat (diathermy treatment). The subjects will be asked to sit and relax for five minutes and the machine will not be turned on with a timer timing the treatment.
68184|NCT03651128|Biological|bb2121|bb2121
68185|NCT03651128|Drug|Daratumumab|Daratumumab
68186|NCT03651128|Drug|Pomalidomide|Pomalidomide
68187|NCT03651128|Drug|Dexamethasone|Dexamethasone
68188|NCT03651128|Drug|Bortezomib|Bortezomib
68189|NCT03651128|Drug|Ixazomib|Ixazomib
68190|NCT03651128|Drug|Lenalidomide|Lenalidomide
68191|NCT03651115|Diagnostic Test|therapeutic drug monitoring|To monitor the blood concentrations of gentamicin and vancomycin
68192|NCT03651102|Drug|Thalidomide Oral Product|Dosage: 1-2mg/kg/day
68193|NCT03651089|Drug|SP16|subcutaneous injection of experimental anti-inflammatory drug
68194|NCT03651089|Drug|Placebos|subcutaneous injection of sterile saline
68195|NCT03651076|Device|Traxi panniculus retraction (Clinical Innovations, LLC)|class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
68196|NCT03651063|Other|social robot|Reach To Grasp games with a social robot
68197|NCT03651063|Other|computer group|reach to grasp games with a computer screen
68198|NCT03651063|Other|self-training|reach to grasp games with no externa feedback.
68199|NCT03651050|Behavioral|Faith Based Outreach (FBO)|Faith base outreach groups will be trained in P-MHDT
68200|NCT03651050|Behavioral|community-health-workers (CHW)|COmmon health workers will be trained in P-MHDT
68201|NCT03651037|Behavioral|Thrivors+BH|Digital health platform for breast cancer patients that measures adherence and engagement.
68202|NCT03651024|Device|ED surgery|The surgical implant for ED treatment
68208|NCT03650972|Other|Samarin|Arm: Active Comparator: B, Bicarbonate group When labour arrest is diagnosed and the first AFL > 12 mmol/L the participants will be randomized to two groups. In group B the participant will drink bicarbonate (2 packages of Samarin®) dissolved in 200 ml of water. Then after one hour the AFL will be measured again and the stimulation with oxytocin will be started if there is no progress in the cervix.
68209|NCT03650959|Other|Method of learning simple interrupted sutures with instrument tie|Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
68210|NCT03650946|Diagnostic Test|Ga-68 PSMA PET|Ga-68 PSMA PET
68211|NCT03650933|Biological|G-CHOP|6 cycles(each cycle is 3 weeks)
68212|NCT03650933|Biological|R-CHOP|6 cycles(each cycle is 3 weeks)
68213|NCT03650920|Procedure|Liver Transplantation|A HCV negative or previously successfully treated recipient with a HCV positive liver graft
68214|NCT03650907|Behavioral|Group exercise program|"Patients in experimental group attend group exercise program, instructed by fitness trainer, at long-term care institutions.~Frequency: 3 times per week. Type: resistance/flexibility/balance training, including warm-up and cold-down. Duration: 1 hour per time, for 16 weeks."
68215|NCT03650907|Behavioral|Self exercise program|Patients in control group receive oral education for self exercise program, mainly resistance muscle training. Patients are requested to do self-training for 16 weeks.
68216|NCT03650894|Drug|Nivolumab|Nivolumab 240 mg IV every 2 weeks
68217|NCT03650894|Drug|Ipilimumab|Ipilimumab 1 mg/kg IV every 6 weeks.
68218|NCT03650894|Drug|Bicalutamide|Oral bicalutamide 150mg (3 x 50mg tablets) daily
68219|NCT03650881|Drug|Neutrogena ® Light Therapy Acne Mask (MASK)|Daily use of the OTC Neutrogena Light Therapy Acne Mask once daily for 10 minutes
68220|NCT03650881|Drug|Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene|Daily treatment with Reference Therapy OTC topical generic benzoyl peroxide 2.5% gel in the morning and OTC generic adapalene 0.1% gel at night
68221|NCT03650868|Procedure|Thoracal paravertebral block|Thoracal paravertebral block will be performed before the surgery to the TPVB group.
68222|NCT03650842|Device|Near infrared spectroscopy (NIRS)|One monitor will be placed on the forehead to measure cerebral oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation.
68223|NCT03650816|Other|Doppler ultrasonography|Blood flow measurement in in the internal and common carotid arteries during the 10th minute of inhalation of a gas mixture containing 5% CO2, 16% O2 and 79% N2, compared to the baseline blood flow value measured after 10 minutes rest in lying position.
68224|NCT03650816|Other|Biospecimen collection|Blood: ET-1, bigET-1, ADMA plasma concentration; plasma renin activity
68225|NCT03650803|Device|3D MR Fingerprinting scan|"3D MR Fingerprinting technique is a non-contrast technique and generates quantitative information about MR-visible tumors without having to administer contrast.~MR Fingerprinting software is used in conjunction with a standard-of-care MRI scan."
68226|NCT03650790|Diagnostic Test|Blood test|For serum analysis, approximately 2 cc antecubital vein venous blood serum will be taken from each patient to be studied for CTRP9 Level analysis. Adult blood will be centrifuged at 4000 rpm for 10 minutes to separate greenhouses. The obtained serum samples will be stored at -80 ° C until analysis.
68227|NCT03650777|Other|Warfarin Telehealth Education|Patients received education on warfarin through a video on an iPad, and were assessed on knowledge pre and post video, and at follow up visit
68228|NCT03650764|Drug|Ramucirumab|Ramucirumab is an investigational agent for this trial and will be supplied by Lilly Oncology, free of charge to the patient
68229|NCT03650764|Drug|Pembrolizumab|Pembrolizumab is commercially available
68230|NCT03650764|Other|EORTC QLQ-30|-Screening, start of cycle 2, start of cycle 5
68231|NCT03650764|Other|FACT H&N|-Screening, start of cycle 2, start of cycle 5
68232|NCT03650764|Procedure|Peripheral blood|-Baseline
68233|NCT03650751|Other|Nursing observation indexes|It provides nursing staff with a unified reference standard for nursing observation indicators and sets monitoring and warning values according to the score, which is helpful to improve the timeliness and accuracy of nursing observation for patients with cerebral apoplexy.
68234|NCT03650738|Drug|Apatinib|Neoadjuvant program: apatinib 250mg oral d1-21; albumin paclitaxel 260mg/m2 intravenous drip d1; carboplatin AUC=5-6 intravenous drip d1; 21 days for 1 cycle. The treatment regimen was used for a total of 6 cycles, or to PD, or the toxicity was not tolerated.
68235|NCT03650725|Other|Mandatory Split bowel preparation|Intervention describes the standard of care patient split bowel preparation instructions as mandatory, instead of giving patient instructions with option of choice between split or day before bowel prep.
68236|NCT03650712|Diagnostic Test|Oral glucose tolerance test|oral glucose solution is given by mouth, blood is drawn prior to the administration of the oral glucose beverage and then at timed intervals afterward. This is the standard test to diagnosis cystic fibrosis related diabetes mellitus. However, this study will have more time points than standard screening for cystic fibrosis related diabetes mellitus
68237|NCT03650712|Diagnostic Test|Continuous glucose monitoring|a device is placed on the subject's arm that continuously monitors subcutaneous glucose levels for up to 10 days
68238|NCT03650712|Diagnostic Test|Dexa scan|low dose x-rays are used to measure the subject's bone density. This is the standard test to diagnose osteoporosis
68239|NCT03650699|Device|Electropalatography Biofeedback Training|The study agent is electropalatography (EPG). The LinguaGraph EPG device is a biofeedback technology that creates a digital visualization of tongue function during speech. The visualization is accomplished by a custom made mouthpiece that fits over the hard palate with 62 sensors that capture tongue position. The information from the sensors in the mouthpiece, as well as the audio output, is processed in an EPG Unit that converts the information from mouthpiece to a visual representation on a computer screen. The visual information with respect to tongue position can be used to provide biofeedback training.The computer can be used in the clinic during a patient visit or it can be seen over the internet with the patient at home and the speech and language pathologist at the clinic.
68240|NCT03650686|Other|Food weighing (gold standard)|Method which consists in weighing precisely the main dish at the beginning and then end of meal using a SOEHNLE scale (+/- 1g).
68622|NCT03647488|Drug|spartalizumab|Concentrate for solution for infusion, intravenous use
68241|NCT03650686|Other|Automated photographic method (method to be evaluated)|The nursing staff will position the tray for automatic picture taking before and after the meal. Taking a photograph of the entire tray will allow the patient's identity to be identified by his meal card which will then be coded for analysis and the plate will be targeted at the time of the nutritional analysis by the software. This method will automatically provide the percentage of each main dish food consumed using an advanced image processing algorithm and an optimized artificial intelligence system that will recognize the food before and after consumption. Automatic processing and transfer will enable food intake to be collected.
68242|NCT03650686|Other|Semi-quantitative method (routine method)|Staff will indicate whether 1, ¾, ½, ¼ or 0 (corresponding to 100%, 75%, 50% 25% or 0) of the food in the main course has been consumed.
68243|NCT03650673|Diagnostic Test|Identification of subgroups of patients with early AD with risk of progression|Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
68244|NCT03650660|Other|Trans-thoracic ultrasound|Trans-thoracic ultrasound performed by an expert and a non-expert
68245|NCT03650647|Procedure|Carious dentin removal|Carious tissue removal and managing deep cavitated carious lesions in primary teeth.
68246|NCT03650621|Device|Magnetic acupuncture|5 magnetic acupuncture stickers will be placed on the infants ear
68247|NCT03650621|Device|stickers (magnets removed)|in this group 5 stickers (magnets removed) will be placed on the infants ear
68248|NCT03650608|Drug|Cohort 1: HL217 Ophathalmic Solution QD|Cohort 1 (Once a day)
68249|NCT03650608|Drug|Cohort 2: HL217 Ophathalmic Solution BID|Cohort 2 (Twice a day)
68250|NCT03650608|Drug|Cohort 3: HL217 Ophthalmic Solution QID|Cohort 3 (Four times a day)
68251|NCT03650608|Drug|Placebo Ophthalmic solution|Placebo
68252|NCT03650595|Device|"The TRANBERGCLS|Thermal Therapy"|"MRI Guided Focal Laser Ablation of Prostate Cancer by The Diode Laser System - The TRANBERGCLS|Thermal Therapy"
68253|NCT03650582|Drug|Glucagon|Intranasal glucagon
68254|NCT03650582|Drug|Placebo|Intranasal placebo
68255|NCT03650556|Device|TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™|Ablation procedure for Persistent AF
68256|NCT03650543|Drug|amoxicillin clarithromycin omeprazole 1|Patients in this received triple standard therapy for eradication of H.pylori with standard doses of proton pump inhibitor (omeprazole), in combination with amoxicillin and clarithromycin in absence of antibiotic resistance.
68257|NCT03650543|Drug|amoxicillin clarithromycin omeprazole 2|The treatment for patients in this group was prescribing triple standard therapy for H.pylori eradication with amoxicillin and clarithromycin in absence of antibiotic resistance but with different doses of proton pump inhibitor (omeprazole) according to CYP2C19 genotype in each patients.
68258|NCT03650530|Other|The Family Talk Intervention|The family meets two interventionists at six time points.
68259|NCT03650517|Procedure|Extracorporeal Anastomosis|Anastomosis is performed by pulling out the bowel through a laparotomy wherever that laparotomy is performed.
68260|NCT03650517|Procedure|Intracorporeal Anastomosis|Anastomosis is performed inside the abdominal cavity with a laparoscopic or robotic technique
68261|NCT03650517|Procedure|Robotic Surgery|Procedure is performed using robotic instruments
68262|NCT03650517|Procedure|Laparoscopic Surgery|Procedure is performed using standard laparoscopic instruments
68263|NCT03650504|Procedure|Above Artery Catheter Placement|Nerve catheter placed between superficial femoral artery and sartorial muscle
68264|NCT03650504|Procedure|Between Artery and Vein Placement|Nerve catheter placed between superficial femoral artery and femoral vein
68265|NCT03650491|Drug|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
68266|NCT03650478|Device|NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (1 hour). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
68267|NCT03650478|Device|NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)|Patients will be successively ventilated with conventional NIV (30 min with the conventional ventilator, 30 min with the NeuroBOX), and NeuroPAP (3 hours). An additional 20-hour period of recordings (with conventional NIV) will be conducted to characterize the neural breathing pattern, prevalence of apneas and tonic activation during conventional treatment. Finally, a second 1-hour period with NeuroPAP will be conducted
68268|NCT03650465|Behavioral|Cognitive-behavioral therapy (CBT)|Cognitive-behavioral therapy (CBT)
68269|NCT03650452|Drug|TAK-935|TAK-935 tablets or mini-tablets.
68270|NCT03650452|Drug|Placebo|TAK-935 placebo-matching tablets or mini-tablets.
68271|NCT03650439|Diagnostic Test|culture on Sabouraud's Dextrose Agar (SDA)|• Clinical samples will be cultured onto Sabouraud's Dextrose Agar (SDA) plates supplemented with chloramphenicol. the culture was incubated at 25 C° and at 37° C (for yeasts and moulds isolation )
68272|NCT03650426|Procedure|Total knee with onlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded on the patellar bone.The patellar implant is placed on top of a flat tibial osteotomy or cut-surfaced bone
68273|NCT03650426|Procedure|Total knee with inlay patellar resurfacing technique|The patellar resurfacing technique that the patellar implant is embedded in the patellar bone.The patellar implant is surrounded by a rim of cortical bone and supported by hardened, sclerotic bone
68275|NCT03650400|Drug|Fevipiprant|Chewable tablet
68276|NCT03650387|Device|RADIESSE® (+) Lidocaine|RADIESSE® (+) Lidocaine will be injected as per its current approved labelling and investigator's usual practice
68277|NCT03650374|Other|Standard of Care Rehabilitation|Knee flexion and extension strength training exercises for the contralateral (non-operative) lower extremity in addition to standard of care postoperative rehabilitation.
68314|NCT03650036|Drug|Pulp Therapy CTZ Paste|CTZ paste is composed of 62.5 mg of chloramphenicol, 62.5 mg of tetracycline and 125 mg of zinc oxide and manipulated with 0.1ml of eugenol in a sterile glass plate with flexible metal spatula at the time of use.
68278|NCT03650374|Other|Experimental Strength Training|Will be performed with moderate resistance and will require moderate effort. Exercises will include unilateral leg presses, lunges, step ups, and step downs. These exercises are performed as standard of care but are not typically introduced into the physical therapy regimen until 10-12 weeks postoperatively. In the experimental group, these exercises will be introduced starting with the first postoperative physical therapy session, but only for the contralateral (non-operative) leg.
68279|NCT03650361|Drug|Adapalene Gel 0.3%|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
68280|NCT03650361|Drug|Differin 0.3% Topical Gel|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
68281|NCT03650361|Drug|Adapalene Gel 0.3% Vehicle Placebo|Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
68282|NCT03650348|Drug|PRS-343 in Combination with Atezolizumab|HER2/4-1BB Bispecific
68283|NCT03650322|Behavioral|Yoga|12 weeks, total of 150 minutes of exercise per week.
68284|NCT03650322|Behavioral|Stretching and Toning|12 weeks, total of 150 minutes of exercise per week.
68285|NCT03650322|Behavioral|Aerobic Walking|12 weeks, total of 150 minutes of exercise per week.
68286|NCT03650309|Device|Deep Brain Stimulation|All patients will undergo surgical implantation of a deep brain stimulation (DBS) system, which involves placement of stimulating electrodes in the brain. These electrodes will be used to deliver electrical current to target two brain structures involved in the pathophysiology of obesity.
68287|NCT03650296|Device|ePER vs PS vs PaedER|see detailed description of methods
68288|NCT03650283|Other|monitoring|The bispectral index (BIS) and skin conductance (SC) monitors will be connected when patient will be positioned on the operating table. A BIS value greater than 60 will be considered an indicator of light anaesthesia. The SC monitoring will be achieved using the MEDSTORM AS 2005 monitor. Number of fluctuations in mean skin conductance (NFSC) of >0.1 s-1 in a period of 15 s might be counted as a significant change and indicates an increase in the sympathetic outflow. General anaesthesia will be performed and laryngeal mask will be inserted. Blood pressure, heart rate, BIS, SC, and PRST (pressure, rate, sweating, tears) score will be recorded.
68289|NCT03650270|Drug|Phenobarbital|Three repeated doses of pareneteral phenobarbital was compared to a single parenteral infusion of phenytoin followed by an infusion of parenteral midazolam
68290|NCT03650257|Biological|gp96|25 mcg IH
68291|NCT03650257|Drug|Temozolomide|temozolomide monotherapy (150-200 mg / m2 / day for 5 days, then discontinuance for 25 days , 28 days for a a cycle, a total of 6 cycles ).
68292|NCT03650257|Radiation|radiotherapy|Stupp regimen of radiotherapy
68293|NCT03650244|Device|REMEEX implantation|Device implantation
68294|NCT03650231|Other|Serological giagnosis|The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). 91 routinely collected samples were analyzed by Immulite, Architect, and Liaison Blood samples were centrifuged for 15 min at 2500g at room temperature. Sera were aliquoted and first analyzed by Immulite. All samples were tested for EBV VCA IgG, EBV VCA IgM and EBV EBNA IgG in order to determine infection status (primary EBV infection, past infection, absence of infection and indeterminate status).
68295|NCT03650218|Device|THIODERM STRONG|Soft tissue filler containing crosslinked hyaluronic acid and Na-hyaluronate, supplemented with lidocaine hydrochloride as ancillary substance.
68296|NCT03650205|Drug|Ivabradine|Ivabradine capsule
68297|NCT03650205|Drug|Placebo|Placebo oral capsule.
68298|NCT03650179|Other|Observational study : No intervention|Observational study : No intervention. Only exporting data
68299|NCT03650166|Other|MyBP|This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
68300|NCT03650166|Other|Personal BP monitor|Battery-powered BP monitor for personal use
68301|NCT03650153|Procedure|Trans-rectal MRI targeted Biopsy|Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.
68302|NCT03650153|Procedure|Trans-perineal MRI targeted Biopsy|Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
68303|NCT03650140|Dietary Supplement|Tart cherry extract 60 mL|Subjects will receive a single 60 mL oral dose of tart cherry extract.
68304|NCT03650140|Dietary Supplement|Tart cherry extract 120 mL|Subjects will receive a single 120 mL oral dose of tart cherry extract.
68305|NCT03650114|Biological|Ofatumumab|subcutaneous injection of 20 mg ofatumumab every 4 weeks
68306|NCT03650114|Biological|Tetanus toxoid (TT) containing vaccine (Td, Tdap)|0.5mL Vial/Syringe Containing 5 limit of flocculation (LF) tetanus toxoid
68307|NCT03650114|Biological|13-valent pneumococcal conjugate vaccine (13-PCV)|0.5mL Vial/Syringe
68308|NCT03650114|Biological|23-valent pneumococcal polysaccharide vaccine (23-PPV)|0.5mL Vial/Syringe
68309|NCT03650114|Biological|Seasonal Quadrivalent influenza vaccine|Seasonal 2020-2021 0.5mL Vial/Syringe (trivalent may be used where quadrivalent is not available)
68310|NCT03650114|Biological|Keyhole limpet hemocyanin (KLH) neo-antigen|1mg Vial
68311|NCT03650101|Procedure|ETV/CPC|The Endoscopic Third Ventriculostomy/Choroid Plexus Cauterization (ETV/CPC) will comprise a standard frontal approach with flexible endoscopy.
68312|NCT03650088|Behavioral|Behavioral weight loss with digital tools|Participants will monitor their diet in a study smart phone app using a 'traffic light' approach where foods are categorized as red (high fat and/or calorie), yellow (moderate fat/calorie, high nutrient), or green (low fat/calorie, high nutrient) and adhere to a red food limit recommendation, weigh daily on a digital scale whose data syncs to the study app, gradually increase physical activity and track it using a wearable device for which data is also synced to the app, and monitor blood glucose using Continuous Glucose Monitoring. Participants will meet weekly with a trained interventionist for behavioral lessons (adapted from Diabetes Prevention Program curriculum) and counseling.
68313|NCT03650075|Drug|MG-S-2525|The investigational product is MG-S-2525, which is an oral, small-molecule, anti-inflammatory agent. MG-S-2525 is being developed by Metagone Biotech Inc. and contains the new molecular entity HL0, an inhibitor of MAP3K19 which is up-regulated in disease pathobiology and in response to inflammatory stimuli in IPF.
68316|NCT03650023|Dietary Supplement|Chitosan Oligosaccharide (GO2KA1)|Chitosan Oligosaccharide (GO2KA1) capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
68317|NCT03650023|Dietary Supplement|White egg|White egg capsule was consumed within 15 min, and then 2-h oral sucrose tolerance test was conducted.
68318|NCT03650010|Procedure|Total ankle replacement|total ankle prosthesis through a lateral or an anterior approach
68319|NCT03649997|Drug|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
68320|NCT03649997|Drug|Placebo|Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
68321|NCT03649997|Drug|JNJ-61393215|Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
68322|NCT03649984|Behavioral|Symptom Navi© Program|Trained nurses provide two semi-structured patient education consultations with Symptom Navi© Flyers. Patients will use the Symptom Navi© Flyers individually at home.
68323|NCT03649971|Drug|Guselkumab|Guselkumab SC will be administered every 4 weeks.
68324|NCT03649971|Drug|Placebo|Placebo SC will be administered every 4 weeks.
68325|NCT03649958|Device|HIRREM-SOP|HIRREM-SOP for ten 90 minute sessions
68326|NCT03649945|Drug|Docetaxel|75mg/m2，3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
68327|NCT03649945|Drug|Nedaplatin|80 mg/m2,3 weeks for one cycle，dosed on the first day of every cycle,totally 6 cycles
68328|NCT03649945|Drug|Endostar|7.5mg/m2，once a day, continuously dosed for 14 days, then stop for 7 days,3 weeks for one cycle, totally 6 cycles
68329|NCT03649932|Dietary Supplement|Enteral L-citrulline|"L-Citrulline as 10 % solution (100 mg/ml) will be provided to the bedside nurse by the Investigational Pediatric Pharmacy. The drug will be given via gavage feeding by bolus infusions followed by a 0.5 ml water flush twice daily (0900 and 2100). Bolus dosing will be needed due to the small volumes (0.5-1.5 ml per dose in most infants). The volume of nasogastric tubing used in preterm infants (Ameritus 4.0 Fr 50 cm) is 0.48 ml, therefore we will follow the administration with 0.5 ml of saline/water flush to ensure all the study drug is delivered to the patient.~Administration of study drug - Will be given via gavage feeding tube twice daily (0900 +/- 30 mins, 2100 +/- 30 mins). L-citrulline will be given by the bedside nurse as a bolus followed by 0.5 ml water flush. L-citrulline will be given separate from feeds to avoid any confusion.~Study drug will be started when infant has been off of TPN for at least 3 days so that IV arginine in TPN does not interfere."
68330|NCT03649906|Procedure|Optimized Localization Technique|The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
68331|NCT03649893|Device|Active Office|Active Office intervention includes sit-to-stand desk, bike desk, seddle chair, and active breaks.
68332|NCT03649880|Drug|¹⁸F-Fluoromisonidazole|Given IV
68333|NCT03649880|Procedure|Computed Tomography|Undergo PET/CT
68334|NCT03649880|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
68335|NCT03649880|Procedure|Positron Emission Tomography|Undergo PET/MRI
68336|NCT03649867|Other|Semi-structured interviews|Each participant will attend a 30-45 minute semi-structured interview conducted by the CI
68337|NCT03649841|Drug|Antiandrogen Therapy|Undergo ADT
68338|NCT03649841|Drug|Abiraterone Acetate|Undergo Abiraterone Acetate Treatment SOC
68339|NCT03649841|Drug|Prednisone|Undergo Prednisone Treatment SOC
68340|NCT03649841|Radiation|Radiation Therapy|Undergo neutron radiation therapy
68341|NCT03649841|Drug|Abiraterone|Undergo Abiraterone
68342|NCT03649828|Dietary Supplement|probiotic milk fermented with kefir grains|Participants received probiotic milk fermented with kefir grains for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
68343|NCT03649828|Dietary Supplement|curd|Participants received the curd for consumption for 11 weeks. Before and after treatment, blood samples were collected for biochemical analysis and anthropometric data were also evaluated.
68344|NCT03649815|Combination Product|App4Independence|"The mobile, app-based platform was designed to:~Help prevent social isolation through personalized prompts, scheduling of activities, and connections to a range of resources relevant to social engagement~Enhance hopeful and informed engagement in the recovery process through functions that foster resilience and draw on evidence based strategies to enhance wellness (e.g., personalized affirmations; tip sheets; relaxation exercises)~Encourage and check-in on daily essential activities for patients - addressing memory, attention, and initiation challenges that often occur as a part of this illness~Provide basic health/safety functionality and track level of wellness~Provide an anonymous peer-peer online network for strategy sharing~Provide an ambient sound detector to assist with identifying hallucinations"
68345|NCT03649802|Dietary Supplement|Low dose vitamin D3|Low dose arm-800 IU given daily
68346|NCT03649802|Dietary Supplement|High dose vitamin D3|High dose arm-5000 IU given daily
68347|NCT03649776|Other|Mental Health First Aid|Mental Health First Aid (MHFA) is listed in the Substance Abuse and Mental Health Services Administration's National Registry of Evidence-based Programs and Practices. The program also teaches the common risk factors and warning signs of specific types of illnesses like anxiety, depression, substance use, bipolar disorder, eating disorders, and schizophrenia. Participants are introduced to local mental health resources, national organizations, support groups, and online tools for mental health and addictions treatment and support.
68348|NCT03649763|Drug|Lidocaine|lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
68349|NCT03649763|Drug|Bupivacaine|Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
68350|NCT03649763|Drug|Lidocaine|lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
68351|NCT03649750|Drug|Mucinex®|Mucinex® 600 mg ER bi-layer tablets
68352|NCT03649737|Behavioral|Exercise|Exercise program
68353|NCT03649737|Other|Questionnaire Administration|Ancillary studies
68354|NCT03649737|Other|Survey Administration|Ancillary studies
68355|NCT03649724|Drug|Placebo|Placebo injections will consist of 1.5 cc of 0.9% Sterile Sodium Chloride Injection, USP, administered with a 12 cc single-use syringe with a 21-gauge needle.
68623|NCT03647488|Drug|docetaxel|Concentrate for solution for infusion, intravenous use
68356|NCT03649724|Drug|LUPRON DEPOT 22.5 mg|LUPRON DEPOT 22.5 mg (or placebo) will be administered intramuscularly, in accord with manufacturer's direction, once every twelve weeks for 48 weeks.
68357|NCT03649711|Drug|Ticagrelor 90mg|Ticagrelor Pill
68358|NCT03649711|Drug|Clopidogrel 75mg|Clopidogrel Pill and a matching placebo to conceal frequency
68359|NCT03649711|Drug|Aspirin 81 mg|Aspirin Pill
68360|NCT03649698|Behavioral|Home-based training program|Exercise intervention: During the intervention period, the participant will perform the optimized and personally adapted Otago Exercise Program (OEP). The participant is encouraged to perform the resistance exercises three times a week with a rest day in between. The participant is advised to perform the exercises in close temporal proximity to one of the moments of the intake of the protein supplement. The participant will also follow a walking plan in which he or she needs to walk 30 minutes twice a week. These 30 minutes can be broken down to three 10-minute walks throughout the day. During the follow-up period, participants may continue the OEP, but no personal encouragement will be given during this period.
68361|NCT03649698|Dietary Supplement|High-quality protein supplement|The participant will receive an individually adapted protein supplement to achieve the recommend total (usual diet and supplements) daily intake of 1.5 g/protein/kg for frail elderly. This will be realized by adding an individualized amount (g) of protein powder during breakfast, lunch, dinner or snack between meals, or before breakfast or after dinner, based on the subjects' food intake assessed by a food diary. The participant will take the protein supplement from 5 days before the start of the intervention. The protein powder is commercially available and consists of 4.5g protein/5g powder. During the follow-up, no protein supplement is added.
68362|NCT03649698|Dietary Supplement|Omega-3 fatty acid|Four weeks before the start of the intervention, the participant will start the intake of 1 omega-3 capsule providing in total 500 mg EPA and 450 mg DHA until the end of the intervention. He or she has to take the supplement once daily at a chosen time. During the follow-up, no omega-3 supplement will be given.
68363|NCT03649698|Drug|Placebo protein powder|Isocaloric maltodextrin powder. Amount based on food diary.
68364|NCT03649698|Drug|Placebo omega-3|Peanut oil soft gel capsules. 1g/ capsule. 1 capsule/day
68365|NCT03649685|Device|Continuous theta burst stimulation (cTBS)|50Hz of 90% MT for 3 pulses train over will be repeated at 200ms for the 40s, 600 pulses
68366|NCT03649685|Device|shame rTMS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
68367|NCT03649672|Device|TOF Watch SX|Neuromuscular monitoring via the TOF Watch SX device
68368|NCT03649659|Drug|Silver Diamine Fluoride|SDF will be applied twice during the study
68369|NCT03649659|Drug|Placebo|This is being compared to the SDF and will also be applied twice
68370|NCT03649633|Drug|Stress-dose Hydrocortisone plus Vitamin C|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
68371|NCT03649633|Drug|isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
68372|NCT03649620|Dietary Supplement|unripe Bokbunja Extract|tablet(1 tablet/d, 600 mg/d) for 12 weeks
68373|NCT03649620|Dietary Supplement|Placebo|Placebo for 12 weeks
68374|NCT03649607|Other|Accelerated Resolution Therapy|ART was developed to treat both physiological and cognitive aspects of PTSD, which has been described as a consequence of failed memory processing. The use of Voluntary Image Replacement (VIR) parallels imaging re-scripting in which a preexisting negative mental image is transformed into a more benign image. This has been successfully used to treat survivors of traumatic industrial accidents suffering from PTSD. Participants will complete five sessions over a 21-day period.
68375|NCT03649581|Other|compare the two groups of schizophrenic patients|"Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:~abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),~abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia)."
68376|NCT03649581|Other|compare the two groups of schizophrenic patients versus volunteers|compare the results of the schizophrenic patient group with healthy volunteers
68377|NCT03649568|Other|Pork|1 oz lean pork
68378|NCT03649568|Other|Egg|1 large whole egg
68379|NCT03649568|Other|Black beans|0.5 cups cooked black beans
68380|NCT03649568|Other|Almonds|1 oz almonds
68381|NCT03649555|Drug|[18F]-FTC-146|Two 5 mCi [18F]-FTC-146 doses will be administered intravenously on two separate scan days at least one week apart (total per study = 10 mCi) Participants who complete both test days will receive 10 mCi total dose; however, if a participant is unable to return for a second test day due to unforeseen circumstances, they will receive 5 mCi total dose.
68382|NCT03649542|Other|Fluidotherapy plus exercise|The Fluidotherapy® unit (ULTRA 115: Henley International, Sugar Land, Texas) is a high intensity heat modality consisting of a dry whirlpool of finely divided solid particles suspended in a heated air stream. A certified technician The cleaned the Fluidotherapy® unit per the user manual.
68383|NCT03649529|Biological|GPA-TriMAR-T|Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
68384|NCT03649516|Device|iCKD APP|Use iCKD APP to upload home bio-information data
68385|NCT03649503|Other|No intervention|
68386|NCT03649490|Procedure|Extreme Lateral Interbody Fusion|Lateral interbody spinal fusion
68387|NCT03649477|Drug|intranasal carbetocin Dose 1|three times per day before meals
68388|NCT03649477|Drug|intranasal carbetocin Dose 2|three times per day before meals
68389|NCT03649477|Drug|placebo|three times per day before meals
68390|NCT03649464|Drug|OKN-007|"Dose escalation/PK cohort (Phase Ib): 1000mg twice daily (BID), 1000mg thrice daily (TID), 1500mg thrice daily (TID).~Expansion cohort (Phase 2): MTD defined in the dose escalation (Phase Ib) study."
68737|NCT03646630|Procedure|Quadratus Lumborum Block|Posterior or QL block type 2 , a bolus of 0.5 ml/Kg bupivacaine 0.25%
68391|NCT03649438|Drug|131 I-Metaiodobenzylguanidine|"Minimum dose of 10 mCi/kg for patients without a stem cell source whose renal function is above the upper limit of normal but still meets eligibility criteria.~Dose of 12 mCi/kg for patients without a stem cell source with normal renal function and meets other eligibility criteria.~Dose of > 12 mCi/kg to 18 mCi/kg maximum at investigator's discretion for patients meeting eligibility criteria with stem cells available."
68392|NCT03649438|Drug|Potassium Iodide|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection.
68393|NCT03649438|Drug|G-csf|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000). This will start 24 hours after stem cell infusion (if stem cells are to be infused).
68394|NCT03649412|Drug|GSK2982772 Modified Release|GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.
68395|NCT03649412|Drug|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
68396|NCT03649399|Diagnostic Test|Abdominal ultrasound|Abdominal ultrasound for detection of the pancreatic stent
68397|NCT03649386|Device|Heated and humidified breathing circuit on|Heated and humidified breathing circuit will be turned on.
68398|NCT03649386|Device|Heated and humidified breathing circuit off|Heated and humidified breathing circuit will be turned off.
68399|NCT03649373|Procedure|Noergaard technique|The patient is placed standing in an upright position in front of the rail on a hospital bed. Legs should be stretched with a wide well balanced stance. The patient is then instructed to bend forwards, resting the forehead on the back of the non-affected forearm, which is put on the rail. The affected arm should now be relaxed and stretched, hanging straight down toward the floor. The patient is then instructed to attempt to relax and make pendular and circular motions with the affected arm hanging down. Successful reduction occurs when sufficient muscle relaxation allows the humeral head to reposition to its natural position in the glenoid fossa. Often the patient will experience a popping sensation when the shoulder is reduced.
68400|NCT03649347|Behavioral|Augmented reality exposure therapy|Exposure therapy via utilization of augmented reality. Virtual objects will be placed on the patient's real environment for exposure therapy.
68401|NCT03649334|Drug|ketamine-ketorolac|The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
68402|NCT03649334|Drug|fentanyl- ketorolac|The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
68403|NCT03649321|Drug|BGB324|Bemcentinib is a small molecule, orally bioavailable, highly specific inhibitor of Axl kinase.
68404|NCT03649321|Drug|Nab-paclitaxel|25 mg/m^2 Day 1 /8 every 21 days.
68405|NCT03649321|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 Day 1 /8 every 21 days
68406|NCT03649321|Drug|Cisplatin|Cisplatin 25 mg/m^2 Day 1 /8 every 21 days
68407|NCT03649308|Device|Negative Pressure Wound Therapy|An immediate mobilization and negative pressure wound therapy (PICO) initiated after surgery.
68408|NCT03649308|Procedure|Conventional treatment|Traditional treatment with conventional wound dressing and 5 days of immobilization after surgery.
68409|NCT03649295|Other|Functional Electrical Stimulation|"Functional electrical stimulation device obeying the following steps:~Muscle heating - 2 min, 10 Hz, 250 μm; Potentiation of muscle fibers type I - 8 min, 30 Hz, 250 μm; Potentiation of muscle fibers type II - 8 min, 80 Hz, 300 μm; Toning - 8 min, 30 Hz, 300 μm; Muscle Relaxation - 4 min, 5 Hz, 200 μm One channel of electrodes will be placed in the submental region and the other in the thyroid. Treatment should be started at minimum levels of intensity, increasing carefully until appropriate effects are achieved in the procedure"
68410|NCT03649295|Other|Conventional Speech Therapy|Conventional speech therapy with laryngeal elevation exercises, stimulation of oral reflexes such as swallowing reflex, tongue movements, lips and cheeks, gustatory therapy
68411|NCT03649282|Other|HFNC|HFNC therapy will be delivered with a system that provides heated, humidified high flow of gas through a tube that maintains the temperature and humidification. This intervention will involve the delivery of gas (air/oxygen) at a high flow rate, using an adequate nasal cannulae size and a cannula/nostril diameter ratio between 0.5-0.8.
68412|NCT03649282|Other|NCPAP|NCPAP will be provided as either bubble CPAP or through a ventilator, and will deliver a regulated pressure of gas (air/oxygen) to the patient through infant binasal prongs as interface. Nasal prong sizes will be chosen according to manufacturer recommendations.
68413|NCT03649269|Dietary Supplement|PC-300 tea.|Patients had to drink one cup of the tea half an hour before breakfast, main meal and dinner.
68414|NCT03649269|Drug|Bezafibrate|Patients were prescribed 200 mg/day at night.
68415|NCT03649256|Diagnostic Test|Thickness of lower uterine segment scar|Ultrasound measurement of thickness of the uterine scar at 3 and 6 months
68416|NCT03649243|Drug|Propolis spray|Propolis was added at the site of injury, 3 puff for any wound in the foot of patients. All the patients decide voluntary if they want to receive the propolis spray treatment or only receive they normal wound healing care.
68417|NCT03649230|Drug|300mg netupitant/0.5mg palonosetron hydrochloride|Antiemetic (NK1 receptor antagonist/5-HT3 receptor antagonist)
68418|NCT03649217|Device|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
68419|NCT03649204|Behavioral|HY-PAD|Hybrid intervention that includes supervised on-site and home-based components in people with PAD
68738|NCT03646630|Procedure|Caudal Block|caudal block with 1 ml/kg of bupivacaine 0.25%.
68420|NCT03649191|Other|The BABEL Approach to Advance Care Planning in Nursing Homes|In intervention nursing homes, eligible residents will: (i) receive The BABEL Approach to Advance Care Planning (ACP), (ii) after these ACP discussions occur, the resident's primary care physician will be notified of the residents' ACP wishes, (iii) a brightly colored document will be placed in a standard location of the NH chart that identifies the resident's ACP wishes, (iv) paramedics will be educated to know about these sheets and where to find them, and that they should be taken with any resident transferred to another care setting.
68421|NCT03649191|Other|Control group Advance Care Planning|Eligible residents in each control nursing homes will receive the prevalent approach to Advance Care Planning in that nursing home. No elements of The BABEL Approach to Advance Care Planning will be introduced in the control homes.
68422|NCT03649178|Other|salt|Participants will randomly eat a high salt diet for 8 weeks and a low salt diet for 8 weeks
68423|NCT03649165|Drug|Treatment A|During Part 1 of the study, participants will receive single doses of selumetinib 25 mg granule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
68424|NCT03649165|Drug|Treatment B|During Part 1 of the study, participants will receive single doses of selumetinib 50 mg capsule under fasted conditions. The dose will be administered after an overnight fast of at least 10 hours. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose.
68425|NCT03649165|Drug|Treatment C|During Part 2 of the study, participants will receive single doses of selumetinib 25 mg granule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
68426|NCT03649165|Drug|Treatment D|During Part 2 of the study, participants will receive single doses of selumetinib 50 mg capsule under fed conditions. Following an overnight fast of at least 10 hours, participants will start consumption of the recommended meal within 30 minutes before administration of the IMP. Participants will be required to consume the entire meal in 30 minutes or less; however, the IMP should be administered 30 minutes after start of the meal. The IMP will be administered with approximately 240 mL of water. No food will be allowed for at least 4 hours post-dose, where after a meal may be provided.
68427|NCT03649165|Drug|Acetaminophen|Participants will receive a single 500mg dose of acetaminophen at the same time.
68428|NCT03649152|Drug|Propagermanium|Immediate release capsule
68429|NCT03649152|Drug|Placebo|Placebo capsule
68430|NCT03649139|Drug|sublingual immunotherapy drops|artemisia annua (sweet sagewort) allergen extract drops
68431|NCT03649139|Drug|Placebo drops|sublingual placebo drops
68432|NCT03649126|Behavioral|Implementation tools|Implementation tools developed by experts in order to increase the use of SSR in pathology
68433|NCT03649113|Procedure|sclerotherapy arm|The liver mass will be punctured under guidance of ultrasonography with a 20- or 22-gauge Chiba needle. Contrast medium will be injected under fluoroscopy guidance to assess any possible communication with the biliary tree and to evaluate the amount of sclerosing agent which could be safely injected. Then, the mixture of Bleomycin (Bleocin-S; Korea United Pharm Inc., South Korea) and Lipiodol (Ultra-Fluid, Guerbet, France) will be slowly injected under continuous guidance of fluoroscopy. No more than 45 units of Bleomycin and 15 cc of Lipiodol will be injected in a single session.
68434|NCT03649100|Procedure|Implant placement|Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
68435|NCT03649087|Other|Vitrification|Vitrification of ovarian tissue
68436|NCT03649074|Device|AKL-T01|"AKL-T01 multitasking digital treatment. AKL-T01 multitasking treatment employs perceptual discrimination attention/memory task as well as a continuous motor driving task."
68437|NCT03649061|Drug|Etanercept 50 MG/ML|Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme
68438|NCT03649061|Drug|Leflunomide 10 milligram (MG)|Leflunomide 10mg PO daily added to the COBRA-Slim scheme
68439|NCT03649048|Drug|High-Dose Cisplatin|Intravenous administration of High-Dose Cisplatin
68440|NCT03649048|Drug|Low-Dose Cisplatin|Intravenous administration of Low-Dose Cisplatin
68441|NCT03649048|Radiation|Radiotherapy|Participating centres are to follow their local radiation treatment planning and delivery techniques.
68442|NCT03649035|Device|HTP treatment|Elegible patients will undergo HTP treatment, followed by standard of care Chemo therapy and SBRT protocol.
68443|NCT03649022|Device|Catheter ablation|Ventricular Tachycardia ablation, that will be performed per clinical practice, by using EnSite Precision mapping system with the Flexability catheter (St.Jude, now Abbott)
68444|NCT03649009|Other|Normal Saline|Normal Saline 50 mls infused over 1 hour 3 times per day for total 3 days after recruitment and randomization.
68445|NCT03649009|Drug|Thiamine|IV Thiamine 200 mg diluted in 50 mls normal saline infused over 1 hour 3 times per day for total 3 days after recruitment and randomization
68446|NCT03649009|Drug|Hydrocortisone|If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given
68447|NCT03649009|Other|Metoclopramide|If patient develop nausea after IV thiamine infusion, IV metoclopramide 10mg stat will be given. If patient develop redness or rashes after normal saline infusion, IV hydrocortisone 200 mg stat will be given.
68448|NCT03648996|Other|Low-fructose diet|6 month of consumption a low fructose diet
68449|NCT03648996|Drug|Allopurinol|6 months of allopurinol treatment with the goal of decreasing uric acid compared to control group
68450|NCT03648996|Drug|Placebo|6 months of placebo treatment
68451|NCT03648983|Procedure|arm circumference measurement|Undergo arm circumference measurement
68452|NCT03648983|Device|Bioimpedance spectroscopy|bioimpedance spectroscopy
68453|NCT03648970|Drug|Pravastatin|The participant will be given pravastatin 2 x 20 mg per oral daily
68739|NCT03646617|Radiation|Hypofractionated Radiation Therapy (HFRT)|The dose of HFRT will be 8 Gy x 3 fractions, given over a maximum of 7 days timespan.
68454|NCT03648957|Behavioral|Lifestyle counselling|First behavioral counselling session will be conducted before discharge and follow-up session will be offered with 3-4 weeks intervals either by telephone or in the outpatient clinic.
68455|NCT03648957|Behavioral|Usual care|Usual stroke care discharge session; including written and verbal encouragement to a healthy lifestyle.
68456|NCT03648957|Device|Activity tracker|Participants are encouraged to wear a activity tracker to monitor their physical activity
68457|NCT03648944|Other|Accelerated Rehabillitation|
68458|NCT03648944|Other|Non-Accelerated Rehabillitation|
68459|NCT03648931|Behavioral|Focus Group Discussion (FGD)|"No actual intervention is planned. A single focus group discussion (FGD) with community members in the same group assignment will be conducted to assess study outcome measures. In particular, the FGDs will focus on:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~Willingness to join a VR and/or oral PrEP study during pregnancy and breastfeeding"
68460|NCT03648931|Behavioral|In-depth Interview (IDI)|"No actual intervention is planned. A single in-depth interview (IDI) will be conducted to assess study outcome measures, focusing on the following topics:~Perceptions of taboos and acceptable and/or typical practices during pregnancy, childbirth and breastfeeding~Perceptions of HIV risk during pregnancy and breastfeeding~Perceived role of male partners during pregnancy and breastfeeding~Main challenge(s) perceived with VR and oral PrEP use during pregnancy and breastfeeding~Main factor(s) perceived to facilitate VR and oral PrEP use during pregnancy and breastfeeding~How others in their professional and social networks and communities would view the VR and/or oral PrEP use by pregnant and breastfeeding women"
68461|NCT03648918|Other|Blood Collection|Blood will be collected via venipuncture and analyzed. Blood samples will be analyzed for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), plasma-induced signature, diabetes autoantibodies, complete blood count with differential, and serum and plasma for storage. For family members with diabetes, blood will also be tested for A1c.
68462|NCT03648879|Device|Endoscope+Cellvizio(R) 100 microscope|Patients will undergo white-light, upper endoscopy. In addition, during this endoscopy patients will undergo CEM using the Cellvizio probe (Mauna Kea Technologies) to scan the same anatomic zones.
68463|NCT03648866|Other|interview|"Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds"
68464|NCT03648853|Device|Tetanic Stimulus|5 second 100 Hz 70 mA tetanic stimulus will be applied to three different locations in a random order
68465|NCT03648840|Behavioral|Aversive cue|Participants will be exposed to unpleasant pictures and tones during performance of a task to earn alcohol
68466|NCT03648840|Behavioral|Neutral cue|Participants will be exposed to neutral pictures and tones during performance of a task to earn alcohol
68467|NCT03648827|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
68468|NCT03648814|Procedure|Intracameral injection|A/C injection of 1.25 mg/0.05 mL bevacizumab
68469|NCT03648814|Procedure|Intravitreal injection|Vitreous injection of 1.25 mg/0.05 mL bevacizumab
68470|NCT03648788|Other|NA (Observation study)|NA (Observation study)
68471|NCT03648775|Device|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
68472|NCT03648762|Behavioral|Aerobic Exercise Intervention|Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
68473|NCT03648762|Behavioral|Combined Aerobic and Strength Exercise Intervention|Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise
68474|NCT03648762|Behavioral|Inspiratory Muscle Training Exercise Intervention|Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
68475|NCT03648749|Behavioral|Speech-to-noise feedback|A target speech-to-noise level is specified and feedback about achievement of the target level is provided.
68476|NCT03648736|Other|blood withdrawal|"peripheral-venous before TASH, day 1, 2, 3, one week and one month after TASH procedure~central-venous during TASH"
68477|NCT03648710|Other|Peer Community Health Worker|Participants will be communicating with their CHWs on a weekly basis, which is consistent with other successful community health worker protocols with published efficacy. Community Health Workers will be peers with sickle cell disease, who have successfully transitioned and are under 30 years of age.
68478|NCT03648710|Other|Mobile Health|A mobile health application created as a resource for young adults transitioning.
68479|NCT03648697|Biological|EBV-TCR-T (YT-E001) cells|"EBV-TCR-T (YT-E001) cells are prepared via lentiviral infection. 6-10 days prior to infusion of TCR-T cells (YT-E001), subjects receive fludarabine at dose 30mg/m2/day for 4 days and cyclophosphamide treatment at dose 30mg/kg/day for 2 days and take a rest for one day before infusion.~Patients, who receive an infusion of YT-E001, will remain in the hospital to be monitored for adverse events until they have recovered from the treatment. Patients will have frequent follow-up visit to monitor the persistence of modified T cells and efficacy of the treatment."
68480|NCT03648684|Behavioral|Caffeine-Based Expectancy Challenge|Intervention to alter expectancies and encourage safe drug substitution (harm reduction plus expectancy modification)
68481|NCT03648684|Behavioral|Placebo-Based Expectancy Challenge|Intervention to alter expectancies (expectancy modification only)
68482|NCT03648671|Drug|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
68483|NCT03648671|Drug|safinamide metansolfonato (12 weeks)|safinamide metansolfonato
68484|NCT03648671|Drug|rasagilina mesilato (12 weeks)|rasagilina mesilato
68485|NCT03648671|Drug|rasagilina mesilato (12 weeks)|rasagilina mesilato
68486|NCT03648658|Drug|Paracetamol 120Mg/5mL Oral Suspension|The subjects will be treated with paracetamol in therapeutic doses, 15mg/kg/dose every six hour, with a maximum dosage of 1 g x 4 per day, for three consecutive days.
68555|NCT03648047|Other|Additional face-to-face rehabilitation sessions|Patients will receive face-to-face sessions in addition to sessions performed with the Digital Rehabilitation Device
68487|NCT03648645|Device|Self measurement of blood pressure|"Patients in the distant follow-up group, perform the measurement of blood pressure at their home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected to a tele-communicating box which automatically and securely transmits the data to the healthcare team via a secure web platform.~A trained nurse or midwife participating in the project will daily consult the blood pressure values and alert history through a secure web interface. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient."
68488|NCT03648645|Other|Standard follow-up consultation in the hospital|"Standard care includes several follow-up visits in the maternity wards where the patient is cared for and at a frequency set by the coordinating physician on a case-by-case basis depending on the severity of the AH.~During the follow-up visits, the following examinations will be carried out in the maternity services in charge of the patient. Examinations will be conducted routinely as part of a follow-up pregnancy."
68489|NCT03648632|Radiation|Stereotactic Radiotherapy|Patients should be treated with 50 Gy in 5 fractions within a total of 7 - 8 days.
68490|NCT03648619|Diagnostic Test|Semi whole-body MRI|Single semi-automatic, semi whole-body MRI protocol (Dot engine)
68491|NCT03648606|Other|mesure of skin temperature|"The infants are placed in a closed incubator to study the variability of the heart and respiratory frequencies according to the regulation of the incubator and to quantify the time spent outside. Data will be collected during the first 10 days of life of the preterm infant. Skin temperatures at six body sites (the abdomen, pectoral region, eye, hand, thigh and foot) were measured (using infrared thermography) during nocturnal polysomnography in 29 9-day-old preterm neonates (postmenstrual age:~209 9 days). The investigators then determined whether the duration of the W episode depended upon the local skin temperatures measured at the start, during and end of the episode."
68492|NCT03648593|Behavioral|work recovery intervention|Recover! app: one hour weekly for two months
68493|NCT03648593|Behavioral|waiting list control|no treatment during 6 months,then Recover! app
68494|NCT03648580|Dietary Supplement|Ensure Complete powder|Supply the Ensure Complete powder that will be the oral nutrition supplement, with the dose of 6 scoops (53.8 grams) twice daily.Duration: 12 weeks
68495|NCT03648580|Other|verbal nutrition education|give the verbal nutrition education
68496|NCT03648554|Drug|dulaglutide (TRULICITY®) 1.5 mg|dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
68497|NCT03648554|Other|reinforced dietary monitoring|moderate caloric restriction individually adjusted according to the ideal weight and activity level, encouraging regular physical activity (about 30 minutes per day or 150-200 min per week)
68500|NCT03648528|Drug|cholecalciferol|
68501|NCT03648528|Drug|placebo|
68502|NCT03648515|Diagnostic Test|Plaster models|The impressions taken of the dental arches will be poured with hard gypsum in order to make use of the models for taking measurements. These measurements will be considered the gold standard.
68503|NCT03648515|Diagnostic Test|Digital Images of the dental arches|The dental arches will be captured using a dedicated camera in order to be used for measuring the outcomes.
68504|NCT03648515|Diagnostic Test|Digital images of models|The poured dental models will be captured using a dedicated camera in order to be used for measuring the outcomes.
68505|NCT03648502|Diagnostic Test|Cognitive tests and hearing tests|Several cognitive and hearing (peripheral and (central) auditory process) tests
68506|NCT03648489|Drug|Paclitaxel|Please refer to arm/group description
68507|NCT03648489|Drug|TAK228|Please refer to arm/group description
68508|NCT03648476|Behavioral|ICAN|A 6-week group therapy sessions once a week for 90-120 minutes.
68509|NCT03648463|Procedure|arthroscopy of the affected knee/ Bone Marrow Concentrate Injection|Subjects will undergo knee arthroscopy for debridement, menisectomy and synovectomy of the cartilage defects. Subjects will also be injected with bone marrow aspirate concentrated harvested from the pelvis and centrifuged (produced produced using the Harvest/Terumo BCT system)
68510|NCT03648450|Other|Hailie Smart Inhaler EMD|Hailie Smart Inhaler electronic monitoring device is a sleeve that fits over inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
68511|NCT03648437|Drug|Paracetamol 10Mg/mL|Experimental drug
68512|NCT03648437|Drug|0.45% Sodium Chloride|Placebo comparator
68513|NCT03648437|Drug|Ibuprofen|Standard therapy
68514|NCT03648411|Genetic|Drug resistance molecular markers|Proportion of the drug resistance molecular markers will be found-out and compared.
68515|NCT03648398|Other|EDUMICILOR|Patients will participate in the online therapeutic education program for about 6 months
68516|NCT03648385|Drug|DHEA tablet|DHEA tablet (50 mg) taken by mouth once a day for 18 weeks.
68517|NCT03648385|Other|Placebo|1 placebo tablet taken by mouth once a day for 18 weeks
68518|NCT03648372|Drug|TAK-981|Intravenous infusion.
68519|NCT03648359|Procedure|multiparametric MRI Diagnostics|Patients with newly diagnosed prostate cancer enrolled in active surveillance following standard protocol including PSA, DRE and TRUS biopsies and intervention with multiparametric MRI + additional biopsies if suspicious lesions are found
68520|NCT03648346|Drug|Cohort 1: HL217 Ophathalmic Solution BID|Two drops of 3 mg/mL of the treatment in one eye twice a day
68521|NCT03648346|Drug|Cohort 2: HL217 Ophathalmic Solution QID|Two drops of 3 mg/mL of the treatment in one eye 4 times a day
68522|NCT03648346|Drug|Placebo|Placebo eye drops
68523|NCT03648333|Drug|Exforge tab. 10/160mg|
68524|NCT03648333|Drug|Lodivixx tab. 5/160mg|
68525|NCT03648320|Other|Peanut oral immunotherapy|Daily doses of peanut flour (with 2-weekly incremental interval)
68526|NCT03648307|Diagnostic Test|Blood sample|Blood sample for Hb A1C and lipid profile, blood pressure and BMI
68556|NCT03648034|Procedure|ropivacaine|To perform scalp nerve blocks with ropivacaine
68557|NCT03648034|Procedure|saline|To perform scalp nerve blocks with saline
68527|NCT03648294|Other|adrenalectomy for primary addosteronism|All of the clinical and biological data were retrospectively compiled from the patient computerized record. The variables analyzed were: age, sex, body mass index (BMI), PAH discovery circumstances, pre- and postoperative systolic and diastolic blood pressure assessments, number of pre-hypertensive antihypertensive drug - and postoperatively, the laterality, the size and nature of the lesions, the operating time, the surgical technique used. The biological data evaluated were pre- and postoperative plasma and plasma creatinine, preoperative serum aldosterone concentrations, plasma renin activity, and preoperative aldosterone / renin ratio. Hypokalemia was defined as serum concentration below 3.5 mmol / L.
68528|NCT03648281|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
68529|NCT03648268|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|"rTMS is a technique of TMS that allows the selective external manipulation of neural activity in a non-invasive manner. During TMS, a rapidly changing current is passed through an insulated coil placed against the scalp. This generates a temporary magnetic field that in turn induces electrical current in neurons and allows the modulation of neural circuitry. The combination of TMS with fMRI allows the selective targeting and modulation of brain networks. The repeated application of rTMS can cause long term changes in behavior and task performance that is reflected in altered brain network connectivity.~The pattern of rTMS will consist of either:~intermittent Theta Burst Stimulation (iTBS) pattern consisting of 2 s trains of 3 pulses at 50 Hz, repeated at 5 Hz, every 10s for a total of 600 pulses.~OR~sham stimulation"
68530|NCT03648242|Behavioral|Interruptive Clinical Decision Support|"An interruptive, soft-stop alert will pop up when a pediatric primary care provider open a child's electronic health record (i.e., a new window in the forefront of the screen interrupting workflow and requiring the clinician to take an action) alerting them that the child meets criteria for obesity based on their age/sex-specific BMI percentile. The pop-up alert includes:~One-click addition of elevated BMI to problem list~Reminder to utilize Suggested PowerPlan~One-click access to a patient handout on evidence-based behavior change goals (screen time, sugary drinks, physical activity, sleep) and link to additional handouts and resources~Tables displaying trends in growth measures, blood pressure and relevant laboratory tests~Links to existing, evidence-based childhood obesity screening and management guidelines"
68531|NCT03648229|Procedure|Selective laser trabeculoplasty (SLT)|Delivery of laser energy to the trabecular meshwork of the eye with the goal of reducing intraocular pressure
68532|NCT03648229|Drug|Latanoprost ophthalmic solution|Prostaglandin analogue topical ophthalmic medication for reduction of intraocular pressure
68533|NCT03648229|Drug|Timolol ophthalmic solution|Timolol ophthalmic solution 0.5% for reduction of intraocular pressure
68534|NCT03648216|Behavioral|HAPA behavioural counseling|Behavioural counseling grounded in the Health Action Process Approach (HAPA; i.e., action planning and coping planning) to maximize sedentary behaviour and minimize steps taken.
68535|NCT03648203|Behavioral|Technology Enabled Asthma Management System|See description of arm
68536|NCT03648190|Diagnostic Test|Flowcytometry analysis of platelets surface receptors|"BD FACSCalibur flowcytometry instrument.~Platelet flow cytometry is an emerging tool in diagnostic and therapeutic hematology. It is eminently suited to study the expression of platelet surface receptors both qualitatively as well as quantitatively.~Flow cytometry rapidly measures the specific characteristics of a large number of cells in suspension. Typically, the cells are labeled with fluorescently conjugated monoclonal antibodies (mAbs)."
68537|NCT03648177|Behavioral|IPGT|Behavioral Intervention for Patients with Chronic Pain
68538|NCT03648177|Behavioral|Treatment as Usual|Standard Care
68539|NCT03648164|Other|CHAT-CS Survey|Students will complete a computer-based survey
68540|NCT03648138|Behavioral|Sugary drink warning labels|This information appears in the description of the study arms.
68541|NCT03648125|Device|with artificial occlusal disturbance|"A silicon artificial occlusal disturbance is made from a mould of the rowers mouth and placed in the mouth during the training session.~With artificial occlusal disturbance : Maximal Intercuspal Occlusion (MIO) with silicone splint increases the vertical dimension of occlusion of 1, 2 and 4 mm."
68542|NCT03648125|Device|without artificial occlusal disturbance|The training session is performed without occlusal disturbance
68543|NCT03648112|Dietary Supplement|Intervention 1|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude oat flakes per day.
68544|NCT03648112|Dietary Supplement|Intervention 2|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted oat flakes per day.
68545|NCT03648112|Dietary Supplement|Intervention 3|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of crude barley flakes per day.
68546|NCT03648112|Dietary Supplement|Intervention 4|The study participants receive recipes for breakfast for 21 days. The recipes imply 80 g of roasted barley flakes per day.
68547|NCT03648112|Dietary Supplement|Control|"White toastbread (control) (dietary supplement) White toastbread was chosen because of its low fibre content. To achieve the same energy value (kcal) as 80 g cereal flakes the participants have to consume four slices of white toastbread.~The study participants receive recipes for breakfast for 21 days. The recipes imply four slices of white toastbread."
68548|NCT03648099|Behavioral|Labor dance|The dance group which involved pregnant women who performed the labor dance
68549|NCT03648099|Behavioral|Music|The music group involving pregnant women who were exposed to music.
68550|NCT03648086|Other|intestinal microbiota transplantation|Participants in Exprerimental group take 6 times IMT with 2-week intervals
68551|NCT03648073|Diagnostic Test|[68Ga]DOTATATE-PET/MRI|[68Ga]DOTATATE-PET/MRI
68552|NCT03648060|Device|Digital kinematic biofeedback system|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed by the therapist and edited according to patient evolution.
68553|NCT03648047|Device|Digital kinematic biofeedback device|The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team.
68554|NCT03648047|Other|Conventional rehabilitation|Patients will receive conventional face-to-face sessions by a Physical Therapist.
68558|NCT03648021|Drug|Paracetamol|">50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose"
68559|NCT03648021|Drug|Placebo|100mL of chlorure de sodium 0.9% administred intravenously. 1 dose
68560|NCT03648008|Drug|Hydromorphone|0.002 mg*kg-1 bolus with 0.002 mg*kg-1 background infusion for group BH 0.002 mg*kg-1 bolus without background infusion for group NBH Drug is administered through PCIA pump.
68561|NCT03648008|Drug|Morphine|0.015 mg*kg-1 bolus without background infusion for group M Drug is administered through PCIA pump.
68562|NCT03647995|Dietary Supplement|Probiolife by Green Made (Pharma M)|A box containing 30 capsules of a dietary supplement containing 25 Bn CFU (detailed in previous sections)
68563|NCT03647995|Other|Placebo|A box containing 30 capsules containing an inactive substance with 0 Bn CFU.
68564|NCT03647982|Drug|Meditoxin|injection of MEDITOXIN into the intradermal of each contralateral upper back in equal doses
68565|NCT03647982|Drug|Botox|injection of Botox into the intradermal of each contralateral upper back in equal doses
68566|NCT03647969|Drug|mFOLFOX, Nivolumab, Ipilimumab|"Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks Ipilimumab 1mg/kg i.v. d1 over 30 minutes every 6 weeks Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks"
68567|NCT03647969|Drug|mFOLFOX|Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks
68568|NCT03647956|Drug|Atezolizumab|Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
68569|NCT03647956|Drug|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
68570|NCT03647956|Drug|Carboplatin|Carboplatin, sold under the trade name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.
68571|NCT03647956|Drug|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
68572|NCT03647943|Device|Transcranial direct current stimulation|Transcranial direct current stimulation, involving low-levels of electrical stimulation applied to the right and left DLPFC will be used in conjunction with cognitive training for 46 minutes.
68573|NCT03647943|Device|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation, involving no electrical stimulation will be used in conjunction with cognitive training for 46 minutes.
68574|NCT03647930|Device|Microporous Polysaccharide Hemospheres (MPH)|Microporous Polysaccharide Hemospheres (MPH)
68575|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
68576|NCT03647917|Biological|Platelet Rich Plasma|"Autologous Platelet Rich Plasma (PRP) will be isolated from the blood collected from each subject at each treatment time point.~Face: Using a 30 gage needle, about four points of PRP or saline will be injected into the malar area; about six points will be injected into the mandibular area; and seven points will be injected into the forehead (0.2 mL per point) with a total volume of approximately 3.5 mL. PRP and saline application will be followed by microneedling.~Hands: Using a 30 gage needle about 1 cc of PRP or saline will be injected into the dorsal area of the hands (0.2mL per point) at five points. No microneedling will be performed on the hands."
68577|NCT03647904|Behavioral|SEMS Project|TThe intervention is a culmination of five empirically supported interventions: (1) The MS Wellness Program aimed at developing lifestyle strategies to enhance quality of living and cope with various aspects of MS; (2) The FACETS intervention, which aims to reduce fatigue and improve self-efficacy; (3) The Modified Story Memory technique, which improves new learning and memory; (4) The Speed of Processing training, which improves performance on measures of processing speed in persons with MS. Finally, the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders, a cognitive behavioral intervention, which improves psychological functioning and functional outcomes.
68578|NCT03647891|Device|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether or not CPAP can improve clinical outcomes in patients with cardiovascular disease. Therefore, our investigators plan to initiate CPAP therapy in patients hospitalized for cardiovascular disease to investigate whether there is an improvement in cardiac function and clinical outcomes (e.g. mortality).
68579|NCT03647865|Procedure|Osseous Genioplasty|Surgical Procedure that cuts the chin and reposition it in the correct place
68580|NCT03647852|Drug|Methylprednisolone|1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
68581|NCT03647852|Drug|IVIG|1. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
68582|NCT03647852|Drug|other basic supportive treatment|"Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day~Low molecular weight heparin calcium 50IU/kg.d"
68583|NCT03647839|Drug|Nivolumab 10 MG/ML|Nivolumab will be supplied free of charge by Bristol‐Myers Squibb (BMS) as sterile liquid in 10mL glass vials.
68621|NCT03647488|Drug|capmatinib|Tablets, given orally
117438|NCT03268460|Diagnostic Test|Blood anion gap|(Na+) - (Cl- + HCO3-)
68584|NCT03647839|Drug|BNC 105|BNC105 will be provided free of charge by Bionomics, as a sterile solution of BNC105P. BNC105P is a clear, colorless to yellow liquid presented in a clear glass vial and is intended to be diluted with commercially available sterile 0.9% saline prior to IV administration.
68585|NCT03647839|Drug|BBI608|BBI‐608 will be supplied free of charge by Boston Biomedical as capsules.
68586|NCT03647826|Behavioral|Mind Power Intervention|The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
68587|NCT03647813|Radiation|Photobiomodulation|Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
68588|NCT03647813|Radiation|Placebo|The same laser protocol was followed but with the device switched off.
68589|NCT03647800|Biological|APVO436|APVO436
68590|NCT03647787|Other|observational study|This study is a longitudinal observational study
68591|NCT03647774|Drug|Extended release naltrexone|380mg injectable extended release naltrexone every four weeks
68592|NCT03647761|Device|Tetra-grip|Tetra-grip is a tubular elastic bandage that provides both compression and support
68593|NCT03647748|Device|Sham Comparator|A modified device utilizing a pigtail connector to bypass active treatment.
68594|NCT03647735|Other|patient-controlled sedation|Patient-controlled propofol boluses for patients undergoing elective orthopaedic surgery under central neuraxial block
68595|NCT03647722|Other|Assessment of leukocyte function.|The function and phenotype of regulatory B-cells, regulatory T-cells and alternatively-activated monocytes will be assessed directly ex vivo from PBMC.
68596|NCT03647709|Other|opioids|dosage frequency and duration
68597|NCT03647683|Other|Self-Compassion|"Participants are introduced to the concept of self-compassion. Treating oneself with kindness, while being mindfully aware of the present moment as well as the fact that suffering is part of human life - a shared human experience.~Participants are instructed to use this strategy to cope with the following heat stimulus."
68598|NCT03647683|Other|Acceptance|"Participants are introduced to the concept of acceptance. Thoughts, Emotions and Reactions do not need to be related. Being aware of the present moment helps with accepting the present state and reacting contradictory to the thoughts and feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
68599|NCT03647683|Other|Distraction|"Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus."
68600|NCT03647683|Other|Heat pain|Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
68601|NCT03647670|Drug|PF-04965842|orally bioavailable small molecule that selectively inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
68602|NCT03647670|Drug|Midazolam|substrate which undergoes extensive metabolism by CYP3A4 and CYP3A5 and acts as a sensitive probe for evaluating drug interaction with respect to these isoenzymes
68603|NCT03647657|Drug|177Lu-PP-F11N|Intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without co-medication with Sacuitril (100 mg Entresto) in each patient
68604|NCT03647657|Drug|Sacuitril|Medication with Sacuitril (100 mg Entresto) additional to the injection of 177Lu-PP-F11N
68605|NCT03647644|Diagnostic Test|Coagulation Laboratory Testing|Standard coagulation testing (Platelet count, Fibrinogen, PT/INR, aPTT), and Thromboelastogram as is routine and per institutional protocol in this population.
68606|NCT03647631|Procedure|sentinel lymph node biopsy|Authors discuss a possible usefulness of SNLB for staging and diagnosis in porocarcinoma.
68607|NCT03647618|Other|Ultrasound|Ultrasound-guided regional anaesthesia
68608|NCT03647605|Behavioral|VR Mind|"Two VR Mind sessions using virtual reality scenarios concerning social situations in which social phobics are prone to experience anxiety. The pilot study will consist of two scenarios: Public Speaking in Lecture Hall and Telephoning in Public. Two sessions are planned, each containing two expositions to virtual reality environment, each lasting 10 minutes."
68609|NCT03647592|Drug|Erlotinib/Gefitinib combined with Bevacizumab|Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
68610|NCT03647579|Drug|midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine|midazolam intravenously (i.v.) in a dose of 0.05 mg/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
68611|NCT03647579|Drug|Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine|Dexmedetomidine intravenously (i.v.) in a dose of 2mic/kg diluted by 50ml saline over 10 minutes using syringe pump plus 1 mg/kg ketamine
68612|NCT03647566|Diagnostic Test|18F Sodium Fluoride Positron Emission Tomography / Computed Tomography|PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
68613|NCT03647566|Diagnostic Test|CT Aortic Angiogram|CT scan to assess aortic morphology and contextualise PET scan
68614|NCT03647566|Diagnostic Test|Aortic MRI|Aortic MRI to assess aortic morphology and contextualise PET scan
68615|NCT03647540|Procedure|fluorescent laparoscopic radical gastrectomy|The gastrectomy for group F would be underwent by the fluorescence laparoscopy. All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
68616|NCT03647540|Procedure|traditional laparoscopic radical gastrectomy|The gastrectomy for group L would be underwent by the laparoscopy.All surgical procedures will be performed by the surgery team ,which is leaded by professor Wang Quan.
68617|NCT03647514|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
68618|NCT03647514|Drug|Xeloda|Tailored neoadjuvant chemotherapy with 4 cycles of PX(weekly Abraxane 125mg/m2, Q3week Xeloda 1250mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
68619|NCT03647501|Device|Interbody cage (titanium)|Subject will be implanted with a 3D-printed titanium cage during their lumbar interbody fusion surgery.
68620|NCT03647501|Device|Interbody cage (PEEK)|Subject will be implanted with a poly-ether-ether-ketone (PEEK) cage during their lumbar interbody fusion surgery.
68624|NCT03647475|Combination Product|Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT|To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
68625|NCT03647462|Device|Continuous Positive Airway Pressure|CPAP is an FDA approved therapy machine for patients diagnosed with OSA. CPAP provides positive air pressure to the patients throat to ensure the patients airway stays open during sleep. CPAP is the gold standard treatment for OSA, but there is limited research that demonstrates whether CPAP can improve clinical outcomes in patients with COPD. Therefore, our investigators want to initiate CPAP therapy in patients hospitalized for COPD to investigate whether there is an improvement in cardiac function and clinical outcomes (i.e. mortality).
68626|NCT03647449|Dietary Supplement|Juice|Participants will be drinking 800-900 kcal/day in cold-pressed juices.
68627|NCT03647449|Behavioral|Caloric restriction via Plant-based meals|Participants' caloric intake will be limited to 800-900 kcal/day.
68628|NCT03647449|Dietary Supplement|Plant-based meal|Participants will be eating ~900 kcal/day in pre-prepared plant-based meals.
68629|NCT03647436|Other|Comprehensive Geriatric Assessment. Both groups.|Evaluation of the incidence of geriatric syndromes: depression, delirium, cognitive disorders, falls, gait disturbances, urinary and fecal incontinence
68630|NCT03647423|Biological|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
68631|NCT03647423|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
68632|NCT03647423|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
68633|NCT03647423|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1]
68634|NCT03647423|Biological|GI-6301|Brachyury yeast
68635|NCT03647423|Biological|haNK|haNK™, NK-92 [CD16.158V, ER IL-2]
68636|NCT03647423|Drug|Avelumab|injection
68637|NCT03647423|Drug|Cetuximab|Injection
68638|NCT03647423|Drug|Cyclophosphamide|Capsules
68639|NCT03647423|Radiation|SBRT|Stereotactic body radiation therapy
68640|NCT03647410|Device|lumbopelvic fixation|Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
68641|NCT03647397|Device|Photo Electrochemical Oxidation (PECO) for Air Purification|PECO air purifiers from Molekule will be placed in every patient room. Health metrics will be tracked for patients whose diagnosis is respiratory distress.
68642|NCT03647384|Drug|Gulingji capsules|Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
68643|NCT03647384|Drug|Ginko Biloba Extract tablet|Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
68644|NCT03647371|Device|Macintosh laryngoscope|intubation with direct laryngoscope
68645|NCT03647371|Device|McGrath Videolaryngoscope|intubation with McGrath Videolaryngoscope
68646|NCT03647358|Device|PET/CT Scan|Up to four whole-body PET scans (approximately 24, 48, and 120 hours post 124I oral dose) will be performed on one of the GE Discovery 710 or 690 PET scanners.
68647|NCT03647358|Drug|Iodine-124|Patients will receive 0.9 mg injections of rhTSH on two consecutive days. Twenty-four hours after the last injection of rhTSH each patient will receive approximately 5 mCi (range: 4-7 mCi) of 124I orally as a single dose.
68648|NCT03647345|Device|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
68649|NCT03647345|Device|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
68650|NCT03647345|Device|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
68651|NCT03647332|Procedure|Cooled RFA treatment|cooled radiofrequency ablation
68652|NCT03647332|Drug|Steroid Drug|steroid injection
68653|NCT03647319|Device|High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and anodal tDCS over the right DLPFC are simultaneously stimulated.
68654|NCT03647319|Device|High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC|10Hz rTMS over the left DLPFC and cathodal tDCS over the right DLPFC are simultaneously stimulated.
68655|NCT03647319|Device|High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC|10Hz rTMS over the left DLPFC and sham tDCS (no stimulation) over the right DLPFC are simultaneously stimulated.
68656|NCT03647306|Behavioral|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
68657|NCT03647306|Behavioral|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
68658|NCT03647306|Behavioral|Extended Overnight Fast|Provide subjects a regimented amount of calories at each meal.
68659|NCT03647293|Procedure|Ultrasound Guided Central Catheter Insertion|
68660|NCT03647293|Procedure|Peripherally Inserted Central Catheter|
68661|NCT03647280|Drug|Abraxane|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
68662|NCT03647280|Drug|Epirubicin|Tailored neoadjuvant chemotherapy with 4 cycles of PE(weekly Abraxane 125mg/m2, Q3week Epirubicin 100mg/m2, 21day/cycle) is planned for early breast cancer patients(stage of T2-4N0-3M0) who are eligible for primary systemic therapy.
68663|NCT03647267|Device|Pneumatic Vitreolysis (C3F8 injection)|Pneumatic Vitreolysis will be performed via an intraocular injection of C3F8 gas. Perfluoropropane (C3F8) is an inert gas under pressure and is administered by injection into the vitreous cavity. It was approved by the FDA in February 1993 (P900066) for the use of placing pressure on detached retina.
68664|NCT03647267|Other|Observation|No intervention; sham injection only
68705|NCT03646877|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
68665|NCT03647254|Behavioral|Patient education group|Group meetings with educational sessions will be organised in health center. A group educational intervention was practiced to half of the patients, by one expert patient, so that every patient must attend to one group meeting
68666|NCT03647241|Device|Self-Ligating Brackets|These brackets can be opened and closed through the use of a sliding cap embedded into the design of these brackets. There is no need to use elastic modules to ligate the arch.
68667|NCT03647241|Device|Traditionally-Ligated Brackets|These brackets are used in the conventional manner, where the orthodontist is obliged to use elastic modules to engage the arch into the slot of the bracket.
68668|NCT03647241|Procedure|Corticotomy|Corticotomy without flap elevations will be performed in order to induce acceleration in tooth movement during the orthodontic treatment in only one group.
68671|NCT03647202|Drug|Milademetan Treatment A|Treatment A: Single oral dose of milademetan 160 mg capsules under fasted conditions
68672|NCT03647202|Drug|Milademetan Treatment B|Treatment B: Single oral dose of milademetan 160 mg capsules with a high-calorie, high-fat meal
68673|NCT03647202|Drug|Milademetan Treatment C|Treatment C: Single oral dose of milademetan 160 mg capsules with a standard meal.
68674|NCT03647189|Device|Hybrid Fractional Laser|Hybrid Fractional Laser
68675|NCT03647176|Other|Cold snare polypectomy|cold snare polypectomy (CSP), which does not include electrocautery to do a polypectomy with a snare
68676|NCT03647163|Biological|VSV-IFNβ-NIS|Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
68677|NCT03647163|Biological|Pembrolizumab|Pembrolizumab
68678|NCT03647150|Drug|amoxicillin|At enrollment the child will receive a 2 week course of amoxicillin
68679|NCT03647150|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|1 sachet RUTF per day (525 calories) till child MUAC is greater than 12.4 cm or 12 weeks have elapsed
68680|NCT03647150|Behavioral|Mother Care group|Nutrition education via mother care groups lead by a respected elder in the local community
68681|NCT03647137|Other|Detailed motor testing, including FoG, in PD subjects|"Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state."
68682|NCT03647124|Drug|Lenalidomide|Lenalidomide
68683|NCT03647111|Drug|Crizotinib|Crizotinib 250mg po bid
68684|NCT03647098|Genetic|kras|the gene mutation
68685|NCT03647085|Device|Wearable cardiac monitor|Participants will be fitted with a wearable cardiac monitor placed on the skin that measures physiologic signals.
68686|NCT03647072|Drug|CHOP|CHOP only
68687|NCT03647072|Drug|CHOP Plus Lanzoprazole|CHOP plus Lanzoprazole 60 mg
68688|NCT03647072|Drug|CHOP Plus Famotidine|CHOP Plus Famotidine 40 mg
68689|NCT03647059|Diagnostic Test|LSCM examination|Cut a piece of donor liver and conduct the LSCM examination after staining fluorescein
68690|NCT03647046|Device|Customized Scleral Lens|A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
68691|NCT03647033|Device|iStent implantation|The iStent is a FDA and Health Sciences Authority (HSA) approved micro-bypass stent device that bypasses the trabecular meshwork (filtration membrane of the aqueous fluid exit pathway) and reroutes aqueous from the anterior chamber directly into canal of Schlemm and out of the eye. It lowers the intraocular pressure (IOP) by increasing the outflow of fluid from the eye from the micro-bypass. In angle closure, the lens has to be removed to create enough space for the iStent to be inserted.
68692|NCT03647007|Other|FIFA 11 for health|The training consists of various football exercises, such as passing, shooting, dribbling, etc., and small-sided games. The small-sided games are performed as e.g. 3v3 with small goals (2x5 m).
68693|NCT03646994|Drug|Crizotinib|Crizotinib Cap 250 mg po bid
68694|NCT03646981|Device|Leishmania Ab Rapid Test (CTK, Biotech)|Rapid diagnostic tests to detect antibodies anti-Leishmania
68695|NCT03646968|Drug|Anlotinib and Docetaxel|Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)
68696|NCT03646955|Radiation|No partial breast irradiation|Omission of radiation therapy
68697|NCT03646942|Radiation|low level laser therapy|low level laser therapy will be used in order to induce tooth movement. low level laser with a wave length of 830 nm, output of 150 mw, energy of 2 j per point and application time of 15 seconds per point will be applied on each tooth of the six upper incisors according to this protocol: the root will be divided into 2 halves; gingival and cervical. Laser will be applied in the center of each half from both the buccal and palatal sides which means 4 application points and a total energy of 8 Joules/each tooth.
68698|NCT03646942|Device|Lingual Orthodontics|Lingual braces will be used to conduct the orthodontic treatment of patients with moderate level of crowding on the upper dental arch.
68699|NCT03646929|Diagnostic Test|MEP using standard facilitation technique|measuring of MEP using standard facilitation technique according to the Guidelines of International Federation of Clinical Neurophysiology
68700|NCT03646929|Diagnostic Test|MEP using modified facilitation technique|measuring of MEP using modified facilitation technique (application of additional 8-12x magnetic stimuli for arms and legs)
68701|NCT03646916|Drug|Dexamethasone|Gluco-corticosteroid
68702|NCT03646916|Other|No dexamethasone|Nothing
68703|NCT03646903|Behavioral|Cognitive Bias Modification|Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
68704|NCT03646903|Behavioral|Psychoeducation|Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
118929|NCT03256656|Other|Electrical stimulation on renal urine production|
68706|NCT03646877|Other|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
68707|NCT03646864|Drug|ACT-541468|ACT-541468 will be orally administered as a tablet (50 mg strength) at a once daily (o.d.) dose of 50 mg in the evening.
68708|NCT03646864|Other|Placebo|Placebo will be orally administered as a tablet matching ACT-541468, o.d. in the evening.
68709|NCT03646851|Diagnostic Test|Questionnaries|patients will have to do a sputum and to complete some questionnaries
68710|NCT03646825|Dietary Supplement|Natural Antioxidant supplement|1 capsule orally three times a day for 12 weeks
68711|NCT03646812|Other|Glucose Reference 1|Glucose contains 50g of available carbohydrates
68712|NCT03646812|Other|Glucose Reference 2|Glucose contains 50g of available carbohydrates
68713|NCT03646812|Other|Glucose Reference 3|Glucose contains 50g of available carbohydrates
68714|NCT03646812|Other|Semolina Penne|Semolina Penne contains 50g of available carbohydrates
68715|NCT03646812|Other|Wholegrain Penne|Wholegrain Penne contains 50g of available carbohydrates
68716|NCT03646812|Other|Semolina Spaghetti|Semolina Spaghetti contains 50g of available carbohydrates
68717|NCT03646812|Other|Wholegrain Spaghetti|Wholegrain Spaghetti contains 50g of available carbohydrates
68718|NCT03646812|Other|Jasmine Rice|Jasmine Rice contains 50g of available carbohydrates
68719|NCT03646812|Other|Asian Noodles|Asian Noodles contains 50g of available carbohydrates
68720|NCT03646799|Drug|CKD-387|test drug
68721|NCT03646799|Drug|D484|reference drug
68722|NCT03646786|Device|Virtual reality tests|"The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:~10 minutes sitting test: detection of 5 targets in a 360 ° field of vision~10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe~Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe"
68723|NCT03646760|Behavioral|HYCR|"This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site."
68724|NCT03646760|Behavioral|CBCR|This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
68725|NCT03646747|Diagnostic Test|MRI scan|Additional imaging using MRI scan
68726|NCT03646721|Drug|DA-1241|"[Part1] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~[Part2] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)"
68727|NCT03646721|Drug|Placebo|[Part1] Administration once daily for 28 days. [Part2] Administration once daily for 56 days.
68728|NCT03646721|Drug|Sitagliptin|[Part2] Administration of Sitagliptin 100mg once daily for 56 days.
68729|NCT03646695|Procedure|ILM flap transposition|during ILM flap Transposition, an ILM flap is placed on the macular hole
68730|NCT03646695|Procedure|ILM peeling|during ILM Peeling the ILM is removed around the macular hole
68731|NCT03646682|Procedure|vitrectomy with membrane peeling|during vitrectomy with membrane peeling a prob of the vitreous body and the excised epiretinal membrane will be harvested for gas-chromatography/mass spectrometry
68732|NCT03646669|Behavioral|PEF Feedback|Patients in the PEF feedback arm will receive a one-time session including asthma management education, discussion of their asthma symptoms, review of individual PEF results and perception of symptoms, and problem-solving techniques to improve asthma self-management. After the session, the participants in this arm will be able to view in the display of the AM2 device their PEF values and will be instructed to mentally note their actual results with their pre-effort estimated BPF. They will also set a motivational message for themselves that will appear on the device.
68733|NCT03646669|Behavioral|Asthma education|General asthma education, AM2 training, and positive counseling, but no discussion linking asthma symptom perception to SMB. Following the session, these participants will use the AM2 to track PEF actual and perceived values twice per day, but they will be blinded to the actual PEF values. Control arm patients will see a standard motivational message appear on the screen of the AM2 device.
68734|NCT03646656|Behavioral|reciprocal peer support and non reciprocal coach support|Peers and peer coaches provide mutual or one-way support to initiate and sustain behavioral improvements for cardiovascular health, with additional education from study staff.
68735|NCT03646643|Procedure|Standard Atrial fibrillation ablation|The AF ablation procedures should follow the sequence below: Diagnostic catheter placement Electrophysiology study; Transseptal puncture; Left atrial electro-anatomical mapping is required prior to an ablation procedure. Post ablation pacing procedure(s) and/or infusion of cardiac medications to localize triggers/ assess and localize pulmonary vein reconnections (e.g., Adenosine, Isoproterenol 2-20 mcg/min). Study procedure requirements are outlined below: Isolation of all pulmonary veins and Non-pulmonary vein trigger ablation for all patients. Linear ablation lines are only required to treat documented macro-reentry atrial tachycardias and limited to the following targets only: LA roof line, mitral valve isthmus line, LA floor line, right atrial carvotricuspid isthmus linear ablation.
68736|NCT03646643|Procedure|Coronary sinus to left atrium connection elimination|Distal coronary sinus pacing will be utilized to localize distal connections between the main coronary sinus body and the left atrium. Focal lesions will be applied to early left atrial activation sites, until no distal coronary sinus to left atrial connections are electrically manifest. If vein of marshall connections to the left atrium are present, differential pacing will be utilized to prove the lack of distal coronary sinus to left atrium connections.
68740|NCT03646617|Drug|Nivolumab|"Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.~After these 4 doses, nivolumab (240 mg) will be administered as monotherapy for 18 additional doses starting week 12 as an IV infusion over 30 minutes, as per the package insert, every 2 weeks (+/- 3 days)."
68741|NCT03646617|Drug|Ipilimumab|Nivolumab (1 mg/kg) will be administered as an IV infusion over 30 minutes, followed by ipilimumab (3 mg/kg) on the same day given as an IV infusion over 90 minutes. The two drugs will be given on day 1, then every 3 weeks for a total of four doses.
68742|NCT03646604|Drug|Upadacitinib (ABT-494)|Upadacitinib will be administered orally.
68743|NCT03646591|Drug|Chemotherapy|5-FU+CF+Docetaxel+Oxaliplatin
68744|NCT03646578|Other|State of anxiety|"Patient anxiety assessment by STAI-Y-A self-assessment questionnaire provided before and after pediatric interview.~The assessment is given to patients upon arrival in the hospitalization service of pregnancies and again after the pediatric interview. This pediatric interview should take place between 1 and 7 days after admission to the hospital ward.The second part includes a 6-week inclusion period with assessment of patients' state of anxiety by a STAI-Y-A self-assessment questionnaire given before and after pediatric interview associated with the delivery of a written document. on prematurity."
68745|NCT03646552|Drug|THX-110|"Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days."
68746|NCT03646539|Behavioral|Use of smartphone application (app)|Use of a CBT-based automated conversational agent available as a mobile device smartphone application for the management of mood.
68747|NCT03646539|Other|Treatment as usual|Treatment as usual will include (but may not be limited to) the participant's 6-week postpartum follow-up visit with their obstetrics care team. Participants will be sent surveys to evaluate their depressive and anxiety symptoms.
68748|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）|Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）is a generic product manufactured by Hunan Dongting Pharmaceutical Co., Ltd.
68749|NCT03646526|Drug|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）|Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）is a generic product manufactured by Sandoz Inc;
68750|NCT03646513|Device|SMF Short Modular Femoral Hip System|Primary Total Hip Arthroplasty with SMF Short Modular Femoral Stem Hip System.
68751|NCT03646500|Procedure|Retrobulbar Block|Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure
68752|NCT03646500|Procedure|Remifentanil|Remifentanil administered as intravenous infusion prior to transcleral diode procedure
68753|NCT03646487|Dietary Supplement|Probiotic LP299v 10x10 colony forming units in capsule form|Daily lactobacillus plantarum (LP299v) 10x10 colony forming units in capsule form
68754|NCT03646487|Other|Placebo in capsule form|Daily placebo in capsule form
68755|NCT03646474|Drug|tranexamic Acid infusion|The tranexamic Acid group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision.
68756|NCT03646474|Drug|saline infusion|In the placebogroup, patients will receive a placebo of 100 mL 0.9% normal saline.
68757|NCT03646461|Drug|Ibrutinib 560mg PO daily (Imbruvica)|BTK inhibitor combined with PD-1 inhibitor
68758|NCT03646461|Drug|Cetuximab|Cetuximab 400mg/m2 x 1 then 250 mg/m2 weekly 28 day cycle
68759|NCT03646461|Drug|Nivolumab|Nivolumab 3mg/kg biweekly 28 day cycle
68760|NCT03646448|Behavioral|Motivational Interviewing|Up to three counseling sessions on telephone based on Motivational Interviewing and elements of Cognitive Behavioral Therapy. Counselings are within 12 weeks after the baseline diagnostic interview and follow the stepped care approach.
68761|NCT03646435|Device|Fitbit Charge 2|The Fitbit Charge 2 is the electronic wearable chosen for this pilot study. This particular Fitbit is capable of measuring patient heart rate, sleep and physical activity. The data collected will then be analyzed with respect to the outcomes of this study. To determine the accuracy of the Fitbit, data collected will be compared to the nurses' standard patient assessment (for HR and physical activity) and to patient responses on the Richards-Campbell Sleep Questionnaire (for sleep).
68762|NCT03646422|Other|Registry of patients (exposure is Cutaneous Lymphoma)|
68763|NCT03646409|Other|Venous thromboembolic event, arterial thromboembolic event, bleeding events|Whether or not venous or arterial thromboembolic and bleeding events occur in patients with esophageal cancer receiving neoadjuvant chemotherapy
68764|NCT03646396|Drug|Sofosbuvir-daclatasvir|Sofosbuvir-daclatasvir for 3 months
68765|NCT03646383|Procedure|Radiofrequency ablation|The procedure will include an ultrasound with radiofrequency ablation of the benign thyroid nodule percutaneously
68766|NCT03646370|Drug|Tenofovir Alafenamide|Patients with HIV infection who are virally suppressed receiving a tenofovir disoproxil fumarate-based antiretroviral therapy regimen that switched to tenofovir alafenamide without switching any other components of their treatment regimen.
68767|NCT03646357|Other|Non-betablocker|No betablocker will be administered. Patients randomized to no beta-blockade will be discouraged to use beta-blockade as long as there is no other indication than strictly secondary prevention after myocardial infarction. Any other treatment or management is to be given as per usual care.
68768|NCT03646357|Drug|Betablocker|"A betablocker will be administered. To reflect contemporary management, for which this study is designed to test, there will not be a defined minimum dosage. The type and dose of BB will be left at the discretion of the PI. Generic drug and accepted dosages will be:~Metoprolol succinate up to a total dose of 200mg daily~Bisoprolol up to a total dose of 10mg daily~Carvedilol up to a total dose of 50mg daily~The treating physician will be encouraged to aim for an equipotent dose of 100 mg metoprolol succinate or higher. Any other treatment or management is to be given as per usual care."
68769|NCT03646344|Drug|Heme Arginate 25 MG/ML|IMP - to be administered at a dose of 3mg/kg to a maximum dose of 250mg over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
68944|NCT03645070|Device|Single probe thermometer|Will be evaluated if a single probe thermometer is superior to a multipolar and self expandable thermometer or to no probe thermometer at prevention of esophageal thermal injury
68770|NCT03646344|Drug|0.9% Sodium-chloride|Placebo - 100ml of 0.9% Sodium Chloride will be given over 30 mins. Participants will receive intervention twice during the trial, one on Day 0 (day of transplantation) and then again on D1 (20-28 hours after dose 1).
68771|NCT03646331|Drug|Imeglimin Reference product|Reference product
68772|NCT03646331|Drug|Imeglimin|Test product (new formulation tablet)
68773|NCT03646318|Drug|Ketanserin|"The dose of 0.75 ug/kg/min is a dose that has been used frequently in critically ill patients. The concentration of the study drug infusion will be 40 mg/40 ml glucose 5%. The maximum dose however will be 4.5 mg per hour for patients with a weight more than 100 kg. The pre-filled 50 ml syringes will be filled with 40 ml of a solution containing 40 mg ketanserin or 0 mg ketanserin in glucose 5%.~The minimum number of ketanserin vials (2 ml with 5 mg/ml) that are needed is 240 (40 mg = 4 vials per patient). Duration of intervention: 8 hours"
68774|NCT03646318|Other|Placebo|Glucose 5% solution
68775|NCT03646305|Behavioral|Cognitive Defusion|Cognitive defusion aims to change one's relationship to their thoughts - as opposed to changing the content, form, or frequency - by reframing internal experiences as less threatening (Hayes, Luoma, Bond, Masuda, & Lillis, 2006). It is the process of detaching the link between one's thoughts and perceptions of reality and acknowledging the role one's thoughts play in their internal events. A number of techniques have been developed to remove the literal quality of such thoughts, including repeating the thought, and, more recently, singing the thought.
68776|NCT03646292|Drug|Pioglitazone|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
68777|NCT03646292|Drug|Empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
68778|NCT03646292|Drug|Combination of pioglitazone and empagliflozin|The investigators will compare the degree of liver fat between Pioglitazone monotherapy, Empagliflozin monotherapy, Combination of pioglitazone and empagliflozin following randomization.
68779|NCT03646279|Device|Calibrace|The CALIBRACE is a new product designed to improve posture using a front-to-back tensioning system that lifts shoulders up and back.
68780|NCT03646266|Drug|Rocuronium Bromide|Titration with rocuronium bromide until tidal volume 6ml/kg PBW
68781|NCT03646253|Other|Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)|
68782|NCT03646240|Drug|ABI-009|For dose finding, ABI-009 will start at 5 mg/m2/dose IV, once a week for three weeks, in cohorts of 3 participants each using the standard 3+3 dose-finding design
68783|NCT03646227|Other|Standard of Care|There is no prescribed intervention for this study. Standard of care will be captured in the eCRF.
68784|NCT03646214|Device|Midline traction oral appliance|Device positions the mandible forward to open airway; device can be titrated to gradually advance the mandible.
68785|NCT03646201|Behavioral|FFF|FFF teaches authoritative parenting skills for reducing children's exposure to and intakes of SoFAS, including changes to the family eating environment, mothers' own eating behaviors, and food parenting practices.
68786|NCT03646188|Drug|Placebo-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering a placebo.
68787|NCT03646188|Drug|25 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 25 µg of doxorubicin hydrochloride.
68788|NCT03646188|Drug|50 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 50 µg of doxorubicin hydrochloride.
68789|NCT03646188|Drug|100 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 100 µg of doxorubicin hydrochloride.
68790|NCT03646188|Drug|200 µg doxorubicin-containing MNA|A 15 x 15 mm array containing 400 tip-loaded, dissolvable microneedles delivering 200 µg of doxorubicin hydrochloride.
68791|NCT03646175|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
68792|NCT03646175|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
68793|NCT03646162|Drug|Veru-944|Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
68794|NCT03646162|Drug|Placebo|Placebo
68795|NCT03646136|Procedure|Retained fluid|Retained fluid
68796|NCT03646136|Procedure|Emptied fluid|Emptied fluid
68797|NCT03646123|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion
68798|NCT03646123|Drug|doxorubicin|25 mg/m^2 by IV infusion
68799|NCT03646123|Drug|vinblastine|6 mg/m^2 by IV infusion
68800|NCT03646123|Drug|dacarbazine|375 mg/m^2 by IV infusion
68801|NCT03646123|Drug|G-CSF|Granulocyte colony stimulating factor (G-CSF) primary prophylaxis administered 24-36 hours after each dose of A+AVD
68802|NCT03646123|Drug|nivolumab|240 mg by IV infusion
68803|NCT03646110|Procedure|Minimally invasive esophagectomy|Minimally invasive esophagectomy is a surgical procedure for esophageal resection
68804|NCT03646097|Procedure|Angio-PCI|PCI only with angiography and without OCT findings
68805|NCT03646097|Procedure|OCT-PCI|PCI with OCT-measurements but no transfer of landingzone-markers to angiography
68806|NCT03646097|Procedure|ACR-PCI|PCI with OCT-measurements and transfer of landingzone-markers to angiography
68807|NCT03646084|Other|Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program|To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.
68808|NCT03646084|Other|Rehabilitation program|Rehabilitation program current clinical practice
68809|NCT03646071|Drug|RX108|RX108
68810|NCT03646058|Drug|Buprenorphine|Buprenorphine, 0.4mg pills, sublingual
68811|NCT03646058|Drug|Placebo|Placebo pills, sublingual, specifically made to mimick buprenorphine pills
68812|NCT03646045|Other|Transpyloric feeding|Preterm infant feeding using transpyloric feeding tube (nasoduodenal tube)
119096|NCT03255330|Drug|Tramadol|Standardized treatment
68813|NCT03646032|Behavioral|SAAFE|After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.
68814|NCT03646032|Behavioral|Control|This group will receive the standard of care by launching a mobile app that will play a knowledge-based You-tube video on risky sexual behavior, which we will name SAAFE video. They will also receive pamphlets that provide information on testing location and care if they have HIV/STI.
68815|NCT03646006|Drug|Bupivacaine|10 mL (5mg/mL)
68816|NCT03646006|Drug|Placebo|10 mL normal saline
68817|NCT03645993|Genetic|Genetic Testing|A one time blood sample will be taken.
68818|NCT03645980|Drug|DKN-01 300 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
68819|NCT03645980|Drug|DKN-01 600 mg|DKN-01 will be administered intravenous (IV) over a minimum of 30 minutes and up to a maximum of 2 hours given on days 1 and 15 of each 28 day cycle.
68820|NCT03645980|Drug|Sorafenib|For combination with DKN-01, sorafenib will be administrated according to standard clinical practice. Part A: After 8 weeks monotherapy with DKN-01, the study will be continued as combination therapy of DKN-01 and sorafenib until objective disease progression (PD) or unacceptable toxicity occurs. Part B:After PD1, study treatment will be continued as combination therapy of DKN-01 and sorafenib until disease progression (PD2) or unacceptable toxicity occurs.
68821|NCT03645967|Device|ReadyCleanse Cloths|ReadyCleanse cloths and the standardized cleansing procedure will be the standard-of-care for catheter care and maintenance; patients will undergo routine perineal care for a minimum of twice per day and after each incontinent episode.
68822|NCT03645954|Procedure|Femoral Nerve Block|"Procedure: Femoral Nerve Block~The femoral nerve block will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 50 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral nerve block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral nerve block."
68823|NCT03645954|Procedure|Femoral Triangle & Adductor Canal Blocks|"Procedure: Femoral Triangle & Adductor Canal Blocks~These two blocks will be performed as described in Arms section.~Device: Ultrasound~Linear ultrasound transducer probe (Flex Focus 400 exp, bk medical, Denmark) will be used to guide the needle placement.~Device: Needle~20-gauge 100 mm Ultraplex needle (B. Braun Medical Inc., Melsungen, Germany) will be used to perform the femoral triangle block and adductor canal block.~Drug: Local anesthetic~Bupivacaine 0.125% 20 mL will be used to perform the femoral triangle block and adductor canal block (10 mL for each block)."
68824|NCT03645941|Behavioral|Facebook Group|The pilot trial, a two-arm, parallel groups, randomized controlled design, will enroll 60 participants randomized with 1:1 allocation to the intervention or control condition. Participants will be randomized within stratified blocks based on sex (male, female), age group (19-29, 30-49, 50+ years), and region (urban, rural); potential variables related to outcomes. Assessments will be conducted for both study groups at baseline and at 1, 3, and 6 month follow-up.
68825|NCT03645928|Biological|Lifileucel|"A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.~Lifileucel will be administered to patients once (on Day 0) during the study."
68826|NCT03645928|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration. TIL will be administered to patients once (on Day 0) during the study.
68827|NCT03645928|Drug|Pembrolizumab|Humanized antibody. Pembrolizumab 200 mg IV will be administered approximately every 3 weeks for up to 2 years.
68828|NCT03645915|Other|Immunohistochemistry|Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor.
68829|NCT03645902|Diagnostic Test|Magnetic resonance imaging|
68830|NCT03645889|Other|PLTG|A combination of 13 herbal granules
68831|NCT03645889|Other|Placebo|90% starch filler and 10% PLTG
68832|NCT03645876|Drug|SHR-1210|200mg
68833|NCT03645876|Drug|BP102|7.5mg/kg
68834|NCT03645876|Drug|oxaliplatin|130mg/m2
68835|NCT03645876|Drug|capecitabine|1000mg/m2
68836|NCT03645863|Drug|MT-6548|Oral tablet
68837|NCT03645863|Drug|Iron supplement A|Oral tablet
68838|NCT03645863|Drug|Iron supplement B|Oral tablet
68839|NCT03645863|Drug|Iron supplement C|Oral tablet
68840|NCT03645863|Drug|Iron supplement D|Oral tablet
68841|NCT03645850|Device|Vismed gel Multi 0.3% eye drops|Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
68842|NCT03645850|Device|Vismed Multi 0.18% eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
68843|NCT03645837|Other|Compression clamp release|Standard compression clamp is used and will be released at different times according to randomization
68845|NCT03645811|Behavioral|Breathing Technique|The breathing technique was applied take a deep breath while counting from 1 to 8, and then to hold their breath while counting from 1 to 8, and then breathe out while counting from 1 to 8 again.
68846|NCT03645811|Behavioral|Music Therapy|Music therapy was applied in the application room. Via a portable computer, students listened to the mahur maqam for 20 minutes under the supervision of the investigators using an MP3 player.
68847|NCT03645811|Behavioral|EFT|EFT includes taps, nine gamut sequences, and eye movements on the meridian system, focusing on the individual's inhibiting thoughts, disturbing emotions, or memories. EFT regulates the flow of energy in the meridian system of the individual, causing relaxation in the mind, body, and emotions.
68945|NCT03645057|Drug|Crisaborole|This topical ointment is FDA-approved to treat atopic dermatitis of moderate or less severity in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
68848|NCT03645798|Behavioral|"Three good things therapy"|"To maintain an emphasis on the positive experience, participants were directed to record three good things that went well each day. These things could be minor, ordinary, or important. Next to each good thing, participants were required to answer the question: Why did this good thing happen?"
68849|NCT03645798|Behavioral|Normal psychological instruction|Normal psychological instruction is a convenient method set by the hospital. Nurses who have stress or psychological problem could find help through this intervention. It was delivered by psychologists.
68850|NCT03645785|Dietary Supplement|Normal fluid intake without true lemon|16.9oz water with True Lemon
68851|NCT03645785|Dietary Supplement|Double fluid intake plus 3 bottles of water with True Lemon|No intervention
68852|NCT03645772|Other|Exercise intervention|12-week progressive training intervention
68853|NCT03645759|Behavioral|I'm Whole|I'm whole will provide 6 behavioral health treatment sessions that focus on stroke self-management, psychological distress and social re-integration.
68854|NCT03645759|Other|Education + usual care|Will receive the standard usual care for stroke self-management provided by the Michael E. Debakey VA Medical facility and will receive 6 brief health education calls unrelated to stroke or psychological distress.
68855|NCT03645746|Drug|REGN5069|REGN5069 will be administered by IV infusion or SC injection
68856|NCT03645746|Drug|Placebo|Placebo-matching REGN5069
68857|NCT03645733|Procedure|Lower Temperature Group|Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
68858|NCT03645720|Device|Plastic cannula|puncture using plastic cannula
68859|NCT03645707|Behavioral|CAR Training and Psychoeducational Sessions|"Participation in the CAR Training Program, a 1-day training program developed by the J&J Human Performance Institute (HPI). The CAR Training Program uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.~Participants will attend eight weekly follow-up psychoeducational group sessions facilitated by a licensed mental health counselor that will meet for 90 minutes. The themes of these sessions will be RISE - Resilience, Insight, Self-Compassion, and Empowerment. Due to limited time and flexibility in sessions, participants will practice skills through optional homework activities to facilitate learning between sessions."
68860|NCT03645694|Device|Social Support Aid|Please see earlier; the social support aid technology consists of a smartphone with a facial recognition software application and a smartwatch. Up to 1,000 individuals can be enrolled in the facial recognition application. Enrollment includes typing individuals names and relationships of the person with memory concern into the application and taking pictures of PWMC's faces at multiple angles. Once enrolled and in view of the smartphone's camera, the SSA's application recognizes the individual's face and alerts the smartwatch. The watch then vibrates and displays the individuals' name and relationship to the PWMC.
68861|NCT03645681|Device|InnAVasc arteriovenous graft surgical implant|An InnAVasc AVG will be surgically implanted into the upper arm or forearm of enrolled participants
68862|NCT03645668|Drug|Meropenem Injection|Different administration types between two groups
68863|NCT03645655|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II, AFP, and biochemical tests.
68864|NCT03645642|Drug|Midodrine|Midodrine 5 mg thrice daily
68865|NCT03645642|Biological|Albumin|Albumin 20g/l
68866|NCT03645642|Drug|Diuretics|Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
68867|NCT03645629|Diagnostic Test|skin test with food at different storage times|Perform skin tests to each foods at 0, 3, 6 months after preparation and compare the results
68868|NCT03645616|Diagnostic Test|6-minute walk test|"First day: Participants undertook 6-minute walk test. There was a 30-minute interval between the first and second test, when the patient was asked to rest. During the resting period, they respond a pain intensity, functional capacity and physical activity level questionnaire.~Second day: the participants repeated the test and questionnaires."
68869|NCT03645616|Diagnostic Test|10 meters walk test|"First day: After the second 6-minute walk test the participants perform the 10-meter walk test, the test must be performed three times with a 30-second interval, at the end the average test velocity.~Second day: the participants repeated the test."
68870|NCT03645616|Diagnostic Test|30 Second Sit to Stand Test|At the end of the tests the participants perform the 30 Second Sit to Stand Test on the first and second day.
68871|NCT03645603|Drug|Dexmedetomidine|intravenous infusion
68872|NCT03645603|Drug|Placebo|intravenous infusion of physiological saline solution to mimic dexmedetomidine infusion
68873|NCT03645590|Behavioral|Stroke Ready|Stroke Ready community intervention consists of peer facilitated educational workshops, stroke music video, and mass media campaign including print materials (e.g. posters, brochure), health promotion mailers, radio/Television public health service announcements, and the Stroke Ready website and Facebook page.
68874|NCT03645564|Other|Specialized nurse consultation|The purpose of this consultation is to establish a partnership between the patient and the nursing staff. Tools were set up (notebook, movie) to answer the questions of the patient. In case of specific question, an expert will meet the patient (doctor of the service, psychologist, pharmacist or hematologist).
68875|NCT03645551|Diagnostic Test|checkup, no test|In this study we would like to examine if existing restorations already applied in teeth which we treated with laminate veneers had an effect. We will evaluate the laminate veneers by sight and take pictures and use a questionnaire
68876|NCT03645538|Other|Parkinson's disease patients|"The neurophysiological evaluation will be conducted during ON (with medication) and OFF (without medication) period, by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG."
68877|NCT03645538|Other|No drug|The neurophysiological evaluation in healthy subjects will be conducted by transcranial magnetic stimulation by single pulse (EMT-p) and by EEG.
68878|NCT03645525|Drug|Human Umbilical Cord-derived Mesenchymal stem cell|The Human Umbilical Cord-derived Mesenchymal stem cells suspension (2×10^7/kg per KG of the infant 's weight ) will be instilled once through a catheter into the infant' s endotracheal tube
68879|NCT03645525|Drug|placebo|saline
69861|NCT03637556|Drug|DST-0509|Novel iron chelator with improved absorption characteristics
68880|NCT03645512|Behavioral|Corporate Athlete Resilience (CAR) Training Program|A 1-day training program developed by the J&J Human Performance Institute (HPI), which uses a holistic approach that focuses on moving between stress and strategic recovery to help build resilience and enable higher performance.
68881|NCT03645499|Drug|Topical TA-102 A|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
68882|NCT03645499|Drug|Topical TA-102 B|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
68883|NCT03645499|Drug|Topical TA-102 C|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
68884|NCT03645499|Drug|Topical TA-102 D|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
68885|NCT03645499|Drug|Topical TA-102 E|applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks
68886|NCT03645486|Genetic|Infusion of lentiviral TYF-CGD-modified autologous stem cells|Infusion of lentiviral TYF-modified autologous stem cells at 1~10x10^6 gene-modified cells per kg body weight
68887|NCT03645473|Device|Monarch Airway Clearance System|HFCWO Airway Clearance Device
68888|NCT03645460|Genetic|TYF-ADA gene-modified autologous stem cells|Infusion of TYF-ADA-modified autologous stem cells at 1~10x10^6 gene-modified cells per kg body weight; or more infusions depending on the circumstances
68889|NCT03645447|Diagnostic Test|Taste test|A device is used to present a pseudo-randomised series of taste solutions to the participant for identification, in order to establish taste thresholds.
68890|NCT03645434|Drug|AZD8871|Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.
68891|NCT03645434|Drug|Anoro® Ellipta®|Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
68892|NCT03645421|Drug|MEDI0382 100 μg|Solution for injection in 1.0 mL pre-filled syringe, 100 μg per dose, 1 dose
68893|NCT03645421|Drug|MEDI0382 200 μg|Solution for injection in 1.0 mL pre filled syringe 200 μg per dose, 1 dose
68894|NCT03645421|Drug|MEDI0382 300 μg|Solution for injection in 1.0 mL pre filled syringe, 300 μg per dose, 1 dose
68895|NCT03645421|Drug|PlaceboA|1.0 mL liquid formulation per Vial
68896|NCT03645421|Drug|MEDI0382 50 ug|Solution for injection, 1.0 mL per vial, 50 ug
68897|NCT03645421|Drug|PlaceboB|Solution for injection in 1.0 mL pre-filled syringe.
68898|NCT03645408|Drug|Exenatide|5 mcg dose of immediate release exenatide
68899|NCT03645408|Other|Sham injection|Subjects will have a sham injection with no study drug
68900|NCT03645395|Drug|MT-3724|Experimental treatment with MT-3724 in combination with LEN therapy.
68901|NCT03645382|Dietary Supplement|baked barley powder|The baked barley was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The baked barley powder capsule had approximately 900 mg/day, 336 mg of baked barley and 564 mg of nondigestible maltodextrin.
68902|NCT03645382|Dietary Supplement|jeju steam onion|The jeju steam onion was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The jeju steam onion capsule had approximately 900 mg/day, 336 mg of jeju steam onion powder and 564 mg of nondigestible maltodextrin.
68903|NCT03645369|Device|ShotBlocker|ShotBlocker is a drug-free tool with no side effects and does not require preparation. It is a flexible, plastic, C-shaped device with a number of short (2 mm) blunt contact points on its back.
68904|NCT03645369|Device|Ice pack|Ice pack containing gel
68905|NCT03645356|Device|Fixed Appliances|Using an MBT-prescription of metallic brackets, patients will be treated in the conventional way
68906|NCT03645356|Device|Clear Aligners|Using a sequence of clear aligners, patients will be give an aligner every two weeks until the completion of treatment
68907|NCT03645343|Device|Activator|This appliance is constructed in one piece to guide the position of the mandible on closure
68908|NCT03645343|Device|Twin Block|This appliance is constructed in two pieces to guide the position of the mandible on closure
68909|NCT03645317|Diagnostic Test|Blood tests & cardiac imaging|Blood tests (full blood count, lipids, cholesterol, high sensitivity Troponin levels, C-reactive protein (CRP) and brain natriuretic peptide) Cardiac imaging - cardiac CT, cardiac ultrasound, 12-lead ECG
68910|NCT03645304|Drug|Ropivacaine|"Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics."
68911|NCT03645304|Drug|0.9% saline group|Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
68912|NCT03645304|Device|ON-Q Painbuster Silver Soaker|ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
68913|NCT03645291|Diagnostic Test|Local insect allergen extracts skin test|Every patient received both local and commercial insect allergen extracts but in blinded methods
68914|NCT03645278|Drug|SHR0532|Ascending dose oral adminstration
68915|NCT03645278|Drug|Placebo|Ascending dose oral administration
68916|NCT03645265|Behavioral|Auditory|Use of auditory cues to improve speech production
68917|NCT03645265|Behavioral|Gestures|Use of gestures to improve speech production
68946|NCT03645057|Drug|Tacrolimus 0.03% Ointment|This topical ointment is FDA-approved to treat atopic dermatitis in children. Subjects will apply the topical ointment to all affected areas twice daily for 12 weeks.
119427|NCT03252782|Device|Herbst Appliance|Acrylic Splint Herbst Appliance
68918|NCT03645252|Procedure|Vein interruption before any other surgical manipulation|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the vein first group, the lobar vein is dissected and the cartridge and anvil of a vascular cartridge stapler are placed on either side of the vein. The vein is punctured above the stapler with a 23-gauge needle and 7.5 ml of blood is drawn. Finally, the vein is cut. The intervention then proceeds in the usual manner."
68919|NCT03645252|Procedure|Arteries interruption before vein interruption|"The pulmonary tumor-drainage vein is first exposed and punctured with a 23-gauge needle, and 7.5 ml of blood is drawn from the pulmonary vein prior to subsequent surgical manipulation for lobectomy. Collected blood is versed in a Cellsearch tube provided by the manufacturer (Menarini Silicon Biosystems, Castel Maggiore, Italy).~In the arteries before vein group, lobar arteries are first dissected and interrupted (+/- the bronchus and inter-lobar fissures). The lobar vein is then dissected and blood sample is performed as described above."
68920|NCT03645239|Procedure|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
68921|NCT03645239|Other|Preoperative pain assessment|"Patients will be asked to rate, using a 0-10mm visual analog scale (VAS), their surgical anxiety level (On a scale of 0-100, with 0 being not anxious at all to 100 being extremely anxious, how anxious are you about your upcoming surgery?), their anticipated pain (On a scale of 0-10, with 0 being no pain at all and 10 being pain as bad as you can imagine, how much pain do you anticipate experiencing after your upcoming surgery?), and using a categorical scale, their anticipated pain medication need (On a scale of 0 to 5, with 0 being none at all, 1 being much less than average, 2 being less than average, 3 being average, 4 being more than average, and 5 being much more than average, how much pain medication do you anticipate needing after your upcoming surgery?)."
68922|NCT03645239|Other|Questionnaires|Questionnaires including Hospital Anxiety and Depression Scale (HADS), EQ-5D-3L, Edinburgh Postnatal Depression Scale (EPDS), Pain Catastrophizing Scale (PCS), Central Sensitisation Inventory (CSI), pain survey and breastfeeding questionnaire will be administered to the patient.
68923|NCT03645226|Diagnostic Test|Colonoscopy|All subjects will undergo standard mechanical bowel preparation with 4 liters of polyethylene glycol (Klean-Prep, Norgine Ltd., Middlesex, UK). Total colonoscopy will be performed by experienced endoscopists under conscious sedation with intravenous benzodiazepines and narcotics. A conventional intermediate-length colonoscope (Olympus Corporation, Tokyo, Japan) will be used. One mucosal biopsy will be taken in the descending colon. Biopsies will be performed using standard biopsy forces without needle (Olympus Corporation, Tokyo, Japan). Half of the samples will be immersed in 4 oC normal saline solution. All samples will be immediately sent to pathology department and will be stored in a -80 oC freeze for processing of microbiota analyses.
68924|NCT03645213|Device|Virtual Reality Box|Virtual Reality box, a head-mounted display with stereo earphones transmits the cartoon image onto screens in front of the child's eyes. It was showed on Samsung Galaxy Note5 phone and Samsung Gear VR box /SM-R323N.
68925|NCT03645213|Device|Tablet Computer|The tablet computer is a device that children watch on a 7-inch screen.
68926|NCT03645200|Drug|Fluzoparib combined with Apatinib|"Fluzoparib :~40mg.bid, morning and evening each time, interval of 12 hours or so, the first oral administration 72 hours later~Apatinib :~250mg or 500mg take one day, 72 hours later, the continuous drug delivery phase (B-C1D1) was entered into the Fluzoparib, that is, the Fluzoparib capsule with 40mg.bid, every morning and evening, each time, interval of 12 hours, the Apatinib tablets daily with the Fluzoparib capsule with the same service, fixed doses of 250mg or 500mg, daily. Continuous drug delivery for 28 days for one cycle"
68927|NCT03645187|Drug|FOLFOX|FOLFOX regimen
68928|NCT03645187|Drug|Folfox and celecoxib|Folfox regimen and celecoxib
68929|NCT03645174|Device|Using long tube|Fiberoptic-guided intubation through LMA, using long tube
68930|NCT03645174|Device|Aintree catheter|Fiberoptic-guided intubation through LMA, using Aintree catheter
68931|NCT03645161|Diagnostic Test|rat and mouse skin test|Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
68932|NCT03645148|Biological|iNeo-Vac-P01|Neoantigen peptides
68933|NCT03645148|Other|GM-CSF|immune adjuvant
68934|NCT03645135|Other|Goal elicitation|Patients will be asked to list 2 goals for their visit
68935|NCT03645122|Procedure|Stimulation|This study is a novel approach to studying neuroplasticity after stroke. Previous work in humans with incomplete spinal cord injury demonstrates that the resulting plasticity transiently enhances motor output, indicating that there is also therapeutic potential. This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb. Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects.
68936|NCT03645109|Dietary Supplement|Vitamin D3|Capsules with 5,000 IU of vitamin D3 once a day (one capsule)
68937|NCT03645109|Other|Capsules with placebo (talcum food grade)|Capsules with placebo (talcum food grade)
68938|NCT03645096|Drug|Pregnenolone 500 mg|Pregnenolone 500 mg capsule.
68939|NCT03645096|Drug|Pregnenolone 800 mg|Pregnenolone 800 mg capsule.
68940|NCT03645096|Drug|Placebo|Placebo capsule manufactured to mimic pregnenolone capsule.
68941|NCT03645083|Behavioral|Telephone call|Participants in the intervention group receive a one-time telephone call reminder to attend follow-up treatment at the acupuncture clinic
68942|NCT03645083|Behavioral|Text message|Participants in the intervention group receive a one-time text messaging reminder to attend follow-up treatment at the acupuncture clinic
68943|NCT03645070|Device|multipolar and self expandable thermometer|Will be evaluated if a multipolar and self expandable thermometer is superior to no probe or to single probe thermometer at prevention of esophageal thermal injury.
68947|NCT03645031|Other|Acute Intermittent Hypoxia|AIH entails continuous breathing as the level of oxygen in the air is decreased, then returned to normal. Participants will alternate between breathing normal air and breathing hypoxic air (air that has less oxygen). Participants will complete a single 45 minute session of acute intermittent hypoxia (AIH). Breathing, muscle activity and heart activity will be monitored before, during and after the procedure. The intervals will last 1 minute each.
68948|NCT03645031|Other|Sham Acute Intermittent Hypoxia|Participants will complete the sham acute intermittent hypoxia, consisting of a single 45 minute session of breathing air with normal oxygen levels. All aspects of this procedure will otherwise be the same as for the AIH procedure. Breathing, muscle activity and heart activity will be monitored before, during and after the procedure.
68949|NCT03645018|Diagnostic Test|diagnosis with tomosynthesis|Re-evaluation of lung nodule detection rate at 5 years in patients with early diagnosis of lung cancer
68950|NCT03645005|Behavioral|"My Guide (psychoeducation & self-management program)"|"My Guide is a Smartphone application incorporating elements informed by the extant literature, designed to improve quality of life and symptom burden among Hispanic breast cancer survivors. My Guide components are designed to improve breast cancer knowledge, cancer-relevant self-efficacy, stress and symptom management skills, Both intervention and active comparator conditions are administered to participants for 8 weeks."
68951|NCT03645005|Behavioral|"My Health (health education program)"|"My Health is a health promotion Smartphone application with health education content on nutrition, and general advice on lifestyle choices and prevention. The My Health control content was based on similar content tested in other psychosocial interventions with cancer survivors. Both intervention and active comparator conditions are administered to participants for 8 weeks."
68952|NCT03644979|Other|Skydiving|Tandem skydiving (with an experienced instructor)
68953|NCT03644966|Dietary Supplement|Bifidobacterium infantis|Probiotics
68954|NCT03644966|Other|Placebo|Sugar pill manufactured to mimic probiotic tablet
68955|NCT03644966|Drug|Antibiotics|Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women
68956|NCT03644953|Drug|Hydroxyurea|Participants will be started on hydroxyurea 20 ± 2.5 mg/kg/day in addition to continuing simple chronic transfusion every 4 weeks ± 1 week. Hydroxyurea will be dose escalated to achieve a HAT target dose (HAT-TD). Hydroxyurea will be increased by 5 mg/kg/day after 8 weeks of a dose if HAT-TD is not achieved (maximum daily dose 2,000 mg). After HAT-TD has been achieved, minor dose increases may occur if subject grows a significant amount to maintain the same mg/kg dose.
68957|NCT03644940|Diagnostic Test|CustomSight|Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
68958|NCT03644927|Behavioral|Progressive exercise training|The 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
68959|NCT03644927|Behavioral|Waitlist Control|Participants will be screened for eligibility and if randomized into the waitlist control group. Wait list participants will wait for 12-weeks before they can participate in the progressive exercise training program. The 12 week progressive exercise program is identical to the one used in the intervention group. Specifically, the 12 week progressive exercise program gradually increases the walking/running intensity and length of exercise every 2 weeks for the first 6 weeks and then maintains the higher intensity level for weeks 7-12,. The exercise intensity is based on percentile targets defined by the baseline cardiopulmonary test (CPX test). Participants will be called at weeks 4 and 10 to assess and foster exercise motivation, using basic principles of motivational interviewing..
68960|NCT03644914|Behavioral|10-week Reading Program|Intervention sessions will be carried out during the school day in a private school room. In each session, the investigator will work with the child individually to help him or her read better. Intervention will incorporate word recognition and phonetic decoding of words established as meeting 1st grade essential literacy standards. Learning techniques will involve games, play, movement, music, and breaks (i.e., the child is able to move about and associate words with color, video, and music. Three 5-minute breaks will be integrated into each 1-hour session to allow the child time to rest and process learned material). Intervention will also use each child's personal interests as a context around which sight words will be learned.
68961|NCT03644901|Procedure|nonsurgical periodontal treatment|patients will undergo nonsurgical periodontal treatment to reduce the relative attachment level and improve the probing depth. An initial session will be conducted to remove supra gingival plaque and calculus. another appointment is set to perform full moth scalling and root planing.
68962|NCT03644888|Other|Cycle ergometer training|Already in arm/group descriptions
68963|NCT03644888|Other|Airway clearance program|Already in arm/group descriptions
68964|NCT03644888|Device|Vibration therapy|Already in arm/group descriptions
68965|NCT03644888|Device|Sham vibration therapy|Already in arm/group descriptions
68966|NCT03644875|Device|etacoat|Etacoat is a HPMC formulation intended to be used in ophthalmic anterior segment cataract surgery.
68967|NCT03644862|Device|etafill|Etafill is a HA formulation intended to be used in opthalmic anterior segment cataract surgery.
68968|NCT03644849|Device|CO2RE® (Syneron Candela Corp, Wayland, MA)|The intervention will include a single treatment of a lower extremity wound with ablative fractional carbon dioxide laser after MMS surgery.
68969|NCT03644849|Other|Sham laser treatment|A physician who is not blinded will perform a sham laser treatment on blinded subjects.
68970|NCT03644836|Drug|Amino Acids|Sweet taste cocoa flavored drink
68971|NCT03644836|Drug|Placebos|Sweet taste cocoa flavored drink
68972|NCT03644823|Drug|Atezolizumab|PDL1- inhibitor
68973|NCT03644823|Radiation|Radiotherapy|6 Gy x 3
68974|NCT03644810|Diagnostic Test|PPT measurement|The sensitivity to pressure which is gradually increased is assessed. The procedure is performed at the back and the lower leg
68975|NCT03644810|Diagnostic Test|Pain catastrophizing scale|A validated questionnaire that measures three domains of pain-related catastrophizing thoughts: helplessness, rumination and excessive magnification
69003|NCT03644615|Other|Usual care|No intervention on the patients
68976|NCT03644810|Procedure|Cold Pressor Test|The participant submerges one hand into a tank of cold (5 deg C), circulating water. The procedure is commonly know to decrease the sensitivity to pressure (PPT procedure) so that a difference appears in pain sensitivity when comparing PPT values before and after the procedure
68977|NCT03644797|Genetic|Exome sequencing|Detection of a second (likely) pathogenic molecular event on exome data for intellectual disability beyond the 16p13.11 Copy Number Variant.
68978|NCT03644784|Diagnostic Test|Standardized protocol for assessing aortic regurgitation using videodensitometry|Standardized protocol for assessing aortic regurgitation using videodensitometry
68979|NCT03644771|Drug|Acthar|4 treatment periods of 3 months each with 20 units biweekly, 40 units biweekly, and 80 units biweekly, with a tapering period to no drug for the fourth 3 month period. Then one year f/u.
68980|NCT03644758|Diagnostic Test|socio-demographic data and personal medical history|Socio-demographic data and personal medical history is a self-administered questionnaire.
68981|NCT03644758|Diagnostic Test|Pittsburgh Sleep Quality Index (PSQI)|Pittsburgh Sleep Quality Index (PSQI) is a self-administered questionnaire. This score evaluates sleep disturbances.
68982|NCT03644758|Diagnostic Test|Epworth Sleepiness Scale|Epworth Sleepiness Scale is a self-administered questionnaire. This score evaluates excessive drowsiness.
68983|NCT03644758|Diagnostic Test|Insomnia Severity Index (ISI)|Insomnia Severity Index (ISI) is a self-administered questionnaire. This score evaluates insomnia severity.
68984|NCT03644758|Diagnostic Test|stop-BANG questionnaire|Stop-BANG is a self-administered questionnaire. This score evaluates Obstructive Sleep Apnea (OSA).
68985|NCT03644745|Behavioral|VM @ Home Usability|Our primary outcome measures will be use of the coaching system features, level of daily physical activity, mood, self-efficacy, and user satisfaction. Secondary outcomes that will inform our further development and be important outcomes in subsequent trials include user adherence to their coaching goals, physical function and level of socialization. For the pilot study, we plan to assess physical function and level of socialization at baseline and at the end of 3 months. For the other outcome measures, we will be able to integrate the data collection into the VM@Home platform and coaching process.
68986|NCT03644732|Procedure|SEEG Group|Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
68987|NCT03644719|Behavioral|Cognitive behavioral skills training|A brief cognitive behavioral skills training was applied to teach ketamine abusers about stimulus control, refusal skills, communication skills, decisional balance, and infectious diseases prevention.
68988|NCT03644706|Drug|ADV7103|Each dose of ADV7103 contains a fixed ratio of 1/3 of ADV7103-CK (potassium citrate) and 2/3 of ADV7103-BK (potassium bicarbonate) based on the mass of active substances. The strength is 6.44 (± 10 %) mEq/g of ADV7103 (alkalinizing power).
68989|NCT03644706|Drug|Placebos|"Placebo is a combination of 2 mm green coated lactose granules and 2 mm white coated lactose granules.~Each dose of placebo contains a fixed ratio of 1/3 of green granules and 2/3 of white granules."
68990|NCT03644693|Dietary Supplement|Nutritional Formulation Containing Exogenous Ketones|A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
68991|NCT03644693|Dietary Supplement|Placebo Formulation|A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
68992|NCT03644680|Diagnostic Test|Nasal Provocation with Birch Extract|Nasal spray containing birch extract from Allergopharma
68993|NCT03644680|Other|Nasal Provocation with NaCl 0.9%|Nasal spray containing sterile sodium chloride 0.9%
68994|NCT03644667|Biological|tocilizumab|6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
68995|NCT03644667|Biological|Placebo|The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.
68996|NCT03644667|Drug|Standard of Care Triple IS|"Standard of care triple maintenance IS includes:~A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.~Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.~An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.~Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.~Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol."
68997|NCT03644654|Procedure|Standard care group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. Fluid boluses will be used according to anesthesiologists decision (timing and amount of fluids). In case of drop of mean arterial pressure (MAP) below 65 mmHg norepinephrine will be started (with initial bolus of 5 - 10 ug).
68998|NCT03644654|Procedure|Noninvasive monitoring group|Patient will receive 2 ml/kg/hour of crystalloids (Ringerfundin BBraun) intraoperatively. In case of hypotension (defined as a mean arterial pressure below 65 mmHg), the intervention will be led according to a protocol based on cardiac index, systemic vascular resitance and stroke volume variation (SVV) values (ClearSight, Edwards).
68999|NCT03644641|Procedure|Desflurane Group|General anesthesia will be held using desflurane in end- tidal concentration according to target value of entropy levels (between 40 and 60).
69000|NCT03644641|Procedure|Propofol Group|General anesthesia will be held using Schnider effect model for propofol (target control anesthesia). Titration will be done according to target value of entropy levels (between 40 and 60).
69001|NCT03644628|Procedure|Laparoscopic repair of anterior and apical pelvic organ prolapse|Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
69002|NCT03644615|Other|Mindfluness and usual care|Intervention based on a mindfulness training program as a therapeutic alternative in osteoarthritis of the knee or hip. Mindfulness is a technique of attention training, which is to focus one's attention on the present moment and to examine the sensations that come to mind, how they appear, how they last time, and how they disappear.
69004|NCT03644602|Dietary Supplement|low FODMAPs diet|Low FODMAPs diet was a diet containing low amount of poorly absorbed short-chain carbohydrates (Fermentable, Oligo-, Di-, Mono-saccharides And Polyols)
69005|NCT03644589|Biological|Pembrolizumab|200mg,Given intravenous (IV) infusion, every 21 days
69006|NCT03644589|Drug|Cisplatin|75mg/m2, intravenous (IV) infusion, every 21 days, for 6 cycles Given IV
69007|NCT03644576|Drug|ozanimod|ozanimod
69008|NCT03644576|Drug|Pseudoephedrine|Pseudoephedrine
69009|NCT03644576|Drug|ozanimod placebo|ozanimod placebo
69010|NCT03644550|Drug|LMB-100|Given IV at RP2D on days 1, 3 and 5 of two (2) 21 day cycles.
69011|NCT03644550|Biological|Pembrolizumab|Given IV at approved dose on day 1 of each 21 day cycle, starting with cycle 3, for up to 2 years with the option of a second course for patients meeting criteria.
69012|NCT03644537|Procedure|Orthodontic intrusion|"27 female patients coming to the Orthodontic department, Cairo University seeking orthodontic treatment, where their age ranges from 15 - 18 years, where their treatment plan include extraction of upper first premolars, and using the split-mouth technique, one side will be control group without application of force where the other side will receive intrusive mechanics for the same patient in the upper arch (one side will not receive any force and the same tooth on the other side of the arch will suffer intrusive mechanics, that's why named SPLIT MOUTH TECHNIQUE - as if the arch is split into two subjects, one control subject (tooth) and the other study subject (tooth) . According to the amount of force of the working side, the total number of patients will be divided into 3 groups.~Each of 9 subjects, the first group where a light force will be applied (10 gm), the second group where moderate force will be applied (25gm), the third group where heavy force will be applied(100 gram)."
69013|NCT03644524|Behavioral|Heat therapy|Regular hot tub use
69014|NCT03644511|Drug|Regorafenib (Stivarga, BAY73-4506)|Prescribed by physician.
69015|NCT03644511|Drug|Sorafenib (Nexavar, BAY43-9006)|Prescribed by physician.
69016|NCT03644498|Other|Non-Interventional|Non-Interventional
69017|NCT03644485|Drug|Tacrolimus immediate-release formulation|oral
69018|NCT03644485|Drug|Tacrolimus prolonged-release formulation|oral
69019|NCT03644485|Drug|Induction therapy|All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.
69020|NCT03644485|Drug|Mycophenolic acid drugs|All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.
69021|NCT03644485|Drug|Corticosteroids|All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.
69022|NCT03644472|Drug|nitrate rich beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
69023|NCT03644472|Drug|nitrate depleted beetroot juice|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
69024|NCT03644459|Biological|LYN00101|"Concentrate for intravenous infusions (10 mg / ml) with Molecular Weight 150 - 151 kDa.~Each cycle of treatment consists of 24 weeks. Patients who enroll into this study will receive an infusion of assigned dose of LYN00101 biweekly. No intra-patient dose escalation is allowed. The proposed dose escalation sequence is 10mg/kg, starting from 8 mg/kg."
69025|NCT03644446|Biological|Bisoprolol plasma residual concentration dosage|Bisoprolol plasma residual concentration dosage will be subsequently studied by renal function (altered if creatinine clearance < 30mL/min, mild altered between 30-60mL/min, normal > 60mL/min as estimated by the CKD-EPI formula)
69026|NCT03644433|Procedure|Single layer closure|Uterine incision will be approximated with continuous unlocked suture avoiding the inclusion endometrium and without trimming incision edges.
69027|NCT03644433|Procedure|Double layer closure after resection uterine scar|Uterine incision will be trimmed and old scar tissue will be removed. Then first, endometrium will be approximated by continuous unlocked suture mimicking subcuticular suture avoiding the inclusion of endometrium and second, upper part of myometrium will be approximated by a continuous unlocked suture.
69028|NCT03644420|Diagnostic Test|Clinical evaluation|Functional scores for the pathological joint will be determined
69029|NCT03644420|Diagnostic Test|Radiology|
69030|NCT03644420|Diagnostic Test|Dynamic contrast-enhanced magnetic resonance imaging|Patients will be examined using a 3T MR scanner (MR 750W, General Electrics, Milwaukee, WI) with a dedicated knee coil. Subchondral bone marrow vascularization in medial and lateral femorotibial compartments will be assessed with DCE-MRI and lesions will be graded on MR images.
69031|NCT03644420|Diagnostic Test|Evaluation of histological status|Upper tibial resection pieces will be collected and the vascularization will be determined according to the OARSI score
69032|NCT03644407|Other|Spine Surgery|Patients undergoing spine surgery, who are the subjects eligible for participation to this observational prospective registry
69033|NCT03644394|Device|Implantation of IMES sensors|Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
69034|NCT03644381|Other|Oral Immunotherapy|Starting from a very low level and over a period of several months, participants in the treatment group receive escalating doses of milk. Participants will also have blood and saliva draws to assess parameters of their immune system as well as skin prick testing
69035|NCT03644355|Behavioral|Lifestyle counseling|Inter-disciplinary, interactive, family based behavioral intervention for overweight children
69036|NCT03644342|Drug|Nirapaib|(see treatment regimen and method of treatment assignment)
69037|NCT03644329|Other|Control group|The volunteers will not performed the interventions.
69038|NCT03644329|Other|Lower-load resistance training (LL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 30% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
69039|NCT03644329|Other|Higher-load resistance training (HL)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, three sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
69261|NCT03642626|Drug|Fludarabine|25 mg/m2 i.v. daily for 3 days
69040|NCT03644329|Other|Higher-volume resistance training (HV)|The volunteers will be perform the resistance training, three times a week for 12 weeks on non-consecutive days, six sets with 80% of 1RM and repetition until or close to failure in each set and 1.5-min of rest between sets and exercises.
69041|NCT03644316|Device|BandGrip skin closure device|topical skin closure device
69042|NCT03644303|Radiation|SBRT + ADT|Short course SBRT to 1 or 2 oligo-progressing metastases in addition to continued abiraterone or enzalutamide
69043|NCT03644290|Behavioral|Cognitive training|Five sessions of semantic strategy training and face-name association training
69044|NCT03644290|Behavioral|Control Condition|Five sessions of active control information and education
69045|NCT03644277|Device|Acute Intermitted Hypoxia|Subjects will be fitted with a latex-free full non-rebreather mask with a custom neoprene head strap, mask and oxygen delivery system are commonly used for altitude training. The mask will first provide a normoxic air (room air) mixture (FiO2 = 0.21) via the mask.
69046|NCT03644277|Procedure|Massed Practise|"Address gross upper extremity movements, grip and pinch strength, and coordination.~Tasks utilized may include, but are not limited to: lifting a weighted can, squeezing, cutting paper, popping bubble wrap, translating different resistance clothespins, etc. The ultimate goal of the session is to achieve a total of 300 repetitions during training. Task difficulty may be progressed (making it more difficult), if the participant is able to achieve >100 repetitions in less than 15 minutes, on two different occasions. A task may be made easier if the participant is unable to achieve 50 repetitions of a task within 15minutes. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for a task to be deemed successful, increasing/decreasing the size of the object used. The number of total repetitions and any item progressions will be recorded."
69047|NCT03644277|Device|Rapael Glove|The Rapael Smart Glove is a virtual reality hand exoskeleton rehabilitation device. The tasks selected will address gross movement and hand function during a 45 minute session. Additional time may be required for device set up and activity selection/modification. Tasks utilized will include, but are not limited to: fly swat, throwing darts, squeezing an orange, catching a baseball, and floating fish. Tasks will be modified based on participants' perceived fatigue and challenge levels, as determined by a rating from 0-10. The participant goal will be to maintain the task difficulty between a 5-8/10 range. This would depict a moderate to difficult task rating, but an ability to complete the task. Progressing a task may include: changing the task, addition of resistance, increasing the range of motion required for task success, and increasing the duration of contraction. The number of total repetitions and activity outcomes will be recorded.
69048|NCT03644264|Drug|PA21|sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
69049|NCT03644264|Drug|sevelamer carbonate|sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
69050|NCT03644251|Other|amniotic and umbilical cord matrix|Cryopreserved human amniotic and umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability.
69051|NCT03644238|Diagnostic Test|Oral Glucose Tolerance Test|75g of glucose is consumed
69052|NCT03644238|Behavioral|Inactivity|Lying or sitting down.
69053|NCT03644238|Behavioral|Physical activity|20 minutes of fixed intensity exercise on a bicycle ergometer.
69054|NCT03644225|Device|Measurment with Aspirational Medical Device|The mechanical properties of healthy and SSc-diseased skin will be assessed by suction based measurements with a new developed Aspirational Medical Device.
69055|NCT03644225|Device|Measurment with Cutometer MPA 580|The mechanical properties of healthy and SSc-diseased skin will be assessed by CE-marked Cutometer MPA 580
69056|NCT03644212|Drug|Vitamin D3|Sixty-three vitamin D deficient women (16 with PCOS and 47 without PCOS) were supplemented with 50.000 IU of oral vitamin D3, once weekly for 8 weeks. Serum 25-hydroxyvitamin D (25OH-D), sRAGE and AMH levels were checked before and after treatment.
69057|NCT03644199|Other|Oral Glucose Tolerance Test (OGTT) assessment arm|Hormonal and motility responses to a standard OGTT evaluation arm
69058|NCT03644199|Other|Mixed meal test evaluation test arm|Evaluate the hormonal and motility responses to a standard mixed meal test through the day
69066|NCT03644173|Behavioral|Personal Resilience Empowerment Program including 5 sessions with health coaches|5 coaching sessions that will take place either in-person or over the phone with a research nurse (RN)-Health Coach. During the sessions, the health coach will focus on introducing the 5 pillars of health and well-being: sleep, activity, purpose, nutrition and resilience. Will introduce breathing techniques participants and will teach patients how to acquire mind-body skills to assist in stress management, learn to thrive by building resilience, feel empowered to manage their health, gain self-care skills to decrease anxiety, pain and nausea naturally, control the stress response and trigger the relaxation response to promote well-being and discover what foods fuel the body in preparation for healing, during recovery and overall health.
69067|NCT03644160|Behavioral|Physical activity and behaviour change|The intervention group (group A) will receive an 8 week individualised, tailored behaviour change intervention to promote PA and an information booklet about physical activity to include an initial 1:1 session with a physiotherapist with training in behaviour change techniques and motivational interviewing. Using a range of behaviour change and self-regulation techniques (eg goal-setting, self-monitoring), participants will be guided towards physical activity maintenance at the end of the 8 weeks. In addition, participants will be signposted to physical activity classes, facilities and resources in the local community. This group will continue with their routine care for their condition throughout the study period.
69068|NCT03644147|Drug|Acetaminophen|Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
69069|NCT03644134|Behavioral|Assessment of physiological stress and sleep pattern|The personalized intervention consists of (i) information session (ii) pre-assessment (first assessment) of stress and recovery levels, and sleep patterns (iii) individual feedback sessions and action plans based on the outcomes of the initial assessment (iv) monitoring and follow-ups (v) post-assessment (second assessment) of stress and recovery levels and sleep patterns.
69070|NCT03644108|Drug|Mucinex® ER 600 mg|Single dose of Mucinex® 600 mg ER Bi-Layer tablet
69071|NCT03644095|Drug|Mucinex® SE|Single dose of Mucinex® SE extended-release 600 mg bi-layer tablet
69072|NCT03644095|Drug|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (200 mg guaifenesin q4h) immediate release (IR) syrup
69073|NCT03644082|Behavioral|Luminosity Trial Memory Match|Working memory task that has users indicate whether the current symbol matches the one presented 2 symbols previously. As the user makes correct responses, the previous symbols reduce in contrast and fade int the background, ultimately disappearing, forcing the user to rely entirely on working memory to achieve success
69074|NCT03644082|Behavioral|Luminosity Trial Memory Matrix|The purpose id to remember the location of squares on a grid
69075|NCT03644082|Behavioral|Luminosity Trial Famliar Faces|The purpose is to create associations between visual and verbal information
69076|NCT03644082|Behavioral|Luminosity Trial Brain Shift|The purpose is to decide whether or not cards with numbers and letters are either even or vowels. This measures inhibition, flexibility, and monitoring response set. Also, letterfluency, category fluency, and category switching.
69077|NCT03644082|Behavioral|Luminosity Trial Star Search|The purpose is to visually scan several different objects and find the different object in array of pictures. This measures selective attention.
69078|NCT03644082|Behavioral|Luminosity Trial Word Bubbles|"The purpose is to decide what suffix to use in order to complete a word whena prefix is given. The subject needs to come up with he ending of three different prefixes to complete the word.~This task measures verbal modality, deductive reasoning, integration of multiple bits of information, and flexibility of thinking."
69079|NCT03644082|Behavioral|Luminosity Trial Color Match|The purpose is to identify whether colors and words match each other. This measures the ability to inhibit a dominant and automatic verbal response
69080|NCT03644082|Behavioral|Luminosity Trial Ebb and Flow|Identify which direction leaves are pointing or moving depending on their color.This measures inhibition of impulsive and perseverative responding, and the ability to establish and maintain instructional set.
69081|NCT03644082|Behavioral|Luminosity TrialChalk Board Challenge|purpose is to problem solve quantitative reasoningequationsand to decide which card is greater or if the 2 cards are equal when the math problem is solved.
69082|NCT03644082|Behavioral|Luminosiuty Follow that Frog|The purposeis to remember the path a red frog takes as it jump from lilypad to lily pad in a pond. This measures flexibility of thinking on a visual-motor sequencing task and working memory
69083|NCT03644082|Behavioral|Luminosity Train of Thought|purpose is to guide specific colored trains into corresponding colored matching houses by attending to the different tracks. This measures divided attention.
69084|NCT03644069|Biological|Nexvax2|Nexvax2 subcutaenous (SQ) injections: 32 in total, at twice weekly intervals
69085|NCT03644069|Biological|Placebo|Placebo SQ injections: 32 in total, at twice weekly intervals
69086|NCT03644056|Drug|IMC-001|Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
69087|NCT03644043|Device|EEG scan|WAVi EEG and evoked potential platform. Participants will be scanned using the ElectroCap (FDA Class II) and/or the WAVi Headset with the WAVi Co EEG P300 system, along with the structured clinical interviews and assessments for the various ailments or baseline screenings
69088|NCT03644017|Device|WRAPSODY Stent Graft Placement|The stent graft will be placed into a target lesion (stenosis or occlusion) of a vein
69089|NCT03644004|Other|frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.|"Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data."
69090|NCT03643991|Other|Weighted Blanket|Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
69091|NCT03643978|Other|Decision aid|The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
69092|NCT03643965|Drug|Nefecon|Nefecon 16 mg for daily administration by mouth for 9 months.
69093|NCT03643965|Drug|Placebo oral capsule|Placebo capsules for daily administration by mouth for 9 months.
69094|NCT03643952|Drug|Daptomycin|Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 ml saline over 30-60 minutes depending upon infection type and age level.
69095|NCT03643939|Device|High Flow Nasal Catheter|"HFNC will deliver through AIRVO2. FiO2 from 21 to 100% and heated humidified gas flow up to 60 l / min with temperature of the circuit maintained at 37 degrees.~Oxygen flow will be offered through a humidified nasal catheter. Flow and FiO2 will be titrated according to the protocol to maximize patient´s comfort and SpO2."
69096|NCT03643939|Device|Noninvasive ventilation|NIPPV will be performed using a facial mask (either oronasal or full face). NIPPV will deliver pressures and FiO2 tailored to specific ARF subgroups, according to the protocol. Adjustments of the inspiratory pressure (IPAP) and expiratory pressure (EPAP) and FiO2 according to protocol
69097|NCT03643926|Procedure|Arthroscopic Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by arthroscopic view
69098|NCT03643926|Procedure|Open Brostrom|Brostrom-Gould lateral ligament ankle reconstruction performed by an open approach.
69099|NCT03643913|Procedure|Deep neuromuscular block|Deep neuromuscular block requiring higher doses of Esmeron to target a post tetanic count (PTC) of 1-2 and higher doses of Bridion to reverse the block (4mg/kg).
69100|NCT03643913|Procedure|Moderate neuromuscular block|Normal neuromuscular block requiring dosis of Esmeron to target a train of four (TOF) count of max 2 and lower doses of Bridion to reverse the block (2mg/kg).
69101|NCT03643913|Drug|Neuromuscular Blocking Agents and reversing agents|Deep neuromuscular block versus moderate neuromuscular block.
69102|NCT03643900|Device|pancreatic duct stenting|Place the pancreatic duct stent
69103|NCT03643900|Drug|rectal indomethacin|rectal indomethacin 100mg at preoperative 30min
69104|NCT03643887|Drug|FMT Capsule DE|30 capsule one-time oral dose
69105|NCT03643887|Drug|Placebo oral capsule|30 capsule one-time oral dose
69106|NCT03643874|Drug|Halix albuterol 90 mcg|albuterol unit dose disposable DPI delivers 90 mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 720 mcg
69107|NCT03643874|Drug|albuterol HFA MDI 90 mcg|albuterol HFA MDI delivers 90 mcg of albuterol with each inhalation. Albuterol 90 mcg will be given on one of the treatment days in cumulative doses up to a total dose of 1440 mcg
69108|NCT03643861|Radiation|5 Fraction Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
69109|NCT03643848|Behavioral|Sleep with Sound Cues|Experimental manipulation to observe effects on memory for learned material.
69110|NCT03643848|Behavioral|Sleep with Sham Cues|Sham manipulation
69111|NCT03643835|Device|Thermal Rehab Machine|The Polar Breeze unit is a microenvironmental air-chiller. That means it is a single-pass air-conditioner capable of cooling external air
69112|NCT03643835|Other|Forearm Ice Towels|Towels that are wetted with ice water and wrapped around participants forearms (length of arm from wrist to elbow)
69113|NCT03643822|Drug|Dexamethasone 4mg|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
69114|NCT03643822|Drug|Dexmedetomidine|To guarantee rapid onset as well as effective postoperative analgesia, a 20 mL volume of local anesthetic has been selected for performing the ACB. The block solution will be a 20 ml volume for all groups, prepared by mixing 18 ml of ropivacaine 0.5% mixed with an additional 2 ml prepared according to the randomization.
69115|NCT03643822|Other|Saline|Control/Placebo intervention
69116|NCT03643796|Drug|Remifentanil|Remifentanil infusion of 0.05 to 0.2 mcg/kg/minute started just prior to induction and stopped at emergence from anesthesia.
69117|NCT03643796|Drug|Ketamine|Ketamine infusion of 2 mcg/kg/minute will be started at induction. It will be stopped at the beginning of the emergence from anesthesia, roughly 45 minutes from extubation.
69118|NCT03643796|Drug|Dexmedetomidine|dexmedetomidine bolus of 0.5 mcg/kg over 10 minutes starting 5 minutes prior to induction followed by an infusion of 0.2-0.7 mcg/kg/hour that will be stopped with the start of closing the surgical wound.
69119|NCT03643770|Combination Product|Upper extremity training/Armeo Spring|Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs.
69120|NCT03643757|Procedure|Thoracic epidural analgesia|Before the initiation of the procedure, in the intervention group epidural catheter was inserted by loss of resistance method at the level of T3-T7 with the help of an 18 G Thuohy needle (Pajunk, Geisingen, Germany) while the patient was on sitting position. A test dose of 2 ml, 2% Lidocaine HCL was administered through the catheter. Once, efficacy was confirmed, 10 ml bolus dose of 0.1% Bupivacaine was injected. Analgesia maintenance was provided by infusion of 0.1% Bupivacaine (0.1 ml/kg/hour) both intra- and postoperatively for 24 hours.
69121|NCT03643757|Drug|Bupivacaine|In addition to multimodal analgesia protocol, epidural bupivacaine was administered in TEA arm and pain relief was achieved by intravenous pethidine infusion in IVA arm.
69122|NCT03643744|Drug|Celecoxib 200mg|14 Celecoxib 200mg taken 1 in the morning and 1 in the evening.
69123|NCT03643744|Drug|Placebo|14 placebo capsules taken 1 in the morning and 1 in the evening.
69124|NCT03643731|Device|HeatTens (HV-F311-E)|Patients need to apply the device during 30 minutes.
69125|NCT03643718|Procedure|Emergency General Surgery|Emergency General Surgery operative/non operative management
69126|NCT03643705|Other|Multi-component intervention|4 components as described
69127|NCT03643705|Other|General prevention education|General education as described
69128|NCT03643692|Device|ARISES|The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
69129|NCT03643679|Other|Kwit smartphone app|The Kwit smartphone app combines several popular features of tobacco cessation apps, including game-like features (e.g., unlocking achievement milestones for completing cessation-related tasks), useful statistics (e.g., money saved), and an ability to share progress with friends. Users can actively engage with the app to track cravings or view progress, such as life expectancy gained. A passive component notifies users when milestones have been achieved, e.g., when blood no longer contains nicotine. Motivational messages can be actively requested at any time; they can also appear unsolicited, as when the user logs cravings.
69130|NCT03643666|Drug|dexamethasone|before closure of the laparoscopic entering sites the patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone
69131|NCT03643666|Drug|magnesium sulphate|patients will receive instillation of 40 ml of normal saline containing 16mg dexamethasone plus magnesium sulphate 2 gm into the peritoneum at the end of the operation
69132|NCT03643666|Drug|Placebo (saline)|before closure of the laparoscopic entering sites the patients received instillation of 40 ml normal saline into the peritoneum
69133|NCT03643640|Behavioral|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
69134|NCT03643640|Other|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
69135|NCT03643627|Drug|SYNT001|single IV infusion
69136|NCT03643627|Drug|Placebo|single IV infusion
69137|NCT03643614|Procedure|Injection of autologous regenerative cells of adipose tissue|Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
69138|NCT03643601|Other|Non-Interventional|Epidemiological overview of CKD-associated anemia and treatment patterns, rather than to evaluate specific drugs
69139|NCT03643588|Device|HYAJOINT Plus|Single-injection, 60 mg / 3 ml (2%) cross-linked hyaluronan
69140|NCT03643588|Device|Hyalgan|Three-injection, 20 mg / 2 ml (1%) linear hyaluronan
69141|NCT03643575|Drug|Vicks Cough Syrup for Chesty Coughs|Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
69142|NCT03643575|Drug|Robitussin Extra Strength Chest Congestion|Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water
69143|NCT03643575|Drug|Organ-I- NR tablet|Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water
69144|NCT03643562|Drug|VTS270|Lumber intrathecal infusion of VTS-270
69145|NCT03643549|Drug|Bortezomib and Temozolomide Phase IB|In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
69146|NCT03643549|Drug|Bortezomib and Temozolomide Phase II|The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
69147|NCT03643536|Other|12-WPEP|The 12-WPEP (week physical exercise program) was carried out in 3 sessions each 40 or 60minutes with alternate days per week during 3 months, and with an intensity between 40 to 80 percent of their VO2 max, as the AHA recommends
69148|NCT03643523|Diagnostic Test|Albumine detection|Control of serum albumine levels in postoperatori of colorectal surgery
69149|NCT03643510|Drug|Fulvestrant|Fulvestrant will be dosed 500mg intramuscularly (IM) on days 1 and 15 during cycle 1 and then on Day 1 during subsequent cycles.
69150|NCT03643510|Drug|Abemaciclib|Abemaciclib 150 milligrams mg orally once every 12 hours on days 1-28.
69151|NCT03643497|Drug|anti-infective drugs|According to the models of population pharmacokinetics, the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children
69152|NCT03643471|Device|MRI|Magnetic resonance imaging with advanced sequences including volumetry, spectroscopy and tractograpghy.
69153|NCT03643445|Behavioral|Motivational Orientated Treatment|The motivation-oriented treatment condition is intended to create a context for treatment that is patient-centered, non-judgmental, and will create a therapeutic environment wherein patients can make an informed decision around their goals for treatment and their willingness to commit to the behavioural changes required for recovery from an eating disorder. In general, MI is a psychotherapeutic stance aimed at helping patients in resolving ambivalence toward change and increasing their intrinsic motivation to engage in healthy behaviour choices.
69154|NCT03643445|Behavioral|Psychoeducation-Oriented Treatment|The psychoeducation-oriented treatment condition is intended to teach patients about the causes of eating disorders, the expected course of recovery, obstacles to recovery, and the importance of behavioural changes required for recovery from an eating disorder. In this condition, in order to maximize the differences between groups, no attention will be given to discussing the patient's stage of change, their level of motivation, or their own personal values around recovery. Rather, emphasis during individual meetings with their therapist will be on the importance of symptom abstinence and normal eating.
69155|NCT03643432|Behavioral|Exercise adherence intervention|Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
69156|NCT03643432|Behavioral|Usual Care|Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
69157|NCT03643419|Procedure|Laminectomy|According to the standard procedure of laminectomy for acute spinal cord injury
69158|NCT03643419|Device|Spinal nerve laser therapeutic apparatus（Composed of 808-band fully automatic control laser device and implantable 360° scattering medical fiber）|According to the standard procedure of decompression of laminectomy for acute spinal cord injury, the patient in the Near Infrared Light Irradiation Group placed the implantable 360° scattering fiber laterally above the operation area at the end of the operation. Near infrared light irradiation is applied by spinal nerve laser therapeutic apparatus every day from the day after surgery, once a day for 60 minutes each time.
69159|NCT03643406|Other|Mental Fatigue|modified stroop task
69160|NCT03643406|Other|Control|documentary
120094|NCT03247673|Drug|CT-P16|CT-P16 is a biosimilar product for Avastin
69161|NCT03643393|Procedure|perineal rectosigmoidectomy|In an Altemeier perineal rectosigmoidectomy, a full-thickness circumferential incision is made in the prolapsed rectum about 1-2 cm from the dentate line (see the image below). The hernia sac is entered, and the prolapse is delivered. The mesentery of the prolapsed bowel is serially ligated until no further redundant bowel can be pulled down. The bowel is transected and either hand-sewn to the distal anal canal or stapled with a circular stapler. Before anastomosis, some surgeons plicate the levator ani muscles anteriorly, which may help improve continence.
69162|NCT03643380|Device|AHLeveeS System|AHLeveeS System for treatment of overactive bladder
69163|NCT03643367|Drug|Sevoflurane|Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.
69164|NCT03643367|Drug|Control Group|Included patients randomized in control group, intravenouse sedation is continued with propofol
69165|NCT03643354|Diagnostic Test|Epley maneuver/Barbeque maneuver|Subjects will be rotated using the Rotundum Device to perform the previously described maneuvers Epley/Barbeque to evaluate the presence of BPPV.
69166|NCT03643341|Behavioral|Family Healthy Living|Children aged 8-12 and at least one caregiver will meet for 10 weekly intervention sessions (1.5 hours per session), and 4 extra sessions to be chosen by families and intervention Leaders. During the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. Four biweekly maintenance sessions will follow the main program.
69167|NCT03643328|Biological|blood samples|Blood samples will be collected at inclusion, at 6 months and 12 months for hematological and immunological analyses.
69168|NCT03643328|Biological|nasal swabs|Two nasal swabs will be collected at inclusion, at 6 months and 12 months for virology analyses.
69169|NCT03643315|Behavioral|Exercise and Meal (EX)|30 minute acute bout of high intensity intermittent exercise followed by ad-libitum meal
69170|NCT03643315|Behavioral|No-Exercise and Meal (NEX)|30 minute non-exercise period where participants will be watching a video/movie followed by ad-libitum meal
69171|NCT03643302|Device|Version BF-1T26 electronic bronchoscope|Interventions involving the therapy of bronchoalveolar lavage by Version BF-1T26 electronic bronchoscope
69172|NCT03643276|Drug|Blinatumomab|Experimental therapy in randomizations R-HR and R-MR
69173|NCT03643276|Drug|Bortezomib|Experimental therapy in randomization R-eHR
69174|NCT03643276|Drug|Cyclophosphamide|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
69175|NCT03643276|Drug|Cytarabine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block DNX-FLA for patients with very high relapse risk
69176|NCT03643276|Drug|Daunorubicin|Part of standard chemotherapy
69177|NCT03643276|Drug|DAUNOrubicin Liposomal Injection [DaunoXome]|Part of intensification block DNX-FLA for patients with very high relapse risk
69178|NCT03643276|Drug|Dexamethasone|Part of standard chemotherapy
69179|NCT03643276|Drug|Doxorubicin|Part of standard chemotherapy
69180|NCT03643276|Drug|Etoposide|Part of standard chemotherapy
69181|NCT03643276|Drug|Fludarabine Phosphate|Part of intensification block DNX-FLA for patients with very high relapse risk
69182|NCT03643276|Drug|Ifosfamide|Part of standard chemotherapy
69183|NCT03643276|Drug|6-Mercaptopurine|Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
69184|NCT03643276|Drug|Methotrexate|Part of standard chemotherapy
69185|NCT03643276|Drug|Pegaspargase|Part of standard chemotherapy
69186|NCT03643276|Drug|Prednisolone|Part of standard chemotherapy
69187|NCT03643276|Drug|Tioguanin|Part of standard chemotherapy
69188|NCT03643276|Drug|Vincristine|Part of standard chemotherapy
69189|NCT03643276|Drug|Vindesine|Part of standard chemotherapy
69190|NCT03643276|Drug|Erwinase|Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
69191|NCT03643250|Other|Smaller Portion Size and Standard Appeal (non-divided plate)|Food with Smaller Portion Size and Standard Appeal on a non-divided plate
69192|NCT03643250|Other|Smaller Portion Size and Enhanced Appeal (divided plate)|Food with Smaller Portion Size and Enhanced Appeal on a divided plate
69193|NCT03643250|Other|Larger Portion Size and Standard Appeal (non-divided plate)|Food with Larger Portion Size and Standard Appeal on a non-divided plate
69194|NCT03643250|Other|Larger Portion Size and Enhanced Appeal (divided plate)|Food with Larger Portion Size and Enhanced Appeal on a divided plate
69195|NCT03643250|Other|Smaller Portion Size and Standard Appeal (divided plate)|Food with Smaller Portion Size and Standard Appeal on a divided plate
69196|NCT03643237|Behavioral|Video game-based intervention|The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, & Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
69197|NCT03643237|Other|Control group|The active control group will have access to a platform of online therapeutically inactive information related to active aging.
69198|NCT03643224|Device|Radiofrequency Ablation|A procedure will be performed using a radiofrequency ablation catheter.
69199|NCT03643198|Drug|ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)|The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
69200|NCT03643198|Other|CONTROL|NO treatment
69262|NCT03642626|Drug|Cyclophosphamide|250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
69263|NCT03642600|Dietary Supplement|dietary advice plus myo-inositol and folic acid|dietary advice and lifestyle interventions and myo-inositol
69264|NCT03642600|Drug|dietary advice plus Liraglutide Pen Injector|dietary advice and lifestyle interventions and liraglutide pen injector
69201|NCT03643159|Combination Product|Abilify MyCite - Digital Medicine System|The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
69202|NCT03643159|Drug|Aripiprazole or other oral antipsychotics|For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
69203|NCT03643146|Behavioral|Lifestyle Management|Will use passive ubiquitous sensing through FitBit to 1)learn behavioral profiles of subjects who have pre-HTN/HTN and/or pre-diabetes /Diabetes 2) provide personalized recommendations through mobile based messaging app that will increase the likelihood of engaging in health diet/nutrition, physical activity and sleep practices
69204|NCT03643146|Behavioral|Control Group|will receive standard medical care where research assistant will give pamphlets, with one size fits all recommendations for diet/nutrition, physical activity and sleep, to 10 subjects with comorbid HTN and T2D.
69205|NCT03643133|Drug|Mifamurtide|48 doses overall over 36 weeks
69206|NCT03643133|Combination Product|EI or M-API regimen depending on patient age|"M-API regimen:~One course of high-dose Methotrexate (optional) followed by 5 courses of API, every 21 days~EI regimen :~5 course of EI, every 21 days"
69207|NCT03643120|Other|Qualitative interview|Explorative study of gender dysphoria.
69208|NCT03643107|Drug|Irofulven|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
69209|NCT03643107|Combination Product|Prednisolone 10 mg|"Irofulven will be administered as an intravenous dose of 0.45 mg/kg, over a 30-minute infusion period by venous access at day 1 and 8 of a three week cycle.~Irofulven will be administered in combination with a daily dose of 10 mg orally administered prednisolone."
69210|NCT03643094|Dietary Supplement|Golden Black Seed|1 capsule per day for 8 weeks.
69211|NCT03643081|Device|"Use of the camera Fluobeam"|"Use of the camera Fluobeam to localize, visualize the parathyroid glands during a parathyroidectomy."
69212|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 0.6 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (0.6 mg dose).
69213|NCT03643068|Drug|KSP-QRH-E3-IRDye800 (Peptide 919288G), 1.8 mg|The investigational agent to be used in this study is KSP/QRH dimer: a fluorescently-labeled peptide dimer composed of a 14-amino acid sequence [Lys-Ser-Pro-Asn-Pro-Arg-Phe] and [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a PEG3, Lys and Cys linker [PEG3]2-Lys-Cys to a near-infrared fluorophore, IRDye800CW (1.8 mg dose).
69214|NCT03643055|Diagnostic Test|18F-fluorocholine PET/CT|18F-fluorocholine PET/CT imaging of the neck, mediastinum and whole body.
69215|NCT03643042|Other|Transfusion|Transfusion with Hb maintain between 80 and 100g/L or Hb maintain between 100 and 120g/L
69216|NCT03643029|Device|Video-laryngoscopy following SAD insertion|Following insertion of a supraglottic airway device (SAD), the placement and performance tests are carried out. If the tests are successful, a video-laryngoscopy will be performed to confirm the placement of the SAD in the hypopharynx.
69217|NCT03643016|Other|Surgical strategy based on a software|Surgical strategy décision based on a software
69218|NCT03643003|Behavioral|Music therapy|"Music therapy consists of live singing of participant-preferred music, with guitar accompaniment, by a board-certified music therapist (i.e., MT-BC), following a protocol regarding how to manipulate the music in real time per participant responses. Dosage: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
69219|NCT03643003|Behavioral|Non-Music Verbal Interaction (Placebo)|"Non-music verbal interaction consists of conversation of participants' interests, without music, by a board-certified music therapist, following a protocol regarding how to respond verbally in real time per participant responses. Dosage is the same as for music therapy: participants engage in a small-group (3-6 participants) session at their nursing home, 3 times per week, across 2 consecutive weeks. Each session lasts 25 minutes and occurs in the afternoon."
69220|NCT03642990|Drug|Nicotinamide Riboside|Capsule
69221|NCT03642977|Diagnostic Test|Real time PCR and RT-PCR for DNA and RNA viral species|Qualitative and quantitative real time PCR and RT-PCR assays will be performed on hematopoietic stem cell transplant recipients' plasma samples collected at five specific time points over a one-year period after transplantation (the day of transplantation (D0), 30 days (D30), 3 months (M3), 6 months (M6) and one year (Y1) after transplantation), for the screening of a selection of at least 21 DNA and RNA viruses (belonging to the Herpesviridae, Polyomaviridae, Adenoviridae, Parvoviridae, Anelloviridae, Picornaviridae and Flaviviridae families).
69222|NCT03642964|Drug|CTC-501|pramipexole IR, given with ondansetron
69223|NCT03642951|Device|Active Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
69265|NCT03642587|Other|There is no intervention in this study.|There is no intervention in this study.
69224|NCT03642951|Device|Sham Treatment|The study patients will be randomly assigned to two groups, each consisting of 10 patients: Group A - patients stimulated by devices marked A; Group B - patients stimulated by devices marked B. Since the devices used for actual and sham stimulation (placebo control) are similar in all respects including external appearance and the sound produced while activated, the technician(s), investigators and the patients will be completely blind to whether actual or sham stimuli are being delivered, i.e. whether Group A or Group B patients are receiving the actual stimuli. Indeed, both devices marked A&B could be used to deliver either type of stimuli. Only the person who constructed the devices will know which is which. Therefore, this study will be a truly randomized double-blinded placebo-controlled clinical trial. In case of emergency, un-blinding of the device will be available to the study team via a sealed envelope, stored with the study documents, separate from the subjects study files.
69225|NCT03642938|Behavioral|Walking Exercise|Exercise groups will perform moderate intensity treadmill walking at a speed of 3.5 mph at a 0% incline for 30 minutes.
69226|NCT03642938|Behavioral|Control|The Control group will perform 30 minutes of quiet rest.
69227|NCT03642925|Dietary Supplement|Meal replacement diet|Obese subjects were requested to replace two meals/day (breakfast and lunch or dinner) by balanced nutritional meal replacement diet (equal to 240 kcal) for 8 weeks with one regular meal and make sure the daily target calorie limit should be less than 1500 kcal/day for men and 1200 kcal/day for women.
69228|NCT03642886|Behavioral|Prescribed Detraining|Detraining is the deliberate act of reducing volume of exercise to observe subsequent changes in cardiac indices over time or the partial or complete loss of training of induced anatomical, physiological and performance adaptions. Detraining is primarily employed as a diagnostic tool to help differentiate Athletes' heart from cardiac pathology.
69229|NCT03642873|Drug|Humibid®|Humibid® 1200 mg (single extended release) tablet
69230|NCT03642873|Drug|Hydrocodone Bitartrate|Hydrocodone Bitartrate (3.33 mg q4h X 3)
69231|NCT03642873|Drug|Humibid® and Hydrocodone Bitartrate tablet|Humibid® 1200 mg (single extended release) tablet and Hydrocodone bitartrate (3.33 mg q4h X 3)
69232|NCT03642860|Drug|Triheptanoin|Daily treatment with Triheptanoin oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
69233|NCT03642860|Drug|Placebo Oil|Daily treatment with Safflower oil for 14 days (7 days titration period in addition to 7 days full dose period with 1g/kg/day).
69234|NCT03642847|Biological|Prevnar 13|13 valent Pneumococcal Conjugate
69235|NCT03642847|Biological|multivalent pneumococcal conjugate formulation 1|multivalent pneumococcal conjugate formulation 1
69236|NCT03642847|Biological|multivalent pneumococcal conjugate formulation 2|multivalent pneumococcal conjugate formulation 2
69237|NCT03642834|Drug|ICP-105|25mg, 100mg capsule
69238|NCT03642821|Device|intracranial aneurysm coiling|endovascular treatment of intracranial aneurysm by coiling procedure using OPTIMA coils system
69239|NCT03642808|Other|rehabilitation program|Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
69240|NCT03642795|Other|Questionnaire|Patients are asked to complete several questionnaires
69241|NCT03642782|Device|Electroretinogram Pattern (Diopsys® NOVA System)|it's an additional examination that extends the duration of the ophthalmological consultation by 30 minutes
69242|NCT03642769|Other|Fluid administration|Fluid administration of bolus and maintenance fluids
69243|NCT03642756|Device|different intra-arterial catheter size|in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
69244|NCT03642743|Other|postoperative follow up appointment|Comparison of two and six week postoperative follow up versus a six week postoperative follow up alone
69245|NCT03642730|Device|TransThoracic Echocardiography imaging|ultrasound scanning
69246|NCT03642717|Drug|JARDIANCE DUO®|empagliflozin and metformin
69247|NCT03642704|Drug|Reinforced preventive ARV therapy|"If the mother is HIV-1 or HIV 1/2 infected:~zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks.~nevirapine: 15mg/OD if weight ≥ 2500g / 10mg/OD if weight = 2000-2499g / 2mg/kg/OD if weight < 2000g for 12 weeks in case of HIV-1 infection. After 6 weeks, nevirapine will increase at 20mg/OD~If the mother is HIV-2 infected:~- zidovudine / laminvudine (60/30 mg), ¼ cp morning and evening orally for 12 weeks."
69248|NCT03642691|Biological|Ryplazim|Plasminogen IV replacement therapy
69249|NCT03642678|Dietary Supplement|ONS|High-risk patients identified by prediction model in study group are intervened by pre-defined intervention protocol, which include oral nutrition supply, infection prevention, bp control and improving of dialysis therapy options and so on.
69250|NCT03642665|Drug|Natural cycle|no medication
69251|NCT03642665|Drug|Estradiol Valerate|Oestradiol valerate (Progynova, Bayer, Germany) 6mg daily will be given from day 2 of the cycle. The dose of Progynova is increased to 8mg daily if the endometrial thickness is less than 7mm after 7-10 days of Progynova use. Progynova will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Progynova will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
69252|NCT03642665|Drug|Micronized progesterone|Micronized progesterone (Utrogestan, Besins, Belgium) 200 mg vaginally three times daily is started as soon as the endometrial thickness is 7 mm. Utrogestan will be discontinued the day of the pregnancy test in case of a negative result. In case of a pregnancy, Utrogestan will be continued until 12 weeks or until diagnosis of a non-viable pregnancy.
69253|NCT03642652|Behavioral|SMS|Text reminders to mobile telephone
69254|NCT03642639|Device|Spectra Micrusframe and Spectra Galaxy coils|Spectra MICRUSFRAME and Spectra GALAXY Coils
69255|NCT03642626|Drug|KYMRIAH|FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
69256|NCT03642626|Drug|YESCARTA|CD19-directed genetically modified autologous T cell immunotherapy
69257|NCT03642626|Drug|Fludarabine|30 mg/m2 IV daily for 4 doses
69258|NCT03642626|Drug|Cyclophosphamide|500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
69259|NCT03642626|Drug|Fludarabine|30 mg/m2 IV daily for 3 doses
69260|NCT03642626|Drug|Cyclophosphamide|500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
69266|NCT03642574|Procedure|DNA methylation level|Embryo with methylation level closest to the optimal level (from one couple patients) is the one for embryonic transfer to uterus
69267|NCT03642574|Procedure|blastocyst biopsy and sequencing|All blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
69268|NCT03642561|Device|radiotherapy ablation|We using Cool Tip system or RITA system to perform RFA
69269|NCT03642561|Device|transarterial chemoembolization(TACE)|TACE treatment is a first line treatment for BCLC stage B HCC
69270|NCT03642548|Drug|bifico|Patients in BIFICO group receive platinum‐based doublet chemotherapy for first-line treatment chemotherapy plus Bifico.
69271|NCT03642548|Drug|placebo|Patients in control group receive platinum‐based doublet chemotherapy for first-line treatment chemotherapy plus Placebo.
69272|NCT03642535|Drug|ALA|In all face treatment group, a 1-mm thick layer of 10% ALA was applied to the all face; In AK lesion treatment group, a 1-mm thick layer of 10% ALA was applied to the lesion and to 5 mm of surrounding healthy tissue. And Vehicle control cream was applied to the non-lesion area.
69273|NCT03642522|Device|repetitive transcranial magnetic stimulation|rTMS is a Health-Canada- and FDA-approved treatment for treatment-resistant depression (TRD), using focused magnetic field pulses to stimulate brain regions involved in emotion regulation, safely and non-invasively. rTMS can be applied at varying discharge frequencies which have differential effects on cortical excitability. At a low frequency (≤ 1Hz), rTMS reduces cortical excitability, while at frequencies greater than 1 Hz, rTMS facilitates cortical excitability3. In MDD, either high- frequency rTMS (HF-rTMS) applied over the left dorsolateral prefrontal cortex (DLPFC) or low- frequency rTMS (LF-rTMS) applied over the right DLPFC have similar efficacy. This study utilizes low frequency rTMS to the right DLPFC.
69274|NCT03642509|Device|Left atrial appendage occlusion|Interventional left atrial appendage occlusion with the Amulet or Watchman device
69275|NCT03642509|Drug|NOAC|Medical treatment arm. Patients will be treated with one of the available NOAC drugs; Apixaban, Dabigatran, Edoxaban or Rivaroxaban. The specific drug and dose is at the discretion of the treating physician.
69276|NCT03642496|Biological|Low dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 0.75×10*6/kg.
69277|NCT03642496|Biological|Middle dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 1.5×10*6/kg.
69278|NCT03642496|Biological|High dose ET019002- T Cells|ET019002- T Cells are autologous T cells transduced expressing a novel anti-CD19 (ET019002) chimeric antigen receptor,and are administered by intravenous infusion with the dose of 3.0×10*6/kg.
69279|NCT03642457|Drug|Bupivacaine|20 cc 0.5%
69280|NCT03642457|Drug|Bupivacaine liposome|133mg liposomal bupivacaine
69281|NCT03642444|Device|Cane|Assistive walking device
69282|NCT03642444|Device|Elasticated worn orthotic-garment|Assistive walking device -elasticated worn orthotic garment
69283|NCT03642405|Diagnostic Test|Electrocardiogram examination|12-lead ECG monitored by Holter
69284|NCT03642405|Diagnostic Test|Echocardiography|Echocardiography in accordance to Danish Society of Cardiology
69285|NCT03642405|Procedure|Blood Samples|Blood Samples include, Genetic analysis, serum-Methylphenidate, serum-Citalopram. Sodium, Potassium, Magnesium, Calcium, Chloride, White-Blood-Count, Hemoglobin, C-reactive-Protein, Creatinine, Carbamide, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), Glucose and pro-brain natriuretic peptide (Pro-BNP).
69286|NCT03642405|Behavioral|Questionnaire|Questionnaire regarding patients quality of life
69287|NCT03642392|Other|Identification and treatment of early tendinopathy|Participants receive initial guidance about load reduction when tendinopathy
69288|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (1)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
69289|NCT03642366|Other|Dornier Aries2 LiST Device + 5mg Tadalafil (2)|Patients will receive shockwave treatments (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks.
69290|NCT03642366|Other|Sham LiST Device + 5mg Tadalafil|Patients will receive sham shockwave treatment (12 sessions for all subjects, 5000 shockwaves at each session, at energy level 7)using a sham probe identical to active probes, three times a week (total of 4 weeks) without treatment interval. Starting at first LiST session and finishing at the final week of LiST sessions, subjects will receive Tadalafil 5mg for 4 weeks daily. Total treatment period = 4 weeks. The IIEF-ED domain will be evaluated at Visit 1 and, consequently, at baseline and all follow up visits together with the SEP diaries.
69291|NCT03642353|Drug|Triclosan|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
69292|NCT03642353|Drug|Placebo|Children will be included in a cross-over study with control of plaque using Triclosan/placebo toothpaste for 4 months. Each child will be tested for placebo toothpaste for 45 days and for Triclosan toothpaste for more 45 days. At the beginning of each test, they will be included in a washout period with placebo toothpaste for 15 days.
69293|NCT03642327|Behavioral|Experimental: Maintenance of Certification (MOC)|MOC training will lead to more positive attitudes, comfort level and competence in addressing risk factors for Child Maltreatment.
69294|NCT03642327|Other|Independent online training (IND)|IND refers to practitioners Independently doing the online training.
69295|NCT03642314|Diagnostic Test|HIV self test kit|HIVST receptor will be invited to priority access to PrEP sites
69296|NCT03642288|Drug|Gastrografin|Patients with CRE-induced SBO or ASBO both received GG challenge.
69862|NCT03637556|Drug|Jadenu|Commercial iron chelator with standard absorption characteristics
69297|NCT03642275|Behavioral|iCardia4HF|Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
69298|NCT03642262|Drug|Mucinex®|Mucinex® 600 mg single dose ER bi-layer tablet
69299|NCT03642249|Behavioral|OSCEs|Scenario-based education intervention, including objective structured clinical examinations (OSCEs)
69300|NCT03642249|Behavioral|Lecture|Face-to-face Education using Delirium Care Flip Chart
69301|NCT03642249|Behavioral|E-learning|Including 7 parts of delirium care video
69302|NCT03642236|Drug|Ibrutinib|Ibrutinib 420mg day -3 to d14 combining with chemotherapy with/without sorafenib based on whether the patients are naive to sorafenib before relapse.
69303|NCT03642223|Other|Stable iron isotopes|Participants have to consume a test meal containing stable iron isotopes in order to determine iron absorption
69304|NCT03642210|Combination Product|Levonorgestrel 52 mg intrauterine system|Levonorgestrel 52 mg intrauterine system
69305|NCT03642197|Behavioral|Attendance|The SFA and PA arms will be instructed to attend pre-surgery classes and clinical visits with the patients.
69306|NCT03642184|Drug|Empagliflozin|Dosage adjustment based on glucose targets . Once daily
69307|NCT03642184|Drug|Linagliptin|Dosage adjustment based on glucose targets. Once daily
69308|NCT03642158|Device|repetitive Transcranial Magnetic Stimulation|repetitive Transcranial Magnetic Stimulation (rTMS) utilizes a magnetic coil of wire to non-invasively and painlessly activate small sections of the brain through the skull.
69309|NCT03642145|Drug|Deflazacort|Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
69310|NCT03642132|Drug|Chemotherapy + avelumab followed by avelumab + talazoparib|"Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib"
69311|NCT03642132|Drug|Chemotherapy followed by talazoparib maintenance|"Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib"
69312|NCT03642132|Drug|Chemotherapy + bevacizumab followed by bevacizumab|"Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab"
69313|NCT03642119|Device|iButton®|Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
69314|NCT03642106|Behavioral|Unidos Se Puede|The intervention consists of: (1) encouraging parental involvement in child schooling, general parenting skills, and coping strategies ; (2) fostering child social emotional learning (SEL) through assigning a near-peer success coach to help develop critical thinking, problem solving, and goal setting skills; and (3) promoting positive peer affiliations through participation in regular activities that facilitate bonding to prosocial institutions.
69315|NCT03642093|Combination Product|Nutritional Intervention|Nutritional Supplementation for all subjects and Pancreatic Enzyme Replacement Therapy only for subjects with Exocrine Pancreatic Insufficiency
69316|NCT03642093|Behavioral|Physical Activity Intervention|Walking and Inspiratory Muscle Training
69317|NCT03642067|Drug|Nivolumab|Nivolumab (480 mg) will be administered IV on day 1 (28 day cycle).
69318|NCT03642067|Drug|Relatlimab|Relatlimab (160 mg) will be administered IV on day 1 (28 day cycle).
69319|NCT03642041|Behavioral|smoking|smoking behavior
69320|NCT03642028|Drug|Suvorexant|Suvorexant, a dual orexin receptor antagonist, is the first in a new class of drugs with great promise of addressing insomnia in Veterans with PTSD. Suvorexant targets the orexin neuropeptide system and has been shown to be highly successful in treating insomnia.
69321|NCT03642028|Other|Placebo|Visibly matched, equally weighted placebo tablets. In addition to matching in appearance and weight, they will have identical packaging and labeling as randomized, blinded study medication.
69322|NCT03642015|Behavioral|Music listening|listening the music 15 min
69323|NCT03642002|Other|Toning|"Music therapist will begin gentle breathing and toning on a descending Ah vowel to stimulate vibration in the chest and increase awareness of the breath. The patient will be encouraged to join the music therapist as is comfortable"
69324|NCT03642002|Other|Ocean drum & SOK melody|Music therapist will introduce ocean drum to mimic breathing sounds and will hum the melody of Song of Kin to begin entrainment process. Patient will be invited to join the music therapist in humming as is comfortable
69325|NCT03642002|Other|SOK|Music therapist will introduce sung lyric content of Song of Kin accompanied on guitar. Patient will be invited to sing with music therapist as is comfortable.
69326|NCT03642002|Behavioral|Process|Music therapist will process patient experience and provide psycho-education on strategies for using music to promote comfort and enhance breath.
69327|NCT03642002|Other|Holding Harmonic Container|"Music therapist will provide a holding harmonic container of IM7 - IVM7 and will improvise a repeating melody on ah based on the ambient sounds in the patient's immediate environment"
69328|NCT03641989|Other|Plaque disclosing toothpaste|Plaque identifying toothpaste with a FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD&C Blue No. 1.
69329|NCT03641989|Other|Non-plaque disclosing toothpaste|Toothpaste that does not contain the FDA-registered seed-extract dye (Annatto (Bixa Orellana)) and FD&C Blue No. 1.
69330|NCT03641976|Drug|A-FOLFOXIRI|"Arm I (A-FOLFOXIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV~Drug: oxaliplatin Given IV"
69331|NCT03641976|Drug|Arm II (A-FOLFOX/A-FOLFIRI)|"Arm II (A-FOLFOX/A-FOLFIRI)~Biological: bevacizumab Given IV~Drug: fluorouracil Given IV~Drug: irinotecan hydrochloride Given IV~Drug: leucovorin calcium Given IV"
69332|NCT03641963|Device|Vittamed 205 Non-invasive intracranial pressure (ICP) meter|Non-Invasive intracranial pressure measurement
69333|NCT03641950|Drug|Botulinum toxin type A|Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml ~ 0.1ml per site).
69334|NCT03641924|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidence-based psychotherapy for PTSD.
69335|NCT03641898|Procedure|FFR-guided PCI|After the angiographic screening for lesions with 40%-90% diameter stenosis, FFR will be performed according to standard protocol using the s5 console and PrimeWire Prestige PLUS coronary pressure wire (Volcano Corporation, San Diego, California). FFR is calculated as the ratio of mean distal intracoronary pressure measured by the pressure wire, and the mean arterial pressure measured through the coronary guiding catheter. An FFR ≤0.8 or >90% diameter stenosis should result in a treatment decision for revascularization by PCI and lesions with FFR >0.80 are defined as FNLs and should result in deferral of PCI.
69336|NCT03641898|Diagnostic Test|Intravascular ultrasound|After the successful FFR-guided PCI, IVUS will be performed in all FNLs with the ultrasound Imaging Catheter Atlantis™ SR Pro (40 MHz, mechanical-type transducer, 3.2 F, Boston Scientific Corporation, Natick, MA, USA). Quantitative analyses of grayscale IVUS include contouring external elastic membrane (EEM) and luminal borders and the measurement of EEM cross-sectional area (CSA), luminal CSA, plaque and media CSA, plaque burdenand remodeling index. Virtual assessment of plaque is performed with iMap software (QIvus 2.0; Medis Medical Imaging Systems, Leiden, The Netherlands). Plaque components are categorized as dense calcium, necrotic core, fibrofatty, and fibrous tissue and reported as absolute area and proportion of total plaque area.
69337|NCT03641885|Behavioral|mothers and adolescents|The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
69338|NCT03641885|Behavioral|adolescents|The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
69339|NCT03641885|Behavioral|active control|The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
69340|NCT03641872|Other|Standary therapy|Standary therapy for chronic liver disease with ALI and/or AD
69341|NCT03641859|Device|virtual reality|"The virtual reality headset can be used for 45 minutes with the need to pause for 5 minutes if the gesture lasts longer. The VR sequence will be complete when the end of the programmed time is reached to preserve the patient's immersion. The patient will be able to see the final sequence at the end of the gesture in order to get used to the real world again. The programs and their durations will be adjusted to the duration of the gesture concerned. Regarding the pain, anxiety and satisfaction visual analogue scales, they will be performed just after the removal of the VR helmet.~Virtual reality videos are from Healthy Mind® software. The videos are contemplative with three kinds of relaxing landscapes accompanied by a sound universe specifically composed to relax the patient. The patient can choose one of three interactive worlds (an Asian garden, a forest or a mountain)."
69342|NCT03641846|Other|DornierAries2 LiST device + 5 mg Tadalafil|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Tadalafil 5mg. Total treatment period = 4 weeks
69343|NCT03641846|Other|DornierAries2 LiST device + Placebo Pill|All patients will receive shockwave treatment (6 sessions for all subjects, 5000 shockwaves at each session, at energy level 7), twice per week (total of 3 weeks) without treatment interval. Starting at first LiST session and finishing one week after final LiST session, subjects will receive for 4 weeks daily Placebo pills. Total treatment period = 4 weeks.
69344|NCT03641833|Diagnostic Test|blood sample for brain biomarkers|Transcranial Doppler will be performed to evaluate a.cerebri media blood flow speed during surgery.
69345|NCT03641807|Other|Acupuncture|Bilateral BL23, BL33, BL35 and SP6 will be inserted using Hwato-brand disposable acupuncture needles. With patients prone, after routine sterilization, bilateralBL33 will be inserted to a depth of 50 to 60mm with a 30° to 45° angle in an inferomedial direction using needles (0.30mm in diameter, 75mm in length). Bilateral BL35 will be inserted to a depth of 50 to 60mm with a slightly superolateral direction using needles (0.30mm in diameter, 75mm in length). BL23 and SP6 will be inserted vertically to a depth of 25 to 30mm using needles (0.30mm in diameter, 40mm in length). Manipulation of the needles by lifting and thrusting combined with twirling and rotating evenly will be performed until deqi occurs, defined as a sensation of soreness, numbness, heaviness, and ache. Manipulations will be applied every 10minutes and each session will last for 30minutes.
69346|NCT03641807|Other|Sham acupuncture|Bilateral sham BL 23, BL 33, BL 35 (15mmto BL23, BL33, and BL35) and SP6 (10mmto SP6) will be inserted by needles (0.20mm in diameter, 25mm in length) to a depth of 2 to 3mm without manipulation.
69347|NCT03641794|Drug|DN1406131|IDO1 and TDO2 inhibitor
69348|NCT03641794|Drug|Placebo|Placebo
69349|NCT03641781|Other|isometric strength training and isokinetic strength training|"Isokinetic strength program included strength training at 5 different velocities from slow to fast. Participants were trained on speed of 30°/sec, 90°/sec, 150°/sec, 210°/sec and 270°/sec. Flexion and extension movements were completed with 5 repetitions at each speed.~Participants of isometric strength training group performed isometric contractions at 30°, 45° and 60° of knee flexion with five repetitions at each angle for both hamstring and quadriceps."
69350|NCT03641768|Device|MRI|You will be asked to undergo a scan of your brain called an MRI. The MRI scan can measure the functioning of your brain.
69351|NCT03641768|Device|PET|You will be asked to undergo a scan of brain called a positron emission tomography (PET) scan. The PET scan is a test that uses radioactive glucose (sugar) and a computer to create images of how your brain is functioning. Abnormal cells in the body use glucose at a different rate than normal cells and this allows the scanner to create a detailed picture of how your body is working.
69352|NCT03641768|Device|18F-Florbetapir|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
69863|NCT03637556|Drug|Exjade|Commercial iron chelator with standard absorption characteristics
70974|NCT03629067|Drug|Treatment T|Fixed dose Combination of Fimasartan/Amlodipine/Hydrochlorothiazide
69353|NCT03641768|Device|Radioligand 18F-AV-1451|At the Duke University PET Center you will be in a quiet dimly lit space with only ambient room sound, with your eyes open and ears unplugged. Your safety will be monitored by a physician and nurse. 18F-florbetapir will be administered to you as a bolus injection through a peripheral vein followed by a flush and 10 minute continuous brain PET imaging will begin 50 minutes post-injection.
69354|NCT03641755|Drug|Sapacitabine|Sapacitabine may help to stop the growth of some types of cancers
69355|NCT03641755|Drug|Olaparib|Olaparib is an inhibitor of PARP (poly [adenosine diphosphate-ribose] polymerase), which means that it stops PARP from working
69356|NCT03641729|Other|individualized exercise training program|The exercise training program was performed once daily, included 2- to 5-minute warm-up session (stretching, coordination and balance exercises), 10 to 20 minutes of moderate-intensity aerobic exercise using a cycle ergometer, 3 - to 5-sets to ten repetitions of sit-to-stand exercises with a 1-minute rest interval between each set. A cool-down period of 2- to 5-minutes of stretching and breathing exercises was delivered at the end of the exercise session. The aerobic training target zone was set at 50% to 70% of heart rate (HR) reserve.
69357|NCT03641716|Behavioral|Mealtime PREP Intervention|Each session will include didactic elements and skills training along with skills practice and feedback. Parents will learn to build structured mealtime routines, manage child mealtime behavior, and incorporate exploration and play into routines.
69358|NCT03641703|Biological|FLT180a|FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
69359|NCT03641690|Other|Empirical antimicrobial therapy|All patients with pulmonary symptoms received empirical antimicrobial therapy with ceftriaxone and rovamycin or levofloxacin on admission and this was subsequently adapted to any documented bacterial infection if positive.
69360|NCT03641677|Device|Centralized Lung Evaluation System|Assessment of allograft lung for transplant suitability
69361|NCT03641677|Procedure|Lung Transplant|Orthotopic single or double lung transplantation.
69362|NCT03641664|Behavioral|Family Centered Treatment|Family Centered Treatment® (FCT) is a promising practice for providing home-based services to families at-risk for their children being removed from home.
69363|NCT03641664|Behavioral|Level III Out of Home Placement|Residential care for children with emotional, behavioral, and/or mental health in North Carolina who have experienced a level of dysfunction that makes it impossible to function at an age appropriate level in their own homes or in a lower level of care. These services can be provided in a variety of locations from urban to rural, from facility based to community based and from public sector to private sector. This service provides a structured and supervised environment for the acquisition of skills necessary to enable the child to improve level of functioning to achieve and/or to maintain the most realistic level of independent function where earlier treatment gains are somewhat fragile and the child is subject to regression.
69364|NCT03641651|Other|Rehabilitation technology|"Series of tailored rehabilitative training with the use of new technology which provide feedback and allow for a targeted and intensive and dense training.~With supervision based on patients preconditions and therapy device (e.g. patient/ therapist ratio= 3/1).~A training series lasts four weeks and comprises 3-5 training-days per week. Maximum training break of 7 days.~Five sessions of training with duration of 45 min per session, and up to four hours each day are foreseen.~The training can take place in an outpatient or inpatient setting.~Training will be organized in individual one-to-one or group session"
69365|NCT03641625|Device|Muscular tissue oxygen saturation guided care|Muscular tissue oxygen saturation monitored at flank and arm will be maintained > 70% (absolute measurement) and > baseline throughout the entire procedure.
69366|NCT03641612|Other|one shape|canal fluid sample before and after root canal instrumentation
69367|NCT03641612|Other|protaper next|canal fluid sample before and after root canal instrumentation
69368|NCT03641599|Diagnostic Test|echocardiography|echocardiographic assessment of the RV and LV systolic function
69369|NCT03641586|Drug|BGB-283|
69370|NCT03641573|Drug|[14C] ASN002|[14C] ASN002
69371|NCT03641560|Drug|Enzalutamide|Enzalutamide will be administered orally
69372|NCT03641560|Drug|Androgen deprivation therapy (ADT)|All participants will be required to maintain ADT during study treatment, either using a Gonadotropin Releasing Hormone (GnRH) agonist/antagonist or having a history of bilateral orchiectomy
69373|NCT03641547|Drug|M6620|M6620 is an unlicensed small molecule ATR inhibitor which can be used in combination with DNA damaging agents. In pre‐clinical models it has substantial activity when given with DNA damaging drugs or ionising radiation. The clinical agent (M6620) is currently studied in a phase I trial in Oxford and other centres in combination with gemcitabine, cisplatin, gemcitabine/cisplatin and cisplatin/etoposide.
69374|NCT03641547|Drug|Cisplatin|Cisplatin is a platinum based chemotherapy drug licensed to treat a number of different types of cancer. Cisplatin use is not considered standard practice in Stage A2 & B, therefore Cisplatin is considered an investigational medicinal product for the purpose of this trial.
69375|NCT03641547|Drug|Capecitabine|Capecitabine is a chemotherapy drug licensed to treat a number of different types of cancer, it is a noncytotoxic pre‐cursor of the cytotoxic 5‐fluourouracil. Capecitabine use is not considered standard practice in Stage A2 & B, therefore Capecitabine is considered an investigational medicinal product for the purpose of this trial.
69376|NCT03641547|Radiation|Radiotherapy|Stage A1 uses palliative radiotherapy. Stage B uses definitive radiotherapy.
69377|NCT03641534|Procedure|Lung Ultrasound examination|Use of lung ultrasound to detect pulmonary complications
69378|NCT03641534|Procedure|Compression ultrasonography (CUS)|CUS is a highly sensitive and specific modality used to recognize lower extremity deep venous thrombosis (DVT)
69379|NCT03641534|Procedure|Echocardiography|Echocardiogram can be (i) identify imminent life-threatening causes of hemodynamic failure, (ii) recognize coexisting diagnoses that complicate management, (iii) follow the evolution of the disease process, and (iv) monitor response to treatment
69380|NCT03641534|Procedure|Inferior Vena Cava ultrasound|Measurement of the inferior vena cava diameter
69440|NCT03641144|Device|Traditional laser|Traditional laser is a slitlamp based instrument.Surgeon operate traditional laer device while watching Participant's image(infrared, colour, fluorescein angiography) and then manually aim at and trigger laser.
69381|NCT03641534|Procedure|Passive leg raising test (PLR)|Baseline assessment (including pulse rate, systolic and diastolic blood pressure, velocity time integral (VTI) and stroke volume (SV) echocardiographic measurements) will be performed in the resting semi-recumbent position, defined as a position with the trunk elevated 30° to 45° relative to the lower limbs.
69382|NCT03641534|Procedure|Orthogonal polarization spectral imaging (OPS)|Measurement of capillary flow in the rectal microcirculation
69383|NCT03641534|Procedure|Urine collection (Foley catheter)|For urinalysis, biochemistry, urine microscopy, pH, and culture.
69384|NCT03641534|Procedure|Venous blood samplings|for: parasitological and microbiological diagnostics, complete blood count, biochemistry, red cell deformability analyzed by laser assisted rotational cell analyser (LORCA), markers of oxidative stress (peripheral intravenous catheter)
69385|NCT03641534|Procedure|Electrocardiogram|all patients will have an ECG performed on enrolment as a non-invasive investigation
69386|NCT03641534|Procedure|GlycoCheck|GlycoCheck is a clinical sublingual handheld, bedside microscope that detects erythrocytes within the small sublingual blood vessels measuring 5 to 25 micrometers in diameter. The sublingual vasculature is a validated site for measuring thickness of the endothelial glycocalyx.
69387|NCT03641521|Behavioral|Parent-led behavioral strategies|Intervention parents participated in an additional 20-25-min segment led by the nutrition educator during which the week's behavioral strategy was introduced. The following six behavioral strategies were introduced (one each week) as a segment of each cooking skills session: 1) have your child help prepare vegetables for meals (Child Help), 2) use a plate that shows the amount of vegetables to include for a meal (My Plate), 3) make vegetables visible and accessible by removing other foods from the dining area during the meal and leaving the vegetables (Make Avail/Visible), 4) serve at least 2 vegetables with the meal (Serve 2), 5) serve vegetables before the meal (Serve First), and 6) use a bigger spoon to serve the vegetables (Big Spoon).
69388|NCT03641508|Drug|Triamcinolone|Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
69389|NCT03641508|Drug|Dexamethasone|dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
69390|NCT03641495|Other|PE+ET|"To explain the physiology of nervous system and the mechanism and modulation of acute and chronic pain.~To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate."
69391|NCT03641495|Other|ET|To perform different whole body aerobic exercises with a mild to moderate intensity according to Borg scale and maximum heart rate.
69392|NCT03641482|Drug|NBF|Once the molar is extracted, the socket is cleaned with water, NBF gel is introduced, and the flap is closed. Then, the patients are instructed to apply NBF Gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
69393|NCT03641482|Device|Placebo|Once the molar is extracted, the socket is cleaned with water, placebo gel is introduced, and the flap is closed. Then, the patients are instructed to apply placebo gel in the surgical wound 3 times per day for 7 days after brushing their teeth. Previously they have to dry the area of the wound with gauze.
69394|NCT03641469|Device|Green Sun Dynamic Brace|Change from standard-of-care TLSO to GSM brace
69395|NCT03641456|Drug|bortezomib|The investigators gave patients subcutaneous bortezomib 1.3mg/m2 on days 1, 8,15, and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of bortezomib on days 1 and 15 at the dose level of 1.3mg/m2. Patients discontinued treatment if they had progressive disease or or unacceptable toxic effects not controlled with dose modifications.
69396|NCT03641456|Drug|Lenalidomide|The investigators gave patients oral lenalidomide 25mg on days 1 to 21 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.Responding patients could receive maintenance therapy comprising 4-week cycles of lenalidomide on days 1 to 21 at the dose level of 10mg. Patients discontinued treatment if they had progressive disease or unacceptable toxic effects not controlled with dose modifications.
69397|NCT03641456|Drug|Dexamethasone|The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 and 22 of a 28-day cycle. More two induction cycles after obtaining maximum response but no less than six cycles totally.
69398|NCT03641443|Device|Non-invasive measurement of intracranial pressure|Non-invasive measurement of intracranial pressure in patients with mass effective brain Tumors
69399|NCT03641430|Other|Supportive care with OCT product|Participants will apply over-the-counter product for a certain period with or without light challenge. We will perform clinical assessments of the skin associated with product application as well as assess these changes with and without light challenge. Skin biopsies will be obtained following standard medical practice and will be used to analyze skin markers related to photoaging, pigmentation, oxidative stress, and other dermatologic conditions.
69400|NCT03641417|Drug|GLWL-01|"Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circualting acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)"
69401|NCT03641417|Other|Placebo|Same as GLWL-01, but no active ingredient
69402|NCT03641404|Dietary Supplement|ergothioneine|Ergothioneine is naturally occurring thiol compound obtained solely from diet in humans. Ergothioneine is widely reported to be a natural antioxidant and anti-inflammatory compound. In addition we hypothesize that this compound will be beneficial in improving cognition.
69403|NCT03641404|Dietary Supplement|placebo|Placebo. Study control (99% microcrystalline cellulose)
69404|NCT03641391|Procedure|Intraoperative direct cortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate cortex, was performed using a 5-mm wide bipolar electrode with a pulse frequency of 60 Hz and an amplitude of 1.5 to 6 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
69439|NCT03641144|Device|Navigation laser|Navigation laser device is a scanning slit-based instrument.before treatment the surgeon plan laser spots on the screen based on image(infrared, colour, fluorescein angiography)and then apply automated patterns and single spots as appropriate.the device will automatically carry out the plan.
69405|NCT03641391|Procedure|Intraoperative direct subcortical electrical stimulation|Intraoperative direct electrical stimulation on language or language-associate subcortical pathways, was performed using a biphasic square-wave pulse delivered at 60 Hz with a current amplitude ranging from 1.5 to 10 milliamperage. The somatosensory evoked potential was recorded with a 6-contact subdural strip electrode. If after-discharge activity indicated that the stimulation current was too high, the current amplitude was decreased by 0.5 to 1 milliamperage. The participants would be undergone awake anesthesia and asked to perform language tasks during the stimulation.
69406|NCT03641378|Other|Palliative Care Intervention|team of clinicians that specialize in the lessening (palliation) of many distressing symptoms
69407|NCT03641378|Other|Standard Transplant Care|Standard care per hospital guidelines
69408|NCT03641365|Device|Test group|Guided Implant placement Positioning/placement of dental implants thought the fully acrylic surgical template without metallic sleeves.
69409|NCT03641365|Device|Control group|Guided Implant placement Positioning/placement of dental implants thought the acrylic surgical template with metallic sleeves.
69410|NCT03641352|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759
69411|NCT03641352|Drug|Placebo|Placebo, orally, 1 tablet once a dqy for 24weeks or 52weeks (if extension study) with D150 and D759. CKD-501 placebo will be changed to CKD-501 from extension study to EOS(end of study).
69412|NCT03641339|Other|Vector Feeding|Controlled feeding by 1 of 3 colony- reared vectors (Aedes aegypti mosquitos, Anopheles gambiae mosquitos, or Lutzomyia longipalpis sand flies). Participants will undergo either 1 feeding (Cohort A) or 4 feeings, each about 2 weeks apart (Cohort B), with the same vector type.
69413|NCT03641326|Drug|Sunitinib|Sunitinib will be administered at a dose of 50 mg daily for 2 consecutive weeks followed by 1 week of rest until there is disease progression or development of intolerable side effects.
69414|NCT03641326|Device|wGT3x-BT|Participants will given a small, portable pager-type and watch accelerometers to wear at the hip or non-dominant wrist. Worn daily for 6 cycles
69415|NCT03641313|Drug|ATR Kinase Inhibitor M6620|Given IV
69416|NCT03641313|Drug|Irinotecan|Given IV
69417|NCT03641300|Device|Magnetic Seizure Therapy (MST)|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
69418|NCT03641300|Device|Electroconvulsive Therapy (ECT)|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
69419|NCT03641287|Other|Exercise Counseling|Meet with exercise physiology
69420|NCT03641287|Other|Aerobic Exercise|Receive prescription for moderate aerobic exercise
69421|NCT03641287|Other|Physiological Support|Receive motivational support via telephone care
69422|NCT03641287|Other|Quality-of-Life Assessment|Ancillary studies
69423|NCT03641287|Other|Questionnaire Administration|Ancillary studies
69424|NCT03641287|Other|Best Practice|Undergo habitual level of physical activity
69425|NCT03641274|Other|Case-management intervention for frequent users of the emergency department|The CM intervention to be implemented is an evidence-based practice. It consists of individualized services based on a detailed baseline evaluation using validated scales to identify all of the social and medical needs of each FUED. The CM team provides counseling and education on health care utilization, substance abuse and the social determinants of health directly to the FUEDs, using skills such as motivational interviewing and cross-cultural competences. Additionally, the CM team provides concrete services including, referral to psychiatric or substance abuse treatment, or medical services (such as a GP or medical specialist), on a case-by-case basis. Another key element of the CM intervention is to connect all health care or social service providers within the hospital or in the community, promoting continuity of care and improving the FUEDs' ability to navigate the complex health care system.
69426|NCT03641261|Other|Therapeutic patient education program|WebIchtyose is a specific therapeutic patient education program for patients with hereditary Ichthyosis targeting the problems of each patient by means of a personalized follow-up and a constant interaction between the patient and the educational team
69427|NCT03641248|Drug|Enteric coated Devil's Claw|Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
69428|NCT03641248|Drug|Non-enteric coated Devil's Claw|Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
69429|NCT03641235|Biological|Sputum collection|Analysis of Sputum collection
69430|NCT03641222|Device|Acupuncture|Traditional Chinese Medicine (TCM) Acupuncture
69431|NCT03641209|Drug|Paracetamol 10mg/mL infusion solution|Intravenous paracetamol solution for infusion
69432|NCT03641209|Other|Placebo|Half physiological saline solution as the non-active placebo solution
69433|NCT03641196|Device|Fixed appliance|Use of a cemented modified palatal Nance appliance presenting a bite-plane
69434|NCT03641196|Procedure|Composite bite plane|treatment with a composite build up in the palatal aspect of the upper central incisors.
69435|NCT03641170|Behavioral|Physical activity|Interval walking performed after each main meal.
69436|NCT03641170|Behavioral|Inactivity|Inactivity after each main meal.
69437|NCT03641170|Other|Fixed diet.|Participants will receive a fixed diet through out the intervention period and control period.
69438|NCT03641157|Other|Easy Intubation|
69613|NCT03639727|Diagnostic Test|Citric acid aerosol bronchial challenge|Inhalation challenge by citric acid aerosol to investigate the subject's cough sensitivity
69441|NCT03641118|Diagnostic Test|Cardiopulmonary exercise test|The CPET test involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
69442|NCT03641105|Diagnostic Test|Diagnostic test|detect the contents of glucose metabolism molecules using mass spectrum
69443|NCT03641092|Behavioral|CenteringParenting Intervention|The CenteringParenting(CP) intervention includes group well child care visits during the first 24 months of life. Participants receive a journal with child safety, health and development information. The groups are co-led by a practitioner and support staff member. This bundled intervention supports healthy parent-child interactions and early learning through education and experiential learning within the well-child visit.
69444|NCT03641092|Behavioral|Routine Well Child Care|The Comparison Clinical Sites will receive the Routine Well Child Care standard individual clinical care. This clinic will receive delayed training in the CenteringParenting(CP) intervention approximately 3 months after the completion of recruitment at their study site [when recruited families will be ineligible for CenteringParenting groups that will start in control sites]. They will receive anticipatory guidance and handouts that are standard for the clinic.
69445|NCT03641079|Drug|Brinjal peel extract containing cream|Brinjal peel extract, white wax, white petrolatum, stearyl alcohol
69446|NCT03641066|Device|Ankle Brace|Each participant will complete the 1 minute walking and 2 minute running under 5 conditions [1] un-braced, [2] Active Ankle 329 Ankle Sleeve, [3] AS1Pro (a lace-up brace), [4] Eclipse 1 (single-upright brace), and [5] Eclipse 2 (double upright brace)
69447|NCT03641053|Other|Honey|Substance is given topically after the wound has been sutured
69448|NCT03641053|Other|Povidone-iodine|Substance is given topically after the wound has been sutured
69449|NCT03641053|Other|Paraffin gauze|Substance is given topically after the wound has been sutured
69450|NCT03641040|Diagnostic Test|Video-oculography|measure and analyze angles of ocular deviations between dominant and non-dominant eye using VOG with alternate cover.
69451|NCT03641040|Diagnostic Test|Alternative prism cover test|measure and analyze angles of ocular deviations between dominant and non-dominant eye using APCT
69452|NCT03641027|Other|Increased physical activity|"Preoperatively~Individual coaching by a physical therapist to:~increase physical activity 30 minutes/day (At least 150 min/week)~decrease time spent sitting/lying~Telephone follow up one week after the intervention starts~At the hospital~-Frequent mobilization~After discharge~A telephone follow up one week postoperatively with coaching by a physical therapist to:~increase physical activity 30 minutes/day (At least 150 min/week) until 8 weeks postoperatively~decrease time spent sitting/lying~The intervention includes a prescribed FaR (Fysisk aktivitet på recept) with frequency, duration and intensity of the activity corresponding 12-15 on the BORG-RPE scale."
69453|NCT03641027|Other|Standard care|
69454|NCT03641014|Other|pH Effect on blastocyst formation|to investigate which pH is suitable for each stage of embryo development
69455|NCT03641001|Behavioral|Child feeding counselling, food voucher, micronutrient powder, WASH|Child feeding counselling will be assisted by food voucher, micronutrient powder and WASH messages
69456|NCT03640988|Device|dermaPACE|Shockwave application
69457|NCT03640975|Other|Endoscopy|The endoscopy will be performed under general anaesthesia using a flexible endoscope with an external diameter of between 4.9 and 9.2 mm, depending on the size of the child. In line with the guidelines, eight biopsies will be collected from the proximal, median and distal oesophagus for the routine analysis of esophageal remodelling and inflammation. Three of these biopsies will be used in the context of this study to analyse innate immune cells using flow cytometry and to determine the profile of cytokine expression. Two biopsies will be placed in sterile, 0.5 ml Nunc tubes containing a storage buffer (MACS® Tissue Storage Solution) and then stored in ice until the extraction of cells for cytometric analysis . The third specimen will be placed in a sterile tube and frozen immediately in liquid nitrogen for analyses of the esophageal microbiome.
69458|NCT03640962|Other|Evaluation|This cross-sectional study was conducted in 368 postmenopausal women aged between 40 and 65 years. This study was carried out in family health centers in Istanbul. Data were collected via face-to-face interviews by the researchers.
69459|NCT03640949|Drug|Vasopressin, Arginine|20 IE of vasopressin per dose for a maximum of four doses (80 IU)
69460|NCT03640949|Drug|Methylprednisolone|40 mg methylprednisolone once
69461|NCT03640949|Drug|NaCl|Placebo
69462|NCT03640936|Behavioral|Induced Sputum|Total IgE and Specific IgE to Dermatophagoides pteronyssinus in Induced Sputum
69463|NCT03640923|Other|a swab of mucous membrane|a swab of mucous membrane in oredre to analyse the genome
69464|NCT03640910|Device|OT Equators® (Rhein83)|Attachment systems to retain an implant overdenture
69465|NCT03640910|Device|Locator® (Zest)|Attachment systems to retain an implant overdenture
69466|NCT03640897|Device|Liniderm|Cleaning of the diaper area with Liniderm at each diaper change during 28 days
69467|NCT03640897|Other|Wipes|Cleaning of the diaper area with wipes at each diaper change during 28 days
69468|NCT03640897|Other|Water|Cleaning of the diaper area with water and cotton pads at each diaper change during 28 days
69469|NCT03640884|Drug|Xueshuantong-Injection|Xueshuantong-Injection is a kind of natural compound injection extracted from Chinese herb Notoginseng. The major bioactive ingredient is panax notoginseng saponins.
69470|NCT03640871|Device|URGO AWC_019 dressing (AWC=Advanced Wound Care)|URGO AWC_019 dressing 10x10 cm (AWC=Advanced Wound Care)
69471|NCT03640858|Device|Theranova Dialyzer|The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the beginning of the dialysis week on week 14. This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer.
69614|NCT03639727|Diagnostic Test|Mannitol aerosol bronchial challenge|Inhalation challenge by mannitol aerosol to investigate the subject's cough sensitivity
69615|NCT03639714|Biological|GRT-C901|a patient-specific neoantigen cancer vaccine prime
69472|NCT03640845|Other|tele-expertise|"Tele-expertise consists of the remote realization of a multi-professional medication review (clinical pharmacist and doctor / geriatrician), ie a complete and systematic analysis of sociodemographic, clinical, biological and pharmaceutical data transmitted in such a way standardized at the EHMP and aimed at optimizing the therapeutics of the resident patient of the EHPAD requesting tele-expertise.~Tele-expertise is realized in three stages, that are~the transmission, the collection and the organization of the data,~the analysis of the data and their confrontation with the referential and recommendations~the writing of a Personalized Pharmaceutical Plan"
69473|NCT03640832|Other|Developmental Serum|A 30millilitre (mL) bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
69474|NCT03640832|Other|Physiogel Calming Relief Anti-Redness Serum|A 30mL bottle with a piston pump will be dispensed to the participants, to be used as a topical dermal (facial) application, twice daily as per normal home use.
69475|NCT03640819|Procedure|Tattooing of biopsied node|Tattooing (marking) of biopsied node with carbon dye (SPOT dye) at the time of fine needle aspiration or core biopsy or separate visit under ultrasound guidance. The dye will be injected in the cortex of the node and the perinodal tissue under ultrasound guidance. Patients will undergo standard (routine) armpit surgery and may receive neoadjuvant chemotherapy as planned by the clinical team. This could be removal of a few lymph glands (sentinel node biopsy) or removal of all the lymph glands (axillary lymph node dissection) in the armpit. The surgeon will try to identify and remove the tattooed lymph gland at the time of planned armpit surgery.
69476|NCT03640806|Other|PHYSICAL ACTIVITY|3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
69477|NCT03640793|Device|Implantation|Implantation of 6 PPIS implants
69478|NCT03640780|Other|observation|The surgical ages and other information between two groups were compared.
69479|NCT03640767|Behavioral|Message-based lifestyle intervention|Peripheral artery disease patients who have received revascularization in the past 6 months, are randomized into 2 groups. The total sample size will be 160. Both intervention and control groups will receive face-to-face lifestyle adherence counseling and booklets at baseline. The intervention group will receive 4 mobile phone messages per week for 24 weeks. The messages are motivational advice to support lifestyle behavioral modification in various stages of behavioral changes.
69480|NCT03640754|Biological|G-CSF|G-CSF injected subcutaneously 3 times (Days 0, 28, 56)
69481|NCT03640754|Other|Placebo/Saline|Placebo/saline injected subcutaneously 3 times (Days 0, 28, 56)
69482|NCT03640741|Procedure|Laparoscopy|The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
69483|NCT03640728|Drug|Tenofovir Alafenamide|Tenofovir alafenamide 25 mg/day orally
69484|NCT03640728|Drug|Entecavir|Entecavir 0.5 mg/day orally
69485|NCT03640728|Drug|Tenofovir disoproxil fumarate|Tenofovir Disoproxil Fumarate 300 mg/day orally
69486|NCT03640715|Other|ENVU|"ENfant VUlnerable: a clinical tool for screening for social and health vulnerability in pediatrics - tool: VUlnerable Child (ENVU) -; to allow for an appropriate orientation of the patient care pathway. The metrological validation of diagnostic performances (sensitivity, specificity, positive and negative likelihood ratios) will be studied in confrontation with the opinion of an expert caregiver in the care of vulnerable populations."
69487|NCT03640702|Other|Protocol change|To examine the effect of prolonging the second stage of labor on the rate of cesarean delivery, maternal and neonatal outcomes
69488|NCT03640689|Device|Endovenous ablation + iliac US +/- iliac stenting|Concomitant Ablation of the GSV with endovenous therapy with associated iliac vein interrogation and stenting if required
69489|NCT03640689|Device|Endovenous ablation of Great Saphenous Vein|Ablation of the Great Saphenous Vein and subsequent Graduated Compression
69490|NCT03640676|Device|FlowOx|FlowOx is a CE marked device developed to increase blood flow to the lower extremities. A pressure chamber is sealed around the leg below the knee and is connected to a control unit which induces pulses of 10 sec negative pressure, and 7 sec of atmospheric pressure.
69491|NCT03640663|Other|Midwife led continuity model of care|Midwives from the hospitals provided outreaching caseload ante- and postnatal care to women in rural villages clinics and homes
69492|NCT03640650|Combination Product|Dropless Therapy|The Dropless will be injected, as a single administration, into the vitreous cavity during the cataract surgery.
69493|NCT03640650|Drug|Usual Care|In order to reflect real-world clinical practice, the choice of topical ophthalmic medications as well as dosage, posology, and duration of treatment will be left to the discretion of the treating ophthalmologist.
69494|NCT03640624|Combination Product|Multidisciplinary treatment|"Assessment by gynaecologist and dermatologist, resulting in tailored vulvar care, including daily topical lidocaine 5% ointment. Other topical or oral medication, such as oestradiol cream or oral antidepressants will be prescribed on individual basis.~Tailored physiotherapy targeting muscular dysfunction, utilizing: Patient education, pelvic floor muscle exercises (contraction and relaxation), EMG-biofeedback. Low frequent electrical stimulation, massage, stretching and myofascial release and trigger point treatment of the pelvic floor. Desensitization exercises (manually or vaginal dilator). Relaxation and body awareness. Minimum one visit per month.~Guided imagery sessions, minimum twice a week using a sound track that is developed for vulvodynia patients."
69495|NCT03640624|Combination Product|Treatment as usual|Treatment as usual in accordance with local guidelines by specialist in gynaecology, including a minimum of two visits (when diagnosis is made and after 3 months)
69496|NCT03640598|Procedure|Ilioinguinal/iliohypogastric nerve blocks|The patient will receive ultrasound-guided Ilioinguinal/iliohypogastric nerve blocks with0.5 ml/kg 0.125 mg/kg bupivacaine + fentanyl 2ug/ml injectate
69497|NCT03640598|Procedure|Erector spinae nerve block|The patient will receive ultrasound-guided erector spinae nerve block 0.5 ml/kg 0.125 bupivacaine + fentanyl 2ug/ml injectate.
69498|NCT03640585|Other|Music therapy|Only the neurodevelopmental therapy was applied in the second group without music. A total of 15 treatments were administered for 5 weeks, 3 sessions per week for all patients. The sessions were 45 minutes.
69616|NCT03639714|Biological|GRT-R902|a patient-specific neoantigen cancer vaccine boost
69617|NCT03639714|Biological|nivolumab|anti-PD-1 monoclonal antibody
69618|NCT03639714|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
120095|NCT03247673|Drug|EU-approved Avastin|EU-approved Avastin
69499|NCT03640572|Diagnostic Test|Bone marrow analysis to identify disseminated tumour cells|Pelleted cells from bone marrow samples were incubated with an excessive amount of lysing solution for 10 min, repeated 3-4 times to remove erythrocytes. The slides were dried, fixed with a mixture of ethanol and acetone (1 : 1 v v−1), and then stained for 30 min with A45-B/B3 monoclonal antibodies (5 μg ml−1) (Micromet GmbH, Germany), which recognise common epitopes of cytokeratins (CK) including CK 8, 18 and 19.
69500|NCT03640559|Drug|Seroguard|
69501|NCT03640559|Drug|Placebos|
69502|NCT03640546|Behavioral|Within My Reach/ Within Our Reach|Relationship education workshops
69503|NCT03640533|Behavioral|Nanit-Insights|Nanit-Insights is an app-based intervention that provides personalized sleep tips to parents.
69504|NCT03640520|Device|FACETS: Pediatric Resuscitation|Family-centered & Trauma-informed Support in Pediatric Resuscitation (FACETS: Pediatric Resuscitation) is an online skills training module for health care professionals involved in pediatric resuscitation in general EDs. The module combines didactic information and scenario-based learning with opportunities for the learner to practice applying their knowledge of FCC practices at key choice points in realistic pediatric resuscitation case scenarios. Training content is guided by evidence regarding FCC practices that are effective in reducing concurrent and ongoing emotional distress in children and family members, and in promoting child and family involvement and satisfaction with care.
69505|NCT03640520|Device|Control|An online training module in which participants will receive information and policy education about national pediatric readiness standards for all EDs (including a brief mention of family-centered care as one of these standards), with no specific skills training in FCC. The module provides practice-relevant knowledge related to pediatric differences and pediatric readiness
69506|NCT03640507|Drug|Chlorhexidine-alcohol|Intervention is a 30-second vaginal preparation or topical wash with three chlorhexidine-alcohol 0.5% solution-soaked sponge sticks.
69507|NCT03640507|Drug|Povidine-iodine|Intervention is a 30-second vaginal preparation or topical wash with three povidine-iodine 10% solution-soaked sponge sticks.
69508|NCT03640507|Drug|Sterile saline|Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
69509|NCT03640494|Device|Optical Coherence Tomography|This is an observational study in which subjects will be imaged with optical coherence tomography (OCT). OCT systems are optical imaging technology that allow non-contact imaging of the microanatomy of the retina, optic nerve head and retinal blood vessels. The OCT devices are held above (and do not touch) the eye. Unlike visible light from many examination devices, the infrared OCT beam is barely visible to the human eye as it sweeps across the retina. Thus the infant is not disturbed by the light.
69510|NCT03640481|Drug|KD025|KD025 is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
69511|NCT03640468|Drug|Ketamine full dose|This group will receive induction of anesthesia using Ketamine 1 mg/Kg
69512|NCT03640468|Drug|Ketamine half dose|This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg
69513|NCT03640468|Drug|Lidocaine|This group will receive lidocaince 1 mg/Kg
69514|NCT03640468|Drug|Midazolam|This group will receive midazolam 0.05 mg/Kg
69515|NCT03640468|Drug|Normal saline|This group will receive normal saline 10 mL
69516|NCT03640455|Device|Placebo|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; placebo (dummy stimulation), according to the patient's randomization arm.
69517|NCT03640455|Device|Anodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in anodal polarity, according to the patient's randomization arm.
69518|NCT03640455|Device|Cathodal|A tDCS (Low Current Transcranial Stimulation) device with two electrodes: active and reference, will be used. The tDCS will be applied next to the cortical representation zone of the primary motor cortex and left pre-motor for 30 minutes; intensity 2 mA, in cathodal polarity, according to the patient's randomization arm.
69519|NCT03640442|Other|Modified ramped position|This position will be achieved using a special pillow. Shoulders will be elevated and neck will be extended to bring the breasts away from the laryngoscopy. The patient will be positioned so that the tip of the last spinous process (C7) will be at the edge of the pillow. The neck will be extended to the most possible range.
69520|NCT03640442|Other|Ramped position|This position will be achieved by elevation of the shoulders and the head elevation till achieving alignment of sternal notch and external auditory meatus
69521|NCT03640429|Device|non-invasive blood pressure monitor|non-invasive oscillometric blood pressure monitor will be applied at the arm, forearm, and at the wrist.
69522|NCT03640429|Device|invasive blood pressure monitor|invasive blood pressure monitor will be connected to a cannula inserted at the radial artery.
69523|NCT03640416|Device|Fitbit® Charge HR smart watch|The Fitbit® Charge HR is a commercial product widely used worldwide, and data from the device is sent to a secured online server and can be accessed by each user to see only data collected from his own device. Data collected from the Fitbit® Charge HR is described earlier.
69524|NCT03640403|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
69525|NCT03640403|Drug|Artesunate-amodiaquine|Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria. It will to be given every 4 months 3 rounds for a year.
69526|NCT03640390|Drug|Dexmedetomidine|This group will receive Dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour.
69527|NCT03640390|Drug|Magnesium Sulphate|This group will receive Magnesium sulphate infusion at a rate of 15 mg/Kg/hour
69528|NCT03640390|Drug|Normal saline|This group will receive normal saline infusion
69529|NCT03640377|Drug|Praziquantel|Praziquantel given as crushed tablets (40 or 60 mg/kg)
69619|NCT03639701|Drug|Thymidine|Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
69897|NCT03637283|Procedure|fan-shaped photocoagulation|vitreoretinal surgery combined with intraoperative fan-shaped photocoagulation
69530|NCT03640351|Drug|1. Use of preservative free diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
69531|NCT03640351|Drug|2. Use of preservative containing diquafosol ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
69532|NCT03640351|Drug|3. Use of preservative free sodium hyaluronate ophthalmic solution after cataract surgery|Participants are randomly assigned into the preservative free diquafosol group (Group 1), the preservative containing diquafosol group (Group 2) or the hyaluronate group (Group 3) using a simple unrestricted randomization method by the controller. The group 1 uses preservative free 3% diquafosol tetrasodium ophthalmic solution (Diquas-S; Santen Pharmaceutical Co, Ltd, Osaka, Japan) 6 times a day, the group 2 uses 3% diquafosol tetrasodium ophthalmic solution (Diquas; Santen Pharmaceutical Co, Ltd) 6 times a day and the group 3 uses 0.15% sodium hyaluronate ophthalmic solution (New Hyaluni 0.15%; Taejoon, Seoul, Korea) 6 times a day. All three groups instill each eye drop from postoperative day 1 to postoperative 12 weeks.
69533|NCT03640338|Device|Cold-Therapy System|After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
69534|NCT03640325|Behavioral|PRISM (Promoting Resilience in Stress Management)|Manualized Skills-Training Program targeting resilience resources: stress-management, goal-setting, cognitive reframing, and meaning-making
69535|NCT03640312|Drug|QUARTET LDQT|Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.
69536|NCT03640312|Drug|Candesartan|Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.
69537|NCT03640299|Procedure|ERAS procedure|Optimized preoperative, intraoperative and postoperative procedures.
69538|NCT03640286|Device|VeSTAL|The aim of this study is to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation in combination with a lifestyle modification program, as a method of reducing excess body weight and body fat, as compared to a sham device in combination with the same lifestyle modification program.
69539|NCT03640273|Drug|Prapchompoothaweep remedy|Take Prapchompoothaweep remedy capsule at 1,000 mg for 3 times a day before meals.
69540|NCT03640273|Drug|Loratadine 10 Mg|Take Loratadine 10 mg once a day before meals.
69541|NCT03640260|Behavioral|breathing regulation with physical activity|The subjects will have education leaflets with breathing and oximetry level evaluation training.
69542|NCT03640247|Drug|Non-narcotic group regimen|Non-Narcotic Group. Receives only alternating acetaminophen and ibuprofen
69543|NCT03640247|Drug|Narcotic group regimen|Narcotic Group: Alternating acetaminophen and ibuprofen, with a prescription of 10 tablets oxycodone (or if needed based on patient allergies, hydrocodone 5 mg/tramadol 50 mg) for break through pain.
69544|NCT03640221|Drug|Ertugliflozin|The sodium-glucose cotransporter 2 (SGLT2) inhibitors are an exciting new class of antidiabetic drugs that cause a modest reduction in high blood pressure and large reductions in the risk of cardiovascular disease (CVD) outcomes and renal outcomes in patients with advanced type 2 diabetes and very high CVD risk. However, the mechanistic underpinning of these CVD benefits is not well understood. this arm will allow us to test our hypothesis.
69545|NCT03640221|Drug|Hydrochlorothiazide 12.5mg|comparator arm allow us to mimic the mild anti hypertensive effect seen with the SGLT-2 inhibitors in order to enable us to differentiate whether the cardiovascular protection seen with the SGLT-2 inhibitors is secondary to its antihypertensive effects vs the potential decrease in sympathetics.
69546|NCT03640221|Device|Microneurography|"Multiunit recordings of postganglionic sympathetic nerve activity will be obtained with unipolar tungsten microelectrodes inserted selectively into skeletal muscle nerve fascicles of the peroneal nerve. The nerve signals are amplified, filtered (bandwidth 700-2000 Hz), rectified and integrated to obtain a mean voltage display of sympathetic nerve activity. Sympathetic bursts are counted by inspection of the neurograms. A deflection on the mean voltage display is counted as a burst if it has a minimal signal to noise ratio of 2:1. The interobserver and intraobserver variations in identifying bursts are <10% and < 5%, respectively."
69547|NCT03640221|Other|SKNA recordings|SKNA recordings will be captured by placing ECG electrodes on the chest wall. Recordings will be obtained simultaneously with microneurographic recording. The two techniques will undergo identical filtering and processing of the neurophysiologic inputs which are then displayed simultaneously using identical output functions.
69548|NCT03640221|Other|Static Handgrip|Subjects will perform static handgrip at 33% MVC for 2 minutes, using a Stoelting recording handgrip dynamometer. Force output will be recorded continuously and displayed on the computer screen in real time to provide the subject with visual feedback. MVC will be determined for each subject at the beginning of each experiment. Subjects will be instructed to avoid straining maneuvers, changes in breathing, and contraction of non-exercising muscles during the experimental protocols. Ratings of perceived exertion (RPE) will be obtained at the end of each exercise by using a 6- to 20-unit Borg scale. Static handgrip at 33% MVC is accompanied by reflex increases in muscle sympathetic nerve activity caused by activation of the acid-sensing unmyelinated muscle afferents.
69620|NCT03639688|Procedure|Left sided threading|threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
69621|NCT03639688|Procedure|Right sided threading|threading of the endotracheal tube over the fiberoptic bronchscope from the right lip commissure
69549|NCT03640221|Other|Post-handgrip forearm vascular occlusion|This will be performed by inflating a pneumatic cuff on the upper exercising arm to suprasystolic pressure (220 mmHg) beginning 10 seconds before the subject stops gripping and ending 2 minutes into the post-exercise period. The vascular occlusion maintains intramuscular acidosis and thus the stimulation of acid-sensing unmyelinated skeletal muscle afferents and their reflex increase in muscle sympathetic nerve activity and BP, while the muscular relaxation eliminates central command and the attendant increase in heart rate (which returns to the baseline level). As soon as the cuff is release and the forearm circulation is restored, muscle sympathetic nerve activity quickly returns to the baseline level and BP soon follows.
69550|NCT03640221|Other|Testing of the Arterial Baroreflex Function|We will compare effects of Ertugliflozin vs. low-dose HCTZ on sinoaortic baroreflex function in hypertensive diabetic subjects during both spontaneous fluctuations in arterial pressure and during decreases and increases in arterial pressure induced by the Valsalva maneuver. The aim of this protocol is to determine if the sympathetic nerve, as well as the heart rate, component of the sinoaortic baroreflex can be augmented by the SGLT2 inhibitor. After obtaining stable baseline recordings, arterial pressure, heart rate, and muscle sympathetic nerve activity will recorded during spontaneous fluctuations in BP over 5 minutes and during both decreases in BP during phase III of the Valsavla maneuver and during the phase IV overshoot in BP upon its release. Frequent accurate measurement of arterial pressure will be obtained with a highly-rated oscillometric arm monitor that records 6 BP readings per minute (Welch Allyn Vital Signs Monitor).
69551|NCT03640208|Behavioral|Education presented by trained caregiver|After participants complete the Pre-test, an educational session will be presented by a trained caregiver, delivered in a lecture-style manner with Power Point projection of educational material. The slides in this presentation will be scripted to mitigate variability among different presenters. Topics addressed in the presentation include: CRC basics (including brief anatomy), data on disparity, risk factors, screening modalities, preventative measures, population disparities of CRC, colonoscopy exam and other screening tests. The emphasis will be on CRC risks factors and prevention. All required information that is needed to correctly answer post-test questions is embedded within the presentation.
69552|NCT03640195|Other|Device: Transcutaneous acupoint electrical stimulation and seeds for auricular acupressure|"Experimental group received Acupoint stimulation, Transcutaneous acupoint electrical stimulation20 minutes/weeks, once a week for six consecutive weeks.~The second part of The Experimental group received Auricular acupressure applied to four acupoints, including shenmen (TF2), mouth (IC6), subcortex (CW2), Occiput (AT3). each point is 1min, 5days/week, 3 times/day."
69553|NCT03640182|Other|Health management model of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Medical Ba-Duan-Jin duo-in qigong practice.
69554|NCT03640169|Other|Health management of TCM preventive medicine|The Health management model include: (1) Body constitution measurement (2) Health promotion literacy education lectures (3) Duo-in qigong practice.
69555|NCT03640156|Drug|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
69556|NCT03640156|Other|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
69557|NCT03640143|Other|venous blood lead|data about ve,nous blood lead
69558|NCT03640130|Behavioral|Gaze-contingent text enhancement|"In different testing blocks, the efficacy of the different enhancements will be evaluated, such as inverting the text in a gaze-contingent inverted spotlight."
69559|NCT03640104|Behavioral|Intervention-Nutrition guidelines|Subjects will receive an individualized dietary plan according to their nutritional status, socioeconomic and cultural preferences. Protein intake 1-1.5g/kg body weight; 30% fat (mono and polyunsaturated fatty acids), vitamin A sources (1300 RAE). Each subject will have 7 interchangeable options for every meal time, all equivalent in macronutrient content, and every two weeks a new menu will be provided by a nutritionist.
69560|NCT03640104|Behavioral|Nutrition guidelines|Nutritional recommendations based on international guidelines
69561|NCT03640091|Procedure|Post-extractive inter-radicular implant bed preparation|Implant placement in mandibular molars
69562|NCT03640078|Other|acquisition imaging|The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
69563|NCT03640065|Drug|freeze-dried probiotic sachets|"The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~This procedure will be repeated once daily for the following 4 weeks.~4 weeks supply will be given to the participants."
69564|NCT03640065|Dietary Supplement|fermented dairy product ( yogurt)|"The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home"
69565|NCT03640052|Drug|Placebo oral capsule|Placebo capsule before sleep
69566|NCT03640052|Drug|LTM1201L|LTM1201L capsule before sleep
69567|NCT03640052|Drug|LTM1201LN|LTM1201LN capsule before sleep
69568|NCT03640052|Drug|LTM1201LB|LTM1201LB capsule before sleep
69569|NCT03640052|Drug|LTM1201LD|LTM1201LD capsule before sleep
69570|NCT03640039|Procedure|3d strut plate.|Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
69571|NCT03640026|Drug|Tacrolimus|Tacrolimus will be initiated at 0.1 mg/kg/day in two separate 12-hour oral doses (capsules) for 14 days.
69572|NCT03640013|Procedure|Hall Technique PMC|Hall Technique primary fitted crowns to restore carious primary molars
69573|NCT03640000|Diagnostic Test|Impedance measurements in Cardiac Resynchronization therapy|Bioimpedance measurements
69574|NCT03639987|Drug|Aducanumab|Administered as specified in the treatment arm.
69575|NCT03639987|Drug|Placebo|Administered as specified in the treatment arm.
69622|NCT03639675|Drug|Aflibercept (EYLEA, BAY86-5321)|2 mg (0.05 mL), Intravitreal injection (IVT), single dose.
69623|NCT03639675|Drug|Topical IOP-lowering drugs|A combination of at least 3 topical IOP-lowering drugs will be administered during a run-in phase before treatment and should be kept unchanged until IOP evaluation at Week 1, after which they may be reduced according to the investigator's opinion
69576|NCT03639974|Other|PEP in a blow-bottle device|A 500-milliliter enteral nutrition vial will be used, which will contain a hole in the side, where two silicone tubes of 20 centimeters long will be inserted together with tape on the bottleneck of the vial. To perform the exercise, the vial will be filled with water leaving a water column of 10 cm high. Deep inspirations will be requested at a volume greater than the tidal volume and less than the total lung capacity that can be performed via nasal or oral, then with the mouth connected to the extensors, the patient will exhale slowly, avoiding to totally empty the lungs. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA.
69577|NCT03639974|Other|EPAP|The Vital Signs ® EPAP kit will be used. Exercises will be performed in the bed, and as soon as the patient is released by the medical team to leave the bed, they can be performed in the sitting position or in orthostasis. For performing the exercise, the EPAP mask will be connected to the face of the patient. The expiratory pressure will be adjusted to 10cmH2O. Deep inspirations will be requested at a volume greater than the tidal volume and below the total lung capacity, then the patient will exhale slowly. The protocol will be executed twice a day, three sets of ten repetitions. The group will receive the conventional physiotherapy of the cardiac intensive care unit of the HCPA, as described in the conventional physiotherapy group.
69578|NCT03639974|Other|conventional physiotherapy|Conventional physical therapy consists of ventilatory exercises, bronchial hygiene techniques, passive, active-assisted or active exercises for upper and lower limbs, and resisted lower limb exercises; stretching, cough and walking guidelines. Initially the exercises will be performed in the bed, as soon as this is withdrawn and the patient is released by the medical team to leave the bed, the progression of the exercises to be performed in the sitting position, orthostasis, and ambulation is performed, this usually occurs on the 2nd postoperative day, after the removal of the mediastinal drain . Under supervision of the physiotherapist, the protocol will be performed twice daily, two sets of ten repetitions.
69579|NCT03639961|Behavioral|Integrated leading, managing and governing for results model|Integrated leading, managing and governing for results model is an intervention launched to improve institutional delivery.
69580|NCT03639961|Behavioral|Traditional model|Traditional model is a health service delivery model already in place in the government health system.
69581|NCT03639948|Drug|Carboplatin|Intravenous solution
69582|NCT03639948|Drug|Docetaxel|Intravenous solution
69583|NCT03639948|Drug|Pembrolizumab|Intravenous solution
69584|NCT03639948|Drug|Pegfilgrastim|Injectable product
69585|NCT03639935|Drug|Rucaparib|Rucaparib 600 mg PO BID days 1-28
69586|NCT03639935|Drug|Nivolumab|Nivolumab 240 mg IV days 1 and 15
69587|NCT03639922|Drug|Imatinib 400mg|2 tablets of Imatinib 400mg per day for 6 days
69588|NCT03639922|Drug|Placebo Oral Tablet|2 tablets of placebo per day for 6 days
69589|NCT03639909|Procedure|sweating function|Sweating dysfunction by Sudoscan
69590|NCT03639909|Procedure|Cardiovascular function|Cardiovascular (CV) tests
69591|NCT03639896|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
69592|NCT03639896|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
69593|NCT03639883|Drug|AIV001|Intradermal injection
69594|NCT03639870|Device|Model iS3 three-stent trabecular micro-bypass system|Provided in Arm/Group descriptions.
69595|NCT03639857|Device|532nm laser|532nm laser will be used to treat the lesion in this study arm.
69596|NCT03639857|Device|1064nm laser|1064nm laser will be used to treat the lesion in this study arm.
69597|NCT03639857|Drug|Topical corticosteroid|The topical corticosteroid will be used to treat the lesion in this study arm.
69598|NCT03639844|Biological|rivogenlecleucel|BPX-501 T cells are genetically modified with a suicide safety switch. The cells are infused after T cell-depleted HSCT to potentially enhance immune reconstitution while reducing severity and duration of GVHD.
69599|NCT03639844|Drug|rimiducid|Rimiducid induces activation of the Caspase 9 suicide gene in BPX-501 T cells inducing apoptosis of the modified T cells in case of GVHD
69600|NCT03639831|Dietary Supplement|Proprietary, standardized botanical extract|2 capsules/ day providing the proprietary botanical extract as unique active ingredient
69601|NCT03639831|Dietary Supplement|Placebo (maltodextrin)|2 capsules/ day providing no active component
69602|NCT03639818|Other|individual sessions of cognitive remediation|The cognitive remediation will be led by a psychologist specialized in neuropsychology, trained and experienced in this method. Cognitive remediation will be performed at a rate of 1 to 2 sessions per week for the duration of the study. This treatment will be carried out individually for half in face-to-face session in the clinical immuno-hematology department, face-to-face with the neuropsychologist, half at home with computer-based home exercises using PRESCO software ® from HAPPYNEURON®
69603|NCT03639805|Other|Music therapy program MUSIC CARE® + standard care|Administration of a specific music therapy program (U method) delivered through headphones from an iPad, under the direction of trained nurses. The program will be proposed 3 times a day and will last 20 minutes at each session.
69604|NCT03639805|Other|standard care of vaso-occlusive crises|administration of standard care only
69605|NCT03639792|Procedure|gastric cancer surgery|Gastric cancer surgery
69606|NCT03639779|Drug|Sodium Thiosulfate|A volume of 0.1 ml/cm2 of STS will be injected into each lesion.
69607|NCT03639779|Other|Saline Solution|A volume of 0.1 ml/cm2 of normal saline will be injected into the control lesion.
69608|NCT03639766|Drug|AbobotulinumtoxinA|AbobotulinumtoxinA reconstituted in non-bacteriostatic saline solution
69609|NCT03639766|Other|Saline solution|Non-bacteriostatic saline solution
69610|NCT03639753|Behavioral|Parent-Teen Intervention|Parent health coaching and resources + teen on-road driver experience
69611|NCT03639753|Other|Usual Practice|Standard care for teens who get licensed in the state of AL.
69612|NCT03639740|Drug|Secukinumab 150 milligram [Cosentyx]|For intervention description: see arm/group description
70028|NCT03636269|Drug|Placebo|IV placebo administered three times/week
69624|NCT03639662|Other|sophrology sessions|"Patients benefit from additional support consisting of at least 3 sessions of sophrology, one per week, from the week following the announcement of the diagnosis and until the week preceding the hospitalization for irathérapie. It will be group sessions, 1h carried out in the participating center by a nurse sophrologist who will use the techniques of sophrology such as relaxation, breath control, mastery of thoughts and visualization. Each session will be recorded in digital format and the recording will be given to the patient at the end of the session so that he can, if he wishes, reproduce it at home.~Patients will also be able to share their feelings and ask questions"
69625|NCT03639649|Diagnostic Test|STHLM3|
69626|NCT03639636|Other|non surgical and surgical periodontal therapy|scaling and root planing periodontal flap surgery
69627|NCT03639623|Drug|Saroglitazar|Saroglitazar magnesium 4 mg tablet once daily (OD) in the morning 60 minutes before breakfast without food
69628|NCT03639610|Drug|Melflufen|intravenous infusion
69629|NCT03639610|Drug|Dexamethasone|oral tablets
69630|NCT03639597|Device|VytronUS Ablation System|
69631|NCT03639571|Drug|Ibuprofen 200 mg TEPI Medicated Plaster|Ibuprofen 200 mg TEPI Medicated Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
69632|NCT03639571|Other|Placebo TEPI Plaster|Placebo TEPI Plaster, manufactured by AdhexPharma, France on behalf of Medherant Ltd., UK
69633|NCT03639558|Drug|Haloperidol + Promethazine + Chlorpromazine|This is the usual treatment given by this hospital during an aggressive psychiatric episode.
69634|NCT03639558|Drug|Haloperidol + Promethazine|This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
69635|NCT03639545|Drug|Empagliflozin 25mg|The patients receive empagliflozin (25 mg daily) for 12 weeks.
69636|NCT03639545|Drug|Metformin|The patients receive metformin (2000 mg daily) for 12 weeks.
69637|NCT03639545|Drug|Empagliflozin/Metformin|The patients receive empagliflozin 25 mg daily and metformin 2000 mg daily or placebo for 12 weeks.
69638|NCT03639545|Drug|Placebos|The patients receive for 12 weeks.
69639|NCT03639532|Procedure|COC THA|standard total hip arthroplasty is done, with ceramic on ceramic for the bearing.
69640|NCT03639532|Procedure|COP THA|standard total hip arthroplasty is done, with ceramic on highly cross linked polyethylene for the bearing.
69641|NCT03639519|Drug|Ascorbic Acid 500Mg Chew Tab|Ascorbic acid will be administered at the night before surgery and will be continued for five days
69642|NCT03639519|Other|Carbonated orange beverage|The carbonated orange beverage will be administered at the night before surgery and will be continued for five days
69643|NCT03639506|Procedure|autologous mitochondria transplantation|inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte
69644|NCT03639506|Combination Product|autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|autologous mitochondria transplantation
69645|NCT03639506|Drug|intracytoplasmic sperm injection (ICSI)|intracytoplasmic sperm injection (ICSI)
69646|NCT03639493|Drug|Exforge® tab 10/160mg, Crestor® tab 20mg|Co-administration of Amlodipine 10mg/ Valsartan 160mg(combination drug) and Rosuvastatin 20mg
69647|NCT03639493|Drug|CJ-30060 10/160/20mg|Fixed-dose combination drug containing Amlodipine 10mg and Valsartan 160mg and Rosuvastatin 20mg
69648|NCT03639480|Drug|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg|Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg
69649|NCT03639480|Drug|Amlodipine 10mg+Valsartan 160mg|Amlodipine 10mg+Valsartan 160mg
69650|NCT03639480|Drug|Valsartan 160mg+Atorvastatin 40mg|Valsartan 160mg+Atorvastatin 40mg
69651|NCT03639467|Drug|Anlotinib plus gemcitabine/cisplatin|"In the phase Ib portion, patients received dose escalation of anlotinb (from 8mg to 12mg orally once daily on days 1-14 of a 21-day) in combination with fixed dose of gemcitabine (1000mg/m2 intravenously on days 1 and 8) and cisplatin (80mg/m2 intravenously on day 1) every 3 weeks.~In the phase II portion, patients received anlotinb at recommended phase II dose determined in the phase Ib portion, in combination with fixed dose of gemcitabine and cisplatin every 3 weeks.~The combination of anlotinib plus gemcitabine / cisplatin was repeated every 3 weeks for up to six cycles. Patients with disease control (defined as a complete response, a partial response, or stable disease) continue to receive anlotinb until disease progression or unacceptable toxic effects, whichever occurred first."
69652|NCT03639454|Procedure|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
69653|NCT03639454|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
69654|NCT03639441|Procedure|dry needling|Dry needling, also known as myofascial trigger point dry needling, is an well-proved technique in alternative medicine similar to acupuncture. It involves the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, including pain related to myofascial pain syndrome. Dry needling is sometimes also known as intramuscular stimulation (IMS).
69718|NCT03638843|Procedure|Gastric mucosal devitalization|Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
69719|NCT03638830|Drug|Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo"
69720|NCT03638830|Drug|Ftortiazinon (tablets 300 mg) full dose + Maxipim|"Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)"
69721|NCT03638830|Other|placebo+Maxipim|placebo
69655|NCT03639441|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical battery operated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
69656|NCT03639428|Drug|Midazolam|All subjects received a sigle 0.3mg/kg midazolam dose os ADV6209
69657|NCT03639415|Drug|Increasing the Controlled-Release Oxycodone dose frequency|Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
69658|NCT03639402|Behavioral|Health education classes|Community empowerment through involvement of local mothers (peer mothers) for dissemination of education regarding health diet and physical activity to others eligible mothers in the community (fellow mothers).
69659|NCT03639389|Drug|Bupivacaine|Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
69660|NCT03639389|Drug|Analgesics|Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
69661|NCT03639363|Drug|4% chlorhexidine gluconate soap-like solution|"humidify the whole body surface with the exception of the face using water-impregnated washcloths~use 4% CHG-impregnated washcloths to bath the whole body surface with the exception of the face; use at least 30 ml of 4% CHG~wait for at least 30 seconds~rinse using water-impregnated washcloths"
69662|NCT03639363|Other|standard soap|"humidify the whole body surface with the exception of the face using water-impregnated washcloths~use standard soap-impregnated washcloths to bath the whole body surface with the exception of the face~wait for at least 30 seconds~rinse using water-impregnated washcloths"
69663|NCT03639350|Behavioral|IER+MED group|Follow a Mediterranean diet 5 days per week and follow intermittent energy restriction 2 days per week.
69664|NCT03639350|Behavioral|DASH group|Follow the distribution of macronutrients and food groups prescribed by the DASH diet 7 days per week.
69665|NCT03639337|Dietary Supplement|Multi-strain probiotic|30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63
69666|NCT03639324|Drug|Rituximab, Idelalisib, and Venetoclax|Patients will start on dose level 1, then escalate or de-escalate (if lower dose is available) based upon the estimated probabilities of toxicity from an extension of the continual reassessment method for 2 agents.
69667|NCT03639311|Drug|CAB LA|Administered CAB LA (600 mg) Q2M, intravenously.
69668|NCT03639311|Drug|RPV LA|Administered RPV LA (900 mg), Q2M, intravenously.
69669|NCT03639311|Drug|RPV|Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
69670|NCT03639311|Drug|DTG|Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.
69671|NCT03639298|Device|Intendu|intensive training with Motion Based Cognitive Video Games Software
69672|NCT03639272|Procedure|open reduction and internal fixation (ORIF).|Depending on the fracture location, a single anteromedial or anterolateral approach was carried out. The fracture site was cleaned to make it visible, allowing anatomical reduction. Subsequently, fixation of provisional fragments was achieved using temporary Kirschner wires under radiographic guidance. Having obtained satisfactory reduction as seen with the radiographic intensifier, definitive fixation of the main bone fragments was carried out using two or more 3.5 mm titanium cannulated screws or 4.0 mm lag screws, placed anteriorly to posteriorly. Fractures complicated by severe comminution necessitated 3.5 mm cortical screws in order to avoid shortening, translation or angulation of the fragments.
69673|NCT03639246|Drug|AVB-S6-500|AVB-S6-500 is experimental drug
69674|NCT03639246|Drug|Paclitaxel (Pac)|Paclitaxel is active comparator
69675|NCT03639246|Drug|Pegylated liposomal doxorubicin (PLD)|PLD is active comparator
69676|NCT03639246|Other|Placebo|Placebo comparator
69677|NCT03639233|Behavioral|YESS!|Web based self-management education
69678|NCT03639220|Device|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical™ (Solon, OH, EUA)
69679|NCT03639194|Drug|ABBV-011|intravenous
69680|NCT03639194|Drug|ABBV-181|intravenous
69681|NCT03639181|Biological|GB226|3mg/kg treat every 2 weeks
69682|NCT03639168|Drug|Chidamide combined with cisplatin|Chidamide combined with cisplatin
69683|NCT03639155|Drug|vadadustat reference tablets|oral tablet
69684|NCT03639155|Drug|vadadustat test tablets|oral tablet
69685|NCT03639142|Other|Prunus domestica|Patients will receive prunes at dose 3,5 g/kg/d (max.100mg/day) in three portions a day, for 4 weeks (amount of prescribed prunes will be calibrated with the weight that child ought to have on WHO growth charts at 50th percentile). Prunes should be introduced every day in three meals. Prunes can be chopped or grinded before eating them. They can be eaten alone or child may eat them as a part of bigger meal (which is preferred version). Prunes can be introduced with yogurt, cereals, nuts and seeds as a morning meal.
69686|NCT03639142|Drug|Polyethylene Glycol 4000|Patients will receive PEG at dose 0,5 g/kg/d once daily orally, for 4 weeks.
69687|NCT03639129|Device|Contrast-enhanced mammography|Contrast-enhanced mammography was FDA approved in 2012 and is currently being used in both clinical and research settings at breast imaging centers throughout the world
69688|NCT03639129|Procedure|Biopsy|Standard of care
69689|NCT03639116|Procedure|Stimulation|This study is a novel approach to studying neuroplasticity after stroke. Previous work in humans with incomplete spinal cord injury demonstrates that the resulting plasticity transiently enhances motor output, indicating that there is also therapeutic potential. This study will attempt to induce bi-directional plasticity in corticospinal-motoneuronal synapses serving an intrinsic hand muscle of the hemiparetic limb. Control experiments will be completed to provide evidence of the neurophysiological mechanism(s) mediating the effect and to examine behavioral effects.
69821|NCT03637959|Device|Mechanical Vibrations with Ultrasound Shear Wave Imaging|Measuring liver tissue density during mechanical liver tissue vibration.
120096|NCT03247673|Drug|US-licensed Avastin|US-licensed Avastin
69690|NCT03639103|Procedure|Distal Metatarsal Metaphyseal Osteotomy (DMMO)|The scalpel is advanced at an oblique angle of about 45° until it reaches the dorsal aspect of the distal metatarsal bone to undergo osteotomy. First a bone rasp specific for percutaneous surgery is used to separate the periosteum at the level of the osteotomy site. A Shannon Isham burr is introduced until it reaches the metatarsal neck where the periosteum was previously removed. Fluoroscopy is used to confirm the correct position of the osteotomy site. The lateral cortical surface is cut first, then the plantar, medial, and lastly, the dorsal cortical surface. During the osteotomy process, the incision site is irrigated by normal saline, as the burr can cause excessive heat, causing skin burn and resulting subsequently in fibrosis and pseudoarthrosis at the bone level.
69691|NCT03639090|Diagnostic Test|mass spectrometry|mass spectrometry for bladder cancer cells
69692|NCT03639077|Device|Allograft bone alone|The subject will receive an allograft as graft material of choice for sinus augmentation
69693|NCT03639077|Device|Allograft and xenograft mixture|The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
69694|NCT03639064|Drug|Cannabis Oil|"Mixed oil cannabis preparation consisting of 3 differing formulations of ∆-9THC and CBD is clinically available in Canada as CanniMed®. The 3 differing formulations of CanniMed® oils contain varying proportions of ∆-9THC and CBD in the following ratios: 18:0; 10:10; 1:20.~All CanniMed® oil formulations consist of cannabinoids extracted from dried cannabis, and diluted in olive oil."
69695|NCT03639051|Device|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) Therapy is a bronchoscopically guided, minimally invasive procedure using the Nuvaira™ Lung Denervation System.
69696|NCT03639051|Other|Optimal Medical Care|Taking regular maintenance medication that minimally includes a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA).
69697|NCT03639025|Device|OCS Lung System|"The OCS™ Lung System is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state prior to transplantation. This technology was designed to overcome the limitation of cold storage and has the potential to expand the utilization of donor lungs. The OCS™ Lung System accomplishes this by performing 3 key functions:~Reducing ischemic injury through the use of warm, oxygenated blood based perfusion.~Optimizing the lung condition by ventilatory recruitment maneuvers and high-oncotic perfusion solution supplemented with hormones and nutrients.~Allowing for ex-vivo functional assessment of the donor lung during preservation and prior to transplant."
69698|NCT03639012|Dietary Supplement|Carbohydrate drink|Children randomised to this group will receive a preoperative carbohydrate drink 90-120mins prior to surgery
69701|NCT03638986|Other|No intervention planned|No Intervention planned.
69702|NCT03638973|Procedure|Biopsy|Removal of specimen biopsies in patients with leukoplakic or lichenoid mucosal lesions using Er: YAG laser or scalpel under previous local anesthesia.
69703|NCT03638960|Drug|Bupivacaine liposome|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.
69704|NCT03638960|Drug|Bupivacaine Hydrochloride|The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
69705|NCT03638947|Device|Swab and decolonization using povidone-iodine cleansing|Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
69706|NCT03638934|Other|Videos about ACP|Three videos about advanced care planning are provided for self-education.
69707|NCT03638934|Other|Brochure about Life-Sustaining Treatment Act|Brochure about Life-Sustaining Treatment Act are provided for self-education.
69708|NCT03638921|Drug|MEOPA|Patients included in the study will receive MEOPA with a high concentration mask (bottle stored for at least 48 hours horizontally) at a minimum flow rate of 10 L / min under supervision of a health care worker after explanation of use to the patient in a quiet environment (box). MEOPA will be administered for a maximum total duration of 20 minutes, continuously or not depending on the needs of the patient, but after a continuous phase at the beginning of treatment of at least 3 minutes.
69709|NCT03638908|Drug|Fluoxetine|
69710|NCT03638895|Device|ECAL Indirect Calorimeter|The ECAL is an open-circuit portable indirect calorimeter that measures both volume of CO2 expired and O2 consumed using a small mixing chamber. Participants will breathe through a mouthpiece with a nose clip applied whilst lying in a restful and comfortable position for 15 minutes. ECAL device will provide breath-by-breath measurements of the resting energy expenditure and respiratory quotient which will allow both practitioners and participants to monitor their metabolic health and compare the effect of dietary and physical activity intervention over the course of the structured intensive lifestyle intervention (24-weeks).
69711|NCT03638895|Behavioral|Diet, exercise & behaviour modification therapy|Standard care (SC) - participants receive standard care (diet, exercise & behaviour modification therapy) as part of the multicomponent weight management intervention within the tier 3 weight management service. Practitioners will rely on standard predictive equations to provide dietary advice and intervention.
69712|NCT03638882|Behavioral|Duolingo|Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.
69713|NCT03638882|Behavioral|BrainHQ|Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.
69714|NCT03638882|Behavioral|Passive Control|No Intervention.
69715|NCT03638869|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 25 mg, 50 or 75 mg REL-1017 for 10 days, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL.
69716|NCT03638869|Drug|Placebo|
69717|NCT03638856|Drug|Misoprostol 200Mcg Tab|patient takes 2 tab of 200 mcg of Misoprostal 3 hr before hysteroscopy
120904|NCT03241472|Drug|Letrozole|oral tablets 5 mg
69722|NCT03638817|Drug|Eltrombopag|"Eltrombopag will be prescribed at doses recommended in primary immune thrombocytopenia (50, 25 or 75 mg), starting 4 weeks before the procedure and stopped 2 days before. PC will be administrated prophylactically if the platelet count is < 80 G/L or per/post-operatively in case of bleeding of undetermined cause.~Antifibrinolytics will be authorized and low molecular weight heparin prescribed if indicated for the prophylaxis of postoperative venous thrombosis according to the standard dose and duration, , irrespective of the platelet count"
69723|NCT03638804|Diagnostic Test|89Zr-KN035|Single injection of 89Zr labeled KN035 in subjects to observe KN035 affinity in PD-L1 expressed Solid tumors by using PET imaging.
69724|NCT03638791|Behavioral|Exposure and response inhibition|Cognitive behavioural therapy designed for treatment of Obsessive-compulsive disorder
69725|NCT03638778|Drug|Semaglutide 3 mg|Semaglutide 3 mg will be administered once daily (OD) orally in the morning from day 1 to 5.
69726|NCT03638778|Drug|Semaglutide 7 mg|Semaglutide 7 mg will be administered OD orally in the morning from day 6 to 10.
69727|NCT03638778|Drug|Semaglutide B 3 mg|Semaglutide B 3 mg will be administered OD orally in the morning from day 1 to 5.
69728|NCT03638778|Drug|Semaglutide B 7 mg|Semaglutide B 7 mg will be administered OD orally in the morning from day 6 to 10.
69729|NCT03638778|Drug|Semaglutide C 3 mg|Semaglutide C 3 mg will be administered OD orally in the morning from day 1 to 5.
69730|NCT03638778|Drug|Semaglutide C 7 mg|Semaglutide C 7 mg will be administered OD orally in the morning from day 6 to 10.
69731|NCT03638778|Drug|Semaglutide D 3 mg|Semaglutide D 3 mg will be administered OD orally in the morning from day 1 to 5.
69732|NCT03638778|Drug|Semaglutide D 7 mg|Semaglutide D 7 mg will be administered OD orally in the morning from day 6 to 10.
69733|NCT03638765|Biological|DCVax-Direct|activated, autologous dendritic cells
69734|NCT03638752|Other|Comprehensive education group|"The details of Comprehensive education are as follows:~introduce the purpose, method and function of breathing training and the whole process of gastroscopy;~instruct patients to take deep breath training, inhaling with his/her nose and exhaling with his/her mouth,~provide patients with a disposable dental biting device and repeat exercising deep breathing again until he/she is fully mastered,~inform patients to cooperate with the instructions issued by endoscopist and endoscopy nurse during the whole process of gastroscopy,~inform patients to inhale with nose and exhale with mouth when the gastroscope passes through the throat, then he/she should perform inhaling and exhaling with his/her nose until the end of the gastroscopy when the endoscopist ask to adjust the breathing method,~inform patients that there would be some normal physiological reaction when gastroscopy, such as throat discomfort and nausea/vomiting."
69735|NCT03638739|Other|Twice-weekly exercise|An individualized exercise plan, incorporating aerobic and resistance exercises, following the Physical Activity Guideline recommendations will be provided for each participant.
69736|NCT03638726|Drug|Atropine sulfate and epinephrine|Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.
69737|NCT03638726|Drug|Topical cyclopentolate and phenylephrine|Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.
69738|NCT03638713|Behavioral|colonoscopy first|Received water exchange colonoscopy followed by EGD
69739|NCT03638713|Behavioral|EGD first|Received EGD followed by water exchange colonoscopy
69740|NCT03638700|Device|VisiGlide™ angled tip|Arm A: Primary use of VisiGlide™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (straight tip) resp. to VisiGlid2e™ (tip according to the examiner)
69741|NCT03638700|Device|VisiGlide2™ angled tip|Arm B: Primary use of VisiGlide2™ guidewire (angled tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (straight tip) resp. to VisiGlide™ (tip according to the examiner)
69742|NCT03638700|Device|VisiGlide™ straight tip|Arm C: Primary use of VisiGlide™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide™ (angled tip) resp. to VisiGlide2™ (tip according to the examiner)
69743|NCT03638700|Device|VisiGlide2™ straight tip|Arm D: Primary use of VisiGlide2™ guidewire (straight tip). In case it should not be possible to complete one step toward the therapeutic goal after 8 to max. 12 minutes after start of the examination, the wire system is changed: primary change to VisiGlide2™ (angled tip) resp. to VisiGlide1™ (tip according to the examiner)
69744|NCT03638674|Other|DXA + CT|Two dual-energy X-ray scans + CT scan
69745|NCT03638661|Dietary Supplement|vegetable (canola, flaxseed) derived n-3 fatty acid|vegetable (canola, flaxseed) derived n-3 fatty acid was used for fat source.
69746|NCT03638661|Dietary Supplement|soybean oil|soybean oil used formula
69747|NCT03638648|Drug|Capecitabine|Capecitabine 2500mg/m2/day, d1-d14, every 3 weeks a cycle for 8 cycles
69748|NCT03638635|Drug|Bupivacaine|Abdominal injection of bupivacaine into fascial layer.
69749|NCT03638635|Drug|Bupivacaine liposome|Abdominal injection of bupivacaine liposome into fascial layer.
69750|NCT03638622|Combination Product|Photodynamic Therapy|Patients receive aminolevulinic acid orally with orange juice in 3 fractions at 0,1,2 hours before undergoing photodynamic therapy using LED based Device on day one.
69751|NCT03638609|Device|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
69752|NCT03638596|Behavioral|Contingency Management|Incentive provided for changing alcohol drinking patterns based on ankle monitor
69753|NCT03638596|Behavioral|Control|Incentive provided is not contingent on alcohol drinking patterns based on ankle monitor
69754|NCT03638557|Other|Nutritious Lunch|"The intervention package consists of the following;~Balanced Nutrition and Clean and Healthy Lifestyle Behavior Education for the boarding school students (once a week with the duration of 30-60 minutes. 3 weeks are delivered by trained teachers, and 1 week by research team.~Nutritious lunch, for 7 days a week. With the total of 220 days. The lunch menu is designed to meet 30% of the students RDA, which consists of 635-777 Kcal and 18-22 grams of protein"
69755|NCT03638544|Dietary Supplement|Reduced gluten bread and Pasta compared o normal gluten bread and Pasta|Pasta with low gluten (50% of the normal) content achieved by optimization of techological parameters such as dough yield, time of fermentation and concentration of fungal proteases The gluten reduction is obtained without any other intervention of wheat breeding or the endogenous proteolytic enzymes of flours.
69756|NCT03638531|Device|Anodal tDCS|Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
69757|NCT03638531|Device|SHAM tDCS|SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
69758|NCT03638518|Other|Acupuncture|Acupuncture 5 weeks treatment. 2 sessions a week (30 minutes each session)
69759|NCT03638518|Other|Physiotherapy|Core stability exercises programme. 2 sessions a week (30 minutes each session) during 5 weeks
69760|NCT03638505|Other|PSP-QoL|"PSP-QoL is a patient-reported outcome measure for progressive supranuclear palsy (PSP). The Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.~PSP-QoL consists of 28 items scored on a 3‐ or 5‐point Likert scale, with the total score ranging from 0 to 100. Each item is scored from either 0 to 4, with the exception of four items, which are scored from 0 to 2, with higher scores indicating more‐severe disability or movement abnormality. Items are in six categories: daily activities (by history); behavior; bulbar; ocular motor; limb motor; and gait/midline. The scale includes comments and/or instructions for each item and word anchors to explain the ratings."
69761|NCT03638492|Procedure|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
69762|NCT03638492|Procedure|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
69763|NCT03638479|Other|Data Capture|This is no intervention. Participants of all groups will receive data Capture with smartphones, smartwatches and tablets.
69764|NCT03638466|Drug|SPN-810|Single dose of SPN-810
69765|NCT03638466|Drug|Placebo|Placebo
69766|NCT03638453|Other|PediCARE|PediCARE provides support for groceries (using an online grocery delivery service called Instacart) and transportation to and from the hospital (using rides through RideHealth).
69767|NCT03638453|Other|Usual Care|Standard care per hospital guidelines.
69768|NCT03638440|Drug|Naloxegol|Naloxegol is a PEGylated derivative of the μ-opioid receptor antagonist naloxone
69769|NCT03638427|Diagnostic Test|Menstrual Blood Analysis (Menstrual Blood Analysis)|We will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing HR-HPV DNA and HPV E6/E7 mRNA via self-collected menstrual blood from a menstrual pad.
69770|NCT03638414|Other|ePainQ questionnaire|This is a questionnaire which will be given to the intervention group about their perceptions of treatment. It will be online.
69771|NCT03638401|Procedure|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.|This arm will received perioperative transversus abdominis plane (TAP) block followed by continuous infusion of local anaestheic by wound catheters and an IV morphine PCA.
69772|NCT03638388|Procedure|Dry needling (DN)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of my muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and the subject will sit in a chair without moving my arms or head, for 10 minutes. After 10 minutes the needles are removed and discarded.
69773|NCT03638388|Procedure|Dry needling with intramuscular electrical stimulation (DNES)|One to three filament needles (similar to an acupuncture needle) with no medication will be inserted into the tender area of the muscle. The needles will be repositioned a few times to make the muscle twitch. After several twitches occur, the researcher will leave the needles as they are, and attach alligator clips to the needles to provide electrical stimulus for 10 minutes while the subject sits in a chair without moving arms or head. After 10 minutes, the electrical stimulus will be turned off and detached, and the needles removed and discarded.
69774|NCT03638375|Drug|Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha|"During 15 weeks patients will be treated with nivolumab (3mg/kg i.v.) once every two weeks. Four weeks after starting nivolumab, patients will receive their first TIL infusion (2.5-7.5x10^8 T cells i.v.) once every three weeks for three infusions.~In the second group treatment with IFN-alpha (3 million IU s.c.) daily will be added one week before the first TIL infusion and will be continued for 11 weeks."
69775|NCT03638362|Dietary Supplement|Placebo|Participants consumed placebo beverage for 4 weeks.
69776|NCT03638362|Dietary Supplement|Tart cherry juice|Participants consumed tart cherry juice (8 ounces; 240 mL) per day for four weeks.
69777|NCT03638336|Device|ILY robotic flexible ureteroscopy|fragmentation of nephrolithiasis
69778|NCT03638323|Other|Speech therapy|During a 1-hour speech-language consultation, a lack of word evaluation will be conducted and patient will answer a Hearing Difficulty Questionnaire
69779|NCT03638310|Procedure|intratympanic application of gentamicin|under local anesthesia is gentamicin instilled through tympanic membrane to tympanic cavity
69780|NCT03638310|Procedure|microsurgical removal of vestibular schwannoma|surgery under general anesthesia
69781|NCT03638297|Drug|PD-1 antibody + cox inhibitor|"BAT1306 100mg on day 1 + aspirin 200mg oral (celebrex 400mg oral when there is contraindication to aspirin) on day 1-21 every three weeks~Contraindication to aspirin :~Allergic or intolerance to aspirin; With peptic ulcers; With hemophilia or other bleeding tendencies; Have the gentic disease glucose-6 phosphate dehydrogenase deficiency."
69822|NCT03637946|Other|Device: SHOFU beautifil II LS|Restorative system FL-Bond II (self-etching adhesive system)/ beautifil II (composite restorative) were used following manufacturer's instructions
69782|NCT03638284|Device|Transcranial Direct Current Stimulation|tDCS is a non-invasive brain stimulation that does not require general anaesthesia or surgical implantation of a device. It uses two AA size batteries to deliver direct current via rubber electrodes enclosed in saline soaked sponges.
69783|NCT03638271|Diagnostic Test|Cardiac magnetic resonance imaging|Patients in different sex and age groups diagnosed with any type of nonischemic cardiomyopathy clinically or with echocardiography will undergo cardiac magnetic resonance imaging and compare their results.
69784|NCT03638258|Drug|ARQ-151 Cream 0.3%|Applied once daily for 12 weeks
69785|NCT03638258|Drug|ARQ-151 Cream 0.15%|Applied once daily for 12 weeks
69786|NCT03638258|Drug|ARQ-151 vehicle cream|Applied once daily for 12 weeks
69787|NCT03638232|Other|Administrative data|Gender Birthdate Department and town of residence Date of death Affiliation to french Universal Health Coverage
69788|NCT03638232|Other|Medical data|Long term affection code, number and medical codification Date of onset and end of care Codification of medical acts and consultation (With common classification of medical acts)
69789|NCT03638232|Other|Drug exposition data|Speciality of prescribing physician CIP code of drug Name of speciality prescribed Date of deliverance Date of prescription Number of treatment box delivered
69790|NCT03638219|Other|Data collection about eligible patients presented to our department from 2015 to 2018. Then follow up for 2 years till 2020.|Data collection, follow up and bioscore calculation at the end of study
69791|NCT03638206|Biological|CAR-T cell immunotherapy|According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
69792|NCT03638193|Biological|CART-meso cells|CART-meso is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m^2 of cyclophosphamide, which will be administered according to standard procedures, Thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
69793|NCT03638180|Drug|BLU-5937|BLU-5937 oral tablet
69794|NCT03638180|Drug|Placebo|Matching placebo to BLU-5937
69795|NCT03638167|Biological|EGFR806-specific chimeric antigen receptor (CAR) T cell|Autologous CD4+ and CD8+ T cells lentivirally transduced to express an EGFR806 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
69796|NCT03638154|Procedure|GF+GMSCs carried on β TCP|"surgical augmentation of GF+GMSCs carried on β TCP in intrabony periodontal defect and covered by collagen membrane(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Cytoplast, RTM Collagen Cytoplast, Barrier Membranes, Osteogenics Biomedical, New Gersey, USA).~Ibuprofen"
69797|NCT03638154|Procedure|β TCP bone substitute only|surgical augmentation by β TCP in intrabony periodontal defect(Bioresorb, Sybron, implant solutions GmbH Bremen, Germany) Ibuprofen
69798|NCT03638141|Drug|Durvalumab|Durvalumab IV
69799|NCT03638141|Drug|Tremelimumab (Cohort A dose)|Tremelimumab IV
69800|NCT03638141|Drug|Tremelimumab (Cohort B dose)|Tremelimumab IV
69802|NCT03638115|Device|VaSecure™|Drug Coated PTA Balloon Catheter
69803|NCT03638102|Behavioral|Sleep extension|Sleep extension aims to increase sleep duration for at least 30 minutes using weekly coaching
69804|NCT03638102|Behavioral|Healthy living|Participants will receive weekly health education
69805|NCT03638089|Behavioral|Fall-recovery training|Participants practice recovering from simulated, treadmill-induced slips and trips.
69806|NCT03638076|Drug|GLS4|Subject in group A will receive Mesilate Capsule 120mg twice daily. Subject in group B will receive Mesilate Capsule 120mg three times daily.
69807|NCT03638076|Drug|RTV|Subject in group A will receive Ritonavir tablet 100mg twice daily.Subject in group B will receive Ritonavir tablet 100mg three times daily.
69808|NCT03638063|Diagnostic Test|Adenosine Triphosphate|Adenosine Triphosphate aerosol
69809|NCT03638063|Diagnostic Test|capsaicin|capsaicin aerosol
69810|NCT03638050|Other|Functional Capacity Assessment|Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
69811|NCT03638037|Diagnostic Test|Vitamin D measurement|Maternal serum 25- hydroxyl vitamin D level
69812|NCT03638024|Diagnostic Test|Maternal plasma cell free fetal DNA levels|Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
69813|NCT03638011|Drug|Exparel|Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
69814|NCT03637998|Behavioral|Problem-solving Pain to Enhance Living Well (PROPEL)|PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.
69815|NCT03637985|Device|resistive exercise|resistive exercise by elastic band for 12 weeks
69816|NCT03637985|Device|aerobic exercise in form of treadmill walking|aerobic exercise in form of treadmill walking for 12 weeks
69817|NCT03637972|Other|Access to Experimental Marketplace: Ventilated cigarettes only|Participants given vouchers that are exchanged for ventilated cigarettes study cigarettes.
69818|NCT03637972|Other|Access to Experimental Marketplace: Unventilated cigarettes only|Participants given vouchers that are exchanged for unventilated cigarettes study cigarettes.
69819|NCT03637972|Other|Access to Experimental Marketplace: Ventilated cigarettes + alternative nicotine delivery systems|Participants given vouchers that are exchanged for ventilated cigarettes + alternative nicotine delivery systems cigarettes.
69820|NCT03637972|Other|Access to Experimental Marketplace: Unventilated cigarettes + ANDS|Participants given vouchers that are exchanged for unventilated cigarettes + ANDS.
69823|NCT03637933|Procedure|endoscopic tattooing|The tattoo has to be placed 1 or 2 cm distal to the lesion and tattooing has to be performed in at least 2 of the 4 quadrants of the bowel. A 0.5-1 mL saline bleb has to be raised submucosally and then a similar quantity of India Ink or Sterile Carbon Particle Suspension has to be injectiected into that bleb.
69824|NCT03637907|Other|Not applicable - no intervention.|No intervention is performed, just a CT with a new detector and comparison with the same patients older image.
69825|NCT03637894|Dietary Supplement|Feeding infants with fermented formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
69826|NCT03637894|Other|Feeding infants with standard formula milk|Infants enrolled were fed either with fermented formula milk or with standard formula during the first four months of life. Breastfed infants were the reference group.
69827|NCT03637894|Other|Breastfeeding infants|Reference group
69828|NCT03637868|Drug|Eribulin|Patients will receive eribulin 1.4 mg/m² administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
69829|NCT03637842|Drug|Lorcaserin|Lorcaserin XR 20mg per day
69830|NCT03637842|Drug|Placebo oral capsule|Placebo
69831|NCT03637829|Other|Control|Water
69832|NCT03637829|Other|White chocolate|Experimental snack treatment
69833|NCT03637829|Other|Dark chocolate 1|Experimental snack treatment
69834|NCT03637829|Other|Dark chocolate 2|Experimental snack treatment
69835|NCT03637816|Drug|Anamorelin Hydrochloride|Given PO
69836|NCT03637816|Other|Placebo|Given PO
69837|NCT03637816|Other|Questionnaire Administration|Ancillary studies
69838|NCT03637803|Drug|MRx0518|MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
69839|NCT03637803|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
69840|NCT03637790|Drug|PF-04965842|single oral 200 mg dose of PF 04965842 in the morning on Day 1 under fasted conditions.In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842.
69841|NCT03637790|Other|rifampin|In Period 2, subjects will receive rifampin 600 mg QD in the mornings of Day 1 to Day 7, approximately 1 hour before the morning meal. On the morning of Day 8, after an overnight fast of approximately 9 hours, subjects will be administered rifampin 600 mg 1 hour prior to administration of a single 200 mg oral dose of PF 04965842
69842|NCT03637777|Diagnostic Test|16S rRNA gene sequencing|Specimens collected from patients will be used for next generation sequencing of the bacteria-specific 16S rRNA gene
69843|NCT03637764|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
69844|NCT03637764|Drug|Atezolizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
69845|NCT03637751|Behavioral|Behavioral|Trier Social Stress Test
69846|NCT03637751|Behavioral|Control condition|In the no-stress control condition, participants will be instructed to sit in a room, read magazines, and to refrain from any stressful activities (e.g., cell-phone use will be restricted).
69847|NCT03637738|Radiation|RIOP-Intrabeam® system|The radiation source is inserted at the immediately on surgical resection bed after tumorectomy and started for 20 to 55 minutes to perform intraoperative radiotherapy precisely targeting the tissues that present the greatest risk of local recurrence. The applied dose will be 20 Gy on the applicator surface.
69848|NCT03637738|Radiation|conventional surgery +RTE|Conventional EBRT, 5 to 10 weeks after surgery, according to the usual recommendations, 2 Gy per session, 5 sessions per week, with a total dose on the mammary gland of 50 Gy + a boost of 16 Gy on surgical resection bed .
69849|NCT03637712|Device|Computer Algorithm|This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
69850|NCT03637699|Behavioral|Positive Psychology|5-week positive psychology intervention
69851|NCT03637673|Other|No intervention|No intervention
69852|NCT03637660|Drug|Benzathine Penicillin|BPG will be administered as a deep intramuscular injection in the upper, outer quadrant of the buttock.
69853|NCT03637647|Diagnostic Test|Cardiopulmonary exercise testing|The CPET involves cycling on an exercise bike for 8-12 minutes. Starting with a very low resistance on the pedals the patient will pedal at 60 revolutions per minute. After 3 minutes of cycling, the resistance will gradually increase until the patient can no longer turn the pedals at the required speed. The test will be thoroughly explained to the patient beforehand and trained staff will make the experience as comfortable as possible. CPETs will be stopped early by the study researcher/doctor in the presence of any adverse events. Each CPET appointment will last approximately one hour.
69854|NCT03637621|Other|ORIF|open reduction internal fixation of the distal humerus
69855|NCT03637595|Procedure|Acupuncture|3 sessions of acupuncture will be the reference therapy against which the energy medicine intervention is being compared.
69856|NCT03637595|Procedure|Enery Medicine Intervention|3 sessions performed by Energy Medicine practitioner, who will perform an assessment followed by the intervention.
69857|NCT03637595|Procedure|Sham Energy Medicine|a non-energy trained confederate to be determined from the clinical research coordinators and non traditional volunteers enrolled administering assessments and providing therapeutic company.
69858|NCT03637582|Drug|lidocaine gel|Lidocaine (4%) gel from Quest Products, Inc.
69859|NCT03637582|Other|Plain aqueous gel|KY jelly lubricant from Reckitt Benckiser
69860|NCT03637569|Other|Measurement of triceps skinfold thickness|By using skin thickness caliper, measure triceps skinfold thickness on the half of forearm (Rt side). In every 3 weeks, triceps skinfold thickness will be measured.
69864|NCT03637543|Drug|Nivolumab|Nivolumab is an antibody inhibitor of the programmed death-1 (PD-1) pathway. By blocking PD-1, this medication may allow the immune system to recognize and fight cancer
69865|NCT03637530|Other|inverse ratio ventilation|during general anaesthesia in laparoscopic surgeries, this group of patients will receive inverse ratio ventilation with proper observation of hemodynamics
69866|NCT03637517|Drug|DSM265-TPGS 34% SDD, 400 mg fasted|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fasted state.
69867|NCT03637517|Drug|DSM265-TPGS 34% SDD, 400 mg fed|New formulation allowing smaller volumes of dissolution in a common vehicle (water), administered to subjects in a fed state.
69868|NCT03637517|Drug|DSM265 25% SDD, 400 mg fasted|Reference formulation used in early clinical trials.
69869|NCT03637504|Behavioral|MedActionPlan®|web-based, mobile medication management application [MedActionPlan® (MAP)]
69870|NCT03637491|Drug|Avelumab|IV treatment
69871|NCT03637491|Drug|Binimetinib|Oral treatment
69872|NCT03637491|Drug|Talazoparib|Oral treatment
69874|NCT03637465|Behavioral|Hydrate Philly|"Hydrate Philly is a multi-component intervention that includes water safety testing, provision of 1-2 hydration stations per recreation center, distribution of reusable water bottles for youth, a campaign to promote the acceptability of tap water, and the reduction of access to competing unhealthy beverages through vending machine standards and discouraging black bags (characteristic small, black, plastic bags provided to customers with their corner store purchases, typically including a sugar sweetened beverage and/or unhealthy snack foods)."
69875|NCT03637439|Other|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
69876|NCT03637439|Other|Ultrasound-guided Percutaneous Needle|Same protocol without electricity
69877|NCT03637426|Other|Laser|GLASER received the laser application using the infrared light spectrum with wavelength of 808 nm with its active AsGaAl medium in two points of the vestibular face of the hypersensitive teeth. It was applied at each point 60 J / cm², for 16 seconds. The laser was applied in 2 sessions with a time interval of 24 hours.
69878|NCT03637426|Other|nano-hydroxyapatite|The GnHAP volunteers were submitted to the application of Desensibilize Nano P on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds in each tooth, according to the manufacturer's specifications
69879|NCT03637426|Other|Laser + nano-hydroxyapatite|GLASERnHAP first received laser application and subsequently the application of nanohydroxyapatite according to the manufacturer's recommendations.
69880|NCT03637426|Other|PLACEBO|In this group, a toothpaste without addition of fluoride or any other desensitizing agent (Natural, Contente®, Uberlândia, MG, Brazil) was applied to hypersensitive dentine. The GPLACEBO volunteers were submitted to the application of placebo dentifrice on the vestibular surfaces of hypersensitive teeth with the aid of a Microbrush applicator (Microbrush, 3M ESPE, São Paulo, Brazil) for 10 minutes. Then, a rubber cup (Unid Microdont, São Paulo, SP, Brazil) mounted on a low speed handpiece (Dabi Atlante, Ribeirão Preto, SO, Brazil) was used to scrub the desensitizing gel on teeth for 20 seconds on each tooth.
69881|NCT03637413|Dietary Supplement|Hindmilk|Mother will be taught to separate her milk and infant will receive only hindmilk for feeds
69882|NCT03637400|Drug|TMP-SMX|TMP-SMX will be administered over a period of 7 days.
69883|NCT03637400|Drug|DOXY|DOXY will be administered over a period of 7 days.
69884|NCT03637387|Drug|BIIB074|Administered as specified in the treatment arm
69885|NCT03637387|Drug|Placebo|Matched placebo
69886|NCT03637374|Device|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
69887|NCT03637374|Device|Unitary Manifold|Endovascular stent graft system
69888|NCT03637374|Device|TAAA Debranching Stent Graft System|Endovascular stent graft system
69889|NCT03637361|Drug|REL-1017|The investigational product, REL-1017 is prepared as a solution with Ocean Spray® Diet Cranberry Juice on site to obtain a final volume of 100 mL for dosing. The study drug will be administered as a solution of 5 mg, 20 mg, 60 mg, 100 mg, 150 mg or 200 mg REL-1017, based on randomization prepared in Ocean Spray® Diet Cranberry Juice with a final volume of 100 mL
69890|NCT03637361|Drug|Placebo|
69891|NCT03637348|Device|TrueTear|Ues of TrueTear neurostimulator
69892|NCT03637335|Combination Product|irradiation + carboplatin|30 Gy en 10 fractions de 3 Gy + 10 injections of carboplatin
69893|NCT03637335|Combination Product|irradiation + placebo|30 Gy en 10 fractions de 3 Gy + 10 injections of placebo
69894|NCT03637309|Behavioral|BeReady2Smile Video and App|BeReady2Smile is a coordinated oral health prevention intervention program that includes video content that features demonstrations/content on encouraging brushing, proper loading of toothbrush, brushing duration and frequency, fluoride myths, and limiting sugar sweetened beverages and milk in baby bottles while in bed. BeReady2Smile will also include a mobile application built within a web-based infrastructure, so parents can participate in multi-media educational activities, develop dental health behavior plans, tailor features and receive feedback from the system on a secure website.
69895|NCT03637296|Other|Critical time intervention|Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
69896|NCT03637283|Procedure|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
69898|NCT03637270|Dietary Supplement|Dietary supplementation|Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
69899|NCT03637270|Other|Exercise training|Including aerobic cycling training and progressive resisted exercise
69900|NCT03637257|Device|modified Guedel airway|Monitoring of breathing
69901|NCT03637244|Behavioral|Decision Support Aid and PrEP for Black Canadians|Ottawa Decision Support Framework Adaptation.Investigators will use the inputs from the qualitative findings, CDC public health guidance and the tenofovir + emtricitabine product monograph to tailor the ODSF for use in the C5TM PrEP decision support web-app.
69902|NCT03637231|Diagnostic Test|Ultra low-dose CTAC|All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
69903|NCT03637218|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
69904|NCT03637218|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
69905|NCT03637205|Procedure|ECLS insertion|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned. ECLS insertion should be performed preferably before revascularization
69906|NCT03637205|Other|Revascularisation and optimal medical treatment|After diagnostic angiography the culprit lesion should be identified and revascularization (preferably by PCI, alternatively CABG) should be planned.
69907|NCT03637192|Other|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
69908|NCT03637192|Other|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
69909|NCT03637179|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
69910|NCT03637179|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
69911|NCT03637166|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
69912|NCT03637166|Other|Exposure to High Altitude (2500m above sea level)|"Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours"
69913|NCT03637153|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
69914|NCT03637153|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
69915|NCT03637140|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
69916|NCT03637140|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
69917|NCT03637127|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
69918|NCT03637127|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
69919|NCT03637114|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
69920|NCT03637114|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
69921|NCT03637101|Diagnostic Test|Ischemia modified albumin (IMA)|Ischemia modified albumin is a biomarker for cardiac ischemia and acute stroke whether ischemic or hemorrhagic
69922|NCT03637088|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
69923|NCT03637088|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask"
69924|NCT03637075|Other|intranasal insulin|intranasal administration of insulin (160 IU)
69925|NCT03637075|Other|Placebo|placebo intranasal administration
69926|NCT03637062|Drug|Progesterone|progeaterone:Utrogestan is one of the normal drugs in China to prevent spontaneous preterm birth, the Utrogestan used in this study is from Laboratories Besins International.
69927|NCT03637062|Device|pessary|pessary: The cervical pessary is a vaginal device (silicone ring) that is used to treat pregnant women for preventing spontaneous preterm birth.
69928|NCT03637049|Drug|PBI-4050 and midazolam|A single oral dose of midazolam (1 mL of 2mg/mL syrup) will be given to all subjects in Period 1 and on Day 5 of Period 2. 1200 mg of PBI-4050 (3 X 400 mg tablets) will be administered for 5 days (Day 1 to Day 5) of Period 2 and a single dose of midazolam (1 mL of 2mg/mL) on Day 5.
69929|NCT03637036|Other|Communication intervention|The intervention is a communication inviting staff to take up the influenza vaccination. Different versions of the communication are created, and the investigators will compare uptake rates between staff that received different letters.
69930|NCT03637023|Behavioral|Virtual Reality|Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking
69931|NCT03637023|Behavioral|Exercise Therapy|The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
69932|NCT03637023|Drug|Pharmacological Treatment|Anti-parkinsonian medication given by a specialist neurologist will continue.
69933|NCT03637010|Other|Breakfast in the Classroom|For all breakfasts, the students will use the 'grab and go' approach from hallway kiosks. The students will take the breakfasts back to their respective classroom and consume them there.
69934|NCT03636997|Procedure|Draining seton|Number 1 silk suture was passed through the fistula track and tied as loose seton
70150|NCT03635541|Other|observational group of NAFLD|there's no intervention for patients for it is a observational study
69935|NCT03636997|Procedure|Rerouting of track|The seton and fistula track were rerouted to involve the internal anal sphicnter only and spare the external sphincter
69936|NCT03636984|Drug|recombinant TNF-α receptor: IgG Fc fusion protein|50mg weekly
69937|NCT03636971|Drug|hyaluronic acid with mannitol|single shot injection (Ostenil Plus®, TRB Chemedica SA, CH, 1800kD)
69938|NCT03636971|Drug|hyaluronic acid with sorbitol|single shot injection (Synolis®, Gebro-Pharma AG, CH, 2000 kD)
69939|NCT03636971|Drug|Placebos|single shot injection of saline, same volume
69940|NCT03636958|Drug|Perampanel|Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
69941|NCT03636958|Drug|conventional antiepileptic treatment|choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
69942|NCT03636945|Other|PET at 18F-FDOPA|18F-fluorodihydroxyphenylalanine (18F-FDOPA) PET imaging
69943|NCT03636932|Drug|N-acetylcysteine (NAC)|Intravenous injection of 2 gram of N-acetylcysteine (NAC) during 4 weeks, 3 times per week during the first three hours of dialysis.
69944|NCT03636932|Drug|Placebo|Intravenous injection of 2 gram of Placebo during 4 weeks, 3 times per week during the first three hours of dialysis.
69945|NCT03636932|Biological|Blood sample|Circulating tissue factor assay
69946|NCT03636932|Biological|Blood sample|The test of pro-coagulant activity of the tissue factor
69947|NCT03636919|Other|e-BOOK|Patients will filled an e (carnet) included the questionnaire includes the Control of Allergic Rhinitis and Asthma Test (CARAT)
69948|NCT03636906|Biological|Respiratory syncytial virus (RSV) vaccine GSK3389245A|2 doses of study vaccine administered intramuscularly in the left anterolateral thigh side, at Day 1 and Day 31
69949|NCT03636906|Biological|Bexsero|3 doses of active comparator administered intramuscularly in the left anterolateral thigh side, at Day 61, Day 121 and at the end of RSV season, or at Day 1, Day 61 and end of RSV season.
69950|NCT03636906|Biological|Nimenrix|3 doses of active comparator administered intramuscularly in the left anterolateral thigh side, at Day 61, Day 121 and at the end of RSV season, or at Day 1, Day 61 and end of RSV season.
69951|NCT03636906|Biological|Menveo|2 doses of active comparator administered intramuscularly in the left anterolateral thigh side, at Day 61 and at the end of RSV season, or at Day 31 and end of RSV season.
69952|NCT03636906|Biological|Synflorix|3 doses of active comparator administered intramuscularly in the left anterolateral thigh side, at Day 61, Day 121 and at the end of RSV season, or at Day 1, Day 61 and end of RSV season.
69953|NCT03636906|Drug|Placebo|2 doses of placebo administered intramuscularly in the left anterolateral thigh side at Day 1 and Day 61, or at Day 31 and Day 121
69954|NCT03636893|Drug|Chemotherapy|5-FU+CF+Docetaxel+Oxaliplatin
69955|NCT03636893|Drug|Chemotherapy|Oxaliplatin+TGO
69956|NCT03636880|Behavioral|Brief treatment for Insomnia|This behavioral intervention provides participants with an individualized plan to modify sleep patterns contributing to insomnia, as well as education about sleep hygiene and habits that help and hurt sleep.
69957|NCT03636880|Behavioral|Sleep Monitoring|This intervention involves using sleep diaries to track daily aspects of sleep, including bed time, wake time, hours of sleep, nighttime awakenings, daytime naps, and sleep quality.
69958|NCT03636867|Other|data and specimen collection|to identify laboratory, cellular and molecular determinants of clinical success after treatment, several clinical information and specimens will be collected by Authors from each patient
69959|NCT03636854|Other|Concentric exercises|Resistance concentric straight leg raise and knee extension will be done.
69960|NCT03636854|Other|Eccentric exercises|Resistance eccentric straight leg raise and knee extension will be done.
69961|NCT03636841|Device|medical device with CE marking (Ultravision ©)|Ultravision © is a medical device that is used during laparoscopy to reduce the discomfort caused by surgical smoke produced by the electrical section of tissue. It works by using the principle of electrostatic precipitation, that is to say it causes the precipitation of suspended smoke droplets on the organs and walls of the abdomen.
69962|NCT03636828|Diagnostic Test|ultrasonographic measurement of gastric antral cross-sectional area|Each participant fasted for 10 hours and subjected to a baseline gastric ultrasound and serial sonographic gastric evaluations was performed every hour after 2 hours of the ingestion of a 420 g, 536 Kcal rice-based meal (bibimbap) until the stomach was completely empty.
69963|NCT03636815|Other|physical therapy|Cardiopulmonary rehabilitation for patients who receive left ventricle assist device
69964|NCT03636802|Other|Questionnaire BPI|Brief Pain Inventory (BPI) This is a scale of self-assessment, the Concise Pain Questionnaire in French. For all adult patients For any type of pain This is to ask the patient to answer questions in order to learn about us characteristics of his pain (its intensity and its repercussions on the plane biopsychosocial).
69965|NCT03636789|Other|Neurological consultation|study of horizontal, vertical, reflex and voluntary saccades, and of horizontal and vertical ocular pursuit by a BrainTracker eye-oculography system
69966|NCT03636776|Other|Quality of life in metastatic BC|"1 month after metastatic stage diagnosis, patients complete their 1st therapeutic sequence evaluation visit (T1) within the recommended standard time frames. If the disease remains stable or if a response to treatment is observed then patients continue their follow-up in the same therapeutic sequence (T1).~If progression occurs, treatment is modified and patients move on to the next therapeutic sequence (T2).~And so on as many times as necessary. Before each evaluation visit with investigator, patients complete the questionnaires QLQ-C30, BR23, STAI, BDI II"
69967|NCT03636763|Drug|data report|"the information gliptin exposure will be reported"
69968|NCT03636750|Drug|HB002.1T|HB002.1T is a Vascular Endothelial Growth Factor Receptor Decoy
69969|NCT03636737|Other|pathology associated|list of pathology associated to Pyoderma gangrenosum
70029|NCT03636256|Drug|NanoDoce (direct injection)|Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
69970|NCT03636724|Behavioral|E-intervention|The 8-week e-health intervention will target HAPA-based social-cognitive variables of PA and FVI. Particularly, Week 1: risk perception and outcome expectancies; Week 2: goal setting; Week 3: development of action plans; Week 4: revision and adjustment of previous action plans; Week 5: development of coping plans; Week 6: revision and adjustment of previous coping plans; Week 7: development of perceived social support; Week 8: revision and adjustment of previous social support. Self-efficacy will be a fixed intervention variable involved from week 2 to week 8. Additionally, some behaviour change techniques will be employed in the intervention in order to facilitate the implementation and maintenance of behaviour.
69971|NCT03636711|Other|antibiotic protocol, according to a syndromic approach|Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
69972|NCT03636698|Other|chorioamnionitis|It is a observation research. We didn't intervene anything. The chorioamnionitis groups included the infants whose mothers were diagnosed chorioamnionitis by placental histopathology.
69973|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase I|"Non-squamous cell lung cancer, Anlotinib Plus PC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus pemetrexed and carboplatin. middle-dose groups: Anlotinib 10mg per day plus pemetrexed and carboplatin. high-dose groups: Anlotinib 12mg per day plus pemetrexed and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
69974|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase I|"Squamous cell lung cancer, Anlotinib plus TC~This study will include a sequential evaluation of 3 subjects per dose group. low-dose groups: Anlotinib 8mg per day plus paclitaxel and carboplatin. middle-dose groups: Anlotinib 10mg per day plus paclitaxel and carboplatin. high-dose groups: Anlotinib 12mg per day plus paclitaxel and carboplatin to determine the appropriate dose of anlotinib in combination with paclitaxel and carboplatin"
69975|NCT03636685|Drug|Anlotinib combined with pemetrexed and carboplatin, phase II|Anlotinib: established dose QD PO d1-14, pemetrexed,carboplatin, 21 days per cycle after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
69976|NCT03636685|Drug|Anlotinib combined with paclitaxel and carboplatin, phase II|"Anlotinib :established dose QD PO d1-14, paclitaxel,carboplatin, 21 days per cycle~after 4-6 cycles, Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent"
69977|NCT03636672|Procedure|perturbation training|perturbation training during stationary bicycle riding
69978|NCT03636659|Drug|Amphotericin B Liposome|Manufactured for: Auromedics Pharma LLC, USA
69979|NCT03636659|Drug|AmBisome (Amphotericin B) Liposome|Marketed by: Astellas Pharma US, Inc. USA
69980|NCT03636646|Device|X.ray|Surgical treatement of posterior acetabular wall fractures
69981|NCT03636633|Other|Standard respiratory physiotherapy|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques.
69982|NCT03636633|Other|Standard respiratory physiotherapy and inspiratory muscle training|Standard respiratory physiotherapy content; diaphragmatic breathing, pursed lip breathing, segmental breathing, incentive spirometer exercises (Triflo) and coughing techniques. Addition to that, threshold IMT device will be used for the training. Training intensity will set at 40% of the maximum inspiratory pressure.
69983|NCT03636620|Device|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization
69984|NCT03636620|Device|radiofrequency ablation/microwave ablation|radiofrequency ablation/microwave ablation
69985|NCT03636607|Diagnostic Test|PET/CT dynamic scan|The purpose of this study is to carry out 18F-FDG PET/CT dynamic scans and biopsy of primary or primary and metastatic lesions in newly diagnosed patients with primary liver cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of 18F-FDG PET/CT dynamic imaging in primary liver cancer metastases are discussed.
69986|NCT03636594|Other|Dance|The dance program consisted of one-hour dance classes delivered twice a week for 8 weeks. The classes featured different dance types (such as partnered and non-partnered) and genres (such as salsa, ballroom and jazz) with increasing complexity.
69987|NCT03636581|Behavioral|Lifestyle counseling|This group will receive online education modules to educate them on exercise prescription, nutrition and behavioral changes.
69988|NCT03636568|Other|Fluid Restricted Group|"Patients will be started on a weight-based intravenous fluid replacement with D5 ½ NS on POD 0 (75 cc/hr for patients < 70kg, 100 cc/hr for patients 70-100kg, and 125 cc/hr for patients >100kg). Patients will be allowed to drink water freely after surgery on POD #0. Fluids will be stopped at 8am on POD 1 and patients will be started on a moderate fluid restriction on POD #3 based on their weight (1000 cc/24 hours for patients who weigh <=100 kg and 1200 cc/24 hours for patients who weigh > 100kg). Prior to initiation of a fluid restriction all of the following criteria have to be met:~Serum Na level must be < 145 mEq/l~Patient should be taking fluids by mouth~Patient should not have evidence of DI (as determined by endocrine team following patient) If a patient in Fluid Restricted group develops DI, the fluid restriction will be stopped/not initiated."
69989|NCT03636555|Drug|Oxytocin|Oxytocin will be given in an intranasal spray (Syntocinon Spray) twice daily (10 insufflations, 1.0 mL, 40 IU/dose) for 12 weeks
69990|NCT03636555|Drug|Placebo|Placebo solution (contained all the ingredients in Syntocinon Spray except for oxytocin) will be given as an intranasal spray twice daily (10 insufflations, 1.0 mL/dose) for 12 weeks
69991|NCT03636542|Drug|liposomal bupivacaine|Experimental
69992|NCT03636542|Drug|bupivacaine|Active comparator
69993|NCT03636529|Dietary Supplement|Tart cherry juice|Participants randomized to consume for 4-weeks either placebo beverage or single-strength tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage for 4 weeks to account for timing and order effects.
69994|NCT03636529|Other|Placebo|Participants randomized to consume either placebo beverage or tart cherry juice at beginning of the study followed by a 4 week washout then switch over to the alternate beverage to account for timing and order effects.
69995|NCT03636516|Device|SWL|extracorporeal shockwave lithotripsy apply
70145|NCT03635567|Drug|Paclitaxel|IV infusion
70146|NCT03635567|Drug|Cisplatin|IV infusion
69996|NCT03636503|Drug|Rituximab|Rituximab works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells. Stem cells (young cells in the bone marrow that will develop into the various types of cells) do not have the CD20 antigen. This allows healthy B-cells to regenerate after treatmen
69997|NCT03636503|Drug|Utomilumab|Utomilumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
69998|NCT03636503|Drug|Avelumab|Avelumab is a drug which may stimulate the immune system against tumor cells. Because it activate the immune system, it is sometimes called immunotherapy drug
69999|NCT03636503|Drug|PF04518600|In the presence of tumor-associated antigens (TAAs), this may promote a T-cell-mediated immune response against TAA-expressing tumor cells. OX40
70000|NCT03636490|Behavioral|Psychological Stress Intervention|Participant will be shown a series of words for five minutes and a research coordinator will ask him/her to name the color of each (Stroop Color-Word Conflict Task). Then, for another five minutes, the participant will be asked to count backwards out loud by sevens starting from 1,000 (Mental Arithmetic Task). The research assistant will ask the participant to work as quickly and accurately as possible for both tasks.
70001|NCT03636477|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection~intratumoral injection of Ad-RTS-hIL-12"
70002|NCT03636477|Drug|veledimex|"2 doses (10mg/day, 20mg/day)~15 oral daily doses of veledimex"
70003|NCT03636477|Drug|Nivolumab|"2 doses (1mg/kg, 3mg/kg)~Every 2 weeks"
70004|NCT03636464|Other|Blood collection|Pharmacokinetics
70005|NCT03636451|Drug|0.5% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing Paracervical block containing 38mL of 0.5% lidocaine buffered with 2mL 8.4% sodium bicarbonate and 2 units Vasopressin
70006|NCT03636451|Drug|1% Lidocaine|Prior to cervical dilation, paracervical block will be placed one time containing Paracervical block containing 18mL of 1% lidocaine buffered with 2mL 8.4% sodium bicarbonate and 2 units Vasopressin
70007|NCT03636438|Other|No Intervention|No Intervention
70008|NCT03636425|Other|Questionnaire administration to gather information|In the questionnaire there are questions about the training (number of kilometers traveled by runners on average, total height difference, number of training sessions per week, training ground) questions on other activities carried out (gym, bicycle, etc.) number of competitions that runners participated in the month, used footwear, musculoskeletal disorders in the last 12 months, which health professional the runner has addressed, which physiotherapy therapies did.
70009|NCT03636412|Other|Ambulation|An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
70010|NCT03636399|Behavioral|Standard GIST|13 group modules will be administered to outpatients in 12 x 2,5-3 hours sessions. Manualized intervention; In every group session a new topic is presented, discussed and practiced in group exercises. Homework assignments between sessions.
70011|NCT03636399|Behavioral|Intensive GIST|13 group modules will be administered to inpatients during 4 weeks in hospital. The participants are given extended leave every weekend to work om homework Assignments between each treatment week.
70012|NCT03636386|Device|Percutaneous microelectrolysis|284/5000 Application of Direct Current through an acupuncture needle with intensities in microamps (μA) in the PGm of the upper trapezius muscle. The acupuncture needle will correspond to the negative electrode or cathode. The intensity of work will be 610μA at the myofascial trigger point.
70013|NCT03636386|Device|Ultrasound therapy|Application of conventional ultrasound (US) on PGm with a frequency of treatment 1MHz, intensity of 1.5W / cm2, ERA 5cm2, Duty Cycle 100%, treatment time 6 minutes.
70014|NCT03636373|Drug|Etanercept|Subjects will receive 50 mg of study drug on visit 1. A second dose of study drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
70015|NCT03636373|Drug|Triamcinolone Acetonide|Subjects will be administered triamcinolone acetonide 40 mg intramuscularly on visit 1. A second dose of drug will be administered if the pain intensity is ≥ 5 on a pain scale of 0-10 at Visit 2
70016|NCT03636360|Device|Light|15 hours of light exposure
70017|NCT03636347|Drug|Placebo Oral Tablet|twice daily administration
70018|NCT03636347|Drug|Alvelestat oral tablet - dose 1|twice daily administration
70019|NCT03636347|Drug|Alvelestat oral tablet - dose 2|twice daily administration
70020|NCT03636334|Behavioral|Computer-based decision support system|At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
70021|NCT03636321|Procedure|living donor liver transplantation with intraductal stent|living donor liver transplantation with intraductal stent
70022|NCT03636308|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 125 mg/m2 intravenously on day 1 of each 14 day cycle or day 1 and 8 of 21 day cycle.
70023|NCT03636308|Drug|S1|S-1 is orally administered (BSA<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2, 50mg bid, BSA>1.5m2, 60mg bid) on day 1-7 of each 14 day cycle.
70024|NCT03636308|Drug|Gemcitabine|Gemcitabine is given at 1000mg/m2 intravenously on d1 and 8 of each 21 day cycle.
70025|NCT03636295|Drug|Warfarin|Participants in both arms will be on warfarin therapy post-mechanical valve replacement as is standard, but will have different INR target ranges.
70026|NCT03636282|Behavioral|Hockey FIT Program (Immediate Delivery)|"Hockey FIT is comprised of a 3-Month Active Phase and a 9-Month Minimally-Supported Phase.~Active Phase: 12 weekly, 90-minute group-based sessions consisting of classroom-based education and exercise. Outside of sessions, participants follow their individualized lifestyle prescriptions for healthy eating, physical activity (steps), and exercise. Participants are encouraged to regularly use health technology support tools customized to Hockey FIT. Minimally-supported phase: Participants are encouraged to continue with their healthy lifestyle behaviour changes and to regularly use the health technology support tools."
70027|NCT03636269|Drug|CR845 0.5 mcg/kg|IV CR845 0.5 mcg/kg administered three times/week
70030|NCT03636256|Drug|NanoDoce (intravesical instillation) - Visit 2 Instillation|All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
70031|NCT03636256|Other|Institutional Standard of Care|Group 2 (MIBC) will receive institutional standard of care treatments after the Visit 2 intravesical instillation.
70032|NCT03636256|Drug|NanoDoce (intravesical instillation) - Induction and Maintenance Instillations|Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
70033|NCT03636243|Biological|Vascularly biological assessment|22.5 ml of blood will be collected at day -15, month 3 and month 12.
70034|NCT03636243|Biological|Analysis of vasomotor endothelial function|Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system [Itamar Medical Ltd., Caeserea, Israel] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.
70035|NCT03636243|Biological|Analysis of arterial compliance|Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' [Alam Medical, France] at day -15, month 3 and month 12
70036|NCT03636243|Biological|Exploration of microcirculation|The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12
70037|NCT03636243|Biological|Venous Doppler Ultrasound|aneurysm screening at day -15, month 3 and month 12
70038|NCT03636243|Biological|Arterial pressure measurement|measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12
70039|NCT03636243|Biological|Intima-Media Thickness measurement|Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12
70040|NCT03636243|Biological|Exploration of neuropathy|non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12
70041|NCT03636243|Behavioral|level of physical activity|pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12
70042|NCT03636230|Device|Remote Monitoring|Remote Monitoring only
70043|NCT03636230|Other|Standard of care|In-Clinic visits only
70044|NCT03636217|Other|LGI-Milk Breakfast|This test meal with low glycemic index and milk were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
70045|NCT03636217|Other|LGI-Kefir Breakfast|In crossover design, this test meal with low glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast.
70046|NCT03636217|Other|HGI-Kefir Breakfast|In crossover design, this test meal with high glycemic index and kefir was served as a breakfast to compare the LGI-Milk Breakfast and the LGI-Kefir Breakfast.
70047|NCT03636204|Biological|AL001|Active dose of AL001
70048|NCT03636204|Other|Placebo|Saline solution administered as a single infusion as palcebo.
70049|NCT03636191|Dietary Supplement|Probiotic strain|Lactobacillus
70050|NCT03636191|Dietary Supplement|Placebo|Placebo
70051|NCT03636178|Procedure|Classic alar base suture technique|An index finger will be used to apply extraoral pressure on the alar base region, and a dentate forceps will grasp this tissue through the intraoral incision. A suture bite will be taken at this point through the tissue previously held by the forceps. The same procedure will be applied on the opposite side. After passing the suture on both sides, it will be tightened with attention to the alar base response. If the alar base suture will be judged to be adequate, the vestibular incision will then be closed in a routine fashion, with or without performing a V-Y lip closure
70052|NCT03636178|Procedure|Modified alar base suture technique|The alar base will be marked with 3 landmarks: left alar base (point LAB), columella (point C), and right alar base (point RAB). A needle will be inserted through the skin at the nasofacial skin fold and exited through the fibroareolar tissue. A nonabsorbable suture without a needle will be inserted through the needle from the oral cavity to the outside. The needle will be retracted through point RAB without leaving the skin point, then returned to the oral cavity in a medial position. Finally the needle will be retracted from point RAB, leaving the suture through the soft tissue. The same procedure will be repeated on the other side. The 2 free ends of the sutures will be then tied together after passing through a hole made in the nasal spine.
70053|NCT03636165|Drug|Methylprednisolone|The local infiltration solution containing 1.25mg Methylprednisolone per milliliter.
70054|NCT03636165|Drug|Ropivacaine|The local infiltration solution containing 2mg Ropivacaine per milliliter.
70055|NCT03636152|Procedure|MRI carotid|To assess the carotid atherosclerotic plaques
70056|NCT03636152|Procedure|APWV|Doppler measurement of the APWV
70057|NCT03636152|Drug|Hydroxychloroquine|Active Drug
70058|NCT03636152|Drug|Matching Placebo|Matching Placebo for the control group.
70059|NCT03636139|Device|transcranial DC stimulation : anodal|anodal stimulation of the right dlPFC (i.e. F4) for 20 minutes
70060|NCT03636139|Device|transcranial DC stimulation : sham|sham stimulation of the right dlPFC (i.e. F4) for 20 minutes
70061|NCT03636126|Device|VR + TACS|TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.
70062|NCT03636113|Device|Clarity RMS Electronic Sensor|The urinary foley catheter with electronic sensor will be placed within the Operating Room prior to surgery. Upon arrival to the ICU, the device will be connected to an electronic console by study coordinator. The study coordinator will weigh the urine drainage bag and record the weight every hour for 4-6 hours. The device will record urine flow on a 15 minute interval up to 6 hours
70063|NCT03636100|Device|Cryoballoon ablation|Cryoballoon ablation using standard equipment and techniques
70147|NCT03635567|Drug|Carboplatin|IV infusion
70148|NCT03635567|Biological|Bevacizumab|IV infusion
70064|NCT03636087|Procedure|Access cavity preparation|High speed handpieces will be used with access burs to open the pulp chamber and get access to the root canal system (As a part of conventional root canal treatment established protocol)
70065|NCT03636087|Procedure|Working Length Determination|The length of the root canal will be measured using periodical radiographs and Electronic Apex Locators (As a part of conventional root canal treatment established protocol)
70066|NCT03636087|Procedure|Root canal instrumentation and chemo-mechanical preparation|Rotary files used to properly instrument and prepare canals length and size (As a part of conventional root canal treatment established protocol)
70067|NCT03636087|Procedure|Root canal obturation|Gutta Percha filling materials will be used to fill the root canal space with root canal sealer (As a part of conventional root canal treatment established protocol)
70068|NCT03636087|Procedure|Coronal restoration build up|A Build up material to seal the accessed tooth properly (As a part of conventional root canal treatment established protocol)
70069|NCT03636087|Other|Changing gloves before obturation|The treating dentist will change gloves before obturation
70070|NCT03636087|Other|Disinfecting rubber dam|2.25% Sodium Hypochlorite solution will be used to disinfect the rubber dam surface
70071|NCT03636087|Other|The use of new instruments at time of obturation|A new instrument's kit will be use at the time of obturation
70072|NCT03636087|Radiation|Cone Beam Computed Tomography scanning (CBCT)|CBCT will be taken before treatment and one year after completion
70073|NCT03636087|Radiation|Radiographic imaging using periapical radiographs|Periapical radiographs will be taken before, during and one year after the treatment completion (As a part of conventional root canal treatment established protocol)
70074|NCT03636074|Procedure|Hypothermia during Extracorporeal Circulation|Normothermia during Extracorporeal Circulation
70075|NCT03636061|Drug|OC-01|OC-01
70076|NCT03636061|Drug|Placebos|Placebo
70077|NCT03636048|Drug|Bupivacaine Hcl 0.5% Inj|The patients undergo surgery under spinal anesthesia and a catheter would be inserted into epidural space during the procedure. 0.5% bupivacaine is injected into intrathecal space for spinal anesthesia. For pain control, 0.2% ropivacaine is continuously infused into epidural space postoperatively.
70078|NCT03636048|Drug|Propofol 10 milligram/ML|The patients undergo surgery under general anesthesia and a catheter would be inserted to abdominal incision site at the end of the operation. Propofol is used for induction of general anesthesia, and sevoflurane is used for maintenance of anesthesia. At the end of the operation, the surgeon inserts wound catheter in the surgical site and connects wound patient-controlled analgesia device filled with 0.5% ropivacaine.
70079|NCT03636035|Dietary Supplement|Tregocel®|Coated tablet (oral)
70080|NCT03636022|Device|Virtual Reality|Virtual Reality exposure therapy system
70081|NCT03636022|Behavioral|Traditional Therapy|Imaginal therapy
70082|NCT03636009|Other|concurrent traction and neuromobilization technique|participant will be on a mechanical traction machine with an on:off cycle. During the on cycle, the primary researcher will be performing a neuromobilization technique on the symptomatic arm. Patients will also receive exercise and manual therapy
70083|NCT03636009|Other|sequential traction and neuromobilization technique|Participants will receive neuromobilzation techniques followed by supine cervical traction
70084|NCT03636009|Other|active exercise program|Participants will have 4-5 exercises to perform at each session
70085|NCT03636009|Other|manual therapy to cervical and thoracic spine|Lateral glides to cervical spine and thoracic manipulations
70086|NCT03635996|Drug|Etripamil NS 70 mg|All patients will receive a total of 200 micro-liters of etripamil NS 70 mg via the Aptar Pharma Nasal Spray Bidose System each time they self-administer study drug. The devices will be prefilled and packaged into child-resistant boxes.Instructions for its use will be provided in the study drug box.
70089|NCT03635970|Procedure|celular therapy|application of cell therapy with a concentrate of hematopoietic progenitor cells or celular therapy
70091|NCT03635931|Procedure|Concentrated Growth Factor|surgical treatment with CGF for papilla regeneration
70092|NCT03635918|Device|NightOwl HSAT|Patient wears the NightOwl sensor device
70093|NCT03635905|Drug|Gabapentin|Gabapentin (Neurontin®) is FDA-approved for the treatment of post-herpetic neuralgia and seizure disorder. Off-label uses include chronic refractory cough, neuropathy, hot flashes, restless leg syndrome, social anxiety disorder, and post-operative pain
70094|NCT03635905|Drug|Placebo|Methylcellulose placebo capsule
70095|NCT03635892|Drug|cabozantinib|cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
70096|NCT03635892|Drug|nivolumab|Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
70097|NCT03635879|Other|MCTprocal medical food|32 g MCTprocal (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
70098|NCT03635879|Other|Milk/tricaprilin oil blend|154 mL of lactose-free skim milk/21 mL of tricaprilin oil blended and then mixed in 180 mL of water at Hour 0 Day 1
70099|NCT03635879|Other|AC-1207|AC-1207 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
70100|NCT03635879|Other|AC-1205|AC-1205 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
70101|NCT03635879|Other|AC-1206|AC-1206 (20 g MCT) mixed in 180 mL of water at Hour 0 Day 1
70102|NCT03635879|Drug|AC-1202|AC-1202 (20 g MCT) mixed in 240 mL of water at Hour 0 Day 1
70103|NCT03635866|Diagnostic Test|Fluciclovine PET/MRI|It is unknown how many negative MRFTBs of PI-RADS 4 lesions are false negative biopsies or false positive tests.
70104|NCT03635853|Drug|drug containing extract from cock's comb|a container containing 25 mg of ointment having extract from cock's comb as active ingredient two times daily for 3 months
70105|NCT03635840|Device|Intra Aortic Balloon Pump|"Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand."
70106|NCT03635827|Combination Product|NBTX-001 Xenon Inhaler|The NBTX-001 medical gas consists of 30% xenon, 30% oxygen, and 40% nitrogen. The dose of medical gas is 10 L by volume.
70107|NCT03635827|Combination Product|Placebo|The placebo medical gas consists of 30% oxygen and 70% nitrogen.The dose of placebo medical gas is 10 L by volume.
70108|NCT03635814|Drug|YD312 50mg|Imatinib mesylate 50mg * 1 + placebo 6 tablet
70109|NCT03635814|Drug|YD312 150mg|Imatinib mesylate 50mg * 3 + placebo 6 tablet
70110|NCT03635814|Drug|YD312 350mg|Imatinib mesylate 50mg * 7
70111|NCT03635814|Drug|Placebo|Imatinib mesylate 0mg * 7
70112|NCT03635801|Device|MyoVista 12 lead Electrocardiogram (ECG)|MyoVista 12 Lead Electrocardiogram (ECG)
70113|NCT03635788|Drug|Standard of Care (SOC) Oral ART|SOC oral ART regimen must include at least 3 drugs with 2 or more drugs predicted to be fully active, including a boosted protease inhibitor (PI) and/or an integrase strand transfer inhibitor (INSTI)
70114|NCT03635788|Drug|Oral RPV|RPV 25 mg tablets
70115|NCT03635788|Drug|Oral CAB|CAB 30 mg tablets
70116|NCT03635788|Drug|RPV-LA Loading Dose|900 mg administered as one 3 mL (900 mg) intramuscular injection in the gluteal muscle
70117|NCT03635788|Drug|CAB-LA Loading Dose|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
70118|NCT03635788|Drug|RPV-LA Maintenance Dose|600 mg administered as one 2 mL (600 mg) intramuscular injection in the gluteal muscle
70119|NCT03635788|Drug|CAB-LA Maintenance Dose|400 mg administered as one 2 mL (400 mg) intramuscular injection in the gluteal muscle
70120|NCT03635775|Device|Active tDCS|Low-level (1.5 milliampere) current delivered to the scalp using saline-soaked sponges.
70121|NCT03635775|Device|Sham tDCS|Sham-setting--no electrical current delivered.
70122|NCT03635762|Behavioral|Be In Charge|comparison of pre and post-program weight and calorie intake
70123|NCT03635749|Drug|Dual antiplatelet|"Day 1：clopidogrel 300mg/day+ aspirin100-300mg/ day~Day2 - 21: clopidogrel 75mg/day+ aspirin 100mg/day~Day22 - 90: clopidogrel 75mg/day+aspirin placebo"
70124|NCT03635749|Drug|Aspirin|"Day 1: Aspirin 100-300mg/day + clopidogrel placebo~Day 2 - 90: Aspirin 100mg/day+ clopidogrel placebo"
70125|NCT03635749|Drug|Early intensive statin|"Day 1 - 21：Atorvastatin calcium 80mg/day~Day 22 - 90：Atorvastatin calcium 40mg/day"
70126|NCT03635749|Drug|Delayed intensive statin|"Day 1 - 3：Atorvastatin calcium placebo~Day 4 - 21：Atorvastatin calcium 40mg/day + Atorvastatin calcium placebo~Day 22 - 90：Atorvastatin calcium 40mg/day"
70127|NCT03635736|Other|multiple-spectral-sonography as acustocerebrography (ACG)|After inclusion three times at day measurements with ACG for each 45 minutes; a (non-invasive) sonography. The measurements will be stopped after final evaluation of the neurological status using common methods like magnetic resonance tomography, transcranial doppler sonography, electroencephalography and other methods.
70128|NCT03635710|Device|The patient will undergo no intervention|Night coughs will be monitored using smartphone a app and interpreted using machine learning algorithm.
70129|NCT03635697|Behavioral|Mindfulness Auditory Intervention|This intervention is a short audio clip that focuses on the practices and principles of mindfulness. The goal of mindfulness is to bring awareness to a person's physical body as well as their thoughts and feelings.
70130|NCT03635684|Drug|Acetaminophen|"Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~local side effects;~pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes."
70131|NCT03635671|Diagnostic Test|Optical Coherence Tomography Angiography|Retinal scans will be acquired at each follow up visit
70132|NCT03635658|Procedure|titanium mesh|the non resorbable titanium mesh is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
70133|NCT03635658|Procedure|collagen membrane (Sausage technique)|the resorbable collagen membrane is used to fix the 1:1 mixture of autograft and xenograft particulate bone on the severely atrophies maxillary ridge.
70134|NCT03635645|Device|New visual processing unit (VPU) with asymmetric waveforms|A VPU will apply asymmetric and symmetric stimulation pulses.
70135|NCT03635645|Device|New VPU with bipolar stimulation|A VPU will apply bipolar stimulus pulses.
70136|NCT03635632|Genetic|C7R-GD2.CART cells|"Dose Level 0: 1 x 10^7 C7R-GD2.CART cells without Lymphodepletion~Dose Level 1: 1 x 10^7 C7R-GD2.CART cells with Lymphodepletion~Dose Level 2: 3 x 10^7 C7R-GD2.CART cells with Lymphodepletion~Dose Level 3: 1 x 10^8 C7R-GD2.CART cells with Lymphodepletion"
70137|NCT03635632|Drug|Cyclophosphamide|If patients receive lymphodepletion, they will receive 2 daily doses of cyclophosphamide (500mg/m2/day) finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle).
70138|NCT03635632|Drug|Fludarabine|If patients receive lymphodepletion, they will receive 3 daily doses of fludarabine (30mg/m2/day) finishing at least 24 hours before T-cell infusion. The drug will be given intravenously (through an IV needle).
70139|NCT03635619|Other|No intervention|No intervention
70140|NCT03635593|Drug|CBD|Participants will be randomized to CBD 10mg capsules for 12 weeks. Participants will start with 1, CBD (10mg) capsule per day and self-titrate up to 8, 10mg CBD capsules (80mg) per day as needed.
70141|NCT03635593|Drug|CBD+THC|Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
70142|NCT03635593|Other|Placebo|Participants randomized to placebo 10mg capsules for 12 weeks. Participants will start with 1, 10mg placebo capsule per day and self-titrate up to 8 10mg placebo capsules (80mg) per day.
70143|NCT03635580|Other|Negative control|Untreated-control group
70144|NCT03635567|Biological|Pembrolizumab|IV infusion
70151|NCT03635515|Device|Gentlewave|The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.
70152|NCT03635515|Procedure|Standard Endodontic Protocol|The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
70153|NCT03635489|Drug|Paclitaxel|175 mg/m^2 IV infusion on Day 1 of each 21-day cycle.
70154|NCT03635489|Drug|Bevacizumab|15 mg/kg IV infusion on Day 1 of each 21-day cycle.
70155|NCT03635489|Drug|Carboplatin|Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.
70156|NCT03635489|Drug|Placebo|Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.
70157|NCT03635476|Other|Qualitative interview study|The group in question is part of a research program aimed at developing and evaluating the LIFANA Nutrition Solution, a meal planning recommended system, which suggests meals based on the user's personal profile. This may include general preferences, such as culture, taste, and budget, but more importantly automated and personalised nutritional recommendations based on advice provided by professional nutritionists and allergists.
70158|NCT03635463|Device|twin block appliance|a functional appliance that enhances mandibular growth in growing patients made from vaccum sheets (esthetic)
70159|NCT03635463|Device|modified twin block appliance|a convetional twin block functional appliance that enhances mandibular growth in growing patients
70160|NCT03635450|Biological|Infusion of hCT-MSC|Infants who meet enrollment criteria for moderate to severe hypoxic ischemic encephalopathy will receive 1 infusion of hCT-MSC within the first 48 postnatal hours. hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked. hCT-MSCs are manufactured from umbilical cord tissue donated to the Carolinas Cord Blood Bank, an FDA-licensed, FACT-accredited, public cord blood bank at Duke University Medical Center, after written informed consent from the baby's mother. Cord tissue is harvested from the placentas of male babies delivered by elective C-section after a normal, full- term pregnancy.
70161|NCT03635437|Drug|Gamma-Aminobutyric Acid (GABA)|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
70162|NCT03635437|Drug|Alprazolam|Patients eligible for the main study will be randomized in a 1:1:1 ratio stratified by the C-peptide level to receive 200 mg of GABA (Remygen) for 6 months, 600 mg of GABA (Remygen) for 6 months, or Alprazolam 0.5 mg combined with GABA 600 mg (Remygen) for 3 months followed by treatment with GABA 600 mg (Remygen) only for another 3 months. The start of the arms with high dose GABA will be delayed and started first after that a data safety monitoring board has evaluated and approved the safety data of the first 4 patients included in the arm with low dose GABA. All patients will continue to receive intensive insulin treatment from their personal physicians during the whole study period.
70163|NCT03635424|Device|Medtronic TAVR Systems|Treatment of patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR with Medtronic Evolut PRO and Evolut R systems
70164|NCT03635411|Dietary Supplement|Nicotinamide Riboside and Pterostilbene|Nicotinamide riboside and pterostilbene manufactured by Basis
70165|NCT03635411|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Basis supplement.
70166|NCT03635398|Device|Sipnose device|SipNose's intranasal drug delivery platform uses an innovative mechanism that is suposed to improves efficacy, patient compliance and safety
70167|NCT03635398|Device|MAD (Mucosal Atomization Device)|MAD (Mucosal Atomization Device)
70168|NCT03635398|Drug|midazolam|oral administration of midazolam
70169|NCT03635385|Procedure|Apheresis technics|Blood draw will be performed for anti bodies dosages
70170|NCT03635372|Drug|Alginate|10 cc of Alginate peroral
70171|NCT03635372|Drug|Sucralfate|10 cc of Sucralfate peroral
70172|NCT03635372|Drug|Hydrotalcite|10 cc of Hydrotalcite peroral
70173|NCT03635359|Diagnostic Test|blood test|analysis of cell-free DNA in maternal plasma
70174|NCT03635333|Drug|Nicotine|Nicotine level (6 or 18 mg)
70175|NCT03635333|Drug|Flavor|Flavor of e-juice (tobacco, menthol, strawberry)
70176|NCT03635320|Device|TFNA|intramedullary nail 'Trochanteric Fixation Nail Advanced' to treat proximal femur fracture undergoing internal fixation
70177|NCT03635320|Device|PFNA-II|intramedullary nail ' Proximal Femoral Nail Antirotation' to treat proximal femur fracture undergoing internal fixation
70178|NCT03635307|Other|End Tidal Carbon Dioxide measure|End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
70179|NCT03635294|Other|Blood sample|combining genomics, transcriptomics, metabolomics and morphological analyses performed on induced pluripotent stem cell (iPSC)-derived neural cells
70207|NCT03635073|Drug|TAK-935|TAK-935 tablets or mini-tablets.
70374|NCT03633786|Diagnostic Test|assessment of urinary symptoms|assessment of urinary symptoms using a validated questionnaire (Bristol Female Lower Urinary Tract Symptoms (BFLUTS)), before and 3 months after surgery
70180|NCT03635281|Procedure|Recruitment manoeuvers|"Recruitment manoeuvers will be performed as follow Recruitment manoeuvers~set FIO2 at 1.0~Ppeak limit at 45 cmH2O~Respiratory rate set at 6~I:E set at 1:1~Raise the VT at step of 2 ml/kg PBW until the Pplat is between 30-40 cmH2O~If the maximum VT is set without rasing the Pplat, raise PEEP~Allow three respiratory cycles with Pplat between 30 and 40 cmH2O~End of RM~The recruitment manouvers will be performed after 20 minutes of OLV. At the end of the RM, the VT will be set back to 5 ml/kg while the PEEP will be chosen according to the best static compliance with a decremental trial (from 16 cmH2O, lowering PEEP with steps of 2 cmH2O each until the best compliance is reached)."
70181|NCT03635281|Procedure|incremental PEEP|In this group the a PEEP level will be added after 20 minutes from OLV. PEEP values will be chosen according to the best static compliance with an incremental trial (i.e. starting from ZEEP, the PEEP values will be increased in step of 2 cmH2O each until the best compliance is reached
70182|NCT03635268|Other|Data collection|Sociodemographic, medical and hospital, on ambulatory care consumption data.
70183|NCT03635242|Other|Control. no therapeutic program|The control group continued to perform their daily activities without changing any habit. Group of healthy subjects Assessment of postural control through accelerometry and pressure platform
70184|NCT03635242|Other|Experimental. Therapeutic program|"People with chronic back pain of at least 3 months duration, to whom the therapeutic exercise of motor control and pain education based on neuroscience will be applied 2 days a week for 2 months.~Prior to the intervention, a postural control assessment will be made by accelerometry and pressure platform"
70185|NCT03635203|Device|CBCT|Observation of C-shaped root canal in mandibular first and second molars in Egyptian sub-population
70186|NCT03635190|Device|Orbital Circumferential Atherectomy|Remove atherosclerotic plaque and modify vessel wall compliance within peripheral arterial vessels. The therapy is intended for patients who are acceptable candidates for percutaneous transluminal atherectomy.
70187|NCT03635177|Procedure|Remote ischemic conditioning|Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
70188|NCT03635164|Drug|Durvalumab|Patients will receive one dose of neoadjuvant durvalumab 1500 mg approximately 3-6 weeks prior to standard of care surgery. It will be given concurrently with the first dose of radiation (RT). Patients will receive up to six doses of durvalumab and radiation post-operatively.
70189|NCT03635164|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting RT dose level will be given as 6 Gy for 2 fractions (12 Gy total) every other day over approximately one week to sites of gross disease only to minimize exposure to normal tissue. If toxicity develops and surgery is delayed by more than 6 weeks (qualifying as a DLT), the radiation dose will be dropped per protocol for the next set of patients. If this dose is tolerated, the dose will be increased to 6 Gy for 3 fractions (18 Gy total) for the next 3 patients.
70190|NCT03635164|Procedure|Standard of Care Therapy|Patients will proceed to surgical resection 3-6 weeks after radiation as recommended by the ENT surgeon.
70191|NCT03635151|Behavioral|Telephone Assessment and Skill-Building Kit (TASK III) Group|The TASK III group will receive a TASK III Resource Guide that we developed and 8 weekly calls from a nurse. The nurse will call again a month later. The TASK III nurse will help you assess your needs and concerns, build your skills as a caregiver, and refer you to community resources.
70192|NCT03635151|Behavioral|Information Support and Referral (ISR) Group|The ISR group will receive an American Heart Association brochure and 8 weekly calls from a nurse. The nurse will call again a month later. The ISR nurse will provide information, support, and referral to community resources.
70193|NCT03635138|Other|Metal nanoparticles ( O Zn and Cu)|Np of OZn nanoparticles mixed with dental adhesive
70194|NCT03635138|Other|Dental Adhesive pure|Dental Adhesive with commercial preparation
70195|NCT03635125|Drug|Nebivolol I|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20 mg or Metoprolol 100mg
70196|NCT03635125|Drug|Nebivolol II|Low dose treatment phase: Nebivolol 10 mg or Metoprolol 50 mg High dose treatment phase: Nebivolol 20mg or Metoprolol 100mg
70197|NCT03635125|Other|Baseline Washout Phase|2 to 4 week Baseline Washout Phase
70200|NCT03635099|Drug|BI 730357|Film-coated tablet
70201|NCT03635099|Drug|Placebo|Film-coated tablet
70202|NCT03635086|Biological|MV-CHIK lyophilised formulation, low dose|"MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, in concentrations of:~5x10^4 (+/-0.5 log) TCID50 / dose - lyophilised - low dose on day 0 and day 28~- Lyophilised formulation: powder for suspension in water for injection~MV-CHIK vaccine administered by intra muscular (i.m.) injection."
70203|NCT03635086|Biological|MV-CHIK liquid frozen formulation, low dose|"MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, in concentrations of:~1x10^5 (+/-0.5 log) TCID50 / dose - liquid frozen - low dose on day 0 and day 28~- Liquid frozen formulation: suspension for injection~MV-CHIK vaccine administered by intra muscular (i.m.) injection."
70204|NCT03635086|Biological|MV-CHIK SPS® formulation, low dose|"MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, in concentrations of:~1x10^5 (+/-0.5 log) TCID50 / dose - liquid SPS® - low dose on day 0 and day 28~- Liquid SPS® formulation: suspension in a proprietary Stabilising and Protecting Solution for injection~MV-CHIK vaccine administered by intra muscular (i.m.) injection."
70205|NCT03635086|Biological|MV-CHIK liquid frozen formulation, high dose|"MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, in concentrations of:~1x10^6 (+/-0.5 log) TCID50 / dose - liquid frozen - high dose on day 0 and day 28~- Liquid frozen formulation: suspension for injection~MV-CHIK vaccine administered by intra muscular (i.m.) injection."
70206|NCT03635086|Biological|MV-CHIK liquid frozen formulation, high dose and placebo|"MV-CHIK, a live-attenuated recombinant measles vaccine expressing Chikungunya virus antigens, in concentrations of:~1x10^6 (+/-0.5 log) TCID50 / dose - liquid frozen - high dose on day 0 and placebo day 28~- Liquid frozen formulation: suspension for injection~MV-CHIK vaccine administered by intra muscular (i.m.) injection.~Placebo:~Physiological saline solution (0.9% NaCl), administered by i.m. injection"
70208|NCT03635060|Procedure|Dorsal Bridge Plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
70209|NCT03635060|Procedure|Volar locking plating|This study will be a pilot randomized control trial that will focus on treating patients with the described fracture pattern either with dorsal distraction plating with or without any additional fragment specific fixation or standard open reduction internal fixation.
70210|NCT03635047|Biological|AL002|Single-doses of AL002 in up to 9 dose-escalating cohorts
70211|NCT03635047|Other|Saline Solution|Saline solution will be administered as a single infusion for each cohort in a ratio of 6 active and 2 placebo subjects for HV and 8 active and 2 placebo for patients
70212|NCT03635034|Device|Insert bladder catheter|Bladder catheter will be inserted according to randomization schema
70213|NCT03635034|Device|No catheter|Subjects will not receive a bladder catheter during the ablation procedure
70214|NCT03635021|Drug|FOLFOX regimen|oxaliplatin 85 mg/m2 administered by IV infusion over 120 minutes on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46- 48 hours on Days 1 and 2
70215|NCT03635021|Drug|Panitumumab|6 mg/kg administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 14-day cycle
70216|NCT03635021|Drug|Bevacizumab|5 mg/kg administered by IV infusion over 60 minutes on Day 1 of each 14-day cycle
70217|NCT03635021|Drug|FOLFIRI regimen|irinotecan 180 mg/m2 administered as a 90 minutes IV infusion on Day 1, L-leucovorin 200 mg/m2 administered as a 2-hour IV infusion on Day 1 and 5-FU 400 mg/m2 administered as IV bolus over approximately 2 to 4 minutes on Day 1 followed by 5-FU 2400 mg/m2 administered as IV infusion over 46-48 hours on Days 1 and 2
70218|NCT03635008|Device|tDCS|Regard to the anodal tDCS, the anode will be placed over the contralesional premotor area (2.5 cm anterior to the C3 or C4 in 10-20 EEG system) and cathode will be placed over the contralateral supraorbital area. The stimulation intensity will be 2mA. For the sham tDCS the stimulation will be applied for just first 30 seconds.
70221|NCT03634982|Drug|RMC-4630|RMC-4630 for oral administration
70223|NCT03634956|Drug|Group B. Sugammadex sodium-IONM|Group B.the vagal nerve is detected and then 2 mg / kg of sugammadex sodium is administered to remove the muscle relaxant effect
70224|NCT03634943|Other|Patients with Nutritional Support|Evaluation of Enteral Nutrition or Parenteral Nutrition or both administered to the patients needing artificial Nutritional Support
70225|NCT03634930|Behavioral|observation|Observation of growth, infant bodycomposition, 24h-drinkingvolume
70226|NCT03634917|Drug|Acamprosate Calcium|"1 capsule with 666 mg Acamprosate~1 capsule with 950 mg Calcium Citrate"
70227|NCT03634917|Drug|Calcium Citrate|1 capsule with 950 mg Calcium Citrate
70228|NCT03634917|Drug|Placebo|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
70229|NCT03634917|Drug|Placebo lead in|1 Capsule with Placebo (lactose monohydrate, micro crystalline cellulose, magnesium stearate)
70230|NCT03634904|Drug|Drug bood sampling|"Total: 6 per patient~after the first administration of ceftazidime (loading dose): sampling #1: at trough before 1st dialysis; sampling #2: after the end of the dialysis session;~after the second administration of ceftazidime (maintenance dose): sampling #3: at trough before 2d dialysis session;~after the third administration of ceftazidime (maintenance dose): sampling #4: at trough before 3d dialysis session;~after the fourth third administration of ceftazidime (maintenance dose): sampling #5: at trough before 4th dialysis session; sampling #6: after the end of the dialysis session"
70231|NCT03634878|Other|perineal ultrasound|Ultrasound measurement of the size and position of the prostheses.
70232|NCT03634852|Drug|Moxifloxacin hydrochloride 0.5% eye drops|were prescribed four times a day for 1-month postoperatively
70233|NCT03634852|Drug|Dexamethasone 0.1% eye drops|were prescribed four times a day for 1-month postoperatively
70234|NCT03634852|Drug|Intracameral Moxifloxacin 0.1%|"Auromox (0.5%): is a sterile clear yellow pale colored preservative free isotonic ophthalmic solution with pH 6.0 to 7.5 and osmolarity 620 -320 milliosmol ( mOsm).The sterile Auromox vial contains 1cc Moxifloxacin hydrochloride 5.45 mg equivalent to 5mg of Moxifloxacin. This product is manufactured by Aurolab an Indian pharmaceutical company. Auromox is available in many countries including Iraq.~Each vial enough for 15 different patients by using a sterile needle and 5cc syringe. By the sterile hand's, the surgeon draws the whole 1cc of Moxifloxacin 0.5% and diluted with 4 cc of balanced salt solution (BSS) to get 5 mg in 5 cc (0.1%) then draw 0.2 cc for each patient."
70235|NCT03634852|Drug|Subconjunctival Triamcinolone acetonide 4 mg /0.4 ml|"Aurocort is a preservative-free Triamcinolone acetonide (40 mg /1cc), with along acting depot preparation of triamcinolone in 1cc vial also the product of Aurolab company and commercially available in our country.~The whole 1cc had been drawn and diluted with 3cc of BSS and SC injection of 4 mg in 0.4 cc of Triamcinolone was given (as a final step in the surgery) 6mm from the limbus usually an inferotemporal site that is easily accessible and the plaque that formed will be not visible within palpebral fissure"
70236|NCT03634839|Drug|Flavor|Flavor of e-liquid - sweet or tobacco
70237|NCT03634839|Drug|Nicotine|Nicotine level (0, 3, or 12 mg)
70238|NCT03634813|Device|High Blood Pressure Monitor|High Blood Pressure Monitoring device (Omron MX3 model BP742, Omron, Shaumberg, IL)
70239|NCT03634813|Procedure|Usual Care|Usual Care
70240|NCT03634800|Drug|Nivolumab 240mg|Patients with multiple myeloma will receive Nivolumab intravenously at 240 mg every two weeks. Infusions will be given over 60 minutes (not bolus or IV push). Patients will continue to receive infusions every two weeks until disease progression or dose limiting toxicity is reached.
70241|NCT03634800|Radiation|Radiation therapy|Patients will receive radiation for 5 consecutive days. A dose of 6 Gy x 5 days will be administered. Patients may receive radiotherapy to an additional site at 12 weeks if they have stable disease.
70242|NCT03634787|Diagnostic Test|CT Scan Day 5-7|Computed Tomography on Day 5-7 according to a clinical protocol.
70243|NCT03634774|Other|CHOICE+ Training Program|CHOICE+ is a program where team members and other stakeholders are engaged in making changes to dining in a long term care home to improve the experience. An external coach supports behaviour change.
70244|NCT03634761|Behavioral|Competency based model|Qualified Learning course and workshop to preschool staff combined with monthly on-site coaching at preschool sites to improve overall intervention setting quality and use of evidence bases practices, provided by external expert from habilitation center.
70245|NCT03634761|Behavioral|Comprehensive program|Comprehensive program of EIBI for Children with ASD supervised by external expert from habilitation center (treatment as usual)
70246|NCT03634735|Drug|Thiamine|Vitamine B1
70247|NCT03634735|Other|Placebo|Placebo tablets
70248|NCT03634722|Device|PHENIX4-8-8 PLUS|transcutaneous electrical nerve stimulation by PHENIX4-8-8 PLUS
70249|NCT03634709|Behavioral|Memory Flexibility training (MemFlex)|MemFlex is a primarily self-guided, paper workbook-based program which aims to reduce overgeneral memory bias and improve recall of positive, specific event memories. Prior to completing one month of self-guided, workbook-based intervention, the participant will attend one 45 minute face-to-face session in which the facilitator outlines the importance of autobiographical memory in everyday life, discusses the impact of trauma on autobiographical memory, and provides information on the different types of autobiographical memories (e.g., specific, general) and their potential everyday functions. The session also introduces the cued-recall tasks which were used to train the memory skills throughout the workbook, and provides facilitator-assisted practice with the tasks. Once participants are comfortable with the training exercises, they set a schedule for completion of the eight-session workbook over the following four weeks.
70250|NCT03634696|Other|mPCL|Smart phone application to support palliative care among late-stage cancer patients
70251|NCT03634696|Other|Usual Care|Usual care through OCRI palliative care clinic
70252|NCT03634683|Biological|LioCyx|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
70253|NCT03634670|Other|Interdisciplinary multimodal pain therapy (IMPT)|The IMPT-program is provided in a specialized day-clinic setting over a period of 20 treatment days. There are two different treatment programs with either 5 days per week over a period of 4 weeks or 3 days per week over a period of 7 weeks. IMPT comprises individual pharmacotherapy evaluated in regular consultations with a physician as well as a structured physiotherapy and psychotherapy programs on group level and individual level. Group physiotherapy comprises exercise therapy, movement experience and relaxation techniques. Additionally individual physiotherapy is provided in two extra sessions focusing on the individual needs and problems of the patient. Group psychotherapy comprises educational contents (e.g. pathophysiology and biopsychosocial aspects of pain) as well as cognitive-behavioral-interventions e.g. regarding stress-management. Additionally individual psychotherapy is provided in four extra sessions focusing on the individual needs and problems of the patient.
70254|NCT03634657|Radiation|Plain X-ray protection shield|Coronary angiography with mere X-ray protection shield
70255|NCT03634657|Radiation|Protection shield & X-ray protective strips|Coronary angiography with X-ray protection shield & X-ray protective strips
70256|NCT03634657|Radiation|Protection shield & protective strips & patient cut-outs|Coronary angiography with X-ray protection shield & X-ray protective strips & X-ray protection patient cut-outs
70257|NCT03634644|Drug|Omega 3 fatty acid|Omega 3 fatty acid,mainly composed of EPA and DHA.
70258|NCT03634644|Drug|Placebo oral capsule|mainly composed of corn oil
70259|NCT03634631|Other|Focused Ultrasound|Test ultrasound in 7T MRI scanner
70260|NCT03634618|Other|Mirror Therapy|Mirror therapy is the treatment method in which mental performance of movements is performed by observing the movements of the healthy extremities. In the case of mirror treatment, the mirror box is placed on a fixed floor. The mirror is positioned so that the patient's body can be fully centered and the mirror image can be seen. While the affected limb is placed on the rear side of the mirror, the firm extremity is opposite to the mirror. The patient focuses on the mirror image of the moving healthy hand and, through artificial visual feedback, perceives the affected limb as moving. The exercises are as follows: flexor tendon gliding exercises, median motor exercises, wrist and forearm ROM exercises and function-oriented exercises.
70261|NCT03634618|Other|Convantional Physiotherapy|The first two weeks involve only immobilisation with plaster. The next 4 weeks, patients do the exercises which follows: 15 minutes water bath, scar tissue massage, flexor tendon gliding exercises, median motor exercises, wrist flexion-extention, median nerve gliding exercise (in addition, one week after plaster removal), hand wrist stretching exercise (in addition, 2 weeks after plaster removal).
70262|NCT03634605|Procedure|Chemical pleurodesis|
70263|NCT03634605|Drug|Tetracycline Topical Ointment|
70264|NCT03634605|Drug|Normal saline|
70265|NCT03634605|Drug|Lidocaine 2% Injectable Solution|
70266|NCT03634592|Procedure|Catheter ablation|Radiofrequency catheter pulmonary vein isolation
70267|NCT03634579|Device|MRI Guided Focal Laser Interstitial Thermal Ablation|"The procedure is done under general anesthesia. Laser fiber placement will be performed by one of two approaches (Trans gluteal or trans rectal) based on the target location within the prostate gland. When the needle position is deemed satisfactory, a 1.5-cm-active tip diode laser fiber will be introduced within an internally cooled catheter through the introducing sheath.~The catheter tip location will be confirmed on Turbo Spin-Echo (TSE) T2-weighted images in the axial and sagittal oblique planes.The introducer sheath will be withdrawn to allow contact of the active laser tip with the lesion. A laser test dose will be done at 9 Watts for about 30 seconds to confirm the site of fiber placement with the subsequent delivery of full dose ablation at 12-27 Watts. Ablation duration is determined based on real time feedback of response using real time temperature and damage estimate maps."
70268|NCT03634566|Drug|N-Acetylecysteine|N-Acetylecysteine 150 mg/kg diluted in 100 ml glucose 5 % over 40 minutes followed by NAC 12.5 mg/kg in 500 ml glucose 5% over 4 hours, followed by NAC 6.25 mg/kg for 2 postoperative days
70269|NCT03634566|Drug|Placebo|Ringer acetate continuous infusion at the same rate for 2 days.
70371|NCT03633786|Procedure|robot-assisted surgery|"removal of endometriotic lesions with da Vinci Xi robotic system (Intuitive Surgical Inc., Sunnyvale, CA, USA), using 5 transperitoneal abdominal accesses and trocars from 8 and 12 mm.~The robotic mechanical arms are associated with the 8 mm abdominal trocars to allow intervention by the first operator, with the aid of a surgical console."
70270|NCT03634553|Other|Training with e-health product|The training program follows the recommendations for training from ACSMS and SoS who states the importance that exercise programs should include muscle strengthening, cardiovascular as wells as balance exercises. Therefore, the training program includes: Strengthening exercises for the upper and lower extremities (number: 5-8 pc. with progression in three levels), daily (5-7 times / week), 30 minutes walks and balance training.
70271|NCT03634553|Other|Usual care|usual care, i.e. participates in regular training regime at the physiotherapy department
70272|NCT03634540|Drug|PT2977 in combination with cabozantinib tablets|PT2977 inhibits hypoxia-inducible factor (HIF-2α) an upstream regulator of vascular endothelial growth factor (VEGF) activation. In combination with the VEGF inhibitor cabozantinib tablets, this is a novel approach to treatment for this patient population.
70273|NCT03634527|Behavioral|Auricular Point Acupressure|Light touch using vaccaria seeds on specific points of the ear
70274|NCT03634527|Behavioral|Control Auricular Point Acupressure-|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
70275|NCT03634514|Drug|Recombinant human growth hormone - Biomatrop|The subjects who recieve Biomatrop first, after a period maximum of 24 hours will recieve a dose of Hormotrop.
70276|NCT03634514|Drug|Recombinant human growth hormone - Hormotrop|The subjects who recieve Hormotrop first, after a period maximum of 24 hours will recieve a dose of Biomatrop.
70277|NCT03634501|Biological|Activated NK|Cell suspension
70278|NCT03634488|Drug|hydroxyurea (20mg/kg/day)|Treatment of severe malnutrition in children with SCA in northern Nigeria
70279|NCT03634488|Dietary Supplement|Nutritional Supplement|Treatment of severe malnutrition in children with SCA in northern Nigeria per local protocol with SoyaPlus
70280|NCT03634475|Drug|PP-001|Drug - no placebo
70281|NCT03634462|Other|CDT with graded negative pressure|Complete Decongestive Therapy (CDT)is a common conservative intervention involving stimulation of the lymphatic system, use of compression, skin care and exercise. The use of graded negative pressure in conjunction with CDT is another conservative therapy intervention used to help clear the lymphatic congestion.
70282|NCT03634449|Device|i-gel|i-gel is a supraglottic airway devices with a gastric suction channel.
70283|NCT03634449|Device|endotracheal tube|Endotracheal intubation is a traditional use for protect airway during the laparoscopic surgery.
70284|NCT03634436|Drug|SHR-1209|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
70285|NCT03634436|Drug|Placebo|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
70286|NCT03634423|Behavioral|Sweet Spot: Flexible high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70287|NCT03634423|Behavioral|Sweet Spot: Flexible low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70288|NCT03634423|Behavioral|Sweet Spot: Rigid high incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70289|NCT03634423|Behavioral|Sweet Spot: Rigid low incentive condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70290|NCT03634423|Behavioral|FOTW: High incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70291|NCT03634423|Behavioral|FOTW: Low incentive control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70292|NCT03634423|Behavioral|FOTW: High incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70293|NCT03634423|Behavioral|FOTW: Low incentive treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70294|NCT03634423|Behavioral|Think Twice: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70295|NCT03634423|Behavioral|Think Twice: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70296|NCT03634423|Behavioral|WDR: Control condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70297|NCT03634423|Behavioral|WDR: Treatment condition|Participants receive text reminders 30 minutes before their workouts and weekly emails reminding them of their schedule.
70298|NCT03634397|Behavioral|Less-Impaired Arm Training|Participants receive virtual reality and manipulation training in their less impaired arm.
70299|NCT03634397|Behavioral|Contralesional Arm Comparison|Participants receive therapy in their paretic arm, based on the best-practices framework for arm recovery post stroke.
70300|NCT03634371|Drug|Drug Levothyroxine 150 mcg|Administration of a 600 mcg levothyroxine dose
70301|NCT03634371|Drug|Drug Eutirox 150 mcg|Administration of a 600 mcg levothyroxine dose
70302|NCT03634358|Procedure|Bipolar scissors|
70303|NCT03634358|Procedure|classic scalpel|
70304|NCT03634345|Drug|Period 1 - Day 1: PF-04965842 administered|Period 1: Single administration of 100 mg PF 04965842.
70305|NCT03634345|Drug|Period 2: Cohort 1: Fluvoxamine & PF-04965842|Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.
70306|NCT03634345|Drug|Period 2: Cohort 2: Fluconazole & PF-04965842|Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
70307|NCT03634332|Drug|PEGPH20|PEGPH20 is a PEGylated, neutral-pH-active human hyaluronidase PH20 produced by recombinant DNA technology
70308|NCT03634332|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2
70372|NCT03633786|Diagnostic Test|assessment of sexual function|assessment of sexual function using a validate questionnaire (Female Sexual Function Index (FSFI)), before and 3 months after surgery
70574|NCT03632174|Other|Topical Ointment with L. reuteri|Topical Ointment containing live Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
70309|NCT03634319|Device|Brown Glaucoma Implant|"The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye.~Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma."
70310|NCT03634306|Device|Ultravision System|Laparoscopic surgery will be performed with the Ultravision Visual Field Clearing System. This system is indicated for the clearance of smoke and other particulate matter that is created during laparoscopic surgery. Ultravision Visual Clearing System removes surgical smoke by means of electrostatic precipitation.
70311|NCT03634306|Procedure|Laparoscopic Hysterectomy|Laparoscopic hysterectomy will be performed according to standard of care without the Ultravision Visual Field Clearing System
70312|NCT03634293|Drug|Alirocumab Injectable Product|Alirocumab is an human monoclonal antibodies directed against Proprotein convertase subtilisin/kexin type 9 (PCSK9). It is administered once every two weeks subcutaneously.
70313|NCT03634293|Drug|Saline Solution|The placebo will be 2 ml' of 0.9% saline injected subcutaneously.
70314|NCT03634280|Other|Kinesio taping|In patients in the splint group, 16-18 layers of cotton gauze (15-cm cast gauze) were applied from the tip of the toes to the beginning of the fibula. Following the gauze application, short leg splint application was performed in a neutral ankle position.
70315|NCT03634267|Radiation|Internal Radiation Therapy|Undergo brachytherapy
70316|NCT03634267|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
70317|NCT03634254|Other|Satisfaction survey of communication quality:|a conversation from phone call to survey primary caregivers of AAC users in New Taipei City who think the users communication quality
70318|NCT03634241|Other|Best Practice|Receive standard of care
70319|NCT03634241|Biological|Pembrolizumab|Given IV
70320|NCT03634241|Other|Quality-of-Life Assessment|Ancillary studies
70321|NCT03634228|Drug|Cytarabine|Given SC
70322|NCT03634228|Drug|Milademetan Tosylate|Given PO
70323|NCT03634215|Diagnostic Test|fibrinogen plasma concentration, coagulation factor XIII activity|blood sampling for a routine coagulation test
70324|NCT03634202|Combination Product|IMRT + oral chemotherapy|"It's a dose escalation of radiation (IMRT), during 5 to 7 weeks, 5 days per week.~Concomitantly, patient have oral chemotherapy (capecitabin)"
70325|NCT03634189|Drug|Cannabidiol|Patients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol
70326|NCT03634176|Diagnostic Test|optical nerve sheet diameter|The ONSD in each eye was measured vertically and horizontally 3 mm behind the optic disc, with the two values averaged. No pressure was applied to the orbit. At each time point, measurements were taken within 5 min. The measurements were made before (T1) and after some of the strategies according to group 30 min (T2), 60 min (T3), and 90 min (T4).
70327|NCT03634163|Behavioral|Neighbourhood exchange|Facilitated coaching support to identify needs and priorities and link with resources - personal, community, friend and family, or from professional service providers; plan and implement a personalized care pathway through community exchange
70328|NCT03634163|Behavioral|Quality of Life Assessment|Completion of baseline measures
70329|NCT03634150|Biological|Nerofe is a first in class derivative of a human hormon-peptide(TCApF), with Cancer suppressive properties.|Once weekly treatment, with IV doses of Nerofe (96mg\m2) and low dose (20 mg/m2) Doxorubicin 5 or 24 hours from one another) .
70330|NCT03634137|Drug|Afamelanotide Group 1|One 16 mg bioresorbable afamelanotide implant (Group 1) from the previous manufacturing process.
70331|NCT03634137|Drug|Afamelanotide Group 2|One 16 mg bioresorbable afamelanotide implant (Group 2) from the optimized final manufacturing process.
70332|NCT03634124|Biological|Blood test|Additional blood test of 4,5 ml of venous blood
70333|NCT03634124|Other|Doppler ultrasound|Vascular ultrasonic vascular exploration of the lower limbs
70334|NCT03634111|Procedure|TAP block|TAP block was performed under guidance with 0.25% ropivacaine 20 ml each side.
70335|NCT03634111|Drug|Morphine|Single dose was 1 mg. The locked time was 6 minutes. The limited dose was 40 mg/ 4 giờ.
70336|NCT03634111|Drug|Ropivacaine|Ropivacaine 0.25% 20 ml each side
70337|NCT03634098|Device|new quantitative imaging techniques|magnetic resonance and ultrafast ultrasound UFUS
70338|NCT03634098|Diagnostic Test|blood sample|extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
70339|NCT03634098|Diagnostic Test|second generation tests|second generation tests NIT-NASHr et NIT-A2F2
70340|NCT03634085|Drug|BDM-2 in Bottle (50 mg - 3600 mg); oral suspension|BDM-2 in bottle will be reconstituted with a 100 mL vehicle (0.2% Sodium Dodecyl Sulfate and water) to achieve a suspension for oral administration.
70341|NCT03634072|Procedure|PVR|Subjects will undergo PVR via surgery or cardiac catheterization. PVR using cardiac catheterization may require a much shorter hospital stay than traditional heart surgery. If the valve is repaired by surgery, this will require open heart surgery to directly implant a pulmonary valve
70342|NCT03634059|Drug|Apatinib|apatinib 500mg qd po plus Erlotinib 150mg qd po / apatinib 500mg qd po plus Icotinib 125mg tid po
70343|NCT03634046|Procedure|Percutaneous transforaminal endoscopic discectomy|The same as the descriptions in experimental group.
70344|NCT03634046|Procedure|Radiofrequency ablation|The same as the descriptions in active comparator group.
70345|NCT03634033|Behavioral|MiCAP with IF|Sites will conduct MiCAP strategies described as follows. Relationship Building; Assess readiness to implement of the site; Internal Facilitator (IF) Champion Coalition Building, which will include IFs training in CAPABLE and facilitation and online IF coalition meetings; Facilitation by the IF, which will include training the clinicians, reviewing home visits with the clinician to assure CAPABLE was provided; IF developing a clinical team for implementation of CAPABLE and leading interdisciplinary coordination of individual beneficiary care; Intervention and implementation strategy fidelity data will be placed in a dashboard for audit and provided to IFs. IFs will use the data to provide feedback to clinicians; and develop action plans for improvement in training or care
70838|NCT03630146|Other|Waitlist control|The control group will receive standard care but without the iPeer2Peer Program.
70346|NCT03634033|Behavioral|MiCAP with IF and EF|"Sites will conduct MiCAP strategies described above in MiCAP with IF with an addition of External Facilitation. Centralized Oversight will be conducted by External Facilitators. External Facilitators will train in facilitation. The work of the External Facilitators will be tailored (i.e., type of discipline) to each site's needs. Intervention and implementation strategy fidelity data will be placed in a dashboard and will be provided to External Facilitators. External Facilitators will use the data to provide feedback to Internal Facilitators; and develop action plans for improvement in site clinician training or beneficiary care as needed."
70347|NCT03634020|Device|DynamX Sirolimus-eluting Coronary Bioadaptor System|de novo native coronary artery lesions
70348|NCT03634007|Biological|AAVrh.10hPOE2 vector|AAVrh.10hAPOE2 is a serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human apolipoprotein E2 (APOE2).
70349|NCT03633994|Drug|Heparin|Heparin is a readily available glycosaminoglycan (GAG) chemically similar to hyaluronic acid and chondroitin sulfate that is currently used to treat chronic painful bladder or interstitial cystitis. Heparin intravesical treatment is an inexpensive second-line treatment for chronic painful bladder, characterized by urinary frequency, urgency and pain. Heparin has been shown to re-establish the bladder urothelial GAG layer and as already noted was shown to reduce recurrent urinary tract infections by 50%.
70350|NCT03633994|Drug|Normal saline|Normal saline bladder instillation
70351|NCT03633981|Other|clinical examinations|"Collection of data from the following tests at H0 (as soon as the ECLS is put in place), H12 (within 12 hours following stabilisation of the dynamic state), H24 and every day until complete neurological recovery:~right and left pupillometry (3 times)~BIS values~right and left NIRS values~right and left transcranial Doppler~neurological clinical examination"
70352|NCT03633981|Other|neurological assessment when a neurological event occurs|"next neurological event:~seizures~pupillary asymmetry~myoclonias~brain stem reflex abnormalities~osteotendinous reflex abnormalities"
70353|NCT03633981|Other|mortality assessment|to 28 days
70354|NCT03633968|Procedure|maxillary sinus lift|maxillary sinus floor elevation by using balloon through either small or large antrostomy without using graft material with simultaneous implant placement
70355|NCT03633955|Drug|FLT|F18 labeled thymidine PET/CT scans will be performed before and after patient receives therapies.
70356|NCT03633942|Device|LMA Supreme|Placement of the LMA Supreme supraglottic airway device for patients undergoing outpatient spine surgery in the prone position.
70357|NCT03633929|Other|KIOS OUD|Study Participants will evaluate software known as KIOS-OUD
70358|NCT03633916|Behavioral|Classroom sensitization session|"A one-off classroom information and engagement session will be delivered in addition to school-level sensitization activities. Individual classroom sessions will be conducted by a 'lay' counsellor with support from a researcher.~The classroom session will start with a short animated video which provides age-appropriate information about types, causes, impacts and ways of coping with common mental health problems. The video will be followed by a guided group discussion, structured around a standardized script that builds on the topics covered in the video. In case of technical difficulties that may prevent the video from being shown, a flipchart based on still illustrations from the video will be used.~At the end of the session, students will be handed a self-referral form which includes normalizing information and question-based prompts to assist with self-identification of mental health problems."
70359|NCT03633916|Behavioral|School-level sensitization activities|"The control condition intervention will comprise sensitization activities conducted at the whole school level. These activities will include:~Posters containing information about the school counselling program and referral pathways will be displayed in prominent locations at each school.~A drop-box for student self-referral slips will be set up in a prominent location at each school.~Information meetings with teachers and the principal will be conducted at each school from the beginning of the trial."
70360|NCT03633903|Behavioral|Mindfulness|Mindfulness based stress reduction adapted for teens is a mindfulness intervention designed to aid adolescents in understanding stress, better coping with stress, and promoting resilience
70361|NCT03633890|Drug|DaZhu Rhodiola Rosea Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
70362|NCT03633890|Drug|DaZhu Rhodiola Rosea Simulation Capsule|Oral administration, 4 capsules, 3 times a day, for 8 weeks
70363|NCT03633877|Device|DuraporeTM and Hy-Tape®|Medical tapes
70364|NCT03633864|Biological|Fecal microbiota transplantation|Fecal donors are selected according to the predefined criteria. Fecal microbiota suspension is prepared by using fresh feces from the selected fecal donors. Then, administration of 200 ml fecal microbiota suspension through a transendoscopic enteral tubing or retention enema.
70365|NCT03633851|Device|Toric intraocular MX60T lens|one eye will receive toric MX60T lens
70366|NCT03633851|Other|Standard MX60 plus corneal incisions|the other eye will receive standard MX60 lens with corneal incisions
70367|NCT03633825|Behavioral|Brief help-seeking barrier reduction intervention|The BRI was designed to overcome common concerns and misconceptions (i.e., barriers) related to using crisis services. It works by first asking the user about what potential barriers may keep them from using the crisis service referrals, and then, based on the user's response, by providing information intended to help the user overcome the potential barrier(s) they selected. By exploring the menu of barriers, users could read brief messages designed to dispel common misconceptions or concerns related to each barrier. For example, a common concern among Koko users was that calls to lifelines invariably result in visits by the police or other emergency services. Users who feared this possibility could tap on the associated button and learn that active rescues such as these are extremely rare, and occur in less than one percent of all cases. Whenever possible, we used language throughout the intervention to help validate the experiences of the users.
70368|NCT03633812|Other|Observational study, Beta blocker medication history|Observational study, Beta blocker medication history
70369|NCT03633799|Drug|VeraCept|VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
70370|NCT03633786|Procedure|standard laparoscopic surgery|removal of endometriotic lesions with laparoscopic instruments (KARL STORZ Gesellschaft mit beschränkter Haftung & Co., Tuttlingen, Germany) using 4 transperitoneal abdominal accesses and trocars from 5 to 12 mm
70373|NCT03633786|Diagnostic Test|assessment of bowel symptoms|assessment of bowel symptoms using a validated questionnaire (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS)), before and 3 months after surgery
70375|NCT03633773|Biological|MUC-1 CART cell immunotherapy|After fludarabine and cyclophosphamide pre-chemotherapy，MUC-1 CART immunotherapy is given. A decent interval later, levels of specific antibodies, CART cells and serum cytokines will be assessed.
70376|NCT03633760|Drug|Bilastine 40mg single dose|Single-dose only cohort treatment duration is 1 day. After the screening period, eligible subjects will be allocated to receive a single dose of 40 mg of bilastine
70377|NCT03633760|Drug|Bilastine 20mg single-dose followed by multiple-dose|Single-dose followed by multiple-dose cohort treatment duration of this cohort is 9 days. Subjects will receive a single dose of bilastine 20 mg on the morning of Day 1; and six doses of bilastine 20 mg in the morning from Day 4 to Day 9.
70378|NCT03633747|Drug|Propranolol Hydrochloride|Oral propranolol hydrochloride tablets are administration for 6 months at dose of 1.5 mg/kg or the maximum dose tolerable.
70379|NCT03633734|Drug|Sequential Treatment|One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
70380|NCT03633721|Drug|Cannabis|7% delta9-THC cigarettes will be smoked by 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
70381|NCT03633721|Other|Placebo|0% THC cigarettes will be administered to HIV negative women. Participants will be instructed to 'light the cigarette' (30 sec), 'get ready' (5 sec), 'inhale' (5 sec), 'hold smoke in lungs' (10 sec) and 'exhale.' Participants will smoke 3 puffs in this manner, with a 40-sec interval between each puff.
70382|NCT03633708|Drug|Etelcalcetide|Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
70383|NCT03633695|Device|IC-8 IOL|The AcuFocus IC-8 IOL will be surgically implanted in one eye of each subject. A monofocal or monofocal toric IOL will be surgically implanted in the fellow eye of each subject.
70384|NCT03633695|Device|Monofocal|A monofocal or monofocal toric IOL will be surgically implanted in both eyes of each subject.
70385|NCT03633682|Behavioral|Headspace - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Headspace meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
70386|NCT03633682|Behavioral|Stop, Breathe, & Think - Meditation and Mindfulness App|Participants randomized to this arm will receive 1-month full access to the Stop, Breathe, & Think meditation app. They will be asked to listen to at least one meditation a day over the four week study period. Mindfulness is the ability to intentionally and nonjudgementally observe thoughts, bodily sensations, or feelings in the present moment. The apps include guided mindfulness meditations targeting several different areas, such as stress, anxiety, compassion, and sleep.
70387|NCT03633669|Diagnostic Test|Fecal calprotectin|Testing every 3 months
70388|NCT03633669|Other|Routine care|As per treating gastroenterologist
70389|NCT03633656|Device|Model predictive control|Computer aided dose selection for the treatment of iron deficient anemia.
70390|NCT03633643|Drug|oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets)|"five oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets) at the evening of the surgery and thereafter twice daily on day~1 and 2 after surgery while the patient is in hospital."
70391|NCT03633643|Drug|oral applications of Placebo|five oral applications of Placebo at the evening of the surgery and thereafter twice daily on day 1 and 2 after surgery while the patient is in hospital.
70392|NCT03633630|Drug|Amla|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
70393|NCT03633630|Drug|Placebo|Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
70394|NCT03633617|Drug|Dupilumab|Solution for injection administered subcutaneously
70395|NCT03633617|Drug|Placebo|Matching placebo
70396|NCT03633604|Biological|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
70397|NCT03633591|Drug|Tolcapone|Multiple doses of tolcapone tablets in the fasted state
70398|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype in the fasted state
70399|NCT03633591|Drug|Tolcapone Divided Dose|Tolcapone (suspension) in equal divided doses in the fasted state
70400|NCT03633591|Drug|Tolcapone Modified Release Prototype|A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
70401|NCT03633578|Behavioral|walk test|"The patient will have to walk on a treadmill in four different conditions:~without distraction at preferential speed~with distraction at preferential speed~without distraction at the speed of 130% of the preferential speed~with distraction at the speed of 130% of the preferential speed"
70402|NCT03633565|Drug|Sildenafil (Phosphodiesterase inhibitors)|tablet 25mg
70403|NCT03633565|Drug|Prednisolone (Steroids)|tablet 20 mg
70404|NCT03633565|Procedure|Mesenchymal stem cell transplantation|stem cell transplantation intramuscular
70405|NCT03633552|Drug|Temozolomide|The patients will initially undergo surgery. Within 4 to 6 weeks after surgery, all patients will receive chemoradiation. After completion of chemoradiation, the cases will receive 12 cycles of adjuvant Temozolomide (prescribed as 150 to 200 milligram per square meter body surface per day for the first 5 days of every 28 days). In the control group, the patients will receive 6 cycles of adjuvant Temozolomide (in the same dosage).
70406|NCT03633539|Procedure|Single-incision Laparoscopic Surgery|Patients undergo single-incision laparoscopic surgery. In this group，the surgery is performed through a transumbilical port. The surgeon will adjust surgical position to expose the operative field with the help of gravity. Besides，hand over hand cross and parallel techniques are needed to achieve the SILS. All the other operative procedures are the same as conventional laparoscopic surgery.
122299|NCT03230656|Other|Early cognitive-communication therapy|
70407|NCT03633539|Procedure|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery. In this group，the surgery is performed through 3-5 ports according to the surgeons habits and specific conditions.
70408|NCT03633526|Drug|VX-659|Fixed dose combination (FDC) tablet (VX-659/TEZ/IVA)
70409|NCT03633526|Drug|TEZ|FDC tablet (VX-659/TEZ/IVA)
70410|NCT03633526|Drug|IVA|FDC tablet (VX-659/TEZ/IVA) and IVA mono tablet
70411|NCT03633513|Diagnostic Test|LBT-3627|Immunomodulatory agent
70412|NCT03633513|Diagnostic Test|Immunological profiling|Comprehensive profiling of inflammatory and anti-inflammatory markers (incl. cellular, molecular) including cellular functional assays
70413|NCT03633500|Other|Sterile water|Placebo Comparator: Sterile water: 0.2 ml of sterile water is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The liquid is given time to get absorbed, any pooled liquid is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours.
70414|NCT03633500|Biological|Breastmilk|Experimental: Breastmilk: 0.2 ml of mothers' own colostrum/ breast milk is instilled into the posterior buccal cavity in aliquots of 0.1 ml over a 30 second period. The colostrum is given time to get absorbed, any pooled milk is swabbed in the infants' cheek and gum. This is performed every 4 hours until independent safe cup feeds, breastfeed or bottle feed is established consistently for 48 hours. independently sucks at breast, bottle or cup feed
70415|NCT03633487|Drug|Mucinex®|Mucinex® 1200 mg ER Bi-Layer tablet
70416|NCT03633474|Biological|N. lactamica|Stocks of N. lactamica (strain Y92-1009, sequence type 3493, clonal complex 613) in Frantz medium containing 30% (v/v) glycerol have been previously prepared using the Good Manufacturing Practices pharmaceutical manufacturing facilities at Public Health England (Porton Down, United Kingdom).
70417|NCT03633474|Other|PBS only|Sterile PBS only containing no bacteria
70418|NCT03633461|Drug|OC-02|OC-02
70419|NCT03633461|Drug|Placebo|Placebo
70420|NCT03633448|Drug|Children's Mucinex® Grape Flavor|1 x 200 mg (10 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
70421|NCT03633448|Drug|Children's Mucinex® Grape Flavor|1 x 400 mg (20 mL) Children's Mucinex® Grape Flavor 100 mg Guaifenesin/5 mL immediate-release formulation
70422|NCT03633435|Procedure|assisted home hemodialysis patients|Arteriovenous fistula cannulation at the patient's home provided by a trained private nurse at each dialysis session with the rope-ladder technique, and connection to the Nxstage System One
70423|NCT03633396|Biological|ANB019|Humanized Monoclonal Antibody
70424|NCT03633396|Drug|Placebo|Solution
70425|NCT03633383|Device|Transcatheter aortic valve|Self-expandable aortic valve prothesis
70426|NCT03633370|Other|Multifaceted intervention including 3 components|Multifaceted intervention including Dispatcher training to improve cardiac phone recognition, mobile application to send bystanders on cardiac arrest location before first professionals rescuers and motivational support for volunteer bystanders
70427|NCT03633357|Drug|JNJ-18038683|"JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days."
70428|NCT03633357|Drug|Placebo|Participants will take two placebo tablets daily, for seven days.
70429|NCT03633344|Drug|Carbowhite|
70430|NCT03633344|Drug|Carbowhite placebo|
70431|NCT03633331|Drug|Palbociclib|Given PO
70432|NCT03633331|Drug|Letrozole|Given PO
70433|NCT03633331|Drug|Fulvestrant|Given IM
70434|NCT03633331|Other|Questionnaire Administration|Ancillary studies
70435|NCT03633331|Other|Quality-of-Life Assessment|Ancillary studies
70436|NCT03633318|Device|electrical impedance myography (EIM)|EIM is a measure of impedance. EIM is a measure of the obstruction of flow of current through the tissue. It is a completely painless assessment of muscle health.
70437|NCT03633305|Drug|Hypnotics|Medication used 1 to 7 nights/week for 6 to 8 weeks.
70438|NCT03633305|Behavioral|Online CBT|Internet self-help program for insomnia with 6 cores.
70439|NCT03633305|Behavioral|Face-to-face CBT|Face-to-face therapy with 3 to 4 individual sessions in a period of 6 to 8 weeks.
70440|NCT03633292|Drug|Antiseptic clorhexidine gel (Lacer, Barcelona, Spain)|"Together with the dispensing container, the dosing and dosage of the gel in research will be attached, with the description of the pharmaceutical form, packaging and labeling of the product. Packages with 8 ml of the gel under investigation, sufficient treatment for 1 month of applications. Posology: After tooth brushing, apply a small amount of gel on the fingertip of a freshly washed finger and spread it over the gum, doing a gentle massage, for 15 , 2 times a day after proper oral hygiene and it is recommended not to ingest no liquid or food until after half an hour of use."
70441|NCT03633292|Drug|Master formula of aloe vera gel 80%|Blindly and in the same container as chlorhexidine, patients will be instructed to apply aloe vera gel on the gums and mucous membranes once the orthodontic appliances have been cemented
70442|NCT03633279|Drug|Branched chain amino acid|Branched chain amino acid 10 grams packet (L-Isoleucine (952 Mg), L-Leucine (1904 Mg.), L-Valine(1144 Mg).
70443|NCT03633279|Drug|Placebo|an equinitrogenous amount of lactoalbumin 2.1 grams, and equicaloric amount with 4.0 g saccharose and 3.0 g mannitol for a total of 33.6 kcal/packet.(one packet at 6pm and two at 9pm)
70444|NCT03633266|Procedure|anti-VEGF|vitreoretinal surgery combined with intraoperative anti-VEGF
70445|NCT03633266|Procedure|PRP|vitreoretinal surgery combined with intraoperative PRP
70472|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment if lung cancer has not been confirmed.
70473|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment.
70507|NCT03632720|Biological|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine MenACYW conjugate vaccine|Pharmaceutical form: solution for injection; route of administration: intramuscular, 0.5 mL
70508|NCT03632720|Biological|Meningococcal group B vaccine|Pharmaceutical form: solution for injection; route of administration: deep intramuscular, 0.5 mL
122589|NCT03228446|Other|no training (control)|no training applied
70446|NCT03633253|Other|Summarize of participants' characteristics using means and standard deviations or frequencies and percentages|First, prevalence of MCR syndrome will be determined by classifying participants into MCR and non-MCR syndrome groups. Second, between-group comparisons of participants' characteristics will be performed using unpaired t-test, Mann-Whitney, analysis of variance with LSD correction or Chi-square test, as appropriate. Third, multiple regressions will be performed to examine the association between MCR syndrome (dependent variable) and cardio-vascular risk factors and/or diseases (independent variables) adjusted on participants' characteristics. Fourth, the incidence of MCR syndrome during the follow-up period of NuAge study will be reported. Fifth, regression will be performed to examine the association between MCR syndrome (dependent variable) and cognitive decline as well cognitive impairment (independent variables, separated model) adjusted on participants' characteristics.
70447|NCT03633240|Other|ER assessment|"To measure the effects of recommendations of ER2, the investigators will use ER users who will have an ER2 assessment without any recommendations as the referent group the older. This choice is possible because ER2 will be integrated into ER care in two steps:~The first step will be limited to its assessment component in order to learn how to use the tool.~The second step will be to follow the recommendations provided after the assessment.~Participants will follow-up during their hospitalization via a review of their chart. They will be censored when they will be discharged from the JGH or when the duration of hospitalization will exceed 31 days."
70448|NCT03633227|Drug|Obeticholic Acid (OCA)|Moderate and Severe hepatic impairment classified as Child-Pugh Class B and C: 5 mg tablet of OCA once weekly titrating up to 5 mg OCA twice weekly based on tolerability at 3 months and subsequently titrating up to a maximum dose of 10 mg OCA twice weekly based on safety and tolerability for the duration of the study.
70449|NCT03633227|Drug|Placebo|One tablet twice weekly (or a lower frequency based on safety and tolerability) for the duration of the study
70450|NCT03633214|Other|Online training module|Responses of GPs in the intervention group will then be compared before and immediately after the online training video and also 3-months later; as well as to the control group.
70451|NCT03633201|Device|Cruciate Retaining|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The standard insert.
70452|NCT03633201|Device|Medial Congruent|Zimmer Biomet's Personalized Knee system for knee osteoarthritis treatment. The new anatomical congruent shaped insert.
70453|NCT03633188|Biological|Patients treated by antibiotherapy|"Biological samples (stool, blood, swabs) will be collected :~Blood sampling (12 ml) at baseline (week 0) at the end of treatment (W6/W24),and 15 days after antibiotherapy stop (optional) (W8/W26),~Feces collection at baseline (week 0) during antibiotic treatment (W2), at the end of treatment (W6/W24),15 days after antibiotherapy stop (W8/W26), and W26 after baseline~Swab samples (nasal and rectal) at baseline at week 0 and at the end of treatment (W6/W24),"
70454|NCT03633175|Drug|Vaginal progesterone|400 mg vaginal progesterone [Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
70455|NCT03633149|Behavioral|Computer tablet-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered on a computer-tablet.
70456|NCT03633149|Behavioral|Person-delivered C4H|Two session CHOICES intervention targeting ineffective contraception and risky alcohol use and/or cigarette smoking and/or marijuana use to reduce the risk of a substance-exposed pregnancy delivered by a counselor.
70457|NCT03633149|Behavioral|Brief Advice|Brief advice delivered by a research associate about healthy behaviors for women including use of contraception and alcohol, tobacco, and marijuana use
70458|NCT03633136|Behavioral|electronic video education|Solid Organ Transplantation: An Educational Mini-Series for Patients consists of 6 videos ranging in length between 3 and 23 minutes, and has been developed according to best practice for designing education for patients with end-stage renal disease pursuing transplant. Each video outlines a subsequent stage of the transplant process, featuring an animated character embarking on a transplant journey. Animated segments illustrate difficult concepts for patients with poor health literacy, and patient narratives keep the content relevant and culturally inclusive. The educational intervention was developed with experts in medication adherence, video education, motivational psychology, cultural education (First Nations perspective), healthcare providers, and most importantly patients.
70459|NCT03633123|Drug|D_PLEX|D_PLEX is reconstituted into paste and administered in a single application following closure of the fascia, on the fascia suture line, and on the soft tissues of the abdominal wall along the whole length of the surgical wound (including muscle, fat and dermis).
70460|NCT03633123|Other|Standard of Care (SoC)|"Prophylactic, pre-operation: 1st or 2nd generation of Cephalosporine family, plus Metronidazole.~Post-operation: this is each participating center standard practice for this type of procedure"
70461|NCT03633110|Biological|GEN-009 Adjuvanted Vaccine|GEN-009 Adjuvanted Vaccine consists of GEN-009 Drug Product mixed with Hiltonol (poly-ICLC, adjuvant) and is administered by subcutaneous injection.
70462|NCT03633110|Drug|Nivolumab|Nivolumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
70463|NCT03633110|Drug|Pembrolizumab|Pembrolizumab is a PD-1 checkpoint inhibitor approved by the FDA to treat the tumor types in this study.
70464|NCT03633097|Other|Acupuncture and Usual care|patients after surgery receive usual care(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet) as well as acupuncture treatment as an adjunctive therapy
70465|NCT03633097|Drug|Usual care|patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
70466|NCT03633084|Drug|RBM-007 Injectable Solution|(No additional description)
70467|NCT03633071|Other|Web-knee brace|Web -Knee Brace
70468|NCT03633058|Drug|Ketamine|oral ketamine dosed twice daily for 5 days
70469|NCT03633032|Diagnostic Test|Acquiring of ultrashort echo time (UTE) MRI sequences|Modern MRI sequences (ultrashort echo time (UTE)) for a better depiction of bone anatomy
70470|NCT03633019|Drug|rhTPO|high dose rhTPO ih
70471|NCT03633006|Other|Blood Sample Collection|Subjects participating in the study will have blood drawn at enrollment. Additional blood samples may be collected at 12 months from enrollment.
70572|NCT03632187|Drug|Abatacept|Subcutaneous abatacept every weeks during 3 months
70474|NCT03632993|Drug|collagenase clostridium histolyticum (CCH)|Endo Pharmaceuticals Inc. (Endo) is developing collagenase clostridium histolyticum (CCH) for the treatment of EFP. Because CCH is a proteinase that can hydrolyze the triple-helical region of collagen under physiological conditions, CCH has the potential to be effective in lysing sub-dermal collagen, such as those observed in the dermal septa, which are the underlying cause of the skin dimpling in women with Edematous Fibrosclerotic Panniculopathy (EFP). CCH targets the collagenase structural matrix (e.g., dermal septa) at the site of injection and does not require systemic exposure to be effective.
70475|NCT03632980|Device|"Ablatherm Foc/Dyn or Focal One HIFU treatment"|"Non invasive treatment of localized prostate cancer by High Intensity Focused Ultrasound therapy, endorectal application.~or Non invasive treatment of localized prostate cancer recurrency by High Intensity Focused Ultrasound therapy after radiotherapy failure, endorectal application."
70476|NCT03632967|Device|Tricinch Coil System Implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
70477|NCT03632954|Device|ACell Arm|Cytal® Wound Matrix and/or MicroMatrix®
70478|NCT03632941|Biological|VRP-HER2|VRP (alphavirus-like replicon particles) containing self amplifying replicon RNA for HER2
70479|NCT03632941|Biological|Pembrolizumab|A humanized antibody specific for the programmed cell death 1 (PD-1) receptor.
70480|NCT03632928|Other|Ultrasound Elastography|Measuring muscle hardness at the trapezius and neck bilateral
70481|NCT03632928|Other|Pressure Pain threshold|Measuring Pressure pain threshold at the trapezius and neck bilateral
70482|NCT03632915|Drug|Levetiracetam|Standard of care
70483|NCT03632915|Drug|Lacosamide|Standard of care
70484|NCT03632915|Drug|Phenytoin|Standard of care
70485|NCT03632915|Drug|Phenobarbital|Standard of care
70486|NCT03632915|Drug|Ketamine|Standard of care
70487|NCT03632915|Drug|Valproic Acid|Standard of care
70488|NCT03632902|Device|supraglottic device|airway management will be collected
70489|NCT03632889|Behavioral|GoToSleep Program|For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
70490|NCT03632876|Dietary Supplement|retinyl palmitate|The intervention is a daily vitamin A supplement.
70491|NCT03632863|Behavioral|Electronic Patient Decision Aid|"The electronic PDA is an interactive website with 3 main sections:~Review of depression treatment options (non-pharmacological and pharmacological) along with their respective risks and benefits.~Interactive values clarification exercises to help women determine which risks and benefits are most important to them.~Exercises to help women consider how partners, family, providers and the social context impacts decision-making.~A summary of how a woman feels about each option along with risks and benefits is generated which can be provided to treating clinicians for use in follow-up.~A printable pdf with standard published information and resources is also included."
70492|NCT03632863|Behavioral|Standard Resource Sheet|A control group aims to isolate the PDA's effects from time and clinical care. Controls login to the study website and receive the same printable pdf as in the PDA so that they can access standard publicly available information/resources, even if they will not receive the PDA.
70493|NCT03632850|Other|web-based interactive tool|an online tool to assist users in decision-making in choice of treatment for advanced cancer
70494|NCT03632837|Device|Hemoadsorption|see arm description
70495|NCT03632824|Drug|Tranexamic Acid|"One gram( 2 ampules ) of tranexamic acid was received by the participant intravenously twice daily for 48 hours followed by 500 mg tranexamic acid tablet three times daily for 5 days .~follow up of the patient was done by recurrence of the bleeding latter on during pregnancy . the course of treatment was repeated again ."
70496|NCT03632811|Other|A structured interview with every patient|The comprehension test will be done through structured interviews in which the principal investigator will ask if the patient has had difficulty understanding the recommendations and questions, will check the interpretation of all items and the understanding of each word by the patient. In case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives.
70497|NCT03632798|Diagnostic Test|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
70498|NCT03632798|Drug|Chemotherapy|"Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer.~Chemotherapy list:~Liposomal Doxorubicin;~Docetaxel;~Paclitaxel;~Carboplatin;~Cisplatin;~Gemcitabine;~Topotecan;~Carboplatin, Gemcitabine;~Cisplatin, Gemcitabine;~Carboplatin, Liposomal Doxorubicin;~Carboplatin, Paclitaxel;~Carboplatin, Docetaxel."
70499|NCT03632772|Drug|Solifenacin 5Mg|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
70500|NCT03632772|Drug|Mirabegron 50 MG|We compared the safety and therapeutic efficacy between Solifenacin and Mirabegron in men with benign prostate hyperplasia and having overactive bladder symptoms immediately after Transurethral Resection of the Prostate.
70501|NCT03632759|Drug|Liraglutide|Participants will receive subcutaneous (SC) liraglutide for 8 weeks
70502|NCT03632759|Drug|Golimumab|Participants will receive subcutaneous (SC) golimumab for 8 weeks
70503|NCT03632733|Drug|Tetracycline|Tetracycline cream
70504|NCT03632733|Drug|Clotrimazole|Clotrimazole cream
70505|NCT03632733|Drug|Tetracycline and Clotrimazole|Combination cream
70506|NCT03632733|Other|Placebo|Placebo cream without active drug ingredients
70573|NCT03632187|Drug|Placebos|Subcutaneous placebo every week during 3 months
70509|NCT03632720|Biological|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine|Pharmaceutical form: powder and suspension for suspension injection; route of administration: deep intramuscular, 0.5 mL
70510|NCT03632720|Biological|Human rotavirus RIX4414 strain vaccine|Pharmaceutical form: oral suspension; route of administration: oral, 1.5 mL
70511|NCT03632720|Biological|Pneumococcal 13-valent polysaccharide conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular, 0.5 mL
70512|NCT03632707|Radiation|Magnetic Resonance Imaging of the knee|After clinical assessment, all the patients will examined by Magnetic Resonance Imaging to diagnose the medial meniscal posterior root tear,and the suspected cases of meniscal extrusion will make MRI using the knee coil for varus stress Overloading simulating weight bearing
70513|NCT03632707|Procedure|Knee Arthroscopy|Correlate all the magnetic resonance imaging results with the Knee Arthroscopy
70514|NCT03632694|Behavioral|Health Coaching and Tech Support|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. Additionally, this arm receives health coaching to provide encouragement and further motivate and help study participants to modify their sedentary behavior."
70515|NCT03632694|Behavioral|Tech Support Only|"Participants will receive a Jawbone UP2 activity monitor and education materials about the negative consequences of sedentary behavior and suggestions for breaking up sedentary time with light physical activity. Participants receive 5 telephone coaching calls to set up the Jawbone UP2 monitor with their smartphone app and receive tech support help with changing the settings/goals on the app. However, there is no additional health coaching."
70516|NCT03632681|Drug|Intranasal Insulin|Intranasal insulin
70517|NCT03632681|Drug|Intranasal Placebo|Intranasal placebo manufactured to mimic smell of insulin
70518|NCT03632668|Drug|AD-2071 10/20mg|AD-2071 10/20 mg tablet
70519|NCT03632668|Drug|AD-2072 80/5mg|AD-2072 80/5mg tablet
70520|NCT03632668|Drug|AD-2071 10/20mg + AD2072 80/5mg|AD-2071 10/20 mg + AD-2072 80/5mg tablet
70521|NCT03632655|Procedure|prostate biopsy|Men will be randomized to receiving either TPM or TRUS targeted biopsy
70522|NCT03632642|Drug|Benzylpenicillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
70523|NCT03632642|Drug|Flucloxacillin|The study drug will be administered for a minimum of 2 weeks (the minimal currently accepted duration of IV therapy for SAB.) For patients who do not fulfill criteria for 2 weeks of therapy, the duration of treatment will be 4 to 6 weeks and will be made by the treating clinician.
70524|NCT03632629|Other|interactive cognitive training|Using interactive brain club system training to children with attention deficit hyperactivity disorder with developmental delay
70525|NCT03632616|Other|PANQOLI (quality of life instrument)|A quality of life instrument, the PANQOLI, will be administered prior to endoscopic intervention, and at 1,3, and 6 months post-intervention.
70526|NCT03632603|Radiation|No intervention|No intervention during study period.
70527|NCT03632590|Dietary Supplement|Magnesium Citrate|450 mg of Magnesium Citrate per day (6 capsules per day) for 24 weeks
70528|NCT03632590|Dietary Supplement|Magnesium Sulfate|450 mg of Magnesium Sulfate per day (6 capsules per day) for 24 weeks
70529|NCT03632590|Dietary Supplement|Magnesium Oxide|450 mg of Magnesium Oxide per day (6 capsules per day) for 24 weeks
70530|NCT03632590|Drug|Placebo|The placebo capsules will contain starch (Amylum solani) for 24 weeks
70531|NCT03632577|Device|High Flow Oxygen (HFO)|HFO is a mix tap of air and oxygen. It permits to control FiO2 and generated controlled high flow air until 60/min. Air and oxygen are mixed, warmed, humidified and issued to patient by a warming monopod inspiratory circuit to nasal cannulas of a large diameter. Expiration is free.
70532|NCT03632577|Device|Non Invasive Ventilation (NIV)|NIV was already evaluated in post-extubation. This technic is now used in daily consolidation processing after extubation because it provides a ventilator help with two levels of pressure helping in respiratory work. Adding Automated Flow Oxygen Titration could optimized patient's oxygenation and reduce workload of caregivers.
70533|NCT03632564|Device|REVIVIEW dichoptic audio-visual stimulation|REVIVIEW dichoptic audio-visual stimulation using video goggles
70534|NCT03632551|Other|Specific binaural hearing evaluations|Specific binaural hearing evaluations (recognition of sentences in noise, sound source localization) and quality of life (SSQ questionnaire) will be carried out. Thereafter, the electroencephalographic examination will be performed
70535|NCT03632538|Diagnostic Test|"Biomarker (penKid, adrenomedulin, C-terminal alpha-1 antitrypsin peptide)"|Drawing of patients blood for measurement of biomarkers for AKI before and after cardiac surgery (times: 0, 6, 24, 72, 168 hours).
70536|NCT03632525|Drug|Ferric carboxymaltose|Single dose of 20 mg/kg ferric carboxymaltose (maximum 1000 mg for patients with haemoglobin <14 g/dL or 500 mg for patients with haemoglobin ≥14 g/dL).
70537|NCT03632512|Dietary Supplement|Hericium honey bolus|The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
70538|NCT03632512|Dietary Supplement|Placebo honey bolus|The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.
70539|NCT03632499|Other|rehabilitation|rehabilitation
70540|NCT03632486|Other|Bedside Ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck.~Lung ultrasound to assess for pleural effusions and sonographic b lines."
122590|NCT03228433|Drug|TAK-418|TAK-418 Capsule.
70541|NCT03632473|Diagnostic Test|multimodal evoked potentials (mmEP)|combination of visual evoked potentials (VEP) and motor evoked potentials (MEP) or the combination of VEP, MEP and somato-sensory evoked potentials (SSEP)
70542|NCT03632460|Drug|Dexmedetomidine Injection [Precedex]|epidural administration of dexmedetomidine added to ropivacaine
70543|NCT03632447|Device|Leva|Subjects randomized to Leva will use a vaginal probe containing motion-based sensors to direct the performance of pelvic muscle exercises.
70544|NCT03632447|Device|PFDx|All subjects (in both study arms) will be evaluated using a vaginally placed device that will evaluate pelvic floor motion to document change in pelvic floor muscle function resulting from pelvic floor muscle exercises.
70545|NCT03632434|Device|transcranial direct current stimulation|tDCS generates a small electric current which modulates how easy it is for active brain cells to discharge. The device is a neoprene cap worn over the head, and in the cap there are two electrodes, which are small metal discs, where the current comes from.
70546|NCT03632421|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
70547|NCT03632421|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
70548|NCT03632408|Drug|Zopiclone|Oral, single dose, 7.5 mg
70549|NCT03632408|Behavioral|hangover|as per subjects choice to consume alcohol
70550|NCT03632408|Drug|Placebo oral capsule|oral
70551|NCT03632395|Diagnostic Test|computed tomography|computed tomography
70552|NCT03632382|Diagnostic Test|3D acquisition of maxillofacial characteristics|A 3D acquisition of maxillofacial characteristics will be performed for each patient in order to validate a predictive model comparable to data obtained by polysomnography
70553|NCT03632369|Diagnostic Test|Hyperpolarized xenon-129 MRI|Participants will be asked to inhale the xenon-129 contrast agent according to procedure for gas administration. The success criterion of the drug is a obtained Xe MRI lung image with reasonable signal level. The clinical MRI scanner Philips Achieva 3.0T will be equipped with 129Xe Quadrature Transreceive Lung Coil (Large and Small) to acquire 129Xe lung images. The resonator length of the large coils is equal to 122 cm, whereas the same size of the small coil is equal to 106 cm. The success criterion of the device performance is the obtained reasonable Xe MRI lung image.
70554|NCT03632356|Behavioral|Stepped Care Intervention (STEP)|A stepwise progression of intervention according to the participant's response to the increasing levels of therapy. There will be 1 session of psychoeducation, followed by 5 sessions of Cognitive Behavioral Therapy (CBT) if panic symptoms do not improve at 1-month follow-up.
70555|NCT03632356|Diagnostic Test|Screening only|Screening for probable panic attacks or panic disorder using the Structured Clinical Interview for DSM-5
70556|NCT03632343|Other|Pain Squad+ with Nurse Support|Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain >3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.
70557|NCT03632343|Other|Pain Squad+|Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
70558|NCT03632330|Drug|Dexmedetomidine|Dexmedetomidine group
70559|NCT03632330|Drug|Midazolam|Midazolam group
70560|NCT03632330|Drug|Propofol|Propofol group
70561|NCT03632330|Drug|Midazolam/Propofol|Midazolam/Propofol group
70562|NCT03632317|Drug|Panobinostat|30 mg/m^2
70563|NCT03632317|Drug|Everolimus|3.0 mg/m^2
70564|NCT03632304|Procedure|Local anesthesia with minimal sedation|The operating surgeon will perform a digital or wrist block to numb the surgical area prior to the surgery, instead of using a brachial plexus block.
70565|NCT03632291|Biological|UB-221|UB-221 (75 mg/ml)
70566|NCT03632278|Behavioral|Mindfulness psychoeducation Programme|"A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien & Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties."
70567|NCT03632252|Device|Powered ankle prosthesis|This device is a custom designed ankle prosthesis. Motors control force on the device through cables but are not worn by the person.
70568|NCT03632226|Drug|18F-OGA-1|
70569|NCT03632213|Drug|Losartan|Losartan group: 15 patients, both sexes, will receive Losartan 0.4 to 1.4 mg/kg/day orally for 12 months.
70570|NCT03632213|Drug|Placebo|Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
70571|NCT03632200|Other|Experimental group|"The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions"
70575|NCT03632174|Other|Topical Ointment without L. reuteri|Topical Ointment that does not contain Lactobacillus reuteri DSM17938 applied twice daily in dry areas of the entire body
70576|NCT03632161|Drug|Dexmedetomidine|isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg)
70577|NCT03632161|Drug|Bupivacaine|isobaric bupivacaine 0.5% (0.3ml/kg)
70578|NCT03632135|Diagnostic Test|ChemoID assay|"The ChemoID test is a CLIA-certified and CAP-accredited drug response assay performed by a hospital clinical pathology laboratory that uses patient's live tumor cells to indicate which chemotherapy agent (or combinations) will kill not only bulk of tumor cells, but importantly the cancer stem cells (CSCs) that are known to cause cancer to recur. During the assay, cancer stem cells and bulk tumor cells from an individual patient are exposed to FDA-approved chemotherapy drugs.~The test measures the cytotoxic effect of actual doses of standard-of-care chemotherapies. The ChemoID drug response assay reports a prioritized list of effective and ineffective chemotherapies. The test is designed to target cancer stem cells to mitigate tumor relapse."
70579|NCT03632135|Drug|Chemotherapy|Chemotherapies chosen by Physician or ChemoID assay are in the same list of FDA approved drugs to treat recurrent ovarian cancer
70580|NCT03632109|Drug|gentamicin 360mg IM|360mg IM of gentamicin
70581|NCT03632096|Radiation|Photobiomodulation|The parameters are: Laser Diode ArGaAl, DMC, 808nm, 4J per point, continuously and in contact with the irradiated surface, resulting in irradiance of 3571 mW/cm2, distributed as follows: 6 points in each parotid, 2 points in each sublingual (external) and two in each submandibular (internal), totaling 16 extra oral and 4 intra oral, totaling 20 points. The exposure time will be 40s per point, corresponding to 800s per session and 3600s at the end of the four treatment sessions. The radiant exposure will be 142J/cm2.
70582|NCT03632096|Radiation|Sham|The sham group will have a simulation of laser application, following the same procedures as the active group, but with the device switched off.
70583|NCT03632083|Device|Hy-Care Contact Lens Solution|Hy-Care Contact Lens Solution
70584|NCT03632083|Device|Lite Contact Lens Solution|Lite Contact Lens Solution
70585|NCT03632083|Device|fanfilcon A soft contact lens|fanfilcon A soft contact lens
70586|NCT03632083|Device|comfilcon A soft contact lens|comfilcon A soft contact lens
70587|NCT03632070|Behavioral|Data acquisition of functional abilities|MRI data, motor evoked potentials, and behavior data acquisition
70588|NCT03632057|Device|Fixed Tilt (65%)|This is the standard group, so device programming for shock energy is the default setting
70589|NCT03632057|Device|Fixed Pulse Width|The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
70590|NCT03632044|Drug|Ropivacaine|A single injection into the pterygopalatine fossa bilaterally of 0.2% ropivacaine at a dose of 0.15 mL/kg (block) after the induction of general anesthesia
70591|NCT03632044|Other|Sham Comparator|The subcutaneous placement of a 25 Gauge needle as a sham control after the induction of general anesthesia. Nothing will be injected.
70592|NCT03632031|Device|Oasis extracellular matrix|Use of Oasis ECM for the treatment of non-healing ulcers
70593|NCT03632018|Behavioral|HEART-PLAY|Participants assigned to the HEART-PLAY intervention will receive standard CR. Additionally, they will receive pedometers, group education, and educational materials introduced by peer Health Coaches for 12 months. Before or after their regularly scheduled CR appointments, they will meet at the clinic as a group twice per week to receive Health Tips and participate in discussions. At 8 weeks in to the 12-week CR, they will begin to discuss with their peer Health Coaches the transition from the formal CR setting into community-based exercise. As part of this transition, peer Health Coaches will slowly introduce group community walks and train participants in the proper use of resistance bands. Health Coaches will have talk with their assigned participants about relapse prevention and sustaining exercise following the termination of formal CR.
70594|NCT03632018|Behavioral|Standard Cardiac Rehabilitation|During the 12-week intervention period, the STANDARD intervention participants will receive standard of care by attending the 36 sessions of standard CR as prescribed by his/her physician and administered by the Step Clinic.
70595|NCT03632005|Device|Vacuum Assisted Closure|Patients will be randomized to receive either standard dressing changes or the Prevena™ System on the day of their operation.
70596|NCT03632005|Other|Sterile dressing|Standard wound care involves the application of an occlusive dressing in the operating room, a dressing change on Post-operative Day 3 and then dressing changes as needed until suture/staple removal on Post-operative Day 14.
70597|NCT03631992|Behavioral|Low Sweet|Children in the experimental group get repeated exposure to lower sweet snacks and mothers get education lessons on dental care, reading food labels, portion size, and nutrition.
70598|NCT03631992|Behavioral|Regular Sweet|Children in sham comparator get typical snacks and mothers get education lessons on portion size, physical activity, sleep, and screen time.
70599|NCT03631979|Other|Intestinal lavage with normal saline|Specially trained pediatric surgeon will administer 10ml/kg pre-warmed (37oC) normal saline via a single-use rectal tube of size 6FR twice per day, aiming at a depth of maximum 10 cm/kg, starting after randomization and not later than 24 hours of age, and continued until full enteral nutrition of 170ml/kg/day is achieved or NEC diagnosis (Bell stage II or more) is established, which one comes first. However, the intervention will be applied at a maximum of 2 weeks from birth.
70600|NCT03631966|Drug|Dysport|BTX-A (Dysport-Ipsen Inc.) will be injected into the proximal third of the medial and lateral gastrocnemius muscles of the symptomatic leg(s). Total dose per leg will be 400 units, 200 per injection site. Injections will be performed with the aid of real-time ultrasound (Sonosite, Bothwell, WA) guidance.
70601|NCT03631953|Drug|Trametinib|Trametinib administered at a fixed dose (1.5 mg daily)
70602|NCT03631953|Drug|Alpelisib|A panel of 3 doses of ALPELISIB could be tested
70603|NCT03631953|Biological|Blood sample|Therapeutic biomarkers
70604|NCT03631953|Device|MRI|A MRI with contrast will be performed before treatment start. Assessment of tumor growth.
70605|NCT03631940|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
70606|NCT03631940|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
70839|NCT03630133|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
70607|NCT03631914|Procedure|Infraclavicular brachial plexus block|An infraclavicular brachial plexus block is performed using ultrasound guidance.
70608|NCT03631901|Drug|oral melatonin|Both melatonin and diazepam were given only during the febrile illness.
70609|NCT03631901|Drug|oral diazepam|Both melatonin and diazepam were given only during the febrile illness.
70610|NCT03631888|Diagnostic Test|preoperative abdominal ultrasound examination|Performing preoperative abdominal ultrasound examination in patients that will be scheduled for elective laparoscopic surgery for any gynecologic indication
70611|NCT03631875|Drug|Ketamine|use a low dose 0.5 mg/kg of ketamine in coinduction with propofol in children induction anesthesia
70612|NCT03631862|Drug|Apatinib|Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
70613|NCT03631862|Drug|CHOP Regimen|CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
70614|NCT03631849|Procedure|peri implantitis sanitation surgery|"an intrasulcular vestibular and lingual / palatal incision with respect to the implant-supported restoration involved is performed, it extends to at least one tooth on either side in order to give laxity to the flap. The use of an incision of discharge will be necessary if the muco-periosteal detachment of the flap (that is to say of full thickness) is considered insufficient to access and unclamp the peri-implant lesion.~Then, the debridement will be carried out using manual curettes in titanium: the products (waste) removed with this curette will constitute the peri-implant pocket specimens. This sample will be deposited in a Roswell Park Memorial Institute Medium (RPMI) supplemented with serum.The surface of the titanium implant will then be disinfected with betadine, or with hydrogen peroxide for patients with an allergy to polyvidone iodine.~The flap will then be repositioned and sutured with simple stitches made with a resorbable suture of Vicryl type 5.0."
70615|NCT03631849|Other|Care|descaling and maintenance of implants
70616|NCT03631836|Drug|Monoclonal antibody|3 doses of Monoclonal antibody could be tested
70617|NCT03631836|Drug|Bevacizumab|fixed dose of bevacizumab (10 mg/ kg every two weeks)
70618|NCT03631836|Biological|Blood sample|Evaluate the biomarkers plasma levels during administration of drug
70619|NCT03631836|Device|Dynamic Contrast Enhanced magnetic resonance imaging (DCE-MRI)|Assess antiangiogenic effects by DCE-MRI
70620|NCT03631823|Other|Chemotherapy with temozolomide or no chemotherapy|This study is just an observational study.
70621|NCT03631797|Procedure|Microvascular reactivity evaluation|Microcirculation will be evaluated for each patient before surgery with a laser speckle contrast imaging (LSCI) placed on the forearm. Tests will be performed for evaluation of endothelium reactivity: Iontophoresis.
70622|NCT03631784|Drug|Pembrolizumab 200 mg|Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
70623|NCT03631784|Drug|Paclitaxel 45 mg/m^2|Paclitaxel 45 mg/m^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
70624|NCT03631784|Drug|Carboplatin AUC6|Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
70625|NCT03631784|Drug|Cisplatin 75 mg/m^2|Cisplatin 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
70626|NCT03631784|Drug|Pemetrexed 500 mg/m^2|Pemetrexed 500 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
70627|NCT03631784|Radiation|Thoracic Radiation Therapy (TRT)|The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
70628|NCT03631784|Drug|Paclitaxel 200 mg/m^2|Paclitaxel 200 mg/m^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
70629|NCT03631784|Drug|Carboplatin AUC2|Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
70630|NCT03631771|Drug|Iohexol|Iohexol administered intravascularly
70631|NCT03631771|Drug|Iodixanol|Iodixanol administered intravascularly
70632|NCT03631771|Drug|Iopromide|Iopromide administered intravascularly
70633|NCT03631771|Drug|Ioversol|Ioversol administered intravascularly
70634|NCT03631758|Other|Evidence-based information|Evidence-based information on mammography such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
70635|NCT03631758|Behavioral|Patient Decision Aid|Patient Decision Aid for breast cancer screening decision
70636|NCT03631758|Other|Sham information|Educational information not specific to mammography or cancer screening
70637|NCT03631745|Behavioral|NAMI Mental Health 101 and NAMI FaithNet|"Congregants of Intervention Churches will receive:~NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families."
70638|NCT03631732|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
70639|NCT03631732|Drug|NRTIs|"NRTIs could include one of the following:~Abacavir (ABC)~Didanosine (ddI)~Emtricitabine (FTC)~Lamivudine (3TC)~Stavudine (d4T)~Tenofovir alafenamide (TAF)~Tenofovir disoproxil fumarate (TDF)~Zidovudine (ZDV or AZT)~NRTIs will be administered as prescribed until Week 24 without regard to food."
70640|NCT03631732|Drug|Third Agent|"Third agent could include one of the following:~Non-nucleoside reverse transcriptase inhibitors (NNRTIs)~Delavirdine (DLV)~Efavirenz (EFV)~Nevirapine (NVP)~Rilpivirine (RPV)~Integrase inhibitors~Dolutegravir (DTG)~Elvitegravir (EVG)~Raltegravir (RAL)~Protease inhibitors (PIs)~Atazanavir (ATV)~Darunavir (DRV)~Lopinavir~Nelfinavir NFV)~Saquinavir (SQV)~Tipranavir (TPV)~Third agents will be administered as prescribed without regard to food. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir."
70641|NCT03631719|Biological|Wolbachia-carrying Ae.aegypti mosquitoes|Wolbachia-infected Ae. aegypti mosquito eggs and adults sequentially deployed into Medellin and Bello, Colombia. Deployments cease once Wolbachia prevalence has reached a predetermined frequency (usually ≥60%).
70642|NCT03631706|Drug|M7824|Participants will receive an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks starting from Day 1 up to disease progression.
70643|NCT03631706|Drug|Pembrolizumab|Participants will receive an intravenous infusion of 200 mg Pembrolizumab once every 3 weeks starting from Day 1 up to disease progression.
70975|NCT03629067|Drug|Treatment R|Co-administration of Fimasartan/Amlodipine and Hydrochlorothiazide
70644|NCT03631693|Procedure|Simplified papilla preservation flap|The simplified papilla preservation flap (SPPF) surgery is a conservative surgical procedure aimed at the preservation of the tissues between the teeth providing access for the debridement of the root surface in sites with residual pockets.
70645|NCT03631693|Procedure|Resective periodontal flap with osseous recontouring|The Resective periodontal flap with osseous recontouring (RPFO) is a surgical procedure that achieves predictable pocket depth reduction by soft and hard tissue resection to obtain a more convenient soft and hard tissue architecture for oral hygiene.
70646|NCT03631680|Procedure|Bilateral Oophorectomy Surgery|Women undergoing elective, laparoscopic bilateral oophorectomy surgery will be enrolled.
70647|NCT03631667|Drug|[14C]-benzo[a]pyrene|Oral micro-dose (50 ng) (5.4 nCi)
70648|NCT03631667|Drug|[14C]-benzo[a]pyrene plus phenanthrene|Oral micro-dose of 50 ng (5.4 nCi) [14C]-benzo[a]pyrene plus 1250 ng phenanthrene
70649|NCT03631654|Drug|Ivabradine|Ivabradine administration--tablets given 5 mg twice daily for 2 weeks, then 7.5 mg twice daily
70650|NCT03631654|Drug|Placebos|Placebo
70651|NCT03631641|Biological|Nivolumab|Given IV
70652|NCT03631628|Device|Transcutaneous electrical nerve stimulation (TENS)|TENS will be delivered to the median and radial nerves at the wrist regions. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
70653|NCT03631628|Behavioral|Mirror Therapy (MT)|"A customised angle-adjustable frame with a mirror board will be used. All subjects are instructed to perform~Wrist flexion and extension exercise~Forearm pronation and supination exercise~Gripping exercises~Fingers opposition exercises bilaterally during the 30 minutes period."
70654|NCT03631628|Behavioral|sham-Mirror Therapy (sham-MT)|"A customised angle-adjustable frame with a mirror board will be used while the reflecting surface of the mirror was covered with paper. All subjects are instructed to perform~Wrist flexion and extension exercise~Forearm pronation and supination exercise~Gripping exercises~Fingers opposition exercises bilaterally during the 30 minutes period."
70655|NCT03631628|Behavioral|Conventional Rehabilitation Program|All subjects attended 1 hour multi-disciplinary conventional rehabilitation program offered by the Rehabilitation Clinic of The Hong Kong Polytechnic University. The conventional rehabilitation program involves the training of upper and lower limbs in order to improve the muscle strength, balance and functional mobility.
70656|NCT03631615|Drug|Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)|"Patients will be given the perioperative treatment as below once recruited:~induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery."
70657|NCT03631602|Drug|antifungal prophylaxis|posaconazole oral suspension vs itraconazole oral solution
70658|NCT03631589|Biological|MSCs|mesenchymal stem cells therapy
70659|NCT03631576|Biological|CD123/CLL1 CAR-T Cells|CD123/CLL1 CAR-T Cell Therapy
70660|NCT03631563|Drug|Immunosuppressive Agent|ATG-Fresenius versus ATG
70661|NCT03631537|Other|NST group|Nutrition-support-team based intervention on nutrition, including dietary supplement, parenteral nutrient solutions and patient education
70662|NCT03631524|Device|Telerehabilitation|The treatment arm will be given up to 1 hour of physiotherapist-prescribed resistive training exercises administered via a telerehabilitation device per day in addition to standard therapy for a total of 10 sessions over a 2 week period.
70663|NCT03631511|Procedure|direct pulp capping with RetroMTA|The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
70664|NCT03631485|Other|Exposure_having children with cancer|No intervention. The exposure is having children with cancer.
70665|NCT03631472|Device|RheOx|RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
70666|NCT03631459|Drug|Kanglaite Injection/Capsules|Kanglaite injection 200 mL, iv. gtt qd×7d or more, followed by Kanglaite capsule 0.45g×6 tablets qid po×14d as one cycle for at least 4 cycles
70667|NCT03631446|Drug|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Combination powder for oral solution
70668|NCT03631433|Drug|Ibuprofen 600 mg|identical appearing tablets containing 600 mg of ibuprofen
70669|NCT03631433|Drug|ibuprofen 600 mg and acetaminophen 650 mg|identical appearing tablets of the combination of ibuprofen and acetaminophen
70670|NCT03631420|Biological|Human Umbilical Cord Derived-Mesenchymal Stem Cells|Cohort 1 : 3 million cells/kg ; Cohort 2 : 10 million cells/kg ; Cohort 3 : 30 million cells/kg
70671|NCT03631407|Drug|Vicriviroc|Vicriviroc tablets administered orally, QD at dose level 1 or 2.
70672|NCT03631407|Biological|Pembrolizumab|Pembrolizumab administered by IV infusion at 200 mg Q3W, given on cycle day 1.
70673|NCT03631394|Other|beetroot and anthocyanin|Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
70674|NCT03631394|Other|beetroot and placebo|Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
70675|NCT03631368|Drug|Botox|Intradermal injection with Botox 100U/mL will be performed using a 25g needle. Each subject will receive three treatments spaced 1 month apart.
70676|NCT03631355|Drug|Tranexamic Acid|One gram of intravenous tranexamic acid will be administered before tourniquet inflation and 1 gram of IV TXA before closure of the incision.
70677|NCT03631342|Other|VCV20|controlled volume ventilation mode under constant flow of 20 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
70678|NCT03631342|Other|VCV40|volume controlled ventilation mode under constant flow of 40 Lpm. The inspired volume was progressively increased until the Pmax reached 40cmH2O.
70976|NCT03629054|Drug|Empagliflozin (fixed dose combination)|single dose
70679|NCT03631342|Other|PCV|controlled ventilation mode, 1 second inspiratory time. The inspiratory pressure was increased every 5 cmH2O, until reaching the maximum pressure of 40 cmH2O.
70680|NCT03631342|Other|PCV+Tins|controlled ventilation and inspiratory pressure was increased every 5 cmH2O until the maximum pressure was 40 cmH2O. The inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP.
70681|NCT03631342|Other|PSV|ventilatory mode with pressure support, with progressive increases of 5 cmH2O at inspiratory pressure, until reaching Pmax of 40 cmH2O. The expiratory sensitivity was adjusted by 25% for all patients.
70682|NCT03631329|Diagnostic Test|Doppler sonographic measurement|First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
70683|NCT03631316|Drug|Generic Valganciclovir|900 mg daily during 4 days
70684|NCT03631316|Drug|Innovative Valganciclovir|900 mg daily during 4 days
70685|NCT03631303|Device|Cardiac stimulation through the device leads|During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
70686|NCT03631290|Behavioral|Deprescribing Intervention|Participants who are taking specific potentially inappropriate medications and their nephrologist will be engaged in the deprescribing process. The process involves deprescribing decision-making, implementation of deprescribing, and monitoring for adverse drug withdrawal events. The specific details of the deprescribing process are TBD.
70687|NCT03631277|Device|photo-activated oral disinfection|Application of PAD solution using disposable tip with agitation of the solution for 60 seconds using a brush; Placement of the light disposable tip in center of lesion and holding it just above the surface; Activation of the red light for 60 seconds; (h)Sealing the cavity with glass ionomer and then filling with composite resin as a final restoration
70688|NCT03631277|Drug|Calcium Hydroxide|calcium hydroxide( Dycal ® Dentsply Caulk )was applied using calcium hydroxide applicator followed by glass ionomer and then composite resin as a final restoration
70689|NCT03631264|Device|Kinesiotape|Kinesiotape application to masseter and hyoid muscles of late preterm infants to improve sucking and swallowing.
70690|NCT03631251|Drug|Open Placebo|Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
70691|NCT03631238|Diagnostic Test|Blood sampling for total cholesterol and homocysteine and cognitive assessment by psychometric tests.|"all participant are subjected to cognitive assessment by psychometric tests by using the arabic version of Mini Mental State Exam (MMSE) and Memory Assessment Scale (MAS).~Blood samples were collected in the morning using 10 mL yellow top (plain) Vacutainer tubes.~Lipid profile (triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)) were measured by Assiut university labs using Cholesterol Kits and analyzed by COBAS Integra analyzer.~Total cholesterol levels were calculated using the sum of the LDL and HDL plus one-fifth of triglyceride levels.~Samples of serum homocysteine are collected, centrifuged to separate plasma within 30 minutes after venipuncture and stored in specialized container in the Department of Clinical Pathology at (-20◦C) temperature.~Total homocysteine was measured by ELISA technique, Sinogen kits (Research Use Only) and Statfax-2100 microplate analyzer."
70692|NCT03631225|Diagnostic Test|Vectra DA|Each arm will have the Vectra DA test however, scores will not be provided for the Usual Care Arm until end of study (12 month time point)
70693|NCT03631212|Behavioral|Flexiquit|Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
70702|NCT03631186|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
70703|NCT03631173|Procedure|Surgical og radiological intervention, antibiotics|Intervention might be a new drainage catheter, replacement of old drainage catheter, reoperation, somatostatin- and antibiotic administration.
70704|NCT03631160|Device|TAES treatmen|"In the acupoints group patients are treated with low-frequency pulse electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) at SP6 and BL 32 points during the operation in the operating room ,and at CV3 and CV4 acupoints for 45 minutes in postanesthesia Care Unit. After Deqi, electroacupuncture stimulation apparatus is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 milliamp (mA) (gradually increase to the patient's maximum tolerance) and maintained until the end of treatment."
70705|NCT03631160|Device|Sham TAES treatmen|"Participants in the acupoints group receive shallow acupointing at SP6, BL 32 ,CV3 and CV4 (nonacupoints located 1 inch beside acupoints, about 20mm).Specifically, the acupoint is shamed without manual stimulation and Deqi and the stimulation apparatus is inefficiency without actual current output ."
70706|NCT03631147|Drug|Rifaximin|400mg bid for 8 weeks
70707|NCT03631134|Drug|SGLT2 inhibitor|Patients will be gave SGLT2 inhibitor 10mg per day
70708|NCT03631121|Drug|Basalin to Lantus|continuous glucose monitoring system will used twice when patients are using Basalin and Lantus respectively to assess glycemic variation.
70709|NCT03631108|Diagnostic Test|OCTA (ZEISS)|All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens.
70710|NCT03631082|Other|Slump stretching|Slump stretching will be provided to this group along with standardized exercises.
70711|NCT03631082|Other|Lumbar mobilization|Lumbar mobilizations will be provided to this group along with standardized exercises.
70712|NCT03631043|Procedure|Biopsy Specimen Radiography|Undergo collection of blood and bone marrow
70713|NCT03631043|Biological|Vaccine Therapy|Given personalized vaccine SC
70714|NCT03631030|Device|Cooled radiofrequency ablation|Cooled Radiofrequency ablation (CRFA) is a well-established method for delivering lesions into nervous tissue to accomplish neurotomy procedures
70715|NCT03631017|Drug|[18F]- PARPi|injection of a microdose (< 100 ug) of [18F]- PARPi
70716|NCT03631017|Diagnostic Test|PET/CT Scans|"Patients will be injected with approximately 10 mCi of [18F]PARPi and a dynamic PET scan of will be acquired for approximately 30 minutes. A second body PET/CT scan will be started approximately 60 min post injection, and a third PET/CT scan will be started at approximately 120 min post injection. The first (dynamic) and the second (body) PET/CT scan will use ultra -low dose CT scan for attenuation correction. The last PET/CT scan will be performed with the investigator's regular clinical low-dose CT settings."
70717|NCT03631004|Drug|Olanzapine|olanzapine 10 mg is given before surgery
70718|NCT03630991|Drug|Edetate Calcium Disodium|Given IV
70719|NCT03630991|Dietary Supplement|Multivitamin|Given PO
70720|NCT03630991|Drug|Succimer|Given PO
70721|NCT03630978|Procedure|Liver resection|Major or minor, open or laparoscopic liver resection
70722|NCT03630965|Other|CPR Video|"A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale."
70723|NCT03630952|Biological|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based pro re nata (PRN) approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
70724|NCT03630952|Biological|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
70725|NCT03630952|Biological|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) through Week 36. At the Week 40 visit, the criteria-based PRN approach will begin through the end of the treatment period at Week 92, for a total of 92 weeks treatment in the study eye.
70726|NCT03630939|Drug|ESR-114|ESR-114 Topical Gel
70727|NCT03630939|Other|Placebo|Placebo Topical Gel
70728|NCT03630926|Diagnostic Test|NV-VPAC1 PCa Urine Diagnostic Test|The NV-VPAC1 PCa Urine Diagnostic Test is intended for use by clinicians to detect the presence of prostate cancer cells shed in voided urine of men at risk for prostate cancer.
70729|NCT03630913|Procedure|Tagged axillary metastatic node|"First, initially metastatic lymph node is tagged with a metal clip under sonography. Then, patients receive NAC before surgery.~Breast surgery (conservative or radical) and axillary surgery are performed during the same procedure, 4 to 6 weeks after completion of NAC.~SLN isotope detection is performed with or without blue dye. All patients undergo the resection of the tagged axillary node, SLN biopsy and a complementary axillary lymphadenectomy."
70730|NCT03630900|Other|Sequential O2 Culture|We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
70731|NCT03630887|Device|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied in the preanesthetic room during different time periods.
70732|NCT03630874|Other|Evaluate the impact of a prescription support tool|"From a systematic review of international guidelines (2012-2018), we developed a prescription support-tool synthesizing national and international guidelines on chronic management (≥ 1 month) of oral AT agents without considering in-hospital management and bridging therapy.~In the experimental group, the tool will be provided with an explanatory guide. Selected physicians will receive 3 different clinical vignettes, each corresponding to a specific situation for which the physician will have to indicate (thanks to the tool) the right prescription of ATs by answering a multiple-choice question, with the number, type, duration and dosage of AT provided."
70733|NCT03630848|Other|Effect of Protein on Blastocyst Development|Embryo Development Related to The Protein Concentration
70734|NCT03630835|Other|99mTc-Annexin-V-128 uptake on scintigraphy|"An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours."
70735|NCT03630822|Behavioral|Psychiatric Advanced Directive|The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry.
70736|NCT03630822|Behavioral|Standard care|standardized maintenance with the patient
70873|NCT03629873|Drug|Chidamide|Chidamide 30mg po d-7、-4、0、3; Carmustine 300mg/m^2 IVD d-6; Etoposide 150mg/m^2/d qd IVD d-5~-2; Cytarabine 150mg/m^2 q12h IVD d-5~-2; Cyclophosphamide 1.0g/m^2/d qd IVD d-5~-2
70737|NCT03630809|Biological|HER2 DC1 Vaccine|Ultrasound (US) guided intranodal delivered vaccines will be administered at each participating site by a radiologist experienced in ultrasound guided procedures along with the principal investigator or his/her designee. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1 right and 1 left normal groin lymph nodes.
70738|NCT03630796|Drug|Sevoflurane|Use of sevoflurane (compared to total intravenous anesthesia) in congenital heart deffects surgeries.
70739|NCT03630796|Drug|TIVA|Total intravenous anesthesia
70740|NCT03630783|Behavioral|Combined Cognitive Bias Modification|
70741|NCT03630770|Drug|Medium-Chain Triglyceride (MCT) Oil|Infants receive 0.5 ml/oz of MCT oil to their prescribed feedings for 21 days or until hospital discharge.
70742|NCT03630757|Other|Treatment|In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
70743|NCT03630744|Other|Fluid therapy|"Analyze the type of fluid administered:~crystalloids:~Saline serum 0.9% ....... ml~Ringer Lactate ........ ml~Isofundin ® ........ ml~Plasmalyte® ... ... ml~Glucose Serum 5% ....... ml~Glucose serum 10% ........ ml~Glucosaline serum ........ ml~colloids:~Hydroxyethyl starch 130 / 0.4 ... ... ml~Hydroxyethyl alimdon 130 / 0.42 ... .... ml~Gelatins ... ....... ml~Albumin 5% .......... ml~Albumin 20% .......... ml.~Analyze the total amount of crystalloids and liquid colloids administered in 24 hours in milliliters.~Analyze the form of administration:~Standard~Standard with dosimeters~on pump"
70744|NCT03630731|Drug|chidamide|For those who responded to induction chemotherapy, chidamide will be given OR orally 30mg biw for at least half a year
70745|NCT03630718|Behavioral|Psychoeducational Intervention|"The psychoeducational intervention will be a structured education programme and will consist of informing patients about fatigue dimensions, aetiology and treatments, by helping them to develop strategies to cope with fatigue better and by teaching them to manage the balance between activities and rest.~The construction of the contents of the sessions of this intervention will aim to reduce fatigue via the programme developed by Reif et al. in cancer patients and is composed of 6 sessions of 90 minutes, one session per week. It is a group intervention for 8 patients. For this project, the investigators have reorganised the sessions and their content to fit with an individual format adapted to PBC. This format is more appropriate to take into account the specificity of the manifestation of fatigue for each patient."
70746|NCT03630718|Behavioral|Hypnosis intervention|"The hypnosis intervention will consist of decreasing fatigue and the related distress, and increasing feelings of energy and well-being.~Therefore, each hypnosis exercise will be audiotaped and given to the patient at the end of the session. Patients will be asked to use these recordings as much as they want to help them to manage fatigue. The techniques used are inspired by those used in chronic pain management and fatigue."
70747|NCT03630705|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine|Pharmaceutical form:liquid solution; route of administration: intramuscular
70748|NCT03630705|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|Pharmaceutical form: lyophilized powder combined with liquid component; route of administration: intramuscular
70749|NCT03630705|Biological|Measles, Mumps, and Rubella Virus Vaccine Live|Pharmaceutical form: lyophilized live virus vaccine; route of administration: subcutaneous
70750|NCT03630705|Biological|Varicella Virus Vaccine|Pharmaceutical form: suspension for injection; route of administration: subcutaneous
70751|NCT03630705|Biological|Pneumococcal 13-valent Conjugate Vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular
70752|NCT03630705|Biological|Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular
70753|NCT03630705|Biological|Diphtheria, Tetanus, Pertussis (Acellular, Component) Poliomyelitis (inactivated) Vaccine, and Haemophilus influenza type b Conjugate Vaccine|Pharmaceutical form: powder and suspension for injection; route of administration: intramuscular
70754|NCT03630705|Biological|Hepatitis B Vaccine|Pharmaceutical form: suspension for injection; route of administration: intramuscular
70755|NCT03630705|Biological|Rotavirus Vaccine, Live, Pentavalent|Pharmaceutical form: oral solution; route of administration: oral
70756|NCT03630705|Biological|Japanese encephalitis vaccine (live, attenuated)|Pharmaceutical form: powder and diluent for suspension for injection; route of administration: subcutaneous
70757|NCT03630692|Drug|observance of oral drug treatment|Completion of questionnaires at 4 times during patient's oral route drug treatment
70758|NCT03630666|Drug|IADT|Patient will receive one injection of IADT at randomization
70759|NCT03630666|Combination Product|IADT + radiotherapy|Patient will receive one injection of IADT at randomization then will receive irradiation 3 months after injection of IADT
70760|NCT03630653|Procedure|Sentinel LN in breast cancer recurrence|Sentinel Lymph-Node (LN) procedure and Axillary LN dissection ; Mastectomy or breast conservative surgery
70761|NCT03630640|Drug|Nivolumab Injection [Opdivo]|Intravenous Nivolumab 240 Q2W neoadjuvant Intravenous Nivolumab 480 mg Q4W- adjuvant up to 12 months after EP
70762|NCT03630627|Drug|SB26|SB26 administered intravenously
70763|NCT03630627|Drug|Placebo|Placebo administered intravenously
70764|NCT03630614|Drug|Electronic cigarette without nicotine (ECwN) plus active varenicline tablets|"The ECwN group use EC liquids containing 0 mg/mL of nicotine. Because nicotine delivery can be adjusted according to the user's need, all participants are able to adjust their individual nicotine dose by varying the wattage of their EC, by varying puff frequency and puff volume similarly as they are doing (or used to do) with conventional cigarettes.~EC device:~Mini iStick kit (20 W) Eleaf Clearomiser :GS Air M with resistance of 1.5 ohm, the clearomiser's Pyrex window is of blue colour not allowing to distinguish an eventual coloration of the e-liquid containing nicotine. Liquids for EC use are delivered in white opaque 10 mL vials not allowing to distinguish the color of the liquid.~Varenicline, Champix® 0.50 mg tablets Posology of vareniclin follows varenicline's monograph."
70874|NCT03629860|Procedure|Atrophic maxillary alveolar ridge augmentation|Autogenous bone blocks from chin and ascending ramus are obtained and used for reconstruction of atrophic maxillary ridges
70875|NCT03629847|Drug|Everolimus|Drug: Everolimus will be administrated in combination with the intravenous radiolabelled Lu-177 DOTATATE therapy.
70765|NCT03630614|Drug|Electronic cigarette without nicotine (ECwoN) plus placebo tablets of varenicline|"The ECwoN group receives EC liquids with 0 mg/mL of nicotine on a double blind manner (in identical non-transparent refill bottles of 10 mL).~Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph."
70766|NCT03630614|Drug|Electronic cigarette with nicotine (ECwN) plus placebo tablets of varenicline|The ECwN group use EC liquids containing 12 mg/mL of nicotine. Placebo of varenciline The placebo of varenicline is presented as a capsular-shaped, biconvex, white film-coated tablet. Posology of varenicline or its placebo follows varenicline's monograph.
70767|NCT03630601|Procedure|Photoacoustic Imaging|Undergo PAI
70768|NCT03630588|Combination Product|Surimi intervention|"The bioactive compounds used to obtain the surimi product are:~Inulin (3.4 grams per 100 grams of surimi, 1.7 grams per 50 grams of surimi): Obtained from Chicory originating in Europe.~EPA + DHA (740 mg per 100 g of surimi, therefore 370 mg per 50 g): Obtained from sardine and anchovy fish oil, encapsulated in tilapia gelatine, originating in the United States.~Probiotic BPL1~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi."
70769|NCT03630588|Combination Product|Placebo|"Conventional surimi~It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi."
70770|NCT03630575|Procedure|Umbilical cord blood and hair collection|At the birth of the newborn, a first hair sample and a cord blood sample will be taken. A follow-up of the newborn will be performed between 4 and 6 months in order to obtain a second hair sample.
70771|NCT03630562|Procedure|Aqueous humor samples collection|In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.
70772|NCT03630549|Other|Standard of Care|Clinic-based HIV care
70773|NCT03630549|Other|Village-based ART refill|Option to get ART refill and care by the village health worker
70774|NCT03630523|Biological|Influvac Tetra|Tetravalent seasonal flu vaccination 2018/2019
70775|NCT03630510|Other|Ventilator hyperinflation|The ventilator hyperinflation maneuver with inspiratory time adjustment was performed in the pressure controlled ventilation mode (PCV). The inspiratory pressure was increased gradually every 5 cmH2O until reaching a maximum pressure of 35 cmH2O, according to the tolerance of the patient determined by the absence of cough. PEEP remained unchanged throughout the study. After reaching a maximum pressure of 35 cmH2O (PCV + PEEP level), the inspiratory time was gradually increased until the inspiratory flow reached the baseline. Concomitantly, the respiratory rate was decreased to allow the expiratory flow also to reach the baseline, to avoid self-PEEP. The maneuver was performed for 5 min, followed by tracheal aspiration.
70776|NCT03630497|Drug|Comparison of BN201 treatment with Placebo|Single Dose or Multiple Dose of BN201 IV administration
70777|NCT03630484|Other|Expiratory Rib Cage Compression|Compression was performed in 6 sets of 6 cycles, with 1 cycle interval. Ventilatory mode and parameters were maintained.
70778|NCT03630484|Other|Compression + Ventilator Hyperinflation|Mechanical ventilator hyperinflation was performed by increasing the inspiratory pressure to every 5 cmH2O until the total pressure reached 40 cmH2O, remaining the same. In Expiratory Rib Cage Compression associated with ventilator hyperinflation, thoracic compression maneuver was performed at the end of inspiration, at the exact moment of cycling.
70779|NCT03630471|Behavioral|PRIDE 'Step 1' problem-solving intervention|"The PRIDE problem-solving intervention is one component of the PRIDE stepped care treatment architecture which comprises two sequential treatments of incremental intensity. 'Step 1' is a brief, first-line treatment. It is grounded in stress-coping theory, with a technical focus on practical problem-solving to modify developmentally salient stressors.~Step 1 has been designed as a 'low-intensity' intervention requiring fewer resources than conventional psychological treatments. This is achieved through a relatively brief delivery schedule (up to 5 x 20-30-minute sessions spread over approximately 3 weeks) and limited requirement for specialists. The delivery agents are lay counsellors receiving a combination of specialist and peer supervision. The counsellors offer guidance sessions to support the learning and implementation of problem-solving and complementary coping skills. Illustrated booklets are used to support learning of problem-solving concepts and skills practice at home."
70780|NCT03630471|Behavioral|Enhanced usual care|There is no established mental health service provision in the collaborating schools. The control arm participants will receive an enhancement of this 'usual care' (essentially, no care) by having access to the same illustrated booklets used in the Intervention arm, albeit without any counsellor contact.
70781|NCT03630458|Other|Pearl millet couscous - made in Senegal|Pearl millet couscous (made in Senegal) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
70782|NCT03630458|Other|Pearl millet couscous - made in USA|Pearl millet couscous (made in USA) was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
70783|NCT03630458|Other|Pearl millet thick porridge|Pearl millet thick porridge was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
70784|NCT03630458|Other|Wheat couscous|Wheat couscous was tested for gastric emptying rate, glycemic response, fermentability, and appetitive response.
70785|NCT03630458|Other|White rice|White rice was tested as a comparator for gastric emptying rate, glycemic response, fermentability, and appetitive response.
70786|NCT03630445|Other|Isomaltooligosaccharides (IMOs)|Isomaltooligosaccharides (IMOs) incorporated into yogurt were tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
70787|NCT03630445|Other|Xtend® sucromalt|Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
70788|NCT03630445|Other|Combination of IMOs and Xtend® sucromalt|A combination of IMOs and Xtend® sucromalt incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
70789|NCT03630445|Other|Raw corn starch|Raw corn starch incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
70790|NCT03630445|Other|Maltodextrin|Maltodextrin incorporated into yogurt was tested for gastric emptying rate, glycemic response, appetitive response, and fermentability.
70876|NCT03629834|Diagnostic Test|Epworth Sleepiness Scale|Maintenance Wakefulness Test
70977|NCT03629054|Drug|Linagliptin (fixed dose combination)|single dose
70791|NCT03630432|Behavioral|Pulmonary rehabilitation|"The pulmonary rehabilitation course will be provided on a rolling basis and for each individual will be of 8 weeks duration including once weekly, 1.5 hour hospital sessions and encouragement to perform twice weekly home exercise sessions. Hospital sessions will include 1 hour of supervised exercise and 30 minutes education.~Exercise Component: This will include a combination of aerobic, resistance and flexibility training.~Educational Component will cover many topics including what is asthma, treatments and inhaler technique, self-management, importance of exercise and health promotion.~On completion of the formal pulmonary rehabilitation course, participants will be encouraged to continue regular exercise sessions by accessing community based Vitality Classes."
70792|NCT03630432|Other|Usual Care|Usual Care
70793|NCT03630419|Dietary Supplement|Mito-Food Plan|Specialized anti-inflammatory diet plan based on subject's physiological results
70794|NCT03630419|Other|Cellular Repair Therapy|the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
70795|NCT03630406|Diagnostic Test|Vaginal Tactile Imaging|Vaginal Tactile Imaging
70796|NCT03630393|Other|Pneumoperitoneum Pressure 6 mmHg|A pneumoperitoneum insufflation pressure of 6 mmHg will be used during RALP.
70797|NCT03630393|Other|Pneumoperitoneum Pressure 15 mmHg|A pneumoperitoneum insufflation pressure of 15 mmHg will be used during RALP.
70798|NCT03630380|Other|Clinical History|We will collect clinical history for each patient (days of illness, history of fever, cough, difficulty breathing, vomiting, chest pain).
70799|NCT03630380|Other|Physical Exam Findings|We will collect physical exam findings including vital signs, WHO criteria for diagnosing pneumonia, and lung auscultation findings.
70800|NCT03630380|Other|Laboratory Findings|We will collect laboratory findings (white blood cell counts, differential, and c-reactive protein) if ordered by the clinician.
70801|NCT03630380|Other|Lung Ultrasound|We will perform lung ultrasound on all patients.
70802|NCT03630367|Drug|Dexamethasone|Intramuscular injection 8 mg
70803|NCT03630367|Drug|L-Carnitine 1G/5mL Injection|slow intravenous injection
70804|NCT03630354|Behavioral|Exercising Together, supervised|Participant couples attend supervised classes together
70805|NCT03630354|Behavioral|Exercising separately, supervised|Couples will attend separate group exercise classes for survivors and for spouses
70806|NCT03630354|Behavioral|Exercising at home, unsupervised|Couples will be given equipment and an exercise program to do at home or at a facility.
70807|NCT03630354|Other|Questionnaire Administration|Ancillary studies
70808|NCT03630341|Drug|Clomiphene Citrate 50mg|oral 50 mg tablets
70809|NCT03630341|Drug|L-carnitine|1000 mg oral tablet
70810|NCT03630341|Drug|Placebo Oral Tablet|oral tablets identical to L-carnitine
70811|NCT03630328|Dietary Supplement|Cogni.Q|AGN
70812|NCT03630328|Other|Placebo|Placebo
70813|NCT03630315|Drug|OTX-TKI|OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
70814|NCT03630302|Device|DBS|Deep Brain Stimulation
70815|NCT03630289|Procedure|Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)|Surgical tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multiforme (GBM) patients.
70816|NCT03630276|Diagnostic Test|Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP|Lab
70817|NCT03630263|Other|Raw Corn Starch|Raw corn starch (30 g) will be added to 200 g of applesauce and served to participants, gastric emptying rate, and postprandial glucose will be measured.
70818|NCT03630263|Other|No Raw Corn Starch|200 g of applesauce will be consumed and gastric emptying rate, and postprandial glucose will be measured.
70819|NCT03630250|Biological|N. lactamica|Genetically modified N. lactamica
70820|NCT03630224|Drug|Plasmalyte Viaflo|Intervention description: fluid resuscitation using exclusively Plasmalyte up to 20L during the first 5 days
70821|NCT03630224|Drug|NaCl 0.9%|Intervention name: NaCl 0.9% Intervention description: fluid resuscitation using exclusively NaCl 0.9% up to 20L during the first 5 days
70822|NCT03630211|Drug|Cyclophosphamide|Stem Cell Mobilization
70823|NCT03630211|Drug|Mesna|Stem Cell Mobilization
70824|NCT03630211|Drug|Rituximab|Transplantation Conditioning
70825|NCT03630211|Drug|Alemtuzumab|Transplantation Conditioning
70826|NCT03630211|Drug|Thiotepa|Transplantation Conditioning
70827|NCT03630211|Drug|GM-CSF|Transplantation Conditioning
70828|NCT03630211|Drug|Intravenous immunoglobulin|Transplantation Conditioning
70829|NCT03630211|Radiation|Total Body Irradiation|Transplantation Conditioning
70830|NCT03630198|Drug|Corticosteroid with lidocaine|Intralesional corticosteroid injection
70831|NCT03630198|Drug|Corticosteroid with normal saline|Intralesional corticosteroid injection
70832|NCT03630185|Device|Custom-manufactured compression hosiery (Isobar)|The custom-fitted garment is manufactured specifically for each patient based on measurements taken with a 3-dimensional volumetric laser scan of the extremity, and can be sized individually to each limb.
70833|NCT03630185|Device|Off-the-rack stockings (Sigvaris)|Currently available off-the-rack compression hosiery are manufactured in eight fixed sizes (S-XLFC) that cannot be varied in size over their length to accommodate unusual anatomic patterns (eg., small ankle with large calf or vice versa) and may not achieve a comfortable fit that meets the compression goal over a uniform distribution of the limb.
70834|NCT03630172|Procedure|Dry needling|Using a thin, filiform needle to penetrate a muscle and its trigger point to produce a local twitch response
70835|NCT03630159|Biological|Tisagenlecleucel|Gene modified autologous T cells
70836|NCT03630159|Drug|Pembrolizumab|anti PD-1
70837|NCT03630146|Behavioral|iPeer2Peer program|In addition to standard care, youth in the experimental group will receive the iPeer2Peer Program. The iPeer2Peer program is a peer mentorship program that will provide modeling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with IBD aged 18-25 years) who have learned to function successfully with their disease. Mentors will encourage youth to develop and engage in disease self-management skills and provide social support.
70840|NCT03630120|Drug|Lenvatinib|"Standard of Care: Lenvatinib 24 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
70841|NCT03630120|Drug|Sorafenib|"Standard of Care: Sorafenib 400 mg twice daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
70842|NCT03630120|Drug|Cabozantinib|"Standard of Care: Cabozantinib 140 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
70843|NCT03630120|Drug|Vandetanib|"Standard of Care: Vandetanib 300 mg daily. All participants will start receiving standard of care treatment.~Participants in the Adaptive Therapy regimen will receive TKI therapy in cycles: continuous treatment at the indicated dose until the patients' tumor marker (thyroglobulin in DTC or calcitonin in MTC patients) drops by ≥50% from the level at the time of enrollment (baseline level). A new cycle of TKI treatment will begin when/if the tumor marker increases to or above the baseline level."
70844|NCT03630107|Other|WO 5101 Shampoo for Scalp and Hair|Wash the hair at least three times a week for a period of four weeks
70845|NCT03630094|Drug|FEP-ZID|A total of 7 doses of FEP-ZID via intravenous infusion over 60 min at q8hr dosing regimen
70846|NCT03630081|Drug|FEP-TAZ 4 g|4 g (2 g FEP and 2 g TAZ) IV q8h, infused over 90 min
70847|NCT03630081|Drug|Meropenem|1 g IV q8h, infused over 45 min
70848|NCT03630081|Drug|ciprofloxacin 500 mg Optional Oral Switch|ciprofloxacin 500 mg PO q12h
70849|NCT03630081|Other|Placebo infusion|Placebo infusion (normal saline) over 45 min
70850|NCT03630068|Procedure|Stereotactic percutaneous image-guided microwave ablation|Stereotactic percutaneous image-guided microwave ablation implies the use of computer-assisted navigation technology for 3D trajectory planning and stereotactic placement of ablation probes, before applying local microwave ablation therapy
70851|NCT03630055|Drug|Rivaroxaban 15 MG Oral Tablet [Xarelto]|Patients will receive rivaroxaban 15mg orally daily for 7 days following transradial access.
70852|NCT03630042|Drug|Pembrolizumab|200 mg IV dose given on day 1 of a three week cycle
70853|NCT03630042|Drug|Rituximab|375 mg/m2 IV dose given up to 8 times in the trial
70854|NCT03630029|Drug|FeS and SnPP|Escalating doses of drug will be compared for biomarker changes
70855|NCT03630016|Diagnostic Test|Pulse oximetry with Owlet BabySat v1.0 sensor|A comparative, single-center, non-randomized study to evaluate the SpO2 accuracy guidelines for pulse oximetry over the range of 70-100% SaO2 under non-motion conditions. Arterial blood sampling measured by functional SaO2 CO-Oximetry, was used as the basis for comparison with Owlet BabySat v1.0 and Owlet Smart Sock 2 sensors
70856|NCT03630003|Device|MOCS|"The device consists of a tablet computer that can produce visual and auditory components designed to improve subject knowledge about setting and communication, mounted on a table or at the side of the bed in a place that is visible to the subject.~The Arduino will be connected to switches/buttons and implemented in a 3D-printed platform."
70857|NCT03630003|Other|Post-use interview|The Study team conducts an interview with participants to evaluate their experience with use of the MOCS device.
70858|NCT03629990|Behavioral|Approach Bias Modification (ABM)|Approach bias modification (ABM) is a novel treatment that involves retraining the implicit action tendency to approach a drug cue by manipulating contingencies in a stimulus-response paradigm.
70859|NCT03629990|Behavioral|Sham ABM|"Sham ABM involves similar computerized procedures that mimic the active experimental condition, but do not involve manipulation of response contingencies and thus it does not contain any active intervention."
70860|NCT03629990|Behavioral|Psychosocial therapy for cannabis use disorder.|All participants will receive psychosocial therapy for cannabis use disorder.
70861|NCT03629977|Device|CRRT|Continuous Renal Replacement Therapy
70862|NCT03629964|Device|Wiersma Head Stabilizer|Experimental device attached to treatment table.
70863|NCT03629964|Device|AlignRT system|The AlignRT system (an FDA approved medical device that automatically turns off the radiation beam if the head moves beyond a set distance) will be used to track real-time motions of the head. This system is used with radiation therapy as standard of care.
70864|NCT03629951|Drug|Oral Antipsychotics (OAP)|This is an observational study. Participants enrolled in this study will continue to receive routine treatment of OAPs for example, risperidone (1 to 6 mg OD to BID), olanzapine (5 to 20 mg OD), haloperidol (5 to 20 mg OD to TID) etc, as directed by their treating physician.
70865|NCT03629938|Other|evaluation|evaluation and classification of medial longitudinal arch height of foot in adults
70866|NCT03629925|Drug|Sintilimab|10 mL:100 mg，200mg，Q3W, day1, I.V.
70867|NCT03629925|Drug|Gemcitabine|1000mg/m^2,D1D8/Q3W;first 4 cycles.
70868|NCT03629925|Drug|Placebo|10 mL:100 mg，200mg，Q3W, day1, I.V.
70869|NCT03629925|Drug|Platinum|Q3W, day1, I.V.; first 4 cycles.
70870|NCT03629912|Behavioral|Socially-Based Exercise Intervention for Older Adults|A socially-based app that incorporates exercise and/or health education into a format familiar and engaging to older adults, designed to improve adherence to health-promoting behaviors
70871|NCT03629899|Device|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
70872|NCT03629886|Biological|Cervarix|Three doses of Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (20 µg HPV-16, 20 µg HPV-18) administered intramuscularly in the deltoid region of the upper arm, according to a 0, 1, 6-month schedule.
70971|NCT03629093|Drug|General Anesthetics|General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
70877|NCT03629821|Other|Ballet|The classic ballet classes will respect biological limits of children. The sessions will be 75 minutes long, twice a week during 8 weeks. The class sequence will be: warm-up, follow by exercises about upper and lower limbs ballet positions and sequences of ballet jumps, and at the end a cool-down.
70878|NCT03629808|Procedure|4-6cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 4-6cm during operative.
70879|NCT03629808|Procedure|2-4cm from starting point of gastrectomy to pylorus|The starting point of gastrectomy of the distance from the pylorus is 2-4cm during operative.
70880|NCT03629769|Drug|Proxelan|Administration of one suppository of proxelan once a day for 30 days
70881|NCT03629756|Drug|AB928|AB928 is an A2aR and A2bR antagonist.
70882|NCT03629756|Drug|AB122|AB122 is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1.
70883|NCT03629743|Device|EEG|EEG will be collected with Brain Product's VAMP-16 channel EEG Monitor using the accompanying software. (Website with further specifications and product details: https://www.brainproducts.com/productdetails.php?id=15)
70884|NCT03629743|Device|ECOG|ECOG will be collected with Nihon Kohden acquisition System and accompanying software and depth electrodes.
70885|NCT03629730|Behavioral|Coordination training|The intervention will consist of 8 weeks of exercises to decrease the variability of participants' body and gait coordination. The intervention will consist of 1 training session /week in the Mobility Research Laboratory and 4 days of home-based training. In each session participants will perform 6 trials of 4 body coordination exercises and 1 gait exercise. In the intervention sessions participants will perform interlimb coordination exercises, synchronizing body segments with auditory metronome tones. Participants also will perform a gait exercise by synchronizing steps with an auditory metronome during walking. The metronome will assist participants to retrain their movement timing to decrease coordination variability.
70886|NCT03629717|Procedure|Ultrasound-guided core needle biopsy|Tissue collection for this research proposal will be used for research purposes only and will not inform participant care
70887|NCT03629717|Drug|Denosumab|Denosumab is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL
70888|NCT03629717|Procedure|Blood draw|20 mL of fasting whole blood will be collected before denosumab (Day 1) and one month after denosumab administration (day 60 +/- 10 days)
70889|NCT03629717|Drug|Calcium|1200mg daily
70890|NCT03629717|Drug|Vitamin D|800 IU daily
70891|NCT03629704|Diagnostic Test|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
70892|NCT03629691|Other|lung cavitation|apatinib treated patients developed lung cavitation
70893|NCT03629678|Other|mobile health application|The user-driven technological tool will include an mHealth mobile phone application. Features of the application will be based on preliminary work from the investigators' sites. The mobile app will include fully searchable provider-facing and patient-facing interfaces with the SCD-specific guidelines. The provider-facing interface, designed to be used by providers, will be separated by patient's age to accommodate pediatric and adult providers. The patient-facing interface will display the guidelines that are age- and health literacy-appropriate. Through the mobile app, the investigators will reinforce important points of guideline content; motivate patient engagement through quizzes and text-message reminders; and facilitate peer support, for instance by forming teams to compete against each other to attain goals.
70894|NCT03629665|Behavioral|Intensive Language-Action Therapy (ILAT)|ILAT includes communicative language games played in an interactive small-group setting. Three persons with aphasia and one therapist sit around a table and have picture cards in front of them. The card sets include two items of each object or action picture. All participants take turns in making verbal requests. There will be 5 daily sessions (3 hours per session) for two weeks.
70895|NCT03629665|Device|Repetitive navigated Transcranial Magnetic Stimulation during naming training|Magnetic stimulation will delivered with a figure-of-eight cooled coil of Navigated Brain Stimulation System during picture naming training. The primary targeted area is the right pars triangularis. In each session, rTMS will be applied at 1-Hz for 20 minutes, 5 daily sessions per week for four weeks.
70896|NCT03629652|Other|head-down position treatment|In the head-down position, the body is in the supine position with the head lowered to 30 degrees
70897|NCT03629652|Other|Conventional Rehabilitation|The body is in the supine position without lowered head
70898|NCT03629639|Drug|Metformin|An intervention of either metformin or placebo 500mg twice daily plus standard care for 12 weeks. Besides Metformin, standardized topical treatment is given to all patients; For severe psoriasis patients(PASI>8), Methotrexate will be treated orally 7.5mg every week for both the intervention group and the placebo group as a systemic standard care.
70899|NCT03629626|Procedure|ERAS protocol|"preoperative management Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling~intraoperative management Multimodal prevention of prophylaxis against nausea and vomiting (PONV) (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.~postoperative management Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV.~It is proposed to chew gum three times daily , fluid therapy, early mobilization, early feeding within 2 hours postoperative for at least 15 minutes and eventually to promote a faster bowel function."
70900|NCT03629613|Dietary Supplement|Oral antioxidant cocktail|"Oral antioxidant cocktail intake will occur after baseline measurements:~Dose 1 (immediately after baseline testing): 300 mg alpha-lipoic acid, 500 mg vitamin C, 200 IU vitamin E Dose 2 (30 minutes after Dose 1): 300 mg alpha-lipoic acid, 500 mg vitamin C, 400 IU vitamin E"
70901|NCT03629613|Other|Baseline|No oral antioxidant cocktail intake or placebo intake will occur prior to baseline measurements
70902|NCT03629600|Drug|Lactated Ringer|High-volume Lactated Ringer Solution
70903|NCT03629600|Drug|Rectal Form Indometacin|Post-ERCP rectal administration of 100 MG Indomethacin
70904|NCT03629574|Procedure|Ventilation during cardiopulmonary bypass|Mechanical ventilation during cardiopulmonary bypass
70905|NCT03629548|Procedure|early amniotomy|10 mg PGE2 vaginal ovul will be inserted to the posterior fornix. Early amniotomy will be done in the early active phase of labor for early amniotomy group ( half of participants) when the cervix will be dilated 3 cm using the amniotomy hook.
70906|NCT03629548|Device|foley catheter balloon|an 18-F Foley catheter which filling with 30 mL of saline solution will be placed into the cervix and 10 mg PGE2 vaginal ovul will be inserted to the posterior fornix and
70907|NCT03629535|Device|Non-invasive non-oscillometric blood pressure wristband device|The device is a band intended to be worn on the wrist for intermittent blood pressure measurements. The device applies no inflatable mechanics or moving parts. The wristband is watertight and can be worn as any type of bracelet.
70908|NCT03629535|Device|Invasive intra-arterial blood pressure monitors.|Because the subjects also have an intra-arterial blood pressure monitor in place, the subjects will serve as their own control
70909|NCT03629522|Drug|Ondansetron 8Mg/4mL Injection|investigators administrated intravenously Ondansetron 8 mg 5 minutes before spinal anesthesia.
70910|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid in clinical practice
70911|NCT03629509|Behavioral|BEFORE decision aid|Implementation of the BEFORE decision aid on RUBY communication portals
70912|NCT03629509|Behavioral|BEFORE decision aid|Review impact of BEFORE decision aid implementation in clinical practice
70913|NCT03629496|Other|Arts-based intervention|6x1 hourly facilitated art sessions during haemodialysis. Participants will be provided with an option of visual art or creative writing, the artistic materials used will include graphite pencils, colouring pencils, water colour paints and graphic pens. Participants will be provided with their own art supplies for infection control purposes. During each session participants will be allowed to self-select a subject matter or be provided with binary prompts to facilitate decision making. Participants will also have an option of displaying completed work in the reception area of the unit during their haemodialysis sessions.
70914|NCT03629483|Drug|Dexmedetomidine|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250ml and 3.75 ug/kg dexmedetomidine. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h (equivalent to a dexmedetomidine infusion at a rate of 0.075 ug/kg/h).
70915|NCT03629483|Drug|Placebo|Patients in this group receive continuous femoral nerve block analgesia for 48 hours after surgery. The formula is a mixture of 0.2% ropivacaine 250 ml and placebo. The analgesic pump is set to administer a continuous infusion at a rate of 5 ml/h.
70916|NCT03629470|Other|Standard Conservative Treatment|Range of motion exercises, medication and activity modification.
70917|NCT03629470|Other|Nerve Gliding Exercises|Taught by occupational therapist. These exercises involve motions of the wrist, arm and neck. Subjects will be instructed to perform exercises regularly following the occupational therapists' protocol
70918|NCT03629457|Behavioral|Mindfulness and Mindful Self-Compassion|Mindfulness Based Stress Reduction (MBSR) and Mindful Self-Compassion
70919|NCT03629444|Radiation|ct scan|all patients will be subjected to CT scan and anthroprometric measurments
70920|NCT03629431|Procedure|Prophylactic non-invasive ventilation|"The sessions of NIV last 1 hour and are repeated every 2 to 3 hours with a goal of a daily assistance period of 6 to 8 hours for a minimum of 24 hours.~The sessions are spaced by periods of unassisted ventilation of 2 hours allowing the patient to rest, feed, receive care including physiotherapy sessions."
70921|NCT03629431|Procedure|postoperative standard care|Standard care received postoperatively
70922|NCT03629418|Drug|Targeted blood-pressure management|Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
70923|NCT03629418|Drug|Routine blood-pressure management|Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
70924|NCT03629405|Other|C - pH 4 Cosmetic Product WO 3741|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
70925|NCT03629405|Other|D - pH 5.8 Cosmetic Product WO 4081-1|Application of the product on the pre-defined skin area on the forearms twice daily for four weeks
70926|NCT03629392|Behavioral|Low met/cys diet|Dietary intervention with low contents of methionine and cysteine
70927|NCT03629392|Behavioral|Moderate met/cys diet|Dietary intervention with moderate contents of methionine and cysteine
70928|NCT03629392|Behavioral|High met/cys diet|Dietary intervention with high contents of methionine and cysteine
70929|NCT03629379|Drug|Ustekinumab|Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
70930|NCT03629379|Drug|Vedolizumab|Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14. Patients with Crohn's disease could receive an extra infusion at week 10.
70931|NCT03629366|Behavioral|Supported Employment (SE)|Supported Employment
70932|NCT03629366|Behavioral|Treatment as usual (TAU)|Treatment as usual
70933|NCT03629353|Procedure|endotracheal intubation|After preoxygenation with FiO2 1.0 and flow rate of 8 L/min for 3 minutes, the enrolled patients will be intubated with endotracheal tube and maintained oxygenation during surgery.
70934|NCT03629353|Procedure|high flow nasal cannula|After preoxygenation with 100% oxygen through high flow nasal cannula for 3 minutes, the enrolled patients will be maintained intubationless oxygenation with flow rate of 70 L/min during surgery.
70935|NCT03629340|Drug|Metformin|500 mg PO BID x 1 week then increase to 1000 mg PO BID x 11 weeks
70936|NCT03629340|Drug|Placebo oral capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
70937|NCT03629327|Drug|ASA 100mg|Participants will be randomized to take either 100mg, 300mg or placebo orally on a daily basis for a duration of 6 months
70938|NCT03629327|Drug|Placebo|Participants will be randomized to take either 100mg, 300mg or placebo orally on a daily basis for a duration of 6 months
70939|NCT03629327|Drug|ASA 300mg|Participants will be randomized to take either 100mg, 300mg or placebo orally on a daily basis for a duration of 6 months
70940|NCT03629314|Other|Educational pamphlet arm|Educational pamphlets will be provided to review and questionnaire will be provided to complete before and after review of the pamphlet
70972|NCT03629080|Biological|HB-101 vaccine|HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
70941|NCT03629301|Behavioral|ID-DPP group|This group will receive a 6 month long online behavioral change protocol adapted from the Diabetes Prevention Program. It includes 18 sessions, 12 delivered weekly (during the first 3 months) and 6 delivered biweekly (during the last 3 month period). A web page will be used to deliver the sessions, while the nutritional counseling will be delivered using video calls via Facebook chat. Participants will receive an hypocaloric (1200-1800 kcal, carbohydrates: 45-65%, fats: 20-35% and protein: 10-35%), personalized diet.
70942|NCT03629301|Other|Wait-list Group|This group will only receive written information with recommendations on healthy eating. When the study has finished this group will receive a behavioral change protocol with nutritional counseling using a face-to-face format.
70943|NCT03629288|Other|Lactose tab|Tablet containing lactose Procedure: Periodontal treatment Scaling and root planning
70944|NCT03629288|Drug|Azithromycin|Tablet containing 500mg Azithromicyn. Procedure: Periodontal treatment Scaling and root planning
70945|NCT03629275|Combination Product|CTX0E03 Drug Product and delivery device|Includes stereotactic surgery and a burr hole drilled through the skull to allow for a one time intracerebral injection of 20 million CTX0E03 Drug Product stem cells into an area of the brain adjacent to the area affected by the stroke.
70946|NCT03629275|Drug|Placebo|Sham surgical comparator includes stereotactic surgery and a partial thickness burr hole drilled into the skull. No injection of any kind is made into the brain, and no other intervention is given.
70947|NCT03629262|Drug|Dexmedetomidine|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and sufentanil (1.25 ug/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
70948|NCT03629262|Drug|Placebo|Patients in this group receive patient-controlled intravenous analgesia for 1-3 days after surgery. The formula is a mixture of placebo and sufentanil (1.25 ug/m), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
70949|NCT03629249|Drug|Placebo|Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 Dose 1, one tablet blinded placebo to QAW039 Dose 2).
70950|NCT03629249|Drug|QAW039 Dose 1|QAW039 Dose 1 once daily (one tablet of blinded QAW039 Dose 1 dosage strength to be given together with one tablet blinded placebo to QAW039 Dose 2)
70951|NCT03629249|Drug|QAW039 Dose 2|QAW039 Dose 2 once daily (one tablet of blinded QAW039 at Dose 2 dosage strength to be given together with one tablet blinded placebo to QAW039 Dose 1)
70952|NCT03629236|Other|GrafixPL|Debridement, GrafixPL application, dressing application, standard compression therapy
70953|NCT03629236|Other|Control|Debridement, dressing application, standard compression therapy
70954|NCT03629223|Drug|Tepotinib TF2|Participants will receive single oral dose of Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.
70955|NCT03629223|Drug|Tepotinib TF3|Participants will receive single oral dose of Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.
70956|NCT03629210|Drug|OZURDEX|OZURDEX® (DEX implant, 0.7 mg) is a micro-ionized and non-preserved dexamethasone within a cylindrically-shaped 0.45 mm diameter x 6.5 mm length biodegradable Poly D, L-lactate-co-glycolic acid pellet allowing for sustained delivery dexamethasone into the vitreous cavity and retina following intravitreal injection. Health Canada has granted approval for use of DEX implant in the treatment of ME following central retinal vein occlusion, non-infectious uveitis affecting the posterior segment and pseudophakic DME in adult patients. (OZURDEX® Canadian Product Monograph, April 14, 2015). DEX implant will be provided as investigational treatment by Allergan Inc., Markham, ON, Canada.
70957|NCT03629210|Biological|Eylea|EYLEA® (AFL 2.0 mg intravitreal injections) is an anti-VEGF treatment. AFL (2.0 mg) has received approval from Health Canada for the treatment of DME. Health Canada has also granted approval for AFL (2.0 mg) in the treatment of age-related macular degeneration, and ME secondary to retinal vein occlusion.
70958|NCT03629197|Behavioral|Communication skills training|Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient
70959|NCT03629197|Other|Attention control|Physician will review materials based on CDC opioid prescribing guidelines.
70960|NCT03629184|Drug|Baloxavir Marboxil|"Baloxavir marboxil will be administered as oral suspension in a single dose on Day 1.~Oseltamivir matching placebo will also be administered as oral suspension twice daily (BID) for 5 days."
70961|NCT03629184|Drug|Oseltamivir|Oseltamivir will be administered as oral suspension BID for 5 days. Participants receiving oseltamivir will also receive baloxavir marboxil matching placebo as oral suspension, single dose on Day 1.
70962|NCT03629171|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
70963|NCT03629171|Drug|Venetoclax|Given PO
70964|NCT03629158|Behavioral|CLIMB intervention|"The intervention group will receive the Cardiac Lifestyle Intervention for Maintaining healthy Behaviors (CLIMB) intervention. Participants will participate in a 3-session, one-on-one intervention that takes place over the course of two weeks. Sessions range from 1-2 hours in length, including questionnaire completion. Participants will be given information and taught relevant skills to increase engagement in lifestyle behaviors relevant to cardiac health."
70965|NCT03629145|Behavioral|Live Music Therapy|Investigator will begin play live guitar and voice music.
70966|NCT03629145|Behavioral|Recorded Music Therapy|Investigator will play recorded music.
70967|NCT03629132|Procedure|Platelet-rich plasma|Platelet-rich plasma intrauterine injection
70968|NCT03629132|Procedure|gel|Self-crosslinking sodium hyaluronate gel intrauterine injection
70969|NCT03629119|Dietary Supplement|Dietary Fiber Supplement|Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
70970|NCT03629106|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
70982|NCT03629041|Device|Microneedle Patch|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
70983|NCT03629041|Device|Patch with no microneedles|At the first visit participants will have either the buccal or palatal treated. At the second visit the other area will be treated.
70984|NCT03629028|Diagnostic Test|Residual myometrium thickness|The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6th month by saline infusion sonography.
70985|NCT03629028|Diagnostic Test|Niche Presence|The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6th month by saline infusion sonography.
70986|NCT03629028|Diagnostic Test|Total myometrium thickness|The myometrium will be closed by single or double layer during cesarean and total myometrium thickness will be evaluated in 6th month by saline infusion sonography.
70987|NCT03629028|Diagnostic Test|Niche Measurements in 3D|The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6th month by saline infusion sonography.
70988|NCT03629015|Biological|Stemchymal®|ALF/ ACLF patients will receive Stemchymal® through intravenous infusion
70989|NCT03629002|Biological|Study of the gene expression profile|qPCR analysis
70990|NCT03628989|Device|Technology Arm (i.e Virtual Reality, Augmented Reality)|If parent and child consent to be in the study, the clinician will offer the use of one of the technologies: Virtual Reality (VR) headset or Augmented Reality (AR) headset. Active content includes video games, interactive avatars, and interactive experiences, while passive content includes video clips and movies. All patients will be offered the opportunity to use these technologies during their minor procedures if they meet eligibility criteria. Those who decline or who are switched over to the standard of care due to patient preference, health providers monitoring and assessment during the procedure will be noted in the database.
70991|NCT03628976|Other|tVNS|Intervention
70992|NCT03628963|Device|Concerto+|a user-centered, multifunctional and personalized eHealth platform
70993|NCT03628950|Procedure|ICSSB group|At supine position with abducted limb, the probe of ultrasound will be translocated in costoclavicular space; the subclavian artery will be identified. The three cords of the brachial plexus will be visualized lateral to the artery. By using an in-plane technique and a cephalad-to-caudate direction, the block needle will be advanced until its tip will be in the middle of three cords and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected. Then at lateral decubitus position, by using in-plane technique the probe will be translocated in suprascapular fossa, lateral-to-medial direction, the block needle will be advanced until its tip in the floor of the suprascapular fossa ventral to the fascia of the supraspinatus muscle and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected .
70994|NCT03628950|Procedure|ISB group|The probe of ultrasound will be applied in lateral side of the neck at the level of the cricoid cartilage to obtain a view of the three hypoechoic structures which represent the roots of the brachial plexus. Using an in-plane technique and a lateral to-medial direction, the block needle will be advanced until its tip will be positioned under the prevertebral fascia between the two most superficial hypoechoic structures and 10 mL of 0.25 % bupivacaine Hydrochloride will be injected at level of C5-6 and another 10 ml of 0.25 % bupivacaine Hydrochloride will be injected at level of C7-8.
70995|NCT03628937|Dietary Supplement|Decaffeinated Green Tea Polyphenol|Intervention group will be given decaffeinated green tea polyphenol capsules (400 mg, EGCG accounted for 50%). Participants need take it once a day after breakfast for 12 weeks.
70996|NCT03628937|Other|Placebo control|The starch capsule was used as a placebo control, which has the same dosage, appearance and smell compared to decaffeinated green tea polyphenol capsule. The use frequency and duration are consistent with intervention group.
71001|NCT03628911|Device|Tetanizing Burst Therapy|Tetanizing Burst Therapy tetanizes skeletal muscle with a brief burst of stimulation prior to ICD shock, thereby reducing muscular contraction due to the shock
71002|NCT03628885|Behavioral|Top Concern Tailored Intervention|General Vaccine Information video plus a brief (< 50 sec) animated video address the parent's top ranked question or concern from the provided list of possible concerns.
71003|NCT03628885|Behavioral|All Concerns Tailored Intervention|General Vaccine Information video plus one or more brief (< 50 sec) animated videos that address all of the parent's indicated question or concern from the provided list of possible concerns.
71004|NCT03628872|Procedure|Scaling and root planing|"A non-surgical procedure that treats periodontal disease, sometimes called a deep cleaning, is considered the gold standard (standard of care) of treatment for patients with chronic periodontitis."
71005|NCT03628872|Device|Er:YAG Laser|This laser is intended to be used for dental surgery. The Er:YAG Laser emits an infrared beam which is readily absorbed by water contained by both hard and soft tissues of the human body. As a result, energy of the laser beam instantly vaporizes the water molecules in soft and hard tissues of the tooth and surrounding tissues causing the tissues to crumble away or resection of the soft tissues of gingival.
71006|NCT03628872|Device|Hand instruments|11/12 and 13/14 gracey, 4R/4L curette and sickle - standard of care choices for performing scaling and root planing.
71007|NCT03628859|Biological|Immunological and tumour characterization|FFPE, blood samples (liquid biopsy, heparin and EDTA blood) performed in patients presenting a renal metastatic cancer receiving treatment as standard practice according to physician's choice (2nd or 3rd line of treatment with nivolumab, everolimus, axitinib or cabozantinib [in France only], as per product SmPC)
71008|NCT03628833|Device|Incontinence Management System|Incontinence detection device
71009|NCT03628820|Behavioral|Dog Therapy|5 minutes spent with therapy dog during shift
71010|NCT03628820|Behavioral|Coloring|5 minutes spend coloring mandalas during shift
71041|NCT03628560|Device|RespirAct Step-Wise Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
71011|NCT03628794|Device|D-SCAN|"Subjects will receive a digital patient navigator service in the form of a mobile application (app), which has been designed at Duke, with feedback from Duke Cancer Institute (DCI) patients, caregivers and clinicians. Its purpose is to facilitate awareness of available Cancer Patient Support Program (CPSP) services at Duke, and to also help patients recognize their unmet symptom management needs. Subjects receiving the D-SCAN mobile app will also complete a survey every week within the app. The first 15 patients and 5 caregivers randomized into the intervention arm (those receiving the app) will also be asked to participate in a qualitative interview assessment at week 12, +/- 3 weeks"
71012|NCT03628781|Other|Behavioral tools integrated within mehealth for ADHD software|Integrated functionality within the mehealth for ADHD software allows parents and teachers to set up and deliver behavioral interventions such as daily report card systems and home-based program such as star charts. Automated wizards lead parents and teachers through the process of selecting target behaviors and setting up reward schedules. Baseline data is gathered online and algorithms derive a set of behavioral goals for the child. Thereafter, parents or teachers record the child's performance directly into the software. Once behavioral monitoring begins, parents and teachers receive daily email or text communications from mehealth for ADHD alerting them to the daily rewards earned by their child. Finally, online algorithms exist that detect how a child is doing in meeting behavioral goals and prompt users to modify goals accordingly.
71013|NCT03628781|Other|mehealth for ADHD|"The mehealth for ADHD software has multiple functionalities including 1) online training regarding the American Academy of Pediatrics (AAP) ADHD guidelines; 2) an ADHD workflow wizard that guides pediatricians through the creation of an efficient office workflow to deliver quality ADHD care; 3) online collection of parent- and teacher-report ADHD rating scales for the assessment of ADHD as well as monitoring response to medication treatment; 4) integrated algorithms that automatically score rating scales in real time and provide pediatricians with assessment and treatment reports as well as immediate warnings; 5) a communication feature that allows parents, teachers, and pediatricians to communicate with each other; 6) an online pediatrician report card; and 7) a Plan-Do-Study-Act wizard that allows pediatricians to select a practice behavior to improve based on their report card and guides them through the creation of small tests of change to improve their office systems."
71014|NCT03628768|Other|Data collection|telephone interview questionnaire, in-home face-to-face interview, and data from the Collection Site
71015|NCT03628755|Behavioral|Digital Manipulation of Thyroid cartilage|"Digital manipulation of thyroid cartilage was applied to the anterior aspect of thyroid cartilage while using the thumb or finger and the patient was asked to speak.~prolongation of vowel is 7 to 8 seconds, voice rest after each set is 10 second.~total repetition is 60."
71016|NCT03628755|Behavioral|Fluency Shaping Therapy|FST session comprised of speech techniques such as prolongation of sounds, easy onset, continuous phonation, light articulatory contact, in reading and conversation in three speaking situations (speaking with therapist, reading aloud, and free conversation Reading task was for 80 short phrases.
71017|NCT03628755|Behavioral|combination Group|combination group intervention of DMT + FST
71018|NCT03628729|Other|Embrace™ WetBond™ Pit & Fissure Sealant|pit and fissure sealant that contain the precursor in the formation of hydroxyapatite which is Amorphous Calcium Phosphate (ACP) ,which has anti-cariogenic effect as well as remineralization potential as it contain bioactive material which stimulate crystal growth within the lesion by increasing the concentration of calcium and phosphate ions
71019|NCT03628729|Other|Seal-Rite™ Pit & Fissure Sealant, Pulpdent Corportation, USA|Fluoride releasing resin based pits and fissures sealant
71020|NCT03628716|Biological|CV301|"Prime with MVA-BN-CV301 (nominal titer 1.6 x 10^9 Inf.U) given subcutaneously (SC) on Day 1 and Day 22. One dose = four 0.5 mL injections. One injection = nominal titer 4 x 10^8 Inf.U in 0.5 mL.~Boost with FPV-CV301 (nominal titer of 1 × 10^9 Inf.U in 0.5 mL, given SC every 21 days for 4 doses (on days 43, 64, 85, and 106), followed by boosts every 6 weeks until 6 months on trial (i.e., days 148 and 190), then every 12 weeks until completion of 2 years. One dose = one 0.5 mL injection."
71021|NCT03628716|Biological|Atezolizumab|Atezolizumab fixed dose of 1200 mg intravenous on Day 1 of each 21-day cycle
71022|NCT03628703|Device|Repetitive TMS|Repetitive Intermittent Theta-Burst Transcranial Magnetic Stimulation over the right Pre-supplementary Motor Area
71023|NCT03628690|Device|BandGrip|Topical skin closure device
71024|NCT03628690|Device|Suture|Wound closure
71025|NCT03628677|Drug|AB154|AB154 is a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT
71026|NCT03628677|Drug|AB122|AB122 is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
71027|NCT03628664|Radiation|CT scan|Assessment of the actual posterior condylar angle using the CT scan
71028|NCT03628651|Other|Blood Sample Collection|HCC subjects will have one blood sample collected.
71029|NCT03628651|Other|Blood Sample Collection|Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.
71030|NCT03628638|Other|Blood Sample Collection|Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
71031|NCT03628625|Drug|Letrozole 2.5mg|total dose 7.5 mg per day for 3 days
71032|NCT03628625|Drug|Placebo|Folic acid for 3 days
71033|NCT03628625|Drug|Misoprostol|Misoprosrol 800mcg will be given to all patients for induction of abortion
71035|NCT03628599|Device|Delefilcon A contact lenses|Water Gradient silicon hydrogel daily disposable contact lenses
71036|NCT03628599|Device|Senofilcon A contact lenses|Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
71037|NCT03628573|Device|repetitive transcranial magnetic stimulation (MagPro X100).|accelerated rTMS.
71038|NCT03628573|Device|Intermittent Theta burst stimulation ( iTBS)|
71039|NCT03628560|Device|RespirAct Step-Wise Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
71040|NCT03628560|Device|RespirAct Slope Normocapnia desaturation sequence|Blood carbon dioxide controlled at normal value (normocapnia).
71042|NCT03628560|Device|RespirAct Slope Hypocapnia desaturation sequence|Blood carbon dioxide controlled at lower than normal value (hypocapnia).
71043|NCT03628560|Device|ROBD Step-Wise desaturation sequence|Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
71044|NCT03628547|Behavioral|Measuring devices and questionnaires|Measuring devices and questionnaires will be applied to assess the pain and psychosocial states of musculoskeletal system of athletes. The Expanded Scandinavian Muscle Skeleton Questionnaire (NMQ) and Visible Analogue Scale (VAS) will be used to identify and assess the symptoms of musculoskeletal discomfort as 'pain'. The participant will be evaluated with the algometer, the sporty trust will be questioned with the Sporty Trust Continuous Inventory, and the Quality of Life will be assessed with the World Health Organization Quality of Life Scale Short Form and Depression will be evaluated with Beck Depression Inventory.
71045|NCT03628534|Device|Saline Enhanced Radiofrequency (SERF) ablation|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
71046|NCT03628521|Drug|Anlotinib，Erlotinib，IBI308，Pemetrexed，gemcitabine，carboplatin|Patient harboring EGFR mutation will be enrolled into arm A. Patients without sensitive EGFR mutation will be assigned to either arm B or arm C based on patients' or treating physicians'choice
71047|NCT03628508|Other|Exercise|Comprehensive exercise program including strengthening, stretching, gait modification etc.
71048|NCT03628495|Device|compression|compression will be delivered using compression garment
71049|NCT03628495|Device|occlusion|occlusion will be delivered using silicone gel sheeting
71050|NCT03628482|Procedure|CRF|For continuous radiofrequency ablation the electrode tip temperature was raised to 80°C during 90 s.
71051|NCT03628482|Procedure|PRF|The procedure for PRF is almost identical to that applied for CRF, except that the current is typically carried out in 20 ms pulses every 0.5 s at a temperature that does not exceed 42 °C during 360 s.
71052|NCT03628469|Behavioral|Proactive Health Support|Active listening, coaching and counselling
71053|NCT03628456|Device|International Biophysics AffloVest|High-frequency chest wall oscillation vest
71054|NCT03628456|Device|Hill-Rom Monarch|High-frequency chest wall oscillation vest
71055|NCT03628443|Diagnostic Test|Fibroblast Growth Factor 23|A sample of blood is tested for levels of fibroblast growth factor 23
71056|NCT03628430|Procedure|lidocaine with epinephrine|Local anesthesia with lidocaine with epinephrine
71057|NCT03628430|Procedure|sodium bicarbonate|sodium bicarbonate as adjuvant to lidocaine with epinephrine in Local anesthesia
71058|NCT03628430|Procedure|Normal saline|normal saline as adjuvant to lidocaine with epinephrine in Local anesthesia
71059|NCT03628417|Procedure|Calcium Electroporation|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
71060|NCT03628417|Procedure|Bleomycin based electrochemotherapy|"If the patient agrees biopsies will be performed from the tumor area before and after electroporation during local anaesthesia. Maximum of 8 biopsies will be done, depending on the patient's number of metastases.~All patient's regardless of the number of metastases will have one biopsy from area treated with calcium and one from area treated with bleomycin, after the randomization code is revealed at day 180.~Patients with more than 6 metastases: One to two biopsies before treatment, one to two biopsies one week after treatment from metastases treated with calcium and bleomycin respectively.~All biopsies will be handled according to current guidelines and analyzed by a pathologist for amount of tumor tissue, inflammation, fibrosis and necrosis."
71061|NCT03628391|Drug|Haloperidol|haloperidol for ICU delirium, titrated on validated screening tool-based diagnosis
71062|NCT03628391|Drug|Placebo|placebo for ICU delirium, titrated on validated screening tool-based diagnosis
71063|NCT03628378|Device|Verasense|Ligamentous balancing device
71064|NCT03628365|Dietary Supplement|HMB (beta-hydroxy beta-methylbutyrate)|1.5 g, b.i.d., by the enteral route, from Day 4 to Day 30 (minimum 10 days)
71065|NCT03628352|Drug|Tricaprilin|Tricaprilin with flavoring agents added
71066|NCT03628339|Drug|Midazolam|Participant will receive single oral dose of midazolam on Day 1 of treatment period 1 and co-administration of tepotinib and midazolam on Day 11 of treatment period 2.
71067|NCT03628339|Drug|Tepotinib|Participants will receive single oral dose of tepotinib for 10 days in treatment period 2.
71068|NCT03628326|Other|Pulmonary arterial tree|The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
71069|NCT03628313|Other|Transthoracic ultrasound|Patients are prospectively identified during echocardiography performed in the echocardiography laboratory of the two participating centers when a diagnosis of aortic stenosis is made.
71070|NCT03628300|Other|piperacillin serum concentration monitoring|initiation of a continuous piperacillin infusion at the standard dose and who underwent piperacillin serum concentration monitoring.
71071|NCT03628287|Other|Revised Care Coordination Program|Greater focusing, tailoring and cues for delivery of key components of Care Coordination
71072|NCT03628287|Other|Original Care Coordination Program|Original Care Coordination
71073|NCT03628274|Device|Magnetic Resonance Imaging (MRI) 7 Tesla|An MRI performed as part of the project
71074|NCT03628274|Device|Magnetic Resonance Imaging (MRI) 1,5 Tesla|An MRI performed as part of the care
71075|NCT03628261|Device|Serious Game|Surface EMG detection for the myoelectric control of the EMG-based serious games and for the EMG assessment during gait will be performed with a wireless system.This device is composed of seven modules (sensor units), each detecting and transmitting two bipolar EMGs at 2 kilo Hertz (kHz). During the evaluation protocol EMGs will be detected from peroneus longus, gastrocnemius medialis, soleus and tibialis anterior muscles of both limbs using pre-gelled electrodes.
71112|NCT03628053|Drug|Inotuzumab|CD22-directed antibody-drug conjugate
71076|NCT03628261|Other|physical therapy|Children receive the regular rehabilitation for the treatment of ankle plantar flexor muscle overactivity and the paresis of ankle dorsal flexor muscle
71077|NCT03628248|Procedure|embolization of the inferior mesenteric artery|proximal occlusion of the inferior mesenteric artery, before its divisional branches, by coils or plug 3-4 weeks prior to surgery.
71078|NCT03628248|Procedure|Inferior mesenteric artery ligation|Endovascular ligation of Inferior mesenteric artery
71079|NCT03628235|Behavioral|Online survey|Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions
71080|NCT03628222|Device|ENB-TBLB|"ENB Guidance: The iLungTM SuperNavigator system will be used, it comprises of iLungTM ENB system, location catheter and guide catheter. The guide catheter can supply a 1.9 mm working channel for biopsy tools.~The location catheter is inserted into the guide catheter beforehand, then both are introduced via the working channel of the bronchoscope. Under guidance of ENB system, the location catheter reaches the lesion, and actual distance is confirmed by the X-ray.~TBLB: Location catheter is retracted, then the biopsy forceps and brush was introduced, and pathologic specimens are obtained."
71081|NCT03628222|Device|X-ray-TBLB|Based on chest CT, the physician determines the lesion location. Under X-ray guidance, via the bronchoscope's working channel, the biopsy forceps and brush are introduced and pathologic specimens are obtained.
71082|NCT03628209|Drug|Nivolumab|Participants will be treated with Nivolumab intravenously (IV), 3 mg/kg on days 1 and 15 of each cycle.
71083|NCT03628209|Drug|Azacitidine|Phase I Dose Escalation - Dose level 1: NA. Dose level 2: 60 mg/m^2. Dose level 3: 75 mg/m^2. Phase II Expansion - Treated at recommended Phase II dose (RP2D).
71084|NCT03628209|Procedure|Post Treatment Surgery|Resection surgery at end of Cycle 1 treatment, day 28-35.
71085|NCT03628183|Other|Hydrolysate Infant Formula 1|Feed ad lib
71086|NCT03628183|Other|Hydrolysate Infant Formula 2|Feed ad lib
71087|NCT03628170|Other|platelet rich fibrin|platelet rich fibrin will be prepared from patient's venous blood and inserted in the centrifuge at 2000 r.p.m. for 12 minutes Then, the Platelet rich fibrin plug will be placed in the socket after extraction for socket preservation covered by platelet rich fibrin membrane.
71088|NCT03628170|Other|Free gingival graft|Free gingival graft will be taken from the palate to cover the socket after extraction of the tooth for socket preservation.
71089|NCT03628157|Other|Geistlich Bio-Oss® bovine bone alone|Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
71090|NCT03628144|Dietary Supplement|Impact® Advanced Recovery|The intervention drink Impact® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
71091|NCT03628144|Dietary Supplement|Boost® High Protein|The control supplement drink Boost® will be ingested every two weeks since usually chemotherapy is delivered concurrently with radiation therapy in 2 week cycles. For patients who are placed on weekly or every 4 weeks chemotherapy dosing schedules, the treatment and control supplements will still be given every two weeks.
71092|NCT03628144|Radiation|Radiation Therapy|Standard of Care: Weekly radiation therapy as already planned for each participant, at Moffitt clinic visits.
71093|NCT03628144|Drug|Chemotherapy|Standard of Care: Chemotherapy as already planned for each participant.
71094|NCT03628144|Other|Quality of life (EORTC-QLQ-30)|Participants will undergo pre- and post-treatment assessments.
71095|NCT03628144|Other|Evaluation of Cognitive Function (FACT-Cog, v. 3.0)|Participants will undergo pre- and post-treatment assessments.
71096|NCT03628144|Other|Mindfulness Questionnaire (FFMQ)|Participants will undergo pre- and post-treatment assessments.
71097|NCT03628131|Drug|Pazopanib|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
71098|NCT03628131|Drug|Ifosfamide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
71099|NCT03628131|Drug|Carboplatin|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
71100|NCT03628131|Drug|Etoposide|Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
71101|NCT03628105|Behavioral|CR Before Exposure|"Participants complete 15 minutes of CR (Preparation) using the evidence technique outlined in the cognitive-behavioral manual Mind Over Mood (Greenberger & Padesky, 2016). This technique involves evaluating the validity of expected feared outcomes. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Finally, participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted after exposure in the other arm of the study."
71102|NCT03628105|Behavioral|CR After Exposure|Participants complete the 15-minute self-report filler task (including questions from the MMPI-2, Butcher et al., 1989) which acts as a no-treatment comparison to CR being conducted before exposure in the other arm of the study. Next, participants complete six 5-minute exposure trials using a claustrophobic chamber and other materials (e.g., scarf, mask, handcuffs). Then, participants complete 15 minutes of CR (Consolidation, Craske et al.'s, 2014) by calculating the difference between predicted and actual expected feared outcomes, and identifying identify (1) whether they believe their feared outcomes occurred (Yes/No), (2) describe how they know this to be true, and (3) reflect on what they learned about their feared outcome or expectancy through exposure.
71103|NCT03628092|Device|CO2 Fractional Ablative Laser|Vaginal / vulval laser treatment
71104|NCT03628092|Device|Placebo|Sham Device
71105|NCT03628079|Drug|ReposMBZ|Capsules 50mg, 100mg, 200mg
71106|NCT03628066|Drug|Letrozole|Letrozole 2.5 mg by mouth daily for 24 weeks
71107|NCT03628066|Drug|Palbociclib|Palbociclib 125mg by mouth daily for 21 days per 28-day cycle (21 days on, 7 days off) for 24 weeks
71108|NCT03628066|Drug|Goserelin|Goserelin 3.6mg subcutaneous injection x 1 on Day 1 of each 28-day cycle for 24 weeks
71109|NCT03628066|Diagnostic Test|Oncotype DX Breast Recurrence Score|Prior to assignment to Arm 1 the Oncotype DX diagnostic test will be conducted on diagnostic tissue to assign a recurrence score for stratification to cohort 1 or 2.
71110|NCT03628053|Biological|Tisagenlecleucel|autologous cellular immunotherapy product
71111|NCT03628053|Drug|Blinatumomab|bispecific CD19-directed CD3 T-cell engager
71113|NCT03628040|Drug|Ropivacaine Injection [Naropin]|Ropivacaine will be injected in the erector spinae plane
71114|NCT03628040|Drug|Normal saline|Normal saline will be injected in the erector spinae plane
71115|NCT03628027|Device|Computerised decision support algorithm|The algorithm is integrated into the EMIS computer system used by GPs. The algorithm advises on which antidepressants should be prescribed based on a patient's treatment history.
71116|NCT03628014|Other|Inpatient-care program|"Patients enrolled in the Hospital Elder Life Program can receive four types of personalized volunteer-led interventions based on the needs identified by the care team. These interventions include:~Daily orientation and visiting program~Basic active movements~Meal assistance~Recreational activities"
71117|NCT03628001|Procedure|ERCP|Pts will be randomized with or without sphinterectomy.
71118|NCT03627988|Other|Patients with invasive breast cancer will receive:|"Total mastectomy with Immediate prosthetic breast reconstruction~Adjuvant therapy by TomoTherapy (radiation therapy alone or preceded by chemotherapy)."
71119|NCT03627975|Procedure|Conservative treatment|"The conservative treatment of hemorrhagic moyamoya disease mainly includes the control of hypertension, prevention and treatment of secondary epilepsy, the control of intracranial hypertension, and the corresponding symptomatic and neurotrophic treatment.~In addition to the pharmacotherapy used in conservative treatment, encephalo-duro-arterio-synangiosis(EDAS) will be performed according to the procedures described by Matsushima.~In addition to the pharmacotherapy used in conservative treatment, the superficial temporal artery(STA) and middle cerebral artery(MCA) by pass surgery is performed. The operation is the modified EDAS which basically similar to EDAS, but the surgical incision is as low as possible. And the STA may not be preserved."
71120|NCT03627962|Other|gaze-directed oculomotor training|"Device: Tobii PCEye~Protocol: Visual span was calculated by the distance between human-computer and dpi of fonts. Pointer speed was programmed 120pixels (5 degrees)/1sec for image drift of reading.~Dosage: 1) gaze-access required 20 to 10 degrees per fixation to activate text-to-speech (TTS) read-aloud function; about 30 repetitions of saccade and fixation.~2) gaze-directed OMT limited to 10-5 degrees. Chinese characters recognition in multiple choice format, about 60 repetitions.~Target behavior - gaze-directed access by Tobii PCEye: reading from left to right (=horizontal mouse mover); read-aloud function by gaze dwell > 500ms. To enhance purposeful and repetitive eye movement.~Frequency: 2 session/wk x 8 wks~Duration: 30 min/session"
71121|NCT03627949|Behavioral|E-intervention|The intervention will address the basic elements of the HAPA model via the use of behaviour change techniques. In line with Abraham and Michie (2008), we use several behaviour change techniques like providing information about behavioural risk and benefit of behaviour change, prompting intention formation, prompting barrier identification, providing instructions how to perform a behaviour, prompting specific goal setting and review of behavioural goals, providing feedback on performance, prompting practice and providing follow-up prompts, prompting to plan social support and finally prompting relapse prevention, also based on strategies used by other effective computer tailoring programs. Students attended e-health intervention session once a week with about 20 minutes each time.
71122|NCT03627936|Drug|Lorcaserin manufactured at Zofingen|Lorcaserin XR tablets manufactured at Zofingen.
71123|NCT03627936|Drug|Lorcaserin manufactured at Kawashima|Lorcaserin XR tablets manufactured at Kawashima.
71124|NCT03627910|Dietary Supplement|symbiotic|Feed supplementation
71125|NCT03627910|Dietary Supplement|zinc and arginine|Feed supplementation
71126|NCT03627897|Drug|Regional Anesthetics|The erector spinae plane blocks proceed with 0,5 ml/kg of 0,25% bupivacain (Group B).
71127|NCT03627897|Drug|Saline|The erector spinae plane blocks proceed with 0,5 mlt/kg salin (Group S).
71128|NCT03627884|Drug|Sodium Bicarbonate Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
71129|NCT03627884|Drug|Normal Saline Catheter Lock Solution|Using Sodium Bicarbonate Catheter Lock Solution
71130|NCT03627871|Behavioral|Majority Norm|Participants receive information about exercise norms that apply to the majority of the population but are given no information about trends in this norm.
71131|NCT03627871|Behavioral|Trending Minority Norm|Participants receive information about exercise norms that apply to the minority of the population and have recently been trending up.
71132|NCT03627871|Behavioral|Minority Norm|Participants receive information about exercise norms that apply to the minority of the population but are given no information about trends in this norm.
71133|NCT03627871|Behavioral|Control|Participants receive information about exercise that is unrelated to social norms or trends in social norms.
71134|NCT03627871|Behavioral|Trending Majority Norm|Participants receive information about exercise norms that apply to the majority of the population and have recently been trending up.
71135|NCT03627858|Drug|beclomethasone / formoterol / glycopyrronium|As this is a non-interventional study, all treatment decisions will be made at the discretion of the treating physician prior to enrolment in the study and during the entire period of the study. Treatment will be prescribed according to the product label in the summary of product characteristics.
71136|NCT03627845|Drug|PHP-303|Investigational drug
71137|NCT03627845|Other|Placebo|Matching placebo
71140|NCT03627819|Dietary Supplement|Plant sterol-enriched margarine|Margarine enriched with plant sterol esters
71141|NCT03627819|Dietary Supplement|Plant stanol-enriched margarine|Margarine enriched with plant stanol esters
71142|NCT03627819|Dietary Supplement|Control margarine|Margarine without any addition
71143|NCT03627793|Other|resistance training|Moving muscles against loads with the purpose of increasing strength.
71144|NCT03627780|Diagnostic Test|DNA extraction|DNA will be extracted from white cells
71145|NCT03627767|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
71146|NCT03627767|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
71147|NCT03627767|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 40 weeks
71148|NCT03627754|Drug|Glasdegib 100 mg single oral dose|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow-up.
71149|NCT03627741|Drug|Triamcinolone Acetonide|A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.
71150|NCT03627728|Drug|Regorafenib|regorafenib/placebo
71151|NCT03627728|Other|placebo|regorafenib/placebo
71152|NCT03627715|Drug|Propagermanium|Immediate release capsule
71153|NCT03627715|Drug|Placebo|Placebo capsule
71154|NCT03627702|Radiation|Irradiated VIP (Visible Incoherent Polarized)|20 irradiations were performed twice a day. The exposure time was 10 minutes. Exposure was made at a distance of 10 cm.
71155|NCT03627689|Other|Active air purifier in respiratory allergies/asthma|Continuous use of air purifier to improve allergies and asthma control
71156|NCT03627689|Other|Sham air purifier|control arm
71157|NCT03627676|Procedure|Cryoablation|Two percutaneous cryoprobes would be used for all patients. The 17-Gauge cryoprobes is introduced into the masses under US guidance. Mean distance to the skin has to be 5mm at least. Although US guidance is used, a non-enhanced CT scan may be used to assess the position of the cryoprobes before ablation, and to obtain a baseline examination in order to avoid thermal injuries to adjacent tissues such as the bowel during the ice growth. No ice extension to the skin has to be observed during cycles assessed by real-time US monitoring. Each cryoablation procedure involves 3 successive cycles: 10 minutes freeze with Argon gas, followed by 9 minutes passive and 1 minute active thawing with Helium gas, followed by a second 7 minutes freeze. The ice covered the entire targeted lesion on the short axes is visualize by US or CT-scan performed at the end of the three cycles or after repositioning. At the end of the cryoablation procedures, the probes are removed through active thawing.
71158|NCT03627663|Behavioral|Dialectic Behavior Therapy - Skills System|Treatment with Dialectical Behavior therapy adapted for cognitively challenged individuals
71159|NCT03627650|Procedure|lipofilling/ fat grafting|liposuction, processing/ cleaning of fat tissue; reinjection with sharp needle transcutaneous
71160|NCT03627650|Procedure|placebo injection|
71161|NCT03627637|Dietary Supplement|Soy nuts|Study volunteers will receive daily 70 g of soy nuts (roasted soybeans containing approximately 100 mg isoflavones). The amount of soy protein provided by the nuts equals the FDA recommended daily intake of 25-30 g.
71162|NCT03627624|Other|Pulmonary rehabilitation|Stable COPD inpatients undergoing 30-STST and 6-minute walk test (6MWT) before and after PR were included. Responsiveness to PR was determined by pre-to-post PR (Δ) evaluation of 30-STST.
71163|NCT03627611|Drug|Levothyroxin|3 months
71164|NCT03627611|Drug|Liothyronine|3 months
71165|NCT03627598|Device|HFNC|patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
71166|NCT03627598|Device|standard|patients will receive low flow oxygen therapy at 1 to 4 liters per minute
71167|NCT03627585|Device|Personalised programming|Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
71168|NCT03627572|Other|No intervention|Not applicable (no intervention)
71169|NCT03627559|Procedure|Pancreaticoduodenectomy microdialysis catheter analyses|A thin microdialysis catheter is implanted before skin closure after pancreaticoduodenectomy. Analyses of the microdialysate are done at certain timepoints postoperatively. No intervention is done based on the results. The patients are following standard of care.
71170|NCT03627546|Drug|Sofosbuvir and Velpatasvir|Sofosbuvir/velpatasvir (Epclusa) is an FDA-approved treatment for HCV. It is provided in the intervention arm as part of a rapid treatment strategy,
71171|NCT03627533|Procedure|Electroacupuncture|Electroacupuncture therapy is done at the point of CV3 Zhongji, CV4 Guanyuan, and EXCA-1 Zigong with continuous wave, 2 Hz frequency for 30 minutes. Acupuncture manuals on endocrine ear points, GV20 Baihui, ST36 Zusanli, SP6 Sanyinjiao, BL57 Chengsan and KI3 Taixi for 30 minutes.
71172|NCT03627520|Drug|[14C]Sulfatinib|300 mg Sulfatinib with 100 µCi [14C]
71173|NCT03627507|Biological|Hepa-B|Incepta will manufacture a locally produced Hepatitis B vaccine named 'Hepa- B' which contain recombinant Hepatitis B surface antigen obtaine. This bulk is formulated to prepare finished dosage to manufacture large scale in fully GMP compliant plant. Incepta has conducted preclinical study at Bioneed, India. After successful completion of preclinical study, this non inferiority clinical trial with innovator product is needed for Licensure in Bangladesh.
71174|NCT03627507|Biological|Engerix B|.'Engerix B' is a recombinant DNA hepatitis B vaccine. It is sterile suspension of purified surface antigen of hepatitis B virus obtained by culturing genetically yeast cells (Saccharomyces cerevisiae cells), which carry the gene that codes for HBsAg
71175|NCT03627494|Drug|GSK3439171A|Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
71176|NCT03627494|Drug|Placebo|Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
71177|NCT03627481|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery for nasal polyposis
71178|NCT03627468|Drug|Sofpironium Bromide Gel, 5%|Sofpironium Bromide Gel, 5%
71179|NCT03627468|Drug|Sofpironium Bromide Gel, 15%|Sofpironium Bromide Gel, 15%
71180|NCT03627455|Other|Percutaneous coronary intervention|Percutaneous coronary intervention
71181|NCT03627442|Procedure|Mastectomy with PhotonBlade|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with PhotonBlade
71182|NCT03627442|Procedure|Mastectomy with Bovie|One of the breasts of each patient undergoing double mastectomy will be randomly assigned to breast flap creation with Bovie
71183|NCT03627416|Device|rTMS|high frequency rTMS to induce the long term potentiation of primary motor areas for the muscles of lower extremities
71184|NCT03627403|Drug|Selinexor|Selinexor will be administered orally at a dose of 80 mg once weekly for a maximum of 6 months
71185|NCT03627390|Drug|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
71186|NCT03627390|Drug|BP-C2|BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
71187|NCT03627377|Behavioral|Multi-component Intervention for Diabetes in Adults with Serious Mental Illness|Main components of MIDAS include: (1) Education about diabetes and lifestyle, (2) Dietary intervention at the facility and resident level, (3) Increased physical activity, and (4) Smoking cessation / reduction.
71188|NCT03627338|Diagnostic Test|questionaire, interview|questionaire, interview
71189|NCT03627325|Other|Patients who are scheduled for any surgical procedure|looking for correlation for estimating the complications between the anesthesiologists and the computerized method.
71190|NCT03627312|Combination Product|Omega-3|1g of omega-3 supplement to be taken per day for a duration of 3 months in the form of a fruit juice drink
71191|NCT03627312|Combination Product|Placebo|Fruit juice drink only
71192|NCT03627312|Other|Treatment as Usual|Young Offenders Intervention Programme
71193|NCT03627299|Drug|300mg glecaprevir/pibrentasivir 120mg|300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
71194|NCT03627273|Diagnostic Test|6 minutes walking test with walker|to walk during 6 minutes with walker
71195|NCT03627273|Diagnostic Test|6 minutes walking test|to walk during 6 minutes with walker
71196|NCT03627260|Behavioral|Fill up a handful of sunscreen and spread it all over your body. Sunscreen, Actinica|"Volunteers were asked to follow the rule of thumb: Fill up a handful of sunscreen and spread it all over your body."
71197|NCT03627247|Behavioral|Cognitive Behavioral Stress Management|Interactive activities (e.g., role-playing, use of physical props to introduce concepts related to coping and stress) were designed for each class to optimize participant engagement and understanding of the course material while tailoring class content to the stressors commonly reported by participants. Each week, participants were given coping and relaxation skills to practice at home (e.g., cognitive reappraisal, diaphragmatic breathing) and were asked to record their experiences on an activity log that was collected and discussed in class the following week. Course content was taught from a detailed training manual (Urizar & Kofman, 2012).
71198|NCT03627234|Behavioral|Same Day Discharge|Patients will be randomized to same day discharge
71199|NCT03627234|Behavioral|Overnight Stay|Patients will be randomized to stay overnight
71200|NCT03627221|Behavioral|music listening and social network|The 12-week combination of music care and social network program consists of three parts: sleep related variables assessment and monitoring, sleep management education and outcome evaluation. Participants in the intervention group will receive weekly online (social network) education and music listening interventions for 12 weeks provided by the PI.
71201|NCT03627195|Drug|DSP-1349M|DSP-1349M injectable
71202|NCT03627195|Drug|placebo|placebo injection
71203|NCT03627182|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with D150 and D745
71204|NCT03627182|Drug|Placebo|"Placebo, orally, 1 tablet once a day for 24weeks with D150 and D745.~CKD-501 placebo will be changed to CKD-501 from extension stydy to EOS(end of study)."
71205|NCT03627169|Device|MATRx plus|The MATRx plus device will be used in its capacity as a Level III home sleep apnea test (HSAT). Note: MATRx plus is approved for use in Canada; therefore, the study does not involve any investigational devices.
71206|NCT03627156|Behavioral|guided counseling|Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
71207|NCT03627143|Other|KTI activities|"The Investigators also plan the following activities to encourage adherence to the guidelines, with an ultimate goal of rhythm or rate control and discharge home for most patients.~Selection of one or more local physician champions from both the ED as well as the cardiology group;~Review and discussion of the goals of the study, as well as perceived barriers and enablers, by the ED and cardiology physician groups;~Formal introduction of the CAEP AAFF Guidelines to the ED physicians and residents by means of presentations at rounds and staff meetings, emails, online video, and web-based resources;~Development of local action plan addressing local barriers to implementation;~Provision of the free Smartphone App to be developed for the guidelines;~Regular reminders provided by the local research staff;~Audit and feedback charts of site compliance"
71208|NCT03627130|Drug|Potassium Nitrate|Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days
71209|NCT03627130|Drug|Potassium Chloride|Potassium Chloride capsules for 5 days
71210|NCT03627117|Drug|Verum|Single vape of 0.25mL of CBD e-Liquid containing: 5% CBD (low-temperature extracted Cannabidiol from Cannabis sativa L., purity 99%), Glycerine (vegetable), Propylene glycol, water
71211|NCT03627117|Drug|Placebo|Single vape of 0.25ml e-liquid La Baronne Jaune, BORDO2.
71212|NCT03627104|Dietary Supplement|Normoprotein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
71213|NCT03627104|Dietary Supplement|Normoprotein diet with vegetable protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with percentage of standard protein (12-18%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
71214|NCT03627104|Dietary Supplement|High-protein diet with animal protein|Each patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of animal protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
71215|NCT03627104|Dietary Supplement|High-protein diet with vegetable protein|ach patient will be attended for 1 month through 4 weekly visits. Weekly menus will be delivered according to diet with high-protein percentage (25-35%) with a predominance of vegetable protein (60%). Regardless of the type of protein, menus will contain the same amount of energy and concentration of carbohydrates, fats and saturated fats (less than 7%).
71216|NCT03627091|Drug|SHP647|SC injection of 25 mg or 75 mg SHP647 will be administered using a prefilled syringe.
71217|NCT03627091|Other|Placebo|SC injection of placebo matched with SHP647 will be administered using a prefilled syringe.
71218|NCT03627078|Other|motor interference therapy|
71219|NCT03627078|Other|Relaxation exercises|In a top-down sequence, beginning with the upper body and proceeding to the lower parts. patients contract and relax a specific muscle group following the instructions given by the audio track. We use a shorter version that excludes the legs because of the time.
71220|NCT03627065|Drug|Parsaclisib|Parsaclisib administered orally once daily at the protocol-defined dose.
71221|NCT03627052|Drug|Itacitinib|In the double-blind period, itacitinib administered orally once or twice daily at the protocol-defined dose according to treatment group randomization. In the open-label extension, itacitinib administered at doses determined from the double-blind period.
71222|NCT03627052|Drug|Placebo|Placebo administered orally twice daily in the double-blind period.
71223|NCT03627039|Drug|SGLT2|All SGLT2 medications approved prior to 2017 will be included (Canagliflozin, empagliflozin, dapagliflozin (all doses, all of the medications are oral)
71224|NCT03627039|Drug|Metformin|Metformin is the main comparator of interest. In a secondary analysis GLP1 will be the comparator
71225|NCT03627026|Other|Blood samples will be collected at different time points:|"Baseline~Week 6 Day 1~Week 12 Day 1~If feasible, an optional tumor biopsy specimen will be collected during baseline visit for a maximum of 30 patients included in IUCT-O center."
71226|NCT03627013|Drug|Custodiol-N Solution|Perfusion
71227|NCT03627013|Drug|Custodiol HTK Solution|Perfusion
71228|NCT03627000|Other|failure after reimplantation|description of cinical and microbiological failure
71229|NCT03626987|Diagnostic Test|mass spectrometry (MALDI-TOF)|The determination of the protein composition of the bacterial spectrum
71230|NCT03626974|Biological|Venipuncture|Venipuncture for blood collection
71231|NCT03626974|Device|Diffuser spreading odor|Diffuser will place under a Hood with an air-flow
71232|NCT03626961|Other|readmission|Readmission after 48 hours
71233|NCT03626961|Other|discharge|Discharge
71234|NCT03626948|Drug|SK-1403|Patients receive SK-1403 three times a week administered by intravenous bolus injection at the end of each hemodialysis for the whole treatment periods (52 weeks), with individual dose adjustment.
71235|NCT03626935|Device|3D-printed customized guide plate|3D-printed customized guide plate will be used in the ankle arthrodesis to help reduce operation time and reduce intra-operative radiation.
71236|NCT03626922|Drug|Pembrolizumab|Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
71237|NCT03626922|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV on Day 1 of each 21 day cycle until maximum of 35 cycles.
71238|NCT03626922|Drug|Oxaliplatin|"Oxaliplatin-Dose level1: 85 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~Dose level 2: 120 mg/m2 IV on Day 1 of each 21 day cycle until a maximum of 35 cycles or until discontinued due to patient election, toxicity, disease progression.~The MTD dose of oxaliplatin in the study combination of Cohort 2 will be the recommended Phase II dose (RP2D) for the cohort expansion."
71239|NCT03626922|Drug|Dexamethasone|Dexamethasone-4 mg by mouth twice daily on: the day before, the day of, and the day after each dose of pemetrexed.
71240|NCT03626922|Dietary Supplement|Folic Acid|Folic Acid-400 micrograms by mouth daily starting 5 days prior to first dose of pemetrexed and continue daily to include 21 days after the last dose of pemetrexed.
71241|NCT03626922|Dietary Supplement|Vitamin B-12|1000 micrograms administered intramuscularly 7 days prior to the first dose of pemetrexed, every 9 weeks, and should continue until 3 weeks after the last dose of pemetrexed.
71242|NCT03626909|Other|Primary visit and assessment|"At the initial visit on entry into the program CHW will collect information and the application will guide initial treatment and referral recommendations. At this visit:~Collection of demographic information and relevant past medical history Medication history, adherence and side effects Glycemic testing, vital signs, and other anthropometric data. Screening for possible complications of diabetes Recommendations for referrals Medication recommendations and counseling"
71243|NCT03626909|Other|Follow up visits|CHWs will meet with patients once per month to follow up on adherence and tolerance to medications, assess glycemic control, assess for complications of diabetes, refill medications (with dosing adjustments as needed for side effects, non-adherence or poor glycemic control), and provide diabetic education. These monthly visits will be facilitated by the smartphone application monthly protocol
71244|NCT03626909|Other|3 month visits|At every 3rd monthly visit, starting with the visit 3 months after enrollment, A1c will be assessed. When A1c is checked, the month 3 medication titration algorithm, is used rather than the monthly titration algorithm, which uses blood glucose. Other than checking A1c and using the A1c-based algorithm as indicated, the procedures performed at the month 3 visit are identical to those of the monthly visit.
71245|NCT03626909|Other|Unscheduled visits|The CHWs live in the same communities as the patients they will be serving. As such, the investigators recognize that patients may come to them with concerns outside of the structure of monthly visits as described above. The investigators have designed an additional module for the smartphone application that guides the CHWs through an assessment for hypoglycemia or severe hyperglycemia and possible complications of diabetes. If a patient or CHW has a concern outside of the scope of these protocols, the CHW will contact a CHW coordinator and/or the medical director for guidance
71246|NCT03626896|Device|NaviFUS System|BBB Disruption by FUS in recurrent GBM Other Name: Neuronavigation-guided focus ultrasound system
71247|NCT03626883|Procedure|single-bundle, single-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with single hamstring tendon
71248|NCT03626883|Procedure|single-bundle, double-hamstring ACL reconstruction|anterior cruciate ligament reconstruction with 2 hamstring tendons
122591|NCT03228433|Drug|TAK-418 Placebo|TAK-418 placebo-matching capsules.
71249|NCT03626857|Device|Neuromuscular Electrical Stimulation (NMES)|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40& of the contralateral MVIC.
71250|NCT03626857|Other|Eccentric Exercise (ECC)|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
71251|NCT03626857|Device|Neuromuscular Electrical Stimulation (NMES) placebo|The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period. Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
71252|NCT03626857|Other|Eccentric Exercise (ECC) placebo|4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
71253|NCT03626844|Procedure|Manual Lysis of Placenta after 15 minutes (Intervention)|Manual Lysis of Placenta after 15 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
71254|NCT03626844|Procedure|Manual Lysis of Placenta after 30 minutes (Control)|Manual Lysis of Placenta after 30 minutes: We administer prophylactic antibiotics, under epidural analgesia, under aseptic conditions, we perform manual lysis of placenta by introducing the hand through the vagina to the uterine cavity, separating and removing the placenta.
71255|NCT03626831|Drug|Evolocumab Prefilled Syringe|Injection of study drug
71256|NCT03626831|Drug|Placebos|Injection of placebo
71257|NCT03626792|Other|Hypertensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
71258|NCT03626792|Other|Normotensive group|Pilates 12-week training on the ground, often 3 times a week for 50 minutes of prescribed method exercises.
71259|NCT03626779|Other|Prf|Take 10cc blood from patient and gain prf blug
71260|NCT03626766|Behavioral|Photo in Verification Alert|Patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
71261|NCT03626766|Behavioral|Photo in Banner|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record.
71262|NCT03626766|Behavioral|Photo in Banner and Verification Alert|Patient photograph will be displayed in the banner at the top of the screen in the electronic health record AND patient photograph displayed in a patient ID verification alert when placing electronic orders in the electronic health record.
71263|NCT03626753|Drug|Nefopam 20 MG/ML|given by Oral route the dose of 20mg every 6 hours.
71264|NCT03626753|Drug|"Nefopam (Acupan) 20 MG/ML Injectable Solution"|given by intravenous route at the dose of 20mg every 6 hours.
71265|NCT03626753|Drug|"Acetaminophen, (paracetamol) 500Mg Tab"|"2 tablets of Acetaminophen (paracetamol) 500Mg Tab administrated orally every 6 hours."
71266|NCT03626753|Drug|"(Acetaminophen paracetamol) IV Soln 10 MG/ML"|Acetaminophen IV Soln 10 MG/ML, 1g paracetamol administrated intravenously every 6 hours.
71267|NCT03626753|Drug|"(Piroxicam piroxan) 20 MG Oral Tablet"|"2 tablets of piroxicam (piroxan) administrated orally once per 24 hours."
71268|NCT03626753|Drug|"(Piroxicam piroxan) 20Mg/1mL Injection"|"2 ampoules of (piroxicam piroxan) administrated intravenously once per 24 hours."
71269|NCT03626740|Other|TheraCal|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with TheraCal
71270|NCT03626740|Other|MTA|Caries removal without pulp exposure (stepwise excavation) followed by indirect pulp capping with MTA
71271|NCT03626727|Drug|Sodium Oxybate Oral Solution [Xyrem]|Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
71272|NCT03626714|Drug|Sustained Release Injectable Tacrolimus|Long-acting formulation of tacrolimus developed using Auritec's proprietary Plexis drug delivery technology.
71273|NCT03626701|Device|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings.
71274|NCT03626701|Combination Product|Mepilex® Wound Dressing|Application of Mepilex® Wound Dressing on partial-thickness burn injury
71275|NCT03626701|Procedure|Conventional autografting (only when indicated)|When indicated, conventional autografting in accordance with Investigator's standard practice
71276|NCT03626688|Drug|Ralinepag|Active
71277|NCT03626688|Drug|Placebo|Placebo
71278|NCT03626675|Procedure|phaco- trabeculectomy|combined phaco-trabeculectomy surgery
71279|NCT03626662|Drug|AMG 890|Ascending Single Doses of AMG 890
71280|NCT03626662|Drug|Placebo|Calculated volume to match experimental drug.
71281|NCT03626649|Device|DiamondTemp Cardiac Ablation System|"The DiamondTemp Ablation System is the test device in this investigational study. The DiamondTemp Ablation System consists of:~DiamondTemp Ablation Catheter~o Unidirectional and Bidirectional models~DiamondTemp Catheter-to RFG Cable~DiamondTemp GenConnect Cable~DiamondTemp FASTR Generator with Footswitch~DiamondTemp Irrigation Pump~DiamondTemp Irrigation Tubing Set"
71282|NCT03626636|Drug|Risuteganib|Subjects injected intravitreally with 1.0mg of Luminate®
71283|NCT03626636|Other|Sham|Sham injection
71284|NCT03626623|Device|Cytal Wound Matrix 1-Layer|Cytal® Wound Matrix 1-Layer is composed of a porcine (pig) derived extracellular matrix known as urinary bladder matrix. It is intended for the management of a variety of wounds.The individual device is intended for one time use.
71285|NCT03626623|Other|Standard of Care (SOC)|Standard of care (SOC) is defined as the usual care a licensed health care provider would give patients to treat diabetic foot ulcers or wounds. SOC associated procedures and policies may vary across clinical settings.
71286|NCT03626610|Behavioral|Exercise prehabilitation during chemotherapy before surgery|Monitored exercise training in patients with a new diagnosis of oesophageal adenocarcinoma
71287|NCT03626597|Diagnostic Test|Urine Pregnancy Test|CHV will provide all participants with in-person urine pregnancy tests (UPTs)
71288|NCT03626597|Behavioral|CHV-based post-test counseling & referral|CHVs will provide in-person post-test counseling & referral to care
71369|NCT03625856|Dietary Supplement|Chlorella Vulgaris|Chlorella capsules 1500 mg/day
71289|NCT03626597|Behavioral|Phone-based post-test counseling & referral|Participants will call/SMS or be called/SMSed for phone-based counseling & referral to care
71290|NCT03626584|Other|18F-NaF PET|Hybrid 18F-NaF PET/MR imaging for observational diagnostic purposes
71291|NCT03626571|Other|18F-FDG|Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
71292|NCT03626558|Other|ultrasound measures|It is three diaphragmatic ultrasounds measures of a duration of twenty minutes each approximately. The diaphragmatic ultrasound is practised by trans-thoracic way and is non-invasive, completely painless and does not require the exposure of patients to radiation.
71293|NCT03626545|Drug|Canakinumab|Canakinumab, subcutaneous, administred at the recommended Phase III regimen (defined in the safety run-in part)
71294|NCT03626545|Drug|Docetaxel|Standard of care: docetaxel 75mg/m2, intravenous, every 3 weeks
71295|NCT03626545|Other|Placebo|Placebo, sub-cutaneous, administered at the recommended Phase III regimen (defined in the safety run-in part).
71296|NCT03626532|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|"The MBSR program is a mind-body approach developed by Kabat-Zinn to reduce pain and stress through mindfulness meditation. MBSR is a form of mental training characterized by the self-regulation of attention and focal orientation to present moment experiences. Mindfulness practice is thought to effectively promote emotional and cognitive control. Mindfulness includes directing awareness away from thoughts, emotions and sensations towards some specific anchor to the present, such as the breath. Participants will engage in various practices including breath awareness, body scans, mindful listening, etc."
71297|NCT03626532|Behavioral|Lifestyle Education (LifeEd)|This group will engage in light stretching exercises at each session. They will also be provided with information drawn from the scientific literature on topics related to healthy aging, including physical activity, sedentary behavior, nutrition, hydration, stress, sleep, and cognitively stimulating activities. Group discussion will be incorporated throughout.
71298|NCT03626519|Other|Test with Menthol|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
71299|NCT03626519|Other|Test with placebo|patients will perform a Six-minute walk test according to American Thoracic Society guidelines
71303|NCT03626480|Other|No treatment|No treatment
71304|NCT03626467|Biological|HPV9v|Single-arm, phase 4 study. Patients will be treated with HPV9v vaccine at baseline, week 8 and week 24
71305|NCT03626454|Drug|Norepinephrine Bolus|'Norepinephrine Bitartarte' bolus of 6 µg/mL for 30 seconds immediately after intrathecal injection
71306|NCT03626454|Drug|Norepinephrine infusion|an infusion of 6 µg/mL norepinephrine that was started at 6 µg/kg/h immediately after intrathecal injection
71307|NCT03626454|Drug|Normal Saline Flush, 0.9% Injectable Solution|10 ml normal saline in syringe for bolus for 30 seconds immediately after intrathecal injection
71308|NCT03626454|Drug|Normal Saline 0.9% Infusion Solution|50 ml syringe with normal saline infuse at a rate 1ml/kg/h immediately after intrathecal injection
71309|NCT03626441|Dietary Supplement|Ginger|Capsules containing 0.5g ginger powder, flavoured with non-active essence of ginger
71310|NCT03626441|Dietary Supplement|Placebo|Two coloured capsules containing 0.5 mg of cornstarch and flavoured with non-active essence of ginger.
71311|NCT03626415|Drug|PF-04965842|PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
71312|NCT03626402|Behavioral|Planning for the Care You Want|25-minute culturally specific educational video informing viewers about advance care planning options, palliative care, and hospice care and meeting with a lay health advisor to discuss content of the video.
71313|NCT03626389|Other|Physiotherapy|
71314|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily|Treatment used in standard of care
71315|NCT03626376|Drug|oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops|Topical steroid medications to be used in this study include Prednisolone acetate 1.0% or Prednisolone sodium phosphate 1%. The choice of formulation will be dependent on physician preference and medication availability. Formulations of other potencies such as Difluprednate emulsion will not be used in this study. Patients in the study arm will be started on topical corticosteroid 1 drop once a day in the affected eye.
71316|NCT03626363|Behavioral|Stress Management|An eight week stress reduction course.
71317|NCT03626337|Drug|Thiamine 100 MG/ML|100 mg thiamine provided as intramuscular injection
71318|NCT03626324|Device|C2P|The C2P is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The C2P is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
71319|NCT03626311|Dietary Supplement|AKBM-3031|"Krill are shrimp-like small crustaceans (up to 6 cm) found in all the world's oceans, but mostly in the Arctic and Antarctic polar seas. Krill are rich in the long-chain omega-3 polyunsaturated fatty acids or LC-PUFAs eicosapentaenoic acid (EPA, C20:5n3) and docosahexaenoic acid (DHA, C22:6n3). The lipid pool of krill is composed of phospholipids and triglycerides and the LC-PUFAs are primarily in the phospholipid fraction.~The product is produced under food Good Manufacturing Practice (GMP) regulations and has status as GRAS or Generally Recognized As Safe. GRAS is defined by the US Food and Drug Administration (FDA) as a substance that is generally recognized, among qualified experts, to be safe under the conditions of its intended use."
71370|NCT03625856|Dietary Supplement|Placebo|Starch 1500 mg
71320|NCT03626311|Other|Placebo|The placebo will be provided in capsules looking exactly as the krill oil capsules and will contain a fatty acid mixture (olive oil, corn oil, palm oil and medium chain triglycerides) which has the same composition as the average European diet (26.0% C16:0, 4.6% C18:0, 35.8% C18:1n9, 16.7% C18:2n6, 2.1% C18:3n3, 0% C20:4n6 and 14.8% other compounds) and contains no EPA or DHA.
71321|NCT03626298|Drug|Adapalene|third-generation topical retinoid primarily used in the treatment of mild-moderate acne. It is effective against acne conditions where comedones are predominant.
71322|NCT03626298|Drug|Nicotinamide, ABA and Zinc PCA|combination of three non-antibiotic active ingredients of nicotinamide, anti-bacterial adhesive agent (ABA) and zinc, or abbreviated as ANAZ to be well-tolerated by patients with acne vulgaris
71323|NCT03626298|Drug|Placebos|Placebo cream. to resemble an active medication or therapy so that it functions as a control; this is to prevent the recipient(s) and/or others from knowing (with their consent) whether a treatment is active or inactive, as expectations about efficacy can influence results.
71324|NCT03626285|Procedure|Bone Marrow Transplantation|Undergo BMT
71325|NCT03626285|Device|CliniMACS CD34 Reagent System|CD34 selection ex vivo
71326|NCT03626285|Procedure|Peripheral Blood Stem Cell Transplantation|Receive CD34-selected peripheral blood stem cells from related or unrelated donors
71327|NCT03626272|Other|educational intervention|The simulation scenarios were constructed using the service environment, with real equipment and materials and a low fidelity mannequin. The interventions were not filmed, and the clinical cases elaborated were fictitious, with clear objectives and developed according to the context of the unit. The simulations took place during the working hours of the participants, with the expected duration of the 10 minutes (average) for the scenario, and the average duration of the debriefing was 10 minutes, which took place immediately after the simulation and in the same location of the scenario.
71328|NCT03626259|Drug|Losartan and Amlodipine|Losartan and amlodipine in fixed combination capsules, 100mg/5mg. One time daily with the first bite of eat meal per 8 weeks
71329|NCT03626259|Drug|Losartan|Losartan capsules, 100mg. One time daily with the first bite of eat meal per 8 weeks
71330|NCT03626246|Other|Kidney disease|"Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~Bone density (DXA)~Thoracic and lumbar spine plain films.~HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~Measure levels of Advanced Glycation End products (AGEs) in the skin."
71331|NCT03626233|Other|collect of placenta, blood and urinary samples at delivery|collect of placenta, blood and urinary samples at delivery
71332|NCT03626220|Procedure|acupuncture|manually manipulate acupuncture at CV6 and three acupoints on each arms and legs
71333|NCT03626181|Device|Theta Burst Stimulation ( Transcranial Magnetic Stimulation)|"Participants will receive bilateral TBS, 5 times daily (15 minutes between), over 5 consecutive days (25 sessions total). In each session they will receive intermittent TBS (iTBS) over left dorsolateral prefrontal cortex (DLPFC), followed by continuous TBS (cTBS) over right DLPFC. Stimulation sites will be targeted with the Localite neuronavigation system and Visor2 software, and according to Talairach coordinates in relation to individual MRIs. Intensity will be standardized at 120% of RMT.~The MagPro stimulator will deliver iTBS over left DLPFC with 1620 pulses in 54 triplet bursts (5Hz) with train duration of 2 seconds, and intertrain interval of 8 seconds. cTBS over right DLPFC will consist of 1620 pulses in 54 triplet bursts, train duration of 2 seconds, with no intertrain interval."
71334|NCT03626168|Dietary Supplement|100% watermelon juice|Participants drank two 12-ounce servings of 100% watermelon juice per day for a four-week period.
71335|NCT03626168|Other|Placebo beverage|Participants drank two 12-ounce servings of a placebo beverage per day for a four-week period.
71336|NCT03626155|Behavioral|Walking|Walking will last 50 minutes and will be at 5.0 km/h and at 0.5% incline
71337|NCT03626155|Behavioral|Seated Control|Participants will be asked to sit quietly and read during a 50 minute control period
71338|NCT03626129|Procedure|Oximetry guided deflation|"At the cath.lab. (Step 1) a hemostasis test is performed: oxymetry device on the thumb, compress a.ulnaris, evaluate if curve on device (=Patent hemostasis). If patent no further action. If not patent, air is deflated until a.radialis is patent (curve on device and no bleeding). If bleeding occurs before patency then re-inflate 1-2 ml. air until hemostasis (=no patent hemostasis). In patients with Patent hemostasis no action is taken in sixty minutes whereafter the TR-band is fully deflated (Step 2), and if bleeding then air is re-inflated until hemostasis and step 2 is repeated every 20 minutes until the TR-band is fully deflated with hemostasis. If no patent hemostasis at cath.lab. a hemostasis test is performed after 20 min. If patent hemostasis is achieved no action is taken in sixy minutes (as above). If still not patent then further action as in group A."
71339|NCT03626116|Procedure|silicone metacarpophalangeal arthroplasty (SMPA)|Replacement of the metacarpophalangeal (MCP) joint using a silicone arthroplasty
71340|NCT03626103|Behavioral|+ Brief ED Intervention (BI)|Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant
71341|NCT03626103|Behavioral|+ Text|Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
71342|NCT03626090|Biological|Autologous BM MSC|A total of 100-200ml will be harvested from the subject, in either a single or multiple punctures. This will be processed for autologous MSC infusion.
71343|NCT03626077|Other|physical therapy program|this group received specially designed physical therapy program to facilitate eye-hand coordination and fine motor to improve VMI, VP and MC, which included: unbutton buttons, and button in all again; put the pellets in the bottle as fast as he/she can; place the shapes on its form board; build steps, wall, pyramid and a tower from cubes; cut out a line, square, triangle, and rectangular shapes on a paper by scissor; string squared cubes and lace the holes of strip.Children were trained for 60 minutes per session, three times a week for three consecutive months.
71371|NCT03625843|Behavioral|Mindfulness exercises|
71372|NCT03625830|Device|Paclitaxel-eluting PTCA-Balloon Catheter(SeQuent® Please)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
71344|NCT03626077|Device|E-Link Upper Limb Exerciser|The exercises in the E-Link Upper Limb Exerciser System are in the form of simple and exciting games such as soccer, hitting walls, space shooting, driving, arnd throwing balls into a bucket.Children were trained for 60 minutes per session, three times a week for three consecutive months.
71345|NCT03626077|Combination Product|physical therapy program and E-Link Upper Limb Exerciser|physical therapy program and E-Link Upper Limb Exerciser. Children were trained for 60 minutes per session, three times a week for three months.
71346|NCT03626064|Behavioral|Smoking Cessation Counselling|One on one smoking cessation counselling with a certified mental health nurse
71347|NCT03626064|Drug|Nicotine Replacement Therapy|Access to a range of nicotine replacement therapy: nicotine patch, nicotine gum, nicotine lozenge, nicotine inhaler
71348|NCT03626051|Device|Rigid tape|This taping method used an anchor, two stirrups, three figure-six's (two preventing inversion and one preventing eversion), heel lock and a lock off. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
71349|NCT03626051|Device|Fibular tape|This taping method used a rigid strapping tape to reinforce a posterior-superior mobilisation of the distal fibula. Tension was applied on the tape in a posterior and superior direction. Adhesive rigid strapping tape (Leuko Sports Tape, Beiersdorf Australia Ltd, North Ryde) of 3.8 cm thickness was used for all participants
71350|NCT03626038|Device|A.L.P.S. Proximal Humerus Plating System|Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
71351|NCT03626025|Other|Spaced learning|Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
71352|NCT03626012|Drug|BIIB078|Administered as specified in the treatment arm.
71353|NCT03626012|Drug|Placebo|Administered as specified in the treatment arm.
71354|NCT03625999|Behavioral|video game training exercise|"The game, called The Silent Service and developed by our collaborators, is an online game with an underwater theme, and is comprised of 5 distinct mini-games, each of which demands auditory attention. The mission is to navigate an underwater scene, listening and responding to 'sonar' (e.g., an oddball in a stream of sounds). For example, participants may have to respond to an oddball sound stream to protect their submarine from a looming sea monster, while successfully ignoring a distractor sound stream (responses to the distractor sound stream allow the sea monster to damage the submarine). The five games share the same underlying framework of detecting oddballs while ignoring distractors but have unique artwork and 'backstories' to keep players interested. There is a hierarchical reward structure for 'leveling up' across the game that helps players to stay engaged and interested while playing."
71355|NCT03625986|Other|Nicotine-Containing Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a vape pen-style device and comprises a replaceable pre-filled liquid reservoir (tank) and a rechargeable power supply unit. The experimental group in this project will receive a SREC device with liquid containing 15 mg/mL of nicotine."
71356|NCT03625986|Other|Non-Nicotine Electronic Cigarette|"The electronic cigarette (e-cig) used in this study will be the Standardized Research Electronic Cigarette (SREC). The SREC product is a vape pen-style device and comprises a replaceable pre-filled liquid reservoir (tank) and a rechargeable power supply unit. The placebo group in this project will receive a SREC device with liquid containing 0 mg/mL of nicotine."
71357|NCT03625973|Behavioral|3D-RT|Objects printed using 3D printing media will be used as stimuli in Reminiscence Therapy
71358|NCT03625973|Behavioral|RT-Verbal|Verbal cues will be used as stimuli in Reminiscence Therapy
71359|NCT03625960|Drug|Cantharidin|A thin film of cantharidin is applied to the surface of the wart and to 1 millimeter area surrounding the wart. After the film dries, it is covered with an occlusive dressing for 24 hours. The patient removes the area the next day and thoroughly washes the area with soap and water. Patients return to clinic a week later.
71360|NCT03625960|Drug|Trichloroacetic Acid|Trichloroacetic acid is applied to the surface of the wart with a wooden applicator and after drying the area is washed with soap and water in an hour.
71361|NCT03625947|Other|Argon Plasma Coagulation|Patients will be treated with Argon Plasma Coagulation. Argon plasma coagulation (APC) is a form of non contact electrocoagulation. APC utilizes electrically conductive argon plasma as a medium to deliver high-frequency current via a flexible probe. The argon plasma flow transfers electricity between the probe and the target tissue. Tracheobronchial access is obtained by passing the probe through the working channel of the bronchoscope. On arrival to the tissue, the application of energy causes uniform zones of desiccation, coagulation and devitalization in the areas receiving treatment, thus inducing hemostasis.
71362|NCT03625934|Biological|VVX001|5 s.c. injections of 20 micrograms of VVX001 four weeks apart
71363|NCT03625934|Biological|Placebo|5 s.c. injections of matching Placebo four weeks apart
71364|NCT03625921|Behavioral|Powered device with physical therapy|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in a device-specific physical therapy (PT) program.
71365|NCT03625921|Behavioral|Powered device with standard of practice|Subjects will be fit with a powered prosthesis (Ottobock emPOWER) and enrolled in the current standard of practice training, which includes basic device education and prosthetic training.
71366|NCT03625908|Device|OCT-guided PCI|Patients will receive PCI under OCT-guidance. Predefined criteria for optimization of PCI under OCT-guidance will be recommended to achieve as far as possible.
71367|NCT03625908|Device|Angiography-guided PCI|Stent optimization using high-pressure non-compliance balloon will be highly recommend. Balloon size would not be less than the stent diameter.
71368|NCT03625869|Device|PiCSO|After blood flow restoration, the subjects meeting all inclusion and none exclusion criterial will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes (at minimum 30 minutes) whereas the treatment should be continued during and post stent insertion, but should not exceed a maximum duration of 90 minutes. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
71373|NCT03625830|Device|rapid exchange PTCA -Balloon Catheter (SeQuent® Neo)|SeQuent® Please in length of 10 mm, 15 mm, 17 mm, 20 mm, 26 mm, 30 mm and in diameter of 2.0 mm, 2.5mm, 2.75mm will be used in the trial.
71374|NCT03625817|Behavioral|Mountainous setting|The mountainous setting is characterized by lower temperatures (about 8-10C ambient air temp.) than those in urban setting, also having >800m altitude.Each period will last for 1 week with a wash out period of minimum 2 days. Continuous skin temperature and ambient temperature monitoring will take place in the last day of each period, towards the end. During the 2 sampling days, 24-hour urine voids will be collected in different vials. Participants will be required to fulfill a diary with their daily activities, meal times, collection of urine times, sleep/wake times and times of leaving/entering a closed environment.
71375|NCT03625804|Genetic|PNS+AO+Training|Electrical stimulation was applied to the radial and ulnar nerve (PNS) of the paretic arm for 60 minutes. During the last 30 minutes of PNS, action observation (AO) was introduced in which subjects were required to watch a series of video clips. After one hour's PNS+AO, the subjects then proceeded to a 30-minute period of motor training of paretic hand.
71376|NCT03625804|Genetic|PNS+AOsham+Training|PNS was given as described before. During the last 30 minutes of the PNS, subjects were shown different photos illustrating a letter, a number or a hand as AOsham. The protocol of motor training was the same as described before.
71377|NCT03625804|Genetic|PNSsham+AOsham+Training|The 1-hour PNSsham was conducted with the electrical stimulation unit turned on but without current output. The protocols for AOsham and motor training were the same as those described before.
71378|NCT03625791|Biological|blood sample|1 tube with 4 ml of blood per patient
71379|NCT03625778|Drug|MEDI0382|MEDI0382 administered subcutaneously daily
71380|NCT03625778|Drug|Placebo|Placebo administered subcutaneously daily
71381|NCT03625765|Device|SmartGoggles|the system is wearable and simulates natural binocular human vision, which minimizes the training curve for new users. The wide-field stereoscopic imaging allows clinicians to rapidly determine the extent of lesions and the hand-held microscopy probe assist clinician to visualize the lesions with high resolution.
71382|NCT03625752|Device|Active Comparator: Active tDCS + Active TUS|Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
71383|NCT03625752|Device|Sham|Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes. Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
71384|NCT03625739|Drug|anti-tuberculosis drug|The intervention drugs are prescribed by treating caregiver
71385|NCT03625726|Biological|Thrombin generation assay (in vitro)|One blood sample.
71386|NCT03625700|Drug|Oxygen gas|Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
71387|NCT03625687|Drug|Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 12 weeks|12 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)
71388|NCT03625674|Behavioral|explanation when prescribing psychoactive medicine|explanation of the pathogenesis of FD and the mechanism of psychoactive medicine
71389|NCT03625661|Drug|Ferinject|Ferinject 50mg/ml, one injection
71390|NCT03625648|Drug|Pentoxifylline|The non-specific phosphodiesterase inhibitor pentoxifylline (PTX) was approved by the FDA in 1984 for the treatment of peripheral vascular disease.
71391|NCT03625648|Drug|Placebo|placebo
71392|NCT03625635|Other|Individualized food-based intervention|Diet plans and recommendations will be based on the individual's nutritional status, symptoms and treatment side-effects, socioeconomic and cultural preferences; as well as the WCRF/AICR guidelines adapting 1.5g/kg/d of dietary protein and when required, a caloric restriction (500-1000 kcal/d). Garlic and cruciferous vegetables will be encouraged as well as 5-9 servings of fruits and vegetables a day. The program will be based on the macronutrient meal-equivalent menu method, and standard food servings will be based on the Mexican Food Equivalent System. Breast cancer patients follow-up will be every 2-weeks and a different diet menu will be provided in each session by a specialized dietitian, unto 6-mo are completed.
71393|NCT03625622|Drug|AR1001|AR1001 Active Oral Tablet
71394|NCT03625622|Drug|Placebo|Placebo Oral Tablet
71395|NCT03625596|Dietary Supplement|L-Arginine|Acute intervention (3 hours)
71396|NCT03625596|Dietary Supplement|Nitrate / Nitrite|Acute intervention (3 hours)
71397|NCT03625596|Dietary Supplement|Placebo|Acute intervention (3 hours)
71398|NCT03625570|Behavioral|Power training combined with interval treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors according to resistance training guidelines for muscle power training. The interval treadmill training portion will include short-bursts (30 seconds) of high speed walking intervals alternating with 30 seconds of low to moderate speed walking for a total of 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
71399|NCT03625570|Behavioral|Strength training combined with traditional treadmill training|Training will consist of unilateral and bilateral leg presses, targeting the quadriceps, hip extensors, and plantarflexors following the dosing and resistance training guidelines for muscle strength. Traditional treadmill training will consist of walking at steady-state speeds for 30 minutes. Participants will train 3 x per week for 8 weeks. Total duration of each session will be approximately 1 hour.
71400|NCT03625544|Procedure|Instrumented posterolateral spinal fusion|Instrumented posterolateral spinal fusion, with or without an additional interbody device
71401|NCT03625544|Device|MagnetOs™ Granules|8-10cc of MagnetOs™ Granules per spinal level at the randomized allocation side of the spine (left or right)
71402|NCT03625544|Procedure|Autologous bone graft|8-10cc autologous bone graft per spinal level at the control side of the spine (left or right). This can be a combination of local bone and iliac crest bone, but at least 50% of the volume has to be iliac crest bone graft.
71403|NCT03625531|Other|Acupuncture|Women in both personalized and fixed acupuncture groups will receive acupuncture treatment three times a week. Acupuncture treatment will start on day 3 after a spontaneous period or after a withdrawal bleeding following progestin. Each treatment session will last for 30-60 minutes, with a maximum of 48 treatment sessions over 16 weeks. If they become pregnant, the acupuncture treatment will be stopped. For personalized and fixed acupuncture group, credibility and expectancy questionnaires will be completed on the third acupuncture treatment and the last acupuncture treatment.
71404|NCT03625531|Drug|Letrozole|Letrozole will be started on day 3 to day 7 of the spontaneous period or a withdrawal bleeding following progestin. If there is response with ovulation, this dose will be maintained. In those with no ovulatory response, letrozole tablets of the next ovulation cycle will be take on the day 28 of the menstrual cycle and the letrozole dose will be increased to 5 mg (2 pills) a day for 5 days. If there is still no response, the dose will be increased to 7.5 mg per day for 5 days in the next cycle. The maximum daily dose of letrozole will be 7.5 mg (3 pills) daily for five days.
71405|NCT03625531|Drug|Placebo letrozole|Placebo letrozole will be given in the same way as letrozole. Women will receive 1 tablet a day of placebo letrozole from the day 3 to day 7 of the menstrual cycle and placebo letrozole dose will be increased 2 tablets a day in the next cycle if there is no response. The maximum daily dose of placebo letrozole will be 3 tablets daily for five days.
71406|NCT03625518|Drug|prostaglandins E2|insertion of vaginal PGE2 for up to 30 hours, up to two attempts for cervical ripening and induction
71407|NCT03625518|Device|intracervical balloon catheter combined with pitocin|insertion of Foley catheter intra cervical and inflating the balloon with 50-60 cc of saline, with IV pitocin according to hospital protocol
71408|NCT03625505|Drug|Venetoclax|tablet, oral
71409|NCT03625505|Drug|Gilteritinib|tablet, oral
71410|NCT03625492|Behavioral|Reducing Potentially Irritating Beverages|This group will receive a 7 minute video teaching participants to replace beverages that include caffeine, alcohol, artificial sweeteners, or acidic juices with equal volume intake of water, milk, or other beverages that do not have these ingredients in them.
71411|NCT03625492|Behavioral|Adopting the USDA Healthy Eating Habits|This group will receive a 7 minute video teaching them the USDA guidelines for healthy eating.
71412|NCT03625466|Drug|LUM|Fixed-dose combination (FDC) granule (LUM/IVA)
71413|NCT03625466|Drug|IVA|FDC tablet or granule (LUM/IVA)
71414|NCT03625466|Drug|Matched Placebos|Placebo will be used as a comparator.
71415|NCT03625453|Drug|ABX-1431|Part 1: 8 weeks with daily administration; Patients who choose to enter Part 2: additional 4 weeks with daily administration
71416|NCT03625453|Drug|Placebo|Part 1: 8 weeks with daily administration
71417|NCT03625440|Diagnostic Test|The Digit span test and PASAT with waterpipe smoking|Cognitive tests at baseline and 30minutes after waterpipe smoking
71418|NCT03625440|Diagnostic Test|The Digit span test and PASAT without waterpipe smoking|The Digit span test and Paced Auditory Serial Addition Test (PASAT) at baseline and 30minutes later
71419|NCT03625427|Dietary Supplement|Placebo|The placebo is olive oil, stripped of polyphenols, 70% oleic acid, administered as two 1-gram capsules per day. Packaged as single-serve packets containing 2 capsules for each daily dose.
71420|NCT03625427|Dietary Supplement|Palmitoleic acid, 500 mg (Dose 1)|Palmitoleic acid (POA) 1 gram capsules containing 500 mg POA
71421|NCT03625427|Dietary Supplement|Palmitoleic acid, 1,000 mg (Dose 2)|Palmitoleic acid (POA) taken as two 1 gram capsules each containing 500 mg POA
71422|NCT03625401|Drug|AD-35 60mg group|AD-35 60mg QD
71423|NCT03625401|Drug|AD-35 90mg group|AD-35 90mg QD
71424|NCT03625401|Drug|Placebo group|Placebo: 3 placebo of AD-35 30mg tablets
71425|NCT03625388|Drug|Dasatinib|Film coated tablet contains dasatinib monohydrate
71426|NCT03625375|Other|Exercise|Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
71427|NCT03625362|Dietary Supplement|Hydrogen|Hydrogen-rich water
71428|NCT03625362|Dietary Supplement|Placebo|Tap water
71429|NCT03625349|Drug|NG-Monomethyl-L-Arginine|Inhibitor of nitric oxide synthase.
71430|NCT03625336|Diagnostic Test|MRI|An MRI will be obtained utilizing 3 different MRI sequences
71431|NCT03625323|Drug|Eftilagimod alpha|APC activator, MHC II agonist, LAG-3 fusion protein
71432|NCT03625323|Drug|Pembrolizumab|anti-PD-1 antibody
71433|NCT03625310|Drug|Sodium Fluoride|
71434|NCT03625310|Drug|Sodium Fluoride with TCP|
71435|NCT03625310|Drug|Sodium Fluoride with CXP|
71436|NCT03625310|Drug|Sodium Fluoride with CPP-ACP|
71437|NCT03625297|Other|shelter cat|families will adopt a shelter cat
71438|NCT03625284|Dietary Supplement|Placebo|Edible oil
71439|NCT03625284|Dietary Supplement|FucoVital|Microalgae oil extract
71440|NCT03625271|Device|The PEER Report|PEER Interactive references a subject's QEEG to a normative and then symptomatic database. By comparing a given subject's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER provides useful information regarding the response of neurophysiologically similar subjects to a wide number of medications - providing clinicians with useful information as to medication outcomes before a medication regime is started. Clinicians have also reported that negative findings (in which neurophysiologically similar subjects reported resistant outcomes for certain medications) can be extremely useful in reducing trial and error. It has also been used to help select the medication that best matches the QEEG brainwave pattern.
71441|NCT03625245|Other|Control Yogurt|125 g/day
71442|NCT03625245|Other|Yogurt Variety 1|125 g/day
71443|NCT03625245|Other|Yogurt Variety 2|125 g/day
71501|NCT03624751|Radiation|radioiodine|Patients with thyroid cancer need to choose between Thyrogen® injection and Eltroxin® withdrawal before radioiodine therapy or scan.
71576|NCT03624140|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
71444|NCT03625232|Device|CompuFlo® Epidural Computer Controlled System|"The CompuFlo® Epidural Instrument allows the objective identification of the epidural space by pressure measurement at the needle tip and consequently enables the HCP to perform epidural anesthesia and epidural injections using standard methods. Currently, HCPs rely on their subjective perception to feel a loss of resistance when inserting an epidural needle to identify the epidural space. The CompuFlo® Epidural Computer Controlled Anesthesia System has received a CE mark in the European Union and it received 510(k) clearance from the FDA in June 2017."
71445|NCT03625219|Drug|Prednisone|40 mg (8 x 5mg tablets) for three consecutive days, then 30 mg (6 x 5mg tablets), 20 mg (4 x 5 mg tablets), 10 mg (2 x 5 mg tablets) and 5 mg (1 x 5 mg tablet) daily for two consecutive days for each dose level for a total of 11 days of treatment.
71446|NCT03625219|Drug|Placebo|8 tablets for 3 consecutive days; then 6 tablets, 4 tablets, 2 tablets, and 1 tablet daily for 2 consecutive days for each tablet count for a total of 11 days
71447|NCT03625206|Behavioral|Cognitive bias modification training|These training sessions aim to modify a selective attention bias towards threat and a tendency to interpret ambiguous situations in threatening ways
71448|NCT03625206|Behavioral|Control training|These exercises are matched to the task demands of the modules of cognitive bias modification training
71449|NCT03625180|Biological|NAMIC: nanofractured autologous matrix-induced chondrogenesis|the NAMIC technique consists in: debridement of damaged tissue, removal of calcified cartilage with retention of healthy surrounding vertical cartilage, minimally invasive subchondral bone marrow stimulation, nanofracture (Nano FX, Arthrosurface, USA), and a posteriori protect the lesion, stabilization of the clot, and facilitate stem cell adhesion and proliferation that migrate from the bone marrow with a type I/ III collagen and elastine membrane (Cartimaix, Matricel, Germany).
71450|NCT03625167|Other|Treatment with petrolatum|Petrolatum is applied twice daily to the intervention arm.
71451|NCT03625154|Procedure|ankle open reduction internal fixation|Open Reduction and Internal Fixation with plates and screws
71452|NCT03625154|Other|non operative management|closed reduction and splinting followed by progressive weight bearing
71456|NCT03625128|Drug|F-18|This is an open-label study to evaluate the performance of a novel tau imaging ligand in up to 36 subjects (12 AD, 3 FTD, 3 PSP, 3 CBS, 3 VCI and 12 HV).
71457|NCT03625115|Behavioral|Family Navigator (FN)|The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
71458|NCT03625102|Drug|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
71459|NCT03625102|Other|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
71460|NCT03625089|Drug|Atorvastatin|"Group 1 patients will be prescribed statin when FRS > 10%; while group patients will be prescribed statin upon presence of carotid plaque as reported from carotid ultrasound. The decision will solely be made base on the randomized group by either FRS>10% or presence of carotid plaque.~Atorvastatin 20 mg is recommended as the preferred initial high intensity statin to use because it is clinically and cost effective for the primary prevention of CVD according to the national institute for Health and Care Excellence (NICE) guideline from the United Kingdom."
71461|NCT03625076|Drug|Intra-articular Lidocaine|20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
71462|NCT03625076|Drug|Procedural Sedation with etomidate or propofol|Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
71463|NCT03625063|Other|Exercise training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day at patient's room. Inspiratory muscle training (threshold loading device (Threshold®- Inspiratory Muscle Trainer) at 20-30% of maximal inspiratory pressure (MIP)), upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) will be performed in the treatment group during acute hematopoietic stem cell transplantation process.
71464|NCT03625063|Other|Control training group|All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session each day in patient's room.Upper extremity aerobic exercise training (arm ergometer, at 60-80% of maximum heart rate, dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale) and progressive resistance training (shoulder flexors, shoulder abduction and knee extensors at 4-6 level according to modified Borg scale) except inspiratory muscle training will be performed in the control group during acute hematopoietic stem cell transplantation process.
71465|NCT03625050|Procedure|Chuna + Usual care(Celecoxib and esomeprazole)|"Chuna therapy (CT), 2 sessions/week, 4 weeks (8 sessions in total) Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp).~CT and UC group will receive the same UC regimen."
122593|NCT03228420|Other|CMM|Conventional Medical Management
71466|NCT03625050|Drug|Usual care(Celecoxib and esomeprazole)|"Usual care therapy (UC, Celecoxib 200mg, qd and esomeprazole 20mg, qd), 4 weeks~Usual care consists of physical therapy, CP based medications and patients education. Physical therapy consists of meridian muscle interferential current electricity (or meridian transcutaneous electricity) and hot pack (or infrared lamp)."
71467|NCT03625037|Biological|GEN3013 (DuoBody®-CD3xCD20)|GEN3013 will be administered in cycles of 4 weeks i.e. 28 days. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
71468|NCT03625024|Behavioral|Cognitive-behavioral therapy|Individual cognitive-behavioral therapy, including homework and behavioral change methods.
71469|NCT03625011|Drug|Gabapentin|This double blinded randomized control trial will enroll 50 children age 3-18 years, undergoing T/As. Patients will be receiving either one gabapentin dose (15mg/kg up to 600mg) or placebo preoperatively. Both control and test group will receive the standard narcotic regimen intraoperatively.
71470|NCT03624998|Other|Cognitive and physiatric testing|Neuropsychological test battery and physiatric tests
71471|NCT03624985|Drug|Intravenous Lidocaine Infusion|Patients will be randomly assigned to receive 1 mg/kg lidocaine bolus and intraoperative infusion of 2 mg/min.
71472|NCT03624985|Drug|Placebo Infusion|Patients will be randomly assigned to receive a 1mg/kg bolus of water with 5% dextrose and an intraoperative infusion of 2mg/min. of water with 5% dextrose
71473|NCT03624972|Behavioral|Starting the Conversation Video|The Starting the Conversation program is designed to increase self-efficacy and outcome expectancies for communicating with providers about sexual health and related issues, reduce barriers to communication, and provide basic training in skills for communicating with providers about these topics, including prioritizing concerns, tips for effective communication, communication practice, and self-feedback.
71474|NCT03624972|Behavioral|Sexual and Menopausal Health Resources|Patients will receive a resource list that includes both web-based resources on menopausal and sexual health and center-specific resources, such as contact information for a menopausal & sexual health clinic.
71475|NCT03624959|Drug|Ozanimod|ozanimod
71476|NCT03624959|Drug|Gemfibrozil|Gemfibrozil
71477|NCT03624959|Drug|Itraconazole|Itraconazole
71478|NCT03624959|Drug|Rifampin|Rifampin
71479|NCT03624946|Biological|Zika Virus Immune Globulin (ZIKV-IG)|Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.
71480|NCT03624946|Other|Placebo|Placebo is a normal saline solution (0.9% sodium chloride).
71481|NCT03624933|Behavioral|Weekly Behavioral Coaching Session|The participants will be provided with a 20-minute individual behavioral support session weekly for 4 weeks (28 days of abstinence), designed to provide them with tools and techniques to manage the craving and withdrawal symptoms that occur with cessation.
71482|NCT03624933|Behavioral|Contingency Management|If the participant's weekly abstinence is successful as determined by the urine results on day 28, the participant will receive an additional $300.00 cash bonus on top of their hourly $10 compensation for attending all visits. We predict that this cash bonus is enough incentive to allow for the behavioural change of abstinence in this patient population.
71483|NCT03624920|Drug|THN102 Dosage A|THN102 Dosages A: placebo
71484|NCT03624920|Drug|THN102 Dosage B|THN102 Dosage B : 200mg/2mg
71485|NCT03624920|Drug|THN102 Dosage C|THN102 Dosage C: 200mg/18mg
71486|NCT03624907|Radiation|Daily Stereotactic Body Radiotherapy|After randomization, participants will receive daily standard of care doses of radiotherapy at treating physicians discretion.
71487|NCT03624907|Radiation|Non-Daily Stereotactic Body Radiotherapy|After randomization, participants will receive non-daily standard of care doses of radiotherapy at treating physicians discretion.
71488|NCT03624894|Other|impression|common polyvinylsiloxane oral impression
71489|NCT03624881|Device|Catheter ablation with EPU|Subjects undergoing electrophysiology mapping and RF ablation with THERMOCOOL SMARTTOUCH ® SF (STSF) and THERMOCOOL SMARTTOUCH ® (ST) catheters with VISITAG SURPOINT Module with External Processing Unit for pulmonary vein isolation
71490|NCT03624868|Behavioral|Tai Chi|See above description
71491|NCT03624868|Behavioral|Wellness Education|See above description
71492|NCT03624855|Other|Bone or joint infection due to Pseudomonas aeruginosa|Description of bone or joint infection on implant due to Pseudomonas aeruginosa
71493|NCT03624842|Drug|Trappsol (R) Cyclo (TM)|
71494|NCT03624829|Other|Shared care|The intervention is an adapted version of shared care with close collaboration by services and professional groups, mainly localized in three GP centers. At each GP center one clinical psychologist specialist from the community mental health center (CMHC) works two and a half day a week, and a psychiatrist from the CMHC work at each GP center 1-2 hours a week. The psychologist and the psychiatrist are available for the GPs for consultation and discussions, and they give assessments and brief treatments to patients as requested by the GPs. Other primary health and social care and other specialized mental health or substance addiction services are involved or consulted according to needs of the patients.
71495|NCT03624816|Device|Restylane Defyne|hyaluronic acid dermal filler gel
71496|NCT03624790|Biological|rRSV A/Maryland/001/11|10^5 PFU; delivered intranasally
71497|NCT03624777|Behavioral|Outdoor Fall prevention brochure|Participants in the wait list control group will initially receive written information only about preventing outdoor falls
71498|NCT03624777|Behavioral|Stroll Safe outdoor fall prevention program|Participants in the treatment group will attend a once a week 7-week outdoor fall prevention program that includes didactic presentations, group discussions/ problem solving, practice in strategy use, and action planning for safe community mobility.
71499|NCT03624764|Procedure|Laparostopic promontofixation using surgical glue|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by the surgical glue (cyanoacrylate biocompatible adhesive)
71500|NCT03624764|Procedure|Laparostopic promontofixation using threads|The technique involves implanting a prosthetic tissue (tape) between the bladder and the vagina, suspending the cervix or the vagina affectionately, associated or not with a posterior strip placed between the rectum and the vagina fixed on the small pelvis muscles. Each strip is held by sutures with threads
71502|NCT03624738|Procedure|Procedure|"Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used"
71503|NCT03624725|Procedure|modified BII+Braun|modified BII+Braun digestive tract reconstruction
71504|NCT03624712|Diagnostic Test|uterine neoplasms|Analysis of circulating (CTC) and disseminating tumor cells (DTC), determination of Human Papilloma Virus (HPV), Douglas cytology, DNA analysis in blood, proteome analysis, sentinel lymph node detection
71505|NCT03624699|Device|Glaukos iStent inject®|iStent inject® Devices Implanted in Combination with Cataract Surgery in Patients with Open-Angle Glaucoma
71506|NCT03624686|Other|peripheral blood|draw peripheral blood
71507|NCT03624673|Procedure|endoscopic robot-assisted simple enucleation|Simple enucleation consists of excising the tumor by blunt dissection following the natural cleavage plane between the peritumoral capsule and the renal parenchyma without removing a visible rim of healthy renal tissue.
71508|NCT03624673|Procedure|standard robot-assisted partial nephrectomy|Standard partial nephrectomy is defined as the excision of the tumor and of an additional margin of healthy peritumor renal parenchyma.
71509|NCT03624660|Radiation|HR-A|"The prostate and proximal seminal vesicles will be treated to 2 cobalt gray equivalent per fraction for 39 fractions for a total of 78 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
71510|NCT03624660|Radiation|HR-B|"The prostate, proximal seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and proximal seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 16 fractions for a total of 32 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
71511|NCT03624660|Radiation|HR-C|"The prostate, entire seminal vesicles, and pelvic nodes will be treated to 2 cobalt gray equivalent per fraction for 23 fractions for a total of 46 cobalt gray equivalent.~The prostate and entire involved seminal vesicles will be treated to an additional 2 cobalt gray equivalent per fraction for 7 fractions for a total of 14 cobalt gray equivalent.~The prostate, entire involved seminal vesicle, and at least the proximal seminal vesicle on the uninvolved side will be treated to an additional 2 cobalt gray equivalent per fraction for 9 fractions for a total of 18 cobalt gray equivalent.~Simultaneous integrated boost to the IPT will be delivered to 2.2 cobalt gray equivalent per fraction for 39 fractions for a total of 85.8 cobalt gray equivalent.~Treatment will be given once a day, approximately 5 treatments per week (Monday- Friday), over 8-9 weeks."
71512|NCT03624647|Device|Power toothbrush|Experimental power toothbrush
71513|NCT03624647|Device|Manual toothbrush|Marketed manual toothbrush
71514|NCT03624621|Behavioral|Functional Remediation|Functional remediation includes directed group sessions tapping into the main cognitive domains affected in depression (executive functioning, attention and memory) as well as their implication in daily living.
71515|NCT03624621|Device|Computerized Cognitive Training (CCT)|12 add-on sessions (20-minute long) after each group session to train cognitive domains.
71516|NCT03624621|Behavioral|Psychoeducation|12 sessions of psychoeducation on depression, providing information about the disease, causes, consequences and other useful data for the management of depression.
71517|NCT03624621|Device|Online games|Participants play non-directed online games during 20 minutes after each psychoeducation grup session to make the two active intervention more similar.
71518|NCT03624608|Device|AuryzoN Family of Devices|The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
71519|NCT03624595|Drug|Dexmedetomidine|Dexmedetomidine infusion is administered from 16:00 to 08:00 during the night of surgery in the intensive care unit; and will repeated for a maximum of 5 consecutive nights. For patients with mechanical ventilation, the infusion rate is 0.2-0.7 ug/kg/h; for those without mechanical ventilation, the infusion rate is 0.05-0.2 ug/kg/h. The target depth of sedation is Richmond Agitation-Sedation Scale (RASS) -1.
71520|NCT03624595|Drug|Placebo|Placebo (normal saline) infusion is administered in the same rate for the same duration as in the dexmedetomidine group. The conventional sedation is provided when necessary with propofol and/or midazolam by intravenous infusion/injection. The target depth of sedation depth is RASS -1.
71521|NCT03624569|Other|Bagel|A bagel will be consumed daily for 2 weeks.
71522|NCT03624569|Other|Potato|A potato will be consumed daily for 2 weeks.
71523|NCT03624556|Dietary Supplement|EGCG FontUp|Intake of 10mg/kg/day of EGCG, in the form of a dietary supplement (FontUp), two times a day.
71524|NCT03624556|Other|Placebo FontUp|Intake of placebo, in the form of a dietary supplement (FontUp) (without EGCG), two times a day.
71525|NCT03624543|Drug|CFI-400945|"Cycle 1 dose assigned at enrollment, cycle1: day 1-7, 15-21; 28 day cycle.~Cycle 2 onwards (28 days duration):"
71526|NCT03624530|Drug|Tyrosine kinase inhibitor (TKIs)|TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
71527|NCT03624517|Drug|Octreotide|Octreotide infusion for 24-hours in patients with bleeding esophageal varices.
71528|NCT03624504|Device|Micra Transcatheter Pacing System (TPS)|Treatment of subjects eligible for the single chamber ventricular pacemaker per study requirements
71529|NCT03624491|Other|Esophageal pressure measurement guided ventilation|Use of esophageal pressure measurements to guide mechanical ventilation
71530|NCT03624478|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
71531|NCT03624465|Device|Levita Magnetic Surgical System|Device for use as a surgical tool.
71532|NCT03624452|Other|rIPC + Exercise|The interventions consist of exercise training on a static bike three times per week and/or three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes cuff deflation repeated 4 times.
71533|NCT03624452|Other|rIPC only|Three bouts of rIPC per week for 8 weeks. A single bout of rIPC consists of cycles of upper arm cuff inflation for 5 minutes, followed by 5 minutes deflation repeated 4 times.
71534|NCT03624439|Device|Standard double-lumen tube|intubation using standard double-lumen tube with Macintosh laryngoscope
71535|NCT03624439|Device|Double-Lumen Tube Vivasight-DL|intubation using Double-Lumen Video Tube Vivasight-DL with Macintosh laryngoscope
71536|NCT03624426|Device|Automated Somatosensory Evoked Potential device (EPAD@)|After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
71537|NCT03624413|Behavioral|social media intervention|Determine the acceptability and feasibility of the social media intervention among adolescents living with HIV who are transitioning to adult care in South Africa
71538|NCT03624400|Behavioral|Internet-based CBT-I|The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 10 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
71539|NCT03624400|Behavioral|Internet-based psychoeducation|Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 10 weeks modules.
71540|NCT03624387|Other|Painting Sessions|During the GIA painting session, each participant will be given a white canvas, four brushes and four different colors of painting.Their only instruction will be to cover the white color of the canvas. At the end of each session, the performance of the participants will be evaluated based on their neuropsychological conditions before and after Geriatric Inclusive Art session.
71541|NCT03624361|Device|Glaucoma device implantation in a stand-alone procedure|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
71542|NCT03624348|Behavioral|meditation|10 minute per day, 8 week digital meditation
71543|NCT03624335|Procedure|ECC|Early clamping of the umbilical cord
71544|NCT03624335|Procedure|DCC|Delayed clamping of the umbilical cord
71545|NCT03624335|Procedure|Blood Test 6hours|Blood Test 6hours
71546|NCT03624335|Procedure|Blood Test 24hours|Blood Test 24hours
71547|NCT03624335|Procedure|Blood Test 48hours|Blood Test 48hours
71548|NCT03624335|Procedure|Blood Test 28days|Blood Test 28days
71549|NCT03624322|Drug|Zyprexa IM|5mg
71550|NCT03624322|Drug|Zydis|10mg orally disintegrating wafer
71551|NCT03624322|Drug|INP105|Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)
71552|NCT03624322|Device|I231 POD® Device|Precision Olfactory Delivery (POD) device
71553|NCT03624309|Drug|Anlotinib Plus Docetaxel|Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
71554|NCT03624309|Drug|Docetaxel|Docetaxel (75mg/m2 IV d1)
71555|NCT03624296|Device|MRI 7T|MRI 7T
71556|NCT03624296|Other|TEST EDSS|EDSS - Expanded Disability Status Scale
71557|NCT03624296|Other|TEST MSFC|MSFC - Multiple Sclerosis Functional Composite
71558|NCT03624283|Drug|Betahistine|Betahistine is used in the treatment of and vertigo.
71559|NCT03624283|Behavioral|Exercise-based vestibular rehabilitation|Exercise-based vestibular rehabilitation (VR) has proven to be an effective way for managing dizziness by relieving symptoms and improving balance and postural stability.
71560|NCT03624270|Drug|Oral Arsenic Trioxide|Oral arsenic trioxide-based frontline induction, consolidation and maintenance will be provided to patients with newly diagnosed acute promyelocytic leukemia.
71561|NCT03624257|Device|Laser treatment|The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
71562|NCT03624257|Procedure|Mucosal flap surgery|The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
71563|NCT03624244|Drug|Aromatase Inhibitors|Maintenance of AI versus interruption of AI
71564|NCT03624231|Drug|Durvalumab|Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
71565|NCT03624231|Drug|Tremelimumab|Tremelimumab (75 mg) for up to 4 doses/cycles
71566|NCT03624231|Radiation|Radiotherapy|Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)
71567|NCT03624218|Behavioral|Prolonged Exposure Therapy|Using a combination of In vivo and Imaginal exposure, Prolonged Exposure therapy aims to treat those with Posttraumatic Stress Disorder.
71568|NCT03624205|Device|paclitaxel-releasing coronary balloon (SeQuent® Please)|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
71569|NCT03624192|Device|RECELL® Autologous Cell Harvesting Device|Application of RES prepared using the RECELL® Autologous Cell Harvesting Device along with Telfa™ Clear primary and Xeroform™ secondary wound dressings
71570|NCT03624192|Other|Telfa™ Clear and Xeroform™ dressings|Telfa™ Clear and Xeroform™ dressings
71571|NCT03624166|Drug|Ketamine|patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
71572|NCT03624166|Drug|isotonic saline|patients will receive 3 ml of isotonic saline after spinal anesthesia
71573|NCT03624153|Behavioral|robotic-assisted training|Participant will practice about 80-minute robot-assisted training. The fingers motions will include flexion, extension, two fingers pinch and tripod pinch.
71574|NCT03624153|Behavioral|traditional occupational therapy|traditional occupational therapy with clinical rehabilitation tools
71575|NCT03624140|Device|blood measurement|Hemoglobin measurement
71577|NCT03624140|Device|hemoCue|non invasive method of hemoglobin measurement
71578|NCT03624127|Drug|BMS-986165|Specified dose on specified days
71579|NCT03624127|Other|Placebo|Specified dose on specified days
71580|NCT03624127|Drug|Apremilast|Specified dose on specified days
71581|NCT03624114|Procedure|comparison of data from MRI with data from CT compared with intraoperative data from endoscopic pituitary adenoma surgery|A comparison of MRI with CT of the skull base or paranasal sinuses and intraoperative Video documentation of the anatomical site will be used.
71582|NCT03624101|Drug|Tezacaftor/Ivacaftor|CFTR correctors
71583|NCT03624088|Behavioral|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
71584|NCT03624075|Other|application of kinesio taping|application of kinesio taping in the rectus femoris muscle and in the medial and lateral region of the knee
71585|NCT03624062|Drug|MAS-1 adjuvanted Insulin B-chain|MER3101 (MAS-1 adjuvanted insulin B chain (IBC)), is a white, free-flowing 30:70 (w/w) water-in-oil (W/O) emulsion. MER3101 contains in the aqueous (disperse) phase 33, 109, or 327 µg per 0.25 mL dose of IBC (Drug Substance) and the oil (continuous) phase is comprised of MAS-1 oil vehicle.
71586|NCT03624049|Other|Exercise|Community based exercise programs held 2-3 times per week
71587|NCT03624049|Other|Health Class|Community based health class held 1 time per week
71588|NCT03624036|Biological|KTE-X19|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
71589|NCT03624036|Drug|Fludarabine|Administered intravenously
71590|NCT03624036|Drug|Cyclophosphamide|Administered intravenously
71591|NCT03624023|Drug|TWB-103|TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
71592|NCT03624010|Drug|Levosimendan 2.5 mg/ml Injectable Solution|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
71593|NCT03623997|Other|Iron stable isotope labeled iron(II) sulfate|Administration of oral stable isotope labels using different dosings and different regimens in women with iron deficiency anemia
71594|NCT03623984|Drug|Gallium Dotatate|Radioguided Surgery for Pancreatic- Neuroendocrine Cancers
71595|NCT03623971|Device|Cataract AI agent|An artificial intelligence to make comprehensive evaluation and treatment decision of different types of cataracts.
71596|NCT03623958|Device|Image guided Video-Assisted Thoracic Surgery (VATS) resection|Image guided placement of a fiducial consisting of a needle directed placement of a T-Bar next to the target lesion in order to lead the surgeon to the lung region to be removed
71597|NCT03623958|Procedure|Video-Assisted Thoracic Surgery|Standard of Care Video-Assisted Thoracic Surgery (VATS) resection
71598|NCT03623945|Other|Collection of blood|Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer
71599|NCT03623932|Drug|immunosuppressor/TNFalpha|Standard Treatment : immunosuppressor/TNFalpha as in standard practice
71600|NCT03623932|Behavioral|Hypnosis|8 hypnosis group sessions during 2 months
71601|NCT03623919|Other|FallSensing multiplayer games|"FallSensing multiplayer games is a technological solution based on an interactive (exer)game.~Players will wear a strap on the lower limbs contaning an inertial sensor. This device enables movement identification on the characterization in real time, triggering actions in the game.~The exercise games are based on a validated fall prevention exercise plan - the Otago Exercise Programme. The exercises were designed to promote mobility and improve muscle strength and balance."
71602|NCT03623906|Procedure|Carbon dioxide insufflation colonoscopy|Carbon dioxide insufflation colonoscopy
71603|NCT03623906|Procedure|Air insufflation colonoscopy|Room air insufflation colonoscopy
71604|NCT03623893|Procedure|Contralateral exploration|Surgery eventually performed when a patent processus vaginalis or hernia exists on the other side than the side on which the child has to be operated on, will be exactly the same as the inguinal hernia repair on the 'symptomatic' side. Exploration of the contralateral side will increase anaesthesia time by 10-15 minutes.
71605|NCT03623880|Behavioral|Unified Protocol|The unified protocol is a form of cognitive behavior therapy focused on helping the person reduce emotional distress through cognitive changes and behavioral skills. Exercises included confronting emotional-driven behaviors and mindfulness activities.
71606|NCT03623880|Behavioral|Supportive Therapy|Supportive therapy seeks to improve self-esteem, aid the patient with problem solving, and provide structured support using empathetic listening.
71607|NCT03623867|Drug|Secukinumab|Subject will take secukinumab once weekly in week 0-4, and once monthly till week 48
71608|NCT03623867|Drug|Placebo|Subject will take placebo once weekly in week 0-4, and once monthly till week 48
71609|NCT03623854|Biological|Nivolumab|Given IV
71610|NCT03623854|Biological|Relatlimab|Given via infusion
71611|NCT03623841|Other|Dual-task training|Participants in experimental group will do dual-task training via exer-game which combined with treadmill
71612|NCT03623841|Other|Treadmill training|Participants in control group will do treadmill training only
71613|NCT03623828|Drug|Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe|Product administered using an external continuous subcutaneous infusion pump.
71639|NCT03623646|Drug|Immunotherapy + Radiotherapy arm|Radiation Therapy in combination with Immunotherapy drug (Durvalumab)
71640|NCT03623633|Drug|denosumab|denosumab 60 milligrams subcutaneously every 6 months
71641|NCT03623633|Drug|alendronate|alendronate 70 milligrams weekly
71642|NCT03623633|Drug|raloxifene|raloxifene 60 milligrams daily
71866|NCT03621865|Dietary Supplement|TG|Turmipure GOLD™ 30% curcuminoids (300 mg)
71614|NCT03623815|Other|transcranial direct current stimulation|"Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour.~This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered."
71615|NCT03623802|Other|Local Movement Therapy|Loads and intensity of exercises will be increased according to participants' abilities. Modifications of exercises are made through different body positions or increasing the load. When a participant will be able to perform a certain number of repetitions and sets of a required exercise, without any compensatory movements, he/she can proceed to the next level of exercise. Breaks between exercises and sets are the same as in the integral movement therapy protocol. Protocol consists of four basic exercises, which are progressed through sessions: (I) Abdomen curl. (II) Trunk extension on roman chair. (III) Hip bridge. (IV) Side plank.
71616|NCT03623802|Other|Integral Movement Therapy|Protocol consists of four basic exercises, which are progressed through sessions: (I) Proprioception - sitting on an unstable surface - Swiss ball, with additional tasks with legs and arms. (II) Strength - pushing task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (III) Strength - pulling task in different body positions: a) Unstable position - from single plane to multi-plane arm movements. b) Stable position - high number of repetitions - single plane movement. (IV) Lifting and carrying the loads: a) Stoop lifting. b) Squat lifting. c) Half kneeling lifting.
71617|NCT03623789|Drug|intravenous application of tranexamic acid|intravenous application of tranexamic acid1 g TXA before incision, followed by two boluses (1g TXA) three hours later and six hours later.
71618|NCT03623789|Drug|Floseal hemostatic matrix|application of Floseal® on potential bleeding sites after prosthesis implantation
71619|NCT03623789|Drug|Normal saline|Equivalent volume of saline injection before incision, followed by two boluses (1g TXA) three hours later and six hours later.
71620|NCT03623776|Drug|JS001|JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
71621|NCT03623776|Drug|Pemetrexed|Subjects receive pemetrexed of 500 mg/m^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
71622|NCT03623776|Drug|Carboplatin|Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
71623|NCT03623776|Procedure|Thoracic Surgery|Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy.
71624|NCT03623763|Diagnostic Test|Serologic tests of blood samples|Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
71625|NCT03623750|Drug|EGFR-TK Inhibitor|Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
71626|NCT03623750|Biological|EGF-PTI|"The first day of dosing with EGF-PTI will be designated Day 1. Immunisation with EGF-PTI will commence 3 days after low dose cyclophosphamide and commencement of EGFR TKI, and will be repeated on Day 14, Day 28, Day 43, and Day 92. After the 5~th vaccination, patients will enter a maintenance phase during which reduced dose vaccinations will be performed every 2 or 3 months in conjunction with the interval between detailed check-up of the patient. As this interval can vary between patients, the interval for maintenance vaccination can also vary between 2 and 3 months."
71627|NCT03623750|Drug|Cyclophosphamide|Eligible patients will receive a single pre-treatment of low dose of intravenous cyclophosphamide 200 mg/m2 (Day -3).
71628|NCT03623737|Drug|neoadjuvant chemoradiation|"Neoadjuvant chemoradiation:~Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection"
71629|NCT03623724|Behavioral|blended Cognitive-behavioral Therapy|The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
71630|NCT03623724|Other|Treatment-As-Usual|The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
71631|NCT03623711|Drug|Escitalopram|participants take escitalopram tablets based on their severity of depression (10-20mg/day) at least for 12 weeks.
71632|NCT03623711|Drug|Duloxetine|participants take Duloxetine capsule based on their severity of depression (60mg/day) at least for 12 weeks.
71633|NCT03623711|Drug|Bupropion|participants take Bupropion tablets based on their severity of depression (75-300mg/day) at least for 12 weeks.
71634|NCT03623711|Other|Healthy control|Healthy control take placebo tablets
71635|NCT03623698|Drug|Nebulised hypertonic saline|Nebulised hypertonic saline used for a period of at least 12 months
71636|NCT03623685|Diagnostic Test|measurement of uterocervical angle|We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
71637|NCT03623659|Procedure|Laser assisted hatching|After warming, blastocysts are subjected to laser assisted hatching (LAH) following the standard procedure.The LAH procedure lasts one minute per blastocyst.
71638|NCT03623646|Drug|Chemoradiotherapy arm|Radiation Therapy in combination with Chemotherapy (Cisplatin)
71643|NCT03623620|Behavioral|Digital Delivery of Mindfulness-Based Cognitive Therapy|12-week program that emphasizes mindfulness and cognitive behavioral skills
71644|NCT03623594|Procedure|Surgical repair of the diastasis|Repair of the diastasis with a double row plication using absorbable Quill suture
71645|NCT03623581|Biological|GB226|3mg/kg treat every 2 weeks
71646|NCT03623568|Drug|glecaprevir/pibrentasvir tablets|12 weeks of treatment with Mavyret
71647|NCT03623555|Behavioral|Trier Social Stress Test|"The participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. The TSST consists of three successive phases: (1) A preparation period (3min), (2) a free speech task in which the participants have to argue why they are the best candidate for the job they wish to apply for (5min), and (3) a mental arithmetic task in which participants have to sequentially subtract an odd two-digit number from an odd four-digit number (e.g., 17 from 2023; 5min). The two tasks are performed in front of a selection committee (two members), dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback."
71648|NCT03623555|Biological|Salivary cortisol|Saliva samples will be obtained by means of Salivette collection devices before, 10 minutes after, and 30 minutes after the beginning of the TSST
71649|NCT03623529|Drug|LJPC-501 (angiotensin II)|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
71650|NCT03623529|Drug|Placebo|Placebo Arm
71651|NCT03623503|Other|Observational study|
71652|NCT03623490|Other|managment of oral therapy|Initial consultation with a trio oncologist / pharmacist / nurse
71653|NCT03623477|Behavioral|Cognitive Remediation (CRT)|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The cognitive remediation therapy group will complete computerized training activities in attention, memory, processing speed, problem solving, and executive functions.
71654|NCT03623477|Behavioral|CRT+ Social Cognition Training|Study compares two configurations of cognitive training--computerized cognitive remediation versus a combination of computerized cognitive remediation and social cognition training. The combined cognitive remediation and social cognition training group will complete computerized training that target neurocognitive functions, facial affect emotion recognition and mentalizing tasks.
71655|NCT03623464|Other|Mobile health application and Fitbit + standard of care|Mobility data will be generated using a mobile health tracker designed for smartphone devices, which allows the phone to automatically and passively (no patient input needed) capture information on the patient's activity; i.e. if the person is walking, remaining stationary, or moving at a rapid speed (eg. in a car). The app will prompt patients once daily to answer a series of questions that will collect patient reported symptoms and health status data. Physicians will be alerted to abnormal values within 24-48 hours and patients will be triggered to call their physicians immediately if the values are outside of normal parameters.
71656|NCT03623464|Other|Standard of care|Post-operative standard of care information
71657|NCT03623451|Drug|Chinese Medicine Formula|Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for six months.
71658|NCT03623438|Behavioral|Self-administered acupressure group|Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.
71659|NCT03623438|Behavioral|Sleep hygiene education (SHE) group|Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
71660|NCT03623425|Drug|68Ga-PSMA-11 PET|a 68GA-PSMA-11 PET exam before the a 18F-FCH PET exam
71661|NCT03623425|Drug|18F-FCH PET|a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
71662|NCT03623412|Diagnostic Test|75g oral glucose tolerance test|Women with one abnormal value in the OGTT during pregnancy (minor degree of glucose intolerance) will be offered a post-partum 75g GTT (Glucose Tolerance Test), similar to that offered to women with GDM
71663|NCT03623412|Diagnostic Test|75g GTT|post-partum GTT
71664|NCT03623399|Procedure|low gas pressure laparoscopy|To apply different CO2 entrance and intraoperative pressures
71667|NCT03623373|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m^2 IV over 30 minutes on Days 1 and 2 of Cycles 1-3
71668|NCT03623373|Drug|Rituximab|In Cycle 1, rituximab will be administered at a dose of 375 mg/m^2 IV on Day 1 or 2 at the investigator's discretion in order to reduce the risk of a first infusion reaction. Rituximab will be given on Day 1 of Cycles 1 through 6.
71669|NCT03623373|Drug|Acalabrutinib|The capsules should be swallowed intact with water and with or without food.
71670|NCT03623373|Drug|Cytarabine|On Days 1 and 2 of Cycles 4-6, following rituximab dosing, cytarabine will be administered IV every 12 hours for a total of 4 doses.
71671|NCT03623373|Procedure|Leukapheresis|Until collection of ≥ 2 x 106 CD34+ stem cells / kg
71672|NCT03623373|Procedure|Peripheral blood|-Baseline, end of Cycle 3, 4-6 weeks after Cycle 6 Day 1, and if the patient discontinues protocol therapy prior to completion of Cycle 6
71673|NCT03623373|Procedure|Oral rinse|-Baseline
71674|NCT03623373|Procedure|Bone marrow collection|-Bone marrow will be collected at baseline if the patient requires a marrow for staging purposes and at end of treatment if the patient requires a marrow for restaging.
71675|NCT03623360|Diagnostic Test|Free breathing DCE-MRI|Free breathing DCE-MRI
71676|NCT03623347|Other|TMZ and BEV induction before chemoradiotherapy|New approaches are needed for patients newly diagnosed with bulky glioblastoma (GB) and/or with severe neurological impairment that cannot benefit from first line temozolomide (TMZ)-based chemoradiotherapy.
71677|NCT03623334|Radiation|Image-Guided Radiation Therapy|Radiotherapy to a potent tumorcidal dose
71678|NCT03623321|Drug|Pimavanserin|• Pimavanserin 34 mg is provided as 2×17 mg tablets as single dose, once daily by mouth. Dose adjustments of pimavanserin down to 20 mg (provided as 2×10 mg tablets as a single dose, once daily by mouth) and up to 34 mg are permitted based on Investigator assessment of clinical response.
71679|NCT03623308|Other|Fiber cereal|Whole grain and bran cereal
71680|NCT03623295|Other|Blood sample|Blood withdrawal.
71681|NCT03623295|Other|Questionnaire|Online questionnaire about the bleeds that patients experienced in the past.
71682|NCT03623295|Other|MRI-imaging|MRI imaging of joints.
71683|NCT03623295|Other|Physical examination|Physical examination of joint status.
71684|NCT03623282|Drug|Synatura® 15 mL|All subjects will receive Synatura® 15 mL every day three times for 3 months.
71685|NCT03623269|Procedure|posterior approach to total shoulder arthroplasty|The posterior approach to total shoulder arthroplasty approaches the patient from the back of the shoulder and spares the rotator cuff.
71686|NCT03623256|Drug|Spinal fentanyl|25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
71687|NCT03623256|Drug|Spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route.
71688|NCT03623256|Drug|Spinal Fentanyl and Bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL), and 25 mcg of fentanyl (0.5 mL) will be administered by intrathecal route.
71689|NCT03623256|Drug|Epidural fentanyl /spinal bupivacaine|1.25 mg of preservative-free bupivacaine 0.25% (0.5 mL) will be administered by intrathecal route, and 100 mcg of fentanyl (2 mL) will be administered by epidural route.
71690|NCT03623243|Drug|Siponimod|S1P1 and S1P5 receptor agonist
71691|NCT03623230|Procedure|Ultrasound Guided Femoral Nerve Block|Femoral nerve block will be applied post-operatively with guidance of USG and nerve stimulator
71692|NCT03623230|Other|Dressing|Only dressing will be applied to related area to protect blindness between groups
71693|NCT03623230|Drug|Bupivacaine 0.25% Injectable Solution|Perineural Injection
71694|NCT03623230|Drug|Bupivacaine 0.125% Injectable Solution|Perineural Injection
71695|NCT03623217|Behavioral|Qualitative interviews with participants|For the development and validation of a questionnaire.
71696|NCT03623204|Other|Dyspnea evaluation|
71697|NCT03623191|Other|Clinical examination|
71698|NCT03623178|Other|Assertive Community Treatment|The intervention program is a type of very flexible community treatment. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialized in SUD treatment. The time of the intervention differs, there is no prefixed limitation but the duration of the intervention depends on the goals agreed on with the patient. The main objective of this intervention is to ensure an adherence to an addiction treatment program and establish or consolidate a stable healthcare and social network for the patient. The intervention aims to prevent service disengagement. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs.
71699|NCT03623178|Other|Treatment As Usual|The treatment as usual is the intervention given in our outpatient addictology unit. It consists of an individual treatment program at our outpatient unit with regular appointments with psychiatrists and nurses. The patient can also take part in therapeutic groups and receive help from a psychologist for a targeted program or psychotherapy. The multidisciplinary team also comprises a social worker and an occupational therapist.
71700|NCT03623165|Device|Cordella™ Heart Failure System|The Cordella™ Heart Failure System electronically transfers communications and data from a set of medical devices in a heart failure patient's home to a database for storage, retrieval, and display to healthcare providers.
71701|NCT03623139|Behavioral|Standard nutritional education|Routine dietary care consists of three individual consultations with a trained dietitian. The individual guidance will be in accordance with the dietary guidelines in type 2 diabetes.
71702|NCT03623139|Behavioral|Basic carbohydrate counting|The BCC concept is a group-based program consisting of three group sessions delivered by trained dietitians.
71703|NCT03623126|Other|Questionnaire|A questionnaire to evaluate clinical improvement and quality of life after ESSURE removal will be completed by patients at least one month after the procedure.
71704|NCT03623113|Behavioral|BCC intervention|Structured training and education i basic carbohydrate counting principles
71705|NCT03623113|Behavioral|ABC-ACC intervention|Structured training and education i advanced carbohydrate counting principles including the use of a automated bolus calculator carbohydrate
71706|NCT03623113|Behavioral|Standard dietary education|Personalized individual dietary counselling based on overall meal planning, dietary guidelines and the patient's need and preferences
71707|NCT03623100|Behavioral|Speech Production Treatment.|Speech production treatment will be delivered in two phases: Imitation and Spontaneous Production. Treatment will be provided two times weekly in 1-hour sessions, for up to 19 sessions. Every child's intervention program will target a single phoneme that was excluded from his or her phonemic inventory. Each treatment phoneme will be targeted through the production of five words that will be initially introduced to the child using a storybook reading format. Imitation treatment will continue until a child maintains 75% accurate production of the treated phoneme over two consecutive sessions (i.e. performance-based criterion) or until seven consecutive sessions are completed (i.e. time-based criterion). Spontaneous Production will continue until the child maintains either a performance-based criterion of 90% accurate production of the treated phoneme over 3 consecutive sessions, or a time-based criterion of 12 consecutive sessions.
71747|NCT03622814|Behavioral|Partners at Meals|The focus of the intervention is to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals.
71795|NCT03622450|Drug|Colistin|Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
71708|NCT03623100|Behavioral|Speech Production + Speech Perception Treatment.|This speech treatment condition will be administered in the same way as the Speech Production treatment. The difference in conditions will be that speech treatment in this condition will last for 50 minutes rather than 60 minutes. The remaining 10 minutes of each session will involve the speech perception training. These speech perception tasks will involve previously recorded word-level productions focusing on the same phoneme that is addressed in speech production treatment in word-initial position. A variety of words produced correctly and incorrectly by adults and children will be presented in pairs and the children will have to determine if the words contain the same word-initial phoneme or two different phonemes.
71709|NCT03623087|Drug|Cisplatin|SIMPLE
71710|NCT03623087|Drug|Gemcitabine|SIMPLE
71711|NCT03623087|Drug|Etoposide (VP-16)|SIMPLE
71712|NCT03623087|Device|Ifosfamide|SIMPLE
71713|NCT03623087|Drug|Dexamethasone|SIMPLE
71714|NCT03623087|Drug|L-asparaginase|SIMPLE
71715|NCT03623074|Device|Novel spectacle lens design|Use of lenses may reduce the rate of progression of juvenile myopia
71716|NCT03623074|Device|Spectacle lenses|Use of lenses may reduce the rate of progression of juvenile myopia
71717|NCT03623061|Diagnostic Test|F-Point|F-Point (point of care in vitro diagnostic device for measuring plasma fibrinogen concentration)
71718|NCT03623048|Other|chlorhexidine|antibacterial and anti-inflammatory mouthwash
71719|NCT03623048|Other|saline|anti-inflammatory cleansing mouthwash
71720|NCT03623048|Other|Propolis extract|antibacterial mouthwash
71721|NCT03623048|Other|pomegranate extract|antibacterial mouthwash
71722|NCT03623022|Drug|Clinical Center Reference Endotoxin (CCRE)|subjects will undergo an exposure to inhaled endotoxin through a nebulizer for approximately 10 minutes.
71723|NCT03623022|Drug|Normal saline|subjects will undergo an exposure to inhaled normal saline through a nebulizer for approximately 10 minutes
71724|NCT03623009|Behavioral|An article meant to trigger certain psychosocial behaviors|An article meant to trigger certain psychosocial behaviors is administered to the intervention arm prior to laparoscopic skills assessment.
71725|NCT03623009|Behavioral|a neutral article|The control arm will receive a neutral article prior to completing the assessment.
71726|NCT03622983|Other|collection of sample and data|Recovery of surgical waste during surgery planned in the current care and clinical data collection
71727|NCT03622970|Device|VGBT with Nintendo® Wii and LMC games|Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.
71728|NCT03622970|Behavioral|NDT-based upper limb rehabilitation|NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
71729|NCT03622944|Procedure|Muscle Energy Technic|post isometric relaxation technics were applied to levator scapulae, trapezius, pectoralis muscles three sessions per week, totally six weeks.
71730|NCT03622944|Procedure|Deep Friction Massage|deep friction massage was applied to cervical region included tendons, muscles and soft tissue.
71731|NCT03622944|Procedure|Exercise|spinal stabilization exercise were applied three sessions in a week totally six weeks.
71732|NCT03622931|Drug|Standard chemotherapy|Chemotherapy
71733|NCT03622931|Drug|Romiplostim|
71734|NCT03622931|Drug|Placebos|
71735|NCT03622918|Drug|colistin and rifampin combination therapy|Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Rifampin (600 mg, rifampin, Yuhan, Seoul, Korea) will be orally administered daily. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
71736|NCT03622918|Drug|colistin monotherapy|. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment wil be determined through discussion by pulmonology and infection specialist .
71737|NCT03622905|Device|DBS-f On|Deep Brain Stimulation of the fornix
71738|NCT03622905|Device|DBS Off|Deep Brain Stimulation of the fornix turned off
71739|NCT03622879|Behavioral|MT|A customised angle-adjustable frame with a mirror board (60 × 90 cm) will be used. All subjects are instructed to perform hip flexion/abduction, knee flexion/extension and ankle dorsiflexion/plantarflexion on the intact-limb during a 15 minutes period.
71740|NCT03622879|Device|TENS|TENS will be delivered to the common peroneal nerve of the paretic leg. The stimulation frequency will be 100Hz and with an intensity just below the motor threshold.
71741|NCT03622879|Behavioral|Lower-limb task-oriented training|The lower-limb task-oriented training comprises 6 exercises, namely stepping up and down, heel lift a dorsiflexed position, partial squatting, kicking a ball with alternate legs, gait re-education and transition training. Each exercise last for 10 minutes
71742|NCT03622866|Device|Ultra-high pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
71743|NCT03622866|Device|Traditional pulse width stimulation|Algovita Spinal Cord Stimulation System with associated components
71744|NCT03622853|Drug|Steroid (shincort)|intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
71745|NCT03622840|Behavioral|Cognitive Remediation|Weekly 30-45mins Cognitive Remediation Sessions over 11 weeks
71746|NCT03622827|Combination Product|Chemoradiotherapy+ Endostar|"Chemoradiotherapy with Endostar：~Chemoradiotherapy: pelvic radiotherapy starts 2-3 weeks after surgery. Intensity modulated radiotherapy (IMRT) is given five fractions per week at 1.8-2 Gy/fraction/day with total dose summed up to 45-50Gy. The external beam radiotherapy should be completed within 6 weeks.~Concurrent chemotherapy is consisted of cisplatin (75 mg/m2, day 1-3) and 5-fluorouracil (5-FU; 1000mg/m2/day, civ, day 1-4) for 2 cycles every 3 weeks.~Endostar: recombinant human endostatin (15mg/m2/d, civ, d1-7) is given 3 days before the concurrent chemoradiotherapy for 2 cycles every 3 weeks."
71865|NCT03621878|Other|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device aiming to decrease patient's symptoms.
71748|NCT03622814|Behavioral|Enhanced Usual Condition|Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites will receive training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month. The Project Manager will attend the monthly support group for family members about communication. The administrator of the EUC RCC will be interviewed every 6 months the project is in place.
71749|NCT03622801|Drug|Iopromide (Ultravist, BAY86-4877)|Patients who have received Iopromide (iodine concentrations of 300 mg/mL or 370 mg/mL) either intra-venously or intra-arterially.
71750|NCT03622788|Biological|Anti-Thymocyte Globulin|Given IV
71751|NCT03622788|Drug|Cyclophosphamide|Given IV
71752|NCT03622788|Biological|Cytokine-treated Veto Cells|Given IV
71753|NCT03622788|Drug|Fludarabine|Given IV
71754|NCT03622788|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
71755|NCT03622788|Radiation|Total-Body Irradiation|Undergo TBI
71756|NCT03622775|Biological|Daratumumab|Given IV
71757|NCT03622762|Drug|green tea extract|Capsules of green tea extract, 400 mg twice a day, fasting
71758|NCT03622762|Drug|Placebo|Placebo capsules, 400 mg twice daily fasting
71759|NCT03622749|Device|Transcranial Magnetic Stimulation (TMS)|Non-Invasive neuromodulation
71760|NCT03622710|Other|Rehabilitation therapy|Subjects are trained to walk overground (control) or over WTDS (experimental) for 5 days/week over 4 week. Then they will be monthly follow-up for fall data.
71761|NCT03622697|Behavioral|Mindfulness Meditation Phone Application|Mindfulness meditation intervention: patients will be asked to complete a guided mindfulness meditation intervention using a phone application for at least 4 weeks with periodic survey assessments using validated psychometric tools.
71762|NCT03622684|Behavioral|Muscle relaxation according to Jacobson|
71763|NCT03622671|Procedure|Skeletonized LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura
71764|NCT03622671|Procedure|Pedicled LIMA|Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura
71765|NCT03622658|Biological|Placebo|Placebo solution for subcutaneous injection.
71766|NCT03622658|Biological|Namilumab|Namilumab solution for subcutaneous injection
71767|NCT03622645|Device|Assessment of Range of Motion with Leap Motion sensor|An ROM measurement method called as HandROM by us will be developed with leap motion sensor
71768|NCT03622619|Other|Optimel Antibacterial Manuka+ Dry Eye Drops|Leptospermum sp Honey 165mg/g
71769|NCT03622619|Other|Systane Ultra Lubricating Eye Drops|Polyethylene glycol 400 0.4% and propylene glycol 0.3%
71770|NCT03622606|Diagnostic Test|Right Language screening test (R-LAST)|Validation of the Right Language screening test in acute and subacute phase of right stroke
71771|NCT03622593|Drug|Aflibercept|Aflibercept will be administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
71772|NCT03622593|Drug|Faricimab|Faricimab will be administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or as specified in the protocol in arm B.
71773|NCT03622593|Drug|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in all three treatments arms at applicable visits to maintain masking among treatment arms.
71774|NCT03622580|Drug|Aflibercept|Aflibercept will be administered by intravitreal (IVT) injection into the study eye once every 8 weeks (Q8W).
71775|NCT03622580|Drug|Faricimab|Faricimab will be administered by IVT injection into the study eye either once every 8 weeks (Q8W) in arm A or as specified in the protocol in arm B.
71776|NCT03622580|Drug|Sham Procedure|The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in all three treatments arms at applicable clinic visits to maintain masking among treatment arms.
71777|NCT03622567|Behavioral|Smartphone push notifications|The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
71778|NCT03622554|Other|Adapted Physical Activity (APA)|12 APA sessions of 60 minutes
71779|NCT03622554|Other|Therapeutic Patient Education (ETP)|Personalized ETP with 3 group sessions (1h30) and one at the end of the course (1h) and educational follow-up by phone at 3, 6 and 12 months
71780|NCT03622541|Drug|Sorafenib|Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
71781|NCT03622528|Radiation|Chest CT scan|Standard dose chest CT scan
71782|NCT03622515|Combination Product|Anesthesia level and cerebral perfusion pressure|Anesthetic dose and blood pressure
71783|NCT03622502|Drug|Dexmedetomidine|Dexmedetomidine 0.5mcg/kg was infused over 10 min before end of the surgery
71784|NCT03622502|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
71785|NCT03622502|Drug|Normal saline|Normal saline was infused over 10 min before end of the surgery
71786|NCT03622489|Drug|Acetaminophen|mentioned above
71787|NCT03622489|Drug|Ibuprofen 400 mg|mentioned above
71788|NCT03622489|Drug|Dipyrone|mentioned above
71789|NCT03622489|Drug|Tramadol|mentioned above
71790|NCT03622489|Drug|Morphine|mentioned above
71791|NCT03622489|Drug|Tramal|mentioned above
71792|NCT03622476|Drug|concentrated FVIII|Intervention if the assessment considers that the treatment is inadequate
71793|NCT03622463|Drug|Antroquinonol|Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
71794|NCT03622463|Other|Placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
71864|NCT03621878|Other|Neural mobilization exercises -Slider technique|Exercise aiming to slide/glide the neural structure using more than one joint.
71796|NCT03622450|Drug|Carbapenem + Aminoglycoside/ Quinolone|Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
71797|NCT03622437|Behavioral|Patient-led follow-up|"Patient-education, with information about signs of recurrent disease (alarm-symptoms), potential late effects, and how these can be managed.~The patients are instructed to contact a specialist nurse in case of alarm-symptoms, concerns or other problems related to the cancer disease throughout the entire follow-up period. The specialist nurse responds to the referrals, according to a standardized algorithm.~In addition, all patients receive:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years~Only for patients with a stoma:~- access to stoma care by specialist nurses"
71798|NCT03622437|Other|Standard follow-up|"Patients with sphincter-preserving resection:~- outpatient visits incl. rectoscopy at 6, 12, 18, 24 and 36 months~Patients with rectal amputation and a permanent stoma:~outpatient visits at 3, 12 and 36 months~access to stoma care by specialist nurses~All patients:~CEA and CT of the chest, abdomen and pelvis at 1 and 3 years after surgery~perioperative clean colon colonoscopy, and then every 5 years until the age of 75 years"
71799|NCT03622424|Device|Gelesis200|Gelesis200: Three (3)Gelesis200 capsules (2.10 g) three (3) times per day (i.e., breakfast, lunch, and dinner)
71800|NCT03622424|Device|Placebo|Placebo: Three (3)placebo capsules three (3) times per day (i.e., breakfast, lunch, and dinner)
71801|NCT03622424|Device|Gelesis200 and Placebo|Placebo and Gelesis200: Three (3) placebo capsules at breakfast,and three (3) Gelesis200 capsules (2.10 g)two (2) times per day (i.e., lunch and dinner)
71802|NCT03622411|Device|speech app|language exercises provided by the speech therapist in hospital + independent practice of language exercises via a tablet and speech app
71803|NCT03622411|Device|brain games|language exercises provided by the speech therapist in hospital + independent recreational tablet use via brain games
71804|NCT03622411|Behavioral|aphasia therapy|language exercises provided by the speech therapist in hospital
71805|NCT03622398|Procedure|Total knee arthroplasty with HXLPE liner|Replacing arthritic knee with a metal device, and using a highly cross-linked polyethylene(HXLPE) liner in between metallic surfaces.
71806|NCT03622398|Procedure|Total knee arthroplasty with conventional polyethylene liner|Replacing arthritic knee with a metal device, and using a conventional polyethylene liner in between metallic surfaces.
71807|NCT03622385|Other|DNA Methylation|No intervention will be performed. Blood and tissue samples will be analyzed for biomarkers that may be used to develop a diagnostic panel for early detection and diagnosis of high grade serous epithelial ovarian cancer.
71808|NCT03622372|Procedure|Operative repair of Zone 2 FDP tendon lacerations|Zone 2 tendon laceration(s) will be surgically repaired either using the experimental device or the active comparator
71809|NCT03622372|Device|CoNextions TR Implant System|The CoNextions TR Implant System will be used to repair Zone 2 FDP tendon laceration(s).
71810|NCT03622372|Device|4-strand locked cruciate repair|A 4-strand locked cruciate repair utilizing either 3.0 or 4.0 prolene suture will be used to repair Zone 2 FDP tendon laceration(s).
71811|NCT03622359|Diagnostic Test|SPECT/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
71812|NCT03622359|Diagnostic Test|PET/CT perfusion imaging|Subjects will receive a standard clinical dose of a radionuclide for perfusion imaging of the lower extremities before and after revascularization procedures.
71813|NCT03622346|Procedure|Semi-constrained total knee arthroplasty|Semi-constrained total knee arthroplasty
71814|NCT03622333|Genetic|Research of constitutional genetic alterations|Tumor DNA extraction Blood sample and constitutional DNA extraction CGH-array, Exome sequencing Bio-informatic analysis
71815|NCT03622320|Other|Blood sample|Blood sample for fasting blood sugar (FBS), High density lipoproteins (HDL), Triglycerides (TG) ,HOMA-IR, serum leptin
71816|NCT03622307|Device|Subcutaneous ICD Therapy Combined with VT Ablation|S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
71817|NCT03622294|Device|Bella Blankets protective coverlets|Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
71818|NCT03622281|Other|quality improvement intervention using artificial intelligence|Colonoscopists received performance measure monitoring and feedback
71819|NCT03622255|Procedure|MINST|Minimally invasive non-surgical technique (MINST) for the treatment of intrabony defects has been compared with minimally invasive surgical treatment of these defects and has shown to achieve similar beneficial clinical results. In this study MINST will be used as the control treatment.
71820|NCT03622255|Procedure|MINST with EMD|Enamel matrix derivative (EMD) has been widely used in the surgical treatment of periodontal intrabony defects, using a minimally invasive surgical technique (MINST). Recent studies have suggested that this product could also be used in the non-surgical treatment of intrabony defects using a minimally invasive technique with very good results. This study will evaluate the effect of enamel matrix derivative in the non-surgical treatment of periodontal intrabony defects when a minimally invasive technique is used. Besides clinical measurements, radiographic analysis will also be performed to evaluate the treatment results.
71821|NCT03622242|Device|Pain threshold index|In pain threshold index monitor, monitor patients' pain threshold index based on electroencephalography and adjust infusion rate of remifentanil and propofol according to pain threshold index
71822|NCT03622242|Device|Wavelet index|In wavelet index monitor, monitor patients' wavelet index based on electroencephalography as an indicator of depth of anesthesia and adjust infusion rate of propofol according to wavelet index
71823|NCT03622229|Diagnostic Test|Histologic evaluation|Samples collected by EUS-FNB without ROSE will be processed as histologic samples
71824|NCT03622216|Drug|Bradanicline|Three different doses over the course of the study
71825|NCT03622216|Drug|Placebo|Matching placebo for Bradanicline
71826|NCT03622203|Device|Biofreedom|Use of Biofreedom in real life patients
71827|NCT03622177|Procedure|biopsie|Additional colorectal mucosal biopsies during rectoscopy or colonoscopy
71828|NCT03622177|Biological|blood drawn|Additional blood drawn by venepuncture
71829|NCT03622164|Radiation|Radiotherapy to ipsilateral neck lymphatics and tumor bed (radiotherapy to one side of the neck)|CTV54 includes only the ipsilateral neck, including levels 2-4 plus levels 1 and/or 5 as clinically indicated.
71830|NCT03622164|Radiation|Radiotherapy to the bilateral neck lymphatics and tumor bed (radiotherapy to both sides of the neck)|CTV54 includes the entire surgical bed, including bilateral neck lymphatics at risk of harboring microscopic disease
71831|NCT03622151|Other|Primer la Llar program|Housing First model: permanent housing without previous requirements such as abstinence, sobriety or compliance with treatment.
71832|NCT03622138|Other|Impact|Impact is an easy to use, cost- and time-efficient technology platform that is capable of (a) gathering relevant process and outcomes data in a feasible way within real-world service settings; (b) producing real-time analytics (e.g., graphical displays) and meaningful reports at the provider, service setting, and broader levels (e.g., state-wide); and (c) linking data analytics to continuous quality improvement (CQI) feedback to help providers achieve best practices and targeted youth outcomes.
71833|NCT03622125|Diagnostic Test|Vital signs|Axillary temperature sampling, at the site of the scorpion sting and the contralateral site with infrared thermometer, and heart rate, respiratory rate and blood pressure on admission, 30 minutes after applying the vial and the medical discharge
71834|NCT03622112|Drug|AZD7594 DPI 55μg/50μg.|A non-steroidal and selective modulator of the GR.
71835|NCT03622112|Drug|AZD7594 DPI 99 µg/90 µg|A non-steroidal and selective modulator of the GR.
71836|NCT03622112|Drug|AZD7594 DPI 198 µg/180 µg|A non-steroidal and selective modulator of the GR.
71837|NCT03622112|Drug|AZD7594 DPI 396 µg/360 µg once daily.|A non-steroidal and selective modulator of the GR.
71838|NCT03622112|Drug|AZD7594 DPI 792 µg/720 µg|A non-steroidal and selective modulator of the GR.
71839|NCT03622112|Drug|Placebo for AZD7594 once daily.|Placebo for AZD7594
71840|NCT03622112|Drug|FF 100 µg once daily (open-label)|Fluticasone furoate
71841|NCT03622099|Drug|Normal Saline Flush, 0.9% Injectable Solution|As a routine work in adult critical care unit at Menoufia University hospital for patients with circulatory failure, A 100 ml bolus of Normal Saline Flush, 0.9% Injectable Solution was given to the patient over 1 minute through a central venous catheter or jugular cannula. For prediction of responders, echocardiographic parameters measured followed by infusion of the remaining 400 ml of Normal Saline Flush, 0.9% Injectable Solution at a constant rate over 10 minutes then echocardiographic parameters measured again to detect the patient response.
71842|NCT03622086|Other|Foundations of Fitness Program|The Foundations of Fitness Program is a 12 week, bi-weekly community intensive lifestyle program which focuses on healthy diet, daily physical activity, self-esteem and support for individual and family behavior change, components supported by USPSTF evidence review. Class sessions, which involve both parent/caregiver and child will include structured fitness activities, hands on nutrition, cooking, shopping and meal planning and facilitated discussions about goal setting, self-monitoring, stimulus control and healthy homes and families. Content will be offered in a context that supports self-esteem and behavior change. The program was developed by the Carter Community Building Association (CCBA) in collaboration with the Dartmouth-Hitchcock Weight & Wellness Center research core.
71843|NCT03622073|Other|Misoprostol treatment by Midwife|Medical management of incomplete abortion
71844|NCT03622073|Other|Misoprostol treatment by Doctor|Medical management of incomplete abortion
71845|NCT03622060|Drug|Nitroglycerin|200 microgram intraarterial nicardipine and 500 microgram nitroglycerin administered before sheath removal
71846|NCT03622047|Drug|Dexmedetomidine ropivacaine|Observing the effect of 0.5 μ g / ml sufentanil+ 0.1 % ropivacaine with 2 hours after fetal delivery, and the patients leave the delivery room without abnormality.
71847|NCT03622047|Drug|No analgesia labor|No analgesia labor control group
71848|NCT03622034|Other|posterior condylar offset measurement|the tangent to the medial tibial plateau is considered to be the proximal reference line. This is the line connecting the highest anterior and posterior points of the medial plateau. The second reference is the axis of the tibia, defined as a line through the middle of the shaft at 10 and 20 cm. The angle between these two lines is the tibial slope
71849|NCT03622021|Drug|AK111 or Placebo|All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
71850|NCT03622008|Drug|FEP-TAZ 4 g|FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
71851|NCT03622008|Other|Placebo|Placebo IV
71852|NCT03621995|Other|Malondialdehyde and Catalase level measurement|Malondialdehyde and Catalase level measurement by colorimetric method
71853|NCT03621982|Drug|ADCT-301|intravenous infusion
71854|NCT03621969|Other|Physical exam and medical history|This will be completed by a medical doctor on the research team
71855|NCT03621969|Diagnostic Test|Assessments|One assessment in Phase I, and three assessments in Phase II (baseline, and following each 2 week active study period)
71856|NCT03621969|Device|Patient Instruction and use of Device (RePlay)|"providing measurable upper extremity movement, control, and coordination feedback for patients, therapists, and physicians~improving assessment and evaluation of patients involved in future interventional studies,~producing a dynamic, responsive, inexpensive physical therapy system that can be used in the comfort of the participants' own home."
71857|NCT03621956|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
71858|NCT03621956|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
71859|NCT03621943|Procedure|Umbilical Cord Milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.
71860|NCT03621943|Procedure|Early Cord Clamping|The umbilical cord is clamped within 30 seconds of delivery.
71861|NCT03621917|Device|Near-infrared spectroscopy reading|Non-invasive readings will be taken from forehead with near-infrared spectroscopy
71862|NCT03621904|Drug|Hormonal Antineoplastics|Hormonal therapy used for treatment in endometrial cancer patients
71863|NCT03621878|Other|Neural mobilization exercises -Tensioner technique|Exercise aiming to lengthen the neural structure using more than one joint.
71867|NCT03621865|Dietary Supplement|STE|Standard turmeric powder extract 95% curcuminoids (1500 mg)
71868|NCT03621865|Dietary Supplement|NOV|Novasol® Liquid micellar formulation 6% curcuminoids (1000 mg)
71869|NCT03621865|Dietary Supplement|PHYT|Meriva® Turmeric Phytosome formulation 20% curcuminoids (1000 mg)
71870|NCT03621865|Dietary Supplement|TEP|Turmeric extract C3 complex® 95% curcuminoids (1500mg) + BioPerine® 95% piperine (15 mg)
71871|NCT03621852|Device|Endoultrasound guided FNB|EUS FNB with Aquire TM device
71872|NCT03621826|Other|Questionnaire/Interview|A convenience sample of patients/parents and stakeholders will be asked to participate in a survey and/or interview to evaluate barriers to care in sickle cell.
71873|NCT03621813|Behavioral|Exercise Rehabilitation|This training is designed to improve fitness, target the major muscle groups for strength, and to improve balance. Aerobic exercise of walking on a treadmill will be performed. Thera-Bands will be used for resistance exercise for the lower and upper body. Balance program includes core exercises (stepping, weight shifts, etc.) and other progressive exercises.
71874|NCT03621813|Other|Control|Participants are instructed to maintain current activity level and are monitored for changes.
71875|NCT03621800|Other|Menthol popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 20ml ultrafiltered water and 2% cereal alcohol. The menthol popsicle was supported by a stick, allowing patients to taste more comfortably, with autonomy and safety
71876|NCT03621787|Device|Implant insertion device|Device designed to assist healthcare providers in administering subcutaneous implants safely and accurately.
71877|NCT03621774|Behavioral|Mobile-assisted CBT-informed Skills Training|mCBTn combines the CBT-informed components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group skills training and mobile smartphone interventions from our prior clinical trials research.
71878|NCT03621774|Behavioral|Supportive Contact|The SC intervention will provide the same amount of group and mobile device contact as the mCBTn condition. Participants will be carrying a phone but will not have access to the CBT-informed app. Group contact sessions will be semi-structured and consist of trouble-shooting device use and check-in about symptoms and potential crisis management, followed by a flexible discussion involving psychoeducation, instructions for accessing community crisis lines and related community resources, empathy, and non-directive reinforcement of health, coping, and symptom management behaviors that grow out of group discussions, with only minimal group leader guidance.
71879|NCT03621761|Behavioral|Telephone-based Cognitive Behavioral Therapy|"Cognitive behavioral therapy (CBT) is a behavioral-based treatment that promotes effective self-management skills, including adaptive thought processes and behaviors (i.e. coping skills). CBT also commonly teaches goal-setting and behavioral activation strategies for engaging in physical, social, and other valued activities in the context of fatigue."
71880|NCT03621761|Drug|Modafinil|Modafinil is a safe, well-tolerated and effective wake-promoting agent (oral medication) that is FDA-approved for the treatment of fatigue related to sleep disorders. Modafinil is also one of the most commonly used medications for multiple sclerosis related fatigue in clinical practice, with doses ranging from 50 - 400 mg per day, in divided doses (once to twice daily).
71881|NCT03621748|Procedure|Awake Anesthesia Protocol|Awake is defined as the patient being awake with electrical brain stimulation mapping during the critical portions of the procedure.
71882|NCT03621748|Procedure|Non-awake Anesthesia Protocol|Non-awake is general anesthesia as per convention with intubation.
71883|NCT03621735|Device|Burst-SCS/sham SCS|"The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
71884|NCT03621735|Device|Sham SCS/Burst-SCS|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone.~For each arm of the study subjects will have daily treatments for 30-60 minutes for 6 weeks."
71885|NCT03621722|Other|Elequil Aromatabs|There will be a variety of different Aromatabs such as orange/peppermint or lavender
71886|NCT03621696|Drug|Cisplatin|-100 mg/m^2 intravenous push bolus (IVPB)
71887|NCT03621696|Radiation|Intensity modulated radiation therapy|-IMRT or IMPT can be used
71888|NCT03621696|Radiation|Intensity modulated proton therapy|-IMRT or IMPT can be used
71889|NCT03621696|Procedure|Surgery|-Standard of care
71890|NCT03621696|Other|FACT-H&N|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
71891|NCT03621696|Other|MD Anderson Dysphagia Inventory|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
71892|NCT03621696|Other|University of Michigan Xerostomia Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
71893|NCT03621696|Other|Scale of Subjective Total Taste Acuity|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
71954|NCT03621241|Diagnostic Test|Flow cytometry|Flow cytometry
71894|NCT03621696|Other|Neck Dissection Impairment Index|-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy
71895|NCT03621683|Procedure|blood rich plasma platelets|Injection of blood rich platelet into the ovaries.
71896|NCT03621683|Dietary Supplement|Antioxidant therapy|"Antioxidants:~Q10, DHEA, Vitamina E, Vitamin C, Omega 3"
71897|NCT03621670|Biological|Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)|Bexsero is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group.
71898|NCT03621670|Biological|Prevnar13|Prevnar13 (PCV13) is to be administered intramuscularly on upper side of the left thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group
71899|NCT03621670|Biological|Pediarix|Pediarix (DTPa-HBV-IPV) is to be administered intramuscularly on lower side of the left thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
71900|NCT03621670|Biological|Hiberix|Hiberix (Hib) is to be administered intramuscularly on lower side of the right thigh as a 3-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) and Visit 3 (Day 121) to all subjects in the MenB+PCV group and Placebo+PCV group.
71901|NCT03621670|Biological|Rotarix|Rotarix (HRV) is to be administered orally as a 2-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61) to all subjects in the MenB+PCV group and Placebo+PCV group.
71902|NCT03621670|Biological|M-M-R II|M-M-R II (MMR) is to be administered subcutaneously on upper side of the right arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group
71903|NCT03621670|Biological|Varivax|Varivax (VV) is to be administered subcutaneously on upper side of the left arm as a single dose on Visit 5 (Day 301) to all subjects in the MenB+PCV group and Placebo+PCV group
71904|NCT03621670|Biological|Placebo (saline water)|Placebo is to be administered intramuscularly on upper side of the right thigh as a 4-dose schedule on Visit 1 (Day 1), Visit 2 (Day 61), Visit 3 (Day 121) and Visit 5 (Day 301) to all subjects in the Placebo+PCV group
71905|NCT03621657|Drug|Low Dose FMT Capsule DE|5 FMT Capsule DE along with antibiotic; followed by five capsules FMT Capsule DE x 7 days post-antibiotic course.
71906|NCT03621657|Drug|Single Dose FMT Capsule DE|30 pill FMT Capsule DE treatment x 1, 48-72 hours following completion of antibiotic treatment.
71907|NCT03621657|Drug|Placebo oral capsule|Five capsules per day along with antibiotic; followed by five capsules per day for seven days post-antibiotic treatment.
71908|NCT03621644|Radiation|Stereotactic MRI-guided On-table Adaptive Radiation Therapy|Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
71909|NCT03621631|Behavioral|Optimized Tai Chi intervention|Optimized Tai Chi intervention
71910|NCT03621631|Behavioral|Traditional Tai Chi intervention|Traditional Tai Chi intervention
71911|NCT03621618|Diagnostic Test|dobutamine|evaluation of effects of dobutamine on dynamic arterial elastance in cardiac failure
71912|NCT03621618|Diagnostic Test|norepinephrine|evaluation of effects of norepinephrine on dynamic arterial elastance in sepsis
71913|NCT03621605|Biological|VIB9600|"Part 1 (SAD): IV infusion (30, 100, 200, 300 or 1000 mg) or SC injection (300 mg) on Day 1.~Part 2 (MAD): IV infusion (100 and 300 mg) every 2 weeks for 4 weeks (3 doses total; Days 1, 15 and 29)."
71914|NCT03621605|Drug|Placebos|Placebo administered by slow IV infusion or SC injection.
71915|NCT03621592|Device|Cutimed® Sorbact®|Dialkylcarbomoyl chloride based wound dressing
71916|NCT03621592|Device|Acticoat®|Silver impregnated contact layer dressing
71917|NCT03621579|Procedure|cataract surgery|To measure the RNFLT and CMT in congenital cataracts before and after the cataract extraction with IOL implantation surgery
71918|NCT03621566|Other|No intervention|Routine care (registry)
71919|NCT03621553|Drug|Ergocalciferol|Vitamin D2 50,000 units
71920|NCT03621553|Drug|Placebo|Sugar pill manufactured to mimic ergocalciferol 50,000 units
71921|NCT03621553|Drug|Calcium Citrate with Vitamin D2|To meet the recommended minimum daily dietary requirements
71922|NCT03621540|Device|active tDCS|Using the NeuroConn Plus tDCS device, 2 mA anodal tDCS will be applied to the right dorsolateral prefrontal cortex (F4). 15 s fade in and fade out. Total stimulation time of 1365 s. Cathode over contralateral deltoid muscle.
71923|NCT03621540|Device|sham tDCS|Sham mode of the NeuroConn Plus tDCS device with 2 mA stimulation for 45 s at the beginning. Anode over right dorsolateral prefrontal cortex (F4), Cathode over contralateral deltoid muscle. After that, only continuous impedance checking is performed.
71924|NCT03621540|Behavioral|Adaptive working memory training|Adaptive spatial n-back training.
71925|NCT03621527|Other|anesthesia combined with intravenous analgesia by remifentanil|intravenous analgesia by remifentanil is provided and adapted to the patients' needs during the whole procedure
71926|NCT03621527|Other|fluoroscopy-guided epidural anesthesia|Identification of the epidural space using fluoroscopy and the injection of a small quantity of contrast medium or air. An additional, anesthesia combined with intravenous analgesia by remifentanil is provided and adapted to the patients needs during the whole procedure
71927|NCT03621514|Procedure|painless indwelling catheter|Catheterization after anesthesia (14 F Foley's urinary catheter), the patient was removed before the anesthesia was awakened and the catheter was removed(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization).
72042|NCT03620422|Other|Sodium Chloride 0.9% Inhl 3Ml|Nebulized 0.9% saline given prior to Mannitol-Induced Cough Challenge
71928|NCT03621514|Procedure|indwelling catheter|The patients underwent catheterization(14 F Foley's catheter) after anesthesia,and the catheter was indwelled(Fully lubricate the anterior end of the catheter with a lidocaine ointment 2.5g before catheterization). The patient was routinely removed for 24 to 72 hours after surgery.
71929|NCT03621501|Device|Percutaneous coronary intervention|At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
71930|NCT03621488|Other|Efficacy of Behavioral Self-Activation with virtual reality|Efficacy of Behavioral Self-Activation with virtual reality
71931|NCT03621488|Other|Efficacy of Behavioral Self-Activation without virtual reality|Efficacy of Behavioral Self-Activation without virtual reality
71932|NCT03621475|Device|Novel restraint|Use of a novel arm restraint
71933|NCT03621462|Device|Artificial Intelligence Dermatology Assistant (AIDA™)|The Artificial Intelligence Dermatology Assistant (AIDA™) collects conventional demoscopic images and images at various spectral bands. Following image acquisition, the AIDA™ software presents users with (1) similar lesion images from the International Skin Imaging Collaboration archive, (2) Hypodermoscopy™ images, and (3) images providing an indication of lesion depth, based on the spectral data.
71934|NCT03621436|Device|TRVD Therapy|A catheter-mounted expandable flow pump is to be deployed in a transfemoral venous catheterization procedure. Once in place, renal venous pressure is reduced to a pre-selected physiologic target pressure and kept there for up to 24 hours. After termination of TRVD therapy, the device is removed.
71935|NCT03621423|Procedure|ultrasound guided injection|"Patient will be positioned lying on side with the hemiplegic side up. The shoulder will be placed in a flexion and external rotation/abduction position, as possible by the patient, to give the ultrasound probe access to the posterior axillary fold.~As previously described in the literature, a line of best fit was calculated by bisection of hypothetical line connecting the inferior spine and the acromial tip, an 18-gauge, 10-cm needle will be inserted under direct ultrasound guidance and by a nerve stimulation . After placing the needle tip in the target point's 100 units of botulinum toxin will be injected."
71937|NCT03621371|Behavioral|Metacognitive therapy|Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.
71938|NCT03621371|Behavioral|Intolerance of uncertainty therapy|Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
71939|NCT03621358|Other|Control gummy with free flavour (without encapsulating)|12 g/day (3 gummies)
71940|NCT03621358|Other|Experimental gummy with 50% free/50% encapsulated flavour|12 g/day (3 gummies)
71941|NCT03621358|Other|Experimental gummy with 100% encapsulated flavour|12 g/day (3 gummies)
71942|NCT03621345|Procedure|Erector spinae plane block|Ultrasound guided bilateral erector spinae plane block will be administered. An intravenous patient control analgesia device with morphine will be given to patients.
71943|NCT03621345|Other|sham block|A sham block will be applied. Skin will be infiltrated with local anesthetics, and 2 mL subcutaneous saline injection will be applied.An intravenous patient control analgesia device with morphine will be given to patients.
71944|NCT03621332|Other|Questionnaire|Online/paper questionnaires
71945|NCT03621319|Device|Hybrid argon plasma ablation (HAPC)|-The assigned HAPC ablation will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
71946|NCT03621319|Device|Radiofrequency ablation (RFA)|-The assigned RFA procedure will be performed at 8 to 12 week intervals until eradication of BE has been achieved or a total of 4 treatments have been performed
71947|NCT03621306|Device|DXA and pQCT precision testing|The participants are only being observed; there is no intervention other than DXA and pQCT testing for the purposes of looking at instrument/technician precision..
71948|NCT03621293|Drug|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
71949|NCT03621280|Drug|Levoketoconazole|Levoketoconazole up to 1200 mg daily
71950|NCT03621267|Other|Interactive Stepping Exercise|Interactive Stepping Exercise will perform on a thin mat, stepping pattern will display through a monitor screen, immediate auditory feedback will give for adjustment
71951|NCT03621267|Other|Home exercise program|Home exercise program includes stretching exercise, general strengthening exercise on lower extremity muscles, posture control and balance exercise.
71952|NCT03621254|Other|[LO-LONG]|Both interventions are different modalities of FES-evoked leg exercise, three-four times per week for 6-8 weeks (24 therapy sessions). The comparator intervention ([LO-LONG]) uses 20-40 min (patient state of fitness dependent) of continuous leg exercise of lower intensity.
71953|NCT03621254|Other|[HI-SHORT|One intervention ([HI-SHORT]) uses a variety of leg exercise interval training of higher intensity for 10 x 2-min intervals.
71955|NCT03621228|Device|MindfulGarden|MindfulGarden (MG) is an interactive digital technology that combines use of a smart television with sensors to intelligently generate content based on patient voice and gesture input, triggering a multi-layered visual 'garden' on-screen to arrest and de-escalate anxiety and aggression in treatment of hospitalized elderly diagnosed with hyperactive delirium.
71956|NCT03621215|Dietary Supplement|Tart cherry juice|30 mL tart cherry juice concentrate (CherryActive, UK), diluted with water to 250 mL. This is consumed daily by participants, with breakfast, for 12 months.
71957|NCT03621215|Other|Fruit-flavoured placebo drink|Consumed daily by participants, with breakfast, for 12 months.
71958|NCT03621202|Device|Saranas Early Bird Bleed Monitoring System (EBBMS)|Participants will undergo their planned endovascular procedure with monitoring for internal bleeding using the Saranas EBBMS.
71959|NCT03621189|Device|intermittent theta burst stimulation|stimulatory protocol
71960|NCT03621176|Other|Home-based exercise|A booklet with detailed information will be provided, and the exercises will be previously reviewed with every patient by the researcher. Participants will be encouraged to perform at least 3 sessions per week and monitor their heart rate. They will be instructed that the exercises should be perceived as 'somewhat hard' from a rate of perceived exertion. Adaptations to increase the intensity of the exercises will be provided so that participants can progress in exercise intensity
71961|NCT03621163|Procedure|Bleaching agent ( BOOST 40%)|Opalescence Boost 40% is a 40% hydrogen peroxide, medical power bleaching gel. The jet mix syringe ensures freshness for each application and precise dosing of the activator. One barrel contains a unique chemical activation with sodium fluoride and potassium nitrate, which have been demonstrated to reduce caries susceptibility, lower sensitivity, and improve enamel micro-hardness. The other barrel contains the concentrated hydrogen peroxide. When mixed, Opalescence Boost results in a 1.1% fluoride and 3% potassium nitrate concentration.
71962|NCT03621163|Procedure|laminate veneers(lithium-silicate)|A lithium-silicate glass ceramic is newly introduced to the market. After crystallization, it demonstrates an ideal combination of strength, aesthetics and translucency that mirrors the vitality of natural teeth for fabrication of full anatomic anterior and posterior crowns. It differentiated from other ceramics by its high chipping resistance, due to their monolithic composition and average flexural strength of 385 MPa. Also Milling Block has good wear resistance due to the high content of ultra-fine nano-meter size crystalline structure. Lithium-silicates ceramic blocks are available in the commonly used VITA Classical and Chromascop Bleach shades.
71963|NCT03621137|Other|No study-specific intervention|Treatment of atopic eczema with phototherapy or systemic immunomodulating therapy according to usual clinical practice
71964|NCT03621124|Procedure|Resting Energy Expenditure|During each visit, the participant will be assessed in a resting state in a stable temperature controlled environment, and will undergo tests to find out how the body adjusts its metabolism to different temperatures.
71965|NCT03621124|Other|Thermal Comfort Questionnaire|Patients will be given a questionnaire to assess their thermal response (whether they felt warmer or colder) during each study visit.
71966|NCT03621111|Behavioral|Patient-counseling|After one month from the hospital discharge, the pharmacist will give to the patient general advices and suggestions regarding disease, therapy and drugs.
71967|NCT03621111|Behavioral|Patient self-administered questionnaire|The pharmacist will submit the questionnaire to the patient for the evaluation of drug adherence, life style, feelings and approach to therapies, at 30 days, 3, 6, 9 and 12 months from the enrollment. This self-questionnaire of 13 questions contains the 8 multiple choice questions of the Morisky medication adherence scale (MMAS-8-Item, Italian version).
71968|NCT03621111|Behavioral|Pills counts|At the time of the monthly drug re-supply at the community pharmacy, the patient will bring the boxes of the drugs taken in the previous month (empty or not), for the pill counts. The pharmacist will verify the correct assumption of the pharmacological therapies.
71969|NCT03621085|Drug|Ketamine Hydrochloride|A total of 20 mg of Ketamine Hydrochloride will be administered intravenously
71970|NCT03621085|Other|Placebo|Subjects will receive placebo
71971|NCT03621072|Drug|Fluconazole 150mg Capsule Originator|150mg fluconazole capsule (originator) manufactured at Pfizer Fareva, Amboise, France
71972|NCT03621072|Drug|Fluconazole 150mg Capsule Localized Originator|150mg Fluconazole capsule (localized originator) manufactured at Pfizer, Dalian, China
71973|NCT03621059|Behavioral|habit reversal training (HRT)|"The intervention group received 4 sessions during 3months of behavior intervention and then, were reassessed at 3 and 6 months following treatment.~Pyridoxine(50mg)"
71974|NCT03621046|Drug|Zolpidem|Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.
71975|NCT03621046|Other|Placebo|Placebo
71976|NCT03621033|Procedure|colonic transendoscopic enteral tubing|The procedure colonic transendoscopic enteral tubing is as follows:The TET tube was inserted into the ileocecal junction through the endoscopy channel at the first time of the cecal intubation after examination and evaluation of the whole colon. Then, the colonoscope was removed from the colon while the TET tube was maintained at the ileocecal junction. Then the endoscopy was inserted into the ileocecum again for affixing the TET tube to cecum with titanium clips.
71977|NCT03621020|Diagnostic Test|T-TAS 01 PL Chip|Flow chamber microchip system specific for measuring primary hemostatic ability
71978|NCT03621020|Diagnostic Test|PFA-100 Col/Epi and Col/ADP|System for measuring platelet dysfunction
71979|NCT03620981|Drug|Brexpiprazole|Drug: 1 tablet /day Once daily for 10 weeks
71980|NCT03620981|Drug|Placebo|Placebo: 1 tablet /day Once daily for 10 weeks
71981|NCT03620968|Other|cognitive training|15 minutes day of brain training by an APP
71982|NCT03620955|Other|Justified risk stratification based on MRD after three course chemo therapy|All patients are routinely divided into different risk groups according to the NCCN guild based on cytogenetic and molecular abnormality. Then all patients are treated with anthracycline combined with cytarabine regimens for two courses . The patients without obtaining CR will go on one cycle of salvage therapy and then be bridged to allo-HSCT. Those acquiring CR will be given one more course of HDAC as consolidation treatment and then be detested MRD with flow cytometry after that. The patients with MRD positive would be moved to a higher risk class.The stratified therapy should be considered according to the new risk stratification.
72077|NCT03620149|Drug|Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]|Denosumab 120 mg, SC, on day 1 of every 12-week cycle
71983|NCT03620942|Drug|Phenylephrine|"Phenylephrine will be administered with conditions as below:~When systolic blood pressure is between 90-110% of baseline, 25mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min;~When systolic blood pressure is less than 90% of baseline, 25 to 75mcg phenylephrine will be given either in infusion or bolus if heart rate ≥ 60 beats/min."
71984|NCT03620942|Drug|Ephedrine|"Ephedrine will be administered with conditions as below:~When systolic blood pressure is between 90-110% of baseline, 2mg ephedrine will be given either in infusion or bolus if heart rate < 60 beats/min;~When systolic blood pressure is less than 90% of baseline, 2 to 6mg ephedrine will be given either in infusion or bolus if heart rate < 60 beats/min."
71985|NCT03620942|Device|ADIVA System|"When systolic blood pressure (SBP) is 100-110% of baseline, 25mcg phenylephrine (infusion) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion) is given if heart rate < 60 beats/min;~When SBP is 90-100% of baseline, 25mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 2mg ephedrine (infusion or bolus) is given if heart rate < 60 beats/min;~When SBP is 80-90% of baseline, 50mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 4mg ephedrine (infusion or bolus) is given if heart rate < 60 beats/min;~When SBP < 80% of baseline, 75mcg phenylephrine (infusion or bolus) is given if heart rate ≥ 60 beats/min, and 6mg ephedrine (infusion or bolus) is given if heart rate < 60 beats/min."
71986|NCT03620942|Device|DIVA System|"DIVA system works as below:~When systolic blood pressure is between 90 to 100% of baseline, 25mcg phenylephrine (bolus) will be given if heart rate ≥ 60 beats/min, whereas 2mg ephedrine (bolus) will be given if heart rate < 60 beats/min;~When systolic blood pressure is less than 90% of baseline, 50mcg phenylephrine (infusion or bolus) will be given if heart rate ≥ 60 beats/min, whereas 4mg ephedrine (infusion or bolus) will be given if heart rate < 60 beats/min."
71987|NCT03620929|Drug|Estradiol Valerate|In all cases hormone therapy will be started from the day of operation, consisting of estradiol valerate at a dose of 4mg/d for 21 days, with the addition of dydrogesterone at a dose of 10 mg/d for the last 7 days of the estrogen therapy. After the withdrawal bleed, the hormone therapy will be repeated for another cycle. Second-look hysteroscopy will be carried out in the early proliferative phase, 4 weeks after the initial operation; a third-look hysteroscopy will be carried out 8 weeks after the initial operation. After assessment of the extent and severity of any reformed adhesion, hysteroscopic adhesiolysis will be carried out at the time of the second-look or third-look procedure, if adhesion had recurred.
71988|NCT03620916|Procedure|Intravenous morphine|Single dose of intravenous morphine (0,15 mg/kg body mass) immediately after the operation, patient controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days
71989|NCT03620916|Procedure|Intrathecal morphine|Single dose (0,4 mg) intrathecal morphine immediately before operation, patient-controlled analgesia with morphine (2 mg intravenously, a least 20 min interval) over first 24 postoperative hours and subcutaneous morphine (5 mg in case of numerical rating scale>4, at least 6 hour interval) over next two days in the postoperative period
71990|NCT03620903|Drug|Ibrutinib|First line treatment in Waldenstrom Macroglobulinemia
71991|NCT03620890|Drug|Neutral Protamine Hagedorn (NPH)|NPH will peak between 4-12 hours after injection with a duration of action around 14 hours
71992|NCT03620890|Drug|Detemir insulin|Detemir is characterized by a gentle rise and fall with a longer duration of action (18-20 hours)
71993|NCT03620877|Behavioral|Personalized intervention|Personalized intervention by a preventive nurse, relying on validated prevention models, in improving participation in the colonoscopic screening of siblings
71994|NCT03620864|Other|Motor Control Exercises|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling.
71995|NCT03620864|Other|Motor Control Exercise Plus Neurodynamic Intervention|Patients will receive 8 sessions of motor control exercise program of 30 min duration for 4 weeks, twice per week. Exercises will be demonstrated to the participants by an experienced physical therapist. On each session, the therapist will correct each subject personally. Participants will be asked for practicing the exercises at home once daily for 20 minutes over the 8-week intervention period. The motor control exercise program will consist of a progression from isolated contraction of the transversus abdominis and/or isolated contraction of the multifidi to combined contraction of both transversus abdominis in different positions from supine or prone to bridging or four-point kneeling. In addition, participants allocated to the neurodynamic group will also receive a nerve neurodynamic slider intervention targeting the main trunk of the sciatic nerve of the affected side during al treatment sessions (n=8).
71996|NCT03620851|Other|effect of age|effect of age on the efficiency of enhanced recovery program
71997|NCT03620838|Drug|oral contraceptive pill, oral progesterone|ovarian endometrioma cyst excision
71998|NCT03620825|Other|Dehydration by sauna exposure|Participants repeatedly undergo sauna exposures until they loose 3% of their body weight.
71999|NCT03620825|Drug|Indomethacin|Participants take indomethacin in tablet form the evening before and the morning of the visit to induce intestinal permeability
72000|NCT03620812|Dietary Supplement|rapeseed or soy protein or no protein|25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
72001|NCT03620799|Procedure|Manual therapy|A manual intervention technique is employed to the intervention group based on a roller treatment.
72002|NCT03620786|Device|Sonablate HIFU device|In this study, we will be using the Sonablate 450 HIFU System. The Sonablate HIFU device was approved by the U.S. FDA for prostate tissue ablation in October, 2015. HIFU is an example of focal therapy, where the intervention involves targeting diseased areas of prostate tissue, while preserving healthy prostate tissue and minimizing damage to surrounding structures.
72003|NCT03620773|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
72004|NCT03620773|Drug|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
72005|NCT03620773|Procedure|Vertical Sleeve Gastrectomy|Participants will undergo vertical sleeve gastrectomy surgery, a laparoscopic bariatric surgery procedure designed for weight loss in obese patients
72006|NCT03620760|Drug|Ticagrelor 90 mg|Ticagrelor (AZD6140) 90 mg twice daily dose
72007|NCT03620760|Drug|Ticagrelor 45 mg|Ticagrelor (AZD6140) 45 mg twice daily dose
72008|NCT03620760|Drug|Aspirin|Aspirin 100 mg once daily dose
72009|NCT03620747|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: prefilled syringes~Route of administration: subcutaneous"
72010|NCT03620721|Behavioral|mindfulness|8-week mindfulness based group intervention
72011|NCT03620708|Behavioral|Motivational Interviewing|Participants are provided with a 35 minute counseling session designed to increase motivation to quit smoking and then provided with a written referral for tobacco dependence treatment.
72012|NCT03620708|Drug|Nicotine Replacement Therapy Sampling|Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.
72013|NCT03620708|Behavioral|Referral Only|Participants are provided with a written referral for tobacco dependence treatment.
72014|NCT03620682|Behavioral|Coaching sessions|Participants receive three 30-minute phone sessions with a doctorate-level therapist over the course of one month. These sessions are skills-based and focus on improving participants' problem solving through cognitive-behavioral techniques. Participants are allowed to text the therapist between sessions for information and support.
72015|NCT03620682|Behavioral|Mobile applications|Participants will have access to 3 mobile apps for the duration of the study, and after it ends. One app will push participants a daily, self-reflective survey to complete, and a daily motivational or instructional tip to rate. Other apps will provide education and exercises on various aspects of mental health and wellness, such as sleep and relaxation.
72016|NCT03620669|Drug|Durvalumab|Durvalumab 1500mg q4W until progression or unacceptable toxicity
72017|NCT03620656|Diagnostic Test|FibriCheck|Photoplethysmography-based smartphone or smartwatch sensor to assess cardiac rhythm
72018|NCT03620643|Drug|Crizotinib Oral Capsule [Xalkori]|Crizotinib 250 mg Crizotinib 200mg
72019|NCT03620643|Drug|Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex]|Fulvestrant (Faslodex) is supplied as two 5-mL clear neutral glass (Type 1) barrels, each containing 250mg/5mL of fulvestrant solution for intramuscular injection and fitted with a tamper evident closure.
72020|NCT03620630|Device|myCOPD|myCOPD is a multi faceted web based application designed to support people with COPD in the Long term management of their COPD.
72021|NCT03620617|Dietary Supplement|Raspberry supplement|During the 8-week protocol, participants will be invited either to consume 280g of frozen raspberries daily (morning and evening). The daily dose is equivalent to 2 cups of raspberries.
72022|NCT03620604|Device|Stress urinary incontinence surgery|All patients were treated according to the Urology protocols of our unit. They were patients with stress urinary incontinence refractory to pelvic floor exercises so they underwent surgery
72023|NCT03620591|Drug|Lidocaine|Intraoperative administration of lidocaine
72024|NCT03620591|Drug|Placebo|Intraoperative administration of normal saline
72025|NCT03620578|Drug|DA-EPOCH-R followed by Nivolumab|5 induction cycles of DA-EPOCH-R protocol, for patient with Deauville imaging response criteria proven complete metabolic response followed with one year Nivolumab consolidation therapy
72026|NCT03620552|Drug|18F-S16|A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
72027|NCT03620539|Other|Lifestyle intervention|Sauna bathing
72028|NCT03620526|Drug|Iloprost|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
72029|NCT03620526|Drug|Placebo|Investigators performed cardiac catheterization as previously described. Hemodynamic values were recorded for the ﬁrst exercise phase (before any drug administration) and after return to steady state baseline hemodynamic values, and the second exercise phase (after drug administration). Subjects were randomized 1:1 to inhalation of placebo (normal saline solution) or iloprost (50 mg/kg/min) (Bayer Pharmaceuticals, Scottsdale, Ari-zona) for 5 min. The iloprost/placebo inhalation were identical in appearance and prepared by the research pharmacy, ensuring double-blinding of inhalation content. After finishing inhalation process for 10 min, hemodynamic measurements were repeated at rest, followed by repeat supine exercise at a 20-W workload for 6 min, identical to the study's ﬁrst phase.
72030|NCT03620513|Drug|Decongestant (oxymetazoline 0.05%)|As described in arm/group
72031|NCT03620513|Drug|Anesthesia (Lidocaine 15%)|As described in arm/group
72032|NCT03620513|Drug|Decongestants and Anesthesia (oxymetazoline and lidocaine)|As described in arm/group
72033|NCT03620513|Drug|Normal saline|Spray of normal saline as premedication
72034|NCT03620500|Behavioral|Gross motor and developmental balance testing|Balance (Pediatric Balance Scale) and gross motor skill development (Peabody Developmental Motor Scales, 2nd edition). Quality of life will be assessed using the Life-H (Assessment of Life Habits).
72035|NCT03620474|Drug|PRI-724|twice a week for 4 hours continuous intravenous administration of PRI-724
72036|NCT03620461|Drug|Gemcitabine - nabpaclitaxel|efficacy and safety
72037|NCT03620448|Device|bCPAP Arm|bCPAP (Rice 360◦c low cost bCPAP device)
72038|NCT03620448|Other|Oxygen Arm|Oxygen therapy from oxygen cylinders
72039|NCT03620435|Drug|Atezolizumab|Atezolizumab (1200mg iv, every 3 weeks) administered concurrently with TMT and adjuvant for up to one year
72040|NCT03620422|Other|Mannitol|Mannitol-Induced Cough Challenge
72041|NCT03620422|Drug|Salbutamol 5mg/mL|Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
123192|NCT03223753|Other|Questionnaire Administration|Ancillary studies
72043|NCT03620396|Procedure|Scaling and root planing|After the serum collection is done from the patient for the assessment of trefoil factor 3, Non surgical periodontal therapy is carried out.
72044|NCT03620383|Procedure|Topical Heat|Warm heat pack applied topically in participant hand.
72045|NCT03620370|Drug|Normobaric oxygen therapy|In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
72046|NCT03620357|Device|CGM|CGM Group: Dexcom G6 CGM
72047|NCT03620357|Device|SMBG|SMBG Group: Blood Glucose Meter
72048|NCT03620344|Other|ADH-Me Book and ADHD Informational Brochure|"Understanding ADHD information brochure published by American Academy of Pediatrics and a children's book about ADHD condition"
72049|NCT03620344|Other|ADHD Informational Brochure Only|"Understanding ADHD information brochure published by American Academy of Pediatrics"
72050|NCT03620331|Procedure|Surgery with a previous non-surgical approach|Non-surgical phase done prior to the surgical treatment of peri-implantitis
72051|NCT03620331|Procedure|Surgery without a previous non-surgical approach|Non-surgical phase not done prior to the surgical treatment of peri-implantitis
72052|NCT03620318|Drug|Crenolanib besylate|
72053|NCT03620305|Other|Description of treatment of septic pseudarthrosis|description of chirurgical 2 steps management of septic pseudarthrosis
72054|NCT03620292|Drug|Bevacizumab-IRDye800CW|Intravenous administration of Bevacizumab-IRDye800CW prior to surgery for hilar cholangiocarcinoma
72055|NCT03620292|Device|near infrared (NIR) fluorescence imaging|Intraoperative NIR fluorescence imaging of hilar cholangiocarcinoma, lymph nodes, resection margins, resection specimens
72056|NCT03620279|Behavioral|Magic camp intervention|Hand-arm bimanual motor skills training
72057|NCT03620266|Dietary Supplement|Bilberry|The dietary intervention will be initiated within 72 hours post PCI and will be continued for three months. After randomization, subjects will be given bilberry shakes (active), liquid oat shakes (active) or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake three times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
72058|NCT03620266|Dietary Supplement|Placebo|The dietary intervention will be initiated within 72 hours post PCI and will be continued for three months. After randomization, subjects will be given bilberry shakes (active), liquid oat shakes (active) or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake three times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
72059|NCT03620266|Dietary Supplement|Liquid oats|The dietary intervention will be initiated within 72 hours post PCI and will be continued for three months. After randomization, subjects will be given bilberry shakes (active), liquid oat shakes (active) or reference shakes (placebo product containing no active bilberry or active oats but with similar taste and texture), for intake three times a day (t.i.d). The formula for the shakes to be used in the intervention will be finalized during the initial project period.
72060|NCT03620253|Drug|Modafinil|Participants randomized to the modafinil group will receive 100 mg of modafinil capsules for 1 week, followed by 200 mg for 7 weeks (as long as the drug is well tolerated), which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
72061|NCT03620253|Drug|Placebo|Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
72062|NCT03620240|Behavioral|Sleep Education|Assessing the effectiveness of a Sleep Education Program in improving sleep behaviors in secondary school students.
72063|NCT03620227|Other|Exercise|40 minutes of aerobic exercise on a treadmill, with a fixed speed of 5.5 km/h and intensity imposed by treadmill inclination until it reaches the frequency zone between 60% and 75% of the reserve heart rate.
72064|NCT03620227|Dietary Supplement|Beetroot juice|Ingestion of 350ml of concentrated beetroot juice (400mg of nitrate) 100 minutes before an exercise session.
72065|NCT03620227|Dietary Supplement|Placebo|Ingestion of 350ml of placebo (0mg of nitrate, with the same color, taste and smell) 100 minutes before an exercise session.
72066|NCT03620201|Drug|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
72067|NCT03620188|Other|Standard of care|Standard of care in PsA is outline in treatment guidelines as adjustment of therapy every 3 months until goals of treatment are being met. Goals of treatment are defined as remission or low disease activity.
72068|NCT03620175|Drug|TolaSure Topical Gel|TolaSure topical gel is applied to skin punch biopsies daily over the course of 2 weeks.
72069|NCT03620162|Biological|Prevnar 13™|Prevnar 13™ pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
72070|NCT03620162|Biological|V114|V114 pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
72071|NCT03620162|Biological|RotaTeq™|RotaTeq™ (Rotavirus Vaccine, Live, Oral, Pentavalent)
72072|NCT03620162|Biological|Pentacel™|Pentacel™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine for IM injection in the opposite limb to V114 and Prevnar 13™ administration.
72073|NCT03620162|Biological|Recombivax HB™|RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant) for IM injection in the opposite limb to V114 and Prevnar 13™ administration.
72074|NCT03620162|Biological|Hiberix™|HIBERIX™ [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] for IM injection in the opposite limb to V114 and Prevnar 13™ administration.
72075|NCT03620162|Biological|M-M-R™ II|M-M-R™ II (MEASLES, MUMPS, and RUBELLA VIRUS VACCINE LIVE) for subcutaneous injection in the opposite limb to V114 and Prevnar 13™ administration.
72076|NCT03620162|Biological|Varivax™|VARIVAX™ Varicella Virus Vaccine Live for subcutaneous injection in the opposite limb to V114 and Prevnar 13™ administration.
72078|NCT03620136|Drug|locoregional analgesia by a block on the adductor channel|"The block at the adductor channel will be realized under echo guidance, before the spinal anesthesia, by puncture at the upper 1/3 of the thigh. It will be used echogenic needle adapted to the morphotype of each patient, of varying length from 50mm to 100mm. A single injection of 20mL of ROPIVACAINE 2mg / ml, the efficacy of which should be checked before spinal anesthesia is performed by a cold test.~Knee analgesia will be supplemented by per-operative infiltration of 50mL of ROPIVACAINE 2mg / ml at the posterior capsule, once the surfaces joints prepared to accommodate the prosthesis and by two placebo infiltrations of 50mL each of physiological saline in the medial and lateral ligaments and in the edges of the incision."
72079|NCT03620136|Drug|locoregional analgesia by periarticular local infiltrations|"A placebo injection to the adductor channel of 20 mL of physiological serum will be performed in the pre-induction room before surgery, according to the same procedures as the patients of the ACB group.~During the surgical procedure, patients in the ILA group will receive a total dose of 300mg of ROPIVACAINE 2mg / ml in the form of 3 periarticular injections. The first injection of 50mL of ROPIVACAINE 2mg / ml will be made once the articular surfaces are prepared to receive the prosthesis, at the level of the posterior capsule. The second injection of 50mL of ROPIVACAINE 2mg / ml will be performed once the total knee prosthesis is installed, in the medial and lateral ligaments. Finally, the last injection will also include 50mL of ROPIVACAINE 2mg / ml and will be made in the edges of the incision at the time of closure."
72080|NCT03620123|Drug|Nivolumab and Ipilimumab|Nivolumab 3 mg/kg of body weight intravenous infusion every two weeks and ipilimumab 1 mg/kg of body weight intravenous infusion every six weeks
72081|NCT03620123|Drug|Docetaxel|docetaxel 75 mg/m² intravenous infusion every three weeks
72082|NCT03620097|Dietary Supplement|EuPoly-3 DHA Infant|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
72083|NCT03620097|Other|Placebo|Children will be selected in the first 18 months of the study, and patients with ASD will be included in the trial consecutively, and will be divided into two parallel groups according to the randomization generated by the SIGESMU® computer program with random assignment 1: 1: 30 subjects will receive 800mg of DHA per day and another 30 children, a placebo with similar lipid characteristics except that it will not have DHA content, and for a period of 6 months, double blind. After 6 months, a clinical evaluation and the same baseline analytical study will be carried out again.
72084|NCT03620084|Device|Expiratory Muscle Strength Training (EMST)|The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).
72085|NCT03620071|Other|GoalKeeper|Mobile-health communication tool for parents of children with medical complexity
72086|NCT03620071|Other|Standard Care|Standard Clinical Care
72087|NCT03620058|Biological|CART22-65s cells|Autologous T cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
72088|NCT03620058|Biological|huCART19 Cells|Autologous T cells transduced with lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB
72089|NCT03620045|Behavioral|Acute moderate physical activity|For 20 minutes, participants will walk on a treadmill at a moderate intensity based on a combination of evidence-based and pre-determined parameters, including ratings of perceived exertion and heart rate
72090|NCT03620032|Drug|Nimotuzumab|humanized therapeutic monoclonal antibody against epidermal growth factor receptor (EGFR)
72091|NCT03620032|Drug|Vinorelbine|Chemotherapy
72092|NCT03620032|Other|Radiotherapy|RADIOTHERAPY SCHEDULE IS DESCRIBED FOR BOTH GROUPS IN THE PERAGRAPH TITLET ARMS
72093|NCT03620019|Drug|Denosumab|A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
72094|NCT03620019|Drug|Pembrolizumab|Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
72095|NCT03620019|Drug|Nivolumab|Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
72096|NCT03619993|Device|On-body injector|Medical device for subcutaneous injection of a supportive medicine (Pegfilgrastim) automatically after 27 hours after application of device.
72097|NCT03619993|Device|Pre-filled syringe|For subcutaneous injection of a supportive medicine (Pegfilgrastim).
72098|NCT03619980|Other|No intervention|Retrospective study to evaluate time to event and healthcare resource utilisation of prostate cancer patients throughout the different disease stages, until progression or death.
72099|NCT03619967|Device|Multispectral imager|"Device: Bio-inspired multispectral imager~-Manufactured at University of Illinois at Urbana Champaign"
72100|NCT03619954|Biological|NK cells infusion|"Pretreatment：patients enrolled in this study will receive 20 mg/kg of cyclophosphamide for solid tumor or 20-60 mg/kg of cyclophosphamide for hematological tumor once daily for 3 times. NK cells infusion is allowed within 2-14 days after treatment.~NK cells infusion：30-60 minutes before infusion，ant-allergic agents are applied (promethazine 25mg,i.m. ; Cimetidine 0.4g i.v. ; diphenhydramine 50mg po.). NK cells are intravenously infused into patients with 15-30 minutes every other day for one to three times. The number of every infused NK cells is 1-3×10^7/kg, counted as the number of CD56+ cells. Patients with severe pleural or ascites can also receive pleural or abdominal cavity perfusion simultaneously. The total number of infused NK cells is no more than 5×10^9 cells. 4 hours after NK cells infusion，IL-2 is applied every other day for six times"
72101|NCT03619941|Dietary Supplement|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
72166|NCT03619447|Drug|serratus block group|USG guided serratus plane block will perform bilaterally
72102|NCT03619941|Dietary Supplement|Placebo|Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
72103|NCT03619928|Device|Dry needling|20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
72104|NCT03619928|Device|Massotherapy|A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.
72105|NCT03619915|Diagnostic Test|Spirometry|The test will follow the norms of the American Thoracic Society and reference values relative to the Brazilian population. The tests will be performed by physical therapists using the One Flow FVC® portable spirometer (Clement Clarke, England) and met the criteria for acceptance and reproduction of manoeuvres
72106|NCT03619915|Other|Functional Independence Measure|Will be used to evaluate the functional independence of patients containing eighteen items encompassing six dimensions. Each item can receive scores of one to seven, where one corresponds to total dependency and seven to full independence. Each dimension is analysed by the sum of the items that compose it and the total score is given by the sum of each dimension, being able to vary from 18: complete dependence; 19 to 60: greater dependence (assistance of up to 50% of tasks); 61 to 103: less dependency (assistance of up to 25% of tasks); and 104 to 126: independent.
72107|NCT03619902|Drug|ANB019|Humanized Monoclonal Antibody
72108|NCT03619889|Other|Manual pressure release technique on trigger points.|A specific pressure is applied on trigger points of masticatory and neck muscles between pain pressure threshold and pain tolerance (7-8 visual analog scale).
72109|NCT03619889|Other|Sham|A simulated pressure release technique is applied around masticatory and neck muscles.
72110|NCT03619876|Drug|Abatacept|125 MG/ML subcutaneous injections
72111|NCT03619876|Drug|Adalimumab|40 Mg/0.8 mL Subcutaneous Kit
72112|NCT03619850|Drug|Ferumoxytol|Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.
72113|NCT03619850|Drug|Iron sucrose|Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).
72114|NCT03619837|Drug|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
72115|NCT03619837|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|"Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks."
72116|NCT03619824|Drug|Sintilimab|Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
72117|NCT03619824|Drug|Gemcitabine|Gemcitabine 1g/m2, d1 & 8 of every cycle, every 3 weeks for 3 cycles before radiation.
72118|NCT03619824|Drug|Cisplatin|Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
72119|NCT03619824|Radiation|intensity-modulated radiotherapy|Definitive IMRT of 66-70Gy will be given in six to seven weeks.
72120|NCT03619811|Diagnostic Test|Reza Band® Upper Esophageal Sphincter (UES) Assist Device|UES augmentation via the UES assist device is effective in true Reflux associated laryngeal symptoms. In our first pilot trial with the UES assist device, patients had significant symptom reduction following 2 weeks of UES assist device use. Based on our preliminary work, we theorize that the UES assist device is effective in Reflux associated laryngeal symptoms.
72121|NCT03619798|Device|HemoTypeSC|Point-of-Care Rapid Test for Detection of Sickle Cell Disease-Relevant Hemoglobin Phenotypes in Whole Blood
72122|NCT03619785|Drug|Bupivacaine|Patient will be positioned supine or in the lateral decubitus position on the side contralateral to the fracture(s). A 3.5 in 20-gauge needle, extension tubing, and a 30 mL syringe loaded with 0.25% bupivacaine and 3 mL of 1% lidocaine loaded in a 5 mL syringe with a 27-gauge needle will be prepared. The ribs, teres minor, latissimus dorsi, and serratus anterior will be identified with bedside US and the site of entry marked along the lateral aspect of the 4th-5th rib. The skin will be sterilized and lidocaine placed at the site of entry. The needle will be introduced at a steep angle and advanced in-plane, under US-guidance, to the plane superficial to the serratus anterior muscle. A test dose of normal saline will confirm proper needle tip placement with opening of the intramuscular layer. Injection with aliquots of 3-5 mL after negative aspiration will continue until 30mL of 0.25% bupivacaine are administered.
72123|NCT03619785|Drug|Fentanyl, morphine, hydromorphone, hydrocodone, acetaminophen, ketorolac, gabapentin, ketamine, ibuprofen|Oral or IV pain medication as needed.
72124|NCT03619772|Other|Bilateral|Participants will control game using EMG from both upper limbs.
72125|NCT03619772|Other|Unilateral|Participants will control game using EMG from the more impaired upper limb.
72126|NCT03619759|Drug|Sugammadex|Sugammadex injection as a reverse agent of neuromuscular blocking
72127|NCT03619746|Behavioral|POCUS Educational Intervention|Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
72128|NCT03619733|Other|no intervention|this is an observational study. no intervention is planned
72129|NCT03619720|Other|Records|Respiratory records, Vocal records Video records Questionnaires
72130|NCT03619707|Drug|Progesterone|Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
72131|NCT03619694|Device|MRI Spectroscopy|Patient with brain SOL underwent MRI Spectroscopy to be compared with later pathology
72132|NCT03619681|Drug|KN026|Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.
72133|NCT03619655|Procedure|SPECT CT|MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.
72134|NCT03619655|Drug|18F-DCFPyL PET/CT|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
72135|NCT03619655|Drug|18F-NaF PET/CT|A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.
72136|NCT03619655|Procedure|WB-MRI|Whole body MRI exam (total examination time < 50 minutes)
72137|NCT03619642|Other|Robotic assessment of finger proprioception|The assessment will be performed using a robotic device specifically designed for the assessment of finger proprioception at the metacarpophalangeal (MCP) joint .
72138|NCT03619629|Other|Kinesio-tape|"Kinesiotape will be applied both ankles as Correction technique."
72139|NCT03619629|Other|Mulligan's mobilization with movement|'Posterolateral glide mobilization with movement' will be applied 10 times to both ankles.
72140|NCT03619629|Other|Sham Kinesio-taping|Sham Kinesio-taping technique will be applied both ankles.
72141|NCT03619629|Other|Sham Mulligan's mobilization with movement|Sham Mulligan's mobilization with movement technique will be applied both ankles.
72142|NCT03619616|Drug|ZSP1603 7.5 mg|ZSP1603 capsule administered orally once daily under fasted condition.
72143|NCT03619616|Drug|ZSP1603 12.5 mg|ZSP1603 capsule administered orally once daily in the fasting state.
72144|NCT03619616|Drug|Placebo 12.5mg|Participants will receive placebo matching to ZSP1603 orally once daily under fasted condition.
72145|NCT03619616|Drug|ZSP1603 25 mg|ZSP1603 capsule administered orally once daily under fasted condition.
72146|NCT03619616|Drug|Placebo 25mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
72147|NCT03619616|Drug|ZSP1603 50 mg|ZSP1603 capsule administered orally once daily under fasted state.
72148|NCT03619616|Drug|Placebo 50mg|Participants will receive placebo matching to ZSP1603 orally once daily in the fasting state.
72149|NCT03619590|Other|Data Collection|When the pregnancy is reported prospectively, the Registry will collect registration data from the reporter through telephone interview or a short registration form. In the month of the estimated date of delivery, follow-up will be sought by telephone contact or a form mailed to the health professional. Information about maternal events throughout the pregnancy, pregnancy outcome, and neonatal health is requested. Additional follow-up is not sought from subsequent health care providers.
72150|NCT03619577|Behavioral|Sequential training|For cognitive training, the BrainHQ program, self-made teaching aids and board games will be used to train different cognitive functions of the participants. For physical exercise, we design the programs that involve balance or strength training components in the aerobic exercises. All participants will first perform 60 minutes of physical exercise followed by 60 minutes of cognitive training.
72151|NCT03619551|Drug|Busulfan|Randomization between low and medium doses of busulfan for TCR αβ+/CD19+ depleted haploidentical related and unrelated donor HCT.
72152|NCT03619551|Device|Cell processing for TCRαβ+/CD19+ depletion|T-cells and B-cells will be removed from the stem cells collected from the donor by an investigational process called alpha-beta CD3+/CD19+ t-cell depletion using a device called CliniMACS® prior to recipient infusion, hopefully minimizing the risk of significant graft vs. host disease (GVHD) or lymphoproliferative disorder.
72153|NCT03619538|Drug|Nefopam|The nefopam group received 120 mg nefopam (Acupan, Pharmbio, France) by continuous iv infusion over the study period (48h)
72154|NCT03619538|Other|saline solution|The Control group received 120 mg placebo infusion (saline solution) by continuous iv infusion over the study period (48h).
72155|NCT03619525|Procedure|lung recruitment|During bypass, patients in this group will receive a lung protective design in the form of continuous positive airway pressure (CPAP) by closing APL valve at pressure of 5 Cm H2o combined with intermittent recruitment by sustained manual lung inflation at a pressure of 35 cmH2O for 30 seconds every (30-40) minute
72156|NCT03619512|Genetic|Whole exome sequencing.|Retrospective biological exploration of the samples, including tumoral DNA exploration.
72157|NCT03619512|Genetic|RNA sequencing|Characterization of tumor transcriptomic profile.
72158|NCT03619512|Other|Mass spectrometry|Characterization of tumor proteomic profiles.
72159|NCT03619499|Device|non invasive ventilation|patients who will fulfill the criteria of severe bronchiolitis will be connected to non invasive ventilation including continuous positive airway pressure via nasal prongs or nasal mask. Mode of ventilation, inspired oxygen levels, oxygen saturation, respiratory rate, and blood gas values from arterial samples prior to and after 2 and 4 hrs of ventilation or nearest time, will be documented.
72160|NCT03619486|Device|Low energy shock wave|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second and maximum total energy flow density 0.25 millijoule/mm2 once a week for 4 weeks
72161|NCT03619486|Device|Placebo|Probe be transcutaneous applied to the suprapubic bladder region with 2000 shocks, frequency of 3 pulses per second but no energy once a week for 4 weeks
72162|NCT03619473|Behavioral|Standard motorcycle child safety helmet|"Educational session followed by demonstration on~proper helmet wearing~how to differentiate non-standard and standard helmets~how to keep motorcycle safe using ABCD concept~importance of wearing bright clothes~police summon for not wearing helmets~live demo on poor performance of non-standard helmet~giving away standard motorcycle child safety helmets~oath taking by parents and children~distribution and placement of VEM on parents' motorcycles"
72163|NCT03619460|Procedure|piezoelectric extraction|Only Piezoelectric device will be used for surgical wisdom teeth extraction
72164|NCT03619460|Procedure|conventional extraction|Only manual instruments and burs on straight handpick will be used for wisdom teeth extraction
72165|NCT03619447|Drug|ESP block group|USG guided Erector spinae block (ESP) will perform bilaterally.
72373|NCT03617783|Drug|Placebo|placebo-OEI
72167|NCT03619434|Procedure|Femtosecond Laser|The laser will be used to make incisions in the cornea for the graft.
72168|NCT03619434|Procedure|Trephine blade|A trephine blade will be used to make incisions in the cornea for the graft
72169|NCT03619421|Dietary Supplement|Zinc supplement|25 mg
72170|NCT03619408|Drug|Antacids|Omeprazole 1 mg/kg/dose BID or Omeprazole 1mg/kg/dose BID plus Ranitidine 3 mg/kg/dose BID
72171|NCT03619382|Radiation|Cone Beam Computed Tomography|Computer tomography (CT) of the foot/ankle for determination of motion and morphology
72172|NCT03619382|Radiation|Radiographs|Standard radiographs of the foot/ankle as part of the screening criteria
72173|NCT03619369|Procedure|Circumcision|Early vs. Routine vs. Delayed Circumcision and their impact on exclusive breastfeeding rates
72174|NCT03619343|Procedure|ETOIMS(Electrical Twitch Obtaining Intramuscular Stimulation)|When the abdominal wound is closed, the operator performs needle insertion at 14 sites near the incision site under the guidance of ultrasonography. When the needle is in the abdominal muscle, the operator performs muscle stimulation for about 10 seconds per needle insertion.
72175|NCT03619330|Drug|liraglutide|In the liraglutide group liraglutide was initiated at a dose of 1.2 mg injected sc once per day and increased to 3 mg/day after 1 week.
72176|NCT03619330|Drug|Testosterone|In the testosterone group Androtop gel 5 grams (50 mg of testosterone) was applied once a day on a dry skin.
72177|NCT03619304|Dietary Supplement|coffee|coffee beverage
72178|NCT03619291|Other|Aerobic Exercise|walking on a treadmill at moderate intensity, total duration 15 minutes
72179|NCT03619291|Other|High-intensity functional training|functional exercises in circuit format at 20/10 s (work/rest) intervals, total duration 15 minutes
72180|NCT03619291|Other|control|physical inactivity, reading sports science literature, total duration 15 minutes
72181|NCT03619278|Other|Boosted iHIVARNA|Will receive 3 vaccines of HIVARNA01.3 prime, 2 MVA-vectored vaccine boosts, 1 dose of 10-1074 antibodies and 3 doses of romidepsin
72182|NCT03619278|Other|iHIVARNA|Participants will receive 5 vaccines of HIVARNA01.3, 1 dose of 10-1074 antibodies and 3 doses of romidepsin
72183|NCT03619278|Other|HIVACAR|Participants will receive 5 vaccines of personalized RNA vaccine (HIVACAR01), 1 dose of 10-1074 antibodies and 3 doses of romidepsin
72184|NCT03619278|Other|only antibody|Participants will receive 1 dose of 10-1074 antibodies and 3 doses of romidepsin
72185|NCT03619265|Dietary Supplement|Prickly pear juice|3 ounces daily for 8 weeks.
72186|NCT03619265|Dietary Supplement|Pear-flavored juice|3 ounces daily for 8 weeks.
72187|NCT03619252|Biological|Vaccination with pneumococcal conjugate vaccine (PCV13)|Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to nontoxic diphtheria cross-reactive material. Vaccination regimen: 3 doses monthly, with a booster dose 6 months later.
72188|NCT03619252|Drug|Standard Antibacterial Prophylaxis|Levofloxacin 500 mg once daily during the median four cycles of treatment by novel agents.
72189|NCT03619239|Drug|GX-I7|During Treatment Period, patients will receive the assigned dose of GX-I7 intramuscular injection every 4 weeks per cycle up to 6 cycles in the absence of unacceptable toxicity or clinically compelling evidence of disease progression.
72190|NCT03619226|Other|test patch|the test patch consists of an adhesive patch
72191|NCT03619213|Drug|Dapagliflozin|10 mg tablets given once daily, per oral use.
72192|NCT03619213|Drug|Placebo|Placebo matching dapagliflozin 10 mg
72193|NCT03619187|Drug|Ivabradine|Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
72194|NCT03619174|Device|Viveve Treatment|The Viveve system is a monopolar radiofrequency system that uses surface cooling and radiofrequency (RF) energy delivery to provide a non-surgical and minimally-invasive approach to generate heat within the submucosal layers of vaginal tissue while keeping the surface cool.
72195|NCT03619161|Other|Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap)
72196|NCT03619161|Other|Bleach and Bubbles|All bathrooms with showers or bathtubs will be cleansed with simple products (dilute bleach, dilute white vinegar, baking soda, and dilute Dawn dish soap).
72197|NCT03619148|Device|High-Flow Humidified Nasal Oxygen|High-Flow Humidified Nasal Oxygen
72198|NCT03619135|Device|Buzzy|The Buzzy is a reusable device that applies vibration to the skin surface to override the body's gate control pain pathway. It has been used effectively to reduce the discomfort of intravenous cannulation (IV placement) in pediatric patients. Also, it has been utilized to reduce the discomfort of injections in pediatric and adult patients. We are preforming this study to evaluate the effectiveness of the Buzzy in reducing the discomfort associated with intravenous cannluation (IV placement) in adults.
72199|NCT03619135|Other|Placebo|No use of the Buzzy (standard IV access techniques)
72200|NCT03619122|Procedure|Second Examination|The colonoscopy is passed to the cecum and then withdrawn to hepatic flexure. Then, the scopy is inserted to the cecum and withdrawn to hepatic flexure again for second foreard view examination.
72201|NCT03619096|Procedure|tunnel technique for Root coverage with Porcine collagen Matrix|Tunnel technique for root coverage for multiple gingival recessions, using porcine collagen matrix
72202|NCT03619096|Procedure|extended fla technique for Root coverage with Porcine collagen Matrix|Extended flap technique for root coverage for multiple gingival recessions, using porcine collagen matrix
72203|NCT03619083|Other|SAE battery|The SAE battery yields 12 variables.
72204|NCT03619083|Behavioral|Assessments|Assessments of their neurocognitive performance will be assessed longitudinally, at 4 time points: prior to adjuvant treatment (post-surgery); 1 month (with a +4 week window) post-chemotherapy; and again at the 12 and 24 months (with a +4 week window) post-treatment time points. These assessment time points are denoted as T1 though T4, respectively. The assessment schedule for the HC and CT- groups will be yoked against that of the CT+ cohort.
72205|NCT03619070|Other|Resistance training, LL|In LL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and low load (i.e. 30% of one repetition maximum)
72206|NCT03619070|Other|Resistance training, HL|In HL, the postmenopausal women will be submitted to 12 weeks of Resistance training with moderate volume (i.e. three sets per exercise) and high load (i.e. 80% of one repetition maximum)
72207|NCT03619070|Other|Resistance training, HVHL|In HVHL, the postmenopausal women will be submitted to 12 weeks of Resistance training with high volume (i.e. six sets per exercise) and hig load (i.e. 80% of one maximum repetition)
72208|NCT03619070|Other|Control group, CG|The CG groups do not will performed the exercise.
72209|NCT03619057|Other|General anesthesia with laryngeal mask i-gel|General anesthesia with laryngeal mask i-gel
72210|NCT03619044|Other|2 FES-PET Imaging will be performed:|"before treatment initiation~before treatment cycle 3 initiation"
72211|NCT03619031|Other|LONG LEAVENING|a long-leavened (60 h) pizza composed of sourdough and a flour mix.
72212|NCT03619031|Other|SHORT LEAVENING|a short-leavened (5 h) pizza composed of sourdough and a flour mix.
72213|NCT03619031|Other|TRADITIONAL|a short-leavened (5 h) pizza composed of brewer's yeast and 00 flour.
72214|NCT03619018|Device|Data collection from Ablation therapy patients|Data collection from arrhythmia patients undergoing catheter-based electrophysiological (EP) intervention in order to develop a patient specific optimized therapy (PSOT).
72215|NCT03619005|Drug|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
72216|NCT03619005|Drug|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
72217|NCT03618992|Other|Cholesterol-containing moisturizers|Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
72218|NCT03618979|Biological|PPP with ECM treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of PPP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PPP mixed with extracellular matrix. The physician will then repeat the procedure on the opposite side.
72219|NCT03618979|Biological|PRP treatment|The day prior to or the morning of the procedure, patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP depending on if there is lumbar multifidus atrophy in one or two levels. Using sterile technique and ultrasound guidance, once touching the lamina the physician will inject 2.5 cc of PRP and remove the needle. The physician will then repeat the procedure on the opposite side and at the next level if indicated.
72220|NCT03618979|Biological|PRP and PL Combo treatment|The day prior to or the morning of the procedure patient will have their blood drawn by a phlebotomist and processed into 5 or 10 cc of 5x PRP and 5 or 10 cc of PL and 2 or 4 cc of 14x PRP depending on if there will be one or two levels injected. Using sterile technique, under ultrasound visualization into the lumbar multifidus and onto the lamina, the physician will inject the PRP and remove the needle. Under intermittent x-ray, epidural flow is confirmed with contrast, the physician will inject 2cc of the PL and 1cc of 0.5% ropivacaine into the epidural space. Once flow is confirmed for the epidural injection and facet with contrast, 1cc of the 14x PRP is injected into the facet joint. Procedure repeated on the opposite side and next level if indicated.
72221|NCT03618966|Device|Neuromuscular magnetic stimulation (NMMS)|It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
72222|NCT03618953|Biological|Ad-E6E7|Adenovirus vaccine expressing mutant HPV E6 and E7
72223|NCT03618953|Biological|MG1-E6E7|MG1 Maraba oncolytic virus expressing mutant HPV E6 and E7
72224|NCT03618953|Biological|Atezolizumab|monoclonal antibody; checkpoint inhibitor
72225|NCT03618940|Behavioral|Knowledge and Attitude on burn prevention|"1.Introduction to Home Safety~2 Fire Safety & Burn Safety (Cooking Safety, Safety around Motorcycle Exhaust &First Aid for Minor Burns~3 Electrical Safety (Safety around Electrical & Appliances & Outlets)~4 Firecrackers Safety (Safety around Firecrackers & Open Flames)~5. Escaping from Fire (Escaping from Fire, Calling for Help, Stop, Drop & Roll, Emergency Calling Number (By Fire Department Kuala Lumpur), Show equipment/gear that firefighters use, Demonstrate how to use the fire extinguisher, Crawl low in smoke"
72226|NCT03618927|Behavioral|Daily physical activity intervention|
72227|NCT03618914|Biological|Dultavax and Vaxigrip|All the women got an influenza/DTP vaccine in order to induce acute inflammation
72228|NCT03618901|Other|Rock Steady Boxing|Boxing programs as offered by the Rock Steady Boxing institution,
72229|NCT03618901|Other|PD SAFEx|Progressive proprioception training.
72230|NCT03618888|Other|Instructor-led training|The Instructor-led training contents a supervised practical training with a standard kit for training in BLS
72231|NCT03618888|Other|Self-learning training|The self-learning training contents a standard kit for self-directed training in BLS
72232|NCT03618875|Other|ice pack|ice pack was placed on eyelid 5 minutes prior to IVIT
72233|NCT03618875|Other|room temperature pack|room temperature pack was placed on eyelid 5 minutes prior to IVIT
72234|NCT03618862|Biological|Blood sampling|Peripheral venous blood collection of 56 mL during a sampling required by routine monitoring of human immunodeficiency virus infection.
72235|NCT03618849|Device|tDCS|Real and sham tDCS/Mozart piano sonata (K.448)
72236|NCT03618836|Other|Microbiological and biological patterns on vaginal samples|To compare the microbiological and biological patterns between groups
72237|NCT03618823|Drug|Oxycodone|Oxycodone will be prescribed at a dose in the range of 0.025 mg/kg to 0.10 mg/kg every four hours or as needed for adequate pain management. The total supply will be limited to seven days. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
72374|NCT03617770|Behavioral|Sleep Opt-In|8-week intervention that includes a wearable sleep tracker, didactic content, smartphone application and counseling
72238|NCT03618823|Drug|Ibuprofen|Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
72239|NCT03618823|Drug|Acetaminophen|Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.
72240|NCT03618810|Drug|PEGCSF first level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in all cycles of chemotherapy
72241|NCT03618810|Drug|PEGCSF second level prophylactic use|6mg (≥45kg) or 3mg (<45kg) i.h. once 24h after chemotherapy in next cycle if FN or 4 grade neutropenia happened
72242|NCT03618797|Drug|HL-PIF cap.160/2mg + Placebo|Fenofibrate pellet (as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
72243|NCT03618797|Drug|Livalo tab. 2mg + Placebo|Pitavastatin ca 2mg
72244|NCT03618784|Biological|FURESTEM-RA Inj|"The allogeneic umbilical cord blood-derived mesenchymal stem cells of each dose level as below were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump.~Dose level 1: 5.0 x 10^7 cells~Dose level 2: 1.0 x 10^8 cells"
72245|NCT03618784|Other|sterile saline|"Placebo were mixed into an IV bag containing 100 ml of sterile saline solution and the IV bag was gently massaged to obtain homogeneous mixture of the cell suspension.~Administer the constituted cell suspension by IV infusion to a subject. The infusion should be completed in 60 minutes using infusion pump."
72246|NCT03618771|Device|Total knee arthroplasty|Parts of the knee joint diseased by osteoarthritis are replaced by metal and plastic prostheses.
72247|NCT03618758|Drug|Paclitaxel|"Intraperitoneal application of Paclitaxel Phase 1: Dose determination of Paclitaxel (Recommended Dose) Starting from 40mg/m² upto 100mg/m² maximum~Phase 2: Intraperitoneal Paclitaxel with recommended dose"
72248|NCT03618758|Drug|mFOLFOX6 regimen|Systemic mFOLFOX6: 5-FU(2400mg/m²), Oxaliplatin(100mg/m²), Leucovorin(100mg/m²)
72249|NCT03618745|Device|CT brain|noninvasive medical examination or procedure that uses specialized X-ray equipment to produce cross-sectional images of the body.
72250|NCT03618732|Other|Bilateral movement-based computer training|
72251|NCT03618732|Other|Video-directed conventional training|
72252|NCT03618706|Radiation|Involved-field radiotherapy|After the diagnosis of recurrences, patients will receive involved-field radiotherapy (gross tumor volume + margin) with any radiation dose scheme (≥45 Gy Biological Equivalent dose) as physician's discretion.
72253|NCT03618693|Procedure|Spinal anesthesia|Injection of a single shot of local anesthetic bupivacaine 0.5% combined with 20 mcg fentanyl intrathecally.
72254|NCT03618693|Device|TAP Block|TAP block with a single shot of 20ml ropivacaine 0.375% combined with 75 mcg clonidine bilaterally
72255|NCT03618693|Other|Standard|Concomitant systemic administration of lidocaine (as an adjuvant) to the standard general anaesthesia. Lidocaine will administered initially during induction with a bolus of 1.5 mg per kgBW, followed by an infusion of 1.5 mg per kgBW per hour for 24 hours.
72256|NCT03618667|Drug|GC1118|GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
72257|NCT03618654|Drug|Metformin|Given PO
72258|NCT03618654|Biological|Durvalumab|Given IV
72259|NCT03618641|Drug|CMP-001|A molecule comprised of a 30 nucleotide strand, flanked by 10 guanines on either end. The nucleotide strand is surrounded by a Qβ viral-like protein. The intended mechanism of action of CMP-001 in oncology is the activation of TLR9 in pDC within the tumor or the tumor-draining lymph nodes (tumor-associated pDC).
72260|NCT03618641|Biological|Nivolumab|A fully human Ig G4 antibody that blocks PD-1. Nivolumab was initially approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. Nivolumab has also been FDA approved to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, as well as advanced renal cell carcinoma.
72261|NCT03618628|Device|Carbon Fiber Off Loading Orthosis (CFO)|A finite element (FE) model will be created to determine properties that will improve CFO strength while maintaining reduction of peak plantar pressures of the CFO and plantarflexor power. A new CFO will then be fabricated for the participant. Participants will be tested in while walking barefoot, wearing their current CFO, and wearing the FE model driven CFO.
72262|NCT03618615|Biological|artericitc surgery|biological sample (leg) from leg amputation surgery used for research
72263|NCT03618602|Drug|Bisthianostat|Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
72264|NCT03618589|Drug|Pregabalin|Patients in the pregabalin add-on group received 75mg of pregabalin twice a day for the first week (150 mg/day) and 150mg of pregabalin twice a day (300 mg/day) for the second week and 300mg of pregabalin twice a day (600mg/day) for subsequent 6 weeks.
72265|NCT03618589|Drug|Opioid|Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
72266|NCT03618576|Procedure|Balance specific exercise|Balance specific exercise consists of total 10 days' physical therapy (PT) sessions (twice per day for 60 min) after surgery. It will be conducted with a computed posturographic system for diagnostics of balance and movement skills (Balance Master® System NeuroCom®) designed to objectively quantify balance and postural function of different origin. PT (weight-bearing, strengthening, gait training, aerobic, and functional exercises) was gradually increased based on the patient's functional level. Intensive patient education by multidisciplinary rehabilitation members was also provided.
72375|NCT03617770|Behavioral|Healthy Living|8-week intervention that includes weekly telephone counseling on healthy living.
72267|NCT03618563|Other|functional individualized therapy for teenagers with executive deficits|Intervention to improve self-perceived performance and performance satisfaction in daily activity goals that adolescent selected,
72268|NCT03618550|Drug|pembrolizumab|Age 10-17: 2mg/kg (cap at 200mg), Age ≥ 18: 200 mg (flat) ,Day 1 of each 3 week cycle IV infusion 2-4 cycles (pre-ASCT)
72269|NCT03618550|Drug|gemcitabine|1000mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
72270|NCT03618550|Drug|vinorelbine|20mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
72271|NCT03618550|Drug|liposomal doxorubicin|15mg/m^2 Days 1 and 8 of each 3 week cycle IV infusion 2-4 cycles
72272|NCT03618550|Procedure|Stem cell mobilization and collection|Stem cell mobilization and collection will be performed as per standard MSKCC guidelines after 2-4 cycles of pembrolizumab-GVD.
72273|NCT03618537|Drug|Ixazomib|Ixazomib at a fixed dose of 4mg on days 1, 8, and 15 of a 28-day cycle. Ixazomib will be given orally on days 1, 8, and 15 of a 28 day cycle.
72274|NCT03618537|Drug|Dexamethasone|Dexamethasone 4mg-12mg will be allowed on days 1, 8, 15 if patients previously tolerated dexamethasone without issue.
72275|NCT03618524|Other|Lower limb hot water immersion|Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
72276|NCT03618511|Behavioral|Financial Incentive|Financial Incentive: Participants will receive monthly financial incentives each time they refill the ART medication on time for six months
72277|NCT03618511|Behavioral|Reminders|Reminders: Participants will receive monthly reminder phone calls before their ART medication refill is due for six months.
72278|NCT03618511|Behavioral|Financial Incentive and Reminders|Interaction: Participants receive both the Financial Incentives and Reminder Calls.
72279|NCT03618511|Behavioral|Information|Information: show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART.
72280|NCT03618511|Behavioral|Stigma-relieving|Stigma-Reliving: Upon recruitment, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
72281|NCT03618511|Behavioral|Information and Stigma-relieving|Information and Stigma-relieving: Upon recruitment, show the participants a video about HIV progression, mechanism of ART, the benefit of adhering to ART. In addition, inform the participants of the results of a recent population survey regarding people's attitudes towards HIV, if they overestimate the social stigma related to HIV. This intervention intends to reduce the stigma-concern faced by the patients.
72282|NCT03618498|Procedure|ILM flaps insertion techniques or free ILM flaps.|The ILM flap anchoring on the hole edge was inverted and covered the hole.Otherwise, temporal side ILM flap was used. However, if the risk of ILM flipping back was judged to be high, ILM insertion instead of ILM hole coverage was adopted.If the size of the ILM flaps was judged inadequate, the double ILM insertion technique was used, done by adding a piece of previously obtained free ILM flap on top of the inverted ILM tissue until they were securely in place.
72283|NCT03618472|Drug|Metformin Hydrochloride 850 MG|Regular strength metformin (850 mg/tab)
72284|NCT03618472|Drug|Placebo Oral Tablet|Starch based placebo manufatured to mimic Metformin 850 mg
72285|NCT03618459|Other|Phone questionnaire|Patients were contacted by phone 6 months after surgery and, after oral consent, a standardized questionnaire was administered in order to inquiry about the length and nature of post-operative pain, the incidence of post-discharge pain, its characteristics, its impact on daily life, its treatment and its rate of chronicity
72286|NCT03618446|Other|The presence of a pelvic fracture|
72287|NCT03618433|Other|study group|The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .
72288|NCT03618433|Other|Control group|The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
72289|NCT03618420|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
72290|NCT03618420|Drug|Iohexol Inj 300 mg/mL|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
72291|NCT03618394|Dietary Supplement|MCT/ω-3-PUFA|lipid emulsion
72292|NCT03618394|Dietary Supplement|Soybean Based|lipid emulsion
72293|NCT03618381|Biological|second generation 4-1BBζ EGFR806-EGFRt|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt
72294|NCT03618381|Biological|second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG|Autologous CD4 and CD8 T cells lentivirally transduced to express a second generation 4-1BBζ EGFR806-EGFRt and a second generation 4 1BBζ CD19-Her2tG
72295|NCT03618368|Device|THERANOVA-500 dialyzer|THERANOVA-500 dialyzer is an improved version of REVACLEAR-400 dialyzer which are both hemofilters required for the performance of hemodialysis
72296|NCT03618368|Device|REVACLEAR-400 dialyzer|REVACLEAR-400 dialyzer is the usual hemofilter required for the performance of hemodialysis
72297|NCT03618355|Drug|eRapa (encapsulated rapamycin)|"The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).~This improved formulation and better bioavailability enables eRapa to consistently provide approximately 30% more drug than sirolimus (unpublished data). Improved and predictable delivery allows for consistent and sustained lower dosing, which will result in an improved toxicity profile since the latter is proven to be related to blood concentration levels. This is a phase Ib trial in low risk (Gleason score ≤7 (3+4)) prostate cancer patients under active surveillance to establish dosage safety and treatment levels."
72298|NCT03618329|Other|Prehabilitation|exercise, nutrition and anxiety reduction in the preoperative period
72299|NCT03618316|Drug|Imeglimin|2 singles oral doses of imeglimin 1,500 mg (one at day 1 and one at day 8)
72300|NCT03618316|Drug|Cimetidine|400 mg of cimetidine bid from Day 5 to Day 10
72376|NCT03617757|Diagnostic Test|Oral Glucose Tolerance Test|Patients will be invited to have oral glucose tolerance test. 2mL blood will be taken for analysis at 0 minute and 120 minutes.
72301|NCT03618303|Diagnostic Test|PET-MRI scan|Patients will undergo combined Positron Emission Tomography and Magnetic Resonance Imaging prior to a planned invasive angiogram (performed as standard of care). During the angiogram procedure, an additional imaging test (optical coherence tomography) will be performed.
72302|NCT03618290|Diagnostic Test|Analyze plasma free fatty acid in blood|"This study is prospectively designed with the purpose of investigating potential new lipid targets and the free fatty acids as specific markers of acute brain injury.~Dynamic measurement of lipid profile in 3 consecutive samples at (I) the time intervals of admission, (II) 8 hours and (III) 24 hours after admission will give the opportunity of comparison mass-spectrometric analysis of highly complex plasma samples thus reducing variability between analyzed samples and allowing precise focusing on essential lipid target changes during stroke progression."
72303|NCT03618277|Procedure|Biopsy|Micro-biopsies will be performed using a punch of 1 mm in diameter, by pulling the skin at the time of sampling, after disinfection and anesthesia.
72304|NCT03618264|Drug|Miscible liquid of dexamethasone and ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with dexamethasone, ropivacaine and normal saline miscible liquids for participants who will undergo elective craniotomy. The local infiltration solution containing 0.33mg dexamethasone and 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
72305|NCT03618264|Drug|Ropivacaine|Intervention in this study will be peri-incisional scalp infiltration with ropivacaine for participants who will undergo elective craniotomy. The local infiltration solution containing 5mg ropivacaine per milliliter will be infiltrated along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigator.
72306|NCT03618251|Diagnostic Test|specific MRI sequences|MRI with B 2000 of diffusion weighted imaging and the coefficient of apparent diffusion
72307|NCT03618238|Drug|Anlotinib|12 mg daily for continus 14 days every 21 days
72308|NCT03618225|Drug|Oral Duloxetine 60mg|duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
72309|NCT03618225|Drug|placebo pill|placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
72310|NCT03618212|Diagnostic Test|MRI|Skeletal MRI and pelvic and spinal MRI
72311|NCT03618199|Device|Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing|"Transcranial vibrating system will be on then off (or off then on in a random order) during a repeated application of the calorics testingstimulus, i.e. warm or cold water irrigated in the left (then right) ear canal. The effect of the vibrating system on 1) resulting dizziness and nausea often experienced by patients and 2) clinical parameters measured by caloric testing will be quantified."
72312|NCT03618186|Combination Product|Tau PET scan|Patient will receive a dose of flutaucipir and be scanned appropriately
72313|NCT03618173|Drug|Dexamethasone|IV dexamethasone at the dose of 0,2mg/kg = 0,2mL/kg of a solution of 1mg/mL max 8mg
72314|NCT03618173|Drug|Placebos|IV saline serum at the dose of 0,2mL/kg maximum 8mL
72315|NCT03618160|Drug|JNJ-64565111|Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions. Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
72316|NCT03618160|Drug|Placebo|Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
72317|NCT03618134|Biological|Durvalumab|Given IV
72318|NCT03618134|Procedure|Modified Radical Neck Dissection|Undergo modified radical neck dissection
72319|NCT03618134|Other|Quality-of-Life Assessment|Ancillary studies
72320|NCT03618134|Other|Questionnaire Administration|Ancillary studies
72321|NCT03618134|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
72322|NCT03618134|Procedure|Transoral Robotic Surgery|Undergo TORS
72323|NCT03618134|Biological|Tremelimumab|Given IV
72324|NCT03618121|Device|Biofeedback plus gaming (Nevermind)|Participants will receive relaxation training from a trained therapist while receiving biofeedback through the game Nevermind. Participants receive two 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
72325|NCT03618121|Device|Biofeedback only (The Pip)|Participants receive relaxation training from a trained therapist with biofeedack through The Pip device. The Pip connects with 4 apps, The Loom, Relax & Race, PipStressTracker, and Clarity. All 4 will be used in this study. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
72326|NCT03618121|Behavioral|Relaxation training|Standard relaxation training protocol often used in clinical care. Participants receive 2 30-minute sessions per week, for 4 weeks, for a total of 8 sessions.
72327|NCT03618121|Behavioral|Gaming only|"Intervention is identical to the Biofeedback plus gaming (Nevermind) intervention, but in this case participants play Nevermind without any biofeedback. Thus, they receive 2 30-minute sessions of relaxation training per week, for 4 weeks, totaling 8 sessions. During relaxation training, they will play the Nevermind game, but without attaching to any biofeedback devices."
72328|NCT03618108|Drug|Doxycycline Capsule|doxycycline capsule
72329|NCT03618108|Drug|Azithromycin Capsule|azithromycin capsule
72330|NCT03618108|Drug|Rifabutin Oral Capsule|rifabutin capsule
72331|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to doxycycline
72332|NCT03618108|Drug|Placebo Oral Tablet|Placebo oral capsule identical in size and form to azithromcyin
72333|NCT03618108|Drug|Placebo oral capsule|Placebo oral capsule identical in size and form to rifabutin
72335|NCT03618082|Drug|Anesthesic agent guided by ANI (Interventional Group)|Anesthesic agent guided by ANI (Interventional Group) The remifentanil administration will be piloted by the ANI, as well as the prophylactic administration of morphine at the end of the intervention.
72336|NCT03618082|Drug|Administration of the lowest effective concentration of desflurane (Interventional Group)|Administration of the lowest effective concentration of desflurane (Interventional Group) Desflurane will be administered with a targeted purpose of minimal alveolar concentration (MAC).
72337|NCT03618069|Diagnostic Test|CCI scanning (CTA, cardiac CT), and MRI scanning|Scanning
72338|NCT03618056|Biological|AIDSVAX® B/E|Administered by intramuscular injection
72339|NCT03618043|Drug|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
72340|NCT03618030|Drug|PRC-063 oral capsules|Daily dose
72341|NCT03618030|Drug|Placebo oral capsules|Daily dose
72342|NCT03618017|Behavioral|CCC website|ContinuingCancerCare (CCC) is a web-based guide to support survivorship care for women who have been treated for early-stage (stages 0-II) breast cancer. It encourages patients to utilize team-based care by oncologists and primary care physicians and provides them with the information on cancer surveillance, screenings and preventive healthcare during survivorship.
72343|NCT03618017|Behavioral|Static care plan|"The control is a static survivorship care plan template in PDF format that includes information similar to what an oncologist currently provides as standard of care."
72344|NCT03618004|Other|Experimental group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects of the experimental group made use of the restriction of blood flow, using a pressure cuff coupled in the most proximal region of the arm, 10 cm wide. The pressure was calculated based on the initial systolic pressure of the subjects."
72345|NCT03618004|Other|Control group|"The intervention lasted 17 minutes each session, 2 weekly sessions were carried out, during 4 weeks. The training started with a warm-up on the hand bike without a load for 5 minutes. Later, we did a work of 3 series of 30 seconds, in maximum power, with 5 minutes of rest between them. The intensity was calculated by 0.048 kp.kg.~The subjects in the control group did not use pressure cuffs."
72346|NCT03617991|Other|Exercise Group|An 8-week home exercise program will be given to the participants. The program is designed to have four phases, progressed every two weeks. The participants will receive and email from study personnel every two weeks with new videos detailing the progression of exercises. The participants will be given all of the equipment to complete the exercises. The exercises will include balance and strength training exercises for the core and lower extremity.
72347|NCT03617978|Procedure|Hemodynamics parameters|real-time evaluation of cardiac output parameters using the ICON device
72348|NCT03617965|Diagnostic Test|Platelet count|All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
72349|NCT03617952|Behavioral|P3 Bio Intervention|Two types of improved biomass burning cookstoves (ACE1 and Greenway Jumbo) are offered to participants in both arms at varying prices.
72350|NCT03617939|Procedure|Biospeciman Collection|Collection of blood, tissue, and other biological samples.
72351|NCT03617939|Other|Survey Assessments|Data taken from patient surveys and assessments, including quality of life.
72352|NCT03617939|Other|Medical Chart Reviews|Data taken directly from the patients' medical charts.
72353|NCT03617926|Device|X92001666|the X92001666 product is a lotion to be applied on dry hair for 15 minutes and then washed out using shampoo. The product is to be applied on Day 0 and repeated again on Day 7.
72354|NCT03617926|Other|RID shampoo|Active Comparator: RID shampoo The RID shampoo is to be applied on dry the hair for 10 minutes and then rinsed out with water. the product is to be applied on Day 0 and repeated again on Day 7.
72355|NCT03617913|Drug|Avelumab|Given IV
72356|NCT03617913|Drug|Cisplatin|Given IV
72357|NCT03617913|Drug|Fluorouracil|Given IV
72358|NCT03617913|Drug|Mitomycin|Given IV
72359|NCT03617913|Other|Quality-of-Life Assessment|Ancillary studies
72360|NCT03617913|Radiation|Radiation Therapy|Undergo RT
72361|NCT03617900|Drug|Ginger|Ginger extract is contains 100 mg/capsules. Use 2 capsules 3 times/day
72362|NCT03617900|Drug|Placebo oral capsule|Lactose monohydrate 400 mg/capsules
72363|NCT03617900|Drug|Paracetamol|500 mg paracetamol. use in need
72364|NCT03617887|Other|Experimental group|"Plank exercise, Lateral plank exercise, Bird dog exercise, Pelvic drop exercise, and Stabilization of the middle gluteus in the knee valgus.~The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region in the control group, and a specific work of gluteus medius, added to the previous one, in the experimental group."
72365|NCT03617887|Other|Control group|Plank exercise, Lateral plank exercise and Bird dog exercise. The intervention consisted of sessions of approximately 20 minutes, taking place 2 days a week, for 8 weeks. The exercises were performed at the beginning of the training session, and consisted of a work of the abdominal region.
72366|NCT03617874|Other|PC4PrEP- Intervention Clinics|PC4PrEP is a comprehensive, multi-level, structural and sustainable intervention designed to address barriers at system, provider, and user levels to increase PrEP uptake.
72367|NCT03617874|Other|Standard of Care Clinics|The standard of care model is the model approved by the health system for their health care clinics.
72368|NCT03617861|Drug|Human Secretin|Injected once over one minute
72369|NCT03617861|Drug|Placebo|Injected once over one minute
72370|NCT03617835|Drug|Spesolimab|single-dose
72371|NCT03617809|Procedure|Preoperative warming|The prewarming time will not be decided by the clinical investigator. Prewarming time will depend on the time the patient has to wait before entering in the operating room.
72372|NCT03617783|Drug|Prebiotin|Prebiotin (12g/day), an oligofructose-enriched inulin (OEI)
72377|NCT03617757|Diagnostic Test|HbA1c|2mL blood will be taken for analysis of HbA1c.
72378|NCT03617744|Procedure|Sleeve gastrectomy|Open sleeve gastrectomy
72379|NCT03617731|Drug|Lenalidomide|25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)
72380|NCT03617731|Drug|Bortezomib|all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles
72381|NCT03617731|Drug|Dexamethasone|20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.
72382|NCT03617731|Drug|Isatuximab|10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)
72383|NCT03617718|Drug|Glycine Buffer|Subjects will be asked to perform an Inhaled Glycine Buffer followed by a series of Pulmonary Function Tests (PFTs) and then a research bronchoscopy will happen at visit 3.
72384|NCT03617705|Device|Skyn Monitor Lab Session 1|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session.
72385|NCT03617705|Device|Skyn Monitor Field Test with EMA App|After Skyn Monitor Lab Session 1, participants will be instructed to wear Skyn monitor for the rest of the day and the following two weeks. Participants will also enter information on each drinking session during the two week time using a mobile-based ecological momentary assessment (EMA) to collect real-time data in daily life.
72386|NCT03617705|Device|Skyn Monitor Lab Session 2|Participants will be instructed to wear the Skyn wrist-worn alcohol monitor and drink 3 beers over the course of an hour and a half. BrAC will be measured every 15 minutes throughout the session. Participant will also complete device acceptability and usability survey.
72387|NCT03617679|Drug|Rucaparib|Participants allocated to the active ingredient arm will receive Rucaparib twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Medication should be taken around the same time every day, with 8 or more ounces of water.
72388|NCT03617679|Drug|Placebo Oral Tablet|Participants allocated to the placebo arm will receive a placebo tablet (that looks identical to the active ingredient tablet) twice daily, 600mg, to be take by mouth. Patients will take the medication continuously over a 28 day cycle, until disease progression or other indication of discontinuation. Tablet should be taken around the same time every day, with 8 or more ounces of water.
72389|NCT03617666|Drug|Avelumab|Patients with newly diagnosed cHL will receive 4 doses of single agent avelumab intravenously given every 2 weeks.
72390|NCT03617653|Diagnostic Test|Group A|Refer to detailed study Description
72391|NCT03617627|Behavioral|Self-management intervention|Self-management intervention will include presentation and discussion of various topics regarding chronic pain mechanisms and pain self-monitoring. The intervention will also incorporate a task-oriented approach focused on relevant activities in order to acquire coping skills.
72392|NCT03617614|Behavioral|Collaborative Care Model|"Trained care managers (CM) work collaboratively with patients, caregivers, and primary care providers to provide education, care navigation and behavioral activation. The latter includes a stepped psychotherapy intervention called ENGAGE, that focuses on reward exposure engagement in meaningful, rewarding activities for patients. Patients (home) visits are delivered over a period of 6 to 16 weeks. Progress is assessed with standardized measures for depression (PHQ-9), anxiety (GAD-7) and functioning (WHO-DAS). Furthermore, patients are presented by the CM at Systematic Case Review meetings where an integrated team of medical, psychiatric and allied health professionals work collaboratively to review the patient's goals and treatment to formulate a care plan and recommendations."
72393|NCT03617614|Behavioral|Mood Consultation|A meeting with a psychiatrist to do assessment, provide education and make recommendations regarding the care of the patient for the Primary Care Provider.
72394|NCT03617601|Diagnostic Test|MET|Testing of the metabolic equivalent of task before aortic procedure
72395|NCT03617588|Drug|Gallium-68 THP-PSMA|Subjects will undergo a Gallium-68 THP-PSMA scan in addition to standard of care monitoring. The results of this scan may influence the patient management plan.
72396|NCT03617575|Dietary Supplement|apo-Lactoferrin|1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.8 mg of iron naturally in apo-Lf [total of 1.5 mg iron]) in a maize porridge (extrinsically labeled)
72397|NCT03617575|Dietary Supplement|holo-Lactoferrin|1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge
72398|NCT03617575|Dietary Supplement|FeSO4|1.5 mg FeSO4 as 54Fe in a maize porridge
72399|NCT03617575|Dietary Supplement|1. FeSO4|10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge
72400|NCT03617575|Dietary Supplement|FeSO4 after 1 day break|10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period
72401|NCT03617575|Dietary Supplement|FeSO4 after 2 day break|10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period
72402|NCT03617562|Procedure|Superior Capsule Reconstruction|Residual rotator cuff defect is reconstructed with a dermal allograft secured to the glenoid and humeral head.
72403|NCT03617562|Procedure|Partial Repair|Rotator cuff is repaired with residual defect left remaining.
72404|NCT03617536|Drug|CR845 0.25 mg Oral Tablet|CR845 0.25 mg medication taken orally 1 time/day
72405|NCT03617536|Drug|CR845 0.5 mg Oral Tablet|CR845 0.5 mg medication taken orally 1 time/day
72406|NCT03617536|Drug|CR845 1 mg Oral Tablet|CR845 1 mg medication taken orally 1 time/day
72407|NCT03617536|Drug|Placebo Oral Tablet|Placebo tablet taken orally 1 time/day
72408|NCT03617523|Biological|Fluzone Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
72551|NCT03616535|Other|Exercise training|The investigators will provide participants with foot peddlers.
72409|NCT03617523|Biological|Flublok Quadrivalent vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
72410|NCT03617523|Biological|Fluzone High-Dose vaccine, 2018-2019 formulation|Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
72411|NCT03617510|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the drug was given 7 times,3 times/day,once every 8 hours. It means the drug was given 3 times on D3 and D4,once on D5.
72412|NCT03617510|Drug|Placebos|Normal saline will be infused IV in 100 mL normal saline,in a 30-minute period using a programmable pump.Three days after the single dose,the Placebo was given 7 times,3 times/day,once every 8 hours.It means the Placebo was given 3 times on D3 and D4,once on D5.
72413|NCT03617497|Diagnostic Test|scalp EEG and polysomnography|48 hour 22 channel EEG with polysomnography
72414|NCT03617497|Diagnostic Test|scalp EEG with foramen ovale electrodes with polysomnography|long-term scalp EEG with additional foramen ovale electrodes with polysomnography
72415|NCT03617484|Drug|Bortezomib|Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m^2 on days 1, 4, 8, and 11 of each 21-day cycle.
72416|NCT03617484|Drug|Ibrutinib|Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
72417|NCT03617471|Procedure|Venopuncture for PK profiling|Blood samples at T0, T0.5, T1, T2, T4, T6
72418|NCT03617458|Drug|Metformin|Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.
72419|NCT03617458|Drug|Placebo|A treatment with no active ingredients or therapeutic effect.
72420|NCT03617458|Device|mHealth Intervention|Our Health Insurance Portability and Accountability Act (HIPPA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
72421|NCT03617458|Device|Usual Care|Our HIPPA compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
72422|NCT03617445|Drug|FMT enema|FMT enema one time
72423|NCT03617445|Drug|Oral Vancomycin|Oral Vancomycin 125 mg capsules every 6 hours for 10 days, followed by 125 mg oral placebo every 12 hours for 7 days, followed by 125 mg oral placebo once daily for 7 days, followed by 125 mg oral placebo every 3 days for 14 days
72424|NCT03617445|Drug|FMT enema placebo|FMT placebo one time
72425|NCT03617445|Drug|Oral Vancomycin placebo|Placebo oral vancomycin capsules every 6 hours for 10 days, followed by 125 mg oral vancomycin every 12 hours for 7 days, followed by 125 mg oral vancomycin once daily for 7 days, followed by 125 mg oral vancomycin every 3 days for 14 days.
72426|NCT03617432|Drug|Chidamide|Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
72427|NCT03617432|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
72428|NCT03617432|Drug|Doxorubicin|Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
72429|NCT03617432|Drug|Vincristine|Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
72430|NCT03617432|Drug|Etoposide|Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
72431|NCT03617432|Drug|Prednisone|Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
72432|NCT03617419|Device|GE VScan Access R2 Ultrasound System|A diagnostic ultrasound imaging system manufactured by the study Sponsor.
72433|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device to record a continuous fetal heart rate.
72434|NCT03617419|Device|GE Corometrics 170 Series Fetal Monitor|A reference device for verification of scanning the fetal heart.
72435|NCT03617406|Diagnostic Test|Volume Challenge|Addition volume challenge with passive leg raising method in LDDSE as well as administration of normal saline and dobutamine during TEE
72436|NCT03617380|Other|Usual Care|patients participating Usual Care discharge services
72437|NCT03617380|Other|PharmD TOC|patients participating in a community pharmacy-based Transitions of Care Program (PHARMD-TOC)
72438|NCT03617367|Biological|daxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
72439|NCT03617354|Procedure|Total Laparoscopic Hysterectomy|The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
72440|NCT03617341|Procedure|Brain MRI|Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
72441|NCT03617328|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
72442|NCT03617328|Drug|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
72443|NCT03617328|Drug|polyICLC|polyICLC, local adjuvant
72444|NCT03617328|Drug|CDX-1127|CDX-1127, anti-CD27 monoclonal antibody
72445|NCT03617315|Drug|Hylauronic Acid|Schirmer Test, BUT test and OSDI test. Previous and After treatment
72446|NCT03617302|Drug|Experimental: Nitrate-containing|Experimental
72447|NCT03617302|Drug|Placebo: Nitrate-depleted|Placebo
72448|NCT03617289|Drug|Magnesium Sulfate|
72449|NCT03617289|Drug|D5W|
72450|NCT03617263|Drug|Saroglitazar Magnesium 4 mg Tablet|Patients randomly assigned to this group will receive Saroglitazar Magnesium orally once daily for 24 weeks.
72451|NCT03617263|Drug|Placebo|Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
72452|NCT03617250|Other|Disease Activity Score-28|Assessment of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio and their association with Disease Activity Score-28
72453|NCT03617237|Other|Retrospective Populations|"All patients who are currently treated by any physician at the University of Texas Southwestern campus Aston Clinic, Seay Clinic, PHHS Clinic, Moncrief Radiation Oncology, St. Paul West Campus Radiation Oncology, East Radiation Oncology Clinic will be included in the registry. The data from the charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number.~The research involves no more than minimal risk to the subjects.~The waiver will not adversely affect the rights and welfare of the subjects.~The research could not practicably be carried out without the waiver.~Whenever appropriate, the subjects will be provided with additional pertinent information after participation."
72454|NCT03617224|Radiation|TSEBT|"The regimen includes a rule-based 3+3 design for escalating regimen intensity of combined TSEBT and pembrolizumab."
72455|NCT03617198|Biological|CD4 CAR+CCR5 ZFN T-cells|A dual cohort, open-label, randomized study of the safety and tolerability of a single infusion of autologous T cells genetically modified to express a CD4 chimeric antigen receptor while also having zinc finger nuclease-mediated disruption of the CCR5 gene
72456|NCT03617185|Other|High Intensity Interval Training (HIIT)|Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.
72457|NCT03617185|Other|Routine Exercise|Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
72458|NCT03617185|Procedure|Bariatric surgery|Patients will undergo bariatric surgery as part of their routine care
72459|NCT03617172|Drug|Misoprostol 100Mcg Tab|Two 100mcg capsules twice per day
72460|NCT03617172|Other|Placebo|Two capsules twice per day
72461|NCT03617159|Device|Magnetic Resonance Imaging|Diagnostic Modality
72462|NCT03617146|Behavioral|Health coaching|The intervention will seek to help participants express their diabetes emotional needs and to work with them to figure out what can be done to meet those needs. Depending on the unique needs of each participant, the coaching approach for this study will include: improving motivation and self-efficacy for diabetes management using motivational interviewing and appreciative inquiry; building trust and rapport through mindful listening, open-ended inquiry, and perceptive reflections; and expressing empathy through nonviolent communication. Each participant will receive eight individual coaching sessions over a five month period. All coaching sessions will be delivered over the phone (i.e. telecoaching). The coaching intervention will be done by a certified health and wellness coach.
72463|NCT03617146|Other|Diabetes Distress-specific Education|A diabetes distress-specific education that explains what diabetes distress is, why it matters, and its four domains. In addition, the participant is given feedback on his or her distress score and advised on ways to deal with the areas of greatest distress. Participant is linked with resources to overcome any expressed needs. The education is provided by a trained medical assistant.
72464|NCT03617133|Radiation|Increased use of IC/IS technique in BT|In EMBRACE II, the improved therapeutic window (through increased application of IC/IS) will be exploited for tumour dose-(de-)escalation and/or OAR dose de-escalation. In tumours with large residual CTVHR volumes at time of brachytherapy, dose-escalation has the potential to improve local control significantly. In limited size CTVHR volumes dose-de-escalation will be performed since dose de-escalation has minor impact on local control while it has potential to reduce morbidity. The strategy of EMBRACEII is to aim for an application of the IC/IS technique in at least 20% of the patients in each institution. The threshold of 20% is relevant for a classical stage distribution of ~20% IB, ~50% IIB, ~20% IIIB and ~10% others. If a given patient population includes significantly higher proportions of limited or extensive disease, the threshold of 20% IC/IS applications must be adapted.
72465|NCT03617133|Radiation|Reduction of vaginal source loading|A multicenter investigation in 50 EMBRACE patients from 3 institutions (Mohamed SM. et al, in submission 2015) shows that reduced loading in ring/ovoids and increased loading in tandem (and needles when available) can be applied without compromising CTVHR and GTVres dose. Decrease of relative vaginal loading from a mean of 50% to 33% had potential to reduce ICRU recto-vaginal dose by a mean of 4±4Gy, and furthermore, bladder and rectum doses could be reduced by 2-3Gy with the same re-arrangement of loading. Similar evidence is available from a study on simulation of different intracavitary standard loading patterns in EMBRACE patients, where it was shown that limited size tumours could often be covered by tandem loading alone (Nkiwane KS. et al. 2013).
72466|NCT03617133|Radiation|Systematic utilisation of IMRT|Many institutions deliver 3D conformal radiotherapy (3D CRT) based on a four-field box technique although IMRT has been available for a number of years. The practice in EMBRACEI has been utilisation of IMRT and 3D CRT in 27% and 73% of the patients, respectively. However, EMBRACE morbidity data as well as data published by Mundt et al (Mundt AJ. et al. 2003) indicate that IMRT significantly reduces the incidence of bowel morbidity, and therefore IMRT is considered as instrumental for reducing the incidence of bowel morbidity and with a potential also to be beneficial for urinary morbidity.
72467|NCT03617133|Radiation|Utilisation of daily IGRT (set-up according to bony structures)|PTV margins of 10 mm to the elective lymph node target are currently applied in many institutions. This margin is related to set-up uncertainties with patient positioning performed based on skin marks. However, currently, most institutions have in-room imaging available which makes it possible to perform daily imaging and couch correction according to fusion on bony anatomy. With daily imaging, bony image fusion, and couch correction, a margin reduction from 10mm to 5mm can be performed without compromising target coverage (Laursen LV. et al. 2012). The 5mm margin reduction has potential to decrease the volume irradiated to 43Gy by approximately 500cm, which is expected to decrease bowel morbidity by ~50%.
72468|NCT03617133|Radiation|EBRT target concept related to the primary tumor (CTV-T) and internal motion; concepts for OAR contouring|New target concepts are introduced for EBRT related to primary tumor: initial CTV-T, initial CTV-HR, initial CTV-LR and ITV-LR. Use of this novel contouring approach in conjunction with available MRI allows to target safely the visible tumor (CTV-T) and the high risk region (CTV-HRintitial) while consenting for dose to a low risk region (CTV-LRinitial). Anatomical changes due to organ filling variation and cervix/uterus position are considered. ITV-LR is outlined using planning scan and MR images in patients with MRI in treating position while a fixed margin is added to the CTV-LR initial in patients with only diagnostic MRI. New concepts are introduced for OAR contouring. Bowel loops are outlined in one volume restricted to the outer contour, including the mesenterium, for better approximation of the bowel volume and dose constraints. Rectum/sigmoid structures are contoured distinctly. Vaginal lower border is 2,5cm from the caudal extend of the tumor (2cm ITV-LR initial + 0,5cm PTV).
72469|NCT03617133|Radiation|EBRT dose prescription and reporting|There is currently a significant variation with regard to EBRT dose and fractionation in the EMBRACE study with doses ranging from 45Gy to 50Gy and being delivered in 25-30 fractions. Furthermore, there is a wide variety of lymph node boosting strategies. In EMBRACEII, the EBRT dose and fractionation to the elective lymph node CTV and initial CTV-T is fixed at 45Gy in 25 fractions, and lymph node boosting must be performed as a simultaneous integrated boost. The dose de-escalation from 50Gy to 45Gy has potential to reduce morbidity. A system of reporting dose to targets and OARs is introduced in terms of dose volume parameters and a system of point dose reporting for the vagina.
72470|NCT03617133|Radiation|Adaptation of EBRT nodal elective CTV according to risk of nodal and systemic recurrence|"EMBRACEII applies a risk adapted target concept for nodal CTV. This target concept is based on pattern of nodal recurrence analysis which shows 50% of recurrences beyond the classical L5/S1 cranial pelvic field border. A target volume Large Pelvis is defined for intermediate risk patients and includes internal, external, common iliac, obturator and presacral nodes. For high risk patients, defined as common iliac or >2 nodes involved, the para-aortic region is included. For low risk patients, defined as stage IA/IB1/IIA1, N0, small cell carcinoma (SCC), no uterine invasion, Small Pelvis is defined which is Large Pelvis without common iliac nodes. Intermediate risk is defined as not high and not low risk."
72471|NCT03617133|Drug|Systemic application of simultaneous chemotherapy|According to international standard and evidence, simultaneous chemotherapy (CHT) (min. 5x40 mg/m2 cis Platinum) was prescribed in the EMBRACE protocol for all patients, who qualify for its administration. Certain rules were given for adaption according to international guidelines. 90-95% of EMBRACE patients received simultaneous CHT. Most of the EMBRACE cohort is consecutive patients representing the cervix cancer patient population in the respective centers. About 70% of patients received ≥5 cycles, while 30% received 0-4 cycles. CHT has impact on systemic control, which is pronounced in high risk patients (node positive and/or stage III/IV) with a 20% difference in systemic recurrence. A center effect has been found in the ability to administer chemotherapy with 15-85% of the patients receiving ≥5 cycles of CHT. To reach optimal outcome, particularly in the high risk group, the EMBRACEII protocol also focusses on appropriate administration of CHT following international guidelines.
72472|NCT03617133|Other|Reduction of overall treatment time|Several studies indicate that maintaining an overall treatment time (OTT) of <=50 days is important for local control. RetroEMBRACE data confirms that OTT remains of importance in the realm of IGABT. As there is significant variation of OTT across patients and institutions in retroEMBRACE, the EMBRACEII study aims to reduce the OTT so that the majority of patients (>80%) will adhere to the <=50 day threshold. The measures to reduce OTT in EMBRACE is to systematically apply 25 fractions of EBRT including lymph node boost, and furthermore to carefully plan the BT schedule, so that brachytherapy is delivered towards the end of EBRT and/or directly after EBRT.
72473|NCT03617120|Device|Ergonomic Brace vs hard brace|"Visit 1:~Usual check-up: standing in-brace radiograph of hard brace and doctor consultation~Pressure measurement of participant wearing their hard brace~Visit 2:~Brace Questionnaire (BrQ) for hard brace; Trunk Appearance Perception Scale (TAPS)~3D body scanning (before wearing the Ergonomic Brace)~Fitting of the Ergonomic Brace~Pressure measurement of participant wearing the Ergonomic Brace (instant)~Pressure measurement of participant wearing the Ergonomic Brace (after 2 hours)~3D body scanning (after wearing the Ergonomic Brace for 2 hours)~Brace Questionnaire (BrQ) for the Ergonomic Brace~Visit 3:~Standing in-brace radiograph of the Ergonomic Brace~Doctor consultation"
72474|NCT03617107|Other|reverse total shoulder arthroplasty|reverse total shoulder arthroplasty
72475|NCT03617094|Device|Early percutaneous vertebroplasty (EPV)|Treatment consists of percutaneous acrylic bone cement injection using a trocar under scope control and general anesthesia.
72476|NCT03617094|Device|Standard Conservative treatment (CT)|Treatment consists of using a made-to-measure 3 point thoracolumbar corset,that is worn for 3 months: night and day during the first 6 week period of the treatment, and then only the day for the next 6 week period.
72477|NCT03617081|Drug|NNC0113-2023|Participants will receive dose levels of 1 mg, 2 mg, 4 mg, 8 mg, 16 mg or 32 mg of NNC0113-2023 orally. Each participant will receive only one dose.
72478|NCT03617081|Drug|Placebo (NNC0113-2023)|Participants will receive NNC0174-0833 matched placebo orally.
72479|NCT03617068|Drug|Cocos Nucifera Whole|Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance
72480|NCT03617068|Drug|Cocos Nucifera Whole|For dermatopharmacokinetic evaluation using tape/ skin stripping
72481|NCT03617055|Diagnostic Test|serum cystatin c|Blood sample for serum cystatin c will be taken on the first and third days of life for all neonates with clinical or laboratory signs of perinatal asphyxia who are admitted to NICU for early detection of AKI in the study group.
72482|NCT03617029|Device|Microcoil|Needle localization with microcoil
72483|NCT03617029|Drug|Lipiodol|Needle localization with contrast injection
72484|NCT03617016|Drug|Domperidone|Participants will receive domperidone tablets orally.
72485|NCT03617016|Drug|Placebo|Participants will receive matching placebo to domperidone tablets orally.
72486|NCT03617003|Drug|WST11 mediated vascular targeted phototherapy (VTP)|All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.
72487|NCT03617003|Procedure|Endoscopy|Endoscopy of the bladder
72488|NCT03616990|Behavioral|TASC Service Linkages - Discharge Area Only|Individuals will meet with TASC Care Coordinators in the discharge area of the Cook County Jail. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
72489|NCT03616990|Behavioral|SRC Overnight Stay|Individuals receiving SRC services will have the option to stay at the SRC overnight. At the SRC, individuals will be able to rest, have a meal, receive a change of clothes, and take a shower in a therapeutic, non-coercive environment.
72490|NCT03616990|Behavioral|TASC Services Linkages - SRC Onsite|While at the SRC, individuals will meet with TASC Care Coordinators. Individuals will be screened for housing, health and behavioral health needs and then linked to appropriate community-based services.
72491|NCT03616990|Behavioral|APN Appointment|Individuals at the SRC will be able to meet with an Advanced Practice Nurse. As part of that visit, the APN will be able to prescribe medications or reroute prescriptions previously administered by the Cook County Jail's hospital, Cermak, to a participant's desired location as needed.
72492|NCT03616977|Drug|LY900014 U-200|Administered SC
72493|NCT03616977|Drug|LY900014 U-100|Administered SC
72494|NCT03616964|Drug|Baricitinib|Administered orally.
72495|NCT03616964|Drug|Placebo|Administered orally
72496|NCT03616938|Procedure|Cardiopulmonary resuscitation|2-min cycle of cardiopulmonary resuscitation accorind to the American Heart Association 2015 guidelines
72497|NCT03616925|Biological|Platelet Rich Fibrin Matrix kit|Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine
72498|NCT03616925|Procedure|surgical open flap debridement|only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
72499|NCT03616912|Drug|Baricitinib|Administered orally.
72500|NCT03616912|Drug|Placebo|Administered orally.
72501|NCT03616899|Drug|KPI-121 Ophthalmic Suspension|KPI-121 Ophthalmic Suspension
72502|NCT03616899|Drug|Vehicle|Vehicle for KPI-121 0.25% ophthalmic suspension
72503|NCT03616886|Drug|Paclitaxel|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
72504|NCT03616886|Drug|Carboplatin|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
72505|NCT03616886|Drug|MEDI4736|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
72506|NCT03616886|Drug|MEDI9447|Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
72507|NCT03616873|Other|Early Mobilization|The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.
72508|NCT03616860|Device|Focused Ultrasound (FUS) BBB Disruption|FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
72509|NCT03616847|Other|Standard care|Hallux valgus/hallux rigidus surgery with the calf tourniquet remaining in situ until the wound is closed.
72510|NCT03616847|Other|Tourniquet release|Hallux valgus/hallux rigidus surgery with the calf tourniquet released five minutes before the wound is closed.
72511|NCT03616834|Drug|Tomivosertib (eFT-508)|Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
72512|NCT03616821|Drug|Brazikumab|Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning at day 71.
72513|NCT03616821|Drug|Vedolizumab|Intravenous vedolizumab on day 1, day 15, and day 43 followed by Intravenous vedolizumab every 8 weeks beginning at day 99.
72514|NCT03616821|Drug|Placebo|Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning at day 71.
72515|NCT03616808|Other|Thromboelastometry-guided haemostatic treatment|Administration of blood products and/or procoagulants is based on thromboelastometric assays.
72516|NCT03616795|Drug|LY3154207|Administered orally
72517|NCT03616795|Drug|[14C]-LY3154207|Administered orally
72518|NCT03616782|Drug|Ixazomib|Ixazomib 3mg on day 1, 8, 15 q 4 weeks for 24 months or until progression
72519|NCT03616769|Drug|antiplatelet drugs ,statins ,antihypertensive drugs|According to the international guidelines, we treated patients who suffered from different disease.
72520|NCT03616756|Behavioral|Authentic Connections|Authentic Connections support groups for nurse leaders who are also mothers. Meetings occur once a week for one hour.
72521|NCT03616756|Behavioral|Protected time|Participants have one hour per week protected time scheduled on their calendar to do with what they choose.
72522|NCT03616743|Behavioral|Psychoeducation|Psychoeducation about the links between smoking and chronic pain.
72523|NCT03616743|Behavioral|Brief smoking control arm|Psychoeducation about the general adverse effects of smoking.
72524|NCT03616730|Diagnostic Test|NICOM (non-invasive cardiac output monitor)|Transthoracic bio-reactance, or the non-invasive cardiac output measurement [NICOMTM, Cheetah Medical Inc., Portland, OR] system, is a new technique that is able to measure multiple hemodynamic parameters with four transdermal electrodes placed on the patients' thorax. It is based on frequency- and phase-modulation of the voltage signal measured in response to an applied transthoracic current. It has shown acceptable accuracy, precision and responsiveness for cardiac output monitoring in patients experiencing a wide-range of hemodynamic situations and is a FDA-approved device.
72552|NCT03616535|Other|Combined cognitive and exercise training|The investigators will provide participants with tablets to play brain games for cognitive training and stationary foot peddlers for exercise training.
72553|NCT03616522|Other|a novel mobile phone-based intervention for automated electronic PRO collection|Over the three-month study period, patients will be prompted weekly via text message to self-report up to eleven common symptoms, as well as their performance status and quality of life.
72525|NCT03616717|Drug|Modafinil|"Drug: modafinil Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.~Other Names:~Provigil Alertec Modavigil"
72526|NCT03616717|Drug|placebo|Drug: Placebo Each participant receives a single pill of placebo or active drug (modafinil 100 mg or 200 mg) 30 minutes after arriving at the lab. The participant then completes approximately 6 hours of testing in the laboratory. The participant stays at the lab for 7.5 hours in order to monitor physical condition in case the participant received the active pill. One week later, that participant receives a single pill of an alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and two active pills, each time separated by one week.
72527|NCT03616691|Drug|Atezolizumab|Stage I: The dose level of atezolizumab proposed to be tested in this study is 1200 mg administered by IV infusion every 3 weeks (q3w)
72528|NCT03616691|Drug|Bevacizumab|Stage II: Once radiologic progression confirmed from atezolizumab monotherapy (stage 1), 1200mg of atezolizumab would be administered with 15mg/kg of bevacizumab as combination therapy every 3 weeks.
72529|NCT03616678|Device|VenTouch System|"The VenTouch™ System consists of a delivery tool with a pre-loaded implant (VenTouch device) and accessories, which include a sizing tool, PEMS, chamber positioning tool, and accessories kit with luer fitting, tubing clamp, and titanium plug. The VenTouch device is offered in 6 sizes, with 4 different sized inflatable chambers available. Please refer to the VenTouch Instructions for Use for and system details.~The VenTouch device consists of three (3) inflatable silicone chambers attached to the wall of a knitted polyester support. The VenTouch device is implanted around the base of the heart and positioned at the level of the atrio-ventricular (AV) groove and the adjacent ventricular muscle. The VenTouch device is composed of biocompatible, medical-grade silicone and polyester."
72530|NCT03616665|Behavioral|CBASPersonalized|"Patients will receive the 6 week inpatient CBASPersonalized program (see above). In addition, algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After after completion of the six-week inpatient treatment, patients will be offered the six-week blended-online-aftercare CBASPersonalized@home.~The amount of psychotherapeutic contact (dosage) will be balanced between the two active conditions."
72531|NCT03616665|Behavioral|CBIntegrative|"Patients will receive the inpatient CBIntegrative program (see above). In addition, algorithm-based pharmacotherapy in compliance with current national and international guidelines for depression treatment and according to clinical expert supervision. Of note, the intake of the medication is documented and taken into account in the analyses.~After after completion of the six-week inpatient treatment, patients will be offered the six-week blended-online-aftercare CBIntegrative@home. The amount of psychotherapeutic contact (dosage) will be balanced between the two active conditions."
72532|NCT03616652|Drug|Placebo|Placebo pill
72533|NCT03616652|Other|Film sequence|The experimental group watches a film about the power of placebo effects.
72534|NCT03616652|Other|Film sequence|The control group watches a film about sleep.
72535|NCT03616639|Drug|Oxycodone|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
72536|NCT03616639|Drug|Morphine|Both continuous administration by a syringe driver as well as bolus administration every 4 hours will be regarded as continuous subcutaneous infusion (CSCI). Dosage and dosage modifications are in accordance with the Dutch national guideline.
72537|NCT03616626|Radiation|Once Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 once daily fractions given over 2 weeks
72538|NCT03616626|Radiation|Twice Daily APBI|Adjuvant 3D Conformal Accelerated Partial Breast Irradiation to a dose of 38.5 Gy in 10 twice daily fractions given over 1 week
72539|NCT03616626|Radiation|Whole Breast Irradiation|Adjuvant 3D Conformal Radiation Therapy to a dose of 50 Gy in 25 fractions over 5 weeks. Boost is given as 10 Gy in 5 fractions over one week to patients with high grade tumors or age younger than 50 years
72540|NCT03616613|Diagnostic Test|ABDOMINAL DUPLEX ULTRASONOGRAPHY|Abdominal ultrasonography performed by both primary care doctors or vascular surgeons in Hospital de la Santa Creu i Sant Pau area
72541|NCT03616600|Other|Breath-O-Correct Lens|Breath-O correct lenses are new designed ready-made orthokeratology lenses which are made of new material with more elasticity as compared traditional lens material
72542|NCT03616587|Drug|AZD9833|Part A: AZD9833 monotherapy dose escalation.
72543|NCT03616587|Drug|AZD9833 with palbociclib|Part C: AZD9833 in combination with palbociclib dose escalation.
72544|NCT03616587|Drug|AZD9833|Part B: AZD9833 monotherapy expansion
72545|NCT03616587|Drug|AZD9833 with palbociclib|Part D: AZD9833 in combination with palbociclib expansion
72546|NCT03616574|Drug|CA102N|CA102N is a covalently bound conjugate of the biological polymer sodium hyaluronate (NaHA) and nimesulide (Nim).
72547|NCT03616574|Drug|LONSURF|LONSURF is a cytotoxic combination treatment of 2 new drugs: trifluridine, a thymidine-based nucleoside analog, and tipiracil, an inhibitor of thymidine phosphorylase.
72548|NCT03616561|Drug|Apremilast|Target nail ultrasound will be performed in patients on apremilast by two expert dermatologists and each one will determine the ecographic parameters described in the protocol. These variables would be measured in one target nail in each patient, the greatest and most severely affected, at the investigator's criterion. The same nail will be assessed in all visits of the study (baseline, weeks 4, 16, 24, 38 and 52) . The ultrasound study will be performed with the same device in both hospitals: Esaote's MyLab ultrasound with a 20 MHz transducer. Prior to the start of the study the investigators evaluated the ultrasonographic inter-intraobserver concordance.
72549|NCT03616548|Diagnostic Test|Endoscopic surveillance|Magnifying endoscopy under narrow band imaging system via chimney ileostomy after intestinal transplantation
72550|NCT03616535|Other|Cognitive training|The investigators will provide participants with tablets to play brain games.
72554|NCT03616509|Drug|Growth hormone|12 months on Growth hormone, initial dose 0,2 mg per day, then adjusted by insulin like growth factor (IGF-1) level
72555|NCT03616509|Drug|Placebo|2 months on placebo, sodium chloride 0,9% injections
72556|NCT03616496|Drug|Neuraceq 300MBq/mL Solution for Injection for PET imaging|PET with Neuraceq 300MBq/ml, blood and urine sampling for protein electrophoresis, bone scintigraphy for the three arm
72557|NCT03616483|Other|This is a non-interventional trial|This is a non-interventional trial
72558|NCT03616470|Drug|Uproleselan|A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin
72559|NCT03616470|Drug|Placebo|Saline, 0.9% Sodium Chloride
72560|NCT03616457|Device|Automated Breast Ultrasound (ABUS)|Participants will undergo imaging with ABUS.
72561|NCT03616444|Drug|Xiaoai Jiedu Decoction|"The experimental group took Xiaoai Jiedu Decoction twice a day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year， last two years.~The control group took placebo twice a day, 28 days for each course of treatment, 2 days rest, followed by the second course of treatment, 3 consecutive courses of treatment in every year，last two years."
72562|NCT03616431|Diagnostic Test|Pancreo-KIT breath test|"Pancreo-Kit (Isomed Pharma, Madrid, Spain) is a breath test devised to measure Pancreatic Enzyme Insufficiency. It is a non-invasive method to obtain information about the digestion of consumed lipids; this in turn is informative about the exocrine enzyme activity of the pancreas (specifically pancreatic lipase). This kit is manufactured to EC directive 98/79/EEC and carries the CE mark.~The test is based on measurement of 13C which is a stable naturally occurring environmental isotope of carbon with a nucleus containing 6 protons and 7 neutrons (note, it is not radioactive)."
72563|NCT03616418|Drug|antiplatelet drugs;statins;antihypertensive drugs|
72564|NCT03616405|Drug|rabeprazole, amoxicillin, tetracycline, furazolidone (only for the first 7 days), colloidal bismuth pectin (for the second 7 days)|Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment. Then, patients will receive a 14-day modified sequential therapy for the Helicobacter pylori eradication. The regimen contains rabeprazole, amoxicillin, tetracycline and furazolidone for the first 7 days, followed by rabeprazole，amoxicillin, tetracycline and colloidal bismuth pectin for the second 7 days.
72565|NCT03616392|Drug|D308, CKD-501|"D308~CKD-501: Lobeglitazone sulfate 0.5mg"
72566|NCT03616379|Behavioral|Psychoeducational Control|The Psychoeducational Control condition will consist of a brief script describing the body's response to stress and will not discuss cognition or the role of interpretation or affect labeling during stress.
72567|NCT03616379|Behavioral|Affect Regulation|In the Affect Regulation Condition, participants will be provided instructions for how to reappraise negative thoughts in the context of stress by developing statements consistent with more benign interpretations of stress (e.g., This won't last forever.).
72568|NCT03616379|Behavioral|Affect Labelling|In the Affect Labeling Condition, participants will be provided with instructions for how to verbalize their emotional response during the stressor.
72569|NCT03616353|Procedure|Perineural Hydrodissection|The subcutaneous tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. While continuing to use ultrasound guidance and aseptic technique, the needle will then be angled superficial to the median nerve within the carpal tunnel, and 5 ml of a 50%/50% mixture of lidocaine 1% and sensorcaine 0.5% will be injected under pressure. The needle will be returned to its original angle deep to the median nerve, and the syringe will be changed to inject 40 mg Depo-Medrol in 1ml of saline.
72570|NCT03616353|Procedure|Corticosteroid Injection|The subcutaneous soft tissues of the ulnar aspect of the wrist at the level of the carpal tunnel will be infiltrated with 2 ml of lidocaine 1% for local anesthetic. Using ultrasound guidance and aseptic technique, the needle will then be angled deep to the median nerve within the carpal tunnel, and 40 mg Depo-Medrol in 1ml of saline will be injected into the area deep to the median nerve.
72571|NCT03616340|Drug|Shoulder injection|intra articular or subacromial shoulder injection
72572|NCT03616340|Drug|knee injection|intra-articular knee injection
72573|NCT03616327|Device|MATRx in-lab, MATRx plus|The MATRx remotely controlled mandibular positioner (RCMP) consists of temporary dental trays connected to an extra-oral linear actuator that protrudes the mandible. MATRx is used during polysomnography, where sleep and cardio-respiratory variables are recorded during sleep. The position of the mandible is controlled remotely by a sleep technologist, who moves the mandible while monitoring cardio-respiratory variables. The test determines if mandibular protrusion eliminates pharyngeal obstruction and the required protrusion. The MATRx plus is used in the home. Like the RCMP, the patient sleeps with the motorized mandibular positioner (MP) in place. However, the MP's position is controlled by a computer, making it a feedback controlled mandibular positioner (FCMP). The FCMP detects apneas and hypopneas in real time. Using this information, the controller decides when to move the mandible and by how much. The test predicts of therapeutic outcome with OA and provides a target protrusion.
72574|NCT03616314|Device|stepping verticalization plus functional electrical stimulation|patients hospitalized in ICU are rehabilitated using 30 minutes/day of conventional physiotherapy + 30 minutes/day of verticalization using a tilt table with an integrated robotic stepping device synchronized with an electrical stimulation of the lower limbs muscles
72575|NCT03616314|Device|stepping verticalization|patients receive 30 minutes/day of conventional physiotherapy + 30 minutes7day of verticalization using a tilt table with a robotic stepping device
72576|NCT03616314|Other|conventional physiotherapy|patients are treated only with 60 minutes/day of conventional physiotherapy
72577|NCT03616301|Drug|Clavamox|Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, manufactured by Pharmtechnology LLC, Belarus
72578|NCT03616301|Drug|Augmentin®|Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml, marketed by CJSC GlaxoSmithKline Trading, Russia
72579|NCT03616288|Dietary Supplement|thiamine (as thiamine hydrochloride)|Opaque capsules containing varying amounts of thiamine hydrochloride and cellulose filler. All thiamine is delivered as thiamine hydrochloride, calculated using a 1.271 correction factor (ratio of molecular weights of thiamine hydrochloride and thiamine).
72580|NCT03616275|Other|HRV biofeedback|HRV biofeedback protocol is modified from Lehrer's HRV biofeedback manual (2000), which had been successfully used to improve functioning and quality of life for patients with asthma and COPD. A noninvasive biofeedback system with a NeXus-10 with BioTrace+ (Mind Media B.V., Netherlands) and laptop computer will be used for biofeedback intervention. The intervention protocol is including paced breathing in resonant frequency, abdominal breathing and pursed-lip breathing, and visual biofeedback. The designed intervention protocol will include 8 once-a-week, individual, 20-min in hospital training sessions and twice-a-day, 20-min home self-practices.
72581|NCT03616262|Drug|Botox + Lidocaine|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
72582|NCT03616262|Drug|Lidocaine alone|The total dose per patient in the lower extremity or upper extremity will be based on common doses given in spasticity patients in the neurology injection clinic. If the target is a symptomatic arm, we will inject as follows: biceps 30 units, triceps 40 units, flexor carpi radialis 20 units, extensor carpi radialis 20 units. If the target is a symptomatic leg, we will inject in the following pattern: vastus lateralis 50 units, rectus femoris 30 units, medial gastrocnemius 40 units, tibialis anterior 40 units.
72583|NCT03616249|Other|Sleep|Initially, all volunteers will undergo the following pre and post-intervention tests: Polysomnography; Actigraphy for 10 days; Maximum exercise test; blood collection; Physical performance evaluation; Assessment of muscle strength, assessment of body composition; And application of questionnaires.
72584|NCT03616249|Other|Resistance Exercise|After these procedures, the sarcophagic elderly will Resistance training, will be performed according to the latest positioning of the American College of Sports Medicine for the training of the elderly . The training will last 12 weeks, 3 times / week, with intervals of 48h between the training sessions, which will have a maximum duration of 60min. The periodization of the training will be done in a linear way, in which the volunteers will be submitted to training with 1 series of 12 to 15 repetitions at 60% of 1RM in the first week; In the second week volunteers will train at 70% of 1RM, performing 2 sets of 10 to 12 repetitions; And from the third week to the end of the training period the volunteers will train at 80% of 1RM performing 3 sets of at most 8 replicates and the intervals between sets may range from 60min to 180min. The training load will be readjusted in the 6th week of training from a new 1RM test and the training will be on the same test equipment.
72585|NCT03616236|Drug|Buprenorphine/Naloxone|Participants will begin buprenorphine pharmacotherapy using the MedicaSafe buprenorphine dispensing device immediately after an on-site intake at a community supervision office and continue such treatment until they are transitioned to community buprenorphine treatment
72586|NCT03616236|Other|Treatment as usual|Participants will receive a referral to buprenorphine treatment in the community
72587|NCT03616223|Drug|FX-322|Cohort of 8 subjects
72588|NCT03616223|Drug|Placebo|2 Cohorts of 4 subjects each
72589|NCT03616210|Procedure|Protective ventilation|Protective ventilation strategy with tidal volume of 6 to 7 ml.kg-1 of predicted body weight and PEEP of 6 to 8 cmH2O.
72590|NCT03616197|Procedure|free gingival graft|A horizontal incision was made along the mucogingival line with a scalpel number 15 to prepare a bed of periosteum and a thin immobilized connective tissue. The moving gingival tissues were removed coronally, and the bed was prepared so that the immobilized keratinized gingival tissue was preserved and the graft was placed apically. The template of the recipient region was placed in the donor region to be 2-3 mm more apically than the gingival margins of the teeth. The number of 15 scalpel was used to make incision at the template border and perpendicular to the keratinized tissue. The graft thickness was standardized in all patients between 1.5-2 mm. FGG was placed over the recipient bed and 5/0 non-resorbable monofilament sutures were used for fixing the four corners of the graft.
72591|NCT03616184|Drug|Ruxolitinib|Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
72592|NCT03616171|Behavioral|SLEEP-Extend intervention|"One education session (5-10 minutes) consisting of strategies for sleep hygiene which is the routine for going to sleep~Instructions on extending time in bed by at least one hour but can be up to 2 hours total per night for 4 weeks which can be accomplished by either going to bed earlier or staying in bed later"
72593|NCT03616171|Other|Control|Control group will receive 1. One educational session (5-10 minutes) consisting of safety practices used for an urban environment (a safety brochure and safety information will be given and reviewed with the subject)
72594|NCT03616145|Procedure|Osteopathic Manipulative Treatment (OMT)|Experimental Condition
72595|NCT03616145|Other|Light Touch|Comparator Arm
72596|NCT03616132|Device|Device: Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
72597|NCT03616106|Other|Infographic intervention|All study participants will receive health education using infographics during their regularly scheduled clinic appointments.
72598|NCT03616093|Other|Test Beet Shot|Active supplement containing 6.2 mmol nitrate
72599|NCT03616093|Other|Placebo Beverage|Placebo supplement containing negligible nitrate
72600|NCT03616080|Behavioral|soccer play program|once a week for an hour of a soccer program for 8 weeks
72601|NCT03616067|Drug|Botox® injection|Botox® injection in salivary glands will be performed one month after inclusion. It will be performed with one injection point per gland (parotids and submandibulars)
72602|NCT03616067|Drug|Scopoderm® patches arm|Scopoderm® patches will be initiated one month after inclusion. The patches will be renewed every 3 days, alternating behind each ear.
72629|NCT03615885|Dietary Supplement|Montmorency Tart Cherry Capsules|Capsules are made from 100% natural, tart Montmorency cherries. Carefully prepared Montmorency cherry skins are freeze-dried and milled into a fine powder to protect the cherry phytonutrients and optimise absorbtion. This powder is then encapsulated into a 100% vegetarian shell.
125444|NCT03206047|Other|Laboratory Biomarker Analysis|Correlative studies
72603|NCT03616041|Device|Second-generation colon capsule endoscopy system|The PillCam (TM) Colon 2 which is a second-generation colon capsule endoscopy system, developed by Medtronic Inc. Colon capsule endoscopy, in contrast to current generation small bowel capsules, is capable of visualizing the entire lumen and mucosa from esophagus to rectum. This can be crucial for patients being screened or evaluated for colon disorders. This new generation of colon capsule endoscopy has a battery life of at least 10 hours and preserves energy using adaptive frame rate technology.
72604|NCT03616028|Device|left atrial appendage closure|Closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the CLAAS device will be performed according to device specific instructions for use based on both TEE guidance, ICE and angiography, femoral access and inter-atrial septum crossing
72605|NCT03616015|Biological|blood samples|20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)
72606|NCT03616015|Biological|fecal samples|1 g of feces (D-8, D0, D15, D30, D90)
72607|NCT03616015|Behavioral|Anxiety test|Test of Spielberger
72608|NCT03616015|Behavioral|Stress test|Test of Cohen
72609|NCT03616002|Other|Hookah smoking|ad lib hookah smoking for 30 minutes in a controlled laboratory environment.
72610|NCT03615989|Behavioral|Resistance and Plyometric Exercise|A single resistance and plyometric exercise bout per trial.
72611|NCT03615989|Dietary Supplement|Carbohydrate (Maltodextrin powder mixed with water)|51 grams immediately after exercise bout. 51 grams 1 hour after exercise bout.
72612|NCT03615989|Dietary Supplement|Skim Milk|555 ml immediately after exercise bout. 555 ml 1 hour after exercise bout.
72613|NCT03615989|Dietary Supplement|Creatine powder mixed with water|Creatine Loading Phase: 5 grams x 4 times per day for 6 days. 5 grams before exercise bout. 5 grams immediately after exercise bout 5 grams consumed with last meal on day of exercise bout and the day following.
72614|NCT03615976|Procedure|arthroscopic circumpatellar denervation with or without lat. Patellar facetectomy|arthroscopic management of resistant cases anterior knee pain to medical and physiotherapy pre operative group ( by circumpatellar denervation plus or minus lat. facetectomy according to stage of O.A ) and Comparison between pre and post-operative results in pain reduction, improving knee joint by using 2 knee scores
72615|NCT03615963|Diagnostic Test|echocardiography and coronary angiography|transthoracic echocardiography will be done for all subjects to measure aortic stiffness and elaticity then coronary angiography was used to differentiate between normal subjects and who have coronary artery disease
72616|NCT03615950|Diagnostic Test|Bone Mineral Density (DEXA) scan|Radiologic assessment of bone mineral density in the lumbar spine. This will be performed at screening. If abnormal at screening, subjects will not be enrolled. For enrolled subjects, DEXA will be repeated at 12 months.
72617|NCT03615950|Diagnostic Test|Vitamin D Measurement|Measurement of 25-hydroxy vitamin D levels through the blood at baseline and 12 months. If low for age, subjects will receive dietary counseling to increase intake to recommended levels. Primary care providers of enrolled subjects will be notified of abnormal results.
72618|NCT03615950|Diagnostic Test|Height measurement|Height will be measured at baseline and 12 months.
72619|NCT03615950|Other|Assessment of medication compliance|Subjects enrolled in the intervention group will undergo assessment of compliance with swallowed corticosteroids prescribed by their clinical provider. This will be performed at 6 and 12 months.
72620|NCT03615937|Behavioral|Child interactive intervention|The Child Interactive Intervention will be delivered through a Dialogic Reading Program, which is an individual/group level intervention component for both families and kindergartens. The original Dialogic Reading Program aims to enhance children's literacy and oral language skills by using the specific technique of shared book reading developed by Whitehurst and colleagues (1988). However, this project will expand from the original Dialogic Reading Program template to include alignment with local kindergarten curriculum and themed interactive activities that help build social competence and emotional maturity in children, in addition to cognitive skills.
72621|NCT03615937|Behavioral|Family Empowerment|Family empowerment in this project can be conceptualized across three main pillars: 1) adaptive parenting; 2) adaptive extended family environment; and 3) familial resources. Typically, adaptive parenting is translated into positive parenting programs for primary caregivers, and the rest of the family environment involves extended caregivers. However, families from disadvantaged environments encounter many hurdles that hinder effective parenting and relationship nurturing, and parents' mental wellbeing are also consistently impacted by competing demands.
72622|NCT03615937|Behavioral|Access to Community Hub and its services|A new model of Community Hub will be implemented and there will be two hubs established in two respective districts. The Community Hubs act as an alternative venue to implement service delivery of intervention packages, such as activity sessions in the Child Interactive Intervention, Parenting Program, and mentor-mentee experience exchange, which provide families institutional flexibility and extended support while internalizing new practices. There will also be health education, consultation support and developmental assessments. The Hubs will play the roles of promoting and interweaving play-based learning into the lives of families frequently faced with competing demands and a lack of resources, and enable a protracted network for parents.
72623|NCT03615937|Other|Enhancement to the kindergartens|This intervention package aims at providing a better physical and social kindergarten environment to maximize developmental reach and expedite timely interception and feedback without adding burden to teachers and frontline service professionals.
72624|NCT03615937|Other|Health education, screening, and support|Health seminars and interactive workshop will be provided to the families. Screen for common child health problems (e.g. dental and visual) will also be conducted. A support hotline and website will be established for the participants.
72625|NCT03615924|Drug|Ticagrelor|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Ticagrelor 30 mg, twice a day~>48 kg: Ticagrelor 45 mg, twice a day."
72626|NCT03615924|Drug|Placebo|"The double-blinded study drug dose will be weight dependent:~≥12 to ≤24kg: Placebo to match ticagrelor 15 mg, twice a day~>24 to ≤48 kg: Placebo to match ticagrelor 30 mg, twice a day~>48 kg: Placebo to match ticagrelor 45 mg, twice a day."
72627|NCT03615911|Biological|vaccine candidate MVA-MERS-S|vaccination with MVA-MERS-S in two escalating dose regimes
72628|NCT03615898|Other|Medication errors analysis|TEN YEAR ANALYSIS OF MEDICATION ERRORS IN THE SPANISH INCIDENTS REPORTING SYSTEM IN ANAESTHESIA
125445|NCT03206047|Drug|Poly ICLC|Given SC
72630|NCT03615885|Dietary Supplement|Montmorency Tart Cherry Juice|"100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar."
72631|NCT03615885|Dietary Supplement|Placebo|"130ml serving~Placebo composition: Water (100ml), Cherry Cordial Concentrate (30ml), Citric Acid (1.5g), Maltodextrin (24.75g), Black Food Colouring (2ml)."
72632|NCT03615872|Device|pessary use|evaluation of satisfaction of pessary use in case of symptomatic genital prolapse
72633|NCT03615833|Drug|Cholecalciferol|Cholecalciferol 2.5mg (100 000 UI) , once a month for 3 months
72634|NCT03615820|Drug|Niosomal PPE oromucoadhesive film|Niosomal PPE oromucoadhesive film in which Propolis entrapped in niosomal vesicles and incorporated in oromucoadhesive film
72635|NCT03615820|Drug|Oromucoadhesive film|Oromucoadhesive film without PPE control testing which represents Placebo group
72636|NCT03615807|Procedure|Surgical debridement (if needed)|Surgical debridement
72637|NCT03615807|Diagnostic Test|Microbiological sampling|Microbiological sampling
72638|NCT03615807|Procedure|Revascularisation (if needed).|Revascularisation (if needed).
72639|NCT03615807|Device|Off-loading|Off-loading by Special shoes
72640|NCT03615807|Behavioral|Patient's education and instructions|Patient's education and instructions by specialized nurses
72641|NCT03615807|Procedure|Wound debridement|Regular wound debridement by specialized nurses
72642|NCT03615807|Drug|Antibiotic duration|Systemic antibiotic duration according to the study arms
72643|NCT03615781|Procedure|Two week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
72644|NCT03615781|Procedure|Four week's arm - surgery|The investigators perform a surgical drainage of the infection along with the complete removal of the infected orthopedic implant.
72645|NCT03615781|Drug|Two week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 2 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
72646|NCT03615781|Drug|Four week's arm - drugs|After the surgical implant removal, the investigators prescribe a total of 4 weeks of systemic targeted antibiotic therapy against the causative pathogen(s), of which one week is recommended to be intravenously.
72647|NCT03615768|Combination Product|Adapalene-Clindamycin Combination Gel|5mg Adapalene/50mg Clindamycin per 5g, applied nightly for 12 weeks
72648|NCT03615768|Drug|Adapalene Gel|Differin 0.1% Gel, applied nightly for 12 weeks
72649|NCT03615768|Drug|Clindamycin Gel|Clindamycin Phosphate 1% Gel applied twice daily for 12 weeks
72650|NCT03615755|Other|Hyperbaric Oxygen Therapy (HBOT)|The investigators used 10 sessions of HBOT. One session of HBOT uses oxygen at 2.4 ATA for 90 minutes per day at multiplace hyperbaric chamber. This therapy is given five sessions in a week, so it takes two weeks.
72651|NCT03615742|Other|Placebo|Inhalation of air through a Turbuhaler that contains no medication, as a control.
72652|NCT03615742|Drug|Budesonide|1.6mg of budesonide from a Turbuhaler.
72653|NCT03615742|Other|Filtered Air|Exposure to HEPA filtered air, as a control.
72654|NCT03615742|Other|Diesel Exhaust|Diesel exhaust standardized to 300µg/m³ of particulate matter with a diameter of 2.5 micrometers or less (PM2.5).
72655|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Boys|Comprehensive, Multi-level Violence Prevention Intervention. The intervention consists of three components: (1) a 15-week after-school program, (2) group mentoring, and (3) community enhancement activities. Adolescents and mentors will attend a 2-hour weekly session at a community center, and will conduct up to four community enhancement activities. At the end of the program, a graduation celebration will be planned, and parents/guardians and stakeholders (e.g., coalition members) will be invited.
72656|NCT03615716|Behavioral|Multi-level Violence Prevention Intervention - Caregivers|This is arm is measuring the Multi-level Violence Prevention Intervention that is administered to the boys, from the perspectives of their caregivers. The caregivers themselves will not receive an intervention, but their perspectives of the impact on the interventions on the boys will be examined
72657|NCT03615690|Other|Fasting Mimicking Diet|5 day reduced calorie diet, commercially available
72658|NCT03615690|Other|Regular Diet|Regular Diet
72659|NCT03615677|Drug|LXI-15028 50mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products (LXI-15028 50mg active agent + Esomeprazole 40mg matching placebo . If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
72660|NCT03615677|Drug|Esomeprazole 40mg|The investigational products are administrated orally, once in the morning every day, and each dose includes 2 tablets of investigational products ( LXI-15028 50mg matching placebo + Esomeprazole 40mg active agent ). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 or 8 weeks.
72661|NCT03615664|Drug|Bendamustine|Bendamustine (B) 90 mg/m2 i.v. day 1, 2
72662|NCT03615664|Drug|Gemcitabine|Gemcitabine (G) 800 mg/m2 i.v. day 1, 4
72663|NCT03615664|Drug|Dexamethasone|Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4
72664|NCT03615664|Diagnostic Test|PET/CT|"PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~in case of SMD - exclusion from the trial~in case of PMD - exclusion from the trial"
72665|NCT03615664|Procedure|Autologous Stem Cell Transplant|"Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT."
72666|NCT03615651|Dietary Supplement|Probiotic|The Probiotic Formula is commercially available and contains a combination of 3 probiotic strains in addition to other nutrients. The total daily amount of probiotic strain in the product will be no less than 3 billion colony-forming units (CFU) per 3 g powder sachet.
72667|NCT03615651|Other|Placebo|Placebo intervention.
72668|NCT03615638|Other|Fall prevention program|12-week fall prevention program (including warm-up, cool-down, education, Tai Chi, and lower limb strengthening)
72669|NCT03615625|Behavioral|Power Training Session|"3 sets of 8-10 repetitions at an intensity corresponding to 50%1RM in 5 exercises (bench press, upright row, leg press, knee extension and knee flexion). The concentric phase of each repetition will be performed as fast as possible, while the eccentric phase of the movement last approximately 1 to 2 seconds duration. Two minutes of rest between sets and exercises will be adopted."
72670|NCT03615612|Other|QuickSee refractive error assessment + glasses|QuickSee refractive error assessment + glasses
72671|NCT03615586|Other|With Chaperone|Female patients examined by male physicians in the presence of a female (nurse) chaperone.
72672|NCT03615586|Other|Without Chaperone|Female patients examined by male physicians without the presence of a female (nurse) chaperone.
72673|NCT03615573|Other|Quality of Life Surveys|Patients with breast cancer diagnosis complete questionnaires over 20-30 minutes at baseline and at 3, 6, and 12 months after enrollment.
72674|NCT03615547|Drug|Clomifene Citrate|"After randomization, the andrologist will give a prescription with the first three months of treatment (Clomifene Citrate or placebo) to be collected to the local hospital pharmacy. The andrologist will be blind of the treatment arm.~Treatment unit and their shipment to local pharmacy will be provided and organized by the East group pharmacy of the Hospices Civils of Lyon which is the coordination pharmacy for this study. Prescription and delivery will be renewed for three months at the 3 month and 6 months visit.~The experimental treatment consists in a daily dose of 50mg of Clomifene Citrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The dose level was set according to Chua et al 2013 (cf 1.2.2). One capsule containing 50 mg of CC will be orally administered in the morning every day."
72675|NCT03615547|Other|Placebo|The placebo treatment consists in a daily dose of 50mg of lactose monohydrate per os during 9 months followed by a second TESE if no spermatozoid has been obtained from semen. The capsule containing the placebo will have the exact same size, weight, color, taste and will be delivered in the exact same condition as the experimental treatment capsule.
72676|NCT03615534|Other|Therapeutic Lifestyle Changes|Four-week therapeutic lifestyle changes run-in period, comprising individualized moderate physical activity and total calories reduction.
72677|NCT03615534|Other|Placebo|
72678|NCT03615534|Drug|Fenofibrate|
72679|NCT03615534|Dietary Supplement|Wax Matrix Extended Release Niacin (WMER Niacin)|
72680|NCT03615521|Other|Hotpack|Hotpack applied 20 minutes for knee 3 session for 6 weeks
72681|NCT03615521|Other|Ultrasound|Ultrasound applied 10 minutes for knee 3 session for 6 weeks
72682|NCT03615521|Other|Combine Exercise|Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week
72683|NCT03615521|Other|Repeated Contraction Exercise|Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week
72684|NCT03615521|Other|Standart Exercise Therapy|"Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week"
72685|NCT03615508|Drug|10% phenylephrine|10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
72687|NCT03615482|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
72688|NCT03615482|Biological|QIV|QIV protects against the influenza viruses that research indicates will be most common during the upcoming season, and includes antigens from influenza A (H1N1) virus, influenza A (H3N2) virus, influenza B/Victoria virus, and influenza B/Yamagata virus
72689|NCT03615482|Biological|Placebo|Placebo matching V114 vaccine
72690|NCT03615469|Device|Transcutaneous electrical stimulation|For the Sham group, electrodes will follow the same landmarks, but the stimulation will only increase to an intermittent tingling sensation with the machine setting on TENS instead of NMES which is not enough to make noticeable changes in muscle mass or circulation. Intensity settings will not change over time.
72691|NCT03615469|Device|Neuromuscular electrical stimulation|When applying the stimulation, the intensity will be gradually increased from an intermittent tingling until a gentle pumping sensation is felt and muscle contraction is seen. Participants will direct the amount of stimulation acceptable on both thighs to improve acceptance of the modality.10,24,29-31 To assist better tolerance large electrodes (2x4) will be used and participants will also be instructed to be in a seated position with chair close to the wall so that their leg is 90-degree angle and then push against the wall to decrease any uncomfortable feeling during the contraction. 5 sessions per week for 6 weeks done independently at home, with 15 minutes per session (15 minutes per day/session, 15 seconds stimulation on, 15 seconds recovery time) to both legs. We expect the participant to develop tolerance to the treatment and thus increase the intensity of the NMES over time.
72692|NCT03615456|Procedure|Conventional thyroidectomy|Thyroid vessels are ligated with sutures and divided
72693|NCT03615456|Procedure|Harmonic scalpel thyroidectomy|Thyroid vessels are sealed using harmonic scalpel device
72694|NCT03615443|Diagnostic Test|Guardant360|Guardant360 is a comprehensive, non-invasive tumor sequencing test.
72695|NCT03615430|Procedure|serratus plane block with local anesthetic|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml 0.25% ropivacaine was administered.
72696|NCT03615430|Procedure|serratus plane block with saline|The high-frequency linear array ultrasound transducer (UST) was placed parallel to the cephalocaudal axis of the body in T4 levels on the side of the mid-axillary line, identifying latissimus dorsi and serratus anterior, through the thoracic artery to help to find the serratus anterior and 15 ml saline was administered.
72758|NCT03615014|Other|Filling questionnaires|Questionnaires will be submitted to patients during their visit to emergency service and 3 months later to evaluate the prevalence of Post Traumatic Stress Disorder and to identify predictive biopsychosocial factors
125446|NCT03206034|Behavioral|Stylistic Memory Enhancement|
72697|NCT03615417|Device|High Flow Nasal Cannula (HFNC)|"Preoxygenation trough High Flow Nasal Cannula (HFNC) at 100% FiO2, 50 liters/min and closed mouth.~After Rapid Sequence Induction (RSI), maintenance of apnea with HFNC at 100% FiO2, 70 liters/min and jaw thrust.~At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
72698|NCT03615417|Device|Standard anesthesia FaceMask (FM)|"Preoxygenation trough standard anesthesia FaceMask (FM) at 100% FiO2, 12 liters/min, CPAP 7 cmH2O.~After Rapid Sequence Induction (RSI), maintenance of apnea without mask. At time of peripheral oxygen saturations (SpO2) decreases by 2% or after 10 minutes of apnea, the participant is intubated."
72699|NCT03615404|Biological|CMV-DCs with GM-CSF|CMV-DCs are autologous dendritic cells derived from PBMCs loaded with RNA encoding the human CMV matrix protein pp65 as a fusion protein with the full-length LAMP protein (pp65-flLAMP) plus GM-CSF.
72700|NCT03615404|Biological|Td (tetanus toxoid)|Patients will receive preconditioning with Td in the right groin, and approximately 6-24 hours later, they will receive their first CMV-DC vaccination. Patients will also receive Td preconditioning approximately 6-24 hours prior to their 4th vaccine and subsequent vaccines, if any.
72701|NCT03615378|Dietary Supplement|5000 IU D3|Daily
72702|NCT03615378|Dietary Supplement|1000 IU D3|Daily
72703|NCT03615378|Dietary Supplement|Placebo|lactose/sugar tablet
72704|NCT03615352|Procedure|ovarian cystectomy|laparoscopic ovarian cystectomy in endometrioma
72705|NCT03615352|Procedure|ovarian cyst aspiration and coagulation|laparoscopic ovarian cyst aspiration and coagulation in endometrioma
72706|NCT03615339|Dietary Supplement|Molkosan|Twice daily (AM and PM) 20ml of fermented whey concentrate consumed diluted in 200ml water
72707|NCT03615326|Biological|Pembrolizumab|200 mg on Day 1 of each 3-week cycle as an IV infusion.
72708|NCT03615326|Biological|Placebo|Solution for IV infusion on Day 1 of each 3-week cycle.
72709|NCT03615326|Drug|Cisplatin|80 mg/m^2 on Day 1 of each 3-week cycle as an IV infusion, administered as part of FP chemotherapy regimen.
72710|NCT03615326|Drug|5-FU|800 mg/m^2/day continuous on Days 1-5 of each 3-week cycle (120 hours or per local standard), administered as part of FP chemotherapy regimen.
72711|NCT03615326|Drug|Oxaliplatin|130 mg/m^2 on Day 1 of each 3-week cycle over 2 hours as an IV infusion, administered as part of CAPOX chemotherapy regimen and as part of SOX chemotherapy regimen.
72712|NCT03615326|Drug|Capecitabine|1000 mg/m^2 as oral capsules BID on Days 1-14 of each 3-week cycle, administered as part of CAPOX chemotherapy regimen.
72713|NCT03615326|Drug|S-1|Combination product of tegafur, CDHP, and Oxo. Oral capsules BID on Days 1-14 of each 3-week cycle based on body surface area (BSA): <1.25 m^2 BSA =40 mg, 1.25 to <1.5 m^2 BSA=50 mg, ≥1.5 m^2 BSA=60 mg. Administered as part of SOX chemotherapy regimen.
72714|NCT03615326|Biological|Trastuzumab|8 mg/kg loading dose and then 6 mg/kg maintenance dose administered IV on day 1 of each 3-week cycle.
72715|NCT03615313|Biological|PD-1 antibody expressing mesoCAR-T cells|Patients with mesothelin positive cancer will be infused the PD-1 antibody expressing mesoCAR-T cells. The modified mesoCAR-T cells can specifically kill mesothelin positive cancer cells and secrete PD-1 antibody, which could enhance the cytotoxicity of mesoCAR-T cells and activate the tumor infiltrating lymphocytes.
72716|NCT03615300|Diagnostic Test|serum NGAL|serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
72717|NCT03615274|Device|Executive function training|Home-based executive function training with adaptive difficulty, through Cogmed and Cognifit systems over 6 weeks (30-45 minuts/day, 5 days per week). Cognitive training will consist on working memory training (Cogmed, www.cogmed.com) and executive/inhibitory function training (Cognifit, www.cognifit.com).
72718|NCT03615274|Other|Psychoeducation|Learning basic healthy habits through daily Prezi presentations that include healthy food recommendations, funny receipts to families, ideas for exercising, emotion and behavioral management strategies, etc.
72719|NCT03615274|Device|Placebo non-adaptive training|Executive function training with non-adaptive difficulty through Cognifit system over 6 weeks (30-45 minuts/day, 5 days per week). Exercices will be the same as the ones in the experimental group but minimizing the executive/working memory component and without incresing difficulty.
72720|NCT03615261|Behavioral|Mothers and Babies (Enhanced)|"The course is a manualized stress-reduction intervention with an integrated tech suite designed for timely detection and response to stress. Based on Cognitive-Behavioral Therapy & attachment theory, MB is divided into 3 sections: Pleasant Activities; Thoughts; Contact with Others. Each module has been enhanced with mindfulness as a strategy to help center participants and facilitate practice of skills. Participants receive skills training in each of the three sections as tools to improve and manage their mood. The MB course emphasizes developing & strengthening the bond with the baby. The technology enhancement includes wearing a BioStamp sensor, and text message-based extra intervention content. Participants get worksheets linked to the 12 sessions."
72721|NCT03615248|Device|BreatheSuite|"BreatheSuite (patent pending) is a device and mobile application developed by Mr. Brett Vokey, an engineering student at Memorial University of Newfoundland. BreatheSuite has been recognized by numerous provincial competitions, featured at the Eastern Health Innovation Showcase, and was recently selected as a finalist for the New York Health Innovation Challenge.~This device attaches to metered dose inhalers and it can determine if:~the dose was given,~the metered dose inhaler was properly shaken,~the metered dose inhaler is properly aligned,~the flow of medication is appropriate and~there is no accidental exhalation into the inhaler."
72722|NCT03615222|Behavioral|Acceptance and Commitment Therapy to promote functional recovery in war veterans (ACT-FX)|Acceptance and Commitment Therapy to promote functional recovery in war veterans (ACT-FX) will be an individually-tailored intervention to reduce functional impairment associated with any combination of the most common mental and physical wounds of war. ACT is an evidence-based, mindfulness-based behavioral treatment. The ACT model posits that low levels of psychological flexibility leads to functional impairment across a range of mental and physical health problems; thus, ACT is aimed at increasing psychological flexibility. ACT-FX will be a 12-session, individual, outpatient treatment, with sessions occurring approximately weekly. Each session includes: 1) mindfulness training; 2) review of between-session mindfulness practice and behavioral assignments; 3) new content and experiential exercises; and 4) development of values-consistent behavioral assignments to improve functioning. Daily mindfulness practice will be assigned.
126770|NCT03196804|Drug|LC28-0126|LC28-0126
72723|NCT03615222|Behavioral|Treatment as usual (TAU)|Among Veterans randomized to TAU, those already receiving TAU will continue in TAU. Those who are not already receiving TAU will be offered a clinical referral to address the Veterans' most pressing mental or behavioral health concern (e.g., to the PTSD clinic or to primary care-behavioral health for pain management). Offering such referrals has been the investigators' procedure throughout the SERVE research program. Because of the complexity of the target population, TAU will involve a variety of interventions. In accordance with recommendations, a brief (5 minute) weekly phone will be conducted with TAU participants to closely track their use of VA and non-VA mental health services.
72724|NCT03615209|Device|Transauricular vagus nerve stimulation|Stimulation will be performed for 150 minutes (throughout the entire OGTT).
72725|NCT03615209|Device|Transauricular sham stimulation|Sham stimulation will be performed for 150 minutes (throughout the entire OGTT)
72726|NCT03615196|Drug|USB005 (aclerastide) Ophthalmic Solution|Aclerastide ([Nle3]-Angiotensin II (1-7)) is aseptically formulated in USB005 Ophthalmic Solution for topical ophthalmic administration. Active pharmaceutical ingredient (API) levels ranging from 0.03% to 0.45% are formulated in a sterile vehicle consisting of 0.06% Sodium Phosphate Monobasic Anhydrous, USP; 3% Glycerol, USP; 1.4% Polyvinyl Alcohol, USP; and 0.5% Hydroxyethylcellulose (HEC 250 HHX), NF in Sterile Water for Injection, USP.
72727|NCT03615196|Drug|USB005 Ophthalmic Solution Placebo|A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
72728|NCT03615183|Drug|MK-8527|Single oral capsule
72729|NCT03615157|Other|Exercise rehabilitation|Patients will be submitted to a twelve-week combined exercise program of aerobic and peripheral muscle training. They will be randomized in two groups: Home-based and Supervised.
72730|NCT03615144|Drug|Melphalan|Melphalan 70 mg/m2/day x 2
72731|NCT03615144|Drug|Thiotepa|Thiotepa 7.5 mg/kg/day x 2
72732|NCT03615144|Drug|Clofarabine|Clofarabine 20-30 mg/m2/day x 5
72733|NCT03615144|Drug|Fludarabine|Fludarabine 30 mg/m2/day x 5
72734|NCT03615144|Drug|Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)|antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
72735|NCT03615144|Procedure|CliniMACS reagents|Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
72736|NCT03615131|Diagnostic Test|MRI-TRUS fusion prostate biopsy|First an advanced MRI prostate image is obtained, annotated and recorded by the Radiology of the Kantonsspital Winterthur. Next, using special fusion technology, the recorded MRI image is fused with a live transrectal ultrasound by the Urologist who performs a MRI/TRUS fusion biopsy.
72737|NCT03615118|Other|IVR/SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale; An automated phone system for monitoring and improving self-care and health outcomes
72738|NCT03615118|Other|SMS|Daily SMS messages asking participants to report their mood on a 1 to 9 scale
72739|NCT03615105|Radiation|Hyperfractionated total body irradiation|Hyperfractionated TBI is administered by a linear accelerator at a dose rate of <20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
72740|NCT03615105|Drug|Thiotepa|Thiotepa 5 mg/kg IV
72741|NCT03615105|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV
72742|NCT03615105|Drug|Busulfan|Busulfan (adult/ped dose)
72743|NCT03615105|Drug|Fludarabine|Fludarabine 25 mg/m2 IV
72744|NCT03615105|Drug|Melphalan|Melphalan 70 mg/m2 IV
72745|NCT03615105|Drug|Clofarabine|Clofarabine 20-30 mg/m2 IV
72746|NCT03615105|Procedure|HPC(A) stem cell allograft|All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
72747|NCT03615105|Drug|Rituximab|Rituximab 200 mg IV flat dose
72748|NCT03615105|Device|Rabbit antithymocyte globulin|Rabbit antithymocyte globulin 2.5 mg/kg IV
72749|NCT03615092|Procedure|Root coverage with extended flap technique and acelular dermal matrix|At one side, the root coverage have been done with a extended flap technique and acellular dermal matrix and there was no cervical lesion. At the other side, the same technique was performed, but the gingival recession was associated with a noncarious cervical lesion.
72750|NCT03615079|Behavioral|Cognitive behavioral therapy|An 8-week, internet-based cognitive behavioral therapy (CBT) program for depression
72751|NCT03615066|Drug|Selgantolimod Placebo|Tablet(s) administered orally every 7 days for 24 doses in fasted state
72752|NCT03615066|Drug|Selgantolimod|Tablet(s) administered orally every 7 days for 24 doses in fasted state
72753|NCT03615066|Drug|TAF|25 mg tablet(s) administered orally once daily for 48 weeks with food
72754|NCT03615053|Other|Implementation of WAPPS-Hemo personalized dosing regimen|Twelve months after enrollment in the study, WAPPS-Hemo will be used to calculate each patients individual pharmacokinetic estimate. Once completed, the WAPPS-Hemo clinical calculator will be used to calculate the optimal regimen based on individual needs.
72755|NCT03615040|Drug|MSTT1041A|"MSTT1041A (RO7187807; formerly made by Amgen [AMG] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2."
72756|NCT03615040|Drug|Placebo|Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
72757|NCT03615027|Behavioral|Dementia-specific advance care planning|see detailed description
72759|NCT03615001|Device|TDOC NXT|Assessing the Performance, Safety and Usability of our Next Generation T-DOC® NXT Catheter for Performing Urodynamic Studies
72760|NCT03614988|Other|Evening Levothyroxine Administration|Bedtime levothyroxine intake, with 60-minute meal-free interval
72761|NCT03614988|Other|Morning Levothyroxine Administration|Morning levothyroxine intake, 60 minutes before breakfast.
72762|NCT03614975|Biological|Flucelvax inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Flucelvax inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
72763|NCT03614975|Biological|Fluzone inactivated influenza vaccine|Participants randomized to this study influenza vaccine arm will receive Fluzone inactivated influenza vaccine at baseline after the baseline blood draw is complete. (Provided that this vaccine is available clinically in time for the study.)
72764|NCT03614962|Device|Warmth + TENS|"A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.~A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius."
72765|NCT03614962|Device|Warmth + placebo-TENS|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. The TENS electrodes are presented in the cap but no output will be delivered via these electrodes.
72766|NCT03614962|Device|TENS|A hat device will offer the electrical stimulation (pulse width of 120 milliseconds at about 100 Hz with constant current 0.02mA-0.7 mA, intensity setting at sensory threshold) over 4 acupuncture points over the scalp, including Baihui (GV20), Sishencong (EX-HN1), Fengchi (GB20) and Shenting (GV24). Selection of acupuncture points has been based on the recommendation of traditional Chinese medicine.
72767|NCT03614962|Device|Warmth only|A custom-built warmth pad surrounding the TENS electrodes could produce the controlled comfortable warmth sensation, with default setting at 37degrees to 40 degrees Celsius. No built-in TENS electrodes in the cap.
72768|NCT03614962|Device|control|No warmth pad and TENS electrodes presented in the cap.
72769|NCT03614949|Radiation|Stereotactic body radiation therapy (SBRT)|SBRT with 24 Gy in 3 fractions to participants with ≥ 2 metastatic sites.
72770|NCT03614949|Drug|Atezolizumab|Atezolizumab 1200 mg intravenously (IV) every 3 weeks.
72771|NCT03614936|Other|Geriatric Screening Test G8|Geriatric screening test (Oncodage-G8). The oncologist realizes it and proposes the oncological treatment which seems to him then the most adapted (treatment which can be different from that proposed after the oncological evaluation only).
72772|NCT03614936|Other|Geriatric fragility test GERICO|"GERICO geriatric frailty test (if possible the same day as the G8 and in any case in the same week): Realized by the oncologist, it includes:~the socio-cultural evaluation scale,~the ADL autonomy questionnaire,~assessment of locomotor disorders,~nutritional assessment,~the MMSE Cognitive Function Evaluation Questionnaire,~the GDS-4 mood rating scale,~the comorbidity assessment test (Charlson Index)"
72773|NCT03614923|Biological|Etokimab|SC, Q4W
72774|NCT03614923|Biological|Placebo|SC, Placebo Q4W
72775|NCT03614923|Biological|Etokimab|SC, Q8W
72776|NCT03614910|Device|Nanoknife Irreversible Electroporation|Irreversible electroporation will be delivered between electrodes that are placed by intraoperative ultrasound guidance around the tumor
72777|NCT03614897|Behavioral|Education|Education on guidelines for care of individuals at risk of falling
72778|NCT03614884|Behavioral|Gambling and Smoking Treatment|The treatment condition will have access to 7 treatment modules on content surrounding both gambling and smoking behaviours. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling and smoking behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially. Participants in this condition will also be provided with nicotine replacement therapy (NRT) in the form of nicotine patches to use for the duration of the study.
72779|NCT03614884|Behavioral|Gambling only treatment|The control condition will have access to 7 treatment modules on content surrounding gambling only. Participants will have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, participants will identify goals related to gambling behaviours, learn strategies to cope with cravings and triggers, and learn how to prevent relapse. Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
72780|NCT03614871|Other|Epidemiological study|
72781|NCT03614858|Biological|CART-19/22|Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10^6 CART-19/22 cells/kg).
72782|NCT03614845|Procedure|VCV|after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
72783|NCT03614845|Procedure|PCV-VG|after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
72784|NCT03614845|Diagnostic Test|lung ultrasonography|all patients will be performed lung ultrasonography pre and postoperatively
72785|NCT03614832|Drug|Ticagrelor 90 mg|half-dose ticagrelor treatment (90 mg loading dose, then 90 mg once daily) for 1 week.
72786|NCT03614832|Drug|Clopidogrel 150 mg|double standard-dose clopidogrel treatment (150 mg loading dose, then 150 mg once daily) for 1 week.
72817|NCT03614663|Drug|ZYN002 - CBD Transdermal Gel|Pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery)
72818|NCT03614663|Other|Placebo Transdermal Gel|Placebo formulated as a clear gel (transdermal delivery)
72819|NCT03614650|Biological|engineered immune cells|Engineered immune effector cells (EIE)
72820|NCT03614637|Other|Cannabis use abstinence for 11 weeks|Cannabis user group will be asked to abstain from any form of Cannabis use for 11 weeks. During their contingency management phase/abstinence phase, they will be required to come to the clinic for 25 visits over an 11 week period of abstinence.
73585|NCT03608761|Other|autologous serum and rebamipide 2%|rebamipide and autologous serum for 3 months
72787|NCT03614819|Procedure|Diode laser group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying, followed by application of diode laser (Sirolaser, Sirona Dental Systems GmbH, Bensheim, Germany) with wavelength of 970 nm +/- 10 nm, maximum power of 7 W CW, 1mW guide beam and 320μm optical fiber. Irradiation will be performed on the entire occlusal surface in contact mode, with power of 0.7 W (energy of 70 mJ) and frequency of 10 Hz for 30 seconds, having an energy density of 222.82 J / cm2. The FieldMaxII-TOP power meter (Coherent, Inc, USA) will be used prior to and after the applications. The laser will be applied in a sweeping motion throughout the affected surface, the fiber being maintained positioned perpendicular to the occlusal surface throughout the movement. The irradiation time will be standardized in 30 seconds.
72788|NCT03614819|Procedure|Glass Ionomer Sealing Group|Prophylaxis of the selected region for the study with Robson brush and prophylactic paste, washing and drying with cotton balls, followed by relative insulation with cotton rollers of the tooth in question, application of acid polyacrylic for 15 seconds throughout the surface, light drying with cotton ball, insertion of the high viscosity glass ionomer (Equia Forte in capsule - GC) through a specific applicator, after loss of the gloss of the digital pressure material with Vaseline for due drainage and surface protection of the material, removal of the excess, checking the occlusion with carbon paper, occlusal adjustments if necessary, superficial protection with petroleum jelly.
72789|NCT03614806|Diagnostic Test|Simultaneous Transcutaneous and End-tidal CO2 measurements|Included patients will be invited to fill in the Nijmegen questionnaire. During the hyperventilation test, PtcCO2 (mmHg) will be recorded simultaneously with the standard End-tidal Cpartial pressure CO2 measurement
72790|NCT03614793|Procedure|Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome|Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.
72791|NCT03614780|Behavioral|30 minutes outdoors|Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
72792|NCT03614767|Diagnostic Test|urodynamics|Bladder filling and pressure is measured by the insertion of probes within the bladder, urethra and anorectum.
72793|NCT03614754|Diagnostic Test|Somatosensory evoked potentials|Stimulation of the pudendal nerve while recording at the sensory cortex.
72794|NCT03614741|Drug|Tinzaparin continuous infusion|4500 IU continuous infusion of Tinzaparin
72795|NCT03614741|Drug|Tinzaparin bolus|4500 IU bolus of Tinzaparin
72796|NCT03614728|Drug|GSK3326595|GSK3326595 is available as 25 and 100 mg strengths as free-base drug substance to be administered orally with water with no food or antacids for 1 hour before and 2 hour after each dose.
72797|NCT03614728|Drug|5-azacitidine|5-azacitidine is available as Lyophilized powder in 100 mg single-dose vials administered 75 mg/m2 subcutaneously or intravenously for 7 days out of a 28 day cycle, as per local standard.
72798|NCT03614728|Drug|Best available care|Best available care will be the treatment of choice as considered by the investigator.
72799|NCT03614715|Drug|Interferon Beta-1A|A single dose of Interferon Beta-1A (Stage 1: 30 or 60 µg, stage 2: 30 µg) was administered IM to healthy subjects (cross over treatment)
72800|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
72801|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Candy)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Candy) through mouth at 0, 28, 56 days schedule.
72802|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
72803|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Candy) through mouth at 0, 28, 56 days schedule.
72804|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
72805|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Candy)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Candy) through mouth at 0, 28, 56 days schedule.
72806|NCT03614702|Biological|1-dose cIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose cIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
72807|NCT03614702|Biological|1-dose sIPV + 2-doses bOPV (Liquid)|Health subjects received 1-dose sIPV intramuscularly in the centre of anterolateral thigh followed by 2-doses bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
72808|NCT03614702|Biological|2-doses cIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
72809|NCT03614702|Biological|2-doses sIPV + 1-dose bOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose bOPV(Liquid) through mouth at 0, 28, 56 days schedule.
72810|NCT03614702|Biological|2-doses cIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses cIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
72811|NCT03614702|Biological|2-doses sIPV + 1-dose tOPV (Liquid)|Health subjects received 2-doses sIPV intramuscularly in the centre of anterolateral thigh followed by 1-dose tOPV(Liquid) through mouth at 0, 28, 56 days schedule.
72812|NCT03614676|Procedure|Blood sample collection|Venous blood samples will be collected from the maternal subjects at Day 1 and Day 56 of the study and at delivery.
72813|NCT03614676|Procedure|Cord blood sample collection|Collection of cord blood samples from maternal subjects will occur, at delivery
72814|NCT03614676|Other|Maternal Diary Card|Completion of Diary Card about health by pregnant woman/ mother, from enrolment through week 6 post delivery.
72815|NCT03614676|Procedure|Nasal Swab collection|Collection of nasal swabs from infants with potential LRTIs, from birth to 12 months of age.
72816|NCT03614676|Other|Infant Diary Card|Completion of Diary Card about health of infant from birth to 12 months of age.
126771|NCT03196804|Drug|Placebo|Placebo
72821|NCT03614624|Device|Comparative standard echocardiography between two devices : Vivid 9 General Electric and Epiq 7 Philips|Comparison of the various values of strain with the echograph General Electric and the electrograph Philips.
72822|NCT03614611|Device|Contiform pessary|"Patients will be asked to use the device for 12 weeks and to become comfortable with self-insertion and self-removal. The device can be worn continuously for 1 month. When placed in the vagina it retains its shape and supports the urethra during episodes of varied intraabdominal pressure. During the assessment test (24 hours pad test), patients will be encouraged to undertake any activity that would normally induce stress leakage.~The contiform device is approved by Health Canada since 2017-04-10 (Licence No.: 98950, Company ID: 134089, Device identifier: SKU 184)"
72823|NCT03614598|Procedure|Insertion of LMA-UNIQUE(TM) device|LMA-UNIQUE(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
72824|NCT03614598|Procedure|Insertion of LMA-SUPREME(TM) device|LMA-SUPREME(TM) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
72825|NCT03614598|Procedure|Insertion of I-GEL(R) device|I-GEL(R) single-use adult supraglottic airway device inserted during short general anesthesia under controlled ventilation
72826|NCT03614585|Behavioral|16 weeks of high-intensity interval training|Cardiovascular exercise
72827|NCT03614585|Behavioral|16 weeks of moderate-intensity continuous training|Cardiovascular exercise
72828|NCT03614572|Behavioral|Group MI|refer to the arm description
72829|NCT03614546|Radiation|SBRT|Stereotactic Body Radiation Therapy (SBRT)
72830|NCT03614546|Radiation|IMRT|Intensity-modulated Radiation Therapy (IMRT)
72831|NCT03614546|Procedure|Hepatectomy|Hepatectomy
72832|NCT03614546|Procedure|TACE|transarterial chemoembolization (TACE)
72833|NCT03614533|Biological|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
72834|NCT03614533|Biological|Inactivated Poliovirus Vaccine (IPV)|Single 0.5-ml intramuscular injection
72835|NCT03614520|Other|Administration of olive oil|25 mL of extra virgin olive oil
72836|NCT03614520|Other|Administration of red wine|150 mL or Red Wine
72837|NCT03614520|Other|Combination of red wine and olive oil|150 mL of Red wine + 25 mL of Extra Virgin Olive oil will be administred at the same time
72838|NCT03614520|Other|Water|Mineral water will be given as placebo
72839|NCT03614520|Other|Dark beer|250 mL of IPA beer (alcohol 8.5% vol)
72840|NCT03614520|Other|Light Beer|250 mL of blonde ale beer (alcohol 4,5% vol)
72841|NCT03614520|Other|Alcohol free Beer|250 mL of alcohol free beer (alcohol 0.0% vol)
72842|NCT03614507|Device|FreeO2 (modèle FO2-220-00) automatic adjustment|"Automatic adjustment of oxygen through the Free O2 device and in mode medical data collecting (SpO2)"
72843|NCT03614507|Device|FreeO2 (modèle FO2-220-00) manual adjustment|"Manual adjustment of oxygen by the nurse or medical staff. The Free O2 device will only be used in mode medical data collecting (SpO2)"
72844|NCT03614494|Drug|Piroxicam 40 mg|Additional co-treatment
72845|NCT03614494|Drug|Levonorgestrel 1.5mg|Standard treatment
72846|NCT03614481|Genetic|Sampling|Sampling
72847|NCT03614468|Other|Formula A|Formula A is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
72848|NCT03614468|Other|Formula B|Formula B is to be feed as the sole source of nutrition for 52 weeks to healthy term infants.
72849|NCT03614455|Drug|Milademetan|Milademetan 100 mg capsule for oral administration
72850|NCT03614455|Drug|Itraconazole|Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
72851|NCT03614455|Drug|Posaconazole|Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
72852|NCT03614442|Other|slopped shoulder implant|different implant design to enhance soft and hard tissue outcome
72853|NCT03614429|Drug|Chlorhexidine gel will be prepared according to an international product Instillagel®|"Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed.~Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition:~6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216)~The other ingredients are:~Hyetellose, propylene glycol* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not."
72854|NCT03614416|Device|EOXY device|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
72855|NCT03614416|Device|Gold standard oximeter|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
72856|NCT03614416|Procedure|SaO2 sampling|Sp02 and HR measures from EOXY device are simulateously compared to gold standard measures : Sa02 sampling measures and pulse oximeter gold standard
72857|NCT03614403|Drug|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
72858|NCT03614390|Behavioral|mindfulness based cognitive therapy (MBCT)|a well described and structured intervention, which is published previously. The psychoeducation materials in the MBCT will be titrated to discuss about low mood and burnout
72859|NCT03614377|Diagnostic Test|Device interrogation|All devices are interrogated at every follow-up, and two questionnaires are performed 2 years after enrollment.
72860|NCT03614364|Drug|nanoxel|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
72861|NCT03614364|Drug|herzuma|D1 Nanoxel 75 mg/m2 + D5W 100mL MIV over 1hr D1 Herzuma 8mg/kg (loading dose) + N/S 250mL miv over 90mins 6mg/kg (maintenance) + N/S 250mL MIV over 30mins (since 2 cycle) repeated every 3 weeks
72918|NCT03613922|Other|Routine Physiotherapy|Routine physiotherapy program consisted of range of motion, flexibility and strengthening exercises, and home exercise program was applied.
72862|NCT03614351|Dietary Supplement|Protein (PROT)|Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
72863|NCT03614351|Other|Control (CONT)|Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
72864|NCT03614338|Behavioral|Small changes weight loss program|"This intervention uses a small-changes approach to calorie reduction (operationalized as 6 100-calories changes per day) along with increasing leisure-time physical activity and self-regulation strategies to produce weight loss. The intervention will be delivered via 12 face-to-face group sessions."
72865|NCT03614325|Other|Virtual Reality Immersive Relaxation|The software developed by VRHealth allows patients to select from scenery such as mountains, the beach or from a selection of short videos, which are intended to promote relaxation.
72866|NCT03614299|Other|Ecological symptom measurements using a webapp|A webapp will be installed on the patients' smartphone, which will be used to collect everyday the symptoms of the patients (ESSPRI score)
72867|NCT03614299|Diagnostic Test|Interferometry|Evaluation of the mebomian function using the LipiView methodology
72868|NCT03614286|Diagnostic Test|culture and pcr|The swab immersed in Diamond's Modified medium culture tube and squeezed for cultivation and examined daily with a light microscope to identify T. vaginalis Samples from culture will be placed in 1 ml of a commercial PCR transport medium (AMPLICOR; Roche Diagnostic Systems, Branchburg, N.J.) and kept at 4°C until arrival at the laboratory within 4 days of collection. An equal volume of specimen diluent (AMPLICOR) was added to the sample , and the preparation was mixed, incubated at room temperature for 10 min, and stored at −70°C until tested.
72869|NCT03614273|Drug|Hypertonic saline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
72870|NCT03614273|Drug|Adrenaline|The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
72871|NCT03614260|Device|Paradise Renal Denervation System|Following renal angiogram according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
72872|NCT03614260|Procedure|Renal Angiogram|Following renal angiogram to standard procedures, subjects remain blinded and renal angiogram is considered the sham procedure.
72873|NCT03614247|Procedure|Retrograde intrarenal surgery|The procedure was performed with the patient in the dorsal lithotomy position under general anesthesia. Firstly, diagnostic ureteroscopy was done with a 6/7.5 Fr semi-rigid ureteroscope (Richard Wolf, Knittlingen, Germany). A 0.035mm double-tipped sensor guidewire was placed to the renal pelvis. A 10/12 Fr ureteric access sheath (Cook Medical, Indiana, USA) was used. A 7.5 Fr flexible ureteroscope (Flex X2, Karl Storz, Tuttlingen, Germany) was used for the main procedure. The stones were fragmented using a Holmium:Yttrium Aluminum Garnet laser (272 microns). At the end of each procedure, a double-j ureteric catheter and urethral catheter were routinely placed.
72874|NCT03614247|Procedure|Micro-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 4.8 Fr for micro PNL (PolyDiagnost, Pfaffenhofen, Germany). Stone fragmentation was carried out using laser in micro PNL. No nephrostomy was placed in any patient whom underwent micro PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
72875|NCT03614247|Procedure|Ultra-mini PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 7.5 Fr for ultramini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using laser in ultramini PNL. No nephrostomy was placed in any patient whom underwent ultramini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
72876|NCT03614247|Procedure|Mini-PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 12 Fr for mini PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in mini PNL. No nephrostomy was placed in any patient whom underwent mini PNL surgical technique. A double- j stent was placed in necessary (e.g., pelvis perforation, rest stone, stone migration to ureter). A urethral catheter was placed routinely in all patients.
72877|NCT03614247|Procedure|Standard PNL|The PNL procedures were performed with the patient in the prone position under general anesthesia. A 6-F ureteric catheter was placed at the beginning of the procedure. Calyceal access was provided using a 22-G Chiba needle. A 0.038mm sensor-tipped guidewire was inserted through the calyceal puncture into the renal pelvis. After tract dilatation, a sheath was inserted. The instruments used were a 24 Fr for standard PNL (Karl Storz, Tuttlingen, Germany). Stone fragmentation was carried out using pneumatic, ultrasonic or laser in standard PNL. A nephrostomy was placed in all standard PNL patients at the end of the procedure
72878|NCT03614234|Biological|pegunigalsidase alfa|Recombinant human alpha galactosidase A
72879|NCT03614221|Drug|Lindioil ointment|Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
72880|NCT03614221|Drug|Protopic ointment 0.1%|Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
72919|NCT03613909|Device|CP950|Off The Ear (OTE) Cochlear Implant Sound Processor
72920|NCT03613909|Device|BTE|Behind The Ear (BTE) Cochlear Implant Sound Processor
72881|NCT03614208|Behavioral|Home-care rehabilitation group (HCRG)|The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.
72882|NCT03614195|Device|MCDTT|The MCDTT group will undertake sitting to standing, standing balance, and treadmill walking training while concurrently perform motor and cognitive tasks.
72883|NCT03614195|Device|MDTT|The MDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only motor task.
72884|NCT03614195|Device|CDTT|The CDTT group will train the same set of sitting to standing, standing balance, and walking activities as the MCDTT group while simultaneously performing only cognitive task.
72885|NCT03614182|Device|physical training concurrent with cognitive training|The P+C group will undertake standing balance, stepping, and treadmill walking training while concurrently perform cognitive tasks.
72886|NCT03614182|Device|physical training followed by cognitive training|The P-then-C group will train the same set of standing balance, stepping, and treadmill walking activities as the P+C group while followed by cognitive training later.
72887|NCT03614182|Device|physical training without cognitive training|The P group will only train the same set of standing balance, stepping, and treadmill walking activities as the other two groups.
72888|NCT03614169|Procedure|Implantation of a HIS-pacing lead|This intervention is attempted first
72889|NCT03614169|Procedure|Implantation of a LV-pacing lead|This intervention is attempted first
72890|NCT03614156|Drug|Rapastinel|Rapastinel 450 mg or 225 mg (prefilled syringe, weekly intravenous IV administration) or Rapastinel 450 mg or 225 mg (prefilled syringe, clinically driven schedule IV administration, variable interval, placebo on intervening weeks)
72891|NCT03614156|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration)
72892|NCT03614117|Dietary Supplement|Lactobacillus salivarius PS7 during 6 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. Then, a 1 month follow-up period will be completed.
72893|NCT03614117|Dietary Supplement|Lactobacillus salivarius PS7 during 3 months|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 3 months of intervention the participants will intake one daily dose of the product that contains 1*10E9 CFU of L. salivarius PS7. After that, the participants will intake one daily dose of the placebo. Then, a 1 month follow-up period will be completed.
72894|NCT03614117|Dietary Supplement|placebo|7 months intervention study: A 6 months intervention period and 1 month follow-up after intervention finishing time. During the 6 months of intervention the participants will intake one daily dose of placebo supplement.Then, a 1 month follow-up period will be completed.
72895|NCT03614104|Behavioral|Mobile Health Technology (short message service)|Health education through mobile technology with Short Message Service (SMS)
72896|NCT03614091|Procedure|Erector spinae plane block|20 ml Bupivacaine 0.5% below erector spinae muscle groups
72897|NCT03614091|Procedure|Paravertebral plane block|20 ml Bupivacaine 0.5% between pleura and costotransverse ligament
72898|NCT03614078|Drug|PRCL-02|Oral tablets
72899|NCT03614078|Drug|Placebo|Oral tablets
72900|NCT03614065|Drug|endostar|endostatin
72901|NCT03614065|Drug|Placebos|saline solution
72902|NCT03614065|Radiation|radiotherapy|radiotherapy
72903|NCT03614052|Drug|Tamsulosin Hydrochloride 0.4 milligrams|Tamsulosin hydrochloride 0,4mg for 5 days before ureteroscopic treatment of urolithiasis
72904|NCT03614052|Drug|Placebo Oral Tablet|Placebo oral tablet 1 tablet per day for 5 days before ureteroscopic treatment of urolithiasis
72905|NCT03614039|Dietary Supplement|"Symbiter Forte"|"Symbiter Forte which contains combination of smectite gel (250 mg), and biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g)"
72906|NCT03614039|Dietary Supplement|Placebo|
72907|NCT03614026|Behavioral|Teachers and Parents as Partners|Family-school partnership intervention
72908|NCT03614013|Other|Immunotherapy responders/non-responders|paraffin samples will be collected retrospectively along with clinical data
72909|NCT03614000|Other|Screening Questionnaires|"Measurement tools:~Social Responsiveness Scale (SRS-2) is a validated 65-item scale for the screening of ASD that requires parents to rate the child's behaviors in the previous 6 months. The questionnaire assesses interpersonal behavior, communication and repetitive/stereotypic behavior characteristics of ASD.~The Aseba Questionnaires are validated diagnostic tools that can be filled in by the parents, teachers or children to evaluate various behavioral and emotional problems. The CBCL assesses internalizing (i.e., anxious, depressive and over-controlled) and externalizing (i.e., aggressive, hyperactive, noncompliant and under-controlled) behaviors.~The VG&O The VG&O is a questionnaire developed in Dutch that gives a subscale of parental stress (OBVL), family functioning (VGFO), education habits (VSOG) and life events (VMG)."
72910|NCT03613987|Device|NAVA technology to synchronize NIPPV|Neurally adjust ventilator assist is used to synchronize the NIPPV
72911|NCT03613974|Drug|Lidocaine|patients will receive different lidocaine concentrations
72912|NCT03613961|Drug|Anesthetics|The ANS plays an important role in the regulation of hemodynamics during anesthesia. Manually blous of propofol during induction anesthesia is reported to reduce both sympathetic and parasympathetic tone; however, it is not clear whether the changes in heart rate variability are associated with propofol concentration. We will observe the relationship of anesthetics and HRV dynamics.
72913|NCT03613935|Other|Product 1|Comparison with products 2, 3, and 4
72914|NCT03613935|Other|Product 2|Comparison with products 1, 3, and 4
72915|NCT03613935|Other|Product 3|Comparison with products 1, 2, and 4
72916|NCT03613935|Other|Product 4|Comparison with products 1, 2, and 3
72917|NCT03613922|Other|Early Manual Therapy|Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
72921|NCT03613896|Procedure|conventional dentures|conventional dentures
128423|NCT03184272|Procedure|baseline|measurement in supine position
72922|NCT03613896|Procedure|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional heat processing
72923|NCT03613883|Procedure|Endovascular management|"Embolic materials (coils / glue): the glue will be routinely used when access into the aneurysm's outflow vessel will be unattainable.~Endovascular stent to slow the flow inducing thrombosis of the sac of aneurysm. CT angiography will be performed later to evaluate and confirm the diagnosis and viability of the endovascular procedure"
72924|NCT03613870|Device|PermeaDerm|Wound treatment with PermeaDerm
72925|NCT03613870|Device|Mepilex Ag|Wound treatment with Mepilex Ag
72926|NCT03613857|Drug|Clopidogrel|8 tablets 75 mg clopidogrel loading dose before PCI
72927|NCT03613857|Drug|Ticagrelor 90mg|2 tablets 90 mg brilique before PCI
72928|NCT03613844|Drug|DHA|DHA supplementation
72929|NCT03613844|Drug|Placebo|Placebo for DHA
72930|NCT03613831|Device|patient who used Rhythmia system and Orion catheter|suitable for Rhythmia system and Orion catheter according to relevant clinical guidelines and products instruction for use, per investigator's discretion
72931|NCT03613818|Behavioral|eCHECKUP TO GO|eCHECKUP TO GO is a personalized normative feedback intervention intended to help participants make better choices about alcohol use by changing beliefs about alcohol, alcohol expectancies, and perceptions of peer drinking
72932|NCT03613805|Device|Dexcom G5-Eversense|Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered
72933|NCT03613805|Device|Eversense-Dexcom G5|"Patients will wear sensor for 3 months, monitor blood capillary values 4 times/day. At the beginning and at the end of the period HbA1c will be measured and questionnaires will be administered.~After 30-50 days of sensor implantation patients will wear also Dexcom G5 for a week to compare accuracy simultaneously"
72934|NCT03613792|Drug|Remifentanil|Opioid analgesic
72935|NCT03613792|Drug|Fentanyl|Opioid analgesic
72936|NCT03613792|Drug|Midazolam|Benzodiazepine
72937|NCT03613792|Drug|Ketamine|Analgesic
72938|NCT03613779|Combination Product|LUS-guided therapy|Lung ultrasound guided therapy; if pulmonary congestion (more or equal than 3 B-lines), high dose (80-120mg PO/day furosemide) will be prescribed until next follow up re-assessment. If no congestion (less than 3 B-lines), low dose (0-40mg PO/day furosemide) will be prescribed until next follow up re-assessment
72939|NCT03613779|Other|Standard of Care|Standard of care will be provided.
72940|NCT03613766|Other|Physical activity program|
72941|NCT03613753|Drug|irinotecan plus lobaplatin|irinotecan plus lobaplatin chemotherapy
72942|NCT03613753|Drug|irinotecan|irinotecan chemotherapy alone
72943|NCT03613740|Drug|Fucoxanthin|Intervention will be administered 30 minutes before breakfast.
72944|NCT03613740|Drug|Placebo|Intervention will be administered 30 minutes before breakfast.
72945|NCT03613727|Drug|Intravenous (IV) and oral Vitamin C|"Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180"
72946|NCT03613714|Other|At-home Blood Pressure Monitoring|Participants will use over-the-counter digital monitor to measure blood pressure and pulse rate at home. Automatically averages the last 3 readings taken over 10 minutes.
72947|NCT03613688|Dietary Supplement|Deepure|Pu'erh Tea extract
72948|NCT03613675|Device|Video games|"The 4 videos games consists of:~Asthmonaut, a desktop game in which the child navigates through different scenarios and interacts with nine characters to learn about asthma symptoms and management (30 minutes)~Lung Launcher, a mobile game in which the character encounters different asthma triggers (customizable to the child) and the child has to find the correct preventive method to address each trigger (4 minutes)~Asthma Heroes, a desktop game where the player interacts with several characters to learn about their symptoms, treatment and context, and collects objects to help them manage their asthma (30 minutes)~Bloïd, a mobile game where the player uses a pressure sensor as an input device to guide a spacecraft and destroy meteorites in its path (4 minutes)."
72949|NCT03613662|Drug|SP-102|Injection
72950|NCT03613649|Drug|AZD0914|Spiropyrimidinetrione antibacterial drug, which inhibits bacterial DNA synthesis by a novel mechanism. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of zoliflodacin is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
72951|NCT03613649|Drug|Moxifloxacin|Broad-spectrum 8-methoxy fluoroquinolone with activity against both Gram-positive and Gram-negative bacteria, including anaerobes. A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.
72952|NCT03613649|Other|Placebo|Composed of 4 g of the same excipients found in zoliflodacin. Powder will be reconstituted in 60 mL of tap water and dosed orally after an overnight fast. After the cup containing 60 mL of placebo is taken, approximately 60 mL of tap water will be added to the cup and consumed by the subject to chase the initial dose.
72953|NCT03613636|Diagnostic Test|Enzyme-linked immunospot (ELISpot) assay [Blood]|The ASC ELISpot will be developed based on the improved methods recently described [Nat Protoc 2013;8:1073-87]. This protocol allows rapid (6-8 h) detection of specific ASCs in small volumes (1-2 ml) of blood. M. pneumoniae protein P1 (50 μl/ml) will be used as antigen. The optimal concentration of coating antigen will be assessed in advance in two-fold serial dilutions for clear spot definition. The M. pneumoniae-specific T cell ELISpot will be developed based on methods recently described [Nat Protoc 2009;4:461-9].
72954|NCT03613610|Radiation|Radio-frequency ablation of genicular nerves|Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
72955|NCT03613597|Drug|etoposide plus lobaplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus lobaplatin
72956|NCT03613597|Drug|etoposide plus cisplatin|Thoracic intensity modulated radiation therapy (IMRT) + etoposide plus Cisplatin
72957|NCT03613584|Drug|Von Willebrand Factor|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
73103|NCT03612440|Other|normal saline|receive matching placebo (equal volum of normal saline)
72958|NCT03613584|Drug|Saline Solution|Bolus and continuous infusion of the Investigational Medicinal Product (IMP) during extracorporeal membrane oxygenation (ECMO)
72959|NCT03613571|Drug|ILB|The investigational medicinal product ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock, in that order of priority. Subjects will be observed for at least 3 hours after injection.The IMP is a sterile, colourless to pale yellow solution for subcutaneous injection.
72960|NCT03613558|Drug|Dexmedetomidine|Dexmedetomidine is an alpha-2 agonist that provides both sedation and analgesia
72961|NCT03613558|Drug|Placebo|saline solution
72962|NCT03613545|Procedure|fecal microbiota transplantation|200 mL of prepared fecal microbiota suspension from heathy donors' fresh feces was injected into the colon
72963|NCT03613545|Procedure|Infusion of sham|Infusion of sham
72964|NCT03613545|Drug|probiotics, antibiotics or antidepressants|Drugs such as probiotics, antibiotics, antidepressants
72965|NCT03613532|Drug|Venetoclax|6-7 total doses depending on dose level assigned
72966|NCT03613532|Drug|Fludarabine|◦Fludarabine : given once daily for 4 days
72967|NCT03613532|Drug|Busulfan|◦Busulfan: given twice daily for 4 days
72968|NCT03613519|Behavioral|SHUTi|A woman assigned to SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of 6 to 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
72969|NCT03613519|Behavioral|modified SHUTi|A woman assigned to modified SHUTi receives access to an online program that includes 6 interactive sessions that are designed to be reviewed over a period of 6 to 8 weeks. The online sessions include videos and written material that give information about factors that affect sleep, changes that might help sleep patterns, and how to make those changes. Each session takes about 45 to 60 minutes to complete. During and between sessions, the participant fills out sleep diaries to gather information about daily sleep patterns. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health as well as sleep diaries. Time 1 is just before starting the first session of the modified SHUTi program. Time 2 is about 9 weeks later and Time 3 is about six months after that. The questionnaires will be used to assess the effect of the online program on the participant's sleep and health.
72970|NCT03613519|Behavioral|Usual care|A woman assigned to usual care receive access to a website that provides detailed information on habits and environments that may help or hinder sleep. The site can be visited as often as desired. At 3 different times, the woman is asked to fill out questionnaires about her sleep and health, as well as sleep diaries to gather information about her daily sleep pattern. Time 1 is just before first logging into the sleep information website. Time 2 is about 9 weeks later and Time 3 is six months after that. The questionnaires will be used to assess the effect of the sleep information program on the participant's sleep and health.
72971|NCT03613506|Drug|Captopril 12.5 Mg|Taking captopril 12.5mg b.i.d for two months before radiotherapy.
72972|NCT03613493|Diagnostic Test|HPV self-sampling kit|The HPV self-sampler kit will include the collection swab and the vial for collecting and storing the specimen, and an instructional sheet that visually depicts the steps for self-sampling.
72973|NCT03613493|Behavioral|Culturally-targeted Fear Appeal Message|Participants will receive culturally-targeted and fear appeal messages in a graphically designed kit.
72974|NCT03613493|Behavioral|Fear Appeal Message|Participants will receive fear appeal messages (only) in a graphically designed kit.
72975|NCT03613493|Behavioral|Interview|Participants will be interviewed about experiences using the self-sampling tool (qualitative).
72976|NCT03613480|Other|Motivational Interviewing|Regular sessions of Motivational Interviewing at 2 weeks and then at monthly intervals for a period of 6 months
72977|NCT03613467|Procedure|VATS lobectomy|Patients who received lobectomy by video-assisted thoracoscopic surgery
72978|NCT03613467|Procedure|Thoracotomy lobectomy|Patients who received lobectomy by thoracotomy
72979|NCT03613454|Device|Splenic artery embolization with vascular embolic coils|Splenic artery embolization with vascular embolic coils
72980|NCT03613454|Device|Splenic artery embolization with vascular embolic plugs|Splenic artery embolization with vascular embolic plugs
72981|NCT03613441|Behavioral|Mindful Awareness Practices (MAPs)|Please refer to arm description
72982|NCT03613428|Drug|Ruxolitinib|Dose escalation up to 80 mg administered orally
72983|NCT03613428|Drug|Vincristine|1.4 mg/m2 i.v. weekly for 4 weeks
72984|NCT03613428|Drug|Prednisone|1 mg/kg orally 5 consecutive days per week for 4 weeks.
72985|NCT03613415|Other|Expansion|non invasive technique to increase thickness of thin ridge
72986|NCT03613389|Dietary Supplement|oral topical vitamin E|Vitamin E is an antioxidant agent which may limit tissue damage from free oxygen radicals and, thus, may reduce the severity of mucositis during cancer treatments and protect cell membranes from radiation damage (Alterio et al., 2007). It has a very low toxicity and is generally well-tolerated (Geeraert et al., 2015).
72987|NCT03613376|Other|Class II compression stockings|Patients in this group will use class II compression stocking continuously until next evening and then next 4 days during daytime
72988|NCT03613350|Diagnostic Test|Pad test|20-minutes pad test and urodynamic study (including uroflowmetry, filling and voiding cystometry, and urethral pressure profile) were conducted to every patient.
72989|NCT03613337|Other|clinical restenosis|The primary endpoints is clinical restenosis, the investigators will compared the incidence of clinical restenosis by different smoking status.
72990|NCT03613324|Diagnostic Test|Pad test|20-minutes pad test and urodynamic study including uroflowmetry, filling cystometry and voiding cystometry.
72991|NCT03613311|Diagnostic Test|Urodynamic study|Urodynamic study: including uroflowmetry, filling cystometry, voiding cystometry, and urethral pressure profile
73104|NCT03612427|Dietary Supplement|S. Cholesterol S. Triglyceride|S. Cholesterol S. Triglycerides
72992|NCT03613298|Device|HIFU (Focal One®)|Endometriosic lesion localization and HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using sonography, pelvic MRI and a transrectal sonography data. Once the pre-defined lesion will be located with Focal One device, succession of HIFU exposure will then be used to treat maximum lesion volume, excluding a security margin of 3 mm with the digestive mucosae.
72993|NCT03613285|Device|conventional brackets|conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
72994|NCT03613285|Device|smart clip passive self ligating brackets|smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
72995|NCT03613285|Device|Empower active self ligating brackets|Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
72996|NCT03613272|Procedure|Subxiphoid approach extended thymectomy by VATS|Extended thymectomy performed through the subxiphoid-right VATS approach with double elevation of the sternum
72997|NCT03613272|Procedure|Intercostal approach extended thymectomy by VATS|Extended thymectomy performed through the traditional intercostal VATS approach
72998|NCT03613259|Drug|Fluorothymidine F-18|Given IV
72999|NCT03613259|Other|Laboratory Biomarker Analysis|Correlative studies
73000|NCT03613259|Procedure|Positron Emission Tomography|Undergo fluorothymidine F-18 PET
73001|NCT03613233|Procedure|Glaucoma surgery|phacoemulsification
73002|NCT03613220|Drug|ribociclib|600 mg ribociclib oral once daily
73003|NCT03613220|Drug|letrozole|letrozole 2.5 mg oral once daily
73004|NCT03613207|Other|Dermal pharmacokinetic measurement|"Each subject will have 9 test sites: 4 on the left thigh, 4 on the right thigh, 1 on the arm~Each test site receives 2 dOFM probes~Dosing:~2 test sites: 15 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 10 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~2 test sites: 5 mg/cm² lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US)~1 test site: 10 mg/cm² Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany)~2 test sites: untreated test site~ISF sampling: 24 hours post-dose~Blood sampling: 7 samples post-dose"
73005|NCT03613207|Drug|Lidocaine and prilocaine cream|lidocaine and prilocaine cream (2.5% lidocaine, 2.5% prilocaine, ACTAVIS LABORATORIES UT INC, US) will be applied to 6 test sites per subject
73006|NCT03613207|Drug|Oraqix® gel|Oraqix® gel (2.5% lidocaine, 2.5% prilocaine, Dentsply Pharmaceutical Inc., US/Dentsply DETRY GmbH, Germany) will be applied to 1 test site per subject
73007|NCT03613207|Device|dOFM-System|Dermal open flow microperfusion system will be used to collect interstitial fluid in order to assess lidocaine/prilocaine concentrations over 24 hours
73008|NCT03613207|Procedure|Blood sampling|8 blood samples will be collected in order to assess systemic lidocaine/prilocaine concentrations pre-dose (1 sample) and 24 hours post dose (7 samples)
73009|NCT03613194|Procedure|Sampling|"After inclusion in the study, eligible patients having hepatic metastases and/or péritonéales of a colorectal cancer considered as resecables will have biological and tissue samples.~The samples will be carried out at the time of the surgical gesture envisaged under general anaesthesia and will concern:~Tumoral material: primitive tumour (if available), hepatic metastases and/or peritoneal~Peritoneal liquid~none tumoral peritoneum~Portal blood~Peripheral blood~Cellulo-lymphatic material The necessary time to carry out the whole of these samples is estimated at 10-15 minutes maximum.~In the event of complex situations being able to complicate the surgical gesture initially envisaged or to increase by them morbidity, one or more these samples will not be carried out. This decision will be made at the discretion of the investigator."
73010|NCT03613181|Drug|ANG1005|Investigational drug
73011|NCT03613181|Drug|Physician's Best Choice|Active Comparator: one of 3 pre-determined choices of therapies: capecitabine or eribulin or high-dose IV methotrexate.
73012|NCT03613168|Drug|Trastuzumab|Trastuzumab plus gemcitabine/cisplatin
73013|NCT03613155|Other|Administration of MEOPA as part of the care|Patients should be managed by a SMUR team from Toulouse and benefit from MEOPA administration as part of their management, with a view to analgesia for a painful complaint or prevention of induced pain (for example during mobilization or venous route).
73014|NCT03613142|Procedure|Double tract anatomosis|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
73015|NCT03613142|Procedure|Esophagogastrostomy|After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. Next, end-to-end or side to end esophagogastrostomy is performed with a circular stapler.
73016|NCT03613129|Drug|CT38|Infusion
73017|NCT03613116|Dietary Supplement|Vitamin D3|One-half of each diagnostic group will be randomized to treatment with high-dose vitamin D3 or to standard dose Vitamin D
73018|NCT03613103|Device|Video laryngoscopy|Intubation with videolaryngoscopy with highly curved blade
73019|NCT03613103|Device|Direct laryngoscopy|Intubation with direct laryngoscopy with macintosh blade
73020|NCT03613090|Drug|Collagen-hydroxyapatite scaffold (Syn-Oss)|The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot
73021|NCT03613090|Drug|Collagen Scaffold (Colla-Plug)|Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
73105|NCT03612414|Dietary Supplement|Aqualief|Three tablets/day
73022|NCT03613077|Procedure|surgical placement of an endosteal implant|Subjects, male or female at least 18 years old, with the need of dental implant therapy and restoration according to the cleared indications for the implant
73023|NCT03613064|Other|Socially Enhanced Transitional Care Intervention|Components: 1) Standardized social vulnerabilities assessment tool, to be developed and incorporated into admission workflows. 2) Electronic community service referrals to existing community resources (i.e. food banks, shelters, community rehab), via the Dallas IEP or other information technology platform, for material (food, housing) and psychosocial needs (mental health/drug treatment). 3) Community-based cardiovascular self-management interventions, to be developed and piloted in conjunction with #3 - e.g., customized 'heart healthy' food baskets for CHF/IHD; risk factor monitoring (i.e., weight and blood pressure measurement at food banks, shelters, churches, modeled on the barber shop hypertension intervention); and 'heart buddy' support groups for CHF and IHD at community sites.
73024|NCT03613051|Behavioral|Movement Assessment Battery for children|this test measures manual dexterity , balance , aiming and catching
73025|NCT03613038|Behavioral|Phonetic complexity effects on speech motor performance|Use of 3D electromagnetic articulography to examine phonetic complexity effects of single word stimuli at the articulatory kinematic level in talkers each with preclinical, mild, and moderate dysarthria, relative to healthy controls.
73026|NCT03613025|Diagnostic Test|Sampling of non-invasive and/or non-targeted respiratory tract specimens|Sampling of oral fluids, sputa, bronchial aspiration in addition to BAL for the molecular diagnosis of PCP
73027|NCT03613012|Diagnostic Test|Pain index|Record the patients' EEG and extract pain index before and after pain treatments
73028|NCT03612999|Device|Dexcom continuous glucose monitor|Continuous glucose monitors (CGMs) record subjects glucose levels
73029|NCT03612999|Device|Fitbit activity tracker|Activity trackers will record subjects' physical activity, heart rate, and sleep.
73030|NCT03612999|Behavioral|Subjects record daily activity|Subjects will record their daily activities, either on paper or on a secure texting app.
73031|NCT03612999|Behavioral|Subjects record psychological state|Subjects will record their psychological state, either on paper or on a secure texting app.
73032|NCT03612986|Dietary Supplement|SYALOX® 300 Plus|Reduction of pain and improvement of the knee mobility in patients affected by knee osteoarthritis
73033|NCT03612986|Dietary Supplement|Placebo|Placebo comparator. No chemical effect expected
73034|NCT03612973|Diagnostic Test|lipid profile|Serum samples will be withdrawn after fasting 12 hours then performed on Siemens Dimension Max: Total cholesterol and triglyceride concentrations will be estimated using enzymatic methods ( Roche Diagnostics, Mannheim, Germany). High density lipoprotein cholesterol will be determined after precipitation with phosphotungstic acid/magnesium chloride. Low density lipoprotein(LDL) cholesterol will be measured directly with a commercially available direct LDL-C assay (LDL-C Plus assay; Roche Diagnostics)
73035|NCT03612973|Diagnostic Test|fasting insulin|serum samples used for doing the test by ELISA after fasting for 8 h
73036|NCT03612973|Diagnostic Test|fibro scan|liver stiffness by fibro scan before and after treatment
73037|NCT03612960|Drug|Very low nicotine content cigarettes|Very low nicotine content cigarettes
73038|NCT03612960|Drug|Normal nicotine content cigarettes|Normal nicotine content cigarettes
73039|NCT03612947|Drug|Bupivacaine +magnesium sulphate|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
73040|NCT03612947|Drug|Bupivacaine only|Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
73041|NCT03612934|Procedure|Specialist Palliative Care|In the research, Specialist Palliative Care was provided according to the guidelines established by Mid-Western Health Board in a Report of the National Advisory Committee on Palliative Care as well as according to recommendations of Polish Society of Palliative Medicine and Polish National Healthcare Fund. In order to ensure interdisciplinary and integrated palliative care, a team of specialists was appointed. Team members were engaged in the process of treatment of each patient during the time of the study and applied their specialist skills according to the needs of the patients
73042|NCT03612921|Drug|oral Amantadine sulfate|oral amantadine
73043|NCT03612921|Drug|i.v Amantadine Sulfate|intra venous amantadine
73044|NCT03612921|Drug|placebo tablet|placebo tablet
73045|NCT03612895|Behavioral|Internal Care Coordination|This individual will primarily initiate, guide, and optimize adherence to the care that others deliver, rather than providing direct care his or herself. S/he will call the smoker to conduct a brief assessment of tobacco use and readiness to quit, offer brief counseling and motivational intervention, describe the available pharmacologic and behavioral options, help the smoker to choose among them, and link the smoker to chosen resources. The resources offered will include both internal (health care system based) and external (community based) tobacco cessation resources.
73046|NCT03612895|Behavioral|External Community Referral|Massachusetts (MA) Helpline services include an assessment of smoking history and readiness to quit, advice to quit, self-help materials and telephone counseling. For smokers who set a quit date in the next 30 days, the Helpline offers up to 5 proactive telephone counseling calls with options for text messaging and web-based resources. It also provides eligible smokers 4 weeks of free nicotine patch or gum mailed to their home.
73047|NCT03612895|Behavioral|Usual Care|Participants will be given the number to the MA Smokers Helpline and advised to contact their primary care provider for additional assistance in quitting smoking.
73048|NCT03612882|Other|Online questionnaire|Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
73049|NCT03612869|Drug|LYS-SAF302|Treatment will involve direct injections of the investigational product into both sides of the brain through image-guided tracks, in a single neurosurgical session.
73050|NCT03612856|Drug|xisomab 3G3|AB023 (xisomab 3G3) specified dose on specified day administered as a single intravenous injection
73051|NCT03612856|Drug|placebo|placebo specified dose on specified day administered as a single intravenous injection
73052|NCT03612843|Other|Observational dry needle|No intervention provided by the study. Observation of any adverse events that occur surrounding dry needling by a physical therapist.
73053|NCT03612830|Procedure|Laparoscopy endoscopy cooperated surgery|LECS resects the tumor completely by laparoscopy with the help of the precise positioning and guidance of endoscopy
73054|NCT03612830|Procedure|Dan Vinchi robot endoscopy cooperated surgery|RECS resects the tumor completely by Dan Vinchi Robot with the help of the precise positioning and guidance of endoscopy
73055|NCT03612817|Drug|Tafluprost/timolol fixed combination|Evaluation of 24-hour pressure control with tafluprost/timolol given in the evening or morning
73056|NCT03612804|Behavioral|Unsigned note to provider about cessation medication prescription|For patients of providers assigned to the proactive study group, a local coordinator will review the patient's cessation medication history. If the patient is not currently being provided cessation support medication, the coordinator will enter a note and unsigned order for the provider about the recommended medication indicated by VA formulary guidelines.
73057|NCT03612804|Behavioral|Proactive Telephone Counseling from VA Quitline|Patients of providers assigned to the proactive study group will be contacted by specially trained counselors at the VA Quitline. Counselors will attempt to provide two sessions of proactive telephone support.
73058|NCT03612791|Drug|Atezolizumab|atezolizumab administered IV 1200 mg Q3W, starting one week before EBRT (Week -1) and continued as an adjuvant for a total maximum of 20 cycles.
73059|NCT03612791|Radiation|Radiotherapy|"Pelvic +/- para-aortic EBRT (IMRT): 45 Gy in 25 fractions over 5 weeks (Weeks 1-5, with simultaneously integrated boosts to macroscopically involved lymph nodes, if any, in order to deliver a total dose of 60 Gy to macroscopic lymph nodes (including the dose delivered by brachytherapy).~Uterovaginal brachytherapy (Week 7; maximum interval between EBRT and brachytherapy: 14 days). If appropriate and feasible, dose escalation will be assumed, particularly for advanced disease, with the objective to deliver a total dose of 85 Gy (equivalent dose in 2-Gy fractions with α/β=10 Gy) to 80% of the High Risk-Clinical Target Volume (HR-CTV), including 45 Gy through EBRT. The total dose might be lower in case of close proximity to organs at risk (OARs).~Total duration of RT (including brachytherapy) should be ≤ 55 days."
73060|NCT03612791|Drug|Cisplatin|"Cisplatin infused 40 mg/m2 (maximum 70 mg) weekly IV during EBRT (Weeks 1-5).~Not administered: during the interval between EBRT and brachytherapy, or during brachytherapy, or if radiotherapy is interrupted."
73061|NCT03612778|Behavioral|Plant-based diet|Prescription of a meal plan based on unrefined plant-based foods supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a low-fat, unrefined, plant-based nutritional pattern.
73062|NCT03612778|Behavioral|Mediterranean diet|Prescription of a meal plan based on Mediterranean diet pattern supported by peer group meetings and dietary counselling. Change from the standard western-type nutritional pattern to a Mediterranean nutritional pattern.
73063|NCT03612765|Behavioral|Push-Pull-Hold Program|Developed based on concepts of motivational interviewing, temporal framing, empowerment. It is tailored to Singaporean patients and includes contextual self-care information and tips.
73064|NCT03612752|Dietary Supplement|CMI-168|Dietary supplement
73065|NCT03612752|Other|Placebo|Placebo
73066|NCT03612739|Biological|NKR-2 CAR-T Cells|"The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5."
73067|NCT03612713|Drug|Oxycodone Medication First|Participants will be given 15mg oxycodone one hour before fMRI scan. After at least 1 week wash out participants will be given placebo one hour before fMRI scan.
73068|NCT03612713|Drug|Placebo First|Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
73069|NCT03612700|Other|CPFA-rich foods|Daily consumption of Grana Padano cheese (50 g) and whole milk (250 mL) for 3 weeks.
73070|NCT03612687|Device|Minimally invasive hemodynamic monitoring|Use of advanced minimally invasive hemodynamic monitoring with PreSep™ Central Venous Oximetry Catheter, Vigileo™ monitor, and FloTrac™ sensor for perioperative fluid management
73071|NCT03612674|Procedure|Standard colonoscopy|Current standard of care colonoscopy.
73072|NCT03612674|Device|ARC Endocuff Vision|Subjects randomized to undergo a colonoscopy procedure with ARC Endocuff Vision will have this device placed on the top of the colonoscope used during their procedure.
73073|NCT03612661|Behavioral|Group Intervention|Participants in the group intervention will attend eight weekly, 90-minute sessions involving group activities and discussions. They will complete homework between sessions to reinforce learning. The intervention focuses on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
73074|NCT03612661|Behavioral|Guided Self-Help|Participants in the GSH condition will follow the intuitive eating content through self-guided study, with eight weekly scheduled phone calls with an interventionist (~20 minutes each). Interventionists will review homework assignments, answer questions, and reinforce adherence. The intervention materials are the same as the group and also focus on cultivating attunement to bodily sensations and fostering self-compassion to improve physical and mental health.
73075|NCT03612648|Radiation|Three Fraction Accelerated Partial Breast Irradiation|"TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System"
73076|NCT03612648|Procedure|Partial mastectomy|-Standard of Care
73077|NCT03612635|Device|Implantation of a cardiac implantable electronic device|All patients enrolled in the registry underwent cardiac implantable electronic device implantation
73078|NCT03612622|Other|transcranial magnetic stimulation|Intermittent Theta-Burst Transcranial Magnetic Stimulation
73079|NCT03612609|Biological|blood, urine and semen sample|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 15, 30, 60 and 90 days after. Dengue virus RNA being diagnosed with blood and/or urine sample positive for dengue virus RNA. Dengue virus RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
73080|NCT03612596|Behavioral|Narrative visualization|Participants use narrative visualization procedures to connect their step data to important events or feelings that occurred at the same time, then reflect on their behavior
73081|NCT03612596|Behavioral|Standard self-regulation|Participants self-monitor steps using a wearable device, app, and a hand-written step log
73106|NCT03612414|Dietary Supplement|Placebo|Three tablets/day
73107|NCT03612401|Drug|Mirabegron|Beta-3 adenoreceptor agonist
73082|NCT03612583|Procedure|Lung- and Diaphragm-Protective Ventilation|Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
73083|NCT03612570|Device|Nano-Pulse Stimulation Device|NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.
73084|NCT03612557|Drug|penicillin G benzathine|2.4 million units (IM) of benzathine benzylpenicillin
73085|NCT03612544|Other|ENDS (Vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73086|NCT03612544|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73087|NCT03612531|Procedure|Manual Therapy|Receive manual therapy
73088|NCT03612518|Behavioral|Text and Voice Messages|Participants in this study arm will periodically receive information regarding antenatal- and postnatal care and family planning services through text and voice messages from the fifth gestational month until the post-partum period of 42 days.
73089|NCT03612518|Behavioral|Interactive Phone Call|Participants in this study arm will receive information regarding antenatal- and postnatal care and family planning services through periodic interactive phone calls from the fifth gestational month until the post-partum period.
73090|NCT03612505|Behavioral|Mother groups using principles of UNICEF/World Health Organization's Care for Child Development|"The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~Introduction (10 minutes)~Lesson on *Early Childhood Development* topic (20 minutes)~Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~Observe caretakers one-on-one in play role with the child (25 minutes)~Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future"
73091|NCT03612492|Drug|Esmolol|Esmolol group (EG) will receive a bolus of esmolol 1.5mg / kg in 10 min following by continuous infusion at a rate of 0.1mg / kg / min.
73092|NCT03612492|Drug|Lidocaine|Lidocaine (LG) group will received lidocaine bolus of 1.5mg / kg in 10 min following by continuous infusion at a rate of 1.5mg / kg / h.
73093|NCT03612479|Behavioral|KIDFIT Healthy|The KIDFIT Healthy intervention promotes the DASH diet, physical activity, limited screen time, and adequate sleep, through a combination of traditional in-person and electronic participant contacts. See NCT03405246 for details.
73094|NCT03612479|Behavioral|KIDFIT Safe|The KIDFIT Safe active control provides electronic material about safe home environments and activities (e.g., sun screen, choking hazards, pet safety) for children. See NCT03405246 for details.
73095|NCT03612466|Drug|153Sm-DOTMP|For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 & 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.
73096|NCT03612466|Radiation|External beam radiotherapy.|The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)
73097|NCT03612466|Drug|Calcium Carbonate|Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..
73098|NCT03612466|Drug|Mozobil|Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.
73099|NCT03612466|Drug|Neupogen Injectable Product|Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
73100|NCT03612453|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73101|NCT03612453|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73102|NCT03612440|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg)for 20min follow by a maintenance infusion (0.4ug/kg/h) continued until the end of the surgery
129431|NCT03176771|Drug|MT-5199|MT-5199 40 mg capsules
73108|NCT03612388|Procedure|use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation|use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
73109|NCT03612375|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73110|NCT03612375|Other|smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73111|NCT03612362|Device|"Improved Injera Baking Biomass Stove"|"Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence & HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements & suitably short follow-up period to decrease attrition."
73112|NCT03612349|Behavioral|Experimental Tobacco Marketplace Task|Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
73113|NCT03612336|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73114|NCT03612336|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
73115|NCT03612323|Drug|Intra-ligamentary Piroxicam|Piroxicam is a long-acting potent analgesic non selective oxicams derivative, has a half-life of 50 hrs in the plasma.The onset of action of oral piroxicam is 2-4 hrs, but it is anticipated that injectable piroxicam could produce more rapid onset of action. It could favourably overcome the intense pain up to 48 hrs following the treatment
73116|NCT03612323|Drug|Intra-ligamentary Articaine|Articaine is a local anesthetic agent , has been reported to be an effective anesthetic in controlling pain during root canal treatment
73117|NCT03612310|Procedure|Skin biopsy/Urine Collection/Blood Sample Collection|"Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. Clinician will collect a 5-7mm section of skin, the area may be numbed beforehand and stitches may be used to close the wound when required. The wound will be dressed if deemed necessary by medical professional.~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or phlebotomost will use a disposable needle to remove a blood sample (normally 50ml but could be up to 320ml for adults).~Participant will meet clinician in a suitable local clinical setting, in select circumstances the clinician may attend the participants home. The clinician or other nominated member of the clinical team will provide a sterile urine collection vessel and direct the volunteer to a suitable private toilet area to provide the sample."
73118|NCT03612297|Diagnostic Test|Selective reporting of Antibiotic Susceptibility Tests|Selective reporting of antibiotic susceptibility tests for all E. coli identified in urine cultures of adults: results of susceptibility are reported back to the practitioner only for few (n=5-6) antibiotics, those that should be used in first line according to guidelines. Susceptibility results not mentioned in the selective reporting of AST are available at the practitioners' request to the microbiologist. Data used to determine which antibiotic to report for UTIs are the isolated microorganism, the patient age and gender, and antibiotics recommended in national guidelines. As guidelines for UTIs treatment differ by gender, two algorithms have been developed and pilot-tested by three GPs, one microbiologist and two infectious disease physicians.
73119|NCT03612284|Device|contact lens insertion solution|"This contact lens solution is being tested for safety and comfort and is not an intervention. Subjects will have their scleral contact lenses filled with the test saline in the examination room and applied to their eyes. They will be monitored for symptoms and will be examined. Six to 8 hours later or whenever their lens clouding typically occurs they will return for further assessment and dispensing of solution if acceptable. subjects will use the solution for 5-9 days and return for a follow-up appointment. At each visit, subjects will complete an OSDI questionnaire and a Current Symptoms questionnaire."
73120|NCT03612271|Behavioral|mGlide|BP will be automatically transmitted to the providers. The transmitted BP will be used for adjustment of anti-HTN medications as it occurs in clinical practice.
73121|NCT03612258|Diagnostic Test|Functional Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging scans will be completed to assess neural responses to painful, non-painful sensory, and emotion-eliciting stimuli.
73122|NCT03612232|Drug|Cabozantinib-s-malate|oral cabozantinib-S-malate 60 mg as a daily single oral dose continuously
73123|NCT03612219|Drug|Apatinib mesylate tablet|Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
73124|NCT03612219|Radiation|Intensity-modulated radiation therapy (IMRT)|Intensity-modulated radiation therapy (IMRT):GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.
73125|NCT03612219|Drug|Cisplatin|Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
73126|NCT03612180|Drug|Metoprolol Succinate|Pharmacokinetics
73127|NCT03612167|Behavioral|cognitive intervention|a 12 consecutive 90-minute weekly cognitive groups that included cognitive training and rehabilitation, with activity-based cognitive exercises and discussions with a focus on applications of cognitive strategies in daily lives.
73128|NCT03612167|Behavioral|nutritional group|12 consecutive 90-minute weekly nutritional groups that included nutrition classes (lecture and discussion).
73129|NCT03612154|Drug|Lorlatinib|Subjects will be treated with lorlatinib 100mg PO daily. A cycle will be defined as 28-days for the convenience of analysis.
73130|NCT03612128|Other|control group|Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
73131|NCT03612128|Other|intervention group|Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
73132|NCT03612115|Device|Neuromuscular electrical stimulation|"Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)"
73133|NCT03612102|Behavioral|Intensive Group Behavioral Treatment (IGBT)|IGBT is a 5-day intensive treatment program, where cognitive behavioral therapy is provided to children and their parents delivered over 6-8 hours per day over the course of 5 days.
73134|NCT03612076|Other|Global cost of management of PJI|estimation of the global cost to manage PJI with 2-step exchange over 3 years
73135|NCT03612063|Device|Fitbit Iconic HR and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
73136|NCT03612063|Device|Fitbit Iconic HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
73137|NCT03612063|Device|Garmin Vivosmart HR and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
73138|NCT03612063|Device|Fitbit Iconic HR and Apple Watch III|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
73139|NCT03612063|Device|Apple Watch III and Garmin Vivosmart HR|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
73140|NCT03612063|Device|Apple Watch III and TomTom Spark 3|"During testing, participants will wear two different wrist-worn heart rate monitors, the Polar H7 heart rate sensor, and will be connected to an ECG machine. Participants will be asked to perform a series of movements on a treadmill. Heart rate will be assessed under the following conditions:~At rest~4 mph~5 mph~6 mph~7 mph~8 mph~9 mph~Post-exercise 1 minute~Post exercise 2 minutes"
73141|NCT03612050|Behavioral|Meaning Centered Psychotherapy|"Manualized, 3-session existential psychotherapy (30-45 minutes/session) with an optional 4th booster session. Content focuses on enhancing patients sense of meaning and purpose in life."
73142|NCT03612037|Dietary Supplement|alpha lipoic acid|600 mg/day oral dose of alpha lipoic acid
73143|NCT03612037|Dietary Supplement|Cellulose|600mg/day oral dose of placebo cellulose
73144|NCT03612024|Behavioral|questionnaire|a standardized questionnaire was sent to all participants
73145|NCT03612011|Other|Onco-Repair/ Placebo|Cream must be applied twice a day, in the morning and evening, on the hands and feet (palmo-plantar areas and interdigital spaces included) previously cleaned with Atoderm Intensive Foaming Gel, chosen as a standardized hygiene product.
73146|NCT03611998|Behavioral|Occupation-based programming|Group sessions consisted of specific tasks performed to completion that emphasized skills such as problem-solving, decision-making, frustration tolerance, appropriate pacing, attention, inquiring, sequencing, gathering, organizing, adjusting, responding, enduring, initiating and cooperating. Examples of tasks included projects that the women were specifically interested in learning such as jewelry making, holiday decorations, clay work and other home décor projects. Investigators observed these and other behaviors during the group sessions, and scored individuals using the OTTOS instrument.
73184|NCT03611725|Procedure|Radial artery|The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
73185|NCT03611712|Drug|Astragalus Polysaccharides 500 mg|PG2 Lyo. Injection 500 mg will be given on 1 week before CCRT (Week 1, PG2 Lyo. Injection 500 mg, b.i.w), during CCRT (Week 2-6, PG2 Lyo. Injection 500 mg, t.i.w for 5 weeks), and after CCRT (Week 7-8, PG2 Lyo. Injection 500 mg, t.i.w for 2 weeks)
73186|NCT03611699|Drug|Umeclidinium / Vilanterol Dry Powder Inhaler|umeclidinium/vilanterol dry powder inhaler
73187|NCT03611699|Drug|Placebo|Placebo inhaler
73147|NCT03611985|Drug|Epidiferphane|"During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each of the two taxane regimens (weekly paclitaxel or docetaxel every 3 weeks).~All subjects in the phase IIa portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months."
73148|NCT03611985|Drug|Taxane Chemotherapy|All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
73149|NCT03611972|Dietary Supplement|Sugar-sweetened beverage|Sugar-sweetened koolaid-flavored water.
73150|NCT03611959|Other|Non Applicable|
73151|NCT03611946|Biological|rZIKV/D4Δ30-713|Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection
73152|NCT03611946|Biological|Placebo|Administered by subcutaneous injection
73153|NCT03611933|Other|position change applied at different times|Time 1 - in the first fifth minute after the procedure supine position in which the HOB was elevated 15° Time 2 - in the first hour low fowler's position were given in which the HOB was elevated 15-30° Time 3 - in the third hour semi high fowler's position were given in which the HOB was elevated 30-45° Time 4 - in the fourth hour left or right lateral position were given in which the HOB was elevated 15° Time 5 - in the fifth hour low fowler's position were given in which the HOB was elevated 15-30° Time 6 - in the sixth hour standard fowler's position were given in which the HOB was elevated 45-60°
73154|NCT03611920|Procedure|Tetracycline|Teeth were soaked in topical tetracycline 5% for 5 minutes before replantation
73155|NCT03611920|Procedure|Dexamethasone|Teeth were soaked in topical dexamethasone (60μ ml-1) for 20 minutes before replantation
73156|NCT03611907|Procedure|Oocyte retrieval with only aspiration system|In this intervention a 17-Gauge needle is used to aspirate the follicles
73157|NCT03611907|Procedure|Oocyte retrieval with aspiration and flushing system|In this intervention a 17-Gauge needle is used to aspirate follicle, and consequently a 1 mL flush is injected and aspirated twice for each punctured follicle
73158|NCT03611894|Other|radiological comparison|comparison between clinical and radiological characteristics
73159|NCT03611881|Behavioral|Counseling|4 or 8 weeks of behavioral counseling support to promote smoking cessation.
73160|NCT03611881|Drug|Nicotine patch|2 or 8 weeks of nicotine patch given in a tapering dose of 21 mg, 14 mg, 7 mg.
73161|NCT03611881|Behavioral|Community Resource|Counselor-facilitated referral to a community-based program to address social needs.
73162|NCT03611868|Drug|APG-115+Pembrolizumab|dose escalation of APG-115 in combination with label dose of pembrolizumab, Four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3-weeks a cycle. Pembrolizumab is administrated following FDA approved label dose, i.e.: 200mg intravenous infusion at Day 1 of every 3 weeks as a cycle.
73163|NCT03611855|Device|BCI Rehabilitation|Patients use electroencephalography (EEG) signals to control a motorized glove worn on their affected hand. The glove moves the patient's hand according to the type of signal detected (Rest vs Motor Imagery).
73164|NCT03611855|Other|Range of Motion Therapy|Patients repeatedly move or stretch the joints and muscles of their affected limb, either by actively moving the limb or assisting the limb with no active motion.
73165|NCT03611842|Other|preservation of mucosal otitis media|Suction of the middle ear fluid and conservation of the fluid to be collected instead of thrown away into children Healthy eardrum and Atrophic eardrum
73166|NCT03611829|Behavioral|ACT Intervention|
73167|NCT03611829|Behavioral|Standard Care|
73168|NCT03611816|Biological|Blood taken|Collection of clinical data
73169|NCT03611816|Genetic|Blood taken|Collection of DNA
73170|NCT03611816|Genetic|Blood taken|Collection of plasma
73171|NCT03611803|Device|Physiotherapy + Robotic-device|Daily use of an exoskeleton (robotic-device) on 5 successive days as well as daily physiotherapy sessions
73172|NCT03611803|Other|Physiotherapy only|Participants will engage in daily physiotherapy sessions (without the exoskeleton) and/or home-based sit-to-stand exercises
73173|NCT03611790|Device|NeVa VS|mechanical dilatation
73174|NCT03611777|Drug|Inhaled corticosteroid|Drug
73175|NCT03611764|Behavioral|Body Scan|-All efforts will be made to normalize their experience: for example, the desire to open their eyes, thinking about other things, wanting to move around - these are all normal and participants will be encouraged to become interested in and curious about, and to allow these natural tendencies
73176|NCT03611764|Other|Rotterdam Symptom Checklist|"39 Likert-scale items, including physical and psychological symptoms (30 questions), daily function (8 questions), and overall valuation of life (one question)~For the 30 questions pertaining to symptoms, the four-item Likert scale ranges from 'not at all=1' to 'very much=4'; the higher the total score, the greater the score, the higher the level of distress. The single question pertaining to overall valuation of life asks participants to circle one of the seven items, ranked from extremely poor to excellent"
73177|NCT03611764|Other|Practice Logs|-Describe frequency of the Zen Den
73181|NCT03611738|Drug|Ceritinib|Ceritinib daily by mouth (PO) with food, according to the dosage schedule outlined in the treatment arm.
73182|NCT03611738|Drug|Docetaxel|Docetaxel intravenously (IV) every 3 weeks, according to the dosage schedule outlined in the treatment arm.
73183|NCT03611725|Procedure|Distal radial artery|The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
73188|NCT03611686|Drug|Local chemotherapy|Local chemotherapy will be administrated according to local recommendation
73189|NCT03611673|Other|Smell Test|Oils are used for each of the different scents. Each scent will be put on an aromatherapy inhaling stick.
73190|NCT03611660|Behavioral|Traditional Healthy Lifestyle Program|Twice weekly meetings that focus on nutrition and exercise for 12 weeks.
73191|NCT03611660|Behavioral|Mindfulness Meditation Instruction|Participants receive six mindfulness sessions.
73192|NCT03611647|Dietary Supplement|Probiotic|Probiotic dietary supplement containing a mixture of Lactobacillus and Bifidobacterium species, taken by mouth once daily for 4-6 weeks.
73193|NCT03611647|Dietary Supplement|Placebo|Placebo, taken by mouth once daily for 4-6 weeks.
73194|NCT03611634|Other|BIOLOGICAL COLLECTION FROM THE GUT MICROBIOTE|collection of saddles
73195|NCT03611621|Drug|Imlifidase|This is a five year, long-term follow up, observational study. The study will primarily determine the time of graft survival in subjects who have received imlifidase prior to kidney transplantation. Subjects that have participated, or are currently participating, in the imlifidase kidney transplantation studies (called feeder studies) 13-HMedIdeS-02, 13-HMedIdeS-03, 14-HMedIdeS- 04 and 15-HMedIdeS-06 will be included. The subjects will attend 4 follow up visits, 1, 2, 3 and 5 years after imlifidase administration.
73196|NCT03611608|Drug|LY3316531|Administered IV
73197|NCT03611608|Drug|Placebo|Administered IV
73198|NCT03611595|Drug|Cabozantinib|Cabozantinib will be given orally once every day with cycles repeated every 4 weeks (28 days, +/- 3 days), with no rest periods between cycles
73199|NCT03611595|Drug|13-cis-retinoic acid|13-cis-retinoic acid at 80mg/m2/dose twice daily for two consecutive weeks (14 days) out of every four weeks (28 days, +/- 3 days).
73200|NCT03611582|Drug|Semaglutide|Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
73201|NCT03611582|Drug|Placebo (semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
73202|NCT03611569|Drug|Lu AF82422|Lu AF82422 - concentrate for solution for infusion; vials containing 50mg/ml, single dose
73203|NCT03611569|Drug|Placebo|placebo - concentrate for solution for infusion, single dose
73204|NCT03611556|Biological|oleclumab|Subjects will receive oleclumab with or without durvalumab and in combination with chemotherapy viz. gemcitabine and nab-paclitaxel or mFOLFOX (5FU, leucovorin and oxaliplatin) until disease progression
73205|NCT03611556|Biological|durvalumab|Subjects will receive durvalumab with oleclumab and in combination with chemotherapy viz. gemcitabine and nab-paclitaxel or mFOLFOX (5FU, leucovorin and oxaliplatin) until disease progression
73206|NCT03611556|Combination Product|gemcitabine|Subjects will receive gemcitabine in combination with nab-paclitaxel and with or without oleclumab and/or durvalumab until disease progression
73207|NCT03611556|Combination Product|nab-paclitaxel|Subjects will receive nab-paclitaxel in combination with gemcitabine and with or without oleclumab and/or durvalumab until disease progression
73208|NCT03611556|Combination Product|oxaliplatin|Subjects will receive oxaliplatin (as part of modified FOLFOX) in combination with or without oleclumab and/or durvalumab until disease progression
73209|NCT03611556|Combination Product|leucovorin|Subjects will receive leucovorin (as part of modified FOLFOX) in combination with or without oleclumab and/or durvalumab until disease progression
73210|NCT03611556|Combination Product|5-FU|Subjects will receive a bolus of 5-FU followed by continuous 5-FU infusion (as part of modified FOLFOX) in combination with or without oleclumab and/or durvalumab until disease progression
73211|NCT03611543|Device|New investigational curved paddle|X-ray imaging of breast tissue
73212|NCT03611530|Device|Coqun® ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Coqun® ophthalmic solution
73213|NCT03611530|Other|Placebo ophthalmic solution|Prostaglandin analogue (PGA) monotherapy + Placebo ophthalmic solution
73214|NCT03611517|Behavioral|Sexual rehabilitation programme|The intervention consists of 4 patient/couple sessions (each max. 60 minutes) scheduled at 1, 3, 6 and 12 months post-RT. Patients treated with RTBT have an additional session 2 months post RT. If preferred, one extra session of 30 minutes can be scheduled between 6 and 12 months after RT. The intervention includes (1) education on the specific cancer diagnosis and treatment, (2) education on the importance of regular dilation for prevention of vaginal stenosis (if indicated), (3) discussing and resolving potential fears and experienced barriers to performing vaginal dilation (if indicated) and sexual activity,(4) promoting couples' mutual coping and support processes and (5) specific sexual therapy techniques to address sexual and body image concerns.
73215|NCT03611504|Device|Hemospray®|Hemospray® application
73216|NCT03611491|Device|Princess FILLER Lidocaine|Princess FILLER Lidocaine injection up to 10 ml given to the patients at baseline time point. After 2 week a touch up is given in case to be consider necessary.
73217|NCT03611478|Dietary Supplement|Probiotic formulation|Probiotic capsule
73218|NCT03611478|Dietary Supplement|Placebo|Placebo capsule identical in taste and appearance to probiotic capsule
73219|NCT03611465|Other|Pace-mapping|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
73220|NCT03611465|Other|Standard pace-mapping examination|Acquire pace-mapping on three distinct populations to better understand the influence of heart disease on electrical conduction.
73221|NCT03611452|Procedure|Episiotomy|repair of perineal muscles and skin
73222|NCT03611439|Dietary Supplement|ReBuilder|8-component botanical dietary supplement
73223|NCT03611439|Dietary Supplement|Placebo|Inactive Placebo Capsule
73224|NCT03611426|Drug|rhThrombin ( Topical )|Active Substance
73225|NCT03611426|Drug|placebo|saline solution
73226|NCT03611413|Procedure|ERAS care|ERAS PROTOCOL
73227|NCT03611400|Dietary Supplement|Probiotic|This probiotic is commercially available and contains L. helveticus R0052 (0.2 x 10^9 CFU/capsule) and L. rhamnosus R0011 (3.8 x 10^9 CFU/capsule) as active ingredients and ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide, and maltodextrin as excipients.
73228|NCT03611400|Dietary Supplement|Placebo|The placebo contains ascorbic acid, hypromellose, magnesium stearate, saccharose, potato starch, titanium dioxide and maltodextrin.
73229|NCT03611387|Device|CASIA 2 OCT|Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
73230|NCT03611374|Procedure|Bilateral Erector Spinae Plane Block (ESPB)|Bilateral ESPBs will be placed after anesthesia induction in eligible and consented patients who are undergoing a sternotomy for congenital heart repair. Patients will receive a local anesthetic agent through each catheter prior to surgery start. If possible, levels of the local anesthetic will be measured during the case. After surgery, patients will be admitted to the CVICU and extubation will be managed by the CVICU team. The ESPB group will have an automatic, alternating side boluses of the local anesthetic started through their nerve block catheters. Levels of the local anesthetic will be measured at intervals.
73231|NCT03611361|Device|SpectralMD DeepView Wound Imaging System 2.0|The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.
73232|NCT03611348|Drug|Latanoprost|"Topical application of latanoprost 0.005% eye drops solution only twice daily for 3 months.~To apply latanoprost solution, one drop of the solution will be distributed over 1cm2 of depigmented skin. Side effects will be recorded."
73233|NCT03611348|Device|Microneedling|A superficial micro-needling technique will be done in millimeters according to depth of skin. The vitiliginous area and a thin surrounding rim (about 2 mm) will be subjected to micro-needling with dermapen. The depth of abrasion will be guided by the depth adjustor according to depth of skin on the affected area. This will be followed by the appearance of multiple, tiny, punctate, bleeding points
73234|NCT03611335|Behavioral|CATCH Interviews|Baseline interviews are conducted with CATCH staff (5/site); while Post-implementation interviews are conducted 9-12 months after introduction of CATCH, with CATCH staff (5/site) and patients (5/site)
73235|NCT03611322|Drug|Semaglutide, 0.25 mg|Semaglutide will be administered subcutaneously (s.c., under the skin) on day 1 and 8 in the morning after an overnight fast of at least 8 hours
73236|NCT03611322|Drug|Semaglutide, 0.5 mg|Semaglutide will be administered s.c. (under the skin) on day 15 and 22 in the morning after an overnight fast of at least 8 hours
73237|NCT03611322|Drug|Semaglutide, 1.0 mg|Semaglutide will be administered s.c. (under the skin) on day 29 in the morning after an overnight fast of at least 8 hours
73238|NCT03611322|Device|DV3372|DV3372 device will be used for administration of semaglutide
73239|NCT03611322|Device|PDS290 pen-injector|PDS290 pen-injector will be used for administration of semaglutide
73240|NCT03611309|Other|Surgeon-palliative care team co management|Surgeon-palliative care team co management includes surgeon alone care and palliative care specialist team
73241|NCT03611309|Other|Surgeon team alone management|The surgeon and surgical team will manage
73242|NCT03611283|Other|Mouthwash treatment|60 seconds after meals (3 times/day) during 28 days
73243|NCT03611283|Other|Toothpaste treatment|3 minutes after the mouthwash (3 times/day) during 28 days
73244|NCT03611283|Other|Mouthwash placebo|60 seconds after meals (3 times/day) during 28 days
73245|NCT03611283|Other|Toothpaste placebo|3 minutes after the mouthwash (3 times/day) during 28 days
73246|NCT03611270|Device|Pulmonary Denervation|Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.
73247|NCT03611257|Diagnostic Test|dRAST|Infectious diseases specialists will do active antimicrobial stewardship according to dRAST results in addition to Gram staining results and current standard method.
73248|NCT03611257|Diagnostic Test|Current standard method|Infectious diseases specialists will do active antimicrobial stewardship according to Gram staining results, and current standard method without dRAST results.
73249|NCT03611244|Device|Portable seat device devised to maintain lumbar lordosis|"The posterior lumbar spine pads are used to maintain lumbar lordosis and fix it with the shoulder strap so that the hip does not slip forward (so that it does not become a sacral sitting posture).~The seat is equipped with a 5 cm air filled villus cushion to relieve pressure on the ischial tuberosity when sitting for a long time. The portable seat device can be moved so that the DMD can sit on the device even when sitting in a wheelchair or a chair for home, school, or outdoors, so that the lumbar lordosis can be constantly maintained."
73250|NCT03611231|Drug|Chidamide|Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
73251|NCT03611218|Device|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX P600 (Fresenius Medical Care), comparator Sureflux-17UX and comparator Polyflux 170 H
73252|NCT03611205|Procedure|Computed Tomography|Undergo dPET/CT
73253|NCT03611205|Procedure|Positron Emission Tomography|Undergo dPET/CT
73254|NCT03611192|Other|Multicomponent exercise|Aerobic exercise: 15~20 mins Resistance exercise: 15 mins Balance exercise: 15~20 mins Flexibility exercise: 10 mins
73255|NCT03611192|Other|Home-program exercise|60 mins exercise
73256|NCT03611179|Drug|Bevacizumab|"The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)"
73257|NCT03611153|Drug|Oral Myeloperoxidase Inhibitor|A single administration dose of 30 mg oral MPO inhibitor given orally following baseline, resting and exercise testing in patients during right heart catheterization.
73258|NCT03611153|Drug|Placebo oral capsule|A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
73259|NCT03611140|Dietary Supplement|DP|a package containing a mix of functional foods
73260|NCT03611140|Dietary Supplement|Placebo|a package containing maltodextrins and caseinate calcium to mimic the DP
73261|NCT03611127|Other|pulmonary rehabilitation|pulmonary rehabilitation standardized program
73262|NCT03611114|Dietary Supplement|Blood orange juice|
73263|NCT03611114|Dietary Supplement|Control drink|
73264|NCT03611088|Other|Kangaroo Position.|The kangaroo position - the newborn is positioned in the adult's breasts, face down, should be dressed in light clothes and wrapped in a flexible cloth.
73265|NCT03611075|Other|No Intervention|No interventions are administered in this study
73266|NCT03611062|Behavioral|VR Executive Functions Training|"The Windows 10-based VICT program invites children to rescue an animated character named Lubdub from a castle. The program consists of three challenging and child-friendly tasks that correspond to the three core EFs."
73267|NCT03611062|Behavioral|VR Placebo Game|In this game, children in the control group will use the VR hand controller to cast different types of spells (bees, bouncy balls, sparkler spells) to objects in the virtual world. Objects in the VR world will all react differently to a spell being cast so as to provide children a relaxing and EF-free gaming experience.
73268|NCT03611049|Dietary Supplement|High dose Vitamin D3|High dose arm- 5000IU given daily
73269|NCT03611049|Dietary Supplement|Low dose Vitamin D3|Low dose arm-800 IU given daily
73270|NCT03611036|Other|Strength training|Upper limbs Strength training; done with dumbbells whose weight corresponds to 60-80% of the maximal voluntary force in abduction measured initially, during 4 weeks
73271|NCT03611036|Other|Endurance training|Upper limbs Endurance training of the ; done with dumbbells whose weight corresponds to 30% of the maximum voluntary force in abduction measured initially, during 4 weeks
73272|NCT03611010|Drug|Atorvastatin injection|statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection
73273|NCT03610997|Procedure|Photorefractive keratectomy|
73274|NCT03610984|Other|type 1 diabetes structured education|The structured education is based on a regular outpatients visit.It is an education that integrated several diabetes related subjects,which mainly aimed at T1D self-management.
73275|NCT03610971|Drug|Ruxolitinib|Ruxolitinib: 15 mg by mouth (PO) twice a day (BID).
73276|NCT03610971|Drug|BCR-ABL Tyrosine Kinase Inhibitor (TKI)|The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.
73277|NCT03610958|Device|Epitomee Device|A non-surgical, non-pharmacologic, medical Device designed to enhance the feeling of satiety.
73278|NCT03610945|Drug|Fluconazole|Subjects will receive fluconazole once daily from Day 5 to Day 18
73279|NCT03610945|Drug|Quinidine|Subjects will receive quinidine twice daily from Day 5 to Day 12
73280|NCT03610945|Drug|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 14
73281|NCT03610945|Drug|EDP-305|Subjects will receive a single dose of EDP-305 on Day 1 and Day 8
73282|NCT03610932|Dietary Supplement|Vitamin C|Taken as 3 500mg capsules.
73283|NCT03610932|Other|Placebo|Taken as 3 500mg capsules.
73284|NCT03610919|Drug|Nasal Sprays|Intranasal administration of 24 international units per dose.
73285|NCT03610906|Procedure|Tumor and Blood Specimens|If available, specimen will be sampled from within the tumor, and not include portions of the tumor capsule. If the tumor includes a cyst, fluid from the cyst will be sampled if available. For each tumor specimen, a companion sample of blood that would otherwise be disposed of through usual clinical practice in the operating room will also be collected.
73286|NCT03610893|Drug|Dexamethasone|Dexamethasone as perineural local anesthetic adjuvant
73287|NCT03610893|Drug|Dexmedetomidine|Dexmedetomidine as perineural local anesthetic adjuvant
73288|NCT03610880|Drug|TG-2349 (400 mg) plus DAG181 (200 mg)|Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
73289|NCT03610880|Drug|DAG181 (200 mg) plus TG-2349 (400 mg)|Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg
73290|NCT03610867|Drug|Furaprevir capsule (SAD)|There are four doses in this part, 100 mg, 200 mg, 400 mg, and 600 mg. Each subject will receive the sample once by oral administration.
73291|NCT03610867|Drug|Furaprevir capsule (MAD)|There are three doses in this part, 200 mg, 400 mg, and 600 mg. Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
73292|NCT03610867|Drug|Placebo (SAD)|Each subject will receive the sample once by oral administration.
73293|NCT03610867|Drug|Placebo (MAD)|Each subject will be allocated into one dosing regimen and receive the sample once daily for 5 consecutive days by oral administration.
73294|NCT03610854|Device|Fitness Tracker|Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.
73295|NCT03610841|Diagnostic Test|preterm labor|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
73296|NCT03610841|Diagnostic Test|healthy|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
73297|NCT03610828|Other|Vegetarian or Vegan Diets|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
73298|NCT03610815|Behavioral|Screening, Brief Intervention, Referral to Treatment|Screening, Brief Intervention, Referral to Treatment
73299|NCT03610789|Device|REDAPT|REDAPT Monolithic Sleeveless Stems and Acetabular Cup Components
73300|NCT03610776|Device|Portion control plate|Portion control plate including demarcations and pictures for recommended amounts of main food groups (starch, protein and vegetables), 25 cm in diameter, enamel, white background.
73301|NCT03610776|Device|Conventional plate|Conventional plate without demarcations or images, 25 cm in diameter, enamel, white.
73332|NCT03610542|Behavioral|Goal Setting|Students learn how to set goals, monitor goal progress, and check when goals have been achieved. Students then identify their own goals.
73333|NCT03610542|Behavioral|Overcoming avoidance|Students identify ways that they avoid anxiety-provoking situations (e.g., procrastinating exam study). Students develop plans for exposure to anxiety-provoking situations and learn study strategies to build confidence.
73586|NCT03608722|Other|SLUMS|A pen and paper screening tool of cognitive impairment
73302|NCT03610763|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a portable neurostimulation method that modulates cortical excitability. The technique involves placing two saline-soaked electrodes (anode and cathode) on the scalp and passing a small direct current (1.5 milliamps; mA) between them. Cortex underlying the anode is more easily excited due to lowered thresholds for depolarization of glutamatergic neurons, while thresholds are increased in neurons beneath the cathode, making them less excitable. Sham stimulation is easily implemented, and the technique can be effectively double-blinded.
73303|NCT03610763|Behavioral|Modified Constraint Induced Movement Therapy|In CIMT, patients are required to wear a mitt that restricts use of the unaffected limb while they practice structured tasks and also engage in activities of daily living.
73304|NCT03610750|Other|psychiatric medications and evidence-based psychotherapies|Patients who screen positive with any psychiatric condition are referred for evaluation and treatment according to the treatment arm. This may combine psychiatric medications or evidence based psychotherapies according to treatment.
73305|NCT03610737|Device|MILD Procedure|"The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression"
73306|NCT03610737|Other|Conventional Medical Management (CMM)|CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
73307|NCT03610724|Biological|Tisagenlecleucel|Single intravenous infusion
73308|NCT03610711|Drug|Nivolumab|240mg administered IV over 30 minutes every 2 weeks for one year
73309|NCT03610711|Drug|Relatlimab|every 2 weeks for one year
73310|NCT03610698|Behavioral|LEAF Positive Emotion Intervention|5-week online intervention teaching 8 positive emotions skills for caregivers
73311|NCT03610698|Other|Emotion Reporting Control Condition|Daily reporting of emotions for participants assigned to the control condition.
73312|NCT03610685|Drug|Prednisolone|Given daily for 2 weeks
73313|NCT03610685|Drug|Placebo oral capsule|Given daily for 2 weeks
73314|NCT03610672|Behavioral|OD prevention/response training|Participants will view a 13-minute OD prevention and response training video (available online free-of-charge). This video covers NY State's recommended curriculum for Overdose Prevention: how to prevent, identify, and respond to an OD, including information on the factors that could heighten risk for overdose (mixing drugs, changes in tolerance and drug purity, and using alone), how to respond to an overdose (rescue breathing, calling 911), and specific instructions on how and when to administer naloxone to someone who is overdosing. After the video, research staff will review key information, answer any questions participants may have, demonstrate assembly of the intranasal naloxone atomizer and ensure participants are able to assemble it. A prescription for naloxone, as well as a standard naloxone kit containing two doses of the medication and atomizers for intranasal administration, will be given to participants, along with printed literature reviewing key training information.
73315|NCT03610672|Behavioral|OD prevention/response training + PI mobile application|Participants will receive the same OD intervention as those in the first arm, as well as receiving mobile phones pre-loaded with the PI App. This intervention includes daily prompts plus key components of evidence-based cognitive behavioral interventions, including Functional Analysis of Drug Use, Self-Management, and Social/Recreational Counseling and additional content on Distress Tolerance, the relationship between Peer Networks and Drug Use, and pertinent resources.
73316|NCT03610646|Drug|MYL-1701P|"Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
73317|NCT03610646|Drug|Eylea|"Subjects will receive intravitreal injections of Eylea throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol."
73318|NCT03610633|Drug|Oxytocin|The neuropeptide oxytocin (OT) increases social approach, trust, and reduces anxiety to social stress.
73319|NCT03610633|Drug|Placebo|Saline solution.
73321|NCT03610607|Behavioral|Intense education|we will inform patients with their own data including the number of P. gingivalis and ratio of S. cristatus and P. gingivalis detected immediately after periodontal treatment and 3 month after the treatment. Explaining these data in detail, in terms that the patient can understand, are equally as important as teaching the plaque control techniques.
73322|NCT03610594|Other|Kalaripayattu|Combination of Exercise, breathing, meditation, combat practices
73327|NCT03610568|Behavioral|Growing up GREAT! Intervention|The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
73328|NCT03610555|Other|new patient centered website|
73329|NCT03610542|Behavioral|Triggers for anxiety|Students learn about different triggers for anxiety, what the signs and indicators of anxiety are, and identify their own triggers for anxiety
73330|NCT03610542|Behavioral|Identifying and challenging negative thoughts|Students learn about the types of unrealistic thoughts that underpin anxiety and how anxiety can be reduced with more realistic thoughts. Students identify their own unrealistic thoughts that contribute to anxiety and what more realistic thoughts can be used.
73331|NCT03610542|Behavioral|Relaxation|Students are taught to relax through (1) breathing exercises, (2) progressive muscle relaxation, and (3) imagery. Student practice these techniques.
73334|NCT03610529|Device|CardioSenseSystem|CardioSensySystem is a novel wireless ECG monitoring system developed by Novosense AB for monitoring of ECG in health care departments.
73335|NCT03610529|Device|Philips Intellivue|Philips Intellivue in an established ECG monitoring system used at the clinical investigational device.
73336|NCT03610516|Drug|CFZ533|multiple doses of CFZ533 intravenous infusion
73337|NCT03610516|Drug|Placebo|multiple doses of placebo intravenous infusion
73338|NCT03610503|Other|Music|Participants in this arm will listen to music during the EMG testing
73339|NCT03610490|Biological|Autologous Tumor Infiltrating Lymphocytes MDA-TIL|Given IV
73340|NCT03610490|Drug|Cyclophosphamide|Given IV
73341|NCT03610490|Drug|Fludarabine|Given IV
73342|NCT03610490|Drug|Fludarabine Phosphate|Given IV
73343|NCT03610490|Biological|Interleukin-2|Given IV
73344|NCT03610490|Other|Quality-of-Life Assessment|Ancillary studies
73345|NCT03610477|Dietary Supplement|Medium chain triglycerides|Gel capsules, each containing 1 gram
73346|NCT03610477|Dietary Supplement|Long chain triglycerides|Gel capsules, each containing 1 gram
73347|NCT03610464|Drug|Amphetamine Extended Release Suspension [Dyanavel]|1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
73348|NCT03610451|Behavioral|Floatation-REST plus usual care|Individuals will receive Floatation-REST plus usual care. Floating creates an environment with minimal visual, auditory, tactile, proprioceptive, and thermal input to the brain. The float rooms are lightproof and soundproof. A high concentration Epsom salt water solution allows individuals to effortlessly float on their back while remaining completely still, reducing both proprioceptive and tactile input to the brain. The temperature of the water is calibrated to the temperature of the skin (~94° F) and the temperature of the air is calibrated to the temperature of the water, making it difficult to discern the boundary between air and water, thus reducing thermal input to the brain while minimizing the need for thermoregulation of the skin.
73349|NCT03610451|Behavioral|Usual care|Individuals will receive usual care on the inpatient unit of the Laureate Eating Disorders Program.
73350|NCT03610438|Drug|Inotuzumab Ozogamicin (IO)|"After course 1 MRD will be evaluated:~- patients MRD negative will enter into short maintenance or long maintenance according to investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance."
73351|NCT03610438|Drug|Inotuzumab Ozogamicin (IO)|After course 2 MRD will be evaluated; patients MRD negative will enter into short maintenance or long maintenance by investigator choice. After 4 to 12 weeks in short maintenance patient will undergo SCT, otherwise, patients will enter long maintenance.
73352|NCT03610412|Other|Cinnamomum Cassia|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
73353|NCT03610412|Other|Placebo (calcined magnesia)|The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
73354|NCT03610399|Drug|Primaquine|Different total dose and supervision.
73355|NCT03610386|Other|Adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will receive menthoxypropanediol topically.
73356|NCT03610386|Other|No adding menthoxypropanediol to the biopsy|Two biopsies of skin (4 mm diameter each) will be taken under local anesthetic in the service of dermatology of Brest CHRU. They will be situated in a pruritic lesion area little or not visible (inside of the arm, the back …). One of the two biopsies will not receive menthoxypropanediol.
73357|NCT03610373|Behavioral|Modular Approach to Therapy for Children (MATCH)|MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
73358|NCT03610360|Drug|MesoPher|Subjects in Arm A will undergo leukapheresis to obtain monocytes from which dendritic cells will be generated. These dendritic cells will be loaded in vitro with an allogeneic tumor cell lysate (PheraLys). Treatment with autologous dendritic cells loaded with PheraLys is called MesoPher
73359|NCT03610347|Device|Bare metal Stent plus Paclitaxel Balloon|
73360|NCT03610347|Device|Drug Eluting Stent|
73361|NCT03610334|Drug|IFB-088 oral capsule|"In SAD phase: single daily dose of IFB-088 will be administered in doses ranging from 2.5mg (cohort #1 in one intake) to 60mg (cohort #2 to #6 in two intakes separated by a interval of 12 hours).~In MAD phase: multiple doses of IFB-088 will be administered daily during 14 days, in two intakes separated by an interval of 12 hours. The dose levels of the 3 cohorts will be determined after SAD phase."
73362|NCT03610334|Drug|Placebo oral capsule|"In SAD phase: single daily dose of placebo (cellulose microcrystalline) will be administered in doses ranging (equivalent-weight) from 2.5mg (cohort #1 in one intake) to 60mg (cohort #2 to #6 in two intakes separated by a interval of 12 hours).~In MAD phase: multiple doses of placebo (cellulose microcrystalline) will be administered daily during 14 days, in two intakes separated by an interval of 12 hours."
73363|NCT03610321|Drug|Gefarnate|Gefarnate (100 mg, three times daily, oral) treatment for 1 month.
73364|NCT03610321|Drug|Statin|Statin treatment for 1 month.
73365|NCT03610295|Procedure|PPI group|The patients underwent cataract extraction, posterior capsulotomy, anterior vitrectomy combined with prophylactic peripheral iridectomy.
73366|NCT03610295|Procedure|cataract extraction|The patients underwent cataract extraction, posterior capsulotomy combined with anterior vitrectomy and leave the iris intact.
73367|NCT03610282|Drug|IV Methylphenidate|Subjects will receive a bolus of IV methylphenidate during propofol infusion at one of the study visits.
73368|NCT03610282|Drug|Propofol|Subjects will received propofol for up to 100 minutes.
73369|NCT03610269|Device|INVSENSOR00026 (Pulse CO-Oximeter and sensor)|Noninvasive Pulse CO-Oximeter and sensor that measures noninvasive hemoglobin (SpHb)
73370|NCT03610256|Procedure|SADI-S|Laparoscopic SADI-S, recently described as an evolution of the BPD-DS, combining the physiological advantages of pylorus preservation and the technical benefits of single-loop reconstruction, associating a sleeve gastrectomy and a duodeno-ileal bypass at 2.5 meters from the ileo-caecal valve if BMI ≥ 50 kg/m² or at 3 meters if BMI < 50
73371|NCT03610256|Procedure|RYGB|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~a small gastric pouch (about 30cc)~an antecolic alimentary limb~a gastro-jejunal anastomosis using a linear stapler~a 150cm long alimentary limb~a 50cm biliary limb~a latero-lateral jejuno-jejunal anastomosis~closure of the mesenteric defects"
73372|NCT03610243|Behavioral|Self-administered acupressure|Two 2-hour one-on-one training sessions in patient-centered self-administered acupressure will be provided by trainers in the first week (4 hours) in the patient's home or at the university, depending on his/her preference. From the second to fourth weeks of the intervention, participants will engage in 15 minutes of self-administered acupressure twice a day (for a total of 10.5 hours over the 3 weeks). They will log the frequency of self-practice in a diary and be encouraged to undertake self-practice beyond the 4-week intervention. At weeks 2, 3, and 4, a 1-hour follow-up visit will be conducted by the same team of trainers to reinforce learning and self-practice (for a total of 3 hours over the 3 weeks).
73373|NCT03610230|Drug|Iron Isomaltoside|Iron Isomaltoside 1000 (Monofer®) consists of iron with a tighter binding to its carbohydrate moiety with less free iron
73374|NCT03610230|Drug|Iron sucrose|the currently most widely used intravenous iron preparation with good safety profile
73375|NCT03610217|Other|Interstitial lung disease induction algorithm|Patients failing first line mycophenolic acid (MFA) will be randomized to MFA plus rituximab or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option.
73376|NCT03610217|Other|Pulmonary arterial hypertension algorithm|Patients diagnosed with pulmonary arterial hypertension secondary to systemic sclerosis will be randomized to receive anticoagulation (warfarin, rivaroxaban or apixaban)
73377|NCT03610217|Other|Raynaud's phenomenon algorithm|"Patients with mild Raynaud's phenomenon not responding to the first line treatment (nifedipine), will be randomized to receive losartan or nifedipine plus atorvastatin or nifedipine plus losartan. If they fail the second line they will be crossed over to the other options randomly.~Patients with severe Raynaud's phenomenon not responding to the first line treatment (nifedipine) or failing the previous mild Raynaud's algorithm, will be randomized to receive nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option."
73378|NCT03610217|Other|Digital ulcer algorithm|"Patients with active digital ulcers not healing after 3 months or developing new ones with nifedipine will be randomized to nifedipine plus sildenafil or nifedipine plus intravenous iloprost. If they fail the second line they will be crossed over to the other option.~Patients who develop new digital ulcers under treatment with nifedipine will be randomized to nifedipine plus atorvastatin plus standard of care or nifedipine plus standard of care. If they fail the second line they will be crossed over to the other option."
73379|NCT03610217|Other|Inflammatory arthritis algorithm|Patients with inflammatory arthritis failing methotrexate and/or prednisone and/or hydroxychloroquine and/or sulfasalazine will be randomized to receive intravenous rituximab or subcutaneous tocilizumab. If they fail the second line they will be crossed over to the other option.
73380|NCT03610217|Other|Gastroesophageal reflux algorithm|Patients with gastroesophageal reflux failing standard doses of proton pump inhibitors (PPI) will be randomized to receive double doses of PPI or standard dose of PPI plus ranitidine or double doses of PPI plus domperidone or double doses of PPI plus prucalopride/erythromycin. If they fail the second line they will be crossed over to the other options randomly.
73381|NCT03610217|Other|Bacterial overgrowth algorithm|Patients with bacterial overgrowth will be randomized to receive erythromycin or metronidazole or amoxicillin. If they fail the second line they will be crossed over to the other options randomly.
73382|NCT03610217|Other|Constipation algorithm|Patients with constipation will be randomized to receive bisacodyl or magnesium sulphate or polyethylene glycol or senna.If they fail the second line they will be crossed over to the other options randomly.
73383|NCT03610217|Other|Skin involvement algorithm|"Patients with skin involvement and modified Rodnan skin score <32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option.~Patients with skin involvement and modified Rodnan skin score >32 will be randomized to receive methotrexate plus mycophenolic acid or intravenous cyclophosphamide. If they fail the second line they will be crossed over to the other option."
73384|NCT03610217|Other|Pain algorithm|Patients with pain failing first line treatment with acetaminophen or celecoxib or ibuprofen will be randomized to receive pregabalin or duloxetine. Patients with skin involvement and modified Rodnan skin score <32 will be randomized to receive methotrexate or mycophenolic acid or methotrexate plus mycophenolic acid. If they fail the second line they will be crossed over to the other option. In case they fail the second line they will be treated with medical marijuana.
73385|NCT03610204|Other|Buffalo horn technique|The participants receive a 30-min massage session, twice a week for a total 6 sessions.
73386|NCT03610191|Diagnostic Test|Serum biomarker tests|Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.
73387|NCT03610191|Behavioral|Neuropsychological battery tests|both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.
73388|NCT03610191|Procedure|Cardiac surgery|patients scheduled for cardiac surgery will accept the surgical procedure.
73389|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.1 mmol/L fasting and <7.0 mmol/L postprandial) are not achieved insulin therapy is started
73390|NCT03610178|Other|Life-style modification, insulin therapy if needed|All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (<5.3 mmol/L fasting and <7.8 mmol/L postprandial) are not achieved insulin therapy is started
73391|NCT03610165|Device|Acumen HPI-enabled EV1000 screen|Acumen HPI-enabled EV1000 screen.
73392|NCT03610165|Device|Control|Arterial waveform and pressures
73393|NCT03610152|Behavioral|Hospital Policy change|Implementation of a hospital wide policy whereby medically necessary preoperative tests for patients undergoing ambulatory surgery will be ordered at the discretion of the consulting anesthesiologist based on their clinical assessment of the patient.
73394|NCT03610139|Dietary Supplement|Vitamin D3|At baseline, patients with deficient 25(OH)D levels will be randomly assigned 1:1 to receive either the high dose or standard dose vitamin D supplementation.
73395|NCT03610126|Procedure|volume controlled ventilation|the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway
73396|NCT03610126|Procedure|pressure controlled ventilation|the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway
73397|NCT03610113|Device|Reverse shoulder arthroplasty|The implantation of reverse shoulder prosthesis, and reattachment of greater and lesser tuberosities
73398|NCT03610100|Drug|Acelarin|825 mg/m2 administered intravenously over 15 to 30 minutes on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
73399|NCT03610100|Drug|Gemcitabine|1000 mg/m2 administered intravenously as a 30 minute infusion on days 1, 8 and 15 of a 28 day cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.
73400|NCT03610087|Behavioral|Low Intensity Intervention|Participants will have access via the online platform to the NAVIGATE self-help modules for physical activity, nutrition and quitting smoking with a list of community resources. Subjects will be sent a standard reminder emails once per week to complete their modules and connect with their main provider for any assistance.
73401|NCT03610087|Behavioral|High Intensity Intervention|Participants will receive individualized treatment planning, in collaboration with a Care Coordinator, and the Virtual Care Team (VCT). Interactive modules on physical activity, nutrition and quitting smoking will be provided via the online platform. the virtual team will be engaged to provide treatment and/or recommendations regarding the following: increasing physical activity, improving nutrition and diet, smoking cessation (psychosocial support plus medications), and medication adherence. Participants in this arm will have weekly check-ins with their assigned Care Coordinator where they will be able to discuss VCT recommendations, and progress on their goals.
73402|NCT03610074|Other|Mint Ice Cube|Application in patient's mouth of 3 mint ice cubes
73403|NCT03610074|Procedure|Blood test|Additional blood test 5 min after mint ice cubes application
73404|NCT03610074|Other|Patient's questioning|Patient's questioning before mint ice cubes application and at 5 min, 1h, 2h, 4h, 12h and 24h from mint ice cubes application
73405|NCT03610061|Drug|Durvalumab|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
73406|NCT03610061|Radiation|Radiotherapy|"All patients will receive:~Day 1-Day 5: External Beam Radiotherapy to target site(s)-daily for 5 days (i.e. 5 fractions).~D2: Commence durvalumab. Continue 4-weekly until disease progression. Patients can continue until a second radiological progression if clinical benefit is ongoing."
73407|NCT03610048|Drug|ALKS 5461|samidorphan + buprenorphine administered sublingually
73408|NCT03610035|Drug|NPT189|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
73409|NCT03610035|Drug|Placebo|Placebo
73410|NCT03610022|Drug|Treatment with vismodegib|Vismodegib 150 mg capsules is administered daily with or without food until disease progression or unacceptable toxicity. Patients are followed in the dermatologic unit of Bordeaux University Hospital (Saint André Hospital) every month. At each consultation, clinical and biological datas, and two blood samples are collected just before taking the drug. One sample is for vismodegib quantification (pharmacokinetic protocol), and the other for the determination of alpha-1 glycoprotein acid level
73411|NCT03610009|Device|2D ultrasound|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
73412|NCT03610009|Device|SonoAVC|The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
73413|NCT03609996|Device|Panretinal Photocoagulation|Laser treatment for PDR
73414|NCT03609996|Drug|Lucentis|Intraviteral injection
73415|NCT03609983|Other|Daily weighing with daily feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each day upon rising from bed beginning in one week, every day for four weeks. After 2 weights have been collected, participants will begin to receive daily feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since yesterday. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
73416|NCT03609983|Other|Weekly weighing with weekly feedback on weight|"Participants will weigh themselves using a Yunmai SE Scale one time each week upon rising from bed beginning the following day for four weeks. After 2 weights have been collected, participants will begin to receive weekly feedback on their change in weight and suggestions to maintain energy balance. They will receive an email stating, Your weight today is _______. Your weight has (increased/decreased) _____ pounds since last week. If their weight has increased, the email will include one example of how to decrease their energy balance by 150 calories. If participants' weight has decreased, the email will include one example of how to increase energy balance by 150 calories."
73417|NCT03609970|Dietary Supplement|Vitamin D|Daily 4X 1000IU cholecalciferol
73418|NCT03609970|Radiation|UVR (Solar simulated radiation)|1.25 SED Solar simulated radiation twice weekly
73419|NCT03609957|Other|Aerobic Exercise Training|Traditional, continuous aerobic exercise (cycling) at a moderate intensity
73420|NCT03609957|Other|Interval Training|High-intensity interval exercise consisting of short bursts of exercise interspersed with rest periods
73421|NCT03609944|Procedure|ERCP with miES|Endoscopic retrograde cholangiopancreatography with minor papilla endoscopic sphincterotomy
73422|NCT03609944|Procedure|EUS|Endoscopic ultrasound
73423|NCT03609931|Procedure|Mitral Valve Model|Creation of a mitral valve patient specific model to see if it mimics the patients valve
73424|NCT03609905|Biological|Adipose-cord mesenchymal stromal cells (A-MSCs)|A-MSCs 5 x 10~7 diluted on 100 mL of normal saline
73425|NCT03609905|Other|Conventional drugs|5-amino-salicylic acid or glucocorticoid
73456|NCT03609710|Device|Robotic surgery|Robotic low anterior resection for rectal cancer
73426|NCT03609892|Drug|Berberine|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of berberine 100 mg 3 tablets TID, amoxicillin 500 mg 2 capsules BID ，esomeprazole 20 mg BID, ,and Bismuth 100 mg 2 capsules BID.
73427|NCT03609892|Drug|Amoxicillin|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Amoxicillin 500 mg 2 capsules BID plus berberine 100 mg 3 tablets TID, esomeprazole 20mg 1tablet BID, and bismuth 100 mg 2 capsules BID
73428|NCT03609892|Drug|Esomeprazole|Berberine-amoxicillin quadruple therapy group: given for 14 days at a dose of Esomeprazole 20mg 1 tablet BID plus berberine 100 mg 3 tablets TID,amoxicillin 500 mg 2 capsules BID, and bismuth 100 mg 2 capsules BID
73429|NCT03609892|Drug|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsules TID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
73430|NCT03609892|Drug|Tetracycline|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of Tetracycline 250mg 2 capsulesTID plus furazolidone 100mg 1 tablets BID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
73431|NCT03609892|Drug|Furazolidone|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of furazolidone 100mg 1 tablets BID plus Tetracycline 250mg 2 capsulesTID，esomeprazole 20 mg 1 tablets BID and bismuth 100 mg 2 capsules BID
73432|NCT03609892|Drug|Esomeprazole|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of esomeprazole 20 mg 1 tablets BID plus Tetracycline 250mg 2 capsules TID, furazolidone 100mg 1 tablets BID， and bismuth 100 mg 2 capsules BID
73433|NCT03609892|Drug|Bismuth|Tetracycline-furazolidone containing quadruple therapy group: given for 14 days at a dose of bismuth 100 mg 2 capsules BID plus Tetracycline 250mg 2 capsules TID ，furazolidone 100mg 1 tablets BID and esomeprazole 20 mg 1 tablets BID
73434|NCT03609879|Device|Ambu Perfect ACE|patient with a fitted cervical collar (Ambu Perfect ACE) established by an experienced instructor. Cervical collar set up for 20 minutes
73435|NCT03609879|Device|Philly One-Peace Collar|patient with a fitted cervical collar (Philly One-Peace Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
73436|NCT03609879|Device|Necloc Collar|patient with a fitted cervical collar (Neclock Collar) established by an experienced instructor. Cervical collar set up for 20 minutes
73437|NCT03609879|Device|NexSplit Plus|patient with a fitted cervical collar (NexSplit Plus) established by an experienced instructor. Cervical collar set up for 20 minutes
73438|NCT03609879|Device|NECKLITE|patient with a fitted cervical collar (NECKLITE) established by an experienced instructor. Cervical collar set up for 20 minutes
73439|NCT03609866|Procedure|abdominal thoracic compression technique|in the expiratory time of the ventilation set, it will be applied a rapid abdominal thoracic compression
73440|NCT03609866|Procedure|ankle passive mobilization|it will be performed a ankle passive mobilization technique on the patient
73441|NCT03609853|Drug|Placebo|Placebo vapor (distilled water)
73442|NCT03609853|Drug|Vaporized THC, limonene, or THC and limonene|Acute drug exposure
73443|NCT03609801|Behavioral|ACTV|"Achieving Change Through Values-Based Behavior (ACTV) - pronounced ACTIVE - is a new intervention program for domestic violence offenders. ACTV was developed as a collaboration between researchers, practitioners, and the criminal justice system in the state of Iowa (Zarling, Lawrence, Oregno, 2017). It is based on Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999), which is an evidence-based cognitive-behavioral psychotherapy. ACTV is innovative in two primary ways; first, ACTV applies the ACT model to the treatment of domestic violence, and second, ACTV is specifically designed for use in the correctional setting as part of criminal justice programming."
73444|NCT03609801|Behavioral|The Duluth Model|The Duluth Model is based on the premise that domestic abuse happens when men believe they have the right to authority over women who are their intimate partners. The Duluth Model Men's Nonviolence Classes help men stop battering and explore the consequences of the violence for themselves, their partner and their children.
73445|NCT03609775|Drug|ACT-541468|One tablet of 50 mg ACT-541468 will be administered orally.
73446|NCT03609775|Other|ACT-541468 placebo|Matching ACT-541468 placebo will be administered orally as 1 tablet.
73447|NCT03609775|Other|Ethanol 10%|Ethanol 10% w/v solution in 5% glucose will be administered i.v. for 5 h and clamped at an ethanol level of 0.6 g/L.
73448|NCT03609775|Other|Ethanol placebo|Matching placebo for the ethanol infusion (i.e., 5% glucose solution) will be administered i.v. for 5 h.
73449|NCT03609762|Behavioral|EQ-5D-5L HRQOL results be available to the attending doctor|subjects will repeat the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
73450|NCT03609749|Behavioral|Mindfulness Training for Primary Care|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)"
73451|NCT03609736|Diagnostic Test|18F-DCFPyL PET/CT|"A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push.~After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v).~Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL.~At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base."
73452|NCT03609723|Procedure|CABG|CABG with application of a myocardial protection system (MPS ®) and using a minimal extracorporeal circulation system (MiECC) or CABG without use of a minimal extracorporeal circulation system (Off-pump coronary artery bypass grafting = OPCABG)
73453|NCT03609710|Device|Transanal tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
73454|NCT03609710|Procedure|Left colic artery preservation|Left colic artery preservation during operation for lower rectal cancer
73455|NCT03609710|Procedure|Anastomotic reinforcing sutures|Anastomotic reinforcing sutures during operation for lower rectal cancer
73457|NCT03609697|Behavioral|group-based lifestyle intervention|Involve education about pre-diabetes self-management, weight loss, behavioural modification skills, nutrition and physical activity.
73458|NCT03609697|Behavioral|Minimal intervention (SMS intervention)|Text message related to general information about T2DM, pre-diabetes, and lifestyle modification.
73459|NCT03609684|Other|Gymnastic and Core Stabilization|People who regularly do gymnastics and also do 30-45 minutes core stabilization exercises
73460|NCT03609684|Other|Only Gymnastic Training|People can do gymnastics twice a week but can't do core stabilization exercise
73461|NCT03609684|Other|Sedentary Group|People who are not interested in any sports and don't do any exercises
73462|NCT03609671|Behavioral|Standard of Care + Experimental Individualized Therapy|Participants will receive standard of care plus supportive psychotherapy for a one hour, weekly, during the time they are undergoing neoadjuvant treatments.
73463|NCT03609671|Other|Control: Standard of Care|Participants will undergo standard of care only (no Intervention/no individualized therapy) .
73464|NCT03609658|Behavioral|Nurse Navigator Pathway|In the Nurse Navigator Pathway, nurse navigators are being used as leverage to: approach qualified patients to initiate advance care planning discussions, schedule advance care planning visit with patients' primary care provider to further discuss advance care planning and to mail advance care planning resources to patients after their initial advance care planning discussion.
73465|NCT03609658|Behavioral|Usual Care|In the Usual Care arm, there is no approach by nurse navigators to initiate advance care planning discussions and it does not have a structure advance care planning visit. Therefore, no further action is required for the patients who were randomly assigned to the usual care arm.
73466|NCT03609645|Procedure|Fascia iliaca block|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
73467|NCT03609645|Procedure|Femoral articular branches block(FAB)|"FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)"
73468|NCT03609632|Other|Dietary Supplement: Glucose|Intake of 75g of glucose with 1g of 13C leucine pre-feeding
73469|NCT03609619|Drug|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily, during the treatment period.
73470|NCT03609619|Drug|Placebo|Oral doses of Placebo will be administered twice daily, during the treatment period.
73471|NCT03609606|Drug|D013, D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
73472|NCT03609606|Drug|D013|Daily oral administration of 1 tablet under fasting conditions for 7 days
73473|NCT03609606|Drug|D326 and D337|Daily oral administration of 1 tablet for each drug under fasting conditions for 7 days
73474|NCT03609593|Drug|Bendamustine|Subjects will receive Bendamustine 50-90 mg/m2 on days 1-2 for three cycles with each cycle being 28 days.
73475|NCT03609593|Drug|Venetoclax|"Venetoclax: 12 cycles~Venetoclax will then be started after 3 cycles of BR. Dosing for venetoclax will be in a step wise fashion as follows:~Cycle 4 days 1-7 (Week 1): 20 mg once daily~Cycle 4 days 8-14 (Week 2): 50 mg once daily~Cycle 4 days 15-21 (Week 3): 100 mg once daily~Cycle 4 days 22-28 (Week 4): 200 mg once daily~Cycle 4 day 29 and thereafter (Week 5 and on): 400 mg once daily; continue until disease progression, unacceptable toxicity, or 12 cycles duration."
73476|NCT03609593|Drug|Rituximab|For cycles 1 through 3, subjects will receive BR on days 1 and 2. For cycles 5-10, subjects will receive rituximab monotherapy at 375 mg/m2 (cycle 5) or rituximab at 500 mg/m2 (cycles 6-10) on day 1 (or days 1 and 2 if split-dose).
73477|NCT03609580|Drug|Tamsulosin|The investigators hypothesize that pre-operative administration of Tamusolin (Flomax, 0.4mg/day x 1 week), with ongoing use post-operatively until normal voiding resumes, will result in a significant decrease in the incidence of POUR after a thoracic surgical procedure.
73478|NCT03609567|Other|Aromatherapy|Aromatherapy using essential oils
73479|NCT03609567|Other|Placebo|Aromatherapy using odorless placebo oil
73480|NCT03609554|Other|Pilates|The Pilates exercise programme was implemented over 6 weeks, with 2 sessions/week (55 minutes/session). The Pilates programme was conducted by the Physical Education teacher, who was certified in Pilates training. The Pilates programme began at the basic level, incorporating more difficult principles and exercises gradually. The sessions were divided into the warm-up (7 min), the main part (41 min), and the cool down (7 min). Tt concentrated on basic Pilates exercises involving the principal regions of the body (spine flexions, extensions and rotations; hip flexions, extensions and rotations; and shoulder abductions, adductions and rotations).
73481|NCT03609528|Device|CamPROBE|To be completed
73482|NCT03609515|Other|Patient-controlled admission|The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.
73483|NCT03609502|Behavioral|behavioral training|the participants will be trained to perceive a non-native speech contrast
73484|NCT03609489|Drug|Capecitabine|Capecitabine, 1000mg/m2, oral administration, twice daily (once in the morning and once in the evening with an interval of 12 hours, equivalent to a total daily dose of 2000 mg/m2), continuous medication for 14 days and off for 7 days. Every 21 days is a cycle, and there shall be a total of 8 cycles. If the subject is still unable to tolerate toxicity after experiencing two dose adjustments, he/she should be moved out of the group.
73485|NCT03609489|Drug|Apatinib|Apatinib, 500 mg, administered orally (after breakfast) once daily from day 1 to day 21 (including day 21) with continuous administration. Every 21 days serve as a cycle. If after 2 dose adjustments, the subject is still unable to tolerate toxicity, he/she should be moved out of the group.
73486|NCT03609476|Procedure|Room temperature saline instillation|Saline is used as room temperature
73487|NCT03609476|Procedure|Warmed saline instillation|Saline is warmed to 37Celcius prior to instillation
73488|NCT03609476|Procedure|No saline instillation|No saline is used prior to catheter removal
73518|NCT03609216|Drug|Cisplatin|Given IV
73519|NCT03609216|Biological|Pegfilgrastim|Given SC
73489|NCT03609463|Behavioral|Small change intervention|The small change intervention is a behavioral intervention to help people gradually lose weight by making small changes in their lifestyle. At the beginning of the intervention participants will be met in person to be guided in setting an eating and a physical activity goal. Participants will be then contacted through the phone or met in person weekly for 3 months to check on their adherence to the selected goals and to discuss about facilitators and barriers to goal completion, in order to increase their motivation and problem solving skills. Every weekly contact will last about an hour and will be administered in an individual setting. At each contact selected goals can be revised, changed or another goal can be added based on levels of adherence.
73490|NCT03609463|Behavioral|Well-being intervention|The well-being intervention is a coaching intervention aimed at motivating people in making lifestyle changes by reducing levels of stress through the promotion of psychological well-being. It will consists in 4 weekly sessions to be held before starting the small change intervention. Each session will last about an hour and will be administered in an individual setting.
73491|NCT03609463|Other|Treatment as usual|The treatment as usual includes any recommendation given to the participants by their physicians, including diet, physical activity, medication and glycemic control instructions.
73492|NCT03609450|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action plan during Week 7. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
73493|NCT03609450|Behavioral|Low-Dose Comparator|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, and discussion. They are also given a list of leading community, online, print, and smartphone mindfulness resources. Participants are called every two weeks for the first eight weeks for 5-10 minute engagement calls which focus helping participants cultivate a relationship with study staff, giving participants a place to ask questions, and supporting participants in completing study visits.
73494|NCT03609424|Drug|PDR001, Imatinib|"-Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~Recommended dose defined in phase Ib part will be tested"
73495|NCT03609411|Procedure|Splenectomy|Splenectomy was performed after hepatectomy, in an extra-hilar manner with manual ligation of splenic vessels.
73496|NCT03609398|Biological|RVF Vaccine|1.0 mL dose given SQ in upper arm
73497|NCT03609385|Diagnostic Test|Coronary angiography|In patients eligible for participation in the study coronary angiography, echocardiography and EKG will be performed systematically.
73498|NCT03609372|Behavioral|The STOP-HPV Trial 6: Maintenance|In this period, study team support will be withdrawn after previous bundled intervention (including HPV vaccine communication, performance feedback and provider prompts) was given to reduce MOs and increase HPV vaccination rates.
73499|NCT03609359|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) in 21-day cycles at approximately the same time each day. On Day 1 of each cycle, in case concomitantly administered, it will be administered approximately within 1 hour after completion of pembrolizumab administration.
73500|NCT03609359|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg as a 30-minute IV infusion, Q3W (25 minutes to 40 minutes are acceptable).
73501|NCT03609346|Device|PCI|The placement of 1 or more stents in the diseased coronary artery lesion(s).
73502|NCT03609333|Device|Multimodal Neuromonitoring|Application of multimodal neuromonitoring
73503|NCT03609320|Behavioral|The STOP-HPV Trial 5: Bundle Intervention|This intervention will implement a 3-component bundle intervention (communication skills training, performance feedback and prompts) together in practices that previously received standard of care.
73504|NCT03609307|Drug|Combined Intravitreal bevacizumab and propranolol|these patients receive two injections at each session Bavacizumab and propranolol
73505|NCT03609307|Drug|Intravitreal bevacizumab|these patients receive only Bevacizumab
73506|NCT03609294|Drug|Treatment A (Fimasartan, Linagliptin)|Co-administration of Fimasartan and Linagliptin
73507|NCT03609294|Drug|Treatment B (Fimasartan/Linagliptin)|Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
73508|NCT03609281|Radiation|Ultrasound assessement of uterine scar|3D ultrasound assessment of scar characteristics
73509|NCT03609268|Device|microwave ablation (MWA)|microwave ablation (MWA) for recurrent small liver cancer
73510|NCT03609268|Radiation|stereotactic body radiotherapy (SBRT)|stereotactic body radiotherapy (SBRT) for recurrent small liver cancer
73511|NCT03609255|Behavioral|Reducing sedentary behavior|Educational handouts for sedentary behavior and strategies reducing sedentary behavior and weekly videos related to reduced sedentary behavior
73512|NCT03609255|Behavioral|Reducing stress|Educational handouts for sedentary behavior and stress management handout and weekly videos related stress management
73513|NCT03609255|Behavioral|Control|An educational handout for sedentary behavior and weekly neutral topic videos
73514|NCT03609242|Behavioral|STOP-HPV bundle intervention|This intervention will be the bundle (training in communication skills, with the addition of performance feedback followed by the addition of provider prompts).
73515|NCT03609229|Procedure|Burch|polyglactin suture was passed through the Cooper's ligament bilaterally with the guidance of the valve
73516|NCT03609229|Procedure|Abdominal Sacrocolpopexy|"By careful dissection (to avoid large veins in this region), expose the back of the pubic bone and the lateral aspects of the urethra.~The right-handed operator double gloves, and places the left hand in the vagina.~With fingers on either side of the catheter in the vagina, define the urethrovesical junction (at the balloon).~Place three Ethibond J-shaped sutures on either side of the urethrovesical junction."
73517|NCT03609216|Drug|Gemcitabine Hydrochloride|Given IV
73523|NCT03609203|Other|10 Weeks of Strength Trailing|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
73524|NCT03609203|Other|Group Nutrition Discussion: week 1, week 5 and week 10|"Week 1 (pre training session): self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool sample~Week 5: self efficacy survey; Functional status and body composition~Week 10: self efficacy survey; 5-point frailty assessment*; diet survey; metabolic assessment; Functional status and body composition; blood and stool samples"
73525|NCT03609190|Drug|Ketamine|i.v. infusion of 0.25 mg/kg S-ketamine over 40 min
73526|NCT03609190|Drug|Placebo|i.v. infusion of NaCl over 40 min
73527|NCT03609177|Other|Clinician Communication Skills Training|Communication skills training
73528|NCT03609177|Other|Advance Care Planning (ACP) Decisions Videos Decisions Aids|ACP Decisions video decision aids
73529|NCT03609177|Other|Video Declarations (ViDec)|Recording of patient advance care planning videos
73530|NCT03609164|Procedure|Suture-bridge augmentation of single-row repair|
73531|NCT03609151|Procedure|laparoscopic hepatectomy (surgery)|Patients receive laparoscopic hepatectomy.
73532|NCT03609151|Radiation|stereotactic body radiotherapy|Patients receive stereotactic body radiotherapy(SBRT)
73533|NCT03609138|Device|Spinal Hardware|Pedicle screws and patient specific rods
73534|NCT03609125|Other|CBS eyedrop|The product is dispensed as sterile frozen vials containing 0.8 ml of product for the daily administration. The product is thawed and administered at a dose of 1 drop / 8 times each eye during the waking period.
73535|NCT03609112|Other|The WISC-IV|"The WISC-IV (Weschler, 2003) which is measured with several indices:~A Verbal Understanding Index (VUI), which comprehensively assesses the child's verbal skills~Perceptual reasoning index (PRI), which assesses isuoperceptive and visuo-practical capacities~An index of working memory (IWM), which assesses the child's ability to do several things at the same time (double-tasks)~A rate of treatment index (RTI) that assesses grapho-motor speed"
73536|NCT03609112|Other|The CMS (CHILD MEMORY SCALE)|It is an evaluation scale of episodic memory with an immediate recall (after reading the story to remember) and a delayed recall (25-35 min after)
73537|NCT03609112|Other|CONNERS|"The CONNERS which allows the assessment of attentional skills through a questionnaire that will be completed by parents"
73538|NCT03609112|Other|BRIEF|"The BRIEF which is an inventory of behavioral evaluation of executive functions completed by parents and which makes it possible to determine if the child has, for example, difficulties of organization, planning or behavioral regulation."
73539|NCT03609112|Other|PEDS-QL|"The PEDS-QL quality of life that will be completed by the parents and the patient concerns the day-to-day functioning of the child (in school, relationships to others, physical abilities and emotional state)"
73540|NCT03609112|Other|State Trait Anxiety Inventory|The State Trait Anxiety Inventory (STAI), which assesses the anxiety of the child (trait and situational anxiety).
73541|NCT03609112|Other|Child Depression Inventory|The Child Depression Inventory (CDI) assessing any signs of depression in the child.
73542|NCT03609099|Drug|Moxifloxacin|400 mg / day once a day oral treatment during 3 days.
73543|NCT03609099|Drug|Placebo|once a day oral treatment during 3 days.
73544|NCT03609086|Other|Melatonin analysis|Measurement of 6-hydroxymelatonin
73545|NCT03609073|Device|Endomina|Suturing system then cutting the bridge between the diverticulum and the esophagus.
73546|NCT03609060|Drug|Dexamethasone|Dexamethasone 10 mg/12h, IV over 30 minutes, D1 to D3 concomitant to induction and post remission chemotherapy in elderly patients with AML Induction
73547|NCT03609047|Drug|Palbociclib|CDK4/6 inhibitor
73548|NCT03609047|Drug|Docetaxel / cyclophosphamide|Adjuvant Chemotherapy
73549|NCT03609047|Drug|doxorubicin/cyclophosphamide|Adjuvant Chemotherapy
73550|NCT03609047|Drug|epirubicin/cyclophosphamide|Adjuvant Chemotherapy
73551|NCT03609047|Drug|paclitaxel|Adjuvant Chemotherapy
73552|NCT03609021|Procedure|Screening Mammography|Provide bilateral mammogram
73553|NCT03609021|Procedure|Biospecimen Collection|Undergo collection of blood sample
73554|NCT03609008|Drug|Levcromakalim|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
73555|NCT03609008|Drug|Saline|Intravenous administration of levcromakalim or placebo for 20 minutes. To investigate the role of levcromakalim/placebo on cerebral hemodynamic in healthy volunteers.
73556|NCT03608995|Diagnostic Test|Premaquick (Diagnostic test)|"PREMAQUICK® is a rapid multiparametric test which aim to detect the presence of IGFBP-1 (Insulin-like Growth Factor-Binding Protein 1), fragmented IGFBP-1 and IL-6 (Interleukin 6) in vaginal secretions. By combining biomarkers of myometrial activation, cervical maturity and inflammation / infection, PREMAQUICK® integrates the main pathogenic mechanisms responsible for premature delivery, which makes it possible to predict or, on the contrary, rule out the risk of childbirth within 7 to 14 days. This test is intended for in vitro diagnostic use.~Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and then 3 drops are deposited in each wells of the test device for 10 minutes. Visual reading should be done between 10 and 15 minutes."
73557|NCT03608995|Diagnostic Test|Quikcheck fFN ™|- The Hologic QuikCheck fFN test is intended to be used for the qualitative detection of fetal fibronectin in cervicovaginal secretions. The presence of fetal fibronectin in cervicovaginal secretions between 22 weeks, 0 days and 34 weeks, 6 days of gestation is associated with elevated risk of preterm delivery. Quick Check fFN test® is a 10 min, one-step, visual test consists of a sterile polyester-tipped applicator, fetal fibronectin test strip, and sample extraction buffer. The QuikCheck fFN is a solid-phase immunogold assay which aim to detect fetal fibronectin. A positive specimen will result in two visible lines and a negative specimen will result in one visible line (control).
73582|NCT03608774|Other|Placebo|Azithromycin placebo (4 capsules), administered orally as a single dose; Doxycycline placebo (1 capsule), administered orally twice daily for 7 days.
73558|NCT03608982|Other|Simulated patient|The simulated patient is a professional actor and Belgian Red Cross employee, who combines acting distress and pain with moulage, to mimic the injuries as truthfully as possible. For feasibility reasons, the simulant will only be included in two sections of the course: the respective treatments of burns and stroke. The remainder of the course will be taught without simulated patient by the professional first aid tutors.
73559|NCT03608982|Other|No simulated patient|Instead of a simulated patients, participants get to watch video clips on first aid techniques.
73560|NCT03608969|Other|NOT-S|Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
73561|NCT03608943|Other|There is no specific intervention other than an individual changing their treatment as part of their usual care|There is no specific intervention other than an individual changing their treatment as part of their usual care
73562|NCT03608930|Device|Disposable Polypectomy Snare,JHY-SD-23-230-30-A1|The technique is hot snare resection of the polyp with electrocautery. Details are as follows: (1) insert the snare into the colonoscopy; (2) connect the snare with the high-frequency device;(3) advance sliding handle to open the loop; (4) adjust the direction of the snare by rotating the handle as required, rotate the loop until the loop reaches target polyp; (6) encircle the target polyp with loop; (7) pull the sliding handle, lasso the target polyp;(8) resect the polyp with electrocautery, then inhaling the transected polyp into a trap followed by submission to the histological evaluation.
73563|NCT03608917|Drug|Total Glucosides of Paeony(TGP)|Total Glucosides of Paeony(TGP) as a traditional Chinese medicine, peony root is the dried root of peony of Ranunculaceae, cultivated all over the country.TGP is new drug of western medicine, original discovered by Professor Xu who is a famous pharmacologist. The main ingredient is a group of glycosides, including paeoniflorin, hydroxy paeoniflorin, paeoniflorin, paeoniflorin, benzoyl paeoniflorin etc, collectively referred to as total glucosides of paeony（TGP）
73564|NCT03608917|Device|Narrow band-ultraviolet b（NB-UVB）|phototherapy on treating vitiligo
73565|NCT03608917|Drug|Total Glucosides of Paeony(TGP) analogue|Total Glucosides of Paeony(TGP) analogue as a placebo for Control group
73566|NCT03608904|Other|Music listening|Familiar and unfamiliar music selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
73567|NCT03608904|Other|Spoken word (language) listening|Familiar and unfamiliar spoken word (language) selections, listening duration of approximately 15 minutes, three times daily, 90-day listening duration.
73568|NCT03608891|Device|Computer guided patient specific 3D titanium plate|CBCT or CT scan will be done preoperatively and dicom files will be imported to mimics software to design and print the patient specific 3D titanium plate.
73569|NCT03608891|Device|Conventional titanium miniplates|In this group two miniplates of titanium Mini-System 2.0 mm will be used. The plate has profile height 1.0 mm whereas the screw length varies according to the site of the plate. According to Champy osteosynthesis lines for fixation of the posterior mandibular fracture ,the first plate will be placed at the inferior border from the buccal side, using bicortical screws engaging the buccal and lingual cortices to achieve rigid fixation, while the second plate will be placed at about 5mm superior to the inferior plate in the subapical region, using monocortical screws engaging only the buccal cortex to avoid injuring the teeth roots.
73570|NCT03608878|Biological|adagloxad simolenin/OBI-821|"Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21.~Adagloxad simolenin will be mixed with OBI-821 before administration."
73571|NCT03608878|Procedure|TACE|Transarterial chemoembolization
73572|NCT03608865|Drug|Durvalumab with Tremelimumab|Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons. All trial treatments will be administered on an outpatient basis. Durvalumab 1500mg + tremelimumab 750 mg will be administered as a 60 minute each one IV infusion every 4 weeks. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site.
73573|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,01 ml|0,01 ml intravitreous dexamethasone solution 4mg/ml injection.
73574|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,03 ml|0,03 ml intravitreous dexamethasone solution 4mg/ml injection.
73575|NCT03608839|Drug|Intravitreous Dexamethasone Solution 4mg/ml - vol 0,05 ml|0,05 ml intravitreous dexamethasone solution 4mg/ml injection.
73576|NCT03608826|Device|Investigational LINQ™ HF RAMware|The Reveal LINQ™ device and the 2090 programmer are market-released, but once the investigational LINQ™ HF RAMware is downloaded into the devices, they are considered investigational.
73577|NCT03608813|Other|Serum Metabolomics profiling|Untargeted serum metabolomics profiling
73578|NCT03608800|Behavioral|Intermittent fasting|The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
73579|NCT03608787|Behavioral|S-STOP|Pseudo-intoxicated patrons will enter each participating establishment and attempt to be served an alcoholic beverage. In the intervention phases, feedback on staff performance will be provided to owners/managers along with supporting materials and a link to a website with a video of a typical pseudo-intoxicated patron. Staff will be provided with a link to a website providing tips for preventing overservice.
73580|NCT03608774|Drug|Azithromycin|Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg), administered orally as a single dose.
73581|NCT03608774|Drug|Doxycycline|Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) as a course of 100 mg (1 capsule), administered orally twice daily for 7 days.
73587|NCT03608722|Other|MMSE|A pen and paper screening tool of cognitive impairment
73588|NCT03608722|Other|MoCA|A pen and paper screening tool for cognitive impairment
73589|NCT03608722|Device|BrainCheck|A computerized neurocognitive test administered via an electronic device, such as a phone, tablet or computer, that contains several assessments that will aid in establishing an individuals cognitive performance
73590|NCT03608696|Drug|Buprenorphine|buprenorphine 0.075 mg/ml solution
73591|NCT03608670|Device|Defibrillation|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
73592|NCT03608657|Drug|Apremilast|Apremilast
73593|NCT03608631|Drug|Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA|Given IV
73594|NCT03608618|Biological|MCY-M11|Intraperitoneal administration
73595|NCT03608605|Device|MRI|magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery
73596|NCT03608592|Biological|umbilical cord derived mesenchymal stem cells (UCMSCs) suspension|Clinical grade human umbilical cord derived mesenchymal stem cells (passage 3-5) suspension are provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University. Cells are made of suspension packages (60million cells in 100ml normal saline per bag) and infused intravenously in 2 hours.
73597|NCT03608592|Biological|normal saline|A bag of 100ml clinical grade normal saline are also provided by biotherapy center of the third affiliated hospital of Sun Yat Sen University.
73598|NCT03608579|Drug|Autologous Adipose Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices
73599|NCT03608553|Device|MR Guided Focused Ultrasound|Blood Brain Barrier Disruption using FUS
73600|NCT03608540|Device|Endomina|Suturing system with sutures apposition then bulging then cutting
73601|NCT03608527|Behavioral|Voluntary-based upper limb motor rehabilitation|Exercises for neuromuscular control to improve proprioceptive sensibility, muscle strength, stability and coordination of the upper limbs, mainly including task-oriented movements with the goal to improve activities of daily living. Both proximal and distal muscles are involved, in actions such as grasping wooden cubes of different sizes, pinching, reaching targets displayed in front of the patient, and doing patchwork or paper mandala.
73602|NCT03608527|Behavioral|Passive upper limb mobilization|Passive mobilization delivered by a physical therapist of shoulder, elbow, wrist and fingers without detectable muscle activity.
73603|NCT03608514|Drug|Experimental|Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
73604|NCT03608501|Drug|Ixazomib|Ixazomib capsules.
73605|NCT03608501|Drug|Thalidomide|Thalidomide capsules.
73606|NCT03608501|Drug|Dexamethasone|Dexamethasone tablets.
73607|NCT03608488|Dietary Supplement|Vitamin D|Vitamin D3 50.000 IU/per week, for 8 weeks
73608|NCT03608488|Other|Exercise|Core stability, balance exercises
73609|NCT03608475|Other|Limited Ultrasound Imaging|Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits
73610|NCT03608475|Other|Standard Ultrasound Imaging|Ultrasound imaging will be performed at all clinic visits
73611|NCT03608462|Device|repetitive transcranial magnetic stimulation(DLPFC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on dorsolateral prefrontal cortex(DLPFC) .Duration:10 days.
73612|NCT03608462|Device|repetitive transcranial magnetic stimulation(LPC)|high frequency(20Hz) repetitive transcranial magnetic stimulation on left parietal cortex(LPC).Duration:10 days
73613|NCT03608449|Other|questionnaires|questionnaire about mental health status during psychotherapy
73614|NCT03608436|Procedure|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
73615|NCT03608436|Drug|Rocuronium Bromide|Deep (PTC 1-2) versus moderate (Tof count 1-2) neuromuscular block
73616|NCT03608423|Device|Minimally-invasive endoscopy-guided surgery|Surgery started within 8 hours of onset of spontaneous intracerebral hemorrhage.
73617|NCT03608410|Other|Weekly Internet based PRO questionnaires|If core symptoms worsen and exceeds a predefined threshold, a PRO-notification is sent to the hospital.
73618|NCT03608397|Biological|DaxibotulinumtoxinA for injection|DaxibotulinumtoxinA for injection is a sterile, white to off-white lyophilized product containing the active ingredient, daxibotulinumtoxinA, and inactive ingredients to be reconstituted with sterile, non-preserved, 0.9% sodium chloride solution saline.
73619|NCT03608397|Biological|Placebo|Placebo is a sterile lyophilized product consisting of inactive ingredients without the neurotoxin to be reconstituted with sterile, non-preserved 0.9% sodium chloride solution.
73620|NCT03608371|Drug|BTRX-246040|oral capsule 40 mg
73621|NCT03608371|Drug|Placebo|oral capsule matching BTRX-246040 40 mg capsule
73622|NCT03608358|Drug|Dapagliflozin 10 mg|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
73623|NCT03608358|Drug|Dapagliflozin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
73624|NCT03608358|Drug|Dapagliflozin 10 mg placebo to match|10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
73625|NCT03608358|Drug|Dapagliflozin 5 mg placebo to match|5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
73626|NCT03608358|Drug|Saxagliptin 5 mg|5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
73627|NCT03608358|Drug|Metformin|Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
73628|NCT03608345|Other|space maintainer|Space maintainers are applied after the missing teeth in pediatric dentistry for protection of size of extracted area.
73629|NCT03608332|Device|diaphragmatic ultrasound|Diaphragmatic excursion; Diaphragmatic movement will be measured with a 3.5-MHz US probe (Mindray machine, DC-N6).
73630|NCT03608319|Drug|A4250|9.6 mg
73631|NCT03608306|Other|Resin-modified glass ionomer|enhanced RMGIs with an ionic resin matrix, a shock-absorbing resin component, and bioactive fillers that mimic the physical and chemical properties of natural teeth.
129432|NCT03176771|Drug|Placebo|MT-5199 placebo capsules
73632|NCT03608306|Other|Bulk-fill glass hybrid restorative|It's a bulk-fill, fluoride-releasing restorative system that combines EQUIA Forte Fil, which is a high strength glass hybrid restorative, and EQUIA Forte Coat, a wear-resistant, self-adhesive, light-cured resin coating.
73633|NCT03608293|Diagnostic Test|Broncho Alveolar Lavages (BAL)|BEAS-2 B cells are exposed to EVs isolated from BAL of smokers and non-smokers.
73634|NCT03608280|Procedure|Bone autograft|The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.
73635|NCT03608280|Procedure|Orbital reconstruction by 3D-printed porous titanium implant|"From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure."
73636|NCT03608267|Device|Endomina|The jejunum between the two loops is sutered with Endomina and cut 15 days later.
73637|NCT03608254|Other|100% watermelon juice|Participants consumed a one-time dose of 100% watermelon juice. Blood was sampled before and 2 hours after ingestion. Blood pressure and brachial artery flow-mediated dilation were measured before and 2 hours after ingestion.
73638|NCT03608241|Drug|PF-06651600|200 mg by mouth (PO) Once daily (QD) for 11 days
73639|NCT03608241|Drug|Ethinyl estradiol (EE) and levonogestrel (LN)|Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
73640|NCT03608228|Other|Measuring electrical signals from the brain|If patients participate in this study, after the deep brain stimulator leads have been implanted, the researcher(s) will plan to measure electrical signals from the brain while patients perform hand movement tasks.
73641|NCT03608215|Device|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
73642|NCT03608215|Device|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
73643|NCT03608202|Behavioral|POCUS protocol group|"The findings of multiorgan ultrasound can modify diagnoses and treatments and immediate interventions (eg volume loading with saline solution, pleural or pericardial drainage, initiation of diuretics, increase in positive end expiratory pressure, etc.).~This protocol is performed in the first 24 h of admission to the Intensive Care Unit (ICU) and is repeated at 24 h."
73644|NCT03608202|Other|Control group|Routine protocol of the treating team is followed
73645|NCT03608176|Other|PASO diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol. They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).
73646|NCT03608176|Other|Low-fat diet group|This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
73647|NCT03608176|Other|Waiting list group|This group will only receive written information with recommendations on healthy eating. When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
73648|NCT03608163|Drug|Naloxone|Naloxone Nasal Spray
73649|NCT03608163|Drug|Diazoxide|Diazoxide (oral)
73650|NCT03608163|Drug|Placebo (for Naloxone)|Sterile water nasal spray
73651|NCT03608163|Drug|Placebo (for Diazoxide)|Taste matched oral placebo for diazoxide
73652|NCT03608137|Other|Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships|To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.
73653|NCT03608124|Behavioral|Behavior management techniques|Pediatric dentists will be questionnaired regarding their adopted behavior management techniques for pediatric patients
73654|NCT03608111|Other|single task balance training|single task balance training
73655|NCT03608111|Other|dual task balance training|dual task balance training
73656|NCT03608098|Device|Short Pulse Duration|The holmium laser device will be used on a short laser pulse duration setting (300 μs or 350 μs)
73657|NCT03608098|Device|Long Pulse Duration|The holmuim laser device will be used on a long laser pulse duration setting (700 μs or 1500 μs)
73658|NCT03608085|Behavioral|Pharmacist Heart failure MTM training|"The MTM training for pharmacists will consist of:~Online material for home self-study (10 contact hours);~Didactic coursework to obtain a national American Pharmaceutical Association (APhA) MTM certification (8 contact hours); and HF pharmacotherapy (4 contact hours);~1 60-minute sessions of point of care training in the community pharmacy practice lab setting by URI faculty;~Monthly coaching conference calls/webinars with URI and Brown Faculty;"
73659|NCT03608085|Behavioral|Patient Heart failure MTM intervention|"The baseline visit will take place >= 7 but <= 30 days post discharge from the HF hospitalization. Follow-up visits will occur either in person at the patients local pharmacy or via telephone at 30, 60, 90 and 120 days post baseline and will consist of the following:~Preparation: Develop personal medication record (PMR). Assessment: Medication therapy reconciliation; Education: Review heart failure basics and behavioral goals Planning: Documentation of a medication related action plan and identify medication related problems Implementation: Communication of medication related action plan and changes in heart failure symptoms to the patients providers.~Follow up: Monitor and evaluate the care plan in collaboration with the patient's providers."
73660|NCT03608072|Drug|BI 690517|3 sequential dose groups
73661|NCT03608072|Drug|Placebo|3 sequential dose groups
73662|NCT03608059|Drug|ATG/PTCy|low dose Antithymocyte Globulin plus low dose post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
73663|NCT03608059|Drug|standard ATG|in vivo T cell depletion (TCD) with anti-thymocyte globulin (ATG) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation
73664|NCT03608059|Drug|standard PTCy|post-transplant cyclophosphamide (PTCy) as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell
73665|NCT03608046|Drug|Avelumab|Avelumab will be administered at a fixed dose of 10 mg/kg once every 2- week
73666|NCT03608046|Drug|Cetuximab Injection|Cetuximab will be administered at 400 mg/m2 loading dose week 1, 250 mg/m2 from week 2 followed by 500 mg/m2 from week 3 and irinotecan administered every 2 weeks (180 mg/m2).
73667|NCT03608046|Drug|Irinotecan|Irinotecan will be administered every 2 weeks (180 mg/m2)
73668|NCT03608033|Biological|OMS721|Biological: OMS721
73669|NCT03608033|Other|Vehicle (D5W or saline)|5% Dextrose in water or normal saline solution
73670|NCT03608020|Drug|BMX-001|Manganese butoxyethyl pyridyl porphyrin
73671|NCT03608020|Radiation|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy per standard of care.
73672|NCT03608007|Drug|X-396 Capsule|225 mg once daily
73673|NCT03607994|Device|HIRREM-SOP|HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.
73674|NCT03607994|Device|NCC|Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.
73675|NCT03607968|Procedure|The novel anterior TVM surgeries|A novel transvaginal mesh (TVM) surgery fro women with pelvic organ prolapse (POP) had been reported. Chang TC, Hsiao SM, Chen CH, Wu WY, Lin HH. Clinical outcomes and urodynamic effects of tailored transvaginal mesh surgery for pelvic organ prolapse. Biomed Res Int http;//dx.doi.org/10.1155/2015/191258.
73676|NCT03607955|Drug|AVB-S6-500|AVB-S6-500 is supplied by Aravive Biologics
73677|NCT03607955|Drug|Paclitaxel|Commercially available
73678|NCT03607955|Drug|Carboplatin|Commercially available
73679|NCT03607955|Procedure|Tissue from Diagnostic Laparoscopy|-For patients scheduled to undergo a diagnostic laparoscopy for tissue diagnosis prior to neoadjuvant chemotherapy, a tissue biopsy section from the ovary or an intra-abdominal implant will be performed
73680|NCT03607955|Procedure|Tissue from Core biopsy|-Standard of care procedure but research specimens will be collected
73681|NCT03607955|Procedure|Interval Debulking|"Standard of Care~Research tissue samples will be collected"
73682|NCT03607955|Procedure|Peripheral blood|-Before initiation of neoadjuvant chemotherapy and at the time of interval debulking surgery either pre-operatively, intraoperatively, or post-operatively.
73683|NCT03607955|Procedure|Ascites collection|-A total of 25-100ml of ascites will be collected prior to chemotherapy treatment, if available.
73684|NCT03607942|Dietary Supplement|HMO supplement|HMO supplement will be given three times a day, not mixed with any feeding.
73685|NCT03607942|Dietary Supplement|Placebo comparator|Control product without any HMOs. The Placebo Comparator will be matched to the experimental product in energy content.
73686|NCT03607929|Procedure|optimal|Physiological Saline Solution
73687|NCT03607929|Procedure|variability|Other solutions
73688|NCT03607916|Drug|Hyperbaric prilocaine 2%|Varying dose according to sensitive response of previous subjects. All study doses of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
73689|NCT03607916|Drug|Hyperbaric prilocaine 2%|The dose of 60 mg of Hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine
73690|NCT03607916|Drug|Morphine|100µg morphine
73691|NCT03607903|Biological|Adalimumab ID|Adalimumab intradermal using MicronJet600 microneedle from NanoPass
73692|NCT03607903|Biological|Adalimumab SC|Adalimumab subcutaneous using regular needle
73693|NCT03607903|Other|Saline ID|Saline intradermal using MicronJet600 microneedle from NanoPass
73694|NCT03607903|Other|Saline SC|Saline subcutaneous using regular needle
73695|NCT03607890|Drug|Nivolumab|Patients will receive treatment every 28 days for up to 2 years. Nivolumab (480 mg) will be administered IV on day 1 (28 day cycle).
73696|NCT03607890|Drug|Relatlimab|Patients will receive treatment every 28 days up to 2 years. Relatlimab (160 mg) will be administered IV on day 1 (28 day cycle).
73697|NCT03607877|Behavioral|Pedometer walking training and positive education|"Intervention: (1)Positive education: Six psychosocial sessions were designed to enhance elders' positive emotion, motivation and self-efficacy to walk.~(2) Pedometer walking training: walk at least 30 minutes per day and at least three times per week with family support and exercise companions."
73698|NCT03607877|Behavioral|Pedometer walking with training|Intervention:walk at least 30 minutes per day and at least three times per week with family support and exercise companions.
73699|NCT03607877|Behavioral|pedometer walking|Intervention: pedometer walking at least 30 minutes per day and at least three times per week
73700|NCT03607864|Device|coral bone graft and xenograft|"ligible patients will be randomized in equal proportions between control group(immediate implant placement with grafting with xenograft) and study group (immediate implant placement with grafting with coral bone) Patients of both groups will be subjected to standard panoramic radiographs, cone beam ct .~Crestal bone level will measured by cone beam ct. Local anesthesia will be given to the patient. Only sulcular incision line with reflection is used A peritome will be used for a traumatic extraction of remaining roots. The extraction socket will be evaluated for absence of any fenestration or granulation tissues implant will be inserted in extraction socket bodily palatal with grafting with coral bone and xenograft The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 5/0 prolene sutures."
73701|NCT03607851|Drug|Lacosamide - conventional titration|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose at weekly intervals by 50 mg PO BID; up to 200 mg BID
73702|NCT03607851|Drug|Lacosamide - rapid titration 1|Administration of lacosamide by the following schedule, Initial: 100 mg PO BID Increase dose to 200 mg BID after one week
73703|NCT03607851|Drug|Lacosamide - rapid titration 2|Administration of lacosamide by the following schedule, Initial: 50 mg PO BID Increase dose every two days by 50 mg PO BID; up to 200 mg BID
73704|NCT03607838|Drug|SI-6603|SI-6603 will be injected into an intervertebral disc.
73705|NCT03607838|Drug|Sham injection|The injection will be performed without needle placement into an intervertebral disc.
73706|NCT03607825|Device|Neurapheresis System|CSF filtration system and lumbar catheter
73707|NCT03607799|Behavioral|Dietary Intervention|Individualized diet advice will be developed for each participant by a dietitian familiar with South Asian foods.
73708|NCT03607799|Behavioral|Control|"Control group participants will be provided with paper copies and website links to The Sensible Guide to a Healthy Pregnancy, which provides advice on healthy eating, physical activity, and other lifestyle factors during pregnancy."
73709|NCT03607786|Procedure|Retrograde Inferior Vena Caval Perfusion|Retrograde Inferior Vena Caval Perfusion is achieved by tethering the inferior vena cava with a band around the cannula and by clamping the distal end of the inferior vena cava drainage tube, which allowed a pump to drive oxygenated blood into the inferior vena cava. Pump pressure is maintained at 20-30 mmHg, and blood flow is maintained at 8-12 mL/min/kg. The aim of RIVP is to maintain the lower body perfusion during circulation arrest, and reduce the ischemia-associated vital organ injury.
73710|NCT03607786|Procedure|Select antegrade cerebral perfusion|Antegrade cerebral perfusion is achieved using a 12 F cannula inserted into the brachiocephalic artery or right axillary artery. The antegrade perfusion flow rate is maintained at 6-12 mL/min/kg
73711|NCT03607773|Behavioral|Mindfulness Behavioural Intervention (MBI) group|While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
73712|NCT03607760|Device|ECMO|the patients with severe respiratory failure were supported by ECMO
73713|NCT03607760|Device|conventional mechanical ventilation|the patients with severe respiratory failure were supported by conventional mechanical ventilation
73714|NCT03607734|Drug|Amoxicillin|"A graded oral challenge test, using amoxicillin in syrup form, will be administered as follows:~50mg amoxicillin (10% total dose)~250mg amoxicillin (50% total dose)~200mg amoxicillin (remainder needed to complete a 500mg full dose) A 20 minute interval will separate each dose given, and participants will be observed throughout the test. They will be required to stay for one hour after the final dose has been administered. Fully trained staff and all equipment for emergency resuscitation will be immediately available."
73715|NCT03607721|Device|Body Motion Evaluation DARI|Dynamic Athletic Research Institute (DARI) Software to evaluate motion tridimensionally with a camera system and without the use of body sensors.
73716|NCT03607708|Other|Mindfulness-Based Cognitive Therapy (MBCT)|The MBCT intervention will consist of group conducted meditative practices, lasting 2 hours per week for 8 weeks. Patients will be invited to try various techniques during sessions (brief silent meditations, guided meditations, body scans, gentle arm movement exercises).
73717|NCT03607708|Other|Health Enhancement Program (HEP)|Health Enhancement Program (HEP) : Has been previously designed and used for the purpose of being a manualized active control in meditation-based intervention trials, controlling for several non-specific factors found in a mindfulness meditation group. Participants will learn about health promotion, healthy diet, music, exercise as well as implementing positive health-enhancing life changes both in-session and during at-home practice with the support of a group facilitator, but do not learn mindfulness techniques.
73719|NCT03607682|Procedure|Tumor Treating Fields (TTF) Therapy|Undergo TTF therapy
73720|NCT03607682|Device|NovoTTF-200A Device|Undergo TTF therapy
73721|NCT03607682|Other|Quality-of-Life Assessment|Ancillary studies
73722|NCT03607669|Other|Mangafodipir trisodium|Manganese-based MRI contrast agent
73723|NCT03607656|Drug|Oxaliplatin|Oxaliplatin powder injection
73724|NCT03607656|Drug|Capecitabine|Capecitabine tablet
73725|NCT03607656|Other|TCM|TCM decoction orally taken twice a day for at least 3 months
73726|NCT03607656|Drug|S-1|S-1 capsule
73727|NCT03607656|Drug|Docetaxel|Docetaxel injection
73728|NCT03607656|Drug|5-FU|5-FU injection
73729|NCT03607643|Drug|Cannabidiol|"Sublingual dose of 1 mL (0.910 g) of BRCX014 in the morning, prior to the first meal of the day~Sublingual dose of 1 mL (0.910 g) of BRCX014 in the afternoon, prior to the evening meal"
73730|NCT03607643|Drug|Bortezomib|Standard of care (SOC) chemotherapy for multiple myeloma will include a bortezomib-based regimen given at 1.3 mg/m2 on days 1, 4, 8 & 11 schedule to be repeated every 21 days.
73731|NCT03607643|Drug|Leucovorin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
73732|NCT03607643|Drug|5-FU|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
73733|NCT03607643|Drug|Oxaliplatin|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
73734|NCT03607643|Drug|Bevacizumab|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
73735|NCT03607643|Drug|Irinotecan|Standard of care chemotherapy for Stage IV colon or rectal cancer, will include leucovorin 350 mg/m2 IV over 2 hours Day 1, 5-FU 400 mg/m2 IV bolus followed 2400 mg/m2 IV over 46 hours, oxaliplatin 100 mg/m2 IV Day 1, bevacizumab 5 mg/kg IV day1. Irinotecan can be substituted for oxaliplatin.
73736|NCT03607643|Drug|Gemcitabine|Stage IV pancreatic cancer will include a gemcitabine-based regiment at 1000 mg/m2 day 1, 7, 15 of a 21-day cycle.
73737|NCT03607643|Drug|Temozolomide|Standard of care chemotherapy for patients with glioblastoma multiforme includes concurrent radiation therapy (2 Gy per day for a total of 60 Gy) and temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle).
73738|NCT03607630|Other|Imagery Rescripting|psychological therapy
73739|NCT03607617|Other|SDH Tool|The SDH tool is embedded in the EMR to collect and act on individualized social determinants of health data.
73740|NCT03607604|Genetic|Next generation sequencing (NGS)|Patients will be tested for known MODY genes with specific focus on HNF1A, GCK and HNF4A genes. Furthermore, gene panel testing may be performed for any known diabetes genes.If the results are negative, WES/WGS will be performed in patients suspected of having MODY for identification of novel MODY mutations.
73741|NCT03607591|Other|rTMS|rTMS is a non-invasive and safe brain stimulation technique, that uses a magnetic pulse, administrated through a coil, set on the DLPFC
73742|NCT03607578|Behavioral|Other: Control Group - Minimal Intervention|Basic Campaign Folder
73743|NCT03607578|Behavioral|Experimental: Protection Routine 1|New folder, sun advice of Danish Sun Safety Campaign, rationale, prioritization, overview of sun prevention. Activity planner with outdoor activities like bathing, sports and excursions before and after noon (UVI maximum) and indoor activities; shopping, lunch, relaxation and transportation in middle of day and possibility to plan vacation to minimize risk. Instructions for download of UV-App includes use of alert, and information about the features of the app; how to be informed of current UV risk before and during vacation. Link for download of the app is sent by text-message and e-mail. Skintype guide is included in the app and as an individual entity. It includes scoring questions about tan and burn reaction in the sun, a color scale, eye and hair color and freckles. Participants get a description of their skin type and examples of time their particular skin type will resist the sun before erythema occurs at particular UV-levels and functions as an eye-opener.
73744|NCT03607578|Behavioral|Experimental: Protection Routine 2|The sunscreen application instruction is based on a recently developed thorough application instructions for use of sunscreen to counter the problems and deficits of current sunscreen use. It describes every part of the body, the needed volume for that part and application patterns. The package will also include a hat specifically designed for protection and comfort and the availability of a hat will function to increase the use of hat. The hat is simple bucket hat version with a brim, cheap, in light fabric and foldable for easy packing.
73745|NCT03607552|Device|Non-contrast DWI|Diffusion-weighted imaging (DWI) is a non-contrast MRI technique that typically can be acquired in under 5 minutes. DWI reflects the microscopic cellular environment and can demonstrate differences between normal and malignant breast tissue without the aid of intravenous gadolinium.
73746|NCT03607552|Device|Non-contrast MRI|Non-contrast MRI scans will include DWI along with anatomical T1-weighted and T2-weighted sequences.
73747|NCT03607539|Drug|Sintilimab|10 mL:100 mg，200mg，Q3W, day1, I.V.
73748|NCT03607539|Drug|Pemetrexed|500mg/m^2; Q3W, day1, I.V.
73749|NCT03607539|Drug|Platinum|Q3W, day1, I.V.; first 4 cycles.
73750|NCT03607539|Drug|Placebos|10 mL:100 mg，200mg，Q3W, day1, I.V.
73751|NCT03607526|Other|Barriers|NGT sessions identifying barriers to vegetable intake.
73752|NCT03607526|Other|Facilitators|NGT sessions identifying facilitators to vegetable intake.
73753|NCT03607513|Drug|JNJ-64264681|For all cohorts except the solid dose formulation cohort, JNJ-64264681 wlll be administered as oral solution. For the solid dose formulation cohort, JNJ-64264681 will be provided as capsules for oral administration.
73754|NCT03607513|Drug|Placebo|Matching placebo to JNJ-64264681 will be administered as oral solution.
73755|NCT03607500|Behavioral|caloric intake reduction|The caloric intake reduction arm will been seen by the kidney disease dietitian at all clinical visits for the first 3 months (weekly for month 1, every other week for months 2 and 3).
73756|NCT03607487|Drug|INCB054707|INCB054707 tablet administered orally once daily at the protocol-defined dose.
73757|NCT03607487|Drug|Placebo|Placebo tablet administered orally once daily.
73758|NCT03607474|Other|Questionnaires of life quality for patients|"the WhoQoL~a specific scale of Cushing's syndrome~The Beck II scale~HAD scale~Rosenberg questionnaire~Stunkard, Sorensen and Schlusinger (1983) figurines~Brief Cope scale"
73759|NCT03607474|Other|Questionnaires of life quality for caregivers|"the WhoQoL~The Beck II scale~HAD scale"
73760|NCT03607461|Device|Smartphone App|Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
73761|NCT03607461|Combination Product|Control Group|Home Health users will have received traditional home health physical therapy and skilled nursing services.
73762|NCT03607448|Device|Freestyle Libre Flash Glucose Monitoring System|Subjects will wear the Abbott Sensor based FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes
73763|NCT03607435|Device|Spectroscopy for Analyte Quantification|Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).
73766|NCT03607383|Drug|Red Rice Yeast Extract|adults requiring moderate intensity treatment will be provided red rice yeast extracts or statins, depending on the randomization; followed for compliance and adverse effects check, and reevaluated in a final visit with blood test after 8 weeks
73767|NCT03607383|Drug|Statin|Statin choice is done at the discretion of the treating physician for a moderate intensity treatment equivalent according the American College of Cardiology/American Heart Association (ACC/AHA) guidelines definitions, for 8 weeks
73768|NCT03607370|Procedure|Surgery after 12 weeks of delay after chemoradiotherapy.|Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.
73769|NCT03607357|Device|High Flow Nasal Oxygen|The initial flow speed is set at 30L/min and increases at 5L/min in titrated type until the patient feels uncomfortable. The temperature is set at 37℃. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
73770|NCT03607357|Device|Non-invasive Ventilation|The values of initial pressure are set at a lower level (inspiratory pressure: 6-8cmH2O, expiratory pressure: 4cmH2O) and adjusted to a suitable level in 10-20min. The fraction of inspiration O2 is set in accordance with specific condition of patient to insure oxygen saturation more than 95%.
73771|NCT03607344|Procedure|Cohort|Patients undergoing ambulatory laparoscopic sacrocolpopexy
73772|NCT03607331|Device|Auricular vagus nerve stimulation|Auricular vagus nerve stimulation is a typical representative of TCM modernization.
73773|NCT03607331|Drug|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
73774|NCT03607318|Behavioral|iASIST|Integrated Alcohol and Suicide Intervention for Suicidal Teens
73775|NCT03607305|Procedure|BP limb 70cm|Performance of RYGB with a BP limb of 70cm
73776|NCT03607305|Procedure|BP limb 120cm|Performance of RYGB with a BP limb of 120cm
73777|NCT03607292|Procedure|Anterior sciatic nerve block|A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.
73778|NCT03607292|Procedure|Posterior sciatic nerve block|Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
73779|NCT03607279|Procedure|NGAL|
73780|NCT03607253|Other|repetitive heel rise activity|Participants will perform a maximal number of single-legged heel rises on a 10 degrees incline board. Participants will be permitted to apply for fingertip support at shoulder height on a wall in front of them. The test will be terminated when participants could no longer lift their heels from the incline board. The number of correct heel rises will be counted for each leg and will be used as Heel Rise Test score.
73781|NCT03607240|Procedure|lung ultrasound-guided alveolar recruitment|Alveolar recruitment maneuver will be performed under lung ultrasound-guidance. Positive pressure will be not exceed 40cmH2O and duration of positive pressure inflation will not exceed 10 seconds.
73782|NCT03607240|Procedure|conventional alveolar recruitment|Alveolar recruitment will be provided with positive pressure of 30cmH2O for 10 seconds
73783|NCT03607227|Drug|Levobupivacaine|Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
73784|NCT03607227|Drug|Saline Solution|Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
73785|NCT03607214|Other|Placebo|"Placebo nasal spray~Film Sequence"
73786|NCT03607201|Other|No intervention|Routine care
73787|NCT03607188|Drug|Alkotinib|Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
73788|NCT03607175|Drug|Triamcinolone-impregnated CMC foam|same information as included in the arm/group descriptions
73789|NCT03607175|Device|Propel Stent|same information as included in the arm/group descriptions
73790|NCT03607162|Diagnostic Test|DIAFEVER algorithm|PCT rapid test-based predictive algorithm
73791|NCT03607149|Drug|Pemetrexed|"standard arm : calculating the dose of pemetrexed according to body surface area~experimental arm: calculation of the dose of pemetrexed as a function of creatinine clearance (CrCLCG)"
73792|NCT03607136|Other|exercise training|Aerobic exercises, strengthening exercises, flexibility training for 60min, twice a week for 12 weeks
73793|NCT03607123|Other|programing of pacemaker|Different programing parameters will be set in different group/stage
73794|NCT03607123|Procedure|AF ablation|AF ablation can only be performed in Step 3
73795|NCT03607123|Drug|Anti arryhthmic drugs|Anti arryhthmic drugs can be prescribed in Step 2, Step3 and SAFE PAF-SND
73796|NCT03607110|Drug|Ketamine|sedation drugs
73797|NCT03607110|Drug|fentanyl|sedation drugs
73798|NCT03607110|Device|patient control analgesia|patient control analgesia
73799|NCT03607097|Procedure|Secondary prevention program for drug related problems|The interventions consists of three stages: 1) actions aimed at improving the chronic prescription of the patient, 2) actions aimed at improving the therapeutic adherence and 3) actions aimed at improving the assistance healthcare levels coordination
73800|NCT03607084|Behavioral|School Health Worker Program|The intervention trains selected teachers to deliver health lessons to students, perform basic first aid, recognize common illnesses, refer student to skilled medical attention when needed. The intervention provides schools with basic medical supplies including pain relief medication, thermometers, bandages, antiseptics, and oral rehydration solution. Vitamin A supplementation and presumptive deworming medication are administered to students during biannual health screenings.
73801|NCT03607071|Drug|Prednisolone and taper|Prednisolone 30 mg/d and taper 5-10 mg per 2 weeks until off at week 24.
73802|NCT03607058|Other|Kinect + Exercise Training|Kinect + Exercise Training : Patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks. After 1 week washout period, patients will take the treatment 1-hour, 3 days in a week for 8 weeks.
73803|NCT03607058|Other|Exercise Training|Exercise Training: Patients will take the treatment 1-hour, 3 days in a week for 8 weeks. After 1 week washout period, patients will play Xbox Kinect games for 40 minutes and take the treatment for 20 minutes, 3 days in a week for 8 weeks.
73804|NCT03607045|Device|headless screw|headless screw group
73805|NCT03607032|Device|Respin Pad|RespinPad slid into the back of the patient sitting at 45° in the armchair or bed.
73806|NCT03607032|Other|usual treatment|medical aerosol session followed by aspiration or not, as required
73807|NCT03607006|Procedure|Patient specific PEEK sheets|Computer aided sheet design
73808|NCT03607006|Procedure|Autogenous bone shell|autogenous retromolar/chin bone graft
73809|NCT03606993|Other|Lucky Iron Fish (TM) - An iron ingot that is a Cooking supplement|For Mother-infant dyads enrolled into the LIF arm, mother receives one ~ 200g iron ingot, instructions on use: add 2-3 drops of lemon juice to one-liter of water, place iron ingot in water, bring to boil for 10 minutes, remove iron fish from water and then use that water for cooking or drinking.
73810|NCT03606980|Drug|Dexamethasone Sodium Phosphate|Dexamethasone sodium phosphate administered via iontophoresis
73811|NCT03606980|Procedure|Iontophoresis|Iontophoresis on affected knee
73812|NCT03606980|Procedure|Physical Therapy|Physical therapy of affected knee
73813|NCT03606967|Drug|Carboplatin|Given IV
73814|NCT03606967|Biological|Durvalumab|Given IV
73815|NCT03606967|Drug|Gemcitabine Hydrochloride|Given IV
73816|NCT03606967|Drug|Nab-paclitaxel|Given IV
73817|NCT03606967|Biological|Personalized Synthetic Long Peptide Vaccine|Given SC
73818|NCT03606967|Drug|Poly ICLC|Given SC
73819|NCT03606954|Combination Product|Combination topical corticosteroid|Comparison of a vasoconstriction index between the 2 study arms
73820|NCT03606941|Device|electroacupuncture treatment|"Participants in the electroacupuncture group received acupuncture (0.30mm×70mm) at bilaterally Shenmen (HT7) acupoints (0.3-0.5 inch), Neiguan (PC6) acupoints (0.5-1 inch), Baihui (DU20) acupoint (0.5-0.8 inch) and Yintang (EX-HN3) acupoint (0.3-0.5 inch) 30 minutes before anesthesia induction. After Deqi, electroacupuncture stimulation apparatus (HANS G6805-2, Huayi Co, Shanghai, China) is connected with the density wave (2/100 Hz), width 0.25 ms, intensity of 1 ~ 30 mA (gradually increase to the patient's maximum tolerance) and maintained the end of operation."
73821|NCT03606941|Device|sham electroacupuncture treatment|"Participants in the sham electroacupuncture group received shallow needling (0.30mm×25mm) at bilateral sham HT7, PC6, DU20 and EX-HN3 (nonacupoints located 1 inch beside acupoints, about 20mm). Specifically, the depth of needle insertion into nonacupoints is 3-5mm and avoided manual stimulation and no Deqi without actual current output, and retained the needle until the end of surgery."
73822|NCT03606928|Drug|docetaxel, oxaliplatin, 5-FU, leucovorin|This is a single-arm study with all patients receiving mFLOT chemotherapy.
73823|NCT03606915|Behavioral|pain evaluation|collect CSF during spinal anesthesia
73824|NCT03606902|Procedure|Group f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
73825|NCT03606902|Drug|Group F: Continous epidural infusion of bupivacaine plus fentanyl|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
73826|NCT03606902|Drug|Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine|Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
73827|NCT03606902|Procedure|Group L f : Epidural catheter insertion|Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
73828|NCT03606889|Diagnostic Test|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
73829|NCT03606889|Diagnostic Test|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
73830|NCT03606889|Drug|Bupivacaine|0.2 ml/kg bupivicaine
73831|NCT03606876|Drug|BAT1806 injection|Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
73832|NCT03606863|Drug|Perioperative peripheral parenteral nutrition|
73833|NCT03606850|Device|Measurements of markers of cortical excitability by TMS|"In the arm experimental treatment by citalopram, measurements of markers of cortical excitability by Transcranial Magnetic Stimulation will be applied. These measurements were: the cortical silent period CSP, the evoked potential MEP, the intra-cortical inhibition ICI and the intra-cortical facilitation ICF). Electromagnetic coil is placed upon the vertex, according to the International 10-20 EEG system. Gathering of the peripheral signal by a surface EMG electrode (non invasive device) placed regarding one of the first dorsal interosseous muscle."
73834|NCT03606837|Drug|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
73835|NCT03606837|Drug|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
73836|NCT03606824|Drug|Pitavastatin and placebo|The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
73837|NCT03606824|Drug|Pitavastatin and levothyroxine|The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.
73838|NCT03606811|Procedure|fluroscopic guided block|SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.
73839|NCT03606811|Procedure|double modality (ultrasound and fluroscopic) guided block|SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A & dead lateral)
73840|NCT03606798|Other|3 Home visits made by a psychologist|Patient and caregiver interviews with a psychologist at home
73841|NCT03606785|Drug|Tranexamic Acid Injection|The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision
73842|NCT03606785|Drug|placebo injection|patients will receive a placebo of 100 mL 0.9% normal saline
73843|NCT03606772|Other|Questionanniare|Filling printed questionnaire + Pelvic examination
73844|NCT03606759|Procedure|Weekly assessment|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours)"
73845|NCT03606759|Procedure|Weekly assessment ajusted|"Weekly assessment during 3 months :~Severity of addiction (Addiction Severity Index, ASI) Mini International Neuropsychiatric Interview, MINI Craving intensity (BILAN-7 jours) Individual cues of each participant (QSA) Substance use and gambling (BILAN-7 jours) Individually Adjusted Therapy scale (ATI)"
73846|NCT03606746|Drug|MDR-103|MDR-103 Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
73847|NCT03606733|Procedure|Custom suorachoroidal needle|Custom made Supra Choroidal Space needle
73848|NCT03606720|Other|low level laser therapy|low level laser therapy (LLLT) is a modality that has been used by the medical profession for decades to treat acute and chronic pain conditions ranging from tendonitis and bursitis, to back pain and pelvic girdle pain.
73849|NCT03606720|Other|pelvic stabilization exercises|special program of pelvic stabilization exercises depending on exercising of transverse abdominal in addition to co activation of lumbar multifidus muscles at the lumbosacral area , exercising of oblique abdominal, gluteus maximus, latissimus dorsi muscles , quadratus lumborum, erector spinae, also, hip abductors and adductors. will done by all patients
73850|NCT03606707|Drug|Steroids|intra-articular steroid injection for atlantoaxial joint
73851|NCT03606694|Drug|Dihydromyricetin|The intervention wiil be 300 mg, two times per day before break-fast and dinner during 12 weeks.
73852|NCT03606694|Drug|Metformin|The intervention wiil be 850 mg, two times per day before break-fast and dinner during 12 weeks.
73853|NCT03606681|Drug|Calcium Hydroxide|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in the same session.
73854|NCT03606681|Drug|Mineral Trioxide Aggregate|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity and restoration was finished in in the same session.
73855|NCT03606681|Drug|TheraCal LC|After cleaning the caries with partial removal (non-exposed pulp), cavity disinfected with sodium hypochlorite then indirect pulp capping agent was applied to cavity (2 milimeter layer) and polymerized and restoration was finished in in the same session.
73856|NCT03606668|Device|Virtual Reality Headset|Study will use the HTC Vive VR system running on a high performance desktop computer
73857|NCT03606655|Drug|Kava|Kava: 75 mg three times daily (3 capsules)
73860|NCT03606629|Device|Endoprosthesis implantation|Endoprosthesis implantation by Percutaneous Angioplasty
73861|NCT03606616|Procedure|no further ALND arm|Patients meeting the Z0011 inclusion criteria to receive no additional ALND
73862|NCT03606590|Device|NovoTTF-100L(P) device|Patients will be treated continuously with the NovoTTF-100L(P) device. NovoTTF-100L(P) treatment will consist of wearing four electrically insulated electrode arrays on the abdomen. The treatment enables the patient to maintain regular daily routine.
73863|NCT03606590|Drug|Sorafenib|Sorafenib 400 mg (2 x 200 mg tablets) taken twice daily without food (at least 1 hour before or 2 hours after a meal).
73864|NCT03606577|Drug|Carfilzomib|Induction 6 cycles 20/36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 cycle 1 only) Consolidation 4 cycles Carfilzomib 20 or 36 mg/m² on days 1, 2, 8, 9, 15, 16 (20 mg/m² on D1 and 2 first cycle only)
73865|NCT03606577|Drug|Daratumumab|induction: 6 cycles Daratumumab 8/16mg/kg IV on Days 1, 8, 15, 22 for the first two cycle 2 and on days 1 and 15 for cycles 3 to 6. (8mg/kg on D1 & D2 cycle 1 only) Consolidation: daratumumab 4 cycles 16mg/kg IV Day 1, Day 15 Maintenance Daratumumab 16mg/kg IV once every 8 weeks for 2 years (or until documented disease progression)
73866|NCT03606577|Drug|Lenalidomide|induction: 6 cycles Lenalidomide 25 mg/day from day 1 to day 21 Consolidation: 4 cycles 15 mg/day from Day 1 to Day 21 (first cycle ) 25 mg/day from Day 1 to Day 21 (in the following cycle) Maintenance therapy 10mg/day, Day 1 to 21, for 2 years (or until documented disease progression)
73867|NCT03606577|Drug|Dexamethasone|induction 6 cycles 20 mg/day on days 1-2, 8-9, 15-16 and 22-23 Consolidation 4 cycles 40 mg/Day on Days 1, 8, 15 and 22
73868|NCT03606564|Other|study of fasting time among pediatric patients undergoing day care surgery|parents of children undergoing day care surgery were given a questionnaire to be filled containing questions regarding time of fasting that was instructed and
73934|NCT03606018|Drug|Insulin Lispro Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
73935|NCT03606018|Drug|Humalog® Mix 25|insulin lispro biphasic in doses 0.4 ME/kg
73869|NCT03606551|Device|EXD-959 Bracket System|EXD-959 Ceramic Self-ligating Brackets are a new type of esthetic ceramic bracket developed by 3M™ Oral Care Solutions. The brackets have a sliding door and are composed of alumina (aluminum oxide) and small amounts of related oxide compounds (glass powder) to give them a clear appearance. A nickel-titanium wire serves as part of the door mechanism and is attached to the bracket using 3M ESPE™ Scotchbond™ Universal Adhesive. The brackets are classified as a Class II medical device. A FDA 510(k) submission of EXD-959 was submitted the first quarter of 2018.
73870|NCT03606538|Drug|MDMA|80 mg MDMA
73871|NCT03606525|Procedure|subarachnoid block|Vertebral column length and abdominal girth will be measured before routine subarachnoid block is given to recruited patients
73875|NCT03606499|Drug|Ustekinumab|No study treatment will be administered as a part of this study. Participants who are initiating the treatment with ustekinumab, will be observed according to standard clinical practice.
73876|NCT03606486|Other|Biospecimen Collection|Undergo collection of tumor sample and blood draw
73877|NCT03606486|Other|Laboratory Biomarker Analysis|Correlative studies
73878|NCT03606486|Other|Lavage|Undergo uterine lavage
73879|NCT03606486|Other|Pap Smear|Undergo pap smear
73880|NCT03606473|Drug|d-amphetamine|is used to stimulate dopamine release in the brain
73881|NCT03606473|Radiation|[C-11]NPA|PET radiotracer
73882|NCT03606460|Drug|Ocrelizumab Dose 1|300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.
73883|NCT03606460|Drug|Ocrelizumab Dose 2 and Dose 3|600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48
73884|NCT03606447|Drug|Uproleselan|[14C]-Uproleselan
73885|NCT03606434|Other|Hypoxic exposure|30 minutes of intermittent hypoxia
73888|NCT03606408|Drug|osilodrostat|osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.
73889|NCT03606395|Drug|NV-5138|single ascending dose
73890|NCT03606395|Drug|Placebos|Placebo liquid solution to mimic NV-5138
73891|NCT03606382|Diagnostic Test|HostDx Fever Test|HostDx Fever test to distinguish between viral and bacterial infections
73892|NCT03606382|Diagnostic Test|HostDx Sepsis Test|HostDx Fever test to determine the severity of a presented, suspected infection.
73893|NCT03606369|Drug|Palonosetron|Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.
73894|NCT03606369|Drug|Ondansetron|Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
73895|NCT03606356|Drug|Onabotulinum toxin A|Cranial Subcutaneous Injections
73896|NCT03606343|Behavioral|Teaching Academic Skills to Kids|Group treatment
73897|NCT03606330|Diagnostic Test|Cardiac imaging tests|"2D transthoracic echocardiography~128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~Shear stress evaluation via computational fluid dynamics.~Intracoronary imaging techniques: IVUS and OCT."
73898|NCT03606330|Diagnostic Test|Venous blood sample collection|Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP
73899|NCT03606304|Behavioral|Problem-solving therapy|See previous
73900|NCT03606291|Radiation|isotoxic hypofractionation|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible
73901|NCT03606278|Other|Structured debriefing assisted by video|In the structured debriefing assisted by video, the process was based on the immediate review of the video, stopping and rewinding the recording as required. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
73936|NCT03605992|Other|Home-based Rehab|This intervention will have the duration of 12 weeks, with a total of 60 sessions: 2 supervised and 58 at home (to complete five exercise's sessions for week).
73937|NCT03605992|Other|CentreRehab|This intervention will last 12 weeks, with a total of 60 sessions: 24 supervised and 36 at home (to complete five exercise's sessions for week).
73938|NCT03605940|Combination Product|Methoxsalen + ECP device|2 sessions per week during 4 weeks and 1 session per week during 8 weeks
73939|NCT03605940|Drug|Corticosteroids|2 mg/kg/day
73975|NCT03605667|Drug|troriluzole|Oral BHV-4157 will be given daily for up to 48 weeks
73902|NCT03606278|Other|Structured oral debriefing|In the structured oral debriefing, the process was based by the mental search of their memories of what occurred. The debriefing session was conducted in the debriefing room of the simulation laboratory with an assigned time of 15 minutes. Each session was developed in three phases. The first phase, descriptive, in which each participant was encouraged to recount what they had lived and experienced, clarifying how the events unfolded, verifying the appropriate decisions and the errors committed in the scenario and the ways they could have solved them and corrected them. The second phase, analytical, the participant reflected on what occurred in the scenario, commenting on how their feelings were involved in the development of the case. The third phase, application or transference, in which the group was encouraged to draw conclusions from what had occurred, realizing an application of this experience in a real-life.
73903|NCT03606265|Device|App+Web|Patients will use an app daily twice and physicians will use a website to consult the characteristics of the alarms the app will send them in the presence of an unwanted event
73904|NCT03606265|Device|Treatment as usual|Patients will be offered the usual treatment for their pain, which is not changed by study participation
73905|NCT03606252|Other|Blood sampling|6 blood sample, 3 at J0 and 3 at J7 ( 2 tubes EDTA of 7mL, 1 tube Blood RNA of 3 mL)
73906|NCT03606252|Other|urine sampling|2 urine sample (1 at J0 and 1 at J7)
73907|NCT03606239|Radiation|isotoxic hypofractionated group|the normal tissue limits are uniform, such as: V20% ≤ 30%, spinal cord 0> 45Gy, etc., and used hypofractionated radiotherapy technology so that each patient received the maximum individualized radiation dose as possible，and the same time use the Platinum-containing drugs: docetaxel + lobaplatin Docetaxel 60 mg/m2, d1; Lobaplatin 30 mg/m2, d1, repeated every 28 days. The first cycle of chemotherapy started on the first day of radiotherapy.Consolidate chemotherapy up to 4 cycles after radiotherapy, as above.
73908|NCT03606213|Biological|PENNVAX-GP|PENNVAX®-GP is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag, Pol and Env proteins.
73909|NCT03606213|Biological|INO-6145|INO-6145 is a circular, double stranded, deoxyribonucleic acid consisting of expression plasmids that encode synthetic HIV-1 multiclade consensus Gag and Pol proteins.
73910|NCT03606213|Biological|INO-9012|The IL-12 DNA adjuvant (INO-9012) consists of a single plasmid containing a dual promoter system for expression of both the IL-12 p35 and p40 genes necessary for production of the active heterodimeric (p70) IL-12 protein.
73911|NCT03606213|Device|CELLECTRA® 2000|Electroporation (EP) is a technology in which an electrical field is applied to increase the permeability of cell membranes and thereby enhance the uptake of drugs, vaccines, or other agents into target cells. This technology has been used in the last decade in both therapeutics and vaccinations. EP is currently being used to deliver cancer vaccines and therapeutics as well as in gene therapy. The expression levels are increased by as much as 3 orders of magnitude over plasmid injection alone.
73912|NCT03606187|Device|Stimgenics SCS Programming Approach|Stimgenics SCS Programming approach Using Intellis(TM) SCS system
73913|NCT03606187|Device|Standard SCS Programming Approach|Standard SCS Programming approach using Intellis(TM) SCS system
73914|NCT03606174|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases
73915|NCT03606174|Drug|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
73916|NCT03606161|Other|Questionnaire Administration|Ancillary studies
73917|NCT03606161|Procedure|Transcranial Magnetic Stimulation|Undergo nrTMS
73918|NCT03606148|Diagnostic Test|SurePathTM|In the liquid-phase cytology, a fine-aspirated sample is immediately inserted into a container containing a commercially available preservative solution without a separate slide-smearing procedure and immediately after the fine-needle aspiration.
73919|NCT03606135|Other|The Pneumonia Group|
73920|NCT03606135|Other|The Control Group|
73921|NCT03606122|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²
73922|NCT03606109|Drug|Intravenous Tranexamic Acid (TXA)|Patients will be given 1 gram of intravenous tranexamic acid (TXA) before tourniquet inflation and 1 gram of IV TXA before closure of the incision.All patients will receive a standardized regimen of aspirin for DVT prophylaxis and Percocet for pain management, which is standard of care post-operative treatment.
73923|NCT03606096|Biological|Boostrix IPV infant acellular Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant acellular pertussis
73924|NCT03606096|Biological|Boostrix IPV infant whole Pertussis|mother is randomized to receive Boostrix ® Polio (GSK) and infant whole Pertussis
73925|NCT03606096|Biological|TT infant acellular Pertussis|mother is randomised to receive Tetanus Toxoid and infant acellular Pertussis
73926|NCT03606096|Biological|TT infant whole Pertussis|mother is randomised to receive Tetanus Toxoid and infant whole Pertussis
73927|NCT03606083|Device|Endovascular repair|Endovascular repair of aorto-iliac or iliac aneurysms using an iliac branch device (IBD)
73928|NCT03606070|Diagnostic Test|PET-MRI|"a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI)."
73929|NCT03606057|Drug|JNJ-64565111|Participants will receive JNJ-64565111, subcutaneously on days 2, 9, 16, and 23.
73930|NCT03606057|Drug|Moxifloxacin|Participants will receive moxifloxacin capsule on days 1 or 27 in a nested crossover manner.
73931|NCT03606057|Drug|JNJ-64565111-matching Placebo|Participants will receive JNJ-64565111-matching Placebo vehicle solution subcutaneously on days 2, 9, 16, and 23.
73932|NCT03606057|Drug|Moxifloxacin-matching Placebo|Participants will receive moxifloxacin-matching placebo capsule on days 1 and 27 in treatment group 1 and on day 1 or 27 in treatment group 2.
73933|NCT03606044|Device|3D-models|"The study radiologist will generate a patient-specific virtual 3D model of the participant's body from their pre-operational medical scans (CT, and MRI if available) using regulated commercial medical image analysis software, specifically Osirix MD 9.0 (Pixmeo, Geneva, Switzerland).(Rosset et al. 2004)~The CRFw checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon checks that the medical scan segmentation is accurate and validates the virtual 3D model.~The surgeon uses all available medical scan data, and the virtual 3D model as an adjunct, to assess the patient anatomy and plan the operation accordingly"
73940|NCT03605927|Drug|BMS-986004|BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended phase II dose.
73941|NCT03605927|Drug|Sirolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
73942|NCT03605927|Drug|Tacrolimus|"Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.~In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.~Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions."
73943|NCT03605914|Drug|diclofenac|The non-steroidal anti-inflammatory drug (NSAID) used in this study is diclofenac.
73944|NCT03605914|Drug|Norco|The opioid used in this study is Norco. Norco is a combination medication that contains both an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen).
73945|NCT03605901|Drug|Standard dosing of methadone|Subject will receive 0.2 mg/kg based on ideal body weight of methadone after the intubation and before positioning.
73946|NCT03605901|Drug|Aliquots of methadone titrated to apnea|Subjects will receive incremental aliquots of methadone up to 0.5 mg/Kg based on ideal body weight titrated to apnea. Each subject will receive a 10 mg loading dose then aliquots of 5mg each, given at 3 to 5 minute time intervals.
73947|NCT03605888|Behavioral|Koa Family|"Koa Family is a 6-month program consisting of a whole-person lifestyle program (WPLP) combined with text messaging and social media support and a neighborhood tree planting campaign. The WPLP will bring groups of 8 to 10 mothers living in the same community together for 22 weekly 90-minute support sessions. Each session will cover a topic on whole-person living, including healthy eating, physical activity, stress reduction, coping, and well-being. Participants will receive brief text messages on their cell phones to encourage healthy lifestyle choices. Participants also will be invited to join a secret Facebook group where they can support one another in healthy lifestyle change. Finally, participants will have an opportunity to take part in a neighborhood tree planting campaign."
73948|NCT03605875|Behavioral|Web-App|Cambian IT Health solutions from Surrey BC developed the infrastructure
73949|NCT03605875|Behavioral|Paper|Contains similar questions to the Web-App tool
73950|NCT03605862|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
73951|NCT03605862|Drug|Placebo|Placebo administered orally twice daily for five days
73952|NCT03605849|Drug|Centanafadine SR|200 mg, BID, oral tablets
73953|NCT03605836|Drug|Centanafadine SR|100 mg, BID, oral tablets
73954|NCT03605836|Other|Placebo|BID, oral tablet
73955|NCT03605836|Drug|Centanafadine SR|200 mg, BID, oral tablets
73956|NCT03605823|Device|Express Mini shunt|Implantation of Express Mini shunt through pars plana in vitrectomized eyes
73957|NCT03605810|Other|No Intervention|This study is the development of algorithms/models to predict eGFR values and/or classes for patients at certain time point based on entries in claims database (demographic characteristics, clinical diagnoses, procedures and drug treatments) for a general population and a variety of use-cases (AF, CAD, T2DM patients sub-populations).
73958|NCT03605797|Other|follow up of cases fixed by posterior tension band plate|Follow up of the reduction and functional outcome evaluation using the Majeed functional outcome score
73959|NCT03605771|Other|Daily Clinical Practice|The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
73960|NCT03605758|Drug|Ivermectin|Ivermectin is an anti-parasitic
73961|NCT03605745|Device|Prostatic Vapor Ablation|"Rezūm uses the stored thermal energy in water vapor (steam) to treat the extra prostate tissue that is causing symptoms such as frequency, urgency, irregular flow, weak stream, straining and getting up at night to urinate.~Inside a hand-held device, radiofrequency energy is applied to a few drops of water to create vapor (steam). The water vapor is injected into the prostate tissue that is blocking the flow of urine from the bladder, where it immediately turns back to water, releasing the energy stored in the vapor into the cell membranes. At this point, the cells are gently and immediately damaged, causing cell death. Over time, the body absorbs the treated tissue through its natural healing response."
73962|NCT03605732|Behavioral|self help sleep hygiene intervention application|This intervention lasts for six weeks. The intervention is App-based and mainly consists of the most potent CBT techniques as well Health action process approach. Weekly feedback is provided by health psychologists.
73963|NCT03605732|Other|patients education|Participants in the PE group will receive written weekly information on accurate and relevant information regarding insomnia symptoms, physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors
73964|NCT03605719|Drug|Carfilzomib|Given IV
73965|NCT03605719|Drug|Dexamethasone|Given IV
73966|NCT03605719|Biological|Nivolumab|Given IV
73967|NCT03605719|Biological|Pelareorep|Given IV
73968|NCT03605706|Drug|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
73969|NCT03605706|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment on D1-D2 of every 2 weeks
73970|NCT03605706|Drug|Sorafenib|Subjects receive Sorafenib orally every day
73971|NCT03605693|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session treatment in which participants write about their trauma event in a specified manner.
73972|NCT03605680|Drug|Centanafadine SR|100 mg, BID, oral tablets
73973|NCT03605680|Other|Placebo|BID, oral tablet
73976|NCT03605667|Drug|Placebo oral capsule|Oral matching placebo will be given daily for up to 48 weeks
73977|NCT03605654|Biological|MDR-102|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
73978|NCT03605654|Drug|Standard Anti-Rejection Medications|Standard Anti-Rejection Medications that would be given to kidney transplant recipients who are outside the study
73979|NCT03605641|Device|JUUL|JUUL Virginia Tobacco
73980|NCT03605641|Device|VUSE Solo|VUSE SOLO Original
73981|NCT03605641|Other|Conventional Cigarette|Subject preferred conventional cigarette
73982|NCT03605628|Other|measuring tape|measurement of change in abdominal wall length [cm] during neuromuscular block with a measuring tape.
73983|NCT03605628|Other|neuromuscular block|Measurement of the time course of the neuromuscular block: neuromuscular transmission is measured by assessment of the post tetanic count and the train of four ratio using acceleromyography (TOF Watch SX™, Essex Pharma GmbH, Munich, Germany) at the right adductor pollicis muscle with transcutaneous Ag/AgCl electrodes (electrocardiogram electrodes; Ambu Inc., MD 21060 USA);
73984|NCT03605628|Other|Surgical rating score|"assessment of operating conditions by means of a standardized score: surgical rating score:~extremely poor conditions~poor conditions~acceptable conditions~good conditions~optimal conditions"
73985|NCT03605615|Other|vocalization|The vocalization will be taught in voice form exhaled / sung in grave tones with the vowels, A, O and U.
73986|NCT03605602|Other|No treatment is included in this protocol.|No drug intervention or tissue sampling will be included in this study.
73987|NCT03605589|Drug|Blinatumomab|Continuous IV infusion
73988|NCT03605589|Drug|Pembrolizumab|IV infusion
73989|NCT03605576|Procedure|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
73990|NCT03605576|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
73991|NCT03605563|Procedure|Fu's subcutaneous needling|"Fu's Subcutaneous Needle (FSN), is an innovation for the treatment of myofascial pain and trigger points. The needle is a non-injection needle, and the fact that both needles are manipulated and act on soft connective tissue.~FSN abstains from the muscle and deep fascia layers and is confined to only the subcutaneous layer where collagen fibers are most abundant. As the subcutaneous layer is poorly innervated, pain is less than other needling therapies.~FSN is also currently being used successfully to treat non-musculoskeletal conditions."
73992|NCT03605563|Procedure|Transcutaneous electrical nerve stimulation|"Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes.~TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to treat pain. The unit is usually connected to the skin using two or more electrodes. A typical batteryoperated TENS unit is able to modulate pulse width, frequency and intensity. Generally TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction."
73993|NCT03605550|Drug|PTC596|Oral Capsules
73994|NCT03605550|Radiation|Radiotherapy|Course 1
73995|NCT03605537|Drug|Drug-eluting Stent Mometasone|The subject will have a mometasone drug-eluting stent placed during their choanal atresia repair procedure instead of no stent being placed.
73996|NCT03605524|Other|Sensory training|12 weeks sensory training
73997|NCT03605511|Diagnostic Test|ADAMTS 13, complement and angiogenic biomarkers|ADAMTS 13, complement and angiogenic biomarkers
73998|NCT03605485|Device|Nasal Pillows CPAP mask|Investigative Nasal pillows Mask to be used for OSA therapy
73999|NCT03605472|Other|cervical ultrasound|cervical ultrasound will be realized by a endocinologist trained in the cervical ultrasound
74000|NCT03605459|Device|Comfort Plug™|
74001|NCT03605446|Dietary Supplement|Biscuit acceptance|Acceptance of high protein biscuits
74002|NCT03605433|Drug|Rivaroxaban|Rivaroxaban 2.5 mg or Rivaroxaban 20 mg or no oral anticoagulation
74003|NCT03605420|Other|Family visit prior to hospital admission|Family receiving one visit prior to hospital admission for surgery
74004|NCT03605407|Other|Patient visit prior to hospital admission|Patient and family receiving one visit prior to hospital admission for surgery
74005|NCT03605368|Behavioral|Virtual Reality Intervention|Floreo's Police Safety Module (PSM) offers a supervised VR experience for people with ASD. The software is an application that provides a 3D immersive scene for headset-compatible smartphones. The person with ASD will use a smartphone capable of running the application with a dedicated headset providing the virtual environment. The PSM provides an immersive story-based intervention that shows a fully realized and intricately detailed urban environment designed to engage the user in a virtual encounter with a law enforcement officer. The immersive VR environment engages the person with ASD as an actor in a virtual narrative, incorporating strategies from both story-based intervention and video modeling. The video demonstrates the approach and initial engagement efforts of two police officers in the virtual environment, from the perspective of the person wearing the headset. The PSM allows a monitoring therapist to use a tablet or phone to supervise the person's virtual world.
74070|NCT03604835|Other|No Intervention|Access to any treatment is through authorized commercial use or available expanded access programs only and not as a part of this DMP.
74006|NCT03605368|Behavioral|Video Modeling Intervention|The video modeling intervention is a subset of the BE SAFE The Movie Curriculum Lessons (https://besafethemovie.com/curriculum/) that were selected to match Floreo PSM on length. The BE SAFE The Movie Curriculum consists of video-based instruction on police officer interaction expectations and safety. Within each of three sessions, participants will watch videos, complete worksheets, and discuss topics related to police safety knowledge and behaviors with the study administrator.
74007|NCT03605342|Drug|Buprenorphine|Participants will be started at a dose of 2mg/0.5 mg BUP/NLX and this dose will be increased as needed for stabilization of opioid withdrawal symptoms up to 24 mg per day, which is standard practice.
74008|NCT03605342|Behavioral|Cognitive Processing Therapy (CPT)|CPT-C is a manualized, 12-session 1:1 cognitive therapy that has been designed for patients with PTSD. In this study the sessions will be conducted weekly. CPT-C uses Socratic questioning targeting distorted cognitions such as self-blame, hindsight bias, and other guilt cognitions. CPT-C is focused on the cognitive components of the therapy without exposure.
74009|NCT03605342|Behavioral|Individual Drug Counseling (IDC)|IDC will serve as the control group. The current standard of treatment for Veterans entering buprenorphine maintenance is to do drug counseling. Standard counseling is the primary means to achieve goals. IDC uses a semi-structured, time-limited addictions-counseling model in a 1:1 setting. The IDC manual provides an organized, concise version of what is currently practiced by most addiction counselors.
74010|NCT03605329|Other|to explore the severity of NAC in case of OSAS|"After overnight polysomnography, cardiovascular autonomic neuropathy will be evaluated by different methods: study of HRV, cardiovascular autonomic reflex test (Ewing), measurements of urinary levels of catecholamines and measurements of sweat gland dysfunction using Sudoscan.~The severity of CAN will be evaluated in T1D patients with moderate to severe OSAS (apnea hypopnea index (IAH) ≥15 / hour) compared to T1D patients with IAH <15 / hour."
74011|NCT03605316|Procedure|Deep brain stimulation (DBS)|Neurosurgical treatment by stereotactic implantation of electrodes in the brain that affects the functioning of subcortical neuronal circuits
74012|NCT03605303|Device|Test/Control|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Test/Control sequence with a 7 to 9-day washout period in between treatments
74013|NCT03605303|Device|Control/Test|Subjects that are between the ages of 18-70 years old and habitual wearers of hydrogel daily disposable contact lenses will be randomly assigned to Control/Test sequence with a 7 to 9-day washout period in between treatments
74014|NCT03605290|Diagnostic Test|REHAGAIT ANYLIZER|Gait analysis instrumentation
74015|NCT03605277|Drug|Asciminib|40 mg single dose
74016|NCT03605251|Drug|TAS5315 low dose|Oral administration for 12 or 36 weeks
74017|NCT03605251|Drug|TAS5315 high dose|Oral administration for 12 or 36 weeks
74018|NCT03605251|Drug|Placebos|Oral administration for 12 weeks (At Week 12, participants in the placebo group will be assigned to TAS5315 low or high dose group)
74019|NCT03605238|Biological|Corticosteroids & tanCART19/20|Twelve days of high-dose IV methylprednisolone (1000mg×3 days, 500mg×3 days, 240mg×3 days, 120mg×3 days) before anti-CD19/20 CAR T cells infusion. The dose is 1E5~2E6 anti-CD19/20-CAR positive T cells. The cells infusion process may last for 30 min.
74020|NCT03605225|Device|mobile cellphone application test|Placement of cellphone on the patient´s hand and recording accelerometric data during elicited muscular contractions.
74021|NCT03605212|Drug|Febuxostat|
74022|NCT03605199|Drug|Denosumab|Denosumab will be given in a dose of 120mg subcutaneously (SC) on day 1 of every 4 week cycle with a loading dose of 120mg SC on days 8 and 15 of the first cycle.
74023|NCT03605186|Other|Chamomile oral cryotherapy|The infusion of chamomile will be prepared in the clinic with 400 mL of distilled water and 10 g of chamomile flowers (Chamomile classic infusion, Royal Herbs). Patients are asked to swish the chamomile ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
74024|NCT03605186|Other|Oral cryotherapy|The plain icecubes will be prepared in the clinic with 400 mL of distilled water. Patients are asked to swish the ice cubes around their oral cavities starting 5 minutes before chemotherapy infusion, continuing 30 minutes throughout the session and for additional 35 minutes after completion of intravenous chemotherapy session.
74025|NCT03605173|Diagnostic Test|free vitamin d test|using the patient's blood serum ELISA test for free vitamin d can be performed
74026|NCT03605173|Diagnostic Test|total vitamin d|routinely measured from serum
74027|NCT03605160|Procedure|traditional polish|After phacoemulsification and I/A, switch to polish mode and use I/A instrument to remove the RLFs visible on the posterior capsule before injection of viscoelastic agent. IOP: 55mmHg; Aspiration: 0-10; Vacuum: 0-20. The standard for stopping polish is that the RLFs can no longer be absorbed by the side holes on the I/A instrument in this mode, or there are no discernible RLFs on the posterior capsule. If RLFs on the posterior capsular are found after IOL implantation, polish to remove them after the removal of viscoelastic agents.
74028|NCT03605160|Procedure|fluid-jet|After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule.
74029|NCT03605147|Dietary Supplement|CaHMB|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by abdominal CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
74069|NCT03604848|Drug|NGS-guided regimen: Regimen C|"Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, ＞70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, ＞70kg 1200 mg daily;"
74030|NCT03605147|Dietary Supplement|Placebo|Supplements, labeled only with the identification number of the participant, will be provided to the participants in the Department of Gastroenterology of Zhongshan Hospital. After 4 weeks, subjects will receive medical center visit to evaluate the compliance and side effects. After 12 weeks, changes in body composition will be assessed by CT. An online application will be used to monitor the compliance everyday.Their diets will be recorded by a nutritionist. Blood will be collected pre- and post treatment. Extensive laboratory tests will be performed.
74031|NCT03605134|Diagnostic Test|level of cardiac troponin|blood test
74032|NCT03605134|Diagnostic Test|diastolic function assessment|transthoracic echocardiography
74033|NCT03605121|Procedure|cardiac surgery|The relationship between body mass index or waist circumference and clinical outcome in patients undergoing cardiac surgery will be assessed
74034|NCT03605108|Dietary Supplement|Probiotic|"• Probiotic fomula per capsule:~2 Billion CFUs~HU36 - 30 mg~HU58 - 20 mg~Bacillus clausii -25 mg~Bacillus coagulans 10B - 35 mg~Prepro - 22 mg. The prebiotic that is to be used in the proprietary blend is a vegetable grade cellulose."
74035|NCT03605108|Other|Placebo|Rice flour only
74036|NCT03605095|Drug|nitroglycerin|Vasodilatator solution is dropped on the gingiva.
74037|NCT03605082|Drug|UCB0107|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
74038|NCT03605082|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
74039|NCT03605069|Drug|QR-313|QR-313 will be applied topically three times a week for 8 weeks of treatment.
74040|NCT03605069|Drug|Placebo|Placebo will be applied topically three times a week for 8 weeks of treatment.
74041|NCT03605056|Drug|chidamide|20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
74042|NCT03605056|Drug|lenalidomide|25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
74043|NCT03605056|Drug|dexamethasone|40mg weekly, will be administered orally or intravenously
74044|NCT03605043|Other|Blood pressure management in the HIV program|Integrated care for hypertension and HIV in the HIV program
74045|NCT03605030|Device|Novel Lead Based Armboard|Novel Lead Based Armboard
74046|NCT03605030|Device|Standard Armboard|Standard Armboard (without lead)
74047|NCT03605017|Behavioral|Virtual Reality Executive Function Training (VREFT)|
74048|NCT03604991|Drug|Carboplatin|Given IV
74049|NCT03604991|Biological|Ipilimumab|Given IV
74050|NCT03604991|Biological|Nivolumab|Given IV
74051|NCT03604991|Drug|Paclitaxel|Given IV
74052|NCT03604991|Radiation|Radiation Therapy|Undergo radiation therapy
74053|NCT03604978|Biological|Ipilimumab|Given IV
74054|NCT03604978|Biological|Nivolumab|Given IV
74055|NCT03604978|Radiation|Stereotactic Radiosurgery|Undergo multi-fraction stereotactic radiosurgery
74056|NCT03604965|Drug|GP+CCRT|Patients receive Neoadjuvant gemcitabine (1000mg/m2 on day1 and day8 ) and cisplatin (80mg/m2 on day1)every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
74057|NCT03604965|Drug|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 or day2)every 21 days for three cycles during radiotherapy
74058|NCT03604952|Diagnostic Test|COPD patients|Tests performed one week before Ramadan (C), and during the second (R-2) and the fourth weeks of Ramadan (R-4)
74059|NCT03604939|Diagnostic Test|Evaluation of social, cultural and behavioral factors|Evaluation of the social, cultural and behavioral factors that impact the uptake of the NCD prevention and control services among women, using the RARE methodology
74060|NCT03604939|Diagnostic Test|Evaluation of the feasibility and acceptability of delivery of early detections services|Evaluation of the feasibility and acceptability of delivery of the NCD early detections services by the trained community health workers at home settings
74061|NCT03604913|Procedure|Aortic valve sparing operation|Aortic valve sparing instead of replacement during aortic root replacement
74062|NCT03604913|Procedure|Bentall operation|Aortic root replacement with replacement of aortic valve
74063|NCT03604887|Diagnostic Test|ultrasonography|"Ultrasound evaluation will be done with transducer abdominal probe. The amount of amniotic fluid and umbilical cord sections will be determined by evaluating the images obtained from the sagittal plane in the ultrasound evaluations in the 4 abdominal quadrants.~When the anatomical structure of the umbilical cord is considered, it is folded in amniotic fluid. The folds appear as umbilical cord rings, side-by-side at the sagittal sections.~Scoring of umbilical cord length index~1 point will be given for each quadrant where the umbilical cord was observed.~0.5 point will be given for each umbilical cord ring in one quadrant. Every quadrant will be evaluated in this manner, and the total score will be calculated."
74064|NCT03604874|Drug|Oxytocin|intravenous infusion
74065|NCT03604861|Other|Not applicable - no defined intervention|Participants who received at least one injection of RBP-6000 or placebo and either withdrew from or completed the Phase III clinical program which included studies NCT02357901 (RB-US-13-0001) and NCT02510014 (RB-US-13-0003) were eligible for the RECOVER Study.
74066|NCT03604848|Drug|WHO-approved MDR-TB regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, ＞70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, ＞70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily.
74067|NCT03604848|Drug|NGS-guided regimen: Regimen A|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, ＞70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, ＞70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily.
74068|NCT03604848|Drug|NGS-guided regimen: Regimen B|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, ＞70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, ＞70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily.
74071|NCT03604822|Procedure|Music therapy|ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.
74072|NCT03604809|Other|OT Guided Cognitive Interventions|"RASS is defined as the level of sedation and agitation of a patient. Cognitive interventions are evidence based strategies that enhance the cognition of patients and include memory training using visual imagery; metacognitive training using self-awareness and self-regulation approaches for recovery of executive functioning; and neuropsychological rehabilitation to help improve cognitive and functional deficits. Interventions will be adjusted according to the RASS score. Cognitive interventions include discussion of patient status and education of family around reorientation, cognitive screening and graded exercises according to patient ability. The deepest levels of sedation and highest levels of agitation will be included in the intervention arm.~Interventions will be provided by the Occupational Therapist; Monday to Friday, BID, 20 minutes per session, for the duration of ICU admission."
74073|NCT03604796|Drug|Rectal Solution|Rectal acetaminophen at 15 mg/kg x 4/day for three days
74074|NCT03604796|Drug|Intravenous Infusion|Loading dose of 15 mg/kg IV acetaminophen followed by a continuous infusion at a rate of 2.5 mg/kg/hr for 72 hours
74075|NCT03604783|Drug|TP-1287|TP-1287 by oral administration
74076|NCT03604770|Other|Survey & Food Diary|Patients will be provided with a 8 question patient survey to complete and return, as well as a food diary that they will complete over a 3 day period to assess their average caloric intake.
74077|NCT03604757|Drug|68Ga-PSMA-617 PET/CT|PET/CT Imaging with 68Ga-PSMA-617 injection
74078|NCT03604757|Drug|68Ga-RM2 PET/CT|PET/CT Imaging with 68Ga-RM2 injection
74079|NCT03604744|Drug|LSD|LSD 0.1 mg per os, single dose
74080|NCT03604744|Drug|LSD|LSD 0.2 mg per os, single dose
74081|NCT03604744|Drug|Psilocybin|Psilocybin 15 mg per os, single dose
74082|NCT03604744|Drug|Psilocybin|Psilocybin 30 mg per os, single dose
74083|NCT03604731|Device|cytokine adsorbtion during extracorporeal circulation|preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
74084|NCT03604718|Biological|Beltavac® Polymerized with Alternaria alternata|Adminstration of Beltavac® Polymerized with Alternaria alternata according to the routine clinical practice
74085|NCT03604705|Drug|APX001|APX001
74086|NCT03604692|Drug|SNDX-6352|SNDX-6352 is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). It has shown evidence of anti-tumor and anti-metastatic efficacy through its ability to limit the number and activity of immunosuppressive cells such as tumor associated macrophages.
74087|NCT03604679|Drug|SyB C-0501|Specified dose on specified days
74088|NCT03604666|Other|Health care process with Nurse Navigator|"A Nurse Navigator will:~Be present at the announcement consultation~Give information on the outpatient circuit~Offer assistance for patients over 75 years~Complete onco-geriatric orientation questionnaires~Take care of patients on the ambulatory circuit"
74089|NCT03604653|Device|HIPEC|Heated chemotherapy is pumped into the abdomen and circulated for 90 minutes
74090|NCT03604653|Drug|Mitomycin c|MMC 30mg@ T0, 10mg@T45 min
74091|NCT03604653|Drug|CDDP 50|50mg/m2@T0
74092|NCT03604653|Drug|CDDP 75|75mg/m2@T0
74093|NCT03604653|Drug|Doxorubicin|15mg/m2@T0
74094|NCT03604640|Other|Physical Training|Physical exercise program and health education
74095|NCT03604627|Other|Coronal calcium score measurement|"A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. . Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research."
74096|NCT03604614|Drug|Hyperthermic Intraperitoneal Chemotherapy|The investigators use Paclitaxel as peritoneal hyperthermic perfusion chemotherapy drugs，75mg/m2 for the first time，50mg/m2 for the second time and third time.The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
74097|NCT03604614|Drug|Without Hyperthermic Intraperitoneal Chemotherapy|The chemotherapy is SOX(Tiggio d1-d14 bid po and Oxaliplatin 130mg/m2 ivd d1 qd).The Tiggio dosage depends on the patient's body surface area, body surface area <1.25m2 40mg/time, 1.25-1.50m2 50mg/time, >1.50m2 60mg/time.
74098|NCT03604601|Procedure|salvage surgery|Salvage surgery hopes to control the recurrence of larynx, pharynx, fistula and neck tumor and improve the quality of life and survival rate
74099|NCT03604588|Diagnostic Test|HPV OncoTect™|"Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results."
74100|NCT03604575|Drug|Insulin Lispro|
74101|NCT03604575|Drug|Humalog®|
74102|NCT03604549|Drug|Lipiodol UF|Up to 10cc of Lipiodol UF will be infused via intrauterine catheter
74103|NCT03604549|Drug|Saline|Up to 10cc of saline will be infused via intrauterine catheter
74104|NCT03604523|Device|Dilation by Balloon|Esophageal dilation by balloon device.
74105|NCT03604523|Device|Dilation by Semi-rigid Savary|Esophageal dilation by semi-rigid savary device
74106|NCT03604510|Procedure|Electroencephalographic recordings|24 hours of electroencephalographic recordings (EEG-Holter) of prefrontal activity of Tourette's syndrome (TS) patients in ecological conditions.
74107|NCT03604497|Behavioral|beacon alerts|alerts via unidirectional communication from beacons to smartphones when smartphones are approaching pedestrian crossing at activated intersection
74108|NCT03604497|Behavioral|no alerts retention|no alerts will appear, but we will measure retention of behavior learned during the active intervention stage
74109|NCT03604484|Procedure|Tricuspid annuloplasty|Tricuspid annuloplasty
74110|NCT03604471|Drug|Atorvastatin|Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
74111|NCT03604445|Drug|BI 905677|Solution for infusion
74112|NCT03604419|Drug|PB-119 100 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
74113|NCT03604419|Drug|PB-119 150 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
74114|NCT03604419|Drug|PB-119 200 μg+ Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
74115|NCT03604419|Drug|PB-119 placebo + Glucophage®|Each patient will subsequently be randomized within the designated cohort to active drug or placebo
74116|NCT03604406|Biological|Varicella Zoster Vaccine|live-attenuated vaccine to prevent herpes zoster
74117|NCT03604406|Other|Placebo Injection|Saline solution injection
74118|NCT03604393|Behavioral|Practice facilitation|For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
74119|NCT03604380|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
74120|NCT03604380|Other|Active Comparator|Commercially available computerized training requiring a total maximum of 36 treatment sessions, up to 7 sessions per week, 36 minutes per session.
74121|NCT03604367|Device|GAITRite assessment|The fMRI Bipedal Paradigm will allow investigators to study the effects treadmill-assisted gait training have on cortical control of bipedal movement in chronic stroke patients.
74122|NCT03604354|Drug|Tapentadol 100 MG Oral Tablet|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions tapentadol 100mg oral tablets.
74123|NCT03604354|Drug|Pregabalin 150mg|This arm will receive drugs one hour before undergoing unilateral total knee arthroplasty. Interventions pregabalin 150mg oral tablets.
74124|NCT03604341|Drug|Dronabinol 5mg Cap|Subjects randomized to Dronabinol 5mg Cap and ibuprofen 800mg for pain
74125|NCT03604341|Other|Placebo|Subjects randomized to placebo and ibuprofen 800mg for pain
74126|NCT03604328|Drug|PA5108|single ocular implant, administered on day 1
74127|NCT03604315|Procedure|Computed Tomography|Undergo FDG PET/CT
74128|NCT03604315|Procedure|Computed Tomography|Undergo [18F]FTT PET/CT
74129|NCT03604315|Radiation|Fludeoxyglucose F-18|Given IV
74130|NCT03604315|Radiation|Fluorine F 18 Fluorthanatrace|Given IV
74131|NCT03604315|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
74132|NCT03604315|Procedure|Positron Emission Tomography|Undergo [18F]FTT PET/CT
74133|NCT03604302|Device|fMRI Paradigms|T2*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR=2500ms, TE=30ms, FA=80°, slice thickness=4 mm, FOV= 240mm2, matrix=64×64) covering the whole brain.
74134|NCT03604289|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
74135|NCT03604289|Drug|Saline|Saline will be used as the placebo comparator
74136|NCT03604263|Device|ArcticLine Cardiac Cryoablation Catheter|Cryoablation
74137|NCT03604250|Dietary Supplement|Lifestyle plus prebiotic supplement|Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
74138|NCT03604237|Diagnostic Test|Targeted group|Forceps biopsy is taken after surface evaluation of the large colorectal tumors.
74139|NCT03604224|Drug|Canagliflozin 300 mg|Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
74140|NCT03604211|Radiation|Cyberknife Radiation Therapy|Stereotactic Radiotherapy of lymphnode recurrence after prostatectomy +/- salvage radiotherapy
74141|NCT03604198|Drug|relacorilant|CORT125134 is supplied as capsules for oral dosing.
74142|NCT03604185|Behavioral|Choir Singing|A weekly 2-hour group choral session over fourteen weeks. Plus an optional weekly 1-hour online musical and vocal training session.
74143|NCT03604185|Behavioral|Music Appreciation|A fourteen week course which will emphasize analytic listening to musical excerpts, and will match the choir class in terms of duration, homework demands, and instructor.
74144|NCT03604172|Behavioral|Cognitive behavioral therapy|The cognitive behavioral therapy intervention will consist of weekly, 50-minute individual meetings for 16 weeks with a clinician trained in cognitive behavioral therapy for binge eating disorder.
74145|NCT03604172|Behavioral|Waitlist|The waitlist group will have a 16-week waitlist period. After the waitlist period, they will be offered cognitive behavioral therapy.
74146|NCT03604159|Drug|Buprenorphine Extended Release|XRB is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each dose is provided in a prefilled syringe with a 19 gauge 5/8-inch needle.
74439|NCT03602157|Drug|Fludarabine|30 mg/m^2/day Fludarabine for 3 days for lymphodepletion prior to cell infusion
129562|NCT03175757|Dietary Supplement|Placebo|Placebo
74147|NCT03604159|Drug|Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)|SLB is administered sublingually or buccally as a single daily dose. Medication should be prescribed in consideration of the frequency of visits. Provision of multiple refills is not advised in early treatment or without appropriate follow-up visits. After treatment induction and stabilization, the maintenance dose of SLB is generally in the range of 4mg/1mg buprenorphine/naloxone to 24mg/6mg buprenorphine/naloxone per day depending on the individual patient and clinical response.
74148|NCT03604146|Behavioral|Medical quality control intervention strategy|Training and education for diagnosis, treatment and management of COPD for doctors and nurses; Regular inspection and supervision of medical quality
74149|NCT03604120|Device|Preoxygenation with high flow therapy by nasal cannula|Preoxygenation during 4 minutes with High Flow Nasal Cannula (60l/min FiO2 = 1) before fiber-optic or laryngoscopic intubation. The device will be maintained in place throughout the intubation procedure in order to achieve oxygenation.
74150|NCT03604120|Device|Preoxygenation by standard Facial mask|"For Fiber-optic intubation: patients will receive a 4 minutes FIBROXY facial mask preoxygenation with FiO2=100%. The FIBROXY facial mask will be maintained in place during the intubation procedure.~For Laryngoscopic intubation: patients will receive a 4 minutes standard facial mask preoxygenation with FiO2=100%. The standard facial mask will be removed after crash induction to proceed to intubation."
74151|NCT03604107|Genetic|Preimplantation Genetic Testing-Aneuploidy|trophectoderm biopsy samples will be analyzed for karyotype after clinical outcome is determined
74152|NCT03604094|Procedure|Ultrasonographic evaluation|Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
74153|NCT03604081|Other|CIMT|Intervention group will receive one hour of intense massed practice of lower extremity either in the form of shaping or task practice.
74154|NCT03604081|Other|Conventional Physical Therapy|1 hour as per current standard of care that follows stroke clinical practice guideline.
74155|NCT03604068|Device|RecoveryRx|A pulsed shortwave therapy medical device
74156|NCT03604068|Device|Sham RecoveryRx|A sham pulsed shortwave therapy medical device
74157|NCT03604055|Procedure|Endobronchial hamartomas treatment|General anesthesia was administered by an intravenous anesthesia technique. Patients were intubated with a rigid bronchoscope. Debulking procedures were performed by mechanical tumor resection (MTR) using the tip of the rigid bronchoscope, rigid pliers or argon plasma coagulation assisted MTR or cryorecanalization or electrocautery - snare probe. An innovation of our study was that cryotherapy was performed in the regions where the lesions originated after debulking
74158|NCT03604042|Combination Product|Protein fortifier|Protein Fortifier to be added to Fortified human milk according to feeding regimen
74159|NCT03604029|Device|Near Infrared Spectroscopy|Near Infrared Spectroscopy (NIRS) sensors are applied to injured leg compartments and a control compartment to continuously measure tissue oxygenation.
74160|NCT03604016|Drug|Besifovir dipivoxil|Besifovir dipivoxil 150 mg
74161|NCT03604016|Drug|L-carnitine|Besifovir dipivoxil 150 mg
74162|NCT03604016|Drug|Tenofovir Alafenamide|Tenofovir Alafenamide 25mg
74163|NCT03604003|Drug|potassium losartan|treated with bedtime or awakening doses of potassium losartan
74164|NCT03603990|Procedure|Vitrectomy|Standard pars plana vitrectomy
74165|NCT03603990|Procedure|Usual care|"In the complete absence of guidelines, usual care is given according to the investigator choice after discussion with the patient. It could include continuation of the same anti-VEGF drug, or switch to another approved anti-VEGF drug. The frequency of injections is also left to the appreciation of the investigator (a maximum of one injection per month, ie a maximum of 24 injections during the study). An additional macular photocoagulation is possible during the follow up.~After First Six Months : Therapies for DME may be given at the discretion of the investigator.~After six months of conventional treatment, the investigator may propose an implant of dexamethasone or even propose a vitrectomy if the results of surgery on the other eye seem encouraging."
74166|NCT03603977|Drug|Lpv/r+3TC|It is a simplified therapy regimen study of lopinavir and ritonavir combined with lamivudine for HIV-1 infected patients in the real world of China.
74167|NCT03603964|Drug|Guadecitabine|Guadecitabine
74168|NCT03603951|Drug|SHR2554|SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.
74169|NCT03603938|Drug|potassium losartan|treated with bedtime or awakening doses of potassium losartan
74170|NCT03603925|Diagnostic Test|Positron Emission Test / Magnetic Resonance (PET/MR)|The Philips Ingenuity PET/MR is used for research scanning. Patients receiving a clinically indicated PET/CT, will be approached to be included in this study. There is no special preparation other than that needed for the prerequisite PET/CT scanning. At the completion of the PET/CT scanning, the subject will be taken to the PET/MR scanner, which is in close in proximity, for research scanning. The research scanning would take up to one hour or as tolerated.
74171|NCT03603925|Diagnostic Test|Positron Emission Test / Computed Tomography (PET/CT)|Patients will receive PET / CT imaging for the detection of cancer or other clinically indicated anomalies. The completed study visit is expected to take approximately 2 hours and not longer than 3 hours.
74172|NCT03603912|Drug|Metformin|Metformin ER 500 mg daily, titrated at 1 month intervals to 500 mg twice daily, then 750 mg twice daily, as tolerated, for 2 years.
74173|NCT03603912|Behavioral|Lifestyle/Risk Factor Modification|Diet/nutrition counseling and exercise prescription with follow-up visits, sleep apnea screening and treatment if detected, optimization of guideline-directed medical therapies for hypertension, coronary artery disease (CAD), hyperlipidemia and heart failure (HF).
74174|NCT03603899|Drug|Hp 129Xenon|129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
74175|NCT03603886|Behavioral|Telemedicine Pain Management Intervention (immediate group)|Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management.
74247|NCT03603483|Procedure|procedure|"Patients of sever aortic stenosis 1: increase the diameter of aortic anulus by prosthetic patch or pericardial patch.~Patients of sever aortic stenosis 1:only conventional aortic valve prosthesis will be used"
74176|NCT03603886|Behavioral|Telemedicine Pain Management Intervention (waitlist group, intervention administered following 4-week waitlist period)|"Four week waitlist period during which participants receive treatment as usual. Following the waitlist period, participants will receive the telemedicine pain management intervention:~Four weekly telemedicine pain management sessions with a trained provider. Intervention will be delivered via video conferencing platform, and each session will last between 30 and 45 minutes. Intervention topics will include: pain psychoeducation, pain coping tools, pain communication, and pain-related stress management."
74177|NCT03603860|Device|Non-invasive monitoring|Comparing blood pressure measurement using the Biobeat non-invasive monitor to arterial line
74178|NCT03603834|Drug|mFOLFOXIRI|"mFOLFOXIRI consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours~Leucovorin, 400 mg/m2, IV over 2 hours~Irinotecan, 150 mg/m2, IV over 90 minutes~5 FU, 400 mg/m2, IV bolus~5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles"
74179|NCT03603821|Diagnostic Test|CLINICAL ASSESMENT|IPSS questionnaire, uroflowmetry, prostate and bladder ultrasonography, voiding diary, medical interview
74180|NCT03603808|Device|Electroporation|Undergo electroporation
74181|NCT03603808|Biological|HPV DNA Plasmids Therapeutic Vaccine VGX-3100|Given IM
74182|NCT03603808|Other|Laboratory Biomarker Analysis|Correlative studies
74183|NCT03603795|Drug|Eltrombopag|Eltrombopag concomitant with induction chemotherapy in patient with AML
74184|NCT03603795|Drug|Placebo|Placebo concomitant with induction chemotherapy patients with AML
74185|NCT03603782|Dietary Supplement|2.5% protein|2.5%
74186|NCT03603782|Dietary Supplement|protein 5%|5%
74187|NCT03603782|Dietary Supplement|protein 10%|10%
74188|NCT03603782|Dietary Supplement|protein 15%|15%
74189|NCT03603782|Dietary Supplement|A2: Peptamen 1.5 Vanilla without Breakfast|Peptamen withoug breakfast
74190|NCT03603782|Dietary Supplement|B2: only breakfast (no product)|only breakfast
74191|NCT03603782|Dietary Supplement|C2: 5% protein with breakfast|C2: 5% protein consumed with breakfast
74192|NCT03603782|Dietary Supplement|D2: 5% protein 30 min before breakfast|D2: 5% protein consumed 30 min before breakfast
74193|NCT03603769|Dietary Supplement|Food supplement capsules containing Salmon-Polar Lipids|Postprandial decreased Platelet activation/aggregation in subjects, after the food supplement capsule consumption
74194|NCT03603769|Dietary Supplement|Placebo food supplement capsule|Postprandial unaffected platelet activation/aggregation in subjects, after the food supplement capsule consumption
74195|NCT03603756|Drug|SHR-1210|a novel anti-PD-1 antibody
74196|NCT03603756|Drug|Apatinib|a VEGFR-2 tyrosine kinase inhibitor
74197|NCT03603756|Drug|Irinotecan Injection|cytotoxic agent that binds to topoisomerase I
74198|NCT03603756|Drug|Paclitaxel liposome|cytotoxic agent that prevent depolymerization of cellular microtubules
74199|NCT03603756|Drug|Nedaplatin|cytotoxic agent that cross-links and denatures strands of DNA
74200|NCT03603743|Behavioral|exercise training in heart failure with HIIT|to compare MICT vs HIIT 5 days/week during 4 weeks in a Cardiovascular Centre.
74201|NCT03603730|Device|taVNS|Active or inactive taVNS delivered to the external ear at a moderate, non-painful level.
74202|NCT03603717|Behavioral|Cognitive Behavioral Therapy for Insomnia|The intervention will consist of a standard, structured, multi-component intervention for insomnia that includes sleep education, sleep hygiene, sleep restriction, stimulus control, and cognitive therapy.
74203|NCT03603717|Behavioral|Sleep Hygiene|The intervention will include basic psychoeducation about sleep, discussion of sleep hygiene factors that disrupt and improve sleep, setting sleep hygiene goals, and developing action steps to achieve those goals.
74204|NCT03603704|Drug|LY3209590|Administered SC
74205|NCT03603704|Drug|Placebo|Administered SC
74206|NCT03603691|Diagnostic Test|Modified Manual Muscle Test|Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
74207|NCT03603691|Diagnostic Test|BMRC manual muscle test|muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
74208|NCT03603691|Diagnostic Test|MicroFET2 handhold dynamometer|MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
74209|NCT03603691|Diagnostic Test|Modified Tardieu Scale|Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
74210|NCT03603691|Diagnostic Test|Fatigue Scale for Motor and Cognitive Functions|Measures cognitive and motor fatigue for people with MS
74211|NCT03603691|Diagnostic Test|numeric rating scale Fatigue|visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
74212|NCT03603678|Drug|BAY2253651|100 µg (500 µg/ml * 200 µl) BAY2253651 intranasally
74213|NCT03603678|Drug|Placebo|Matching Placebo dosing
74214|NCT03603665|Biological|NTM-1633|NTM-1633 is an equimolar mixture of three IgG1 monoclonal antibodies (mAb), referred to as XE02, XE06, and XE17 which bind to non-overlapping epitopes on Botulinum Neurotoxin (BoNT/E). Administered as a single intravenous infusion of NTM-1633 over one hour.
74215|NCT03603665|Other|Placebo|0.9% Sodium Chloride Injection administered as a single intravenous infusion over one hour.
74216|NCT03603652|Device|Microwave Ablation|Ablations will be performed under general anesthesia via transbronchial approach by an interventional pulmonologist or thoracic surgeon. Prior to the ablation, the treating physician will perform an endobronchial ultrasound to confirm disease staging.
74217|NCT03603639|Drug|Placebo|Participants will receive E2730-matched placebo capsule, orally.
74218|NCT03603639|Drug|E2730|Participants will receive E2730 capsule, orally.
74219|NCT03603626|Drug|Pregabalin 150mg|Preemptive pregabalin 150 mg administered 1 hour before surgery
74220|NCT03603626|Drug|Placebo oral capsule|Placebo administered 1 hour before surgery
74248|NCT03603470|Other|EOS imagery|Whole body EOS imaging in seated and standing position
74249|NCT03603444|Other|No intervention are provided|
74250|NCT03603431|Drug|MRG-110|Single ascending doses of MRG-110
74251|NCT03603431|Drug|Placebo|Single doses of placebo
74221|NCT03603613|Behavioral|YRI|The YRI is designed to assist youth facing complex problems using evidence-based treatments that have been tested and shown to work well in other settings and cultures. The YRI has three specific goals: 1) develop emotion regulation skills for healthy coping; 2) develop problem-solving skills to assist with achieving goals, and; 3) improve interpersonal skills to enable healthy relationships and effective communication. It integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.
74222|NCT03603613|Behavioral|EPP|The youth capacity development component of GIZ's EPP includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
74223|NCT03603600|Device|enVista MX60E|enVista MX60E monofocal IOL
74224|NCT03603600|Device|enVista MX60EF|enVista MX60EF (trifocal) multifocal IOL (MIOL)
74225|NCT03603587|Procedure|biopsy|Biopsy 4 to 5 mm from the distal part of the tips of the excision pieces. Three biopsies of 3 mm, made with punch, occipital hair zone (ZT) A completely painless sample, using a swab (soaked with a buffer solution) on the scalp of the ZH and ZT zone.
74226|NCT03603587|Diagnostic Test|blood sample|Blood sample will be collected for performed for HIV serology, B and C hepatitis.
74227|NCT03603587|Diagnostic Test|questionnaire on sun exposure|Questionnaire on sun exposure will be completed by patients.
74228|NCT03603587|Diagnostic Test|examination of the scalp|A complete examination of the scalp will be completed by dermatologist.
74229|NCT03603587|Diagnostic Test|Norwood scale|Norwood scale measure the evolution of baldness. It will be completed by dermatologist.
74230|NCT03603587|Diagnostic Test|questionnaire of clinicals signs|Questionnaire of clinicals signs will be completed by dermatologist and patient.
74231|NCT03603587|Diagnostic Test|scinexa score|It's a assessment score of skin aging. It will be completed by dermatologist.
74232|NCT03603587|Diagnostic Test|questionnaire of the history of the hair loss|Questionnaire of the history of the hair loss will be completed by dermatologist and patient.
74233|NCT03603574|Device|EWA through the needle|In the EWA-N group, 5 mL of normal saline are injected through the epidural needle after the occurrence of loss-of-resistance (LOR). The needle is connected to the pressure transducer. A satisfactory endpoint is defined as the presence of waveforms synchronized with arterial pulsations. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of normal saline through the epidural needle and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection, the operator removes the needle and reattempts the epidural block at a different intervertebral level. A maximum of 3 levels is permitted: if waveforms are still absent at the third level, the operator simply accepts LOR as the technical endpoint.
74234|NCT03603574|Device|EWA through the catheter|In the EWA-C group, the epidural catheter is advanced 5 cm beyond the needle tip after the occurrence of LOR. Subsequently, the operator injects 5 mL of normal saline through the catheter and the latter is connected to the pressure transducer via the sterile, rigid extension tubing. A satisfactory endpoint is defined as the presence of waveforms. In the absence of pulsatile waveforms, the operator injects an additional 2.5 mL-bolus of saline through the catheter and reconnects the latter to the pressure transducer. If no waveforms are detected after the second injection are still absent at the third level, the operator simply accepts this position for catheter placement (intent-to-treat analysis).
74235|NCT03603561|Device|cTBS|In the cTBS arm, the patients will receive 5 daily session cTBS (5 times uninterrupted train of 900 pulses) separated by a 15 min interval. Patients will be treated with in total 20 cTBS sessions over the right dorsolateral prefrontal cortex, spread over 4 days. A stimulation intensity of 100 % of the resting motor threshold (rMT) of the right abductor pollicis brevis muscle will be used.
74236|NCT03603561|Device|Sham cTBS|The sham coil has been specifically developed to mimic the real one but is not associated with a stimulus sensation compared to the coil delivering real stimulation cTBS.
74237|NCT03603548|Drug|Envarsus|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
74238|NCT03603548|Drug|Advagraf|Patients after liver transplantation initially treated with traditional Tacrolimus variant- Prograf, switched on day 10 after OLTx on prolonged released Tacrolimus variant in 1:1 ratio ( Advagraf vs. Envarsus)
74239|NCT03603535|Device|sensiTVT|The study is designed as a prospective single arm study. All women with an indication for suburethral tape placement for therapy of SUI and meeting the inclusion criteria will be offered study participation to record the objective outcome after one year.
74240|NCT03603522|Dietary Supplement|BioGaia-DSM17938|2mL per day (1x10^9 CFU) per day taken orally for 28 days
74241|NCT03603522|Other|Placebo Comparator: Placebo Control|2mL per day of placebo formulation taken orally for 28 days
74242|NCT03603509|Drug|Fluad Vaccine|110 subjects will be randomized to receive the high dose influenza vaccine, Fluad
74243|NCT03603509|Drug|Fluzone High-Dose|110 subjects will be randomized to receive the high dose influenza vaccine, Fluzone High-Dose
74244|NCT03603496|Behavioral|Personalized Tobacco Care Management|PTCM will provide sustained care after discharge by offering (1) 8 weeks of nicotine replacement therapy at no cost provided at hospital discharge and (2) up to 7 proactive contacts over 3 months delivered by automated IVR call, supplemented by text messaging and email (patient choice). At each contact the patient is offered a return call from the hospital-based tobacco coach who offer counseling, medication advice, and coordination of care with the patient's outpatient health care team.
74245|NCT03603496|Behavioral|eReferral to State Tobacco Quitline|Referral from hospital to the state Quitline will be made by the research team on behalf of each enrolled patient. Feedback from the Quitline will be included in the patient's medical chart.
74246|NCT03603496|Drug|Nicotine replacement therapy|Up to 8 weeks of nicotine replacement therapy provided at no cost to the patient.
74254|NCT03603418|Drug|Dexamethasone Sodium Phosphate|Dexamethasone is a synthetic glucocorticoid that is commonly used in human medical practice as potent anti-inflammatory, immunosuppressive and analgesic agent.
74255|NCT03603418|Other|Distilled water|Distilled water
74256|NCT03603405|Drug|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
74257|NCT03603392|Other|Physical activity program|
74258|NCT03603379|Drug|C225-ILs-dox|C225-ILs-dox will be administered at a dose of 50 mg/m2. i.v., on day 1 of each cycle, cycle length is 28 days. In total, 4 cycles are planned to be applied.
74260|NCT03603353|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|"Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling.~Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit."
74261|NCT03603353|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
74262|NCT03603340|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
74263|NCT03603340|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
74264|NCT03603327|Drug|Direct acting anti-viral agents|Standard of care for Hepatitis C treatment
74265|NCT03603314|Drug|SENS-401|29 mg dose group: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
74266|NCT03603314|Other|Placebo Oral Tablet|placebo, oral route, by mouth, twice a day, during 4 weeks
74267|NCT03603314|Drug|SENS-401|43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks
74268|NCT03603288|Drug|idebenone 150 mg film-coated tablets|900 mg idebenone/day
74269|NCT03603275|Drug|Antihemophilic Factor (Kovaltry, BAY81-8973)|Kovaltry prescribed by the treating Physician
74270|NCT03603262|Drug|SH-1028|Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (100mg,200mg,300mg,400mg) of SH-1028.
74271|NCT03603249|Drug|Trimetazidine|Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in >80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several—not yet fully understood—mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).
74272|NCT03603236|Diagnostic Test|preeclampsia|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
74273|NCT03603236|Diagnostic Test|control|liver function tests, kidney function tests and platelets measures the ratio of protein to creatinine
74274|NCT03603223|Biological|Pembrolizumab|Given IV
74275|NCT03603210|Device|Drug coated balloon angioplasty|Drug coated balloons are semi compliant percutaneous coronary angioplasty balloons coated with a chemotherapeutic drug such as Paclitaxel used with an excipient which allows rapid absorption to vessel wall upon balloon expansion for 30-60s. This allows coronary angioplasty without any permanent or semi- permanent stent or scaffold provided there are no vessel threatening dissections or significant acute recoil.
74276|NCT03603197|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
74277|NCT03603197|Drug|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
74278|NCT03603184|Drug|Atezolizumab|Atezolizumab will be administered as I.V. infusion at a fixed dose of 1200 mg, every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
74279|NCT03603184|Drug|Placebos|Placebo will be administered as I.V. infusion every 21 days until objective radiological disease progression as assessed by the investigator if they do not meet any other discontinuation criteria (patient refusal, toxicity).
74280|NCT03603184|Drug|Paclitaxel|Paclitaxel 175 mg/m2 will be administered every 21 days for 6-8 cycles or until progression of disease.
74281|NCT03603184|Drug|Carboplatin|Carboplatin AUC 5 or AUC 6 will be administered every 21 days for 6-8 cycles or until progression of disease.
74282|NCT03603171|Diagnostic Test|DM1-ActivC|A Rasch-built activity and participation scale for clinical use in myotonic dystrophy type 1 (DM1)
74283|NCT03603171|Diagnostic Test|R-PAct|A Rasch-built Pompe-specific activity scale.
74284|NCT03603171|Diagnostic Test|Beck depression inventory|A self-reported depression inventory administered verbally or self administered.
131190|NCT03164109|Drug|Placebo|Infused IV over 15 minutes
74285|NCT03603171|Diagnostic Test|McGill pain questionnaire|The short form of the MPQ, used to evaluate the qualitative aspect of pain and categorized in three dimensions of pain experience: sensory qualities, affective qualities and overall intensity.
74286|NCT03603171|Diagnostic Test|Brief Pain Inventory Short-Form|A 9 item self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning
74287|NCT03603171|Diagnostic Test|Fatigue and Daytime Sleepiness Scale|A Rasch-built combined fatigue and daytime sleepiness scale (FDSS) specifically designed for patients with DM1.
74288|NCT03603171|Diagnostic Test|Myotonia Behaviour scale|It consists of six framed sentences, which most closely describe the impact of the stiffness on everyday life
74289|NCT03603171|Diagnostic Test|Hand opening time|A simple test to evaluate clinical myotonia: the patient makes a tight fist for 5 seconds, then rapidly open them and the opening time is measured.
74290|NCT03603171|Diagnostic Test|Pressure pain threshold|Thresholds for pressure pain were obtained over eight muscles on the left and right side of the body: extensor digitorum communis, deltoid, quadriceps and anterior tibialis. The average value of two measurements will be recorded.
74291|NCT03603171|Diagnostic Test|Manual muscle testing|The patient is instructed to hold the corresponding limb or appropriate body part to be tested at the end of its available range while the practitioner provides opposing manual resistance. The strength is measured by the modified-MRC scale. The average value of two mesurements is considered. The following muscles were assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and Extensors, digit flexors and extensors and thumb abductors.
74292|NCT03603171|Diagnostic Test|Quantitative muscle testing|Strength testing using sophisticated strength measuring devices during an isometric contraction. The average value of two measurements is considered; in case of difference > 10% between measurements, a third attempt is performed. The following muscles are assessed: neck flexors and extensors, hip flexors and extensors, knee flexors and extensors, shoulder abductors, elbow flexors and extensors, ankle dorsiflexors and plantar flexors, wrist flexors and extensors and digit flexors.
74293|NCT03603171|Diagnostic Test|Scale for Assessment and Rating of Ataxia|SARA is a clinical scale which assesses a range of different impairments in cerebellar ataxia.
74294|NCT03603171|Diagnostic Test|Berg balance scale|It is a 14 item objective measure designed to assess static balance and fall risk in adult populations
74295|NCT03603171|Diagnostic Test|Quick motor function test|Assessment of proximal motor function.
74296|NCT03603171|Diagnostic Test|GSGC|GSGC score provides a detailed picture of motor function by including quantitative measures of four main motor performances (Gait, Walking, Stair, Gower's) and a qualitative global assessment of the manner to accomplish them.
74297|NCT03603171|Diagnostic Test|30 seconds sit to stand test|It is a measurement that assesses functional lower extremity strenght in older adults.
74298|NCT03603171|Diagnostic Test|Functional Index-2|Disease-specific functional outcome assessing muscle endurance. In this trial, only the part of the test for the upper extremities is used.
74299|NCT03603171|Diagnostic Test|Six minute walking test|It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.
74300|NCT03603171|Diagnostic Test|Myotonia (from Individualised Neuromuscular Quality of Life Questionnaire)|A subscale derived from the Individualised Neuromuscular Quality of Life Questionnaire (INQoL). 3 questions reguarding stiffness/myotonia.
74301|NCT03603145|Procedure|Immediate insertion|Immediate insertion of intrauterine contraception within 48 hours of medical abortion
74302|NCT03603132|Drug|Hetrombopag Olamine|7.5mg in each cycle
74303|NCT03603119|Drug|Midazolam|2 mg of injection midazolam intravenous 30 minutes prior to the end of surgery versus a combination of dexamethasone and ondansetron
74304|NCT03603119|Drug|Dexamethasone, ondansetron|8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
74305|NCT03603106|Drug|P03277|"Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: P03277 was administered intravenously with a flow rate of 2 mL/s."
74306|NCT03603106|Drug|Placebo|"Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s.~Part II: Placebo was administered intravenously with a flow rate of 2 mL/s."
74307|NCT03603080|Drug|Administration of weight loss drug (Metformin or Topiramate)|Patients in this arm will receive either Metformin (500 mg, twice per day) or Topiramate (50 mg, once per day) starting at 4 weeks after laparoscopic sleeve gastrectomy
74308|NCT03603067|Procedure|Ocular surgery|Different ocular surgeries (including vitreoretinal surgery, cataract surgery, anti-glaucoma surgery etc) will be performed in one eye of the patient. In monophthalmic patient group the surgery will be performed in eye with better visual acuity.
74309|NCT03603054|Other|Active neck mobilization|The subjects, receive an active neck mobilization intervention.
74310|NCT03603054|Other|Active Mobilization of the sciatic nerve|The subjects, receive an active sciatic nerve mobilization intervention.
74311|NCT03603041|Dietary Supplement|Whey protein|Participants in the protein arms will receive whey protein daily for 16 weeks.
74312|NCT03603041|Dietary Supplement|Omega-3 fatty acids|Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.
74313|NCT03603028|Device|Exergaming|Mixed Reality Gaming for Chronic Low Back Pain
74314|NCT03603015|Diagnostic Test|Penile cuff test|Comparison of invasive vs non-invasive urodynamics
74315|NCT03603002|Diagnostic Test|Post-SABR Biopsy|Post-SABR Biopsy
74316|NCT03602989|Device|AI-enabled Diabetic Retinopathy Screening Software|Color fundus images of both eyes are captured on site before being uploaded to and analyzed by the cloud-based Artificial Intelligence software
74317|NCT03602976|Drug|Ursodeoxycholic Acid|weight-based dosing
74318|NCT03602963|Device|Dexcom G5 Mobile CGM system|The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
74319|NCT03602950|Biological|PRP|autologous PRP will be injected subcutaneously before skin closure at time of elective CS
74320|NCT03602937|Dietary Supplement|Renastep|Renastep is a ready-to-use, high energy, low volume liquid renal specific feed that can be administered enterally via tube or oral consumption.
74321|NCT03602911|Drug|The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT|All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
74322|NCT03602898|Biological|Anti-Thymocyte Globulin|Given IV
74323|NCT03602898|Drug|Busulfan|Given IV or PO
74324|NCT03602898|Drug|Cyclophosphamide|Given IV
74325|NCT03602898|Drug|Cyclosporine|Given IV or PO
74326|NCT03602898|Drug|Fludarabine Phosphate|Given IV
74327|NCT03602898|Drug|Methotrexate|Given IV
74328|NCT03602898|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplantation
74329|NCT03602898|Other|Quality-of-Life Assessment|Ancillary studies
74330|NCT03602898|Other|Questionnaire Administration|Ancillary studies
74331|NCT03602898|Drug|Tacrolimus|Given IV or PO
74332|NCT03602898|Radiation|Total-Body Irradiation|Undergo TBI
74333|NCT03602885|Behavioral|Usual chemotherapy education (CE)|Standard chemo education will given per hospital guideline
74334|NCT03602885|Behavioral|Chemotherapy education intervention (CEI)|Video, booklet, and website educational materials
74335|NCT03602872|Biological|Human allogeneic mesenchymal bone marrow derived stem cells|Intraarticular administration of 20x10^6 MSCs
74336|NCT03602859|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
74337|NCT03602859|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
74338|NCT03602859|Drug|Placebo|Capsule with no active drug to mimic Niraparib, or IV fluid with no active drug to mimic TSR-042
74339|NCT03602846|Dietary Supplement|Medical Nutrition Therapy|Only given medical nutrition therapy.
74340|NCT03602846|Drug|Insulin|Prescribed with rapid acting, intermediate acting, mixed or long acting insulin.
74341|NCT03602846|Drug|Oral Antidiabetics|Prescribed with all types of oral anti-diabetics.
74342|NCT03602833|Drug|Compound 451238|Each patient will receive compound 451238 until disease progression unacceptable toxicities.
74343|NCT03602820|Biological|AAV2-hRPE65v2|
74344|NCT03602807|Device|Extracorporeal Shockwave Therapy|"2 treatments a week for 3 weeks consisting of 3000 focused shockwaves of 4Hz and 0,20mJ/mm2 applied over the kidney allograft.~Treatment is performed using the STORZ DUOLITH® SD1 T-TOP F-SW ultra"
74345|NCT03602794|Procedure|PECs Block|Regional Anaesthesia Technique ie Pectoralis Nerve Block under ultrasound guidance
74346|NCT03602794|Procedure|Local infiltration|LIA will be performed by surgeon during the operation. The upper skin flap will be raised in the standard manner for mastectomy. The lateral border of the major pectoralis muscle will then be visualised. A volume of 10 ml ropivacaine 0.5% will be delivered between the inter-fascial planes of the pectoral muscles. The lower skin flap will then be raised in the standard manner for mastectomy and the breast is raised off the pectoralis muscle exposing the serratus anterior muscle. A volume of 20 ml ropivacaine 0.5% will be delivered between the muscle planes of the serratus anterior and pectoralis minor muscles.
74347|NCT03602781|Drug|Placebo|Placebo at a dose setting of 75 mcg/kg IBW/hr
74348|NCT03602781|Drug|iNO|iNO at a dose setting of 75 mcg/kg IBW/hr
74349|NCT03602768|Behavioral|Goal Management Training|Pre-recorded videos and games combine psycho-education, targeted skills training, and mindfulness practice to teach a system where participants can take control of their attention and cognitive faculties.
74350|NCT03602768|Behavioral|Memory & Aging Program|Pre-recorded videos and activities combine psycho-education, memory strategy training, and social support to educate about normal memory change in aging, normalize the experience of participants going through it, and equip them to handle age-related memory change.
74351|NCT03602768|Behavioral|Cambridge Brain Sciences|Commercial brain training software available for subscription to the general public and for research studies.
74352|NCT03602742|Device|EZYPRO®|Wear two devices including 24-hour Holter and 14-day continuous EZYPRO® to evaluate the performance
74353|NCT03602729|Other|Breastfeeding education|Breastfeeding education in three different forms: written/verbal/video
74354|NCT03602716|Device|HD-tDCS|HD-tDCS is going to be delivered at 1.5 mA intensity for 20 minutes once a day (+15 s fade-in and fade-out); sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. HD-tDCS will be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system.
74355|NCT03602716|Device|Sham HD-tDCS|HD-tDCS is going to be used with the anode placed over the left DLPFC (F3) surrounded by four cathodes at F5, F1, FC3, and AF3 based on the 10/20 international EEG system; sessions will be performed on 10 days 5 consecutive weekdays with sustained effects at T1 and T2. This group will have a 20-min-sham stimulation.
74356|NCT03602703|Diagnostic Test|Flow cytometry and Western Blot analysis|Diagnostic tests
74357|NCT03602690|Drug|Dolutegravir + Darunavir/ritonavir + optimized NRTI|Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
74358|NCT03602677|Device|ICG fluorescence imaging|The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.
74359|NCT03602651|Other|Hamilton-anxiety scale (HAM-A)|Evolution of anxiety disorders is evaluated by the Hamilton-anxiety scale (HAM-A)
74360|NCT03602638|Drug|Sitagliptin|Sitagliptin 100mg QD
74361|NCT03602638|Drug|Acarbose|Acarbose
74362|NCT03602612|Drug|Cyclophosphamide|300 mg/m^2 IV over 30 minutes on days -5, -4, and -3
74363|NCT03602612|Drug|Fludarabine|30 mg/m^2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
74364|NCT03602612|Biological|Anti-BCMA CAR T cells|0.75x10^6 - 12.0X10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
74365|NCT03602586|Drug|Epacadostat|Given PO
74366|NCT03602586|Biological|Pembrolizumab|Given IV
74440|NCT03602144|Other|Carbohydrate|Participants will receive a carbohydrate-based breakfast beverage everyone morning for 42 days.
131300|NCT03163329|Procedure|TAVR|Transcatheter Aortic Valve Replacement
74367|NCT03602560|Drug|seladelpar 5-10 mg|Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study
74368|NCT03602560|Drug|seladelpar 10 mg|Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study
74369|NCT03602560|Drug|Placebo|One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
74370|NCT03602547|Drug|CM082 plus JS001|CM082：200mg once a day (qd) orally (taken within half an hour after breakfast). JS001 :An intravenous infusion of a solution having a concentration of 1-10 mg/ml was prepared with 0.9% physiological saline, and administered once every two weeks. Using an inline filter (0.2 or 0.22 μm), the drug was diluted with physiological saline and intravenously administered within 60 minutes.
74371|NCT03602521|Other|Interpersonal stress|"Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?"
74372|NCT03602508|Drug|mirabegron|oral
74373|NCT03602508|Drug|solifenacin|oral
74374|NCT03602508|Drug|darifenacin|oral
74375|NCT03602508|Drug|imidafenacin|oral
74376|NCT03602508|Drug|tolterodine|oral
74377|NCT03602508|Drug|oxybutynin|oral
74378|NCT03602508|Drug|trospium|oral
74379|NCT03602508|Drug|fesoterodine|oral
74380|NCT03602508|Drug|propiverine|oral
74381|NCT03602495|Drug|Donafenib|after continuing to intolerance or progress in double blind treatment period,for progress but tolerance into open therapy period for Donafenib evaluated by investigator
74382|NCT03602495|Drug|Placebo|after continuing to intolerance or progress in double blind treatment period,for progress but tolerance into open therapy period for Donafenib evaluated by investigator
74383|NCT03602482|Behavioral|Standing|Participants will stand and complete cognitive tests.
74384|NCT03602482|Behavioral|Supine|Participants will complete cognitive tests while supine.
74385|NCT03602469|Drug|Bupivacaine|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline
74386|NCT03602469|Drug|Bupivacaine-magnesium|Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)
74387|NCT03602469|Drug|Propofol|Using propofol 1.5-2.5 mg/kg
74388|NCT03602469|Device|Ultrasound|Ultrasound-guided suprascapular nerve block
74389|NCT03602469|Drug|Sevoflurane|Sevoflurane 0.7-1.5 MAC in 40% oxygen
74390|NCT03602469|Drug|Rocuronium|Rocuronium 0.6 mg/kg
74391|NCT03602456|Other|Kentucky HEALTH|KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
74392|NCT03602443|Behavioral|LSVT®BIG Intervention|Participants will complete LSVT®BIG intervention which consists of 16 one-hour sessions on 4 consecutive days for 4 weeks, and a home program component.
74393|NCT03602443|Behavioral|Waitlist Control|Participants randomized to this arm will be followed for the 4-week time period. We will track engagement in any daily exercise (not therapy services) through self-report.
74394|NCT03602430|Drug|Cholecalciferol|Native vitamin D dose of 200IU to be given once per month to hemodialysis patients
74395|NCT03602430|Drug|Placebo|A Placebo ampule will be given to hemodialysis patients once per month with their standard treatment for 3 months period. Same color, odor and size, only without the active constituent.
74396|NCT03602417|Device|Flare type stent|Flare type has a wide diameter at proximal portion to prevent stent migration.
74397|NCT03602417|Device|Conventional D-type stent|This stent is an original full covered stent to treat malignant colorectal obstruction.
74398|NCT03602391|Behavioral|SCP Plus|The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
74399|NCT03602378|Diagnostic Test|salivary cortisol|5 samples of saliva (first sample before around 22:00 and other samples the next morning, after awakening (00, 15, 30 and 60 minutes).
74400|NCT03602378|Device|Holter Medilog AR12 Plus|Holter Medilog AR12 Plus - electrocardiogram during 5 minutes for measuring HRV
74401|NCT03602378|Device|Polar V800|Polar V800 with sensor - during 5 minutes for measuring HRV
74402|NCT03602378|Device|AGE reader|for measuring Advanced Glycation End products (AGEs)
74403|NCT03602365|Device|Gentle Jogger (GJ)|Gentle jogger is a passive jogging device which passively moves the feet up and down simulating jogging
74404|NCT03602339|Drug|Gadoterate (Dotarem®/Clariscan™)|Patients receive a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
74405|NCT03602339|Drug|BAY86-4875 (Gadobutrol; Gadovist®/ Gadavist®)|Patients receive a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
74441|NCT03602144|Other|Protein|Participants will receive a protein-based breakfast beverage everyone morning for 42 days.
74406|NCT03602326|Other|Neurodevelopmental Therapy-Bobath group|Neurodevelopmental Therapy-Bobath (NDT-B) is one of the most commonly used models for therapeutic management and treatment in patients with stroke. The basic philosophy underlying this approach is that; lesions in the central nervous system cause impairments in the coordination of movement and posture combined with problems in muscle tone which lead directly to functional limitations. According to the NDT-B approach, practice has a great role in treatment due to the fact that more practice leads to better motor learning and increases neural plasticity. According to NDT-B, the duration of treatment should not be limited to rehabilitation sessions, but should be designed to be implied throughout the day and should be adapted to the patients' daily life.
74407|NCT03602326|Other|Standart Rehabilitation Group (SR group)|Standard Rehabilitation for Stroke consists of the hospitals' physiotherapy and rehabilitation routine.
74408|NCT03602313|Device|Body Weight Support Gait Training|
74409|NCT03602313|Other|Traditional Gait Training|
74410|NCT03602300|Drug|Ravidasvir test formulation produced by Doppel|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
74411|NCT03602300|Drug|Ravidasvir reference formulation produced by EEPI|"To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions."
74412|NCT03602287|Drug|Lignocaine 2% Injection 20Ml Vial (Product)|2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
74413|NCT03602287|Drug|Normal saline|5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
74414|NCT03602274|Diagnostic Test|Hepatic function monitoring|AST, ALT, GGT, AP, Bilirubin
74415|NCT03602274|Diagnostic Test|Nutritional status assesment|PINI, MNA nutritional assessment, PG-SGA assessment, anthropometric measurements
74416|NCT03602274|Other|Biomarker research sampling|Blood collection for proteomic, genetic, metabolomic and microRNA transcriptomic profiling
74417|NCT03602261|Drug|Calcifediol Oral Capsule|Capsule, weekly
74418|NCT03602261|Drug|Placebo oral capsule|Capsule, weekly
74419|NCT03602248|Other|Speed endurance training protocol A|1 set of 8 repetitions interspersed by 2,5 minutes of recovery with a work to rest ratio of 1:5 (25-30 seconds all out work)
74420|NCT03602248|Other|Speed endurance training protocol B|1 set of 8 repetitions interspersed by 4 minutes of recovery with a work to rest ratio of 1:8 (25-30 seconds all out work)
74421|NCT03602235|Other|Ascorbate|Ascorbate is in the vitamin drug class
74422|NCT03602235|Drug|Melphalan|Melphalan is an alkylating agent coupled to an amino acid
74423|NCT03602222|Behavioral|Mobile web training LGBT mental health|Mobile web training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in a the mobile fashion (on the web).
74424|NCT03602222|Behavioral|In-person training LGBT mental health|In-person training LGBT mental health: Half of the participants were randomly assigned to receive the training in LGBT mental health in-person.
74425|NCT03602209|Procedure|Removal of infected implant|
74426|NCT03602209|Drug|Antibiotic durations|
74427|NCT03602196|Other|Perineal ultrasound assessment|"women were assessed in lithotomy position with an empty bladder at rest, perineal contraction and Valsalva maneuver using a linear translabial probe. We measure the distance between symphysis and ano-rectal angle. In the same position we investigate the levator ani viscoelastic properties using shear wave elastography at rest, Valsalva maneuver and maximal contraction. During the same examination, we assess the viscoelastic properties of the external anal sphincter using shear wave elastography for the 3 conditions: rest, Valsalva, contraction.~This pelvic floor muscles assessment is performed for each of the three planned visits~For the ancillary study on non pregnant women: viscoelastic properties of levator ani are assessed at rest, stretch and contraction using shear wave elastography.~This pelvic floor muscle assessment is performed for each of the two planned visit in the ancillary study."
74428|NCT03602196|Other|Peripheral muscles assessment|"The visco elastic properties of the biceps brachii muscle and the gastrocnemius medialis muscle are assessed rest, stretch and maximal contraction using shear wave elastography.~This peripheral muscle assessment is perform for each of the three planned visits.~For the ancillary study on non pregnant women: viscoelastic properties of biceps brachii and gastrocnemius medialis muscles are assessed at rest, stretch and contraction using shear wave elastography.~This peripheral muscles ultrasound assessment is performed for each of the two planned visit in the ancillary study."
74429|NCT03602196|Other|Clinical pelvic floor assessment|"Women undergo a pelvic floor assessment using the Pelvic organ prolapse quantification system. Such an assessment is performed for each of the three planned visits.~Women included in the ancillary study are not involved with this examination"
74430|NCT03602183|Device|Macintosh laryngoscope|intubation will be performed using standard direct laryngoscopy - Macintosh laryngoscope
74431|NCT03602183|Device|Miller laryngoscope|intubation will be performed using Miller laryngoscope
74432|NCT03602183|Device|McGrath MAC EMS|intubation will be performed using McGrath MAC EMS video - laryngoscope
74433|NCT03602183|Device|GlideScope|intubation will be performed using GlideScope video - laryngoscope
74434|NCT03602170|Behavioral|High-Intensity Interval Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 20 minutes of exercise by completing 10 repetitions of 60 seconds of exercise at 90-95% maximal heart rate with 60 seconds of active rest between each repetition at 50-60% maximal heart rate.
74435|NCT03602170|Behavioral|Moderate-Intensity Continuous Training|Supervised exercise sessions will be performed on a upright cycle ergometer. Training sessions involve 30 minutes of continuous exercise at 65-70% maximal heart rate.
74436|NCT03602157|Biological|ATLCAR.CD30.CCR4 cells|Three dose levels are being evaluated: 2x10^7, 5x10^7, 1x10^8
74437|NCT03602157|Biological|ALTCAR.CD30 cells|Fixed dose level of 1x10^8
74438|NCT03602157|Drug|Bendamustine|70 mg/m^2/day Bendamustine for 3 days for lymphodepletion prior to cell infusion
74442|NCT03602131|Drug|Chidamide|30 mg oral twice weekly for 2 weeks
74443|NCT03602131|Drug|Cladribine|6 mg/m2 intravenously once daily for 5 days
74444|NCT03602131|Drug|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
74445|NCT03602131|Drug|Busulfan|3.2 mg/kg intravenously once daily for 4 days
74446|NCT03602131|Procedure|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
74447|NCT03602118|Drug|Phenobarbital Sodium Injection|Phenobarbitone Inj, Phenobarbitone SOD, Phenobarbitone Sodium
74448|NCT03602105|Behavioral|Exercise|Exercises in group and/or individually
74449|NCT03602092|Other|Observation|This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
74450|NCT03602079|Drug|A166|A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.
74451|NCT03602066|Drug|Chlorine Dioxide Sterilization|Given via oral rinse
74452|NCT03602066|Other|Laboratory Biomarker Analysis|Correlative studies
74453|NCT03602066|Other|Placebo|Given via oral rinse
74454|NCT03602053|Biological|ROTAVAC®|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
74455|NCT03602053|Biological|ROTAVAC 5CM|0.5 ml of the vaccine will be administered orally thrice at 6, 10 and 14 weeks of age.
74456|NCT03602053|Biological|Rotarix®|1.5 ml of the liquid vaccine will be administered orally twice at 6 and 10 weeks of age.
74457|NCT03602040|Behavioral|PISICC|"PISICC consists of:~Standard disease-specific information leaflet~Personalised lifestyle consideration form~1-hour group session with up to 10 participants facilitated by the PhD student who is also an experienced cardiac genetic nurse. This will include discussions of 2 scenarios (communicating with clinicians and communicating with family) and a question and answer session based on the personalised lifestyle consideration form Components a) and b) will be given to the patient after the baseline assessment and there will be an interval of 2 weeks before the participants attend for component c)."
74458|NCT03602027|Drug|Anlotinib|Anlotinib 8mg p.o. qd in low-dose groups (3 subjects). 10mg p.o. qd in middle-dose groups (3 subjects). 12mg p.o. qd in high-dose groups (3 subjects).
74459|NCT03602027|Drug|Gefitinib|Gefitinib 250mg orally daily for three weeks
74460|NCT03602014|Drug|Northera|Study 1 is a dose optimization, open-label trial of Northera from a dose range of 200mg up to 800mg. Study 2 is blinded placebo controlled trial using the individualized optimal dose of droxidopa determined by study 1.
74461|NCT03602001|Behavioral|Attentive eating smartphone application.|A smartphone application that encourages a more attentive eating style.
74462|NCT03602001|Behavioral|Standard dietary advice and text tips.|Standard dietary advice for weight loss booklet and weekly text tips containing dietary advice.
74463|NCT03601988|Radiation|Concurrent chemo-radiotherapy|Experimental group receive 6 cycles of XELOX chemotherapy and concurrent chemo-radiotherapy. The radiotherapy dose of 45Gy in 25 fractions delivered by IMRT Radiotherapy
74464|NCT03601988|Drug|Chemotherapy|Chemotherapy group receive 8 cycles of XELOX.
74465|NCT03601975|Drug|Gemcitabine/Cisplatin|gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
74466|NCT03601962|Dietary Supplement|Aqualief|400mg oral mucoadesive tablets
74467|NCT03601962|Other|Placebo|400mg Placebo oral mucoadesive tablets
74468|NCT03601949|Device|SInergy Cooled Radiofrequency|ablation of low back pain
74469|NCT03601949|Other|Medical Management|physical therapy, medications, lifestyle changes
74470|NCT03601936|Device|Evivo Infant Gut Bifidobacterium Screening Test|Operators at each test site will collect and test infant stool specimens according to the Evivo Infant Gut Bifidobacterium Screening Test protocol.
74471|NCT03601923|Drug|Niraparib|"Niraparib belongs to a class of anti-cancer agents known as PARP (poly ADP ribose polymerase) inhibitors. PARP is a protein in the body that repairs damage to DNA (one of the building blocks of a cell). In cells that are rapidly growing, such as cancer cells, blocking repair of DNA may be of benefit, since it will cause the cell to die.~Niraparib will be given at an initial dose of 200mg or 300 mg by mouth once daily depending on the patient's platelet count and weight at the start of the trial."
74472|NCT03601910|Drug|D308 10mg Tab.|D308 10mg Tab.1T single oral administration under fasting condition
74473|NCT03601910|Drug|CKD-380 10mg Tab.|CKD-380(Dapagliflozin) 10mg Tab.1T single oral administration under fasting condition
74474|NCT03601897|Drug|rebastinib|25 mg tablets or 75 mg tablets
74475|NCT03601897|Drug|Paclitaxel|Paclitaxel administered by IV infusion at 80 mg/m2
74476|NCT03601884|Behavioral|Optimal Health Program|The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication & Metabolic Monitoring, Collaborative & Strategies, Change enhancement, Visioning & Goal Setting and Maintain Well-being.
74477|NCT03601884|Other|Treatment as Usual|"Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients."
74478|NCT03601871|Drug|Thalidomide|Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
74479|NCT03601871|Drug|Dexamethasone|Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
74480|NCT03601871|Drug|5-HT3 antagonists|Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
74481|NCT03601845|Other|Stimuli|Visual stimulation while using additional sequencing
74482|NCT03601845|Other|No stimuli|Additional sequencing only
74483|NCT03601832|Procedure|4-D navigated stereotactic radiosurgical ablation|4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
74484|NCT03601819|Drug|Pacritinib|Patients will receive continuous treatment until progressive disease, toxicity, or until any other condition for treatment discontinuation has been met.
74485|NCT03601806|Other|Laboratory Biomarker Analysis|Correlative studies
74486|NCT03601806|Drug|Pomalidomide|Given PO
74487|NCT03601793|Behavioral|Alcohol Help Center|An internet intervention based on CBT consisting of about 20 modules aimed at helping people with drinking problems
74488|NCT03601793|Behavioral|Assistance from a health educator|This entails email contact with a health educator that guides the participant through the Alcohol Help Center during the first two weeks
74489|NCT03601780|Drug|local wound infiltration plus usual care|local wound infiltration plus usual care
74490|NCT03601780|Drug|usual care only|usual care only
74491|NCT03601754|Diagnostic Test|Treadmill/Bicycle exercise testing|"Exercise testing will be scheduled on the same day as the enrollment visit and within 30 days after post-implant visit.~The standard protocol will be typically set at an initial workload of 15Watts and go up by increments of 10 Watts every 3 minutes, as follows:~Stage 1 - 15 W Stage 2 - 25 W Stage 3 - 35 W Stage 4 - 45 W"
74492|NCT03601741|Other|Daily Antimicrobial Stethoscope Diaphragm Cover|Patients will receive package with instructions to use stethoscope cover, and are then instructed to switch in 7 days
74493|NCT03601741|Other|Uncovered Stethoscopes|Patients receive instruction to begin with no covers, and are then instructed to switch in 7 days
74494|NCT03601728|Behavioral|personalized prehabilitation|The 60-minute education session includes a 30-minute general education on exercise in older adults and a 30-minute instruction on participating in the study intervention (how to work with the personalized circadian-based activity guideline). The education session will be developed and presented by the PI and the certified exercise trainer. The general education session will be designed using materials from Go4Life program from the National Institute on Aging (https://go4life.nia.nig.gov). The personalized circadian-based activity guideline (exercise goal and plan) will be developed by the investigators and the exercise trainer based on the individual's typical daily circadian profile, functional status, preference for exercise.
74495|NCT03601715|Other|Coplanar|The coplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
74496|NCT03601715|Other|Contraplanar|The contraplanar arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
74497|NCT03601715|Other|Longitudinal|The longitudinal arrangement will be applicated in each one of the subjects. The intervention will last 20 minutes. A towel will be placed between the pad electrode and the skin to improve contact, besides, the tight and the electrode will be wrapped with an elastic band for the same purpose. The subject will receive orientation related to the heat intensity, it must be a comfortable perception of heat (the intensity will be regulated on the equipment to guarantee that).
74498|NCT03601702|Device|Mechanical thrombectomy with EmboTrap ® II Device|Endovascular treatment with mechanical thrombectomy using EmboTrap ® II Device (Neuravi)
74499|NCT03601689|Procedure|rectal resection|total mesorectal excision
74500|NCT03601676|Other|Integration of electronic clinical decision support|Integration of an electronic clinical decision support system into the emergency department patient care workflow to assist with site-of-care decision-making for emergency department patients with acute pulmonary embolism.
74501|NCT03601663|Behavioral|Physical Activity Information|Participants will receive a copy of the Canadian Physical Activity Guidelines.
74502|NCT03601663|Behavioral|Physical Activity Monitoring|Participants will receive a wearable activity tracker (Polar A300).
74503|NCT03601663|Behavioral|Autonomy-support|Participants will receive eight autonomy-supportive weekly emails containing information and activities to help them set goals and make changes to become physically active.
74504|NCT03601650|Behavioral|Mindful eating|Attending to the sensory properties of food as it is eaten
74505|NCT03601650|Behavioral|Eating without distractions|Eating without intentionally attending to something else such as a television, smartphone, computer, book etc
74506|NCT03601637|Drug|LUM|Fixed Dose Combination (FDC) granule (LUM/IVA)
74507|NCT03601637|Drug|IVA|FDC granule (LUM/IVA)
74508|NCT03601624|Drug|Pomalidomide|"Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )"
74509|NCT03601611|Drug|Tocilizumab (RoACTEMRA®)|Prednisolon will be given in case of worsening of symptoms
74510|NCT03601598|Drug|SHR-1210|SHR-1210 was administered 200mg iv every 2 weeks
74511|NCT03601598|Drug|SHR6390|SHR6390 was administered 150mg or 100mg oral daily with 3 weeks on and 1 week off
74512|NCT03601585|Device|Comparison of dental biofilm removal.|Comparison of the use of 4 methods for dental biofilm removal
74513|NCT03601572|Other|No intervention|No intervention
74514|NCT03601559|Dietary Supplement|Lactobacillus paracasei Lpc-37|Live probiotic bacteria
74515|NCT03601559|Dietary Supplement|Placebo|Inert placebo matched for taste and appearance
74516|NCT03601546|Other|Clinical examination|Blood test and patient interview as for standard patient care
74517|NCT03601533|Drug|Phenol|1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
74518|NCT03601507|Drug|Alpelisib|Given PO
74519|NCT03601507|Other|Laboratory Biomarker Analysis|Correlative studies
74520|NCT03601507|Other|Pharmacodynamic Study|Correlative studies
74521|NCT03601507|Procedure|Therapeutic Conventional Surgery|Undergo surgery
74547|NCT03601234|Procedure|laparoscopic and endoscopic cooperative surgery|compare to the traditional surgery to resect the tumor,we will add the endoscopy during the operation to improve the safety and effectiveness of surgery
74548|NCT03601234|Procedure|laparoscopic surgery|the traditional surgery
74549|NCT03601221|Other|Sample collection|Collection of one sampling pouch from each blood donor
74964|NCT03597815|Drug|Aflibercept 40 MG/ML [Eylea]|Intravitreal injection, form of anti-VEGF therapy
131301|NCT03163329|Procedure|SAVR|Surgical Aortic Valve Replacement
74522|NCT03601494|Other|perineural injection of platelet-rich plasma|Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in‐plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.
74523|NCT03601494|Drug|medical|vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
74524|NCT03601455|Biological|Durvalumab|Given IV
74525|NCT03601455|Radiation|External Beam Radiation Therapy|Undergo EBRT
74526|NCT03601455|Biological|Tremelimumab|Given IV
74527|NCT03601442|Biological|CTL019|CTL019
74528|NCT03601429|Dietary Supplement|Lactogyn|capsules
74529|NCT03601429|Dietary Supplement|Placebo|capsules
74530|NCT03601416|Drug|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to participants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
74531|NCT03601416|Drug|No Transplantation of Mesenchymal Stem Cell|Human umbilical cord-derived mesenchymal stem cell will be not given to participants through intravenous infusion.
74532|NCT03601403|Device|inhaler technique|The first day of the intervention consisted primarily of ventilatory re-education. During the realization of the technique, he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
74533|NCT03601390|Device|PET/CT and EBV DNA|PET/CT and EBV DNA will be proformed after the IMRT treatment
74534|NCT03601377|Behavioral|Training away from threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
74535|NCT03601377|Behavioral|Training towards threat|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
74536|NCT03601377|Behavioral|Placebo|Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (< or >) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
74537|NCT03601351|Other|ELISA for MOR-1 expression|To evaluate MOR-1 expression differences by immunohistochemical analysis (ELISA - semiquantitative) in paraffin samples from patients with colorectal cancer stage II / III submitted scheduled colorectal surgery between the tumor tissue and the adjacent nontumorous tissue.
74538|NCT03601338|Drug|Bemiparin|second generation low molecular weight Heparin
74539|NCT03601338|Other|multivitamins and routine antenatal follow up|multivitamins and routine antenatal follow up
74540|NCT03601312|Behavioral|Exposure and Response Prevention|Exposure and response prevention is an evidence-based behavioral treatment that primarily focuses on exposures, in which the child faces OCD-related fears in a methodical manner and acquires more adaptive coping strategies.
74541|NCT03601312|Behavioral|OC-Go|OC-Go is a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices. Individuals receiving this intervention will receive exposure and response prevention with OC-Go.
74542|NCT03601299|Other|Traditional food|Increasing traditional food consumption through Head start programs in Alaska
74543|NCT03601286|Drug|Lentiviral vector transduced CD34+ cells|Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
74544|NCT03601273|Procedure|Left gastric artery embolization|"450-micron Embozene microparticles will be used intraarterially to occlude the left gastric artery and its branches.~30-day post-embolization endoscopic biopsy"
74545|NCT03601260|Drug|Allopurinol|Treatment of gout patients by oral dosage of 100 mg-300mg/ day of Allopurinol
74546|NCT03601247|Device|silicone gel|"Patients who have consented to the study will receive two tubes labeled only left and right, corresponding to the side of the face to which the tube contents will be applied. One tube will contain silicone gel and the other tube will contain aquaphor. Neither the patient nor the surgeon will know what side will receive which treatment. These tubes will be given to patients at post-operative week 1 visit. Patients will be instructed to rub the solution into their eyelid incisions gently with their fingers for 2-3 minutes twice a day"
75298|NCT03595150|Drug|Diclofenac|Diclofenac rectally given before the ERCP to prevent pancreatitis
74550|NCT03601208|Diagnostic Test|Mitra|When the patients have their bloods done through venepuncture, an additional 5-10mls will be taken (one EDTA bottle for tacrolimus and one serum bottle for creatinine; and two Mitra VAMs). Patients will also have a fingerprick test and 20 microlitres of blood taken using Mitra volumetric absorptive microsampling (VAMs)
74551|NCT03601169|Dietary Supplement|Low Dose MMFS-205-SR|Twice daily, oral 500mg tablets
74552|NCT03601169|Dietary Supplement|High Dose MMFS-205-SR|Twice daily, oral 500mg tablets
74553|NCT03601169|Dietary Supplement|Placebo|Twice daily, oral
74554|NCT03601156|Device|intraarterial chemoembolization|
74555|NCT03601156|Device|intravenous chemotherapy|
74556|NCT03601143|Other|Blood samples prior to a new line of AR-targeted therapy|Blood will be drawn at baseline prior to a new line of AR-targeted therapy.
74557|NCT03601130|Device|HydroxyColl Bone Graft Substitute|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
74558|NCT03601130|Device|DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)|The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
74559|NCT03601117|Device|Accelerated theta burst stimulation|All participants will receive iTBS (intermittent theta burst stimulation), either to the left DLPFC or ACC. Stimulation intensity will be individualized according to the individual's resting motor threshold.
74560|NCT03601104|Other|High intensity eccentric training|High intensity eccentric training group with 80% of isometric peak torque.
74561|NCT03601104|Other|High intensity eccentric training with BFR|Eccentric high intensity training group with 80% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
74562|NCT03601104|Other|Low intensity eccentric training with BFR|Low intensity eccentric training group with 40% of isometric peak torque associated with blood flow restriction (40% of absolute occlusion pressure).
74563|NCT03601091|Drug|Precedex 200 MCG in 2 ML Injection|Infusion therapy of the drug
74564|NCT03601091|Drug|DORMICUM 5MG/5 ML|Infusion therapy of the drug
74565|NCT03601078|Biological|bb2121|bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
74566|NCT03601065|Other|Videos of polyps, resection of polyps|Ther is no study specific intervention. Video sequences will be taken if polyps are found in the colon. Polyps will then be resected routinely.
74567|NCT03601052|Drug|Remlarsen|Intradermal injection at site of one excisional wound
74568|NCT03601052|Drug|Placebo|Intradermal injection at site of second excisional wound
74569|NCT03601039|Device|Absnow Absorbable ASD Closure System|the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
74570|NCT03601026|Behavioral|Genetic counselling|Participants will receive information on risk/protective factors and causes of mental illness. Participants are not required to receive numeric/genetic risk information. Participants who choose to receive genetic and/or numeric risk information will be counselled on their risk of NOT developing and of developing SMI based on their genetic test results and/or family history information they provide. Risk estimates will be derived by genetic counsellors, according to standard practice guidelines. Participants who receive genetic information will be counselled on the possible influence of cannabis use on risk of mental illness based on their genotype. Participants who choose to not receive genetic information will be counselled on the influence of cannabis on mental health.
74571|NCT03601013|Other|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy|Demographical and Clinical Profile of Patients on Dual Antıplatelet Therapy
74572|NCT03601000|Drug|Yi-Zhi-An-Shen|Yi-Zhi-An-Shen Granules 5g given three times a day for up to 16 weeks.
74573|NCT03601000|Drug|Placebo|Placebo granules 5g given three times a day for up to 16 weeks.
74574|NCT03600987|Behavioral|Simultaneous music and reading lyrics|listening to music with singing of the lyrics simultaneously with reading the written lyrics.
74575|NCT03600987|Behavioral|Priming with music|priming by listening to music and singing of the lyrics followed by reading the written lyrics.
74576|NCT03600987|Behavioral|Control|control condition using reading materials without music.
74577|NCT03600974|Procedure|Stretta|Stretta for Endoscopy-E(+),Acid-A(+),Reflux-symptom association-S(+) or lower oesophageal sphincter-L(+) group
74578|NCT03600974|Procedure|Laparoscopic Nissen fundoplication|Laparoscopic Nissen fundoplication for E(+),A(+) or L(+) group
74579|NCT03600974|Drug|Probiotic Agent|Probiotic Agent for I(+)G/W；Live Bacillus Licheniformis Cranules 0.5g bid； Bifidbacterium 0.63g bid
74580|NCT03600974|Drug|PPI|PPIs for A(+),E(+)or S(+) patients: Nexium 20mg Qd/Bid;Lansoprazole 30mg Qd/Bid；omeprazole 10mg-30mg Qd-Bid;Rabeprazole 10mg Qd/Bid;Esomeprazole 20mg Qd/Bid;Pantoprazole 40mg Qd/Bid
74581|NCT03600974|Drug|Prokinetic Motility Agents|Prokinetic Motility Agents for M(+) group; Mosapride 5mg Tid; Domperidone 10mg Tid
74582|NCT03600974|Drug|Neuromodulators|Neuromodulators for P(+) or S(+);Flupentixol and Melitracen 1# bid;
74583|NCT03600961|Device|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
74584|NCT03600948|Device|Orsiro Sirolimus Eluting Coronary Stent System|Percutaneous coronary intervention
74585|NCT03600935|Other|Vancouver Clinical Pathway|Vancouver Clinical Pathway
74586|NCT03600922|Procedure|the patella was resurfaced.|Patellar resurfacing was undertaken using a cemented, inset domed component in TKA.
74885|NCT03598413|Dietary Supplement|Omega-3|200ml, pre-mixed oral nutritional supplement supplying 1.42g per bottle of EPA and DHA.
75154|NCT03596255|Diagnostic Test|Estimated level of DA|the dental personnel estimated the patient's level of DA (eDA) on a 100mm VAS
74587|NCT03600909|Drug|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
74588|NCT03600909|Drug|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
74589|NCT03600909|Drug|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
74590|NCT03600909|Drug|Anti-Thymocyte Globulin (Rabbit)|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment
74591|NCT03600909|Device|The CliniMACS device|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)
74592|NCT03600909|Drug|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
74593|NCT03600896|Drug|CYT107|"Phase I: Patients will be treated with CYT107 post CBT (from 60 to 180 days), in with 1 of 3 doses below:~5 mcg/kg/dose for 3 doses~10 mcg/kg/dose for 3 doses~20 mcg/kg/dose for 3 doses~The optimal recommended dose determined in Phase I will be used to treat all patient enrolled in Phase II."
74594|NCT03600883|Drug|AMG 510|Characterize the pharmacokinetics (PK) of AMG 510 following administration as an oral Tablet formulation
74595|NCT03600870|Drug|Midodrine|Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
74596|NCT03600857|Other|Home administration of misoprostol|First dose of misoprostol administration at home
74597|NCT03600844|Behavioral|Community distribution of SP for IPTp|SP is distributed to eligible pregnant women by trained Community Health Workers (CHWs) at community level. Demand creation activities are implemented within the community as well.
74598|NCT03600831|Drug|Docetaxel plus cisplatin|cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks
74599|NCT03600831|Radiation|radiotherapy|radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)
74600|NCT03600818|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
74601|NCT03600818|Drug|Sarilumab-matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
74602|NCT03600818|Drug|Prednisone|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
74603|NCT03600818|Drug|Prednisone-matching placebo|Pharmaceutical form:over-encapsulated tablets Route of administration: oral administration
74604|NCT03600818|Drug|Prednisone|Pharmaceutical form:tablets Route of administration: oral administration
74605|NCT03600805|Drug|Sarilumab SAR153191|Pharmaceutical form:solution for injection Route of administration: subcutaneous
74606|NCT03600805|Drug|Sarilumab matching placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
74607|NCT03600805|Drug|Prednisone|Pharmaceutical form:tablets or capsules Route of administration: oral administration
74608|NCT03600805|Drug|Prednisone matching placebo|Pharmaceutical form:capsules Route of administration: oral administration
74609|NCT03600792|Genetic|whole exome sequencing (WES)|"WES analysis will be performed in the UF de Génomique du Développement (APHP, Pitié-Salpêtrière hospital), using DNA extracted from amniotic fluid for the foetus (also used for chromosomal studies) and DNA extracted from peripheral blood for both parents. There will be no supplemental invasive sampling for this study. The result of WES will be returned during a consultation with the geneticist and the associated prognosis will be explained in case of molecular diagnosis"
74610|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
74611|NCT03600779|Device|inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T|robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
74612|NCT03600766|Drug|Mirabegron|oral mirabegron 50 gm plus tamsulosin 0.4 mg once daily for 8 weeks.
74613|NCT03600766|Drug|placebo|oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
74614|NCT03600753|Other|culturomic|Culturomic is a high-throughput culture strategy based on the multiplication of culture conditions coupled with the rapid identification of bacteria by MALDI-TOF (Matrix-Assisted Laser Desorption / Ionization-Time-Of-Flight) mass spectrometry
74615|NCT03600753|Other|Metagenomic|Metagenomics is an high throughput sequencing and will be performed using Miseq ( Illumina technology) targeting the V3-V4 hypervariable regions of the 16S RNA gene.
74616|NCT03600740|Device|DBS Programming|DBS Programming may be temporarily altered based on imaging data to measure a change in clinical symptoms.
74617|NCT03600727|Drug|Propofol|Propofol will be used to offer intraoperative sedation for patients in Propofol group.
74618|NCT03600727|Drug|Dexmedetomidine|Dexmedetomidine will be used to offer intraoperative sedation for patients in Dexmedetomidine group.
74619|NCT03600714|Drug|Peg-interferon lambda|Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated IFN lambda and a 20-kDa linear PEG chain.
74620|NCT03600714|Drug|Lonafarnib|Oral prenylation inhibitor
74621|NCT03600714|Drug|Ritonavir|Booster of lonafarnib action
74622|NCT03600701|Drug|Atezolizumab|Given IV
74623|NCT03600701|Drug|Cobimetinib|Given PO
74624|NCT03600688|Device|Edwards Cardioband System|Transcatheter mitral valve repair
74625|NCT03600675|Other|No intervention element, observational study.|No intervention will be applied to any group. It is an observational study and all measurements are collected during one visit.
74626|NCT03600662|Other|TriRec|Trileaflet Reconstruction of the Aortic Valve
74627|NCT03600662|Other|Aortic valve replacement|Biological Prosthesis, Device: St. Jude Medical Trifecta GT
74628|NCT03600649|Drug|SP-2577|Dose escalation and dose expansion of SP-2577
74629|NCT03600636|Procedure|Diffusion tensor imaging MRI|"axial diffusion weighted sequence with 32 gradient encoding directions and two values b, 0 s / mm 2 and 1000 s / mm 2.~Fluid-attenuated inversion recovery~three-dimensional axial image weighted in T1~axial echo-planar image sequence~three-dimensional pulse sequence axial flight time"
74630|NCT03600623|Drug|Folfirinox|SBRT will follow Folfirinox at the completion of Cycle 2 (if eligible).
74631|NCT03600623|Drug|Gemcitabine nab-Paclitaxel|SBRT will follow Gemcitabine nab-Paclitaxel at the completion of Cycle 2 (if eligible).
74632|NCT03600610|Device|gadolinium-enhanced cardiac MRI|cardiac magnetic resonance imaging with gadolinium injection used T1-Mapping
74633|NCT03600584|Procedure|Modified one-layer duct-to-mucosa Pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Modified one-layer duct-to-mucosa Pancreaticojejunostomy was performed.
74634|NCT03600584|Procedure|Invagination pancreaticojejunostomy|After the completion of the preparation of the remnant pancreas for reconstruction was performed. Invagination Pancreaticojejunostomy was performed.
74635|NCT03600571|Procedure|medial midpatellar (MMP) portal|injection medial under horizontal patella midline was administrated with the lower limb extension
74636|NCT03600571|Procedure|anteromedial (AM) portal|injection medial from patella tendon towards intercondylar notch was performed with the target knee 90° flexion
74637|NCT03600545|Other|Brain Fitness App|Brain exercises using an iPAD
74638|NCT03600545|Other|no brain exercise|no brain-exercise during the study
74639|NCT03600532|Behavioral|Teachable Moment Brief Intervention (TMBI)|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt.
74640|NCT03600519|Device|NOTAL OCT V2.5|AMD Patients
74641|NCT03600506|Drug|Dexmedetomidine|Patients will receive infusion of study drug intravenously 10 minutes before induction of anesthesia as 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr till the start of wound closure.
74642|NCT03600506|Drug|Placebo|Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
74643|NCT03600493|Drug|Dexmedetomidine|Dexmedetomidine 1 mcg/kg over 10 min followed by 0.4 mcg/kg/hr. till the start of wound closure.
74644|NCT03600493|Drug|Lidocaine|Lidocaine given as 1mg/kg over 10 min followed by 1mg/kg/hr till the start of wound closure.
74645|NCT03600480|Drug|NNC0174-0833|Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous [s.c.], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.
74646|NCT03600480|Drug|Semaglutide|Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
74647|NCT03600480|Drug|Placebo (NNC0174-0833)|Participants will receive once weekly injections of NNC0174-0833 matched placebo.
74648|NCT03600467|Drug|SEVI-D (Seviteronel in combination with dexamthasone)|"Use of SEVI-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.~Serivteronel will be administered orally at 450 mg (3 tables) once daily. It will be given in combination with one oral tablet of 0.5 mg tablet of Dexamethosone. SEVI-D will be continuously administered daily while on the study.~Clinical and safety assessments are scheduled every 4 weeks during the study and then every 8 weeks after the end of the safety follow up period of the study."
74649|NCT03600454|Drug|General anesthesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2µg/kg and propofol
74650|NCT03600454|Drug|Spinal anesthesia|The level of puncture will be L4 - L5. 10 mg bupivacaine will be injected in the subarachnoid space, after spontaneous surge of cerebrospinal fluid
74651|NCT03600454|Drug|General anesthesia and epidural analgesia|The induction of general anesthesia will be delivered in a standardized manner with the intravenous administration of fentanyl 2 µg/kg and propofol. A thoracic epidural catheter will be placed with 3 ml of xylocaine 2% (with epinephrine 1/200.000).
74652|NCT03600441|Drug|Abexinostat|Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
74653|NCT03600428|Biological|Live Attenuated Influenza Vaccine (LAIV)|1 dose, 0.2 mL, intranasal administration
74654|NCT03600428|Biological|Inactivated Influenza Vaccine (IIV)|1 dose, 0.5 mL, intramuscular administration
74655|NCT03600415|Other|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
74656|NCT03600415|Other|Säntis; 2500m above sea level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
74657|NCT03600402|Other|Experimental|6 sessions of ankle manual therapy
74658|NCT03600402|Other|Control|6 sessions of placebo intervention
74659|NCT03600389|Behavioral|Patient Priorities Care|
74660|NCT03600376|Drug|Ryanodex and Standard of Care|Ryanodex to be administered as a rapid IV push
74661|NCT03600376|Other|Standard of Care|Body cooling measures and supportive measures
74662|NCT03600363|Drug|Metformin|metformin (1.0g, bid) as a maintenance therapy in patients with complete remission
74663|NCT03600363|Drug|Placebos|oral placebos as a maintenance therapy
74664|NCT03600350|Biological|pTVG-HP|Plasmid DNA vaccine encoding Prostatic Acid Phosphatase (PAP)
74665|NCT03600350|Drug|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
74666|NCT03600350|Drug|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a growth factor that supports the survival, clonal expansion and differentiation of hematopoietic progenitor cells including dendritic antigen presenting cells.
74667|NCT03600337|Behavioral|Working to Optimize Wellness in Tees with PCOS (WOW)|5 week, 75 minutes weekly, integrated mindfulness-based mental and physical health promotion intervention
74965|NCT03597815|Diagnostic Test|OSA diagnostic test - overnight sleep study|Overnight with specialist care in hospital - heart, lung and brain activity monitored.
74668|NCT03600324|Behavioral|T-REV|For any intervention that involves physical exercise, four parameters must be specified to complete the prescription; Type (mode), Intensity, Frequency, and Time. o The standard of care vestibular rehabilitation exercise program consists of three types of treatments that target the specific impairments and limitations discovered during the examination. The three types are: 1) gaze stabilization for vestibulo-ocular reflex dysfunction, 2) visual-vestibular habituation exercise for visual motion sensitivity, and 3) balance exercises for standing balance or gat dysfunction.
74669|NCT03600311|Other|Caloric Restriction|Participants will consume 15 kcal/kg FFM/day.
74670|NCT03600311|Dietary Supplement|Post-Exercise Protein|Participants will ingest 30 g of protein following exercise.
74671|NCT03600311|Other|Energy Balance|Participants will consume 40 kcal/kg FFM/day.
74672|NCT03600311|Dietary Supplement|Post-Exercise Carbohydrate|Participants will ingest 30 g of carbohydrate following exercise.
74673|NCT03600311|Dietary Supplement|Calcium and Vitamin D|Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
74674|NCT03600298|Other|Simulation|Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
74675|NCT03600285|Device|TB1-K|Use of TB1-K for preservation and transport of donated kidneys
74676|NCT03600272|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.
74677|NCT03600272|Procedure|Epidural analgesia|Epidural analgesia is a well-accepted technique using for pain relief during labor.
74678|NCT03600246|Device|WATCH-PAT|WatchPAT is an FDA-approved portable diagnostic device that uniquely uses finger based physiology and innovative technology to enable simple and accurate Obstructive Sleep Apnea (OSA) testing while avoiding the complexity and discomfort associated with traditional air-flow based systems.
74679|NCT03600233|Drug|CVM-1118|"Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose).~Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met."
74680|NCT03600220|Other|acupuncture|antihypertension drug, acupuncture twice a week for 3 months
74681|NCT03600207|Other|Complex training|The training program contains stretching, mobilizing, strengthening exercises on the trunk and hip muscles and a proprioceptive training.
74682|NCT03600207|Other|Diaphragm training|The training program contains strengthening exercises on the diaphragm muscle.
74683|NCT03600181|Device|RAD - 97 pulse co-oximeter|"non-invasive sensor capable of measuring ORI (Rainbow® Sensor, R2-25, Revision L, Masimo Corp.) will be applied to the third or fourth finger on the contralateral side of the inflatable cuff for non-invasive blood pressure monitoring.~Values from the RAD 97 monitor will be blinded to clinicians who perform intubation (clinical research nurse will be in charge of watching RAD 97 monitor)"
74684|NCT03600168|Device|PuraStat®|Synthetic haemostatic material
74685|NCT03600155|Biological|Ipilimumab|Given IV
74686|NCT03600155|Biological|Nivolumab|Given IV
74687|NCT03600142|Behavioral|Mashia|Maisha is a brief, scalable, theory-based counseling intervention that addresses HIV stigma at entry into antenatal care. The intervention will be developed in a formative phase and includes 1) a video and counseling session prior to HIV testing that addresses HIV stigma, and 2) two post-test HIV counseling sessions for HIV-infected individuals, building on the video content to provide emotional support, address stigma, and reinforce the value of care engagement.
74688|NCT03600129|Procedure|Qadratus Lumborum Block|Bilateral, ultrasound - guided Quadratus Lumborum Block
74689|NCT03600129|Drug|30 milliliters of 0.375% Ropivacaine|30 milliliters of 0.375% Ropivacaine used for Quadratus Lumborum Block
74690|NCT03600129|Drug|30 milliliters of 0.9% NaCl|30 milliliters of 0.9% NaCl used for Quadratus Lumborum Block
74691|NCT03600116|Drug|Insulin Lispro|Subjects will be given an insulin injection with insulin lispro (Humalog) to correct them for their breakfast meal and to correct their plasma glucose value down to 40mg/dL.
74692|NCT03600103|Behavioral|Tech2Check|The intervention uses behaviors to improve HIV adherence and self-care. Investigators will use the Center for Disease Control (CDC) Partnership for Health (PfH) Medication Adherence.The CHN will administer PfH at all home/venue-based encounters, using communication styles that are more receptive to adolescents and young adults. Resources will be provided. At the end of the session, the participant will be able to state/demonstrate: goals of HIV care and adherence, meaning of CD4 and Viral Load (VL) measurements and the significance of their own measurements,signs of complications or problems for which participants need to seek additional care,understanding of optimal self-care.Further, CHNs will also provide tips to stay on schedule with taking their ART and problem-solve adherence barriers.
74693|NCT03600090|Biological|EOC202|EOC202 will be SC injection.
74694|NCT03600090|Drug|Paclitaxel|Paclitaxol will be IV injection
74695|NCT03600064|Drug|Misoprostol|the women will be received two tablets of misoprostol 400 mcg vaginally before IUD removal (Misotac®; Sigma Pharma, SAE, Egypt).
74696|NCT03600051|Device|Automated Heart Murmur Detection AI|"Automated AI algorithm-based analysis of digital heart sound recordings to detect pathological heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. Algorithm results for each recording included: AHA classification (I pathologic versus III innocent/no murmur), murmur timing, murmur grade, heart rate and S1/S2 identification."
74697|NCT03600038|Behavioral|Experimental smoking cessation smartphone app|The experimental arm includes an intervention using a novel/experimental smartphone smoking cessation app.
74698|NCT03600038|Behavioral|Standard of care smoking cessation smartphone app|The control intervention uses a standard of care smartphone smoking cessation app.
74699|NCT03600025|Biological|Typbar-TCV vaccine|vaccine will receive intramuscularly
74700|NCT03600012|Other|Cycling Functional Electrical Stimulation|
74701|NCT03600012|Other|Physiotherapy|
74702|NCT03599999|Drug|Adverse events detection|type of adverse events detected during treatment with Temocillin and imputed to Temocillin
75004|NCT03597464|Drug|Placebo Oral Capsule|Voclosporin placebo, oral, 3 capsules BID
74703|NCT03599973|Other|Plasmalyte A Viaflo|Fluid therapy to be given according to the principle of 4-2-1 (4 ml of crystalloid fluid for each of the first 10 kg of weight (0-10 kg), 2 ml of crystalloid fluid for each of the second 10 kg of weight (11-20 kg) and 1 ml of crystalloid fluid for each kg of weight over 20.
74704|NCT03599960|Drug|Chemotherapy|"Idarubicin 12mg/m2 IV at D1~Methotrexate : 3000 mg/m2 IV at D1 (24H infusion, dosing modification (1500 mg/m²) if CrCl between 50 to 80ml/min or Age ≥70y, alkaline hydration, leucovorin rescue)~L-asparaginase (KIDROLASE) : 6000 units/m2 IV at D2, 4, 6, 8 (switch to Erwinia asparaginase 25 000 U/m² with the same drug regimen in case of hypersensitivity reactions or significant diminution of asparaginase activity)~Dexamethasone 40mg PO or IV at D1-4 (dose diminution at 20 mg for Age ≥70y)"
74705|NCT03599934|Other|Lifestyle integrated functional exercise program|Lifestyle-integrated exercise training targeting to improve strength and balance. Strategy to embed the exercise in the daily activity would also be taught so that the life exercise can be performed at any time of the day. The exercise would be taught in 6 home visits over 6-months.
74706|NCT03599934|Other|Home safety assessment|Home safety assessment and modification that targets to reduce environmental risk factors of falls.
74707|NCT03599921|Behavioral|Family-based treatment|"Family-based treatment, or FBT, is the leading evidenced based therapy for children and adolescents with an eating disorder.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore the patient's weight, then hand control of eating back to the patient as is age appropriate. Toward the end of treatment, it is concerned with developmental issues that may have been impacted by the illness."
74708|NCT03599921|Behavioral|Enhanced Cognitive behavioral therapy|"Enhanced Cognitive behavioral therapy, or CBT-E, is a leading evidence based treatment for adolescents and adults with an eating disorder.~The treatment is a one-to-one talking type of treatment that primarily focuses on what is keeping the eating problem going. It is therefore mainly concerned with the present and the future. It addresses the origins of the problem as needed."
74709|NCT03599921|Behavioral|Family-based treatment modified for ARFID|"Family-based treatment modified for individuals with an ARFID diagnosis is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and primarily focuses on helping parents play an active and positive role in helping to restore patient's weight and variety in eating, as needed."
74710|NCT03599921|Behavioral|FBT + UP for ARFID|"Family-based treatment combined with the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Children and Adolescents is a proposed therapy for treating ARFID.~The treatment is a talking type of treatment that involves the whole family and begins with focus on psychoeducation, family engagement, and weight gain as needed. The Unified Protocol is then added to build skills that empower the patient to cope with difficult emotions, address avoidance, and increase tolerance of emotions or disgust responses."
74711|NCT03599895|Procedure|3D printing model|Combine the 3D printing technique with imaging examination ,making the 3D model of da Vinci robot assisted radical gastrectomy
74712|NCT03599895|Procedure|non 3D printing model|da Vinci robot assisted radical gastrectomy
74713|NCT03599882|Device|Fibroscan|Fibroscan with controlled attenuation parameter and transient elastography
74714|NCT03599856|Other|TraceBook|TraceBook offers the user intelligent dynamic clinical checklist that shows patient specific items to a specific user while being context aware.
74715|NCT03599843|Behavioral|Exercise|Participants will complete a 12 week exercise session that will be comprised of aerobic and/or resistance and/or flexibility training.
74716|NCT03599830|Other|Cognitive test passations|"Tests :~MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences"
74717|NCT03599817|Behavioral|Healthy lifestyle promotion program|Before implementing the healthy lifestyle program, it will be adapted according to the characteristics of the Yaqui community, their type of food and the activities they carry out, so that the intervention program is culturally accepted by the community. The intervention will consist of two stages, an intensive phase and a maintenance phase. In the intensive phase, 16 weekly group sessions will be given with the aim of achieving a 5% body weight loss and ensuring that the participants do at least 150 minutes of physical activity per week. In the maintenance phase, 6 monthly group sessions will be given in order to maintain the results achieved in the first stage. In the same maintenance phase, but from 12 to 18 months, the lifestyle trainers will make home visits to the participants. Lifestile trainers will record body weight, physical activity and food consumption. In this period there will be no sessions, only monthly visits.
74718|NCT03599791|Drug|Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT|Dymista Nasal spray suspension
74719|NCT03599791|Drug|Azelastine Hydrochloride 0.137 MG/ACTUAT|AZEP Nasal spray solution
74720|NCT03599791|Drug|Fluticasone Propionate 0.05 MG/ACTUAT|Fluticasone propionate nasal spray suspension
74721|NCT03599778|Drug|Apatinib|XELOX + apatinib's MTD
74722|NCT03599765|Other|Best Practice|Receive routine therapy
74723|NCT03599765|Procedure|Local Consolidation Therapy|Receive LCT
74724|NCT03599752|Drug|Chemotherapy|Receive chemotherapy
74725|NCT03599752|Procedure|Metastasectomy|Undergo pulmonary metastasectomy
74726|NCT03599739|Biological|Influenza|Facilities will be asked to complete a survey to evaluate the impact of the influenza vaccine choice on hospitalization risk for the 2017-2018 influenza season.
74727|NCT03599726|Drug|Donepezil|Donepezil 5 mg per day for week 1-2 or 5-6
74728|NCT03599726|Drug|Placebo|Placebo 5 mg per day for week 1-2 or 5-6
74729|NCT03599713|Drug|INCMGA00012|INCMGA00012 administered at the recommended Phase 2 dose by IV infusion once every 28 days.
74730|NCT03599700|Diagnostic Test|myeloproliferative neoplasms|BLOOD SAMPLING
74731|NCT03599687|Other|Training in SALAD technique|The training session will be delivered, and will take around 45 minutes to complete, including time for participant practice. The training intervention will adopt the Advanced Life Support Group/Resuscitation Council 4-stage approach of skills teaching, and is comprised of: A real-time demonstration of the SALAD technique by the researcher; A repeated demonstration with an explanation of the rationale of the steps taken when performing SALAD (not real-time); Another demonstration of the SALAD technique conducted by the researcher, but guided by one of the participants; An attempt by the same participant who guided the researcher in the previous step, followed by a practice attempt by the other participants.
74732|NCT03599674|Behavioral|Family Bridge Program|Families receive Family Bridge Program services which include orientation to the hospital, concrete needs assessment, communication preferences assessment, communication coaching, follow-up during the hospital stay, and a follow-up phone call after discharge.
74733|NCT03599661|Other|Interview|Participants will review a computer prototype of Fertilit-e alpha. Using an interview guide, participants will be asked about issues of content, functionality, and ease of use (i.e., comprehensibility and usability). Interviews will be completed within 45-60 minutes.
74734|NCT03599661|Other|Questionnaire Administration|All participants will complete an interviewer administered screener for health literacy and self-report items for technology use, eHealth literacy, and need for cognition.
74735|NCT03599648|Behavioral|BPT-M|"Participants randomized to the BPT-M condition receive the Mindfulness-Based Stress Reduction (MBSR) intervention, followed by Behavioral Parent Training (BPT). The MBSR module includes six weekly 2.5 hour group sessions, 30-45 minutes of daily home practice guided by audio CDs, and an MBSR parent workbook. In the sessions, participants practice formal mindfulness exercises, and are provided instruction on stress physiology and using mindfulness for coping with stress in everyday life.~The BPT component of the intervention includes 10 weekly sessions lasting 2.5 hours. Each session is structured around videotape vignettes and uses discussion, role-playing, modeling, and feedback to foster mastery of the material. Parents are given weekly homework assignments and practice their skills."
74736|NCT03599648|Behavioral|BPT-E|Participants randomized to the BPT-E condition will received 6 weeks of a psychoeducation program followed by 10 weeks of the Behavioral Parent Training (BPT) used in both conditions. The psychoeducation module consists of 6 weekly 2.5-hour sessions, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Each of the 6 weekly sessions includes a general topic for discussion. These include preparing for IEP meetings, navigating the regional center and developmental service agencies, communicating with teachers, advocacy, sibling issues, and community resources.
74737|NCT03599635|Drug|liposomal bupivacaine|Experimental
74738|NCT03599635|Drug|Bupivacaine|Active Comparator
74739|NCT03599622|Drug|BMS-986165|oral administration
74740|NCT03599622|Other|Placebo|oral administration
74741|NCT03599609|Drug|Simvastatin 40mg|Simvastatin 40mg, once daily
74742|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly until delivery
74743|NCT03599596|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets twice before delivery
74744|NCT03599583|Behavioral|STOP-HPV prompts intervention|This intervention will be the addition of the prompts intervention (in the presence of communication skills training and continued performance feedback).
74745|NCT03599570|Behavioral|STOP-HPV performance feedback intervention|This intervention will be the addition of performance feedback (in the presence of communication skills).
74746|NCT03599557|Behavioral|STOP-HPV communication intervention|This intervention will be communication skills training.
74747|NCT03599544|Behavioral|Robot-Assisted Therapy (RT)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks).
74748|NCT03599544|Behavioral|Robot + Active Learning Program(RT-ALPS)|Highly intensive robot-assisted therapy for the paretic arm with the Armeo exoskeleton (1 hour sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo robot (3x week for 3 weeks). In addition, participants will receive training in active problem solving, analysis of performance and goal setting focused on home action plan activities to assist with carry-over and generalization to every day activities.
74749|NCT03599518|Drug|DS-1205c|DS-1205c 200 mg capsule for oral administration
74750|NCT03599518|Drug|Gefitinib|Gefitinib 250 mg tablet for oral administration
74751|NCT03599505|Procedure|localization group|Intraoperative ultrasonographic localization will be performed using an ultrasound system (HI VISON Ascendus), which is equipped with a 5-10MHz mechanical probe (EUP-OL531). The accuracy rate of localization will be evaluated using gray scale mode and elastography mode.
74752|NCT03599492|Diagnostic Test|SMART Pill Pre-TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
74753|NCT03599492|Diagnostic Test|SMART Pill Post TIPS|Assessment of motility with Smart Pill, which will be read and confirmed by gastroenterologist trained to interpret motility studies
74754|NCT03599479|Device|Virtual reality group|Virtual reality group The study intervention is to provide acute pain management for the subject undergoing fluoroscopic pain intervention by using the virtual reality program provided by the collaborator through virtual reality device (headset, headphone, and smartphone) that are commercialized on the market.
74755|NCT03599466|Drug|BF-Lisinopril Tablets 20mg|BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
74756|NCT03599466|Drug|Zestril Tab 20mg|Zestril Tab 20mg will be used as a reference drug in this study
74757|NCT03599453|Procedure|Biopsy|Undergo Biopsy
74758|NCT03599453|Procedure|Chemokine Modulation Therapy|Undergo chemokine modulation therapy
74759|NCT03599453|Drug|Celecoxib|Given by mouth
74760|NCT03599453|Biological|Recombinant Interferon Alfa-2b|Given intravenously
74761|NCT03599453|Drug|Rintatolimod|Given intravenously
74762|NCT03599453|Biological|Pembrolizumab|Given intravenously
74763|NCT03599440|Other|Pressure line extensions|"Two types of extension lines are connected:~Perfusor® line 150cm (polyethylene)~conventional arterial extension line"
74764|NCT03599427|Drug|systemic lidocaine|Systemic lidocaine is administrated at induction of anesthesia and at the end of surgery (1.5 mg/kg).
74765|NCT03599427|Drug|Placebo|Placebo is administrated at induction of anesthesia and at the end of surgery (0.075 ml/kg)
74766|NCT03599401|Other|Scaling and root planing|"Scaling and root planing was done by using ultrasonic scalers with high speed suction apparatus to prevent aerosol contamination.~."
75077|NCT03596853|Other|Usual Care|This group will receive standard usual, which will be monitored, but not protocolised.
74767|NCT03599388|Behavioral|Self- management for adequate sleep intervention (SASI)|Bedtimes and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains >90%. Earlier betimes will extend sleep duration by increasing the opportunity for sleep. Wake times will not be changed because wake times are often determined by external demands, such as work schedules
74768|NCT03599375|Biological|CD19-targeted CART cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv.This is a second generation CRAT.
74769|NCT03599362|Drug|Nivolumab + Cabiralizumab|Will be administered on Day 1 and Day 14; Subjects will continue treatment every 2 weeks with subsequent imaging every 8 weeks.
74770|NCT03599362|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will be simulated supine with the addition of a 4D C T if appropriate. A stereotactic immobilization device with abdominal compression will be used.
74771|NCT03599349|Device|Microfocused ultrasound w/ visualization|
74772|NCT03599336|Device|ReUnion RSA (Reverse Shoulder Arthroplasty System)|Surgical management will include placement of fracture specific, cemented reverse total shoulder arthroplasty components.
74773|NCT03599336|Other|Nonoperative Treatment|Subjects allocated to the nonoperative treatment arm will maintain sling immobilization for 3 weeks. The sling will be removed for elbow, wrist and hand range of motion (ROM), hygiene, and dressing only. At 3 weeks passive ROM in external rotation (ER) and forward elevation (FE) will be added. At 6 weeks from injury, the sling will be removed and stretching in all planes will be allowed. Use of the arm will be up to a fork/knife/toothbrush only. At 3 months from injury, strengthening will be added. Supervised physical therapy will be offered to patients for use at their discretion, as is current practice.
74775|NCT03599310|Behavioral|Advance care planning|The ACP guide is adapted from the Serious Illness Communication Guide and a culturally-sensitive ACP programme developed in the local context. The trained ACP facilitators will initiate the conversation by introducing the concepts of ACP with the support of the guide and assessing the patient's illness understanding and readiness to think about end-of-life care issues.
74776|NCT03599310|Behavioral|Usual care|In the current practice, patients will have to take the initiative themselves if they would like to discuss their end-of-life care or make an advance directive.
74777|NCT03599297|Procedure|Bilateral synchronous simultaneous stone surgery|Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
74778|NCT03599284|Drug|Vicagrel 5mg|Experimental group 1 : Vicagrel 20mg loading followed by 5mg/day for 28 days
74779|NCT03599284|Drug|Vicagrel 6mg|Experimental group 2 : Vicagrel 24mg loading followed by 6mg/day for 28 days
74780|NCT03599284|Drug|Vicagrel 7.5mg|Experimental group 3 : Vicagrel 30mg loading followed by 7.5mg/day for 28 days
74781|NCT03599284|Drug|Clopidogrel 75mg|Control group : Clopidogrel 300mg loading followed by 75mg/day for 28 days
74782|NCT03599258|Device|Skylife|Newly FDA approved device
74783|NCT03599258|Device|Standard Therapy|Both devices are considered standard therapy
74784|NCT03599245|Drug|Ocrelizumab|Participants will receive a single 600-mg infusion of Ocrelizumab. (In case of pregnancy, treatment will be interrupted, and the participant will be monitored for safety; however, the participant can be re-started with the treatment after the pregnancy and breastfeeding period.)
74785|NCT03599232|Other|Formative objective structured clinical examination (OSCE)|
74786|NCT03599219|Biological|sample|confirmation of platelet dysfunction
74787|NCT03599206|Drug|Ozone|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
74788|NCT03599206|Other|Filtered Air|Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing filtered air.
74789|NCT03599193|Drug|Tazarotene Lotion, 0.1%|DFD-03 (Tazarotene Lotion, 0.1%) applied Twice Daily for 1 minute and rinsed off
74790|NCT03599193|Drug|Tazarotene Cream, 0.1%|Tazorac® (tazarotene) Cream, 0.1% applied Once Daily and left for approximately 12 hours
74791|NCT03599180|Device|microdialysis|Use microdialysis skill to collect dialyzate at sensitization acupoints
74794|NCT03599128|Other|43.3 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
74795|NCT03599128|Other|86.6 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
74796|NCT03599128|Other|173 mg hydrolyzed green coffee extract|Reconstituted in water and given to subjects
74797|NCT03599128|Other|Placebo|Reconstituted in water and given to subjects
74798|NCT03599115|Behavioral|Inhibitory Control Training|Computerized go/no-go task where individuals make responses to certain items (go trials) and withhold responses from certain items (no-go trials, in this case, trials surrounded by a black box). Intervention is designed to target and improve inhibitory control cognitive mechanisms in general (generic arm) or towards high-calorie foods specifically (food arm).
74799|NCT03599102|Behavioral|LOVED Intervention|
74800|NCT03599089|Drug|CA-008|single-dose wound infiltration prior to surgical incision closure
74801|NCT03599089|Drug|Placebo|single-dose wound infiltration prior to surgical incision closure
74802|NCT03599076|Other|HD Wear|Wearable sensor system for monitoring Huntington's chorea during activities of daily living
74803|NCT03599063|Biological|PF-06946860|PF-06946860 administered subcutaneously
74804|NCT03599063|Other|Placebo|Placebo, administered subcutaneously
74805|NCT03599050|Behavioral|Audiotaped Counseling Session|Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
75153|NCT03596268|Diagnostic Test|Lumbar Puncture|CSF will be collected
74806|NCT03599037|Other|ICOUGH Recovery App v2.0|"The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol."
74807|NCT03599024|Procedure|PCEA|The patients were able to control the administration of analgesics by themselves.
74808|NCT03599024|Procedure|Non-PCEA|The patients were receiving analgesics according to the physician's prescription.
74809|NCT03599024|Procedure|Total hip replacement|All patients enrolled in the study were indicated for total hip replacement surgery.
74810|NCT03598998|Biological|Pembrolizumab|Given IV
74811|NCT03598998|Drug|Pralatrexate|Given IV
74812|NCT03598985|Diagnostic Test|"Smartphone MyAnkle balance application"|"Balance will be assessed simultaneously using MyAnkle application and the Biodex balance system. The smartphone will be fixed to the middle of the shin with an armband. Participants will assume a single leg stance on each side under two conditions: eyes opened and closed. Testing will be done at three levels of difficulty; least difficult (level 8), moderate (level 6) and severe difficult (level 4). A conditioning trial for each level will be given for 30 seconds. Further, a 2-minute rest between tests will be given. During the testing, participants should not touch the ground or stance limb by other limb nor to grasp the handrail. Participants will repeat the same testing in two separate sessions, with one-week interval in between."
74813|NCT03598972|Other|intervention|elementary analysis
74814|NCT03598959|Drug|tofacitinib|orally 10 mg daily
74815|NCT03598959|Drug|chidamide|orally 20 mg twice weekly
74816|NCT03598946|Device|Urinary test|Women use a home urinary test themselves
74817|NCT03598920|Device|AsspireAssist|Endoscopic bariatric procedure using the AsspireAssist device
74818|NCT03598920|Other|Nutritional consulting|Nutritional consulting provided by a specialized consultant.
74819|NCT03598907|Other|Fresh frozen plasma|Fresh frozen plasma will be used according to anaesthetist ,,blind,, decision
74820|NCT03598894|Other|Ambulatory blood pressure measurements|Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
74821|NCT03598881|Other|Treatment|
74822|NCT03598868|Drug|Vortioxetine|Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.
74823|NCT03598868|Drug|Placebo|Augmentation : Placebo for week 1,2,4,6
74824|NCT03598855|Other|Ischemic Preconditioning|Ischemic preconditioning (IPC) refers to cycles of 5 minutes of upper arm cuff inflation with 5 minute periods of cuff deflations, repeated 4 times.
74825|NCT03598842|Dietary Supplement|Nutritional Supplementation Meal|Study participants will be given a nutritional supplementation for 6 months. The supplementation consists of a vegan meal plan.
74826|NCT03598842|Dietary Supplement|Multivitamin|Study participants will be given a daily multivitamin to take for 6 months.
74827|NCT03598842|Drug|Anti-parasitic medications|Study participants will be given anti-parasitic medications per Indian guidelines such as albendazole, ivermectin, metronidazole, or other medications to treat their parasitic infection.
74828|NCT03598816|Drug|Durvalumab|-Durvalumab infusion will start approximately 1 hour (maximum 2 hours) after the end of the tremelimumab infusion
74829|NCT03598816|Drug|Tremelimumab|-Tremelimumab will be administered first
74830|NCT03598816|Device|TDS-IM System|-Integrated electroporation device
74831|NCT03598816|Biological|Neoantigen DNA Vaccine|-At each vaccination time point, patients will receive two injections of the neoantigen DNA vaccine, one injection into each deltoid or lateralis.
74832|NCT03598816|Procedure|Research blood draw|-Baseline, C2D1, C3D1, C5D1, C7D1, and C9D1
74833|NCT03598803|Other|Survey|Urinary Incontinence Survey
74834|NCT03598790|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
74837|NCT03598764|Procedure|Classic head extraction during Cesarean section|by putting the fingers of the right inside the lower uterine segment to deliver the head
74838|NCT03598764|Procedure|External pop out technique|The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
74839|NCT03598751|Drug|BCD-085|120 mg / 2 mL subcutaneously
74840|NCT03598751|Drug|Placebo|2 mL
74841|NCT03598738|Drug|Esomeprazole 40mg|Esomeprazole 40mg oral tablet, once a day
74842|NCT03598725|Drug|Coagulation Factor VIII|Domastic plasma derived factor FVIII (with intermidiate vWF) 50IU/kg every other day
74843|NCT03598725|Drug|Prednisone|2mg/kg every day for 4 weeks then typering in 3 months
74844|NCT03598725|Drug|Rituximab|375mg/Square meter for consecutive 4 months
74845|NCT03598712|Device|Compression by chest bandage urgo K2®|"- Installation of a short stretch belt (urgo K2® kit)~- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).~- Control of the pressure exerted by the bandage by the KIKUHIME® Sub Bandge pressure Monitor device"
74846|NCT03598712|Procedure|punctures|Every 7 days after the second puncture of a volume > 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.
74847|NCT03598699|Drug|AXR-159|AXR-159 Ophthalmic Solution
74886|NCT03598400|Behavioral|high intensity interval training|Participants will complete 6 sessions of high intensity interval training during a 2 week intervention period. The programme involves repeated 1 minute bouts of simple on the spot movements interspersed with 1 minute of rest.
74887|NCT03598400|Behavioral|moderate intensity continous training|Participants will complete 6 sessions of moderate intensity continous training during a 2 week intervention period. Participants will be asked to complete 30 minutes of continuous exercise.
75374|NCT03594578|Behavioral|Episodic future thinking|Prospective thinking intervention
74848|NCT03598686|Diagnostic Test|OraQuick|Most trials assessing oral HIVST make use of OraQuick® (OraQuick ADVANCE HIV I/II test kits, packaged for self-use), an oral-fluid rapid self-test. OraQuick® is a 2nd generation serology assay with a sensitivity of 99.3% (95%CI; 98.4%, 99.7%) and a specificity of 99.8% (95%CI; 99.6%, 99.9%). In a pilot study with 59 participants conducted in Lesotho in 2015 more than 90% of the participants found utilization of OraQuick® easy, and trusted the results of the self-test kit. The WHO recently has announced that OraQuick becomes the first prequalified HIV self-test, in order to improve diagnosis in low-resourced health systems and in countries where stigma prevents people from getting tested. Therefore, OraQuick® is now available in Lesotho for as little as 2 USD per test kit.
74849|NCT03598673|Drug|The Efficacy and Tolerability of Nebivolol in Nigerians|To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
74850|NCT03598660|Genetic|Sorcin gene expression|Sorcin gene expression Will be measured by real time PCR
74851|NCT03598660|Other|Annexin A3 serum mesurement|serum mesurement of Annexin A3 by enzyme linked immuno sorbent assay (ELISA)
74852|NCT03598647|Behavioral|Affect and physical activity|The focus of this intervention is to help the participant to become more aware of their positive feelings and experiences related to exercise. They will learn about typical affective responses to exercise, view their own affective responses to exercise, and they will be taught cognitive strategies for altering affective responses to exercise. Participants will also receive general information about exercise safety, physical activity guidelines, and exercise intensity.
74853|NCT03598647|Behavioral|Physical activity information|Participants will receive general information about exercise safety, physical activity guidelines, and exercise intensity.
74854|NCT03598634|Procedure|administration of riboflavin for epi-off cross-linking|riboflavin 0.1% in 20% dextran solution
74855|NCT03598634|Procedure|administration of riboflavin for epi-on cross-linking|riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid
74856|NCT03598621|Drug|Semaglutide, 0.5 mg/mL|A single dose will be administered subcutaneously (s.c.; under the skin) in the morning after an overnight fast of at least 8 hours.
74857|NCT03598621|Drug|Semaglutide, 1.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
74858|NCT03598621|Drug|Semaglutide, 1.34 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
74859|NCT03598621|Drug|Semaglutide, 2.0 mg/mL|A single dose will be administered s.c. in the morning after an overnight fast of at least 8 hours.
74860|NCT03598621|Device|DV3372, 0.5 mg/mL|DV3372 device will be used for administration of semaglutide 0.5 mg/mL.
74861|NCT03598621|Device|DV3372, 1.0 mg/mL|DV3372 device will be used for administration of semaglutide 1.0 mg/mL.
74862|NCT03598621|Device|PDS290|PDS290 pen-injector will be used for administration of semaglutide 1.34 mg/mL.
74863|NCT03598621|Device|NovoPen®4|NovoPen®4 will be used for administration of semaglutide 2.0 mg/mL.
74864|NCT03598608|Biological|pembrolizumab|Administered as an IV infusion every 3 weeks (Q3W)
74865|NCT03598608|Biological|MK-4280|Administered as an IV infusion Q3W
74866|NCT03598595|Drug|Docetaxel|Given IV
74867|NCT03598595|Drug|Gemcitabine|Given IV
74868|NCT03598595|Drug|Hydroxychloroquine|Given PO
74869|NCT03598582|Drug|Epoetin Zeta|"Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol."
74870|NCT03598569|Other|dyspnea|dyspnea assessment
74871|NCT03598556|Dietary Supplement|Vitamin D3|180,000IU Vitamin D3 oral emulsion
74872|NCT03598556|Other|Placebo|Placebo
74873|NCT03598543|Other|no intervention|no intervention, this is an obervational study.
74874|NCT03598530|Procedure|Surgery|Surgical fracture fixation, using osteosynthesis, including single or multiple staged procedures (e.g. primary External Fixation and later conversion to internal fixation).
74875|NCT03598517|Radiation|high dose chemoradiotherapy|"Radiation therapy: 60 Gy at 2 Gy/Fx/d over 6 weeks, immediately followed by 28.8 Gy in 24 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 88.8 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy is planned 6 weeks after high dose chemoradiation."
74876|NCT03598504|Device|Wearable EMG/Vibration device|The device is a combination of an EMG recorder/detector and a vibrator
74877|NCT03598478|Behavioral|TC-MPT|Participants will receive two levels of training within each 90-minute session over a 12-week period: (1) TC training and (2) MPT. The TC training protocol consists of five basic TC movements. After receiving TC training, the participants in this group will take a 5-minute break and then receive MPT. During MPT, the participants will contract their major postural muscles bilaterally as fast as possible against a resistance equivalent to 70% of one repetition maximum.
74878|NCT03598478|Behavioral|TC|Children in the TC group will skip the MPT session and practice TC movements repeatedly for 90 minutes. The exercise progression pattern in the TC-alone group will be the same as that in the TC-MPT group.
74879|NCT03598478|Behavioral|MPT|Those children in the MPT group will perform strengthening exercises repeatedly for 90 minutes, with a short 5-minute break between the three sets of exercises if necessary. The exercise progression pattern in the MPT-alone group will be the same as that in the TC-MPT group.
74880|NCT03598452|Drug|Ganciclovir|Intravitreal Injection of Ganciclovir (IVG) was conducted in a week interval. The initial dose was 6mg/0.1ml at the first injection and it was reduced to 4.5mg/0.1ml at the second time; 3mg/0.1ml of IVG was maintained until the CMV could not be detected in aqueous humor.
74881|NCT03598439|Biological|Standard IIV4|Standard inactivated influenza vaccine
74882|NCT03598439|Biological|Recombinant|Influenza vaccine that uses a hemagglutinin protein manufactured in insect cells with a baculovirus vector
74883|NCT03598439|Biological|Cell-culture|inactivated influenza vaccine manufactured using mammalian cell lines; current vaccine uses a cell-propagated H3N2 strain.
74884|NCT03598426|Drug|Dexamethasone|Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
74888|NCT03598387|Other|Automated peritoneal dialysis|"The prescription of automated peritoneal dialysis:~The first 48-72 hours dose: 0.8-2.0 liter exchange with 1-2 hour-cycle (8-36 liters per day); After initial 48-72 hours, 1.0-2.5L exchange with 2-6 hour-cycle (at least 8 liters per day), if the acidosis, hyperkalemia and pulmonary edema are corrected.~The minimal target weekly Kt/V is 2.1-3.5/W."
74889|NCT03598387|Other|Intermittent hemodialysis|Intermittent hemodialysis will be performed 3-4h of each session and 2-5 times per week. The prescription will be adjusted based on patients' conditions to ensure spKT/V≥1.3.
74890|NCT03598374|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation of for 6 months or until pregnancy conception:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
74891|NCT03598374|Dietary Supplement|Folic acid|"Daily oral supplementation of for 6 months:~Folic acid: 400 mcg"
74892|NCT03598374|Behavioral|Regular intercourses|Couples are required to have regular intercourses with the aim to achieve a spontaneous conception.
74893|NCT03598348|Drug|Apatinib+Capecitabine|Capecitabine 1000mg/m2 po bid, d1-14, Apatinib 250mg po Qd, Q21d
74894|NCT03598348|Drug|Apatinib|Apatinib 250mg po Qd
74895|NCT03598335|Device|Ultrasound|Ultrasound imaging of women arriving at clinic for routine care
74896|NCT03598322|Procedure|Dextrose 1mL injection|Dextrose 1mL injection and hydrodissection for CTS
74897|NCT03598322|Procedure|Dextrose 2mL injection|Dextrose 2mL injection
74898|NCT03598322|Procedure|Dextrose 4mL injection|Dextrose 4mL injection
74899|NCT03598309|Drug|Curcumin C3 complex®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
74900|NCT03598309|Drug|Lovaza®|Groups A and B as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
74901|NCT03598309|Other|Placebo|Groups B and Placebo as outlined in study arm. Drug will be dispensed by investigational pharmacists and self-administered by the participants.
74902|NCT03598296|Other|Large size tube|Patients in Group A are inserted the large size tube (28F).
74903|NCT03598296|Other|Drainage ball|Patients in Group B are inserted the small-bore tube connects with a negative pressure ball(drainage ball).
74904|NCT03598283|Device|Ultrasound/transient elastography|The evaluation of the liver will be performed non-invasively with liver fibrosis scores based on standard blood parameters, the ultrasound-guided measurement of the liver size and the measurement of liver stiffness (correlated with liver fibrosis) and controlled attenuation parameter (CAP, correlated with hepatic steatosis) via transient elastography (FibroScan©, Echosens SA, Paris, France). The thyroid will be assessed by ultrasound and standard blood parameters and the pancreas by standard blood parameters only, respectively.
74905|NCT03598270|Drug|Placebo|Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
74906|NCT03598270|Drug|Carboplatin|Intravenous. Day 1
74907|NCT03598270|Drug|Paclitaxel|175 mg/m². Intravenous. Day 1
74908|NCT03598270|Drug|Niraparib|200 mg or 300 mg. Oral. From day 1 to 21
74909|NCT03598270|Drug|Gemcitabine|1000 mg/m². Intravenous. Day 1 and day 8.
74910|NCT03598270|Drug|Pegylated liposomal doxorubicin (PLD)|30 mg/m². Intravenous. Day 1
74911|NCT03598270|Drug|Atezolizumab|1200 mg. Intravenous. Day 1
74912|NCT03598257|Drug|Olaparib|Given PO
74913|NCT03598257|Radiation|Radiation Therapy|Undergo radiation therapy
74914|NCT03598244|Drug|Savolitinib|Given PO
74915|NCT03598231|Device|Sacral neuromodulation|"After the definitive implantation, stimulators are placed in position OFF for the first arm and in position ON for the second arm during 4 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 2 weeks.~Finally stimulators are maintained in position ON for the first arm and switched OFF for the second arm during 4 weeks.~Since this is a cross-over study, patients can be randomly assigned to any arm first, but they will go to the other arm since the patient is its own control. 50% of randomized patients will go through ON-OFF and the other 50% OFF-ON.~After this cross-over phase, ALL stimulators will be in ON position until the end of the study period."
74916|NCT03598218|Radiation|Hypofraction radiation|"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
74917|NCT03598218|Radiation|Standard dose IMRT|"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."
74918|NCT03598205|Combination Product|DIABEC plus intravitreal dexamethazone|Patients with diabetic macular edema undergoing to intravitreal dexamethazone will be randomized to curcumin formulation (DIABEC)
74919|NCT03598192|Procedure|TAP|The TAP group will be performed at four points at abdominis plane with ropivacaine 0.375%
74920|NCT03598192|Procedure|PVB|The PVB group will be performed at paravertebral space T7 with ropivacaine 0.5%
74921|NCT03598192|Drug|Ropivacaine|Ropivacaine has been treated the both group
74922|NCT03598192|Drug|Sufentanil|Sufentanil has been included in Arm/Group Descriptions
74923|NCT03598179|Biological|chimeric antigen receptor T cells|Dose CAR+ cells/kg B-cell lymphoma 4×10^6 Acute lymphocytic leukemia 2×10^6 Chronic lymphocytic leukemia 10×10^6
74924|NCT03598166|Diagnostic Test|Septin9|Septin9 is a FDA-approved blood test for colorectal cancer screening
74925|NCT03598153|Drug|Shujinjianyao Pill|According to the usage and dosage of the instructions, patients should use the medicine dialectically and rationally for 4 weeks.
74926|NCT03598140|Drug|Sildenafil Citrate|Sildenafil 60mg once (Group 1) or daily for 2 weeks (Group 2)
74927|NCT03598140|Drug|Placebo oral capsule|Placebo once (Group 1) or daily for 2 weeks (Group 2)
74961|NCT03597867|Drug|Indom|Dosing of drug 3 days prior to surgery
74962|NCT03597867|Drug|Yellox|Dosing of drug 3 days prior to surgery
74963|NCT03597841|Drug|Combination therapy|Patients who are given combination therapy will be allocated to this group.
132259|NCT03155425|Drug|SHR-1210|A humanized monoclonal immunoglobulin
74928|NCT03598114|Behavioral|Program Sustainability Action Planning Model and Training Curricula|The Program Sustainability Action Planning Model and Training Curricula's conceptual model is driven by the theory of change and incorporates aspects of Kolb's experiential learning theory to produce a six step process: defining the program, assessing the program, developing an action plan, executing the action plan, evaluating sustainability, and reassessing and modifying. The study team will deliver in-person, hand-on workshops incorporating each of these aspects of the conceptual model. Following the workshop, intervention states will partake in technical assistance activities with the study team to track progress and troubleshooting challenges.
74929|NCT03598101|Device|TONEFITreha|The newly developed Tonefit Reha is based on the existing fitness device, the TONEFIT belt. Similar to Nordic Walking, the device aims to include upper limb activity in walking exercise to train the shoulder girdle and arm. While Nordic Walking uses poles, the existing TONEFIT belt uses body-worn resistance handles to actively involve the upper body. It is worn around the waist, like a belt. The two independent pull-push elements with non-adjustable resistance on each side allow increased intensity for strengthening and endurance training during walking, particular for upper extremities and trunk stability.
74930|NCT03598088|Device|Ovaprene|non-hormonal contraceptive ring
74931|NCT03598075|Other|Amylin (Pramlintide)|Pramlintide is a amylin analog. It will be given intravenously at the rate of 1.5 microgram /ml over 20 minutes .
74932|NCT03598075|Other|CGRP|CGRP It will be given intravenously at the rate of 1.5 microgram /ml over 20 minutes.
74933|NCT03598049|Device|densah burs osseo densification drills|osseo densification of the alveolar bone in maxillary posterior ridge during implant placement
74934|NCT03598049|Device|conventional surgical burs drilling|conventional implant osteotomy site drilling with implant surgical kit
74935|NCT03598036|Drug|Voclosporin|"Voclosporin softgel capsules. Approximately 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID).~The dose of voclosporin for Cohort 2 (approximately 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 6 subjects in Cohort 1."
74936|NCT03598023|Device|Cytal® Burn Matrix|Cytal® Burn Matrix
74937|NCT03598023|Device|EZ-Derm® Porcine Xenograft|EZ-Derm® Porcine Xenograft
74938|NCT03598010|Device|Actitan-F (7dd)|1 sack every 4 hours, maximum 4 sacks/day for 7 days.
74939|NCT03598010|Device|Actitan-F (28dd)|1 sack every 4 hours, maximum 4 sacks/day for 28 days.
74940|NCT03597997|Drug|Propofol|Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.
74941|NCT03597997|Drug|Sevoflurane|Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.
74942|NCT03597984|Radiation|Simultaneous Integrated Boost-SIB on macroscopic metastases|"Delivery of a boost on macroscopic secondary lesion with Simultaneous Integrated Boost technique according this schedule:~- 5 Gy x 3 fr (Whole Vertebra) + SIB 10 Gy x 3 fr on the macroscopic disease Gross Tumor Volume - (GTV)"
74943|NCT03597971|Drug|HMPL004-6599|For each cohort, 6 subjects will receive HMPL004-6599
74944|NCT03597971|Drug|Placebo|For each cohort, 2 subjects will receive placebo
74945|NCT03597958|Genetic|Next generation sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS), transcriptome analysis
74946|NCT03597945|Procedure|lidocaine with epinephrine|lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
74947|NCT03597945|Procedure|normal saline|normal saline as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
74948|NCT03597945|Procedure|Magnesium sulfate|Magnesium-sulfate as adjuvant to lidocaine with epinephrine in prehospital femoral nerve block for patient with diaphysial femoral fracture
74949|NCT03597932|Device|standardized handover checklist|Following a review of relevant literatures and guidelines, a checklist consisting of the various key items necessary for giving continuing and safe intraoperative patient care was designed and validated by anesthesia residents and staff. Following 2-week to 1-month baseline data collection, each anesthesiologists and anesthesia residents in participating hospitals were asked to implement the safe-anesthesia checklist to improve practice over another 2-week to 1-month period. The checklist consists of an oral confirmation and closed-loop communication between the primary anesthesiologist and the replacement anesthesiologist. Evaluation of the effect of implementation of a standardized checklist during anesthesia care handover on patient safety during follow-up.
74950|NCT03597919|Biological|Sabin IPV|We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
74951|NCT03597906|Procedure|topography guided ablation|using the data obtained from the topolyzer for correction of refractive errors specially astigmatism we use 3 different treatment protocols
74952|NCT03597906|Procedure|manifest refraction|using for ablation the exact manifest refraction
74953|NCT03597906|Procedure|full topography modified refraction|full topography modified refraction means changing both sphere and cylinder power in the ablation profile
74954|NCT03597906|Procedure|partial topography modified refraction|partial topography modified refraction means changing only cylinder power and axis in the ablation profile
74955|NCT03597893|Drug|Oxytocin|intranasally administrated
74956|NCT03597893|Drug|Placebo|intranasally administrated
74957|NCT03597880|Other|obese patients|underwent bariatric surgery
74958|NCT03597867|Other|Placebo|Artificial tears for 3 days preoperatively
74959|NCT03597867|Drug|Dicloftil|Dosing of drug 3 days prior to surgery
74960|NCT03597867|Drug|Nevanac|Dosing of drug 3 days prior to surgery
74966|NCT03597815|Device|CPAP therapy for OSA positive patients|positive airway pressure ventilator, applies mild air pressure in a continuous basis to keep the airways continuously open in patients who are able to breath spontaneously on their own.
74967|NCT03597802|Other|Exercise at workplace - Three times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
74968|NCT03597802|Other|Exercise at workplace - Four times per week|The exercise at workplace will be occur during the workday during the rest breaks. The exercises perform are stretching, and using load.
74969|NCT03597789|Behavioral|Helping the Noncompliant Child (HNC)|HNC is a mastery-based, family-focused, clinic-based treatment for young children aged 3-8 years with problem behavior.
74970|NCT03597776|Drug|Lidocaine|Bolus of lidocaine will be given over 5 minutes before skin incision
74971|NCT03597776|Drug|Saline|Bolus of saline will be given over 5 minutes before skin incision
74972|NCT03597750|Device|Repose®|"Repose® Mattress~Repose® Cushion~Repose® Wedge or Foot Protectors"
74973|NCT03597737|Other|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
74974|NCT03597737|Other|Pain APP|pain app Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
74975|NCT03597724|Other|Questionnaire composed of 13 choice questions.|In this Discrete Choice Experiment (DCE), patients will be asked to choose which one of two hypothetical patients (Patient A and Patient B) suffering from sarcopenia with different levels of outcomes deserves the most the treatment. After completion of the choice tasks, respondents will be asked how difficult they found the choice tasks on a seven-point scale and to questions on their socio-economic and disease characteristics.
74976|NCT03597711|Device|IVcannulation|Peripheral venous cannulation is a common procedure on neonatal NICU, especially in preterm infants
74977|NCT03597659|Genetic|phenome-wide association study (PheWAS)|Phenome-wide association study (PheWAS) identifying clinical diagnoses associated with a polygenic predictor of TSH levels identified by a previously published genome-wide association study (GWAS) which included North American and European participants. A phenome-wide scanning of 1,318 phenotypes will be performed, using a cohort of 37,154 North American individuals of European ancestry with electronic-health-record (EHR) data.
74978|NCT03597646|Device|Kinesio Tape|
74979|NCT03597646|Device|Threshold Inspiratory Muscle Trainer|
74980|NCT03597620|Drug|Metaderm|Metaderm cream and spray will be apply to subjects scalp and body.
74981|NCT03597607|Behavioral|Intensive Smoking Cessation Group|This group will meet with the pharmacist more frequently and for longer periods than other groups.
74982|NCT03597607|Behavioral|Abbreviated Smoking Cessation Group|This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
74983|NCT03597594|Drug|Anti-thymocyte globulin (rabbit)|given intravenously
74984|NCT03597594|Drug|Busulfan|given intravenously
74985|NCT03597594|Drug|Fludarabine|given intravenously
74986|NCT03597594|Drug|Thiotepa|given intravenous infusion
74987|NCT03597594|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
74988|NCT03597594|Other|Donor Lymphocyte Infusion|given intravenous infusion
74989|NCT03597581|Drug|RGX-202-01|RGX-202-01 is a small molecule inhibitor of the creatine transporter, SLC6a8.
74990|NCT03597581|Drug|FOLFIRI|FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.
74991|NCT03597568|Dietary Supplement|Resveratrol|Oral supplementation for 6 weeks
74992|NCT03597568|Other|Placebo|Oral supplementation for 6 weeks
74993|NCT03597555|Drug|Sodium Oxybate Oral Solution 500 MG/ML|"First night after V1: Dose prescribed at 4.5 g per night (2.25 g x 2) for 2 weeks First night after V2: Dose increased to 6 g per night (3 g x 2) for 2 weeks, according to investigator's opinion, tolerance of drug and CGI-S First night after V3: Dose either maintained stable at 6 g or increased to 9 g per night (4.5 g x 2) with dose increments of 1.5 g per night (0.75 g x 2) every week, based on benefit-risk ratio, for 2 weeks.~First night after V4: Dose maintained at 9 g or reduced at 6 g per night according to benefit-risk ratio for 2 weeks. No dose adjustment during the Maintenance period.~First night after V5: Taper period. Dose decrease by 2.25 g x 2 every two days until complete withdrawal"
74994|NCT03597555|Drug|Placebos|Xyrem Placebo: sodium citrate solution in equimolar concentration of sodium in the 500 mg/mL Xyrem oral solution, PH adjusted with malic acid
74995|NCT03597542|Other|Eggs and Carbohydrates|Participants are asked to consume both egg based powder or maltodextrin dissolved in 500mL of water at two different time points at least one week apart. Participants will then submit to a venous blood draw to assess levels of cellular inflammation.
74996|NCT03597529|Drug|Melatonin|melatonin
74997|NCT03597516|Drug|RP-G28|powder for reconstitution for oral administration
74998|NCT03597516|Drug|Placebos|powder for reconstitution for oral administration
74999|NCT03597503|Drug|SPN-810|Flexible dose
75000|NCT03597503|Drug|Placebo|Placebo
75001|NCT03597490|Combination Product|Multimodal physical therapy with exercise|Multimodal physical therapy will compose of thermotherapy (hot pack or cold pack) and electrotherapy (transcutaneous electrical nerve stimulation or interferential current) and therapeutic ultrasound (at least two of them). Therapeutic exercise will compose of combination of range of motion, stretching, strengthening,neuromuscular and task specific exercises according to the clinical condition of patient under the supervision of a physiotherapist. Additionally, all patients will be allowed to carry on home exercise program.
75002|NCT03597477|Drug|Dexmedetomidine|participants were randomly allocated to receive sedation with oral midazolam(0.3 mg/kg) combined with 4 doses of intranasal dexmedetomidine(1.0, 1.5, 2.0, 2.5)
75003|NCT03597464|Drug|Voclosporin|Calcineurin inhibitor, oral, 23.7 mg BID
75005|NCT03597425|Procedure|Cardiopulmonary resuscitation|Cardiopulmonary resuscitation (CPR) is an emergency treatment for patients with respiratory arrest and cardiac arrest in an attempt to restore the patient to spontaneous breathing and heartbeat through cardiopulmonary resuscitation
75006|NCT03597412|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
75007|NCT03597412|Drug|Monorova|Rosuvastatin 20mg
75008|NCT03597399|Biological|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (voretigene neparvovec-rzyl) to both eyes via surgical procedures on separate days.
75009|NCT03597373|Other|reintubation|Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
75010|NCT03597360|Radiation|CT scan|Participants will receive the first LDIR treatment in one session on the same day, i.e., two CT scans of the brain that delivers a total X-ray dose (CTDIvol)10 of about 80 mGy. Participants will then be transported back to Baycrest Health Sciences. Participants will receive another LDIR treatment, i.e. a single CT scan of the brain (40 mGy), 2 weeks after the first session. They will receive a third LDIR treatment, i.e., a single CT scan of the brain (40 mGy), 2 weeks after the second session. Date, time and X-ray dose will be recorded for each participant and sent to their family physician for entry into in their health record.
75011|NCT03597347|Drug|Molgramostim nebulizer solution|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
75012|NCT03597347|Device|PARI eFlow nebulizer system|Nebulizer
75013|NCT03597334|Behavioral|aerosol therapy|Aerosol inhalation therapy refers to a local administration method in which a drug is made into aerosol particles having a very small diameter and is inhaled by a patient and the drug directly acts on the airway
75014|NCT03597321|Biological|prophylactic donor lymphocyte infusion (DLI)|DLI will be collected from the donor by leukapheresis according to local standard procedures of each center. Cell product could be collected in one time or more, and administered fresh or after a frozen storage, according to each center's guidelines. A sufficient amount of T-cell dose should be collected to theoretically perform 3 DLI. DLI procedure will be performed according to local guidelines of each center.
75015|NCT03597308|Drug|5mg of Oxycodone every 6 hours as needed for pain|5mg of Oxycodone every 6 hours as needed for pain
75016|NCT03597308|Drug|600mg of Ibuprofen every 6 hours as needed for pain|600mg of Ibuprofen every 6 hours as needed for pain
75017|NCT03597308|Drug|500mg of Acetaminophen every 6 hours as needed for pain|500mg of Acetaminophen every 6 hours as needed for pain
75018|NCT03597295|Drug|INCMGA00012|INCMGA00012 administered at the recommended Phase 2 dose by intravenous infusion once every 28 days.
75024|NCT03597256|Device|Restylane Defyne|Intradermal injection
75025|NCT03597243|Other|Cash Transfer|Girls enrolled receive a quarterly direct cash transfer of a total of 70,000 Tshs (30 USD) quarterly through mobile phone based cash transfer over a period of two years, for which they will receive mobile phones and SIM cards form the program.
75026|NCT03597230|Other|Dye|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study and/or among similar interventions At the beginning of the surgical procedure, 1 ml of blue patent will be injected in the normal remaining part of the pancreas. The diffusion of the dye among all lymph node areas will be noticed by the surgeon.
75027|NCT03597217|Drug|PF-05221304|3, 10, 50 mg
75028|NCT03597217|Drug|PF-05221304|50 mg multiple dose
75029|NCT03597217|Drug|Placebo|Placebo
75030|NCT03597204|Diagnostic Test|Fecal immunochemical test (FIT)|Annual fecal immunochemical test (FIT) for selected high risk individuals to undergo CRC screening. And colonoscopy for those with FIT positive result
75031|NCT03597191|Other|Exercises|Participants in the treatment group will be instructed in the spinal stabilization exercises (SSEs), modeled after the spinal stabilization exercise program designed by Hicks et al. (2005). The SSE program targets muscle activation of spinal stabilizers specifically, the transversus abdominus and lumbar multifidus muscles. Each exercise will be progressed by increasing repetitions and hold time.
75032|NCT03597178|Device|senofilcon A|ACUVUE OASYS® 1-DAY with HydraLuxe™ Technology
75033|NCT03597165|Other|Incidental Genomic Sequencing Results|"Patient will receive GS results related to their primary indication (cancer), as well as the option to learn incidental GS results. Incidental results will be categorized into five bins based on Berg et al.'s framework (medically actionable and pharmacogenetic, common disease SNPs, Mendelian conditions, early-onset brain diseases, and carrier status). In pre-test counseling, patients will have the option to select which bins of incidental results they would like to learn, if any."
75034|NCT03597165|Other|GS Results for Primary Indications only|Patients will receive GS results related to the primary indication (cancer) only.
75035|NCT03597152|Dietary Supplement|WelTract|Supplement commercially available from the sponsor containing powdered extracts from Hibiscus flowers and cranberry fruit, lactoferrin, D-mannose, and vitamins C and D
75036|NCT03597152|Dietary Supplement|Placebo|Inert placebo custom manufactured for the sponsor
75037|NCT03597139|Drug|Voclosporin Ophthalmic Solution|Investigational Drug
75038|NCT03597139|Drug|Restasis®|Comparator
75039|NCT03597126|Device|Robot-assisted surgery|robot-assisted intersphincteric resection for low location rectal cancer(T=1&2)
75040|NCT03597126|Device|Laparoscopic surgery|laparoscopic intersphincteric resection for low location rectal cancer(T=1&2)
75041|NCT03597100|Device|Cala TWO|Wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves
75042|NCT03597087|Procedure|Anesthesia before transurethral resection of the bladder tumor|"General anaesthesia or general anesthesia (see spelling differences) is a medically induced coma with loss of protective reflexes, resulting from the administration of one or more general anaesthetic agents.~Spinal anaesthesia is a form of regional anaesthesia involving the injection of a local anaesthetic into the subarachnoid space, generally through a fine needle"
75043|NCT03597087|Drug|Anesthesia|"General anaesthesia : propopol~Spinal anaesthesia : bupibacaine"
75044|NCT03597074|Diagnostic Test|color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization|Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
75045|NCT03597061|Behavioral|Healthy Start to Feeding|The intervention provides parent education and skills training on a responsive feeding approach to introduction of healthy foods in infancy. Session content is manualized and administered by interventionists with expertise in child development and behavioral strategies for managing child eating behaviors under the supervision of a licensed clinical child psychologist and pediatric occupational therapist. Sessions are conducted individually with participants and primary caregivers and include educational content, handouts and instructions, modeling of skills by the interventionist, caregiver practicing of skills in session, establishment of behavioral goals, and problem solving barriers to implementation of treatment content. Content will include topics such as allowing infants' own hunger and satiety cues to guide the feeding experience, introducing healthy foods, parental attunement to infant satiety cues, and promoting infants' own self-feeding.
75046|NCT03597048|Behavioral|Curriculum|The curriculum intervention is a three- module, three-hour curriculum delivered by teachers in sixth grade classrooms over a three- to six-day period. The curriculum is designed to increase knowledge and improve attitudes about mental illnesses so as to improve the school climate with respect to mental illness stigma and encourage help seeking for youth in need.
75047|NCT03597048|Behavioral|Contact|The contact intervention involves two college students—a 27-year-old male with a history of bipolar I disorder and a 24-year-old female with a history of bipolar II disorder—who each make a ten-minute in-class presentation (20 minutes total) describing onset and course of their symptoms, hospitalizations and treatments, their feelings about the illness, coping strategies, and impact of the illness on social relationships and functioning at school and work.
75048|NCT03597048|Behavioral|Materials|"The materials intervention is implemented by teachers who prominently display posters in the classroom for two weeks and provide students with bookmarks. The materials focus on individuals' with mental illnesses emphasizing their personal traits and abilities as opposed to language that labels a person as mentally ill."
75049|NCT03597035|Drug|Spironolactone|The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose. If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
75050|NCT03597022|Drug|BAY1093884|Patients will receive a subcutaneous injection of BAY1093884 once per week.
75051|NCT03597009|Drug|Talimogene laherparepvec (TVEC)|Talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles, with or without nivolumab
75052|NCT03597009|Drug|Nivolumab|Nivolumab (240 mg IV) will be co-administered with talimogene laherparepvec (TVEC) (4ml of 108 pfu/ml) for up to 9 cycles in the Dose Level 2 cohort
75053|NCT03596996|Dietary Supplement|Ferrous Sulfate|Ferrous sulfate dosed by WHO guidelines by age for the prevention of iron deficiency and anemia.
75054|NCT03596996|Dietary Supplement|Placebo|Placebo with identical appearance comparison intervention arm
75055|NCT03596983|Behavioral|Sleep Intervention|"Sleep Diaries (Daily)~Fitbit 24/7~Phone/ video conference calls (weekly with study team)~Epworth Sleepiness Scale (weekly)~PROMIS fatigue scale-evening (weekly)"
75056|NCT03596983|Behavioral|Week 2 Intervention|"Sleep Diaries (Daily)~Phone Calls (weekly with study team)~Wrist Accelerometry and fitbit 24/7 for 14 days~SAFTEE Questionnaire~ASA24~Behavioral risk factor surveillance system (smoking and alcohol use questions)~Psychological well-being (SF36)~Index of Self Regulation~PROMIS fatigue scale-morning (weekly)~PROMIS fatigue scale-evening (weekly)~Epworth Sleepiness Scale (weekly)"
75057|NCT03596970|Drug|TAC withdrawal|Everolimus (RAD001) with MMF and Steroids
75058|NCT03596970|Drug|Everolimus with reduced TAC|Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
75059|NCT03596957|Drug|Tolvaptan|At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability
75060|NCT03596944|Drug|Statin|Prescribed with statins for primary prevention
75061|NCT03596931|Drug|Statins (Cardiovascular Agents)|Prescribed with statins
75062|NCT03596918|Biological|Bleomycin Sulfate|Given IV
75063|NCT03596918|Other|Laboratory Biomarker Analysis|Correlative studies
75064|NCT03596918|Other|Quality-of-Life Assessment|Ancillary studies
75065|NCT03596918|Other|Questionnaire Administration|Ancillary studies
75066|NCT03596918|Drug|Vincristine Sulfate|Given IV
75067|NCT03596905|Drug|Plecanatide|Taken orally daily for 4 weeks
75068|NCT03596905|Drug|Matching placebo|Taken orally daily for 4 weeks
75069|NCT03596892|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
75070|NCT03596892|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
75071|NCT03596892|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
75072|NCT03596879|Behavioral|dCBTI|Online access to the digital CBTI program Sleepio based off of traditional face-to-face Cognitive Behavioral Therapy, six weekly sessions done online.
75073|NCT03596879|Behavioral|Sleep Education|Six weekly email messages with sleep hygiene recommendations. Subjects are encouraged to read through the information and apply it to their sleep.
75074|NCT03596866|Drug|Brigatinib|Brigatinib Tablets.
75075|NCT03596866|Drug|Alectinib|Alectinib Capsules.
75076|NCT03596853|Other|Progressive mobilization|"Will be applied once a day, 5x/ week, performed into 4 levels: N1 (bridge and rolling for both sides); N2 (transfer training from lying down to sitting on both sides); N3 (sit and stand up from a chair); N4 (running training). According to their functional level, patients will perform, once a day, 8 sets of each movement, alternating 20 seconds of execution with 10 seconds of rest. Patients will be stimulated constantly to perform the movements with the highest possible speed.~If the patient performs adequately within of your level functional level, can will progress in level, if can not progress, there will be an increase in training volume within the level itself. Adequate performance within the functional level means that the patient is able to complete more than eight sets of exercise and does not present increased sensation of pain, present sensation of perceived exertion within the safety limit of the protocol (Borg ≤ 6)."
75078|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E10 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
75079|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E9 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
75080|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E8 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonization Factor Antigen II (CFA/II) and provides 75% protection against challenge with an LT, ST, CFA/II strain
75081|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E7 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
75082|NCT03596827|Biological|E. coli strain E1392-75-2A dose 1E6 CFU|Diarrhoeagenic E. coli strain E1392/75-2A serotype O6:H16 belongs to Pathogen class 2 . The strain has a deletion of genes encoding the heat-labile (LT) and heat-stable (ST) toxins and can not produce any toxins. However, it continues to express Colonizat
75083|NCT03596814|Other|No Interventional study|Retrospective data
75084|NCT03596801|Biological|RSV 6120/∆NS1|Delivered as nose drops
75085|NCT03596801|Biological|RSV 6120/F1/G2/∆NS1|Delivered as nose drops
75086|NCT03596801|Biological|Placebo|Delivered as nose drops
75087|NCT03596788|Dietary Supplement|Carbohydrate Beverage|The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)
75088|NCT03596788|Dietary Supplement|Placebo Beverage|The placebo beverage will contain aspartame.
75089|NCT03596775|Drug|Dexmedetomidine|Children in Dexmedetomidine group receive intravenous dexmedetomidine 0.5 ug/kg over 10 minutes after induction of anesthesia.
75090|NCT03596775|Drug|saline|Children in Control Comparator group receive intravenous saline 10ml over 10 minutes after induction of anesthesia.
75091|NCT03596762|Drug|NT-814|NT-814 capsules
75092|NCT03596762|Drug|Placebo|Placebo capsules
75093|NCT03596749|Drug|Sevelamer Carbonate|Sevelamer carbonate 1600mg (p.o. b.i.d) with meals
75094|NCT03596736|Procedure|Elbow Hemiarthroplasty|
75095|NCT03596736|Procedure|Total Elbow Arthroplasty|
75096|NCT03596723|Drug|KPI-121 1%|eye drops
75097|NCT03596723|Drug|Prednisolone acetate|eye drops
75098|NCT03596710|Procedure|Image Guided Biopsy|Undergo image guided biopsy
75099|NCT03596697|Drug|CRV431|Single or multiple dose(s) of CRV431
75100|NCT03596697|Drug|Placebo|Single Placebo dose
75101|NCT03596697|Drug|TDF|Single or multiple dose(s) of TDF
75102|NCT03596684|Dietary Supplement|citrulline supplementation|2.5 g per os of citrulline on the morning and the evening (5 g/ jour) during 4 weeks.
75103|NCT03596684|Dietary Supplement|placebo supplementation|2.5 g of the product in the morning and in the evening during 4 weeks.
75104|NCT03596684|Procedure|glucose tolerance test|2 exploration mornings distant from 28 days (before and after citrulline) will allow carrying out an oral glucose tolerance test of 2 hours (75 g glucose per os)
75105|NCT03596671|Device|RENOVA iStim™ System|Tibial implantable neuromodulation device
75106|NCT03596658|Drug|SHR9549|If initial dosing of SHR9549 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose(MTD) is defined
75109|NCT03596632|Drug|Fenebrutinib|200-mg (100 µCi) oral solution 14C/12C]-fenebrutinib
75110|NCT03596619|Device|PBN|The PBN-ALA-PDT group underwent vertical skin tapping with PBN before applying 10% ALA cream and narrow-band light-emitting diode (LED) irradiation (mean 633 nm, with a standard deviation [SD] of 10 nm; 100-200 J/cm2). The ALA-PDT group received ALA cream and irradiation only.
75111|NCT03596606|Procedure|Osteopathic Treatment|"The Osteopathic treatment will be adapted to each patient at the discretion of the therapist, being able to select all or part of the following osteopathic techniques in each session.~Soft tissue techniques.~Articulatory techniques applied at cervical level~Osteopathic manipulation techniques applied at the affected jaw/s.~Functional Indirect technique at the level of the affected jaw/s: For Type I or II diagnosis."
75112|NCT03596606|Procedure|Myofunctional Motor control exercises|"The protocol is a set of 8 exercises to improve the execution of the function in the stomatognathic and cervical area.~The therapist explains the objectives of the exercises and the patient performs it after each session and at home three times a day.~The first day before performing the myofunctional exercises, will be an explanatory talk prior to the exercises in order to educate the patient. The second day, before doing the exercises, will review the concept of memory of pain and the benefits of doing the exercises"
75113|NCT03596593|Diagnostic Test|SPANOM (identifying MSI status from ctDNA)|SPANOM technique, which has been developed by 3D Medicines Inc. Shanghai, China and made it possible to identify MSI status from blood samples, will be used in patients with refractory advanced solid tumors.
75114|NCT03596567|Drug|Glasdegib single 100 mg dose in normal healthy subjects|A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
75115|NCT03596567|Drug|Glasdegib single 100 mg dose in moderate renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
75116|NCT03596567|Drug|Glasdegib single 100 mg dose in severe renal impairment subjects|A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
75117|NCT03596554|Other|Descriptive study|Description of the circulating values of Fibroblast Growth Factor 21 in X-linked hypophosphatemia children compared to controls in the VITADOS cohort (healthy children and adolescents aged 10-18 years), after age-matched, pubertal stage and sex).
75118|NCT03596541|Device|Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)|We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
75119|NCT03596528|Procedure|Lung biopsy|Each patient will be brought to the operating room and will undergo cryobiopsy and surgical biopsy of the lung sequentially in the same surgical stage.
75120|NCT03596515|Other|Sensory Integration|Sensory Integration (SI) is a theory and framework conceptualized by Dr. Jean Ayres, a highly experienced occupational therapist, with its main objective as enhancing the brain's capacity to perceive and organize sensory information to produce a more normal, adaptive response; thus, to provide the foundation for mastering academic tasks.
75121|NCT03596502|Drug|Direct oral anticoagulants (DOACs)|Exposure to DOACs will be defined as a new prescription for apixaban (ATC B01AF02), dabigatran (ATC B01AE07), or rivaroxaban (ATC B01AF01) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
75122|NCT03596502|Drug|Warfarin|Exposure to warfarin will be defined as a new prescription for warfarin (ATC B01AA03) at cohort entry date in patients diagnosed with non-valvular atrial fibrillation.
75123|NCT03596476|Procedure|Upper gastrointestinal (GI) endoscopy|An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.
75124|NCT03596476|Procedure|Wireless pH monitoring|Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).
75125|NCT03596476|Procedure|Post prandial esophageal High Resolution Impedance Manometry|Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.
75126|NCT03596476|Procedure|pH-impedance monitoring|24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).
75127|NCT03596463|Other|Breast cancer treatment|Multidisciplinary approach for breast cancer treatment is more beneficial for the patients
75128|NCT03596450|Drug|Semaglutide|Participants will be prescribed commercially available semaglutide and will be instructed to initiate treatment with semaglutide according to the approved label. The study doctor will determine the intended maintenance dose of semaglutide, as well as changes to the maintenance dose thereafter.
75129|NCT03596450|Drug|Standard of care|Participants will receive standard of care, defined as commercially available oral or injectable antidiabetic medication other than semaglutide. Participants will be prescribed and instructed to initiate commercially available antidiabetic medication according to the approved label and, if relevant for the specific antidiabetic medication, adjusted at the discretion of the study doctor.
75130|NCT03596437|Device|Ultra High Frequency ultrasound system|Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
75131|NCT03596424|Drug|Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
75132|NCT03596424|Drug|Dexmedetomidine Hydrochloride|Intraoperative bolus and infusion (see arm description)
75133|NCT03596424|Combination Product|dexmedetomidine Hydrochloride and Ketamine Hydrochloride|Intraoperative bolus and infusion (see arm description)
75134|NCT03596398|Genetic|GLA gene|Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
75135|NCT03596385|Drug|Beta blocker|long-term maintenance beta-blocker therapy
75136|NCT03596372|Drug|BAY1834942|"Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part."
75137|NCT03596359|Behavioral|Education with Teach-Back method|
75138|NCT03596359|Other|Received routine treatment|
75139|NCT03596346|Other|Rapeseed ingredient (RI)|2 snack bars daily containing 10 g of RI each.
75140|NCT03596346|Other|Control product without added RI|2 snack bars daily containing 0 g of RI.
75141|NCT03596333|Other|Retrospective chart review|We conducted a retrospective chart review to evaluate the stored ultrasound images used during labor epidural placement, as well as demographic and anesthetic variables.
75142|NCT03596320|Procedure|colonoscopy|description of the results of colonoscopy im managment of children with rectal bleeding
75143|NCT03596307|Dietary Supplement|Ashwagandha extract|Shoden 180 mg capsule.
75144|NCT03596307|Dietary Supplement|Placebo|Placebo 180 mg (Sucrose) capsule.
75145|NCT03596294|Drug|Clazosentan|Continuous i.v. infusion of 15 mg/h of clazosentan for 3 h
75146|NCT03596294|Drug|Rifampicin|Single i.v. dose of 600 mg rifampicin for 30 min
75147|NCT03596294|Other|Saline (0.9% sodium chloride)|Single i.v infusion of 500 mL saline for 30 min
75148|NCT03596281|Drug|Pembrolizumab|200mg Q3W IV
75149|NCT03596281|Drug|Bevacizumab|400 or 300 mg Q3W IV
75150|NCT03596281|Drug|pegylated liposomal doxorubicin (PLD)|15 or 20 or 30 mg/m² Q3W IV
75151|NCT03596268|Diagnostic Test|Imaging|3T Prisma MRI
75152|NCT03596268|Diagnostic Test|Serum Laboratory Tests|Blood (plasma and cellular) will be collected.
75155|NCT03596255|Diagnostic Test|MDAS|The patient rated their DA using the Modified Dental Anxiety Scale (MDAS)
75157|NCT03596216|Other|PENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is an invasive intervention by ultrasound and needles.
75158|NCT03596216|Other|TENS|This intervention consisted in the application of an asymmetric biphasic rectangular current of 150 microseconds and 10 Hz using a specifically developed medically certified device (Physio Invasive, Enraf Nonius, Prim, SPAIN). This is a non-invasive intervention by self-adhesive electrodes.
75159|NCT03596203|Device|TransCutaneous Magnetic Stimulator (TCMS)|TCMS coils which are connected to feet and pulse generator. The generator will then be turned on to deliver 50 pulses at a pulse period of 6 seconds and at a pulse intensity of 100% to the bottom of the foot with the TCMS coil.
75160|NCT03596190|Diagnostic Test|ultrasonographic diaphragmatic assessment|"Diaphragmatic dysfunction will be determined by intercostal diaphragm thickening. The available image will be saved.~Diaphragmatic motion assessments will be conducted on the side to be blocked both at baseline, and then every 5 minutes until patient leaves for operating room or 30 minutes (whatever is earlier)."
75161|NCT03596177|Drug|MEDI0382|MEDI0382 administered subcutaneously
75162|NCT03596177|Drug|Placebo|Placebo administered subcutaneously
75163|NCT03596164|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
75164|NCT03596164|Device|Syringe|Teduglutide will be administered using syringe. Syringe is approved for use in Japan by PMDA.
75165|NCT03596164|Device|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
75166|NCT03596164|Device|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
75167|NCT03596151|Device|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
75168|NCT03596138|Other|Evaluate the reliability and reproductibility of the automated angular measurement by the Gazelab|Compare the results of the Gazelab to the alternate occlusion by prism bar (standard gold) examiners.
75169|NCT03596125|Drug|N-acetylcysteine|N-acetylcysteine supplementation
75170|NCT03596125|Drug|Placebo|per os: jelly tablets Intravenous Route: Glucidion G5
75171|NCT03596112|Other|application of a polyacrylate wound pad|A sterile polyacrylate wound pad with activated carbon cloth treatment will be applied to chronic wounds in an outpatient clinic from a specialist nurse
75172|NCT03596112|Other|Hydrocellular foam|Active Comparator: hydrocellular foam pad serile hydrocellular standard foam pad will be applied to chronic wounds in an outpatient clinic from a specialist nurse
75173|NCT03596099|Dietary Supplement|Mizkan rice vinegar with acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar and 750mg acetic acid.
75174|NCT03596099|Dietary Supplement|Mizkan rice vinegar without acetic acid|200mL serving of a fruit-flavored beverage containing diluted Mizkan rice vinegar that has undergone a freeze-drying process to remove the acetic acid
75175|NCT03596086|Drug|ADV/HSV-tk (gene therapy)|The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
75176|NCT03596073|Drug|Topical Calcipotriene Ointment|Calcipotriene is a form of vitamin D. It works by slowing down the growth of skin cells.
75177|NCT03596073|Other|Topical Vaseline|Placebo
75178|NCT03596060|Drug|Fentanyl|Fentanyl will be used for introduction in both regional and general anesthesia. It will also be used for general anesthesia maintenance.
75179|NCT03596060|Drug|Propofol|Propofol will be used for introduction in general anesthesia.
75180|NCT03596060|Drug|Rocuronium|Rocuronium will be used for introduction in general anesthesia.
75181|NCT03596060|Drug|Chirochaine|Chirochaine 0.5% will be used in regional anesthesia.
75182|NCT03596060|Drug|Morphine|Morphine will be administered bolus iv in General anesthesia group postoperatively before patients leave OR.
75183|NCT03596047|Device|Radial wave therapy|6 radial waves' sessions. A weekly session of radio waves will be applied with the following parameters: 6000 pulses at 1.5-2.6 bar (depending on patient tolerance), with a frequency of 12Hz, the frequency should increase to 17HZ the first 500 impulses to create mild anesthesia in the area; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area, specifically in the ischiocavernosus and bilateral bulbo-sponge muscles. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation.
75184|NCT03596047|Device|Placebo therapy|"There will be a weekly session of placebo wave therapy, using the respective device to prevent the patient from receiving the radial wave. The same parameters of the real therapy will be used: 6000 pulses at 2.6 bar, with a frequency of 17 Hz; in all the sessions of radial waves, 4000 impulses will be distributed in the body of the penis in scanning technique and 2000 impulses in the perineal area. During the period of therapy application, patients will receive oral treatment with sildenafil according to the patient's degree of affectation."
75185|NCT03596034|Device|JUUL 5%, Virginia Tobacco, ENDS product|Subjects participate in a 15 day product use period during which subjects will be requested to predominantly use the JUUL 5% product ad libitum as their primary source of nicotine. Subjects will be asked to report their daily use of the JUUL 5% product and CPD throughout the 15 day product use period.
75186|NCT03596008|Dietary Supplement|Active drink|The freeze-dried strawberry powder (25 g) in active drink
75187|NCT03596008|Dietary Supplement|Placebo drink|Placebo drink
75188|NCT03595995|Biological|UB-621|Monoclonal antibody by SC injection
75189|NCT03595995|Other|Placebo|The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.
75190|NCT03595982|Drug|Procardia XL 30Mg|Procardia XL 30 mg XL Q 12h
75191|NCT03595982|Drug|Procardia XL 60Mg|Procardia XL 60 mg Q 24h
75192|NCT03595969|Diagnostic Test|Relative copy number of mitochondrial DNA|Mitochondria are responsible for multiple cellular functions including regulation of energy production, modulation of oxidation-reduction status, generation of reactive oxygen species and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome comprised of independently replicating double stranded DNA (mtDNA).
75193|NCT03595956|Other|Medical gender affirmation|The intervention to be evaluated is medical gender affirmation delivered in primary care (medical gender affirmation: hormones and/or surgery vs none).
75194|NCT03595943|Dietary Supplement|Low glycemic index, pulse-based diet|Diet that includes pulses (i.e. meals that contain chickpeas, lentils, beans, or peas)
75195|NCT03595943|Dietary Supplement|Moderate glycemic index hospital diet|Diet that is derived from a regular hospital menu for patients
75196|NCT03595930|Drug|Arnuity|ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
75197|NCT03595917|Drug|ABL001|•ABL001 is administered daily per 28 day cycle
75198|NCT03595917|Drug|Dasatinib|Fixed doses oral once a day per 28 day cycle
75199|NCT03595917|Drug|Prednisone|Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
75200|NCT03595904|Behavioral|E-Motivate group|Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders). They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy. The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
75201|NCT03595904|Behavioral|Usual Care Group|Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy. In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
75202|NCT03595891|Other|Non-Interventional|Non-Interventional
75203|NCT03595878|Radiation|Parotid sparing WBRT|Whole Brain Radiation Therapy with avoidance of the parotid glands
75204|NCT03595878|Radiation|Standard WBRT|Standard Whole Brain Radiation Therapy
75205|NCT03595865|Drug|tafluprostin|Both patients in PACG and POAG groups will dose 1 time daily in each eye for 6months. Each eye will be preformed tafluprostin 0.0015% at 9 PM.
75206|NCT03595852|Drug|Cefazolin|Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery
75207|NCT03595852|Drug|Placebos|IV normal saline will be given to patients 30-60 minutes prior to incision
75208|NCT03595839|Procedure|Fistulotomy|The fistula track is laid open after complete probing till the internal opening
75209|NCT03595839|Procedure|Marsupialization|The laid open track will be marsupialized using interrupted absorbable sutures
75210|NCT03595826|Drug|Neurostimulant pharmaceutical drugs|The Pi will only administer the exercise intervention. This will consist of minimum of 8 sessions of group exercises, working on improving muscle tone, core stability, balance, fine and gross motor skills and visual motor integration. The pharmacological therapy will be administered and monitored by medical practitioners, as is the norm with most children diagnosed and treated for ADHD/ADD. Parents of participants will remain responsible entirely for the monitoring of the pharmacological therapy of their children.
75211|NCT03595813|Procedure|Blood sample collection|Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
75212|NCT03595813|Procedure|Biopsy collection|Optional biopsy collection at baseline and progression
75213|NCT03595800|Procedure|Hematopoietic stem cells transplantation|Allogeneic Hematopoietic stem cells transplantation
75214|NCT03595787|Procedure|Coaching and Habilitation|nutritional support, adapted physical activity and coaching
75215|NCT03595774|Dietary Supplement|Beet root juice|Beet root juice
75216|NCT03595748|Behavioral|Peer mentorship|Participants randomized to this arm of the study will speak with their dialysis peer mentor once a week about fluid intake and adherence to dialysis.
75217|NCT03595735|Device|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
75218|NCT03595722|Device|High Intensity Focused Ultrasound|High intensity focused ultrasound to rectal/pelvic cancer
75219|NCT03595709|Drug|3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)|All eligible subjects will receive 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg) once daily for 24 weeks orally on empty stomach before bedtime. If the event of toxicity or tolerability issues requires a change from study drug, switching to the best available treatment will be recommended.
75220|NCT03595696|Other|Core Muscle Strength Training|Targeted weekly workouts consisting of low-impact aerobic exercises and resistance exercises designed to address muscle imbalance common in women who exhibit DRA and to prompt automatic core engagement while performing compound, multi-joint movements.
75221|NCT03595683|Drug|Pembrolizumab|200 mg given by intravenous (IV) infusion once every 3 weeks.
75222|NCT03595683|Biological|EDP1503|Taken by mouth twice daily. Each capsule will contain ≥ 7.5x10^10 colony-forming units (CFU).
75223|NCT03595670|Other|standardized questionnaires|standardized questionnaires concerning the perception
75224|NCT03595670|Other|interview|Semi-directive interviews will be conducted. The purpose of this approach is to question the meaning of the disease (beliefs, representations), the psycho-social management of the disease, its inscription in the socio-cultural condition of the patients.
75225|NCT03595657|Biological|CS1001|monoclonal antibody
75226|NCT03595644|Radiation|SBRT+TKI|Received SBRT after three months after EGFR-TKI treatment
75227|NCT03595644|Drug|TKI|Received EGFR-TKI treatment
75228|NCT03595631|Other|Physical Therapy|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week.
75265|NCT03595423|Procedure|Surgical AVR with bioprosthetic or mechanical prosthesis|Surgical AVR with bioprosthetic or mechanical prosthesis
75266|NCT03595410|Other|Recurrence laryngeal cancer|Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
75229|NCT03595631|Other|Physical Therapy plus Neurodynamic|Patients will receive 5 session of multimodal physiotherapy treatment of 30min duration including low-load strength exercises, soft tissue mobilization and muscle-tendon stretching exercises twice per week. In addition, they will also receive bilateral nerve slider neurodynamic interventions targeting the median, ulnar and radial nerves.
75230|NCT03595618|Drug|GLPG1972|Film-coated tablets of GLPG1972 for oral use.
75231|NCT03595618|Drug|Placebo|Film-coated tablets of matching placebo for oral use.
75232|NCT03595605|Behavioral|Ambulation|This group will be encouraged twice daily to ambulate
75233|NCT03595605|Other|Standard of Care|Care as usual at inpatient NYU Langone
75234|NCT03595592|Drug|Trastuzumab|Trastuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
75235|NCT03595592|Drug|Pertuzumab|Pertuzumab will be given i.v. on day 1 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
75236|NCT03595592|Drug|Carboplatin|Carboplatin will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
75237|NCT03595592|Drug|Paclitaxel|Paclitaxel will be given i.v. on day 1 and day 8 every 3 weeks in arms HPCT, ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
75238|NCT03595592|Drug|Doxorubicin|Adriamycin will be delivered i.v. on day 1 every 3 weeks in arm ACy followed by HPCT for the first 3 cycles
75239|NCT03595592|Drug|Cyclophosphamide|Cyclophosphamide will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab for the first 3 cycles
75240|NCT03595592|Drug|Atezolizumab|Atezolizumab will be given i.v. on day 1 every 3 weeks in arm ACy followed by HPCT and atezolizumab and in arm HPCT and atezolizumab
75241|NCT03595592|Procedure|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 4 weeks from the last dose of neoadjuvant therapy in all study arms
75242|NCT03595579|Drug|AXS-05|AXS-05 taken daily for 6 weeks.
75243|NCT03595579|Drug|Bupropion|Bupropion taken daily for 6 weeks.
75244|NCT03595566|Drug|ridinilazole|ridinilazole 200mg bid
75245|NCT03595566|Drug|vancomycin|vancomycin 125mg qid
75246|NCT03595553|Drug|ridinilazole|ridinilazole (200 mg bid)
75247|NCT03595553|Drug|vancomycin|vancomycin (125 mg qid)
75248|NCT03595540|Other|Prolon|Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides ~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide ~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
75249|NCT03595527|Diagnostic Test|HIV and HCV screening|HIV test: ARCHITECT HIV Ag/Ab Combo, Abbott HCV test: ARCHITECT Anti-HCV, Abbott
75250|NCT03595514|Other|Single injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus
75251|NCT03595514|Other|Double injection|Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.
75252|NCT03595514|Drug|lidocaine, bupivacaine, epinephrine, dexamethasone|lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
75253|NCT03595501|Device|Hematology Analyzer - OLO|Complete blood counts from OLO will be determined from analysis of whole blood samples
75254|NCT03595501|Device|Hematology Analyzer - Predicate|Complete blood counts from Predicate will be determined from analysis of whole blood samples
75255|NCT03595488|Drug|Dupilumab|dupilumab 300 mg subcutaneous injection every 2 weeks
75256|NCT03595462|Other|Snack|"Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be ~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be ~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat."
75257|NCT03595462|Other|No Snack|The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
75258|NCT03595449|Drug|Lidocaine jelly|lidocaine 2% jelly applied during Mohs surgery
75259|NCT03595449|Drug|Surgilube|surgilube (placebo) applied during Mohs surgery
75260|NCT03595436|Dietary Supplement|Pea Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 20 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75261|NCT03595436|Dietary Supplement|Pea Protein-30g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 30 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 32 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75262|NCT03595436|Dietary Supplement|Pea Protein-40g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 40 g pea protein, 5 g mixed protein (from yogurt and peanut-butter), 24 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75263|NCT03595436|Dietary Supplement|Whey Protein-20g|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 20 g whey protein, 5 g mixed protein (from yogurt and peanut-butter), 40 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
75264|NCT03595436|Dietary Supplement|Carbohydrate Control|The study participants will be provided with breakfast preloads to consume. The energy content of the breakfast preload will be standardized to ~325 kcal. This preload will include 5 g mixed protein (from yogurt and peanut-butter), 59 g carbohydrates, and 7 g fat. The preload is a yogurt-based (chocolate-peanut butter flavored) breakfast.
132596|NCT03152474|Drug|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
75267|NCT03595397|Drug|Bupivacaine|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125% bupivacaine, followed by continuous infusion of 8 ml/hour
75268|NCT03595397|Drug|Magnesium Sulfate|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml mixture of 0.125% bupivacaine and 30 mg/kg Magnesium Sulfate, followed by continuous infusion of 8 ml/hour mixture of 0.125% bupivacaine and 20% Magnesium sulfate
75269|NCT03595397|Drug|Fentanyl|20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.
75270|NCT03595397|Procedure|Thoracic epidural|All patients will receive mid-thoracic epidural analgesia
75271|NCT03595384|Behavioral|Soccer-based adaptation to the DPP|"Participants will complete online education modules during an initial 12 week conditioning phase where they will participate in soccer drills and other fitness routines (two 1-hour sessions per week). At the 12 week mark participants will transition onto a soccer league team for the following 12 weeks where they will continue to complete online modules and meet with the soccer coach monthly.~During the soccer sessions and games participants will be fitted with a wearable soccer-specific device to measure how much they move and their heart rate. In addition, they will also be asked to wear a Garmin fitness tracker for the duration of the study to measure steps and moderate and vigorous activity.~The online education will be a version of the Diabetes Prevention Program and can be completed on a phone or computer with internet access."
75272|NCT03595371|Drug|dapansutrile|500 mg dapansutrile administered twice daily (with a potential to increase the dosage to 2 g dapansutrile daily) for a duration of up to 14 consecutive days.
75273|NCT03595358|Diagnostic Test|Ellume Home Flu Test|The Ellume Home Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples.
75274|NCT03595358|Diagnostic Test|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is a rapid in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples.
75275|NCT03595358|Diagnostic Test|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT_PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
75276|NCT03595358|Diagnostic Test|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
75277|NCT03595345|Procedure|Liver transplantation|Liver transplantation
75278|NCT03595332|Other|Summer activity program|Children receive a summer scorecard to facilitate access to local facilities for exercise.
75279|NCT03595319|Drug|Sevoflurane|Inhaled sevoflurane until allocated dose (see adaptive protocol)
75280|NCT03595306|Dietary Supplement|Prebiotic A - inulin|Pre-weighed packages will be given twice daily for 5 days.
75281|NCT03595306|Dietary Supplement|Prebiotic B - galactooligosaccharides(GOS)|Pre-weighed packages will be given twice daily for 5 days.
75282|NCT03595306|Dietary Supplement|Prebiotic C - wheat dextrin|Pre-weighed packages will be given twice daily for 5 days.
75283|NCT03595293|Device|fNIRs-based Neurofeedback|Patients receive fNIRs-based neurofeedback from the rDLPFC to allow them to modify activation within this area.
75284|NCT03595293|Device|Sham feedback|Patients receive fNIRs-based sham feedback from the left zygomatic area to allow them to modify activation within this area.
75285|NCT03595280|Behavioral|Hookah tobacco risk messages|Mobile multimedia messages consisting of text and imagery conveying the risks of hookah tobacco use.
75286|NCT03595267|Other|Point-of-care screening|"After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations. If a participant has no primary care provider, one will be found."
75287|NCT03595254|Behavioral|Thrive|Computerized Cognitive Behavior Therapy program
75288|NCT03595241|Device|Spinal cord stimulation by implanted device.|Spinal cord stimulation (SCS) protocol from the implanted device. This involves activation of the device for the (SCS) protocol including Burst DR therapy.
75289|NCT03595228|Biological|BN-Brachyury plus radiation|MVA-BN-Brachyury injections will be given on day 0 and 14. FPV-Brachyury injection will be given on day 28, followed by radiation on days 42 through approximately day 70. FPV-Brachyury will then be given two weeks after radiation then every 6-12 weeks through 110 weeks after radiation is complete.
75290|NCT03595215|Device|TENS|Transcutaneous electrical nerve stimulation
75291|NCT03595202|Drug|TS-143|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
75292|NCT03595202|Drug|Placebo|Subjects should take 4 capsules once and 3 times per day in step 1. Subjects should take 2 capsules once and 3 times per day in step 2.
75293|NCT03595189|Drug|Cilastatin|Dose escalation 3-hour single intravenous administration
75294|NCT03595189|Drug|Placebo|3-hour single intravenous administration
75295|NCT03595176|Device|Lithotripsy|Deliver Lithotripsy to the target vessel prior to placing a coronary stent.
75296|NCT03595163|Drug|Sevoflurane|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
75297|NCT03595163|Drug|Propofol|After anesthesia induction and at the end of the operation, all patients were taken 2-3ml arterial blood respectively.The blood was put at normal temperature for 30 minutes.Then the serum was centrifuged to measure the homocysteine and folic acid concentrations.
133476|NCT03145558|Drug|Doxorubicin|Standard of care for TACE
75299|NCT03595137|Device|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, sono-guided internal jugular vein cannulation was performed.
75300|NCT03595137|Device|Sono only|In group S, sono-guided internal jugular vein cannulation was performed after induction of anesthesia
75301|NCT03595124|Drug|Axitinib|Given PO
75302|NCT03595124|Biological|Nivolumab|Given IV
75303|NCT03595111|Procedure|myocardial biopsy|Myocardial cell edema either focal or diffuse was detected in histopathological examination
75304|NCT03595098|Behavioral|Family Based Cognitive Behavioural Therapy|Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
75305|NCT03595098|Behavioral|Family Based Psychoeducation/Relaxation Training|Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
75306|NCT03595085|Procedure|catheter directed fragmentation and thrombolysis|A(6)F multipurpose catheter will be advanced over a guide wire under fluoroscopic guidance and used to measure right heart and pulmonary artery pressures, then mechanical catheter fragmentation will be done using a pigtail catheter. The catheter will be quickly spun manually so as to fragment the central thrombus and establish initial flow into pulmonary artery. After ensuring initial flow, Initial bolus dose of streptokinase (250.000 international unit) will be given over 10 min followed by continuous infusion of (100.000 international unit per hour)for 24 hours
75307|NCT03595085|Drug|Streptokinase|intravenous streptokinase at a dose of 250 000 international unit as a loading dose over 30 minutes, followed by 100 000 international unit per hour over 12-24 hours
75308|NCT03595072|Other|observation of VNS stimulation effects|ECOGs will be recorded during VNS stimulation and inter stimulation periods
75309|NCT03595059|Drug|ABBV-155|intravenous
75310|NCT03595059|Drug|Paclitaxel|intravenous
75311|NCT03595059|Drug|Docetaxel|intravenous
75312|NCT03595046|Procedure|erector spinae plane block (20 mL of 0.25% ropivacaine with dexamethasone 5mg)|In group E, The patient was placed in a sitting position and a high-frequency linear ultrasound transducer was placed in a longitudinal orientation 3 cm lateral to the thoracic spinous process. Three muscles were identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle was inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between transverse process and erector spinae muscles, as evidenced by visible linear spread of fluid between erector spinae muscles and the bony acoustic shadows of the transverse process. A total of 20 mL of 0.25% ropivacaine with dexamethasone 5mg was injected here.
75313|NCT03595046|Procedure|thoracic paravertebral block(10 mL 0.25% ropivacaine with dexamethasone 5mg)|2) In group P, an appropriate thoracic spinous precess is located by positioning the probe in the transverse plane. Then the probe is moved laterally to locate the transverse process. The probe is manipulated slightly caudad or cephala to locate the intercostal space. The transverse process is visualized medially with the pleura dipping under the inferolateral aspect. The internal intercostal membrane, which is contiguous with the superior costotransverse ligament, was generally seen as a thin, radiopaque line extending from the transverse process, creating a wedge-shaped pocket, which represents the thoracic paravertebral space. A 22-gauge, facet-tip needle is advanced, in plane, from the lateral aspect of the ultrasound probe. When the needle pierced the internal intercostal membrane, and after aspiration demonstrated the absence of air or blood, 10 mL 0.25% ropivacaine with dexamethasone 5mg deposited in 5-mL increments.
75314|NCT03595033|Device|iPad app-based intervention|The 1-hour of home based intervention will break into three 20-min sessions, each including iPad apps targeting one of the three domains of deficits: visual attention, visual-spatial reasoning, and visual-motor skills.
75315|NCT03595007|Behavioral|Kids Kicking Cancer program|Individual instruction on how to lower stress and life challenges. Patient and martial artist will work together to identify obstacles that interfere with methadone goal reduction. Training will include learning certain martial arts rituals and breathing techniques. Patients will receive audio meditations for smart phone devices and regular reminders to practice. Each weekly meeting will be supplemented by 3 phone calls per week from the martial artist to support the training. Additionally a virtual reality device will be used to help lower stress.
75316|NCT03594994|Behavioral|Sleep extension|Extend time-in-bed to 8 hours
75317|NCT03594981|Biological|CMV/AdV /EBV/BKV specific T cells|Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.
75318|NCT03594968|Diagnostic Test|polycystic ovary syndrome|3 to 5th day of the women's normal cycle, we will perform a routine gynecological examination, a basic vaginal ultrasound, a basal hormone profile evaluation
75319|NCT03594955|Drug|SAR440234|Pharmaceutical form:lyophilisate to be resuspended in solution Route of administration: intravenous
75320|NCT03594942|Diagnostic Test|procto sigmoidoscopy and biopsy if required|procto sigmoidoscopy of patients presenting with per rectal bleed will be carried out to locate the source of bleeding and biopsy if required.
75321|NCT03594929|Device|Active RIC|
75322|NCT03594929|Device|Sham Control|
75323|NCT03594916|Device|Active tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied continuously for 20 minutes.
75324|NCT03594916|Device|Sham tDCS|The anode and cathode sponge electrode (51 cm2) will be placed over C3 and FP2 (10-20 system) respectively. 2 mA current will be applied for 30 seconds at the beginning.
75371|NCT03594604|Drug|Norethindrone|Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.
75325|NCT03594903|Behavioral|video intervention (therapy expectation violation)|The investigators asked experts (psychotherapist and scientists in the area of clinical psychology) about typical therapy expectation violations in therapy and searched the literature for information about typical therapy processes and outcomes. Having these information they designed a script for the experimental video. The patients in the video are played by actors aged from 28 to 58 years (two male and two female actors). Patients are representing common mental disorders (depression, anxiety disorder, alcohol addiction, depression after physical disease). The abbreviated name, age and disorder of the patients is displayed for 3 seconds in the video. The patients are giving information about the mostly positive outcome and the process of their therapy. All participants are watching a video with all patients (7 minutes). The videos (control and experimental group) have been evaluated by 12 experts (psychotherapist and scientists in the area of clinical psychology).
75326|NCT03594903|Behavioral|video intervention (symptoms+ expectation)|Participants in the control group are watching a video with the same patients (actors) as in the experimental video. In this video patients are shown before or after the first therapy session. They are giving information about symptoms and their expectation on therapy but NOT about therapy outcome.
75327|NCT03594890|Biological|OVX836 (Intramuscular)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
75328|NCT03594890|Biological|Placebo (Intramuscular)|2 consecutive administrations of placebo at Day 1 and Day 29.
75329|NCT03594890|Biological|OVX836 (Intranasal)|2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
75330|NCT03594890|Biological|Placebo (Intranasal)|2 consecutive administrations of placebo at Day 1 and Day 29.
75331|NCT03594877|Dietary Supplement|Sublimated mare milk|The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
75332|NCT03594864|Procedure|Liver transplantation with hyper-reduced grafts|Live donor liver transplantation using non-anatomical in-situ ultrasound-guided reduction of left lateral segments with preparation of a graft that is larger than a monosegment, but smaller than Segments 2 and 3.
75333|NCT03594851|Behavioral|Pittsburgh Sleep Quality Index|The Pittsburgh Sleep Quality Index (PSQI) is a self-report questionnaire that assesses sleep quality over a 1-month time interval. The measure consists of 19 individual items, creating 7 components that produce one global score, and takes 5-10 minutes to complete. Developed by researchers at the University of Pittsburgh, the PSQI is intended to be a standardized sleep questionnaire for clinicians and researchers to use with ease and is used for multiple populations. The questionnaire has been used in many settings, including research and clinical activities, and has been used in the diagnosis of sleep disorders. Clinical studies have found the PSQI to be reliable and valid in the assessment of sleep problems to some degree, but more so with self-reported sleep problems and depression-related symptoms than actigraphic measures.
75334|NCT03594851|Behavioral|Sleep diary|A sleep diary is a record of a patient's sleep patterns and habits that can be extremely useful in helping doctors make a diagnosis of a sleep disorder and better determine if a sleep study should be prescribed.
75335|NCT03594851|Behavioral|Katz Index of Independence in Activities of Daily Living|Katz Activities of Daily Living is a validated tool to assess functional status as a measurement of the elder's ability to perform activities of daily living independently. Elders are scored yes/no for independence in each of six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less implies severe functional impairment.
75336|NCT03594851|Behavioral|Lawton Instrumental Activities of Daily Living|"Lawton's Instrumental Activities of Daily Living (IADL) scale was developed to assess more complex activities (termed instrumental activities of daily living) necessary for functioning in community settings (e.g., shopping, cooking, managing finances). The capacity to handle these complex functions normally is lost before basic activities of daily living which are measured by Activities of Daily Living scales. Therefore, assessing Instrumental Activities of Daily Living may identify incipient decline in older adults who are otherwise capable and healthy.The Lawton Instrumental Activities of Daily Living scale takes approximately 10 to 15 minutes to administer. It contains 8 items that are rated with a summary score from 0 (low functioning) to 8 (high functioning). This scale can be administered through an interview or by a written questionnaire. The patient or a caregiver who is familiar with the patient can provide the answers."
75337|NCT03594851|Behavioral|Neuropsychiatric Inventory (Cummings)|"Neuropsychiatric Inventory is submitted to the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.~The Neuropsychiatric Inventory (NPI) was developed by Cummings et al. (1994) to assess dementia-related behavioral symptoms which they felt other measures did not sufficiently address. The NPI originally examined 10 sub-domains of behavioral functioning: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, and aberrant motor activity. Two more sub-domains have been added since its development: night-time behavioral disturbances and appetite and eating abnormalities (Cummings, 1997). This wide variety of domains means that, unlike other dementia measures, the NPI is able to screen for multiple types of dementia, not just Alzheimer's Disease."
75338|NCT03594851|Behavioral|Mini Zarit Caregiver Burden Scale, for the caregiver|Mini Zarit Caregiver Burden Scale, for the caregiver, if the patient has a Mini Mental State Examination score between 10 and 20.
75339|NCT03594851|Behavioral|Mini Mental state examination|"It is an 11-question tool to evaluate cognitive functions. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment. The Mini Mental state examination takes only 5-10 minutes to administer and is therefore practical to use repeatedly and routinely.~The MMSE has been validated and extensively used in both clinical practice and research, since its creation in 1975"
75340|NCT03594851|Behavioral|Cornell Scale for Depression in Dementia|The Cornell scale For Depression in Dementia is a scoring system specifically developed to assess signs and symptoms of major depression in patients with dementia. The 19 parameters measured are clustered into five groups: mood-related signs, behavioural disturbances, physical signs, cyclic functions and ideational disturbances. The Cornell scale For Depression in Dementia has been shown to be sensitive, reliable and valid for assessing depression in patients with Alzheimer's disease.
75372|NCT03594604|Drug|oral contraceptive pill|Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.
75373|NCT03594591|Drug|Antidiabetic treatment by usual care|Observation of changes in the microcirculation after optimization of antidiabetic therapy by usual care.
75341|NCT03594851|Behavioral|Quality of Life in Alzheimer's Disease|The Quality of Life in Alzheimer's Disease is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life from both the patient and the caregiver. It was developed for individuals with dementia, based on patient, caregiver, and expert input, to maximize construct validity, and to ensure that the measure focuses on quality of life domains thought to be important in cognitively impaired older adults. It uses simple and straightforward language and responses & includes assessments of the individual's relationships with friends and family, concerns about finances, physical condition, mood, and an overall assessment of life quality
75342|NCT03594838|Other|HCV viremia testing approaches|Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)
75343|NCT03594825|Drug|Valsartan|Different time of taking medicine
75344|NCT03594812|Device|Radiofrequency|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45º. The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis.
75345|NCT03594812|Device|Radiofrequency without power|Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45ºC (Celsius degrees). The application was in capacitive mode, with a 5 cm electrode, always in movement. The duration of the application was established in 20 minutes, maintaining the local temperature between 40ºC to 42 ºC at the epidermis. In this group, the radiofrequency device was switched off.
75346|NCT03594812|Device|Aerobic exercise|Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 35 minutes); and cooling (from 35 to 40 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.
75347|NCT03594799|Other|Bed Rest Control Group|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days.
75348|NCT03594799|Dietary Supplement|Cocktail intervention|Subjects are in strict head down tilt bed rest at all time (including for taking showers etc.) for 60 days. In addition subjects are receiving a daily supplementation of a Cocktail. The daily dose of Cocktail consists of 6 pills per day: 2 at breakfast, 2 at lunch and 2 at diner. This will be equivalent to a daily dose of around 741 mg of bioactive polyphenols associated with Omega-3, Selenium and Vitamine E.
75349|NCT03594786|Device|endovascular aneurysm repair (EVAR)|Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
75350|NCT03594773|Behavioral|Cognitive Behavioral Therapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
75351|NCT03594773|Behavioral|Interpersonal Psychotherapy|Participants will receive 8 one-on-one sessions over 8 to 12 weeks.
75352|NCT03594760|Diagnostic Test|18F-DCFPyL IV injection|Patient will receive one injection of 18F-DCFPyL and undergo PET-CT imaging
75353|NCT03594747|Drug|Tislelizumab Carboplatin Paxlitaxel|Treatment for advanced NSCLC
75354|NCT03594747|Drug|Tislelizumab Carboplatin Nab-paxlitaxel|Treatment for advanced NSCLC
75355|NCT03594747|Drug|Carboplatin Paclitaxel|Treatment for advanced squamous NSCLC
75356|NCT03594734|Behavioral|Group Lifestyle Balance™|The Group Lifestyle Balance™ (GLB) program is a self-management intervention that has been shown to result in weight-loss and reduce the risk for Type 2 diabetes through increased physical activity and healthy eating behaviors in the general population. The GLB program curriculum used in this RCT will be adapted for individuals with TBI.
75357|NCT03594734|Other|Attention Control Group|"The attention control group will receive the same contact or attention as the intervention group. The attention control group will meet at the same frequency as the intervention group. Education for the sessions will be composed of content from the TBI Model Systems Knowledge Translation Center's factsheets. General topics will include discussion on (1) healthy brain and effects of TBI on cognitive, emotional, and behavioral functioning, (2) expectations for recovery, (3) preventative and management strategies for common TBI sequela (e.g. inability and impulsivity), (4) stress management, (5), signs and symptoms of depression, and (6) strategies for effective communication."
75358|NCT03594721|Other|Marvel AM|Study staff will perform each application of approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back at each of ten sequential visits.
75359|NCT03594708|Dietary Supplement|Nutrition supplement|Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc
75360|NCT03594708|Dietary Supplement|Placebo supplement|rice starch, light olive oil, vegetable oil
75361|NCT03594695|Diagnostic Test|HSCRP and NLR|hs-CRP levels and NLR values will be studied from routine blood samples.
75362|NCT03594682|Other|Intervention/treatment|"experimentalgroup initial dose：~250mg qod~250mg qd/500mg qd by turn~500mg qd control group： 750mg qd"
75363|NCT03594669|Other|Intervention|Multi-modal sensorimotor training interventions, including vestibular, oculomotor, neuromotor, and postural control/ balance exercises.
75364|NCT03594656|Drug|Ganoderma|0.8g twice daily
75365|NCT03594656|Drug|Placebos|0.8g twice daily
75366|NCT03594630|Drug|Chemotherapy|Receive chemotherapy
75367|NCT03594630|Other|Patient Observation|Receive active surveillance
75368|NCT03594630|Other|Questionnaire Administration|Ancillary studies
75369|NCT03594630|Procedure|Resection of Rectum|Undergo surgical resection
75370|NCT03594617|Behavioral|Interaction Competencies with Children - for Caregiver|"Interaction Competencies with Children - for Caregiver (ICC-C) aims to reduce maltreatment and to improve care quality in institutional care facilities. Following the idea of a train-the-trainer approach, ICC-C is designed to be delivered by trained local facilitators. ICC-C is based on attachment, behavioral and social learning theories.~The key principles are its feasibility in low-resource contexts, participatory approach, and practical orientation. ICC-C includes sessions on (a) caregiver-child interaction, (b) maltreatment prevention, (c) effective non-violent caregiving strategies, and (d) identifying and supporting burdened children."
134629|NCT03136406|Biological|aNK for Infusion|NK-92 cells
75375|NCT03594578|Behavioral|Episodic recent thinking|Sham episodic thinking
75376|NCT03594565|Drug|Fluticasone Propionate|Local Fluticasone Propionate use prior to continuous glucose monitoring system insertion
75377|NCT03594552|Drug|Arbaclofen_15|Single oral dose (15mg)
75378|NCT03594552|Drug|Arbaclofen_30|Single oral dose (30mg)
75379|NCT03594552|Drug|Placebo|Single oral dose placebo (oral tablet)
75380|NCT03594539|Other|Withholding standard phosphate binder|In this trial, placebo represents the intervention and not the control. Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder. In this trial the intervention will be to withhold the phosphate binder and use placebo instead. In this way the effect of a higher serum phosphate can be evaluated.
75381|NCT03594526|Behavioral|Maternal support to become mother|"AMACOM-PRI: Apoyo Materno para Convertirse en Madre - Primerizas. Maternal support to become first-time mothers is an intervention based on the mid-range nursing theory of Ramona Mercer, whose purpose is to empower first-time mothers in their new maternal role, favoring the mother-child bond, strengthening social support and maternal self-efficacy, consists of.~Four Home visits , in the first week; first month of baby life; at three months; and the fourth postpartum month.~Four Educational sessions and support sessions for maternal empowerment in each home visit.~Telephone follow-up: at 15 days; a month and a half; at two and a half months; and three and a half months postpartum."
75382|NCT03594526|Behavioral|Control Group: usual care|"This intervention is usual care, which consists of:~care of the mother and her newborn during the puerperium~Teaching about breastfeeding."
75383|NCT03594513|Procedure|MCAF|Periodontal surgical technique to treat gingival recessions.
75384|NCT03594513|Procedure|PR|Restorative procedure to treat tooth structure loss.
75385|NCT03594513|Procedure|CTG|Autogenous graft harvested from palate placed in the surgical site.
75386|NCT03594513|Procedure|XMD(Mucoderm®)|Xenogenous graft placed in the surgical site.
75387|NCT03594513|Drug|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
75388|NCT03594513|Drug|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
75389|NCT03594500|Other|PockeTalker|The intervention group will receive PockeTalkers (hearing assistance devices) while they receive care in the ED
75390|NCT03594500|Other|No PockeTalker|The control group will not receive PockeTalkers while they receive care in the ED
75391|NCT03594487|Drug|FMP30 Donor Stool|FMP30 is manufactured by the non-profit stool bank Openbiome. Each FMP30 filtered donor stool engraftment has approximately 12.5g of stool per 30mL of normal saline. It is homogenized in sterile normal saline.
75392|NCT03594487|Procedure|Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|Three doses of filtered donor stool engraftments homogenized in sterile normal saline (FMP30), obtained from the non-profit stool bank OpenBiome, will be administered via colonoscopy in patients with Relapsing-Remitting Multiple Sclerosis. FMT dosage via colonoscopy may include a lower amount of transplanted stool at the discretion of the study gastroenterologist if there are any peri-procedural safety or technical considerations. Total FMT dose (in milliliters) will be documented.
75393|NCT03594487|Other|Observational Control|Subjects, who otherwise satisfy study inclusion criteria based on their MS phenotype, demographics, disease duration and prior use of allowable MS therapies, will be recruited as a comparison observational group to measure stability of stool and serum immunological measures.
75394|NCT03594474|Other|Intravenous lipid emulsion|using higher dose of IV lipids after birth
75395|NCT03594461|Drug|Aflibercept Injection|Intense Treatment Regimen for Refractory Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy
75396|NCT03594448|Procedure|Specimen Collection|Undergo collection of blood samples
75397|NCT03594448|Procedure|Serial Liquid Biopsy|Undergo serial liquid biopsy
75398|NCT03594435|Drug|Ibudilast|targets neurotrophin signaling and neuroimmune function
75399|NCT03594435|Drug|Placebo oral capsule|matched to active drug, ibudilast
75400|NCT03594422|Drug|HQP1351|HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
75401|NCT03594409|Diagnostic Test|Biochemistry of gall stones|Analysis of gallstones is done to determine the biochemical types of gallstone like cholesterol stone, pigmented stones or mix stones
75402|NCT03594396|Drug|Olaparib|Olaparib 300mg bid will be given on days 1-28 days without rest.
75403|NCT03594396|Drug|Durvalumab|A fixed dose of durvalumab 1500 mg is given via IV infusion on Day 15.
75404|NCT03594383|Device|ULTRASOUND|Lung ultrasound done through POCUS to diagnose pneumonia
75405|NCT03594344|Procedure|Hyperbaric oxygen therapy|Breathing 100% oxygen for 30+30+30 min at 2,4 ATA. in a multiplace hyperbaric chamber. Total of 30 sessions
75406|NCT03594331|Drug|Low-dose PvP001|Low-dose PvP001
75407|NCT03594331|Drug|Medium-dose PvP001|Medium-dose PvP001
75408|NCT03594331|Drug|High-dose PvP001|High-dose PvP001
75409|NCT03594331|Drug|Placebo|100 mL liquid with no drug
75410|NCT03594305|Behavioral|Educational seminar|Religious leaders will be invited to participate in a one-day seminar led by Tanzanian religious leaders and physicians. The religious, cultural, and medical aspects of family planning will be discussed and seminar attendees will be given ample time for group discussions.
75411|NCT03594292|Device|FASTFORWARDTM Bunion|The participants will be assign to implantation of FASTFORWARDTM Bunion correction system surgery as a experimental group.
75412|NCT03594292|Procedure|Conventional surgery|The participants will assign to conventional surgery as a control group, the procedure is a standard treatment for the 1st metatarsal hallux valgus.
75413|NCT03594279|Behavioral|Community Mobilization|Community Mobilization
75414|NCT03594279|Behavioral|Community Mobilization and Community Incentive|Community Mobilization and Community Incentive
75415|NCT03594266|Device|Therapy A Spinal Cord Stimulation Parameter Set|Therapy A stimulation patterns
75416|NCT03594266|Device|Therapy B Spinal Cord Stimulation Parameter Set|Therapy B stimulation patterns
75417|NCT03594253|Behavioral|Regulation Focused Psychotherapy for Children|RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
75418|NCT03594240|Drug|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM)|Vitamin B complex tablets (Neurorubine TM -Forte Lactab TM) once daily
75419|NCT03594240|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to Vitamin B complex tablets and the administered dose was as the same schedule as Vitamin B complex.
75420|NCT03594227|Drug|ATI-501 Low dose|ATI-501 oral low dose
75421|NCT03594227|Drug|ATI-501 Mid dose|ATI-501 oral low dose
75422|NCT03594227|Drug|ATI-501 high dose|ATI-501 high dose for oral administration
75423|NCT03594227|Drug|Placebos|Vehicle - oral administration
75424|NCT03594214|Diagnostic Test|serum vitamin d level measured by ELISA kit|serum vitamin d level will be measured by a blood sample from newly diagnosed breast cancer patients just after diagnosis (either by surgery specimen or FNA or excisional biopsy specimen) and before receiving any type of treatment for breast cancer
75425|NCT03594201|Other|semen pretreatment|semen pretreatment
75426|NCT03594188|Procedure|anesthetic methods|Patients will receive standard GA or LA for RF surgery.
75427|NCT03594175|Drug|CUSA-081|Participants will receive 1 or 2 doses of CUSA-081 0.7 mg/2 mL directly into the catheter lumen
75428|NCT03594175|Drug|Placebo|Participants will receive 1 or 2 doses of placebo (normal saline) directly into the catheter lumen
75429|NCT03594175|Drug|Alteplase|Participants will receive 1 or 2 doses of alteplase, 2 mg/2 mL, directly into the catheter lumen
75430|NCT03594162|Drug|iC9-CAR19 cells|One of two dose levels will be given: 1 x 10^5 or 5 x 10^5
75431|NCT03594162|Drug|AP1903|Subjects who develop grade 4 CRS or grade 3 CRS that is refractory to standard of care interventions will be given AP1903 at .4 mg/kg.
75432|NCT03594162|Drug|Cyclophosphamide|900 mg/m^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
75433|NCT03594162|Drug|Fludarabine|25 mg/m^2/day IV over 30 minutes administered for 3 consecutive days.
75434|NCT03594149|Drug|Levofloxacin|Levofloxacin 500 mg/d p.o.
75435|NCT03594136|Device|Raumedic Neurovent-P-tel|Insertion of a Neurovent-P-tel in adults to study normal intracranial pressure
75436|NCT03594123|Drug|Brexpiprazole|2 mg tablet
75437|NCT03594123|Drug|Brexpiprazole|3 mg tablet
75440|NCT03594097|Other|Treatment cookies|Plain flour, Coconut Nourish, Queen Garnet Plum, Unsalted Butter, Artificial Sweetener
75441|NCT03594097|Other|Control cookies|Plain flour, Coconut Powder, Unsalted Butter, Artificial Sweetener, Food Colour
75442|NCT03594071|Device|The Q-Fix™ All-Suture Anchor|Observational, post-market, clinical follow-up study
75443|NCT03594058|Drug|Solabegron modified release tablets, low dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
75444|NCT03594058|Drug|Solabegron modified release tablets, high dose|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
75445|NCT03594058|Drug|Matching Placebo|Solabegron modified release tablets low dose or high dose or matching placebo once daily for 12 weeks.
75446|NCT03594045|Drug|Apixaban|Apixaban is an anticoagulant that works by inhibiting the coagulation factor, Factor Xa.
75447|NCT03594019|Procedure|Connective tissue graft|Connective tissue graft (CTG) is an oral and maxillofacial surgical procedure first described by Alan Edel in 1974. It includes the preparation the recipient site of tissue exhibiting recession by incising the gingival, obtaining the CTG from the donor site, securing the CTG at the recipient site and suturing the incised gingival tissue at both the donor and recipient sites.
75448|NCT03594019|Procedure|socket shield technique|The procedure is used to split the teeth and preserve the buccal part
75449|NCT03594019|Procedure|Immediate implant placement|The implant will be placed in the frest socket immediately after tooth extraction
75450|NCT03594006|Behavioral|CCI; cancer care coordination instrument|Designed to assess cancer patients' perceptions of care coordination
75451|NCT03593993|Procedure|Surgical Cohort|Blood, cerebrospinal fluid, and surgical tissue collected during procedure
75452|NCT03593980|Dietary Supplement|Cranberry juice|400ml cranberry juice
75453|NCT03593967|Behavioral|ARTISAN|"In the first four weeks, dyads will engage in museum tours facilitated by a docent from the National Museum, followed by a guided storytelling/art-making session (inspired by the artifacts in the gallery), writing activity and group sharing/debrief. The first three weeks of art making will be pair-work by the seniors and youth, while the fourth week will be a collaborative art piece that is created by all participants in the working group. In the last week, the participants will be involved in a mini-exhibition where they will share their works with the group and members of the public, and engage in guided reflection on each other's artworks.~The main content and discussion point for each session are as follows:~Week 1: Food and Play as our National Heritage~Week 2: Our Voices, Our Singapore: Strengthening Bonds~Week 3: Overcoming Adversities: Stories of Resilience~Week 4: Beholding the Future: Dreams and Aspirations~Week 5: Passing It On: The Stories We Share"
75454|NCT03593954|Drug|JNJ-61393215|Participants will receive 2 oral administrations of 2 mg JNJ-61393215 as oral suspension.
75455|NCT03593954|Drug|Ritonavir|Participants will receive 100 mg of ritonavir tablet orally.
75456|NCT03593941|Other|Standard Diet|Participants will consume the standard diet provided in care home
75457|NCT03593915|Combination Product|Alvocidib Plus Decitabine|"PHASE 1b:~Decitabine administered as a 1-hour intravenous (IV) infusion daily for 5 days at a dose of 20 mg/m2 followed on Day 8 by alvocidib as a loading dose over 30 minutes followed by a 4-hour IV infusion~PHASE 2:~The Phase 2 study will use the RP2D from the Phase 1b study and follow a Simon 2-stage minimax design"
75458|NCT03593902|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
75459|NCT03593902|Drug|Fludarabine|A chemotherapy medication commonly used in the treatment of leukemia and lymphoma
75460|NCT03593902|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
75461|NCT03593902|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
75462|NCT03593902|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
75499|NCT03593694|Behavioral|TECH DMBAT Other|Technology delivered diabetes education
75463|NCT03593902|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
75464|NCT03593902|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
75465|NCT03593902|Biological|IVIg|Pooled immunoglobulin (IgG) from thousands of plasma donors that has immunomodulatory and anti-inflammatory effects
75466|NCT03593902|Biological|Autologous Stem Cells|Infusion of patient's own stem cells
75467|NCT03593889|Behavioral|Collaborative stepped care and peer support programme|"For at-risk group, 4 weeks of selective prevention group sessions will be provided at the elderly service level by trained peer supporters with registered social worker supervision, on wellness topics tailored to the person's concern as entry point, packaged with mental health information, followed by a review.~For mild group, 6-8 weeks of indicated prevention with psychoeducation or low-intensity psychotherapy would be provided. For moderate group, 6-8 weeks high-intensity cognitive behavioral therapy (CBT) would be provided. All intervention for depressed elderly would be conducted by registered social workers. The trained peer supporters will be matched to individual older adults to walk them through the process with regular follow-up for 1 year."
75468|NCT03593889|Other|Treatment as usual|The control group will receive treatment as usual, which will be determined by the responsible workers from NGO units.
75469|NCT03593876|Behavioral|Strategy Training|This study will use an adapted form of strategy training for people with communication impairments.
75470|NCT03593863|Behavioral|Physical Education (PE) programme|The intervention consists of a 10-month (one academic year, September-June) physical activity programme delivered by PE teachers during regular Year-8 PE lessons. The Intervention involves roughly 20 minutes of prescribed activities per week.
75471|NCT03593850|Behavioral|Music group|The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).
75472|NCT03593850|Behavioral|Silence Group|Audio file that contained no sounds.
75473|NCT03593837|Drug|Huang qi gui zhi wu wu granule|Patients are given HQGZWWT granules (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
75474|NCT03593837|Drug|Huang qi gui zhi wu wu granule placebo|Patients are given HQGZWWT granules placebo (orally twice a day for 3 months and instructed to dissolve one package (4 g) with hot water (200 mg)
75475|NCT03593824|Procedure|bilateral cataract removal surgery for dense cataract|Participants were born with dense bilateral cataracts (extreme adversity) will undergo surgery for bilateral cataract removal at an early age, mostly around 3 months of age.
75476|NCT03593824|Procedure|bilateral cataract removal surgery for non-dense nuclear cataract|Participants were born with non-dense and nuclear bilateral cataracts (watered-down adversity) will undergo cataract removal surgery bilaterally in a compromised timing, mostly around one year old.
75477|NCT03593811|Diagnostic Test|Questionnaires|Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.
75478|NCT03593811|Diagnostic Test|4 channel electrogastrogram (EGG)|EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
75479|NCT03593811|Diagnostic Test|36 channel high resolution electrogastrogram (HR-EGG)|HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.
75480|NCT03593811|Diagnostic Test|Magnetogastrogram (MGG)|MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
75481|NCT03593811|Diagnostic Test|Electrocardiogram (EKG)|Electrocardiography is the process of recording the electrical activity of the heart over a period of time using electrodes placed on the skin
75482|NCT03593811|Drug|Ondansetron|Patients will be administered 8 mg ondansetron in order to assess the effect of ondansetron on the symptoms of nausea and changes in slow wave dysrhythmias.
75483|NCT03593811|Drug|Cyproheptadine Oral Tablet|Patients will be prescribed a 5 day maintenance dose of cyproheptadine using dosing 0.04-0.62 mg/kg/day to examine the effects of pharmacological alteration of specific nausea pathways on gastric slow wave patterns in functional nausea patients
75484|NCT03593798|Other|Lifestyle|Lifestyle intervention an effect on weight and physical capacity
75485|NCT03593785|Drug|AZD8233|Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
75486|NCT03593772|Behavioral|Mission Reconnect|This four-year randomized controlled trial with one intervention arm and one wait-list control arm will utilize mixed methods to evaluate the effectiveness and perceived value of the MR program in relation to physical and psychological symptoms, global health, and social outcomes.
75487|NCT03593759|Drug|Prednisone|Oral prednisone tablet
75488|NCT03593759|Drug|Methotrexate|Oral, subcutaneous, or intramuscular methotrexate
75489|NCT03593746|Other|Physical training|Type 2 diabetic patients will be subjected to different types of physical training (high intensity interval training or combined training).
75490|NCT03593746|Other|Light-Emitting Diode (LED) therapy|Type 2 diabetic patients will be subjected to Light-Emitting Diode (LED) therapy (active or sham).
75491|NCT03593733|Other|Photobiomodulation Therapy|Photobiomodulation Therapy
75492|NCT03593733|Other|Cold Water Immersion|Cold Water Immersion
75493|NCT03593720|Procedure|Measurement in Office|Penile length and glans size in 3 dimensions
75494|NCT03593720|Procedure|Measurement in OR|Penile length and glans size in 3 dimensions
75495|NCT03593707|Drug|Metformin|Metformin
75496|NCT03593707|Drug|PF-06865571|PF-06865571
75497|NCT03593694|Behavioral|TECH DM-BAT|Multi-component, high intensity intervention, technology delivered, diabetes-modified behavioral activation treatment.
75498|NCT03593694|Behavioral|TECH DMBAT Active Comparator|Technology delivered diabetes education and home tele monitoring
75500|NCT03593681|Device|Hysteroscopic cell sampling of the fallopian tube|Hysteroscopic fallopian tube biopsy
75501|NCT03593668|Drug|Metformin|"2-week dose adjustment period（0-2weeks）[before meals] 0-2d： - ;250mg，po; -. 3-4d： - ;250mg，po; 250mg，po. 5-6d： 250mg，po; 250mg，po; 250mg，po. 7-9d: 250mg，po; 500mg，po; 250mg，po. 10-11d: 250mg，po; 500mg，po; 500mg，po. 12-14d: 500mg，po; 500mg，po; 500mg，po.~10-week dose stabilization period（3-12weeks） Metformin Hydrochloride Tablet 500mg tid po."
75502|NCT03593668|Drug|Benaglutide|"2-week dose adjustment period（0-2weeks） [before meals] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH"
75503|NCT03593655|Device|Dapivirine vaginal ring|Vaginal ring containing 25 mg of dapivirine
75504|NCT03593655|Drug|FTC/TDF|Tablet containing 200 mg FTC/300 mg TDF
75505|NCT03593642|Drug|Continuous infusion of ropivacain in ESP catheter|administration of ropivacaine in ESP catheter to provide regional analgesia after surgery
75506|NCT03593642|Drug|Continuous infusion of Iso Saline in ESP catheter|administration of Iso Saline in ESP catheter to be the control group
75507|NCT03593629|Combination Product|6-month PrEP + blood-based HIV self-test|Participants receive 6-month PrEP supply plus two blood-based HIV self-tests (Atomo Diagnostics Blood-Based HIV-1 Self-Testing Kit) for quarterly HIV testing.
75508|NCT03593629|Combination Product|6-month PrEP + oral fluid HIV self-test|Participants receive 6-month PrEP supply plus two oral fluid HIV self-tests (OraQuick Oral Fluid-based HIV-1 Self-Testing Kit) for quarterly HIV testing.
75509|NCT03593616|Procedure|Phacoemulsification|insertion of intra-ocular lens after emulsification of catractous lens
75510|NCT03593603|Device|Nellcor™ Bedside Respiratory Monitoring System|Nellcor™ Bedside Respiratory Patient Monitoring System with Nellcor™ Respiration Rate Software and the Nellcor™ Adult Respiratory Sensor to provide continuous respiration rate monitoring
75511|NCT03593590|Drug|Ocrelizumab|Ocrelizumab is administered as an intravenous infusion in accordance with the approved labelling.
75512|NCT03593564|Behavioral|KINDER|KINDER is an online course for people assisting an older adult with dementia. It is intended to improve the quality of caregiver's relationship with the care recipient and reduce the chance of risky relationship behavior (e.g., yelling). Courses will cover topics including understanding cognitive impairments, navigating evolving roles, and dealing with frustration. During this course, participants will learn skills to deal with difficult situations caregivers frequently encounter in ways that support a healthy caregiving relationship. Videos will be story-based and represent different types of caregiving relationships and challenges encountered.
75513|NCT03593551|Combination Product|five relaxation treatments and one control|Five treatments are relaxation meditation tape, music tape, relaxation lighting, meditation tape plus lighting, and music plus lighting. The control session have no intervention, participants will just be asked to sit comfortably for 10 minutes.
75514|NCT03593538|Drug|Metformin|Metformin capsule
75515|NCT03593538|Drug|Placebo|Sucrose filler in gel capsules
75516|NCT03593525|Other|SPARK|see above
75517|NCT03593512|Procedure|Deep brain stimulation|Bilateral deep brain stimulation of the pedunculopontine nucleus
75518|NCT03593499|Drug|omaveloxolone|
75519|NCT03593486|Device|Low-level Pulsed EMF|Low-level pulsed electromagnetic field stimulator delivered through a Helmholtz coil positioned around the participant's head and neck. Stimulation parameters are 0.032 µG at 0.89 Hz for 60 minutes.
75520|NCT03593486|Device|Sham Stimulation|The stimulator will be placed around the participant's head and neck, but no EMF will be delivered.
75521|NCT03593473|Drug|Intranasal Oxytocin|Six intranasal sprays of oxytocin. Each insufflation delivers 4 IUs of oxytocin for a total oxytocin dosage of 24 IUs.
75522|NCT03593473|Drug|Placebo|Six intranasal sprays of placebo manufactured to mimic oxytocin nasal spray containing all equivalent ingredients except oxytocin.
75523|NCT03593460|Drug|Synthetic PreImplantation Factor|peptide
75524|NCT03593447|Drug|non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin|Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg
75525|NCT03593447|Drug|non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg
75526|NCT03593447|Drug|non-cirrhotic subjects. low TG-2349+ low DAG181|Group 3: TG-2349 200 mg + DAG181 100 mg
75527|NCT03593447|Drug|non-cirrhotic subjects. high TG-2349+ high DAG181|Group 4: TG-2349 400 mg + DAG181 200 mg
75528|NCT03593447|Drug|cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin|Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg_
75529|NCT03593447|Drug|cirrhotic subjects. high TG-2349+ high DAG181|Group6: TG-2349 400 mg + DAG181 200 mg
75530|NCT03593434|Drug|hyperpolarized Xenon gas|This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits.
75531|NCT03593421|Drug|synthetic PreImplantation Factor|peptide
75532|NCT03593408|Drug|Dexmedetomidine|Administered for sedation management per hospital protocol
75533|NCT03593408|Drug|Fentanyl|Administered for sedation management per hospital protocol
75534|NCT03593408|Drug|Midazolam|Administered for sedation management per hospital protocol
75535|NCT03593408|Drug|Morphine|Administered for sedation management per hospital protocol
75536|NCT03593395|Other|Peer Mentoring [PM]|Virtual Peer Mentoring in addition to Structured Education Transition QI
75537|NCT03593395|Other|Structured Education Based Transition Program STE|Education-based program without Peer Mentoring
75538|NCT03593369|Device|KLOX BioPhotonic System (single treatment)+SOC|"KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
75539|NCT03593369|Device|KLOX BioPhotonic System (consecutive treatments)+SOC|"In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week.~Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks)."
75540|NCT03593369|Other|Standard of Care (SOC)|Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
75541|NCT03593356|Behavioral|Monthly cash gift payments of $333|These subjects receive $333 each month for 40 months via debit card.
75542|NCT03593356|Behavioral|Monthly cash gift payments of $20|These subjects receive $20 each month for 40 months via debit card.
75543|NCT03593343|Behavioral|Overnight fasting duration|Subjects will adhere to overnight fasting protocol for 6 days
75544|NCT03593330|Other|Transitional Care Programme|These patients will receive a pre-admission overview of their surgery, an anticipated discharge date, and a pre-scheduled discharge appointment to set patient expectations for a shorter hospitalization. On the day of discharge, the patient and his or her caregiver will attend an extended discharge appointment with a TCP-trained nurse. Finally, patients will receive a surveillance phone call 48 hours after discharge.
75545|NCT03593317|Drug|Ramipril|The doses used in the study are the doses used in standard clinical practice. The dose will be adjusted in steps of 2.5 mg every week until the optimal dose. The optimal dose is usually between 5mg to 10mg per day. Ramipril must be taken before, during or after meals; Ramipril will be take once a day at the same time of day. The duration of treatment for each patient is 36 months.
75546|NCT03593317|Drug|Placebo|Placebo will be take once a day at the same time of day. The duration of treatment for each patient is 36 months.
75547|NCT03593304|Drug|Injection Mecobalamin|Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
75548|NCT03593304|Drug|Tablet Pyridoxine hydrochlorid|Tablet Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks.
75549|NCT03593304|Drug|Normal saline|Injection Normal saline(1ml) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
75550|NCT03593304|Drug|Oral Placebo|Placebo Oral Tablet (25 mg) 2 tablets thrice daily for 5 weeks.
75551|NCT03593291|Diagnostic Test|Anti Xa|Levels of Anti Xa measure
75552|NCT03593278|Drug|ACT-246475|Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475
75553|NCT03593265|Other|MUNIX|Motor unit number index in 4 muscles: tibialis anterior, abductor digiti mini, abductor pollicis brevis et deltoideus
75554|NCT03593252|Drug|Senna|Laxative,used for bowel preparation
75555|NCT03593252|Drug|Sodium Picosulfate, Magnesium Oxide and Citric Acid|Laxative used for bowel preparation
75556|NCT03593252|Drug|Erythromycin|Oral non-absorbable antibiotic
75557|NCT03593252|Drug|Kanamycin|Oral non-absorbable antibiotic
75558|NCT03593252|Drug|Cefazolin|Intravenous antibiotic to be given on anesthesia induction and prior to incision as a prophylactic antibiotic.
75559|NCT03593252|Drug|Metronidazole|Intravenous antibiotic to be given on anesthesia induction and prior to incision as prophylactic antibiotic.
75560|NCT03593252|Other|Nil per os|Fasting orders according to anesthesia prior to surgery: No solid for >=8 hours, no formula milk/full liquids >= 4hours; no breast milk or clear fluids >=2hours.
75561|NCT03593239|Device|Tobacco flavored JUUL 1.7% ENDS|Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)
75562|NCT03593239|Device|Tobacco flavored JUUL 5% ENDS|Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)
75563|NCT03593239|Device|Mint flavored JUUL 1.7% ENDS|Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)
75564|NCT03593239|Device|Mint flavored JUUL 5% ENDS|Treatment with Mint flavored JUUL 5% ENDS(10 puffs)
75565|NCT03593239|Device|Fruit Medley flavored JUUL 1.7% ENDS|Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)
75566|NCT03593239|Device|Fruit Medley flavored JUUL 5% ENDS|Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)
75567|NCT03593239|Device|Crème brulee flavored JUUL 1.7% ENDS|Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)
75568|NCT03593239|Device|Crème brulee flavored JUUL 5% ENDS|Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)
75569|NCT03593239|Device|JUUL 1.7% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs
75570|NCT03593239|Device|JUUL 5% ENDS 10 puffs vs. ad lib puffs|Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
75571|NCT03593226|Drug|AGI-134|AGI-134 via IT injection. The proposed treatment is one dose of AGI-134 monotherapy per cycle; each cycle consists in three weeks, dosing will be given for 4 cycles.
75572|NCT03593213|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily.
75573|NCT03593213|Drug|Placebo|Matching placebo capsules, oral administration, once daily.
75574|NCT03593200|Drug|APL-2|Complement (C3) Inhibitor
75575|NCT03593187|Drug|Cal-1 (LVsh5/C46) drug product|Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
75576|NCT03593174|Device|Ossur Rigid Dressing|Removable Rigid Dressing
75577|NCT03593174|Device|Elastic Bandage|Usual modality: Elastic bandage
75578|NCT03593161|Behavioral|Humor therapy|Clown visits
75579|NCT03593148|Other|Lifestyle|Lifestyle treatment
75580|NCT03593135|Dietary Supplement|Apple Cider Vinegar and tablet Tagipmet (Metformin + Sitagliptin group)|15ml apple cider vinegar (American garden organic vinegar) (containing 5% acetic acid) mixed in 200ml water during meal at night time, for 3 months and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
75581|NCT03593135|Other|Water with Apple Cider vinegar flavor and tablet Tagipmet (Metformin + Sitagliptin group)|Flavor of apple cider vinegar in 200 ml water is added and given to have a placebo effect and tablet Tagipmet 50mg/1000mg (Metformin + Sitagliptin group) twice a day. NOTE medical treatment is our inclusion criteria.
75582|NCT03593122|Device|WO2085 Moisturising Cream|"Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day)."
75651|NCT03592511|Dietary Supplement|WGPF-burger|Volunteers consumed a WGPF-burger daily
75652|NCT03592511|Dietary Supplement|Control-burger|Volunteers consumed a Control-burger daily
134630|NCT03136406|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
75583|NCT03593109|Drug|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.
75584|NCT03593096|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
75585|NCT03593096|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
75586|NCT03593083|Other|Low altitude: 470m above sea level|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
75587|NCT03593083|Other|Säntis; 2500m above sea Level|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
75588|NCT03593070|Behavioral|Chronic Grief Management Intervention-Video|The CGMI-V participant manual will be provided to participants either mailed or emailed. We will mail hard copies of the manual to caregivers who prefer them over the e-format. The technology assistant will review with each participant the use of technology Cisco WebEx and iPads) via e-mailed step-by-step written instructions and over-the-phone conferencing. Group sessions will take place using WebEx (an internet platform providing video connection) and iPads, at mutually agreed-upon times and days of the week. All group sessions will be audio and video-recorded for fidelity purposes, with caregivers' approval documented in the informed consent. The interventionists will label each recorded meeting group identification number, session number, and date.
75589|NCT03593057|Other|Manual therapy|Manual therapy protocol and self-care advice and body awareness.
75590|NCT03593057|Other|Control group|Advice on self-care and body awareness.
75591|NCT03593044|Drug|0.01% concentration atropine drops|One drop of 0.01% concentration atropine in each eye at night for seven days.
75592|NCT03593031|Behavioral|Office Based Vergence and Accommodative Therapy|Exercises that will stimulate disparity vergence or accommodation independently and then combined will be used.
75593|NCT03593018|Drug|Oral azacitidine|Azacitidine tablets
75594|NCT03593018|Drug|Romidepsin|Romidepsin injection
75595|NCT03593018|Drug|Bendamustine|Bendamustine injection
75596|NCT03593018|Drug|Gemcitabine|Gemcitabine injection
75597|NCT03593005|Other|Assessment at Low Altitude (470m above sea level)|Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure
75598|NCT03593005|Other|Exposure to High Altitude (2500m above sea level)|Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
75599|NCT03592992|Drug|Spinal Hydromorphone|75 mcg of hydromorphone will be prepared in a non-identifiable syringe by central hospital pharmacy. The resulting solution will then be added to the spinal anesthetic mixture(fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
75600|NCT03592992|Drug|Spinal Morphine|150 mcg of morphine will be prepared in a non-identifiable syringe by central hospital pharmacy.The resulting solution will be added to the spinal anesthetic mixture (fentanyl 15 mcg and 0.75% hyperbaric bupivacaine 1.4-1.6 mcg at the discretion of the attending anesthesiologist, adjusted to height and weight)
75601|NCT03592979|Device|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
75602|NCT03592979|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
75603|NCT03592966|Dietary Supplement|Wild Blueberry Powder|Freeze-dried whole fruit blueberry drink.
75604|NCT03592966|Dietary Supplement|Placebo|Freeze-dried placebo powder
75605|NCT03592953|Other|Serious game simulation training sessions|"Each participant of the Serious game groups played 3 scenarios of Perinatsims, a screen-based simulation on the management of a post partum hemorrhage. The serious game control group played basic scenarios and the experimental group played specific scenarios."
75606|NCT03592940|Dietary Supplement|Mediterranean diet|We aim to determine the effects of the traditional Mediterranean Diet on neuroendocrine tumours
75607|NCT03592927|Device|Simulated Altitude (FiO2: 15.1%)|"Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask."
75608|NCT03592927|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask"
75609|NCT03592901|Drug|brachial plexus anesthesia|Anesthesia to some part of the brachial plexus prior to surgery. Patients are already receiving this regardless of participation in study.
75610|NCT03592888|Drug|mDC3/8-KRAS Vaccine|Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
75611|NCT03592875|Behavioral|Professional nurses|The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
75612|NCT03592862|Drug|HTL0018318|Oral capsule
75613|NCT03592862|Drug|Placebo|Oral capsule
75614|NCT03592849|Procedure|UC-MSCs therapy|After history taking, physical examination, ultrasound examination and hysteroscopy examination，infertile women diagnosed with thin endometrium or endometrial scarring will be included in the clinical trial. A collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity during hysteroscopy, and participants will receive hormone replacement therapy before and after the treatment. Postoperative observations including ultrasound examination once a month for 3 times and hysteroscopy in the third month after first UC-MSCs therapy. Those whose endometrium is suitable for pregnancy will be recommended attempting conception actively. The next round of cell therapy will be conducted 3 cycles after the first month if the endometrial growth is unsatisfactory.
75615|NCT03592836|Drug|Loop Diuretics|intravenous administration of diuretics
75616|NCT03592823|Drug|Hydroxychloroquine Sulfate 200 Mg Tablet|200 mg, bidpo.
75617|NCT03592810|Other|Settings of the extracorporeal membrane oxygenation (ECMO)|Compare the settings of the ECMO in different European hospitals and relate them to cerebral saturation and neurological outcome, using Cerebral Performance Category (CPC) score
75653|NCT03592498|Drug|Sulfadiazine, Silver|Application of silver sulfadiazine ointment, bandage covered with gauze and bandage.
75618|NCT03592797|Other|Laser acupuncture therapy|Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
75619|NCT03592797|Other|Sham laser acupuncture therapy|Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
75620|NCT03592784|Behavioral|Food Order Therapy|Instructing patient to, whenever possible, eat carbohydrates at the end of their meal.
75621|NCT03592784|Behavioral|Medical Nutrition Therapy|Key components of this therapy include counseling to incorporate portion control, increased intake of vegetables and low glycemic index carbohydrates, and mild carbohydrate restriction.
75622|NCT03592771|Behavioral|Prompts to report adherence and symptoms via study app|Text message prompts to report medication adherence and symptoms via the web-enabled study app Weekly prompts to report AET use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app. All participant-reported data will be automatically entered into the patient's electronic health record and easily available to the care team for review. Any concerning symptoms or changes will trigger an email alert to the patient's oncology team.
75623|NCT03592771|Behavioral|Feedback messages|Participants will receive weekly tailored feedback messages and/or images.
75624|NCT03592745|Device|Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear.
75625|NCT03592745|Device|Sham Transcutaneous Vagus Nerve Stimulation (tVNS)|tVNS is a non-invasive form of vagus nerve stimulation, activating the auricular branch of the vagus nerve transcutaneously through the cymba concha at the pinna of the ear. Sham tVNS means the patient is wearing the device, but it is turned off and not delivering current during the treatment. This is a placebo condition, which is used as a study control.
75626|NCT03592732|Other|Blood sample|Blood sample
75627|NCT03592719|Behavioral|Experimental Intervention (MI-PrEP)|The experimental intervention will consist of two sessions. The first session will involve psycho-education on PrEP and Motivational Interviewing to explore ambivalence about PrEP uptake. The second session will involve Motivational Interviewing and case management to explore barriers to accessing PrEP.
75628|NCT03592719|Behavioral|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the control condition will receive two sessions, both of which involve psychoeducation on PrEP.
75629|NCT03592706|Biological|IKC (Immune Killer Cells)|
75630|NCT03592706|Procedure|TACE (Transcatheter Arterial Chemoembolization)|
75631|NCT03592693|Drug|Combined Vitamin C and Stress-Dose Hydrocortisone|Treatment of septic shock with vitamin C and stress-dose hydrocortisone aimed at the attenuation of the systemic inflammatory response and the improvement of vasopressor responsiveness.
75632|NCT03592693|Drug|Placebo plus placebo|Treatment of septic shock with placebo (corresponding to Vitamin C) and placebo (corresponding to hydrocortisone).
75633|NCT03592680|Dietary Supplement|Vitamin C|1 gram Vitamin C will be administrated orally, twice a day from 5 days before until 10 days after surgery.
75634|NCT03592680|Other|Placebo|1 gram Placebo will be administrated orally, twice a day, from 5 days before until 10 days after surgery
75635|NCT03592667|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
75636|NCT03592667|Drug|Placebo - Cap|One per day before breakfast during 12 weeks.
75637|NCT03592654|Behavioral|infant telehelp|Adapted from Early Start Denver Model (ESDM), a naturalistic developmental behavioral intervention
75639|NCT03592628|Other|Visual Aid|The visual aid was a one-sheet diagram with illustrations of important features of post-cesarean wound care.
75640|NCT03592628|Other|Standard Instructions|Standard discharge instructions WITHOUT supplement of visual aid.
75641|NCT03592615|Procedure|cataract surgery|Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
75642|NCT03592615|Procedure|Corneal refractive surgery|Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
75643|NCT03592602|Procedure|arm abduction and adduction|All PICC lines will be placed under the guidance of intravascular ECG. Before the PICC placement procedure, basal ECG will be examed. During the procedure, intravascular ECG data will be collected with the punctured arm adduction and abduction while the catheter advances to the cavoatrial junction. After the procedure, chest X-ray radiographs will be taken with arms 90° abducted and adducted (i.e., 0°abducted) in a supine position.
75644|NCT03592589|Device|high flow nasal canula|high flow nasal canula to obtain a positive expiratory pressure
75645|NCT03592576|Drug|Navitoclax|tablet
75646|NCT03592563|Behavioral|Neuro-QoL questionnaire|Follow-up over time will continue (either in-person or over the phone) using the same questionnaires (depending on which group they are belongs to) at approximately 6-month intervals. During each follow-up, participants will be screened for any new signs, symptoms and diagnoses of neurological and/or psychiatric disorders, in order to correlate these outcomes with risk factors captured using the procedures described above.
75647|NCT03592550|Device|Ultrasound imaging|Abdominal ultrasound imaging of the liver
75648|NCT03592537|Drug|Fentanyl|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia patient care or in data collection. Children will be randomly allocated into two groups of 30 children
75649|NCT03592537|Drug|Midazolam|The study drugs will be prepared by an anesthesiologist not involved in performing the anesthesia, patient care or in data collection. Children will be randomly allocated into two groups of 30 children
75650|NCT03592524|Behavioral|Fasting Ramadan|Muslims recipients refrain from eating and drinking anything from dawn until sunset(14-15 hours)
75654|NCT03592498|Device|Skin of Nile tilapia|Application of skin of Nile tilapia (Oreochromis niloticus), as a biological occlusive dressing.
75655|NCT03592485|Procedure|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
75656|NCT03592485|Procedure|Pectoral Fascia block|Before the beginning of the procedure, PECS type I and II blocks will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.1 mL per patients' KG. The maximum dose is 20 mL.
75657|NCT03592485|Drug|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
75658|NCT03592485|Procedure|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
75659|NCT03592485|Drug|paracetamol|Paracetamol will be given i.v. every 6 hours.
75660|NCT03592472|Drug|Pazopanib|All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.
75661|NCT03592472|Drug|Abexinostat|The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
75662|NCT03592472|Other|Placebo|The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
75663|NCT03592459|Device|Macy Catheter|Undergo placement of Macy catheter
75664|NCT03592459|Procedure|Pain Therapy|Receive opioids via Macy catheter
75665|NCT03592459|Other|Questionnaire Administration|Ancillary studies
75666|NCT03592459|Other|Survey Administration|Ancillary studies
75667|NCT03592446|Device|Transcutaneous electrical vagus nerve stimulation|All subjects receive electrical VNS stimulation at cymba conchae.
75668|NCT03592446|Device|Sham vagus nerve stimulation|All subjects receive electrical stimulation at earlobe.
75669|NCT03592433|Behavioral|I Can PIC|Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
75670|NCT03592420|Behavioral|Interdisciplinary multicomponent interventions|
75671|NCT03592420|Behavioral|Usual care|standard care
75672|NCT03592407|Drug|Epacadostat|Given PO
75673|NCT03592407|Other|Laboratory Biomarker Analysis|Correlative studies
75674|NCT03592407|Biological|Pembrolizumab|Given IV
75675|NCT03592407|Other|Pharmacodynamic Study|Correlative studies
75676|NCT03592394|Device|Immersive Virtual Reality (Gear VR)|Immersing the user in a total visual environment.
75677|NCT03592381|Procedure|Ridge Expansion by ossedensification|Osseodensification is a new concept facilitated by Densah® Burs which are a multi- fluted osteotome like drilling instrumentsThe idea behind the technique is using a non-subtractive drilling mode that preserves bone and increases its density along the osteotomy walls instead of cutting it away (Huwais and Meyer 2015)
75678|NCT03592381|Procedure|ridge expansion by ridge splitting|using the piezotome,Piezoelectric ridge splitting allows exact, clean, and smooth even curved cutting of the bone tissue, with proper visibility.
75680|NCT03592355|Other|Virtual Visit|Clinicians will have a synchronous video visit with their patients.
75681|NCT03592342|Drug|Clobetasol Propionate|Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
75682|NCT03592329|Behavioral|Stress Reduction Training A|twice weekly instructor-led sessions for 8 weeks plus home practice sessions
75683|NCT03592329|Device|active tVNS|non-painful electrical stimulation of the auricle
75684|NCT03592329|Behavioral|Stress Reduction Training B|twice weekly instructor-led sessions for 8 weeks plus home practice sessions
75685|NCT03592329|Device|sham tVNS|sham stimulation
75686|NCT03592316|Other|Lower Extremity Amputation Pathway|"Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.~Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.~Quality of life surveys will be given at several time points during post-operative care."
75687|NCT03592290|Diagnostic Test|Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.
75688|NCT03592277|Drug|Vitamin C|Patients will receive 1.5g of vitamin C in 100mL of 0.9% sodium chloride (normal saline) every six hours for four days or until discharge from the ICU, whichever happens first (seventeen dose maximum).
75689|NCT03592277|Drug|Vitamin B1|Patients will also receive 200 mg of IV vitamin B1 every 12 hours in 50 mL of normal saline for four days or until ICU discharge (whichever happens first, nine dose maximum).
75690|NCT03592264|Drug|OBI-3424|liquid formulation for Intravenous infusion
75691|NCT03592251|Dietary Supplement|Olive Oil Placebo|6 months placebo supplementation
75692|NCT03592251|Dietary Supplement|EPA-rich|6 months placebo supplementation
75693|NCT03592251|Dietary Supplement|DHA-rich|6 months placebo supplementation
75694|NCT03592238|Other|Aerobic Exercise Intervention|The protocol will include a 25-min bout of exercise at an intensity of 75% HRmax, such that participants will engage in a 1-min warm up and a 1-min cool down, with the majority of time (i.e., 23-min) spent exercising at 75% of HRmax.
75695|NCT03592238|Other|Trier Social Stress Test for Children|Participants will be asked to imagine that they are in a new class with 20 other students, and that their teacher has asked them to stand in front of the class and introduce themselves. The mental arithmetic task will entail asking children to serially subtract the number 5 from a larger number as quickly as possible.
75696|NCT03592238|Other|Seated Rest|Children will be asked to sit quietly or read a book of their choosing.
75697|NCT03592225|Behavioral|Educational workshop|the intervention is a 3 hours educational workshop designed to address all the potential questions that the general practitioners (GP) and their patients might have regarding HPV vaccination.
75698|NCT03592212|Drug|Salbutamol|Measurement of bronchodilator response (BDR)
75699|NCT03592199|Drug|Sunitinib|1st line sunitinib on a 4/2 schedule followed by axitinib 5 mg twice a day on 2nd line therapy
75700|NCT03592186|Behavioral|Parenting Wisely+|Parenting Wisely+ consists of access to the Parenting Wisely computer program, paired with engagement strategies: up to four parent coaching sessions, daily text messages, and access to an online networking forum
75701|NCT03592186|Behavioral|Treatment as Usual|The active comparator is residential treatment as usual
75702|NCT03592173|Diagnostic Test|Paired TMS & Peripheral Nerve Stimulation|Method of assessing neurophysiology and activity of the spinal cord
75703|NCT03592160|Other|Physiotherapy treatment|Physiotherapy treatment consisted of pelvic floor exercises assisted by manometric biofeedback. In addition, active lumbopelvic stabilization exercises, including the contraction of pelvic floor muscles was performed in supine, plank and quadruped position.
75704|NCT03592147|Other|Guided Imagery Relaxation Tape|The meditation is approximately 7 minutes in duration.
75705|NCT03592147|Other|Music Listening|Participants have the option of selecting one of the following music categories: New age, classical, and oriental. The songs were selected based on criteria established in a previous study to induce relaxation. All songs were also modified in length to be approximately 7 minutes in duration.
75706|NCT03592147|Other|Relaxation Lighting|The participants were asked to select either orange or blue lighting settings using the Philips Hue lighting. The intensity of the light will be fixed to control for that measure. They were asked to sit for approximately 7 minutes in duration.
75707|NCT03592147|Other|Meditation and Relaxation Light|The guided imagery meditation and relaxation lighting were combined.
75708|NCT03592147|Other|Music and Relaxation Light|The music and relaxation lighting were combined.
75709|NCT03592147|Other|Control/Silence|The participants were asked to relax for a duration of 7 minutes, with no explicit advice given. Lighting was adjusted to a specific intensity and colour (basic yellow light) as was used in the music and guided imagery interventions.
75710|NCT03592134|Other|esophageal pressure measurement|Measurement of esophageal pressure to determine the optimal non invasive respiratory support
75711|NCT03592121|Drug|AB-101|Apply approximately 1 hour prior to sexual activity
75712|NCT03592121|Drug|Placebo|Apply approximately 1 hour prior to sexual activity
75713|NCT03592108|Other|CSR remote monitoring|The intervention will consist to modify the method used to analyse the data collected by remote monitoring in OSA-patients treated by CPAP (device : AirSense™10 Autoset™, ResMed) in order to alert physicians when Cheynes-Stokes respiration (CSR) occurs during sleep and then to set up emergency pulmonology and cardiology consultations to screen the onset of a significant cardiac event (heart failure, rhythm disorder, diastolic dysfunction).
75714|NCT03592095|Device|Dry needling|The principal researcher will carry out a treatment consisting of introducing a needle into the localized MTP using a so called ͚fast in and fast out needling technique͛ This technique is characterized by fast longitudinal movements in the direction of the MTP. This procedure avoids tissue damage caused by side movements of needle or the grabbing of needle by an elicited LTR. In the sham-arm of the study, the same procedure will be carried out. Instead of a real DN technique, a sham technique will be used.
75715|NCT03592095|Device|Placebo needle|A sham needle will be used as placebo (Steitberger's Park sham device (PSD)). This needle has a blunt tip and retractable handle that created the illusion of a needle penetrating the skin. When this needle touches the skin, a pricking sensation will be created. However, when pressure will be increased, the shaft of the needle disappears into the handle creating the
75716|NCT03592082|Drug|Bismuth Subsalicylate|BSS 524 mg ((2) 262 mg tablets) given four times per day for 14 days
75717|NCT03592082|Drug|standard antibiotic therapy|antibiotic therapy administered per standard protocol
75718|NCT03592069|Drug|10 day concomitant regimen|10 Day Concomitant Hp therapy Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid
75719|NCT03592069|Drug|14 day hybrid regimen|14 Day Hybrid Hp therapy Hybrid for 14 days, including 40 mg of esomeprazole bid and amoxicillin 1g bid, for the first 7 days followed by esomeprazole 40mg bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid, for another 7 days.
75720|NCT03592043|Device|MitraClip|Transcatheter Mitral Valve Repair with MitraClip
75721|NCT03592017|Device|Long-wavelength autofluorescence imaging|Long-wavelength autofluorescence imaging will be performed with a prototype confocal scanning laser (cSLO) ophthalmoscope which will be equipped with additional laser sources and a reference for quantification of the signal. The experimental long-wavelength laser sources will be integrated into a custom-modified Spectralis HRA cSLO from Heidelberg Engineering. The additional laser sources will operate with long wavelength which are less energetic compared to the conventional short-wavelength lasers used currently for routine autofluorescence imaging. All safety standards have been considered and the light exposure for all imaging modes is well below the exposure limits for Class 1 and Class1M laser products as defined in the standard IEC 60825-1, edition 3.0, 2014-5.
75722|NCT03592004|Other|neoadjuvant chemotherapy|neoadjuvant chemotherapy
75723|NCT03591991|Drug|Empagliflozin|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
75821|NCT03591315|Diagnostic Test|diffusion tensor imaging|Define the integrity of white matter fibers in the visual pathway.
75724|NCT03591991|Other|placebo|After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg placebo . After admission, patients were treated with 10 mg placebo once daily for 3 mouths.
75725|NCT03591978|Diagnostic Test|Isolation of Circulating Pulmonary Cells in peripheral blood|Blood samples from healthy volunteers will be collected in EDTA tubes (Vacutainer, BD Bioscience). CPC will be isolated according to previous patented method (P201730724)
75726|NCT03591965|Drug|ATG-008|"Route of Administration：Oral Medication~All subjects will receive ATG-008 once daily in continuous 28-day cycles (except cycle 1) until the appearance of radiologic disease progression, toxicity, subject or physician decision or death. At the discretion of the Investigator, treatment may continue beyond radiologic progression until clear symptomatic deterioration if no other treatment options are available. Dose interruptions of up to 3 weeks, and up to two dose reductions (to 20 mg and 15 mg) will be allowed to mitigate toxicity. Dose reescalation will be allowed only one time if the same toxicity does not recur at the reduced dose for least one cycle (4 weeks)."
75727|NCT03591952|Procedure|Suction-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
75728|NCT03591952|Procedure|Gravity-Driven Thoracentesis|Thoracentesis is a procedure in which a needle is inserted into the pleural space between the lungs and the chest wall. This procedure is done to remove excess fluid, known as a pleural effusion, from the pleural space to help one breathe easier.
75729|NCT03591939|Diagnostic Test|laboratory test|role of T- regulatory cells in the patients of diabetic nephropathy
75730|NCT03591926|Drug|SM04646|"Nebulized, inhaled solution; single dose concentration dosed once per day for 12 weeks; dosing pattern will follow a 2 weeks on, 2 weeks off regimen, wherein subjects will dose 5 consecutive days of each 7 day on week."
75731|NCT03591913|Drug|Misoprostol|Oral tablets
75732|NCT03591900|Device|insulin pump/CGMS|"A-Continuous glucose monitoring system (CGMS) : A glucometer will be given to each patient and will be asked to measure blood glucose before meals and snacks and record the valus in the CGMS for better calibration (Khammar A et al., 2009).~B-Therapeutic intervention:~Thalassemia patients who proved to have diabetes according to the ADA criteria will be subjected to~• Insulin pump will be tried in each diabetic thalassemic patient versus conventional insulin therapy(Bruttomesso D et al., 2009)."
75733|NCT03591887|Biological|ABY-035|ABY-035 solution for injection
75734|NCT03591887|Biological|Placebo|Placebo to ABY-035 solution for injection
75735|NCT03591874|Drug|Brimonidine Tartrate|Brimonidine Tartrate Nanoemulsion Eye Drops given 2 times a day for 12 weeks.
75736|NCT03591874|Drug|Placebos|Opthalmic buffered saline solution Eye Drops given 2 times a day for 12 weeks.
75737|NCT03591861|Procedure|Ketogenic diet|"Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner."
75738|NCT03591861|Drug|BCNU|-Standard of care
75739|NCT03591848|Behavioral|Online support decision tool|Online support decision tool, in addition of the standard oral information
75740|NCT03591848|Behavioral|standard oral information|standard oral information
75741|NCT03591835|Other|Weight+6|For the Tochen formula in Group 1, ETT depth will be calculated by taking the infant's actual weight within the last 24 h and adding 6 cm.
75742|NCT03591835|Other|NTL+1|The infants in Group 2 will be intubated by measuring the NTL, the distance from the basement of the nasal septum to the the tragus of the ear. Measurements will be recorded as centimeters.
75743|NCT03591822|Behavioral|A : Systemic evaluation of the pain and mediation with the PARO therapeutic robot|Each session with the PARO robot will encompasses the same four following steps (a) Meeting Paro (b) Proposing contact (c) Individually using Paro during the care (d) End of the exposure.
75744|NCT03591822|Behavioral|B : Systemic evaluation of the pain|A systematic evaluation of the pain
75745|NCT03591809|Other|combined exercise training|The combined exercise training group will be given combined exercise training, consisting of Pilates and aerobic exercise, three times during 8 weeks.
75746|NCT03591796|Device|HFOV|Ventilated infants were randomized to HFOV
75747|NCT03591796|Device|CMV|Ventilated infants were randomized to CMV.
75748|NCT03591770|Biological|SHINGRIX|"SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.~SHINGRIX is a suspension for injection supplied as a single-dose vial of lyophilized gE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. A single dose after reconstitution is 0.5 mL.~Dose and Schedule: Two doses (0.5 mL each) administered intramuscularly according to the following schedule: A first dose at Month 0 followed by a second dose administered anytime between 2 and 6 months later."
75749|NCT03591757|Drug|Tolcapone|Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
75750|NCT03591744|Drug|Bortezomib|Given SC
75751|NCT03591744|Biological|Daratumumab|Given IV
75752|NCT03591744|Drug|Dexamethasone|Given IV and PO
75753|NCT03591744|Drug|Lenalidomide|Given PO
75754|NCT03591744|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
75755|NCT03591731|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
75756|NCT03591731|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
75757|NCT03591718|Drug|BI 456906|Solution for injection
75758|NCT03591718|Drug|Placebo|solution for injection
75759|NCT03591705|Drug|TACE-HAIC|transcatheter arterial chemo-lipiodolization with EADM 30mg/m2, followed by hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
75760|NCT03591705|Drug|HAIC|hepatic artery infusion Oxa 85 mg/m2, CF 400 mg/m2, 5-Fu 400 mg/m2, 5-Fu 1200mg/m2 infusion 23h.
75822|NCT03591315|Diagnostic Test|automated visual field|Identify the existence and type of visual field defect.
75823|NCT03591315|Diagnostic Test|visual acuity|Assess the visual acuity by using ETDRS scales.
75761|NCT03591692|Procedure|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
75762|NCT03591692|Procedure|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
75763|NCT03591679|Drug|Oxytocin|20 units by slow intravenous drip injection
75764|NCT03591679|Procedure|bilateral uterine artery ligation|• The peritoneum over the vesico-uterine pouch already being incised horizontally, the peritoneum over the uterine isthmus and cervix was dissected downwards, and this dissection was then extended laterally.
75765|NCT03591666|Drug|Anlotinib|Anlotinib p.o. qd
75766|NCT03591653|Drug|LXI-15028|The investigational products are administrated orally, once in the morning every day, and each dose includes one tablet of investigational products (LXI-15028 50mg active agent or placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 weeks.
75767|NCT03591653|Drug|Placebo|Placebo
75768|NCT03591640|Diagnostic Test|Blood test|Standard blood test
75769|NCT03591627|Diagnostic Test|Transesophageal echocardiography|Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
75770|NCT03591614|Biological|DKK1|The investigational agent is a DKK1 peptide-loaded autologous dendritic cell vaccine dispensed at a dose of 5-10x106 in 0.5 mL Plasma-Lyte A + 5% HSA.
75771|NCT03591601|Other|Manual Therapy protocol|Treatment based on manual therapy with proven evidence.
75772|NCT03591601|Other|Foam Rolling protocol|Treatment based on massage with a Foam Rolling
75773|NCT03591601|Other|Placebo control|Placebo treatment based on the placement of the hands on the head without intention to treat.
75774|NCT03591588|Other|diet|The study includes 2 phases, each of which includes 2 arms: phase 1 includes high-saturated fat diet and low-fat diet; phase 2 includes high-saturated fat diet and high monounsaturated fat Mediterranean type diet. The diets are provided to each participant in a randomized crossover design.
75775|NCT03591575|Drug|Deferiprone oral solution|Liquid formulation of deferiprone, with a concentration of 80 mg/mL
75776|NCT03591575|Drug|Placebo|Liquid solution that matches deferiprone oral solution in appearance and taste
75777|NCT03591549|Drug|Faslodex|intramuscular injection monthly
75778|NCT03591549|Drug|Zoladex|intramuscular injection monthly
75779|NCT03591536|Other|Pentoxifylline|400 mg pentoxifylline oral tablet from 3 days before surgery and on the day of surgery
75780|NCT03591536|Other|Placebo|oral placebo tablets from 3 days before surgery and on the day of surgery
75781|NCT03591523|Diagnostic Test|Quantitative MR angiography|Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
75782|NCT03591523|Diagnostic Test|Duplex sonography|Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
75783|NCT03591510|Drug|Midostaurin|midostaurin titrated from 30mg/m2 bid to 60mg/m2
75784|NCT03591510|Drug|FLUDARABINE|30mg/m2/day on D 1-D5 of block 2 FLADx
75785|NCT03591510|Drug|cytarabine|2000mg/m2/day D1 to D5 of block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 3000mg/m2 every 12 hours D1 to D 3 block 4 3000mg/m2 every 12 hours D1 to D 3 block 5
75786|NCT03591510|Drug|Daunorubicin liposomal or daunorubicin or idarubicin|daunorubicin 60 mg/m2/day OR Idarubicin : 12mg/m2/day On Day 2, D4, D6 block 2 FLADx
75787|NCT03591510|Drug|Mitoxantrone|10mg/m2/days days 3 and 4
75788|NCT03591510|Drug|Etoposide|100mg/m2/day Day 1 to Day 5
75789|NCT03591497|Other|Virtual Reality|As described in Experimental arm description.
75790|NCT03591484|Radiation|Photodynamic therapy|Treatment with Photodynamic therapy. The evaluation of halitosis and the microbiological analysis will be repeated before this step
75791|NCT03591484|Device|Treatment with tongue scraper|Treatment with tongue scraper. The evaluation of halitosis and the microbiological analysis will be repeated before this step
75792|NCT03591484|Procedure|Periodontal treatment|Periodontal treatment will be performed with curettes and ultrassom. The evaluation of halitosis and the microbiological analysis will be repeated before this step
75793|NCT03591484|Procedure|hygiene procedures for the mucosa and dentures|edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis and the microbiological analysis will be repeated before this step
75794|NCT03591471|Drug|Glycosides Of Tripterygium Wilfordii Hook(GTW)|"For severe HSPN GTW is 2mg/kg/d for the first 2 weeks , continued with 1.5mg/kg/d (maximum to 90mg/d) for another 2 weeks; For light HSPN GTW is 1.5mg/kg/d(maximum to 90mg/d) for 4 weeks.~Both the 2 types are continued with 1mg/kg/d of GTW for another 4 weeks . Besides,Sulfotanshinone Sodium Injection,Qingrezhixue graunles,Chinese herbs by syndrome differentiation are plused at the same time"
75795|NCT03591471|Drug|Sulfotanshinone Sodium Injection|Intravenous drip of Sulfotanshinone Sodium Injection with the dosage of 1mg/kg/d(maximum to 50mg), combined with 100-250ml 5% Glucose Solution (G.S) for 2 weeks in both the light and serious type of TCM group.
75796|NCT03591471|Drug|Chinese herbs based on syndrome differentiation|"For both the light and serious type of HSPN in TCM group,five traditional Chinese medicine patterns of syndrome are classified on the main pathogenesis Blood Stasis: based on Qingre Zhixue granule,for wind-heat complicated with blood stasis, add Forsythia, Honeysuckle,;for blood-heat complicated with blood stasis,add Buffalo horn,Comfrey; for yin deficiency complicated with blood stasis, add Rhizoma anemarrhenae,Cortex phellodendri;for both qi and yin deficiency complicated with blood stasis,add Astragalus, Heterophylla;for damp-heat complicated with blood stasis,add Scutellaria baicalensis,Lalang Grass Rhizome."
75797|NCT03591471|Drug|Prednisone Acetate Tablets|Prednisone Acetate Tablets are necessary for serious HSPN in controlled group,the initial dosage is 2mg/kg/d(maximum to 30mg,4 weeks),continue to reduce the dosage until discontinued（Reduce the dosage at the rate of 5mg every other day in 4-8 weeks，then reduce the dosage at the rate of 5-10mg per week in 8-12weeks）
75798|NCT03591471|Drug|Benazepril Hydrochloride Tablets|In controlled group, Benazepril Hydrochloride Tablets are used for both the light and serious type with the dosage of 5-10mg/d(10mg/d for children with weight above 30kg) ,12 weeks in total.
75799|NCT03591471|Drug|Low Molecular Weight Heparin Calcium Injection|In controlled group,Low Molecular Weight Heparin Calcium Injection are used for both the light and serious type with the dosage of 100u/kg/d by hypodermic injection for 2 weeks
75800|NCT03591471|Drug|Dipyridamole Tab 25 MG|In controlled group,Dipyridamole Tab 25 MG are used for both the light and serious type of HSPN with the dosage of 3mg/kg/d ,3 times a day,12 weeks in total.
75801|NCT03591471|Drug|Chinese medicine placebo|In controlled group,take a potential necessary for patients who come to the hospital of TCM to take traditional Chinese medicine in consideration, we add the traditional Chinese medicine placebo in controlled group.
75802|NCT03591458|Drug|Amitriptyline|Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.
75803|NCT03591458|Drug|Placebo|Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
75804|NCT03591445|Device|Flexible Bronchoscopy|Flexible Bronchoscopy
75805|NCT03591432|Device|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)|Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.
75806|NCT03591432|Device|Facemask ventilation|Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
75807|NCT03591419|Device|polymer clip|polymer clips will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
75808|NCT03591419|Device|endoloop|endoloop will be used to ligate the stump of appendix during appendectomy and time for application and cost of clips will be calculated
75809|NCT03591406|Drug|Ferric carboxymaltose|Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection; Strength: 10 mL vials containing 500 mg iron per vial; Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening); Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline); Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
75810|NCT03591406|Drug|Iron sucrose|Dosage Form: Sterile solution for injection containing 2% w/v iron; Strength: 5 mL ampoules containing 100 mg iron per ampoule; Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given; Route of administration: IV injection or drip infusion; Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
75811|NCT03591393|Diagnostic Test|questionnaire|"Validated self-administered questionnaires with five domains: Wexner questionnaire for anal incontinence, PAC-SYM for constipation, International Consultation on Incontinence Questionnaire Short Form for urinary incontinence, the Pelvic Organ Prolapse Distress Inventory for pelvic organ prolapse, POP/UI Sexual Questionnaire - IUGA revised for sexual function.~The body image perception will be assessed using the Dutch-validated version of the self-administered Body Image Disturbance Questionnaire."
75812|NCT03591380|Drug|Belimumab|Kidney transplant recipients (n=5) will receive standard of care (SOC) therapy consisting of alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression, plus induction and treatment for 6 months with belimumab.
75813|NCT03591367|Diagnostic Test|MicroRNAs-155|Quantitative analysis of cell-free miR-155 using RT-qPCR.
75814|NCT03591367|Diagnostic Test|Human telomerase reverse transcriptase|Analysis TERT by TERT messenger RNA (mRNA)expression by reverse transcription-quantitative polymerase chain reaction.
75815|NCT03591354|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 insulin pump with Control-IQ Technology & Dexcom G6 CGM for 3 months.
75816|NCT03591354|Device|t:slim X2 with Basal-IQ & Dexcom G6 CGM|Participants will use a Tandem t:slim X2 insulin pump with Basal-IQ and a study CGM (Dexcom G6) for 3 months.
75817|NCT03591341|Diagnostic Test|melatonin level in pumped breast milk|diagnostic test of melatonin level in pumped breast milk
75818|NCT03591328|Diagnostic Test|Coronary CT angiography|"CCTA images will be screened for APC and CFD analyses. The presence of APC (low-attenuation plaque, positive remodeling, napkin-ring sign, and spotty calcification) will be assessed in each lesion by an independent observer blinded to the clinical data and CFD results according to the definitions from previous studies.~In order to evaluate incremental value of hemodynamic parameters, CFD will be performed in the independent core laboratory (HeartFlow Inc.). In consideration of potential clinical implications proposed in previous studies, 4 hemodynamic parameters will be computed for covariates in prediction models: 1) per-vessel FFR derived from cCTA (FFRCT); 2) change in FFRCT across the lesion (△FFRCT); 3) wall shear stress (WSS); and 4) axial plaque stress."
75819|NCT03591315|Diagnostic Test|resting state fMRI|Define the visual resting state network.
75820|NCT03591315|Diagnostic Test|visual tasking state fMRI|Using visual task stimulation to identify the activation characteristic of primary visual cortex.
76375|NCT03586960|Device|Peak Force Measurement|Force will be measured at 5,10, and 30 minutes
75824|NCT03591302|Biological|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from living donor.
75825|NCT03591302|Radiation|Total Lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
75826|NCT03591289|Drug|NMB with rocuronium bromide|Moderate versus deep neuromuscular block Not a device study
75827|NCT03591276|Drug|Chemotherapy Drugs, Cancer|IV pembrolizumab 200 mg flat dose with IV PLD 30 mg/m2 (chemotherapy drugs) every 3 weeks in eligible breast cancer patients.
75828|NCT03591263|Other|Pulmonary rehabilitation|Pulmonary rehabilitation as routine care includes, airway clearance techniques, breathing exercise, and physical training instruction
75829|NCT03591237|Behavioral|Mindfulness-Based Cognitive Therapy|The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
75830|NCT03591224|Other|Pharmacogenomic Testing|pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism
75831|NCT03591224|Other|Pharmacist Standard of Care|Pharmacist providing standard of care as per usual practice
75832|NCT03591211|Behavioral|Qigong Training|Eight-Section Brocades; participants were trained individually.
75833|NCT03591211|Behavioral|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
75834|NCT03591198|Behavioral|Qigong Training|Eight-Section Brocades
75835|NCT03591198|Behavioral|Cognitive Training|Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
75836|NCT03591185|Other|FallSensing Clinical Tool|"FallSensing clinical tool will be applied to a group of community-dwelling adults aged 50 years or over, including a initial evaluation, 24 intervention sessions (2 or 3 sessions per week) and a final evaluation.~Inicial and final evaluation consists in six functional tests (Grip Strength, Timed Up and Go, 30 seconds Sit-to-Stand, Step test, 4 Stage Balance test modified and 10 meters Walking Speed) and a questionnaire concerning self-efficacy for exercise."
75837|NCT03591172|Drug|Propolis|Using propolis as a final irrigation in revascularization
75838|NCT03591172|Drug|Nano-propolis|Using Nano-propolis as a final irrigation in revasculariztion
75839|NCT03591172|Drug|saline|Using saline as a final irrigation in revasculariztion
75840|NCT03591159|Other|Membran Sweeping|Cervical Membrane Sweeping by digital examination
75841|NCT03591146|Drug|TLC590|TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
75842|NCT03591146|Drug|Naropin|Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg [0.5%, 5mg/mL] x 30mL
75843|NCT03591133|Drug|TS-143|
75844|NCT03591133|Drug|Placebo|
75845|NCT03591120|Other|Control|Standard of Care without Preventative Delirium Protocol
75846|NCT03591120|Other|Preventative Delirium Protocol|Preventative Delirium Protocol
75847|NCT03591107|Other|PTSD Care Management (PCM)|Collaborative care for PTSD facilitated by a trained CM who will engage the patient into care, monitor progress over 6 months, coordinate care with primary care and behavioral healthcare providers and social services, and receive monthly supervision by the study psychiatrist in addition to education and feedback
75848|NCT03591107|Other|Minimally Enhanced Usual Care (MEU)|Education and feedback alone
75849|NCT03591094|Drug|PTI-428|Active
75850|NCT03591094|Drug|Placebo|Placebo
75851|NCT03591081|Other|Intellin smart phone application|This feasibility study will explore if creating an electronic platform Intellin smart phone application can promote and support timely self-referral for individuals with a recently healed DFU. It will explore the software applications acceptance and ease of use for patients.
75852|NCT03591068|Drug|OPN-375|OPN-375, 186 μg BID
75853|NCT03591055|Other|CGA, medication review, exercise and cognitive stimulation|Comprehensive geriatric assessment. Patient-centered interventions according to the different target areas identified in the geriatric assessment. Medication review. Groupal Exercise plan and memory workshops.
75854|NCT03591042|Diagnostic Test|cervical length screening|transvaginal ultrasound cervical length
75855|NCT03591029|Other|blood samples|blood samples will be obtained from the superior vena cava (via centra venous catheter), from the pulmonary artery (via Swan Ganz catheter), and from a radial or femoral artery catheter
75856|NCT03591016|Other|Recording number of IV attempts|Recording number of IV attempts in the operating room
75857|NCT03591003|Diagnostic Test|Yellow fever neutralizing antibodies measure|Yellow fever neutralizing antibodies measure before vaccination, within the year after vaccination and at any delay after vaccination
75858|NCT03590990|Diagnostic Test|Ultrasonsography, mammography, biopsy|Ultrasonsography of lump in breast Mammography of patents above 35 years Biopsy if indicated
75859|NCT03590977|Other|licorice extract mouthwash|mouth rinse that contains a natural herbal licorice root extract used as a preventive measure that reduce caries index.
75860|NCT03590977|Other|chlorohexidine mouthwash|mouth wash that contains chlorohexidine as an active component
75861|NCT03590964|Procedure|Open sinus lift using chin bone graft|Patients with atrophied posterior maxilla will undergo open sinus lift with chin bone graft according to standardized surgical approach.
75862|NCT03590964|Procedure|Sinus lift using bone ring containing the implant.|Patients with atrophied posterior maxilla will undergo sinus lift with chin bone ring containing the implant.
75863|NCT03590951|Other|Retrospective chart review|A retrospective chart review was conducted to evaluate the effect of body mass index on obstetric, anesthetic and neonatal complications in patients who underwent cesarean section at our institution
75864|NCT03590912|Drug|Fluticasone Nasal|Dose to be added.
76382|NCT03586934|Drug|Acetaminophen Injectable Product|Acetaminophen injection
75865|NCT03590912|Drug|Anti Histamine plus Nasal decongestents|Oral cetirizine, standard dose for 4 weeks, plus oxymetazoline 0.025%, 4 drops twice daily for two weeks
75866|NCT03590912|Drug|Steroid Drug|Oral prednisolone, 1mg/kg body weight daily for 10 days
75867|NCT03590899|Device|Optical coherence tomography angiography (Zeiss Cirrus HD OCT 5000 AngioPlex)|Non-invasive, non-contact optical coherence tomography angiography scans of the retina are done per built-in device protocol using the Zeiss Cirrus HD OCT 5000 AngioPlex machine.
75868|NCT03590886|Other|total response Group|biochemical response for UDCA treatment more than 1 year according to Paris-I/II standard
75869|NCT03590873|Drug|Vasopressin|Vasopressin, is a hormone synthesized as a peptide prohormone in neurons in the hypothalamus, and is converted to arginine vasopressin. It then travels down the axon of that cell, which terminates in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). Arginine vasopressin has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, arginine vasopressin constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.
75870|NCT03590860|Drug|LY3322207|Administered by SC injection
75871|NCT03590860|Drug|Placebo|Administered by SC injection
75872|NCT03590847|Behavioral|Intermittent Fasting|Study participants will be asked to fast for a target of 16 hours per day for a period of 4 weeks. Participants will be allowed to consume calorie-free beverages, water, tea, black coffee or sugar-free gum during the fasting period. Participants will be asked to record the time of first and final food/drink consumption each day.
75873|NCT03590834|Behavioral|Center-based Intervention|"Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~Staff training and technical assistance~Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~Health contests~Gross motor and physical activity program~Miranos! activity cards based on children storybooks"
75874|NCT03590834|Behavioral|Home-based Intervention|"Monthly interactive poster education sessions led by parent peer educators during child pick-up time. Held at Head Start Center. These sessions include family health challenges and take-home activities.~Three Home Visits delivered by Head Start staff. Obesity prevention goal-setting integrated into existing Head Start home visits~16 semi-monthly, Family Newsletters with stories, tips, and strategies to promote healthy habits for preschool children~Incorporating activities related to PA, nutrition and sleep into existing Head Start Center Summer Calendars"
75875|NCT03590834|Behavioral|Active Control|"Children will receive Head-Start-approved health education program for children: I Am Moving, I Am Learning. In addition, the investigators will deliver an early childhood literacy program to all active control children to increase buy-in and retention."
75876|NCT03590821|Drug|Aspirin 81 mg|timed administration of aspirin in the evening
75877|NCT03590821|Drug|Celecoxib 200mg capsule|daily administration of celecoxib
75878|NCT03590808|Biological|Influenza vaccination|Purified inactivated influenza virus antigen (Green Cross Corp) 0.5 mL once IM
75879|NCT03590795|Other|Sleep survey|The Sleep survey was created by the Collaborative Research Center (CRC), a joint effort of the Australian Government, Academia and Industry [including Philips]).
75880|NCT03590782|Other|Erector Spinae Block|An ultrasound guided erector spinae block will be performed.
75881|NCT03590769|Drug|18F-FDG|All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
75882|NCT03590756|Other|16 weeks mango intake|Participants will be provided fresh frozen Ataulfo mangoes.
75883|NCT03590743|Drug|Apixaban|Active anticoagulation with apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily to complete a total of 3 months treatment.
75884|NCT03590743|Other|Placebo|apixaban matching placebo 2 tablets twice daily for 7 days followed by one tablet twice daily to complete a total of 3 months.
75885|NCT03590730|Device|ICD implantation|ICD will be implanted according to current guidelines recommendations.
75886|NCT03590717|Behavioral|BCC-Only|Households in the 'BCC-only' arm receive SBCC but do not receive vouchers.
75887|NCT03590717|Other|Small-voucher|Households in the 'Small-voucher' arm receive a voucher (~$12-17) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
75888|NCT03590717|Other|Large-voucher|Households in the 'Large-voucher' arm receive a larger voucher (~$21-23) every month that entitles them to purchase fresh foods (fruits, vegetables and animal sourced foods). The households in this arm also receive the same social behavioural change communication (SBCC) messages as the 'BCC-only' arm.
75889|NCT03590704|Device|Vitaltape® bandage|The neuromuscular bandage will be applied after skin antisepsis with 70% alcohol. A 5 cm width Vitaltape® neuromuscular bandage will be used. For the bandage application, a distal base (anchor) with two centimeters of diameter will be maintained with maximum stretching on the seroma and finalized with another base no stretching, of 2 cm, in the proximal region. How many bundles of bandages are required according to the patient's body characteristics and aspect of the flotation region.
75890|NCT03590691|Other|Vietnam National Hypertension Program|A training program for health care workers including physicians and nurses and a health educational program for general public regarding hypertension management at community level will be implemented
75891|NCT03590691|Other|Expanded community health worker services|A training program will be implemented for community health workers regarding hypertension management at community level so that they can assist patients better manage their blood pressure at home.
75892|NCT03590691|Behavioral|Storytelling intervention|The storytelling intervention consists of interactive, literacy-appropriate, and culturally sensitive multimedia storytelling modules for motivating behavior change through the power of patients speaking in their own voice. Based on preferences that emerged during the researchers' formative work with the partnering rural communities, the storytelling intervention will be delivered by DVD, with serial installments at baseline and at 3, 6, and 12 months after trial enrollment.
75893|NCT03590691|Behavioral|Home blood pressure self-monitoring|Patients with hypertension will be provided blood pressure monitors and guided to self-measure their blood pressure and to record their blood pressure daily at home.
75894|NCT03590665|Other|Hand grip exercise and lower body negative pressure|For participants with Down syndrome, the first visit includes baseline measures and familiarization with the graded maximal exercise test protocol. If necessary, additional familiarization sessions will be scheduled for people with Down syndrome. The second visit, we perform the graded maximal exercise test and familiarize the participant with the procedures for the third visit: the hand grip exercise protocol and the lower body negative pressure (LBNP) box. The third visit we assess the peripheral blood flow during the hand grip exercise protocol without and with the LBNP. For control subjects, the first and second visit are combined. Their second visit is the same as the third visit for individuals with Down syndrome.
75895|NCT03590652|Drug|Ixazomib|4mg PO days 1,8,15 on 28-day cycle
75896|NCT03590652|Drug|Pomalidomide|4mg days PO 1-21/28 days
75897|NCT03590652|Drug|Dexamethasone|"40mg** PO weekly~** starting dose for age >75 may be 20mg"
75898|NCT03590652|Drug|Daratumumab|16mg/kg IV weekly x 8 weeks, biweekly x 8 doses, then monthly
75899|NCT03590626|Drug|Dulaglutide|0.75 mg weekly for 4 weeks followed by 1.5 mg weekly for 20 weeks
75900|NCT03590613|Drug|GSK2982772|GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route
75901|NCT03590613|Drug|Placebo|Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
75902|NCT03590600|Drug|BTZ-043|Powder and solvent for oral suspension
75903|NCT03590600|Drug|Placebo|Matching placebo: powder and solvent for oral suspension
75904|NCT03590587|Drug|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
75905|NCT03590587|Device|0.19 mg fluocinolone acetonide (FAc) implant|0.19 mg fluocinolone acetonide (FAc) implant
75906|NCT03590574|Biological|AUTO4|AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 25 to 225 x 10^6 RQR8/aTRBC1 CAR T cells. Following Phase 2 dose determination patients will be treated with selected doses of RQR8/aTRBC1 CAR T cells (AUTO4).
75907|NCT03590561|Other|High caloric diet|After dietary counseling, subjects will receive high caloric snacks for five days.
75908|NCT03590548|Diagnostic Test|gausher disease|lab investigation and radio logical
75909|NCT03590535|Diagnostic Test|4th Gen cTnT|"Current Fourth Generation Cardiac Troponin T Enzyme Assay"
75910|NCT03590535|Diagnostic Test|5th Gen cTnT|"New Fifth Generation (High-sensitivity) Troponin T Enzyme Assay"
75911|NCT03590522|Genetic|Ryanodine Receptor 2 gene expression|Ryanodine Receptor 2 gene expression will be measured by real time PCR. In addition, amino acids analysis will be measured in plasma by amino acid analyzer.
75912|NCT03590509|Other|Integrated Telemedicine-Home Visitation Program|A telemedicine platform (Zoom) will be added to comprehensive care (CC) to be used by the CC providers to make observations in the home to augment care, help address acute problems remotely at any hour, better coordinate care with healthcare personnel, and thereby reduce clinic visits, ED visits, and hospitalizations. Home visits will be conducted by a nurse home visitor whenever considered likely to be beneficial for any of the CMC and at least once by the assigned CC provider immediately following enrollment of children with chronic respiratory failure requiring mechanical ventilation at home
75913|NCT03590509|Other|Usual Comprehensive Care|Comprehensive care (CC) provided in an enhanced medical home to assure effective care at any hour for or children with medical complexity
75914|NCT03590496|Drug|Atorvastatin 10mg|Atorvastatin-Calcium Film-coated tablets
75915|NCT03590496|Dietary Supplement|Calcium-Propionate 500mg|Calcium-Propionate capsules
75916|NCT03590496|Other|Placebo|Placebo capsules without any active ingredient
75917|NCT03590470|Other|Implementation of a nurse-led model of care|A nurse-model of care consisting of a specifically trained geriatric nurse expert, communication and quality improvement tools will be implemented in 11 nursing homes in the German speaking part of Switzerland
75918|NCT03590457|Device|Airvo 2; High-Flow nasal cannula system|Noninvasive device used to deliver humidified oxygen at high flow rates up to 60 liters per minute
75919|NCT03590444|Drug|Ranibizumab 0.5 MG/0.05 ML Intraocular Solution|"Focal laser treatment will be performed using argon laser photocoagulation (VISULAS 532s®, Carl Zeiss Meditec) operating at 532nm and Ranibizumab 0.5 MG/0.05 ML Intraocular Solution.~Ranibizumab 0.5 MG/0.05 ML Intraocular Solution"
75920|NCT03590431|Dietary Supplement|extrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (extrinsic iodine, low protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 50 µg/L. The iodine content of the extrinsically labelled milk will be adjusted to the required concentration (same as intrinsic iodine milk) by adding iodine in form of potassium iodide.
75921|NCT03590431|Dietary Supplement|intrinsic iodine in milk|300 ml whole cow's milk delivering ≈ 200 µg iodine (intrinsic iodine, high protein-bound fraction) The whole cow's milk will be produced in an experimental barn feeding supplementary iodine to reach a final iodine concentration of ≈ 600 µg/L. This concentration will define final supplemental iodine given to the participants (adapting the total portion size).
75922|NCT03590431|Dietary Supplement|water iodine solution|300 ml water delivering ≈ 200 µg iodine (control)
75923|NCT03590405|Procedure|uterus transplantation surgery and IVF|IVF before surgery living donor uterus transplantation ET
75924|NCT03590392|Biological|ChAdOx1 Chik|ChAdOx1 Chik, a replication-deficient simian adenoviral vector expressing CHIKV antigens.
75925|NCT03590379|Drug|CHF 5993 DPI|BDP/FF/GB DPI
75926|NCT03590379|Drug|CHF5993 pMDI|BDP/FF/GB pMDI
75927|NCT03590379|Drug|CHF 1535 pMDI|BDP/FF pMDI
75928|NCT03590379|Drug|Placebo DPI|CHF 5993 DPI matched placebo
75929|NCT03590379|Drug|Placebo pMDI|CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
75930|NCT03590366|Biological|B244|B244 Suspension
75931|NCT03590366|Biological|Vehicle|Vehicle suspension
75953|NCT03590171|Drug|Bortezomib|Patients randomised to the HR-B arm receive induction, consolidation with the modified ALL R3 protocol. In this arm, patients are randomized to receive Bortezomib together with the ALL R3 protocol during induction. Administration of Bortezomib: 1.3 mg/m2 as intravenous bolus or subcutaneously (SC, at the discretion of the treating physician) on days 1 and 4 of weeks 1 and 3.
75932|NCT03590353|Device|Dual Chamber Pacemaker|1. Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. 2.Putting 2 sheathing canals into heart along with guiding wires. 3.Locating the sheathing canals, and putting electrodes into canals. 3.Adjusting the electrodes and revolving them anticlockwise to lead them to right atrium and right ventricle respectively under the X-ray. 4.Immobilizing electrodes. 5. Some ways to determine whether the electrode is fixed or not: the head of the electrodes could beat rhythmically with atrium or ventricle or by testing damage current. 6.Removing the canals and suturing.
75933|NCT03590353|Device|His Bundle Pacemaker|1.Conducting venipuncture. Subclavian vein is our first choice. Then we set up two venous channels and implant two guiding wires into postcava. One of the guide wire is 120cm in length, 0.035 or 0.038 in diameter, which is required to lead the C315 sheathing canal. 2.Putting C315 sheathing canal into heart along with guiding wires. 3.Locating the C315 sheathing canal, and adjusting the head of C315 towards ideal pacing location. 3.Implanting the spiral electrodes and fixing them. Leading the spiral electrode to the side of his bundle along the C315 canal under the X-ray. The other electrode is leaded to right atrium like dual chamber pacemaker under the X-ray. 4.Revolving the 3830 electrode suitably to Immobilizing it in cardiac muscle. If the electrode can get his electric potential and produce his bundle pacing successfully, we revolve the 3830 electrode and immobilize it.
75934|NCT03590340|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
75935|NCT03590340|Other|Normal saline|Normal saline is 0.9% sodium chloride
75936|NCT03590340|Biological|PfSPZ Challenge (for CHMI)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
75937|NCT03590327|Device|Transcranial Magnetic Stimulation|rTMS
75938|NCT03590314|Device|Experimental group - robot assisted arm training (Armotion®)|"Passive mobilization and stretching exercises for affected upper limb (10 minutes) followed by robot-assisted exercises (35 minutes). Were selected four types of exercises contained within the Armotion® software:~Collect the coins~Drive the car~Wash the dishes~Burst the balloons~For increment the difficulty, we have varied the assisted and non-assisted modality, increasing the number of repetitions over the study period."
75939|NCT03590314|Other|Control group - conventional treatment|Upper limb passive mobilization and stretching (10 minutes) followed by exercises (35 minutes) that incorporated single or multi-joints movements for the scapula, shoulder and elbow, performed in different positions (i.e. supine and standing position). The increase of difficulty and progression of intensity were obtained by increasing ROM, repetitions and performing movements against gravity or against slight resistance.
75940|NCT03590301|Behavioral|FUNPALs Playgroup|Based on Self-Determination Theory, the FUNPALs Playgroup aims to enable and inspire parents to improve their toddlers dietary intake and physical activity habits through authoritative parenting, structured feeding practices, and a healthy home environment. Playgroups will include open but structured experiential learning activities, free play, and instruction/discussion.
75941|NCT03590301|Behavioral|Healthy Toddler Parent Group|The parent class will serve as our instruction only control group. Parents in this class will receive information about nutrition and activity recommendations regarding their toddler age children and will discuss it in a group with other parents. No experiential learning activities, information about parenting, or children will be involved in this class.
75942|NCT03590288|Procedure|Transjugular intrahepatic portosystemic shunt|"Covered stents will be used, that will be dilated to 8 or 10 mm according to the hemodynamic response. The aim will be to reduce the portal pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted.~Measurement of pressure gradient will be repeated within 3 days after the procedure and then at 1 month and 6 months after the procedure.~A TIPS revision will be performed once shunt dysfunction is suspected."
75943|NCT03590275|Drug|FOLFIRINOX|Patients treated with first-line FOLFIRINOX (oxaliplatin + irinotecan + lederfolin + 5-fluorouracil) as per clinical practice were included in the study
75944|NCT03590262|Drug|Metformin|take the metformin 500mg twice or three times a day
75945|NCT03590249|Procedure|Osteopathic Manipulative Treatment|Osteopathic manipulation involves a number of different manual (hands-on) techniques. These include muscle inhibition (applying pressure to a muscle to induce relaxation); myofascial release (applying pressure to the fascia and moving it toward/away from a strain); muscle energy stretch (contraction of a stretching muscle); counterstrain (shortening a strained muscle); facilitated positional release (moving a vertebra into a restriction and applying a gentle compression); osteopathy in the cranial field (balancing the cranial tissue); balanced ligamentous tension/ligamentous articular strain (moving a joint into ease to release tension in the ligament); one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure. Treatment will last approximately 45 minutes.
75946|NCT03590236|Other|Graded exposure therapy|Patients included in this group received graded exposure therapy consisting on counselling, a graded activity through postural exercises and individual training focused on 5 activities selected by the patients. The treatment will include 5 sessions added to the 12 sessions of physiotherapy.
75947|NCT03590236|Other|Physiotherapy|Physiotherapy intervention will include soft tissue mobilizations and myofascial release combined with deep-pressure massage to decrease trigger point-related pain and tension. In addition joint mobilization and muscle energy techniques will be included.
75948|NCT03590223|Procedure|Coronary Bypass Revascularization|analysis of perioperative major cardiovascular events in diabetic patients
75949|NCT03590210|Drug|Trabectedin|Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w
75950|NCT03590210|Drug|Nivolumab|Cycle 4 to 13 240 mg IV over 30 minutes, q3w
75951|NCT03590197|Drug|Melatonin 3 mg|Melatonin 3 mg/ day with Valproate
75952|NCT03590197|Other|Placebo|Placebo with Valproate
75954|NCT03590158|Behavioral|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
76019|NCT03589690|Dietary Supplement|Alpha lipoic acid|22 Patients will consume 600 mg Alpha lipoic acid for 12 weeks .
75955|NCT03590145|Diagnostic Test|Clinical examination|Standardized clinical examination consisting of pain provocation test, including palpation, muscle resistance and stretch test.
75956|NCT03590132|Behavioral|Strong African American Families Program|SAAF is a 7 session family skills training program
75957|NCT03590132|Behavioral|Strong African American Families--Teen Program|SAAF-T is a 5 session family skills training program
75958|NCT03590119|Drug|Lutetium Lu 177-DOTATATE|Intra-arterial infusion of Lu-177-DOTATATE
75959|NCT03590106|Behavioral|Peer Recovery Support Program|See above
75960|NCT03590093|Procedure|Periodontal surgery|After local anesthesia injection an intrasulcular flap is designed according to minimally invasive techniques. After flap elevation, careful removal of granulation tissues from the periodontal defects is performed. Scaling and root planing of the involved dental roots is ensured and finally suture is placed.
75961|NCT03590093|Procedure|EMD application|Application of Pref-Gel for 2 minutes and then the application on Enamel Matrix Derivatives on the surgically exposed root surface
75962|NCT03590080|Drug|Methylprednisolone|
75963|NCT03590067|Other|Questionnaire|The data will be collected through a questionnaire that will be obtained through an interview between the investigator and the parent or the legal guardian
75964|NCT03590054|Drug|Abexinostat|"Dose Level~-1: 20 mg/m2 PO BID days 1-4, 8-11 of every 21 day cycle~30 mg/m2 PO BID days 1-4, 8-11 of every 21 day cycle~45 mg/m2 PO BID days 1-4, 8-11 of every 21 day cycle"
75965|NCT03590054|Biological|Pembrolizumab|200 mg IV on day 1 of every 21 day cycle
75966|NCT03590041|Behavioral|Standardized SMA|Patients receiving the Standardized SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, delivered only by health educators. The Standardized SMA approach will be uniformly administered at each practice. Topics will be covered in a predetermined order and patients will not have a say in terms of what content they wish to cover. Patients receive the Standardized SMA approach if their practice is randomly assigned to the Standardized SMA arm. Practices are cluster-randomized to deliver a standardized or patient-driven group visit model.
75967|NCT03590041|Behavioral|Patient-driven SMA|Patients receiving the Patient-driven SMA intervention will be part of group visits that cover a modified TTIM 6-session curriculum, but patients are in control of time spent and order of the topics. The Patient-driven SMA will be delivered by a multidisciplinary team consisting of a Health Educator, medical provider, Behavioral Health Professional, and a diabetes peer mentor. Patient-driven SMAs may be delivered differently at each practice, as patients choose the topics that are most important to spend the most time on. All topics will be covered, but the order and time spent is up to the group. Patients receive the Patient-driven SMA approach if their practice is randomly assigned to that arm. Practices are cluster-randomized to deliver a standardized or patient-driven SMA model.
75968|NCT03590028|Other|Early Nephrology Consult (ENC)|The electronic risk prediction algorithm (ESTOP-AKI) will interface with electronic medical data to determine the likelihood for the patient to develop AKI. Early Nephrology Consult (ENC) will be implemented. A nephrologist will assess the subject and consult with their care team to advise a treatment plan during the hospitalization.
75969|NCT03590028|Other|Standard of Care (SOC)|Subjects will receive nephrology consultation at the typical timepoint after symptoms of AKI appear.
75970|NCT03590015|Other|Old invitation letter|Invitation Letter written by researchers/doctors
75971|NCT03590015|Other|New invitation Letter|Invitation Letter written in simple sentences and a sequential structure of basic information in the rewritten information Letter
75972|NCT03590002|Device|Electronic ICU Medical Transfer Tool|Patient transfers of care from the ICU to inpatient wards prepared using the electronic ICU medical transfer tool within the health zone's clinical information system, Sunrise Clinical Manager.
75973|NCT03589989|Other|ENDS (vaporizer/e-cig) and smoking cessation counseling|Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
75974|NCT03589989|Other|Smoking cessation counseling|Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
75975|NCT03589976|Drug|Sirolimus 2 MG|Dose will be adjusted trhoughout this trial based on sirolimus plasma levels and the presence of drug-related adverse events.The maximum dose will be 6mg/day.
75976|NCT03589976|Other|Placebo|Patients receiving placebo will undergo analog sham level measurements and the number of tablets will be also adjusted to maintain the blinding of the trial.
75977|NCT03589963|Behavioral|Postnatal Lactation Support|In-home breastfeeding support delivered by professional lactation consultants and provision of a high-quality breast pump
75978|NCT03589950|Drug|anlotinib plus chemotherapy|Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
75979|NCT03589950|Drug|chemotherapy|Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
75980|NCT03589924|Procedure|Immediate IBBR+TiLoop®Bra|Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra
75981|NCT03589924|Procedure|Immediate-delayed IBBR+TiLoop®Bra|Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra
75982|NCT03589898|Drug|Gabapentin|Single dose of gabapentin 900 mg
76017|NCT03589703|Other|Comparison Group (CG-1)|Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
76018|NCT03589703|Other|Enhanced Educational Control Group (CG-2)|No contact with the subject. Participants in the enhanced educational control group will be given the cLBP educational booklet.
75983|NCT03589885|Drug|Placebo 2 mL auto-injector|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
75984|NCT03589885|Drug|Placebo 1 mL prefilled syringe|"All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8.~PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48.~PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48"
75985|NCT03589885|Drug|Secukinumab 2 mL auto-injector|2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48
75986|NCT03589885|Drug|Secukinumab 1 mL prefilled syringe|2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48
75987|NCT03589872|Diagnostic Test|Fine motor dexterity test, nine hole peg test|The nine hole peg test will be performed under two different task (1)single task, (2)adding a cognitive task
75988|NCT03589846|Device|Grass S88 Muscle Stimulator|The Grass S88 nerve and muscle stimulator is a widely-used tool in electromyography and nerve conduction studies. Under anesthesia, fine-wire electrodes will be placed into the right genioglossus muscle (in the floor of the mouth) and the right palatoglossus muscle (in the anterior tonsillar pillar).
75989|NCT03589833|Drug|Tripterygium Wilfordii|Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
75990|NCT03589833|Drug|Methotrexate|Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.
75991|NCT03589833|Drug|Yisaipu|Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
75992|NCT03589820|Other|artificial liver support system|Patients will receive the treatment of artificial liver support system using combination of plasma exchange and continuous hemodiafiltration and internal medicine. The volume of fresh frozen plasma used in plasma exchange is 2000 millilitre. The time for continuous hemodiafiltration is about 8 hours.
75997|NCT03589794|Other|AP10-602|Glucopyranosyl Lipid A -liposome-Quillaja Saponaria 21 (GLA-LSQ).
75998|NCT03589794|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
75999|NCT03589794|Biological|rCSP|The rCSP malaria vaccine is a recombinant full-length P. falciparum circumsporozoite protein comprised of an amino terminus that binds heparin-sulfate proteoglycans, a four-amino-acid repeat region and a carboxy-terminus that contains a thrombospondin-like Type I region domain.
76000|NCT03589781|Dietary Supplement|Mikei Red Reishi Essence EX|Dosage is 490 mg per capsule, 3 capsules twice a day with food or water. Total of 6 capsules per day.
76001|NCT03589781|Dietary Supplement|Placebo|Matching placebo. Consume 3 capsules twice a day with food or water. Total of 6 capsules per day.
76004|NCT03589755|Behavioral|Mindfulness meditation|The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
76005|NCT03589742|Device|AblaView® Ablation Catheter|The AblaView® Ablation Catheter is a regular RF ablation catheter with the same physical characteristics and the same biocompatible materials, with an 8 French (2.66 mm) sheath and 180º deflection angle. The tip of the catheter has 15 holes distributed around it where the irrigation will be delivered into the patient's blood. The front irrigation hole will deliver at the same time the infrared light for the OCR system.
76006|NCT03589729|Drug|Cladribine|Given IV
76007|NCT03589729|Drug|Cytarabine|Given IV
76008|NCT03589729|Drug|Dexrazoxane Hydrochloride|Given IV
76009|NCT03589729|Drug|Gemtuzumab Ozogamicin|Given IV
76010|NCT03589729|Drug|Idarubicin|Given IV
76011|NCT03589716|Other|Vital Moto Mod|All participants receive vital signs measurement using the Vital Moto Mod device and reference devices. The vital signs measured are blood pressure, heart rate, respiratory rate, oxygen saturation and temperature.
76012|NCT03589716|Other|Welch Allyn Connex Spot Vital Signs Monitor|This is the FDA approved reference device to measure heart rate, SpO2 and temperature.
76013|NCT03589716|Other|Capnostream 20 Portable Bedside Capnograph|This is the reference device to be used to obtain etCO2 waveforms for respiratory rate assessment.
76014|NCT03589716|Other|Welch Allyn 767 Mobile Aneroid Sphygmomanometerand 3M Littmann Master Classic II Teaching Stethoscope|These reference devices will be used together for blood pressure measurements.
76015|NCT03589716|Other|Scifit 1000R cycle ergometer|This is the device that will be used for exercise testing
76016|NCT03589703|Other|APA|Light touch using vaccaria seeds on specific points of the ear.
76020|NCT03589690|Dietary Supplement|Placebo|Participants will be supplemented with 600 mg/day placebo (Starch).
76021|NCT03589651|Drug|INCMGA00012|"Part 1: INCMGA00012 at the protocol-defined starting dose administered intravenously every 4 weeks, with dose escalation to determine the maximum tolerated dose.~Part 2: INCMGA00012 at the recommended dose from Part 1."
76022|NCT03589651|Drug|Epacadostat|"Part 1: Epacadostat at the protocol-defined starting dose administered orally twice daily, with dose escalation to determine the maximum tolerated dose.~Part 2: Epacadostat at the recommended dose from Part 1."
76023|NCT03589651|Drug|INCB050465|Part 1: INCB050465 at the protocol-defined starting dose administered orally once daily, with dose escalation to determine the maximum tolerated dose. Part 2: INCB050465 at the recommended dose from Part 1.
76024|NCT03589638|Device|Direct laryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
76025|NCT03589638|Device|C-MAC videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
76026|NCT03589638|Device|McGrath videolaryngoscope|Endotracheal intubation was applied by anesthesiologist wtih direct laryngoscope. SAP (systolic arterial pressure), DAP (diastolic arterial artery pressure), MAP (mean arterial pressure) were measured before and 5 minutes after intubation, , Heart rate (HR), SPO2 (oxygen saturation by pulse oximetry), PI (perfusion index), and intraocular pressure values measured by the eye clinician using the device.
76027|NCT03589625|Other|Solar Suitcase|"The intervention is a Solar Suitcase. The Solar Suitcase comes with: 2 LED lights, 1 battery, 1 aluminum glass 100 watt solar panel, 2 rechargeable LED headlamps, 1 universal cell phone charger, 1 USB adapter, 1 fetal Doppler, 1 AA/AAA battery charger and expansion box (provides 2 additional lights).~Installers will teach health workers how to use and maintain the Solar Suitcase on the day of installation. Within one week following installation, the contractor will contact the facility over the phone and/or in-person to check if there are any problems with the Suitcase. Additional checks will be made to ensure the solar suitcase is functioning and being used properly."
76028|NCT03589599|Other|Flavored tobacco|Effects of flavored tobacco
76029|NCT03589599|Other|Non-flavored tobacco|Effects of non-flavored tobacco
76030|NCT03589586|Other|DermACELL AWM|DermACELL AWM is a sterile, ready to use acellular dermal matrix
76031|NCT03589560|Drug|Biodentine|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
76032|NCT03589560|Drug|Mineral Trioxide Aggregate|a procedure used to regenerate a pulp-dentine complex that restores functional properties of this tissue, fosters continued root development for immature teeth, and prevents or resolves apical periodontitis.
76033|NCT03589547|Drug|Durvalumab|Durvalumab10mg/kg Q2 weeks (+/- 4 days) for a total of 12 months (maximum of 26 treatments total)
76034|NCT03589547|Radiation|SBRT|"SBRT boost will consist of 2 fractions delivered to the primary tumor only, over 1-2 weeks between the first and second treatments with durvalumab.~The dose will consist of 20Gy (2 fractions of 10Gy)~*3 fractions are allowed for centrally located tumors"
76035|NCT03589534|Diagnostic Test|home pregnancy test|Each participant will use 4 different home pregnancy tests
76036|NCT03589521|Behavioral|ABCT_Military|15 Weekly Couple Therapy Sessions
76037|NCT03589508|Behavioral|In-person sessions: ABCP_P|6 weekly sessions of alcohol prevention conducted in person.
76038|NCT03589508|Behavioral|Video conference sessions: ABCP_T|6 weekly sessions of alcohol prevention conducted by video conference.
76039|NCT03589495|Drug|N Acetyl L Cysteine|100 mg/kg n acetyl cysteine dissolved in dextrose5%
76040|NCT03589495|Other|dextrose 5%|
76041|NCT03589482|Device|Electrical Impedance Tomography|Electrical impedance tomography (EIT) is a new technique that enables real-time visualization of the distribution of ventilation at the bedside. This technique allows clinicians and investigators to immediately determine how applying higher or lower PEEP levels affect stress and strain in the lung. The investigators propose to apply this new technique to test a strategy for finding the optimal level of PEEP that prevents lung injury and improves outcomes in critically ill patients.
76042|NCT03589482|Other|ExPRESS-derived PEEP level|The ExPRESS algorithm is a traditional approach to selecting PEEP based on respiratory mechanics.
76043|NCT03589469|Drug|Loncastuximab tesirine|intravenous infusion
76044|NCT03589456|Other|No intervention|There are no interventions associated with this registry as it is purely observational.
76045|NCT03589443|Drug|Multiplexed heptapeptides|Heptapeptides QRH and KSP
76046|NCT03589430|Other|Laboratory investigations ( protein C, protein S , antithrombin III)|laboratory investigations ( protein C , protein S , antithrombin)
76047|NCT03589417|Other|Assessments with Biodex Balance System®|Postural Stability, limits of stability and fall risk tests will be applied with the Biodex Balance System®
76048|NCT03589404|Device|rso2|The regional oxymetry probe will be placed in the abdominal region of the umbilicus in the middle clavicular line before the disease operation begins.
76049|NCT03589391|Device|LOR measurement via device|The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
76050|NCT03589378|Procedure|PEAF|PEAF that is therapeutic plasma exchange (TPE) with 20ml/kg/d Fresh frozen plasma (Blood pump: 120ml/min, replacement pump 20ml/kg/min, dialysate pump 0ml/kg/min, waste pump 20ml/kg/min, plasma exchange 1 hour) plus plasma filtration adsorption (PFA ) with acute multitherapeutic system( AMPLYA™ ITALY) ≥30ml/min lasting 15 hours plus High volume plasma diafiltration (HVPDF) with CUREFLO™(ACF180W Japan) or Ultraflux® (AV1000S Fresenius Germany) Blood pump: 120ml/min, replacement fluid pump 2000ml/h, dialysate pump 2000ml/h, waste pump 4000ml/h,and with high-volume plasma diafiltration for 15 hours）in the first 3 days. the treatment after three days later is same as the control group.
76051|NCT03589365|Other|Magnetic resonance imaging (MRI)|"Compare the left ventricular mass of a young adult population born prematurely (Prema group) to that of a group of young adults born at term (Witness group~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume~The measurements made during this examination are:~Coronary Reserve Presence of fat in the myocardium Left ventricular mass Left ventricular volume"
76052|NCT03589339|Drug|NBTXR3|Single intra Tumoral injection
76053|NCT03589326|Drug|Ponatinib|Ponatinib Tablets.
76054|NCT03589326|Drug|Imatinib|Imatinib Tablets.
76055|NCT03589326|Drug|Vincristine|Vincristine IV injection.
76056|NCT03589326|Drug|Dexamethasone|Dexamethasone Tablets.
76057|NCT03589326|Drug|Cytarabine|Cytarabine IV infusion.
76058|NCT03589326|Drug|Methotrexate|Methotrexate IV infusion.
76059|NCT03589326|Drug|Prednisone|Prednisone Tablets.
76060|NCT03589313|Drug|GLPG3067 single dose|GLPG3067 film coated tablets provided at Day 1.
76061|NCT03589300|Device|Persona TM Tibia|Trabecular Metal tibia used in primary cementless total knee arthroplasty
76062|NCT03589287|Biological|Chondrochymal®|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
76063|NCT03589274|Behavioral|I-FS-CBT|12 manual-guided sessions of I-FS-CBT
76064|NCT03589274|Behavioral|G-FS-CBT|12 manual-guided sessions of G-FS-CBT
76065|NCT03589261|Device|MRI (magnetic resonance imaging)|Fluid challenge will be performed with 500 ml of intra venous NaCl (0.9%). Hepatic blood flow measurement will be performed using MRI.
76066|NCT03589248|Diagnostic Test|GIF score|assessment by GIF score
76067|NCT03589248|Diagnostic Test|US score|assessment by ultrasonography score
76068|NCT03589235|Procedure|A free gingival graft|A free gingival graft will be used for the treatment of gingival recession
76069|NCT03589235|Device|A Platelet-Rich Fibrin dressing|A Platelet-Rich Fibrin dressing (PRF) will be applied in both donor and receiving sites after the free gingival graft.
76070|NCT03589235|Device|A non-eugenol-based dressing|A non-eugenol-based dressing (Coe-Pak™) will be applied in both donor and receiving sites after the free gingival graft.
76071|NCT03589222|Drug|Selinexor|Selinexor will be administered via oral at flat dose of 100 mg weekly in 4 out of each 4-week cycle
76072|NCT03589222|Drug|Daratumumab|daratumumab at dose of 16 mg/Kg iv weekly on days 1, 8, 15 and 22 during the first two cycles; on days 1 and 15 (Q2W) during the cycles 3 to 6; and on day 1 (Q4W) thereafter
76073|NCT03589222|Drug|Bortezomib|bortezomib will be given via subcutaneous at dose of 1.3 mg/m2 on days 1, 8, 15 and 22 starting from the first cycle and on days 1 and 15 (Q2W) since cycle 9
76074|NCT03589222|Drug|Dexamethasone|dexamethasone is 20mg (IV) when given on days that daratumumab is administered (as pre-infusion medication) plus 20 mg of dexamethasone (VO) the day after and the dose of dexamethasone is 40mg (VO) on days when daratumumab is not administered
76075|NCT03589196|Procedure|Ejaculation Preserving Photoselective Vaporization|Ejaculation Preserving Photoselective Vaporization
76076|NCT03589196|Procedure|Ejaculation Preserving Plasma Kinetic Vaporization|Ejaculation Preserving Plasma Kinetic Vaporization
76077|NCT03589196|Procedure|Ejaculation Preserving Transurethral Resection Of The Prostate|Ejaculation Preserving Transurethral Resection Of The Prostate
76078|NCT03589170|Diagnostic Test|Opportunistic atrial fibrillation screening|Opportunistic pulse palpation and/or ECG at least once a year when they visit doctors or nurse for other reasons.
76079|NCT03589157|Device|drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with spot stenting of drug-eluting stent (DES) for treating diffuse coronary artery lesions
76080|NCT03589157|Device|drug-coated balloon (DCB) combined with second-generation of drug-eluting stent (DES)|using drug-coated balloon (DCB) combined with second-generation DES for treating diffuse coronary artery lesions
76081|NCT03589131|Procedure|Total Operative time|Investigators compare the preparation time of the procedure in the operating room and the actual operative time
76082|NCT03589131|Procedure|Margin assessment|In this intervention investigators measure the proximal, distal and the important circumferential radial margin away from the tumor to determine if this arm is oncologically safe or not.
76083|NCT03589131|Procedure|Conversion rate to open surgery|In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery
76084|NCT03589131|Procedure|Baseline demographics|These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
76085|NCT03589131|Procedure|Preoperative data|"These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared"
76086|NCT03589131|Procedure|Postoperative data|These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission & 30-days mortality. All were analyzed and compared
76087|NCT03589118|Other|Qi Gong sessions|13 sessions of Qi Gong in a 9 weeks period
76088|NCT03589105|Drug|Ocrelizumab 300 mg|Two doses of 300 mg infusion administered 14 days apart.
76089|NCT03589105|Drug|Ocrelizumab 600 mg|A single does of 600 mg infusion administered 24 weeks after the initial dose.
76090|NCT03589092|Genetic|Next generation sequencing (NGS)|NGS Panel, Whole exome/genome sequencing
76091|NCT03589079|Genetic|Sanger and/or Next Generation Sequencing (NGS)|NGS panel, whole exome / genome sequencing (WES/WGS)
76092|NCT03589066|Drug|LY03003|28 mg intramuscular suspension
76093|NCT03589053|Device|Limb remote ischemic conditioning|The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 90 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.
76094|NCT03589053|Device|Control group|Participants in the control group receive both sham LRIC and standard clinical therapy.
76383|NCT03586934|Drug|Oxycodone|oxycodone tablet
76095|NCT03589040|Drug|Etonogestrel 68Mg Implant|Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants
76096|NCT03589040|Drug|rilpivirine|Oral rilpvirine 25mg
76097|NCT03589040|Drug|darunavir|Oral darunavir+ritonavir 600/100mg
76098|NCT03589027|Drug|Levonorgestrel two rod sub-dermal implant|Levonorgestrel (75 mg/rod), 2 rods (150 mg) inserted subdermally
76099|NCT03589027|Drug|Rilpivirine|Oral ripilvirine 25mg once daily
76100|NCT03589027|Drug|Darunavir+Ritonavir|Oral DRV/r 600/100mg twice daily
76101|NCT03589014|Drug|Propranolol|Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
76102|NCT03589001|Other|Activity modification|Activity modification, exercises and gradual return to sport
76103|NCT03588988|Drug|Dexmedetomidine IV infusion|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The DEX group injects DEX at 0.2 ug / kg / hr from 9 pm to 7 am. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
76104|NCT03588988|Drug|Normal saline|Patients who underwent spine, hip or femur surgery and who were admitted to the ICU after institutional exhalation were randomly assigned to the DEX group and the control group. Both groups can be combined with remifentanil for appropriate postoperative analgesia. The control group is inoculated with saline solution. At this time, the patient's blood pressure, oxygen saturation and cardiopulmonary function are continuously monitored.
76105|NCT03588975|Biological|MACI|autologous cultured chondrocytes on porcine collagen membrane
76106|NCT03588975|Procedure|microfracture|Arthroscopic microfracture treatment
76107|NCT03588962|Biological|In-stent restenosis|Patch tests for the metals applicated in each of the patients
76108|NCT03588949|Dietary Supplement|Dietary Supplement with L-carnitine (FertilHom)|1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
76109|NCT03588949|Dietary Supplement|Control Dietary Supplement|1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first
76110|NCT03588936|Drug|Nivolumab|Patients will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
76111|NCT03588936|Drug|Tocilizumab|Patients will receive 2 doses of tocilizumab
76112|NCT03588923|Drug|SH229|tablet, oral, 400 mg once daily for 3 days
76113|NCT03588923|Drug|Placebos|tablet, oral, once daily for 3 days
76114|NCT03588923|Drug|SH229|tablet, oral, 600 mg once daily for 3 days
76115|NCT03588923|Drug|Placebos|tablet, oral, once daily for 3 days
76116|NCT03588923|Drug|SH229|tablet, oral, 800 mg once daily for 3 days
76117|NCT03588923|Drug|Placebos|tablet, oral, once daily for 3 days
76118|NCT03588910|Drug|Acetaminophen|50 tablets of acetaminophen 500mg (1-2 tablets every 6 hours as needed)
76119|NCT03588910|Drug|Ibuprofen 600 mg|25 tablets ibuprofen 600mg (1tablet every 6 hours as needed)
76120|NCT03588910|Drug|Oxycodone|The number of tablets of oxycodone prescribed is the only difference between the two arms.
76121|NCT03588897|Dietary Supplement|Nutridrink Multi Fibre|Dietary supplementation of 300 kcal for 14 days
76122|NCT03588884|Drug|Calcifediol Oral Capsule|Capsule, daily
76123|NCT03588884|Drug|Calcifediol Oral Product|Capsule, once a month
76124|NCT03588884|Drug|Cholecalciferol|Capsule, once a month
76125|NCT03588884|Drug|Paricalcitol Oral Capsule|Capsule, daily
76126|NCT03588871|Other|Dental bleaching with PaintOn Plus VivaStyle|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent)
76127|NCT03588871|Other|Dental Bleaching impact in quality of life with PaintOn Plus Vivastyle|Evaluation of oral quality of life after dental bleaching treatment with PaintOn Plus Vivastyle 6% HP (Ivoclar Vivadent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
76128|NCT03588871|Other|Dental bleaching with Opalescence GO|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence GO 6% HP (Ultradent)
76129|NCT03588871|Other|Dental Bleaching impact in quality of life with Opalescence GO|Evaluation of oral quality of life after dental bleaching treatment with Opalescence GO 6% HP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
76130|NCT03588871|Other|Dental bleaching with Opalescence PF|Procedure of tooth bleaching using products with 6% hydrogen peroxide or its equivalent, specifically the Opalescence PF 16% CP (Ultradent)
76131|NCT03588871|Other|Dental Bleaching impact in quality of life with Opalescence PF|Evaluation of oral quality of life after dental bleaching treatment with Opalescence PF 16% CP (Ultradent) using an oral quality of life measuring questionnaire, specifically the Oral Health Impact Profile-14
76132|NCT03588858|Other|structured interview questionnaires|"Module (1): Socio-demographic characteristics~Module (2) :Occupational history~Module (3): Presence of work related injuries and diseases by history and observation.~Module (4): Food frequency questionnaires (FFQ) during the past week.~Module (5): Mental health screening: Self-reporting questionnaire 20 questions for assessment of mental health status of children."
76133|NCT03588845|Other|Treatment Protocol|Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of < 5.
76384|NCT03586934|Drug|Tramadol|Tramadol tablet
76134|NCT03588845|Other|Standard of Care|Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
76135|NCT03588832|Diagnostic Test|Evaluation Upper Extremity patterns.|The procedure involves evaluating subjects who meet the eligibility criteria and agree to participate in the study by signing informed consent. The study includes a measurement, applying a registration form, the Barthel scale and the FIM scale.
76136|NCT03588819|Radiation|SABR|26 Gy in 2 fractions to the prostate and DIL dose of up to 32 Gy in 2 fractions of MR-guided SABR delivered 1 week apart
76137|NCT03588806|Drug|Xtampza ER (oxycodone)|Following baseline assessments, subjects will have their current opioid medication changed to Xtampza ER (oxycodone) for the duration of the study.
76138|NCT03588793|Other|Two Point Discrimination|Validity of mechanism in phantom limb pain i.e. cortical reorganisation to be tested using comparison of data from interventions above
76139|NCT03588767|Drug|Vitamin D3 + anabolic substance|Prospectively enrolled patients with polytrauma, administration of vitamin D3 + anabolic substance
76140|NCT03588767|Other|No Vitamin D3 + anabolic substance|Retrospectively analyzed group of patients, no Vitamin D3 + anabolic substance administration
76141|NCT03588754|Drug|Propranolol|Propranolol Extended Release (160mg/day).
76142|NCT03588754|Drug|Placebo|Placebo pill administered orally.
76143|NCT03588741|Drug|Turoctocog alfa|"Intravenous (i.v., under the skin) administration.A maximum dose of 200 IU/kg daily.~The maximum treatment period for this trial is 24 months and the patient(s) will be called for visit to the clinic every 3rd month."
76144|NCT03588728|Other|Transcranial Direct Current Stimulation|Transcranial direct current stimulation targeting the right inferior frontal gyrus
76145|NCT03588728|Behavioral|Cognitive Remediation (CR)|Cognitive exercises on a computer designed to increase attention, memory, and processing speed.
76146|NCT03588715|Drug|Pegylated Interferon alpha 2b (peg-IFN-α2b)|Pegylated Interferon alpha 2b (peg-IFN-α2b) will be administered weekly via subcutaneous route.
76147|NCT03588715|Drug|3BNC117 + 10-1074|Broadly Neutralizing Antibodies - Sequential, separate IV infusions of 3NBC117 + 10-1074.
76148|NCT03588702|Device|RF and PEMF treatment|Treatment with Venus Legacy LB2 body applicator
76149|NCT03588689|Procedure|Continuous fascia iliaca block|Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.
76150|NCT03588689|Drug|Ropivacaine|Ropivacaine local anesthetic will be used for the fascia iliaca block
76151|NCT03588676|Other|Melatonin|5mg Melatonin
76152|NCT03588676|Other|Placebo|5mg Placebo capsule
76153|NCT03588663|Device|Baseline Bionic Leg Assessment|The 'Bionic Leg' (BL) [Alter G, Fremont, CA, USA; approved by the Food and Drug Administration (FDA) in 2014], is an externally-wearable, battery-operated robotic device that assists patients and therapists during rehabilitation by providing adjustable and progressive functional mobility training. A patient or therapist can programme the BL to provide motor assistance during sit-to-stand exercises, over-ground walking, and stair climbing, with either more or less robotic-assistance, as desired by the therapist. As the BL increases stability and actively engages the affected leg during functional tasks, it enables patients to undertake more repetitions of specific tasks than when not wearing a BL.
76154|NCT03588663|Other|Baseline Control Condition Assessment|Participants will complete identical tasks as that undertaken with the Bionic Leg, but will complete the tasks without wearing the Bionic Leg.
76155|NCT03588663|Other|Training|Participants will take -part in a 30-minute training session whilst wearing the Bionic Leg. The training programme will ask participants to engage in a variety of walking, balance and stair exercises. The training programme will include a 15-minute rest period after completion of the 30 minutes of exercises. This will take 45 minutes in total.
76156|NCT03588663|Other|Follow-up Assessment|45 minutes after the baseline assessment, immediately following the Training programme, the following tests (PCI, TUG, postural sway, 6-min walk, sit-to-stand) will be completed. These tests will be undertaken whilst not wearing the Bionic Leg. It is anticipated that this session will last approximately 2 hours.
76157|NCT03588650|Drug|HLX20|a Human Monoclonal Antibody Targeting Programmed Death Ligand-1 (PD-L1) Protein
76158|NCT03588637|Other|No intervention|No intervention
76159|NCT03588624|Device|TearCare|The TearCare procedure includes the delivery of thermal energy to the external surface of the eyelids for 15 minutes, immediately followed by manual expression of each eyelid.
76160|NCT03588611|Drug|Bivalirudin|0.75mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
76161|NCT03588611|Drug|Bivalirudin|0.6mg/kg+ 1.75 mg/kg▪h for the duration of PCI;
76162|NCT03588598|Drug|SHC014748M|a selective PI3Kδ inhibitor
76163|NCT03588585|Procedure|Tension|Tension applied to catheter and taped firmly to leg.
76164|NCT03588585|Procedure|NO TENSION|Foley balloon will be taped loosely to the leg and not placed on tension. All other care will remain the same
76165|NCT03588572|Drug|Venlafaxine hydrochloride capsules|The patients in venlafaxine group begin to take the venlafaxine hydrochloride capsules after the first visitation(the first day after randomization), each containing venlafaxine 75mg, 1 capsule per day, until 4 weeks after randomization
76166|NCT03588559|Diagnostic Test|Blood Pressure Measurement|Measurement blood pressure by Transtek BPM TMB-1591-A-002 and reference device.
76167|NCT03588533|Drug|Trastuzumab|"Trastuzumab (Herzuma) 8mg/kg loading over 90min (1st cycle)~Trastuzumab (Herzuma) 6mg/kg maintenance over 30min (2nd cycle~ ) every 3 weeks"
76168|NCT03588533|Drug|Capecitabine|- Capecitabine 1000mg/m2 p.o. bid D1-D14 every 3 weeks
76169|NCT03588533|Drug|Cisplatin|- Cisplatin 60~100mg/m2 i.v. D1 every 3 weeks
76202|NCT03588260|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
76203|NCT03588247|Procedure|transcatheter aortic valve implantation|Patients with severe aortic valve stenosis undergo transcatheter aortic valve implantation
76264|NCT03587779|Drug|Desflurane|Throughout the study period, anesthesia is maintained with desflurane of age-corrected equivalent minimum alveolar concentration.
76170|NCT03588520|Diagnostic Test|Home Blood Pressure Monitoring|Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
76171|NCT03588507|Combination Product|PPF+NCHA bone graft substitute|nanocrystalline hydroxyapatite bone graft is a a newly developed HA containing about 65% water and 35% nanostructured apatite particles. This gave the nanocrystalline hydroxyapatite bone graft many advantages such as providing a close contact with the surrounding tissues, bioresorbability and extremely high number of nano-sized particles and molecules on the surface .
76172|NCT03588494|Combination Product|concurrent chemoradiotherapy (CCRT)|"Chemotherapy: Cisplatin (50 mg/m2) on days 1, 8, 29, and 36 and etoposide (50mg/m2) on days 1～5 and 29～33.~Radiotherapy: Thoracic radiotherapy (TRT) started with a linear accelerator (6MV-X) on the first day of chemotherapy.A minimum dose of 60 Gy (2 Gy per fraction, Monday～Friday) was delivered, and a range of 60-66 Gy in 2 Gy fractions was allowed."
76173|NCT03588494|Drug|Endostar for one cycle|Endostar(15mg/m2) was durative transfused during the normalization window of the first chemoradiotherapy cycle(days -5～-1).
76174|NCT03588494|Drug|Endostar for two cycles|Endostar(15mg/m2) was durative transfused during the normalization window of the first and the second chemoradiotherapy cycles(days -5～-1 and 24～28).
76175|NCT03588481|Device|DESyne X2|Novolimus-eluting stent
76176|NCT03588468|Other|Electrophysiological biomarkers|Motor and sensory nerve conduction study will be performed on median, ulnar, tibialis, peroneal and sural nerves.
76177|NCT03588468|Other|MRI biomarkers|T1, T2, STIR and magnetisation transfer ratio (MTR) will be performed unilaterally on the thigh and the leg.
76178|NCT03588429|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
76179|NCT03588429|Drug|Isoflurane|Anesthesia was maintained with isoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
76180|NCT03588403|Radiation|TOMO|Tomotherapy
76181|NCT03588403|Radiation|IMRT|Intensity modulated radiotherapy
76182|NCT03588390|Drug|BI 1323495|Low strength tablet
76183|NCT03588390|Drug|BI 1323495|Middle strength tablet
76184|NCT03588390|Drug|BI 1323495|High strength tablet
76185|NCT03588390|Drug|Placebo|Placebo to low strength tablet
76186|NCT03588390|Drug|Placebo|Placebo to middle strength tablet
76187|NCT03588390|Drug|Placebo|Placebo to high strength tablet
76188|NCT03588377|Device|Pulse Oximetry|"In Interventions Clusters, LHWs will define 'severe' pneumonia as 2-59 months old children with hypoxemia (Sa02<92%) using Pulse Oximetry and/or as 2-59 month old children with chest indrawing and 1/more danger sign"
76189|NCT03588364|Other|Osteopathic Manipulation|Osteopathic manipulation involves a number of different manual techniques. These include muscle inhibition; myofascial release; muscle energy stretch; counterstrain; facilitated positional release ; osteopathy in the cranial field ; balanced ligamentous tension/ligamentous articular strain; one or all of these techniques may be used. Participants will be positioned on an exam table supine, seated, lateral decubitus, prone, or in their position of greatest comfort for the procedure.
76190|NCT03588351|Drug|chitosan nanoparticles gel|intracanal medicament
76191|NCT03588351|Drug|chitosan gel|intracanal medicament
76192|NCT03588351|Drug|chlorhexidine gluconate|intracanal medicament
76193|NCT03588338|Drug|Perfalgan|For postoperative pain
76194|NCT03588338|Drug|Metoclopramide|For postoperative nausea and vomiting
76195|NCT03588325|Diagnostic Test|CBC-DIFF with MDW, PCT, CRP|Tests will be run to determine early identification of sepsis and added value of the combination of tests. Results will not be used to manage patients
76196|NCT03588312|Procedure|Aortoplasty using autologous pericardial patch|hypoplastic aortic arch repair using a glutaraldehyde treated, autologous pericardial patch.
76197|NCT03588299|Drug|BAY2599023 (DTX201)|Single escalating doses with 3 dose steps; Single intravenous (IV) administration.
76198|NCT03588286|Procedure|Electrophysiology study (EPS)|EPS will be performed in all patients in the intervention arm with programmed ventricular stimulation with a drive train of 8 beats at 400 ms with up to 4 extrastimuli and stimulation from the right ventricular apex with current delivered at twice pacing threshold. The end point for stimulation will be sustained monomorphic ventricular tachycardia (VT) lasting > 10 seconds. If sustained monomorphic VT with cycle length (CL) ≥200ms is induced by ≤4 extra stimuli the EPS result will be considered positive for inducible VT.30 Ventricular fibrillation or flutter with CL<200ms will be considered a negative result. The Programmed Ventricular Stimulation (PVS) induction will be repeated a second time if the initial induction was negative for VT.
76199|NCT03588286|Other|Standard Care|The control group receive ongoing standard care according to the practise of their institution. This includes discharge from hospital as per their treating physician and follow up as usual in the community. Participants in this group would be eligible to receive an ICD according to the standard practise of their cardiologist (guideline recommendations are after 40 days following myocardial infarction or 90 days following revascularisation only in patients with left ventricular ejection fraction less than or equal to 30% or less than or equal to 35% in the presence of heart failure).
76200|NCT03588286|Procedure|Cardiac Magnetic Resonance (CMR)|CMR will be performed on either a 1.5-T or 3-T scanner. Gadolinium contrast (Gd-BOPTA, MultihanceTM) will be administered for quantification myocardial perfusion imaging with subsequent late gadolinium enhanced imaging after a total dose of 0.1mmol/kg. Exclusion criteria specific for CMR will include pregnancy, renal insufficiency defined as glomerular filtration rate (GFR) <30 mL/min, contraindication to MRI (including non-MRI compatible pacemaker/ICD or metal implants, non-MR safe prosthetic heart valves), claustrophobia which cannot be controlled via standard methods (benzodiazepines and/or sedative antihistamine administration) and prior allergic reaction to gadolinium-based contrast agent.
76201|NCT03588273|Drug|Amoxil 500 MG Oral Capsule|
76204|NCT03588221|Procedure|four sets of hand hygiene measurements per participant|"Six-step hand hygiene technique with an application time of 30 seconds~Six-step hand hygiene technique with an application time of 15 seconds~Three-step hand hygiene technique with an application time of 30 seconds~Three-step hand hygiene technique with an application time of 15 seconds"
76205|NCT03588208|Other|Progressive resistance training program|Progressive resistance training program were performed twice a week for 12 weeks. The charge intensity was progressively increased from 40% to 80% of 1 repetition maximum. The following muscle groups were worked: trunk flexors and extensors, elbow flexors and extensors, knee flexors and extensors, hip abductors and adductors and shoulder abductors. In addition to strength training.
76206|NCT03588208|Other|Educational Program|Structured education program were performed during one hour class once a week for five weeks
76207|NCT03588195|Other|Educational Program|Educational program consist in 5 consecutive sessions held once a week, with a duration of 60 minutes each class and at the end of the last class, a booklet was delivered for each patient with all the contents of the classes. This group also received Transcutaneous Nerve Electro-Stimulation twice weekly, for 5 weeks for 40 minutes each session
76208|NCT03588195|Device|Transcutaneous Nerve Electro-Stimulation|Transcutaneous Nerve Electro-Stimulation performed twice weekly, for 5 weeks for 40 minutes each session
76209|NCT03588182|Other|Virtual Reality Experience|Virtual reality visualization and experience of a 3-dimensional relaxing nature scene with the accompanying audio.
76210|NCT03588169|Dietary Supplement|semi-structured interviews|"About 30 minutes and touching on the following subjects:~perception of hospital meals~patient representation of ONS~taking ONS and feelings about it"
76211|NCT03588156|Drug|Benapenem|Dose-escalation For 11 level dose groups A1 ~ A11(each 62.5mg/kg, 125mg/kg, 250mg/kg, 500mg/kg, 1000mg/kg 60min infusion, 1000mg/kg 30min infusion, 2000mg/kg 60 min infusion, 2000mg/kg 30min infusion, 3000mg/kg, 4000mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group
76212|NCT03588156|Drug|Placebo|Placebo
76213|NCT03588143|Device|Electrical stimulation|Two kinds of electrical stimulation (TENS and HVPS) and placebo intervention
76214|NCT03588130|Drug|EscharEx (5% EX-02 formulation)|Enzymatic debridement
76215|NCT03588130|Drug|Gel Vehicle|Control arm
76216|NCT03588117|Behavioral|Physician-supervised nonsurgical weight management program|Participants of a physician-supervised nonsurgical weight management program were observed as they received weekly in-person coaching sessions with licensed clinicians. In-person coaching sessions were focused on educating participants on strategies to manage their weight and adopt a healthy lifestyle. Prescribed diets were individualized based on each participant's behavior, level of physical activity, and total energy expenditure. Supplements, appetite suppressant medications, and compounded injections were used to control appetite and/or boost energy during a period of low-caloric intake. The program was generally divided into three phases: Acute, Short-Term Maintenance, and Wellness.
76217|NCT03588104|Device|POWER2DM system|This system consists of two components: 1) the web-based Shared Decision Making Dashboard, used to set self-management goals together with a health care professional with the use of both short- and long-term predictive computer simulation models, and 2) the POWER2DM Self-Management Support System as a mobile application and webpage, used to support behavioural change in DM self-management. The system is fed with data from an activity tracker, a glucose monitor and manual data entry. Power2DM support will be provided as an adjunct to usual care
76218|NCT03588104|Other|Usual care|Usual care as given to diabetes patients by the patient's diabetes care team.
76219|NCT03588091|Drug|Pyrotinib|pyrotinib: 400mg orally daily;
76220|NCT03588091|Drug|Placebo Oral Tablet|placebo: 400mg orally daily;
76221|NCT03588091|Drug|Trastuzumab|trastuzumab:8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 4 cycles;
76222|NCT03588091|Drug|Docetaxel|docetaxel:after the biological window, 100mg/m2 for a total of 4 cycles
76223|NCT03588078|Drug|APR-246|Azacitidine at maximum tolerated dose. APR246 at the Dose limited Toxicity (DLT) dose
76224|NCT03588078|Drug|Azacitidine|azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m2
76225|NCT03588065|Diagnostic Test|FMS|"The evaluation of the risk of sports injury was obtained from the score in the Functional Movement Screen test suite.~The Functional Movement Screen (FMS) is a battery of tests that allows the integral assessment of the risk of injury, evaluating the basic patterns of movement and motor control through the performance of seven tests in which the combination of force is reflected muscle, flexibility, range of motion range, coordination, balance and proprioception"
76226|NCT03588065|Other|TICS|The educational activities were directed to soccer players belonging to Equidad, Bogotá-Colombia. Computerized media were used within the reach of footballers, applied with professionals of physical activity sciences under blind study methodology, using the new tendencies of Information and Communication Technologies (ICT) in Health Education. The investigators counted on the advice of the group manager of knowledge of the secretary of the district of the city of Bogotá. In the educational intervention seven aspects were addressed, distributed in four weekly modules for a total of four months
76227|NCT03588065|Other|CONFERENCE|The face-to-face educational intervention (conference) consisted of four educational sessions, distributed over four weeks during the sports transition period of the Equity sub-20 team. During these sessions, workshops (conferences) were held with the players following a face-to-face methodology . All these activities were concerted with the multidisciplinary team of the Equity football team and were carried out by the researcher at the University of La Sabana, a physiotherapist, who was studying the needs of the prevention of musculoskeletal injuries in football.
76228|NCT03588052|Procedure|VISTA using PRF|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Freshly prepared platelet-rich fibrin will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
76263|NCT03587779|Drug|Sevoflurane|Throughout the study period, anesthesia is maintained with sevoflurane of age-corrected equivalent minimum alveolar concentration.
76229|NCT03588052|Procedure|VISTA using SCTG|"Vertical vestibular access incision will be done through the periosteum to elevate a subperiosteal tunnel, exposing the facial osseous plate. The tunnel will be extended beyond mucogingival junction and at least one or two teeth beyond the teeth indicated for root coverage to mobilize gingival margins and allow for low-tension coronal repositioning of the gingiva.~Subepithelial connective tissue graft will be secured in the tunnel to cover the root dehiscence, coronal advancement of gingival margin and suturing to the facial aspect of each tooth to avoid apical relapse of the gingival margin during the initial phase of healing. The vertical incision will be then approximated and sutured"
76230|NCT03588039|Drug|Oraxol|Oral paclitaxel will be supplied in capsules and oral HM30181AK-US will be supplied in tablets
76231|NCT03588039|Biological|Pembrolizumab|Intravenously administered
76232|NCT03588026|Drug|rVA576|6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
76233|NCT03588026|Other|Standard of care (SOC)|6 months on SOC followed by 3 months of treatment with rVA576 plus SOC. In total, 3 months on rVA576 plus SOC.
76234|NCT03588013|Other|Nutritional education|4 week home delivered educational program that will focus on breast feeding and complimentary feeding. If child remains WHZ < -2 at by 9 months of age families will be shown 10 minute educational video detailing best practices for complimentary feeding.
76235|NCT03588013|Dietary Supplement|Ready to Use Therapeutic Food|If child remains WHZ < -2 despite nutritional education then will be managed according to Pakistan's Community Management of Acute Malnutrition protocol. This will include provision of ready to use therapeutic food (RUTF) to the child at home with close follow up. Utilization of the RUTF will be monitored closely by bi-weekly home visits.
76236|NCT03588013|Procedure|Upper gastrointestinal endoscopy with biopsy|If child remains at WHZ < -2 despite educational and dietary interventions, then will undergo medical evaluation for assessment of need for more advanced workup of malnutrition, including UGI endoscopy at AKUH. Results of the advanced work up, including the UGI endoscopy, will guide future management of these children.
76237|NCT03588000|Other|Strengthen self-monitoring of blood glucose|Strengthen self-monitoring of blood glucose by Internet mobile terminal（APP）.
76238|NCT03587987|Device|Neopff|manual ventilation
76239|NCT03587987|Device|rPap|Manual ventilation
76240|NCT03587974|Behavioral|REACH-VIETNAM|Family caregiver education, stress-reduction, and skill-training related to providing care for a person with Alzheimer's disease
76241|NCT03587961|Drug|Symdeko|explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
76242|NCT03587948|Diagnostic Test|Diabetes mellitus|Children and adolescents who is diagnosed with diabetes will be involved in case-group, and others will be involved in control-group.
76243|NCT03587935|Other|3D-Colonoscopy Progression Score|The score is based on a movement analysis of the colonoscope from anus until max insertion(cecum). It is scaled from 0-1000. A score of zero equals an incomplete procedure and a score of 1 is a very poor score but the cecum was reached. Increasing score represents better technical performance with a maximum score of 1000.
76244|NCT03587935|Other|3D-Colonoscopy Retraction Score|The score is based on a movement analysis of the colonoscope from cecum to the anus. It is scaled from 0-1000. A score of zero equals a very poor score, Increasing score represents better technical performance with a maximum score of 1000.
76245|NCT03587922|Device|Fantom|Treatment of den ovo coronary lesions
76246|NCT03587909|Procedure|Phacoemulsification Cataract SUrgery|Phacoemulsification in eyes with shallow anterior chamber (<2.5mm depth)
76247|NCT03587909|Procedure|Femtosecond Cataract Surgery|Femtosecond Cataract Surgery in eyes with shallow anterior chamber < 2.5mm
76248|NCT03587896|Behavioral|Self Help Plus|5-session psychosocial intervention
76249|NCT03587883|Other|Cocoa flavanols I|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
76250|NCT03587883|Other|Control I|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
76251|NCT03587883|Other|Cocoa flavanols II|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 300mg of cocoa flavanols per capsule consumed for 2 weeks.
76252|NCT03587883|Other|Control II|Cocoa-based, flavanol-free, control-matched capsules consumed for 2 weeks.
76253|NCT03587870|Other|Enteral nutrition with Fresubin Intensive|Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
76254|NCT03587857|Other|Mobile Health Application|This mobile health app is a modular, adaptive, and personalized intervention delivered via a mobile phone. It is grounded in the Information Motivation Behavioral Skills (IMB) model. It was created in collaboration with YLWH (18-29 years-old) using a Human-Centered Design approach to help improve engagement in HIV care among this age group.
76255|NCT03587844|Drug|brentuximab vedotin|MF/SS no prior brentuximab vedotin- Brentuximab vedotin 0.9 mg/kg 0R 1.2 mg/kg.
76256|NCT03587844|Drug|brentuximab vedotin|LyP Brentuximab vedotin 0.9 mg/kg2
76257|NCT03587844|Drug|brentuximab vedotin|MF/SS prior brentuximab vedotin-Brentuximab vedotin dose to be determined from Cohort 1
76258|NCT03587831|Procedure|Vertical Sleeve Gastrectomy|Surgical Procedure: Vertical Sleeve Gastrectomy
76259|NCT03587831|Behavioral|Lifestyle Modification Counseling|Behavioral Intervention: Lifestyle Modification Counseling
76260|NCT03587818|Other|person-centred communication|The intervention aimed to actively make use of a person-centred approach to support patients undergoing CRC surgery to be prepared for surgery, discharge and recovery in relation to CRC. This was accomplished through person-centred communication, which was based on a standardized dialogue tool with tailored written information material (component I), in combination with an approach for professionals to facilitate person-centred communication (component II) in consultations.
76261|NCT03587805|Drug|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
76262|NCT03587792|Procedure|stapedectomy|Stapedectomy as described in literature with stapes removal, Carbon Dioxide (CO2) laser platinectomy and placement of a prothesis(piston) between the incus long process and the stapes footplate
76267|NCT03587753|Other|Dietary fatty acid partitioning|There is no intervention as such, just a physiological assessment of the partitioning and oxidation of two different types of dietary fatty acids
76269|NCT03587714|Diagnostic Test|HCV RT-PCR|HCV ribonucleic acid by reverse transcriptase polymerase chain reaction (RT-PCR)
76270|NCT03587701|Drug|Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
76271|NCT03587701|Drug|Placebo injection (Period 1)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)
76272|NCT03587701|Drug|Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)|pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
76273|NCT03587701|Drug|Placebo injection (Period 2)|pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
76274|NCT03587688|Procedure|mitral valve surgery|pre-, intra- and postoperative data on patients undergoing mitral valve surgery at the Department for Cardiac Surgery of Universitätsspital Basel/ Switzerland since 2009
76275|NCT03587675|Diagnostic Test|EVH test|
76276|NCT03587662|Drug|Doxorubicin|Given IV
76277|NCT03587662|Drug|Doxorubicin Hydrochloride|Given IV
76278|NCT03587662|Drug|Gemcitabine|Given IV
76279|NCT03587662|Drug|Gemcitabine Hydrochloride|Given IV
76280|NCT03587662|Drug|Ixazomib|Given PO
76281|NCT03587662|Drug|Ixazomib Citrate|Given PO
76282|NCT03587649|Drug|[18F]MNI-1126|"Florbetapir PET imaging will be completed in all healthy volunteers and AD subjects as part of the screening procedures.~DaTscan SPECT imaging will be completed in those PDsubjects who have not previously had DaTscan imaging as part of the screening procedures."
76283|NCT03587636|Drug|liposome bupivacaine|interscalene block with liposomal bupivacaine plus bupivacaine
76284|NCT03587636|Drug|Bupivacaine|interscalene block with bupivacaine
76285|NCT03587610|Biological|Remedial vaccination|"if the patients vaccinations are up to date: no remedial vaccination is done and the patient is informed of the next remedial vaccination date~if the patients vaccinations are not up to date: remedial vaccination is realised in the unit in the absence of contraindication, in case of a temporary contraindication the vaccination will be performed on an outpatient basis by the patients primary care provider and he will be given a prescription at hospital discharge for the remedial vaccination."
76286|NCT03587597|Procedure|socket shield technique|socket shield technique with immediate temporization
76287|NCT03587597|Procedure|conventional immediate implant placement with immediate temporization|conventional immediate implant placement with immediate temporization
76288|NCT03587584|Drug|liposomal bupivacaine|Experimental
76289|NCT03587584|Drug|Bupivacaine|Active Comparator
76290|NCT03587571|Procedure|Surgical intervention|Open reduction and plate osteosynthesis.
76291|NCT03587558|Drug|Carvedilol|Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
76292|NCT03587558|Drug|Flecainide|Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
76293|NCT03587545|Other|Probiotic nasal spray|Total daily nasal administration of 2*10^8 CFU of probiotic bacteria delivered via 2 servings.
76294|NCT03587545|Other|Placebo nasal spray|Two servings of nasal administration of placebo nasal spray (not containing probiotic bacteria)
76295|NCT03587532|Diagnostic Test|Indocyanine green angiography|ICGA will be performed twice during standard esophagectomy: 30 minutes after the stomach graft creation and immediately before the esophagogastric anastomosis. stock dose of 25 mg ICG (Pulsion Medical Systems, Germany) will be diluted to 5 mg/mL with sterile water. An IV bolus of 0.5 mg/kg of ICG will be injected via a central venous catheter. Video data will be obtained with a charge-coupled device (CCD) camera fitted with a light-emitting diode emitting at a wavelength of 760mm (Visera® elite II, Olympus medical system corp, Tokyo, Japan). Images will be recorded starting immediately prior to injection until 3 minutes afterwards.
76296|NCT03587532|Diagnostic Test|Hemodynamic evaluation|Advanced continuous hemodynamic monitoring during surgery will be performed using a PiCCO® (Pulse index Continuous Cardiac Output, Pulsion Medical Systems, Germany) catheter.
76297|NCT03587532|Diagnostic Test|Biological and pathological markers of ischemia|"Systemic and local capillary lactate on blood samples~Mitochondrial Respiratory activity analyses on biopsies at 3 region of interest (ROI)~Pathological analyses of the biopsies at 3 ROI"
76298|NCT03587519|Procedure|Early|Early ileostomy closure
76299|NCT03587519|Procedure|Late|Late ileostomy closure
76300|NCT03587493|Other|BLOOD SAMPLE ANALYSIS|Peripheral venous blood sampling just before lung transplantation, at day 15 and at post-transplantation M1 for lymphocyte phenotyping by cytometry
76301|NCT03587480|Procedure|TME+LLND|patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)
76302|NCT03587480|Procedure|TME+nCRT|patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)
76303|NCT03587467|Other|collect fecal specimens|collect fresh fecal specimens of participants
76304|NCT03587454|Diagnostic Test|Teleglaucoma|Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
76305|NCT03587441|Drug|Neostigmine Methylsulfate|20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
76306|NCT03587441|Drug|Dextrose 5% in water|intrathecal
76307|NCT03587428|Drug|Zinc-A toothpaste|Participants received 6.0 grams (g) [± 0.3g] of the Zinc-A toothpaste in the form of slurry, one day per treatment (with at least 2 [generally 7] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
76376|NCT03586947|Drug|Vitamin D3 400 UNT Oral Capsule|50,000 IU of vitamin D once a week for 8 weeks, 1500-2000 IU/day.
76308|NCT03587428|Drug|Zinc-B toothpaste|Participants received 6.0 grams (g) [± 0.3g] of the Zinc-B toothpaste in the form of slurry, one day per treatment (with at least 2 [generally 7] days between treatments. Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
76309|NCT03587428|Other|Mineral water|Participants received 6.0g (±0.3g) of mineral water (by weighing out), one day per treatment (with at least 2 [generally 7] days between treatments). Participants emptied the contents of the dosing cup into their mouth, swilled the product around their mouth for 2 timed minutes then they expectorated into a sink.
76310|NCT03587415|Diagnostic Test|preptin and amylin level|we will take both of group blood samples to compare them serum preptin and amylin
76311|NCT03587402|Other|Transcutaneous perineal stimulation|Surface stimulation
76312|NCT03587402|Other|Anal stimulation|Intra-cavitary stimulation
76313|NCT03587389|Biological|Rotarix vaccine|In this study, the 1st dose of Rotarix vaccine will be administered when infants are at ages between weeks 8-9 and the 2nd dose is 28-37 days after the 1st dose, which means that there is an interval of 28-37 days or 4-5 weeks between doses. A reminding call will be set at about 4 weeks after the 1st dose to remind parents to bring their children back to Hung Vuong Hospital for the 2nd dose of Rotarix to ensure the completion of the 2nd dose of Rotarix vaccine.
76314|NCT03587376|Drug|Atabecestat|Blood samples will be collected from participants previously treated with atabecestat.
76315|NCT03587363|Drug|Erdafitinib|Participants will receive 6 mg (2*3 mg tablet) erdafitinib as a single oral dose on Day 1. Participants in Cohort 4 may receive a lower dose if warranted by preliminary safety and PK data from Cohorts 2 and 3.
76316|NCT03587350|Device|Shimmer monitoring|The shimmer monitor, monitors movement and the range of movement.
76317|NCT03587337|Other|POEM|Pt. are going to submit a POEM procedure.
76318|NCT03587324|Drug|Whole blood aggregometry before and after vascular treatment (ASA/ Clopidogrel).|"To identify possible risk factors demographic data, concomitant medication, laboratory parameters, co-morbidities, severity of the condition and the type of procedure performed are documented.~Other Name: ASA (aspirin), Clopidogrel (Plavix)"
76319|NCT03587311|Biological|Anetumab Ravtansine|Given IV
76320|NCT03587311|Biological|Bevacizumab|Given IV
76321|NCT03587311|Drug|Paclitaxel|Given IV
76322|NCT03587298|Procedure|Real-Time (Supersonic)- 2D shear wave elastography (rt-SWE)|"The SWE is carried out intercostally. If possible, the patient should hold the breath for 5-10 seconds. So-called colour charts are used, which indicate the derived liver stiffness in colour-coded form. In addition to the visual assessment of these colour charts, the quantitative ROI-based measurement of the SWE in kPa is performed in the hardest appearing areas. The measurement is performed at 5 different sites of the liver parenchyma and all SWE values are recorded."
76323|NCT03587285|Biological|Tcm+ Goserelin acetate+ Bicalutamide|Autologous Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,50 mg bicalutamide administered orally daily
76324|NCT03587285|Biological|Tcm+Goserelin acetate+Abiraterone acetate|Tcm cells administered intravenously on Day 1 and Day 42,3.6mg goserelin acetate injection administered subcutaneously monthly,1000 mg abiraterone acetate administered orally daily plus 5 mg prednisone administered orally twice daily
76325|NCT03587272|Drug|Alemtuzumab intravenously, low dose total body irradiation, Sirolimus|"The conditioning regimen (SUN regimen) will consist of alemtuzumab intravenously daily for 5 days (0.03mg/kg on Day -7, 0.1mg/kg on Day -6, 0.3mg/kg on Days -5 to -3) and low dose total body irradiation (TBI) 300 cGY on Day -2 with gonadal shielding if possible. The HSCT graft will be G-CSF mobilized PBSCs with minimum CD34+ of 5 x106/kg recipient weight, goal of 10 x 106/kg (no upper limit). A peripheral blood stem cell (PBSC) graft was selected as it engrafts faster than bone marrow and would lead to shorter period of neutropenia and infection and less thrombocytopenia and need for platelet transfusion.~GVHD prophylaxis will be sirolimus with a loading dose 3 mg/m2 on day -1. Sirolimus will be continued at 1 mg/m2/day starting on day 0 and dose adjusted to maintain a target trough level 5-15 ng/mL for the first 3 months and 5-10 ng/mL for the remainder of the first year."
76326|NCT03587259|Diagnostic Test|Tomosynthesis|DBT is a x-ray examination that allows to visualize the breast on 3 planes (3D) and therefore to help to see lesions hardly visible to mammography due to the overlap of glandular tissue.
76327|NCT03587259|Diagnostic Test|2D mammography|2D mammography is a X-ray examinations used to detect breast cancer in the screening programme.
76328|NCT03587246|Diagnostic Test|3DTVUS : Uterine peristaltic frequencies|Perform three-dimensional transvaginal ultrasonography To observe uterine peristaltic frequencies in embryo transfer cycles
76329|NCT03587233|Behavioral|Physical assessment|Besides the demographic features of the participants, the interventions on physical assessment will be performed including weight in kilogram and height in meter; and weight and height will be combined to report body mass index in kg/m2. The waist circumference will be measured to understand the central fattening from costal margins or above umbilicus in cm. If it is measured above 95cm for men and 80cm for women is considered as higher than normal; if higher than 110cm for men and 88cm for women is considered as having risks for obesity, diabetes, cardiovascular diseases etc. Hand and pinch grip power will be assessed. It the elbow is in extension upper extremity power, and if it is flexed at 90 degree and forearm is supported on the table handgrip power is to assess.
76330|NCT03587233|Device|Analyses of body composition|The analyzes of body composition will be measured with bioelectrical impedance analysis method by a body composition analyzer.
76331|NCT03587233|Behavioral|physical activity level assessment|The physical activity level will be assessed through the intervention titled with the Turkish version of the 'International Physical Activity Questionnaire-Short Form'. It consists of seven questions searching for the amount of walking and low, moderate and high intensity physical activities as total time in minutes per day and frequency in days per week. Sitting, as a sedentary behavior, will be evaluated separately. The scores will be achieved by the multiplication of the minutes, days and metabolic equivalent time values in a week, and over the last 7 days. Walking score and total weekly walking duration will be calculated as medium and vigorous; the physical activity level will be classified as low, moderate and high level activity.
76332|NCT03587220|Drug|Capsaicin Topical|Capsaicin patches (dosage form: patch 8% Qutenza) will be applied on 4x4 cm squared areas on the volar forearm. The patches will be left in place for 24h and 3 hours after which they will be removed.
76333|NCT03587220|Radiation|Ultraviolet-B (UVB) irradiation|Two circular areas (Ø 2 cm) on the forearm are irradiated with 2 x MED (Minimal Erythema Dose) dose of UVB using a calibrated UVB machine (290-320nm wavelength), Saal Mann Multi Tester (Mann Saal, LT SBC 400 Herford, Germany).
76334|NCT03587220|Other|Histamine 1%|To deliver histamine, standard allergy skin prick test (SPT) lancets are applied. The lancets have a 1 mm shouldered tip adapt to introduce a small amount of test substance extremely locally and approximately at the dermo-epidermal junction.
76335|NCT03587220|Drug|Lidocaine|Cutaneous anaesthesia will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine)
76336|NCT03587207|Biological|MenABCWY vaccine|Two doses administered intramuscularly in the deltoid region of the non-dominant arm.
76337|NCT03587207|Biological|rMenB+OMV NZ (Bexsero) vaccine|Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group, rMenBOMV+ACWY_D Group and rMenBOMV Group
76338|NCT03587207|Biological|MenACWY (Menveo) vaccine|Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY_S Group and rMenBOMV+ACWY_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group
76339|NCT03587194|Drug|Otezla|Otezla 30mg BID
76340|NCT03587181|Procedure|Cryoablation of the pulmonary veins and myocardial biopsy|"Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.~In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required."
76341|NCT03587168|Other|the timed 360° turn test|Turning ability is assessed by using the timed 360° turn test.
76342|NCT03587168|Other|Berg Balance Scale|Functional balance is assessed by using the Berg Balance Scale.
76343|NCT03587168|Other|Four Square Step Test|The Four Square Step Test measures dynamic balance.
76344|NCT03587168|Other|Functional Reach Test|The Functional Reach Test assesses limits of stability.
76345|NCT03587168|Other|Trunk Impairment Scale|Trunk performance is assessed by using the trunk impairment scale.
76346|NCT03587168|Other|Timed Up and Go Test|Functional mobility is assessed by using the timed up and go test.
76347|NCT03587168|Other|Hoehn and Yahr Scale|Disease stage is assessed by the Hoehn and Yahr Scale.
76348|NCT03587168|Other|Unified Parkinson's Disease Rating Scale|The Unified Parkinson's Disease Rating Scale assesses disease severity.
76349|NCT03587142|Drug|Buspirone|Buspirone tablet
76350|NCT03587142|Drug|Placebo|"Sugar pill manufactured to mimic buspirone 10 mg tablet"
76351|NCT03587129|Drug|Apatinib|An anti-tumor Targeted drug
76352|NCT03587116|Drug|Standard of Care FIX Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.
76353|NCT03587116|Drug|Standard of Care FVIII Replacement therapy|There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
76354|NCT03587103|Behavioral|Protocol initiate with A|The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.
76355|NCT03587103|Behavioral|Protocol initiate with C|The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.
76356|NCT03587103|Behavioral|Protocol initiate with D|The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.
76357|NCT03587090|Diagnostic Test|echocardiography|echocardiography by subcostal and transhepatic views
76358|NCT03587077|Drug|Misoprostol|vaginal application
76359|NCT03587077|Drug|Placebos|vaginal application
76360|NCT03587077|Drug|isosorbide mononitrate|vaginal application
76361|NCT03587064|Device|Conventional 3-lead CRT defibrillator system implantation|Conventional 3-lead(1 atrial and 2 ventricular leads) system implantation
76362|NCT03587064|Device|2-lead CRT defibrillator system implantation|2-lead (2 ventricular leads with dipole for atrial sensing) DX system implantation
76363|NCT03587051|Dietary Supplement|Low glycemic index post-exercise diet|Feeding of a low-glycemic index, lentil meal after 90 minutes of walking exercise
76364|NCT03587051|Dietary Supplement|High glycemic index post-exercise diet|Feeding of a high-glycemic index meal (i.e. instant mashed potatoes, white bread, egg whites) after 90 minutes of walking exercise
76365|NCT03587038|Drug|OKN 007|400 mg OKN-007/mL in a phosphate buffer
76366|NCT03587038|Drug|Temozolomide|75 mg/m2
76367|NCT03587038|Radiation|Photon/Proton IMRT|standard of care treatment to be given 1 to 2 hours after OKN-007
76368|NCT03587025|Drug|Amitriptyline|Amitriptyline compared with placebo for preemptive analgesia in women after abdominal hysterectomy.
76369|NCT03587025|Drug|Placebo|Placebo
76370|NCT03587012|Other|Brain fitness app|Daily practices of brain exercises on an iPAD
76371|NCT03587012|Other|Brain fitness app with tACS|Daily practices of brain exercises on an iPAD with simultaneous transcranial alternating current stimulation (tACS)
76372|NCT03586999|Drug|Nivolumab and EPOCH|Nivolumab injection is to be administered as an IV infusion. DA-EPOCH dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a >10% weight gain or loss. Patients receive six 21 day cycles of the medications.
76373|NCT03586986|Diagnostic Test|Brain MRI|Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
76385|NCT03586934|Drug|Morphine Injectable Solution|Morphine Patient Controlled Analgesia
76386|NCT03586934|Drug|hydrocodone bitartrate and acetaminophen|Norco tablet
76387|NCT03586934|Drug|Morphine|morphine injection
76388|NCT03586934|Drug|Oxycodone Hydrochloride|oxycodone hydrochloride tablet
76389|NCT03586934|Drug|Meloxicam|meloxicam tablet
76390|NCT03586921|Behavioral|Psychosocial Group Intervention|The intervention included two psycho-educational sessions with information about depression and anxiety disorders, two sessions on the development of pleasant activities including relaxation exercises, two sessions on solving problems therapy, one session on the problem of overcoming negative thoughts and emotions, one session on relapse prevention, and a final closure and review session which included a small party.
76391|NCT03586921|Other|Enhanced Usual Care|All patients received enhanced primary care: (1) Nurses and doctors from the Family Health Teams were trained by Matrix team mental health professionals on clinical aspects of depression and anxiety. (2) Given the high co-occurrence of anxiety and depression, the intervention was modified from the depression-only Chile model to emphasize co-occurring anxiety and depression in diagnoses, appropriate prescription of anxiolytics and antidepressants. (3) All providers received weekly group or individual consultation with a Matrix team mental health professional, either psychiatrist or psychologist. An qualitative study of participating Petrópolis Family Health Programme doctors and nurses demonstrated their satisfaction with the training.
76392|NCT03586908|Drug|PHP-201 0.5% ophthalmic solution (topical eye drop)|D1, D7: PHP-201 0.5% topical eye drop OU QD(AM), D2~D6: PHP-201 0.5% topical eye drop OU TID
76393|NCT03586895|Device|e-Connect|e-Connect
76394|NCT03586882|Device|Spinal Cord Stimulation|Stimulation provided by the generator to electrodes on the leads inhibits ascending pain signals, thereby decreasing pain perception.
76395|NCT03586869|Drug|Aldoxorubicin HCl|Aldoxorubicin Hydrochloride
76396|NCT03586869|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
76397|NCT03586869|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
76398|NCT03586869|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2
76399|NCT03586869|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
76400|NCT03586869|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
76401|NCT03586869|Biological|GI-4000|RAS yeast
76402|NCT03586869|Biological|GI-6207|Carcinoembryonic Antigen (CEA) yeast
76403|NCT03586869|Biological|GI-6301|Brachyury yeast
76404|NCT03586869|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
76405|NCT03586869|Biological|bevacizumab|Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
76406|NCT03586869|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
76407|NCT03586869|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
76408|NCT03586869|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
76409|NCT03586869|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
76410|NCT03586869|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
76411|NCT03586869|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
76412|NCT03586869|Biological|Avelumab|Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
76413|NCT03586869|Procedure|SBRT|Stereotactic Body Radiation Therapy
76414|NCT03586856|Device|Nasal mask interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
76415|NCT03586856|Device|Nasal prongs interface|Nasal masks is a standard interface used for CPAP treatment of newborn infants. The CPAP device allows for easily switching between the nasal prongs or nasal mask interface as well as adjustment of size.
76416|NCT03586843|Drug|JNJ-64565111|JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
76417|NCT03586830|Drug|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
76418|NCT03586830|Drug|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
76419|NCT03586830|Drug|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
76420|NCT03586830|Drug|Placebo|Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
76421|NCT03586817|Drug|Palonosetron|75 mcg during the anesthesia
76422|NCT03586817|Drug|Fosaprepitant|150 mg during the anesthesia
76423|NCT03586804|Other|dual task|mental and motor tasks will be performed while standing. Motor task: holding mini blocks Mental task: Counting the numbers from 200 to 1
76424|NCT03586791|Procedure|Pupillometry guided anesthesia|"At least 10 min after anesthesia induction by target-controlled infusion of propofol and remifentanil, baseline values for pupillary diameter is recorded before any surgical procedure.~During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60. Remifentanil Ce is adapted every 5 min based on the changes of pupillary diameter. If the pupillary diameter is increased by more than 30% compared to baseline value, remifentanil concentration is increased by 0.5 ng/ml. If the pupillary diameter is maintained between 5 and 30 % change compared with baseline, remifentanil is not modified. In a case of pupillary diameter is decreased less than 5 % change of baseline, remifentanil concentration is decreased by 0.5 ng/ml."
76425|NCT03586791|Procedure|SPI guided anesthesia|During the operation, SPI value should be maintained between 20 and 50 by changing the infusion rate of remifentanil. Even if the SPI is maintained within the target range, the remifentanil infusion rate is increased by 0.5 ng/ml in a case of the SPI value suddenly arises by more than 10.
76528|NCT03586024|Drug|Pembrolizumab|dose of pembrolizumab will be 200 mg IV every 3 weeks
76529|NCT03586011|Behavioral|Predicting factors for increased physical activity|
76426|NCT03586791|Procedure|Standard management|"During the operation, propofol effect-site target concentration (Ce) is adjusted to maintain the bispectral index (BIS) value between 40 and 60.~Remifentanil concentration is controlled by the discretion of the anesthesiologist in charge of the patients."
76427|NCT03586778|Other|dry needling|Dry Needling targeting the posterior musculature of the thoraco-lumbar spine and hips
76428|NCT03586778|Other|manual therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the thoraco-lumbar spine and hips
76429|NCT03586778|Other|therapeutic exercise|Exercise designed to improve performance of the paraspinal and abdominal musculature as well as the hip musculature. The exercise portion will also include a stretching program targeting the trunk and hip muscles which have been placed in a shortened position as a result of poor postures.
76430|NCT03586765|Other|Female urinary incontinence|Assess prevalence of urinary functional disorders in women of 40 and more, visiting a general practitioner, occupational medicine or health examination center in Puy-de-Dôme. Study conducted for a month using a self-filled survey distributed by secretaries or nurses.
76431|NCT03586752|Other|On-line program|18 minutes on-line video at home and 30 minutes CPR skill practice at scene in 3 days after watching on-line video
76432|NCT03586752|Other|Standard program|60-minute CPR teaching video with practice, 20 minutes of automated electrical defibrillator operation, and a 10-minute discussion with regard to the legal issues associated with bystander CPR in Taiwan
76433|NCT03586739|Procedure|endovascular angioplasty using covered stents|Primary endovascular angioplasty using one or several covered stents
76434|NCT03586739|Procedure|endovascular angioplasty using bare metal stents|Primary endovascular angioplasty using one or several bare metal stents
76435|NCT03586739|Device|Duplex-scan|a Duplex-scan will be performed during patient follow up.
76436|NCT03586739|Device|computerized tomography scan (CT-scan)|"a CT-scan will be performed in the event of symptoms of recurrence or restenosis as confirmatory exam according to clinical practice during patient follow up.~The CT-scan will be mandatory at 12 and 24 months if it has not been planned in the current practice follow-up."
76437|NCT03586739|Device|digital angiography|In case CT-scan cannot be performed (e.g. occurrence of a non-preexisting contra-indication), a digital angiography will be authorised instead to confirm restenosis during patient follow-up.
76438|NCT03586739|Other|Short Form-36 (SF-36) questionnaire|The patient will complete a quality-of-life questionnaire (SF-36 form) during their follow up.
76439|NCT03586726|Drug|Balovaptan|"In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16."
76440|NCT03586726|Drug|Rifampicin|In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
76441|NCT03586713|Diagnostic Test|light induced fluorescence camera|The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
76442|NCT03586700|Drug|Xiao zhong fang granules|Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.
76443|NCT03586700|Radiation|Short wave infrared radiation|Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.
76444|NCT03586700|Drug|Placebo Xiao zhong fang granules|Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
76445|NCT03586687|Drug|Triamcinolone|Ultrasound guided glenohumeral shoulder joint injection
76446|NCT03586674|Drug|Lipanthyl|Tablet
76447|NCT03586674|Drug|Ursogal|suspension
76448|NCT03586661|Drug|Copanlisib|Given IV
76449|NCT03586661|Drug|Niraparib|Given PO
76450|NCT03586635|Other|neurological exam|"Patients participating in the study are recruited from the investigator's tertiary multiple sclerosis management centre. They are systematically examined neurologically as part of their routine follow-up.~the patient will be exceptionally examined by two distinct persons, a senior doctor and a junior doctor (internal or external) independently.~At the end of the neurological examination, each examiner will evaluate the EDSS score in a classical way (using paper definitions) then using the smartphone application"
76451|NCT03586622|Dietary Supplement|Low FODMAP diet (LFD)|The Low FODMAP diet (LFD) is an acronym for Fermentable Oligo-, Di-, and Monosaccharides And Polyols - all of which are small osmotic active carbohydrates or sugar alcohols that are poorly absorbed in the small intestine and therefore easily fermented by the gut microbiota. The fact that they are fermented rapidly and osmotic active makes them potential and likely candidates for causing luminal distension due to accumulation of gas and water in the intestine.
76452|NCT03586622|Dietary Supplement|VSL#3®|VSL#3® is a dietary supplement that helps maintain the balance of the intestinal flora. VSL#3® has been recognized and classified as GRAS (Generally Regarded as Safe) by a panel of experts in the USA for both adult and pediatric IBD and IBS patients. VSL#3® is a probiotic food containing 450 billion freeze-dried live lactic acid bacteria and bifidobacteria from 8 different strains per bag/sachet: Streptococcus thermophilus BT01, Bifidobacteria (B. breve BB02, B. longum* BL03, B. infantis* BI04), Lactobacillus acidophilus BA05, Lactobacillus plantarum BP06, Lactobacillus paracasei BP07, Lactobacillus delbrueckii subsp. bulgaricus** BD08; *Recently reclassified as B. animalis subsp. lactis ** Recently reclassified as L. helveticus. The recommended daily dose is 1-2 bags.
76453|NCT03586609|Drug|Azacitidine|Given SC or IV
76454|NCT03586609|Drug|Cladribine|Given IV
76455|NCT03586609|Drug|Cytarabine|Given SC
76456|NCT03586609|Drug|Venetoclax|Given PO
76530|NCT03585998|Drug|Durvalumab|Concurrent radiotherapy Maintenance therapy
76531|NCT03585985|Procedure|Standard patient monitor|Measurement of reference data: heart rate, heart rate variability and respiratory rate
76457|NCT03586596|Behavioral|The Decídetext program|Decídetext participants will be directed to the tablet-based software. Participants will receive an interactive education session that will lead them through language-appropriate, culturally-relevant information about stopping smoking, collection of basic smoking history data, and choices/plans about preparing to quit. Quit plans include: 1) choice of quit date, 2) NRT preference, 3) plan to remove smoking cues, 4) identification of trigger situations and 5) choice of suggested coping strategies. Participant data and choices are used to generate a printed 1-page individualized treatment plan. Tablet components, assessment items, audio narrative, brief multimedia instructional video clips, and the printed treatment plan have been developed to address low-literacy levels.
76458|NCT03586596|Behavioral|Standard Care Control|Educational Material provided as of suggested by American Cancer Society and, the National Cancer Institute
76459|NCT03586583|Device|FBP|Old processing
76460|NCT03586583|Device|ISR|New processing
76461|NCT03586570|Drug|Aprocitentan 25mg|Oral tablets in strength of 25 mg
76462|NCT03586570|Drug|Placebo|Oral tablets matching aprocitentan tablets
76463|NCT03586557|Device|Corticosteroid & Plasma exchange|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper, combined simultaneous plasma exchange 5 times in all
76464|NCT03586557|Drug|Corticosteroid|High-dose intravenous methylprednisolone 1000mg 3~5 days and subsequent taper
76465|NCT03586544|Behavioral|Interval Warm-up exercise|Participants will undergo eight 30 sec bouts of high intensity exercise with 45 second recovery between bouts. After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
76466|NCT03586544|Drug|Albuterol|Participants will inhale 2 puffs of albuterol (90mcg per actuation). After 15 minutes, participants will undergo an exercise induced bronchoconstriction test
76467|NCT03586544|Other|Control|This is the control arm. After 15 minutes of seated rest, participants will undergo an exercise induced bronchoconstriction test
76468|NCT03586531|Procedure|renal biopsy|Renal biopsy samples will be obtained by a percutaneous method using a spring-loaded Trucut® biopsy needle under real time ultrasound guidance. Biopsy samples will be processed for light microscopy with special staining will be done: Schiff periodic acid, Masson trichrome and methenamine silver.and immunofluorescence studies to evaluate IgA, IgG, IgM, complement C1q and C3, fibrin, and kappa and lambda light chain deposits.
76469|NCT03586518|Diagnostic Test|Cardiac MRI scan|"A non-contrast cardiac MRI (CMR) scan at 3-Tesla platform (Skyra, Siemens Medical Imaging, Erlangen, Germany).~This non-contrast CMR scan will principally determine: Left ventricular (LV) mass and volumes/ejection fraction and; fibrosis using T1 mapping."
76470|NCT03586518|Diagnostic Test|Echocardiogram|Assessments will include: LV size and function as per the American Society of Echocardiography guidelines. In addition specific focus will be paid end-diastolic integrated backscatter measurements.
76471|NCT03586518|Procedure|Cardiac explantation|A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
76472|NCT03586518|Diagnostic Test|48-Hour continuous cardiac monitoring|Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
76473|NCT03586518|Diagnostic Test|Blood samples|Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
76474|NCT03586505|Device|Light exposure|"The 6 lights used randomly are :~482nm =standard blue light illumination,~650nm,~675nm,~700nm,~750nm~800nm"
76475|NCT03586492|Diagnostic Test|CZT SPECT acquisition|CZT SPECT acquisition, with dynamic stress and rest acquisitions to calculate CFR If pathological, coronarography with FFR measurement if necessary In case of intermediate coronary stenosis with medical treatment, SPECT CFR evaluation after one year of treatment
76476|NCT03586479|Behavioral|Interactive storybook reading|Children will be taught 30 words prior to, during, and after reading a commercially available storybook by an adult.
76477|NCT03586466|Device|BupreCare|"Subjects will receive their medication in a MedicaSafe device. Medication will be dispensed in accordance with the programmed treatment plan for each subject. Subjects will complete a Check-In remotely each week with their device."
76478|NCT03586466|Drug|Buprenorphine/naloxone|Subjects will be given buprenorphine/naloxone as a component of Medication Assisted Treatment (MAT).
76479|NCT03586466|Other|MEMS|Subjects will receive their medication in a MEMS pill bottle.
76480|NCT03586453|Drug|Osimertinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Osimertinib.~After the screening procedures confirm participation in the research study:~Osimertinib: Oral, Daily 28 day cycle.~Radiographic assessment: every 2 cycles for first 6 months and then every 3 cycles until disease progression.~Tumor biopsy between C4 and C8 and at disease progression"
76481|NCT03586427|Drug|AGN-241751|AGN-241751 administered orally as a single tablet
76482|NCT03586427|Other|Placebo|Placebo administered orally as a single tablet
76483|NCT03586414|Dietary Supplement|MITOQUINOL MESYLATE then placebo|MITOQUINOL MESYLATE then placebo: 'MITOQUINOL MESYLATE' administered twice daily for 4 weeks followed by a washout, then placebo capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
76484|NCT03586414|Dietary Supplement|Placebo, then MITOQUINOL MESYLATE|'Placebo, then MITOQUINOL MESYLATE' : Placebo administered twice daily for 4 weeks followed by a washout, then 'MITOQUINOL MESYLATE' capsule administered twice daily for 4 weeks. Capsules with active product contain 20 mg of 'MITOQUINOL MESYLATE'.
76485|NCT03586388|Other|Oral immunotherapy protocol|"In hospital setting: three increasing doses every 30 minutes of 1ml, 5ml and 10ml of cow milk (CM). Oral food challenge (OFC) stopped at 10ml even if no clinical reactions occurred.~At home: every child will take the dose tolerated in hospital, starting the day after the OFC, for 3-4 weeks.Once reached the dose of 40ml of CM without reactions for at least 2 weeks, families increment the dose of 5 ml every week, till the tolerance of 50 ml, then of 10 ml every week, till the tolerance of 100ml and then, of 10 ml every 3 days till the tolerance of 150 ml of milk."
76486|NCT03586375|Other|Intensive Support Team Care|Intensive Support Teams (ISTs) are specialist teams which have been advocated for many years as the right services to help people with intellectual disabilities (ID) and challenging behaviour stay in their local communities. They may be staffed by one or more professions, e.g. psychology, nursing, psychiatry, and usually deliver interventions such as positive behaviour support and accept people with ID who are in a crisis when challenging behaviour emerges or provide support when a person is admitted to a local inpatient facility.
76487|NCT03586336|Device|ReDS-Guided|ReDS measurements will be shared with the treating clinicians who can use the information to guide diuresis and determine the appropriate timing of discharge
76488|NCT03586336|Device|Usual Care|ReDS measurements will not be shared with the treating clinicians, who will guide diuresis using standard clinical criteria
76489|NCT03586323|Drug|superior laryngeal nerve block with lidocaine|SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
76490|NCT03586310|Device|ear-EEG|soft silicone electrode array placed in each ear (outer ear-canal and concha), connected to a battery powered EEG amplifier.
76491|NCT03586284|Drug|Valganciclovir Hydrochloride|28 days of oral valganciclovir treatment
76492|NCT03586284|Drug|Ganciclovir Sodium|28 days of topical ganciclovir solution treatment
76493|NCT03586284|Drug|Placebo Oral Tablet|28 days of placebo pill treatment
76494|NCT03586284|Drug|Topical placebo|28 days of topical placebo treatment
76495|NCT03586271|Procedure|trifocal lens|phacoemusification + trifocal lens(AT Lisa tri 839MP) implantation
76496|NCT03586271|Procedure|bifocal lens 1|phacoemusification +bifocal lens(Diff-aay) implantation
76497|NCT03586271|Procedure|bifocal lens 2|phacoemusification +bifocal lens (ReSTOR +3.0D) implantation
76498|NCT03586271|Procedure|bifocal lens 3|phacoemusification +bifocal lens (ReSTOR +2.5D) implantation
76499|NCT03586258|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests
76500|NCT03586258|Other|Brain Imaging|Anatomical, diffusion, and/or functional MRI
76501|NCT03586258|Other|Galvanic Vestibular Stimulation (GVS)|Stimulation versus Sham
76502|NCT03586245|Dietary Supplement|Ferric pyrophosphate|57 Iron isotopically labeled FePP powder.
76503|NCT03586245|Dietary Supplement|Aspiron|58 Iron isotope intrinsically labeled Aspergillus oryzae.
76504|NCT03586245|Dietary Supplement|Ferrous sulfate|57 Iron isotopically labeled FeSO4 powder.
76505|NCT03586232|Dietary Supplement|Arnica Montana|Arnica Montana is from the Asteraceae plant family and is native to the mountain areas in Europe and western North America. It is reported to have anti-inflammatory, antiseptic, and vasodilatory properties and is often used in plastic surgery to help reduce pain, edema, and ecchymosis postoperatively.
76506|NCT03586232|Dietary Supplement|Bromelain|Bromelain is a protease enzyme derived from the pineapple plant, Ananas comosus, which has been used to reduce swelling, inflammation, and pain and may help to reduce wound healing time.
76507|NCT03586232|Other|Placebo|A pharmacologically inert preparation
76508|NCT03586219|Behavioral|Opioid-specific educational patient pamphlets|See prior description
76509|NCT03586193|Procedure|Pars plana vitrectomy|pars plana vitrectomy without ICG staining and ILM peeling
76510|NCT03586180|Behavioral|Medical Clowning for children|Clowns in clinical setting have been found to be effective in reducing children's experiences of these effects during hospitalization and before procedures.
76511|NCT03586154|Combination Product|Platelet rich plasma|combined platelet rich plasma and 1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
76512|NCT03586154|Drug|ketamine and bupivacaine injection|1 ml ketamine in a dose of o.5 ml/kg plus 5ml bupivacaine 0.5% in a total volume 10 ml
76513|NCT03586141|Diagnostic Test|Pronto® hemoglobin measurement tool|All patients who are planned to undergo elective surgery come to the preoperative anesthetic ambulance. They are all measured by the Pronto® hemoglobin measurement tool
76514|NCT03586128|Drug|PrEP|PrEP will be introduced into clinics according to Uganda national guidelines using a stepped wedge design. Uganda guidelines recommend any tenofovir disoproxil fumarate (TDF) containing medication be used for PrEP; this includes emtricitabine (FTC)/TDF, lamivudine (3TC)/TDF or TDF alone.
76515|NCT03586128|Drug|ART|ART medication will be provided according to Uganda national guidelines for persons living with HIV.
76516|NCT03586115|Device|Critical flicker frequency assessment|All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
76517|NCT03586102|Dietary Supplement|High protein supplementation|To increase protein content of human milk, a fixed amount of commercially available hydrolyzed bovine protein will be added to fortified human milk. With this pragmatic approach, preterm infants assigned to the high protein supplementation group will receive > 4.5 g/kg/day of enteral protein after establishment of full enteral feeding.
76518|NCT03586102|Dietary Supplement|Standard protein supplementation|Infants assigned to the standard protein supplementation group will receive fortified human milk (< 4.5 g/kg/day of enteral protein)
76519|NCT03586089|Drug|Phenobarbital Sodium|Single IV dose of phenobarbital (7.5 mg per kg of body weight prepared in 250 ml D5W)
76520|NCT03586089|Drug|Inactive placebo|Single dose of inactive placebo prepared in 250 ml D5W).
76521|NCT03586076|Biological|JHL1922|Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer
76522|NCT03586076|Biological|dornase alfa|Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer
76523|NCT03586063|Other|Data collection|"This is a non-interventional (observational) national multicentre prospective study.~Treatment was administered according to the Summary of Product Characteristics (SmPC): maximum 6 injections administered every 28 days.~The decision to prescribe GnRH-a (Diphereline 3,75 mg) was made prior to and independently from the decision to enroll the patient into the study."
76524|NCT03586050|Device|Microwave ablation|All patients will receive microwave ablation using the NeuWave Microwave Ablation System and Accessories
76525|NCT03586037|Drug|AD-2011 10/20 mg|AD-2011 10/20 mg tablet
76526|NCT03586037|Drug|AD-2012 80mg|AD-2012 80mg tablet
76527|NCT03586037|Drug|AD-2011 10/20 mg + AD-2012 80mg|AD-2011 10/20 mg + AD-2012 80mg tablet
76532|NCT03585985|Procedure|Photoplethysmographie-Imaging (PPGI) + Infrared thermography (IRT)|Camera-based technology for the determination of heart rate variability (PPGI) and contactless measurement of breathing rate (IRT)
76533|NCT03585972|Behavioral|Frailty Prevention Program|4 face-to-face sessions, with a occupational therapist over 4 months to address function, safety, social participation, diet, exercise, sleep, and medication management. Sessions are expected to last between 60-120 minutes. The first session is a comprehensive occupational therapy evaluation and treatment plan. Sessions 2 and 3 involved physical activity and dietary education, counseling and goal setting. Session 4 involves reviewing program progress, and setting maintenance goals.
76534|NCT03585959|Device|superDimension™ Navigation System Version 7.2|superDimension™ Navigation System Version 7.2 with Fluoroscopic Navigation Technology in subjects undergoing lung lesion biopsy
76535|NCT03585946|Drug|Site specific standard of care comparison|Patients outcomes will be assessed and compared based on the medication they receive which will be assigned based on the standard of care at each enrolling site.
76536|NCT03585933|Diagnostic Test|Cardiac magnetic resonance imaging|Echocardiography: assessment of aortic stenosis severity, evaluation of LV diastolic and systolic function; CMR: chambers quantification, LGE, T1 mapping; Intraoperative myocardial tissue biopsy for patients undergoing SAVR; DPD scintigraphy: assessment of cardiac transthyretin amyloidosis
76537|NCT03585920|Behavioral|Expanded Corn Snack|A standard expanded snack will be used in each of the 3 arms, the content and type of fat added to the snack is varied in the two experimental arms.
76538|NCT03585907|Dietary Supplement|MAD|A high fat, low carbohydrate diet
76539|NCT03585907|Dietary Supplement|MIND|A combination of the Mediterranean and DASH diets
76540|NCT03585894|Other|Sumatriptan|Receive intravenous infusion of sumatriptan
76541|NCT03585894|Other|Ketorolac|Receive intravenous infusion of ketorolac
76542|NCT03585881|Device|3DPrinted Windowed Bracket- Positioning tray|3 D printed tray with windows for accurate positioning of brackets
76543|NCT03585868|Other|Placebo|Beverage with no flavonoids
76544|NCT03585868|Other|Flavonoids|Flavonoids-enriched cacao beverage
76545|NCT03585868|Dietary Supplement|No Flavonoids|Beverage with alkalinized cocoa which eliminates flavonoid content
76546|NCT03585855|Other|MSC transplantation|MSC transplantation: patients with ABMR treated with MSC transplantation
76547|NCT03585842|Other|No intervention|No intervention
76548|NCT03585829|Drug|Hydrocortisone|at a substitutive dosage
76549|NCT03585829|Drug|Prednisolone|at a substitutive dosage
76550|NCT03585803|Drug|KMRC011 5μg or Placebo|Intramuscular Injection of KMRC011 5μg or Placebo(Normal Saline) 0.1ml
76551|NCT03585803|Drug|KMRC011 10μg or Placebo|Intramuscular Injection of KMRC011 10μg or Placebo(Normal Saline) 0.2ml
76552|NCT03585803|Drug|KMRC011 20μg or Placebo|Intramuscular Injection of KMRC011 20μg or Placebo(Normal Saline) 0.4ml
76553|NCT03585803|Drug|KMRC011 30μg or Placebo|Intramuscular Injection of KMRC011 30μg or Placebo(Normal Saline) 0.6ml
76554|NCT03585803|Drug|KMRC011 45μg or Placebo|Intramuscular Injection of KMRC011 45μg or Placebo(Normal Saline) 0.9ml
76555|NCT03585803|Drug|KMRC011 60μg or Placebo|Intramuscular Injection of KMRC011 60μg or Placebo(Normal Saline) 1.2ml
76556|NCT03585803|Drug|KMRC011 75μg or Placebo|Intramuscular Injection of KMRC011 75μg or Placebo(Normal Saline) 1.5ml
76557|NCT03585790|Device|Contact lens with Multifocal Optics|This contact lens has optics to aid the accommodative and convergence systems
76558|NCT03585790|Device|Contact lens with Single Vision Optics|This contact lens has standard single vision optics
76559|NCT03585764|Drug|MOv19-BBz CAR T cells|intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy.
76560|NCT03585764|Device|Alpha Folate Receptor expression test|Patients will first be pre-screened for alpha folate receptor expression. The test for alpha folate receptor expression is a laboratory developed test+, developed and conducted by the Hospital of the University of Pennsylvania Pathology and Laboratory Medicine lab to determine subject eligibility. This test is not an approved FDA device and its use is investigational.
76561|NCT03585751|Procedure|Pulpectomy for primary molars + triple antibiotic mix|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with a triple antibiotic mix mixed with a Carrier ( MP) as an obturating material
76562|NCT03585751|Procedure|Pulpectomy for primary molars + 3mixstatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with one of .Following instrumentation and copious irrigation ,the root canals are filled with 3mixstatin (triple antibiotic mix + simvastatin) as an obturating material mixed with a Carrier ( MP) as an obturating material
76563|NCT03585751|Procedure|Pulpectomy for primary molars + simvastatin|complete extirpation of infected pulp from primary molars. Following instrumentation and copious irrigation ,the root canals are filled with simvastatin as mixed with a Carrier ( MP) as an obturating material
76564|NCT03585738|Dietary Supplement|Inositol + Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Myo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg"
76565|NCT03585738|Dietary Supplement|Folic acid|"Daily oral supplementation before spontaneous conception until delivery:~Folic acid: 400 mcg"
76566|NCT03585725|Drug|Ribavirin|"Ribavirin is FDA-approved oral medication for antiviral indications. Ribavirin will be obtained commercially for this trial.~Treatment will be administered on an outpatient basis. Ribavirin should be administered with food."
76567|NCT03585712|Drug|Norgestrel 0.075 MG|Subjects will take norgestrel 75 mcg every day at the same time for three 28-day treatment periods, except for 1 specific day during treatment period 2 and treatment period 3
76568|NCT03585699|Diagnostic Test|Fluoroscopy Guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
76660|NCT03585010|Behavioral|Cognitive-Behavioral Therapy|12 sessions with child
76569|NCT03585699|Diagnostic Test|CT guided Spinal Biopsy|"Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis."
76570|NCT03585686|Drug|Vemurafenib|vemurafenib 20 mg/kg/day
76571|NCT03585686|Drug|Cytarabine|100 mg/m2/12 h, days 1-5
76572|NCT03585686|Drug|2-chlorodeoxyadenosine|6 mg/m2/d, days 1-5
76573|NCT03585673|Drug|Docetaxel-PM|Docetaxel-PM 35mg/m2 intravenous over 1hour day1 and 8 every 3 weeks till progression
76574|NCT03585673|Drug|Oxaliplatin|Oxaliplatin 120mg/m2 intravenous over 2 hour day 1 every 3 weeks till progression
76575|NCT03585660|Procedure|Diagnostic MRI|Participants will be scanned using a standard clinical prostate MRI protocol.
76576|NCT03585660|Procedure|Diagnostic Prostate Biopsy|Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.
76577|NCT03585660|Device|Risk Map DSS tool|The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.
76578|NCT03585647|Procedure|hip arthroplasty|Hip replacement is a surgery for people with severe hip damage. The most common cause of damage is osteoarthritis.
76579|NCT03585634|Behavioral|Dads in Gear Program|
76580|NCT03585621|Radiation|SBRT|Each radiation treatment plan will be customized to the patient and tumour in order to deliver highly conformal, conebeam CT guided SBRT radiotherapy in 4 fractions delivered over 2-4 weeks.
76581|NCT03585608|Procedure|Neck extension|The neck extension is routine posture during palatoplasty. We will evaluate the change in optic nerve sheath diameters before and after neck extension.
76582|NCT03585595|Other|Blood pressure lowering strategy|The proposed trial will test a treatment strategy of different systolic BP goals and not specific medications. It remains unclear whether a particular class of antihypertensive drug offers an advantage over others in secondary stroke prevention. Therefore, the BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications. However, we will emphasize the use of drugs best demonstrated to be effective in lowering CVD in outcome trials and recommended in current clinical guidelines.
76583|NCT03585582|Other|Prospective follow-up|This is a prospective follow-up study to assess of outcomes at 1 year following the discharge from the hospitalization during which PARDS was diagnosed
76584|NCT03585569|Biological|Abobotulinumtoxin A|Treating Patients with Multiple Sclerosis with lower extremity spasticity using Dysport (Abobotulinumtoxin A)
76585|NCT03585556|Drug|Intravitreal anti-VEGF|Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
76586|NCT03585556|Biological|Intravitreal AAVCAGsCD59|An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
76587|NCT03585556|Drug|Oral prednisolone|A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
76588|NCT03585543|Behavioral|Voice Crisis Alert V2|Intervention consists of a mHealth app delivered via smartphone
76589|NCT03585530|Drug|raltitrexed|Raltitrexed 2.6mg/m2 was administered on d1、d22
76590|NCT03585517|Drug|IM23|T Cells Expressing an Anti-CD123 Chimeric Antigen Receptor
76591|NCT03585504|Drug|Etonogestrel contraceptive implant|Etonogestrel contraceptive implant
76592|NCT03585491|Procedure|Latarjet Procedure|Participants will undergo open or arthroscopic Latarjet procedure.
76593|NCT03585491|Procedure|Bankart Procedure|Participants will undergo arthroscopic stabilization.
76594|NCT03585478|Drug|Latiglutenase|Latiglutenase administered orally (daily)
76595|NCT03585478|Other|Placebo|Placebo administered orally (daily)
76596|NCT03585465|Drug|Vinblastine|"Experimentals Arm A or C (First stage): 2 mg/m2/day IV, weekly per cycle, 28 days cycle~Experimental Arms Metronomic or Metronomic+Nivolumab (second stage): see A or C"
76597|NCT03585465|Drug|Cyclophosphamide|"Arm A (First stage): 30 mg/m2/day PO, D1-4// D8-11// D15-18// D22-25 per cycle, 28 days cycle~Arm C (First stage): 30 mg/m2/day PO, D1-D4// D15-D18 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see A or C"
76598|NCT03585465|Drug|Capecitabine|"Arm B (First stage): 400 to 600 mg/m2/day PO, all days per cycle, 28 days cycle~Arm C (First stage): 400 to 600 mg/m2/day PO, D8-D11// D22-D25 per cycle, 28 days cycle~Metronomic or Metronomic+Nivolumab Arm (second stage): see B or C"
76599|NCT03585465|Drug|Nivolumab|"Arm A, B or C (First stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle~Metronomic+Nivolumab Arm (second stage): 3 mg/kg IV, D1 & D15 per cycle, 28 days cycle"
76600|NCT03585452|Drug|Dexmedetomidine Infusion|Additional dexmedetomidine infusion, as an element of general anesthesia
76601|NCT03585439|Procedure|Observational study evaluating the results of an intervention for isthmic spondylolisthesis: surgical procedure with double approach: Anterior lumbar Interbody Fusion then postero-lateral fusion|First in supine position, an ALIF is performed: with a Pfannenstiel incision, through a retroperitoneal approach, a discectomy is performed at the level of the spondylolisthesis then a cage is placed between the two vertebral bodies. Then, in prone position, a standard posterior approach is performed, pedicle screws are placed to achieve a postero-lateral fusion. A decompression may be associated.
76602|NCT03585426|Drug|Vancomycin|Vancomycin, a novel intravenously administered glycylcycline antibiotic, currently plays a key role in the management of complicated multi-organism infections.
76603|NCT03585413|Dietary Supplement|Micronutrient-probiotic-combination|Specific combined micronutrient-probiotic-supplement with different vitamins, minerals, phytochemicals and bioactive substances, and a mixture of 10 different probiotic bacteria.
76604|NCT03585413|Dietary Supplement|Micronutrient-placebo-combination|micronutrient (capsule)-placebo (powder)-supplement
76605|NCT03585400|Other|Observational Study|Observational Study: Not Applicable for Observational Studies
76606|NCT03585387|Procedure|Navigation|Navigation of a balloon catheter using two navigation methods (1-Fluoroscopy only; 2- Fluoroscopy + CPS).
76607|NCT03585374|Combination Product|Methoxyflurane and Penthrox inhaler|3ml of methoxyflurane vaporized through an inhaler (Penthrox). Inhalation, by regular breathing, last about 25 minutes.
77197|NCT03580785|Radiation|CT scan of maxillary and mandible|CT scan of maxillary and mandible
76608|NCT03585374|Drug|Morphine|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a dose of 0.10 mg/Kg body weight. The time of infusion should be not longer than 10 minutes.
76609|NCT03585374|Drug|Paracetamol|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 1 g dose The time of infusion should be not longer than 10 minutes.
76610|NCT03585374|Drug|Ketoprofen|Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
76611|NCT03585361|Behavioral|Health centers provide PPFP counseling and services|Providers trained on PPFP counseling skills and insertion technique for placing intrauterine devices (IUDs) immediately after birth with a refresher on insertion techniques for IUDs and implants. Training also included how to use tools to document PPFP services and referrals. Follow up supervision ensured skill mastery and retention.
76612|NCT03585361|Behavioral|HEWs provide PPFP counseling and services|HEWs trained in PPFP counseling with a refresher on implant insertion skills. Training also included how to use tools to document PPFP services, method choice, and pregnancy risk at every contact during pregnancy and up to 12 months after birth. Follow up supervision ensured skill improvement and retention.
76613|NCT03585361|Behavioral|Volunteers (Development Army) promote PPFP|HEWs orient volunteers on promoting PPFP and how to use a pictoral tool to remind women to access ANC, immunization, and PPFP services and to document women's method preferences and pregnancy risk at every contact during pregnancy and up to 12 months after birth.
76614|NCT03585361|Behavioral|Health centers conduct data reviews|Health center staff document PPFP counseling, provision, and referrals in registers and use a facility dashboard to display and track aggregate PPFP data.
76615|NCT03585361|Behavioral|HEWs and volunteers track PPFP|HEWs and volunteers track PPFP counseling, choice of method, receipt of methods, and pregnancy risk starting in pregnancy through 12 months postpartum. HEWs and volunteers meet and review data.
76616|NCT03585348|Other|Neuromuscular blocking agents|Neuromuscular blocking agent ED95 equivalent dose by provider
76617|NCT03585322|Drug|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .
76618|NCT03585309|Procedure|The impact of electrocoagulation on ovarian reserve after laparoscopic excision of ovarian cysts:|"Randomization Randomization will be conducted using computer generated table. Group A (48 CASES) without coagulation~Group A 6 89 92 35 1 15 21 16 60 49 53 91 34 5 94 64 88 58 7 33 8 75 29 56 10 23 37 19 32 71 55 84 36 77 50 2 46 70 82 9 51 54 72 18 25 31 14 63~Group B (48 CASES) with coagulation Group B 79 38 93 43 52 44 62 47 68 76 86 95 81 83 42 80 94 30 78 61 12 17 66 13 41 59 22 73 39 65 4 90 28 26 3 87 40 85 69 48 27 24 74 57 11 20 67 45~Allocation and concealment Nineteen six opaque envelopes will be numbered serially and in each envelope the corresponding letter which denotes the allocated group will be put according to randomization table then all envelopes will be closed and put in one box. When the first patient arrives the first envelope will be opened and the patient will be allocated according to the letter inside."
76619|NCT03585296|Drug|ATI-502|Topical Solution
76620|NCT03585283|Other|Myofascial Group|Manual myofascial release will be applied at prone position. Patient's upper thoracic and cervical region will be undressed. Researcher will use direct and indirect myofascial release techniques on upper thoracic and cervical region focusing on trigger point located muscles (most frequently m. trapezius)
76621|NCT03585283|Other|Sham Group|Patient's upper thoracic and cervical region will be undressed. Researcher will place his hands on points that used for myofascial release however no pressure or release techniques will be used.
76622|NCT03585270|Drug|Clazosentan|Clazosentan will be administered as a continuous I.v infusion at the dose of 15 mg/h
76623|NCT03585270|Drug|Placebo|Placebo will be administered at the same corresponding infusion rate
76624|NCT03585257|Biological|25% IV albumin|"Intravenous 25% albumin infusion 1.5 g/kg body weight (maximum 100gm) once a week for four weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if >4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
76625|NCT03585257|Other|Placebo|"Normal saline infusion 1.5g/kg body weight once a week for four weeks for a maximum of 5 infusions. These infusions will be administered over sixty minutes per clinical treatment protocols for this population. Patients and investigators will be blinded as to the characteristic of the infusion. Pre-infusion serum albumin will be checked and if >4.0gm/dl, then normal saline will be given instead as mentioned in the blinding section above. Samples will be collected before and one hour after the infusion for all patients.~The total grams of albumin infused over the 4 weeks during and outside the study will be collected and compared between groups."
76626|NCT03585244|Other|weekly weight|weekly weight data collection for six months
76627|NCT03585231|Behavioral|Immediate access to novel messaging program intervention|The experimental arm includes an immediate intervention using a novel messaging program for smoking cessation.
76628|NCT03585231|Behavioral|Immediate access to standard of care messaging program intervention|The immediate control intervention uses a standard of care messaging program for smoking cessation.
76629|NCT03585231|Behavioral|Delayed access to novel novel messaging program intervention|The delayed control intervention uses the novel messaging program for smoking cessation.
76630|NCT03585218|Biological|Inhalation of essential oils|"Intervention Inhalation of essential oils: From the T1 (2nd Cycle QT), Experimental Group Arms will undergo the inhalation of the hedonic aroma selected by them at the time of chemotherapy (among several types of aromas). It is intended that the participant, when receiving the QT, inhales the aroma phase-in and under the investigator's observation until the end of the treatment (about two hours). The inhalation of essential oils will occur using cotton rolls impregnated with the selected oil. The control group is not subject to intervention during chemotherapy treatment."
76661|NCT03584997|Procedure|ABB And Autogenous Particulate|Mixing the autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
76631|NCT03585205|Behavioral|Stress and cognitive load Induction|"Participants will engage in demanding cognitive load computerized tasks (such as N-back and Stroop tasks). They will engage in these tasks once in a non-stressful (neutral condition), and once in a stressful condition.~Psychological stress will be induced by the following methods:~Limiting time for task completion~Providing negative feedback on participants' performance in relation to others~Presentation of sudden, loud sounds during task"
76632|NCT03585192|Other|Skin Group|"If the newborn is vigorous (crying, good respiratory effort, good tone) after vaginal delivery, newborn will be able to go directly to Mother's chest for immediate SSC~A pulse oximeter will be placed on the newborn's right wrist. Saturations will be monitored on a pulse oximeter located next to the Mother's bed for the first hour of life."
76633|NCT03585192|Other|Warmer Group|"Newborn will go to the radiant warmer, pulse oximeter placed on newborn's right wrist, and saturations will be monitored on the Panda Warmer.~If stable per Baby RN after 20 minutes of observation, the newborn will be placed on Mother's chest for SSC. Vital signs will be monitored for the first hour of life."
76634|NCT03585179|Drug|Oral Tranexamic Acid|Participants will take a pill of 250 mg bid for 12 weeks
76635|NCT03585179|Drug|5% topical tranexamic acid|Participants will apply a layer of gel on the affected skin bid for 12 weeks
76636|NCT03585179|Drug|4% hydroquinone|Participants will apply a layer of cream on the affected skin once at night
76637|NCT03585166|Procedure|lpaparoscopic hepatectomy|laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.
76638|NCT03585166|Procedure|open hepatectomy|open hepatectomy: open hepatectomy for hepatocellular carcinoma
76639|NCT03585153|Other|Non-contrast magnetic resonance imaging|subjects lie in an MRI machine (non-contrast) for 30 minutes while we take pictures of their pancreas
76640|NCT03585140|Other|Normal diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins.
76641|NCT03585140|Other|Low glycemic diet|The energy consumption of each of the participants will be calculated, using the Mifflin-St Jeor formula. Each participant will receive a standard menu of 6 days according to their metabolic requirements and a list of equivalent foods. A list of foods classified as having low index and glycemic load was used according to the mexican equivalent food system. The distribution of macronutrients will be: 45% carbohydrates, 30% lipids and 25% proteins. Milk and vitamin supplements will be eliminated from the diet.
76642|NCT03585140|Drug|Adapalene 0.1% Gel|Adapalene 0.1% gel daily at night for 12 weeks, applied on the face, chest and back.
76643|NCT03585140|Drug|Doxycycline|Doxycycline 100 mg per day orally, before breakfast
76644|NCT03585127|Behavioral|Cognitive Behavioral Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist trained in Cognitive Behavioral Therapy for psychosis (CBTp). The program is derived and adapted from current evidence-based treatments for hallucinations. The 9 CBTp sessions will consist of a succession of learning modules and suggested task assignments.
76645|NCT03585127|Behavioral|Avatar Therapy|Participants will be offered 9 individual and weekly sessions of 1 hour, which will be administered in an individual format by a licensed psychologist or psychiatrist experienced with psychosis patients. The therapy will consist in prompting participants to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the avatar's speech and tone will gradually be changed by the therapist to echo participants' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce participants' feeling of empowerment over their voices.
76646|NCT03585114|Drug|[F-18] DCFPyL|[18F]DCFPyL will be used for study imaging. It will be administered intravenously on the day of imaging. Subjects will receive a bolus injection of 9mCi (331 MBq) of [18F]DCFPyL through a peripheral IV catheter. 60 to 120 minutes after injection, a whole body (toes to vertex) lowdose CT will be obtained (120 kVp, 80 mA maximum).
76647|NCT03585114|Procedure|PET/CT imaging|As per standard of care, acquisition will be performed on PET/CT scanner (Siemens, Germany) operating in 3D emission mode with CT-derived attenuation correction.
76648|NCT03585101|Drug|Elbasvir/grazoprevir|Daily fixed-dose combination (FDC) elbasvir (EBR) (50 mg)/grazoprevir (GZR) (100 mg) for 12 weeks
76649|NCT03585088|Device|surgical pleth index|All patients applied surgical pleth index after recovery of spontaneous breathing at the time of peritoneum and skin closure under Bispectral index score <=60.
76650|NCT03585062|Drug|S1,|S-1 is a combination of tegafur, gimeracil and oteracil at a molar ratio of 1:0.4:1, and is a new oral fluoropyrimidine anticancer agent shown to be effective for pancreatic cancer. cancer
76651|NCT03585062|Drug|Paclitaxel-albumin|Paclitaxel-albumin is a drug which showed a survival benefit in Pancreatic Cancer when combined with S1
76652|NCT03585049|Other|Vaginal swabs|The protocol includes the secondary use of vaginal swabs that are primarily used for routine diagnostic assessment in a vulvovaginal clinic
76653|NCT03585036|Drug|dexketoprofen|"Drug: dexketoprofen Women will receive oral dexketoprofen 25mg 2 hours before the procedure~Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure."
76654|NCT03585036|Drug|Tramadol|"Drug: Tramadol Women will receive oral Tramadol 100 mg 2 hours before the procedure~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
76655|NCT03585036|Drug|Placebo|"Drug: Placebo 1 Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.~Drug: Placebo 2 Women will receive an oral placebo similar to dexketoprofen 2 hours before the procedure"
76656|NCT03585023|Diagnostic Test|Spontaneous miscarriage|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
76657|NCT03585023|Diagnostic Test|Voluntary pregnancy interruption|Viral DNA and RNA analysis of HPyV and HPV, BKV and JCV. Bacterial DNA and RNA analysis of Chlamydia trachomatis, Ureaplasma parvum, U. urealyticum, Mycoplasma hominis.
76658|NCT03585010|Behavioral|Supportive Parenting for Anxious Childhood Emotions|12 sessions with parents
76659|NCT03585010|Behavioral|Parent Educational Support|12 sessions with parents
76662|NCT03584997|Procedure|PRF, ABB & Autogenous Particulate|adding an injectable platelets rich fibrin to a Mixture of autogenous bone graft aquired at the time of surgery with a 50:50 ration of anorganic bovine bone and filling the socket
76663|NCT03584984|Procedure|Mixture of Autogenous bone & Anorganic Bovine Bone (ABB)|Filling the socket with Mixing of autogenous bone graft and anorganic bovine bone in a 50:50 ratio
76664|NCT03584984|Procedure|Anorganic Bovine Bone (ABB)|Filling the socket with Anorganic bovine bone graft material only
76665|NCT03584984|Procedure|Absorbable gelatin sponge|Filling the socket with an absorbable gelatin sponge foam pack
76666|NCT03584945|Behavioral|Cognitive Behavioral Therapy|The treatment team will offer a course of cognitive behavioral therapy (CBT) (45 minute sessions for 12 to 16 weeks), augmented by medication treatment when clinically indicated based on the clinical treatment standards. Cognitive-behavioral therapy (CBT) is a treatment based on learning and cognitive theories. CBT for Obsessive-Compulsive Disorder (OCD) involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
76667|NCT03584945|Other|Community Referral as appropriate|Participants with Obsessive Compulsive Symptoms will be referred to the community for treatment
76668|NCT03584932|Behavioral|LINK2 Youth Services Navigation Intervention|There will be 6 in-person sessions delivered by a youth services navigator, plus weekly check-in calls after session 2 for a total of six months. As part of the learning sessions, the participant will learn important information about HIV and how to get the most out of his/her HIV care.
76669|NCT03584919|Drug|doxycycline|patients received oral doxycycline 100 milgrams bid for 15 days
76670|NCT03584919|Drug|Cefuroxime Axetil 500Mg Tab|patients received cefuroxime axetil 500 milgrams bid for 15 days
76671|NCT03584919|Other|control subjects|no intervention
76672|NCT03584906|Procedure|DGG Harvesting approach|An epithelialized graft is harvested from the superficial palate and then extraorally de-epithelialized in order to obtain a connective tissue graft
76673|NCT03584906|Procedure|ET harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
76674|NCT03584906|Procedure|TDT harvesting approach|A connective tissue graft is harvested from the palate after reflecting a primary palatal flap
76675|NCT03584906|Procedure|MT harvesting approach|An epithelialized graft is harvested from the maxillary tuberosity and then extraorally de-epithelialized in order to obtain a connective tissue graft
76676|NCT03584906|Procedure|Root coverage procedure|A single or multiple gingival recession is treated with a coronally advanced flap and a connective tissue graft
76677|NCT03584893|Procedure|Blood sampling for Cholestanol Analysis|Cholestanol analysis will be performed to see the Rate of juvenile cataract patients whose cholestanol test result is above threshold (3.75 mg/mL) and suspected CTX cases
76678|NCT03584880|Device|Diode laser disinfection|Root canal disinfection using a 940 nm dental laser after the removal of root canal filling of failed endodontic cases.
76679|NCT03584880|Device|Pseudo diode laser disinfection|Without activating laser energy, same procedure as experimental group was performed (Sham laser application)
76680|NCT03584867|Other|refresher training at six months|a 5 cycles of 30:2 compression to ventilation ratio will be offered to experimental group at six months from BLS certification.
76681|NCT03584854|Drug|15-methyl prostaglandin F2α|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."
76682|NCT03584854|Drug|Methylergonovine Maleate|"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."
76683|NCT03584841|Diagnostic Test|Iontophoresis sessions in forearm of subjects with pilocarpine|The test with two iontophoresis sessions is performed in a forearm of subjects. Pilocarpine is applied during the first iontophoresis session to evoke cholinergic-induced sweat secretion. Atropine, isoprenaline and aminophylline are applied during the second iontophoresis session, to block the cholinergic component and to evoke β-adrenergic-induced sweat secretion.
76684|NCT03584828|Behavioral|Tele Cardiac Rehabilitation|"A multidisciplinary intervention that aims to optimize structured exercise performed in the community as prescribed by rehabilitation cardiologist, cardiac care nurse, and exercise physiologist.~Additionally, in the intervention arm, we will provide psychological support, dietary intervention and disease management services that complement the structured physical activity - all by innovative smartphone applications and smart wearable devices, thus complementing the comprehensive secondary prevention program."
76685|NCT03584815|Procedure|Surgery/Fasciotomy|Open fasciotomy of the anterior and lateral compartment + standard post-operative physiotherapy for 12 weeks
76686|NCT03584815|Other|Physiotherapy|Intensive physiotherapy for 12 weeks including a change to forefoot/midfoot strike during running
76687|NCT03584802|Other|Therapeutic plasma exchanges|The patient will initially receive Methylprednisolone bolus of 1g i.v. day 1, then 20 mg/day (or oral prednisone equivalent) for 21 days; and then he will have nine therapeutic plasma exchanges of 1.5x the estimated plasma volumes using albumin:saline (3:1) or fresh frozen plasma in case of an INR superior to 1.5, on days 1,2,3,5,7,9,11,13,15; followed by administration of low dose of intravenous immunoglobulin (100 mg/kg). On days 7 and 15, the patient will receive rituximab 1 g i.v. on days 7 and 15 (after therapeutic plasma exchange and premedication); and intravenous immunoglobulin 0.5 g/kg/d on days 16 to 19.
76688|NCT03584802|Other|Conventional treatment of AE-IPF|Conventional treatment of AE-IPF
76689|NCT03584789|Other|Clinical Decision Support|A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
76690|NCT03584789|Other|Patient education|Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
76691|NCT03584776|Device|Virtual Reality|Participants randomized to the VR condition will experience an an immersive guided relaxation VR experience during research visits in the post-operative period. They will also have the opportunity to choose additional VR games and relaxation experiences during their inpatient stay.
76692|NCT03584763|Diagnostic Test|Umbilical artery Doppler|Umbilical artery Doppler ultrasound will be performed by most expert sonographer in umbilical artery Doppler at the special care unit, using a 3.5MHz transabdominal probe of SAMSUNG MEDISON, SONOACE R5 ultrasound machine, using the standard protocol of the unit for minimizing the interobserver variations.
76693|NCT03584750|Other|Floating|Floating in specialized tank with full floatation and sensory deprivation.
76694|NCT03584750|Other|Placebo floating|Floating in specialized tank with reduced floatation and sensory deprivation.
76695|NCT03584737|Diagnostic Test|rapid in vitro diagnostic test|IVD for qualitative detection of 3 bacterial pathogens (Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae)
76696|NCT03584737|Diagnostic Test|bacterial culture|Quantitative bacterial culture assay with isolate identification by MALDI-TOF.
76697|NCT03584737|Diagnostic Test|PCR assay|Qualitative real-time PCR assay
76698|NCT03584724|Drug|Norflo Oro|Norflo Oro is highly bioavailable curcumin complexed into phytosomes
76699|NCT03584724|Drug|Placebo for Norflo Oro|Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
76700|NCT03584711|Combination Product|FOLFOX + panitumumab|"FOLFOX + panitumumab according to a stop and go strategy with a reintroduction loop after progression on fluoropyrimidine as maintenance treatment"
76701|NCT03584698|Drug|Misoprostol 100Mcg Tab|women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
76702|NCT03584698|Drug|Evening Primrose Oil 1000 MG|women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
76703|NCT03584685|Device|Mask|All participants will initially be treated without the mask. In the next appointment, half will be treated with the mask.
76704|NCT03584685|Procedure|Routine wound treatment|All participants will initially be treated for their wounds without the mask. In the next appointment, half will again be treated for their wounds without the mask.
76705|NCT03584672|Other|Static Balance Test|Balance control is assessed by the Static Balance Test.
76706|NCT03584672|Other|Berg Balance Scale|Functional balance is assessed by the Berg Balance Scale.
76707|NCT03584672|Other|Timed Up an Go Test|Functional mobility is assessed by the Timed Up and Go test.
76708|NCT03584672|Other|Four Square Step Test|Dynamic balance is assessed by the Four Square Step Test.
76709|NCT03584672|Other|Functional Reach Test|Limits of stability is assessed by the Functional Reach Test.
76710|NCT03584672|Other|One-leg Stance Test|Postural steadiness is assessed by the One-leg Stance Test.
76711|NCT03584659|Device|Electronic patient-reported outcomes|Weekly reporting of patient-reported outcomes for closer contact between patient and clinic between treatment cycles.
76712|NCT03584646|Device|Nokia GO Wearable StepTracker|All participants will be provided with a Nokia GO step tracker to monitor daily step counts. The device is not subject to FDA regulation.
76713|NCT03584646|Other|Medication Reminder|Medication reminders are sent to participants in Arm 2 on a daily basis.
76714|NCT03584646|Other|Weekly Check-in appointment with study team or provider|Virtual meeting or telephone call between participants and study team to assess study involvement, adherence to procedures, and following of medical care recommendations.
76715|NCT03584633|Drug|Indocyanine Green|The subjects will be exercising on a Nu-Step exercise machine that will exercise their arms and legs simultaneously for five-minute intervals. Every five minutes their limbs will be imaged with an ICG lymphography device to determine the plateau rate of indocyanine green dye after exercise.
76716|NCT03584620|Other|Inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
76717|NCT03584620|Other|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
76718|NCT03584594|Diagnostic Test|Presepsin measurement|Presepsin measurements are performed with PathFast immunoassay analytical system on the ICU, bedside method. (Mitsubishi Chemical, Japan).
76719|NCT03584581|Dietary Supplement|Olive polyphenols|The amount of polyphenols to be supplied is within the ranges of absolute biosecurity food described by different authors and used in different studies.
76720|NCT03584581|Dietary Supplement|Control|Placebo
76721|NCT03584568|Behavioral|Perspective Taking Reappraisal|Interventions involving 1) appreciating relational insights; 2) enhancing self-awareness; 3) empathetic understanding of care-recipient; 4) integrating self-care and caring for others and 5) negotiation.
76722|NCT03584568|Other|Basic Skill Building|These skill-building exercises are commonly used in psycho-education programs for caregivers:monitoring mood and activities, relaxation techniques and scheduling pleasant events, basic communication with the care recipient, communicating the caregivers' own needs with other family member or related persons including helpers and professional staff.
76780|NCT03584113|Other|Video assisted thorascopic decortication|Video assisted thorascopic decortication surgery as primary intervention for empyema
77198|NCT03580772|Device|Persona TKR|Persona® TKR (Zimmer Biomet)
76723|NCT03584555|Procedure|SMILE using 120μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
76724|NCT03584555|Procedure|SMILE using 140μm cap thickness|The surgery was performed with standardized techniques with triple centration technique using the 500-KHz VisuMax system (Carl Zeiss Meditec AG, Jena, Germany). The superior cap depth was set as 120 or 140 µm, and the length of the side cut was set to 2 mm. Once the anterior (upper) and posterior (lower) planes of the lenticule were defined, the anterior and posterior interfaces were dissected using a micropetala with a blunt circular tip and extracted with midforceps. The integrity of the lenticule was assessed subsequently.
76725|NCT03584542|Other|No interventional study|No Interventional study - Only one questionnaire will be done for patients and for general practitioners
76726|NCT03584529|Drug|Vitamin D 3|Non-Vitamin D3 Drops group Patients in this group would take nothing.
76727|NCT03584516|Drug|Itacitinib|In Part 1 participants will receive itacitinib administered orally once daily at the protocol-defined dose according to cohort enrollment. In Part 2, participants will receive the recommended dose from Part 1.
76728|NCT03584516|Drug|Placebo|In Part 2, participants will receive matching placebo.
76729|NCT03584516|Drug|Methylprednisolone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
76730|NCT03584516|Drug|Prednisone|Administered in Parts 1 and 2 as background reference therapy at a dose level that is commensurate with institutional guidelines based on organ involvement and severity of disease.
76731|NCT03584503|Other|Suction Above Cuff Endotracheal Tube|Suction Above Cuff Endotracheal Tube (SACETT) has a dorsal port above the cuff designed to allow continuous or intermittent suctioning of secretions from the subglottic space
76732|NCT03584490|Other|Computerized Talking Touchscreen|"The intervention is a computerized talking touchscreen designed to aid people with low health literacy.~All Participants in both arms will complete a battery of health questionnaires. One group will complete questionnaires in traditional pen-and-paper format. The other group will receive the computerized talking touchscreen, which reads questions to participants on demand."
76733|NCT03584477|Device|Robot InMotion 2.0|Repetitive work of large numbers of targeted alternative movements with or without assistance. The passage between with and without assistance taking place according to the evolution of performance judged by the investigator therapist. Note that the duration of the training using the assisted mode should be at least 3 weeks, i.e. half of the total duration of treatment.
76734|NCT03584477|Other|Conventional rehabilitation|Conventional rehabilitation implemented by an occupational therapist, involving stretching movements in submaximal passive amplitude, inhibition postures (Bobath), active efforts assisted of varied difficulty, exercises of direction of the arm towards a target with or without elbow support and grasping tasks, adapted to the capacities of the paretic upper limb.
76735|NCT03584464|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
76736|NCT03584451|Behavioral|rehabilitation sport|rehabilitation Sport over 52 weeks after THA, start 6 weeks postoperatively
76737|NCT03584438|Device|Real iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the active coil (double blinded using the Universal Serial Bus key)
76738|NCT03584438|Device|Sham iTBS|This will be delivered with the Magventure Magpro system; pulses are delivered with the sham coil (double blinded using the Universal Serial Bus key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
76739|NCT03584425|Diagnostic Test|Rasch modified version of the Fugl-Meyer Motor assessment|All participants will receive a comprehensive clinical assessment of motor function including the Rasch modified version of the Fugl-Meyer Motor assessment and a kinematic assessment of unimanual and bimanual movements using a 45 sensor 3D active marker based motion capture system. The three primary measures investigated in the kinematics include: 1) movement efficiency, 2) movement smoothness, and 3) motor compensation.
76740|NCT03584425|Diagnostic Test|Anatomical image acquisition|High-resolution structural scans will be obtained using an inversion recovery 3D spoiled gradient echo (3DSPGR) sequence using a matrix size of 256 x 256, field of view of 24 cm, section thickness of 1.5 mm with no gap between sections, and 128 slices, giving an in-plane resolution of 0.94 mm. This sequence will be used for anatomic overlays of the functional data and for spatial normalization to a standard atlas.
76741|NCT03584425|Diagnostic Test|Functional MRI task and acquisition|Briefly, patients will be given two pressure-sensitive bulbs (one to be held in each hand and fastened lightly to their wrists with Velcro such that they do not drop it during the scan. During two 2½ minute runs they will be prompted to squeeze the bulb in either their affected or unaffected hand in blocks of 15 seconds. These blocks will be interspersed with blocks of rest. The pressure from the bulbs will be digitally recorded and quantified offline in order to: 1) verify that the patient was squeezing the ball, and 2) assess the presence of 'mirror movements' from the opposing hand that may inform the imaging results regarding loss of laterality).
76742|NCT03584412|Behavioral|ACT OPEN|Participants will access the ACT OPEN treatment through a secure online platform. Each session consists of brief videos and audio recordings that provide information about pain and guide participants through experiential exercises (e.g., mindfulness, values clarification, goal-setting). Participants will respond to questions assessing their experiences during the session and their progress using online messaging and/or brief telephone calls according to their preference. Therapists will provide individualised feedback. ACT OPEN consists of 12 sessions over 6 weeks. Participants will be given two further weeks to finish any uncompleted sessions, or to complete additional sessions (up to four) as agreed with their therapist.
76779|NCT03584126|Diagnostic Test|Electrocardiography, ecocardiography and MRI.|AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
76743|NCT03584412|Other|Waiting list control|Participants will receive their usual treatment for 5 months, after which they will complete ACT OPEN as described. A waiting list control was chosen as there is no clearly credible active psychotherapy to serve as the comparator in this context, particularly in light of high drop-out rates in two previous studies of CBT for pain in HIV. Providing the online treatment without therapist support may appear to be a logical comparison group instead of a waitlist control. However, there is evidence that therapist support is a key component of online CBT and, therefore, without this support it may not represent a credible treatment against which to judge the full treatment. In the context of the feasibility aims of this trial these reasons, the use of a waiting list control is thus justified.
76744|NCT03584399|Other|PICS in critically ill pediatric population|Collection of additional blood sample from those subjects meeting criteria for the study.
76745|NCT03584386|Device|V-CAMS|V-CAMS is an integrated software system for use on any device by suicidal patients in the ED.
76746|NCT03584373|Drug|Ketorolac Oral Tablet [Toradol]|Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
76747|NCT03584373|Drug|Acetaminophen|Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
76748|NCT03584373|Drug|Percocet|Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
76749|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and placebo
76750|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and betamethasone
76751|NCT03584360|Drug|Betamethasone-Calcipotriene Topical|Comparison between betamethasone-calcipotriol and propionate de clobetasol
76752|NCT03584347|Behavioral|Injection of filler material|Subjects will be blind folded and asked to deposit 0.2cc's of each of the four investigational products, in a randomized order. First, over a weight and then into a porcine membrane.
76753|NCT03584334|Radiation|18FDG PET|Diagnostic performance of 18FDG PET for identification of early tumor escape to immunotherapy in patients with unresectable melanoma or Broncho-Pulmonary Carcinoma No to Advanced or Metastatic Small Cells
76754|NCT03584308|Dietary Supplement|Viusid®|The VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner.
76755|NCT03584308|Dietary Supplement|Glizigen®|The GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
76756|NCT03584308|Dietary Supplement|Viusid Placebo|The placebo of VIUSID nutritional supplement is presented in the form of envelopes and will be administered orally diluted in water, juice or milk, according to the patient's preference and will be administered 3 times a day, 15 minutes before breakfast, lunch and dinner .
76757|NCT03584308|Dietary Supplement|Glizigen Placebo|The placebo of GLIZIGEN® product is presented in spray bottles and will be administered orally to swallow, away from meals 2 times a day.
76758|NCT03584295|Device|Extracorporeal carbon dioxide Removal|Patients with acute exacerbation of severe COPD, requiring invasive mechanical ventilation will be treated with vv-ECCO2R to facilitate early extubation
76759|NCT03584295|Other|Conventional Care|Patient with acute exacerbation of severe COPD, requiring invasive mechanical ventilation treated with Conventional Care. Conventional care includes invasive mechanical ventilation and the attempt to extubate the patient and switch to NIV. If extubation fails tracheostomy can be performed according to the treating physician.
76760|NCT03584282|Behavioral|Text Messaging|The text messaging intervention will send three text messages per day from a library. One will be a reminder to take PrEP, one will include PrEP information, and the third will have the content of the participant's choosing from categories of harm reduction messages and health information. Participants will also select the time period to receive these texts.
76761|NCT03584282|Behavioral|Peer Navigation|The peer navigation intervention will provide support from a peer that is responsive to a participant's individualized needs. Peer support may include phone call reminders, help refilling PrEP prescriptions, transit assistance, or other referrals.
76762|NCT03584269|Device|NIV Device + LTOT|Respiratory assistance by a facial mask without intubation or tracheotomy
76763|NCT03584269|Device|LTOT|Long term oxygenatory tyherapy without NIV
76764|NCT03584243|Procedure|A crosslinking with oxygen treatment|"A supplemental oxygen system during the cross linking will be used to apply filtered, humidified oxygen across the surface of the eye through a mask. The oxygen flow will be turned on immediately prior to initiation of irradiation, and will continue through the irradiation period. The supplemental oxygen flow will be shut off following completion of the programmed irradiation time.~All subjects will be evaluated at screening, day 3, and 1, 3, 6, 12 and 24 months after treatment. At the same time all the potential adverse effects will be relieved."
76765|NCT03584230|Behavioral|Assigned to positive group|See arm description
76766|NCT03584230|Behavioral|Assigned to negative group|See arm description
76767|NCT03584217|Drug|Aminohippurate Sodium Inj 20%|Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
76768|NCT03584217|Drug|Iohexol Inj 300 MG/ML|Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
76769|NCT03584204|Diagnostic Test|imaging|computed tomography
76770|NCT03584191|Other|No treatment given|Completion of a survey
76771|NCT03584178|Device|Budesonide via MAD device|Delivery through Mucosal Atomization Device
76772|NCT03584178|Device|Budesonide via intranasals Saline Irrigation|delivery via nasal irrigation bottle
76773|NCT03584165|Genetic|AAV2-REP1|Sub-retinal injection of AAV2-REP1 after vitrectomy.
76774|NCT03584152|Drug|Norco 5Mg-325Mg Tablet|Opioid Analgesics
76775|NCT03584152|Drug|Tylenol 325Mg Caplet|Non opioid analgesics
76776|NCT03584152|Drug|Ibuprofen 200 mg|Non opioid analgesics
76777|NCT03584139|Device|IRIS HOOK|iris hook assisted maneuver in phacoemulsification
76778|NCT03584139|Device|TRADITION|traditional phacoemulsification or phacoemulsification with 25-gauge vitreous irrigation
76878|NCT03583424|Procedure|Hematopoietic Cell Transplantation|Undergo hematopoietic cell transplantation
76781|NCT03584113|Other|Interventional radiology guided chest tube insertion with MIST2 trial fibrinolytics|Image guided chest tube insertion by IVR with intrapleural fibrinolytics (six doses of dornase [5mg] and alteplase [10mg] Q12hours).
76782|NCT03584100|Device|Tourniquet 8000|Pneumatic tourniquet with appropriate upper extremity cuff, pressure sensing, and ability to set device at 40 mmHg of pressure
76783|NCT03584087|Drug|Normal Saline|TG 0 (0Hr)
76784|NCT03584087|Drug|Terlipressin|Duration of Terlipressin after EVL
76785|NCT03584074|Drug|Pregabalin 75mg|Orally taken twice daily for 8 weeks
76786|NCT03584074|Drug|Celebrex 200Mg Capsule|Orally taken once daily for 8 weeks
76787|NCT03584061|Procedure|Fat grafting|The area of dermal pain is identified and marked prior to surgery. The surgery starts with liposuction, either on the abdomen or the thigh. The harvested fat is prepared for fat grafting by sedimenting it for 10 minutes. The fat is then injected into the painful area, marked pre-surgery.
76788|NCT03584048|Other|Alert to provider|Providers receive alerts of sub-optimal patient attendance using 4 rules.
76789|NCT03584035|Behavioral|sensory motor integration exercises|Sensorimotor integration exercises will be given in study group. The exercises will be performed in standing, sitting and walking. Exercises will be progressively increased from eye open to closed , floor to mat and head turns to right & left under the supervision of physiotherapist. Sensorimotor integration exercises will take 45 minutes in each session.
76790|NCT03584035|Behavioral|conventional physiotherapy|Conventional physiotherapy will take 30 minutes in each session, taking three sessions per weeks for six weeks. The exercises include simple lower extremity exercise and ambulatory training such as sit to stand, stepping, lateral and backward walking, and tandom walking etc.
76791|NCT03584022|Device|Biopsy + Nerve Repair|During the standard sural nerve biopsy procedure, a single-use, biodegradable implant designed to repair damaged peripheral nerves will be used to repair the nerve. The MCNS1 is a hollow nerve tube made of poly(caprolactone-fumarate) (PCLF), to connect severed nerve ends and promote the growth of regenerating axons.
76792|NCT03584022|Procedure|Biopsy Only|Standard sural nerve biopsy only, without nerve repair.
76793|NCT03584009|Drug|Venetoclax|Venetoclax will be administered orally, 800-mg tablet beginning on Cycle 1 Day 1
76794|NCT03584009|Drug|Fulvestrant|Fulvestrant will be administered orally, 500 mg administered as two 250-mg intramuscular (IM) injections on Cycle 1 Days 1 and 15 and on Day 1 of each subsequent 28-day cycle
76795|NCT03583996|Combination Product|HepQuant SHUNT Liver Diagnostic Test|One time testing using the HepQuant SHUNT Liver Diagnostic Test kit (the combination product) in subjects with CLD and undergoing a standard of care EGD. The SHUNT test will be completed prior to the EGD. Each subject will receive an IV push dose of 13C Cholate mixed with Albumin simultaneously with an oral dose of d4 Cholate
76796|NCT03583983|Behavioral|Personalized Health Recommendations|Includes 3-month gym membership, personalized exercise and meal plans, and genetic information related to health and wellness traits. The genetic information provided to study participants will consist of scores ranging from 0 to 100 based on the population percentile of the combined effects of many genetic variants, herein referred to as polygenic scores (PGS). PGS for approximately twenty traits related to health, fitness and nutrition will be provided to study participants. These traits are chosen for their relevance to healthy lifestyle habits (e.g. genetic predisposition to adiposity or muscle strength), entertainment value (e.g. preference for mornings) or both (e.g. bitterness taste perception, which while entertaining can also help guide vegetable choices).
76797|NCT03583983|Behavioral|Generic Health Recommendations|Includes 3-month gym membership and generic recommendations (Canada Food Guide / Health Canada Physical Activity guidelines)
76798|NCT03583970|Device|Left Ventricular Assist Device Implantation|Veno-arterial extracorporeal membrane oxygenation prior to left ventricular assist device implantation : initial patients characteristics and 6 Month Follow-up
76799|NCT03583957|Device|N/A Observational only|N/A Device is only observational
76801|NCT03583931|Procedure|VATS Decortication|Surgical procedure to unroof all located collections of the pleural space through a chest wall incision
76802|NCT03583931|Drug|Fibrinolytic Therapy|Instillation of DNAse and tPA together through patient's chest tube already in placed to break down complex fluid collection in the pleural space. DNAse and tPA are are administered together only i.e. are not mutually exclusive.
76803|NCT03583918|Device|HighThroughput Micro Coring Device|Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device
76804|NCT03583905|Drug|CKD-330|CKD-330 Tab.
76805|NCT03583905|Drug|Placebo of CKD-330|Placebo of CKD-330 Tab.
76806|NCT03583905|Drug|D086|D086 Tab.
76807|NCT03583905|Drug|Placebo of D086|Placebo of D086 Tab.
76808|NCT03583905|Drug|D723|D723 Tab.
76809|NCT03583905|Drug|Placebo of D723|Placebo of D723 Tab.
76810|NCT03583892|Drug|Gabapentin|One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
76811|NCT03583879|Other|Exoskeleton exercise|Functional exercise with a robotic exoskeleton
76812|NCT03583879|Other|Standard exercise|Functional exercise without a robotic exoskeleton
76813|NCT03583879|Other|No treatment|Wait-list control
76814|NCT03583866|Drug|Candesartan|7 days of Candesartan (16mg/day)
76815|NCT03583866|Drug|Placebo|7 days of Placebo
76816|NCT03583853|Device|real time PCR|real time PCR will be used for determination of expression of autophagy genes
76817|NCT03583840|Behavioral|ScreenMen website|An educational website that aims to improve evidence-based health screening uptake in men
76818|NCT03583827|Other|Virtual reality|Virtual reality is a simulation of the real world generated by computer software and experienced by users via a man-machine interface, providing them with intensive repetition of complex tasks, directed by visual and auditory stimuli, creating dynamic individual-task interaction, a motivating environment and immediate feedback on performance and results, stimulating motor skill learning and motor control of complex behaviors.
76879|NCT03583424|Drug|Melphalan|Given IV
76880|NCT03583424|Drug|Venetoclax|Given PO
76819|NCT03583827|Other|Conventional physical therapy|Exercises of stretching and strengthening of the upper and lower limbs, as well as coordination, gait and balance.
76820|NCT03583814|Behavioral|CASE Program|Controlling Asthma in Schools Effectively (CASE) provides school-based education and environmental assessments. This program takes place over the course of about 4 weeks and involves in-school asthma education for school aged children, after-school education sessions for their parents, asthma care training for school staff, and an evaluation of asthma triggers in the school.
76821|NCT03583814|Behavioral|HARP Program|Home Asthma Response Program (HARP) is a home-visiting program consisting of 3 home visits (over about 6 weeks). HARP provides individualized asthma education, home-based environmental assessment, and strategies and supplies for controlling environmental asthma triggers.
76822|NCT03583801|Other|Olfactory aromatherapy|2 drops of the essential oil choosed by the patient are applied on a compress placed next to his head from his arrival in the recovery room to his leaving from the operating theatre. The method of administration is the respiratory tract..
76823|NCT03583801|Other|without aromatherapy|no intervention
76824|NCT03583788|Behavioral|Hypnotherapy|The intervention consisted of hypnotherapy given as five one-hour sessions over 5 weeks as individual therapy instead of motivational interviewing.
76825|NCT03583788|Other|Motivational Interviewing|The intervention consisted of Motivational Interviewing given as five one-hour sessions over 5 weeks as individual therapy instead of hypnotherapy.
76826|NCT03583775|Other|Cardiovascular Magnetic Resonance Imaging|Cardiovascular Magnetic Resonance Imaging or MRI exam from children's with congenital heart disease
76827|NCT03583762|Diagnostic Test|Mass spectrometry|Molecular diagnostic test for bacterial identification from bacterial colony
76828|NCT03583762|Diagnostic Test|Microarray assay|Bacterial identification by Microarray assay from positive blood culture and confirmed by Mass spectrometry technique from bacterial colony. Adjusted antibiotic therapy according to AST Re-evaluation after treatment
76829|NCT03583749|Drug|Subcutaneous (SC) route for antibiotic treatment|Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
76830|NCT03583749|Drug|Intravenous (IV) route for antibiotic treatment|Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
76831|NCT03583736|Behavioral|Virtual visit|Virtual visit with oncologist following uterine cancer diagnosis prior to scheduled office visit.
76832|NCT03583736|Behavioral|Office visit|Scheduled office visit with oncologist following uterine cancer diagnosis.
76833|NCT03583723|Radiation|Radiotherapy Group|Patients will be immobilized with customized devices. Either four-dimensional CT or slow CT images using a multislice CT scanner will be acquired to evaluate internal target motion. Initially, gross tumor volume (GTV) will be determined in the maximum intensity projection on the initial size of the tumor and involved lymph nodal sites defined as PET-positive nodes and/or a node diameter greater than 1 cm, clinical target volume (CTV) will be defined as equal to the GTV plus node-positive stations and hilar stations, and planning target volume (PTV) will be created equal to the CTV plus a 0.5-cm safety margin. Treatment will be performed with a linear accelerator in a photon regimen, with a 6-to 15-megavolt (MV) nominal energy and three-dimensional (3D) conformal technique.
76834|NCT03583710|Drug|Cisplatin|Given IV
76835|NCT03583710|Drug|Etoposide|Given IV
76836|NCT03583710|Drug|Mitotane|Given PO
76837|NCT03583710|Procedure|Quality-of-Life Assessment|Ancillary studies
76838|NCT03583697|Drug|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily, Subject to adjustment per protocol
76839|NCT03583697|Drug|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily, Subject to adjustment per protocol
76840|NCT03583684|Behavioral|Pivotal Response Treatment Program (PRT-P)|The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.
76841|NCT03583658|Drug|ambroxol BIH1526|Pharmaceutical form: lozenges Route of administration: oromucosal
76842|NCT03583658|Drug|placebo|Pharmaceutical form: lozenges Route of administration: oromucosal
76843|NCT03583645|Behavioral|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
76844|NCT03583645|Other|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
76845|NCT03583632|Other|visual acuity testing|testing of visual ycuity by ETDRS charts
76846|NCT03583632|Device|optical coherence tomography|optical coherence tomography generates sectional slides of the retinal tomography with light
76847|NCT03583619|Radiation|APBI|Patients receive radiation to the breast tumor bed to a total dose of 40Gy/10fx/2wks, using intensity-modulated radiation therapy technique.
76848|NCT03583619|Radiation|WBI|Patients receive radiation to the whole breast to a total dose of 43.5Gy/15fx/3wks, using intensity-modulated radiation therapy technique.
77199|NCT03580772|Device|Attune TKR|Attune® TKR (Depuy synthes)
76852|NCT03583593|Dietary Supplement|DIAMEL|Diamel is administered 6 capsules a day divided into three doses that are ingested before each meal.
76853|NCT03583593|Dietary Supplement|Placebo|Placebo is administered 6 capsules a day divided into three doses that are ingested before each meal.
76854|NCT03583580|Radiation|Accelerated Partial Breast Irradiation|Patients are irradiated to the region of tumour bed using intensity modulated radiation therapy (IMRT)
76855|NCT03583567|Drug|Chlorpheniramine and ranitidine|Patient will receive intravenous chlorpheniramine and ranitidine prior to protamine.
76856|NCT03583567|Drug|0.9% Normal Saline|Patient will receive normal saline as placebo.
76857|NCT03583554|Drug|AV-101 720 mg|Single dose of 2 360 mg AV-101 oral capsules + 2 placebo oral capsules
76858|NCT03583554|Drug|Placebo|Single dose of 4 placebo oral capsules
76859|NCT03583554|Drug|AV-101 1440 mg|Single dose of 4 360 mg AV-101 oral capsules
76860|NCT03583541|Behavioral|HIV Risk Reduction|This is an intervention comprised of 4 sessions provided twice per week for 2 weeks of an evidence-based, HIV/STI risk reduction intervention.
76861|NCT03583541|Behavioral|Financial Literacy|This evidence-based Financial Education Core Curriculum addresses the importance of savings, banking services, budgeting debt management. Undarga adaptation for FSWs included shortening and simplifying sessions while retaining core elements; adding weekly check-ins due to safety concerns FSWs share related to intervention participation, and safety planning as needed. We will further adapt sessions in months 1-6 to assure language and illustrative examples are culturally consonant, and to infuse BE principles consistent with HIVRR. During sessions 1 & 2 we will include information on delay discounting, for example, learning to understand the tendency to prefer small immediate rewards over larger available at a later time; sessions 3 & 4 will include details on economic utility; sessions 5 will contain information on salience (e.g. understanding occasions when women may minimize triggers to unsafe sex); and session 6 will address loss aversion.
76862|NCT03583541|Behavioral|Mentorship|Mentorship. Mentorship to bridge the transition from FL and savings to a vocational change is a critical component of this intervention. These sessions are intended to support the transition -equipped with financial literacy and savings -- to vocational, educational, employment or small business development training using matched savings. The mentorship sessions are adapted from the pilot study and integrate components (such as referral and linkage, coaching, exchange visits to model farmers) from income generating activities provided by our collaborating partner, RTY. All sessions include check-in and individual attention. The first 4 sessions focus on identifying options for vocational, educational, employment or business development training. The second 4 sessions include invited experts in identified areas of interest by group members for more intensive time and attention to individualized needs to make the transition.
76863|NCT03583541|Behavioral|Matched savings individual development account|A matched savings individual development account (hereafter IDA) is a savings account held at a local bank whereby deposits made by the woman are matched by the intervention to encourage savings and investment in skills and asset development. The accounts introduce women to financial management skills, introduce them to formal financial institutions, and by matching their deposits, incentivize women to save small amounts. Each woman will receive an IDA held in her own name. Women will be allowed and indeed encouraged to contribute up to 50,000 shillings (~15 USD) per month towards their IDAs. The maximum amount of women's contribution to be matched will be an equivalent of US$15 per month for 10 months. During the intervention, monthly account statements will be generated for women to note their accumulated savings. During the intervention, women will have direct access to both their personal savings deposited in the accounts and the match provided by the study.
76864|NCT03583528|Diagnostic Test|68Ga-DOTATOC PET/CT|"Blood pressure, heart rate, and oxygen saturation levels will be recorded prior to the injection and at 5 - 15 minutes after injection.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. After this uptake phase, the blood pressure, heart rate, and oxygen saturation levels will be recorded again. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
76865|NCT03583528|Diagnostic Test|18F-FDG PET/CT|"18F-FDG PET/CT For 18F-FDG as fasting period of 6 hours is required before the scan.~Each study subject will have an intravenous catheter inserted. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site.~The subject will rest in a comfortable chair for 60 minutes. The subjects will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract.~Subjects are positioned supine, arms down, and centered on the scanner bed and the PET/CT images will be acquired."
76866|NCT03583515|Behavioral|Alcohol-Specific Personalized Normative Feedback|Participants will receive personalized normative feedback about drinking.
76867|NCT03583515|Behavioral|Social Media Personalized Normative Feedback|Participants will receive personalized normative feedback about social media use.
76868|NCT03583502|Dietary Supplement|krill oil and fish oil supplement|Administration of 2 gelatin soft capsules per day of a combined krill and fish oil supplement, providing 250 mg/day of DHA and 70 mg/day of EPA, for overall 30 days.
76869|NCT03583489|Drug|APD421|10 mg IV
76870|NCT03583489|Drug|Placebo|IV
76871|NCT03583489|Drug|Ondansetron|4 mg IV
76872|NCT03583476|Drug|Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole|Triple or quadruple therapy consist of Proton pump inhibitor,clarithromycin,amoxicillin or metronidazole.
76873|NCT03583450|Device|Perioperative virtual reality headset with mobile app|Perioperative virtual reality headset with mobile app (Samsung Gear VR headset, ChariotVR software)
76874|NCT03583437|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
76875|NCT03583424|Drug|Carmustine|Given IV
76876|NCT03583424|Drug|Cytarabine|Given IV
76877|NCT03583424|Drug|Etoposide|Given IV
76881|NCT03583411|Other|Epidemiological data collection|To profile each subject enrolled in the study, anamnesis and different personal, clinical, procedural, pharmacological and follow up related variables will be collected. Data collection, maintenance and analysis will be performed using a database that will be developed, managed and updated by study promoter, in accordance with Good Clinical Practice (GCP)
76882|NCT03583398|Procedure|transcatheter aortic valve implantation, surgical aortic valve replacement|Transcatheter aortic valve implantation using transaortic and transfemoral access and surgical aortic valve replacement.
76883|NCT03583385|Drug|Glucophage XR (Test drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
76884|NCT03583385|Drug|Glucophage XR (Comparator drug)|Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
76885|NCT03583372|Drug|Vibegron|Single daily dose 75mg
76886|NCT03583372|Drug|placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
76887|NCT03583372|Drug|Tolterodine Tartrate ER|active comparator
76888|NCT03583359|Device|Radiesse (+)|"Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl).~Mode of application: intradermal and/or supraperiosteal injection in the jaw Region. Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline during the initial injection and at the optional Week 48 re-treatment, and 1.5cc per jawline during the optional touch-up."
76889|NCT03583346|Drug|M6495|Participants will receive escalated dose of M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
76890|NCT03583346|Drug|Placebo|Participants will receive placebo matched to M6495 bi-weekly on Day 1, 15 and 29 in cohort 1 to 3 and weekly on Day 1, 8, 15, 22, 29 and 36 in cohort 4.
76891|NCT03583333|Drug|IMI/REL FDC|500 mg Imipenem, 500 mg Cilastatin and 250 mg Relebactam powder FDC provided in a single vial
76892|NCT03583333|Drug|PIP/TAZ FDC|4000 mg Piperacillin and 500 mg Tazobactam powder FDC provided in a single vial
76893|NCT03583333|Drug|Linezolid|Open-label 600 mg Linezolid
76894|NCT03583320|Diagnostic Test|Cardiac CT angiogram|To the best of the author's knowledge this study will provide the first prospective and randomised data pertaining to hospital length of stay as a primary outcome in the use of CTCA on this acute chest pain cohort (with an intermediate observational zone category) on initial high sensitivity-cardiac troponin (hs-cTn) results presenting to the emergency department in a tertiary care hospital.
76895|NCT03583307|Drug|Sirolimus|Sirolimus was initiated at a dosage of 0.8 mg/m2 administered twice daily. Subsequently, the sirolimus dosage was adjusted monthly to achieve trough levels between 10 and 15 ng/mL.
76896|NCT03583294|Other|MRI pelvic|Pelvic MRI
76897|NCT03583281|Dietary Supplement|Capsules containing flax oil|Capsules containing flax oil to provide 4 grams ALA per day for 4 weeks
76898|NCT03583281|Dietary Supplement|Capsules containing DHA-enriched fish oil|Capsules containing fish oil to provide 4 grams DHA per day and 0.8 grams EPA per day for 4 weeks
76899|NCT03583268|Other|Exercise|The intervention will be the different high intensity sessions. Time spent in hypoglycemia and glucose variability will be compared as follows: 70% vs. moderate, 80% vs. moderate, and 90% vs. moderate to see if high intensity is protective against hypoglycemia and provides lower glucose variability levels.
76900|NCT03583255|Drug|Dexamethasone|Given PO
76901|NCT03583255|Behavioral|Exercise Intervention|Complete resistance training and moderate intensity walking
76902|NCT03583255|Other|Placebo|Given PO
76903|NCT03583242|Drug|Antiangiogenic Agents|3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
76904|NCT03583242|Drug|Corticosteroid|1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
76905|NCT03583229|Drug|Aspirin 75mg|7 days treatment with 75 mg aspirin daily.
76906|NCT03583229|Other|Extracorporeal photopheresis|4 x ECP treatments in 60 days.
76907|NCT03583216|Diagnostic Test|Diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
76908|NCT03583216|Diagnostic Test|Non-diabetic pregnancy|Blood samples will be drawn before delivery to evaluate Factor XII level.
76909|NCT03583203|Device|personalized information about lung damage|Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
76910|NCT03583190|Other|Cervical-cranial dry needling|Segmental needling of the neck and needling in the patient's headache distribution. Peripherally sensitized areas of the neck may also be dry needled based on the findings of the clinical evaluation.
76911|NCT03583190|Other|Orthopedic manual therapy|Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.
76912|NCT03583190|Other|Thoracic Manipulation|Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
76913|NCT03583190|Other|Exercise|Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
76914|NCT03583190|Other|Patient Education|Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
76915|NCT03583177|Diagnostic Test|No intervention|No intervention
76916|NCT03583164|Drug|F901318|30mg tablets with a maximum daily dose of 300mg with dose adjustments according to plasma levels of F901318 and concomitant treatment with CYP inducers or inhibitors
77075|NCT03581877|Drug|Alteplase|As stated before, low dose r-tpa will be administered through a peripheral vein for PLST.
77233|NCT03580473|Drug|Vigadexa®|opthalmic solution, 4 times a day
76917|NCT03583151|Biological|Amniotic fluid injection|Amniotic fluid contains various proteins that support cell proliferation, movement and differentiation. Amniotic fluid also includes collagen substrates, growth factors, amino acids, polyamines, lipids, carbohydrates, cytokines, extracellular matrix molecules like hyaluronic acid and fibronectin, cells and other chemical compounds that are needed for tissue protection and repair.
76918|NCT03583151|Biological|Steroid injection|Solu-medrol
76919|NCT03583138|Drug|buprenorphine|To provide buprenorphine for 12 months for those who are interested in receiving it.
76920|NCT03583125|Drug|EOC317|tablet(s) PO
76921|NCT03583112|Drug|Dapoxetine Hydrochloride Tablet|oral one dapoxetine hydrochloride tablet before MRI scan
76922|NCT03583112|Drug|Placebo Tablet|oral one placebo tablet before MRI scan.
76923|NCT03583099|Other|COPD plus CAPTURE education and patient-level information|Basic COPD Education plus CAPTURE education and patient-level CAPTURE information will be provided to all practice personnel randomized to the 'CAPTURE + COPD Education' arm.
76924|NCT03583099|Other|COPD Education Only|Practice clinicians will receive basic COPD education only. Patient-level CAPTURE information will not be provided.
76925|NCT03583086|Drug|VEGFR/PDGFR Dual Kinase Inhibitor X-82|Given by mouth
76926|NCT03583086|Biological|Nivolumab|Given by IV
76927|NCT03583073|Behavioral|Enhanced Referral/Linkage to Care|"The JJ worker reviews with the family psychoeducation material about the role of mental health care in emotional/behavioral problems. The JJ intake worker will contact the CSC program directly with the family for a warm hand-off. The CSC worker will speak with the parent and arrange for an intake evaluation. For families already receiving treatment, the CSC referral will be for consultation. Via phone, the CSC clinician will use a motivational interviewing style to encourage families to attend the appointment. Three and seven days after referral, the JJ worker will text the caregiver to see if the CSC appointment was kept. If not, the JJ worker will text the parent the CSC phone number and also ask permission to contact the CSC to assist the family in setting up another appointment."
76928|NCT03583073|Behavioral|Standard Care|Referral to the Coordinated Specialty Care (CSC) clinic
76929|NCT03583060|Behavioral|Mindful Awareness in body-oriented therapy|teaches interoceptive awareness skills for self care
76930|NCT03583034|Procedure|Holmium laser enucleation of the prostate (HoLEP)|Surgery for benign prostatic hyperplasia
76931|NCT03583021|Drug|Sugammadex Injectable Product|Sugammadex of 3 mg/kg is injected.
76932|NCT03583021|Drug|Neostigmine Injectable Product|Neostigmine of 50 ug/kg and Glycopyrrolate of 10 ug/kg are injected.
76933|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Academic Detailing|One hour online web-based academic detailing session to develop an anticoagulant (AC) learning plan.
76934|NCT03583008|Behavioral|Anticoagulation (AC) Intervention--Prescribing Practices|Education and support related to anticoagulant prescribing practices.
76935|NCT03582995|Procedure|Flap Surgery for root coverage with Alloderm and xenograft|A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage
76936|NCT03582995|Procedure|Tunnel Surgery for root coverage with Alloderm and xenograft|A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
76937|NCT03582982|Behavioral|Eccentric overload exercise|12 weeks of 2x per week of the following eccentric exercises: squat, shoulder press, row, and bicep curl.
76938|NCT03582969|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
76939|NCT03582969|Other|Placebo|Placebo capsules
76940|NCT03582956|Procedure|Euglycemic hyperinsulinemic clamp with tracer enhancement|To characterize the impact of adiposity on metabolism during puberty, adolescents will undergo the euglycemic hyperinsulinemic clamp study with tracer enhancement.
76941|NCT03582956|Procedure|Euglycemic hyperinsulinemic clamp with tracer enhancement|A comparison control group of 36 lean young adults with T1D will also be enrolled, since they will be unaffected by the adverse metabolic effects of puberty or obesity.
76942|NCT03582943|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.
76943|NCT03582943|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.
76944|NCT03582943|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
76945|NCT03582930|Combination Product|Infasurf Aero|Aerosolization of Infasurf administered to premature babies suffering from RDS. Successful administration of Infasurf by aerosolization will provide two important benefits for patients. (1) endotracheal intubation may be able to be avoided in some patients, and (2) the adverse events at instillation due to filling the airway with liquid and interrupting breathing may be diminished or abolished.
76946|NCT03582917|Drug|Alphacalcidol|Alphacalcidol 0,5mg tablet
76947|NCT03582904|Procedure|tDCS|real or sham tDCS delivered to primary motor cortex
76950|NCT03582878|Drug|Sirolimus Oral Product|Oral form of sirolimus, daily dosing to achieve target trough levels between 5-10ng/ml since 1.day of transplantation
76951|NCT03582878|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil dosing 1g before transplantation and 1g bid afterwards
76952|NCT03582865|Drug|Tamoxifen 20 mg|Tamoxifen 20 mg is a selective estrogen receptor modulator
76953|NCT03582852|Procedure|Surgical treatment of genital prolapse|Laparoscopy performed according to the usual technique of the participating center with pneumoperitoneum between 12 and 15 mmHg. Placement of the 5 mm trocar operator left and right iliac fossa and 5 mm pubic addition.
76954|NCT03582839|Behavioral|PROTECT+|The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
76955|NCT03582826|Behavioral|Nutritional counselling|Behavioral nutritional counselling delivered via the Internet.
76956|NCT03582826|Behavioral|Stress-reduction counseling|The psycho-behavioral intervention includes administering questionnaires and monthly maintenance psychological support delivered via the Internet.
76957|NCT03582813|Behavioral|Self-directed care|Traditional and non-traditional behavioral health services are chosen from within and outside the public mental health system
76958|NCT03582813|Behavioral|Services as usual|Traditional behavioral health services are chosen from along those delivered at the patient's community mental health agency
76959|NCT03582800|Drug|STS|"M0-M6 (run-in phase): medical care and follow-up as usual~M6-M12 (STS phase):~Patients with iPPSD2 will be treated with subcutaneous infusion using a portable pump.~Patients with dermatomyositis or systemic sclerosis will be treated with repeated injections every two weeks.~Patients will receive a maximal total number of 11 STS injections. M12: final visit (V5): clinical evaluation, photograph and CT scan of the treated lesion, pain and quality of life evaluation."
76960|NCT03582787|Device|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
76961|NCT03582787|Device|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
76962|NCT03582774|Drug|68Ga-PSMA-11|If 68Ga-PSMA-11 PET/CT scan detects PSMA-positive lesions in the pelvis: SRT will be performed per discretion of the treating radiation oncologist. SRT can be performed as routinely planned in accordance with the initial general treatment plan. SRT can also be performed with adapted/extended target volumes to include all pelvic PSMA-positive lesions within the radiation fields. SRT also may be performed with focal dose escalation on the PSMA-positive lesions if feasible. If 68Ga-PSMA-11 PET/CT scan detects PSMA-positive lesions outside the pelvis: treatment management will be performed as per discretion of the treating radiation oncologist. However, the patient will not be included in analysis of the primary endpoint. We assume that approximately 13% of subjects randomized to Arm 2 will be found to be ineligible for SRT and will not be included for further analysis.
76963|NCT03582761|Biological|EV71 vaccine|EV71 vaccine of 320U /0.5ml will be given to 40000 children aged 6-35 months old on day0,28
76964|NCT03582748|Procedure|sleeve gastrectomy|removal of most of stomach as a bariatric surgical procedure
76965|NCT03582748|Procedure|No sleeve gastrectomy|Non-receipt of sleeve gastrectomy procedure
76966|NCT03582735|Other|Nerve gliding exercise|A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
76967|NCT03582722|Drug|Orlistat|One-month supply of orlistat capsules (60mg) to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
76968|NCT03582722|Drug|Placebo capsule|One-month supply of placebo capsules to be taken up to 3x daily with meals containing fat, daily multivitamins, and instructions for dietary modification and exercise for six months.
76969|NCT03582696|Behavioral|CHANGE Study|The CHANGE strategy is designed to improve the dissemination and implementation of CVD EBIs by strengthening clinical-community linkages
76970|NCT03582683|Behavioral|Chronic Pain Self-Management Program (CPSMP)|Stanford University's Chronic Pain Self-Management Program (CPSMP) was developed by Sandra LeFort in 1996 and based on Stanford's Arthritis Self-Management Program and the Chronic Disease Self-Management Program. The 6-week community-delivered workshop consists of 2.5-hour weekly sessions for people with a primary or secondary diagnosis of Chronic Pain.
76971|NCT03582670|Behavioral|Strategy Training|Participants will attend four strategy training sessions total. In sessions 1 and 2, in addition to teaching about event- and time-based tasks, the trainer teaches the participant specific strategies for each type of task (implementation intentions for event-based and strategic clock-checking for time-based). In sessions 3 and 4, the trainer tells the participant s/he will be practicing both types of tasks in the training games and can support the participant's strategy use if needed. Feedback on accuracy and strategy use are provided after each training game. At the end of each session after completing the training games, the trainer and participant discuss how the strategies can be applied to the participant's real-life prospective memory goals, and the trainer helps the participant develop written action plans to do so. Plans are reviewed (and modified if necessary) at each session.
76972|NCT03582670|Behavioral|Process Training|Participants will attend four process training sessions in this group. In sessions 1 and 2, the trainer teaches the participant about event- and time-based prospective memory tasks, respectively. In sessions 3 and 4, the trainer simply tells the participant that s/he will be practicing both types of tasks in the training games. In all sessions, the participant completes the training games with no strategy instruction from the trainer. Feedback on accuracy is provided after each training game. At the end of each session after completing both training games, the trainer reminds the participant of his/her real-life prospective memory goals, provides a handout that lists the goals, and instructs the participant to try to complete them as intended. Of note, even this minimal level of discussion of real-life cognitive tasks is not typical of process training interventions, but we include it to control for that which is occurring in the strategy training group.
76973|NCT03582670|Behavioral|Control Group|Participants in this group do not attend any sessions during the time the other groups are participating in the Strategy or Process Training
76974|NCT03582657|Device|dental implant (KONTACT N)|Implant-supported prosthetic restoration
77076|NCT03581877|Device|EKOS|As stated before, the EKos device will be used for ultrasound assisted catheter directed thrombolysis or ACDT, same dose t-tpa will administered through the pulmonary catheter. It will be given at a fixed dose over 24 hours.
77441|NCT03579069|Other|Ductus venosus Doppler|Ductus venosus Doppler
76975|NCT03582644|Other|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
76976|NCT03582631|Procedure|Emergency abdominal surgery|Emergency surgery for high-risk abdominal pathology using a protocol for optimized perioperative care
76977|NCT03582618|Drug|Sorafenib|Sorafenib will be administered orally at a starting dose of 400mg BID daily and the necessity of dose reduction will be assessed during sorafenib tolerability assessment period
76978|NCT03582618|Drug|CVM-1118|CVM-1118 will be administered orally at 150 mg BID or 200 mg BID daily and combined with the tolerable dose of sorafenib for a 28-day cycle
76979|NCT03582605|Drug|Amoxicillin|see previous descriptions
76980|NCT03582605|Drug|Placebo oral capsule|see previous descriptions
76981|NCT03582592|Behavioral|Fluid Distribution Timetable|It is a scheduled distribution of pre-determined amounts of fluid intake on a daily basis depicted via a 5x6 table. The timetable includes three major columns. The first column has six timepoints of a day with a four-hour interval. The second column, which was further divided into four sub-columns, reflects the percentage of fluid allotment for food, activities, medication, and thirst encounters. The percentage of fluid allocation was computed based on the patient's prescribed fluid restriction, usual time of food intakes in a day, usual level of activity, time of medication intake, and common time they encounter thirst in a day. Lastly, the third column indicates the converted percentages of fluid allotment in milliliters.
76982|NCT03582579|Behavioral|Training in Virtual Reality|Action Video Game Based Training in Virtual Reality
76983|NCT03582579|Behavioral|Training on a computer screen|Action Video Game Based Training on a computer screen
76984|NCT03582566|Behavioral|Phonological Awareness|Earobics training
76985|NCT03582566|Behavioral|Working Memory|Cogmed training
76986|NCT03582566|Behavioral|Phonological Awareness + Working Memory|Earobics + Cogmed training
76987|NCT03582566|Behavioral|Active Control|Spashmath
76988|NCT03582553|Dietary Supplement|Naringenin|An extract of Citrus Sinensis containing naringenin and its precursor naringin
76989|NCT03582553|Other|Placebo|Cellulose
76990|NCT03582540|Procedure|Double-guidewire cannulation technique|With the DGT, a guidewire is first inserted deep into the PD. The cannulation device is then withdrawn, reloaded with a second guidewire, and reinserted through the working channel of the endoscope to cannulate the common bile duct.
76991|NCT03582527|Other|all study participants|patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
76992|NCT03582514|Radiation|Preoperative brain irradiation (single fraction)|Dose and volume escalation of preoperative single fraction stereotactic radiotherapy.
76993|NCT03582501|Other|Lower body negative pressure|Simulated hypovolemia by applied suction to lower extremities to cause venous pooling.
76994|NCT03582488|Drug|18F-Flortaucipir|Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
76995|NCT03582475|Drug|Carboplatin|Given IV
76996|NCT03582475|Drug|Cisplatin|Given IV
76997|NCT03582475|Drug|Docetaxel|Given IV
76998|NCT03582475|Drug|Etoposide|Given IV
76999|NCT03582475|Biological|Pembrolizumab|Given IV
77000|NCT03582462|Drug|IONIS FXI-LRx|Ascending single and multiple doses of IONIS FXI-LRx by subcutaneous (SC) injection
77001|NCT03582462|Drug|Placebo|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
77002|NCT03582436|Procedure|Kidney transplantation|"For the patients with the kidney transplantation, these parameters will be analysis:~Transcriptomics analysis Characteristics of anti HLA DSA analysis Non-HLA antibodies analysis Omics blood analysis Urine chemokines analysis"
77003|NCT03582423|Other|electro-acupuncture|Eight acupoints are chosen: he gu (LI4), nei guan (PC6), qu chi (LI12), ba xie (EX-UE9), zu san li (ST36), san yin jiao (SP6), tai chung (LV3) and ba feng (EX-LE10). The use of ba xie (EX-UE9) and ba feng (EX-LE10) will be optional if skin lesions of hands and feet occurs due to Capecitabine (Xeloda).Disposable acupuncture needles will be inserted at a depth of 10-25mm into the points. We will deliver electrical stimulation with continuous waves at 2 Hz, at an intensity of each patient's minimum sensation of stimulation through the electrical acupuncture stimulation instrument to the points. The needles will be retained in position for 25 minutes.
77004|NCT03582410|Procedure|laparoscopic sacral colpopexy with absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
77005|NCT03582410|Procedure|laparoscopic sacral colpopexy with non absorbable suture|laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
77006|NCT03582397|Device|Virtual Reality Mirror Therapy|Virtual reality mirror therapy (WiseMind) developed by Realiteer and delivered via Oculus Rift virtual reality platform.
77007|NCT03582384|Drug|Tocofersolan|After baseline labs are obtained, therapy with tocofersolan will be initiated at an initial dose of 17 mg/kg of d-alpha-tocopherol in the form of tocofersolan (0.34 ml/kg/day) and titrated based on blood levels.
77008|NCT03582371|Procedure|Stand-Up Paddle Rehabilitation|Patients in the Aqua SUP group will benefit from a 1 hour Aqua SUP session, twice a week, for 8 weeks in a therapeutic pool.
77009|NCT03582371|Procedure|Physiotherapy Rehabilitation|Patients in the control group will receive a conventional physiotherapy session of 1 hour, twice a week, for 8 weeks.
77010|NCT03582358|Other|Food weighing|Quantification of food intake over three consecutive days (D5, D6 and D7 then D26, D27 and D28) by weighing the food served and the leftovers at and after mealtimes.
77077|NCT03581851|Device|Simulated Altitude: (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
77078|NCT03581851|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
77079|NCT03581838|Behavioral|Observed eating session|Eating a Jimmy Johns turkey or vegetarian sandwich
77080|NCT03581812|Dietary Supplement|Intervention snack 1|To be eaten instead of regular snacks twice a day for 4 weeks.
135434|NCT03130205|Radiation|Computed Tomography|Computed Tomography
77011|NCT03582345|Procedure|EEG/fMRI|"All the patients recruited will undergo to the following interventions:~1. Presurgical assesment protocol of the recruited patients (RU1 and RU2) that will includes: (a) detailed medical and epilepsy patients' history; (b) neurologic evaluation; (c) structural 3 Tesla MRI; (d) prolonged video-EEG monitoring including one-overnight EEG recording; (e) neuropsychological evaluation including quality of life evaluation. 2. EEG-fMRI coregistration: All subjects will undergo to a Video-EEG/fMRI study. This protocol will include a 32-channels EEG recorded simultaneously to fMRI data acquisition (3T scanner, Philips). This phase will be articulated in two steps: (i) acquisition of the EEG-fMRI data; (ii) fMRI data analysis (conventional and DCM analysis). RU1 will be charged for both steps. 3. Surgical resection of the epileptic foci and/or intracranial electrode recording (icEEG). The DRE patients in whom an intracranial recording will be considered unnecessary, will be operated at the RU2."
77012|NCT03582332|Drug|Indomethacin SR, 75 Mg Oral Capsule, Extended Release|Indomethacin SR, 75 Mg Oral Capsule, Extended Release orally twice daily
77013|NCT03582332|Drug|Indomethacin 25 Mg Oral Capsule|Indomethacin 25 Mg Oral Capsule, 2 capsule orally twice daily
77014|NCT03582332|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg once daily orally
77015|NCT03582332|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg once daily orally
77016|NCT03582319|Other|Biodentine|Biodentine is mainly composed of tricalcium silicate, calcium carbonate and zirconium oxides while the liquid contains calcium chloride as the setting accelerator and water reducing agent
77017|NCT03582319|Other|Formocresol|Formocresol is a devitalizing and fixing agent which was introduced to dentistry since 1904 with full concentration of Buckley's formula (19% formaldehyde, 35 % cresol, and 15 % glycerin in distilled water). A five times diluted formula of Buckley's formocresol was used in this study.
77018|NCT03582306|Behavioral|High chlorophyll diet - intervention 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
77019|NCT03582306|Behavioral|High chlorophyll diet - control 1st|Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
77020|NCT03582293|Drug|Tranexamic Acid 500Mg Tablet|orally twice daily for 28 days
77021|NCT03582293|Drug|Placebo oral capsule|Oral placebo capsule two times a day for a total of 28 days
77022|NCT03582280|Drug|Amorphous Calcium Carbonate (ACC) - Amor|Amor Powder is composed of Amorphous Calcium Carbonate and is administered oral Amor Inhaled Double Pack is composed of 1% ACC in solution and is administered by inhalation
77023|NCT03582267|Dietary Supplement|Docosahexaenoic Acid (DHA)|Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.
77024|NCT03582254|Radiation|[18F]-FDG PET/MR|"[18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:~prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (PET#1),~after two chemotherapy cycles (PET#2),~at the end of the first-line chemotherapy regimens (PET#3)."
77025|NCT03582228|Behavioral|Virtual Envrionment for Social Communication|"Once the Virtual Envrionment for Social Communication intervention begins, participants will meet online from home for one-hour sessions twice a week (twelve sessions over six weeks).~Weekly sessions will follow a standardized format:~15 minutes- Social support group (guided discussion of experiences related to weekly topic)~20 minutes- Didactic instruction~15 minutes- Role playing~10 minutes- Debriefing and group feedback"
77026|NCT03582215|Drug|Part 1: Sunscreen Product #1 (Cream)|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
77027|NCT03582215|Drug|Part 1: Sunscreen Product #2 (Lotion)|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
77028|NCT03582215|Drug|Part 1: Sunscreen Product #3 (Spray)|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
77029|NCT03582215|Drug|Part 1: Sunscreen Product #4 (Spray)|Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
77030|NCT03582215|Drug|Part 2: Sunscreen Product #1, 2, 3 or 4|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
77031|NCT03582215|Drug|Part 2: Sunscreen Product #5 (Spray)|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
77032|NCT03582215|Drug|Part 2: Sunscreen Product #6 (Spray)|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
77033|NCT03582215|Drug|Part 2: Sunscreen Product #7 (Spray)|Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
77034|NCT03582202|Procedure|Nutritional assessment and therapy|Nutritional screening, nutritional plan, follow-up and instructions on discharge
77035|NCT03582202|Procedure|Standard care|Nutritional handling by nurse
77036|NCT03582189|Other|MRI|Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
77037|NCT03582176|Drug|Lactose Placebo|One capsule by mouth twice per day
77038|NCT03582176|Drug|Ketotifen Fumarate 2mg|2 mg tablets (over-encapsulated into one capsule) by mouth twice per day
77039|NCT03582176|Drug|Ketotifen Fumarate 5mg|5 mg tablets (over-encapsulated into one capsule) by mouth twice per day
77081|NCT03581812|Dietary Supplement|Intervention snack 2|To be eaten instead of regular snacks twice a day for 4 weeks.
77082|NCT03581812|Dietary Supplement|Control snack|To be eaten instead of regular snacks twice a day for 4 weeks.
77040|NCT03582150|Device|Remote Monitoring with Ambulatory Detox|"Each Subject willing to participate will sign an Informed Consent and will receive a Subject Number.~Study staff will assist Subject in setting up the Soberlink Device as well as the Bluetooth enabled blood pressure cuff and Smartphone APP.~Study staff documents Subject's resting and standing blood pressure and pulse to establish a safety range for the study.~Subjects will use the blood pressure cuff and the Soberlink Device four times a day per a set schedule to determine blood pressure and pulse and blood alcohol concentration (BAC). Results will be sent to the Soberlink System for study staff to review.~If the Subject misses a Soberlink test, tests positive for alcohol, or the identity cannot be approved, the staff will be immediately notified by the Soberlink System.~The Subject will be enrolled on a Monday and evaluated by the study physician and return to the site for an evaluation by the study physician and staff on Tuesday, and a final assessment on Thursday."
77041|NCT03582137|Drug|Cannabidiol|Subjects randomized to this arm will receive Cannabidiol Cannabis extract oral solution
77042|NCT03582137|Other|Placebo|Subjects randomized to this arm will receive Placebo
77043|NCT03582124|Procedure|Near-Infrared Fluorescence Imaging|Undergo imaging
77044|NCT03582124|Drug|Panitumumab-IRDye800|Given IV
77045|NCT03582124|Other|Pharmacokinetic Study|Correlative studies
77046|NCT03582124|Procedure|Therapeutic Conventional Surgery|Undergo surgery
77047|NCT03582111|Other|Study of medical records|Study of medical records
77048|NCT03582098|Drug|Idelalisib|Tablets were administered in accordance with the marketing authorization.
77049|NCT03582098|Drug|Rituximab|Tablets were administered in accordance with the marketing authorization.
77050|NCT03582085|Biological|Bacillus Calmette Guerin Vaccine|Experimental
77051|NCT03582085|Biological|Saline Injection|Placebo
77052|NCT03582072|Behavioral|letter from the CMO|informed GPs that: The great majority (80%) of practices in England reduced or stabilised their antibiotic prescribing rates in 2016/17. However, your practice is in the minority that have increased their prescribing by more than 4%.*
77053|NCT03582059|Procedure|High Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of high frequency stimulation.
77054|NCT03582059|Procedure|Burst Frequency Spinal cord stimulation|An electrode will be implanted into the patients back. A defined stimulation patter will be applied. The patient will be randomised to received 7-10 days of burst frequency stimulation.
77055|NCT03582046|Device|Abdominal Perfusion Pressure (APP)|Intra-abdominal Pressure (IAP) recorded every four hours and mean arterial pressure (MAP) adjusted to maintain abdominal perfusion pressure (APP) levels.
77056|NCT03582033|Drug|SEA-BCMA|Intravenous (IV) infusion every 2 weeks (or every 4 weeks if recommended by the Safety Monitoring Committee)
77057|NCT03582020|Dietary Supplement|menu plans|menu plans, recommendations ensuring an optimal nutrient intake according the guidelines of the German Society of Nutrition
77058|NCT03582007|Drug|Murepavadin|Murepavadin + ertapenem
77059|NCT03582007|Drug|One anti-pseudomonal antibiotic|Either meropenem or piperacillin-tazobactam
77060|NCT03581994|Diagnostic Test|DDI Test Report|Test results of simulated patients
77061|NCT03581981|Behavioral|Prolonged Exposure for Primary Care (PE-PC)|Brief version of PE provided in 30 minute sessions in PC
77062|NCT03581981|Behavioral|Treatment as Usual|Veterans assigned to PCMHI-TAU will receive standard PCMHI care for PTSD in PC that does not include any PTSD-specific therapy in PCMHI but may include referral for specialty care (including specialty MH), medication management or general supportive contact while awaiting referral. All PTSD care received during the study will be collected and monitored as TAU.
77063|NCT03581968|Device|Artificial Pancreas|"The system is composed of 3 main components:~Insulin infusion pump to infuse insulin. The pump model used in the study is t:slim, Tandem Diabetes Care.~Continuous glucose monitor (CGM) to continuously measure glucose levels in the interstitial fluid. Glucose levels will be measured by Dexcom G5® CGM.~MAP application (iMAP) that computes insulin infusion based on the glucose values. The application also alarms the user when glucose sensor values are approaching the hypoglycemic or hyperglycemic range. The iMAP runs on an android smartphone.~Every 10 minutes, iMAP retrieves the glucose values from the Dexcom G5 CGM via Bluetooth. The application computes an optimal insulin infusion rate based on i) the current glucose reading, ii) the glucose trend (i.e. how quickly the glucose level is rising or falling) and iii) the open-loop basal rates (study parameters). The insulin recommendations are then sent wirelessly via Bluetooth to the insulin pump."
77064|NCT03581955|Other|Banana Cavendish|240g of fruit plus 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)
77065|NCT03581955|Other|Tomato|"300g of raw tomato (coeur de boeuf) with refined sunflower oil (12g) and 150ml of control drink (Fresubin ® 2kcal fiber neutral flavor)."
77066|NCT03581955|Other|Fresubin ® 2kcal fiber neutral flavor|250 ml Fresubin ® 2kcal fiber neutral flavor
77067|NCT03581942|Drug|Ibrutinib|Dose level 1: Ibrutinib 560 mg daily, Dose level 2: Ibrutinib 840 mg daily, Dose level -1: Ibrutinib 560 mg daily
77068|NCT03581942|Drug|Copanlisib|Copanlisib 60 mg weekly (3w on/1w off), Copanlisib 60 mg weekly (3w on/1w off), Copanlisib 45 mg weekly (3w on/1w off)
77069|NCT03581929|Dietary Supplement|Memormax|Memormax is a food supplement indicated to support cognitive functions thanks to the Melissa officinalis; it also contains lyophilized Royal Jelly, Blueberry extract and Blueberry juice.
77070|NCT03581929|Other|Placebo|Placebo comparator
77071|NCT03581916|Drug|18F-JNJ-64326067|18F-JNJ-64326067 will be administered intravenously between a dose of 185 Megabecquerel (MBq) to 370 MBq.
77072|NCT03581903|Biological|H7N3 pLAIV|Approximately 10^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device
77073|NCT03581903|Biological|H7N9 pIIV|30 micrograms administered by intramuscular (IM) injection
77074|NCT03581890|Other|Socioeconomic position|"Socioeconomic position is the exposure in both study 1 and 2. Four different socioeconomic measures will be tested. The primary socioeconomic position measure is highest attained education the year before surgery (short/medium/long). Secondary measures are:~age- and sex-adjusted available income the year before surgery~Cohabitation status at the year of surgery (living alone/living with a partner) at the year of surgery.~Urbanicity (in four officially, predefined categories)."
77194|NCT03580785|Radiation|panoramic radiography|panoramic radiography
77083|NCT03581799|Other|Oral dispersible tablet|Administration of a 5 mm calcium carbonate based ODT placed in the buccal pouch (children aged 2-5 years) or on the tongue (children aged 6-10 years).
77084|NCT03581786|Biological|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy|TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy
77085|NCT03581786|Drug|Placebos|placebo combine with chemotherapy
77086|NCT03581773|Drug|Folic Acid|5 mg pr day for 12 weeks
77087|NCT03581773|Drug|Placebo Oral Tablet|1 placebo pill pr day for 12 weeks
77088|NCT03581760|Other|Cycling Exercise|Cycling exercise will be performed in the patients once a day.
77089|NCT03581760|Other|Conventional Physiotherapy|Conventional physiotherapy will be performed in the patients twice a day.
77090|NCT03581747|Device|Nevisense|Measurement of electrical impedance
77091|NCT03581734|Biological|Oral Polio Vaccine|OPV is a mixture of live attenuated poliovirus strains of each of the three serotypes, selected by their ability to mimic the immune response following infection with wild polioviruses, but with a significantly reduced incidence of spreading to the central nervous system.
77092|NCT03581734|Biological|Oral Cholera Vaccine|Bivalent, Killed, Whole Cell Oral Cholera Vaccine
77093|NCT03581721|Device|enFlow® IV fluid warmer and from July 2019 Fluido®Compact IV fluid warmer|"The fluid warmer will be set up by an external co-investigator in every patient included in the study. It will be turned on in patients belonging to the warming group, and turned off in the control group"
77094|NCT03581708|Other|lung cancer|If the patient is diagnosed with lung cancer in advanced stage, he/she will be followed up for VTE incidence
77095|NCT03581695|Other|Blood test|Blood test
77096|NCT03581682|Other|Tele-Clinic Visits Using Parent-Acquired Echos|"Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other."
77097|NCT03581669|Device|Cerclage and total hip arthroplasty|acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty
77098|NCT03581656|Device|ChordArt System|The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
77099|NCT03581630|Drug|naltrexone/bupropion|Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.
77100|NCT03581630|Behavioral|Mediterranean Diet|Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
77101|NCT03581617|Diagnostic Test|NK cell analysis|"We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal:~- pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometry"
77102|NCT03581617|Diagnostic Test|Herpesvirus detection|Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCR
77103|NCT03581617|Diagnostic Test|sHLA-G analysis|sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
77104|NCT03581617|Diagnostic Test|HLA-G 14bp INS/DEL typing|Genomic DNA will be genotyped by RealTime PCR
77105|NCT03581617|Diagnostic Test|sHLA-E analysis|sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)
77106|NCT03581604|Diagnostic Test|Allergy work-up|Allergy work-up
77107|NCT03581604|Other|Blood samples and microbiological samples.|Blood samples and microbiological samples
77108|NCT03581591|Biological|Burosumab|recombinant human IgG1 monoclonal antibody to fibroblast growth factor 23)
77109|NCT03581565|Other|zinc polycarboxylate (with the requirements of ISO 9917)|intraoral cementation of single-tooth implant crowns with three different technique, intraoral removal of cement excess upon setting
77110|NCT03581539|Procedure|Transverses Abdominis Plane (TAP) block|TAP block - Participants will get an injection of bupivacaine and exparel (numbing medicine) in the four different locations of your stomach. To be more specific, the injection placed between your oblique muscles in four different locations right after you are asleep and just before the start of surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
77111|NCT03581539|Procedure|Quadratus Lumborum (QL) block|QL block - Participants will get an injection of bupivacaine with exparel (numbing medicine) in two locations in your lower stomach. To be more specific, an injection will take place inside your quadratus lumborum muscle which is slightly deeper than your oblique muscles right after you are asleep and right before surgery. Investigators will use an ultrasound machine (the machine works by taking pictures of internal organs by bouncing sound waves off them and recording the echoes) to find the abdominal muscle layers and find the correct location to inject the numbing medicine between the muscle layers.
77195|NCT03580785|Radiation|teleradiography|teleradiography
77196|NCT03580785|Radiation|intraoral X-rays|intraoral X-rays
77112|NCT03581539|Procedure|Surgeon Infiltration using Exparel|SI group - at the end of the surgery and just prior to you waking up, the surgeon will use a needle to inject the surgical incision site with bupivacaine and exparel (numbing medicine) spreading the medicine evenly as the needle is slowly withdrawn to make sure all layers are evenly filled with the medicine that will numb the area.
77113|NCT03581513|Device|Index of microcirculatory resistance（IMR）|IMR can be used to measure the microcirulatory resistance of coronary artery.It is not clear whether the IMR value could determine the time of PCI for STEMI patients.
77114|NCT03581500|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
77115|NCT03581500|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
77116|NCT03581487|Biological|Durvalumab|Given IV
77117|NCT03581487|Drug|Selumetinib|Given PO
77118|NCT03581487|Biological|Tremelimumab|Given IV
77119|NCT03581474|Device|Bronchoscopic procedure|Single-use flexible bronchoscope aScope 3 Large
77120|NCT03581461|Behavioral|Trauma-Informed Mindfulness-Based Yoga|The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
77121|NCT03581448|Behavioral|Sensory Restoration During Prosthesis Control|Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
77122|NCT03581422|Drug|hCG administration before embryo transfer|Thawed embryo transfer with ovulation triggered by hCG
77123|NCT03581409|Drug|Aspirin|Aspirin protect tablet
77124|NCT03581409|Drug|Prasugrel|Prasugrel tablet
77125|NCT03581409|Drug|Clopidogrel|Clopidogrel 75mg tablet
77126|NCT03581409|Drug|Cilostazol|Cilostazol tablet
77127|NCT03581383|Behavioral|PREP-C|The Psychosocial Readiness Evaluation and Preparation for Hepatitis C Treatment (PREP-C) is an interactive online tool that enables providers to provide a thorough assessment of a patient's psychosocial readiness to begin Hepatitis C treatment, and make a treatment plan to improve treatment readiness.
77128|NCT03581383|Behavioral|Modified ECHO|The heart of the ECHO (Extension for Community Health Outcomes) model is its hub-and-spoke knowledge-sharing networks, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. The key modification is one patient visit in the specialty center resulting in co-management of patients with data sharing.
77129|NCT03581370|Drug|1 hour infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 60 minutes every 8 hours.
77130|NCT03581370|Drug|4 hours infusion|Intravenous administration of ceftolozane-tazobactam (ZERBAXA®) : 2000 mg by infusion for 4 hours every 8 hours
77131|NCT03581357|Behavioral|Online Mindful Meditation|It is hypothesized that participants who are randomized into one of the treatment conditions (OMM or OMM app) will have significantly less anxiety, pain, fatigue, and sleep disturbance than their counterparts in the control condition.
77132|NCT03581344|Diagnostic Test|Repetition of Re-staging|Second clinical and instrumental re-evaluation after 11-12 weeks and then surgery 13-16 weeks after the end of chemoradiotherapy if major or complete response at 7-8 weeks
77133|NCT03581331|Diagnostic Test|orthoptic balance|"Measurement of visual acuity by far: Monocular measurement, right eye, left eye and binocular Measurement of visual acuity closely: Monocular measurement, right eye, left eye and binocular Corneal reflection method or Hirschberg: Analysis of the corneal reflection after fixation of a point of fixation of light from a distance, then from near.~Cover-Test: Study of the restitution movement following the fixation of the fixation point"
77137|NCT03581279|Device|T2Lyme Panel testing|The T2Lyme Panel is an investigational use in vitro diagnostic (IVD) designed to qualitatively detect and identify the major causative agents of Lyme disease (Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, as well as an inclusive Borrelia spp. detection channel) from K2EDTA human whole blood samples.
77138|NCT03581266|Other|Rye/Wheat|Mechanistic study of glucose kinetics after ingestion two kinds of bread
77139|NCT03581253|Other|"Facial disability Index (FDi)"|questionnaires regarding to quality of life
77140|NCT03581253|Other|"Facial Clinimetric Evaluation (FaCE)"|questionnaires regarding to quality of life
77141|NCT03581240|Drug|eflornithine HCl|"In this study subjects without CNS disease will receive oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID~Subjects with CNS disease will receive a dose of 2500 mg/m2/dose BID in order to facilitate crossing into the CNS."
77142|NCT03581227|Other|CAPTURE Tool|CAPTURE Tool: a self administered 5-item questionnaire with peak expiratory flow measurements
77143|NCT03581214|Other|No oxygen|No facemask, room air only
77144|NCT03581214|Other|Oxygen|10Liters/minute oxygen by facemask
77145|NCT03581201|Diagnostic Test|Laboratory measurements|"Laboratory measurements will be collected every week during the Duration of one menstrual cycle and includes the following:~Hormone analysis~Clinical chemistry~Complete blood count~Adipokines~Glucose and HbA1c-levels~Urinary Chemistry"
77146|NCT03581201|Diagnostic Test|Stool samples|For a Duration of one menstrual cycle the study participants will be instructed to collect stool samples every two days. The investigation of the intestinal microbiome will be done by sequencing the 16S rRNA gene.
77147|NCT03581201|Diagnostic Test|Bioimpedance analysis|The Bioimpedance analysis (BIA) is used for the measurement of body composition and will be done at every study visit.
77148|NCT03581188|Behavioral|Self-examination of the skin|Participants will use a dermatoscope device to conduct self-examination of the skin.
77149|NCT03581175|Procedure|Colonoscopy|
77150|NCT03581175|Drug|Bowel cleansing regimen|
77151|NCT03581162|Diagnostic Test|Carotid Ultrasound and venous blood sampling|Carotid ultrasound and blood sampling
77152|NCT03581149|Drug|Sodium Picosulfate/Magnesium Citrate Laxative|● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
77153|NCT03581149|Drug|2L polyethylene glycol/ascorbic acid|"First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet."
77154|NCT03581136|Device|Dose Fractionation|Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 15 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
77155|NCT03581123|Behavioral|Supported-Self Management (SSM)|Provides low back pain sufferers opportunities to develop the capacity and motivation to self-manage their pain in an adaptive manner. This includes psychological/behavioral strategies, mind-body approaches, lifestyle advice, pain education and pain coping.
77156|NCT03581123|Other|Spinal Manipulation Therapy (SMT)|SMT will address the biological and physical aspects of low back pain (e.g. spinal dysfunction) with the intention of restoring maximum movement and functional ability of the spine.
77157|NCT03581123|Combination Product|SMT + SSM|Combination Treatment
77158|NCT03581123|Drug|Standard Medical Care (SMC)|Guideline based medical care informed by the American College of Physicians' guidelines on noninvasive treatment for low back pain.
77159|NCT03581110|Diagnostic Test|computed tomography|noncontrast-enhanced chest computed tomography
77160|NCT03581097|Other|Video Group|Patients in the film group watched the film using a laptop computer equipped with headphones, and Visual Analog Pain Scale (VAS) was repeated after the movie. Video was recorded by the Anaesthesiology department team, in order to explain and show in a detailed way on a model, the sequence of events, which occurs between the arrival of patients in the operating room and the performance of Intra-Venous Regional Anesthesia (IVRA)
77161|NCT03581084|Drug|N-acetylcysteine|Research participants that meet the study inclusion criteria will be admitted to a medical-surgical ward in Moffitt-Long Hospital (UCSF Medical Center) for 6 days and 5 nights and treated with an inhaled mixture of NAC and albuterol four times per day spaced at 4 to 6 hours apart.
77162|NCT03581071|Drug|TS-143|
77163|NCT03581058|Drug|Cannabis|Participants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.
77164|NCT03581032|Device|Active reprogam|Reprogram Changes in AV/PV delays
77165|NCT03581019|Procedure|uterus transplantation|uterus transplantation from deceased donor
77166|NCT03581006|Dietary Supplement|Low-Calorie Mediterranean Diet|Participants in the intervention group will receive 6 months of education and behavioral counseling with self-monitoring to help them adopt a Mediterranean-style, calorie-restricted diet, and engage in physical activity
77167|NCT03581006|Combination Product|Technology based monitoring and behavioral participation|Intervention participants will use smart phones to connect to intervention applications, WebEx, MyNetDiary
77168|NCT03581006|Other|Usual care group|Control group, who will receive no dietary or behavioral intervention during the trial
77169|NCT03580993|Diagnostic Test|Lung Ultrasound|Lung ultrasound and Echocardiography used to derive parameters for prediction of successful SBT.
77170|NCT03580980|Drug|Paracetamol and ketamine|intravenous paracetamol and ketamine followed by ketorolac
77171|NCT03580980|Procedure|Caudal levobupivacaine|an epidural injection of morphine and levobupivacaine through the caudal space
77172|NCT03580980|Drug|Morphine|patient controlled analgesia by morphine
77173|NCT03580967|Drug|Vortioxetine|Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
77174|NCT03580954|Device|Transcranial Magnetic Stimulation|Stimulation or inhibition using TMS will be delivered guided by a neuronavigator system in different brain regions.
77175|NCT03580928|Drug|Venetoclax|Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
77176|NCT03580928|Drug|Obinutuzumab|Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die
77177|NCT03580928|Drug|Acalabrutinib|Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
77178|NCT03580915|Behavioral|Functional Literacy Program|The intervention will be provided twice weekly in 2-hour sessions, over 8 weeks. The 16 intervention sessions will provide the opportunity for participants to learn functional literacy skills to (1) manage an apartment, (2) access community resources, (3) manage finances, (4) access free recreational activities. All sessions will address literacy skills needed to complete basic daily life activities in the home and community environments. Literacy skills will first be learned and practiced within the supported shelter, and then extended to the community.
77179|NCT03580915|Behavioral|Usual Care Management Services|The control group will receive the usual housing services without additional intervention.
77180|NCT03580902|Behavioral|CBT4CBT-Buprenorphine|Computerized, user-driven cognitive-behavioral therapy (CBT) web-based program adapted for use in office based buprenorphine treatment
77181|NCT03580902|Drug|Buprenorphine/naloxone|Standard outpatient buprenorphine maintenance
77182|NCT03580889|Drug|Atropine|Comparison between atropine, glycopyrrolate and Normal Saline
77183|NCT03580889|Drug|Glycopyrrolate|Comparison between glycopyrrolate, atropine and Normal saline
77184|NCT03580889|Drug|Normal Saline Flush, 0.9% Injectable Solution|Comparison between Normal saline, atropine and glycopyrrolate
77185|NCT03580876|Drug|addition of azathioprine|impact of addition of azathioprine after a switch of a second anti-TNF agent
77186|NCT03580876|Drug|Switch to a second anti-TNF drug alone|Switch to a second anti-TNF drug alone without addition of azathioprine
77187|NCT03580850|Other|No intervention in this restrospective study|This study is an obervational study
77188|NCT03580824|Biological|R21 in Matrix- M adjuvant vaccine|R21: Protein particle malaria vaccine candidate in Matrix-M: Saponin based vaccine adjuvant.
77189|NCT03580811|Device|Dental Implant &ADMG|A dental implant will be placed and the buccal soft tissue will be grafted using ADMG .
77190|NCT03580811|Device|Dental implant & ADMG & BDX|Dental Implant will be placed with ADMG that covers the BDX
77191|NCT03580798|Procedure|Delayed graft|8 weeks post-extraction 15 test patients will receive implant placement plus osseous grafting.
77192|NCT03580798|Procedure|Simultaneous graft|At the time of extraction osseous graft will be placed in the socket and implant placed 4 months later.
77193|NCT03580785|Genetic|genetic analysis|saliva is collected for DNA extraction
77200|NCT03580759|Behavioral|PREHAB|After three supervised training sessions, subjects will be asked to participate in a daily exergaming activity tailored to their physical activity capabilities and needs. Subjects will be taught to rate their perceived exertion and monitor their target heart rate using a Fit Bit Charge HR. Daily exercise diaries will be used to monitor subject-perceived progress throughout the intervention period.
77201|NCT03580746|Procedure|Taping and posteromedial release|
77202|NCT03580746|Procedure|Ponseti|
77203|NCT03580733|Drug|caspofungin antifungal therapy|caspofungin
77204|NCT03580733|Other|placebo|placebo
77205|NCT03580720|Other|Inspiratory threshold loading protocol|Subjects will be instrumented with catheters that measure electrical activity of the diaphragm and transdiaphragmatic pressure. Subjects will perform a stepwise inspiratory threshold loading protocol to induce a wide range of diaphragm activity.
77206|NCT03580707|Drug|BRV vs LEV in randomized double blinded, crossover fashion|Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
77207|NCT03580694|Drug|REGN4659|REGN4659 will be administered by intravenous (IV) infusion.
77208|NCT03580694|Drug|Cemiplimab|Cemiplimab will be administered by intravenous (IV) infusion.
77209|NCT03580681|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
77210|NCT03580681|Dietary Supplement|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
77211|NCT03580668|Drug|B/F/TAF|B/F/TAF administered in accordance with the approved product monograph
77212|NCT03580655|Drug|Avapritinib|Avapritinib tablet
77213|NCT03580642|Device|eHealth Technologies|The controls will get a conventional treatment from the acute to the chronic phase of stroke and the cases will get a conventional treatment till the end of the subacute phase. However, in the chronic period they will use the developed STARR App and DSS, as well as commercial wearables.
77214|NCT03580629|Behavioral|Liver Live Donor Champion Program|Even with adequate education of live donation, many liver transplant candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide instrumental support. A Live Donor Champion (LDC) is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed the Liver Live Donor Champion program to provide education and advocacy training to waitlist candidates and their LDCs. The support provided by the LDC bridges a critical link between education and action. Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
77215|NCT03580616|Drug|L-Serine|L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.
77216|NCT03580603|Other|Visualization tool|Visual representation of past microbiological culture data
77217|NCT03580590|Drug|oral Diltiazem|Diltiazem, a calcium channel blocker reduced arteriolar tone and fall in blood pressure
77218|NCT03580590|Drug|IV Tranexamic Acid|Tranexamic acid inhibits fibrinolysis, which reduces blood loss
77219|NCT03580590|Drug|Placebo Oral Tablet|Placebo Oral Tablet
77220|NCT03580577|Device|thromboelastography|thromboelastography will assess all coagulation abnormalities including platelets function in cirrhotic group with venous thromboembolism , and guide us about is there increased thrombosis risk or not, for that a fresh blood sample will be withdrawn from each patient before starting any treatment
77221|NCT03580564|Drug|KL-A167|KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
77222|NCT03580551|Behavioral|Intervention Group|"Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status."
77223|NCT03580551|Behavioral|Waitlist Control Group|"At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment."
77224|NCT03580538|Other|resistive exercise with elastic tube|performed training with elastic tubing for six weeks, twice a week and the load was progressively increased every 15 days.
77225|NCT03580525|Drug|Nicotine saline infusion 0.00mcg/kg/s|saline 0.00mcg/kg/s
77226|NCT03580525|Drug|Nicotine infusion 0.24mcg/kg/s|nicotine 0.24mcg/kg/s
77227|NCT03580525|Drug|Nicotine infusion 0.096mcg/kg/s|nicotine 0.096mcg/kg/s
77228|NCT03580525|Drug|Nicotine infusion 0.048 mcg/kg/s|nicotine 0.048mcg/kg/s
77229|NCT03580525|Drug|Nicotine infusion 0.024mcg/kg/s|nicotine 0.024mcg/kg/s
77230|NCT03580499|Dietary Supplement|Vitamin B6|Given PO
77231|NCT03580486|Other|The squares test|The squares test (ST) originally used in handedness is modified. The ST is a reliable, not time-consuming and easy to administer test for evaluated hand function.
77232|NCT03580473|Drug|SATURNO II association|opthalmic solution, 4 times a day
77234|NCT03580460|Behavioral|Computer delivered smoking cessation counseling|15 to 20 minute computer-delivered interactive smoking cessation counseling
77235|NCT03580447|Dietary Supplement|Citrus extract|Citrus extract
77236|NCT03580447|Dietary Supplement|Placebo|Maltodextrin
77237|NCT03580434|Device|V-STRUT|Minimally invasive implantation of V-STRUT
77238|NCT03580421|Procedure|ambulatory surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
77239|NCT03580421|Procedure|standard surgery|total hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy
77240|NCT03580408|Drug|Nivolumab|240 mg
77241|NCT03580408|Drug|Vinblastin|6mg/m²
77242|NCT03580395|Drug|Apatinib|500mg, day1-21,neoadjuvant therapy
77243|NCT03580395|Drug|paclitaxel|paclitaxel 165mg/m2 day 1
77244|NCT03580395|Drug|cisplatin|cisplatin 40mg, day 1-3
77245|NCT03580382|Drug|Trametinib daily Until PD|1.0 mg daily
77246|NCT03580382|Drug|CDX-3379 (ERBB3 antibody)|15mg/kg IV Q3W
77247|NCT03580369|Biological|Ligelizumab|Liquid in vial
77248|NCT03580369|Biological|Omalizumab|Lyophilized powder for solution in vial
77249|NCT03580369|Other|Placebo|Liquid in vial
77250|NCT03580356|Biological|Ligelizumab|Liquid in vial
77251|NCT03580356|Biological|Omalizumab|Lyophilized powder for solution in vial
77252|NCT03580356|Other|Placebo|Liquid in vial
77253|NCT03580343|Drug|tofacitinib|tofacitinib extended release, 11mg, daily, oral
77254|NCT03580330|Other|mHealth intervention|Individual in the intervention group receive a weekly educational health SMS for the intervention period of 1 year. SMS content covered different health themes providing health information on lifestyle, dietary habits, body weight, smoking, medications, importance of compliance, as well as symptoms and self-management of HTN and diabetes. Community individuals who were diagnosed and were receiving necessary care previous to the investigator's intervention were sent weekly informative health SMS, as well as customized SMSs reminders to follow up on their scheduled medical appointments (eg, to check their HbA1c levels and have their annual foot or eye exams).
77255|NCT03580317|Other|EA+ Carbamazepine|"Acupoints selection: Si-bai(ST2), Xia-guan(ST7), Di-cang(ST4), Quan-liao(SI18), Jia-che(ST6) and A-shi-xue of affected side. He-gu(LI4) and Wai-guan(TE5) of two sides.~Operation:The needles(0.18×25 mm) will be selected to stimulate the local points with shallow row needling according to the distribution of neuropathy branch of trigeminal neuralgia.The needles(0.25×40mm) will be selected to stimulate the distal acupoints. The Xia-guan(ST7) and Quan-liao(SL18) (or Jia-che(ST6)), He-gu(LI4) and Wai-guan(SJ5) acupoints will be received EA treatment by HuaTuo SDZ-ⅡB acupoint neural stimulator. The EA parameter is 2/100 Hz, 60 minutes and the current intensity is comfortable to subjects. Carbamazepine tablets should be took orally, 0.1g each time, thrice daily."
77256|NCT03580317|Other|EA+Placebo|In this group, the selection, positioning and manipulation of acupoints, the frequency, duration and retaining needle time of treatment are same as EA + Carbamazepine Group; placebo, that appearance and specifications are the same as carbamazepine, are cooperated taken of dose 0.1g, thrice daily.
77257|NCT03580317|Other|sham EA+Carbamazepine|"Selection of points and locations: the non-meridional points which are means to the points beside 5-10mm of the real acupoints (avoid the trigger point) in the EA group will be selected and needled with more shallow acupuncture (the depth of needling is about 1-2mm).~The operation of shame EA: The HuaTuo SDZ-ⅡB acupoint neural stimulator with damaged electrode wires will be selected to connect the points next to the Xia-guan(ST7) and Quan-liao (SI18) , He-gu (LI4) and Wai-guan(TE5).The frequency, intensity and retaining time will be same as EA group, The subjects can see the display screen and parameter settings of stimulator, however there is no electricity output in fact.~The dosage and frequency of oral carbamazepine tablets are same as above part."
77258|NCT03580317|Other|sham EA+Placebo|The points selection, positioning and manipulation are same as Shame EA+ Carbamazepine group，placebo are cooperated taken of dose 0.1g, thrice daily.
77259|NCT03580304|Behavioral|Industrial work|Subjects perform simulated industrial work in lab setting. The industrial task exists of a physical component and a cognitive component. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Mental fatigue will be determined by questionnaires and a cognitive stroop task before and after the trial.
77260|NCT03580304|Behavioral|Physical load|The physical load of an industrial task will be simulated during this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
77261|NCT03580304|Behavioral|Cognitive load|The cognitive load of an industrial task will be simulated in this intervention. Physical load is measured by questionnaires and basic physiological measurements (e.g. heart rate). Before and after the trial, mental fatigue will be determined by questionnaires and a cognitive stroop task (10 min)
77262|NCT03580291|Other|Mesenchymal stem cells|The group receive pulse infusion of MSCs once of 2 x 10^6/kg body weight
77263|NCT03580291|Drug|Mycophenolate Mofetil|This group receive oral MMF of 2.0 g / d.
77264|NCT03580291|Other|Placebo of Mesenchymal stem cells|The group receive placebo of Mesenchymal stem cells.
77265|NCT03580291|Drug|Placebo of Mycophenolate Mofetil|The group receive placebo of oral mycophenolate mofetil.
77266|NCT03580278|Biological|ABY-035/AFO2|Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 30 subjects will receive for treatment of their active plaque psoriasis
77267|NCT03580265|Device|laser phototherapy device with low level laser|The wavelength of low level laser is 808nm and the power output of low level laser is 300mW.
77268|NCT03580252|Other|Correlation analyses for the outcomes|No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
77269|NCT03580239|Drug|Everolimus|Everolimus will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
77270|NCT03580239|Drug|Placebo|Placebo will be treated at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days. The patients also receive the best supportive care.
77271|NCT03580226|Other|No intervention|No intervention
77637|NCT03577509|Drug|ABCD|Intravenous infusion of dexamethasone 5mg before ABCD intravenous administration; Single infusion.
77272|NCT03580213|Other|Hand therapy MCPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices.
77273|NCT03580213|Other|Hand therapy PIPJ affected|Prevention of oedema, treatment of scar, splinting to maintain or improve extension, exercises, activity of daily living as exercise. Instructions, demonstration and advices. Possible additional splint and exercises specifically for the PIPJ extension.
77274|NCT03580200|Other|Trigger Point Dry Needling|For the purposes of this study, the term trigger point dry needling will be used to describe deep dry needling of muscle tissue. The goal of trigger point dry needling is to eliminate myofascial trigger points within muscle tissue, thereby reducing pain as well as improving motor control and function (Caramagno et al., 2015; Dommerholt et al., 2006; Shah et al., 2015). Trigger point dry needling utilizes a solid filiform needle and focuses on the penetration of a palpable myofascial trigger point at various depths. The needle is then manipulated within the tissue in an attempt to elicit a localized twitch response. Once the localized twitch response has ended, the needle is removed and another myofascial trigger point is located.
77275|NCT03580187|Drug|Morphine (+)|"We performed a first nebulization of 10 mg (1mL) of morphine diluted in 4 mL of normal saline using a nebulizer with an oxygen flow rate of 8 L / min. The quality of analgesia was assessed by VAS at rest and cough after 10 minutes. If ≤ 4, we concluded to a success. If VAS was still> 4, a second nebulization was performed. After 20 minutes, if VAS still higher than 4 we performed a third nebulization. If pain level was ≤ 4, we concluded to a success. After 30 minutes, if VAS still> 4, we concluded to a failure of morphine nebulization.~The patients were divided into two groups:~morphine (+) group: good response to morphine in nebulization morphine (-) group: failure of morphine in nebulization"
77276|NCT03580174|Other|Goal directed physiotherapy group|Ten children with CP will receive structural, comprehensive activity based, goal directed therapy protocol one hour in a session, 2 times in a week during 8 weeks. GDPT will be a structural protocol and consists of daily life activities as sit to stand and reach, treadmill exercises, balance exercises with bosu-ball, orthotics, home program, following with exercise-diary.
77277|NCT03580174|Other|Routine physiotherapy group|Ten children with CP will RPT applications will consist of unstructured stretching exercises, massage, passive range of motions, muscle strengthening, orthotics etc.) one hour in a session, 2 times in a week during 8 weeks.
77278|NCT03580161|Other|18-F FDG PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
77279|NCT03580161|Other|Ga-68 PSMA PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
77280|NCT03580161|Other|68-Ga Dotatate PET/CT dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
77281|NCT03580161|Other|99mTc Pertechnetate Thyroid dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
77282|NCT03580161|Other|99mTc DMSA(III) Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
77283|NCT03580161|Other|99mTc MAG3 Renal dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
77284|NCT03580161|Other|99mTc MDP Bone dosimetry scans and measurements|Participants will have additional scans and retention measurements for dosimetry alongside their routine diagnostic scans
77285|NCT03580148|Drug|Cortisone|Patients randomized to receive this study intervention will undergo one ultrasound guided 80mg Depo Medrol GHJ injection
77286|NCT03580148|Biological|Bone Marrow Aspirate|Patients randomized to receive this study intervention will have, under sterile conditions and after injection of local anesthetic, 10 mls of bone marrow aspirate taken from the posterior superior iliac spine and injected under ultrasound guidance to the glenohumeral joint
77287|NCT03580135|Drug|Propolis|One and half gram of Standardized Propolis Extract powder (Y.S. Eco Bee Farms Propolis Powder) at 100% was mixed with 1.75 mL of polyethylene glycol (Continental Chemicals, New Delhi, India) to form a thick consistency on a clean dry glass slab with a metal spatula. The paste was carried to the pulp stumps with a metal carrier and then condensed lightly to a thickness of 2 - 3 mm followed by placement of thick mix of GIC to seal the cavity and covered by st.st crown.
77288|NCT03580135|Drug|Mineral Trioxide Aggregate|MTA paste will be prepared as per the manufacturers' instructions to obtain a putty-like consistency. The mixture will be delivered to the pulp stumps and condensed lightly with a moistened sterile cotton pellet to ensure a thickness of 2 to 3 mm. A thick mix of glass ionomer cement (GIC) will applied over the MTA and covered by st.st crown.
77289|NCT03580122|Drug|Arginine Aspartate|Asparten
77290|NCT03580109|Other|Immediate spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
77291|NCT03580109|Other|Late spa treatment|Spa treatment linked education therapeutic in lymphoedema post breast cancer (whirlpool bath with automatic air and water massage cycles, massaging shower/individuals and groups educational sessions)
77292|NCT03580096|Other|Core stability|Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.
77293|NCT03580096|Other|Standard intervention|Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.
77294|NCT03580083|Genetic|RGX-111|Recombinant adeno-associated virus serotype 9 capsid containing α-L-iduronidase expression cassette
77295|NCT03580070|Biological|Immunotherapy|Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
77296|NCT03580057|Behavioral|Breastfeeding promotion intervention|Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.
77297|NCT03580057|Behavioral|Diet and weight loss intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
77298|NCT03580044|Combination Product|ATM-AVI|"ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the maintenance dose are dependent on renal function. Subjects will be given a loading dose of 500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours.~Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period."
77299|NCT03580044|Drug|BAT|The comparator treatments in this study are to be the best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT for each subject must be recorded prior to randomization. Acceptable BAT may include but not limit to the following Aminoglycoside; Colistin (or polymixin B if colistin not available/accessible); Fosfomycin; Meropenem; Tigecycline. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.
77300|NCT03580031|Drug|hCG|A booster dose (10,000 IU of hCG) was given IM 48 hours after first triggering dose
77301|NCT03580031|Drug|Saline Solution|2 ml of normal saline will be injected 48 hours after first triggering dose
77302|NCT03580018|Drug|Tranexamic Acid Powder|Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
77303|NCT03580018|Procedure|Post-anterior cruciate ligament reconstruction (ACLR)|Post-anterior cruciate ligament reconstruction (ACLR)
77304|NCT03580005|Drug|methylphenidate HCl ERCT|methylphenidate HCl ERCT
77305|NCT03580005|Drug|Placebo|Placebo to Match Quillichew ERCT
77306|NCT03579992|Behavioral|60-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 60 minutes per session
77307|NCT03579992|Behavioral|90-min isometric MyCI training|EMG-controlled in-lab training with arm restrained for 90 minutes per session
77308|NCT03579992|Behavioral|90-min movement MyCI training|EMG-controlled in-lab training without restraint for 90 minutes per session
77309|NCT03579979|Drug|Methylene Blue|Subcutaneous injection of injection point at the periphery of the areola or tumor, injecting 1% methylene blue 0.5ml at each point, a total of 2-3 points.
77310|NCT03579979|Drug|Indocyanine Green|Within 5 minutes after MB injection, 2.5mg/ml ICG 0.5ml was injected at each point, a total of 2-3 points. Methylene blue and ICG injection points do not coincide
77311|NCT03579966|Drug|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
77312|NCT03579953|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key).
77313|NCT03579953|Device|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
77316|NCT03579927|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
77317|NCT03579927|Drug|Carmustine|Given IV
77318|NCT03579927|Drug|Cytarabine|Given IV
77319|NCT03579927|Drug|Etoposide|Given IV
77320|NCT03579927|Biological|Filgrastim|Given SC
77321|NCT03579927|Drug|Melphalan|Given IV
77322|NCT03579927|Biological|Rituximab|Given IV
77323|NCT03579927|Biological|Umbilical Cord Blood-derived Natural Killer Cells|Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
77324|NCT03579914|Drug|intravenous Placebo|Patients receive intravenous Placebo injection
77325|NCT03579914|Drug|Metoprolol Injectable Product|Patients receive intravenous Metoprolol injection
77326|NCT03579914|Device|Romote Ischemic Post-Conditioning (RIPC)|Patients receive RIPC treatment
77327|NCT03579901|Device|Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants|Breast augmentation
77328|NCT03579888|Biological|Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells|Given IV
77329|NCT03579888|Drug|Cyclophosphamide|Given IV
77330|NCT03579888|Drug|Fludarabine|Given IV
77331|NCT03579875|Drug|Total Body Irradiation (TBI) (Plan 1)|300 cGy with thymic shielding on day -6
77332|NCT03579875|Drug|Cyclophosphamide (CY) (Plan 1)|10 mg/kg IV daily on days -5, -4, -3, and -2
77333|NCT03579875|Drug|Fludarabine (FLU)|35 mg/m2 IV daily on days -5, -4, -3, and -2
77334|NCT03579875|Drug|Methylprednisolone (MP)|1 mg/kg IV q12h on days -5, -4, -3, -2, and -1
77335|NCT03579875|Device|Donor mobilized PBSC infusion|T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation on day 0
77336|NCT03579875|Drug|G-CSF|Initiate G-CSF 5mcg/kg per day IV on day +1 (continue until ANC >2.5 x 10^9/L for 3 consecutive days)
77337|NCT03579875|Drug|Cyclophosphamide (CY) (Plan 2)|5 mg/kg IV daily on days -5, -4, -3, and -2
77338|NCT03579875|Drug|Rituximab|200 mg/m2 IV once on day -1
77339|NCT03579862|Other|Blood Draw|
77340|NCT03579849|Diagnostic Test|Pulmonary tomoscintigraphy|The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
77341|NCT03579836|Drug|BEY1107|Take orally with water once a day on a 3-weeks-on (21 days) continuously and 1-week-off (7 days) schedule.
77342|NCT03579836|Combination Product|Gemcitabine|Administer 1,000 mg/m2 of Gemcitabine intravenously for 30 minutes on Day 1, 8, 15 and 1-week-off (7days) schedule.
77343|NCT03579823|Drug|Adalimumab 100 MG/ML [Humira]|prefilled syringe at a concentration of 100MG/ML and delivering 40MG of adalimumab, as a single dose on day 1 day 1
77344|NCT03579823|Drug|AVT02 100MG/ML|prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
77345|NCT03579810|Other|Investigational|"The educational intervention helped to increase the knowledge of attitudes, and habits of healthy lifestyle in children, parents and teachers and it was based on health promotion models and social cognitive theory, to be articulated with the Institutional Educational Project through the pedagogical component that integrates three areas, physical activity, healthy eating, and the knowledge of the body and the heart with the dynamics of the educative community.~The program covered self-care of the body and heart, healthy diet, and physical activity"
77346|NCT03579810|Other|Control|The control group did not receive an educational intervention in areas of physical activity, healthy eating, and the knowledge of the body and the heart. Instead, children received the standard curriculum in health and physical activity of the national Ministry of Education.
77347|NCT03579797|Behavioral|Screening, referral, follow-up and health management|Field screening, remote diagnosis, comprehensive assessment, referral, and eye health management of diabetics were the main study processes. The community health service centers (CHSC) are responsible for the field screening. The designated medical institutions (DMI) of each district are responsible for the remote diagnosis and comprehensive assessment of diabetic eye diseases, especially diabetic retinopathy (DR), based on comprehensive evaluation through the remote reading system (RRS) and Shanghai eye health information service system (SEHISS). The staff of CHSC urged the referral objects promptly for further diagnosis and treatment in DMI. According to the diagnosis after clinically confirmed, all the study participants will be recommended appropriate eye health management.
77348|NCT03579784|Drug|Paclitaxel|Paclitaxel 80 mg/m2 mg iv on D1, D8, D15 Every 4 weeks
77349|NCT03579784|Drug|Olaparib|Olaparib 150mg bid on D1-28 Every 4 weeks
77350|NCT03579784|Drug|Durvalumab|Durvalumab 1.5 g iv on D1 Every 4 weeks
77351|NCT03579771|Drug|Cisplatin|Given IV
77352|NCT03579771|Drug|Gemcitabine|Given IV
77353|NCT03579771|Drug|Nab-paclitaxel|Given IV
77354|NCT03579758|Drug|Capecitabine|Given PO
77355|NCT03579758|Drug|Cisplatin|Given IV
77356|NCT03579758|Drug|Gemcitabine|Given IV
77357|NCT03579745|Procedure|Lingual orthodontics|A coil spring will be attached from the lever arm to the first molar tube
77358|NCT03579732|Drug|Aspirin (Acetylsalicylic Acid, BAYE4465)|Low dose of aspirin, i.e. < 150 mg daily
77359|NCT03579732|Other|No drug|Non-consumers
77360|NCT03579719|Drug|Balovaptan|"In Period 1, balovaptan was administered orally once daily (qd) on Days 1 to 10.~In Period 2, balovaptan was administered qd on Days 6 to 20."
77361|NCT03579719|Drug|Itraconazole|In Period 2, 200 mg itraconzole was administered bid for 4 days and qd on Days 5-20, approximately 12 hours apart. On Days 6-20, 200 mg itraconazole was administered qd.
77362|NCT03579706|Behavioral|Cognitive Anxiety Sensitivity Treatment|The Cognitive Anxiety Sensitivity Treatment is a computerized treatment that is a combination of psychoeducation plus interoceptive exposure for anxiety sensitivity (AS). The psychoeducational component will focus on the nature of stress and its effect on the body. Interoceptive exposure (IE) exercises, designed to correct the conditioned fear to these bodily sensations, will be explained and practiced.
77363|NCT03579706|Behavioral|Physical Health Education Training|The Physical Health Education Training is a computerized active placebo matched in time and structure to CAST that includes information about general health and wellness (e.g. diet, exercise etc.).
77364|NCT03579693|Dietary Supplement|CoQ10|CoQ10 tablet
77365|NCT03579693|Dietary Supplement|Nicotinamide riboside|NR tablet
77366|NCT03579693|Dietary Supplement|Placebo|Sugar pill designed to mimic coQ10 and NR
77367|NCT03579667|Behavioral|Diet intervention|12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
77368|NCT03579654|Biological|Proscavax|Proscavax is a prostate cancer vaccine which combines the prostate antigen PSA with immune stimulatory cytokines (IL-2 and GM-CSF).
77369|NCT03579641|Device|HeartLogic™ Sensors|HeartLogic™ Sensors
77370|NCT03579628|Drug|AsiDNA|"All patients will receive a loading dose of AsiDNA iv infusion (D1, D2, D3) followed by weekly iv administrations.~At cycle 1: Part B1: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion. Part B2: Carboplatin will be administered by a 1 hour IV infusion at D8, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered by a 1 hour IV infusion at D8, D15, D22 or 1 hour after the end of AsiDNA infusion for weekly administrations.~At each other cycle: AsiDNA will be administered on a weekly basis. Part B1: Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion. Part B2; Carboplatin will be administered by a 1 hour IV infusion at D1, 1 hour after the end of AsiDNA infusion and Paclitaxel will be administered on a weekly basis by a 1 hour IV infusion.~Patients will continue study treatment until disease progression, unacceptable toxicity or patient's refusal to continue."
77371|NCT03579615|Device|FIASP + closed loop device|Participants will be advised to change their usual insulin to the corresponding study visit insulin formulation, 24 hours prior to admission. (For example; if the participant is on insulin aspart, this will be changed to faster-acting aspart 24-hour prior to the admission for closed loop with faster-acting aspart and vice versa).
77372|NCT03579615|Device|Insulin aspart (standard of care insulin) + closed loop device|Participants will be advised to maintain their usual insulin 24 hours prior to admission.
77373|NCT03579602|Drug|tozuleristide|Tozuleristide will be administered at least 1 hour and no more than 36 hours prior to planned surgical excision of their tumor.
77374|NCT03579602|Device|Canvas System|All subjects enrolled in the study will have their tissue imaged with the Canvas System.
77375|NCT03579589|Drug|Sugammadex vs Neostigmine|Patients will be randomized into either Sugammadex or Neostigmine neuromuscular blockade reversal.
77376|NCT03579576|Drug|sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.|Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
77377|NCT03579563|Other|Audiologist-based fitting|Hearing aids will be fitted by audiologists using established procedures.
77378|NCT03579563|Other|Over-the-counter fitting|In this group, pre-configured Hearing aids will be provided to subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
77379|NCT03579563|Other|Hybrid fitting|Audiology professionals provide streamlined services to fit pre-configured amplification devices.
77380|NCT03579550|Procedure|office hysteroscopic metroplasty intervention arm|One group will be performed hysteroscopic metroplasty Second group will be undertaken to six months spontaneous coitus and three cycles of COH/IUI
77381|NCT03579537|Other|Intradyalisis without exercise programe|patients on hemodialysis are evaluated with all the variables at first (T1) and without intervening in the treatment for 3 months they are evaluated again (T2).
77382|NCT03579537|Other|Intradyalisis with exercise programe|After 3 first month without intervention and also during the time of hemodialysis, the patients star the exercise programe, the first part of the session, an exercise was carried out for cardiovascular work (pedaling on ergometer) and muscle toning, with special attention to the muscular development of the lower limbs (exercises with elastic bands and / or weighted ankles). The session increased in duration and intensity as the physical action program progressed throughout the duration of the permitted period (3 months) and always attending to the individual needs of each subject. In addition, each of the participants will be given a series of recommendations of exercise practice to be carried out during non-hemodialysis days, in order to complement the work done during the sessions.3 month later the investigator evaluated all the variable again (T3)
77383|NCT03579524|Procedure|Erector Spinae Plane Block|At lateral decubitus with the operation site up, the vertebrae will be counted from cephalad to caudal direction until reaching T5 spinous process as the first palpable spinous process is C7. The ultrasound probe will be placed vertically 3 cm lateral to the T5 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle will be introduced from superior to inferior direction in-plane until the tip lay deep to erector spinae muscle. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread under erector spinae muscle. A total of 20 mL of 0.25% bupivacaine will be injected next.
77384|NCT03579524|Procedure|Serratus Anterior Plane Block|At supine position with the arm abducted, the ribs will be counted in the mid-axillary line from downward upwards until the 5th ribs. The linear probe will be placed horizontally then three muscles will be identified: latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior). The needle will be inserted in-plane with respect to the ultrasound probe from supero-anterior to posteroinferior. 0.5: 1 mL of non-active fluid will be injected to confirm correct needle tip position by visualizing spread over serratus anterior muscles, then a total 20 ml of bupivacaine 0.25% will be injected.
77385|NCT03579511|Procedure|External Pop-out|The original techniques of fetal head extraction entail the introduction of the obstetricians' hands or other instruments into the LUS. This puts the LUS at risk of damage and incision extensions with its consequences of increased blood loss, increased operative time,infection adhesions and blood transfusion.To the available, the generated good quality evidence bases practice in CS is anticipated to decrease such morbidities
77386|NCT03579472|Drug|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
77387|NCT03579472|Drug|Eribulin Mesylate|Given IV
77388|NCT03579459|Biological|Clostridium difficile vaccine|Toxoid based Clostridium difficile vaccine
77389|NCT03579459|Biological|placebo|Normal saline solution
77390|NCT03579446|Drug|Hydrocodone|Given PO
77391|NCT03579446|Drug|Hydromorphone|Given PO
77392|NCT03579446|Drug|Hydromorphone Hydrochloride|Given PO
77393|NCT03579446|Drug|Levorphanol|Given PO
77394|NCT03579446|Drug|Morphine|Given PO
77395|NCT03579446|Drug|Morphine Sulfate|Given PO
77396|NCT03579446|Drug|Oxycodone|Given PO
77397|NCT03579446|Drug|Oxymorphone|Given PO
77398|NCT03579446|Drug|Oxymorphone Hydrochloride|Given PO
77399|NCT03579446|Other|Questionnaire Administration|Ancillary studies
77400|NCT03579433|Device|ORA System with VerifEye+|Intraoperative device that measures total corneal astigmatism in the aphakic condition and is used for the selection of IOL power. In the pseudophakic condition, ORA provides guidance for the alignment of the toric axis mark.
77401|NCT03579433|Other|Alcon Toric Calculator|Online calculator (Barrett) that includes estimates of the posterior corneal astigmatism for the selection of IOL power
77402|NCT03579433|Device|Acrysof® IQ Toric IOL|Intraocular lens implanted as a replacement for the cataractous lens during cataract surgery
77403|NCT03579420|Behavioral|Brief lifestyle program|3-session program for modification of lifestyle habits (exercise and diet)
77404|NCT03579420|Behavioral|Conventional lifestyle program|6-session program for modification of lifestyle habits (exercise and diet)
77405|NCT03579407|Procedure|BMA cell therapy injection|The bone marrow aspirate will be injected into the affected knee joint.
77406|NCT03579394|Procedure|Retarded IDS (Interval Debulking Surgery)|"Patient will receive 6 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C6D1. After surgery patient will undergo 2 more courses of carboplatine and paclitaxel chemotherapy~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
77495|NCT03578653|Behavioral|Merging Yoga and Occupational Therapy for Parkinson disease|The group occupational therapy portion focuses on lecture, group discussion, and activities to reduce fall risk. The yoga program is part of an ongoing community yoga program specifically designed for people with Parkinson disease.
77638|NCT03577496|Other|Peppermint oil|A cotton ball with three drops of peppermint oil will be waved under the patient's nares.
77407|NCT03579394|Procedure|Standard IDS (Interval Debulking Surgery)|"Patient will receive 3 courses of i.v carboplatine and paclitaxel every 3 weeks followed by IDS (Interval Debulking Surgery) within 6 weeks from C3D1. After surgery patient will undergo 5 more courses of carboplatine and paclitaxel chemotherapy.~Treatment accepted :~Paclitaxel and carboplatin could will be administred according to the site practice and Saint-Paul-de-Vence recommendation (Joly et al, 2017):~paclitaxel 175 mg/m² + carboplatin AUC 5-6, D1=D21 or~paclitaxel 80 mg/m² at J1-J8-J15 + carboplatin AUC 5-6, D1=D21 or~paclitaxel 60 mg/m² D1-D8-D15 + carboplatin AUC2 D1-D8-D15, D1= D21~Adjuvant therapy and maintenance (optional)according to national recommendations (Saint Paul de Vence)"
77408|NCT03579368|Device|Symfony implantation|Bilateral Symfony IOL Implantation
77409|NCT03579355|Behavioral|DFND Program|The DFND program consisted primarily of a 10-session curriculum, each session lasting about an hour. The curriculum was comprehensive and incorporated information about tobacco and its adverse health effects, social influences, and social competence skills.
77410|NCT03579342|Behavioral|App-technology and active coaching to improve lifestyles behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
77411|NCT03579342|Behavioral|App-technology to improve lifestyle behaviors|Access to the smartphone-app during 12 weeks. A personal health goal related to for example diet, physical activity or stress habits, is set together with a heath coach. Participants receive continuous coaching every 4 weeks during follow-up.
77412|NCT03579329|Procedure|Total Knee Arthroplasty|Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee
77413|NCT03579316|Drug|Adavosertib|Given PO
77414|NCT03579316|Drug|Olaparib|Given PO
77415|NCT03579303|Other|Homoeopathic Remedies|comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
77416|NCT03579290|Behavioral|CBT4CBT program|"The 'CBT for CBT' program is modeled closely on our NIDA-published CBT manual. Seven core skill modules will cover the following topics, which correspond to the major session topics in the manual:~Understanding and changing patterns of drug use,~Coping with craving,~Substance refusal skills,~Seemingly irrelevant decisions,~Planning for emergencies, and~Problem-solving skills.~Staying Safe"
77417|NCT03579277|Procedure|Radial Forearm Free Flap|Subjects in this arm will undergo a radial forearm free flap.
77418|NCT03579277|Procedure|Ulnar Forearm Free Flap|Subjects in this arm will undergo an ulnar forearm free flap.
77419|NCT03579264|Behavioral|My Viva Plan|Use of the online platform, My Viva Plan, to support health and wellness.
77420|NCT03579251|Behavioral|Black Men's Care|12 weeks of behavioral intervention, including an in-person session and two-way SMS, to re-engage in HIV care HIV-positive Black men who have fallen out of care
77421|NCT03579238|Procedure|CV4|The occiput of a supine patient is held such that flexion motion is inhibited and extension motion is reinforced.
77422|NCT03579238|Procedure|touching|the clinician allows the participant's head to rest quietly upon his open palms on a table.
77423|NCT03579225|Device|MATRx plus test|The MATRx plus is a home-based test that allows the healthcare provider to determine if a patient with obstructive sleep apnea will benefit from oral appliance therapy. Prior to the test, a dentist fits the patient with dental trays and measures the patient's comfortable jaw range of motion. The trays are connected to a mandibular positioner. During sleep, the device collects airflow from a nasal cannula and blood oxygen saturation from a pulse oximeter. These signals are used by the device software to control the mandibular positioner and protrude the mandible. During the test, the device moves the lower jaw within the patient's range of motion to predict if the patient is likely to benefit from oral appliance therapy and, if so, the appropriate amount of protrusion. Additional study nights may be required if the data from either of the first two nights are insufficient or if a more precise determination of the amount of jaw protrusion that provided a therapeutic benefit can be made.
77424|NCT03579212|Device|Y-STRUT® (Hyprevention, Pessac, France)|The studied medical device consists of two components implanted in the proximal femur, combined with bone cement.
77425|NCT03579199|Device|exploration of abdominal cavity and liver using a NIR/ICG camera|exploration of abdominal cavity and liver using a NIR/ICG camera
77426|NCT03579186|Device|OKS|Optokinetic stimulation
77427|NCT03579173|Diagnostic Test|Infant PFT|Assessed through the raised volume rapid thoracoabdominal compression technique and plethysmography
77428|NCT03579173|Diagnostic Test|Lung Clearance Index|The Lung Clearance Index is derived from the Multiple Breath Washout test. It is the cumulative exhaled volume (the volume of gas needed to wash out resident gas mixture out of the lungs) divided by the FRC. The FRC is the amount of air left in the lungs after normal exhalation.
77429|NCT03579173|Diagnostic Test|Passive tidal breathing|During quiet sleep, tidal breathing flow-volume curves are obtained. The tPEF/tE is calculated by taking the time it takes to reach peak expiratory flow divided by the total peak expiratory time.
77430|NCT03579160|Drug|0.25% timolol gel with full-thickness skin grafts|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied.
77431|NCT03579160|Other|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied.
77432|NCT03579147|Device|Treatment with BTL EMSCULPT device|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
77433|NCT03579134|Device|partial overlay denture|removable appliance similar to a removable partial denture but with overlay occluslal rests covering the full occlusal surface of the remaining posterior teeth
77434|NCT03579134|Other|fixed temporary crowns|fixed crowns made from temporary material placed to the newly altered vertical dimension
77435|NCT03579121|Other|Pharmacogenomic (PGx)|Administer a pharmacogenomics test (buccal swab) during the pre-operative setting
77436|NCT03579121|Other|Review results|Pharmacogenomic (PGx) results reviewed by the clinicians during their treatment and the results may guide clinical decisions.
77437|NCT03579108|Other|Retrospective Chart Review|Chart review
77438|NCT03579095|Dietary Supplement|Cereboost|200mg Cereboost and Maltodextrin capsules
77439|NCT03579095|Dietary Supplement|Placebo|200mg Maltodextrin capsules
77440|NCT03579082|Drug|Decitabine|Given ivgtt
77442|NCT03579043|Other|Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
77443|NCT03579043|Other|Non-Nutritive Sweetener|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
77444|NCT03579043|Other|Carbonated Water|Participants will receive twelve, 12-ounce cans of a beverage that represents their assigned condition. Participants will be instructed to drink their assigned beverages Tuesday through Thursday, and to consume one beverage at 12pm, the second at 3pm, and the third at 6pm. Participants will be instructed that the beverages need to be consumed within +/- 30 minutes of the instructed time. Participants will be instructed that any other beverage consumed on Tuesday through Thursday should be water.
77445|NCT03579030|Drug|Placebo oral capsule|Placebo capsule matched to an RTA 1701 capsule
77446|NCT03579030|Drug|RTA 1701 capsules|Capsule containing RTA 1701, multiple dosages
77447|NCT03579017|Diagnostic Test|ECAS-N|All participants included will be tested with the ECAS-N
77448|NCT03579017|Diagnostic Test|MoCA|All included patients With ALS will be tested With the MoCA
77449|NCT03579004|Drug|Paclitaxel|Paclitaxel is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
77450|NCT03579004|Drug|Cisplatin|Cisplatin is used in two cycles of neoadjuvant chemotherapy and concomitant chemoradiotherapy
77451|NCT03579004|Drug|Fluorouracil|Fluorouracil is used in two cycles of neoadjuvant chemotherapy
77452|NCT03579004|Radiation|chemoradiotherapy|Distant 3D radiotherapy, single dose 2 Gray (Gy), total dose 44Gy.
77453|NCT03579004|Procedure|Ivor Lewis esophagogastrectomy|Open Ivor Lewis esophagogastrectomy
77454|NCT03578991|Device|Smart pillbox|The smart electronic pillbox will monitor adherence to pharmacological treatment by means of registering time of medications intake. It will incorporate visual and auditory reminders for taking medications (all of them, being or not being inside the dispenser such as insulin or eye drops). The dispenser will also have sensors and alarms to ensure the proper preservation of the medicines contained. The dispenser will be recharged weekly by a trained pharmacist. Each dispenser will be identified unequivocally with one user, and it will be interconnected with a mobile application (app).
77455|NCT03578991|Other|Interactive digital platform|The digital interactive platform will allow communication between patients and caregivers and healthcare professionals. Its aims are to provide feedback and guidelines on treatment adherence and also, on how to better optimize treatment on cardiovascular risk factors. The platform will inform about medication dosages and intake schedule, healthy lifestyles related to diabetes, occurrence of adverse events, and it will also monitor patients' glycemic control. In this sense, several alarms are programmed to warn caregivers or even healthcare professionals when the patient has hyperglycemia or hypoglycaemia. The platform will provide too guidelines on how to treat hypo or hyperglycemia as well as most common adverse events, and it will describe reasons to have suffered it.
77456|NCT03578978|Other|No intervention|No intervention will be given to study subjects. Only blood will be obtained from study subjects.
77457|NCT03578965|Drug|Cefazolin|-If patient has a penicillin allergy then clindamycin will be used. Prophylactic antibiotics should be administered prior to skin incision
77458|NCT03578952|Device|TAVR with Evolut R valve|TAVR with Evolut R valve
77460|NCT03578926|Device|fanfilcon A toric lens|contact lens
77461|NCT03578926|Device|senofilcon A toric lens|contact lens
77462|NCT03578913|Other|PEEK crown|The main concern of dental implants is their lack of elasticity, therefore with the use of PFM, all ceramic or zirconia crowns; the load is directly transferred to bone. That is why up till now researchers are in quest of different materials to enhance soft and hard tissue reaction around implant supported restorations. Recently the use of PEEK as a final restoration on dental implants has wide acceptance, due to its excellent biocompatibility and exceptional physical and chemical properties regarding toughness, hardness and elasticity. In term of load cushioning capacity of the prosthetic elements, PEEK has a comparable modulus of elasticity (4GPa) to that of bone (4.2GPa). Thus, the bone could allow bone stimulation favoring its remodeling without overloading.
77463|NCT03578913|Other|PFM Crown|Although metal free restorations are gained popularity recently, PFM restorations, whether they are tooth-supported or implant-supported are still considered as the gold standard due to their excellent biocompatibility, consistent esthetics, superior strength, and marginal adaptation.2 PFM restorations are also considered durable and long-lasting
77464|NCT03578900|Drug|Xeros|
77465|NCT03578900|Drug|Citric Acid based Mouthwash|
77466|NCT03578887|Behavioral|Behavioral Weight Loss Program|Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program (DPP).
77467|NCT03578887|Procedure|Roux-en-Y Gastric Bypass|Subjects undergoing Roux-en-Y gastric bypass
77468|NCT03578874|Drug|Sorafenib|PO
77469|NCT03578874|Drug|Capecitabine|PO
77470|NCT03578874|Drug|Oxaliplatin|IV
77471|NCT03578861|Other|Dementia related mobility and counseling|"The DESKK mobility program is based on the already existing day structure of the RC facility with two slots a day for physical activation activities (1 ½ hours forenoon and 1 ½ hours afternoon). The program structures these activities based on specific developed exercises, which are focused on the individual mobility level of every PwD and his/her mobility level.~The DESKK counseling program is an effort to structure and systemize counseling processes focused on the respite care setting by different documents and assessments."
77496|NCT03578640|Drug|Elbasvir, Grazoprevir 50-100Mg Oral Tablet|Daily, fixed-dose combination of Elbasvir 50 mg and Grazoprevir 100 mg given in a single oral tablet for 8 weeks.
77687|NCT03577119|Dietary Supplement|Non-fat yogurt|Controlled diet that includes three daily servings of fat-free yogurt.
77472|NCT03578848|Device|uAOBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
77473|NCT03578848|Device|Home BP|As for the home BP measurements, a validated device (WatchBP Home; Microlife AG, Widnau, Switzerland) will be provided for all subjects allocated to the home BP arm to measure their BP at home. Subjects are requested to take BP in the morning (within 2 hours after awakening) and afternoon before meals for 7 consecutive days before the scheduled clinical visits. BP in the first day of the measurements will be discarded and an average of home BP (all BP reading and BP in the morning and in the afternoon) will be generated and provided for clinicians to guide their treatment.
77474|NCT03578848|Device|CBP|For the uAOBP and CBP, the measurements will be conducted in a quiet room without the presence of clinical personnel. Patients will be seated in a quiet room without talking and taken as an average of 3 measurements with an automated device (HEM-907, Omron Healthcare, Lake Forest, IL) that has been preset to wait 5 minutes before measurements. Simultaneously, the central BP will be measured in the other upper arm. (WatchBP Office Central; Microlife AG, Widnau, Switzerland). The determination of the right or left upper arm for uAOBP or central BP will be made in a random order by computer generated random codes before the enrollment.
77475|NCT03578822|Drug|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
77476|NCT03578822|Drug|Aspirin|Aspirin 300mg is taken orally at the beginning of thrombolysis.
77477|NCT03578822|Drug|rhPro-UK simulation agent|Patients receive rhPro-UK simulation agent 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
77478|NCT03578822|Drug|Aspirin simulation agent|Aspirin simulation agent 300mg is taken orally at the beginning of thrombolysis.
77479|NCT03578809|Biological|MEDI6012|MEDI6012
77480|NCT03578809|Other|Placebo|Placebo
77481|NCT03578796|Diagnostic Test|ECAS-N|assessing ALS-specific cognitive impairment
77482|NCT03578796|Diagnostic Test|MoCA|assessing cognitive impairment
77483|NCT03578796|Diagnostic Test|CDR|assessing global cognitive impairment, as well as possible diagnosis- and Level of dementia
77484|NCT03578796|Other|Questionnaire|Questions related to work situation and car driving
77485|NCT03578783|Drug|Placebo|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
77486|NCT03578783|Drug|PSD502|"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."
77487|NCT03578770|Device|Hot Axios stent|Hot Axios stent
77488|NCT03578757|Behavioral|21-day residential program|"Both groups will benefit of a 21-day residential program at the thermal spa resort combining corrections of eating disorders (and a negative energy balance of 500 kcal/day), physical activity (2h30 per day, minimum), thermal spa treatment (2h per day, minimum), and health education (1h30 per day, minimum: cooking, nutrition and physical activity classes…). Physical activity will be diverse (endurance, strength, circuit training) and personalized to the target of each participant.~The intervention group will benefit from psychological interventions based on validated approaches of stress (3 x 1h30 per week). Participants will attend psychological sessions by group of less than 10 individuals. Individual meeting with the psychologist will occur at least twice: at the beginning of the residential program and at the end.~After the spa residential program, participants will undergo a one-year at-home follow-up."
77489|NCT03578744|Procedure|Conventional Flap surgery|After administering local anaesthetic a full thickness flap will be raised and reflected to expose the furcation defects. The furcation defects would then be debrided and the graft and membrane secured in position. Later the flap would be sutured back.
77490|NCT03578731|Device|app|"The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~Interview during regular consultation with doctor~Web-App for gathering doctors data~Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~Well-being through a patient rating on a visual analog scale~Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app"
77491|NCT03578705|Device|"Electrical Impedance Myography unit or EIM"|
77492|NCT03578679|Drug|Ivermectin Oral Product|treatment of pediculosis (head lice)
77493|NCT03578666|Other|Massage|The intervention will be applied to both legs to a constant distal to proximal stroking rhythm. Firstly, participants will be lying in a prone position for 22 min: 1 min on the sole of the foot, 1 min on the Achilles tendon, 1 min on the soleus muscle, 3 min on the triceps muscle, 4 min on the hamstring muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings. Then they will assume a supine position for 18 min: 1 min on the sole of the foot, 3 min on the tibialis anterior and peroneus lateralis muscles and 4 min in the quadriceps, adductors and lata muscles, 30 s tapotement from the sole of the foot to the hamstrings and 30 s superficial effleurage from the sole of the foot to the hamstrings.
77494|NCT03578666|Other|Cold water immersion|The cold water immersion group immersed their lower limbs (ensuring that the iliac crests were fully immersed) in an ice bath filled with cooled water for 10 min. The water was maintained at a mean temperature of 10 degrees (±0.5°) by the addition of ice.
77570|NCT03578081|Other|Placebo|Given IV
77571|NCT03578055|Drug|BDD with UDCA|Dosage: Udex 1 capsule, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
77497|NCT03578627|Behavioral|BioBehavioral Intervention|Psychological (stress and quality of life), behavioral (health behaviors and compliance), and biologic (neuroendocrine and immune) factors, and pathways by which health outcomes (e.g. disease endpoints—recurrence, disease free interval) might be affected.
77498|NCT03578614|Other|Physical Activity|"3 physical activity sessions are planned by week, 2 supervised and 1 non-supervised conducted over 6 months. On the first 2 months, the supervised sessions have 10 minutes of warm-up + 5 minutes active pause (balance, agility and coordinative exercises) + 15 minutes walking + 5 minutes active pause (resistance exercises - 1 series of 12 repetitions~- 3 callisthenic exercises) + 15 minutes walking + 5 minutes flexibility (1 series of 10 seconds in 3 different postures). The aimed intensity in these first two months is 12/13. Between the 2nd and the 4th months, the duration of the walking period increases, as well as the intensity, RPE 13/14. Between the 4th and the 6th months, again the duration of the walking period increases, as well as the intensity, RPE 14/15. To measure the intensity level of the physical activity, the Borg Rating of Perceived Exertion (RPE) ranging from 6 (rest) to 20 (maximum effort) is used."
77499|NCT03578601|Other|Thyroid surgery|Patient undergoing thyroid surgery
77500|NCT03578588|Drug|Banapenem|Twelve healthy adult volunteers, half male and female, are enrolled and randomly assigned to three groups, B1, B2, and B3. The subjects in three groups receive three doses, 250 mg, 500 mg and 1000 mg. Each group of subjects receive single-dose test drug at different dosages in each period. The subjects are divided into two groups, C1 and C2, 12 subjects in each group, half males and half females. 250 mg group is performed first. After completion of observation and confirming that the drug can be safely tolerated, study on 500 mg group is then performed
77501|NCT03578575|Drug|Danggui Buxue Tang|Danggui Buxue Tang is an extracted powder of traditional Chinese medicine formula.
77502|NCT03578575|Drug|Placebo|Placebo is a very low dose Danggui Buxue Tang powder.
77503|NCT03578562|Other|Targeted training intervention|An 8-week progressive homebased training intervention with supervised booster-sessions
77504|NCT03578549|Device|Pulse Oximetry|Pulse Oximeter is being applied with a special holding tool to test the oximeter for its ability to measure pulpal blood flow, but no effect of the oximeter is being measured. Thus, to that degree the use is observational rather than interventional.
77505|NCT03578536|Device|Recovery Rapids|This project utilizes a new gaming system technology called Recovery Rapids. The game is custom-made by Games That Move You, LLC and runs on an XBOX platform with motion input via a Kinect system.
77506|NCT03578523|Other|3 Tesla multiparametric MR|Renal MRI Scan to assess blood flow, perfusion, oxygenation and microstructure (MR T1 relaxation time and diffusion). Each patient will have 3 renal MRI scans.
77507|NCT03578523|Other|renal histopathology scoring|Blinded fibrosis scoring of renal histopathology (If biopsy performed for clinical indication)
77508|NCT03578523|Biological|Blood and urine sampling|"Blood and urine sampling around scan sessions; this will include routine patient care biochemistry and haematology panel,~urine protein and albumin measurements, stored plasma/serum/urine for subsequent analysis"
77509|NCT03578523|Biological|Iohexol clearance test|Iohexol clearance to measure GFR within 1 week of the scan session
77510|NCT03578510|Device|Hemocontrol hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.
77511|NCT03578510|Device|Standard hemodialysis|Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.
77512|NCT03578497|Drug|IL-1 receptor antagonist Anakinra|IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
77513|NCT03578484|Diagnostic Test|Aesthetic assessment 3D breast scanning|Vectra TM - Canfield Inc breast scan. 3D digital photography scan.
77514|NCT03578471|Device|Hearing Aid without NR and BF|Each participant will be fitted with the Noise Reduction (NR) and Beamforming (BF) disabled. Disabled means that no sound processing algorithm that removes noise from the speech signal is active.
77515|NCT03578471|Device|Hearing Aid with NR|Each participant will be fitted with the Noise Reduction (NR)(Sound Changing) program on the same hearing aid. Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The Noise Reduction is working spatially independent.
77516|NCT03578471|Device|Hearing Aid with BF|Each participant will be fitted with a beam forming program on the same hearing aid. Beam forming (BF) principle is a sound processing algorithm to remove noise from certain directions to improve the speech intelligibility and comfort.
77517|NCT03578458|Other|subjects will install a mobile app for use|novel mobile application
77518|NCT03578445|Device|EUS-guided microbiopsy|Use of EUS-guided through-the-needle microbiopsy forceps for obtainment of tissue from the wall of the cystic lesion
77519|NCT03578445|Diagnostic Test|Next Generation Sequencing|Prevalence of genetic mutations in known cancer-associated genes in the microbiopsy tissue examined using the Ion AmpliSeq Cancer Hotspot Panel v2 (Life Technologies, Carlsbad, USA). The multigene panel explores selected regions of 50 cancer-associated genes, among others KRAS, GNAS, CDKN2A and SMAD4 genes.
77520|NCT03578432|Drug|Everolimus|Given PO
77521|NCT03578432|Other|Laboratory Biomarker Analysis|Correlative studies
77522|NCT03578432|Other|Survey Administration|Ancillary studies
77523|NCT03578419|Device|Small-Volume Blood Collection Tubes|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
77524|NCT03578419|Device|Standard-Volume Blood Collection Tubes|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
77525|NCT03578406|Drug|HPV E6-specific TCR-T cells|Patients were infused with HPV E6-specific TCR-T cells
77526|NCT03578393|Device|Virtual Reality Educational Program|The study group, in addition to providing the usual information about the anaesthetic-surgical process, will visualize an educational video through virtual reality glasses, of a maximum duration of 5 minutes. The video's explanation will be adapted according to the age ranges. Once the video is finished, if there aren't doubts, the visit will be concluded.
77527|NCT03578380|Procedure|Surgery|Lymphovenous anastomosis
77528|NCT03578380|Other|Compression and drainage therapy|Treatment with compression stockings and manual drainage (massage therapy)
77529|NCT03578367|Drug|Asciminib add-on|Asciminib 60 mg or 40 mg taken orally once daily in addition to Imatinib 400 mg taken orally once daily
77530|NCT03578367|Drug|Imatinib|Imatinib 400 mg taken orally once daily
77531|NCT03578367|Drug|Nilotinib|Nilotinib 300 mg taken orally twice daily (total daily dose of 600 mg)
77532|NCT03578354|Drug|4-aminopyridine|an oral drug to be swallowed
77533|NCT03578354|Drug|Atenolol|an oral drug to be swallowed
77534|NCT03578354|Other|Placebo|a masked placebo to be swallowed
77535|NCT03578341|Biological|Orally Colostrum|Group 1, Will receive colostrum 0.3 mL every 4 hours in the oropharyngeal mucosa, for 3 days.
77536|NCT03578328|Procedure|targeted temperature management|Temperature control to targeted temperature (32-36C) after return of spontaneous circulation after cardiac arrest and resuscitation
77537|NCT03578315|Device|HGM|3D camera photography for facial model establishment Harmonic generation microscopy for Solar lentigo histopathological diagnosis
77538|NCT03578315|Device|HGM|3D camera photography for facial model establishment Harmonic generation microscopy for Nevus zygomaticus histopathological diagnosis
77539|NCT03578289|Behavioral|Telemental Health - CBT|The experimental group will received cognitive behavioral therapy (CBT) via TMH for 8 sessions.
77540|NCT03578276|Drug|Pred-Gati-Brom|The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
77541|NCT03578276|Drug|Prednisolone acetate 1% ophthalmic suspension|Steroidal anti-inflammatory
77542|NCT03578276|Drug|Gatifloxacin Ophthalmic|Antibiotic
77543|NCT03578276|Drug|Bromfenac 0.075% Oph Solution|Non-steroidal anti-inflammatory
77544|NCT03578263|Drug|Carbetocin|Group (A): included 100 patients who received carbetocin 100 µg diluted in 10 ml normal saline and administered slowly (over 30-60 seconds) intravenously by anesthetist after the birth of the baby.
77545|NCT03578263|Drug|oxytocin|Group (B): included 100 patients who received a combination of intraoperative oxytocin 5 I.U which was diluted in 10 ml normal saline and administered slowly over (30-60 seconds) intravenously by anesthetist and
77546|NCT03578263|Drug|ergometrine|intramuscular ergometrine 0.2 mg.
77547|NCT03578250|Other|Robotic Training|Upper extremity training on a robotic device with or without error augmentation force field.
77548|NCT03578237|Device|Cryoneurolysis (active)|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: Epimed PainBlocker device: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with an active probe which results in a decrease in temperature
77549|NCT03578237|Device|Sham cryoneurolysis procedure|Mastectomy (subjects 1-18): Myoscience Iovera device: full cryo cycle. Mastectomy (subjects 19-end) and all other procedures: 3 cycles of 2-minute gas activation separated by 1-minute defrost periods with a SHAM probe that does not deliver gas to the tip or result in a drop in temperature
77550|NCT03578224|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)|Undergo EUS-FNA
77551|NCT03578224|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
77552|NCT03578224|Procedure|Fine-Needle Aspiration|Undergo FNA
77553|NCT03578224|Drug|Sonazoid (Perflubutane)|Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance
77554|NCT03578211|Behavioral|Shared decision making with decision aids|For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
77555|NCT03578198|Drug|Rituximab + MG4101|"Induction phase:~Rituximab (Truxima) 375mg/m2 IV Weekly (X4)~MG4101 3x107 cells/kg IV Weekly (X4)~Maintenance phase~Rituximab (Truxima) 375mg/m2 IV q 4 weeks (X4)~MG4101 3x107 cells/kg IV q 4 weeks (X4)"
77556|NCT03578172|Drug|human menopausal gonadotrophin|experimental group:Women will be given HMG 37.5-150IU daily followed by monitoring of the follicular growth (folliculometry) when serum Estradiol (E2)＜100pg/ml，progesterone (P)＜1ng/ml. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle ≥20mm in diameter followed by luteal phase support (using progesterone supplements) after 24 hours.
77557|NCT03578172|Drug|hormone replacement therapy|Women will be given 17 β-estradiol hemihydrate 2 mg and estrogen gel 5 g daily from day 3 of the cycle then the endometrial thickness will be assessed on day 7 by transvaginal sonography (TVS). If the endometrium is ≥ 9 mm, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 9 mm, estradiol will be continued until reaching appropriate endometrial thickness and then the luteal phase support will be started. The cycle will be cancelled If the estradiol administration ＞60 days.
77558|NCT03578159|Other|Chhatralaya|Chhatralaya, home for children provide living resources along with spiritual practices.
77559|NCT03578146|Combination Product|PRT064445/Rivaroxaban|
77560|NCT03578146|Combination Product|Placebo/Rivaroxaban|
77561|NCT03578146|Drug|Placebo|
77562|NCT03578133|Diagnostic Test|InBios® Active Melioidosis DetectTM-Lateral Flow Assay|Evaluation of a lateral flow assay for the detection of B.pseudomallei 6-deoxyheptan capsular polysaccharide antigen from sputum
77563|NCT03578120|Biological|Pre-school booster vaccine|Routine vaccination with pre-school booster vaccine
77564|NCT03578107|Behavioral|improvement of quality of stroke care|"hospital tool kits for quality improvement of reperfusion therapy ;~organizational stakeholder and opinion leader meetings;~data monitoring and feedback reports；~webinar for hospital teams"
77565|NCT03578081|Drug|Palonosetron Hydrochloride|Given IV
77566|NCT03578081|Drug|Ondansetron Hydrochloride|Given IV or PO
77567|NCT03578081|Drug|Dexamethasone|Given PO
77568|NCT03578081|Drug|Fosaprepitant Dimeglumine|Given IV
77569|NCT03578081|Drug|Olanzapine|Given PO
77572|NCT03578055|Drug|Placebo|Dosage: 1 capsule of placebo, 3 times daily Time of administration: 30 minutes after meal Duration of administration: From the day before surgery to 4 weeks after surgery
77573|NCT03578042|Drug|Losartan and amlodipine and hydrochlorothiazide|this is a fixed combination containing the 3 drugs
77574|NCT03578042|Drug|Standard of care|any free triple combination therapy for hypertension given as 2 or 3 pills
77575|NCT03578029|Drug|RGN-137|It will be applied topically to the appropriate wound once a day for up to 84 days.
77576|NCT03578029|Drug|Placebo|It will be applied topically to the appropriate wound once a day for up to 84 days.
77577|NCT03578016|Other|Circle of Security-Parenting|COS-P is a brief, behavioral and insight oriented therapeutic group approach for parents with the aim to promote parental sensitivity and attachment and autonomy in the parent-child relationship. The parents will participate in ten weekly 1,5-hour sessions at the clinic conducted by two COS-certified therapists. Groups will include 4-5 families at a time.
77578|NCT03578016|Other|Treatment as Usual|TAU consists of clinical assessment and treatment.
77579|NCT03578003|Other|Morning Bright Light Therapy|60 minutes of bright light therapy (10,000 lux) received within 90 minutes of waking
77580|NCT03577990|Behavioral|ITEC|As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.
77581|NCT03577990|Behavioral|No ITEC|After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without ITEC. Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
77582|NCT03577977|Drug|Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)|Betaferon was injected subcutaneously as prescribed by the treating physician.
77583|NCT03577964|Diagnostic Test|Glucose Measurements,|Measurement of glucose Levels in bronchio alveolar secretions
77584|NCT03577951|Procedure|high position space group|The left and right Trocar meet at the level of the sternum angle and begin to establish the operating space.
77585|NCT03577951|Procedure|low position space group|The left and right Trocar meet under the sternum angle and begin to establish the operating space.
77586|NCT03577938|Drug|Chinese herbal medicine|One dosage of CHM includes Artemisiacapillaris Thunb (30g), Salvia miltiorrhiza Bge (30g), Rhizoma Atractylodis Macroce- phalae (30g), Rubia cordifolia L (30g), Sieyesbeckiaorientalis L (30g). Paeoniae Radix Rubra (60g), Gardenia jasminoides Ellis (9g), Hedyotis diffusa Willd (30g) and Bletilla striata (15g) are involved for excess syndrome, and Astragalus membranaceus (30g), Radix Pseudostellariae (15g), Radix Aconiti Lateralis Praeparata (10g), Galli Gigeriae Endothelium Corneum (20g), Polygonum cuspidatum Sieb.et Zucc (15g) are involved for deficiency syndrome.
77587|NCT03577938|Other|Control (blank)|SMT therapy includes a high-calorie diet; nucleoside analogues for HBV DNA-positive patients; sodium restriction, diuretics and paracentesis combined with albumin infusion for ascites; lactulose and L-ornithine aspartate and lactulose for HE and hyper-ammonia; hemostatic treatment for gastrointestinal hemorrhage; antibiotics for infections and renal replacement for HRS and uremic symptoms.
77588|NCT03577925|Diagnostic Test|HPV genotype test|HPV genotype test is a diagnostic test by smearing the cervix to find out whether a patient is hpv infected, and if infected, the test can descover the concrete hpv genotype.
77589|NCT03577912|Procedure|TAP block administered by Surgery|TAP block administered by Surgery
77590|NCT03577912|Procedure|TAP block administered by Anesthesia|TAP block administered by Anesthesia
77591|NCT03577899|Biological|0.5 mg Conbercept Intravitreal Injection|Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.
77592|NCT03577899|Biological|1.0 mg Conbercept Intravitreal Injection|Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.
77593|NCT03577899|Biological|2.0 mg Aflibercept Intravitreal Injection|Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
77594|NCT03577886|Drug|CDX-6114|CDX-6114 will be administered as a single, oral dose solution at dose levels of 0.225, 0.75, 2.25, and 7.5 g.
77595|NCT03577886|Drug|Placebo|Phosphate Buffer Diluent oral solution
77596|NCT03577873|Other|gallbladder preserved|Gallbladders will be remained after clearance of bile duct stones with ERCP and conventional therapy, such as fluid replacement and prophylactic anti infection, will be accepted.
77597|NCT03577873|Procedure|cholecystectomy|Cholecystectomy will be done right now after clearance of bile duct stones with ERCP, and then conventional therapy will be accepted.
77598|NCT03577860|Drug|Bupivacaine 4 mL|The interscalene brachial plexus block is performed with 4ml of bupivacaine-epinephrine 0,5%- 1:200,000
77599|NCT03577860|Drug|Bupivacaine 15 mL|The interscalene brachial plexus block is performed with 15ml of bupivacaine-epinephrine 0,5%- 1:200,000
77600|NCT03577847|Diagnostic Test|Rural CT scanning|Rural computer tomography for acute stroke
77601|NCT03577834|Dietary Supplement|liquid vinegar|6% red wine vinegar (2 tablespoons providing 1.7 g acetic acid)
77602|NCT03577834|Dietary Supplement|vinegar pill|Apple Cider Vinegar Tablets (1 tablet providing 0.0225 g acetic acid)
77603|NCT03577808|Other|Biopsy|Patients with locally advanced rectal cancer will receive biopsy of the primary tumor before neoadjuvant chemoradiation.
77604|NCT03577782|Biological|Entyvio (Vedolizumab)|"Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48."
77605|NCT03577756|Other|Neurodevelopmental assessments|Infants' neurodevelopmental assessments will be done by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. Bayley-III assess the development of five distinct scales to be consistent with areas of appropriate developmental assessment for children from birth to age 3. The Bayley-III revision includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales.The Gross Motor Function Measure (GMFM) has 5 dimensions: A-lying and roll- ing; B-sitting; C- kneeling and crawl- ing; D-standing; and E-walking, run- ning, and jumping. The items are scored from 0 to 3. All items are summarized and expressed as a value of total points for each dimension of the GMFM.
77606|NCT03577743|Drug|Bevacizumab|-bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
77607|NCT03577730|Drug|Caffeine Citrate|Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
77608|NCT03577730|Drug|Dextrose Water|Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
77609|NCT03577717|Other|computerized cognitive training|participants will be trained 30 minutes/day, 3 days/week for 4 consecutive weeks.
77610|NCT03577717|Other|occupational therapy|participants will receive craft activities of occupational therapy for 30 minutes/day, 3 days/week for 4 consecutive weeks.
77611|NCT03577704|Drug|HLX07+Gemcitabine+Cisplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Gemcitabine and Cisplatin.~HLX07, IV, weekly."
77612|NCT03577704|Drug|HLX07+Paclitaxel+Carboplatin|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Paclitaxel and Carboplatin.~HLX07, IV, weekly."
77613|NCT03577704|Drug|HLX07+mFOLFOX6|"Recombinant anti-EGFR humanized monoclonal antibody in combination with Oxaliplatin, Calcium Folinate and 5-FU.~HLX07, IV, weekly."
77614|NCT03577691|Other|Training for use of web based Decision Aid|Subjects will be guided during a 30 minutes training session to use the website
77615|NCT03577691|Other|No training for use of web based Decision Aid|Subjects will not be guided during a 30 minutes training session to use the website
77616|NCT03577691|Other|Pretest surveys and posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pre test and posttest surveys or only posttest surveys that will take 15 mts of time
77617|NCT03577691|Other|Only posttest surveys|Subjects will be randomized to one of two groups initially: Those who do not receive training for the decision aid and those who are trained to navigate the decision aid. subjects in each group will be randomized to complete pretest and posttest surveys or only posttest surveys.
77618|NCT03577678|Procedure|Surgery to fix lateral half prosthesis for clavicle|Surgery to fix lateral half prosthesis for clavicle
77619|NCT03577665|Radiation|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
77620|NCT03577652|Drug|Ticagrelor|Ticagrelor, 90mg, 90mg twice daily
77621|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fasted dosing on period one followed by fed dosing on period two.
77622|NCT03577626|Drug|Hemay005|Hemay005 tablets will be taken orally in dose of 52.5mg at fed dosing on period one followed by fasted dosing on period two
77623|NCT03577613|Procedure|Open radical hysterectomy|
77624|NCT03577613|Procedure|laparoscopic radical hysterectomy|
77625|NCT03577613|Procedure|Robotically assisted radical hysterectomy|
77626|NCT03577600|Procedure|QMRT with the Cytotron®|Cytotron® utilizes a combination of instantaneous magnetic field and RF at the safe, lowerend of the EM spectrum. Radiofrequency waves are computed based on individualized PD measurements of the target lesion(s) for therapeutic purpose. Its working principle is based on the underlying theory of magnetic resonance.
77627|NCT03577587|Dietary Supplement|Silitidil for 21 days|daily ingestion of herbal galactagogue Silitidil over time period of 3 weeks
77628|NCT03577587|Dietary Supplement|Placebo for 21 days|daily ingestion of Placebo preparation over time period of 3 weeks
77629|NCT03577574|Procedure|retrobulbar anesthesia|2% lidocaine 4ml injected into retrobulbar space
77630|NCT03577574|Procedure|peribulbar anesthesia|2% lidocaine 4 to 8ml injected into peribulbar space
77631|NCT03577574|Procedure|two step anesthesia|conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
77632|NCT03577561|Other|Proficiency Based Progression Training in Phlebotomy|Trainees will receive an online didactic education package and a simulation skill training module. Both of these education and training platforms will be derived from the procedure characterisation and benchmarked on experienced practitioner's performance. Trainees will be required to engage with the education and training platforms in a process of deliberate practice learning until they demonstrate the requisite performance benchmark. Proficiency demonstration will be mandatory before progressing to ward proctored skill supervision on real patients. In addition, the doctors in training will receive ongoing and proximate feedback on their sampling mislabeling.
77633|NCT03577548|Other|Auto- questionnaires|10 auto-questionnaires are submitted to the patient during his/her consultation (which is part of the standard care).
77634|NCT03577535|Dietary Supplement|Oncoxin®|Chemo-, radiotherapy or their combination + standard oral mucositis treatment + ONCOXIN 25 ml twice daily for 20 days;
77635|NCT03577522|Device|Avenir cementless hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
77636|NCT03577522|Device|Corail HA-coated hip stem|Avenir cementless hip stem vs Corail HA-coated hip stem
77639|NCT03577483|Procedure|voice recordings|A digital processing of voice recordings (from 30 to 45 minutes) will be performed for each participant, using a high quality digital recorder: the DIANA (computerized device of acoustic analysis) and the EVA-2 workstations (assisted Evaluation system Voice).
77640|NCT03577470|Drug|D/C/F/TAF Fixed-Dose Combination (FDC)|Participants in treatment with D/C/F/TAF FDC, coming from different treatment histories will be observed in this study. No interventions will be administered as a part of this study.
77641|NCT03577457|Drug|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
77642|NCT03577457|Drug|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
77643|NCT03577457|Drug|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
77644|NCT03577457|Drug|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
77645|NCT03577431|Biological|arTreg-CSB|"Participants will receive a single dose of Treg product (arTreg-CSB). The target dose is 2.5 to 500 x 10^6 total cells. If a minimum arTreg-CSB dose of 1 to < 2.5 x 10^6 cells, the product will be infused. If the dose obtained after product manufacture is < 1 x 10^6 cells, the product will not be infused. When the dose obtained after product manufacture is > 500 x 10^6 cells, a dose aliquot will be prepared so that the administered dose will be ≤ 500 x 10^6 cells, and ≥ 2.5 to 500 x 10^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 15 to 30 minutes."
77646|NCT03577431|Procedure|leukapheresis|"Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg-CSB) IV infusion."
77647|NCT03577431|Drug|cyclophosphamide|40 mg/kg administered intravenously (IV) within 24 hours after completion of leukapheresis on Day -3 (-1 day) prior to Treg product (arTreg-CSB) infusion.
77648|NCT03577431|Drug|mesna|"Mesna is administered intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide.~The first dose will be administered intravenously before cyclophosphamide administration and the subsequent 3 doses at 3, 6 and 9 hours after the cyclophosphamide infusion."
77649|NCT03577431|Drug|everolimus|"EVR, an immunosuppressant (IS), is approved by the FDA for the prophylaxis of allograft rejection in adults receiving a liver transplant. Between day 30 and wk. 22 post-transplant, participant evaluation for eligibility to be converted to an EVR-based IS regimen will occur.~At the start of conversion from tacrolimus (TAC) to EVR IS:EVR will be started at 1.5 mg taken by mouth BID, with dose adjusted to achieve a trough blood level of 5-8 ng/mL. Once an EVR trough level of ≥ 5 ng/mL is achieved, baseline TAC dose will be reduced to achieve a trough level of 3-5 ng/mL.~When target EVR and TAC levels are achieved/ maintained over two consecutive measurements, and liver function tests, ALT and GGT, are ≤50 U/L, participants will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered, monitored and adjusted over time, per protocol."
77650|NCT03577418|Behavioral|Clinician-facilitated educational intervention|People with dementia (PWD) will complete the Preferences for Everyday Living (PELI). Care partners will complete the PELI from the perspective of the PWD (i.e., as if acting as surrogate decision-makers). Research staff will then review these assessments, highlighting areas of discrepancy in the importance of various preferences. A 30-minute preferences-based discussion will then be facilitated by the research clinician. This discussion will include review of the discrepancies identified in the assessments. The PWD and the care partners will then be encouraged to identify one area of discrepancy and to come together with a concrete action plan to resolve that area of discrepancy. A standardized document describing neuropsychiatric symptoms and reviewing the unmet needs hypothesis will be discussed with PWD and the care partners.
77651|NCT03577418|Behavioral|Enhanced usual care|In addition to the usual clinical care, the standardized document describing NPS and reviewing the unmet needs hypothesis will be given to the PWD and the care partner to review.
77652|NCT03577392|Drug|oxaliplatin + capecitabine (XELOX chemotherapy)|Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
77653|NCT03577392|Drug|rebombniant human endostatin|Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
77654|NCT03577379|Other|Whole Blood Fibrin Clot|For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
77655|NCT03577353|Behavioral|Dual Task Walking (DTW)|Each training session began with 8 min of general warm-up and 2 min walk around the gym. Then, for safety reasons, the participants were attached to a harness. The participants began walking slowly on the treadmill for 3 min. In the following phases the participants walked at the same speed, while training with 3 VR games. Each session lasted 3 min, and 3 min of single walking was performed between VR sessions. After the final VR session, 2 min of single-task walking was performed in order to allow for recovery. The time walked in each trial from the starting point to the destination was kept constant at 20 min.
77656|NCT03577353|Behavioral|Single-task Treadmill Walking (TMW)|this intervention, participants performed 8 min of general warm-up and 2 min walk around the gym, and then continued to walk for another 20 min on the treadmill at a speed that was equivalent to the intensity of 60%-70% of their heart rate reserve.
77657|NCT03577340|Other|implant of cardiac device as per guidelines|Observation of performance to validate matrix
77658|NCT03577314|Other|miscarriage|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
77659|NCT03577301|Behavioral|Clinic-based Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.
135791|NCT03127345|Drug|Intralipid|Standard of care
77660|NCT03577301|Behavioral|Remote Delivery|A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.
77661|NCT03577288|Behavioral|manipulation of the level of realism|"The realism of the virtual experience will be manipulated. In one condition the realism will be high and in another condition the realism will be low. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., high realism with negative stimuli, low realism with negative stimuli, high realism with positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement (only in part A) and Late Positive Potential (EEG - only in part B) will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
77662|NCT03577288|Behavioral|manipulation of the presence of avatar|"The presence of avatar in the virtual experience will be manipulated. In one condition the avatar will be present and in another condition the avatar will not be present. In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., with avatar and negative stimuli, without avatar and negative stimuli, with avatar and positive stimuli, etc.).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
77663|NCT03577288|Behavioral|manipulation of interaction|"Virtual experience condition will be manipulated. In one condition the participants will be exposed to the virtual experience in which they will be able to interact with some of the stimuli, in another condition they will not be able to interact with the stimuli (passive watching). In addition, emotional category of stimuli for each virtual experience condition will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., interaction possible - negative stimuli, interaction impossible - negative stimuli, interaction possible - positive stimuli).~The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion."
77664|NCT03577288|Behavioral|manipulation of the nature of stimulus|The nature of the stimuli with which the participants will interact will be manipulated. During virtual experience the participants will have a choice to interact or not with the virtual environment, in one condition with animate stimuli and in another condition with inanimate stimuli. In addition, emotional category of animate and inanimate stimuli will be manipulated. Thus, each participant will be submitted to six virtual experiences (e.g., condition with animate negative stimuli, condition with inanimate negative stimuli, condition with animate positive stimuli). The measures of the pupillary responses, gaze fixation, heart rate, head movement will be realized. In addition, the participants will respond to the scales and questionnaire evaluating their emotion, feeling of presence and feeling of immersion.
77665|NCT03577275|Drug|NST-4016 600mg|Likely maximum therapeutic dose of NST-4016
77666|NCT03577275|Drug|Placebo oral capsule|Placebo for comparison with moxifloxacin and potential NST-4016 effects
77667|NCT03577275|Drug|Moxifloxacin 400mg|Active comparator with known effect on QT interval
77668|NCT03577275|Drug|NST-4016 2000mg|Supratherapeutic dose of NST-4016
77669|NCT03577262|Other|[11C]-UCB-J|IV radioligand given prior to and during positron emission tomography (PET) scan
77670|NCT03577249|Drug|Dialysis Solutions|Solution A: 3mmol/L of acetate anion; Solution B: 1mmol/L of citrate anion
77671|NCT03577236|Device|Zenflow Spring System|The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
77672|NCT03577223|Other|Whole Eggs|3 whole eggs per day for 4 weeks
77673|NCT03577223|Other|Egg White-Based Egg Substitute|3-egg equivalent of egg white-based egg substitute per day for 4 weeks
77674|NCT03577210|Procedure|augmentation genioplasty|augmentation genioplasty with patient-specific PEEK implant
77675|NCT03577184|Drug|Metformin/Vildagliptin|Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.
77676|NCT03577171|Drug|ABI-H0731|Participants will receive 300mg QD of ABI-H0731 tablets orally.
77677|NCT03577171|Drug|SOC NUC (ETV)|Participants will receive SOC NUC (0.5 mg QD of ETV) orally as per approved package insert.
77678|NCT03577171|Drug|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
77679|NCT03577158|Device|Closed-loop controller with exercise mitigation module|"Each subject will undergo three exercise tests, each one at 1-2 week intervals, thus completing the 3 experiments in about 6 weeks. The day of the experiment, the participant will do 3 sets of 15 minutes of cycloergometer at 70% of VO2max with 5 minutes of rest between them. On the first arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration with a mitigation mode, based on subcutaneous continuous glucose monitoring (First arm, Closed-loop study with mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
77680|NCT03577158|Device|Closed-loop controller without exercise mitigation module|"On the second arm, participants will receive Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration without a mitigation mode, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study without mitigation module).~Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
77681|NCT03577158|Device|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin sensibility. Commercial insulin infusion systems and continuous subcutaneous glucose monitoring devices will be used.
77682|NCT03577145|Dietary Supplement|Tomato, onion & lovage soup with inulin|Source of polyphenols and non digestible carbohydrate
77683|NCT03577145|Dietary Supplement|Tomato, onion & lovage soup|Source of polyphenols
77684|NCT03577145|Dietary Supplement|Inulin|Source of non digestible carbohydrate
77685|NCT03577132|Drug|Neoadjuvant atezolizumab|"Atezolimumab~At a fixed dose of 1200 mg as a 60-minute intravenous infusion (1st), then as a 30-minute intravenous infusion (2nd and 3rd)~Every 3 weeks, for a total of 3 cycles prior to radical cystectomy"
77686|NCT03577119|Dietary Supplement|Full-fat yogurt|Controlled diet that includes three daily servings of whole (3.25% fat) yogurt.
77688|NCT03577106|Device|Transcranial magnetic stimulation (TMS)|Theta Burst Stimulation (TBS), a form of TMS, will be targeted to the Inferior Parietal Cortex based on neural navigation software. TBS will be delivered for about 5-6 minutes, five days a week for two weeks, for a total of ten sessions.
77689|NCT03577093|Other|There is no intervention at all.|There is no intervention at all.
77690|NCT03577080|Other|ET+RT+ NMES|Endurance training, resistance training and neuromuscular electrical stimuation were prformed. Intensity was gradually increased.
77691|NCT03577067|Procedure|Liver resection for primary and secondary disease|Liver resection in parenchyma-sparing setting for primary and secondary disease
77692|NCT03577054|Behavioral|HBB Prompt|Mobile app developed through user-centred design in phase 1 of this study
77693|NCT03577054|Behavioral|Low-Dose High Frequency training|Participants will be encouraged to practice their HBB skills daily
77694|NCT03577028|Biological|HPN424|In Part 1 (Dose Escalation), HPN424 will be administered once weekly via IV infusion. In Part 2 (Dose Expansion), HPN424 will be administered at the recommended phase 2 dose(s) once weekly via IV infusion.
77695|NCT03577002|Other|Serious Illness Care Program (SICP)|SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
77696|NCT03576989|Dietary Supplement|EPA+DHA|EPA+DHA are the n-3 polyunsaturated fatty acids contained in fish oil
77697|NCT03576989|Other|placebo|placebo contains mineral oil
77698|NCT03576976|Behavioral|Cognitive Remediation|Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition to and bridge newly learned cognitive skills to everyday life.
77699|NCT03576963|Drug|Guadecitabine|Given SC
77700|NCT03576963|Biological|Nivolumab|Given IV
77701|NCT03576937|Diagnostic Test|GUARDANT360|GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.
77702|NCT03576924|Behavioral|Imposed-MICT|Moderate-Intensity Continuous Training (MICT) is continuous exercise for 30 min/session at 60-65% of heart rate max for 5 times/week, consistent with the physical activity guidelines of 150 min/week of moderate activity. Individuals are asked to engage in MICT exercise only (IM-MICT) during the supervised and unsupervised exercise sessions. During the supervised exercise the intensity will be based on the HR monitors, and affective and psychophysiological responses of perceived exertion. The exercise training is paired with 30 min behavioural counselling that is identical for all three interventions.
77703|NCT03576924|Behavioral|Imposed-HIIT|Individuals randomized to IM-HIIT will be asked to engage in High-Intensity Interval Training (HIIT) exercise only, which is 5 repeated vigorous intervals of 1-min duration at 85-90% of heart rate max with 1-min recovery periods, with 3-min warm-up and 2-min cool-down. Total session duration is 15 min for 5/week and it matches the guidelines of 75 min of vigorous exercise per week. During the supervised and unsupervised exercise sessions participants will perform a 15 min bout of HIIT. During the supervised exercise the intensity will be based on the HR monitors, and affective and psychophysiological responses of perceived exertion. The exercise training is paired with 30 min behavioural counselling that is identical for all three interventions.
77704|NCT03576924|Behavioral|CHOICE|Participants will first be familiarized with HIIT and MICT in randomized, counter-balanced order and subsequently they will always self-select the exercise type for the supervised and unsupervised exercise sessions. The IM-HIIT and IM-MICT protocols will match to the parallel imposed conditions. During the supervised exercise the intensity will also be based on affective and psychophysiological responses of perceived exertion. Throughout the 3-week intervention as well as during the 12-month follow-up, participants in the CHOICE condition will be told to choose either HIIT or MICT each time they exercise. The exercise training is paired with 30 min behavioural counselling that is identical for all three interventions.
77705|NCT03576911|Dietary Supplement|Coenzyme Q10|
77706|NCT03576911|Other|Placebo|
77707|NCT03576885|Drug|inhaled nitric oxide|inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
77708|NCT03576885|Drug|Placebo|placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
77709|NCT03576872|Other|Psychoeducational|Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
77710|NCT03576859|Other|blood sample|Peripheral venous blood is collected before liver transplantation and after restoration of liver function
77711|NCT03576846|Other|Stretching and Spinal manipulative therapy|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles. In addition, subjects will be treated with Spinal manipulative therapy
77712|NCT03576846|Other|Stretching|Subjects will be instructed to perform a series of progressively difficult stretching exercises for the neck and upper back muscles.
77713|NCT03576833|Device|Elipse Balloon system|intragastic balloon
77714|NCT03576820|Drug|Lidocaine|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
77715|NCT03576820|Drug|Placebo|Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
77716|NCT03576807|Drug|CD20 CAR-T cells|A total of 1 - 20×10^6 CD20 CAR-T cells/kg will be administered by IV infusions.
77717|NCT03576794|Drug|Leflunomide 20 mg|During the first 2 weeks after randomization patients will receive Leflunomide 20 mg every other day. After 2 weeks Leflunomide will be increased to 20 mg once daily and this therapy will be continued during 12 months.
77864|NCT03575832|Behavioral|Telephone-Based Intervention|Receive telephone coaching calls
77718|NCT03576794|Drug|Prednisolone|Patients in both groups will receive prednisolone 15 mg once daily and will be randomized within 4 weeks of the start of glucocorticoid therapy (prednisolone). Prednisolon will be tapered according to a short fixed protocol with a slow gradual taper till 0 in week 27.
77719|NCT03576781|Device|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
77720|NCT03576781|Device|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
77721|NCT03576781|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
77722|NCT03576781|Device|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
77723|NCT03576768|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key)
77724|NCT03576768|Device|Sham cTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
77725|NCT03576768|Device|Real iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key).
77726|NCT03576768|Device|Sham iTBS|This will be delivered with the Magventure Magpro system; 600 pulses with the active sham coil (double blinded using the USB key). The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
77727|NCT03576755|Drug|Spironolactone 100mg|Spironolactone capsules will be prepared from USP grade powder at a dose of 100 mg.
77728|NCT03576755|Drug|Placebo oral capsule|Matching placebo capsules of the same color, mass, and appearance to the spironolactone capsules will be filled using microcrystalline cellulose powder.
77729|NCT03576742|Diagnostic Test|potential biomarkers|facs analysis, microbiome analysis
77730|NCT03576716|Drug|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
77731|NCT03576703|Other|Exercise with and without SSB ingestion|Consumption of a prescribed diet with and without SSB and performance of moderate aerobic exercise or resting/control
77732|NCT03576690|Biological|REGN3470-3471-3479|
77733|NCT03576677|Drug|Levosimendan|"Levosimendan, 2.5 mg/mL concentrate for dilution. 5 mL of the study drug will be injected into a 245 mL isotonic glucose solution.~Patients will receive a 6 hours infusion of this study drug at an infusion rate of 0.2 µg/kg/min."
77734|NCT03576677|Drug|Placebo|"The placebo solution will be prepared by adding 10 mL of 5% dextrose to a vial containing Soluvit (vitamin B) under aseptical conditions. 5 mL of this solution is then added to 245 mL of isotonic sodium chloride solution.~5% dextrose and vitamin B are added to ensure yellow coloring indistinguishable from the active drug (levosimendan).~Patients will receive a 6 hours infusion of this study drug. Infusion rate will be calculated in similar fashion to the levosimendan group."
77735|NCT03576664|Drug|Carvedilol 25mg|Cross-over, randomized, placebo-controlled study.
77736|NCT03576664|Drug|Placebo oral capsule|Cross-over, randomized, placebo-controlled study.
77737|NCT03576651|Biological|JHL1149|Each patient may receive single dose of JHL1149 1mg/kg by intravenous infusion
77738|NCT03576651|Biological|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
77739|NCT03576651|Biological|Bevacizumab|Each patient may receive single dose of Avastin 1mg/kg by intravenous infusion
77740|NCT03576638|Drug|Accordion Pill Carbidopa/Levodopa|AP 50/500 TID days 2-7
77741|NCT03576638|Drug|Sinemet CR 25Mg-100Mg Extended-Release Tablet|25/100 1.5 pills five times/day
77742|NCT03576625|Dietary Supplement|High Oleic Sunflower Oil|Consume oil smoothie (emulsified HOSO) with a meal once daily for 9 weeks
77743|NCT03576625|Dietary Supplement|Buglossoides Oil|Consume oil smoothie (emulsified Buglossoides oil) with a meal once daily for 9 weeks
77744|NCT03576612|Biological|AdV-tk|Given IT
77745|NCT03576612|Drug|Valacyclovir|Given PO days 1-14; 1-3 days post surgery
77746|NCT03576612|Radiation|Radiation|Undergo RT, 60Gy in 30 daily fractions M-F for 6weeks
77747|NCT03576612|Drug|Temozolomide|Given PO during RT 75mg/m2 daily during RT Post RT cycle 1: 150mg/m2 days 1-5 150mg/m2 cycle 2-6: days 1-5 (150-200mg/m2)
77748|NCT03576612|Biological|Nivolumab|day 15 post surgery 240mg IV q2wks x 26 doses , up to 52 weeks
77749|NCT03576612|Other|Laboratory Biomarker Analysis|correlative studies
77750|NCT03576599|Drug|Zoledronic Acid Injectable Product|One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
77751|NCT03576599|Drug|Placebo|Placebo
77752|NCT03576586|Behavioral|Brief computerized intervention|"Brief computerized intervention (computer game Tetris) plus usual care in the maternity department"
77753|NCT03576586|Behavioral|Attention placebo control|Brief cognitive task plus usual care in the maternity department
77754|NCT03576573|Device|PROFEMUR Xm, PROFEMUR Gladiator Plasma Stems , PROCOTYL® C|Hip Arthroplasty
77755|NCT03576560|Other|Retrospective Chart Review|Retrospective Chart Review
77756|NCT03576547|Drug|Dexamethasone|Given PO or IV
77757|NCT03576547|Drug|Ponatinib Hydrochloride|Given PO
77758|NCT03576547|Biological|Rituximab|Given IV
77759|NCT03576547|Drug|Venetoclax|Given PO
77760|NCT03576534|Other|Use of prebypass ultrafiltration (PBUF)|In addition to standard of care for cardiopulmonary bypass, in the study arm prebypass ultrafiltration will be performed.
77791|NCT03576313|Other|standard malaria control interventions only|this is the standard malaria control interventions in the Gambia
77792|NCT03576287|Drug|Apremilast Oral Product|Apremilast
77793|NCT03576274|Behavioral|TEHE only|A six-week 60-minute goal setting and exercise training program
77761|NCT03576521|Combination Product|CT + Ocoxin-Viusid|"The included patients received the Ocoxin-Viusid nutritional supplement at a rate of 75 ml daily (25 ml in 3 doses every 8 hours) administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment* and up to three weeks after the end of the treatment.~*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
77762|NCT03576521|Combination Product|CT + Placebo|"The included patients received the OV placebo in oral solution at a rate of 75 ml daily (25 ml in 3 doses every 8 hours), administered after main meals diluted in milk or juice. The treatment will start a week before, it will be maintained throughout the coventional chemotherapy treatment* and up to three weeks after the end of the treatment.~*All patients should receive the CT Adriamycin 60 mg per m2 of Body Surface (BS) and Cyclophosphamide Infusion intravenous every 21 days, up to a total of 4 to 6 cycles according to protocols provided in the center."
77763|NCT03576508|Drug|CNTX-4975-05|1 mg (2mL) IA injection
77764|NCT03576508|Drug|Qutenza|8% topical patch
77765|NCT03576508|Drug|Lidocaine (without epinephrine)|15 mL IA injection of 2% lidocaine (without epinephrine)
77766|NCT03576495|Other|PACTS curriculum|"The cultural dexterity curriculum, known as PACTS (Provider Awareness Cultural Dexterity Toolkit for Surgeons) focuses on developing cognitive skills to adapt to individual patients' needs to ensure personal, patient-centered surgical care.~The curriculum is comprised of four educational modules on establishing trust in the physician-patient relationship, communicating effectively with patients with limited English proficiency, discussing informed consent, and issues surrounding pain management. Each module consists of an independent learning activity, an interactive role-play, and a post-lesson assessment."
77767|NCT03576482|Other|Transport on foot|Patients go to operating room walking with their families and with their normal clothes
77768|NCT03576469|Biological|C1-esterase inhibitor [recombinant] (C1-INH-R)|C1-INH-R is FDA approved and indicated for the treatment of acute attacks of angioedema in adolescent and adult patients with Hereditary Angioedema (HAE) as a replacement for low levels of C1-esterase inhibitor or low function of C1-esterase inhibitor
77769|NCT03576456|Drug|Alprazolam 0.5 mg|receive alprazolam prior to angio
77770|NCT03576456|Drug|Placebo Oral Tablet|receive placebo prior to angio
77771|NCT03576443|Drug|Idelalisib|Idelalisib 150 mg x 2 p o
77772|NCT03576430|Device|active stress handling|biofeed back stress handling
77773|NCT03576417|Drug|Cisplatin|Intravenous
77774|NCT03576417|Drug|Nivolumab|Intravenous
77775|NCT03576417|Radiation|RT|IMRT 66 Gy / 6.5 weeks
77776|NCT03576404|Other|Patient-Centered Pharmacist Care|A comprehensive interview applying the concepts of Medication Therapy Management (MTM) and Motivational Interview (MI)
77777|NCT03576391|Behavioral|Control condition|45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
77778|NCT03576391|Behavioral|Rapid Arm Movements|2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
77779|NCT03576391|Behavioral|Physical fatigue condition|40 minutes rest while seated followed by static endurance tasks, i.e. modified Biering-Sörensen task and static abdominal curl task.
77780|NCT03576391|Behavioral|Cognitive fatigue condition|45 minutes of a cognitively fatiguing condition consisting of a modified incongruent Stroop color-word task.
77781|NCT03576378|Drug|BrentuximabVedotin (BV)|All patients will be treated with 6 cycles of BV-EPEM
77782|NCT03576365|Behavioral|VOICE Intervention Arm|"Introductory and background information about voice problems and psychosocial distress~Examples of concerns raised by patients with voice problems (e.g., I feel left out of conversations because of my voice problem)~Information about perceived control and how improving perceived control can lead to decreased distress~Examples of strategies that have helped patients identify controllable and uncontrollable aspects of their voice problems (e.g., I learned to plan to take breaks to rest my voice between teaching classes)~Self-guided exercises designed to help improve perceived control and develop better management skills for voice problem symptoms"
77783|NCT03576365|Behavioral|Information-Only Arm|"General introduction of the program and background on voice related information in an interactive manner~Examples of what patients want to learn more about the voice (e.g., I would like to learn more about how the voice works when it is healthy)~Information on the anatomy of the voice and how the voice works~Educational materials to help understand voice physiology and function~Self-guided learning exercises (e.g., what are some things about vocal function that you would like to learn more about?)"
77784|NCT03576352|Other|a rapid sequence tracheostomy (RST) on rabbit cadaver|"The Rapid Sequence Tracheostomy (RST) consists of the following steps:~Orientational palpation and vertical midline skin incision followed by separation of the strap muscles~Exposure of the trachea and cricoid followed by anterior luxation of the trachea with a Backhaus towel clamp~Perform a vertical puncture with a tip scissors between the Cricoid and 1st tracheal ring followed by a vertical incision of no more than 2 rings in length.~An age adapted tracheal tube is inserted into the trachea and the lungs are ventilated."
77785|NCT03576339|Procedure|Free Gingival Graft|Free gingival graft removal from palate for socket preservation
77786|NCT03576339|Device|SHAM Electric stimulation|Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
77787|NCT03576339|Device|Electric Stimulation|Local Electric Stimulation for 120 seconds once a day in five consecutive days.
77788|NCT03576326|Behavioral|Drawing Incentive|The Monetary Reward intervention is a drawing reward, in which participants are eligible for weekly rewards based on toothbrushing performance.
77789|NCT03576313|Drug|dihydroartemisinin-piperaquine (DP)|DP will be available as tablets of 320/40mg and 160/20mg piperaquine/ dihydroartemisinin per tablet. Administration of a full course of DP will be done as per manufacturer's guidelines once daily for 3 days and according to body weight. DP will be taken orally with water and without food
77790|NCT03576313|Drug|ivermectin (IVM)|IVM will be available as tablets of 3mg or 6mg strength. It will be given at 300-400μg/kg/day over 3 days (to the nearest whole tablet). IVM will also be taken on an empty stomach with water
77794|NCT03576274|Behavioral|Auricular Point Acupressure|A non invasive complementary method to provide pressure on the ear points.
77795|NCT03576274|Behavioral|Mindfulness body scan|The open, nonjudgmental attention to move one's attention calmly to the different part of the body
77796|NCT03576261|Other|Preoperative colloid fluid bolus (Gelofusine)|Preoperative colloid fluid bolus
77797|NCT03576261|Diagnostic Test|Preoperative transthoracic echocardiography|Screening of biventricular systolic and diastolic function of the heart and level of venous return by transthoracic echocardiography approximately one hour before preoperative fluid therapy and anesthesia induction.
77798|NCT03576248|Device|In-phase 6 Hz prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
77799|NCT03576248|Device|Sham prefronto-parietal tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
77800|NCT03576248|Device|2 mA left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
77801|NCT03576248|Device|Sham left prefrontal tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
77802|NCT03576235|Drug|PG102P|Daily dose of 1.5g
77803|NCT03576235|Drug|Placebo|Daily dose of placebo
77804|NCT03576222|Device|PICO DRESSING|USE PICO DRESSING ON SURGICAL INCISION AFTER ABDOMINAL WALL REPAIR IN THE SURGICAL ROOM
77805|NCT03576222|Device|MEPORE dressing|MEPORE dressing
77806|NCT03576209|Behavioral|Walking intervention|Participants (intervention group) are following a 12 week health promotion program. They will count daily steps by pedometers and participate in weekly organised walks (within socio-cultural organisation)
77807|NCT03576196|Other|Preoperative Pain Neuroscience Education|"Single session of pain neuroscience education a week prior to surgery, of an individual character, lasting approximately 30 minutes, performed by a physiotherapist trained. The main contents addressed in the educational session were: neurophysiological aspects of pain, biopsychosocial aspects of pain, concept of peripheral and central sensitization, using audio-visual support, examples and metaphors for a better understanding by the patient, as reported in previous studies.~This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist."
77808|NCT03576196|Other|Usual Care|This treatment was combined with a hand therapy session seven days after the surgery, verbal and written instruction was given to the patients to perform exercises at home of active sliding of the digital flexor tendon, active opposition of the thumb and active range of flexion and extension of the wrist.
77809|NCT03576183|Biological|VLA1701|VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)
77810|NCT03576183|Biological|Placebo|buffer component of VLA1701
77811|NCT03576183|Other|Challenge Strain|LSN03-016011/A
77812|NCT03576170|Other|aromatherapy|aromatherapy by inhalation and/or therapeutic massage
77813|NCT03576157|Other|Kilkari|Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
77814|NCT03576144|Drug|BI 1265162|Multiple rising inhaled doses
77815|NCT03576144|Drug|Placebo|Multiple rising inhaled doses
77816|NCT03576131|Biological|GEN1029 (HexaBody®-DR5/DR5)|GEN1029 will be administered intravenously once every 14 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.
77817|NCT03576118|Drug|Deep neuromuscular block|Deep neuromuscular block using high dose rocuronium and 8 mmHg pneumoperitoneum
77818|NCT03576118|Drug|Moderate neuromuscular block|Moderate neuromuscular block using moderate dose rocuronium and 12-15 mmHg pneumoperitoneum
77819|NCT03576105|Combination Product|irrigation /sterile saline|mechanical removal of bacteria with sterile saline
77820|NCT03576105|Combination Product|Conventional methylene blue as photosensitizer|Irrigation with 0,04mL of photosensitizer (0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
77821|NCT03576105|Combination Product|Methylene blue for oral use as photosensitizer|Irrigation with 0,04mL of photosensitizer(0,005%) inside the gingival sulcus around the third molar with pericoronarite for 3 minutes
77822|NCT03576105|Combination Product|Photodynamic therapy|Red laser for photodynamic therapy (Therapy XT,DMC,Sao Carlos,Sao Paulo,Brazil) Device irradiation with low intensity laser λ = 660 nm, 9J per point and radiant 90 seconds
77823|NCT03576092|Diagnostic Test|Lung Ultrasound|Lung sonography will be performed on a SonoSite portable ultrasound machine with a C60e 5 - 2 MHx 30cm probe using a modified standard technique examining four lung regions; anterior mid-clavicular high and low on left and right sides, and one on each side posteriorly) in the semi-recumbent position.
77824|NCT03576079|Device|Laser therapy|epic model biolase with an output of 4W, 1800 J wavelength with a continuous Laser mode.
77825|NCT03576079|Device|anterior re-positioning splint|hard acrylic anterior re-positioning splint
77826|NCT03576079|Device|inactive Laser therapy|sham Laser, with inactive beam
77827|NCT03576066|Drug|ABI-H0731|Participants will receive 300 mg QD ABI-H0731 tablets orally.
77828|NCT03576066|Drug|SOC NUC|Participants will continue on their SOC NUC (ETV, TDF or TAF) tablet orally (QD frequency) as per approved package insert.
77829|NCT03576066|Drug|Placebo Oral Tablet|Participants will receive matching QD placebo tablets orally.
77830|NCT03576066|Drug|SOC NUC|Participants will receive SOC NUC (ETV, TDF or TAF) tablet orally as per approved package insert.
77831|NCT03576053|Drug|Lidocaine|Lidocaine intradermal injection
77832|NCT03576053|Other|Histamine|Skin Prick Test with Histamine
77833|NCT03576053|Other|Cowhage|Manually skin insertion of cowhage spicules
77834|NCT03576053|Other|Heat stimulation|Short heat stimulation
77835|NCT03576053|Other|Pre-heating|Mild skin pre-heating
77837|NCT03576040|Device|Whole Body Dynamic 68Ga-DOTATOC PET/CT|"68Ga-DOTATOC PET-CT will be performed in the nuclear medicine department of the University Hospital of Brest on a Biograph mCT S64 machine (Siemens medical, Erlangen, Germany) Time of Flight system after intravenous injection of 150MBq of 68Ga-DOTATOC. In the usual conditions for performing this exam, the patient must remain at a strict rest for 60 minutes following the injection of the tracer and before a static 3D acquisition. For this protocol, a complementary 4D dynamic acquisition (15-60 minutes post-injection) will be performed during this usual rest period."
77838|NCT03576027|Other|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy
77839|NCT03576014|Biological|BD03|BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2~4 weeks after the transplant.
77840|NCT03576001|Drug|Testosterone Undecanoate|administered through injections by study staff
77841|NCT03576001|Behavioral|hybrid exercise|hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
77842|NCT03575988|Other|Diabetes|The patients have diabetes without diabetic retinopathy from the diabetic outpatient
77843|NCT03575975|Device|Total Ankle Replacement Prosthesis|Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
77844|NCT03575962|Drug|GSK3640254 bis-hydrochloride salt capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
77845|NCT03575962|Drug|GSK3640254 Mesylate Salt Capsule|Administered orally (as single dose) on morning of Day 1, as 2 capsules of , 100 mg following a moderate calorie and fat meal during Period 1 and Period 2, at the specified sequence, as per study.
77846|NCT03575949|Procedure|Computed Tomography|Undergo FDG PET/CT
77847|NCT03575949|Other|Fludeoxyglucose F-18|Given IV
77848|NCT03575949|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
77849|NCT03575936|Device|Home INR Monitoring|The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.
77850|NCT03575936|Procedure|Standard of Care|The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
77851|NCT03575923|Behavioral|Urban street greening|The interventions are located on four publicly accessible sites; the total size of the floor area of green space in each of the intervention sites is small, ranging from 0.09 to 0.35 acres. Components of the interventions include tree and flower planting (expected to bloom by March 2018) and artificial tree decorations such as strings of small electric lights and tree socks (the interventions are hereafter collectively referred to as urban street greening). The total cost for all components across all four intervention sites is approximately £6,000, although this excludes artist fees connected to the project. All components of the interventions were implemented within a one week period in November 2017 by two arborists, two local artists, staff members at Southway Housing Trust, and local community members from Old Moat and a local school.
77852|NCT03575897|Diagnostic Test|Assessment of infant body composition|Serial assessments of infant body composition with air displacement plethysmography in very preterm infants will occur in the first 14 days after birth (baseline measure), at 32 weeks postmenstrual age (PMA), and at 36 weeks PMA or hospital discharge (whichever occurs first)
77853|NCT03575884|Behavioral|Screen Time Reduction Curriculum|"Fit5Kids classroom curriculum, weekly parent newsletters, in-person (or by telephone) goal setting on their child's screen time, a lending library of resources (books, games, arts/crafts, etc), and text messages on screen time parenting practices offered over 7-8 weeks in the Fall semester. The classroom component will be taught by bilingual (English/Spanish) research staff interventionists. Parent newsletters, goal setting, and text messages will be offered in English and Spanish per parent preference. There will also be two booster weeks of classroom activities, daily parent newsletters, goal setting, and daily text messages on screen time parenting practices offered during the booster weeks in the Spring semester. The lending library of resources for parents/children will be available throughout the entire school year."
77854|NCT03575871|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
77855|NCT03575871|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
77856|NCT03575871|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
77857|NCT03575858|Device|Barrel shaped interdental brush|Barrel shaped interdental brush Size SS 0.8mm
77858|NCT03575858|Device|Tapered interdental brush|Tapered interdental brush Size SS 0.6mm
77859|NCT03575845|Behavioral|Occupational Therapy Informed Yoga|Occupational therapy informed yoga met weekly for six, 60-minute sessions. Each session started with a seated warm-up to coordinate breath and movement and promote upper extremity mobility. Standing postures followed to target balance. Sessions closed with restorative postures in seated and supine variations.
77860|NCT03575832|Other|Counseling|Complete nutrition counseling sessions
77861|NCT03575832|Other|Informational Intervention|Receive an exercise plan and printed materials
77862|NCT03575832|Other|Quality-of-Life Assessment|Ancillary studies
77865|NCT03575819|Drug|FOR46|FOR46 is an intravenously (IV) administered antibody-drug conjugate (ADC) directed against CD46
77866|NCT03575806|Combination Product|TACE plus autologous Tcm immunotherapy|"TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro."
77867|NCT03575806|Procedure|TACE|TACE:transcatheter arterial chemoembolization.
77868|NCT03575793|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities.
77869|NCT03575793|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity originally developed by Nereus Pharmaceuticals, Inc., and now by BeyondSpring Pharmaceuticals, Inc. It belongs to the diketopiperazine class of compounds with a chemical name 2, 5-piperazinedione, 3-[[5-(1,1-dimethylethyl)-1H-imidazol-4-yl[methylene]-6-(phenylmethylene)-, (3Z,6Z) (trivial name t-butyl-dehydrophenylahistin).
77870|NCT03575793|Drug|Ipilimumab|Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
77871|NCT03575780|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical Actinic Keratosis on the face or balding scalp.
77872|NCT03575767|Other|Myeloablative Hematopoietic Stem Cell Transplantation|Myeloablative hematopoietic stem cell transplantation from many kinds of donors, including matched related donor, matched unrelated donor, haploidentical related donor.
77873|NCT03575741|Diagnostic Test|Balance Tests|"Following balance exercises will be performed by the participants:~Bipedal, hip wide stand, eyes open and hands on hips, 60sec~Bipedal, hip wide stand, eyes closed, hands on hips, 30sec~Tandem-stand, eyes open, hands on hips, 60sec (front foot chosen by participant)~Tandem-stand, eyes closed, hands on hips, 30sec (same front foot)~One-leg-stand, eyes open, hands on hips, 30sec (randomized supporting leg)~One-leg-stand, eyes open, hands on hips, 30sec (other leg)~Bipedal, hip wide stand, eyes open, hands on hips, counting backwards in steps of two (367 - 365 - 363 - ...), 60sec~The rest between the trials will last for at least 30sec, but can be extended by the participants as long as they want. The overall measurement will not exceed 30 minutes."
77874|NCT03575728|Other|MyChart-MHT|All participants in this study will receive targeted psycho-educational interventions from time to time based on symptom severity reports as determined by the software algorithm
77875|NCT03575715|Device|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
77876|NCT03575702|Drug|Uritos®|film-coated tablets 0.1 mg
77877|NCT03575702|Drug|Urotol®|film coated tablets, 2 mg
77878|NCT03575689|Device|Doyle Splint|Using Doyle splints following septoplasty is the standard of care and may help with stability of the septum in the immediate post op period. owever these splints are associated with morbidity in the post-op period. The quilting technique was developed to prevent complications and stabilize the septum. This study examines the efficacy of these splints in stabilizing the septum and preventing complications after septoplasty
77879|NCT03575676|Drug|SOM3355 100mg BID|Oral
77880|NCT03575676|Drug|SOM3355 200mg BID|Oral
77881|NCT03575676|Drug|Placebo BID|Oral
77882|NCT03575663|Diagnostic Test|Indirect bronchial challenge|Mannitol dry powder inhalation
77883|NCT03575663|Other|Sham bronchial challenge|Mock dry powder inhalation
77884|NCT03575650|Other|Cardiac imaging modalities|Repeat cardiac echocardiographies, MRI-scans and CT-scans for early subclinical biomarker assessments in breast cancer patients treated with chemotherapy and radiotherapy
77885|NCT03575637|Drug|Olanzapine|Patients who have failed first-line treatment of advanced gastric cancer receive second-line treatment with paclitaxel regimen and olanzapine 5 mg QD.
77886|NCT03575624|Behavioral|Nutritional and goal-setting education, yoga|"This integrative program series, Live Well, was delivered bi-weekly from January-May 2017, by an interdisciplinary team of a registered nurse, occupational therapist/researcher, registered dietitian, and certified yoga instructor.~Session experiences were designed to build:~Sisterhood for health promotion and support, Individual and group health promotion through goal-setting, Healthy family nutrition and meal planning skills , Family integrated yoga practice"
77887|NCT03575611|Radiation|Stereotactic Body Radiation Therapy|Study doctor discusses with participant the dose and schedule of radiation that participant receives, based on the disease site. It can take 1 day to 3 weeks.
77888|NCT03575598|Drug|Sitravatinib|Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a variety of in vitro and in vivo model systems.
77889|NCT03575598|Biological|Nivolumab|Nivolumab (OPDIVO®) is a human IgG4 kappa immunoglobulin that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
77890|NCT03575585|Behavioral|BEST assessment only|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels.
77891|NCT03575585|Behavioral|BEST assessment plus feedback report|Patients complete the BEST assessment, a self-report measure containing questions about patients' substance use, sexual risk behaviors, and partner risk levels. Based on their responses they also receive a personalized feedback report that .provides individualized risk levels in five behavior domains: 1) number of partners, 2) riskiness of partners, 3) condom use, 4) riskiness of sex acts, and 5) sex under the influence of drugs or alcohol.
77892|NCT03575585|Behavioral|Standard Counselor Training|2 hours of training on how to use the BEST patient feedback report
77893|NCT03575585|Behavioral|Enhanced Counselor Training|Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
77914|NCT03575390|Dietary Supplement|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
77894|NCT03575572|Drug|Colchicine|Colchicine is an alkaloid approved in 1961 for the use in Familial Mediterranean Fever in adults and children 4 years of age or older. It has been widely used for decades in other indications, such as Gout, recurrent pericarditis, pericardial effusions and other inflammatory diseases. This drug is commercially available and is approved in children 4 years and older.
77895|NCT03575559|Behavioral|Individual planning|Each participant forms up to three action and up to three coping plans individually, without consulting the participating friend, but discussing the plans with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
77896|NCT03575559|Behavioral|Collaborative planning|Both friends together create up to three if-then plans on when, where, and how both will implement PA together. In addition, up to three coping plans will be formed together. This jointly developed plan is discussed with the experimenter. CONTENT: The planning materials and forms have the following sections: (a) information on the importance of planning (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans based on the if-then structure. Action plans refers to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in PA). All materials are formulated using the plural.
77897|NCT03575559|Behavioral|Education and motivation treatment|Adolescents will watch a movie from the Federal Office of Public Health Switzerland including the guidelines of physical activity (PA) for adolescents. All adolescents respond to a quiz afterwards. After the quiz, the experimenter repeats the guidelines for PA based on a brochure that all adolescents can take home with them. In addition, the experimenter asks for barriers and benefits of PA the adolescents perceive. Next to it, the experimenter explains that a weight gain might be possible due to PA in the beginning. Furthermore, the experimenter presents how the data of the accelerometer should look like if one is sufficiently physical active. As a last part self-efficacy as an important aspect of goal success is mentioned. The materials exclude any planning statements.
77898|NCT03575533|Diagnostic Test|Bayesian network 'Sherlock'|Primary objective is to validate the Bayesian Hemodynamics model 'Sherlock'. Criterion for validation is a match between Sherlock's estimate of the Hemodynamic status of a patient and a ground truth based on a cardiologist's judgement.
77899|NCT03575520|Drug|Pegfilgrastim|A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
77900|NCT03575520|Drug|Doxorubicin/Cyclophosphamide(AC) treatment|"doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks."
77901|NCT03575507|Device|Treatment with BTL EMSCULPT device.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the buttock area. Visible contractions will be induced by the device.
77902|NCT03575494|Other|Intraoral and Radiographic Dental Examination|(ORTHOPANTOMOGRAPH® OP300 PANORAMIC, Instrumentarium Dental, Tuusula, Finland,63 kVp, 0.8 mA, 0.5 s).
77903|NCT03575481|Diagnostic Test|The RAT and The TST|The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
77904|NCT03575468|Behavioral|Enhanced E-cigarette Coaching|The EEC intervention calls will include assessment of e-cigarette use and discussion about how and why e-cigarettes are being used on every call. In addition to the standard quitline cessation program, the enhanced program will include education (via quit coaches and two tailored quit guides), behavioral support tailored to dual users, and shared decision making strategies to address how and why FDA-approved quitting aids and ENDS are being used and to develop an integrated quit plan based on callers' decisions.
77905|NCT03575468|Behavioral|Quitline treatment as usual|The standard tobacco quitline program is a proactive 5-call intervention grounded in social cognitive theory and the U.S. Public Health Service clinical practices guidelines for treating tobacco use and dependence. All enrollees in the study are eligible for 2-8 weeks of nicotine replacement therapy (depending on their standard quitline benefit offering), if they medically qualify and/or return a medical override letter from their doctor.
77906|NCT03575455|Behavioral|Exercise|HR-controlled treadmill walking
77907|NCT03575442|Behavioral|"3 session program of art therapy"|With this program, we expect to offer socio-emotional well-being in the psychiatric context, and creative self-expression through painting. In addition, we hope to provide contributions towards the creation of quality standards of the professional practice of nurses, within the context of implementing psychosocial programs in mental health.
77908|NCT03575429|Behavioral|Engagement Intervention|"Family navigators will use MI to engage families to decrease resistance and build motivation and commitment to challenging behavior changes by eliciting and reflecting broader goals and values, linking those values to specific behavior change, and negotiating a menu of options for change based on individual preferences. PSE will be used by the Family Navigators to guide families in selecting an objective, measurable problem, then proceed through a series of steps that involve goal setting, brainstorming and evaluating solutions, choosing a solution, and action planning."
77909|NCT03575429|Behavioral|Engagement + Coaching Intervention|ESI program planning entails identifying goals and objectives for the child and teaching strategies and supports for parents. Each session includes the following components: 1) setting the stage to develop that visit's agenda and gather updates; 2) intervention implementation that must include the following steps to coach the parent: a) review the objective, b) use modeling, guided/caregiver practice, or video review to teach the strategy, c) provide specific feedback to the parent, and d) problem solving and plan for next time; steps a-d are repeated for 3-5 activities per session; and 3) summarize plans for parent implementation between sessions. Families are invited to Autism Navigator How-To Guide for Families, a self-guided web-based course, with an online weekly group meeting.
77915|NCT03575390|Dietary Supplement|Pomegranate|Pomegranate extract 500mg
77916|NCT03575377|Other|Disposal Aid|Deterra® drug deactivation system
77918|NCT03575351|Drug|Standard of Care|Standard of Care
77919|NCT03575351|Genetic|JCAR017|JCAR017
77920|NCT03575338|Procedure|Open Scarf Osteotomy|Open Scarf Osteotomy
77921|NCT03575338|Procedure|Minimally invasive scarf Osteotomy|Minimally invasive scarf Osteotomy
77922|NCT03575325|Drug|CPX-351|The infusion of CPX-351 (cytarabine:daunorubicin) Liposome Injection will be performed through a central venous catheter, using an infusion pump to ensure that the drug is infused over the specified time period.
77923|NCT03575312|Drug|Enrofloxacin|dermal application, inhalation rsp. oral administration of Enrofloxacin
77924|NCT03575299|Biological|The adoptive treatment of allogeneic γδT cells|Allogeneic γδT cells will be administered to patients with MDR-TB every two weeks, for 12 times in a total of 6 months.
77925|NCT03575299|Other|Control|No allogeneic γδT cells will be administered to patients with MDR-TB.
77926|NCT03575299|Drug|Conventional treatment|Patients will be treated with anti-tuberculosis drugs throughout the entire process of the study.
77927|NCT03575286|Diagnostic Test|Pregnancy test|Detects hormone (hCG, Human Chorionic Gonadotropin) produced by the body during pregnancy
77928|NCT03575273|Behavioral|Sniffin' Sticks Odor Identification and Hedonic Scale|This task measures odor identification accuracy and perceived pleasantness of odors.
77929|NCT03575273|Behavioral|Sucrose Taste Preference Assessment|This task measures participant ratings of sucrose preference.
77930|NCT03575273|Behavioral|Food Preferences Task|Participants rate images of various food stimuli. Variables derived include relative preferences and reaction time (in milliseconds).
77931|NCT03575273|Behavioral|Progressive Ratio (PR) Task|In the PR task, the subject is required to make an increasing number of operant responses for each successive reward
77932|NCT03575273|Procedure|Clinical Electrophysiology|To examine motivated attention in response to food stimuli, brain electrophysiology via event related potentials (ERPs) will be assessed while participants view and rate images of food and non-food items.
77933|NCT03575273|Dietary Supplement|Standardized Meal and Hunger and Satiety Ratings|Participants will receive a standardized meal and complete hunger and satiety ratings.
77934|NCT03575247|Drug|Glucocorticoids|Long-term use of glucocorticoids
77935|NCT03575234|Drug|Cyclophosphamide|Given IV
77936|NCT03575234|Biological|IRX-2|Given SC
77937|NCT03575234|Biological|Nivolumab|Given IV
77938|NCT03575234|Procedure|Surgery|Undergo surgery
77939|NCT03575208|Biological|hepatitis B immune globulin|HBIg 20,000 U/L iv. Dosing interval will depend on anti-HBs levels.
77940|NCT03575208|Drug|Pegylated interferon alfa|peginterferon alfa-2a 180ug sq q weekly for 24 weeks
77941|NCT03575195|Drug|Rifaximin|Rifaximin 550mg orally
77942|NCT03575195|Other|Placebo|Placebo control
77943|NCT03575182|Other|Gait retraining program|Supervised gait retraining with verbal and real-time visual feedback.
77944|NCT03575169|Device|BIS Monitor|Unilateral BIS electrode
77945|NCT03575156|Biological|blood sample|36 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
77946|NCT03575156|Biological|urine sample|6 ml
77947|NCT03575130|Drug|Ripasudil eye drops|Rho-kinase-Inhibitor (IMP)
77948|NCT03575130|Drug|Optive eye drops|Artificial tears (placebo)
77949|NCT03575130|Procedure|Descemetorhexis|Corneal endothelial cells are removed prior to IMP administration by Descemetorhexis.
77950|NCT03575117|Behavioral|Common-Sense Model (CSM) Be Well|Theoretically informed text messages and images that cover how physical activity is linked to decreasing colorectal cancer risk.
77951|NCT03575117|Behavioral|ACS usual messages|Information distributed by the American Cancer Society as information on the link between physical activity and cancer risk (source: www.cancer.org)
77952|NCT03575117|Behavioral|NCI HealthyYouTXT--Get Active (HYT--GA)|Text messaging program developed by National Cancer Society (NCI). It is a free SMS program that promotes physical activity.
77953|NCT03575104|Drug|ACT-541468|Administered orally as tablets.
77954|NCT03575104|Other|Placebo|Administered orally as tablets.
77955|NCT03575091|Other|Changing positions|Comparing two experimental interventions with standard care
77956|NCT03575091|Other|Physiotherapy|Comparing two experimental interventions with standard care
77957|NCT03575078|Drug|ARQ761, Olaparib|ARQ761: weekly infusion. Olaparib Dose 1 D-7 administered orally twice daily
77958|NCT03575065|Drug|BGB-290|BGB-290 BID continuously from Day 1 of Cycle 1 and in subsequent 28 day cycles until occurrence of disease progression as assessed by the investigator, unacceptable toxicity, death, withdrawal of consent, lost to follow-up, or study termination by sponsor.
77959|NCT03575052|Drug|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
77960|NCT03575052|Drug|Placebo|Placebo, tablets, once daily by mouth (provided as two placebo tablets)
77961|NCT03575039|Device|VitaFlow II Transcatheter Aortic Valve System|VitaFlow II Transcatheter Aortic Valve System contains a Valve stent -VitaFlow Aortic Valve, a Delivery system-VitaFlow II Delivery System and a Introducer set
77962|NCT03575026|Behavioral|Music-with-movement|Subjects will listen their preferred music and move their body actively with music
77963|NCT03575026|Behavioral|Usual care|Social activity acts as control with similar dose and intensity with intervention arm
77964|NCT03575013|Drug|Avelumab|Avelumab is a fully human anti-programmed death ligand 1 (PD-L1) IgG1 antibody
77965|NCT03575013|Drug|Docetaxel|Docetaxel is a antineoplastic agent belonging to the taxoid family
77966|NCT03575000|Drug|Bromocriptine|This is an open-label study, so there is no comparator group. As such there is only one arm. Subjects will receive bromocriptine at a starting dose of 2.5mg daily which will be increased, if tolerated, to 5mg daily after one week. Bromocriptine will be continued for a total of 6 weeks. Laboratory investigations, telephonic interviews, and face to face visits with subjects will be conducted before, during, and after the time period that bromocriptine will be used as detailed in the study design section.
135870|NCT03126916|Radiation|Iobenguane I-131|Given IV
77967|NCT03574987|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
77968|NCT03574974|Device|Experimental Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators believe that this feedback may help participants learn to control their PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
77969|NCT03574974|Device|Control Feedback|"Feedback is presented in the form of a line graph that is updated every 2 seconds throughout the scan to indicate activity in the target area. A red diamond will indicate periods of symptom provocation, during which participants are exposed to symptom-provoking auditory stimuli in the form of personalized trauma scripts and sound clips. A blue arrow will indicate periods of down-regulation, where participants will try to bring the feedback line down as much as possible (by trying to decrease their fear/anxiety). The investigators do not believe this feedback can help participants' PTSD symptoms.~Participants will attend a total of 18 feedback scans over the course of 3 sessions."
77970|NCT03574961|Behavioral|e-Support group|Online (remote), web-based support group via private video link.
77971|NCT03574961|Behavioral|e-Journaling placebo|Online journaling activity.
77972|NCT03574948|Drug|5-HTP|8 weeks active substance 5-HTP (2 x 100mg per day)
77973|NCT03574948|Drug|Placebo oral capsule|8 weeks placebo (2 x 1 caps per day)
77974|NCT03574935|Drug|External Chinese medicine|"External Chinese medicine:~For patients in the treatment group, they will accept one of three specific External Chinese medicine according to their lesions and corresponding syndromes:~Chinese herb of Clear heat-Remove dampness-Detoxicate for patients belong to heat syndrome;~Chinese herb of Activating blood-Removing stasis for patients belong to stasis syndrome;~Chinese herb of Supplement deficiency-Generate muscles for patients belong to deficiency syndrome."
77975|NCT03574935|Drug|External Western medicine|"For patients in the control group, they will accept one of three specific external Western medicine according to their lesions:~1.Ethacridine Lactate Solution(lesions with much effusion)； 2.1% Sulfadiazine Silver Cream（lesions with infection）； 3.rb-bFGF(lesions with no slough and look clear)."
77976|NCT03574922|Other|Balance exercises|Balance Exercises
77977|NCT03574922|Other|Core Stabilization exercises|Core Stabilization exercises
77978|NCT03574909|Drug|Aspirin|Tromalyt® 150mg prolong release capsule for oral ingestion. The capsule contains 150mg of anti-platelet agent acetylsalicylic acid, maize starch and Sucrose 20:80. The capsule also contains Copovidone (Kollidon VA-64), Eudragit L, Ethylcellulose and Triacetin. The capsule is made with gelatin, erythrosine, quinoline yellow, titanium dioxide.
77979|NCT03574909|Drug|Placebos|Size 0 hard gelatin capsules containing 99% of microcrystalline cellulose and 1% of magnesium stearate (Sanitatis®). The capsules contain 198mg microcrystalline cellulose and 2mg of magnesium stearate
77980|NCT03574896|Other|Computer model predictions of acute kidney injury|Comparison of the performances of AKIpredictor and physicians in predicting AKI stage 2 or 3 in the 7 days following ICU admission
77981|NCT03574883|Device|tACS|tACS is a non-invasive stimulation technique that works by delivering a weak sinusoidally oscillating electrical current to the surface of the skull to entrain oscillations in the brain.
77982|NCT03574883|Device|tDCS|tDCS is a form of neuromodulation method where very low levels of constant current are delivered to specifically targeted areas of the brain
77983|NCT03574870|Device|wearable sensor|A commercially-available wearable fitness sensor
77984|NCT03574857|Drug|Metolazone Oral Tablet|Day 1: Metolazone 5 mg PO Day 2: Metolazone 5 mg PO
77985|NCT03574857|Drug|Chlorothiazide Injection|Day 1: Chlorothiazide 500 mg IV Day 2: Chlorothiazide 500 mg IV
77986|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 500|Experimental arm
77987|NCT03574844|Dietary Supplement|Saccharomyces cerevisiae, dose 1000|Experimental arm
77988|NCT03574844|Dietary Supplement|Placebo|Placebo comparator arm
77989|NCT03574831|Device|Stretta|Stretta
77990|NCT03574818|Drug|Necitumumab-Gemcitabine-Cisplatin|"Gemcitabine 1250mg/m2 IV on D1, D8~Cisplatin 75mg / m2 IV on D1~Necitumumab 800mg IV on D1, D8 (peripheral blood for effector cells and cytokine measurements prior to each cycle) Repeat cycle every 21 days up to 3 cycles."
77991|NCT03574818|Diagnostic Test|Evaluation to determine if patient is a candidate to proceeed with surgical resection or not|Patients will be evaluated with repeat imaging studies (PET/CT or CT Chest, Abdomen, Pelvis) and will be re-evaluated for surgical resection. Patients who had progressive disease or are NOT a surgical candidate will come off the study and will be treated according to standard therapies. All patients will be followed up for 2-year disease-free survival and overall survival
77992|NCT03574805|Drug|PRS-060|Study drug
77993|NCT03574805|Drug|Placebo|Inhalant designed to mimic PRS-060
77994|NCT03574792|Drug|Gabapentin|Given PO
77995|NCT03574792|Drug|Methadone|Given PO
77996|NCT03574792|Drug|Oxycodone|Given PO
77997|NCT03574792|Other|Quality-of-Life Assessment|Ancillary studies
77998|NCT03574792|Other|Questionnaire Administration|Ancillary studies
77999|NCT03574792|Drug|Venlafaxine|Given PO
78000|NCT03574792|Drug|Venlafaxine Hydrochloride Extended Release|Given PO
78001|NCT03574779|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
78002|NCT03574779|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
78003|NCT03574779|Drug|Bevacizumab|Bevacizumab is an FDA approved antiangiogenic recombinant humanized monoclonal Ig G1 antibody against the vascular endothelial growth factor protein, which has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma.
78004|NCT03574766|Behavioral|Meditation|Daily meditation
78005|NCT03574753|Drug|ABBV-399|ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days
78006|NCT03574740|Other|Tobacco Smoking|Influence of Tobacco Smoking on the development of OSA
78007|NCT03574727|Procedure|Injection to or release of anterior cutaneous nerves|Patients who have undergone at least one injection to the nerves
78008|NCT03574714|Other|Extracellular pH|Extracellular pH gradient
78009|NCT03574701|Dietary Supplement|Vitamin A|The use of Vitamin A , in the treatment of olfactory loss has been previously studied in both animals and humans. These studies have shown promising results in the treatment of olfactory loss.
78010|NCT03574688|Dietary Supplement|Water|Increased daily water intake with 1.5 Liters of water per day on top of habitual water intake.
78011|NCT03574675|Device|Simulated Altitude (FiO2: 15.1)|"Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
78012|NCT03574675|Device|Shamed Hypoxia (FiO2: 20.9)|"Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask."
78013|NCT03574662|Other|Frailty assessment|This assessment consists of a combination of gait speed measurement via infrared sensors as well as a grip strength assessment. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
78014|NCT03574662|Other|Quality of life assessment|This assessment consists of two questionnaires, Kansas City Cardiomyopathy Questionnaire and Minnesota Living with Heart Failure questionnaire. Patients will then attend cardiac rehabilitation for an abbreviated six week program.
78015|NCT03574649|Drug|Nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
78016|NCT03574649|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
78017|NCT03574649|Drug|5Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
78018|NCT03574649|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
78019|NCT03574649|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
78020|NCT03574649|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
78021|NCT03574649|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
78022|NCT03574649|Biological|GI-4000|RAS yeast vaccine
78023|NCT03574649|Biological|GI-6301|Brachyury yeast vaccine
78024|NCT03574649|Drug|Aldoxorubicin|INNO-206
78025|NCT03574649|Drug|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
78026|NCT03574649|Drug|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]
78027|NCT03574649|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
78028|NCT03574649|Drug|Docetaxel|Docetaxel
78029|NCT03574649|Drug|carboplatin|carboplatin
78030|NCT03574636|Device|OCT guidance|OCT guide stent implantation
78031|NCT03574636|Device|IVUS guidance|IVUS guide stent implantation
78032|NCT03574636|Device|QCA|QCA guide stent implantation
78033|NCT03574623|Device|Electrical Stimulator|An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).
78034|NCT03574623|Behavioral|Occupational Therapy|Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.
78035|NCT03574610|Device|Transcranial Rotating Permanent Magnet Stimulator (TRPMS)|"TRPMS is a wearable non-invasive transcranial rotating permanent magnet stimulator. It has been determined to be a Non Significant Risk device by the FDA.~The amount and frequency of therapy are prescribed by the physician, and the device is custom configured to the patient to deliver the required amount of treatment. The device does not turn on until it is time for the treatment. It consists of three main parts: Neoprene cap with microstimulator(s), stimulator console (device controller box) and the tablet with TRPMS app which activates the console. The neoprene cap prevents the microstimulator(s) from coming in direct contact with the scalp. Microstimulators deliver the magnetic stimulation to the brain based on a prescription program uploaded in the stimulator controller."
78038|NCT03574584|Drug|NNC0165-1562|Participants will receive NNC0165-1562 subcutaneous (s.c., under the skin) injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
78039|NCT03574584|Drug|Semaglutide|Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
78040|NCT03574584|Drug|Placebo (NNC0165-1562)|Participants will receive placebo (NNC0165-1562) s.c. injection(s) once-weekly for 20 weeks.
78041|NCT03574571|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered IV every three weeks for 10 doses.
78042|NCT03574571|Drug|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered IV every 3 weeks for 10 doses.
78043|NCT03574571|Drug|Radium-223|Radium-223 will be administered at 55 kBq/kg, 6 injections at 6 weeks intervals.
78044|NCT03574558|Device|MD-Logic Switch Advisor|Study algorithm will be used in order to determine the initial pump setting/ MDI dosing while switching from from MDI to pump therapy or vice versa
78045|NCT03574545|Biological|VAY736|Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
78046|NCT03574519|Behavioral|Non-contingent incentives|Incentives are provided for participation
78047|NCT03574519|Behavioral|Contingent incentives|Incentives are provided for attaining daily goals
78048|NCT03574519|Behavioral|Weekly feedback|Text message feedback is delivered weekly summarizing the past week's progress
78049|NCT03574519|Behavioral|Daily feedback|Text message feedback is delivered daily summarizing the current day's progress
78050|NCT03574493|Procedure|TME with LAR|Several surgical techniques are used to perform TME. Dissection using open laparotomy and minimally-invasive laparoscopic or robot-assisted abdominal approaches is performed in a 'top-down' manner, where the instruments are inserted transabdominally and the procedure progresses from splenic flexure/sigmoid colon mobilization to rectal resection. A transanal approach may also be used, a 'bottom-up' procedure where instruments are inserted through the anus to perform rectal resection and TME
78051|NCT03574480|Behavioral|Intervention (training in use of a Smartphone application)|The intervention group will be added a training for 3 months in use of a Smartphone application, designed to promote a healthy diet, increased physical acivity and decreased sedentary.
78052|NCT03574480|Behavioral|Control (Advice on healthy diet and physical activity recommendations)|Advice on healthy diet and physical activity recommendations
78053|NCT03574467|Behavioral|Bobath Neurodevelopmental Treatment Approach|The Bobath Neurodevelopmental Treatment (NDT) rehabilitation approach is effective in increasing the functional capacity and acquiring independence in patients with stroke and brain tumor.
78054|NCT03574454|Other|Machine Learning (ML)|Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
78055|NCT03574441|Device|Tegaderm dressing + catheter support pad|Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter
78056|NCT03574441|Device|Tegaderm dressing + Steri-strip dressing|Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter
78057|NCT03574441|Device|Tegaderm dressing only|Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
78058|NCT03574428|Drug|GNbAC1|Monoclonal Antibody infused i.v.
78059|NCT03574428|Other|GNbAC1 Placebo|Equivalent to GNbAC1 Buffer
78060|NCT03574415|Drug|DWP14012|DWP14012 tablets
78061|NCT03574415|Drug|Placebo|DWP14012 placebo-matching tablets
78062|NCT03574402|Drug|Avitinib Maleate|Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
78063|NCT03574402|Drug|Afatinib|Afatinib will be administered 40mg orally once a day, 28 days as one cycle.
78064|NCT03574402|Drug|Crizotinib|Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28.
78065|NCT03574402|Drug|X-396|Patients with MET amplification receive ensartinib 225mg PO QD on days 1-28.
78066|NCT03574402|Drug|Chidamide|Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle.
78067|NCT03574389|Biological|13vPnC|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
78068|NCT03574389|Biological|Hib|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
78069|NCT03574376|Drug|Bupivacaine Liposome Injection|Under ultrasound guidance, corresponding ribs will be identified. 3-5 ml of a 1.3% (13.3 mg/mL) of liposomal bupivacaine will be drawn into a syringe with a 1.5-in, 22-gauge needle. The needle will then be advanced 20° cephalad to the skin 3-4 cm lateral to midline at the level of each fractured rib, and 1-2 ribs levels above and below injury. The needle will be advanced 3 mm below the inferior margin of the rib, placing the tip in the space containing the neurovascular bundle. Following negative aspiration for blood or air, 3-5 mL of local anesthetic will be infused and the needle withdrawn. No more than 266 mg, or 20 ml, of the 1.3% (13.3 mg/mL) liposomal bupivacaine solution will be injected
78070|NCT03574376|Drug|Bupivacaine|The anesthesia department will manage CEA. If possible, the patient will be in the sitting position. The skin will be prepped with chlorhexidine and sterilely draped. 3 mL of lidocaine 1% will be infiltrated the closest interspace to the rib fractures between T4 -T12. A Touhy needle will be inserted, the epidural space identified by loss of resistance technique. An epidural catheter will then be inserted to a depth of 12cm. 3 mL of test solution with lidocaine 1.5% with epinephrine, 1:200,000 will be injected with continuous EKG and SpO2 monitoring. Delivery of a 0.125% bupivacaine solution be continuously infused and titrated based on the patient's clinical status
78071|NCT03574363|Drug|KBP-5074|KBP-5074 tablet formulation
78072|NCT03574350|Behavioral|KS in Kangaroo Position|KSKP was applied daily at regular interval corresponding to the presence of parents. Our protocol is based on the Tiffany Field's protocol with some adjustments corresponding to the constraints of the hospital : the KS was applied 3 times a day and during 15 consecutive days in the hospital or at home and parents were responsible of delivering the intervention. Sunflower oil was used. During the first 5 days, parents performed KSKP with the support of the psychologist. After day 5, parents were expected to perform KSKP by themselves but could ask for help at any moment while in hospital or in the ambulatory follow-up. The KS always began approximately 60 minutes after the feed.
78073|NCT03574350|Behavioral|KS in incubator|The infant is in the incubator, unclothed with diaper. Parents delivered KSI with the infant in supine position, stroking with the flats of the fingers with moderate pressure. Five 1-minute intervals, consisting of six 10-s periods of stroking, were applied to the following body regions: head, back, both legs and arms. The same process was repeated in prone position. The last part of the intervention was composed of 6 flexions of each extremity.
78074|NCT03574337|Drug|Sugammadex|No additional information
78075|NCT03574337|Drug|neostigmine/glycopyrolate|No additional information
78076|NCT03574324|Drug|TPF+CCRT|Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy
78077|NCT03574324|Drug|CCRT+PF|Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
78078|NCT03574311|Drug|Ferric carboxymaltose|A single dose of drug or placebo is administered preoperatively to participants
78079|NCT03574311|Other|Physiological saline|Single infusion 100 ml physiological saline infusion preoperatively
78080|NCT03574285|Drug|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
78081|NCT03574285|Drug|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
78082|NCT03574272|Other|Patient Transfer Monitoring System|The subjects will be provided with portable oximeter and smart-phone which application for monitoring is installed, and the transmitted data will be monitored in real time via monitoring equipment in the (Patient-hospitalized) ward.
78083|NCT03574246|Drug|chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15|chlorhexidine gluconate + benzydamine hydrochloride oral rinse
78084|NCT03574246|Other|%0.9 NaCl Solution|isotonic sodium chloride
78085|NCT03574220|Drug|Pembrolizumab|200mg IV every 21 days over 6 months
78086|NCT03574220|Radiation|Stereotactic body radiotherapy|50 Grays (Gy) in 5 fractions over 5-14 days, or 60 Gy in 3 fractions over 8-14 days
78087|NCT03574207|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation non-invasively applies very small amounts of electrical current to brain tissue; sham stimulation uses the same approach but applies little or no actual stimulation to the brain by using less power or greater distance between the head and the stimulator.
78088|NCT03574194|Dietary Supplement|Methionine-restricted diet|The methionine-restricted diet diet (MRD) will begin 2 weeks prior to radiation therapy to deplete methionine stores in the body, continue during radiation, and extend for approximately 2 weeks after the last radiation fraction for a total of 6-10 weeks (depending on duration of radiation course).
78089|NCT03574181|Other|Smart watch to measure Blood Alcohol Level|Subjects will wear a wrist watch that measures blood alcohol level during a 1 hour period of consuming alcohol followed by a 5 hour observation period.
78090|NCT03574168|Biological|CD19-CAR-T Cells|T cells purified from the PBMC of subjects or subjects' relatives which depends on their conditions, transduced with 4-1BB/CD3-ζ lentiviral vector, expanded in vitro for future administration.
78091|NCT03574155|Behavioral|Pre-operative Counseling and Education|"Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines."
78092|NCT03574142|Drug|Epanova|A single dose of Epanova 4 g will be administered as 4 capsules (each containing 1 g of Epanova) followed by a 72-hour washout period in Chinese healthy subjects. Subsequently, multiple doses of Epanova 4 g will be administered once daily for 14 consecutive days.
78093|NCT03574129|Behavioral|Adolescent Transition Package|Clinic level intervention composed of an adolescent transition package with tools to support health care workers to disclose HIV status to adolescents and to track transition to adult care.
78094|NCT03574103|Behavioral|Caloric restriction only|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements), without restriction in time for feeding, for 8 weeks.
78095|NCT03574103|Behavioral|Caloric restriction plus TRF morning|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 12 p.m. to 8 p.m.) and 16 hours of fasting, for 8 weeks.
78096|NCT03574103|Behavioral|Caloric restriction plus TRF night|Participants in this group will receive a eating plan with caloric restriction (513 to 770 kcal from estimated energy requirements) and 8 hours for eating (from 8 a.m. to 4 p.m.) and 16 hours of fasting, for 8 weeks.
78097|NCT03574090|Drug|Amoxicillin Clavulanate|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
78098|NCT03574090|Drug|Physiological Saline|To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
78099|NCT03574077|Behavioral|Instant Messaging (IM)|Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.
78100|NCT03574077|Behavioral|AWARD advice|AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
78101|NCT03574077|Behavioral|NRT sampling|One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.
78102|NCT03574077|Behavioral|Active referral|SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
78173|NCT03573700|Biological|CD19- specific CAR engineered autologous T-cells (SJCAR19 product)|Given IV
78307|NCT03572660|Biological|Bone marrow derived mononuclear cells and G-CSF|Intra-coronary infusion
78103|NCT03574077|Behavioral|SMS messaging|All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
78104|NCT03574064|Other|Glucagon-Like Peptide-2 (GLP-2)|Glucagon-Like Peptide-2 (GLP-2) injection.
78105|NCT03574064|Other|Glucose-dependent insulinotropic polypeptide (GIP)|Glucose-dependent insulinotropic polypeptide (GIP) injection.
78106|NCT03574064|Other|GLP-2+GIP|GLP-2+GIP injection.
78107|NCT03574064|Other|Placebo|Placebo injection.
78108|NCT03574051|Drug|Probiotic|Evaluate probiotics for preventing adverse effects of hypothyroidism and improvement of side effects caused by 131I treatment
78109|NCT03574038|Device|Transcranial Direct Current Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
78110|NCT03574038|Other|Sham Stimulation|Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the cap and electrodes in place, and sham switch moved but without prolonged delivery of electrical stimulation.
78111|NCT03574025|Other|Questionnaire|To telephone the patient/family to look into how the patient is doing, moderate/severe brain damage.
78112|NCT03574012|Device|Monitoring Device|Use Fitbit tracker
78113|NCT03574012|Other|Informational Intervention|Receive individualized health and fitness information from clinician, supplemented with peer support through the study's social media platform
78114|NCT03574012|Other|Informational Intervention|Receive general health and fitness information from clinician
78115|NCT03574012|Other|Questionnaire Administration|Ancillary studies
78116|NCT03573999|Drug|Mannitol|4.6 ml/kg will be administered before dura opening
78117|NCT03573999|Drug|NaCl 7.5%|2 ml/kg will be administered before dura opening
78118|NCT03573986|Biological|[18F]fluoromisonidazole|positron emitting radiopharmaceutical that has been studied in vivo in humans for measurement of regional hypoxia in a number of tumor types with positron emission tomography (PET/CT)
78119|NCT03573986|Drug|Bevacizumab|Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.
78120|NCT03573986|Radiation|positron emission tomography (PET/CT).|PET-CT Scan 1.) before start of Bevacizumab up to approximately 4 weeks and 2.) within 12-22 days of start of Bevacizumab
78121|NCT03573973|Other|Improved product placement of fresh fruit and vegetables|The intervention includes the creation of a new fresh fruit and vegetable section at the store entrance with expanded range thus improving the placement (availability and position) of fresh fruit and vegetables.
78122|NCT03573973|Other|Sham comparator|The control condition is the existing store layout with a limited range of fresh fruit and vegetables that are placed at the back of the store.
78123|NCT03573960|Drug|Lenvatinib|Lenvatinib capsules.
78124|NCT03573947|Drug|Nivolumab|360 mg intravenously every 3 weeks
78125|NCT03573947|Drug|Ipilimumab|1 mg/kg intravenously over 30 minutes
78126|NCT03573947|Drug|Paclitaxel|80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
78127|NCT03573934|Other|GLP-2|GLP-2
78128|NCT03573934|Other|GIP|GIP
78129|NCT03573934|Other|GLP-2+GIP|GLP-2+GIP
78130|NCT03573934|Other|Placebo|Placebo
78131|NCT03573921|Drug|Gastrograﬁn|Patients will receive a single dose of Gastrografin via the nasogastric tube at 24 hours after hospital admission. After receiving Gastrografin, patients will receive the same standard non-surgical management that patients outside of the trial receive.
78132|NCT03573921|Other|Saline solution (control treatment)|Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after hospital admission. After receiving saline solution, patients will receive the same standard non-surgical management that patients outside of the trial receive.
78133|NCT03573908|Drug|Linaclotide|Oral capsule
78134|NCT03573908|Drug|Placebo|Matching placebo oral capsule
78135|NCT03573895|Other|Foam-Roller|Application of foam roller in the posterior part of thigh.
78136|NCT03573895|Other|Neuromuscular stretching|Use of a neuromuscular stretching applied to the hamstring muscles
78137|NCT03573895|Other|Pasive stretching|Use of a pasive stretching applied to the hamstring muscles
78138|NCT03573882|Drug|Voxelotor|300 mg Tablet, Oral, With or Without Food
78139|NCT03573869|Procedure|Cryoballoon ablation|Left atrial ablation using cryoballoon to achieve pulmonary vein isolation
78140|NCT03573856|Behavioral|Active Living|Participants will be provided with education and support for diet and lifestyle modification related to healthy eating and active living.
78141|NCT03573856|Other|Health and Safety|Participants will be provided with education related to general health and safety topics.
78142|NCT03573843|Other|Prevention software|All patients will have a tablet with the software PREVEDEL between 09:00-19:00 hrs.
78143|NCT03573843|Other|Placebo|All patients will have a tablet without the software PREVEDEL between 09:00-19:00 hrs.
78144|NCT03573830|Behavioral|Transport Canada material|The current Transport Canada booster seat education material focuses on imparting guidelines; that is, it describes, in plain language, the minimum and maximum ages, heights, and weights to determine when a child should use a booster seat, and when it is safe for a child to use only the seat belt. This material does not describe the principle of operation of seat belts (i.e., redirecting crash forces to the rib cage and pelvis), nor the principle of operation of booster seats (i.e., ensuring the seat belt is placed correctly across the chest and hips).
78206|NCT03573440|Other|mindful education on eating|Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
78145|NCT03573830|Behavioral|Enhanced material|Enhancements to the booster seat education material were developed based on the hypothesis that parents would better appreciate the additional injury risk reduction afforded by booster seats, if they understand that: (1) seat belts prevent injuries by redirecting crash forces to stronger parts of the body (i.e., rib cage and pelvis); and (2), without booster seats, children would wear the seat belt on their abdomen and neck, which directs crash forces to more vulnerable anatomical structures (i.e., internal organs and spine).
78146|NCT03573817|Drug|revefenacin|(see arm/group description)
78147|NCT03573817|Drug|Placebo|(see arm/group description)
78148|NCT03573817|Drug|Formoterol|administered sequentially in both Revefenacin and placebo arms
78149|NCT03573804|Other|Prone to Supine MRI|The patient will be placed in the prone position and undergo a standard Gd contrast-enhanced bilateral breast MRI. Immediately after the prone MRI is completed, the patient will be repositioned for the supine MRI. Prior to starting the prone MRI, the study MRI technician/investigator will explain to the patient and practice with the patient the steps needed to transition from the prone to the supine MRI, so as to facilitate a timely transition. Additional MRI images will only take about 10-15 minutes to obtain and will not require a second injection of contrast material.
78150|NCT03573778|Behavioral|iHEAL|Women work with a Registered Nurse in 10-18 visits (over 6 months) that focus on 6 inter-related 6 components (areas): Safeguarding, Managing Symptoms, Getting Basics, Cautiously Connecting, Regenerating Family, Renewing Self. Using a standard 3 phase process, and guided by 5 principles, the nurse discusses each of these components with the woman in order to identify the woman's needs, experiences and priorities. The nurse then provides personalized support to assist the woman in address the concerns that she sees as most important for her health and well-being; this support includes linking women to existing services if she chooses.
78151|NCT03573778|Behavioral|Information about Community Services|Women are provided with information about community services appropriate for women experiencing intimate partner violence and consistent with what service providers might recommend (usual care). Women are encouraged to use this information as they see fit.
78152|NCT03573765|Procedure|Shoulder arthroplasty|Any form of joint replacement of the glenohumeral joint including prosthetic and excision.
78153|NCT03573765|Procedure|Elbow arthroplasty|Any form of joint replacement of the elbow joint including prosthetic and excision.
78154|NCT03573765|Procedure|Hand and wrist arthroplasty|Any form of joint replacement of joints of the hand and wrist including prosthetic and excision.
78155|NCT03573765|Procedure|Nerve decompression|Open or endoscopic release of peripheral nerve entrapment - subdivided by anatomical site of compression. Specific subgroups will include carpal tunnel and cubital tunnel release.
78156|NCT03573765|Procedure|Tendon repair|Open or arthroscopic repair or reconstruction of tendons of the shoulder, hand and upper limb in general.
78157|NCT03573765|Procedure|Joint stabilisation|Any procedure designed to increase stability of a joint, including soft tissue and bony blocking procedures.
78158|NCT03573765|Procedure|Excision/division/release of palmar fascia|Any procedure performed for treatment of Dupuytren's contracture.
78159|NCT03573765|Procedure|Surgical fixation of fractures|Any internal or external fixation of upper limb fractures - analysed by anatomical site.
78160|NCT03573765|Procedure|Soft tissue release/debridement/excision|Any removal or release of soft tissue for treatment of stiffness, functional impairment or pain. Specific subgroups will include trigger finger release, subacromial surgery and surgery for frozen shoulder.
78161|NCT03573765|Procedure|Intra-articular injection|Any intra-articular injection
78162|NCT03573752|Other|outpatient management for promontofixation by laparoscopy|postoperative H8 exit after laparoscopic promontofixation
78163|NCT03573752|Other|questionnaire|Each patient will complete a questionnaire on the experience of management, both in terms of pain management, anxiety and overall satisfaction.
78164|NCT03573739|Procedure|low-calorie low-protein|In the low-calorie low-protein (Low) group, the calorie target will be 6 kcal/kg/day and the protein target 0.2-0.4 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
78165|NCT03573739|Procedure|standard-calorie/standard-protein|In the standard-calorie/standard-protein (Standard) group, the first-line calorie target calculated based on body weight is 25 kcal/kg/day and the protein target 1.0-1.3 g/kg/d during the acute phase, i.e. from D0 to D7. On D8, the calorie target will be 30 kcal/kg/d and the protein target 1.2-2.0 g/kg/d.
78166|NCT03573726|Other|Closed diurnal indwelling catheter (CDIC)|Each participant underwent an evaluation during standard of care CIC use vs evaluations during use of the study intervention (CDIC).
78167|NCT03573713|Other|Care Groups|The Care Groups model has strong evidence of improvement of maternal and child health and maternal hygiene/nutrition behaviors.Through Care Groups, women will learn about proper water, sanitation, and hygiene behaviors; Infant and Young Child Feeding practices; management of childhood illnesses; home management, referral and care seeking for sick children; family planning; and use of preventive services available at health facilities (e.g., growth monitoring, deworming, vitamin A supplementation). All children under five years of age will also be screened for acute malnutrition by the Care Group Volunteers, and receive deworming medication and vitamin A supplementation twice a year through the Ministry of Health and Community Health Workers as part of national campaigns.
78168|NCT03573713|Behavioral|IPT-G|"IPT-G is an effective, low-cost, short-duration community-based method for decreasing depression has been established that was first rigorously tested in Uganda. Several Private Voluntary Organizations in Africa have used this low-cost, short-duration, community-based group psychosocial approach and found it to be a culturally-sensitive, acceptable, and feasible approach to address depression.~IPT-G treatment spans 12 weeks of treatment, consisting of 3 phases (early, middle, and termination). Within this treatment, participants are also assessed for symptoms of depression every week."
78169|NCT03573700|Drug|Cyclophosphamide|Given IV
78170|NCT03573700|Drug|Fludarabine|Given IV
78171|NCT03573700|Drug|Mesna|Given IV
78172|NCT03573700|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest.
78174|NCT03573687|Dietary Supplement|Micellar Casein Protein|The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.
78175|NCT03573687|Other|Resistance Exercise Training|Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
78176|NCT03573674|Behavioral|CE - Cognitive Ergonomics (KERGO)|"CE Cognitive ergonomics Intervention deals with themes such as disruptions, interruptions, information overload.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
78177|NCT03573674|Behavioral|RS - Recovery Support (KUORMA)|"RS Recovery Support / Stress Management Intervention deals with themes such as workload management, recovery, work-family balance.~A cognitive behaviour change method was applied in the intervention tasks. Both the tasks of discussing and developing new practices within the groups of individuals and the tasks for individuals were constructed to utilize mental contrasting with implementation intentions (MCII) method"
78178|NCT03573661|Device|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
78179|NCT03573648|Drug|Avelumab|Avelumab (10 mg/kg) will be given intravenously on cycles 2 - 4, every 2 weeks.
78180|NCT03573648|Drug|Tamoxifen|Tamoxifen (20 mg) will be given orally daily x 4 cycles
78181|NCT03573648|Drug|Palbociclib|Palbociclib (125 mg) will be given orally on days 1-21 of each cycle x 4 cycles.
78182|NCT03573635|Device|Supratube|Aspiration of orotracheal secretions with supratube device
78183|NCT03573635|Other|Reference|Usual aspiration with any other device
78184|NCT03573622|Drug|Anpl-one SR Tab. 300mg|Anpl-one SR Tab. 300mg tablets followed by Sarpodipil SR Tab. 300mg tablets
78185|NCT03573622|Drug|Sarpodipil SR Tab. 300mg|Sarpodipil SR Tab. 300mg tablets followed by Anpl-one SR Tab. 300mg tablets
78186|NCT03573609|Device|Supranav|Continuous supraglottic suction device for patients with orotraqueal intubation an mechanical ventilation
78187|NCT03573596|Drug|Dasatinib|CML patients who have failed a first stopping attempt and have used any TKI for one year will switch to dasatinib 100 mg qd for an additional 2 years before second stop attempt.
78188|NCT03573583|Behavioral|Resistance Training|The intensity, volume, tempo, and progression will be based on the Federal Physical Activity guidelines. The resistance training exercises will include mainly multi-joint exercises using selectorized machines. Each session will include upper body exercises (Chest Press, Shoulder Press, Seated Rows, Bicep curls, and Tricep Extensions) and lower body exercises (Leg Press, Leg Extension and Leg Curls, and Calf raise) that will be tailored to the participant needs.
78189|NCT03573583|Behavioral|Successful Aging|The successful aging will attend stretching and health lectures as a group . The topics might include, medication management, disease management (e.g. blood pressure, diabetes, arthritis, dementia, pain management, diet) and other health related matters.
78190|NCT03573570|Other|Fortified rice kernels|The proposed project will leverage the existing state-run public distribution system (PDS) to provide fortified rice through Fair Price Shops (FPS) using a domestically manufactured rice grain (Fortified Rice Kernels: FRK). FRKs are grains made from rice flour, enriched with iron, zinc, Vitamin A, Vitamins B1, B3, B6, B9 and B12, and shaped like a conventional grain of rice. It is mixed into conventional rice in specified ratio of 1:100. The proposed study will be conducted as a cluster-randomized controlled trial, with baseline and follow-up surveys conducted 12-15 months apart. In the interim, 110 Treatment FPS, and all households receiving rice from them, will be randomly assigned to receive fortified rice, and another 110 randomly assigned Control FPS, and the households receiving rice from them, will continue receiving conventional rice and represents the status quo. This study will be conducted in one sub-district of Tamil Nadu with a population of about 1/2 million people.
78191|NCT03573557|Device|Pink Pad|Pink Pad made by Xodus Medical Inc. used for patients in steep Trendelenburg position during surgery.
78192|NCT03573557|Device|Bean Bag|Vac-Pac Bean Bag made by Olympic used for patients in steep Trendelenburg position during surgery.
78193|NCT03573557|Device|Gel Pad|Gel Pad used for patients in steep Trendelenburg position during surgery.
78194|NCT03573544|Drug|OBI-888|For the dose-escalation phase, OBI-888 will be given weekly at the dose levels of 5, 10, and 20 mg/kg.
78195|NCT03573544|Drug|OBI-888|For the dose-expansion phase, OBI-888 will be given weekly at 20 mg/kg dose level.
78196|NCT03573544|Device|Globo H IHC Assay|This assay will be used to identify eligible patients who may clinically benefit from the OBI-888 treatment, defined by Globo H expression.
78197|NCT03573531|Other|Laboratory analysis|Analysis of lipid peroxidation markers (malondialdehyde, 4 hydroxy-2-nonenal, hexanal, and 8-iso-PGF2α) Analysis of fatty acid content Analysis of total antioxidant capacity
78198|NCT03573518|Drug|BTX 1503|BTX 1503 Dose 1 liquid formulation, or BTX 1503 Dose 2 liquid formulation
78199|NCT03573518|Drug|Vehicle|Placebo
78200|NCT03573505|Drug|BG00011|Administered as specified in the treatment arm.
78201|NCT03573505|Drug|Placebo|Administered as specified in the treatment arm.
78202|NCT03573492|Other|Education|Type of teaching being assigned to student arms
78203|NCT03573479|Other|PICU Liber8 Bundle|Bundle of elements for quality improvement
78204|NCT03573466|Procedure|Muscle biopsy|A motor point biopsy of deltoid muscle will be carried out at the time of inclusion using a standardized procedure, as routinely performed. Muscle samples will be removed from the deltoid muscle by open biopsy under local anaesthesia. The region containing NMJs will be determined by the small twitch provoked by the tip of the scalpel on the surface of the muscle fascicles.
78205|NCT03573453|Other|enteral nutrition|administration of enteral nutrition
78208|NCT03573414|Other|raspberry powder, milled flaxseed and soy milk|"The participants will consume a breakfast consisting of 30 g of milled flaxseed, 40 g of raspberry powder and 250 ml of soy milk for 3 days~The participants will provide blood and urine samples"
78209|NCT03573401|Combination Product|Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
78210|NCT03573401|Combination Product|Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)|The Main Target Lesion will be marked by at least 3 ink marks prior to PDT to enable precise excision for histopathological assessment 12 weeks after the first or second PDT cycle dependent on the clearance status of the lesion. All target lesions should be prepared prior to drug application by degreasing, removal of all scabs and crusts, and roughening of the surface, if appropriate. Bleeding should be avoided. The formulations will then be applied to the lesions (maximal combined lesion area incl. margin is 20 cm²) located in 1 to 2 illumination areas. The medication should be applied to the entire lesion(s) plus a 0.5 - 1.0 cm margin surrounding each lesion at a thickness of 1 mm, allowed to dry (for approximately 10 minutes), covered with occlusive dressing, and incubated for approximately 3 h. Thereafter, any remnants of the IMP will be removed carefully and the PDT illumination will be administered using the light emitting diode (LED) red light device BF-RhodoLED®.
78211|NCT03573388|Device|Optical coherence tomography (OCT)|Lesion OCT assessment
78212|NCT03573375|Behavioral|Questionnaires|Participants complete a series of questionnaires about exercise, symptoms, and physical abilities. These should take about 5 minutes to complete.
78213|NCT03573362|Device|ViziShot FLEX 19G needle|EBUS-TBNA using the ViziShot FLEX 19G needle
78214|NCT03573362|Device|Vizishot 22G needle (standard)|EBUS-TBNA using the Vizishot 22G needle (standard)
78215|NCT03573349|Drug|Ketamine|We will enroll 20 adults with treatment-resistant unipolar major depression and will provide one i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Adults (aged 18-65 years) with treatment-resistant depression will be included. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), during (at 20 minutes), and following ketamine treatment (change biomarkers). This will be an open label feasibility trial.
78216|NCT03573336|Drug|Vilaprisan (BAY1002670)|Intake orally, 2 mg (treatment group 1) or 4 mg (treatment group 2) once daily
78217|NCT03573336|Drug|Matching Placebo|Intake orally, once daily
78218|NCT03573323|Drug|Ixekizumab|Administered SC
78219|NCT03573323|Drug|Guselkumab|Administered SC
78220|NCT03573323|Drug|Placebo|Administered SC
78221|NCT03573310|Drug|JNJ-64619178|JNJ-64619178 capsules to be administered orally.
78222|NCT03573297|Drug|Cariprazine|Cariprazine capsules, oral administration, once daily
78223|NCT03573297|Drug|Placebo|Matching placebo capsules, oral administration, once daily
78224|NCT03573284|Diagnostic Test|fractional exhaled nitric oxide(FeNO)|FeNO level was evaluated according to the American Thoracic Society (ATS)/ERS recommendations using a NIOX MINO analyzer (Aerocrine, Solna, Sweden) .Subjects were informed to deeply inhale NO-free air and immediately exhale in full via a mouthpiece at a constant flow rate (50 ml/s) for 10s.
78225|NCT03573284|Diagnostic Test|impulse oscillometry(IOS)|The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
78226|NCT03573271|Device|MCD|Micro-coring skin removal with automated coring device
78227|NCT03573258|Dietary Supplement|Fiber or Placebo (depending on the randomization)|ingestion of dietary fibers prior to meal intake
78228|NCT03573245|Drug|Tranexamic Acid|Tranexamic acid effect on perioperative bleeding in orthopedic surgery
78229|NCT03573219|Radiation|Short-wave diathermy|The application of SWD will be carried out by a CEC M-8 short-wave thermotherapy unit. The device has capacitive applicators, that will be situated around the muscle to be irradiated on top of a cotton towel, in order to absorb perspiration and avoid undesired heating effects. Afterwards the emission mode (continuous or pulsed) will be selected, and application of SWD will start. The intensity of SWD will be gradually increased until the volunteer perceives a warm sensation, and once familiarized with this perception, the intensity will be increased until a sensation of constant but tolerable pain is evoked. This sensation will be maintained throughout the duration of the SWD application, estimated in approximately 10 minutes.
78230|NCT03573206|Device|Cardiva Mid-Bore Venous Vascular Closure Device (VVCS)|The device will be used to close all femoral venous access sites at the end of the case.
78231|NCT03573193|Other|ridge preservation|"Intra operative procedures (for both groups) ridge preservation~Local anesthesia will be given to the patient.~Scrubbing and draping of the patient will be carried out in a standard fashion for intra oral procedures.~A crestal incision was made, and a mucoperiosteal flap was elevated. Implant osteotomies were prepared according to the recommendations and desired dimensions of implants.~In study group: tooth extraction with ridge preservation using deproteinized bovine bone mineral Bio-Oss~In the comparators group: tooth extraction with ridge preservation using an alloplastic ceramic material beta tricalcium phosphate (TCP)."
78232|NCT03573167|Behavioral|In-Person Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted in-person (face-to-face) between the investigator and the participant.
78233|NCT03573167|Behavioral|Mobile Motivational Interviewing (MI)|This is a counseling intervention to support behavior change conducted entirely over the mobile phone between the investigator and the participant
78444|NCT03571633|Drug|Pegfilgrastim|During neoadjuvant period, weekly pegfilgrastim (every 3 weeks, Q3W)
78234|NCT03573154|Other|administration of the liquid 1 and then the liquid 2|The patient will received the e-liquid 1 in the first visit and the e-liquid 2 in the second
78235|NCT03573154|Other|administration of the liquid 2 and then the liquid 1|The patient will received the e-liquid 2 in the first visit and the e-liquid 1 in the second
78236|NCT03573141|Other|Physical Therapy|Subjects received a comprehensive physical therapy evaluation after baseline data collection and received a normal course pf physical therapy treatment based on impairments identified.
78237|NCT03573128|Behavioral|Students with Autism Accessing General Education|With study team coach support, teacher implemented modules addressing student behavioral/academic goals.
78238|NCT03573128|Other|Enhanced Services As Usual|Teaching staff access in-service presentations and print materials with no active study team coaching.
78239|NCT03573115|Drug|Adapalene-Benzoyl Peroxide Gel 0.1-2.5%|Topical gold microparticles (SEB-250) are delivered to two facial areas at baseline, patients are then prescribed a topical Adapalene-Benzoyl Peroxide Gel 0.1-2.5% for 6 weeks followed by a new exposure to gold microparticles (SEB-250)
78240|NCT03573102|Drug|SGLT2 inhibitor|SGLT2 inhibitor 10 mg/day
78241|NCT03573102|Drug|ACE inhibitor|ACE inhibitor once daily
78242|NCT03573089|Drug|Liberal phosphate target|All phosphate-lowering medications in use at baseline will be discontinued. Phosphate-lowering medications will be prescribed only if serum phosphate concentration exceeds 2.50 mmol/L. The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
78243|NCT03573089|Drug|Intensive phosphate target|This will be achieved by prescribing phosphate-lowering medications aimed to intensively lower serum phosphate concentration towards normal level (≤1.50 mmol/L). The choice and dosages of phosphate-lowering medications will be at the discretion of treating physicians and/or participants.
78244|NCT03573076|Combination Product|Photodynamic therapy|Photodynamic therapy with Methyl Aminolevulinate creme and red light.
78245|NCT03573076|Device|Non-ablative Thulium laser (NAFL)|Non-ablative Thulium laser (NAFL).
78246|NCT03573076|Device|Radio-frequency microneedles (RF-MN)|Radio-frequency microneedles (RF-MN).
78247|NCT03573063|Other|Androgen metabolism after starvation|"The 20 women will all undergo the same process of starvation for 48 hours. During this time three blood samples and three 24-hours urine samples will be collected. At baseline, the investigators will draw blood, perform a pregnancy test and collect the 24 hours urine as well as a spot urine.~Then the 48 hours starvation starts and two blood and two 24 hours urine samples and spot urines will be collected after 24 and 48 hours in the morning. After the third visit the study is completed for the participant."
78248|NCT03573050|Drug|RIV-TDS 13.3 mg/24 h|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
78249|NCT03573050|Drug|Exelon® 13.3 mg/24 hours transdermal patch|5 consecutive transdermal patch applications, each with a nominal release rate of 13.3 mg/24 hours
78250|NCT03573037|Drug|Oral anticoagulant|1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
78251|NCT03573024|Drug|Azacitidine|On day 1 of cycle 1, azacitidine 75 mg/m2 SC or IV will be given, and will continue for 7 days.
78252|NCT03573024|Drug|Venetoclax|Starting on day 1 of cycle 1, venetoclax will be initiated. It will be dose escalated to a target dose of 600 mg in the following manner: 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5. The patient then continues to take the 600mg dose for the remainder of the 28 day cycle. Each dose of venetoclax will be self-administered with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. The dose should be administered at the same time each day. On days the subject is given azacitidine, venetoclax must be given first.
78253|NCT03573011|Diagnostic Test|[18F]PSMA-11|18F-PET imaging
78254|NCT03572998|Drug|Indocyanine Green (ICG)|Injection of ICG as a fluorophore for Near Infrared fluorescence Imaging (NIRF)
78255|NCT03572985|Other|Road-tracking test|Driving with simulator program for SDLP measurement
78256|NCT03572985|Other|Car-following test|Driving with simulator program for DCV measurement
78257|NCT03572985|Other|Harsh-braking test|Driving with simulator program for BRT measurement
78258|NCT03572972|Drug|Apixaban|Treatment for NVAF patients
78259|NCT03572972|Drug|Dabigatran|Treatment for NVAF patients
78260|NCT03572972|Drug|Rivaroxaban|Treatment for NVAF patients
78261|NCT03572972|Drug|warfarin|Treatment for NVAF patients
78262|NCT03572972|Drug|Antiplatelets|Treatment for NVAF patients
78263|NCT03572959|Drug|0.1 % topical triamcinolone acetonide|0.1 % topical triamcinolone acetonide preparation was used where the patients' were instructed to apply the gel 4 times daily, with no food or fluid taken one hour after application.
78264|NCT03572959|Device|SIROIaser|"Oral Lichen Planus lesions were irradiated with a 970-nm diode laser with a 2 W irradiation power in a continuous non-contact mode. The laser beam was delivered using a fiber-optic tip with a 320 µm diameter with defocused mode directed at the lesions plus 0.5 cm peri- lesional tissues with a slight overlapping in order to evenly distribute energy covering all the lesional and peri-lesional tissues until blanching of the area was observed.14 Diode laser was calibrated to an output power of 3W, frequency of 30 Hz, energy of 180 joule and time interval of 8 minutes divided into 4 sessions , two min each with one minute rest in between to allow for tissue relaxation.~Irradiation was done twice weekly (once every third day) for two months until the resolution of signs for a maximum of ten sessions."
78265|NCT03572946|Procedure|Targeted prostate biopsy|MRI-guided targeted prostate biopsy
78266|NCT03572946|Procedure|Standard biopsy|Transperineal ultrasound guided prostate biopsy(SB).
78267|NCT03572933|Drug|ganaxolone|active drug
78268|NCT03572933|Drug|Placebo|inactive
78269|NCT03572920|Device|Objective sleep evaluation by actigraphy|Each subject will wear a wrist activity monitor (actigraphy) to detect his/her sleep behaviour during hospitalization.
78270|NCT03572920|Other|Pittsburgh Sleep Quality Index (PSQI)|Each subject will fill twice the Pittsburgh Sleep Quality Index (PSQI), before hospitalization and after the 10th day, to evaluate his/her subjective sleep quality.
78271|NCT03572920|Other|Epworth Sleepiness Scale (ESS)|Each subject will fill the Epworth Sleepiness Scale (ESS) every day, untill the 10th hospitalization day, to evaluate his/her daytime sleepiness.
78272|NCT03572907|Other|Rhinoplasty questionnaire|Each patient will complete a validated rhinoplasty questionnaire (Rhinoplasty Outcome Evaluation) before and after the intervention
78273|NCT03572894|Device|PVI and RPVI measurements|"PVI and RPVI measurements during variations of the tidal volume (Vt challenge) and a recruitment maneuver in anesthetized and mechanically ventilated patients.~T0 : Vt 6 mL/kg of predicted body weight (PBW) during 5 minutes~T1 : Vt 8 mL/Kg of PBW during 5 minutes~T2 : Vt 10 mL/kg of PBW during 5 minutes~T3 : Vt 6 mL/kg of PBW during 5 minutes~T4 : A single recruitment maneuver~Data will be recorded at each step."
78274|NCT03572881|Device|Endocardial mapping|An endocardial mapping of the pulmonary infundibulum will be performed during the electrophysiological exploration between asymptomatic patients with Brugada type 1 and patients with symptomatic Brugada type 1.
78275|NCT03572868|Other|Evaluation of the long term neurodevelopmental outcome|Evaluation of the long-term neurodevelopmental outcome of newborns who have an isolated transverse cerebellar diameter < 5th centile during the second or the third trimester of pregnancy.
78276|NCT03572855|Combination Product|Scoliosis Brace|Brace will be fitted to each subject by a spine orthopedic surgeon before the testing. The subject will wear the fitted brace for 2 months.
78277|NCT03572842|Other|quantiferon monitor test|different blood test with quantiferon monitor
78278|NCT03572829|Drug|Aprepitant|Intensity-modulated radiotherapy was given to the patients with regimen of 69.96 Gy-73.92 Gy to the gross target volume of nasopharynx,69.96 Gy to the gross target volume of positive nodes, 60.06 Gy the high risk clinical target volume, 50.96 Gy to the low risk clinical target volume. Concurrent chemotherapy is administrated with cisplatin 100mg/m2 at d1, d22, d43 during radiotherapy. Patients receive concurrent aprepitant 125mg, dexamethasone 12mg, and ondansetron 8mg p.o. on day1. AND then patients received aprepitant 80mg, dexamethasone 8mg on day 2-5 at every chemotherapy cycle.
78279|NCT03572816|Device|Settner shoe|custom-made heel-unloading orthosis ('Settner shoe') in aftercare of calcaneus fractures (used according to manufacturer), certified 'CE' product with more than 10 years experience
78280|NCT03572803|Other|Group of Dry Needling|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
78281|NCT03572803|Other|Group of Electrolysis|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
78282|NCT03572803|Other|Control Group|Every group will receive a total of 3 treatment sessions distributed throughout 4 weeks of treatment. The program of eccentric exercises will be done by participants at home 5 days a week, two times a day.
78283|NCT03572790|Drug|Prucalopride|1mg prucalopride capsule, once daily for seven days
78284|NCT03572790|Other|Placebo|Lactose placebo capsule, once daily for seven days
78285|NCT03572777|Drug|Concomitant therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days.
78286|NCT03572777|Drug|Concomitant therapy|Clarithromycin ('Makcin') 500 mg bid for 14 days
78287|NCT03572777|Drug|Concomitant therapy|Metronidazole ('Medazol') 500 mg bid for 14 days
78288|NCT03572777|Drug|Concomitant therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
78289|NCT03572777|Drug|Hybrid therapy|Amoxicillin ('Amoksicilin') 1 g bid 14 days
78290|NCT03572777|Drug|Hybrid therapy|Esomeprazole ('Emanera') 40 mg bid for 14 days
78291|NCT03572777|Drug|Hybrid therapy|Clarithromycin ('Makcin') 500 mg bid for the last 7 days
78292|NCT03572777|Drug|Hybrid therapy|Metronidazole ('Medazol') 500 mg bid for the last 7 days
78293|NCT03572764|Drug|CPX-351|-CPX-351 will be provided by Jazz Pharmaceuticals
78294|NCT03572764|Procedure|Research skin biopsy|"-And/or buccal swab~Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)"
78295|NCT03572764|Procedure|Research blood draw|"Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~Post-consolidation 1 (if applicable)~Post-consolidation 2 (if applicable)~Post-transplant Day 30 (if applicable)~Post-transplant Day 100 (if applicable)"
78296|NCT03572764|Procedure|Research bone marrow aspirate|"Pre-treatment~Post-induction (no earlier than Day 28 and no later than Day 56 from last induction)~Post-consolidation 1 (if applicable)~Post-consolidation 2 (if applicable)~Post-transplant Day 30 (if applicable)~Post-transplant Day 100 (if applicable)"
78297|NCT03572751|Diagnostic Test|Bed-, wrist- and ECG-sensor monitoring|Bed-, wrist- and ECG-sensor monitoring
78298|NCT03572725|Procedure|Gas tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
78299|NCT03572725|Procedure|Air tamponade|Removal of intraocular fluid and replacement with intraocular tamponade. No restriction of postoperative positioning with exception to the supine position. A tennis ball is attached to the back of patients at night. This measure will assists them in avoiding the nocturnal supine position.
78300|NCT03572712|Other|No Interventional study|every patient will be monitored with a blood gase, a nocturnal oximetry and a transcutaneous capnography
78301|NCT03572699|Other|diabetic retinopathy|This is an observational study of patients with diabetes. Patients undergoing routine care will undergo retinal imaging using a nonmydriatic fundus camera. The images will be run on an artificial intelligence (AI) algorithm. The diagnosis of the artificial intelligence algorithm will be compared to the image diagnosis given by the ophthalmologists. The ophthalmologists will be blinded to the diagnosis of the AI and vice versa. The data will be analyzed to evaluate the performance of the AI.
78302|NCT03572686|Drug|Ropivacaine 0.5% 20mL|In Group RH, participants received supraclavicular brachial plexus block with ropivacaine 0.5% 20ml at the end of surgery.
78303|NCT03572686|Drug|Ropivacaine 0.25% 20ml|In Group RL, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml at the end of surgery.
78304|NCT03572686|Drug|Ropivacaine 0.25% 20ml + dexamethasone 8mg|In Group RLD, participants received supraclavicular brachial plexus block with ropivacaine 0.25% 20ml + dexamethasone 8mg at the end of surgery.
78305|NCT03572673|Device|Flexima 3S|Flexima 3S (2-piece appliance) with drainable pouch
78306|NCT03572673|Device|New 2-piece ostomy appliance|New 2-piece ostomy appliance with drainable pouch
78308|NCT03572647|Drug|Eritromax|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
78309|NCT03572647|Drug|Eprex|The subjects will receive a single dose of 4000 IU epoetin alfa in each period, according to randomisation.
78310|NCT03572634|Drug|TP-0903|"Monotherapy: PHASE 1: TP-0903 will be a 25 mg flat dose. The study drug will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period).~Patients may continue to receive TP-0903 in 28-day cycles at the same dose given during Cycle 1 until they experience unacceptable toxicity or unequivocal disease progression. No intrapatient escalation of the TP-0903 dose is permitted.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. TP 0903 will be administered orally at a fixed dose once daily for 28 days (each cycle is 28 days; no drug-free period) with repeated cycles permitted until a patient experiences unacceptable toxicity or unequivocal disease progression."
78311|NCT03572634|Combination Product|TP-0903 and ibrutinib combination therapy|"Combination therapy: PHASE 1: TP-0903 and ibrutinib combination therapy: The starting dose of TP-0903 will be a 20 mg flat dose. TP-0903 will be administered orally once daily for 28 days (each cycle is 28 days; no drug-free period). Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment.~Patients should continue with the combination of ibrutinib and TP-0903 for at least 3 months after study start.~PHASE 2: The starting dose of TP-0903 will be the RP2D determined during Phase 1. Patients will also receive ibrutinib at the same dose that they were receiving immediately prior to study enrollment. Both TP 0903 and ibrutinib will be administered orally at fixed doses once daily for 28 days (each cycle is 28 days; no drug-free period)."
78312|NCT03572621|Other|Therapeutic education|"Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid."
78313|NCT03572621|Other|Collection of data concerning their sexuality|Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).
78314|NCT03572621|Other|Participation|Participation in a therapeutic education day.
78315|NCT03572608|Other|Acupuncture treatment|Classical acupuncture points will be used without a formal traditional Chinese medicine diagnosis in the intervention group. Neither manual needle stimulation nor moxibustion will used. The needles will left in place for 30 min and de qi was not sought. The points will be selected bilateral Heart-7, bilateral Large Intestine-4, Governing Vessel-20 and ear shenmen for the first session. Bilateral Conception Vessel-3,4,6, bilateral Liver-3, bilateral Stomach-30, bilateral Spleen-6, bilateral Governing Vessel-20 will be used for the second session. Bilateral Large Intestine-4, bilateral Spleen-6,9, bilateral Stomach-36 will be used for the last session. All acupuncture points will be selected and localized on the basis of the WHO Standardised Acupuncture Point Location.
78316|NCT03572595|Diagnostic Test|F-18 FDG-PET/CT|imaging using Positron Emission Tomography/ Computed Tomography with 18F-fluoro-2-deoxyglucose (18F- FDG PET/CT) in Patients with colorectal cancer either for staging or suspecting recurrence
78317|NCT03572582|Drug|Nivolumab|Nivolumab therapy combined with standard TACE treatment
78318|NCT03572582|Drug|TACE|TACE is performed by using drug eluting beads
78319|NCT03572556|Biological|Blood samples|"5 mL dry tube to separate serum~Two 6 mL EDTA tubes for plasma separation~Eight 6 mL heparinized tubes for flow cytometry (quantification of TANG such as CD3+CD31+CXCR4+ and CEC) and quantification of angiogenesis markers."
78320|NCT03572556|Other|Epistaxis charts|Three monthly epistaxis charts to be completed
78321|NCT03572543|Device|tDCS|Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
78322|NCT03572530|Drug|5-Azacytidine (5-AZA) group 1|"5-AZA (20 mg) will be prepared in preservative-free normal saline to a total volume of 1ml. 5-AZA will be infused over a minimum of 30 seconds 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 1 will receive two 5-AZA infusions per week (typically Monday and Thursday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
78323|NCT03572530|Drug|5-Azacytidine (5-AZA) group 2|"5-AZA (20 mg) will be prepared in preservative-free normal saline to a total volume of 1ml. 5-AZA will be infused over a minimum of 30 seconds 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 2 will receive three 5-AZA infusions per week (typically Monday, Wednesday, and Friday but may be given on other days based upon logistical considerations) for 8 consecutive weeks."
78324|NCT03572530|Drug|5-Azacytidine (5-AZA) group 3|"5-AZA (20 mg) will be prepared in preservative-free normal saline to a total volume of 1ml. 5-AZA will be infused over a minimum of 30 seconds 5-AZA will be followed by a 1 ml preservative-free normal saline flush over a minimum of 30 seconds.~Patients will receive two, three, or four 5-AZA infusions per week depending on the dosing algorithm (see below). We refer to these dosing schedules as dose 1, 2, or 3.~Patients assigned to dose 3 will receive four 5-AZA infusions per week (on any 4 weekdays based upon logistical considerations) for 8 consecutive weeks."
78325|NCT03572517|Procedure|Subarachnoid block|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) associated with subarachnoid block (bupivacaine and morphine)
78326|NCT03572517|Procedure|Spinal morphine|Balanced general anesthesia (Induction of anesthesia: Propofol, fentanyl and rocuronium. Maintenance: Desflurane /remifentanil) and spinal analgesia with morphine
78327|NCT03572504|Other|critically ill children|Compare a series of measurement or size estimation techniques to the WHO standard to identify the most reliable method (s) of pediatric resuscitation.
78328|NCT03572491|Biological|influenza vaccine|Allantoic split inactivated seasonal influenza vaccine
78329|NCT03572478|Drug|Rucaparib|600 mg taken by mouth twice daily.
78330|NCT03572478|Drug|Nivolumab|480 mg given by intravenous (IV) infusion every 4 weeks.
78331|NCT03572465|Device|Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)|Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
78332|NCT03572452|Behavioral|McKenzie Method|Treatment according to the Mechanical Diagnosis and Therapy Approach
78333|NCT03572452|Behavioral|Advice to saty active|Physiotherapy councelling advicing to stay normally active
78334|NCT03572439|Diagnostic Test|Sensory block level check using ice|Patients are asked to report when the ice feels as cold as it does on the forehead.
78335|NCT03572426|Other|genotyping all subjects|genotyping using SNaPshot genotyping method.
78336|NCT03572413|Procedure|Low pressure pneumoperitoneum|Lowering intra-abdominal pressure during laparoscopic surgery
78337|NCT03572413|Drug|Rocuronium bromide|Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block
78338|NCT03572400|Drug|Gemcitabine|Neoadjuvant: Weekly Gemcitabine 200 mg/m2 iv Adjuvant: Gemcitabine 1000mg/m2, D1, 8, 15 Q 4 weeks total 6cycles
78339|NCT03572400|Drug|Durvalumab|Neoadjuvant: Durvalumab 1.5g iv Q 4weeks Adjuvant: Durvalumab 1.5g iv Q 4weeks for 1 year
78340|NCT03572387|Drug|5-Azacitidine|subcutaneously on days 1-5 at a dose of 40 mg/m^2
78341|NCT03572387|Drug|all trans retinoic acid|45 mg/m^2, will be taken orally on days 3-7 of each cycle, divided into two doses
78342|NCT03572387|Drug|Lupron|7.5 mg x 1
78343|NCT03572374|Other|TEAMWork App|"The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance."
78344|NCT03572374|Other|Information Booklet|Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
78345|NCT03572361|Biological|V3-MOMMO|Tableted vaccine (V3-OVA) containing breast cancer antigens administered once daily for 3 months
78346|NCT03572348|Procedure|Transecting anastomotic repair (tAR)|Classic technique, which involves full thickness transection of the corpus spongiosum and the embedded urethral blood supply.
78347|NCT03572348|Procedure|Vessel-sparing anastomotic repair (vsAR)|Alternative technique, leaving the bulbar arteries intact, only transecting and excising the narrow segment of the urethra and the surrounding spongiofibrosis.
78348|NCT03572335|Diagnostic Test|PFT's (pulmonary function testing)|The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.
78349|NCT03572322|Other|Focus Group|Focus Group
78350|NCT03572322|Other|Interviews|Interviews
78351|NCT03572296|Dietary Supplement|Placebo|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
78352|NCT03572296|Dietary Supplement|Polyphenol and fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
78353|NCT03572296|Dietary Supplement|Fibre|Drinks will be delivered in random order at 3 separate study visits immediately before a high carbohydrate meal. A minimum of 4 days (ideally 7 days) wash-out period will be required between study days.
78354|NCT03572283|Drug|Bethanechol|Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
78355|NCT03572270|Diagnostic Test|AMH test|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
78356|NCT03572270|Diagnostic Test|pelvic ultrasound|Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
78357|NCT03572257|Drug|Quetiapine|Patients randomized to the study treatment group will received quetiapine at 0.5 mg/kg, three times a day for 10 days. Doses can be increased up to a maximum of 6 mg/kg/day, in increments of 0.5 mg/kg, based on the subject's clinical delirium symptoms. PRN doses of 0.5 mg/kg can be given up to three times a day based on the clinical judgement of the subject's ICU care team.
78445|NCT03571620|Drug|Q301 Cream|1.0% or 1.4% Q301 Cream
78358|NCT03572257|Other|Placebo|Patients randomized to the placebo group will be given an equivalent volume of sterile liquid or sugar pill, based on the individual subjects dosing preference or ability. Dosing will be done on the same schedule as the quetiapine group
78359|NCT03572244|Device|Laser-Lok|A microgrooved abutment will be placed
78360|NCT03572244|Device|Machined|A machined transmucosal healing abutment will be placed
78361|NCT03572231|Drug|mirabegron|oral
78362|NCT03572231|Device|solifenacin|oral
78363|NCT03572231|Drug|darifenacin|oral
78364|NCT03572231|Drug|imidafenacin|oral
78365|NCT03572231|Drug|tolterodine|oral
78366|NCT03572231|Drug|oxybutynin|oral
78367|NCT03572231|Drug|trospium|oral
78368|NCT03572231|Drug|fesoterodine|oral
78369|NCT03572231|Device|propiverine|oral
78370|NCT03572218|Behavioral|BWL|The BWL sessions will be based on the Diabetes Prevention Program (DPP) manual. A diet of 1200-1499 calories per day will be prescribed for participants < 250 lb, and 1500-1800 for those ≥ 250 lb. Participants will be instructed to eat a balanced deficit diet. Session topics during the first 12 weeks will include self-monitoring, stimulus control, slowing eating, social support, cognitive restructuring, portion sizes, and goal-setting. Those during weeks 13-26 will focus on continued self-monitoring and skills required for weight loss maintenance and relapse prevention. Physical activity will be prescribed at a level consistent with data showing that >250 min/wk is associated with improved long-term weight loss. BWL sessions will last 60 minutes.
78371|NCT03572218|Behavioral|BIAS|Following 60 minutes of BWL treatment, the BIAS intervention will devote 30 minutes to stigma-related content. Session topics will include: psychoeducation about weight and weight stigma; challenging myths and cognitive distortions related to weight; strategies for coping with instances of stigma; and increasing empowerment and body esteem. The effects of weight stigma on health behaviors will be discussed, and sessions will focus specifically on helping participants overcome stigma-related barriers to weight management. In the every-other-week and monthly weight loss maintenance sessions from weeks 13-26, strategies for coping with weight stigma and challenging internalized beliefs will be reviewed, and participants will be encouraged to use these strategies in the context of weight management.
78372|NCT03572205|Dietary Supplement|LA|The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
78373|NCT03572205|Dietary Supplement|ALA|The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
78374|NCT03572179|Device|3d printed positioning tray|3d printed positioning tray for lingual fixed retainer placement in treatment group
78375|NCT03572166|Diagnostic Test|Arginine infusion|Intravenous Infusion of Arginine is given, copeptin measurement will be collected before and 60minutes after start of infusion
78376|NCT03572166|Diagnostic Test|Hypertonic saline infusion|Intravenous Infusion of hypertonic Saline is given, copeptin measurement will be collected before and once Plasma sodium rises above 149mmol/l
78377|NCT03572153|Behavioral|Self-Administered Hypnosis|Participants will be listening to six 20-minute hypnosis audio recordings with hypnotic induction. Participants will be encouraged to practice daily, and each recording will build on the content of the previous recordings. They will also be provided with booklets of information about hot flashes, including treatment options.
78378|NCT03572153|Behavioral|Self-Administered White Noise Hypnosis|Participants will be listening to the same 20-minute white noise audio recordings for 6 weeks and will be encouraged to practice daily.They will also be provided with booklets as well as an audio recording with information about hot flashes including treatment options.
78379|NCT03572140|Diagnostic Test|RAVS In relapsed and resistent cases|assessment of RAVS in relapsed and resistant cases after sofosbuvir plus daclatasvir regimen
78380|NCT03572127|Other|Diet|High protein diet derived from either animal or non-animal sources.
78381|NCT03572114|Diagnostic Test|3Tesla MRI|"A previously validated multi-parameter mapping protocol sensitive to neuromelanin and iron content~Iron mapping and micro-bleed detection: QSM (quantitative susceptibility mapping), a fully flow-compensated, susceptibility-weighted gradient-echo sequence (5 minutes).~1-mm isotropic anatomical MPRAGE (magnetization-prepared rapid gradient-echo)~conventional FLAIR sequence"
78382|NCT03572114|Behavioral|Burke-Fahn-Marsden Dystonia Rating scale|internationally standardized examination/quantification of dystonia
78383|NCT03572114|Behavioral|MDS-United Parkinsons Disease Rating Scale, Part III|most recent, internationally standardized examination/quantification of bradykinesia / rigidity according to the Movement Disorder Society
78384|NCT03572114|Behavioral|Beck Depression Inventory|internationally standardized examination to quantify traits of anxiety and depression
78385|NCT03572114|Behavioral|MoCA: Montreal Cognitive Assessment:|internationally standardized examination to quantify cognition, frequently used in studies of dystonia and parkinsonism
78386|NCT03572088|Drug|Terlipressin|Terlipressin is a synthetic vasopressin analogue with relative specificity for the splanchnic circulation(Terlipressin was started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.)
78387|NCT03572088|Drug|normal saline|Patients received 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
78388|NCT03572075|Diagnostic Test|assessment of symptoms at the first medical examination|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) at the first medical examination
78446|NCT03571620|Drug|Vehicle|Vehicle Control
78389|NCT03572075|Procedure|pelvic floor physiotherapy|six individual sessions (weeks 1, 3 , 5, 8, 11 from the randomization) with pelvic floor consciousness exercises with mild contractions and relaxation (ex. 'kegel reverse' exercises); respiratory rate control exercises; extra exercises to perform at home are suggested.
78390|NCT03572075|Procedure|standard care protocol|the treatment is the same as usual in our center
78391|NCT03572075|Diagnostic Test|assessment of symptoms after four months|assessment of endometriosis related symptoms using NRS (Numerical Rating Scale); intestinal, sexual and urinary functions are evaluated with validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire (KESS), Female Sexual Function Index (FSFI), Bristol Female Lower Urinary Tract Symptoms (BFLUTS)); pelvic floor morphometry at rest, during pelvic floor contraction and during Valsalva manoeuvre is evaluated using 3D/4D transperineal ultrasound through the assessment of the levator hiatus area (LHA) after four months from the randomization.
78392|NCT03572062|Biological|Formulation A|RSV vaccine
78393|NCT03572062|Biological|Formulation B|Adjuvanted RSV vaccine
78394|NCT03572062|Biological|Formulation C|RSV vaccine
78395|NCT03572062|Biological|Placebo|Placebo
78396|NCT03572049|Drug|SUBA itraconazole|SUBA itraconazole study drug will consist of two 65 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 65mg capsules will be taken twice daily with food.
78397|NCT03572049|Drug|Conventional itraconazole|Conventional itraconazole comparator drug will consist of two 100 mg capsules to be taken three times a day with food for days 1-3 of study. For days 4-180 of study, two 100 mg capsules will be taken twice daily with food.
78398|NCT03572023|Other|Integrative characterization of MINOCA patients|"Characterization of MINOCA patients will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
78399|NCT03572023|Other|Characterization of MI patients with coronary obstruction|"Characterization of patients with myocardial infarction and obstructive atherosclerosis will be based on integrative evaluation of imaging data, blood levels of proinflammatory and anti-inflammatory cytokines, and genetic testing for thrombophilia risk.~MSCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.~SPECT: Single-Photon Emission Computed Tomography enable assessment of myocardial perfusion and viability.~Blood tests.~Genetic tests."
78400|NCT03572010|Dietary Supplement|FeFum fortified maize test meal|Maize porridge extrinsically labeled with 2 mg ferrous fumarate (58FeFum); only for iron deficient children (defined by plasma ferritin <30 mikrogramm/L and/or sTfR >8.3 mg/L); cereal staple foods, like maize, depending on milling, may be high in phytic acid, a potent iron absorption inhibitor
78401|NCT03572010|Dietary Supplement|FeSO4 fortified LNS|self-made Lipid-based nutritional supplement (LNS) extrinsically fortified and labeled with 6 mg ferrous sulfate (57FeSO4); only for iron deficient children (defined by plasma ferritin <30 mikrogramm/L and/or sTfR >8.3 mg/L); LNS may be a better food matrix for iron supplementation compared to maize-based porridge; contains canola oil, peanut paste, milk powder, sugar, maltodextrin and palm stearin
78402|NCT03572010|Dietary Supplement|FeSO4 supplement|170 mg iron tablets as FeSO4 (containing 65 mg of elemental iron) with 6 mg extrinsically labeled 57Fe; will be given together with a glass of water; only for iron deficient children (defined by plasma ferritin <30 mikrogramm/L and/or sTfR >8.3 mg/L);
78403|NCT03572010|Dietary Supplement|FeSO4 fortified fruit juice|Fruit juice labeled with 12 mg 57Fe as FeSO4; in the group for iron sufficient children
78404|NCT03571984|Behavioral|Moving on ABC Plus|The intervention has two components. CBT Moving on After Breast Cancer
78405|NCT03571971|Other|Load modification education|Load modification education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities, but will also include education on common daily postures and movement patterns that may increase load and stress on the muscles and tendons around the hip.
78406|NCT03571971|Other|Standard exercise education|Standard exercise education includes exercises currently prescribed by physical therapists, like stretching and strengthening activities.
78407|NCT03571958|Behavioral|BMI|A derivative of motivational interviewing (MI), which is a patient-centered, collaborative counseling approach to strengthen an individual's intrinsic motivation towards a positive behavior change. BMI is intended for healthcare providers with limited time (5-10 minutes) to support a positive behavior change.
78408|NCT03571945|Device|Bi-spectral Index (BIS QUATRO REF #186-0106)|GA will be monitored and controlled with Bi-spectral index (BIS).
78409|NCT03571945|Device|End tidal anaesthesia gas concentration (ETAG)|GA will be monitored and controlled with end-tidal anaesthesia gas concentration
78410|NCT03571932|Behavioral|Family planning and immunization service integration|The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
78411|NCT03571919|Drug|Lidocaine infusion|Intravenous bolus of lidocaine (1.25 mg/kg) and then infusion at 1 mg/kg/hr
78412|NCT03571919|Drug|Saline infusion|Intravenous bolus of saline and then infusion
78447|NCT03571607|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
78448|NCT03571594|Drug|ONO-5788|Investigational drug
78449|NCT03571594|Drug|ONO-5788 Placebo|Placebo Comparator
78450|NCT03571594|Drug|Octreotide|Active Comparator in Part D
78413|NCT03571906|Behavioral|Tele - Cardiac Pre-Rehabilitation|We intend to enroll 50 stable subjects with valvular heart disease scheduled for surgical intervention. Following a comprehensive clinical and physiological evaluation subjects will be randomized (1:1) to a Prehab arm (PHB) vs. usual care (UC). Subjects in the prehab arm will receive a hybrid institution and home-based exercise prescription, nutritional and psychological intervention and periodic calls. Adherence will be assessed and encouraged by smartwatch and matching smartphone software. In the usual care arm subjects will receive general recommendations following the baseline stress test performed by both groups (prehab is not standard of care or guideline based). Another stress test will be performed days prior to valve surgery Adherence to the rehab program will be assessed and a structured motivational program and follow-up will be provided in order to maximize goal completion.
78414|NCT03571893|Behavioral|Weight Watchers Freestyle (Flex)|Participants will be referred to their local Weight Watchers meeting and provided with a promotional code to allow them to participate in the Weight Watchers program free of charge for 12 months. At the randomization visit, study staff will help participants identify a convenient Weight Watchers meeting location and download the program app onto their smartphone.
78415|NCT03571893|Behavioral|DIY Personal Plan|Participants will be provided with a written resource with descriptions of a variety of approaches that have been shown to promote healthy weight loss through behavioral modification. Participants will be encouraged to assess their preferences for dietary change and physical activity and adopt an approach that will lead to negative energy balance and moderate (1-2 lbs. per week) weight loss.
78416|NCT03571880|Device|Biodex-assisted isometric strength testing|The maximum voluntary isometric and dynamic strength of back and abdominal muscles is measured using an isokinetic dynamometer (System 3, Biodex, Enraf-Nonius, New York).
78417|NCT03571854|Device|Group PCV-VG|Pressure controlled ventilation-volume guaranteed
78418|NCT03571854|Device|Group VCV|Volume controlled ventilation
78419|NCT03571841|Behavioral|Group Session|The 4-hour group session will be structured around three 60-minute modules and creation of a personal action plan
78420|NCT03571841|Behavioral|Telephone Booster|One month following the group session, women will receive a telephone booster session (<15 minutes). This brief telephone check-in is intended to help women review progress with their individualized action-plan, problem-solve around continuing problems, and plan for maintenance moving forward.
78421|NCT03571828|Drug|AMG 562|AMG 562 is a BiTE® antibody construct that targets CD19 and is intended for the treatment of patients with B-cell malignancies.
78422|NCT03571815|Drug|5% sodium fluoride varnish|application of sodium fluoride varnish on teeth
78423|NCT03571815|Other|WATER ON TEETH|control group
78424|NCT03571802|Drug|Simvastatin|"The subject will take simvastatin 20mg at 0 h (after stopping simvastatin for 5 days). 5 mL of blood will be sampled at 0 h, 1 h, 2 h, 3 h, 5 h, 7 h.~There will be 2 blood sampling sessions: 1 before and the other 3 months after surgery."
78425|NCT03571789|Device|Vine™|"The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters"
78426|NCT03571776|Procedure|Surgery|Laparoscopic ovarian cystectomy
78427|NCT03571776|Procedure|Sclerotherapy|US-aspiration and alcohol sclerosis
78428|NCT03571763|Other|SWI sequence|Acute ischemic stroke patient confirmed by SWI sequence
78429|NCT03571750|Behavioral|Building Stronger Allies|"BSA was developed to model the educational and behavioral techniques commonly employed in the treatment of individuals with mood psychopathology. The psychoeducation portion uses Cognitive Behavioral Therapy principles to correct problematic ideas and behaviors related to PB/TB. More specifically, the program was designed to correct myths regarding PB/TB. The program emphasizes the idea that social interaction is a critical need, just like other basic needs such as the need for food and water. Participants are taught that negative beliefs about being isolated and being a burden are usually inaccurate. Following this, behavioral activation techniques are introduced as a way to decrease isolation and feelings of burdensomeness."
78430|NCT03571750|Behavioral|Health Education Training|In the HET condition, participants will spend approximately the same amount of time with a program that will present information regarding the importance and benefits of a maintaining a healthy lifestyle and then will provide guidelines to achieve a healthy lifestyle. HET is shown to engage participants with beneficial information while being inert with respect to the risk mechanisms of interest (i.e., PB/TB). The program covers a number of health related topics including: diet, alcohol use, water consumption, exercise, and sleep. The program reviews with the Participants how to monitor their own daily health habits, which will be reinforced by the Smartphone application.
78431|NCT03571737|Drug|Ibuprofen|Ibuprofen tablet
78432|NCT03571737|Drug|Lidocaine Patch 4%|Lidocaine patch
78433|NCT03571724|Other|Non-Menthol Very Low Nicotine Cigarettes|King size non-menthol cigarettes containing 0.4mg nicotine /g tobacco
78434|NCT03571724|Other|Menthol Very Low Nicotine Cigarettes|King size menthol cigarettes containing 0.4mg nicotine /g tobacco
78435|NCT03571711|Drug|Meropenem Injection|Meropenem is administered as prescribed by treating physician
78436|NCT03571698|Device|Neuromuscular Electrical Stimulator|The treatment group received exercise programme with simultaneously active contraction with NMES with large or standart electrodes.
78437|NCT03571685|Behavioral|Sustainable Early Episode Clinic Model of Care|The first 8 weeks is the education phase. Patients attend classes every week for up to 6 hours. From 9 weeks to 10 months patients attend classes for 5 hours every other week. Based on individual progress. Patients can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
78438|NCT03571685|Behavioral|Usual Care|Care path depending on insurance provider
78439|NCT03571672|Drug|DEFINITY|All subjects will receive a single dose of DEFINITY®
78440|NCT03571659|Procedure|Laser|
78441|NCT03571646|Behavioral|Capnostream 20 monitoring|Continuous monitoring on a general ward
78442|NCT03571646|Device|PM1000N-RR monitoring|Continuous monitoring on a general ward
78443|NCT03571633|Drug|Trastuzumab + Paclitaxel|During neoadjuvant period, weekly paclitaxel + trastuzumab (every 3 weeks, Q3W) During adjuvant period, weekly trastuzumab (every 3 weeks, Q3W)
135871|NCT03126916|Drug|Isotretinoin|Given PO
78451|NCT03571581|Behavioral|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
78452|NCT03571568|Biological|BI1206|375 mg/m2, as per SmPC
78453|NCT03571555|Behavioral|Sentebale Psychosocial Programme|Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
78454|NCT03571542|Other|pulmonary function|The aim of this study is to assess the respiratory function thanks to pulmonary function tests in renal transplanted children in France.
78455|NCT03571529|Device|EMG-driven exoskeleton hand robot|"Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~Action Research Arm Test~Motor Activity Log~Data from force and EMG measurement records of HOH robot~Grip strength (with hand dynamometer)~Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~Manuel muscle testing for wrist and finger muscles.~Modify Asworth sclale At the beginning of each robotic treatment session, superficial EMG recording will be taken at relax position ( without muscle contraction) and then during maximal voluntary isometric contraction (MVC) after the patient's hand is placed in the exoskeleton. For both, EMG recording is performed for 7 seconds and Root Mean Square (RMS) is calculated from this record."
78456|NCT03571529|Other|Conventional physiotherapy|"Primary Outcome Measurement:~1. Fugl-Meyer Upper Extremity Assessment~Secondary Outcome Measurements:~Action Research Arm Test~Motor Activity Log~Data from force and EMG measurement records of HOH robot~Grip strength (with hand dynamometer)~Range of motion measurements of Wrist, and MCP, PIP and DIP joints of the fingers~Manuel muscle testing for wrist and finger muscles.~Modify Asworth sclale"
78457|NCT03571516|Drug|Teduglutide|SC injection of 0.05 mg/kg teduglutide will be administered QD into abdomen or into either the thigh or arm for 24 weeks.
78458|NCT03571516|Other|Standard Medical Therapy|Standard medical therapy will be administered for 24 weeks.
78459|NCT03571516|Device|Syringe|Teduglutide will be administered using syringe (510k number: K980987).
78460|NCT03571516|Device|Needle|Teduglutide will be administered using needle (510k number: K021475).
78461|NCT03571503|Procedure|Doin (conduction exercise)|An acupuncture physician will administer acupuncture at 4-8 acupoints in the low back and gluteal area (mandatory points: BL54, and GB30 ipsilateral to the dysfunctional site; and selective points: BL23, BL24, BL25, BL26, BL31, BL32, Ah-shi points, local acupuncture points and/or trigger points. Doin (conduction exercise) will be performed as active and passive movement with the needles in situ to the aim of effective treatment of pain and functional disability by increasing the hip joint range of motion (flexion and extension) with physician guidance and isometric resistance exercise (flexion and extension) as needed. Doin (conduction exercise) sessions will be performed 1 session/day for the duration of hospitalized treatment while the patient presents radiating leg pain (NRS≥1).
78462|NCT03571503|Drug|Herbal medicine|Herbal medicine will be mainly administered in water-based decoction (120ml) and dried powder (2g) form (the ingredients are mainly, but not restricted to: Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
78463|NCT03571503|Procedure|Chuna manual therapy|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered at the physician's discretion.
78464|NCT03571503|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
78465|NCT03571503|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
78466|NCT03571503|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
78467|NCT03571503|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
78468|NCT03571503|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
78469|NCT03571503|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
78470|NCT03571490|Drug|Ropivacaine|Single shot of ropivacaine 0.325%
78471|NCT03571490|Drug|Saline|Single shot of saline 0.9%
78472|NCT03571477|Device|ApneaBand|Mesure of oxygen saturation (oximetry), pulse wave (photoplethysmography), electrodermal activity and movements (tri-axial accelerometer)
78473|NCT03571464|Device|GGRO Mobile App|"GGRO was designed to challenge maladaptive beliefs that underlie common OCD symptoms (e.g., contamination, repugnant thoughts) as well as relationships obsessions. Users are presented with 'blocks' featuring statements such as I take things as they come or Everything can end in a catastrophe. Users then have to respond to these statements by either pulling 'blocks' towards themselves (i.e., downwards) or throwing the blocks away from themselves (i.e., rejecting them upwards)."
78474|NCT03571438|Combination Product|CK2 and ATM inhibitors serine/ threonin Kinase combination|Treatment of cell culture with CK2 and ATM inhibitors serine/ threonin Kinase combination
78475|NCT03571438|Drug|Sunitinib|Treatment of cell culture with Sunitinib
78476|NCT03571438|Drug|Pazopanib|Treatment of cell culture with Pazopanib
78477|NCT03571438|Drug|Temsirolimus|Treatment of cell culture with Temsirolimus
78478|NCT03571425|Other|Oral Placebo|A placebo beverage will be consumed orally
78479|NCT03571425|Other|Oral Protein|A protein beverage will be consumed orally
78480|NCT03571425|Other|Enteral Protein|A protein beverage will be consumed via a naso-gastric feeding tube
78481|NCT03571412|Device|repetitive Transcranial Magnetic Stimulation|Subject will receive 5Hz LDLPFC or 5Hz DMPFC rTMS
78482|NCT03571386|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|Standardized 8-week Cognitive and Behavioral Psychotherapy group with 26 hrs of in-class training and homework, along with 1 all-day retreat in which core mindfulness skills are developed
78483|NCT03571386|Behavioral|Mindfulness-based Stress Reduction (MBSR)|Standardized 8-week patient-centered educational approach which uses relatively intensive training in core meditation practices that teaches people how to take better care of themselves using mindfulness skills and live healthier and more adaptive lives.
78484|NCT03571373|Other|No intervention|No intervention due to the observational set-up of this study.
78485|NCT03571360|Other|PD-L1 positive vs PD-L1 negative NSCLC patients|Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
78486|NCT03571347|Behavioral|Self Help Plus|5-session psychosocial intervention
78487|NCT03571347|Other|Enhanced Treatment As Usual|Routine social support and/or care, and information about freely available mental health services, social services, NGOs, and community networks providing support to asylum seekers and refugees
78488|NCT03571334|Drug|IncobotulinumtoxinA (Xeomin®, Merz) (INA)|IncobotulinumtoxinA (Xeomin®, Merz) (INA) will be reconstituted with preservative-free normal saline to a dilution of 5mL:100 units. Study participants will receive 50u INA (total volume 2.5mL) injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, INA will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, INA will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
78489|NCT03571334|Drug|Normal saline|Study participants will total volume 2.5mL of 0.9% Normal saline injected into each limb, max 2 limbs per subject (either bilateral hands or bilateral feet.) Study participants will receive one series of injections during the trial. In the hands, 0.9% Normal saline will be injected across the palmar surface of the digits in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). In the feet, 0.9% Normal saline will be injected across the dorsal surface of the foot in a grid like pattern covering a total of 25 sites per limb (0.1mL/site). Injections will be performed intradermally using a 5/16-inch, 32-g needle
78490|NCT03571321|Drug|Ruxolitinib|"Participants will receive one of 3 doses [taken by mouth] (30 mg, 40 mg, or 50 mg) depending on when they are enrolled to the study.~Remission consolidation regimen:~Days 1-14 and 29-43~Interim maintenance regimen:~Days 1-14 and 29-43~Delayed Intensification regimen:~Days 1-14 and 29-43"
78491|NCT03571321|Drug|Cyclophosphamide|"Remission consolidation regimen:~1000 mg/m2 by intravenous infusion (IV) on Day 1 and Day 29~Delayed Intensification regimen:~1000 mg/m2 IV on Day 29"
78492|NCT03571321|Drug|Cytarabine|"Remission consolidation regimen:~75 mg/m2/day IV or subcutaneously (SC) on Days 1-4 (i.e., 4 doses), 8-11, 29-32, and 36-39~Delayed Intensification regimen:~75 mg/m2/day IV or SC on Days 29-32 and 36-39"
78493|NCT03571321|Drug|Mercaptopurine|"Taken by mouth.~Remission consolidation regimen:~60 mg/m2 on Days 1-14 and 29-42~Maintenance Therapy:~75 mg/m2 on Days 1-84"
78494|NCT03571321|Drug|Vincristine|"Remission consolidation regimen:~1.5 mg/m2 (maximum 2 mg) IV once per week on Days 15, 22, 43, and 50~Interim maintenance regimen:~1.5 mg/m2 (maximum 2 mg) IV on Days 1, 11, 21, 31, and 41~Delayed Intensification regimen:~1.5 mg/m2 (maximum 2 mg) IV on Days 1, 8, 15, 43, and 50~Maintenance Therapy:~1.5 mg/m2 (maximum 2 mg) IV on Days 1, 29, and 57"
78495|NCT03571321|Drug|Pegaspargase|"Remission consolidation regimen:~2500 IU/m2 given by intramuscular (IM) injection or IV on Days 15 and 43~Interim maintenance regimen:~2500 IU/m2 IM or IV on Days 2 and 22~Delayed Intensification regimen:~2500 IU/m2 IM or IV on Day 4 (OR Day 5 OR Day 6) AND Day 43."
78496|NCT03571321|Drug|Rituximab|"For patients that have cluster of differentiation antigen 20 positive (CD20+) disease only.~Remission consolidation regimen:~375 mg/m2 IV on Days 1, 8, 29 and 36~Interim maintenance regimen:~375 mg/m2 IV on Days 1 and 11~Delayed Intensification regimen:~375 mg/m2 IV on Days 1 and 8"
78497|NCT03571321|Drug|Methotrexate (Intrathecal Administration)|"Drug is given through a needle which is inserted in one of the spaces between the bones in the lower back (intrathecal [IT] administration).~Remission consolidation regimen:~15 mg on Days 1, 8, 15, and 22~Interim maintenance regimen:~15 mg on Days 1 and 31~Delayed Intensification regimen:~15 mg on Days 1, 29, and 36~Maintenance Therapy:~15 mg on Day 1~15 mg on Day 29 (First 4 courses only)"
78498|NCT03571321|Drug|Methotrexate (Intravenous Administration)|"Interim maintenance regimen:~100 mg/m2 IV on Days 1, 11, 21, 31, and 41"
78499|NCT03571321|Drug|Dexamethasone|"Taken by mouth or given by IV infusion.~Delayed Intensification regimen:~10 mg/m2 per day (divided into 2 doses) on Days 1-7 and 15-21~Maintenance Therapy:~6 mg/m2 per day (divided into 2 doses) on Days 1-5, 29-33, and 57-61"
78500|NCT03571321|Drug|Doxorubicin|"Delayed Intensification regimen:~25 mg/m2 IV on Days 1, 8, 15"
78501|NCT03571321|Drug|Thioguanine|"Taken by mouth at least 1 hour after evening meal.~Delayed Intensification regimen:~60 mg/m2 on Days 29-42"
78502|NCT03571321|Drug|Methotrexate Oral Product|"Taken by mouth.~Maintenance Therapy:~20 mg/m2 weekly (on Days 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78)~Not given on Day 29 of first 4 courses (on days when IT Methotrexate is given]"
78503|NCT03571308|Drug|R-CHOP + acalabrutinib|Patient will be given R-CHOP and acalabrutinib
78504|NCT03571295|Device|King Vision aBlade|endotracheal intubation performed with King Vision aBlade
78505|NCT03571295|Device|direct laryngoscopy|endotracheal intubation performed with direct laryngoscopy
78506|NCT03571282|Drug|conbercept|After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
78507|NCT03571269|Device|optical coherence tomography|optical coherence tomography was used to detect the pathological characteristics of culprit lesion. doctors decided whether or not PCI according to de OCT results.
78511|NCT03571243|Other|no intervention|observational study
78512|NCT03571230|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
78513|NCT03571230|Drug|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
78514|NCT03571230|Drug|one proton pump inhibitor(PPI)|All the patients need this drug.
78515|NCT03571230|Drug|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
78516|NCT03571230|Drug|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
78517|NCT03571204|Biological|3BNC117 and 10-1074|Both 3BNC117 and 10-1074 will be administered intravenously at 30 mg/kg dose level. Both study groups will receive 8 infusions of 3BNC117 and 10-1074 at weeks 0, 2, 4, 8, 12, 16, 20, and 24. The total duration of therapy is 24 weeks; the duration may be shorter if criteria listed in section 3.1 are met. The dose of both 3BNC117 and 10- 1074 for this study is 30 mg/kg in 250 ml normal saline. The two antibodies will be mixed in separate bags of saline for sequential administration. To prepare an IV infusion, the pharmacist will calculate the total milligrams of each antibody needed, thaw the minimum number of vials needed to obtain the full dose and add the calculated total milligrams needed to a final volume of 250 ml of normal saline using good pharmacy practices to maintain sterility. The infusion solution must be used within 3 hours. Any unused portion of an antibody vial will not be used for another subject.
78518|NCT03571204|Biological|Normal saline placebo|8 infusions of placebo at weeks 0, 2, 4, 8, 12, 16, 20, and 24 will be administered. The total duration of therapy is 24 weeks; the duration may be shorter if criteria listed in section 3.1 are met. The placebo will be normal saline alone. The placebo will be in separate bags for sequential administration.
78519|NCT03571191|Drug|Denosumab|Denosumab will be administered at 120 mg per dose every 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
78520|NCT03571191|Drug|Denosumab|Denosumab 120 mg per dose Q 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
78521|NCT03571191|Drug|Denosumab|120 mg/dose Q 4 weeks for six months, with loading doses on days 8 and 15 of month 1.
78522|NCT03571178|Other|Physical Therapy|Physical therapy consisting of the application of hotpack, TENS and treatment ultrasound
78523|NCT03571165|Behavioral|My Tools 4 Care - In Care|Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
78524|NCT03571152|Other|Educational videos|The level of practice and knowledge of the caregiver will be evaluated according to the video(s) corresponding to the session. Patient participation is expected for the evaluation of the caregiver's level of practice. After thirty minutes of use of the video, the level of practice and knowledge of the caregiver will be evaluated again for the same video. In each session this methodology will continue until the eighth video. At the end of all the videos, the level of satisfaction of the caregivers in relation to the videos will be evaluated.
78525|NCT03571139|Device|Phacoemulsification|Cataract surgery and in the bag posterior chamber lens implantation
78526|NCT03571126|Drug|Olanzapine|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Olanzapine (10mg/d) (Days1-4)
78527|NCT03571126|Drug|Placebos|Dexamethasone (10mg/d) (Days1-3) Tropisetron (4mg or 4.48mg or 5mg /d) (Days1-3) Placebos (Days1-4)
78528|NCT03571113|Other|Survival / not survival|Outcome with good neurological status vs. bad neurological status at hospital discharge
78529|NCT03571100|Drug|Chlorhexidine|Chlorhexidine administration prior to intravitreal injection (compared to gold standard povidine-iodine)
78530|NCT03571100|Drug|Povidine-Iodine|Povidine iodine administration prior to intravitreal injection (compared to chlorhexidine)
78531|NCT03571087|Drug|HL140 5/10|"1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~●: HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab.5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
78532|NCT03571087|Drug|HL140 10/10|"1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~○: HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
78533|NCT03571087|Drug|HL140 20/10|"1) Treatment(W0~W8), Extension(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
78534|NCT03571087|Drug|Rosuvastatin 5mg → HL140 5/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg : ○♤♡■△◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo,♡: HL140 20/10mg placebo, ■: Crestor Tab. 5mg, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo~Extension period(W9~W20): 6Tab./q.d. HL1405/10(Rosuvastatin5mg/Ezetimibe10mg) : ●♤♡□△◇~HL140 5/10mg, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
78535|NCT03571087|Drug|Rosuvastatin 10mg → HL140 10/10|"Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg : ○♤♡□▲◇~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, ▲: Crestor Tab. 10mg, ◇: Crestor Tab. 20mg placebo~Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg) : ○♠♡□△◇~HL140 5/10mg placebo, ♠: HL140 10/10mg, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
78649|NCT03570268|Other|Experimental Group: Education|Participants in the experimental intervention group received an educational program and tailored home exercises.
135872|NCT03126916|Other|Laboratory Biomarker Analysis|Correlative studies
78536|NCT03571087|Drug|Rosuvastatin 20mg → HL140 20/10|"Treatment(W0~W8): 6Tab./q.d.Rosuvastatin 20mg : ○♤♡□△◆~○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♡: HL140 20/10mg placebo, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◆: Crestor Tab. 20mg~Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg) : ○♤♥□△◇ ○: HL140 5/10mg placebo, ♤: HL140 10/10mg placebo, ♥: HL140 20/10mg, □: Crestor Tab. 5mg placebo, △: Crestor Tab. 10mg placebo, ◇: Crestor Tab. 20mg placebo"
78537|NCT03571074|Other|Oxygenation|Oxygenation measured as oxygen supply and saturation before cardiac arrest, and oxygenation measured as PaO2 after cardiac arrest.
78538|NCT03571061|Procedure|whole colon water immersion and sigmoid water immersion|we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
78539|NCT03571048|Behavioral|Reduced Calorie Diet (RCD)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD.
78540|NCT03571048|Behavioral|Time Restricted Feeding (TRF)|Participants will be given an individualized calorie goal. Participants in this group will also receive a 12 week comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support RCD. Participants in this group will also instructed to eat only during a window of 10 hours, starting within 3 hours of waking. They will also be instructed in specific strategies to support TRF including: strategies to deal with hunger outside eating windows, distraction techniques, and choosing a balanced diet/appropriate portions during feeding windows.
78541|NCT03571035|Diagnostic Test|Mandibular movements recordings by a mono vision system|To examine the mandible's movements, vision analysis was employed and performed with the digital camera which featured 1920 x 1080 resolution and was fixed on an aluminium extension arm attached to a headset worn by the subject.The camera was aligned parallel to the subject's face at a distance of 0.3 meters. The study used two 10 mm x 5 mm reference markers, which were accurately reproduced on the camera recorded images. In line, one marker was put on the medial cleft above the upper lip, and the other one was positioned below the first one in a straight line, in the middle of the chin. Then, the patient was asked to open maximally and close the mouth twice.To establish the mandible's trajectory, the line was drawn between the positions of the two markers to connect the two points. The line's parameters were calculated only during initial measurements and were constant throughout the study.
78542|NCT03571022|Behavioral|USE-MI System|Subjects will continue with their ART or PrEP medication but immediately begin using the USE-MI system. Subjects will wear a smartwatch every day which will monitor their pill taking activity. The smartphone app will send electronic medication reminders if it looks like subjects may have missed taking their daily ART or PrEP pill(s). Every month, subjects will come to the research office to complete a brief questionnaire about their experience with the system. They will also be asked to bring in their pill bottles so that the study staff can manually count their pills to check for adherence.
78543|NCT03571022|Behavioral|USE-MI System after 6 Months Follow-Up|"Subjects will continue with their ART or PrEP medication but for the first 6 months, subjects will come to the research office every month to complete a brief questionnaire about how they are taking their daily ART or PrEP pill(s). They will also be asked to bring in their pill bottles so that the study staff can manually count their pills to see if any have been missed.~After 6 months, subjects will wear a smartwatch every day which will monitor their pill taking activity. The smartphone app will send electronic medication reminders if it looks like subjects may have missed taking their daily ART or PrEP pill(s). Subjects will continue come to the research office every month to complete a brief questionnaire about their experience with the system. They will also be asked to bring in their pill bottles so that the study staff can manually count their pills to check for adherence."
78544|NCT03571009|Device|utilization of PAAS|utilization of real-time pain assessment and analysis system (PAAS) consists of wearing device and reporting a real-time pain using the device
78545|NCT03570996|Procedure|Esophagectomy|"Esophagectomy with minimally invasive approach of the chest including:~3 hole with R video-assisted thoracoscopic surgery (VATS), Ivor Lewis R VATS, Transhiatal"
78546|NCT03570996|Procedure|Transversus abdominis plane catheter|TAP group will have bilateral subcostal TAP catheters and single shot bilateral rectus sheath blocks placed at the end of the surgery, prior to emergence. Bilateral subcostal TAP catheters will be bolused with 20ml of .2% ropivacaine on each side and then infused with .2% ropivacaine at 10ml/ hr for 75 hours each. Rectus sheath blocks will be bilateral bolus 20ml of .2% ropivacaine
78547|NCT03570996|Procedure|Epidural|Patients randomize the TEP group will have bilateral TEP placed at T8-9 +/- one level based on patient anatomy. TEP will be bolused with 5ml of 1.5% lidocaine with epinephrine and then started on infusion of .0625% bupivacaine plus 4 mcg/ml fentanyl plus 2 mcg/ ml epinephrine at 6ml/hr with a range of 6-12 ml/hr, titrating to optimize patient comfort. Epidurals are placed before surgery start time.
78548|NCT03570983|Drug|Allopurinol|Dosage: Allopurinol 200 mg/m2/day starts on the day prior to BCNU, day -8 and stops on day -1.
78549|NCT03570983|Drug|Carmustine|Dosage: Carmustine 300 mg/m2 IV x 1 will be infused over 3 hours on autografting day -7. Carmustine should not be infused with solutions or tubing containing or previously containing bicarbonate solution.
78550|NCT03570983|Drug|Etoposide|Dosage: Etoposide 100 mg/m2 IV BID will be administered in 500-1000 cc normal saline over 2 hours on autografting days -6, -5, -4, and -3 for a total dose of 800 mg/m2. Etoposide may not be infused with sodium bicarbonate solutions.
78551|NCT03570983|Drug|Cytarabine|Dosage: Cytarabine 100 mg/m2 IV BID will be infused over 3 hours on autografting days -6, -5, -4 and -3. Availability and administration: Cytarabine is available in a reconstituted form in solutions containing 20, 50 and 100 mg of cytarabine per mL.
78552|NCT03570983|Drug|Melphalan|Melphalan will be administered at a dose of 200 mg/m2 IV x 1 infused over 30 minutes on autografting day -2.
78553|NCT03570970|Drug|Banapenem|Banapenem to be used anti-infection
78554|NCT03570957|Drug|MT-2990|MT-2990 solution for injection in vial
78555|NCT03570957|Drug|Placebo|Placebo solution for injection in vial
78556|NCT03570944|Procedure|HRS, KRS|Elective HRS or KNR in adult patients, with any ERAS compliance
78557|NCT03570931|Drug|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
78558|NCT03570918|Biological|MGD014|HIV-1 x CD3 bispecific DART molecule
78706|NCT03569748|Device|E-CIG|ELECTRONIC CIGARETTE FOR 12 WEEKS
78559|NCT03570905|Other|Sugar Tong Splint|A splint made of 8-10 layers of plaster rolled into a single long sheet which begins at the distal volar crease of the hand and traverses around the elbow and stops at the dorsal metacarpal heads. The skin is protected with cotton cast padding (webril) and the splint is held in place with ace bandages
78560|NCT03570905|Other|Clam Shell Splint|A 2-part splint made of 8-10 layers of plaster. The piece traverses from the distal volar crease of the hand to the volar aspect of the proximal forearm. The second piece runs along the dorsal aspect of forearm from metacarpal heads to proximal forearm. The elbow is left free. In the same fashion as the sugar tong splint, the skin is protected with cotton cast padding (webril) and held in place with ace wrap
78561|NCT03570892|Drug|Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy|Investigator's choice of optional platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP) + Lymphodepleting chemotherapy (fludarabine with cyclophosphamide or bendamustine) + Tisagenlecleucel (a second generation CAR-T composed of a CD19 antigen-binding domain, a 4-1BB costimulatory domain and a CD3-ζ signaling domain)
78562|NCT03570892|Drug|Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)|"Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT.~*Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy"
78563|NCT03570879|Device|Power morcellation|Power morcellation of surgical specimens after laparoscopic myomectomy.
78564|NCT03570879|Procedure|Transvaginal extraction|Transvaginal extraction of surgical specimens after laparoscopic myomectomy.
78565|NCT03570866|Diagnostic Test|Positron emission tomography and computed tomography|Preoperative staging of early stage intermediate and high-risk endometrial cancer with positron emission tomography and computed tomography.
78566|NCT03570866|Procedure|Surgical treatment|Surgical treatment of early stage intermediate and high-risk endometrial cancer by usual practice: peritoneal cytology, total abdominal hysterectomy, bilateral salpingo-oophorectomy, systematic pelvic and para-aortic lymphadenectomy.
78567|NCT03570853|Behavioral|SMART-3RP|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology). The program consists of 8, 1.5 hour sessions.
78568|NCT03570827|Drug|Androgen Suppression|Given androgen suppression therapy
78569|NCT03570827|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
78570|NCT03570827|Other|Quality-of-Life Assessment|Ancillary studies
78571|NCT03570827|Other|Questionnaire Administration|Ancillary studies
78572|NCT03570814|Drug|Administration of Albendazole on Day 1|Participants will receive Albendazole 400mg on study day 1.
78573|NCT03570814|Drug|Administration of Ivermectin on Day 1|Participants will receive Ivermectin 150mcg/kg (max 12mg) on study day 1. Doses of Ivermectin will be determined using a standard dosing pole.
78574|NCT03570814|Drug|Administration of Azithromycin on Day 1|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 1. Doses of Azithromycin will be determined using a standard dosing pole.
78575|NCT03570814|Drug|Administration of Azithromycin on Day 15|Participants will receive Azithromycin 20mg/kg (max 1gm) on study day 15. Doses of Azithromycin will be determined using a standard dosing pole.
78576|NCT03570801|Other|Expert Panel Review|There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
78577|NCT03570788|Procedure|Amputation|Major amputation defined as at or above ankle
78578|NCT03570775|Device|Sleeping bag phototherapy|This device has a LED light emitter that incorporates one fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. The phototherapy sleeping bag is conceived with the aim of increasing the surface of phototherapy by means of a double exposure: ventral and dorsal, which allows the insertion of two phototherapy devices of 20x30 centimeters. The ventral and dorsal caps incorporate mesh optical fibers that are connected to the light emitter, in which the phototherapy time can be programmed. The fiber optic meshes are protected by a vinyl cover and a disposable lining for patient comfort and hygiene.
78579|NCT03570775|Device|Conventional phototherapy|This is a phototherapy device with six fluorescent tubes, four white and two blue, with adjustment of inclination and height incorporated. The device has a minimum height of 106 cm and a maximum of 152 cm, a depth of 64 cm and a width of 72 cm. The manufacturer recommends not using the lamp at distances of less than 50 cm because, although the heat radiation is minimal, this can influence distances less than 50 cm when the child is also exposed to infrared thermal radiation, typical of the servo cribs It is recommended to control temperature and eye protection due to the risk of ophthalmic injury from light, since the intensity of the light is concentrated in a single point.
78580|NCT03570762|Procedure|hybrid percutaneous intervention|
78581|NCT03570749|Drug|Baricitinib|Administered orally.
78582|NCT03570749|Drug|Placebo|Administered orally.
78583|NCT03570736|Procedure|Minimal invasive surgical technique|Minimal Invasive Surgical technique using either Modified Papilla Preservation or Simplified Papilla Preservation Technique.
78584|NCT03570736|Procedure|Open Flap Debridement|Buccal and lingual intrasulcular incisions will be done extending at least one tooth mesial and distal to the tooth associated with the intrabony defect. Full thickness mucoperiosteal flaps will be reflected to allow access for debridement of the defect.
78585|NCT03570723|Procedure|A glove-loaded Foley's catheter tamponade|A glove-loaded Foley's catheter tamponade, the internal os of the cervix was identified and a double-way 20 Fr Foley's catheter with a 30-50-ml balloon was inserted through the cervix to be handled by an assistant through the vagina and fixed to the patient's lower limb after inflation of the catheter balloon by 300 ml warm saline and pulling it against the lower uterine segment between the two transverse sutures. Only one glove-loaded Foley's catheter was used for tamponade.
78707|NCT03569709|Behavioral|Aerobic Exercise|Progressive sub-threshold aerobic exercise
78586|NCT03570723|Procedure|stepwise uterine devascularization|"Uterine hemostatic sutures, through examination of the placental bed, may use some hemostasis at the placental bed,overswing was commenced using endo-uterine sutures. If there is still significant bleeding, bilateral uterine artery ligation, and internal iliac artery ligation when needed.BUAL started immediately through blunt dissection downwards and laterally of the peritoneum covering the uterine isthmus and cervix. The peritoneum is mobilized freely at the uterine angles to expose both uterine arteries and avoid inclusion of the ureters in the ligation. The uterine artery pulsations were palpated digitally at the level of the internal os."
78587|NCT03570710|Drug|intravenous tranexamic acid|1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt) intravenous just before skin incision plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
78588|NCT03570710|Drug|Topical tranexamic acid|2 gm topical tranexamic acid ( 4 ampoules of Capron 500 mg/5 ml applied typically) in 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy plus In topical tranexamic acid group gauze soaked with 2g tranexamic acid (20 ml) diluted in 200 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) applied on the pelvic bed after Cesarean hysterectomy. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
78589|NCT03570710|Drug|Normal saline|110 ml normal saline IV just before skin incision plus topical application of 200 ml normal saline applied on the pelvic bed after Cesarean hysterectomy
78590|NCT03570697|Biological|Evolocumab|Subjects will receive Evolocumab (AMG 145) subcutaneous monthly.
78591|NCT03570697|Other|Placebo|Subjects will receive Evolocumab (AMG 145) matching placebo subcutaneous monthly.
78592|NCT03570684|Device|Cable Tie|During the operation, after mobilization the rectum, the disinfected Cable Tie was introduced into the pelvic cavity.then the rectum was bundled by the tie which was easy as the tie is auto-locked. pulling the tie and the rectum would be explored clearly, and then the endoscopic linear cutter was introduced to transect the rectum. the tie made the rectum folded not applanate, that the cutter was able to transect the rectum easily and with less reloader. when the rectum was resected completely, the tie was get out with the specimen, and do not live in the abdomen.
78593|NCT03570671|Diagnostic Test|Spasm positive|"Investigators define the positive criteria for VSA on MDCTA as follows:~Significant stenosis (≥ 50%) with negative remodeling but no definite evidence of plaques, which completely dilated on IV nitrate CT, or~Diffuse small diameter (< 2mm) of a major coronary artery with beaded appearance which completely dilated on IV nitrate CT."
78594|NCT03570671|Diagnostic Test|Spasm negative|Suspected vasospastic angina subjects with negative MDCTA-derived VSA are considered as reference modality.
78595|NCT03570658|Drug|RO7049389|RO7049389 will be administered orally either as a single dose (SAD) or as multiple doses defined by the SAD portion of the study (MAD).
78596|NCT03570658|Drug|Placebo|Placebo will be administered orally at a dose and frequency matched to RO7049389.
78597|NCT03570645|Drug|Dexmedetomidine Group|combination of ropivacaine and dexmedetomidine 100 ug every time
78598|NCT03570645|Drug|dexamethasone group|combination of ropivacaine and dexamethasone 10mg every time
78599|NCT03570645|Drug|control group|block with only ropivacaine
78600|NCT03570632|Drug|Metformin|Participants randomized to metformin will receive metformin in addition to standard treatment of diabetes during pregnancy
78601|NCT03570619|Drug|Nivolumab|All patients will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 52 weeks of total therapy.
78602|NCT03570619|Drug|Ipilimumab|All patients will begin receiving combination therapy with nivolumab 3 mg/kg IV and ipilimumab 1 mg/kg IV every 3 weeks for up to 4 cycles if tolerated, followed by nivolumab maintenance therapy at flat dose 480 mg IV every 4 weeks through the end of the planned study duration, for up to 52 weeks of total therapy.
78603|NCT03570606|Device|bone graft substitute|orthopaedic or spine bony defects
78604|NCT03570593|Procedure|REMOVAL OF URINARY CATHETER AFTER RADICAL SURGERY|Removal of urinary catheter on the first day after radical surgery
78605|NCT03570580|Other|OSA scoring|OSA scoring (four scores: STOP-Bang, P-SAP, OSA50, DES-OSA were performed by several scorers on each patients, after what agreement between scores will be evaluated).
78606|NCT03570567|Device|Piranha Treatment|The piranha device is used with an endoscope to breakup/dislodge the food bolus.
78607|NCT03570554|Drug|Treatment A (Naproxen Sodium [Aleve , BAY117031] + Placebo)|Patients receive 440 mg naproxen sodium, placebo, 220 mg naproxen sodium and placebo on Days 1 to 3, and 440 mg naproxen sodium on Day 4
78608|NCT03570554|Drug|Treatment B (Acetaminophen + Placebo)|Patients receive 1300 mg acetaminophen, 1300 mg acetaminophen, placebo and 1300 mg acetaminophen on Days 1 to 3, and 1300 mg acetaminophen on Day 4
78609|NCT03570554|Drug|Treatment C (Celecoxib + Placebo)|Patients receive 100 mg celecoxib, placebo, 100 mg celecoxib and placebo on Days 1 to 3, and 100 mg celecoxib on Day 4
78610|NCT03570554|Drug|Treatment D (Placebo)|Patients receive 4x placebo on Days 1 to 3, and 1x placebo on Day 4
78611|NCT03570541|Drug|Ropivacaine|30 mL ropivacaine 0,375% administered on each side as bilateral TQL blocks
78612|NCT03570541|Drug|Acetaminophen|Every six hours postoperative, all patients are administered 1 g of acetaminophen.
78613|NCT03570541|Device|Patient controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
78614|NCT03570541|Drug|Morphine|intravenously administered morphine via PCA-pump
78615|NCT03570541|Drug|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
78616|NCT03570541|Diagnostic Test|Blood samples|On the day of surgery, postop day 1+2 and day 10-14, all patients will have blood samples taken for immunological analysis
78617|NCT03570541|Behavioral|Quality of recovery-15 questionaire|On the day of surgery, postop day 1+2 and day 10-14, all patients are asked to fill out a short questionaire.
78618|NCT03570541|Diagnostic Test|Orthostatic hypotension|Before surgery, and 3, 6 and 24 hours postop. All patients are tested for orthostatic hypotension.
78619|NCT03570515|Behavioral|Yoga|Yoga group participants will attend two, 75-minute yoga classes/week for 4 weeks, then one class/week for 8 weeks, and do a 30-minute home practice on non-class days, recording their practice on a yoga homework log provided to them.
78620|NCT03570515|Behavioral|Educational film|Educational film group participants will attend one, 75-minute film class/week for 12 weeks, recording any RLS treatments they use at home.
78621|NCT03570489|Behavioral|Exercise|Patients will bicycle for 20 minutes per day for 5 days per week for 6 months
78622|NCT03570489|Behavioral|Relaxation|Patients will listen to a relaxation tape 20 minutes per day 5 Days a week for 6 months
78623|NCT03570476|Drug|Olaparib|Given PO
78624|NCT03570476|Procedure|Radical Prostatectomy|Undergo surgery
78625|NCT03570463|Behavioral|GLA:D Back|The intervention aims at improving the participant's ability to self-manage low back pain (LBP). The content is based on a cognitive behavioural approach aimed at supporting pain self-efficacy. An individual session at the beginning and the end of the group sessions involve goal-setting and physical tests. Key messages of the patient education include that pain is not a sign of danger and back pain is explained using a behavioural model of (im)balance between demands and capacity rather than emphasising tissue damage. The exercises aim at restoring natural variation in movement and provides guidance for patients in exploring movement rather than teaching exercises in only one correct manner.
78626|NCT03570450|Drug|Adipose derived Stem Cell|3 doses
78627|NCT03570450|Drug|placebo|placebo
78628|NCT03570437|Drug|Paclitaxel|80 mg/m2 on three days in a 28 day cycle (with 6 cycles)
78629|NCT03570437|Drug|Cediranib|20 mg per day
78630|NCT03570437|Drug|Olaparib|Olaparib tablets, 300 mg twice-daily
78631|NCT03570424|Dietary Supplement|Nutrient support to HIIT|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max <50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).
78632|NCT03570424|Dietary Supplement|Placebo|3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max <50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following >10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).
78633|NCT03570411|Diagnostic Test|T-SPOT®.CMV Test|The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
78634|NCT03570398|Other|unenhanced abdomino-pelvic CT scan|unenhanced abdomino-pelvic CT scan
78635|NCT03570398|Other|abdominal ultrasound|abdominal ultrasound
78636|NCT03570385|Device|MRI|MRI in diffusion tensor (DTI : Diffusion Tensor Imaging)
78637|NCT03570372|Behavioral|Internet-based treatment for adults with autism spectrum|Internet-based CBT. The intervention includes 36 modules focusing on: Psychoeducation, individual goal setting, behavioral change, management strategies, mindfulness techniques, stress management, sleep techniques, information about societal rights.
78638|NCT03570372|Behavioral|Psychoeducation about autism spectum disorder|"Self-studies by reading the book What does the disability mean ?: Living with autism / Asperger syndrome. Project Empowerment (2004), by Norrö & Swing Åström, as well as a book of biographical stories of people who have ASD. The first book will be read during the first half of the project, and the second will be in the second half."
78639|NCT03570359|Drug|Interferon Beta-1A|Interferon Beta-1A via inhalation
78640|NCT03570359|Other|Placebo|Placebo via inhalation
78641|NCT03570346|Drug|Hemay005|Subjects will be randomized into 3 dose groups orally twice daily.
78642|NCT03570346|Drug|Placebo|Subjects will be randomized into 3 dose groups orally twice daily.
78643|NCT03570333|Diagnostic Test|progenitor potential of Gingival Mesenchymal cells|tissues collected from the molar and premolar sites will be sent to the lab for cell culturing. once in the lab, the tissues will be already separated and labeled (molar) and ( premolar) and then treated to extract the cells from them. then, these cells will be tested for their capacity to form different kinds of cells and tissues ( bone, cartilage, fibers for periodontal ligaments). After this test, results will be collected for how many cells were collected from each tissue sample.
78644|NCT03570320|Other|Modification of opioid prescription method|Patients in the interventional arm of the study will receive post-op opioid medications in three small prescriptions as opposed to one large prescription. They may fill these prescriptions as needed.
78645|NCT03570307|Other|medical VS surgical evacuation of the uterus|mentioned above
78646|NCT03570294|Drug|Atosiban|The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.
78647|NCT03570281|Drug|Edoxaban|Edoxaban, per oral, 60mg qd (may consider reduced dose to 30mg qd in patients with proper clinical reason by attending physician, estimated creatinine clearance of 30 to 50 ml per minute, a body weight of 60 kg or less, or the concomitant use of verapamil or quinidine), for 90 days.
78648|NCT03570281|Drug|Enoxaparin|Enoxaparin, subcutaneous injection, 1mg/kg BID (may consider reduced dose to 1mg/kg qd in patients with proper clinical reason by attending physician, Creatinine clearance <30 mL/min), for 90 days.
135873|NCT03126916|Drug|Melphalan|Given IV
78650|NCT03570268|Other|Control Group: Usual care|Participants allocated to the control group received stretching exercises.
78651|NCT03570242|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
78652|NCT03570229|Other|Hyperbaric oxygen treatment|"Participants in this study will receive hyperbaric oxygen treatment (HBOT) but the investigators do not assign this specific intervention to the study participants. Thus, the patients in this study will receive HBOT as part of routine medical care. Consequently, we regard this as an observational study because the patients will get HBOT independently of the study and they are NOT assigned prospectively to HBOT according to a protocol to evaluate the effects.~HBOT for pelvic radiation injury typically involves a treatment pressure of 2.4 ATA (Atmospheres Absolute) breathing oxygen for 90 minutes. The treatment is delivered as series treatment, usually daily treatment up to 30 dives."
78653|NCT03570216|Other|Moderate-intensity continuous exercise|Participants will perform a 35-minute session of moderate-intensity continuous exercise
78654|NCT03570216|Other|High-intensity interval exercise|1 week later, participants will perform a 14-minute session of high-intensity interval exercise
78655|NCT03570203|Diagnostic Test|Serum Sodium|Measurement of serum sodium.
78656|NCT03570190|Other|Coordinator|"A THV coordinator will be responsible for communication with the patients and the caregivers as well as for monitoring medical documentation and treatment pathways. The registry will consist of 3 phases:~Determination of the status quo~Dedicated reflection and training followed by implementation of tailored changes~Determination of the effect"
78657|NCT03570164|Drug|Sevoflurane|End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
78658|NCT03570164|Drug|Desflurane|End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
78659|NCT03570151|Other|no intervention|no intervention will be done
78660|NCT03570138|Device|FREESTYLE LIBRE device, a Flash Continuous Glucose Monitoring System|Specific therapeutic education for diabetes self management
78661|NCT03570138|Device|Usual self monitoring Blood Glucose device|Standard therapeutic education for diabetes self management
78662|NCT03570125|Dietary Supplement|Prolon|The diet consists of natural ingredients, which are Generally Regarded As Safe (GRAS). In case the PROLON product will be unavailable at the time of the project we will design fasting mimicking diet without the usage of specifically designed commercial product
78663|NCT03570112|Drug|SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg|sofosbuvir 400mg and velpatasvir 100mg once daily for 12 weeks
78664|NCT03570099|Drug|Naloxone Nasal Spray|Naloxone Nasal Spray will be distributed at the addiction centres.
78665|NCT03570099|Other|Historical control cohort|Historical data will be retrieved from quality registries.
78666|NCT03570086|Diagnostic Test|diagnostic|using radiomics features from multiparametric thick-section clinical-quality brain MRI to distinguish migraineurs from health controls.
78667|NCT03570073|Other|Manual vitrification|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
78668|NCT03570073|Other|Vitrification with GaviTM system|Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
78669|NCT03570060|Biological|Blood sample|2 ml of blood for testing for serum biomarkers (IL-6, GDF-15, soluble ST-2 soluble, osteoprotegerin, galectin 3)
78670|NCT03570060|Procedure|Long term ECG monitor|Fitting and removal of a long term ECG monitor (SpiderFlash, LivaNova)
78671|NCT03570060|Procedure|Monitoring ECG|Recording of automatic ECG monitor results (CSM Philips IntelliVue MP50 system)
78672|NCT03570034|Device|Obalon Balloon System|Obalon Balloon System with a moderate intensity Weight Loss Behavioral Modification Program
78673|NCT03570021|Procedure|total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection|"total thyroidectomy with bilateral prophylactic central compartment (level VI) neck dissection as defined by the American Thyroid Association [American Thyroid Association Surgery Working Group, Thyroid 2009]. This is a standard treatment recognized by the French Society of Otolaryngology Head and Neck Surgery [French Society of Otolaryngology Head and Neck Sugery].~- The number of lymph nodes resected, the number of metastatic nodes, their size and the presence or absence of extranodal spread will be recorded. Due to the large natural variability of the number of lymph nodes retrieved in a prophylactic neck dissection [Hartl DM, Ann Surg 2012], no patient will be excluded on the basis of number of lymph nodes. Furthermore, the participating surgeons routinely perform complete central neck dissections, and were chosen to participate in this study due to a homogenous technique among these surgeons [Hartl DM, World J Surg 2012]."
78674|NCT03570021|Procedure|total thyroidectomy alone without neck dissection|This is recognized as a standard treatment by the Francophone Association of Endocrine Surgery
78675|NCT03570008|Behavioral|9 days spa residential program|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
78708|NCT03569709|Behavioral|Rest|No structured exercise.
78709|NCT03569709|Behavioral|Stretching|Gentle progressive upper and lower extremity stretching program
78747|NCT03569449|Behavioral|Enhanced pediatric surveillance|"In Massachusetts, behavioral screening is mandated at every pediatric visit, which for children in the target population (ages 3-12 years) is annually. With enhanced monitoring, Family Partners will screen children using validated instruments quarterly and communicate results to the child's care team"
79208|NCT03566017|Biological|pegunigalsidase alfa|Recombinant human alpha galactosidase A
78676|NCT03570008|Behavioral|3 sessions of 10 minutes per day of physical exercise|"After the inclusion visit, the participants will be involved in a short-term spa residential program of 9 days (Sp). The will be randomized into 3 groups of 30 participants:~Sp-Ex: spa residential program including physical activity~Sp-alone: spa residential program alone~Ex-alone: physical activity alone~After the spa residential program, participants will undergo a one-year at-home follow-up. The participants will be required to complete the same program by themselves.~A journal and an accelerometer-pedometer watch will record the weekly physical activity performed. Monitoring will be further monthly assessed by a health-care professional from the spa resorts."
78677|NCT03569995|Drug|Rituximab|500 mg/m2 + 5%DW 500 mL IVF Begin with 50 mg/hr (increase by 50 mg/hr per 30 min until 400 mg/hr is reached)
78678|NCT03569995|Drug|Methotrexate|500 mg/m2 + 5%DW 200 mL IV over 15 minutes 3000 mg/m2 + 5%DW 500 mL IVF over 3 hrs Concurrent hydration and subsequent leucovorin rescue is mandatory
78679|NCT03569995|Drug|Cytarabine|3000 mg/m2 + 5%DW 200 mL IVF over 2 hrs steroid eye drop 0.1%, 2 drops q 6hrs, on days 1-9
78680|NCT03569982|Other|Integrative medicine care|Including acupuncture, relaxation/breathing, and manual/touch modalities
78681|NCT03569969|Procedure|device: Tympanoplasty with Membrane Amniotic|amniotic membrane Tympanoplasty
78682|NCT03569969|Procedure|Tympanoplasty With Autologous Fascia|Autologous Temporalis fascia Tympanoplasty
78683|NCT03569956|Other|556 Razor|In the Razor group, subjects will use the 556 Razor with their regular shaving products, and shave at least 5 or more times per week. In the Regimen group, subjects will use the 556 Razor, Pre-Shave Gel, Cleansing brush and Shaving Gel, and shave at least 5 or more times per week. All subjects will be given the 556 Razors during the 12-week study. The Regimen group will also be given the Pre-Shave Gel, Cleansing Brush, and Shaving Gel.
78684|NCT03569943|Device|Robot Based Transtympanic drain placement|Placement of a transtympanic drain with a robot based device assistance called RobOtol
78685|NCT03569930|Drug|flavonoid-based supplements|Ingredients: soybean oil (glycine max), edible gelatin, rutin, borage seed oil (borago officinalis), pineapple dry extract (ananas sativus), glycerol, thickeners (mono and diglycerides of fatty acids), emulsifier (soy lecithin).
78686|NCT03569930|Drug|Centella Complex|The components are: Centella Asiatica, Beta-glucan, Arnica, Aloe Vera, Menthol, Devil's claw, perform actions useful to alleviate the painful symptomatology, restore the tone of the venous wall, assist the treatment of microcirculatory damage.
78687|NCT03569930|Behavioral|standard of care|diet rich in water and vegetable fibers, hygienic and anal dilator
78688|NCT03569917|Other|Rectal swab collection|Rectab swab collection will be performed at inclusion and 5 and 30 days later.
78689|NCT03569891|Genetic|AAV5-hFIXco-Padua|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
78690|NCT03569878|Behavioral|Peer-Integrated Multidisciplinary Collaborative Care|Case management, behavioral intervention elements, psychopharmacologic medication recommendations and 24/7 cell phone coverage for 6 months post-injury.
78691|NCT03569878|Behavioral|Trauma surgery team notification|Trauma surgery team notification of patient emotional distress, with plan for mental health inpatient consultation will be the comparator condition.
78692|NCT03569865|Device|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study.
78693|NCT03569852|Behavioral|Time Restrictive Feeding|Volunteers will adhere to a form of time restrictive feeding, 16 hours fasting and 8 hours eating per day.
78694|NCT03569852|Behavioral|Traditional Eating Pattern|Volunteers will adhere to a more traditional eating pattern, 12 hours fasted and 12 hours eating per day.
78695|NCT03569839|Drug|Propofol|Patients undergoing surgery, TIVA (total intravenous anaesthesia)
78696|NCT03569826|Other|Observational; no intervention|Observational; no intervention
78697|NCT03569813|Behavioral|PrEP@Home System|"The PrEP@Home system includes a home care kit mailed quarterly to participants. The kit includes components for self-collection of urine, rectal swab, pharyngeal swab and microtube blood collection, and materials for return shipping. Biological tests routinely performed at PrEP follow-up visits will be conducted on the specimens. At months 6 and 12, the kit will include materials to assess for protective levels of TFV-DP.~The system includes a study app through which participants may track the mailing of home testing kits, access quarterly surveys, and communicate with study clinicians. The surveys will include domains that physicians assess at PrEP care quarterly follow-up visits (sexual risk, illicit substance use, PrEP adherence, side effects).~Lab and survey results will be sent to study clinicians and if the results show no contraindications for PrEP continuation, the clinician may renew a participant's PrEP prescription. Telemedicine visits will be scheduled as necessary."
78698|NCT03569813|Other|Standard of Care|Control participants will receive clinic-based PrEP follow-up. After the baseline assessment, control participants will receive active linkage to standard, clinic-based PrEP care for their next PrEP care follow-up visit. Participants will also download the control version of the study app, which will contain only research elements pertinent to their participation in the control arm of the study including quarterly surveys. At months 6 and 12, control arm participants will be sent materials for DBS self-collection and return shipping to allow for measurement of the study outcome, TFV-DP levels.
78699|NCT03569800|Other|self completed questionnaire|self completed questionnaire
78700|NCT03569787|Diagnostic Test|MRI Pituitary|Identification of whether of not patients had had an MRI pituitary following hyperprolactinaemia reading
78701|NCT03569774|Procedure|One-lung ventilation with individualized PEEP|During one-lung ventilation for lung resection surgery, PEEP will be applied. After a subject's individualized PEEP (PEEP that corresponds to maximum lung compliance) is determined, the subject will receive one-lung ventilation with individualized PEEP.
78702|NCT03569774|Procedure|One-lung ventilation with low PEEP|Subjects will receive one-lung ventilation with low PEEP (5 cmH2O)
78703|NCT03569761|Behavioral|Colorectal Cancer Screening Decision Aid|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
78704|NCT03569761|Behavioral|Control Group|Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments. Information previously discussed in arm/group descriptions. There will be baseline, post-encounter, and 5-month follow-up assessments.
78705|NCT03569748|Device|IQOS|IQOS USE FOR 12 WEEKS
78710|NCT03569696|Biological|nivolumab|The treatment phase will begin 10 ± 2 weeks from completion of R- anthracycline based therapy. Cycle 1 day 1 will occur within 72 hours from enrolment. Study treatment will be continued until nivolumab discontinuation due to disease progression, unacceptable toxicity or completion of 2 years or 30 doses of therapy. Study drug nivolumab will be administered intravenously every 2 weeks as described in the investigator brochure (IB) in a dose of 240mg over 30 minutes 46 for 8 cycles and then 480mg every 4 weeks for two years (cycle 9-30)to a maximum of 30 doses whichever comes first.
78711|NCT03569683|Procedure|External bevel gingivectomy|External bevel gingivectomy will be performed on 30 patients wherein the suprabony pockets will be eliminated with the help of a Bard parker blade no 15. The incision would be given 1mm apical to the pockets which would be marked by a Crane and Kaplan pocket marker, then the incision would be given and the tissue would be removed with the help of kirkland and orbans knives and the gingiva would be shaped. After the surgical procedure the patients would be treated either with the Diode laser(Group A), Hyaluronic acid gel (Group B), or Herbal gel(Group C).
78712|NCT03569683|Device|Diode laser Biostimulation|After gingivectomy, laser irradiation will be done using bio-stimulation tip in the anterior sextants of the mouth. (Group A)
78713|NCT03569683|Other|Hyaluronic acid (Gengigel) topical application.|After gingivectomy, Hyaluronic acid gel(Gengigel) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group B)
78714|NCT03569683|Other|Herbal gel (Hiora SG) topical application|After gingivectomy, Herbal gel(Hiora SG) will be applied topically. Then it will be covered with a tin foil and periodontal dressing would be given. (Group C)
78715|NCT03569670|Device|Posterior stabilized all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a posterior stabilized, all-polyethylene tibial component used during surgery.
78716|NCT03569670|Device|Cruciate retaining all-polyethylene tibial component|Patients randomized to this arm will have a Triathlon implant with a cruciate retaining, all-polyethylene tibial component used during surgery.
78717|NCT03569657|Behavioral|A positive psychology workshop|Group workshop
78718|NCT03569644|Other|qualitative study|Interviews
78719|NCT03569631|Drug|BPN14770|25 mg BPN14770 capsules
78720|NCT03569631|Drug|Placebo|Placebo capsules to mimic 25 mg BPN14770 capsules
78721|NCT03569618|Device|Tablet-based Game|Tablet-based game aimed at improving processing speed and attention.
78722|NCT03569605|Behavioral|Self-help|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group.
78723|NCT03569605|Behavioral|Intervention|Participants will receive an individual session, Fitbit activity tracker, and access to a secret Facebook group with the addition of behavioral lessons, adaptive physical activity goals, tailored feedback summaries, and text messages.
78724|NCT03569592|Behavioral|Overdose Prevention Intervention|Evaluate an overdose prevention education with incarcerated people living with HIV/AIDS.
78725|NCT03569579|Drug|Memantine Tab. 10mg|Memantine Tab. 10mg* 2T/day, QD, PO
78726|NCT03569579|Drug|Memantine Tab. 10mg + Donepezil Tab. 10mg|Memantine Tab. 10mg* 2T/day + Donepezil Tab. 10mg * 1T/day, QD, PO
78727|NCT03569566|Other|Age, Genes, Training, Tickbourne Disease and Endurance|Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
78728|NCT03569553|Drug|AIGIV|Anthrax Immune Globulin Intravenous (Human)
78729|NCT03569540|Drug|Glibenclamide|Placebo-controlled; Double blind test
78730|NCT03569540|Other|Placebo|Amylum
78731|NCT03569527|Dietary Supplement|Kiwifruit|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive kiwifruit (2 green kiwifruit per day for the 4 week intervention period.
78732|NCT03569527|Dietary Supplement|Fiber|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive psyllium fiber (24 g/day, fiber=6g/day) for the 4 week intervention period.
78733|NCT03569527|Dietary Supplement|Prunes|The total duration of the study will be 8 weeks (2- week baseline, 4-week intervention, and 2-week follow-up). Eligible patients will be randomized to receive prunes/dried plums (100g, fiber=6 g/day) for the 4 week intervention period.
78734|NCT03569514|Drug|AIGIV|Anthrax Immune Globulin Intravenous (Human)
78735|NCT03569501|Dietary Supplement|DHA|500 mg DHA tablets
78736|NCT03569501|Dietary Supplement|oat grains|90 mg oat, containing 4.05 mg β-glucan
78737|NCT03569488|Diagnostic Test|FT-LARS questionnaire|FT-LARS questionnaire
78738|NCT03569475|Drug|Levomilnacipran ER|During the double-blind treatment period, patients will take levomilnacipran 10 mg/day on Days 1-3, 20 mg/day on Days 4-7, and 40 mg/day during Weeks 2 through 8. Based on therapeutic response and tolerability, an additional dose increase to 80 mg/day is permitted at Week 3. During the down-taper period, patients will take levomilnacipran 40 mg/day for 2 days, and then levomilnacipran 20 mg/day for 5 days
78739|NCT03569475|Drug|Fluoxetine|During the double-blind treatment period, patients will take Fluoxetine 10 mg/day on Days 1-7, and then 20 mg/day during Weeks 2 through Week 8. During the down-taper period, patients will take Fluoxetine 10 mg/day for 7 days.
78740|NCT03569475|Drug|Placebo|Patients randomized to the placebo arm will take placebo capsules once daily
78741|NCT03569462|Behavioral|"Mobile WeChat intervention"|Participants watch a demonstration of HIV self-testing, receive HIV self-testing kits, and receive access to a mobile application that delivers content to promote HIV self-testing and reduce HIV risk behavior
78742|NCT03569462|Behavioral|Control condition|Participants watch a demonstration of HIV self-testing and receive HIV self-testing kits.
78743|NCT03569449|Behavioral|Usual care|Family partners will keep records and communicate with families using standard information technology, including telephones, electronic medical records, and standard desktop software.
78744|NCT03569449|Behavioral|Clinic-based visits|Family partners will be restricted to working at the primary care clinic - communication will be restricted to telephone, text, and clinic visits
78745|NCT03569449|Behavioral|Standard pediatric surveillance|Monitoring is determined by standard pediatric practice. Behavioral screening is usually done annually.
78746|NCT03569449|Behavioral|Structured, schedule-based visits|Family Partners will utilize a predetermined schedule of contacts with families
78748|NCT03569449|Behavioral|Technology enhanced care coordination|Behavioral: technology enhanced care coordination FPs will also have access to Act.MD, a cloud-based care coordination and communication tool that offers the potential to improve communication with families, schools, and the primary care site through administration of online questions, videoconferencing, and common portals that can be used by parents and multiple providers (e.g., FP, pediatrician, teacher).
78749|NCT03569449|Behavioral|:Individually-tailored visits|Family Partners will be able to meet with families on an as-needed basis, with no predetermined schedule of contacts
78750|NCT03569449|Behavioral|Clinic-based visits and community visits|In clinic-based visits the Family Partner is restricted to working at the primary care clinic and communication is restricted to telephone, text, and clinic visits. However in conditions with clinic based and community visits, the Family Partners will be available to meet families in their home and community (as well as the clinic), and accompany families to community-based meetings at school or childcare.
78751|NCT03569436|Other|Non-Interventional|Non-Interventional
78752|NCT03569423|Procedure|Transepithelial photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
78753|NCT03569423|Procedure|Alcohol assisted photorefractive keratectomy|ablations were performed with the Schwind Amaris excimer LASER 750S. Paired student's t-tests and Mann-Whitney tests were used for statistical analysis.
78754|NCT03569410|Behavioral|increased protein intake via natural foods|Patients had to eat 1.4g/kg/day of natural protein.
78755|NCT03569410|Behavioral|increase protein intake via protein supplements|Patients ate enough protein supplements in addition to their regular diet to reach eat 1.4g/kg/day of protein intake.
78756|NCT03569397|Other|Music Therapy|For patients having surgery with spinal anesthesia, administration of music therapy during the operation decreases sedation requirements, anxiety and may improve patient satisfaction. Music therapy during surgery may also lead to a decreased stress response, as evidenced by more stable cortisol levels.
78757|NCT03569384|Combination Product|Tele Rehab|The intervention group will obtain telerehabilitation
78758|NCT03569371|Drug|INCB054707|INCB054707 administered once daily orally with water without regard to food for 8 weeks.
78759|NCT03569358|Device|Immersive Virtual Reality|The immersive virtual reality headgear used is the commercially available FOVE VR headset. It incorporates a 2560x1440 pixel display, position tracking-and eye-tracking. The headset weight 520g with adjustable velcro straps. Softwares are run via a computer connected by HDMI or USB cables.
78760|NCT03569358|Device|EEG headband|The EEG headband is commercially available MUSE band. It incorporates 4-channel dry electrode EEG system where data can be recorded with bluetooth connection.
78761|NCT03569345|Drug|AFXl-assisted ingenol mebutate delivery|"Patients will receive ablative fractional laser (AFXl)-assisted ingenol mebutate (IM) as a treatment for their cutaneous basal cell carcinoma (BCC). Treatment areas consisting of tumors and a 5 mm margin will undergo AFXl exposure (CO2 laser) followed by IM 0.015% or 0.05% under occlusion for 2-3 days. .~local skin reactions are monitored at baseline (day1), day 3/4, day 8, day 15, day 29, day 90, and tumor response monitored at baseline, day 29, and day 90. An additional repeat AFXl-IM treatment on day 29 will be offered if tumors persist, based on clinical evaluation and imaging on day 30."
78762|NCT03569332|Other|Alarm|"Alarm is provided from 9am to 9pm.~Alarm is active every 50 minutes if the exercise goal(10 times/hour) hasn't satisfied."
78763|NCT03569332|Other|Nurse's dashboard|"Wireless data transmission system~The practicing rate of participants on study group is sent to Nurse's Dashboard.~It is only to display."
78764|NCT03569319|Behavioral|"THINK-MED resource (baseline)"|"The THINK-MED resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
78765|NCT03569319|Behavioral|"THINK-MED resource (staged)"|"This group of participants will receive the THINK-MED resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
78766|NCT03569319|Behavioral|Control|"Participants will receive the THINK-MED resource after their final 6 month study visit (i.e. delayed intervention)."
78767|NCT03569306|Device|ENB|ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
78768|NCT03569306|Device|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
78769|NCT03569293|Drug|Upadacitinib|It is administered orally.
78770|NCT03569293|Drug|Placebo for Upadacitinib|It is administered orally.
78771|NCT03569280|Combination Product|KPG-121 dose escalation + Enzalutamide|Antitumor treatment
78772|NCT03569267|Drug|OLX10010|A cell penetrating asymmetric siRNA (cp asiRNA)
78773|NCT03569267|Drug|Placebo|Placebo
78774|NCT03569254|Device|Neomedlight Phototherapy Blanket|The NeoMedLight® phototherapy blanket is an innovative new fiber-optic device based on LED light. Its light emitting surface area is 40.5x30 cm or 1200 cm2. The device size is 40.5 x30 cm. It incorporates fiber optic mesh and is protected by a vinyl cover and a disposable liner for patient comfort and hygiene. This device provides therapeutic light (404-515nm) to a wide extension of the body surface area. Its average irradiation footprint is 35uW / cm2 / nm ± 15%. The phototherapy was done intermittently in periods of 2 hours with 1 hour of rest for a total time of 6 hours in kangaroo position.
78775|NCT03569254|Device|Ohmeda-Fiber Optic Phototherapy Blanket|This device is a high performance version of Ohmeda Medical's Biliblanket that uses a fiber optic cable to deliver light from a high-intensity lamp to a device composed of a fiber optic fabric. The device has a disposable liner and is left in direct contact with the patient. The patient is exposed to a light with a wavelength between 400 and 550 nanometers. The phototherapy system consists of a light emitting unit, a fiber optic cable four feet long (121.9 cm) and a lightweight mattress. It has two available sizes: 4.38 x 9.38 inches (11.12 x 23.83 cm) and 4.00 x 6.00 inches (10.16 x 15.2 cm).
78776|NCT03569241|Radiation|whole pelvic radiotherapy|addition of prophylactic whole pelvic radiotherapy to a local metastasis-directed treatment
78777|NCT03569241|Radiation|metastasis-directed treatment|stereotactic body radiotherapy
78778|NCT03569241|Procedure|salvage Lymph Node Dissection|metastasis-directed treatment
78779|NCT03569241|Drug|androgen deprivation therapy|LHRH-agonist (+ anti-androgen) or antagonist for a duration of 6 months
78780|NCT03569228|Device|Study 1 - ITE hearing aids|Experienced users of in-the-ear (ITE) hearing aids will receive replacement ITE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
78781|NCT03569228|Device|Study 1 - BTE hearing aids|Experienced users of behind-the-ear (BTE) hearing aids will receive replacement BTE hearing aids that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
78782|NCT03569228|Device|Study 3 (open-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling using the standard of care approach, then undergoing a 4-week field trial.
78783|NCT03569228|Device|Study 3 (closed-fit comparison)|This group will serve as the active comparator group for experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling using the standard of care approach, then undergoing a 4-week field trial.
78784|NCT03569228|Device|Study 3 (experimental open-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with OPEN coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
78785|NCT03569228|Device|Study 3 (experimental closed-fit)|Experienced hearing aid user receiving replacement receiver in the canal (RIC) or receiver in the aid (RITA) hearing aids with CLOSED coupling that are fitted and verified in a test box coupler, then mailed to the patient for a 4-week field trial.
78786|NCT03569215|Behavioral|Questionnaire|All included patients will be exposed to questionnaires and psychiatric diagnostic tests
78787|NCT03569202|Device|Piiloset Trehalose Emulsion Eye Drops|Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily
78788|NCT03569202|Device|Control Eye Drops|Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
78789|NCT03569189|Other|High Fat Diet|"Participants will consume a high fat diet for 7 days with 65% of energy from fat. The diet will also provide an energy excess at 150% of energy requirements.~Participants will be provided with all of their meals and snacks throughout the study."
78790|NCT03569176|Device|Autism Glass|The intervention uses the outward-facing camera on the google glasses to read facial expressions and provides social cues within the child's natural environment during usual social interaction and during games accessed via the smartphone application. Participants who receive the Google Glass intervention will be asked to use it for around 20 minutes 3 times a week with their parents or during ABA therapy.
78791|NCT03569163|Device|Spry Loop oximeter|Oximetry was performed on the subjects and accuracy was determined based on comparison with blood gas analysis.
78792|NCT03569150|Other|Cultural adaptation/implementation COMFORT CC|The COMFORT Communication Curriculum (CC) will be culturally-adapted for 2 Native American reservation communities. The investigators will then implement the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities by training interdisciplinary healthcare professionals to conduct culturally-respectful and relevant Advance Care Planning. The investigators will then conduct a cluster-assigned pilot, wait-list controlled trial of the culturally-adapted COMFORT Communication Curriculum in 2 tribal communities to evaluate feasibility, acceptability, and perceived effectiveness by comparing 30 Native Americans completing Advance Care Planning with a trained healthcare professional and 30 Native Americans receiving usual care.
78793|NCT03569124|Other|Teaching tool for identification of colorectal polyps|This is a teaching session on how to identify the colorectal polyps shot in blue light imaging.
78794|NCT03569111|Device|Bronchoscopic ablation catheter|The Emprint™ Ablation Catheter Kit with Thermosphere™ Technology is deployed endoscopically and will be used to conduct bronchoscopic ablations in the lung using the superDimension™ navigation system.
78795|NCT03569098|Biological|Botulinum toxin type A|Investigators will inject the reconstituted solution into foot muscles.
78796|NCT03569098|Drug|Placebo|Investigators will inject the reconstituted solution into foot muscles.
78797|NCT03569085|Drug|Sevoflurane|The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
78798|NCT03569085|Drug|Isoflurane|The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
78799|NCT03569072|Radiation|Functionally adapted, dose escalated VMAT radiotherapy|Volumetric Modulated Arc Therapy planning and treatment delivery to treat primary and nodal planning target volume with 60 Gy in 30 fractions and a simultaneous integrated boost to the primary tumour to a total dose 69Gy in 30 fractions while avoiding organs at risk including functional lung, heart and oesophagus.
78800|NCT03569059|Device|Early Robotic/VR Therapy (EVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
78801|NCT03569059|Behavioral|Dose-Matched Usual Physical Therapy Care|Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.
78802|NCT03569059|Device|Delayed Robotic/VR Therapy (DVR)|Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
78803|NCT03569046|Drug|local anaesthetic injection|ear block by 0.25% bupivacaine
78804|NCT03569046|Drug|Normal Saline Flush, 0.9% Injectable Solution|ear block by Normal Saline Flush, 0.9% Injectable Solution
78805|NCT03569046|Drug|general anesthetic|general anesthetic by midazolam 0.02 mg kg-1 , propofol 2-3 mg kg-1 and lidocaine 0.5 mg kg-1 , fentanyl 2 μg kg-1 , atracurium 0.5 mg kg-1 , isoflurane in 50% oxygen/air.
78806|NCT03569046|Drug|Hypotensives|hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol
78807|NCT03569033|Drug|Gefapixant|Gefapixant 45 mg will be administered orally.
78808|NCT03569033|Drug|Placebo|Placebo tablet matching gefapixant will be administered orally.
78810|NCT03569007|Drug|Larazotide|Synthetic 8-amino acid peptide formulated as enteric-coated beads in gelatin capsules
78811|NCT03569007|Drug|Matching Placebo|enteric-coated beads in gelatin capsules
78812|NCT03568994|Drug|Atovaquone|"Patients will receive standard of care MRC based Induction chemotherapy (such as ADE 10+3+5 with daily atovaquone dosing starting on day 6. In order to accommodate potential drug shortages modifications to ADE 10+3+5 that retain the MRC based induction backbone regimen of DA are allowed (see second Arm). These include but are not limited to substitution of etopophos for etoposide, exclusion of etoposide, use of CPX-351 (VYXEOS (daunorubicin and cytarabine) liposome) only, and daunorubicin and cytarabine (DA) + gemtuzumab ozogamicin (GO).~Patients will be monitored for adherence to and tolerance of daily dosing of atovaquone. Peripheral blood (PB) and bone marrow plasma samples will be obtained to measure atovaquone concentrations."
78813|NCT03568994|Drug|Cytarabine|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
78814|NCT03568994|Drug|Daunorubicin|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
78815|NCT03568994|Drug|Etoposide|As part of routine Induction 1 chemotherapy (ADE 10+3+5)
78816|NCT03568994|Drug|Gemtuzumab Ozogamicin|As part of routine Induction 1 chemotherapy(DA 3+10 + GO)
78817|NCT03568981|Radiation|Partial breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
78818|NCT03568981|Radiation|Whole breast irradiation|After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
78819|NCT03568968|Dietary Supplement|Nicotinamide Riboside|1000mg one time daily. Given as tablets. Duration of the trial, 52 weeks.
78820|NCT03568968|Drug|Placebo|Placebo drug, given 1 time daily for the duration of the trial; 52 weeks.
78821|NCT03568955|Diagnostic Test|International Prolonged Grief Disorder Scale (IPGDS)|Assessment measure for Prolonged Grief disorder based on the ICD-11 (International Classification of Disorders) criteria for PGD (Prolonged Grief Disorder). 15 items
78822|NCT03568942|Drug|Gepotidacin|Gepotidacin tablets will be available at a dose strength of 750 mg. Tablets will be administered BID with water after consumption of food.
78823|NCT03568929|Drug|Idelalisib|Tablets administered according to the product information and treatment guidelines in routine clinical practice
78824|NCT03568916|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
78825|NCT03568916|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
78826|NCT03568916|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
78827|NCT03568903|Other|Comprehensive physical therapy|Each session included exercises for posture, strength, range of motion, balance. In addition, different transfers and gait training was performed. Each session began with exercises in laying position (15 minutes), thereafter exercises in sitting were performed for 10 minutes. Then different exercises in standing position were performed for 15 minutes, followed by 10 minutes of gait training. 10 minutes of exercises for manual dexterity and upper limb function ended the session.
78828|NCT03568890|Drug|Rivaroxaban, dabigatran, apixaban, or edoxaban|Duration of treatment: 8 weeks
78829|NCT03568890|Drug|Clopidogrel -75 mg/day|Duration of treatment: 8 weeks
78830|NCT03568890|Drug|Low dose aspirin -80 to 125 mg/day-|Duration of treatment: 8 weeks
78831|NCT03568877|Dietary Supplement|Metabolaid®|500 mg per day, in fasting conditions.
78832|NCT03568877|Dietary Supplement|Placebo|500 mg per day, in fasting conditions.
78833|NCT03568864|Other|Low nucleotide meal|The participants will consume a mixed meal (sandwich) containing a nucleotide depleted mycoprotein product (low in nucleotides)
78834|NCT03568864|Other|High nucleotide meal|The participants will consume a mixed meal (sandwich) containing a non nucleotide depleted mycoprotein product (high in nucleotides)
78835|NCT03568838|Drug|Enoxaparin|Patients allocated to the experimental arm will receive a parenteral (IA/IV) bolus dose of enoxaparin (0.75 mg/kg) pre PPCI followed by an infusion of 0.75 mg/kg over a 6-hour period to be started as soon as possible when PPCI starts.
78836|NCT03568825|Procedure|Osteopatic Manual Therapy (OMT)|OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
78837|NCT03568812|Drug|Rillus®|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
78838|NCT03568812|Other|Placebo|Eligible subjects will be divided into 2 groups randomly (Rillus® or placebo). The colour, smell, flavour, and size of the chewing tablet are the same between active and placebo drugs. Subjects will consume the tablet once daily at night for 12 weeks.
78839|NCT03568799|Radiation|18F-(2S,4R)4-fluoroglutamine|Undergo 18F-(2S,4R)4-fluoroglutamine PET/CT
78840|NCT03568786|Procedure|End-inspiratory pause 10%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 10% of the total inspiratory time
78841|NCT03568786|Procedure|End-inspiratory pause 30%|Percentage of the total inspiratory time in which there is no gas flow. It is the period of time between the cessation of the inspiratory flow and the start of expiration. In this intervention arm it would correspond to a 30% of the total inspiratory time
78883|NCT03568500|Drug|Olanzapine|Oral tablet; dosage will be determine by the health care providers and is independent from the protocol
78842|NCT03568773|Other|High-intensity interval training|HIIT training is being conducted on a three-day weekly frequency on a stationary bike. The protocol consisted of two weeks of adaptation with 12 weeks of training that alternated between sprints ranging from 30 s to 60 s (> 95% VO2max), and active recovery ranging from 180 s to 120 s (30 W on the bicycle).
78843|NCT03568773|Other|Aerobic exercise moderate intensity|The aerobic training is performed in a walking or running mode, with three weeks of adaptation (2x / wk - 20 to 30 minutes / session, <threshold 1) and 12 weeks of training (3 to 5x / wk - 40 to 60 minutes / session, with prescribed intensities between the anaerobic threshold - L1 and the respiratory compensation point - L2).
78844|NCT03568773|Other|Control Group|The control group is participating in lengthening classes to increase the adherence and control of the influencing variables. Classes are being held once a week for 60 minutes.
78845|NCT03568760|Behavioral|Semantic feature analysis|Confrontation naming training and training in doing circumlocutions
78846|NCT03568760|Behavioral|Comprehension training|Reading and hearing comprehension
78847|NCT03568747|Device|noninvasive ventilation|dual-limb circuit NIV were given on maquet servo i apparatus
78848|NCT03568747|Device|oxygen therapy|oxygen therapy were introduced to the side port of the facemask
78849|NCT03568734|Other|Fecal transplant|At delivery, i.e. 39-40 weeks of gestation, the newborn infant is given 0.1 g maternal fecal sample (in 0.5 ml of the isotonic saline+10 % glycerol) dissolved in 10 ml of bank milk orally. The sample is given within 2 h of birth. Milk containing fecal sample (2 ml) is given as a part of a total feeding of 5-10 ml.
78850|NCT03568721|Drug|Ibuprofen|prescription of ibuprofen 400 mg
78851|NCT03568721|Drug|Acetaminophen|prescription of acetaminophen 500 mg
78852|NCT03568721|Other|Chewing gum|prescription of one tablet of chewing gum
78853|NCT03568708|Drug|Transdermal Estrogen|In an open-label fashion, participants with POI will receive transdermal estradiol (beginning at a dose of 25 µg/patch applied weekly), with the dose increased at 3, 6 and 12 months (to 37.5, 50, and 75 µg/patch).
78854|NCT03568695|Diagnostic Test|Two samples on each of the three sites (pharynx, rectum, urine)|two new samples on each of the three sites (pharynx, rectum, urine) which will make it possible to compare the difference of sensitivity between real-time multiplex PCR from pools of 3 samples and the usual technique .
78855|NCT03568682|Behavioral|Nutritional counseling + urban gardening|Peer nutritional counseling and urban gardens
78856|NCT03568669|Other|NIH Toolbox Cognition Battery|An app-based cognitive assessment of executive function, attention, memory, and language that takes approximately 45 minutes to complete on an iPad
78857|NCT03568656|Drug|CCS1477|Capsules, oral
78858|NCT03568656|Drug|Abiraterone acetate|Abiraterone acetate 500mg tablets plus prednisone/prednisolone
78859|NCT03568656|Drug|Enzalutamide|Enzalutamide 40mg capsules
78860|NCT03568643|Drug|Azithromycin|Children enrolled in the trial and randomized to azithromycin will receive a single directly observed dose of oral azithromycin at 20 mg/kg up to the maximum adult dose of 1 g. Oral azithromycin will be administered at the time of enrollment. Enrolled children will also receive RUTF.
78861|NCT03568643|Drug|Amoxicillin|Children enrolled in the trial and randomized to azithromycin will receive a 7-day course of oral amoxcillin given in twice-daily doses of 50-100 mg/kg, per the Burkina Faso guidelines for the management of severe acute malnutrition. The first dose will be administered at the time of enrollment and the remaining dose will be administered by the caregiver at home. Enrolled children will also receive RUTF.
78862|NCT03568630|Diagnostic Test|Mixed Meal Tolerance Test|The goal of the test is to determine hormone secretion from the pancreas and small intestine in response to the mixed meal.
78863|NCT03568630|Diagnostic Test|Hemoglobin A1c|This test provides the average level of blood glucose over the last 3 months.
78864|NCT03568630|Diagnostic Test|Other exploratory blood biomarkers|Other exploratory blood biomarkers including cell free DNA and other markers in development
78865|NCT03568617|Device|rTMS|The subjects will receive 20 trains of 100 stimuli each delivered at 10 Hz and 80% of MT over the left MC (M1), 3 days a week, for 4 weeks.
78866|NCT03568604|Drug|Prasterone|6.5 vaginal insert prasterone (dehydroepiandrosterone)
78867|NCT03568591|Procedure|Psychosensory Therapy|Havening Techniques are a psychosensory therapy that incorporate the application of sensory input to alter neurochemical responses influencing thought, emotion and behaviour (Ruden, 2011).
78868|NCT03568578|Drug|Entecavir 0.5 mg|Patients in this group will be given Entecavir 0.5 mg a day for 2 years.
78869|NCT03568578|Drug|Anluohuaxian Pill 12g|Patients in this group will be given Entecavir 0.5 mg and Anluohuaxian Pill 12g a day for 2 years
78870|NCT03568565|Behavioral|ePREP Program|see arm descriptions
78871|NCT03568565|Behavioral|OurRelationship Program|see arm descriptions
78872|NCT03568552|Behavioral|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
78873|NCT03568539|Biological|IBI308|IBI308 200mg IV infusion, every 3 weeks.
78874|NCT03568526|Other|Educational Intervention|Attend a therapy session
78875|NCT03568526|Behavioral|Exercise Intervention|Complete exercise
78876|NCT03568526|Other|Quality-of-Life Assessment|Ancillary studies
78877|NCT03568526|Other|Questionnaire Administration|Ancillary studies
78878|NCT03568526|Other|Survey Administration|Ancillary studies
78879|NCT03568513|Dietary Supplement|Curcumin|The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.
78880|NCT03568513|Dietary Supplement|Placebo|The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.
78881|NCT03568500|Device|Digital Medicine System|A CoE containing an approved antipsychotic medication enclosed with an ingestible sensor pill
78882|NCT03568500|Drug|Aripiprazole|Oral tablet; dosage will be determine by the health care providers and is independent from the protocol
78884|NCT03568500|Drug|Quetiapine|Oral tablet; dosage will be determine by the health care providers and is independent from the protocol
78885|NCT03568500|Drug|Risperidone|Oral tablet; dosage will be determine by the health care providers and is independent from the protocol
78886|NCT03568487|Other|Intensive scapula-focused approach|scapula-focused approach with exercises, 3 x 20 min training per week for 4 weeks
78887|NCT03568487|Other|Control Therapy|not have any physical training but is encouraged to stay active as usual.
78888|NCT03568474|Drug|Silver Diamine Fluoride|Indirect pulp capping material
78889|NCT03568474|Drug|Glass Ionomer|Indirect pulp capping material
78890|NCT03568461|Biological|tisagenlecleucel|single infusion
78891|NCT03568448|Other|Response monitoring (no intervention)|Response monitoring (no intervention)
78892|NCT03568435|Other|Non-Interventional|Non-Interventional
78893|NCT03568422|Drug|CFI-402257|Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 & 16
78894|NCT03568422|Drug|Paclitaxel|80 mg/m2 IV days 1, 8 & 15 every 28 days
78895|NCT03568409|Device|ABO-GLYC|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
78896|NCT03568409|Other|ABO-GLYC Placebo|3 tablets twice a day, before the main meals (lunch and dinner) continuatively for 24 weeks.
78897|NCT03568396|Device|Pupillometer|Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.
78898|NCT03568383|Drug|Delamanid (DLM)|"Adults and children ≥30 kg: delamanid 200 mg orally once daily.~Children ≥2.5 kg to <30 kg: weight-band dosing orally once daily as per the study protocol. As children gain weight, their DLM dose should be adjusted, typically every month or as the visit schedule permits."
78899|NCT03568383|Drug|Isoniazid (INH)|"Adults and children ≥24 kg: INH 300 mg orally once daily.~Children ≥2.5 kg to <24 kg: INH weight-band dosing orally once daily as per the study protocol. As children gain weight, their INH dose should be adjusted."
78900|NCT03568383|Dietary Supplement|Pyridoxine (vitamin B6)|All HHCs in Arm B must receive pyridoxine (vitamin B6) with each dose of INH based on the current local dosing guidelines. For children up to 3 years of age and nursing women, pyridoxine will be given as per local standard of care. Pyridoxine is not supplied through the study.
78901|NCT03568370|Other|olive oil|Evaluate the effectiveness of olive oil and human milk in the prevention of nipple cracking, nipple pain and maternal satisfaction in lactating women during the first 3 days of treatment and the 7th and 10th day after delivery.
78902|NCT03568357|Procedure|Reoxygenation|After one minute of full bypass, fraction of inspired oxygen (FiO2) in conservative group was increased at increments of 0.1 per minute to reach an FiO2 target of 40% that was adjusted to maintain an arterial PO2 in the range of 250 mm Hg or less during the bypass, while FiO2 in liberal group was increased at increments of 0.1 per minute to reach a FiO2 target of 80% adjusted to maintain PO2 in the range of 300 mm Hg or more, on the basis of arterial PO2 level measured via a point of care blood gas analyzer.
78903|NCT03568331|Drug|Tradipitant|Oral Capsule
78904|NCT03568331|Drug|Placebo|Oral Capsule
78905|NCT03568318|Drug|Upadacitinib|It is administered orally.
78906|NCT03568318|Drug|Placebo for Upadacitinib|It is administered orally.
78907|NCT03568318|Drug|Topical corticosteroids (TCS)|It is administered concomitantly with Upadacitinib or Placebo.
78908|NCT03568292|Other|Best Practice|Receive standard of care
78909|NCT03568292|Other|Laboratory Biomarker Analysis|Correlative studies
78910|NCT03568292|Device|Oculus Rift Headset|Subject wears headset for virtual reality intervention during bone marrow biopsy or lumbar puncture procedure
78911|NCT03568292|Other|Questionnaire Administration|Ancillary studies
78912|NCT03568279|Procedure|Two-handed jaw thrust|The assistant applied two-handed jaw thrust for intubation.
78913|NCT03568279|Procedure|Control|The intubation was done without two-handed jaw thrust.
78914|NCT03568266|Procedure|Biospecimen Collection|Undergo collection of saliva
78915|NCT03568253|Other|Caries treatment|Treatment by Bulk fil composite after randomization of the tooth
78916|NCT03568253|Other|Caries treatment|Treatment by High viscosity glass ionomer after randomization of the tooth
78917|NCT03568240|Diagnostic Test|Patients suffering from Sleep apnea|PSG test
78918|NCT03568227|Procedure|Hypnosis|The hypnosis intervention consists of two elements: A hypnotic induction and a hypnotic deepening. The induction aims at guiding the participant into the first hypnotic state (state 1). The participants will remain in this state for 10 minutes, the duration of the fMRI-scan. The hypnotic deepening guides the participants into a very deep hypnotic state (state 2). Participants also remain in this state for 10 minutes, during which their brain activity is measured using fMRI
78919|NCT03568227|Procedure|Control|The control intervention consists of texts corresponding to the induction and deepening of the hypnosis intervention. They are matched in duration and consist of textually matched excerpts from www.wikipedia.org. Control induction will be presented, resulting in the control state 1 (10 min). Then the control deepening will be performed, leading to the control state 2 (10 minutes). During both control states the brain activity will be recorded using fMRI.
78920|NCT03568214|Other|Exercise|The MICT will be prescribed according to two exercise intensity methods: individualized (i.e., VT1 and VT2) and standardized (i.e., HRR). The HIIT will be prescribed based on individual fitness (i.e., VO2max).
78921|NCT03568201|Diagnostic Test|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves.
78922|NCT03568188|Procedure|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
78923|NCT03568188|Biological|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
78924|NCT03568188|Device|MRI|MRI exam will be regularly performed during patient follow up.
78925|NCT03568188|Other|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function).
78926|NCT03568188|Procedure|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
78927|NCT03568188|Biological|blood test|if the patient decides to participate in the ancillary study, a blood test (for immunological analyzes and detection of CTC (circulating tumor cells)) will be performed during their follow up.
78928|NCT03568188|Biological|urine test|if the patient decides to participate in the ancillary study, a urine test (for PCA3 test) will be performed during their follow up.
78929|NCT03568175|Drug|JR-141|IV infusion, 2.0 mg/kg/week
78930|NCT03568162|Drug|GBR 830 - Group 1|Subcutaneous injection (SC)
78931|NCT03568162|Drug|GBR 830 - Group 2|Subcutaneous injection (SC)
78932|NCT03568162|Drug|GBR 830 - Group 3:|Subcutaneous injection (SC)
78933|NCT03568162|Drug|Placebo - Group 4|Subcutaneous injection (SC)
78934|NCT03568149|Procedure|assessment of pain symptoms at first medical examination|First medical examination consists of collection of medical history and standard gynecological examination (bimanual gynecological examination and abdominopelvic ultrasounds). Data regarding age, Body Mass Index, ongoing hormone therapy and pelvic pain symptoms, assessed according to Visual Analogue Scale (VAS) (from 0= no pain to 10= unbearable pain), are collected. The presence of perineal or lower limb varices and the presence and localization of evoked pain at bimanual gynecological examination are also evaluated.
78935|NCT03568149|Procedure|assessment of pelvic vascular insufficiency signs|"Assessment of pelvic vascular insufficiency in conducted using abdominopelvic ultrasounds, according to the following parameters:~Ovarian vein diameter <4mm~Slow ovarian blood flow (<3cm/sec)~Retrograde blood flow~Dilated arcuate veins communicating with pelvic varices The presence of pelvic varices is evaluated qualitatively as normal, moderate and serious~This evaluation includes the study of uterine and ovarian vessels, using different techniques:~Standard 2D study, to measure vessels diameter~Vascular doppler study, to evaluate flow direction and blood speed~3D color study, for a three- dimensional reconstruction of vessels and a more accurate qualitative assessment of the congestion degree."
78936|NCT03568136|Drug|Secukinumab 300 mg|Solution for injection in pre-filled syringe
78937|NCT03568136|Drug|Placebo|Solution for injection in pre-filled syringe
78938|NCT03568123|Device|MC polyethylene bearing|"Zimmer Biomet Persona Total Knee System with MC polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
78939|NCT03568123|Device|CR polyethylene bearing|"Zimmer Biomet Persona Total Knee System with CR polyethylene bearing. Femoral component: Only cemented femoral components will be used for this study. Both standard as well as narrow femoral components will be used, depending on the patient anatomy.~Tibial component: Only cemented tibial components will be used for this study. Polyethylene materials: Conventional polyethylene will be used for patients >65 years old and Vitamine-E infused poly insert for patients ≤ 65 years old."
78940|NCT03568097|Drug|Avelumab|10 mg/kg will be given as intravenous infusion (IV) every two weeks (q 2 weeks) until disease progression.
78941|NCT03568084|Other|MEFAP|multicomponent physical activity program (MEFAP) with 12 weekly sessions of an hour and a half which includes 1) briefing 2) exercises for improving aerobic resistance, muscle strength, proprioception-balance and flexibility and 3) delivery of exercise chart to do at home (two times per week).
78942|NCT03568084|Other|control usual practice|Individuals allocated to this arm, will be look after as usual in their health Centers.
78943|NCT03568071|Drug|MOR 106|The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.
78944|NCT03568071|Drug|Placebo|A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.
78945|NCT03568058|Drug|personalized vaccine|Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
78946|NCT03568058|Drug|Pembrolizumab|200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
78947|NCT03568045|Device|standard light|usual care
78948|NCT03568045|Device|10,000 lux bright light, 4 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
78949|NCT03568045|Device|10,000 lux bright light, 8 hours|Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
78950|NCT03568032|Diagnostic Test|Measurement of intima media thickness of carotid artery|IMT measurements were performed using ultrasound machine in the pre-radiation and the post-radiation group. IMT was assessed at the common carotid artery (CCA) and the internal carotid artery (ICA) of both the left and right side.
78951|NCT03568032|Diagnostic Test|Detection and measurement of carotid plaques|Detection and measurement of plaques within internal carotid artery and common carotid artery by ultrasound
78952|NCT03568032|Diagnostic Test|Carotid Color Flow Duplex Testing|Velocity measurement of carotid artery to determine carotid stenosis
78953|NCT03568032|Diagnostic Test|Montreal Cognitive Assessment|Cognitive assessment
78954|NCT03568032|Other|Medical history of cardiovascular risk factors and cardiovascular diseases|Cardiovascular risk factors include smoking, alcohol consumption, hypertension, diabetes mellitus, hypercholesterolemia, obesity. Cardiovascular diseases include ischemic stroke, ischemic coronary heart disease, TIA, etc.
78955|NCT03568019|Other|Retrospective study|No subjects will be contacted or recruited. All data will be acquired retrospectively.
78956|NCT03568006|Other|Specific passive mobilization|Specific passive mobilizations for the shoulder
78957|NCT03568006|Other|Standardized treatment (standard protocol)|Infrared rays, a program of therapeutic exercises and indications to improve their postural hygiene
78958|NCT03567993|Behavioral|Comparison|Participants randomized to the comparison arm will receive twice-monthly abstinence assessments from the text messaging system, with no motivational feedback. Those in the comparison arm are neither offered nor encouraged to participate in the intervention.
78959|NCT03567993|Behavioral|Intervention|"Participants randomized to the intervention arm will receive:~Motivational Messages~Abstinence and Motivation to Use Services Assessments~Encouragement to access the Quitline~Encouragement to use Nicotine Replacement Therapy (NRT)~Provision of NRT, if requested~Intervention subjects are encouraged to access the Quitline and use NRT. However, these are not mandatory components of the intervention and subjects can choose if they would like to engage with the Quitline or use NRT."
78960|NCT03567980|Drug|Crisaborole|Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
78961|NCT03567967|Behavioral|Fruit and vegetable voucher|Participants will receive four vouchers, each dated for a month, to be used on fruits and vegetables at specified local corner stores, supermarkets, and farmer's markets for a duration of six months. Each study participant will have the same intervention, as this is a non-inferiority trial to compare voucher use in LA and test whether the nutritional effects of that use are non-inferior to use in SF.
78962|NCT03567954|Diagnostic Test|Ultrasound examination of the rotator cuff tendons|An ultrasound scan of the rotator cuff tendons will be performed to determine the presence of a rotator cuff tear or not
78963|NCT03567941|Drug|Placebo|Tablet orally administered under fasting
78964|NCT03567941|Drug|Hydrocodon bitartrate-acetaminophen arm 1|Tablet orally administered under fasted conditions
78965|NCT03567941|Drug|Hydrocodon bitartrate-acetaminophen arm 2|Tablet orally administered under fed conditions
78966|NCT03567941|Drug|Reference|Tablet orally administered under fasted conditions
78967|NCT03567928|Device|Sedation with Gastro Cuff Pilot Laryngeal Mask|This specific type of laryngeal mask allows to separate the gastric and respiratory tract and allows the anesthesiologist to support patient's ventilation as (and only if) necessary.
78968|NCT03567928|Drug|Propofol|Target controlled infusion (TCI) with propofol
78969|NCT03567915|Other|Evaluation of gastric volume and content|The gastric volume and gastric content are assessed at 4, 5, 6, 7, and 8 hours after eating a meal.
78970|NCT03567902|Device|C-MAC videolaryngoscope intubation|C-MAC videolaryngoscope intubation
78971|NCT03567902|Device|Direct laryngoscope intubation|Direct laryngoscope intubation
78972|NCT03567889|Drug|Daromun|Patients in Arm 1 will receive intratumoral administrations into injectable cutaneous, subcutaneous, and nodal tumors of Daromun once weekly for up to 4 weeks. Surgery will follow within 4 weeks.
78973|NCT03567889|Procedure|Surgery alone|Patients in Arm 2 will receive surgery within 4 weeks from randomisation.
78974|NCT03567889|Procedure|Surgery|Surgery
78975|NCT03567876|Drug|Venetoclax|Consolidation and maintenance phases with Venetoclax (for a total of 2 years) after an induction phase R-BAC (up to 6 cycles for law risk patients and up to 4 cycles for high risk patients)
78976|NCT03567863|Device|20-GAUGE PROCORE® first, then 22-GAUGE ACQUIRE®|The two punctures performed successively with the 20-GAUGE PROCORE® (COOK) and the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC)
78977|NCT03567863|Device|22-GAUGE ACQUIRE® first, then 20-GAUGE PROCORE®|The two punctures performed successively with the 22-GAUGE ACQUIRE® (BOSTON SCIENTIFIC) and the 20-GAUGE PROCORE® (COOK)
78978|NCT03567850|Behavioral|Problem solving Skills Training|"Participants will be encouraged to identify specific problems particularly relevant to them and to their family's situation (instead of providing them with standardized examples) to be discussed and solved during the PSST sessions. The eight sessions of PSST will be organized in a systematized, therapeutic manner. Session 1 will be face-to-face and devoted to rapport building and understanding relevant social and medical information. The therapist (RA) will introduce PSST and the Bright IDEAS paradigm, present worksheets to guide PSST homework assignments, and give an overview of subsequent sessions. Starting at session 2, participants will continue training over the phone, with the same general structure and format. In sessions 2-7, the therapist and patient, with a supportive other (SO) if available, will review the patient's identified problems and work on application of problem-solving strategies and skills learned earlier."
78979|NCT03567837|Other|Fructose + Glucose Beverage|The intervention is an oral sugar challenge with blood sampling over three hours.
78980|NCT03567824|Drug|Magnesium L-lactate dihydrate|Magnesium L-lactate dihydrate 10 mEq extended release caplets
78981|NCT03567824|Drug|Placebo Oral Tablet|Placebo will have the same appearance, taste, odor and mode of administration as MLD10.
78982|NCT03567811|Procedure|Submaximal bicycle exercise stress test on Days 1 and 2|Identical submaximal stress tests were performed on both days to see if Day 1 exercise reduced performance on Day 2, or caused changes between BOLD scans during cognitive testing between Day 1 and Day 2.
78983|NCT03567798|Dietary Supplement|UPLAT|Carica papaya leaf Extract + Tinospora cardifolia Extract
78984|NCT03567798|Other|Placebo|Placebo
78985|NCT03567772|Device|Wiifit Nintendo video game|
78986|NCT03567772|Other|Pulmonary rehabilitation program|
78987|NCT03567746|Procedure|Underwater EMR|Polypectomy is performed under full water emersion avoiding the use of submucosal injection.
78988|NCT03567746|Procedure|Conventional EMR|It will be performed in a 2-step procedure. First the formation of a submucosal injection underneath the polyp to create a submucosal safety cushion. Then EMR is performed with a polipectomy snare.
78990|NCT03567720|Biological|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid delivered by electroporation every 6 weeks
78991|NCT03567720|Biological|Pembrolizumab|Intravenous 3 weekly treatments
78992|NCT03567720|Device|Immunopulse|Device that administers electroporation
79085|NCT03566979|Drug|Commercial naproxen sodium liquid gels capsule|Single dose of 2 naproxen sodium 220 mg liquid gel capsules
79086|NCT03566979|Drug|Placebo tablet|2 placebo tablets
79087|NCT03566966|Biological|Non-organ-specific Ab positive|Antiviral administration and evaluation of SVR24 and side effects
78993|NCT03567707|Biological|C-section -Vaginal seeding|Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding.
78994|NCT03567707|Drug|C-section - Placebo Seeding|Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.
78995|NCT03567707|Other|standard care|Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
78996|NCT03567694|Drug|HA115|Test Drug
78997|NCT03567694|Drug|Placebo|Placebo
78998|NCT03567681|Drug|Extended release oxcarbazepine vs Immediate release oxcarbazepine|Extended release oxcarbazepine vs Immediate release oxcarbazepine
78999|NCT03567668|Procedure|mitral valvuloplasty|Commissural plication was the most commonly used technique to repair mitral insufficiency, which was selectively supplemented by a specific combination of one or more of the following procedures: cleft closure, chordal shortening, transposition or replacement, edge-to-edge repair, leaflet augmentation, or division of papillary muscles, depending on the individual etiology and anatomy.
79000|NCT03567655|Drug|Farlutal tab. 500mg/ Pfizer|Medroxyprogesterone Acetate
79001|NCT03567642|Drug|Osimertinib|Osimertinib 80mg daily
79002|NCT03567642|Drug|Platinum|Cisplatin 60mg/m2 or Cisplatin 45mg/m2 Carboplatin AUC 5 or Carboplatin AUC 4
79003|NCT03567642|Drug|Etoposide|Etoposide 100mg/m2 or Etoposide 80mg/m2
79004|NCT03567629|Drug|Irinotecan|Irinotecan 180 mg / m2, intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.
79005|NCT03567629|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 (two-week regimen) or 130mg/m2 (three week regimen), intravenous drip, D1, combined with fluorouracil / calcium folinate or Capecitabine or S1; combine or not combine with Bevacizumab or Cetuximab; every 14 or 21 days for a cycle.
79006|NCT03567616|Drug|Venetoclax|tablet; oral
79007|NCT03567616|Drug|Pomalidomide|capsule; oral
79008|NCT03567616|Drug|Dexamethasone|administered orally
79009|NCT03567590|Procedure|Pulsed Radiofrequency treatment|The pulse treatment generator (PMF-21-100-5, Baylis Medical Inc., Montreal, Canada) with a length of 10 cm, 21-gauge, and an active tip length of 5 mm is inserted vertically into the puncture point. The pulse treatment generator is set to the pulsed radiofrequency automatic mode, with a temperature of 42 °C, pulse frequency of 2 Hz, pulse width of 20 ms, and treatment duration of 360s.
79010|NCT03567590|Procedure|Nerve Block treatment|A mixture of 40 mg Triamcinolone + 2 ml of 1% Bupivacaine + 2 ml of 2% mepivacaine + 1:100000 epinephrine is injected for nerve block treatment using a puncture needle.
79011|NCT03567577|Drug|Solnatide 25 mg powder for reconstitution for solution for inhalation|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
79012|NCT03567577|Drug|0.9% Saline Solution|Inhalation of an aerosol every 12 hours (± 30 min), for a total of 7 days.
79013|NCT03567564|Diagnostic Test|Abdominal muscles ultrasound|Abdominal muscles ultrasound during a spontaneous breathing trial using the M-mode to calculate the thickening fraction of the anterior and lateral abdominal muscles under multiple circumstances (tasks performed by the patients)
79014|NCT03567551|Other|Women w/ Preeclampsia w/o Visual Disturbances or Headache|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
79015|NCT03567551|Other|Women w/ Preeclampsia w/ Visual Disturbances or Headaches|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
79016|NCT03567551|Other|Women w/o Preeclampsia|Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
79017|NCT03567538|Procedure|Thoracic surgery|Thoracic surgery, pulmonary resection, minimally invasive thoracic surgery, video assisted thoracic surgery (VATS)
79018|NCT03567525|Procedure|lymph node dissection using the peritoneal iliac flap approach to seal lymphatic vessels|After pelvic lymph node dissection, lymphatic vessels will be sealed by formation of a peritoneal iliac flap in which the bladder in folded over the area of lymph node dissection
79019|NCT03567525|Procedure|Standard surgical approach|After pelvic lymph node dissection, lymphatic vessels will be sealed using the standard approach
79020|NCT03567512|Behavioral|Smoking hygiene intervention|The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).
79088|NCT03566966|Biological|Non-organ-specific Ab negative|direct-acting antiviral agents
79089|NCT03566940|Biological|sIPV|Participants will receive 0.5 milliliter (mL) of sIPV as a solution for IM injection.
79090|NCT03566940|Biological|cIPV|Participants will receive 0.5 mL of cIPV as a suspension for IM injection.
79091|NCT03566927|Combination Product|FLEX Scoring Catheter with Lutonix DCB|Treatment by the FLEX Scoring Catheter, a plain balloon angioplasty, followed by a Lutonix DCB.
79021|NCT03567512|Behavioral|Placebo intervention|"The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (~20 minutes), 2 week telephone counseling (~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (~20 minutes), and 4 month telephone counseling (~20 minutes)."
79022|NCT03567499|Drug|GSK3039294|GSK3039294 capsules will be available with a dose strength of 100 mg and 200 mg to be taken as single or multiple capsules orally along with water depending on the dosage required.
79023|NCT03567499|Drug|Placebo|Matching placebo capsules to match active 100 mg and 200 mg dose strength will be available and to be taken as single or multiple capsules orally along with water depending on the number of active capsules to blind.
79024|NCT03567473|Drug|Oral dexamethasone|Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later
79025|NCT03567473|Drug|Nebulized Epinephrine|Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
79026|NCT03567473|Drug|Oral placebo|Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.
79027|NCT03567473|Drug|Nebulized normal saline|Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment
79028|NCT03567460|Behavioral|Exercise|Across studies in adolescents in general population, 60 minutes of recommended daily exercise level is achieved, on average, within a total volume of 10,000-11,700 steps. The investigators will assess baseline physical activity quantitatively by using an accelerometer worn on the wrist during waking hours over a 7-day period. Each participant will be given a Garmin device to place on their wrist that will track their steps. Then patients will be asked to complete 10,000 steps daily for 6 months (acclimation over a week), which will be encouraged by daily text messages or e-mail, and weekly phone calls by the intervention team in addition to a Garmin and Facebook peer group.
79029|NCT03567447|Drug|Droxidopa|starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
79030|NCT03567447|Other|Placebo|appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
79031|NCT03567434|Other|Alcohol vs. Placebo|Using a randomized, cross-over design, all subjects will consume evening alcohol (and a fluid-control placebo) in a dose that mimics binge drinking.
79032|NCT03567408|Procedure|Selective PCI|Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.
79033|NCT03567408|Drug|Bivalirudin|Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
79034|NCT03567395|Dietary Supplement|Melatonin|Melatonin (5 mg sublingual tablet) administered for 3 days
79035|NCT03567395|Dietary Supplement|Honey|Raw Honey (1.5 tablespoons) administered for 3 days
79036|NCT03567382|Drug|Tenofovir Disoproxil Fumarate|300 mg tablet of TDF once daily from 28-32 weeks gestation through 12 weeks postpartum.
79037|NCT03567382|Biological|Monovalent HBV vaccine|Infants born to HBsAg-positive women will be given a single dose of monovalent HBV vaccine within 24 hours of life.
79038|NCT03567369|Drug|Dexamethasone|Dexamethasone 4,0 mg/mL
79039|NCT03567369|Drug|Traumeel S|Traummel S 2,2 mg/mL
79040|NCT03567356|Other|"MAT-PLUS Helping Hands"|"1) Significant other engagement through the Helping Hands approach empowers designated concerned helpers, providing concrete guidance for monitoring, supervision, and improving adherence for their loved one in treatment; 2) Care coordination and case management by counselors to enhance adherence to XRNTX ; 3) Assertive outreach incorporates frequent multi-channel outreach with the goal of achieving XRNTX dosing."
79041|NCT03567343|Dietary Supplement|Proprietary Spearmint Extract Blend|Water extracted spearmint extract and green tea blend
79042|NCT03567343|Other|Control|Placebo
79043|NCT03567343|Dietary Supplement|Proprietary Blend And Melatonin|Water extracted spearmint extract and green tea blend and Melatonin (Proprietary Spearmint Extract Blend and Melatonin)
79044|NCT03567343|Dietary Supplement|Melatonin|Melatonin Alone
79045|NCT03567330|Behavioral|Family-based attachment-focused intervention|5 2-hour biweekly sessions involving parent and/or adolescent(s).
79046|NCT03567330|Behavioral|Psychoeducation|Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
79047|NCT03567317|Device|CPAP withdrawal|Patients randomized to withdrawal will stop CPAP use for one week before study evaluations. Patients will also undergo a polysomnography to confirm the presence of severe OSA.
79048|NCT03567304|Drug|Rilpivirine 25 mg|Rilpivirine 25 mg PO OD with meal (and continue 2 back bone of NRTIs)
79049|NCT03567291|Drug|TEV-50717|6, 9, and 12 mg oral tablets
79050|NCT03567291|Drug|Placebo|Placebo comparator
79051|NCT03567278|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement surgery.
79052|NCT03567252|Behavioral|Walking Group|Participants will walk 1 kilometer to a Farmer's Market.
79053|NCT03567239|Device|Using adaptive device.|Participant uses the specially designed device for a specified length of time (no less than two days) and feedback is then gathered from the participant through questionnaires. These questionnaires include NASA-TLX, PIADS, QUEST, and a single question asking if the device improved their ability to address their specific need.
79092|NCT03566914|Drug|Tadalafil 10 MG|Tadalafil 10 mg per oral once daily for 3 months
79093|NCT03566914|Other|Placebo|TPlacebo tablet per oral once daily for 3 months
79054|NCT03567226|Behavioral|WeChat Group|"Consenting participants will be randomized to either the intervention or the control arm after successfully wearing an accelerometer for one week. The WeChat Group will be a community forum to share information, encourage each other, and receive communications from the study team. In addition, the study team will disseminate the following information through the group:~Daily/Weekly Reminders to exercise~Health education materials regarding glaucoma and general health and exercise~Motivational content~Surveys to gauge what information participants found most interesting and useful to help them exercise"
79055|NCT03567226|Behavioral|Counselling|Study participants in the control group will receive a handout telling them to increase walking and will be counseled that walking may be helpful for the eye at the return visit
79056|NCT03567213|Device|Surgical implantation of CortiCom system|Implantation of Cortical communication system, consisting of one or two Electrocorticography (ECoG) grids connected to a transcutaneous patient pedestal.
79057|NCT03567200|Behavioral|Single-Arm Feasibility|Participants in each of the 8 participating groups (N=10-12 per group) are exposed to an integrated intervention program (integration of physical activity and psychosocial components). Each session is co-facilitated by a trained research staff member and a registered social worker, providing participants with the opportunity to engage in physical activity behaviours as well as discuss various psychosocial topics that are applicable to the participants interests. Physical activities include participating in group activities such as rock climbing, self-defence, yoga, etc. Psychosocial topics addressed include group discussions around cyber-bullying, sexual abuse and exploitation, gender issues, etc.
79058|NCT03567187|Device|iovera|The iovera° device is 510(k)-cleared (K133453 and K161835) and is used to form a precisely controlled, sub-dermal cold zone of -20 to -88.5 degrees Celsius to temporarily disrupt peripheral nerve function, ultimately blocking pain. It is not indicated for the treatment of central nervous system tissue.
79059|NCT03567174|Other|Integrated care van (ICV)|Structural service delivery intervention
79060|NCT03567161|Procedure|Cavitron ultrasonic surgical aspirator|"Cavitron Ultrasonic Surgical Aspirator (CUSA) has proven to be effective in biofilm disruption and cell stimulation . The hypothesis is that the employment of CUSA for non-surgical treatment of infrabony defects thanks to its abilities to disrupt, fragment and aspirate granulation tissue, will allow the formation of larger and more stable blood clot.~According to the anatomy of the osseous sites, the sonotrode (Sonocare 300 by Söring GmbH, Justus-von-Liebig-Ring 2 -25451 Quickborn Germany) will be inserted both intrasulcularly and trans gingivally (smallest tip is 0,8 mm); intrasulcularly in the cases of three wall defects, and trans gingivally in cases of one to two wall defects ."
79061|NCT03567148|Procedure|PRF|Applying to the palatal wounds
79062|NCT03567148|Procedure|Essix retainer|Applying to the palatal wounds
79063|NCT03567148|Procedure|Ozone therapy|Applying to the palatal wounds
79064|NCT03567148|Procedure|LLLT|Applying to the palatal wounds
79065|NCT03567148|Procedure|Collagen fleece|Applying to the palatal wounds
79066|NCT03567135|Drug|Apatinib|These drugs are planned to inhibit the proliferation and metastasis of tumors.
79067|NCT03567135|Drug|Temozolomide（TMZ）|Radiotherapy is a common treatment for glioblastoma.Accompanied with TMZ, the damages caused by tumors to the normal tissues will be reduced.
79068|NCT03567122|Other|Internal Focus of Attention|Information already included in arm/group descriptions.
79069|NCT03567122|Other|External Focus of Attention|Information already included in arm/group descriptions.
79070|NCT03567122|Other|Control|Information already included in arm/group descriptions.
79071|NCT03567109|Other|hand laterality judgment task|participants are asked to identify laterality of the hand presented on the screen
79072|NCT03567096|Device|BiV pacing with MPP and SyncAV|This cohort will receive Bi-Ventricular Pacing (left ventricle and right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
79073|NCT03567096|Device|LV only pacing with MPP and SyncAV|This cohort will receive left ventricular only pacing (no right ventricle pacing) with MultiPoint Pacing of the left ventricle (two stimulation sites) and the SyncAV algorithm active.
79074|NCT03567083|Behavioral|Problem Management Plus (PM+)|This intervention is based on the WHO treatment guidelines for conditions related to stress (WHO, 2013). It is a 5-session intervention that is delivered by trained non-specialized workers or lay people, and is available in individual and group delivery formats for both children and adults. PM+ includes evidence-based techniques such as; problem solving, stress management, behavioral activation, and accessing social support. It has proved to be effective by two randomized controlled trials (RCTs) in Kenya and Pakistan (Bryant, Dawson, Schafer, Sijbrandij, & van Ommeren, 2016; Rahman, Hamdani, Awan, Bryant, Dawson, Khan, Mukhtar-ul-Haq Azeemi, et al., 2016).
79075|NCT03567070|Other|qualitative study based on an individual clinical interview|qualitative study based on an individual clinical interview
79076|NCT03567057|Drug|ADS-5102|Oral capsules to be administered once daily at bedtime for the 52-week open-label treatment period.
79077|NCT03567044|Diagnostic Test|Blood Draw|Eligible subjects will have blood draws at the following times: baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks.
79078|NCT03567031|Procedure|EtCO2 modification|Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
79080|NCT03567005|Device|Nelfilcon A digital contact lenses|Silicone hydrogel digital contact lenses
79081|NCT03567005|Device|Nelfilcon A contact lenses|Silicone hydrogel spherical contact lenses
79082|NCT03566992|Procedure|Gastric|Placement of a nasoenteric tube
79083|NCT03566979|Drug|Test naproxen sodium tablet|Single dose of 2 test naproxen sodium 220 mg tablets
79084|NCT03566979|Drug|Commercial naproxen sodium tablet|Single dose of 2 naproxen sodium 220 mg tablets
79207|NCT03566030|Drug|Tenofovir Alafenamide 25 mg|Administered Tenofovir Alafenamide 25 mg QD
79094|NCT03566901|Device|G-EO System|The G-EO Systems can reproduce the gait pattern and realistically simulates the ability to carry out stairs up and stairs down. It provides real-time feedback on the patient's movements with the Visual Scenario and offers the possibility to experience augmented reality further enhance the effectiveness of each therapy session. An intelligent control (G-EO System Evolution) reacts and adapts to each patient's individual capability by either supporting the patient - active assistive mode - or increasing resistance - active mode. The G-EO Systems rehabilitation robot allows to secure the subjects with a harness while they stood on the foot plates of the machine. The foot plates has 3 DoF each, allowing to control the length and the height of the steps and the foot plate angles. The maximum step length corresponded to 550 mm, the maximum achievable height of the steps is 400 mm, the maximum angles is ±90°. The maximum speed of the foot plates is 2,3 km/h.
79095|NCT03566901|Other|Conventional Physiotherapy|Overground walking training including real stair climbing up/down and lower limb mobilization and stretching exercises.
79096|NCT03566888|Device|Blood pressure assessment|Validation of an automated blood pressure device
79097|NCT03566875|Procedure|Total knee arthroplasty with the Stryker's MAKO™ system|The robot assisted surgery is performed using the Stryker's MAKO™ system. The precision with this system is very accurate. It should help the surgeon to improve the positioning accuracy of prosthetic implants compared to the conventional method.
79098|NCT03566875|Procedure|Total knee arthroplasty with mechanical ancillary|The arthroplasty is performed with the mechanical ancillary refering to the the conventional method.
79099|NCT03566862|Diagnostic Test|Leicester Cough Monitor (LCM)|The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
79100|NCT03566849|Other|KC group|"1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Ball modified prone Cobra, Ball prone V-raise, Ball prone row, Ball side plank, Ball one-leg bridging~2nd week: each 10 rep/set, 3 set/day. Half sit-up with rotation to left/right, Side plank with ER, Prone extension with rotation to left/right, Bilateral one-leg squat with flexion, Squat to row~3rd week: 5 rep/set, 3 set/day (sling exercise). Prone shoulder protraction, Supine shoulder retraction, Side-lying hip ABD/ADD, Supine pelvic lift, Prone bridging~4th week: each 10 rep/set, 3 set/day. Lateral lunges with shoulder ABD/ER, Lunge with trunk rotation, Forward punch plus with serape effect, Spiking exercise, One-quarter vertical squat jump"
79101|NCT03566849|Other|CT group|"1st week: each 10 rep/set, 3 set/day. PNF scapular pattern: posterior depression (Combination of isotonic, COI), Knee push up plus, Modified prone Cobra, Prone V-raise, Prone row, Side-lying ER~2nd week: each 10 rep/set, 3 set/day. Supine punch, Prone horizontal ABD, Prone V-raise, Prone row, Side-lying ER~3rd week: each 10 rep/set, 3 set/day. Sitting chest press, Sitting ABD in scaption, Sitting overhead press, Long-sitting resisted extension, Sitting ER~4th week: each 10 rep/set, 3 set/day. Standing horizontal pull-apart, Standing retraction plus ER, Standing resisted extension, Ball pushed on wall and controlled rolling, Wall push-up"
79102|NCT03566836|Device|Garmin Smart Watch|Garmin Smart Watch
79103|NCT03566836|Device|Garmin Chest Band|Garmin Chest Band
79104|NCT03566823|Biological|SHP647|Subcutaneous injection of SHP647 will be administered using a prefilled syringe.
79105|NCT03566823|Other|Placebo|Subcutaneous injection of placebo matched with SHP647 will be administered using a prefilled syringe.
79106|NCT03566810|Drug|Test GXR|Participants will receive single oral dose of GXR tablet manufactured in Merck Nantong China (Test Drug) in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
79107|NCT03566810|Drug|Reference GXR|Participants will receive single oral dose of GXR tablet manufactured in Merck Darmstadt Germany (Reference Drug) in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
79108|NCT03566784|Procedure|Inguinal hernia repair|Standard procedure for inguinal hernia repair
79109|NCT03566771|Behavioral|Usual care|The child and parent(s) at regular visits to the pediatric clinic for childhood obesity treatment
79110|NCT03566771|Behavioral|CLOSS|Usual care plus using mobile applications to register weight and physical activity as well as for communication with the clinic. A web-based support system enables health care professionals to follow the patient's daily objectively measured weight and physical activity online.
79111|NCT03566745|Diagnostic Test|Blood for protein activity|Blood for protein activity
79112|NCT03566719|Other|Exercise program|Intervention group has been submitted to an exercise program directed to prevent and reduce fall risk
79113|NCT03566706|Behavioral|Discussion Tool: Unhealthy Eating|Parents will randomly be assigned to one of three discussion tools that will provide parents with tools on how to communicate with their children about unhealthy eating, marijuana use, or sedentary behavior.
79114|NCT03566706|Behavioral|Discussion Tool: Marijuana Use|Parent Discussion Tools
79115|NCT03566706|Behavioral|Discussion Tool: Sedentary Behavior|Parent Discussion Tools
79116|NCT03566693|Device|Dexcom G6 CGM System|continuous glucose monitor
79117|NCT03566693|Device|Blood glucose meter|Blue-tooth enabled blood glucose meter
79118|NCT03566680|Device|Orthokeratology|Orthokeratology is a type of contact lens that is worn over night to reduce refractive error, so patients do not need to wear vision correction during the day.
79119|NCT03566667|Drug|Metoprolol|Betablocker
79120|NCT03566667|Drug|Standard care|Standard care
79121|NCT03566654|Device|remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times， two times per day. The duration of the treatment is 30+/-2days.
79122|NCT03566654|Device|ambulatory blood pressure monitoring|A diagnostic technique for measuring blood pressure in daily life by means of automatic intermittent timing. Because ABPM has overcome the limitations of clinic blood pressure measurement, observation error and white coat effect, it can objectively reflect the actual level and fluctuation of blood pressure. Each patient of the two arms will use ABPM measure blood pressure before and after RIC or sham RIC treatment.
79123|NCT03566654|Device|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times. The duration of the treatment is 30+/-2days.
79124|NCT03566641|Device|Negative pressure wound therapy|The application of a vacuum across the surface of a wound through a foam dressing cut to fit the wound.
79125|NCT03566641|Other|standard care dressing|The application of a standard care dressing (instead of negative pressure wound therapy) across the surface of wound.
79126|NCT03566628|Other|Warmed Isotonic Saline|Isotonic saline warmed to 39ºC.
79127|NCT03566628|Other|Room-Temperature Isotonic Saline|Isotonic saline at room temperature
79128|NCT03566615|Device|CAP-straight|This study is to detect any differences in the detection rate of adenomas using straight caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
79129|NCT03566615|Device|CAP-daisy|This study is to detect any differences in the detection rate of adenomas using daisy caps that will be attached to the colonoscope and to compare it to the control method where no cap is used in the colonoscopy procedure.
79130|NCT03566615|Other|water|using water instead of traditional air insufflation to help insertion
79131|NCT03566602|Device|Dura Sealant Patch|Adjunctive bioresorbable patch
79132|NCT03566589|Dietary Supplement|Lactobacillus plantarum PS128|daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
79133|NCT03566576|Drug|Anlotinib|Anlotinib 8mg p.o. qd in first cohort (3 subjects). 10mg p.o. qd in second cohort (3 subjects). 12mg p.o. qd in third cohort (3 subjects).
79134|NCT03566576|Drug|Pemetrexed|Pemetrexed 500mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
79135|NCT03566576|Drug|Docetaxel|Docetaxel 60mg/m2 as a 10-minute intravenous infusion on day 1 of a 21-day cycle.
79136|NCT03566563|Other|Screening|Patients tested positive for Hepatitis C will be referred to Hospital through the conventional health care services and by an alternative direct access method to determine if this improves linkage to care
79137|NCT03566550|Diagnostic Test|MRI scans|Repeated MRI scans imaging digestion of standard meals
79138|NCT03566537|Procedure|Thyroidectomy|Thyroidectomy
79139|NCT03566524|Dietary Supplement|arginine|Ketosis prone diabetes patients (n=13) will be randomly assigned to receive dietary supplements of arginine
79140|NCT03566524|Dietary Supplement|Citrulline|Ketosis prone diabetes patients (n=13) will be randomly assigned to receive dietary supplements of citrulline
79141|NCT03566524|Dietary Supplement|Alanine|Ketosis prone diabetes patients (n=13) will be randomly assigned to receive dietary supplements of alanine as placebo
79142|NCT03566511|Drug|Diazoxide|Healthy and T2D participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) between baseline MRI scan and second MRI scan.
79143|NCT03566511|Drug|Placebo|Healthy and T2D participants will receive placebo between baseline MRI scan and second MRI scan.
79144|NCT03566498|Dietary Supplement|Immediate hydration|They will be allowed to start oral fluids immediately (within the first 2 hours post operatively) beginning with water or clear fluids (but not milk or soda containing drinks), the amounts will be according to their needs, solid food will be given gradually after tolerating the drinks and intravenous fluids will be given beside all of that and till the return of intestinal movements
79145|NCT03566498|Dietary Supplement|Early hydration|They will receive the routine intravenous fluids and the oral fluids will be given after 8 hours post operatively and gradually, solid food will be allowed after that gradually too and the intravenous fluids will be stopped after return of intestinal movements.
79146|NCT03566485|Drug|Atezolizumab|Given by IV
79147|NCT03566485|Drug|Cobimetinib|Given by mouth
79148|NCT03566485|Drug|Idasanutlin|Given by mouth
79149|NCT03566472|Diagnostic Test|Continuous Glucose Monitoring System|Continuous Glucose Monitoring System for 72 hours
79150|NCT03566459|Other|CBOC offering MAT for opioid use disorder|CBOC offering MAT for opioid use disorder using telemedicine
79151|NCT03566446|Biological|CALRLong36 peptide|200 ug CALRLong36 peptide in water mixed with 500ul montanide
79152|NCT03566433|Procedure|Tep surgery for inguinal hernia|TEP surgery
79153|NCT03566433|Procedure|Lichtenstein|Lichtenstein surgery for inguinal hernia
79154|NCT03566407|Procedure|Colonoscopy|Colonoscopy will be required for all subjects at 6 months - Visit 3.
79155|NCT03566394|Drug|Gabapentin 300mg|Gabapentin 300mg orally three times a day, from 2 days before to 5 days after taxane infusion
79156|NCT03566381|Device|Application of a soft patch composed of medical-grade silicone that collects sweat during a subject's natural behaviors.|This device contains sweat sensors embedded in an elastomer and is applied to the skin with a medical grade adhesive.
79157|NCT03566368|Diagnostic Test|Electrocardiogram|a 12 lead surface electrocardiogram taken after connecting limb and chest electrodes
79158|NCT03566368|Diagnostic Test|Transthoracic Echocardiogram|Transthoracic echocardiogram performed to evaluate Cardiac function in parasternal - long and short axis, Apical - 4 chamber and 5 chamber views.
79159|NCT03566368|Diagnostic Test|Cardiac enzyme - Troponin I Levels|Blood sample - venous collected to measure blood troponin - I levels.
79160|NCT03566355|Radiation|curative proton therapy|Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
79161|NCT03566329|Drug|Magnesium sulphate|Magnesium sulphate 50 mg/kg over 10 minutes loading followed by 15mg/kg/hr infusion. .
79162|NCT03566329|Drug|Lidocaine Hydrochloride|lidocaine hydrochloride 1.5mg/kg loading followed by 2mg/kg/hr infusion
79163|NCT03566329|Drug|Normal saline|Normal saline infusion with the same rate of infusion as the study drugs
79164|NCT03566316|Drug|Telmisartan/Amlodipine|
79165|NCT03566316|Drug|Rosuvastatin|
79166|NCT03566316|Drug|Telmisartan|
79167|NCT03566303|Drug|Rivaroxaban 15 mg|Rivaroxaban 15 mg BID
79168|NCT03566303|Drug|Warfarin|Warfarin
79169|NCT03566290|Drug|GTx-024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024. Subjects will be required to take one 3 mg Softgel capsule per day.
79170|NCT03566277|Behavioral|Self-monitoring|Participants will have access to a wrist-worn activity monitor and have a daily step goal
79171|NCT03566277|Behavioral|Incentives|Participants will have a deposit contract, wherein they will lose money if a goal is not reached, or double their money if a goal is reached
79172|NCT03566277|Behavioral|Feedback|Participants will receive text message feedback each day about progress towards their goal
79173|NCT03566264|Other|Non-Interventional|Non-Interventional
79174|NCT03566251|Other|Balance|Balance was assessed by Biodex Biosway Portable Balance System (Biodex Medical Systems Inc., Shirley, New York). Postural Stability (PS), Limits of Stability (LOS) and Modified Sensory Organization Tests (MSOT) were evaluated with this system. PS test assesses static balance during standing up by the ability to hold the center of gravity on the support surface. The test was performed on both feet and on the left and right foot separately. LOS test assesses how much the center of gravity is displaced on the support surface without losing balance during the standing position. MSOT assesses the effects of somatosensory, visual and vestibular senses on postural control during the standing position. It evaluates the sensory component of balance in two different visual conditions and on two different support surfaces.
79175|NCT03566251|Other|Functional mobility|Timed Up and Go (TUG) tests were used to evaluate functional mobility. The TUG measures the time it takes a subject to stand up from an armchair, walk a distance of 3 m, turn, walk back to the chair and sit down. Time was recorded in seconds with a stopwatch.
79176|NCT03566251|Other|Core stability|Core endurance and core strength, which are two specific components of core stability, were evaluated separately. Trunk flexor, trunk extensor, right and left side bridge and prone bridge tests were applied to assess the endurance of the core muscles. Tests were terminated when the subjects said they could not continue the test or when the test position was broken. A stopwatch was used for the measurements and the results were recorded in seconds. The power of core muscles was evaluated with sit-ups and modified push-ups tests. It was recorded how many times the subject could do each test for 30 seconds. The tests were repeated twice and the best measurement score was recorded for use in the statistical analyses.
79177|NCT03566251|Other|Trunk position sense|Trunk position sense was evaluated by the trunk reposition test with Dualer IQ digital inclinometer (J-TECH medical, Salt Lake City, UK, USA). Measurements were made in two levels: lumbosacral (LS) and thoracosacral (TS) regions. The testing took place while standing under three visual-surface conditions. Participants flexed the trunk approximately 30° in the sagittal plane, holding the position for a count of 3 seconds (position 1) and then participants attempted to repeat the previously attained angle. Participants indicated verbally when they felt they had reached the angle and held their position for a count of 3 seconds (position 2). The absolute difference in degrees between positions 1 and 2 was defined as the trunk reposition error (TRE) degree. Participants generated five scores for each visual-surface condition. For each condition, the highest and lowest scores were discarded and the mean of the remaining three scores represented the TRE score
79178|NCT03566238|Drug|A4250 (odevixibat)|A4250 is a small molecule and selective inhibitor of IBAT.
79179|NCT03566238|Drug|Placebo|Placebo identical in appearance to active drug (A4250)
79180|NCT03566225|Drug|Pioglitazone|Insulin sensitizing agents
79181|NCT03566225|Drug|Metformin|Insulin sensitizing agent
79182|NCT03566225|Drug|Clomiphene Citrate|Induction drug
79183|NCT03566212|Device|Conventional Syringe|local anesthesia was administered in first group using Conventional syringe
79184|NCT03566212|Device|Camouflage Syringe|local anesthesia was administered in second group using Camouflage syringe
79185|NCT03566199|Drug|Panobinostat Nanoparticle Formulation MTX110|Given IT
79186|NCT03566199|Drug|Convection-Enhanced Delivery (CED)|Undergo CED
79187|NCT03566186|Other|Phototherapy|Photobiomodulation or photobiostimulation, this technique is the application of monochromatic light that can influence cellular activity through inhibition or stimulation of chemical and biological functions.
79188|NCT03566186|Other|Placebo|The same procedures as in the active phototherapy group was applied to the placebo group; however, the emitter was disabled. The device was emit the same sounds regardless of the programmed mode (active phototherapy).
79189|NCT03566186|Other|Passive recovery|Participants was remain sat for passive recovery supervised by an independent therapist during the period when the other groups are received recovery strategies.
79190|NCT03566160|Device|Cryobiopsy probe, administered to study participants|Cryobiopsy probe as a tool for gastrointestinal biopsy
79191|NCT03566147|Biological|Human primary Retinal Pigment Epithelial (HuRPE) cells|HuRPE will be transplanted by a board-certified vitreoretinal surgeon, which will be administered into the subretinal space of experimental eye through a standard surgical approach.
79192|NCT03566134|Drug|DA-8010 Placebo|Participants receive placebo to match DA-8010 orally once a day.
79193|NCT03566134|Drug|DA-8010 2.5mg|Participants receive DA-8010 2.5mg orally once a day.
79194|NCT03566134|Drug|DA-8010 5mg|Participants receive DA-8010 5mg orally once a day.
79195|NCT03566134|Drug|Solifenacin 5mg|Participants receive solifenacin 5 mg orally once a day.
79196|NCT03566134|Drug|Solifenacin succinate placebo|Participants receive placebo to match solifenacin 5 mg orally once a day.
79197|NCT03566121|Other|Pelvic ultrasound / Urodynamic ultrasound|Gynecological consultation: calculating the score ICI-Q Ultrasound consultation: pelvic ultrasound Urodynamic ultrasound during a Valsalva manoeuvers
79198|NCT03566108|Procedure|VISTA|Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
79199|NCT03566108|Procedure|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
79200|NCT03566095|Behavioral|Coaching and Voices for Food Kit|Community Coaching and Voices for Food Kit
79201|NCT03566095|Behavioral|Voices for Food Kit|Voices for Food Kit
79202|NCT03566069|Drug|Intranasal Oxytocin|32IU (16IU*2) of OT, Sorbitol, Benzyl, alcohol glycerol, distilled water.
79203|NCT03566069|Other|Intranasal Placebo|32IU (16IU*2) of Sorbitol, Benzyl, alcohol glycerol.
79204|NCT03566056|Other|Complications to Whipples procedure|Patients undergoing the Whipple procedure often tend to have a lot of complications. This study aims to investigate what complications these patients experience
79205|NCT03566043|Genetic|RGX-121|Recombinant adeno-associated virus serotype 9 capsid containing human iduronate-2-sulfatase expression cassette
79206|NCT03566030|Drug|Tenofovir disoproxil fumarate 300mg|Administered Tenofovir disoproxil fumarate 300 mg QD
79209|NCT03566004|Diagnostic Test|Stool specimen collection|The stool specimen collection was performed at the hospital or at home using a disposable device to be placed on the toilet seat and an E-nat Tube sent by postal to the lab.
79210|NCT03565991|Drug|Avelumab|IV treatment
79211|NCT03565991|Drug|Talazoparib|Oral treatment
79212|NCT03565978|Device|BAMA solution|Use of BAMA cardiac post-discharge management solution for patients education and follow up management
79213|NCT03565965|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
79214|NCT03565965|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
79215|NCT03565952|Other|Cranial massage|Manual cranial therapy consisting of massage and cranial relaxing techniques, lasting 30 minutes each session approximately, for 3 weeks and one month follow-up. Manual therapy consists of a prone and supine cranial massage.
79216|NCT03565952|Other|Control group|The control group does not receive treatment
79217|NCT03565939|Biological|Trichuris suis ova|Eggs from the pig whipworm
79218|NCT03565939|Biological|Placebo|Solution without TSO
79219|NCT03565926|Other|Manual Therapy|"Articulation technique L4-S1~Lumbar neuromuscular technique~Fascial technique of crossed hands~Posteroanterior mobilizations of the lumbar vertebrae"
79220|NCT03565926|Other|Hypopressive exercises|Protocol 5 Hypopressive exercises
79221|NCT03565913|Drug|EffCaMgCit|Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.
79222|NCT03565913|Other|CaAcS|CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years
79223|NCT03565900|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose.
79224|NCT03565900|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
79225|NCT03565900|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
79226|NCT03565887|Drug|RVL-1201|RVL-1201 ophthalmic solution, 0.1%
79227|NCT03565887|Other|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
79228|NCT03565874|Device|Heart rate variability biofeedback|Before the start of the program and after one week of adherence to the program, two sessions will be conducted with a psychologist in order to define each participant's individual resonance frequency (i.e., breathing rhythm allowing for cardiac coherence), using the Nexus program from Mindmedia company. Then, each participant will receive training on the HRVB program using an Emwave device. The HRVB program itself will be carried individually for 20 min daily over the course of two weeks. Five daily sessions of 10 minutes will be considered as the minimum adherence to the program. Each participant will be asked to report in a diary all eventual major stressful life events.
79229|NCT03565861|Drug|Placebo|Intravenous vehicle
79230|NCT03565861|Drug|NP10679|NP10679
79231|NCT03565848|Procedure|Mesenteric vascular and nerve sparing surgery in laparoscopic segmental colorectal resection|Laparoscopic segmental colorectal resection performed by dissecting adherent to the intestinal wall with mesenteric vascularization and innervation entirely preserved.
79232|NCT03565835|Drug|Abiraterone Acetate|Abiraterone Acectate with Prednisone and with Discontinuation of GnRH Analogue
79233|NCT03565835|Drug|Prednisone|Abiraterone Acectate with Prednisone and with Discontinuation of GnRH Analogue
79234|NCT03565822|Other|Interview|individual interview and/or focus group Grounded theory qualitative analysis of data related to socio-demographic and child characteristics data First, data will be prepared for qualitative analysis. Digital audio files from the focus groups will be transcribed verbatim and questionnaire data will be entered into an Excel/word data file. Second, focus group data will be qualitatively analyzed using the constant comparative process. A qualitative data analysis program, NVivo11 (Victoria, Australia/ QSR International)) will be used to assist with this coding process.
79235|NCT03565809|Other|Incidence analysis|Incidence analysis between the 2 groups (ADRS/non ADRS). For each pair, an index date was defined as the ADRS identification date. In both groups, a 5-year period free of these three ADRS criteria was required before the index date, to ensure incident ADRS cases.
79236|NCT03565796|Behavioral|Personalized active referral plus financial incentive|Smokers will be introduced to various SC services in Hong Kong and be motivated to use the services.Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment.Smokers are informed at baseline that they will receive financial incentive (supermarket coupon HK$300) if they attend or use any of the SC services within 3-month.
79237|NCT03565796|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
79238|NCT03565796|Behavioral|Warning leaflet|The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
79296|NCT03565419|Device|Smart glasses|Participants confirm the real-time ultrasound image displayed on the viewer of smart glasses.
79239|NCT03565796|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
79240|NCT03565796|Behavioral|COSH booklet|A general smoking cessation self-help booklet
79241|NCT03565783|Biological|Cemiplimab|Given IV
79242|NCT03565770|Other|individual coaching|coaching on the phone or with messages on line twice a month in order to help patients to adjust their insulin doses and fill in their self-assessment test.
79243|NCT03565770|Other|Standard care|completion of the self-assessment test at inclusion, at M6 and M12 for all study participants
79244|NCT03565757|Behavioral|SMART intervention|All participants will attend a 90-minute SMART small group session. This session provides education on the stress response and the principles of gratitude, compassion, mindful presence, and resilient mindset. In addition to the class, there will be follow-up online and written resources.
79245|NCT03565744|Behavioral|B'N Fit POWER|Participants will undergo a medical assessment and using an Electronic Medical Record (EMR) template, providers will screen for a healthy weight and the 7 target behaviors. Participants will set goals with the provider to attain one of the target behaviors and will receive an EMR-generated treatment plan summarizing healthy weight and target behavior goals. At 20-minute follow-up visits during the school day, the provider will review weight and target behavior attainment and monitor co-morbidities and barriers to participation. Group 1 participants will also have access to daily MMCC afterschool programming from 3-6pm from September through May each year with tailored programming including weekly core nutrition, behavior, and cooking classes and at least five hours of physical activity.
79246|NCT03565731|Behavioral|ACT-PA|The overall goal of the intervention is to increase bout-related moderate-to-vigorous physical (MVPA) activity to greater than 200 minutes per week. The basic structure is an initial on-site, group-based intervention workshop, written materials, weekly emails, and monthly phone calls for a total of 3 months.
79247|NCT03565718|Behavioral|Dietary Intervention: Restaurant|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.
79248|NCT03565718|Behavioral|Dietary Intervention: Standard/Grocery|Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
79249|NCT03565705|Procedure|Open abdominal prostatectomy|Patients undergo standardized open abdominal prostatectomy.
79250|NCT03565692|Biological|the lung mycobiota and microbiota profile|"All sputum samples will follow regarding mycological and metagenomic analyses as summarized :~Pre-analytical treatment combining pre-treatment with mucolytic agent and sonication action~Separation of the pellet and supernatant, stored at -20 ° C until testing~Galactomannan (GM) Assay on each sputum supernatant to correlate with Aspergillus colonization history~Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification)~Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts.~Pseudomonas aeruginosa load measured by qPCR"
79251|NCT03565692|Biological|the gut mycobiota and microbiota profile|All stool samples will follow regarding mycological and metagenomic analyses as summarized : - Separation of the pellet and supernatant, stored at -20 ° C until testing - Targeted metagenomics of bacterial communities (based on 16S amplification) and of fungal community (based on ITS2 amplification) - Bioinformatic analysis of metagenomics raw data, correlation with bioclinical data of each patient, statistical analysis, and characterization of phenomena of co-evolution/co-exclusion according to evolutionary ecology concepts. - Measurement of inflammation.
79252|NCT03565679|Device|MEDLINE RENEWAL PULSE OXIMETRY SENSORS|An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. Pulse oximetry monitoring is considered a standard physiological measurement and is used by clinicians in everyday situations to estimate arterial oxygen saturation. Because an arterial sample of blood is not required to make the measurement, the pulse oximeter can provide non-invasive real time information.
79253|NCT03565679|Device|CO-OXIMETRY SENSORS|A whole blood analyzer (CO-Oximeter) is used as the reference standard device for obtaining the functional SaO2 value from arterial blood samples obtained during the study.
79254|NCT03565666|Device|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog|iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog
79255|NCT03565666|Drug|iLet Bionic Pancreas insulin-only configuration with Fiasp|iLet Bionic Pancreas insulin-only configuration with Fiasp (faster insulin aspart)
79256|NCT03565666|Other|Usual care|Usual care
79257|NCT03565653|Other|High dietary salt|~4,000 mg Na+/day
79258|NCT03565653|Other|Placebo|dextrose
79259|NCT03565640|Device|Capio Slim Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Capio Slim Device.
79260|NCT03565640|Device|Anchorsure Device|Participants who have been assigned to sacrospinous ligament fixation for pelvic organ prolapse will have sacrospinous ligament fixation performed with the Anchorsure Device.
79261|NCT03565627|Device|Exercise app: 7 Minute Workout Challenge|7 Minute Workout Challenge by Fitness Guide Inc. combines aerobic and resistance training into short, 7 minute high intensity circuit training.
79262|NCT03565627|Device|Running app: One You Couch to 5K|One You Couch to 5K by Public Health England is a popular app that aims to increase fitness by asking the user to follow a running programme with a goal to run for 30 min without break.
79263|NCT03565614|Behavioral|Reablement|Intensive home-based rehabilitation is delivered up to 3 months by an interprofessional team (nurse, enrolled nurse, physiotherapist, occupational therapist, social worker). The entire team completed a 5-week college course. The team negotiates goal-directed contents of the rehabilitation initiatives with the user. Each user is handled deliberately based on decisions in the team in cooperation with the care managers overarching goals in admitted services. All participants have personal contact persons, and these contact persons have twice the time per participant as compared to traditional home care. The interprofessional team also has regular meetings to discuss every participant, and all rehabilitation goals activities related to those are documented.
79368|NCT03564821|Drug|Ivosidenib|Ivosidenib is an inhibitor of the protein IDH1
79264|NCT03565614|Behavioral|Traditional home care|Traditional home care and required rehabilitation efforts as by the municipality's current practice. Includes the same professions as is included in the reablement intervention, but the team has had no joint college course, does not use the systematic goal-directed and negotiated approach as the reablement intervention, and has about half the time per participant as compared to the reablement intervention.
79265|NCT03565601|Other|Follow-up|Clinical data, radiological data and laboratory tests follow-up
79266|NCT03565588|Behavioral|Education session with fixed incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants assigned to receive fixed incentives will receive payment through mobile payments. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
79267|NCT03565588|Behavioral|Education session with lottery incentive|"All participants will receive an education session on the risk of HIV infection and benefits from medical male circumcision. The sessions will be implemented by trained male healthcare workers who have undergone VMMC.~All participants will receive contributions towards transport costs to access medical male circumcision at participating clinics. On completing VMMC, participants will participate in a lottery with prizes equivalent in expected value to the fixed incentives. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
79268|NCT03565575|Behavioral|Interactive tablet-based quiz|"Intervention participants play an interactive tablet based quiz including the following information components:~Risks of HIV infection under different scenarios such as between two hypothetical individuals and with different behaviours.~Interactive counselling on key facts around PrEP, its usability and local availability~All individuals will have the option to sign up for contact by a nurse from the health clinic to discuss PrEP further and make an appointment for a visit. Participants will also be given a PrEP referral letter which they can present directly at one of the participating study clinics to begin PrEP. In two sites a community-led intervention will also be implemented to address social obstacles and to increase support from peers, families and social structures."
79269|NCT03565562|Other|Promotion of the e-health tool by local authorities|Local authorities participating in the trial will select a referent person who will be in charge of the implementation and follow-up of the promotion. A promotion toolkit with recommendations, posters, web banners, leaflets and ready-made messages and press articles will be provided to the local authorities.
79270|NCT03565562|Other|Promotion of the e-health tool by local authorities and GPs|In those local authorities, GPs will participate passively to the promotion of the e-health tool, by providing posters and leaflets in their waiting rooms.
79271|NCT03565549|Behavioral|Mnemonic|A mnemonic used as a memory aid
79272|NCT03565549|Behavioral|CCHR rule|A list of the CCHR items
79273|NCT03565536|Drug|Nexavar|for Unresectable tumors ,After the patient had diagnosed as anaplastic thyroid cancer, Nexavar 400mg Bid was used for neoadjuvant treatment. At 1 month and 2 months after treatment, it was assessed whether surgery could be performed.
79274|NCT03565536|Procedure|operation|If computed tomography (CT) evaluates for possible surgical treatment, complete thyroidectomy and cervical lymph node dissection are performed to completely resect thyroid tissue and metastatic lymphatic tissue.
79275|NCT03565536|Radiation|External radiation therapy|As the successful surgery, then continue on the basis of taking on Nexavar plus external beam radiation therapy
79276|NCT03565523|Other|Beetroot|Containing 385 mg nitrate
79277|NCT03565523|Other|Placebo beverage|<0.1 mmol nitrate in sucrose solution with beet coloring
79278|NCT03565510|Dietary Supplement|High-Protein Diet|The high-protein diet is composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement.
79279|NCT03565497|Behavioral|Wellness Education Control Condition|As per arm of the same name
79280|NCT03565497|Behavioral|Mindfulness Training|As per arm of the same name
79281|NCT03565497|Behavioral|Mindfulness Training Plus IE|As per arm of the same name
79282|NCT03565484|Drug|two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)|Patients will receive a 14-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.
79283|NCT03565484|Drug|one proton pump inhibitor(PPI)|All the patients need this drug.
79284|NCT03565484|Drug|two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)|Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.
79285|NCT03565484|Drug|Colloidal Bismuth Pectin|All the patients treated with 14-day bismuth-based quadruple therapy need this drug.
79286|NCT03565484|Drug|two antibiotics for failed eradication(tetracyclin,furazolidone)|If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
79287|NCT03565471|Diagnostic Test|Echocardiography|Standard echocardiography.
79288|NCT03565471|Diagnostic Test|Right side catheterization|Right side catheterization with the purpose of measuring pulmonary vascular pressures and blood saturation.
79289|NCT03565471|Diagnostic Test|Exercise test|Exercise test on a supine bicycle with gradual increase in work load while wearing a mask that measures ventilation, oxygen uptake, carbon dioxide release and respiratory exchange rate.
79290|NCT03565471|Diagnostic Test|Holter monitor|Holter monitor worn for 2 whole days registering heart rate.
79291|NCT03565458|Drug|Gemigliptin|zemiglo 50mg,LG Chem
79292|NCT03565458|Drug|Dapagliflozin|forxiga, dapagliflozin 10mg
79293|NCT03565458|Drug|Empagliflozin|jardiance 25mg, empagliflozin
79297|NCT03565406|Drug|Mocetinostat Induction Phase + Ipilimumab + Nivolumab|"Treatment Cycle 1: Mocetinostat at a dose of 90 mg PO TIW; ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles.~Treatment Cycle 2: Mocetinostat at a dose of 70 mg PO TIW ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg during the 12-week induction period. The induction phase will last for 2 treatment cycles."
79298|NCT03565406|Drug|Mocetinostat Maintenance Phase + Ipilimumab + Nivolumab|"De-escalation Phase 1: Mocetinostat will be administered 50 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 1 mg/kg and nivolumab will be administered IV at a dose of 3 mg/kg~De-escalation Maintenance Phase 2: Mocetinostat will be administered 40 mg PO TIW during each 84-day treatment cycle. Ipilimumab will be administered IV at a dose of 0.3 mg/kg and nivolumab will be administered IV at a dose of 1 mg/kg during period"
79299|NCT03565393|Combination Product|Fibersol-2|A placebo-controlled, randomized; double-blind 2 arm trial
79300|NCT03565380|Other|12-week community-based Tai Chi rehabilitation program|"The program will be held at the Flora Ho Sports Centre at The University of Hong Kong twice per week (90 minutes each) for 12 weeks. Each training session will involve warm-up, Tai Chi training, and cool down exercises. A certified Tai Chi for Arthritis instructor will teach the 12-form Sun style Tai Chi alongside behavioral modification education in a group of 6 to 8 participants. Participants will be instructed to practice at least 30 minutes of daily Tai Chi at home. Upon completion of the 12-week intervention, participants will be encouraged to continue their home exercises. A research personnel will phone participants once a month to remind them to document their Tai Chi practice duration on the exercise logbooks until the post-operative 52-week follow-up."
79301|NCT03565380|Other|Usual post-operative care without outpatient physiotherapy|No intervention will be provided
79302|NCT03565380|Other|Untreated asymptomatic controls|No intervention will be provided
79303|NCT03565367|Other|Gadolinium|gadolinium enhanced MRI
79304|NCT03565367|Drug|Hyperpolarized Carbon C 13 Pyruvate|Given IV
79305|NCT03565367|Procedure|Magnetic Resonance Imaging|Undergo MRI
79306|NCT03565367|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MRSI
79307|NCT03565354|Drug|iron isomaltoside(Monofer®)|intravenous iron isomaltoside
79308|NCT03565341|Device|PiQo4|PiQo4 Laser System for treatment of Melasma
79309|NCT03565328|Dietary Supplement|Niagen|NR will be started at 500 mg daily (250 mg BID) be increased at two weekly intervals by 250 mg/dose (BID) (500 mg/day) to a final dose of 1000mg PO BID (2000 mg/day).
79310|NCT03565315|Biological|VRC-HIVMAB95-00-AB (10E8VLS)|10E8VLS is an Investigational Monoclonal Antibody targeted to the membrane proximal external region and proximal viral membrane lipid region of HIV-1.
79311|NCT03565315|Biological|VRC-MAB075-00-AB (VRC07-523LS)|VRC 07-523LS is an investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
79312|NCT03565302|Drug|Formoterol|Subjects are treated with daily inhalation of formoterol
79313|NCT03565302|Drug|Terbutaline|Subjects are treated with daily inhalation of terbutaline
79314|NCT03565302|Other|Placebo|Subjects are treated with placebo
79315|NCT03565289|Diagnostic Test|Blood sample collection|During a routine blood draw an additional tube of blood will be taken for the study.
79316|NCT03565276|Drug|Tranexamic Acid|A single dose of intravenous TxA in 100ml of 0.9% sodium chloride at 50mg/min, via a dose-escalation design
79317|NCT03565250|Other|self understanding interview|semi-structured interview designed for assessment of identity according to Damon & Hart's 7-dimension develomental model
79318|NCT03565237|Biological|RIXUBIS: On-Demand|RIXUBIS used under standard clinical practice in India: On-Demand treatment.
79319|NCT03565237|Biological|RIXUBIS: Prophylaxis|RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
79320|NCT03565211|Drug|Progesterone vaginal ring (PVR)|A flexible, non-degradable PVR containing progesterone in micronized formulation and dispersed evenly throughout the ring.
79321|NCT03565185|Other|robot-assisted gait training|Investigators will use robot-assisted gait training for rehabilitation of stroke
79322|NCT03565172|Diagnostic Test|isokinetic dynamometer with ultrasound|children are lying prone on a isokinetic dynamometer with ultrasound which stretches spastic and paretic plantarflexors muscles very slowly until maximal torque tolerated. The parameters can be measured.
79323|NCT03565172|Other|Visual Analog Scale (VAS)|the discomfort level will be measured by Visual Analog Scale (VAS) completed by children. 0 = no discomfort and 10 = maximum discomfort
79324|NCT03565172|Diagnostic Test|Stretching|the ankle of children will be mobilized for 5 minutes (first two weeks) to 10 minutes (last two weeks).
79325|NCT03565159|Biological|Prevenar 13|Pneumococcal polysaccharide conjugate vaccine
79326|NCT03565159|Other|Sodium Chloride 0.9%|Placebo
79327|NCT03565146|Device|PiQo4 Laser System|PiQo4 Laser System for treatment of pigmented lesions
79328|NCT03565133|Dietary Supplement|Quinine sham feeding quinine|Oral sham feeding with quinine
79329|NCT03565133|Dietary Supplement|Gastric quinine|A gastric capsule containing quinine
79330|NCT03565133|Dietary Supplement|Oral sham feeding placebo|Oral sham feeding with placebo (tap water)
79331|NCT03565133|Dietary Supplement|Gastric placebo|A gastric capsule containing placebo (cellulose)
79332|NCT03565120|Radiation|Aggressive Thoracic Radiotherapy|The target of the radiotherapy includes primary tumor and the locoregional positive lymph nodes, with a dose(BED)≥53Gray(Gy)
79333|NCT03565094|Drug|Lu AF28996 solution|"Oral solution (0.1-0.2 mg/mL)~Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses"
79334|NCT03565094|Drug|Lu AF28996 capsule|hard capsule orally QD: one dose lower than the highest dose level in part A
79335|NCT03565081|Device|PWS elastic band training group|PWS participants received 9 sets exercises for the major muscle groups, over 24 weeks, three times a week, for a total of 72 sessions.
79366|NCT03564834|Procedure|Laparoscopic gastrectomy|Patients will receive laparoscopic gastrectomy within one week after randomization.
79367|NCT03564834|Procedure|Open gastrectomy|Patients will receive open gastrectomy within one week after randomization.
79336|NCT03565068|Drug|MK-8189|MK-8189 4 mg tablet(s) administered orally QD; total dose titrated from 4 mg to 24 mg over the course of an 18-day treatment period in Panels A, B, and C. For Panel D, MK-8189 4 mg tablet administered orally QD; total dose titrated from 8 mg to 48 mg over the course of a 15-day treatment period.
79337|NCT03565068|Drug|Placebo|Placebo tablet(s) administered orally QD over the course of an 18-day treatment period in Panels A, B, and C. For Panel D, placebo tablets administered orally QD over the course of a 15-day treatment period.
79338|NCT03565068|Drug|Background Atypical Antipsychotic (AAP) Therapy|Participants with schizophrenia in Panel C will continue background therapy with an AAP medication (e.g., Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone) throughout the study. These participants should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
79339|NCT03565055|Behavioral|IPCST|"Integrative Psychosocial & Community Skills Training (IPCST) programme~The IPCST programme includes:~psychoeducation, internalized stigma reduction, & strength and coping enhancement~motivational interviewing skills~Neurocognitive and social cognitive training (Au, Tsang, So, Bell, Cheung, et al., 2015)~augmented supported employment with social skills training (Tsang, Fung, Li, Leung & Cheung, 2010) and~family and patient involvement in care"
79340|NCT03565055|Behavioral|E.A.S.Y|"The E.A.S.Y. (Early Assessment Service for Young People with Early Psychosis) Programme is a service programme for people suffering from early psychosis.~The E.A.S.Y programme includes:~Extensive public education~Early referral and assessment~Ongoing treatment services"
79341|NCT03565042|Procedure|Arthroscopy|Arthroscopy of swollen joint (ankle/knee)
79342|NCT03565029|Drug|XELOX|Capecitabine and Oxaliplatin (4x cycles)
79343|NCT03565029|Radiation|Radiotherapy|Pelvic radiotherapy
79344|NCT03565016|Other|no interventional study|no interventional study
79345|NCT03565003|Drug|JAB-3068|25 mg,100 mg
79346|NCT03564990|Other|interactive, multifaceted approach|A health education module consisting of a lecture and workshop was incorporated into a health-care course.
79347|NCT03564990|Other|conventional approach|conventional follow-up
79348|NCT03564977|Biological|CD19-targeted CAR-T cells|MDR+ patients after autologous stem cell transplantation were treated with CD19-targeted CAR-T cells.
79349|NCT03564964|Drug|SUVN-502|Tablet
79350|NCT03564951|Procedure|Atrial fibrillation ablation|ablation of Atrial fibrillation using spatio-temporal dispersion
79351|NCT03564951|Procedure|Atrial fibrillation ablation|ablation of concordance zones using isochrone and voltage maps
79352|NCT03564938|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg, once daily, 3 weeks on therapy and 1 week off therapy.
79353|NCT03564925|Procedure|Wide area circumferential ablation|Wide area circumferential ablation with contact force catheter will be performed in Patients allocated in this group,the induction of atrial fibrillation by isoproterenol or programmed stimulation and burst pacing will be performed. If frequent atrial premature beats are found beyond pulmonary vein, activation mapping will be performed for eliminating the triggers. If atrial tachycardias(ATs)are induced, activation mapping the ATs and ablation will be performed. Electrical isolation of pulmonary veins and elimination the triggers and ATs induced by isoproterenol or programmed stimulation and burst pacing are the endpoints of ablation
79354|NCT03564925|Procedure|Cryoballoon ablation|In the cryoballoon procedures, pulmonary vein isolation (PVI) was achieved using fluoroscopic guidance to position the cryoballoon catheter. Once PV-to-balloon occlusion was confirmed by retrograde radiopaque contrast agent retention, circumferential ablation was performed by freezing with a single-shot delivery of coolant to the balloon.
79355|NCT03564912|Drug|Capecitabine Oral Tablet [Xeloda]|2 week group: capecitabine 1000mg/m2 d1-10; oxaliplatin 85mg/m2; q2w 3 week group: capecitabine 1000mg/m2 d1-14; oxaliplatin 130mg/m2; q3w
79356|NCT03564899|Behavioral|Lighter intensity physical activity intervention|Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve
79357|NCT03564899|Behavioral|Higher intensity physical activity intervention|Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
79358|NCT03564886|Drug|Hyperosmolar Saline|The hyperosmolar solution will be created by adding 120cc of 23.4% NS solution to a 3L bag of LR.
79359|NCT03564886|Drug|Normal saline|Lactate Ringer's (LR, 273mOsm/L)
79360|NCT03564873|Drug|Omacetaxine|Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
79361|NCT03564873|Drug|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
79362|NCT03564873|Drug|Omacetaxine|Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
79363|NCT03564873|Drug|Azacitidine|Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
79364|NCT03564860|Procedure|Device data collection|Collection of device electrograms and 12-lead ECG during a device follow-up visit
79365|NCT03564847|Behavioral|LTP Plus|"LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management."
79369|NCT03564808|Drug|MSC|Adipose tissue enriched with mesenchymal stem cells
79370|NCT03564795|Device|KeraStat Gel|Wound dressing for partial thickness burns
79371|NCT03564795|Device|Silver Sulfadiazine|Wound dressing for partial thickness burns
79372|NCT03564782|Biological|PVSRIPO|The live, attenuated, oral (Sabin), serotype 1 poliovirus vaccine booster will be administered 1 week before PVSRIPO injection. The study drug, PVSRIPO, is the live attenuated, oral (Sabin) serotype 1 poliovirus vaccine containing a heterologous internal ribosomal entry site (IRES) derived from the human rhinovirus type 2 (HRV2). It will be given at a dose of 1x10^8 TCID50 (tissue culture infectious dose) directly into the breast tumor.
79373|NCT03564769|Behavioral|Intervention Arm|Individuals randomized to the intervention group will receive skin cancer screening educational materials.
79374|NCT03564769|Other|AAD SPOTmeⓇ skin cancer screening|All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
79375|NCT03564756|Dietary Supplement|Vitamin C|1000mg Vitamin C per day
79376|NCT03564743|Diagnostic Test|Evaluation of ASAS criteria|Perform ASAS criteria at the time of physician diagnosis of chronic low back pain in rheumatological practice.
79377|NCT03564730|Procedure|Simultaneous Knee Arthroplasty (UKA)|Patient will have both knees completed under one anesthetic.
79378|NCT03564730|Procedure|Staged Knee Arthroplasty (UKA)|Patient will have knees completed under 2 anesthetics.
79379|NCT03564717|Other|Segmented three dimensionally printed transfer tray|Segmented indirect bonding transfer tray
79380|NCT03564704|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ALL-LBL protocol.
79381|NCT03564704|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
79382|NCT03564704|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
79383|NCT03564704|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
79384|NCT03564704|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ALL-LBL protocol.
79385|NCT03564704|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79386|NCT03564704|Drug|Methotrexate|Methotrexate will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79387|NCT03564704|Drug|6-mercaptopurine.|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ALL-LBL protocol.
79388|NCT03564704|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79389|NCT03564704|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ALL-LBL protocol.
79390|NCT03564704|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ALL-LBL protocol.
79391|NCT03564704|Procedure|Intrathecal injection|Intrathecal injection of chemotherapy will be performed in PDT-ALL-LBL protocol.
79392|NCT03564704|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia/lymphoma in PDT-ALL-LBL protocol.
79393|NCT03564704|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ALL-LBL protocol.
79394|NCT03564704|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be added to LBL patients with available donor in PDT-ALL-LBL protocol.
79395|NCT03564704|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ALL-LBL for bone marrow and cerebrospinal fluid samples.
79396|NCT03564704|Diagnostic Test|FISH|FISH will be added to PDT-ALL-LBL for bone marrow samples.
79397|NCT03564704|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ALL-LBL protocol.
79398|NCT03564704|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ALL-LBL protocol.
79399|NCT03564704|Drug|Chidamide|HDACi chidamide will be added to induction regimen, consolidation and maintenance module of PDT-ALL-LBL.
79400|NCT03564704|Diagnostic Test|PET-CT scan|PET-scan will be performed for T-LBL patients for MRD assessment in PDT-ALL-LBL.
79401|NCT03564691|Drug|MK-4830|MK-4830 will be administered intravenously (IV) Q3W. In Part C, MK-4830 will be administered after completion of pembrolizumab infusion. Dose escalation will proceed based on emerging safety and tolerability data of MK-4830 as monotherapy (Part A and B) and as combination therapy with pembrolizumab (Part C). For each dose level, an assessment will be made of the safety and tolerability data in order to define the next dose level to be tested.
79402|NCT03564691|Drug|Pembrolizumab|Pembrolizumab will be dosed at 200 mg IV Q3W - Part C only.
79403|NCT03564678|Dietary Supplement|Levocarnitine|Given IV
79404|NCT03564678|Drug|Vitamin B Complex|Given PO
79405|NCT03564665|Dietary Supplement|400mg Magnesium Glycinate BID|400mg Magnesium Glycinate BID for 8 weeks.
79406|NCT03564665|Other|Placebo|Placebo BID for 8 weeks.
79407|NCT03564652|Dietary Supplement|LNS PLW|Lactating women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.
79408|NCT03564652|Drug|Azithromycin|A single prophylaxis dose of 20 mg/kg in suspension form, reconstituted by trial staff before dose administration by the same.
79409|NCT03564626|Other|Health-IT Only|"Training patient and caregiver on Patient Buddy and EncephalApp~Counseling regarding readmission~Daily contact through app~Standard of care counseling regarding readmission and discharge instructions~Follow up phone calls and visits per standard of care or as necessitated by app"
79410|NCT03564626|Other|Health-IT + Scheduled Follow Up|"Training patient and caregiver on Patient Buddy and EncephalApp~Counseling regarding readmission~Daily contact through app~Standard of care counseling regarding readmission and discharge instructions~Follow up phone calls at Week 1 and Week 3~In-person follow up visits at Week 2 and Week 4"
79411|NCT03564613|Drug|DTG|Subjects with DTG exposure during any trimester will be included
79491|NCT03563963|Other|Air|Air will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
79412|NCT03564587|Behavioral|AWAKE|Behavioral intervention called Achieving Wellness After Kancer in Early Life (AWAKE) is focused on increasing hope in order to improve quality of life and health-promoting behaviors in survivors of young adult cancer. The AWAKE mobile app contains eight modules for participants to complete over 8 weeks with the ability to review prior modules. Participants receive a prompt on their mobile device weekly to complete each module and/or they will receive a text reminder. The app includes health education messaging, weekly homework assignments, the ability to track progress towards goals with self-monitoring and graphical depictions of progress, videos of inspirational materials, and a portal for interacting with their coach.
79413|NCT03564574|Combination Product|Lipid Emulsion|All patients in the 'Study group' received a single dose of 100 ml of 20 percent Lipid emulsion as an infusion over 1 hour along with routine treatment as per institution protocols. Atropine was administered to patients by doubling dose method, which comprised of administering atropine starting from 2mg and to double the dose and administer till complete atropinization. Following this an infusion of 10 percent of the atropinizing dose was given every hour. Patients were evaluated using a standardized clinical interview, physical examination, laboratory tests.
79414|NCT03564548|Combination Product|PPP001|Group assigned to PPP001 during the open-label
79415|NCT03564548|Drug|FBT|Group assigned to FBT during the open-label
79416|NCT03564548|Combination Product|Active PPP001 with FBT Placebo|Group assigned to active PPP001 in the randomized placebo-controlled trial
79417|NCT03564548|Drug|Active FBT with PPP001 Placebo|Group assigned to active FBT in the randomized placebo-controlled trial
79418|NCT03564535|Device|Self fixating group|Monofilament polyester mesh with polylactic acid (PLA) microgrips of size 11*15 will be used. It is an isoelastic large-pore knitted fabric with a density of 73g/m2 at implantation and 38g/m2 after microgrips absorption which will be at 18 months. The resorbable micro grips provide immediate adherence to surrounding muscle and adipose tissue during the initial days post hernia surgery, serving as an alternate method of fixation to traditional sutures, tacks, staples, or fibrin sealants. No additional tacks, staples, sutures, or fibrin sealant will be used.
79419|NCT03564535|Device|Tacker fixation group|Patients will be undergoing polyester mesh ﬁxation with non-absorbable tacks. The tacks would be used such that they avoid bony prominences and vascular and neural structures. One or two tacks will be put at the Cooper's ligament and another applied laterally superior to the iliopubic tract in the anterior abdominal wall. In any patient, the maximum number of tacks applied will not exceed three.
79420|NCT03564522|Procedure|cardiac catheterization|cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
79421|NCT03564522|Radiation|Cardiac MRI|If clinically indicated, the study will collect data from MRIs.
79422|NCT03564509|Drug|FE 999302 (dose 1) and follitropin delta|Dose 1 of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualised follitropin delta dose
79423|NCT03564509|Drug|FE 999302 (dose 2) and follitropin delta|Dose 2 of FE 999302, a rhCG solution for subcutaneous injection; individualised follitropin delta dose
79424|NCT03564509|Drug|FE 999302 (dose 3) and follitropin delta|Dose 3 of FE 999302, a rhCG solution for subcutaneous injection; individualised follitropin delta dose
79425|NCT03564509|Drug|FE 999302 (dose 4) and follitropin delta|Dose 4 of FE 999302, a rhCG solution for subcutaneous injection; individualised follitropin delta dose
79426|NCT03564509|Drug|FE 999302 (dose 5) and follitropin delta|Dose 5 of FE 999302, a rhCG solution for subcutaneous injection; individualised follitropin delta dose
79427|NCT03564509|Other|Placebo and follitropin delta|Placebo and individualised follitropin delta dose
79428|NCT03564496|Other|Active tDCS|The simultaneous tDCS will be performed at up to 2 mA dose intensity to determine CMRO2 changes from when the tDCS is on when the tDCS is off. The stimulation (left anodal at DLPFC regions) consists of 15-min up to 4 mA tDCS using 5x5 cm electrode sponge with ~30s ramp-up and ramp-down periods.
79429|NCT03564496|Other|Sham (placebo) stimulation|MRI-compatible tDCS off (immediately before and after tDCS)
79430|NCT03564470|Drug|Chidamide|Chidamide will be administrated at dose of 10mg/day in chidamide arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for chidamide arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (chidamide, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (chidamide, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
79431|NCT03564470|Drug|Dasatinib|Dasatinib will be administrated at a dose of 100mg/day in dasatinib arm in PDT-Ph-Like protocol. PDT-Ph-Like protocol for dasatinib arm consists of diagnostic test (bone marrow aspiration, flow immunophenotyping, karyotyping，FISH, NGS, Flow-MRD), induction regimen (dasatinib, prednisone, vincristine, cyclophosphamide, idarubicin, pegaspargase), consolidation regimen (dasatinib, cytarabine, methotrexate, dexamethasone, cyclophosphamide, etoposide, 6-mercaptopurine, pegaspargase), MRD assessment and maintenance regimen, intrathecal injection chemotherapy, radiation therapy for CNS-involved leukemia and allogeneic hematopoietic stem cell transplantation.
79432|NCT03564457|Other|No interventions will take place (observational)|No interventions will take place (observational)
79433|NCT03564444|Biological|Bivalent influenza vaccine|A single dose of Influenza Vaccine 10^(7.0 +/- 0.5) FFU strain of bivalent influenza vaccine will be administered as intranasal spray on Day 1.
79434|NCT03564444|Other|Placebo|A single dose of placebo matched to bivalent influenza vaccine will be administered as intranasal spray on Day 1.
79435|NCT03564431|Device|Magnetic resonance|magnetic resonance spectrum of brain
79488|NCT03563976|Other|Retrospective Study|The medical charts are the subjects. The institutional charts will be identified by the use of definitive radiation therapy correlating with an early stage lung cancer diagnosis during the above time frame. The data from these charts will be entered into a password protected excel spreadsheet. The charts will be identified by name, medical record number, date of birth, and social security number. These are all patients treated by all hospitals and clinics affiliated with UTSW and Parkland. At the time of study, some of the patients will have expired but some will be alive and in the regional North Texas area. Thus, given the minimal risk nature of this retrospective chart review, we could not reasonably conduct this research with a full waiver of consent. The NLST external dataset is proved by the NCI, with no identifying characteristics.
79436|NCT03564418|Procedure|Ultrasound-Guided Thermocoagulation of Lumbar facet joints|"Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
79437|NCT03564418|Procedure|Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints|"Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds."
79438|NCT03564405|Device|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
79439|NCT03564392|Behavioral|Acceptance Based Behavioral Intervention|This intervention focuses on acceptance-based strategies with an emphasis on willingness to experience less pleasurable internal experiences (e.g., pleasure from eating calorically-dense foods) and aversive internal experiences (e.g., hunger, food cravings). Strategies to increase this willingness will be taught, including defusion (i.e., getting psychological distance from internal experiences to allow oneself to act independently of them). Mindful decision-making, as it relates to eating and exercise, will also be emphasized. Clarification and commitment to core values is another key component, as living life in accordance with one's values (e.g., health) makes willingness to make difficult choices worthwhile. Standard behavioral techniques for weight loss (i.e., self-monitoring, stimulus control, psychoeducation) will also be included.
79440|NCT03564379|Drug|JNJ-42165279|25 mg JNJ-42165279 tablet will be administered orally.
79441|NCT03564379|Drug|Placebo|Matching placebo tablet will be administered orally.
79442|NCT03564353|Device|tDCS|tDCS
79443|NCT03564340|Drug|REGN4018|REGN4018 will be administered in a series of dose escalation cohorts by intravenous (IV) infusion during 6-week cycle (42 days).
79444|NCT03564340|Drug|cemiplimab|Cemiplimab will be administered by IV infusion once a REGN4018 monotherapy dose has been selected .
79445|NCT03564327|Procedure|Wide antrum circle ablation|As standard hospital policy
79446|NCT03564327|Procedure|External electric cardioversion|Three attempts (200-250 joules)
79447|NCT03564314|Other|SUPPORT AKI Clinical Decision Support|Surgical units will receive a multidimensional clinical decision support intervention consisting of: (1) electronic and non-computerized tools to alert for early recognition of AKI, (2) educational program for physicians and nursing staff, (3) decision support tools with guidance on fluid therapies, medication management, investigations for AKI, and consultation with specialists.
79448|NCT03564301|Drug|Placebo oral capsule|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the placebo to be taken during the following days will be given to the patient.
79449|NCT03564301|Drug|Metronidazole 250 MG|Immediately after the end of non surgical treatment of periimplantitis and depending on the result of randomization, the exact number of tablets of the antibiotic to be taken during the following days will be given to the patient.
79450|NCT03564288|Drug|SKI-G-801|SKI-G-801 is administered as an IV infusion over 10 minutes
79451|NCT03564275|Radiation|Proton Boost|13-15 treatments with proton therapy given as a boost to standard of care photon therapy
79452|NCT03564262|Other|Low Sodium Meal (138 mg sodium)|One Low Sodium Meal
79453|NCT03564262|Other|High Sodium Meal (1,495 mg sodium)|One High Sodium Meal
79454|NCT03564249|Device|MiniCap|The MiniCap device consists of small, completely inert mini-capsules that, once ingested, can be imaged inside the gastrointestinal tract using MRI, thereby creating a new MRI alternative to the radiopaque marker X-ray test to measure gut transit. The MRI mini- capsules are visualised in the gut using a single fat, water, in-phase and out-of-phase scan
79455|NCT03564236|Device|Nasal High Flow Therapy|Nasal High Flow Therapy (nHFT) is an innovative therapy for patients with respiratory diseases. It supplies heated, humidified, and oxygen-enriched air at high flow rates through a nasal cannula. Because the air is provided through an open system with a nasal cannula, it is relatively easy to apply and suggested to be very comfortable for patients. The technique has been shown to be effective in the treatment of hypoxemic respiratory failure, mainly in neonates[2] and patients with acute hypoxemic respiratory failure on intensive care units (ICU).[3]
79456|NCT03564236|Other|Standard care|Standard regular care of a COPD exacerbation
79457|NCT03564210|Behavioral|Screen time permitted|Cohort will not be directed to abstain from screen time
79458|NCT03564210|Behavioral|Screen Time Abstain|Cohort will be directed to abstain from screen time
79459|NCT03564197|Other|18F-PD-L1|18F-PD-L1 PET/CT scan
79489|NCT03563963|Drug|Ropivacaine 0.5% Injectable Solution|Ropivacaine 0.5% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
79492|NCT03563950|Drug|Rifampin|Specified dose on specified days
79493|NCT03563950|Drug|BMS-986224|Specified dose on specified days
79494|NCT03563937|Drug|Phenprocoumon|Follow the physician's prescription.
79460|NCT03564184|Behavioral|MT during NICU|Music therapy (MT) by trained music therapist, 3 times/week for 30-40 minutes/session during NICU hospitalization. Involves primary caregiver and infant in musical communication matched to infant post-menstrual age, family/cultural preferences, and infant readiness for stimulation. Music therapist assesses infant´s needs and behavior state, supports caregiver in using basic touch (e.g., hand lightly and statically on infant´s chest or back to perceive breathing pattern) and caregiver´s hummed/sung voice matched to infant behavioral responses, to promote infant state regulation and bonding. Music includes input from music therapist as needed, and multimodal aspects such as gentle dynamic touch when infant demonstrates readiness. MT may occur while infant is held in a static manner by caregiver or is resting in his/her isolette or basinet. MT may occur during skin-to-skin care, if such care is part of standard care.
79461|NCT03564184|Behavioral|MT after NICU|Music therapy offered by trained music therapist, 7 times for approximately 45 minutes/session across first 6 months following discharge from initial NICU hospitalization. Sessions include infant and caregiver, and siblings, if desired, and occur at home or in municipal settings. MT after NICU consists of a consult-to-parent model with each session including a brief verbal check-in regarding infant´s progress, musical interactions with music therapist modelling musical engagement, discussion of current challenges and strategies for using musical interactions to address needs in areas such as infant self-regulation, parent/infant interaction, and challenges with bonding. Caregivers will demonstrate techniques discussed during session, and form a brief plan for use of musical interaction in the interim before next session. Sessions will be adapted to infant developmental level and ongoing needs.
79462|NCT03564184|Other|Standard care|Includes necessary medical care and standard supportive interventions offered as part of care during hospitalization, and standard follow-up procedures post-hospitalization.
79463|NCT03564171|Combination Product|Prehabilitation|stress counseling, exercise, nutritional counseling, smoking cessation counseling
79464|NCT03564158|Drug|meropenem-vaborbactam|Meropenem-Vaborbactam being studied for effects on TQT
79465|NCT03564158|Drug|Placebo|Placebo
79466|NCT03564158|Drug|Moxifloxacin|Active Comparator
79467|NCT03564145|Drug|S5G4T-1|once a day topical cream
79468|NCT03564132|Drug|Yigansan|Yigansan granules
79469|NCT03564132|Drug|Placebo|One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
79470|NCT03564119|Drug|S5G4T-1|once a day topical cream
79471|NCT03564119|Drug|S5G4T-2|once a day topical cream
79472|NCT03564106|Drug|intraarticular radiofrequency + intraarticular methylprednisolone|intraarticular radiofrequency + intraarticular methylprednisolone (30 mg)
79473|NCT03564106|Drug|intraarticular methylprednisolone|intraarticular methylprednisolone (30 mg)
79474|NCT03564093|Drug|Intranasal Drug|1µg/kg of dexmedetomidine is given 30 minutes prior to intravenous cannulation or lumbar puncture
79475|NCT03564093|Drug|Intranasal Drug|Intranasal 4,5% saline is given as a placebo 30 minutes prior to intravenous cannulation or lumbar puncture
79476|NCT03564080|Other|Combined - PAD and CAD|12-week supervised exercise programme in a hospital setting
79477|NCT03564067|Device|Soterix Medical tDCS mini-Clinical Trials system (mini-CT)|Participants are provided with an activation code. This code will unlock a single session with the pre-set 30 minute duration and intensity (direct current 2mA, current density 0.80A/m2, with anode over the left and cathode over the right dorsolateral prefrontal cortex, respectively). Home-based tDCS will involve 30-min tDCS (3 days per week) for the first 3 months and once weekly for the subsequent 3 months.
79478|NCT03564067|Behavioral|Computerized CBT (cCBT)|Each tDCS session will be delivered in combination with a computerized CBT module and participants will progress through the computerized CBT course (Beacon Therapist-Assisted-Internet-Delivered CBT) over the 6 months of treatment at their own pace.
79479|NCT03564054|Procedure|Photodynamic Therapy|Participants on this arm will be treated with photodynamic therapy. PDT is a two-stage process. The first stage of PDT is the intravenous injection of porfimer sodium (Photofrin) administered as a single slow intravenous injection over 3 to 5 minutes. The second stage involves the application of laser light to the tumor by bronchoscopy.
79480|NCT03564054|Procedure|Argon Plasma Coagulation|"Participants on this arm will be treated with argon plasma coagulation. A flexible probe housing a wire delivers high-frequency, high-voltage electric current to a monopolar tungsten electrode present at the tip of the probe. Argon gas flows through the probe, and is charged or ionized to produce plasma as it flows around the tungsten electrode. Electric current flows through the plasma to the nearest tissue, and heat is produced as it passes through the tissue. Increased resistance created by coagulated tissue impairs the flow of electric current, and keeps the ablation depth to 1 to 2 mm."
79481|NCT03564041|Behavioral|Sahaj Samadhi Meditation (SSM)|This is the experimental arm of the study, where participants will be trained in a form of meditation that may improve depressive symptoms.
79482|NCT03564041|Behavioral|Health Enhancement Program (HEP)|This is the active control group of the study, where participants will be educated on health promotion, healthy diet, music, and exercise, but do not learn breathing techniques, or meditation.
79483|NCT03564028|Other|energy conservation technique|During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.
79484|NCT03564028|Other|control session|Patients will realize one session of stair climbing at their own pace
79485|NCT03564015|Other|Smartphone app|Apple or Android app to provide education to guide functional recovery and allow recording of pain, management, and functional outcome using the Activities Scale for Kids performance version (ASKp) at home
79486|NCT03564015|Other|Paper handout|Paper handout to guide functional recovery. Also includes a version of the smartphone app described above that only allows recording of pain, functional outcome, and management at home.
79487|NCT03563989|Device|Implantation of Stent (PCI)|Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent
79490|NCT03563963|Drug|Lidocaine 2% Preservative-Free Injectable Solution|Lidocaine 2% will used to inflate the endotracheal tube cuff using the stethoscope guided inflation technique described by Kumar and Hirsch (2). The anesthesiologist will documented the volume in millilitres instilled into the cuff to create a seal. Once a seal was created the anesthesiologist will documented the ETT cuff pressure. If an endotracheal cuff leak occurred during the surgical procedure, the randomized solution was used to inflate the cuff.
79496|NCT03563937|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg or 20 mg, once daily
79497|NCT03563937|Drug|Edoxaban|30 mg or 60 mg, once daily
79498|NCT03563924|Other|"Setting up a specific care path AlloTC for management of TVE in patients with cancer"|"Setting up a specific care path AlloTC for management of TVE in patients with cancer with a specific coordination nurse within the AlloTC multidisciplinary team as a privileged interlocutor for health professionals and patients with the aim of simplifying the care pathways and ensuring a hospital-city interface organized in collaboration with the attending physician, to develop and publicize tools available for patients and caregivers (information documents, patient monitoring protocols, etc.)"
79499|NCT03563911|Behavioral|Brief Mindfulness-Based Intervention (BMBI)|The BMBI is be based on a BMBI which demonstrated analgesic effects in a previous study. Relative to full-length interventions, we will employ a brief intervention; the 20-minute BMBI session will include education on the foundational concepts of mindfulness and its relevance to chronic pain (5 minutes) and a guided mindfulness practice involving focused attention on the breath and monitoring of thoughts, feelings, and body sensations (15 minutes). BMBI participants will be encouraged to practice the taught mindfulness technique at home at least 20 minutes/day for 4 weeks (a handout and link to an online guided mindfulness practice will be provided).
79500|NCT03563911|Behavioral|Control/Nutrition Education|The Control intervention will involve nutrition education, adapted from an existing manual of cognitive-behavioral therapy for opioid-treated chronic pain. Control intervention protocol will match the BMBI in terms of time / structure to control for the non-specific, non-mindfulness effects of BMBI. The 20-minute Control session will include education on the relationship between diet and pain (10 minutes) and recommendations for a healthy diet (10 minutes). Control participants will be encouraged to prepare healthy meals at home at least 20 minutes/day for 4 weeks (a handout and link to online resources will be provided).
79501|NCT03563898|Other|Sweating with Portable Sauna Bath|Patients will be subjected daily for 30 minutes to the Portable Sauna Care steam bath (45 degree C temperature). The patient will decide if the time and / or temperature of the Sauna Bath is reduced to Tolerance. Before being subjected to the sauna bath, blood pressure will be taken 10 minutes prior. Weigh the patient with a Scale. You will be informed of the symptoms that may occur during the bath, and if present, you will let the health staff know that you will be present at all times during the bathing period, which will have a SURVEILLANCE TABLE which It will be filled during the intervention where they are monitored and comply with the stipulated norms as well as notes for adverse effects. After the completion of the bath, there will be a space of 15 minutes for the patient to dry the skin and the bathing suit with a towel. After 15 minutes, the patient will be weighed and the blood pressure will be taken again.
79502|NCT03563885|Procedure|bariatric surgery|subjects already scheduled Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery
79503|NCT03563872|Other|Intervention|Enhancements to team-based care include clinical decision support and improved protocols for telehealth prescribing.
79504|NCT03563872|Other|Active Comparator|Usual, team-based care
79505|NCT03563846|Drug|RP-G28|RP-G28 is a purified galacto-oligosaccharide (GOS) product
79506|NCT03563833|Other|Minimal Flow Anesthesia|Minimal Flow Anesthesia with 0,4 L min-1
79507|NCT03563833|Other|High Flow Anesthesia|High Flow Anesthesia with 2 L min-1
79508|NCT03563820|Behavioral|Resilience and Well-Being Program|"The Resilience and Well-Being Program is offered through VA Puget Sound Rehabilitation Care Services as part of standard clinical care offerings. The program includes five (5) positive psychology group sessions once a week for five weeks. Participants will use strengths-based strategies, narrative strategies, and prospective strategies to learn ways to deal with stressful life challenges and improve their mental health and well-being.~Each participant will be given a brief rating sheet at the end of each session to fill out. The rating sheet will ask participants to rate different aspects of the session (e.g., how helpful or interesting the session was to the participant), if home practice activities were assigned, whether the participant completed the home practice assignment, as well as feedback to improve that session."
79509|NCT03563807|Other|Golf Instruction|Subjects will participate in two weekly hour-long golf classes. Classes will be led by professional golf instructors that will work with individuals to teach participants how to play golf. This will include stretching, individual coaching, and working with participants to maximize their golf swing.
79510|NCT03563807|Other|Tai Chi Class|Tai Chi is an ancient martial art that uses meditative movement to improve strength, flexibility, and balance. Subjects will participate in two weekly hour-long Tai Chi classes.The class will be led by a certified Tai Chi instructor and consist of approximately 12 people.
79511|NCT03563794|Drug|CSII+Vildagliptin|Vildagliptin(50mg b.i.d po.) will be added to Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment in T2DM. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
79512|NCT03563794|Drug|CSII(insulin Lispro)|T2DM patients will receive Continuous Subcutaneous Insulin Infusion(insulin Lispro) treatment. Doses of insulin Lispro will be instructed on a titration schedule, adjusted every 2 days.
79513|NCT03563781|Procedure|Sentinel node detection|Patients will receive injection of tracer in the ovarian ligaments to identify the lymphatic drainage of the affected ovary and ultimately the sentinel node. Afterwards, systematic lymphadenectomy will be accomplished according to current guidelines.
79514|NCT03563768|Procedure|One-stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
79515|NCT03563755|Other|Cognitive Bias Modification|CBM-Attention (CBM-A) will be used with the aim of ameliorating negative cognitive biases in attention by redirecting attention towards positive social stimuli (accepting faces). Similarly CBM-Interpretation (CBM-I) will be used to ameliorate negative interpretation bias, by reinforcing benign outcomes of ambiguous social scenarios. Implementation intentions will be used to guide participants in planning new ways to face difficult social situations involving the risk of social rejection/criticism. Participants will continue to receive their usual treatment.
79516|NCT03563742|Drug|Rilpivirine 25 mg|Participants will receive rilpivirine 25 mg tablet orally once daily.
79517|NCT03563742|Drug|Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)|Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
79518|NCT03563729|Drug|Pembrolizumab Injection [Keytruda]|Alone
79519|NCT03563729|Drug|Ipilimumab Injection [Yervoy]|In combination with nivolumab.
79520|NCT03563729|Drug|Nivolumab Injection [Opdivo]|In combination with ipilimumab.
79521|NCT03563716|Drug|Atezolizumab|Atezolizumab at a fixed dose of 1200 mg will be administered first by IV infusion Q3W on Day 1 of each 21-day cycle.
79522|NCT03563716|Drug|MTIG7192A|MTIG7192A at a fixed dose of 600 mg will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
79523|NCT03563716|Drug|Placebo|Placebo will be administered by IV infusion Q3W on Day 1 of each 21-day cycle.
79524|NCT03563703|Device|Ultrasound|Ultrasound allows viewing veins and surrounding anatomical structures, making it easier to perform the placement of a cannula into a peripherally located vein in real time. This process allows the cannulation of veins that are unable to be visualised or palpated.
79525|NCT03563703|Device|Near Infrared Light|Infrared technologies allows illuminating the vein with a near-infrared light, which is absorbed by blood and reflected by adjacent tissue.
79526|NCT03563690|Other|treatment1|"Acupoints：Liangqiu（ST34）,Xuehai（SP10）,Neixiyan（EX-LE4）,Dubi(ST35),Yanglingquan (GB34)and Yinlingquan (SP9)~operation: the needles will be manipulated using techniques including lifting, thrusting, twisting, and rotating, until De Qi is achieved for 30 minutes."
79527|NCT03563690|Other|treatment2|"Acupoints：Needling points are the same to the above group~operation: The electrode will be connected Neixiyan (EX-LE4) and Dubi (ST35) and electrode wire will be connected to the electro-acupuncture apparatus using dilatational wave with a frequency of 2/100 Hz, the current intensity is within participants'tolerance, for 30 minutes."
79528|NCT03563690|Other|treatment3|"Acupoints：treating points are the same to the above group~Operation: During treatment, participants will choose to sit with knee buckling natural 90 degrees ,with the affected knee(s) exposed. Mild moxibustion are applied at the distance of 2-3 cm away from the skin of both the Neixiyan (EX-LE4) and Dubi (ST35) for 30 minutes."
79529|NCT03563690|Other|treatment4|"Acupoints：Needling points are the same to the above group~Operation: Warm-needling acupuncture are applied at both Neixiyan (EX-LE4) and Dubi (ST35). That is to insert one zhuang(about 2cm)of Huai Qing Ai on the top of the needle, and burn the moxa at the lower end ,each acupoint applied 2 Zhuang for 30 minutes."
79530|NCT03563690|Other|treatment5|"points：Sham Liangqiu（ST34）,Sham Xuehai(SP10), Sham Neixiyan(EX-LE4), Sham Yanglingquan(GB34),Sham Yinlingquan (SP9)~Operation: Sham acupuncture with non-meridian and non-acupoint needling method, respectively acupuncture 1cm away lateral to the above sham acupoints with a 0.18 * 25mm single-use needle with the depth of 1-2mm."
79531|NCT03563690|Drug|Celebrex|Drug: Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd), which will be applied 1 time daily( taken 0.2g one time orally ) Time of treatment :4 weeks Other Name: celecoxib
79532|NCT03563677|Other|dual expert guidance structure|Two medical experts, one somatic specialist and one psychiatrist/psychosomatic specialist see all medical records and the patients together
79533|NCT03563664|Procedure|Pre-treatment endometrial biopsy|Timed suction endometrial biopsy was obtained from participants via Wallach Endocell® 908014A endometrial cell sampler timed during the implantation window of the pretreatment cycle; followed by immunohistochemical staining using immunoperoxidase staining incorporating avidin-biotin complex (ABC) method.
79534|NCT03563664|Drug|Danazol|Participants were treated with danazol (Danol® 200mg capsules, Sanofi, Guildford, UK) in daily dosage of 400 mg for 12 weeks.
79535|NCT03563664|Procedure|Post-treatment endometrial biopsy|Post-treatment suction endometrial biopsy was obtained during the implantation window following the first ovulation after danazol treatment, timed, processed and stained as described previously.
79536|NCT03563651|Procedure|Biopsy|Undergo biopsy
79537|NCT03563651|Procedure|Biospecimen Collection|Undergo collection of blood, urine, and stool
79538|NCT03563651|Other|Laboratory Biomarker Analysis|Correlative studies
79539|NCT03563651|Other|Questionnaire Administration|Ancillary studies
79540|NCT03563638|Diagnostic Test|75gOGTT|oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
79541|NCT03563625|Procedure|Caudal block|Caudal block/bupivacaine 0.25%
79542|NCT03563625|Procedure|Wound infiltration|Local anesthetic wound infiltration/bupivacaine 0.25%
79543|NCT03563625|Drug|Bupivacaine|bupivacaine
79544|NCT03563612|Device|cpap|application of cpap to the non-dependent lung, during one lung ventilation
79545|NCT03563599|Drug|Telacebec (Q203)|High, Mid, Low dose of telacebec
79546|NCT03563599|Drug|Rifafour e-275|RHZE (R=rifampicin: H=isoniazid: Z=pyrazinamide: E=ethambutol)
79547|NCT03563586|Other|Bowel Preparation plus antibiotics|Preoperative oral antibiotic therapy with rifaximin 400 mg plus metronidazole 500mg the day prior to surgery at 2:00, 3:00 and 10:00 pm, with mechanical bowel preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm)
79548|NCT03563586|Other|Bowel Preparation|Mechanical Bowel Preparation (2 vials sodium phospate 45ml at 1:00 and 7:00 pm) alone Both groups will receive iv antibiotics (cefoxitin 2 gr plus metronidazole 500gr) perioperatively and discontinuation within 24 hours
79549|NCT03563573|Drug|Potassium Gluconate Oral Capsule|Each subject will receive a dose of ~8 mg/kg of potassium. We will be giving a maximum of 14 mEq in a single dose.
79550|NCT03563573|Drug|Placebo oral capsule|Each subject will receive a dose of ~8 mg/kg of a placebo capsule
79551|NCT03563560|Drug|Alvocidib|ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3
79552|NCT03563560|Drug|Cytarabine|300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)
79553|NCT03563560|Drug|Mitoxantrone|14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)
79554|NCT03563560|Drug|Cytarabine|100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)
79555|NCT03563560|Drug|Daunorubicine|60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7
79586|NCT03563287|Drug|cocktail of nine CYP probe drugs|"Two equally loaded capsules containing:~Melatonin (2.0 mg) Nicotine (1.0 mg) Bupropion (37.5 mg) Repaglinide (0.25 mg) Losartan (12.5 mg) Omeprazole (10 mg) Chlorzoxazone (62.5 mg) Midazolam (1.85 mg) Dextromethorphan (30 mg) as an oral solution was administered separately after the capsules."
79556|NCT03563547|Behavioral|Dietary counseling (fat modifed diet)|Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.
79557|NCT03563547|Behavioral|Dietary Counseling (fat modified + soy enriched diet)|"Subjects in both groups had been instructed to achieve specific daily maximum intakes in total fat (≤ 30% of total energy intake), saturated fatty acids (≤10% of total fat intake) and cholesterol (≤ 300 mg). Furthermore the participating families had been trained to replace as many visible fat sources as possible with rapeseed oil due to its favorable composition of polyunsaturated fatty acids.~Subjects allocated to the soy group and their families were additionally instructed to consume at least 0.25 g of soy protein per kg bodyweight per day and were provided with recipes and practical advice on how to achieve this goal. Example provided: a child with a bodyweight of 30kg would have to consume the equivalent of approx. 50g of Tofu per day to meet the treatment target."
79558|NCT03563534|Drug|Silver Diamine Fluoride|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, and apply 38% silver diamine fluoride.
79559|NCT03563534|Drug|Glass Ionomer|Margins of cavitated lesion(s) will be excavated.The carious teeth will be isolated, kept dry, apply resin modified glass ionomer.
79560|NCT03563495|Other|tissue engineered group|cultured and bone marrow derived autologous mesenchymal stem cells, loaded on collagen matrix (Osteovit)
79561|NCT03563495|Procedure|autogenous bone graft group|
79562|NCT03563482|Diagnostic Test|PET scan|Tumor biopsy at baseline; PET scan performed after 8 weeks of treatment
79563|NCT03563469|Other|Salivary bacterial and pH level|"Saliva sample will be collection ask the patient to stop eating and drinking for one hour before collecting the sample,(2) Give the patient distilled water and ask them to rinse their mouth well for 1 min,five minutes after this oral rinse, ask the patient to spit into 50ml sterile tube, collect 5ml of saliva and return to the laboratory within an hour.~The dental caries of all patients will also be recorded using dental mirror and explorer. The caries experience will be recorded in diagnostic chart using the World Health Organization (WHO) criteria for deciduous teeth and dmft caries index."
79564|NCT03563456|Behavioral|structured combined exercise|A structured designed exercise consists of three times per week interval cardiorespiratory training of High Intensity Interval Training incorporates cycles of 1:4 interval and two times per week Resistance Exercise consists of nine-movement.
79565|NCT03563456|Behavioral|cardiorespiratory exercise|Once per week continuous cardiorespiratory training of moderate intensity
79566|NCT03563443|Diagnostic Test|Genomic Imprinting Testing|The changes of LOI The obtained LOI from morning urine and tumor will be tested by LiSen imprinting diagnostic (LSID)
79567|NCT03563430|Other|Active Recovery Group|Participants in this group will exercise for 15 minutes, for a range of 65 to 70% of the maximum heart rate as a recovery method following a single bout high-intensity interval exercise program
79568|NCT03563430|Other|Self-Massage with Foam Roller Group|This group will perform 15 minutes self-massage with foam roller following the exercise session as a recovery method following a single bout high-intensity interval exercise program.
79569|NCT03563430|Other|Neuromuscular Electrical Stimulation|Participants of this group will be applied electrical stimulation on quadriceps femoris and hamstring muscles for 15 minutes while they are comfortable lying position as a recovery method following a single bout high-intensity interval exercise program.
79570|NCT03563417|Procedure|Percuteneous Coronary Intervention|PCI of Chronic Total Occlusions
79571|NCT03563417|Other|Optimal Medical Therapy|Initiation and titration of optimal medical therapy in the control arm.
79572|NCT03563391|Other|New Infant Formula|New Infant Formula is a specialized, nutritionally complete, nutrient-dense infant formula specifically formulated for infants with growth failure.
79573|NCT03563378|Drug|Lactated Ringer|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
79574|NCT03563378|Drug|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
79575|NCT03563365|Other|Replenix Power of 3 Cream with resveratrol|Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids
79576|NCT03563365|Drug|Adapalene and Benzoyl peroxide gel, 0.1%/2.5%|FDA approved topical agent for the treatment of acne
79577|NCT03563352|Other|Interview|Attend an interview
79578|NCT03563352|Other|Survey Administration|Ancillary studies
79579|NCT03563339|Behavioral|P-POD|. P-POD will include seven 30-minute online, educational, interactive modules that teach at-risk pregnant women skills derived from the gold standard, empirically supported cognitive-behavioral treatment for anxiety disorders and OCD. Additionally, P-POD will include three modules for fathers, to help them support their partners during the postpartum period. We will modify P-POD from an already existing in-person prevention program for postpartum OCD (developed by Co-Investigator Kiara Timpano). The m-health foundation of P-POD will be an already existing Internet-delivered treatment infrastructure (OurRelationship.com, developed by Co-Investigator Brian Doss).
79580|NCT03563326|Biological|CAR-T cells targeting EpCAM|Biological: CAR-T cells targeting EpCAM
79581|NCT03563326|Biological|Chemotherapy|Chemotherapy: determined by medical Oncologist
79582|NCT03563313|Device|t:slim X2 with Control-IQ Technology & Dexcom G6 CGM|Participants will use the Tandem t:slim X2 with Control-IQ Technology & Dexcom G6 CGM for 6 months at home.
79583|NCT03563313|Device|Sensor-augmented pump (SAP)|Participants will use an insulin pump with no automated insulin delivery and a study CGM (Dexcom G6) for 6 months at home. Pump-users at the time of enrollment will use their personal pump in this arm. Multiple daily injection (MDI) users at the time of enrollment will use a t:slim X2 insulin pump without Control-IQ technology.
79584|NCT03563300|Other|Wheat flour|Wheat flour will be administered once daily for 7 days
79585|NCT03563300|Other|Placebo Comparator|Placebo will be administered blindly versus wheat flour for 7 days
79631|NCT03563157|Drug|Capecitabine|XELODA® tablets
79632|NCT03563157|Drug|Cetuximab|ERBITUX® injection
79633|NCT03563157|Drug|Cyclophosphamide|Cyclophosphamide Capsules
79587|NCT03563274|Device|Selective Internal Radiation Therapy with QuiremSpheres®|The main purpose of this study is to further assess treatment efficacy and safety after using QuiremSpheres® for the treatment of patients with unresectable primary liver cancer or unresectable liver metastases suitable for SIRT and allocated to this treatment by a multidisciplinary tumor board.
79588|NCT03563261|Dietary Supplement|Collagen supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
79589|NCT03563261|Dietary Supplement|Placebo supplement group|Participants from both group will take their supplement every morning prior to breakfast. Supplementation period will be 4 months. They will perform tendons loading activities 30 minutes after ingestion of the supplement. Tendons loading activities will be heel raises and knee extensions while seated. Participants will be asked to keep the exercise intensity low as it is not a strengthening intervention.
79590|NCT03563248|Drug|FOLFIRINOX|"FOLFIRINOX is a combination of 4 chemotherapy agents that may help shrink your tumor before surgery~5-Fluorouracil (5-FU) - 400 mg/m2 on day one, followed by 1200 mg/m2 by continuous infusion for the subsequent 46-48 hours~Oxaliplatin - 85 mg/m2 by intravenous infusion over 120 minutes on day 1 of each 14 day cycle~Irinotecan - administered at a starting dose of 180 mg/m2 by intravenous infusion over 90 minutes on day 1 of each 14 day cycle~Leucovorin - Administered at a starting dose of 400 mg/m2 over 2 hours on day 1 of each 14 day cycle"
79591|NCT03563248|Drug|Losartan|Losartan is a drug that is used to lower blood pressure
79592|NCT03563248|Drug|Nivolumab|Nivolumab is an antibody that may cause programmed cell death of cancer cells
79593|NCT03563248|Radiation|SBRT|Radiation therapy is believed to increase the likelihood of response of immunotherapy
79594|NCT03563248|Procedure|Surgery|definitive surgical resection
79595|NCT03563235|Drug|Xulin Jiangu granules|Xulin Jiangu granules tablets
79596|NCT03563235|Drug|Calcitriol capsules|Calcitriol capsules tablets
79597|NCT03563222|Drug|Smoflipid|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
79598|NCT03563222|Drug|Intralipid, 20%|"The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy."
79599|NCT03563196|Radiation|Chest Radiograph|Chest radiogram will be obtained on day 1
79600|NCT03563196|Diagnostic Test|Lung Ultrasound|Lung ultrasound will be done on day 1
79601|NCT03563183|Other|Encoding of data collected in Zoster 006 and Zoster 022 studies|Not applicable (disease epidemiology study)
79602|NCT03563170|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79603|NCT03563170|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
79604|NCT03563170|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
79605|NCT03563170|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
79606|NCT03563170|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
79607|NCT03563170|Drug|Cyclophosphamide|anhydrous
79608|NCT03563170|Drug|5-Fluorouracil|5-FU; Fluorouracil
79609|NCT03563170|Drug|Leucovorin|Leucovorin calcium salt
79610|NCT03563170|Drug|nab-Paclitaxel|ABRAXANE® [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]
79611|NCT03563170|Drug|Sorafenib|NEXAVAR® tablets, for oral use
79612|NCT03563170|Procedure|SBRT|Stereotactic Body Radiation Therapy
79613|NCT03563170|Biological|Aldoxorubicin hydrochloride|HCl
79614|NCT03563170|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79615|NCT03563170|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
79616|NCT03563170|Biological|GI-6207|CEA yeast vaccine
79617|NCT03563170|Biological|GI-6301|Brachyury yeast vaccine
79618|NCT03563170|Drug|Cetuximab|ERBITUX® injection, for IV infusion)
79619|NCT03563170|Biological|N-803|Recombinant human super agonist IL-15 complex [also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex]
79620|NCT03563157|Biological|Aldoxorubicin Hydrochloride|Aldoxorubicin Hydrochloride HCI
79621|NCT03563157|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D;IL-15RaSu/IgG1 Fe complex1]
79622|NCT03563157|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79623|NCT03563157|Biological|ETBX-021|Ad5 [E1-, E2b-]-[HER2]
79624|NCT03563157|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
79625|NCT03563157|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1]
79626|NCT03563157|Biological|GI-4000|RAS yeast
79627|NCT03563157|Biological|GI-6207|CEA yeast
79628|NCT03563157|Biological|GI-6301|Brachyury yeast
79629|NCT03563157|Biological|haNK|haNK™, NK-92 [CD16.158V, ER IL-2]
79630|NCT03563157|Drug|Avelumab|BAVENCIO® injection
79636|NCT03563157|Drug|Nab-paclitaxel|ABRAXANE® for Injectable Suspension [paclitaxel protein-bound particles for injectable suspension] [albumin-bound]
79637|NCT03563157|Drug|Oxaliplatin|ELOXATIN® injection
79638|NCT03563157|Drug|Regorafenib|STIVARGA® tablets
79639|NCT03563157|Procedure|SBRT|Stereotactic body radiation therapy
79640|NCT03563144|Drug|Gemcitabine|Gemcitabine is a type of chemotherapy medication used to interfere with the cancer cells' ability to grow and divide.
79641|NCT03563144|Drug|Nab-paclitaxel|NAB-paclitaxel is a type of chemotherapy called a microtubule inhibitor. Microtubule inhibitors interfere with a cancer cell's ability to grow and divide.
79642|NCT03563144|Drug|Aldoxorubicin HCl|Albumin-binding prodrug of doxorubicin HCl
79643|NCT03563144|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
79644|NCT03563144|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
79645|NCT03563144|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
79646|NCT03563144|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
79647|NCT03563144|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
79648|NCT03563144|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
79649|NCT03563144|Biological|GI-6207|CEA yeast vaccine
79650|NCT03563144|Biological|GI-6301|Brachyury yeast vaccine
79651|NCT03563144|Biological|haNK|NK-92 [CD16.158V, ER IL-2]
79652|NCT03563144|Drug|Avelumab|Avelumab
79653|NCT03563144|Drug|Bevacizumab|Bevacizumab
79654|NCT03563144|Drug|Capecitabine|Capecitabine
79655|NCT03563144|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
79656|NCT03563144|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
79657|NCT03563144|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
79658|NCT03563144|Drug|Oxaliplatin|Oxaliplatin
79659|NCT03563131|Device|Persona® total knee arthroplasty|Insertion of the cemented or uncemented Persona® total knee arthroplasty
79660|NCT03563105|Device|The Ox-Imager Mini (Desaturation)|Vascular Occlusion Test
79661|NCT03563092|Procedure|Laparoscopic Inguinal Hernia (TEP/TAPP) Surgery|Standardized minimally invasive approach to inguinal hernia repair
79662|NCT03563079|Other|Instrument Assisted Soft Tissue Mobilization|Soft Tissue Mobilization
79663|NCT03563079|Other|Manual Myofascial Release|Myofascial Release Technique
79664|NCT03563066|Drug|Benralizumab|Subcutaneous benralizumab injections once per month for 3 months on Days 0, 28 & 56.
79665|NCT03563066|Drug|Placebo Control|Subcutaneous placebo injections once per month for 3 months on Days 0, 28 & 56.
79666|NCT03563053|Combination Product|EryDex System|EryDex System is a combination product that is used to load dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EDS) creating the EDS-end product which is infused into the patients
79667|NCT03563040|Drug|Methoxsalen|"Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.~During each photopheresis treatment with methoxsalen, the dosage of methoxsalen is calculated according to the treatment volume (which is displayed on the display panel of the instrument) using the formula:~Treatment volume x 0.017 ml of methoxsalen (20 µg/mL) for each treatment For example: Treatment volume = 240 mL x 0.017 = 4.1 mL of methoxsalen (20 µg/mL)"
79668|NCT03563040|Device|THERAKOS CELLEX Photopheresis System|Methoxsalen is used in conjunction with the THERAKOS CELLEX Photopheresis System.
79669|NCT03563027|Behavioral|Social Incentive Gamification|Game-based intervention with points and levels
79670|NCT03563027|Behavioral|Support Sponsor|Participants select a support sponsor to receive weekly updates on progress in the game
79671|NCT03563027|Behavioral|Financial Incentive|Participants receive a loss-framed financial incentive allocated upfront each week and financial incentives taken away each day the goal is not met
79672|NCT03563014|Drug|Radium-223 (Xofigo, Bay88-8223)|Follow the physician's prescription in routine clinical practice.
79673|NCT03563001|Drug|Budesonide(160ug) and Formoterol(4.5ug) bid|For both groups of subjects,small airways function of is assessed at baseline.And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with the same examinations after 3 months` treatment.
79674|NCT03562988|Dietary Supplement|Vitafusion Power C gummy|vitamin C
79675|NCT03562988|Dietary Supplement|Nature Made vitamin C tablet|vitamin C
79676|NCT03562975|Drug|Ocrelizumab|Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds
79677|NCT03562962|Behavioral|Functional Analytic Psychotherapy|FAP is a therapeutic procedure based on behavior analytic principles. This approach seeks to implement procedures to manipulate the contingencies of reinforcement involved in clients' problem and alternative behaviors within the context of a meaningful therapeutic relationship that is functionally equivalent to other interpersonal contexts outside (Follette, Naugle & Linnerooth, 2000; Kohlenberg & Tsai, 1991). FAP therapists modify CRBs by implementing contingent responding (TCRB) within the therapeutic setting. That is, FAP aims to administer differential reinforcement (TCRB1) to reduce CRB1s and to provide positive reinforcement to enhance CRB2s. Based on the changes within the therapeutic setting, clients are prompted to discriminate contexts where those repertoires are likely reinforced and to generalize those responses to such environments (Kohlenberg & Tsai, 1991).
79678|NCT03562949|Drug|Test Product|Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg
79679|NCT03562949|Drug|Reference Product|QVAR® 40 mcg (Beclomethasone Dipropionate HFA)
79680|NCT03562949|Drug|Placebo|Placebo Product
79681|NCT03562923|Drug|Test Product|Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder
79682|NCT03562923|Drug|Reference Product|ADVAIR DISKUS® 100/50 (Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder)
79683|NCT03562923|Drug|Placebo|Placebo Product
79684|NCT03562910|Other|HelpSteps application|Mobile or tablet-based tool that screens for social needs and refers to local agency based on needs and proximity.
79685|NCT03562897|Dietary Supplement|Ocoxin-Viusid|Ocoxin-Viusid group (Experimental): Oral solution Ocoxin-Viusid (30 ml vials) were used at a rate of 60ml / day (1 vial every 12 hours), preferably administered after breakfast and dinner. The treatment will start a week before start Chemotheray treatment (CT) and, It will maintenance until 3 weeks after finished the last cycle of CT (3 cycles of CT of Carboplatin/Paclitaxel or Cisplatin/ Paclitaxel with neoadjuvant intent).
79686|NCT03562884|Drug|BLI800|Two bottles of BLI800 are needed for appropriate cleansing of the bowel. Prior to administration, the content of each bottle must be diluted in water, using the cup provided, to a total volume of approximately 0.5 L, and must be followed by the ingestion of 1 additional litre of water.
79687|NCT03562884|Drug|Fortrans®|Fortrans® (Powder for Oral Solution) will be given according to Chinese approved Summary of Product Characteristics (SmPC). Fortrans® is provided as a powder for Polyethylene Glycol (PEG) based solution available in sachets containing a white powder readily miscible with water. The dosing for Fortrans® administration will be adapted to subjects' body weight as following: 1 L of solution for 15 to 20 kg, an average of 3 to 4 L (maximum 4 L).
79692|NCT03562858|Procedure|Immediate dentin sealing protocol|Sealing of the dentin before impression taking directly after cavity preparation to prevent postoperative hypersensitivity during provisionalization and after cementation
79693|NCT03562858|Procedure|Delayed dentin sealing protocol|Sealing the dentin just prior to cementation
79694|NCT03562845|Other|NA-Observational only|NA-Observational only
79695|NCT03562832|Drug|PARP inhibitor 2X-121|600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients
79696|NCT03562806|Diagnostic Test|PET/MR image acquisition|Acquisition of PET and MR sequences on SIGNA PET/MR device.
79697|NCT03562793|Behavioral|Communication and Activation in Pain to Enhance Relationships and Treat Pain with Equity (COOPERATE)|. COOPERATE seeks to improve patient activation in minority Veterans with chronic pain by focusing on two major skill sets: 1) goal clarification and prioritization, and 2) communication skills (Table 1). By understanding, clarifying, and prioritizing goals, and having the skills to communicate their goals, priorities, and preferences to providers, Veterans will gain knowledge, confidence, and skills to be actively involved in managing their chronic pain. The intervention consists of 6 total sessions delivered individually over 12 weeks: 4 sessions focused on teaching skills related to goal clarification/prioritization and communication (30-minutes each), delivered weekly for the first 4 weeks, plus 2 booster sessions (20-25 minutes each) delivered once per month for the next 2 months.
79698|NCT03562780|Drug|Fortolin Tab 500mg|Fortolin Tab 500mg is a generic product manufactured by Fortune Pharmacal Co. Ltd.
79699|NCT03562780|Drug|Panadol Caplet 500mg|Panadol Caplet 500mg is manufactured by GlaxoSmithKline (Dungarvan) Ltd.
79700|NCT03562767|Behavioral|Group-based Cognitive Behavioral Intervention|This intervention will include six 1-hour group sessions held biweekly for twelve weeks. Each sixty-minute session will consist of 15 minutes of diabetes education regarding exercise and food planning and approximately 45 minutes of CT-CB presentations/engagement activities. Participants will be encouraged to bring along their family members or friends for support.
79701|NCT03562767|Behavioral|Web-based Cognitive Behavioral Intervention|This intervention will include six 1-hour web-based sessions held biweekly for twelve weeks. Subjects in the web-based CT-CB will be asked to reserve a 1 hour period for a web call from the Behavioral Interventionist team. Text reminders will be sent to the participants prior the sessions. During this period, approximately 15 minutes will be reserved for diabetes exercise and food planning education and approximately 45 minutes of CT-CB engagement activities.
79702|NCT03562767|Behavioral|Usual Care|Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
79703|NCT03562754|Procedure|reduced systemic heparin anticoagulation|receive intermittent hemodialysis (Frésenius 4008) with blood flow at least of (200 ml/min) with double vascular access, biocompatible membrane dialyzer, low dose non fractionated heparine (5000 UI initially) and predilution with 25 mls/min dialysate
79704|NCT03562754|Procedure|Regional Citrate Anticoagulation|intermittent hemodialysis using Prometheus System with blood flow at least of 200 ml/min with double vascular access, biocompatible membrane dialyzer
79705|NCT03562741|Procedure|Fecal Microbiota Transplantation|Transplantation of Screened donor stool as part of Fecal Microbiota Transplantation
79706|NCT03562728|Device|MRP and NMES(neuromuscular electric stimulation)|nutrition supplementation includes addition of essential amino acids 3 times a day to feeding
79707|NCT03562728|Other|Standard of Care|Patients in the control group are going to receive standard of care
79708|NCT03562702|Other|Standard IV Rehydration Therapy|IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)
79709|NCT03562702|Other|Oral Rehydration Therapy (ORT)|Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge
79710|NCT03562689|Other|Delirium and with septic encephalopathy.|Delirium or septic encephalopathy survivors will be analized in the same way: Cognitive tests, EEG and MRI.
79711|NCT03562676|Other|weightlessness|parabolic flight
79712|NCT03562663|Device|Transcranial direct current stimulation|A constant, low current stimulation is provided non-invasively through sponge electrodes positioned over the motor cortex of the affected arm. The stimulation is provided for 20 minutes at an intensity of 2 mA.
79713|NCT03562663|Device|Upper extremity robotics|Participants complete robotic training 3 days per week for 12 weeks, or 36 sessions. The protocol alternates between planar (shoulder/elbow) and wrist robots for the duration of the study.
79714|NCT03562650|Behavioral|Safety Behavior Fading|Participants are asked to fade their three most common safety behaviors associated with their social anxiety
79715|NCT03562650|Behavioral|Present Centered|Participants are asked to try to increase their focus on the present.
79716|NCT03562637|Biological|adagloxad simolenin combined with OBI-821|In the neoadjuvant and adjuvant phases of the study for a total 100 weeks; subcutaneously injections.
79717|NCT03562637|Biological|Phosphate-buffered saline (PBS)|In the neoadjuvant and adjuvant phases of the study for a total 100 weeks; subcutaneously injections.
79718|NCT03562637|Device|Globo H IHC Assay|The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
79719|NCT03562624|Drug|BAY98-7443|"Active ingredient content (in mg IND/LNG):~low dose 6.5 / 13.5; middle dose 12.5 / 13.5; high dose 15.4 / 13.5"
79720|NCT03562624|Drug|Levonogestrel (Skyla, BAY86-5028)|Comparative LNG dose
79721|NCT03562611|Drug|Nalbuphine|Nalbuphine administration during surgery
79722|NCT03562611|Drug|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
79723|NCT03562611|Drug|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
79724|NCT03562585|Diagnostic Test|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies|with sandwich ELISA immunoassay with fluorescence labeled monoclonal antibodies
79725|NCT03562572|Procedure|Ischemia driven revascularization|In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
79726|NCT03562572|Other|Usual care group|In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
79727|NCT03562559|Other|Measurements Using Ultrasound|Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.
79728|NCT03562546|Other|Strength From Within|A 12 week at home structured resistance exercise programme using resistance bands. Participants will also receive a walking programme, a warm up and cool down, and ankle range of motion exercises.
79729|NCT03562533|Drug|pegylated liposomal doxorubicin (PLD) + carboplatin (CD)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
79730|NCT03562533|Drug|carboplatin + paclitaxel (CP)|carboplatin AUC 5 plus paclitaxel 175 mg/m2 every 3 weeks for at least 6 cycles
79731|NCT03562520|Behavioral|Behavior change counseling|"Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers."
79732|NCT03562507|Drug|ESK981|ESK981: 160 mg (4 capsules) PO daily for 5 consecutive days followed by a 2-day off drug in each week, repeated weekly in 4-week (28-day) cycles
79733|NCT03562507|Drug|Nivolumab|480 mg/dose IV, Day 1 of each 28-day cycle
79734|NCT03562494|Biological|VY-AADC02|Adeno-associated viral vector serotype 2 encoding human aromatic L-amino acid decarboxylase (AAV2-hAADC). VY-AADC02 is infused by a neurosurgeon into the brain.
79735|NCT03562494|Other|Placebo|Placebo (sham) Surgery
79736|NCT03562481|Drug|1% Buffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 1% Buffered Lidocaine (30mg) 1:100,000 Epinephrine using the Halstead technique.
79737|NCT03562481|Drug|2% Unbuffered Lidocaine 1:100,000 Epinephrine|A single IAN block with 3cc 2% Unbuffered Lidocaine (60mg) 1:100,000 Epinephrine using the Halstead technique.
79738|NCT03562468|Dietary Supplement|300 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment with 300 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
79739|NCT03562468|Dietary Supplement|1000 mg/day of TRU NIAGEN (nicotinamide riboside)|Treatment 1000 mg/day of TRU NIAGEN (nicotinamide riboside) will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
79740|NCT03562468|Dietary Supplement|Placebo|Treatment with placebo capsules will be administered daily as 4 capsules in a double-blind, randomized, crossover manner for three 8-week treatment periods. Each subject will receive one placebo and two active treatments in a crossover design. The two active treatments are 300 mg/d TRU NIAGEN (nicotinamide riboside) and 1000 mg/d TRU NIAGEN (nicotinamide riboside).
79741|NCT03562455|Other|VRSim 3.0|VRSim 3.0 is a virtual reality training module.
79742|NCT03562455|Behavioral|In-Person Wheelchair Training|A therapist will be used to train power wheelchair users.
79743|NCT03562442|Behavioral|Smoking cessation|Smoking cessation with or without professional / medical support
79744|NCT03562429|Drug|TGF|TGF is a powder formulation of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
79745|NCT03562429|Drug|TGFP|TGFP is 1/20 concentration of Hu-Qian Wan (HQW). HQW is composited of 10 herbs, Chinemys reevesii (Gray), Phellodendron chinense Schneid., Achyranthes bidentata Blume, Anemarrhena asphodeloides Bunge, Rehmannia glutinosa Libosch., Paeonia lactiflora Pall., Cynomorium songaricum Rupr., Angelica sinensis (Oliv.) Diels, Citrus reticulata Blanco and Zingiber officinale Rosc..
79746|NCT03562416|Drug|Nintedanib|Nintedanib (BIBF 1120, Ofev)
79747|NCT03562416|Drug|Placebo Oral Tablet|Placebo
79748|NCT03562403|Device|Deep Brain Stimulation|stimulation of different basal ganglionic nuclei by a inserting a device
81659|NCT03547362|Dietary Supplement|Dairy protein blend 4|See arm description
79749|NCT03562390|Drug|Irinotecan|The patients will receive treatment using intravenous irinotecan hydrochloride until the patient develops disease progression or fulfills a withdrawal criterion.
79750|NCT03562377|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.
79751|NCT03562377|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
79752|NCT03562377|Biological|Tdap vaccine|Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.
79753|NCT03562377|Biological|Meningococcal vaccine|This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
79754|NCT03562364|Other|AlterG anti-gravity treadmill|The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
79755|NCT03562351|Other|Verbal Instructions Educational Intervention|Caregivers will undergo training with verbal instructions
79756|NCT03562351|Other|Video Educational Intervention|Caregivers will undergo training with an educational video
79757|NCT03562351|Other|Mannequin Educational Intervention|Caregivers will undergo training with a mannequin
79758|NCT03562338|Other|Manual Therapy and Exercise (Physiotherapy Intervention)|Participants in this group will receive a 6-weeks program of mobilization and progressive exercise for the neck flexors, 2 times a week.
79759|NCT03562338|Other|Usual Care (Physiotherapy Intervention)|Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
79760|NCT03562325|Behavioral|Acceptance and Commitment Therapy (ACT)|The main target in ACT for ME/CFS (as for Fibromyalgia and Chronic pain in previous studies by our group) is to promote a shift of perspective in life from symptom reduction (when it does not work) to a valued life. As such it entails acceptance and exposure to discomfort, in order to lessen the effects of negative experiences (symptoms, emotions, thoughts) on behaviours in everyday life.
79761|NCT03562312|Other|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
79762|NCT03562312|Other|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
79763|NCT03562299|Device|OrthoPure™ XT|A decellularized, sterile, single use, xenograft device for reconstruction of the anterior cruciate ligament
79764|NCT03562286|Procedure|Fetoscopy|Performing a minimally invasive procedure using a fetoscopic technique in order to access to amniotic cavity and make the endoscopic repair of the fetal neural tube defect.
79765|NCT03562273|Radiation|Quality Of Life Sizing Nomogram|"If the participant meets the eligibility criteria of the study, and participant chooses to take part, they will receive the tumor bed boost in 8 Gy in 1 fraction just prior to starting whole breast radiation after joining the study. Treatment to the whole breast will begin within 7-8 days from the TB boost (GammaPodTM) treatment.~The radiation therapy will take approximately 6 weeks to complete. Follow-up visits specifically for this study will continue for one year, although the physician will continue to follow as part of routine care."
79766|NCT03562260|Procedure|bipolar release|the bipolar release is the surgery that cut the origin and insertion of the sternocleidomastoid muscle that cause the torticollis from its contracture
79767|NCT03562247|Other|Usual Care of IPF|standard of care given to patients with IPF
79768|NCT03562247|Other|Telenursing|scheduled phone calls with the patient and care giver
79769|NCT03562247|Other|Telenursing and Remote Monitoring|scheduled phone calls and home monitoring of physiologic parameters
79770|NCT03562234|Diagnostic Test|MR|Liver fat (measured as a percentage - hepatic fat fraction) will be measured by Magnetic Resonance imaging
79771|NCT03562234|Diagnostic Test|LiMAx|Liver function will be measured using the relatively new CE licenced non-invasive LiMAx (Liver Maximum Capacity) test device, manufactured by Humedics GmbH
79772|NCT03562221|Other|Gluten free diet|Controlled gluten free diet
79773|NCT03562221|Dietary Supplement|Probiotics|Capsules
79774|NCT03562221|Dietary Supplement|Placebo|Capsules
79775|NCT03562208|Biological|Adult Bone Marrow Stem Cells|Autologous Bone Marrow Stem Cells Transplant
79776|NCT03562195|Drug|Mepolizumab 100 milligrams|Mepolizumab will be given as a lyophilized cake in sterile vials for individual use. The vial will be reconstituted with Sterile Water for Injection, just prior to use.
79777|NCT03562195|Drug|Placebo|Placebo will be given as 0.9 percent sodium chloride solution.
79778|NCT03562195|Drug|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
79779|NCT03562182|Other|blood draw|Blood draw (2.5mL) to assess mRNA LPCAT1 levels
79780|NCT03562169|Drug|Ixazomib, thalidomide, & dexamethasone (ITD) re-induction|"4 - 6 ITD 28-day cycles as follows:~Ixazomib 4mg capsule on days 1, 8 and 15~Thalidomide 100mg capsule on days 1-28~Dexamethasone 40mg tablets on days 1, 8, 15 and 22"
79781|NCT03562169|Drug|Conventional autologous stem cell transplant (ASCT-con)|Melphalan 200mg/m2 IV infusion on Day -1, followed by ASCT on Day 0.
79782|NCT03562169|Drug|Augmented autologous stem cell transplant (ASCT-aug)|Melphalan 100mg/m2 IV infusion on Day -3 and Day -2 plus ixazomib 4mg capsules on Day -4 and Day -1. ASCT will then be given on Day 0.
79783|NCT03562169|Drug|ITD consolidation and ixazomib maintenance vs. No further therapy|"Participants will be randomised to either 'no further therapy' or 'ITD consolidation and ixazomib maintenance'. Participants randomised to 'no further treatment' will not receive any further treatment but will be followed up at 8 weeks post randomisation 2 and at 3-monthly clinic visits until disease progression.~Participants randomised to ITD consolidation and ixazomib maintenance will receive:~Two 28-day cycles of ITD consolidation (same doses as in ITD re-induction). This will be followed by ixazomib maintenance as follows: Ixazomib 4mg capsule on days 1, 8 and 15 of each 28-day cycle until disease progression."
79784|NCT03562156|Drug|VT-1161|VT-1161 150mg capsule
79785|NCT03562156|Drug|Placebo|matching placebo capsule
79786|NCT03562143|Dietary Supplement|Ferrous Sulfate|Patients will take iron supplementation given as 2 tabs of 325 mg ferrous sulfate (equivalent to 130 mg of elemental iron) on alternate day for 6 weeks.
79787|NCT03562143|Dietary Supplement|Ferrous Sulfate|Patients will take iron supplementation given as 1 tab of 325 mg ferrous sulfate (equivalent to 65 mg of elemental iron) daily for 6 weeks.
79788|NCT03562130|Drug|Teduglutide|Daily sub cutaneous injection 0,05 mg/kg/day
79789|NCT03562117|Drug|Gepotidacin|It is an immediate-release tablet (1500 mg (2 x 750 mg), containing gepotidacin (free base) an inactive formulation excipients.
79790|NCT03562104|Other|videofluoroscopy|Swallowing description in Minimally consciousness Patient
79791|NCT03562104|Other|Wessex Head Injury Matrix scale|Wessex Head Injury Matrix scale in Minimally consciousness Patient
79792|NCT03562091|Other|Data collection|The study is an observational evaluation that does not affect physician practices, the physician-patient relationship, or the care of subjects. The prescriptions will be decided prior to inclusion of the subject into the study. The information will be recorded using the data available in the medical file or collected during the visit (as part of the routine subject management).
79793|NCT03562078|Behavioral|Tai Chi Quan|the first section of Yang style 108 form, including 10-minute warm-up, 40-minute training, and 10-minute cool-down exercise, twice a week
79794|NCT03562065|Biological|mesenchymal stem cells|"Allogeneic Umbilical Cord derived-MSCs injected by slow intravenous infusion according to the weight of the recipient and patient groups in the study, at doses of:~1.10^6 CSM / kg~2.10^6 CSM / kg~4.10^6 CSM / kg 1 injection during 30min to 1h by Intravenous infusion"
79795|NCT03562039|Procedure|M-MIST|minimal invasive surgical technique without thorough removal of granulation tissue
79796|NCT03562000|Device|Cough Assistance and Systematic Non-Invasive Ventilation|"A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough."
79797|NCT03562000|Procedure|control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation|"After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age > 65 years-old, BMI > 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery."
79798|NCT03561987|Procedure|Bariatric surgery|There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
79799|NCT03561974|Device|Humidification|Patients will benefit of humidification and warming of delivered gaz by non-invasive ventilation thanks humidification system.
79800|NCT03561961|Radiation|Moderate Hypo-fractionation|66-68Gy in 25#
79801|NCT03561961|Radiation|Extreme Hypo-fractionation|35-36.25 Gy in 5#
79802|NCT03561948|Procedure|Experimental group|After performing the surgical intervention, the patient will undergo intraoperative intra-abdominal chemotherapy with mitomycin C. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
79803|NCT03561948|Procedure|Control group|In the control group (60 patients), after laparotomy and revision, peritoneal lavage will also be performed with subsequent immunological examination. Patients of this group will not receive intraperitoneal chemotherapy. After performing the surgical intervention, the patient will be irrigation of the abdominal cavity with physiological saline. Further, lavage of the abdominal cavity will be repeated, followed by immunological examination.
79804|NCT03561935|Drug|Propafenone|prescribing propafenone for the management of premature ventricular complex
79805|NCT03561935|Drug|Indenol|prescribing indenol for the management of premature ventricular complex
79806|NCT03561922|Device|RETINA IMPLANT Alpha AMS|Implantation of the subretinal RETINA IMPLANT Alpha AMS
79807|NCT03561909|Other|Platelet transfusion|Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
79808|NCT03561896|Radiation|IGRT|Image-Guided Radiation Therapy
79809|NCT03561896|Radiation|SRS|stereotactic radiation therapy
79810|NCT03561883|Drug|IW-3718|oral tablet
79811|NCT03561883|Drug|placebo|oral tablet
79812|NCT03561870|Drug|Olaparib 150 MG|Olaparaib: 600 mg/day: 300 mg BID (2 x 150 mg tablets taken orally) each 28 days cycle, until disease progression or unacceptable toxicity
79813|NCT03561857|Device|Confocal Laser Endomicroscopy|"The study is divided in 2 parts.~Ex vivo study~Prostate specimens will be stained using Fluorescein~Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~In vivo study~Intravenous injection of contrast agent~pCLE imaging every 5mm of the NVB dissection zone."
79814|NCT03561844|Other|aromatherapy|Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
79815|NCT03561831|Drug|Propofol|propofol based anesthesia
79816|NCT03561831|Drug|Sevoflurane|sevoflurane based anesthesia
79849|NCT03561532|Other|Fecal microbiota transplantation (FMT)|FMT administered into the cecum of the patient in colonoscopy.
79817|NCT03561818|Other|Hospital-based pulmonary rehabilitation|The patients who undergo two days pulmonary rehabilitation under supervision in our clinic and three days a week at home during two months will taken as hospital group. The exercises include breathing exercises, treadmill (15sc), cycle training (15sc), arm ergometer training (15sc), peripheral muscle training and stretching exercises with free weights.
79818|NCT03561818|Other|Home-based pulmonary rehabilitation|The patients who follow a home-based pulmonary rehabilitation program for two months comprising breathing exercises, training in chest hygiene techniques, peripheral muscle strengthening training and self-walking for 5 days in a week for two months. An exercise follow-up form will give to the patients to record their daily exercises. A similar form will fill by physiotherapist once a week during phone call.
79819|NCT03561805|Device|ECG monitoring|Prolonged continuous ECG monitoring using the CardioSTAT® device within the 3 months prior to the TAVI procedure
79820|NCT03561792|Other|Diaphragm ultrasound|In the semi-sitting position ultrasonography for diaphragmatic displacement was performed by the same intensivist. Diaphragmatic movement was evaluated by using 2 to 5 MHz US probe (Sonosite M-Turbo machine). The right hemidiaphragm was examined by two-dimensional (2D) and M-mode to record diaphragm displacement.in M-mode, the diaphragmatic displacement (cm) was measured and then DRSBI was calculated by respiratory rate (RR)/ diaphragmatic displacement (DD) (in mm)
79821|NCT03561779|Drug|YYD302 2ml|YYD302 2ml
79822|NCT03561779|Drug|Active comparator: Synovian Inj.|Active comparator: Synovian Inj.
79823|NCT03561753|Drug|Group A (the standard 2HRZE/4HR regimen）|The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin. The six-month regimen is the standard regimen for the treatment of drug-susceptible tuberculosis recommended by WHO.
79824|NCT03561753|Drug|Group B (New short course PRS regimen, 4EZ(high dose)PtoCfz)|The PRS regimen I（new short course PRS regimen） is 4 months of daily Cfz, Emb, Pto, and high dose pyrazinamide, dosed by weight.Comparison of Standard Regimen：The standard six-month regimen is eight weeks of daily treatment with isoniazid, rifampin, ethambutol, and pyrazinamide followed by sixteen weeks of isoniazid and rifampin.
79825|NCT03561740|Drug|capecitabine|additional metronomic chemotherapy of capecitabine
79826|NCT03561727|Procedure|Mass closure technique|Abdominal cavity will be closed by a single layer of 2 continuous sutures beginning on the opposite ends of the wound towards the median line and involving peritoneum, transversalis fascia, posterior and anterior layer of rectus abdominis muscle fascia and, in case of incisions beyond the lateral border of rectus abdominis muscle, also the oblique abdominal muscles fascia.
79827|NCT03561727|Procedure|Layered closure technique|he first layer will include peritoneum, transversalis fascia and posterior layer of the rectus abdominis muscle fascia closed with 2 continuous sutures beginning at both ends of the wound. In case of incisions exceeding the lateral border of rectus abdominis muscle, the second layer of the continuous suture will start at the lateral border of rectus abdominis muscle, process laterally to the lateral end of the wound involving internal oblique abdominal muscle fascia. Subsequently, the suture will be led out on the anterior surface of the external oblique abdominal muscle, put through by the created loop in the medial direction and processed medially to close the external oblique abdominal muscle fascia and anterior layer of the rectus abdominis muscle fascia.
79828|NCT03561714|Behavioral|Cardometabolic Team Intervention|The CMC-TI team included a registered nurse/certified diabetes educator (RN/CDE) Care Manager, medical assistant (MA) Health Coach, and RN Depression Care Manager. Decision support tools guided therapy for glucose, BP, low-density lipoprotein cholesterol (LDL-c), and depression. At the intervention clinic, the 12-month CMC-TI was delivered to all qualifying patients; surveys were administered to evaluate relevant patient-reported outcomes over 12 months.
79829|NCT03561701|Drug|VT-1161|VT-1161 150mg capsule
79830|NCT03561701|Drug|Placebo|matching placebo capsule
79831|NCT03561688|Device|Foot orthotics|Insoles for shoes
79832|NCT03561688|Device|Standard insole|Sham foot orthotic
79833|NCT03561675|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
79834|NCT03561675|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
79835|NCT03561662|Dietary Supplement|Alpro soya drinks|12 weeks
79836|NCT03561649|Drug|Adalimumab|This trial will be conducted by rheumatologists who can follow patients with SpA and conduct this trial in good conditions and in accordance with regulatory and legal recommendations.
79837|NCT03561623|Other|magnetic resonance (MR) Imaging|MRI of spinal cord and brain
79838|NCT03561623|Other|quantitative muscle force assessment|quantitative assessment of muscle force
79839|NCT03561610|Dietary Supplement|sip feed|normal oral Nutrition + sip feed (Fresubin2.0®; covers individual energy and nutrient demands; high in protein)
79840|NCT03561610|Dietary Supplement|gumdrops|normal oral Nutrition + gumdrops (Nutrimed®; covers individual energy and nutrient demands; high in protein)
79841|NCT03561597|Behavioral|Mobile health intervention|The Kurbo program is a multifunctional mobile application that aid adolescents and their families to learn healthy eating habits and weight management through the use of a mobile application with dietary self-monitoring and weekly interactive coaching sessions. Using the Kurbo app, adolescents track their food and exercise, as well as learn about healthy behaviours through games and videos. The Kurbo coaches check in with adolescents for 15 minutes once a week via video, phone or text over a 12 weeks period.
79842|NCT03561584|Drug|Sulfasalazine|Patients will be initiated on a low dose of sulfasalazine (500 mg) twice daily (bid). Dosage will be increased throughout the study.
79843|NCT03561584|Drug|Placebo|Patients will be initiated on 1 placebo tablet twice daily (bid). Dosage will be increased throughout the study.
79844|NCT03561571|Other|butter based breakfast|ingestion of proteins : 5 g, lipids 20 g, glucides 57 g
79845|NCT03561571|Other|Chocolate spread based breakfast|ingestion of proteins 7 g, lipids 20 g, glucides 56 g
79846|NCT03561558|Drug|Ibuprofen D|Ibuprofen D, oral suspension, 200 mg / 5ml, manufactured by LLC Pharmtechnology, Belarus
79847|NCT03561558|Drug|Nurofen® for Children|Nurofen® for Children, Oral Suspension, 100 mg / 5 ml, marketed by Reckitt Benckiser Healthcare International Ltd, UK
79848|NCT03561545|Other|weightlessness (parabolic flight)|weightlessness (parabolic flight)
79850|NCT03561532|Other|Placebo|Autologous FMT (fecal suspension made of patients own feces) administered into the cecum of the patient in colonoscopy.
79851|NCT03561519|Other|Fecal Microbiota Transplantation (FMT)|Fecal suspension administered in colonoscopy into the cecum of the patient.
79852|NCT03561519|Other|Placebo|As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
79853|NCT03561506|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
79854|NCT03561506|Drug|0.9% Normal Saline|Placebo(0.9% Normal Saline) to be administered as IV drip infusion or bolus injection to consented patients with preoperative anemia before total knee arthroplasty.
79855|NCT03561493|Other|zumba exercise|Participants will engage in 16 classes of 60-minute Zumba® fitness for two consecutive menstrual cycles (an 8-week period, twice weekly). Each class was one hour in length and a recovery period of at least 48 h was taken between classes. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced. The Zumba sessions will be supervised by three certiﬁed Zumba instructors, each responsible for regular sessions per week.
79856|NCT03561480|Drug|Ferric carboxymaltose|Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
79857|NCT03561480|Drug|0.9% Normal Saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
79858|NCT03561467|Other|Observational|Evaluation of dysfunctions in the continuous city-hospital journey of a patients cohort treated by oral chemotherapy
79859|NCT03561454|Device|IORT|Intra-Operative Radiation Therapy
79860|NCT03561441|Drug|Tailored aggressive hydration|"Hydration with lactated Ringer's solution with rate of 3.0 milliliter(mL)/kg/hr during and after ERCP and bolus injection of 20mL/kg for 1 hour after ERCP.~At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the upper normal limit (UNL), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~At 8 hours, if pain (<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
79861|NCT03561441|Drug|Tailored standard hydration|"Hydration with lactated Ringer's solution with rate of 1.5milliliter(mL)/kg/hr during and after ERCP.~At 4 hours after ERCP (patients with ERPD stent insertion ; 6 hours), abdominal pain and serum amylase are checked. If pain (≥ Numeric rating scale (NRS) scale 3) is absent and amylase is below 1.5 times the UNL(upper normal limit), patient starts feeding and stops hydration. If patient has any of these signs, fasting and hydration continues.~At 8 hours, if pain (<NRS scale 3) is absent, patient starts feeding and stops hydration. If patient has pain (≥ NRS scale 3) and previously checked amylase or re-checked serum amylase is above 3 times the UNL, patient is regarded as post-ERCP pancreatitis and receives 3mL/kg hydration. Patient with pain (≥ NRS scale 3) and previously checked serum amylase above 1.5 times but below 3 times the UNL, serum amylase is re-checked."
79862|NCT03561415|Other|Universal Posaconazole Prophylaxis|All patients assigned to this arm will start posaconazole between Day 4 and Day 14 post lung or heart-lung transplant for a minimum of 3 months.
79863|NCT03561415|Other|Pre-emptive Posaconazole Therapy|Posaconazole will be started if a fungal pathogen is identified or there is serological evidence of a fungal pathogen in the absence of any evidence of invasive fungal disease for 3 months.
79864|NCT03561402|Drug|Teriflunomide|Each patient will receive 1 tablet (14 mg) on a daily basis.
79865|NCT03561376|Drug|Topical zinc oxide vs. petrolatum post-surgical scars|"Following linear closure on non-scalp skin with scar length > 4.5 cm, incision site will be split and petrolatum applied to one half and zinc oxide ointment to the other half daily for one month following surgery."
79866|NCT03561363|Behavioral|High-fat diet|The aim of the intervention is to evaluate whether insulin sensitivity and selected Health parameters is affected, when the intake of saturated fatty acids or polyunsaturated fatty acids are highly increased, even when subjects are in energy balance.
79867|NCT03561337|Dietary Supplement|PROTEIN-CARBOHYDRATE|PRO before and PRO-CHO after training
79868|NCT03561337|Dietary Supplement|CARBOHDYRATE|CHO before and after training
79869|NCT03561324|Device|Imaging Beta Probe (IBP)|Using IBP for imaging of PET positive lymph nodes
79870|NCT03561311|Device|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
79871|NCT03561311|Device|sham remote ischemic conditioning|Sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
79872|NCT03561298|Drug|BGB-3111 and Drug Cocktail|BGB-3111 and Drug Cocktail (midazolam, warfarin, omeprazole, digoxin and rosuvastatin)
79873|NCT03561285|Diagnostic Test|antiphospholipid Abs|Laboratory test
79874|NCT03561272|Other|Smart Phone Application|Oral medication adherence phone application.
79875|NCT03561272|Other|POD|Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
79876|NCT03561259|Drug|131I-MIBG|Subjects will receive 18 mCi/kg of 131I-MIBG administered via either a central or a peripheral intravenous catheter over 1.5 to 2 hours on Day 0. The maximum absolute dose of 131I-MIBG on this protocol is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.
79877|NCT03561246|Other|Incline treadmill walking|Those with a Pp 0.47 will undergo INCLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
79878|NCT03561246|Other|Decline treadmill walking|Those with a Pp 0.53 will undergo DECLINE training during which individuals will walk for 15 minutes at a 10-degree treadmill tilt, stopping each five minutes for monitoring of vital signs.
79879|NCT03561233|Drug|Omeprazole 20mg|omeprazole 20 mg twice daily 30 minutes before meal for 4 weeks
79880|NCT03561220|Radiation|Standard of Care IMRT (Photon)|As this trial is pragmatic, all treatment will be standard of care.
79881|NCT03561220|Radiation|Standard of Care Proton Therapy|As this trial is pragmatic, all treatment will be standard of care.
79882|NCT03561220|Radiation|Proton Arm 1: Standard Proton Therapy|78.0 Gy (RBE) in 39 fractions
79883|NCT03561220|Radiation|Proton Arm 2: Hypofractionated Proton Therapy|60.0 Gy (RBE) in 20 fractions
79884|NCT03561207|Diagnostic Test|EV3D Assay|The EV3D assay uses freshly obtained tumor specimen to predict tissue drug response.
79885|NCT03561194|Dietary Supplement|Omegaven|After the diagnosis of PNALD is made, patients who are followed by the Neonatal Intensive Care Unit, NICU, will contact Dr. Honrubia and Dr. Swarup. Cases may also include referrals of patients with PNALD from other healthcare facilities or self-referrals. If the patient's parents or guardians agree to participate in the study, informed consent will be obtained. The history of present illness and past medical history will be reviewed with the guardian and pertinent demographic and medical information will be recorded on data collection forms. This form will be used to record all laboratory results, nutritional history, and descriptions of any liver biopsies performed.
79886|NCT03561181|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
79887|NCT03561181|Biological|S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
79888|NCT03561168|Diagnostic Test|Change in plan of care based on MRI results|"Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results."
79889|NCT03561155|Device|Robot assisted treatment (Amadeo®)|"The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon."
79890|NCT03561155|Other|Conventional treatment|"The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control"
79891|NCT03561142|Radiation|Radiotherapy|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
79892|NCT03561142|Drug|Chemotherapy|chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29. After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of: Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
79893|NCT03561142|Other|Deep regional hyperthermia|"Deep regional hyperthermia to the pelvis, total time 90 min, target temperature 41-42°C. Twice weekly, up to a total of 10 sessions within d1 and d38.~Deep regional hyperthermia is offered at the centers in Tübingen and Erlangen."
79894|NCT03561129|Other|Embryo transfer|all the fresh embryo transfers, performed between January 1997 and December 2016 at Humanitas Fertility Center after IVF-ICSI cycles, divided per operator
79895|NCT03561116|Dietary Supplement|XAN|Daily intake of a sachet containing 12 mg of XAN
79896|NCT03561116|Dietary Supplement|Placebo|Daily intake of a sachet containing excipient
79897|NCT03561103|Behavioral|Client-Centered Representative Payee|CCRP is a structural intervention wherein Social Security authorizes a representative payee to serve as financial manager for people who need help managing their money. By helping clients to consistently pay their bills including rents and utilities, CCRP may redirect the expenditure of participants' resources toward improved health behaviors. Shifting the focus of material and biopsychosocial resources may change the context in which health behaviors are produced, contributing to higher rates of adherence and viral suppression. CCRP modifies the implementation of a current policy of the Social Security Administration (SSA) to create an intervention that is highly replicable.
79898|NCT03561090|Drug|IW-3718|oral tablet
79899|NCT03561090|Drug|placebo|oral tablet
79900|NCT03561077|Other|Mindfulness-based interventions (MBI's)|Mindfulness Based Intervention with eight sessions (one session per week) of two hours dedicated to adolescents will be provided. The intervention will focus on skill building and will incorporate mindfulness meditation, exercises and activities specially adapted to teenagers with chronic pain. Topics will include mind body connection, the effect of stress on pain, living in the present moment, focused awareness, responding versus reacting to pain and/ or difficult situations, non judgement, gratitude, kindness and compassion towards self and others.
79901|NCT03561064|Behavioral|CBT-I|Eligible participants will receive CBT-I by a licensed clinical psychologist.
79902|NCT03561038|Device|Franseen Needle|Comparing 2 needles designed for tissue acquisition
79903|NCT03561038|Device|Fork-tip Needle|Comparing 2 needles designed for tissue acquisition
79904|NCT03561025|Diagnostic Test|18F-FDG-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-FDG
79905|NCT03561025|Diagnostic Test|18F-GE180-PET/MRI|Contrast-enhanced MRI scanning after injection of 18F-GE180
79939|NCT03560635|Behavioral|Weight Loss Maintenance (Control vs. Reverse Diet)|Participants in both groups will receive a 12-week comprehensive, individually delivered behavioral weight loss maintenance intervention, adapted from the Diabetes Prevention Program (DPP) Post-CORE program. This program focuses on utilization of tools and strategies to maintain a healthy lifestyle and prevent weight regain, and is therefore most appropriate for the weight-reduced population we will enroll. While the DPP Post-CORE program includes 15 sessions delivered over 15-months, we will deliver sessions #1-12 and 15 over a 12-week period. Content for sessions 13 and 14 from the DPP Post-CORE curriculum focus specifically on Type 2 Diabetes Mellitus and Heart Disease. The informational handouts will be provided to participants, but not specifically covered in weekly meetings. Groups will differ only in specific caloric prescriptions (described in the Arms section).
79906|NCT03561012|Behavioral|Team-Based Goals and Incentives|The intervention included 3 main components. 1) The intervention fostered a sense of team collective responsibility and solidarity (TEAM) by emphasizing the value of teamwork and front-line community health workers (FLWs) reciting a pledge at meetings to serve beneficiaries. 2) To establish goals and coverage targets related to maternal and child health outcomes (GOALs), 7 targets were identified related to delivery preparations, newborn care, exclusive breastfeeding, and family planning. 3) Small non-cash incentives were awarded to FLWs each quarter if their team met greater than 70% of the collective subcenter goals; incentives were most common cookware products (e.g., dish, cooking vessel, steamer). Non-cash incentives also included a certificate of recognition for teams that met their targets in all quarters (INCENTIVES). In the areas of the intervention and control arms, the Ananya program was also underway (see Brief Summary of the project).
79907|NCT03561012|Other|Control Condition|Standard of care
79908|NCT03560986|Drug|Neridronic acid|Neridronic acid administered by 4 intravenous infusions within 10 Days
79909|NCT03560986|Drug|Placebo|Matching placebo administered by 4 intravenous infusions within 10 Days
79910|NCT03560973|Drug|Gemcitabine|ramucirumab/ placebo was added to gemcitabine
79911|NCT03560973|Drug|Ramucirumab|ramucirumab/ placebo was added to gemcitabine
79913|NCT03560947|Other|Manual Therapy and Exercise (Physiotherapy Intervention)|Experimental group: Manual Therapy and Exercise Participants in this group will receive a 6-weeks program of mobilization and progressive exercise programme for the neck flexors, 2 times a week.
79914|NCT03560947|Other|Usual Care (Physiotherapy Intervention)|Active Comparator: Usual Care Participants in this group will receive usual care in physiotherapy during the 6-weeks period.
79915|NCT03560934|Drug|Dronabinol|Single dose oral administration of 10-60mg dronabinol prior to night 2 or 3 sleep in the clinical laboratory.
79916|NCT03560921|Diagnostic Test|urinary NGAL|measurement urinary NGAL using the ARCHITECT technique
79917|NCT03560908|Drug|Dasatinib|Dasatinib 70mg twice a day will be administered orally for 2 weeks along with re-induction chemotherapy from day 1 of chemotherapy. Recommended re-induction regimens include (1)FLAG: Fludarabine 30mg/m2/d,d1-5;cytarabine 1g-2g/m2/d,d1-5;±G-CSF;(2)IA/DA:idarubicin 8-12mg/m2/d,d1-3 or daunorubicin 45-60mg/m2/d，d1-3;cytarabine 100-200mg/m2/d，d1-7;(3)CAG:Aclarubicin 20mg/d,d1-4；cytarabine 15mg/m2/Q12h,d1-14; ±G-CSF.The chemotherapy regimen is not limited to recommended regimens. Patients will be recommended to receive allogeneic hematopoietic stem cell transplantation (HSCT) once complete remission is achieved. Otherwise, they will continue the consolidation chemotherapy.
79918|NCT03560895|Device|MICROCUFF * endotracheal tube|Patients will be anesthetized using low-volume cuffed Kimberly-Clark * MICROCUFF * endotracheal tube (Microcuff, Halyard Health Inc., Atlanta, GA, USA), with its outer diameter determined by ultrasonography.
79919|NCT03560895|Device|cuffed endotracheal tube|Patients will be anesthetized using high-volume low-pressure cuffed endotracheal tube
79920|NCT03560895|Device|Uncuffed endotracheal tube|Patients will be anesthetized using uncuffed endotracheal tube
79921|NCT03560882|Drug|Atorvastatin|Atorvastatin tablet, 80mg
79922|NCT03560869|Other|Hydration State|Hydration State
79923|NCT03560856|Drug|Fulvestrant + palbociclib|Patients will be treated by Fulvestrant 500mg (day 1 and day 15) and then on Day 1 of each subsequent cycle and every 28 days with palbociclib 125 mg daily for 3 weeks on/1 week off (3/1 schedule).
79924|NCT03560843|Behavioral|MBSR|Mindfulness Based Stress Reduction
79925|NCT03560830|Other|2 submaximal exercise stress tests|
79926|NCT03560804|Drug|Olmesartan|Administration of olmesartan at starting dose and titrating in order to reach the target blood pressure.
79927|NCT03560804|Drug|Chlorthalidone|Administration of chlorthalidone at starting dose and titrating in order to reach the target blood pressure.
79928|NCT03560765|Device|MED|Training in the use of mainstream electronic devices with accessibility options
79929|NCT03560765|Other|Buddy|A buddy who will meet with the participant regularly for social interaction, and assistance with use of any MED purchased
79930|NCT03560752|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given via injection
79931|NCT03560739|Drug|OMB157|20 mg sc. injection
79932|NCT03560726|Behavioral|Cognitive Behavioral Stress Management|Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
79933|NCT03560713|Device|Functional Electrical Stimulation (FES)|Participants will perform 12 weeks of FES (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 25Hz, pulse rate of 200μs, ON:OFF 5:5, individual maximum tolerated intensity; minimum at strong but comfortable visible muscle contraction (without causing undue pain or discomfort to the participant). during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
79934|NCT03560713|Other|Functional Electrical Stimulation (FES) sham|Participants will perform 12 weeks of Functional Electrical Stimulation (FES) sham (Neurodyn High Volt, IBRAMED, São Paulo/SP, Brasil), three times a week, frequency 5Hz, pulse rate of 200μs, ON:OFF 5:5, without muscle contraction during 30 minutes nd receive aerobic exercise training and resistance exercises for upper limbs and lower limbs.
79935|NCT03560700|Dietary Supplement|lactobacillus probiotic strain|Approved Dietary supplement
79936|NCT03560700|Other|placebo|placebo comparator
79937|NCT03560687|Drug|Sucrosomial Iron|CardioSideral 2 caps per day
79938|NCT03560648|Device|High definition surface electromyography combined with accelerometer|HD-sEMG and accelerometer data will be collected by Mobita 32® (TMSi) device.
79988|NCT03560297|Behavioral|Delayed Intervention|Participants receive intervention after delay
79941|NCT03560609|Device|Ophthalmodynamometer|The ODM (Baillart ophthlmodynamometer) is a disc attached to a piston that induces a controlled force on a fixed area. The device will be used to apply a pressure within the range of 10 mmHg - 50 mmHg 4 times to each eye. Each increase of pressure will last approximately 30 seconds. The device is FDA approved and will be used as routinely used in clinical practice
79942|NCT03560609|Device|Goldmann applanation tonometer|The Goldmann applanation tonometer (Haag-Streit, Basel, Switzerland) measures the IOP after the eye is numbed with a drop of anesthetic (proparacaine), which is approved by the FDA. Proparacaine is part of routine patient care using a tonometer regardless of participation in this study. The instrument's tip lightly touches the surface of the cornea and the IOP is measured. The device is FDA approved is routinely used in clinical practice.
79943|NCT03560609|Device|Pentacam|This device maps the cornea and provides pachymetry, topography and corneal aberration maps. The device is FDA approved and routinely used in clinical practice.
79944|NCT03560609|Device|ORA|ORA is an air puff tonometer that applies controlled force to flattens the cornea and provides the corneal hysteresis and corneal resistance factor. The device is FDA approved and routinely used in clinical practice.
79945|NCT03560609|Device|Optical Coherence Tomography (OCT)|OCT is a non-contact,real-time, high resolution, and reproducible imaging modality that provides in-vivo optical cross-sectional scanning of the retina, the ONH and of the anterior segment structures including the cornea. Clinical staff will perform subject testing, not research coordinators. Information about these non-FDA approved OCTs and the multi-modal adaptive optics system can be found in appendices A, B, C, and D. With all devices, the participant sits in a slit lamp like frame. A low power laser light is projected toward the back of their eyes while the subject fixates on a target. None of the systems produce harmful radioactive radiation.
79946|NCT03560596|Behavioral|Adherence Intervention|9 sessions with bilingual health coaches who will utilize a culturally tailored adherence checklist to identify patients specific medication adherence barriers.
79947|NCT03560596|Behavioral|Usual Care|standard hypertension treatment recommendations as determined by PCP
79948|NCT03560583|Drug|Metoclopramide|Metoclopramide 10 mg BID
79949|NCT03560583|Drug|Placebo Oral Tablet|Placebo 10 mg BID
79950|NCT03560570|Biological|Coagulation assay|Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin
79951|NCT03560570|Other|Clinical data collection|At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)
79952|NCT03560544|Behavioral|Breaking up sitting|"A three-part behaviour change intervention, including:~Supportive organisational culture and knowledge of consequence of prolonged sitting~Environmental Modification~Behavioural Changes"
79953|NCT03560531|Drug|ZN-c5|ZN-c5 is a study drug
79954|NCT03560531|Drug|Palbociclib|Palbociclib (IBRANCE®) is an approved drug
79955|NCT03560518|Drug|Rapastinel|Rapastinel (prefilled syringe, weekly intravenous IV administration)
79956|NCT03560518|Drug|Placebo|Placebo (prefilled syringe, weekly IV administration)
79957|NCT03560505|Diagnostic Test|Ultrasound protocol|High-resolution ultrasound protocol at pre-defined sites bilaterally. Pre-defined sites: Sciatic nerve (proximal and distal), tibial nerve (proximal and distal), common fibular nerve (proximal and distal), superficial fibular nerve (proximal and distal) and sural nerve (proximal and distal).
79958|NCT03560492|Other|Exercises|5 sessions of exercises of 20 minutes each. Participants have to do a set of cervical, dorsal and abdominal stretching and strengthening exercises. Participants receive instructions to continue at home on a daily basis for 3 months and record compliance in a logbook.
79959|NCT03560492|Device|Posture garment|Participants are provided with the appropriate size of a posture garment which includes thoracic and abdominal tensional bands. They are instructed to wear it 2 to 4 h per day for a 3 month period and record compliance in a logbook daily.
79960|NCT03560479|Drug|alpha1H, 7.4 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79961|NCT03560479|Other|placebo|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79962|NCT03560479|Drug|alpha1H, 37 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79963|NCT03560479|Drug|alpha1H, 74 mg/mL|Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
79964|NCT03560466|Drug|Dupilumab (SAR231893/REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)"
79965|NCT03560466|Drug|Asthma controller therapies (incl. prednisone/prednisolone)|"Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral"
79966|NCT03560466|Drug|Asthma reliever therapies|"Pharmaceutical form: powder or solution~Route of administration: inhaled"
79967|NCT03560453|Behavioral|Project SEARCH Plus ASD Supports|Project SEARCH is an intensive 9-month job training program where youth with developmental disabilities in their last year of high school are embedded in a large community business such as a hospital, government complex, or banking center (Daston et al., 2012). Students with developmental disabilities who participate in this model rotate through three 10-12 week internships within the business where they log approximately 720 hours of internship time learning marketable skills while receiving supported employment. They also get 180 hours of classroom time at the business for a total of approximately 900 hours embedded in the business setting. In addition to these important training components, Project SEARCH requires collaboration between multiple community partners to support students in attaining employment upon completion of the program. Collaborations include students with developmental disabilities and their family, a LEA, a local CRP, the state VR, and a host business.
79968|NCT03560440|Other|Plasma exposure vancomycin|Investigation of plasma exposure of vancomycin.
79989|NCT03560271|Drug|Cyclo-Z|Cyclo (His-Pro) and zinc
79990|NCT03560271|Other|Placebo|Matching placebo
79991|NCT03560258|Biological|p24CE1/2 pDNA vaccine|4 mg administered by one injection/electroporation
79969|NCT03560427|Drug|Duloxetine 60mg|"Patients will receive duloxetine, 60 mg tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with 2 ml bupivacaine, 0.5% + morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
79970|NCT03560427|Drug|placebo|"Patients will receive placebo tablet 2 hour before operation and will be anesthetized by combined spinal-general anesthesia that includes: spinal anesthesia with 2 ml bupivacaine, 0.5% + morphine 0.3 mg delivered in L4-5 inter spinous space.~General anethseia: Induction of anesthesia was done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation was achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia was done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia was consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg."
79971|NCT03560414|Procedure|simple plasma exchange|simple plasma exchange treatment
79972|NCT03560414|Procedure|conventional PDF treatment group|conventional PDF treatment group
79973|NCT03560414|Procedure|less plasma PDF treatment group|less plasma Plasma diafiltration treatment
79974|NCT03560401|Device|Knight-Taylor [chairback] brace|Knight-Taylor [chairback] brace, is one kind of rigid lumbosacral orthosis. The manufacturer was Rehabilitation and Technical Aid Center, Taipei Veterans General Hospital.
79975|NCT03560388|Other|Acupuncture and touch/relaxation|Pre-operative integrative care (touch-relaxation) that follows with intra-operative acupuncture
79976|NCT03560375|Behavioral|Circuit resistance training (CRT)|"Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27"
79977|NCT03560375|Behavioral|Vegeterranean diet (V-Med diet)|The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.
79978|NCT03560375|Drug|Empagliflozin 10 MG|Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
79979|NCT03560362|Drug|Bupivacaine liposome|
79980|NCT03560362|Drug|Bupivacaine / Epinephrine|
79981|NCT03560349|Drug|Lidocaine HCl Gel 2%|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
79982|NCT03560349|Drug|placebo gel|"Patients will be prescribed a regimen of 1 g acetaminophen q 8hrs alternating with 600 mg ibuprofen q 6 hours. In addition they will be instructed to continue oral fluid hydration and minimal activity for 24 hours.~At 2-hours following the SPG blockade an EBP will be offered to patients. Patient will also be informed that they can request an EBP at any time. The SPG blockade will be performed twice daily in the hospital and twice daily at home, by the patient. The patient will also be informed, if that at anytime, they would like an EBP, it can be provided.~While the study is being conducted, patients will not be offered a SPG block unless enrolled in the study."
79983|NCT03560336|Drug|Liraglutide|Patients will initiate treatment with liraglutide according to the approved label in Korea. Patients will initiate 0.6 mg daily and weekly increase the dose by 0.6 mg until reaching 3.0 mg daily. Patients will then continue to stay on 3.0 mg/day (total treatment duration: 26 weeks).
79984|NCT03560323|Drug|Beta-hydroxy-butyrate|"Following completion of the baseline MRI and blood samples, subjects will be divided into three groups (12 subjects per group). Each group will receive a 6-hour (3-hour in group III) prime-continuous infusion of racemic B-OH-B (100 mg/mL solution; pH adjusted to 7.4) to increase the plasma B-OH-B concentration by 0.5, 2.0, and 5.0 mmol/L.~GROUP I: Prime = 0.4 mg/kg.min for 20 minutes and constant rate = 0.2 mg/kg.min until study end GROUP II: Prime = 1.5 mg/kg.min for 20 minutes and constant rate = 0.75 mg/kg.min until study end GROUP III: Prime = 4.0 mg/kg.min for 20 minutes and constant rate = 2.0 mg/kg.min until study end"
79985|NCT03560310|Drug|Ticagrelor 90mg twice daily and ASA 75-100 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
79986|NCT03560310|Drug|ASA 75-160 mg daily|Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
79987|NCT03560297|Behavioral|SeRenade Parent-Child Music Class|Parent-Child Music Class involving parent training, peer inclusion, and musical play
79992|NCT03560258|Biological|p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine|2 mg p24CE1/2 pDNA admixed with 2 mg full-length p55^gag pDNA administered by one injection/electroporation
79993|NCT03560258|Biological|Full-length p55^gag pDNA vaccine|4 mg full-length p55^gag pDNA vaccine administered by one injection/electroporation
79994|NCT03560258|Biological|Placebo|1 mL placebo administered by one injection/electroporation
79995|NCT03560245|Drug|Bryostatin|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
79996|NCT03560245|Other|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the experimental drug
79997|NCT03560232|Drug|Ceftriaxone|See arm description
79998|NCT03560232|Drug|Ampicillin/sulbactam|See arm description
79999|NCT03560232|Drug|Piperacillin/tazobactam|See arm description
80000|NCT03560232|Drug|Cefazolin + Gentamicin|See arm description
80001|NCT03560232|Drug|Clindamycin + Gentamicin|See arm description
80002|NCT03560219|Diagnostic Test|Biomarkers, Cardiac Magnetic Resonance Imaging, Echocardiography, Flow Mediated Dilatation, Genetic Analysis|"Key variables that will be recorded include the following:~Clinical~Age~Gender~BMI~Diabetes Mellitus~Hypertension~Heart Failure~Ischemic Stroke / TIA~Thromboembolism~Coronary Artery Disease~Peripheral Arterial Disease~Glomerular Filtration Rate~Contrast-enhanced MRI~o Presence and extent of atrial fibrosis~Biomarkers~IL-6~CRP~D-dimer~Fibrinogen~Transthoracic Echocardiography~LA Volume Index (LAVI)~LA Strain, Global~LA Strain rate, Positive peak, Global~LA Strain rate, early negative peak, Global~LA Strain rate, late negative peak, Global~LA Emptying Fraction (LAEF)~LVH~LVEF~Endothelial function o FMD"
80003|NCT03560206|Behavioral|Family SWaP intervention with mini iPad|The Family Sodium Watcher Program (Family SWaP) proposed in this study incorporates the use of a unique electronic salt monitoring device that easily measures salt content in food—the major source of sodium. The intervention is designed to improve adherence to a sodium restricted diet by both patients and family caregivers through education and strategies for gradual taste adaptation to low salt foods. The Family SWaP intervention (6 weekly 45-minute sessions followed by 5 bi-weekly booster sessions) will be delivered remotely using a video-conferencing program on an iPad tablet.
80004|NCT03560206|Behavioral|usual care|The usual care group will receive their routine medical and nursing care for heart failure that consists of a recommendation to follow a sodium restricted diet without explicit skills training to do so.
80005|NCT03560193|Drug|2%Chlorhexidine-70%Isopropanol|2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
80006|NCT03560193|Drug|5%Povidone Iodine- 69%Ethanol|5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes
80007|NCT03560180|Diagnostic Test|Dutch score|leakage score (DUtch LeaKage, DULK), that consider several items (fever, heart rate, respiratory rate, urinary production, mental status, clinical conditions, signs of ileus, gastric retention, fascial dehiscence, abdominal pain, wound pain, leukocytosis, CRP, increase of urea or creatinine and nutrition status), to give a score
80008|NCT03560180|Diagnostic Test|Serum C-reactive Protein|see study protocol
80009|NCT03560180|Diagnostic Test|serum Procalcitonin|see study protocol
80010|NCT03560167|Device|AccuCinch® Ventricular Repair|AccuCinch® Ventricular Repair System in Patients with Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation
80011|NCT03560154|Other|Whole Body Vibration Training|whole body vibration application will be performed in the range of 25-40 Hz, with amplitude 1-2 mm, 30-60 seconds (30-45 seconds) application and resting times of 60 seconds, 2-5 sets each session. Also, as a home program; respiratory exercises will be taught every day of the week for 10 minutes a day.
80012|NCT03560128|Device|Endocuff Vision device|Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
80013|NCT03560128|Device|AmplifEYE device|Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
80014|NCT03560115|Diagnostic Test|Single-heel rise test|Single heel-rise test is used to assess the strength of plantar-flexors clinically
80015|NCT03560102|Device|Philips Sonalleve® MR-HIFU Breast Therapy System|The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.
80016|NCT03560089|Device|Serious game|Serious game with movements
80017|NCT03560089|Device|Placebo serious game|Serious game without movement
80018|NCT03560076|Other|SBIRT Training and Implementation Strategies|A train-the-trainer approach will be used to train site coordinators on the SBIRT process and implementation strategies.
80019|NCT03560063|Procedure|Corin Optimised Positioning System|"Total hip replacement with implant positioning guided by Corin Optimised Positioning System.~The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient."
80020|NCT03560063|Procedure|Standard templating|Total hip replacement with implant positioning guided by standard templating. The experimental and active comparator arms will use the same implants for total hip replacements. The Corin Trinity shell system will be used for the acetabular system. The Corin MiniHip, TriFit, MetaFix and TaperFit implants will be used for the femoral stem implant. Surgeons will select the implant most appropriate for each patient.
80021|NCT03560050|Behavioral|Nutrition assistance|Participating family child care home providers in and around the Oklahoma City (OKC) area will be randomized to either the Nutrition (n=26), or an environmental health comparison group (n=26). Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
80066|NCT03559647|Drug|Atezolizumab|Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
80022|NCT03560050|Behavioral|Children's environmental health|Participating family child care home providers in and around the OKC area will be randomized to either the Nutrition (n=26), or an environmental health intervention (n=26) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Intervention will consist of three encounters with the intervention team: two home-based, 90-minute visits scheduled at the convenience of the family child care home provider and a 3-hour group class session that will be conducted on a weekend. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention over a period of three months.
80023|NCT03560037|Device|Endocuff Vision Assisted Colonoscopy|Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
80024|NCT03560024|Other|PACAP27|PACAP27 is vasodilator of cerebral vessels
80025|NCT03560024|Other|Placebo|Saline
80026|NCT03560011|Drug|immunoglobulin IV|5 injections of immunoglobulin IV once a month during 5 months (2g/kg at M1, 1.5g/kg at M2 to M5, maximal dose 100g)
80027|NCT03559998|Other|lecture|"Empathy (1 hour)~Doctor- patient relationship (1, 5 hour)"
80028|NCT03559998|Other|Simulation using Role play|"serious illness announcement~abuse demand management~reticent patient management"
80029|NCT03559998|Other|Discussion group|Share about clinical work experience and elaboration about psychoaffective and relational challenge
80030|NCT03559998|Other|Simulation using Simulated patient|"HIV announcement~Refuse of antibiotic prescription"
80031|NCT03559985|Drug|paracetamol|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
80032|NCT03559985|Other|Placebo comparator|"Period 1 (D1 to D7): 500 mg (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day.~Wash-out period (D8 to D14): patients should not take paracetamol during this week.~Period 2 (D15 to D21): 500 mg per dose (paracetamol or placebo) to be repeated if necessary, depending on the intensity of pain, after 4 hours minimum between each treatment intake, with a maximum dose of 3 g/day, corresponding to 6 capsules per day."
80033|NCT03559972|Other|on-label facial injection|Assessing if adding SkinMedica's cosmetic topical skincare regimens improves the appearance of the skin and the subject's experience, when used after pre-elected on-label facial injection
80034|NCT03559959|Behavioral|Vouchers for HIV self-testing kits|Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
80035|NCT03559946|Device|percutaneous tibial nerve stimulation (PTNS)|The PTNS and the sham treatments will be given in 30 min sessions. The PTNS treatment consists of inserting a 34-gauge needle electrode approximately 5 cm cephalad to the medial malleolus and, as well as placing a PTNS surface electrode on the ipsilateral calcaneus. To keep the electrode placement consistent with the sham treatment, 2 inactive transcutaneous electrical nerve stimulation (TENS) surface electrodes are also added, 1 placed under the little toe and 1 on the top of the foot. The PTNS lead set is connected to the Urgent PC stimulator, and a current level of 0.5 to 10 mA at 20 Hz is delivered until the flexion of the big toe is observed or the patient reports a radiating sensation at the sole of the foot.
80036|NCT03559946|Device|Sham procedure|The sham treatment, involves simulating the sensation of the PTNS needle insertion at the same location using a Steritberger placebo needle. This is a blunt tip needle which simulates the sensation of a needle prick when touched to the skin, however, the blunt tip retracts into the handle when pressed into the skin. This creates the illusion of the needle entering the skin, without breaking the skin's surface. An inactive PTNS surface electrode is also placed on the ipsilateral calcaneus. The two TENS surface electrodes, placed in the same location as the PTNS treatment, are active and deliver stimulation mimicking the sensory effects of the PTNS. However, since no electrode needles were inserted near the tibial nerve, there will be no tibial nerve stimulation
80037|NCT03559933|Device|PEPNS System|PEPNS System therapy will be delivered periodically up to 48 hours or less if patient is no longer being mechanically ventilated.
80038|NCT03559920|Procedure|Naso-tracheal group|"Clinical procedure applied to 2 groups is basically same. Investigators sedate the patients in the ICU for several days after head & neck surgery using sevoflurane via anesthetic conserving device.~The only difference between 2 groups is whether the patients are with naso-tracheal intubation status or tracheostomy status."
80039|NCT03559920|Procedure|tracheostomy group|"Clinical procedure applied to 2 groups is basically same. Investigators sedate the patients in the ICU for several days after head & neck surgery using sevoflurane via anesthetic conserving device.~The only difference between 2 groups is whether the patients are with naso-tracheal intubation status or tracheostomy status."
80040|NCT03559907|Behavioral|Cooking Matters for Parents|Cooking Matters for Parents focuses on teaching parents of young children important lessons about self-sufficiency in the kitchen. Participants have the opportunity to practice fundamental lessons including knife skills, reading ingredient labels, cutting up a whole chicken, and making a healthy meal for a family of four on a budget of ten dollars. Each session includes meal preparation, didactic teaching, and sharing the meal as a group. Instructors share their education and experience and discuss how to choose healthy, affordable fruits and vegetables at the grocery store. Each week, adults take home a bag of groceries after each class so they can practice the recipes taught that day.
80091|NCT03559387|Drug|Neulasta®|"Subjects randomized to the Neulasta® treatment arm will receive the comparator drug on Day 2(day after chemotherapy treatment) of each Chemotherapy cycle. Neulasta® will be administered to the subjects at a standard dose of 6.0 mg in 0.6 ml as a subcutaneous injection.~Neulasta® is also provided as a single-use pre-filled syringe."
81694|NCT03547102|Dietary Supplement|Cherry concentrate|
80041|NCT03559907|Behavioral|Mealtime PREP|Parents are trained to deliver each intervention component during mealtimes using a step-wise, behavioral activation approach. The parent-training prong of the Mealtime PREP intervention incorporates four active ingredients of behavioral activation (1. skills training; 2. goal-setting; 3. activity scheduling; and 4. activity monitoring) to help parents build a family meal routine that is enriched with techniques to promote child food acceptance. Each week, parents will take home healthy groceries to practice making healthy snacks and side dishes in the home.
80042|NCT03559894|Diagnostic Test|Trans-thoracic echocardiography|Trans-thoracic echocardiography
80043|NCT03559881|Other|High protein/high dairy|Participants in the interventional group will receive individual dietary instruction on how to achieve at least 1.2 grams of high quality protein / kg of body weight / day, 50% from dairy products, and at least one meal per day consisting of a minimum of 30 g of high quality protein (~14 g of essential amino acids).
80044|NCT03559868|Drug|Digoxin|Different doses of oral digoxin to test if digoxin has an effect on the immune response of peripheral blood levels (PBLs).
80045|NCT03559868|Other|Placebo|Oral placebo
80046|NCT03559855|Behavioral|Real Essentials|The REAL Essentials curriculum is a healthy relationship education program for youth developed by the Center for Relationship Education.
80047|NCT03559829|Device|RAPAEL Smart Glove|The RAPAEL Smart Glove is a commercially available, non-invasive biofeedback based system for distal upper extremity rehabilitation. The Smart Glove is very lightweight and allows for easy movement of all distal upper extremity joints. It is made of an elastomer material that is simple to maintain and clean. The Bending Sensor is a variable resistor that changes as it is bent. The sensor is a 9-axis movement and position sensor that consists of 3 acceleration channels, 3 angular rate channels, and 3 magnetic field channels that measure wrist movements. They are connected to a computer system which can accurately compute the amount of individual finger movements.
80048|NCT03559816|Other|Classification of perineal tears based on new classification|Classifications according to the American College of Obstetricians and Gynaecologists (ACOG) and the Royal College of Obstetricians and Gynaecologists (RCOG) and sub classification of second-degree lacerations based on the assumption that episiotomy involves the same anatomic structures of a second-degree laceration (perineal muscle, mucosa and skin), and divides them in two sub-groups, named A (if spontaneous vaginal tear is smaller than episiotomy) and B (if spontaneous vaginal tear is bigger than episiotomy).
80049|NCT03559816|Procedure|Selective use of Episiotomy|Standardized selective use of Episiotomy as recommended by guidelines.
80050|NCT03559803|Drug|Cisplatin|"Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion)."
80051|NCT03559790|Drug|tenofovir alafenamide|To evaluate of efficacy and safety in patients with TDF-TAF switch therapy
80052|NCT03559777|Other|closed sinus lifting by Osteotome|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy preparation, which should be ended 1mm short of sinus floor.~The widening drills can be sequentially used to widen the osteotomy site to the same level~An osteotome of diameter a little less than the planned implant body, will be inserted in the prepared osteotomy site and gently tapped to reach the same level.~The osteotome will be tapped gently to fracture up the sinus floor.~Xenograft will be added to the osteotomy as the grafting material.~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
80053|NCT03559777|Other|closed sinus lifting by Densah bur|"Local anesthesia will be injected intra-orally~A full thickness flap will be elevated~A pilot drill will be used to start the osteotomy , which should be ended 1mm short of sinus floor.~Change the drill motor to reverse- densifying Mode~with the densah bur (2.5mm) until 1 mm short of the sinus floor.~Use the next wider Densah Bur (3.0) in densifying-mode until feeling the haptic feedback of the bur reaching the dense sinus floor, modulate pressure with a gentle pumping motion to advance past the sinus floor in 1 mm increments.~densah burs (3.5mm) advance in the osteotomy.~Xenograft will be added to the osteotomy .~Once the desired height of sinus elevation will be gained and grafted, the implant fixture will be inserted.~Smart peg will be placed on implant and Ostell will be used to record ISQ.~Healing collar will be placed on implant.~Suturing the flab around healing collar."
80054|NCT03559764|Biological|Anti-BCMA CAR T cells|Transparent colorless or slightly yellow liquid
80055|NCT03559751|Other|VLN cigarettes (A)|0.4mg nicotine / g tobacco king size filter cigarette
80056|NCT03559751|Other|Usual Brand Cigarettes (B)|Usual brand king size non-menthol cigarettes
80057|NCT03559751|Drug|Nicotine gum (C)|4 mg nicotine gum
80058|NCT03559725|Other|VLN menthol cigarettes (A)|0.4mg nicotine / g tobacco king size filter menthol cigarette
80059|NCT03559725|Other|Usual Brand Menthol Cigarettes (B)|Usual brand king size menthol cigarettes
80060|NCT03559725|Drug|Nicotine gum (C)|4 mg nicotine gum
80061|NCT03559712|Other|Collaborative care, Telemental health|Children who are referred to the collaborative tele-mental health care arm, Arm (1), will be given a follow-up appointment with the physician at the same primary care center who have successfully completed the pre-trial didactic program designed by Drs. Albanna and Hamoda. The trained child health physician will conduct assessments, treat and manage the patient. All while having weekly clinical supervision with the specialist.
80062|NCT03559699|Drug|AG-348|"Part 1 (Dose Optimization Period): All participants will begin by receiving 5 milligrams (mg) orally, twice a day. Each participant's dose of AG-348 may be increased to 20 mg twice a day or 50 mg twice a day depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Last dose received in Part 1, twice a day."
80063|NCT03559686|Drug|Certolizumab Pegol|The recommended maintenance dose of Cimzia® (Certolizumab Pegol) for adult patients with Rheumatoid Arthritis (RA) is 200 mg every 2 weeks (single 1 mL injection of 200 mg) .
80064|NCT03559673|Drug|Lacosamide|Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.
80065|NCT03559660|Drug|Certolizumab Pegol|
80067|NCT03559634|Diagnostic Test|Intervention Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. Contraceptive choices being offered include the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. The participant can then decide if they would like to start a medication they qualify for in the ED.
80068|NCT03559634|Other|Control Group|The electronic application will collect screening health information and contraceptive preferences about the participant. Then, using branch logic, decide which contraceptive options the participant would qualify for based on health history answers. This includes the contraceptive implant, injection, pill, patch, or ring. They will then be able to watch videos about methods they are eligible for. Participants will then be given follow up information on outpatient locations where they can receive these contraceptive methods.
80069|NCT03559621|Behavioral|mobile-based lifestyle intervention|one face-to-face coaching within 2 weeks after randomization, monthly telephonic coaching -and continuous use of the app as needed
80070|NCT03559595|Behavioral|Project Prevent|The Project Prevent intervention entails 1) a media campaign to raise PrEP awareness, 2) geographically targeted education initiatives with medical personnel to increase access to consumers, and 3) programming with AIDS service organizations to improve service delivery around PrEP.
80071|NCT03559569|Biological|Biological samples will be done to evaluate the endothelial and leukocyte senescence.|Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
80072|NCT03559556|Other|CT angiography|CT angiography uses a CT scanner to produce detailed images of both blood vessels and tissues in various parts of the body. An iodine-rich contrast material (dye) is usually injected through a small catheter placed in a vein of the arm.
80073|NCT03559543|Dietary Supplement|Ocoxin-Viusid|"An oral solution of Oncoxin® (30 ml vials) will be used at a rate of 60 ml daily (1 vial every 12 hours), preferably administered after breakfast and lunch. It will be prescribed for a period of 2 weeks before starting the QT up to 3 weeks after finishing the treatment.~The treatment with Oncoxin®-Viusid® will continue in the possible periods of time of suspension of the chemotherapy treatment due to toxicities attributable to the oncospecific treatment.~The treatment will be administered continuously for approximately 29 weeks from the patient's inclusion in the study."
80074|NCT03559530|Drug|Antimicrobial|Antimicrobial therapy according to A. baumannii susceptibility profile
80075|NCT03559517|Biological|SHP647|Subcutaneous injection of SHP647 will be administered using a prefilled syringe.
80076|NCT03559517|Other|Placebo|Subcutaneous injection of placebo matched with SHP647 will be administered using a prefilled syringe.
80077|NCT03559504|Drug|Sevoflurane Inhal Soln|Anesthesia will be induced by sevoflurane inhalation only with a tight-fitting facemask and a 4-l airflow of 100% oxygen. Sevoflurane inhalation will be adjusted in all age groups to maintain 1.0 MAC concentration
80078|NCT03559491|Drug|Intravitreal injection|Long term release steroid injection
80079|NCT03559478|Procedure|Sharp dissection with scalpel plus electrocautery to vessels|A scalpel will be used for dissection for TKA implantation. Bleeding vessels will be managed as encountered with electrocautery. Electrocautery will not be used for dissection.
80080|NCT03559478|Procedure|Electrocautery for all dissection|Skin incision will be made with a scalpel, but all other dissection will be performed with electrocautery.
80081|NCT03559465|Procedure|skin biopsy|"A skin biopsy will be performed in 10 patients in the form of 2 punches of 5 mm in the injured area in aseptic condition with a Rodnan score.~In this study, 10 skin biopsies are needed, and will be performed on the first 10 patients accepting this biopsy."
80082|NCT03559465|Other|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of B lymphocyte
80083|NCT03559452|Procedure|Eccentric exercise|300 eccentric contractions of the knee extensors
80084|NCT03559439|Biological|CD19 CAR T|CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
80085|NCT03559426|Drug|Antipsychotic Reduction|Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
80086|NCT03559426|Drug|Antipsychotic Maintenance|Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
80087|NCT03559413|Biological|Individual peptide vaccination with adjuvant GM-CSF and Imiquimod|Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
80088|NCT03559400|Drug|local gentamicin injection|Treatment includes debridement and administration of the local antibiotic which will consist of 80mg of liquid gentamicin diluted in 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
80089|NCT03559400|Drug|placebo saline injection|Treatment includes debridement and administration of the local antibiotic which will consist of 40mL normal saline injected after inserting a 22 gauge needle down to bone after wound closure. The injection will continue until either all 40cc are injected or there is fluid extravasation from the wound.
80090|NCT03559387|Drug|ANF-RHO™|"Subjects randomized to the ANF-RHO™ treatment arm will receive the investigational product on Day 1(day of chemotherapy treatment) of each Chemotherapy cycle. ANF-RHO™ will be administered to the subjects as a subcutaneous injection. Subjects will receive the ANF-RHO™ dose with a volume equivalent to 10 µg/kg, 20 µg/kg and 30 µg/kg.~ANF-RHO™ is provided as a single-use glass vial containing 1.0 ml of solution at a concentration of 5 mg/ml"
81695|NCT03547102|Dietary Supplement|Placebo concentrate|
80092|NCT03559374|Other|Vanadis NIPT system|A novel cost effective not NGS (next-generation sequencing) test, based on imaging single DNA molecules for high precision NIPT (non-invasive prenatal testing)
80093|NCT03559361|Dietary Supplement|EPA-rich|6 months omega 3 supplementation
80094|NCT03559361|Dietary Supplement|DHA-rich|6 months omega 3 supplementation
80095|NCT03559361|Dietary Supplement|Olive oil Placebo|6 months placebo supplementation
80096|NCT03559348|Drug|chemotherapy: TS-1, Leucovorin and Gemcitabine|Gemcitabine 800 mg/m2 , on day 1 S-1 80, 100 or 120 mg/d, orally twice daily on day 1 - 7; Leucovorin 60 mg/d, orally twice daily on day 1 - 7; Every 14 days as one cycle.
80097|NCT03559322|Device|iNAP® Lite Sleep Therapy System|Class II intraoral devices for snoring and/or obstructive sleep apnea
80098|NCT03559309|Diagnostic Test|Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing|Patients treated with Alirocumab in the clinical routine will have additional diagnostic tests as stated above. The clinical trial will be conducted as an open label, single arm study. The diagnostic tests will be done at baseline (BL) and after 10 weeks of treatment (W10) with Alirocumab.
80099|NCT03559296|Diagnostic Test|Ultrasonographic assessment of postmastectomy lymphedema|Qualitative assessment of postmastectomy lymphedema via ultrasound (Subcutaneous echogenicity (SEG) and subcutaneous echo-free space (SEFS) grade systems for postmastectomy lymphedema) and circumferential tape measures ( The circumferential measurement of affected arm at MCP joint, wrist joint, 15 below elbow joint, elbow joint 15cm above elbow point) to assess upper extremity volume
80100|NCT03559283|Diagnostic Test|Walking and Record Cortical Activity|"The cortical activity of each patient is recorded by NIRS under the following conditions:~Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer."
80101|NCT03559270|Drug|Baricitinib|Administered orally
80102|NCT03559257|Drug|Galcanezumab|Administered SC.
80103|NCT03559257|Drug|Placebo|Administered SC.
80104|NCT03559244|Other|Dynamic compression brace|custom-fitted brace adjusts the pressure on the thoracic wall and enables lateral expansion of the thorax
80105|NCT03559244|Other|Exercises|posture exercises, deep breathing exercises, exercises for manipulation and mobilization of ribs, and core exercises
80106|NCT03559231|Procedure|dFTRD|Duodenal Full-Thickness Resection
80107|NCT03559231|Procedure|EMR|Endoscopic Mucosal Resection
80108|NCT03559218|Device|KeraStat(R) Cream|KeraStat Cream is a cream wound dressing that contains 5% keratin.
80109|NCT03559218|Other|Standard of care|Patients will be instructed to follow institutional standard of care for radiation dermatitis
80110|NCT03559205|Other|MSK-Tracker|"The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~Pre-clinic preparation.~Clinic dashboard.~Summary action plan.~Personal goal setting.~Follow-up and monitoring."
80111|NCT03559192|Drug|JNJ-67953964|JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.
80112|NCT03559192|Drug|Placebo|Matching placebo will be administered as 2 capsules orally once daily.
80113|NCT03559179|Other|Opioid Wizard|The Opioid Wizard is an OUD clinical decision support tool for primary care providers.
80114|NCT03559166|Drug|BLD-2660|Randomized to active product or placebo
80115|NCT03559153|Other|Shiatsu massage|The shiatsu massage will be during the rest break by 15 minutes.
80116|NCT03559153|Other|Physical Exercise|The Physical Exercise will be during the rest break by 15 minutes.
80117|NCT03559140|Procedure|Applied saline solution at 2.5 oC (Cryotherapy group)|Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
80118|NCT03559140|Procedure|Applied saline solution at 8oC (Cryotherapy )|Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
80119|NCT03559140|Procedure|Applied saline solution at room temperature (No cryotherapy)|Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
80120|NCT03559127|Procedure|For the Group A. Applied Cryotherapy at 6 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (6 oC) 17% EDTA followed with 20 mL cold (6 oC) sterile saline solution dispensed to the WL using a cold (6 oC) metallic micro-cannula included in the Endo Vac System (Kerr Endo) for 5 minutes.
80121|NCT03559127|Procedure|For the Group B. Applied Cryotherapy at 2.5 oC|Patients assigned to this group receive a final irrigation with 5 mL cold (2.5 oC) 17% EDTA followed with 20 mL cold (2.5 oC) sterile saline solution dispensed to the WL using a cold (2.5 oC) metallic micro-cannula included in the Endo Vac System for five minutes.
80122|NCT03559127|Procedure|Control Group (CG). Applied irrigant at room temperature|Patients assigned to this control group were treated identically to the experimental groups, except that receive a final flush with 5 mL (room temperature) 17% EDTA followed with twenty mL (room temperature) sterile saline solution delivered to the WL using a metallic micro-cannula included in the Endo Vac System for five minutes.
80123|NCT03559114|Drug|Dalteparin|Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.
80124|NCT03559114|Drug|Saline|Saline in prophylactic doses administered daily if screening criteria are satisfied.
80261|NCT03558113|Diagnostic Test|light induced fluorescence intraoral camera|intraoral oral light induced fluorescence diagnostic camera
80125|NCT03559101|Other|Distilled water|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
80126|NCT03559101|Other|Medical Food 1|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
80127|NCT03559101|Other|Medical Food 2|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
80128|NCT03559101|Other|Pedialyte|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
80129|NCT03559101|Other|Gatorade|"Commercially available beverage~Subjects collect all morning urine and drink 500 milliliters of water. Baseline vital measurements (heart rate, blood pressure, oral temperature) and body weight collected Baseline blood samples and urine collected Beverage pretreatment consumed (1 liter over 30 minutes) Body weight measured and blood and urine collected at 5 minutes, 10 minutes, 15 minutes, and then every 30 minutes for 4 hours post beverage consumption"
80130|NCT03559088|Other|Migraine App|Smart phone app used to report migraine burden to the EHR.
80131|NCT03559062|Drug|TEZ/IVA|Fixed-dose combination (FDC) tablet (TEZ/IVA)
80132|NCT03559062|Drug|IVA|IVA tablet
80133|NCT03559062|Drug|Placebo|Matching placebo.
80134|NCT03559049|Drug|Pembrolizumab|200mg IV every 21 days
80135|NCT03559049|Drug|Pemetrexed|500mg/m^2 IV every 21 days
80136|NCT03559049|Drug|Carboplatin|AUC 5 IV every 21 days
80137|NCT03559049|Drug|Rucaparib|600mg PO, BID days 1-21 of each 21 day cycle
80138|NCT03559036|Procedure|Locomotor Training|Body-weight supported stepping on a treadmill.
80139|NCT03559023|Procedure|Ultrasound Only|The anesthesia team will use ultrasound to scan on subject's upper back (thoracic spine) to identify a place to begin the epidural procedure. A pen will be used to place markings on subject's back.
80140|NCT03559023|Procedure|Manometry Only|The anesthesia team will use an extra piece of tubing to confirm the epidural space one the epidural space is established.
80141|NCT03559023|Procedure|Ultrasound Plus Manometry|The anesthesia team will use both ultrasound and manometry to assist with epidural placement.
80142|NCT03559023|Procedure|Usual Care/Management|"The epidural will be placed using the usual technique utilized by the anesthesiology department. The the usual care/management group will receive a sham (fake) ultrasound exam of subject's upper back with fake pen markings placed on subject's back. The ultrasound machine will not be turned on."
80143|NCT03559010|Drug|Norgestrel 0.075 mg tablets|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet."
80144|NCT03558997|Drug|Dupilumab|Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe
80145|NCT03558997|Drug|Timothy Grass SCIT|Timothy Grass extract will be administered subcutaneously (SC)
80146|NCT03558997|Drug|Placebo matching dupilumab|Placebo matching dupilumab is prepared in the same formulation without the addition of protein
80147|NCT03558997|Drug|Placebo matching SCIT|Placebo matching SCIT is prepared in the same formulation (SCIT diluent) without the addition of Timothy Grass extract
80148|NCT03558984|Drug|D-PLEX|D-PLEX is a new formulation of extended release of Doxycycline (active ingredient)
80149|NCT03558984|Other|Standard of Care|"The SOC prophylactic antibiotic treatment will be consistent and standardized for all sites in the clinical study. is based on The society of thoracic surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery, part II: antibiotic choice."
80150|NCT03558971|Drug|Cortisol|Participants determine when to administer 5-day regimens of cortisol
80151|NCT03558958|Drug|P-188 NF|Poloxamer administered daily via sc injection at 5 mg/Kg
80152|NCT03558945|Biological|Personalized neoantigen vaccine|"Personalized neoantigen vaccines will be injected on day 1 of weeks 1, 3, 5, 7, 9, short interval or 1-2 months after the end of their post-operative chemotherapy, and two boosts will be on day 1 of weeks 12, 20.~Vaccines will be given in a total volume of up to 1.0ml/shot consisting of 0.3mg peptide+0.5mg ployICLC injected subcutaneously into two to four separate sites of the subject's thighs."
80153|NCT03558932|Diagnostic Test|pleural biopsy|diagnostic sampling
80154|NCT03558919|Drug|Mirabegron 25mg|
80155|NCT03558919|Drug|Solifenacin Succinate 5 MG|
80156|NCT03558893|Behavioral|Forced Desynchrony|All sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
80157|NCT03558880|Procedure|Erector Spinae Plane Block|Erector Spinae Plane Block was performed
80158|NCT03558880|Procedure|Tumescent Anesthesia|Tumescent Anesthesia was applied
80159|NCT03558867|Drug|Metformin + Healthy diet|Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
80160|NCT03558867|Drug|Metformin + Personalized diet|Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
80161|NCT03558854|Drug|Acetylsalicylic acid|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
80162|NCT03558854|Drug|Placebo oral capsule|Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
80163|NCT03558841|Other|Gait training with the THERA-Trainer Lyra|Gait training with the THERA-Trainer Lyra end-effector gait trainer 3x/week during the inpatient and the outpatient periods.
80164|NCT03558841|Other|Physical therapy|Conventional geriatric rehabilitation physical therapy (6x/week) during the inpatient period. After discharge home, discontinuation of physical therapy.
80165|NCT03558828|Behavioral|Step 1: PA Monitor|The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.
80166|NCT03558828|Behavioral|Step 1: PA Monitor + Text|"The participant will receive an enhanced physical activity monitor treatment for weeks 1-8, which includes goal setting with a physical activity prescription, and self-monitoring with a physical activity monitor.~In addition, these participants will receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent."
80167|NCT03558828|Behavioral|Step 2: PA Monitor with Calls|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
80168|NCT03558828|Behavioral|Step 2: PA Monitor with Meetings|"Nonresponders to the enhanced physical activity monitor, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
80169|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Calls|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition they will receive ten brief motivational telephone calls, made by an interventionist, every two to three weeks during weeks 9-34."
80170|NCT03558828|Behavioral|Step 2: PA Monitor + Texts with Meetings|"Nonresponders to the enhanced physical activity monitor plus text messaging, will receive an augmented treatment.~The participant will continue to receive an enhanced physical activity monitor treatment for weeks 9-34.~In addition, these participants will continue to receive motivational text messages. For participants who remain less than halfway to their daily step goal by a designated daily time, a motivational text message with a strategy to overcome barriers will be sent.~In addition, the participant will take part in five 45-minute group meetings held every four to six weeks during Weeks 9-34."
80171|NCT03558828|Behavioral|Step 3: PA Monitor|During Weeks 35-50, all women will receive enhanced physical activity monitors only.
80172|NCT03558802|Other|questionnaire|questionnaire
80173|NCT03558789|Biological|bovine lactoferrin|mouthwash
80174|NCT03558776|Dietary Supplement|linseed oil|linseed oil and defined background diet
80175|NCT03558763|Device|Telemonitoring|During the telemonitoring treatment period the subjects will register; vital functions (blood pressure, heart rate, weight, SpO2) twice a week, physical movement daily by using a fitness device, have video calls with a nurse weekly the first 4 weeks and thereafter every fourth week the last 5 months. Twice a week (± 2 days) questionnaires (CAT and MRC) should be filled out at home.
80176|NCT03558763|Other|Normal Care|During normal care the subjects will get the possibility to call the COPD-center via telephone on their own initiative e g with worsening symptoms as usual.
80177|NCT03558750|Biological|Nivolumab|Given by IV
80178|NCT03558750|Biological|Rituximab|Given by IV
80179|NCT03558750|Drug|Lenalidomide|Given by mouth
80180|NCT03558737|Other|Nasal high-frequency jet ventilation (nHFJV)|Non-invasive high-frequency jet ventilation provided via the Bunnell Life Pulse high-frequency JET ventilator through a Rusch latex nasopharyngeal airway
80181|NCT03558737|Other|Nasal intermittent positive pressure ventilation (NIPPV)|Non-invasive positive pressure ventilation delivered via a conventional ventilator through Hudson prongs
80182|NCT03558724|Drug|Bevacizumab-IRDye800CW|Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to the endoscopic procedure
80183|NCT03558724|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
80184|NCT03558711|Diagnostic Test|18F-PSMA|18F-PET imaging
80185|NCT03558698|Other|Good ventilation|Good ventilation with a low concentration of CO2
80186|NCT03558698|Other|Ventilation CO2|CO2 High and Good ventilation
80187|NCT03558698|Other|Poor Ventilation|Poor ventilation with high concentrations of CO2 and bio effluents
80188|NCT03558685|Behavioral|Weight loss diet|Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
80189|NCT03558672|Device|Flexitouch system with Head and Neck Garments|Flexitouch system or Flexitouch Plus Head and Neck Treatment, as prescribed
80190|NCT03558659|Device|Positional therapy belt|The positional therapy belt produced by SlumberBUMP will be used by stroke patients during sleep, which helps to avoid sleep in the supine position.
80191|NCT03558646|Other|There is no intervention planned (observational)|There is no intervention planned (observational)
80693|NCT03554889|Biological|NK Cell adaptive transfer|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
80192|NCT03558620|Procedure|mask ventilation|mask ventilation (one-handed ventilation, one-handed with an endoscopic bite block, and two-handed ventilation)
80193|NCT03558607|Drug|Ruxolitinib|"Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows;~If Age < 55 years and ECOG PS < 2 : 7+3 regimen~If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen~Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months."
80194|NCT03558594|Behavioral|Hypnosis|Behavioral Condition
80195|NCT03558594|Behavioral|Mindfulness|Behavioral Condition
80196|NCT03558581|Other|Educational|
80197|NCT03558568|Device|Deep Brain Stimulation|Deep Brain Stimulation is an established surgical method for Parkinson's Disease.
80198|NCT03558555|Drug|Acetaminophen IV Soln|1000mg of IV acetaminophen
80199|NCT03558555|Drug|Oral Acetaminophen|oral acetaminophen 975mg pills
80200|NCT03558555|Drug|Placebo Pills|placebo match to acetaminophen
80201|NCT03558555|Drug|Saline|Intravenous saline
80202|NCT03558542|Other|cardiopulmonary rehabilitation plus neurorehabilitation|Patients with stroke will undergo an accompanying structured cardiopulmonary rehabilitation program along with a neurorehabilitation program
80203|NCT03558516|Drug|Magnesium group|We will dilute magnesium 6 gram with 0.9% sodium chloride to 30 ml. The patient will receive magnesium sulfate 40 mg/kg infuse over 30 min started at skin incision and continuous drip 10 mg/kg/hr until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
80204|NCT03558516|Drug|Normal saline group|The patient will receive 0.9% sodium chloride the same amount of magnesium sulphate infuse over 30 min started at skin incision and continuous drip until the dura is closed. Anesthesia is standardized with propofol, fentanyl, cisatracurium and sevoflurane. Vasopressor or antihypertensive drug are used to control hemodynamics.
80205|NCT03558503|Drug|UGN-102|Six (6) intravesical instillations of UGN-102 (1.33 mg) will be given weekly.
80206|NCT03558490|Device|ZEMY software|"The ZEMY software medical device integrates specific algorithms based on international and validated guidelines. It provides individually customized information and defines for the patient an adapted action to follow for each of the following reported symptoms or anti-cancer treatment-related toxicities: diarrhea, fatigue, nausea, vomiting, cutaneous and mucosal toxicities, pain, fever/febrile neutropenia, high blood pressure, anxiety and depression.~During the 3-month study period, participants will be asked to enter their symptoms among the 10 symptoms listed in ZEMY on their smartphone dedicated to the study. Consequently, ZEMY software will provide to the participants adapted real-time information to advise them on the management of the experienced symptom and recommend hygienic-dietetic advice and symptomatic treatments."
80207|NCT03558490|Drug|Investigator's choice of anti-cancer treatment (except immunotherapy)|All anti-cancer treatments (except immunotherapy) will be left to the free choice of investigators. Participants shall be prescribed by the healthcare team both of the following symptomatic treatments: loperamide or any other anti-diarrheic treatment in case of diarrhea; and a prescription for any medication indicated in case of nausea/vomiting. A written prescription will be made by the investigator at screening for loperamide or any other anti-diarrheic treatment and symptomatic treatment for nausea/vomiting with documented dosage and duration.
80208|NCT03558477|Drug|YYD601 1|YYD601 1
80209|NCT03558477|Drug|YYD601 2|YYD601 2
80210|NCT03558477|Drug|YYD601 3|YYD601 3
80211|NCT03558477|Drug|Nexium|Nexium
80212|NCT03558464|Dietary Supplement|Intervention (integrated package)|"During whole study (pregnant women and offspring):~Soap (for daily hand washing)~Chlorine solution (for daily drinking water treatment)~Life stage-appropriate (pregnancy, lactation, IYCF) monthly nutrition and WASH trainings~During pregnancy and up to when offspring turns 6 months old:~LNS (Enov' Mum, 20g sachet daily)~Anthelminthic treatment (single-dose mebendazole (500mg), once during second trimester of pregnancy)~Children 6-24 months of age~MNP (MixMe, 1g sachet every three days)~ORS + zinc~1 egg per day~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group. All women will follow regular antenatal care as provided by the Kenyan government as part of their routine health system (e.g. intermittent preventive malaria treatment and iron-folic acid-supplements)."
80213|NCT03558464|Other|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads"
80214|NCT03558451|Other|Complex intervention in sexual health|EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.
80215|NCT03558451|Other|Usual care|According to available protocols applicable to the patient and the health service standardized portfolio
80216|NCT03558438|Other|No interventions|No interventions
80217|NCT03558425|Drug|CKD-381|1 tablet administered before the breakfast during 7 days
80218|NCT03558425|Drug|D026|1 tablet administered before the breakfast during 7 days
80219|NCT03558412|Combination Product|CODOX-M/IVAC|Given ivgtt
80220|NCT03558412|Drug|Decitabine|Given ivgtt
80221|NCT03558399|Other|FET according to ERA|Single euploid FET will be performed at the time indicated by the ERA test results.
80222|NCT03558399|Other|FET according to standard protocol|Single euploid FET will be performed according to our standard FET protocol.
80223|NCT03558386|Behavioral|ePRO survey|An electronic patient reported outcomes survey will be completed by the patient.
80224|NCT03558373|Drug|Immunosuppressive|Immunosuppressive therapies
80225|NCT03558360|Diagnostic Test|Impedance measurement|Measurement of dry lean body mass berfore bariatric surgery by impedance measurement.
80226|NCT03558347|Device|short implants with splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, splinted lithium disilicate crowns
80227|NCT03558347|Device|short implants with non-splinted crowns|7 mm short implants (CONELOG® Implant System), individualized titanium abutments, non-splinted lithium disilicate crowns
80228|NCT03558334|Drug|Transplantation of mesenchymal stem cell|"Human umbilical cord-derived mesenchymal stem cell will be given to preterm infants through intravenous infusion.~Dose A - 1 million cells per kg Dose B - 5 million cells per kg"
80229|NCT03558334|Drug|No transplantation of mesenchymal stem cell|Human umbilical cord-derived mesenchymal stem cell will be not given to preterm infants through intravenous infusion.
80230|NCT03558321|Procedure|Hysteroscopic guided fractional curretage|Under general anaesthesia , evaluation of the endometrial cavity was done followed by biopsy of the whole endometrial tissue
80231|NCT03558321|Procedure|total abdominal hysterectomy, bilateral salpingo oophrectomy, with or without pelvic lymph nodal dissection|Through abdominal incision , removal of the whole uterus , both tubes and ovaries and in some cases pelvic lymph nodes removal was done
80232|NCT03558308|Behavioral|Computer based cognitive rehabilitation|Computer based cognitive rehabilitation is a supplementary computerized tool for cognitive rehabilitation design to train various cognitive functions. Many programmes are available. The current study investigates the effects on two such programmes on rehabilitation of executive functions in the chronic phase after acquired brain injury.
80233|NCT03558308|Other|Sham computerized gaming|Sham training with generally stimulating computer-games
80234|NCT03558295|Drug|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, edoxaban
80235|NCT03558282|Other|Recession Observation|Soft tissue measurements
80236|NCT03558282|Diagnostic Test|Crown Contour Observation|Ultrasound measures of implant crown contour.
80237|NCT03558269|Biological|Autlogous UCB infusion|Infants delivered with hypoplastic left heart syndrome and transposition of great arteries undergoing surgery in the 1st 2 weeks of life will be treated with autologous UCB after the surgery. Each group will be followed by MRI before (1-3 days) and after the surgery between at 10 POD. Developmental follow up will be done at 1, 6 and 12 months. Another brain MRI will be done at 6 months of age.
80238|NCT03558256|Behavioral|Mindfulness-based Cognitive Therapy|Patients participating in the experimental group will receive the MBCT intervention besides the usual medication treatment. The intervention is implemented by the manual adapted from the MBCT for Depression (Segal et al. 2013). The modified version of the program has the same structure with the original manual combined the mindfulness training and the cognitive elements from CBT, but the content is more suitable for the Chinese. The instructors in this study are trained and certificated psychiatrists and psychotherapists with rich experience of working with MDD, and they will receive a weekly supervision conducted by a senior supervisor.
80239|NCT03558256|Drug|Medication|Both of the MBCT group and the medication group will receive the medication treatment. The initial dose conforms the drug instructions, the dosage can be adjusted once a week, and the maximum dosage should not exceed the maximum amount by the instructions. MDD patients with sleep disorders can use drugs combined with benzodiazepine drugs, but not continuing for more than two weeks; while other psychotropic drugs are not allowed. All of the drugs used in this study are usual clinical drugs with good security, the common adverse reactions include nausea, dry mouth, constipation, diarrhea, indigestion, dizziness, drowsiness, fatigue, sweating, heart palpitations, delayed ejaculation in male, increasing blood aminotransferase without symptoms occasionally and so on.
80240|NCT03558243|Procedure|Patent Hemostasis arm|Patent hemostasis with TR BAND
80241|NCT03558243|Procedure|ULTRA arm|Patent hemostasis protocol plus ipsilateral ulnar compression
80242|NCT03558243|Device|Hemostatic disc arm|StatSeal disc plus TR Band
80243|NCT03558230|Behavioral|Standardized Constraint-Induced Movement Therapy|The standardized Constraint-Induced Movement Therapy aims to improve the child's weak upper extremity through intensive frequent and repetitive movements. The therapy duration is 6 hours/day for 5 consecutive days.
80244|NCT03558230|Behavioral|Vibration|Vibration applied to the wrist.
80245|NCT03558230|Behavioral|Placebo (for vibration)|No vibration applied to the wrist.
80246|NCT03558217|Device|Collared Femoral Implant|Corail collared femoral implant for total hip arthroplasty
80247|NCT03558217|Device|Collarless Femoral Implant|Corail collarless femoral implant for total hip arthroplasty
80248|NCT03558204|Procedure|Denervation of the thumb CMC joint|Removal/disconnection of the nerve branches to the joint from their attachments to the joint
80249|NCT03558204|Procedure|trapeziectomy with ligament reconstruction (LRTI)|excision of the trapezium and suspension of the thumb metacarpal with the flexor carpi radialis tendon
80250|NCT03558191|Drug|SHR-1210|A humanized monoclonal immunoglobulin PD-1 antibody
80251|NCT03558178|Procedure|Doin with acupuncture|Doin (conduction exercise) will be performed with the needles in situ by increasing the cervical range of motion (rotation) with physician guidance and isometric resistance exercise as indicated. Doin sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
80252|NCT03558178|Device|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks (total 10 sessions).
80253|NCT03558165|Diagnostic Test|Oncomine Comprehensive Assay|Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay
80254|NCT03558152|Drug|UTTR1147A|UTTR1147A will be administered intravenously (IV) at dose levels 1, 2, or 3 in Part A, and at the maintenance dose level in Part B, per the respective arm descriptions.
80255|NCT03558152|Drug|UTTR1147A Placebo|The matching placebo to UTTR1147A (UTTR1147A Placebo) will be administered IV.
80256|NCT03558152|Drug|Vedolizumab|Vedolizumab will be administered IV, as specified in the prescribing information.
80257|NCT03558152|Drug|Vedolizumab Placebo|The matching placebo to vedolizumab (Vedolizumab Placebo) will be administered IV.
80258|NCT03558139|Drug|Hu5F9-G4|Hu5F9-G4
80259|NCT03558139|Drug|Avelumab|Avelumab
80260|NCT03558126|Device|silicone tube|
80694|NCT03554889|Drug|Nimotuzumab|Nimotuzumab will enhance the ADCC effect of NK Cell adaptive transfer
80262|NCT03558100|Behavioral|Obstacle crossing intervention for adults with obesity|The obstacle crossing intervention will be done for reducing falls risks in obesity. The intervention will provide gait practice to individuals with obesity who are eligible for and prior to weight loss surgery.
80263|NCT03558087|Drug|Nivolumab|Nivolumab 360mg will be administered on Day 1 of each 21 day cycle for four 21-day cycles. Based on response and a balanced patient-physician discussion, subjects may receive nivolumab 240 mg for 8 cycles (cycle = 14 days).
80264|NCT03558087|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 will be administered on Days 1 and 8 for four 21-day cycles.
80265|NCT03558087|Drug|Cisplatin|Cisplatin 70mg^m2 will be administered on Day 1 for four 21-day cycles.
80266|NCT03558074|Drug|ALK4290|ALK4290 400 mg tablet twice a day
80267|NCT03558061|Drug|ALK4290|ALK4290 400 mg tablet twice a day
80268|NCT03558048|Diagnostic Test|Blood draw|Subjects will have their blood drawn during clinic visits over the course of the study period to measure their serum prostate specific antigen levels.
80269|NCT03558035|Drug|Induction CT+ CRT group|Induction CT: Paclitaxel 175mg/m2 IV on d1 and d22, cisplatin 75mg/m2 IV on d1 and d22, 5-Fluorouracil 750mg/m2 IV continuously on d1-4 and d22-25, CRT: cisplatin 80mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
80270|NCT03558035|Radiation|Concurrent CRT group|cisplatin 100mg/m2 IV on d1 of each 21 days cycle and 70 Gy radiotherapy
80271|NCT03558022|Dietary Supplement|Salt Pills|7 days of a low sodium diet plus 4 salt pills (sodium chloride) taken 3 times daily with meals (approximately 7000 milligrams per day)
80272|NCT03558022|Dietary Supplement|Placebo Pills|7 days of low sodium diet plus 4 placebo pills (microcrystalline cellulose) taken 3 times daily with meals
80273|NCT03557996|Drug|Silver Diamine Fluoride|SDF will be applied with a brush
80274|NCT03557996|Drug|Sodium Fluoride Varnish|NaF will be applied with a brush
80275|NCT03557983|Drug|Fenofibrate|Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
80276|NCT03557983|Drug|Saline|Saline is topically spread three times per day at the irradiated areas for one week.
80277|NCT03557970|Drug|FMS Inhibitor JNJ-40346527|Given PO
80278|NCT03557970|Other|Pharmacokinetic Study|Correlative studies
80279|NCT03557957|Other|Targeted correction of plasma sodium levels|Targeted correction of hyponatremia
80280|NCT03557957|Other|Standard care|Standard care of hyponatremia
80281|NCT03557944|Other|Medication reduction|Systematic approach to reduction in polypharmacy.
80282|NCT03557931|Drug|ASP4345|oral administration
80283|NCT03557931|Drug|placebo|oral administration
80284|NCT03557931|Drug|risperidone|oral or depot administration
80285|NCT03557931|Drug|quetiapine|oral administration
80286|NCT03557931|Drug|olanzapine|Oral or depot administration
80287|NCT03557931|Drug|ziprasidone|Oral or depot administration
80288|NCT03557931|Drug|aripiprazole|Oral or depot administration
80289|NCT03557931|Drug|brexpiprazole|Oral administration
80290|NCT03557931|Drug|paliperidone|Oral or depot administration
80291|NCT03557931|Drug|lurasidone|Oral administration
80292|NCT03557918|Drug|Tremelimumab|"Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria."
80293|NCT03557905|Device|RM|Patients will receive recruitment maneuver (RM) followed by decremental PEEP titration 1min. after establishment of mechanical ventilation and after documented lung re-collapse.
80294|NCT03557905|Device|PEEP|The patient will be ventilated with volume control mode with tidal volume 6 ml/kg, PEEP 3 cmH2O, an inspiratory expiratory ratio of 1:1.5, respiratory rate 20-25 breaths per minute depending on the patient's age and FiO2 of 0.5.
80295|NCT03557892|Device|CGM+CSII|Animas Vibe Platinum insulin pump and Dexcom G4 CGM
80296|NCT03557892|Device|MDI with degludec|Multiple injection therapy with any short-acting analogue as bolus insulin and degludec as basal insulin
80297|NCT03557879|Genetic|Exome sequencing|DNA extracted from samples will undergo exome sequencing, i.e. sequencing of the coding regions of all known human genes (about 22,000)
80298|NCT03557866|Diagnostic Test|running|individuals will be asked to run for 5 km in self selected speed
80299|NCT03557853|Drug|Golimumab Injection|Simponi (golimumab) in fixed dose of 50 mg sc per month according to local label and local clinical practice.
80300|NCT03557840|Drug|temocillin|Drug dosing and blood sampling as per the protocol
80301|NCT03557827|Drug|Photodynamic Therapy with indocyanine green and diode laser|mechanical debridement by periodontal curets plus Indocyanine green solution activated by diode laser. The diode laser is classified as a Class I medical device according to the Directive 93/42/EEC
80302|NCT03557827|Procedure|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
80303|NCT03557814|Device|LED appliance during mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
80304|NCT03557814|Device|LED appliance after mechanical debridement|Mechanical debridement by periodontal curets LED appliance is classified as a Class IIa medical device according to the Directive 93/42/EEC
80305|NCT03557814|Device|Mechanical debridement alone|Mechanical debridement by periodontal curets alone
80306|NCT03557801|Behavioral|Mammography with Community Health Worker (individual)|Immediately following consent and completion of the baseline assessment, alone with the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
80408|NCT03557034|Device|Kardia Monitoring|Kardia Mobile is an FDA approved device that allows one lead ECG recording for 30 seconds using the patient's smart phone. The device has a built-in algorithm that detects AF. KardiaPro is a secure platform that allows the physician to access the patient's recording at any time. The platform can also be programmed to send a notification to the healthcare provider if AF is detected by the software.
80307|NCT03557801|Behavioral|Mammography with Community Health Worker (group)|Immediately following consent and completion of the baseline assessment, women in the intervention arm will participate in a 20-30 minute group educational session from the community health worker. Well woman screening will follow the educational session. The community health worker will be available to assist with questions and language interpretation as necessary. After standard delivery of screening results, the community health worker will contact these participants to answer any questions about their screening results and to assist with scheduling any additional tests necessary.
80308|NCT03557801|Other|Standard of Care Mammography|Immediately following consent and completion of the baseline assessment, women in the control arm will receive standard of care well woman screening. The control arm will receive screening results per standard protocol.
80309|NCT03557788|Drug|Rifaximin Oral Tablet|PO 550mg TDS for 2 weeks
80310|NCT03557775|Device|Inspiratory Muscle Strength Training (IMST)|IMST will be conducted using an inspiratory pressure threshold trainer (Philips Respironics® Threshold IMT or POWERbreathe® Medic Plus), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
80311|NCT03557775|Device|Expiratory Muscle Strength Training (EMST)|EMST will be conducted using an expiratory pressure threshold trainer (EMST150®), which consists of a mouthpiece with a spring-loaded valve. The valve blocks the airflow until the threshold pressure is achieved by breathing out forcefully into the device. This allows airflow as long as the sufficient pressure is maintained.
80312|NCT03557775|Behavioral|Voice Exercises|Voice exercises will consist of the Vocal Function Exercises (VFE) protocol, developed by Stemple (2005). It contains 4 steps: (a) sustain the vowel /i/ on the musical note F for as long as possible. Repeat as judged by the SLP. (b) Glide from the lowest note to the highest note. Repeat as judged by the SLP. (c) Glide from the highest note to the lowest note. Repeat as judged by the SLP. (d) Sustain the notes C-D-E-F-G for as long as possible. Each note will be repeated until the participant finds the right placement (forward-focused voice), as judged by the SLP. Humming will be used to facilitate placement.
80313|NCT03557762|Behavioral|Mindfulness|A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state, through meditation and gentle mindful movements.
80314|NCT03557749|Diagnostic Test|Blood Sample|60 ml heparinized blood 10 ml serum
80315|NCT03557749|Diagnostic Test|Stool Sample|pea-sized amount
80316|NCT03557749|Diagnostic Test|Urine Sample|10 ml
80317|NCT03557749|Diagnostic Test|Bronchoalveolar Lavage (BAL) fluid|10 ml
80318|NCT03557749|Diagnostic Test|Gastrointestinal biopsy x 2-4|rectosigmoid site preferred
80319|NCT03557749|Diagnostic Test|Skin biopsy|2-4 mm punch
80320|NCT03557749|Diagnostic Test|Skin, mouth, and/or ocular swab|Involved skin, mouth, and/or ocular swab for microbiota studies
80321|NCT03557749|Diagnostic Test|Apheresis Product|Up to 10 ml of apheresis product
80322|NCT03557749|Diagnostic Test|Final cellular product|A second washing from the infusion bag after product and initial bag wash has infused, or up to 10 ml of final cellular product
80323|NCT03557736|Behavioral|Training mode|type of exercise training completed for 12 weeks
80324|NCT03557723|Other|Art activities program|"The intervention will be the MMFA art activities program Les Beaux Jeudis. Three activities will be examined:~Cultural mediation workshop~Supervised visit and tour of the museum~Cultural mediation workshop combined with supervised visit and tour of the museum~The duration of the MMFA art activities program Les Beaux Jeudis will be 3 months. Each participatory-based art activity is a weekly activity."
80325|NCT03557710|Behavioral|Devaluing energy-dense foods for cancer-control|A 3-arm randomized controlled trial experiment study over 12 months. At baseline, participants will complete behavioral, neural, and self-report measures related to food, specifically measures of food valuation and of the proximal neural systems hypothesized to be linked to each of the 2 experimental arms. We will also measure food intake and body composition at baseline. Then participants will be randomized to one of 3 arms (2 experimental + 1 active control) for 8 30-min sessions to occur twice weekly at the University of Oregon for 30 days. At endpoint (~1 month following baseline), all behavioral, neural, and self-report measures will be reassessed, as will eating, habit, and body composition measures. Follow-ups at 3, 6, and 12 months will assess all measures except neuroimaging.
80326|NCT03557697|Behavioral|Standard of Care|At the end of the study the control group will be provided with the opportunity to receive counseling videos delivered via SMS
80327|NCT03557697|Behavioral|SMS Intervention|Participants in the intervention group will receive SMS based video counseling which include both educational and SCT=-based behavioral content.
80328|NCT03557684|Dietary Supplement|leucine|amino acid leucine in powder
80329|NCT03557684|Other|PO placebo|maltodextrin
80330|NCT03557684|Biological|lipopolysaccharide (LPS)|purified bacterial wall component as an inflammatory challenge
80331|NCT03557684|Other|IV placebo|0.9% saline
80332|NCT03557671|Dietary Supplement|rice formula|new rice based thickened formula
80333|NCT03557671|Dietary Supplement|placebo|formula previously tolerated by the subject - only for the 1st part of the study
80334|NCT03557658|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
80335|NCT03557645|Device|Baseline Mechanical Ventilation|The subjects will be kept in Volume Control Continuous Mandatory Ventilation (VC-CMV).
80336|NCT03557645|Device|VHI With Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) with an inspiratory pause.
80337|NCT03557645|Device|VHI Without Inspiratory Pause|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV) without an inspiratory pause.
80338|NCT03557632|Behavioral|Virtual Reality Cue Exposure Therapy|As above.
80339|NCT03557632|Behavioral|Relapse Prevention Drug Education|As above.
80340|NCT03557619|Drug|Venetoclax|tablet; oral
80341|NCT03557619|Drug|ethinyl estradiol/levonorgestrel|oral
80409|NCT03557021|Diagnostic Test|HIV Drug resistance testing|HIV Drug resistance testing by HIV pro DNA sanger sequencing
81912|NCT03545386|Other|Fecal microbiota transplantation|Stool from healthy donor administered via enema
80342|NCT03557606|Procedure|Alar treatment with BMC using anterior approach|Patients with CCJ instability will undergo a bone marrow aspiration of approximately 30-60 cc. Platelet rich plasma (PRP) and platelet lysate (PL) will be derived from the bone marrow aspirate and later mixed with the bone marrow cell layer. While under TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate.
80343|NCT03557593|Other|Educational|Multi component educational intervention in long-term care
80344|NCT03557580|Drug|IS-5-MN R|single orally dose under fed conditions on day 1 of treatment period 1 for group 1, on day 1 of treatment period 2 for group 2, on day 1 of treatment period 3 for group 3.
80345|NCT03557580|Drug|IS-5-MN T1|single orally dose under fed conditions on day 1 of treatment period 2 for group 1, on day 1 of treatment period 3 for group 2, on day 1 of treatment period 1 for group 3.
80346|NCT03557580|Drug|IS-5-MN T2|single orally dose under fed conditions on day 1 of treatment period 3 for group 1, on day 1 of treatment period 1 for group 2, on day 1 of treatment period 2 for group 3.
80347|NCT03557567|Diagnostic Test|NGS molecular screening|
80348|NCT03557554|Other|Massage|A 20 minute massage protocol will be administered in a chair by a licensed massage therapist no more than 24 hours prior to each paclitaxel infusion.
80349|NCT03557541|Dietary Supplement|Sardine|They received 200gr of canned sardine in olive oil per week (+a common T2D-preventive diet)
80350|NCT03557541|Dietary Supplement|Control|They received a common T2D-preventive diet
80351|NCT03557528|Procedure|Laparoscopic colorectal resection|Gruop 1: laparoscopic rectosigmoid resection with standard ligation of mesenteric artery at its origin Group 2: Laparoscopic rectosigmoid resection with low ligation of inferior mesenteric artery and its skeletonization with en bloc removal of all lymph nodes
80352|NCT03557515|Behavioral|Stress Management and CBT|"Stress Management will focus on:~Mind-Body Connection~Coping Skills~Communication~Social Support~Cognitive Behavioral Therapy will focus on:~Intro to CBT-Tracking Automatic Thoughts~Identifying Distorted Thoughts~Challenging Distorted Thoughts~Core Beliefs/Relapse Prevention"
80353|NCT03557515|Behavioral|Stress Management and Metta-Meditation|"Stress Management will focus on:~Mind-Body Connection~Coping Skills~Communication~Social Support~Metta-Meditation will focus on:~Intro to Meditation vis Mindfulness of the Breath and Body-Noticing Critical Self Talk~Intro to Brief Loving-Kindness Meditation and Self-Care~Continuing with Additional Metta-Based Exercises to Cultivate Compassion for Oneself and Others and Mitigating Self-Criticism~Review/Plan for Future"
80354|NCT03557502|Other|Heat Therapy Group|30 sessions of immersion in 40.5 degree celsius water for 45 minutes per session
80355|NCT03557502|Other|Aerobic Exercise Group|30 sessions of aerobic exercise training for 45 minutes at 60% of VO2peak
80356|NCT03557489|Device|Mepilex Border Sacrum|Patients use gel pad(in usual) in addition to use Mepilex Border Sacrum foam pad during surgery.
80357|NCT03557476|Dietary Supplement|Octacosanol|One capsules (20-mg) of 100% refined octacosanol powder from sugar cane (Swanson, Fargo ND, USA) was consumed twice a day
80358|NCT03557476|Dietary Supplement|Placebo|A placebo pill was taken twice a day in a double-blinded method at the same frequency and time as the octacosanol supplement
80359|NCT03557463|Dietary Supplement|Dairy protein|A controlled, randomized, double blind pilot study was conducted using two different protein sources as nutritional supplementation to enhance vaccine response.
80360|NCT03557450|Device|PET/CT Scan|PET/CT scanning with sodium fluoride
80361|NCT03557437|Drug|Esomeprazole|Proton pump inhibitor
80362|NCT03557437|Drug|Amoxicillin, Metronidazole|Antibiotics for H. pylori eradication
80363|NCT03557437|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
80364|NCT03557424|Drug|Polyglucosamine Glucomannan normal dose (Verum)|Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
80365|NCT03557424|Drug|Polyglucosamine Glucomannan high dose (Verum)|Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
80366|NCT03557424|Drug|Placebo Comparator: Placebo|Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
80367|NCT03557411|Drug|SHR-1210|SHR-1210 （an Anti-PD-1 Inhibitor） Simultaneously Combined with Hypofraction Radiotherapy
80368|NCT03557398|Device|Hydeal-D vaginal pessaries|One vaginal application of Hydeal-D vaginal pessaries every 3 days to a total of 12 consecutive weeks.
80369|NCT03557385|Drug|Iopamidol|"aFFR measurement with drug: Iopamidol (ISOVUE®-370). Subjects will receive an injector-based intracoronary bolus of contrast~Rate of 4 mL/sec, volume of 10 cc (left coronary system)~Rate of 3 mL/sec, volume of 6 cc (right coronary system)."
80370|NCT03557385|Drug|adenosine|FFR measurement with drug: adenosine. Intravenous adenosine will be administered at a rate of 140 μg/kg of body weight per minute x 2 minutes
80371|NCT03557385|Device|Navvus® Catheter|the NAVVUS RXi microcatheter will be used with a workhorse wire of the operator's choosing
80372|NCT03557385|Device|CVi® Contrast Delivery System|The CVi® Contrast Delivery System will be used to deliver the contrast medium
80373|NCT03557372|Radiation|Mathematical Model-Adapted Radiation Fractionation Schedule|"Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks~Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes.~Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment."
80374|NCT03557359|Drug|Nivolumab|Nivolumab (Opdivo®) is a human monoclonal antibody (HuMAb; immunoglobulin G4 (IgG4)- S228P) that targets the PD-1 cluster of differentiation 279 (CD279) cell surface membrane receptor.
80375|NCT03557346|Device|the WAM-5500 binocular autorefractor/keratometer (Grand Seiko Co. Ltd., Hiroshima, Japan)|: Subjects underwent a basic ophthalmic examination and the accommodative response to refractive stimuli was measured. Refractive stimuli were given at 0.25 diopters (D) (4 m distance), 2D (50 cm), 3D (33 cm), and 4D (25 cm) and stimulation was applied with the eyes in binocular, monocular (dominant eye, non-dominant eye, ipsilateral, and contralateral), and pinhole conditions. In addition, changes in the astigmatic value and direction of the astigmatism axis under binocular stimulus were evaluated.
80376|NCT03557333|Combination Product|INP104|No more than 2 doses within 24 hours, 3 doses within 7 days. 1.45 mg in a divided dose, one actuation per nostril.
80377|NCT03557307|Biological|Benralizumab|Benralizumab subcutaneous injection
80378|NCT03557294|Drug|1.0mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
80379|NCT03557294|Drug|0.5mg Varenicline b.i.d.|Varenicline is classified as a selective nicotine receptor partial agonist (SNRPA) that works both to stimulate the nicotine receptor and block smoking reward at the α4β2 nicotinic receptor subtype.
80380|NCT03557294|Drug|0.0mg placebo Varenicline b.i.d.|Product that looks like active varenicline, but contains no active ingredient
80381|NCT03557281|Drug|GSK3036656|GSK3036656 will be available as an oral capsule with dosing strengths of 1 milligrams or 5 milligrams or 25 milligrams.
80382|NCT03557281|Drug|RIFAFOUR e-275|RIFAFOUR will be available as an oral tablet with a standard dose of 150/75/400/275 milligrams of rifampicin, isoniazid, pyrazinamide and ethambutol per tablet respectively.
80383|NCT03557255|Drug|Levosimendan|Preoperative 24 hours infusion of levosimendan for chronic heart failure patients prior to major abdominal cancer surgeries.
80384|NCT03557255|Drug|Saline|Preoperative 24 hours infusion of normal saline for chronic heart failure patients prior to major abdominal cancer surgeries.
80385|NCT03557242|Device|TAVR|Transcatheter Aortic Valve Replacement
80386|NCT03557242|Other|Warfarin plus Aspirin|Subjects randomized to this arm will receive Warfarin plus aspirin for 30- 45 days post TAVR
80387|NCT03557242|Other|Aspirin Only|Subjects randomized to this arm will receive aspirin only post TAVR
80388|NCT03557229|Drug|Melatonin 5 mg|Oral: 50 mg once daily for 5 days
80389|NCT03557229|Drug|Vitamin C 1 GM Oral Tablet|Oral: 1 GM every 6 hours for 5 days
80390|NCT03557229|Drug|Vitamin E 400 UNT|Oral: 400 UNT every 8 hours for 5 days
80391|NCT03557229|Drug|N-acetylcysteine|Oral: 1200 mg every 12 hours for 5 days
80392|NCT03557216|Diagnostic Test|Colonoscopy|Anal introduction of a long, flexible, tubular instrument about 1/2-inch in diameter that transmits an image of the lining of the colon so the doctor can examine it for any abnormalities
80393|NCT03557216|Diagnostic Test|Fecal immunochemical and occult blood test|A test for fecal occult blood looks for blood in your feces. It can be a sign of a problem in the digestive system, such as a polyp or cancer in the colon.
80394|NCT03557216|Diagnostic Test|Fecal calprotectin test|Calprotectin is a protein released by neutrophils. When there is inflammation in the colon, neutrophils move to the area and release calprotectin, resulting in an increased level in the stool. This test measures the level of calprotectin in stool as a way to detect inflammation and lesions in the colon.
80395|NCT03557151|Other|Usual Care|Usual Care participants will receive the same excellent multidisciplinary Care they would receive at the same center were they not enrolled in the trial. In clinic visits scheduled at approximately 3-month intervals, they will see subspecialty board certified or eligible pediatric endocrinologists, supplemented as needed with involvement of certified diabetes educators, dietitians, social workers or psychologists. HbA1c target is < 7.5% with no severe hypoglycemia and acceptable quality of life. About half are expected to be on insulin pumps and carbohydrate counting, while the great majority of others are following basal-bolus multiple daily injection regimens, also based on carbohydrate counting. A rising proportion of patients use continuous glucose monitors and this trend is likely to accelerate during the study.
80396|NCT03557151|Behavioral|Transdisciplinary Care-In Person|TC In-Person participants will receive all elements of the Usual Care intervention but they will do so in the context of face to face TC follow-up visits with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
80397|NCT03557151|Behavioral|Transdisciplinary Care-Telehealth|TC Telehealth participants will receive all elements of the Usual Care intervention but they will do so in the context of TC follow-up visits via a telehealth platform with simultaneous involvement of an advanced practice nurse, dietitian and psychologist at each visit.
80398|NCT03557138|Behavioral|alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside|positron emission tomography and magnetic resonance imaging (PET/MRI) of kidneys of diabetic patients using alpha-Methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside (Me4FDG)
80399|NCT03557125|Other|QL Block|If the subject has been randomized to the block group, a subcutaneous lidocaine skin wheel placed will be placed followed by a quadratus lumborum regional block with 40 ml, 0.25% ropivacaine deposited deep to the transversus abdominus apnoneurosis and superficial to the fascia transversalis with direct ultrasound guidance. Local anesthetic will be injected in 5 ml aliquots with aspiration for blood performed before and after the injection of each aliquot. Local anesthetic injection will also be observed with real time ultrasound guidance.
80400|NCT03557125|Other|Saline Skin Wheel|"The skin will be cleaned with chlorhexidine. If the subject has been randomized to the no block group, a subcutaneous saline skin wheel will be placed and the procedure would end at this point."
80401|NCT03557112|Drug|Nimotuzumab|TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
80402|NCT03557112|Drug|Cisplatin|TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
80403|NCT03557099|Drug|Hetrombopag Olamine|once daily
80404|NCT03557086|Behavioral|Advance Care Planning Video Decision Support Tool|Advance care planning video intervention as previously described
80405|NCT03557086|Other|Verbal Narrative|Verbal description of end of life care options
80406|NCT03557073|Behavioral|Postoperative phone call|The intervention is a phone call on the day following surgery.
80407|NCT03557060|Drug|Nucala|NUCALA injections will be administered to eligible subjects with diagnosis of EGPA. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
80410|NCT03557008|Biological|Rabies Vaccine|A single 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.
80411|NCT03557008|Drug|Metronidazole|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.
80412|NCT03557008|Drug|Vancomycin|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.
80413|NCT03557008|Drug|Neomycin Sulfate|The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
80414|NCT03556995|Other|bariatric surgery patients|
80415|NCT03556982|Biological|CART-123 cells|CD123-Targeted CAR-T cells are infused to patient received FC chemotherapy
80416|NCT03556969|Other|Observation|no intervention
80417|NCT03556956|Drug|Masitinib|Tyrosine kinase inhibitor
80418|NCT03556943|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
80420|NCT03556917|Combination Product|iontophoresis + caffeine|we will use cafeislaine c (caffeine) +galvanic current
80421|NCT03556904|Radiation|Radiation Therapy|Radiotherapy will be delivered to a total EQD2 (Equivalent dose in 2Gy fractions) that ranges between conventional 30 Gy in 10 fractions, to SBRT with 50 Gy in 5 fractions.
80422|NCT03556904|Drug|Enzalutamide|Current standard of care dosing
80423|NCT03556904|Drug|Abiraterone|Current standard of care dosing
80424|NCT03556904|Drug|Docetaxel|Current standard of care dosing
80425|NCT03556891|Device|eCoin Tibial Nerve Stimulation|Subcutaneous stimulation of the tibial nerve using the eCoin device.
80426|NCT03556878|Behavioral|Fitted Transdiagnostic Sleep and Circadian intervention|Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
80427|NCT03556865|Other|A self administered questionnaire|"The questionnaire is in English language, it contains binary questions related to KAP on different preventive measures in pediatric dentistry and consists of 38 items divided into 4 sections as follows:~I) Socio-demographic data: (7 items). It includes gender, total years in practice, nature of primary practice, school of graduation, scientific degree and specialty II) Assessment of Knowledge towards preventive measures in pediatric dentistry. (16 items) III) Assessment of Attitude towards preventive measures in pediatric dentistry. (10 items) IV) Assessment of Practice towards preventive measures in pediatric dentistry. (5items) One score is given for each response to items."
80428|NCT03556852|Drug|Carbetocin|1 ampoule of Carbetocin (100 μg/ml) added to 10 cc saline and given IV after the delivery of the baby
80429|NCT03556852|Drug|Misoprostol|2 rectal misoprostol tablets (800 μg) after the delivery of the baby.
80430|NCT03556839|Drug|Atezolizumab|Intravenous Infusion
80431|NCT03556839|Drug|Bevacizumab|Intravenous Infusion
80432|NCT03556839|Drug|Cisplatin|Intravenous Infusion
80433|NCT03556839|Drug|Paclitaxel|Intravenous Infusion
80434|NCT03556826|Behavioral|Social Value Learning Training|For each child, two faces will be assigned the high-value (HV) status and the other two the low-value (LV) status. Value status will be randomized between the faces and children and all four faces will have the same probability of being assigned HV or LV across all participants. A gaze fixation on a HV face will always activate a dynamic display and the face will smile brightly. A gaze fixation on a LV face will always result in no change to its display.
80435|NCT03556813|Other|survey|non-inferiority study, randomized, blind, excluding health product, with no risk or constraint, in which all the acts are performed in the usual way and do not modify the patient's management.
80436|NCT03556800|Drug|Estrogel|"Each subject will receive the following IMPs in accordance with the randomisation code:~Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~Reference IMP: a single-dose of 1.25g EstroGel"
80437|NCT03556787|Device|BPI 1000013 (Dr Scholls Insole)|Full length foam insole
80439|NCT03556761|Drug|Oral furosemide|Furosemide (Lasix), 20 milligram, PO, PO, daily
80440|NCT03556761|Drug|Placebo Oral Tablet|Placebo, PO, daily
80441|NCT03556748|Other|whole-body electromyostimulation|WB-EMS training is performed 2x/week for a total of 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
80442|NCT03556735|Device|Treatment with PEMF equipment|Treatment with PEMF in 8 weeks
80443|NCT03556722|Device|Repetitive Transcranial Magnetic Stimulation.|High frequency r-TMS on left dorsolateral prefrontal cortex.
80444|NCT03556722|Device|Sham r-TMS|Sham r-TMS without the active magnetic coil on left dorsolateral prefrontal cortex
80445|NCT03556709|Device|Treadmill Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system, during treadmill walking, over a 6-week intervention period.
80446|NCT03556696|Device|ANI-REMI-loop|experimental medical device using expert rules and continuous reading of heart rate, blood pressure and Analgesia Nociception Index for automatic remifentanil administration
80447|NCT03556696|Device|remifentanil pK/pD target administration device|standard practice, remifentanil administration using Minto's pK/pD model
80510|NCT03556215|Device|Eustachian tube dilatation device|Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
80448|NCT03556696|Drug|Remifentanil|Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the [50-70] range.
80449|NCT03556696|Drug|Propofol|propofol is used for induction and maintenance of general anesthesia using Schnider pK/pD model. Propofol Ce target is adapted in order to maintain BiSpectral Index in [40-60] range
80450|NCT03556696|Device|ANI monitor|"ANI (Analgesia Nociception Index) value is used in the std_practice arm for guidance of the remifentanil Ce target"
80451|NCT03556683|Device|Hypertonic Saline|4 mL of 7% hypertonic saline
80452|NCT03556670|Behavioral|Total Worker Health|The intervention combines organizational and individual level strategies. Participants will be given access to pedal stands, health and safety messaging, and other environmental modifications. Intervention activities that participants could be asked to complete include: computer based training, goal setting and behavioral self-monitoring, scripted team-based health and safety discussions, and team competitions with pedal stands. Supervisor participants could additionally be asked to complete additional computer based training, goal setting and behavioral self-monitoring of supportive behaviors, and inter-supervisor observations. The intervention is six-months in duration.
80453|NCT03556670|Other|Control|Usual practice control
80454|NCT03556657|Other|Music Therapy|Patient receives 6 sessions of music therapy with a board-certified music therapist. Patient will learn various music interventions for pain management that he/she will utilize at home.
80455|NCT03556644|Radiation|CTCA imaging|All the studied patients will have CTCA before percutaneous coronary intervention and 3 vessel NIRS-IVUS imaging during percutaneous coronary intervention
80456|NCT03556631|Drug|live combined Bifidobacterium and Lactobacillus Tablets|take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day
80457|NCT03556618|Behavioral|Whole Person Care (WPC) Reentry Program|Social network intervention to provide care coordination and social support during youth reentry.
80458|NCT03556605|Other|OneTouch Reveal® Mobile APP system|Improved glycemic control in people with diabetes using the OneTouch Verio® Flex Blood Glucose Monitor and the OneTouch Reveal® Mobile APP system (intervention group) compared to subjects continuing to use their own Blood Glucose Monitor without connection to mobile diabetes apps (control group).
80459|NCT03556605|Other|Current Blood Glucose Monitor|Subjects continue to use current Blood Glucose Monitor without connection to mobile diabetes apps.
80460|NCT03556592|Drug|Tralokinumab|Human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. Presented as a liquid formulation for subcutaneous injection.
80461|NCT03556592|Drug|Caffeine|1x 100 mg tablet
80462|NCT03556592|Drug|Warfarin|2x 5 mg tablets
80463|NCT03556592|Drug|Omeprazole|1x 20 mg capsule
80464|NCT03556592|Drug|Metoprolol|1x 100 mg tablet
80465|NCT03556592|Drug|Midazolam Hydrochloride|1 mL of 2 mg/mL oral solution/syrup
80466|NCT03556579|Device|senofilcon A with new UV blocker|Test Lens
80467|NCT03556579|Device|senofilcon A|Control Lens
80468|NCT03556566|Biological|Tableted vaccine (V3-OVA) containing ovarian cancer antigens|One pill of V3-OVA per day for three months
80469|NCT03556553|Device|Vertise Flow|Composite resin
80470|NCT03556553|Device|LuxaFlow|Composite resin
80471|NCT03556553|Device|Teco Adhesive|Adhesive system
80472|NCT03556540|Other|physical exercise|Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
80473|NCT03556501|Diagnostic Test|Endoscopy|Purpose of this study is to create a prospective registry of patients with pancreatic collections and their imaging studies
80474|NCT03556488|Diagnostic Test|US air bronchogram score|"On ultrasonographic examination, lung consolidation is defined as a subpleural echo-poor region or one with tissue- like echotexture, depending on the extent of air loss and fluid predominance, which is clearly different from the normal pattern.~The air bronchogram is characterized as: absent, static, dynamic, dynamic with areas of lung recruitment."
80475|NCT03556462|Other|Sleep Health Education|Parents and children receive sleep health education
80476|NCT03556449|Diagnostic Test|High resolution ultrasound|Using a high-frequency linear array transducer (18L6 HD)
80477|NCT03556436|Drug|YH25448 240mg|period 1: A single oral dose of YH25448 240 mg an overnight fast period 2: A single oral dose of YH25448 240 mg after a high-fat breakfast
80478|NCT03556410|Behavioral|sleep|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored.
80479|NCT03556410|Behavioral|exercise|Shortened sleep will be requested of all subjects. During this time normal physical activity will be monitored and 45 min of exercise will be required during the shortened sleep days .
80480|NCT03556397|Procedure|Sentinel lymph node biopsy (SLNB)|Sentinel lymph node biopsy will be performed in the patients
80481|NCT03556397|Procedure|Axillary dissection|Axillary dissection procedure will be performed in the patients
80482|NCT03556384|Drug|Temozolomide|"Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters"
80483|NCT03556371|Drug|N-Acetylcysteine|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
80511|NCT03556215|Procedure|Myringotomy|Myringotomy will be performed using a standard procedure.
80512|NCT03556202|Drug|Mirikizumab|Administered SC
80729|NCT03554616|Other|Piperonyl butoxide LLIN|Combination insecticide and synergist Long Lasting Insecticidal Net
80484|NCT03556371|Drug|Placebo oral capsule|In each patient recruited, assignation to placebo or N-Acetylcysteine group treatment wil be performed, after he/she has signed the informed consent. In the first visit, the evaluation by the psychiatrist and with the nurse team (structured evaluation, which includes the CCQ-N-10, CSSA, general health evaluation, urine drug test and basal blood screening), will be carried out. The nurse team will supervise the drug intake and they will observe 2 hours late the ADRs and general health status of patient, who will be responsible for the intake of the following medication doses. Each patient will be asked to attend twice week to his/her treatment center, during four weeks and each patient visit the clinical team will record the primary and secondary outcome.
80485|NCT03556358|Biological|TX05 (trastuzumab)|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
80486|NCT03556358|Biological|Herceptin®|8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
80487|NCT03556358|Drug|Paclitaxel|175 mg/m^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
80488|NCT03556358|Drug|Epirubicin|75 mg/m^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
80489|NCT03556358|Drug|Cyclophosphamide|600 mg/m^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
80490|NCT03556345|Drug|RC48-ADC|2.5 mg/kg IV every 2 weeks
80491|NCT03556332|Drug|Carfilzomib|Dara-CRd Induction Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 27 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-4: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Carfilzomib 27 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
80492|NCT03556332|Drug|Lenalidomide|Dara-CRd Induction Cycles 1-4: Lenalidomide 25 mg/day, days 1-21 every 28 days Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
80493|NCT03556332|Drug|Dexamethasone|Dara-CRd Induction Cycles 1-4: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23 Dara-CRd Consolidation (60-90 days post HCT) Cycles 5-8: Dexamethasone 20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, 23
80494|NCT03556332|Drug|Daratumumab|"Dara-CRd Induction Cycles 1 and 2: Daratumumab 16 mg/kg weekly (days 1,8, 15, 22) Dara-CRd Consolidation (60-90 days post HCT)~Cycles 3 and 4: Daratumumab 16 mg/kg every other week, days 1 and 15.~Cycles 5-6:Daratumumab 16 mg/kg every other week, days 1 and 15. Schedule together with Carfilzomib and use scheduled dexamethasone as premed.~Cycles 7-8: Daratumumab 16 mg/kg days 1 of each cycle."
80495|NCT03556332|Procedure|autologous hematopoietic cell transplantation|High Dose Melphalan and Autologous Hematopoietic Cell Transplantation Patients will receive Melphalan 200 mg/m2 per institutional guidelines, or if over 70 years of age or creatinine >2mg/dL, they will receive 140 mg/m2.
80496|NCT03556319|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
80497|NCT03556319|Dietary Supplement|Placebo|Placebo Comparator
80498|NCT03556306|Procedure|Bariatric surgery|"The gastric bypass (simplified technique) was performed in an antecolic fashion, with a calibrated 2 cm gastro-jejunal anastomosis (linear stapler); biliary and alimentary limbs measured 70 and 150 cm respectively [17] . Mesenteric defects were closed and the omentum divided. The sleeve gastrectomy was performed at 5-6 cm from the pylorus over a 36 Fr. bougie, with oversuture of the staple line (2-0 polypropylene). Methylene blue test and the use of drains were done routinely."
80499|NCT03556293|Behavioral|AKI Prevention Toolkit|AKI Prevention Toolkit. Intervention: All sites will receive the AKI Prevention Toolkit including 3 core interventions: 1. Standardized order sets; 2. IV and oral fluids; and 3. Reduced contrast volume. The interventions adhere to the KDIGO guidelines and add interventions developed and tested in our pilot intervention to implement AKI preventive strategies.
80500|NCT03556293|Behavioral|Technical Assistance (TA)|Technical Assistance (TA). Intervention: TA will be offered to the 8 teams randomized to the TA condition and will receive the AKI Prevention Toolkit plus monthly technical calls independently. TA arms will include TA with and without automated surveillance reporting (ASR).
80501|NCT03556293|Behavioral|Virtual Learning Collaborative (VLC)|Virtual Learning Collaborative (VLC). Intervention: The VLC will be offered to 8 teams and will receive the AKI Prevention Toolkit plus monthly virtual training calls with the other VLC sites. Each participating site will be supported to establish a multidisciplinary team charged with continuously improving AKI, which will include interventional cardiologists, cardiac catheterization lab manager and technicians, nursing representatives from the intensive care unit and/or holding areas, cardiology administration, nephrology, and representation from the quality improvement department (VA Clinical Application Coordinator [CAC] and Systems Redesign). VLC arms will include VLC with and without automated surveillance reporting (ASR).
80502|NCT03556293|Behavioral|Automated Surveillance Reporting (ASR)|Automated Surveillance Reporting (ASR). Intervention: The ASR will be offered to 8 teams. In addition to either TA or VLC, ASR teams will receive automated monthly reports in the form of an dashboard focused on AKI outcome and preventative measures overtime. The ASR report will be customized to each team and each individual operator and linked to their national VA-CART registry.
80503|NCT03556280|Device|GammaSense Stimulation System (Active Settings)|Proprietary auditory and visual sensory stimulation device.
80504|NCT03556280|Device|GammaSense Stimulation System (Sham Settings)|Proprietary auditory and visual sensory stimulation device.
80505|NCT03556267|Device|spinal needle|It is a spinal needle with `QUINCKE` Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
80506|NCT03556254|Drug|GGT|In the absence of 23S rRNA mutation, clarithromycin based sequential therapy will be given. In the presence of 23S rRAN mutation but the absence of gyrase A mutation, levofloxacin based sequential therapy will be given. In the presence of both 23S rRNA and gyrase A mutations or if genotyping fails, bismuth quadruple therapy will be given
80507|NCT03556254|Drug|SGT|In the absence of clarithromycin resistance, clarithromycin based sequential therapy will be given. In the presence of clarithromycin resistance but the absence of levofloxacin resistance, levofloxacin based sequential therapy will be given. In the presence of both clarithromycin and levofloxacin resistance or if culture fails, bismuth quadruple therapy will be given.
80508|NCT03556241|Device|Case management|Case management consists keeping patient's current pacemaker mode during surgery
80509|NCT03556228|Drug|VMD-928 300-mg Capsules|Taken orally once daily
80513|NCT03556189|Device|Case management|Case management consists adjusting AV delay of pacemaker to achieve best cardiac output measured by trans-thoracic echocardiogram
80514|NCT03556176|Behavioral|Exercise|Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
80515|NCT03556176|Behavioral|Quiet rest|Quiet rest during 30 min
80516|NCT03556163|Procedure|Modified vertical internal mattress sutures + MWF surgery.|Modified vertical internal mattress sutures were given after modified Widman flap surgery.
80517|NCT03556163|Procedure|Simple loop interrupted sutures + MWF surgery.|Simple loop interrupted sutures were given after modified Widman flap surgery.
80518|NCT03556150|Other|Manual Therapy protocol|"This protocol consists of:~Six minutes of joint's mobilisation (two minutes of each technique).~Nine minutes of ischemic pressure . Three minutes per muscle in this order: temporal muscle, masseter muscle and lateral pterygoid. Choosing the two most painful trigger points.~Three minutes of trigemino's nerve stretching."
80519|NCT03556150|Other|Effleurage|"The protocol consists of:~Five minutes in temporal muscle.~Ten minutes superficial massage in the neck and cheek of the most painful joint.~Five minutes of effleurage in the cheek, with the index finger inside the mouth and the thumb outside."
80520|NCT03556137|Drug|[18F]FTC-146|Adult participants will be injected with 5-10 mCi of [18F]FTC-146 and undergo a PET/MRI scan. Pediatric pain participants will be injected with 0.07-0.14 mCi/kg [18F]FTC-146 and undergo a PET/MRI scan.
80521|NCT03556124|Device|Active - HD tDCS|Non-invasive neuromodulation using HD electrodes placed on the scalp to deliver a constant, low current at 2 mA.
80522|NCT03556124|Device|Sham - HD tDCS|Sham neuromodulation using HD electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
80523|NCT03556124|Device|Active - Conventional tDCS|Non-invasive neuromodulation using standard 7 cm x 5 cm electrodes placed on the scalp to deliver a constant, low current at 2 mA.
80524|NCT03556124|Device|Sham - Conventional tDCS|Sham neuromodulation using standard 7 cm x 5 cm electrodes electrodes placed on the scalp to deliver a low current ramped up/down for 20 sec.
80525|NCT03556111|Procedure|Sticky bone augmentation|"Autogenous sticky bone augmentation for the first group~Autogenous sticky bone preparation with xenograft usage~After 5-month of bone grafting; esthetic implant placement"
80526|NCT03556098|Drug|glucose-dependent insulinotropic peptide|Infusion of GIP
80527|NCT03556098|Drug|Glucose-Dependent Insulin-Releasing Hormone[3-30]|Infusion of GIP antagonist GIP[3-30]
80528|NCT03556098|Drug|Saline Solution|Infusion of Saline
80529|NCT03556085|Device|Venous sinus stenting (Serenity River)|Patient is placed under general anesthesia. From femoral vein access, a standard guide-catheter is advanced in the internal jugular vein (on the side considered for stenting). The sigmoid then transverse sinus is catheterized with a microcatheter and guide-wire and an exchange guide-wire is placed in the superior sagittal sinus. The River stent delivery catheter is advanced over the exchange guide-wire in the sigmoid then transverse sinus up to the torcula. The River stent is deployed to cover the entire transverse sinus and the proximal half of the sigmoid sinus. The catheters are removed and hemostasis obtained by using a closure device or manual compression. The patient is kept overnight in the hospital for observation.
80530|NCT03556072|Other|Routine ERCP|
80531|NCT03556059|Other|Role of EOSS|The Edmonton Obesity Staging System (EOSS) is a more comprehensive measure of obesity-related diseases and predictor of mortality than body mass index (BMI) or waist circumference. Its application for the selection of obese patients for obesity surgery has been suggested. This study evaluates the role of the Edmonton Obesity Staging System (EOSS) in predicting postoperative outcome (next to the Clavien Dindo Classification) and 30-day mortality after metabolic surgery.
80532|NCT03556046|Diagnostic Test|89Zr-Girentuximab|Single diagnostic injection on Day 0, followed by diagnostic scans on Days 3 and 7±1, as well as the whole body dosimetric imaging on Days 0, 1, 3 and 7±1
80533|NCT03556033|Drug|Dapagliflozin|8 weeks treatment with dapagliflozin on top of insulin treatment
80534|NCT03556033|Drug|Placebo oral capsule|8 weeks treatment with placebo capsules on top of insulin treatment
80535|NCT03556020|Drug|PB1046|PB1046, Once Weekly Subcutaneous Injection
80536|NCT03556007|Drug|NKTR-358|NKTR-358 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% Sodium Chloride solution for Injection (USP) prior to administration.
80537|NCT03556007|Drug|Placebo|The placebo dosing solution is 0.9% Sodium Chloride for Injection (USP).
80538|NCT03555994|Drug|MEDI0382|MEDI0382 administered subcutaneously
80539|NCT03555994|Drug|Placebo|Placebo administered subcutaneously
80540|NCT03555994|Drug|Liraglutide|Liraglutide administered subcutaneously
80541|NCT03555981|Other|Early Kangaroo Mother Care|Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
80542|NCT03555981|Other|Standard care|Incubator or radiant heater care until stable, off oxygen and >24h of admission, at which point will start intermittent or continuous kangaroo mother care
80543|NCT03555968|Drug|THC 0|THC dose = 0 ug/kg
80544|NCT03555968|Drug|THC 125|THC dose = 125 ug/kg
80545|NCT03555968|Drug|THC 250|THC dose = 250 ug/kg
80546|NCT03555968|Other|BAC 0|Blood alcohol concentration = .000%
80547|NCT03555968|Other|BAC .025|Blood alcohol concentration = .025%
80548|NCT03555968|Other|BAC .049|Blood alcohol concentration = .049%
80549|NCT03555955|Drug|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
80550|NCT03555955|Drug|CPX-351|CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
80551|NCT03555942|Drug|Follicular phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the follicular phase (day 2 or 3 of the menstrual cycle)
80552|NCT03555942|Drug|Luteal phase corifollitropin alfa|GnRH antagonist protocol with corifollitropin alfa initiated in the luteal phase (5 days after an LH peak)
80553|NCT03555929|Drug|Dexamethasone|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
80730|NCT03554616|Other|Standard LLIN|Standard Long Lasting Insecticidal Net with one insecticide
80554|NCT03555929|Drug|Normal saline|80 minutes after achievement of axillary block, if the surgery is not ended, patients will be randomly assigned to one of the two groups : DEXA or Control. Injection will be done 90minutes after achievement of axillary block.
80555|NCT03555916|Drug|BOTOX®, Allergan|50 U BTX-A (BOTOX®, Allergan) powder diluted in 2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
80556|NCT03555916|Drug|Placebo|2 mL saline solution (0.9% NaCl) administrated at visit 2 by intra oral injection
80557|NCT03555903|Other|Endometriosis cohort|"The investigator record data on risks factors, symptoms (pain), quality of life (using standardized quality of life questionnaires), infertility history, and management of the disease with a 5-years follow up.~Different surgical procedures exist to treat DIE and are they are described in the database, to allow comparison."
80558|NCT03555890|Drug|Levocetirizine IRT 5 mg|Levocetirizine IRT will be available as film-coated tablets. Subjects will receive a single dose of 5 mg levocetirizine IRT. Subjects will receive levocetirizine IRT with 150 mL water in both Part (1 and 2).
80559|NCT03555890|Drug|Levocetirizine ODT 5 mg|Levocetirizine ODT will be available as oral disintegrating tablet. Subjects will receive a single dose of 5 mg levocetirizine ODT. In Part 1, subjects will receive levocetirizine ODT with 150 mL water and in Part 2 subjects will receive levocetirizine ODT without water.
80560|NCT03555877|Drug|Ribociclib|Ribociclib in addition to endocrine maintenance therapy. Endocrine therapy, at the discretion of the investigator, could have already been started up to 4 weeks before randomization but not later than with first dose of ribociclib.
80561|NCT03555877|Drug|Anastrozole|1mg once daily as indicated in the SmPC
80562|NCT03555877|Drug|Letrozole|2,5mg once daily as indicated in the SmPC
80563|NCT03555877|Drug|Exemestane|25mg once daily as indicated in the SmPC
80564|NCT03555877|Drug|Fulvestrant|(prefilled syringes with fulvestrant 250mg each), 500mg given once a month, with an additional 500mg dose given two weeks after the first dose as indicated in the SmPC
80565|NCT03555877|Drug|Tamoxifen|20mg once daily as indicated in the SmPC
80566|NCT03555864|Device|infrared transluminescent device|use of infra red for venous access for second intravenous access
80567|NCT03555851|Drug|Cyclophosphamide|Pharmacogenomics of candidate genes and pharmacokinetic analyses of cyclophosphamide administered as part of a reduced intensity conditioning (RIC) regimen and as post-transplant GVHD prophylaxis will be examined.
80568|NCT03555851|Other|Specimen collection|Buccal swabs will be obtained from donors for pharmacogenomics.
80569|NCT03555838|Other|transcranial direct current stimulation|Transcranial direct current stimulation, a form of neuromodulation that uses a low direct current delivered via sponge electrodes on the head.
80570|NCT03555838|Other|sham transcranial direct current stimulation|an inactive or placebo version of transcranial direct current stimulation placed on the head via sponge electrodes.
80571|NCT03555825|Device|Hocoma ArmeoSpring|A spring-loaded upper extremity exoskeleton with 3 joints and 6 degrees of freedom. Participants use the more affected upper extremity to control and engage in therapeutic games.
80572|NCT03555812|Other|Pelvic inclination measurement|Measurement of pelvic inclination per ultrasound
80573|NCT03555799|Diagnostic Test|Inferior vena cava ultrasound|Abdominal ultrasound to identify IVC between hepatic veins and right atrium. Measurement of dimensions throughout respiratory cycle (before and after labor epidural)
80574|NCT03555786|Other|minimum effective volume|"The determination of MEV90 and its 95% confidence interval (CI) will be based on a biased coin up-and-down sequential design"
80575|NCT03555773|Procedure|Lipogems|After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
80576|NCT03555760|Behavioral|Observation of informed consent form readings of all patients who are scheduled for surgery|All patients who are scheduled for surgery will be observed for their initial reflex of inform consent form readings.
80577|NCT03555747|Other|Canine distalization|GCF was sampled from the mesial (tension) and distal (pressure) sides of maxillary right and left canines immediately before appliance placement (baseline) and after force application (24 hours and 28 days)
80578|NCT03555734|Other|Dietary pulses or legumes|Dietary pulses (dried beans, dried peas, chickpeas, lentils). If no data available specifically for dietary pulses than legumes will be assessed as the exposure (includes pulses, soybeans, peanuts, fresh peas, fresh beans).
80579|NCT03555721|Other|Oral examination with incandescent light|Suspicious oral lesions will be identified by oral examination with incandescent light.
80580|NCT03555721|Other|Oral examination with OralID|OralID uses a proven, optically based fluorescence technology that provides the clinician an aid in visualization of oral cancer, pre-cancer and other abnormal lesions.
80581|NCT03555721|Diagnostic Test|Biopsy|Tissue will be collected to identify pre-cancerous or cancerous cells
80582|NCT03555721|Diagnostic Test|CytID|CytID™ is an adjunctive process that is a noninvasive, pain-free, chair-side procedure for assessment of suspicious oral cavity lesions using a brush swab. The test is based on an objective measure of gross changes in the nuclear DNA content of oral epithelial cells; thereby, providing information about the pre-cancerous or cancerous state of a lesion.
80583|NCT03555721|Diagnostic Test|hpvID|hpvID™ testing can detect all major HPV types and shows the current HPV status of the patient. This provides additional clinical information to correlate and compare hpvID™ trends with routine standard of care biopsy or cytology results.
80584|NCT03555708|Other|Physical Therapy|Physical therapy will be implemented three times a week with subjects over an eight week span. Each physical therapy session will last 40-minutes and will be conducted by a licensed physical therapist.
80585|NCT03555695|Behavioral|Karate Classes|Eligible subjects will engage in twice-weekly karate classes for 10 weeks, specifically designed for individuals with early to middle stage PD, focused on incorporating upper and lower limb movements in multiple directions, increasing awareness throughout the body, shifting body weight and rotation, relaxation of the muscles, improving reaction time, using complex repetitive actions to improve coordination, footwork training and centered weight shifts to help with fall prevention, and striking shields for self-defense and stress relief.
80806|NCT03554109|Biological|GI-6301|Brachyury yeast vaccine
80807|NCT03554109|Drug|Avelumab|Avelumab
80586|NCT03555695|Behavioral|Pre-Intervention Focus Group|At the pre-intervention focus group, the study logistics will be reviewed, informed consent process will occur, the subject will complete a brief, individual pre-intervention assessment focused on overall mobility, gait, balance, mood, neurological status, and quality of life, and the subjects will be prompted to share aloud their thoughts on exercise, balance, and mindfulness practices in general and in PD specifically, and any expectations or preconceptions that they have regarding karate classes for PD.
80587|NCT03555695|Behavioral|Post-Intervention Focus Group|At the post-intervention focus group, the pre-intervention assessments will be readministered, along with an assessment of the subject's global impression of change. Subjects will be prompted to share their thoughts on how the intervention impacted their overall wellbeing, balance, and mindfulness; whether the intervention achieved their expectations; and they will be asked to provide feedback for improvements.
80588|NCT03555682|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
80589|NCT03555682|Dietary Supplement|Placebo|Placebo Comparator
80590|NCT03555669|Other|Depression Treatment|The depression treatment program combines measurement-based antidepressant treatment with PST with clinical response appropriate to the level of depressive severity. Patients scoring 0-4 on the PHQ-9, indicating no depression, receive no treatment. Patients scoring 5-9 on the PHQ-9, indicating mild depressive symptoms that likely are not a full major depressive episode, are offered PST. Patients scoring 10 or above on the PHQ-9, indicating moderate-to-severe depressive symptoms, are first offered anti-depressants. For this group, PST will be an alternative or augmentation option for those who do not tolerate or respond to antidepressant treatment. All patients' depressive severity is monitored with the option of modifying their treatment plan if their symptoms worsen or do not improve.
80591|NCT03555656|Behavioral|Repeated intervention|Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
80592|NCT03555656|Behavioral|Single session|Single 2-h group session educating patients at foot hygiene and ulcer prevention
80593|NCT03555630|Diagnostic Test|Thromboelastogram|Blood sample processing for thromboelastogram
80594|NCT03555617|Drug|TD-1473|oral capsule/tablet, QD
80595|NCT03555617|Drug|Itraconazole|oral solution, QD
80596|NCT03555604|Diagnostic Test|Gastric ultrasound|Gastric ultrasound to measure antrum cross sectional area
80597|NCT03555591|Drug|Trelagliptin|Trelagliptin tablets
80598|NCT03555578|Drug|Leuprorelin Acetate|Leuprorelin Acetate Injection Kit
80599|NCT03555565|Drug|Alogliptin and Metformin hydrochloride|Alogliptin and Metformin hydrochloride combination tablets
80600|NCT03555552|Device|Anticoagulation and Thrombosis Point of Care Test(AT-POCT)|Capillary action automatically draws blood into the channel containing printed assay reagents which solubilize upon contact with blood and react with analytes of interest.
80601|NCT03555552|Device|Duke Central Automated Laboratory (DCAL)|DCAL measurement of INR will occur by an ACL TOP 750 Analyzer (IL Inc.), and LDH by standard enzymatic activity assay will be run on the automated Beckman DxC800.
80602|NCT03555539|Drug|ACH-0144471|Oral Tablet
80603|NCT03555526|Drug|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 14 days
80604|NCT03555526|Drug|Amoxicillin|amoxicillin, 1000mg, bid, for 7 days (day 1-day 7)
80605|NCT03555526|Drug|metronidazole|metronidazole, 500mg, bid, for 7 days (day 8-14)
80606|NCT03555526|Drug|Levofloxacin 500mg|levofloxacin 250mg, bid, for 7 days (day 8-14)
80607|NCT03555526|Drug|Clarithromycin ER|clarithromycin 500mg, bid, for 7 days (day 8-14)
80608|NCT03555526|Drug|Esomeprazole 40mg|Nexium (esomeprazole), 40mg, bid, for 10 days
80609|NCT03555526|Drug|Dibismuth trioxide|Dibismuth trioxide，KCB F.C. TABLETS，300mg，qid, for 10 days
80610|NCT03555526|Drug|metronidazole|metronidazole, 500mg, tid, for 10 days (day 1-10)
80611|NCT03555526|Drug|tetracycline|tetracycline 500mg, qid, for 10 days
80612|NCT03555513|Procedure|living kidney transplantation|receiving kidney transplantation from living donor
80613|NCT03555500|Other|Non fasting|Non fasting group is allowed for clear fluids and food up to the time of the procedure.
80614|NCT03555487|Drug|18F-choline PET|5mCi of 18F-FCH will be injected intravenously. PET imaging will be performed on PET/CT scanner. PET/CT from skull base to diaphragm will be started at 50 minutes after the injection.
80615|NCT03555474|Procedure|Theta burst stimulation|Patients were given intermittent TBS to the affected hemisphere and continuous TBS to the unaffected hemisphere for 4 weeks along with physiotherapy.
80616|NCT03555474|Procedure|Functional Electrical Stimulation|Patients were given functional electrical stimulation of affected upper extremity for four weeks along with physiotherapy.
80617|NCT03555474|Procedure|Physiotherapy|Patients received active and passive physiotherapy of the affected extremity for four weeks.
80618|NCT03555448|Drug|Once daily immunosuppression regimen|Intervention focuses on the type of regimen, in this case the intervention arm will receive a once daily regimen for immunosuppression compared to the twice daily regimen.
80619|NCT03555448|Drug|Twice daily immunosuppression regimen|This is the arm which we are designating the standard, which will be the comparison to the active drug arm.
80620|NCT03555435|Other|Moving Forward On Your Own|Participants in this group will use the online program on their own for 6 weeks.
80621|NCT03555435|Behavioral|Moving Forward with Peer Support|Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
80622|NCT03555435|Behavioral|Wait|Participants in this group will wait 6 weeks.
80623|NCT03555422|Drug|Selinexor|oral medication
80624|NCT03555422|Drug|Placebo|oral medication
80625|NCT03555396|Behavioral|SMART Couples 2|The intervention will consist of 4 sessions with activities designed to strengthen communication and support within the couple to improve adherence to antiretroviral therapy and increase linkage to drug treatment services. The activities are based on cognitive-behavioral therapy. Participants' adherence will be monitored continuously through electronic monitoring devices and surveys completed at baseline and follow-up periods.
80808|NCT03554109|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
80809|NCT03554109|Biological|haNK|NK-92 [CD16.158V, ER IL-2]
80626|NCT03555396|Behavioral|Standard of Care|Standard of Care consists of an appointment with an AIDS Center nurse at baseline and two months later. Under current Standard of Care in Almaty, no behavioral intervention is provided. Participants obtain prescription refills and give blood for viral load and CD4 tests once every 6 months.
80627|NCT03555383|Diagnostic Test|Coagulation factor levels|The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).
80628|NCT03555370|Behavioral|Vestibular Exercise Intervention|The vestibular exercise intervention group will complete behavioral management activities, and prescribed in--office/at home vestibular exercises from four groups: 1) gaze stability training (integrated eye and head movements on fixed target), 2) visual motion training (integrated eye and head movements on moving target), 3) standing balance (standing with eyes closed in different stances), and 4) dynamic gait (walking with head turns and eye movements). Participants will be prescribed to one of four levels of these exercise groups based on presentation of symptoms/impairment as indicated on VOMS. Progression through the levels will be based on symptom tolerance and successful completion of all exercises at the current level.
80629|NCT03555370|Behavioral|Standard of Care|The standard of care consists of standardized in office/at home behavioral management including sleep, hydration, nutrition, and stress management interventions.
80630|NCT03555357|Other|Platelet Rich Fibrin|Platelet Rich Fibrin (PRF) is the next generation of PRP and contains very high concentrations white blood cells, fibrin and a small amount of mesenchymal stem cells found circulating in our bloodstreams. Due to a lack of anticoagulant in the tube, PRF becomes a gel after 15-20 minutes of being isolated. These properties make PRF useful in reconstructive and aesthetic medicine but may also be beneficial for scar therapy in the same way PRP is currently used.
80631|NCT03555357|Other|Platelet Rich Plasma|Platelet Rich Plasma (PRP) has been used in surgical settings to stimulate healing and promote tissue regeneration. In the field of cosmetic medicine, PRP has been used topically or as an injection to stimulate collagen production and enhance the efficacy of cosmetic procedures such as fat transfer, hair loss therapies, laser treatments, and microneedling. Harvested PRP has platelets, fibrin, and white blood cells, which contribute to wound healing, neocollagenesis, and elastogenesis
80632|NCT03555344|Other|Mantra Chikitsa|Specific Mantra were given to chants for 15 mins and resting in the impact of chants for following 15 mins.
80633|NCT03555331|Behavioral|Child Safety Control Intervention|In the study period which spanned from early infancy through age 3 years, the child safety intervention group was given an educational program with messages focused on child and home safety, guided by the American Academy of Pediatrics and the Academy's guide for health supervision, Bright Futures. The observation-only study extension will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
80634|NCT03555331|Behavioral|Responsive Parenting Intervention|During infancy, the Responsive Parenting group was given an educational program containing messages providing developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle aimed at preventing rapid weight gain in infancy and overweight at age 3 years. The new study period will not include any intervention, rather it will assess any long term outcomes from the education given to parents when their children were 0-2 years old.
80635|NCT03555318|Other|Ambulatory visit|All patients will have an ambulatory visit with the cardiologist.
80636|NCT03555318|Other|Combined ambulatory visit|Both the geriatrician and cardiologist will evaluate the patient and cardiac treatment will be agreed on between both specialists.
80637|NCT03555318|Other|Geriatric intervention|After the geriatric assessment, measures to improve frailty will be started.
80638|NCT03555305|Drug|LY2963016|Administered SC
80639|NCT03555305|Drug|Insulin Glargine (Lantus)|Administered SC
80640|NCT03555292|Drug|11C-PiB|11C-PIB with 555MBq were intravenously injected into the patients immediately before the PET/CT scans
80641|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--PS Arm|HIV Prevention Behavioral Health Intervention delivered by Probation Staff
80642|NCT03555279|Behavioral|PHAT Life: Preventing HIV/AIDS Among Teens--YR Arm|HIV Prevention Behavioral Health Intervention delivered by Youth Representatives
80643|NCT03555266|Device|NSS-2 Bridge|NSS-2-Bridge auricular therapy will be given in addition to standard of care ERAS protocol.
80644|NCT03555266|Device|Sham NSS-2 BRIDGE|NSS-2-Bridge sham will be used in addition to standard of care ERAS protocol.
80645|NCT03555253|Behavioral|Resilience-Based Program for Support Partners of PwMS|Support Partners will participate in six resilience coaching Program Sessions conducted weekly by a study resilience coach. PwMS will participate in the initial and final coaching Program Sessions with their Support Partners. The MyHealios Resilience Program for PwMS and their Support Partners has been designed to be interactive and include skills-based activities led by the Resilience coach. This includes skills of communication, problem solving, and learning about resilience and cognition in MS.
80646|NCT03555240|Other|Biobank creation and Pharmacogenetic analysis|Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.
80647|NCT03555227|Procedure|USG PECS2 with Drug A (active)|Ultrasound guided Pecs 2 blocks with 0.25% levobupivacaine
80648|NCT03555227|Procedure|USG PECS2 with Drug P (placebo)|Ultrasound guided Pecs 2 blocks with placebo (0.9% saline)
80649|NCT03555227|Procedure|Wound infiltration with Drug P (placebo)|Wound infiltration at the end of surgery with Drug P (0.9% saline)
80650|NCT03555227|Procedure|Wound infiltration with Drug A (active)|Wound infiltration at the end of surgery with 0.25% levobupivacaine
80692|NCT03554902|Procedure|Endoscopic gastric tubulization|Endoscopic gastric tubulization is performed using the CE marked endoscopic suture device Overstitch (Apollo Endosurgery, Austin, Tx. USA).
80651|NCT03555214|Other|Manual Therapy Group|"Manual Therapy:~Technique of suboccipital inhibition.~Technique of decompression of the lumbosacral hinge.~Decompression technique of sphenobasilar synchondrosis.~Fourth ventricle technique.~Technique of lifting the front."
80652|NCT03555214|Other|Control group|Placebo treatment
80653|NCT03555201|Other|Manual therapy|protocol of soft tissues techniques
80654|NCT03555201|Other|Regular treatment control.|Regular treatment control.
80655|NCT03555188|Drug|Ondansetron|Ondansetron is a highly selective receptor antagonist (5-HT3RA)
80656|NCT03555175|Other|Eccentric exercise|The group make hamstring eccentric exercise. The participants have to do 12 serie of 6 repeats
80657|NCT03555175|Other|Proprioception|The group have to do three kinds of exercise in a inestable area during 15 second in 2 repeats for each one
80658|NCT03555175|Other|Control group|Any exercise
80659|NCT03555162|Other|fMRI|Imaging examination
80660|NCT03555149|Drug|Regorafenib|Regorafenib will be administered orally on Days 1−21 of each 28-day cycle.
80661|NCT03555149|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab arm where the Atezolizumab IV infusion will be every 2 weeks (Q2W) on Days 1 and 15 of 28-day cycles.
80662|NCT03555149|Drug|Imprime PGG|Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.
80663|NCT03555149|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.
80664|NCT03555149|Drug|Isatuximab|Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.
80665|NCT03555149|Drug|Selicrelumab|Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.
80666|NCT03555149|Drug|Idasanutlin|Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.
80667|NCT03555136|Drug|Vortioxetine|Treatment with vortioxetine as per local SmPC
80668|NCT03555123|Drug|Simdax|Levosimendan2.5mg/ml
80669|NCT03555110|Behavioral|Personality Factor Battery Test (PFB Test)|Psychological instrument built for personality evaluation from the model of the Five Great Factors (FGF), that includes the following dimensions: Neuroticism, Extroversion, Socialization, Effort / Commitment), focusing on the component of the aspects of Neuroticism.
80670|NCT03555110|Behavioral|Eye Movement Desensitization and Reprocessing Therapy (EMDR)|"It is a psychotherapeutic approach effective on treatment for trauma and post-traumatic stress disorder. It is an intervention that allows the desensitization of negative emotions from traumatic experiences.This therapy modifies memories that have been processed non-adaptively and become painful and dysfunctional memories. During the procedure, the patient is encouraged to move the eyes from side to side, associating these movements with a target situation, previously defined at the beginning of the session. The ocular movements can be replaced by tactile or sonorous stimuli. The series of stimuli must continue until the memory of the traumatic event can be reprocessed adaptively, that is, without the emotional, negative or painful process associated with that memory."
80671|NCT03555097|Procedure|incremental pressure support|Inspiratory positive airway pressure (IPAP) gradually increases from 10 to 24 cm water column (cmH2O) with 2 water column (cmH2O) increments. The expiratory positive airway pressure (EPAP) remains 4 water column (cmH2O), and each pressure level is maintained for 5 to 10 minutes.
80672|NCT03555084|Device|Extension of Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
80673|NCT03555084|Device|Virto B-Titanium|In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
80674|NCT03555071|Biological|Vaccine manufactured at commercialized scale|Single subcutaneous injection of the investigated live attenuated varicella vaccine (0.5 ml) on Day 0
80675|NCT03555071|Biological|Vaccine manufactured at trial-scale|Single subcutaneous injection of the control live attenuated varicella vaccine (0.5 ml) on Day 0
80676|NCT03555058|Other|Treatment escalation|Treatment escalation per TDM and physician's decision.
80677|NCT03555045|Procedure|conducting the slanted recession technique on the superior and inferior poles|conducting the slanted recession technique on the superior and inferior poles of the muscle based on far and near deviations.
80678|NCT03555045|Procedure|conducting the augmented recession technique on the muscle|conducting the augmented recession technique on the muscle for 1 to 1.50 mm more compared with the standard method.
80679|NCT03555032|Drug|Talimogene laherparepvec (T-VEC)|One dose of 1 x 106 PFU/mL. Two doses of 1 x 108 PFU/mL. Given by intra-tumoural (i.t.) injection.
80680|NCT03555019|Dietary Supplement|Formulaid|Supplementation with ARA and DHA
80681|NCT03555019|Dietary Supplement|MCT-oil|Supplementation with medium chain fatty acids
80682|NCT03555006|Other|"Dual ultrasound reading local vs remote"|The examination will be interpreted by a department's radiologist and by a remote radiologist in blind of the first interpretation and a posteriori by a third radiologist.
80683|NCT03555006|Other|"Dual ultrasound reading local vs local"|The examination will be interpreted by two department's radiologists and a posteriori by a third radiologist.
80684|NCT03554993|Drug|CC-99677|CC-99677
80685|NCT03554993|Other|Placebo|Placebo
80686|NCT03554980|Drug|Silver Diamine Fluoride|SDF will be applied with a brush.
80687|NCT03554980|Drug|Sodium Fluoride varnish|NaF will be applied with a brush
80688|NCT03554941|Device|noise stimulation|noise stimulation
80689|NCT03554928|Diagnostic Test|magnetic resonance imaging|Participants will receive a 60 minute magnetic resonance imaging assessment
80690|NCT03554915|Other|Ketamine-based protocol|For profoundly agitated (physically violent) patients, intramuscular ketamine 5 mg/kg will be administered first line. For severely agitated patients, intramuscular ketamine 3 mg/kg will be administered first line.
80691|NCT03554915|Other|Midazolam-based protocol|For profoundly agitated patients, intramuscular midazolam 15 mg will be administered. For severely agitated patients, intramuscular midazolam 5 mg will be administered.
80848|NCT03553901|Procedure|Acupressure|Acupressure was performed before the injection onto GB30 point
80695|NCT03554876|Device|Multi-Im Machined transepithelial component.|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM machined transepithelial component is connected to the implant.
80696|NCT03554876|Device|Multi-Im Nanogolden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Nanogolden transepithelial component is connected to the implant.
80697|NCT03554876|Device|Multi-Im Ti-Golden transepithelial component|Once the implant is placed, the implant loading protocol will be decided following the clinical criteria. When implant loading is to be done, then the Multi-IM Ti-Golden transepithelial component is connected to the implant.
80698|NCT03554863|Device|Nasal High Flow Oxygen|Nasal High Flow Oxygen using Optiflow device of Fisher and Paykel
80699|NCT03554863|Device|Facial Mask|Preoxygenation with facial mask
80700|NCT03554850|Device|Trevo® Retriever|Stent retriever procedure
80701|NCT03554811|Device|Functional electrical stimulation assisted supine cycling (FESC)|A supine cycle ergometer attached to a six-channel stimulator will be used for FESC. Surface electrodes will be applied to the hamstrings, quadriceps, and calf muscles on both legs. Muscles will be stimulated at specific stages throughout the cycling phase. Each session will start with a 1 minute motor-driven passive cycling warm-up at a rate of 20 revolutions per minute. Patients will continue with passive, active-assisted, or active cycling, according to their level of participation. If the patients stop cycling actively, the ergometer will revert to passive cycling.
80702|NCT03554811|Other|Conventional early exercise and mobility interventions|These interventions will be based on the patient's alertness and medical stability, and includes activities to maintain or increase limb range of motion and strength, in and out of bed mobility, sit to stand, and transfer training, as well as assisted ambulation.
80703|NCT03554798|Biological|nOPV2 (monovalent oral polio vaccine)|"50 IPV and/or OPV vaccinated participants aged 1 to 5 years vaccinated with candidate 1 or 2; two 10‸6 CCID50 (50% cell culture infective dose) doses separated by 28 days.~162 infants enrolled at 6 weeks of age (-7 to +14 days) vaccinated with 3 doses of bOPV at 6, 10 and 14 weeks of age and 1 dose of IPV at 14 weeks of age, followed at 18-22 weeks of age with one 10‸5 CCID50 dose of candidate 1 or 2."
80704|NCT03554785|Behavioral|Clinician and Non-clinician staff training|"An optimized training program for non-clinical staff, clinicians and administrators developed by TFI's National LGBT Health Education Center that will include content-specific webinars and Office Hours for specific CHC consultations to optimize the provision of SGM health services at each CHC and to foster the development of in-house expertise to sustain ongoing training and quality improvement in the provision of care for LGBT patients."
80705|NCT03554772|Drug|DFN-15 Active Dose A|Oral Solution
80706|NCT03554772|Drug|DFN-15 Active Dose B|Oral Solution
80707|NCT03554772|Drug|DFN-15 Active Dose C|Oral Solution
80708|NCT03554772|Drug|Placebo|Oral Solution
80709|NCT03554759|Drug|Avatrombopag|Avatrombopag dosing will be determined by the treating physician in conjunction with the FDA-approved package insert.
80710|NCT03554746|Other|GC group|"core stability training: hold 5s/rep, 20 reps/times~supine, pelvic posterior tilt with TrA contraction.~supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~All four position with leg raise~Stretching ex. : hold 15 s/reps, 5 reps/times~Hamstring~Quadriceps~Additional gluteal muscle control training: hold 10 s/reps, 20 reps/times 1st to 2nd:~clam ex. without resistance~single leg bridge with maintain bil. ASIS even level 3rd to 4th: maintain 1st to 2nd ex. with resistance 5th:~maintain 3rd to 4th ex.~single leg standing on rock board to maintain balance 6th:~maintain 5th ex.~lunge ex. without hip internal rotation"
80711|NCT03554746|Other|CG group|"core stability training: hold 5s/rep, 20 reps/times~supine, pelvic posterior tilt with TrA contraction.~supine, pelvic posterior tilt and maintain bil. knee on 90 degrees.~All four position with leg raise~Stretching ex. : hold 15 s/reps, 5 reps/times~Hamstring~Quadriceps"
80712|NCT03554733|Behavioral|ReInventing Yourself after SCI|6-week, manualized, cognitive-behaviorally based group educational intervention
80713|NCT03554720|Device|ATTUNE PS Knee|The ATTUNE PS Knee is the standard implants.
80714|NCT03554720|Device|ATTUNE S+ PS Knee|The ATTUNE S+ PS Knee is the enhanced fixation.
80715|NCT03554707|Genetic|SGT-53|2.1 mg DNA/m2 or 2.8 mg DNA/m2 twice weekly
80716|NCT03554707|Radiation|Radiation|Standard radiation plan
80717|NCT03554707|Drug|Irinotecan|50mg/m2/dose IV daily for five days in a 4-week cycle
80718|NCT03554707|Drug|Temozolomide|100mg/m2 PO daily for five days in a 4-week cycle
80719|NCT03554707|Drug|Bevacizumab|10mg/kg IV every two weeks in a 4-week cycle
80720|NCT03554694|Dietary Supplement|Prebiotics|Galactooligosaccharides (GOS) (prebiotics) will be consumed by the participants for 4-6 weeks
80721|NCT03554694|Dietary Supplement|Maltodextrin (placebo)|Maltodextrin (placebo) will be consumed by the participants for 4-6 weeks
80722|NCT03554668|Diagnostic Test|Blood draw|We take blood samples at pre-op and subsequent time points, up to three months post op.
80723|NCT03554655|Device|Momentum app|The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
80724|NCT03554642|Device|Walkbot|Walkbot is a Robot Assisted Gait Training System. This system is designed to maximize muscle strength, range of joint motion, and gait function while participants engage in a virtual reality game.
80725|NCT03554642|Behavioral|Physical Therapy|30-minute session of standard physical therapy focused on pre-gait and/or gait training activities 5-days per week during the duration of their stay (14 days).
80726|NCT03554629|Device|Capnography CO2 Sampling Filterline|Use of up to 8 Capnography CO2 Sampling FIlterlines during scripted activities
80727|NCT03554616|Other|Chlorfenapyr LLIN|Dual active ingredient Long Lasting Insecticidal Net
80728|NCT03554616|Other|pyriproxyfen LLIN|Dual active ingredient Long Lasting Insecticidal Net
81913|NCT03545386|Other|Placebos|Saline with food coloring administered via enema
80731|NCT03554603|Behavioral|Modified Report|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important.
80732|NCT03554590|Behavioral|carbohydrate counting|patients will attend a 5 meetings-structured training to learn how to manage their insulin therapy depending on the amount of carbohydrates contained in foods
80733|NCT03554590|Behavioral|insulin therapy according to standard care|patients will not manage their insulin therapy depending on the amount of carbohydrates contained in foods, but will follow a fix basal bolus scheme
80734|NCT03554577|Device|Hearing Aid without NR|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
80735|NCT03554577|Device|Hearing Aid with NR_A|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
80736|NCT03554577|Device|Hearing Aid with NR_B|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
80737|NCT03554577|Device|Hearing Aid with NR_C|"Each participant will be fitted with the 4 different Noise Reduction (Sound Changing) principles on the same hearing aid, saved to 4 manual programs.~Noise Reduction principle is a sound processing algorithm to remove noise from a speech signal to improve the speech intelligibility and comfort. The experimental conditions vary in their parametrization to result in different degrees of noise suppression and good speech quality."
80740|NCT03554538|Behavioral|Web app exercises program|Exercise on an evidence based program for shoulder pain with web app animations to improve performance and adherence
80741|NCT03554538|Behavioral|Exercise program|Exercise on an evidence based program for shoulder pain
80742|NCT03554525|Dietary Supplement|Fat-binder damm|3 sticks every day during 12 months
80743|NCT03554525|Dietary Supplement|Placebo|3 sticks every day during 12 months
80744|NCT03554512|Other|Telehealth virtual appointment|Appointment with NICU clinician via telehealth equipment.
80745|NCT03554499|Procedure|Bichectomy with hydrodissection|Intraoral removal of buccal fat pads using hydrodissection technique
80746|NCT03554499|Procedure|Bichectomy|Intraoral removal of buccal fat pads using conventional technique
80747|NCT03554486|Drug|Fiasp|Fiasp insulin will be used for 2 weeks with the 670G hybrid closed-loop system
80748|NCT03554486|Drug|Novolog|Novolog insulin will be used for 2 weeks with the 670G hybrid closed-loop system
80752|NCT03554460|Device|dual-limb NIV|dual-limb NIV was served with servo i ventilator
80753|NCT03554447|Drug|Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet|Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
80754|NCT03554447|Drug|Escitalopram 20 mg tablet + Placebo|Selective serotonin reuptake inhibitor plus placebo
80755|NCT03554434|Biological|AM0010|AM0010
80756|NCT03554421|Procedure|Percutaneous tibial nerve stimulation|A 20Hz electrical current is given via an electrode inserted through the skin over the posterior tibial nerve above the medial malleolus of the foot and the nerve is stimulated until a motor reflex of the big toe is acheived. Treatment is then continued for 30 minutes at this level. The treatment is then repeated for a total of 10 sessions within a 2 week period.
80757|NCT03554408|Drug|10-1074-LS|Subcutaneous injection of 10-1074-LS
80758|NCT03554408|Drug|10-1074-LS|Intravenous infusion of 10-1074-LS
80759|NCT03554408|Drug|3BNC117-LS|Subcutaneous injection of 3BNC117-LS
80760|NCT03554408|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS
80761|NCT03554395|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
80762|NCT03554395|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
80763|NCT03554382|Other|system to support self-management of hypertension|The patients are provided with a home BP monitor. Thereafter they will be asked to use the self-management support system and self-report, once daily in the evening, via their own mobile phone during eight weeks. At each occasion, the patients first answer the questions on wellbeing, symptoms, lifestyle, medication intake and side effects and then measure their BP and pulse, and when these data (mean of three readings) are input into the mobile phone, they automatically register in the database. During intervention the paient has regular access to self-reported data via graphs
80764|NCT03554369|Radiation|Prostate SBRT|Patients will receive 45Gy in 5 fractions of radiation. A minimum of 36 hours and a maximum of 8 days should separate each treatment. No more than 3 fractions will be delivered per week (7 consecutive days). Total dose will depend on the phase of the study
80765|NCT03554356|Device|CryoBalloon Focal Ablation System|CryoBalloon Focal Ablation System
80766|NCT03554343|Diagnostic Test|test for SMN1 exon 7 deletion|Newborns are screened for SMN1 exon 7 deletion through standard NBS practice Positive case are promptly referred to reference centers
80767|NCT03554330|Other|Radiofrequency catheter ablation|(1) In control group: only graded balloon atrial septostomy will be carried out and there is no radiofrequency catheter ablation. (2) In single-RFA group: after graded balloon atrial septostomy identical to control group, radiofrequency catheter ablation will be performed immediately around the rim of created inter-atrial fenestration. (3) In double-RFA group: the first step is radiofrequency catheter ablation on fossae ovalis; and then the other two steps are identical to the single-RFA group (BAS and RFA around the rim of fenestration).
80768|NCT03554330|Other|Balloon atrial septostomy|Graded balloon atrial septostomy is performed in all patients.
80769|NCT03554317|Drug|Testosterone cypionate|Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
80770|NCT03554317|Drug|Nivolumab|Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
80771|NCT03554304|Drug|WCK 5222|FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)
80772|NCT03554304|Drug|IV placebo matched to WCK 5222 / Moxifloxacin IV solution|"Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet"
80773|NCT03554304|Drug|Moxifloxacin 400-mg|Moxifloxacin 400-mg positive control (overencapsulated tablet)
80774|NCT03554291|Drug|Famotidine 20 MG|Famotidine 20 mg capsule taken daily for 24 weeks.
80775|NCT03554291|Other|Placebo|Placebo capsule taken daily for 24 weeks.
80776|NCT03554265|Drug|Somatropin|Genotropin given by injection
80777|NCT03554252|Other|Frequencies|Results are presented as natural frequencies (e.g. the drug was effective for 1 out of 10 people) while side effects are presented as percentages (e.g. 40% participants experienced severe side effects)
80778|NCT03554252|Other|Percentages|Results are presented as percentages (e.g. the drug was effective for 10% of people) while side effects are presented as natural frequencies (e.g. 4 out of 10 participants experienced severe side effects)
80779|NCT03554239|Genetic|genotyping|Blood sample
80780|NCT03554226|Behavioral|NeuroPsychiatric Inventory Clinician (NPI-C)|All scales that will be administered to the patient during this study, (ADL, MMSE, QoL-AD, NPI and CMAI), are the subject of recommendations for the management of patients with AD (HAS 2009, HAS 2011)
80781|NCT03554213|Biological|Typhoid Conjugate Vaccine|Typbar TCV Vi-TT (Vi capsular polysaccharide conjugated with tetanus toxoid protein) manufactured by Bharat Biotech International Limited
80782|NCT03554200|Drug|Empagliflozin|Standard of Care + Empagliflozin: 10 mg (tablets) once daily
80783|NCT03554200|Drug|Placebo|Standard of Care + Placebo: Matching Placebo (tablets) once daily
80784|NCT03554187|Device|Ultrasonic periodontal Debridement, with appropriate device|Dental procedure that includes therapeutic interventions such as scaling to remove calculus and all soft deposits, root planing to eliminate subgingival calculus and smooth the tooth surface, and root débridement to eliminate subgingival biofilm and lightly mineralized deposits.
80785|NCT03554187|Biological|Analyzes of periodontopathogenic bacteria|Collection of plaque, to analyze the bacteria in the pocket
80786|NCT03554187|Genetic|IL1B test|susceptibility to periodontal disease (scratch swab onto the tongue) (no invasive)
80787|NCT03554187|Biological|Salivary Sampling|Salivette to chew. To analyse salivary microbiota
80788|NCT03554187|Device|Halitosis measure|With appropriate device : halimeter
80789|NCT03554174|Drug|Low Dose Psilocybin|0.1 mg/kg psilocybin capsule
80790|NCT03554174|Drug|Placebo|microcrystalline cellulose capsule
80791|NCT03554174|Drug|Medium Dose Psilocybin|0.3 mg/kg psilocybin capsule
80792|NCT03554161|Biological|Tocilizumab (TCZ)|Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.
80793|NCT03554148|Other|No intervention|This is purely an observational study. Groups SSI/No SSI are defined by the occurence of a surgical site infection.
80794|NCT03554135|Other|Personalization of palliative radiotherapy|Observe the rates of pain control and the need to retreat patient, when applied to personalization of indications and maximum technological support for palliative radiotherapy to patients with < 6 months prognostic score attendance
80795|NCT03554122|Procedure|Shotblocker|Patients spinal injections were performed with Shotblocker placed onto injection site
80796|NCT03554122|Procedure|Placebo|Patients spinal injections were performed without Shotblocker
80797|NCT03554109|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
80798|NCT03554109|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
80799|NCT03554109|Drug|Aldoxorubicin HCl|albumin-binding prodrug of doxorubicin HCl
80800|NCT03554109|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
80801|NCT03554109|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
80802|NCT03554109|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
80803|NCT03554109|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
80804|NCT03554109|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
80805|NCT03554109|Biological|GI-6207|CEA yeast vaccine
80810|NCT03554109|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
80811|NCT03554109|Drug|Doxorubicin HCL|Doxorubicin HCL
80812|NCT03554109|Drug|paclitaxel|paclitaxel
80813|NCT03554096|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
80814|NCT03554083|Drug|Atezolizumab|Given IV
80815|NCT03554083|Drug|Cobimetinib|Given PO
80816|NCT03554083|Drug|Vemurafenib|Given PO
80817|NCT03554070|Procedure|Thulium Fiber Laser Enucleation of the Prostate|Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.
80818|NCT03554070|Device|"Thulium Fiber Laser Urolase"|"Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm."
80819|NCT03554057|Diagnostic Test|Coronary Computed Tomographic Angiography|All low-risk patients referred for invasive coronary angiography will be potentially eligible to receive the intervention over a 12-month period. The intervention will include risk stratification using Coronary Computed Tomographic Angiography (CCTA) at HHS and NHS as an alternative to upfront invasive angiography. All CCTAs will be read by both a level 3-trained cardiologist and a radiologist. The results of the CCTA, coupled with evidence-based management recommendations will be sent to the referring physician and an invasive angiogram will be arranged only when indicated as per these management recommendations
80820|NCT03554044|Drug|Anastrozole|Given PO
80821|NCT03554044|Drug|Exemestane|Given PO
80822|NCT03554044|Drug|Fulvestrant|Given IM
80823|NCT03554044|Drug|Letrozole|Given PO
80824|NCT03554044|Drug|Paclitaxel|Given IV
80825|NCT03554044|Biological|Talimogene Laherparepvec|Given IT
80826|NCT03554044|Drug|Tamoxifen|Given PO
80827|NCT03554031|Drug|Recombinant Human Growth Hormone (rhGH) Injection|Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.
80828|NCT03554018|Drug|Acetaminophen|Acetaminophen 500-1000mg every 6 hours
80829|NCT03554018|Drug|Ibuprofen 600 mg|Ibuprofen 600mg every 6 hours
80830|NCT03554018|Behavioral|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp)
80831|NCT03554018|Drug|Placebo oral capsule|To match acetaminophen, patients will take one or two capsules every 6 hours
80832|NCT03554005|Drug|PEG Interferon Alfa-2b|Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
80833|NCT03554005|Drug|Acetaminophen|Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
80834|NCT03553992|Behavioral|POP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to SGM young adults~Drug: nicotine patch 14-day supply of nicotine patch"
80835|NCT03553992|Behavioral|TSP-6:|"90 days of Facebook messaging, weekly live sessions targeting tobacco use~Drug: nicotine patch 14-day supply of nicotine patch"
80836|NCT03553979|Behavioral|Stress management program (SM)|Participants follow the SM program.
80837|NCT03553979|Behavioral|Stress management + Buddy program (SM-B)|In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
80838|NCT03553966|Procedure|Prophylactic|Tooth Brushing HA 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
80839|NCT03553966|Procedure|Cleaning teeth|Tooth Brushing F 3x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
80840|NCT03553966|Device|Restorative dentistry|If in a subject a significant increase of carious lesions will be observed, her/his parents are informed about the necessity for further caries preventive measures (e.g. dietary changes, use of fluoride products, reduction of cariogenic microflora with chlorhexidine, xylitol chewing gum, etc.) and caries preventive treatment (removing caries and placing a restoration) by the study centers is offered.
80841|NCT03553953|Device|BIS device|Recording data from BIS device from patients who undergo elective surgery under general anesthesia
80845|NCT03553927|Dietary Supplement|Low Energy Diet|Caloric restriction to achieve weight loss
80846|NCT03553927|Other|NHS advice on healthy eating|Advice on energy requirements as per the British Dietetic Association
80847|NCT03553914|Drug|PLM60|PLM60 will be administered via intravenous infusion in 28-day cycles for up to 7 cycles.
80849|NCT03553875|Drug|Memantine Hydrochloride|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to memantine for the course of the 12-week randomized controlled trial (RCT).
80850|NCT03553875|Drug|Placebo|Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
80851|NCT03553862|Behavioral|collaborative care|The intervention arm will receive collaborative care from a team of healthcare professionals that consists of pharmacist, physicians, nurses and dietitians. Patients in the intervention group will also receive clinical interventions carried out by the pharmacist.nurses and dietitians as well as a pharmacist.
80852|NCT03553849|Dietary Supplement|Very low calorie diet|The VLCD is a prescribed diet with well-balanced macro and micronutrients. It is intended for significant weight loss in a short period of time, is intended only for the extremely obese, and must be completed under the supervision of a trained physician.
80853|NCT03553836|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
80854|NCT03553836|Other|Placebo|Administered as an IV infusion every 3 weeks (Q3W)
80855|NCT03553823|Procedure|Skin biopsies|At Baseline, two 6-mm punch biopsies will be taken, one from the identified active plaque (TCS ≥ 6) and one from never-lesional skin. At the End-of-study Visit, one biopsy will be taken from the same area of the active plaque sampled at Baseline.
80856|NCT03553810|Drug|Entresto|Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
80857|NCT03553810|Drug|Valsartan|Valsartan 40mg once a day, up-titrating to 80 or maximum 160 mg to achieve target systolic blood pressure below 140mmHg, over a duration of 52 weeks. If necessary, amlodipine and/or hydrochlorothiazide may be added to achieve target systolic blood pressure.
80858|NCT03553784|Other|Group delivered Low Intensity Cognitive Behavioural Therapy|The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
80859|NCT03553771|Device|LVIS and LVIS JR|Braided coil assist stents used for aneurysm embolization
80860|NCT03553758|Drug|Ketamine|Subjects' brain waves will be monitored by EEG recording under ketamine general anesthesia over the course of approximatel 60 minutes.
80861|NCT03553745|Behavioral|Gentle Yoga Intervention|10-week exercise program structured around gentle yoga practice.
80862|NCT03553745|Behavioral|Rigorous Yoga Intervention|10-week exercise program structured around rigorous yoga practice.
80863|NCT03553745|Behavioral|Physical Exercise Intervention|10-week exercise program structured around cardiovascular exercise.
80864|NCT03553732|Other|Registry|Patients who are diagnosed with prostate cancer and elect to be monitored by an Active Surveillance protocol by the Urology Clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing but suboptimal systems for tracking patients. All Active Surveillance patients monitored by the clinic will be included.
80865|NCT03553693|Other|RAPID-VL study intervention|"Viral load (VL) ordering flowsheet with periodic health facility performance feedback~Rapid near-point-of-care VL testing and telephone delivery of results~Structured VL counseling package"
80866|NCT03553680|Behavioral|Emotion-Focused CBT|10 CBT Sessions to improve emotional regulation and emotional intelligence.
80867|NCT03553667|Device|Standard group|Use radial arterial line to monitor mean arterial pressure
80868|NCT03553667|Device|ClearSight|Use Edwards EV1000 Clinical Platform NI with ClearSight finger sleeve to monitor SV(stroke volume)
80869|NCT03553654|Diagnostic Test|low dose CT|CT-based protocol for detection of anthracycline-induced myocardial dysfunction at early stages
80870|NCT03553628|Other|Chlorhexidine, Propolis and Clove Oil mouthwash|Chlorhexidine Gluconate 0.12% with Propolis 1% and Clove Oil 1% mouthwash
80871|NCT03553628|Other|Chlorhexidine mouthwash|Chlorhexidine HCL 0.12% mouthwash
80872|NCT03553615|Drug|Ivermectin Pill|oral anti-parasitic agent taken as a weekly dose for four weeks
80873|NCT03553602|Radiation|HDR Brachytherapy + EBRT + STAD|"HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen[until end of radiotherapy])"
80874|NCT03553589|Other|Blood sampling|Blood sampling (10 mL) prior to standard care (e.g. surgery, medical treatment)
80875|NCT03553576|Drug|Low volume bolus|Administration of a low-volume bolus (6.25 mL) of greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
80876|NCT03553576|Drug|High volume bolus|Administration of a high-volume bolus (10 mL) of lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
80877|NCT03553563|Drug|D961H capsule 10mg|All Groups can select either capsule or sachet during the study.
80878|NCT03553563|Drug|D961H sachet 10mg|All Groups can select either capsule or sachet during the study.
80879|NCT03553550|Other|biospecimen collection|Peripheral blood collection Archival tissue collection
80880|NCT03553537|Drug|Decitabine|10mg/m² iv on day 1-5
80881|NCT03553537|Drug|Cyclophosphamide|750mg/m² iv on day 6
80882|NCT03553537|Drug|Doxorubicin|DOX
80883|NCT03553537|Drug|Vincristine|1.4mg/m² iv on day 6
80884|NCT03553537|Drug|Prednisone|100mg/m² po on day6-10
80885|NCT03553524|Other|morning HIIT --> afternoon HIIT|Arm 1 will start with morning HIIT at visit 2 and afternoon HIIT at visit 3
81914|NCT03545373|Drug|Azithromycin|Azithromycin tablet taken orally
80886|NCT03553524|Other|afternoon HIIT --> morning HIIT|Arm 2 will start with afternoon HIIT at visit 2 and morning HIIT at visit 3
80887|NCT03553511|Procedure|Vaginal vault suspension to the uterosacral ligaments|Laparoscopic hysterectomy with vaginal vault suspension to the uterosacral ligaments
80888|NCT03553511|Procedure|McCall culdoplasty|Vaginal hysterectomy with McCall culdoplasty
80889|NCT03553498|Drug|IV acetaminophen|acetaminophen given intravenously
80890|NCT03553498|Drug|IV placebo|given intravenously
80891|NCT03553498|Drug|hydromorphone|hydromorphone given intravenously
80892|NCT03553485|Device|Transcutaneous vagus nerve stimulation|The transcutaneous auricular vagus nerve stimulator Parasym consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The patient can regulate and adapt the intensity of the stimulation (current intensity) according to his/her individual sensitivity, which can vary from day to day or even over the period of the therapy.
80893|NCT03553485|Device|Sham|Sham Earclip electrodes are electrodes that appear identical to functioning electrodes, however do not deliver any stimulation due to removed wiring.
80894|NCT03553485|Radiation|Radiotherapy|Standard treatment for included patients
80895|NCT03553459|Diagnostic Test|Trendelenburg Maneuver|In the Trendelenburg position, the body is laid supine, or flat on the back with the feet higher than the head by 15-30 degrees. The venous return increases in the trendelenburg position which in turn increases the stroke volume.
80896|NCT03553446|Drug|children receiving sevoflurane|Children receiving pre-determined sevoflurane concentration using modified Dixon's up-and-down method
80897|NCT03553433|Drug|Apremilast 30mg|Anti-psoriatic drug
80898|NCT03553433|Drug|Placebo Oral Tablet|Indistinguishable tablets not containing apremilast, Placebo Oral Tablet
80899|NCT03553407|Device|Low Level Laser - Pulse|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
80900|NCT03553407|Device|Low Level Laser - continuous|The laser will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
80901|NCT03553407|Device|Low Level Laser - placebo|placebo will be applied at a single point in contact, perpendicular to the surface of the tooth in a region that presents healthy enamel, towards the pulp chamber. The laser chosen was the low power diode laser with the following protocols: Group 1 (880nm, 30mW, 3.6 J / cm², 25 Hz) and Group 2 (880nm, 30mW, 3.6 J / cm²), after 10 minutes we will ask to the patient again from 0 to 3 the level of pain, to then proceed to the anesthetic phase.
80902|NCT03553394|Drug|Ringer's Acetate|Will receive a fluid bolus immediately (Ringer's Acetate 5 mls/kg bw) if oliguric/anuric for two consecutive hours
80903|NCT03553381|Other|hypocaloric balanced diet|
80904|NCT03553368|Diagnostic Test|HF-NIV-MR|MRI data will be acquired with the use of HF-NIV.
80905|NCT03553368|Diagnostic Test|HF-NIV-PET|PET data will be acquired with the use of HF-NIV.
80906|NCT03553368|Diagnostic Test|MR|MRI data will be acquired without the use of HF-NIV as a reference.
80907|NCT03553368|Diagnostic Test|PET/CT breath hold|PET/CT data will be acquired in inspiratory breath hold without the use of HF-NIV.
80908|NCT03553355|Device|Infrared Laser Moxibustion|We will use SX10-C1 laser moxibustion devices (Shanghai Wonderful Opto-Electrics Tech Co Ltd, Shanghai, China) for the ILM and SILM groups. Four laser probes will be synchronously aligned with 4 points (tST36 (bilateral), CV4, and CV6 acupoints) and we will irradiate each acupoint 2 cm away from the skin surface for 20 minutes. Each patient will receive this treatment twice per week for six weeks (12 sessions total).
80909|NCT03553355|Device|Sham Infrared Laser Moxibustion|The sham laser moxibustion instrument appears to be identical as the real one.
80910|NCT03553342|Drug|Corticoids|Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
80911|NCT03553342|Other|Placebo|Patients will receive placebo for seven days.
80912|NCT03553329|Drug|dabrafenib|Monthly biological assessment which included: blood count, a blood electrolytes, an creatininemia, a dosage of urea, a dosage of transaminases, of gammaGT, of phosphatases alkaline, of LDH and of albumin.
80913|NCT03553316|Drug|PK101-002|-(Single) PK101-002
80914|NCT03553316|Combination Product|PK101|-(Combination) PK101-001, PK101-002
80915|NCT03553303|Drug|Sacubitril / Valsartan Oral Tablet|Increasing doses of Sacubitril/Valsartan
80916|NCT03553290|Device|A.R.C. FOX Laser-FOX Q-810nm|805-810 nm dichotomous laser, 12 Watt within the power of sensitive parts of the affected teeth
80917|NCT03553290|Procedure|Control|Mechanical debridement alone
80918|NCT03553277|Other|transfluthrin|passive emanator with formulated transfluthrin
80919|NCT03553277|Other|placebo|passive emanator with formulated inert ingredients
80920|NCT03553264|Device|Virtual Reality Rehabilitation|Track Speed Racing 3D game will run with HMD 'Revelation' 3D VR Headset and each HMD group patient will be instructed to perform the game protocol uninterruptedly for 20min/day, while sitting on a chair or sofa.
80921|NCT03553264|Other|Vestibular Rehabilitation|The home exercise program will include a patient-tailored combination of adaptation (without and with the target moving in pitch and yaw planes for 1min each three times per day), substitution, habituation, and balance exercises
80922|NCT03553238|Drug|Chidamide|Chidamide will be administrated at a dose of 10mg/day in PDT-ETP-ALL protocol.
80923|NCT03553238|Drug|Dexamethasone|Dexamethasone will be added in Pre-phase Regimen, Induction-Regimen, Consolidation-Module of PDT-ETP-ALL protocol.
80924|NCT03553238|Drug|vincristine|Vincristine will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
80963|NCT03553082|Drug|Sevoflurane|Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance
80925|NCT03553238|Drug|Cyclophosphamide|CTX will be added to Induction-Regimen, Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
80926|NCT03553238|Drug|Idarubicin|IDA will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
80927|NCT03553238|Drug|Pegaspargase|PEG-ASP will be added to Induction-Regimen and Consolidation-Module of PDT-ETP-ALL protocol.
80928|NCT03553238|Drug|Adriamycin|Adriamycin will be added to Consolidation-Module of PDT-ETP-ALL protocol.
80929|NCT03553238|Drug|Methotrexate|Methotrexate will be added to consolidation module of PDT-ETP-ALL protocol.
80930|NCT03553238|Drug|6-Mercaptopurine|Mercaptopurine will be added to Consolidation-Module and Maintenance-Module of PDT-ETP-ALL protocol.
80931|NCT03553238|Drug|Etoposide|VP-16 will be added to Consolidation-Module of PDT-ETP-ALL protocol.
80932|NCT03553238|Drug|Cytarabine|AraC will be added to Consolidation-Module of PDT-ETP-ALL protocol.
80933|NCT03553238|Procedure|Bone marrow aspiration|Bone marrow aspiration and additional tests will be performed in all module of PDT-ETP-ALL protocol.
80934|NCT03553238|Procedure|Intrathecal injection|Intrathecal injection chemotherapy will be performed in PDT-ETP-ALL protocol.
80935|NCT03553238|Radiation|Radiation therapy|Radiation therapy will be performed for mediastinum and/or central nervous system leukemia in PDT-ETP-ALL protocol.
80936|NCT03553238|Genetic|NGS|Next-Generation-Sequencing (NGS) will be performed in PDT-ETP-ALL protocol.
80937|NCT03553238|Procedure|allogeneic hematopoietic stem cell transplantation|Allo-HSCT will be performed for patients with available donor in PDT-ETP-ALL protocol.
80938|NCT03553238|Diagnostic Test|Flow-MRD|Flow-MRD will be added to PDT-ETP-ALL for bone marrow and cerebrospinal fluid samples.
80939|NCT03553238|Diagnostic Test|FISH|FISH will be performed in PDT-ETP-ALL for bone marrow samples.
80940|NCT03553238|Diagnostic Test|Flow immunophenotyping|Flow immunophenotyping will be performed in PDT-ETP-ALL protocol.
80941|NCT03553238|Diagnostic Test|Karyotyping|Karyotyping will be performed in PDT-ETP-ALL protocol.
80942|NCT03553225|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors
80943|NCT03553225|Dietary Supplement|Concord Grape extract 1|1 g Concord Grape extract in 2 capsules
80944|NCT03553225|Dietary Supplement|Concord Grape extract 2|500 mg Concord Grape extract in 2 capsules
80945|NCT03553212|Radiation|tomotherapy|20-23 Gy in 2 fractions on the whole prostate gland +/- seminal vesicles and 24-27 Gy in 2 fractions as simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL) 2 weeks in all.
80946|NCT03553199|Device|TRS, Tissue Retraction System|Tissue Retraction System
80947|NCT03553186|Drug|Tranexamic Acid 100 MG/ML|TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation and prior to grafting. Excess solution will be suctioned away using a non-cell saver suction and the wound grafted and closed without further deep irrigation.
80948|NCT03553186|Drug|Placebo|Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation and prior to grafting. Excess solution will be suctioned away using a non-cell saver suction and the wound grafted and closed without further deep irrigation.
80949|NCT03553173|Other|So-Lo-Mo|So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).
80950|NCT03553173|Behavioral|Psychological advice|Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy
80951|NCT03553173|Drug|Bupropion Pill|Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.
80952|NCT03553173|Drug|Varenicline Pill|Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.
80953|NCT03553160|Other|Frequent Self-Weighing|Were given scales to weigh themselves daily. Change in weight was measured at the beginning and end of the two year observation period.
80954|NCT03553147|Other|SARC-F score, handgrip test and impedancemetry|Participation in the study will be offered to any patient admitted to the geriatric ward, those who meet the inclusion criteria and do not have exclusion criteria will have to complete the SARC-F questionnaire during their stay, and to do the handgrip test and impedancemetry performed by a third party. Biological data (albumin, pre-albumin and C-Reactive Protein) and anthropometric data will be collected and analyzed to determine if the patient is malnourished or not, and the results of SARC-F will be compared between these 2 groups.
80955|NCT03553134|Diagnostic Test|transcranial doppler ultrasound scan|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 10 minutes)
80956|NCT03553134|Diagnostic Test|ultrasound scan centered on the arterial canal|Carried out at 4 different times: at birth, 6, 24 and 48 hours of life (duration: 5 minutes)
80957|NCT03553121|Other|walking|walking and not walking
80958|NCT03553108|Drug|Olaparib Treatment A|Olaparib Tablet 25 mg
80959|NCT03553108|Drug|Olaparib Treatment B|Olaparib Tablet 100 mg
80960|NCT03553108|Drug|Olaparib Treatment C|Olaparib Tablet 150 mg
80961|NCT03553108|Drug|Olaparib Treatment D|Olaparib Tablet 250 mg
80962|NCT03553095|Procedure|Periodontal Surgery|Samples will be collected from patient in need of periodontal therapy (surgical procedures i.e. gum surgery, tooth extraction and or dental implant surgery). As standard during this procedures remnant tissue is otherwise discarded.
81915|NCT03545373|Drug|Amoxicillin|Amoxicillin tablets taken orally
80964|NCT03553082|Drug|Propofol|Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance
80965|NCT03553056|Other|NZ Step Away app|Access to 10 modules of the app (namely: drinkers profile, goal setting, rewards, cravings, strategies, support, reminders, high risk times, moods, activities)
80966|NCT03553056|Other|Modified NZ Step Away app|Access to 2 modules of the app (namely: drinkers profile and goals setting)
80967|NCT03553043|Behavioral|Intervention|Energy label condition.
80968|NCT03553043|Behavioral|Control|No label
80969|NCT03553030|Device|coronary artery angiography|In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
80970|NCT03553017|Device|Binocular OCT|Participants in the study will undergo OCT imaging using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA) twice to assess repeatability.).
80971|NCT03553004|Drug|Niraparib Treatment|Niraparib treatment by mouth (oral)
80972|NCT03552991|Drug|Agiocur Pregranules|6g before breakfast and 12g after dinner for first 28 days, and no medication for next 28 days for washout
80973|NCT03552978|Behavioral|Tech-Facilitated IC Intervention|The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smartphone application (app) and the iCO Smokerlyzer device and app. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with posttraumatic stress disorder (PTSD). The experimental intervention condition in the proposed study differs from the standard of care in that participants will be receiving tailored, individualized smoking cessation counseling for veterans with PTSD.
80974|NCT03552978|Behavioral|VA Quitline|Participants in the control condition will receive the VA's standard care, which is referral to the VA Quitline. This active control condition involves weekly telephone sessions through the VA's proactive telephone Quitline, which is available to all veterans for up to 8 weeks. Participants will initiate the first call, and subsequent calls will be made by the Quitline counselor.
80975|NCT03552965|Other|Robust Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that minimize the dose of radiation to normal tissue
80976|NCT03552965|Other|Margin-Based Radiotherapy planning|Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that introduce a margin to the target area
80977|NCT03552952|Other|No intervention|No intervention
80978|NCT03552913|Procedure|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery|One year before awareness-raising phase in favour of Enhanced Recovery After Surgery
80979|NCT03552913|Procedure|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery|One year after awareness-raising phase in favour of Enhanced Recovery After Surgery
80980|NCT03552913|Procedure|No specific program toward improving practices|No specific program toward improving practices
80981|NCT03552900|Behavioral|7 Cups Mobile App|Participants who receive the 7 Cups mobile app will get access to direct online social support by messaging with a listener, participating in group chats as well as evidence-based information and exercises to promote their mental health.
80982|NCT03552900|Behavioral|Bliss Mobile App|Participants who receive the Bliss mobile app will get access to an app that that provides information and offers a personal approach to navigate through mental health resources on Harvard's campus.
80983|NCT03552887|Procedure|Cardiac Surgery|Any type of cardiac surgery
80984|NCT03552887|Procedure|Physiotherapy|Any type of physiotherapy intervention, performed by physiotherapists outside of the protocol
80985|NCT03552874|Other|The Performance of Upper Limb Questionnaire (PUL)|
80986|NCT03552861|Device|repetitive transcranial magnetic stimulation(rTMS)|Each patient will be given 5 treatment sessions per week for 2 weeks (a total of 10 sessions).In each rTMS conditioning session,1200 pulses of stimuli at an intensity of 100% rest motor threshold (RMT) will give over the left and rigt DLPFC.Each session is 45 minutes long and will be consisted of 10Hz stimulation trains (active) over the left DLPFC and 1Hz over the right DLPFC，Interval of 5 minutes each side.During rTMS blocks, the coil will be oriented tangential to the surface. For sham control rTMS blocks, the coil will be oriented 90◦ away from the scalp so that no pulses perturbed underlying neural tissue.
80987|NCT03552848|Biological|MSC|MSC at a dose of 1000000 cells per kilogram of body weight will be given intravenously once every 4 days for 4 times
80988|NCT03552835|Procedure|no caries removal|occlusal caries were treated with no caries removal and placement of stainless steel crown
80989|NCT03552835|Procedure|partial caries removal upto soft dentin|occlusal caries were treated by partial caries removal upto soft dentin followed by Glass Ionomer Cement placement as a base and composite restoration
80990|NCT03552835|Procedure|partial caries removal upto firm dentin|occlusal caries were treated by partial caries removal upto firm dentin followed by Glass Ionomer Cement placement as a base and composite restoration
80991|NCT03552822|Other|ERAS Protocol Implementation|Implementation of ERAS Protocol Implementation
80992|NCT03552809|Device|Gigaa Cheese 810 nm Diode Laser|Diode Laser assisted frenectomy operation.
80993|NCT03552809|Procedure|Conventional Frenectomy Operation|Frenectomy operation performed by surgical blades with suturing.
80994|NCT03552796|Other|Pharmacokinetic Study|Correlative studies
80995|NCT03552796|Biological|Recombinant EphB4-HSA Fusion Protein|Given intravesically
80996|NCT03552783|Behavioral|FFL + Cognitive Behavioral Therapy|Participants in the intervention arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime in addition to 12 weekly, one-hour, group CBT sessions, and three (3), one-hour, one-on-one therapy sessions throughout the 12-week FFL program. We will implement an individual and group CBT mental health intervention that will align with the topics addressed in the FFL weekly curriculum.
80997|NCT03552783|Behavioral|Fathers for a Lifetime (FFL) only|"The participants in the comparison arm will receive the standard, 12-week program curriculum of Fathers for a Lifetime. The curriculum is broken into three categories:~Personal responsibility~Personal responsibility to your child~Responsibility to your family and community"
80998|NCT03552770|Drug|Bevacizumab|pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
81916|NCT03545360|Device|BTL-703 (Treatment group)|Treatment with BTL-703 device
80999|NCT03552757|Drug|Semaglutide 1.0 mg|Subcutaneous (s.c.) injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
81000|NCT03552757|Drug|Semaglutide 2.4 mg|Subcutaneous injections of semaglutide once weekly at an escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
81001|NCT03552757|Drug|Placebo I (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 2.4 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week, 1.7 mg/week and 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
81002|NCT03552757|Drug|Placebo II (Semaglutide)|S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide 1.0 mg (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg mg/week). The dose will be escalated to next level every 4 weeks.
81003|NCT03552744|Other|Mailed training intervention|"PCPs from the intervention group will be mailed an intervention package that includes:~2-page structured evidence summary on CRC screening and information about Colonoscopy & FIT (Decision box)~patient decision aid (20-page booklet) on CRC screening for distribution to patients (Decision Aid)~video example for the PCP, which illustrates a participatory approach to discussing CRC screening with a patient~4-page abridged version of the booklet to support PCPs when they discuss CRC screening with patients during a clinical visit (Decision Board)~individualized 1-page summary of PCP screening practices comparing their individual prescription patterns to group patterns, based on the data collected in 2017 (Performance card)~2-page document that encourages PCPs still using the inferior guaiac-based FOBT to switch to FIT and includes list of laboratories from which they can order FIT~sample FIT for PCPs who may not be familiar with its contents and use"
81004|NCT03552731|Behavioral|Surveys|GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
81005|NCT03552718|Biological|YE-NEO-001|Personalized recombinant yeast-based vaccine engineered to express multiple neoantigen epitopes (neoepitopes) based on an individual subject's tumor molecular profile.
81006|NCT03552705|Drug|Tranexamic Acid|5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
81007|NCT03552705|Drug|Placebos|5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
81009|NCT03552679|Diagnostic Test|Echocardiography|Echocardiography
81010|NCT03552666|Dietary Supplement|vitamin D3|
81011|NCT03552653|Dietary Supplement|Vitafusion Extra Strength Vitamin D|Monitor Vitamin D blood levels
81012|NCT03552627|Drug|Oxygen|Medical Oxygen
81013|NCT03552614|Device|Upper limb robot-assisted rehabilitation|"Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames."
81014|NCT03552614|Other|physiotherapy|Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
81015|NCT03552601|Other|traditional speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1000mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
81016|NCT03552601|Other|faster speed|ARDS patients are performed negative fluid balance strategy with intravenous furosemide (4mg/h) or continuous veno-venous hemofiltration. The target amount of every day's net negative fluid balance for the first three days is 1500mL.Termination of the strategy is performed when mean arterial pressure drops below 65mmHg or perfusion index drops below 0.82 or lactate increases above 2mmol/L or acute kidney injury occurs.
81017|NCT03552588|Diagnostic Test|Continuous Electrocardiogram|A high-sensitivity, 14-day continuous ECG monitor.
81018|NCT03552575|Drug|sacubitril/valsartan|Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
81019|NCT03552575|Drug|Valsartan|is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
81020|NCT03552562|Device|Fourier Domain Color Doppler Optical Coherence Tomography (FDOCT)|Fourier domain OCT is based on a local phase analysis of the backscattered signal and allows for bidirectional Doppler flow imaging.(Leitgeb et al. 2003a; Leitgeb et al. 2003b) It does not need reference arm scanning and records one full depth and Doppler profile in parallel. The system operates with an equivalent A-scan rate of 25 kHz and allows real time imaging of the color encoded Doppler information together with the tissue morphology at a rate of 2-4 tomograms (40 x 512 pixel) per second. Despite the high detection speed we achieve a system sensitivity of 86dB using a beam power of 500μW at the cornea. The fundus camera allows simultaneous view for selection of the region of interest. We observe bi-directional blood flow and pulsatility of blood velocity in retinal vessels with a Doppler detection bandwidth of 12.5 kHz and a longitudinal velocity sensitivity in tissue of 200μm/s. Diffuse luminance flicker will be applied during the measurements for 60 seconds.
81021|NCT03552549|Biological|PEG-Intron|Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.
81022|NCT03552549|Biological|INTRON A|Interferon alfa-2b, recombinant for intravenous injection.
81023|NCT03552536|Drug|MK-8583|A single oral dose of MK-8583 in capsule form
81024|NCT03552523|Device|Bionic Pancreas|During this arm the subject will ONLY use our bionic pancreas device with an insulin only configuration using a rapid-acting insulin analog. Subjects will wear a continuous glucose monitoring device (the Dexcom G5) as part of the bionic pancreas, and use the study provided glucose meter.
81025|NCT03552523|Other|Usual Care|Subject will wear a continuous glucose monitoring device (the Dexcom G5) and use the study provided glucose meter.. Subject will not change their prescribed home insulin therapy regimen during this arm whether that be an insulin pump or multiple daily injections.
81026|NCT03552510|Procedure|Oro-pharyngeal Administration of Mother's Milk|Infants will receive mother's milk (to the maximum of 0.2 ml ) by dropper to the oro-pharyngeal pouch, tongue and cheeks every 3 hours (5 minutes before time of feeding)
81027|NCT03552497|Diagnostic Test|Radiomics|The high-throughput extraction of large amounts of quantitative image features from radiographic medical images
81028|NCT03552484|Behavioral|Home Visit Program|Informed consent discussion, documentation; UPDRS I-IV, medical history, vitals, medication reconciliation, patient medical history and comorbidities; home safety assessment; psychosocial assessment of dyad, resource utilization questionnaire, caregiver medical history and comorbidities, MCSI; patient and caregiver short MoCA, satisfaction surveys, EQ5D; counseling, summarizing plan of care
81029|NCT03552484|Behavioral|Usual Care/Online Survey|Patients and caregivers, if available, will be asked to complete an online survey that asks about demographics, disease history, resource utilization, and unmet needs. The will be asked to complete a follow-up survey 12 months after completion of the initial survey.
81030|NCT03552471|Other|Laboratory Biomarker Analysis|Correlative studies
81031|NCT03552471|Biological|Mirvetuximab Soravtansine|Given IV
81032|NCT03552471|Other|Pharmacokinetic Study|Correlative studies
81033|NCT03552471|Drug|Rucaparib Camsylate|Given PO
81034|NCT03552458|Drug|Lactobacillus Reuteri Oral Solution [BioGaia]|BioGaia Lactobacillus Reuteri drops
81035|NCT03552458|Drug|Placebos|Placebo will be identical in physical appearance and color to the study agent and will be made by the manufacturer
81036|NCT03552445|Biological|Tetanus-diphtheria (Td) and PCV13|154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
81037|NCT03552445|Biological|PCV13 alone|154 PCV13 recipients: one vaccine injection administered on Day 0
81038|NCT03552445|Biological|Td alone|437 Td recipients: one vaccine injection administered on Day 0
81039|NCT03552432|Drug|Alirocumab|the administration of Alirocumab by Subcutaneous injection 75mg every 2 weeks plus Rosuvastatin10mg/daily by oral for 9 months
81040|NCT03552406|Biological|ISU104|Intravenous Infusion for 1 hour.
81041|NCT03552393|Drug|Mircera|The initial dose of Mircera will be one of nine starting doses corresponding to the prefilled syringe strengths based on the total weekly erythropoiesis-stimulating agent (ESA) dose during the screening period.
81042|NCT03552380|Drug|Entinostat|RP2D will be determined with a 6 patient safety lead-in. Entinostat will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 14 day cycles.
81043|NCT03552380|Drug|Nivolumab|Nivolumab will continue until disease progression or prohibitive toxicity. Cycles 1-4 are 21 day cycles. Cycles 5 and subsequent are 14 day cycles.
81044|NCT03552380|Drug|Ipilimumab|Ipilimumab will be administered in combination with entinostat and nivolumab for Cycles 1-4 only.
81045|NCT03552367|Other|Personalized structured exercise program|The type of exercise offered to patients in this arm is precisely designed for obese patients according to age and physical fitness parameters. Patients are monitored using a heart rate monitor to evaluate treatment adherence and compliance
81046|NCT03552367|Other|Non personalized non-structured exercise program|The type of exercise is non-structured and patients' heart rate is not monitored. Patients receive exercise recommendations without any personalization according to their fitness parameters
81047|NCT03552354|Drug|Argatroban plus dual antiplatelet|A continuous argatroban infusion of 1.0 ug/kg per minute for 2-5 days adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%). For the first day, clopidogrel with loading dose 300mg, and aspirin 100mg were given, and followed by clopidogrel 75 mg and aspirin 100mg each day
81048|NCT03552341|Other|Maternal iodine status|Urinary iodine concentration during pregnancy at 26 weeks' gestation (Bord in Bradford study) and at 12, 26 and 36 weeks' gestation, 6, 18 and 30 weeks postpartum (Hiba longitudinal study). This is primarily in the form of Iodine to Creatinine ratio, to take spot urine volume into account. There is no intervention in this observational study.
81049|NCT03552328|Other|Lunch with Medical Student|Each student will bring provided lunches once a week to their elder participant's residence, and they will share lunch together for an hour once a week for six weeks. Students will enroll as Meals on Wheels volunteers and participate in the Meals on Wheels pre-program training. On the day of their scheduled lunch, students will first arrive at the Meals on Wheels designated meal-drop location and pick up two lunches, one for them and one for their assigned elder. They will then drive to their assigned elder's residence and eat lunch with them for one hour.
81050|NCT03552328|Other|Control|Students will not bring provided lunches to an elder participant's residence. The elder participants in this arm will simply continue receiving daily meals from Meals on Wheels with no accompanying student.
81051|NCT03552315|Dietary Supplement|Carbonated water with amino acids and chromium|The active carbonated water containing amino acids and chromium picolinate is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
81052|NCT03552315|Dietary Supplement|Placebo Carbonated Water|The placebo carbonated water is consumed with a standardized test meal. Postprandial glucose and insulin response is documented for 180 minutes
81053|NCT03552302|Behavioral|Yoga|"Yoga stretch warm-up exercise for 15 minutes.~Five kinds of yoga correction method for 30 minutes (abdominal breathing, throat breathing, wind box breathing, nasal alternating breathing, buzzing breathing).~Great rest for 15 minutes"
81054|NCT03552289|Device|Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|The Enforcer balloon device will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
81055|NCT03552289|Device|Conventional angioplasty balloon catheters|Commercial available angioplasty balloon devices will be used in treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistula
81056|NCT03552276|Drug|tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL)|at Baseline and Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44,48, 52, and all subsequent 4-weekly time points to Week 200.
81057|NCT03552276|Drug|tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL)|at Weeks 8, 20, 32, 44, 56, and all subsequent 12-weekly time points to Week 200, as well as placebo (two 1-mL injections) at interim 4-weekly time points commencing at Baseline of the Phase 2 parent study to Week 196.
81058|NCT03552276|Drug|tildrakizumab 100 mg (one 1-mL injection of 100 mg/mL + 1 mL placebo)|at Weeks 8, 20, 32, 44, 56, and all subsequent 12-weekly time points to Week 200, as well as placebo (two 1-mL injections) at interim 4-weekly time points commencing at Baseline of the Phase 2 parent study to Week 196.
81059|NCT03552276|Drug|tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL)|at Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and all subsequent 4-weekly time points to Week 200.
81060|NCT03552263|Drug|T89 capsule|T89 capsules (75mg), orally, twice daily.
81061|NCT03552263|Drug|Placebo capsule|Placebo capsules (0mg), orally, twice daily.
81062|NCT03552250|Behavioral|Parenting for Lifelong Health for Young Children|In this study, the 12 sessions-PLH version for parents of young children (2-9 years) will be delivered. The PLH (2 - 9) programme is delivered in groups of parents and includes the following general content 1) One-on-one time, 2) Say what you see, 3) Talking about feelings, 4) Praising and rewarding our children, 5) Giving positive, specific, and realistic instructions, 6) Establishing household rules and routines, 7) Redirecting negative behavior, 8) Ignoring negative attention seeking and demanding behavior, 9) Using consequences to support compliance, 10) Using Cool-down as a consequence for aggressive behavior, 11) Avoiding and resolving conflicts, 12) Reflection celebration, and moving on.
81063|NCT03552237|Dietary Supplement|dietary fiber|We will investigate in a 4 week intervention whether consumption of dietary fiber supplement affect the microbiota composition in schizophrenia patients with central obesity.
81064|NCT03552224|Procedure|Recording of auditory nerve activity|near field recording of auditory nerve activity with contact electrode
81065|NCT03552211|Drug|biotin|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
81066|NCT03552211|Other|propensity score|This is a national, academic, observational and retrospective study comparing one group of progressive MS patients with high dose biotin to another group without this treatment using a propensity score, in intention to treat.
81067|NCT03552198|Behavioral|Alternative health advice|These messages targeted specific beliefs about air pollution and protective actions aimed at reducing exposure to air pollution. In addition, message specificity was targeted, which means that compared to the usual messages, the alternative messages reported more detailed health recommendations.
81068|NCT03552172|Other|Physical activity|PHYSICAL ACTIVITY: Rhythm of meetings, number of meetings, place of meetings
81069|NCT03552172|Other|Absence of or suspended physical activity|the brakes responsible for a stop or lack of practice
81070|NCT03552159|Behavioral|Behavioral activation|Activity scheduling, monitoring, review and re-scheduling
81071|NCT03552159|Other|Psychoeducation|Education on dementia, caregiving stress, event scheduling and communication skills
81072|NCT03552146|Drug|Propofol|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
81073|NCT03552146|Drug|Dexmedetomidine|Patients will be randomized to either propofol or dexmedetomidine and then observed for sedation-related events from time of drug administration to discharge.
81074|NCT03552133|Device|Smart CO2|A lightweight, cylindrical reservoir attached to a face mask which monitors breathing breath-by-breath and automatically adjusts the level of dead space rebreathe volume so that CO2 will be increased and sleep apnea treated.
81075|NCT03552120|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.
81076|NCT03552120|Behavioral|Supportive Psychotherapy|Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
81077|NCT03552107|Drug|Lorcaserin|Treatment initiation with Lorcaserin
81078|NCT03552094|Other|Blood donations of hemochromatosis or polycythemia patients|Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
81079|NCT03552094|Other|Blood donations of healthy donors|Blood samples are from blood donations of healthy donors.
81080|NCT03552081|Other|Fragmented DNA evaluation in blood and semen samples|The objective will be to evaluate the decrease in the percentage of sperm with spermatic DNA fragmentation by the TUNEL technique following the evolution of this rate to 3 months, 6 months and 12 months after cessation of smoking by blood and semen samples.
81081|NCT03552068|Drug|placebo|"Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening)."
81082|NCT03552068|Drug|Clonidine|Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
81083|NCT03552055|Other|Non-interventional Study|no interventions in this study, just specimen collection
81084|NCT03552042|Behavioral|Counterclockwise program|A group of older adults (aged 75+) will take part of a residential role-play game, in which they will relive their previous self, acting as if they were in the year 1989. The whole residential program, which will last one week, is designed to enhance this perception, including a retrofitted environment and social activities that will prime participants to relive that period.
81950|NCT03545100|Other|motor control therapy|scapular muscle progressive resistive exercise(PRE)
81085|NCT03552042|Behavioral|Active control group|Participants in the active control group will follow the same agenda of the Counterclockwise Program group, without the constant reference to 1989. The intervention will take place in the same location of the Counterclockwise Program, without any specific change. Activities will mirror the ones of Counterclockwise Program, but participants will not live as if they were younger. The agenda will be the same, but no mention to 1989 will be done. All discussion activities will refer to present days (e.g., instead of discussing the open of the Berlin Wall, they can discuss Brexit or Trump presidency).
81086|NCT03552029|Drug|Quizartinib|20 or 30 mg tablets for oral administration
81087|NCT03552029|Drug|Milademetan|5, 20, 80 or 200 mg capsules for oral administration
81088|NCT03552029|Drug|Milademetan|30, 45, 80, or 100 mg capsules for oral administration
81089|NCT03552016|Drug|Oral Riboflavin|The intervention doses will be 200 mg oral riboflavin and 400 mg oral riboflavin doses; the placebo dose will be 0 mg of oral riboflavin
81090|NCT03552003|Other|Treatment for clinical practise|Prospective data collection with the aim to to develop a prognostic index for elderly patients with newly diagnosed cHL
81091|NCT03551990|Procedure|whole-body electromyostimulation WB-EMS|Patients of the WB-EMS group will perform whole-body electromyostimulation (WB-EMS) training sessions twice a week over a period of 8 weeks. To allow muscle recovery a break of at least 2 days between the sessions will be scheduled. To adapt the patients to the WB-EMS intervention, the training duration will be gradually increased (week 1, 12 min; increase of 2 min/week; week 5-8, 20 min). WB-EMS training sessions will include light physical exercises according to a video tutorial and individually supervised by certified physio therapists.
81092|NCT03551977|Behavioral|iCanCope with Pain|The participants are free to use the Norwegian iCanCope with Pain app as much as they want during the 8 week intervention period. The only support available is technical support.
81093|NCT03551977|Behavioral|iCanCope with Pain control|The participants are free to use the Norwegian iCanCope with Pain control app as much as they want during the 8 week intervention period. The only support available is technical support.
81094|NCT03551964|Drug|Cangrelor|"Cangrelor: IV bolus 30 μg/kg (application < 1 minute), immediately followed by continuous infusion in the dose of 4 μg/kg/min. To accelerate the initiation of therapy, tables containing calculations of the bolus dose in ml and the speed of infusion therapy for individual weights will be prepared.~Cangrelor therapy will be stopped after circulatory stabilization - when sBP > 100 mmHg persists for one hour / when IABP will be terminated / when vasoactive treatment with norepinephrine, dopamine (in the dose ≥ 5 μg/kg/min) will be stopped, but not later than 4 hours after PCI~30 minutes before stopping Cangrelor infusion, administration of initial dose of crushed Ticagrelor 180 mg and then Ticagrelor maintenance dose 90 mg twice a day for 12 months."
81095|NCT03551964|Drug|Ticagrelor|Initial dose crushed Ticagrelor 180 mg. Maintenance dose Ticagrelor 90 mg twice daily for 12 months.
81096|NCT03551951|Diagnostic Test|Test for circulating tumor cells, DNA alterations|
81097|NCT03551938|Behavioral|Relationship skills session for YMSM partnered-individuals and couples|Relationship skills session as an addition to the current CTR and CHTC intervention for 15-24 year old YMSM and their partners.
81098|NCT03551925|Behavioral|Treatment as Usual Plus Occupational Therapy|The IMeds consists of a three-step process that leads the client from the reflection of past performance, to goal setting, and onto strategy identification and implementation. This intervention guides the client through identifying strategies in the following six areas: altering the medication management activity, advocacy, assistive technology, environmental modifications, and securing refills on time (Schwartz et al., 2017).
81099|NCT03551925|Behavioral|Treatment as Usual|A clinical pharmacist counsels participants on proper medication adherence.
81100|NCT03551912|Procedure|Surgery|All patients coming for elective surgery
81101|NCT03551899|Other|Different ventilation parameters|mode of ventilation, tidal volume per body weight and PEEP settings
81102|NCT03551886|Behavioral|Advanced Emotion App|The app is designed to help TAY better recognize their emotions using enhanced features
81103|NCT03551886|Behavioral|Basic Emotion App|The app is designed to help TAY better recognize their emotions using basic features
81104|NCT03551873|Drug|Plecanatide|Subjects will have been breastfeeding or pumping for at least 4 weeks and must have been prescribed and taking TRULANCE® for at least 14 continuous days prior to Baseline. Breast milk for measurement of TRULANCE® (plecanatide) concentrations will be collected at Day 1.
81105|NCT03551860|Procedure|TQL|"For the intervention of TQL peripheral nerve block the needle tip will be advanced by in-plane technique and local anaesthetic will be deposited between psoas major and quadratus lumborum muscles. 20 ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
81106|NCT03551860|Procedure|FIB|"The needle tip will be advanced by in-plane technique and local anaesthetic will be deposited deep to the fascia iliaca. 20ml of 0.25% bupivacaine will be administered under ultrasound guidance following careful intermittent aspiration. The needle tip will not be repositioned unless the patient complains of paraesthesia.~For the intervention of spinal neuraxial blockade the needle will be advanced into the subarachnoid space. Once clear CSF is visualised 3.2ml 0.5% plain bupivacaine will be infiltrated."
81107|NCT03551847|Drug|Antibiotic|The intervention involves giving an infected patient antibiotics.
81108|NCT03551847|Drug|No antibiotics|The intervention involves not giving an infected patient antibiotics.
81109|NCT03551834|Other|Conventional scleral patch graft glaucoma implantation|conventional AGV implantation by using scleral patch graft to cover the tube and prevent tube exposure
81110|NCT03551834|Other|New surgical method (short tunnel small flap technique)|a novel technique named short tunnel small flap (STSF) by tunneling the sclera to pass the AGV tube without using scleral patch graft.
81111|NCT03551821|Drug|ATI-50002|Topical Solution
81112|NCT03551808|Drug|using of Ketorolac Tromethamine Eye Drop|using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
81113|NCT03551795|Biological|Infusion of iNKT cells|The eligible patients receive twice infusions of iNKT cells(1E8~1E10) in one course of treatment.
135874|NCT03126916|Other|Pharmacological Study|Correlative studies
81114|NCT03551782|Drug|Cetrelimab 480 mg|Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
81115|NCT03551782|Drug|Apalutamide 240 mg|Apalutamide 240 mg (4*60 mg) tablets per day will be administered orally.
81116|NCT03551769|Drug|tricaprilin|Tricaprilin formulated as AC-SD-01
81117|NCT03551769|Other|standard meal|standard meal
81118|NCT03551769|Other|high-fat meal|high-fat meal
81119|NCT03551769|Other|overnight fast|fasting for at least 9 hours
81120|NCT03551756|Other|Biomarker Assessment|Exploratory Biomarker Analysis for cardiac patients versus healthy adults
81121|NCT03551743|Combination Product|PRT064445/Edoxaban|
81122|NCT03551743|Combination Product|Placebo/Edoxaban|
81123|NCT03551743|Drug|Placebo|
81124|NCT03551730|Combination Product|PRT064445/Enoxaparin|
81125|NCT03551730|Combination Product|Placebo/Enoxaparin|
81126|NCT03551730|Drug|Placebo|
81127|NCT03551717|Other|Optical Coherence Tomography angiography|At the inclusion visit for all patients and at M3 only for 50 patients.
81128|NCT03551717|Other|Fundus|At the inclusion visit for all patients and at M3 only for 50 patients.
81129|NCT03551717|Other|cardiac ultrasound scan|Only for 50 patients, 3 months after the initial cardiovascular event
81130|NCT03551704|Behavioral|CBT + EFT|"The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices."
81131|NCT03551704|Behavioral|CBT + EFT + CM|This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
81132|NCT03551691|Drug|Omeprazole 40mg Capsule|Omeprazole 40mg daily for 28 days
81133|NCT03551691|Drug|Placebo oral capsule|Identically-appearing capsule to omeprazole
81134|NCT03551678|Device|Active feedback gait retraining|The device measures pressure/force under the lateral side of the foot and activates vibration if loading crosses a set threshold. The location of the vibration is customized for each subject to achieve maximal sensitivity.
81135|NCT03551665|Behavioral|Protective step training|Participants will undergo 2 weeks of training, in which they will be exposed to repeated slips on a treadmill. This approach is aimed at improving protective steps.
81136|NCT03551652|Drug|Pharmacokinetics of rocuronium induced neuromuscular block|Measurement of rocuronium induced neuromuscular block comparing patients aged > 80 years with patients aged 18 to 50 years
81137|NCT03551626|Drug|Dabrafenib|Supplied as dabrafenib 50 mg, 75 mg Capsules for oral use
81138|NCT03551626|Drug|Trametinib|supplied as trametinib 0.5mg, 2.0mg tablets for oral use
81139|NCT03551613|Dietary Supplement|honey supplementation|honey supplementation
81140|NCT03551600|Procedure|Near-infrared spectroscopy (NIRS)|NIRS analyzes regional oxygen saturations (rSO2)
81141|NCT03551587|Device|Vibringe|The Vibringe is the first endodontic sonic irrigation system that enables delivery and activation of the irrigation solution in the root canal, in only one step.
81142|NCT03551561|Drug|CSAAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes, followed by a sterile and soaked with 70% alcohol compress. After removing the chlorhexidine-based soap excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
81143|NCT03551561|Drug|CSAC|Skin preparation with 4% chlorhexidine-based soap for a period of 5 minutes and the of a simple, dry and sterile compress to remove the excess. After removing the excess, antisepsis was performed with alcoholic chlorhexidine and surgical drapes and gowns.
81144|NCT03551548|Drug|Spironolactone 25mg|25 mg oral spironolactone once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
81145|NCT03551548|Drug|Placebo oral capsule|oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
81146|NCT03551535|Behavioral|Monitored, At-Home Exercise Intervention|Patients will be enrolled in the BurnAlong program as well as receive FitBit heart rate + activity monitors to track adherence rates to the prescribed exercise regimen on BurnAlong, with subsequent motivational interventions triggered if compliance varies from prescription
81147|NCT03551522|Drug|Seladelpar|10 mg, 20 mg, or 50 mg
81148|NCT03551522|Drug|Placebos|Matching placebo Capsule
81149|NCT03551509|Biological|ArthroFLEX ECM scaffold graft|In patients receiving a graft, thru mini open technique the lateral portal incision will be extended vertically approximately 5-6 cm. A standard, deltoid-splitting, mini-open approach will then be performed, leaving the deltoid attachment to the acromion intact. For arthroscopic technique same method of fixation will be used below. The dermis graft will be sized and cut so as to cover the entire repair site in both medial-lateral and anterior-posterior dimensions.
81150|NCT03551509|Procedure|Control|This group will undergo rotator cuff repair surgery, but will not receive the ECM scaffold graft.
81151|NCT03551509|Biological|Crossover|Patients randomized to the control arm who cannot be repaired without an augmented graft will be followed for safety and remain in the study and put into a group for the intention to treat.
81152|NCT03551496|Combination Product|Drug Eluting Stent - Below the Knee|Treatment arm with DES-BTK, starting with one size of the device - 3.5 mm X 80 mm
81153|NCT03551496|Device|Standard PTA Control Arm|The PTA device used must be market-released in the investigational center's geography and the size (ie, diameter, balloon length and catheter length) will be determined by the investigator.
81407|NCT03549234|Drug|Paravertebral (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
81154|NCT03551483|Device|ArtontheBrain|The ArtontheBrain intervention has three activities focused on a user selected artwork. The activities promote an in-depth analysis of the artwork and are organized into three activity categories; learn, play, and mingle. In 'learn', the options are to read and/or listen to the curatorial description of the artwork. In 'play', the options are to engage in a word search game, to engage in a visual puzzle game, or to engage in a storytelling game whereby a reminiscence or imaged story can be written. In 'mingle' the options involve social communications about the artwork that include seeing what other comments and seeing how the artwork has been rated by others. The mingle option permits the user to engage only with a select circle of users or to engage with a group of public users.
81155|NCT03551483|Device|Seniors Online Victoria|The active control group will use a freely available website, which is updated daily with online games for seniors through an organization called Seniors Online Victoria (https://www.seniorsonline.vic.gov.au/services-information/games).
81156|NCT03551470|Procedure|Robotic one-stage colorectal and liver resection|
81157|NCT03551457|Diagnostic Test|Biopsy|Patient-derived xenograft treatment response phenotype.
81158|NCT03551444|Drug|Administration of DAA-based treatment|"Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~Virological failures and early discontinuations of therapy due to adverse events will be also registered."
81159|NCT03551431|Diagnostic Test|Video EEG with verbal suggestion|Video EEG with verbal suggestion will be done by attaching EEG electrodes to the child along with verbals suggestion in isolation or verbal suggestion and tuning fork, verbal suggestion and cotton swab.
81160|NCT03551418|Behavioral|Watching a video|Watching a video of an adult with DS washing his hands
81161|NCT03551405|Radiation|CBCT scan|CBCT is a standard image guidance procedure for patient setup in image-guided radiation therapy at the Department of Radiation Oncology, UTSW. Our study will deliver three additional CBCT scans to each patient in only one fraction. These additional scans will increase radiation doses to the patients, which elevate the radiation-associated risks of secondary cancer.The other risk involved in this study is a possible violation of patient confidentiality. The imaging data will be completely anonymized, since the patient related information is not needed for this study.
81162|NCT03551392|Device|Medx Console System|This intervention delivers near infrared (NIR) light using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
81163|NCT03551392|Device|Sham Medx Console System|This intervention uses sham application of near infrared light (NIR) using light emitting diodes applied to the head and via an intranasal applicator for a period of approximately 1.5 hours. A total of 16 sessions take place in the lab over 12 weeks.
81164|NCT03551392|Device|Vielight 810 intranasal stand alone unit|Daily at home intranasal NIR stimulation sessions, 25 minutes in duration, 4 days each week.
81165|NCT03551392|Device|Sham Vielight 810 intranasal stand alone unit|"Daily at home intranasal sham NIR stimulation sessions, 25 minutes in duration, 4 days each week."
81166|NCT03551379|Device|Double Balloon Endoluminal Platform|A DBA platform will be use din this registry study to facilitate ESD
81167|NCT03551366|Behavioral|Linear|The linear pedagogy arms consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives aligned to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. Linear curriculum lessons will be focused on the functioning of the body and children learning movement patterns. These lessons will be far more prescriptive and have clearly stated outcomes/goals for each lesson, with a typical lesson structure following the structure of warm up, isolated practice of technique or skill, simulated game and warm down.
81168|NCT03551366|Behavioral|Nonlinear|The non-linear pedagogy arm consists of three, five-week phases of lesson delivery, commencing around two weeks after baseline assessments. The first phase focuses on dance, the second on gymnastics and the final phase on ball sports. Each phase has its own schemes of work which includes five lessons objectives, each taught over a two lesson period. The lesson objectives align to the aims of English national curriculum. Lessons are delivered twice a week by trained coaches, with each lesson lasting 60 minutes in total, with 45 minutes of on task teaching time. The nonlinear curriculum lessons will look to make sure that children are both engaged and empowered throughout the learning process. In adherence to representative learning design, we will look to contextualise lessons and guide learning through the use of books/stories, lived experiences and the sharing of ideas.
81169|NCT03551353|Other|Group before Video-assisted feedback|Ten anesthesia residents will be included in this group. Preoperative evaluation in terms of general anesthesia will be completed for a patient before anesthesia induction. After receiving informed consent from the patient resident will complete the preparations by checking the above-mentioned list (anesthesia machine, operating room desk, monitorization methods, aspirator systems, operating room gas systems, waste systems and other anesthesia equipment) then induction will be started. All these steps will be recorded with a camera system. Once the anesthetic application is completed and all stages are recorded, the video records will be evaluated in terms of ASA guideline
81170|NCT03551353|Other|Group after Video-assisted feedback|Before the second phase of the study, the resident will be informed about the guideline (checkout procedure) by a staff. Then induction of general anesthesia in another patient will be recorded at all stages. Once the anesthesia application is complete, the camera record will be monitored. Differences and developments or possible similar mistakes between the records will be discussed.
81171|NCT03551340|Diagnostic Test|Gastro-intestinal panel by PCR|The study will evaluate the change in medical management with the replacement of traditional stool investigations (microscopy and culture) by the new gastrointestinal multiplex PCR panels
81172|NCT03551327|Behavioral|Experimental: Intervention plus information|The intervention will include six sessions with a therapist, each separated by two weeks. During the two weeks between sessions, participants will work on the goals identified during the sessions. At the final session, the participants will agree how to maintain any improvements in fatigue. Then there will be a review phone call about 4-6 weeks after completion of the intervention, to check on progress and to offer ongoing encouragement to continue with the changes that have been made during the intervention. The intervention can be delivered by video conferencing as well as by phone.
81173|NCT03551327|Other|Active Comparator: Information only|Participants in this arm will be provided with information about fatigue.
81174|NCT03551314|Other|Nasal Intermittent Positive Pressure|"- NIPPV The following parameters: inspiratory pressure = 15 cmH2O / final expiratory positive pressure = 6 cmH2O / inspiratory time = 0.40 / flow = 6-8 L.min-1 / respiratory rate = 24.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
81175|NCT03551314|Other|Continuous Positive Airway Pressure|"- CPAP The following parameters: pressure of 6 cmH2O, with flow of 6-8L/min.~Respiratory inductive plethysmography is used to evaluate breathing pattern (tidal volume, respiratory rate, minute ventilation, mean inspiratory flow) and chest wall motion (labor breathing index - LBI, phase relation in inspiratory breathing - PhRIB, phase relation in expiratory breathing - PhREB, total phase relation - PhRTB and phase angle)."
81176|NCT03551301|Other|Transitional Case Management|"TCM program is a type of very flexible community treatment in terms of frequency and intensity of care. This is facilitated by a small case load ratio per health care professional (1:10). The healthcare workers are specialised in SUD treatment. The intervention begins during hospitalisation and lasts around 4 weeks after discharge from the hospital.~The main aim of this intervention is to accompany the patient in the difficult phase of transition between hospital and outpatient care and ensure their adherence to the treatment program. The healthcare workers will explore specific patient needs and ensure that health and social services are better coordinated to fit their needs. Another important aim is to reduce the number of (unplanned) hospitalizations and emergency room visits."
81177|NCT03551288|Drug|SUVN-911|Tablet
81178|NCT03551275|Biological|BCD-132|Dose Escalation Study
81179|NCT03551262|Device|OTSC|Positioning of OTSC in bleeding peptic ulcer
81180|NCT03551262|Device|TTS clip|Positioning of TTS clip in bleeding peptic ulcer
81181|NCT03551249|Device|Focused ultrasound (FUS)|FUS involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets.
81182|NCT03551223|Biological|Neuron specific enolase (NSE)|5 cc of venous blood will be drawn from all of the participants and be examined for NSE and S100 B serum levels in order to evaluate evaluate which anesthetic method (general anesthesia versus spinal anesthesia) is associated with reduced neuronal injury in a preeclamptic parturients undergoing a cesarean section.
81183|NCT03551210|Drug|Nemonoxacin|Solution for infusion, 500 mg (250 ml)
81184|NCT03551210|Drug|Nemonoxacin|Capsules, 250 mg
81185|NCT03551210|Drug|Tavanic|Solution for infusion, 500 mg (100 ml)
81186|NCT03551210|Drug|Tavanic|Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
81187|NCT03551210|Drug|Placebo (250 ml)|0.9% NaCl (250 ml), solution for infusion
81188|NCT03551210|Drug|Placebo (100 ml)|0.9% NaCl (100 ml), solution for infusion
81189|NCT03551197|Drug|Budesonide and formoterol bid|At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months` treatment.
81190|NCT03551184|Biological|Endotoxin|Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
81191|NCT03551184|Biological|Placebo|Saline administered intravenously
81192|NCT03551171|Drug|ZL-2306 (niraparib)|"About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group).~All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose."
81193|NCT03551158|Diagnostic Test|Echocardiography|Cardiac imaging for the assessment of the left atrium anatomy and function.
81194|NCT03551145|Other|Acellular collagen matrix|3D collagen matrix consists of the collagen porcine type I and III
81195|NCT03551145|Other|Autogenous free gingival graft|Autogenous graft harvested from the posterior palate
81196|NCT03551132|Other|Exercise test|Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
81197|NCT03551119|Behavioral|Exercise|See previous description
81198|NCT03551119|Other|Enhanced usual care|See previous description
81199|NCT03551106|Other|Web based learning module|Web based learning module available on a especially designed website
81200|NCT03551093|Device|ISS SPG stimulation|The ISS is intended to deliver electrical stimulation to the nerves within the greater palatine canal and pterygopalatine fossa (SPG).
81201|NCT03551080|Biological|Lipopolysaccharide|Endotoxin at 0.8 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
81202|NCT03551080|Biological|Placebo|Saline administered intravenously
81203|NCT03551067|Drug|Dexmedetomidine|Dexmedetomidine mixed with juice was given to the child orally preoperatively.
81204|NCT03551067|Combination Product|Midazolam/Ketamine|Midazolam/Ketamine was mixed with juice and given to the child orally preoperatively
81205|NCT03551054|Behavioral|Healthy for Two, Healthy for You|Remotely delivered health coaching in pregnancy and postpartum to promote healthy weight gain.
81206|NCT03551054|Behavioral|Health Education|
135875|NCT03126916|Biological|Sargramostim|Given SC
81207|NCT03551028|Device|HPV self collection|The proposed community based participatory study aims to determine whether offering self-collection for HPV testing through the mobile mammography unit is an acceptable and feasible method to increase access to cervical cancer screening for under-screened women in Southwest Virginia.
81208|NCT03551015|Other|Change in the timing of components of usual care|Bringing forward outpatient review, and cardiac rehabilitation after CABG by 3 and 4 weeks respectively.
81209|NCT03550989|Other|Non-Exposure Event|Non-Exposure event of 4h duration for the individual participants, where no use of any tobacco or nicotine-containing product is allowed, designed to establish background measurements in the absence of exposure to IQOS.
81210|NCT03550989|Other|Exposure Event|Exposure Event designed to measure urinary BoExp to selected HPHCs representative of ETS in all participant groups, with up to 5h of exposure to IQOS tobacco environmental aerosol for non-smokers, cigarette smokers (not using any tobacco or nicotine-containing product, including cigarettes), and IQOS passive users (not using IQOS). Additionally, this event includes up to 8h of exposure for IQOS active users (using IQOS).
81211|NCT03550976|Behavioral|The low-GI diet and muscle training|During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
81212|NCT03550963|Other|rice-richen meal|Participants in group one will be provided with rice-richen meal. All participants will be required to test and record blood glucose.
81213|NCT03550963|Other|wheaten-richen meal|Participants in group two will be provided with wheaten-richen meal.All participants will be required to test and record blood glucose.
81214|NCT03550950|Drug|JNJ-64232025 IV|JNJ-64232025 will be administered as IV infusion.
81215|NCT03550950|Drug|JNJ-64232025 SC|JNJ-64232025 will be administered as SC injection.
81216|NCT03550950|Drug|Placebo|Matching placebo will be administered as IV infusion or SC injection.
81217|NCT03550924|Procedure|low flow passive oxygenation|low flow passive oxygenation during laryngoscopy with 10l/min oxygen via standard nasal prongs
81218|NCT03550924|Procedure|high flow passive oxygenation|high flow passive oxygenation during laryngoscopy with 120l/min oxygen via THRIVE system
81219|NCT03550911|Other|Biological Collection From Samples From The Gut Microbiota|The aim of this study is just to constitute a biological collection from samples from the Gut microbiota in patients having a bone or joint infection treated by a suppressive subcutaneous antibiotherapy with betalactamine. No analysis will be done for instance.
81220|NCT03550898|Diagnostic Test|Dynamic Ultrasonography|Dynamic Ultrasonography was performed with patients in supine position, with a suprapubic sagittal position transductor, during filling phase of urodynamics.
81221|NCT03550885|Other|High taurine and saturated fat diet|This is a 3-week (21 day) isocaloric Western-type diet with all meals, snacks, beverages and condiments provided.
81222|NCT03550885|Other|Low in taurine and saturated fat diet|This is a 3-week (21 day) isocaloric largely plant-based diet with all meals, snacks, beverages and condiments provided.
81223|NCT03550872|Behavioral|Physical Training|Participants will perform physical training three times a week on a stationary bicycle. The exercise intensity will be controlled between 14 and 16 by the Borg Scale for 40 minutes
81224|NCT03550859|Drug|Telmisartan/Rosuvastatin 40/10mg|Telmisartan/Rosuvastatin 40/10mg qd for 48 weeks
81225|NCT03550859|Drug|Telmisartan 40mg|Telmisartan 40mg qd for 48 weeks
81226|NCT03550833|Behavioral|Questionnaire|Questionnaire
81227|NCT03550833|Biological|blood sample|7 ml whole blood for Peripheral blood
81228|NCT03550794|Drug|Thiamine Hydrochloride|Thiamine hydrochloride is a water soluble vitamin (vitamin B1). 200mg of thiamine hydrochloride in 50ml 0.9%NACL will be administered twice daily for 3 days.
81229|NCT03550794|Drug|Placebo|50ml of 0.9% NACL will serve as the placebo
81230|NCT03550781|Drug|Prednisone, cyclophosphamide|Prednisone 0.5mg/(kg•d) and/or cyclophosphamide 2mg/kg
81231|NCT03550768|Other|MDP|evaluate the anatomy of each major duodenal papilla before selective cannulation during ERCP
81232|NCT03550755|Biological|V3-Cervix|Oral tableted preparation containing hydrolyzed tumor antigens derived from peripheral blood and tumor tissue
81233|NCT03550742|Other|Fuco-N-Tetraose|Daily bolus of Fuco-N-Tetraose
81234|NCT03550729|Behavioral|Endurance training|Endurance training 3 times per week during 3 months using interval training above 70% of load peak reached in the incremental exercise test. The duration of the sessions will be adapted individually to each patient (approximately 60 minutes).
81235|NCT03550716|Procedure|mTESE|mTESE is performed according to the initial description by Schlegel (4). General anesthesia is used. Midline incision of the scrotum is made and carried down to the level of the tunica vaginalis, which is opened to deliver the testis. Equatorial incision is made and the testis bivalved. The operating microscope is used to identify plump-appearing seminiferous tubules, and biopsies are taken from these areas. These samples are examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24G angiocatheter. The procedure is stopped if spermatozoa are found. If no plump tubules are found, random biopsies targeting every area of the testis are taken. If necessary the procedure is carried out on the contralateral testis. Hemostasis is obtained with careful bipolar cautery, and the tunica albuginea and the tunica vaginalis are closed with a running 4-0 Vicryl. Standard scrotal closure is performed and gentle pressure dressing is applied.
81236|NCT03550716|Procedure|TESA|In general anesthesia an 18 gauge needle is introduced into each testis, and negative pressure applied with a 10 ml syringe. Multiple passes throughout the entire testis, numbering 50-100 passes, are made through a single percutaneous/tunical entry and continued until tissue is visible in the hub of the needle. This is removed by brisk extraction of the needle and pressure held to tamponade bleeding. The aspirated tissue is examined by an embryologist in the operating room after initial gross dispersion by passing the tissue through a 24 gauge angiocatheter.
81237|NCT03550703|Biological|V3-Myoma|Once daily oral pill of V3-Myoma
81238|NCT03550690|Device|Large Volume Paracentesis|Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards
81239|NCT03550690|Device|Rocket Indwelling Pleural Catheter|A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
135923|NCT03126591|Drug|Pembrolizumab|Administered IV
81240|NCT03550677|Procedure|general anesthesia|The patient will be monitored with ECG, pulse oximetry and noninvasive blood pressure. Anesthesia will be induced using 2-2.5 mg/kg propofol, 1-2 mcg/kg fentanyl, 10-20 mg rocuronium and proper size Laryngeal mask airway will be placed securely the airway.
81241|NCT03550677|Procedure|ankle block|ankle nerve block will be performed in group ankle block patients using a mixture of 5 ml of 2% lidocaine and 10 ml of 0.5% bupivacaine and same amount placebo (saline) in groups placebo under the guidance of peripheral nerve stimulator the anesthesia will be discontinued and LMA will be removed. The patients will be transferred from postoperative care unit to the ward after they are eligible for discharge according to modified Aldrete scoring system.
81242|NCT03550664|Device|Monitoring of neuromuscular transmission|Monitoring of neuromuscular transmission will be done by TOFScan (IdMed, Marseille, France). This device is CE marked, and is used routinely in daily clinical practice. Prior to induction of anesthesia, the TOFScan is placed on a patient's hand and the two stimulation electrodes (ECG electrodes) are placed at the level of the ulnar nerve at the wrist. After induction of anesthesia and before administration of a curare, the TOFScan is calibrated according to the manufacturer's instructions. The TOFScan is placed in automatic mode, it will then automatically adapt its mode of stimulation to the depth of the curarization. The TOFScan measurements will be recorded on a PC connected to the TOFScan.
81243|NCT03550651|Other|Licorice|Licorice, since years is known for its anti-inflammatory, antimicrobial, antiviral, antiprotozoal, antioxidative, hepatoprotective, cardioprotective, immunomodulatory and antitumour activity. Licorice can be beneficial for oral health. Glycyrrhizin, the sweet component of licorice root has antiplaque property. Pterocarpenes isolated from G. uralensis root extract exerts an antibacterial activity against Streptococcus mutans.
81244|NCT03550651|Other|Hypertonic salt solution|The antiseptic and bactericidal qualities of salt help in removing plaque which is a cause of gingivitis and caries. Warming water with a pinch of table salt can reduce or even be an alternative to anti-inflammatory drugs intra-orally. Its high osmolality reduces inflammation and can be microbicidal. Moreover, efficacy of luke warm hypertonic salt solution has shown antimicrobial, anti-inflammatory and immunomodulatory properties.
81245|NCT03550651|Other|Essential oil|Essential oils have a wide application in folk medicine, food flavoring and preservation as well as in fragrance industries. The antimicrobial properties of essential oils have been known for many centuries. In recent years, a large number of essential oils and their constituents have been investigated for their antimicrobial properties against some bacteria and fungi. Essential oils have the potential to be used as therapeutic agents for chronic gingivitis and periodontitis conditions that have both bacterial and inflammatory components.
81246|NCT03550651|Other|Chlorhexidine Gluconate|Chlorhexidine is a symmetrical bisbiguanide synthetic antiseptic. It is available in three forms, digluconate, acetate and hydrochloride salts. Which have broad spectrum antimicrobial activity; it is effective against both Gram-positive and Gram-negative bacteria including aerobes and anaerobes, yeasts, fungi and lipid enveloped viruses. Chlorhexidine is considered to be the most effective plaque inhibitor against which other antiplaque agents are measured.
81247|NCT03550651|Other|Distilled water|Distilled water is commonly placebo in various research projects and it is also useful in as placebo treatment.
81248|NCT03550638|Device|Coil system(Ton-bridgeMT)|1. It consists of a push system with a development mark, and a Detachable platinum-tungsten alloy coil which is connected to the push system. It can be used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
81249|NCT03550638|Device|Axium Detachable Coil(Medtronic)|2. It is made up of a push system with a development mark, a platinum-tungsten alloy embolized coil connected to the push system and a manual release device for releasing the coil from the distal end of the push system. It is mainly used for embolization of intracranial aneurysms, and other neurovascular abnormalities, such as arteriovenous malformation and arteriovenous fistula.
81250|NCT03550625|Diagnostic Test|Computer program|No study specific intervention. Still images of polyps are collected. Histopathological reports of the resected polyps will be evaluated in order to create a computer program.
81251|NCT03550612|Diagnostic Test|magnetic resonant imaging,cranial ultrasound.|Magnetic resonant image performed at term gestation neonate suffer of hypoxic ischemic encephalopathy and its results will be analysed in details and classified according to global score of magnetic resonant image injury.Cranial ultrasound results will be analysed regards (periventricular - interventricular haemorrhage-Ventricular size-basal ganglia, thalamus and cerebellum affection) and Doppler (peak systolic flow velocity-end diastolic peak flow velocity-mean velocity and resistance index).Cerebral bleeding will be diagnosed be cranial ultrasound and confirmed be standard magnetic resonant image in term equivalent age.
81252|NCT03550612|Diagnostic Test|Amplitude integrated electroencephalogram|"Amplitude integrated electroencephalogram before and during cooling will be assessed and classified according to Hellstrom Westas et al 2006 and it will be compared with the results of cranial ultrasound and magnetic resonant imaging.~Neurodevelopment study at 12 and 14 month age using Bayley ɪɪɪ score will be compared with the results of cranial ultrasound,magnetic resonant imaging and Amplitude integrated electroencephalogram."
81253|NCT03550599|Other|Patients accessing to Radiotherapy Unit|No intervention; information about patient and disease characteristics will be recorded as well as information about pain and analgesic treatment
81254|NCT03550586|Other|Questionaires|Parturients will be assed for postpartum depression using the Edinburgh Postnatal Depression Scale (EPDS)translated into Hebrew . They will also be assed for PTSD using the validated PTSD questionnaire . Additionally in order to examine long term risk for chronic pain and backache parturients will be assed for persistent pain using the validated Brief Pain Inventory questionnaire ,and the validated Oswestry low back pain questionnaire .
81255|NCT03550573|Device|CardioInsight™ Noninvasive 3D Mapping System|"The CardioInsight system uses a proprietary, single-use, disposable multi-electrode vest to capture electrical signals from the body surface. The CardioInsight software provides various cardiac signal analyses and displays interactive 3-D color maps including activation, voltage, composite and phase maps. The vest wearing is coupled with a CT scan.~This exam will be performed only at baseline visit."
81256|NCT03550560|Procedure|EUS-Guided drainage|Drainage of refractory malignant ascites by endoscopic ultrasound-guided (EUS-Guided) implantation of plastic prostheses.
81438|NCT03548987|Drug|Placebo|Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
136093|NCT03125395|Drug|Ivacaftor|LUM/IVA will be administered q12h
81257|NCT03550547|Other|Educational workshops|1 workshop : Knowledge of the pathology ; 2a workshop: Educational physical activity; 2b workshop : Educational physical activity; 4 workshop : Dietary; 5 workshop : Management of pain, fatigue and the medical treatments; 6 workshop : Articular hygiene and ergonomics; 7 workshop : Technical assistance, an adaptation of the living condition
81258|NCT03550547|Other|Spa Therapy|Approved Spa therapy of knee osteoarthritis patients
81259|NCT03550534|Drug|Calcium Carbonate|Calcium carbonate was obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
81260|NCT03550534|Drug|Placebo oral capsule|Placebo oral capsule was also obtained from Pharmacy Department, Faculty of Medicine, University of Indonesia. Subjects were randomized to receive calcium carbonate or placebo for 12 weeks.
81261|NCT03550521|Behavioral|Mindfulness|Participants will be instructed to focus on the sensations of breathing. Subsequently, whenever their minds wander to distressing thoughts or emotions, they will be instructed to acknowledge those thoughts or emotions, and then bring their attention back to the sensations of breathing.
81262|NCT03550508|Biological|Anti-RANKL Monoclonal Antibody|JMT103 is recombinant fully human anti-RANKL monoclonal antibody. JMT103 is provided as the injection,120 mg/vial. JMT103 was administered subcutaneously in the upper arm, upper thigh, or abdomen.
81263|NCT03550495|Behavioral|psychiatry involvement|See arm description.
81264|NCT03550482|Dietary Supplement|ONCOXIN®|Adjuvant chemotherapy regimen (XELOX or paclitaxel+carboplatin) + Oncoxin 25 ml twice daily for 20 days. In case of nausea/vomiting after ONCX use patients were advised to dilute it in water, juice or milk. Patients with BMI <20 and serum albumin levels <30 g/l received nutritional support.
81265|NCT03550469|Device|Computer-assisted Oxygen Weaning|Oxygen therapy weaning will be guided by a model-based computer algorithm. The computer will detect patients' oxygen saturation and made recommendations for oxygen weaning. A clinical at the bedside will make the adjustments in oxygen therapy if appropriate.
81266|NCT03550456|Other|ECC|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
81267|NCT03550456|Other|ECC with CLE|Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.
81268|NCT03550456|Other|Speech therapy|Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
81269|NCT03550443|Drug|Bardoxolone methyl|Bardoxolone methyl 5 mg capsules
81270|NCT03550443|Drug|Placebo|Capsules containing an inert placebo
81271|NCT03550430|Behavioral|alpha/delta neurofeedback|neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.
81272|NCT03550430|Behavioral|beta/theta neurofeedback|neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.
81273|NCT03550430|Other|Diary completion|completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
81274|NCT03550404|Behavioral|Seasons of Care App|A web-based mobile application (app) called the Seasons of Care Elder Navigation Guide will assist elders, their families/caregivers, healthcare providers, outreach workers, and other community members in navigating healthcare and insurance systems. The app has the added advantage of being easy to update to respond to future changes in health care and insurance, and sustainable because it is not dependent on intensive training, developing, and retaining of individuals in professional navigation positions.
81275|NCT03550391|Drug|Memantine|20 mg (10 mg divided twice daily). Dose will be escalated by 5 mg per week. Memantine should start at 5 mg, and then increased in 5 mg increments at the following schedule, depending on the patient's response and tolerance:
81276|NCT03550391|Radiation|Hippocampal-avoidant (HA-WBRT) Radiotherapy|30Gy in 10 fractions
81277|NCT03550391|Procedure|Stereotactic Radiosurgery (SRS)|18-20 or 22 Gy in single fraction
81278|NCT03550378|Drug|MEDI0382|MEDI0382 administered subcutaneously
81279|NCT03550378|Drug|Placebo|Placebo administered subcutaneously
81280|NCT03550365|Other|Rye bran bread intervention|4 week dietary intervention rich in rye bran bread
81281|NCT03550365|Other|Rye bread intervention|4 week dietary intervention rich in rye bread
81282|NCT03550365|Other|Wheat bread diet|4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
81283|NCT03550352|Drug|Low CBD dose TN-CT11LM oral capsules(THC2.5 mg/CBD2.5 mg)|Participants will start by taking 1 capsule twice daily for 1 week (5 mg THC/5 mg CBD) and increase the number of capsules as tolerated to a maximum of 10 capsules taken throughout the day by weeks 5-12 (25 mg THC/25 mg CBD total per day).
81284|NCT03550352|Drug|High CBD dose TN-TC19LM oral capsules (THC 5 mg / CBD 45 mg)|Participants will start by taking 1 capsule once daily for 1 week (5 mg THC/45 mg CBD) and increase the number of capsules as tolerated to a maximum of 5 capsules taken throughout the day by weeks 5-12(25 mg THC/225 mg CBD total).
81285|NCT03550339|Procedure|SURG|bariatric surgery according to Finnish Current Care Guidelines for Obesity in adults
81286|NCT03550339|Behavioral|DIET|dietary weight loss program according to Finnish Current Care Guidelines for Obesity in adults
81287|NCT03550339|Behavioral|HAES|treatment is based on the previously published procedure (e.g. Bacon et al. 2002) and Health At Every Size trademark, consisting of body acceptance, eating behaviour, physical activity, nutrition, and social support
81288|NCT03550326|Procedure|airway management|patients will be intubated or will be placed an airway device
81289|NCT03550313|Biological|Multivalent|Pneumococcal conjugate vaccine
81290|NCT03550313|Biological|Prevnar 13|Pneumococcal conjugate vaccine
81291|NCT03550287|Dietary Supplement|Experimental product|10 g/day
81292|NCT03550287|Dietary Supplement|Placebo product|10 g/day
81317|NCT03550014|Procedure|Low Back+Hip|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
81318|NCT03550001|Procedure|Injection CNP before NAT|Injection carbon nanoparticle via rectal mucosa before neoadjuvant therapy
81293|NCT03550274|Device|App-based exercise rehabilitation|"App-based exercise rehabilitation available on any mobile device and/or tablet using Android or iOS operating systems. The app Injurymap© is hosting the exercise program. The app requires user-registrations and a monthly paid subscription fee to access the exercise program. The participants in this study will not be charged for using the app.~The exercise program consists of three phases with increasing difficulty. Each phase consists of several categories of exercise types. The categories are 1) mobility, 2) stability/balance, 3) strength and 4) stretching. Within each phase, there can be more than one exercise for each category. This makes it possible to adjust the difficulty of the exercises depending on user-feedback."
81294|NCT03550248|Behavioral|Healthy Together|The Healthy Together (HT) program is designed to reduce overweight and obesity among children and youth in priority populations such as Indigenous, immigrant and refugee, and low income families.The HT program consists of 30 sessions, each of which includes cooking and eating together, physical activity and a learning activity covering topics that promote healthy weights. The HT program is delivered by trained facilitators who are provided with a program manual and resources. Trained facilitators in participating community organizations offer the HT program by integrating it within core programming.
81295|NCT03550209|Drug|LCPUFA Oil Supplement|EPA + DHA + GLA + OA oil supplement twice per day for 90 days at a dose of 50, 100, or 150mg, based on weight of child.
81296|NCT03550209|Dietary Supplement|Canola Oil Placebo|90 days, equal volume
81297|NCT03550196|Other|Provisional stenting with rePOT technique|"All revascularizations have to be performed with complete rePOT technique: initial POT + side branch inflation + final POT. Compliant or semi compliant balloon have to be preferred to inflations. The POT balloon positioning have to be precise as obtain the loose of the parallelism just at the carina cut plan. The rest of the medication or procedure characteristics stay at the discretion of the operator.~The follow-up will be clinic every years."
81298|NCT03550183|Biological|mesenchymal stem cells|Patients with PD in the therapy group were given UC-MSCs by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1 month, 3 months, 6 months and 12 months were evaluated respectively the curative effect.
81299|NCT03550170|Behavioral|Teleconference|This intervention arm will be a 7-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-7 participants) to maximize participants' opportunities for interaction. A program manual divided into 7 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
81300|NCT03550170|Behavioral|Internet|The internet course is similar to the teleconference format. It will occur in a 7-week period and be group based; i.e., 8-10 participants will begin the intervention at the same time and interact with each other during the 7-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions
81301|NCT03550170|Behavioral|1-to-1, in-person|Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person course will vary over the 7-week period. The OT will cover all 7 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session
81302|NCT03550144|Behavioral|Awe Walk|To examine the effect of weekly awe walks in cognitively healthy older adults.
81303|NCT03550144|Behavioral|Control Walk|To examine the effect of weekly walks in cognitively healthy older adults.
81304|NCT03550131|Behavioral|Innovations in Dementia Empowerment and Action (IDEA)|The IDEA intervention has the same exposure to treatment as the RDAD intervention. The behavioral component of the treatment manual is adapted to incorporate 3 risk factors that are empirically known to affect midlife and older LGBT populations.These include: 1) identity management; 2) stigma-related adverse/traumatic life events; and 3) lack of social support. All other aspects of the treatment are preserved.
81305|NCT03550131|Behavioral|Reducing Disabilities in Alzheimer's Disease (RDAD)|The RDAD intervention includes behavioral management training for caregiver and activities and exercise training for caregiver and care receiver.
81306|NCT03550118|Device|Adjustable socket|The adjustable prosthetic socket will be used to test the influence of socket size adjustments during sitting, standing, and walking activities to determine if these strategies can be used to improve socket fit and reduce fluctuations in limb volume.
81307|NCT03550105|Device|Gentle Jogger|Gentle Jogger is a passive simulated jogging device to be used 3 times per day for at least 30 mins for 7 days in this study
81308|NCT03550092|Behavioral|Abstract Semantic Association Network Training (AbSANT)|In each session, the participant will be asked to categorize words, choose/discuss semantic features for each word that accurately describe the word, and generate as many words as possible within a category.
81309|NCT03550079|Procedure|fixation|treated with different fixation method
81310|NCT03550066|Behavioral|Values affirmation|A health message with a prompt asking participants to reflect on important personal values
81311|NCT03550066|Behavioral|No affirmation|A health message alone
81312|NCT03550053|Device|3D mandibular plate|Patients will be randomly assigned to either have the mandibular plate bent before their surgery, using a 3D model of their mandible or have the mandibular plate bent during their surgery, which is standard of care.
81313|NCT03550040|Procedure|Radical prostatectomy|Surgical removal of the prostate
81314|NCT03550027|Device|PleurX|Positioning of drainage PleurX
81315|NCT03550027|Device|Pleurocath|Positioning of drainage Pleurocath
81316|NCT03550014|Procedure|Low Back Only|The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will only be directed at the lower back. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
81536|NCT03548155|Drug|placebo|The placebo were matched to Berberine in shape, smell and colour and capsules were sealed in identical bottles
81319|NCT03549988|Other|Fecal Calprotectin (FC) measurements with IBDocTM|"Each IBDocTM kit measure one fecal calprotectin value. The IBDoc® is an in-vitro diagnostic immunoassay analyzed by a downloadable smartphone application (CalApp®). A patient is able to process their stool at home using a test cassette.~The IBDocTM test results are displayed in a light signal system as three titre categories; normal <100 µg/g (green), 100-300 µg/g (yellow), >300 µg/g (high). Patients' results will be sent directly to the central research coordinator through the IBDoc® Web Portal. If the FC is >250 µg/g a second FC will be performed within 2 weeks. If this result is <250 µg/g patients will continue to monitor their FC every 2 months. If the second result is >250 µg/g, the attending physician will review the patient either by telephone or in the office within 7 days."
81320|NCT03549975|Drug|Botulinum Toxin Type A 100 unit/Vial (Product)|Botulinum toxin type A injection followed by functional electrical stimulation
81321|NCT03549962|Procedure|TKA|Total Knee Arthroplasty
81322|NCT03549936|Other|Low lactose or regular formula|"If infant is not breast feeding and parents plan to formula feed, following written informed consent, infant is randomized to receive low lactose formula or regular formula which arrives from milk lab blinded and labeled as formula A or formula B."
81323|NCT03549923|Device|Simultaneous CRRT|The patients in the simultaneous CRRT group will receive CRRT within 24 hours after the initiation of ECMO support.
81324|NCT03549923|Device|Conventional-indication CRRT|The patients in the conventional-indication group will not receive CRRT until the patient demonstrates AKI and fulfills any one of the criteria of the conventional CRRT indication.
81325|NCT03549923|Drug|Esmolol|The patients in esmolol group will receive a continuous esmolol infusion in addition to the standard care.
81326|NCT03549923|Drug|Standard care|The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
81327|NCT03549910|Procedure|APRVplus protocol|Physiology-driven APRVplus protocol
81328|NCT03549910|Procedure|Low tidal volume ventilation|Low tidal volume lung protective ventilation
81329|NCT03549897|Drug|Placebo|Placebo Product
81330|NCT03549897|Drug|90 mcg Reference Product|90 mcg Reference Product - PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]
81331|NCT03549897|Drug|180 mcg Reference Product|180 mcg Reference Product- PROAIR HFA ALBUTEROL SULFATE [TEVA RESPIRATORY, LLC]
81332|NCT03549897|Drug|90 mcg Test Product|90 mcg Test Product - ALBUTEROL SULFATE HFA [AMNEAL IRELAND LIMITED]
81333|NCT03549884|Procedure|Delayed cord clamping|Cord clamping will be performed after 60 seconds of life in infants delivered by cesarean section
81334|NCT03549884|Procedure|Early cord clamping|Cord clamping will be performed within 10 seconds of life in infants delivered by cesarean section
81335|NCT03549871|Drug|Fitusiran|Pharmaceutical form: solution for injection Route of administration: subcutaneous
81336|NCT03549858|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
81337|NCT03549845|Behavioral|Cardiovascular Health Awareness Program|Cardiovascular disease prevention and health promotion
81338|NCT03549832|Drug|Sofosbuvir|Sofosbuvir 400 mg oral pills
81339|NCT03549832|Drug|Simeprevir|Simeprevir 150 mg oral pills
81340|NCT03549832|Drug|Daclatasvir|Daclatasvir 60 mg oral pills
81341|NCT03549832|Drug|Ribavirin|Ribavirin 200 mg oral pills
81342|NCT03549832|Drug|Ombitasvir/paritaprevir/ritonavir|Ombitasvir/paritaprevir/ritonavir oral pills
81343|NCT03549819|Drug|Cannabidiol (CBD) Oil Capsules|"200 mg CBD- titrated as tolerated up to a maximum 2 capsules twice daily (200 mg- 800 mg total dose)~Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)"
81344|NCT03549819|Drug|Sunflower Lecithin Oil in Capsule|Start at 1 capsule/day (at bedtime) for one week and be titrated to 1 capsule twice/daily for one week. At the end of Week 2, dose may be titrated to 1 capsule in the morning and 2 capsules at bedtime; then at the end of Week 4, dose may be titrated to 2 capsules twice daily (the maximum of 800 mg/day total dose)
81345|NCT03549806|Diagnostic Test|No Intervention. Test is computer algorithm.|Diagnostic algorithms (test) will be run on already acquired clinical data. No study intervention in operator-prescribed clinical ablation. Predictive accuracy of test for study outcome will then be determined in follow-up
81346|NCT03549793|Behavioral|Dance Therapy|the intervention is aimed to ameliorate, through dancing, crucial motor symptoms in PD patients, as walking, balance, postural changes and arm swing
81347|NCT03549793|Behavioral|exercises without dance|the intervention consists of exercises aimed at training the walking, the balance, the postural changes and the arm swing
81348|NCT03549780|Device|Stomal Occlusion Device|Insertion of a novel stomal occlusion device into patients with Brooke Ileostomy and assess feasibility and patient satisfaction
81349|NCT03549767|Device|Springfusor|Springfusor for administration of magnesium sulphate
81350|NCT03549767|Procedure|Standard of care|Pritchard regimen. Magnesium sulphate is administered using hospital practice
81351|NCT03549741|Drug|Clomiphene Citrate 50mg|oral tablets
81352|NCT03549741|Drug|Cabergoline Oral Tablet|oral tablets
81353|NCT03549741|Drug|Placebo Oral Tablet|oral tablets
81354|NCT03549728|Drug|Granulocyte Colony-Stimulating Factor|In group A, at the day of oocyte retrieval, after oocytes collection, 30 mU (300 mcg/0.5 ml) of G-CSF (NeupogenTM, Filgastrim, Amgen Inc., Thousand Oaks, CA, USA) was administered by slow transcervical intrauterine infusion with IUI catheter (AINSEGREY, RIMOS, Italy). In controls, normal saline was used for intrauterine infusion instead of G-CSF.
81355|NCT03549728|Procedure|Intrauterine infusion of normal saline|In group B (controls), normal saline will be used for intrauterine infusion instead of granulocyte colony-stimulating factor on the day of oocyte retrieval.
81356|NCT03549715|Drug|Durvalumab|1500 mg IV D1 every 28 days (2 doses for each patient)
81357|NCT03549715|Drug|Tremelimumab|75 mg IV D1 every 28 days ((2 doses for each patient)
81358|NCT03549715|Drug|MVAC Protocol|"Methotrexate 30 mg/m2 IV D1~Vinblastine 3 mg/m2 IV D1~Adriamycin (doxorubicin) 30 mg/m2 IV D1~Cisplatin 70 mg/m2 IV D1"
81359|NCT03549702|Drug|Povidone iodine 1% solution|irrigation of subcutaneous tissue with Povidone-Iodine prior to skin closure
81360|NCT03549689|Drug|Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)|Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
81361|NCT03549689|Drug|Current tenofovir alafenamide (TAF)-containing ART regimen|Continuation of current TAF-containing ART for 96 weeks.
81362|NCT03549676|Biological|Fecal Microbiota Transplantation|For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
81363|NCT03549663|Drug|Tacrolimus|Tacrolimus capsules: 0.5mg/pill, 50 pills/box, AstellasPharma (China) Co., Ltd.; Tacrolimus capsules: 1mg/pill, 50 pills/box, Hangzhou ZhongmeiHuadong Pharmacy Co., Ltd. Start to administer on the randomized grouping day (D0) with an initial dose by weight: initial dose of 0.05-0.075mg/kg/d (bid) following a strict administration interval of 12 hours or fasting or 2 hours after meal. Adjust TAC dose according to 24-hour urine protein, plasma concentration and eGFR changes. It is recommended that plasma trough concentration should be remained at 5-8ng/ml and TAC dose during the whole therapy stage should not be lower than 0.5mg/d. Drugs should be stopped if the 6-month therapy is ineffective. After 6-month therapy, for those whose urine protein achieved complete remission (CR) or partial remission (PR), TAC dose should be reduced gradually with a total therapy duration of 48 weeks.
81364|NCT03549663|Drug|Prednisone|Glucocorticoid (prednisone): 5mg/pill, 100 pills/bottle: Shanghai Sine Pharmaceutical Factory Co., Ltd. The initial dose of prednisone should be 0.5mg/kg/d orally (maximum dose of 40mg/d) and administration should be continued for 8-12 weeks; then reduced by the monthly decreased amount of 0.1mg/kg/d till to 0.2mg/kg/d (5-10mg) to maintain. Prednisone should be stopped after administration for the entire 48 weeks.
81365|NCT03549650|Drug|Pentosan Polysulfate Na 100Mg Cap|"Participants will be randomly assigned to receive Pentosan Polysulfate Na 100Mg Cap TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
81366|NCT03549650|Drug|Placebo oral capsule|"Participants will be randomly assigned to receive Placebo oral capsule TID for 6 weeks.~For blinded distribution, each bottle of medications will be labeled with a random number for identification.~The study participants will be monitored every 2 weeks with phone calls from the study team to evaluate their condition and decide if the medication is tolerated and whether it should be continued or stopped."
81367|NCT03549637|Diagnostic Test|Psychiatric population|Genetic and biological analysis of patients
81369|NCT03549611|Drug|Multimodal Oral Drug Regimen|Regimen of 4 pharmacologic agents that provides analgesia by acting on 4 different physiologic pain pathways
81370|NCT03549611|Drug|Acetaminophen|Acetaminophen 975mg
81371|NCT03549598|Drug|68Ga-DOTATATE PET/CT|5.4 mCi of 68Ga-DOTATATE will be administered by intravenous route.
81372|NCT03549598|Drug|18FDG PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 18FDG will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
81373|NCT03549598|Drug|13NH3 PET/CT scan|This scan will be performed as part of the planned clinical care for the patient. Dose of 13NH3 will be administered intravenously in accordance with the institutional policy and accepted norms. CT attenuation scan will also be performed as part of this examination per institutional protocol.
81374|NCT03549585|Other|Criteria for Screening and Triaging to Appropriate aLternative care|CriSTAL Tool (Criteria for Screening and Treatment of Appropriate Long-Term Care) is a multidimensional geriatric tool that lists 18 elements of the literature, under construction and validation by an Australian retrospective study. This tool is a practical questionnaire and easy to use in current care, with items adapted to the geriatric dimension. The investigators chose to target hospitalized geriatric patients through emergencies.
81375|NCT03549572|Behavioral|Coma Recovery Scale-Revised|Patients will be assessed using the CRS-R and the CRSR-FAST. The CRS-R is a standardized neurobehavioral rating scale that consists of 23 items organized into six subscales that address arousal, auditory, visual, motor, oromotor/verbal, and communication systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors. Reliability and validity have been demonstrated in multiple studies. The CRSR-FAST consists of 10 items organized into 4 subscales that address arousal, visual, motor and verbal/oromotor systems. Each subscale is organized hierarchically, with lower items representing reflexive behaviors and higher items indicative of cognitively-mediated behaviors.
81376|NCT03549559|Drug|11C-Martinostat|Imaging probe for evaluating the activity of histone deacetylase in the heart
81377|NCT03549559|Device|PET-MRI|Siemens PET-MR Scanner (Biograph MMR)
81378|NCT03549546|Biological|Blood samples|"Blood samples will be collected in patients undergoing lung cancer surgery:~before lung cancer surgery,~the next day lung cancer surgery,~3 days after lung cancer surgery. They will be treated in flow cytometry."
81379|NCT03549533|Other|samples of sperm|As in the usual practice during artificial insemination a samples of sperm will be collected and analyzed.
81380|NCT03549520|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
81381|NCT03549507|Drug|Sulfur hexafluoride lipid-type A microspheres|Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
81405|NCT03549247|Behavioral|quality of life in healthy,gingivitis,periodontitis groups|a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
81406|NCT03549234|Drug|Erector Spinae (single injection)|Ropivacaine 0.5% (with epinephrine 1:200,000-400,000) will be administered via the needle into the target plane.
81382|NCT03549494|Dietary Supplement|Ocoxin-Viusid®|Ocoxin-Viusid group (Experimental). Oral solution of Ocoxin-Viusid (vials of 30 ml), at a rate of 60 ml daily (1 vial every 12 hours), administrado preferably administered after breakfast and dinner. The product will dilute in water, milk or juice. The treatment will have a period of 19 weeks, starting 2 weeks before the onco-specific treatment with FOLFOX chemotherapy and will end 3 weeks after the end of the sixth cycle of chemotherapy. QT FOLFOX will be prescribed intravenously every 14 days for 6 cycles as follows: Oxaliplatin (85 mg x m2) on day 1 Folinic acid (200 mg x m2) on day 1 and 2 5 Fluoracil (400 mg x m2, bolus) on day 1 and 2 5 Fluoracil (600 mg x m2, continuous infusion) on day 1 and 2
81383|NCT03549468|Device|Low level tragus stimulation|All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
81384|NCT03549455|Behavioral|Exposure Therapy and Self Distancing|Weeks 1 and 2 will be introductory sessions (background, rationale, motivational enhancement); Weeks 3 & 4 will have Exposure therapy with Self-Distancing; Weeks 5 & 6 will have Exposure therapy only; Weeks 7 & 8 will have Exposure therapy with Self-Distancing;
81385|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
81386|NCT03549442|Combination Product|CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive CART-BCMA + huCART19. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
81387|NCT03549442|Combination Product|Single-dose infusion of CART BCMA or CART BCMA + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Cohort 1 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA alone; Cohort 2 refers to the group of subjects assigned to receive single dose infusions of CART-BCMA + huCART19. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
81388|NCT03549442|Combination Product|BCMA CART + huCART19|The target dose for CART-BCMA and huCART19 will be 5x108 CAR-expressing cell for each product. Split dose infusions will consist of a 10% dose (of one or both products) on the first infusion day, 30% dose (of one or both products) on the second infusion day, or 60% dose (of one or both products) on the third infusion day. Infusion days may be spread over 7 calendar days due to scheduling constraints or to allow observation of suspected early cytokine release syndrome or other toxicity. Infusions will begin 3 days (+/- 1 day) after completion of lymphodepleting chemotherapy with cyclophosphamide + fludarabine.
81389|NCT03549429|Device|Medical tapes: TegadermTM and EyeGard®|TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.
81390|NCT03549403|Behavioral|Patient-centered telephone education|The intervention will be carried out in accordance with the guidelines and the contents of the patient-centered telephone education intervention in the same way with every patient. The education call duration is approximately 15 to 30 minutes.
81391|NCT03549390|Behavioral|Physical activity|Light-moderate intensity physical activities
81392|NCT03549377|Behavioral|Deception|Participants will be deceived during delayed gratification task.
81393|NCT03549364|Behavioral|Endurance Race|1 CT and lab tests, 2 CT and lab tests within 24h of a race, 3 follow up investigations 1-2 weeks after the race with CT and lab tests
81394|NCT03549351|Other|Measurable residual disease measured by flow cytometry|Measurable residual disease measured by flow cytometry
81395|NCT03549338|Drug|Sym004|Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
81396|NCT03549338|Drug|Futuximab|Futuximab is one of two mAb components that constitute Sym004.
81397|NCT03549338|Drug|Modotuximab|Modotuximab is one of two mAb components that constitute Sym004.
81398|NCT03549325|Biological|Neisseria lactamica|Colonisation by bacteria is an immunising event; we proved this in humans by inoculating university students intranasally with the harmless commensal N. lactamica and we observed both specific systemic and mucosal antibody responses by 4 weeks. Experimental challenge with defined bacteria could tease out the Th17-mediated response mechanisms, which include waning of immunity over time, the induction of an incorrectly polarised T cell response, lack of cross-reactivity between strains or active immune evasion mechanisms employed by bacteria to subvert host immune effector mechanisms.
81399|NCT03549312|Drug|Genvoya|"Switching to Genvoya for 12 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone as opioid substitution therapy.~Plasma HIV-1 RNA < 50 copies/mL at weeks 12 and 48."
81400|NCT03549312|Drug|Epclusa|HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.
81401|NCT03549299|Biological|LSC2|Topical application of IMP on target eye
81402|NCT03549286|Other|Questionnaire passation|Questionnaires assessing general knowledge about Down's syndrome screening, specific knowledge of NIPT for Down's syndrome and patient's satisfaction about provided information.
81403|NCT03549273|Dietary Supplement|Glizigen® + Ocoxin-Viusid®|"Glizigen® spray, topical use, 2 times a day for 6 months with an interruption for 2 months at the end of the third month.~Ocoxin®-Viusid® 60 ml daily (1 vial every 12 hours) by oral route for 8 months, preferably administered after breakfast and lunch, without interruption."
81404|NCT03549260|Biological|LIB003|LIB003 or placebo
81539|NCT03548129|Drug|Culture specific antibiotic therapy|Culture-specific antibiotic treatment for 5 days
81408|NCT03549221|Drug|0.6 mg 1:1000 epinephrine (0.6 ml)|In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
81409|NCT03549208|Biological|LBVE01|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
81410|NCT03549208|Biological|LBVE02|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
81411|NCT03549208|Biological|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
81412|NCT03549195|Procedure|ICG|The ICG powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
81413|NCT03549195|Procedure|ICG-CP|The ICG-CP powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
81414|NCT03549195|Procedure|ICG-TMTP1|The ICG-TMTP1 powder was diluted and injected into the cervix, divided into 3 and 9 o'clock position, 4 hours before surgery.
81415|NCT03549182|Drug|ATD treatment|oral administration of ATD (100g)(Acute Tryptophan Depletion)
81416|NCT03549182|Drug|placebo treatment|oral administration of placebo (102.3g)
81417|NCT03549169|Behavioral|TOMAS|Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
81418|NCT03549169|Behavioral|Regular attention|Regular attention focused on education for therapeutic adherence
81419|NCT03549156|Dietary Supplement|C-RUSF|-RUSF contains whey permeate, WPC 80, peanut paste, sugar, soy oil, canola oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier
81420|NCT03549156|Dietary Supplement|HIPRO RUSF|HIPRO RUSF contains extruded soy flour, skimmed milk, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate
81421|NCT03549143|Other|IBS|No intervention, description of routine practice only
81422|NCT03549130|Device|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
81423|NCT03549130|Other|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
81424|NCT03549117|Device|Breathe Right Tan (small/medium) nasal strips|Participants of this treatment arm applied sufficient quantity of commercially available nasal strips (Breathe Right Tan), small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
81425|NCT03549117|Other|Placebo nasal strip|Participants of this treatment arm applied sufficient quantity of Asymmetric Butterfly Placebo ABP-NH Nasal Strips, small/medium sized outside of the nose, from alar crease to alar crease, as per dispensing instructions, prior to sleeping. Participants used their assigned strip every night, for approximately 8 hours, but no more than 12 hours per night, for two weeks
81426|NCT03549104|Behavioral|Fear Reduction Intervention|FREE
81427|NCT03549104|Behavioral|Attention Control|DSMES
81428|NCT03549091|Diagnostic Test|transthoracic echocardiography|This involves the acquisition of 1 additional sequence: a 10-minute sequence for transthoracic echocardiography.
81429|NCT03549091|Diagnostic Test|Cardiovascular Magnetic Resonance Imaging|This involves the acquisition of 1 additional sequence: a 10-minute sequence for Cardiovascular Magnetic Resonance Imaging 4D Flow.
81430|NCT03549078|Behavioral|Intervention|"Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity."
81431|NCT03549065|Device|Brain Stimulation|"Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation method that stimulates the brain of an individual focally(George & Belmaker, 2007). TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS).~Transcranial direct current stimulation (tDCS) is another form of non-invasive brain stimulation that is being investigated as an intervention for neurological and psychiatric disorders. A weak direct electrical current (0-2 mA) flows between two small electrodes via saline soaked sponges placed on the scalp (Nitsche MA et al, 2008)."
81432|NCT03549026|Drug|Duloxetine|The investigator will give the patients duloxetine capsule 60 mg orally before operation (skin incision) and anesthetize them with general anesthesia, then the investigator will test the postoperative analgesic efficacy in the form of 24 h analgesic consumption
81433|NCT03549026|Drug|placebo|Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
81434|NCT03549000|Other|NZV930|NZV930, Specified dose on specified days, intravenous (IV)
81435|NCT03549000|Other|PDR001|PDR001, Specified dose on specified days, intravenous (IV)
81436|NCT03549000|Drug|NIR178|NIR178 Specified dose on specified days, Orally
81437|NCT03548987|Drug|Semaglutide|Subcutaneous (under the skin) injection of semaglutide once-weekly.
81654|NCT03547362|Dietary Supplement|Casein|See arm description
81439|NCT03548974|Behavioral|Treatment group 1|The ms-intakt/MOTOmed-intervention is a home-based program using the MOTOmed movement trainer: 12 week passive, motor-driven movement therapy followed by 12 weeks of intermittent active and passive training after the 3month assessment. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. Therapists aimed at eliciting a BORG Feedback of between 10 (fairly light) and 15 (hard). The exercise training was home-based and supervised via the internet.
81440|NCT03548974|Behavioral|Treatment group 2|The subjects assigned to interventiongroup2 started with 12 weeks intermittent active and passive training followed by 12 weeks of no intervention (Wash out phase)
81441|NCT03548961|Drug|FOLFOX regimen|FOLFOX regimen will be administered for 6 cycles. Each cycle is 14 days followed by restaging, local surgery and concurrent chemo radiation therapy
81442|NCT03548948|Other|High heme iron diet|"A Typical American diet with high heme/non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
81443|NCT03548948|Other|Low iron diet|"A Typical American diet with low heme/non-heme iron (8 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
81444|NCT03548948|Other|Plant-based high non-heme iron diet|"A plant-based diet with high non-heme iron (18 mg total). Diet is isocaloric and has a macronutrient composition of total fat 35%, carbohydrates 50%, protein 15% of calories and fiber 9g/1000 calories. Subjects consumes the diet for 3 weeks with a minimum 3 week washout before the next diet."
81445|NCT03548935|Drug|Semaglutide|Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks. Dose escalation of semaglutide will take place as follows: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 68.
81446|NCT03548935|Drug|Placebo (semaglutide)|Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly as well as diet and physical activity counselling for 68 weeks.
81447|NCT03548922|Other|Tanner stage|a scale of pubertal development in children, adolescents
81448|NCT03548922|Other|Risser stage|a measure showing the growth left in the spine
81449|NCT03548922|Other|Pressure of correction|an indirect parameter of the chest wall's flexibility. It is defined as the pressure applied to the patient, in the most protruding area of the chest, needed to accomplish a proper shape of the thorax.
81450|NCT03548922|Other|Pectus carinatum protrusion|distance from the point of maximum protrusion to the estimated normal level of chest wall
81451|NCT03548909|Diagnostic Test|VITROS Immunodiagnostic Products|NT-proBNP II assay
81452|NCT03548896|Procedure|Post extraction socket|**Dental implant will be placed 3 months after tooth extraction
81453|NCT03548870|Other|CWRT with low frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes will be positioned by pair on quadriceps. Patients will have a low frequency TENS for 20 min at rest. During this period, intensity will be increased every 5 minutes to the maximum tolerated by the patient (below pain threshold, sensation strong but comfortable). Thereafter, intensity is not increased anymore during the test.~Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional"
81454|NCT03548870|Other|CWRT with sham-low frequency transcutaneous electrical nerve stimulation|4 self adhesive surface electrodes are positioned by pair on quadriceps. Patients will have a sham-low frequency TENS for 20 min at rest. During this period, intensity will be increased for 1 minute to the maximum tolerated by the patient. After this procedure, intensity will be progressively setted back to 1mA. Current characteristics : Rehab 400, CefarCompex 5Hz 200 µs frequency bidirectional
81455|NCT03548857|Other|Lung transplantation|Single or double lung transplantation in patients with COPD
81456|NCT03548844|Procedure|local excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to observation (local excision group) .
81457|NCT03548844|Procedure|total mesorectal excision|Pathologically verified ypT0-1cN0 rectal cancer patients after local excision are randomized to complementary rectal excision (total mesorectal excision group).
81458|NCT03548818|Drug|Interferon Gamma-1B|Study function and biochemistry of neutrophils off the drug for one week and then 12 hours after first dose and fourth dose.
81459|NCT03548805|Procedure|ologen® Collagen Matrix|Ologen is a collagen matrix used to modulate wound healing in the postoperative period to promote diffuse blebs
81460|NCT03548805|Procedure|Trabeculectomy with low dose mitomycin C|Trabeculectomy with low dose MMC
81461|NCT03548792|Radiation|RSA radiostereometric analysis|Tantalum beads will be inserted in polyethylene Component and in bone to assess micromotion of Components in radiographs
81462|NCT03548792|Behavioral|Clinical comparison|ActivePAL, walking speed
81463|NCT03548779|Behavioral|Pre-visit prep|Patient and provider surveys will be used to measure the impact of pre-visit preparation on the primary outcomes of engagement of participants in the clinical interaction and their view of the interaction as patient-centered, in addition to secondary outcomes that may be affected by this intervention (described above). The study investigators will test the hypothesis that patients will benefit from pre-visit preparation by: (1) rating their clinical encounters as more patient-centered and (2) asking more questions during their clinical encounters.
81464|NCT03548779|Diagnostic Test|usual care + exome seq|Provider surveys will be used to assess impact of exome sequencing on diagnostic thinking and management planning. Health utilization and condition-specific general clinical outcomes will be assessed from health records data.
81465|NCT03548766|Biological|Homologous Blood Transfusion|Homologous, or allogenic, blood transfusions involves someone collecting and infusing the blood of a compatible donor into him/herself.
81466|NCT03548766|Biological|Autologous Blood Transfusion|Autologous blood transfusion is the collection and re-infusion of the patient's own blood or blood components.
81467|NCT03548740|Biological|Human Papillomavirus|women with high-risk Human Papillomavirus or not
81468|NCT03548727|Diagnostic Test|PET/CT Imaging|PET/CT Imaging of tumor hypoxia and proliferation
81469|NCT03548714|Drug|PT150|Intervention 1 includes PT150 with alcohol consumption
81470|NCT03548714|Other|Beverage|Alcohol beverage will be prepared by an in-house pharmacist at the MEDVAMC in a volume of 450 ml for a 70 kg individual and adjusted for body weight by varying the volume. Alcohol will be administered in a concentration of 16% alcohol (Everclear, St. Louis, MO) by volume in grape Kool-Aid (Kraft Foods, Northfield, IL). Placebo will be prepared in the same manner but contain 1% alcohol to mask taste.
81471|NCT03548701|Diagnostic Test|Thromboelastometry testing|Thromboelastometry testing - a form of testing in whole blood for coagulation abnormalities
81472|NCT03548675|Drug|TCA treatment|All patients fulfilling inclusion criteria will be genotyped for CYP2C19 and CYP2D6 genes. Based on the genetic test results patients will be classified into a metabolisation phenotype (UM, EM, IM or PM).
81473|NCT03548662|Biological|Platelet-Rich Plasma|Platelet-Rich Plasma prepared by RegenKit® PRP, Regenlab SA
81474|NCT03548662|Drug|Hyaluronic Acid|Hyruan Plus Inj. produced by LG Life Sciences, Ltd.
81475|NCT03548662|Other|Exercise|passive range of motion (PROM) exercise, active-assisted range of motion (AAROM) exercise, active range of motion (AROM) exercise, rotator cuff strengthening exercise, and peri-scapular muscle strengthening exercise
81476|NCT03548649|Device|exoskeleton robot training|subjects will learn to independently use the exoskeleton robot to perform functional activities (including stand-up, sit-down, stepping forward, and walking).
81477|NCT03548636|Behavioral|Single-Arm Feasibility Study|Groups of 8 to 12 participants, consisting of >50% breast cancer survivors, were invited to apply for up to $2000 to enable access to equipment, resources, facilities, instruction and/or transportation to implement a physical activity intervention. Applicants were assessed by a Grant Review Panel. Successful applicants were informed that they would receive an additional $500 incentive if they increased their group's mean physical activity at six month follow-up (assessed via accelerometry).
81478|NCT03548610|Other|Nanofat-seeded biological scaffold on surgical defect|Nanofat-seeded biological scaffold in healing larger surgical defects (>1.5cm) involving the lower limbs
81479|NCT03548597|Device|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery|Evaluation of the Diagnostic of Hepatic Fibrosis With the XL Probe of the Fibroscan Versus Biopsies in Severe Obese Patients Candidates to Bariatric Surgery
81480|NCT03548584|Drug|Brexpiprazole|Tablet
81481|NCT03548584|Other|Placebo|Tablet
81482|NCT03548571|Biological|Dendritic cell immunization|Intradermal injection
81483|NCT03548571|Drug|Adjuvant temozolomide|After a 4-week break, patients were then to receive up to six cycles of adjuvant temozolomide according to the standard 5-day schedule every 28 days at 150 mg per square meter for the first cycle and thereafter increase to 200 mg per square meter beginning with the second cycle.
81484|NCT03548558|Behavioral|Group sessions|Mother-child dyads in Arm 1 households will receive biweekly ECD sessions for a total of 16 sessions over 7 months. CHVs will record attendance at each session. To maximize participation, prior to each session the CHVs will send an SMS reminder of the session's topic, time and location to all participants.
81485|NCT03548558|Behavioral|Group+Home sessions|Households in Arm 2 will receive a total of 16 sessions with identical content similar to Arm 1, but 4 of those sessions will replace group sessions held at the level of villages for personalized home visits, in which the CHV will visit each participant household to deliver these sessions. These home visits will cover identical material and topics as the group sessions in Arm 1 villages, but will be delivered on a personalized basis in the home of the mother and child. Personal barriers to the practices will be discussed and an active resolution strategy developed in concert with the CHV. Households in Arm 2 will also receive two additional booster visits 3 and 6 months after the end of the ECD sessions.
81486|NCT03548545|Device|tDCS|subjects will receive a total of 8-structured CBT sessions administered by a certified therapist(according to the NICE guidelines).In the first two weeks, participants will undergo 6-sessions of CBT every other day(3 CBT sessions per week) and 10 daily sessions of either active or sham tDCS(2 mA, 30 minutes).They will undergo additional booster sessions of the same intervention(active or sham tDCS followed by CBT) by week 4 and 6.
81487|NCT03548532|Device|G210 incubator|very stable culture temperature, up to 0.1°C, in both arms
81488|NCT03548519|Behavioral|MCAT-only|Mouse-gaze contingent Attention Training without prior psychoeducation
81489|NCT03548519|Behavioral|MCAT-sham|Placebo version of Mouse-gaze contingent Attention Training without prior psychoeducation
81490|NCT03548519|Behavioral|MCAT-combo|Mouse-gaze contingent Attention Training with prior psychoeducation
81491|NCT03548506|Device|Omnidirectional Deep Brain Stimulation of STN|Deep Brain Stimulation
81492|NCT03548506|Device|Directional Deep Brain Stimulation of STN|Deep Brain Stimulation
81493|NCT03548493|Drug|Magnesium sulphate|Magnesium sulphate will be given to the experimental group in a dose of 50mg/kg IV over 15 minutes followed by continuous infusion at 15 mg/kg/h
81494|NCT03548493|Drug|Fentanyl|Fentanyl will be given to the active comparator group in a dose of 1 μg /kg IV bolus over 15 minutes followed by continuous infusion starting at 0.5 μg /kg/h
81495|NCT03548493|Drug|Propofol|In both groups Fentanyl and magnesium sulphate will be accompanied by IV propofol at a dose of 50- 150 μg /kg) bolus over 15 minutes to achieve target sedation level, that is Ramsay sedation scale (RSS) 3,if RSS afterwards does not reach 3, a supplementary bolus dose of 0.2 mg/kg propofol will be given to the patients, followed by ( 20-40 μg /kg/ min) to maintain Intraoperative level of sedation by bispectral index (BIS ) reading by 60-80%
81496|NCT03548480|Dietary Supplement|Placebo|Intervention with a daily dose of placebo
81497|NCT03548480|Dietary Supplement|Probiotic|Intervention with a daily dose of probiotic
81498|NCT03548467|Drug|VB10.NEO|VB10.NEO is a vaccine and is supplied as a sterile, ready to use solution (14 vaccinations will be given).
81499|NCT03548454|Drug|Duloxetine|Open label prescription
81500|NCT03548454|Drug|Desipramine|Open label prescription
81501|NCT03548441|Procedure|Surgery|Patients receiving surgical treatment undergo various types of posterior decompressive surgery with or without spinal fusion. The method used for decompressive surgery or fusions is determined solely by the surgeon.
81537|NCT03548142|Behavioral|provision of relevant information|caregivers are provided with brochure that informs about end-of-life issues for persons with advanced dementia
81538|NCT03548129|Drug|phosphomycin|Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach
81502|NCT03548441|Other|Non-surgical management|Patients managing lumbar spinal stenosis non-surgically are either referred to rehabilitation primary health care center or referred back to their general practitioner for treatment. Treatment may include physiotherapy, chiropractic treatment, lifestyle changes and/or pain management. Post-surgically patients may also be referred to rehabilitation at a primary health care center.
81503|NCT03548428|Drug|Atezolizumab|1200mg IV every 3 weeks for 4 months
81504|NCT03548428|Radiation|SBRT|3 to 5 fractions depending on tumor size
81505|NCT03548415|Drug|IONIS-GHR-LRx|Single Dose of IONIS GHR-LRx administered subcutaneously once every 28 days for 16 weeks
81506|NCT03548415|Drug|Placebo|Placebo (sterile saline 0.9%) Calculated volume to match active comparator administered subcutaneously every 28 days for 16 weeks
81507|NCT03548402|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is based on the theory that rigid attempts to control internal states, thoughts and feelings, and other forms of experiential avoidance contribute to symptom development and maintenance of anxiety and self-injury.
81508|NCT03548389|Other|Skin to skin contact|By assistance of the researcher, intervention infants were placed undressed in a prone position against their mothers' bare chest between breasts immediately after birth and before placental delivery and suturing of tears or episiotomy. The Apgar score was determined, the infant's nose and mouth were suctioned while on the mother's chest, it was well dried, and both mother and infant were covered with a pre-warmed blanket. To prevent heat loss, the infant's head was covered with a dry cap that was replaced when it became damp. Dressing and measuring of the infant were postponed to an hour after the delivery by registered midwife.
81509|NCT03548376|Other|Hippotherapy|Hippotherapy is a therapeutic intervention that is typically conducted by a physical or occupational therapist and is aimed at improving impaired body function. Hippotherapy has been proposed as a technique to decrease the energy requirements and improve walking in patients with cerebral palsy. It is thought that the natural swaying motion of the horse induces a pelvic movement in the rider that simulates human ambulation. In addition, variations in the horse's movements can also prompt natural equilibrium movements in the rider.
81510|NCT03548363|Dietary Supplement|Gingest powdered extract obtained from Ginger rhizomes|"Description: Powdered extract obtained from Ginger rhizomes. Botanical name: Zingiber officinale Roscoe Plant part used: Dried rhyzome Extraction solvent: CO2 Extract Ratio 45-60 / 1 100mg of extract are equivalent to an average of 4400 mg of dry ginger rhizomes~Composition: Natural extract, Calcium Hydroxide, Polysorbate 80, De-oiled soya lecithin, Calcium silicate"
81511|NCT03548363|Dietary Supplement|Placebo|200 mg/d maltodextrin
81512|NCT03548350|Behavioral|HealthyKidz physical activity programme|A 24 week physical activity intervention to promote fitness and wellbeing in primary schools
81513|NCT03548337|Biological|13vPnC|13vPnC MultiDose Vial with preservative compared to a Prefilled syringe containing 13vPnC without any preservative
81514|NCT03548324|Device|HHHFNC|Application to HHHFNC to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
81515|NCT03548324|Device|NCPAP|Application to NCPAP to treat respiratory distress syndrome in preterm infants previously demonstrated to be stable on a non-invasive respiratory support (HHHFNC or NCPAP).
81516|NCT03548311|Drug|methylcobalamin|Patients receive methylcobalamin 50mg intramuscular injection twice a week.
81517|NCT03548311|Drug|saline solution|Patients receive saline solution intramuscular injection twice a week.
81518|NCT03548298|Procedure|ARAT|After confirmation of GERD, participants will undergo to ablation with Hybrid-APC (ARAT). Participant will be admitted to hospital 24 hrs before procedure. Technique consist in ablation with hybrid-APC, submucosal injection of saline solution with methylene blue at 3-4 cm from 60-70% cardias and 1 cm esophageal. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic, esophageal manometry and pHmetry up to 1 year after procedure.
81519|NCT03548285|Radiation|Radiation therapy|Stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy (SBRT)
81520|NCT03548272|Procedure|Percutaneous Coronary Intervention with stent implantation|PCI with BiOSS LIM C or rDES depending on the randomization
81521|NCT03548259|Procedure|Platelet-rich plasma|Platelet-rich plasma injection
81522|NCT03548259|Procedure|Platelet-poor plasma|Platelet-poor plasma injection
81523|NCT03548246|Drug|Abiraterone acetate|Daily oral abiraterone acetate for 2 years. The dose will be specified based on pharmacodynamic data from Phase 1.
81524|NCT03548246|Drug|Placebo|Daily placebo for 2 years.
81525|NCT03548246|Drug|Hydrocortisone|Hydrocortisone will be administered at a starting dose of 7-9 mg/M2/d and adjusted as necessary based on 17-hydroxyprogesterone and ACTH levels.
81526|NCT03548246|Drug|Fludrocortisone|Fludrocortisone will be administered at the dose the subject was taking a study entry and adjusted as necessary to keep plasma renin in the high normal range.
81527|NCT03548233|Biological|bcg vaccine|live attenuated vaccine
81528|NCT03548220|Drug|AG-348|"Part 1 (Dose Optimization Period): Participants will begin by receiving 5 milligrams (mg) orally, twice a day. Each participant's dose of AG-348 may be increased to 20 mg twice a day or 50 mg twice a day depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Last dose received in Part 1, twice daily."
81529|NCT03548220|Drug|Placebo|"Part 1 (Dose Optimization Period): Participants will begin by receiving placebo matching AG-348 orally, twice a day. Each participant's dose of placebo matching AG-348 may be increased to 20 mg twice a day or 50 mg twice a day depending on their response to the placebo matching AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Last dose received in Part 1, twice daily."
81530|NCT03548207|Biological|JNJ-68284528|JNJ-68284528 consist of autologous T lymphocytes transduced with LCAR-B38M, a lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
81531|NCT03548194|Drug|BNC210|BNC210 300 mg b.i.d
81532|NCT03548194|Drug|Placebo|Placebo b.i.d.
81533|NCT03548181|Behavioral|Virtual Autonomous Physiotherapist Agent (VAPA)|A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
81534|NCT03548155|Drug|Berberine|Berberine 300mg（three times a day） plus any atypical antipsychotic drug
81535|NCT03548155|Drug|atypical antipsychotic|Any atypical antipsychotic drug as the basic treatment
81540|NCT03548129|Diagnostic Test|Pre-treatment Urine Culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
81541|NCT03548129|Diagnostic Test|Antimicrobial sensitivity testing|Susceptibility of urinary pathogens to various antimicrobials
81542|NCT03548129|Diagnostic Test|Post-treatment urine culture|Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
81543|NCT03548116|Device|Ultrasound|This study involves a specially designed ultrasound being placed against the abdomen of an individual in order to administer low levels of insonification to the spleen as specified by the individual's assigned study group.
81544|NCT03548116|Device|Sham Ultrasound|This study involves a specially designed ultrasound being placed against the abdomen of an individual in order to administer sham insonification to the spleen as specified by the individual's assigned study group.
81545|NCT03548103|Dietary Supplement|Green tea extract|Green tea extract 500 mg tid for 16 weeks
81546|NCT03548103|Dietary Supplement|Placebo|Placebo tid for 16 weeks
81547|NCT03548090|Other|Skateboard exercise at an incline angle of 0 degrees and 50% body weight|Participants will stand on a specified incline angle (0 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
81548|NCT03548090|Other|Skateboard exercise at an incline angle of 5 degrees and 50% body weight|Participants will stand on a specified incline angle (5 degrees) and with a specified body weight (50%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
81549|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (75%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
81550|NCT03548090|Other|Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight|Participants will stand on a specified incline angle (either 0 or 5 degrees, whichever is determined during phase 1 to be optimal) and with a specified body weight (90%) on the paretic LE and will simultaneously move a small skateboard forward with the non-paretic LE.
81551|NCT03548090|Other|Control 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The control group will perform three sets of ten repetitions of the following 4 exercises, for a total of 120 repetitions: 1) standing hip abduction against green theraband resistance with upper extremity support, 2) sit to stands from chair with no upper extremity support, 3) bilateral calf raises with upper extremity support, and 4) right and left weight shifting exercises using a wobble board with upper extremity support available if needed.
81552|NCT03548090|Other|Experimental 4-week exercise intervention|This intervention occurs in phase 3. Subjects will participate in 1-hour sessions three times per week for four weeks. The experimental group will perform the skateboard exercise with the optimal parameters established during studies 1 and 2 (that is, an incline angle of either 0 or 5 degrees and a body weight percentage of 50%, 75%, or 90%)--the forward and backward speed of the skateboard will be cued with a metronome that will set at a beats per minute that matches the foot strike cadence of someone walking at 0.7 m/s, and the magnitude of forward excursion of the skateboard will be individualized to the participant based on GAITRite® data (that is, step length of the non-paretic LE).
81553|NCT03548090|Other|Over-ground multi-directional gait training|In the over-ground multi-directional gait protocol, the participant will walk 750 steps forward, 50 steps backward, and 200 side steps over level surfaces. The over ground gait training will focus on equalizing step length while performing multi-directional gait training.
81554|NCT03548090|Other|Home exercise|Home exercise consists of three sets of ten repetitions of the following three exercises to be performed on non-therapy days over the four weeks of phase 3: 1) sit to stands from chair with no upper extremity support, 2) bilateral calf raises with hand support, and 3) resisted side stepping to the non-paretic side using a green theraband with upper extremity support.
81555|NCT03548077|Behavioral|POWERPLAY|"All men from participating worksites are invited to completed surveys prior to and following implementation of a workplace wellness program (called POWERPLAY)"
81556|NCT03548064|Other|Placebo|Placebo
81557|NCT03548064|Other|Placebo|Placebo
81558|NCT03548064|Other|Placebo|Placebo
81559|NCT03548064|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
81560|NCT03548064|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
81561|NCT03548064|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
81562|NCT03548051|Procedure|Fecal Microbiota Transplantation (FMT)|100 grams of thawed processed stool diluted into 250 ml of saline and delivered by retention enema
81563|NCT03548051|Drug|Saline|250 ml of saline delivered by retention enema
81564|NCT03548038|Other|taste test|All subjects will complete a procedure to determine their taste sensitivity to sweet tastants.
81565|NCT03548025|Device|BTL-703 (Treatment group)|Treatment with BTL-FR2000 Device
81655|NCT03547362|Dietary Supplement|Dairy protein blend 1|See arm description
81656|NCT03547362|Dietary Supplement|Whey protein|See arm description
81566|NCT03548012|Behavioral|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
81567|NCT03547999|Drug|mFOLFOX6|The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
81568|NCT03547999|Biological|MVA-BN-CV301|The experimental arm (Arm B) will receive MVA-BN-CV301 in 4 injections of 4 x 10(8) infectious units/0.5 mL given subcutaneously prior to the start of chemotherapy on days -28 and -14.
81569|NCT03547999|Biological|FPV-CV301|The experimental arm (Arm B) will receive FPV-CV301 in 1 dose of 1 x 10(9) infectious units/0.5 mL given subcutaneously concurrently with chemotherapy (at least an hour prior to chemotherapy) on days 0, 14, 28 and 42 pre-operatively, and FVP-CV301 boosters on day 0 and 14 and then every 4 weeks (day 42, 70, 98). After day 98, FVP-CV301 will then be administered every twelve weeks completing therapy at week 110.
81570|NCT03547999|Drug|Nivolumab|Nivolumab at a dose of 240 mg as a 30 minute IV infusion every 2 weeks until progression. Arm B will receive Nivolumab starting with the vaccinations. Arm A will begin the Nivolumab with the initiation mFOLFOX.
81571|NCT03547986|Diagnostic Test|Duplex Ultrasound (DUS)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
81572|NCT03547986|Diagnostic Test|Intraarterial pressure measurement (IAP)|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intraarterial pressure measurement
81573|NCT03547986|Diagnostic Test|Intraarterial pressure measurement (IAP) with IVUS|Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intraarterial pressure measurement associated with Intra-vascular ultrasound
81574|NCT03547973|Drug|Sacituzumab govitecan|All subjects will receive Sacituzumab govitecan (IMMU-132) 10 mg/kg intravenously on Days 1 and 8 of a 21 day cycle.
81575|NCT03547960|Dietary Supplement|Guar gum|Fibre supplement to be taken with each meal
81576|NCT03547960|Dietary Supplement|Cellulose|Placebo. Fibre supplement to be taken with each meal
81577|NCT03547947|Device|Medacta Shoulder System|Total Shoulder Arthroplasty
81578|NCT03547934|Device|High Intensity Focused ElectroMagnetic system.|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
81579|NCT03547921|Device|iu22 ultrasound system - phillips|iu22 ultrasound system - phillips
81580|NCT03547908|Drug|B/F/TAF|50/200/25 mg B/F/TAF FDC tablet administered orally once daily, without regard to food
81581|NCT03547908|Drug|Placebo to match DTG|Tablet administered orally once daily, without regard to food
81582|NCT03547908|Drug|Placebo to match F/TDF|Tablet administered orally once daily, without regard to food
81583|NCT03547908|Drug|DTG|50 mg tablet administered orally once daily, without regard to food
81584|NCT03547908|Drug|F/TDF|200/300 mg tablet administered orally once daily, without regard to food
81585|NCT03547908|Drug|Placebo to match B/F/TAF|Tablet administered orally once daily, without regard to food
81586|NCT03547895|Drug|Sofosbuvir 400mg (Sovaldi) + Daclatasvir 60 mg (Daklinza) + Ribavirin 200 mg (Rebetol)|sofosbuvir 400mg+ribavirin 400mg+daclatasvir 60 mg were adminstered for 3 months
81587|NCT03547895|Drug|vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion|symptomatic therapy for liver support, control of ascites and bleeding tendency.
81588|NCT03547869|Device|Active tDCS|Active tDCS will be adminestered
81589|NCT03547869|Device|Sham tDCS|Sham tDCS will be administered
81590|NCT03547843|Behavioral|Group-based education|The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.
81591|NCT03547843|Behavioral|Waiting list|No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.
81592|NCT03547843|Other|Standard treatment|Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
81593|NCT03547830|Drug|Plerixafor|Plerixafor for Conditioning before HSCT.
81594|NCT03547830|Drug|Gcsf|GCSF for Conditioning before HSCT.
81595|NCT03547817|Device|Intermittent negative pressure device|Pressure levels of 0 mmHg, -10 mmHg, -20 mmHg, -40 mmHg and -60 mmHg will be tested, with washout periods of 5 minutes between the different pressure levels
81596|NCT03547804|Drug|Apatinib|500 mg qd/250mg
81597|NCT03547804|Drug|chemotherapy|Chemotherapeutic agents are limited to irinotecan or docetaxel alone.
81598|NCT03547791|Drug|Betamethason Sodium Phosphate|The antecorticosteroid that will be administered to Group 1 is betamethasone, produced by Dawon Parm(Korea). It contains betamethason sodium phosphate 5.2mg(Betamethasone 4.0mg) in 1 ample(1mL). Each drug is carried in a syringe by pharmacist who does not participate in study after the patient was enrolled in the study and administered to the patient twice 24hours apart.
81599|NCT03547791|Drug|Normal saline|Intramuscular injection of normal saline 3ml twice 24hours apart
81600|NCT03547778|Drug|Misoprostol 50 mcg pesssary|Participants in the study arm will receive vaginal misoprostol (50 mcg) to be inserted the night before the procedure. Whereas the control group will get a placebo.
81601|NCT03547778|Drug|Placebos|The control group will receive placebo pessaries to be inserted vaginally the night before the procedure.
81657|NCT03547362|Dietary Supplement|Dairy protein blend 2|See arm description
136662|NCT03120923|Drug|Triamcinolone Acetonide|
81602|NCT03547752|Other|observed action and motor imaginery|Observation of a video of neck movement and imagination of the same observed movement, feeling the realization of the movement but not developing it.
81603|NCT03547739|Behavioral|Home visits|If a couple has been randomized to the home visit intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the couple about optimal times for a home visit. As described above, the intervention arm will consist of five home visits conducted by one female and one male lay health worker, including two home visits during pregnancy, one at six weeks after the birth, and two booster sessions, one at six months after the birth and one at 12 months after the birth. Home visits are designed for all pregnant couples (regardless of woman's initial HIV test result at the antenatal clinic) and include topics important for maternal, paternal, and child health during pregnancy and postpartum.
81604|NCT03547739|Behavioral|HIV Self-testing|Women in this study group will receive oral-fluid-based rapid HIV test kits for themselves and their male partner at up to 4 time points (twice during pregnancy and twice postpartum). Each test will be accompanied with a self-testing instruction sheet describing step-by-step procedures in multiple languages. Study staff will also conduct a brief demonstration on how to use the tests. Participants will be encouraged to offer a test kit to their male partner or to undertake couples testing. They will also be counseled on how to talk to their partners and the possibility of adverse partner reactions. Participants will be instructed to seek clinic-based confirmatory testing if a reactive self-test result is obtained.
81605|NCT03547726|Other|Physical Therapy|These patients will receive a formal physical therapy protocol by seeing a physical therapist in clinic.
81606|NCT03547726|Other|Self-Rehab|These patients will be provided with a list of actions NOT to perform and allowed to self rehabilitate. They will not see a physical therapist.
81607|NCT03547713|Behavioral|social feedback|Social feedback regarding performance of a public speech is delivered to participants
81608|NCT03547700|Drug|Romidepsin|Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
81609|NCT03547700|Drug|Ixazomib|Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
81610|NCT03547687|Device|Electrical Stimulation Treatment|"An Intelect Neuromuscular Electrical Stimulator (NMES) (Chattanooga Group) device will be used to provide the stimulation. The stimulator will be set up and taken off the patients by a member of the study team or a trained ICU staff member. The stimulation parameters will be as follows:~Electrode location: Proximal and distal quadriceps Waveform: pulsed biphasic Pulse duration: 300 microseconds Pulse frequency: 35 pulses per second Amplitude: palpable, visible quadriceps muscle contraction On/off time: 5 seconds on, 15 seconds off Ramp up and down time: 2 seconds each"
81611|NCT03547674|Other|barefoot|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
81612|NCT03547674|Other|shoes only|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order.
81613|NCT03547674|Other|untuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. AFO are walking aids to improve gait pathologies. They are custom-built using plaster casts. AFO for equinus and/or drop foot pathologies are specifically indicated to control excessive ankle plantar flexion. Push-up elements that return the energy from the stance-phase to support lifting the foot during the swing-phase (similar to a spring) are used.
81614|NCT03547674|Other|tuned AFO with shoes|Gait analysis under 4 conditions (barefoot, shoes only, untuned AFO with shoes, tuned AFO with shoes) will be performed in a random order. Modular AFO tuning means that patients try different pushup elements with varying stiffness and design before the final design is determined.
81615|NCT03547661|Other|P-Dragees rosa Lichtenstein|Placebo dragées
81616|NCT03547648|Procedure|peak airway pressure|Patients' peak airway pressures will be raised to observe intraoperative bleeding in thyroidectomy surgery. Aim is to prevent postoperative bleeding.
81617|NCT03547635|Other|AMNIOEXCEL Plus Amniotic Membrane|AMNIOEXCEL Plus is a human placental-based tissue consisting of dehydrated, tri-layer Placental (Amnion/Chorion/Amnion) Allograft Membrane (T-PAM) layers. T-PAM is a minimally manipulated placental membrane product made from tissues donated by pre-screened mothers during planned C-sections and is intended for use as a wound covering. This product is an allograft tissue intended for homologous use for the repair, reconstruction and replacement of skin at the direction of a physician. AMNIOEXCEL Plus contains Human Cellular and Tissue Based Products (HCT/P) as defined by US FDA 21 CFR Part 1271. All donor recoveries are performed by BioDlogics, LLC, and adhere to the regulations regarding HCT/P recovery and the screening and testing of the tissue donor as verified through supplier audits.
81618|NCT03547635|Device|A Marketed Comparator|bi-layered skin substitute: the epidermal layer is formed by human keratinocytes and has a well-differentiated stratum corneum; the dermal layer is composed of human fibroblasts in a bovine Type I collagen lattice. It is indicated for use with standard therapeutic compression for the treatment of non-infected partial and full-thickness skin ulcers due to venous insufficiency of greater than 1-month duration and which have not adequately responded to conventional ulcer therapy. This product is also indicated for use with standard DFU care for the treatment of full-thickness neuropathic DFUs of greater than three weeks' duration which have not adequately responded to conventional ulcer therapy and which extend through the dermis but without tendon, muscle, capsule or bone exposure.
81619|NCT03547635|Other|Standard of Care|"Coban™~Conforming gauze~Optifoam® non-adhesive dressing~Cotton Gauze~Normal saline (liquid or gel)~Non-adhering dressings~Steristrips~An offloading boot (Pneumatic Short Leg Walker), as appropriate"
81620|NCT03547622|Drug|MAT taper with galantamine|Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
81621|NCT03547622|Drug|MAT taper with placebo|Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
81622|NCT03547609|Other|No arm intervention|No arm intervention
81623|NCT03547596|Other|questionnaire passation|Questionnaires to evaluate lower urinary tract symptoms and erectile dysfunction.
81658|NCT03547362|Dietary Supplement|Dairy protein blend 3|See arm description
81624|NCT03547583|Drug|Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets|Oral use. Vericiguat, which will be started at 2.5 mg at randomization and up-titrated to 5 mg at week 2, and to 10 mg at week 4, with sham titration or up-titration to 15 mg at week 6.
81625|NCT03547583|Drug|Placebo|Placebo and sham up-titration at weeks 2, 4, and 6
81626|NCT03547570|Other|Progressive heavy shoulder resistance training|The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.
81627|NCT03547557|Device|Exablate 2000 strappable system|
81628|NCT03547531|Other|Natural Tooth Brushing Method|Natural tooth brushing method is the method that is naturally used by the people with horizontal, rotary, or simple up and down motions and any position of the brush without any instruction of particular tooth brushing method.
81629|NCT03547531|Other|Modified Circular Tooth Brushing Method|Modified Circular tooth brushing method is a combination of small circular motion of brushing with the position of the brush slightly reach underneath the gingival that are applied for each jaw in all facial surfaces and posterior lingual of tooth arches.
81630|NCT03547518|Device|PTNS treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
81631|NCT03547518|Device|Sham treatment|One-week induction consisting of three active PTNS treatments, each 2 hours long
81632|NCT03547505|Procedure|R-Pilot®|Glide path preparation using R-Pilot® in reciprocating manner.
81633|NCT03547505|Procedure|ProGlider®|Glide path preparation using ProGlider® in a rotating manner.
81634|NCT03547505|Procedure|Manual preparation|Glide path preparation using manual K-files numbered from 08 to 15.
81635|NCT03547492|Behavioral|Teaching Talking|Written packet including 8 lessons: What's My Corrected Age, Watch Me Learn (language milestones in the 1st year of life), Reading Aloud, Sing-a-long: Sleepy Songs, Sing-a-long: Alert Songs, Copying First Sounds, Playing Games, Talk to Your Baby.
81636|NCT03547492|Behavioral|LENA recordings-language|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, after reviewing Teaching Talking and linguistic feedback of first recording, 4 and 12 months of age. Participants are mailed feedback of their 2nd, 4 and 12 month recordings.
81637|NCT03547492|Behavioral|LENA recordings-motor|LENA a special recording device. It records for 16 hours inside a specially designed infant vest. The recording is analyzed by a computer that generates an output of total number of adult words, infant vocalizations and conversational turns during the recording period. 4 LENA recordings are obtained: baseline, 2nd, 4 and 12 months of age. Participants are mailed feedback on recordings after completing study.
81638|NCT03547492|Behavioral|Mastering Movement|A written curriculum containing 5 lessons adopted from Beautiful Beginnings: What's My Corrected Age, Watch Me Move! (review of motor milestones in 1st year), Gentle Stretching and Exercise, Tummy Time, Help Me Learn to...
81639|NCT03547492|Behavioral|Language text messages|12 weekly text messages. Each is 1-2 sentences to review concepts of Teaching Talking
81640|NCT03547492|Behavioral|Motor text messages|4 text messages sent every 4 weeks. Each is 1-2 sentences reviewing concepts of Mastering Movement
81641|NCT03547479|Behavioral|VDOT|In VDOT, reminder notifications are sent x minutes prior to the scheduled pill time, and continue every y minutes until the user sends a video of themselves taking their pill via the app. Instructions will be provided in Khmer. The web system has an administrator component whereby a healthcare provider can log in via the Internet to monitor and validate all the videos received that day, and reasons for non-submission.
81642|NCT03547479|Behavioral|VDOT + mobile money|The VDOT intervention above will be paired with financial incentives in the form of mobile payments in one of the experimental arms.
81643|NCT03547427|Other|Basal insulin alone|A study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at according to the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
81644|NCT03547427|Other|Basal pramlintide and reduced basal insulin|A study insulin pump containing pramlintide will be programmed to deliver pramlintide at 6:1 pramlintide:insulin ratio. Simultaneously, a study insulin pump containing lispro insulin will be programmed to deliver basal lispro insulin at ~25% reduced rate from the subject's normal basal profile. The carbohydrate ratio(s) and insulin sensitivity factor(s) will be programmed per the subject's usual home parameters.
81645|NCT03547427|Other|CGM|Subjects will be instructed to initiate a Continuous Glucose Monitor (CGM) session 2-3 days prior to both the experimental and control CRU admissions.
81646|NCT03547427|Other|Acetaminophen test|Consumption of a standardized meal mixed with added 1.5 g liquid acetaminophen
81647|NCT03547427|Other|Insulin-induced hypoglycemia|During insulin-induced hypoglycemia admission, subjects will receive an insulin bolus(s) dosed to reach blood sugar of less than 55 mg/dL.
81648|NCT03547427|Other|Exercise-induced hypoglycemia|During exercise-induced hypoglycemia admission, subjects participate in three 15 minute exercise bouts (45 minutes total) to lower blood sugar to less than 55 mg/dL.
81649|NCT03547414|Other|Nephrocheck test|A fresh urine sample was collected on inclusion (maximum 6 hours after starting catecholamines) through the urine collecting tube and frozen at -80°C. At the end of the study, urine samples were thawed and centrifuged as recommended by the manufacturer and the urinary TIMP2*IGFBP7 concentration was determined using the Nephrocheck™ test. The Nephrocheck™ test simultaneously measures into the Astute 140™ meter (a bench top analyzer) the urinary concentrations of TIMP2 and IGFBP7 on 100 µl of urine mixed with 100 µl of buffer. The result is expressed as a single number corresponding to the product of TIMP2 and IGFBP7 concentrations.
81650|NCT03547401|Device|Ankle Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the arm (model IntelliVue M8105a MP5 Phillips, calibrated).
81651|NCT03547401|Device|Arm Non-invasive Blood pressure measurement|Non-invasive blood pressure measured simultaneously at the ankle (model IntelliVue M8105a MP5 Phillips, calibrated).
81652|NCT03547388|Device|Moderate whole body hyperthermia using water-filtered IR-A-radiation|four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging
81653|NCT03547375|Drug|Apatinib|Apatinib 500mg/d po,28 days as one cycle
81660|NCT03547349|Device|Digital Incentive Spirometer|This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer
81661|NCT03547349|Device|Jamboxx Respiratory Therapy Device|THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
81662|NCT03547336|Device|Theranova 400 Dialyzer|Dialysis performed in HD mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
81663|NCT03547336|Device|FX800 Dialyzer|Dialysis performed in HDF mode. Treatment duration for each individual subject will vary based on clinical requirements determined by the Investigator, based on the subject's need, residual renal function, access function, tolerance to HD/HDF and other relevant factors. The participating subjects' HD/HDF prescriptions should be kept stable throughout the study.
81664|NCT03547323|Device|Theranova 400 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
81665|NCT03547323|Device|FX80 Dialyzer|An existing functioning vascular access (AVF, graft) must be in place and will be used for dialysis. Treatments will be administered by trained clinical staff. The use of temporary or tunneled dialysis catheters will not be allowed.
81666|NCT03547310|Behavioral|MyoBeatz|Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
81667|NCT03547284|Drug|sugarless gum|81 patients will receive 1 stick of sugarless gum(Samara gum) for 15 minutes every 2 hours
81668|NCT03547271|Biological|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, 0.5 mL, intramuscular
81669|NCT03547271|Biological|Nimenrix®|Meningococcal group A, C, W-135, and Y conjugate vaccine, 0.5 mL, intramuscular
81670|NCT03547271|Biological|DTaP-IPV-HB-Hib vaccine|Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b vaccine
81671|NCT03547271|Biological|Pneumococcal vaccine (13-valent)|Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)
81672|NCT03547271|Biological|Pneumococcal vaccine (10-valent)|Pneumococcal polysaccharide conjugate vaccine (10-valent, adsorbed)
81673|NCT03547271|Biological|MMR vaccine|Measles, mumps, and rubella vaccine
81674|NCT03547258|Genetic|Clinical and Molecular data collection|Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
81675|NCT03547245|Biological|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|20 μg
81676|NCT03547245|Biological|eOD-GT8 60mer + AS01B/ DPBS sucrose/IM|100 μg
81677|NCT03547245|Biological|DPBS Sucrose|Placebo
81678|NCT03547232|Drug|Indomethacin SR|Indomethacin SR 50mg given q12h from admission day 1 to day 7
81679|NCT03547232|Drug|Placebos|Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
81680|NCT03547219|Drug|Escitalopram|
81681|NCT03547206|Drug|RPh201|RPh201 is a proprietary, isolated botanical extract of gum mastic for treatment of nonarteritic anterior ischemic optic neuropathy (NAION).
81682|NCT03547206|Other|Placebo|The placebo is composed of RPh-201 excipients (cottonseed oil stabilized with butylated hydroxytoluene [BHT]).
81683|NCT03547180|Behavioral|Cognitive Therapy|The training included four components: (a) educating patients about exacerbating panic symptoms through catastrophic thoughts (vicious cycle), (b) identifying negative cognitions associated with physical sensation triggers of recent panic attacks, (c) practicing replacement of maladaptive cognitions with non catastrophic explanations, and (d) instructing patients in between session exercises during Phase I.
81684|NCT03547180|Behavioral|Capnometry-Assisted Respiratory Training|The training included four components: (a) educating patients about the exacerbation of panic symptoms through hypocapnia; (b) directing patients' attention to potentially detrimental respiratory patterns; (c) teaching patients techniques to control their respiration, in particular end-tidal PCO2; and (d) instructing patients in between-session exercises. Between-session exercises using a portable capnometer were to be performed twice a day for 17 min at home or elsewhere during Phase I.
81685|NCT03547180|Behavioral|In-vivo exposure|In this two-phase intervention, patients were randomized (within each site) to first receive five individual, weekly, 1-hr sessions of respiratory skill training (CART) or cognitive skill training (CT; Phase I, Skill Acquisition Training), followed by three weekly sessions of in-vivo exposure (Phase II, Application Training) plus a fourth session at 2-month follow-up.
81686|NCT03547167|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
81687|NCT03547167|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg), and aluminum phosphate adjuvant (125 mcg aluminum) in each 0.5 ml dose
81688|NCT03547167|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
81689|NCT03547154|Biological|Pegylated interferon alfa-2b|Weekly SC injection of pegylated interferon alfa-2b, 6.0 microg/kg
81690|NCT03547154|Biological|Interferon alfa-2b|Daily SC injection of interferon alfa-2b, 5 MIU/m^2
81691|NCT03547141|Drug|MBA-P01|injection of MBA-P01 into the muscle of each contralateral foot in equal doses
81692|NCT03547141|Drug|BOTOX|injection of BOTOX into the muscle of each contralateral foot in equal doses
81693|NCT03547115|Drug|Voruciclib|Voruciclib is provided as 50 mg and 100 mg capsules and is administered orally once a day
81696|NCT03547089|Device|Viveve®|A single treatment using Viveve® with 110 pulses administered to the vaginal introitus at 90 J/cm2
81697|NCT03547076|Diagnostic Test|Focused ultrasound diagnostics|"Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler)."
81698|NCT03547050|Other|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
81699|NCT03547050|Other|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
81700|NCT03547037|Drug|JNJ-63723283|JNJ-63723283 will be administered intravenously.
81701|NCT03547037|Drug|Erdafitinib|Erdafitinib will be administered orally.
81702|NCT03547024|Drug|JNJ-55308942 High Dose|Participants will receive high dose of JNJ-55308942 orally once daily.
81703|NCT03547024|Drug|JNJ-55308942 Low Dose|Participants will receive low dose of JNJ-55308942 orally once daily.
81704|NCT03547024|Drug|Levonorgestrel/Ethinyl Estradiol Fixed Dose combination (FDC)|Participants will receive 0.150 milligram (mg) levonorgestrel and 0.030 mg ethinyl estradiol FDC tablet orally.
81705|NCT03547024|Drug|Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)|Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
81706|NCT03547011|Procedure|US guided Quadratus Lumborum block|Patients will receive ultrasound guided quadratus lumborum block with 0.3 ml /kg bupivacaine 0.25% on each side with catheter insertion for maintenance doses 0.1ml/kg/hr on each side.
81707|NCT03547011|Procedure|US guided Paravertebral block.|Patients will receive ultrasound guided thoracic paravertebral block with 0.3 ml/kg bupivacaine 0.25 % on each side with catheter insertion for maintenance doses 0.1 ml/kg/hr on each side.
81708|NCT03546998|Diagnostic Test|Clinical instrumental examinations|Achalasia patients were periodically submitted to clinical assessment, barium swallow (esophageal diameter and residual barium column were measured), endoscopy. Mucosal esophageal biopsies were taken in order to diagnose dysplasia or epidermoid carcinoma.
81709|NCT03546985|Device|episil®|Firmly press the pump and apply the stream of liquid to the oral cavity 3 times (a total volume of 0.45 mL approximately). Distribute to affected areas in the mouth, for example by using the tongue. Wait for 5 minutes for the protective film to form.
81710|NCT03546985|Device|Kang Su|Gently pour 5 mL of rinse into the mouth, keep the rinse staying in the oral cavity for at least 1 minute, and spilt out the liquid.
81711|NCT03546972|Other|Behavioral, Psychological or Informational Intervention|Take part in DDP
81712|NCT03546972|Other|Behavioral, Psychological or Informational Intervention|Take part in HT
81713|NCT03546972|Other|Questionnaire Administration|Ancillary studies
81714|NCT03546959|Other|Lycra sleeve|custom-fitted lycra sleeve extending from axilla to wrist
81715|NCT03546959|Other|Rehabilitation|Passive, active and active assistive range of motion and stretching exercises for shoulder, elbow, wrist, facilitation and inhibition techniques, neuromuscular electrical stimulation for wrist extensors, strengthening exercises for affected upper extremity, occupational therapy
81716|NCT03546959|Drug|Botulinum Toxin|Botulinum toxin injection for upper limb spasticity after stroke
81717|NCT03546946|Behavioral|Gaze-Contingent Music Reward Training|Participants will hear their selected music track playing, dependent on their gaze location, when viewing a grid on neutral and negative faces.
81718|NCT03546946|Behavioral|Control Training|Participants will hear their selected music track playing, regardless of their gaze location, when viewing a grid on neutral and negative faces.
81719|NCT03546933|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
81720|NCT03546920|Behavioral|ALIGN Intervention Phase|"Communication: The PCSW will follow this structured process to improve and facilitate communication for intervention patients. 1. Attend routine weekly facility-led rounds/meetings reviewing patients, their needs and attend discharge planning conference; 2. Visit with patient and caregiver after the discharge planning conference to ensure understanding of the plan of care; 3. Ensure all appropriate community programs (home health, community palliative care) have made contact and established care, assess the transition, and revisit domains from the initial assessment; 4. Suggest questions that need to be asked of community providers. Throughout the intervention, the PCSW will communicate updates from the visits to all involved providers.~Visits will also focus on increasing goal alignment with the objective that all participants have a ROLT score that is most aligned. Visits will also explore goals of care; this includes completion or review of advance directives."
81721|NCT03546907|Drug|Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled
81722|NCT03546907|Drug|Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled
81723|NCT03546907|Drug|Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Pharmaceutical form:Aerosol or Dry Powder inhaler Route of administration: Inhaled
81724|NCT03546907|Drug|Any short-acting β agonist as prescribed by treating physician as standard of care|Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: inhaled
81725|NCT03546894|Drug|Brigatinib|Brigatinib tablets.
81726|NCT03546894|Drug|Alectinib|Alectinib capsules.
81727|NCT03546894|Drug|Ceritinib|Ceritinib capsules.
81728|NCT03546894|Drug|Lorlatinib|Lorlatinib capsules.
81729|NCT03546894|Drug|Any FDA Approved ALK Inhibitors|FDA approved ALK inhibitors available for treatment.
81730|NCT03546881|Procedure|fusion imaging guidance technology|Imaging fusion guidance overlay used during PAOD endovascular revascularisation
81731|NCT03546881|Procedure|2D X-ray screen|2D X-ray screen during PAOD endovascular revascularisation
81732|NCT03546868|Drug|[18F]FSPG|Patients will receive 200 MBq of [18F]FSPG and undergo PET/CT for assessing disease activity in inflammatory bowel disease
81733|NCT03546855|Drug|Apatinib|Apatinib 500mg/d po,28 days as one cycle
81734|NCT03546842|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine in a 0.5-mL intramuscular injection
81735|NCT03546829|Drug|Vancomycin|125 mg, 4x daily for 5 weeks
81736|NCT03546829|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients planned to undergo SBRT to a lung lesion will be randomized to either vancomycin for 1 week before RT and for 1 month after start of RT,
81737|NCT03546816|Drug|5mg Serlopitant Tablets|Serlopitant Tablets
81738|NCT03546816|Drug|Placebo Tablets|Placebo Tablets
81739|NCT03546803|Other|3M™ Cavilon™ Advanced Skin Protectant|liquid skin protectant on skin to protect from radiation dermatitis
81740|NCT03546790|Drug|Marijuana|Marijuana smoked via blunts with different cigar wrappers
81741|NCT03546777|Device|magnetic resonance imaging|magnetic resonance imaging of shoulder
81742|NCT03546764|Device|Percutaneous catheter|tube inserted to drain hemothorax
81743|NCT03546751|Device|Continuous Positive Airway Pressure|This device delivers air pressure non invasively through a mask to stent open the upper airway to prevent obstruction during sleep. This is an FDA approved device that has been used for several decades to treat OSA.
81744|NCT03546751|Other|Diet And Exercise|This will consist of weekly telephone and monthly face to face visits to monitor and suggest measures to improve diet and regular exercise as conducted by a registered dietician.
81745|NCT03546738|Procedure|Burst Spinal Cord Stimulation|Burst stimulation utilizes complex programming to deliver high-frequency stimuli of a 40 Hz burst mode with 5 spikes at 500 Hz per spike delivered in a constant current mode
81746|NCT03546738|Procedure|Sham spinal cord stimulation|No spinal cord stimulation is provided
81747|NCT03546738|Device|SCS implant|"a subcutaneously implantable pulse generator (pacemaker) for long-term therapy"
81748|NCT03546725|Device|Compression stocking|Compression stocking with length below the knee and a class two compression level (corresponding to 23-32 mmHg compression).
81749|NCT03546712|Other|Tactile Localization|tactile localization is help to assess touch sensation
81750|NCT03546699|Diagnostic Test|Estimation of hospital-wide incidence of ARDS|"Estimation of hospital-wide incidence of ARDS defined according to both the Berlin definition and the Kigali modification.~To describe clinical characteristics and outcomes for these patients.~To analyze the prognosis and time course of patients who initially meet criteria for Kigali-defined ARDS and subsequently progress to Berlin-defined ARDS.~For the subset of patients who have chest CT, to determine the sensitivity and specificity for bilateral opacities of both chest radiographs and chest ultrasound done within 12 hours as compared to the reference standard CT scans."
81751|NCT03546686|Drug|Ipilimumab|Patients will receive ipilimumab 1-5 days prior to core biopsy and cryoablation.
81752|NCT03546686|Drug|Nivolumab|Patients will receive nivolumab 1-5 days prior to core biopsy and cryoablation and every 2 weeks post surgery for 3 additional doses
81753|NCT03546686|Procedure|Core Biopsy/Cryoablation|MRI-guided core biopsy and cryoablation 7-10 days prior to surgery.
81754|NCT03546686|Procedure|Breast Surgery|Standard-of-care definitive surgery.
81755|NCT03546673|Behavioral|Self-Regulation Condition|
81756|NCT03546673|Behavioral|Emotional Disclosure Condition|
81757|NCT03546660|Device|SECM capsule|Subjects will swallow a SECM capsule and the SECM imaging will be performed
81758|NCT03546647|Device|Dailies Aqua Comfort Plus Toric|Daily disposable soft toric contact lens
81759|NCT03546647|Device|Dailies Aqua Comfort Plus Sphere|Daily disposable soft spherical contact lens
81760|NCT03546634|Biological|Sabin IPV|We select one Sabin IPV product, produced by China National Biotec Group, which is available for China's National Immunization Program in the selected study sites.
81761|NCT03546621|Drug|Myrcludex B|2 mg, once daily, subcutaneously
81762|NCT03546621|Drug|Myrcludex-B|5 mg, once daily, subcutaneously
81763|NCT03546621|Drug|Myrcludex-B|10 mg, once daily, subcutaneously
81764|NCT03546621|Drug|Tenofovir|tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
81765|NCT03546608|Drug|Tepotinib|Participants will receive a single oral dose of tepotinib in Part 1.
81766|NCT03546595|Other|Auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
81767|NCT03546595|Other|Sham auricular acupoints acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
81768|NCT03546582|Drug|Pembrolizumab|Anti-PD-1 targeted immunotherapy
81769|NCT03546582|Radiation|Stereotactic Body Radiation Therapy (SBRT)|High-precision radiotherapy
81770|NCT03546556|Drug|Fluorothymidine (FLT)|A total of 12 patients who have undergone allogenic bone marrow transplantation will undergo FLT-PET-MRI imaging on two separate occasions. In addition to the 12 allogenic transplant patients, 3 patients undergoing autologous stem cell transplant will also be imaged the same two time points in order to determine how much of the FLT signal observed after allogeneic transplant is unique to that population and the result of allo-antigen driven T cell expansion.
81771|NCT03546543|Procedure|Position change|Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
81772|NCT03546530|Drug|Interferon|Interferon
81773|NCT03546530|Drug|Interferon+resveratrol|Interferon+resveratrol
81774|NCT03546517|Other|Dry Needling|Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
81775|NCT03546517|Other|Sham Dry Needling|Sham Dry needling of biceps brachii, brachialis, flexor digitorum superficialis and flexor digitorum profundus, triceps brachialis, extensor digitorum and adductor pollicis
81776|NCT03546504|Behavioral|Procedure alteration and occupational therapy|Modification of the dental environment and procedures to decrease sensory stimulation. Occupational therapy (8 weeks; 2x/week): sensory desensitization, habit training, social stories around dental visits
81777|NCT03546491|Drug|Preventive Gel|0.4% Stannous Fluoride
81778|NCT03546491|Drug|Marketed Control|0.243% Sodium Fluoride
81779|NCT03546478|Biological|99mTc-ABH2|99mTc-ABH2 were injected into the patients before the SPECT/CT scans
81780|NCT03546465|Drug|ropeginterferon alfa-2b|6 subjects in each cohort will receive a single dose by subcutaneous injection
81781|NCT03546452|Diagnostic Test|in vitro NGS-panel|cell free DNA ,which was purified from hydrothorax, is used to be tested by NGS-panel
81782|NCT03546426|Drug|Pembrolizumab|200 mg IV q3w until disease progression, unacceptable toxicity or informed consent withdrawal, or for a maximum of 2 years
81783|NCT03546426|Biological|Autologous dendritic cells|Autologous dendritic cells (DC) loaded with autologous tumor homogenate, 10 x7 cells ID every 3 weeks for up to six doses
81784|NCT03546426|Drug|Interleukin-2|3 MU s.c. from day +2 to day +6 after each DC administration
81785|NCT03546400|Drug|methylphenidate HCl ERCT|methylphenidate HCl ERCT
81786|NCT03546387|Other|Wechsler Intelligence Scale for Children, Fifth Edition (WISC-V)|the WISC-V assessment produces a Full Scale IQ (FSIQ) used for primary power consideration in this study. The FSIQ is the most comprehensive global ability score on the WISC-V, and it has been conventionally reported and interpreted as an estimation of overall intellectual ability
81787|NCT03546387|Other|California Verbal Learning Test, Children's Version|Used to assess verbal learning and memory in children and adolescents
81788|NCT03546387|Other|Beery Developmental Test of Visual Motor Integration, 6th edition|Helps assess visual-motor skills in children and adults.
81789|NCT03546387|Other|Grooved Pegboard Test|Measures dexterity
81790|NCT03546387|Other|Behavior Assessment System for Children/Parent Report|The Behavior Assessment System for Children/Parent Report is a questionnaire that assesses the social-emotional and behavioral functioning (e.g., anxiety, depression, attention, hyperactivity, adaptability, leadership, social skills, etc.) in children between the ages of 2 and 22 years, and is available in English and Spanish.
81791|NCT03546374|Procedure|Surgical Ablation|In addition to the concomitant surgery, subjects are required to have amputation or closure (with sutures or ligation) of the left atrial appendage.The Cox Maze IV lesion set is required to be performed.
81792|NCT03546374|Device|Cardioblate and Cryoflex hand held devices|The Cardioblate hand held devices consist of the Cardioblate iRF and Cryo surgical ablation devices.
81793|NCT03546361|Genetic|Ad-CCL21-DC 1 x 07|Ad-CCL21-DC dose is 1 x 107
81794|NCT03546361|Genetic|Ad-CCL21-DC 3 x 07|Ad-CCL21-DC dose is 3 x 107
81795|NCT03546361|Genetic|Ad-CCL21-DC .05 x 07|Ad-CCL21-DC dose is .05 x 107
81796|NCT03546361|Drug|Pembrolizumab|intravenous pembrolizumab 200mg one hour after DC injection on days 0, 21, and 42, and intravenous pembrolizumab 200mg every three weeks thereafter for up to a year.
81797|NCT03546361|Genetic|Ad-CCL21-DC ExD|Ad-CCL21-DC dose at determined maximum tolerated dose (MTD) or maximum administered dose (MAD)
81798|NCT03546348|Other|no intervention|only measurement of the carrying angle
81799|NCT03546335|Drug|89Zr-DFO-CZP|89Zr-DFO-Certolizumab pegol (89Zr-DFO-CZP) is a radiopharmaceutical imaging agent that will be produced under CGMP (Current Good Manufacturing Practice) regulations in the Department of Radiology and Biomedical Imaging Radiopharmaceutical Facility at UCSF.
81800|NCT03546322|Other|Registry|Patients who are diagnosed with head and neck cancer and monitored by the Otolaryngology - Head and Neck Surgery clinic at Zuckerberg San Francisco General Hospital and Trauma Center will be included in this group. The intervention is the implementation of a registry, designed to replace existing paper-based systems for tracking patients. All head and neck cancer patients monitored by the clinic will be included.
81801|NCT03546309|Device|RIC group|Patients allocated to the RIC group will undergo RIC procedure during which bilateral arm cuffs are inflated to a pressure of 50 mmHg over systolic blood pressure for five cycles of 5 min followed by 5 min of relaxation of the cuffs.
81802|NCT03546309|Device|sham group|patients allocated to the sham group will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 30 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs.
81803|NCT03546283|Drug|Placebos|The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
81804|NCT03546283|Drug|Cattle Encephalon Glycoside and Ignotin|The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
81805|NCT03546270|Behavioral|Swimming|This group completed 20-weeks of swimming
81806|NCT03546257|Device|magnifying endoscopy with narrow band imaging (ME-NBI)|A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
81807|NCT03546244|Behavioral|musical treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with musical treadmill
81808|NCT03546244|Behavioral|Traditional treadmill|Patients will undergo a 4-week, 2 daily, incremental session of training with traditional treadmill
81809|NCT03546218|Device|Smartphone Application (SPSRS)|"Participants use application on iPhone and watch videos showing positive-word stimuli. This application repeats positive-word stimuli every 5 seconds.~The participants watch 3-minute motion picture displaying positive-word stimuli."
81810|NCT03546218|Device|Smartphone Application (YouTube)|Participants will watch the same motion picture as the experimental group. However, a positive-word stimulus does not appear in the motion picture.
81811|NCT03546205|Drug|JNJ-64565111|All participants will receive a single SC dose of JNJ-64565111 solution on Day 1.
81812|NCT03546192|Biological|Fluzone Quadrivalent Influenza Vaccine|0.5-mL, Intramuscular, SH 2015 formulation
81813|NCT03546179|Diagnostic Test|tidal volume challenge test|Tidal volume (VT) will be increased from 6 to 8 ml/kg of for one minute and hemodynamic variables, including PVI with 8 ml/kg tidal volume ventilation (PVI8) will be recorded. After these two baseline hemodynamic measurements, volume expansion will be performed for 10 min using an infusion of balanced crystalloid solution (6ml/kg of predicted body weight). The same hemodynamic parameters will be measured under ventilation with a VT of 6 ml/kg 5 min after volume loading.The percentage change in SVI according to volume loading will be used as the principal indicator of fluid responsiveness. Responders or non-responders will be determined when the increase in SVI is 10% or <10% after volume loading, respectively. Doses of vasoactive medications and PEEP will be kept constant.
81814|NCT03546166|Drug|Picato 0.05% Topical Gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
81815|NCT03546153|Behavioral|Aerobic exercise program|Exercise program consists of training for 60 minutes, three times per week for 12 weeks. Participants will use a treadmill, Nu stepper/bike or elliptical to exercise.
81816|NCT03546127|Genetic|Next Generation Sequencing (NGS): exome, RNA seq|"Tumor and blood samples will be sequenced at medium-high coverage at the whole genome (exome) and transcriptome levels (RNA Seq). This will allow detecting variants in a larger set of samples even though only from the main clone will be precisely measured. The whole exome will be performed at a mean coverage of at least 60x for the normal DNA samples and 120x for the tumor DNA samples. The transcriptome of the tumor will be performed at enough depth of coverage to detect gene fusions, transcriptome variants and measure the digital expression of already annotated isoforms.~For both sequencing configurations:~Data from each cancer and normal genome will be analysed for the presence of somatic variants.~DNA and RNA sequencing results will be integrated.~Technical replication for the mutations / chromosome alterations / transcript fusions that most likely drive the tumour process will be performed via Target Resequencing of the genomic / coding regions of interest."
81817|NCT03546114|Other|Gender Questionnaire|13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
81818|NCT03546088|Device|fiberoptic naso-tracheal intubation|The trachea will be intubated under direct fiberoptic view after a fiberoptic upper airway examination. The flexible nasolaryngoscope will be armed with an intubating tube and passed inside tracheal lumen trough one of the nostrils.
81819|NCT03546088|Drug|Topical anaesthesia|Topical anaesthesia with lidocaine will be provided through nebulisation and instillation. The intubating tube will be lubricated with a gel containing lidocaine.
81820|NCT03546088|Drug|Light sedation|The patient will be sedated with a combination of midazolam, fentanyl and droperidol administered intravenously in small boluses until the desired level of sedation is achieved as expressed of The Observer's Assessment of Alertness/Sedation Scale (OAA/S) of 3 or 4. The droperidol dose will not exceed 2.5 mg.
81821|NCT03546075|Dietary Supplement|Resveratrol|
81822|NCT03546075|Other|Placebo|
81823|NCT03546062|Other|patients treated by HTx|From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
81824|NCT03546049|Procedure|US-guided percutaneous biliary drainage|"Device: metal stent. The self-expandable metal stent is implanted percutaneously by a transhepatic access route.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed).~Length: 6-10 cm. Diameter: 8-10 mm."
81825|NCT03546049|Procedure|EUS-guided biliary drainage|"Device: metal stent. The transluminal (transgastric, transduodenal or transenteric) implanted self-expandable metal stent is released via echoendoscope.~The metal stent is partially covered or non-covered (in cases in which the gallbladder is not removed) or mixed covered (one half covered, one half non-covered). The mixed covered stent is used for the transhepatic access.~Length: 6-10 cm. Diameter: 8-10 mm."
81826|NCT03546036|Device|Weighted metal chain blanket|Use of a weighted metal chain blanket of 8 kg
81827|NCT03546036|Device|Control plastic chain blanket|A blanket with light plastic chains
81828|NCT03546023|Other|Patient Interview|BPI scores will be asked by the Doctor or the Research Nurse
81829|NCT03546010|Behavioral|Neuropsychological tests|WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test
81830|NCT03546010|Behavioral|Oculometric tests|When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
81831|NCT03545997|Drug|Montelukast 10mg|The capsules will be presented in box of 95 capsules packaged in unit blister
81832|NCT03545997|Drug|Placebo|Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
81833|NCT03545984|Other|Simulation-based learning|Simulation-based teaching involves using done on a mannequin to simulate actual conditions
81834|NCT03545984|Other|interactive problem based learning|Standard teaching (problem based learning discussion) during cardiac/vascular rotation
81835|NCT03545971|Drug|IBI310|IBI310 is anti CTLA-4 antibody
81836|NCT03545971|Drug|Sintilimab|PD-1 monoclonal antibody
81867|NCT03545685|Other|specific memory and attention realtime training|The investigator will conduct a pilot study of 80 APS subjects (age 18-45). The investigator will examine SMART feasibility and user engagement using a randomized control trial research design. Using a simple random method, 40 APS subjects will be randomly assigned to the experimental group to receive add-on SMART intervention for 3 months and 40 APS subjects will just get naturalistic treatment with no SMART intervention. At baseline and 3-month follow-up, subjects will complete questionnaires on app use habits and attitudes towards SMART feasibility and engagement. In-depth interviews will be conducted at both time points to cross-validate the findings obtained from the questionnaires.
136701|NCT03120624|Drug|Technetium Tc-99m Sodium Pertechnetate|Given IV
81837|NCT03545958|Behavioral|High-intensity Interval Training (HIT)|Following the mind-motor training component, participants in the experimental group will then continue in the 45-minute HIT intervention, which will be composed by a 10-minute warm-up, a 25-minute core activity, and a 10-minute cool down. The 25-minute core activity will be carried out based on a 4 x 4 minutes aerobic interval training model. The intensity in each cycle will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
81838|NCT03545958|Behavioral|Moderate-intensity Continuous Training (MCT)|After the mind-motor training component, participants in the comparison/control group will then continue in the 45-min MCT intervention, which will be composed by a 10-minute warm-up a 25-minute moderate-intensity continuous aerobic exercise training, and a 10-minute cool down. The exercise intensity will be prescribed at an individual level, and training heart rates will be determined via a sub-maximal excise testing at baseline and monitored during exercise using a wrist-based heart rate monitor (Suunto). In order to ensure progression in aerobic training over the 6-month intervention, training heart rates will be recalculated at the intervention midpoint (i.e., 3 months), where a new sub-maximal exercise test will be performed. Participants will exercise 60 minutes/day, 3 days/week for 6 months.
81839|NCT03545945|Procedure|Additional office hysteroscopy|Patients in the study arm will undergo diagnostic office hysteroscopy where they look for any underlying polyp, fibroids or uterine anomaly in addition to endometrial biopsy.
81840|NCT03545945|Procedure|Endometrial biopsy|Patients randomized to endometrial biopsy only group will be prepped with betadine solution and local anesthesia in the form of lidocaine gel placed in the external cervical canal and biopsy will be performed using a Pipelle catheter.
81841|NCT03545932|Other|exercise program hydrogymnastics|4 months of practice hydrogymnastics
81842|NCT03545906|Other|TEAM-UP Intervention Group|Children randomly assigned to TEAM-UP will have a telemedicine assisted specialist visit scheduled after 4 weeks of initiating DOT at school, as well as 2 subsequent follow-up visits. The visits will be performed by a specialist in pediatric asthma, to implement guideline-based care. Prescriptions for asthma medications will be prescribed to be delivered as directly observed therapy in school.
81843|NCT03545906|Other|Enhanced Care Comparison|Similar to the TEAM-UP group, children in the Enhanced Care group will receive a symptom assessment and asthma education materials at baseline, and we will contact the PCP by facsimile or email and will recommend DOT of preventive asthma medication through school as well as a referral to specialist. However specialist visits will not be facilitated via telemedicine.
81844|NCT03545893|Drug|Ibuprofen 600 mg|Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
81845|NCT03545893|Drug|OxyCODONE 5 Mg Oral Tablet|Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
81846|NCT03545880|Other|Kinesiotaping|A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling
81847|NCT03545880|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
81848|NCT03545867|Behavioral|Seated control (CON)|Seated rest
81849|NCT03545867|Behavioral|Moderate intensity continuous (MICT)|Arm cycling at a continuous power output
81850|NCT03545867|Behavioral|High intensity interval training (HIIT)|Arm cycling at power outputs that vary between high and low intensity intervals
81851|NCT03545867|Behavioral|Circuit resistance training (CRT)|Alternating between six upper extremity resistance maneuvers interspersed with low-resistance/high-speed arm cycling.
81852|NCT03545867|Other|Liquid Meal|A liquid meal consisting of 600 kcal comprised of 50% carbohydrate, 35% fat, and 15% protein (by kcal).
81853|NCT03545854|Procedure|Erector Spinae Plane Block|Ultrasound guided injection of coloring solution (methylene blue diluted in water) with a 18G echogenic tuohy needle deep to the plane of the erector spinae muscles.
81854|NCT03545841|Other|HIT|Participants completed 6 weeks of HIT
81855|NCT03545841|Other|MICT|Participants completed 6 weeks of MICT
81856|NCT03545828|Diagnostic Test|Multi-channel aEEG monitoring|18 channel aEEG monitoring in comatose TTM-treated patients
81857|NCT03545815|Biological|anti-mesothelin CAR-T cells|Cells will be infused 1 day after the completion of conditioning regimen.
81858|NCT03545802|Behavioral|Home-HIT|Participants completed 6 weeks of home-based high-intensity interval training 3 times per week
81859|NCT03545789|Drug|[18F]MNI-958|Subjects will undergo PET imaging using [18F]MNI-958, a PET radioligand for imaging tau.
81860|NCT03545776|Other|Critical Care EEG Course|"Medical and nursing staff will be given a 10-points EEG face-to-face initial training course followed by an online teaching and educational quizzes at day-1, day-15 and day-30 after initial training. A final evaluation will be performed at day-90 after beginning of the training course.~10-points EEG educational objectives : physiological rhythms, reactivity, symmetry, effects of sedation, burst suppression, paroxysmal activities, periodic / pseudoperiodic activities, rhythmic activities, artifacts, null EEG"
81861|NCT03545763|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
81862|NCT03545737|Other|Measurement|The distances between the midpoint of the thyroid cartilage to suprasternal notch base on body surface measurement add the distance between suprasternal notch to carina of trachea according to chest CT
81863|NCT03545737|Other|Formula|The formula base on patient's height as a guide for the intubation of a Left-sided Double-lumen tube
81864|NCT03545724|Device|Neofitoroid®|NeoFitoroid® forms a protective barrier mucosa and on perianal region that can aid the physiological process of healing.
81865|NCT03545711|Drug|Anlotinib Hydrochloride with Irinotecan|Dose escalation of anlotinib starts from 8mg qd d1-14/q21d in combination with fixed dose of irinotecan at 180mg/m2 d1/q14d.
81866|NCT03545698|Other|Avizia Telehealth Platform|Avizia will be utilized as a communication tool between home-based caregivers (family members, formal caregivers, or informal caregivers) and the House Calls care management team.
81911|NCT03545399|Dietary Supplement|Placebo|The dose was taken with a glass of water during the evening meal once daily
81868|NCT03545672|Diagnostic Test|CMR examination|After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on in order to detect the cardiac impairment.
81869|NCT03545659|Other|Mode of relapse detection|Mode of relapse detection: whether the relapse was diagnosed because of symptoms of leukaemia or diagnosed at a routine visit in the outpatient clinic.
81870|NCT03545646|Device|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
81871|NCT03545633|Device|Treatment with High Intensity Focused ElectroMagnetic system.|"The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area.~Visible contractions will be induced by the device."
81872|NCT03545620|Device|rescue technique|which rescue technique will be preferred while established/predicted difficult airway/intubation occurs in the operation room after failed direct laryngoscopy
81873|NCT03545607|Biological|MultiStem|single intravenous infusion 18-36 hours after stroke
81874|NCT03545607|Biological|Placebo|single intravenous infusion 18-36 hours after stroke
81875|NCT03545594|Other|Patient-centered in home rehabilitation|Eight contacts (six in-home visits of 1-2 hours duration each and two telephone contacts) delivered over a 4-month period in three phases
81876|NCT03545594|Other|Control|Usual follow-up in the municipality
81877|NCT03545581|Other|Experimental diet Fru rich diet|7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
81878|NCT03545581|Other|Experimental low Fru diet|7 days (day 1 to day 7) with low-fructose diet (<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
81879|NCT03545568|Other|Neu5Ac supplementation|Sialic acid as N-Acetyl-neuraminic acid dehydrate (Neu5Ac) 150 mg/kg/d (max 12g/d) in three doses orally in subjects with NANS deficiency compared to controls
81880|NCT03545555|Dietary Supplement|"Kale Preparation Kale Powder"|Effect of kale preparation kale powder on lipid status
81881|NCT03545555|Dietary Supplement|"Kale Preparation Kale Extract"|Effect of kale preparation kale extract on lipid status
81882|NCT03545555|Dietary Supplement|"Kale Preparation Flavonoid Extract"|Effect of kale preparation flavonoid extract on lipid status
81883|NCT03545555|Dietary Supplement|Placebo|Effect of placebo on lipid status
81884|NCT03545542|Diagnostic Test|Initial fecal microbiome|Stool sampling for fecal microbiome analysis by 16S rDNA pyrosequencing. Neuroblastoma group and Control group.
81885|NCT03545542|Diagnostic Test|Initial fecal volatile organic compounds|Volatile organic compound analysis of stool samples by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
81886|NCT03545542|Diagnostic Test|Initial breath volatile organic compounds|Breath sampling for organic compound analysis by gas chromatography/mass spectroscopy Neuroblastoma group and Control group.
81887|NCT03545542|Diagnostic Test|Microbiome under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
81888|NCT03545542|Diagnostic Test|Fecal volatile organic compounds under chemotherapy|"Stool sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
81889|NCT03545542|Diagnostic Test|Breath volatile organic compounds under chemotherapy|"Breath sampling under chemotherapy of children in neuroblastoma group (1 sample 1 week after completion of each chemotherapy cycle). Chemotherapy according to SIOPEN guidelines.~Neuroblastoma group"
81890|NCT03545542|Diagnostic Test|Final microbiome|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
81891|NCT03545542|Diagnostic Test|Final fecal volatile organic compounds|Stool sampling 3 weeks after completion of chemotherapy Neuroblastoma group
81892|NCT03545542|Diagnostic Test|Final breath volatile organic compounds|Breath sampling 3 weeks after completion of chemotherapy Neuroblastoma group
81893|NCT03545529|Other|Innovativ supported|addition of connected tools and stronger accompaniment to prevent falls
81894|NCT03545516|Drug|Bupivacaine|Injection of bupivacaine into the surgical incision prior to its closure.
81895|NCT03545516|Drug|Dexmedetomidine|Injection of dexmedetomidine ( an adjuvant) into the surgical incision prior to its closure.
81896|NCT03545516|Drug|Placebo|Injection of a placebo into the surgical wound
81897|NCT03545503|Drug|Etomidate|Etomidate will be administered as the sedative for RSI on even days
81898|NCT03545503|Drug|Ketamine|Ketamine will be administered as the sedative for RSI on odd days
81899|NCT03545490|Other|Ensure|Ensure(Supplement) +Nutrition education Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
81900|NCT03545477|Other|Novel locomotion treatment: curved-walking training|"Each training session is comprehensive of a 30-minute walking training on curved trajectory (S trajectory composed by two semicircle with a radius of 1.2 m)"
81901|NCT03545477|Other|Standard locomotion treatment: straight-walking training|It consists of 30 minutes of locomotion training on straight trajectories, as typically proposed during traditional gait rehabilitation
81902|NCT03545477|Other|Standard physical therapy|It consists of 60 minutes of stretching, muscular conditioning and coordination,postural exercises for trunk control, standing, functional exercies and upper limb rehabilitation, customized on patient's need.
81903|NCT03545464|Drug|Placebo Oral Tablet|Placebo of cortancyl Oral Tablet 20mg
81904|NCT03545464|Drug|Cortancyl Oral Tablet|Cortancyl oral Tablet 20 mg
81905|NCT03545464|Drug|Levocetirizine Oral Tablet|Levocetirizine Oral Tablet 5 mg
81906|NCT03545451|Device|Videogames|Videogames
81907|NCT03545438|Biological|LIB003|LIB003 or placebo
81908|NCT03545425|Procedure|Biofluid samplings|Blood and Urine
81909|NCT03545412|Device|Microfocused ultrasound with visualization|Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
81910|NCT03545399|Dietary Supplement|Ulva Lactuca|The dose was taken with a glass of water during the evening meal once daily
81917|NCT03545347|Drug|Nandrolone Decanoate|Injections every 3 weeks, last injection at week 12. Women 50 mg, men with total testosterone ≥ 11 nmol/l will receive 100 mg, and men with total testosterone < 11 nmol/l will receive a dose of 200 mg.
81918|NCT03545347|Dietary Supplement|Protein-rich nutritional supplement|The protein-rich nutritional supplement is a liquid containing 18 g milk-based protein pr bottle. Patients will receive a minimum of 1.35 g/kg bodyweight/day); which means that most patients will receive 2 bottles per day for 12 weeks.
81919|NCT03545347|Other|Physical therapy|The physical therapy intervention will include progressive strength training initiated daily on weekdays during hospitalization and continued twice per week in the outpatient rehabilitation program in the municipality (treatment as usual but with strength training as an obligatory component) for a total intervention period of 12 weeks from time of inclusion.
81920|NCT03545347|Drug|Sodium Chloride 9mg/ml Injection|Placebo injection of 1 ml Sodium Chloride
81921|NCT03545334|Diagnostic Test|Visionsense™ VS3 - Stereoscopic High Definition Visualisation System (VS3-3DHD)|Injection of ICG intradermally around the scar of the primary excision of the tumour and transcutaneous assessment of fluorescence with the VS3-3DHD camera (Visionsense™ VS3 - Stereoscopic High Definition Visualisation System ).
81922|NCT03545321|Behavioral|MOON+|MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
81923|NCT03545308|Drug|Rocuronium|Dose: 1 mg/kg
81924|NCT03545295|Procedure|Quadratus Lumborum Block type 2|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, posterior to the Quadratus Lumborum muscle
81925|NCT03545295|Procedure|Quadratus Lumborum Block type 3|Ultrasound guided injection of coloring solution using a 18g Tuohy echogenic needle, anterior to the Quadratus Lumborum muscle
81926|NCT03545282|Behavioral|Amigas Latinas Motivando el Alma (ALMA)|In a series of 8 weekly sessions, the program uses a group format to teach and encourage women to use coping strategies to reduce depression and anxiety. Over the course of the eight ALMA sessions, 25 women are (1) engaged in activities to identify coping strategies they are currently using and encouraged to continue to use them; (2) introduced to new coping strategies (e.g. mindfulness techniques, increased social ties and social support); and, (3) provided resources for seeking additional help if needed.
81927|NCT03545269|Drug|CartiLife®|CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted the volume of 1 cm3 per the capacity of the syringe to the affected area through injection with fibrin adhesive through minimal arthrotomy.
81928|NCT03545269|Procedure|Microfracture|The surgery is performed by arthroscopy, after the joint is cleaned of calcified cartilage. Through use of an awl, the surgeon creates tiny fractures in the subchondral bone plate.
81929|NCT03545256|Procedure|outpatient surgery for T1-N0 or T2-N0 cancers of the oral cavity or oropharynx with lymph node search|"The surgical procedure associated with the sentinel lymph node technique is carried out in two stages:~- Lymphoscintigraphy at Day-1 : This is the identification of the lymphatic network of the patient by a prior injection of radioactive tracer, nanocolloids labeled with technetium99, around the primary tumor. A planar CT image acquisition is performed to identify the sentinel lymph nodes (Gs(s)) which are then marked on the skin with an indelible marker.~Surgery on D0:~The patient is admitted to the hospital at 7:00 am in outpatient unit. He is reviewed by the anesthetist before the intervention and is transferred to the operating room for the intervention under AG.~The main tumor is operated by mouth."
81930|NCT03545243|Drug|Pantoprazole 40mg|Peroral Pantoprazole 40mg twice daily during 28 days
81931|NCT03545230|Procedure|":Four Not Techniques"|":Four Not Techniques~Not enter posteriorly~Not too much dissection the muscle around the lateral condyle during surgery~Not perfect anatomical reduction~Not using bone graft."
81932|NCT03545217|Behavioral|Lifestyle Intervention|a 6-month intensive lifestyle intervention program led by a multidisciplinary team of diabetes nurses and dieticians, and a follow up at 12 months for these participants. This will be a group-based activity adapted from the Diabetes Prevention Program -Thailand project
81933|NCT03545204|Other|Kangaroo Mother Care|Facility-based KMC and Community-based KMC
81934|NCT03545204|Other|Routine Standard Care|Facility-based KMC and Routine Standard Care
81935|NCT03545191|Drug|ACT-541468|Administered orally as tablets.
81936|NCT03545191|Other|Placebo|Administered orally as tablets.
81937|NCT03545178|Behavioral|glucose control (Substudy A)|Comparison of glucose values during days 0 - 3 with days 4 - 28 and 0 - 7 with days 8 - 28 before a medical consultation at the diabetes clinic in patients suffering from diabetes and wearing a continuous glucose monitoring and/or flash glucose monitoring device
81938|NCT03545178|Diagnostic Test|hypoglycemia prediction (Substudy B)|Use of CGM/FGM data to develop and evaluate a neural network based hypoglycemia prediction model
81939|NCT03545165|Drug|177Lu−PSMA−617|[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)]
81940|NCT03545165|Drug|177Lu−J591|[1.35 GBq/m2 or 36.5 mCi/m2]
81941|NCT03545165|Drug|68Ga−PSMA−HBED−CC|[185 ±74MBq or 5 ±2 mCi]
81942|NCT03545152|Behavioral|Exercise|"Prescription exercise: frequency, intensity, type, time, and progression (FITT-PRO).~150 min/week (the intensity will be moderate). exercise routine: warming up, resistance training and aerobic exercise training(range of motion and flexibility exercises)"
81943|NCT03545152|Behavioral|Cognitive training|Cognitive training intervention consisted of 12 weekly sessions, lasting 60-90 minutes in groups of 5-8 participants, and 3 monthly boost sessions (to review the strategies and practice solving problems as well). The main strategy was to use cognitive rehabilitation strategies to promote generalization in this process to improve memory and behavior.
81944|NCT03545152|Behavioral|New life-style|Combination of exercise and cognitive interventions
81945|NCT03545139|Biological|NeoMTA nusmile|A new formulation of MTA was developed in which bismuth oxide was omitted.
81946|NCT03545139|Biological|White MTA|Revascularization with Conventional white mineral trioxide aggregate as coronal plug.
81947|NCT03545126|Other|13C6 Leucine|Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)
136702|NCT03120624|Biological|VSV-hIFNbeta-NIS|Given IV
81951|NCT03545100|Other|regular physical therapy|transcutaneous electrical nerve stimulation(TENS), shoulder joint ROM, scapular muscle PRE
81952|NCT03545087|Drug|Lanabecestat|Administered orally
81953|NCT03545087|Drug|Iohexol|Administered intravenously. Administration is at investigator's discretion in participants with severe renal impairment.
81954|NCT03545074|Behavioral|Mindful Awareness Practices- English|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in English)
81955|NCT03545074|Behavioral|Mindful Awareness Practices- Spanish|The 6-week intervention aimed at teaching mindfulness-based strategies to participants (in Spanish)
81956|NCT03545074|Behavioral|Health Education - English|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in English)
81957|NCT03545074|Behavioral|Health Education - Spanish|The health education condition is a weekly 2-hour, 6 session course aimed at knowledge acquisition in subjects related to health care in general (in Spanish)
81958|NCT03545048|Other|Internet based exercises|Exercises for knee OA (online- digital health)
81959|NCT03545035|Drug|idelalisib and rituximab|patients with treatment-naïve chronic lymphocytic leukemia (CLL) with TP53 disruption (i.e. 17p- or TP53 mutations) or relapsed/refractory CLL who were treated with idelalisib and rituximab
81960|NCT03545022|Procedure|Acupuncture|"The application of acupuncture was performed in four sessions, 30 minutes prior to surgery, 24, 48 and 72 hours following the surgery, before variables measurements. The points were manually stimulated and the needles were inserted up to 4mm. There were 11 points, applied bilaterally, two of them, point VG20 and Yintang, for anxiety control, only at the preoperative time and not bilateral. The points to reduce pain, edema, and trismus were IG4 (Hegu), F3 (Taichong) and E44 (Neiting), TA21 (Ermen), ID19 (Ting-Kong), E6 (Jiagle) and E7 (Towei) , point B60 (Kunlum) and VB34 (Yanglingquan). All patients received the same treatment in all sessions.~After the needle devices were inserted, the needles were re-stimulated manually once after 10 minutes and removed after more 10 minutes."
81961|NCT03545009|Dietary Supplement|Sodium Nitrate|70ml sodium nitrate, matched for nitrate concentration in Beetroot Juice arm
81962|NCT03545009|Dietary Supplement|Beetroot Juice no Nitrate|70ml Concentrated Beetroot Juice with nitrate removed
81963|NCT03545009|Dietary Supplement|Beetroot Juice|70ml Concentrated Beetroot Juice
81964|NCT03544996|Combination Product|TD Insulin|Human Insulin USP formulated in a solution capable of transdermal delivery.
81965|NCT03544983|Behavioral|Web + Streamlined Telephone Genetic Counseling|Tailored and interactive web-based education designed to incorporate all aspects of standard genetic counseling followed by a streamlined genetic counseling session with a board-certified genetic counselor.
81966|NCT03544944|Drug|TJP-008-1|Subjects who are randomized into group TJP-008-1 will receive bowel preparation on the same-day.
81967|NCT03544944|Drug|TJP-008-2|Subjects who are randomized into group TJP-008-2 will receive bowel preparation from evening to next morning.
81968|NCT03544944|Drug|Coolprep powder|Subjects who are randomized into group Coolprep will receive bowel preparation from evening to next morning.
81969|NCT03544931|Procedure|Root Instrumentation|Instrumentation of the root surface in order to achieve debridement
81970|NCT03544931|Device|EMD Application|Application of Enamel Matrix Derivatives on the root surface after debridement in sites with probing depth deeper than 5 mm
81971|NCT03544905|Drug|CYH33 for tablet|1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
81972|NCT03544892|Other|Low carbohydrate diet|60-80 g total carbohydrate per day
81973|NCT03544892|Other|Standard of care diet|> 150 g total carbohydrate per day
81974|NCT03544879|Behavioral|Yoga Intervention|The 60-minute yoga sessions began with a brief breathing practice led by the instructor. The yoga instructor then led students through yoga poses at a gentle pace using chairs as props as needed. The pace of the class increased slowly over time as students became more familiar and more capable with the poses. Meditation and breathing was followed by chair poses (15-20 minutes), standing poses (10-15 minutes), floor poses (15 minutes), and lastly a supine resting pose (Savasana; 10 minutes). In the Silver Age Yoga method at that time, there were 73 available postures overall including: 35 Chair Postures, 18 Standing Postures, 20 Floor Postures, with a typical class covering 20-25 poses.
81975|NCT03544879|Behavioral|Healthy Aging Education|The health education comparison intervention consisted of once weekly, 90-minute health information workshops conducted in group format. The 90-minute sessions generally consisted of a 60-minute lecture followed by 30 minutes of questions and discussion. The lecture titles for Weeks 1-10 were as follows: Introduction/ Exploring Communication, The Science of Successful Aging, Acupuncture 101: How it Works & What it is Good for, Quality of Life/Quality of Well Being, Fighting Cancer With Your Fork, Forgiveness via Shakespeare's: A Winter's Tale, Better Eyesight in Minutes a Day, Brain Fitness, The Importance of Organic Foods/ Organic Gardening, How Dementia Can Be Modified. Lectures were provided by a mix of credentialed experts (physicians/psychologists, etc) and other clinicians. Instructors were asked not to talk about yoga or medication in their lectures. Content was not otherwise closely monitored.
81976|NCT03544853|Device|Prosthetic socket for transtibial amputee|To wear a prosthetic socket for evaluation of comfort and biomechanical metrics such as skin loading conditions.
81977|NCT03544840|Other|Physical Therapy Home Program|On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
81978|NCT03544827|Drug|Atropine|Atropine 0.01% then atropine 0.1%
81979|NCT03544827|Drug|Atropine|Atropine 0.1% then atropine 0.01%
82014|NCT03544515|Procedure|Scaling|Scaling and debridement of the implant surface with hand scalers and curettes and an ultrasonic scaling unit (Cavitron -Dentsply Sirona)
81980|NCT03544814|Drug|icotinib combined with pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day) combined with Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with icotinib every four weeks.
81981|NCT03544814|Drug|first icotinib and then pemetrexed plus cisplatin|Continued using the icotinib (125 mg/time, 3 times/day every day)) alone until the investigator judged that continuation was adiaphorous, and switched to Pemetrexed (500 mg/㎡ on day 1) plus cisplatin (75mg/m2 on day 1) alone, repeat every four weeks for up to six cycles and then continue to receive pemetrexed every four weeks.
81982|NCT03544788|Device|Cirvo™ Therapy|The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
81983|NCT03544775|Procedure|Isolated General Anesthesia|No nerve block identified through physician billing codes
81984|NCT03544775|Procedure|Peripheral Nerve Block|Nerve block identified through physician billing codes
81985|NCT03544762|Drug|18F-FES PET|18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
81986|NCT03544749|Device|Ambu® AuraGain™|After induction of anesthesia, Ambu® AuraGain™ will be inserted for the mechanical ventilation.
81987|NCT03544749|Device|I-gel|After induction of anesthesia, I-gel will be inserted for the mechanical ventilation.
81988|NCT03544736|Drug|Nivolumab|Experimental: Nivolumab
81989|NCT03544736|Radiation|Radiotherapy|Radiotherapy
81990|NCT03544736|Drug|Chemotherapy|Chemotherapy
81991|NCT03544736|Procedure|Surgery|Surgery
81992|NCT03544723|Drug|Ad-P53|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
81993|NCT03544710|Other|preoperative bathing with antiseptic|"Preoperative bathing with antiseptic was done as follows; Given warm water and a tablet soap containing chloroxylenol antiseptic.~Asked to bathe under supervision for standardization. Given a clean theatre gown to put on. Taken through the routine pre-operative preparation procedures which involved; Putting an intravenous cannula; administering prophylactic antibiotics. Administering intravenous normal saline 1 liter. taking off a blood sample (3mls) for blood grouping and cross matching. Putting urethral catheter for drainage of urine, Getting an informed consent from the client for the procedure to be done. Informing the theatre team."
81994|NCT03544697|Procedure|Skin expansion and repair with flaps|
81995|NCT03544684|Behavioral|Effects of the type of exercise on blood glucose concentrations|glucose concentrations were assessed over the 24 hour periods following no exercise, a single bout of high intensity interval training and a single bout of moderate intensity continuous training
81996|NCT03544671|Dietary Supplement|Vitamin D|
81997|NCT03544658|Procedure|Dental prophylaxis|Professional dental prophylaxis including dental scaling and dental polishing with prophylactic paste
81998|NCT03544658|Procedure|Tooth color assessment by the participant|Tooth color assessment using the VITA Classical shade guide. Assessment will be done with normal light conditions and with a light correcting device
81999|NCT03544658|Procedure|Tooth color assessment by the investigator|Tooth color assessment using the VITA Classical shade guide and the VITA Toothguide 3D Master. Assessment will be done with normal light conditions and with a light correcting device
82000|NCT03544658|Procedure|Tooth color assessment with SpectroShade|Tooth color assessment using SpectroShade (dental spectrophotometer). Color will be registered in VITA Classical and VITA Toothguide 3D Master and CIELab parameters
82001|NCT03544645|Other|"Audiovisual material video"|an educational video which has content of knowledge, attitude, behavior, and barriers towards insulin therapy.
82002|NCT03544645|Other|"Printed material brochure"|an educational brochure which has content of knowledge, attitude, behavior, and barriers towards insulin theray.
82003|NCT03544632|Drug|Acellular Adipose Tissue (AAT)|"Participants (n=15) will be administered between 5cc and 20cc of AAT, depending on their assigned treatment group, via sterile subcutaneous injection into the target defect. The injection is intended to be permanent. After the 3-month study follow-up visit, participants will have the option to undergo additional AAT injection (up to 20cc per treatment) in order to fully correct the defect. Total injected AAT volume per patient will not exceed 40cc. Additional injection is dependent upon study- and patient-specific adverse / unanticipated events to date.~Each vial contains a 2 milliliter (mL) dose of the injectable AAT. This volume is similar to other commonly used injectable filler materials intended for soft tissue correction."
82004|NCT03544619|Other|Neuropathic Pain Symptom Inventory|Investigators will use the Neuropathic Pain Symptom Inventory for assessing neuropathic symptoms
82005|NCT03544606|Drug|isosorbide mononitrate|isosorbide mononitrate group (study group) 70 patients are induced by Intra vaginal isosorbide mono nitrate at 36, 24 , 12 before induction
82006|NCT03544606|Drug|Placebos|70 patients induced by placebo (pyridoxine) administered in the posterior vaginal fornix.
82007|NCT03544593|Device|Revolve System|Fat grafting system
82008|NCT03544580|Procedure|immediate implant with dentine chips|Using dentin chips
82009|NCT03544580|Procedure|conventional immediate implant|using xenograft
82010|NCT03544567|Drug|Oraxol|oral paclitaxel will be supplied in capsules and oral HM30181A-US in tablets
82011|NCT03544554|Behavioral|a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model. Within the scope of the counseling and training program|The intervention group was provided with a counseling and training program that consisted of a 45-minute presentation based on Pender's Health Promotion Model.
82012|NCT03544528|Procedure|Regeneration|Apical bleeding will be induced by passing a hand instrument beyond the apical foramen to allow blood filling in the canal. Mineral trioxide aggregate will be placed directly over the coagulated blood clot.
82013|NCT03544515|Device|Er,Cr:YSGG laser|Application of Er,Cr:YSGG in peri-implantitis cases as a coadjutant has shown reduction in the pocket depths and bleeding on probing
82015|NCT03544515|Device|Inactive Er,Cr:YSGG|Er,Cr:YSGG laser (inactive form - sham procedure) applied to the surface of the implant
82016|NCT03544502|Device|CD player|CD player opened during anesthesia induction and continued until postoperative 15 minute
82017|NCT03544502|Device|CEL-480 Sound Level Meter Sonometre|Noise level recordings were performed using CEL-480 Sound Level Meter Sonometre.
82018|NCT03544502|Device|Earplug|the independent anesthesiologist placed earplug into the patients' ears during anesthesia induction and the ear plug were removed immediately before tracheal tube extubation.
82019|NCT03544502|Procedure|Ambient operating room noise|patients were exposed to the ambient operating room noise.
82020|NCT03544489|Behavioral|E-ICD Intervention|Home walking 3 days/week x 12 weeks
82021|NCT03544476|Behavioral|Mobile phone TB treatment support app plus usual care|The behavioral intervention is delivered through a mobile phone TB support app. The functions allow the participant to: self-report daily administration of their TB medication, self-report side effects if applicable, review educational material on TB disease and its treatment, complete a treatment adherence monitoring test (urine drug metabolite test), take notes, and review their treatment progress/report. The drug metabolite test will require that the participant place a small amount of urine on the end of the paper strip, wait for results, and take a picture of the paper using the app. The purpose of this test is to confirm that medication was correctly taken within the past 24 hours.
82022|NCT03544476|Other|Usual care|Usual care consists of outpatient treatment management from the time of diagnosis (unless symptoms are severe and hospitalization is recommended), routine clinical and laboratory tests, and follow-up appointments determined by the clinician. In general, patients receive 1-2 month's supply of medication and are asked to return monthly for follow-up.
82023|NCT03544463|Device|iNAP® Sleep Therapy System|The iNAP® provides a pressure gradient within the oral cavity, which pulls the tongue toward the upper palate and pulls the soft palate forward in a way that enhances the patency of the upper airway near the pharynx so that upper airway patency can be maintained to prevent sleep-disordered breathing.
82024|NCT03544450|Behavioral|Psychosocial counselling|"Individuals with psychological distress receive psychosocial counselling and enhanced usual care. The psychosocial the counselling process consists of: (i) introduction, explanation and rapport building; (ii) assessment of and understanding of the problem (including looking for positive assets); (iii) goal setting (asking the client what outcomes are preferred); (iv) problem management (exploring and identifying solutions, brainstorming, working with existing coping strategies, using social and cultural resources, and additional techniques such as relaxation and psycho-education); (v) implementation (making a plan of action and transition); and, finally, (vi) termination of counselling (including closing and follow-up). Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support)."
82025|NCT03544450|Other|Enhanced Usual Care|Enhanced usual care is provided by health workers, who have already been trained on diagnosis and treatment of common mental disorders, and usage of basic psychosocial counseling skills (communication, listening and basic emotional support).
82026|NCT03544437|Procedure|extraperitoneal laparoscopic extended retroperitoneal lymph node dissection|"All patients underwent extraperitoneal laparoscopic RNU with bladder cuff excision with concomitant extended RPLND performed by one of two urology surgeons at Renji Hospital.~The anatomical boundaries of the lymph node dissection were deﬁned by the ipsilateral side of UUT-UC. In patients with right-sided UUT-UC, the template of dissection consisted of (i) right perihilar lymph nodes, (ii) paracaval lymph nodes, (iii) interaortocaval lymph nodes and (iv) right pelvic lymph nodes (common, external and obturator lymph nodes).~In patients with left-sided UUT-UC, the template of dissection included (i) left perihilar lymph nodes, (ii) para-aortic lymph nodes, and (iii) left pelvic lymph nodes (common, external and obturator lymph nodes ). Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
82027|NCT03544424|Other|No intervention|No intervention
82028|NCT03544411|Biological|olive oil|the intervention consist of 15 ml / day of olive oil
82029|NCT03544411|Biological|bran oil|the intervention consist of 15 ml / day of bran oil
82030|NCT03544398|Other|robot assisted gait training|we use two types of robot assisted gait training and we will compare two groups.
82031|NCT03544385|Drug|Ringers Solution|Treatment vs Placebo
82032|NCT03544385|Drug|Placebo - Concentrate|treatment vs placebo
82033|NCT03544372|Other|Assessment of Concussion History using NIH Concussion History Tool|NIH concussion tool
82034|NCT03544359|Device|Transcranial electrical stimulation (tES)|"In tES, a mild electrical current is passed between two or more electrodes placed on the volunteer's head (scalp). In this study, a mild unvarying (constant) electrical 2mA current is passed between two rubber electrodes placed on the head over auditory cortex for 20 minutes per session for 5 consecutive days. Because the electrical current direction (positive/negative) and current amplitude (2mA) does not vary or change during stimulation, this type of tES is also called transcranial direct current stimulation, or tDCS."
82035|NCT03544346|Other|Exploratory brain and general health assessment|Exploratory brain and general health assessment
82036|NCT03544333|Device|transcranial magnetic stimulation|We will assess safety and efficacy of the following protocol: 1Hz of rTMS over the Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al., 1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
82037|NCT03544320|Device|Activity Monitoring-Wrist worn wearable|Participants wear an activity monitor on their wrist.
82038|NCT03544320|Device|Activity Monitoring-Waist-worn wearable|Participants wear an activity monitor on their waist.
82039|NCT03544307|Behavioral|Taekwondo training|Exercise group
82040|NCT03544294|Device|Xience alpine, ultimaster, resolute onyx, synergy|PCI will be performed
82041|NCT03544281|Drug|GSK2857916|Selected doses and schedules of GSK2857916, will be administered as infusion during Part 1 and Part 2, in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone respectively.
82042|NCT03544281|Drug|Lenalidomide|Lenalidomide will be administered as 25 or 10 mg, orally, with GSK2857916 and dexamethasone, during Part 1 and Part 2.
82043|NCT03544281|Drug|Dexamethasone|Dexamethasone will be administered as 20 or 40 mg, orally with GSK2857916, and lenalidomide or bortezomib, during Part 1 and Part 2 respectively.
82044|NCT03544281|Drug|Bortezomib|Bortezomib will be administered as 1.3 mg/m^2, as SC or IV, with GSK2857916 and dexamethasone, during Part 1 and Part 2 respectively.
82045|NCT03544281|Drug|GSK2857916|Selected dose levels and schedules of GSK2857916, will be administered in Part 2, as an infusion. It will be given with lenalidomide and dexamethasone, or with bortezomib and dexamethasone, during Part 2.
82046|NCT03544268|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes."
82047|NCT03544268|Drug|Definity|Baseline B-mode US will be performed to confirm the lesions being imaged (unless it is a subject with no lesions, then a basic B-mode US will be performed). Perflutren is a diagnostic drug that is intended to be used for contrast enhancement. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic solution which is activated by mechanical agitation with Vialmix®.It will be dispensed in inactivated form to a study team member. The contrast agent will be activated just prior to administration (ideally to be used within 5 minutes of activation). Contrast agent Definity will be activated according to package insert instructions, including use of VialMix®, the device used to activate Definity. Administration will occur IV in coordination with staff trained specifically in contrast ultrasound imaging.The total imaging time is anticipated to be less than 30 minutes.
82048|NCT03544255|Procedure|Biopsy|Two extra EUS-FNA guided pancreatic biopsies collected for only research purposes.
82049|NCT03544242|Other|Control|A saline infusion will be administered during the pre-isolation and post-isolation phases.
82050|NCT03544242|Drug|Pre-Isolation Infusion|A nitrite infusion will be administered during the pre-isolation phase and a saline infusion will be administered during the post-isolation phase.
82051|NCT03544242|Drug|Post-Isolation Infusion|A saline infusion will be administered during the pre-isolation phase and a nitrite infusion will be administered during the reperfusion phase.
82052|NCT03544229|Drug|TAK-906 Maleate|TAK-906 Maleate Capsules
82053|NCT03544229|Drug|TAK-906 Maleate Placebo|TAK-906 Maleate placebo-matching capsules
82054|NCT03544216|Device|Multifocal Contact Lens|The multifocal contact lens (Bausch + Lomb ULTRA® for Presbyopia) will be worn for two weeks
82055|NCT03544216|Device|Single Vision Contact Lens|The single vision contact lens (Bausch + Lomb ULTRA®) will be worn for two weeks
82056|NCT03544177|Other|BFR-Walking|Participants will perform 12 training sessions over 6 weeks, including a 10-minute warm up and cool down period. Patients will perform 5 six-minute bouts of over ground intermittent walking exercise (1-minute walk/rest) with their habitual walking device at a prescribed speed maintained by a metronome, starting from 60 steps/minute. A fixed resting period of 3 minutes will follow each walking bout. During walking, participants will wear BFR bands at both tights. Before every walking bout, the bands will be tightened at a low intensity (max 40% of blood systolic pressure) and untied at the end of every walking bout when patients will be asked to grade their RPE (Borg Scale). Walking speed will be weekly increased by 3 steps/minute, if the previous level was well-tolerated by the patient.
82057|NCT03544177|Other|Conventional therapy|Participants will perform 12 training sessions over 6 weeks. Patients will perform assisted over-ground walking for a total of around 40 minutes, inserted between a 10-minute warm-up and cool-down period. The patient will be encouraged by the same experienced physiotherapist to walk back and forth on 50-meter indoor flat corridor with their habitual walking device. Patient will be asked to walk without stopping until reaching an effort corresponding to a value of 8 out of 10 of the rating of perceived exertion (Borg scale). When the exertion level is reached, the patients will be allowed to rest sitting on a chair if necessary; after a suitable rest period, when patients express sufficient desire to start again, the training will restart
82058|NCT03544164|Other|Manual Ventilation|Manual ventilation via endotracheal tube using adult manual resuscitation device
82059|NCT03544151|Device|Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)|Swan-Ganz CCOmbo V insertion
82060|NCT03544138|Device|Hummingbird Tympanostomy Tube System (H-TTS)|The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
82061|NCT03544125|Biological|Durvalumab|Given IV
82062|NCT03544125|Drug|Olaparib|Given PO
82063|NCT03544112|Behavioral|Employ a multifaceted approach to facilitate clinical protocol implementation|Implementation will include developing clinical protocols containing core components of the intervention to which fidelity is expected, along with aspects that may be adapted by local sites to aid implementation. In partnership with multidisciplinary teams at each site, we will adapt clinical practices from other contexts and available information about SL-BUP and XR-BUP to site-specific clinical protocols and implementation strategies. The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
82064|NCT03544112|Drug|Initiate BUP (SL-BUP or XR-BUP) in the ED|The study implementation facilitators will assist local champions to identify potential treatment providers and draw on existing resources for training and ongoing support.
82065|NCT03544099|Drug|Pembrolizumab|Pembrolizumab 200mg Intravenous Solution
82066|NCT03544073|Drug|Saline Solution for Injection|Placebo arm will receive a saline injection
82067|NCT03544073|Drug|Leuprolide Acetate|Treatment arm will receive a Leuprolide injection
82068|NCT03544060|Drug|Volanesorsen|Volanesorsen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.
82069|NCT03544047|Drug|Paclitaxel|Patient was first treated with paclitaxel (PTX) chemotherapy 3 cycles (2 weeks regimen). If the tumor continues to reduce in the first 3 cycles, continue paclitaxel chemotherapy for 3 cycles (6 weeks).
82120|NCT03543644|Other|Non-nutritive sweetened beverages (NSB)|NSBs will be provided to each participant. Participants will be be given the NSB equivalent to the usual SSB chosen from the list in the protocol. They will be instructed to replace their usual SSBs with the NSBs while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
137451|NCT03115112|Drug|Sitagliptin|100 mg, tablet
82070|NCT03544034|Behavioral|HomeTeam Toolkit|"A multi-component intervention (8S's)~Safety at home through partnership.~Safety risk assessment at the admission~Safety agenda setting for coordinating efforts among professionals to prepare patient/ family for self-management~Safety tools. Cognitive tools to support patient/family after discharge~Safety education. Enhanced Patient/ family medication safety education~Safety briefings with patient/family A mechanism to proactively address common and patient/family specific risks.~Safety through learning routines across the care continuum~Safety assessment after discharge"
82071|NCT03544021|Biological|CART-19 cells|CD19-Targeted CAR-T cells are infused to patient received FC chemotherapy
82072|NCT03544008|Other|The use of AXIOS in Endoscopic transmural drainage|
82073|NCT03543982|Dietary Supplement|Oral probiotic product|Once per day (QD), 28 days
82074|NCT03543969|Drug|Vemurafenib|Vemurafenib will be dosed at 960 mg by mouth (PO) twice a day (BID).
82075|NCT03543969|Drug|Cobimetinib|Cobimetinib will be dosed at 60 mg daily.
82076|NCT03543956|Behavioral|Questionnaire|Questionnaire
82077|NCT03543943|Procedure|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon [1]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively.
82078|NCT03543943|Procedure|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
82079|NCT03543943|Procedure|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
82080|NCT03543930|Device|Postoperative preventive CPAP|Administration of a course of 2 hours of CPAP with 7.5 cmH2O pressure and 0.30 FIO2
82081|NCT03543917|Combination Product|Perfusion with New Combination Medication|Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours
82082|NCT03543904|Procedure|Pre-operative physiotherapy education|"Pre-operative education regarding post-operative physiotherapy intervention in children with abdominal surgery which includes,~Deep breathing exercises~Pursed lip breathing exercises~Diaphragmatic breathing exercises~Leg ROM (active hip and knee flexion, extension and abduction exercises)~Ankle toe movements exercises"
82083|NCT03543904|Procedure|Post-operative physiotherapy intervention|"Post-operative physiotherapy intervention which includes,~Deep breathing exercises~Pursed lip breathing exercises~Diaphragmatic breathing exercises~Leg ROM (active hip and knee flexion, extension and abduction exercises)~Ankle toe movements exercises"
82085|NCT03543865|Behavioral|New Hope (NH)|New Hope will be implemented over 1 visit (2-4 hours) in a youth-preferred setting after Emergency Department (ED) discharge for a suicide attempt, and in the past few years has been updated to also target suicide ideation and binge behavior. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by with Native actors, vignettes specific to this community, and Elders speaking in Apache (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life.Youth will be encouraged to choose a support person from his/her family to take part in the intervention.
82086|NCT03543865|Behavioral|Elders Resilience (ER)|Elders' Resiliency is a monthly manualized curriculum taught by Elders in the community intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength. Each lesson introduces youth to cultural knowledge, stories, and songs with an emphasis on respect and the sacredness of each life. Our community-based Apache staff will select Elders who both express an interest in the current project and have demonstrated affinity and skill for teaching the current curriculum in the schools. After this group of Elders is recruited and agree to participate, they will be paired with our paraprofessional Apache study staff.
82087|NCT03543865|Other|Case Management (CM)|Research Program Assistants, who are trained Surveillance System Staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the Suicide Ideation Questionnaire (SIQ) to assess imminent risk, and if youth report not yet having connected to services, referral to Apache Behavioral Health Services (ABHS), the local community mental health center. At CM visits, the Research Program Assistants will also monitor participants' completion of the study battery, which will be self-administered using tablets. In addition, Research Program Assistants will score the SIQ before leaving the youth. If the SIQ reveals the participant is at imminent risk, Research Program Assistants will employ a protocol for rescue services, which involves triaging youth immediately to the ED for further assessment and care.
82121|NCT03543644|Other|Water|Water will be provided to each participant. They will be instructed to replace their usual SSBs with the water while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
82122|NCT03543631|Other|Survey|Online survey
82088|NCT03543852|Behavioral|SurvivorLink|SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
82089|NCT03543839|Biological|Belimumab|Subjects in this arm will receive 200mg belimumab subcutaneously weekly for 2 years
82090|NCT03543839|Biological|Belimumab/Placebo|Subjects in this arm will receive weekly subcutaneous injections of 200mg belimumab for 1 year and then placebo subcutaneous injections for 1 year.
82091|NCT03543839|Other|Placebo|Subjects in this arm will receive weekly subcutaneous injections of placebo for 2 years
82092|NCT03543826|Other|Protocol for rocuronium neuromuscular block|The protocol includes specified appropriate rocuronium dosing and a valid pre-reversal assessment of the adductor pollicis response guides optimal neostigmine vs. sugammadex reversal.
82093|NCT03543813|Drug|CX-2029|CX-2029 Monotherapy
82094|NCT03543800|Device|Cytorich PRP kit|Subjects randomized to the PRP treatment arm will receive PRP only without the anti-inflammatory component of ABP added
82095|NCT03543800|Device|PRP kit|PRP kit legally marketed in Canada for PRP
82096|NCT03543787|Combination Product|Health IT and Peer Support Intervention|"Health IT will support referral system by establishing 1) communication between healthcare providers and peer navigators 2) decision support for clinician to facilitate appropriate referrals 3) tracking of referred patients real-time 4) dashboards to monitor key evaluation metrics.~Peer Support intervention: peer navigators at each level of the referral network will ensure 1) referral adherence by link clinicians and patients 2) health system navigation 3) psychosocial support: leverage their shared disease experience to help patients overcome barriers to health seeking behaviour."
82097|NCT03543774|Drug|Simvastatin 40mg|Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
82098|NCT03543774|Drug|Ezetimibe/simvastatin 10/20 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
82099|NCT03543774|Drug|Ezetimibe/simvastatin 10/40 mg/day|Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
82100|NCT03543761|Device|Dornier Aries 2 device|• Sham group: 6 sessions with placebo LiST probe, 1 session per week. A specific probe design, identical to the active one will allow the double blind fashion of the study.
82101|NCT03543761|Device|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
82102|NCT03543761|Device|Dornier Aries 2 device|LiST groups: 6 sessions with active LiS probe, 1 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7)
82103|NCT03543748|Device|Transcranial Magnetic Stimulation|A total of 2000 trains will be delivered successively. The pulses will be delivered at 80% of motor thresholds.
82104|NCT03543748|Device|Sham Transcranial Magnetic Stimulation|The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field.
82105|NCT03543735|Behavioral|Wisepill+SMS|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox and generate relapse prevention messages that can be later delivered during non-adherent windows; 2) use of the Wisepill device during the intensive treatment program and after discharge; and 3) three forms of tailored SMS messages paired with Wisepill device use: a) supportive messages with medication compliance, b) reminder messages for early non-adherence (e.g., 1 hour late) and c) relapse-prevention messages after longer periods of non-adherence (e.g., several hours).
82106|NCT03543735|Other|Wisepill-only|This will include: 1) an in-person Wisepill orientation session to introduce the pillbox; 2) use of the Wisepill during the intensive treatment program and after discharge.
82107|NCT03543722|Behavioral|National Career Coach Program|Intensive employment services as described above.
82108|NCT03543722|Behavioral|Local Community Resources Program|Usual employment services as described above.
82109|NCT03543709|Diagnostic Test|fibromyalgia 2013 criteria|Frequency of fibromyalgia will be investigated in women diagnosed with Behcet disease
82110|NCT03543709|Other|Behcet's disease current activity form|Disease activity will be investigated in women with Behçet's disease without fibromyalgia.
82111|NCT03543696|Radiation|Single Dose Radiotherapy (SDRT)|
82112|NCT03543683|Drug|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
82113|NCT03543683|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
82114|NCT03543670|Dietary Supplement|Oncoxin-Viusid|Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).
82115|NCT03543657|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat will be titrated based on the subject's Hb (Hemoglobin) response. Administrated orally once daily (OD).
82116|NCT03543657|Drug|Darbepoetin alfa|Starting dose of darbepoetin alfa will be titrated based on the subject's Hb (Hemoglobin) response. Administrated weekly or once every two weeks by intravenous injection.
82117|NCT03543657|Drug|Placebo of Molidustat (BAY85-3934)|Matching placebo of Molidustat.
82118|NCT03543657|Drug|Placebo of Darbepoetin alfa|Matching placebo of Darbepoetin alfa.
82119|NCT03543644|Other|Sugar-sweetened beverage (SSB)|SSBs will be provided to each participant. Participants will be able to choose their SSB of choice from the list in the protocol. They will be instructed to drink their usual SSB intake, study drinks provided, while freely consume their usual background diets. They will revert to their usual SSB intake during wash-out phase during which they will not receive any beverage drinks from the study.
82123|NCT03543618|Device|Sloped|Placement of implant with sloped design
82124|NCT03543618|Device|Control|Placement of implant with conventional design
82125|NCT03543605|Behavioral|PROA Experimental|PROA Control plus clinical advice
82126|NCT03543605|Other|PROA Control|PROA Control
82127|NCT03543592|Diagnostic Test|3 dimensional ultrasonography and Doppler|Three-Dimensional images will be recorded. The volumes will be generated by the automatic rotation of the mechanical transducer 360 degrees. Visualization of the endometrium and myometrium in the three planes will be done to detect endometrial cavity and any lesions. The power Doppler gate will be activated for blood flow mapping of the endometrium and endometrial-myometrial interface (sub-endometrial area). The pulsed Doppler sample volume will be activated to obtain a flow velocity waveform (FVW). Vascularization index (VI), flow index (FI) and vascularization-flow index (VFI) will be automatically calculated from three consecutive FVWs.
82128|NCT03543553|Other|This is not an intervention study|This is not an intervention study
82129|NCT03543540|Biological|Nexvax2|Nexvax2 injections: 14 in total at twice weekly intervals
82130|NCT03543540|Biological|Placebo|Placebo injections: 14 in total at twice weekly intervals
82131|NCT03543527|Other|no intervention|no intervention
82132|NCT03543514|Other|TRIMODAL PREHABILITATION|"Trimodal prehabilitation application in the form of:~Control with the 6-minute walking test and podometer of physical activity~Dietary advice to be able to perform a hyperproteic diet~Mindfullnes to improve the emotional level."
82133|NCT03543501|Device|Real-time ultrasound imaging feedback|Participants will be taught about the anatomy of abdominal wall muscles and the general functioning of RUSI (5 mins). Then, they will be invited to take the supine position, knees flexed. The feedback will consist of an ultrasound image transmitted to a brightness (B)-mode. Participants will receive the necessary education to understand the image and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions held 10 seconds of the TrA with a visible thickening of the TrA on the RUSI monitor exceeding the measurement at rest (visible on the monitor). Forty-five seconds rest will be allowed between each contraction to avoid fatigue. Participants will have to watch the RUSI monitor during the 15 tests.
82134|NCT03543501|Device|PBU feedback|Participants will receive the same instruction on the anatomy of abdominal wall muscles and general information about the PBU device. They will be invited to take the same position as for the RUSI group (supine, knees flexed). The feedback will be to visualize the intensity of pressure on the dial of a STABILIZER PBU (Chattanooga Group, Hixon, TN). Participants will receive the education necessary to understand the tool and the desired recruitment according to a standardized protocol. They will then be asked to perform 15 contractions of the TrA with a duration of 10 seconds while maintaining the constant pressure at 40 mmHg ± 2 mmHg. Forty-five seconds of rest will be allocated between each contraction. Participants will have to watch the PBU dial during the 15 tests.
82135|NCT03543488|Diagnostic Test|Neuromuscular and functional capacity tests|"The Timed Up and Go test; Maximal knee-extensor muscle strength (isometric and concentric tests) was measured with a Biodex System 3 dynamometer; A B-mode ultrasonography system with a linear-array probe (60 mm, 7.5 MHz) was used to determine VL and RF muscle thickness, pennation angle, fascicle length and tendon CSA. Measurements were obtained with the volunteer seated in the dynamometer, during isometric contraction at 90° of knee flexion.~An 8-channel EMG system was synchronized with the dynamometer through a Windaq data acquisition system and used to evaluate the vastus lateralis and rectus femoris electrical activity during isometric knee-extensor tests."
82136|NCT03543475|Device|arabin pessary|arabin pessary: silicon device
82137|NCT03543475|Device|no pessary|control group
82138|NCT03543462|Device|thoracic Drain Tube 24 Fr.|Positioning of Thoracic Drain after diaphragmatic resection and consequently diaphragmatic repair
82139|NCT03543449|Other|Off-Pump Coronary Artery Bypass (OPCAB) surgery|Off-Pump Coronary Artery Bypass (OPCAB) surgery. This study is retrospective study
82140|NCT03543436|Drug|Temocillin|Intravenous temocillin disodium 2g intravenously/8h Or Renally Adjusted Equivalent (ORAE) in 30-40 min infusion.
82141|NCT03543436|Drug|meropenem or imipenem|Intravenous carbapenem (meropenem 1g intravenously/8h Or Renally Adjusted Equivalent (ORAE) or imipenem 1g intravenously/8h ORAE)
82142|NCT03543423|Other|Oral glucose tolerance test|Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG
82143|NCT03543423|Other|Liquid mixed meal test|A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).
82144|NCT03543410|Drug|SEP-4199 200 mg|SEP-4199 200 mg/day (supplied in two 100mg tablets)
82145|NCT03543410|Drug|SEP-4199 400 mg|SEP-4199 400 mg/day (supplied in two 200mg tablets
82146|NCT03543410|Drug|Placebo|Placebo (supplied in two tablets/day)
82147|NCT03543371|Diagnostic Test|Neuropsychological assessment|Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A & B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
82148|NCT03543358|Drug|rovalpituzumab tesirine|Optional retreatment with rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing) for 2 dose cycles
82149|NCT03543358|Drug|rovalpituzumab tesirine|Rovalpituzumab tesirine (0.3 mg/kg or previously adjusted dose) administered intravenously once every 6 weeks beginning on Day 1 (day of dosing). Subjects will receive rovalpituzumab tesirine on Day 1 of each 6-week cycle, omitting every third cycle until disease progression or study drug discontinuation.
82150|NCT03543345|Diagnostic Test|echocardiography study|"Patients with right coronary artery occlusion lesion will be subjected to:~Written consent.~Complete history.~Complete physical examination.~Trans-thoracic echocardiography assessment of the right ventricular function before PCI to the RCA~Follow up Trans-thoracic echocardiography assessment of the right ventricular function four weeks after the PCI."
82151|NCT03543332|Diagnostic Test|Measures of physical activity and kinesiophobia|Groups will be compared regarding kinesiophobia with TSK heart.
82152|NCT03543306|Drug|daborafenib plus trametinib|Dabrafenib 150 mg twice daily and trametinib 2 mg once daily
82153|NCT03543267|Other|MRI exam|MRI before and after resection surgery
82154|NCT03543254|Drug|BoNT-A|"90U BoNT-A, given in one treatment as 18 injections of 5u (0.2 ml) each, on specific preselected sites along the sutures of the skull.~First 100 U of Botox® is solved in 4 ml (cc) of isotone saline water (9 mg/ml), distributed in 4 syringes. This is half the usual concentration, allowing for better diffusion in order to reach the target structures."
82155|NCT03543241|Diagnostic Test|MyoStrain|Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.
82156|NCT03543228|Diagnostic Test|MyoStrain|MyoStrain quantifies myocardial contraction to detect changes in heart function during chemotherapy.
82157|NCT03543215|Other|Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)|All patients with confirmed endometrial cancer will have received Ultrasound and MRI as part of routine standard of care. Textural features from this will be analysed to see if can predict prognosis.
82158|NCT03543202|Drug|Transversus abdominis plane block|will receive 20ml bupivacaine for Transversus abdominis plane block and intravenous patient controlled analgesia
82159|NCT03543202|Drug|local infiltration anesthesia|will receive 20ml bupivacaine for local infiltration anesthesia and intravenous patient controlled analgesia
82160|NCT03543202|Drug|Intravenous patient controlled analgesia|will not receive any regional anesthetic intervention will receive intravenous patient controlled analgesia
82161|NCT03543189|Drug|Nivolumab|Treatment with nivolumab will begin four weeks prior to the first brachytherapy treatment. Nivolumab will be given through a vein every 2 weeks for 4 courses. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response, resulting in decreased tumor growth.
82162|NCT03543189|Radiation|Brachytherapy|High dose rate (HDR) Brachytherapy involves the delivery of a high dose of radiation, internally, directly to the prostate. This procedure is completed in one day as an outpatient procedure.
82163|NCT03543189|Radiation|External Beam Radiation Therapy|External beam radiation therapy to the participant's prostate will be given once a day, five days a week (Monday-Friday), for a total of five weeks. External radiation therapy treatments are given as an outpatient procedure and take about 10-15 minutes each day.
82164|NCT03543189|Drug|Androgen Deprivation Therapy|Standard of care.
82165|NCT03543176|Other|UMEC/VI|UMEC/VI as 62.5/25 mcg, which is a once-daily single inhaler dual therapy, given to subjects, via Ellipta .
82166|NCT03543176|Other|FLUT/SAL|FLUT/SAL as 250/50 mcg, which is a twice-daily single inhaler dual therapy, given to subjects, via Diskus.
82167|NCT03543176|Other|CAT|Questionnaire used to asses Condition-related well-being, for COPD subjects.
82168|NCT03543176|Other|mMRC|Questionnaire used to asses Breathlessness, due to Dyspnea, for COPD subjects.
82169|NCT03543176|Device|Ellipta|It is a single once daily, Dry powder Inhaler (DPI), developed for delivery of therapies in COPD subjects.
82170|NCT03543176|Device|Diskus|It is a plastic device containing twice-daily single inhaler dual therapy, developed for delivery of therapies in COPD subjects.
82171|NCT03543163|Procedure|Non- Pedicled Buccal Fat Pad with Coronally Advanced flap|A horizontal incision of 1.5cm in long will be made at the bottom of the vestibule with the #15 blade in the region of maxillary first and second molars, depending on side of the recipient site. A curved hemostat will be used in the blunt dissection through the buccinators muscle to temporarily reposition and loose the surrounding fascia which will allow the buccal fat pad to be exposed in the oral cavity. A portion of adipose tissue equals to the required graft size will be excised with the microsurgical scissors. The grafting material will be placed on a saline-soaked gauze until its transfer to the recipient site. Finally, the patient's check will be compressed, in order to promote the closure of the wound edges then immediately close the donor site with simple 5.0 silk thread interrupted sutures
82172|NCT03543163|Procedure|sub-epithelial connective tissue graft|a sub- epithelial connective tissue graft is harvested from the hard palate is used to treat area with gingival recession
82173|NCT03543150|Drug|BOTOX|BOTOX injections will be administered to eligible subjects with diagnosis of spasmodic dysphonia. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
82174|NCT03543137|Drug|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
82175|NCT03543137|Drug|Nicorette Mini Lozenge|A single dose of a 4 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
82176|NCT03543124|Device|cap|A commercially available transparent cap (Olympus) will be fitted to the end of the colonoscope.
82177|NCT03543124|Other|Water|Using water instead air to help insertion
82178|NCT03543111|Behavioral|Zest|Zest is an internet-based psychological health enhancement program for women with spinal cord injury. The intervention will occur in Second Life (SL), which is an online virtual word simulator with a group of women with spinal cord injury.The Zest program will consist of 10 weekly 2-hour group sessions with approximately 8 women using avatars to represent themselves.
82179|NCT03543098|Procedure|Early Surgery|Subjects will undergo surgery within 6 weeks after injury.
82180|NCT03543098|Procedure|Delayed Surgery|Subjects will undergo surgery 12 to 16 weeks after injury.
82181|NCT03543098|Procedure|Early Rehab|Subjects will undergo rehabilitation that will include unrestricted range of motion exercises and use of a weightbearing as tolerated gait starting after the first post-operative visit with the surgeon.
82182|NCT03543098|Procedure|Delayed Rehab|Subjects will undergo rehabilitation that will include use of a knee brace locked in extension, no range of motion exercises and use of non-weightbearing gait for the first 4 weeks after surgery.
82374|NCT03541564|Drug|BMS-986165|Specified dose on specified days
82183|NCT03543085|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator (GiMer Medical Model 1000 External Stimulator) to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead in epidural space, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
82184|NCT03543072|Drug|Bisphosphonates|a class of drugs that prevent the loss of bone density, used to treat osteoporosis and similar diseases
82185|NCT03543059|Drug|GnRH analogue|gonadotrophin releasing hormone analogue
82186|NCT03543046|Device|Tortle Midliner|The Tortle Midliner will be applied in the treatment group within the first 3 hours of life and maintained until 72 hours of life.
82187|NCT03543033|Drug|Corticosteroid injection|These subjects will first receive a topical anesthesia to the skin and underlying tissue in a maximum amount of 5 ml of 1% Lidocaine. Following this application, an 18-20 gauge epidural needle will be used to inject a solution containing 80 mg Depo-Medrol in 1 ml of 1% PF Lidocaine and 5ml of sterile PF saline
82188|NCT03543020|Radiation|radiation therapy to brain|OSL placed over the scalp for initial 5 fractions for patients undergoing partial/ whole brain radiation therapy
82189|NCT03542994|Other|EDP1066|EDP1066 is an orally administered monoclonal microbial
82190|NCT03542994|Drug|Placebo oral capsule|placebo
82191|NCT03542981|Device|Interferential Current|
82192|NCT03542981|Device|Sham Interferential Current|
82193|NCT03542968|Procedure|magnetic resonance imaging|Acquisition 4D Flow magnetic resonance Imaging-8 minutes
82194|NCT03542955|Device|ActiPatch|A Pulsed Shortwave Therapy Device
82195|NCT03542955|Drug|Etoricoxib 60 mg|nonsteroidal anti-inflammatory drug used as standard therapy
82196|NCT03542942|Other|treatment with EXIT-target volume|exclusion of the unaffected part of the uterus out of the treatment field
82197|NCT03542929|Device|whole body vibration|whole body vibration training on a vibrating platform with healthy elderly and diabetic elderly
82198|NCT03542916|Drug|CJ-40001 60ug|CJ-40001 60ug SC, IV injection
82199|NCT03542916|Drug|NESP 60ug|NESP 60ug SC, IV injection
82200|NCT03542903|Device|Electroconvulsive therapy|"Electroconvulsive therapy is administered through electrodes positioned bilaterally (for quicker efficacy) on the frontotemporal region.~The stimulation dose is determined by titration method, during the first ECT session.~The dose for therapeutic stimulation will be twice the seizure threshold. This dose may be increased as the crisis does not meet the effectiveness criteria, as is recommended.~For patients undergoing ECT, an intravenous injection of etomidate (between 0.1 and 0.7 mg/kg) and suxamethonium chloride (0.8 and 1.2 mg/kg) is performed. The required doses are adapted according to each patient by the anaesthetist and they are documented in the patients' files. A mixture of etomidate and propofol can be used in second-line or just propofol in third-line (no more than 2mg/kg)."
82201|NCT03542890|Device|Baska Mask|used in adult low risk females undergoing elective gynecological operations
82202|NCT03542890|Device|I-gel|used in adult low risk females undergoing elective gynecological operations
82203|NCT03542877|Drug|Oral Tablet: Cabozantinib|Patients will take 60mg cabozantinib, by mouth, once daily, every day for 12 weeks. This medication should be taken on an empty stomach. Patients should not eat 2 hours before or 1 hour after taking cabozantinib. Only water is permitted during this 3 hour time frame.
82204|NCT03542864|Dietary Supplement|Nasogastroduodenal Protocol|Complete nutrition (carbohydrates, lipids, proteins, vitamins, oligoelements)
82205|NCT03542864|Other|Control|Progress registration of body composition values
82206|NCT03542864|Other|Data analysis|Statistical analysis of all data
82207|NCT03542851|Drug|Pentetrazol (PTZ)|BTD-001 is an oral capsule of PTZ.
82208|NCT03542851|Drug|Placebo oral capsule|Placebo will be presented as oral capsule.
82209|NCT03542838|Drug|Resiniferatoxin|Resiniferatoxin is a compound purified from natural sources.
82210|NCT03542838|Drug|Saline|Saline is a normal physiological solution
82211|NCT03542825|Drug|Lactoferrin|parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
82212|NCT03542825|Drug|Iron Supplement|Iron Sulphate 150 mg once daily
82213|NCT03542825|Drug|Chelates, Iron|Amino acid chelated iron capsules contain 15 mg
82214|NCT03542812|Drug|L-Citrulline|The L-citrulline will be procured in powder form and will be solubilized in sterile water to achieve a concentration of 50 mg/ml. Therefore, 3 ml/kg of the solubilized L-citrulline (50 mg/ml) will be administered per dose for the single-dose groups and the dose administered to the steady-state group will be determined from results from the single-dose studies.
82215|NCT03542799|Biological|EGFR IL12 CART|EGFR IL12 CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%)
82216|NCT03542786|Dietary Supplement|Probiotic|"The probiotic i3.1 is a commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Lactobacillus plantarum CECT7484~Lactobacillus plantarum CECT7485~Pediococcus acidilactici CECT7483"
82217|NCT03542786|Dietary Supplement|Prebiotic|"ProSeed prebiotic is a non-commercialized product. It will be supplied by the promoter and manufactured in ALIFARM S.A.~It contains:~Partially Hydrolyzed Guar Gum (PHGG)~Inulin HPD~Oat Beta-Glucans~Pectin~Inulin Low Protein Diet (LPD)~Polydextrose~Maltrodextrins"
82218|NCT03542786|Dietary Supplement|Placebo|It is a non-commercialized product. It is composed of the same excipients as the probiotic and the prebiotic. It will be supplied by the promoter and manufactured in ALIFARM S.A.
82219|NCT03542773|Drug|18F-DCFPyL Injection|18F-DCFPyL with whole body PET/CT scan
82220|NCT03542760|Drug|Methylene Blue|Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
82221|NCT03542747|Device|Time to ventilation with the iLTS|Time to ventilation (ET) based of insert the iLTS until the chest rise of the simulator in seconds
82222|NCT03542747|Device|Time to ventilation with the Fastrach|Time to ventilation (ET) based of insert the Fastrach until the chest rise of the simulator in seconds
82223|NCT03542734|Other|multimodal magnetic resonance imaging|multimodal magnetic resonance imaging included T1, FLAIR, MRA, PWI and/or ASL, DTI, DKI, SWI, fMRI
82224|NCT03542721|Drug|DA-5515|Crataegi ethanol extract, Garlic oil, Ginkgo leaf extract, Melissa folium extract (three times a day)
82225|NCT03542721|Drug|Placebo of DA-5515|Placebo (three times a day)
82226|NCT03542708|Procedure|A-PRP|The cortex of selected ovary will be injected with autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. The patient will be under IV sedation. Record of which ovary was injected will be kept in the online research database and not in the clinical chart.
82227|NCT03542695|Procedure|Computed Tomography|Undergo PET/CT
82228|NCT03542695|Drug|Copper Cu-64-DOTA-alendronate|Given IV
82229|NCT03542695|Other|Pharmacokinetic Study|Correlative studies
82230|NCT03542695|Procedure|Positron Emission Tomography|Undergo PET/CT
82231|NCT03542682|Device|Quick Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via quick bolus of 15 units per minute during a euglycemic clamp."
82232|NCT03542682|Device|Standard Bolus|"Individuals with Type 1 Diabetes (T1D) given 0.2 units/kg of rapid acting insulin (RAI) via standard bolus of 1.5 units per minute during a euglycemic clamp."
82233|NCT03542669|Biological|6B11-OCIK injection|6B11-OCIK injection
82234|NCT03542656|Drug|amyloid PET|Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
82235|NCT03542643|Dietary Supplement|n-3 Polyunsaturated fatty acid|1g of Eicosapentaenoic acid (EPA)
82236|NCT03542643|Dietary Supplement|Placebo|Olive oil ethyl esters
82237|NCT03542630|Diagnostic Test|salivary MMP8 test|All female participants will make salivary MMP8 test and certain blood parameters to determine systemic inflammatory response
82238|NCT03542630|Other|periodontal examination|Periodontal examination by a specialist of periodontology will be made to all female participants, using periodontal probe and dental mirror.
82239|NCT03542630|Other|blood tests|All female participants who do not have recent blood tests will make new blood tests to determine certain blood parameters.
82240|NCT03542617|Drug|Dexamethasone|
82241|NCT03542617|Drug|Normal Saline Solution|
82244|NCT03542591|Other|"Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet"|No active intervention, only survey as mentioned above.
82245|NCT03542578|Device|outpatient evaluation of fatty liver|outcome of ultrasound evaluation of liver in clinical outpatient settings
82246|NCT03542565|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
82247|NCT03542552|Drug|Magnesium Sulfate|Patients received intravenous 6 g bolus MgSO4 20% followed by a 2 g/h infusion
82248|NCT03542552|Drug|Nifedipine|received oral nifedipine 10 mg every 20 minutes for three doses, followed by 10 mg orally every 6 hours
82249|NCT03542526|Device|electrogradiogram|12 lead ecg ambulatory blood prussre
82250|NCT03542526|Device|ambulatory blood prussre|ambulatory blood pressure to measure blood pressure
82251|NCT03542513|Device|Colli-Pee|Urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium).
82252|NCT03542513|Device|Qvintip|Vaginal self-samples will be collected with the Qvintip (Aprovix AB, Uppsala, Sweden).
82253|NCT03542500|Behavioral|YRI+Entrepreneurship Training|"The Youth Readiness Intervention integrates six CBT-based, empirically-supported practice elements shown to have transdiagnostic efficacy across disorders ranging from major depressive disorder to PTSD and conduct disorders. The YRI's six evidence-based components are delivered in three phases common in trauma-informed interventions: stabilization, integration, and connection.~The Entrepreneurship Training includes the following core components: financial literacy and entrepreneurship delivered through six modules (e.g.governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Our YRI curriculum will be used for the psychosocial competency training module.~In this arm, youth will receive the YRI and then the Entrepreneurship Training"
82254|NCT03542500|Behavioral|Entrepreneurship Training|The youth capacity development component of GIZ's Entrepreneurship Training includes the following core components: financial literacy, entrepreneurship, and vocational training delivered through six modules (agro-processing, solar photovoltaic installation and maintenance, governance and conflict resolution, psychosocial competencies, entrepreneurship, employability). Youth will be trained at training sites and have access to a youth center in the area. These centers will have agricultural equipment and machinery available for youth to use. Our YRI curriculum will be used for the psychosocial competency training module.
82255|NCT03542487|Behavioral|Practice Orientation|Practices will be encouraged to batch order blood glucose flowsheets for all patients with diabetes with active MyChart accounts. This will allow diabetic patients at these practices to enter any self-monitored glucose measurements. The research team will contact physicians and practice managers with an explanation of the initiative and instructions for completing batch orders and viewing entries through the system. Additionally, providers will be given a template for a secure smart-text message to send to all patients receiving the flowsheets, instructing them to enter data for the study period. The secure message will also provide them with information on how to enter data, and on the benefits of tracking blood glucose.
82256|NCT03542487|Behavioral|Standard Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets
82257|NCT03542487|Behavioral|Gift Card Reminder|Patients receive generic biweekly reminders, addressed from Inova Medical Group, to enter glucose measurements in the electronic flowsheets. In these reminders, they will also be notified that that they will be entered to win a $50 gift card for each day entering data.
82258|NCT03542487|Behavioral|Physician Reminders|Patients receive biweekly reminders, addressed from their physician, encouraging them to enter glucose measurements in the electronic flowsheets (Note that though messages will be addressed from physician, they will be sent by Inova IT)
82259|NCT03542474|Behavioral|High Intensity Endurance Exercise|Treadmill exercise at 80%-85% maximum heart rate for 30 minutes a day, 3 times per week, for 6 months.
82260|NCT03542461|Drug|Nivolumab 10 MG/ML Intravenous Solution|240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.
82261|NCT03542461|Other|Best Supportive Care|Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
82262|NCT03542448|Device|Swept source optical coherence tomography|Measurement of choroidal thickness in myopic patients
82263|NCT03542435|Drug|SXC-2023|Oral capsule
82264|NCT03542435|Drug|Placebo|Placebo
82265|NCT03542422|Drug|Apatinib|Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.
82266|NCT03542409|Other|MR Perfusion Scan|MR perfusion scan before and during surgery.
82267|NCT03542409|Other|2HG Spectroscopy Scan|2HG spectroscopy scan before and during surgery.
82268|NCT03542396|Behavioral|ImPuls|Experimental: Participants will receive an supervised exercise intervention and group therapeutic elements (cognitive behavioral therapeutic elements) for 4 weeks and, after that, they are encouraged to engage in physical activity for 8 weeks independently. During this 8-week individual phase, patients have weekly phone contacts with a psychotherapist
82269|NCT03542396|Other|Control|Participants will not receive any intervention. Participants will receive treatment as usual, which means they are on a waiting list of an outpatient unit to receive individual CBT
82270|NCT03542383|Device|High Definition Transcranial Direct Current Stimulation|Administer 1 ma anodal HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
82271|NCT03542383|Device|Sham High Definition Transcranial Direct Current Stimulation|Administer sham HD tDCS over the preSMA for 20 minutes a session for 10 sessions over a two week period
82272|NCT03542370|Other|DASH dietary pattern|A dietary pattern that emphasizes intake of fruits and vegetables, low-fat or non-fat dairy, limiting saturated fat intake, and usually also recommends limiting sodium intake.
82273|NCT03542357|Drug|Calcitonin Gene Related Peptide|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
82274|NCT03542357|Drug|Sumatriptan 50 mg|CGRP is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
82275|NCT03542357|Drug|Placebo Oral Tablet|CGRPis given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
82276|NCT03542344|Drug|BI 1015550|Single rising oral dose
82277|NCT03542344|Drug|Placebo|Single rising oral dose
82278|NCT03542331|Drug|Lipiodol|Endometrial flushing with Lipiodol between day 6 and 8 of the cycle
82279|NCT03542331|Device|Mock catheter|Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
82280|NCT03542318|Other|Pulmonary Rehabilitation|A multidisciplinary PR programme was delivered twice weekly for 12 weeks. Each class was of 2 hours in duration. The first hour had an exercise component. Inspiratory muscle training was carried out using the Respironics IMT Threshold trainer® during the class. Educational sessions covered various aspects of pulmonary fibrosis care and self-management delivered. Patients also received an individualized home exercise programme consisting of exercise similar to what was being carried out during the classes. Each participant was encouraged to perform at least 20 minutes of these exercises per day.
82281|NCT03542305|Drug|Lorlatinib|Lorlatinib single oral dose
82282|NCT03542292|Diagnostic Test|placental drainage|
82283|NCT03542279|Procedure|Plasma exchange|PE treatments are performed on an apheresis device (Fresenius MultiFiltrate hemodialysis filtration machine, German). PE volumes of 1 plasma volume per procedure will be used. Treatments will be given every other day with breaks allowed for weekends for most patients. The anticoagulant used is low molecular heparin. The use of high-dose glucocorticoid is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
82284|NCT03542279|Drug|IVIG, High-dose glucocorticoid|IVIG is given 0.4 g/kg/d for each course for 5 days. The use of high-dose glucocorticoid is 1,000 mg or 500 mg methylprednisolone for 3 or 5 days, and the dosage of glucocorticoid will gradually decrease.
82285|NCT03542266|Drug|CC-486 Administration|CC-486 at 300 mg once daily is to be administered Cycle 1, Day -6 to 0 and Cycles 1 to 5, Day 8 to 21. Antiemetic prophylaxis is recommended before dosing. All efforts should be made to administer CC-486 on all scheduled days of the Cycle 1 priming dosing (7 days, Cycle 1 Day -6 to Cycle 1 Day 0) and the Cycle 1-5 dosing (14 days, Day 8-21). A dose missed earlier in a day can be administered later that day as long as it is taken at least 8 hours before the next scheduled dose. Any missed dose should not be taken beyond the last scheduled day of CC-486 administration for the cycle, but should be returned by the subject for CC 486 accountability. If vomiting occurs after a dose of CC-486 is administrated, that dose should not be made up later that day.
82286|NCT03542266|Drug|CHOP Administration|"CHOP is to be administered on Days 1 to 5 of Cycles 1-6. Chemotherapy can be administer within +72h or -24h of Day 1 of each scheduled Cycle. Preparation and infusion rate are according to the package insert and local practice. The doses to be used are:~Cyclophosphamide: 750 mg/m2 IV on day 1 Doxorubicin: 50 mg/m2 IV on day 1 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 1 Prednisone: 100 mg PO days 1-5"
82287|NCT03542253|Procedure|Surgery|After surgical treatment, pathological specimens were extracted to obtain pathological results
82288|NCT03542240|Dietary Supplement|Curcumin|500 milligram daily supplement
82289|NCT03542227|Device|First-void urine collection|Collection of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
82290|NCT03542214|Combination Product|Calcium electroporation|Patients with inoperable colorectal cancer will be treated with calcium electroporation
82291|NCT03542201|Other|PLS|Participants will have to read standard textual information about the conducted systematic review (approximately 500 words)
82292|NCT03542201|Other|Blogshot|Participants will have to read the blogshot information about the results of the Cochrane systematic review (approximately 100 words)
82293|NCT03542188|Behavioral|Primary Stroke Center (PSC)|Transport to a primary stroke center for early IV-thrombolysis followed by a secondary transport to a comprehensive stroke center for EVT if needed.
82294|NCT03542188|Behavioral|Comprehensive Stroke Center (CSC)|Direct transport to a comprehensive stroke center for IV-thrombolysis and early EVT.
82295|NCT03542175|Drug|Rucaparib|one dose level (300 mg BID, 400 mg BID, 500 mg BID or 600 mg BID) concurrently with a 6-week course of radiotherapy and 4 additional weeks of maintenance rucaparib at the same dose level.
82296|NCT03542175|Radiation|Radiotherapy|50 Gy in 2 Gy per fraction to the breast or chest wall with or without regional nodes plus a 10 Gy boost to the lumpectomy cavity, to a total dose of 60 Gy. A 10 Gy boost to the post-mastectomy scar is allowed at the discretion of the treating physician.
82297|NCT03542162|Biological|Healaflow|For the RRD patients, after 27G PPV, air-liquid exchange and endolaser photocoagulation around the tear(s), Healaflow is going to be fully covered on the surface of all retinal tears using 27G needle, the amount of Healaflow injection was determined according to the size of tears.
82298|NCT03542149|Drug|OZ439 + α-tocopherol polyethylene glycol 1000 succinate|Artefenomel (OZ439), is a novel trioxolane Piperaquine is a bis 4-aminoquinoline and was used mainly in China from the 1960's to the 1980's as an antimalarial monotherapy.
82299|NCT03542136|Device|VibrosSense Meter®|A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
82300|NCT03542123|Device|NeuroTronik CANS Therapy® System|The NeuroTronik CANS Therapy® System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
82301|NCT03542110|Drug|Alirocumab 150 MG/ML subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
82302|NCT03542110|Drug|Matching Placebo subcutaneous injection|Single-dose, pre-filled, disposable, subcutaneous injection pen
82303|NCT03542097|Other|MGMT methylation evaluation|The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples
82304|NCT03542084|Other|Unsolicited endocrine e-consult|The PCP for intervention arm patients will receive an unsolicited e-consult from an endocrinologist with recommendations on how to improve glycemic control in the intervention patient
82305|NCT03542071|Other|Carbohydrate restricted diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 500 g/d, fish 2 times/wk, low-fat instead of high-fat meat, red meat ≤ 3 times/wk, low-fat instead of high-fat dairy, high-fibre instead of low-fibre grains, vegetable oils (excluding palm oil and coconut oil) and soft margarine instead of animal fats, moderate reduction of carbohydrates (targets for macronutrients: carbohydrates 40 E%; fat 40 E%; protein 20 E%; dietary fiber 32g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
82306|NCT03542071|Other|Plant-protein based diet|The intervention is implemented by individual face-to-face counseling and mobile-phone counseling by a nutritionist, as well as food bags and recipes suitable for the diet. Targets: fruits and vegetables 1 kg/d; fish 3/wk; high-fibre grains, mainly rye, oat and barley; plant protein instead of meat protein; low-fat fermented dairy instead of other dairy; rapeseed oil and rapeseed-based margarine instead of other fats; no carbohydrate restriction (targets for macronutrients: carbohydrates 55 E%; fat 25 E%; protein 20 E%; dietary fiber 36g, energy intake approximately 2000 kcal/d; protein intake 20 E%; sucrose: <10 E%; fatty acids: saturated fatty acids < 10 E%, polyunsaturated fatty acids 5-10 E% and the rest of fat as monounsaturated fatty acids)
82307|NCT03542058|Drug|Carvedilol|Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
82308|NCT03542045|Device|Cemented ATTUNE® Knee System|This product is for total knee arthroplasty. Four implant configurations are permitted: Cruciate Retaining Fixed Bearing (CR FB), Cruciate Retaining Rotating Platform (CR RP), Posterior Stabilizing Fixed Bearing (PS FB) and Posterior Stabilizing Rotating Platform (PS RP)
82309|NCT03542032|Other|i-gel placement maneuvers|the i-gel was inserted with triple airway maneuver (mouth opening, head extension and jaw thrust) In the classic maneuver , the index finger used as a guide, pushes the back of i-gel towards the hard palate, inserting it into the pharynx till a resistance is felt and the i-gel is then fixed it its place.
82310|NCT03542019|Device|Dental prosthesis|Replacement of missing tooth structure using Lithium disilicate porcelain
82311|NCT03542019|Device|Dental crown|Replacement og missing tooth structure using monolithic zirconia
82312|NCT03542019|Device|Hybrid ceramic|Restroration of endodontically treated teeth using hybrid ceramic
82313|NCT03542006|Drug|Brinzolamide Ophthalmic|Topical brinzolamide given bd for 3 months
82314|NCT03541993|Dietary Supplement|Resveratrol|
82315|NCT03541993|Other|Placebo|
82316|NCT03541980|Drug|Acetaminophen|Administration of 15 mg/kg (1000 mg max dose) of IV acetaminophen
82317|NCT03541980|Drug|Normal saline|Normal saline volume equivalent
82318|NCT03541967|Device|ADHEAR and PONTO 3 SUPER POWER on softband hearing aids|Device: ADHEAR non-implantable bone conduction hearing aid Comparator: PONTO 3 SUPER POWER bone conduction hearing aid with softband
82319|NCT03541954|Other|Sensory testing of lower urinary tract.|Non invasive lower urinary tract sensitivity testing: provoked diuresis with sonographic estimates of sensory thresholds.
82320|NCT03541954|Other|Sensory testing of lower rectal tract|Lower digestive tract sensitivity testing: rectal electronic barostat with ascending pressure (phasic distension).
82321|NCT03541954|Other|Sensory testing of vulva muscles|Vulvar sensitivity testing: pressure pain threshold evaluated using vulvagesiometer.
82322|NCT03541954|Other|Sensory testing of pelvic muscles|Myofascial sensitivity testing: piriformis, levator ani and obturator internus muscles pressure pain threshold evaluated using intra-vaginal algometer.
82323|NCT03541941|Drug|Exparel|Solution of: 266mg of Bupivacaine Liposome Injectable Suspension (Exparel) mixed with 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
82324|NCT03541941|Drug|Bupivacaine Hcl 0.25% Inj|Solution of: 150mg of Bupivacaine Hydrochloride 0.25% expanded with 60cc of Normal Saline (Nacl0.9%) administered intraoperatively through a transversus abdominis plane (TAP) block
82325|NCT03541941|Drug|Placebo|Normal saline administered intraoperatively through a transversus abdominis plane (TAP) block
82326|NCT03541928|Drug|HSV-Tk|"Injection of the HSV-tk gene therapy product in four quadrants of prostate to enhance the immune system via bystander effect in which cytotoxicity is conferred to non-transduced neighboring cells. In vivo bystander effects are likely due to a combination of host immunological responses and to gap junction-mediated transport of phosphorylated prodrug metabolites to surrounding cells."
82327|NCT03541928|Drug|Valacyclovir|The recommended dose for this trial is 2 g orally t.i.d. for 14 days (day 1 to day 15 and days 31 to 45). This dose has been calculated to give a similar AUC as 10 mg/kg of intravenous acyclovir administered every 8 hours. This is the same dose regimen used in a previous phase I clinical trial of ADV/HSV-tk plus acyclovir and topotecan in patients with recurrent ovarian cancer.
82328|NCT03541928|Drug|Bicalutamide|"The recommended dose for Bicalutamide therapy in combination with an LHRH analogue is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that Bicalutamide be taken at the same time each day.~The use of an oral antiandrogen with medical castration for the treatment of prostate cancer is referred to as combined androgen blockade (CAB). Compared with LHRH-agonist monotherapy, CAB with bicalutamide did not reduce overall QoL but provided an early improvement in QoL related to lower urinary tract symptoms and pain."
82329|NCT03541928|Drug|Leuprolide Acetate|Leuprolide acetate 7.5 mg depot injection will be injected monthly for a total of 2 months.
82330|NCT03541928|Radiation|Brachytherapy, External beam radiotherapy|On day 60, patient will undergo high dose rate (HDR) Brachytherapy. The patient will have 8-14 needle catheters inserted under ultrasound guidance. CT simulation and radiation treatment planning will be performed. The needle catheters will be connected to an HDR afterloader containing an Iridium 192 source. A single dose of 1250cGy will be delivered.
82331|NCT03541928|Procedure|Radical prostatectomy|approximately 2-3 weeks after radiotherapy completion, patient will undergo radical retropubic prostatectomy. Use of laparoscopy or robotic assistance will be at the urologist's discretion. Lymph node dissection will be performed.
82332|NCT03541915|Drug|Mg (magnesium sulfate)|20mg/kg of magnesium sulfate will be infused after induction of anesthesia. And magnesium sulfated will be continuously infused at a rate of 15mg/kg/h during the operation.
82333|NCT03541915|Drug|Control (saline)|The same volume of normal saline will be infused after induction of anesthesia and continuously infused at the same rate of magnesium.
82334|NCT03541902|Drug|Cabozantinib|Given PO
82335|NCT03541902|Drug|Sunitinib Malate|Given PO
82336|NCT03541889|Drug|FLT imaging and TK1 blood measurements|F18 labeled thymidine PET/CT scans will be performed. Serum measurements of TK1 will be obtained.
82337|NCT03541876|Other|Collection of data|"The following data will be collected by the physician :~sociodemographic profile (age, sex, country of birth of child and parents); clinical manifestations; endoscopic aspects (esophagus, duodenum, stomach); different methods of diagnosis of infection; different primary and secondary bacterial resistance profiles ; different first and second line therapeutic combinations; different first and second line bacterial eradication rates ; different signs of side effects and tolerance of first and second line treatments; different methods of bacterial eradication control."
82338|NCT03541850|Drug|Antiandrogen Therapy|Receive luteinizing hormone-releasing hormone agonist or gonadotropin-releasing hormone antagonist, and oral anti-androgen
82339|NCT03541850|Other|Quality-of-Life Assessment|Ancillary studies
82340|NCT03541850|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
82341|NCT03541837|Drug|Ropivacaine|ESP catheter
82342|NCT03541824|Behavioral|Body Acceptance Program|The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
82343|NCT03541811|Diagnostic Test|3-d gait examination (level walking)|"Instrumented 3d-gait-analysis will be carried out in the movement lab of the FH (Fachhochschule; University of Applied Sciences) Campus Wien - University of Applied Sciences. The system used is a 10 camera T40S Vicon system with two floor-mounted AMTI OR6/7-2000 force plates. For assessing gait the Plug-in-Gait Lower Body Model with 14 mm retroreflective skin-mounted markers is implemented in the capturing software Vicon Nexus 2.2. The specific parameters will be extracted from the reporting software Vicon Polygon 4.2.~Markers will be placed by one experienced examiner. Subjects will be instructed to walk barefoot on a 10 meters walkway at self-paced walking speed until five right and five left valid first force plate strikes are captured."
82344|NCT03541811|Diagnostic Test|Anthropometrics and body composition assessment|Body height will be measured with the stadiometer Seca 213 to the next 0.1cm. Body size and weight will be measured without shoes and outerwear. A correction of 1 kg will be subtracted for clothing. Body weight and body composition will be assessed with the medical body composition analyzer Seca mBCA 515 based on bioelectric impedance analysis.
82345|NCT03541811|Diagnostic Test|Biomarkers|"Blood will be collected into Vacuette serum-separating tubes and will be kept at room temperature for 30 min. Samples will be centrifuged at 1500g for 10 min and serum aliquots will be stored at 80 C until use. Urine samples will be collected into Vacuette tubes containing no additive from non-fasted individuals between 8:00 and 12:00 a.m. Urine samples will be kept at 4 °C for a maximum of 8 h, and then aliquoted and stored at 80 °C.~All biomarkers (except vitamin D and CRP) will be measured in duplicates using standard enzyme-linked immunosorbent assay (ELISA) kits. Serum samples will be assessed for the level of sCOMP, sC1,2C, and sCS846, IL-6, IL-1, sTNFR1 and sTNFR2. Vitamin D and CRP will be measured using automated immunoassay. In urine samples uCTX-II will be determined and these levels will be corrected for creatinine levels (Jaffé method, in-house validated method)."
82346|NCT03541811|Diagnostic Test|Clinical examination|Hemophilia joint health score (HJHS) will be assessed. Height will be measured with a stadiometer (SECA 213), weight with a medical scale (Marsden M-420) and leg length according to the Plug-in-Gait protocol with a measuring tape from the Anterior Spina Iliaca Superior to the distal aspect of the Medial Malleolus. Further anthropometrical parameters taken will be knee distance and malleoli distance by using a caliper. Gait relevant passive joint ROM of the knee, hip and ankle will be assessed by means of a handheld goniometer. The flexibility of hamstring muscles will be expressed as Popliteal Angle measured with a goniometer with the subjects supine and the hip in 90° flexion.
82347|NCT03541811|Diagnostic Test|Habitual physical activity tracking (accelerometer based)|Participants will be instructed to wear an Actigraph wGT3X-BT tri-axial accelerometer permanently over a period of seven consecutive days with an elastic band on right hand sided hip. Data will be process with software ActiLife version 6.13. Cut-offs of at least 10 hours daily wear-time and a minimum of three valid weekdays and one valid weekend day will be applied for data cleaning. Count sampling epoch will be set at one minute. The so called Freedson Adult VM2 Cut-Offs will be applied to categorize physical activity intensities. The so called Freedson VM3 Combination will be applied for the estimation of activity energy expenditure.
82348|NCT03541798|Procedure|positions of patients for combined spinal-epidural anesthesia|Patients in groups will be positioned according to the study groups for performing combined spinal epidural anesthesia.
82349|NCT03541798|Procedure|Combined spinal epidural anesthesia|After positioning, a combined spinal epidural anesthesia (CSE) will be applied using a CSE Tuohy Needle (18 G) and 27 G Whitacre spinal needle via needle - through needle technique. The epidural space will be located with loss of resistance to saline. 3 ml hyperbaric bupivacaine 0.5% (15 mg) will be given for spinal anesthesia after identification of subarachnoidal space.
82350|NCT03541772|Dietary Supplement|Oncoxin-Viusid®|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and Oncoxin-Viusid® (75 ml/day) before/during/after both treatments
82351|NCT03541772|Dietary Supplement|Placebo|Radiotherapy for 6-8 weeks, chemotherapy for 1-22-43 days during Radiotherapy and placebo (75ml/day) before/during/after both treatments
82352|NCT03541759|Drug|Hydromorphone Hcl 4Mg Tab|Hydal retard 4Mg Tab 2 times after surgery as basic medication. Hydal retard 2.6Mg maximum 2 per 24h when NRS > 5.
82353|NCT03541759|Drug|Piritramide 15mg s.c.|Dipidolor 15mg s.c. 2 times after surgery as basic medication. Dipidolor 7.5mg s.c. maximum 2 per 24h when NRS > 5.
82354|NCT03541746|Biological|Platelet Rich Plasma|After hysteroscopic adhesiolysis, 30 patients will undergo once injection of 5ml PRP into the wall then lining the uterine cavity by 5ml platelet rich plasma gel. Finally, Foley balloon catheter will be inserted intrauterine then inflated and cutting its stem and to be left for two weeks.
82355|NCT03541746|Device|Intrauterine Foley's Catheter|After hysteroscopic adhesiolysis, 30 patients will undergo intrauterine insertion of one inflated Foley balloon catheter with cutting its stem only to be left for two weeks.
82356|NCT03541733|Other|mid-gut tubing|mid-gut tubing at different time
82357|NCT03541720|Drug|18F-DA|18F-DA is an investigational PET radiotracer
82358|NCT03541707|Device|Deep TMS Brainsway's H coil|"During the treatment trial period all subjects will receive the following dose of TMS: 18 Hz, at 100% RMT, 2 sec pulse train, 20 second inter-train interval, 80 trains, for a total of 57,600 pulses over the complete treatment course. In the placebo group a state of the art sham procedure will be used- the coil is programed to produce the noise and local sensation but with no activation.~EEG Recording is done with and without an acoustic oddball trigger, in order to have both resting state and event related recordings. The evaluation takes approximately 5 minutes."
82359|NCT03541694|Biological|Stamaril®|Routine vaccination with Stamaril yellow fever vaccine
82360|NCT03541681|Procedure|Glucocorticoid Injections|1 ml Dexamethasone + 0,5 ml Bupivacain
82361|NCT03541681|Procedure|Anesthetic Injections|0,5 ml Bupivacain
82362|NCT03541668|Drug|Recombinant human urokinase|Patients receive rhPro-UK 35mg,15mg of which is given as a bolus within 3min followed by dlivery of the remaining 20 mg as a constant infusion over a period of 30 min.
82363|NCT03541668|Drug|Alteplase|Patients receive rt-PA in a dose of 0.9mg per kilogram of body weight(maximum,90mg),10 percent of which was given as a blous followed by delivery of the remaining 90 percent as a constant infusion over a period of 60 minutes.
82364|NCT03541655|Drug|Bupivacaine HCl|0.25% Bupivacaine HCl
82365|NCT03541655|Drug|F14 (celecoxib)|Celecoxib in novel drug delivery system (BEPO™)
82366|NCT03541642|Behavioral|Enhanced Intervention|Targeted PrEP counseling; targeted written/visual materials; follow up supportive text messages; distribution of PrEP at the syringe exchange
82367|NCT03541642|Behavioral|Basic Intervention|General messaging from medical personnel; reminder text messages; distribution of PrEP at the syringe exchange
82368|NCT03541616|Device|ECG Patch, pocket ECG monitor|Two consecutive 14-day ECG monitor patches or one single 28-day pocket ECG monitor (28-days total monitoring) implemented at the time of hospital discharge .
82369|NCT03541603|Drug|Levosimendan|A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
82370|NCT03541603|Drug|Matching Placebo|A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
82371|NCT03541590|Procedure|Percutaneous transhepatic biliary drainage|When ERCPs failed or was not possible to be performed due to an altered anatomy in patients with malignant extrahepatic bile duct obstruction, PTBD was performed next in all patients. Percutaneous bile duct puncture was guided by Color Doppler ultrasound. The further procedure was guided by fluoroscopy. A self-expandable metal stent (SEMS) was inserted into the obstructed bile duct by endoscopic luminal guidance in the first session. After successful SEMS implantation, the percutaneous external catheter was removed at the end of the procedure.
82372|NCT03541577|Device|TruePhysioTM Microcatheter|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
82373|NCT03541577|Device|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve (FFR).
82377|NCT03541551|Procedure|CTT with ologen® Collagen Matrix|ologen® Collagen Matrix approved by Indian health authority with registration numberof MD-1517 will be provided by Aeon Ajanta India Pvt. Ltd. free of cost for this clinical research only.
82378|NCT03541551|Procedure|Trab Trab|combined trabeculotomy with trabeculectomy
82379|NCT03541538|Device|Global manipulation|The therapist positioned himself at the head of the stretcher and with one hand supported the side of the participant's face. With the other hand supported the opposite face of the same and then performed contralateral rotation of the cervical and a slight traction to the tissue barrier to perform the manipulation impulse of high speed and short amplitude in rotation. The procedure was carried out bilaterally.
82380|NCT03541538|Device|Especific manipulation|The therapist positioned himself at the head of the stretcher and with one hand kept the middle phalange of the second finger laterally on the articular processes of the C6-7 vertebrae. With the contralateral hand he supported the opposing face of the participant by performing a tilt up to the C6-7 segment and contralateral rotation up to the tissue barrier to carry out the impulse quickly and short. The procedure was carried out bilaterally.
82381|NCT03541525|Other|Biological sampling|Biological samples including blood, surgical remainder, urine,...
82382|NCT03541512|Behavioral|Mindfulness + Education|"Women in the mindfulness + education group will be asked to meditate daily, 10 minutes a day for the first 4 weeks with the option to increase their time to 20 minutes daily during the second 4 weeks. Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
82383|NCT03541512|Behavioral|Education|"Women will also receive educational materials each week addressing different themes such as; Introduction and Overview, The Vulva, Provoked Localized Vulvodynia (PLV), Treatment of PVL, The Pelvic Floor, Sexuality, Chronic Pain, and Promoting Sexual Health."
82386|NCT03541486|Drug|Ascorbate|75 gram infusion daily (M-F) on days when radiation therapy is administered
82387|NCT03541486|Drug|Gemcitabine|600 mg/m2 once weekly for 6 weeks
82388|NCT03541486|Radiation|radiation therapy|Prescribed to either 50 Gy in 25 fractions or at least 50.4 Gy in 28 fractions, based on tumor. Radiation is delivered 1 fraction/day, 5 days a week, for approximately 5 to 6 weeks.
82389|NCT03541473|Dietary Supplement|Peptamen® 1.5 Vanilla|Nutritionally complete formula with 10g MCT in 250 mL, commercially available
82390|NCT03541473|Dietary Supplement|Boost Plus® Vanilla|Product of same nutritional composition but without MCT
82391|NCT03541447|Drug|Tolvaptan|Starting morning and afternoon doses of 45 and 15 mg, respectively, to be up titrated every two days to 60 and 30 mg and then to 90 and 30 mg, according to tolerability.
82392|NCT03541447|Drug|Octreotide LAR|A single dose of two 20 mg i.m. injections.
82393|NCT03541447|Other|Placebo|A single dose of two 20 mg i.m. injections.
82394|NCT03541434|Diagnostic Test|Complete Blood Count|White blood cell subgroups count
82395|NCT03541434|Diagnostic Test|Tympanometry|Conventional and multifrequency tympanometry, documenting middle ear admittance and absorbance
82396|NCT03541434|Procedure|Tonsillectomy and/or adenoidectomy|Excision of palatine and/or pharyngeal tonsils.
82397|NCT03541421|Other|Patient involvement in administration of drugs|The patient´s own drugs and an updated medication list will be placed in a lockable bedside table. During hospitalization the patient is responsible for taking his own medication. If a new drug is prescribed, the patient will be involved and instructed about it. Furthermore the smallest package will be delivered so that the patient can begin self-administration of the new drug during hospitalization.
82398|NCT03541408|Other|Control|Standard Of Care without Preventative Delirium Protocol
82399|NCT03541408|Other|Preventative Delirium Protocol|Preventative Delirium Protocol
82400|NCT03541395|Drug|GnRH antagonist|
82401|NCT03541382|Device|OraQuick® HIV Self-Test|"Community leaders, including GVHs, Village Health Committee members, Village Development Committee members, and members of key community groups will participate in a workshop to facilitate planning of a HIVST campaign. Identified community distributors, who are unpaid volunteers from the community, will also receive a training package in HIVST promotion.~Campaigns will be conducted over a short period (approximately seven days) and under a fixed budget. Community distributors will deliver HIVST kits free of charge to community members, and provide information on how to self-test and access the nearest clinic for linkage to confirmatory HTS, treatment and prevention. Distributors will also provide HIV prevention messages around serodiscordancy, treatment as prevention and VMMC."
82403|NCT03541356|Combination Product|Experimental: INP103|Delivered via the I231 POD (Precision Olfactory Delivery) device with one puff to one nostril
82404|NCT03541356|Combination Product|Placebo|Delivered via the I231 POD (Precision Olfactory Delivery) device with one puff to one nostril
82405|NCT03541343|Device|GreenBone implant|Patients will receive the GreenBone implant instead of bovine xenograft for iliac crest reconstruction following autologous bone graft harvesting.
82406|NCT03541330|Other|semi-directive interview|semi-structured interview conducted by a clinical psychologist
82407|NCT03541317|Behavioral|Step 1 Strategy: REP|Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
82408|NCT03541317|Behavioral|Step 1 Strategy: REP + Coaching|"Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks."
82409|NCT03541317|Behavioral|Step 2 Strategy: Augment with Facilitation|In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
82410|NCT03541317|Behavioral|Step 2 Strategy: No augmentation|Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
82411|NCT03541291|Device|SMART-SYNC LM02|Doppler ultrasound cardiac gating device for fetal MRI application
82412|NCT03541278|Procedure|MIT|periareolar intraparenchymal, high volume and ultrasonographic guidance
82413|NCT03541278|Procedure|IM-SLNB|IM-SLNB was performed for IMLN visualized patients
82414|NCT03541265|Drug|Exparel|long-acting Bupivacaine extended release liposome compound
82415|NCT03541265|Procedure|Adductor block protocol|Adductor block using Exparel
82416|NCT03541265|Procedure|peri-articular injection protocol|peri-articular injection using Exparel
82417|NCT03541252|Drug|AFL-assisted cisplatin+5-FU|Patients will receive AFL-assisted cisplatin+5-FU as a treatment for their BCC. In brief, treatment areas consisting of tumors and a 5 mm margin will undergo CO2 laser exposure followed by 60 min topical application of a marketed and commercially available IV cisplatin solution (0.1%) After removal of cisplatin, a commercially distributed 5-FU cream (5%) will be applied to the treatment area at a dose of 0.125 ml per cm2 and left under occlusion. After skin evaluations on Day 1 and 5 after treatment, the same 5-FU dose will be applied, again left under occlusion. In total, 5-FU will remain on the skin for 7 days after AFL treatment whereafter it will be washed off. An additional repeat AFL-cisplatin+5-FU treatment on Day 30 will be offered if tumors persist, based on clinical evaluation and imaging on Day 30.
82418|NCT03541239|Device|Single Cuff Tourniquet 8000|If randomized to ischemic conditioning the cuff will be inflated as stated before. If randomized to non-ischemic conditioning the cuff will not be inflated.
82419|NCT03541213|Procedure|myocardial biopsy|Myocardial biopsy (after opening cardiac cavities under general anesthesia for valvular surgery) for mitochondrial metabolism analyses.
82420|NCT03541213|Procedure|sternal bone marrow biopsy|Sternal bone marrow biopsy (after sternal opening under general anesthesia for valvular surgery) for the quantification of iron stores
82421|NCT03541213|Biological|blood sample|blood sample (under general anesthesia for valvular surgery, using the arterial catheter already in place) for hepcidin quantification (hormone not dosed in the usual martial assessment)
82422|NCT03541200|Drug|MT-8554|MT-8554 Oral
82423|NCT03541187|Biological|German cockroach allergenic extract|Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).
82424|NCT03541187|Biological|Placebo for German cockroach allergenic extract|Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
82425|NCT03541174|Drug|Aprocitentan 12.5 mg|Tablet, oral use
82426|NCT03541174|Drug|Aprocitentan 25 mg|Tablet, oral use
82427|NCT03541174|Drug|Placebo|Matching placebo tablet
82428|NCT03541148|Dietary Supplement|Oncoxin-Viusid|Oncoxin-Viusid supplement before/during/after standard surgical and adjuvant treatment or chemotherapy.
82429|NCT03541122|Diagnostic Test|pelvic X-ray examinations|Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
82430|NCT03541109|Drug|Polypill|Polypill tablet
82431|NCT03541109|Drug|Aspirin|Aspirin tablet
82432|NCT03541109|Drug|Atorvastatin|Atorvastatin tablet
82433|NCT03541109|Drug|Metoprolol|Metoprolol tablet
82434|NCT03541109|Drug|Valsartan|Valsartan tablet
82435|NCT03541096|Behavioral|Winter Swimming|Supervised Winter Swimming in Copenhagen
82436|NCT03541096|Behavioral|Control group|No winter swimming activities.
82437|NCT03541083|Drug|Blinatumomab|prephase and consolidation (I and II)
82438|NCT03541070|Device|Kinesiology tape|Kinesiology taping (KT) was developed by Kenzo Kase in the 1970s. KT has similar thickness and flexibility to the skin. These tapes are used in orthopedic and sports injuries as well as neurological and rheumatic diseases, pediatric patients, lymph edema and painful conditions. These tapes are used for correcting muscle function, increasing circulation, increasing proprioception, reducing pain, and repositioning the sublease joint according to the usage method
82439|NCT03541044|Drug|Nicotine Prototype Mini lozenge|A single dose of a prototype nicotine 2mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
82440|NCT03541044|Drug|Nicorette Mini Lozenge|A single dose of a 2 mg nicotine polacrilex mini lozenge (Nicorette Minis) will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
82441|NCT03541031|Dietary Supplement|Micronutrient & Fish oil|Capsule containing a 36-ingredient micronutrient formula (EMPowerplus™) which has been widely researched for its usefulness in several psychiatric conditions. The second product is a capsule containing Fish oil (Wiley's Finest™ Wild Alaskan Fish Oil Peak EPA; 700 mg EPA plus DHA per capsule).
82442|NCT03541031|Dietary Supplement|Olive oil & Safflower oil|Olive oil capsule manufactured to mimic Micronutrient and safflower oil capsule manufactured to mimic Fish oil
82443|NCT03541018|Procedure|Type of repositional maneuvre|Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
82444|NCT03541005|Dietary Supplement|Obex|After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex
82445|NCT03541005|Dietary Supplement|Placebo|After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.
82446|NCT03540979|Procedure|endometrial preparation for frozen blastocyst transfer|medical endometrial preparation for frozen blastocyte transfer
82447|NCT03540979|Drug|Letrozole|Aromatase inhibitor - 2.5mg/d for 5 days
82448|NCT03540979|Drug|Ovidrel|recommbinant hCG 250 mcg- single sc injection to induce ovulation
82449|NCT03540979|Drug|Estrofem|Estrofem 2mg*3/d for endometrial preparation
82450|NCT03540979|Drug|Endometrin 100Mg Vaginal Insert|vaginal tab for lutheal support
82451|NCT03540966|Combination Product|CapulinTM|a kind of camouflage agent
82452|NCT03540966|Other|Chinese version of the vitiligo life quality index, VLQI-C|a questionaire designed for patients with vitiligo
82453|NCT03540953|Drug|Endoscopic injection of Mitomycin C|administration included dilation of the stenotic segment with thermoplastic bougies, followed by the injection of 3mg of Mitomycin C, divided into 4 aliquots of 0.75mg, injected in the four quadrants, at the stenosis level.
82454|NCT03540940|Other|PEEP|7cmH2O positive end expiratory pressure
82455|NCT03540940|Other|ZEEP|0 cmH2O positive end expiratory pressure
82456|NCT03540927|Behavioral|PM+ for entrepreneurs|The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
82457|NCT03540927|Other|Cash transfer to the Entrepreneurs|The entrepreneurs in the control arm will receive cash transfer only for their businesses.
82458|NCT03540914|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
82459|NCT03540914|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
82460|NCT03540901|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3100m
82461|NCT03540901|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3100m
82462|NCT03540888|Other|Deep transverse Friction Massage|The procedure consisted of applying friction massage by fingertips transversely to the hamstrings tendon, in a sitting position. The tendon was located over four finger widths proximal to the medial and lateral epicondyles of the femur
82463|NCT03540888|Other|Dynamic stretching intervention|Participants in this group, swung their tested leg actively into hip flexion while keeping their knee fully extended and their ankle fully plantar flexed until a stretch was felt in the posterior thigh. This was repeated over 30 seconds and included in the participant's warm-up phase.
82464|NCT03540888|Other|Static stretching intervention|In the static stretching intervention, all participants laid on the floor in a supine position with both feet pointing upwards, with the tested limb in full knee extension and the foot in a relaxed position. The tested limb was moved up passively to a point of slight pain or discomfort at the posterior aspect of the thigh. This technique puts the hamstrings muscle at its greatest possible length. This position should be held for 30 seconds and was performed three times for a total of one minute and 30 seconds, 15 minutes after a match or training. The contralateral leg was stabilized by means of another collaborator in order to prevent compensation by rotation or elevation of the pelvis.
82465|NCT03540875|Device|Closed loop anesthesia|"Propofol and Remifentanil are administered automatically using a closed-loop system.~The goal of this study is to compare manual titration versus automated titration of propofol and remifentanil in adult patients undergoing surgery guided by the electro-cortical activity. The aim in both group is to maintain the qCon in the range 40-60 during induction and maintenance of general anesthesia using the propofol in TCI mode. But also the qNox in the range 40-60 using remifentanil. The controller is based on a Proportional-Integral-derivative algorithm which steers a target to the pumps during induction and maintenance of general anesthesia."
82466|NCT03540875|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
82467|NCT03540875|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
82468|NCT03540862|Device|maintenance negative pressure ventilation (Philips Respironics Lifecare NEV-100)|hospital-based NPV once every week as the maintenance program
82469|NCT03540849|Drug|Brentuximab Vedotin (Bv)|HL patients who are eligible for the study, will receive maintenance Bv. The first Bv dosage will be administered three months after allo-SCT (day 90) at the dosage of 1.8 mg/kg every 21 days for 12 cycles. post allo-SCT maintenance Bv for Hodgkin lymphoma
82470|NCT03540836|Drug|Relacorilant (3x100 mg softgel capsules)|A single relacorilant 300mg dose (3x100 mg softgel capsules) will be given once on Day 1 of one of three treatment periods.
82471|NCT03540836|Drug|Relacorilant (3x100 mg hard-shell capsules)|A single relacorilant 300mg dose (3x100 mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
82472|NCT03540836|Drug|Relacorilant (6x50mg hard-shell capsules)|A single relacorilant 300mg dose (6x50mg hard-shell capsules) will be given once on Day 1 of one of three treatment periods.
82473|NCT03540823|Biological|Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)|Single dose of Inactivated and fragmented influenza vaccine (A / Michigan / 45/2015 (H1N1) pdm09-like virus, A / Singapore / INFIMH-16-0019 / 2016 (H3N2) -like virus; B / Phuket / 3073/2013-like virus)
82474|NCT03540810|Drug|Hydroxychloroquine|The patients will additionally receive this drug with their usual treatment to evaluate its efficiency to prevent new thrombotic events in primary antiphospholipid syndrome patients
82475|NCT03540810|Drug|Placebo|The patients will receive placebo with their usual treatment
82476|NCT03540784|Other|WB-EMS|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
82477|NCT03540784|Other|Nutritional support|dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
82478|NCT03540771|Other|Palliative Care|"The intervention will comprise an approach to render palliative care, as taught to hepatologists through an on-line learning platform, and as delivered by PC providers as routine care. The elements of the intervention, which will be guided by a checklist and implemented over the course of interactions with the patient and caregivers at the initial, 1, 2, and 3 month visits, to include:~Patient/caregiver understanding of diagnosis, illness and prognosis~Symptom assessment and management~Psychosocial assessment and management~Distress screening and management~Discussion of goals of care~Advanced directives"
82479|NCT03540758|Drug|Diazoxide|"Non-diabetic participants will receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study.~T2D participants will have their blood sugar levels normalized, and will then receive diazoxide at a dose of 4-7 mg/kg (based upon weight) before undergoing the pancreatic clamp study."
82480|NCT03540758|Drug|Nicotinic acid|T2D participants will have their blood sugar levels normalized and will additionally receive nicotinic acid infusion based on weight (0.01 mg/kg/min) to lower free fatty acid levels before undergoing the pancreatic clamp study.
82481|NCT03540758|Drug|Placebo|"Non-diabetic participants will receive placebo and undergo the pancreatic clamp study.~T2D participants will be admitted the evening before the study day to normalize blood sugar levels to that of a healthy person. They will then receive placebo the next morning and undergo the pancreatic clamp study."
82482|NCT03540745|Device|TES Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
82483|NCT03540745|Device|TES-SHAM Treatment|Device: Nexalin Based Trans-Cranial Electrical Stimulation The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. Other Name: TES
82484|NCT03540732|Other|Indirect Calorimetry directed feeding.|Indirect calorimetry directed feeding (use of indirect calorimetry to calculate daily caloric requirement)
82485|NCT03540732|Procedure|Cycle Ergometry|Up to 60 minutes of cycle ergometry daily in addition to standard physiotherapy sessions.
82486|NCT03540719|Procedure|Osteosynthesis|Osteosynthesis of posterior tibial plateau fracture with a posterior tibial plateau plate
82487|NCT03540706|Diagnostic Test|Care with C-reactive protein assay in micro method|Care with C-reactive protein assay in micro method
82488|NCT03540693|Procedure|RYGB|RYGB-weight loss surgery
82489|NCT03540693|Procedure|SG|SG- weight loss surgery
82490|NCT03540693|Procedure|LAGB|LAGB- weight loss surgery
82491|NCT03540680|Other|Blood punction|"For the arms Term newborns (≥37GA) and Premature newborns the only intervention is a blood punction on the cordon.~For the arms Child between 7 and 15 years old with or without BPD the only intervention is a blood punction on peripheral blood."
82492|NCT03540654|Other|Budget impact|Budget impact, using a probabilistic markov model, of discontinuing TKI treatment in patients with CML in deep molecular response since at least two years, compared with current practice (treatment during entire life), from the healthcare system point of view
82493|NCT03540641|Device|MagVenture MagPro R30|the subjects will receive 1500 or 5000 pulses at 5Hz
82494|NCT03540628|Dietary Supplement|Thiamine and Vitamin C|Supplementary vitamins for the patient in septic shock
82495|NCT03540615|Drug|BAY1830839|Dose escalation in healthy male subjects
82496|NCT03540615|Drug|Placebo|Matching placebo
82497|NCT03540602|Dietary Supplement|Tart Cherry|NordicCherry Tart Cherry Extract Powder 500 mg from Specnova, inc
82498|NCT03540602|Other|Placebo Oral Capsule [CEBOCAP]|Rice flour
82499|NCT03540589|Device|Buzzy specific vibration device|It is a device that produces vibration
82500|NCT03540589|Behavioral|Distraction|The distraction will be obtained through tablet with videos
82501|NCT03540563|Other|Blood draw|Blood will be drawn to assess ctDNA
82502|NCT03540550|Other|Diet based on inulin-rich vegetables|During two weeks, healthy subjects were instructed to adhere to a controlled diet based on ITF-rich vegetables (±15 g ITF/day).
82503|NCT03540537|Other|Patient-controlled intravenous analgesia|PCIA solution: 2 μg/kg weight sufentanil and 8.96 mg tropisetron mesylate diluted in 100 ml normal saline；PCIA parameters: loading dose: 2 ml, background infusion: 2ml/h, bolus: 0.5ml, lockout-time: 15min; PCA duration: 48 hours from the end of suturing
82504|NCT03540537|Other|Quadratus Lumborum Block|Ultrasound-guided Quadratus lumborum block: A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 20 ml of 0.375 % ropivacaine will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
82505|NCT03540537|Other|Thoracic Paravertebral Block|Ultrasound-guided Thoracic paravertebral block: The patient is placed in the lateral position, the spinous processes of T6 and T8 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. Then 15 ml 0.375% ropivacaine is injected into the paravertebral space of T6 and T8.
82506|NCT03540524|Drug|GLPG2451 dose regimen A|GLPG2451 oral suspension, daily.
82507|NCT03540524|Drug|GLPG2451 dose regimen B|GLPG2451 oral suspension, daily.
82508|NCT03540524|Drug|GLPG2222|GLPG2222 tablet for oral use, daily.
82509|NCT03540524|Drug|GLPG2737|GLPG2737 capsules for oral use, daily.
82510|NCT03540511|Diagnostic Test|postoperative troponin|assess postoperative troponin levels after cardiac surgery in patients with renal dysfunction
82579|NCT03539978|Other|SM-THINk|Patients will receive the SM-THINk enhanced discharge method.
82511|NCT03540498|Dietary Supplement|AB-DENTALAC [Probiotics (study)]|Treatment for 6 weeks, which will consist of the consumption of 2 chewing gums AB-DENTALAC with 100mg L.plantarum + L.brevis Probiotics blend (5x108 CFU at the end of shelf life, a day.
82512|NCT03540498|Dietary Supplement|Placebo (control)|Treatment for 6 weeks, which will consist of the consumption of 2 chewing gums placebo, without probiotics strains, a day.
82513|NCT03540485|Drug|Melatonin|Daily administration of 300 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
82514|NCT03540485|Other|Placebo|Daily administration of placebo orally, for 24 months between 10pm to 11pm
82515|NCT03540472|Drug|tacrolimus|On refractory PRCA patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
82516|NCT03540459|Diagnostic Test|sleep polygraphy|sleep polygraphy (one night) in all included patients
82517|NCT03540446|Device|First Relief Treatment|To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
82518|NCT03540420|Drug|Atezolizumab|atezolizumab 1200 mg intravenous every 3 weeks in 12 months
82519|NCT03540407|Dietary Supplement|Oncoxin-Viusid®|Administration of the Oncoxin-Viusid® oral solution 25 mL three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
82520|NCT03540407|Dietary Supplement|Placebo|Administration of the Oncoxin-Viusid® oral solution placebo 25 ml three times a day during the concurrent Radiotherapy and Chemotherapy treatment and up to 3 weeks after the end of the onco-specific treatment
82521|NCT03540381|Other|neoatherosclerosis|
82522|NCT03540368|Drug|Tranexamic acid injection|Administering tranexamic acid loading dose 1 gram in 100 cc sodium chloride 0,9%, followed by maintenance dose 3 grams in infusion for 24 hours.
82523|NCT03540368|Other|Placebo|Administering placebo or sodium chloride 0,9% intravenously
82524|NCT03540355|Drug|Cipros 20 association|oral, once a day
82525|NCT03540355|Drug|Crestor 20 mg|Oral, once a day
82526|NCT03540342|Procedure|One stop strategy group|Percutaneous coronary intervention (PCI) will be performed on the same operating table immediately after the endovascular aortic repair (EVAR)
82527|NCT03540329|Device|Internal Osteogenesis distractor|Internal distraction osteogenesis in mandible
82528|NCT03540329|Device|External Osteogenesis distractor|External distraction osteogenesis in mandible
82529|NCT03540316|Combination Product|Two short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 2 minutes.
82530|NCT03540316|Combination Product|Two short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 2 short dental implants and LLLT for 4 minutes.
82531|NCT03540316|Combination Product|Four short implants and 2 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 2 minutes.
82532|NCT03540316|Combination Product|Four short implants and 4 minutes LLLT|Patients with edentulous atrophied mandibular ridge will receive 4 short dental implants and LLLT for 4 minutes.
82533|NCT03540303|Drug|CAR19 T cells carrying cytoplasmic activated PD-1|"step 1: Collect 50-100ml of peripheral blood for culture of CAR19 T cells carrying cytoplasmic activated PD-1 step 2. After 72 hours, pretreated with FC regimen, details as follow Cyclophosphamide 600-800mg/m2 for 2 days Fludarabine 25-30mg/m2 for 3 days step 3: After another 48 hours transfusion the cells back to the patients the numbers of infused CAR T cells are 2x106 /kg for the first 3 patients, 6x106 /kg for the second 3 patients and 18x106 /kg for the third 3 patients.~After finishing this, another 6 patients will be enrolled for observation of efficacy."
82534|NCT03540290|Procedure|Modification of the implant supported prostheses in order to facilitate oral hygiene|Peri-implant mucositis will be treated by individualized oral hygiene instructions and decontamination of the implant surface by ultrasonic device with a plastic tip and plastic curettes plus the modification of the implant prosthesis in order to facilitate oral hygiene access
82535|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, active parents"|"Prevention program: young In Favor of Myself, with parent participation"
82536|NCT03540277|Behavioral|"Experimental: Prevention Program young In Favor of Myself, no parental involvement"|"Prevention program: young In Favor of Myself, without parent participation"
82537|NCT03540264|Device|Clearfil Majesty TM|Tooth wear - composite resin
82538|NCT03540264|Device|Vita-Enamic®|Tooth wear - polymer-infiltrated-ceramic-network
82539|NCT03540251|Other|Auricular Points Sticking|"Auricular Points Sticking is a kind of acupunture based on Meridians Theory of traditional Chinese Medicine.Sticking and pressing predefined therapeutic auricular points can relieve the frequency and severity of hot flashes and other climacteric symptoms.~Both groups received a booklet with information about self-care indications, auricular points and its management, and patients can record their hot flash score each day for 12 weeks in the booklets.In addition, both group received 8 treatment sessions of sticking and pressing predefined auricular points or placebo auricular points treatments."
82540|NCT03540225|Drug|Progesterone|Utrogestan Vaginal 200 mg or 400 mg daily from 11-14 Week or 20-24 Week until 34 Week
82541|NCT03540212|Drug|Daclatasvir and sofosbuvir|"Daclatasvir is a DAAs that can inhibit the HCV non-structural (NS) 5A protein when used in combination with other HCV-therapies. It has a linear, non-time-dependent pharmacokinetic profile and nanomolar potency in vitro against HCV genotypes 1-6. It is excreted primarily via faeces, about 88% in an unchanged form while renal excretion accounts for approximately 7% of its elimination.~DOSE OF SOFOSBUVIR: 400 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2.~DOSE OF DACLTASVIR: 60 mg tablet orally once daily with food (in the morning) for 12 weeks for adolescents with liver fibrosis Metavir score F0-F2."
82542|NCT03540199|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
82543|NCT03540199|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
82544|NCT03540186|Dietary Supplement|Epigenorm Antivir|1 capsule of Epigenorm Antivir twice daily for 3 months
82580|NCT03539952|Drug|TETA 4HCL|TETA 4HCL
82581|NCT03539952|Drug|Penicillamine|Penicillamine
82545|NCT03540186|Procedure|Acupuncture|Acupuncture involves inserting sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: no less than 15 sessions, based on the physician discretion
82546|NCT03540160|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
82547|NCT03540147|Device|Hokanson Cuffs|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will be completed will be randomly assigned to the participant.
82548|NCT03540147|Device|BStrong Bands|Each subject will participate in all (5) experimental arms. The order in which the experimental arms will completed will be randomly assigned to the participant.
82549|NCT03540134|Device|Intracerebral Infusion of Autologous Cerebral Spinal Fluid|Unilateral infusion of 0.5 ml autologous CSF before DBS electrode insertion with MRI monitoring
82550|NCT03540121|Behavioral|Video education + adherence contract|Participants will receive standard education along with the home-based video education plus an adherence contract. Following the baseline assessment, access to videos will be provided electronically so that the patient can watch them at home. The videos will be initially viewed in the following order: Video 1: Introduction, Video 2: Medications, Video 3: Your New Life. Approximately one month after transplant, after the video series has been viewed in its entirety, participants will receive an email link inviting participants to reflect on their goals about transplantation and pledging to taking their medications as directed. The contract will be non-enforceable, but it will provide patients with the opportunity to formally commit to a goal of taking the medications as prescribed. At 3 months, and 12 months, the participant will have the opportunity to reflect and modify adherence goals as desired.
82551|NCT03540108|Dietary Supplement|Lactobacillus plantarum ECGC 13110402|The study will consist of two phases: a treatment period (12 weeks) with either the active or placebo and a wash-out period (4 weeks). Following a screening visit to ensure adherence to the inclusion criteria, the study will consist of a baseline, midpoint, endpoint (week 6 and 12, respectively) and washout visit (week 16).
82552|NCT03540108|Dietary Supplement|Placebo Comparator: Maltodextrin|Please see intervention description above.
82553|NCT03540095|Drug|Erector Spinae Plane Block|See arm description
82554|NCT03540095|Drug|Paravertebral Nerve Block|See arm description
82555|NCT03540082|Other|Tuck and Roll Group|An instructor will explicitly verbally and visually demonstrate the falling technique and provide feedback on participant performance. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
82556|NCT03540082|Other|Fall Exposure|An instructor will implicitly be exposed to the falling technique. Each group will have 4 sessions to physically practice the skills with each practice session lasting about an hour.
82557|NCT03540069|Behavioral|Care Group Cervical Cancer Screening Education Curriculum|a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
82558|NCT03540056|Diagnostic Test|Ultrasound|We use ultrasound to measure the PRF and the testicular volumes.
82559|NCT03540043|Drug|Administration of Placebo|Botanical Drug Phase 2 clinical study
82560|NCT03540043|Drug|Administration of PUR0110 (Thykamine) 0.05%|Botanical Drug Phase 2 clinical study
82561|NCT03540043|Drug|Administration of PUR0110 (Thykamine) 0.1%|Botanical Drug Phase 2 clinical study
82562|NCT03540043|Drug|Administration of PUR0110 (Thykamine) 0.25%|Botanical Drug Phase 2 clinical study
82563|NCT03540030|Drug|Gabapentin|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82564|NCT03540030|Drug|Celecoxib|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82565|NCT03540030|Drug|toradol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82566|NCT03540030|Drug|acetaminophen|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82567|NCT03540030|Drug|regional block|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82568|NCT03540030|Drug|propofol|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82569|NCT03540030|Drug|IV lidocaine|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82570|NCT03540030|Drug|rocuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82571|NCT03540030|Drug|vecuronium|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82572|NCT03540030|Drug|sevoflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82573|NCT03540030|Drug|desflurane|opioid-free treatment pathway for shoulder arthroplasty with a focus on perioperative pain control and postoperative symptoms from treatment
82574|NCT03540017|Drug|Cisplatin|Heated Intraperitoneal Chemotherapy will be administered after the completion of interval cytoreductive surgery after three cycles of neoadjuvant chemotherapy.
82575|NCT03540004|Device|MolecuLight i:X Imaging Device|The i:X Imaging Device uses built-in light-emitting diodes (LEDs) emitting 405 nm violet excitation light to illuminate the wound during fluorescence imaging in (FL-Mode). The light excites biological components of the wound and surrounding tissues. Non-biological components may also fluoresce although their presence in wounds is less common, provided the wound has been cleaned following standard care protocols. The resulting wound fluorescence wavelengths emitted are typically between 420 - 700 nm in the visible wavelength spectrum. In FL-mode, a customized fluorescence emission filter, which is mechanically placed in front of the built in imaging sensor and allows real-time capture of wound, limits the visualization of fluorescence to wavelengths between 500-545 nm, which typically appears green in color, and 600-665 nm, which typically appears red in color.
82576|NCT03539991|Other|Internet-Based Intervention|Complete online courses
82577|NCT03539991|Other|Meeting|Participate in virtual meetings
82578|NCT03539991|Other|Survey Administration|Ancillary studies
82582|NCT03539939|Procedure|Coronally Advanced Flap|The coronally advanced flap (CAF) is a procedure frequently used in periodontal plastic surgery. The main objective of this surgical technique is to mobilize the gingival margin and reposition it at a level more coronal (incisal direction) than its original location. CAF is mainly used for the treatment of gingival recessions.
82583|NCT03539926|Device|Lit-control®pH Meter|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the Lit-control®pH Meter.
82584|NCT03539926|Diagnostic Test|Reactive strips|Alkalinization products will be used as standard clinical practice together with the pH monitoring through the reactive strips.
82585|NCT03539913|Biological|Probiotic : Saccharomyces boulardii|Treatment for 5 days
82586|NCT03539913|Biological|Probiotic : Bacillus clausii|Treatment for 5 days
82587|NCT03539900|Drug|Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination|NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
82588|NCT03539900|Other|Placebo|Placebo will be inactive and taken daily in pill form.
82589|NCT03539887|Drug|Intranasal ketamine|Intranasal ketamine will be prepared as 100mg/ml ketamine in 0.9% saline. An mucosal atomization device will be used to provide 5 intranasal applications of solution (volume 100 μl), separated by 3 minutes, over a total of 15 minutes. Each of five ketamine applications will provide 10 mg of study drug, for a total of 50mg. The dose to be used (0.5-1mg/Kg) is 6 to 18 times lower than the sedation dose (6-9mg/Kg).
82590|NCT03539887|Drug|Placebo|Saline alone. An mucosal atomization device will be used to provide 5 intranasal applications of saline (volume 100 μl), separated by 3 minutes, over a total of 15 minutes.
82591|NCT03539861|Device|Hemodialysis|Each patient will receive two hemodialysis treatments while on this study. The first hemodialysis treatment will be standard of care hemodialysis. The second treatment will be the experimental hemodialysis treatment using the Selective cytopheretic device.
82593|NCT03539835|Other|Resistance training (RT)|Resistance training (RT) will include 15 repetitions for two sets and to exhaustion on the third set for seven major muscle groups: the leg and chest press, knee extension, leg curl, row, abdominal crunch, and bicep curl. Resistance is gradually increased to account for strength gains when subjects are able to complete 20 repetitions on the third set.
82594|NCT03539835|Behavioral|Cognitively-based compassion training control (CBCT)|Cognitively-based compassion training control (CBCT) classes will be performed in a group setting for 1.5-2 hours per week, and consist of didactics, class discussion, and guided meditation practice. Each class will begin with a period of meditation to calm and focus the mind, followed by analytical practices designed to challenge unexamined assumptions regarding feelings, and actions toward others with a focus on generating spontaneous empathy and compassion for themselves and others.
82595|NCT03539822|Drug|Cabozantinib|by mouth
82596|NCT03539822|Drug|Durvalumab|infusion
82597|NCT03539809|Dietary Supplement|L-Amino Acids|6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
82598|NCT03539796|Procedure|Dural puncture epidurals (DPE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle, but no medications will be injected. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-PF 3mg will be given via epidural after delivery of the fetus.
82599|NCT03539796|Procedure|Traditional epidurals (EPI)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
82600|NCT03539796|Procedure|Combined-spinal epidural technique (CSE)|Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
82601|NCT03539783|Diagnostic Test|Respiratory epithelial cell brushing|At specified time points, nasal brushings will be performed to obtain RNA.
82602|NCT03539770|Procedure|Posterior spinal fusion|Surgical procedure that involves placement of spinal rods to correct spinal curvature
82603|NCT03539757|Device|Non-Contrast Magnetic Resonance Imaging|The investigators plan to prospectively assess the correlation of liver fibrosis and congestion measurements obtained from novel, non-contrast MR imaging methods to histopathologic data obtained from a clinically-indicated liver biopsy in Fontan patients.
82604|NCT03539744|Drug|Pomalidomide|capsule, oral
82605|NCT03539744|Drug|Dexamethasone|oral, locally available form
82606|NCT03539744|Drug|Venetoclax|tablet; oral
82607|NCT03539731|Drug|Fluorine F 18 DASA-23|Given IV
82608|NCT03539731|Procedure|Positron Emission Tomography|Undergo PET scan
82609|NCT03539718|Drug|Taurolidine heparin|Taurolock-hep 500 at end of session
82610|NCT03539718|Drug|Heparin Sodium|Heparin sodium 5000 at end of session
82611|NCT03539705|Other|There is no intervention|There is no intervention
82612|NCT03539679|Other|Encouraging physical activity.|Encouraging physical activity with motion sensor's feedback.
82613|NCT03539666|Other|diet|dietary patterns
82614|NCT03539640|Other|PEEP: 5 cmH2O|During second part of the study (MRI)
82615|NCT03539640|Other|PEEP: 10 cmH2O|During second part of the study (MRI)
82616|NCT03539640|Other|PEEP: 15 cmH2O|During second part of the study (MRI)
82617|NCT03539627|Drug|Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]|patients are to receive azilsartan medoxomil
82618|NCT03539614|Drug|Prazosin|This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.
82619|NCT03539614|Drug|Placebo|This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
82620|NCT03539601|Drug|Crisaborole ointment, 2%|Applied twice a day (BID)
82621|NCT03539601|Drug|Hydrocortisone butyrate cream, 0.1%|Applied BID
82622|NCT03539601|Drug|Pimecrolimus cream, 1%|Applied BID
82623|NCT03539601|Drug|Crisaborole Vehicle|Applied BID
82624|NCT03539588|Device|trigger point dry needling|placement of the dry needle into the muscle tissue to elicit a local twitch response. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
82625|NCT03539588|Device|Electrical Stimulation|uses the dry needles as nodes to stimulate muscular contraction. Only MYOTECH dry needles and ESTIM II dual channel stimulator will be used in this study. However we are not studying the equipment.
82627|NCT03539562|Drug|Morphine Sulfate|Morphine sulfate and promethazine
82628|NCT03539549|Drug|Abicipar pegol|2 mg abicipar administered to the study eye by intravitreal injections at baseline (Day 1) and Weeks 4, 8, 16, and 24
82630|NCT03539510|Behavioral|HF-ACP Website|Each module is broken down into weekly topics and each module takes 3-6 weeks to complete. Participants can access and review the material as often as needed as well as revisiting the information from modules they have completed.
82631|NCT03539497|Diagnostic Test|Biomarker|Plasma mitochondrial DNA, plasma Cytochrome C
82632|NCT03539484|Drug|RO7172508|RO7172508 will be administered at a dose and as per the schedule specified in the respective arms.
82633|NCT03539484|Drug|Obinutuzumab|In the event obinutuzumab treatment is implemented, obinutuzumab will be administered either on Day-7 or on Day-7 and Day-6. If obinutuzumab is given only on one day, then the schedule for Day-7 should be followed including an end of infusion sample.
82634|NCT03539484|Drug|Tocilizumab|Tocilizumab will be administered if required, for the management of severe CRS (cytokine release syndrome)
82635|NCT03539471|Diagnostic Test|interview, Tridimensional Personality Questionnaire|interview of the residents about 15-20 minutes, then use Tridimensional Personality Questionnaire
82636|NCT03539458|Device|Tendyne Mitral Valve System|Mitral valve replacement
82637|NCT03539445|Drug|Butylphthalide|This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
82638|NCT03539445|Drug|Butylphthalide Placebo|This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
82639|NCT03539432|Drug|Gemfibrozil 600 MG|Gemfibrozil capsules (600 mg) taken twice per day
82640|NCT03539432|Drug|Placebo oral capsule|Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
82641|NCT03539406|Biological|UCB-NK cells|Intraperitoneal allogeneic UCB-NK cells infusion
82642|NCT03539406|Drug|Chemotherapy|Cyclofosfamide/fludarabine treatment
82643|NCT03539393|Drug|Fremanezumab|quarterly 675 mg dose (3 subcutaneous [SC] injections of 225 mg each).
82644|NCT03539380|Drug|TRx0237|TRx0237 8 mg/day, with flexible dosing after 3 months (4-20 mg/day)
82645|NCT03539367|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
82646|NCT03539367|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
82647|NCT03539354|Device|Temporary spinal cord stimulation|Percutaneous trial (temporary) electrodes are placed through a 14-gauge needle.The skin is entered at the medial aspect of the pedicle with the Tuohy needle usually angled 30-45° toward the midline for optimal entry into the epidural space at the interlaminar edge 1 or 2 levels of cephalad (usually, Th5-Th6 level). The 14-gauge needle is then passed with the bevel facing up at a 30-45° oblique angle to reach the depth of the midline laminar target.The Tuohy needle is then carefully removed and the operative site is cleaned with chlorhexidine and alcohol. Temporary stimulation is carried out till coronary artery bypass grafting surgery for 3 days, then stimulation turns off during surgery. At the end of coronary artery bypass grafting the temporary stimulation turns on in the intensive care unit and continues for 7 days. After that, the temporary leads will be removed.
82648|NCT03539354|Procedure|Coronary artery bypass grafting|Standart coronary artery bypass grafting procedure.
82649|NCT03539354|Drug|B-blockers|Standart b-blocker therapy will be administered in each group for AF prophylactics
82650|NCT03539341|Behavioral|PLH-Thailand parenting programme|Parenting programmes include developing positive caregiver-child interaction through child-led play and emotional communication, praise and rewards to encourage positive child behaviour, limit-setting behaviours such as effective instruction giving and establishing consistent household rules, and non-violent discipline strategies to replace harsh parenting and corporal punishment.
82651|NCT03539341|Other|Control (care as usual)|The control will be an inactive condition of standard care at the time of the intervention. 'Standard care' may include access to Parent Schools in Mother and Child Health clinics at public hospitals, which are provided in some provinces and districts in Thailand.
82652|NCT03539328|Drug|Pembrolizumab|Humanized antibody used in cancer immunotherapy.
82653|NCT03539328|Drug|Gemcitabine|Chemotherapy medication
82654|NCT03539328|Drug|Paclitaxel|Chemotherapy medication
82655|NCT03539328|Drug|Liposomal Doxorubicin|Chemotherapy medication
82656|NCT03539315|Behavioral|ARCHES|Addressing Reproductive Coercion within Healthcare Settings (ARCHES) is a clinic-based intervention developed in the U.S., and involves training existing health providers to identify RC and IPV during standard family planning clinic-based counselling interactions. The intervention seeks to empower women with harm reduction strategies that minimize their risk for unintended pregnancy by offering a wide range of contraceptive options, providing counseling on correct and consistent use of contraception, and counseling on contraceptive methods that are difficult for a male partner to detect or block such as injectables or IUDs. ARCHES also facilitates access to violence support and counselling services by connecting women with community-based IPV services.
82657|NCT03539302|Drug|Flecainide Acetate|Oral inhalation form using a nebulizer
82658|NCT03539289|Behavioral|MUFA Diet|Control of patient MUFA Diet
82659|NCT03539289|Behavioral|SFA Diet|Control of patient SFA Diet
82660|NCT03539276|Behavioral|Knowledge exchange|OptimaMed
82661|NCT03539263|Dietary Supplement|Bifihappy|"During the six weeks of treatment, the experimental group will take daily doses of 2,5 g with a concentration of 4x109 CFU/sachet of a mixture of lyophilised probiotic strains of the following species:~Lactobacillus fermentum~Lactobacillus rhamnosus~Lactobacillus plantarum~Bifidobacterium longum"
82662|NCT03539263|Other|Placebo|During the six weeks of treatment, the experimental group will take daily doses of 2,5 g of maltodextrin
82663|NCT03539250|Radiation|IMRT|IMRT with and without chemotherapy
82664|NCT03539237|Other|Video demonstration of physical activity intensity levels|In the video demonstration, an approximately 50 year old male explains 1) light-intensity, 2) moderate-intensity, and 3) vigorous-intensity physical activity referring to differences in heart rate, breathing frequency and capability to talk normally. Simultaneously, on a treadmill he demonstrates the body signs of the three intensity levels. He gives examples and points out that there are individual differences in the intensity evaluation of comparable activities.
82665|NCT03539224|Drug|Dolutegravir (DTG)|DTG 50 mg tablet will be orally administered once daily with or without food upto 48 weeks
82666|NCT03539224|Drug|Lamivudine (3TC)|Lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets. It will be orally administered once daily with or without food upto 48 weeks.
82667|NCT03539211|Other|Rotation Exercises|The subjects received 7 trunk rotation stability exercises x 10 reps each
82668|NCT03539211|Other|Control Exercises|The subjects received 7 traditional exercises x 10 reps each
82669|NCT03539198|Radiation|Proton Stereotactic Body Radiation Therapy (SBRT) (5 fractions; 3500-4500 cGy)|Patients will be receiving proton SBRT
82670|NCT03539198|Radiation|Proton Stereotactic Body Radiation Therapy (SBRT) (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients will receive proton SBRT.
82671|NCT03539198|Drug|Nivolumab 3 mg/kg IV q2 weeks|Patients will receive Nivolumab x2 cycles before SBRT q2 weeks, and continued q2 weeks after SBRT until progression or at the discretion of the treating physician.
82672|NCT03539198|Radiation|Proton or Photon SBRT (3-5 fractions; various dose and fractionation regimens depending on treatment site).|Patients with further oligoprogression (5 or fewer sites) will be eligible to receive additional SBRT to all sites of oligoprogression.
82673|NCT03539185|Device|Videolaryngoscope Airtraq|Awake orotracheal intubation with laryngeal nerve block and remifentanil sedation
82674|NCT03539185|Device|Fiberoptic bronchoscope|Awake nasotracheal intubation with laryngeal nerve block and remifentanil sedation
82675|NCT03539172|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily from 2 weeks before the beginning of radiotherapy until the end of whole radiotherapy course
82676|NCT03539159|Other|Allogeneic conventional sized serum eye drops|allogeneic serum conventional sized drops (40-50 µL, administrated using the Meise applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
82677|NCT03539159|Other|Allogeneic micro sized serum eye drops|Allogeneic serum micro eye drops (5-10 µL, administrated using the mu-Drop applicator) applied six times a day (when appropriate, lowering the dose to 3-4 times a day is allowed) for a period of one month
82678|NCT03539146|Other|Dietary fiber|Intake of yogurt containing cascara with 0%, 3%, 7%,13% dietary fiber in a crossover design.
82679|NCT03539146|Other|Control yogurt|Control yogurt
82680|NCT03539133|Other|collection of clinical data|prospectively and systematically collection of clinical research data from STEMI patients
82681|NCT03539120|Other|Follow up for survival|No intervention, this is an observational study of survival outcomes.
82682|NCT03539107|Procedure|Retrograde bladder fill|Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
82683|NCT03539107|Other|spontaneous void|Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
82684|NCT03539094|Other|Intermittent fasting|the subjects randomized to this group will do IF by restricting their diet and consuming few calories two days per week. During the days of fasting, subjects will be allowed to drink water, calorie-free beverages, and eat fresh, steamed or roasted non-starchy vegetables.
82685|NCT03539081|Diagnostic Test|Dual-energy X-ray absorptiometry Scan|Body composition analysis will be obtained by DEXA scan.
82686|NCT03539081|Other|Laboratory Measurements|The following labs will be obtained during the course of the study: pregnancy test (urine), glucose, insulin, catecholamine, and cholesterol (serum).
82687|NCT03539081|Other|Blood Flow Measurement|The blood flow to the arm or leg may also be measured by placing an ultrasonic probe on the skin over the femoral artery of the leg and the brachial artery of the arm.
82688|NCT03539081|Other|Continuous Blood Pressure|Continuous Blood pressure cuff will worn for 2 days with spinal cord stimulator on and off (24 hour on and 24 hour off). Optional procedure.
82689|NCT03539081|Other|Partial pressure of oxygen|Transcutaneous recordings will be captured to measure the partial pressure of oxygen by placing monitors on the subject's chest and foot.
137523|NCT03114605|Behavioral|Mindfulness-based Intervention|
82690|NCT03539081|Other|Microneurography|The sympathetic nervous system activity to the subject's leg muscles will be measured by a tiny microelectrode placed in the peroneal nerve in the leg located just below the knee on the outer part of the leg. When the nerve is located 2 tiny sterile microelectrodes will be inserted through the skin.
82691|NCT03539081|Other|Anthropometric Measurements|Height and weight will be obtained.
82692|NCT03539081|Behavioral|John Hopkins Restless Legs Severity Scale|Subjects will be administered questionnaires to evaluate RLS symptoms using John Hopkins Restless Legs Severity Scale.
82693|NCT03539081|Behavioral|Continuous Blood Pressure Diary|Subjects participating in Continuous Blood Pressure monitoring will be administered continuous blood pressure monitoring compliance diary.
82694|NCT03539068|Behavioral|WEB-ED+ Treatment Arm|"Veterans who screen positive on one or more mental health screens in WEB-ED will be eligible for RCT and those who consent and are randomly assigned to the WEB-ED+ Group. WEB-ED+ augments Current WEB-ED in a next step online interface via Pharos. If successful, this enhancement could be integrated into the next iteration of WEB-ED. Enhancements include:~An eHealth interface tailored to Veterans' VA and MHV enrollment needs, links for an electronic interface with VA enrollment, MHV and MHV premium status enrollment, and secure messaging guidance.~Shared decision making (SDM) interface: Veteran SDM-related educational (e.g., existing YouTube videos) and structured questions about treatment concerns, preferences, and questions and can be accessed through postal and email distribution or Pharos portal.~Access to a health coach (the research coordinators) will be available through a toll-free number to assist both Veterans and providers/Transition Patient Advocates."
82695|NCT03539055|Drug|Dabigatran Etexilate Oral Capsule|Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
82696|NCT03539029|Procedure|Surgery|Surgical fracture fixation
82697|NCT03539029|Procedure|Conservative treatment|immobilisation with plaster cast
82698|NCT03539003|Drug|sevoflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of sevoflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
82699|NCT03539003|Drug|desflurane|anesthesia was induced with propofol (1.5 mg/kg) and target controlled infusion (TCI) of remifentanil (2-3 ng/mL of targeted effect site concentration (Ce). After intubation, inspired concentration of desflurane (0.8-1 MAC) and the Ce of remifentanil TCI (1.0-2.0 ng/ml) were adjusted to a BIS target level for hypnosis of 40-60 during surgery.
82700|NCT03539003|Drug|propofol and remifentanil|anesthesia was induced with an effect-site concentration of 3-4 μg/ml propofol and 2-3 ng/ml remifentanil using target-controlled infusion (TCI). After intubation, The effect site TCI of propofol (2-3 μg/ml) and remifentanil (1.0-2.0 ng/ml) was adjusted to maintain the desired hypnosis (40-60 of the BIS value) during surgery.
82701|NCT03538990|Other|DASH Eating Pattern|The DASH diet is a heart-healthy eating pattern that is focused on adequate consumption of fruits, vegetables, whole grains, low-fat dairy, fish, poultry, beans, nuts, and vegetables oils while emphasizing limited intake of foods containing saturated fat, such as fatty red meats, full-fat dairy products, and tropical oils, such as coconut, palm kernel, and palm oils, as well as sugar-sweetened beverages and sweets.
82702|NCT03538977|Procedure|Hydrotherapy|A re-sterilizable stainless steel bucket with an upper diameter of 30 cm, a depth of 32 cm, with water at a temperature between 37 and 38º Celsius will be used. The amount of water used will be sufficient to keep the baby submerged up to shoulder height. The baby will be immersed in the heated water of the bucket and will be suspended by occipital support performed by the physiotherapist, who alternates lateral-lateral and anteroposterior movements with only static suspension. The therapy will last from eight to ten minutes and will be discontinued if there is agitation, cyanosis, worsening respiratory distress or major evacuation. If the baby is using any type of ventilatory support or oxygen therapy, the same will be maintained during the procedure of hydrotherapy.
82703|NCT03538977|Procedure|Conventional Physiotherapy|Conventional physiotherapy consists of manipulations of Thoracoabdominal Rebalancing, a registered technique which uses simultaneous passive stretching of inspiratory muscles and stimulation of the diaphragm. The manipulation used to improve the dynamic diaphragm included the thoracic-abdominal and lower abdominal support maneuvers. Back repositioning was used to minimize posteriorization of the ribs and costal kyphosis due to thoracic distortion.
82704|NCT03538964|Procedure|toric intraocular lens|cataract surgery with implantation of an toric intraocular lens
82705|NCT03538964|Procedure|non toric intraocular lens|cataract surgery with implantation of a non toric intraocular lens
82706|NCT03538951|Drug|10% VDA-1102|200 mg twice-daily for 12 weeks
82707|NCT03538951|Drug|20% VDA-1102|200 mg once-daily for 12 weeks
82708|NCT03538938|Behavioral|1-Call Quitline Counseling|The 1-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 1 proactive call using a standard, evidence-based protocol lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
82709|NCT03538938|Behavioral|4-Call Quitline Counseling|The 4-Call Quitline Counseling will be provided by the Wisconsin Tobacco Quit Line (WTQL) and consists of 4 proactive calls that use a standard, evidence-based protocol with each call lasting approximately 20 minutes; ad hoc calls that are initiated by the participant are also available.
82710|NCT03538938|Drug|Nicotine patch|Nicotine Patch treatment will consist of a two week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD).
82711|NCT03538938|Drug|Nicotine Patch and Nicotine Lozenge|The Nicotine Patch treatment will consist of a four week supply of over-the-counter nicotine patches (21 mg for those who smoke 10 or more cigarettes per day (CPD); 14 mg for those who smoke fewer than 10 CPD); the Nicotine Lozenge treatment will consist of a four week supply of over-the-counter nicotine lozenges (2-mg dose for those who do not smoke within 30 minutes of waking; 4-mg dose for those who smoke within 30 minutes of waking).
82745|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 5, 28 days
82746|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 6, 28 days
82747|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 7, 28 days
82748|NCT03538743|Drug|PF-06882961|Tablet, dose TBD, twice daily, Cohort 8, 28 days
82712|NCT03538938|Behavioral|SmokefreeTXT|SmokefreeTXT support is a national program offered at no cost to users (apart from data/minute costs charged by cellular providers about which enrollees are advised at enrollment) and is sponsored by the National Cancer Institute. This program sends up to 5 messages per day for up to 2 weeks prior to the target quit day and 6 weeks following the target quit day (total duration may be longer if participants elect to change the target quit day). The text messages offer tips to help enrollees achieve their goal of quitting smoking and offer real-time interactive tips when participants text in responses indicating cravings, negative moods, or slips. Participants have the option to reset quit dates and have the option to unsubscribe at any time by texting STOP to the program.
82713|NCT03538938|Behavioral|No SmokefreeTXT|Proactive information about enrolling in adjunctive SmokefreeTXT text messaging support is not offered.
82714|NCT03538938|Behavioral|Financial Incentives for Treatment Engagement|Incentives for treatment engagement are for each counseling session and for staying enrolled in SmokefreeTXT for six weeks. These incentives are designed to bolster motivation to stay engaged in treatment and to offset the costs and effort of treatment engagement (in terms of cell phone minutes).
82715|NCT03538938|Behavioral|No Financial Incentives for Treatment Engagement|No Financial Incentives for Treatment Engagement are offered.
82716|NCT03538925|Behavioral|AAC Generative Language Intervention|Parent/Caregiver AAC App Operational Training + Direct AAC Input-Output Language Intervention
82717|NCT03538925|Behavioral|Standard of Care / Business as Usual|Parent/Caregiver AAC App Operational Training
82718|NCT03538912|Other|Biomarker strategy|EAT duration is determined by β-D-1,3-glucan and mannan serum assays, performed at day 0 (day of EAT initiation) and day 3.
82719|NCT03538912|Other|Routine strategy|EAT duration is based on IDSA guidelines, which recommend 14 days of treatment for patients without subsequent proven ICI, and who improve under antifungal treatment, or less in other situations.
82720|NCT03538899|Drug|AProArt|Participants will undergo infusion with autologous hematopoietic cells transduced with a lentiviral vector, AProArt, which contains the correct form of DCLRE1C complementary deoxyribonucleic acid DNA, after receiving sub-ablative, exposure-targeted busulfan conditioning.
82721|NCT03538899|Device|CliniMACS® CD34 Reagent System cell sorter device|Processing of hematopoietic progenitor cells to select CD34 cells, using the CliniMACS® CD34 Reagent System, prior to infusion.
82722|NCT03538899|Drug|Busulfan|Busulfan is a cell cycle non-specific alkylating antineoplastic agent, in the class of alkyl sulfonates. Patients will receive low-dose busulfan conditioning targeted over 2 days to achieve a cumulative area under the curve (AUC) of 20 mg*hr/L.
82723|NCT03538886|Procedure|Coronary artery bypass grafting (CABG)|Revascularization of LAD lesion by CABG
82724|NCT03538886|Procedure|Percutaneous coronary intervention (PCI)|Revascularization of LAD lesion by PCI
82725|NCT03538873|Behavioral|Physical activity|
82726|NCT03538860|Behavioral|Active comparator: Human interpreter|A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.
82727|NCT03538860|Behavioral|Intervention: Asynchronous Telepsychiatry|A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.
82728|NCT03538847|Other|Numerical rating scale|Measure of postoperative pain
82729|NCT03538834|Dietary Supplement|Cod meal from residual material|Cod meal from residual material, 8 g protein daily for 8 weeks
82730|NCT03538834|Dietary Supplement|Control|Placebo
82731|NCT03538821|Dietary Supplement|Intact cod protein from fillet|Intact cod protein from fillet 8 g protein daily for 8 weeks
82732|NCT03538821|Dietary Supplement|Intact cod protein from residual material|Intact cod protein from residual material, 8 g protein daily for 8 weeks
82733|NCT03538821|Dietary Supplement|Control|Control group receive tablet containing fillers
82734|NCT03538808|Drug|Varenicline|Participants will be provided varenicline medication
82735|NCT03538808|Other|Placebo|Participants will be provided placebo medication
82736|NCT03538795|Combination Product|iTBS&eCIMT|All will receive eCIMT+iTBS on an outpatient basis for 4 hours/day for 15 consecutive weekdays. eCIMT will include training of the more-affected arm following shaping principles, restraint of the less-affected arm, and the Transfer Package in combination with NDT techniques to reduce tone so that shaping of movement can be carried out. The Transfer Package is a set of behavioral techniques designed to transfer therapeutic gains from the treatment setting to everday life. iTBS will be added to prime the areas of the brain that control movement of the more-affected arm so that the responsiveness of that tissue to motor training is enhanced. Treatment sessions will alternate between 10 minute periods of iTBS (which include time for set-up and transition) and 1-hour periods of eCIMT.
82737|NCT03538782|Procedure|Percutaneous biliary drainage|The initial puncture of the bile duct with an access needle is performed by ultrasound guidance or by fluoroscopic guidance. After injection of the radiopaque contrast media into the bile duct system the rest of the examination is performed by fluoroscopic guidance. All different PTBD procedures are analyzed: insertion, exchange or removal of a plastic catheter, metal stent implantation, PTBD with cholangioscopy, PTBD with ballon dilatation, PTBD with lithotrypsy or diagnostic percutaneous transhepatic cholangiography.
82738|NCT03538769|Other|electronic alert and clinical decision support system|Providers taking care of patients will receive an electronic alert and will be guided to use a clinical decision support system
82739|NCT03538756|Device|Walkasins|Walkasins® consist of two parts for each leg: the leg unit and the foot pad. The leg unit wraps around the lower leg of the user and contains electronics for reading foot pad pressure signals, a microprocessor, and four vibrating motors that provide gentle tactile sensory cues to the front, back, medial, and lateral surfaces of the user's leg. These cues reflect real-time foot pressure information at a location above the ankle where skin sensation is still present.
82740|NCT03538743|Drug|Placebo|Tablet, 0 mg, twice daily, 28 days
82741|NCT03538743|Drug|PF-06882961|Tablet, 15 mg twice daily, 28 days
82742|NCT03538743|Drug|PF-06882961|Tablet, 50 mg twice daily, 28 days
82743|NCT03538743|Drug|PF-06882961|Tablet, 150 mg twice daily, 28 days
82744|NCT03538743|Drug|PF-06882961|Tablet, 300 mg twice daily, 28 days
82749|NCT03538730|Behavioral|Memory Reframing|The intervention will draw from existing narrative-based interventions, past pain memory reframing interventions and findings from our recent data. Specifically, parents will be taught to reminisce with their children about the in-hospital and post-surgery periods by encouraging children to provide more explanations, using less utterances about pain, avoiding repetitions, emphasizing positive aspects of the child's surgery memory (e.g., when children used coping methods such as deep breathing, when they got a treat), and enhancing children's self-efficacy regarding their ability to cope with pain.
82750|NCT03538704|Drug|Metformin|Metformin is given to patients 1-1.5g/d.
82751|NCT03538691|Drug|Brexpiprazole|Tablet
82752|NCT03538691|Drug|Placebo|Tablet
82753|NCT03538691|Drug|Citalopram Hydrobromide|Tablet
82754|NCT03538691|Drug|Escitalopram|Tablet
82755|NCT03538691|Drug|Fluoxetine|Capsules
82756|NCT03538691|Drug|Paroxetine|Controlled-release tablets
82757|NCT03538691|Drug|Sertraline|Tablet
82758|NCT03538691|Drug|Duloxetine|Delayed-release capsule
82759|NCT03538691|Drug|Venlafaxine Extended Release Oral Capsule|Extended-release capsule
82760|NCT03538678|Other|Kwit smartphone app|Kwit smarphone app
82763|NCT03538626|Biological|VRC-HIVMAB091-00-AB|The N6LS antibody binds to the CD4- binding site of HIV-1 gp120 protein and contains a methionine to leucine (L) and asparagine to serine (S) (M428L/N434S,referred to as (LS) change within the C- terminus of the heavy chain constant region to increase its binding affinity for the neonatal Fc receptor (FcRn).
82764|NCT03538613|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg /day X 2 days over 1 hr.
82765|NCT03538613|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
82766|NCT03538613|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
82767|NCT03538613|Biological|CISH inactivated TIL|Day 0: Each bag of autologous CISH inactivated TIL for infusion will be administered intravenously (IV) on the Patient Care Unit over 10-20 minutes.
82768|NCT03538587|Behavioral|Enhanced Mindfulness Intervention|"The 8-week EMI will consist of one initial in-person session with the child and parent, a series of at- home assignments, and two booster sessions. The psychoeducation group will be given educational material about coping with cancer."
82769|NCT03538587|Behavioral|Psychoeducation|The psychoeducation group will be offered the opportunity to participate in the EMI 8 weeks post-baseline
82770|NCT03538574|Behavioral|CBT-I|CBT-I is a behavioral treatment for insomnia
82771|NCT03538574|Behavioral|MAP-I|MAP-I is a mindfulness meditation treatment for insomnia
82772|NCT03538548|Behavioral|CBT-RP|CBT-RP is a time-limited, manual guided intervention that aims to develop behavioral and cognitive skills needed to initiate abstinence and prevent relapse. The treatment will help individuals analyze the decision making process to minimize the influence of more immediate reinforcement, develop cognitive strategies to promote the attainment of longer-term goals, practice behavioral strategies to reduce the influence of socially mediated threats to abstinence, and outline explicit plans for managing situations that threaten their goal of abstinence.
82773|NCT03538535|Behavioral|Go/No-Go Active Learning (GOAL)|Behavioral Activation psychotherapy adapted to engage go/no-go learning
82774|NCT03538522|Drug|N-831(Traneurocin) 10 mg QD|Oral administration of 10 mg capsule of NA-831 QD for 24 weeks
82775|NCT03538522|Drug|NA-831 (Traneurocin) 20 mg QD|Oral administration of 20 mg capsule of NA-831 QD for 24 weeks
82776|NCT03538522|Drug|NA-831 (Traneurocin) 40 mg QD|Oral administration of 40 mg capsule of NA-831 QD or for 24 weeks
82777|NCT03538522|Drug|Placebo oral capsule QD|Oral administration of oral placebo capsule QD or 24 weeks
82778|NCT03538509|Other|PCI and implantation drug eluting stent or bare metal stent|Percutaneous Coronary Angioplasty
82779|NCT03538496|Drug|Bupivacaine Hcl 0.25% Inj|Single shot 20 ml 0.25 bupivacaine
82780|NCT03538483|Drug|Bupivacaine Hcl 0.25% Inj|30 ml %0,25 bupivacaine
82781|NCT03538483|Drug|Bupivacaine HCl Inj 0.25%|20 ml %0,25 bupivacaine
82782|NCT03538470|Other|Spa Treatment|"Bath with immersion shower~Overall penetrating shower~Multiple local application cataplasm~Individual physiotherapy~Mobilisation pool"
82783|NCT03538457|Drug|Paracetamol|Patients are tested for their normal prescription paracetamol medication
82784|NCT03538444|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique which is currently FDA-approved as a treatment for major depressive disorder
82785|NCT03538444|Device|Sham rTMS|Participants will undergo procedures that mimic rTMS, but that are inactive.
82786|NCT03538431|Drug|Buspirone|Buspirone is an atypical anxiolytic medication.
82787|NCT03538418|Other|WAT|The WAT intervention consists of 12 weekly WAT-based exercise sessions and 7 sessions of support for BCTs and technical issues.
82788|NCT03538405|Other|Supporting cushions|Cushions were placed in a way that the head and four limbs were well supported, without leaving empty space between body and cushions or mattress.
82789|NCT03538405|Other|Harmonic techniques|Harmonic techniques (HT) is a group of manual techniques described by Lederman (2000).The goal of this techniques in this study was to reduce the muscle tone and additionally/subsequently increase the ROM.
82790|NCT03538392|Device|Serranator® Alto|Serranator® Alto PTA Serration Balloon Catheter
82791|NCT03538379|Behavioral|Bleeding Control Basic (B-Con) Course|The American College of Surgeons Bleeding Control Basic Course will be provided to participants. This course consists of a 30-minute lecture followed by 30-minutes of hands-on training in hemorrhage control technique application. It teaches how to apply manual pressure and how to apply a Combat Application Tourniquet (CAT). The course will not vary from its typical administration for this study.
82792|NCT03538366|Other|Donor FMT|Fecal transplant from unrelated, healthy donors using enemas
82793|NCT03538353|Other|pain education video|The video was made for the DOD and VHA to educate their soldiers and veterans about chronic pain.
82794|NCT03538340|Procedure|Thoracic Epidural|The control arm will receive standard of care pain management which includes a Thoracic Patient Controlled Epidural
82795|NCT03538340|Procedure|Intercostal Cryoanalgesia|The study arm will receive standard of care pain management which includes a Thoracic Epidural plus Intraoperative Intercostal Cryoanalgesia
82796|NCT03538327|Drug|Silybin|After enrollment, all patients were encouraged to make lifestyle changes according with current guidelines, moreover it was also recommended to take silybin coniugated to vitamin E and phosphatidylcholine that shows higher intestinal absorption and bioavailability (Indena, IBI-Lorenzini spa Italy: Realsil®), as granules for oral solution at a dose of 3 g bid. Each subject was re-evaluated monthly performing a clinical examination to consider the opportunity of antihypertensive treatment. Finally, inflammatory, metabolic and hemodynamic parameters were assessed after 6 months of treatment. In particular, at the end of the follow-up period, a new OGTT was performed, to test the effects of silybin on glucose tolerance and IR status.
82797|NCT03538314|Drug|UV1/GM-CSF|UV1 (300 microgram) GM-CSF (37.5 microgram)
82798|NCT03538301|Drug|ND-L02-s0201|Intravenous administration every 2 weeks
82799|NCT03538301|Drug|ND-L02-s0201|Intravenous administration every 2 weeks
82800|NCT03538301|Other|Other: Placebo|Saline
82801|NCT03538288|Device|rTMS|rTMS will be applied at 10 Hz to the DLPFC
82802|NCT03538275|Other|Monitoring test|Participants wear Zephyr BioPatch for three 24-hour periods and ZMachine Insight for three sleep periods.
82803|NCT03538249|Other|Aerobic training|
82804|NCT03538249|Other|Inspiratory muscle training|
82805|NCT03538249|Other|Resistance Training|
82806|NCT03538249|Other|Aerobic and Inspiratory training|
82807|NCT03538249|Other|Combined|Aerobic, inspiratory and resistance training
82808|NCT03538236|Device|Intragastric balloon|Intragastric balloon insertion will be performed by an endoscopist under monitored anesthesia care. The Intragastric BalIoon (GB) comes as a deflated balloon pre-loaded on a catheter, which is inserted transorally into the proximal gastric body. An endoscope is then inserted alongside the device allowing for direct visualization of the balloon. Once in place, the intragastric balloon will be filled with saline through an external port. The balloon is inserted for 6 months then retrieved endoscopically
82809|NCT03538236|Behavioral|Lifestyle intervention|All patients included in the study will undergo an evaluation by a nutritionist. All participants will receive recommendations for a diet. Participants will be instructed to keep a daily food diary and will meet with the nutritionist to reinforce the behavior every 12 weeks for 12 months.
82810|NCT03538223|Other|Music Listening|Participants will undergo two different types of music before radiotherapy sessions
82811|NCT03538223|Radiation|Radiotherapy|All participants will undergo radiotherapy according to breast cancer post surgery protocol
82812|NCT03538197|Other|clinical and biological correlates|"To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors"
82813|NCT03538184|Procedure|Piezosurgery|Preparation of implant beds entirely with piezo surgery implant tips
82814|NCT03538184|Procedure|Drill|Preparation of implant beds entirely with conventional implant drills
82815|NCT03538171|Drug|Entinostat|Entinostat will be repeatedly administered PO on days 1, 8, 15 and 22 of each treatment cycle. Exemestane PO once daily on day 1-28.
82816|NCT03538171|Drug|Placebo|Patients receive Exemestane as in Arm A and placebo PO on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
82817|NCT03538171|Drug|Exemestane|Exemestane PO once daily on day 1-28.
82818|NCT03538158|Behavioral|Intervention Condition|Participants will have access to Fittle Senior which will provide guided exercises and social support from other participants of the study.
82819|NCT03538158|Behavioral|Control Condition|Participants will have a paper booklet with suggested exercises that they may choose to complete for the duration of the study.
82820|NCT03538132|Other|dental regenerative techniques|dental regenerative techniques
82821|NCT03538119|Other|High intensity interval training program|"The HIIT protocol will consist of four four-minute high-intensity intervals, stimulating 85-95% peak-FC followed by active recovery at 70% peak-FC for a total of 20 minutes. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of maximal HR) and a 3 to 5 minute calm return period was performed at 50% of the HR peak.~The supervised sessions will take place on a cycle ergometer and treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week. Each session will be limited to three participants."
82822|NCT03538119|Other|Moderate continuous training program|"The MCT protocol consists of continuously exerting moderate intensity, causing a peak FC-70-75% for 27.5 minutes to equal the energy expenditure of the HIIT protocol. The protocol will include a warm-up of 10 minutes at low moderate intensity (50-70% of maximal HR) and a 3 to 5 minute calm return period was performed at 50% of the HR peak.~The supervised sessions will take place on a cycle ergometer and treadmill, 3 times a week for 6 consecutive weeks. If a session is lost, it will be recovered that week or the following week."
82823|NCT03538093|Other|Experimental: Local Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus a. activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase:4th-6th week: hot compress + electrotherapy IFT (fr: 4kHz, AMF 100Hz, modulation 20Hz, 20 mins), stabilizer training. Hamstring, quadriceps, gluteus maximus and psoas stretching, stationary bicycle without load. 7th-9th week: stabilizer training elevating a leg, stationary bicycle low load. 10th-12th week: 1kg to elevated leg on stabilizer training, stationary bicycle moderate load."
82857|NCT03537885|Diagnostic Test|Electroencephalography (EEG)|A cap is placed on the head with sensors to detect brain activity during the intervention.
82894|NCT03537586|Diagnostic Test|Diagnostic Coronary Angiography with Non-Obstructive CAD|Platelet activity in patients with and without CMVD (measured as a dichotomous variable) will be compared using the independent samples T-Test (for normally distributed data) of the Mean-Whitney U test.
82824|NCT03538093|Other|Experimental: Global Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: add obliques cross exercises in supine with contralateral leg, lumbopelvic bridge exercises, sitting on the edge of the bed. Day 3: add bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~Outpatient phase: physiotherapy: 4th-6th week: hot compress + electrotherapy IFT, lumbopelvic bridge exercises, obliques cross exercises. Hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, stationary bicycle low load. 10th-12th week: physiotherapy, side plank, unilateral bridge, stationary bicycle moderate load."
82825|NCT03538093|Other|Experimental: Mixed Stabilization Exercise|"Inpatient phase (3-5 days): Day 1: lower limbs active mobilization on bed, abdominal breathing exercises, full body block twists. Day 2: manual transversus abdominis activation exercises, multifidus cross activation exercise, sitting on the edge of the bed. Day 3: bipedal stance, supervised gait reeducation, home care education, medical and physical therapy discharge with instructions.~4th-6th week: hot compress + electrotherapy IFT, stabilizer training, hamstring, quadriceps, gluteus maximus and medius stretching, stationary bicycle without load. 7th-9th week: FST, global exercises, change stationary bicycle load to low load. 10th-12th week: physiotherapy, advanced global exercise (side plank), unilateral bridge,stationary bicycle moderate load."
82826|NCT03538080|Device|ACCUVEIN plus ultrasound|"Intervention is marking of the saphenous veins with ACCUVEIN system. The AccuVein® AV400 vein illumination system is a laser imaging system that detects superficial veins up to 10 mm deep and digitally displays, through a projected red light, a map of the vascularization on the surface of the skin. in real time, allowing clinicians to check vein permeability and position.~This system is portable and lightweight. It can be easily cleaned, and requires no calibration or adjustment. It does not require any contact with the patient. Second time is completion of marking by ultrasound if necessary"
82827|NCT03538080|Device|Ultrasound only|Intervention is marking with ultrasound imaging as in usual practice.
82828|NCT03538067|Procedure|Percutaneous coronary intervention (PCI)|Patients will undergo PCI with intravascular ultrasound (IVUS) as part of standard clinical care in accordance with operator discretion. The research protocol will be observational - using IVUS to determine the effects of balloon inflation time, balloon inflation pressure, balloon type, atherosclerotic plaque morphology on stent expansion (minimal luminal area, MLA)
82829|NCT03538054|Drug|Dextromethorphan|(1)10 mg, by mouth, twice daily every 12 hours.
82830|NCT03538054|Drug|Placebo|1 capsule, by mouth, twice daily every 12 hours.
82831|NCT03538041|Drug|Parsaclisib|Parsaclisib administered orally.
82832|NCT03538028|Biological|INCAGN02385|INCAGN02385 administered as an intravenous infusion over 30 minutes.
82833|NCT03538015|Drug|Carvedilol 3.125 mg|Participants will receive a 3.125 mg oral dose of carvedilol twice daily during the 4-week treatment period
82834|NCT03538015|Drug|Carvedilol 2.5 mg|Participants will receive a 2.5 mg oral dose of carvedilol twice daily during the 4-week treatment period
82835|NCT03538015|Drug|Placebo capsule|Participants will receive a matching oral dose of placebo capsule twice daily during the 4-week treatment period
82836|NCT03538002|Device|Blue-light filtering spectacle lenses|This is a single vision spectacle lens for correction of distant refractions and filtering out the blue light by providing anti-blue light coating.
82837|NCT03537989|Drug|Saline|To reduce the volume of saline administered during surgery of the colon and the rectum
82838|NCT03537976|Other|Static Images and Facial Videos|2D and 3D still and video images obtained from each patient before surgery.
82839|NCT03537963|Other|mHealth Stepped-care Intervention|Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
82840|NCT03537963|Other|Educational Control Condition|General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
82841|NCT03537963|Other|Questionnaire|After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
82842|NCT03537963|Other|Interview|Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
82843|NCT03537963|Other|Qualitative Interviews|To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
82844|NCT03537950|Drug|PLC|Single oral dose of PLC.
82845|NCT03537950|Drug|CBD|Single oral dose of cannabidiol (CBD) - 600mg.
82846|NCT03537950|Drug|CBDV|Single oral dose of cannabidivarin (CBDV) - 600mg.
82847|NCT03537937|Other|Lower SpO2 Target|SpO2 target 90% (range 88-92%)
82848|NCT03537937|Other|Intermediate SpO2 Target|SpO2 target 94% (range 92-96%)
82849|NCT03537937|Other|Higher SpO2 Target|SpO2 target 98% (range 96-100%)
82850|NCT03537924|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
82851|NCT03537924|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
82852|NCT03537911|Behavioral|Cognitive Support Program|Three individual sessions of supportive psychoeducation, mindfulness practice, and strategy training (e.g., strategies to improve memory or concentration), with practice applying program content between sessions.
82853|NCT03537898|Other|Lactated Ringer's|Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
82854|NCT03537898|Other|Normosol|Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
82855|NCT03537885|Diagnostic Test|Transcranial Direct Current Stimulation|Electrodes are placed on that head to deliver a non-invasive brain stimulation to the target area.
82856|NCT03537885|Diagnostic Test|Transcranial Magnetic Stimulation|A coil is held tangential to the head in order to deliver a non-invasive brain stimulation to the target area.
82858|NCT03537872|Behavioral|Miner-Friendly (MF) Service Venues TB/HIV Integration Strategies|"In addition to the control condition strategies (marked PS), the MF intervention includes additional strategies (marked MF):~STRUCTURAL LEVEL Co-location of TB and HIV services (PS); Co-location of clinical and non-clinical services (MF); Demand creation (MF); Weekend service hours (MF) CLINIC LEVEL Intensified TB case finding and IPT (PS); Test and START (PS); Training for healthcare workers (PS); Job aids and mentorship for healthcare workers (MF) INDIVIDUAL/FAMILY LEVEL Health literacy for patients (PS); Family counseling (PS - limited); One-way SMS text messaging and lay counselor support for adherence and retention (MF); A menu of options for medication refills for miners unable to visit the clinic on a monthly basis (MF)"
82859|NCT03537872|Behavioral|Public Sector (PS) Health Facilities TB/HIV Integration Strategies|STRUCTURAL LEVEL Co-location of TB and HIV services CLINIC LEVEL Intensified TB case finding and IPT; Test and START; Training for healthcare workers INDIVIDUAL/FAMILY LEVEL Health literacy for patients; Family counseling (limited); Adherence support from nurses and village health workers
82860|NCT03537859|Other|Augmented Reality|Augmented reality children books. The books will have special markers. The device's camera will read the marker and show 2d and 3D animations with the book's theme.
82861|NCT03537859|Other|Non Augmented Reality|Augmented reality book without electronic device. Since no electronic device will be provided, the children will not be able to see any augmented reality features of the book, making it a conventional children's book.
82862|NCT03537833|Other|pemetrexed-related hematological toxicity|hematological toxicity will be found on biologic data the day or the day before chemotherapy. Classification will based on NCI-CTCAE criteria
82863|NCT03537820|Other|questionnaire|questionnaire EVAN-G
82864|NCT03537807|Drug|Riluzole|For adult patients, one 40mg of BHV-0223, administered sublingually, on a twice daily basis (approximately every 12 hours).
82865|NCT03537794|Diagnostic Test|PET scans|PET scans and PHNO scans
82866|NCT03537781|Behavioral|Food labelling versus no food labelling|Food labelling availability and satiety status
82867|NCT03537768|Drug|Ulipristal Acetate|UPA Tablet
82868|NCT03537768|Drug|Levonorgestrel|LNG Tablet
82869|NCT03537768|Drug|Levonorgestrel|LNG Tablet (x2)
82870|NCT03537755|Other|Observation|Examine thoughts and behaviors
82871|NCT03537742|Biological|alirocumab|alirocumab 75mg Subcutaneous
82872|NCT03537742|Biological|placebo|placebo to match alirocumab
82873|NCT03537729|Behavioral|Salient Cues|Salient cues are those that capture the individual's attention. Information that is complex, novel, and difficult to identify takes more processing resources than those that are simple and familiar. Cues such as pictures and wall hangings, along with bright and meaningful signs, will be placed at key decision points within the senior communities.
82874|NCT03537729|Behavioral|Spaced Retrieval Education|Spaced Retrieval (SR) is an evidence-based memory strategy that is used to teach individuals with memory loss new or previously known information. In this study, participants in Arm 3 will receive twelve 30-minute educational sessions to help them use the salient cues to find their way.
82875|NCT03537716|Device|Treatment with High Intensity Focused ElectroMagnetic system|The treatment administration phase will consist of four (4) treatments, delivered twice a week. The applicator will be applied over the abdomen area. Visible contractions will be induced by the device.
82876|NCT03537703|Combination Product|Active tDCS + Auditory Training|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
82877|NCT03537703|Combination Product|Active tDCS + Control Condition|Active tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 20 min. The control condition will be subjects watching a silent movie for 20 min during active tDCS stimulation.
82878|NCT03537703|Combination Product|Sham tDCS + Auditory Training|Sham tDCS will be cathodal tDCS applied bilaterally over the auditory cortex for 1 min with the current then slowly ramped down to 0 amps over the course of another minute. The auditory training exercise will 20 min of computerized auditory training using the Sound Sweeps module of the Posit Science Brain HQ
82879|NCT03537690|Other|Laboratory Biomarker Analysis|Correlative studies
82880|NCT03537690|Drug|PEOX-based Polymer Encapsulated Paclitaxel FID-007|Given IV
82881|NCT03537690|Other|Pharmacokinetic Study|Correlative studies
82882|NCT03537677|Behavioral|Reduction in Sedentary Behavior|This 12-week intervention targets a reduction in prolonged sitting and includes provision of a wrist-worn activity prompter and in-person group sessions with behavioral counseling.
82883|NCT03537664|Procedure|Root canal preparation|First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
82884|NCT03537664|Procedure|Intracanal medication|The second endodontic treatment includes the intracanal medication with calcium hydroxide paste.
82885|NCT03537651|Drug|TEZ|Fixed-dose Combination (FDC) tablet (TEZ/IVA)
82886|NCT03537651|Drug|IVA|FDC tablet (TEZ/IVA)
82887|NCT03537638|Behavioral|Multicomponent intervention|Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
82888|NCT03537625|Dietary Supplement|Green tea|We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
82889|NCT03537612|Drug|Clonidine|Intrathecal Clonidine 1 mcg/kg (up to 75 mcg) immediatey post-op; 100 mcg capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
82890|NCT03537612|Other|Morphine|Intrathecal spinal morphine (5 mcg / kg) immediatey post-op; Placebo capsule TID Post op day 1-5 (liquid version available if subject cannot swallow capsule)
82891|NCT03537599|Biological|Daratumumab|Given IV
82892|NCT03537599|Procedure|Donor Lymphocyte Infusion|Given via infusion
82893|NCT03537599|Other|Laboratory Biomarker Analysis|Correlative studies
82938|NCT03537300|Behavioral|DCF muscles training using pressure biofeedback in addition to conventional exercises|DCF muscles training using pressure biofeedback in addition to conventional exercises
82895|NCT03537573|Behavioral|Usual Care/Guideline|The Usual Care group (also known as the Guideline group) follows the recent CDC guidelines and, when triggered by an opioid prescription during a qualifying visit, will be delivered real-time in a short checklist of recommendations to: 1) check the state-specific Prescription Drug Monitoring Program; 2) assess risk factors for opioid-related harms (e.g., history of substance use disorder, history of mental health problems, benzodiazepine use); 3) avoid extended-release or long-acting opioids; 4) use a low dose of immediate-release opioid for short period of time (3-7 days); and 5) consider non-opioid management such as acetaminophen, non-steroidal anti-inflammatory agents (NSAIDS), and physical therapy. Epic EHR order sets will be linked to enable easing ordering of non-opioid therapy.
82896|NCT03537573|Behavioral|Opioid Justification|"Providers will be required to enter a free text justification for their decision to prescribe an opioid analgesic for the acute pain condition. The provider will be notified that the justification provided will be visible in the Epic EHR and the phrase no justification provided if the provider decides to enter no text and proceed with the prescription. The provider does not need to enter a justification if they choose to cancel the opioid prescription."
82897|NCT03537573|Behavioral|Provider Comparison|Providers will receive monthly feedback via e-mail on their status in regards to initial opioid prescriptions for acute pain, adherence to safe opioid prescribing guidelines, and proportion of patients started on opioids f or acute pain who transition to chronic opioid therapy (> 3 months). Providers in the lowest decile overall for proportion of patients with initial opioid prescriptions , unsafe opioid prescribing, and transition to chronic opioid therapy (> 3 months) will be given positive feedback for providing high quality, evidence-based care to their patients with acute pain. Providers outside the lowest decile will be notified they are outside the high quality, evidence-based care range and will be provided with their proportions compared to the high performers.
82898|NCT03537547|Other|GeneSight Psychotropic test|GeneSight Psychotropic test, developed by AssureRx Health, is a genetic test that analyses pre-selected pharmacokinetics and pharmacodynamics genes and results in a composite phenotype and interpretive report, addressing both safety and efficacy of psychiatric medications.
82899|NCT03537547|Drug|FDA-approved antidepressant or antipsychotic treatment|Participant is treated with medications included in the GeneSight Psychotropic product.
82900|NCT03537534|Drug|Lidocaine Jet Injector|Applying Lidocaine following endourologic procedure
82901|NCT03537534|Drug|Placebos|Applying surgilube following endourologic procedure
82902|NCT03537521|Procedure|Urgent surgery which can not be postponed to the next 24 hrs|The urgent surgical intervention is not part of the registry protocol. The intervention is the acute event that leads to enrollment in the registry. It might be e.g. the surgical treatment of a trauma, fall, acute abdomen, appendicitis or anything else.
82903|NCT03537508|Biological|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
82904|NCT03537508|Biological|MenACYW-135 conjugate vaccine|Meningococcal (Groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine, 0.5 mL, intramuscular
82905|NCT03537508|Biological|DTaP-IPV//Hib vaccine|DTaP-IPV//Hib vaccine at 2, 4, and 6 months of age
82906|NCT03537508|Biological|Pneumococcal 13-valent conjugate vaccine|Pneumococcal vaccine at 2, 4, 6, and 12 months of age
82907|NCT03537508|Biological|Pentavalent rotavirus vaccine|Rotavirus vaccine at 2, 4, and 6 months of age
82908|NCT03537508|Biological|Hepatitis B vaccine|Hepatitis B vaccine at 2 and 6 months of age
82909|NCT03537508|Biological|Measles, mumps, rubella (MMR) vaccine|MMR vaccine at 12 months of age
82910|NCT03537508|Biological|Varicella vaccine|Varicella vaccine at 12 months of age
82911|NCT03537508|Biological|Hepatitis A vaccine|Hepatitis A vaccine at 15 to 18 months of age
82913|NCT03537482|Drug|APG-2575|APG-2575 will be administered as an oral tablet
82914|NCT03537469|Device|CTU Mega 20 real device|The CTU Mega 20 diamagnetic acceleration system discharges high-field magnetic impulses (with a duration of 5 ms and a period of 1000 ms), generating a magnetic field up to 2 Tesla, with a frequency of 7500 Hz in a volume of approximately 27 cm3.
82915|NCT03537469|Device|CTU Mega 20 sham device|A CTU Mega 20 sham device (with an identical appearance to that of the real device) to avoid treatment identification by the patient or experimenter was used. Of course, the application of this sham device did not provide any magnetic field.
82916|NCT03537456|Device|mRDX-02-17|"mRDX -02-17 is a dermal filler recommended for the correction and treatment of wrinkles and dermal depressions.~It is a sterile and viscous aqueous solution of hyaluronic acid in a concentration of 1.5% (p/v) with acetyl tetrapeptide-9 and palmitoyl tripeptide-5, as auxiliary ingredients which is administrated by intradermal injections.~This medical device encourages repair and restructuring of skin tissue and reduces the signs of aging.~mRDX -02-17 is indicated for patients with hypotrophic tissues, Crow's feet, Glogau III-IV, all skin photo types (Fitzpatrick I - VI) and a WSRS score (Wrinkle Severity Ranking Scale) from 2 to 5."
82917|NCT03537430|Procedure|TNT uniportal VATS mediastinal tumor resection|TNT uniportal video-assisted thoracoscopic surgery refers to the use of conventional uniportal video-assisted thoracoscopic surgery, the use of laryngeal mask anesthesia instead of tracheal intubation anesthesia, intraoperative catheter was not retained, postoperative chest catheter placement.
82918|NCT03537430|Procedure|Traditional uniportal VATS mediastinal tumor resection|The surgical procedures followed principles of mediastinal tumor resection，uniportal video-assisted thoracoscopic surgery in mediastinal tumor resection.
82919|NCT03537417|Procedure|for thoracoscopic ablation of cervical sympathetic chain|bilateral thoracoscopic ablation of cervical sympathetic chain as a treatment for hyperhidrosis
82920|NCT03537404|Drug|Narlaprevir|100 mg, film-coated tablets, taken as 200 mg per os daily
82921|NCT03537404|Drug|Ritonavir|100 mg, film-coated tablets, taken as 100 mg per os daily
82922|NCT03537404|Drug|Tenofovir Disoproxil Fumarate|300 mg, film-coated tablets, taken as 300 mg per os daily
82923|NCT03537404|Drug|Raltegravir|400 mg, film-coated tablets, taken as 400 mg per os daily
82924|NCT03537391|Diagnostic Test|Whole body contrast enhanced computer tomography|Computed tomography of the thorax, abdomen and pelvis will be performed as a part of routine clinical evaluation protocol. The imaging will be done with contrast agent if there are no clinical contraindications for the use of contrast agent.
82925|NCT03537391|Diagnostic Test|99mTC-HMDP planar bone scintigraphy (BS)|Planar bone scintigraphy will be performed as a part of routine clinical evaluation protocol. The subjects will be positioned supine on a Discovery NM/CT 670 CZT, a digital SPECT/CT scanner (General Electric Healthcare). The scanner includes a dual-detector, free-geometry integrated nuclear imaging camera with the advanced digital CZT detector technology combined with the high-performance Optima CT540 subsystem. Whole-body planar images will be scanned from the anterior and posterior views three hours after the intravenous injection of 670 MBq of 99mTc-HMDP. A wide-energy high-resolution (WEHR) collimator, a scan speed of 13 cm/min, a zoom of 1.0 and a matrix size of 256 x 1024 are used in the scintigraphy.
82926|NCT03537391|Diagnostic Test|99mTc-HMDP single photon emission computer tomography/computer tomography|SPECT/CT imaging will be carried out after acquisition of the planar images with the same scanner. Three bed positions of SPECT data will be acquired from the top of the head to mid femoral level using WEHR collimators. A non-circular orbit, 60 views with 15-s scanning time per view will be acquired during 180 degrees of rotation. A 128 x 128 matrix size, a zoom of 1.0 and 15% photopeak and lower scatter energy windows are used. After SPECT a CT topogram and a low-dose tomogram with a modulated mAs (noise index ~ 70), 120 kVp, a pitch of 1.35 and a 2.5-mm slice thickness are scanned. The co-registration of SPECT and CT data is verified after which the SPECT images are reconstructed using modern iterative ordered subsets expectation (OSEM) reconstruction algorithm from General Electric or Hermes Medical Solutions, which includes, e.g., 10 iterations and 5 subsets and attenuation, collimator and scatter corrections.
82927|NCT03537391|Diagnostic Test|Whole-body magnetic resonance imaging|Magnetic resonance imaging examination will be performed using a 1.5T (Philips 1.5T Ingenia, Best, Netherlands and/or Siemens 1.5T Aera/Avant, Erlangen, Germany) or 3T (Philips 3T Ingenia, Best, Netherlands and/or Siemens 3T Skyra fit, Erlangen, German) MR system. The body matrix coil in combination with a spinal coil will be used for image acquisition. T1-weighted anatomic imaging, STIR fat suppressed images and DWI will be performed in axial and coronal directions. DWI will be obtained with single-shot 2D spin-echo echo-planar imaging. The total scan time will be approximately 50 minutes.
82928|NCT03537391|Diagnostic Test|Fluorine-18-prostate specific membrane antigen-1007- positron emission tomography/computer tomography|18F-PSMA-1007 is produced by radiolabelling with fluorine-18 produced by irradiating oxygen-18. Administration of the formulated solution is done shortly (<10h) after production. Imaging is carried out with digital PET/CT scanner (Discovery MI;General Electric Medical Systems, Milwaukee, WI, USA). The patients receive intravenous injection of 200-300 MBq (3 MB/kg) of 18F-PSMA-1007 diluted in 3-5 ml of saline as a 60-sec bolus which will be promptly flushed with saline. Before data acquisition patients will be asked to void. A static emission scan will be acquired 60-min from tracer injection over whole body. The sinogram data will be corrected for deadtime, decay and photon attenuation and reconstructed in a 256x256 matrix. Image reconstruction follows a fully 3D maximum likelihood ordered subsets expectation maximization algorithm incorporating random and scatter correction with two iterations and 28 subsets.The final in-plane full-width half-maximum of the systems is < 6 mm.
82929|NCT03537378|Procedure|Hybrid APC|• HybridAPC is integrated with traditional APC and water-jet technique, which has been successfully applied for endoscopic treatment of mucosal lesions in GI, such as Barrett esophageal and lesions in colon. Submucosal injection of water jet can elevate superficial lesion, and then APC can be more effective in ablation of superficial tumor with a protection for muscular layer. The application of HybridAPC in respiratory intervention could theoretically protect cartilage, adventitia, reduce damage and formation of scare, and increase ablation energy to reach radical treatment. • High-frequency EBUS, could display the boundary between cartilage endomembrane and cartilage, in order to determine the depth of tumor.
82930|NCT03537365|Dietary Supplement|Bovine Colostrum (BC) / intervention group|"Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l.~The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM.~The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an early discharge program), or are transferred to non-participating neonatal units, whichever comes first."
82931|NCT03537365|Dietary Supplement|FM85 / control group|"Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l.~The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM.~FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed."
82932|NCT03537352|Procedure|Any appropriate surgical treatment|Any appropriate surgical treatment for the management of patient's current disorder
82933|NCT03537352|Drug|Any appropriate drug or non-drug treatment excluding surgery|Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
82934|NCT03537339|Other|Record general information|Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients
82935|NCT03537326|Drug|Budesonide|Patients will be given, on an empty stomach since a minimum of 10 hours, a single dose of 3 mg of Budesonide, in the form of Entocord® capsuls. After that, they will remain under medical control for at least an hour, and then will be back home with instructions to collect urine samples at defined times, during 4 days.
82936|NCT03537313|Procedure|Vagina douching|Vaginal douches with 1000 ml of 1% povidone-iodine solution on the night before surgery and again on the morning of surgery
82937|NCT03537313|Procedure|Vagina painting|Vaginal painting of vagina stump after hysterectomy with 10% povidone-iodine solution 30 ml
82939|NCT03537300|Behavioral|conventional exercises|conventional exercises
82940|NCT03537287|Drug|17 alpha hydroxyprogestrone caproate|250 mg of 17 alpha hydroxyprogestrone caproate weekly
82941|NCT03537287|Drug|Vaginal progesterone|200 mg of vaginal progesterone daily
82942|NCT03537287|Drug|Oral dydrogesterone|2 tablets of dydrogesterone daily
82943|NCT03537274|Biological|PEG-Intron|PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
82944|NCT03537274|Biological|Interferon Alfa-2B|Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
82945|NCT03537261|Behavioral|Parent-based Crisis Prevention Institute (CPI) physical management training program (P-CPI)|Parents of children with ASD will be randomly assigned to the 6-hour P-CPI group training session, which includes nonverbal, paraverbal, verbal, and physical intervention techniques. Baseline measures will be administered on the day of training and follow-up measures at 2-week, 1-month, 2-month, and 3-month post baseline. The treatment group will also participate in an in-person follow-up group qualitative interview.
82946|NCT03537248|Device|ASP-57|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
82947|NCT03537248|Device|ReNu® Multiplus|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, ad storing soft contact lenses including silicone hydrogel lenses
82948|NCT03537235|Device|Libramed|
82949|NCT03537235|Device|Placebo|
82950|NCT03537222|Diagnostic Test|Myeloma Patient Outcome Scale (MyPOS)|Patients complete the MyPOS questionnaire on quality of life
82951|NCT03537196|Drug|Sofosbuvir 400 mg and Daclatasvir 60 mg|All patients will receive sofosbuvir 400-mg and daclatasvir 60-mg (1 tablet each per day) during 12 weeks.
82952|NCT03537196|Drug|Sofosbuvir 400 mg and Daclatasvir 90 mg|For HIV/HCV co-infected patients receiving efavirenz or nevirapine, daclatasvir dose will be increased to 90-mg per day.
82953|NCT03537196|Drug|Ribavirin|"In case of cirrhosis:~Ribavirin will be added to sofosbuvir/daclatasvir during the 12 weeks of treatment. The dose will be adapted to the patient weight although the vast majority of patients (weight < 75 kg) will receive 500 mg x 2/day.~In case of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks."
82954|NCT03537196|Drug|Sofosbuvir and Daclatasvir for 24 weeks|In case of cirrhose and of ribavirin contra-indication or side effects leading to ribavirin discontinuation, sofosbuvir/daclatasvir will be used 24 weeks.
82955|NCT03537183|Other|Exercise training|12 weeks, 3 hours a week, moderate intensity exercise training
82956|NCT03537157|Drug|Rifaximin delayed release tablets|Active intervention
82957|NCT03537157|Other|Placebo|Comparator placebo
82958|NCT03537144|Drug|Indomethacin|IV indomethacin will be given every 12 hours for 3 doses. If <48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If >7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
82959|NCT03537144|Drug|Acetaminophen|15mg/kg/dose every 6 hours for 12 doses
82960|NCT03537131|Drug|Dapagliflozin 10 MG Oral Tablet|taken once a day
82961|NCT03537118|Procedure|Fluoroscopic + Ultrasound Guidance|Fluoroscopic Guidance Alone
82962|NCT03537105|Procedure|Skin biopsies|Two skin biopsies (4mm punch) are performed under local anesthesia at the site of cutaneous inflammation/fibrosis.
82963|NCT03537092|Device|Vaginal Film|"2 x 2 vaginal film with no active drug"
82964|NCT03537079|Other|hypoxia air|Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
82965|NCT03537066|Device|CPAP|All patients included will be treated by CPAP
82966|NCT03537053|Behavioral|A plan to Move a Little and Often|"The intervention content is reported using the behaviour change technique (BCT) Taxonomy v1 (Michie, et al. 2013). The video will contain the BCT: information about health consequences. The booklet will consist of BCTs: self-monitoring of behaviour, goal setting behaviour, action planning, commitment, social support (practical), self-talk, and mental rehearsal of successful performance. Lastly, usage of the Facebook group will include BCTs: commitment, and social support unspecified, practical and emotional.~Mental rehearsal, goal setting behaviour and action planning will be delivered through mental simulation exercises (Taylor, et al. 1998). BCTs self-monitoring of behaviour, goal setting behaviour, and commitment will be delivered using implementation intentions (Gollwitzer 1993)."
82967|NCT03537040|Other|Method of Levels|Talking Therapy
82968|NCT03537027|Dietary Supplement|Vitamin D3|In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
82969|NCT03537014|Behavioral|Psychotherapy|Standardized non-directive psychotherapy performed by therapist team
82970|NCT03537014|Drug|MDMA|Administration of 80 to 120 mg MDMA during three sessions of MDMA-assisted psychotherapy followed by a supplemental dose of 40 or 60 mg MDMA offered 1.5/2 hrs after the initial dose, respectively.
82971|NCT03537014|Drug|Placebo|Administration of placebo during three sessions of MDMA-assisted psychotherapy
82972|NCT03537001|Other|Penthrox|Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
82973|NCT03536988|Procedure|TAMIS-IPAA|In TAMIS-IPAA group, transanal minimally invasive surgery of IPAA will be performed.
82974|NCT03536988|Procedure|Lap-IPAA|In Lap-IPAA group, transabdominal minimally invasive surgery of IPAA will be performed.
82975|NCT03536975|Other|Platform|"The groups will be comprised of one intervention group with access to the web platform CAREGIVERSPRO-MMD and another control group without any access to it"
82976|NCT03536962|Other|no intervention|no intervention
82977|NCT03536949|Drug|RVL-1201|RVL-1201 ophthalmic solution, 0.1%
82978|NCT03536949|Other|Vehicle ophthalmic solution|Vehicle placebo ophthalmic solution
82979|NCT03536923|Device|Leva Incontinence System For Pelvic Floor Muscle strengthening|The leva device is placed vaginally for 2.5 minutes twice daily, and pelvic floor muscle exercises are performed based on guidance from data sent from the device to their mobile phone.
82980|NCT03536910|Other|Copeptin|Level of copeptin in maternal blood and umbilical cord blood
82981|NCT03536897|Radiation|IORT|Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
82982|NCT03536884|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-specified time-points.
82983|NCT03536884|Drug|Secukinumab|Subjects will receive secukinumab at pre-specified time-points.
82984|NCT03536884|Other|Placebo|Subjects will receive placebo at pre-specified time-points to maintain the blinding in the double-blind Treatment Period.
82985|NCT03536871|Dietary Supplement|multi-nutrient supplement|Compare the effects of a multi-nutrient supplement following a healthy lifestyles program in healthy young men and women, healthy older men, and sarcopenic older men.
82986|NCT03536871|Other|Exercise|We will evaluate the effect of 12 weeks of combined endurance and resistance home-based exercise in younger and older adults.
82987|NCT03536858|Behavioral|COACH (Communicating about Choices in Transplantation)|COACH is a behavioral communication intervention designed specifically for ESRD patients pursuing kidney transplantation. The COACH program consists of four modules: 1) Kidney transplant options, 2) Discussing your transplant options, 3) Requesting living donation, and 4) Maintaining positive relationships. The content and teaching strategies were guided by the concepts of social cognitive theory as well as principles of adult learning and communication skill acquisition. We believe that patients will transfer these skills to other patients at the hemodialysis clinic who are on their shift.
82988|NCT03536845|Drug|Vitamin D 3|oral drops
82989|NCT03536832|Procedure|Cesarean Section with Vicryl|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.
82990|NCT03536832|Procedure|Cesarean Section with Prolen|Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
82991|NCT03536819|Device|Votiva|The applicator uses radio-frequency energy to treat the vaginal canal
82992|NCT03536806|Drug|Saline 0.9%|Patients assigned to control group will be administered saline 0.9% in bolus of 10 cm3 within 2-3 minutes. BP will be measured before injection.
82993|NCT03536806|Drug|Canrenone|Patients assigned to canrenone group will be administered canrenone in bolus of 200 mg diluted to 10 cm3 within 2-3 minutes in one dose. Drug administration will be stopped in case of serious adverse event. Further treatment of the patient will depend on clinical condition and will follow appropriate clinical guidelines.
82994|NCT03536780|Drug|Avelumab and Gemcitabine|"Avelumab: 10 mg/kg by IV infusion over 1 hour, every 2 weeks~Gemcitabine: 1000 mg/m2 by IV infusion over 100 minutes on Days 1, 8, and 15 of each 28-day cycle"
82995|NCT03536767|Drug|AG10|AG10 800mg twice daily, oral administration
82996|NCT03536754|Other|Placebo|Placebo
82997|NCT03536754|Drug|CCX140-B|CCX140-B is an orally administered selective antagonist of CCR2
82998|NCT03536741|Procedure|TAP block and RS block + General Intravenous Anesthestic|transversus abdominis plane block and rectus sheath block
82999|NCT03536741|Drug|General Intravenous Anesthetic|General Intravenous Anesthetic
83000|NCT03536728|Drug|AMXT1501|AMXT 1501 dicaprate is D-lys(palmitoyl)-spermine dicaprate salt in 40 mg or 200 mg (free base content) enterically-coated capsules
83001|NCT03536728|Drug|DFMO|DFMO is DL-2-(difluoromethyl) ornithine monohydrochloride monohydrate 250 mg in hard gelatin capsules
83002|NCT03536702|Other|Creative Writing Workshop|This group will participate in a writing workshop in group sessions.
83003|NCT03536702|Other|Independent Writing - Control Group|This group will receive a book for a self writing session.
83004|NCT03536689|Diagnostic Test|Amniotic fluid index|Ultrasonography of the amniotic fluid level in each 4 quadrants of uterus then summerize as one value to measure the quantity of amniotic fluid index
83005|NCT03536676|Other|'Egg-cellent' Breakfast in the Classroom|Includes the additional 2 eggs per day
83006|NCT03536676|Other|Breakfast in the Classroom|Receives the standard meal for Breakfast in the Classroom
83007|NCT03536663|Device|Dialyzer with Endexo|Hemodialysis treatments on the dialyzer with Endexo starts at visit 14 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 13 weeks.
83008|NCT03536650|Device|DMR|"Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.~Other Names:~DMR Revita"
83009|NCT03536637|Drug|DMT310|Topical Powder
83010|NCT03536637|Drug|Hydrogen Peroxide|Liquid Diluent
83011|NCT03536637|Drug|Placebo|Placebo Topical Powder
83012|NCT03536624|Behavioral|6 days spa residential program|6 days spa residential program combining psychological intervention, physical activity, thermal spa treatment, health education and corrections of eating disorders.
83013|NCT03536611|Drug|dabigatran|dabigatran etexilate 110 mg bid + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by dabigatran 110mg bid + clopidogrel 75mg/d for at least 5 months
83014|NCT03536611|Drug|warfarin|warfarin (according to clinical routine monitoring of INR, maintain the therapeutic range at 2.0-3.0) + aspirin 100 mg qd + clopidogrel 75 mg qd for 1 month followed by warfarin + clopidogrel 75mg/d for at least 5 months
83015|NCT03536598|Drug|Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg|
83016|NCT03536598|Drug|Amlodipine 10 mg + Valsartan 160 mg|
83017|NCT03536598|Drug|Valsartan 160 mg + Rosuvastatin 20 mg|
83018|NCT03536585|Device|Vulvovaginal treatment|"Radiofrequency and pulsed electro-magnetic fields treatment of the vaginal canal to maintain an internal temperature of approximately 42 C for the proximal thermometer and 45 C for the mid and distal thermometers for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the labia to maintain an external temperature of approximately 40 C - 45 C for 15 minutes.~Radiofrequency and pulsed electro-magnetic fields treatment of the mons pubis to maintain an external temperature of approximately 40 C - 47 C for 15 minutes."
83019|NCT03536585|Device|Baseline|Subject is acting as their own control. The baseline general appearance photograph will act as the comparator.
83020|NCT03536572|Behavioral|Sleep Apnea Self-Management Program|Protocol-based sleep apnea and CPAP education and support
83021|NCT03536559|Drug|CNM-Au8|CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
83022|NCT03536559|Drug|Placebo|Placebo is liquid with identical color and taste
83023|NCT03536546|Behavioral|Alcohol Peer Mentor Intervention|A Veteran Peer research assistant will have contact with a study participant once in person in the emergency department at enrollment, and up to 6 times after enrollment over the course of 2 months. Participants will receive brief advice from a peer. Brief advice content will be based on strengths-based discussions with participants regarding their drinking and personal goals and preferences. Participants will also receive a resource pamphlet on alcohol and other health issues. Follow-up contact will be made by phone. The content of the follow-up peer intervention will be based on the manual developed by the study team to address strengths-based intervention topics.
83024|NCT03536546|Behavioral|Brief Advice|Participants will receive brief substance use advice from a non-peer research staff member in the emergency department. Brief advice content will mirror standard care practices currently provided in VHA when a patient endorses hazardous drinking behaviors. Participants will also receive a resource pamphlet on alcohol and other health issues.
83025|NCT03536533|Other|Exergame|Each of the 8 exercise sessions will last at least 42 minutes, with an actual training duration of 21 minutes. The participants will be accustomed gradually to the game. On one hand this will be achieved by increasing the difficulty in subsequent levels within the exergame.
83026|NCT03536520|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
83027|NCT03536520|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
83028|NCT03536507|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
83029|NCT03536507|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
83030|NCT03536494|Behavioral|Review the use of mirabegron and its discontinuation|"A structured intervention was designed consisting of four major sections:~General practitioners: information and training with written material and patient-centred prescribing.~Specialized hospital care: information regarding the intervention for urologists and gynaecologists.~Management support with the definition of a structured strategy.~Monthly monitoring of the intervention."
83031|NCT03536481|Drug|ensartinib capsules (test product)|Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals
83032|NCT03536481|Drug|ensartinib capsules (reference product)|Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
83033|NCT03536455|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
83034|NCT03536455|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
83035|NCT03536429|Drug|ACETAZOLAMIDE oral capsule|Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
83036|NCT03536429|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
83037|NCT03536416|Behavioral|My Asthma in School|The intervention will include three arms. During the theatre workshop, the children will watch a theatre performance, and engage in a discussion at the end of the play, about what they have watched. The self-management workshops will cover a range of topics identified as barriers to self-management in our earlier study, and will be delivered to children with asthma only. The control group will receive usual care during the intervention.
83038|NCT03536403|Radiation|EOS X-rays|EOS X-rays is done with et without a kyphosis induced corset
83039|NCT03536403|Other|8-meters walk test|8-meters walk test measured by optoelectronic Vicon system with et without a kyphosis induced corset
83040|NCT03536390|Drug|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)|Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
83041|NCT03536390|Drug|Placebo|Placebo
83042|NCT03536377|Other|very low calorie liquid diet|Phase 1: very low calorie liquid formulation Phase 2: Nutritionally balanced solid diet Phase 3: Educational material
83043|NCT03536364|Behavioral|Food Order|carbohydrate (ciabatta bread ) first, followed 10 minutes later by protein (grilled chicken) and vegetables
83044|NCT03536364|Behavioral|Carbohydrate Last|protein and vegetables first, followed 10 minutes later by carbohydrate
83045|NCT03536364|Behavioral|Vegetables first|vegetables first, followed 10 mins later by protein and carbohydrate.
83046|NCT03536351|Behavioral|Interdisciplinary process drama|Process drama program (3 days/week, 12 weeks, 1-1.5 hours per session) of movement-based activities combining music and drama. Activities that target understanding of emotions, intentions, and appropriate social interactions have been planned by a team of drama teachers, occupational therapists, and speech-language pathologists.
83047|NCT03536338|Other|Spinal Stimulation|transcutaneous electrical stimulation of the lumbar spinal cord during rehabilitation.
83048|NCT03536338|Other|Sit-to-stand Training|Rehabilitation of standing from a chair using the Keiser Rack
83049|NCT03536325|Drug|Guselkumab Dose 1|Participants will receive Dose 1 of guselkumab on Day 1.
83050|NCT03536325|Drug|Guselkumab Dose 2|Participants will receive Dose 2 of guselkumab on Day 1.
83051|NCT03536325|Drug|Guselkumab Dose 3|Participants will receive Dose 3 of guselkumab on Day 1.
83052|NCT03536325|Drug|Placebo|Participants will receive matching placebo on Day 1.
83053|NCT03536312|Procedure|Thoracic Aortic Surgery|Thoracic aortic surgery to treat thoracic aortic aneurysm
83054|NCT03536299|Other|Dual-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.
83055|NCT03536299|Other|Single-task gait|During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
83056|NCT03536286|Behavioral|Encouragement|Households will be visited and encouraged to enroll in Asili
83057|NCT03536273|Other|Pilates Group Exercises|For 12 weeks, 3 repetitions per week
83058|NCT03536260|Device|Implant with NanoBone graft|Using of NanoBone graft to fill the gap in the socket after immediate implant placement
83059|NCT03536260|Device|Implant with Xenograft|Using of Xenograft to fill the gap in the socket after immediate implant placement
83060|NCT03536247|Procedure|Initial therapy with papillary balloon dilation|patients will first undergo papillary dilation
83061|NCT03536247|Procedure|Initial therapy with intraductal lithotripsy|patients will first undergo intraductal laser or electrohydraulic lithrotripsy
83062|NCT03536234|Drug|Triptorelin acetate depot|3.75 mg triptorelin depot (monthly injections). 3 doses in total
83063|NCT03536208|Drug|Warfarin|5 different doses of warfarin will be assigned, ranging from 1mg to 5 mg.
83064|NCT03536182|Radiation|Carbon Ion Radiation Therapy (CIRT)|Patient will receive CIRT daily, 4 days a week for a total of 12 fractions/treatments plus concurrent chemotherapy (gemcitabine) weekly for 3 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic. Within 6 weeks of completing radiotherapy, patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
83065|NCT03536182|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Patient will receive IMRT daily, 5 days a week for a total of 28 fractions/treatments plus concurrent chemotherapy (gemcitabine or capecitabine) weekly for 5 weeks. Gemcitabine will be given intravenously over about 1 hour in the outpatient clinic,within 6 weeks of completing radiotherapy,patient will start 4 cycles of chemotherapy. If the doctor chooses gemcitabine+nab-Paclitaxel, patient will receive gemcitabine and nab-paclitaxel intravenously once a week for 3 weeks then 1 week off, for a total of 4 cycles (16 weeks). If the doctor chooses FOLFIRINOX, then patient will receive oxaliplatin, irinotecan, infusional 5-fluorouracil, and possibly leucovorin, all intravenously, every 2 weeks, for a total of 16 weeks.
83066|NCT03536156|Other|Four intra-oral optical impression taken successively|"Four intra-oral optical impression images will be taken successively on a patient:~Optical impressions are designed to record adjacent implant site teeth and peri-implant soft tissue PEI using an Optical Camera. The optical camera works like a camera and does not come into contact with the patient's mucous membranes or teeth. The images obtained are saved in STL format on an anonymized file.~The 4 aligned surfaces thus obtained will be cut using a 3D image processing software. A fixed cylinder will extract the PEI from the 4 surfaces. The volume of these 4 PEIs at T0 min, T30 sec, T2 min and T5 min will be calculated using a software"
83067|NCT03536143|Biological|Topical bercolagene telserpavec|Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
83068|NCT03536130|Device|Electronic chest drainage system|Patients in the intervention arm are connected to Drentech Palm Evo with single standard chest tube (28 Ch) immediately after closure of the chest. Patients with digital devices are managed by setting the pump to -20 cmH2O until the morning of postoperative day (POD) 1 and then setting the pump on physiologic mode (0 cmH2O) thereafter. Management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms and surgeon preference following standard clinical practice of general thoracic patients
83069|NCT03536117|Biological|MTBVAC|Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes
83070|NCT03536117|Biological|BCG|Live-attenuated Mycobacterium bovis obtained by subculture passaging in ox-bile and glycerated potatoes between 1908-1921 by Albert Calmette and Camille Guerin. BCG is the only licensed vaccine today against tuberculosis (TB) mainly used in TB-endemic countries.
83071|NCT03536091|Diagnostic Test|Magnification endoscopy|All IBD patients will undergo magnification endoscopy with 136-fold optical magnification in conjunction with optical chromoendoscopy
83072|NCT03536078|Other|home phototherapy|
83073|NCT03536065|Behavioral|Opioid Reduction Intervention|Patient education discharge sheet, nursing education, opioid prescription reduction based on Pre-Intervention data
83074|NCT03536065|Behavioral|Current Care|Current unchanged care provided; unchanged provider prescribing and unchanged education of patients prior to intervention
83075|NCT03536052|Device|Virtual Heart Guided Ablation|If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
83076|NCT03536039|Drug|NGR-hTNF|dose of 0.8 mcg/sqm
83077|NCT03536039|Other|RITUXIMAB|dose of 375 mg/mq
83078|NCT03536039|Drug|Doxorubicin|dose of 50 mg/mq
83079|NCT03536039|Drug|Cyclophosphamide|dose of 750 mg/mq
83080|NCT03536039|Drug|Vincristine|dose of 1.4 mg/mq (max 2 mg)
83081|NCT03536039|Drug|Prednisone|75 mg
83082|NCT03536026|Procedure|Conventional bronchoscopy|-Standard of care
83119|NCT03535727|Drug|Nab-paclitaxel|IV over 30 minutes; Days 4 and 11
83083|NCT03536026|Device|VIDA Pulmonary Workstation 2|-Virtual bronchoscopic navigation system
83084|NCT03536026|Procedure|Biopsy|-Standard of care
83085|NCT03536013|Other|Other: Full-thickness placental allograft|A full-thickness placental allograft will be applied to the annulus of the index lumbar level prior to site closure.
83086|NCT03536000|Diagnostic Test|Fetal echocardiography using the aCMQ-Strain method|Fetal echocardiography using the aCMQ-Strain method (Automated Cardiac Motion Quantification) at 24, 28, 32 and 36 weeks of gestation
83087|NCT03535987|Device|myocardial PET imaging|using myocardial PET imaging as a means to assess cardiovascular risk in men with prostate cancer planned for androgen-deprivation therapy with external beam radiation therapy
83088|NCT03535974|Dietary Supplement|Preparation with Spirulina|Preparation with Spirulina to ameliorate the size of benign thyroid nodules
83089|NCT03535974|Dietary Supplement|Placebo|Placebo administration for 6 weeks bid
83090|NCT03535961|Drug|apatinib+oral etoposide|apatinib 425/500mg qd, 21days/cycle oral etoposide 50mgmg/m2 d1-10 21days/cycle
83091|NCT03535935|Drug|Astragalus Powder|"3 grams of water soluble astragalus sachets (equivalent to 15g raw herbs) administrated orally on top of standard medical care for 48 weeks.~Patients will have 5 days of medicine per week and will be advised to take the medicine once daily dissolved in boiling water in the first 5 days of the week."
83092|NCT03535935|Other|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker
83093|NCT03535922|Other|PROMs Assessment|Routine measurement and reporting of disease-specific PROMs, generic PROMs, or combination of both
83094|NCT03535909|Diagnostic Test|Noninvasive Hemodynamic Measurement System|Ability of the noninvasive hemodynamic measurement system to determine changes in the hemodynamic status of heart failure patients admitted to the hospital with a primary diagnosis of acute decompensated heart failure.
83095|NCT03535896|Other|HSR|"Participants will complete a heel raise standing with the forefoot on a step. The toes are maximally dorsiflexed by placing a towel underneath them. The heel raise is performed with a raise to maximal plantar flexion and to maximal dorsi flexion.~The exercise is performed with a load as heavy as possible but no heavier than 8RM and for as many sets as possible every other day."
83096|NCT03535896|Drug|Corticosteroid injection|Participants receive an ultrasound-guided corticosteroid injection between 5 and 8 days after baseline. A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid (Lederspan, Meda) + 1 ml Lidocain 10 mg7ml (Xylocain, AstraZeneca). The skin is cleansed with Chlorhexidine alcohol 0.5 % (Medic). The needle is inserted with a medial approach under ultrasound-guidance aligned to the long axis of the ultrasound transducer. The injection is placed anterior to the plantar fascia insertion on the calcaneal bone in the region of maximal fascia thickness.
83097|NCT03535883|Drug|Novel Oral Anti-Coagulants|Novel Oral Anti-Coagulant (NOAC) medications (i.e. Eliquis, Plavix, Xarelto etc.)
83101|NCT03535857|Device|PTNS|Use of PTNS on both ankles for 30 minutes
83102|NCT03535844|Other|Wolfberry|Consumption of cooked dehydrated wolfberry as part of a mixed meal.
83103|NCT03535844|Other|Healthy diet|Compliance to a healthy diet in accordance to recommendations by the Singapore Health Promotion Board.
83105|NCT03535818|Procedure|Radiofrequency ablation|RF application to achieve complete pulmonary vein isolation +/- ganglionated plexus ablation
83106|NCT03535805|Behavioral|Mind My Mind (MMM)|"Mind My Mind (MMM) is a new transdiagnostic and modular cognitive and behavioural therapy (CBT) program comprising evidence-based interventions for children and adolescents with anxiety, depression or disruptive behavior.~MMM manual consists of evidence-based CBT methods that are organized into modules. The intervention is tailored to the individual child by the dosing and the sequencing of the modules. Trauma-focused CBT is available. Parents are engaged in child's therapy and support the child in doing the homework. Parent management training is offered for behavioral disturbances. The educational psychologists deliver the therapy after one-week training in the manual, followed by weekly supervision. The treatment fidelity is monitored by video observation of therapy sessions (>20%).~The MMM training program consists of 9-13 sessions plus one booster, all completed within 17 weeks."
83107|NCT03535805|Behavioral|Treatment as Usual (TAU)|The parents in the TAU group are offered two sessions (week 2 and week 17) to support their attempts to seek help for the child in the municipality. This coordination is provided by psychologists (or other local professionals) who hold records of the currently available treatment options in the municipality. The TAU vary considerably from no intervention to counselling, talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. Some children are offered CBT interventions, but access to manualized treatment is generally very limited.
83108|NCT03535792|Drug|Fentanyl/Hyperbaric bupivacaine|Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.
83109|NCT03535792|Drug|Nalbuphine/Hyperbaric bupivacaine|Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
83110|NCT03535779|Biological|Hepatitis B|The Hepatitis B virus, is a double stranded DNA virus that prevents Hepatitis B in the population
83111|NCT03535779|Biological|Tetanus Toxoid|The Tetanus vaccine, also known as tetanus toxoid (Td/IVP), is an inactive vaccine used to prevent tetanus in the population
83112|NCT03535753|Drug|Decitabine and R-GDP|Decitabine and R-GDP
83113|NCT03535740|Drug|Brigatinib|Brigatinib Tablets
83114|NCT03535727|Drug|Nab-paclitaxel|IV over 30 minutes; Days 1 and 15
83115|NCT03535727|Drug|Gemcitabine|IV over 30 minutes; Days 1 and 15
83116|NCT03535727|Drug|Capecitabine|PO twice daily (BID); Days 1-7, 15-21
83117|NCT03535727|Drug|Cisplatin|IV over 60 minutes; Days 1 and 15
83118|NCT03535727|Drug|Irinotecan|IV over 30 minutes; Days 1 and 15
83125|NCT03535701|Dietary Supplement|Dietary Intervention|Undergo ketogenic diet
83126|NCT03535701|Other|Laboratory Biomarker Analysis|Correlative studies
83127|NCT03535701|Drug|Paclitaxel|Given standard of care therapy with paclitaxel
83128|NCT03535701|Other|Quality-of-Life Assessment|Ancillary studies
83129|NCT03535701|Other|Questionnaire Administration|Ancillary studies
83130|NCT03535688|Drug|D-cycloserine|200 mg BID (twice daily)
83131|NCT03535688|Drug|Placebo|BID (twice daily)
83132|NCT03535675|Drug|Muscadine Plus|Ellagic acid inhibits DNA Methyltransferase. DNA Methyltransferases (DNMTs) are a family of enzymes that regulate chromatin methylation and use S-adenosyl methionine (SAM) as the methyl donor. Ellagic acid's metabolite, urolithin-A inhibits the protein complex nuclear factor kappa-light-enhancer of activated B-cells (NFkB), potentially leading to increased rates of apoptosis and decreases in cancer cell proliferation. Extracts from Vitis rotundifolia have shown inhibition of the phosphatidylinositol 3-kinase-Akt pathway.
83133|NCT03535675|Drug|Placebos|The placebo capsules are rice flour that will be placed in white opaque capsules identical to the ones used for MPX.
83134|NCT03535662|Drug|Orvepitant|Single oral dose
83135|NCT03535662|Drug|Itraconazole|Once daily dosing for 10 days
83136|NCT03535636|Other|Polysomnography|Sleep structure will be assessed by polysomnography
83137|NCT03535623|Other|remote ischemic preconditioning (RIPC)|RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of 200 mmHg and 5-min reperfusion.
83138|NCT03535623|Other|Sham-RIPC|Sham-RIPC consists of 4 cycles of 5-min ischemia using pneumatic cuff pressure of < 10 mmHg and 5-min reperfusion.
83139|NCT03535610|Device|Uterine Embolization|Uterine Embolization with PVA Microspheres
83140|NCT03535597|Device|Quikclot Radial Pad|The QuikClot® Radial® pad will be applied over the radial artery access site covered with either a Coban™ bandage or a Tegaderm™ dressing after TRA.
83141|NCT03535584|Behavioral|Exercise Program|Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
83142|NCT03535571|Dietary Supplement|Salmon Protein Hydrolysate|4g of salmon protein hydrolysate per serving.
83143|NCT03535558|Drug|Fluoroquinolone (FQ)|Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.
83144|NCT03535558|Drug|Azithromycin (AZ)|Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.
83145|NCT03535558|Drug|Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination|Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
83146|NCT03535545|Drug|[68Ga]CBP8|Up to 15 mCi of [68Ga]CBP8 will be administered to each subject.
83147|NCT03535545|Diagnostic Test|PET Imaging|All subjects will undergo PET imaging after administration of [68Ga]CBP8.
83148|NCT03535532|Procedure|unilateral laparoscopic adrenalectomy|unilateral laparoscopic adrenalectomy is a kind of minimally invasive surgery commonly operated in patients diagnosed with adrenal diseases with a high likelihood of malignance or surplus hormone secretion.
83149|NCT03535532|Drug|standard medical treatment|standard medical treatment: detailed medicine strategy chosen for each patient will be associated with their own conditions based on current guidance recommendations.
83150|NCT03535519|Drug|Methotrexate|standard of care treatment with methotrexate
83151|NCT03535506|Drug|Palbociclib|Palbociclib capsules for oral administration contain 125 mg, 100 mg, or 75 mg of palbociclib, a kinase inhibitor.
83152|NCT03535493|Behavioral|Acceptance and Commitment Therapy (ACT)|An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress.
83153|NCT03535493|Behavioral|Float REST|A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
83154|NCT03535493|Behavioral|ACT + Float REST|The combined intervention will combine ACT and Float REST. An ACT session entails a mindfulness-based training to foster and nurture effective behavioral and emotional responding to distress. A float session entails laying supine in a light-proof, sound-proof tank consisting of a shallow pool of water (approximately 10 inches set to approximately 94.5 degrees to match skin temperature) with a high concentration of Epsom salt (approximately 1200 pounds) for 60 minutes.
83155|NCT03535480|Drug|G-CSF|G-CSF subcutaneously during five days
83156|NCT03535480|Combination Product|ASCOT|G-CSF subcutaneously during five days, aphaeresis to hematopoietic stem cell collection and catheterism for ovarian artery infusion
83157|NCT03535467|Other|Caregiver's Burden Inventory|The Caregiver Burden Inventory was developed by Canadian researchers.The authors of the instrument stress the importance of using a multidimensional measurement of burden with separate scores for each dimension in as opposed to global or uni-dimensional scores.
83158|NCT03535454|Other|working hours|weekly working hours
83159|NCT03535428|Diagnostic Test|VENOUS exploration|venous echo doppler ultrasound and abdo pelvic scanner in the 48h before surgery
83160|NCT03535415|Drug|Recombinant Human Growth Hormone Injection (rhGH)|rhGH 0.05mg/kg/d by subcutaneous injection
83161|NCT03535402|Drug|Sarilumab|SC administration of 200 mg twice a week
83162|NCT03535389|Diagnostic Test|Knee 4DCT|Dynamic knee 4DCT
83163|NCT03535376|Drug|Valsartan|Patients are tested for their normal prescription valsartan medication
83164|NCT03535363|Drug|Osimertinib|Drug: Osimertinib 80mg or 40mg
83165|NCT03535350|Drug|Ibrutinib|Dose response of Ibrutinib. Level 1 starting dose is 420mg daily. Level 2 starting dose is 560mg daily. Level -1 starting dose is 280mg daily.
83166|NCT03535350|Radiation|Radiation|2Gy x 30minutes for 6 weeks.
83167|NCT03535350|Drug|Temozolomide (TMZ)|Cycle 1 150mg/m2 and cycle 2-6 will be up to 200mg/m2.
83168|NCT03535337|Behavioral|CPS|Assessment of participant's medication adherence and barrier problem solving via phone conversation
83169|NCT03535337|Behavioral|SMS|Participants will receive a text message, which will be an electronic reminder regarding medication adherence. Participants will then text back a confirmatory response.
83170|NCT03535324|Behavioral|PROA for optimization|The development of a ASP based on Reinforcement, Guidance and Support Programs, to prescribing physicians for the optimization of antimicrobial use based on a non-tax counseling program and evidence-based recommendations.
83171|NCT03535324|Other|Control|There will be no intervention
83172|NCT03535311|Procedure|Measurement of sternal-notch to umbilicus distance|"The sternal notch to upper border of umbilicus length measurement in centimetres.~The length of the umbilical stump in centimetres.~The length of the UVC and/or UAC inserted in centimetres which will be identified using the printed markers on the catheter. The marker which is closest to the end of the umbilical stump will be the recorded value.~The length of the UVC and/or UAC in centimetres when the umbilical stump length is subtracted."
83173|NCT03535298|Drug|Early Highly Effective Therapies Group|Highly Effective MS Therapy group of medications
83174|NCT03535298|Drug|Escalation Therapies Group|Escalation MS Therapy group of medications
83175|NCT03535285|Procedure|Periodontal ligament distraction|decrease the bony resistant during canine retration
83176|NCT03535272|Drug|Bismuth subsalicylate|We aim to determine if there is a biologic benefit to an intervention (BSS administration) in the acquisition of travelers diarrhea and the acquisition of antimicrobial resistance genes.
83177|NCT03535272|Drug|Placebo Oral Tablet|Placebo manufactured to mimic pepto bismol
83178|NCT03535259|Radiation|concurrent sorafenib and IMRT, followed sorafenib maintenance|IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
83179|NCT03535246|Biological|Engineered Immune Cells|Engineered immune effector cells (EIE)
83180|NCT03535233|Drug|Triamcinolone Acetonide|
83181|NCT03535233|Drug|Minoxidil 5 % Topical Spray|
83182|NCT03535233|Drug|clobetasol propionate|
83183|NCT03535220|Combination Product|Protease Inhibitors|Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents
83184|NCT03535207|Radiation|high dose chemoradiotherapy|"Radiation therapy: 50 Gy at 2 Gy/Fx/d on weeks 1-5,followed by 36 Gy in 30 fractions of 1.2 Gy, twice per day,on weeks 6-8 to a total dose of 86 Gy.~concurrent chemotherapy: weekly carboplatin area under the curve (AUC) 1.5-2 and paclitaxel 45-50 mg/m2 over the duration (8 weeks) of radiation therapy.~Adjuvant chemotherapy after high dose chemoradiation is optional."
83185|NCT03535194|Drug|Mirikizumab|Administered SC
83186|NCT03535194|Drug|Placebo|Administered SC
83187|NCT03535194|Drug|Secukinumab|Administered SC
83188|NCT03535168|Drug|BAY1902607|3 different doses over the course of part 1 and 4 different doses over the course of part 2.
83189|NCT03535168|Drug|Matching placebo|Matching placebo for BAY1902607
83190|NCT03535168|Drug|Midazolam|Part 1: The subjects will initially (Day -1) receive a sub-therapeutic dose of 1 mg midazolam as solution in the morning.
83191|NCT03535142|Procedure|Bariatric surgery|Roux en y gastric bypass or gastric sleeve operation
83192|NCT03535116|Drug|Ketorolac|Toradol is a type of brand name. We will be using the generic version.
83193|NCT03535116|Drug|Saline|injectable normal saline
83194|NCT03535103|Drug|Gonal-F®|A single Subcutaneous injection, 225IU
83195|NCT03535103|Drug|LM001|A single Subcutaneous injection, 225IU
83196|NCT03535090|Drug|Methylprednisolone|
83197|NCT03535077|Other|Diagnostic Test|Imaging of the suspicious lesion after application of ORL-1 dye prior to biopsy
83198|NCT03535064|Other|Hand Hygiene Workshop|Workshops included video-clip and interactive lecture about common infections in schools, methods of transmission, and hand washing procedure and time. Puzzle games related to hand hygiene were distributed among schoolgirls. Posters with cartoon princess picture promote for hand hygiene were also distributed among the schools.
83199|NCT03535051|Device|fractional carbon dioxide laser|Monthly fractional carbon dioxide laser sessions
83200|NCT03535051|Drug|Tacrolimus Oint 0.03%|topical daily tacrolimus ointment application
83201|NCT03535038|Diagnostic Test|Inferior vena cava (IVC) diameter using USG|IVC diameter is measured from the distal of right hepatic pain and inferior vena cava meeting point using Philips En Visor C USG.
83202|NCT03535038|Diagnostic Test|Vascular pedicle width (VPW)|VPW is measured by drawing a line from the left subclavian artery exit point from aorta perpendicular to the point where superior vena cava crosses with right bronchi.
83203|NCT03534999|Device|Experimental. This was the group that received TENS|Patients that were on TENS . They were treated twice daily for 5 days. VAS and Hip Score scale were used to assess the pain intensity and disability level
83204|NCT03534999|Other|No intervention|Patients in this group were on their drugs only. There was no physiotherapy intervention for the patient. VAS and Hip Score scale were used to ascertain the pain intensity and hip disability at the before the treatment and after the treatment
83205|NCT03534986|Device|International Biophysics AffloVest|High-frequency chest wall oscillation vest
83206|NCT03534986|Device|Hill-Rom The Vest|High-frequency chest wall oscillation vest
83207|NCT03534986|Device|Respirtech inCourage|High-frequency chest wall oscillation vest
83208|NCT03534986|Device|Electromed SmartVest|High-frequency chest wall oscillation vest
83209|NCT03534973|Other|Caffeine intake|Cataract surgery in eyes with prior caffeine intake
83210|NCT03534973|Other|No caffeine intake|Cataract surgery in eyes without prior caffeine intake
83211|NCT03534960|Device|High Flow Nasal Oxygen Therapy|Nasal cannula flows of 3 to 8 lpm via systems approved to provide increased humidification and warmth to inspired gas
83212|NCT03534960|Device|Nasal CPAP|"Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O"
83213|NCT03534947|Drug|Sonidegib|Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.
83214|NCT03534947|Drug|Imiquimod|Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.
83215|NCT03534947|Procedure|Surgery|Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.
83216|NCT03534947|Other|Best supportive care|Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
83217|NCT03534934|Diagnostic Test|Vital signs|"Heart rate, respirations, blood pressure, temperature, oxygen saturation~arterial oxygen saturation (SaO2), height and weight"
83218|NCT03534934|Diagnostic Test|Urine Pregnancy Test|Urine pregnancy test done on woman of childbearing potential.
83219|NCT03534934|Other|Questionnaires|Subject Questionnaire Calcium Intake Questionnaire Home and Work Activities Survey
83220|NCT03534934|Diagnostic Test|Blood Test|Blood test for vitamin D level, Hemoglobin A1c, and creatinine level
83221|NCT03534934|Diagnostic Test|Duel-energy X-ray absorptiometry scan|Bone density measurement
83222|NCT03534934|Diagnostic Test|Multi-detector computed tomography|Hip and ankle CT scan
83223|NCT03534934|Diagnostic Test|Dual-energy X-ray absorptiometry scan|Vertebral fracture assessment
83224|NCT03534895|Drug|Midazolam Injectable Solution|intravenous
83225|NCT03534895|Other|Normal saline|intravenous
83226|NCT03534895|Procedure|Spinal anesthesia|8mg of heavy bupivacaine 0.5% injected in the subarachnoid space, during lateral decubitus
83227|NCT03534895|Procedure|Surgery|Open inguinal hernia repair, varicose vein stripping, knee arthroscopy or hallux valgus surgery
83228|NCT03534895|Drug|Postoperative analgesia|IV acetaminophen 1g + IV ketorolac 30mg
83229|NCT03534895|Drug|Rescue analgesia|Tramadol 2mg/Kg IV in 100mL of normal saline, if pain NRS>3.
83230|NCT03534895|Drug|Wound infiltration|Wound infiltration with 10mL of ropivacaine 0.75%, in open inguinal hernia repair
83231|NCT03534895|Drug|Analgesia at home|Oral acetaminophen 1g 6/6h + ibuprofen 400mg 8/8h (+ rescue analgesia with tramadol 50mg 6/6h)
83232|NCT03534882|Other|Discontinuation of topical prostaglandin analogue therapy|Participants are asked to discontinue their prostaglandin analogue eye drops for the designated time period (42 days)
83233|NCT03534869|Procedure|Ear acupuncture|French auriculotherapy guidelines - internal genital area, external genital area and Shen Men point.
83234|NCT03534869|Drug|Analgesics|Oral ibuprofen was given as first line therapy, while oral paracetamol was given as second line therapy.
83235|NCT03534856|Behavioral|Mindfulness meditation|Short guided mindfulness meditations were provided on an MP3 player.
83236|NCT03534843|Procedure|Liver resection|Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
83237|NCT03534843|Other|Transcatheter arterial embolization|Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
83238|NCT03534830|Diagnostic Test|MRI|pre-operative MRI to be performed on all patients and then based on the imaging studies, the patient will be divided into the two comparative cohorts
83239|NCT03534817|Behavioral|Early Access CR|Participants in the Early Access CR group will begin CR within 1-week post-hospital discharge following their MI, as opposed to Standard Access CR group which begins 7-weeks post-hospital discharge, and the Canadian average (10-14 weeks post-hospital discharge). No further intervention or differentiation between groups is applied; the actual CR program is standardized between groups, and follows the guidelines regularly practiced by the institution.
83240|NCT03534804|Drug|Cabozantinib|Cabozantinib is administered at 40 mg oral daily
83241|NCT03534804|Drug|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
83242|NCT03534791|Other|Reminders|Personalized email which will aim for reminding of the translator about the PLSs on hold.
83243|NCT03534778|Diagnostic Test|Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)|LNY and LNR will be examined after neck dissection
83244|NCT03534765|Diagnostic Test|CT abdomen +/- pelvis|Diagnostic CT scan (only if requested by responsible clinicians)
83245|NCT03534765|Diagnostic Test|Edmunton Frailty Score|Patient completed previously valided questionnaire quantifying frailty.
83246|NCT03534765|Procedure|Emergency laparotomy for general surgical pathology|Emergency general surgical laparotomy (defined by the UK NELA body)
83247|NCT03534739|Other|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
83248|NCT03534739|Other|Light Touch Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
83249|NCT03534739|Other|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
83250|NCT03534726|Device|7 T CMR|7 tesla MRI device
83251|NCT03534713|Drug|Carboplatin|carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles
83252|NCT03534713|Drug|Paclitaxel|paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
83253|NCT03534713|Drug|Cisplatin|Cisplatin 40mg/m² given once a week during 5 weeks
83254|NCT03534713|Radiation|Radiotherapy|45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines
83255|NCT03534700|Procedure|parasacral flap reconstruction|parasacral flap reconstruction
83256|NCT03534700|Procedure|open excision|open excision and healing by secondary intention, marsupialization, excision and primary closure (midline or off-midline), excision and repair by flap.
83257|NCT03534687|Behavioral|Aerobic Exercise|12-week supervised aerobic exercise
83258|NCT03534674|Dietary Supplement|vitamin D3|a single oral loading dose of 100,000 IU vitamin D3 on the day of hospital admission for aHSCT, then 2000 IU vitamin D3 daily.
83259|NCT03534661|Drug|Teduglutide + Normal Saline|Teduglutide 0.05 mg/kg subcutaneous injection; Normal Saline intravenous infusion
83260|NCT03534661|Drug|Teduglutide + L-NMMA|Teduglutide 0.05 mg/kg subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
83261|NCT03534661|Drug|Placebo + L-NMMA|Placebo subcutaneous injection; L-NMMA 10 mg/kg intravenous infusion
83262|NCT03534648|Drug|PF-06865571 administered Day 7-14|PF-06865571 administered Q12hr on Days 7-14
83263|NCT03534648|Drug|PF-06865571 administered Day 1-14|PF-06865571 administered Q12hr on Day 7-14
83264|NCT03534648|Drug|PF-05221304 administered Day 1-14|PF-05221304 administered Q12hr on Days 1-14
83265|NCT03534648|Drug|PF-05221304 administered Day 7-14|PF-05221304 administered Q12hr Days 7-14
83266|NCT03534635|Drug|Pembrolizumab|Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
83267|NCT03534635|Drug|Pembrolizumab - additional treatment|Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
83268|NCT03534622|Drug|Delafloxacin|In this study, thirty subjects who meet the entry criteria will be assigned to 1 of 5 groups (A, B,C, D, or E) to receive 300 mg delafloxacin IV every 12 hours for a total of 7 doses over 4 days
83269|NCT03534609|Device|Lutronic Genius System|Treatment of the neck using the Lutronic Genius System
83270|NCT03534583|Other|Sudarshan Kriya Yoga|Participants in the SKY group will undergo a 12-week training course conducted by certified teachers of the Art of Living Foundation
83271|NCT03534583|Other|Health Enhancement Program|Participants in HEP will learn about health promotion, healthy diet, music, and exercise, but will not learn breathing techniques, or meditation. HEP will be delivered by trained staff.
83272|NCT03534557|Diagnostic Test|FEV6 spirometry|During the same spirometry, to compare the relative value of FVC and FEV6
83273|NCT03534531|Procedure|Intra-articular cervical zygapophyseal joint injection|Fluoroscopically-guided intra-articular cervical zygapophyseal steroid injection
83274|NCT03534518|Other|BWS overground training|BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. The walking tasks will be roughly divided into different domains like skilled walking, balance, dual tasking, walking speed, walking endurance.
83275|NCT03534518|Other|BWS treadmill training|Training will be conducted on a standard treadmill with an overhead BWS system that can provide active BWS. Participants are allowed to hold the rails but weight bearing is not allowed. BWS will be provided with the goal to impose the maximal lower extremity weight bearing load without excessive knee flexion during stance phase and/ or toe dragging during the swing phase. Main walking tasks will be endurance (walking long distances at preferred speed) and speed (walking at maximal possible speed).
83276|NCT03534505|Other|Ketorolac group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
83277|NCT03534505|Other|Bupivacaine group|patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
83278|NCT03534492|Drug|Durvalumab|Infusion
83279|NCT03534492|Drug|Olaparib|P.O.
83280|NCT03534479|Drug|Polyclonal IgG|Measurement of vascular reactivity before and after Infusion of plyclonal Immunoglobulins G in patients with Common variable immunodeficiency
83281|NCT03534466|Device|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
83282|NCT03534466|Behavioral|Conventional physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
83283|NCT03534453|Drug|Olaparib 300mg tablets|300mg Olaparib tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
83284|NCT03534427|Other|Jump rope exercise intervention|12-week jump rope exercise program
83285|NCT03534414|Dietary Supplement|Portfolio Dietary Pattern|"Portfolio Dietary Pattern consisting of 4 food components, including:~plant sterols (sterol-enriched margarine or supplement)~viscous soluble fibres (oats, barley, psyllium, eggplant, okra, etc)~plant protein (soy products and pulses), and~nuts (tree nuts and peanuts)"
83286|NCT03534414|Dietary Supplement|NCEP Based Diet|A low saturated fat, low cholesterol diet.
83287|NCT03534401|Behavioral|ARCHES Kenya|ARCHES: FP counselors in intervention clinics will ) provide counseling and education regarding risk of partner detection of FP methods, and women's and girls' strategies to use FP methods to minimize partner detection risk integrated into standard FP counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPV (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) distribute palm-sized educational materials on RC and IPV, as well as IPV services.
83288|NCT03534388|Other|Sodium Hypochlorite Cleanser|Cleansing with CLn BodyWash
83289|NCT03534375|Other|The study is an observational cross sectional study|An intervention will not be performed
83290|NCT03534362|Device|Nasopore|Nasopore group will receive frontal drill out procedure as indicated with Kenalog-soaked Nasopore stent applied to the post-operative outflow tract
83291|NCT03534362|Device|Propel|Propel stent group will receive frontal drill out procedure as indicated followed by Propel stent placement applied to the post-operative outflow tract.
83292|NCT03534336|Behavioral|Incentive for Education|"A $150 Incentive for Education is given to the participants for passing at least nine quizzes by the end of the program"
83293|NCT03534336|Behavioral|Incentive for Weight Loss|"A $150 Incentive for Weight Loss is given to the participants for losing at least 5% of baseline weight by the end of the program"
83294|NCT03534323|Drug|Duvelisib|This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
83295|NCT03534323|Drug|Venetoclax|Venetoclax targets a protein called BCL-2, which helps cancer cells survive.
83296|NCT03534310|Drug|LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)|
83297|NCT03534310|Other|lifestyle modification|
83298|NCT03534310|Other|sleeve gastrectomy|
83299|NCT03534297|Drug|dapansutrile capsules|Hard opaque capsules containing 100 mg of API.
83300|NCT03534297|Drug|Placebo capsules|Hard opaque capsules containing 0 mg of API.
83301|NCT03534284|Behavioral|Cognitive Behavioral Therapy for Insomnia|Once weekly treatment sessions for 6 weeks. The content of each of these sessions will be adapted to include changes in behavior during HD treatments (such as napping) and to help patients better adjust to treatment schedules. The CBT-I sessions will be delivered by a therapist face-to-face with the patient via a fully interactive video telehealth platform.
83302|NCT03534284|Drug|Trazodone|trazodone tablet
83303|NCT03534284|Drug|Placebo|Inactive pill manufactured to mimic trazodone tablets.
83304|NCT03534271|Device|iPhone with Kenek Edge and Samsung S8|Smartphones with pulse oximetry and heart rate monitoring capabilities
83305|NCT03534258|Device|Ceribell Rapid Response EEG, Survey|This trial will qualitatively examine how information from rapid response and conventional EEG data changes physicians' diagnostic suspicion or their treatment decisions and confidence levels. In addition, the results will examine the mean time to EEG lead placement, and ease of use.
83306|NCT03534219|Device|EarPopper|The EP device is 510(K) regulated (510(K) Number K073401) as a non-surgical, non-drug related treatment for middle ear pressure problems. The device is based on the Politzer Maneuver, and works by opening the Eustachian tube by delivering a safe, constant stream of air into the nasal cavity. In clinical studies funded by the National Institutes of Health (Grant#: 5R44DC003613-03), the EarPopper has proven to be effective in reducing chronic middle ear effusions. By regularly aerating the middle ear, we hypothesize that the EarPopper device will be an effective prophylactic measure to reduce incidence of AOM in children with recurrent OM. The device delivers a jet of air pressure from the nozzle at 5.2PSI, at a volume velocity of 1,524mL/min.
83307|NCT03534206|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
83308|NCT03534193|Other|Molly Center Diabetes Care Guide (Paper-based)|Diabetes education with Registered Nurse in addition to Paper based education modules
83309|NCT03534193|Other|Tablet based interactive diabetes education modules|Molly Center Standard Diabetes Education plus access to interactive diabetes education modules through bedside tablet.
83310|NCT03534180|Other|Laboratory Biomarker Analysis|Correlative studies
83311|NCT03534180|Drug|Venetoclax|Given PO
83312|NCT03534167|Behavioral|TODAY! App and Coaching|"The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based."
83313|NCT03534154|Diagnostic Test|MRI|Magnetic Resonance Imaging
83314|NCT03534154|Diagnostic Test|Blood Sampling|Sampling of serum
83315|NCT03534154|Diagnostic Test|Microdialysis|Monitoring of cerebral fluid protein levels
83316|NCT03534154|Diagnostic Test|Neuropsychological tests|Battery of tests to assess cognitive function, patient outcomes
83317|NCT03534154|Diagnostic Test|MRI (advanced)|Advanced MRI
83318|NCT03534141|Device|Esophageal cooling/warming device|The EnsoETM (formerly known as Esophageal Cooling Device) is a non-sterile multilumen silicone tube placed in the esophagus for the purpose of cooling or warming a patient while allowing gastric decompression and drainage. It is placed in a manner identical to a standard orogastric tube, which is standard equipment for liver transplant surgery. It is removed at the end of surgery. Control of the patient's temperature is achieved by connecting the EnsoETM to an external heat exchanger (Gaymar Medi-Therm III or similar system). The Medi-Therm III is a standard device used in operating rooms for warming patients with a conductive table warming pad. The Medi-Therm III circulates temperature-controlled water through a closed-loop system via the two outer lumens of the EnsoETM. Water temperature ranges from 4°C - 42°C.
83319|NCT03534141|Other|Mild hypothermia|Cooling will be initiated after induction of anesthesia and maintained throughout the anhepatic phase of liver transplantation. In all feasible cases the surgeon will cover the peritoneal surface over the right kidney, which is exposed during the operation, with ice-cold sponges to enhance cooling of the renal parenchyma. After blood flow is completely restored to the liver, the esophageal cooling device and other standard measures (forced-air, fluid, and table warmers, plus a heated anesthesia circuit) will be used to actively re-warm the patient (expected warming rate ≥ 1 deg C/hour). The goal is to achieve normothermia by case end.
83320|NCT03534141|Other|Normothermia|After induction of anesthesia, the esophageal cooling/warming device and standard warming measures will be used to maintain normothermia throughout the operation.
83321|NCT03534128|Other|Evaluation of the effect of cues on virtual spatial navigation using a virtual district|Evaluation of the effect of cues on virtual spatial navigation using a virtual district
83322|NCT03534115|Dietary Supplement|NAC|solution containing NAC
83323|NCT03534115|Dietary Supplement|Placebo|Placebo
83324|NCT03534102|Drug|Improved Opioid-Tapering Instructions|Applied to first and second experimental groups in the form of discharge instructions and directions from nursing staff.
83325|NCT03534102|Behavioral|Clinical Patient Educator|Applied to second experimental group in the form of regular calls about weaning off narcotic medications.
83326|NCT03534089|Other|Standard infant fomula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula without lactoferrin supplementation.
83327|NCT03534089|Other|Low level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula supplemented with low level of lactoferrin (38mg/100g).
83328|NCT03534089|Other|High level LF infant formula|Infants with iron deficiency anemia randomly divided into this group were given the same dose of ferralia with other groups,and were fed with infant formula middle supplemented with high level of lactoferrin (76mg/100g).
83329|NCT03534076|Other|Cohort Observational study|Cohort Observational study - there is no intervention
83330|NCT03534063|Genetic|CYP2D6-guided post-operative|For patients randomized to the genotype-guided arm, a saliva or buccal cell sample will be collected unless venipuncture is done for other reasons and then a blood sample will be collected for genotyping.
83331|NCT03534050|Radiation|postoperative adjuvant RT|
83332|NCT03534037|Drug|Febuxostat 40 mg|Febuxostat 40 mg orally per day plus dietary control only
83333|NCT03534037|Drug|Benzbromarone 50mg|Benzbromarone 50mg orally per day plus dietary control only
83334|NCT03534037|Other|Control|Dietary control only
83335|NCT03534024|Dietary Supplement|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicelle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
83336|NCT03534024|Dietary Supplement|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomcielle curcumin or placebo. nanomcelle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
83337|NCT03534011|Procedure|Resuscitative Balloon Occlusion of the Aorta|If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
83338|NCT03534011|Device|REBOA catheter|Catheter with a Resuscitative Balloon for Occlusion of the Aorta
83339|NCT03533985|Behavioral|Song of Kin|Music therapists will assess meaningful song/theme (of choice/culture) and provide musical elements in a way that nurtures parents. They will then develop a simplified part of the theme into a soothing lullaby for their infants to be utilized directly by the parent/s and/or the music therapist to comfort, engage or sedate.
83340|NCT03533985|Other|Gato box|Depending on the time of intervention and need of the infant the music therapist will provide rhythmic entrainment that follows the heart rate or suck patterns of the infant
83341|NCT03533985|Other|Ocean disc|Depending on the time of intervention and needs of the infant the music therapist will provide a whoosh sound using the Remo Ocean disc. It will be entrained to the infant's respiratory rate.
83342|NCT03533985|Other|Contingent singing|Depending on the state of the infant, the music therapist will provide short segments of conversant prosody, to enhance quiet-alert, or stimulate relaxation/sleep
83343|NCT03533985|Other|Tonal Vocal holding|Music therapist will provide a vowel, long held tone, sung without vibrato
83344|NCT03533985|Other|Muted shaker|If infant is awake, the muted shaker will be used to entrain to the infant's vital signs-to comfort, soothe or sedate
83345|NCT03533972|Drug|Ashwagandha|ashwagandha capsules given to the subjects twice daily after meals for 1 month
83346|NCT03533972|Other|Placebo|placebo capsules given twice daily after meals for 1 month
83347|NCT03533959|Drug|Alirocumab|the administration of Alirocumab at least 75mg every 2 weeks
83348|NCT03533946|Drug|Rucaparib|Treatment with rucaparib will begin on Cycle 1 Day 1 and continue at 600 mg twice daily. Therapy continues until PSA progression or intolerable toxicities.
83349|NCT03533933|Device|Collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
83350|NCT03533933|Other|autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
83351|NCT03533920|Device|UNI-DEB|Applicate the TACE with UNI-DEB to unresectable hepatocellular carcinoma patient
83352|NCT03533894|Device|colic capsule|colic polyp diagnosis
83353|NCT03533881|Dietary Supplement|Arom Digest Slim|"Arom Digest Slim is a dietary supplement approved in Romania by SNPMAPS, with notification number AA 10802/2017.~It contains: hydrolyzed fish collagen (94,8 %) and volatile oils (5,2 %): Citrus paradisi (2,40 %), Citrus aurantifolia (1,24 %), Menta avensis (0,92 %), Cinamomum zeylanicum (0,56%) Patients take 4 grams of supplement per day; the supplement is dissolved in 750 ml water and drunk throughout the day"
83354|NCT03533881|Behavioral|Nutritional changes|Education to increase the fruits and vegetables, decrease refined carbohydrates, decrease high fat animal products, regulation of meal programme, increase water intake to at least 1,5 liters per day
83355|NCT03533868|Diagnostic Test|Point-of-care viral load monitoring test|For enumerating viral load for patients in the POC arm, we will use the Cepheid Xpert® HIV-1 Viral Load test, a quantitative assay with a quantification range of 40 to 10,000,000 copies/mL. Based on the GeneXpert® technology, Xpert HIV-1 VL automates the test process, including RNA extraction, purification, reverse transcription and cDNA real-time quantitation in one fully integrated cartridge. The pre-loaded disposable single-use cartridges provide a visual read-out within 90 minutes. The assay requires 1 mL of plasma using a precision pipette (1.2 mL using a transfer pipette).
83356|NCT03533855|Diagnostic Test|CS plus FRFSE|"we perform a classic Fast Relaxation Fast Spin Echo (FRFSE) 3D MRI and add compressed sensing sequence"
83357|NCT03533829|Device|Buzzy®|Buzzy® Drug Free Pain Relief which is a medical device designed to reduce vaccination pain when applied to the arm prior to and during a vaccination.
83358|NCT03533829|Behavioral|Music|Music will be selected and listened to as a distraction before and during vaccination.
83359|NCT03533816|Drug|EAGD T-cell infusion (Phase I)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
83360|NCT03533816|Drug|EAGD T-cell infusion (Expansion)|The Alpha Beta (α/β) T-Cell Depletion System utilizes the CliniMACS instrument to yield a gamma delta (γδ) enriched cell therapy product.
83361|NCT03533803|Drug|Indomethacin 100Mg Suppository|Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
83362|NCT03533803|Procedure|IVF/ICSI|patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
83363|NCT03533790|Drug|DEP-Ru|"Drug: ruxolitinib~Drug: doxorubicin~Drug: etoposide~Drug: methylprednisolone"
83364|NCT03533777|Procedure|Peripheral intravenous catheter placement|The region of the upper extremity in which the IV will be placed will be prepped with chlorhexidine and a proximal elastic tourniquet is applied to the upper arm. A 20 gauge 30 millimeter IV catheter is inserted into an upper extremity vein by an anesthesiologist in either an antegrade or retrograde direction depending on which treatment arm the study subject is randomized to.
83365|NCT03533777|Other|Blood draw|A 20 milliliter(mL) syringe will be connected to the study IV tubing and used to aspirate 20 mL of blood from the study IV catheter. If 20 mL are unable to be aspirated over a 2 minute time frame, a proximal rubber tourniquet will be applied to the upper arm and the blood draw will be reattempted.This will occur twice throughout the study.
83366|NCT03533777|Device|Peripheral intravenous catheter|A 20 gauge 30 millimeter long BD Insyte(TM) Autoguard(TM) angiocatheter will be used for peripheral intravenous catheter placement as described above.
83367|NCT03533777|Drug|To keep open (TKO) infusion of 0.9% normal saline|After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
83368|NCT03533764|Behavioral|ASMA|ASMA, grounded in social cognitive theory and utilizing motivational interviewing techniques, guides adolescents in their transition to being consumers and teaching them to navigate the health system, including overcoming challenges to health care access. Briefly, it consists of three complementary components: (1) an 8- week intervention for students; (2) caregiver education; and (3) education for students' medical providers.
83369|NCT03533751|Biological|etokimab (ANB020)|Humanized Monoclonal Antibody
83370|NCT03533751|Drug|Placebo|Solution
83371|NCT03533738|Other|Food sequence 1|Vegetables first then meat & rice together
83372|NCT03533738|Other|Food sequence 2|Meat first then vegetables & rice together
83373|NCT03533738|Other|Food sequence 3|Vegetables first then meat followed by rice
83374|NCT03533738|Other|Food sequence 4|Vegetables first followed by meat and rice together
83375|NCT03533738|Other|Food sequence 5|Rice first followed by vegetables & meat together
83376|NCT03533725|Other|Breastfeeding counseling and education services|Breastfeeding counseling and education by educated and trained peer counselors using mHealth tools
83377|NCT03533712|Dietary Supplement|Fortified balanced energy-protein (BEP) supplement|"The product contains the following target nutrients:~Total energy: 250-500 kcal per daily serving~Fat content: 10-60% of energy intake~Protein content: 16 g (range 14-18 g) with a Digestible Indispensable Amino Acid Score (DIAAS) of ≥ 0.9~Carbohydrate (CHO) Content: no specific recommendations, relative to fat and protein content.~Trans Fats: <1% energy intake Micronutrients include the following: A, D, E, K, B1 (thiamin), B2 (riboflavin), B3 (niacin), B6 (pyridoxine), B9 (folate), B12 and C; minerals: iron, zinc, iodine, calcium, phosphorous, copper, and selenium.~The final composition of macro en micronutrients will be available after the acceptability testing (phase 1) and will be determined by 1) the product type and 2) the preferred taste."
83378|NCT03533712|Dietary Supplement|Fe and folic acid supplement|Routine iron and folic acid supplementation.
83379|NCT03533699|Drug|Propranolol|
83380|NCT03533699|Drug|Placebo Oral Tablet|oral tablets with no active drug
83381|NCT03533686|Device|Adhear Bone Conduction System|Adhear: Non-invasive bone conduction hearing device using adhesive
83382|NCT03533686|Device|Standard of Care|Standard of care: Non-invasive bone conduction hearing device using a headband
83383|NCT03533673|Biological|AAV2/8LSPhGAA|Adeno-associated virus serotype 8 carrying the human GAA gene under the control of the LSP promoter.
83384|NCT03533660|Behavioral|Feedback|Participant will receive a brief feedback on alcohol use data downloaded from the ABM and information about treatment resources
83385|NCT03533660|Behavioral|Enhanced Usual Care|Participant will receive information on self reported alcohol use and information about remaining abstinent and about treatment resources
83386|NCT03533647|Other|Observational|none (observational study)
83387|NCT03533634|Procedure|Open Reduction Internal Fixation superior plate|3.5mm superior reconstruction plate
83388|NCT03533634|Procedure|Open Reduction Internal Fixation anteroinferior plate|3.5mm anteroinferior reconstruction plate
83456|NCT03533179|Drug|Physiologic saline - glucagon dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to glucagon, and injected in identical rates on corresponding days.
83389|NCT03533621|Dietary Supplement|Probiotic - VSL#3|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
83390|NCT03533621|Dietary Supplement|Placebo pill - soy protein powder|Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
83391|NCT03533608|Behavioral|Group PE|Participants will engage in twelve 90-minute sessions of Group PE over the course of 6 weeks. Treatment consists of psychoeducation, rationale for treatment, and in vivo exposure to reduce trauma-related avoidance and thereby improve PTSD symptoms.
83392|NCT03533595|Device|Barbed|Barbed Suture
83393|NCT03533582|Drug|Carboplatin|Given IV
83394|NCT03533582|Drug|Cisplatin|Given IV
83395|NCT03533582|Drug|Doxorubicin|Given IV
83396|NCT03533582|Drug|Etoposide|Given IV
83397|NCT03533582|Drug|Fluorouracil|Given IV
83398|NCT03533582|Drug|Gemcitabine|Given IV
83399|NCT03533582|Drug|Irinotecan|Given IV
83400|NCT03533582|Other|Laboratory Biomarker Analysis|Correlative studies
83401|NCT03533582|Drug|Oxaliplatin|Given IV
83402|NCT03533582|Other|Patient Observation|Undergo watchful waiting
83403|NCT03533582|Drug|Sorafenib|Given PO
83404|NCT03533582|Drug|Vincristine Sulfate|Given IV
83405|NCT03533569|Procedure|Intra-articular corticosteroid injection|Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
83406|NCT03533556|Dietary Supplement|L-theanine|Oral administration of 2.5 mg/kg body weight of L-theanine dissolved in 100 ml of water
83407|NCT03533556|Dietary Supplement|Caffeine|Oral administration of 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
83408|NCT03533556|Dietary Supplement|L-theanine-Caffeine Combination|Oral administration of a combination of 2.5 mg/kg body weight of L-theanine and 2.0 mg/kg body weight of caffeine dissolved in 100 ml of water
83409|NCT03533556|Other|Placebo|Oral administration of 100 ml of water
83410|NCT03533543|Device|CEM|All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
83411|NCT03533530|Diagnostic Test|Low-density ESI (LD ESI)|Electrical source imaging using low density EEG
83412|NCT03533530|Diagnostic Test|High-density ESI (HD ESI)|Electrical source imaging using high density EEG
83413|NCT03533530|Diagnostic Test|No electrical source imaging (ESI)|For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
83414|NCT03533517|Device|AccuCinch® Ventricular Repair|AccuCinch® Ventricular Repair System in Patients with Heart Failure and Reduced Ejection Fraction (HFrEF)
83415|NCT03533504|Other|Variability in individual PK|Multivariate hierarchical analysis will be performed on various factors (age, sex, weight, height, dose and type of factor administered (as total and IU/kg), blood group, baseline factor level, positive history of inhibitors, hematocrit, hemoglobin, and serum creatinine, laboratory methods used to measure factor VIII and factor IX) to explore sources of variability in patient outcome.
83416|NCT03533491|Behavioral|Rewire App|A prototype Rewire app will be designed and created; the first four modules will be evaluated by 60 high-risk adolescents. The teens are asked to complete each module and spend a few minutes each day for two weeks using the practice exercises.
83417|NCT03533478|Dietary Supplement|Oral treatment Alzer y Diamel|"Alzer:~Administration way: Oral Dosage: one 500 mg tablet 3 times a day (1500 mg daily) Frequency: after breakfast, lunch and dinner. Duration: one year.~Diamel:~Administration way: Oral Dosage: two 660mg capsules 3 times a day (3960 mg daily) Frequency: before breakfast, lunch and dinner. Duration: one year."
83418|NCT03533478|Dietary Supplement|Placebo|Placebo treatment
83419|NCT03533465|Behavioral|Complicated Grief Therapy (CGT)|CGT is an evidence based 16 session targeted grief therapy delivered in individual one hour weekly sessions. Treatment will end at 16 sessions (offered over the course of 20 weeks)
83420|NCT03533452|Drug|Ropivacaine|Local anesthetic injection
83421|NCT03533452|Drug|Normal saline|Sham injection
83422|NCT03533439|Diagnostic Test|Near infrared spectroscopy|Four channel measurement of regional haemoglobin oxygen saturation (SO2) in the blood of the bowel, kidney and brain of neonates with gastroschisis during reduction within a silo and after surgery will be performed.• Routine surgical procedure will be followed (clinically indicated silo placement and closure as is currently practised). There will be no change in the clinical practice in place during this pilot study. Clinical management will be as already practiced with the supervision of the consultant with clinical responsibility dictating management
83423|NCT03533426|Procedure|Serratus anterior plane catheter block|Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
83424|NCT03533426|Procedure|Patient controlled analgesia|The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
83425|NCT03533413|Procedure|combined CT-fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by combined CT-Fluroscopy
83426|NCT03533413|Procedure|standard fluroscopy|Radiofrequency ablation of thoracic dorsal root ganglia guided by standard fluroscopy only
83427|NCT03533400|Device|Jamboxx Respiratory Therapy Device|Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece containing a breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
83455|NCT03533179|Drug|Esmolol|Esmolol hydrochloride 10 mg/ml is infused from time -15 min to time + 30 minutes as an initial bolus followed by an infusion. infusion rate is tapered if heart rate declines below 30 beats per minute (bpm) or >25 % from baseline, systolic blood pressure decreases below 80 mmHg or the participant experiences side effects.
83428|NCT03533400|Device|Jamboxx Musical Device|Jamboxx musical device is a hands free, breath controlled music device designed for people with quadriplegia. It resembles a common harmonica in that the user slides a mouthpiece along its horizontal axis to change the pitch of the instrument. The device connects to a personal computer via a mini USB to USB cable to interface with software that provides visual feedback for playing notes and sends the information to the computer speakers. The mouthpiece acts as a transducer, changing air pressure created by the user's lungs to a joystick signal to the computer via a differential pressure sensor. The Jamboxx musical device can produce musical sounds of many instruments (trumpet, drums, etc.) in many different scales and in any key
83429|NCT03533387|Drug|MN-166|an orally available small molecule drug approved in Japan and Korea for asthma and post-stroke complications and has been prescribed for these indications for more than 25 years
83430|NCT03533374|Diagnostic Test|Electroencephalogram (EEG) and visual evaluation|Electroencephalogram (EEG) was recorded using Nicolet-One system, and the standard 25-electrode array. Recordings with sharp transients are inspected by experts (physicians).
83431|NCT03533361|Drug|Lenvatinib|Oral capsules: 4 milligrams (mg) and 10 mg
83432|NCT03533335|Other|Oral spray (chlorhexidine spray, chlorine dioxide spray, sterile water spray)|Application of a daily dose of 12 sprays (each delivering a volume of 0.13ml) to the buccal and lingual gingival third of tooth surfaces in each sextant
83433|NCT03533309|Procedure|Computer guided surgical cutting guide|comprised 6 patient undergoing surgical alveolar ridge splitting using computer guided surgical cutting stent
83434|NCT03533309|Procedure|Conventional alveolar ridge splitting|comprised 6 patient undergoing surgical alveolar ridge splitting using conventional technique.
83435|NCT03533296|Procedure|Positive end expiratory pressure (PEEP)|The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
83436|NCT03533283|Drug|RO7082859|RO7082859 will be administered through IV infusion every 3 weeks (Q3W) beginning Cycle 1, Day 1, for up to 17 cycles (Cycle = 21 days). Step-up dosing, in which an initial lower dose will be followed by a higher dose 1 week later, will be considered for the initial treatment phase and for Cycle 9 of the re-treatment phase.
83437|NCT03533283|Drug|Atezolizumab|Atezolizumab will be administered in combination with RO7082859 through IV infusion Q3W from Cycle 2, Day 1, for up to 16 cycles (Cycle = 21 days).
83438|NCT03533283|Drug|Obinutuzumab|Obinutuzumab will be administered once, through IV infusion, at a fixed dose 7 days before the first dose of RO7082859.
83439|NCT03533283|Drug|Tocilizumab|Tocilizumab will be administered as necessary to treat cytokine release syndrome (CRS).
83440|NCT03533283|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered in combination with RO7082859 (on different days) Q3W from Cycle 1, Day 2, for up to 12 cycles (Cycle = 21 days).
83441|NCT03533270|Procedure|Urethroplasty|Surgical repair of Urethral injury
83442|NCT03533257|Drug|AMX0035|Combination Therapy of TUDCA and Sodium Phenylbutyrate
83443|NCT03533257|Drug|Placebo|Placebo
83444|NCT03533244|Drug|0.1% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
83445|NCT03533244|Drug|0.3% AG-86893 Eye Drops|One drop, three times daily to the study eye for 28 days
83446|NCT03533244|Drug|Vehicle Eye Drops|One drop, three times daily to the study eye for 28 days
83447|NCT03533231|Combination Product|Canal Disinfection Triple Antibiotic Paste (TAP)|"Patients were treated as follows: Caries was excavated; access cavity was prepared. The rubber dam was then applied and working length was determined. Canal space was irrigated using 40 cc of NaOCl 2.6% solution and final flush of saline. Canal space was dried using paper points. One cc of the prepared paste was injected into the canals using a sterile plastic syringe with 20 gauge needle. The access cavity was then sealed using temporary restoration. After the 3 weeks, anesthesia without vasoconstrictor was administrated. The antibiotic paste was removed and the canal was irrigated using a sterile saline and dried using paper points. Sterile hand file size #25 was introduced into the root canal beyond the working length to induce bleeding. The bleeding was allowed to reach a 3-mm level below the cemento-enamel junction. MTA was used to seal the root canal at the cervical level. After one week, adhesive composite resin was used to seal the access cavity."
83448|NCT03533231|Combination Product|Ciprofloxacin + Propolis Paste|
83449|NCT03533231|Combination Product|Ciprofloxacin + Metronidazole Paste|
83450|NCT03533231|Combination Product|Propolis + Metronidazole paste|
83451|NCT03533218|Device|Point of care Ultrasound machine|"POCUS methods of assessing ETT location offer an alternative that is time saving and thereby of critical importance in the neonatal time-is-brain scenario. Recently the government of Pakistan began upgrading health facilities and ensuring placement of essential equipment required to provide competent medical care, which may include provision of ultrasound machines to areas where there is established benefits to their use. Presence of trained staff and provision of portable ultrasound machine with short start-up time can save newborn lives(12).POCUS method empowers health care providers to read and interpret images in real time thereby saving critical time and need for specialized human resources (radiologists)."
83452|NCT03533205|Diagnostic Test|Hypotension Probability Indicator|The accurary of the Hypotension Probability Indicator (HPI) is tested in the created offline database. This means data was prospectively collected but the HPI algorithm was not tested prospectively but after collection in the offline database.
83453|NCT03533192|Behavioral|It's Your Game...Keep it Real|It's Your Game...Keep it Real consists of 12 50-minute lessons delivered in 7th grade (8 in class and 4 via computer) and 12 50-minute lessons delivered in 8th grade (7 in class and 5 via computer). In each grade, the curriculum integrates group-based classroom activities with personalized journaling and individually tailored computer-based activities. A life-skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal rules regarding risk behaviors, detect signs or situations that might challenge these rules, and use refusal skills and other tactics to protect these rules. The curriculum is grounded in social cognitive theory, the theory of triadic influence, and social influence models.
83454|NCT03533179|Drug|Glucagon|"Glucagon 1 mg/ml solution is dissolved in 50 ml isotonic fluid and injected as bolus corresponding to 50 micrograms/kg over 1-3 minutes from time=0 on day C+E. on day D (glucagon 2), 50 micrograms/kg of glucagon is infused over 30 minutes from time=0 to time =30."
83710|NCT03531385|Other|Quality of life|Quality of life will be assessed by the Nottingham Health Profile
83457|NCT03533179|Drug|Physiologic saline - esmolol dummy|Isotonic 0.9 % sodium chloride solution is administered as matching placebo to esmolol, and injected in identical rates on corresponding days.
83458|NCT03533166|Other|Chlorhexidine|0.03% Chlorhexidine + 0.05% CPC mouth rinse
83459|NCT03533166|Other|Placebo|Placebo mouth rinse
83460|NCT03533153|Biological|WJ-MSC cells implantation|Laboratory of Stem Cell of Drum Tower Hospital, Nanjing University Medical School, is able to provide types of Good Manufacture Practice (GMP) level stem cells and stem cell-based medicinal products. Clinical-grade WJ-MSC primary cells are cultured to 4~ 8 passages, and the surface markers (CD90+, CD105+, CD45-, CD31-, CD117-) are identified by flow cytometry. WJ-MSC cells are trypsinized and resuspended in the wash buffer of CTSTMD PBS (+Ca2+, +Mg2+). Within 2 hours after enzyme digestion, WJ-MSC cells are shipped to coronary care unit (CCU) and injected into the body.
83461|NCT03533153|Drug|CTSTMD PBS without WJ-MSC|For Case-control study only.
83462|NCT03533153|Drug|Conventional drug therapy|All patients undergo guideline-recommended treatment for STEMI, including aspirin (loading dose of 300mg before maintenance dose of 100 mg/d), clopidogrel (loading dose of 300mg before maintenance dose of 75 mg/d) or Ticagrelor (loading dose of 300mg before maintenance dose of 90 mg/d), angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), β-receptor blockers, statins and nitrate esters.
83463|NCT03533140|Device|DUCEST Neurostimulator V Group A|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively to stimulate the R.auricularis of the vagus nerve located at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates the device. (The stimulation intensity can be adjusted from 0,05mA to 1,2mA, default value is 0,4mA). The starting stimulation intensity will be adjusted to 1mA and takes place at 1Hz continuously for 40 minutes, followed by a 20 minute break. The built-in 3V battery lasts for approx. 14 days. After 7 days the electrodes are replaced and applied to the other ear of the patient. A plaster with a plastic mounting clip is attached on the shoulder of the patient. The Neurostimulator is connected to the mounting clip. After 14 days or at hospital discharge of the patient, the device is unmounted and the needle-electrodes are removed.
83464|NCT03533140|Device|DUCEST Neurostimulator V Group B|The DUCEST Neurostimulator V needle-electrodes are applied post-operatively at the Fossa triangularis. Connecting the needle-electrode cables to the Neurostimulator V activates only the signal lamp but not the device.
83465|NCT03533127|Drug|LY01008|LY01008+Carboplatin/Paclitaxel
83466|NCT03533127|Drug|Bevacizumab|Bevacizumab + Carboplatin/Paclitaxel
83467|NCT03533114|Drug|JZP-258|Subjects randomized to JZP-258 will receive the dose taken at the end of the Stable Dose Period.
83468|NCT03533114|Drug|Placebo Oral Solution|Subjects randomized to Placebo will receive an oral solution at a volume and regimen equivalent to the JZP-258 dose taken at the end of the Stable Dose Period.
83469|NCT03533101|Drug|Tocilizumab|IL-6 receptor antibody pre-transplant administration to avoid cytokine release syndrome
83470|NCT03533088|Other|scapular stabilization exercise|patients with RC repair surgery are going to have rehabilitation. The scapular stabilization exercise is going to be one of the focused points of rehabilitation process
83471|NCT03533075|Behavioral|Teachable Moment Brief Intervention|Behavioral intervention informed by Collaborative Assessment and Management of Suicidality and Dialectical Behavior Therapy/Cognitive Behavior Therapy to assist in positive recovery trajectory following a suicide attempt
83472|NCT03533062|Drug|botulinum toxin A|botox A injection trigonal or trigonal sparing with trial of anticholinergics 6 months post operative for 3 months
83473|NCT03533049|Other|myFAMI|Patients who are assigned to the myFAMI group will also have the smartphone application downloaded onto either the family member's smartphone or a study-provided smartphone. Following discharge from the hospital, participants will use the smartphone application to answer nine daily questions regarding tracking family coping, transplant symptoms, family management of child transplant symptoms, and family-management difficulty with medication and follow-up regimen daily for the first 30 days following discharge.
83474|NCT03533036|Device|applied VR headset|Virtual reality (VR) is a three-dimensional experience created by a headset fitted with a video display. The device, designed to be worn on the face, immerses the viewer in a virtual world and can create a visual distraction from the patient's present situation. We will use a commercially available VR device, comprised of a phone and headset. The phone is inserted into the headset to act as the visual display that can create three dimensional environments. The patient will then choose the virtual reality experience she prefers from the two relaxation programs available. The VR device will be introduced to the participant and fitted to her head prior to the procedure. The device is intended to be worn during the full length of the procedure until the conclusion of the D&C, however the participant may decide to stop wearing the device and choose to end the VR experience at any time.
83475|NCT03533023|Behavioral|Time Restricted Eating + Standard of Care|Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
83476|NCT03533023|Behavioral|Standard of Care|Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
83477|NCT03533010|Dietary Supplement|Ca500mg|subjects receive a daily dose of 500mg elemental calcium
83478|NCT03533010|Dietary Supplement|VitD800IU|subjects receive a daily dose of 800IU VitD3
83479|NCT03533010|Other|Placebo|subjects receive placebo tablet
83480|NCT03532997|Other|ELOS|"The investigators aim to introduce patients with advanced cancer to supportive care resources, including specialty palliative care, through a novel web-based application called ELOS (stands for extra layer of support) in a prospective cohort study."
83481|NCT03532984|Diagnostic Test|Beam test to predict falls|Dynamic balance will be determined in all participants during beam walking. The beams are 4m long, 2cm high, and 4, 8, and 12cm wide. After a practice trial, participants will perform three trials on each width with and without a calculation task. Trials will be block-randomized based on beam width then on task. Instructions: 'Traverse the entire length of the beam safely at your preferred speed without stepping off, facing forward, with your arms folded in front of your chest. Trials end when you step off, walk sideways, or unfold the arms.' Outcomes are the sum of length traversed, average velocity, number of steps, and average step length determined from video recordings made at 90° relative to the walking direction with full beam length in view using off-the-shelf video cameras.
83482|NCT03532971|Other|Symptom index questionnaire|A survey administered to identify the symptoms of the patient
83483|NCT03532971|Diagnostic Test|BK polyomavirus PCR|quantitative PCR testing
83484|NCT03532971|Other|quality of life questionnaires|Standard questionnaires validated for HCT recipients
83485|NCT03532958|Drug|BNZ-1|PEGylated peptide inhibitor of IL-2, IL-9, and IL-15
83486|NCT03532958|Drug|Normal saline|Random volume of 1 to 5 mL, consistent with weight-based dosing of BNZ-1
83487|NCT03532945|Device|Bioactive Glass-Ceramic Spacer|
83488|NCT03532945|Device|Titanium cage|
83489|NCT03532919|Diagnostic Test|Serum Tropinin|Blodsamples will be taken 4 times from preoperatively to 2 Days postoperatively
83490|NCT03532906|Drug|TAP Block|Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
83491|NCT03532906|Drug|Control|Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
83492|NCT03532893|Other|No intervention|This is a multi-center,observational, prospective, cohort study. A total of 10,000 subjects aged 40～75 without history of lung disease will be recruited and followed for 3 years. So there is no intervention in this study.
83493|NCT03532880|Drug|Olaparib Pill 50 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
83494|NCT03532880|Drug|Olaparib Pill 100 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
83495|NCT03532880|Drug|Olaparib Pill 150 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
83496|NCT03532880|Drug|Olaparib Pill 200 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
83497|NCT03532880|Drug|Olaparib Pill 250 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
83498|NCT03532880|Drug|Olaparib Pill 300 mg|"Olaparib dosing will be twice-daily (BID) dosing. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Drug administration at the dose level will occur on Day 1 (6 - 9 days prior to start of radiotherapy; for logistical considerations this may occur on the day of simulation for radiotherapy) and will continue concurrently with low dose consolidative thoracic radiotherapy until last day of radiotherapy (Day 20 - 23)"
83499|NCT03532880|Radiation|Radiotherapy|The total prescribed dose will be 30 Gy in ten daily fractions of 3 Gy each delivered during business days over 2 calendar weeks.
83500|NCT03532867|Other|Examination of pressures before stopping the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~Macular and peri-papillary OCT in EDI mode (bilateral examination),~Intraocular pressure (bilateral examination)~Measurement of systolic and diastolic blood pressure~Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
83501|NCT03532867|Other|Examination of pressure during the exercise|"In healthy volunteers performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~Macular and peri-papillary OCT in EDI mode (bilateral examination),~Intraocular pressure (bilateral examination)~Measurement of systolic and diastolic blood pressure~Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
83502|NCT03532867|Other|Examination of pressures after stopping the exercise|"In healthy patients performing aerobic physical exercise in the Department of Sports Medicine, the investigators will perform different examinations :~Macular and peri-papillary OCT in EDI mode (bilateral examination),~Intraocular pressure (bilateral examination)~Measurement of systolic and diastolic blood pressure~Heart rate measurement Exercise testing will be performed on bicycle measuring session with 10 minutes at moderate intensity ( 30% OF MPA), 10 minutes at sustained intensity ( 50% of MPA) and 3 minutes at maximum (70% of MPA).~The theoretical maximal aerobic power was calculated by a mathematical formula."
83503|NCT03532854|Drug|Valsartan|Valsartan P.O
83504|NCT03532854|Drug|Ezetimibe/Rosuvastatin|Ezetimibe/Rosuvastatin P.O
83505|NCT03532841|Drug|an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet|Group I will receive an oral tramadol 50 mg(Tramal, Memphis, Giza, Egypt) tablet one hour before the procedure.
83506|NCT03532841|Drug|Placebo Oral Tablet|placebo tablet of the same shape,color and taste will be given in the placebo arm
83507|NCT03532828|Other|polysomnography|Patients will have a polygraphy, a postural evaluation including Vicon system, EOS imaging, ang a force platform
83508|NCT03532815|Behavioral|Lifestyle Modification|
83509|NCT03532802|Drug|Metoprolol Succinate|"week: uptitration with 50 mg capsules per day, until maximum dosage of 150 mg´s/day.~week: steady state treatment with the maximum tolerated dose of the 1.week."
83510|NCT03532802|Drug|Placebo oral capsule|"week: uptitration with 1 capsule per day, until maximum tolerated dosage of 3 capsules/day.~week: steady state treatment with the maximum tolerated dose of the 1. week"
83511|NCT03532789|Drug|herbal patch|One patch with medicine should be applied to the skin every other day within two weeks
83512|NCT03532789|Drug|placebo patch|One patch without medicine should be applied to the skin every other day within two weeks
83513|NCT03532776|Drug|Podofilox Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
83514|NCT03532776|Drug|Condylox Topical Gel 0.5%|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
83515|NCT03532776|Drug|Placebo Gel|Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
83516|NCT03532763|Dietary Supplement|Tocotrienol-rich fraction|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: 200 mg Tocotrienol-rich fraction
83517|NCT03532763|Dietary Supplement|Placebo|1 capsule to be taken twice daily after meals for 6 months. Each capsule contains: Palm olein
83518|NCT03532750|Device|Particle|"300-500 µm Embosphere Particles, Merit Medical (Rockland, MA) 501(k) number K991549.~300-500 µm Embozene Particles, Boston Scientific (Marlborough, MA) 501(k) number K133447.~Ruby detachable coils, Penumbra (Alameda, CA) 501(K) number K103305.~Interlock detachable coils, Boston Scientific (Marlborough, MA) 501(k) number K132578."
83519|NCT03532750|Device|Coil|Ruby or Interlock detachable coils
83520|NCT03532737|Drug|Pembrolizumab|Adding PD-1 inhibitor to the standard of care
83521|NCT03532724|Device|Patient Self-Management of VKA therapy|Trained patients check weekly the INR using a portable coagulometer an decide by themselves the dosis of VKA
83522|NCT03532711|Drug|fluorouracil|chemotherapy treated patients
83523|NCT03532698|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
83524|NCT03532698|Drug|Osimertinib|Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
83525|NCT03532685|Procedure|Bariatric|withdrawing a part of the stomach and may or may not be combined with bowel deviation
83526|NCT03532672|Other|Acute Fasting|The volunteers will fast overnight (10 hours) and breakfast will be offered (bread, butter, ham and industrialized fruit juice) and the participants will fast for more 10 hours during daily activities.
83527|NCT03532659|Other|Active video game|Among the 20 municipal schools, two will be selected between those with 298 or more students (corresponding to the third quartile of the number of students per school). Next will be selected the school in which the adolescents will be submitted to intervention, and the students from the other school will be control. The intervention will aim to promote physical exercise through active video game XBOX 360 with Kinect. The game selected will be Just Dance, to allow the participation of up to four students at the same time. In addition, a gamification protocol will be performed to increase the adolescents engagement in the exercise.
83528|NCT03532646|Procedure|upper endoscopy|endoscopy of the gastrointestinal tract
83529|NCT03532633|Procedure|cord blood|collection of cord blood
83530|NCT03532633|Procedure|blood sample infant|collection of remnant of clinically indicated blood sample
83531|NCT03532633|Procedure|blood sample mother|collection of remnant of clinically indicated blood sample. If not available blood sample is taken after mother agreed
83532|NCT03532633|Procedure|breast milk|collection of breast milk 1/week during neonatal care (maximum 8 weaks)
83533|NCT03532620|Drug|Pitavastatin Calcium|"In Pitavastatin treatment group, Pitavastatin calcium tablet 2mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
83534|NCT03532620|Drug|Atorvastatin Calcium|"In Atorvastatin treatment group, Atorvastatin calcium tablet 20mg/day was given for 12 months in combination with lifestyle modification. But month 3 is the check point. If LDL-C target was achieved at Month 3, doses remained the same. If LDL-C target was not achieved at Month 3, doses were doubled."
83535|NCT03532607|Other|Music|Patients will listen to soothing music for 30 minutes before their standard of care botox injection
83536|NCT03532594|Procedure|PRODOSE Algorithm|Protamine administered according to PRODOSE algorithm
83537|NCT03532594|Procedure|Standard Care|Protamine administered according to Standard Care
83538|NCT03532581|Other|Indocyanine Green Solution|Given Subcutaneous injection
83539|NCT03532581|Procedure|Lymphangiography|Undergo lymphangiography
83540|NCT03532568|Other|skin biopsy|4mm punch skin biopsy
83541|NCT03532568|Radiation|narrowband ultraviolet B|narrowband ultraviolet B for CKD-aP patients
83542|NCT03532555|Dietary Supplement|Zinc Acetate|Zinc Acetate given with elemental zinc dose of 2mg/kg given orally only daily through 35 6/7 weeks corrected gestational age
83543|NCT03532555|Other|No supplemental zinc|Infants will receive standard of care, which is currently no supplemental zinc
83544|NCT03532542|Drug|Casimersen|Casimersen solution for IV infusion
83545|NCT03532542|Drug|Golodirsen|Golodirsen solution for IV infusion
83546|NCT03532529|Other|not applicable, it is an observational study|not applicable, it is an observational study
83547|NCT03532516|Drug|Brivaracetam|"Patients will start on the individual Brivaracetam (BRV) dose that they had reached at the completion of the previous study. The BRV dose can be adjusted based on the individual patient's seizure control and tolerability; however, the BRV dose may not exceed 200 mg/day in divided (preferably symmetrical) morning and evening doses, taken with or without food.~Up- and down-titration steps should be performed in steps of maximum 50 mg/day on a weekly basis. The full down-titration should include a 1-week step at 20 mg/day."
83548|NCT03532503|Device|Foley catheter|Transcervical foley catheter will be applied
83643|NCT03531905|Drug|Bempedoic acid + Ezetimibe FDC Oral Tablet|Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
83549|NCT03532490|Drug|Roflumilast 500 Mcg Oral Tablet|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
83550|NCT03532490|Drug|Placebo oral capsule|The first two weeks the participant will take one tablet every other day. If well tolerated, participant will take one tablet every day.
83551|NCT03532477|Drug|Venlafaxine|Patients are tested for their normal prescription metaprolol medication
83552|NCT03532464|Drug|azithromycin|The route of administration is oral. It is administered at a dose of 1 g (4 tablets), as a single dose with or without food.
83553|NCT03532464|Drug|doxycycline|The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
83554|NCT03532451|Drug|Nivolumab|Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
83555|NCT03532451|Drug|Nivolumab/Lirilumab|Nivolumab 480 mg IV over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
83556|NCT03532425|Drug|B/F/TAF|B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily
83557|NCT03532425|Drug|Atripla|Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily
83558|NCT03532425|Drug|B/F/TAF Placebo|Tablet taken orally once daily
83559|NCT03532425|Drug|Atripla Placebo|Tablet taken orally once daily
83560|NCT03532399|Drug|Bivalirudin|"CPB: Per hospital protocol, bivalirudin 1 mg/kg IV will be administered to the patient 10 minutes prior to the start of CPB along with an infusion of bivalirudin at 2.5 mg/kg/hr. Additional bolus doses of 0.5 to 1 mg/kg will be administered for ACTs less than the specified target (either 2 times baseline ACT or > 400 seconds per the discretion of the patient's providers). 50mg of bivalirudin will be administered to the bypass circuit.~Cardiac Catheterization: Bivalirudin will be administered to the patient as 0.75mg/kg IV bolus followed by a 1.75mg/kg/hr infusion for the length of the procedure. Changes in infusion rate or bolus dosing during the procedure and post-procedure will be at the discretion of the patient's care providers.~ECMO/VAD: Dosing will be informed by the hospital's formulary recommendations(http://online.lexi.com/lco/action/doc/retrieve/docid/chibos_f/6317841), but will ultimately be determined by patient's primary provider."
83561|NCT03532386|Procedure|ICSI|ICSI for both couples
83562|NCT03532373|Other|Preference Elicitation tool|A preference elicitation tool for carpal tunnel syndrome
83563|NCT03532360|Other|Oral immunotherapy|Starting from a very low level and over a period of several months, participants receive escalating doses of the food to which they are allergic
83564|NCT03532347|Device|EUS-FNA needle (Beacon)|Participants will be randomised to an initial 3 passes with Beacon FNA and then Beacon SharkCore biopsy needles or vice versa. 25g needles will be used for trans duodenal puncture and 22g for trans gastric puncture.
83565|NCT03532334|Diagnostic Test|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
83566|NCT03532321|Other|NA : non interventional study|NA : non interventional study
83567|NCT03532308|Drug|Fermented Soy|Two 12.5g packets/day) (~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks.
83568|NCT03532308|Other|Placebo|A placebo compliment to the active intervention with identical packaging and labeling will be used.
83569|NCT03532295|Drug|Epacadostat|-All BID doses will be taken in the morning and evening, approximately 12 hours apart
83570|NCT03532295|Drug|Avelumab|-In order to mitigate infusion-related reactions, patients must be premedicated with an antihistamine and with acetaminophen prior to the first 4 infusions of avelumab
83571|NCT03532295|Drug|Bevacizumab|-The first infusion will be over the course of 90 minutes; if tolerated, the second infusion will be over the course of 60 minutes; if tolerated, all subsequent infusions will be over 30 minutes
83572|NCT03532295|Radiation|Radiation therapy|-3.5 Gy x 10 fractions (during cycle 1)
83573|NCT03532295|Procedure|Peripheral blood draw|"Baseline (prior to administration of any study treatment)~At the end of RT~Cycle 2 Day 1 prior to administration of avelumab and bevacizumab~Cycle 6 Day 1 prior to administration of avelumab and bevacizumab~Cycle 12 Day 1 prior to administration of avelumab and bevacizumab or time of disease progression (if progression occurs before this time point, then collect blood at time of progression only; if no progression has occurred by this time point, the Cycle 12 will be the last collection)."
83574|NCT03532282|Behavioral|ONLINE ONLY|Access to an online cognitive behavioral therapy for insomnia
83575|NCT03532282|Behavioral|STEPPED CARE|A two step treatment that starts with either an online or therapist led cognitive behavioral therapy for insomnia, depending on a decision algorithm. Those with insufficient progress to the online treatment after 8 weeks are switched to a therapist-led treatment
83576|NCT03532269|Device|Nightly App|The Nightly application will be installed independently on the user's smartphone. Once the user has set up their account and has logged in, they can then perform regular sleep quality assessments. In order to record a measurement, the user must first select a film (first screen) and watch it (second screen), the visualizations and acoustics aid in the process of falling asleep. After the film finishes, the participant places the phone on the corner of the bed, firstly with the screen facing up, and then under his/her pillow. Throughout the night, the application registers sleep phases that will be analyzed later.
83577|NCT03532256|Behavioral|Observation|Patients will be contacted postoperatively via an automated text-message to assess pain, functional status, and opioid consumption.
83578|NCT03532256|Behavioral|Text to online survey|Subset of surgical patients will receive an automated text message with a link to a secure online survey with questions that assess pain, functional status, and opioid consumption.
83579|NCT03532256|Behavioral|Bi-directional text script|Subset of surgical patients will receive an automated bi-directional text message script with questions that assess pain, functional status, and opioid consumption.
83644|NCT03531905|Drug|Ezetimibe 10Mg Oral Tablet|Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
83580|NCT03532243|Procedure|incremental inspiratory load|inspiratory load ranges between 10 and 40 cm water column (cmH2O)or intolerable to the patient, each load increment for 5cm water column.
83581|NCT03532230|Procedure|Osteopathic Manipulative Treatment (OMT)|No specific OMT techniques will be required for the present study. However, data on the number of OMT sessions patients receive will be collected.
83582|NCT03532217|Biological|PROSTVAC-V|-Replication-competent vaccinia virus which has been engineered to encode the sequences for a modified human prostate-specific antigen (PSA) and a triad of co-stimulatory molecules (TRICOM)
83583|NCT03532217|Biological|PROSTVAC-F|-Fowlpox virus which does not replicate in human cells and has been engineered to encode the same sequences present in PROSTVAC-V.
83584|NCT03532217|Drug|Nivolumab|-Nivolumab is a human monoclonal antibody (mAb)
83585|NCT03532217|Drug|Ipilimumab|-Ipilimumab is a mAb blocking the inhibitory signal mediated by cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4), a protein receptor that downregulates the immune system.
83586|NCT03532217|Biological|Neoantigen DNA vaccine|Each DNA vaccination will be 1 mL vaccine administered intramuscularly. At each vaccination time point, patients will receive two injections at separate sites.
83587|NCT03532217|Device|TriGrid Delivery System|-Electroporation device
83588|NCT03532217|Procedure|Tumor biopsy|-Pre-treatment, post-treatment A (optional), and end of treatment
83589|NCT03532217|Procedure|Peripheral blood|-At the time of pre-treatment biopsy, mid-treatment of chemo-ADT, at time of enrollment (prior to POSTVAC administration), mid-treatment A, mid-treatment B (multiple)
83590|NCT03532217|Procedure|Fecal samples|-Post chemo/pre-treatment A, post-treatment A, pre-treatment B, post-treatment B
83591|NCT03532217|Procedure|Leukapheresis|"Post-treatment A/pre-treatment B~End of treatment"
83592|NCT03532204|Radiation|SBRT|"Patients will received 2 courses of chemotherapy before SBRT if no hepatic or extra-hepatic progression identified.~All liver metastases will be irradiated. 4 doses prescription are allowed (according to the center, and the technique uded and the dosimetric constraints): 3x15 Gy, 4 x 15 Gy, 5 x10 Gy or 5 x 8 Gy.~The remaining courses of chemotherapy 2 to 3 weeks after completion of SBRT will be administered"
83593|NCT03532204|Drug|Chemotherapy|At investigator's discretion
83594|NCT03532191|Other|PrEP Optimization Intervention (PrEP-OI)|PrEP-Rx + PrEP Coordinator
83595|NCT03532178|Drug|"Group A. Muscle relaxant #1: rocuronium + sugammadex; Muscle relaxant #2: succinylcholine +saline"|"The participants will be randomized to start with Muscle relaxant #1 in the first study treatment, and will switch to Muscle relaxant #2 in the second study treatment period."
83596|NCT03532178|Drug|"Group B. Muscle relaxant #2: succinylcholine +saline; Muscle relaxant #1: rocuronium + sugammadex;"|"The participants will be randomized to start with Muscle relaxant #2 in the first study treatment, and will switch to Muscle relaxant #1 in the second study treatment period."
83597|NCT03532165|Diagnostic Test|Lower extremity Ultrasound|One group may forego a CT angiogram of the chest if they have a positive lower extremity ultrasound. The other group with a negative ultrasound may still require CT angiogram imaging.
83598|NCT03532152|Device|Pure Purr VR technology|"The Pure Purr technology consists of BoboVR X1 headset with pre-installed software. The virtual reality headset reproduces a dynamic video content that is visually perceived with the help of the high-resolution screen. Also, the headset is able to play audio and transmit it via the headphones.~The audio sequence has been modified by adding a binaural effect and has been synchronized with the tact of respiratory movements and the frequency of heart rate."
83599|NCT03532152|Device|Sham VR technology|The sham technology includes an identical BoboVR X1 virtual reality headset with pre-installed software. The audio-visual sequence is similar to the one in the investigational version of the software. The key difference is that the audio sequence has not been modified with the binaural effect and has not been synchronized with the tact of respiratory movements and the frequency of heart rate.
83600|NCT03532139|Drug|Enoxaparin|Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness
83601|NCT03532139|Drug|Enoxaparin + Rosuvastatin|"Rosuvastatin is an anti-cholesterol medication that is FDA (the U.S. Food and Drug Administration) approved to lower cholesterol and reduce the risk of arterial blood clots. There is evidence that rosuvastatin can lower the risk of venous blood clots in healthy individuals~Enoxaparin is used for prevention of blood clots following abdominal or orthopedic surgery and in medical patients with restricted mobility during acute illness"
83602|NCT03532139|Other|Thromboprophylaxis|standard of care therapy
83603|NCT03532126|Device|Dermal filler for midface deficit|During this procedure the device (a dermal filler) will be deep intradermal, subcutaneous or supraperiosteal injected according to its CE mark.
83604|NCT03532113|Behavioral|Updating|Updating is trained across 12 sessions using N-back-type exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of the stimuli (numbers vs. symbols) is changed halfway in each session.
83605|NCT03532113|Behavioral|Inhibition|Inhibition is trained across 12 sessions with Stroop-like exercises. Training is performed on a samsung galaxy tab2. Each session lasts 30 minutes. The difficult is reset and the nature of stimuli (letters vs. numbers) is changed halfway in each session.
83606|NCT03532113|Behavioral|General knowledge|General Knowledge is trained across 12 sessions. Participants complete four-choice questions relating to general knowledge and vocabulary and are provided with the correct answer and a short explanation. Questions are displayed one by one on a computer screen with a maximum of 20 seconds per question. Each session lasts 30 minutes and includes 2 blocks of 40 new questions each (about 220 seconds per block). Questions with wrong answers are displayed again at the end of each block.
83607|NCT03532100|Device|Torsionally adaptive prosthesis with 0:1 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 0:1 means there will be no coupling between the transverse- and sagittal-plane motion. That is, regardless of any motion in the sagittal plane, there will be zero motion in the transverse plane.
83608|NCT03532100|Device|Torsionally adaptive prosthesis with 1:6 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:6 means there will be one degree of motion in the transverse plane for every six degrees of motion in the sagittal plane.
83609|NCT03532100|Device|Torsionally adaptive prosthesis with 1:4 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:4 means there will be one degree of motion in the transverse plane for every four degrees of motion in the sagittal plane.
83610|NCT03532100|Device|Torsionally adaptive prosthesis with 1:3 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:3 means there will be one degree of motion in the transverse plane for every three degrees of motion in the sagittal plane.
83611|NCT03532100|Device|Torsionally adaptive prosthesis with 1:2 coupling ratio|The torsionally adaptive prosthesis can be programmed to couple the motion between the transverse- and sagittal-planes. A coupling ratio (transverse:sagittal) of 1:2 means there will be one degree of motion in the transverse plane for every two degrees of motion in the sagittal plane.
83612|NCT03532087|Drug|Denosumab 120 mg|Denosumab 120 mg every 3 weeks.
83613|NCT03532087|Drug|Denosumab 60 mg|Denosumab 60 mg every 6 months.
83614|NCT03532074|Diagnostic Test|assessment of bowel symptoms before surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis before surgery
83615|NCT03532074|Diagnostic Test|assessment of rectosigmoid during laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. A near-infrared camera-head (KARL STORZ Gesellschaft mit beschränkter Haftung & Co., Tuttlingen, Germany) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
83616|NCT03532074|Diagnostic Test|follow up and assessment of bowel symptoms after surgery|validated questionnaires (Knowles-Eccersley-Scott-Symptom Questionnaire and Gastrointestinal Quality of Life Index) are filled in by patients with rectosigmoid endometriosis after surgery
83617|NCT03532074|Diagnostic Test|assessment of rectosigmoid perfusion during robot-assisted laparoscopy|indocyanine green (0.25 mg/kg) is administered through peripheral line. The robotic Firefly imaging system (daVinciXi surgical platform; Intuitive Surgical, Sunnyvale, CA) is used to visualize bowel perfusion before and after the removal of the rectosigmoid nodule. To estimate the vascularization, a scale with a score between 0 and 4 is used
83618|NCT03532061|Behavioral|FamCare Program|6 in-person sessions of biweekly home care problem-solving skills training (FamCare) delivered by a health educator.
83619|NCT03532061|Other|Caregiver Support Group|6 in-person caregiver support group sessions held biweekly and moderated by a health educator.
83620|NCT03532048|Behavioral|The Papás Saludables, Niños Saludables Program|Papás Saludables, Niños Saludables is a 10 week program for fathers and their children that meets weekly. Each session is 90 minutes long: 15 min introduction, 30 min pull-out sessions for fathers and children, and 45 min active play sessions together. Fathers are encouraged to improve their eating and physical behaviors to lose weight and to be healthy role models for their child. Children are encouraged to help their fathers lose weight and improve their health. The program has been adapted to contextualize the information for low-income Hispanic families and changed to US food and physical activity guidelines. Mothers will be provided a Handbook and will be sent short videos, recipe links, and short motivational messages every week covering the same topics as in the sessions.
83621|NCT03532048|Behavioral|The Papás Saludables, Niños Saludables Wait-list Control|The same program as above delivered to the wait-list control after the T1 follow-up data has been collected.
83622|NCT03532035|Drug|Brincidofovir|Subjects will receive BCV administered as a continuous IV infusion over 2 hours twice weekly (on Days 1, 4, 8, and 11) for a period of 2 weeks (total of 4 doses).
83623|NCT03532035|Drug|Standard of Care|"Subjects randomized to the SoC in each cohort will be managed per local institutional guidelines and investigator judgement. SoC treatment options may include, but are not limited to, taking a watch and-wait approach, with or without decreased immunosuppression (i.e., no active treatment), or treatment with IV CDV, ganciclovir, or ribavirin."
83624|NCT03532022|Drug|Chronocort®|Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.
83625|NCT03532022|Drug|Standard Care|The subject's standard care regimen upon entering the study; this could consist of hydrocortisone, dexamethasone, prednisone or prednisolone.
83626|NCT03532009|Drug|Sodium Zirconium Cyclosilicate|Oral use for approximately 3 months
83627|NCT03532009|Drug|Placebo|Oral use for approximately 3 months
83628|NCT03531983|Procedure|fixation of tochentric fractures by gamma nail|• Thirty patients with recent traumatic extracapsular proximal femoral fractures were treated using a short gamma nail of third-generation assembly
83629|NCT03531970|Drug|2% lidocaine with 1:80,000 epinephrine|Anesthetic solution
83630|NCT03531970|Drug|Dexamethasone|Corticostroide
83631|NCT03531970|Drug|Placebo|Placebo
83632|NCT03531957|Drug|ASN002|Daily dose of ASN002 for 12 weeks
83633|NCT03531957|Drug|Placebo Oral Tablet|Placebo of ASN002 for 12 weeks
83634|NCT03531944|Other|Community pharmacist-involved collaborative care|Community pharmacist-involved collaborative care in the management of individuals with type 2 diabetes mellitus
83635|NCT03531944|Other|Usual care|Usual care with physician and as needed visit to the nurse
83636|NCT03531931|Drug|Apatinib/Capecitatine|Apatinib is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2), now being developed by Jiangsu Hengrui Medicine (China). Even at a low concentration apatinib can still perform magnificent VEGFR2 inhibitory activities, meanwhile at little higher concentration it can inhibit PDGFR and kinases as well, such as c-Kit and c-Src .The action sites of apatinib are the intracellular ATP binding site of the protein tyrosine receptor. Pharmacodynamical study shows that apatinib is able to inhibit the tyrosine kinase activity of VEGFR, block signal conduction after the combination of VEGF, finally contribute to stopping new blood vessel formation in tumor tissue.
83637|NCT03531918|Drug|Cladribine|Given IV
83638|NCT03531918|Drug|Cytarabine|Given IV
83639|NCT03531918|Drug|Gemtuzumab Ozogamicin|Given IV
83640|NCT03531918|Biological|Granulocyte Colony-Stimulating Factor|Given SC
83641|NCT03531918|Other|Laboratory Biomarker Analysis|Correlative studies
83642|NCT03531918|Drug|Mitoxantrone Hydrochloride|Given IV
83645|NCT03531905|Drug|Placebo Oral Tablet|Placebo tablet, matched for the FDC product for blinding purposes
83646|NCT03531905|Drug|Placebo oral capsule|Placebo over-encapsulated for blinding purposes
83647|NCT03531892|Drug|AJM300|AJM300 film-coated tablets.
83648|NCT03531892|Drug|Placebo|Placebo matched to AJM300 tablets.
83649|NCT03531866|Behavioral|DigiKnowIt News|DigiKnowIt News is an online, interactive, multimedia web-based resource designed to educate youth about participating in clinical trials. Youth will learn general information about clinical trials, their rights in a clinical trial, the good and not so good of participating in clinical trials, communication with others during a clinical trial, and specific types of procedures used in clinical trials (i.e., needles, scans). DigiKnowIt News is web-based and youth can complete it at home, on their own time.
83650|NCT03531853|Device|hand-held swept source optical coherence tomography|images the eye
83651|NCT03531840|Drug|Olaparib|all subjects will take olaparib by mouth twice per day until disease progression or unacceptable toxicity
83652|NCT03531827|Drug|enzalutamide|enzalutamide is an AR antagonist that is standard care therapy for metastatic prostate cancer
83653|NCT03531827|Drug|CRLX101|CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
83654|NCT03531814|Behavioral|Medication Event Monitoring System (MEMS)|A computerized method of tracking the dates and times of a pill bottle being opened.
83655|NCT03531801|Other|Pressure algometry and mapping referred pain areas|The described procedures are tested at baseline and 24 hours after exercise-induced muscle soreness conditions.
83656|NCT03531788|Device|Armon Ayura (Kinova)|Actively assisted mechanical arm support (electric powered to balance arm)
83657|NCT03531788|Device|JAECO Wrex|Passive mechanical arm support (elastic bands to balance arm)
83658|NCT03531775|Diagnostic Test|Upright MRI|Participants will be scanned using an upright MRI in sitting/standing position and supine position. They will also be scanned in supine position using a conventional MRI.
83659|NCT03531762|Drug|Tepotinib|Participants will receive single oral dose of Tepotinib in Treatment Period A, B and C.
83660|NCT03531762|Drug|Omeprazole|Participants will receive omeprazole alone on Day 1 to 4 and co-administration of omeprazole with Tepotinib on Day 5 in Treatment Period B and C.
83661|NCT03531749|Dietary Supplement|HIV+ MRPJ|supplemented with (1g/d) MRPJ
83662|NCT03531749|Dietary Supplement|HIV+ ascorbic acid|Supplemented with (1g/d) AA
83663|NCT03531736|Drug|Antithymocyte globulin (Rabbit)|ATG (2 mg/kg/d IV on days-8 through -7)
83664|NCT03531736|Drug|fludarabine|fludarabine (30 mg/m2/d on days -5 through -2)
83665|NCT03531736|Radiation|total body irradiation|TBI 200 cGy (days -2 and -1) given post stem cell infusion
83666|NCT03531736|Drug|cyclophosphamide|cyclophosphamide given post stem cell infusion (50 mg/kg on days +3 and +4)
83667|NCT03531736|Drug|Rituxan|Rituxan (200 mg/m2) will be given to reduce the risk of EBV viremia
83668|NCT03531736|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
83669|NCT03531723|Other|Measuring the size of the 3rd ventricle by ultrasound|The surveillance of the clamping test is essentially clinical. No cerebral imaging is performed systematically in our service protocol.The study consisted of including ultrasound measurements during the usual weaning protocol of the service.All patients receiving a SEV withdrawal test will be included. Inclusion begins when the clinician in charge of the patient initiates the withdrawal test. The measurements will be performed blindly by a trained physician who does not participate in the patient's care. Four measurements will be made, with recording of ultrasound loops
83670|NCT03531710|Biological|UB-311|Intramuscular injection
83671|NCT03531710|Drug|Placebo|Intramuscular injection
83672|NCT03531697|Drug|Generic Loteprednol Etabonate|Drug
83673|NCT03531697|Drug|Reference Listed Drug (RLD)|Drug
83674|NCT03531684|Dietary Supplement|MMFS-205-SR|Twice daily, oral, 500 mg tablets
83675|NCT03531684|Dietary Supplement|Placebo|Twice daily, oral
83676|NCT03531671|Device|Binocular-OCT|Binocular Optical Coherence Tomographer used to assess both eyes in the same session without the need for a trained assistant.
83677|NCT03531645|Drug|Fulvestrant|"Neoadjuvant Treatment (Cycles 1-4): Fulvestrant 500 mg injection in buttocks on Days 1 and 15 of Cycle 1 and Day 1 of Cycles 2-4.~Adjuvant Treatment (Cycles 5 and beyond): Fulvestrant 500 mg injection in buttocks on Day 1 of each cycle.~Study cycle is 28 days."
83678|NCT03531645|Drug|Abemaciclib|"Neoadjuvant Treatment (Cycles 1-4): Abemaciclib 150 mg by mouth On Days 1-28 of each cycle.~Adjuvant Treatment (Cycles 5 and beyond): On Days 1-28 of each cycle, you will take Abemaciclib 150 mg by mouth on Days 1-28 of each cycle.~Study cycle is 28 days."
83679|NCT03531632|Biological|MGD007 + MGA012|MGD007 and MGA012 are administered by IV infusion.
83680|NCT03531606|Drug|Mechnicov probiotics|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
83681|NCT03531606|Drug|Placebo|"Using placebo comparator with experimental one, it will be compared between two group for comparison of placebo comparator with experimental one.~The patients enrolled into expeimental group will take one pack of 'Mechnicov probiotics' twice a day for 4 weeks from 1 week before surgery.~(1 week before surgery and 3 weeks after surgery)~The patients in placebo and experimental group should take a part in this clinical trial under the condition of 'anterior resection of colon cancer'"
83682|NCT03531593|Diagnostic Test|Ultrasound Elastography|Ultrasound elastography is a new, noninvasive technique that can assess the stiffness of the liver by the evaluation of how sound waves propagate through the liver parenchyma.
83707|NCT03531385|Diagnostic Test|Central sensitisation|Central Sensitization Inventory, which is a comprehensive self-report inventory to assess the overlapping symptom dimensions of central sensitisation syndrome will be used to identify participants with central sensitisation.
83708|NCT03531385|Diagnostic Test|Neuropathic pain|Frequency of neuropatic pain will be investigated using Pain Detect Questionnaire
83683|NCT03531580|Device|Magnetic Resonance Imaging|Brain imaging using magnetic resonance imaging, using several MRI sequences: structural imaging (grey matter, using T1-imaging), cerebral perfusion using arterial spin labeling), functional and effective connectivity (using resting-state functional MRI), white matter tracts (using diffusion imaging), white matter lesions (using Fluid-attenuated inversion recovery MRI (FLAIR)) and microbleeds (using Susceptibility weighted imaging (SWI))
83684|NCT03531567|Behavioral|Virtual Reality Mystic Isle Game|8 week virtual reality based exercise program
83685|NCT03531567|Behavioral|Standard Home Exercise Program|8 week standard occupational therapy home exercise program
83686|NCT03531554|Dietary Supplement|ketone ester drink|395 mg of ketone ester/kg
83687|NCT03531554|Behavioral|exercise|35 min cycling test on an upright bicycle, followed by 10 minutes of supine cycling inside a MR scanner.
83688|NCT03531554|Procedure|muscle biopsy|biopsy from the quadriceps muscle prior to and immediately after upright bicycling
83689|NCT03531554|Diagnostic Test|Magnetic Resonance Imaging|1H MR images and 31P MR spectra were acquired from the upper leg prior to-, during and after exercise
83690|NCT03531541|Device|Application of TENS|The subject's skin will be cleaned with mild soap and water. Two square self-adhesive electrodes (5x5cm) will be placed 1 cm below the olecranon of the ulna and 10 cm above the radiocarpal joint of the dominant hand, maintaining the PPT measurement region between two electrodes. Two identical TENS units will be used: an active and a placebo (Neurodyn Portable TENS, IBRAMED). The active unit will be applied with the patient in a supine position at a high frequency of 100 Hz, and pulse duration of 100 µs. Strong but comfortable intensity as dictated by each subject will be applied for 20 minutes. Participants will be asked about the intensity of TENS every 5 minutes, and if the intensity has faded, the intensity will be increased again to a strong but comfortable level.
83691|NCT03531541|Device|CJM|The examiner 3, who is responsible for cervical joint manipulation, will enter the room and stand at the head of the patient. Using the middle phalanx of the second finger of one hand, the examiner will apply pressure laterally on the joint processes of C6 and C7 vertebrae; the examiner will cradle the patient's opposite side with the other hand and then perform an ipsilateral inclination towards the C6, C7 segments, followed by a contralateral rotation to the tissue barrier to perform a high-velocity low-amplitude manipulation (thrust). If the patient does not experience joint cavitation during the maneuver, two more attempts will be made. If no sound occurs on the third attempt, the joints will be considered manipulated.
83692|NCT03531541|Device|Placebo TENS|The application of placebo TENS will be at a frequency of 100 Hz and pulse duration of 100 µs for 30 seconds. After the initial 30 seconds, the current amplitude will gradually decrease over 15 seconds until it reaches zero value. Participants will be informed that TENS can cause a slight tingling sensation or any sensation during the procedure. They will be asked every 5 minutes if they are comfortable, without increasing intensity as in the active TENS group
83693|NCT03531541|Device|Placebo CJM|Placebo CJM will be performed using an identical position to the active manipulation, however, for only 15 seconds, as proposed by some authors that have used placebo group in their studies. The examiner shall not exert tension in the joint capsule of the segment to ensure the placebo effect. The maneuvers will be carried out by a physiotherapist with more than 5 years of experience in manual therapy. The active or placebo manipulation will be performed on the right or left side according to randomization.
83694|NCT03531528|Other|Diet|A 4-week protein-sparing, very low-calorie, ketogenic diet and a subsequent 6-week hypocaloric, low glycemic index, Mediterranean-like diet
83695|NCT03531502|Procedure|Ventricular Tachycardia Ablation|Ventricular Tachycardia Ablation
83696|NCT03531502|Other|Standard Medical Therapy|For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.
83697|NCT03531502|Procedure|Non-Invasive Programmed Stimulation (NIPS)|All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
83698|NCT03531489|Device|AIR-AD|Non-significant risk medical device as decided by institutional review board
83699|NCT03531476|Behavioral|Online Chronic Pain Management Program|With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program. The study therapist is a registered health professional. The program will consist of 5 weeks of mindfulness training. The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
83700|NCT03531463|Procedure|Operative treatment with Reversed Total Shoulder Prosthesis|"The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a horseshoe-graft from the humeral head will be used"
83701|NCT03531450|Behavioral|Cognitive Behavioral Therapy|Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
83702|NCT03531437|Drug|1.5 mg estradiol and 2.5 mg nomegestrol acetate|
83703|NCT03531437|Drug|15 µg ethinylestradiol and 60 µg gestodene|
83704|NCT03531424|Procedure|Angiographic guided PCI|Angiographic guided PCI is coronary revascularization based on stand-alone angiography.
83705|NCT03531424|Procedure|Augmented-Reality CTA guided PCI|Augmented-Reality CTA guided PCI is coronary revascularization based on systematic use of CTA datasets displayed in augmented-reality glass plus coronary angiography.
83706|NCT03531398|Other|Metabolic test meal challenge|Metabolic test meal challenge
83709|NCT03531385|Other|Sleep disturbance|Assessment of sleep disturbance will be assessed by Pittsburgh Sleep Quality Index
83711|NCT03531372|Device|Mipolixin®|1.55g chewable tablet 5 times a day for 2 weeks
83712|NCT03531372|Device|Poliprotect®|1.55 g chewable tablet 5 times a day for 2 weeks
83713|NCT03531359|Device|TIBD|Table-based Interactive Distraction using video-games will be used to prove efficacy in preventing preoperative anxiety.
83714|NCT03531359|Drug|Midazolam|Administration of midazolam oral or rectal 30 minutes to one hour prior to transfer to the theater.
83715|NCT03531346|Other|Daily-disposable soft contact lens|Subjects were refitted with Silicone-Hydrogel (Delefilcon A) or Hydrogel (Omafilcon A) daily-disposable soft contact lenses based on their fit, reported comfort and tear film surface quality.
83716|NCT03531333|Procedure|ultrasound guided surgery.|during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
83717|NCT03531320|Drug|D07001-softgel capsules|Active Ingredient:Gemcitabine hydrochloride
83718|NCT03531307|Other|Data correlation|Correlation between lactate levels and Ki-67 index
83719|NCT03531294|Drug|Aflibercept Injection|intravitreal 2mg aflibercept injection
83720|NCT03531281|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allo-HCT
83721|NCT03531281|Drug|Cyclophosphamide|Given IV
83722|NCT03531281|Drug|Etoposide|Given IV
83723|NCT03531281|Drug|Goat Milk|Given human lysozyme goat milk PO
83724|NCT03531281|Other|Laboratory Biomarker Analysis|Correlative studies
83725|NCT03531281|Biological|Palifermin|Given IV
83726|NCT03531281|Drug|Sirolimus|Given PO
83727|NCT03531281|Drug|Tacrolimus|Given IV and PO
83728|NCT03531281|Radiation|Total-Body Irradiation|Undergo FTBI
83729|NCT03531268|Other|PGx Testing|Pharmacogenomic (PGx) testing will be administered to all subjects. The results of PGx testing will be evaluated for clinical utility. Subjects will be evaluated based on whether PGx testing has clinical utility or has no clinical utility.
83730|NCT03531255|Drug|APL-2|Complement (C3) Inhibitor
83731|NCT03531242|Biological|0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1|"administered as dose(s) of 0.5 mL given subcutaneously in the upper outer aspect of the triceps area. Subjects who showed an initial immune response ≥ 1:20 to TC-83 and whose titer decreased over time or who rollover from a previous VEE C-84 protocol will receive a single 0.5 mL booster dose of C-84 vaccine.~Subjects who were initial non-responders (< 1:20) to TC-83 will be given subcutaneous 0.5 mL injections on Days 0, 28-35, and 56-63"
83732|NCT03531229|Drug|Placebo|Placebo to Lu AF76432 oral solution
83733|NCT03531229|Drug|Lu AF76432|Lu AF76432 oral solution 2.5 mg/ml. Starting dose will be 3,5 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).
83734|NCT03531216|Other|Rosemary essential oil|Topically-applied oil to both dorsal and palmar aspects of the hands
83735|NCT03531216|Other|Placebo|Topically-applied oil to both dorsal and palmar aspects of the hands
83736|NCT03531203|Dietary Supplement|Soursop supplementation|The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.
83737|NCT03531203|Other|Placebo|Control group (without soursop group) was left without treatment during study period
83738|NCT03531190|Dietary Supplement|Nutritional supplement (Protein + MIX)|Protein supplement as needed + 750 mg vitamin C, 15 g. arginine, 35 mg. zinc and two multivitamin tablets, by mouth every day for 35 days.
83739|NCT03531190|Dietary Supplement|Nutritional supplement (Protein)|Protein supplement as needed
83740|NCT03531177|Behavioral|HEAL-D|HEAL-D is a 7 session programme of self-management education and behaviour change support for African and Caribbean patients with type 2 diabetes. The sessions will support participants with behaviour change to adopt evidence-based diet and physical activity targets for type 2 diabetes. The intervention has been systematically developed with defined theory and behavioural change techniques mapped to this theory.
83741|NCT03531177|Behavioral|Control|Participants receive usual care from their healthcare team.
83742|NCT03531164|Other|kAYAK ERGOMETER GROUP|Kayak ergometer training for 30 min 5 times a week for 6 weeks. The training includes a warming (pre charge) during 3 minutes, a training (charge) characterised by 3-5 intervals with medium to high intensity during 2-4 minutes and pauses of 1-2 minutes between active phases and 2 minutes of cooling down (post charge) to complete 30 minutes of training.
83743|NCT03531164|Other|CONTROL GROUP|Proprioceptive neurofacilitation exercises focused in trunk control during 30 minutes 5 times a week for 6 weeks.
83744|NCT03531138|Other|Pulmonary Rehabilitation|All patients will undergo supervised pulmonary rehabilitation program on 2 days per week for 3 months. Apart from that, they will ask to perform the home exercise program which is scheduled as 3 days per week and fill out the exercise follow-up form. Supervised exercise sessions consist of aerobic(treadmill walking, bicycle training, arm ergometer training) and strengthening training(free weights). A 6-min walk test, a 10-meter walking speed test and a 5 times sit to stand test will be performed to determine the exercise capacity of the patient. The tests will be carried out at the beginning and end of rehabilitation. At each testing session, the tests will be performed sequentially by the same physiotherapist, giving 20 minute rest periods within the same day.
83745|NCT03531125|Procedure|Endoscopic Ultrasound|Endoscopic ultrasound for tumour biopsy collection
83746|NCT03531125|Procedure|Pancreaticoduodenectomy|Surgery to remove pancreatic tumour
83747|NCT03531112|Behavioral|Appetite Awareness Treatment|The goal of Appetite Awareness Treatment (AAT) is to enable participants to be able to relearn their stomach's hunger signals and begin to obey and monitor functions of satiety. AAT has been successful in helping participants diagnosed with Binge Eating Disorder (BED) and bulimia nervosa reduce binge eating, overeating, urges to eat in response to non-appetite stimuli, and prevent weight gain. The AAT intervention includes eight 60-minute group sessions. All sessions involve didactic training, review of self-monitoring of eating episodes, interactive activities, and homework assignments to enable participants to practice learned skills. Participants will be provided a workbook, which will include session content, and self-monitoring forms.
83780|NCT03530891|Procedure|Conventional lag screw fixation|Under general anaesthesia: Open reduction and internal fixation for anterior mandibular fracture utilising lag screws.
83781|NCT03530878|Procedure|Hip Arthroscopy|Intraarticular pathology in the form of labral tears and cartilage that are often concomitant with DDH
83748|NCT03531099|Procedure|treatment with focal HIFU|HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.
83749|NCT03531099|Biological|PSA dosage|PSA dosage will be regularly performed during patient follow up thanks to blood sampling.
83750|NCT03531099|Device|MRI|MRI exam will be regularly performed during patient follow up.
83751|NCT03531099|Other|Questionnaires|Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
83752|NCT03531099|Procedure|Prostatic biopsies|Prostatic biopsies will be regularly performed during patient follow up.
83754|NCT03531073|Drug|Methotrexate|This study is observational and patients will receive treatment for their psoriatic arthritis as clinically indicated. As per standard practice in this observational cohort, patients are most likely to be treated with methotrexate as the most common first line therapy in PsA. This cohort is the basis of a TWiCs (Trials Within Cohorts) study design and interventional studies will be nested within this in future. Whilst the cohort will receive treatment for their PsA as part of their routine clinical care, this treatment will be decided according to routine care and not protocolised.
83755|NCT03531060|Drug|IRL790|IRL790 capsule 10 mg
83756|NCT03531060|Drug|Placebo|Placebo capsule
83757|NCT03531047|Procedure|Customised CXL|As for standard CXL, following mechanical removal of the corneal surface layer (epithelium), 0.1% riboflavin drops will be applied every 2 minutes for 10 minutes prior to ultraviolet A (UVA) irradiation - UVA power, distribution and timing as determined by analysis of Pentacam tomography scans. A bandage contact lens will be applied to encourage regrowth of the corneal surface and reduce post-operative pain.
83758|NCT03531034|Other|Combined Exercise Training|The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
83759|NCT03531021|Behavioral|Heart healthy intervention|Intervention consists of educational modules, goal setting and brainstorming around strategies and barriers, and a series of heart healthy challenges such as walking a certain number of steps or eating healthy foods a certain number of times in a week.
83760|NCT03530995|Drug|KD025|Development candidate
83761|NCT03530995|Drug|Itraconazole|Perpetrator drug
83762|NCT03530995|Drug|Rabeprazole|Perpetrator drug
83763|NCT03530995|Drug|Rifampicin|Perpetrator drug
83764|NCT03530995|Drug|Omeprazole|Perpetrator drug
83765|NCT03530982|Other|Intensive goal training|Intensive goal training : 30 hours during 2 weeks
83766|NCT03530969|Behavioral|Self-Efficacy Assessment|"Health Care Professional's self-efficacy will be assessed by 12 ratings of self-reported confidence from (1) strongly disagree to (5) strongly agree in module-specific topics both before and after the training."
83767|NCT03530969|Behavioral|UCLA Geriatrics Attitudes Scale|The UCLA Geriatrics Attitudes Scale is a 14-item scale developed to assess health care providers' attitudes toward older persons and caring for older patients.
83768|NCT03530969|Behavioral|Course Evaluations|The evaluation surveys for each of the three modules will contain fifteen statements assessing post-training attitudes regarding the skills learned and application of skills in oncology clinical practice, measured on a 5-point Likert scale.
83769|NCT03530969|Behavioral|The Consultation and Relational Empathy (CARE) questionnaire|The Consultation and Relational Empathy (CARE) questionnaire is a 10-item self-report scale that measures a patient's satisfaction with how empathic their health care providers (HCP) was within a specific consultation.
83770|NCT03530969|Behavioral|Consumer Assessment of Health Care Providers and Systems Program (CAHPS)|Patients‟ perceptions of the quality of their interactions with their clinicians will be rated with 6 items from the Consumer Assessment of Health Care Providers and Systems Program (CAHPS)
83771|NCT03530969|Behavioral|Patient activation measure (PAM) scale|The PAM scale contains 22 items that assess patient engagement in their care process.
83772|NCT03530956|Device|Ankle Mimicking Prosthetic Foot prototype 4+|The amputee will walk with AMPfoot 4+, a novel bionic foot, designed and built by an engineer of department MECH (VUB, B)
83773|NCT03530943|Behavioral|Animal Assisted Activities|Students interact with canines in small group settings under the supervision of their handlers during structured and semi-structured activities designed to strengthen physiological, emotion and behavioral regulation
83774|NCT03530943|Behavioral|Academic Stress Management tools|Evidence-based workshops focus on evidence-based content and activities designed to enhance academic stress management knowledge and skills, motivation and learning, adaptive sleep, and study and test-taking behavior through strengthening physiological, emotion and behavioral regulation
83775|NCT03530930|Drug|Comarum Palustre|Comarum Palustre tablets 500 mg BID, 1 month
83776|NCT03530917|Drug|RO7020531|4 SAD Cohorts with individual dosages of 40, 100, 140, 170 mg hard capsules and 2 MAD Cohorts hard capsules dose to be determined will be administered orally.
83777|NCT03530917|Other|Placebo|Matching placebo to RO7020531 hard capsules will be given orally.
83778|NCT03530904|Other|mobilization|Early mobilization after CIED implantation
83779|NCT03530891|Procedure|Computer guided lag screw fixation|Under general anaesthesia: Patient specific pre operative prefabricated surgical guide will be used intra operative for open reduction and internal fixation for anterior mandibular fracture using lag screws.
83782|NCT03530852|Device|Relizorb|Tube feeds run across device to digest fats.
83783|NCT03530839|Procedure|Arthrodesis|see study group description
83784|NCT03530839|Procedure|Resection arthroplasty|see study group description
83785|NCT03530826|Other|No intervention|No Intervention
83786|NCT03530813|Other|Ebook Asthma First Aid in School Training|Technology assisted, self-directed learning eBook resource
83787|NCT03530813|Other|Face-To-Face Asthma First Aid in Schools Training|School Asthma First Aid Management Program 3 Hour Face to Face Training
83788|NCT03530800|Drug|Dronabinol|Dronabinol for 10 weeks (5mg per day first 2 weeks, 10mg per day second two weeks, 15mg per day last six weeks)
83789|NCT03530800|Drug|Placebo|Placebo for 10 weeks
83790|NCT03530787|Other|Acetyl Zingerone Topical Cream|Topical cream with an active acetyl zingerone component.
83791|NCT03530787|Other|Topical cream|Topical cream without an active acetyl zingerone component and just the carrier cream.
83792|NCT03530774|Dietary Supplement|powdered egg white protein supplement|consumption of egg white protein supplement daily for 6 months
83793|NCT03530774|Dietary Supplement|maltodextrin supplement|consumption of maltodextrin supplement daily for 6 months
83794|NCT03530748|Procedure|Endovascular therapy and Imaging Acquisition|"Endovascular repair for renal artery stenosis;~Parenchymal Blood Volume(PBV) acquisition and analysis for target kidney"
83795|NCT03530735|Other|Finger-prick Autologous Blood (FAB)|"Patients will be instructed to use FAB therapy by:~Hand hygiene with soap and water. Dry, then wipe their fingertip with an alcohol street before leaving to air dry.~Use a diabetic lancet to prick their cleaned fingertip.~Squeeze 5 drops of blood form their finger into 10ml of saline.~Gargle the blood-saline mixture for 5 minutes.~Swallow the blood-saline mixture.~Repeat this 4 times per day."
83796|NCT03530709|Other|videoconferencing|Parents/caregivers will use smartphones to videoconference in their SCC provider during PCP visits
83797|NCT03530696|Drug|Palbociclib|Compare progression free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1
83798|NCT03530696|Drug|T-DM1|Compare progression free survival of the combination arm (T-DM1 with palbociclib) to single agent T-DM1
83799|NCT03530683|Drug|TTI-622 Monotherapy|"TTI-622 (SIRPα-IgG4 Fc), is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG4). TTI-622 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (anti phagocytic) signal to macrophages"
83800|NCT03530683|Drug|TTI-622 + Rituximab|TTI-622 + Rituximab combination therapy.
83801|NCT03530683|Drug|TTI-622 + PD-1 Inhibitor|TTI-622 plus Nivolumab combination therapy
83802|NCT03530683|Drug|TTI-622 + Proteasome-inhibitor Regimen|TTI-622 plus a proteasome-inhibitor regimen (carfilzomib plus dexamethasone).
83803|NCT03530670|Other|oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before anesthesia induction
83804|NCT03530670|Other|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.|"Patients will be watched a short movie (at URL:~http://www.animaturk.com/animasyon/suko-ameliyat-oluyor.html#.Wd-YhFu0PIU) 20 minutes before induction."
83805|NCT03530670|Other|Playing smartphone game|Patients will be played with smartphone (angry birds, subway surfers or snail Bob) 20 minutes before induction
83806|NCT03530644|Device|WM3.4NR|The investigational medical device will collect spectral Raman data from tissue.
83807|NCT03530644|Device|P0.1|The investigational medical device will collect spectral Raman data from tissue.
83808|NCT03530631|Drug|Adderall|Participants will be administered Adderall
83809|NCT03530631|Drug|Placebo|Participants will be administered placebo
83810|NCT03530618|Device|Flexible tip straight guidewire|Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization
83811|NCT03530618|Device|J-tip|Use a J tip straight guidewire for ultrasound-guided central venous catheterization
83812|NCT03530605|Device|Optune TTF device|portable device which produces electrical fields
83813|NCT03530592|Device|Seated Ankle Robot Training|This intervention employs the use of an adaptive ankle robot control system over a 6-week intervention period.
83814|NCT03530579|Behavioral|Educational group trainings|"Participants will receive 6 two and a half hour educational group training's over the course of 6 months. These sessions will be led by a trained CHW in your language and will be held on a monthly basis in a community based location.~Session 1: What is Diabetes~Why is Prevention Important~Session 2: Nutrition Session 3: Physical Activity Session 4: Cardiovascular Disease & Diabetes Complication Session 5: Stress Management Session 6: Access to Service"
83815|NCT03530579|Behavioral|Community Health Care Worker|A community health care worker answer your questions about diabetes and refer participant to a physician. Survey will be completed at the start of the study and during the 3rd, 6th and 12th months
83816|NCT03530566|Other|PnK® Method|A multidisciplinary program of weight loss based on diet (initially very low ketogenic diet), physical activity and emotional support
83817|NCT03530566|Other|standard diet|standard low calorie diet for weight loss
83818|NCT03530553|Other|Hunt Motivational Scale|The Hunt Motivational Scale is a tool to help facilitate weight loss and motivate patients to track, plan, and practice healthy weight loss and weight maintenance practices.
83819|NCT03530540|Device|low-intensity extracorporeal shockwave therapy|Active shockwaves
83820|NCT03530540|Device|Placebo LI-ESWT|Placebo shockwaves
83821|NCT03530540|Device|Penile pump|both groups will be treated with a penile pump
83822|NCT03530527|Procedure|ERCP with biliary stenting|ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
83823|NCT03530527|Procedure|EUS guided biliary drainage|EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
83824|NCT03530514|Drug|REGN4461|REGN4461
83826|NCT03530501|Other|Diet|Very low calorie ketogenic diet followed by low calorie diet
83827|NCT03530501|Dietary Supplement|Synbiotic1|B. lactis, Lactobacillus rhamnosus, B. longum ES1 and prebiotics fiber
83828|NCT03530501|Dietary Supplement|Synbiotic2|B. animalis subsp. lactis and prebiotics fiber
83829|NCT03530488|Drug|Lidocaine|intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline
83830|NCT03530488|Procedure|Office hystroscopy|A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
83831|NCT03530475|Diagnostic Test|ultrasound and doppler|"• Ultrasound examination (2D gray scale and color doppler )~1. Confirming the presence of placenta previa 2,To assess the possibility of concomitant placenta accreta (Sonographic findings that have been associated with placenta accreta (1) Loss of normal hypoechoic retroplacental zone (2) Multiple vascular lacunae (irregular vascular spaces) within placenta, (3) Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1 (4) Retroplacental myometrial thickness of 1 mm (5) Bladder wall interruption (6) Presence of placental bulge (7) Utero-vesical hypervascularity (8) presence of lacunae feeder vessels.~3. Assessment of uterine artery Doppler in different cases of placenta previa.~. Documentation of the operative findings during cesarean section and/or cesarean hysterectomy procedures.~Histopathological examination of the hysterectomy specimens to assess the degree of myometrial invasion."
83832|NCT03530462|Drug|rituximab|375 mg/m2 weekly for 4 weeks
83833|NCT03530462|Drug|cyclophosphamide|750 mg/m2 monthly for 4-6 cycles depending on the response
83834|NCT03530462|Drug|Steroids|500-1000 mg of methylprednisolone daily for 3 days, then tapered doses
83835|NCT03530462|Drug|Intravenous immunoglobulin|intravenous immunoglobulin (IVIG) with or without plasmapheresis
83836|NCT03530449|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
83837|NCT03530449|Device|Color Fundus Photography|Non-contact white light photography
83838|NCT03530449|Device|Optical Coherence Tomography|Two and Three dimensional cross sectional imaging of the back of the eye to look at vascular structures and is an aid in the detection and management of various ocular diseases.
83839|NCT03530436|Dietary Supplement|Native turmeric extract|207 mg curcumin
83840|NCT03530436|Dietary Supplement|Native turmeric extract with 7-9% volatile turmeric oils|207 mg curcumin
83841|NCT03530436|Dietary Supplement|Turmeric extract plus mixture of phytochemicals|207 mg curcumin
83842|NCT03530436|Dietary Supplement|Cyclodextrin complex of curcuminoids|207 mg curcumin
83843|NCT03530436|Dietary Supplement|Turmeric oleoresin|207 mg curcumin
83844|NCT03530436|Dietary Supplement|Liposomal curcumin|207 mg curcumin
83845|NCT03530436|Dietary Supplement|Phytosomal curcumin|207 mg curcumin
83846|NCT03530436|Dietary Supplement|Micellar turmeric extract|207 mg curcumin
83847|NCT03530410|Device|Intragastric balloon placement|Patients will have endoscopic placement of intragastric balloon that will be removed endoscopically after 6 months
83848|NCT03530397|Biological|MEDI5752|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation.
83849|NCT03530397|Biological|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
83850|NCT03530397|Drug|Pemetrexed|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
83851|NCT03530397|Drug|Carboplatin|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
83852|NCT03530397|Biological|Pembrolizumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease, or development of other reason for treatment discontinuation
83853|NCT03530384|Other|Cognitive training|Computerized cognitive training targeting inhibitory control of motor response used during 45 minutes sessions twice a week for 6 weeks
83854|NCT03530384|Other|Control training|Fictitious computerized training used during 45 minutes sessions twice a week for 6 weeks
83855|NCT03530371|Drug|Dexmedetomidine Hydrochloride|intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients
83856|NCT03530358|Device|Technology-aided rehabilitation|"VRRS involves performing different kinds of motor tasks with the patient holding a real manipulable object in their hands while interacting with a virtual scenario.~Braccio di Ferro task consists in center-out reaching movements and return. The subject is required to start from a central target, reach one of five peripheral targets arranged on a semi-circle with a 20 cm radius and then return to the central target."
83857|NCT03530358|Behavioral|Conventional rehabilitation|The patients will be asked to perform a wide range of exercises, including: shoulder flexion-extension, abduction-adduction, internal-external rotation, circumduction, elbow flexion-extension, forearm pronation-supination, hand-digit motion. Standardized instructions and modalities will be followed when providing exercises to the patients in order to control for any variability in leading the therapy session due to the therapist.
83858|NCT03530345|Drug|Neridronic acid|Neridronic acid administered by 4 intravenous infusions within 10 Days
83859|NCT03530345|Drug|Placebo|Matching placebo administered by 4 intravenous infusions within 10 Days
83860|NCT03530332|Diagnostic Test|PreTRM test|Blood test to determine risk of preterm birth
83861|NCT03530319|Drug|Doxycycline|Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
83862|NCT03530319|Drug|Azithromycin|Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
83863|NCT03530306|Device|PS1-PS4|Participants in this arm shall be given PS1 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
83864|NCT03530306|Device|PS6-PS10|Participants in this arm shall be given PS6 during the first half of treatment and PS10 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
83865|NCT03530306|Device|PS7-PS4|Participants in this arm shall be given PS7 during the first half of treatment and PS4 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
83866|NCT03530306|Device|PS9-PS6|Participants in this arm shall be given PS9 during the first half of treatment and PS6 during the second half of treatment. During the expected 12-week treatment period, the participants will be presented with audio stimuli and electrical pulses for somatosensory stimulation.
83867|NCT03530293|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
83868|NCT03530293|Drug|Placebo oral capsule|non-active dosage form
83869|NCT03530280|Drug|pregabalin (lyrica)|preoperative pregabalin and the postoperative sham block will perform.
83870|NCT03530280|Drug|Placebo oral tablet|The preoperative placebo oral tablet and the postoperative sham block will perform.
83871|NCT03530280|Drug|adductor canal block including bupivacaine|The preoperative placebo oral tablet and adductor channel block including 10 mL of 0.25% bupivacaine with 5 μg/mL epinephrine
83872|NCT03530267|Drug|Aflibercept + mLV5FU2|Patients receive aflibercept 4mg/kg as 1-h infusion followed by folinic acid 350 mg/m² by 2-h intravenous infusion, 5-fluorouracil 1920 mg/m² 46-h intravenous infusion (mLV5FU2) every 2 weeks (qd15).
83873|NCT03530267|Drug|mFOLFOX7|Patients in this arm receive modified (m) FOLFOX 7: Folinic acid 350 mg/m² and oxaliplatin 68 mg/m² by concurrent 2-h intravenous infusion, 5-FU 1920 mg/m² 46-h intravenous infusion every 2 weeks (qd15).
83874|NCT03530254|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice. Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
83875|NCT03530254|Diagnostic Test|ERA Test|The ERA test requires an endometrial biopsy and will determine if the endometrium is receptive or not by analysing the expression levels of 236 genes involved in endometrial receptivity, to assess the optimal time to place an embryo into the uterus and promote a successful implantation and pregnancy.
83876|NCT03530241|Diagnostic Test|Presence of bile duct stones|MRCP verified gall stones in the bile ducts
83877|NCT03530241|Diagnostic Test|Non-presence of bile duct stones|MRCP without bile duct stones
83878|NCT03530228|Drug|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment A
83879|NCT03530228|Drug|Tegoprazan (C1)|Tegoprazan QD, oral administration. Treatment B
83880|NCT03530228|Drug|Treatment C: Tegoprazan (C1)|Tegoprazan BID, oral administration
83881|NCT03530228|Drug|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 1
83882|NCT03530228|Drug|Tegoprazan (C2)|Tegoprazan QD, oral administration, for 7 days. Group 2
83883|NCT03530228|Drug|Esomeprazole (C2)|Esomeprazole QD, oral administration, for 7 days. Group 3
83884|NCT03530228|Drug|Tegoprazan (C3)|Tegoprazan QD, oral administration
83885|NCT03530215|Drug|Antineoplastic and Immunomodulating Agents|Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
83886|NCT03530202|Drug|Creatine monohydrate|Participants will consume creatine monohydrate powder (Creapure, AlzChem AG, Trostberg, Germany) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (~ 5 minutes) mixed in water as post-exercise creatine ingestion enhances its uptake into muscle and promotes increased muscle mass. On non-training days, supplements will be consumed at the participant's leisure.
83887|NCT03530202|Drug|Maltodextrin Powder|Participants will consume Maltodextrin Powder (Globe Plus 10 DE Maltodextrin Powder, Univar Canada) every day for 8 weeks. On training days participants will consume supplement immediately after each training session (~ 5 minutes) mixed in water. On non-training days, supplements will be consumed at the participant's leisure.
83888|NCT03530189|Drug|10% dextrose|After birth the intravenous 10% dextrose at 60-90 ml/kg/day will be started as soon as possible
83889|NCT03530189|Drug|bolus of dextrose, reducing the glucose infusion, insulin|"Hypoglycemia will be treated with 2 mL/kg to 3 mL/kg (200−300 mg/kg) intravenous bolus of 10% dextrose.~Hyperglycemia will be managed by reducing the glucose infusion rate or initiation of an insulin infusion."
83890|NCT03530176|Radiation|18Fluoride-Sodium Fluoride radio-isotope|The investigators will be using 18F-NaF to image premature atherosclerosis in the coronary arteries of diabetic patients.
83891|NCT03530163|Device|Respiratory Muscle Training|Subjects will breathe through a custom isocapnic Respiratory Muscle Training method developed in-house. The initial breathing frequency will be 30 breaths per minute. Subsequent sessions will begin with 20 minutes of breathing at the highest rate attained on the previous training day. During the last 10 minutes of each session, breathing rate will increase by 1-2 breaths/min.
83892|NCT03530163|Device|Sham Breathing Training|Each subject in the sham group will be prompted to hold his breath for 10 seconds every 30 seconds (two times each minute) while breathing on a circuit visibly identical to that used in Respiratory Muscle Training. The subject will breathe ambient air normally after each breath hold. Each sham session will last 30 minutes total.
83893|NCT03530150|Drug|Pirfenidone Oral Product|A pill containing 600 mg of pirfenidone
83894|NCT03530137|Behavioral|Healthy Home|An evidence-based health literacy curriculum will be developed and implemented based on competencies of understanding and applying health information. The
83895|NCT03530137|Behavioral|Attachment and Biobehavioral Catch-up Infant (6-24 months) and Toddler (24-48 months).|ABC includes 10 in-home, manualized sessions with parents and infants, targeting: 1) increasing parents' nurturing when children are distressed, 2) helping parents follow children's lead, 3) decreasing frightening parent behaviors, and (for ABC-Toddler) managing dysregulation.
83896|NCT03530137|Behavioral|HealthySteps|Healthy Steps helps families identify, understand and manage parenting challenges like feeding, behavior, sleep, development and adjusting to life with a young child
83897|NCT03530124|Biological|PCV13|ACIP Recommended vaccine
83898|NCT03530124|Biological|DTaP|ACIP Recommended vaccine
83899|NCT03530124|Biological|HBV|ACIP Recommended vaccine
83900|NCT03530124|Biological|IPV|ACIP Recommended vaccine
83902|NCT03530098|Device|BoneAgeModel|BoneAgeModel is an Artificial Intelligence tool that takes in a pediatric patient's hand radiograph and gender, and outputs their skeletal (bone) age. The intervention involves using this tool as a factor in the clinical decision making process of the participating radiologists. The radiologist's decision will be considered final.
83903|NCT03530085|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -12 to -8.
83904|NCT03530085|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days -5 to -4.
83905|NCT03530085|Drug|Fludarabine(Flu)|Fludarabine(Flu) was administered at 30mg/m2/day on days -5 to -2.
83906|NCT03530072|Diagnostic Test|Karius Test|Next Generation Sequencing
83907|NCT03530059|Other|Home-based rehabilitation|Observational study
83908|NCT03530046|Combination Product|High SID fluid|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
83909|NCT03530046|Combination Product|Hartmann's solution|The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
83910|NCT03530033|Drug|Lidocaine|Local injection of lidocaine reduces muscle tremor
83911|NCT03530020|Other|monolithic zirconia crowns|full anatomical monolithic crowns
83912|NCT03530020|Other|lithium silicate crowns|lithium silicate glass ceramics are highly resistance to chipping
83913|NCT03530007|Drug|Normal saline|normal saline used for prevention of spinal shivering
83914|NCT03530007|Drug|Ondansetron 4 MG|ondansetron 4 MG used for prevention of spinal shivering
83915|NCT03530007|Drug|Ondansetron 8mg|ondansetron 8 MG used for prevention of spinal shivering
83916|NCT03529994|Other|Enrollment|All infants enrolled will have work of breathing assessed.
83917|NCT03529981|Other|Guided mindfulness meditation|Guided 12 minute mindfulness meditation
83918|NCT03529981|Other|Tuned Vibroacoustic Stimulation (TVS)|TVS is an exteroceptive cue that has been shown to reduce subjective and physiological indicators of stress and increase behavioral performance
83919|NCT03529968|Procedure|esophagectomy|Subtotal esophagectomy and proximal gastrectomy with intrathoracic esophagogastric anastomosis. Total gastrectomy and esophageal resection at the level of the azygos vein and Roux-en-Y esophagojejunostomy
83920|NCT03529955|Drug|Apremilast 30mg|Patients with refractory cutaneous dermatomyositis will be started on apremilast 30 mg twice a day in addition to a stable dose of their treatment regimen (including steroids and steroid sparing agents).
83921|NCT03529942|Drug|FX006 32 mg|Extended-release 32 mg FX006 IA injection
83922|NCT03529929|Drug|Methylprednisolone|6 day dosing as dictated by Medrol 6 Day Dose Pack
83923|NCT03529916|Other|isolation of endothelial cells precursors in blood|Circulating endothelial precursor cells will be isolated and then cultured in vitro. RNA will be then isolated.
83924|NCT03529903|Behavioral|Health Coaching|Our trained health coaches will use the Way To Health platform to track patient health behaviors, and will communicate with patients via both SMS text messaging (up to four messages per week) and biweekly phone calls (up to one hour). During these interactions, health coaches will connect the patient to helpful resources and to help them reflect on previous goals and to set realistic, achievable goals for the upcoming weeks.
83925|NCT03529890|Drug|Nivolumab|"Experimental intervention:~Immunotherapy with 4 cycles of Nivolumab: 240 mg intravenously every 2 weeks, starting one week before radiotherapy (week1, d1), last infusion on week 7, d1"
83926|NCT03529890|Radiation|Radiation therapy of the pelvis|Neoadjuvant radiation therapy of pelvis with 45+5,4 Gy for 6 weeks: 28 x 1.8 Gy including a boost of bladder with 5.4 Gy, starting with week 2 (d1)
83927|NCT03529890|Procedure|Radical cystectomy with standardized pelvic lymphadenectomy|Radical cystectomy with standardized bilateral pelvic lymphadenectomy: performed between week 11 - 15 (Aim: week 13)
83928|NCT03529877|Biological|allo-APZ2-EB|intravenous infusion of allo-APZ2-EB
83929|NCT03529864|Other|Exercise Therapy|
83930|NCT03529851|Other|Weekly questionnaires|In case of alarming symptoms reported in the questionnaire, an alert is automatically sent to the hospital. The clinicians will contact the patient, confirm the symptoms and intervene according to standard practice.
83931|NCT03529838|Other|Combined exercise|The program consisted of 36 sessions of combined aerobic and resistance exercises training during 12 consecutive weeks. Each session lasted 60 minutes and consisted of 30 minutes of resistance exercise and 30 minutes of aerobic exercise. The resistance training was performed in two sets of 8 to 12 repetitions in five exercises of weight training (Based on 1 repetition maximum test - 1RM). The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between 65 and 75% of maximun heart rate measured in maximum incremental test. Every week the resistance load and aerobic intensity was readjusted by determined training zone (8 to 12 maximum repetitions) and heart rate predicted in the incremental respectively.
83932|NCT03529825|Drug|Rifaximin|Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
83933|NCT03529812|Behavioral|CBCT-informed training|Cognitively-Based Compassion Training (CBCT) is a secularized compassion meditation program adapted from the Tibetan Buddhist mind training (lojong) tradition. Lojong practices utilize a cognitive, analytic approach to challenge one's unexamined thoughts and emotions toward other people, with the long-term goal of developing altruistic emotions and behavior towards all people.
83934|NCT03529799|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
83935|NCT03529773|Biological|Formulation A|RSV vaccine
83936|NCT03529773|Biological|Formulation B|RSV vaccine
83937|NCT03529773|Biological|Placebo|Placebo
83938|NCT03529747|Other|Online self-help|As detailed in experimental arm description.
83939|NCT03529734|Other|12 min running|This was already explained in the description of arm
83940|NCT03529734|Other|Local strengthening exercises|This was already explained in the description of arm
83985|NCT03529422|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 60 Gray (Gy) at 2Gy per fractions for 30 fractions delivered Monday through Friday for 6 weeks
83941|NCT03529721|Other|zumba dance fitness|females in this group will be instructed to engage into12 classes of 60-minute Zumba® fitness over an 8-week period of continuous dance movements to Latin music with varying intensity level throughout the sessions. Each session will be initiated with low-intensity movements for the ﬁrst 5 min, followed by an increasing intensity throughout the workout. At the end of the training session, the intensity will be gradually reduced.
83942|NCT03529721|Other|non zumba dance|participants in this group will be doing their normal daily activities throughout the 8-week period.
83943|NCT03529708|Radiation|3D CRT plus SBRT boost|Patients will receive urgent standard 3D conformal radiotherapy (3D CRT) of plus stereotactic boost to tumor causing spinal cord compression (SCC). Initial dose for 3D CRT will be either 8Gy in 1 fraction or 20Gy in 5 fractions, with SBRT boost dose15Gy in 2 fractions of 12Gy in 2 fractions (depending on 8Gy/1 or 20Gy/5 initial RT dose respectively), delivered within three weeks of first treatment.
83944|NCT03529695|Behavioral|Standard HVP Curriculum|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on strengthening children's cognitive skills, early literacy skills, social/emotional and physical development.
83945|NCT03529695|Behavioral|Obesity Prevention|Obesity prevention curriculum program targets 4 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, and decreasing fried foods) aimed at reducing obesity risk in mothers and children. The module will also include weekly activity opportunities to develop social networks that foster healthy eating and physical activity.
83946|NCT03529682|Other|exercise|10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.
83947|NCT03529682|Other|control group|60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
83948|NCT03529669|Device|Cytosponge™|Cytosponge™ is a capsule‐sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.
83949|NCT03529656|Behavioral|Early rehabilitation program for liver transplantation|Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
83950|NCT03529643|Drug|Dexmedetomidine|Anesthesia with sevoflurane-remifentanil-dexmedetomidine
83951|NCT03529643|Other|Without dexmedetomidine|Anesthesia with sevoflurane-remifentanil
83952|NCT03529630|Other|Inverted syringe|Application of mild suction over the mother's inverted nipple using an inverted syringe before each breastfeeding.
83953|NCT03529617|Other|Sample collection|Plasma, urine, BAL and ascitic fluid sample collection.
83954|NCT03529604|Other|Saliva sampling|Saliva was collected from the mouth floor using a specially designed saliva collecting apparatus.
83955|NCT03529604|Diagnostic Test|ELISA|Saliva samples will be analyzed using enzyme-linked immunosorbent assay (ELISA) for the detection of SCCA1, SCCA2 and TROP2.
83956|NCT03529604|Diagnostic Test|HPLC|High-performance liquid chromatography (HPLC) will be used to measure Ap4A concentrations in saliva.
83957|NCT03529591|Device|Selective laser trabeculoplasty (SLT)|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
83958|NCT03529591|Procedure|Selective laser trabeculoplasty|In this study, treatment naive patients with bilateral ocular hypertension or primary open angle glaucoma are treated with 180 degrees SLT in one eye and 360 degrees SLT in the contralateral eye. The primary outcome measure is assessing the response to SLT in both eyes and comparing the intraocular pressure outcomes between the two eyes of each patient.
83959|NCT03529578|Procedure|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
83960|NCT03529565|Procedure|Biospecimen Collection|Undergo collection of blood
83961|NCT03529565|Other|Laboratory Biomarker Analysis|Correlative studies
83962|NCT03529565|Other|Quality-of-Life Assessment|Ancillary studies
83963|NCT03529565|Other|Questionnaire Administration|Ancillary studies
83964|NCT03529552|Procedure|Anterior Cruciate Ligament Reconstruction|Placement of an SMS bioresorbable interference screw (DEDIENNE Santé)
83965|NCT03529539|Drug|PSV|
83966|NCT03529526|Drug|KN046|"The modified phase I 3 + 3 study design was used in dose escalation from low dose to high dose to determine the MTD.Sequential assignment of Patient cohorts to one of five dose levels of KN046: 0.3 mg/kg,1 mg/kg,3 mg/kg,5 mg/kg,10 mg/kg."
83967|NCT03529513|Diagnostic Test|Medibio Depression Diagnostic Aid|The Medibio DDA processes the heart rate and actigraphy data from the third-party devices, characterizes these data in comparison to the benchmark patterns of persons currently experiencing a depressive episode.
83968|NCT03529513|Diagnostic Test|Mini International Neuropsychiatric Interview|The Mini International Neuropsychiatric Interview (M.I.N.I.) is a structured diagnostic interview that was developed as a simple tool to assist clinicians to conduct psychiatric diagnoses according to the DSM-IV and International Statistical Classification of Diseases and Related Health Problems tenth revision (ICD-10) criteria.
83969|NCT03529513|Diagnostic Test|Hamilton Rating Scale for Depression - 17 Item|The clinician-administered Hamilton Depression Rating Scale (also known as the HAM-D) is the most widely used depression assessment scale . The original version contains 17 items (HDRS17) pertaining to symptoms of depression experienced over the past week. There are numerous versions with varying lengths that include the HDRS21, HDRS24, and HDRS29. This study will utilize the HDRS17 (HAMD-17) version.
83986|NCT03529422|Drug|Tremelimumab|Tremelimumab 75mg every 3 weeks for 4 cycles
83987|NCT03529409|Behavioral|Project Khanya|This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
83988|NCT03529396|Drug|Chloroquine|Standard chloroquine (three days)
83989|NCT03529396|Drug|Primaquine|Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
83970|NCT03529500|Diagnostic Test|Caries detection - dmtf index|"Dental caries experience was recorded using the dmft index, which was employed following the recommendations of the WHO to establish the prevalence and severity of caries. Active visible white spots were also recorded. The examinations were performed in duplicate for each child with the aim of establishing inter-examiner agreement using the Kappa statistic which demonstrated good agreement (K = 0.81).~The criteria adopted for the determination of prevalence followed by guidelines of the Oral Health Surveys - Basic Methods, 4th edition (WHO, 1997) described in the examiner's manual and annotator's manual produced by the coordination team of the Brazil Oral Health Project. The severity and prevalence of dental caries were determined based on the dmft index."
83971|NCT03529500|Diagnostic Test|Saliva flow rate|Samples of non-stimulated saliva were collected from the participants for five minutes using two aspirator tubes connected to a 15-ml Falcon tube. One aspirator tube was positioned under the child's tongue and the other was attached to the aspirator device. After five minutes, the amount of saliva was measured for the determination of salivary flow. Collections were performed between 9 and 11 am and the time of the last meal was recorded. At least a one-hour interval was required between the last meal and the collection of the saliva sample. The volume of saliva was measured. The salivary flow volume was calculated and expressed as ml/min. The following categories were considered in the analysis of salivary flow: < 0.1 ml/min = xerostomia; 0.1 to 0.6 ml/min = very low flow; 0.7 to 0.9 mL/min low flow; 1.0 to 2.0 ml/min = normal flow; and > 2.0 ml/min = high flow.
83972|NCT03529500|Diagnostic Test|Saliva Buffering Capacity|an aliquot of 1 ml was transferred to a test tube with 3 ml of hydrochloric acid (HCl 5 mM) for titration and the determination of salivary buffering capacity (SBC). The saliva/acid solution was shaken in a q 220 vortex tube agitator (Quimis, Diadema, SP, Brazil) for 15 seconds. Next, pH was determined in a portable pH meter (KASVI K39-0014P, Curitiba, PR, Brazil) for the determination of the SBC. The following categories were considered: ≥ 5.5 = very good buffering capacity; 5.4 to 5.0 = good buffering capacity; 4.9 to 4.5 = medium good buffering capacity; 4.4 to 4.0 = low buffering capacity; and ≤ 3.9 very low buffering capacity.
83973|NCT03529487|Drug|Oxymetazoline|Oxymetazoline gel applied intra-analy
83974|NCT03529474|Other|Psychology and Physiotherapy group|"Psychological program: 4 sessions,2 hours each,4 months~Psychoeducation.Influence of psychological factors on chronic pain: modulators of pain experience. Biopsychosocial model of pain.~Training techniques of psychological management of pain:Diaphragmatic Breathing and Progressive Muscle Relaxation to control vicious circle pain-tension-pain.~Kinesiophobia. Rational regulation of the activity level:Cognitive therapy (management of irrational believes about pain) and Organisation of time and reinforcement activities.~Physiotherapy program:3 sessions per week,1 hour per session,4 months:~Aerobic exercise:walking, cycling~Warm-up: active ROM exercises of inferior and superior extremities (ISE)~Progressive resistance training with elastic bands of ISE~Stretching of ISE"
83975|NCT03529474|Other|Placebo comparator: control group|Control group Normal daily activities Usual daily activities
83976|NCT03529461|Device|Non-invasive positive pressure ventilation through nasal mask|Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
83977|NCT03529461|Device|Rescue non-invasive positive pressure ventilation through nasal mask|If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
83978|NCT03529461|Other|Secondary rescue maneuvers|If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat > 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase > 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
83979|NCT03529448|Drug|TN-TC11G|"TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered."
83980|NCT03529448|Drug|Temozolomide Oral Product|"During RT, patients will receive Temozolomide (TMZ). All patients will be given TMZ at 75 mg/m2/d concurrently with RT for a maximum of 42 days.~At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
83981|NCT03529448|Radiation|Radiotherapy|All the patients will receive the Stupp regimen. The radiotherapy (RT) treatment will be administered in fractions of 1.8-2.0 Gy/day delivered 5 days/week to a total dose of 58-60 Gy. Radiotherapy will be delivered to the gross tumor volume with a 2-3 cm margin for the clinical target volume.
83982|NCT03529435|Behavioral|Massed Prolonged Exposure|Participants will complete fifteen weekday 90-minute Prolonged Exposure therapy sessions over three consecutive weeks. If necessary, the treatment window may be extended for another week.
83983|NCT03529435|Behavioral|Intensive Outpatient Prolonged Exposure|The IOP-PE will include the same primary treatment components as the Massed-PE protocol (fifteen weekday 90-minute PE sessions delivered five days a week over a three-week period) plus eight augmentations designed to maximize treatment outcomes. Similar to the Mass-PE, participants will have three consecutive weeks to complete treatment; however, the treatment window may be extended another week if necessary.
83984|NCT03529422|Drug|Durvalumab|Durvalumab 1500mg IV every 3 weeks for 6 cycles
83990|NCT03529396|Drug|Primaquine|Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
83991|NCT03529396|Drug|Chloroquine|Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
83992|NCT03529396|Drug|Primaquine|Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
83993|NCT03529383|Device|Connected device|Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
83994|NCT03529383|Behavioral|Therapeutic education|"Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~a 1-hour individual session of educational diagnosis (in the month following randomization in the study) to assess their needs and establish a contract of objectives,~two educational sessions of 1h30 each using tools, in group of 10 patients maximum (between months 2 and 4) to improve their daily practice of physical activity,~a 1-hour individual session of educational assessment (month 5 to 6) to evaluate whether their objectives were reached."
83995|NCT03529370|Radiation|optic nerve ultrasound|sonograhy of the optic nerve sheath diameter
83996|NCT03529344|Dietary Supplement|Blue whiting protein hydrolysate|Dietary Supplement: Blue whiting protein hydrolysate 6g protein per day for 6wk
83997|NCT03529344|Dietary Supplement|Placebo Comparator: Control|Control group will receive non-caloric juice without protein supplementation
83998|NCT03529331|Drug|Morphine Sulfate Immediate Release|15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days
83999|NCT03529331|Drug|Oxycodone/Acetaminophen|5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days
84000|NCT03529331|Drug|Hydrocodone/Acetaminophen|5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
84001|NCT03529318|Procedure|Biopsies from endoscopy|"1) Patients scheduled for endoscopy (EGD or colonoscopy) for IBD will be consented to allow physicians who are performing endoscopies to take additional biopsies and blood samples for research purposes."
84002|NCT03529305|Device|rTMS|Receive rTMS treatment to the primary motor cortex (M1)
84003|NCT03529305|Other|Physical therapy|Receive physical therapy
84004|NCT03529292|Device|AmeaCell|Lipoaspirate obtained from liposuction is treated by the AmeaCell® device in order to obtain de modified matrix which contains cellular phase and matrix phase. The modified matrix is injected in the same patient as facial wrinkles filler.
84005|NCT03529279|Drug|CNG Chemotherapy|"CNG I, IMRT plus oral adjuvant chemotherapy, if EBV-DNA > 0,according to CNG II. CNG II, IMRT + concurrent chemotherapy + oral adjuvant chemotherapy. CNG III, systemic chemotherapy, plus IMRT.~Chemotherapy strategy: Concurrent chemotherapy, 5-Fu + nedaplatin (cisplatin), every 28 days; 5-Fu 500mg/m2. D, civ d1-d5, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1. Systemic chemotherapy, 5-Fu + nedaplatin (cisplatin), every 60 days; 5-Fu (100 - 200 mg/m2. D) civ for 30 days, nedaplatin (cisplatin) 80mg (70mg) /m2. D, D1,D28. Aim to achieve CR in imaging.Oral adjuvant chemotherapy, tegafon (400 mg, QID) and Calcium Folinate Tablets (30 mg, QID). Oral 10 days and stop 20 days, 3 months/course. After 6 courses, oral 10 days and stop 50 days, half year/course, 6-7 courses, lasted for 5 years."
84006|NCT03529279|Drug|NCCN Chemotherapy|"UICC I, IMRT. UICC II-IVA, concurrent chemoradiotherapy ± adjuvant chemotherapy, or induced chemotherapy plus concurrent chemoradiotherapy. UICC IVB, platinum based combined chemotherapy, followed by IMRT or concurrent chemoradiotherapy, or concurrent chemoradiotherapy.~Chemotherapy strategy: Concurrent cisplatin with or without cisplatin plus 5-Fu or carboplatin combined with 5-Fu adjuvant chemotherapy; The combined chemotherapy regimen of IVB stage patients may choose cisplatin or carboplatin plus docetaxel or paclitaxel, cisplatin plus 5-Fu, carboplatin and cetuximab, cisplatin plus gemcitabine, and gemcitabine. The combination of vinorelbine and cisplatin, carboplatin, paclitaxel, docetaxel, 5-Fu, methotrexate, gemcitabine and capecitabine can be used in combination with radiotherapy."
84007|NCT03529279|Radiation|CNG Radiation|"IMRT technique. GTV was given to 6810cGy, CTV1 was given to 6000cGy, and CTV2 was given to 4800-5400cGy. 30 fractions, daily, QW1-5.~CT-SIM or MR-CIM was evaluated every 10 fractions. If CR for CNG I and II patients at 10 fractions, radiotherapy were given 25 fractions, that was, GTV was given to 5675cGy, CTV1 was given 5000cGy, and CTV2 was given 4000-4500cGy, 25 fractions, daily, QW1-5.~If tumor reduced less than 50% at 20 fractions, GTV was modified according to tumor size at 20 fractions. The modified GTV was given 300cGy/F×5 after 25 fractions; the original CTV1 and CTV2 were unchanged, that is, GTV was given to 5675cGy/25Fr+1500cGy/5Fr and CTV1 was given to 6000cGy/30Fr, CTV2 was given 4800-5400cGy/30Fr."
84008|NCT03529279|Radiation|NCCN Radiation|"IMRT technique. When IMRT alone, GTV were given (1) 66Gy (2.2Gy/Fr) to 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 6-7 weeks; (2) 69.96 Gy (2.12 Gy/Fr), 6-7 weeks; CTV1-2 were given 44-50 (2.0 Gy/Fr) to 54-63 (1.8 Gy/Fr).~When combined with chemotherapy, GTV were given 70-70.2 Gy (1.8-2.0 Gy/Fr), QW1-5, 7 weeks; CTV1-2 were given 44-50 Gy (2 Gy/Fr) to 54-63 Gy (1.8 Gy/Fr).~When palliative radiotherapy, 50Gy/20Fr; 37.5 Gy/15Fr (if tolerable, increases 5 fractions to 50Gy); 30Gy/10Fr, 30Gy/5Fr, 2 fractions per week, interval more than 3 days; 44.4Gy/12Fr was divided into 3 cycles, 2 fractions a day, 6 hours of interval, 2 consecutive days and 3-4 weeks between two cycles. After second cycles, the treatment plan must completely avoid the irradiation of the spinal cord."
84009|NCT03529266|Biological|Porcine Fibrin Sealant (PFS)|2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
84010|NCT03529266|Procedure|Surgery|McKeown esophagectomy including open or minimally invasive esophagectomy will be performed for patients with resectable thoracic esophageal carcinoma or gastroesophageal junction cancer. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery. At last, 2.5ml Porcine Fibrin Sealant will be instilled over the cervical anastomose line.
84011|NCT03529253|Drug|Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily|Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
84012|NCT03529253|Drug|Rosuvastatin calcium10mg|Rosuvastatin10mg/daily by oral for 9 months.
84154|NCT03528070|Drug|Tranilast|Subjects will be treated with tranilast
84013|NCT03529240|Device|Kinesiology Taping|Kinesiology taping (KT) which was developed by Dr. Kenzo Kase, is a new application of elastic and adhesive taping. KT is applied by specialized physiotherapists and physicians. This type of taping is a very frequently used technique to accelerate recovery after musculoskeletal injuries. Also, this technique is usually used as an alternative to athletic taping to support fascias, muscles, and joints for many purpose such as positioning, inhibition, and fascilitation
84014|NCT03529214|Behavioral|Exposed study site|The study sites will pilot the Team Birth Project designed to improve team communication (between providers, as well as providers and patients). The project includes three key implementation steps that involve: preparing local sites for the implementation of the project; training and coaching on the use of the tools; and sustainment through peer coaching and data feedback. A mixed methods approach will be used to assess acceptability and feasibility, including: (1) clinician surveys and interviews, (2) implementation team focus groups, and (3) patient surveys.
84015|NCT03529201|Procedure|QLB|On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
84016|NCT03529201|Device|PCA|Patient-controlled analgesia
84017|NCT03529201|Procedure|GA|General anesthesia
84018|NCT03529201|Drug|Oxycodone|administered by PCA
84019|NCT03529201|Drug|Sevoflurane|Inhalational anesthetic during GA
84020|NCT03529201|Drug|Fentanyl|painkiller during GA
84021|NCT03529201|Drug|Rocuronium|muscle relaxant during GA
84022|NCT03529175|Drug|Abraxane (nab-paclitaxel)|
84023|NCT03529175|Drug|Gemcitabine|
84024|NCT03529162|Procedure|Long head of Biceps Tenodesis|Patients will be randomized into two different groups to compare biceps tenodesis techniques
84025|NCT03529149|Combination Product|Urapidil Hydrochloride Injection|"Accurate monitoring of blood pressure is carried out under TCD monitoring, that is to maintain （mean flow velocity）MFV or （pulse index）PI target blood pressure. The target values of MFV and PI are MFV>37cm/s of （middle cerebral artery)MCA, PI < 1.34cm/s, aMFV>40cm/s of (basilar artery)BA, PI < 0.8cm/s.~TCD shows that when the MFV of MCA or BA is lower than the target value, the blood pressure is reduced or discontinued according to the insufficiency of blood flow. and the current blood pressure is maintained once MFV is met. TCD showed that the PI index of MCA or BA was higher than the target value . The blood pressure reduction was treated by excessive perfusion: intravenous infusion of blood pressure drugs , once PI index is up to the standard, maintaining the current blood pressure."
84026|NCT03529136|Biological|UC-MSC|Human umbilical cord mesenchymal stem cells have driven from Wharton's jelly and cultured with serum-free medium in Shandong Cell and tissue bank. All of the cells in this study within three passages. Before transfusion, the mesenchymal stem cells were subjected to quality control. The UC-MSC were stained with anti-CD90-FITC, Anti-CD44-FITC, Anti-CD34-FITC and anti-45-FITC.
84027|NCT03529123|Drug|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
84028|NCT03529123|Drug|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
84029|NCT03529123|Drug|Metformin|"Pharmaceutical form: Tablet~Route of administration: Oral"
84030|NCT03529123|Drug|Insulin Glulisine (HMR1964)|"Pharmaceutical form: Injection~Route of administration: Subcutaneous"
84031|NCT03529110|Drug|Trastuzumab deruxtecan (DS-8201a)|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously
84032|NCT03529110|Drug|Ado-trastuzumab emtansine (T-DM1)|The treatment will be in accordance with the approved label
84033|NCT03529097|Drug|0.9% Sodium-chloride|2 liters of 0.9% NaCl IV fluids
84034|NCT03529097|Drug|Placebos|2 liters of 0.9% NaCl bag covered with black bag so the participant could not tell the fluids are not dripping to his vain
84035|NCT03529097|Drug|Optalgin, Voltaren, Morphine|Oral and IV Optalgin, Voltaren IM (intramuscular), Morphine IV. All according to the pain intensity and with concordance to the physician.
84036|NCT03529084|Drug|EFG816|It will be administered orally daily.
84037|NCT03529084|Drug|erlotinib or gefitinib|"Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily."
84038|NCT03529071|Behavioral|CKD-Question Prompt Sheet|The CKD-QPS is a list of 31 questions specific to CKD stage 3 patients about treatment options and self-care management designed to activate patient communication with their providers and question-asking.
84039|NCT03529045|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System is a commercially available device that will be used by licensed medical practitioners trained in the use of VNS Therapy, per the practitioners' medical judgement.
84040|NCT03529032|Drug|Methadone|methadone for control postoperative pain
84041|NCT03529019|Drug|Ensure Surgery Immunonutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
84042|NCT03529019|Drug|Ensure Enlive Advanced Nutrition Shake|An FDA approved nutritional supplement. Prepackaged product designed to be administered 2 weeks prior to and 2 weeks post surgical procedure for a period of one week. .
84043|NCT03529006|Procedure|Sequent Please inflation|PCI procedure for treatment of ISR with DEB - Sequent Please - inflation
84044|NCT03529006|Procedure|Absorb BVS implantation|PCI procedure for treatment of ISR with Absorb BVS implantation
84045|NCT03528993|Other|exercise by hippotherapy device|Hippotherapy device mostly used on cerebral palsy, but we want to use hippotherapy device on patient with Hemiplegia.
84046|NCT03528993|Other|conventional rehabilitation|Bobath exercises: Bobath is a type of physiotherapy treatment which aims to improve movement and mobility in patients with damage to their central nervous system (brain and spinal cord).
84047|NCT03528993|Other|postural control exercises|perturbation on four directions, weight bearing exercises on standing positions
84048|NCT03528967|Drug|Enoxaparin 40 mg / 0.4 mL Prefilled Syringe|
84049|NCT03528967|Drug|Aspirin 100 mg Oral Tablet, Enteric Coated|
84050|NCT03528954|Drug|Propofol|Those who received intravenous propofol
84051|NCT03528941|Drug|Lamivudine|Patients who received lamivudine to prevent hepatitis B
84052|NCT03528941|Other|No prophylaxis|Patients who did not receive any prophylaxis to prevent hepatitis B
84053|NCT03528928|Device|Surface electrical stimulation|Thin electrode with four conductive areas placed over the perineal area.
84054|NCT03528915|Other|Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns treated with rifamycine treatment in delivery room.
84055|NCT03528915|Other|whithout Rifamycine treatment|Phone prospecting: occurrence of conjunctivitis in newborns did not receive eye drop treatment in delivery room according to new guidelines.
84056|NCT03528902|Drug|Tamoxifen|Tamoxifen 20 mg po daily for 24 weeks.
84057|NCT03528902|Drug|Placebo Oral Tablet|Placebo
84058|NCT03528889|Procedure|Femoral Extension and Derotation Osteotomy (ExtFDO)|Correction of malrotation of the femoral bone and flexed knee gait by osteotomy, derotation and osteosynthesis
84059|NCT03528876|Drug|FOLFOX and FOLFIRI|a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.
84060|NCT03528863|Behavioral|Online Mindfulness Meditation|Receive web-based mindfulness meditation
84061|NCT03528863|Other|Questionnaire Administration|Ancillary studies
84062|NCT03528850|Other|Telemedicine evaluation|Weekly virtual visits and daily biometric readings of blood pressure, weight, oxygen saturation and pulse
84063|NCT03528824|Other|Fenugreek wrap|Daily application of fenugreek wraps for 1/2-2 hours per day, 4 weeks application
84064|NCT03528824|Drug|Diclofenac Gel|Daily application of diclofenac gel, 4 weeks application
84065|NCT03528811|Diagnostic Test|Five points test of Tongji university|"In each group, we will evaluate the microcirculation of diabetic foot using the newly-established Five points test of Tongji university before or after the operation, and then compare the temperature of the five points with the other data."
84066|NCT03528785|Drug|Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid|"Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~Irinotecan Liposomal Injection [Onivyde] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle"
84067|NCT03528772|Drug|Minoxidil|application of minoxidil forte 5% gel three time per day on the anus for four weeks
84068|NCT03528772|Drug|Glyceryl trinitrate|application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
84069|NCT03528746|Other|Isotonic Exercise|Participants will complete dynamic leg extension in a leg extension machine with a range of motion from approximately 90 degrees flexion to full extension. Each repetition will be completed with a 3s concentric contraction, 0s isometric and 4s eccentric contraction.This will be repeated for 8 repetitions and for 5 sets with 2 minutes rest between each set, as per Rio and colleagues. The load used during the isotonic exercise will be equivalent to participants 8 repetition maximum, which will be determined by an experienced tester in a standardised manner according to NSCA guidelines.
84070|NCT03528746|Other|Isometric exercise|Participants will complete isometric quadriceps exercise, where they must hold a load statically for 45s with their knee in 60° flexion. This will be repeated for 5 sets with 2 minutes rest between each set. A load of 70% of the maximal voluntary isometric contraction (MVIC) will be used. MVIC will be assessed in an isokinetic dynamometer as per Rio and colleagues. Participants will be seated in a stable position in the dynamometer with the knee at 60° of knee flexion. First they will be familiarised with the procedure. Standardised instructions will be issued for participants to perform a maximal effort knee extension against the dynamometer for 3seconds. After a short break, the test will be repeated three times and the MVIC will be peak torque recorded during these three efforts.
84071|NCT03528733|Device|Multi-Energy Digital Radiography Detector System|A Multi-energy digital flat panel detector for Single Exposure Dual-Energy Subtraction radiography is developed to capture x-ray images with improved tissue differentiation. Tissue-selective images can be produced at various tissue levels such as bone and soft tissue to visualize obscured anomalies that are not apparent to General Radiography.
84072|NCT03528707|Dietary Supplement|Symbiter-Omega|"Symbiter Omega which contains combination of flax and wheat germ oil (250 mg of each, concentration of omega-3 fatty acids 1-5%), supplemented with biomass of 14 alive probiotic strains: Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×101"
84073|NCT03528707|Dietary Supplement|Placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
84074|NCT03528694|Biological|Durvalumab (MEDI4736)|Investigational product
84075|NCT03528694|Biological|Bacillus Calmette-Guerin (BCG)|Standard of care
84076|NCT03528681|Drug|Sodium Zirconium Cyclosilicate 5g|Suspension administered Sodium Zirconium Cyclosilicate 5g orally once daily for 28 days after the first 48-hour open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day.
84077|NCT03528681|Drug|Sodium Zirconium Cyclosilicate 10g|Suspension administered Sodium Zirconium Cyclosilicate 10g orally once daily for 28 days after the first 48-hour open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day.
84078|NCT03528681|Drug|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48- hour open label initial phase with suspension administered Sodium Zirconium Cyclosilicate 10g orally three times per day.
84079|NCT03528668|Device|Virtual Reality Exposure|Exposure to Virtual Reality program for up to 30 minutes
84080|NCT03528655|Other|Decision aid|Decision aid is a tool that helps pregnant women become involved in decision making on choosing rooming-in or separation care. Decision aid provides information about the options and outcomes, and by clarifying personal values.
84081|NCT03528642|Drug|Glutaminase Inhibitor CB-839 Hydrochloride|Given PO
84082|NCT03528642|Other|Questionnaire Administration|Ancillary studies
84083|NCT03528642|Radiation|Radiation Therapy|Undergo RT
84084|NCT03528642|Drug|Temozolomide|Given PO
84085|NCT03528629|Drug|Zolbetuximab|Zolbetuximab will be administered as a 2-hour intravenous infusion.
84086|NCT03528616|Drug|adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.|drugs used for treatment of supraventricular tachycardia
84087|NCT03528603|Other|Oleocanthal-Rich Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a high level of the phenolic oleocanthal
84088|NCT03528603|Other|Oleocanthal-low Extra Virgin Olive Oil|Extra Virgin Olive Oil that contains a low level of the phenolic oleocanthal
84089|NCT03528590|Device|size 3 i-gel supraglottic airway device|Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
84090|NCT03528590|Device|size 4 i-gel supraglottic airway device|Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
84091|NCT03528577|Drug|Zero-dose|Treatment A
84092|NCT03528577|Drug|90 mcg of PROAIR® HFA|Treatment B
84093|NCT03528577|Drug|180 mcg of 90 mcg of PROAIR® HFA|Treatment C
84094|NCT03528577|Drug|90 mcg of albuterol sulfate inhalation aerosol|Treatment D
84095|NCT03528564|Drug|Iron sucrose|Intravenous iron to be administered to all patients (9 x 5 mL Single Dose Vials @ 20mg elemental iron/mL; 900 mg total)
84096|NCT03528564|Drug|Epoetin Alfa|Erythropoietin to be administered to half of study participants (40,000 IU x 1-2 subcutaneous injections)
84097|NCT03528564|Drug|Placebo|Saline to be administered to half of study participants (equal volume to Eprex x 1-2 subcutaneous injections)
84098|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 75 IU/kg body weight will be administered once weekly as intravenous injections for a duration of 2 years.
84099|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 60 IU/kg body weight (for patients younger than 12 years) and 50 IU/kg body weight (for patients, 12 years or older) will be administered twice weekly as intravenous injections for a duration of 2 years.
84100|NCT03528551|Drug|Turoctocog alfa pegol|Turoctocog alfa pegol 50 IU/kg body weight will be administered three times weekly as intravenous injections for a duration of 2 years.
84101|NCT03528538|Dietary Supplement|AlphaFen fenugreek 400 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
84102|NCT03528538|Dietary Supplement|AlphaFen fenugreek 500 mg|A brand of fenugreek supplementation that was produced by SPECNOVA. Pure fenugreek without any additives.
84103|NCT03528538|Other|Placebo|rice flour in a vegetable/ cellulose capsule
84104|NCT03528512|Drug|Ketamine|Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml)
84105|NCT03528512|Drug|Midazolam and fentanyl|Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg)
84106|NCT03528499|Other|Scapular Movement Training|Orientation about the proper scapular position and movement and training to modify the scapular movement pattern.
84107|NCT03528499|Other|General Exercises|Strengthening and stretching exercises.
84108|NCT03528486|Behavioral|Music Training I|Participants will be attending group classes, guided by a trainer, with up to 10 other older adults.
84109|NCT03528473|Other|Exercise|"The exercise intervention consists of 60 minutes sessions, divided into 40 minutes of aerobic exercise and 20 minutes of circuit training for muscular strength and flexibility exercises.~Aerobic exercise is performed using treadmill, exercise bikes, syncro and arm-ergometers, gradually increasing the exercise intensity, after a 10 minutes period of warming-up, to 60-80 % of Maximum Heart Rate.~Resistance training consists of resistance exercises for large muscle groups, performed with body weight-exercises and isotonic machines."
84110|NCT03528447|Other|Pulmonary Rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band."
84111|NCT03528434|Dietary Supplement|Zinc|10mg dispersible zinc sulfate tablet
84112|NCT03528434|Other|Placebo|Dispersible tablet with inert ingredients, identical to zinc in appearance
84113|NCT03528421|Biological|IM19|CAR-T cells
84114|NCT03528421|Drug|Fludarabine|Two days before cell infusion, all patients will be treated with fludarabine for 3 days
84115|NCT03528421|Drug|Cyclophosphamide|Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days
84116|NCT03528408|Drug|Nivolumab|Nivolumab 240 mg IV over 30 minutes given Day 1, 14 and 28 of each Cycle
84117|NCT03528408|Drug|Ipilimumab|Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle
84118|NCT03528395|Other|Semi-immersive virtual reality|Each participant will receive 24 additional sessions of semiinmersive virtual Reality therapy sessions on Monday, Wednesday and Friday, after realizing the conventional therapy sessions. The duration of each VR session will be gradually increased in time-intensity (5 minutes during the first week to 20 minutes during the last week) and motor requirements.
84119|NCT03528395|Other|Conventional Rehabilitation|Conventional rehabilitation consisting of five weekly sessions of Physical therapy and Occupational Therapy, based on a task-oriented approach, lasting 45 minutes each.
84120|NCT03528382|Behavioral|Cardiac rehabilitation quality improvement system|Cardiac rehabilitation quality improvement system is divided into two period. The period I of rehabilitation has three parts, including daily life, rehabilitation exercise training, publicity and education. And the period II of rehabilitation is based on aerobic exercise, as well as combined with resistance and flexibility exercises
84121|NCT03528369|Drug|CGS-200-1|CGS-200-1 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of 1% for this study.
84122|NCT03528369|Drug|CGS-200-5|CGS-200-5 is a multi-component formulation in which the active ingredient for the intended therapeutic effect is capsaicin at a level of up to 5% for this study.
84123|NCT03528369|Drug|CGS-200 Vehicle|CGS-200 Vehicle contains all of the ingredients in CGS-200-1 and CGS-200-5 except for capsaicin.
84124|NCT03528356|Behavioral|Regular diet|Patients will not receive any information regarding their usual diet. They will simply perform home dental bleaching.
84125|NCT03528343|Drug|Non-narcotic pain control|Education to use tylenol and motrin only for pain control unless this is unable to control pain. Rescue prescription provided.
84155|NCT03528057|Device|Hemostat|Hemostatic agents, if used at all during surgery, will be applied laparoscopically into the tumor bed to stop bleeding. The type of hemostat will be decided by the surgeon according to the anatomy of the tumor bed.
84183|NCT03527836|Drug|Bupivacaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine
84126|NCT03528330|Device|Rehabilitation with dental implant with internal hexagon connection|"All patients will receive an implant with internal hexagon connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
84127|NCT03528330|Device|Rehabilitation with dental implant with conical connection|"All patients will receive an implant with conical connection. All implants will be10 mm in length and 3.75 mm in diameter. Implants will be inserted slightly subcrestal. Bone levels will be measured using a calibrated probe.~Torque insertion will be assed using W&H machine Once inserted, implants will be connected to smart pegs to test primary stability.~A periapical x-ray will be done after the operation. Thereafter, a specific coping for digital impression will be connected to the implant and a digital impression will be taken. Aim of this procedure will be to produce a screw retained definitive zirconia prosthesis to be adapted at the time of second surgery"
84128|NCT03528317|Other|Alternate day fasting|Alternate day fasting with a high protein diet
84129|NCT03528304|Behavioral|Contingency management|Contingency management (CM) is a behavioral intervention that uses gift cards, prizes, or access to privileges to reinforce specific healthy behaviors and lifestyle changes. CM has been used successfully for a range of addictive behaviors, including cigarette smoking and heroin, cocaine, methamphetamine, and other illicit substance use, as well as for reducing psychiatric problems and HIV risk. CM has great potential for treating smoking and overweight/obesity, as it reinforces both short- and long-term behaviors. This is important because both smoking cessation and weight loss are highly prone to short-term relapse,
84130|NCT03528278|Behavioral|Motivational interviewing and environmental interventions|"Revision of ward routines towards facilitating physical activity in patients and motivational work by staff~Education of staff with certified MI-expert organized as an intensive course and follow-up guidance. The first course held shortly before start of interventions, the rest arranged within a month~Training equipment~Motivational Interviewing (MI) techniques applied by staff~Weekly treatment plans including physical activity which may consist of any continuous physical exercise."
84131|NCT03528265|Device|Lateral flow immunoassay|Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
84132|NCT03528252|Other|Written advice LDL Cholesterol|One A4 paper with written information on both sides
84133|NCT03528252|Other|Written advice Triglycerides|One A4 paper with written information on both sides
84134|NCT03528239|Other|Refugee patients|To investigate characteristics of outpatient visits of refugee patients
84135|NCT03528226|Behavioral|Exercise Training Procedure|Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)
84136|NCT03528226|Behavioral|Normal life procedure|No supervised exercise training during the 4 month period.
84137|NCT03528213|Drug|Sodium Lactate light dose|bolus 2.5ml/kg then 0.25ml/kg/h
84138|NCT03528213|Drug|Sodium Lactate high dose|bolus 2.5ml/kg then 0.5ml/kg/h
84139|NCT03528213|Drug|Normal saline|normal saline at physician discretion
84140|NCT03528200|Other|Contrast|"The scan requires that the patient lie still on a hard surface for about 5-10 minutes. Before the scan, they will have a special fluid called contrast dye injected through the IV in their arm. This contrast dye helps to see the blood in the arteries using x-ray pictures.~After the IV dyna CBV is completed, they will have their routine conventional angiography to evaluate the lesion for embolizable arteries as part of routine clinical care. If the patient undergoes embolization of the lesion (as part of the standard of care), a post embolization Dyna CBV will be performed."
84141|NCT03528187|Other|MRI|"MRI scan (not involving ionising radiation)~The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher"
84142|NCT03528187|Other|Written Consent|Student researcher or research nurses to take consent. Consent will be taken in the obesity clinic or radiology departments.
84143|NCT03528174|Device|Artificial Pancreas Control system (APC)|This intervention is a single hormone closed loop system including a Nexus 5 smart phone, two tslim insulin pumps, a Dexcom G5 CGM and two PDT glucose sensing cannulas that together make up a new experimental, investigational device system. The algorithm included in the APC is an automated version of the Fading Memory Proportional Derivative (FMPD) insulin and glucagon control algorithm.
84144|NCT03528174|Device|Pacific Diabetes Technologies CGM Insulin Infusion system|An integrated combination CGM/insulin infusion system
84145|NCT03528161|Other|Measurement of hypersensitive troponin|"Telephone follow-up at one month, 3 months and 6 months by a clinical research technician. Collection of serious adverse events, reports of hospitalization.~The hypersensitive troponin assay will be recently proposed in a short-term risk stratification score after syncope (30 days), the canadian syncope risk score. If hypersensitive troponin benefits from interesting performances it needs to be evaluated prospectively, as measured only in 47.9% of syncope in this study. Hypersensitive troponin could be a prognostic marker of early serious adverse cardiovascular events in syncope."
84146|NCT03528148|Behavioral|cycling|Active cycling
84147|NCT03528148|Behavioral|Physical therapy|Conventional physical therapy
84148|NCT03528135|Behavioral|Project PRIDE|See arms section.
84149|NCT03528122|Procedure|Recurrent opened macular hole|pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
84150|NCT03528109|Behavioral|Exposure Therapy|A type of Cognitive Behavioral Therapy shown to be effective in the treatment of pediatric OCD and anxiety
84151|NCT03528096|Device|Somnomat B|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
84152|NCT03528096|Other|Sound|Sound of the moving bed was recorded and played back during the baseline night.
84153|NCT03528083|Other|Bronchiolitis quality improvement|Patients in the intervention group will undergo a quality improvement process to improve care quality for bronchiolitis at our hospital.
84156|NCT03528044|Procedure|Bariatric surgery|In this study, patients will undergo sleeve gastrectomy to reduce the size of the stomach to induce weight loss.
84157|NCT03528031|Other|Intervention Daily Avocado|Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
84158|NCT03528018|Device|REACt system|The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements
84159|NCT03528018|Other|Physical therapy|Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
84160|NCT03528005|Behavioral|Multi-domain intervention|60 minutes cognitive training, 45 minutes physical exercise, 15 diet nutrition and intermittent disease management consultation
84161|NCT03527992|Device|O2 automated|"In the O2 automated group, patients benefit from oxygen therapy via the FreeO2 device. The O2 saturation target is set by the clinician on the device. Saturation is continuously sensed by an oximeter and the oxygen flow is automatically adjusted. The clinician has access to instantaneous values and trends of O2 and SpO2 flow rates."
84162|NCT03527992|Device|O2 standard|"In the O2 standard group, patients benefit from oxygen therapy with nasal goggles or a high concentration mask. Saturation is continuously captured by an oximeter. The flow rate of oxygen, evaluated in L/min, is adapted according to local protocols (every 8 hours in conventional hospital services, continuous in intensive care"
84163|NCT03527979|Procedure|IVF/ICSI|IVF/ICSI
84164|NCT03527966|Biological|5cc Vivigen and local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive 5cc Vivigen and local autograft
84165|NCT03527966|Biological|Small kit rhBMP-2 with local autograft|The single level lumbar instrumented fusion patients assigned to this group will receive small kit rhBMP-2 with local autograft
84166|NCT03527953|Other|Tetric EvoCeram Bulkfill|The preparation will be etched with 37% phosphoric acid. It will be then rinsed with an air-water spray and dried, leaving the dentin slightly moist. An etch-and-rinse adhesive, ExciTE F, will be applied and agitated on the prepared surfaces for at least 10 seconds. The adhesive will be air-thinned and light-cured for 20 seconds with an LED curing unit. The sectional matrix will be placed and fixed with wooden wedges. Then the bulk-fill resin composite, TBF, will be placed in bulk in about 4-mm thickness and then will be cured for 20 seconds.
84167|NCT03527953|Other|Surefil SDR Flowable bulkfill|The preparation will be etched. A two-step etch-and-rinse adhesive, Prime&Bond NT will be applied to all enamel/dentin surfaces, air-dried for 5 seconds, and will be light cured for 10 seconds. After the sectional matrix will be placed, the flowable bulk-fill resin composite, SureFil SDR™ flow (Dentsply Caulk, Milford, DE, USA), will be placed in a 4-mm bulk increment in the dentinal part cured for 20 seconds and will be followed by a covering layer of the nanohybrid resin composite, Ceram.X Mono that will be cured for 20 seconds.
84168|NCT03527953|Other|everX fiber-reinforced resin|The enamel will be etched with 37% phosphoric acid for 10 seconds, then will be rinsed, and dried with an air/water syringe for at least 5 seconds. Self-etch adhesive, G-aenial Bond (GC Co., Tokyo, Japan), will be applied to all enamel/dentin surfaces and gently air thinned and then will be light cured for 10 seconds. After the matrix will be placed and wedged, mesial or distal walls will be built with 1-2-mm layers of G-aenial Posterior resin composite. The fiber-reinforced composite, everX Posterior, will be placed into the cavity in approximately 4-mm thickness. The last 2 mm of the cavity will be restored using the G-aenial Posterior composite as an overlay layer. Each increment will be light cured for 20 seconds using an LED unit.
84169|NCT03527940|Other|No intervention|No special intervention was adopted to patients except for the regular treatment.
84170|NCT03527927|Drug|Any LABA/LAMA|Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
84171|NCT03527914|Other|Goal Based Outcomes|Up to three goals can be tracked during treatment, although patients often decide to just focus on one. Progress on the goal is then quantitatively rated by the patient, with the provider, at every appointment. Adjustments in the care are then made in an iterative process to ensure that the goal will be met.
84172|NCT03527914|Other|Treatment as Usual|Patients will receive their standard care at the Outpatient Mental Health Service
84173|NCT03527901|Diagnostic Test|GCF collection with aMMP-8 chair side test|
84174|NCT03527901|Other|Saliva collection|
84175|NCT03527888|Drug|Anlotinib|Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
84176|NCT03527875|Procedure|PTBD group|Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
84177|NCT03527875|Procedure|ENBD group|Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
84178|NCT03527875|Procedure|EBS group|Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
84179|NCT03527862|Other|Treatment according to lung ultrasonography|Appropriate treatment for atelectasis, pleural effusion, pulmonary edema, pneumothorax or pneumonia which are confirmed by lung ultrasonography
84180|NCT03527849|Behavioral|Mindfulness-Based Stress Reduction|The intervention will be an MBSR course.
84181|NCT03527849|Behavioral|Health Enhancement Program|Propose to use an active control training, the Health Enhancement Program (HEP), an intervention designed to isolate mindfulness as a testable active ingredient. HEP and MBSR are structurally equivalent in that they share the same amount of in- and out-of class work time. The content of the HEP intervention meet the following criteria: (1) class activities match MBSR activities as closely as possible, (2) activities represent valid, active, therapeutic ingredients in their own right, and (3) these ingredients do not include mindfulness.
84182|NCT03527836|Drug|Lidocaine brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with lidocaine
84184|NCT03527836|Drug|Mixture brachial plexus block|Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%
84185|NCT03527810|Procedure|Sleeve Gastrectomy Without Interrogation of Hiatus|Weight-loss procedure to reduce the stomach.
84186|NCT03527810|Procedure|Sleeve Gastrectomy With Interrogation of Hiatus|Weight-loss procedure to reduce the stomach with hiatal repair.
84187|NCT03527797|Other|Titration of support level|Increasing support in case diaphragm activity is too high. Decreasing support in case diaphragm activity is too low.
84188|NCT03527784|Device|Parietene Macro|Parietene Macro is used on retromuscular sublay position. The bowel is brought through opening in the middle of the mesh.
84189|NCT03527784|Device|Parietex Parastomal|Parietex Parastomal is used on intraperitoneal onlay position by modified Sugarbaker technique to prevent parastomal hernia.
84190|NCT03527784|Device|Dynamesh IPST|Dynamesh IPST is used on intraperitoneal onlay position to prevent parastomal hernia
84191|NCT03527771|Device|Video-assisted CPR|Emergency call using a Software capable of video Transmission for Video assistance in CPR
84192|NCT03527771|Drug|telephone-assisted CPR|Emergency call with telephone assistance in CPR
84193|NCT03527758|Device|Flo TracIQ with HPI software|Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.
84194|NCT03527745|Drug|Albendazole|Single dose of albendazole (200mg, dependent on treatment cohort)
84195|NCT03527745|Drug|Albendazole|Single dose of albendazole (400mg, dependent on treatment cohort)
84196|NCT03527745|Drug|Albendazole|Single dose of albendazole (600mg, dependent on treatment cohort)
84197|NCT03527745|Drug|Albendazole|Single dose of albendazole (800mg, dependent on treatment cohort)
84198|NCT03527745|Drug|Placebo|Matching placebo tablets will be obtained from Fagron, Germany.
84199|NCT03527732|Drug|Albendazole|Monotherapy of albendazole (400 mg)
84200|NCT03527732|Drug|Albendazole and Ivermectin|Combination therapy of albendazole (400 mg) and ivermectin (200 µg/kg)
84201|NCT03527719|Other|Strengthen the performance appraisal system|In accordance with the performance evaluation standards for the management of hypertension patients in national basic public health services and on the basis of routine management such as blood pressure monitoring and lifestyle guidance,medication rate, medication compliance, control rate and patient follow-up rate of participants in the intervention group will be included in the performance assessment index system and a complete performance appraisal evaluation and reward and punishment system will be established.
84202|NCT03527719|Other|Establishing a chronic disease management system|Assigning a professional staff for the propaganda and treatment of chronic disease prevention and management for each study village,who is responsible for supervising participants taking medicine according to doctor's prescription, regularly measuring blood pressure, promoting healthy lifestyles, and regularly organizing hypertensive participants to carry out self-management group activities,enhancing the active awareness of hypertension prevention and control of, and cooperating with the village doctor to manage blood pressure control of hypertensive patients.
84203|NCT03527719|Other|Simulating medical insurance reform|"Through the provision of preferential anti-hypertensive drugs to the participants in the intervention group, the increase of Medicare reimbursement proportion for hypertension is simulated to provide affordable, effective free antihypertensive drugs to the participants with poor economic conditions in the management population. Through the measures above, the participants' compliance with medication will be improved.~The project will select the best antihypertensive drugs for rural patients, and to implement preferential policies for buying gifts. At the same time, inexpensive and effective free antihypertensive drugs including nitrendipine tablets, captopril tablets and indapamide tablets will be supplied to the impoverished hypertensive patients free of charge."
84204|NCT03527719|Other|Enhancing village doctors'ability.|Standardizing training programs for village doctors in hypertension prevention,control, management ,diagnosis and treatment capabilities,including clinical norms of hypertension medication, professional knowledge about commonly used antihypertensive drugs' adverse reactions, contraindications and drug adjustment strategies and disposal principles,improve the rationality of managing drug treatment programs for participants, and comprehensively improve participants' compliance and blood pressure control rate. At the same time, a quarterly evaluation and assessment system for the medical treatment capacity of village doctors for hypertension will be established.
84205|NCT03527719|Other|Establishing a supervision mechanism for the effect|Establish a hypertension management effect monitoring team composed of the county (district) health commission, the disease prevention and control center, and the township prevention and protection station to remind and urge village doctors to strengthen the management of blood pressure in participants who do not meet the standard and increase the compliance rate. Periodically form a paper work record and report to the provincial project team's quality control center.
84206|NCT03527719|Other|Establishing a hierarchical management system for patients|Establish a hierarchical management system for participants at the municipal level and above hospitals - county hospitals - village doctors. Three levels of doctors in the management system sign contracted management. Each city-level and above hospital doctor signs three county-level hospital doctors. Each county-level hospital doctor signs up with ten village doctors and established a three-level doctors WeChat(Chinese mainstream social software) communication group to ensure the rationality of the program and the participants' safety during the diagnosis and treatment.
84207|NCT03527719|Behavioral|Enhancing the awareness of blood pressure self-management|Electronic sphygmomanometer will be uniformly distributed among the participants in the intervention group to promote the self-tested blood pressure habits of the participants. The participants will be encouraged to communicate with the village doctors actively to enhance their self-management consciousness of blood pressure.
84208|NCT03527719|Behavioral|Establishing a self-management group|A self-management group for participants was established in each of the study village. They will participate in a group activity every quarter to learn about healthy lifestyles and self-tested blood pressure, the hazards of hypertension, to communicate with other patients about the experience in the treatment process and give feedback to village doctors about the treatment process for the enhancement of the confidence for long-term medication.
84243|NCT03527472|Drug|Memantine|Memantine is an FDA-approved drug for the treatment of Alzheimer's disease.
84209|NCT03527719|Other|Establishing patient encouragement system|A self-administration point encouragement system for participants' blood pressure will be established to accumulate points according to the participants' self-blood pressure measurement, medication compliance, follow-up compliance, and self-management team participation, and rewards will be based on quarterly and annual points to cultivate and enhance participants' initiative consciousness of self-management of blood pressure.
84210|NCT03527693|Device|Lipogems injection|Micro-fragmented adipose tissue (10 cc) was injected intra-articular after the arthroscopic procedure (shaving or shaving + meniscectomy).
84211|NCT03527680|Dietary Supplement|Lactobacillus rhamnosus|daily one capsule containing 1.6*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
84212|NCT03527680|Drug|Placebo - Cap|daily one capsule of placebo
84213|NCT03527667|Behavioral|Financial incentives|Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
84214|NCT03527654|Other|Observational|Surveys, blood and urine collected prospectively over 24 months.
84215|NCT03527641|Behavioral|CookingMatters|Nutrition education and hands-on cooking lessons for the whole family
84216|NCT03527641|Behavioral|Parent Education|Parenting, physical activity and nutrition education, and family health education for parents
84217|NCT03527641|Behavioral|Physical Activity|Physical fitness activities for teens
84218|NCT03527641|Behavioral|Health Education|Health knowledge curriculum for adolescents
84219|NCT03527641|Behavioral|Mindfulness-based Stress Reduction|Adolescent mindfulness curriculum
84220|NCT03527641|Behavioral|Brief Mindfulness Intervention|Parent-based education and experiential learning of mindfulness-based tools
84221|NCT03527628|Drug|Adriamycin|25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
84222|NCT03527628|Drug|Cyclophosphamide|400mg/m2 Infusion in 500ml sodium chloride 0.9%over 30min. in days 1 and 15 of each 28 day cycle
84223|NCT03527628|Drug|Vinblastine|6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
84224|NCT03527628|Drug|Dacarbazine|375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
84225|NCT03527628|Drug|Brentuximab Vedotin|1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
84226|NCT03527628|Drug|ABVD|All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
84227|NCT03527615|Other|Clinical Pharmacist Medication Review|Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.
84228|NCT03527602|Procedure|Foraminal enlargement|After determining the working length, a rotary file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
84230|NCT03527576|Drug|Dexamethasone|Intravenous injection of 0.15 mg/kg of dexamethasone before the surgery.
84231|NCT03527576|Drug|NaCl 0.0308 MEQ/ML Injectable Solution|Intravenous injection of NaCl 0.9% before the surgery.
84232|NCT03527563|Behavioral|Internet Medical Model|Subjects in the Internet group should upload blood pressure monitoring data at least once per day. It is highly recommended to upload two pressure monitoring results to capture more blood pressure information. The warning value of blood pressure set in the cloud database is systolic blood pressure ≥ 180mmHg or ≤ 100mmHg and diastolic blood pressure ≥ 110mmHg or ≤ 60mmHg. After enrollment, subjects and physicians communicate via telephone or Internet every two weeks until blood pressure is well controlled judged by physician. Then the frequency of communication will be changed to once a month. Once there are lacks of blood pressure data in 3 days of each week, or. blood pressure values of the subject exceed the warning value in 2 days of consecutive 3 days, the physician will take the initiative to contact the patient for disease inquiry.
84233|NCT03527550|Other|Cognitive Control Training|Cognitive Control Training involves daily practice with one of two computerized interventions. The first intervention is an adaptive Go/No-Go task to provide practice in the domain of response inhibition. Participants press a key as fast as possible in response to stimuli (letters of the alphabet), but must inhibit responses to a specific letter. The second intervention is an adaptive Paced Auditory Serial Addition Task (PASAT), designed to practice working memory. Participants are presented with single numbers presented aurally, and must add each number they hear to the previous number and click the correct sum on the screen.
84234|NCT03527537|Drug|Insulin|Insulin may be administered base on glucose log values. The dosing of the insulin will be decided by the provider using typical management of gestational diabetes.
84235|NCT03527537|Drug|Glyburide|Glyburide may be administered base on glucose log values. The dosing of the glyburide will be decided by the provider using typical management of gestational diabetes.
84236|NCT03527537|Drug|Metformin|Metformin may be administered base on glucose log values. The dosing of the metformin will be decided by the provider using typical management of gestational diabetes.
84237|NCT03527524|Other|exercise with ball|exercise with ball
84238|NCT03527524|Other|exercise without ball|exercise without ball
84239|NCT03527511|Other|Measure of etecalcetide on osteoclastic biology|In vitro evaluation of osteoclastic biology after blood sampling of patients.
84240|NCT03527498|Device|Baby treadmill|The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.
84241|NCT03527498|Behavioral|Physical rehabilitation training|Suitable for general physical rehabilitation training of all infants with cerebral palsy.
84242|NCT03527485|Diagnostic Test|11UCB-J PET Scan|11UCB-J PET Scan
84244|NCT03527472|Drug|Placebo|The placebo will match the study drug in appearance, dose, and frequency. It will not contain any active drug (memantine).
84245|NCT03527459|Behavioral|SPARC B|SPARC B includes all aspects of the SPARC A clinical program, as well as targeting negative cognitions of perceived burdensomeness.
84246|NCT03527459|Behavioral|SPARC A|SPARC A is an existing clinical program with a general focus on negative cognitions.
84247|NCT03527446|Behavioral|Sprint Interval Training|The 4-week sprint interval intervention will consist of a work-rest ratio of four 30-s intervals of exercise at maximal capacity and 4-min of passive recovery at 50% of maximal capacity between intervals. There will be three sessions per week.
84248|NCT03527433|Procedure|New closure technique|In the intervention arm, an average of two sutures will be placed at each cm length of the wound, thus the number of sutures placed should be equal to at least double the length of the wound in cm.The aim is to have a ratio of 4:1 between the overall lengths of the suture to the length of the wound being closed
84249|NCT03527420|Other|Exercise training|Twelve weeks of aerobic exercise training
84250|NCT03527381|Drug|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.
84251|NCT03527381|Other|Standard CPB|Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
84252|NCT03527368|Behavioral|Time-restricted feeding|Participants consume food earlier in the day
84253|NCT03527368|Behavioral|Usual feeding pattern|Participants consume food later in the day
84254|NCT03527355|Biological|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
84255|NCT03527355|Biological|FluQuadri™|"Manufacturer: Sanofi Pasteur Dose: 0.25 ml~*Participants who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after unblinding."
84256|NCT03527355|Other|0.9% sodium chloride isotonic solution|Manufacture: Euro-Med Inc. Dose: 0.5 mL
84257|NCT03527329|Device|WarmTouch Model 5900, Covidien Ltd, Mansfield, USA|Forced-air warming will be applied following routine clinical practice. The pre-warming time will depend on the time the patient has to wait before entering in the operating room. Prewarming time will be recorded for each patient.
84258|NCT03527316|Drug|MDMA|125 mg MDMA per os, single dose
84259|NCT03527316|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
84260|NCT03527303|Behavioral|Meditation|10 minute per day, 8 week digital meditation
84261|NCT03527290|Behavioral|Time Restricted Eating|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts related to circadian rhythms, metabolism and TRE; and the evidence demonstrating benefit of TRE in animal models and humans. The goal is provide rationale for the potential benefits of a TRE approach. In addition, the RD sessions focus on developing a plan for successfully implementing a TRE approach, identifying challenges for adherence, and a plan for dealing with real or potential challenges. The counseling is focused the TRE concept, with no specific direction or counseling related to modifying the content of the participant's diet or any prescription to reduce energy intake.
84262|NCT03527290|Behavioral|Standard Cardiometabolic Health Diet|The intervention is delivered in a paradigm in which an individual with abdominal obesity would be referred by their physician to receive dietary counseling from a Registered Dietitian (RD). The aim of the intervention is to improve cardiometabolic health and assist with weight management via 4, individualized counseling sessions over the course of 8 weeks. Participants are educated on basic concepts and known benefits related to eating a diet for cardiometabolic health and weight management recommended by the American Heart Association and the Academy of Nutrition and Dietetics as a standard of practice for dietitians in healthcare settings. The RD sessions focus on adopting a dietary pattern aligned with this approach, identifying challenges to adopting this dietary pattern, and education and plans for dealing with real or potential challenges. The counseling gives no direction related to modifying the timing of dietary intake or any prescription to reduce energy intake.
84263|NCT03527277|Other|Naturally-sweetened orange juice|Commercially-available ready-to-serve refrigerated orange juice
84264|NCT03527277|Other|Sugar-sweetened beverage|Sugar-sweetened water flavored with Kool-Aid (TM)
84265|NCT03527264|Drug|Nivolumab induction|2 doses Nivolumab 240mg IV
84266|NCT03527264|Drug|Cisplatin|40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
84267|NCT03527264|Radiation|Radiation|"Total dose of 45 Gy in 25 fractions at 180 cGy/fx~Whole pelvic or extended field"
84268|NCT03527264|Drug|Nivolumab with chemoradiation|Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
84269|NCT03527264|Drug|Nivolumab maintenance|Nivolumab 480 mg IV every 4 weeks for 2 years
84270|NCT03527251|Drug|Ipilimumab|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
84271|NCT03527251|Drug|SHR-1210|Patients received two doses of intravenous ipilimumab (at a dose of 1 mg per kilogram of body weight) every 3 weeks, following by intravenous SHR-1210 (at a fixed dose of 200mg) every 2 weeks.
84272|NCT03527238|Other|PPM-based Computation Assisted Drug Dosing|Tacrolimus dosing based on application of PPM.
84273|NCT03527238|Drug|Tacrolimus|Dosing of calcineurin inhibitor, tacrolimus
84274|NCT03527225|Other|Music|The patient's preferred music will be played during the first radiotherapy treatment session from speakers located inside the treatment room. The duration of the music will be 10 to 20 minutes. The music will be turned off at the patient's request if it bothers them. Length of music playing and if the patient requested that it be turned off, will be recorded.
84275|NCT03527212|Drug|SJP-0035 0.001%|Self-administration of 1 drop (approximately 40 µL) of 0.001% SJP-0035 ophthalmic solution into each eye 4 times daily for 4 weeks
84276|NCT03527212|Drug|Placebo|Self-administration of 1 drop (approximately 40 µL) of placebo ophthalmic solution into each eye 4 times daily for 4 weeks
84684|NCT03524066|Drug|Systemic|Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally
84277|NCT03527199|Diagnostic Test|Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)|Standard of care-Pelvic CT or MRI and MDP bone scan + or - 18F-NaF PET/CT
84278|NCT03527186|Drug|Risperidone ISM® 100 mg|100 mg of risperidone ISM® administered every 4 weeks
84279|NCT03527173|Biological|GSK3536852A vaccine|Subjects receiving 2 doses of study vaccine by intramuscular route, 28 days apart (Day 1 and Day 29) and a challenge dose at Day 57.
84280|NCT03527173|Drug|GAHB-Placebo|Subjects receiving 2 doses of GAHB-placebo by intramuscular route, 28 days apart (Day 1 and Day 29) and a challenge dose at Day 57.
84281|NCT03527147|Drug|AZD9150|AZD9150 will be administered as a 1-hour intravenous (IV) infusion on Days 1, 3, 5 of Cycle 1, followed by weekly infusions (starting Day 8 of Cycle 1 and beyond).
84282|NCT03527147|Drug|Acalabrutinib|Acalabrutinib will be administered orally twice daily (bid).
84283|NCT03527147|Drug|AZD6738|AZD6738 will be administered orally twice daily (bid).
84284|NCT03527147|Drug|Hu5F9-G4|Hu5F9-G4 infusions will be administered weekly.
84285|NCT03527147|Drug|Rituximab|Rituximab infusions will be administered weekly for one cycle (28 days) and then every 4 weeks up to 6 cycles.
84286|NCT03527147|Drug|AZD5153|AZD5153 will be administered orally once per day (qd).
84287|NCT03527134|Drug|Amantadine|patients will receive amantadine 100 mg by month 2 h before the induction of general anesthesia and then 100 mg each time, three times per day for 5 days.
84288|NCT03527121|Other|ESP physiotherapy|A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
84289|NCT03527121|Other|Usual care|A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
84290|NCT03527108|Drug|Nivolumab, ramucirumab|"78 patients diagnosed with non-small cell lung cancer, regardless of histology, immunotherapy-naive, after progression through one line of treatment with an appropriate chemotherapy regimen (platinum doublet, or after appropriate targeted therapies). Normal organ function, Performance Status (PS)- 0-1, no active autoimmune disease, no hemoptysis or cavitary tumor. Core biopsy specimen must be available.~39 patients diagnosed with non-small cell lung cancer, regardless of histology, immunotherapy-exposed, after progression through one line of treatment with an appropriate regimen (immunotherapy alone, or immunotherapy plus chemotherapy). Normal organ function, PS 0-1, no active autoimmune disease, no hemoptysis or cavitary tumor. Core biopsy specimen must be available."
84291|NCT03527108|Drug|Nivolumab|78 patients diagnosed with non-small cell lung cancer, regardless of histology, immunotherapy-naive, after progression through one line of treatment with an appropriate chemotherapy regimen (platinum doublet, or after appropriate targeted therapies). Normal organ function, PS 0-1, no active autoimmune disease, no hemoptysis or cavitary tumor. Core biopsy specimen must be available.
84292|NCT03527095|Drug|FDL169|CFTR corrector
84293|NCT03527082|Other|Questionnaire|"Questionnaire of 20 items evaluating attitudes and perception of mesh use in gynaecological surgery. Questionnaire will take 10 minutes to complete. For non-English speaking patients a translator will be sought, where feasible to help women complete the questionnaire.~Participation will be entirely voluntary and also the questionnaire will be piloted to ensure that questions asked are clear and concise. Questionnaire is anonymised and does not contain patient identifying information thereby eliminating breach of confidentiality."
84294|NCT03527069|Drug|Cipros 10 association|oral, once a day.
84295|NCT03527069|Drug|Crestor 10 mg|oral, once a day.
84296|NCT03527056|Biological|Fecal Microbiota Transplantation|This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
84297|NCT03527043|Drug|Escitalopram|10mg by mouth daily for 6 weeks
84298|NCT03527043|Other|Placebo|matched placebo control by mouth for 6 weeks
84299|NCT03527030|Other|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
84300|NCT03527030|Other|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
84301|NCT03527017|Other|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Germany.
84302|NCT03527017|Other|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in adult IQOS users residing in Germany.
84303|NCT03527004|Other|Survey on Use of Tobacco Products in the General Population|Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of Italy.
84304|NCT03527004|Other|Survey on Use of Tobacco Products in IQOS Users|Online survey to describe patterns of use in IQOS users residing in Italy.
84305|NCT03526991|Device|Spinal Cord Stimulator (SCS)|"The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (4-16). Electrodes will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental."
84306|NCT03526978|Biological|Investigational sIPV|Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
84307|NCT03526978|Biological|Control IPV|Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
84308|NCT03526965|Other|Yoga Chikitsa|Intervention consisted of combination of static movements, yoga style exercise, yoga postures, breathing practices, relaxation and yoga counselling.
84309|NCT03526965|Drug|Usual care|Intervention included pain medications and exercise movements for neck.
84521|NCT03525379|Drug|Placebo|Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.
84310|NCT03526952|Other|Internet-Delivered Intervention for Sexual Re-Adjustment|Couples will meet with a therapist via video-conferencing for two 1.5-hr sessions. The therapist will facilitate couples' communication about their sexual and intimate relationship while providing psychoeducation about couple coping and sexuality after cancer and with an ostomy. Discussion will focus on current concerns, motivations for sex, relational strengths, and intimacy and sensual pleasure. Couples will also be encouraged to practice a sensate focusing exercise between sessions.
84311|NCT03526952|Other|Written Educational Material|Couples will receive written educational material for patients coping with changes in intimacy and sexuality when living with a permanent ostomy. This educational material is published by the United Ostomy Associations of America, Inc. and is available for free download from their website. Couples will have two weeks to read this material.
84312|NCT03526926|Drug|CPX-351|VYXEOS is administered as an intravenous (IV) infusion over approximately 90 minutes.
84313|NCT03526913|Procedure|PRP|PRP: autologous platelet-rich plasma
84314|NCT03526913|Procedure|STSG|skin graft: Split Thickness Skin Grafting (STSG)
84315|NCT03526900|Drug|Atezolizumab|"Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2."
84316|NCT03526887|Drug|Pembrolizumab|200 mg, Q3W
84317|NCT03526887|Drug|Pembrolizumab|200 mg, Q3W
84318|NCT03526874|Drug|Lidocaine 4% Topical Application Cream [LMX 4]|Run-in Step: All subjects receive 32 mg (4 cm ribbon of cream) applied, bilaterally, over greater occipital nerve.
84319|NCT03526874|Drug|Lidocaine Hydrochloride 2 mg/mL Injectable Solution|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the active treatment.
84320|NCT03526874|Drug|Normal Saline|Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
84321|NCT03526861|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the immunoglobulin G4 (IgG4) subclass that specifically binds to human interleukin (IL) 13 and blocks interaction with the IL-13 receptors.
84322|NCT03526861|Drug|Placebos|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
84323|NCT03526848|Drug|3BNC117|Intravenous infusion of 3BNC117
84324|NCT03526848|Drug|10-1074|Intravenous infusion of 3BNC117
84325|NCT03526848|Other|Analytical treatment interruption|Analytical treatment interruption
84326|NCT03526835|Drug|MCLA-158|full-length IgG1 bispecific antibody targeting EGFR and LGR5
84327|NCT03526822|Biological|Blood sample|Five blood sample in pre-, post-operative period, before radiotherapy, before adjuvant temozolomide and at relapse in newly diagnosed glioblastoma
84328|NCT03526822|Biological|Tumor sample|One tumor sample in operative period
84329|NCT03526809|Diagnostic Test|MRI scan and FDG-PET scan|Scanning with MRI and FDG-PET
84330|NCT03526796|Procedure|Hyperbaric oxygen therapy|Patients were maintained at 2.4 ATA with 100% oxygen for 90 min and then decompressed back to 1 ATA. The treatment duration is 4 weeks and extends to 6 weeks if necessary.
84331|NCT03526783|Procedure|Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
84332|NCT03526783|Procedure|Mini/One anastomosis gastric bypass|Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
84333|NCT03526770|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
84334|NCT03526770|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
84335|NCT03526770|Drug|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
84336|NCT03526770|Other|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
84337|NCT03526770|Other|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention."
84338|NCT03526770|Other|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
84339|NCT03526757|Other|Standing Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
84340|NCT03526757|Other|Standard Pilates protocol|Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
84341|NCT03526744|Dietary Supplement|marine protein hydrolysate 1234|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out."
84342|NCT03526744|Dietary Supplement|marine protein hydrolysate 2134|"Dietary Supplement for e.g. in this order: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out."
84343|NCT03526744|Dietary Supplement|marine protein hydrolysate 3124|"Dietary Supplement for e.g. in this order: MPH 2400 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out."
84344|NCT03526744|Dietary Supplement|marine protein hydrolysate 4123|"Dietary Supplement for e.g. in this order: MPH 1600 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 800 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 3200 mg for 7 days, than 7 days wash-out. Dietary Supplement: MPH 2400 mg for 7 days, than 7 days wash-out."
84345|NCT03526731|Other|ultrasound guided quadratus lumborum block|ultrasound guided quadratus lumborum block for post operative pain control after unilateral inguinal hernia repair.
84346|NCT03526705|Device|NB-UVB|Phototherapy
84347|NCT03526692|Behavioral|Neurofeedback|Neurofeedback experiment will consist of 30 sessions of neurofeedback training, twice or three times a week during maximum 4 months. The two experimental groups will undergo questionnaires, EEG recording and neuropsychological assessments in three-time points, pre-training (T0), post-training (T1) and 3 months follow-up (T2). Electroencephalography will be recorded by a technician in EEGFor each participant, EEG power spectrum will be calculated in pre (T0) and post neurofeedback training/psycho-pedagogical care at T2 and T3.
84348|NCT03526679|Drug|Eribulin|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
84349|NCT03526679|Drug|Lenvatinib|lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
84350|NCT03526666|Other|Peripheral blood collection|Peripheral blood collection for the measurement of ascorbic acid levels and banking of plasma and buffy coat for future resrearch.
84351|NCT03526653|Other|exercise without visual stimuli|exercise on an ergometer or motomed in an environment without other visual stimuli
84352|NCT03526653|Other|excercise with National Geografics|exercise on an ergometer or motomed while watching the National Geografics channel on television
84353|NCT03526653|Other|Exercise with MemoRide|excercise on an ergometer or motomed with the interactive software program MemoRide with which participants can exercise in real life on a virtual manner
84354|NCT03526640|Device|The BioSentry Tract Sealant System|The BioSentry Tract Sealant System consists of a delivery system and a coaxial adapter with Bio-Seal™ plug. The hydrogel plug is deployed in the tract created by the lung biopsy needle and self-expands upon contact with moist tissue.
84355|NCT03526601|Diagnostic Test|NT-proBNP, echocardiography|screening
84356|NCT03526588|Biological|Autologous umbilical cord blood|6×10^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
84357|NCT03526575|Drug|Zolpidem|
84358|NCT03526562|Behavioral|Exercise|Exercise according to dose escalation
84359|NCT03526549|Biological|EN3835|Collagenase Clostridium Histolyticum (CCH)
84360|NCT03526536|Drug|IV Novolin R human insulin|Novolin R human insulin, Novo Nordisk Inc. Plainsboro, NJ
84361|NCT03526523|Behavioral|Mindfulness-based stress reduction|8 weekly 2.5-hour group sessions of mindfulness based stress reduction, led by a certified MBSR instructor
84362|NCT03526510|Radiation|Conventionally Fractionated versus Hypofractionated Boost|
84363|NCT03526484|Behavioral|Standard of Care|The provider will review the urinalysis results prior to conducting the in-office procedure and will make clinical decisions taking into account those results.
84364|NCT03526484|Behavioral|Experimental|The provider will not review the urinalysis results prior to conducting the in-office procedure, and therefore will not make clinical decisions taking those results into account.
84365|NCT03526471|Device|Omega™ Left Atrial Appendage (LAA) Occluder|catheter delivery of Omega device in the left atrial appendage
84366|NCT03526458|Device|Holmium:YAG laser|Treatment of urolithiasis is commonly done using the holmium:YAG laser as this has been shown to be a safe and effective method of treating a wide variety of stones and is currently considered the standard of care (AUA Guideline Panel on the Surgical Management of Stones)
84367|NCT03526445|Drug|Glucagon|Glucagon (4 ng/kg/min)
84368|NCT03526445|Drug|Saline|Placebo
84369|NCT03526432|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
84370|NCT03526432|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.
84371|NCT03526419|Drug|Bupivacaine liposome|blood and milk samples will be obtained from those subjects after TAP block
84372|NCT03526406|Dietary Supplement|CP9700|400 mg CP9700 along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
84373|NCT03526406|Dietary Supplement|Matched Placebo|Maltodextrin along with modified cellulose (MCC), magnesioum strearate, slica (sillicon dioxide), Gelatin, FD&C Red No. 40, titanium dioxide, sodium lauryl sulfate, glycerin, brilliant blue FCF consumed with breakfast in a 1 capsule per day regimen.
84374|NCT03526393|Device|Survey training equipment|The survey was checking the equipment designed to assist the lifter training survey with greater precision, in aspects of average height of contact of the ball by striker and maximum perimeter of contact with the ball, for the execution of the attack.
84375|NCT03526393|Device|Attack and serve training equipment|The attack and serve training equipment was designed to assist the athlete in their body positioning for the execution of the fundamentals of the attack and serve, and the correct extension execution of the of trunk, upper limbs and reaction time of contact with the ball.
84376|NCT03526393|Device|Pass training equipment|The equipment for the training of the pass, it was designed to represent the serve forced and technical, variables height, circumference and average speed of the ball. This equipment has been adapted from the conventional volleyball serve equipment, respecting the limits of the sitting volleyball court.
84474|NCT03525678|Drug|GSK2857916 lyophilized|GSK2857916 will be available as frozen liquid or lyophilized powder. Lyophilized powder will be available as 100 mg/vial in single-use vial for reconstitution with unit dose strength of 2.5 or 3.4 mg/kg. GSK2857916 will be administered as IV solution over 30 minutes. Lyophilized GSK2857916 will reconstituted using water for injection.
84377|NCT03526380|Behavioral|Behavioral: the OPT-IN Intervention|A private one-on-one brief motivational interviewing intervention administered by non-research staff at community organizations. This will take up to 30 minutes to complete. The goal of the intervention is to improve opioid safety and reduce related overdoses among those who has a history of misusing opioids (prescription and illicit). The session will use techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This intervention will also seek to empower participants by providing content on bystander response as well as peer outreach, which emphasizes ways to discuss overdose risk with others at risk for overdose.
84378|NCT03526367|Drug|hydration plus rosuvastatin therapy|In experimental group,a loading dose of rosuvastatin 20mg then 10 mg daily followed for at least 7 days and hydration（3ml/kg/h）last 12 hours after randomized
84379|NCT03526367|Drug|Standard therapy|Prohibition of use any statins from randomized to 12 hours after procedure; The hydration or not is determined by physicians but 1 ml/kg/h at most.
84380|NCT03526354|Drug|Brexpiprazole|Brexpiprazole 4mg daily for 12 weeks
84381|NCT03526354|Other|Treatment as Usual|Current antipsychotic medication for 12 weeks
84382|NCT03526341|Device|ReliaTack™ Articulating Reloadable Fixation Device|ReliaTack™ Articulating Reloadable Fixation Device with Deep Purchase Tacks
84383|NCT03526328|Other|EMR and RFA effect on stem cell marker expression in BE/EAC|Observation of EMR and RFA on the expression of putative stem cell biomarkers and correlate them with serum/plasma protein expression and disease progression and/or recurrence (Barrett's esophagus/ esophageal adenocarcinoma)
84384|NCT03526315|Other|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
84385|NCT03526315|Other|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily.
84386|NCT03526315|Other|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after tooth brushing, twice daily.
84387|NCT03526289|Biological|GIP1-42 infusion|5-hour GIP1-42 infusion (time point 0-300 minutes)
84388|NCT03526289|Other|Saline|5-hour infusion of saline (placebo) (time point 0-300 minutes)
84389|NCT03526276|Other|CPP-ACP paste|Children will brush their teeth with CPP-ACP paste twice daily.
84390|NCT03526276|Other|Fluoride toothpaste|Children will brush their teeth with fluoridated toothpaste twice daily
84391|NCT03526276|Other|Both (Fluoride and CPP-ACP)|Children will brush their teeth with fluoridated toothpaste and apply CPP-ACP immediately after toothbrushing, twice daily.
84392|NCT03526263|Procedure|Gastric mucosal devitalization|During routine laparoscopic sleeve gastrectomy surgery, once the greater curvature of the stomach is excised as per normal surgical technique, the investigators will take the specimen out and perform an ablation ex-vivo, with the intention of performing selective mucosal devitalization. This specimen will then be transported to pathology lab for analysis.
84396|NCT03526237|Behavioral|24 week community based DPP Group Lifestyle Balance Program|a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
84397|NCT03526237|Behavioral|Wait-List Control community based DPP Group Lifestyle Balance Program|Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.
84398|NCT03526224|Drug|Dimethyl Fumarate|Individuals with MS treated with dimethyl fumarate (Tecfidera)
84399|NCT03526224|Drug|Teriflunomide|Individuals with MS treated with teriflunomide (Aubagio)
84400|NCT03526211|Device|FES cycling|On the patient, three pairs of electrodes will be applied on tibial hamstring, quadriceps and gluteal muscles of each lower limb. Cycloergometer will be installed in passive mode. Then, optimal stimulation intensity for each muscle will be defined. During twenty minutes, neuromuscular electrical stimulation will generate a passive pedaling on cycloergometer.
84401|NCT03526198|Device|Force plate|Device: force plate An equipment model with the approach of providing the evaluated person with the movement that is closest to the biomechanical and functional reality of the ankle and foot joint and which could equalize the possible changes of the center of mass would contribute to the clinical evaluation and would provide a more efficient therapeutic reasoning rehabilitation.
84402|NCT03526185|Drug|Tumor Infiltrating Lymphocytes|The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
84403|NCT03526185|Drug|Nivolumab and Ipilimumab|• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
84404|NCT03526172|Procedure|High tibial osteotomy|Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.
84405|NCT03526172|Device|Allograft wedge|Insertion of allograft wedge into the osteotomy gap during the HTO procedure
84406|NCT03526172|Device|Accelerometer|ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery
84407|NCT03526172|Other|Questionnaire|Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
84408|NCT03526159|Drug|Gentamicin Sulfate|Gentamicin (formulated as gentamicin sulfate) is a well-known, well-characterized antibiotic that has been used for four decades as a treatment against gram negative bacteria. It, like other aminoglycoside antibiotics, has the well documented added potential to facilitate readthrough of premature termination codons in eukaryotic cells and organisms.
84685|NCT03524066|Other|Bronchoscopy|Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy
84409|NCT03526146|Behavioral|Behavioral: Preventing Loss of Independence through Exercise (PLIE)|PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
84410|NCT03526133|Diagnostic Test|Polysomnography (PSG) and wireless sensor Oxistar|Monitoring the apnea-hypopnea index (AHI) derived from PSG and the oxygen desaturation index (ODI) obtained by the Oxistar.
84411|NCT03526120|Other|Pistachio|Dailly 44 g unsalted pistachios snack for 12 weeks
84412|NCT03526107|Other|CF Control|CF Control: 583 mg of cocoa flavanols, <1 mg caffeine and <1 mg theobromine
84413|NCT03526107|Other|CF-Theobromine|CF-Theobromine: 566 mg of cocoa flavanols, 11 mg caffeine and 93 mg theobromine
84414|NCT03526107|Other|CF-Caffeine|CF-Caffeine: 583 mg of cocoa flavanols, 112 mg caffeine and <1 mg theobromine
84415|NCT03526094|Other|Flavanols-capsules|Capsules containing 456 mg cocoa flavanols and 315 g of milk (1% fat)
84416|NCT03526094|Other|Flavanol-banana blend|Fruit blend prepared by mixing 177 g ripe, frozen bananas, 240 g almond milk and a chocolate flavored powder containing 626 mg cocoa flavanols
84417|NCT03526094|Other|Flavanol-high protein drink|Drink prepared by mixing 225 mL of a chocolate flavored high protein dairy drink with a CF powder containing 533 mg cocoa flavanols
84418|NCT03526094|Other|Flavanol-berry blend|Flavanol-berry blend prepared by mixing 120 g almond milk, 70 g water, 95 g yogurt, 50 g each strawberries, blueberries, blackberries, raspberries, 105 g crushed ice and a fruit-flavored powder containing 561 mg cocoa flavanols
84419|NCT03526094|Other|Flavanol-sports drink|Drink prepared by mixing 488 g of a sports drink with a CF powder containing 533 mg cocoa flavanols
84420|NCT03526094|Other|Flavanol-peanut butter toast|Prepared by mixing 32 g peanut butter with a chocolate flavored powder containing 602 mg cocoa flavanols and spread on 1 slice toasted bread (50 g) and 50 g sliced strawberries
84421|NCT03526094|Other|Flavanol-oats|Prepared by mixing 40 g quick oats with 237 g boiling water and combined with a chocolate flavored powder containing 602 mg cocoa flavanols
84422|NCT03526094|Other|Flavanol-yogurt|Prepared by 227 g yogurt (0% fat) mixed with a fruit-flavored powder containing 561 mg cocoa flavanols
84423|NCT03526094|Other|II- Flavanol drink|Drink prepared by mixing 240 g almond milk with a chocolate flavored powder containing 626 mg cocoa flavanols
84424|NCT03526094|Other|II- Flavanol drink + banana blend|Drink 1 (Flavanol drink): prepared by mixing 120 g almond milk with 626 mg cocoa flavanols Drink 2 (Fruit blend): prepared by mixing 120 g almond milk blended with 177 g ripe, frozen bananas
84425|NCT03526081|Other|Chamomile Tea|Chamomile Tea in 300mL hot water
84426|NCT03526081|Other|Parsley based drink|3.2 g dried parsley in 300mL hot water
84427|NCT03526081|Other|Parsley Yogurt|3.2 g dried parsley in 100g plain yogurt
84428|NCT03526081|Other|Apigenin|Apigenin capsule mixed with 300mL hot water
84429|NCT03526081|Other|Parsley-based drink (II)|3.2 g dried parsley in 300mL hot water
84430|NCT03526068|Device|SafeZoneUVC|SafeZoneUVC® uses a Krypton Chloride (Kr-Cl) excimer lamp as its light source. The Kr-Cl excimer lamp emits UVC light having a main wavelength of 222 nm when the Kr-Cl exciplex is deactivated to non-excited state molecule in the lamp. This 222 nm UVC light can inactivate bacteria, while the Kr-Cl excimer lamp also emits UVC light having a wavelength of 230 nm or more. SafeZoneUVC® effectively eliminates UVC light with a wavelength of 230 nm or more by incorporating an appropriate optical filter inside the unit and also utilizing an opaque guide to ensure that light is not dispersed beyond the target area.
84431|NCT03526055|Device|Algovita Spinal Cord Stimulation System|The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
84432|NCT03526042|Drug|Losartan|Competitive blockade of AT1R-antibodies effect by binding to the angiotensin 1 receptor
84433|NCT03526042|Drug|Enalapril|Renin-angiotensin-aldosterone system (RAAS) blockade without any effect on AT1R-antibodies effect or concentration (control group)
84434|NCT03526003|Diagnostic Test|Measurement of esophageal pressure|Measurement of esophageal pressure during posture changes and pneumoperotoneum
84435|NCT03525990|Other|Questionnaires|Quality of life questionnaires on iPads with CHES (Computer-based Health Evaluation System), paper-based questionnaire (EORTC QLQ-COMU26)
84436|NCT03525977|Procedure|Fascia iliaca block arm|The fascia iliaca block will be performed by the anesthesiologist on call
84437|NCT03525964|Procedure|Individualized treatment of Acute Achilles tendon rupture.|The most proximal border of the calcaneus and the most distal point of the musculotendinous junction of the Achilles tendon and the medial gastrocnemius muscle is identified and marked on the skin. These two points on the un-injured leg defines the original length of the total Achilles tendon and consist of the free tendon and the fascia [1]. The difference in length between the injure and the un-injured leg determines elongation for the ruptured Achilles tendon. The relative elongation of the ruptured tendon together with overlap of the tendon ends on the cross-sectional area determines the treatment for the patients receiving individualized treatment: 1) patients with 0-6% elongation of the tendon and a minimum of 25% tendon are treated non-operatively 2) patients with 7% elongation or more or less than 25% tendon overlap are treated operatively. The cut-off at 7% elongation is determined for 75% sensitivity and 65% specificity of elongation.
84438|NCT03525964|Procedure|Non-operative treatment|Circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
84439|NCT03525964|Procedure|Operative treatment|Open surgery with suture of the ruptured achilles tendon prior to circulated cast below the knee in maximal, unforced plantar flexion over the ankel.
84475|NCT03525678|Other|NEI-VFQ-25 Questionnaire|The NEI-VFQ-25 Questionnaire consists of a base set of 25 vision-targeted questions representing 11 vision-related constructs, plus an additional single-item general health rating question
84476|NCT03525678|Other|OSDI Questionnaire|The OSDI is a 12-item questionnaire designed to assess both the frequency of dry eye symptoms and their impact on vision-related functioning.
84786|NCT03523195|Other|Questionnaire Administration|Ancillary studies
84440|NCT03525951|Behavioral|Parent Early Language Stimulation Training|The intervention in this study is a brief parent training on the use of language stimulation strategies. This training will take place during the last session. Parent training will last approximately 15-20 minutes during which the researcher will provide examples of responsive utterances (e.g., modeling and expanding), using constructive directives, and scaffolding. Each parent will be presented with the same examples. The parent will also receive individualized feedback based on their own use of these language stimulation strategies. This feedback will take the form of one thing that the parent is already doing well and one new thing to try accompanying each strategy based on what the researcher observed during the baseline interaction task.
84441|NCT03525938|Procedure|TAP block|Whilst the patient is in the supine position, a high frequency ultrasound probe (10 MH) is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Upon reaching the plane, 2 ml of saline is injected to confirm correct needle position after which 20 ml of levobupivacaine, 25% plus triamcinolone, 80 mg solution is injected for TAP group and 20 ml of saline only is injected for SHAM group.. The transversus abdominis plane is visualized expanding with the injection ( appears as a hypoechoic space)
84442|NCT03525925|Drug|Ibrutinib|Given PO
84443|NCT03525925|Other|Laboratory Biomarker Analysis|Correlative studies
84444|NCT03525925|Biological|Nivolumab|Given IV
84445|NCT03525912|Drug|Ketamine|continuous infusion of low dose ketamine for postoperative pain
84446|NCT03525899|Procedure|Pars plana vitrectomy|Pars plana vitrectomy combined with Internal limiting membrane peeling, inverted internal limiting membrane flap insertion into the macular hole, or lens anterior or posterior capsular flap insertion into the macular hole
84447|NCT03525886|Drug|NBI-74788|Capsule, administered daily.
84448|NCT03525873|Other|Laboratory Biomarker Analysis|Correlative studies
84449|NCT03525873|Drug|Methylphenidate|Given PO
84450|NCT03525873|Other|Physical Activity|Participate in physical activity
84451|NCT03525873|Other|Placebo|Given PO
84452|NCT03525873|Other|Quality-of-Life Assessment|Ancillary studies
84453|NCT03525873|Other|Questionnaire Administration|Ancillary studies
84454|NCT03525860|Procedure|Acupuncture|"The subject is placed in the selected position (lying down or sitting), based on their comfort level. The areas to be needled are prepped with an alcohol swab. Mandatory standards and safety guidelines for acupuncture will be followed.~The acupuncture treatment protocol will be based on Traditional Chinese Medicine (TCM) theory. The TCM treatment strategy is designed to Benefit the Heart, Tonify Heart Qi and Blood, Calm and Sedate Cardiac Excitability and Regulate the Qi. Current literature supports the use of selected acupuncture points as possibly beneficial in regulating the autonomic nervous system, modulating Heart Rate Variability (HRV), relieving chest pain, and reducing arrhythmias.~11 sterile, single use, disposable needles will be placed one by one until all needles are in place.~Needles remain in place for additional 20 minutes or so as the patient remains in the selected position~."
84455|NCT03525847|Diagnostic Test|Endosonography|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control. Passage in the same pancreatic mass of first using standard FNA method then contrast enhanced FNA method or vice versa according to the randomization
84456|NCT03525834|Drug|everolimus|Everolimus 10 mg oral tablets per day
84457|NCT03525821|Drug|Ketamine Hydrochloride|intranasal use of ketamine 1mg/kg with nitrous oxide
84458|NCT03525808|Device|AXIOS|Patient will receive either transgastric or transduodenal endoscopic drainage for walled-off necrosis that are adherent to the gastric or bowel wall.
84459|NCT03525795|Drug|CPI-1205|Administered orally
84460|NCT03525795|Drug|ipilimumab|Administered intravenously
84461|NCT03525782|Biological|CAR-T Cells|Using the T cells from the patients to produce anti-MUC1 CAR-T Cells and then the cells will be infused back to the patients.
84462|NCT03525782|Combination Product|CAR-T combining PD-1 Knockout|Using the T cells from the patients to prepare anti-MUC1 CAR-T Cells and PD-1 knockout T cells, then the cells will be infused back to the patients
84463|NCT03525782|Biological|PD-1 knockout|Using the T cells from the patients to prepare PD-1 knockout T cells, then the cells will be infused back to the patients
84464|NCT03525782|Drug|PD-1 mAb|Patients will be treated with an identical course with a FDA approved monoclonal antibody against PD-1
84465|NCT03525782|Other|Sham control|Patient's T cell will treated ex vivo with modification and then infused back in a similar time course.
84466|NCT03525769|Diagnostic Test|FibroTouch|"FibroTouch is a non-invasive image-guided integrated detection system, providing an integrated detection and comprehensive evaluation program for hepatic fibrosis and hepatic steatosis.~The FibroTouch is a completely non-invasive liver testing device that can obtain the following results: 1. Liver Fibrosis: quantitative results of hepatic fibrosis; 2. Fatness: quantitative result of hepatic steatosis; 3. Liver tissue morphology: detected by ultrasound imaging."
84467|NCT03525743|Device|NICOM (Non invasive cardiac output monitor)|Non invasive hemodynamic device utilizing bioreactance
84468|NCT03525730|Drug|Valproic Acid|Valproic acid (enteric) 30mg/kg, divided over 2 doses per day, orally on day 1-14.
84469|NCT03525730|Drug|Pyrimethamine|Pyrimethamine 200mg once daily (QD) orally on day 1 and 100mg on day 2-14.
84470|NCT03525717|Dietary Supplement|Routine Dinner|Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
84471|NCT03525717|Dietary Supplement|Late dinner|Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
84472|NCT03525691|Device|Low flow Extracorporeal CO2 removal|Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
84473|NCT03525678|Drug|GSK2857916 frozen|GSK2857916 will be available as frozen liquid or lyophilized powder. Frozen liquid will be available as 30 mg/vial solution in a single use vial with unit dose strength of 2.5 or 3.4 mg/kg. GSK2857916 will be administered as IV solution over 30 minutes. Frozen GSK2857916 will be diluted 0.9 percent saline and administered via infusion pump.
84787|NCT03523195|Other|Physical Performance Testing|Performance of physical tests
84477|NCT03525678|Other|EORTC QLQ-C30 Questionnaire|The EORTC QLQ-C30 is a 30-item questionnaire containing both single and multi-item measures. These include five functional scales (Physical, Role, Cognitive, Emotional, and Social Functioning), three symptom scales (Fatigue, Pain, and Nausea/Vomiting), a Global Health Status/ QoL scale, and six single items (Constipation, Diarrhea, Insomnia, Dyspnea, Appetite Loss, and Financial Difficulties). The scores ranges from 0-100.
84478|NCT03525678|Other|EORTC QLQ-MY20 Questionnaire|EORTC QLQ-MY20 is a supplement to the QLQ-C30. The module comprises 20 questions that address four myeloma-specific HRQoL domains: Disease Symptoms, Side Effects of Treatment, Future Perspective, and Body Image.
84479|NCT03525665|Other|Metabolic activity measured by FDG-PET|To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.
84480|NCT03525652|Biological|Therapeutic vaccine|The therapeutic vaccine will be custom prepared ex vivo using the peripheral mononuclear cells from the patient and the vaccine which presented as maturated dendritic cells will be infused back to the patients in 3 times.
84481|NCT03525652|Biological|PD-1 Knockout T Cells|PD-1 knockout T cells will be custom prepared ex vivo using the white blood cells from the patient and the maturated PD-1 knockout T cells will be infused back to the patients in 3 times.
84482|NCT03525639|Diagnostic Test|Cardiac Magnetic Resonance|Additional CMR study 2 month after the initial diagnosis of acute myocarditis to assess myocardial inflammation persistence (2-month-CMR).
84483|NCT03525626|Behavioral|Online Mindfulness-based Tic Reduction|8-week online group mindfulness-based intervention for tics
84484|NCT03525613|Drug|APL-2|Complement (C3) Inhibitor
84485|NCT03525613|Drug|APL-2|Complement (C3) Inhibitor
84486|NCT03525613|Other|Sham Procedure|Subjects will receive a Sham procedure every month
84487|NCT03525613|Other|Sham Procedure|Subjects will receive a Sham procedure every other month
84488|NCT03525600|Drug|APL-2|Complement (C3) Inhibitor
84489|NCT03525600|Drug|APL-2|Complement (C3) Inhibitor
84490|NCT03525600|Other|Sham Procedure|Subjects will receive a Sham procedure every month
84491|NCT03525600|Other|Sham Procedure|Subjects will receive a Sham procedure every other month
84492|NCT03525587|Other|"Use of MAGHD App/MAGHD Framework"|Patients daily related outcomes will be recorded thanks to the development, implementation and validation of a Smartphone app (MAGHD App) integrated with a software framework able to merge patient's daily activities data on well-being status, QoL, physical activities and sexual function with clinical data collected in their record chart (extrapolated from already available Institutional Databases).
84493|NCT03525574|Drug|VX-445|Fixed-dose combination (FDC) tablets (VX-445/TEZ/IVA)
84494|NCT03525574|Drug|TEZ|FDC tablets (VX-445/TEZ/IVA)
84495|NCT03525574|Drug|IVA|FDC tablets (VX-445/TEZ/IVA)
84496|NCT03525574|Drug|IVA|IVA tablet
84497|NCT03525561|Drug|Acetazolamide Pill|Subjects will take acetazolamide pill (Diamox), 500 mg/ day, and assess effect on exercise performance during 30-hour exposure to 3,500 m simulated altitude.
84498|NCT03525561|Drug|Placebo pill|Subjects will take placebo pill and then we will assess exercise performance during 30-hour exposure to 3,500 m simulated altitude.
84499|NCT03525548|Drug|VX-445|Fixed-dose combination (FDC) tablet (VX-445/TEZ/IVA)
84500|NCT03525548|Drug|TEZ|FDC tablet (VX-445/TEZ/IVA)
84501|NCT03525548|Drug|IVA|FDC tablet (VX-445/TEZ/IVA)
84502|NCT03525548|Drug|TEZ/IVA|FDC tablet TEZ/IVA
84503|NCT03525535|Other|data collection|data from patient included will be collected during the study
84504|NCT03525522|Device|Nd:YAG Laser|Three sessions of Nd:YAG treatment every two weeks.
84505|NCT03525522|Drug|Topical corticosteroid Diprosone|3 months of topical corticosteroids Diprosone
84506|NCT03525509|Drug|Methadone hydrochloride|Epidural bolus of 4mg of preservative free methadone hydrochloride (4mL of 1mg/mL solution)
84507|NCT03525509|Drug|Morphine Sulfate|Epidural bolus of 4mg of preservative free morphine sulfate (4mL of 1mg/mL solution)
84508|NCT03525483|Diagnostic Test|Ultrasound for renal resistivity index measurement|"Collection of urine over 3 hours for creatinine clearance measurement, with serum creatinine in parallel with urine collection to calculate measured creatinine clearance and estimate glomerular filtration rate Evaluation of the renal vascular resistance index in Doppler ultrasound by a resuscitator trained in the technique at the time of inclusion.~Collection of demographic, clinical and biological data for inclusion of the patient such as weight, age, sex, arterial lactatemia, arterial pH, volume status, use of diuretics, use of vasopressors, use of nephrotoxic drugs ..."
84509|NCT03525470|Biological|Water|150 mil of water was drunk on two occasions
84510|NCT03525470|Other|No drink|Although body weight lost no drink consumed
84511|NCT03525457|Procedure|Non Surgical Periodontal Therapy|Non Surgical Periodontal Therapy in 2 to 3 sessions
84512|NCT03525444|Drug|VX-445|Fixed dose combination (FDC) tablet (VX-445/TEZ/IVA)
84513|NCT03525444|Drug|TEZ|FDC tablet (VX-445/TEZ/IVA)
84514|NCT03525444|Drug|IVA|FDC tablet (VX-445/TEZ/IVA)
84515|NCT03525444|Drug|Matched Placebos|Placebo will be used as a comparator.
84516|NCT03525431|Diagnostic Test|Whole Exome Sequencing|Whole Exome Sequencing is a form of Next Generation Sequencing allowing investigators to assess the coding regions of many thousands of genes to find variants implicated in disease.
84517|NCT03525418|Biological|Longeveron Mesenchymal Stem Cells|Allogeneic bone marrow-derived mesenchymal stem cell
84518|NCT03525405|Drug|napabucasin|Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.
84519|NCT03525392|Drug|177Lu-3BP-227 (also called 177Lu-IPN01087)|The cumulative activity of the treatment investigational medicinal product (IMP) formulation will be administered in two intravenous (i.v.) infusions separated by at least 4 weeks (28 days). Up to 6 administrations can be given (2 cycles plus 4 optional additional)
84520|NCT03525379|Drug|Resveratrol|"Subject participation will be approximately 10 weeks in duration. Participants will be randomized to receive one treatment: either resveratrol for 8 weeks OR placebo for 8 weeks. There will be a 2-week run-in period prior to the treatment period.~The schedule for the study is:~Week 0 Screening and randomization Weeks 1-2 Run-in; no treatment Weeks 3-10 Treatment Phase (resveratrol or placebo)"
84522|NCT03525366|Other|Radiofrequency ablation|Radiofrequency Ablation (RFA) as an intervention is part of standard of care at Memorial Herman Hospital, Houston.
84523|NCT03525353|Other|Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care|No intervention has been used and this is an observational study
84524|NCT03525340|Behavioral|Peer Navigation|Peer navigators help participants identify barriers that pose challenges to the participant's engagement in care and adherence and help develop an overall action plan for addressing these barriers by identifying specific changes that can be made/attempted to overcome an identified barrier. This may involve accompanying a participant to their social services/health appointments, or assisting a participant with disclosure of her HIV status to a family member or friend. The overall goal is to develop knowledge of social/HIV-related health services and good problem-solving skills in order to tackle multiple, potentially overlapping barriers. Over time, participants are encouraged to take increasing degrees of responsibility for identifying and implementing their own problem-solving strategies.
84525|NCT03525327|Other|Line Dance Class|"Line or party dances to be taught will include:~Electric Slide (Mainland USA)Hukilau (Hawaii)Cupid Shuffle (Mainland USA)Poco Poco (Philippines)Cha Cha Slide (Mainland USA)Tush Push (Mainland USA)Trojan Crawl (Mainland USA)Wobble (Mainland USA)Goyang Maumere (Indonesia)"
84526|NCT03525301|Radiation|standard treatment|3000 cGy in 10 daily fractions
84527|NCT03525301|Radiation|short course treatment|1800 cGy in 4 fractions administered twice a day
84528|NCT03525288|Radiation|PSMA -PET/CT simulation|"PET/CT simulation.~If no additional lesions detected: RT as planned per standard care.~If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~If PSMA-PET/CT imaging consistent with widely metastatic disease (>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged."
84529|NCT03525288|Radiation|Standard-care simulation|No PSMA-PET/CT as part of RT treatment planning.
84530|NCT03525275|Device|Battlefield Acupuncture|Battlefield Acupuncture uses ASP semi-permanent needles inserted into their ears for pain attenuation in 5 known points. Both groups receive their respective post-surgical rehabilitation protocols
84531|NCT03525275|Procedure|Post-surgical shoulder protocol|Surgery specific post-surgical physical therapy protocol
84532|NCT03525262|Radiation|30Gy (Gray) planning target volume (PTV)|PTV1_30Gy represents a 3mm expansion on the prostate (and proximal seminal vesicle per physician discretion), excluding the neurovascular structures on the side to be spared (left or right). PTV1 will receive 6 Gy per fraction for 5 fractions (30 Gy).
84533|NCT03525249|Dietary Supplement|nutraceutical|Subjects will consume a capsule for eight weeks
84534|NCT03525236|Other|Tasting of flavours|"Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes"
84535|NCT03525223|Procedure|Change of dialysate [Na+]|Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week
84536|NCT03525210|Biological|9-valent HPV vaccine|Vaccination
84537|NCT03525197|Dietary Supplement|Whey protein-based supplement|High quality protein supplement to be consumed twice daily
84538|NCT03525197|Dietary Supplement|Collagen protein-based supplement|Lower quality protein supplement to be consumed daily
84539|NCT03525184|Other|Additional protein and multi-nutrient beverage|During SR+, participants will consume a multi-nutrient beverage and additional protein (~1.5 grams·kg-1 body weight·day-1 versus the lower end of MDRI of ~0.9 grams·kg-1 body weight·day-1) during and after the period of sleep restriction. The multi-nutrient beverage contains arginine, glutamine, vits C & D, zinc and omega-3 fatty acids (DHA and EPA).
84540|NCT03525184|Other|Placebo beverage|The placebo beverage (NS and SR) will be composed of a commercially-available artificially sweetened (e.g., containing aspartame, splenda or another artificial sweetener) beverage powder base and grapefruit extract (i.e., naringen) and/or quinine (i.e., a common ingredient found in tonic water).
84541|NCT03525171|Diagnostic Test|euglycemic hyperinsulinemic clamp|In addition to auxological and baseline biochemical parameters, we performed the clamp to evaluate insulin sensitivity (M-value) at baseline (GHD group and controls) and after 12 months of GH treatment (GHD group).
84542|NCT03525158|Behavioral|Brief cognitive intervention|A one-session intervention with a researcher including a simple cognitive task (a memory cue, 10 minutes time gap and ca. 20 minutes of Tetris game play) with instructions to engage in the task self-guided in the subsequent week.
84543|NCT03525132|Procedure|Laser Doppler Velocimetry + Optic Adaptative Camera|Fluxometry measure while subject is sitting in front of the optic adaptative camera
84544|NCT03525119|Biological|TDV|TDV SC injection
84545|NCT03525119|Biological|Placebo|Normal Saline (0.9% NaCl) IM injection
84546|NCT03525119|Biological|HAV Vaccine|HAV Vaccine IM injection
84547|NCT03525119|Biological|Placebo|Normal Saline (0.9% NaCl) SC injection
84548|NCT03525106|Behavioral|Booklet|Receive positive psychology manual
84549|NCT03525106|Behavioral|Exercise Intervention|Complete positive psychology exercises
84550|NCT03525106|Other|Quality-of-Life Assessment|Ancillary studies
84551|NCT03525106|Other|Survey Administration|Ancillary studies
84552|NCT03525106|Behavioral|Telephone-Based Intervention|Participate in phone sessions
84553|NCT03525093|Behavioral|Hypnosis|"5 session of group hypnosis, each 90 minutes, to reduce subjective levels of stress, improve coping with stress. Additional audiotapes of hypnosis sessions as homework.~Participants receive a health education booklet on improving coping with stress."
84554|NCT03525093|Behavioral|Health education|Participants receive a health education booklet on improving coping with stress.
84555|NCT03525080|Diagnostic Test|PET imagery|Every patients will have a PET imagery in addition to standard MRI
84556|NCT03525067|Other|Bile sampling for bacterial examination|At the beginning of pancreaticoduodenectomy, patients had bile sampling from the gallbladder or from the common bile duct for bacterial examination and study of susceptibility to antibiotics.
84557|NCT03525041|Procedure|CABG|CABG will be performed using standard surgical techniques. All procedures will be performed with cardiopulmonary bypass(CPB). Saphenous vein(SV)will be used as conduit but harvesting methods will not be prescribed, and utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, judging by the surgical investigator.
84558|NCT03525041|Procedure|mitral valve annuloplasty|Surgical techniques for mitral valve annuloplasty may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation.
84559|NCT03525028|Drug|Metformin|The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
84560|NCT03525028|Drug|Placebo|The investigators use placebo in the control group.
84561|NCT03525015|Other|A decision aid booklet about cataract surgery choice|Potential participants receive a decision aid booklet with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
84562|NCT03525015|Other|An usual booklet about cataract and cataract surgery|Potential participants receive an usual booklet with information about cataract and cataract surgery, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks and 1 year.
84563|NCT03525002|Drug|Bromocriptine|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
84564|NCT03525002|Other|Placebo|In each FTO genotype group participants will be randomly receive bromocriptine or placebo.
84565|NCT03524989|Device|Hyperbaric Oxygen Therapy|40 daily sessions, 60 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 2 months.
84566|NCT03524989|Device|SHAM treatment|40 daily sessions, 60 minutes of 21% oxygen at pressure of 1.01 ATA each, five days a week for 2 months.
84567|NCT03524976|Device|Squid|"SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter."
84568|NCT03524963|Drug|Cilostan CR Tab.|Cilostan CR Tab. 200mg once a day for 5 days
84569|NCT03524963|Drug|Pletaal SR Cap.|Pletaal SR Cap. 200mg once a day for 5 days
84570|NCT03524950|Drug|Dexmedetomidine|Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
84571|NCT03524937|Drug|MELATONIN (HIGH DOSE)|Enteral melatonin (3mg) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
84572|NCT03524937|Drug|MELATONIN (LOW DOSE)|Enteral melatonin (0.3mg ) will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days
84573|NCT03524937|Drug|PLACEBO|Study drug will be given at 21:00h daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days.
84574|NCT03524911|Behavioral|CHFFF nutrition education|
84575|NCT03524898|Drug|Nab-Paclitaxel|150 mg/m2 / 125 mg/m2
84576|NCT03524898|Drug|gemcitabine|1000 mg/m2
84577|NCT03524885|Procedure|Short implant placement|"Ten patients will be randomly selected for the short implants option, 2 or 3 implant 4-5 mm length and 4 mm diameter (Syra Short, Sweden & Martina, Padua, Italy) will be positioned. The healing cap will be immediately connected and a vycril suture will be done after soft tissue reflection.~After three months an acrylic screw-retained bridge will be delivered. After further three months, a definitive restauration with a metal ceramic bridge will be seated."
84578|NCT03524885|Procedure|Bone regeneration with longer implants|"Ten patients will be randomly assigned to the regenerative group, 2 or 3 implant from 10 to 13 mm length intentionally exposed putting the implant platform 2 or 3 mm apical to CEJ of the adjacent tooth will be inserted.~A horizontal and vertical regeneration following GBR technique will be performed using not-resorbable PTFE titanium reinforced membrane (Cytoplast Osteogenics, US) fixed by titanium pins or miniscrews to ensure the perfect stability (Pro-fix, Cytoplast Osteogenics, US)."
84579|NCT03524872|Device|Original CAD/CAM prosthetic abutment|Original (Sweden&Martina) CAD/CAM abutments will be screwed to the implants at 32N/cm.
84580|NCT03524872|Device|Compatible CAD/CAM abutment|Compatible (New Ancorvis) CAD/CAM abutments will be screwed to the implants at 32N/cm.
84581|NCT03524872|Procedure|Local anesthesia|Infiltration of 4% articaine with 1:100,000 adrenalin (Inibsa).
84582|NCT03524872|Drug|Painkillers|Patients will be prescribed ibuprofen 600 mg three times per day for five days
84583|NCT03524872|Drug|Mouthwashes|Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
84584|NCT03524872|Device|Implant placement|Dental implants (Sweden & Martina, Padua, Italy) will be placed at crestal level and according to the manufacturer's instructions.
84585|NCT03524846|Drug|Ascorbic Acid 300 MG|Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
84586|NCT03524846|Drug|Ascorbic Acid 600 MG|Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
84587|NCT03524846|Drug|Normal saline|Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
84588|NCT03524833|Drug|Metronidazole|Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
84589|NCT03524833|Drug|Lansoprazole, Amoxicillin, Metronidazole|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
84590|NCT03524820|Drug|Cetuximab|Administration of drug
84818|NCT03522896|Other|test meal 2|orange juice plus hesperidin higher dose
84819|NCT03522896|Other|test meal 3|diluted orange juice plus hesperidin low dose
84591|NCT03524807|Device|Electrophysiologic therapy|Pelvic floor electrophysiological therapy is used after common gynecologic surgery to record anal exhaust time and micturition time after surgery and endometrium recovery of intrauterine adhesions.For intrauterine adhesions patients, Drug: Aspirin(low dose of Aspirin after operation)Device: intrauterine balloon (insert intrauterine balloon after operation)
84592|NCT03524768|Diagnostic Test|skin laser speckle contrast imaging and video-capillaroscopy|Evaluation of endothelial-dependent microvascular reactivity and capillary recruitment
84593|NCT03524755|Other|Exercise|
84594|NCT03524742|Other|Avocado-Mediterranean Diet|Mediterranean diet including 1/2 portion of Hass avocado per day, considering a minimum 35% of calories as fat (22% MUFA fat, 6% PUFA fat, and ±10% saturated fat), 15% proteins, and a maximum of 50% carbohydrates.
84595|NCT03524742|Other|Control-Group Diet|A low fat-high complex carbohydrate diet, during 3 months.
84596|NCT03524729|Device|Rocker bottom shoe|Walking shoe with a anterior posterior rocker sole.
84597|NCT03524729|Device|Ankle foot orthosis|Dynamic carbon fiber ankle brace.
84598|NCT03524729|Device|Standard walking shoe|Standard walking shoe (control shoe) with no rocker sole.
84599|NCT03524716|Behavioral|Fitbit and Text Messages|Physical activity tracker wristband and daily text messages delivered to the participants' phones.
84600|NCT03524703|Other|chewing gum|Chewing gum four times per day for 5 days, 15 minutes each time.
84601|NCT03524690|Dietary Supplement|Energy Balance|Energy Balance Sufficient food provided to maintain energy balance.
84602|NCT03524690|Dietary Supplement|Negative Energy Balance|Negative Energy Balance Insufficient food provided to maintain energy balance resulting in negative energy balance.
84603|NCT03524677|Diagnostic Test|Liquid Biopsy|K-RAS, CDKN2A, SMAD4 and TP53 mutation on circulating cfDNA
84604|NCT03524664|Behavioral|Tuning In to kids intervention|"The Tuning Into Kids Program involves:~Meeting in a small group with other caregivers raising children with FASD.~8-week program that meets weekly for 2 hours at Mt. Hope Family Center or other community location.~Learn and practice an approach of responding to children's emotions and behavior."
84605|NCT03524651|Drug|Ferrous Sulfate|Blisters of 10 capsules containing 150 mg of ferrous sulfate.
84606|NCT03524651|Drug|Fe-ASP|Boxes of 10 vials of 15 ml containing 800 mg of Iron protein acetyl aspartate.
84607|NCT03524651|Drug|Ferrous Sulfate|Boxes of 10 vials of 15 ml containing inactive ingredients of Omalin.
84608|NCT03524651|Drug|Fe-ASP|Blisters of 10 capsules containing inactive ingredients of Microfer.
84609|NCT03524638|Other|Visbiome|Colorectal surgery plus administration of Visbiome on post-operative day 2.
84610|NCT03524638|Procedure|Colorectal Surgery|Colorectal surgery alone
84611|NCT03524612|Drug|eltrombopag|eltrombopag is for oral use and comes in 12.5, 25, 50 and 75 mg tablets; prescribed dose is taken once daily
84612|NCT03524599|Other|Intervention municipality|In intervention municipalities, primary health care centres and the providers working within them will receive training and a range of community support mechanisms.
84613|NCT03524586|Procedure|Ipsilateral rotation of head|Ipsilateral rotation of head against fixed tube
84614|NCT03524586|Procedure|Contralateral rotation of head|Contralateral rotation of head against fixed tube
84615|NCT03524573|Procedure|Appendectomy|Appendectomy is the surgical removal of the appendix.
84616|NCT03524560|Other|Comprehensive geriatric assesment|Comprehensive Geriatric Assesment (CGA) consisting of detailed history and examination, drug consumption information, Body Mass Index (BMI), Waist Circumference (WC), Timed Up & Go test (TUG), Clock Drawing Test (CD), Activities of Daily Living and Instrumental Activities of Daily Living scales (ADL & IADL), Mini Mental State Examination (MMSE), Tinetti Gait and Tinetti Balance scores (TG &TB), 30 items Geriatric Depression Scale (GDS) was performed for each subject
84617|NCT03524547|Device|J shaped stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be molded into a J-shape.
84618|NCT03524547|Device|60-degrees stylet used for endotracheal intubation|After inserting a stylet into the endotracheal tube, the tube will be bent 60-degrees.
84619|NCT03524534|Other|Telephone Call|A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.
84620|NCT03524534|Other|In-Person Primary Care Clinical Follow-Up Visit|This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
84621|NCT03524521|Behavioral|Interval Training|Interval training is prescribed 3 days per week using 5 body weight exercises in a progressive fashion.
84622|NCT03524521|Behavioral|Standard of Care|Walking prescribed to meet current exercise guidelines; 150 minutes per week.
84623|NCT03524508|Drug|Onivyde|The recommended dose and regimen of Onivyde is 70 mg/m2 intravenously over 90 minutes, followed by leucovorin (LV) 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks.
84624|NCT03524508|Drug|5-FU/LV|The recommended dose and regimen of leucovorin (LV) 400 mg/m2 intravenously over 30 minutes, followed by 5-FU 2400 mg/m2 intravenously over 46 hours, administered every 2 weeks
84625|NCT03524482|Behavioral|SmokeFreeText|"SmokefreeTXT is a 6-8 week fully automated text-based cessation intervention. The program is free to U.S. subscribers who have a mobile phone, and is available on smokefree.gov or by texting QUIT to short code 47848. Participants are encouraged to set a quit date within the next 14 days, followed by count-down messages leading to the quit date. Starting on the quit date, participants receive 6 weeks of intervention text messages, and assessment questions (mood, cravings, smoking status). The message library contains 166 messages and 41 behavior change techniques,40 which are delivered at the greatest frequency during the first 2 weeks and taper over time. When in need of assistance, participants can text one of 3 keywords (MOOD, CRAVE, or SLIP) to receive a relevant message from the system. Participants can opt-out by texting STOP at any time. With informed consent, we will be able to access the SmokefreeTXT data for these participants."
84647|NCT03524300|Procedure|Robotic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted total gastrectomy will be performed in the experimental group.
84820|NCT03522883|Dietary Supplement|carbohydrate intake prior to exercise|Participants will be submitted to carbohydrate supplementation prior to exercise
84626|NCT03524482|Behavioral|Path2Quit|Path2Quit will deliver 20-60 second video clips by multimedia messaging service. The message library will include 75-170 messages. Written text messages will be limited to brief phrases to indicate the topic of the video. Messages will be pushed to participants in the morning, in the afternoon, and 2 hours before the reported usual bedtime. The cultural adaptations will be infused throughout the video segments. Topics include deep structure: race and smoking in general, African American smoking statistics; norms for smoking; concerns about nicotine replacement/medication; family/collectivism; unique stressors; racism/discrimination, depression; co-morbid addiction; neighborhood/environmental influences; menthol cigarettes; race-specific weight issues and concerns; and working as a community against the tobacco industry.
84627|NCT03524456|Other|Home blood pressure monitoring|Participants would use a blood pressure device at home, that sends the readings automatically to the health center via SMS. The physicians would use this tool for medication management or rescheduling visits.
84628|NCT03524443|Behavioral|Art Therapy treatment|"The main objective is to describe the evolution at 3 months on the alexithymic dimension in the course of a treatment in art therapy, in patients with anorexia nervosa or bulimia.~Art therapy is a generic term grouping different artistic disciplines adapted and used for therapeutic purposes. It is through commitment to creative work that the therapeutic work of elaboration and reflection takes place in contrast to verbal psychotherapies and mediated psychotherapies that use speech as the main therapeutic tool. All forms of practice referring to categories of art can be used: painting, music, modeling, dance, theater and writing"
84629|NCT03524430|Procedure|Core needle biopsy|1st core needle biopsy for RDA 2 specimens: Time Point: ~2-3 weeks after initiation of 1st cycle of chemotherapy; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin. 2nd core needle biopsy for RDA: Time Point: if therapy is changed (as part of SoC), a second biopsy ~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin.
84630|NCT03524417|Biological|Equine rabies immunoglobulin injection on day 7|The patients with WHO category III rabies exposure, who have received first dose of rabies vaccination a week before and have not received rabies immunoglobulin were enrolled. Blood for Rabies neutralizing antibody titers (RNab) would be examined on day 0. On the same day, Equine rabies immunoglobulin (ERIG) at the dosage of 40 IU/kg would be injected into and around the wound as much as possible and the rest would be injected intramuscularly at the site distance from rabies vaccine. Then blood for RNab would be serially examined on day 7, 14, 90, 365.
84632|NCT03524391|Behavioral|Counselling based on yoga|Counseling sessions were given as one-on-one and group to patients based on yoga philosophy and therapy.
84633|NCT03524391|Drug|Chemotherapy|Usual Care group had standard chemotherapy regimens
84634|NCT03524378|Behavioral|Ergonomic and movement modifications|Introduction of basic ergonomic and self-management principles, participants will review video clips of the prioritized and revised solutions. Adjustments in work tasks, movement strategies or self-management techniques will be self selected by workers after an educational session using videotapes of work processes.
84635|NCT03524365|Procedure|RYGB|Roux-&-Y Gastric Bypass (RYGB) involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume of 30 ml. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz's ligament , through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy. Lifestyle modification counselling is provided to each patient.
84636|NCT03524365|Procedure|SG|The SG is created using a linear stapler with two sequential 4.8/60-mm green load firings for the antrum, followed by two or three sequential 3.5/60-mm blue loads for the remaining gastric corpus and fundus. The stapler is applied alongside a 48-Fr calibrating bougie. The resection line is performed avoiding the ''critical area'' by resecting the fundus 1.5 cm from the angle of His. Staple lines are buttressed with bovine pericardial strips. The resected stomach is grasped at the antral tip by a laparoscopic grasper and retrieved through one of the trocar sites. A methylene blue dye test by a nasogastric tube is routinely performed at the end of the procedure. The residual gastric remnant capacity is 60-80 ml. Drains are not routinely placed, and the nasogastric tube is removed at the end of the procedure. Upper gastrointestinal contrast (Gastrografin) study is performed on the first postoperative day. Lifestyle modification counselling is provided to each patient.
84637|NCT03524365|Other|Intensive Lifestyle Modification|"Resting calorie requirements will be calculated via the Harris Benedict equation (24) and an activity factor, and subjects will be instructed not to change their activity level other than that suggested by physicians during the study. The diet will contain 1/3 kcal less than the calculated energy expenditure and 30% fat of which 10% saturated, 55% lower glycemic index carbohydrates and 15% proteins.~The participants will be encouraged to gradually increase their walking to achieve 10,000 steps per day. A moderate intensity physical activity program of 1 hour of aerobic exercise 2-3 hours per week will be recommended to all subjects. Their physical activity will be assessed by IPAQ-SF as reported below."
84638|NCT03524352|Other|fecal microbiota|fecal microbiota in suspension
84639|NCT03524352|Other|Placebo|sterile saline
84640|NCT03524339|Drug|Placebo oral capsule|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
84641|NCT03524339|Drug|Tamsulosin|Tamsulosin or placebo will be given for 3 days prior to surgery and one week after surgery to determine its effects on postoperative urinary retention.
84642|NCT03524326|Drug|Lenvatinib Pill|24 mg oral daily
84643|NCT03524326|Drug|Lenvatinib Pill|20 mg oral daily
84644|NCT03524326|Drug|Lenvatinib Pill|14 mg oral daily
84645|NCT03524326|Drug|Cetuximab|400mg/m2 IV, then 500mg/m2 IV weekly
84646|NCT03524313|Diagnostic Test|End tidal carbon monoxide|"Evaluation of cardiac output estimated by transthoracic echocardiography and end tidal carbon monoxide~Evaluation of cardiac output estimated by transthoracic echocardiography and portal veinous velocity~Evaluation of femoral veinous velocity"
84683|NCT03524066|Drug|Inhalation|Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation
84648|NCT03524300|Procedure|Laparoscopic Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted total gastrectomy will be performed in the experimental group.
84649|NCT03524287|Procedure|Robotic Assisted No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
84650|NCT03524274|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
84651|NCT03524274|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
84652|NCT03524261|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
84653|NCT03524261|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
84654|NCT03524248|Radiation|Image guided radiation therapy|Real-time 4D video imaging guidance with combination use of cone-beam computerized tomography (CBCT) useful for daily setup and target motion tracking in advanced image-guided radiotherapy (IGRT).
84655|NCT03524235|Radiation|Total Body Irradiation|Pre-Transplantation Total Body Irradiation
84656|NCT03524235|Procedure|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation
84657|NCT03524235|Biological|CD56-Enriched Donor Lymphocyte Infusion|CD56-Enriched Donor Lymphocyte Infusion
84658|NCT03524235|Drug|Bendamustine|Pre-Transplantation Bendamustine
84659|NCT03524235|Drug|Fludarabine|Pre-Transplantation Fludarabine
84660|NCT03524235|Drug|Rituximab|Pre-Transplantation Rituximab (Rituximab for lymphoma diagnosis only)
84661|NCT03524222|Other|Home Hospitalization|See above
84662|NCT03524209|Device|Percutaneous instrumentation of the thoracolumbar spine|The spine is stabilized cranially and caudally of the level of spondylodiscitis. The percutaneous instrumentation consists of a rod and pedicle screw construct. The vertebrae are instrumented through minimal skin incisions using a fluoroscopic guidance or a spinal navigation system based on 3D imaging.
84663|NCT03524209|Other|Brace|Brace treatment is associated in patients presenting back pain and a risk for vertebral body collapse due to infection with subsequent kyphotic deformity of the thoracolumbar spine
84664|NCT03524196|Other|Manage Your Life Online (MYLO)|"Manage Your Life Online (MYLO) is accessed online using a username and password. Client's type into the MYLO conversation box about a problem they are currently experiencing. MYLO operates by analysing the client's input of text for key terms and themes. It responds with questions about the problem aimed at encouraging higher level awareness.~Participants will decide how often to use the MYLO programme over a two week period. This is likely to be a reasonable length of time to allow at least one use of the programme with no upper limit on usage."
84665|NCT03524183|Behavioral|Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
84666|NCT03524170|Drug|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
84667|NCT03524170|Radiation|Radiation Therapy|Undergo radiation therapy
84668|NCT03524157|Drug|PRO-087|The intervention period consists of a therapy with PRO-087administered 4 times a day in the waking period for 10 days. with a security call to day 13.
84669|NCT03524157|Drug|Systane Ultra|The intervention period with active comparator drug consists of a therapy with systane administered 4 times a day in the waking period for 10 days. with a security call to day 13.
84670|NCT03524157|Drug|Xyel Ofteno|The intervention period with active comparator drug consists of a therapy with Xyel administered 4 times a day in the waking period for 10 days. with a security call to day 13.
84671|NCT03524144|Other|gastroscopy|Two endoscopists performed upper gastrointestinal endoscopy and biopsy on all patients; and histological review was performed by two pathologists. From each patient, 10 specimens were taken from 6 areas in the upper gastrointestinal tract and basic informations was collected.
84672|NCT03524131|Other|risk-framed leaflet|2-sided leaflet, emphasizing health risks of not going to the NHS Health Check
84673|NCT03524131|Other|benefits-framed leaflet|2-sided leaflet, emphasizing benefits of attending an NHS Health Check
84674|NCT03524131|Other|current national leaflet|4-sided leaflet
84675|NCT03524118|Drug|MK-1654|Single ascending doses of MK-1654 will be administered via IM injection.
84676|NCT03524118|Drug|Placebo|Placebo (0.9% sodium chloride [NaCl]) will be administered via IM injection.
84677|NCT03524105|Behavioral|Program for Parents (Parenting Program)|Program for Parents (Parenting Program) is implemented by a mental health professional and offered to groups of ~15 parents during the school day and during after school hours. The Program for Parents includes 2-hour sessions provided weekly over a 4-month period. The Program for Students (Friends School Social Emotional Learning Program) is implemented by classroom teachers in the classroom with 90 minute lessons and activities once a week for 14 weeks
84678|NCT03524105|Behavioral|Thrive Professional Learning|Professional Learning is delivered to teachers in groups of 20-40 4 times a year over a two-year period. Professional Learning is delivered to leaders in groups of 20 - 40 three times a year over the same two-year period.
84679|NCT03524092|Drug|Mirikizumab|Administered SC
84680|NCT03524092|Drug|Mirikizumab|Administered IV
84681|NCT03524092|Drug|Placebo|Administered SC
84682|NCT03524079|Drug|Ajmaline 17-(Chloroacetate) Monohydrochloride|Ajmaline 17-(Chloroacetate) Monohydrochloride(1mg/kg in 5 minutes)
84686|NCT03524053|Other|Exercise induced bronchoconstriction|Participants will exercise whilst inhaling dry-air, this is known to exacerbate the bronchoconstrictive response.
84687|NCT03524053|Other|Inhibited EIB|Participants will perform the exercise-test whilst inhaling warm-humid air. This is known to inhibit the EIB response and will provide a direct comparison group for the EIB condition.
84688|NCT03524040|Device|SEB-250|Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
84689|NCT03524027|Procedure|Posterior Vertebral Column Resection (PVCR)|Posterior Vertebral Column Resection (PVCR) Surgical Technique for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS) Spinal Deformity
84690|NCT03524014|Other|Only advice for diagnosis and prevention|Only advice for diagnosis and prevention
84691|NCT03524001|Device|Compare VVi mode versus DDD bifocal stimulation through crossover randomization|All patients undergo bifocal right ventricular resynchronization therapy: right atrial lead is implanted, whereas first ventricular lead is placed in His bundle area, and the second ventricular lead in the right ventricle apex.Then the leads are connected to CRT-D generator.After the implant, all devices are programmed in VVI mode. After the first 40±10 days (first f-up) patients are 1:1 randomized to VVI mode 40 beats/minute (placebo arm) or bifocal DDD-mode 60 beats/minute.After six months (second follow-up) a clinical and instrumental assessment equal to baseline is performed. Then arms cross-over is performed (from VVI-mode to bifocal DDD-mode and vice versa). At 12 months (end of follow-up) an evaluation equal to that performed at 6 months is assessed. Echocardiographic data are unravelled to the investigator that plans stimulation mode able to determine the best clinical improved.
84692|NCT03523988|Drug|Acetaminophen|Acetaminophen gel capsule
84693|NCT03523988|Drug|Ibuprofen|Ibuprofen gel capsule
84694|NCT03523975|Drug|Venetoclax|PO days 8 - 28 cycles during cycle 1 only. Starting with ramp-up dose as follows (50 mg x 7 days then 100mg x 7 days then 200 mg x 7 days then 400 mg for remainder of therapy). Will be given days 1-28 at a dose of 400 mg cycle 2-12.
84695|NCT03523975|Drug|Lenalidomide|10 mg day 1-7 of and 15 mg day 8-14 cycle #1. 20 mg PO day day 15-21 of cycle #1 and days 1-21 cycles 2-12.
84696|NCT03523975|Drug|Rituximab|375 mg/m2 IV day 1, 8, 15, 22 of 1st cycle then on day 1 for cycles 2, 4, 6, 8, 10, 12
84697|NCT03523962|Drug|DuraPrep|The iodine-based treatment intervention is an antiseptic solution comprised of iodine povacrylex (0.7% free iodine) in 74% isopropyl alcohol. 3M™ DuraPrep™ [3M Health Care, St Paul, MN], will be the commercial product used.
84698|NCT03523962|Drug|ChloraPrep|The CHG intervention is an antiseptic solution comprised of 2% CHG in 70% isopropyl alcohol. ChloraPrep® [CareFusion Inc., Leawood, KS, USA] will be the product used.
84699|NCT03523949|Behavioral|PNE|The PNE will be delivered by a physiotherapist in a single, group-based session.
84700|NCT03523936|Dietary Supplement|Prebiotic product|Prebiotic product used during the course of antibiotic treatment
84701|NCT03523936|Dietary Supplement|Placebo|Placebo
84702|NCT03523923|Behavioral|Collaborative Care|"Up to 12 phone sessions over 16 weeks from Collaborative Care Manager (CCM).~Session 1: Establish rapport, perform structured clinical assessment explain the rationale and parameters of the intervention, provide brief education on pain and together with the participant create an overall treatment plan and detailed follow-up plan.~Sessions 2-12 Components:~Care Management Weekly monitoring of response to treatment using standardized measures.~Collaborative Medical Management: Optimized management of problem areas. Medication recommendations will follow evidence-based treatment algorithms with consultation of supervisors.~Psychosocial Treatment: Evidence based, focus on pain self-management skills/education, initially on foundational skills including: (1) pain education; (2) relaxation skills training; (3) behavioral activation and goal setting; 4) importance of physical activity and (5) motivational interviewing to promote adherence to healthcare and goals."
84703|NCT03523910|Device|Magnetic Resonance Imaging (MRI) with exercise|MRI scan with a novel exercise device.
84704|NCT03523897|Procedure|Robot Assisted Total Knee Replacement|A robotic-assisted surgical procedure to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
84705|NCT03523897|Procedure|Traditional Total Knee Replacement|A surgical procedure using mechanical guides to treat a condition in which the patient's knee joints become diseased or injured due to a loss of cartilage that acts as a protective cushion between the knee joints
84706|NCT03523884|Other|Exercise Program plus Education|Rotator cuff exercises outlined in the American Academy of Orthopedic Surgeons (AAOS) guidelines on management of rotator cuff problems.
84707|NCT03523884|Other|Educational Program (EP).|An information sheet form AAOS, outlining the anatomy, description, causes, symptoms, examination and imaging tests performed on individuals with shoulder conditions
84708|NCT03523871|Drug|Mavyret|Patients will be on 8 weeks of Mavyret
84709|NCT03523858|Drug|Ocrelizumab|Ocrelizumab will be administered via intravenous (IV) infusion at an initial dose of two 300-mg infusions separated by 14 days (on Days 1 and 15), and then 600 mg at every subsequent dose every 24 weeks for the remainder of the study treatment period (approximately 192 weeks)
84710|NCT03523845|Other|Observational intervention to diagnose an early apical peri-implantitis|diagnose an early apical peri-implantitis
84711|NCT03523832|Drug|Celecoxib and Pregabaline|Single dose versus repetition dose
84712|NCT03523832|Other|Placebo|Placebo
84713|NCT03523819|Drug|CS1002|Dose levels will be escalated following a modified 3+3 dose escalation scheme
84714|NCT03523806|Behavioral|Solution-Focused Coaching in Pediatric Rehabilitation|A coaching model for children with disabilities, with a strong theoretical basis, and ability to be customized to children and families' resources, environmental settings, child age and developmental stage
84715|NCT03523793|Behavioral|Clinical Practice Guideline Implementation|The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
84716|NCT03523793|Other|Standard Care|Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
84717|NCT03523780|Other|Whole Blood|Whole blood transfusion during cesarean delivery
84718|NCT03523780|Other|Blood component|Blood component therapy during cesarean delivery
84719|NCT03523767|Biological|S.typhi Injection|0.5 ml of S.typhi injection
84720|NCT03523767|Biological|Normal Saline Injection|0.5 ml of normal saline injection
84721|NCT03523754|Drug|Isosorbide Mononitrate 40 MG to study group|Isosorbide Mononitrate will be added to Misoprostol, to determine their combined effect on cervical ripening & induction of labor in study group
84722|NCT03523741|Drug|Clozapine|Clozapine is administered orally according to individual prescribed dosing regimens.
84723|NCT03523728|Drug|Venglustat GZ402671|Pharmaceutical form: capsule Route of administration: oral
84724|NCT03523728|Drug|Placebo|Pharmaceutical form: capsule Route of administration: oral
84725|NCT03523715|Dietary Supplement|Prunes|12 oz of prunes daily
84726|NCT03523715|Drug|Docusate Sodium|Oral docusate sodium twice daily
84727|NCT03523702|Drug|PembroRT|Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.
84728|NCT03523702|Drug|ChemoRT|Patients whose tumors are found to have low (< 50%) PD-L1 expression will automatically be placed in the ChemoRT group. These patients will receive radiotherapy over a course of four to seven weeks. During radiotherapy, patients will also receive two standard chemotherapy agents (carboplatin and paclitaxel) once each week. Following completion of chemotherapy and radiotherapy, patients may receive additional treatments with chemotherapy or immunotherapy as part of routine care. These treatments are optional and are not required by this clinical trial.
84729|NCT03523689|Procedure|Bronchoscopy|Undergo bronchoscopy
84730|NCT03523689|Procedure|Radial Probe Endobronchial Ultrasound|Undergo RP-EBUS
84731|NCT03523676|Diagnostic Test|Red Cell Distribution Width|
84732|NCT03523663|Other|no intervention. measure eye movement data|
84733|NCT03523650|Drug|Propranolol Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Propranolol Oral tablets, tid, for 36 months.
84734|NCT03523650|Drug|Placebo Oral Tablet|A randomized group of patients with cerebral or spinal cavernous malformations, will receive a Placebo Oral Tablet, tid, for 36 months.
84735|NCT03523637|Behavioral|Interoceptive Exposure|The intervention Interoceptive Exposure (IE) is an exposure to bodily sensations used in treatment of variety of problems where body sensations are experienced as threatening. This psychological technique is about focusing attention on pain, 'staying with the pain' without trying to escape it.
84736|NCT03523611|Procedure|Lung Resection|Lung resection surgery
84737|NCT03523598|Other|Placebo gel + Normal Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be normal (Colgate).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
84738|NCT03523598|Other|Placebo Gel + Potassium Nitrate Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be normal tooth paste (Colgate).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the 5% Potassium Nitrate gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
84739|NCT03523598|Other|Potassium Nitrate Gel + Normal Toothpaste|"15 days before and during the period of bleaching sessions: Tooth paste used will be Potassium Nitrate containing (Sensodyne).~Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin.~A 35% hydrogen peroxide based bleaching agent will applied on the vestibular surface of teeth, remaining for 40 minutes."
84740|NCT03523585|Drug|Trastuzumab deruxtecan|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as intravenous (IV) dose
84741|NCT03523585|Drug|Capecitabine|Investigator's choice Standard of Care when combined with trastuzumab or lapatinib
84742|NCT03523585|Drug|Lapatinib|Investigator's choice Standard of Care when combined with capecitabine
84743|NCT03523585|Drug|Trastuzumab|Investigator's choice Standard of Care when combined with capecitabine
84744|NCT03523572|Drug|Trastuzumab deruxtecan (DS-8201a)|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
84745|NCT03523572|Drug|Nivolumab|Nivolumab is an aqueous solution formulated at 10 mg/mL to be administered at a flat dose of 360 mg IV over 30 minutes. Protocol-defined thyroid testing is required while taking nivolumab.
84746|NCT03523559|Genetic|bladder tissue of Interstitial Cystitis and normal bladder tissue|Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
84747|NCT03523546|Other|Cancer Episode Payment Model (CEM)|Oncologists will be paid for an episode of care with the opportunity to receive a value based payment based on 6 quality metrics.
84748|NCT03523533|Procedure|Angiocatheter|Placement of angiocatheter in internal jugular vein
84749|NCT03523520|Drug|Methylnaltrexone Bromide 150 mg Oral Tablet|Methylnaltrexone Bromide 150 mg Oral Tablet
84750|NCT03523520|Drug|Methylnaltrexone Bromide 12 MG/0.6 ML Subcutaneous Solution [RELISTOR]_#1|Methylnaltrexone Bromide 12 MG Subcutaneous Solution
84751|NCT03523520|Drug|Naloxegol 25 MG Oral Tablet|Naloxegol 25 MG Oral Tablet
84821|NCT03522870|Device|Flash glucose monitoring system|Using flash glucose monitoring system continuously on Week 0-12 and Week 14-26
84752|NCT03523507|Device|Active: rTMS|Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
84753|NCT03523507|Device|Sham: rTMS|Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.
84754|NCT03523468|Procedure|uniportal sleeve lobectomy|central lung cancer sleeve resection performed by uniportal VATS
84755|NCT03523468|Procedure|open sleeve lobectomy|central lung cancer sleeve resection performed by open chest
84756|NCT03523455|Dietary Supplement|Iron Aid IPS (Iron Protein Succinylate)|Taken orally in capsule form
84757|NCT03523455|Other|Sugar Pill|Taken orally in capsule form
84758|NCT03523442|Drug|Apalutamide|The participants will receive apalutamide 240 mg once daily orally.
84759|NCT03523429|Drug|blinatumomab|Blinatumomab is a bispecific monoclonal antibody designed to bind specifically to CD19, expressed on the surface of B-cells, and to CD3, expressed on the surface of T-cells. It activates endogenous T-cells by connecting the CD3 on the T-cell receptor complex (TCR) with the CD19 on the B-cells. The anti-tumour activity of blinatumomab does not depend on whether the T-cells carry a specific TCR or peptide antigens present in cancer cells, but it is polyclonal and independent of HLA on the target cells
84760|NCT03523403|Other|Apples|3 whole Ontario-grown Gala apples
84761|NCT03523390|Drug|Avelumab|Subjects will receive an intravenous infusion of avelumab once every 2 weeks (q2w) or every week for the first 12 weeks and then q2w from Week 13 until progressive disease.
84762|NCT03523377|Other|prolonged overnight fasting|Adherence to fasting will be estimated by proportion of the 49 nights (7 weeks) with ≥12 hours of fasting as per text message data from the participant. If the participant neglects to text the fasting duration, that night will be considered not adherent (a conservative adherence estimate).
84763|NCT03523364|Device|dental restorations|partial or complete ceramic restorations bonded to dental tissues after WAB and total etching or after total etching
84764|NCT03523351|Radiation|Radiation Therapy|Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, 3D-CRT, or IMRT technique may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
84765|NCT03523351|Drug|Systemic Therapy|Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
84766|NCT03523338|Drug|Apalutamide|Participants will receive apalutamide 240 mg orally once daily.
84767|NCT03523338|Drug|ADT (Standard of Care)|Participants who did not undergo surgical castration, should receive and remain on a stable regimen of ADT according to local standard of care.
84768|NCT03523325|Other|Exercise treatment|Treatment protocol is an exercise program consisting of four different phases (Silbernagel protocol). The progression consists of increasing number of repetitions, resistance, speed and range of motion of the exercises. A pain-monitoring model is used to adjust the exercise loads and progression through the four phases.
84769|NCT03523312|Radiation|Hypofractionated ablative IMRT (HFA-IMRT)|total dose of 67.5 Gy in 15 fractions or 75Gy in 25 fractions
84770|NCT03523312|Drug|capecitabine|Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
84771|NCT03523299|Procedure|Cryoablation|Cryoablation is a non-surgical, minimally invasive freezing procedure used to destroy tumors. In the breast, cryoablation is performed under ultrasound guidance. Due to the analgesic properties of freezing, no IV sedation or anesthesia is required. After administration of local anesthetic, the physician makes a 2-3 mm incision and inserts needle-like cryoprobes into the tumor, commencing a number of freeze-thaw cycles. Then the probe is removed, pressure is applied to the area, and a bandage is placed. The patient leaves the office without stitches and minimal, if any, pain. Any residual pain after the procedure is routinely treated with over the counter analgesics such as acetaminophen.
84772|NCT03523286|Other|RAPID-VT Software guided ablation|Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
84773|NCT03523273|Drug|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
84774|NCT03523273|Drug|Placebo|Placebo administration will match the study drug.
84775|NCT03523260|Device|Tunneled dialysis catheter placement.|Placement of high-flow tunneled catheter for hemodialysis
84776|NCT03523247|Behavioral|whole food, plant based diet|whole food, plant based diet featuring vegetables, fruits, legumes, whole grains, seeds, and nuts
84777|NCT03523234|Drug|neoadjuvant chemotherapy|etoposide with cisplatin/carboplatin, undergoing in prior to the surgery
84778|NCT03523234|Procedure|radical surgery for stage II and IIIA small cell lung cancer (SCLC)|Lobectomy/total lung resection plus mediastinal lymph node dissection.
84779|NCT03523234|Procedure|prophylactic cranial irradiation|prophylactic cranial irradiation (PCI) undergoing with adjuvant chemotherapy simultaneously
84780|NCT03523234|Drug|Chemotherapy|etoposide with cisplatin/carboplatin
84781|NCT03523221|Drug|Dexamethasone Oral|use of one dose of Dexamethasone orally.or placebo in addition to regular treatment of anaphylaxis
84782|NCT03523195|Behavioral|Exercise Intervention|Complete exercise program
84783|NCT03523195|Other|Informational Intervention|Receive written information on healthy exercise and diet recommendations
84784|NCT03523195|Other|Laboratory Biomarker Analysis|Blood tests
84785|NCT03523195|Device|Monitoring Device|Wear Fitbit
84788|NCT03523182|Dietary Supplement|Spirulina|"Arthrospira platensis, also known as spirulina, is a blue-green micro-algae indigenous to Africa.~Spirulina group (n=251) receive a soya-maize-based porridge with the addition of spirulina.~We used 10 g per day of spirulina powder with a mealie meal and soya flour porridge blend."
84789|NCT03523182|Dietary Supplement|Control|Children receive a soya-maize-based porridge for 12 months. We use a mealie meal and soya flour porridge blend.
84790|NCT03523156|Drug|Azithromycin mass treatment|Standard of care annual community-wide mass drug administration (MDA) will be provided at the normally scheduled time.
84791|NCT03523156|Drug|Azithromycin targeted treatment|Two rounds of treatment targeted to all children aged 6 months to 9 years old. The first targeted round will be 1-2 weeks after the community-wide MDA and the second round will occur another 1-2 weeks later.
84792|NCT03523143|Other|early screening and intervention|The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the IADPSG criteria. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks. The process of screening and intervention in the early screening group is all the same with that in the standard screening group. The only difference between two groups is the time of screening and intervention (18-20 weeks vs. 24-28 weeks of GA).
84793|NCT03523143|Other|standard screening and intervention|The standard screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 24-28 weeks of gestational age (GA). Gestational diabetes mellitus (GDM) is diagnosed according to the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, ie. if one of the plasma glucose levels at fasting, 1-hour, and 2-hour during OGTT is above 92 mg/dL, 180 mg/dL, and 153 mg/dL, respectively. Subjects diagnosed with GDM will receive nutrition counseling, and lifestyle intervention. Pharmacologic therapies exclusively with human insulin or insulin analogues will be given when the target of glycemic control is not achieved within 4 weeks.
84794|NCT03523130|Diagnostic Test|Imaging|Macrophage-specific inflammation
84795|NCT03523117|Drug|Ferric carboxymaltose|Intravenous iron
84796|NCT03523117|Drug|Ferrous Sulfate|oral iron therapy
84797|NCT03523091|Drug|OnabotulinumtoxinA 100Unit Injection|Initial treatment with the option of repeat injections every 3 months
84798|NCT03523078|Procedure|Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.
84799|NCT03523039|Device|CytoSorb® Hemoadsorption|The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
84800|NCT03523026|Device|Neuromuscular Electrical Stimulation|Neuromuscular Electrical Stimulation(NMES) to rectus abdominis will be applied using 4 carbon silicon electrode. In the first sessions, patients ECG will be checked. Patients will be in semi-fowler position (30º),with their lower limbs to be in extension and upper limbs at their sides. The NMES frequency will be at 30 Hertz and the application time will be 30 minutes. Treatment will be programmed for 3 days per week. The patients will coordinate their breath (inspiration) with the contraction which will be generated by the electrical current. The program will continue for 6 weeks.
84801|NCT03523026|Other|Inspirator Muscle Training|Inspirator Muscle Training(IMT) will be applied 7 days per week, twice a day for 15 minutes. The program will continue for 6 weeks duration under weekly control of the investigator.Training intensity will set at 30% of the maximum inspiratory pressure.
84802|NCT03523026|Other|Peripheral Muscle Training|Peripheral Muscle Training will be applied by elastic band and Proprioceptive Neuromuscular Facilitation 3 times per week.The program will continue for 6 weeks.
84803|NCT03523013|Device|CPAP|CPAP treatment with different pressure for OSA patients
84804|NCT03523000|Other|Continuous intrathecal prognostic infusion test|The patient is infused with solution through the percutaneous intrathecal catheter at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours
84805|NCT03522987|Drug|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
84806|NCT03522974|Dietary Supplement|Strawberry powder|Freeze dried strawberry powder
84807|NCT03522974|Dietary Supplement|Placebo powder|40 g/d placebo powder matched for taste and appearance
84808|NCT03522961|Drug|Nitrofurantoin Prophylaxis/Placebo|Drug: Nitrofurantoin Drug: Placebo
84809|NCT03522961|Drug|Cranberry capsules|Drug: TheraCran® One Cranberry capsules
84810|NCT03522948|Behavioral|Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM|Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
84811|NCT03522935|Drug|Elafin|Elafin subcutaneous.
84812|NCT03522935|Drug|Placebo|Placebo subcutaneous.
84813|NCT03522922|Device|Dermaroller|The derma roller used (dermaroller MF8, MT dermaroller Beverly Hills, California USA) is a plastic device with a 12-cm handle that holds a drum-shaped cylinder at the end, similar to a small paint roller, 2 cm in diameter and 2 cm in width. The surface of the cylinder holds 192 titanium needles in eight rows. Each 0.25 mm in diameter and 1.5 mm length sterilized by UV/ Gamma rays.
84814|NCT03522922|Drug|Topical Vitamin C|The used vitamin C product was in the form of 17% concentration of L- Ascorbic Acid serum that was encapsulated in gelatinous capsules each contain 1 mg of the serum. The patient instructed to open one capsule and apply its serum content on the treatment area daily at night. This capsule form for topical application help to insure stability of the product and also insure use of equal dose in each application
84815|NCT03522909|Other|Seen in clinic|"We will be doing a retrospective chart review of patients seen in the Center for Peripartum Optimization to look for:~Primary outcome variable.~- Hospital length of stay~Secondary outcome variables.~Number of admissions from outside hospitals~Adverse outcomes~Intensive Care Unit admissions~Opioid use~NICU admissions~Patient satisfaction~Cost of inpatient admission~Cost of outpatient care~Hospital readmissions rate"
84816|NCT03522896|Other|control|balancing sugars and organic acids
84817|NCT03522896|Other|test meal 1|orange juice plus hesperidin low dose
84822|NCT03522870|Device|SMBG|Performing SMBG at least three times/day on Week 0-12 and Week 14-26
84823|NCT03522844|Other|Mindfulness-Based Stress Reduction|Participants randomized to the MBSR intervention will consist of an 8-week Mindfulness-Based Stress Reduction (MBSR) program, taught and facilitated by a trained instructor. The classes instruct participants in the theory and practice of several forms of mindfulness meditation: a body scan, breathing awareness, and mindfulness stretching exercises designed to bring awareness of the body and current experience of movement. The intervention will include a weekly class for 8 weeks and classes will be 2.5 hours in duration. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.
84824|NCT03522844|Drug|Escitalopram|Escitalopram is an antidepressant, widely used to treat anxiety disorders. During the 8 weeks of randomized treatment with escitalopram, subjects will be seen regularly by a study physician. The pill medication will be initiated at 5 mg/day; which will be continued to week 1, when it will be increased to 10 mg/day if well tolerated (or delayed if not). At week 2, dosage will be increased to 20 mg/day if well tolerated (or delayed if not). Side effects will be assessed at each visit and recorded.
84825|NCT03522831|Drug|Salbutamol|Administration of 400 μg meter-dose inhaler of salbutamol performed using large-volume spacer
84826|NCT03522831|Drug|Placebo|Administration of 400 μg meter-dose inhaler of placebo performed using large-volume spacer
84827|NCT03522818|Behavioral|Manual Trigger|Will use the alarm as provided by the manufacture but parent has to manual trigger the alarm 1-2 hours after the child falls asleep.
84828|NCT03522818|Behavioral|Normal|Will use the alarm as provided by the manufacture.
84829|NCT03522805|Device|High-intensity non-invasive ventilation|Single night of high-intensity non-invasive ventilation
84830|NCT03522792|Other|Neurotensin|Intravenous infusion of neurotensin
84831|NCT03522792|Other|Saline|Intravenous infusion of saline
84832|NCT03522792|Other|Ad libitum meal|Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.
84833|NCT03522792|Other|Liquid meal|A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
84834|NCT03522779|Dietary Supplement|Tart cherry Juice|Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.
84835|NCT03522779|Other|High-fat meal|A high fat meal will be given to elicit postprandial oxidative stress.
84836|NCT03522779|Other|Exercise|The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
84837|NCT03522766|Other|urine sample|The subjects are asked to give a maximum of 15 urine samples during the study
84838|NCT03522753|Device|Metal skin staples|Routine closure methods/material for surgical wounds
84839|NCT03522753|Device|Nylon sutures|Routine closure methods/material for surgical wounds
84840|NCT03522740|Other|Decision Aid for Renal Therapy|DART is a web-based decision aid that informs older adults with advanced kidney disease of kidney disease treatment options and prompts them to consider their preferences and raise questions to discuss with their kidney disease providers.
84841|NCT03522727|Behavioral|Single self-incentivising implementation intention|Participants are asked to form a single self-incentivising implementation intention (if-then plans)
84842|NCT03522727|Behavioral|Multiple self-incentivising implementation intentions|Participants are asked to form multiple self-incentivising implementation intentions (if-then plans)
84843|NCT03522727|Behavioral|Self-generated self-incentivising implementation intentions|Participants are asked to form a self-incentivising implementation intention (if-then plans) without a drop-down menu
84844|NCT03522714|Device|Fluid Immersion Simulation System|Dolphin Fluid Immersion Simulation® System Mattress will be used
84845|NCT03522714|Device|Air Fluidized Bed System|Air Fluidized Bed (Clinitron) will be used.
84846|NCT03522701|Behavioral|CBTI|Refer to the arm description
84847|NCT03522688|Drug|Dexmedetomidine|The treatment group was given dexmedetomidine by constant intravenous (IV) infusion at a rate of 0.4mcg/kg/hour.
84848|NCT03522675|Device|NeoMatriX Wound MatriX Collagen Dressing|Collagen wound dressing
84849|NCT03522662|Drug|GSK1070806|Single 10mg/kg infusion on Day 0
84850|NCT03522649|Drug|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 8~12 hours.
84851|NCT03522649|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 bolus will be administered intravenously immediately following irinotecan/leucovorin infusion, followed by Fluorouracil 1200 mg/m^2/day (total 2400 mg/m^2) continuous infusion.
84852|NCT03522649|Drug|Leucovorin|Irinotecan 180 mg/m^2 followed by or concurrent with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
84853|NCT03522649|Drug|Irinotecan|Irinotecan 180 mg/m^2 followed by or concurrent with leucovorin 400 mg/m^2 will be administered intravenously, over approximately 90 minutes and 2 hours, respectively.
84854|NCT03522623|Other|Non-interventional study|Non-interventional study
84855|NCT03522610|Behavioral|ADAPT|Two hour, once a week in-person parenting program for 14 weeks plus use web-enhanced supplemental ADAPT materials
84856|NCT03522584|Biological|Durvalumab|Given IV
84857|NCT03522584|Other|Laboratory Biomarker Analysis|Correlative studies
84858|NCT03522584|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
84859|NCT03522584|Biological|Tremelimumab|Given IV
84860|NCT03522584|Procedure|Hypofractionated Image-Guided Radiation Therapy|Undergo HIGRT
84861|NCT03522571|Behavioral|Experimental gingivitis|Individual cast models were prepared on alginate impressions. A 2-mm thick film of technical wax was set on the supra gingival area at buccal and proximal surfaces of study teeth on test quadrant. The stent were delivered at day 0. Subjects were instructed to wear the stent prior to the oral hygiene session throughout the experimental gingivitis period to prevent plaque removal during brushing of the remaining dentition. On Day 42 (T6): After recording of clinical parameters, oral hygiene instruction and an additional session of supragingival scaling, as needed, and polishing were given.
85024|NCT03521284|Other|Questionnaires|knowledge questionnaire + parental anxiety questionnaire
84862|NCT03522558|Behavioral|Standardized Medical Nutrition Therapy|Standardized Medical Nutrition Therapy will include nutrition assessment provided by a registered dietitian (RD) at initial clinic visit or first Well Child Check (WCC) and regularly scheduled nutrition follow-up at each WCC visit thereafter.
84863|NCT03522558|Behavioral|Usual Care|At the primary care provider's discretion, a nutrition consult can be requested for the RD to perform nutrition assessment or discuss the patient's plan without full nutrition assessment, as is current practice. Currently in the Neonatal High-Risk Clinic (NHRC) and High Risk Children's Clinic (HRCC) at UTHealth, providers consult the RD as deemed appropriate with no established criteria for when to include the RD in patient care. Usual care will not be modified by the study protocol.
84864|NCT03522545|Biological|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)|Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow
84865|NCT03522545|Biological|Placebo|Placebo for Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs)
84866|NCT03522532|Procedure|Amalgam placement|Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
84867|NCT03522532|Procedure|Tetric EvoCeram placement|Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
84868|NCT03522532|Procedure|Beautifil placement|Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
84869|NCT03522532|Procedure|Zinc phosphate cement placement|Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
84870|NCT03522532|Procedure|Zinc polycarboxylate cement placement|Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
84871|NCT03522532|Procedure|Glass ionomer cement placement|Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
84872|NCT03522519|Behavioral|Real world performance of physical activity and arm use|Patients will be assessed by using movement sensors and standard clinical assessments
84873|NCT03522506|Drug|TAK-925|TAK-925 intravenous infusion.
84874|NCT03522506|Drug|TAK-925 Placebo|TAK-925 placebo-matching given as saline intravenous infusion.
84875|NCT03522506|Drug|Modafinil|Modafinil tablets.
84876|NCT03522506|Drug|Modafinil Placebo|Modafinil placebo-matching tablet.
84877|NCT03522493|Device|"Yaalom Katom"|Full face Gas mask
84878|NCT03522480|Device|Jamboxx Respiratory Therapy Device|The Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx respiratory therapy device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
84879|NCT03522480|Other|Autogenic Draining Training|A respiratory therapist will teach children how to conduct the autogenic draining technique (a series of exhalations and inhalations) by demonstrating the technique to them, and having them practice in their office. Children will also receive an informational packet and short video about the technique for reference
84880|NCT03522467|Drug|MRCP001|MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
84881|NCT03522454|Dietary Supplement|Protein-rich oral nutritional supplement|Ready-to-drink beverage containing 20 g protein and 1.5 g hydroxymethylbutyrate (HMB) per serving, consumed twice daily.
84882|NCT03522454|Behavioral|Home-based supervised exercise program|WEBB (Weight-bearing Exercise for Better Balance) program combining walking and weight-bearing exercises to build strength and balance, administered by a trained therapist at the participant's home.
84883|NCT03522441|Drug|Clindamycin 1% Gel|Topical gel
84884|NCT03522441|Drug|Placebo|Topical Placebo gel
84885|NCT03522428|Dietary Supplement|vitamin b12|Vitamin B12 has been added to the experimental group of pregnant women, at a dose of 5 μg / 100 days
84886|NCT03522415|Drug|HLX01|HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
84887|NCT03522415|Drug|Methotrexate（MTX）|Methotrexate is a slow-acting antirheumatic drug.
84888|NCT03522402|Drug|Sevoflurane|38 patients American Society of Anesthesiologists (ASA) class I or II aged 2-8 years undergoing tonsillectomy surgery were randomized to either the patient's head in the neutral position or 30 degree rotated lateral position. The end-tidal (ET) sevoflurane concentration used for each patient was determined using the Dixon's up-and-down method. The ratio of the end-tidal to predetermined end-tidal concentrations was maintained at 0.95-1.0 for at least 10 minutes to establish equilibration before device insertion was attempted. The first patient received a 5.0% sevoflurane concentration and the step size of increase/decrease was 0.5%.
84889|NCT03522389|Procedure|AOT with gait training|"AOT with gait training composes of program of watching video in different views of normal walk for 5 min.~After that, participants will receive gait training program. The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
84890|NCT03522389|Procedure|Gait training|"To control a total time of training, the gait training group will watch video of Vincent van Gogh's painting for 5 min. After that, participants will training the gait as protocol of experimental group.~The program consists of warm-up, gait training, cool-down, and stretching. Gait training is classified into the different levels of difficulty in each week. The 1st week will be walking over the markers followed by 100 steps/min of metronome. The second week will be walking over the markers followed by 120 step/min of metronome. The 3rd week will be walking followed by 120 step/min of metronome but not has the markers. The 4th week will imagine and imitate the walking in the 2nd week but not has the markers and metronome."
84891|NCT03522389|Other|Education|There will be no intervention exercise program provide for the control group. They will receive education about dementia such as definition, etiology, sign and symptom, and caring.
84892|NCT03522376|Other|Loaded inspiratory muscle test|Loaded inspiratory muscle tests will be set at 30% and 50% of maximal inspiratory pressure. The orders of the two loaded test conditions will be conducted in random order with at least 24 hours separation. This is an observational study. Subjects will perform only 15 breaths with each loaded test condition to exam the performance of their inspiratory muscles. Loaded inspiratory muscle test is not for training.
84893|NCT03522363|Other|Streptococcus dentisani CECT7746|Treatment will be applied topically as an adhesive gel with a dental splint
84894|NCT03522350|Device|EmbryoScope|Standard of care arm
84895|NCT03522350|Device|EmbryoScope+|Experimental arm
84896|NCT03522337|Other|Visual pedagogy (social stories)|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
84897|NCT03522337|Other|Conventional leaflets|Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
84898|NCT03522324|Drug|Cannabis Edible|Self-Directed Use (ad-libitum)
84899|NCT03522311|Procedure|Vitrectomy|
84900|NCT03522298|Drug|GDC-0084|Patients will be dosed orally with GDC-0084 capsules (15-mg each) at the dose and schedule to which they are assigned.
84901|NCT03522285|Other|investigation: erythrocyte sedimentation rate|investigations will be done to detect presence of infection and x-ray also for detection of infection or loosing of hip components
84902|NCT03522272|Device|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with cetylpyridinium chloride
84903|NCT03522272|Device|Ultrasonic cleaning|Ultrasonic cleaning (frequency 42kHz) (for 7 minutes 30 seconds) with water
84904|NCT03522272|Other|Conventional denture hygiene|Mechanical cleaning of denture with a soft toothbrush and liquid detergent
84905|NCT03522259|Drug|Rivaroxaban 10 MG Oral Tablet [Xarelto]|Rivaroxaban 10mg per os is started on the first postoperative day. Patients receive Rivaroxaban 10mg QD for 7days (short arm) or 28 days (long arm)
84906|NCT03522246|Drug|Rucaparib|Oral rucaparib will be administered twice daily
84907|NCT03522246|Drug|Nivolumab|IV nivolumab will be administered once every 4 weeks
84908|NCT03522246|Drug|Placebo Oral Tablet|Placebo tablets will be administered twice daily
84909|NCT03522246|Drug|Placebo IV Infusion|IV placebo will be administered once every 4 weeks
84910|NCT03522220|Behavioral|3D navigation video game intervention|Participants intensively train with a video game (Super Mario DS)
84911|NCT03522220|Behavioral|video game intervention without 3D navigation|Participants train with a video game (Super Mario Bros)
84912|NCT03522220|Behavioral|No 3D navigation|Participants read on a kindle device (control group)
84913|NCT03522207|Diagnostic Test|polysomnography|BASELINE PSG Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
84914|NCT03522207|Drug|Trazodone|100 mg trazodone or placebo given once 30 minutes prior to 2nd PSG
84915|NCT03522207|Drug|Placebos|placebo per os 30 minutes prior to 2nd PSG
84916|NCT03522207|Diagnostic Test|polysomnography|2nd psg, done 1 week after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
84917|NCT03522207|Drug|Trazodone|100 mg trazodone per os 30 minutes prior to 3rd PSG
84918|NCT03522207|Drug|placebos|100 mg placebo per os 30 minutes prior to 3rd PSG
84919|NCT03522207|Diagnostic Test|polysomnography|3rd PSG, done 2 weeks after baseline. Patient has to sleep over at the hospital (sleep lab). The technician will place several sensors on your scalp, temples, chest and legs to record all the data needed for your evaluation. You will be monitored throughout the duration of the test (approximately 6 hours). Brain waves, eye movements, chin muscle tone, breathing patterns, snoring, heart rate, blood pressure, blood oxygen level, body position and muscle activity will be recorded.
84920|NCT03522194|Drug|Sevoflurane|Anesthesia maintenance with Sevoflurane
84921|NCT03522194|Drug|Propofol|Anesthesia maintenance with Propofol
84922|NCT03522181|Other|saline|saline
84923|NCT03522181|Other|Insulin|
84926|NCT03522155|Behavioral|Patient-centered communication of life expectancy|The intervention arm will test if patient-specific LE estimates via a targeted, patient-centered communication approach paired with LE-specific conjoint analysis data improves decisional conflict, quality of LE discussion, and reduces rates of overtreatment of Genitourinary malignancies.
84927|NCT03522142|Drug|INCB081776|INCB081776 administered once daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
84928|NCT03522142|Drug|Nivolumab|Nivolumab administered intravenously according to the label as 240 mg every 2 weeks.
84929|NCT03522129|Drug|CT1812|Active Study Drug
84930|NCT03522129|Drug|Placebo|Non-active study drug
84931|NCT03522116|Other|No intervention|No intervention
84932|NCT03522090|Diagnostic Test|lower neck CT|Computerised tomography of the lower neck done as part of initial CT thorax and lower abdomen
84933|NCT03522077|Device|SoftSeal®-STF hemostatic pad|Chitosan-based, non-woven pad with a unique, proprietary fiber structure that when hydrated with tissue fluids forms a gel-like synthetic clot
85025|NCT03521258|Device|Dehydrated Human Amnion/Chorion Membrane|
84934|NCT03522077|Device|VascBand™ Hemostat|Compression device to assist hemostasis of arterial, venous and hemodialysis percutaneous access sites
84935|NCT03522064|Drug|Testosterone Enanthate|Testosterone Enanthate is the oil-soluble ester of the androgenic hormone testosterone. Testosterone Enanthate is a clear to pale yellow solution for intramuscular injection. Each pre-filled syringe contains 250mg testosterone enanthate/1mL.
84936|NCT03522051|Other|calcium silicate based material,|Its a dental pulp capping material which is biocompatable and induces hard tissue barrier formation
84937|NCT03522038|Procedure|percutaneous coronary intervention|PCI was performed using standard techniques. Antiplatelet and antithrombotic agents were prescribed according to current PCI guidelines. A procedure was considered successful when achieving TIMI flow grade 3 with <30% angiographic residual stenosis in the CTO vessel. All patients received drug-eluting stents and were discharged on dual antiplatelet therapy with duration of at least on year.
84938|NCT03522025|Device|Unicompartmental Knee Arthroplasty (UKA)|Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
84939|NCT03522012|Drug|Tocilizumab|Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.
84940|NCT03521999|Behavioral|AboutFace|AboutFace is an online peer-to-peer digital storytelling resource for Veterans with PTSD. Veterans will have access to AboutFace while they are enrolled in PTSD specialty care through the Charleston PCT.
84941|NCT03521999|Other|Enhanced Usual Care (eUC)|Enhanced Usual Care (eUC) includes access to a PTSD educational brochure. Veterans will have access to the brochure information while they are enrolled in PTSD specialty care through the Charleston PCT.
84942|NCT03521986|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
84943|NCT03521986|Procedure|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
84944|NCT03521973|Biological|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
84945|NCT03521973|Other|Normal Saline|0.9% Sodium chloride
84946|NCT03521960|Drug|Buspirone oral capsule|15 milligrams, three times daily
84947|NCT03521960|Drug|Placebo oral capsule|0 milligrams (placebo), three times daily
84948|NCT03521947|Diagnostic Test|Complete blood picture|Iaboratory investigation
84949|NCT03521934|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
84950|NCT03521934|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
84951|NCT03521921|Device|Mitraclip|Edge-to edge mitral valve repair
84952|NCT03521908|Other|Non-Interventional|Non-Interventional
84953|NCT03521908|Other|Non-Interventional|Non-Interventional
84954|NCT03521895|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Patients observed with regular and irregular treatment course
84955|NCT03521869|Device|Compression bandage|Compression bandage placed after total knee replacement
84956|NCT03521869|Device|Gauze dressing|standard of care gauze dressing placed after total knee replacement
84957|NCT03521856|Behavioral|shoulder exercise|Exercises performed 3 times a week for 12 weeks
84958|NCT03521856|Behavioral|education|
84959|NCT03521843|Device|balloon dilation only|The balloon dilation only will be used to treat the femoropopliteal in-stent restenosis.
84960|NCT03521843|Device|balloon dilation+local drug delivery|The balloon dilation and local drug delivery will be used to treat the femoropopliteal in-stent restenosis.
84961|NCT03521830|Drug|Nivolumab|480mg IV every 4 weeks
84962|NCT03521830|Drug|Ipilimumab|1mg/kg IV every 4 weeks for 4 doses
84963|NCT03521817|Other|Alcohol|"The ethanol group will consume a 30% energy restriction diet that will also include ~2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol."
84964|NCT03521817|Other|No Alcohol|This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
84965|NCT03521804|Device|SoundBite™ Crossing System Active Wire 14|Successful crossing of the CTO into the true arterial lumen distal to the occlusion, following use of the SoundBite™ Crossing Wire during the procedure and using antegrade only approach. An antegrade only approach may involve Antegrade Dissection Re-Entry (ADR) with or without the use of specialized devices (i.e. Stingray). The absence of successful retrograde crossing of a collateral will still be considered an antegrade only approach.
84966|NCT03521791|Drug|PRO-155|"PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% [Lagricel ofteno®] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
84967|NCT03521791|Other|Placebo|"The placebo is constituted by agents, additives and vehicles, of the formulation PRO-155 without pharmacological activity. It is dispensed in dropper bottle of low density polyethylene for multi-dose administration in the form of ophthalmic solution of 5 mL~Sodium hyaluronate 0.4% (Lagricel ofteno®) 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac"
85026|NCT03521258|Procedure|Flap-Based Reconstructive Surgery|Standard of Care surgical intervention
85027|NCT03521245|Other|RNA sequencing|Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
85028|NCT03521245|Other|Transcriptome analysis|Analysis of RNA-seq data using the Oncobox algorithm.
85029|NCT03521245|Drug|Trastuzumab|Standard Trastuzumab treatment regimen recommended for breast cancer
85030|NCT03521245|Drug|Chemotherapy|Standard chemotherapy regimen recommended for breast cancer
84968|NCT03521778|Other|Fascial Distortion Model|"Patients will receive manual treatment according to FDM procedures:~Triggerbands - therapist put a pressure by the thumb along the presented pathway.~Continuum Distortions - therapist put a pressure by the thumb at the exact place of feeling of pain.~Folding Distortions - therapist conduct traction or compression of the affected joint.~Herniated Triggerpoint - therapist put a pressure by the thumb at the place where HTP occurs.~Cylinder Distortions - therapist compress and stretch by the hands affected area.~Tectonic Fixation - Therapist compress and stretch affected area by the hands or tools like vacuum bubble."
84969|NCT03521778|Other|Mulligan Concept|"Patients will receive manual treatment according to Mulligan Concept procedures:~MWM- Mobilization With Movement- application can be defined as the application of a sustained passive force/glide.~NAG - Natural Apophyseal Glide - application can be defined as the oscillatory mobilization techniques from the middle to the end of the range of motion.~SNAG- Sustained Natural Apophyseal Glide- They are weight bearing techniques: all procedures are done with the patient sitting or in standing. They are mobilisations with active movement followed by passive over pressure."
84970|NCT03521778|Other|Traditional physiotherapy|"Patients will receive traditional physiotherapy:~Exercises, laser treatment, magnetic field therapy, ultrasound treatment, light treatment"
84971|NCT03521765|Other|Cancer education|Those participants in the OT intervention group were given a consultation based on a CRC education handbook by an occupational therapist for discharge preparation (about 30 minutes) and after each follow-up visit to the clinic (about 15-20 minutes); the non-intervention group participants were given a CRC education handbook (the same handbook) only for discharge preparation. For the first OT consultation, in the first 15 minutes, the occupational therapist educated the participants based on the CRC education handbook chapter by chapter. The next 15 minutes, the occupational therapist interacted with the participants and provided them customized lifestyle suggestions. For the each following (second and third) consultations, occupational therapists interacted with the participants and provided customized suggestions based on the participants' lifestyle at home.
84972|NCT03521752|Other|Specific Exercise Program|4 weeks of exercise classes, 2 to 3 times a week for a total of 10 sessions. Classes last approximately 40 minutes. The sessions included balance training, motor strength, endurance and flexibility. The training sessions were divided into warm-up, main activity and finally relaxation.
84973|NCT03521726|Drug|Amoxicillin|Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
84974|NCT03521726|Drug|Rabeprazole, Amoxicillin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
84975|NCT03521713|Drug|EPORON|"Strength : 3000 IU/0.3 mL, 5000 IU/0.5 mL, 6000IU/0.6 mL~Formulation : Solution in PFS"
84976|NCT03521713|Drug|EPREX|"Strength : 2000 IU/0.3 mL, 3000 IU/0.5 mL, 4000IU/0.6 mL~Formulation : Solution in PFS"
84977|NCT03521700|Drug|Rosuvastatin|For patients who were assigned to receive intensive lipid lowering, 10 mg/d rosuvastatin was initially prescribed and target LDL-C was < 1.8mmol/L. For patients who were assigned to receive conventional lipid lowering, 5 mg/d rosuvastatin was initially prescribed and target LDL-C was ≥1.8mmol/L, <3.3mmol/L.
84978|NCT03521687|Drug|Apremilast|30 mg BID
84979|NCT03521674|Device|pregnancy termination|Second trimester pregnancy termination for fetal anomali or in utero mord fetus will be done
84980|NCT03521661|Procedure|Kyphoplasty|Fractured vertebral body was reduced with an intravertebral expander and was cement augmented thereafter
84981|NCT03521648|Procedure|PAE|Prostatic artery embolization
84982|NCT03521648|Procedure|TURP|Transurethral resection of the prostate
84983|NCT03521648|Procedure|Other|Other surgical procedures for BPH treatment including holmium laser enucleation of the prostate, open prostatectomy, thulium laser vaporization, resection or enucleation, transurethral incision of the prostate
84986|NCT03521622|Behavioral|brief counseling|Brief counseling for motivated smoker 5 As model Brief counseling for not motivated smokers 5 Rs model Brief counseling for motivated risky drinkers simple advice Brief counseling for not motivated risky drinkers brief alcohol intervention
84987|NCT03521609|Behavioral|Emotional intelligence intervention|Brief group intervention based on emotional intelligence
84988|NCT03521596|Other|MRD and clonal evolution|Patient evaluation at the time of diagnosis and during the disease course using highly sensitive techniques
84989|NCT03521570|Radiation|IMRT|Undergo intensity-modulated radiation therapy
84990|NCT03521570|Biological|Nivolumab|Given IV
84991|NCT03521557|Behavioral|Gaze and Postural Stability|The duration and content of the GPS intervention is specifically designed to focus on gradually increasing difficulty of gaze and postural stability exercises.
84992|NCT03521557|Behavioral|Standard Care Control|The Standard Care Control intervention is specifically designed to be focused on improving overall endurance and lower extremity muscular strength.
84993|NCT03521544|Other|Self-myofascial release|The subjects roll a foam roller under a determinated part of the body to self-massage that area.
84994|NCT03521518|Diagnostic Test|Conner's Continuous Performance Test-3|CPT-3 allows quantitative assessment of visuospatial, attention and reaction time in patients being evaluated for Normal Pressure Hydrocephalus undergoing a CSF tap test.
84995|NCT03521505|Drug|Dexmedetomidine arm|Induction: Dexmedetomidine 1ug/kg infusion for 10 minutes. 5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction Maintenance: Dexmedetomidine 0.5~1.4ug/kg/hour infusion±0.2ug/kg/hour to maintain stable vital signs and The Observer Assessment of Alertness and Sedation scale (OAA/S) 3~2. the infusion rate was increased by 0.2ug/kg/hour if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The infusion rate was reduced by 0.2ug/kg/hour, if the following adverse events occurred: hypoxemia (SpO2 < 90%) or hypotension (mean arterial pressure (MAP) < 65 mmHg, or systolic blood pressure (SBP) < 90 mmHg) in any duration
85031|NCT03521232|Drug|Niclosamide|enema given twice daily for 6 weeks
85032|NCT03521219|Drug|Apatinib|Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
85033|NCT03521206|Behavioral|ACP+ programme|Training program for nursing home staff.
85034|NCT03521193|Device|patent foramen ovale closure|Pts will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure
84996|NCT03521505|Drug|Propofol arm|"5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before induction Induction: The initial effect-site concentration (Ce) of propofol was targeted to 2.0 μg/ml for induction (Schneider model of target-controlled infusion (TCI), Injectomat total intravenous anaesthesia (TIVA) Agilia, Fresenius Kabi, France). If OAA/S did not reach 3 while Ce achieved 2.0 μg/ml, Ce was increased by 0.2 μg/ml every 90 seconds until OAA/S 3~2.~Maintenance: the Ce was increased by 2.0 μg/mL every 90 seconds if the patient persistently had eye opening, talked, or became irritable and interfered with the procedure. The Ce was reduced by 0.2 μg/ml every 90 seconds, if the following adverse events occurred: hypoxemia (SpO2 < 90%) or hypotension (mean arterial pressure (MAP) < 65 mmHg, or systolic blood pressure (SBP) < 90 mmHg) in any duration."
84997|NCT03521492|Diagnostic Test|serum vitamin D , calcium , parathyroid hormone and albumin level|measuring serum level of Vit. D, PTH, Calcium, and Albumin levels
84998|NCT03521479|Drug|Squaric Acid Dibutyl Ester|Repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12 months).
84999|NCT03521466|Behavioral|Smoking Cessation Counseling|Trained medical students will visit patients inpatient while hospitalized and provide smoking cessation counseling and recommend Nicotine Replacement Therapy. They will continue to follow these patients for 2 months after discharge and provide telephone-based counseling.
85000|NCT03521453|Other|PEPPER robot|Presence of a Robot (PEPPER Robot), designed and programmed to give informations, using a screen and vocal. All the patients in the second period will have access to,the robot, while waiting for the visit.
85001|NCT03521440|Behavioral|Psychomotor Massage|Sessions will be conducted by a graduated therapist, experienced in Psychomotor Massage and weekly supervised by a specialist in this therapeutic approach. The Psychomotor Massage involves smoothly touching the head, upper and lower limbs, followed by micro-stretching and slow mobilisations of upper and lower limbs.
85002|NCT03521440|Behavioral|Progressive Muscle Relaxation|Sessions will be conducted by a graduated therapist, experienced in Progressive Muscle Relaxation, and weekly supervised by a specialist in this therapeutic approach. The Progressive Muscle Relaxation protocol consists in tensing and releasing 16 muscle groups for several seconds, following a specific order.
85003|NCT03521427|Other|Intensive bimanual therapy|Ninety hours of intensive bimanual therapy
85004|NCT03521427|Other|Intensive neurodevelopmental therapy|Ninety hours of intensive neurodevelopmental therapy
85005|NCT03521414|Device|Bispectral index (BIS) monitoring|When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug
85006|NCT03521414|Drug|Sevoflurane|we used sevoflurane drug at inoperative
85007|NCT03521401|Behavioral|Exercise|Participants assigned to the exercise group will undergo structured, progressive resistance and aerobic exercise for 8 weeks. Resistance training and aerobic training will each be completed twice weekly for a total of 16 resistance and 16 aerobic exercise training sessions.
85008|NCT03521388|Behavioral|Take care of your mood (CUIDA TU ANIMO in Spanish)|The adolescents will be registered in the Website www.cuidatuanimo.org
85009|NCT03521388|Other|Control|The adolescents will visit the Website www.cuidatuanimo.org, but they can not register
85010|NCT03521375|Procedure|Open Surgery|Conventional open surgery is undertaken through a single incision +/- rib resection and with rib spreading. The operation is performed under direct vision with isolation of the hilar structures (vein, artery and bronchus) which are dissected, ligated and divided in sequence and the lobe of lung resected. The procedures may be undertaken using ligatures, over sewing or with staplers. Lymph node management is undertaken in accordance with the International Association of the Study of Lung Cancer (IASLC) recommendations where a minimal of 6 nodes / stations are removed, of which 3 are from the mediastinum that includes the subcarinal station. The thoracotomy is closed in layers starting from pericostal sutures over the ribs, muscle, fat and skin layers.
85011|NCT03521375|Procedure|Video Assisted Thoracoscopic Surgery (VATS)|VATS lobectomy is undertaken through one to four keyhole incisions without rib spreading. The use of 'rib spreading' is prohibited as this is the key intra-operative manoeuvre which disrupts tissues and causes pain (and is used in open surgery). The procedure is performed with videoscopic visualisation without direct vision. The hilar structures are dissected, stapled and divided. Endoscopic ligation of pulmonary arterial branches may be performed. The fissure is completed and the lobe of lung resected. Lymph node management is the same as described for open surgery. The incisions are closed in layers and may involve muscle, fat and skin layers. This definition of VATS lobectomy is a modification of CALGB 39802.
85012|NCT03521362|Device|MyT1DHero|MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
85013|NCT03521362|Device|Other T1D Mobile App|A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
85014|NCT03521349|Other|Whole Egg Intervention|Participants will consume an isocaloric muffin containing important bioactives from whole eggs.
85015|NCT03521349|Other|Egg White Control|Participants will consume an isocaloric muffin containing egg white, lacking important bioactives from whole eggs.
85016|NCT03521336|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
85017|NCT03521336|Drug|Placebo|Saline，Sham operation
85018|NCT03521323|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells
85019|NCT03521323|Drug|Placebos|Placebos: Saline，Sham operation
85020|NCT03521310|Procedure|Skin-to-skin|Neonates will get Skin-to-skin Contact with parent/caregiver continuously the first 6 hours after birth and as much as possible the first 72 hours after birth.
85021|NCT03521310|Procedure|Conventional care|Neonates will get Conventional care the first 72 hours after birth
85022|NCT03521297|Drug|UDCA combined probiotics|0.25g UDCA po third per day and 2g Live Combined Bifidobacterium and Lactobacillus Tablets po third per day for 6 month
85023|NCT03521284|Other|Parental educational program|Behavior: psychotherapy, life hygiene advice
85035|NCT03521167|Drug|Ketamine|"Intraoperatively use. 0.5 mg/kg with induction bolus, followed by 5mcg/kg/min infusion after induction.~Continue up to 1 hour prior to extubation. maximum total dose 3mg/kg."
85036|NCT03521167|Drug|Lidocaine|Intraoperatively use. start lidocaine infusion at 2mg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
85037|NCT03521167|Drug|Dexmedetomidine|Intraoperatively use. start dexmedetomidine infusion at 0.5 mcg/kg/min after anesthesia induction, and continue up to 1 hour prior to extubation.
85038|NCT03521167|Drug|Gabapentin|Postoperatively use. 300 mg PO TID starting POD1 until discharge Use lower dose for >65y or if patient having significant sedation/dizziness
85039|NCT03521167|Drug|Tylenol|Postoperatively use. 1000 mg PO Q8hr starting POD0 until discharge (max 3000 mg in 24hrs) Reduce to 650 mg PO Q6h if <70kg
85040|NCT03521167|Drug|Gabapentin Pill|Pre-operatively use. 300mg PO up to 1 hour before OR time Reduce to 100 mg PO in patients >65y or with GFR < 50 Consider dose reduction in patients with sleep apnea
85041|NCT03521167|Drug|Tylenol Pill|Pre-operatively use. 1000 mg PO up to 1 hour before OR time Reduce to 650 mg PO if <70kg Don't use if h/o liver disease or anticipated liver injury (right heart failure, pulmonary hypertension, etc leading to systemic venous congestion)
85042|NCT03521154|Drug|Osimertinib 80mg/40mg|The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
85043|NCT03521154|Drug|Placebo Osimertinib 80mg/40mg|"The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily.~Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met"
85044|NCT03521141|Drug|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
85045|NCT03521141|Drug|Varenicline|FDA-approved smoking cessation pharmacotherapy
85046|NCT03521141|Genetic|Nicotine metabolism|Information on nicotine metabolism will be used to inform selection of medication.
85047|NCT03521141|Genetic|Genetically-informed lung cancer risk score|This intervention uses information from a person's genes and smoking and family medical histories to estimate lung cancer risk compared to current smokers.
85048|NCT03521141|Behavioral|"NCI Clearing the Air"|A booklet-led intervention designed by the NCI to support cessation at any stage of a quitter's journey, whether they are still thinking about quitting, have made the decision to quit, or have already taken steps to quit and just need help maintaining their new lifestyle.
85049|NCT03521128|Procedure|radiological tubal blockage|In radiological tubal blockage group, under the fluoroscopy of X-ray, after confirming HX by HSG, selective catheterization will be done for the affected tube and micro spring coils will be put in to the interstitial tube and isthmus through micro catheter. The micro spring coil will be placed into the proximal end of the Fallopian tube (unilateral or bilateral depending on whether one or two HX were present) through micro catheter under the fluoroscopy of X-ray. Then HSG will be carried out to check the position of the micro spring coil and confirm complete blockage. Four weeks after the radiological procedure, a HSG will be performed to recheck the position of the micro spring coil and complete blockage of the tubes. FET is proceeded in the next menstrual cycle after HSG examination.
85050|NCT03521128|Procedure|laparoscopic salpingectomy|In the laparoscopic salpingectomy group, after confirming HX, a unilateral or bilateral salpingectomy will be performed in a standard manner, depending on whether unilateral or bilateral HX are present. In women with extensive pelvic adhesions during laparoscopy, proximal tubal ligation will be performed as an alternative procedure to salpingectomy. FET is proceeded in the next menstrual cycle after the laparoscopic operation.
85051|NCT03521115|Behavioral|Smart Choices 4 Teens|This is a web-based prevention program designed to convey information about alcohol and relationships and the types of choices that they are making regarding these topics. General communications was another core element of the program that provided parents and teens with some key elements of talking to each other.
85052|NCT03521102|Drug|Acetaminophen 1000mg IV|1000mg of IV acetaminophen in 100ml of normal saline, administered as an intravenous drip over 10 minutes + 2ml of normal saline, administered as a slow intravenous push
85053|NCT03521102|Drug|Hydromorphone 0.5 mg IV|100ml of normal saline, administered as an intravenous drip over 10 minutes, + 0.5mg of IV hydromorphone in 2ml of normal saline, administered as a slow intravenous push
85054|NCT03521089|Device|Soterix Medical 1x1 Low Intensity Transcranial Electrical Stimulator (tES) Model 2001|Transcranial direct current stimulation works by sending constant, low direct current through the electrodes. When these electrodes are placed in the region of interest, the current induces intracerebral current flow. This current flow then either increases or decreases the neuronal excitability in the specific area being stimulated based on which type of stimulation is being used. This change of neuronal excitability leads to alteration of brain function, which can be used in various therapies as well as to provide more information about the functioning of the human brain.
85055|NCT03521076|Device|Virtual Reality|Participants will have the opportunity to choose a game or relaxation experience to utilize during a botulinum toxin injection to distract from pain and anxiety during one visit. Virtual Reality will not be available during the other visit. AppliedVR has a number of games and relaxation experiences available for participants to chose from.
85056|NCT03521063|Drug|Budesonide|Drug: Budesonide inhalation suspension
85057|NCT03521063|Drug|Poractant Alfa|Drug: Poractant alfa intratracheal suspension
85058|NCT03521063|Drug|Saline|Sodium chloride injection 0.9%
85059|NCT03521050|Device|defibrillator lead|observation of long-term performance of defibrillator leads
85060|NCT03521037|Drug|Rucaparib camsylate|In Part I, eligible patients will receive a single oral dose of 600 mg rucaparib followed by intensive plasma PK sampling up to Day 7 (hour 144). In Part II, patients may continue to receive continuous oral rucaparib in 28 day cycles.
85061|NCT03521024|Other|poly ether ketone ketone|Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
85062|NCT03521024|Other|lithium disilicate|well documented in the literatures as successful restoration modality.
85063|NCT03521011|Device|MSCT|Non enhanced MSCT Abdomen
85064|NCT03520998|Drug|GRF6019|GRF6019 for IV infusion
85065|NCT03520985|Drug|Pomalidomide|"Pomalidomide (4 mg p.o.) will be administered on every other day of each 28-day treatment cycle.~Treatment duration:~Treatment cycles are repeated until disease progression."
85066|NCT03520985|Drug|Dexamethasone|"For patients ≤ 75 years of age:~Low-Dose Dexamethasone (40 mg p.o.) will be administered once per day on Days 1, 7, 15, and 21 of a 28-day cycle.~For patients > 75 years of age:~Low-Dose Dexamethasone (20 mg p.o.) will be administered once per day on Days 1, 7, 15, and 21 of a 28-day cycle.~Treatment duration:~Treatment cycles are repeated until disease progression."
85067|NCT03520972|Drug|PB-119 75ug|60 eligible patients will be included in this group
85068|NCT03520972|Drug|PB-119 150ug|60 eligible patients will be included in this group
85069|NCT03520972|Drug|PB-119 200ug|60 eligible patients will be included in this group
85070|NCT03520972|Drug|placebo|60 eligible patients will be included in this group
85071|NCT03520959|Biological|CMB305|Sequentially administered LV305 [lentiviral vector encoding New York esophogeal squamous cell carcinoma-1 {NY-ESO-1} gene] and G305 [NY-ESO-1 recombinant protein plus glucopyranosyl lipid A stable emulsion {GLA-SE}]
85072|NCT03520959|Other|Placebo|CMB305 placebo control
85073|NCT03520946|Drug|Ramucirumab|8 mg/kg iv over 60 min on d1+15, q4w
85074|NCT03520946|Drug|TAS 102|35mg/m2 p.o. twice daily (BID) d1-5 and d8-12, q4w
85075|NCT03520933|Diagnostic Test|PGT-A|PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
85076|NCT03520933|Diagnostic Test|niPGT-A|Non-invasive preimplantation genetic test for embryo aneuploidy analyzing the spent culture media where the embryo is incubated up to the time of transfer or freezing. This media contains traces of embryonic cell-free DNA (cfDNA) that can represent the genetic load of the embryo.
85077|NCT03520920|Drug|BGB-3111|"BGB-3111 at a dose of 160 mg orally (PO) twice daily (BID)~Rituximab will be administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10."
85078|NCT03520907|Drug|Transversalis Fascia Plane Block|block will be performed under real-time ultrasound guidance
85079|NCT03520907|Drug|Ilioinguinal/iliohypogastric Nerve Block|block will be performed under real-time ultrasound guidance
85080|NCT03520894|Radiation|Neoadjuvant radiotherapy|single 21 Gy fraction of Radiotherapy before surgery
85081|NCT03520881|Other|Pediatric ASTHMA-Educator mobile application|This intervention represents a mobile application (accessible by iOS and Android devices) that provides asthma education through games and videos.
85082|NCT03520868|Diagnostic Test|Monitoring Anti Factor Xa level|Each patient will have baseline Anti-Factor Xa assay checked. During the procedure, Anti-Factor Xa assay is checked concurrently with ACT after heparin bolus and infusion.
85083|NCT03520855|Other|Serious game|DIVE software will be accessible via internet, children and parents will have to their disposition a room at the hospital specifically to work on the software. The DIVE software is organized in chapters, each matches an item of the therapeutic education process and ends with a knowledge assessment. The child has to end every chapter and succeed every evaluation to pursue on the next chapter. Measures will be taken in order to avoid contamination bias between groups. Children will have to connect to DIVE 2 times per week for a time duration of at last 1 hour.
85084|NCT03520855|Behavioral|ETP|"Initial therapeutic education only will be applied in this group, with the help of doctors and nurses, based on theoretical educational lessons, reported on the AJD book.~Health education sessions will also be taught by nurses."
85085|NCT03520842|Drug|Methotrexate|Given PO
85086|NCT03520842|Other|Pharmacokinetic Study|Correlative studies
85087|NCT03520842|Drug|Regorafenib|Given PO
85088|NCT03520829|Device|Intuitive Plan|dosimetric planning software
85089|NCT03520816|Other|Burn Physiotherapy Protocol|It consisted of parameters such as early mobilisation and ambulatory training, chest physiotherapy, and both active and passive normal joint movement exercises.
85090|NCT03520803|Other|Enhanced recovery after surgery protocol|Experimental enhanced recovery protocol for pre-surgery and post surgery
85091|NCT03520790|Drug|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
85092|NCT03520790|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
85093|NCT03520790|Drug|Paricalcitol|Paricalcitol (IV or oral) is a man-made form of vitamin D. It is thought to work by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor.
85094|NCT03520790|Other|Placebo|Placebo
85095|NCT03520777|Other|Art Intervention|Type of artist intervention will be determined by the subject and the assigned artist.
85096|NCT03520764|Dietary Supplement|New infant formula with synbiotics|Infants are fed with synbiotics formula for 17 weeks from the date of enrollment.
85097|NCT03520764|Dietary Supplement|Standard infant formula with prebiotics|Infants are fed with prebiotics formula for 17 weeks from the date of enrollment.
85098|NCT03520751|Drug|scAAV1.tMCK.NTF3|gene vector
85099|NCT03520738|Other|Blood samples|Blood samples on an empty stomach
85100|NCT03520738|Other|Urinary samples|first urinary in the morning
85101|NCT03520725|Other|No Intervention|This gruop did not have an intervention
85102|NCT03520725|Dietary Supplement|Pineapple snack bar|30 g daily of pineapple snack bar
85103|NCT03520725|Dietary Supplement|Mango snack bar|30 g daily of mango snack bar
85104|NCT03520712|Biological|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
85105|NCT03520686|Drug|N-803 + Pembrolizumab|"The treatment plan in the experimental arm will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~Pembrolizumab (200 mg intravenous infusion [IV])~N-803 (15 μg/kg subcutaneously [SC])"
85106|NCT03520686|Drug|Pembrolizumab|"The reference treatment will consist of repeated 3-week cycles for a maximum treatment period of 2 years, in accordance with the following dosing regimen:~Day 1, every 3 weeks:~• Pembrolizumab (200 mg IV)"
85107|NCT03520673|Diagnostic Test|Urodynamics|All the men in the study will receive the urodynamics procedure as a reference test.
85215|NCT03519828|Other|No intervention has been conducted|It is an observational study, and no intervention has been conducted
85108|NCT03520647|Procedure|haplo-identical transplantation|Recipients will receive a non-myeloablative conditioning regimen of rabbit ATG 0.5 mg /kg (day-9) &amp; 2 mg /kg (day -8, -7), Fludarabine 30 mg/m2 IV daily from day -6 to -2, Cyclophosphomide 14.5 mg/kg IV daily on day -6 and -5 and 200 cG of TBI on day -1; unmanipulated GCSF mobilized PBSC graft on day 0 and GVHD prophylaxis with Tacrolimus, MMF and post-transplant cyclophosphamide administered at a dose of 50mg/kg given daily on days +3 and +4 post-transplant.
85109|NCT03520634|Other|PD-L1 PET imaging|PD-L1 PET imaging
85110|NCT03520621|Other|No intervention|no intervention
85111|NCT03520595|Drug|Arnica 200 drug 3 pills,3 times daily for 3 days|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
85112|NCT03520595|Drug|Diclofenac Sodium 50mg twice daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
85113|NCT03520595|Drug|Placebo pills and distilled water 3 pills,3 times daily|CLP with ostectomy done in patients whose biologic width and crown height is insufficient
85114|NCT03520582|Device|Tube placement|Placement of enteral feeding tubes
85115|NCT03520569|Drug|Octreotide|we are using it to block insulin secretion from the pancreas
85116|NCT03520569|Drug|Insulin|we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
85117|NCT03520569|Drug|Dextrose 20% solution|We are using dextrose to maintain glycemia level
85118|NCT03520543|Drug|[11C]Yohimbine|Each subject will receive an intravenous (IV) bolus injection of [11C]Yohimbine at a dose of 370 MegaBecquerel (MBq) ± 10% with concomitant arterial blood sampling. The distribution of [11C]Yohimbine in brain will be measured by dynamic PET scans obtained from the time of injection for up to 90 minutes along with measurement of the tracer input function with arterial samples for intact tracer and metabolites to establish the total and regional compartmental kinetics of [11C]Yohimbine.
85119|NCT03520543|Drug|[11C]Yohimbine (Part B1) and [11C]Yohimbine + clonidine (Part B2)|"Part B1 : Test Retest Variability will be assessed on percent difference in the binding potential following [11C]Yohimbine PET scan (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) obtained at least 1 week after [11C]Yohimbine PET scan of part A.~Part B2 : Occupancy of alpha2-adrenergic receptors in brain by clonidine will be evaluated by comparing the binding potential of [11C]Yohimbine (IV bolus injection of [11C]Yohimbine at a dose of 370 MBq ± 10%) after single oral dose of clonidine (0,15mg) to the binding potential of [11C]Yohimbine obtained at baseline (part A)."
85120|NCT03520530|Device|Mouth Guard|Patient will wear mouth guard while pushing in the second stage of labor
85121|NCT03520517|Drug|BHV-0223|BHV-0223, 40 mg BID
85122|NCT03520504|Radiation|Proton craniospinal irradiation (CSI)|Patients will be enrolled to receive 30Gy (RBE) in 3Gy (RBE) or 25Gy (RBE) in 2.5Gy (RBE) fractions course of proton CSI.
85123|NCT03520491|Drug|Nivolumab|Nivolumab 3 mg/kg or Nivolumab 1 mg/kg
85124|NCT03520491|Drug|Ipilimumab|Ipilimumab 3 mg/kg
85125|NCT03520491|Procedure|Radical cystectomy|RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)
85126|NCT03520478|Drug|SHR3680|Tablet. Specifications of 80 mg; orally, once a day
85127|NCT03520478|Drug|Bicalutamide|Tablet. Specifications of 50 mg; orally, once a day
85128|NCT03520465|Device|DynaMesh®-CICAT longitudinal measure 10x35 cm|
85129|NCT03520452|Other|Green coffee extract|Reconstituted in water and given to subjects
85130|NCT03520452|Other|Placebo|Placebo
85131|NCT03520439|Drug|Mifepristone|Oral mifepristone 10mg (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
85132|NCT03520439|Drug|Placebo|Oral Placebo Oral Tablet 1# (first menstrual third days), 1 times a day, 12 weeks, fasting or taking 2 hours after eating
85133|NCT03520426|Device|Votiva RF|The Votiva system is approved by the U.S. Food and Drug Administration for treatment of sexual dysfunction as well as in combination with Kegel exercises for tightening of the muscles of the pelvic floor to increase muscle tone. One part of the system, the fractora handpiece, is approved for tissue coagulation for the purpose of skin rejuvenation. The Votiva has two hand pieces, Forma and Fractora, which have been cleared by the United States Food and Drug Administration (FDA) and are used during dermatological procedures.
85134|NCT03520413|Other|PRACTICE-DM|Five-component diabetes intervention: 1) telemonitoring; 2) self-management support; 3) diet/activity support; 4) medication management; and 5) depression support.
85135|NCT03520413|Other|Standard VA Home Telehealth|Standard VA HT care coordination and telemonitoring.
85136|NCT03520400|Behavioral|Exercise Therapy|Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.
85137|NCT03520387|Procedure|Lumbar medial branch nerve radiofrequency ablation (LRFA)|Radiofrequency ablation of the dorsal rami of the lumbar spinal nerves, using electrode placement parallel to the medial branches, 18G electrodes or larger, and 2 lesions per nerve.
85138|NCT03520387|Procedure|Simulated LRFA with targeted steroid injections|Performed in an identical fashion to the experimental arm (LRFA), except for medial branch lesioning, which will not be done in simulated LRFA, and 2) the simulated LRFA control group will receive an injection of triamcinolone acetonide at each site where a radiofrequency lesion would normally be applied.
85139|NCT03520387|Behavioral|AcTIVE-CBT|AcTIVE-CBT involves a standardized CBT protocol for pain, delivered via a video telehealth interface. AcTIVE-CBT also incorporates use of an activity tracker to provide objective feedback on activity levels, which can inform participants' and providers' impressions of goals and progress.
85140|NCT03520387|Behavioral|TBSCE|TBSCE control is a focused program of CBT involving an initial 60-minute telephone education session by a psychologist; the provision of printed educational materials on chronic pain self-management, and a workbook for CBT self-management; and structured, written plans for weekly practice, reading and homework using the workbook.
85141|NCT03520374|Diagnostic Test|Ultrasonography|Ultrasonography use for the evaluation of gastric contents
85142|NCT03520361|Drug|Oral sulfate solution (OSS)|Compositions/177ml : Sodium sulfate 17.5g, Potassium sulfate 3.13g, Magnesium sulfate 1.6g
85216|NCT03519815|Device|Ectoin® Eye Spray - Colloidal|eye spray to be applied to the closed eye lid
85143|NCT03520361|Drug|2L PEG/Asc|Compositions/1L : Sodium chloride 2.89g, Potassium chloride 1.015g, Anhydrous sodium sulfate 7.5g, Polyethylene glycol 3350 100g, Ascorbic acid 4.7g, Sodium ascorbate 5.9g
85144|NCT03520348|Drug|PRO-167|"Dexpanthenol 5%. Ophthalmic gel produced by Laboratorios Sophia, S.A. of C.V., Zapopan, Jalisco, Mexico.~Route of administration: ophthalmic"
85145|NCT03520348|Drug|Corneregel|Dexpanthenol 5%. Ophthalmic gel developed by Bausch and Lomb, Berlin, Germany. Route of administration: ophthalmic
85146|NCT03520322|Device|Mastoid Oscillator|The oscillator will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
85147|NCT03520322|Device|Control Device|The control device will be placed over the mastoid of their involved ear and secured via an elastic/Velcro headband. The subject is positioned so as to place the endolymphatic duct into a gravitationally dependent orientation (the subject lying on their contralateral side with the face slightly tilted towards the floor). The device is turned on and operated for 30 minutes.
85148|NCT03520309|Procedure|Dental treatment|Treatment of all dental restorations of the children according to the diagnosis criteria
85149|NCT03520296|Other|Questionnaire|Questionnaire evaluating well-being in relation to diet and nutrition
85150|NCT03520283|Other|Interview|Ancillary studies
85151|NCT03520283|Other|Questionnaire Administration|Ancillary studies
85152|NCT03520283|Behavioral|System Support Mapping|Complete MAP
85153|NCT03520257|Drug|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.
85154|NCT03520257|Device|Radiotherapy|Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
85155|NCT03520244|Behavioral|Exercise + Holistic Education|The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
85156|NCT03520231|Drug|Denosumab|RANK Ligand Inhibitor
85157|NCT03520231|Other|Denosumab Placebo|Placebo
85158|NCT03520231|Drug|Gemcitabine|Antineoplastic Agent
85159|NCT03520231|Drug|Carboplatin|Antineoplastic Agent
85160|NCT03520231|Drug|Cisplatin|Antineoplastic Agent
85161|NCT03520231|Dietary Supplement|Calcium|Calcium Supplement
85162|NCT03520231|Dietary Supplement|Vitamin D|Vitamin D Supplement
85163|NCT03520218|Device|Performance of R-PEM|R-PEM imaging will produce high-sensitivity images with low levels of F-18 FDG and optional subsequent scans performed will display reduced levels of the injected radiotracer.
85164|NCT03520205|Procedure|Quadratus Lumborum Block|Bilateral block using ultrasound will be performed before surgery and after surgery on patient using Stimuplex 100mm needle with Bupivacaine 0.25% 0.4 mL/kg, maximum dose 25 mL each side under general anaesthesia
85165|NCT03520205|Procedure|Continuous Epidural|Patient will be given 6 mL/hour of Bupivacaine 0.25% for intraoperative analgesia and continued epidural 6 mL/hour Bupivacaine 0,125% as postoperative analgesia in 24 hours.
85166|NCT03520166|Other|Medium frequency electrotherapy (interferential currents)|Treatment with medium frequency electrotherapy, interferential currents between 5500 Hz and 8500 Hz (Combi-200®, Gymna®), was performed using transvaginal application. The frequency was increased progressively over the first six sessions (twice a week), starting with a frequency of 5500 Hz until reaching a frequency of 8500 Hz, which remained until the end of treatment.
85167|NCT03520166|Other|No treatment|No treatment
85168|NCT03520153|Procedure|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
85169|NCT03520153|Procedure|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
85170|NCT03520153|Diagnostic Test|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
85171|NCT03520127|Device|Intact Breast Lesion Excision System (BLES)|Intact BLES is an automated, percutaneous biopsy device capable of delivering a surgical quality specimen for histological review of breast abnormalities. It is uniquely suited to maintain lesion architecture within the biopsy sample, providing an opportunity for pathological assessment and the potential avoidance of an open surgical procedure.
85172|NCT03520114|Device|RP sling placement|A 1.5 cm incision will be made at the mid-urethra through a separate vaginal incision with lateral dissection with Metzembaum scissors. After placement of both trocars, cystoscopy with a 70-degree scope will be performed to assess for bladder and urethral injury. Surgeons will set the tension of the tension-free vaginal tape (TVT) slings so that a spacer can be placed between the sling and the urethra. Sling tensioning will be performed after anterior and apical prolapse is corrected.
85217|NCT03519815|Device|Liposomal eye spray Tears Again®|eye spray to be applied to the closed eye lid
85218|NCT03519776|Diagnostic Test|Progesterone variation|The potential gain for medical caretakers and patients would be a certainty if the progesterone level is affected by variations during daytime
85219|NCT03519763|Diagnostic Test|ultrasound|All the patients will have a transvaginal ultrasound evaluation during the first visit to the clinic to evaluate the presence or not of isthmocele.
85173|NCT03520114|Device|SIS placement|The sling is introduced through a single anterior vaginal incision of 1.5 cm at the mid-urethra. The sling/needle assembly is advanced behind the ischiopubic rami in a transobturator trajectory toward the obturator space bilaterally.The needle is then removed by simply sliding the fixating tip back out. The other side is then completed in an identical fashion. After the fixation of the two anchors at the 2 and 10 o'clock positions, the patient's bladder is filled with 250 mL of NaCl. Afterward, an intraoperative crede maneuver is performed and the tension adjustment suture is pulled, when necessary, to achieve the desired continence. The mesh will lie in direct apposition to the urethra. The adjustment thread is then cut short and the vaginal incision is closed with an absorbable suture.
85174|NCT03520101|Procedure|TAVI_ViV procedure with Edwards valve|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. The decision for selecting either a 20 or 23mm Edwards valve will be based on 3D CT measurements of the mean inner diameter of the surgical aortic bioprosthesis. A 23mm Sapien 3 valve will be recommended if the inner diameter is >18 mm, and a 20mm valve will be selected if the mean inner diameter is ≤18 mm.
85175|NCT03520101|Procedure|TAVI_ViV procedure with CoreValve system|The TAVR procedure will be performed following the standards of each participating center. No restriction or specific recommendation will be given regarding the approach, general vs. local anesthesia, imaging guidance during the TAVI procedure, and post-procedural TAVI management. A 23mm valve will be recommended in all patients randomized to the self-expanding CoreValve Evolut R system.
85176|NCT03520088|Procedure|Inferior mesenteric Vein dissection|Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
85177|NCT03520088|Procedure|Inferior mesenteric Artery dissection|Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
85178|NCT03520075|Drug|ASTX029|Described above
85179|NCT03520062|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|Treatment with Liraglutide (3.0mg per day) for ~6 weeks
85180|NCT03520049|Drug|Oseltamivir|
85181|NCT03520049|Drug|Placebo|
85182|NCT03520036|Drug|MT-7117 low dose|MT-7117 low dose QD, oral, 16 weeks
85183|NCT03520036|Drug|MT-7117 high dose|MT-7117 high dose QD, oral, 16 weeks
85184|NCT03520036|Drug|Placebo|Placebo QD, oral, 16 weeks
85185|NCT03520023|Other|Palliative Care Consult|Consult of hospital palliative care service for those meeting study inclusion criteria
85186|NCT03520010|Behavioral|Externally-facilitated implementation|NHs randomized to the externally-facilitated arm will attend the same kickoff meetings and have access to the same online resources as the control arm but will also be assigned a clinical coach and will have the opportunity to participate in a series of hosted peer-to-peer learning opportunities. The clinical coach will meet regularly with NH staff to guide the facility through implementation of the Wisconsin UTI Improvement Toolkit.
85187|NCT03520010|Behavioral|Internally-driven implementation|Study NHs randomized to the control arm will participate in kickoff meetings introducing the different UTI toolkit components. The meeting will also cover topics on how to assemble a change team, how to use the different tools in the UTI toolkit, and how to track process and outcome measures to monitor progress. NHs assigned to the control arm will have access to a web-based data tracking tool that will allow them to trend a number of study outcomes (e.g., number of monthly urine cultures and UTI treatment events) in their facility over time. Instructions and educational tools will be made available as an online resource but otherwise NHs in the control arm will be expected to implement the Wisconsin UTI Improvement Toolkit using existing internal resources.
85188|NCT03519997|Drug|Pembrolizumab|Pembroluzumab 200mg IV once every 3 weeks
85189|NCT03519997|Drug|Bavituximab|Bavituximab 3mg/kg IV weekly
85190|NCT03519984|Drug|Cytarabine|Given IV
85191|NCT03519984|Other|Laboratory Biomarker Analysis|Correlative studies
85192|NCT03519984|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
85193|NCT03519984|Drug|Vincristine Liposomal|Given IV
85194|NCT03519971|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
85195|NCT03519971|Other|Placebo|Placebo IV (intravenous infusion)
85196|NCT03519971|Drug|Cisplatin/ Etoposide|Cisplatin/ Etoposide, as per standard of care
85197|NCT03519971|Drug|Carboplatin/ Paclitaxel|Carboplatin /Paclitaxel, as per standard of care
85198|NCT03519971|Drug|Pemetrexed/ Cisplatin|Pemetrexed / Cisplatin, as per standard of care
85199|NCT03519971|Drug|Pemetrexed/ Carboplatin|Pemetrexed / Carboplatin , as per standard of care
85200|NCT03519971|Radiation|Radiation|5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)
85201|NCT03519958|Diagnostic Test|Plasma-tissue testing|EGFR T790M mutation plasma-tissue testing in NSCLC patients who progressed on previous EGFR TKI
85202|NCT03519945|Drug|Mirikizumab|Administered SC.
85203|NCT03519932|Device|comfilcon A toric lens|Contact lens
85204|NCT03519932|Device|samfilcon A toric lens|Contact lens
85205|NCT03519919|Device|somofilcon A multifocal lens|contact lens
85206|NCT03519906|Drug|Metoprolol|Patients are tested for their normal prescription metaprolol medication
85207|NCT03519893|Drug|Losartan|Patients are tested for their normal prescription losartan medication
85208|NCT03519880|Device|Custom Mask Interface|Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
85209|NCT03519867|Drug|MK-8616|MK-8616 will be administered at doses of 0.5, 1.0, 2.0, 4.0 and 8.0 mg/kg iv as a 30-second infusion. Doses are based on actual body weight.
85210|NCT03519867|Drug|Zemuron®|Zemuron® (0.6 or 1.2 mg/kg, iv) will be administered as a 10-second bolus infusion to achieve 1 to 2 PTCs. If needed, a maintenance dose of 0.15 mg/kg will be given. Doses are based on actual body weight.
85211|NCT03519854|Drug|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
85212|NCT03519854|Drug|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds), dosed according to participant actual body weight.
85213|NCT03519854|Drug|Esmeron®|Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
85214|NCT03519841|Device|P0.1|Investigational Medical Device collecting spectral Raman data from tissue.
85220|NCT03519750|Drug|Melatonin 25 mg|24-48 hour monitoring of plasma melatonin as well as adverse events.
85221|NCT03519737|Device|tPA in combination with the Sonolysis Headframe (TUS)|tPA: 60 minutes per approved labeling TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
85222|NCT03519737|Device|tPA in combination with the Sonolysis Headframe (Sham TUS)|tPA per approved labeling Sham (inactive) TUS insonation via the Sonolysis Headframe: minimum 90 minutes - maximum 120 minutes
85223|NCT03519724|Drug|Sugammadex|Reversal of deep NMB
85224|NCT03519724|Drug|Neostigmine|Reversal of moderate NMB
85225|NCT03519711|Drug|CNSA-001|Two different doses of CNSA-001 compared to each other
85226|NCT03519698|Other|Warm water|Footbaths were prepared with 12 liters of warm water (40 °C)
85227|NCT03519698|Other|Mustard|12 l footbath with warm water (40 °C) and 80 g mustard flour (Sinapis nigrea semen plv.)
85228|NCT03519698|Other|Ginger|12 l footbath with warm water (40 °C) and 80 g ginger flour (Zingiberis rhizoma plv.)
85229|NCT03519685|Behavioral|Contraceptive Training and Education|Staff at the student health center and local health centers where they refer for contraceptive services will receive a CME-accredited education and training session and technical assistance. The one-day session emphasizes evidence-based and patient-centered contraceptive counseling and provision. Students attending colleges assigned to the intervention arm will receive materials and resources designed to educate young people about contraceptive methods and where to access services.
85230|NCT03519685|Behavioral|Placebo Nutrition Education|Students attending colleges assigned to the nutrition education arm will receive materials and resources designed to educate young people about the impacts of sugar on health.
85231|NCT03519672|Other|No intervention|This is a non-interventional study.
85237|NCT03519646|Drug|Eliglustat|"This is a 3-year study and the enrollment time of this study is 24 months.~The participants have to receive the investigational agent, Cerdelga~The participants have to go back to the hospital and receive the investigational agent and take the test before receving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga.~IMP Administration Method: Cerdelga have 21 mg、42 mg and 84 mg capsule.~No need for fasting before use, but can't take with grapefruit juice.~Five ml Blood and 10 ml urine shoud be taken before receiving Cerdelga, and 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga for Gaucher related biomarkers test."
85238|NCT03519633|Drug|Sugammadex|Reversal of deep NMB
85239|NCT03519633|Drug|Neostigmine|Reversal of moderate NMB
85240|NCT03519620|Other|SWWSV|Behaviours to prevent child obesity
85241|NCT03519607|Behavioral|FertiStrong App|The FertiStrong mobile app is similar to FertiCalm, which is designed for women with infertility. FertiCalm (www.FertiCalm.com) can be downloaded for free anywhere in the US, for both Apple and Android phones. Each app contains twelve main categories and each main category contains up to five tailored situations. For each situation, there are six options. Three of the options are the same for all situations (humor, self-nurture, relaxation) and three are unique (cognitive solutions, behavioral solutions, social solutions).
85242|NCT03519581|Device|Micropulse Laser Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. Application of micropulse laser on retinal surface will occur using TxCell Scanning Delivery System in a 7 x 7 grid to surround the fovea.
85243|NCT03519581|Device|Sham Treatment|Participant's study eye will be dilated prior to being comfortably seated at the slit lamp for treatment. No actual laser treatment will occur.
85244|NCT03519568|Biological|EV71 (inoculation vaccine)|EV71 vaccine 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 10μg HepB 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China 30ug MPSV-A 0.5ml per dose, Wuhan Biological Products Co., Ltd., Wuhan, Hubei Province, China MR 0.5ml per dose, Beijiing Biological Products Co., Ltd., Beijing, China JE-L 0.5ml per dose, Chengdu Biological Products Co., Ltd., Chengdu,Sichuan Province, China
85245|NCT03519542|Drug|Sunitinib|Identify prognosis and predictive biomarkers of response to sunitinib and pazopanib as first line therapy in avanced or metastatic renal cell carcinoma.
85246|NCT03519516|Drug|PRO-174|"Pharmaceutical form: ophthalmic solution~Prepared by: Laboratorios Sophia, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: sterile multi-dose bottle"
85247|NCT03519516|Drug|Sophixín Ofteno®|"Active substance: Ciprofloxacin 0.3%~Pharmaceutical form: Ophthalmic solution~Prepared by: Laboratorios Sophia, S.A. of C.V.~Description of the solution: transparent solution, free of visible particles.~Description of container: sterile multi-dose bottle"
85248|NCT03519490|Device|Hybrid Contact Lens|Hybrid Single Vision or Multifocal Contact Lenses in Near Center and Distance Center Designs
85249|NCT03519477|Diagnostic Test|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples
85250|NCT03519464|Biological|Gardasil 9 (recombinant HPV 9-valent vaccine)|GARDASIL 9 administered as a 0.5-mL intramuscular injection in the deltoid region of the upper arm or in the anterolateral area of the thigh, 3-dose regimen of injections given at month 0, month 2, and month 6.
85251|NCT03519451|Other|Internet-Based Intervention|Given KickAsh smartphone mobile application
85252|NCT03519451|Other|Internet-Based Intervention|Given Breathe2Relax smartphone mobile application
85253|NCT03519451|Other|Questionnaire Administration|Ancillary studies
85254|NCT03519438|Other|Mepitel|Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
85255|NCT03519425|Other|Optimised HIV screening and linkage to care|As described in group descriptions
85256|NCT03519425|Other|Optimised tuberculosis screening and linkage to care|As described in group descriptions
85257|NCT03519412|Drug|temozolomide (induction),|temozolomide is administered to MGMT promoter methylation-positive MMRp patients orally, once daily, at the dose of 150-200 mg/m2/day for 5 consecutive days of each treatment cycle A treatment cycle will comprise 5 days of temozolomide administration (Day 1 to 5) followed by 23 days of rest for a total of 28 days (4 weeks) period (dose-schedule: 150 mg/m2 day 1-5 q28),until disease progression or unacceptable toxicity whichever comes first.
85258|NCT03519412|Biological|pembrolizumab (treatment)|pembrolizumab is administered to MGMT-IHC-negative, MGMT promoter methylation-positive MMRp patients with TMB>20 Mut/Mb after Temozolomide treatment, and to MMRd. Patients receive pembrolizumab IV , 200 mg Q3W, Day 1 of each 3 week cycle for maximum 35 cycles, until disease progression or unacceptable toxicity whichever comes first.
85259|NCT03519399|Device|Monica AN24|Monica AN24 will be used to record maternal and fetal ECGs. The Zephyr will be used to determine maternal lie.
85260|NCT03519386|Combination Product|G2TR intraocular implant containing travoprost|Provided in Arm/Group descriptions.
85261|NCT03519386|Drug|Sham surgery + active-comparator eye drops|Sham surgery plus postoperative active-comparator eye drops (timolol maleate ophthalmic solution, 0.5%).
85262|NCT03519373|Biological|TDaP|Tetanus, Diphteria and Acellular Pertussis vaccine (Boostrix)
85263|NCT03519360|Other|UFR-restricted dialysis|UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
85264|NCT03519360|Other|UFR-unrestricted dialysis|UFR's will be unlimited and prescribed according to the standard of care.
85265|NCT03519347|Other|Potassium Removal Maximization|This intervention will test whether prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia reduces the incidence of clinically significant arrhythmias compared to an approach minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
85266|NCT03519347|Other|Potassium Gradient Minimization|This intervention will test whether minimizing intradialytic fall in serum potassium by using higher potassium dialysates to minimize serum-dialysate potassium gradients reduces the incidence of clinically significant arrhythmias compared to an approach prioritizing lower potassium dialysate to reduce the incidence of hyperkalemia. This will be achieved by utilizing an algorithm which couples point-of-care-testing with the choice of one of two dialysate potassium concentrations (2 or 3 mEq/L) that are widely available in dialysis clinics.
85267|NCT03519347|Other|Alkalosis Avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing alkalosis avoidance by use of lower dialysate HCO3 concentrations.
85268|NCT03519347|Other|Acidosis avoidance|The bicarbonate (HCO3) concentration will be adjusted according to the results of point of care testing of serum chemistries and an algorithm prioritizing acidosis avoidance by use of higher dialysate HCO3 concentrations.
85269|NCT03519321|Device|MID-C|The MID-C system is being connected to the spine via standard unilateral posterior approach. Pedicle screws above and below the main curve are being used to attach the device to the selected vertebra.
85270|NCT03519308|Drug|Nivolumab|Before Surgery Wks 1 &3, After Surgery Wks 1 &3
85271|NCT03519308|Drug|Nab-Paclitaxel|Wks 1,2,3 before surgery and Wks 1, 2,3 after surgery
85272|NCT03519308|Drug|Gemcitabine|Wks 1,2,3 before surgery and Wks 1,2,3 after surgery
85273|NCT03519308|Drug|Paricalcitol|Wks 1,2,3, 4 before surgery and Wks 1,2,3 after surgery
85274|NCT03519295|Drug|MPDL3280A|MPDL3280A (atezolizumab) will be administered every 2 weeks at 800 mg for 12 months.
85275|NCT03519295|Drug|mDCF|Patients will receive 8 cycles of mDCF (docetaxel 40 mg/m2 day 1, cisplatin 40 mg/m2 day 1 and 5FU at 1200 mg/m2/day for 2 days) every 2 weeks
85276|NCT03519269|Device|Navio™ Robotics-assisted Surgical System|Intervention will evaluate the utility of robotic-assistance in patients undergoing total knee arthroplasty
85277|NCT03519256|Biological|Nivolumab|Specified dose on specified day
85278|NCT03519256|Biological|BCG|Specified dose on specified day
85279|NCT03519256|Drug|BMS-986205|Specified dose on specified day
85280|NCT03519243|Biological|BCD-131|subcutaneously monthly
85281|NCT03519243|Biological|Mircera|subcutaneously monthly
85282|NCT03519230|Drug|Pamiparib capsule|60 mg BID, PO
85283|NCT03519230|Drug|Placebo capsule|60mg BID, PO
85284|NCT03519204|Device|JUVÉDERM® VOLBELLA® XC with Lidocaine|JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips.
85285|NCT03519204|Other|No-treatment Control|No-treatment was administered.
85286|NCT03519191|Behavioral|Healthy Relationships Education (HRE)|Healthy Relationships and Economic Pathways involves formal classes in Healthy Relationship Education (HRE), comprehensive case management, and support services and referrals to services.
85287|NCT03519191|Behavioral|HRE+Technology Bootcamp|HRE + Technology Bootcamp involves formal classes in Healthy Relationships Education (HRE), comprehensive case management, support services and referral to services, 6-week intensive website and professional development training, and paid work experience developing a website for a local small business and mentorship.
85288|NCT03519178|Drug|PF-06873600|PF-06873600 tablet for oral dosing
85289|NCT03519178|Drug|Endocrine Therapy 1|Endocrine Therapy 1
85290|NCT03519178|Drug|Endocrine Therapy 2|Endocrine Therapy 2
85291|NCT03519165|Device|EV1000(FloTrac System 4.0)|
85292|NCT03519152|Drug|low dose diclofenac|it is a split mouth design in which one side recieved low dose diclofenac(25mg) after periodontal flap surgery and in next week second side will recieve diclofenac 50mg after flap surgery.
85293|NCT03519139|Other|individual dietary counselling|individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
85294|NCT03519126|Other|electrostimulation|Electrostimulation with asymmetric and depolarized biphasic current with a frequency of 10Hz and a pulse width of 200μs.
85295|NCT03519113|Biological|GC1102 80,000 IU|recombinant human hepatitis B immunoglobulin
85296|NCT03519113|Biological|GC1102 100,000 IU|recombinant human hepatitis B immunoglobulin
85297|NCT03519113|Biological|I.V HBIG|human anti-hepatitis B Immunoglobulin
85298|NCT03519100|Other|quality of life evaluation|quality of life evaluation post surgery
85299|NCT03519087|Other|Interdisciplinary Evaluation for Nonarthritic Hip Disease|The hip arthroscopist will conduct his or her standard-care evaluation including subjective interview, patient history, imaging, and physical examination. The physical therapist will conduct an assessment of posture and movement during sitting, standing, squatting, and walking. After providers discuss their findings, they will discuss the plan of care with the participant.
85300|NCT03519087|Other|Posture and Movement Training|Physical therapists will lead participants through an intervention protocol to normalize seated and standing posture and function movement. Verbal, visual, and tactile cues, along with strengthening exercises will be provided to train posture and movement.
85301|NCT03519087|Other|Treatment-of-choice|Participants may proceed with any treatment-of-choice, which may or may not have been recommended by their health care provider(s). Treatments will be recorded, but not controlled.
85302|NCT03519074|Drug|TS-1 combined with cisplatin|Cisplatin 60mg/m2, day 1, every 21 days Oral TS-1 30mg/m2 bd, days 1-14, every 21 days (absolute dose of oral TS-1 will be 40-60mg bd days 1-14, every 21 days, depending on body surface area)
85303|NCT03519061|Drug|Budesonide|Nasal saline irrigations with budesonide
85304|NCT03519048|Procedure|Nasofibroscopy|every 1-3 months first year post-treatment, every 2-4 months second year, every 4-6 months third year (mean of around 13 visits) and every 6 months thereafter
85305|NCT03519048|Other|Low Dose Chest CTscan|every year in patients with tobacco consumption history of > 20 pack-year
85306|NCT03519048|Other|injected CT-scan|the first performed 12 months after inclusion
85307|NCT03519048|Other|whole body PET-CT|annual whole body PET-CT (the first at 6 months after inclusion)
85308|NCT03519048|Procedure|Lugol upper gastrointestinal endoscopy|the first performed 12 months after inclusion
85309|NCT03519048|Procedure|Biopsy|In both arm, patient will have a confirmation biopsy in case of suspicion of relapse or second primary.
85310|NCT03519035|Other|To pass different questionnaires|Patients will have to pass different questionnaires (DIB-R, DES II, THQ, PCL-S, PSAS, qualitative questionnaire) in order to compare the characteristics between BDL patients with and without hallucinations.
85311|NCT03519022|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and duloxetine.
85312|NCT03519022|Drug|Placebo oral capsule|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
85313|NCT03519022|Drug|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
85314|NCT03519009|Behavioral|IPS Plus Abstinence-Contingent Wage Supplement|Participants are offered abstinence-contingent wage supplements if they obtain and maintain competitive employment. The wage supplements are designed to promote employment while reinforcing drug abstinence. To help participants obtain and maintain competitive employment, participants will receive Individual Placement and Support (IPS) supported employment. IPS is a supported employment intervention that has been proven effective in promoting employment in adults with severe mental illness. To promote employment and prevent relapse to drug use, participants will receive IPS Plus Abstinence-Contingent Wage Supplements.
85315|NCT03518996|Device|rTMS/iTBS/tACS|Subjects with delirium and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
85316|NCT03518996|Device|Sham TMS/tACS|Subjects with delirium and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
85317|NCT03518983|Device|Dornier Aries2 device|The Dornier Aries2 device and will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft and the 2 crura(two sites).
85318|NCT03518983|Device|Dornier Aries2 device (sham probe)|The Dornier Aries2 device and will be used for the purpose of the study but the active probe will be replaced by an identical sham probe.
85319|NCT03518970|Other|Nursing intervention|"The intervention was built on the components of the theory of uncertainty in illness and was designed to give in a face to face meeting with the caregiver education about advanced cancer in palliative care through an educational material.~Educational material: The educational booklet has the purpose of giving information to the family caregiver about palliative care. This material aims to be an easily accessible resource to understand the palliative care of the cancer patient. In addition, this booklet will be used to ensure the standardization of the intervention during the face-to-face meeting with the participants and the investigator.~Face-to-face meeting: The nursing intervention has a face-to-face meeting component between the investigator and the participant. This nursing educational session will be supported by the contents of the booklet and will have the purpose of discussing the contents of the booklet and resolving doubts on the part of the family caregivers."
85320|NCT03518957|Behavioral|Exercise|"Week 1: Patients will undergo an introductory session where the occupational therapist will assess the general condition and physical fitness of the subjects.~Week 1 to Week 12: Group exercise sessions supervised by a physiotherapist, twice per week, each session lasting 1 hour, with no more than 8 participants in each group exercise session. The exercise regimen for each session will be personally tailored for the subjects, and will include stretching, cardiovascular and strength training, and cooling down exercises.~Week 12 onwards: Patients will receive phone calls- monthly for the first 6 months and then 3 monthly up to the 2-year mark, to encourage them to continue with their exercise regimen at home."
85321|NCT03518931|Diagnostic Test|Fitness testing|The intervention in this study was measuring cardiorespiratory fitness and muscular strength and providing normative data to subjects.
85322|NCT03518905|Device|Radiofrequency ablation|Radiofrequency ablation is performed using the Barrx Channel endoscopic catheter (Medtronic, Dublin, Republic of Ireland) generating an energy density level of 12 Joule/cm2. The energy is applied using a simplified protocol of three ablations without removal of coagulated tissue. The device is used on a routinely basis all around the world and already approved. The ablation catheter is applied through the working channel of the endoscope.
85323|NCT03518905|Procedure|esophagoscopy|Patients receive an esophagoscopy without radiofrequency ablation under sedation
85324|NCT03518892|Diagnostic Test|Resting Metabolic Rate|30 minute test to determine daily caloric needs
85325|NCT03518892|Diagnostic Test|Body Composition|Total Body DXA scan to determine fat mass, fat-free mass, and percent body fat
85326|NCT03518892|Behavioral|Dietary Assessment|Self administered dietary logs
85327|NCT03518879|Other|ASTHMA-Educator mobile application|The on-site delivered ASTHMA-Educator mobile application.
85328|NCT03518853|Radiation|Short-course Hypofractionated Once-weekly Radiation Therapy|Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
85329|NCT03518840|Device|SIJ Belt|Support Belts
85330|NCT03518827|Other|Asymmetry measurement|There is no intervention, the study will prospectively assess associations between asymmetries and injury risk. Asymmetry measurement will be conducted, then injuries will be tracked.
85331|NCT03518814|Other|Questionnaires|FACT-M (Functional Assessment of Cancer Therapy - Melanoma) questionnaire, MOS SF (medical outcome study short form) -36 questionnaire
85332|NCT03518801|Behavioral|Prolonged Exposure|psychotherapy
85333|NCT03518801|Drug|Cannabidiol|active medication
85334|NCT03518801|Drug|placebo|non-active medication
85335|NCT03518788|Procedure|Pleur-X|Permanent drainage
85336|NCT03518788|Procedure|Pleurodesis|Pleurodesis with talc in permanent VATS
85337|NCT03518775|Device|Biometry|Measurement of Cornea
85338|NCT03518762|Procedure|Sustained lung inflation (SLI)|SLI was given using a peak pressure of 20 cm H₂O sustained for 15 seconds,using a T-piece resuscitator, Neopuff device
85339|NCT03518762|Procedure|Continuous positive airway pressure (CPAP)|CPAP through an appropriate mask using a pressure 5 cm H₂O,using a T-piece resuscitator, Neopuff device.
85340|NCT03518749|Other|1mA tDCS|transcranial direct current stimulation with the intensity of 1mA
85341|NCT03518749|Other|2mA tDCS|transcranial direct current stimulation with the intensity of 2mA
85342|NCT03518749|Behavioral|Cognitive control training|cognitive control training with the PASAT
85343|NCT03518736|Behavioral|Supporting Play Exploration and Developmental Intervention (SPEEDI)|Physical Therapy intervention
85344|NCT03518723|Other|Non-linear Periodized Resistance Training|8 week non-linear periodized resistance training intervention, 3 sessions per week, 60 minutes per session
85345|NCT03518723|Other|Resistance training|8 week resistance training intervention, 3 sessions per week, 60 minutes per session
85346|NCT03518710|Other|Neuropsychological evaluation|"Neuropsychological evaluation (about 60 min) the same day realized by a student in Science Thesis under the responsibility of Prof. Yves Chaix and including:~Process evaluation:~Oculomotors: DEM test (5min)~Visuo-attention: computerized STROOP (15min)~Visuo-Perceptive: DTVP3 (30min)~Phonological & lexical: Exalang (10min)"
85347|NCT03518710|Other|Evaluation of the reading assistance technique|"Evaluation of the reading assistance technique (about 30 min) and comprising:~- Reading evaluation:Test lark (3min) Experimental task: 3-way help with reading (without help, color help and highlight help (25 min)"
85348|NCT03518697|Behavioral|exercise program|"The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients."
85349|NCT03518684|Drug|Natalis|"A specially-designed sterile obstetric gel (Natalis) will be used for this trial. The obstetric gel is a birth gel with no pharmacologic effects that has a purely physical activity. It contains propylene glycol, glycerol, sodium chloride, xanthan gum, hydroxyethylcellulose and water.~Starting with the first vaginal examination the obstetric gel will be used. After each vaginal examination, 3-5 mL of obstetric gel will be introduced into the vaginal birth canal in the area in front of the child using the sterile obstetric gel applicator without any manipulation or massaging. Additional obstetric gel will be added 15-30 minutes after rupture of the membranesOnce the head of the child is visible, the mouth and nose region will be wiped clean. A dry towel will be used to liberate the child in order to prevent the child from slipping"
85350|NCT03518671|Behavioral|cognitive behavioral therapy, face to face|self-limited cognitive behavioral therapy delivered weekly for 5 weeks via face-face delivery method
85351|NCT03518671|Behavioral|cognitive behavioral therapy, telemedicine|self-limited cognitive behavioral therapy delivered weekly for 5 weeks via tablet-based telemedicine platform
85352|NCT03518658|Other|Evaluation Group|Patient receiving exposure to the MyCareLink Heart App during device pairing
85353|NCT03518658|Other|Control Group|Patients receiving exposure to the CareLink Monitor 2490 (Excluding wireless model 2490C)
85354|NCT03518645|Device|OPN strategy|Predilatation with OPN balloon will be performed as a lesion preparation for BVS Absorb implantation.
85355|NCT03518645|Device|standard strategy|Predilatation with standard balloon will be performed as a lesion preparation for BVS Absorb implantation.
85356|NCT03518632|Behavioral|Interval training|Patients in experimental group will perform a 6 weeks' physical activity program with 3 sessions per week. Physical activity intervention will consist in 2 different interval training programs on cycloergometer: Interval training 1 and Interval training 2, with a difference in exercise intensities.
85357|NCT03518632|Other|Standard Oncologic care|Patients in control group will follow the standard oncologic care. They will perform only 2 sub-maximal exercises.
85358|NCT03518619|Behavioral|PFIcope+EMI|The intervention will be comprised of (1) an initial orientation session where the intervention is introduced, receipt of personalized normative information, motives feedback, and the development of an individual's personalized relapse prevention coping skills messages to be utilized through the course of the intervention; (2) EMA for monitoring of affect, drinking intention, alcohol use, and coping skills use; (3) EMI-tailored text messages sent based on EMA responses: individualized, self-chosen relapse prevention coping skills messages when participants report negative affect and intent to drink.
85359|NCT03518606|Drug|Durvalumab + Tremelimumab + metronomic Vinorelbine|Patient will be treated by metronomic oral vinorelbine associated with durvalumab + tremelimumab combination immunotherapy
85360|NCT03518593|Other|Cash and counselling|Additional 500 Ksh per child per month and household visits by Community health Volunteers (CHVs)
85361|NCT03518580|Other|real-time assessment of biopsychosocial functioning|the participants were asked to provide biopsychosocial data using the mobile device
85362|NCT03518567|Drug|Smoked marijuana cigarettes: High THC dose (6% THC)|Smoked marijuana cigarettes (High THC dose [6% THC])
85363|NCT03518554|Drug|JAB-3068|JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
85364|NCT03518541|Procedure|Femoral Derotation Osteotomy (FDO)|Correction of malrotation of the femoral bone by osteotomy, derotation and osteosynthesis
85365|NCT03518528|Drug|Estradiol 2 MG|Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
85366|NCT03518528|Drug|Estradiol 100 µg|transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
85367|NCT03518515|Other|White potato (french fries)|If randomized to this group, participants will be asked to consume 1 serving of French fries (~300 kcal) each day for 30 days as a part of their usual dietary intake. French fries will be portioned and provided to participants.
85368|NCT03518515|Other|White potato (French fries), +seasoning|If randomized to this group, participants will be asked to consume 1 serving of French fries (~300 kcal) with added potential glycemia modifying seasoning mix each day for 30 days as a part of their usual dietary intake. French fries and seasoning will be portioned and provided to participants.
85369|NCT03518515|Other|Almond|If randomized to this group, participants will be asked to consume 1 serving of almonds that is calorically-matched to the French fries (~300 kcal) serving in the other arms each day for 30 days as a part of their usual dietary intake. Almonds will be portioned and provided to participants.
85370|NCT03518502|Procedure|transarterial chemoembolization (TACE)|Standard therapy for intermediate HCC, but nor for advanced HCC
85371|NCT03518502|Drug|Sorafenib|Standard therapy for advanced HCC
85372|NCT03518489|Drug|Lappaconitine Adhesive Patch|to evaluate the efficacy of lappaconitine adhesive patch in alleviation radiation induced mucositis pain
85373|NCT03518489|Drug|standard care|Standard care will include mouth wash with antibiotics.
85374|NCT03518476|Behavioral|intensive multi-disciplinary education program on tobacco treatment for pharmacists|Participants in the intervention group will participate in an intensive education program delivered by a multi-disciplinary group of educators, researchers, and clinicians with expertise in tobacco control and tobacco dependence treatment. The program will be delivered over 4 days (run over 2 weekends) with an average of eight contact hours per day (a total of 32 contact hours) at Qatar University.
85375|NCT03518476|Other|Control arm|Participants in control arm will receive a non-tobacco related training or educational session
85376|NCT03518463|Combination Product|Enhanced recovery after surgery (ERAS)|The ERAS arm was exposed to standard preoperative, intraoperative and postoperative ERAS protocols of care. However, some were modified to our local resources and requirements as well as to the emergency nature of the surgeries.
85377|NCT03518450|Procedure|Apex Femoral Triangle Block|Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.
85378|NCT03518450|Procedure|Femoral Nerve Block|Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).
85379|NCT03518450|Procedure|Adductor Canal Block|Interfascial block that targets mainly the saphenous nerve.
85380|NCT03518411|Other|Cognitive Behavioral Therapy|One-Session Unified Protocol
85381|NCT03518398|Device|Intense Pulsed Light|E> Eye (E-SWIN, Paris, France) IPL machine
85382|NCT03518398|Combination Product|Standard treatment|warm compression, lid scrub and non-preservative ocular lubricants
85383|NCT03518385|Diagnostic Test|ultrasound,transvaginal scan|The presence of fluid in the uterine cavity during hormonal stimulation.
85384|NCT03518359|Behavioral|Enhanced Stress Resilience Training (ESRT)|ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
85385|NCT03518359|Behavioral|Active Control|Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
85386|NCT03518346|Behavioral|Virtual Reality|Samsung VR Go (VR head set), Samsung S7 (phone), and programmed distraction
85387|NCT03518346|Behavioral|Standard of Care|Books, movies, TV
85388|NCT03518333|Device|Injection of adipose derived cells into penis|Injection of Icellator-derived cells
85389|NCT03518320|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed in the bladder through an inserter and gradually release gemcitabine for four consecutive 21-day dosing cycles for a total period of approximately 84 days
85390|NCT03518320|Drug|Nivolumab Injection [Opdivo]|Nivolumab will be given intravenously on specified days for four consecutive 21-day dosing cycles for a total period of approximately 84 days
85391|NCT03518294|Behavioral|Aerobic Exercise|Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity. Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center. Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
85392|NCT03518281|Dietary Supplement|Whole Cell Euglena containing Beta Glucan|Whole Cell Euglena containing >50% Beta Glucan
85393|NCT03518281|Dietary Supplement|Placebo|microcrystalline cellulose, hypromellose, titanium dioxide, water
85394|NCT03518268|Drug|Vivomixx|The intervention consists of 2 sachets a day containing the probiotic Vivomixx, for 6 months
85395|NCT03518268|Drug|Placebo|The intervention consists of 2 sachets a day of placebo, for 6 months
85396|NCT03518255|Other|Nature video|After signing the Informed Consent Form, the participants will respond to a demographic questionnaire to characterize the sample and then they will watch nature videos. After that, will be applied a scale questionnaire about the physical and psychological symptoms of chemotherapy in the positive and negative mood of that patient.
85397|NCT03518242|Drug|Cyclophosphamide|Oral
85398|NCT03518242|Drug|Methotrexate|Oral
85399|NCT03518242|Drug|Capecitabine|Oral
85400|NCT03518229|Device|Microsoft Band 2 + UV messaging|wearable device (wrist) and associated mobile application; UV sensor and messaging activated
85401|NCT03518229|Device|Microsoft Band 2|wearable device (wrist) and associated mobile application; UV messaging not activated
85402|NCT03518216|Behavioral|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored treatment integrating mindfulness meditation and cognitive behavioral therapy. It consists of 6 sessions and blends pain and anxiety coping strategies. The first 2 sessions will be in person with a trained psychological provider and the following 4 sessions will be web-based. Each web-based session will be followed by therapist phone support.
85403|NCT03518203|Drug|Eculizumab|Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
85404|NCT03518190|Device|Infrared spectroscopy (ODP)|Infrared spectroscopy device will be used to detect non-visible pressure injuries
85405|NCT03518177|Other|Hospital-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, treadmill walking, cycle ergometer, arm ergometer training and strengthening trainning with free weights at hospital.
85406|NCT03518177|Other|Home-based pulmonary rehabilitation|The patient will receive an 8-week Pulmonary Rehabilitation Exercise Program including breathing exercises, free-walking, and strengthening training with free weights at home
85407|NCT03518151|Other|Product placement intervention|The intervention includes 3 components: i) creation of a new fresh fruit and vegetable section and island in the first aisle; ii) placing frozen fruit and vegetables in the first aisle and iii) removal of all cakes, confectionary and sugar sweetened beverages from checkouts (replaced with non-food items, fruit and bottled water).
85408|NCT03518151|Other|Sham comparator|The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
85409|NCT03518138|Drug|Q-122|oral capsule of Q-122
85410|NCT03518138|Drug|Placebo|oral capsule of placebo
85411|NCT03518125|Biological|BioThrax|"Other Names:~Anthrax Vaccine Adsorbed (AVA)"
85412|NCT03518125|Biological|AV7909|Anthrax Vaccine Absorbed plus CPG 7909 Adjuvant
85413|NCT03518125|Drug|Sodium chloride injection USP, 0.9% (placebo)|"Other Names:~Saline Solution"
85414|NCT03518112|Biological|Blinatumomab|Given IV
85415|NCT03518112|Drug|Cyclophosphamide|Given IV
85416|NCT03518112|Drug|Cytarabine|Given IT or IV
85417|NCT03518112|Drug|Dexamethasone|PO or IV
85418|NCT03518112|Biological|Filgrastim|Given SC
85419|NCT03518112|Other|Laboratory Biomarker Analysis|Correlative studies
85420|NCT03518112|Drug|Leucovorin Calcium|Given IV
85421|NCT03518112|Drug|Mercaptopurine|Given PO
85422|NCT03518112|Drug|Methotrexate|Given IT or IV
85423|NCT03518112|Biological|Pegfilgrastim|Given SC
85424|NCT03518112|Biological|Rituximab|Given IV
85425|NCT03518112|Drug|Vincristine Sulfate|Given IV
85426|NCT03518099|Biological|blood sampling|Two tubes of 5ml of blood will be collected for Serum collection, 3 tubes of 5 ml of blood taken for plasma collection and 2 tubes of 7 ml of blood taken for DNA collection
85427|NCT03518086|Drug|Mirikizumab|Administered IV
85428|NCT03518086|Drug|Placebo|Administered IV
85429|NCT03518073|Drug|LY3303560|Administered IV
85430|NCT03518073|Drug|Placebo|Administered IV
85431|NCT03518060|Drug|Juluca|Juluca is a combination of dolutegravir (INSTI) and rilpivirine (NNRTI).
85432|NCT03518047|Drug|risankizumab|rizankizumab subcutaneous (SC) infusion
85433|NCT03518047|Drug|placebo for rizankizumab|placebo for rizankizumab subcutaneous (SC) infusion
85436|NCT03518021|Drug|Naloxone, intranasal|"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
85437|NCT03518021|Drug|placebo, intranasal|"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
85438|NCT03518021|Drug|Naloxone, intramuscular|Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
85439|NCT03518021|Drug|placebo, intramuscular|Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
85440|NCT03518008|Device|verofilcon A contact lenses|Investigational daily disposable soft contact lenses
85441|NCT03518008|Device|somofilcon A contact lenses|Commercially available daily disposable soft contact lenses
85442|NCT03517995|Drug|Sulforaphane Administration|1 capsule (10 mg Prostaphane) taken two times per day (2 capsules, 20 mg Prostaphane total).
85443|NCT03517995|Other|Placebo Administration|1 capsule (placebo) taken two times per day (2 capsules total).
85444|NCT03517995|Procedure|Standard of Care Surgery|The study will be conducted during the time from when participants are diagnosed with bladder cancer to when they undergo a surgical procedure for the treatment or removal of their bladder cancer. The surgical procedure is done as a part of their regular medical care.
85445|NCT03517982|Drug|Mycophenolate Mofetil|Film Coated Tablet, each tablet contains 500mg Mycophenolate Mofetil
85446|NCT03517969|Drug|ATR Kinase Inhibitor M6620|Given IV
85447|NCT03517969|Drug|Carboplatin|Given IV
85448|NCT03517969|Drug|Docetaxel|Given IV
85449|NCT03517969|Other|Laboratory Biomarker Analysis|Correlative studies
85450|NCT03517956|Drug|Rogaratinib (BAY1163877)|"Dose escalation:~Starting dose is rogaratinib 400 mg twice daily (b.i.d.) in continuous 28-day cycles from Cycle 1 Day 3 onwards.~Dose expansion:~With dose identified in dose escalation part."
85451|NCT03517956|Drug|Copanlisib (BAY80-6946)|"Dose escalation:~Starting dose is 45 mg on Days 1, 8 and 15 of each 28-day cycle.~Dose expansion:~With dose identified in dose escalation part."
85452|NCT03517943|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
85453|NCT03517943|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
85454|NCT03517930|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
85455|NCT03517930|Drug|Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)|Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
85456|NCT03517917|Other|Tumour tissue collection|Collection of tumour tissue and blood
85457|NCT03517904|Procedure|IVUS-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
85458|NCT03517904|Procedure|Angiography-guided angioplasty|Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.
85459|NCT03517891|Behavioral|WIC+|"intervention was based on the Health Self-Empowerment Theory. It will be adapted for the web-based platform using the Persuasive Technology and Persuasive System Design models. These models focus on the human-computer interface and how technology can/is used as a persuasive tool for behavior change. We will also include Bandura's Social Cognitive Theory.~The intervention will be delivered through the combination of:~educational modules provided through an interactive distance learning platform designed to provide learning experiences using multiple modalities; short messaging platforms to promote adoption of healthy behaviors and use of the educational platform; one to one sessions with the interventionist over the telephone."
85460|NCT03517878|Behavioral|Comprehensive CHW Program|"The comprehensive CHW Cohort will receive home visits from CHWs recruited, trained, and supervised by the Philani organization. Philani has a 30-year history of non-stigmatizing home-based support for women and children in Cape Town. The organization has been operating their comprehensive CHW program in the rural Eastern Cape since 2010; however, in the research areas, CHWs have only been active for one year prior to initiation of the study. Philani recruits CHWs that are positive peer deviants to serve as role models in the community. The CHWs then receive training, materials, and skills to address major community health challenges of HIV, TB, malnutrition, alcohol use, and depression. The CHWs also receive ongoing monitoring and supervision as well as support for difficult cases."
85461|NCT03517852|Device|Human Intravital Microscopy|Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
85462|NCT03517839|Other|Inspiratory muscle trainig|Inspiratory muscle training in the training group will be administered at least 5 days a week, 15 minutes twice a day, beginning at 30% of the MIP for 8 weeks. Patients will come to the control once a week, the MIP values will be re-measured and the new training intensity will be determined at 30% of the new value. For the control group, a fixed training session will be given for at least 5 days a week, 15 minutes twice a day, not exceeding 15% of the MIP for 8 weeks.
85463|NCT03517813|Device|Contrast-enhanced Spectral Mammography (CESM)|Dual energy mammography images obtained after the administration of an intravenous contrast agent
85464|NCT03517800|Other|Arterial embolization and/or surgical management.|Arterial embolization and/or surgical management.
85465|NCT03517787|Other|FES+TE|Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).
85466|NCT03517787|Other|TE|Group perform only therapeutic exercise. Exercises are the same between all 4 groups.
85467|NCT03517787|Other|REF-FES+TE|Group perform FES+TE, but only participate in 1 session to collect reference data.
85468|NCT03517787|Other|REF-TE|Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
85469|NCT03517774|Device|3D Printed Socket|Twenty participants will be fitted with a 3D Printed socket created using 3DPrintAbility hardware and software. To do this, a 3D model of the participants residual limb will be generated which will be used to create the 3D printed sockets. These 20 participants will also receive standard care for prosthetic fitting at SJR. The fittings will be done by one prosthetist. Our team will compare the feasibility, function, quality and stability of the prosthetics through quantitative, economic and qualitative analyses. All fittings will be done under the supervision of a qualified Sunnybrook prosthetist who has previous experience with using 3D printed technologies for creation of prosthetics.
85635|NCT03516630|Drug|Moxifloxacin 400mg|Tablet
85470|NCT03517761|Biological|Bone Marrow Concentrate treatment|While under unconscious TIVA anesthesia, the injectate is then injected under fluoroscopy into the area in need of treatment using an anterior approach through the posterior oropharynx with direct visualization of the injection site via endoscopy. The alar, transverse, and accessory ligaments are the target areas to be treated with the bone marrow concentrate injectate.
85471|NCT03517761|Other|Sham Control|Control subjects will receive a sham procedure of a small skin puncture to the posterior oropharynx guided under fluoroscopy while under anesthesia.
85472|NCT03517748|Device|DM05 eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
85473|NCT03517748|Device|Optive™ eye drops|Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
85474|NCT03517735|Device|EasyTiva (algorithm is the property of Medsteer SAS)|Propofol and Remifentanil are administered automatically using a closed-loop system. Bispectral index is used as the input signal and an algorithm defines the appropriate concentrations of propofol and remifentanil. Adequate postoperative sedation is defined by a bispectral index between 55 and 75.
85475|NCT03517735|Drug|Propofol|The dosage is modified automatically by the device or according to the new medical prescription.
85476|NCT03517735|Drug|Remifentanil|The dosage is modified automatically by the device or according to the new medical prescription.
85480|NCT03517709|Other|Primary Care Physician Management of blood pressure|"You will receive a 30-minute education session about your blood pressure medications and the need to take them every day.~Your primary care physician will make recommendations on your optimal target blood pressure range and medication recommendations. ."
85481|NCT03517709|Device|Withings Smart Blood Pressure Monitor|We will use the Withings Smart Blood Pressure Monitor for daily blood pressure measurements.
85482|NCT03517696|Procedure|Membrane sweeping|Participants assigned to membrane sweeping will have an additional exam during their initial evaluation in which the membranes will be separated from the cervix and lower part of the uterus with a finger inserted into the cervical os. This would be done with at least one rotation counterclockwise and one rotation clockwise.
85483|NCT03517683|Other|Low speed|Speed of intrathecal injection will be 1ml in 15 seconds
85484|NCT03517683|Other|High speed|speed of intrathecal injection will be 1ml in 5 seconds
85485|NCT03517670|Other|Rhythmic tolerance|Rhythmic intolerance is defined by the occurrence of arrhythmia prompting the initiation of an antiarrhythmic medication and the need to decrease or even to stop the infusion of milrinone
85486|NCT03517670|Other|Hematological tolerance|Hematological tolerance will be considered good if milrinone infusion was not interrupted owing to the occurrence of thrombocytopenia
85487|NCT03517670|Other|Milrinone efficiency on cerebral vasospasm|It will be assessed using ultrasound measurements of middle cerebral arteries velocities. A decrease of at least 20% of the mean velocity or of the Lindegaard index will be considered as a significant positive effect of the treatment (including milrinone).
85488|NCT03517670|Other|Milrinone efficiency using the modified Rankin scale|Scored as follows: 0 = No symptoms, 1 = No significant disability. Able to perform all usual activities, despite certain symptoms, 2= Slight disability. Able to take care of his own affairs without assistance, but unable to carry out all previous activities, 3 = Moderate disability. Requires some help, but able to walk unassisted, 4 = Moderate severe disability. Unable to meet their own physical needs without help and unable to walk without help, 5 Severe disability. Needs constant care and attention, bedridden, incontinent, 6 = Death.
85489|NCT03517657|Behavioral|Bilateral Motor Priming + Task Specific Training (BMP + TST)|"Priming will always precede task specific training. During bilateral motor priming, the Rocker (Exsurgo Bilateral Primer, Aukland, New Zealand) will be used. For the individuals assigned to the bilateral priming group, both hands will be strapped in place in the vertically oriented plates which are attached via a mechanical linkage. They will move both wrists in rhythmic, symmetrical wrist flexion and extension for 15 minutes at a frequency of 1 Hz as cued by a metranome. Subjects do not need to have active flexion and extension of the affected hand as the less affected arm drives the weaker one (through an acutator underneath the surface) in in-phase bilateral symmetrical movement."
85490|NCT03517657|Behavioral|Control Priming + TST (CP + TST)|The control priming intervention for the active comparator group will be intermittent cutaneous electric stimulation of the volar aspect of the paretic forearm, using a standard TENS unit delivered for 15 seconds (including 2-second ramp-up, 2-second ramp-down), once per minute, for 15 minutes. Intensity will be minimized
85491|NCT03517644|Other|DP|Participants are informed that they are about to receive an effective analgesic cream. They are instructed to apply the cream using a cotton pad.
85492|NCT03517644|Other|OLP Hope|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. Therefore, participants are supposed to evaluate the subjective probability for a positive effect of the cream as rather low. However, using verbal instructions, the investigator aims to induce hope among the participants that the cream could have a positive effect for them because this placebo cream did have a positive among some former participants who were similar to the current participant. The emphasis of this similarity (regarding age and sex) aims to induce a feeling of connectedness to previous participants who reported positive effects of the placebo cream.
85493|NCT03517644|Other|OLP Expectation|Participants are informed that they are about to receive an placebo cream. They are told that the cream has no active pharmacological ingredient. However, participants are told that placebos have been shown to contribute substantially to clinical outcomes such as pain intensity/unpleasantness. This positive effect of placebos is reasoned by explaining learning mechanisms such as classical conditioning. We anticipated that after hearing this instruction, participants would consider it to be likely that the placebo has a positive effect for them.
85494|NCT03517644|Other|Placebo cream|The participants receive an inert placebo cream (standard basic cream with oil of thyme produced by a local pharmacy).
85636|NCT03516617|Drug|Acalabrutinib|Given PO
85495|NCT03517644|Other|Heat pain|Participant receive heat pain stimuli using the suprathreshold method of the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
85496|NCT03517631|Biological|shRNA-modified CD34+ cells|Infusion of CD34+ cells transduced with shRNAs.
85497|NCT03517631|Drug|Low dose busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
85498|NCT03517631|Drug|Busulfan preconditioning|A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
85499|NCT03517618|Drug|S-1+leucovorin|"Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study."
85500|NCT03517605|Other|Exercise for cardiac rehabilitation|An exercise program was designed according to the American College of Sports Medicine and performed by the Specialist Nurses in Rehabilitation Nursing. Comprises aerobic and recovery/stretching. Started in the intensive care unit after the 24 hours post-surgery, and later, during hospitalization. Clinical data (Blood Pressure, Heart Rate, Peripheral Oxygen Saturation) and Borg scale will be recorded in the initial, intermediate and final periods of each session. Capillary glycemia will be evaluated at the beginning of each session. Three sessions of exercises will be performed weekly with duration of 30 min to 60 min, divided in heating (10-25 min), aerobic exercise (10 min) and recovery (10-25min). Possible symptoms will be controlled during exercise sessions.
85501|NCT03517592|Other|EMDR|The EMDR SUD Protocol consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol and a further specific protocol for SUD that is focused on the concept of addiction memory.
85502|NCT03517592|Other|Treatment as Usual|The TAU condition includes follow-up visits with the psychiatry, psychology and with the nursing service. Visits with the psychiatrist consist to evaluate clinical status and readjust the pharmacological treatment if necessary while visits with the psychologist consist to assess and detect risk situations and to prevent relapses using a cognitive behavioral approach. Finally, the nursing service will provide health and care habits and will carry out the abstinence controls.
85503|NCT03517579|Device|Cervical Collar Therapy Indicator (COTI)|"Study Device; The CoTI has 3 components;~A collar unit: a gamma detector wrapped around a body part-neck in this case and contains a scintillating crystal and a silicon photomultiplier. The photon pulse signal is then converted to digital signals (measuring the counts per second). Usually two detectors are placed in specified positions.~A cable that connects the collar unit to the Control Unit~A control unit that collects the signals and transmits it wirelessly to a hand-held computer tablet.~Two types of collar devices will be used: the lower activity and the medium activity~Lower activity collar for patients with Graves' disease as well as diagnostic I-123 scan in thyroid cancer patients. These patients typically receive 0.2-1.2 m Ci of I-123/I-131.~Medium activity collar for Patients with thyroid cancer after 131-I ablation, for which patients typically receive 30-100 mci of I-131."
85504|NCT03517566|Drug|Placebo|once daily from baseline until week 16
85505|NCT03517566|Drug|ZPL389|Dose 1 of ZPL389; once daily from baseline to week 16
85506|NCT03517566|Drug|ZPL389|Dose 2 of ZPL389; once daily from baseline to week 16
85507|NCT03517566|Drug|ZPL389|Dose 3 of ZPL389; once daily from baseline to week 16
85508|NCT03517566|Drug|ZPL389|Dose 4 of ZPL389; once daily from baseline to week 16
85509|NCT03517553|Device|EMS users in ESRD|use of passive electrical muscle stimulation on quadriceps muscle 3 times a week for patients in dialysis
85510|NCT03517540|Drug|Tropifexor (LJN452)|Comparison with monotherapy and different combination doses
85511|NCT03517540|Drug|Cenicriviroc (CVC)|Comparison with monotherapy and different combination doses
85512|NCT03517527|Behavioral|Exercise|
85513|NCT03517514|Other|Physical Therapy service|routine physical therapy care
85514|NCT03517501|Drug|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
85515|NCT03517501|Drug|Placebo Comparator - Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
85516|NCT03517488|Biological|XmAb20717|Monoclonal bispecific antibody
85517|NCT03517475|Behavioral|SHS Low-Income|An intervention to train caregivers to supervise their children appropriately.
85518|NCT03517462|Drug|Ivermectin 3Mg Tab|ivermectin tablet
85519|NCT03517449|Drug|Pembrolizumab|200 mg administered by IV infusion on Day 1 of each 21-day cycle.
85520|NCT03517449|Drug|Lenvatinib|20 mg administered orally (PO) QD during each 21-day cycle.
85521|NCT03517449|Drug|Paclitaxel|80 mg/m^2 administered by IV on a 28-day cycle: 3 weeks receiving paclitaxel once a week and 1 week not receiving paclitaxel.
85522|NCT03517449|Drug|Doxorubicin|60 mg/m^2 administered by IV on Day 1 of each 21-day cycle.
85523|NCT03517436|Device|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards CENTERA THV System and accessories
85524|NCT03517423|Drug|Brivaracetam|An antiepileptic drug whose putative mechanism of action is as a result of direct inhibition of SV2A receptors, responsible for the successful release of excitatory neurotransmitters from the the neuronal presynaptic membrane.
85525|NCT03517410|Other|Smart phone use|Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
85526|NCT03517397|Behavioral|Mobile Contingency Management|Participants will be offered 6 counseling sessions, nicotine replacement therapy, and a smartphone app that remotely verifies participant identity and smoking abstinence and automatically credits a gift card account for evidence of smoking abstinence.
85527|NCT03517384|Behavioral|I-CBT for Body Dysmorphic Disorder|The current intervention, is a therapist guided, Internet Cognitive Behavioral Therapy treatment for Body Dysmporhic Disorder which consists of 8 treatment modules administered over the course of 12 weeks.
85528|NCT03517371|Other|mHealth delivered exercise program|"Participants in the mobile health condition have up to 10 in-person visits with a physical therapist over 12 months. The exercise program, consisting of walking, strengthening and stretching exercises, is prescribed through an app and remotely adapted by a physical therapist over 1 year. Approximately 5-7 exercises are implemented 5 days per week."
85637|NCT03516617|Other|Laboratory Biomarker Analysis|Correlative studies
85638|NCT03516617|Biological|Obinutuzumab|Given IV
85529|NCT03517371|Other|Exercise only|Participants in the control group have up to 10 in-person visits with the intervention physical therapist over 12-months. Participants are instructed by the physical therapist to engage in walking and perform progressive resistance and stretching exercises (tailored to their needs and provided in written format) 5 days per week.
85530|NCT03517358|Other|Service of care|Subjects will be receiving care from case management or clinical pharmacy.
85531|NCT03517345|Dietary Supplement|Prebiotic|Prebiotic (Inulin+Oligofructose) consumed as 10 g/d in yogurt (200 g/d)
85532|NCT03517345|Dietary Supplement|Control|The only yogurt consumed as 200 g/d without prebiotic.
85533|NCT03517319|Drug|Normal Saline 0.9% 1.2 ml|
85534|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U|
85535|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U|
85536|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U|
85537|NCT03517319|Drug|Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U|
85538|NCT03517306|Other|No Interventions|No Interventions
85539|NCT03517293|Behavioral|Aerobic Exercise training|
85540|NCT03517267|Diagnostic Test|ultrasound and FNA|The nodule to undergo FNA will be chosen according to TIRADS ACR criteria and the ATA risk criteria ( if there is a disagreement between the methods whether to perform FNA the FNA will be performed ) If both methods do not recommend FNA , but the referring doctor has requested the procedure or the patient is unable to stay on follow up , the FNA will be performed .
85541|NCT03517254|Dietary Supplement|Glutamine|At the beginning and at the end of the training session, the experimental group will receive by mouth 15 grams of glutamine dissolved in 120 milliliters of water. The aminoacid will be inside gray envelopes.
85542|NCT03517254|Other|Strength training program|One training session consists of 20 minutes of warm-up, 40 to 60 minutes of aerobic and anaerobic exercises and 15 minutes of cooling down. The exercises of the lower part of the body consist in 3 sets of 10 repetitions for healthy knee, and 12 repetitions for knee with anterior cruciate ligament reconstruction in a modular leg press, leg curl and leg extension machine.
85543|NCT03517254|Other|Placebo|Maltodextrin powder to mimic glutamine,
85544|NCT03517254|Other|Dietary recommendations|All participants, irrespective of the supplement that they receive, will be closely monitored by a nutritionist, who will give dietary recommendations to standardize protein consumption (1.2 gr/kg weight). Status nutritional will be assessed according to BMI ( 19.9-24.9, 25-29.9).
85545|NCT03517241|Diagnostic Test|functional magnetic resonance imaging (fMRI)|Retinotopic mapping using functional magnetic resonance imaging (fMRI) is based on MR images acquired with blood-oxygenation-level-dependent (BOLD) contrast to reveal areas of neuronal activity in the visual cortex
85546|NCT03517241|Diagnostic Test|Microperimetry (MP)|MP allows localized testing of retinal sensitivity of foveal, parafoveal and even more peripheral macular regions
85547|NCT03517241|Diagnostic Test|Optical coherence tomography (OCT)|Optical Coherence Tomography (OCT) is a non-invasive diagnostic technique that renders an in vivo cross sectional view of the retina.
85548|NCT03517241|Diagnostic Test|Blue light fundus autofluorescence imaging (FAF)|Fundus autofluorescence imaging (FAF), is a non-invasive diagnostic technique focusing on the fluorescent properties of pigments in the retina to generate images.
85549|NCT03517241|Diagnostic Test|Visual testing|Best-corrected visual acuity will be measured using Early Treatment Diabetic Retinopathy Study (ETDRS) charts. Reading acuity and reading speed will be examined using Radner Reading Charts. Reading acuity is measured in logRAD unit (= reading equivalent of logMAR) and in critical font size (critical reading size), reading speed is measured in words per minute (wpm). Contrast sensitivity will be determined using Pelli-Robson contrast sensitivity charts.
85550|NCT03517228|Device|BAUM device|The robotic manipulator will be placed at the start of each case. The manipulator will be cleaned and sanitized using the same process as other reusable OR devices. Feasibility will be determined by the rate of successful robotic manipulator docking and if the manipulation of the uterus was successful for the duration of the procedure. The V-Care is an FDA approved uterine manipulator which will attach to the investigational BAUM. Placement of a BAUM will be noted on the operative note.
85551|NCT03517215|Behavioral|Enhanced CB-ASP|The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.
85552|NCT03517215|Behavioral|Standard CB-ASP|A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
85553|NCT03517189|Procedure|Aorta no-touch|Participants will be submitted to aorta no-touch off-pump coronary artery bypass surgery.
85554|NCT03517176|Drug|CEND-1|CEND-1 will be provided as concentrate for solution to be administered via IV injection.
85555|NCT03517176|Drug|Nab-paclitaxel|Nab-paclitaxel will be provided as solution to be administered via IV infusion.
85556|NCT03517176|Drug|Gemcitabine|Gemcitabine will be provided as solution to be administered via IV infusion.
85557|NCT03517150|Device|mandibular advancement device|
85558|NCT03517137|Drug|Brentuximab Vedotin|For PET positive (score of 4-5 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.8 mg/kg on day 1, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Brentuximab vedotin is administered as an IV infusion over a period of 30 minutes at 1.2 mg/kg on day 1 and 15, every 4 weeks (5 cycles)
85559|NCT03517137|Drug|Adriamycin|For PET positive (score of 4-5 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 40 mg/m² on day 2, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Adriamycin is administered as an IV infusion over a period of 15 minutes at 25 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
85560|NCT03517137|Drug|Vinblastine|For PET negative (score of 1-3 following Deauville Criteria) patients: Vinblastine is administered as an IV infusion over a period of 15 minutes at 6mg/m² on day 1 and 15, every 4 weeks (5 cycles)
85639|NCT03516617|Other|Patient Observation|Undergo observation
85561|NCT03517137|Drug|Dacarbazine|For PET positive (score of 4-5 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 250 mg/m² on day 3 and 4, every 3 weeks (6 cycles); For PET negative (score of 1-3 following Deauville Criteria) patients: Dacarbazine is administered as an IV infusion over a period of 60 minutes at 375 mg/m² on day 1 and 15, every 4 weeks (5 cycles)
85562|NCT03517137|Drug|Etoposide|For PET positive (score of 4-5 following Deauville Criteria) patients: Etoposide is administered as an IV infusion over a period of 60 minutes at 150 mg/m² on day 2,3 and 4, every 3 weeks (6 cycles)
85563|NCT03517137|Drug|Cyclophosphamide|For PET positive (score of 4-5 following Deauville Criteria) patients: Cyclophosphamide is administered as an IV infusion over a period of 30 minutes at 1250 mg/m² on day 2, every 3 weeks (6 cycles)
85564|NCT03517137|Radiation|Radiation Therapy|Patients with residual lymphoma mass(es) showing metabolic activity of Deauville score 4 or 5 after completion of chemotherapy will be offered consolidation radiotherapy.
85565|NCT03517124|Other|Ceramic tooth restoration|Dental restorations
85566|NCT03517111|Behavioral|Nutrition/substance use prevention|Parenting program focusing on diet improvement and substance use prevention
85567|NCT03517111|Behavioral|Substance use prevention only|Parenting program focusing only on substance use prevention
85568|NCT03517111|Behavioral|Academic success program|Program focusing on academic success and college acceptance
85569|NCT03517098|Procedure|The ERAS group|"ERAS pathway for orthopedic surgeons:~Shortened preoperative fasting from intake.~Preoperative tranexamic acid administration.~No indwelling catheters.~No tourniquet used for TKA.~No drainage tube.~Application of the low molecular heparin 6 hours after the operation.~ERAS pathway for anesthesiologist:~Intravenous 20 mg of dexamethasone before anesthetic induction.~Anesthesia will be induced with small dose of long-acting opioids such as sulfentanil, or without long-acting opioids at all.~Laryngeal mask for airway.~Anesthesia will be maintained with short-acting anesthetic agents such as desflurane, sevoflurane, or propofol, with continuous remifentanil , and BIS value will be kept between 40 to 60 during procedure.~Incision infiltration with 40-50ml of 0.2% ropivacaine, and no patient controlled intravenous analgesia devices will be applied."
85570|NCT03517098|Procedure|The non-ERAS group|Patients undergoing THA or TKA will receive conventional care according to different participating center, and there's no standard protocol for pre-operative management, anesthetic technique or medication choice, postoperative analgesia or food intake, or catheters indwelling.
85571|NCT03517085|Genetic|DTX401|DTX401 administered as a single peripheral IV infusion
85572|NCT03517046|Drug|CartiLife|Biological: CartiLife® Procedure: CartiLife® is beads (1.0 to 1.5 mm in diameter) in suspension, developed from autologous chondrocytes. The beads are implanted in a volume of 1 cm3 per the capacity of the syringe to the affected area through injection with a fibrin adhesive through minimal arthrotomy.
85573|NCT03517033|Drug|Torrent's Nebivolol Tablets|
85574|NCT03517033|Drug|Forest Pharmaceuticals Inc.'s Bystolic Tablets|
85575|NCT03517020|Drug|Torrent's Nebivolol Tablets|
85576|NCT03517020|Drug|Forest Pharmaceuticals Inc's Bystolic Tablets|
85577|NCT03517007|Other|Opt-Out Protocol|Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
85578|NCT03516994|Behavioral|Respecting Choices First Steps|Advance Care Planning Approach
85579|NCT03516994|Behavioral|Five Wishes Form|Advance Care Planning Approach
85580|NCT03516981|Biological|Pembrolizumab|200 mg pembrolizumab solution for intravenous (IV) infusion administered Q3W
85581|NCT03516981|Biological|MK-4280|200 mg or 800 mg MK-4280 solution for IV infusion administered Q3W
85582|NCT03516981|Drug|Lenvatinib|20 mg lenvatinib capsules administered orally once daily
85583|NCT03516981|Drug|MK-1308|MK-1308 solution for IV infusion administered at the RP2D (dose and schedule based on study NCT03179436)
85584|NCT03516968|Drug|Monthly bolus of cholecalciferol per os|Bolus therapy (100'000 - 200'000 IU/month depending on age: < or ≥ 9 years old) for 3 months
85585|NCT03516968|Drug|Daily dose of cholecalciferol per os|Daily substitution (3'500 to 6'500 IU/day depending on age: < or ≥ 9 years old) for 3 months
85586|NCT03516968|Other|Control|no cholecalciferol therapy
85587|NCT03516955|Drug|Rosuvastatin|Superstat ® Tablets 10mg, 20mg
85588|NCT03516942|Other|Quality-of-Life Assessment|Ancillary studies
85589|NCT03516942|Other|Questionnaire Administration|Ancillary studies
85590|NCT03516929|Diagnostic Test|carotid duplex, both LL arterial duplex|assessment of carotid stenosis and lower limb peripheral ischemia.
85591|NCT03516916|Other|Questionnaires on HRQoL and sociodemography|All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
85592|NCT03516903|Drug|Methotrexate|ddMTX-LDE (Methotrexate carried by a lipid nanoemulsion)
85593|NCT03516903|Drug|Placebo|Placebo-LDE (Lipid nanoemulsion)
85594|NCT03516903|Drug|Folic Acid|Folic acid pill
85595|NCT03516890|Procedure|Partial hepatectomy|Partial hepatectomy was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
85596|NCT03516877|Behavioral|Enhanced Stress Resilience Training for Faculty Physicians|Enhanced Stress Resilience Training (ESRT) is derived from Mindfulness-Based Stress Reduction with modifications to language, activities and contextualization to tailor the training to physicians involved in the operating room environment. ESRT consists of 5 weekly 1-hour group classes and 2-4 hour retreat. Classes focus on developing sustained attention and open monitoring in addition to training focused on stress and coping. Increasing duration (3-20 minutes per day) of guided mindfulness exercises are assigned each week. A 2-4 hour intensive retreat occurs at week 4 or 5. The central exercises of the training are the body scan, sitting meditation, qi gong and yoga. The weekly teaching sessions will be offered at various days and times each week in order to accommodate complicated physicians schedules that vary at each site. Participants can attend whichever session is most convenient. Daily practice will occur independently, with the duration reported weekly through text or email.
85640|NCT03516617|Other|Quality-of-Life Assessment|Ancillary studies
85641|NCT03516604|Drug|PF-04995274|PF-04995274 tablets
85597|NCT03516864|Device|MIMOSA Imager|The MultIspectral MObile tiSsue Assessment (MIMOSA) Imager acquires digital images to calculate anatomical details of chronic wounds (e.g. diameter, surface area, and perimeter). The device can be worn from a lanyard, and clips onto a smartphone, using natural ambient lighting to capture images of a wound. The MIMOSA also uses up to 6 near-infrared LEDs to illuminate tissue with different wavelengths of light to assess tissue oxygenation.
85598|NCT03516864|Device|Kent Camera|The Food and Drug Administration (FDA) has previously approved a near-infrared device called the Kent camera for the assessment of tissue oxygenation.
85599|NCT03516851|Procedure|Precision bypass group|With the brain cortex exposed after craniotomy, an initial ICG fluorescence angiography will be performed. ICG fluorescence angiography using Flow800 software to determine blood flow velocity and cortical perfusion in different candidate receptors. And electromagnetic neuronavigation system is used to evaluate the cerebral flow under different candidate recipient vessels. The treatment planning station will be situated based on the multimodal neuronavigation data. The vessel was chose as the receptor with lower flow velocity and lower cerebral perfusion area to perform anastomosis. Then a direct bypass surgery will be performed just like in the empirical direct bypass surgery group.
85600|NCT03516838|Drug|ACTIVA™ BioACTIVE|Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
85601|NCT03516838|Drug|Compomer|Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
85602|NCT03516825|Other|Musical Neglect Training|MNT uses musical exercises which are structured in pitch, time and tempo, and musical equipment (tone bars, keyboards, drums) configures to focus attention to the neglect visual field.
85603|NCT03516812|Other|Laboratory Biomarker Analysis|Correlative studies
85604|NCT03516812|Drug|Olaparib|Given PO
85605|NCT03516812|Other|Quality-of-Life Assessment|Ancillary studies
85606|NCT03516812|Other|Survey Administration|Correlative studies
85607|NCT03516812|Drug|Testosterone Enanthate|Given IM
85608|NCT03516812|Drug|Testosterone Cypionate|Given IM
85609|NCT03516799|Other|Acupuncture|Acupuncture is a method of Traditional Chinese Medicine that consists of the insertion of thin, sterile, FDA-approved disposable needles on specific acupuncture points (acupoints).
85610|NCT03516773|Drug|EB612 (EBP05)|Entera Bio's proprietary drug for the administration of PTH(1-34) orally
85611|NCT03516773|Drug|NATPARA/NATPAR|A PTH replacement (PTH [1-84]; NATPARA (Shire-NPS Pharmaceuticals, Inc., Lexington, Massachusetts) was approved by the United States (US) Food and Drug Administration (FDA) in April 2015 / NATPAR (Shire Pharmaceuticals Ltd., Dublin, Ireland) was approved by the European Medicines Agency in April 2017 for use as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Like many other hormonally active peptides, PTH (1 84); NATPARA is parenterally administered. In this protocol when a specific formulation is referenced (e.g. NATPARA) it may be read interchanged with the alternate formulation (e.g. NATPAR).
85612|NCT03516760|Drug|GEM333|infusion of GEM333; administered intravenously and continuously over 10 days
85613|NCT03516747|Diagnostic Test|pre operative parathyroid hormone level measurement|At the clinic, the participants will undergo ultrasound examination with fine needle aspiration. The aspirated material will be sent for parathyroid hormone level measurement.
85614|NCT03516747|Diagnostic Test|pre operative parathyroid cytology|At the clinic, the participants will undergo neck ultrasound examination with fine needle aspiration. The aspirated material will be sent for cytology examination.
85615|NCT03516747|Diagnostic Test|parathyroid hormone level measurement|At surgery, after the pathologic gland is excised , the gland will be aspirated. The material will be sent for parathyroid hormone level measurement.
85616|NCT03516747|Diagnostic Test|parathyroid cytology|At surgery, after the pathologic gland is excised , it will be aspirated again for cytologic examination.
85617|NCT03516734|Dietary Supplement|Iron fortified lentils|Lentils will be iron-fortified using NaFeEDTA iron fortificants
85618|NCT03516734|Other|Non Iron-fortified lentils|Non-fortified lentils will be provided
85619|NCT03516734|Other|Usual Intake|No lentils will be provided.
85620|NCT03516721|Other|the prevalence of chronotropic incompetence CI during maximal cardiopulmonary exercise testing, CPET|
85621|NCT03516708|Drug|Epacadostat|Self-administered orally BID without regard to food
85622|NCT03516708|Procedure|Tumor biopsy|"Baseline (no more than 28 days prior to Day 1 of RT) (this is standard of care from the diagnostic biopsy)~After the end of RT via proctoscopy or sigmoidoscopy (target days 5-28)~Before initiation of chemotherapy via proctoscopy or sigmoidoscopy (target days 5-28)~Surgery (part of the resection specimen) or at the time of SOC pre-surgical proctoscopy"
85623|NCT03516708|Procedure|Peripheral blood draw|"Baseline (no more than 28 days prior to Day 1 of RT) (this is standard of care from the diagnostic biopsy)~After the end of RT (target days 5-28)~Before initiation of chemotherapy (target days 5-28)~Surgery (part of the resection specimen) or at the time of SOC pre-surgical proctoscopy"
85624|NCT03516695|Device|TheraSphere®|Intra-arterial Yttrium-90 glass microspheres
85625|NCT03516682|Behavioral|Reminders|Automated reminders for the 6 month and 12 month vaccine visits for parents experiencing logistic barriers to vaccination.
85626|NCT03516669|Drug|Clarithromycin|Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
85627|NCT03516669|Drug|Amoxicillin, Clarithromycin|Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
85628|NCT03516656|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
85629|NCT03516656|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
85630|NCT03516643|Other|Extracorporeal Shockwave Myocardial Revascularization|extracorporeal shockwave in ischemic area evaluated by SPECT
85631|NCT03516630|Drug|Trazodone 20 mg|Oral drops
85632|NCT03516630|Drug|Trazodone 60 mg|Oral drops
85633|NCT03516630|Drug|Trazodone 140 mg|Oral drops
85634|NCT03516630|Drug|Placebo|Oral drops
85643|NCT03516604|Drug|Placebo Oral Tablet|Placebo tablet, identical to PF-04995274 tablet
85644|NCT03516604|Drug|Placebo oral capsule|Placebo capsule, identical to citalopram capsule
85645|NCT03516591|Drug|AMV564 14-Day CIV|A 14-Day Continuous Intravenous Infusion regimen
85646|NCT03516578|Other|Cardiac magnetic resonance imaging|
85647|NCT03516565|Other|Saliva collection|
85648|NCT03516565|Other|GCF collection|
85649|NCT03516539|Device|Group ML|Mcgrath videolaryngoscope
85650|NCT03516539|Device|Group DL|Macintosh laryngoscope
85651|NCT03516526|Drug|Natalizumab|Extending dose intervals of natalizumab from 4 weeks to maximum of 8 weeks based on trough natalizumab concentrations
85652|NCT03516513|Behavioral|Problem Solving Therapy as Usual|Treatment as usual to deliver 6 weekly sessions to teach patients how to use the seven step process to solve problems.
85653|NCT03516513|Behavioral|Assisted Problem Solving Therapy|Smart note assisted delivery of 6 weekly session to teach patients how to use the seven step process to solve problems
85654|NCT03516500|Drug|Iron Sucrose Injection|The investigators inject Iron Sucrose (100 mg dissolved in 50 mL saline) into the segmental bronchus.
85655|NCT03516487|Drug|SYNB1618|A single (Part 1) or multiple (Part 2) ascending oral dose of SYNB1618 in a buffered solution. In Part 1, subjects receive one dose of SYNB1618 on Day 1. In Part 2, subjects receive SYNB1618 TID for 7 days.
85656|NCT03516487|Drug|Placebo|A single (Part 1) or multiple (Part 2) oral dose of a buffered 100mL solution. In Part 1, subjects receive one dose of buffered solution on Day 1. In Part 2, subjects receive a buffered solution TID for 7 days.
85657|NCT03516474|Device|MIMOSA Diagnostics|"The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing."
85658|NCT03516461|Procedure|Selective Microbiota Transplantation (SMT)|Selective microbiota transplantation for patients via nasointestinal tube (once per day for 3 days)
85659|NCT03516461|Procedure|Fecal Microbiota Transplantation (FMT)|Fecal microbiota transplantation for patients via nasointestinal tube or gastroscopy (once per day and no more than 3 times)
85660|NCT03516448|Drug|Gan Fu Le Tablets|6 Tablets，tid,po
85661|NCT03516448|Drug|Tyroserleutide for injection|6mg/d, 5days,ivgtt
85662|NCT03516448|Drug|Placebo|0mg/d, 5days,ivgtt
85663|NCT03516435|Device|Parasacral transcutaneous electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Parasacral transcutaneous electrical stimulation：Clinic using 2 superficial 3.5 cm electrodes placed on each side of S3 and S4.
85664|NCT03516435|Device|Intravaginal electrical stimulation|Asymmetrical biphasic square current pulse Frequency：10 Hz pulse width：1.0 ms Intensity：highest tolerable intensity(≦80 mA.) Intravaginal electrical stimulation：The electrode plug for vaginal plug was cylinder-formed with ring-formed placed into vaginal.
85665|NCT03516422|Procedure|ULTRASOUND DEBRIDEMENT|Low-frequency ultrasound SonicOne O.R. (Misonix, New York, US) generates ultrasound waves with 22.5 kHz frequency. Each probe is attached to a set of irrigation solution (saline 0.9%), they transform electric energy into mechanical vibrations to induce tiny particles of water from irrigation fluid. Absorbent pads are positioned to catch excess saline. With SonicOne set at continuous mode with minimum pump flow, the debridement will begin at most distal aspect of ulcer with the hand piece in constant motion until entire ulcer surface has been debrided until as much necrotic tissue has been removed. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into wound cavity.
85666|NCT03516422|Other|STANDARD CARE GROUP|The subject positioned so absorbent pads are in position to catch irrigation solution. The saline bottle will be held 10-15 cm from wound bed, and squeezed to spray all surfaces of wound in a sweeping motion, from clean to dirty area of wound. Irrigation will be repeated as necessary to remove exudate, slough, and debris from the wound until the solution draining from the wound is clear. Peri-wound skin will be cleansed using gauze and sterile normal saline and dry. Packing material will be applied (Acticoat®) into the wound cavity, undermining, or tunnel to fill the dead space without causing the wound to stretch or bulge or be packed tightly. Packing should be in contact with entire wound base and edges. Dressings changed once every 3 days by the patient's care provider.
85667|NCT03516409|Dietary Supplement|Biokult|"Bio-Kult Infantis® is a multi-strain formula containing a probiotic formulation comprising 7 strains of probiotics, high content of Omega-3, Vitamin D3 and Preplex® (50% FOS and 50% gum acacia).~Each sachet contains:~Minimum 1 billion microorganisms per sachet (1 x 109CFU/g), guaranteed throughout the shelf life~DHA + EPA: >1mg per sachet~Vitamin D3: 2.5mcg per sachet (50% of Nutrient Reference Value). Bio-Kult Infantis® presents itself in the form of a white powder, packaged in sachets of 1 g each"
85668|NCT03516409|Dietary Supplement|Placebo|"IP placebo is manufactured so to contain maltodextrin DE19 and have the same organoleptic properties of the active product (similar to the study product in appearance and taste) but without active ingredient. It contains 100% maltodextrin DE19.~Moreover, placebo sachets are equal in color, shape and weight (1 g) to IP sachets."
85669|NCT03516396|Behavioral|Training Plus|Training plus enhanced community development activities
85670|NCT03516396|Behavioral|Training Only|Training Only (livestock management and child nutrition) for 24 months then add community development inputs
85671|NCT03516396|Behavioral|No Inputs then Community development and training|No inputs for 24 months then add community development and training
85672|NCT03516383|Device|PWVi|
85673|NCT03516370|Drug|Saccharomyces Boulardii 250 MG|all the patient first recived scaling and root planning as a prophylactic mesaure later after that patient received intrapocket delivery of Saccharomyces Boulardii mixture.
85674|NCT03516344|Procedure|Liver pumping and Spinal manipulation|Interventions are described in group descriptions
85675|NCT03516331|Drug|FDL176 & FDL169 coadministration|CFTR corrector and potentiator
85743|NCT03515746|Device|Exergaming in virtual environment|"The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles"
85744|NCT03515733|Drug|PF-04995274|PF-04995274 tablets
85676|NCT03516318|Behavioral|SMART Connections|SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
85677|NCT03516305|Drug|Staccato Alprazolam 1 mg|alprazolam I mg administered via the Staccato hand-held inhaler device system.
85678|NCT03516292|Diagnostic Test|Urinary Nerve Growth Factor|The subjective patient's discomfort regarding the vaginal prolapse problems and urinary incontinency symptoms will be assessed through the following questionnaires: (a) ICIQ-OAB (b) ICIQ FLUTS (c) ICIQ-VS. Determination of the bladder neck of urethra in midsagittal plane using a transvaginal two-dimensional ultrasound machine at lithotomy position in rest (point OA) and on Valsalva maneuver (point OB). Bladder Neck Mobility is defined as the difference from point OA to OB. BWT is determined and measured as the hypoechoic layer between two hyperechoic layers that is recognized as the urothelium and the perivesical tissue using a transvaginal two-dimensional ultrasound machine at lithotomy position. The measurement is performed with a bladder volume <30 ml and is taken place in 3 different bladder sites: (a) the thickest part of the bladder triangle, (b) the dome of the bladder in the midline, (c) the anterior wall of the bladder. NGF will be measured in urine sample.
85679|NCT03516279|Drug|Dasatinib|Given PO
85680|NCT03516279|Drug|Imatinib Mesylate|Given PO
85681|NCT03516279|Other|Laboratory Biomarker Analysis|Correlative studies
85682|NCT03516279|Drug|Nilotinib|Given PO
85683|NCT03516279|Biological|Pembrolizumab|Given IV
85684|NCT03516253|Dietary Supplement|Fish oil + EPO|Supplementation with both fish oil and EPO
85685|NCT03516240|Other|Biofreeze|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group.
85686|NCT03516240|Other|Placebo|Following a procedure that induces muscle fatigue in the lower extremity, a topical cream will be applied over the quadriceps. The cream will be either a topical analgesic (Biofreeze) or a placebo cream. Evaluation of the movement kinematics and kinetics will be evaluated for each group. Placebo cream will be blinded to both the experimenter and study participant. It will look and smell the same and will be in the same packaging.
85687|NCT03516227|Behavioral|heart rate variability biofeedback|The HRVBF group received four, one-on-one bedside biofeedback training sessions (20-minutes a day for 4 days), and practiced on their own (10-minutes twice a day) using a FDA-regulated, hand-held mobile biofeedback device (StressEraser, Helico Inc., New York, NY, USA).26 The control group received usual care.Afterwards, all participants were telephoned bi-weekly and encouraged to practice slow breathing (HRVBF group) or to perform self-care (control group) for three months.
85688|NCT03516214|Drug|EGF816|Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
85689|NCT03516214|Drug|Trametinib|Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
85690|NCT03516188|Drug|Alginate-antacid group|Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
85691|NCT03516188|Drug|Non antacid alginate group|Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
85692|NCT03516175|Device|High flow transnasal oxygen|High flow nasal oxygen that is Transnasal Humidified Rapid Insufflation Ventilatory Exchange
85693|NCT03516175|Device|Pre oxygenation using tight fitting facemask|100% oxygen via a tight fitting facemask
85694|NCT03516162|Other|There is no study-specific intervention|There is no study-specific intervention
85695|NCT03516149|Other|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets
85696|NCT03516136|Device|EndoFast Reliant SCP|POP repair procedure with the EndoFast Reliant SCP system
85697|NCT03516123|Drug|CS3006|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, participants will receive CS3006 at specified dose level(s)."
85698|NCT03516110|Other|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional assessments or tests will be required.
85699|NCT03516097|Behavioral|Structured school based intervention|Intervention includes behavioral, nutritional and physical activity counselling (online and face-to-face psycho-educative sessions).
85700|NCT03516097|Device|mobile app usage|The e-therapeutic platform and mobile app (TeenPower) includes educational resources, self-monitoring, social support, interactive training modules and motivational tools. In addition to the case manager, the program will also have the direct support of an interdisciplinary team (nurse, nutritionist, exercise physiologist, psychologist among others).
85701|NCT03516084|Drug|ZL-2306(nirapairb)|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
85702|NCT03516084|Drug|Placebo|The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
85703|NCT03516071|Drug|Brivanib 800 mg, QD|Brivanib Alaninate 800 mg QD, PO
85704|NCT03516071|Drug|Brivanib 400 mg, BID|Brivanib Alaninate 400 mg BID, PO
85745|NCT03515733|Drug|Placebo Oral Tablet|Placebo tablet, identical appearance to experimental tablet
85746|NCT03515720|Procedure|Prolotherapy|It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.
85747|NCT03515707|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
85748|NCT03515707|Drug|Busulfan|Given IV or oral
85705|NCT03516058|Other|Simulation-Based Education|"Participating residents receive lectures on TAP block and the use of ultrasound devices from an expert before training, and then receive simulation-based training for an hour from the anesthesiologist's staff. The residents performed three ultrasound guided TAP blocks using an anesthetized porcine model during the training session.~The residents filled out a questionnaire before and after the training session. Ten multiple-choice questions tested general knowledge in abdomen ultrasound and TAP block. Subjective comfort levels with ultrasound machine and block device functionality, patient positioning, proper block technique, image documentation, needle safety and overall procedural confidence and anxiety levels were reported on a 5-point Likert scale before and after training."
85706|NCT03516045|Drug|18F-AlF-NOTA-neurotensin|One injection of the radioligand 18F-AlF-NOTA-neurotensin
85707|NCT03516032|Behavioral|exercises|
85708|NCT03516019|Other|personalized notices|The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
85709|NCT03516019|Other|standard notices|The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
85710|NCT03516019|Other|am notices|notifications sent at 7 am.
85711|NCT03516019|Other|pm notices|notifications sent at 7 pm.
85712|NCT03516019|Other|weekday notices|notifications sent on Wednesday
85713|NCT03516019|Other|weekend notices|notifications sent on Saturday
85714|NCT03516006|Drug|UCMSC|infusion of aUCMSC at day 0, 7, 14, and 21
85715|NCT03516006|Drug|UDCA|oral administration of ursodeoxycholic acid (UDCA) 15mg/kg/d
85716|NCT03515980|Drug|BMS-986231|Intravenous (IV) administration
85717|NCT03515967|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
85718|NCT03515954|Procedure|Treatment of diffuse ocular surface squamous neoplasia|Excision of the conjunctival tumour was done.Amniotic membrane was secured into conjunctival defects. Postoperative topical MMC 0.04% was given. Response to treatment was monitored clinically and by AS-OCT.
85719|NCT03515941|Drug|Oxaliplatin|130 mg/m2 by IV (Arm 1)
85720|NCT03515941|Drug|Capecitabine|625 mg/m2 (Arm 1), 750 mg/m2 by PO (Arm 2)
85721|NCT03515941|Drug|Leucovorin|400 mg/m2 by IV (Arm 1 & Arm 2)
85722|NCT03515941|Drug|5-fluorouracil|400, 2400 mg/m2 by IV (Arm 1), 400,1200 mg/m2 by IV (Arm 2)
85723|NCT03515941|Radiation|radiation|45 Gy in 1.8 Gy/fraction
85724|NCT03515928|Other|Ultrasonic noise exposure|Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.
85725|NCT03515928|Diagnostic Test|Pure Tone Audiometry|Participants will undergo 2 (pre and post exposure) hearing tests
85726|NCT03515902|Device|mouthguard|mouthguard
85727|NCT03515902|Device|mouthguard with desensitizing toothpaste|mouthguard with desensitizing toothpaste containing 8% arginine with calcium carbonate
85728|NCT03515889|Behavioral|Ideal Protein Weight Loss Method|"An initial visit will take place in which each participant assigned to the experimental group will complete a health profile questionnaire.The Ideal Protein method will be explained and the participant will be weighed, measured and given diet related informational materials. A staff member will assist the participant with the selection of foods and snacks to ensure adequate quantity for the week. Weekly follow-up visits of 15 minutes duration will be implemented with a telephone follow-up occurring during the first 4 days after the initial appointment.~For 12 weeks Ideal Protein foods that are of the appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
85729|NCT03515889|Behavioral|Standard Weight Loss|"This arm utilizes evidence-based strategies that have been shown to be effective for long-term weight loss and weight loss maintenance (including behavioral techniques, diet modification, and social support) consistent with the 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Participants in this arm will have an initial one hour consultation with a trained interventionist, where the fat goal and calorie restriction goal are explained.~For 12 weeks low-fat reduced calorie foods that are of appropriate composition and quantity will be provided at weekly or twice monthly intervals as included in the diet. Dietary supplements will be provided (multivitamin, calcium/magnesium, potassium, omega-3, and Ideal Salt substitute)."
85730|NCT03515863|Genetic|DNA extraction and genetic characterization|Collection of blood samples for DNA extraction and genetic characterization using whole-genome sequencing, and for identification of cellular biomarkers using transcriptomics and mass cytometry.
85731|NCT03515863|Device|Orbit MRI examination|Orbit MRI examination is performed to confirm the diagnosis of TAO
85732|NCT03515863|Other|Collection of life style data|Collection of life style data using quality of life questionnaire
85733|NCT03515837|Biological|pembrolizumab|IV infusion
85734|NCT03515837|Drug|pemetrexed|IV infusion
85735|NCT03515837|Drug|carboplatin|IV infusion
85736|NCT03515837|Drug|cisplatin|IV infusion
85737|NCT03515837|Drug|saline solution|IV infusion
85738|NCT03515824|Biological|MK-1697|Administered by IV infusion on Day 1 of each 21-day cycle
85739|NCT03515811|Device|Signia™ Stapling System|Signia™ Stapling System using Signia™ Intelligent Loading Units with Tri- Staple™ 2.0 Intelligent Reloads.
85740|NCT03515798|Drug|Pembrolizumab Injection|Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks
85741|NCT03515798|Drug|neoadjuvant (F)EC-paclitaxel chemotherapy|The cytotoxic regimen is a combination of FEC (if hormone receptor-positive IBC), followed by weekly paclitaxel or combination of dose-dense EC (if hormone receptor negative i.e. triple-negative IBC), followed by weekly paclitaxel
85742|NCT03515772|Drug|Co-administration of darunavir with a cardiovascular drug|Co-administration of darunavir, an HIV agent considered prone to induce drug interactions, with a cardiovascular drug (amlodipine, atorvastatin or rosuvastatin). Note that a patient will be able to participate in the intervention group and the control group if a change in his/her anti-HIV treatment occurs (study partly parallel and partly in cross-over).
85749|NCT03515707|Drug|Etoposide|Given IV
85751|NCT03515694|Drug|Sugammadex Injection [Bridion]|Injection of 10mL of translucide solution
85752|NCT03515681|Behavioral|Text messages|Subjects randomized to intervention will receive text messages to promote seeking care and improving compliance with blood pressure treatment.
85753|NCT03515668|Drug|Ritalin 20Mg Tablet|Single dose for all participants
85754|NCT03515668|Drug|Placebo Oral Tablet|Placebo with same appearance/taste
85755|NCT03515642|Behavioral|HIIT group|Physical Training
85756|NCT03515629|Drug|REGN2810/ipi|REGN2810 plus ipilimumab
85757|NCT03515629|Drug|REGN2810/chemo/ipi|REGN2810 plus chemotherapy plus Ipilimumab
85758|NCT03515629|Drug|Pembrolizumab|Reference drug administered IV infusion
85759|NCT03515616|Diagnostic Test|TP us in labour|TP US will be made to pregnant lady in first stage of labour with OS and PC angel measurements
85760|NCT03515603|Procedure|Endoscopic resection|Transsphenoidal endoscopic resection of pituitary adenoma
85761|NCT03515603|Procedure|Microsurgical resection|Transsphenoidal microsurgical resection of pituitary adenoma
85762|NCT03515590|Other|Emulsion with solid droplets|This will be a 500 mL beverage emulsion in which the droplets are crystalline. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
85763|NCT03515590|Other|Emulsion with liquid droplets|This will be a 500 mL beverage emulsion in which the droplets are liquid. It will have identical composition to the other intervention, i.e. in one the lipid droplets are solid (i.e. crystallized) and the other in which they remain liquid will be introduced at least 7 days apart. The differences in physical state will be achieved simply by changing the temperatures the emulsions are held at. The emulsion will contain 10 % of the lipid palm stearin with 0.4% of the emulsifier sorbitan monostearate (Span60).
85764|NCT03515577|Procedure|Computed Tomography|Undergo PET/CT
85765|NCT03515577|Drug|Fluciclovine F18|Given fluciclovine F18
85766|NCT03515577|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
85767|NCT03515577|Other|Laboratory Biomarker Analysis|Correlative studies
85768|NCT03515577|Procedure|Positron Emission Tomography|Undergo PET/CT
85769|NCT03515564|Behavioral|Dance/Movement Therapy, Art Therapy, Mindful Yoga, or HIIT|Utilizing deep breathing, exercise modalities, and social support in all settings
85770|NCT03515564|Behavioral|Standard Care|Pharmacotherapy, psychotherapy
85771|NCT03515551|Drug|IMCnyeso|Weekly IV infusions of IMCnyeso
85772|NCT03515538|Drug|RRx-001|RRx-001 for injection
85773|NCT03515538|Drug|Cisplatin for injection|Patients will receive 3 doses of cisplatin at 100 mg/m2 in accordance with applicable guidelines such as NCCN; however, these guidelines are not intended to supersede or replace institutional guidelines with respect to appropriate and necessary care for individual patients
85774|NCT03515538|Radiation|Radiation Therapy|Intensity Modulated Radiation Therapy (IMRT) in accordance with the American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for IMRT) is mandatory for this study
85775|NCT03515525|Diagnostic Test|Closed-suction drain fluid volume|To evaluate the clinical value of postoperative drain fluid volume for detection of hematoma, an intra-individual comparison of drain secretion volumes between sides affected by hematoma and the uneventful contralateral breasts was performed.
85776|NCT03515512|Drug|Enasidenib|Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells
85777|NCT03515499|Behavioral|Incentives|Subjects in the treatment arm will be paid up to $1 per day over 3 months for perfect medication adherence. Adherence rates will then be compared between the 2 groups.
85778|NCT03515499|Behavioral|Medication device monitoring and reminders|Bluetooth enabled sensor device for medication reminders, as well as mobile app to track medication use.
85779|NCT03515486|Other|Post stroke mood disorders evaluation|Each patient will be assessed by a clinical evaluation, will have a standardized psychological evaluation, will perform a brain MRI and will be given a smartphone and an actimeter for a one-week period for the purpose of ecological evaluations
85780|NCT03515473|Device|cochlear implant|cochlear implant surgery
85781|NCT03515460|Other|sugar oral load|The individuals will receive a sugar oral load (high sugar meal)
85782|NCT03515460|Other|fat oral load|The individuals will a receive fat oral load (high fat meal)
85783|NCT03515460|Other|sugar and fat oral load|The individuals will a receive sugar and fat oral load (high sugar and high fat meal)
85784|NCT03515447|Other|Non interventional study|
85785|NCT03515434|Procedure|ESP Block|ESP block will be performed at the finishing of surgery under spinal anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 2-3 cm lateral to T10 spinous process. The erector spinae muscles will be identified superficial to the tip of T10 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
85786|NCT03515434|Procedure|TAP Block|TAP block will be performed at the finishing of surgery under spinal anesthesia. A linear ultrasound transducer will be placed to lateral aspect of abdomen. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane between transversus abdominis and internal oblique muscles..A total of 30 mL of bupivacaine/lidocaine mixture will be injected.
85787|NCT03515434|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded and followed by 0., 1.-3.-6.-12.-18.-24.hours. it is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
85788|NCT03515421|Device|Frazier 3 Verio|In vitro diagnostic device (IVDD)
85789|NCT03515421|Device|Frazier 3 UltraPlus|In vitro diagnostic device (IVDD)
85790|NCT03515408|Device|rTMS|The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
85791|NCT03515395|Behavioral|Instruction to a computer game and motivation to use it|Patients who are willing to use the computer game and who have given written informed consent shall have three instruction sessions by a physiotherapist instructor. They will then asked to use the platform at least 3 times per week at their own discretion. The platform will be installed in the patient room, alternatively in a defined training room. The patient will be free to choose the time and duration of the gaming. This allows the patients to select times that do not interfere with their usual therapy schedule or visits (e.g. evening or weekends). Prior to discharge compliance with the platform will be monitored by analyzing the gaming data of each patient.
85792|NCT03515382|Drug|GLPG1690|A single oral dose of GLPG1690.
85793|NCT03515382|Drug|Itraconazole|A single oral dose of itraconazole.
85794|NCT03515382|Drug|Voriconazole|A single oral dose of voriconazole.
85795|NCT03515369|Drug|Babaodan oral capsule|On the basis of conventional liver protecting treatment, take Babaodan oral capsule within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
85796|NCT03515369|Drug|Placebo oral capsule|On the basis of conventional liver protecting treatment, take Placebo oral capsule began within 4 weeks after curative resection. Take two capsules three times daily, two months as a course of treatment and the maximum of eighteen courses, until the recurrence of tumor or death of patients (non tumor related death), or the termination of research.
85797|NCT03515356|Behavioral|MI-Walk Intervention|Eight-week motivational enhancement therapy and home-based aerobic walking intervention
85798|NCT03515356|Behavioral|Physical Activity Education Pamphlet|Physical activity education pamphlet only
85799|NCT03515343|Diagnostic Test|Screening colonoscopy according to resect-and-discard strategy|This strategy uses image enhancing techniques and optical diagnosis instead of histopathology assessment with 2 Pentax optical imaging systems (either Optivista or iScan).
85800|NCT03515330|Other|mHealth Intervention|The mHealth application will allow liver transplant recipients to see their medication regimen, record a video of themselves taking every dose, report side effects or symptoms, visualize their treatment progress, and access educational content. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
85801|NCT03515317|Behavioral|LoRETA Z-score NF|LoRETA Z-score NF will be conducted using a 19-lead cap (Electrocap, Inc), which will be placed on the head according to the standard approach of the international 10-20 system with linked ear and ground reference. After the caps will be less than 5 kΩ. During each session, the participants will sit in front of a computer screen on which predesigned games or animations related to the LoRETA Z-score training are played and instructions regarding the inhibitory and reward aspects of the training are taught.
85802|NCT03515317|Behavioral|theta/beta NF|The goal of theta/beta NF is to increase the beta power(13-20 Hz) and simultaneously inhibit the theta power (4-8 Hz) relative to a baseline assessed at the beginning of a training session. The electrodes will be placed on Fz and Cz with a linked ear model(A1). The study will use both visual and auditory feedback. Each participant will sit in front of a computer screen on which predesigned games or animations related to the training criteria are played and instructions regarding the inhibitory and reward aspects of the training are taught. The threshold will be set according to 5-min baseline EEG measurements before each session. The thresholds are the mean amplitude of the beta and the theta in 5-min baseline EEG.
85803|NCT03515304|Drug|Evolocumab|420 mg evolocumab administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
85804|NCT03515304|Drug|Placebo|Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
85805|NCT03515291|Biological|iMP cells|Immunomodulatory progenitor cells
85806|NCT03515291|Other|Control injection|Cell suspension solution
85807|NCT03515278|Procedure|SCNB group|IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
85808|NCT03515278|Procedure|IACI group|SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
85809|NCT03515265|Other|Fiber reinforced resin composite restoration|a type of resin composite with improved strength due to the fiber's action
85810|NCT03515265|Other|Microhybrid resin composite restoration|a type of conventional resin composite
85811|NCT03515252|Biological|Immune Killer Cells (IKC)|
85812|NCT03515239|Procedure|lumbopelvic fixation for spinopelvic dissociation|unilateral and bilateral lumbopelvic fixation for spinopelvic dissociation
85813|NCT03515226|Behavioral|ITS based training|Training using computerized adaptive training in addition to role play
85814|NCT03515226|Behavioral|Traditional Training|Training using didactics and role plays
85815|NCT03515213|Drug|Fenofibrate|145mg of fenofibrate
85816|NCT03515213|Drug|Placebo|Placebo
85817|NCT03515200|Drug|Palbociclib Oral Capsule|Given orally or nasogastrically (NG).
85818|NCT03515200|Drug|Intrathecal Triple Therapy|Given intrathecally (IT).
85819|NCT03515200|Drug|Dexamethasone|Given orally, nasogastrically (NG) or intravenously (IV).
85820|NCT03515200|Drug|Bortezomib|Given intravenously (IV) or subcutaneously (SC).
85821|NCT03515200|Drug|Dasatinib|Given orally or nasogastrically (NG).
85822|NCT03515200|Drug|Doxorubicin|Given intravenously (IV).
85823|NCT03515200|Drug|Ruxolitinib|Given orally or nasogastrically (NG).
85824|NCT03515187|Drug|0.3% sodium hyaluronate ophthalmic solution|one to two drops in eye, four times per day
85825|NCT03515187|Drug|0.1% sodium bromide solution|one to two drops in eye, twice per day
85826|NCT03515187|Other|Meibomian gland massage|Physiotherapy
85827|NCT03515187|Other|Placebo|Vehicle
85828|NCT03515174|Other|Supportive Care Program|This program takes place within one month post-diagnosis of cancer. It will include three info-educational session. After that, recommendations for further consultation with specific healthcare professionals will be made based on the concerns and needs of patients at baseline. Patient will also be given usual care.
85829|NCT03515174|Other|Usual Care|Patients will be provided with an information booklet by the study team on self-management of cancer- and treatment-related symptoms, which is routinely provided by the National Cancer Centre of Singapore (NCCS) after cancer diagnosis. Usual general advice is provided by the medical oncologists during the routine consultations.
85830|NCT03515161|Device|closed-loop|Vasopressor admnistration in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of vasopressor the patient receives using feedback from standard operating room monitors.
85831|NCT03515148|Procedure|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion. Previously subjects should cold their leg in ice water during sexteen minutes at a temperature of 8ºC (+/-2ºC)
85832|NCT03515148|Procedure|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercise, 3 sets/execise, 15 repetition/set of eccentric exercise of foot plantar flexors First exercise with knee in extension, second exercise with knee in flexion.During the exercise subjects will be subjected to vibration. Vibrations parameters: Frequency: 35Hz, Amplitude: 4 milimeters, Force: 3,9G
85833|NCT03515135|Behavioral|Metacognitive Executive Function Training|Training the executive funtions of preshcool ADHD children through tasks and games repeatly but with fun. Giving the parents strategies to help the prechool ADHD childred coping the symptoms and develop EF in the reallife.
85834|NCT03515109|Procedure|Altis tape|placement of Altis tape through transobturator foramen bilaterally under epidural anesthesia
85835|NCT03515109|Procedure|TVTO|placement of TVTO tape through transobturator foarmen bilaterally under epidural anesthesia
85836|NCT03515096|Drug|Eltrombopag|Eltrombopag 50 mg; po; from day 1 to platelet is completely effective recovered after HSCT.
85837|NCT03515096|Drug|rhTPO|rhTPO 15000 u; subcutaneously injection; from day 1 to platelet is completely effective recovered after HSCT.
85838|NCT03515083|Device|Alive Cor Kardia mobile electrocardiogram monitor|Mobile ECG monitor paired with smart phone application
85839|NCT03515057|Diagnostic Test|Single lead handheld electrocardiogram|Screening for atrial fibrillation during outpatient primary care office visits among patients 65 years and older
85840|NCT03515044|Drug|40 mg Rifaximin SSD once daily|SSD once daily (QD) and lactulose
85841|NCT03515044|Drug|40 mg Rifaximin SSD twice daily|SSD twice daily (BID) and lactulose
85842|NCT03515044|Drug|80 mg Rifaximin SSD once daily|SSD once daily (QD) and lactulose
85843|NCT03515044|Drug|80 mg Rifaximin SSD twice daily|SSD twice daily (BID) and lactulose
85844|NCT03515044|Drug|Placebo|Administered twice daily (BID) and lactulose
85845|NCT03515044|Drug|lactulose|to be taken in the recommended adult size dosage.
85846|NCT03515031|Device|High Flow Nasal Cannula Oxygenation|Delivery of humidified and heated (37ºC) high flow oxygen
85847|NCT03515031|Device|Venturi Mask Oxygenation|delivery of high flow oxygen
85848|NCT03515018|Drug|hydroxyurea|pulse therapy
85849|NCT03515018|Drug|Imatinib|400mg qd PO per day
85850|NCT03515005|Behavioral|Lay Health Advisor|Patients will meet regularly Lay Health Advisors who will address the social context of their hypertension.
85851|NCT03514979|Biological|Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination|Pneumococcal vaccines
85852|NCT03514966|Behavioral|Position change group|Right after ingesting 5 g dimethicone mixed with 100 ml water, subjects in the position change group will be instructed to repeatedly change the body position according to a pre-specified protocol for a period of 15 min: in the order of supine to the left lateral position to prone, left lateral, supine, right lateral, and repeat last four positions twice, each for 1 min; finally supine for 1 min. Thirty and 40 min after dimethicone administration, subjects in both groups will additionally take 200 ml and 800 ml water, respectively before undergoing MCE examination.
85853|NCT03514953|Behavioral|Reduced Physical Activity|"Preliminary Phase (Baseline to Day 7): Subjects will begin wearing an accelerometer for 7 days to track physical activity and sleep patterns.~Experimental Phase 1 (Day 7 to Day 21): Participants will be required to reduce their step count by 5,000 steps per day and engage in no moderate-vigorous physical activity during this timeframe. Every 7 days subjects undergo the blood draw, vascular health measures and questionnaire assessments.~Experimental Phase 2 (Day 21 to 28): During the week of assessment, subjects will be asked to return to their normal physical activity patterns."
85854|NCT03514940|Diagnostic Test|ultrasound|second trimester us scan will be made to pregnant women
85855|NCT03514927|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
85856|NCT03514927|Device|High-Intensity Focused Ultrasound|Under go HIFU
85857|NCT03514927|Other|Laboratory Biomarker Analysis|Correlative studies
85858|NCT03514927|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
85859|NCT03514927|Procedure|Radical Prostatectomy|Undergo prostatectomy
85860|NCT03514914|Behavioral|The CHARM2 Intervention|CHARM2 intervention will involve gender, culture & contextually-tailored family planning and gender equity counseling.
85861|NCT03514901|Other|Experimental combination beyond Focal Progression|"Vemurafenib is taken on a 28-day cycle. Each dose consists of four 240 mg (960 mg) tablets twice daily for 28 consecutive days. The first dose should be taken in the morning and the second dose in the evening approximately 12 hours later. Each dose can be taken with or without a meal. Vemurafenib tablets should be swallowed whole with a glass of water and should not be chewed or crushed.~Cobimetinib is taken on a 28-day cycle. Each dose consists of three 20 mg tablets (60 mg) and should be taken orally, once daily for 21 consecutive days, followed by a 7-day break. Each subsequent treatment cycle should start after the 7-day treatment break has elapsed. The dose should be taken in the morning.~Local treatment (i.e. surgery, radiotherapy)."
85956|NCT03514264|Procedure|PBS CIMMO cement (group B)|Single intervention: endodontic instrumentation and obturation with cement PBS CIMMO
85862|NCT03514901|Drug|Pembrolizumab or Nivolumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes every 3 weeks OR Nivolumab 3 mg/kg is administered intravenously over 60 minutes every 2 weeks.
85863|NCT03514888|Procedure|HIPEC|40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
85864|NCT03514875|Dietary Supplement|MitoQ|MitoQ is a mitochondria-targeting antioxidant, which should improve NO bioavailability, and therefore vasodilation
85865|NCT03514875|Dietary Supplement|Placebo|A placebo will be used in a double blinded, randomized, cross-over design
85866|NCT03514862|Behavioral|Mindfulness Booster Training|Four additional mindfulness booster sessions after the 4-week MBI program.
85867|NCT03514862|Behavioral|Mindfulness-Based Intervention (MBI)|MBI program is delivered once a week for 4 weeks, 90 minutes each preceded by a 90-minute orientation session. The training sessions will include discussion, and introduction and practice of mindfulness practices.
85868|NCT03514862|Behavioral|Self-Practice|4 weeks of self-practice after the MBI training.
85869|NCT03514849|Procedure|prophylactic cranial irradiation (PCI)|Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
85870|NCT03514849|Procedure|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling|lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
85871|NCT03514849|Drug|postoperative adjuvant chemotherapy|If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
85872|NCT03514836|Biological|DCVac/PCa|Oncolytic adenovirus containing immunostimulatory cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF). This is an experimental therapy
85873|NCT03514836|Drug|Cyclophosphamide|immunomodulatory medication given around the ONCOS-102 dosing
85874|NCT03514823|Other|Inspiratory Muscle Training (IMT)|Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.
85875|NCT03514823|Other|No Inspiratory Muscle Training (IMT)|No inspiratory muscle training.
85876|NCT03514810|Combination Product|Combined Sertraline & Ketoprofen|The first group of patients has administered sertralin (50mg)+placebo. The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline & Ketoprofen) daily.
85877|NCT03514810|Other|Interleukins in MDD after treatment|Some interleukine levels were estimated in the first group of patients (administered sertralin,50mg+ketoprofen,100mg) and compared with their level in the second group (administered sertralin (50mg)+placebo).
85878|NCT03514797|Drug|Bleaching Agents|In-office tooth bleaching with 35% hydrogen peroxide in a single application of 45 minutes.
85879|NCT03514797|Drug|Bleaching Agents|At-home tooth bleaching with 10% carbamide peroxide for 1 hour per day.
85880|NCT03514784|Drug|BB-12 with LGG (Higher Dose)|BB-12 with LGG - Higher Dose (10 billion CFUs)
85881|NCT03514784|Drug|Placebo|Maltodextrin
85882|NCT03514784|Drug|BB-12 with LGG (Lower Dose)|BB-12 with LGG - Lower Dose (1 billion CFUs)
85883|NCT03514771|Device|Fraxel DUAL 1550/1927|
85884|NCT03514771|Drug|oral isotretinoin|oral isotretinoin
85885|NCT03514771|Drug|oral valacyclovir|Oral valacyclovir
85886|NCT03514758|Procedure|several virtual 3-D complex audio environments|The focus is a comparison of four virtual 3-D complex audio environments with regard to the sensitivity of hearing aid algorithms.
85887|NCT03514745|Device|GlideScope|Endobronchial intubation is performed using the GlideScope.
85888|NCT03514745|Device|Lighted stylet|Endobronchial intubation is performed using a lighted stylet.
85889|NCT03514732|Drug|MELATONIN (MELATL07959)|Pharmaceutical form:Capsule Route of administration: Oral
85890|NCT03514719|Diagnostic Test|89Zr-avelumab PET|89Zr-avelumab injection followed by 89Zr-Avelumab PET scan
85891|NCT03514719|Drug|Avelumab|"Early stage disease (stage Ia (≥T1b tumor)-IIIa: neo-adjuvant avelumab treatment (10mg/kg iv q2w) for a maximum duration of 2 cycles after PET-imaging, followed by surgical resection of the tumor with curative intent~Stage IIIb-IV disease: systemic treatment with avelumab 10mg/kg iv q2w after PET-imaging"
85892|NCT03514706|Diagnostic Test|volume controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
85893|NCT03514706|Diagnostic Test|pressure controlled ventilation|"Lung ultrasound (LUS) will be performed with a 2-4 MHz phased array probe. Patients will be scanned in supine position by a recording 5 seconds videos. LUS will be assessed for the presence of B lines.~The sum of lung comets produces a score reflecting the extent of lung water accumulation. LUS will be obtained by scanning 12-rib interspaces. The sum of B-lines on each scanning site yields a score from 0 to 36"
85894|NCT03514693|Procedure|PVI|Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
85895|NCT03514693|Procedure|PVI plus additional ablation|In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
85930|NCT03514485|Behavioral|School-Based Asthma Therapy|School-Based Asthma Therapy includes enhanced care coordination for prescribed daily controller medication. The school nurse will coordinate with teachers and the school CHW to schedule daily controller asthma medication administration. The school CHW will assist in obtaining a current asthma care plan and medication administration form from the primary care provider.
85955|NCT03514264|Procedure|Gutta Percha and AHPLUS cement (group A)|"First intervention: endodontic instrumentation and introduction of intact medication that will remain inside the tooth for 4 weeks.~Second intervention: removal of intracanal medication and canal filling with cement AHPLUS and guttapercha"
85896|NCT03514680|Behavioral|CIPN Assessment and Management Algorithm|The revised algorithm incorporates evidence-based CIPN assessment and management strategies and standardized CIPN/pain patient-reported outcomes measures. In terms of processes, trained study staff will administer the screening questionnaires (e.g., PRO-CTCAE, 0 - 10 numerical rating scale of worst CIPN pain intensity) to consented patients before their clinician visit (e.g., in the waiting room). Following patient completion of the screening questionnaires, study staff will provide the clinicians with a color-coded summary of the patients' responses to the screening questionnaires and the CIPN assessment and management algorithm. Clinicians may then use the algorithm at their discretion to guide the assessment and management of their patients' CIPN symptoms
85897|NCT03514667|Dietary Supplement|nanomicielle curcumin|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
85898|NCT03514667|Dietary Supplement|placebo|Participants will be selected from those referring to endocrinology clinics of Shohadaye YaftAbad and Pars Hospital (Tehran, Iran) who meet the inclusion criteria. Each subject will give informed written consent to participate in the study. 10 cc fasting blood samples will be collected from each subject at baseline and at the end of trial. Anthropometric parameters will be measured.In order to control the confounding factors in patients, they will be randomly assigned to receive either nanomicielle curcumin or placebo. nanomicielle curcumin and placebo supplements will be provided from the Elixir Nano Sina Company the patients will advise not to change their lifestyle during the study.
85899|NCT03514654|Procedure|Mastectomy|Removal of the whole breast.
85900|NCT03514654|Procedure|Therapeutic Mammoplasty|Excision via lumpectomy of multifocal or multicentric cancers with breast volume displacement techniques to maximise cosmetic outcomes.
85901|NCT03514641|Drug|Bexagliflozin|Bexagliflozin tablet, 20 mg
85902|NCT03514641|Drug|Placebo|Placebo (inactive) tablet to match the active drug
85903|NCT03514628|Other|Standard Care|The Valsalva strain will be produced using Standard Care techniques
85904|NCT03514628|Device|Valsalva Assist Device (VAD)|Use of Valsalva Assist Device (VAD) to generate VM
85905|NCT03514615|Procedure|Incision|A skin incision will be made on the medial aspect of the upper arm.
85906|NCT03514615|Drug|Active gel|The incision site on one arm will be dosed with the active gel.
85907|NCT03514615|Drug|Placebo gel|The incision site on the other arm will be dosed with placebo gel.
85908|NCT03514602|Behavioral|Multicomponent behavioral intervention|Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
85909|NCT03514602|Behavioral|Education only control|"The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists."
85910|NCT03514589|Drug|nasal Tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
85911|NCT03514589|Drug|IV tetracosactide|Bioavailability of nasal synacthen compared to IV comparator
85912|NCT03514576|Drug|Pasireotide 0.3 MG/ML|See arm description
85913|NCT03514576|Diagnostic Test|Meal tolerance test (MTT)|Subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
85914|NCT03514563|Diagnostic Test|MRI imaging|MRI recordings of the craniofacial region
85915|NCT03514563|Diagnostic Test|Optical scan|Optical intraoral scans
85916|NCT03514563|Diagnostic Test|3D photography|Facial stereophotogrammetry
85917|NCT03514550|Drug|Propofol|Propofol will be used for anesthesia during surgery
85918|NCT03514550|Drug|Sevoflurane|Sevoflurane will be used for anesthesia during surgery
85919|NCT03514550|Procedure|Epidural block|Epidural catheterization Th9-Th10, ropivacaine for perioperative analgesia
85920|NCT03514537|Procedure|Microcannula harvest adipose stromal tissues|Use of disposable, closed syringe microcannula harvest autologous adipose stroma and stem/stromal cells
85921|NCT03514537|Device|Centricyte 1000|Centricyte 1000, closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
85922|NCT03514537|Procedure|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery including 150 micron in-line filtration
85923|NCT03514537|Drug|Liberase|Liberase TM for use to enzymatically isolate cellular stromal vascular fraction
85924|NCT03514537|Drug|Saline Solution|Sterile, Normal Saline 500 for Intravenous use
85925|NCT03514524|Other|PET-MR imaging|Both 18F-MK-6240 and 11C-UCB-J PET-MR will be performed at base-line (all arms) 6 months after TBI/stroke (TBI and stroke arm) and after 2 years (TBI, stroke, CTE and MCI/MBI arls)
85926|NCT03514511|Drug|LEO 138559|LEO 138559 is a compound in development at LEO Pharma A/S
85927|NCT03514511|Drug|LEO 138559 placebo|LEO 138559 placebo
85928|NCT03514498|Procedure|Dental surgery|All types of dental surgery
85929|NCT03514485|Behavioral|Yes We Can Children's Asthma Program|The Yes We Can Children's Asthma Program intervention is a medical-social model based on a chronic care approach, including risk stratification, clinical care management, social care coordination by a community health worker, and primary care physician asthma champions. This intervention includes asthma education, trigger reduction visits and care coordination. There will be five clinic visits and four home visits over 12 months implemented by the primary care CHW who is integrated into the primary care practice.
85931|NCT03514485|Behavioral|Open Airways for School Plus|"Open Airways for Schools Plus was designed to improve the asthma self-management skills in children and enhance control of asthma in the school. The school intervention includes:~Open Airways for Schools curriculum for all students with asthma. Classes will be conducted by the school CHW once each semester.~Environmental classroom assessments conducted by school CHWs for students enrolled in the study. These teachers will receive classroom supplies to create a more asthma-friendly classroom environment.~Asthma education for school staff/personnel at the start of each school year.~School facility walk-through assessments to detect potential environmental asthma triggers will be conducted by the School District of Philadelphia."
85932|NCT03514472|Dietary Supplement|Dried Moringa oleifera leaves|
85933|NCT03514459|Other|Systems Analysis and Improvement Approach|SAIA has five steps. The first step uses an Excel-based tool to quantify drop- offs, or people who did not progress, in each step of a process (Figure 1). This tool also allows the user to see the downstream effect when improving one step in the cascade, and holding the other steps constant. Step 2 involves process flow mapping with clinic staff to identify modifiable bottlenecks in the process. Step 3 develops and implements a workflow modification to address a bottleneck identified in step 2 (continuous quality improvement [CQI] step). Step 4 assesses impact of the modification and recalculates the cascade analysis in step 1 (CQI step). Step 5 repeats the cycle for CQI. SAIA draws from systems engineering in the Toyota Production Systems and from research in LMICs. Studies in quality improvement in LMICs highlight that CQI processes led to more sustainable, effective, and appropriate interventions (42-44).
85934|NCT03514446|Drug|Antibiotic therapy duration for 7 days|Antibiotic therapy for seven days
85936|NCT03514420|Drug|AKCEA-ANGPTL3-LRX|Single open-label cohort
85937|NCT03514407|Drug|INCB059872|Part 1: Initial cohort of INCB059872 administered every other day (QOD) at the protocol-defined starting dose, with subsequent cohort dose escalation based on protocol-defined criteria. Part 2: Expansion with the recommended dose from Part 1.
85938|NCT03514394|Behavioral|Problem Solving Therapy|six weekly sessions to train patients in seven step problem solving method.
85939|NCT03514394|Behavioral|Modified PST|This intervention will contain elements of problem solving therapy, cognitive process therapy, and other interventions clinicians determine are important in their patient population
85940|NCT03514381|Drug|Patients starting a treatment with Doxorubicin and Ifosfamide|"9 blood samples will be collected at each Cycle:~Cycle 1 (Day 1-Day 2-Day 3)~Cycle 2 (Day 1-Day 2-Day 3)"
85941|NCT03514368|Other|Patients treated with immune checkpoint blockade|"Tumor biopsy specimens and blood samples will be collected at different time points:~Baseline~before the 3rd ICB administration (blood samples only)~before the 5th ICB administration (blood samples only)~at the time of treatment permanent discontinuation (blood samples only)~at the time of progression (tumor biopsy specimens only)~after the last dose of ICB treatment (blood samples only taken twice per year until study termination)"
85942|NCT03514355|Behavioral|Mindfulness-Based Stress Reduction|8 weekly 2.5 h sessions plus one day of practice
85943|NCT03514342|Procedure|Interscalene brachial plexus block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are identified between anterior and middle scalene muscles and subsequently blocked.
85944|NCT03514342|Drug|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the 5th to 7th cervical nerve roots
85945|NCT03514329|Device|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.
85946|NCT03514316|Procedure|Scalpel Gingivectomy|The patients were anesthetized in the area around the teeth which were to undergo the procedure with local anesthesia (Drug: 2% lidocaine and 1:80,000 adrenaline). Initially, the Periodontal Probing Depth was measured and when sufficient anesthesia was achieved, biologic width calculation was done by the trans-gingival probing method. Once the amount of gingival tissue to be excised was demarcated, an external bevel incision was performed by using a scalpel blade (Device: scalpel blade No.15) and the gingival tissue was excised. Left out tissue tags and any beads of granulations tissue were removed to attain a smooth surface.
85947|NCT03514316|Procedure|Laser Gingivectomy|In the Laser Gingivectomy group, the procedure was performed by using a 810 nm diode laser (Device: 810 nm FOX III diode laser) . Though a local anesthetic gel is sufficient considering that the procedure is minimally invasive, the area was adequately anesthetized with 2% lidocaine and 1:80,000 adrenaline. The laser unit, comprising of a 300 μm disposable tip, was used in a contact mode with a setting of 1 to 1.5 watts in continuous mode along the demarcated area with a paint brush like strokes progressing slowly to remove the gingival tissue and expose adequate amount of tooth structure. High-volume suction was used to evacuate the laser plume and charred odor
85948|NCT03514316|Procedure|Nonsurgical periodontal treatment|In all subjects of the Control Group a full-mouth periodontal debridement was performed at baseline, 1 and 3 months with an ultrasonic scaler. Chlorhexidine prophylaxis (0.05% chlorhexidine gluconate) was also administered twice a day for 2 weeks after the periodontal treatment. Oral-hygiene instructions were reinforced again.
85949|NCT03514303|Diagnostic Test|Spiriplex Allergenex Microassay|A microassay test using a minimal blood draw for purposes of testing the allergenicity of a subject to specific allergenic proteins.
85950|NCT03514290|Radiation|Low-lever laser|Received Low-lever laser therapy using the infrared spectrum, with a wavelength of 808 nm in its active medium AsGaAl (arsenic-gallium-aluminum), at two points: on the central of cervical and medial regions of incisors, canines and premolars in the corresponding hemi-arch. At each point, 60 J/cm2 was applied during 16 seconds with an irradiance of 3.75 W/cm² using the therapeutic visible infrared device.
85951|NCT03514290|Other|Tooth bleaching|Three 15-minute applications of 35% hydrogen peroxide gel (Whiteness HP, FGM®, Joinville, SC, Brazil) were carried out, totaling 45 minutes in each of the four bleaching sessions, with an one-week interval between applications.
85952|NCT03514290|Other|Placebo|The laser tip was positioned similarly to experimental group but without light irradiation
85953|NCT03514277|Drug|Exparel|1 level patients - 20 mL Exparel; 2 level patients - 20 mL Exparel diluted to 40 mL
85954|NCT03514277|Drug|Bupivacaine|30 mL bupivacaine 0.5% w/v solution
85957|NCT03514251|Procedure|The suture marks the location of the parathyroid gland|When the lower parathyroid gland is first seen, the parathyroid gland is sutured with a suture during the operation, and then during this subsequent cleaning, rapid parathyroid localization and parathyroid glands are performed through this marker. Vascular protection.
85958|NCT03514238|Behavioral|High Intensity Interval Aerobic Exercise (HIIT)|"Cycling at 50-55% heart rate reserve for 5 minutes followed by 2 minutes of cycling at 85-90% heart rate reserve consecutively for a total of 35 minutes.~Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min)."
85959|NCT03514238|Behavioral|Continuous Moderate Aerobic Exercise (MOD)|35 minutes of cycling at 50-55% heart rate reserve. Blood draws will occur at 6 different time points during exercise (0min, 7min, 14min, 21min, 28min, 35min).
85960|NCT03514238|Behavioral|Control Sitting Condition (C)|Blood draws matched for exercise time will be taken while participant remains seated for 35 minutes (0min, 7min, 14min, 21min, 28min, 35min).
85961|NCT03514225|Other|Metacognitive Therapy for Social Anxiety|The transdiagnostic Metacognitive model posits that psychological disorder stems from the activation of a perseverative thinking style called the CAS (Cognitive Attentional Syndrome). This has 3 key elements: worry/rumination, threat-focussed attention and unhelpful coping behaviours. Each of these elements results in extended cognitive responses to negative thoughts, prolonging negative emotions and maintaining an individual's sense of threat. The CAS arises from an individual's positive and negative metacognitive beliefs (beliefs about cognition). Metacognitive Therapy (MCT) aims to bring the CAS under control by modifying metacognitive beliefs and enabling individuals to develop new reactions to negative thoughts.
85962|NCT03514212|Behavioral|ProActiveS|A 12-week behaviour change intervention, during which time participants met with the researcher weekly and used a pedometer to measure step count and completed an activity diary to monitor progress, set goals and plan how to cope with identified barriers.
85963|NCT03514199|Other|Mediterranean-type diet|"Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa."
85964|NCT03514199|Other|Low fat diet|Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
85965|NCT03514186|Behavioral|Speech and Language Therapy|"Includes:~one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~one hour in a conversation group that emphasizes multimodality communication"
85966|NCT03514173|Device|Remote Patient Monitoring|Use of remote patient monitoring
85967|NCT03514160|Behavioral|Group exercise|Group exercise based on the American College of Sports Medicine guidelines.
85968|NCT03514147|Other|Experimental|"Profile of participants: an anamnesis file was used to collect personal data;~To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
85969|NCT03514147|Other|Control|"Profile of participants: an anamnesis file was used to collect personal data;~To evaluate the quality of life: To evaluate the quality of life, using International Consultation on Incontinence Questionnaire (ICIQ-Short form) in women with urinary incontinence in baseline and after 12 weeks of intervention;~To evaluate the pelvic floor muscle functionality: To evaluate the pelvic floor muscle functionality, using PERFECT Scale and Pressure Biofeedback in baseline and after 12 weeks of intervention;"
85970|NCT03514134|Behavioral|Virtual Reality Job Interview Training|Students will engage in didactic training related to strategies to perform well during a job interview as well as repeated practice with a virtual hiring manager. Throughout and after completion of the virtual interviews, participants will receive feedback on their performance.
85971|NCT03514134|Behavioral|Services as Usual|Study participants will be receiving their community-based or school-based services as usual that may include but is not limited to vocational skill training, daily living skill training, and social skill training.
85972|NCT03514121|Biological|FPA150|A monoclonal antibody against B7-H4
85973|NCT03514121|Biological|Pembrolizumab|An anti-PD1 antibody
85974|NCT03514108|Drug|Hydralazine Isosorbide Dinitrate|Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
85975|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 3 daily
85976|NCT03514108|Drug|Metformin Hydrochloride|Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
85977|NCT03514108|Drug|Placebo Oral Tablet|2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
85978|NCT03514095|Other|Individual Cognitive Stimulation Therapy Program|"This program unfolds in 3 weekly sessions of 30 minutes, for 12 weeks, thus completing a total of 36 sessions.~Over the 3 months, the dyad will need to be monitored for orientation / monitoring of intervention by an element of the research team. This monitoring will be bi-weekly, in person or by phone - here according to the choice of the dyad). After each session the caregiver has a questionnaire to complete (intervention monitoring strategy), with the objective of evaluating the acceptability and applicability of the program."
85979|NCT03514082|Device|Rigid Thermoplastic Spinal Brace|Custom made rigid thermoplastic brace with 23 hours daily wearing time.
85980|NCT03514069|Drug|ruxolitinib|Starting dose ruxolitinib 10 mg twice daily
85981|NCT03514069|Radiation|radiation|60gy for 6 weeks
85982|NCT03514069|Drug|temozolomide|75mg/m2
85983|NCT03514056|Diagnostic Test|group 1:Patients diagnosed with Behcet disease|Frequency and severity of fibromyalgia will be investigated in patient diagnosed with Behcet disease
85984|NCT03514056|Diagnostic Test|group 2: Patient diagnosed with fibromyalgia without Behcet disease|Severity of fibromyalgia will be investigated in patient diagnosed with fibromyalgia
85985|NCT03514030|Diagnostic Test|serum AQP4-antibody testing method|there are different methods of testing serum AQP4-antibody
85986|NCT03514017|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
85987|NCT03514017|Drug|Ibrutinib|Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
85988|NCT03514004|Behavioral|ICT-based intervention|"The ICT-based intervention, known as Project Clan, includes both a web-platform and a mobile application. Project Clan includes both informational and interactive features, ranging from traditional suicide prevention strategies (e.g., a chat with a psychologist, emergency phone hotline, and tips) that seek to reduce barriers to access quality, useful, and evidence-based information and rapid professional assistance, to components designed to increase interactions between participants and promote a sense of belonging and connection with the other Clan members."
85989|NCT03513991|Other|Infant formula|
85990|NCT03513978|Other|IAI Exercises Protocol|Progressive exercises to improve the strength and propioception of the male soccer players.
85991|NCT03513978|Other|FIFA 11+|"Progressive exercises protocol to prevent injuries in male soccer players which has been created by FIFA. It is based in different body wieght exercises to improve the neuromuscular control and stabilization."
85992|NCT03513965|Behavioral|Symptoms as Positive Signals Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. However, Symptoms as Positive Signals Mindset families are additionally encouraged to think of symptoms as a positive signal that their immune system is becoming increasingly desensitized to their allergen. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
85993|NCT03513965|Behavioral|Symptoms as Side Effects Mindset|In this intervention, both arms receive the same strategies for managing symptoms and receive the same level of support regarding symptoms. For each arm, four families (six to seven patients per group) meet monthly for eight months in the clinic with at least two members of the patient support team. These visits are an opportunity for families to harness peer support and ask questions, and include a variety of activities that depict symptoms in different ways.
85994|NCT03513952|Drug|Atezolizumab|Given IV
85995|NCT03513952|Biological|Glycosylated Recombinant Human Interleukin-7|Given IM
85996|NCT03513952|Other|Laboratory Biomarker Analysis|Correlative studies
85997|NCT03513939|Combination Product|Sernova Cell Pouch™|The Sernova Cell Pouch™ will be implanted under the skin. A minimum of three weeks after Cell Pouch™ implantation, immunosuppression will be initiated and optimized for another 3 weeks. This will allow for proper vascularization of the Cell Pouch™ chambers and the patient to be stabilized on immunosuppression prior to transplantation. A mass, >3,000 islet equivalent (IEQ) numbers per kg of patient body weight (IEQ/kg), of highly purified islets will be transplanted in the Cell Pouch™.
85998|NCT03513926|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
85999|NCT03513913|Procedure|ICSI|Oocytes are fertilized by conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
86000|NCT03513874|Drug|Metformin|Patients will be subscribed with 850mg metformin orally twice daily. Insulin will be continued as routine therapy.
86001|NCT03513874|Drug|Insulin|Patients will continue insulin therapy following physicians' instructions.
86002|NCT03513861|Other|FASTER Assessment tool|The FASTER assessment tool consists of monitoring mental status, respiratory distress and capillary refill time by parents of children admitted to the hospital with febrile illness. Parents in the intervention group are asked to monitor their child hourly with the FASTER tool and signal severity of illness to the healthcare team via color coded flag system. Number of healthcare provider - patient reassessments will be compared in intervention and control group.
86003|NCT03513848|Device|Retimer|The Retimer light device in this study is a commercially-available wearable light device. It permits ambulation while receiving light from LEDs positioned below the eyes. The LEDs emit green light (~500nm, 230 µW/m2, 500 lux), close to the peak sensitivity of circadian photoreceptors.
86004|NCT03513848|Device|Retimer placebo|The Retimer device has been dimmed to reduce the light intensity to a level that will not shift circadian timing.
86005|NCT03513835|Diagnostic Test|Diagnostic screenings tests|Handgrip test, 12-minute walk test and 6-minute walk test. Biomarkers: acyl-carnitine profile and GDF-15.
86006|NCT03513822|Drug|Ketamine 10 MG/ML|Ketamine infusion 1mg/kg with electric syringe during 2 hours.
86007|NCT03513822|Drug|Placebos|Sodium chloride infusion with the same rate, electric syringe during 2 hours.
86008|NCT03513822|Drug|Midazolam 1 MG/ML|Bolus of Midazolam 1mg before each perfusion.
86009|NCT03513809|Device|Thoracic electrical impedance tomography|Non invasive, radiation-free, bedside monitoring tool for distribution of pulmonary ventilation.
86036|NCT03513575|Other|Group 4: Fluoridated tooth paste|The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
86105|NCT03513146|Procedure|Oropharyngeal Administration of Mother's Milk (OPAMM)|0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
86010|NCT03513783|Other|measurement of human movement|"The objective measurement of human movement through the use of kinematic markers and electromyography is a clinical exam commonly performed to analyze the movements of patients with motor control disorders. The different steps are the following:~A clinical exam is performed by the Physical Medicine & Rehabilitation clinician (passive range of motion , spasticity, muscular force, etc.).~Intramuscular and surface electromyography and kinematic markers are placed on the upper limb of the participant. A maximum of two intramuscular electrodes will be inserted with guiding of an echography system.~The participant will be asked to perform several upper limb movements: specifically, he will be asked to perform consecutive cycles of elbow extension-flexions with the shoulder at different levels of abduction. Times of rest will be given to the participants.~Time of the procedure is estimated to 1h, with only about 2 minutes of active effortless movements from the participants."
86011|NCT03513770|Other|Wrist-to-elbow (W-E) occlusion|"An IV will be inserted in the antecubital fossa of one arm. The arm will be fitted with occlusion cuffs arranged in a continuous fashion from the wrist to the elbow. A final cuff will be placed on the upper arm. The cuffs from the wrist to the elbow will be inflated to the same pressure of up to 300 mmHg using a pressurized air tank.~First, the subject?s arm will be elevated and the subject will make a fist to squeeze blood from the hand. Then the wrist cuff will be inflated. Once that cuff is fully inflated, the next cuff in the sequence will be inflated. Cuffs are inflated in sequence until the elbow cuff is inflated. After a 10-15 second period to allow blood to drain, the upper arm cuff will inflate (up to 250 mmHg) to keep any additional blood from entering the forearm. Next, the cuffs on the forearm will be removed but the upper arm cuff will remain inflated."
86012|NCT03513770|Drug|ketorolac tromethamine|In the COX blockade trial, just after the Wrist-to-elbow occlusion, 6 mg ketorolac tromethamine in 10 ml saline will be infused into the forearm over 1 minute. After 10 minutes, a second infusion of ketorolac tromethamine (up to 3 mg) in 5% of the forearm volume of saline,( ~40-60 ml) will be infused into the occluded forearm at a rate of ~ 30 ml/min. Five minutes of data will then be collected before releasing the upper arm cuff. Infusion 1 is to block the COX pathway, while infusion 2 is to induce venous distension.
86013|NCT03513770|Drug|saline control|In the saline control trial performed on a separate day, saline (without ketorolac) in identical volumes as those in the COX blockade trial, will be infused.
86014|NCT03513757|Drug|propofol|propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 200 mic/kg/minute propofol infusion if movement persists
86015|NCT03513757|Drug|Dexmedetomidine|single dose dexmedetomidine administered at start of sedation. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mic/kg
86016|NCT03513744|Dietary Supplement|human milk oligosaccharides|mixture of five different human milk oligosaccharides
86017|NCT03513731|Device|Adipose-derived stem cell injection|ADRC injection into the facet joint
86018|NCT03513731|Drug|Corticosteroid injection|Corticosteroid injection into the facet joint
86019|NCT03513705|Other|Best practices in pancreatic cancer care|All best practices follow the current state of the Dutch guideline on pancreatic cancer and the literature.
86020|NCT03513692|Device|Fill-Up composite resin|2 arm study comparing restoration of a tooth with either FillUp composite or conventional composite
86021|NCT03513679|Procedure|Surgical intervention|Surgery to decompress the spinal cord, either with or without concurrent fusion
86022|NCT03513666|Combination Product|Drug intervention|anti-PD-1 monoclonal antibody Toripalimab injection combined with Pemetrexed and carboplatin
86023|NCT03513653|Diagnostic Test|Echocardiography with speckle-tracking imaging|Measurement of left ventricular ejection fraction and global longitudinal strain
86024|NCT03513627|Procedure|Post-occlusive reactive hyperemia test (PORH test)|Compression is applied on the buccal side of the attached gingiva, perpendicular to the long axis of the natural or implant born crown 2 mm far from the gingival margin.
86025|NCT03513614|Procedure|Tailored axillary surgery|Sentinel lymph node procedure combined with the documentation of the successful removal of the clipped node by specimen radiography and the removal of all palpably suspicious nodes.
86026|NCT03513614|Radiation|Radiotherapy - Arm A|Breast/chest wall and regional nodal irradiation excluding the dissected axilla as a target volume.
86027|NCT03513614|Radiation|Radiotherapy - Arm B|Breast/chest wall and regional nodal irradiation including the full axilla.
86028|NCT03513601|Drug|(R)-CHOP regimen|(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,epirubicin 50mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and six cycles are required. Efficacy was evaluated every two cycles.
86029|NCT03513601|Drug|(R)-CVP regimen|The dose of the chemical was reduced by 20%，(rituximab 375mg/m2 d0 ivgtt),cyclophosphamide 750mg/m2 d1、8 ivgtt,vincristine 2mg d1、8 ivgtt,prednisone 60mg d1-5 po.Every 21 days for one cycle and one or two cycles are required. Efficacy was evaluated every two cycles. Subsequent (rituximab 375mg/m2 d0 ivgtt)， oral cyclophosphamide .
86030|NCT03513588|Drug|Placebo|tablet, 0 mg, 14 days, every 12 hours
86031|NCT03513588|Drug|PF-06865571|tablet, 50 mg, 14 days, every 12 hours
86032|NCT03513588|Drug|PF-06865571|tablet, 300 mg, 14 days, every 12 hours
86033|NCT03513575|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test flavored milk drink without any intervention.
86034|NCT03513575|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
86035|NCT03513575|Other|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
86103|NCT03513172|Drug|topical brimonidine tartrate 0.15% (Alphagan® P; Allergan, Inc)|The rapid hypotensive effects of topical alpha2-agonists such as brimonidine tartrate on decreasing aqueous production and increasing uveoscleral outflow, in addition to their neuroprotective properties, make them an attractive option for prophylactic treatment of post-injection IOP spikes.
86037|NCT03513575|Other|Group 5: Polyol containing gum|The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention.
86038|NCT03513575|Other|Group 6: 1% sodium bicarbonate solution|The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit, 15minutes after the subject has consumed the test flavored milk drink. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
86039|NCT03513562|Drug|Ibrutinib|Given PO
86040|NCT03513562|Other|Laboratory Biomarker Analysis|Correlative studies
86041|NCT03513562|Drug|Venetoclax|Given PO
86042|NCT03513549|Drug|Loxapine 10 MG|
86043|NCT03513536|Other|Citrus-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
86044|NCT03513536|Other|Mint-Based Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
86045|NCT03513536|Other|Spice-Scented Aromatherapy|This intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
86046|NCT03513536|Other|Control|This control is a blend of plant derived oils which have been expressed from crude plant matter.
86047|NCT03513523|Dietary Supplement|Group 1 NRPT|Two capsules of NRPT and two placebo will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
86048|NCT03513523|Dietary Supplement|Group 2 NRPT|Four capsules of NRPT will be taken once daily in the morning for 26 weeks. Each NRPT capsule will contain 125 mg NR and 25 mg PT.
86049|NCT03513523|Other|Group 3 Placebo|Four placebo capsules will be taken once daily in the morning for 26 weeks.
86050|NCT03513510|Behavioral|iChoose|
86051|NCT03513497|Other|Customized acrylic mouthguard|Customized acrylic mouthguards extended to cover approximately 2 mm over gingival margins will be fabricated for each subject. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will cover the area in one sextant where no brushing and flossing teeth is to occur for 21 days.
86052|NCT03513484|Drug|Azacitidine|Given IV or SC
86053|NCT03513484|Other|Laboratory Biomarker Analysis|Correlative studies
86054|NCT03513484|Drug|Nintedanib|Given PO
86055|NCT03513471|Biological|Anakinra|A single 1mg/kg subcutaneous injection (up to 100mg) of anakinra will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
86056|NCT03513471|Other|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the EPR, directly after the allergen challenge, to model anakinra use in an emergency care setting.
86057|NCT03513471|Drug|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
86058|NCT03513458|Biological|Anakinra|A single 1mg/kg subcutaneous injection (up to 100 mg) of Anakinra will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
86059|NCT03513458|Other|Anakinra Matching Placebo|A single dose of matching placebo will be administered at the onset of the LPR, roughly three hours post allergen challenge, to model Anakinra use in an emergency care setting.
86060|NCT03513458|Drug|Dermatophagoides Farinae|Standardized house dust mite Dermatophagoides farinae (D. farinae) allergen extract at 30,000 allergen units (AU)/mL for inhalation (provided by Greer Laboratories, Lenoir, NC).
86061|NCT03513445|Drug|Morphine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
86062|NCT03513445|Drug|Epinephrine|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
86063|NCT03513445|Drug|naropin|Morphine, epinephrine, and ropivacaine cocktail will be administered peri-incisionally during lumbar spine surgery.
86064|NCT03513432|Dietary Supplement|Beer with 5.20 % alcohol|330 ml beer (5.20 % alcohol)/day during 4 weeks
86065|NCT03513432|Dietary Supplement|Non-alcoholic beer with 0.45 % alcohol|330 ml non-alcoholic beer (0.45 % alcohol)/day during 4 weeks
86066|NCT03513432|Dietary Supplement|Non-alcoholic beer with 0.00 % alcohol|330 ml nonalcoholic beer (0.00 % alcohol)/day during 4 weeks
86067|NCT03513419|Behavioral|The AMOR Method|The parent resilience training involves a series of eight weekly 90-minute group sessions with up to 8 parents of young children with ASD (4- 10:11 years old) per group, as well as three individual sessions.
86068|NCT03513406|Drug|Sugammadex|Sugammadex is indicated for the reversal of neuromuscular blockade.
86069|NCT03513406|Drug|Neostigmine|Neostigmine is indicated for the reversal of neuromuscular blockade.
86070|NCT03513406|Drug|Glycopyrrolate|Glycopyrrolate is used in conjunction with neostigmine to prevent neostigmine's muscarinic effects.
86071|NCT03513393|Drug|velpatasvir|Test 1
86072|NCT03513393|Drug|velpatasvir|Test 2
86073|NCT03513393|Drug|velpatasvir|Reference
86074|NCT03513380|Behavioral|Exergaming|free access to the exergame PedalTanks during 6 months
86075|NCT03513367|Other|Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale|"Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents."
86104|NCT03513159|Behavioral|Pathfinder support|A pathfinder will support the patient with structured activities.
86137|NCT03512821|Drug|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
86076|NCT03513367|Other|The following data of motor function|In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
86077|NCT03513354|Other|Soil group|Exercises in soil.
86078|NCT03513354|Other|Pool group|Exercises in pool.
86079|NCT03513341|Other|No intervention|No intervention is given to the participants. This is an observational study exploring the students' levels of physical activity and sedentary behaviour in their natural setting.
86080|NCT03513328|Drug|Thiotepa--single daily dose|Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
86081|NCT03513328|Drug|Thiotepa--escalated dose|Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
86082|NCT03513315|Behavioral|Implementation of Community-based Home Heat Bundle|This community-based intervention include a set of educational materials to increase awareness about heat-related illness and prevention with the intention of reducing the incidence of heat-related and reducing mortality associated with heat-related illness. Materials used in this intervention will include posters, brochures, in-person training, and SMS messaging.
86083|NCT03513315|Behavioral|Regular Community Healthcare provision|The community will get regular community health workers visit without the focus community mobilization and education on heat-related illnesses.
86084|NCT03513302|Dietary Supplement|placebo|2 x 70 mL concentrated beet root juice depleted of nitrate per day for 14 days.
86085|NCT03513302|Dietary Supplement|nitrate|2 x 70 mL concentrated beet root juice per day for 14 days.
86086|NCT03513289|Other|Patient, Carer, and Clinician Interviews|Post-ICU follow-up interviews conducted over the phone, lasting between 30-60 minutes.
86087|NCT03513276|Drug|100cc of 2% ropivacaine|Multimodal analgesia + Local infiltration anesthesia
86088|NCT03513276|Drug|Saline Solution|Multimodal analgesia + Saline solution
86089|NCT03513276|Drug|Adrenaline 10mcg/ml|
86090|NCT03513263|Procedure|Scaling and polishing|An electronic scaler will be used to clean the gums
86091|NCT03513263|Other|oral hygiene instructions|It will include 15-minute oral session with visual and verbal information on how to use a toothbrush, dental floss, and mouthwash correctly; how to clean bridges and dentures; and how and why to use a plaque disclosing test to perform tooth cleaning
86092|NCT03513250|Drug|hyoscine-n-butylbromide|one ampoule of 20 mg of hyoscine-n-butylbromide (Buscopan, 20mg/Ampoule, CID/Boehringer ) will be administered intravenously immediately before the end of the cesarean section.
86093|NCT03513250|Drug|control group|an equal volume(1 ml ) of normal saline will be administered before the end of cesarean section.
86094|NCT03513237|Procedure|Cervical dilation|manual dilatation of the cervix using surgeon's finger.
86095|NCT03513224|Other|eDosette|The eDosette is an internet-enabled, medication administration monitoring unit that has been previously tested for feasibility in older adults. The eDosette was designed to be compatible with different types of weekly medication blister packs and dosettes, and monitors medication-taking behaviour in a patient's home. The eDosette securely transmits this information to a secure server where the information is converted to individual medication administration records. Patients can also use the eDosette to notify their primary care team of potential medication side effects.
86096|NCT03513211|Drug|SUBA-itraconazole|150mg PO BD
86097|NCT03513211|Drug|Hydroxychloroquine|Escalating doses in Rolling 6 Phase I
86098|NCT03513198|Diagnostic Test|Endoscopic ultrasound (including fine needle aspiration)|"EUS will be performed before (including EUS-FNA for confirmation of diagnosis) and 2 months after the first course of treatment.~Protocol of EUS with EUS-FNA should include linear EUS instruments with complete examinations of the pancreas.~Tumor characteristics (echogenicity, echostructure, size) will be described as well as presence/absence of power Doppler signals.~EUS-FNA will be performed in all pancreatic masses with at least four passes."
86099|NCT03513198|Other|Contrast-enhanced endoscopic ultrasound (CE-EUS)|"CE-EUS will be performed during usual EUS examination before and 2 months after the first course of chemotherapy.~The starting point of the timer will be considered the moment of intravenous contrast injection (Sonovue 4.8 mL).~The whole movie (T0-T120s) will be recorded in a DICOM format on the embedded HDD of the ultrasound system, for later analysis.~All post-processing and computer analysis of digital movies will be performed within the coordinating IT Center using Vue-Box"
86100|NCT03513198|Other|Endoscopic ultrasound elastography (EG-EUS)|"EUS-EG will be performed during usual EUS examinations, before and 2-months after the first course of chemotherapy, with two movies of 10 seconds recorded on the embedded HDD~The region of interest for EUS-EG will be preferably larger than the focal mass. If the focal mass is larger than 3 cm, part of the mass will be included in the ROI, as well as the surrounding structures. Very large ROI for the elastography calculations will be avoided~The following pre-settings will be used in all centers: elastography color map 1, frame rejection 2, noise rejection 2, persistence 3, dynamic rage 4, smoothing 2, blend 50%.~SR and SH will be measured; with three measurements made and recorded on the embedded HDD."
86101|NCT03513198|Diagnostic Test|Contrast-enhanced computed tomography (CT)|"Contrast-enhanced computed tomography will be obtained before treatment to assess the local extension of the tumor, and presence of lymph nodes and distant metastases.~A template will be used to report the imaging results.~The template includes morphologic, arterial, venous, and extrapancreatic evaluations.~Contrast-enhanced computed tomography will be performed 2 months after the first course of chemotherapy, using the same template, in order to evaluate the tumor response. Tumor response will be assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST)."
86102|NCT03513185|Drug|Deanxit, SSRI or SRNI|After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
86106|NCT03513133|Behavioral|working memory training|Hierarchical cognitive training of the different components of working memory according to Baddeley model; 15 tasks are used addressing: the phonological loop (8 tasks), the visuospatial sketchpad (4 tasks) and the central executive 3 tasks). Task are given in a hierarchical order, according to each individual patient's deficits and improvement.
86107|NCT03513107|Other|ospeoporosis score|"Scores will be calculated as indicated in their respective studies after collecting the data pertaining to them (Crandall, 2015); (Cass & Shepherd, 2013); (Reginster, et al., 2004); (Adler, et al., 2003); (Cadarette, et al., 2000); (Weinstein & Ulery, 2000); (Black, et al., 1998); (Lydick, et al., 1998).~Data will be treated as dichotomous for both DXA T-scores and screening scores (i.e. Osteoporosis (Yes or NO) versus positive/negative score)."
86108|NCT03513094|Other|Transversus Abdominis Contraction|Participants were educated on how to contract their transversus abdominis (TA) muscle after having a surface EMG biofeedback device placed on their abdomen to provide audible biofeedback. Participants were asked to ambulate while maintaining TA contraction while ambulating at 50% of maximal volitional isometric contraction.
86109|NCT03513081|Behavioral|Educative session|The experimental group receive nine educational sessions (one per week) about different vegetables and, at lunch time, they are exposed to a different vegetable. If they try it, they will receive a sticker. In each session, researcher will record their preference for the vegetable and the quantity that they consumed in a scale from one to three (1- the child prooved it; 2 - the child repeated it; 3 - the child ate all the quantity). In the end of 9 sessions, all children (experimental and control group) will receive the same salad that they had eaten at baseline and the procedure will be the same: the salad is weighted before and after the consumption of each child to verify the quantity of each one ate.
86110|NCT03513068|Device|Portable Oxygen Concentrator (POC)|COPD patients prescribed with LTOT will be randomized to receive a portable oxygen concentrator (POC)
86111|NCT03513055|Other|nurse inject premixed insulin|nurse inject premixed insulin，coaching in the injection technique
86112|NCT03513042|Radiation|Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy|"Standard of care:~IMPT (conventional fractionation [35x1,55/2Gy, 5 fractions/week] or accelerated fractionation [35x1,55/2Gy, 6 fractions/week])~with or without concurrent cisplatin (100 mg/m2 [d1, d22 and d43] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)"
86113|NCT03513029|Device|VytronUS Ablation System|Catheter Ablation for Paroxysmal Atrial Fibrillation
86114|NCT03513016|Drug|UBX0101|Investigational drug intra-articular injection
86115|NCT03513016|Other|Placebo|Diluent intra-articular injection
86116|NCT03513003|Device|Functional Pacifier|Children swap from their habitual pacifier to the functional pacifier and stop baby bottle
86117|NCT03513003|Behavioral|Stop habit|Children stop the use of their pacifier and/or baby bottle
86118|NCT03512990|Procedure|Bupivacaine - Superior Trunk Block|It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
86119|NCT03512977|Procedure|sphenopalatine ganglion block|the intervention will be performed on sitting position. Lidocaine 2% viscous (0.5ml) will be apply on cotton swab sticks and one will be gently inserted into nostril, along the floor of the nose. Stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab stick will be left undisturbed for 20 minutes.
86120|NCT03512977|Drug|conservative treatment|Conservative treatments are iv hydration, analgesic agents, caffeine or theophylline
86122|NCT03512951|Other|Digital signal processing algorithms|The intervention consists in applying five processing on some recorded speech signals. In particular, the processing performed by one specific algorithm is compared against the four other. The applied processing is supposed to restore sound externalization (expected audio-visual fusion).
86123|NCT03512938|Procedure|Non-surgical periodontal therapy|Patients were motivated and instructed to brush with modified Bass technique and use interdental toothbrushes, dental floss. Each patient underwent quadrant scaling and root planning (SRP) under local anaesthesia over a 4-week period. Root planing (RP) was performed under local anaesthesia (2% lidocaine, epinephrine 1:100.000) and a standard curette set newly sharpened with Arkansas stone was used for each patient.
86124|NCT03512925|Other|Standardized debriefing session of coercive measures|Debriefing session following the developed guidelines including setting and themes.
86125|NCT03512912|Device|transcutaneous electrical calf muscle stimulation + supervised walking therapy|transcutaneous electrical calf muscle stimulation + supervised walking therapy
86126|NCT03512899|Procedure|Right internal jugular access.|Implantation using percutaneous puncture.
86127|NCT03512899|Procedure|Left internal jugular access.|Implantation using percutaneous puncture.
86128|NCT03512899|Procedure|Right axilar vein access.|Implantation using percutaneous puncture.
86129|NCT03512899|Procedure|Left axilar vein access.|Implantation using percutaneous puncture.
86130|NCT03512886|Other|Multi-task training|In the multitasking training group, a second motor task in the first two weeks, a cognitive task in the third and fourth week, both motor and cognitive tasks in the last two weeks will be added to these 10 different motor tasks.
86131|NCT03512886|Other|Single task training|An exercise program consisting of 10 different motor tasks will be implemented in a single task training group.
86132|NCT03512873|Drug|Tranilast|Subjects will be treated with tranilast
86133|NCT03512860|Drug|E4/DRSP|Administered as specified in the treatment arm.
86134|NCT03512860|Drug|VAL|Administered as specified in the treatment arm.
86135|NCT03512834|Drug|Avelumab|Avelumab 10mg/kg, administered via I.V infusion over 1hour, every 2weeks until disease progression or unacceptable toxicity
86136|NCT03512834|Drug|Paclitaxel|Paclitaxel 80mg/m2 D1,8 and 15 , administered via I.V infusion, every 4 weeks.
86298|NCT03511677|Device|Insole|Customized insole
86138|NCT03512821|Drug|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
86139|NCT03512808|Drug|Ursodiol 500 MG|Ursodiol 500mg tablets followed by Urso Forte 500mg tablets
86140|NCT03512808|Drug|Urso Forte 500Mg Tablet|Urso forte 500mg tablets followed by Ursodiol 500mg tablets
86141|NCT03512795|Biological|Blood samples|An additional blood tube will be taken during the patient's follow-up blood collection.
86142|NCT03512782|Other|CARDIOENF|The patients listed in interventional group will have access to software Cardioenf that is a app used in a device (cel phone, tablet) to monitoring signs and symptoms of the heart failure patients after discharge from hospital. In this software, their signs and symptoms will be inserted in three moments during the first 30 days after discharge. Nurses will monitor these data in the follow-up period.
86143|NCT03512769|Device|Restful Jaw Device|The Restful Jaw device is used to support the jaw during dental procedures including surgical removal of 3rd molars (wisdom teeth) with sedation. The device is designed to counter the downward forces placed on the mandible by clinicians during dental procedures and prevent jaw hyperextension (opening too wide) while providing a secure, stable jaw position. When 3rd molar teeth are surgically removed with sedation, a dental assistant stands behind the dental chair and supports the patient's jaw with both hands under the patient's jaw. If needed, the dental assistant also holds the jaw in a slightly forward position to maintain an open airway. This device replicates the dental assistant in holding the jaw during dental procedures.
86144|NCT03512756|Drug|SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)|Daily oral therapy for cancer
86145|NCT03512756|Drug|Capecitabine, Gemcitabine, and 5-FU|"Investigator choice of the following therapies:~Capecitabine, Gemcitabine, and 5-FU"
86146|NCT03512730|Device|Titanium brush|a titanium brush will be tested as mechanical decontamination in regenerative treatment of peri-implantitis
86147|NCT03512730|Other|Classic decontamination|Classic decontamination will be performed by means of H2O2 3% and plastic curettes
86148|NCT03512717|Device|Potenfill|Maximum: 22ml
86149|NCT03512717|Device|Powerfill|Maximum: 22ml
86150|NCT03512704|Other|Collection of possible predictors from patient data|Collection of sociodemographic and clinical parameters, from medical records, and health related quality of life data, that may predict the outcomes of interest (mortality, complications, readmissions)
86151|NCT03512691|Behavioral|Information on CVD Risk|Respondents will be provided three types of information on CVD risks: a CVD base rate, a personalized CVD risk and an optimal CVD risk. The CVD base rate will be predicted from the respondent's age and sex only. After reporting their own chance of having a heart attack or stroke within ten years, the respondents in the treatment group will be told the risk for someone with the same age, sex, smoking status, body mass index (BMI) and blood pressure as them. Finally, a treatment group respondent will receive information on what the 10-year CVD risk would be for someone of the same age and gender who did not smoke, and had normal blood pressure and BMI.
86152|NCT03512691|Behavioral|Lottery Incentive|Respondents will simply be told that they can enter a lottery if they go to the specified clinic for a checkup. The health facilities will be told to conduct an assessment deemed appropriate for any particular patient that requests to be issued with a lottery ticket. No instructions will be given that the facilities should follow the PhilPEN protocol. We will evaluate whether they do implement the protocol for patients who qualify (by age if nothing else) for full risk screening.
86153|NCT03512665|Dietary Supplement|Full dose supplement|A 7ml vial composed of a mixture of pine, macadamia and pomegranate oils.
86154|NCT03512665|Dietary Supplement|Low dose Supplement|A 7 mL vial composed of a mixture containing 50% study supplement (Pine, macadamia and pomegranate oils) and 50% sunflower oil.
86155|NCT03512665|Other|Control Oil|A 7ml vial composed of sunflower oil with appearance and organoleptic properties similar to those of the supplement provided in the intervention groups.
86156|NCT03512652|Device|Patello|The Patello is a new intervention device which mobilizes the Patella passively and continuously in cranial-caudal direction to increase Patella mobility.
86157|NCT03512639|Drug|Homeopathic Medication|Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma
86158|NCT03512639|Drug|Placebo|placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
86159|NCT03512626|Device|OptiVis, Aaren Scientific|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
86160|NCT03512626|Device|Monofocal IOL|All the surgeries were performed under topical anesthesia using a standard phacoemulsification procedure with Infiniti Vision System (all from Alcon Laboratories, Inc, Fort Worth, TX).
86161|NCT03512613|Device|c-FLOW 3310-P|"c-FLOW 3310-P is a continuous, non-invasive monitor of cerebral deep tissue blood flow used to measure relative changes in blood flow.~The device monitors regional micro circulatory blood flow in tissues, by using sensors placed near the area of interest."
86162|NCT03512600|Dietary Supplement|Intervention 0|Without nutritional intervention, it will consist of normal food intake without food derived from cocoa or coffee for a period of 1 day in the group of 20 patients during meals. ( That day the patient can not consume cocoa derivates nor coffe or coffe derivates).
86163|NCT03512600|Dietary Supplement|Intervention 1|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa that will be provided to the paient (Food based on soluble cocoa) during one 1 day period in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
86164|NCT03512600|Dietary Supplement|Intervention 2|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cacao (Food based on black chocolate) during a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
86165|NCT03512600|Dietary Supplement|Intervention 3|"The nutritional intervention will consist of the intake of 40 g daily a base of food derived from cocoa (Food based on chocolate with milk) for a period of 1 day in the group of 20 patients during meals.~That day the patient can not consume cocoa derivates nor coffe or coffe derivates exept the one provided."
86299|NCT03511677|Device|Placebo Insole|Placebo flat insole
86166|NCT03512587|Procedure|Personalized quantum sonotherapy|Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
86167|NCT03512587|Procedure|Placebo|Headphones will be place in patients without playing quantum sonotherapy
86168|NCT03512574|Drug|Pregabalin|One hour before spinal anesthesia, patients received pregabalin 150 mg capsule orally and the same calculated volume of normal saline till completion of the surgery
86169|NCT03512574|Drug|Dexmedetomidine|One hour before spinal anesthesia, patients received placebo and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery
86170|NCT03512574|Other|Placebo|One hour before spinal anesthesia, patients received placebo and the same calculated volume of normal saline till completion of the surgery
86171|NCT03512574|Drug|Pregabalin and dexmedetomidine|One hour before spinal anesthesia, patients received pregabalin 150 mg orally and a bolus dose of 0.5 μg /kg IV dexmedetomidine was given over 10 min before induction of spinal anesthesia, a bolus dose of 0.5 μg /kg IV till completion of the surgery.
86172|NCT03512548|Drug|Relacorilant 350mg|Relacorilant 350mg
86173|NCT03512548|Drug|Itraconazole|Itraconazole 200 mg
86174|NCT03512548|Drug|Relacorilant 300mg|Relacorilant 300mg
86175|NCT03512522|Behavioral|Online Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in an online format.
86176|NCT03512522|Behavioral|Workbook Group|An 8-week remotely-delivered pain self-management program tailored to older adults that will be delivered in a printed (workbook) format.
86177|NCT03512509|Other|Low glycaemic potato|The Carisma potato variety is used as the low glycaemic index potato.
86178|NCT03512509|Other|High glycaemic potato|The Arizona potato variety is used as the high glycaemic index potato.
86179|NCT03512496|Dietary Supplement|Acute energy drink - Placebo|Colored water
86180|NCT03512496|Dietary Supplement|Acute energy drink - Caffein|Sugar free energy drink at 5mg/kg caffeine
86181|NCT03512496|Dietary Supplement|Acute energy drink - Decaf|Sugar free decaf energy drink (vitamins only)
86182|NCT03512483|Behavioral|Virtual Atrial Fibrillation Clinic|Participants in the intervention group will receive usual GP care plus the vAFC which consists of telehealth appointments with Nurse Practitioner/Cardiologist and access to an AF specific educational website. It is anticipated the vAFC, as with the onsite clinic, will include a maximum of four scheduled telehealth appointments: an initial appointment following randomization, at 4-6 weeks, 3 months, and 6 months.
86183|NCT03512470|Device|Sistema Prevena ™(TVAC)|The medications with a negative topical pressure system (Sistema Prevena ™) will be applied directly in the Operating Room. Thereafter medication will be checked in the inpatient ward after 48 h from the intervention, evaluating the possible absorption of exudate on the surface. If no absorption are detected within 48 hours, the medication won't be removed and renewed in the 7th day (± 2 days) post-operative; and to follow every 7 (± 2 days) until the points are removed. If the wound continues to progress towards recovery, the protocol will continue until discharge and / or rehabilitation and / or surgery.
86184|NCT03512470|Other|Standard medication|standard medication in use (sterile gauze and TNT patch or medicated patches).
86185|NCT03512457|Behavioral|Minimal Intervention|Women view an educational poster in changing room, and they receive a brochure.
86186|NCT03512457|Behavioral|Intensive Intervention|Women view an educational poster in changing room, and they receive a brochure.
86187|NCT03512444|Device|Negative Pressure System|Negative Pressure System is a non-invasive system that applies sub-atmospheric(Negative) pressure, through a foam and an air-tight film dressing which is connected by suction tubes to a controller unit by which the primary negative pressure can be adjusted.
86188|NCT03512431|Diagnostic Test|Micro sampling|Compare finger prick micro samples with venous blood samples for measuring whole blood tacrolimus concentrations
86189|NCT03512418|Behavioral|PrEPsteps|Smartphone-based adherence intervention based in 1) LifeSteps, 2) Contingent Reinforcement/Corrective Feedback, and 3) Screening Brief Intervention and Referral to Treatment (SBIRT)
86190|NCT03512418|Device|Digital pill|The digital pill comprises a standard gelatin capsule with an integrated radiofrequency emitter that overencapsulates the desired medication (Truvada). When participants ingest the digital pill, the chloride ion gradient in the stomach activates the radiofrequency emitter which transmits direct evidence of medication ingestion to a wearable reader which relays this data to the participant's smartphone and cloud server.
86191|NCT03512418|Drug|Truvada|Participants receive once daily Truvada as PrEP to prevent HIV
86192|NCT03512405|Biological|Blinatumomab|Given IV
86193|NCT03512405|Other|Laboratory Biomarker Analysis|Correlative studies
86194|NCT03512405|Biological|Pembrolizumab|Given IV
86195|NCT03512392|Other|Conservative fluid and deresuscitation strategy|Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
86196|NCT03512392|Other|Usual care strategy|Usual care at the discretion of the clinical team
86197|NCT03512379|Device|TIANJI Robot|A robotic system for spinal surgery
86198|NCT03512379|Device|Fluoroscopy|For fluoroscopy-based free hand surgery
86199|NCT03512379|Device|Navigation|For navigation-assisted spinal surgery
86200|NCT03512366|Procedure|Desarda's technique|It will be performed by separating a strip from the upper leaf of the external oblique aponeurosis in continuity with the muscle and suturing it with the inguinal ligament below and the newly formed upper leaf of EOA above behind the spermatic cord to form the new inguinal floor. This strip will be put under tension by muscular contraction and works as a shield to prevent recurrence.
86201|NCT03512366|Procedure|Lichtenstein's technique|A 6 × 11 cm polypropylene mesh will be fashioned to fit the posterior wall of the inguinal canal and sutured to the fibro-periosteum of the pubic bone and continued laterally, suturing the inferior edge of the mesh to the shelving edge of the inguinal ligament to a point 2 cm lateral to the internal ring.
86334|NCT03511378|Drug|Lupin's Pegfilgrastim|Administration of Pegfilgrastim
86202|NCT03512353|Combination Product|Dexamethasone|Describe subject´s adherence by evaluating a carfilzomib plus dexamethasone twice-weekly dosing regimen followed by a once-weekly dosing regimen.
86203|NCT03512353|Combination Product|Carfilzomib|Describe subject´s adherence by evaluating a carfilzomib plus dexamethasone twice-weekly dosing regimen followed by a once-weekly dosing regimen.
86204|NCT03512340|Drug|SRF231|SRF231 specifically blocks the interaction between CD47 and signal regulatory protein alpha and acts as a potent enhancer of human tumor cell phagocytosis.
86205|NCT03512327|Other|Autoimmune protocol (AIP) diet|Autoimmune protocol diet, designed as a 6 week step wise elimination phase followed by 5 week maintenance phase.
86206|NCT03512314|Drug|Tadekinig alfa|Open label, 26 weeks on Tadekinig alfa treatment.
86207|NCT03512301|Device|CAMCI|CAMCI battery of computerized tasks
86208|NCT03512288|Biological|Multivalent|Pneumococcal conjugate vaccine
86209|NCT03512288|Biological|13vPnC|Pneumococcal conjugate vaccine
86210|NCT03512275|Drug|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
86211|NCT03512262|Drug|Abaloparatide|Abaloparatide 80 mcg subcutaneous daily
86212|NCT03512262|Drug|Placebo|Placebo 0 mcg subcutaneous daily
86213|NCT03512249|Biological|H56:IC31|5ug H56/500 nmol IC31
86214|NCT03512249|Biological|Placebo|Sterile saline for injection
86215|NCT03512236|Drug|BC Pram Ins|Injection of BC Pram Ins
86216|NCT03512236|Drug|Symlin® and Humulin®|Injection of pramlintide and human insulin
86217|NCT03512236|Drug|Humalog®|Injection of lispro
86218|NCT03512236|Drug|Placebo|Injection of 0.9% NaCl
86219|NCT03512223|Drug|Dexamethasone|Intravenous and Perineural Dexamethasone for Brachial Plexus Block
86220|NCT03512210|Drug|Epclusa|Sofosbuvir/Velpatasvir contains 400 mg of SOF and 100mg of VEL
86221|NCT03512197|Drug|Midostaurin|After randomization, patients will receive midostaurin twice daily until not achieving CR nor CRi, relapse after CR or CRi, intolerable toxicity, or consent withdrawal
86222|NCT03512197|Drug|Midostaurin Placebo|After randomization, patients will receive midostaurin placebo twice daily until not achieving CR nor CRi, relapse after CR or CRi, intolerable toxicity, or consent withdrawal
86223|NCT03512197|Drug|Chemotherapy|Along with the study drug/placebo, chemotherapy will be give as welll: either Daunorubicin or Idarubicin and Cytarabine al take by i.v.
86224|NCT03512184|Behavioral|YMCA class|The Gastroenterologists of Weill Cornell Medical College that are associated with this trial want to implement the YMCA's DPP in the NAFLD population as a structured lifestyle modification/educational intervention. The hypothesis is that the NAFLD patients who complete the YMCA's DPP will also have weight loss and improvement in hepatic steatosis. Importantly, positive results in this New York City-based pilot study would provide a strong rationale for determining whether such a program could be useful to treat NAFLD at established YMCA DPP sites across the country.
86225|NCT03512171|Drug|Dextroamphetamine|One oral dose of dextroamphetamine (0.43mg/kg). The amphetamine is given in order to induce the release of their own dopamine for study with positron emission tomography (PET).
86226|NCT03512171|Drug|Placebo|One oral dose of placebo to estimate D2 receptor levels at baseline with PET imaging (necessary to calculate dopamine release in the amphetamine condition).
86227|NCT03512171|Diagnostic Test|[18F]Fallypride|Radioligand for measuring dopamine D2 receptors with positron emission tomography (PET)
86228|NCT03512171|Diagnostic Test|[18F]-FE-PE2I|Radioligand for measuring dopamine transporters with positron emission tomography (PET)
86229|NCT03512158|Other|Non-invasive respiratory support mode|A mode of providing respiratory support via nasal masks or prongs
86230|NCT03512145|Device|VIPUN Balloon Catheter|Gastric motility is recorded continuously with the VIPUN Balloon Catheter for 10 hours.
86231|NCT03512132|Biological|Blood samples|5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
86232|NCT03512132|Biological|Urine sample|Urine sample on an empty stomach
86233|NCT03512119|Drug|Lumacaftor-Ivacaftor treatment|Lumacaftor-Ivacaftor treatment during one year
86234|NCT03512106|Other|Acupuncture|Chinese traditional acupuncture
86235|NCT03512093|Other|Retrospective chart review|A retrospective chart review of preterm neonates born in one of the birthing SMRU unit between January 2008 and December 2017 and for whom a medical chart is available. In addition we propose to analyze the growth trajectory, the prevalence of anemia (Hct < 33%) and the level of neurodevelopment achieved in the first year of life reported in the clinical charts of preterm neonates born < 34+0 weeks of gestation.
86236|NCT03512093|Other|Focus Group Discussion (FGD) of the medical staff|Focus Group Discussion (FGD) of the medical staff working in the SCBU firstly on the benefits and difficulties in using existing guidelines for preterm care and secondly on the feasibility and acceptability of changes in the guidelines 3-6 months after their implementation.
86237|NCT03512093|Other|Interviews of mothers|Interviews of mothers who delivered preterm neonates (< 37+0 weeks of gestation) to understand the challenges they faced while caring for their child.
86238|NCT03512067|Device|Patients given EMV Ventilation|Baseline mechanical ventilation data with conventional pressure-limited assist/control ventilation mode will then be collected for a 4-hour period. The patients will then be transitioned to pressure-limited entrainment-based ventilation for a 4-hour period. Baseline ventilation monitoring will be carried out either immediately preceding or immediately following EMV in the same patient. The sequence of the control/baseline phase and the experimental phase of the study will be randomized.
86239|NCT03512054|Procedure|Standardized 5-step weaning procedure|"Weaning process in 5 steps (0-4), by a multi-professional team (neurosurgeon, physiotherapist, nurse, caregiver…) Stability criteria are defined for each person, after validation pass the next step. Stability criteria degradation return to the previous step. Weaning process can take back after stability criteria renormalization.~Step 0: cuff deflate. Step 1: occlusion test. Steps 0 and 1 can assess the freedom and protect capacity airway. In failure process, we can propose a nasofibroscopy.~Step 2: Phonatory Valve. Respiratory rehabilitation/ swallowing, limiting breathing effort. The valve ought to stay 12 hours before going to the step 3.~Step 3: Plug. Finish the Respiratory rehabilitation/ swallowing. The plug ought to stay 24hours minimum before going to the step 4.~Step 4: Decannulation"
86240|NCT03512041|Behavioral|RLIC - 5 cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
86241|NCT03512041|Behavioral|RLIC - 4 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
86242|NCT03512041|Behavioral|RLIC - 3 Cycles|RLIC is achieved as listed in the arm/group descriptions. RLIC is performed on visits 1-7, which occur on consecutive weekdays.
86243|NCT03512041|Behavioral|Sham conditioning|Sham conditioning is achieved as listed in the arm/group descriptions. Sham conditioning is performed on visits 1-7, which occur on consecutive weekdays.
86244|NCT03512041|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
86245|NCT03512041|Behavioral|Arm training|All participants undergo training on a cup stacking task, learning to assemble and disassemble cup configurations as fast as they can. Participants perform the cup stacking task 5 trials per day at visits 3-7.
86246|NCT03512041|Behavioral|Sequence production training|All participants undergo training on a discrete sequence production task. Participants learn to associate specific color and shape symbols with sequences of key presses on a keyboard. Participants perform the sequence production task for 10-15 minutes per day at visits 3-7.
86247|NCT03512028|Behavioral|RLIC|See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
86248|NCT03512028|Behavioral|Sham conditioning|See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
86249|NCT03512028|Behavioral|Muscle strength training|All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
86250|NCT03512028|Behavioral|Driving training|All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
86251|NCT03512028|Behavioral|Balance training|All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
86252|NCT03512015|Other|The Lung Cancer App - LuCApp|The Intervention Arm receiving LuCApp (The Lung Cancer App) in addition to standard care
86253|NCT03512015|Other|Standard care|The Standard-of-Care patients receiving following the same schedule identified for LuCApp patients with paper questionnaires during clinic visits, or at home (having received paper questionnaires during the previous visit) or via telephonic interviews with the research team.
86254|NCT03512002|Device|HIRREM|Technology
86255|NCT03512002|Other|Continued Current Care|Continue their current clinical care.
86256|NCT03511989|Device|Bone borne distractor|Bone borne distraction device
86257|NCT03511989|Device|Tooth borne distractor|Tooth borne distraction device
86258|NCT03511989|Procedure|Segmental LF1 Osteotomy group 1|
86259|NCT03511989|Procedure|Segmental LF1 Osteotomy group 2|
86260|NCT03511989|Procedure|Segmental LF1 Osteotomy group 3|
86261|NCT03511976|Behavioral|Tier 1 Classroom Management|The primary teacher for each participating student will receive consultation related to implementing Tier I management strategies at a classroom level for all students including the target child (see Appendix C). Consultation will be provided by trained study personnel and the strategies will be implemented by the general education teacher (i.e., the end user of the intervention)
86262|NCT03511976|Behavioral|Daily Report Card (DRC)|Students in the RTI DRC condition will receive Tier II strategies, namely an individualized DRC. Behavioral consultants will meet with teachers to identify appropriate behavioral targets and establish a DRC according to established protocol (see our website for an example http://ccf.fiu.edu/for-families/resources-for-parents/printable- information/). Consultants will also meet with parents to develop a plan for reinforcing the DRC at home using a hierarchical menu of rewards/privileges that will be provided contingent on meeting daily goals.
86263|NCT03511976|Behavioral|Enhanced DRC (DRC-E)|"In this condition, students who did not show sufficient response to the Phase 1 DRC will receive additional and more intensive Tier II supports.~Following student assignment to RTI-E, the teacher will have meet with one of the consultants to complete a functional behavior analysis (FBA) to identify remaining target behaviors and ascertain their function. The consultant and teacher will then use the completed FBA to develop a treatment plan for an enhanced DRC (DRC-E).~Tier II enhancements will be chosen to directly map on to the functions of the target behaviors as outlined in the FBA."
86264|NCT03511976|Drug|Stimulant|Students will receive either a long-acting methylphenidate preparation or a long-acting mixed amphetamine salts preparation based on parent consultation with the study physician. The prescribed medication will be taken daily.
86265|NCT03511963|Drug|HLX04 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
86266|NCT03511963|Drug|Avastin 100 mg in 4 ml Injection|7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
86267|NCT03511937|Behavioral|Sugar-Sweetened Beverage Health Warning Label|Labels with a health warning will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the text and design of these labels based on previous research and on designs described in US and international legislation.
86268|NCT03511937|Other|Neutral Label|Neutral labels will be applied to the front-of-package of all sugar-sweetened beverage containers in the mock store. Investigators developed the design of these labels.
86269|NCT03511924|Behavioral|Intradialytic resistance training|Progressive resistance training programme performed during haemodialysis, taking into account subject´s medical review summarizing: A. full medical history, B. clinical examination including cardiovascular assessment, C. detailed medication usage history, D. review of recent biochemistry and haematology records and results of lower extremity muscle strength assessments. Construction of intradialytic training programme followed recommendations published by the Exercise & Sports Science Australia (Smart et al., 2013).
86335|NCT03511378|Drug|Neulasta®|Administration of Neulasta®
86336|NCT03511365|Biological|Probiotic Formulation VSL#3|Probiotic VSL#3 administration.
86270|NCT03511911|Diagnostic Test|evaluation of pelvic floor muscle function through the PHENIX instrument|the PHENIX instrument was designed and produced for sensing muscle activity with surface electrodes, pressure probes and external captors,so it could test biological signals of pelvic floor muscle in human body.
86271|NCT03511911|Diagnostic Test|vaginal palpation|vaginal palpation is based on modified Oxford Grading Scale(MOS) and Levator ani testing(LAT) to test patients' pelvic muscle strength
86272|NCT03511898|Drug|THR-149 dose level 1|single intravitreal injection of THR-149 dose level 1
86273|NCT03511898|Drug|THR-149 dose level 2|single intravitreal injection of THR-149 dose level 2
86274|NCT03511898|Drug|THR-149 dose level 3|single intravitreal injection of THR-149 dose level 3
86275|NCT03511885|Other|There is no intervention|
86276|NCT03511872|Other|Basic life support training|"A course design was made to be consistent with ERC guidelines with local modifications made by emergency professionals in duration, instructor-to-trainee ratio, course materials, methods to deliver these materials theoretically, and the type of the manikin used to practice CPR. One-day-course consisting of 75, 20, 20, 20 minutes for theoretical BLS, chocking, recovery position, the practical representation of BLS scenario respectively followed by 40-minute practical training on BLS skills for each subgroup. Both arms of the study follow the same timeline and no extra time is given to any group.~Same manikins were used for the training and the assessment. On the day of the experiment students in each arm are divided into 4 subgroups of maximum 9 students, each led by two trainers of BLS skills with a maximum ratio of 2 instructors to 9 students per group."
86277|NCT03511846|Drug|Oral capsaicin|Subjects will drink a solution with capsaicin
86278|NCT03511846|Drug|Topical capsaicin|Capsaicin cream will be applied to the skin of the forehead, cheek, or leg
86279|NCT03511846|Drug|Intranasal capsaicin|Capsaicin cream will be applied to the nostril
86280|NCT03511846|Other|Cold Water Irrigation|Subjects will be asked to drink up to 2000 ml of cold water or ice water (temperature 0-10 degrees Celsius) as fast as possible, either continuously or intermittently (i.e. 200-800 ml at a time)
86281|NCT03511846|Other|Medical Air|Subjects will be exposed to medical air
86282|NCT03511846|Drug|Low Flow Oxygen|Subjects will be exposed to oxygen gas between 1-9 L/min
86283|NCT03511846|Drug|High Flow Oxygen|Subjects will be exposed to oxygen gas between 10-25 L/min
86284|NCT03511833|Drug|Morphine|IV morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml = 1mg/ml ----> 0.1 ml/kg
86285|NCT03511833|Drug|Ketamine|IN ketamine: 1 mg/kg: Ketamine vial contains 100 mg/2 ml = 50mg/ml ---> 0.02ml/kg
86286|NCT03511820|Drug|Lipo-AB® (amphotericin B) liposome|"Name: Lipo-AB® (amphotericin B) liposome for injection~Dosage form: Lyophilized powder 50 mg/vial~Dose: Based on approved package insert and physician's discretion Recommended initial dose: 3 mg/kg/day~Dosing schedule:~All patients will receive Lipo-AB® based on the approved package insert and physician's clinical decision."
86287|NCT03511807|Other|Electrical|"For the electrical stimulation:~An electrode will be inserted into the ear canal which will be stimulated."
86288|NCT03511807|Other|Acoustic|"For the acoustic stimulation:~A typical sound will be presented for 6 minutes. Loudness is reported for 4 minutes after the stimulus offset to measure the presence and duration of the residual inhibition. If a successful acoustic stimulus is found, the subject will be given a series of sound files to listen to on a digital music player (CD or MP3 player) and will be asked to listen to each sound file (5 minute duration) and record their tinnitus loudness/annoyance during and after each sound stimulation. For some subjects, the investigators will use music on a digital music player (MP3 player) to see if music listening and music exercises will help reduce the intensity or annoyance level of the tinnitus (using the same surveys). These music-based exercises will involve training in recognition of musical intervals (e.g., octaves, fifths, and thirds)."
86289|NCT03511781|Radiation|Hypofractionated Radiotherapy|Palliative Hypofractionated radiotherapy 35 GY in 10 fractions over 2 weeks in advanced incurable Breast Cancer
86290|NCT03511768|Drug|18F-AlF-NOTA-octreotide|One injection of 18F-AlF-NOTA-octreotide
86291|NCT03511768|Device|PET/CT|Following injection of 18F-AlF-NOTA-octreotide the participants will be subjected to whole body PET/CT
86292|NCT03511755|Device|Transdermal Electrical Neuromodulator (TEN)|Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7).
86293|NCT03511716|Device|HRT Mitral Bridge Mitral Valve Repair|Surgical mitral valve implant intended to reduce mitral regurgitation by direct reduction of the septo-lateral mitral annular diameter, promoting early coaptation of the valve leaflets and restraining the leaflets below the intra-annular plane
86294|NCT03511703|Drug|Apatinib|Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, doubleblind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results lso showed good efficacy and safety.
86295|NCT03511703|Drug|Chemotherapy drugs+Iodized oil|Intra-arterial infusion chemotherapy for tumors, commonly used chemotherapy drugs include anthracyclines, platinum, etc.; chemotherapeutic drugs and embolic agents are mixed together and injected through the blood supply artery of the tumor. The most commonly used embolic agent for TACE treatment is a lipiodol emulsion. First infusion of some chemotherapy drugs, the general infusion time should not be <20 min. Then another part of the chemotherapeutic drugs and lipiodol were mixed into emulsions for embolization. The amount of lipiodol is generally 5-20 ml, not more than 30 ml.
86296|NCT03511690|Behavioral|BRCA-Gist|"BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing."
86297|NCT03511690|Behavioral|NCI Arm|Participants randomized to the the NCI arm will have up to 90 minutes to read the information about HBOC and BRCA1/2 that overlaps with the content from the BRCA-Gist
86300|NCT03511664|Drug|177Lu-PSMA-617|Patients randomized to receive the investigational product will receive 7.4 GBq (±10%) 177Lu-PSMA-617 intravenously every 6 weeks (±1 week) for a maximum of 6 cycles. After 4 cycles, patients will be assessed for (1) evidence of response, (2) residual disease, and (3) tolerance to 177Lu-PSMA-617. If all 3 assessments are met the patient may receive an additional 2 cycles of 177Lu-PSMA-617.
86301|NCT03511664|Other|Best supportive/best standard of care|Best supportive/best standard of care as defined by the local investigator
86302|NCT03511651|Procedure|PEEP|Two PEEP levels will be used during mechanical ventilation.
86303|NCT03511638|Device|Bausch & Lomb DVisc40|Ophthalmic viscosurgical device
86304|NCT03511638|Device|Alcon VISCOAT®|Ophthalmic viscosurgical device
86305|NCT03511625|Drug|Acthar Injectable Product|Acthar is a non-specific melanocortin receptor agonist
86306|NCT03511625|Drug|Depo medrol|Depo medrol is an anti-inflammatory glucocorticoid
86307|NCT03511612|Diagnostic Test|Measure ankle brachial index (ABI)|This is a head-to-head comparison of 2 methods of determination of the ABI, taking the Doppler method as the standard and the oscillometric device AVP as the challenger
86308|NCT03511599|Drug|Cycloserine|Cycloserine 100mg
86309|NCT03511599|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
86310|NCT03511599|Drug|Placebo Oral Tablet|Placebo tablet matched to cycloserine tab
86311|NCT03511573|Procedure|bariatric and other laparoscopic surgery|We have obtained liver samples during laparoscopic surgical procedures in the majority of cases. The majority of laparoscopic procedures were sleeve gastrectomies performed for morbid obesity as a primary restrictive procedure; in 5 cases the liver biopsies were performed during laparoscopic cholecystectomies.
86312|NCT03511560|Drug|Tacrolimus Extended Release Oral Tablet|Tacrolimus, extended-release, oral (Envarsus); 0.75 mg, 1 mg, 4 mg tablets will be administered once daily at initial weight-based dose of 0.12 mg/kg.
86313|NCT03511560|Drug|Tacrolimus|Tacrolimus immediate-release, oral; 0.5 mg, 1 mg, 5 mg capsules will be administered twice daily per clinical judgment of supervising physician
86314|NCT03511547|Device|Pitch Patch|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a synthetic (Pitch-Patch™ [PP]) augmentation.
86315|NCT03511547|Device|ArthroFlex|The patients will be operated by shoulder arthroscopy according to the internationally standardized procedure. Patients allocated this group will receive a biologic patch (ArthroFlex® [AF]) augmentation.
86316|NCT03511534|Behavioral|Psychotherapy|Evidenced based psychotherapy by a trained psychologist
86317|NCT03511534|Other|Pharmacotherapy|Pharmacotherapy by a psychiatrist
86318|NCT03511521|Drug|NPH Insulin|Intermediate acting insulin
86319|NCT03511521|Drug|glargine|basal insulin
86320|NCT03511521|Drug|Insulin Aspart|prandial insulin
86321|NCT03511508|Behavioral|ChroPreg + standard care|"Ongoing update of individual maternity care plan.~Extra consultation with the specialized midwife at 20-24 weeks of pregnancy about psychological well-being during pregnancy.~Extra consultation with the specialized midwife at 30-33 weeks of pregnancy about individual birth preparation, breastfeeding and post-partum care.~Possibility for psychologist consultation.~Post-partum: Telephone follow-up by the specialized midwife 1 and 2 weeks after discharge.~Postnatal follow-up: 4-6 weeks after delivery: conversation with specialized midwife about the pregnancy and birth."
86322|NCT03511495|Diagnostic Test|Galilei Corneal Topographer|A series of five measurements via the Galilei corneal topographer of each keratoconic eye in quick succession
86323|NCT03511482|Device|myAsthma Application|myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.
86324|NCT03511482|Device|Lloyds Pharmacy Online Doctor|"Online Doctor is part of Expert Health Ltd a doctor-led initiative providing safe and reliable remote online healthcare to adults in the UK. Their patient-centred model of healthcare allows patients to tailor care around their schedule and increases healthcare access for harder-to-reach patient groups.~As the first ever online healthcare organisation to register with the government regulator of healthcare - and having received outstanding feedback from the Care Quality Commission about the high level of safe, effective, caring, responsive and well led care provided by the service - They pride themselves on their pioneer status and work constantly to expand the boundaries of personalised healthcare."
86325|NCT03511469|Other|Control Group|Control Group: Standart rehabilitation
86326|NCT03511469|Other|Concentric Group|Concentric group: Standart rehabilitation + concentric training
86327|NCT03511469|Other|Eccentric Group|Eccentric group: Standart rehabilitation + eccentric training
86328|NCT03511456|Procedure|PELD operation|"Under local anesthesia, the introduction of 20G needles could be performed with fluoroscopy. After the needle traveled through TFS space, extremely care was needed to avoid nerve root injury.~Discography was recommended. The following steps were performed as usual: the needle was replaced by a guide wire; a 9 mm incision was made in the skin; a tapered cannulated dilator was inserted along the guide wire; and finally a working cannula was inserted.~The remove of disc was performed carefully under endoscope. The first step was to locate the annulus fibrosis of L5/S1 disc, then by using nerve dissector and bipolar elliquence, soft tissue including fat tissue, muscle and fibers of ligaments were pushed cephalad until the blue stained herniated disc was visible and removed."
86329|NCT03511443|Diagnostic Test|hsRDT|Testing highly sensitive RDT detection for low parasitemia
86330|NCT03511417|Device|over-the-counter hearing device|Individuals will use commercially-available over-the-counter hearing devices for specified periods of time.
86331|NCT03511404|Other|physiotherapy rehabilitation|All subjects will receive a course of conventional physiotherapy that incorporating components of pain relief and functional restoration with the use of electrotherapy and exercise therapy for twelve sessions twice weekly in six weeks guided by a registered physiotherapist in Hong Kong.
86332|NCT03511391|Drug|Pembrolizumab or Nivolumab|per national standard of care
86333|NCT03511391|Radiation|SBRT|Stereotactic body radiotherapy is administered to maximally 3 lesions in 3 fractions of 8Gy prior to the third cycle of checkpoint inhibitors.
86337|NCT03511352|Behavioral|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including a 2-min stand every 15 min throughout the 5-hr protocol period. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
86338|NCT03511352|Behavioral|Stand More|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 8-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
86339|NCT03511339|Device|TecTraum device|"A non-invasive hypothermic therapy (cold therapy) TecTraum device that provides localized cooling of the head and neck."
86340|NCT03511326|Drug|Methyl Aminolaevulinate 16% Cream|Subject will received one session of methyl aminolevulinate Daylight Photodynamic therapy
86341|NCT03511313|Device|Renal denervation|After a renal angiography according to standard procedures, subjects are treated with renal denervation (with sterile irrigated deflectable ablation catheter in renal artery), if without renal anatomic abnormality not detected by Renal CT/CTA.
86342|NCT03511313|Diagnostic Test|Renal angiography|A renal angiography according to standard procedure.
86343|NCT03511300|Behavioral|Goal-Setting Instructions|"In the goal-setting instruction condition, participants will be asked to increase their performance by 20% from the previous similar test (e.g., On this task, you generated 10 words when I asked you to name as many words as you could that start with the letter 'F.' Now, I want you to aim to generate at least 12 words for the letter 'F'.)"
86344|NCT03511300|Behavioral|Standard Instructions|Participants in this group will receive the standardized instructions for completing the tests, as outlined in the test appendices.
86345|NCT03511287|Other|Inspiratory Muscle Training|Breathing through a device that offers resistance during inspiration. In this study the POWERbreathe device was used (POWERbreathe® K3, HaB International Ltd, UK).
86346|NCT03511274|Behavioral|Hygiene based educational film|Pregnant women will watch an educational film to increase the awareness of CMV, encourage the adoption of risk reduction behaviours and preventative strategies. The film will include women's views of the risks of CMV infection in pregnancy and how they adopted the preventative strategies.
86347|NCT03511261|Drug|10% Curcumin mucoadhesive gel|Group 1 10%of mucoadhesive gel for topical application two times per day.
86348|NCT03511261|Drug|Curcumin capsules 500mg|Group 2 curcumin 500 mg capsules for oral intake two times per day
86349|NCT03511261|Drug|5% curcumin mucoadhesive gel + Curcumin capsules 250 mg|Group 3 5% curcumin mucoadhesive gel topical application two times per day + curcumin 250 mg capsules for oral intake two times per day
86350|NCT03511261|Drug|Placebo capsule|Group 4 placebo capsules for oral intake two times per day
86351|NCT03511248|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
86352|NCT03511248|Dietary Supplement|Nitrate-deplete Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
86353|NCT03511222|Drug|Vorolanib|Patients should take vorolanib at approximately the same time every day with food.
86354|NCT03511222|Drug|Nivolumab|Standard of care
86355|NCT03511222|Drug|Pembrolizumab|Standard of care
86356|NCT03511222|Procedure|Peripheral blood draw|"Only performed in 20 participants from the Expansion Cohorts~Baseline and Day 1 of each cycle"
86357|NCT03511209|Behavioral|CBTI plus taper method A|This intervention includes CBTI plus the novel hypnotic tapering method.
86358|NCT03511209|Behavioral|CBTI plus taper method B|This intervention includes CBTI plus the usual hypnotic tapering method used by the VA.
86359|NCT03511196|Drug|Adaptive Androgen Deprivation Therapy (ADT)|ADT with Leuprolide, Goserelin, or Triptorelin, as GnRH agonist, every 4 weeks as outlined in study arm description.
86360|NCT03511196|Drug|Abiraterone|Prednisone 5 mg once a day with food.
86361|NCT03511196|Drug|Prednisone|Abiraterone 1000 mg daily with empty stomach.
86362|NCT03511183|Drug|XELIRI + bevacizumab|Irinotecan，200mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
86363|NCT03511183|Drug|XELOX + bevacizumab|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid1-14;Bevacizumab,7.5mg/kg ,d1; every 21 days as a cycle
86364|NCT03511170|Drug|XELIRI|Irinotecan，200mg/㎡,d1;Capecitabine, 850-1250mg/㎡ bid 1-14;every 21 days as a cycle
86365|NCT03511170|Drug|XELOX|Oxaliplatin ,130mg/㎡,d1;Capecitabine, 1000mg/㎡ bid 1-14;every 21 days as a cycle
86366|NCT03511157|Other|Ischemic Preconditioning|See Ischemic Preconditioning Experimental group description
86367|NCT03511157|Other|Control Group|See Control group description
86368|NCT03511144|Device|Unity Knee™ TKR using measured resection|Total knee replacement using the Unity Knee™ implanted with the measured resection surgical technique
86369|NCT03511144|Device|Unity Knee™ TKR using ligament balancing|Total knee replacement using the Unity Knee™ implanted with the ligament balancing surgical technique
86370|NCT03511131|Behavioral|Queer Sex Ed|Comprehensive sexual health education program condition (Informational)
86371|NCT03511131|Behavioral|Keep It Up|Culturally/situation-relevant HIV-prevention experimental condition (Motivational/behavioral)
86372|NCT03511131|Behavioral|Keep It Up-Control|HIV knowledge control condition, attention-matched to KIU (Informational)
86373|NCT03511131|Behavioral|Young Men's Health Project|Motivational enhancement video interviewing condition (Motivational/behavioral)
86374|NCT03511118|Other|Tranexamic acid (TXA)|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86375|NCT03511118|Other|labetalol|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86376|NCT03511118|Other|metformin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86377|NCT03511118|Other|nifedipine|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86378|NCT03511118|Other|clindamycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86379|NCT03511118|Other|oxycodone|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86380|NCT03511118|Other|azithromycin|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86381|NCT03511118|Other|escitalopram|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86382|NCT03511118|Other|sertraline|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86383|NCT03511118|Other|ondansetron|Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.
86384|NCT03511105|Drug|GSK2798745|GSK2798745 will be available as white to slightly colored, round biconvex tablets to be administered via the oral route.
86385|NCT03511105|Drug|Placebo|Placebo matching to GSK2798745 will be available as white to slightly colored, round biconvex tablet to be administered via the oral route.
86386|NCT03511105|Drug|Lipoplysaccharide from Escherichia Coli|LPS will be used as challenge agent. About 4 nanogram per kilogram of LPS will be instilled into the right middle lung segment via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
86387|NCT03511105|Drug|Saline|Sterile saline (0.9%) will be used as control challenge. Saline will be instilled into the lingula segment of contralateral side of lung via bronchoscopy 2 hours after dosing with GSK2798745 or placebo on Day 1.
86388|NCT03511092|Dietary Supplement|HMB-FA|One gram of HMB-FA was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
86389|NCT03511092|Dietary Supplement|HMB-Ca|One gram of HMB-Ca was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days supplement was administered 1 g per meal. The total duration of the intervention was 8 weeks.
86390|NCT03511092|Dietary Supplement|alfa-HICA|Five hundred miligram of alfa-HICA was ingested before exercise, and one gram was ingested at subsequent meals (500 mg per meal). At rest days supplement was administered 500 mg per meal. The total duration of the intervention was 8 weeks.
86391|NCT03511092|Other|Placebo comparator|One gram of magnesium stearate was ingested before exercise, and two grams were ingested at subsequent meals (1 g per meal). At rest days placebo was administered 1 g per meal. The total duration of the intervention was 8 weeks.
86392|NCT03511079|Behavioral|Music|Music will be delivered through Pandora Plus radio via patient's computer or smartphone. The patient will choose a favorite song to create a playlist which will be used for the duration of the entire study. The subgenre of the initial song will be recorded.
86393|NCT03511066|Drug|CT-P27 Dose1|Influenza A treatment drug.
86394|NCT03511066|Drug|CT-P27 Dose2|Influenza A treatment drug.
86395|NCT03511066|Drug|Placebo|Placebo.
86396|NCT03511053|Procedure|Epidural Steroid Injection with Lavage|All participants will receive a saline lavage prior to the epidural steroid injection.
86397|NCT03511040|Device|Lumenate Intraluminal Device|Dilation of vasospastic intracranial vessels
86398|NCT03511027|Device|SME + Karie Device|For the duration of the study, participants will use the Karie device to promote medication adherence. The Karie device prompts users to take their medication in the right amount at the right time.
86399|NCT03511027|Other|SME only|At discharge, participants will be provided with self-medication education.
86400|NCT03511014|Device|Microcurrent|Micrucurrent will be apply
86401|NCT03511001|Other|E-Cigarette Vs. Smoking as Usual|6 weeks of JUUL e-cigarettes vs. 6 weeks of smoking as usual
86402|NCT03510988|Diagnostic Test|Hybrid breast FDG PET/MRI|Hybrid breast FDG PET/MRI
86403|NCT03510975|Drug|desmopressin melt form 120 μg|desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed
86404|NCT03510975|Behavioral|Verbal behavioral therapy|Verbal behavioral therapy includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary
86405|NCT03510975|Behavioral|Behavioral therapy with written check-list|Behavioral therapy with written check-list includes reward system, restriction excessive fluid intake, lifting and waking after sleep to urinate, keeping daily voiding diary, ensuring optimal posture to facilitate good bladder function and bowel movements, avoding holding urine, encouring healthy diet
86406|NCT03510962|Other|Group 1: no intervention|Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test mixed fruit juice without any intervention.
86407|NCT03510962|Other|Group 2: tap water gargle|The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
86408|NCT03510962|Drug|Group 3: 0.2% Chlorhexidine|The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
86409|NCT03510962|Other|Group 4: Fluoridated tooth paste|"The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention."
86410|NCT03510962|Other|Group 5: Polyol containing gum|"The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing as an intervention."
86411|NCT03510962|Other|Group 6: 1% sodium bicarbonate solution|"The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention."
86412|NCT03510949|Device|Nasopharyngeal airway or laryngeal mask airway|Comparing the incidence of postoperative soar throat with the use of nasopharyngeal airway versus laryngeal mask airway
86413|NCT03510936|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5*10^7CFU for 2 weeks
86414|NCT03510923|Other|Inspection and palpation of the appendix|The removed appendix will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The appendix will not be opened. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the appendix, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
86415|NCT03510923|Other|Inspection and palpation of the gallbladder|The removed gallbladder will be evaluated for tumours by the operating surgeon by visual inspection and digital palpation of the specimen. The gallbladder is opened in its length, without cutting the cystic duct, and is inspected and palpated. The surgeon will report his or her findings on a predefined scoring form: he or she will report all abnormalities and writes down whether he or she considers there is an indication for histopathological examination. Subsequently, all specimens will be sent for histopathological examination. Histopathological examination will be conducted according to the local protocol. In case of a neoplasm of the gallbladder, the treatment strategy is discussed and decided by the local multidisciplinary team. If an additional more extensive resection is decided to be appropriate, the specimens of the re-resection will be evaluated for the presence of remaining tumour tissue.
86416|NCT03510910|Drug|Acetaminophen|acetaminophen 600 mg to be taken every 8 hours (TID)
86417|NCT03510910|Drug|Percocet|"Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.~Percocet Group will receive standard of care Percocet 5 mg/325 mg every 6 hours PRN"
86418|NCT03510897|Drug|QPI-1002|IV injection
86419|NCT03510897|Drug|Placebo|isotonic saline
86420|NCT03510884|Drug|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
86421|NCT03510884|Drug|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
86422|NCT03510884|Drug|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
86423|NCT03510884|Drug|Simvastatin|Pharmaceutical form:Tablet Route of administration: Oral
86424|NCT03510884|Drug|Pravastatin|Pharmaceutical form:Tablet Route of administration: Oral
86425|NCT03510884|Drug|Lovastatin|Pharmaceutical form:Tablet Route of administration: Oral
86426|NCT03510884|Drug|Fluvastatin|Pharmaceutical form:Capsule Route of administration: Oral
86427|NCT03510884|Drug|Ezetimibe|Pharmaceutical form:Tablet Route of administration: Oral
86428|NCT03510884|Drug|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
86429|NCT03510884|Drug|Nicotinic acid|Pharmaceutical form:Tablet Route of administration: Oral
86430|NCT03510884|Drug|Fenofibrate|Pharmaceutical form:Tablet Route of administration: Oral
86431|NCT03510884|Drug|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
86432|NCT03510884|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous injection
86433|NCT03510871|Drug|nivolumab, ipilimumab|All enrolled subjects will receive nivolumab 3 mg/kg plus ipilimumab 1 mg/kg intravenously on day 1 of each cycle (every 3 weeks). Tumor assessment will be done after 6 weeks (2 cycles) and 12 weeks (4 cycles).
86434|NCT03510858|Other|Multilevel training intervention (intervention group)|QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act). The QC will then repeat one PDCA cycle. The control group will receive the same intervention one year later.
86435|NCT03510858|Other|Multilevel training intervention (control group with crossover)|The control group will undergo a crossover and receive the same intervention one year after the intervention group. QC meetings with PCPs in the intervention group to reflect on their CRC screening practices and implement changes in sequential Plan-Do-Check-Act (PDCA) quality improvement cycles. In the first meeting, they will be given evidence summaries on CRC screening, a decision support leaflet designed to help them discuss CRC screening with their patients and a patient decision aid in form of a brochure (Plan-Do). PCPs will receive sample FIT kits recommended for organized screening programs and will be encouraged to offer FIT tests if they have not done so before. In the second QC meeting, PCPs will be shown how to fill out the patient data collection form (Check). The third QC meeting will take place after data collection and analysis. Researchers will present their results to the QCs and PCPs will discuss subsequent steps to improve care (Act).
86436|NCT03510845|Procedure|Arthroscopic ACL Primary Repair|"All patients (in both groups) will undergo diagnostic knee arthroscopy at the start of the procedure; those in the experimental arm repairable ACL tear, whose ACL found to be avulsed from its femoral insertion or has a proximal tear, and intra-operatively, found to have a good tissue quality, will undergo arthroscopic ACL primary repair using fiberwires and SwiveLock screw to anchor the ligament into its origin, in the femoral condyle."
86602|NCT03509558|Other|Physical Therapy|physical therapy to improve walking and standing functions
86437|NCT03510845|Procedure|Arthroscopic ACL Reconstruction|Patients whose ACL cannot be repaired, will undergo arthroscopic ACL reconstruction using hamstring tendons.
86438|NCT03510806|Dietary Supplement|Supplement|dietary supplement contain protein from milk and fruit extract
86439|NCT03510806|Other|Placebo|color, taste, and calorie-matched placebo
86440|NCT03510793|Drug|balanced anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive balanced (desflurane + remifentanil) anaesthesia
86441|NCT03510793|Drug|Total intravenous anesthesia|patients undergoing open elective abdominal aortic aneurysm repair will receive total intravenous (propofol + remifentanil with target-controlled infusion) anesthesia
86442|NCT03510780|Procedure|Periodontal surgery with Enamel Matrix Derivative|Patients will be treated by periodontal surgical flaps with the addition of EMD + bone graft
86443|NCT03510780|Procedure|Periodontal surgery with Platlet Rich fibrin|Patients will be treated by periodontal surgical flaps with the addition of PRF + bone graft
86444|NCT03510767|Drug|TQ-B3525|TQ-B3525 p.o. qd
86445|NCT03510754|Procedure|Eus guided biliary drainage|"After reaching the cardia or the lesser curvature of the stomach, for the transgastric approach, or the duodenal bulb, for the transduodenal one, intrahepatic left and extrahepatic bile ducts were punctured with a 19-gouge needle and the access was confirmed the injection of contrast under fluoroscopy to obtain an anterograde cholangiogram.~A 0.035-inch guide was advanced into the selected bile duct and under EUS and fluoroscopic view a stent was placed through the hepatogastrostomy between a left bile duct and the gastric lumen or through the choledochoduodenostomy between the common bile duct and the duodenal lumen."
86446|NCT03510741|Drug|Sodium Benzoate|Sodium Benzoate will be administered at 1000mg daily
86447|NCT03510741|Drug|N-Acetylcysteine|N-Acetylcysteine 1000 mgs twice daily dose
86448|NCT03510741|Drug|Placebo|Placebo added to TAU
86449|NCT03510741|Drug|Sodium Benzoate Plus N-Acetylcysteine|Sodium Benzoate will be administered at 1000mg daily and NAC 1000 mgs twice daily dose
86450|NCT03510728|Behavioral|college drinker's check up|The College Drinker's Check-up (CDCU) is a single session, computer-based brief motivational intervention for heavy drinking college students. It takes a student about 45 minutes to go through it.
86451|NCT03510728|Behavioral|Protective Behavioral Strategies Intervention|This intervention component focuses on educating and promoting PBS activities in future college drinking situations
86452|NCT03510728|Behavioral|Ecological Momentary Intervention|This EMI is delivered during drinking situations and focuses on promoting PBS use during that particular drinking situation.
86453|NCT03510715|Drug|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
86454|NCT03510715|Drug|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
86455|NCT03510715|Drug|Ezetimibe|Pharmaceutical form:tablet Route of administration: oral
86456|NCT03510715|Drug|Cholestyramine|Pharmaceutical form:oral suspension Route of administration: oral
86457|NCT03510715|Drug|Nicotinic acid|Pharmaceutical form:tablet Route of administration: oral
86458|NCT03510715|Drug|Fenofibrate|Pharmaceutical form:tablet Route of administration: oral
86459|NCT03510715|Drug|Omega-3 fatty acids|Pharmaceutical form:capsule Route of administration: oral
86460|NCT03510715|Drug|Atorvastatin|Pharmaceutical form:tablet Route of administration: oral
86461|NCT03510715|Drug|Simvastatin|Pharmaceutical form:tablet Route of administration: oral
86462|NCT03510715|Drug|Fluvastatin|Pharmaceutical form:capsule Route of administration: oral
86463|NCT03510715|Drug|Pravastatin|Pharmaceutical form:tablet Route of administration: oral
86464|NCT03510715|Drug|Lovastatin|Pharmaceutical form:tablet Route of administration: oral
86465|NCT03510702|Diagnostic Test|Levels of epigenetic biomarkers present in the gingival fluid and its possible relationship with bone metabolism.|"Once the anamnesis has been done, all the records corresponding to the Gingival Index and Plaque Index, in both groups are taken.~Subsequently, samples of gingival crevicular fluid are taken for the screening of epigenetic biomarkers."
86466|NCT03510689|Diagnostic Test|echocardiography|Resting echocardiograms (Vivid E9 or E95, GE Healthcare) with conventional measures of systolic and diastolic function, in conjunction with posthoc quantitation of novel measures of strain and strain rate will be obtained at each study time point.
86467|NCT03510689|Other|Cardiopulmonary Exercise Testing|A cardiopulmonary exercise test (CPET, also called V02 test) will be completed at each study time point utilizing a standard clinical protocol, on either a stationary bike or treadmill. The purpose of this test is to estimate maximal oxygen consumption (V02 max) as in index of cardiopulmonary fitness. Resting ECG, heart rate, and BP will be obtained prior to beginning the test, during each stage of the test and for 5 minutes after the test is stopped.
86468|NCT03510689|Other|Blood Collection|We will obtain blood samples (approximately 16mL) at baseline and (approximately 12mL) at each follow-up visit. Typically these will be drawn via peripheral venipuncture, however if patients have a port-a-cath in place, blood may be drawn from the port instead.
86469|NCT03510676|Device|NiTiDES|
86470|NCT03510663|Drug|OPC-61815 16mg|OPC-61815 16mg will be intravenously administered once a week.
86471|NCT03510663|Drug|OPC-61815 32mg|OPC-61815 32mg will be intravenously administered once a week.
86472|NCT03510663|Drug|Moxifloxacin|400mg tablet will be administrated once a week.
86473|NCT03510663|Drug|Placebos|Placebo will be intravenously administered once a week.
86474|NCT03510624|Drug|Rebaudioside A|Rebaudioside A 3g
86475|NCT03510624|Drug|Placebo|Empty capsules
86476|NCT03510611|Drug|Ensartinib with fed or fasting|The two groups of subjects were given an equal dose of Ensartinib capsules (225 mg) after a single cross-over fasting or high-fat high-calorie diet in two different test cycles to examine the effect of food on the pharmacokinetics of Ensartinib.
86477|NCT03510598|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
86478|NCT03510598|Drug|Kybella 20 MG in 2 ML Injection|Injectable drug called KYBELLA® (deoxycholic acid)
86479|NCT03510585|Other|saline and sniffing|This technique is a combination of positioning (laying down), saline instilation (5 ml in each side), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
86480|NCT03510585|Other|sniffing|This technique is a combination of positioning (laying down), sniffing (the side that received saline instilation) and throat vibration. Then the other side.
86481|NCT03510572|Drug|[18F]PI-2620|Imaging for evaluating the accumulation of abnormal tau protein in the brain
86482|NCT03510559|Drug|Forearm Nerve Block|Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
86483|NCT03510559|Drug|Brachial Plexus Block|Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
86484|NCT03510546|Drug|Pyridostigmine|Study dose as per protocol.
86485|NCT03510546|Drug|Placebo oral capsule|Study dose as per protocol.
86486|NCT03510533|Other|Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation|blood samples (12ml) and stool samples (30g) collections
86487|NCT03510520|Device|Medium Cut-Off Haemodialysis|Treatment with medium cut-off haemodialysis using the Theranova dialysis membrane 3 times per week for 6 months
86488|NCT03510520|Device|On-Line Haemodiafiltration|Treatment with on-line haemodiafiltration (HDF) 3 times per week for 6 months (Conventional treatment)
86489|NCT03510494|Behavioral|Augmented physical education program|Augmented physical education program
86490|NCT03510481|Biological|PfSPZ Vaccine|PfSPZ vaccine is Radiation attenuated, aseptic, purified, vialed, cryopreserved, NF54 P. falciparum sporozoites produced by Sanaria, Inc.
86491|NCT03510481|Drug|Normal Saline|Clear liquid indistinguishable from the study product will be used as a placebo rather than a comparator vaccine.
86492|NCT03510481|Drug|Coartem|Licensed antimalarial in the US and Mali for use for uncomplicated malaria.
86493|NCT03510468|Drug|Vemlidy (tenofivir alafenamide)|Each tablet of Vemlidy contains 25 mg of tenofivir alafenamide.
86494|NCT03510468|Drug|Priftin (rifapentine)|Each tablet of Priftin contains 150 mg of rifapentine. Participants who weigh 45 to < 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
86495|NCT03510468|Drug|Isoniazid|Each tablet of generic INH is formulated as 100 or 300 mg of the drug.
86496|NCT03510468|Dietary Supplement|Pyridoxine|Each tablet of pyridoxine contains 50 mg of Vitamin B6.
86497|NCT03510455|Drug|BGJ398|BGJ398, a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor will be orally administered over six 4-week cycles (3 weeks on drug, 1 week off drug). After the initial dose, escalation/de- escalation of BGJ398 will be based on FGF- 23 blood levels and adjusted according to protocol procedures. The six cycles of BGJ398 will be followed by 3 months off the drug and an optional extension phase.
86498|NCT03510429|Dietary Supplement|Postoperative Nutritional Supplement|Postoperative Nutritional Supplement (newly developed ketogenic drink: NDKD)
86499|NCT03510429|Other|Routine post-op care|Routine post-operative care
86500|NCT03510416|Drug|Apatinib|apatinib is a kind of Inhibitor of VEGFR-2
86501|NCT03510416|Radiation|TACE|Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.
86502|NCT03510403|Device|nastent™|Snorer and OSA patients (mild or moderate OSA) use the nasal airway stent for sleeping, each night for 1 month.
86503|NCT03510390|Drug|Metformin|850 mg, oral, twice daily, 9-14 days
86504|NCT03510377|Other|Aquatic physical intervention|For structured aquatic physical intervention group, the Ai-Chi method was selected. Ai-Chi is a simple aquatic exercise and relaxation method that uses a combination of deep breathing and slow movements of the arms, legs and torso in continual flowing patterns. The Ai-Chi intervention will occur in an hydrotherapy pool (34C).
86505|NCT03510377|Other|On-land physical intervention|For controlled comparison of the structured physical intervention group the Tai-Chi method was selected (the same movements as the Ai-Chi). The Tai-Chi intervention will occur in a room.
86506|NCT03510377|Other|Non physical intervention|The people who will be part of the non physical intervention will practice guided imagery of the Ai-Chi method. The guided imagery intervention will occur in a room.
86507|NCT03510364|Behavioral|Dietary intervention|For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
86508|NCT03510351|Drug|Ceftolozane-Tazobactam|Subjects treated with ceftolozane-tazobactam for Pseudomonas infections
86509|NCT03510338|Drug|Sublingual sildenafil|100 mg biphasic sildenafil tablet
86510|NCT03510338|Drug|Oral sildenafil|50 mg oral sildenafil (Viagra)
86511|NCT03510325|Drug|Olanzapine|Commonly used oral antipsychotics intervention therapy.
86512|NCT03510325|Drug|Risperidone|Commonly used oral antipsychotics intervention therapy.
86513|NCT03510325|Drug|Aripiprazole|Commonly used oral antipsychotics intervention therapy.
86514|NCT03510325|Drug|Amisulpride|Commonly used oral antipsychotics intervention therapy.
86515|NCT03510325|Drug|Paliperidone long-acting injection|long-acting injection
86516|NCT03510299|Device|Mcgrath|McGrath assisted insertion of LMA flexible
86517|NCT03510299|Device|Control|Digital manipulation technique of LMA flexible insertion
86518|NCT03510286|Diagnostic Test|Test-it™ PrCr Urinalysis Strips|The LifeAssay Diagnostics prototype PrCr dipstick has been designed to provide the measurement of both protein and creatinine while retaining a very low estimated cost that is comparable to the current protein-only dipsticks at $0.06-0.10 per test. In 2015, an initial laboratory-based validation study of the prototype LAD PrCr test was used on more than 500 characterized urine samples from pregnant women. This validation study demonstrated comparable accuracy for detection of severe proteinuria of the LAD PrCr test to the much more expensive commercial POC test available for PrCr determination, the Siemens Multistix® PRO 10LS. These results were compared to laboratory-based reference standard assays for proteinuria measurement.
86519|NCT03510273|Device|Liger Medical Thermocoagulator (US FDA 510K clearance received)|Thermo-coagulation treatment by Liger Medical device
86603|NCT03509545|Drug|CHF Patients: ER Torsemide 40 mg|ER Torsemide 40mg given once daily to CHF patients
86520|NCT03510260|Other|Study Group I|Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
86521|NCT03510260|Other|Study Group II|The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
86522|NCT03510260|Other|Control Group|Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
86523|NCT03510221|Dietary Supplement|Antioxidants capsules|1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks
86524|NCT03510208|Procedure|Near-Infrared Fluorescence Imaging|Undergo NIR imaging
86525|NCT03510208|Biological|Panitumumab|Given IV
86526|NCT03510208|Drug|Panitumumab-IRDye800|Given IV
86527|NCT03510208|Device|POINPOINT-IR9000|"Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite (back table)."
86528|NCT03510195|Other|MEDICORP HO PREPARATORY MODULE|3 DAY course module to prepare medical graduates to become house officers
86529|NCT03510182|Device|transcranial direct current stimulation|
86530|NCT03510169|Device|NeoVest|Negative pressure ventilation with NeoVest
86531|NCT03510156|Behavioral|Behavior analytic treatment|Function-based treatment
86532|NCT03510143|Device|Neoveil (Polyglycolic Acid Mesh)|Apply the Neoveil (Polyglycolic Acid Mesh) in the neck node dissection area in thyroid cancer surgery.
86533|NCT03510130|Other|Routine leg movement|Routine leg movement to the right and left in the supine position during the second stage of labor, for 3 minutes every 20-30 minutes by the attending physician or nurse.
86534|NCT03510117|Behavioral|Mindfulness|Mindfulness
86535|NCT03510104|Drug|MRX-2843|MRX-2843 capsules
86536|NCT03510091|Behavioral|Counseling|A video will be shown to parents of patients ages 9-18 that review HPV transmission, relation to cancer, role of immunization, myths, side effects, series timing and need for completion. All parents or legal guardians of patients will be given the option to proceed with HPV vaccination, decline, or discuss further with their provider
86537|NCT03510078|Drug|Insulin|Insulin for glycemic control according to the allocation
86538|NCT03510065|Device|Prevision®|One time Evaluation with documentation of one follow-up visit
86539|NCT03510052|Behavioral|Diet Modification Pilot Program (DPM)|Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
86540|NCT03510039|Behavioral|Early device / Follow up|"Early device:~Standardized Nursing Interview (30 minutes) with the Third Party Person Measure and follow the anxiety of the Third Party by rating the AMDP-AT scale, on D0 and D7~Telephone follow-up by nurses:~Interviews built and standardized, to M2, M4 and M6 Quantification of the AMDP-AT anxiety scale on each call"
86541|NCT03510039|Other|Usual care|"Group Before : usual care by nurses"
86542|NCT03510026|Device|Low thermal device preparation|One participant acts simultaneously as a control and active comparator. One internal thoracic artery is prepared with the normal electrocautery device. The other internal thoracic artery is prepared with the new low thermal device. The participant does not know, which internal thoracic artery is defined to be prepared with the low thermal device.
86543|NCT03510013|Procedure|1-1-8 wash-in|wash-in phase during start of low flow anesthesia
86544|NCT03510013|Drug|Sevoflurane|Drug used for wash-in protocol
86545|NCT03510000|Drug|Empagliflozin 25mg|Individuals will test insulin dosing during different meal strategies (carbohydrate counting, plain meal announcement, no meal announcement) in a setting of the single hormone artificial pancreas with or without SGLT2 inhibitor (empagliflozin) addition. After starting the empagliflozin therapy, there will be 1-2 weeks long therapy optimization period and afterwards meal strategies will be administered. Randomization will be used to determine whether participant will start meal strategies on empagliflozin or without empagliflozin, cross-over design enables all participants to undergo all combination of approaches.
86546|NCT03510000|Device|Single hormone artificial pancreas|Single hormone artificial pancreas will be used as a baseline background intervention standardizing the delivery and dosing of insulin. Artificial pancreas (insulin pump, continuous glucose monitoring device and dosing-suggestion algorithm) will be used by all participants on days when meal strategy intervention will be performed.
86547|NCT03510000|Behavioral|Meal strategies|Participants will use different approaches (strategies) to insulin dose estimation for ingested carbohydrates on study days. Goal of these various strategies is to recognize magnitude of empagliflozin effect in situations when artificial pancreas algorithm is working with information of different accuracy. Individual meal approach strategies include carbohydrate counting, meal size announcement and no meal announcement. The exception will be combination of no empagliflozin and no meal announcement, which didn't result in sufficient glucose control in previous trials therefore will not be repeated in a current trial. Meal approach strategies will occur on separate days- 5 days in total each day using one meal strategy for all meals during the day.
86548|NCT03509987|Device|HemaCue|comparing hemoglobin (Hb) levels determined by point of care testing HemaCue and arterial blood gas analyzer with an automated hematology analyzer in critically ill geriatric patients.
86549|NCT03509974|Device|Osseointegrated Steady State Implant|Bone anchored, bone conduction hearing system
86550|NCT03509961|Diagnostic Test|NGS-MRD|Next generation sequencing minimal residual disease (NGS-MRD) is a test that has increased sensitivity over multichannel flow cytometry to better identify risk of key outcomes after HCT. Patients that have a pre-HCT negative NGS-MRD results may be eligible to proceed to the treatment arm of the study that uses a non-TBI conditioning regimen.
86551|NCT03509961|Drug|Myeloablative allogeneic HCT with a non-TBI conditioning regimen|"Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.~day -7: Fludarabine and Busulfan day -6: Fludarabine and Busulfan day -5: Fludarabine and Busulfan day -4: Fludarabine and Busulfan day -3: Fludarabine day -2: Thiotepa day -1: Rest Day 0: Transplant"
86552|NCT03509948|Drug|cytisine|cytisine 1.5 mg film-coated tablets
86671|NCT03509012|Radiation|External beam radiation (dose level 1)|radiation therapy
86553|NCT03509935|Other|Intervention Ultrasound Group|"Protocol:~US 4 pulmonary quadrants in each hemithorax: anterior and lateral, upper and lower regions (figure 1)~US inferior vena cava, collaborative index or distensibility according to the patient's conditions, in spontaneous or controlled ventilation, respectively.~Cardiac US: subjective evaluation of contractility in normal, discreetly reduced or severely reduced."
86554|NCT03509922|Drug|Anplag Tab. 100mg bid|sarpogrelate hydrochloride 100mg bid for 24 weeks
86555|NCT03509922|Drug|Anplag Tab. 100mg tid|sarpogrelate hydrochloride 100mg tid for 24 weeks
86556|NCT03509909|Behavioral|Hatha yoga|Manualized hatha yoga
86557|NCT03509909|Behavioral|Supportive physical activity|Manualized stretching and strengthening
86558|NCT03509896|Other|Non-Interventional|Non-Interventional
86559|NCT03509883|Drug|Apixaban sprinkle capsules|Single dose (25 x 0.1 mg capsules), oral administration
86560|NCT03509883|Drug|Apixaban tablets|Single dose (5 x 0.5 mg tablets), oral administration
86561|NCT03509870|Biological|mesenchymal stromal cells|mesenchymal stromal cells in a collagen scaffold
86562|NCT03509857|Device|BUZZY(tm)|"Risks associated with the BUZZY(tm) device The intervention group will receive vibration only, with application of the BUZZY device just proximal to the intravenous infusion site immediately before and during propofol infusion.~There are no known risks for the use of the BUZZY(tm) device, which is registered as an FDA class III device (therapeutic massager)."
86563|NCT03509857|Other|No Intervention|No intervention
86564|NCT03509844|Behavioral|Psychotherapy|Three established psychotherapeutic models for treatment of complex posttraumatic stress disorders are compared in a residential care setting. Combination of group and individual sessions.
86565|NCT03509831|Drug|INT-2150|"Period: INT-2150~Period: Irsogladine maleate 2 mg+Nizatidine 150 mg"
86566|NCT03509831|Drug|Irsogladine maleate 2 mg+Nizatidine 150 mg|"Period: Irsogladine maleate 2 mg+Nizatidine 150 mg~Period: INT-2150"
86567|NCT03509818|Other|plyometric exercise|acute plyometric exercise
86568|NCT03509818|Other|Aerobic exercise|acute aerobic exercise
86569|NCT03509805|Diagnostic Test|polysomnography|
86570|NCT03509792|Behavioral|Simple cognitive task|"A memory cue followed by playing the computer game Tetris on own smartphone. Options to engage in self-administered booster sessions after day 1."
86571|NCT03509792|Behavioral|Attention placebo|Smartphone activity for same amount of time.
86572|NCT03509766|Device|Histamine skin testing|skin testing using histamine
86573|NCT03509753|Dietary Supplement|High Fiber|See intervention description.
86574|NCT03509753|Dietary Supplement|Low Fiber|See intervention description.
86575|NCT03509740|Drug|tramadol|100 mg tramadol in 100 ml saline with slow infusion
86576|NCT03509740|Drug|paracetamol|Intravenous 1 gm paracetamol in 100 ml saline with slow infusion
86577|NCT03509714|Dietary Supplement|Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)|2 Pills to be taken orally per day during their entire menstrual cycle
86578|NCT03509714|Dietary Supplement|rice flour (Placebo)|250 mg rice flour (Placebo)
86579|NCT03509701|Diagnostic Test|VZV-specific antibody response from blood|Check VZV-specific antibody response, VZV specific T-cell mediated immune response by IFN-γ ELISPOT assay from blood, and real-time PCR results from saliva
86580|NCT03509688|Drug|entecavir+resveratrol|entecavir+resveratrol
86581|NCT03509688|Drug|Entecavir|Entecavir
86582|NCT03509688|Drug|entecavir+thymosin α1|entecavir+thymosin α1
86583|NCT03509675|Drug|Non-Steroidal Anti-inflammatory Topical Rinse|Non-Steroidal Anti-inflammatory Topical Rinse will be used for Symptomatic OLP patients.
86584|NCT03509675|Drug|Placebos|Placebo
86585|NCT03509662|Drug|Vitamin C|Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).
86586|NCT03509662|Drug|Thiamine|All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.
86587|NCT03509662|Drug|Placebos|One group receives a placebo.
86588|NCT03509649|Procedure|Cervical spine manipulation|High-velocity low-amplitude thrust joint manipulation to the cervical spine
86589|NCT03509636|Drug|Fluzoparib|Fluzoparib capsule will be given twice daily orally
86590|NCT03509623|Diagnostic Test|Blood sampling through direct peripheral venous puncture|Fasting blood samples will be collected 10-15 minutes before the first intravitreal injection of aflibercept and at 7 and 30 days post-injection using a 19-gauge needle under minimum stasis. Blood coagulation parameters will be evaluated.
86591|NCT03509610|Other|Diet|Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
86592|NCT03509597|Behavioral|Aerobic Exercise|Physical exercise training consisting of aerobic exercise and strength/resistance training.
86593|NCT03509597|Behavioral|Cognitive Training|Cognitive remediation program using REHACOP rehabilitation program.
86594|NCT03509597|Behavioral|Treatment as usual|Standard care for schizophrenia + Leisure and free time activities.
86595|NCT03509597|Behavioral|Occupational Activities|Engagement in activities aimed to keep patients actively involved in demanding tasks.
86596|NCT03509584|Radiation|hypofractionated radiotherapy|Stereotactic hypo-fractionated irradiation (3 x 8 Gys) radiotherapy fraction
86597|NCT03509584|Drug|nivolumab|administration of nivolumab
86598|NCT03509584|Drug|Ipilimumab|administration of ipilimumab
86599|NCT03509571|Other|Ketogenic Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with ketogenic diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet is a high-fat, low-carbohydrate diet (lipid to carbohydrate + protein ratio of 3:1) that will include ≈75% total energy as fat, ≈20% as protein, and ≈5% as carbohydrate and fiber.
86600|NCT03509571|Other|Standard Diet|Enteral feeding via nasogastric (NG) or nasojejunal (NJ) tubes with SD diet will start within 72 hours of injury and solid feeding will start as soon as the patient is able to swallow. This diet includes ≈35% total energy as fat, ≈27% as protein, and ≈44% as carbohydrate and fiber.
86601|NCT03509558|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of spinal cord over the skin combined with physical therapy to improve walking and standing functions
86604|NCT03509545|Drug|CHF Patients: Furosemide 40 mg|Stable CHF patients taking twice-daily 40 mg Furosemide
86605|NCT03509532|Device|PCI|PCI
86606|NCT03509519|Other|NMES-Millicurrent|Stimulating electrodes will be applied to the quadriceps muscle of each leg 3 times a week for 4 weeks (12 sessions) for 40min per leg.
86607|NCT03509506|Behavioral|App Group|"The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~The vital signs show undesired readings~The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent."
86608|NCT03509493|Diagnostic Test|FibriCheck|Digital health application
86609|NCT03509480|Procedure|Surgical Curettage for benign bone lesion|Surgical curettage for benign bone lesion, created defects will be filled with one of two types of graft material Vitoss versus Prodense, there are no other devices or drugs used
86610|NCT03509467|Behavioral|Personalized Information|Personalized information about ways that participants can protect themselves and their child from developing melanoma.
86611|NCT03509467|Behavioral|Standard Information|Standard information about ways that participants can protect themselves and their child from developing melanoma.
86612|NCT03509467|Other|DNA Extraction Determination of MC1R Genotypes|After signing informed consent, a biologic sample (saliva) will be collected for the purpose of DNA extraction determination of MC1R genotypes. All participants who carry high risk MC1R genotypes and a proportion of those who carry low risk or no MC1R variants will be randomized to the control or intervention arm.
86613|NCT03509428|Behavioral|SRETP|SRETP will involve short periods of exercise at a high intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session. Exercise intensities during the interval exercise-training program are specific to each patient and derived from CPET. Moderate intensity exercise is below the anaerobic threshold (AT). Patients will exercise at 80% of oxygen uptake (VO2) obtained at the anaerobic threshold (80%AT) for moderate intensity exercise - 3 minutes. Severe exercise intensity is recognised as 50% of the difference between the VO2 AT and VO2 Peak (50%∆) - 2 minutes.
86614|NCT03509428|Behavioral|Psychological support|Support sessions will be patient-centred, giving the patient an opportunity to raise any issues/concerns they are having, this may include (but will not be limited to) ways of coping with their reactions to cancer, family and relationship issues, exploring personal issues and dealing with practical issues. Patients will have access to other resources available at the cancer centres including but not restricted to further information about their condition and how to access financial support. These processes reflect the best practice currently being delivered by cancer support centre staff in the Wessex region. Any patient deemed at risk (i.e. from suicidal ideation or self harm) will be reported to their GP, followed up by a letter.
86615|NCT03509415|Diagnostic Test|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
86616|NCT03509402|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal short implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: 6 mm)
86617|NCT03509402|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm|Rehabilitation of the edentulous mandible by a full-arch srew-retained prosthesis with distal cantilevers supported by five interforaminal long implants (ASTRA TECH Implant System, OsseoSpeed™ 4.0 S, length: ≥11mm)
86618|NCT03509376|Procedure|Suture repair|The diastasis is repaired with continous nylon suture
86619|NCT03509376|Procedure|Rolled mesh repair|Continuous nylon suture is done over a narrow strip of self gripping Rolled mesh to repair the diastasis
86620|NCT03509363|Behavioral|Stroke physiotherapy home exercise video|a set of exercise video with QR code provided in home exercise pamphlets
86621|NCT03509350|Drug|Vitamin C|Intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
86622|NCT03509350|Drug|Thiamine|Intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
86623|NCT03509350|Drug|Hydrocortisone|Intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge.
86624|NCT03509350|Drug|Vitamin C Placebo|A placebo to match intravenous vitamin C (1.5 grams every 6 hours) will be administered for 4 days or until ICU discharge.
86625|NCT03509350|Drug|Thiamine Placebo|A placebo to match intravenous thiamine (100 mg every 6 hours) will be administered for 4 days or until ICU discharge.
86626|NCT03509350|Drug|Hydrocortisone Placebo|A placebo to match intravenous hydrocortisone (50 mg every 6 hours) will be administered for 4 days or until ICU discharge. Steroids will be used when clinically indicated.
86627|NCT03509337|Diagnostic Test|shear-wave elastography|Measurement by shear-wave elastography of the nerve, muscle and ulnar tendon before and after the tension of the ulnar nerve
86628|NCT03509324|Drug|Insulin LISPRO|receive short-term insulin pump therapy by using insulin LISPRO, continue treatment for 7 more days when euglycemia achieved
86629|NCT03509298|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
86630|NCT03509298|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
86631|NCT03509285|Drug|Alprazolam Placebo|100 mg lactose tablets
86632|NCT03509285|Drug|Cenobamate placebo|Sugar pill manufactured to mimic cenobamate 100 mg tablet
86633|NCT03509285|Drug|Alprazolam|0.5 mg and 1.0 mg alprazolam tablets
86634|NCT03509285|Drug|Cenobamate|100 mg tablet
86660|NCT03509025|Drug|Jointstem|JOINTSTEM is an OA treatment that uses autologous adipose-derived mesenchymal stem cells. As it does not use allogenic tissues and is incubated without additional genetic modification or mechanical and chemical modification through differentiation, it is classified as 'autologous cell therapy' and is completely free of immunologic rejection.
86661|NCT03509012|Drug|Durvalumab|IV (intravenous)
86662|NCT03509012|Drug|Tremelimumab|IV
86635|NCT03509272|Device|remote monitoring|"Intervention Description: Patients can participate in the study when they're 10 weeks pregnant. At 10 weeks: a NICCOMO, Maternal Venous Doppler Echography and Maltron measurement will be taken. This measurement will be repeated at 20 weeks of pregnancy, and 30 weeks of pregnancy when they're aberrant.~When the measurements are abnormal, the patients will be included in the remote monitoring study. The following protocol and devices will be applied:~Device What When Withings Wireless Blood Pressure Monitor Blood Pressure 2x/day Withings Pulse O² Activity Day and night Withings Smart Body Analyzer Weight~1x/day"
86636|NCT03509246|Drug|Pegylated liposomal doxorubicin plus Bortezomib|Pegylated liposomal doxorubicin 40mg/m2 subcutaneous for 60 - 90 minutes at day 4 plus Bortezomib 1.3mg/m2 subcutaneous injection at day 1,4,8,11 for 6 cycles
86637|NCT03509233|Other|Q-SRP|Quadrant scaling and root planing under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within four sessions in intervals of 1 week
86638|NCT03509233|Other|FMS|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours
86639|NCT03509233|Other|FMD|Full mouth scaling and rootplaning under local anesthesia using ultrasonic devices (Piezon-Master, EMS) and Gracey curettes (Hu-Friedy) within 24 hours with additional disinfection using 0.2% chlorhexidine (mouth rinsing and tonsil spray), subgingival application of 1% chlorhexidine gel and 2 months postoperative home care using chlorhexidine 0.2% (rinse and spray)
86640|NCT03509233|Other|FMDP|FMD protocol (see FMD arm) with additional use of subgingival airpolishing (Air Flow, EMS) using Erythritol powder (Air-Flow Plus powder, EMS) for 20 seconds per tooth
86641|NCT03509220|Drug|PBK-1701TC|The subject will receive PBK-1701TC for colonoscopy.
86642|NCT03509220|Drug|Standard oral preparation|The subject will receive the standard oral preparation for colonoscopy
86643|NCT03509207|Drug|Vorinostat Oral Capsule|Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.
86644|NCT03509181|Behavioral|I-Change|smartphone delivered word-sentence association task that encourages a healthier interpretive style
86645|NCT03509168|Drug|Misoprostol Pfizer Brand|insertion of a preoperative single dose 400 micrograms of Misoprostol Pfizer Brand placed vaginally
86646|NCT03509168|Other|Non-insertion of Misoprostol Pfizer Brand|participants in this arm will receive the standard of care which in our setting involves the use of either a tourniquet to control intraoperative blood loss especially if the fibroids are large or rarely, other interventions like oxytocin, tranexamic acid, vasopressin and occasionally not using either of the interventions.
86647|NCT03509155|Other|National portion & IYCF counseling|Eight or twelve pieces of Biscuits supplementation per day as serving size recommendation based on the requirement from Ministry of Health, accompanied by IYCF Counseling emphasizing on local food optimization. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
86648|NCT03509155|Other|Adjusted portion & local food counseling|four pieces of Biscuits supplementation per day as serving size recommendation, accompanied by IYCF Counseling. The difference in serving size recommendation will be evaluated to see the efficacy of Biscuits supplementation on wasting children age 6-23 months of age
86649|NCT03509142|Device|Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System|Implantation of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)
86650|NCT03509129|Behavioral|TECH (Technology)|"Participants will receive a theory-based physical activity program. They will enroll in the study as part of a self-selected group of 3-8 individuals. They will be provided with a personal step goal and Fitbit Alta HR for self-monitoring physical activity. They will also have access to a study website that will be accessible across conventional and mobile platforms. They will be asked to visit the website each week to receive behavior change information and guidance.~Device: Fitbit Alta HR"
86651|NCT03509129|Behavioral|TECH+COMP (Technology + Competition)|"Participants will receive the same intervention components as the TECH group, as well as a team competition. The competition will be based on the following two aspects: total daily steps accumulated relative to group size and total number of points retained for achieving weekly physical activity challenges.~Device: Fitbit Alta HR"
86652|NCT03509116|Other|Observations|Consultation observations
86653|NCT03509116|Other|Interviews, key stakeholders, documents|Qualitative interviews, key stakeholders, documentary analysis
86654|NCT03509103|Other|Electronic Partograph|"The electronic version of the partograph was a state-of-the-art application that is accessed through smart phone or tablet pc or computer device. The application's user interface (UI) is segmented; users will have to concentrate only on a single portion at a time that would lessen the existing complexity of using paper-based partograph.~e-partograph application's user interface in Android programming language for smart tabs, and in ASP.net with C# language for personal computers. The application has options to save the data in local storage and in a remote central database storage concurrently. Local storage contains data for temporarility; the remote server contains the data permanently which makes the partograph information searchable at any time and place. This application allows partograph data to be monitored remotely."
86655|NCT03509090|Procedure|erector spinae block|erector spinae block will be performed in this group as postoperative analgesia treatment.
86656|NCT03509090|Procedure|Control group|patients will receive only multimodal analgesic treatment including patient-controlled analgesia
86657|NCT03509064|Other|Collection sheet|Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
86658|NCT03509051|Biological|B vaccination|One intramuscular injection of Bexsero (multicomponent B vaccine) from 6 months after transplant. A second similar dose will be given 2 months later.
86659|NCT03509038|Other|Exploratory pathophysiology Study|Urodynamic tests before and after bariatric surgery in obese incontinent women before and after bariatric surgery
86663|NCT03509012|Drug|Cisplatin (dose level 4)|IV
86664|NCT03509012|Drug|Cisplatin (dose level 3)|IV
86665|NCT03509012|Drug|Carboplatin (dose level 1)|IV
86672|NCT03509012|Radiation|External beam radiation (dose level 2)|radiation therapy
86673|NCT03509012|Radiation|External beam radiation (hyperfractionated)|radiation therapy
86674|NCT03509012|Drug|Cisplatin (dose level 1)|IV
86675|NCT03509012|Drug|Cisplatin (dose level 2)|IV
86676|NCT03509012|Radiation|External beam radiation (standard)|radiation therapy
86677|NCT03508999|Drug|Metronidazole gel|The application of metronidazole gel is effective in the management of gingivitis in patients undergoing orthodontic therapy. Additionally, the constant reminder therapy at weekly interval would also lead to improvement in the oral hygiene.16 According to pertinent literature survey, none of the study has been conducted to compare the effectiveness of SMS reminders and use of anaerobic gel to reduce gingival inflammation.
86678|NCT03508999|Other|SMS text reminder|Subjects will be provided biweekly reminder via 'SMS text reminder' in the form of text message reinforcing oral hygiene. Additionally, patients will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
86679|NCT03508999|Other|Placebo gel|Group C will be subjects will be given standard oral hygiene instructions on the visit with a placebo gel topically instructed to apply on the marginal gingiva for the next 4 weeks, twice a day for 30 minutes, after morning and evening tooth brushing.
86680|NCT03508973|Other|Sculpta|
86681|NCT03508947|Drug|WVE-210201|WVE-210201 is a stereopure antisense oligonucleotide (ASO)
86682|NCT03508947|Drug|Placebo|Sodium Chloride
86683|NCT03508934|Device|GTS (Continuous Glucose Monitoring)|Hospitalized patients with DM2 will be monitored with Glucose Telemetry System (GTS)
86684|NCT03508934|Other|POC (Point of Care)|Hospitalized patients with DM2 will be monitored with POC (Point of Care) blood glucose levels.
86685|NCT03508921|Procedure|Periprocedural Antibiotics|"One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection."
86686|NCT03508921|Drug|Extended Antibiotics|"Patients randomized to the Extended Antibiotics arm will receive one dose of trimethoprim/sulfamethoxazole peri-procedurally and additionally be prescribed trimethoprim/sulfamethoxazole twice daily for three days. Patients who are allergic will receive amoxicillin/clavulanic acid (875/125mg) twice daily for three days. If allergic to both of the above antibiotics, patients will receive 100mg nitrofurantoin BID for three days.~For their second injection, they will receive peri-procedural antibiotics only."
86687|NCT03508921|Procedure|Injection of OnabotulinumtoxinA (BTX-A)|Patients will receive injection of OnabotulinumtoxinA (BTX-A) per standard clinic practice protocol. All patients will undergo injection per a standardized protocol of 1ml injection per site at a concentration of 10 units/ml.
86688|NCT03508908|Diagnostic Test|HIV-1 RNA testing|During the intervention period, a blood sample will be obtained and tested for AHI using point-of-care Xpert® HIV Qual assay (Cepheid, Sunnyvale, California, USA). Individuals who test positive will undergo rapid tests to differentiate acute from prevalent HIV infection. Newly diagnosed individuals will be offered immediate ART and assisted partner notification with the HIV-1 RNA testing intervention delivered to partners following the same approach.
86689|NCT03508895|Other|Whole hemp seed protein|The intervention will be provided in a form of a smoothie.
86690|NCT03508895|Other|Whole hemp seed protein plus bioactive peptides|The intervention will be provided in a form of a smoothie.
86691|NCT03508895|Other|Casein protein|The intervention will be provided in a form of a smoothie.
86692|NCT03508882|Drug|Botulinum Toxin Type A 100Unit/Vial (Product)|Botulinum Toxin Type A 100Unit/Vial (Product) comes as a dry powder and is routinely reconstituted with Saline Solution for Injection
86693|NCT03508882|Drug|Saline Solution for Injection|The placebo consists of vehicle only. Saline Solution for Injection is the vehicle substance normally used to reconstitute Botulinum Toxin Type A (see 1st Intervention above).
86694|NCT03508869|Drug|Mirvaso® (brimonidine) topical gel, 0.33%|Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent facial erythema of rosacea in adults 18 years of age or older.
86695|NCT03508869|Drug|Dysport®|Dysport® is an acetylcholine release inhibitor and a neuromuscular blocking agent.
86696|NCT03508869|Drug|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%|Dysport® in conjunction with Mirvaso (brimonidine) topical gel, 0.33%
86697|NCT03508856|Drug|Ingenol Mebutate (Picato®) 0.015% gel|
86698|NCT03508843|Behavioral|interactive virtual presence|installing the car seat with advice via interactive virtual presence
86699|NCT03508830|Drug|Liposomal Bupivacaine|Drug will be percutaneously injected into intercostal spaces 3-10 under direct intrathoracic vision at the conclusion of surgery.
86700|NCT03508830|Drug|Standard Bupivacaine|Drug will be percutaneously injected into intercostal spaces 3-10 under direct intrathoracic vision at the conclusion of surgery.
86701|NCT03508817|Drug|Atropine Sulfate 0.01% Eye Drops|atropine eye drop in study eye once nightly for two years.
86702|NCT03508804|Drug|Lidocaine-Prilocaine Cream|10ml of vaginally self-administered cream composed of an eutectic mixture of 2.5% lidocaine, 2.5% prilocaine
86703|NCT03508804|Drug|Placebo Cream|10ml of vaginally self-administered placebo cream
86704|NCT03508804|Drug|1% Lidocaine Paracervical Block|Paracervical block of 10ml of 1% lidocaine
86705|NCT03508791|Other|Arterial carbon dioxide monitoring|Arterial carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
86706|NCT03508791|Other|End-tidal carbon dioxide monitoring|End-tidal carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
86707|NCT03508791|Other|Transcutaneous carbon dioxide monitoring|Transcutaneous carbon dioxide partial pressure is monitored during the laparoscopic surgery undergoing in the Trendelenburg or reverse Trendelenburg positions.
86708|NCT03508765|Diagnostic Test|Structural Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
86709|NCT03508765|Diagnostic Test|Functional Image|Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.
86710|NCT03508765|Behavioral|Digit Span subtest|Evaluates auditory attention and working memory
86711|NCT03508765|Behavioral|Brief Test of Attention|Assesses selective auditory attention
86712|NCT03508765|Behavioral|Trail Making Test (Parts A & B)|Assesses visual scanning, graphomotor speed, and setshifting
86713|NCT03508765|Behavioral|Auditory Consonant Trigrams Test|Assesses attention and susceptibility to interference
86714|NCT03508765|Behavioral|Controlled Oral Word Association Test|A timed test of verbal fluency.
86715|NCT03508765|Behavioral|Hopkins Verbal Learning Test-Revised|The HVLT-R is a test of verbal learning and recall.
86716|NCT03508765|Behavioral|The Center for Epidemiological Study-Depression|assesses perceived depression
86717|NCT03508765|Behavioral|The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4|A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue
86718|NCT03508765|Other|Blood draw|Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.
86719|NCT03508752|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery dose is based on the largest tumor size
86720|NCT03508739|Drug|Sacubitril/Valsartan 200mg (blinded)|study day 2 for AB and study day 3 for BA
86721|NCT03508739|Drug|Valsartan 160mg (blinded)|study day 3 for AB and study day 2 for BA
86722|NCT03508726|Drug|Ascorbate|"Phase 1 dose escalation:~75gm IV three times a week~Phase II portion:~75gm IV three times a week if no dose limiting toxicities are experienced in the Phase I portion. Otherwise, ascorbate dose will be deescalated to 62.5 gm IV"
86723|NCT03508713|Drug|disease modified antirheumatic drugs or biological agents|Enrolled patients will be treated according to the 2015 American College of Rheumatology Guideline for the Treatment of RA
86724|NCT03508700|Drug|TNX-102 SL 5.6 mg|cyclobenzaprine HCl sublingual tablets
86725|NCT03508687|Drug|300mg Gemcabene|300mg Gemcabene
86726|NCT03508687|Drug|600mg Gemcabene|600mg Gemcabene
86727|NCT03508674|Device|Levita Magnetic Surgical System|use of surgical tool
86728|NCT03508661|Other|SPIN-SSLED Program|The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 &7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
86729|NCT03508648|Drug|GTx-024|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
86730|NCT03508648|Drug|Matching Placebo|Subjects will not be provided with any study treatments and will be off-drug during this extension study. Intervention was administered during study G201002.
86731|NCT03508635|Drug|CORT125134|Oral capsules
86732|NCT03508635|Drug|Matching Placebo of CORT125134|Placebo
86733|NCT03508635|Drug|Mifepristone|Active comparator
86734|NCT03508635|Drug|Prednisone|Challenge agent
86735|NCT03508635|Drug|Glucose|
86736|NCT03508622|Behavioral|Telehealth group sessions|Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.
86737|NCT03508622|Behavioral|Empower clinic|Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.
86738|NCT03508609|Biological|CLBS14|GCSF-mobilized autologous CD34 cells
86739|NCT03508596|Other|educational intervention for the supervisors|The educational intervention is based on a systematic literature review as well as focus-group interviews with health care professionals. It will be developed until the end of 2018
86740|NCT03508583|Other|Participation|"The mpoc 56 and mpoc 20 will be field-tested with a sample of 300 parents of children with disabilities residing in the Turkey.~Professionals working with children with disabilities will be assessed with MPOC SP questionnaires"
86741|NCT03508570|Biological|Ipilimumab|Given i.p.
86742|NCT03508570|Other|Laboratory Biomarker Analysis|Correlative studies
86743|NCT03508570|Biological|Nivolumab|Given i.p.
86744|NCT03508570|Other|Pharmacokinetic Study|Correlative studies
86745|NCT03508557|Behavioral|Advance care planning tools|Structured conversations between patients/substitute decision-maker and clinician based on education about advance care planning using locally relevant booklet/website, values clarification tool for patient engagement, clinician use of the Serious Illness Conversation Guide
86746|NCT03508544|Procedure|Lumbar ESP block|Lumbar ESP block will be performed at the begining of surgery under ganeral anesthesia. A convex ultrasound transducer will be placed in a longitudinal parasagittal orientation 4-6 cm lateral to L4 spinous process. The erector spinae muscles will be identified superficial to the tip of L4 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 22-gauge 10-cm needle will be inserted using an out-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
86874|NCT03507452|Drug|BAY2287411|"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."
86875|NCT03507452|Drug|BAY2287411|"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."
86747|NCT03508544|Procedure|QLB bLock|QLB block will be performed at the begining of surgery under ganeral anesthesia. The convex transducer will be placed in the transverse plane on the flank of the patient cranial to the iliac crest.The 4th lumbar vertebral transverse process, erector spinae muscles, psoas muscles, transverse abdominis muscles, internal and external oblique muscles and the quadratus lumborum muscles will be identified. A 15cm 22G insulated needle will be inserted on the posterior corner of the convex probe. 40 ml of local anesthetic mixture(bupivacaine and lidocaine ) will be administered between the quadratus lumborum and psoas muscles into the fascial plane. We observed the local anesthetic pressing down on the psoas muscle in the ultrasound image.
86748|NCT03508544|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
86749|NCT03508531|Procedure|ESP Block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 40 mL of bupivacaine/lidocaine mixture will be injected.
86750|NCT03508531|Procedure|OSTAP block|The bilateral OSTAP will be performed at the end of the surgery. A total of 40 ml local anesthetic mixture (Bupivacaine and lidocaine) will be injected bilaterally with interfascial plane between the external oblique and transversus abdominis muscles
86751|NCT03508531|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
86752|NCT03508518|Other|Shared care device in psychiatry (DSPP)|The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion
86753|NCT03508518|Other|Usual Care|psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.
86754|NCT03508505|Device|Venoarterial extracorporeal oxygenation|Veno-arterial extracorporeal oxygenation (VA-ECMO) is inserted in the acute setting in case of cardiac low output after adult cardiac surgery in order to provide cardiopulmonary support to recovery or as bridge to transplantation.
86755|NCT03508492|Other|Surgical tinted Chloraprep® applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
86756|NCT03508492|Other|Surgical tinted Nex Clorex 2% applicators|We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
86757|NCT03508479|Biological|RG-HRV16|0.25 mL inoculum intranasally delivered into each nostril (0.5 mL total delivered). Total cumulative dose of 1000 median tissue culture infective dose at 50% of cells inoculated (TCID50).
86758|NCT03508466|Behavioral|hypersensitivity reaction|Previous hypersensitivity reaction
86759|NCT03508453|Biological|IC14|Monoclonal antibody against CD14
86760|NCT03508453|Other|Placebo|sterile normal saline for injection prepared to be identical to study drug
86761|NCT03508440|Procedure|Intratympanic injection|Injection will be up to 1cc of dexamethasone 24mg/mL. The procedure will be performed at supine position under a microscope. Local anesthesia will be achieved with topical phenol. A myringotomy will be made in the tympanic membrane. A 1 mL syringe connected to a needle will be used to slowly inject between 0.2 cc and 1.0 cc of solution through the myringotomy, with the subject's head turned 45 degrees to the opposite side. The subject will be asked to maintain positioning for at least 30 minutes and refrain from swallowing. The dose administered will vary due to subject-specific factors.
86762|NCT03508440|Drug|Prednisone|Oral Steroid
86763|NCT03508427|Other|Daily self-monitoring|Toi Même self-monitoring smartphone application plus treatment as usual which includes pharmacological and/or psychological treatment.
86764|NCT03508414|Behavioral|ketogenic diet|Patients receive a ketogenic diet, which is carbohydrate-reduced with a high amount of fat.
86765|NCT03508414|Behavioral|Intermittent therapeutical fasting|Patients fast for 1 week every six months. Additionally, the patients do an intermittent fasting, that is to say they do not eat for at least 14 hours a day.
86766|NCT03508414|Behavioral|Active comparator|The control group is receiving a vegetarian-focused diet according to the current recommendations of the German Society for Nutrition (DGE) for MS patients.
86767|NCT03508401|Other|Passive leg raising (PLR)|"PLR is a test that predicts whether cardiac output will increase with volume expansion. By transferring a volume of around 300 mL of venous blood from the lower body toward the right heart, PLR mimics a fluid challenge. However, no fluid is infused and the hemodynamic effects are rapidly reversible, thereby avoiding the risks of fluid overload.~PLR starts from the semi-recumbent and not the supine position. PLR is performed by adjusting the bed and not by manually raising the patient's legs"
86768|NCT03508401|Device|Echo-Doppler measurements|"Echo-Doppler measurements are performed with Vivid S6 model (GE Healthcare France, Lyon, France). All measurements are recorded at the end of expiration. Echo-Doppler measurements are performed in the upper part of the SVC, approximately 1 to 2 cm below the brachiocephalic vein. From this view, pulse Doppler is performed. Pulse Doppler waves obtained in the SVC are used to obtain velocity time integrals (VTI). Expiratory VTI is named VTImax and inspiratory VTI is named VTImin. These values will allow the calculation of Respiratory variations of the superior vena cava flow (ΔSVCf).~ΔSVCf is calculated as (VTImax- VTImin )/(1/2(VTImax+ VTImin))."
86769|NCT03508375|Biological|blood samples|blood samples
86770|NCT03508362|Device|Functional Magnetic Resonance Imaging (fRMI)|Acquisition of a functional MRI on the sub thalamic nucleus
86771|NCT03508349|Diagnostic Test|IST|Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
86772|NCT03508336|Diagnostic Test|Coma Recovery Scale-Revised|"Patients with disorders of consciousness were assessed by Coma Recovery Scale-Revised (CRS-R). In addition, we selected four stimuli: 1) only a command (as recommended in CRS-R), which was open your mouth; 2) only a spoon without a command; 3) a spoon and a command, the command was there is a spoon and open your mouth; 4) a spoon with water and a command, the command was there is a spoon with water and open your mouth. In brief, we presented these stimuli orderly in front of the patient's mouth and presented any one of them over 4 trials at 15 second intervals."
86773|NCT03508323|Drug|Teneligliptin|20mg/qd
86774|NCT03508323|Drug|Placebo|1T/qd
86775|NCT03508310|Other|Taking Care of Me Video|The video's conceptual framework incorporates Social Cognitive Theory, Information-Motivation-Behavioral Skills model, and Social Action Theory, which together address cognitive and behavioral factors related to study outcomes. Storylines embedded prevention messages aimed at increasing treatment initiation (n=9), medication adherence (n=35), retention in care (n=22), partner protection (n=12), and communication with health care providers (n=7).
86776|NCT03508297|Diagnostic Test|In-vivo imaging|Skin cancer is imaged using RCM and a diagnosis is recorded before patient is returned to standard of care (biopsy).
86777|NCT03508271|Other|Non-Interventional|Non-Interventional
86778|NCT03508258|Other|Non-interventional|Non-interventional
86779|NCT03508258|Other|Non-Interventional|Non-Interventional
86780|NCT03508245|Other|Wearable short wavelength light therapy|Wearable short wavelength (i.e., blue-green) light-emitting glasses worn for two weeks
86781|NCT03508232|Drug|Placebo|Patients will receive placebo in a loading dose of two capsules initially followed by one capsule every 12 hours for 7 days.
86782|NCT03508232|Drug|Doxycycline Hyclate|Patients will receive doxycycline hyclate in a loading dose of two 100 mg capsules (200 mg total) initially followed by one 100 mg capsule every 12 hours for 7 days.
86783|NCT03508219|Device|BiOSS LIM C|"The BiOSS LIM C (Bifurcation Optimization Stent System, Balton, Warsaw, Poland). The BiOSS LIM C is a dedicated bifurcation stent covered with a mixture of a biodegradable polymer and the antiproliferative substance sirolimus. BiOSS LIM C will be used for treatment of the Left-Main bifurcation, according to its instructions for use.~The Alex-Plus cobaltchromium sirolimus eluting stent (Balton, Warsaw, Poland) will be used for treatment of distal left-main side branches according to its instructions for use (i.e. proximal segments of the left anterior descending and left circumflex arteries as well as the ramus intermedius if the latter vessel is part of a trifurcation).~All other lesions (other than left-main bifurcations) will be treated with XIENCE family everolimus-eluting coronary stent systems."
86784|NCT03508206|Dietary Supplement|SBRP|SBRP capsules
86785|NCT03508206|Dietary Supplement|PLACEBO|Placebo capsules
86786|NCT03508193|Other|Nutritional therapy|Whole-foods based smoothie designed to emulate formulas used in EEN
86787|NCT03508180|Behavioral|INTERVIONNAL|"Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course.~During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient."
86788|NCT03508180|Other|CONTROL|None intervention.
86789|NCT03508167|Device|Thermal Band|Thermal Band used 8 hours per day
86790|NCT03508167|Drug|Dorilax®|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
86791|NCT03508167|Drug|Placebo|"2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets."
86792|NCT03508154|Other|Control Meal 1|carbohydrate test meal
86793|NCT03508154|Other|Control Meal 2|carbohydrate test meal
86794|NCT03508154|Other|Experimental Nutritional Product|ready to drink nutritional formulation
86795|NCT03508141|Drug|Fibrinogen Concentrate|Experimental
86796|NCT03508141|Drug|Cryoprecipitate|Comparator
86797|NCT03508128|Other|surgical procedure|Surgical procedure
86798|NCT03508102|Drug|remifentanil|the effects of remifentanil on the average value of BIS at the time period of before induction , induction , intubation , skin incision, peritoneum incision, uterine incision, and delivery
86799|NCT03508089|Other|Ocular fundus on patient with Multiple Sclerosis|Ocular fundus on patient with Multiple Sclerosis
86800|NCT03508089|Other|Ocular Fundus on voluntary person|Ocular Fundus on voluntary person
86801|NCT03508076|Device|Vibrating Capsule|Patients in this group would be treated with Vibrating Capsule
86802|NCT03508076|Device|Sham Capsule|Capsules can't vibrate but look the same as Vibrating Capsule
86803|NCT03508050|Device|Clamping the Double Lumen Tube|Clamping the non-dependent lung's lumen of the double lumen tube during closed chest one-lung ventilation
86804|NCT03508037|Other|Neuromodulation electroencephalographic signals and functional electrical stimulation based|First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
86805|NCT03508011|Drug|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
86806|NCT03507998|Drug|CGX1321|CGX1321 capsules for oral administration
86807|NCT03507985|Other|Two tests evaluating memory and attention|"The patient will perform two tests assessing memory and attention:~Regarding attention, the test used will be the Stroop Color Word Test, developed to measure visual selective attention, cognitive flexibility and inhibition.~For memory, the test used will be Rey's 15 words test. It provides an indicative standard for the evaluation of episodic verbal memory and learning abilities. This test was compared to the 16-item (18) free recall / booster test in normal aging and Alzheimer's dementia, and although it was more difficult, it . Since it allowed for the classification of participants from both groups without overlap"
86808|NCT03507972|Radiation|ankle ultrasound|Ankle ultrasound performed during emergencies visit.
86809|NCT03507972|Radiation|Member MRI|Member MRI (without injection of contrast product) performed within 7 days following the trauma
86810|NCT03507959|Other|OLP scientifically-objective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
86811|NCT03507959|Other|OLP personally-affective|Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
86812|NCT03507959|Other|DP scientifically-objective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
86813|NCT03507959|Other|DP personally-affective|Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
86814|NCT03507946|Device|Dermawrap - combined 460nm, 633nm and 830nm LED therapy|Daily treatments of 15 minutes of combined LED phototherapy, 5 days per week for 12 weeks.
86815|NCT03507920|Other|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
86816|NCT03507920|Other|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
86817|NCT03507907|Other|Mulligan Mobilization for Study Group|Mulligan Mobilization techniques were applied to the older adults who included in study group.
86818|NCT03507907|Other|Conventional therapy for Control Group|Conventional therapy was applied to the older adults who included in control group.
86819|NCT03507894|Behavioral|Multimodal Exercise Rehabilitation Program|Rehabilitation program based on aerobic exercise, task oriented activities, balance and stretching exercises complemented with a mobile app technology
86820|NCT03507881|Device|fusion|Internal fixation
86821|NCT03507868|Procedure|Nonsurgical periodontal therapy|Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental plaque that is the primary etiology of periodontal diseases.
86822|NCT03507855|Other|Reduced noise|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
86823|NCT03507855|Other|Normal|No change in the normal operating room environment.
86824|NCT03507842|Drug|High dose Cytarabine|High dose Cytarabine 3.0 g/m2 q12hr 3-hour iv infusion on days 1, 3, 5 plus daunorubicin 45 mg/m2/day continuous iv infusion for 3 days (D1-3).
86825|NCT03507842|Drug|Cytarabine|cytarabine 200 mg/m2/day continuous iv infusion for 7 days (D1-7)
86826|NCT03507842|Drug|Hign dose Daunorubicin|Hign dose Daunorubicin 90 mg/m2/day continuous iv infusion for 3 days (D1-3).
86827|NCT03507829|Drug|Human insulin isophane, Humulin N (Eli Lilly)|Human insulin isophane, Humulin N (Eli Lilly)
86828|NCT03507829|Drug|Standard of care|Sliding scale short acting insulin for hyperglycemia; Sulphonylurea for NODAT
86829|NCT03507829|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|Insulin lispro, Humalog (Eli Lilly) in insulin pump
86830|NCT03507803|Other|Gait Biofeedback|Feedback will appear on screen in front of participants during walking. If their foot is too inverted (determined by researcher) the object on the screen will turn red and an audio tone will be heard. If the participant corrects the foot position, the object will turn green and the audio tone will not be heard.
86831|NCT03507790|Drug|CT1812|Active Study Drug
86832|NCT03507790|Drug|Placebo|Non-active study drug
86833|NCT03507777|Device|Coronary PCI guided by OCT|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
86834|NCT03507777|Device|Coronary PCI guided by Angiography|Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
86835|NCT03507764|Other|Use of the treadmill workstation at work|"During the randomized study phase, provision of the treadmill workstation with the recommendation to use it for at least one hour (continuous or split) during each of the working shifts.~After six months, all subjects will use treadmill without restrictions or conditions."
86836|NCT03507751|Drug|Meropenem|1.0 gram of meropenem given intravenously every 8 hours
86837|NCT03507751|Procedure|CRRT|Continuous renal replacement therapy for three days
86838|NCT03507738|Biological|MT-5625 low dose|Intramuscular injection
86839|NCT03507738|Biological|MT-5625 middle dose|Intramuscular injection
86840|NCT03507738|Biological|MT-5625 high dose|Intramuscular injection
86841|NCT03507738|Biological|Rotarix|Oral administration
86842|NCT03507738|Biological|Placebo|Intramuscular injection
86878|NCT03507426|Procedure|Retrobulbar block|Patients will receive a single retrobulbar injection with 3-4ml of an equal mixture of Lidocaine 2% & Bupivacaine 0.5% + Hyaluronidase (10 IU/ml), after induction of general anesthesia.
86993|NCT03506672|Other|Usual practices|Usual practices of formal caregivers regarding vocal behaviours
86843|NCT03507725|Behavioral|Meditation|"The brief mind-body intervention, specifically developed for this study, is a combination of mindfulness meditation with a specific cognitive component of guided imagery. Patient intervention, they will be given headphones connected to an MP4 player in the clinic area to listen to a pre-biopsy mindfulness exercise (10 minutes). They will then be brought into the biopsy procedure room and given a second set of headphones, guiding the patient through the mindfulness intervention during the biopsy procedure (10 minutes)."
86844|NCT03507725|Procedure|Prostate Biopsy|Prostate needle biopsy under local anesthesia
86845|NCT03507712|Procedure|Symmetrical IO weakening|Bilateral IO Myectomy / Bilateral equal graded IO Recession
86846|NCT03507712|Procedure|Asymmetrical IO weakening|IO Myectomy in one eye - IO Recession in the fellow eye / Bilateral IO Recession (different amounts) in each eye
86847|NCT03507699|Radiation|Liver radiation therapy|21 Gy in three fractions to one liver metastasis
86848|NCT03507699|Drug|Nivolumab Injection [Opdivo]|administered IV at a dose of 3mg/kg every 2 weeks
86849|NCT03507699|Drug|Ipilimumab Injection [Yervoy]|administered IV at a dose of 1mg/kg every 6 weeks
86850|NCT03507699|Drug|CMP-001|A TLR9 agonist, will be administered both into the liver metastasis (three times), and also injected subcutaneously at a dose of 5-10 mg every two weeks.
86851|NCT03507686|Drug|AAV2-REP1|Sub-retinal injection of AAV2-REP1 after vitrectomy.
86852|NCT03507673|Diagnostic Test|Blood samples and microbiological swaps|Blood analysis and analysis of vaginal microbiota.
86853|NCT03507660|Other|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
86854|NCT03507647|Behavioral|Mindfulness Based Cognitive Therapy|"MBCT is a manualised group skills-training program (Segal, Williams & Teasdale 2012) consisting of eight weekly sessions of 2.5 hours, plus one day of silent practice. The program includes both formal and informal meditation exercises. Cognitive techniques that are part of the program are education, monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan.~The MBCT treatment will be adapted to address the needs of patients with a bipolar disorder. A few examples of these adaptations are: (more) psychoeducation about manic symptoms in addition to the psychoeduction about depression; introducing the 3-minute breathing space earlier in the programme and more often during sessions, especially when strong emotions are present; repeatedly bringing the focus to self-care; and making use of the mindful movement (yoga) exercises more frequently."
86855|NCT03507647|Other|Usual Care|Usual care will typically consist of pharmacotherapy, psycho-education and self-management interventions (usually with a psychiatric nurse). Usual care will not be restricted, except for proscribing high-frequency psychological interventions such as (group) cognitive behavioral therapy, for practical and methodological reasons.
86856|NCT03507634|Drug|Opioid free Anesthesia dexmedetomidine and lidocaine|Opioid free anesthesia with dexmedetomidine and lidocaine
86857|NCT03507634|Drug|Opioid based anesthesia Fentanyl and Remifentanyl|Opioid based anesthesia with Fentanyl and Remifentanyl
86858|NCT03507608|Drug|Flutamide|50mg flutamide prior to brachytherapy and prostatic biopsy
86859|NCT03507608|Other|Placebo|placebo prior to brachytherapy and prostatic biopsy
86860|NCT03507582|Other|Virtual Reality Distraction|This intervention consists of a disposable virtual reality headset which will enable the use of virtual reality in clinic through the commodity hardware iPod Touch. An additional piece of software on an iPad will allow clinical staff to act as an orchestrator and trigger events that occur for the patient's benefit in the virtual reality environment. The mechanism for the dashboard will be dashboard software running on an iPad tablet that will wirelessly communicate to the iPod Touch the patient is wearing. A study timer will be incorporated into the orchestration dashboard. The VAS/FACES scale will be incorporated into the iPad used for orchestration.
86861|NCT03507582|Other|Standard of Care Distraction|This intervention consists of a two dimensional distraction (ie TV/tablet) as well as verbal distraction (ie singing/talking/music) will be allowed by caregivers, nurses and phlebotomy staff but will not qualified or quantified. IV procedures will proceed in Groups A and B. At the completion of the IV procedure the nurse orchestrator will stop the procedure timer. The Subject, Guardian and Nurse orchestrator will complete the Final VAS/FACES assessment on the iPad.
86862|NCT03507569|Drug|RO7017773|RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
86863|NCT03507569|Other|[11C] Ro15-4513|At the start of each PET scan, participants will receive an intravenous dose of the radiolabeled tracer [11C]Ro15-4513.
86864|NCT03507556|Procedure|Triple paste and induced bleeding|
86865|NCT03507556|Drug|Triple Paste metronidazole, ciprofloxacin and minocycline mixed with sterile glycol|triple paste of metronidazole, ciprofloxacin and minocycline mixed with sterile glycol
86866|NCT03507543|Drug|IMP4297|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
86867|NCT03507530|Other|Assessments|Falls related assessments, functional physical performance evaluations and quality of life assessments.
86868|NCT03507504|Other|SCU-B|"SCU-B is a residential medical structure lying outside of a nursing home, in a general hospital or elsewhere, e.g. in a private hospital, where patients with BPSD are temporarily admitted when their behavioural disturbances are not amenable to control at home."
86869|NCT03507491|Drug|Gemcitabine|Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will be fixed at 1000 mg/m2/dose throughout the study.
86870|NCT03507491|Drug|Nab-paclitaxel|Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3). If the MTD has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated with nab-paclitaxel at a dose of 150 mg/m2/dose (dose level 0).
86871|NCT03507478|Device|BPI1000013|Foam insole
86872|NCT03507465|Drug|Letrozole Plus Low-Dose Metronomic Capecitabine|Letrozole Plus Low-Dose Metronomic Capecitabine
86873|NCT03507465|Drug|EC-T|Epirubicin/Cyclophosphamide Followed by Docetaxel
86879|NCT03507426|Procedure|Ketamine|Patients will receive a 0.5 mg/kg bolus followed by an infusion of 0.25 mg/kg/h of intravenous Ketamine, after induction of general anesthesia.
86880|NCT03507413|Drug|Metformin Glucophage 500mg (IR) tablets M90|oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
86881|NCT03507413|Drug|Placebo Oral Tablet|Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
86882|NCT03507400|Behavioral|Introvision: mental and emotional self-regulation|Participants learn Introvision
86883|NCT03507387|Drug|Phenylephrine|5 mg (1ml) phenylephrine intramuscular injection will be given into the gluteus maximus muscle before anesthesia.100ug (1ml) phenylephrine intravenous injection will be given after the subarachnoid injection is completed .
86884|NCT03507387|Drug|Normal saline|1ml 0.9% normal saline intramuscular injection will be given into the gluteus maximus muscle before anesthesia and after the subarachnoid injection is completed.
86885|NCT03507387|Drug|Bupivacaine|All patients will receive spinal anesthesia with bupivacaine.
86886|NCT03507374|Drug|Alirocumab|Alirocumab is approved by the FDA as a secondary treatment for high cholesterol for adults whose cholesterol can not be controlled by diet and/or statin treatment. Additionally, Alirocumab works to inhibit the PCSK9 protein.
86887|NCT03507374|Drug|Placebo|Placebo to be administered subcutaneously every 2 weeks identical to active drug (alirocumab)
86888|NCT03507361|Other|HRV-BASED MUSIC|Music is produced by Sound-of-Soul technology that translates HRV power frequency spectrum real-time into music. The intervals between the heartbeats are detected in milliseconds and then transferred into a frequency spectrum. Sound of Soul system gets wired into different band pass filters which are linked to the frequencies of the heart (i.e. low frequency and high frequency). Once the signal is detected and computed, the Sound of Soul system links it through a musical instrument digital interface (MIDI). This interface transforms ECG data into music and sounds. The audio production is performed using a virtual instrumentation technology with different music libraries. For the puropose of this study, all patients will ear the same instrument (arp). Once the instrument have been selected, the ECG gets recorded and in real-time the patient can hear a music obtained from his/her own HRV. The investigator will control the volume and the different settings of the music.
86889|NCT03507348|Drug|visits of tocilizumab injection (every 4 weeks, up to 5 visits)|every 4 weeks, up to 5 visits (D-170, D-142, D-114, D-86, D-58).
86890|NCT03507348|Drug|Rituximab 375 mg/m2 at Day-30|Rituximab 375 mg/m2 at Day-30
86891|NCT03507348|Drug|Rituximab 375 mg/m2 at Day-15 (only for donors living)|Rituximab 375 mg/m2 at Day-15
86892|NCT03507348|Other|Transplant Day-0|TRANSPLANTATION
86893|NCT03507335|Device|chest strap and PPG-device for monitoring the rhythm|chest strap and PPG-device for monitoring the rhythm during 24 hours for both groups (atrial fibrillation and sinus)
86894|NCT03507322|Other|Ultrasound texturization|Along several visits to the clinic, the patients will be subjected to 2D/3D ultrasound scanning.
86895|NCT03507283|Procedure|Double head pterygia excision and repair|Complete excision of the pterygia was done. A free conjunctival autograft was obtained. The graft was divided vertically into two parts then secured into conjunctival defects.
86896|NCT03507270|Diagnostic Test|FABP|Assessment of changes in FABP concentrations
86897|NCT03507257|Drug|Flortaucipir|All participants will receive a single bolus intravenous injection of approximately 10 mCi (+/- 10%, 20μg mass dose) of flortaucipir (18F-AV-1451). At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
86898|NCT03507257|Drug|Florbetaben|All participants will receive a single bolus intravenous injection of approximately 8 mCi +/- .8mCi of florbetaben (AV-45). At approximately 90-minutes (+/- 10 minutes) post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
86899|NCT03507244|Drug|Pemetrexed|Pemetrexed, 10 mg,intrathecal injection, plus dexamethasone 5 mg, once per week, 5 to 8 times, 4 to 7 weeks in total.
86900|NCT03507244|Drug|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection, simultaneously with pemetrexed, once per week, 5 to 8 times, 4 to 7 weeks in total.
86901|NCT03507244|Radiation|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
86902|NCT03507231|Behavioral|Email Message|Participants will randomly receive an e-mail message about the availability of free flu vaccines.
86903|NCT03507231|Behavioral|Incentive for Vaccination|$5 gift card offered for vaccination
86904|NCT03507231|Behavioral|Incentive for completing a short survey|$5 gift card offered for completing s short survey after one gets vaccinated
86905|NCT03507205|Device|Biomatrix; Biomatrix Flex; Nobori|Biodegradable polymer-coated biolimus-eluting stents
86906|NCT03507205|Device|Xience Prime|Durable polymer-coated everolimus-eluting stents
86907|NCT03507205|Device|Xience V/Promus; Cypher|Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
86908|NCT03507205|Device|DP-ZES-RI|Durable polymer-coated zotarolimus-eluting stents
86909|NCT03507205|Device|Endeavor; Resolute|Durable polymer-coated zotarolimus-eluting stents
86910|NCT03507192|Device|Muscle relaxation using full body massage machine|Receiving muscle relaxation machine massage every morning and evening for 30 minutes during a year
86911|NCT03507179|Other|3d printed denture|construction of a 3d printed denture through a recent method instead of conventional processing
86912|NCT03507179|Other|conventional dentures|conventional dentures
86913|NCT03507166|Drug|RC48-ADC|2 mg/kg IV every 2 weeks
86914|NCT03507153|Procedure|Bre-flex maxillary partial denture|Partial denture fabricated from Bre.flex material.
86915|NCT03507153|Procedure|PEEK maxillary partial denture|Partial denture fabricated from PEEK material.
86916|NCT03507140|Other|Multiple sampling|"Bile, saliva, feces, urine et blood samples before and after liver transplantation in recipients.~Bile, saliva, feces, urine et blood samples during liver removal in donors."
86917|NCT03507127|Drug|Varenicline|Standard dosing: 0.5 mg/day on days 1-3, 0.5 mg twice daily (morning, evening) on days 4-7, then 1 mg twice daily to the end of the medication period.
86918|NCT03507127|Drug|Placebo|Dosing schedule matched to active comparator: on tablet on days 1-3, one tablet twice daily (morning, evening) on days 4-7, then one tablet twice daily to the end of the medication period.
86919|NCT03507114|Behavioral|Rumination-Focused CBT (RFCBT)|RFCBT consists of six online modules that include psycho-education, mood diaries, on-line experiential exercises using audio-recordings & vignettes of participants experiences of the therapy.
86920|NCT03507101|Other|No intervention|No particular intervention or exposure is of particular interest
86921|NCT03507088|Drug|Fluoroestradiol (18F)|A FES-PET/(CT) will be performed twice during protocol execution. Patients will be injected with approximately 222 MBq 18F-FES each time.
86922|NCT03507075|Behavioral|Contingency management: Contingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
86923|NCT03507075|Behavioral|Contingency management: Noncontingent incentives|Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
86924|NCT03507062|Other|0.9% saline administration|Each patient will receive 0.9%saline based on attending physician decision
86925|NCT03507062|Other|Ringer's lactate administration|Each patient will receive Ringer's lactate based on attending physician decision
86926|NCT03507062|Other|Ringer's acetate administration|Each patient will receive Ringer's acetate based on attending physician decision
86927|NCT03507062|Other|Plasmalyte-like solution administration|Each patient will receive Plasmalyte-like solution based on attending physician decision
86928|NCT03507049|Procedure|iFuse|ifuse will be implanted as described in section on the active comparator arm of the study.
86929|NCT03507049|Procedure|sham group|sham surgery will be performed as desrcribed in section on sham comparator.
86930|NCT03507049|Radiation|fMRI study|Quantitative sensory testing, cerebral MRI and functional MRI will be done to examine pain mechanism and activation in the central nervous system.
86931|NCT03507036|Device|Profound system|Profound system is a bipolar fractional radiofrequency device which uses microneedles and thermal heat to stimulate neocollagenesis. Based on the its effect on facial skin, it can be hypothesized that bipolar fractional radiofrequency will stimulate similar effect on suprapatellar skin, lifting and reducing laxity of the skin in that region. Bilateral suprapatellar regions will be identified and marked for treatment.
86932|NCT03507023|Dietary Supplement|Metabolaid®|500 mg per day, in fasting conditions.
86933|NCT03507023|Dietary Supplement|Placebo|500 mg per day, in fasting conditions.
86934|NCT03507010|Radiation|Radiotherapy|Patients randomized to the Radiotherapy arm will be treated with electrons and receive a total dose of 30 Gy (two separate courses of five daily fractions of 3.0 Gy each).
86935|NCT03507010|Other|Sham Radiotherapy|Patients randomized to the sham-radiotherapy will not be treated and the radiotherapy treatment will only be simulated.
86936|NCT03506997|Drug|Pembrolizumab|Pembrolizumab 200mg given as a 30 minute intravenous (IV) infusion, on day 1 of each 3 week cycle. Patients may continue with pembrolizumab treatment as long as they remain free from intolerable toxicity for a maximum of two years, if in the Investigator's opinion they are receiving clinical benefit, and/or they do not meet any discontinuation criteria.
86937|NCT03506984|Device|Threshold Inspiration Muscle Training Device|Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
86938|NCT03506984|Device|Electronic Bicycle Ergometer|Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
86939|NCT03506971|Other|Psychologist's evaluation|The research coordinator psychologist will evaluate: the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.
86940|NCT03506971|Other|Pediatric Nurse's interventions|"Pediatrics nurses perform preventive home visits that are based on : joint observation with the parents of the baby, play with the baby and his parents, interview with the parents on their parenthood~Rhythm of home visits:~1 every month from birth to 1 year~1 every 2 months from 1 year to 2 years~1 every 3 months from 2 years to 4 years"
86941|NCT03506971|Other|Joint home visits|"Coordinating psychologist and the referent pediatric nurse will perform home visits. During this time, the psychologist evaluate : the development of the baby, the early interactions between the baby and his mother, attachment, maternal psychiatric symptoms, the experience of parenting and maternal sensitivity.~Rhythm of joint home visits:~1 at 4 months~1 at 24 months"
86942|NCT03506958|Procedure|Standard trauma care|In both groups, all procedures and management will be done according to the hospital's standard of care.
86943|NCT03506945|Behavioral|mPEP|Behavioral Activation Therapy
86944|NCT03506945|Behavioral|Bibliotherapy|Provide educational material on coping strategies pertinent to caregivers
86945|NCT03506932|Dietary Supplement|Untreated|Bread made with 20% yellow pea flour that was untreated.
86946|NCT03506932|Dietary Supplement|Heat treated with 0% moisture|Bread made with 20% yellow pea flour that was heat treated with 0% moisture.
86947|NCT03506932|Dietary Supplement|Heat treated with 10% moisture|Bread made with 20% yellow pea flour that was heat treated with 10% moisture.
86948|NCT03506932|Dietary Supplement|Wheat|Bread made with 100% wheat
86949|NCT03506919|Drug|Allopurinol|Allopurinol is used to treat gout and certain types of kidney stones. It is also used to prevent increased uric acid levels in patients receiving cancer chemotherapy. These patients can have increased uric acid levels due to release of uric acid from the dying cancer cells. Allopurinol works by reducing the amount of uric acid made by the body. Increased uric acid levels can cause gout and kidney problems
86950|NCT03506906|Diagnostic Test|Sleep studies under noninvasive ventilation therapy|Polysomnography Transcutaneous capnography
86951|NCT03506906|Diagnostic Test|Routine tests|Spirometry, six minute walk test, blood gas analysis, questionnaires (Epworth sleepiness score, health related quality of life severe respiratory insufficiency questionnaire)
86952|NCT03506893|Device|Alphapump|"Alfapump® device: a completely internalized medical device, implanted under the skin, which mobilizes ascites from the peritoneal cavity to the bladder where they are eliminated by the urinary tract.~Medical device marked CE, used in the indication provided for marking"
86953|NCT03506893|Procedure|Ascites puncture|Hospitalizations for evacuating ascites are performed at least twice a month and can be up to 2 times a week. A clinical and biological examination is carried out at each visit.
86954|NCT03506880|Behavioral|MADD Materials|
86955|NCT03506880|Behavioral|Surgeon General Materials|
86956|NCT03506867|Behavioral|Life skills, training, education and work/volunteer opportunities|Intervention arm will receive proactive and sustained access to enhanced education and socio-economic supports (e.g. volunteer and/or work opportunities).
86957|NCT03506867|Behavioral|Standard Care|Usual care will receive information on locally available services.
86958|NCT03506854|Drug|ISIS 681257|Xmg dose administered as a subcutaneous injection
86959|NCT03506841|Drug|Cerebrolysin|Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
86960|NCT03506828|Procedure|Surgical sympathectomy|thoracoscopic sympathectomy
86961|NCT03506828|Procedure|Radiofrequency ablation with phenol injection|All patient in this group will have radiofrequency ablation of T2 and T3 sympathetic ganglia with phenol injection
86962|NCT03506815|Drug|Rivaroxaban 10 MG|Rivaroxaban 10mg po daily x 90 (+/- 3 days)
86963|NCT03506802|Radiation|18F-FHBG|Given IV
86964|NCT03506802|Biological|Aldesleukin|Given SC
86965|NCT03506802|Biological|Cellular Therapy|LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV
86966|NCT03506802|Procedure|Computed Tomography|Undergo PET/CT
86967|NCT03506802|Biological|Filgrastim|Given SC
86968|NCT03506802|Other|Laboratory Biomarker Analysis|Correlative studies
86969|NCT03506802|Drug|Lenalidomide|Given PO
86970|NCT03506802|Procedure|Leukapheresis|Undergo leukapheresis
86971|NCT03506802|Drug|Melphalan|Given IV
86972|NCT03506802|Drug|Plerixafor|Given SC
86973|NCT03506802|Procedure|Positron Emission Tomography|Undergo PET/CT
86974|NCT03506789|Drug|Dexamethasone|Dexamethasone 24 mg
86975|NCT03506789|Drug|Placebos|Isotonic saline
86976|NCT03506776|Device|Education and Thermometer Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity. One-on-one teaching with the thermometer will be provided. Participants will be given a handout for reference on using the thermometer. The foot model will be marked with a zigzag pattern on the plantar surface to illustrate the path that should be used when measuring temperature. The support person will be included in the teaching if he/she will be assisting the participant to obtain temperature readings.
86977|NCT03506776|Other|Education Only Group|The education will be provided in video format utilizing the Canadian Association of Wound Care (CAWC) diabetic foot management YouTube video and one-on-one teaching. Participants will be provided with an inspection mirror with an extendable handle to assist with visualizing the bottom of the feet and a pedometer to measure daily activity.
86978|NCT03506763|Drug|Placebo Oral + Placebo Oral|Placebo Oral + Placebo Oral
86979|NCT03506763|Drug|Diclofenac oral + Placebo Oral|Diclofenac oral + Placebo Oral
86980|NCT03506763|Drug|Diclofenac oral + scopolamina oral|Diclofenac oral + scopolamina oral
86981|NCT03506750|Drug|IVC|Patients with PDR will receive intravitreal injection of conbercept (0.5 mg/0.05 mL; Chengdu Kanghong Biotech, Inc., Chengdu, Sichuan, China) in the inferior-temporal sector 4 mm from the sclerocorneal limbus before pars plana vitrectomy (PPV) surgery.
86982|NCT03506750|Procedure|Blood and aqueous humor at the time of IVC|Initial blood and aqueous humor will be harvested at the time of IVC.
86983|NCT03506750|Procedure|Collect blood, aqueous humor, and initial vitreous at the time of surgery.|Blood, aqueous humor, and vitreous will be collected at the time of surgery.
86984|NCT03506750|Procedure|IVC-sham|Patients with PDR will receive sham intravitreal injection of conbercept in the inferior-temporal sector 4 mm from the sclerocorneal limbus 4 days before PPV surgery.
86985|NCT03506737|Other|Conventional exercise protocol|Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position
86986|NCT03506737|Other|Cycle ergometer exercise protocol|Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
86987|NCT03506724|Drug|Nifedipine|Nifedipine 10mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, nifedipine 20mg oral will be given and the MAP will then be calculated 20 minutes after medication is given and institution specific protocol will be performed.
86988|NCT03506724|Drug|Labetalol|Labetalol 20mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 40mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, labetalol 80mg IV will be given over 2 minutes and the MAP will then be calculated 10 minutes after medication is given. If SBP is ≥160mmHg or DBP is ≥110mmHg, then another medication will be chosen based on institution specific protocol.
86989|NCT03506711|Diagnostic Test|Isometric Handgrip Exercise during magnetic resonance imaging|Coronary endothelial function are assessed by MRI with imaging studies done at baseline (at rest) and during IHE (under stress). Maximum grip strength is determined using an MRI-compatible dynamometer (Grip Force Fiber Optic Response Pad, Current Designs Inc., Philadelphia, USA) prior to baseline imaging.
86990|NCT03506698|Other|Kangaroo Mother Care (KMC)|Skin to skin contact of newborns with mothers or caregiver for a minimum of at least eight hours over a 24-hours period, along with exclusive breastfeeding or breast milk feeding via tube or spoon
86991|NCT03506685|Other|Dry needling and STM|dry needling and soft tissue mobilization
86992|NCT03506672|Other|Approach based on the meanings of vocal behaviours|Systematic problem-solving approach involving reflecting, deciding, planning and acting together (family and formal caregivers to reduce vocal behaviours and to increase everyone's well-being.
86994|NCT03506659|Device|SUDO-SCAN Device|Sudo-scan is a machine with 2 palets for hands and 2 palets for foots. The patient has to put his 2 hands and 2 foots on the machine. The machine do the measures during 2 minutes.
86995|NCT03506646|Dietary Supplement|Beetroot juice|Beetroot juice serves as a mode of dietary nitrate supplementation. This will be a double-blinded, randomized, cross-over design to examine the effects of beetroot juice on endothelial function, leg function, and thermoregulation.
86996|NCT03506633|Dietary Supplement|MitoQ|"A mitochondrial-targeting antioxidant MitoQ or a placebo will be given to each subject in a crossover, double-blinded design and measures of leg function and leg blood flow will be measured."
86997|NCT03506620|Drug|Ropivacaine injection|Naropin (Ropivacaine HCl) 0.25%; Dose: 20 cc
86998|NCT03506620|Drug|Saline Solution for Injection|20 cc of saline will be injected in the form of a QL block as a placebo.
86999|NCT03506607|Other|Exercise in hypoxia 1500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 16%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
87000|NCT03506607|Other|Exercise in hypoxia 2500m|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). The ambient air will be mixed with nitrogen and inspired oxygen fraction will be reduced to 14%. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
87001|NCT03506607|Other|Exercise in normoxia|Subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air. The first 3 min will be performed at 70% of the mean speed calculated during a previous visit, and the last 3 min at an intensity between 12-14 on the Borg's scale.
87002|NCT03506594|Device|Radiofrequency non ablative|The application of RF was performed by physical therapist trained in the technique of radiofrequency through the Capenergy® brand device with capacitive transfer method using non-ablative handle with active electrode placed intra-vaginal and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration above 20 minutes. The temperature was measured by an infrared thermometer and when it reached 41graus radiofrequency was maintained for 2 minutes in the anterior wall and 2 other minutes in the posterior wall of the vagina.
87003|NCT03506568|Device|Devers Drop Device (D3) app|A universal eye drop cap monitor that accurately measures and improves eye drop-taking behavior.
87004|NCT03506568|Device|Smart phone calendar app|Smart phone calendar app will be updated to give a scheduled medication alert.
87005|NCT03506555|Procedure|Laparoscopic peritoneal entry technique: Veress needle versus Hasson|According to randomization, the closed (Veress needle) or the open (Hasson) laparoscopic entry technique was utilized for general surgical operations
87006|NCT03506542|Device|Ologen|Ologen implant placed over scleral flap during the surgery to avoid usage of Mitomycin C
87007|NCT03506542|Procedure|Phacotrabeculectomy|Trabeculectomy with cataract extraction
87008|NCT03506542|Drug|Mitomycin C|Mitomycin C 0.3 mg/ml for 3 minutes during the surgery (standard procedure)
87009|NCT03506529|Other|questionnary|questionnary on predictif factors about physiological hypermetabolism of anal canal
87010|NCT03506516|Dietary Supplement|Mixing alcohol|Alcoholic beverages, different types
87011|NCT03506516|Dietary Supplement|Single type alcohol|Alcoholic beverages, different types
87012|NCT03506503|Procedure|Nanofat grafting|hair loss area will be treated by processed autologous Nanofat grafting
87013|NCT03506490|Other|Aerobic exercises|The training session lasted 45 minutes and was composed of running exercises.
87014|NCT03506477|Drug|Enstilar® foam|for 4 weeks
87015|NCT03506477|Drug|Vehicle foam|for 4 weeks
87016|NCT03506464|Procedure|Myofascial Release Technique|The same described in the arm description
87017|NCT03506451|Other|Demographics questionnaires and the FACT HN questionnaire|Patients will complete a baseline survey assessing socioeconomic household information, baseline symptoms, QOL, and financial toxicity, as well as attitudes toward cost conversations and educational handouts.
87018|NCT03506438|Behavioral|Needs-focused mobile app|A mobile web app designed to assist both ICU clinicians in addressing patient/family needs and families in reporting their unmet needs.
87019|NCT03506438|Other|Usual care|Usual ICU care
87020|NCT03506425|Drug|Triheptanoin|Triheptanoin is a medium chain triglyceride (MCT) that can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indeed, triheptanoin slowed motor neuron loss and delayed the onset of weakness in a mutant SOD1 model of ALS. The Triheptanoin we will use is a colorless to light yellow oil. The target triheptanoin dose for this study is 1g/kg/d. This target dose was selected because it was safe and tolerable and altered brain MR spectroscopy in patients with Huntington's Disease.
87021|NCT03506412|Drug|Entresto™ 49Mg-51 mg tablet|Entresto™ 49Mg-51 mg will be given twice daily orally for 5 weeks
87022|NCT03506399|Drug|Lanabecestat|Administered orally
87023|NCT03506399|Drug|Oral Contraceptive|Administered orally
87024|NCT03506373|Drug|Ibrutinib|Given PO
87025|NCT03506373|Drug|Ixazomib Citrate|Given PO
87026|NCT03506373|Other|Laboratory Biomarker Analysis|Correlative studies
87027|NCT03506373|Other|Pharmacodynamic Study|Correlative studies
87028|NCT03506373|Other|Pharmacokinetic Study|Correlative studies
87029|NCT03506360|Drug|Dexamethasone|Given PO
87030|NCT03506360|Drug|Ixazomib Citrate|Given PO
87031|NCT03506360|Other|Laboratory Biomarker Analysis|Correlative studies
87032|NCT03506360|Biological|Pembrolizumab|Given IV
87033|NCT03506347|Drug|Vancomycin|Antibiotic
87034|NCT03506334|Device|AVBT using Dynesys System Components|Zimmer Biomet Tether System and Dynesys System components are intended to treat scoliosis in skeletally immature children.
87959|NCT03499418|Other|modified Silverman scale|Clinical assessment of severity of respiratory failure
87035|NCT03506334|Procedure|Spine fusion|Children with scoliosis undergoing fusion surgery will form the control arm
87036|NCT03506321|Diagnostic Test|chromoendoscopy, high definition white light and narrow band imaging|Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar
87037|NCT03506308|Device|LUTONIX 035 Drug Coated Balloon PTA Catheter|All subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
87038|NCT03506295|Device|Radial Endobronchial Ultrasound Probe|The radial EBUS procedure is performed by inserting a miniature ultrasound probe (radial EBUS probe) through the working channel of a flexible bronchoscope or catheter (guide sheath). Real-time imaging of the surrounding tissue enables the clinician to determine the lesion's exact location and size.
87039|NCT03506295|Device|Flouroscopy|Real-time fluoroscopy will be used in all cases to guide the radial probe ultrasound and/or cryobiopsy probe placement.
87040|NCT03506282|Other|Running while listening to a traffic audio track|While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
87041|NCT03506282|Other|Running with music at moderate volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB)."
87042|NCT03506282|Other|Running with music at moderate-to-high volume|"While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB)."
87043|NCT03506256|Drug|Norfloxacin 400 MG|Norfloxacin is an oral fluoroquinolone antimicrobial agent used for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication and is active in vitro against virtually all bacterial pathogens causing urinary tract8
87044|NCT03506243|Biological|Follitrope PFS|Follitrope PFS
87045|NCT03506243|Biological|Gonal-f pen|Gonal-f pen
87046|NCT03506230|Behavioral|Incentives|A bonus to buy their medications if they reduce their HBA1c
87047|NCT03506217|Device|Vigileo Flo-trac device|A Vigileo Flotrac pulse counter invasive arterial cardiac output meter was used for cardiac output measurement. Heart rate, blood pressure, cardiac output, stroke volume variance (SVV), systemic vascular resistance (SVR) values were recorded.
87048|NCT03506178|Drug|Oxymetazoline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
87049|NCT03506178|Drug|Menthol Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
87050|NCT03506178|Drug|Normal saline Nasal Spray|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
87051|NCT03506178|Device|Nasal mask with partly blocked|Obstructive sleep apnea (OSA) Patients and healthy controls were treated with 4 different nasal intervention ,including Oxymetazoline Nasal Spray,Normal saline Nasal Spray,Menthol Nasal Spray or Nasal mask with partly blocked when they sleep onset. At the treatment periods, polysomnograpy, genioglossus enlectromyography, pharyngeal current perception threshold and sleep quality scores were assess.
87052|NCT03506165|Combination Product|Periodontal treatment|oral hygiene instructions, periodontal debridement and removal of other etiologic factors
87053|NCT03506152|Diagnostic Test|Serum Procalcitonin|Seven ml of blood was drawn in gel separator tubes within 24 hours of admission in ICU for Procalcitonin determination
87054|NCT03506139|Radiation|External beam radiation therapy|Radiotherapy to 75 Gy Radiation delivered 1 fraction / day, Monday through Friday, for a total of 30 fractions
87055|NCT03506126|Other|Leucine|There are 8 different leucine test levels ranging from 20 to 120 mg of leucine per kilogram body weight per day (20-120 mg/kg/d)
87056|NCT03506113|Drug|Gram stain-guided antibiotic choice|The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics.
87057|NCT03506113|Drug|Guidelines-based antibiotics choice|Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to IDSA/ATS guidelines
87058|NCT03506100|Other|Water Walking|Practice swimming complemented with water walking at the end of each session and those who only practice swimming. In this study participated 28 subjects (mean age, 7.68 ± 1.16 years) and was divided into two groups: swimming group (SG) (N=9) and swimming complemented with water walking group (SWWG) (N=19). The study was performed in 12 weeks with 3 moments of evaluation (M1, M2 and M3) , with two sessions per week of 45 minutes each, we wanted to identify the benefits in pulmonary function - Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1) and Peak Expiratory Flow (PEF). The water walking activity occurred in the end of each session for 6 minutes, performed in straight line with the water level at the children's chest. The spirometry tests were realized with the microQuark Spirometer®.
87088|NCT03505788|Drug|Acetazolamide|In the experimental group, the patient will receive the standard of care loop diuretics and acetazolamide
87089|NCT03505788|Drug|Placebo|In the placebo group, the patient will receive the standard of care loop diuretics and the placebo
87148|NCT03505424|Other|Group 2: NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.
87059|NCT03506087|Behavioral|Advance care planning coaching session.|A 60-minute in-person coaching session. The advance care planning coach, trained in motivational interviewing, will use a flexible script and checklist to assess the participant's readiness to engage in advance care planning and guide the participant forward in the process, proceeding at the participant's pace. Some participants may complete advance directives while others will not get that far. Some participants may receive a follow-up session 2-4 weeks later. Typically this 20 to 30-minute conversation will be by phone, but it may be conducted at the clinic as indicated for the participant.
87060|NCT03506087|Behavioral|Printed advance care planning materials|Participants are provided with a folder containing an advance care planning guide developed by the Coalition for the Supportive Care of Kidney Patients for persons with Chronic Kidney Disease. The patient folder also contains the advance directive form used by the clinic that is appropriate to the state.
87061|NCT03506074|Diagnostic Test|Flavor test|The flavor test was developed, validated and patented (patent no. 0001426253 of the Italian Ministry for the Economic Development). It consists of a series of 20 aromatic extracts, corresponding to routine dietary use flavors for Italian people. At each administration, participants were invited to identify the aromatic by making a choice from 5 proposed items. A total of 21 aromatics (including one blank) were administered sequentially. The flavor score (FS) was calculated as the sum of correctly identified aromatics and ranged from 0 to 21.
87062|NCT03506061|Drug|Symdeko|Participants will take Symdeko which is comprised of a combination tablet of 100 milligrams (mg) of tezacaftor and 150 mg of ivacaftor (taken in the morning), and 150 mg of ivacaftor taken in the evening.
87063|NCT03506048|Drug|Lenvatinib|Given orally once daily continuously
87064|NCT03506035|Diagnostic Test|Research new biomarker for RA|Analyze T and B cell response against new citrullinated peptides
87065|NCT03506022|Other|standard polysomnography|All participants were admitted in sleep laboratory and screened for one night of 8 hours employing standard polysomnography (Brainnet System - Medatec) parameters : electroencephalogram, electro-oculogram, electromyogram [chin], continuous nasal airflow body position, thoracic and abdominal strain gauges, haemoglobin oxygen saturation (SaO2) with an oximeter (Medatec) attached to finger. Blood pressure was measured in the evening during the physical examines, and then the CGMS recording startedpressure was measured in the evening during the physical examines, and then the CGMS recording started
87066|NCT03506009|Drug|Argatroban combined with rt-PA|Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
87067|NCT03506009|Drug|rt-PA|Intravenous throbolysis with 0.9mg/kg rtPA.
87068|NCT03505996|Biological|CS1001|Monoclonal antibody
87069|NCT03505983|Device|ESR Prosthetic Foot First|Subjects will start with an ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
87070|NCT03505983|Device|Articulating ESR Prosthetic Foot First|Subjects will start with an articulating ESR foot first for 1 week, then will complete an additional week with an articulating ESR foot and a powered foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
87071|NCT03505983|Device|Powered Prosthetic Foot First|Subjects will start with a powered prosthetic foot first for 1 week, then will complete an additional week with an articulating ESR foot and an ESR foot for 1 week. The final 4 weeks of the study, all prosthetic feet will be available and subjects can self-select which foot to use.
87072|NCT03505970|Dietary Supplement|Sodium bicarbonate|Sodium bicarbonate in powder form ingested in gelatine capsules. This leads to an increase bicarbonate concentration in blood, increasing buffering capacity which may lead to improvements in exercise
87073|NCT03505970|Dietary Supplement|Maltodextrin|Maltodextrin will be used as a placebo as it will not lead to any increases in circulating bicarbonate and, at this dose, will not likely have any physiological effect.
87074|NCT03505957|Device|SafeBreak Vascular|SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
87075|NCT03505944|Drug|Venetoclax|venetoclax + lenalidomide + rituximab
87076|NCT03505931|Device|Implantation of Eluvia stent|Implantation of Eluvia stent
87077|NCT03505918|Other|No referral for rehabilitation|Intervention is that some patients will not be refered for postoperative physiotherapy.
87078|NCT03505905|Drug|Pregnenolone|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
87079|NCT03505905|Drug|Placebo|In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
87080|NCT03505866|Behavioral|Community home-based care intervention|HIV-positive people who received community home-based care intervention on a monthly basis for six months after they enrolled in the program.
87081|NCT03505853|Drug|Givosiran|single dose of givosiran by subcutaneous (sc) injection
87082|NCT03505853|Drug|5-probe cocktail|includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
87083|NCT03505840|Diagnostic Test|Ultrasound with Doppler and 3D technology|ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology
87084|NCT03505827|Diagnostic Test|24-2 SITA Standard Humphrey Visual Field Test|Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
87085|NCT03505814|Device|High Flow Nasal Cannula Oxygen therapy (OPTIFLOW®)|High flow and humidified oxygen support for new borns and young infants for post-extubation care
87086|NCT03505814|Device|Conventional oxygen therapy|conventional oxygen support for new born and young infants in post-extubation care
87087|NCT03505801|Device|Confirm Rx ICM insertion procedure|Insertion of Confirm Rx ICM device
87090|NCT03505775|Diagnostic Test|23Na magnetic resonance imaging|Imaging/diagnostic: Evaluation of the muscular and cutaneous sodium storage by 23Na magnetic resonance imaging. 23Na magnetic resonance imaging: 23NA-MRI protocol on a 3T scanner (Magnetom PRISMA, Siemens, Erlangen) implementing a 3D sequence.
87091|NCT03505762|Drug|Cyclophosphamide|Given IV
87092|NCT03505762|Drug|Doxorubicin Hydrochloride|Given IV
87093|NCT03505762|Other|Laboratory Biomarker Analysis|Correlative studies
87094|NCT03505762|Drug|Prednisone|Given PO
87095|NCT03505762|Other|Quality-of-Life Assessment|Ancillary correlative
87096|NCT03505762|Other|Questionnaire Administration|Ancillary studies
87097|NCT03505762|Biological|Rituximab|Given IV
87098|NCT03505762|Drug|Vincristine Sulfate|Given IV
87099|NCT03505749|Behavioral|Trauma Informed Mindfulness-Based Relapse Prevention|Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.
87100|NCT03505749|Behavioral|Treatment As Usual (TAU)|The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
87105|NCT03505723|Drug|Tranexamic Acid|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
87106|NCT03505723|Drug|Placebo (Saline)|Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
87107|NCT03505723|Other|Perioperative hypotension-avoidance strategy|"Perioperative hypotension-avoidance strategy includes:~Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery."
87108|NCT03505723|Other|Perioperative hypertension-avoidance strategy|Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
87109|NCT03505710|Drug|Trastuzumab deruxtecan (DS-8201a)|The investigational product is a sterile lyophilized powder, which is made into solution for intravenous administration.
87110|NCT03505697|Other|inspiratory muscle training|Inspiratory Muscle Training was performed with an exercise tool (Powerbreath®) with a resistance range of 0-90. The training intensity was started with 30% of the Maximum Inspiratory Pressure (MIP) value obtained as a result of the mouth pressure measurement16, training was progressively increased from 30% to 60% considering that they were terminal-stage pulmonary disease patients. Patients were asked to perform IMT for 15 minutes, twice a day, 7 days a week, for 3 months.
87111|NCT03505697|Other|Pulmonary rehabilitation|"Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band"
87112|NCT03505684|Dietary Supplement|CTP|1,000 mg of CTP was orally administered per day for 12 weeks.
87113|NCT03505684|Dietary Supplement|placebo (starch)|placebo (starch)
87114|NCT03505671|Procedure|Acupuncture Therapy|Undergo acupuncture therapy
87115|NCT03505671|Other|Best Practice|Receive usual care
87116|NCT03505671|Other|Quality-of-Life Assessment|Ancillary studies
87117|NCT03505671|Other|Questionnaire Administration|Ancillary studies
87118|NCT03505658|Behavioral|Education and Behavior|Involves 6-weeks of education related to healthy behaviors, nutrition, and exercise.
87119|NCT03505645|Procedure|Periarticular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~Treatment group 1: Periarticular infiltration~Intra-operatively after bone cuts have been made and prior to implant cementation, the multimodal injection will be infiltrated around the knee at 6 specific sites:~Medial femoral condyle periosteum~Medial gutter~Lateral femoral condyle periosteum~Lateral gutter~Posteromedial capsule~Posterolateral capsule"
87147|NCT03505424|Other|Group 1: Standard of Care|"Those who are in Group 1 will receive the usual care which includes:~a welcome packet from the nursing staff~access to their infant's medical team including doctors and nurse~opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team."
87255|NCT03504566|Drug|Sulodexide|Sulodexide
87120|NCT03505645|Procedure|Intra-articular infiltration|"The injection will consist of the same drugs for all patients: 150mg levobupivacaine 0.25%, 10mg morphine; and 30mg ketorolac made up to a volume of 150ml with saline.~The difference between treatment groups is how the multimodal injection is administered: either by periarticular infiltration around the knee, or by simple intra-articular injection after the knee joint capsule has been closed.~After implant cementation and watertight joint capsular closure, the multimodal injection will be injected intra-articularly through the closed capsule."
87121|NCT03505632|Device|Recruitment with low PEEP|Volume controlled ventilation with TV 6-8 ml/PBW . RR adjusted to keep the EtCO2 35-40 mmHg. I/E ratio1:2 and FiO2 0.40.Patients will receive PEEP of 5cmH2O. RM will be done by increasing the PEEP in stepwise manner. First PEEP increase to 10 cmH2O (3 breaths),then to 15 cm H2O (3 breaths) and finally PEEP raise to 20 cmH2O (10 breaths).Then PEEP decrease by 5 cmH2O increments every (3 breaths) until back to PEEP 5 cmH2O. RM will take 2 minutes. RM will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40 cmH2O. Monitoring of the following parameters :Dynamic lung compliance ,Horowitz index ,dead space and driving pressure .
87122|NCT03505632|Device|High PEEP without RM|Volume controlled ventilation will carried out with tidal volume 6-8 ml/kg for predicted body weight. The PBW calculated according to the formula : 50 + 0.91 × {height (cm)−152.4} for men and 45.5 + 0.91 × {height (cm) − 152.4} for women. The respiratory rate adjusted to keep the EtCO2= 35-40 mmHg. The inspiratory to expiratory ratio (I:E ratio) 1:2 and FiO2 0.40.Patients will receive high PEEP of 15cmH2O from the start and continue all through the procedure . Monitoring of dynamic lung compliance,Horowitz index,dead space and driving pressure will be carried out at the following times: post intubation(T1) , after peritoneal insuflation(T2) ,after desuflation (T3) and before extubation(T4) . The peak airway pressure should not exceed 40cmH2O.
87123|NCT03505619|Behavioral|ASSIST 1.0|10 weeks intervention applying a person-centred approach by using goal setting and smart products.
87124|NCT03505606|Diagnostic Test|Visual acuity tests|Participants to have visual acuity tested with the three modified vision tests.
87125|NCT03505567|Device|KOWA OCT Bi-µ|Non-contact, ultra-high resolution ophthalmic imaging system for fundus imaging and axial cross-sectional and three-dimensional imaging of retinal structures.
87126|NCT03505567|Device|Optovue iVue 100|U.S. Food and Drug Administration (FDA) cleared and commercially available Optovue iVue 100
87127|NCT03505554|Drug|Lorlatinib|100 mg QD
87128|NCT03505541|Biological|Adiponectin and TNFa|Adiponectin and TNFa are adipokines. Will be added to the myometrial biopsies to investigate their effect on the force of contractility
87129|NCT03505528|Drug|Nanoparticle albumin-bound paclitaxel|Abraxane is administered intravenous at a constant dose of 100mg/m2
87130|NCT03505528|Drug|Phenelzine Sulfate|Nardil is administered orally from a starting dose of 15mg/d to a maximum of 90mg/d
87131|NCT03505515|Other|Non-interventional|Non-interventional
87132|NCT03505502|Drug|IV tranexamic acid|in IV tranexamic acid group they received 1-gram tranexamic acid (10 ml) in 100 ml saline infusion or placebo (110 normal saline) by slow intravenous injection at an approximate rate of 1 mL per min.In topical tranexamic acid groupA gauze soaked with 2g tranexamic acid (20 ml) diluted in 100 ml of sodium chloride 0.9% or placebo (120ml of sodium chloride 0.9%.) used to compress the myoma bed for 5 minutes. To ensure a sufficiently high concentration, the tranexamic acid was diluted only to a volume sufficient to moisten a large wound surface. 20 ml moisten at least 1500 cm2.
87133|NCT03505489|Procedure|Deep inhalation technique|Use of deep inhalations for administration of inhalant
87134|NCT03505489|Procedure|Tidal breathing technique|Use of tidal breathing for administration of inhalant
87135|NCT03505489|Drug|Methacholine|Methacholine direct bronchoconstrictor used for bronchoprovocation challenge
87136|NCT03505489|Drug|Mannitol|Mannitol indirect bronchoconstrictor used for bronchoprovocation challenge
87137|NCT03505476|Device|Entac Medical device application|Subjects will wear a 3-inch by 3-inch stethoscope device that adheres to the skin of the abdomen via FDA approved adhesive material. It will be applied either in the operating room at the completion of surgery or in the recovery room. The device will remain on the abdomen until discharge or for 10 days, whichever comes first.
87138|NCT03505476|Other|Patient Daily Assessment|The research team will ask questions of the subject regarding nausea, vomiting, passage of flatus, return of bowel function, and satisfaction with the device every day that the subject is hospitalized.
87139|NCT03505476|Other|Patient Discharge Assessment|The research team will ask questions of the subject regarding satisfaction or dissatisfaction with having the device placed and attached to their abdomen.
87140|NCT03505463|Other|Blood samples|"Three blood samples will be collected from the injured participants. The assessment points are <72 hours, 7 days and 365 days post-injury.~One blood sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
87141|NCT03505463|Other|Cerebrospinal fluid sample|"Three cerebrospinal fluid samples will be collected from the injured participants. The assessment points are <72 hours, 7 days and 365 days post-injury.~The collected samples will be analysed by Flow Cytometry and assay techniques. One cerebrospinal fluid sample will be collected from the healthy participants. The collection will be performed as part of clinical diagnostic at the Department of Neurology at Aarhus University Hospital.~Laboratory analysis of the collected samples comprise Flow Cytometry and assay techniques."
87142|NCT03505463|Other|Clinical examination|Clinical examinations will be performed at <72 hours, 7 days and 365 days post-injury.
87143|NCT03505450|Other|Population Sample|full sample of recruited participants
87144|NCT03505450|Other|Purposive sample|purposive sample of recruited participants
87145|NCT03505437|Other|Cold water condition|Cold water condition of the SECPT. Participants immerse their hand into ice-cold water (0-3°C). During the SECPT, participants are videotyped and monitored. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders
87146|NCT03505437|Other|Warm water condition|Warm water condition of the SECPT. Participants immerse their hand into warm water (36-37°C). Participants are neither videotyped nor monitored during the whole procedure. After the SECPT, participants will receive 45 minutes of in-vivo exposure to spiders.
87149|NCT03505424|Other|Group 3: SMART NICU2HOME app|In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.
87150|NCT03505411|Dietary Supplement|melatonin supplementation|
87151|NCT03505398|Procedure|microperimetry|define the retinal fixation point and the differential sensitivity threshold of the retina.
87152|NCT03505398|Procedure|visual acuity|using ETDRS scales
87153|NCT03505398|Procedure|automated visual field|recording visual attention based on central or peripheral visual information
87154|NCT03505398|Procedure|eye movements recording|recording of explicit visual attention based on central or peripheral visual information
87155|NCT03505385|Behavioral|Co-created intervention|The intervention will be co-created with care home residents and staff working in the Care Homes, relatives and relevant stakeholders (including policy makers), following the aforementioned protocol (stage 1 of the study). The co-creation stage will allow us determine the intervention ready to be tested in a pilot randomized clinical trial.
87156|NCT03505372|Device|Contrast enhanced mammography|Contrast enhanced mammography is a new type of mammogram that uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone.
87157|NCT03505359|Other|partial knee immobilization protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength with a 0-60 degrees articulated knee brace in the first 6 weeks in the experimental group.
87158|NCT03505359|Other|standard ACL reconstruction rehabilitation protocol|12 weeks rehabilitation protocol including exercises to improve range of motion, gait, balance, muscle strength.
87159|NCT03505346|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV.
87160|NCT03505333|Procedure|conventional suture|we use Liga-sure device for hysterectomy
87165|NCT03505294|Other|Task-oriented training|"Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks."
87166|NCT03505281|Biological|Blood samples|Collection of two additional tubes at the time of a blood test necessary for patient follow-up.
87167|NCT03505268|Behavioral|Telemedicine|Patients of the Intervention Group will have once biweekly telephonic intervention conversation with dietitian, specialized in diabetes and diabetes nurse. The patients of the control group will have a routine care.
87168|NCT03505255|Drug|Neostigmine|Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction
87169|NCT03505255|Other|Normal saline|Normal saline 0.9 % is given in the control group
87170|NCT03505242|Device|bronchial blocker for BB group|Using bronchial blocker to block right middle lower lobe during surgery.
87171|NCT03505242|Device|double lumen tube for DLT group|Using double lumen tube to achieve single lung ventilation during surgery.
87172|NCT03505229|Radiation|Stereotactic Body Radiotherapy (SBRT)|Stereotactic Body Radiotherapy (SBRT) 30-45 gray in 5 fractions over 2 weeks will be given to all eligible patients.
87173|NCT03505203|Behavioral|Sleep Soothe|An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.
87174|NCT03505203|Behavioral|Sleep Safe|An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
87175|NCT03505190|Drug|RO7062931|RO7062931 will be administered SC in single ascending doses with starting of 0.3 mg/kg and subsequent doses of 1.0 mg/kg, 2.0 mg/kg and 3.0 mg/kg, respectively. Additional (optional) dose of 4.0 mg/kg may be administered based on safety, tolerability and PK data.
87176|NCT03505190|Drug|Placebo|Matching placebo will be administered subcutaneously (SC).
87177|NCT03505177|Dietary Supplement|Chitin-glucan fiber|4.5g per day of chitin-glucan during 3 weeks
87178|NCT03505151|Drug|BI 409306 (C-13/N-15)|i.v solution
87179|NCT03505151|Drug|BI 409306|Film-coated tablet
87180|NCT03505138|Device|Group intervention|"GROUP 1 (telematic group):~These patients will have a tablet connected via internet (Telefónica-e-Health). They have to measure their lung function, temperature, pulse oxymetry and symtoms questionnaire every week. The device (tablet) asks them about possible COPD exacerbation. If the patient has an exacerbation, the device offers them a treatment for this exacerbation and it begins a following of this exacerbation until resolution, every day.~The pneumologists will receive an alert in other tablet when the patients have an exacerbation or worsening of their diseases.~The period of monitoring is 1 year."
87181|NCT03505138|Other|health care system|"GROUP 2 (conventional group or control group) Patients with a COPD exacerbation can go to their family physicians or emergency services and these physicians will establish a treatment and a monitoring of these exacerbation (conventional group).~The period of monitoring is 1 year."
87182|NCT03505112|Other|Goal-directed therapy|"The patients in GDT group will receive intravenous crystalloid fluid or vasopressor or inotropic agent according to the goal-directed therapy protocol utilizing FloTrac / EV1000 clinical platform (Edwards Lifesciences, Irvine, CA, USA).~After induction of anesthesia, the baseline stroke volume index (SVI) is measured and then 200-250 ml of crystalloid is administered over 5-10 minutes. If SVI increase by ≥10%, 200-250 ml of crystalloid is given repeatedly until the increase in SVI <10%. If SVI does not increase by ≥10% and there is no decrease in mean arterial pressure (MAP), revaluate SVI every 10 minutes. Despite an increase in SVI of <10% after fluid challenge, if a decrease in MAP is accompanied by cardiac index (CI) ≤ 2.5 L/min/m2, dobutamine is administered by continuous infusion. If there is a decrease in MAP but no decrease in CI, start low dose norepinephrine continuous infusion."
87256|NCT03504553|Other|Noise reduction|All activity will cease when the patient enters the operating room and nonessential personnel will be removed. Ambient lighting will be reduced and communication devices muted.
87183|NCT03505099|Biological|onasemnogene abeparvovec-xioi|A non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
87184|NCT03505086|Diagnostic Test|Blood withdrawal|"Blood withdrawal will be at regular sampling moments, blood can be collected from a central venous catheter or venepuncture procedure.~Blood withdrawal will be performed for a maximum of 10 times per admission, 10 ml per time.~Urine sampling will be for a maximum of 5 times per admission.~Urine can be sampled from a catheter when present, or collected regular."
87185|NCT03505086|Other|Questionnaire for former bleeding events|Questionnaire to investigate a bleeding tendency before diagnosis.
87186|NCT03505073|Device|12 lead electrocardiogram|A device recording the electrical activity of the heart over a period of time using electrodes placed on the skin.
87187|NCT03505073|Device|Holter Monitor|A type of ambulatory electrocardiography device, a portable device for cardiac monitoring (the monitoring of the electrical activity of the cardiovascular system) for at least 24 to 48 hours (often for two weeks at a time).
87188|NCT03505073|Device|Transthoracic echocardiogram|A standard echocardiogram or cardiac ultrasound in which the echocardiography transducer (or probe) is placed on the chest wall (or thorax) of the subject, and images are taken through the chest wall. This is a noninvasive, highly accurate, and quick assessment of the overall health of the heart.
87189|NCT03505073|Device|Transesophageal echocardiogram|An alternative way to perform an echocardiogram. A specialized probe containing an ultrasound transducer at its tip is passed into the patient's esophagus. This allows image and Doppler evaluation from a location directly behind the heart.
87190|NCT03505060|Biological|DNA CON-S env|Administered by intramuscular injection in the deltoid.
87191|NCT03505060|Biological|IHV01|Administered by intramuscular injection in the deltoid.
87192|NCT03505060|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%; administered by intramuscular injection in the deltoid.
87193|NCT03505047|Device|Copper Intrauterine device|Immediate insertion of the copper intrauterine device after completion of abortion
87194|NCT03505034|Drug|Umbilical Cord Mesenchymal Stem Cells|Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells, 1*10^6 cells/kg, once a month for 4 months
87195|NCT03505021|Drug|Levosimendan|Levosimendan 1 mg capsule for oral administration
87196|NCT03505021|Drug|Placebo for levosimendan|Placebo capsule for oral administration
87197|NCT03505008|Drug|Methotrexate|Route of Administration: Oral
87198|NCT03505008|Drug|Adalimumab|Route of Administration: Subcutaneous
87199|NCT03504995|Device|Focal irreversible electroporation of the prostate cancer|Irreversible electroporation is a non-thermal tissue ablation technique in which short duration electrical fields are used to permanently permeabilize the cell membrane.
87200|NCT03504982|Drug|Vericiguat (BAY1021189)|A : 2.5 mg vericiguat A*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C*: 10 mg vericiguat
87201|NCT03504982|Drug|Moxifloxacin|D: 400 mg moxifloxacin
87202|NCT03504982|Drug|Placebo|A : vericiguat placebo 10 mg A*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg
87203|NCT03504956|Device|Cardiac MRI|MRI with/without administration of a contrast agent and beta-blocker based upon the stage of method development, if no contraindications are present.
87204|NCT03504956|Drug|Contrast|The intravenous gadolinium based contrast agent to be used in this study is Gadavist (up to 0.2 mmol/kg).
87205|NCT03504956|Drug|Beta blocker|Based upon the focus of the study at the time of the scan, a beta- blocker (metoprolol), in pill form based upon blood pressure and heart rate, may be administered to some subjects to improve the heart's ability to relax and slow the heart rate. The slower heart rate may improve image quality and lessen motion artifact.
87206|NCT03504943|Other|Early Intradialytic Exercise|Timing of intradialytic exercise first half of HD
87207|NCT03504943|Other|Late Intradialytic Exercise|Timing of intradialytic exercise second half of HD
87208|NCT03504930|Other|Impact of biotherapy on postoperative morbidity in ulcerative colitis|Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
87209|NCT03504917|Drug|Balovaptan|Participants will receive 10 mg of oral administration balovaptan once a day (QD).
87210|NCT03504917|Drug|Placebo|Participants will receive matching placebo.
87211|NCT03504904|Behavioral|Internet-Delivered ACT and CFT|An 8-week internet-based intervention focused on acceptance and compassion. Psychological intervention based on Acceptance and commitment therapy and compassion focused therapy
87212|NCT03504891|Diagnostic Test|MRI prior to CRT Upgrade|We will perform MRI prior to CRT to inform the optimal CRT implantation strategy in patients with existing devices undergoing upgrades versus those with de novo CRT implants. We will compare outcomes in the two groups.
87213|NCT03504891|Diagnostic Test|MRI prior to de novo CRT|We will perform MRI prior to de novo CRT implants as the comparison group.
87214|NCT03504878|Procedure|Laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
87215|NCT03504878|Procedure|Open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision.
87216|NCT03504865|Drug|Liposomal bupivacaine|Given at the end of the operation.
87217|NCT03504865|Drug|Standard bupivacaine|Given at the end of the operation.
87218|NCT03504865|Other|Placebo|Saline will be administered as the placebo and will be given at the end of the operation.
87219|NCT03504852|Drug|secukinumab 150 mg|sub-cutaneous secukinumab prefilled syringe 150 mg
87220|NCT03504839|Device|Subcutaneous ICD with same day discharge|Receiving a SICD and discharged the same day
87257|NCT03504540|Procedure|Blood test|Blood test for complement factors and genetic polymorphisms of AMD analysis
87221|NCT03504826|Device|Hybrid Assistive Limb (HAL)|Intensive training with the HAL consisting of two components to the intervention session that include: 1) locomotor treadmill training with the HAL device and 2) locomotor training over ground without the HAL device. All training will be overseen by a licensed physical therapist.
87222|NCT03504813|Other|Physical activities program|To implement this line, the protocol of the VIVIFRAIL Project will be used as a reference. That protocol has different physical exercises, divided into itineraries, in order to adapt it to a person's capability. Several sessions of this research line will employ the use of videogames so that the elderly can explore new forms of physical activity and thus establish contact and expertise with new technologies. It is estimated that two sessions per week over two months are needed for each person to continue doing physical activity independently and with autonomy.
87223|NCT03504813|Other|Relaxation training|Will take place with those participants who are included in the research lines of insomnia and risk of falls. It is estimated that two sessions per week for one month are needed.
87224|NCT03504813|Other|Training of the pelvic floor|the intervention will apply to participants enrolled in the research line dealing with urinary incontinence during the six months of intervention, with a frequency of two sessions per week
87225|NCT03504813|Behavioral|Counseling about occupational performance|After the physical activity and relaxation programs, the counselling will start. With each participant, routines and daily activities will be planned that will be adequate according to different recommendations about urinary incontinence, insomnia and risk of falls. Different performance guidelines will be established in order to establish a good balance between activities. The guidelines can include the recommendations about adjustments to the environment. It is estimated that three sessions per week for two months are needed to incorporate advice and routines into the daily lives of participants.
87226|NCT03504800|Device|Optical Coherence Tomography|This device will be used to tightly classify corneal irregularities and determine eligibility of candidates from Group A into Groups B & C.
87227|NCT03504774|Drug|Cashew or Shrimp Oral Immunotherapy|All cohorts will undergo an updosing regimen starting at 5 mg allergen, with dose escalation every 2 weeks to reach a 1000 mg dose at week 28, after which they will be maintained at that dose for 24 weeks. At the conclusion of the maintenance phase (Week 52), participants will undergo DBPCFC.
87228|NCT03504761|Device|ClariCore Optical Biopsy System|Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
87229|NCT03504748|Device|deep rTMS|
87230|NCT03504748|Device|placebo deep rTMS|
87231|NCT03504735|Behavioral|Therapeutic Lifestyle Change|Monthly consult with a dietitian and fitness instructor.
87232|NCT03504735|Drug|Caduet Pill|Take once daily.
87233|NCT03504735|Drug|Placebo|Take once daily.
87234|NCT03504722|Behavioral|RESCUE|RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
87235|NCT03504722|Behavioral|Prolonged Exposure|All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
87236|NCT03504696|Other|Non-interventional|Non-interventional
87237|NCT03504683|Behavioral|Early Time-Restricted Feeding|Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)
87238|NCT03504683|Behavioral|Mid-day Time-Restricted Feeding|Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)
87239|NCT03504683|Behavioral|Control Schedule|Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
87240|NCT03504670|Procedure|Early Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed prior to the cervix being dilated 4cm.
87241|NCT03504670|Procedure|Late Amniotomy|This intervention involves using an amniotomy hook to rupture the membranes during a sterile vaginal exam. This intervention will be performed once the cervix is at least 4cm dilated.
87242|NCT03504657|Device|Drug-coated balloon angioplasty|Angioplasty with a drug-coated angioplasty
87243|NCT03504657|Device|stenting angioplasty|Angioplasty with a stenting
87244|NCT03504644|Other|Laboratory Biomarker Analysis|Correlative studies
87245|NCT03504644|Drug|Venetoclax|Given PO
87246|NCT03504644|Drug|Vincristine Liposomal|Given IV
87247|NCT03504631|Other|No intervention|no intervention
87248|NCT03504618|Drug|FOLFOXIRI|"Treatment of FOLFOXIRI regimen at first line with dosage:~Irinotecan: 165 mg / m2, intravenous infusion for 1 hour. Day 1, 15. Oxaliplatin: 85 mg / m2, intravenously for 2 hours Day 1, 15 Calcium folinate 200 mg / m2, intravenously for 2 hours Day 1, 15 5FU 3200 mg / m 2, intravenous infusion continuously for 48 hours Day 1, 2, 3, 15, 16, 17 Every 4 weeks. Each cycle has 2 infusion times, the first one is the first day, the second one is the 15th day"
87249|NCT03504605|Other|Online self-compassion intervention|Parents are asked to write in an online text box about a parenting event in which they felt shame. They are then given a validated set of instructions asking them to reflect on the event and write self-compassionate responses.
87250|NCT03504592|Behavioral|Completion of Glucose logs|Glucose logs will be assessed by provider for completeness and accuracy
87251|NCT03504579|Other|rt-fMRI neurofeedback|use of real time fMRI neurofeedback to achieve targeted brain changes
87252|NCT03504566|Drug|Linagliptin|Linagliptin
87253|NCT03504566|Drug|Empagliflozin|Empagliflozin
87254|NCT03504566|Drug|Telmisartan|Telmisartan
87258|NCT03504527|Drug|triple combinations|inhaled budesonide(160ug,bid),formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
87259|NCT03504527|Drug|double combinations|inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
87260|NCT03504514|Device|speech trials during different ventilation conditions|ventilator parameters are modified
87261|NCT03504514|Other|speech trial|reading duration, vocal flow, intelligibility and voice quality will be evaluated during speech
87262|NCT03504501|Drug|Lovastatin|oral application prior to transcranial magnetic stimulation intervention
87263|NCT03504501|Drug|Lamotrigine|oral application prior to transcranial magnetic stimulation intervention
87264|NCT03504488|Biological|CAB-ROR2-ADC|Conditionally active biologic anti-ROR2 antibody drug conjugate
87265|NCT03504475|Drug|Paroxetine Hydrochloride Tablet 20 mg|A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.
87266|NCT03504475|Drug|Paxil® 20 mg|Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.
87267|NCT03504462|Procedure|Specific block of medial and lateral plantar nerves|"Specific injection of long duration local anesthetic in contact with medial and lateral plantar nerves.~Local anesthetic : Ropivacaine : 0,375% - 5 ml per nerve."
87268|NCT03504449|Other|neoadjuvant chemoradiotherapy|
87269|NCT03504436|Device|LEO +|LEO +: self-expanding intracranial stent
87270|NCT03504423|Drug|CPI 613, mFolfirinox|CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
87271|NCT03504423|Drug|Folfirinox|Folfirinox
87272|NCT03504410|Drug|CPI-613 + High Dose Cytarabine and Mitoxantrone|CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
87273|NCT03504410|Drug|High Dose Cytarabine and Mitoxantrone|Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine
87274|NCT03504397|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
87275|NCT03504397|Drug|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
87276|NCT03504397|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion
87277|NCT03504397|Drug|folinic acid|Folinic acid will be administered as a 2-hour IV infusion.
87278|NCT03504397|Drug|fluorouracil|Fluorouracil will be administered as IV bolus over 5-15 minutes and continuous IV infusion over 46-48 hours.
87279|NCT03504384|Other|questionnaire|All patients will be interviewed using a semi-structured questionnaire detailing patients' demographic characteristics (age, sex, education, occupation, residence), and the factors that could affect their quality of life such as pain and neurological symptoms, orthopedic disorder in another part of the body and history of spinal surgery.
87280|NCT03504371|Device|bilateral erector spinae block|The patient placed in a lateral position and transducer placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. Three muscles will be identified superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. An 8-cm 22-gauge block needle will be inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane between rhomboid major and erector spinae muscles, as evidenced by visualization of local anesthetic spreading in a linear pattern between erector spinae and the bony acoustic shadows of the transverse processes. 20 mL of 0.25% bupivacaine will be injected then it will be repeated on the other side and preformed in the same way to achieve sensory block T5-T10 .
87281|NCT03504371|Device|Thoracic epidural anesthesia|patients will receive TEA where an epidural catheter will be placed at the T7-8 interspace after proper sterilization and positioning of the patient in the sitting position then standard technique of application will be applied, then a test dose consists of 3 ml of 1.5% preservative free lidocaine with 1:200,000 epinephrine will be injected followed by 5-6 ml of bupivacaine 0.25%.
87282|NCT03504358|Procedure|Liver resection|Partial hepatectomy comprised single or multiple hepatic resections aiming at excising all visible malignant tissue.
87283|NCT03504345|Drug|Prometrium|The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
87284|NCT03504332|Procedure|intracanal disinfection in revascularization|a procedure to create vital cells in the pulp space of immature teeth which enables thickening of the dentinal walls of the root.
87285|NCT03504319|Other|Exposure to high-fat smoothie|Both groups will drink the high-fat smoothie and the study team will observe how they respond metabolically in the subsequent four hours using metabolic analyzer and blood draws.
87286|NCT03504306|Other|Ventriject validation|comparing measurements from echocardiography, echoseismography to measurements of maximal oxygen uptake
87287|NCT03504293|Procedure|Combinatory EUS and ERCP|EUS performed as a supplementary procedure in addition to ERCP
87288|NCT03504280|Drug|Cholecalciferol|
87289|NCT03504267|Other|Physical Activity Education and Resources|The intervention involves receiving evidence-based educational brochures as well as a list of local facilities where the participant can work out at no-cost to them,
87290|NCT03504254|Diagnostic Test|MRI examination|Three kinds of MRI techniques will be used in this study. These are (1) axial T1-weighted (T1WI) and T2-weighted imaging (T2WI), UTE MRI, (2) BOLD-based fMRI, and (3) diffusion tensor imaging (DTI).
87291|NCT03504241|Biological|Donor-derived Mesenchymal Stromal Cells|These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
87292|NCT03504241|Drug|alemtuzumab|Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
87293|NCT03504241|Drug|belatacept|Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
87294|NCT03504241|Drug|sirolimus|Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
87295|NCT03504241|Drug|mycophenolate mofetil|Per protocol, and, only permitted in cases of sirolimus intolerance.
87296|NCT03504241|Drug|mycophenolate acid|Per protocol, and, only permitted in cases of sirolimus intolerance.
87297|NCT03504241|Drug|prednisone|Per protocol, and, only permitted in cases of sirolimus intolerance.
87298|NCT03504228|Device|ROADSAVER|Dual layer micromesh Roadsaver carotid stent
87299|NCT03504215|Other|Exercise Intervention|Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
87300|NCT03504202|Drug|Trimetazidine|After enrollment, experimental group will receive Trimetazidine(35mg tid) for six months .
87301|NCT03504189|Device|PregSense™|PregSense™ wearable device will be applied for maternal-fetal monitoring
87302|NCT03504189|Device|Cardiotocopraphy (CTG)|Cardiotocopraphy (CTG) will be applied for maternal-fetal monitoring
87303|NCT03504176|Other|Ventilation bundle|ventilation targets (pH, spO2, pCO2) tidal volume 3-6ml/kg peak pressures <28-32cmH2O PEEP-FiO2 titration tables
87304|NCT03504163|Drug|Pembrolizumab (MK-3475)|Pembrolizumab (MK-3475) will be administered as a 200 mg IV infusion at 3-week intervals for 9 doses over a 24 week period.
87305|NCT03504150|Behavioral|SPHERE|Comprehensive Internet-based CBT program with no human support
87306|NCT03504150|Behavioral|PRISM|Brief Internet-based CBT program with no human support
87307|NCT03504137|Other|mHealth Intervention|The video DOT app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
87308|NCT03504124|Other|Multicomponent intervention|An 18-month multicomponent intervention, which includes protocol-based treatment using: a standard blood pressure (BP) management algorithm, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
87309|NCT03504111|Procedure|Percutaneous Needle Tenotomy|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided needle tenontomy with be performed at the common extensor tendon at the area of tendinosis. There will be approximately 25 passes through the tendon with an 18 gauge needle. Investigators will keep track of the number of passes through the tendon. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia
87310|NCT03504111|Procedure|PRP|A sham phlebotomy sample will be drawn on all study participants. Participants in this treatment group will be given local anesthesia with 1% lidocaine and then blinded to the intervention using a blind fold or shielding. Ultrasound guided injection of the PRP will be performed at the common extensor tendon at the area of tendinosis. Investigators will keep track of the amount and type of anesthetic used to provide adequate and effective anesthesia to the local skin
87311|NCT03504098|Behavioral|nutrition consult|Post-lung cancer operation diet pattern
87312|NCT03504085|Other|Yoga: Active Hatha|Classical Hatha yoga with influences from Viniyoga and Iyengar yoga. Both Viniyoga and Iyengar yoga styles emphasize modifications and adaptations including the use of props such as straps and blocks in order to minimize the risk of injury and make the poses accessible to people with health problems and limitations
87313|NCT03504085|Other|Yoga: Restorative|Restorative Yoga is a slow-paced yoga style that emphasizes relaxation and includes very little movement.
87314|NCT03504072|Drug|Tofacitinib 5 mg,|tofacitinib 5 mg 12 hourly daily for 9 months
87315|NCT03504072|Drug|Etanercept|Etanercept 50 mg sc every 7 days interval in 1st month, every 15 days interval in 2nd month and then every 21 days interval from 3rd month onward upto 9 months
87316|NCT03504059|Behavioral|Long-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
87317|NCT03504059|Behavioral|Short-term educational program|Comprehensive educational school-based intervention in adolescents on cardiovascular health, including obesity/adiposity and metabolic profiles, through classroom intervention, and complementary intervention in the family setting, at school and on teachers.
87318|NCT03504046|Device|Artificial Pancreas App|The portable Artificial Pancreas System App (APS APP) is an artificial pancreas system comprised primarily of an insulin pump, a continuous glucose monitor (CGM), and a cellular phone device to connect the components.
87319|NCT03504033|Drug|Xenon|inhalation to maintain anesthesia
87320|NCT03504033|Drug|Desflurane|inhalation to maintain anesthesia
87321|NCT03504020|Device|ECG Belt Research System|The ECG Belt Research System is used to identify the best vector and programming parameters.
87322|NCT03503994|Drug|Inhaled Beclomethasone Dipropionate Monohydrate|"Beclomethasone Dipropionate (HFA-BDP, QVAR*) in the following doses will be evaluated:~200 mcg bid~400 mcg bid~600 mcg bid~800 mcg bid"
87323|NCT03503981|Other|Psychotherapy|There are different psychotherapy models offered across the units. All patients receive individual treatment and group therapy or psychoeducative groups.
87324|NCT03503968|Drug|MDG1011|PRAME-T-Cell Receptor Gene Modified Autologous T Cells
87325|NCT03503968|Other|Investigator Choice therapy|Any intervention/therapy chosen by the investigator
87326|NCT03503955|Other|Leap-Motion virtual reality games|Games that Fizyosoft has prepared on Leap Motion equipment to improve hand and grip activities will be played individually and will focus on running hand, wrist and grip movements
87327|NCT03503955|Other|fine motor skills activities|activities that stimulate finger movements such as holding, reaching, catching, writing, and strengthening muscles
87396|NCT03503435|Behavioral|Group art therapy|Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
87960|NCT03499418|Diagnostic Test|echocardiography|echocardiographic evaluation of haemodynamic problems
87328|NCT03503942|Behavioral|Lifestyle modification|Participants in the treatment arm will receive structured, locally tailored, group-based lifestyle interventions that consist of a core intervention phase (3 months) and a maintenance phase (33 months). The core intervention phase will consist of twice weekly group sessions on nutrition, exercise and goal-setting within the first 6 weeks followed by 6 weeks of self-directed lifestyle modification. During the maintenance phase, the participants will receive monthly short message service (SMS) on health tips as well as 6 monthly telephone calls from program coordinators.
87329|NCT03503942|Drug|Metformin|Metformin will be will be prescribed to treatment group participants at highest risk of diabetes conversion (i.e.IFG + IGT or IFG + HbA1c ≥6.0%) after at least 6 months of lifestyle interventions at a starting dose of 250 mg twice a day followed by up-titration to 500 mg twice a day after 3 months if the participants do not experience any gastrointestinal side effects.
87330|NCT03503942|Other|Financial incentives|Participants will be given cash incentives if they meet the weight loss target, which is pre-defined as 5% of baseline weight, at the 3rd, 6th, 12th, 18th, 24th, 30th and 36th month of study period.
87331|NCT03503929|Device|LaparoGuard System|Adjunctive safety system for laparoscopic surgery
87332|NCT03503903|Procedure|Wet Cupping|CT was applied using plastic disposable vacuum cups on the back in the 5 areas of C7 cervical spine (DU14 acupoint), T2-4 lateral spine bilaterally (BL41-42 acupoint) and T6-8 lateral spine bilaterally (BL44-46), which are the recommended sites for headache (12). The cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Secondary suction and bloodletting,Removing and dressing.
87333|NCT03503890|Drug|rovalpituzumab tesirine|intravenous
87334|NCT03503877|Device|EmbryoScope Plus|All embryos in both arms will be cultured in the EmbryoScope Plus to obtain morphokinetic data
87335|NCT03503877|Other|GLOBAL MEDIA|Embryos will be cultured in GLOBAL media
87336|NCT03503877|Other|SAGE MEDIA|Embryos will be cultured in SAGE media
87337|NCT03503864|Drug|Arsenic Trioxide|Patients will receive arsenic trioxide alone on days 1-2 and combined with conventional induction chemotherapy on days 3-10. Arsenic trioxide 0.16mg/kg will be diluted into 250 ~ 500 ml of normal saline or a 5% glucose solution for intravenous drip over 4 hours per day. At the same time vitamin C 0.5 ~ 1.0g will be added in 5% glucose injection 100 ~ 250 ml with arsenic trioxide. Treatment repeats every 28 days for a maximum of 9 cycles in the absence of disease progression or unacceptable toxicity.
87338|NCT03503864|Drug|Conventional induction chemotherapy|Patients received cyclophosphamide 1.2g/m2/d, Pirarubicin 25mg/m2/d, and vincristine 0.022mg/kg/d or 0.67mg/m2/d (CAV) in cycles 1, 2, 4, and 6; and cisplatinum 50mg/m2/d and etoposide 200mg/ m2 (PVP) in cycles 3, 5, and 7.
87339|NCT03503851|Device|MitraClip implantation|Device to approximate the mitral valve leaflets
87340|NCT03503838|Behavioral|Online Yoga|12 weeks of online yoga; 60 min/week
87341|NCT03503825|Drug|[Tc-99m]-RPI-T-087 Injection|A single intravenous injection of [Tc-99m]-RPI-T-087 followed by SPECT/CT imaging of the knee (all subjects) and whole body planar imaging (Healthy volunteers only)
87342|NCT03503812|Behavioral|Intervention (1) for outdoor exposure reduction - Asthma in Children|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the 4-month period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity"
87343|NCT03503812|Behavioral|Intervention (2) for outdoor and indoor exposure reduction - Asthma in Children|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the 4-month period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity~ii) indoor particle levels on a continuous daily basis throughout the 4-month DDS period. This intervention will consist of two recommendations for participants' schools and houses:~Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~Reduce indoor particle levels by using air cleaners."
87344|NCT03503812|Behavioral|Intervention (1) for outdoor exposure reduction - Atrial Fibrillation|"Intervention 1 (I1) aims to reduce exposure to outdoor particles and it will be applied on days with DDS during the 4-month period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity"
87345|NCT03503812|Behavioral|Intervention (2) for outdoor and indoor exposure reduction - Atrial Fibrillation|"Intervention 2 (I2) aims to reduce both:~i) exposure to outdoor particles and it will be applied on days with DDS during the 4-month period. This intervention will consist of two recommendations:~Reduce time spent outdoors and~Reduce physical activity~ii) indoor particle levels on a continuous daily basis throughout the 4-month DDS period. This intervention will consist of two recommendations for participants' houses:~Reduce particle infiltration into residences by keeping windows and doors closed as much as possible and~Reduce indoor particle levels by using air cleaners."
87346|NCT03503799|Other|Observation|"Visit 1 Informed consent Medical history Demographics Result of EndoPredict® Test Status of menopause Disease status Tumor board decision Planned anti-tumor-therapy~Visit 2, 1 year after inclusion This visit will be documented at the study site Status of menopause Disease status Anti-tumor therapy Survival~Following visits For these visits, patients will be asked directly through the Center for Clinical Trials of the Philipps-University Marburg (KKS Marburg) via phone.~Status of Menopause Disease status Anti-tumor therapy Survival~Treatment after end of the study The patient will be treated during and after end of study by physician's choice."
87347|NCT03503786|Drug|Carboplatin|Carboplatin AUC 5 i.v. every 3 weeks for 6 - 8 cycles
87348|NCT03503786|Drug|Paclitaxel|Paclitaxel 175 mg/m2 i.v. every 3 weeks for 6-8 cycles
87349|NCT03503786|Drug|Avelumab|Avelumab 10 mg/kg every 3 weeks for 6-8 cycles + Avelumab 10 mg/kg every 14 days until disease progression or unacceptable toxicity
87350|NCT03503773|Drug|Alcohol|Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries
87351|NCT03503773|Other|Sham control|endovascular, renal angiography
87352|NCT03503760|Device|LIMFA Therapy®|It applies a packages of magneto-electric field sequences having variable geometry, with frequencies and intensities that vary in a range of 0-80 Hertz and 0-100 microTesla, respectively.
87435|NCT03503136|Drug|docetaxel, cisplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
89047|NCT03491176|Procedure|Biospecimen Collection|Undergo collection of blood samples
87353|NCT03503734|Behavioral|Integrated headache care|"The treatment can be realized on an inpatient, outpatient and/or day care basis, according to the severity level of illness and comorbidities.~The inpatient treatment takes place at the Department of Internal and Integrative Medicine. The stay is slated for 14 days.~Day care can follow the inpatient stay or can be applied as sole therapy. As part of the standard care provided at the Department for Internal and Integrative Medicine, it occurs at a semi-residential clinic for 6 hours once a week over a total of 10 weeks.~The outpatient treatment is delivered in the Department's outpatient ward. It consists of acupuncture, cupping, hydrotherapy and massages as well as nutritional counseling. The patients can additionally be offered one-to-one mind-body-medicine interventions."
87354|NCT03503721|Procedure|BipolEP|the prostate will be transurethrally enucleated using a bipolar current
87355|NCT03503721|Procedure|bipolarTURP|the prostate will transurethrally resected using a bipolar current
87356|NCT03503708|Drug|Livitol-70|Livitol-17 detoxifies, purifies and rejuvenates liver, kidney and spleen. Participants will be given the intervention in two bottles at each visit. Participant will be instructed to take two capsule twice daily at a fixed time in the day.
87357|NCT03503695|Device|Sterile acupuncture semi-permanent (ASP) gold needles|
87358|NCT03503682|Radiation|standard treatment|3000 cGy in 10 daily fractions
87359|NCT03503682|Radiation|short course treatment|2000 cGy in 4 fractions administered twice a day
87360|NCT03503669|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
87361|NCT03503669|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
87362|NCT03503656|Device|epidural catheter placement|insertion of an epidural catheter using Compuflo System
87363|NCT03503643|Device|Hemigland Cryoablation|Hemigland cryoablation for the treatment of prostate cancer
87364|NCT03503630|Drug|COMPOUND 2055269|COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
87365|NCT03503630|Radiation|Radiation Therapy|Radiotherapy 25 Gy to be given on Days 1-5
87366|NCT03503630|Drug|mFOLFOX|Given every 2 weeks for 6 cycles
87367|NCT03503630|Procedure|Total Mesorectal Excision|Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269
87368|NCT03503617|Device|RehabTouch|Exercise using the motion sensing devices and a computer
87369|NCT03503617|Other|Conventional tabletop exercise program|Exercise following printed sheets of exercises
87370|NCT03503604|Biological|hPV19 mAb|Intravenous (IV) infusions, 4 and 6 milligrams per kilogram (mg/kg) every 2 weeks
87371|NCT03503604|Biological|hPV19 mAb|Intravenous (IV) infusions, 6 milligrams per kilogram (mg/kg) every 3 weeks
87372|NCT03503604|Drug|5-Fluorouracil|400 mg/m2 bolus followed by a 2400 mg/m2 continuous infusion, every 2 weeks
87373|NCT03503604|Drug|Oxaliplatin|IV Infusion, 85 milligrams per square meter (mg/m2) every 2 weeks
87374|NCT03503604|Drug|Leucovorin|IV infusion, 400 mg/m2 every 2 weeks
87375|NCT03503604|Drug|Paclitaxel|IV infusion, 175 mg/m2 every 3 weeks
87376|NCT03503604|Drug|Carboplatin|IV infusion, AUC=6 every 3 weeks
87377|NCT03503604|Drug|Gemcitabine|IV infusion, 1000 mg/m2 at day1 and day 8 every 3 weeks
87378|NCT03503604|Drug|Carboplatin|IV infusion, AUC=4 every 3 weeks
87379|NCT03503604|Drug|Irinotecan|IV Infusion,180 milligrams per square meter (mg/m2) every 2 weeks
87380|NCT03503591|Device|Hummingbird Tympanostomy Tube System|Insertion of a ventilation tube under sedation and local anesthetic
87381|NCT03503578|Drug|Sevoflurane|Subjects will received sevoflurane for approximately 60 minutes.
87382|NCT03503578|Drug|Ketamine|Subjects will received sevoflurane and ketamine for approximately 60 minutes.
87383|NCT03503565|Procedure|intraoperative neuromuscular blockade|The intensity of intraoperative neuromuscular blockade
87384|NCT03503539|Procedure|Mini percutaneous nephrolithotomy|
87385|NCT03503539|Procedure|Retrograde intrarenal surgery|
87386|NCT03503526|Behavioral|Receptive music therapy|12 weekly trauma-focused Group therapy sessions of a length of 2.5 hours. The core element is receptive music psychotherapy with music listening, art making, and other art based methods.
87387|NCT03503513|Drug|Gentamicin Sulfate|Gentamicin will be compounded by the Michigan Medicine Research Pharmacy in a concentration of 480 milligrams of the active product to 1000 milliliters of normal saline. Participants will do daily instillations of 30 milliliters of solution
87388|NCT03503513|Drug|Saline|Normal saline only, patients will instill 30 milliliters daily.
87389|NCT03503500|Other|Laid-back breastfeeding|"At randomization the Italian version of the video Biological nurturing, which provides detailed information on LB BF, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, adequately trained staff will support women to breastfed in relaxed, laid-back position, with her baby laying prone on her, so that the baby's body is in the largest possible contact with mother's curves. In the maternity ward a daily supervision by an external expert on LB BF will be provided"
87390|NCT03503500|Other|Standard care|"2. the standard care in use at the Institute (WHO/UNICEF 20-hours course) (control group). At randomization, the Italian version of the video Breast is best (Allattare informati), which provides detailed information on standard support to breastfeeding, will be delivered to women with the recommendation to watch it before birth; during the maternity ward stay, the staff will show to mothers how to breastfeed and will help them to attach the baby correctly to the breast"
87391|NCT03503487|Other|3D informed consent|Patients were given an informed consent with the aid of a 3D immersive surgical planner (either a Surgical Theater or Vesalius)
87392|NCT03503474|Other|No intervention|There is no intervention, this is observational only
87393|NCT03503461|Other|exosomes analysis|Perform exosomes analysis in urine sample obtain from usual urine testing in both kidney transplant and control group.
87394|NCT03503448|Procedure|Osteotomy between the maxillary central incisors|Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
87395|NCT03503448|Procedure|Osteotomy between the maxillary lateral incisors and canines|Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
87397|NCT03503422|Procedure|Real transcranial direct current stimulation + therapeutic exercises for back pain|"Real transcranial direct current stimulation associated with therapeutic exercises for back pain~tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively."
87398|NCT03503422|Procedure|Sham transcranial direct current stimulation + therapeutic exercises for back pain|"Sham transcranial direct current stimulation associated with therapeutic exercises for back pain.~tDCS: 20 minutes (30 seconds ON), 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion). Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively"
87399|NCT03503409|Drug|AG-120|500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
87400|NCT03503396|Behavioral|BAC Driving Feedback/Warning|Participants will receive a warning at a set BAC limit, indicating they are too impaired to drive.
87401|NCT03503396|Behavioral|No Feedback|Participants will receive no information about BAC, but will still complete study assessments and provide breath samples during drinking sessions.
87402|NCT03503383|Behavioral|Patient Health Questionnaire-9|PHQ-9 for assessing and monitoring depression severity
87403|NCT03503383|Behavioral|Generalized Anxiety Disorder Scale (GAD-7)|to diagnose generalized anxiety disorder, the GAD-7 also proved to have good sensitivity and specificity as a screener for panic, social anxiety, and post-traumatic stress disorder
87404|NCT03503370|Drug|Chlorhexidine|Participants randomized to the intervention will wash their feet using 2% CHLORHEXIDINE GLUCONATE CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
87405|NCT03503357|Other|IFT Testing1|Command List A
87406|NCT03503357|Other|IFT Testing 2|Command List B
87407|NCT03503357|Other|IFT Testing 3|Command List C
87408|NCT03503357|Other|IFT Testing 4|Command List D
87409|NCT03503344|Drug|Apalutamide|Given PO, 240 mg per day (4 x 60mg tablets)
87410|NCT03503344|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
87411|NCT03503331|Drug|[C-11]PiB-PET/MRI|All study participants will undergo brain imaging with [C-11]PiB-PET/MRI. [C-11]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
87412|NCT03503318|Drug|TV-46000 - A|Subcutaneous injections
87413|NCT03503318|Drug|TV-46000 - B|Subcutaneous injections
87414|NCT03503318|Drug|Placebo|Subcutaneous injections
87415|NCT03503305|Device|adipose-derived stem cell injection|5 ml injection of adipose derived stem cells
87416|NCT03503305|Drug|Corticosteroid injection|5 ml injection of corticosteroid
87417|NCT03503292|Drug|Granisetron|Rapid metabolizer will receive 1mg IV Granisetron
87418|NCT03503292|Drug|Ondansetron|Poor or normal metabolizers will receive 4mg Ondansetron IV
87419|NCT03503279|Device|McGrath MAC® Video Laryngoscope|McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
87420|NCT03503266|Drug|[14C] MT-7117|14-C MT-7117
87421|NCT03503253|Device|Interlock-35 Fibered IDC Occlusion System ;|Use of detachable coil for LAA leak closure
87422|NCT03503253|Device|Concerto Helix Detachable Coil System|Use of detachable coil for LAA leak closure
87423|NCT03503227|Drug|prednisolone|daily oral low dose prednisolone (10 mg/day) :a glucocorticoid
87424|NCT03503227|Drug|Acetyl Salicylic acid|daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
87425|NCT03503214|Diagnostic Test|In vitro determination of non-carbonic buffer power|In vitro measurement of the non-carbonic buffer power by the means of equilibration of whole blood and isolated plasma with gas mixtures containing different concentrations of carbon dioxide
87426|NCT03503214|Diagnostic Test|Classic description of acid-base status|Measurement of plasma electrolytes, hemoglobin concentration, albumin and phosphates to compute acid-base variables according to Stewart's approach.
87427|NCT03503201|Dietary Supplement|Chromium|chromium supplementation as capsules of 200 micrograms of chromium picolinte (Arab company for pharmaceuticals and medicinal plants) daily for 2 months before ICSI cycle
87428|NCT03503188|Device|Littmann ®|electronic stethoscope
87429|NCT03503175|Device|Novel urinary access system (CystoSureTM)|CystoSureTM is a silicone device that was developed by surgeons to enable easy and standardized cystoscopy. The design of the CystoSureTM catheter has separate channels for draining the bladder and performing cystoscopy, so doctors can perform a cystoscopy without removing the catheter (which can, as described above, potentially lead to a UTI).
87430|NCT03503175|Device|Standard Foley catheter|Participants randomized to this arm will receive a standard Foley catheter and standard rigid cystoscopy.
87431|NCT03503162|Device|Pure-Vu System|The Pure-Vu System is FDA cleared device and CE marking received in February 2018, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
87432|NCT03503149|Other|no intervention|observational study
87433|NCT03503136|Drug|docetaxel, nedaplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), nedaplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
87434|NCT03503136|Drug|nedaplatin|Patients receive concurrent nedaplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
87436|NCT03503136|Drug|cisplatin|Patients receive concurrent cisplatin (100mg/m2) every three weeks for two cycles during radiotherapy.
87437|NCT03503136|Drug|docetaxel, cisplatin, and capecitabine|Patients receive docetaxel(60 mg/m2 on day 1), cisplatin (60 mg/m2 on day 1) and capecitabine (625 mg/m2 bid, on Days 1 to 14) every three weeks for three cycles before the radiotherapy.
87438|NCT03503136|Drug|docetaxel, nedaplatin, and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), nedaplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
87439|NCT03503123|Device|Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.|Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
87440|NCT03503110|Other|electrocorticography with electrostimulation|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
87441|NCT03503110|Other|dRMI|The investigators aim to establish a relationship between dMRI SC measures, direct measures of electrical properties of the human brain cortex obtained with electrocorticography (ECoG), and response elicited by direct electrostimulation of the brain (DES)
87442|NCT03503097|Procedure|Biospecimen Collection|Provide saliva samples
87443|NCT03503097|Other|Genetic Counseling|Undergo counseling
87444|NCT03503097|Other|Genetic Testing|Undergo genetic testing
87445|NCT03503097|Other|Laboratory Biomarker Analysis|Correlative studies
87446|NCT03503097|Behavioral|Questionnaire|Complete questionnaire
87447|NCT03503084|Behavioral|Classical Yang's TCC exercise|
87448|NCT03503071|Procedure|Cytoreductive surgery and intraperitoneal chemotherapy|Cytoreductive surgery and intraperitoneal chemotherapy for colorectal cancer or pseudomyxoma peritonei. Either early postoperative intraperitoneal chemotherapy (EPIC) or hyperthermic intraperitoneal chemotherapy (HIPEC) is used for intraperitoneal chemotherapy.
87449|NCT03503058|Biological|PfSPZ Vaccine|Radiation-attenuated, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Vaccine)
87450|NCT03503058|Biological|PfSPZ Challenge under chloroquine (CQ) chemoprophylaxis|Infectious, aseptic, purified, cryopreserved Plasmodium falciparum sporozoites (PfSPZ Challenge) administered under CQ chemoprophylaxis
87451|NCT03503058|Other|Normal Saline|0.9% Sodium chloride
87452|NCT03503032|Procedure|Extracardiac Fontan|Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery [applied to both arms]
87453|NCT03503032|Procedure|Fontan fenestration|Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium [Fenestrated arm]
87454|NCT03502993|Diagnostic Test|Validation of biomarker|
87455|NCT03502993|Other|Antibiotic prescription|
87456|NCT03502993|Other|re-attendance at ED|
87457|NCT03502993|Other|Hospitalisation|
87458|NCT03502980|Device|Bard PowerPICC|PICC Insertion
87459|NCT03502980|Device|Bard PowerMidline catheter|Midline Insertion
87460|NCT03502967|Drug|Hyperpolarized [1-13C] Pyruvate|Bolus injection of study drug
87461|NCT03502967|Drug|Hyperpolarized [2-13C] Pyruvate|Bolus injection of study drug
87462|NCT03502954|Biological|ABY-039|ABY-039
87463|NCT03502954|Biological|Placebo|Placebo
87464|NCT03502941|Dietary Supplement|6.3 g of EAAs mixture and whey protein isolate|A single dose of the mixture of EAAs/whey
87465|NCT03502941|Dietary Supplement|12.6 g of EAAs mixture and whey protein isolate|A double dose of the mixture of EAAs/whey
87466|NCT03502941|Dietary Supplement|12.6 g of whey protein isolate|Whey protein isolate alone, which is an equal amount to the double dose of the mixture of EAAs/whey
87467|NCT03502928|Other|Motor Control|Neck Motor Control
87468|NCT03502928|Other|Manual Therapy|Massage + Joint Mobilizations
87469|NCT03502928|Other|Dry Needling|Dry Needling in Neck Muscles
87470|NCT03502915|Drug|Nitrous Oxide|50% nitrous oxide/50% oxygen via Nitronox delivery device
87471|NCT03502915|Other|Placebo|100% oxygen via Nitronox delivery device
87472|NCT03502902|Drug|HEC 68498|HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
87473|NCT03502902|Drug|Placebo|Placebo
87474|NCT03502889|Procedure|SPANK Block (Sensory Posterior Articular Nerves of the Knee)|Injection of local anesthetic into the tissues on the posterior aspect of the knee to provide sensory blockade of the articular nerves of the knee.
87475|NCT03502889|Procedure|Adductor Canal Block|Injection of local anesthetic into the inner thigh under ultrasound guidance to provide sensory blockade to the anterior aspect of the knee
87476|NCT03502889|Drug|Ropivacaine Hcl 0.5% Inj Vil 30Ml|Amide local anesthetic, this concentration is commonly used to achieve surgical level anesthesia. The drug itself is not being studied and the same concentration will be used in all participants.
87477|NCT03502889|Device|Pajunk sonoplex stim needle|Echogenic needle used for ultrasound guided nerve blockade.
87478|NCT03502863|Device|Digital refraction|A web-based application for obtaining the refractive error and visual acuity of each eye, using a computer and a smart phone.
87479|NCT03502863|Other|Manual Refraction|Manual refraction and ETDRS chart
87480|NCT03502850|Drug|ASK120067|patients take ASK120067 orally once per day at 40,80,120,180,240,320,400mg
87481|NCT03502837|Other|emotional sound and neutral sound|"Neutral voice is a meaningless sound (namely the interjection ah) and the emotional stimuli were the same voice pronouncing the same word with an emotional prosody of happiness or sadness.The stimulus material consisted of positive and negative sound selected from the International Affective Digitalized Sounds (IADS) database.In order to identify experimental stimuli sets that were matched for ratings of arousal and valence between the two valence types,investigators used an algorithm to equate normative valence and arousal ratings for the selection of auditory stimuli."
87482|NCT03502824|Device|PuraPly® Antimicrobial Wound Matrix|PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.
87483|NCT03502824|Other|SOC for Pressure Ulcers|SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.
87484|NCT03502811|Device|MitraClip NTR/XTR System|Percutaneous mitral valve repair using the MitraClip NTR/XTR system.
87485|NCT03502798|Device|scanning a/LCI|Imaging of the cervical epithelium using the scanning a/LCI device.
87486|NCT03502785|Biological|INO-5401|INO-5401 (9 milligram [mg] dose IM): mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen.
87487|NCT03502785|Biological|INO-9012|"INO-9012 (1 mg dose IM): A synthetic plasmid that expresses human interleukin-12 (IL-12).~INO-5401 + INO-9012 will be administered IM followed by EP with CELLECTRA™ 2000 device every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, thereafter every 12 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator."
87488|NCT03502785|Drug|Atezolizumab|Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks until confirmed disease progression, unacceptable toxicity, or deemed intolerable by the investigator.
87489|NCT03502785|Device|CELLECTRA™ 2000|IM injection of INO-5401 and INO-9012 is followed by EP with the CELLECTRA™ 2000 device.
87490|NCT03502772|Other|Pilates exercises|Clinical Pilates training program will be given one session in a week for 8 weeks plus two days home exercise program. Group exercise sessions will be performed. The sessions will be supervised by a physiotherapist who is certified.
87491|NCT03502772|Other|Home exercise program|written exercises that matched the aims of the Pilates exercises, 3 times per week for 8 weeks. These exercises reflect routine clinical practice (flexibility, strength, and balance exercises).
87492|NCT03502759|Behavioral|CHICA SUDEP module|CHICA reminds physicians to counsel patients/families about the risk of SUDEP.
87493|NCT03502746|Drug|Nivolumab|Nivolumab 240mg, IV over 30 minutes.
87494|NCT03502746|Drug|Ramucirumab|8mg/kg, IV over 60 minutes.
87495|NCT03502733|Drug|Copanlisib|Given IV
87496|NCT03502733|Other|Laboratory Biomarker Analysis|Correlative studies
87497|NCT03502733|Biological|Nivolumab|Given IV
87498|NCT03502733|Other|Pharmacological Study|Correlative studies
87499|NCT03502720|Device|Scaphoid fixation using 3D device|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner using a customised 3D exoesqueleton guide
87500|NCT03502720|Procedure|Scaphoid fixation using standard procedure|A headless screw inserted percutaneously from the volar aspect of the scaphoid in a retrograde manner without using the 3D device (standard procedure)
87501|NCT03502707|Biological|Placebo|Placebo for Ad26.RSV.preF, RSV preF protein, Ad26.RSV.preF/RSV preF protein mixture and selected regimen will be administered as sterile saline for intramuscular injection.
87502|NCT03502707|Biological|RSV preF Protein 50 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 50 mcg.
87503|NCT03502707|Biological|RSV preF Protein 150 mcg|RSV preF will be administered as a solution for intramuscular injection at a dose of 150 mcg.
87504|NCT03502707|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be administered as a solution for intramuscular injection at a dose of 1*10^11 vp.
87505|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
87506|NCT03502707|Biological|Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (5*10^10 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
87507|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (50 mcg) will be administered as a solution for intramuscular injection.
87508|NCT03502707|Biological|Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg|Mixture of Ad26.RSV.preF (1*10^11 vp) and RSV preF protein (150 mcg) will be administered as a solution for intramuscular injection.
87509|NCT03502707|Biological|Selected Regimen|A regimen from Cohort 1 or Cohort 2 will be selected and administered as a solution for intramuscular injection at the selected dose.
87510|NCT03502694|Drug|Lumicitabine|Participants will receive loading dose and maintenance dose of lumicitabine tablets orally.
87511|NCT03502694|Drug|Placebo|Participants will receive matching placebo tablets orally.
87512|NCT03502681|Drug|Eribulin Mesylate|"Days 1, 15~Eribulin mesylate:~Dose level -1: 0.7mg/m^2;~Dose level 0: 1.1 mg/m^2;~Dose level +1: 1.4 mg/m^2"
87513|NCT03502681|Drug|Avelumab|Days 1, 15 Avelumab (10mg/kg)
87514|NCT03502668|Drug|ASTX727 LD|oral decitabine (LD) + cedazuridine (E7727)
87515|NCT03502668|Drug|ASTX727 SD|oral decitabine (SD) + cedazuridine (E7727)
87516|NCT03502655|Other|Experimental: Intervention message (first phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
87517|NCT03502655|Other|Placebo Comparator: Control message (first phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a recorded message
87518|NCT03502655|Other|Experimental: Intervention message (second phase)|Effect of positive communication on pain during intravenous cannulation in an emergency department delivered by a care provider
87519|NCT03502655|Other|Placebo Comparator: Control message (second phase)|Effect of usual communication on pain during intravenous cannulation in an emergency department delivered by a care provider
87520|NCT03502642|Device|wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)|After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
87521|NCT03502642|Procedure|Spinal Anesthesia|Cesarean section was conducted under spinal anesthesia in both groups
87522|NCT03502642|Drug|intrathecal morphine|Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group
87523|NCT03502642|Drug|Ropivacaine (Ropivacaina Molteni®)|A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
87524|NCT03502642|Drug|Normal saline|A10ml bolus of normal saline were administered in the wound catheter after skin closure then an infusion of normal saline at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
87525|NCT03502629|Biological|GB226|3mg/kg treat every 2 weeks
87526|NCT03502616|Drug|Tofacitinib|Oral administration twice per day
87527|NCT03502603|Diagnostic Test|Railroad Test|This is a test designed to evaluate visual perception capacities and requires the participant to match photographs with railroads as a central theme. The participant is presented with a photograph image at the top of the screen and is asked to match it to one of the two, three or four choices in the lower portion of the display.
87528|NCT03502603|Diagnostic Test|Swamp Test|This is a test of immediate visual memory/attention for photographs with swamp wetlands as a central theme. The participant is briefly presented with a photograph which is replaced by two, three or four choices, one of which the participant is asked to select as the initially presented image.
87529|NCT03502603|Diagnostic Test|Presidents Recognition Test|This is a test of history knowledge and facial recognition using pictures of US presidents and non-president distractors. The participant is presented with two photographs and is asked to identify which is the picture of a US president
87530|NCT03502603|Diagnostic Test|Judgment of Line Orientation|This test requires participants to visually match the orientation of line segments. This is a test of visual perception and was included as a relative equivalent of the Railroad Test.
87531|NCT03502603|Diagnostic Test|Symbol Span subtest of the Wechsler Memory Scale-IV|This test requires participants to immediately recall a sequence of designs after a brief presentation. This is a test of immediate visual memory/attention and was included as a relative equivalent of the Swamp Test
87532|NCT03502603|Diagnostic Test|Information subtest of the Wechsler Adult Intelligence Scale-IV:|This test requires participants to answer factual knowledge questions. This is a test of fund of knowledge and was included as a verbal equivalent for the non-verbal Presidents Recognition Test.
87533|NCT03502603|Diagnostic Test|Digit Span subtest of the Wechsler Adult Intelligence Scale-I|This test requires the participant to repeat sets of digits forward, backward, and to sequence digits in ascending order. This is a test of immediate memory/attention and was included to investigate possible attentional correlates of the Swamp Test. This test includes a performance validity indicator that will permit analyses of validity indicators included with the experimental tests
87534|NCT03502603|Diagnostic Test|Reading subtest of the Wide Range Achievement Test|This test requires participants to read words printed on a card. This is a test of word knowledge/academic achievement and was included to investigate the academic achievement concomitants of the Presidents Recognition Test.
87535|NCT03502603|Diagnostic Test|Symbol Digit Modalities Test:|This test requires participants to visually match abstract symbols with numbers within a certain time period. The participant either verbalizes or writes the response on an answer sheet. This is a test of speed of information processing and was included to assess speed of response factors pertaining to all of the experimental tests as reflecting speed of information processing.
87536|NCT03502603|Diagnostic Test|Dot Counting Test|This test requires participants to count arrays of dots presented on a card while being timed. This is a performance validity test and was included to ascertain validity factors pertaining to each of the experimental tests.
87537|NCT03502590|Device|IGEL Laryngeal mask|Insertion of an IGEL device in anaesthetised patients
87538|NCT03502577|Biological|BCMA-specific CAR-expressing T Lymphocytes|Receive CAR T infusion
87539|NCT03502577|Drug|Cyclophosphamide|Given IV
87540|NCT03502577|Drug|Fludarabine|Given IV
87541|NCT03502577|Drug|Gamma-Secretase Inhibitor LY3039478|Given PO
87542|NCT03502577|Other|Laboratory Biomarker Analysis|Correlative studies
87543|NCT03502577|Other|Pharmacokinetic Study|Correlative studies
87544|NCT03502564|Behavioral|CBT for ED|Cognitive behavior therapy (CBT) for eating disorders (ED) is a 16-session individual therapy protocol which will focus on maintaining improvements in eating following intensive treatment, as well as addressing overconcern with weight/shape. Interventions will be adopted from the Enhanced CBT for ED manual.
87545|NCT03502564|Behavioral|Concurrent CBT for ED and PTSD|The concurrent ED and PTSD intervention will consist of 16 sessions of CBT for both PTSD and for ED (ED interventions described above). CBT for PTSD will be based on interventions in the Cognitive Processing Therapy (CPT) manual.
87546|NCT03502551|Drug|Ketamine|Ketamine infusion (0.5 mg/kg) over 40 minutes.
87547|NCT03502538|Device|Curaprox 5460 Ultra Soft|The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
87548|NCT03502538|Device|Oral-B Indicator Plus|Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
87602|NCT03502070|Drug|Placebo|One dose (4 capsules) of placebo
87603|NCT03502070|Device|Tobi Podhaler|The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use
87604|NCT03502044|Device|Inactive Kinetic Oscillation Stimulation (KOS)|10 minutes inactive KOS treatment in each nasal cavity.
89048|NCT03491176|Procedure|Magnetic Resonance Imaging|Undergo MRI scan
87549|NCT03502525|Behavioral|Break the Cycle Intervention|The intervention uses motivational interviewing to enhance persons who inject drugs' (PWID) motivation and skills to avoid helping non-PWID transition to injecting. The intervention entails discussions with participants in 8 areas: the participant's first time injecting; the participant's exposures to situations where helping with non-PWIDs' first injections is an option, and the extent to which they helped; their behaviors that might encourage non-PWID to inject for the first time; the risks associated with injection drug use; role-playing in which participants develop behaviors and scripts for avoiding or refusing requests to initiate non-PWID into injection; role- playing talking with other PWID about not encouraging non-PWID to start injecting; imparting safer injection practices when helping with a first injection seems like the best option; and receiving training in and using naloxone to reverse overdoses.
87550|NCT03502512|Other|Questionnaire Administration|Ancillary studies
87551|NCT03502512|Procedure|Reconstructive Surgery|Undergo reconstructive surgery with REVOLVE technique
87552|NCT03502512|Procedure|Reconstructive Surgery|Undergo reconstructive surgery with PureGraft technique
87553|NCT03502499|Drug|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
87554|NCT03502499|Drug|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
87555|NCT03502486|Other|Moderate exercise|20 minutes of cycle ergometry at 50-60% of heart rate max
87556|NCT03502486|Other|Intense exercise|20 minutes of cycle ergometry at 70-80% of heart rate max
87557|NCT03502486|Other|Reading|20 minutes of seated reading
87558|NCT03502473|Device|UltraShape Power device|"UltraShape Power is a non-invasive focused ultrasound device, approved by the FDA (160896K;170370K); CE; Israeli Ministry of Health. The UltraShape Power system works by emitting acoustic waves of focused ultrasonic energy (200 ± 30 KHz frequency) that converge into a confined focal volume underneath the skin, thereby, targeting only subcutaneous fat at a controlled depth. Unlike traditional ultrasound technology, UltraShape Power's energy transmits pulsed ultrasound, allowing control over temperature elevation. The system comprised of two main parts:~The Main console~Transducer"
87559|NCT03502460|Other|Operating Room Fluid Administration Lung Ultrasound|Use of lung ultrasound to limited fluid administration
87560|NCT03502447|Device|TearCare|TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
87561|NCT03502447|Device|Warm Compress and Lid Massage|Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
87562|NCT03502434|Drug|SM04755|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
87563|NCT03502434|Other|Vehicle|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
87564|NCT03502434|Other|White Petrolatum|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
87565|NCT03502434|Other|Sodium lauryl sulfate|Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading.
87566|NCT03502421|Drug|Ketamine|Low dose continuous infusion of ketamine 0.3 to 0.5 mg/kg per hour
87567|NCT03502408|Procedure|Endovascular Thrombectomy|Procedure: Endovascular Thrombectomy Device: Trepo trevor Retriever Device: Solitaire™ FR Revascularization Device
87568|NCT03502408|Procedure|Endovascular Thrombectomy|Procedure:Endovascular Thrombectomy Device: Solitaire™ FR Revascularization Device
87569|NCT03502395|Drug|Lidocaine|): Patients were received intravenous 1 mg/kg of 2 % lidocaine as a loading dose (just before induction of anesthesia) then received 2mg/kg /h lidocaine as maintenance dose (with maximum of 200 mg/h) till the end of the operation (skin closure).
87570|NCT03502395|Drug|Normal saline|A standardized equal volume of intravenous bolus dose of normal saline was given as loading dose then normal saline was administered on an equal rate of infusion.
87571|NCT03502382|Diagnostic Test|x-ray|Radiological: standing antero-posterior full-length digital images of the lower extremities
87572|NCT03502369|Procedure|Anterior Quadratus lamborum block|Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.
87573|NCT03502356|Drug|Azithromycin|In this group, patients will receive standard antibiotic prophylaxis CEFAZOLIN (at a dose of 1 g) and azithromycin (at a dose of 1g) 2 hours preoperative.
87574|NCT03502343|Drug|Modified Gemcitabine plus nab-Paclitaxel Combination Chemotherapy|"All patients will receive slow (over 30-40 minutes) intravenous administration of nab-paclitaxel (125 mg/m2) on days 1 and 15, and gemcitabine (1000 mg/m2) on days 1, 8, and 15 of a 28- day cycle (every 4 weeks). Treatment will discontinue if disease progression or intolerable toxicity is observed, if the patient withdraws from the study, or at the physician's discretion.~Dose reduction of the chemotherapeutic agent and/or delay of administration is allowed if serious treatment-related AEs occur, according to specified guideline in study protocol (Level 1: 100% -> 80%; Level 2: 80% -> 60%). If dose reduction is needed more than Level 2, the patient will be dropped from the trial."
87575|NCT03502330|Drug|APX005M|APX005M is a humanized Immunoglobulin G (IgG) 1 agonistic monoclonal antibody that binds cluster of differentiation (CD) 40. APX005M is administered by intravenous infusion.
87576|NCT03502330|Drug|Cabiralizumab|Cabiralizumab is a humanized Immunoglobulin G (IgG) 4 monoclonal antibody directed against Colony stimulating factor 1 receptor (CSF1R). Cabiralizumab is administered by intravenous infusion.
87577|NCT03502330|Drug|Nivolumab|Nivolumab is a humanized IgG4 monoclonal antibody directed against programmed cell death 1 (PD-1). Nivolumab is administered by intravenous infusion.
87605|NCT03502044|Device|Active Kinetic Oscillation Stimulation (KOS)|10 minutes active KOS treatment in each nasal cavity.
87578|NCT03502317|Behavioral|Physical Prehabilitation|Physical prehabilitation will comprise a personalized, home-based exercise program designed to meet the Cancer Care Ontario Exercise Guidelines for Cancer Survivors. A Registered Kinesiologist (RKin) will complete a baseline physical assessment and prescribe an individualized multi-modal exercise program consisting of 4-5 days of 30+ minutes of aerobic exercise (brisk walking or equivalent to target heart rate of 40-60% of max) and 2-3 days of moderate intensity resistance training of major muscle groups (8-10 repetitions). Participants will be provided with a Fitbit with a heart rate monitor, resistance bands, and a stability ball. Patients will be required to wear their Fitbit and record the number of steps at the end of each day from randomization to 90 days post-surgery.
87579|NCT03502317|Behavioral|Psychological Prehabilitation|Psychological prehabilitation will consist of one in-person coaching session of a 'mindfulness' informed intervention conducted by a specially trained RKin. The 40 minute coaching session will include a guided mindfulness session and debriefing. Participants will be asked to practice for 20 minutes twice a day. The patients will be given access to an audio file that will walk them through the 20 minute sessions.
87580|NCT03502304|Behavioral|Endurance training plus resistant training|CT in women with prediabetes and co-morbidities associated. Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 2 groups proposed. All sessions will be supervised by an exercise physiologist during 20-weeks.
87581|NCT03502291|Biological|Study one: LAIV + Inoculation|Pneumococci bacteria nasal inoculation following vaccination with LAIV and intramuscular placebo
87582|NCT03502291|Biological|Study one: Placebo + Inoculation|Pneumococci bacteria nasal inoculation following vaccination QIV with nasal placebo spray
87583|NCT03502291|Biological|Study two: Inoculation + LAIV|Pneumococci bacteria nasal inoculation prior to vaccination with LAIV and intramuscular placebo
87584|NCT03502291|Biological|Study two: Inoculation + placebo|Pneumococci bacteria nasal inoculation prior to vaccination QIV with nasal placebo
87585|NCT03502278|Behavioral|Islamic Trauma Healing|A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
87586|NCT03502265|Other|Otteroo|Otteroo will be provided for 4 weeks of use, to supplement any standard care. Standard care is not provided.
87587|NCT03502252|Behavioral|Semillas de Apego|Group-based Primary Caregiver Intervention: Group-based psychosocial program for victimized mothers (or alternative primary caregivers) with children 2 to 5, that aims at promoting healthy child-parent attachments as a pathway for a proper development among children exposed to violence.
87588|NCT03502239|Other|Mega Team - video game|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 15 minutes a day, 5 days a week for a minimum of 21 days and a maximum of 25 days.
87589|NCT03502226|Behavioral|Tailored feedback|"Electronic feedback based on participants stage of change which provided risk reduction behavior regarding their sexual health including use of condoms, contraceptions, and STI testing."
87590|NCT03502187|Behavioral|Progressive Exercise Plan|The goal of PEP is to reduce back pain, disability, and improve trunk flexibility, strength and endurance through controlled, gradual, progressive back exercises. PEP teaches muscle strengthening exercises and self-management strategies to promote back fitness. PEP sessions provide a standardized self-management framework for performing the exercises at home. PEP is performed every other day/week for about ~1 hour over a period of 9 weeks. PEP consists of 3 sequential phases with each phase lasting 3 weeks. Exercises become progressively more difficult and intense, focusing on back stretching and strengthening that progressively load and unload the lumbar spine by means of flexion/extension exercises. The PEP group will perform 31 exercise sessions for 60 minutes on alternating days.
87591|NCT03502187|Device|NeuromuscularElectricalStimulation(NMES)|The NMES treatment group will receive a portable battery-operated device, Recovery Back (Neurotech®, Minnetonka, MN) with a 2-garment site-specific system: back & abdomen. NMES muscle contractions will be elicited by an electrical impulse generated by the Recovery Back system. The device delivers a pre-set program of NMES using a symmetrical biphasic square pulse waveform. (Moore SR, Shurman J, 1997) The garments are light-weight, breathable fabric that wraps around the waist with precise placements for the reusable electrodes. The controller uses a rechargeable battery with charger supplied. The NMES protocol consists of 30-minutes of NMES stimulation alternating between the abdominal and lumbar site over 9-weeks (one day Back training, next day Abdominal training).
87592|NCT03502187|Behavioral|Primary Care Management (PCM)|All participants will receive standard primary care management for subacute LBP. Primary Care Management follows the clinical practice guidelines for low back pain.(Chou et al., 2007) Service members are to stay as active as possible and progressively increase their activity. Medications prescribed begin with paracetamol and NSAIDs as first-line drugs. Second-line drugs include antidepressants, benzodiazepines, tramadol, and opioids. All participants will receive an information sheet on LBP advising them to remain active and use self-care options such as heat application. To provide an attention control, the PCM only group will receive weekly communication from the study coordinator regarding pain and medication usage.
87593|NCT03502174|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
87594|NCT03502161|Device|QuantiFERON CMV Assay|Assay to measure cell-mediated immune function using QuantiFERON CMV assay.
87595|NCT03502148|Drug|PRV111 (Cisplatin Transmucosal System)|Each treatment visit will include one application of a permeation enhancer and then 2, 3 or 5 PRV111 (Cisplatin Transmucosal System) applications depending on the Stage subject is enrolled in.
87596|NCT03502135|Drug|Tetracaine HCl and oxymetazoline HCl nasal spray|Two intranasal sprays of anesthetic. Each spray delivers 0.2 mL of solution containing 6 mg tetracaine hydrochloride and 0.1 mg of oxymetazoline hydrochloride
87597|NCT03502122|Other|VR rehabilitation for motor function|rehabilitation for motor function
87598|NCT03502109|Other|Medication review with follow-up|Medication review with follow-up: trained pharmacists will conduct consecutive medication reviews by detecting and resolving drug related problems, educational interventions and applying pharmacotherapy changes made in collaboration with physicians.
87599|NCT03502096|Behavioral|To-Go container|Subjects were provided a to-go container in which leftover foods would be packaged
87600|NCT03502096|Other|Control|Subjects were not provided a to-go container with the meal
87601|NCT03502083|Drug|GLP-1 (7-36)Amide|IV infusion
87606|NCT03502031|Drug|ACE inhibitor|maximum tolerated dose of ACE Inhibitor such Lisinopril, Enalapril, Perindopril.
87607|NCT03502031|Drug|ARB|maximum tolerated dose or ARB such as Losartan, Valsartan
87608|NCT03502018|Drug|Bupivacaine liposome|A long-acting liposomal bupivacaine
87609|NCT03502018|Drug|Saline|Saline injection used as control
87610|NCT03502005|Drug|bictegravir/emtricitabine/tenofovir alafenamide|Discontinue ATRIPLA® and initiate BIKTARVY®
87611|NCT03501992|Behavioral|Current care|The current care arm consists of the contemporary efforts now in practice to support provider recommendation including a shared, standard immunization schedule, a shared rooming process, a shared well child visit schedule, a shared electronic prompt at point-of-care of vaccines due.
87612|NCT03501992|Behavioral|Reminder-recall|The communication will use expectant (announcement-style or presumptive) language noting the child's HPV vaccination status and stating that the child's provider strongly recommends the child receive the HPV vaccination now. The communication will also describe availability of topical anesthetics (less pain), indicate the availability and convenience of nurse visits for HPV vaccination (less fuss), and describe the immunological and logistical benefits of early vaccination (right now).
87613|NCT03501992|Behavioral|Audit-and-feedback|The intervention includes two components. The first is a missed opportunities audit-and-feedback. The second is a provision of a strong recommendation provider-toolkit, along with a broad education of the practice staff—nurses, medical secretaries, receptionists, and clinical assistants—regarding the nature of the intervention, its goals, and its likely impact on the practice. The broad education will be conducted through supervisory communications only to practice staff in practices allocated to the intervention at the beginning of the step.
87614|NCT03501992|Behavioral|Combined reminder-recall and audit-and-feedback|The combination reminder-and-audit arm consists of a simultaneous application of the intervention tested in the reminder-recall arm and the intervention tested in the audit-and-feedback arm.
87615|NCT03501979|Drug|Tucatinib|Tucatinib study drug is given in tablet form and taken daily.
87616|NCT03501979|Drug|Trastuzumab|Trastuzumab is approved by the FDA and is available commercially. Trastuzumab must be prepared and is administered intravenously.
87617|NCT03501979|Drug|Capecitabine|Capecitabine is approved by the FDA and is available commercially as an oral drug.
87618|NCT03501966|Drug|Acetazolamide|Medical therapy including diet
87619|NCT03501966|Procedure|Optic Nerve Sheath Fenestration|Medical therapy including diet + optic nerve sheath fenestration
87620|NCT03501966|Procedure|Ventriculoperitoneal CSF Shunting|Medical therapy including diet + ventriculoperitoneal CSF Shunting
87621|NCT03501953|Behavioral|Physical Activity|Six weeks of instructor-led physical activity sessions.
87622|NCT03501940|Procedure|Computed Tomography|Undergo 18F-DCFPyL PET/CT
87623|NCT03501940|Radiation|Fluorine F 18 DCFPyL|Given IV
87624|NCT03501940|Other|Laboratory Biomarker Analysis|Correlative studies
87625|NCT03501940|Procedure|Positron Emission Tomography|Undergo 18F-DCFPyL PET/CT
87626|NCT03501927|Diagnostic Test|FOCUS (focused cardiac ultrasound)|"A ultrasound of the heart and pleura will be performed. This provide information on~Left ventricular systolic function~Left ventricular diastolic function~Right ventricular systolic function~Right ventricular pressure overload~Biventricular sizes~Pathology of the mitral- and aortic valves~Pericardial fluid~Gross fluid status~Pleural effusion"
87627|NCT03501914|Behavioral|Mindfulness|A mindfulness program based on mindfulness-based principles developed by colleagues in Manchester will be adapted to be accessible for people with intellectual disabilities (ID) in Pakistan. This intervention will be translated into Urdu afterwards focus group will be conducted to get the views from people with ID, thei care takers and other stake holders to adapt and culturally modify the program. It will include some mindfulness based exercises i.e.welcome & introduction, exploring senses, its all in the mind, Mindful eating, breathing, soles of the feet, body scan, guided meditation, mindful stretching and walking.
87628|NCT03501901|Diagnostic Test|Antibiotic susceptibility test|
87629|NCT03501888|Behavioral|Cognitive Behavior Therapy|18 sessions of individual treatment, no manual.
87630|NCT03501888|Behavioral|Acceptance and Commitment Therapy|18 sessions of group treatment, manual based.
87631|NCT03501875|Radiation|CAC Score|Computed tomography angiography (CTA) with an injection of iodine-rich contrast material
87632|NCT03501862|Behavioral|Mindfulness-based cognitive therapy (psychosis)|A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
87633|NCT03501862|Behavioral|Psychoeducation (psychosis)|A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
87634|NCT03501849|Device|Polypectomy using a cold snare|Polyp resection for all detected polyps of 4-20 mm using the cold-snare technique in combination with a sub mucosal injection of saline and Optivista imaging
87635|NCT03501836|Device|Rapid Rhythm Handheld 8-lead ECG Device|"We want to explore whether using 6 electrodes on the chest (as in the Rapid Rhythm Handheld 8-lead ECG device) can give the same diagnostic result to the standard 10 electrode (12-lead) ECG, which uses 6 chest electrodes plus 4 electrodes on the arms and legs.~To do this we need to compare measurements taken with the 6 electrode (8 lead) study device to those taken with the gold-standard 10 electrode (12 lead) method.~We want to find out whether the new equipment can detect the same heart rhythms as the standard method, so that ECG measurements might be made more quickly and easily in the future."
87636|NCT03501823|Other|Photoacoustic tomography|A non-invasive, safe modality that relies on light and sound to generate images.
87637|NCT03501810|Device|Distractor use for vertebrae separation|Distractor use where separation of vertebrae is required, including corpectomy, insertion of disc prosthesis, insertion of an anterior lumbar interbody fusion (ALIF) cage, and tumor surgery
87638|NCT03501797|Behavioral|Singing-based rehabilitation|The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
87639|NCT03501797|Other|Standard care|Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
87640|NCT03501784|Device|Nobio particles incorporated within Novidia Dental Bonding|Nobio particles incorporated within Novidia Dental Bonding and Flow
87641|NCT03501784|Device|Filtek bond and flow composite|standard of care class V composite restoration performed with Filtek and 3M
87642|NCT03501771|Other|Acupuncture|Disposable acupuncture needles will be inserted into acupoints (BL23, BL25, BL40) bilaterally for a depth of 10-30 mm
87643|NCT03501758|Diagnostic Test|Ultrasound|Transabdominal ultrasound of the bowel for categorisation of disease activity
87644|NCT03501758|Diagnostic Test|Analysis of prouroguanyline and uroguanyline in full blood|Withdrawal of full blood at each study visit, Storage in biobank. Analysis of prouroguanyline and proguanyline.
87645|NCT03501745|Behavioral|WeChat|Through remote management and propaganda of intelligent mobile phone, the standard rate of blood pressure control and the change of renal function were observed.
87646|NCT03501732|Behavioral|Values Affirmation|Experimental Group selects two values and describes why they are important
87647|NCT03501732|Behavioral|Risk Feedback|Experimental and comparator conditions both receive normative feedback in domains of risk
87648|NCT03501719|Drug|Number of drugs in the ART regimen|Triple therapy vs. dual therapy vs. monotherapy
87649|NCT03501706|Behavioral|Sequenced Recall of Digits--Auditory|Auditory digit sequence AT memory component.
87650|NCT03501706|Behavioral|Sequenced Reverse Recall of Digits--Auditory|Reversed auditory digit sequence AT memory component.
87651|NCT03501706|Behavioral|Sequenced Recall of Words--Visual|Visual word sequence AT memory component
87652|NCT03501706|Behavioral|Verbal Memory--Visual|word recognition AT memory component
87653|NCT03501693|Device|DBT plus S-View|DBT plus S-View images
87654|NCT03501693|Device|FFDM Alone|FFDM alone images
87655|NCT03501680|Drug|Insulin|"Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump."
87656|NCT03501680|Device|plasmapheresis|Triglyceridemia should be less than 5.65 mmol/l.
87657|NCT03501667|Other|Use of decision support tool|use of a decision support software during clinical assessment of a case
87658|NCT03501667|Other|Use of UpToDate|Control group, participants using current literature prior to assessing a clinical case. Allowing 10 minutes to read on a topic during clinical care is an active intervention in the study participant fund of knowledge.
87659|NCT03501654|Device|TecnisSymfony®|Patients received implantation of unilateral or bilateral TecnisSymfony® IOL after phacoemulsification by a single surgeon (MK Kim).
87660|NCT03501641|Other|image-based virtual reality learning|The participants will use a whole-view, 360 degree image-based virtual reality to learn a competence of history taking and physical examination for otolaryngology and they can see the response of the staffs and standard patients (including image, voice, face expression, movement, ... etc).
87661|NCT03501641|Other|video-based learning|voice of the staffs and standard patients.
87662|NCT03501628|Dietary Supplement|Placebo|Supplementation twice daily (1 serving dose per consumption) of maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
87663|NCT03501628|Dietary Supplement|L-leucine + maltodextrin|Supplementation twice daily (1 serving dose per consumption) of L-leucine + maltodextin while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
87664|NCT03501628|Dietary Supplement|Whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
87665|NCT03501628|Dietary Supplement|Hydrolyzed whey protein concentrate|Supplementation twice daily (1 serving dose per consumption) of hydrolyzed whey protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
87666|NCT03501628|Dietary Supplement|Soy protein concentrate|Supplementation twice daily (1 serving dose per consumption) of soy protein concentrate while engaging in resistance training 3 times per week for a 12-week period. Supplementation occurred during training and non-training days.
87667|NCT03501615|Drug|Moxetumomab Pasudotox|A recombinant conjugated immunotoxin composed of a disulfide-stabilized anti-CD22 Ig Fv genetically fused to a truncated form of Pseudomonas exotoxin, PE38
87668|NCT03501602|Device|LMA protector|In this arm the LMA protector will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
87669|NCT03501602|Device|I-gel LMA|In this arm the I-gel LMA will be inserted. The time from took the LMA to placement of the LMA will be recorded. In patients with adequate ventilation, an Aintree catheter placed on a fiberoptic bronchoscope in LMA will be delivered. Cord vocals will be seen on the monitor and the aintree catheter will be sent into the trachea. After the insertion of the trachea, the fiberoptic bronchoscope and LMA are removed and the patient's intubation tube is advanced through the Aintree catheter to the patient's trachea. Once you have made sure that the tube is in the trachea, it will be removed. The time from insertion of the LMA to placement of the endotracheal tube will be recorded.
87670|NCT03501576|Biological|Inactivated Influenza Vaccine|Given seasonal inactivated influenza vaccine IM
87671|NCT03501550|Drug|CDI-31244|investigational drug
87672|NCT03501550|Drug|SOF/VEL|sofosbuvir and velpatasvir fixed dose combination
87673|NCT03501537|Procedure|Free gingival graft obtained from the palate and debridement of the peri-implant lesion|granulation tissue debridement and grafting of a free gingival strip obtained from the palate
87674|NCT03501524|Device|VATS evacuation|the patient will be randomized to a Video-Assisted thoracoscopy for retained haemothorax
87675|NCT03501524|Device|thoracostomy tube|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
87676|NCT03501511|Behavioral|IDF modules|Patients in this arm will receive Pre-Ramadan education using IDF module for 4 weeks prior to Ramadan fasting
87677|NCT03501511|Behavioral|Conversational Maps|Patients in this arm will receive Pre-Ramadan Education using Ramadan Fasting Diabetes conversation map for 4 weeks prior to Ramadan fasting
87678|NCT03501498|Drug|Loperamide|Alters intestinal transit time.
87679|NCT03501498|Drug|Senna|Alters intestinal transit time.
87680|NCT03501472|Behavioral|text-only PWL|
87681|NCT03501472|Behavioral|low-emot PWL|
87682|NCT03501472|Behavioral|high-emot PWL|
87683|NCT03501472|Behavioral|immed posttest|
87684|NCT03501472|Behavioral|delay posttest|
87685|NCT03501459|Drug|Rituximab|
87686|NCT03501433|Dietary Supplement|Nicotinamide riboside chloride (Niagen)|250 mg capsules 2x/day for 7 days
87687|NCT03501433|Dietary Supplement|Placebo|2x/day for 7 days
87688|NCT03501420|Other|Interview|A one hour survey interview will be completed by the rheumatologists which will contain open and closed questions to probe physician perception and behaviors in relation to pSS management and treatment
87689|NCT03501420|Other|PSC questionnaire|All subjects for whom the physician completes a PRF will be required to complete a PSC questionnaire independently of their physician, immediately after consultation.
87690|NCT03501420|Other|PRFs|PRFs will be completed by the physicians for seven of their consulting pSS subjects.
87691|NCT03501407|Diagnostic Test|Blood samples|1 or 2 blood samples will be collected from the patient.
87692|NCT03501407|Diagnostic Test|skin biopsy|A skin biopsy will be performed on the periphery of the erythema migrans
87693|NCT03501394|Other|Magnetic Resonance Imaging|Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
87694|NCT03501394|Other|Histopathological Analysis|Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
87695|NCT03501394|Other|Health Questionnaire|Health and demographic information will be collected.
87698|NCT03501368|Drug|Ceritinib|Participants will take ceritinib by mouth (PO) once daily at a dose of 450 mg (3 capsules of 150 mg) for up to a year.
87699|NCT03501355|Device|Inspiratory muscle strength training|"Treatment group will receive inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 50% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 50% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
87700|NCT03501355|Device|Inspiratory muscle endurance training|"Treatment group II will receive inspiratory muscle endurance training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 30% of maximal inspiratory pressure (MIP).~The MIP will be measured at supervised session each week, and 30% of measured MIP value will be the new training workload.~The treatment group will train for 30 min-per/day, 7 days/week, for 8 weeks. Six sessions at home and 1 session will be performed at department."
87701|NCT03501342|Other|Virtual reality group|"Immersive virtual reality training protocol consisted of Football and Guillotine games."
87702|NCT03501342|Other|Dynamic Balance Training|Dynamic balance training protocol consisted of holding the ball and running away from the ball with a physiotherapist.
87703|NCT03501329|Combination Product|Biological,Psychological and Social support|
87704|NCT03501316|Device|Hand Instrumentation Treatment|Provision of treatment for periodontal disease using hand instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
87705|NCT03501316|Device|Ultrasonic Instrumentation Treatment|Provision of treatment for periodontal disease using ultrasonic instrumentation. Following this, data will be collected relating to various factors, principle of which being systemic immune response.
87706|NCT03501303|Procedure|No touch technique|Veins for CABG is harvested with the no touch technique
87707|NCT03501303|Procedure|Control technique|Veins for CABG is harvested with the Control technique.
87708|NCT03501290|Dietary Supplement|Fortimel® Protein supplementation|"Patients are supposed to take Fortimel® Protein once daily during the study period. The prescription is one unit a day.~First prescription of the study product will be done for one month. Prescription will be repeated for 2 additional months only after the patient's nutritional status and its global health status, as well as tolerability and compliance to the ONS, were re-assessed during the first follow-up visit at one month."
87709|NCT03501277|Drug|Alogliptin|Alogliptin tablets.
87710|NCT03501277|Drug|Pioglitazone|Pioglitazone tablets.
87711|NCT03501277|Drug|SYR-322-4833 BL|SYR-322-4833 BL FDC tablets.
87712|NCT03501264|Behavioral|Online Game|LGBTQ Bullying game
87713|NCT03501264|Behavioral|LGBTQ Resources|This group receives LGBTQ Resources
87714|NCT03501251|Drug|Moxidectin 8mg|Participants will receive the tablet with clean water and a package of biscuits.
87715|NCT03501251|Drug|Moxidectin 8 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
87716|NCT03501251|Drug|Moxidectin 16 mg|Participants will receive the tablets with clean water and a package of biscuits.
89049|NCT03491176|Other|Quality-of-Life Assessment|Ancillary studies
87717|NCT03501251|Drug|Moxidectin 16 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
87718|NCT03501251|Drug|Moxidectin 24 mg|Participants will receive the tablets with clean water and a package of biscuits.
87719|NCT03501251|Drug|Moxidectin 24 mg + albendazole 400 mg|Participants will receive the tablets with clean water and a package of biscuits.
87720|NCT03501251|Other|Placebo|Participants will receive the tablet with clean water and a package of biscuits.
87721|NCT03501238|Other|Chocolate Milk|Chocolate bovine milk will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
87722|NCT03501238|Other|Chocolate milk substitute|Chocolate milk substitute will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
87723|NCT03501238|Other|Chocolate milk substitute with gelatin|Chocolate milk substitute with gelatin added will be consumed everyday for 1 week. Milks will be store-bought, with added sucrose and added cocoa powder.
87724|NCT03501225|Procedure|ozone|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with ozonated water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with ozonated water according to randomization. The suture was then performed.
87725|NCT03501225|Procedure|water|After local anesthesia, it was performed sulcular incision with scalpel blade number 15 and removal of soft tissues. Osteotomy was performed at low rotation and odontosecion at high speed, under constant irrigation with redistilled water. Tooth removal, careful curettage, bone regularization and surgical shop cleaning were then performed under abundant irrigation with redistilled water according to randomization. The suture was then performed.
87726|NCT03501212|Drug|Topical Anesthetic|EMLA Cream 2.5 gr applied to both wrists
87727|NCT03501212|Drug|Placebo|Placebo Cream 2.5gr applied to both wrist
87728|NCT03501199|Other|platelet-rich fibrin placement|filling the buccal gap with platelet-rich fibrin after immediate dental implant placement
87729|NCT03501199|Other|xenogenic graft placement|filling the buccal gap with xenogenic graft after immediate dental implant placement
87730|NCT03501199|Other|no extra material|filling the buccal gap with no material after immediate dental implant placement
87731|NCT03501199|Procedure|tooth extraction|extraction of tooth which is unrestorable
87732|NCT03501199|Procedure|immediate implant placement|putting dental implant into a socket which has been prepared with compatible drills
87733|NCT03501199|Other|collagen membran placement|placing collagen membran on extraction socket after dental implant placement to cover all
87734|NCT03501199|Procedure|raising flap|raising the buccal flap with two vertical incision to cover extraction socket for primary closure
87735|NCT03501186|Other|Backward walking on sand|the patient will be walking backwards on sand with therapist standing close to support in case of fall.
87736|NCT03501173|Other|Standard of Care|Participants will not receive any intervention in this study. Participants will receive standard of care therapy.
87737|NCT03501160|Other|Face-to face semi-structured in-depth interview|Face-to face semi-structured in-depth interview will be arranged in order to explore the inappropriate social behavior and caregiver stress from caregivers. The interview will be guided by a semi-structured interview guide which specially designed for exploring clinical picture of inappropriate social and affectionate behavior and caregiving distress. The interview guide mainly consisted of specific questions and open-ended questions that encourage the subjects to talk freely in relevant topics during interview. Demographic data was also collected in the beginning of interview. Each interview will be conducted around 60 minutes until data saturated. The interview will be audio-taped with informed consent from subjects.
87738|NCT03501147|Other|Resistance training|15 minutes of resistance training during work every day
87739|NCT03501134|Device|NovoTTF|We are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.
87740|NCT03501108|Other|STOPPFrail deprescribing criteria|STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
87741|NCT03501095|Diagnostic Test|Vocal analysis and Laryngostroboscopy|"Vocal analysis study the acoustic emission of the pneumo-phono-articulatory system, i.e. the vocal signal. Currently, digital technology instruments enable the processing and analysis of the verbal signal quickly and reliably, also offering graphical products and numerical data. Among the various existing software products for the study of the vocal signal, PRAAT is available. In practice, the vocal parameters are acquired in a non-invasive way with a microphone.~Laryngostroboscopy is one of the most widely used techniques for laryngeal clinical evaluation. This is a non-invasive endoscopic practice performed by means of a flexible fibroscope, which, through a pulsed light source, allows visualization of the chordal movement."
87742|NCT03501082|Other|L Reuteri PB-W1 Strain|L. Reuteri PB-W1 strain will be prepared in accordance to the standardized operating procedures to prepare Lactobacillus reuteri in food grade conditions
87743|NCT03501082|Other|L. Reuteri DSM20016T Strain|L. Reuteri DSM20016T strain will be prepared in accordance to the standardized operating procedures to prepare Lactobacillus reuteri in food grade conditions
87744|NCT03501082|Other|Placebo|2 g of maltodextrin will be dissolved in 50 ml water in food grade conditions
87745|NCT03501069|Drug|TAK-418|TAK-418 capsules.
87746|NCT03501069|Drug|TAK-418 Matching Placebo|TAK-418 matching placebo capsules.
87747|NCT03501056|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
87748|NCT03501056|Procedure|Cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
87783|NCT03500822|Procedure|Expiratory-stenosis breathing|three cycles: BF - /min, I : E - 1 : 3; stenosis: 3mm; 2mm; 1,5mm
89050|NCT03491176|Other|Questionnaire Administration|Ancillary studies
87749|NCT03501043|Drug|Dysport|Dysport 1000 to 1500 units to be distributed on the basis of clinical indication to ankle plantar flexors (gastrocnemius and soleus), knee extensors and flexors, tibialis posterior and long toe flexors.
87751|NCT03501017|Other|physical activity program|"The 12-week physical activity program was implemented under the guidance of nurse, in outdoors with the group, 5 days a week with warm up and cooling down for 10 minutes and normal walking tempo at a moderate pace for 30-45 minutes (3-6 km/hour).~Application of WHO Smoking Cessation Algorithm: After fagerström test was applied, the modified smoking cessation algorithm of WHO was applied to the individuals and those who decided to quit smoking were referred to smoking cessation outpatient clinics."
87752|NCT03501017|Other|Routine Practice|As routine practice, a brochure provided from the Public Health Directorate on protection from CVD was delivered to the individuals in the control group.
87753|NCT03501004|Device|Sterile acupuncture needles for single use|Sterile acupuncture needles for single use are made by China Beijing Zhongyan Taihe Medical Instrument Limited Company.Acupuncture needles' specifications are 0.25mm*25mm.
87754|NCT03500991|Biological|HER2-specific chimeric antigen receptor (CAR) T cell|Autologous CD4 and CD8 T cells lentivirally transduced to express a HER2 specific chimeric antigen receptor (CAR) and EGFRt given via indwelling central nervous system (CNS) catheter
87755|NCT03500978|Behavioral|Peer CBT Intervention|Peer specialist delivery of cognitive behavioral therapy intervention over the phone.
87756|NCT03500965|Behavioral|text-only PWL|control condition (no image)
87757|NCT03500965|Behavioral|graphic PWL|pictorial warning
87758|NCT03500965|Behavioral|absolute risk|Percentage risk information for smoking-related diseases for smokers
87759|NCT03500965|Behavioral|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
87760|NCT03500952|Other|Birth Control After Pregnancy|A 27-page patient decision aid in portable document format (and an accompanying 3-page supporting document in portable document format) hosted online.
87761|NCT03500952|Other|Postpartum Birth Control|A 4-page patient information leaflet in portable document format and text format hosted online.
87762|NCT03500939|Drug|Medical oxygen|inhalation of 100% oxygen at high flow via a sealed non-rebreather face-mask with reservoir
87763|NCT03500939|Other|Standard of care|e.g. thrombectomy, thrombolysis
87764|NCT03500926|Device|total hip replacement - standard femoral stem|total hip replacement with standard femoral stem
87765|NCT03500926|Device|total hip replacement - short femoral stem|total hip replacement with short femoral stem
87766|NCT03500913|Drug|Growth Hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
87767|NCT03500900|Drug|Vildagliptin 50 mg|Acute administration of Vildagliptin, 50 mg.
87768|NCT03500900|Drug|Placebo Oral Tablet|Acute administration of placebo tablet
87769|NCT03500887|Device|intragastric bag|
87770|NCT03500874|Drug|FUDR|Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
87771|NCT03500874|Drug|Oxaliplatin|Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
87772|NCT03500874|Drug|Leucovorin|Leucovorin 200mg/m2 ivd over 2 hours on Day 1
87773|NCT03500874|Drug|5FU|followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
87774|NCT03500861|Other|Dry Needling|"The trigger point DN procedure was performed by a certified physiotherapist. While the patient was sitting, the therapist firstly cleaned the area with alcohol. Then, DN was applied into the active TrPs on the basis of the technique described by Hong (19). The needle remained in the trigger points for 20 minutes. Upon removal of the needle, the area was compressed firmly with a cotton swab for 60 secs. The DN procedure used sterile stainless-steel acupuncture needles of 0.25x40 mm and 0.25x 25 mm dimensions (Hua Long ®). DN was applied three times a week for 2 weeks, in previously diagnosed active trigger points located in the musculature of the head and the neck.~the Sham Dry Needling procedure was applied into the adipose tissue located at any area where an active TrPs was absent."
87775|NCT03500848|Drug|Tacrolimus|Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.
87776|NCT03500848|Drug|Tacrolimus (Tacrolimus elimination)|Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.
87777|NCT03500848|Drug|Sirolimus|Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.
87778|NCT03500848|Drug|MMF and/or steroids|For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
87779|NCT03500835|Behavioral|App|"6 month app intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction~Daily Weigh In~App based reminders~Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months."
87780|NCT03500835|Behavioral|Coaching|"6 month addiction based intervention: Problem Food Withdrawal, Snacking Elimination and Food Amount Reduction.~Daily Weighing~Daily Text messages from Coach~Weekly 15 minute phone meetings with Coach~Follow Up: Face-to-face clinic visits at 3,6,12 and 18 months post consent"
87781|NCT03500835|Behavioral|Clinic: Modified KidsNFitness|"6 month in-clinic, evidence-based, multi-disciplinary intervention~90 minute sessions, in clinic that occur every month for 6 months~Follow Up: Face-to-face clinic visits Monthly x 6 months followed by face-to-face visit at12 and 18 months."
87782|NCT03500822|Procedure|Metronome-paced tachypnea|three cycles: breathing frequency (BF) - 40/min, inspiration : expiration (I : E) - 1 : 1; BF - 40/min, I : E - 1 : 2; BF - 30/min, I : E - 1 : 2
87784|NCT03500809|Procedure|Aqueous release of the wound|"Anaesthetic drop (tetracaine 1%) followed by povidone iodine 5% drop is instilled. After 5 minutes, a sterile 30 gauge needle tip is pressed on the posterior lip of the one of the existing cuts (paracentesis or main wound) from cataract surgery to release the fluid and consequently the pressure.~This will be performed under careful monitoring to avoid any undesirable shallowing of the anterior chamber of the eye."
87785|NCT03500796|Procedure|Platelet rich plasma clot implantation|Implantation of a platelet rich plasma clot, which is created from the plasma of the patients, and refrigerated to be inserted under the sealing amniotic membrane
87786|NCT03500796|Procedure|Wound closure with amniotic membrane|Closure of the corneal perforation with a synthetic amniotic membrane with a 2 mm safety margin
87787|NCT03500783|Drug|Nitric Oxide|40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
87788|NCT03500783|Other|Standard CPB|Standard protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit
87789|NCT03500770|Device|Transcranial Direct Current Stimulator|The tDCS device to be used will be an investigational, battery powered, custom-made stimulator able to deliver a biphasic alternate current. Active stimulation consists of 10 active tDCS sessions with current intensity fixed at 2mA for 20 minutes. It has been safely used in several other research studies. The side effects profile for this type of stimulation include tingling/itching at the site of stimulation, skin irritation/redness at the site of stimulation, headache or dizziness.
87790|NCT03500757|Device|HoloLens|use the HoloLens to evaluate new 3D holographic guidance and navigation for percutaneous ablation of solid tumors
87791|NCT03500744|Procedure|Erector spinae plane block|Ropivacaine 0.5% 20 mL at each site of ESPB
87792|NCT03500744|Procedure|Sham block|Skin infiltration only
87793|NCT03500731|Biological|CD3/CD19 negative hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on CliniMACS® depletion device and given at time no less than 8 weeks post lung transplantation
87794|NCT03500731|Drug|Rituximab|Transplantation Conditioning
87795|NCT03500731|Drug|Alemtuzumab|Transplantation Conditioning
87796|NCT03500731|Drug|Fludarabine|Transplantation Conditioning
87797|NCT03500731|Drug|Thiotepa|Transplantation Conditioning
87798|NCT03500731|Drug|G-CSF|Transplantation conditioning
87799|NCT03500731|Drug|Hydroxyurea|Transplantation Conditioning
87800|NCT03500718|Device|Cochlear implant|After cochlear implantation, cochlear nerve is stimulated by giving a current over the electrodes placed in the cochlea and the current is measured by electrically evoked Compound Action Potential (ECAP).
87801|NCT03500705|Device|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair at a table with a standard mirror placed on the table in the mid-sagittal plane between both arms, with the reflective side of the mirror facing the non-affected arm. The patient is instructed to observe the reflection of the non-affected arm during the sessions. The patient was not given any instruction on the use of the affected arm.
87802|NCT03500705|Other|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected arm of each stroke patient.
87803|NCT03500692|Device|MitraClip NT System|Percutaneous mitral valve repair using MitraClip NT System
87804|NCT03500679|Biological|ExPEC4V|Participants will receive ExPEC4V vaccine as an IM injection on Days 1 and 181.
87805|NCT03500679|Biological|Placebo|Participants will receive placebo as an IM injection on Days 1 and 181.
87806|NCT03500666|Device|Robot|Robot lateral neck lymph node dissection
87807|NCT03500666|Device|Total endoscopic|Total endoscopic lateral cervical lymph node dissection
87808|NCT03500653|Dietary Supplement|Curcumin|4 gr curcumin
87809|NCT03500653|Dietary Supplement|Placebo|4 gr placebo
87810|NCT03500640|Behavioral|DPP Intensive: 30-minute calls|Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.
87811|NCT03500640|Behavioral|DPP Support: 15-minute calls|No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
87812|NCT03500627|Drug|OP-101|Intravenous Injection of OP-101 in healthy volunteers.
87813|NCT03500614|Behavioral|Air cleaner use method 1|All interventions in the first cohort will start at noon on Tuesday or Thursday and continue to the next morning of Tuesday or Thursday.
87814|NCT03500614|Behavioral|Air cleaner use method 2|All interventions in the second cohort will start from the beginning to the end of smog episodes.
87815|NCT03500601|Other|Nut components|nut components consumed daily for a period of 28 days
87816|NCT03500601|Other|Placebo|Placebo consumed daily for a period of 28 days
87817|NCT03500588|Diagnostic Test|PCR|Polymerase chain reaction was used to diagnose gene polymorphism.
87818|NCT03500575|Device|photopheresis|• Treated group will receive ECP with Therakos online system. Each session consists in 1 treatment for 2 consecutive days. First session stars within 72 hours after transplantation followed by a session weekly for 3 time and 2 sessions for the next 2 months (6 sessions = 12 treatment)
87819|NCT03500562|Other|Non-Interventional|Non-Interventional
87820|NCT03500549|Drug|APL-2|Complement (C3) Inhibitor
87821|NCT03500549|Drug|Soliris|Complement (C5) Inhibitor
87822|NCT03500536|Behavioral|IntelliCare|A suite of mobile apps that use principles of computerized therapy to decrease symptoms of depression.
87823|NCT03500523|Diagnostic Test|corneal biomechanical properties|We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
87824|NCT03500497|Diagnostic Test|RetHe measurement (Sysmex)|RetHe measurement is done from blood samples gained during standard patient care perioperatively
87826|NCT03500471|Procedure|Robotic-assisted Total Gastrectomy|Robotic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose robotic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
87827|NCT03500471|Procedure|Laparoscopic-assisted Total Gastrectomy|Laparoscopic-assisted total gastrectomy with D2 lymph node dissection will be performed with curative treated intent according to the patients' or their legal representatives'willing to choose laparoscopic-assisted total gastrectomy and exclusing T4b、bulky lymph nodes or distant metastasis case by diagnostic laparoscopy. The alimentary canal reconstruction method is selected as esophageal jejunal R-Y anastomosis. Whether to reinforce the anastomotic manually is decided by the surgeon's experience. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
87828|NCT03500458|Behavioral|Sleep Extension|Participants will be asked to increase time in bed at least 1 hour more than baseline
87829|NCT03500445|Drug|Daratumumab|"Daratumumab (16 mg/kg) will be administered as an IV infusion:~Cycle 1-2: 16 mg/kg weekly~Cycles 3-8: 16 mg/kg IV infusion every 2 weeks~Cycles 9-24: 16 mg/kg IV infusion Day 1"
87830|NCT03500445|Drug|Carfilzomib|"Carfilzomib will be given as an IV infusion over 30 minutes:~Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.~Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16~Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16"
87831|NCT03500445|Drug|Lenalidomide|"Lenalidomide will be taken orally as follows:~• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21"
87832|NCT03500445|Drug|Dexamethasone|"Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:~Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week~Cycles 9-24: 20 mg PO per week~During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after~During weeks with no daratumumab, single dose of 20 mg on day 1"
87833|NCT03500432|Procedure|local anesthesia of trnasperineal prostate biopsy|three different block site with lidocaine
87834|NCT03500419|Device|RestoreX|PTT - open label phase only Penile traction therapy in the straight position.
87835|NCT03500419|Device|RestoreX|PTT - randomized and open label Penile traction therapy in the straight position.
87836|NCT03500406|Device|RestoreX|Penile traction therapy in the straight position
87837|NCT03500406|Other|Control|No treatment
87838|NCT03500393|Behavioral|Remotely Supervised Exercise (REM)|REM is designed to follow in the tradition of stepped care behavioral interventions. As such, participants who are successfully engaging in the prescribed exercise are provided minimal and automated encouragement and praise. Participants who demonstrate less adherence are given interventions that are tailored in content and intensity, depending on the level of success and the nature of the barriers to success
87839|NCT03500393|Behavioral|Unsupervised Exercise (UNSUP)|The control condition represents a minimalist intervention that could occur in any setting: (1) enthusiastic provision on an exercise prescription and (2) provision of a fitness device (i.e., the Garmin VivioActive) that can help participants track their exercise engagement. Participants are instructed in how to use the device to track their adherence to the exercise prescription.
87840|NCT03500380|Drug|RC48-ADC|RC48-ADC 2.0 mg/kg IV every 14 days
87841|NCT03500380|Drug|Lapatinib|Lapatinib 1250 mg orally once daily during each 21-day cycle.
87842|NCT03500380|Drug|Capecitabine|Capecitabine 2000 mg/m^2 orally daily on Days 1-14 of each 21-day treatment cycle.
87843|NCT03500367|Drug|rapamycin|rapamycin, 2 mg a day, orally ,for 3months
87844|NCT03500354|Dietary Supplement|Nutrient drink|High calorie drink with therapeutic supplements
87845|NCT03500328|Other|Early Aggressive Therapy or Traditional Therapy|Participants will be stratified by whether they are at higher versus lower risk for long-term disability and then randomized 1:1 to a higher-efficacy versus a traditional, first-line disease-modifying therapy (DMT) class.
87846|NCT03500315|Other|HIV D+/R+|Kidney from an HIV-infected deceased donor
87847|NCT03500302|Drug|evolocumab|evolocumab sq once a month for a total of two doses
87848|NCT03500289|Drug|Ketamine|One intravenous infusion of ketamine 0.5 mg/kg over 40 minutes
87849|NCT03500289|Drug|Midazolam|One intravenous infusion of midazolam 0.05 mg/kg over 40 minutes
87850|NCT03500276|Behavioral|Yoga program|Yoga classes will be conducted 2xweekly/ 90 minutes and consist of physical exercises (asanas), breathing exercises (pranayama), relaxation and self-enquiry meditation based on Yoga in daily life system.
87851|NCT03500276|Behavioral|Arthritis-education|Arthritis-education classes will be conducted 1xweekly/ 120 minutes and led by rheumatology specialists and consist of lectures on arthritis and related issues followed by group discussion.
87852|NCT03500263|Drug|PTI-808|Active
87853|NCT03500263|Drug|Placebo|Placebo
87854|NCT03500263|Drug|PTI-801|Active
87855|NCT03500263|Drug|PTI-428|Active
87856|NCT03500263|Drug|Placebo|Placebo
87857|NCT03500250|Other|Post-Stroke Depression toolkit|The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
87858|NCT03500237|Behavioral|Team-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. In addition to the online program, a guide from the Online Therapy Unit team will respond within one business day of the client's email. The team of guides consist of registered social workers, psychologists or supervised graduate students, with experience delivering ICBT. Amount of contact will be personalized to participants' needs.
87896|NCT03499964|Device|Optilume Drug Coated Balloon (DCB)|The Optilume Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
87859|NCT03500237|Behavioral|Self-Guided ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) for persons with chronic conditions course will be delivered to participants. Participants are able to contact the Online Therapy Unit regarding any technical issues with logging onto the site. However, no psychoeducational support will be provided. A team member from the Unit will contact the participant only if there is a significant clinical issue requiring attention (e.g., sudden increase in symptoms).
87860|NCT03500224|Drug|[14C]-TAK-954|[14C]-TAK-954 intravenous infusion.
87861|NCT03500211|Drug|Lidoderm 5 % Topical Patch|Lidocaine patch after cesarean section delivery.
87862|NCT03500211|Other|Sham Topical Patch|Sham patch after cesarean section delivery.
87863|NCT03500185|Other|PFMT in group|
87864|NCT03500185|Other|PFMT at home|
87865|NCT03500172|Behavioral|DTP|Provision of antiretroviral therapy (ART) in the community through a mobile-van DTP managed by a nurse capable of initiating and managing ART.
87866|NCT03500172|Behavioral|ICM|Peer-led ICM through quarterly face-to-face meetings, monthly phone calls and biweekly text messages.
87867|NCT03500159|Drug|AQX-1125 200 mg|Synthetic SHIP1 activator
87868|NCT03500159|Drug|Placebo|Appearance and weight matched tablets without the active product ingredient
87869|NCT03500146|Drug|Anticholinergic|Patients prescribed medication for OAB
87870|NCT03500146|Procedure|PTNS|Patients prescribed PTNS for OAB
87871|NCT03500133|Radiation|No radiotherapy if CR at the end of chemotherapy.|Adapted chemotherapy without radiotherapy
87872|NCT03500133|Drug|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.|Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
87873|NCT03500133|Drug|Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
87874|NCT03500133|Radiation|IN 30Gy RT in case of PR at the end of chemotherapy|Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT
87875|NCT03500133|Drug|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.|Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
87876|NCT03500133|Drug|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
87877|NCT03500133|Drug|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
87878|NCT03500133|Drug|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.|High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
87879|NCT03500133|Drug|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.|Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
87880|NCT03500120|Diagnostic Test|Seated saline infusion test|"Seated saline infusion test: All participants received the infusion of 2 liters of 0.9% saline over 4 h in seated posture.~Fludrocortisone suppression test:Patients received 0.1 mg oral fludrocortisone every 6 h for 4 days, together with slow-release potassium chloride and sodium chloride supplements.~Captopril challenge test:Patients received 50 mg captopril orally at 8-9 a.m. after sitting or standing for at least 1 h. Blood samples were drawn at time zero and 2 h after the challenge."
87881|NCT03500107|Device|Blue Light Emitting Diode (LED) 401 +/- 5nm|The participant will be naked, in a ginecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
87882|NCT03500094|Drug|migalastat HCl 150 mg|migalastat HCl 150 mg capsule
87883|NCT03500081|Device|MRI Scan|The MRI scan will not be used for diagnostic purposes. The research team members do not use the sequences for detection of clinical conditions. This is an observational study only, with no interventions.
87884|NCT03500068|Diagnostic Test|biopsies & blood analyses|They will take blood and a biopsy from the metastase in the patient
87885|NCT03500055|Procedure|Abdominal Closure Bundle|Surgeons will re-scrub, change gown and gloves prior to closure of fascia. Will also use new instruments, bovie tip, suction tip, and light handles, for closure of fascia, subcutaneous tissue, and skin
87886|NCT03500042|Device|inspiratory pressure threshold device|The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
87887|NCT03500029|Radiation|Transcranial magnetic stimulation (TMS)|TMS treatment group is treated with TMS for 20-40 minutes a time, 5 times a week. The stimulation parameters were 20 Hz and 80% MT. Each stimulation continues for 2 seconds, and the interval time of stimulation is 58 seconds.
87888|NCT03500029|Drug|antidepressants|Medication group is treated with anti-depression for 6 weeks. The drugs and their doses belong to the first-line treatment for depression in the current guideline .
87889|NCT03500016|Other|Acute exercise|See under arm description.
87890|NCT03500003|Other|Acute milk intake|Food matrix: milk
87891|NCT03500003|Other|Acute Yogurt intake|Food matrix: yogurt
87892|NCT03499977|Behavioral|Sitting|10 min bouts
87893|NCT03499977|Behavioral|Light-Intensity Cycling|10min bout
87894|NCT03499977|Behavioral|Moderate-Intensity Cycling|10 min bout
87895|NCT03499977|Behavioral|High-Intensity Cycling|10 min bout
87958|NCT03499431|Device|Endovascular Thoracoabdominal Aneurysm Repair|Standard of care, treatment of thoracoabdominal aneurysms using endovascular techiniques.
87897|NCT03499964|Device|Control Treatment|A control subject may be dilated with either a rod, uncoated balloon or DVIU until the desired result is reached, based on standard of care for the clinical site and treating physician
87898|NCT03499951|Behavioral|Wheelchair Skills Training - Remote|Individuals will receive wheelchair skills training remotely. They will be provided with the Wheelchair Skills Training Program to review (http://www.wheelchairskillsprogram.ca/eng/index.php), and then will be directed to use this information to perform the wheelchair skills. They will video the attempts, and will receive feedback on methods to improve their techniques.
87899|NCT03499951|Behavioral|Wheelchair Skills Training - In Person|Individuals will receive wheelchair skills training in one-on-one sessions, taught by those who received the wheelchair skills training remotely.
87900|NCT03499938|Device|Structured Light Plethysmography|Non-invasive non-contact measurement of tidal breathing during hospital admission
87901|NCT03499925|Behavioral|cognitive behaviors|Telephone consultation effectiveness and cognitive behaviors
87902|NCT03499925|Behavioral|Telephone consultation|Telephone consultation effectiveness and cognitive behaviors
87906|NCT03499886|Drug|Ketamine Hydrochloride 50Mg/1mL Solution for Injection|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
87907|NCT03499886|Drug|Ketamine Hcl 50Mg/Ml Inj|In the intervention group, ketamine 1% was administered rapidly at a dose of 0.5 mg / kg (within 5 seconds), and in the control group, ketamine 1.5 mg / kg was slowly injected for 30 to 60 seconds.
87908|NCT03499873|Drug|Nepafenac 0.3% Oph Susp|Nepafenac 0.3% Ophthalmic suspension (experimental product)
87909|NCT03499873|Drug|Placebos|Placebo
87910|NCT03499873|Drug|Nepafenac 0.3% Oph Susp (reference)|Nepafenac 0.3% Ophthalmic suspension (Innovator)
87911|NCT03499860|Diagnostic Test|Passive Leg Raising Test|A passive leg raising test is performed in all patients included in the study
87912|NCT03499847|Behavioral|standardised face-to-face counselling session|the healthcare provider will conduct a standardised face-to-face counselling session guided with subjects guided by a check-list of topics to cover regarding the Advanced Medical Directive.
87913|NCT03499847|Behavioral|advanced medical directive pamphlet|A standardised pamphlet containing information about the Advanced Medical Directive produced by the Ministry of Health, Singapore.
87914|NCT03499834|Biological|Immune Killer Cells (IKC)|Autologous cells of the immune system. Intravenous Injection (I.V.) frequency: One injection per week, twenty-four injections on-treatment
87915|NCT03499821|Device|EDOF ICL|The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.
87916|NCT03499808|Biological|Isatuximab|Given IV
87917|NCT03499808|Other|Laboratory Biomarker Analysis|Correlative studies
87918|NCT03499795|Biological|VGX-3100|One milliliter (1 mL) VGX-3100 (deoxyribonucleic acid [DNA] plasmids encoding E6 and E7 proteins of HPV types 16 and 18) will be injected IM and delivered by EP using CELLECTRA™ 5PSP on Day 0, Week 4 and Week 12, and potentially Week 40.
87919|NCT03499795|Device|CELLECTRA™ 5PSP|IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 5PSP device.
87920|NCT03499769|Procedure|natural orifice|laparoscopic total colon surgery and patients who are removed from the natural orifice and conventional will gather
87921|NCT03499756|Behavioral|Couple-based interpersonal psychotherapy|The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
87922|NCT03499743|Drug|hyoscine butyl bromide|intake of 10 mg hyoscine butyl bromide (buscopan) orally in addition to a placebo similar to Celecoxib 2 hours before IUD insertion
87923|NCT03499743|Drug|Celecoxib 200mg|Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
87924|NCT03499743|Drug|Placebo Oral Tablet|a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
87925|NCT03499730|Drug|Midazolam injection|The dose of preoperative midazolam is the predictor variable and will be registered as a continuous variable in a single cohort.
87926|NCT03499704|Drug|SYR-322-4833|SYR-322-4833 tablets.
87927|NCT03499704|Drug|Alogliptin|Alogliptin tablets.
87928|NCT03499704|Drug|Metformin|Metformin tablets.
87929|NCT03499704|Drug|Glimepiride|Glimepiride tablets.
87930|NCT03499691|Device|Theranova 500 medium cut-off dialyzer|The patients randomized in this group using the Theranova 500 medium cut-off dialyzer, and blood flow rate and treatment duration will be maintained stable during the observation period. However, other prescriptions will vary based on the Principal Investigator's (PI's) judgment. If other dialyzers need to be temporarily used during the study period it shall be recorded which alternative dialyzers are used and for how long the study patient is on a different dialyzer. However, prior to Week 12 laboratory assessment it is recommended that the patient undergoes three dialysis sessions on the designated treatment mode.
87931|NCT03499691|Device|Hemodiafiltration|The patients randomized in this group using the on-line high-flux HDF dialyzer, in post dilution mode, will continue to receive treatments according to their current treatment prescriptions for the duration of the study.
87932|NCT03499665|Behavioral|PNF, Myofascial Releasing Maneuvers, Home Exercise Group|For Group 1 (n:20), the PNF, myofascial releasing and home exercises were used to decrease pain, jaw restriction and improve functional mobility on the masseter, lateral and medial pterygoid, buccinator, temporalis, orbicularis oris, orbicularis oculi, upper side of trapezius muscle, splenius, scalenous, and cervical extensor muscle in 20 patients with bruxism, for 2 and 6 weeks after pre-evaluation. PNF, myofascial releasing and home exercises were administered for 2 weeks, followed by 3 sets of 10 repeat home exercises and 6 weeks under physiotherapist control.
87933|NCT03499665|Behavioral|Myofascial Releasing Maneuvers and Home Exercises Group|In Group 2 (n:15), as myofascial releasing and home exercise group,final evaluation was made with 10 sets of myofascial releasing and home exercises for 2 and 6 weeks.
87934|NCT03499665|Behavioral|Control Group|In Group 3 (n:17), as the control group, no myofascial releasing or Proprioceptive Neuromuscular Facilitation exercises were applied.
87935|NCT03499652|Diagnostic Test|neonatal bacterial meningitis risk score|In the validation cohort,according to the neonatal bacterial meningitis risk score, we will suggest neonates who reach certain score to take a lumbar puncture, but we will not interfere with clinicians' decision
87936|NCT03499639|Drug|Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet|"Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks."
87937|NCT03499626|Drug|ASLAN001|"Starting dose at 300mg BD Dose level +1: 400mg BD (which is the target dose for this study)~Dose reduction of ASLAN001 in event of adverse events grade 2 and above:~Dose level -1: 200mg BD Dose level -2: 100mg BD"
87938|NCT03499613|Other|Multidisciplinary rehabilitation program|The multimodal rehabilitation program (MRP) based at the University Hospital is an intensive 3-weeks multidisciplinary rehabilitation program. Patients come daily for individual and group treatments, with a total of 100 hours of intervention during 3 weeks. The MRP includes physiotherapy treatments, aiming at improving cardio-vascular endurance, long-term physical activity adherence, proprioception, mobility and strength. Additionally, occupational therapy is mainly focussed on reassuring patients that spinal movements are safe. Finally, psychologists are involved in the MRP to discuss the meaning of LBP, the psychological implications and the patient's resources.
87939|NCT03499600|Behavioral|Clinical Assessment and CFI|CA and CFI families will participate in the Cultural Formulation Interview prior to their standard intake.
87940|NCT03499600|Behavioral|Clinical Assessment|CA families will participate their standard intake procedures.
87941|NCT03499574|Behavioral|Dysphagia therapy using surface EMG as biofeedback|10 x 45 minute sessions over 14 days
87942|NCT03499574|Behavioral|Usual Care|Usual care may include the following Speech and Language Therapy interventions; assessment, review, therapy, patient/family education etc.. Dose will vary.
87943|NCT03499561|Diagnostic Test|urine analysis|Intervention is (urine analysis ): of a mid stream urine sample will be taken
87944|NCT03499548|Other|INSPiRe Programme|Intensive CBT for suicide
87945|NCT03499535|Behavioral|Radon & Smoking Synergistic|Participants viewed health information detailing the risks of developing lung cancer from exposure to radon gas, smoking, and their synergistic effects. This intervention represents the type of information most commonly presented in radon risk communications.
87946|NCT03499535|Behavioral|Radon Only|Participants viewed health information detailing the risks of developing lung cancer from radon exposure. No information about the risks for developing lung cancer associated with smoking or its synergistic effect with radon exposure are included.
87947|NCT03499535|Behavioral|Radon and Smoking Isolated|Participants viewed health information detailing the risks of developing lung cancer from radon exposure and smoking. No information describing the synergistic effects of smoking and radon exposure on lung cancer risk are included.
87948|NCT03499535|Behavioral|EPA|Health information modeled after the Environmental Protection Agency's (EPA) pamphlet on radon risk.
87949|NCT03499535|Behavioral|Idaho|Health information modeled after the Idaho Department of Health and Human Welfare's pamphlet on radon risk.
87950|NCT03499522|Other|Observational group|"The dependent variables (pain, quality of life, anxiety and coping strategies) and the outcome measures used to measure these variables will be:~Numerical scale of pain~Short Form 36 Health Survey [SF-36].~State-Trait Anxiety Inventory [STAI].~Tampa Scale of Kinesiophofia [TSK-11SV].~Pain catastrophizing scale [PCS].~Coping Strategies Questionnaire [CSQ]."
87951|NCT03499509|Other|Low Glycemic Diet|"Low Glycemic (LG) diet: The LG diet will be made up of foods that do not stimulate insulin secretion. The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., High-Protein SlimFast). Dinner will be a frozen entrée (e.g., Atkins, Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be nuts, berries, and full-fat dairy products (one serving per day), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
87952|NCT03499509|Other|High Glycemic Diet|"High Glycemic (HG) diet: The HG diet will conform to United States Department of Agriculture (USDA) guidelines (http://health.gov/dietaryguidelines/2015/guidelines/). The foods that make up the diet will differ depending on the phase of the study. During the weight loss phase, breakfast and lunch will each consist of one or two meal-replacement shakes (e.g., SlimFast). Dinner will be a frozen entrée (e.g., Lean Cuisine, Healthy Choice) supplemented with a side of vegetables. Snacks will be fruit, fat-free dairy products, and low-fat bars (e.g., Optifast), and will be used to adjust the calorie level of each day's meals to individual calorie needs."
87953|NCT03499496|Diagnostic Test|ultrasound guided detection of atherosclerotic plaques|screening by ultrasound of atherosclerotic plaques
87954|NCT03499483|Drug|bictegravir|Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.
87955|NCT03499470|Other|Protocol for structured discharge and follow-up|
87956|NCT03499457|Drug|Amoxicillin|chalange test of 50 mg, and after an hour 500 mg
87957|NCT03499444|Drug|Rucaparib|Rucaparib will be administered twice daily
87961|NCT03499405|Behavioral|Family Navigator Intervention|Caregivers will be paired with a culturally matched family navigator.
87962|NCT03499392|Other|psychological tests|psychological tests psychological interviews
87963|NCT03499379|Device|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
87964|NCT03499379|Device|Paraguard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
87965|NCT03499366|Diagnostic Test|HFMS, MRC, ACTIVLIM, PedsQl-4.0|Clinical performance tests, quality of life, activity of daily life form.
87966|NCT03499353|Drug|TALAZOPARIB|Talazoparib 1mg/day
87967|NCT03499340|Behavioral|text-only PWL|control condition (no image)
87968|NCT03499340|Behavioral|low arousal graphic PWL|pictorial warning
87969|NCT03499340|Behavioral|high arousal graphic PWL|pictorial warning
87970|NCT03499340|Behavioral|absolute risk|Percentage risk information for smoking-related diseases for smokers
87971|NCT03499340|Behavioral|relative risk|Percentage risk information for smoking-related diseases for smokers and non-smokers
87972|NCT03499327|Dietary Supplement|Wheat germ oil (UV treated)|"Wheat germ oil is naturally rich in vitamin D precursors (ergosterol and 7-dehydrocholesterol), which are converted into vitamin D2 and vitamin D3 by a defined UV light irradiation for the present study (wheat germ oil (UV treated).~The wheat germ oil (UV treated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
87973|NCT03499327|Dietary Supplement|Wheat germ oil (untreated)|"commercial available wheat germ oil The wheat germ oil (untreated) is dispensed in dark glass bottles without label. The distinction between the groups is based on the expiration date (08.05.2018 vs. 09.05.2018). The distinction between the groups is not possible for the participants.~The daily dosage of wheat germ oil is 10 ml and the study products will be consumed over an entire period of 6 weeks (no follow-up).~Recommendation for intake: pure before a main meal."
87974|NCT03499314|Device|Active RS-tDCS +At-Home Manual Dexterity Training|Bilateral M1-SO electrode placement; Active= anodal 2.0 mA dose × 20 minutes
87975|NCT03499314|Device|Sham RS-tDCS +At-Home Manual Dexterity Training|"Designed to ensure blinding, includes initial and ending ramp-up/down stimulation for 60 seconds"
87976|NCT03499314|Other|Manual dexterity training|Manual dexterity training will be based on the at-home study in MS by Kamm and colleagues, where the training was completed by participants in their homes and demonstrated to be superior to strength training.
87977|NCT03499275|Device|Active NMES|Neuromuscular electrical stimulation to the quadriceps muscle
87978|NCT03499275|Device|Sham NMES|Sham neuromuscular electrical stimulation to the quadriceps muscle
87979|NCT03499275|Other|Home exercise programme|Home exercise programme. Both arms of the trial receive this intervention.
87980|NCT03499275|Other|Breathlessness advice|Breathlessness advice. Both arms of the trial receive this intervention.
87981|NCT03499262|Behavioral|Group Social ABCs|Social ABCs coach will facilitate the intervention to small groups of parents in a clinic setting, rather than the family's home. This new format allows the program to be completed in 6 weeks, versus the current 12-week model, and also offers the potential benefit of creating a parent support network within the program. Parents will still get live, one-on-one coaching for strategies to use with their child over the course of the program.
87983|NCT03499236|Device|V-Wave Interatrial Shunt|The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovalis and straddles the interatrial septum.
87984|NCT03499236|Other|Control|Right heart catheterization, invasive echocardiography.
87985|NCT03499223|Drug|Ranibizumab 0.5mg|3 intravitreal injections of ranibizumab 0.5mg, approximately 1 month apart
87986|NCT03499223|Drug|THR-317 8mg|3 intravitreal injections of THR-317 8mg, approximately 1 month apart
87987|NCT03499223|Drug|Sham injection|3 sham injections, approximately 1 month apart. No actual injections. No medication is used.
87988|NCT03499210|Device|ReWalk ReStore device|The ReWalk ReStore device is intended to be used to perform ambulatory functions in rehabilitation institutions under the supervision of a trained therapist for people with hemiplegia/hemiparesis due to stroke.
87989|NCT03499197|Diagnostic Test|cardiac magnetic resonance imaging|Detailed and regular CMR examination (LGE, stress perfusion, T1, T2 mapping)
87990|NCT03499184|Dietary Supplement|P Flor locally delivered|Locally delivered Lactobacillus reuteri 1.2 CFU per gram
87991|NCT03499184|Dietary Supplement|P Flor systemically administered|Systemically administered Lactobacillus reuteri 1.2 CFU per gram
87992|NCT03499184|Drug|Amoxil 500 mg Oral Capsule|Systemically administered Amoxil 500 mg thrice daily
87993|NCT03499184|Drug|Flagyl 400 mg Tablet|Systemically administered Metronidazole 400 mg twice daily
87994|NCT03499171|Drug|Citalopram 20mg|Citalopram is taken once a day as an add-on to PPI treatment (2x/d).
87995|NCT03499171|Drug|Placebo Oral Tablet|Placebo is taken once a day as an add-on to PPI treatment (2x/d)
87996|NCT03499158|Other|nerve conduction study|nerve conduction study
87997|NCT03499145|Device|Ophthalmology diagnostic system.|An artificial intelligence to make comprehensive evaluation and treatment decision of ocular diseases.
87998|NCT03499132|Procedure|anesthesia|Different anesthetic procedures
87999|NCT03499119|Drug|AMG 334 Dose 1|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.~Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2"
88000|NCT03499119|Drug|AMG 334 Dose 2|Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.
88001|NCT03499119|Drug|AMG 334 Dose 3|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.
88002|NCT03499106|Drug|IW-1973|Oral Tablet
88003|NCT03499106|Drug|Itraconazole|Oral Capsule
88004|NCT03499093|Other|OES|"The first seven items of OES refer to face, facial profile, mouth, teeth alignment, teeth form, teeth color and gums. They are combined into an OES summary score ranging from 0 to 70. The eight item of OES is an overall impression item and is not included in the summary score.~Internal Consistency was determined using Cronbach's alpha and inter-item correlation for the OES scores (n=140).~Test-Retest Reliability was assessed using Intraclass Correlation Coefficient. Patients with prosthetic needs (n=20 PP-E subjects and n=15 PP-NE subjects) completed twice the OES-F at an interval of two weeks.~Convergent validity was assessed by comparing mean OES summary scores evaluated by participant of the esthetic group (PP-E, n=35) and by an expert group. Expert OES score were based on three photographs of each participant.~Discriminative validity was tested by comparing the OES summary scores using a one-way ANOVA and Scheffe post hoc test."
88005|NCT03499080|Behavioral|Medication free treatment|Inpatient unit dedicated to medication free treatment. This is an inpatient treatment unit for voluntary, planned treatment. The unit is staffed for a patient group that can be managed within a regime of open doors, voluntary treatment and low supervision. This means that high suicidal risk, severe acting out, active drug abuse etc. is excluded. They have an 8 week treatment program including Illness managment an recovery (IMR), Feedback informed treatment (FIT) and Affect consciousness treatment (ABT).
88006|NCT03499080|Behavioral|Treatment as usual Myrvegen|Inpatient unit on a different location from the others. Same Level of care. Different treatment program. Intermediate treatment duration (mainly 4-6 weeks).
88007|NCT03499080|Behavioral|Treatment as usual Åråsen|Unit colocated with the medication free unit. Similar treatment program. Short treatment duration (average 3 weeks).
88008|NCT03499054|Other|Breathing exercises|During hemodialysis, the participants in the exercise group are asked to keep ttheir muscles relaxed, breathe normally through the nose at a rate of 3-8 times per minute with each breath held over 5 seconds in length. At the same time, the particpants are asked to also perform lower leg lifts for about 8 seconds per lift. The exercise is performed for 15-20 minutes, and after resting, blood pressure, oxygen saturation and HRV are measured.
88009|NCT03499041|Drug|LY3314814|Administered orally
88010|NCT03499028|Other|JointCOACH|Patients randomized to this group will utilize JointCOACH to communicate with their surgical team, receive information
88011|NCT03499015|Procedure|Balloon Eustachian Tuboplasty (BET)|A balloon catheter is used to dilate the cartilage part of the eustachian tube and is inserted through the nose to reach the opening of the tube, located in the nasopharynx.
88012|NCT03499002|Other|Simulated Learning Environment|Intervention is the environment in which the medical student will learn to practice how to suture. The end goal is to determine the impact each environment has on their ability to learn the skill.
88013|NCT03498989|Other|preterm formula milk|"A. complete blood picture~B. C-reactive protein~C. Serum electrolytes~D. Plain x-ray and abdominal ultrasound."
88014|NCT03498989|Other|exclusive breast milk|exclusive breast milk
88015|NCT03498976|Procedure|pulsed radiofrequency|Echoguided technic
88016|NCT03498963|Procedure|bronchoalveolar lavage|Carrying out a bronchoalveolar lavage (BAL) within 24 hours after admission to intensive care with analysis on standard and specific culture media of environmental germs, carrying out antibiograms, DNA extraction, amplification by universal 16 and 18S rDNA primers followed by high flow sequencing and phylogenetic analysis of pathogens found. Comparison of these results with the same analyses performed on seawater samples taken near the drowning site and during a new AML at 72h for patients still intubated and showing signs of pneumonia in order to determine if the pathogens detected at the entrance persist and are present in the environment.
88017|NCT03498950|Other|laser therapy|laser irradiation on the taste papillae
88018|NCT03498937|Device|Active tDCS|10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC
88019|NCT03498937|Device|Sham tDCS|10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
88020|NCT03498924|Diagnostic Test|Measure of biomarkers in serum and endometrial tissue|Blood sample and endometrial sample
88021|NCT03498911|Procedure|Mucogingival surgery|The gingiva around the mucosal recession at implant site will be coronally positioned by releasing the underlying mucosa
88022|NCT03498898|Other|Chronic use of Beta adrenergic receptor blocker|Chronic use of Beta adrenergic receptor blocker
88023|NCT03498885|Procedure|Low ligation|Left colic artery (LCA) is identified, Tie the sigmoid artery and superior rectal artery, Apical lymph node dissection with the left colic artery preservation is performed.
88024|NCT03498885|Procedure|High ligation|The IMA is ligated and divided at 2 cm from its origin. Apicallymph nodes dissection is performed.
88025|NCT03498872|Device|AMPfoot 4.0|The novel prosthetic device, i.e. AMPfoot 4.0, was tested during walking in amputees. A dual-task was conducted and non-invasive electro-encephalography was used to investigate neural dynamics.
88026|NCT03498872|Other|No intervention|The control group included healthy subjects. Comparisons were made between amputees and able-bodied individuals.
88027|NCT03498859|Other|Physiotherapist-supervised training|The intervention is physiotherapist-supervised training once per week during 10 weeks.
88028|NCT03498859|Other|Home-based training|The intervention is home-based training during 10 weeks
88029|NCT03498846|Procedure|Modified EA and AMLK|Two pieces of corneal epithelial tissue with 2mmx3mm will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
88030|NCT03498846|Procedure|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
88031|NCT03498833|Other|Test-retest reliability testing|Set of patient reported outcome measures
88032|NCT03498820|Device|Analgesia Nociception Index|: Non invasive monitor based on heart rate variability analysis, assessing the parasympathetic nervous activity
88033|NCT03498820|Drug|Remifentanil|intravenous short-acting opioid routinely administered during general anesthesia
88034|NCT03498807|Device|Ventiltor P/V Loop|determine the Optimal PEEP and keep 48hr on ARDS patients
88035|NCT03498807|Device|Electrical Impedance Tomography|determine Optimal PEEP and keep 48hr on ARDS patients
88036|NCT03498794|Procedure|Ureteral stent|"Patients will be randomized into 2 groups:~Group (A): 75 patients with the use of ureteral stent. Group (B): 75 patients with the use of PCN.~How the technique will be applied?~Technique of ureteral stent insertion:~The ureteral stent will be inserted retrograde by using flexible cystoscope.~Technique of PCN insertion:~Percutaneous nephrostomy will be performed in the angiography suite by a urologist with the patient under local anesthesia. All the patients will be given non-nephrotoxic antibiotics pre-operatively."
88037|NCT03498781|Other|Exercise-only|Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
88038|NCT03498781|Other|Control|Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
88039|NCT03498768|Other|Questionnaire Administration|Subjects will be invited to complete a detailed questionnaire regarding personal information, known risk factors for lung cancer and psychological status.
88040|NCT03498755|Behavioral|Mobile phone audio messaging|"Audio messages will be pushed to participants' mobile phones twice weekly on a set schedule in discrete modules that include basic information related to each of the four behavioral domains followed by an integration of the information across behaviors through relatable, character-driven narratives that enable message recipients to engage with the content through a real-world context."
88041|NCT03498755|Behavioral|Peer-to-peer learning|Women participants in each community will meet twice monthly for peer-to-peer learning sessions to reinforce the content of audio messages. These sessions will further use women's empowerment approaches including critical examination of gender dynamics, and discussions of solutions for equitable decision-making and control of resources within households. These discussions will be facilitated with male household members and grandmothers in separate learning sessions that will be held three times throughout the intervention period.
88042|NCT03498755|Behavioral|Conditional cash transfer|Participants will receive a conditional cash transfer to support their fish smoking business. The payment will be conditional on their participation in entrepreneurship trainings and the use of the investment into their fish smoking business.
88043|NCT03498755|Behavioral|Entrepreneurship training|Entrepreneurship training will focus on commonly lacking business knowledge, with an emphasis on establishing fundamental entrepreneurial skills (i.e., customer care, accounting), sound business management and decision-making, building strong and sustainable business relationships, and encouraging the use of loans for their intended purposes. This training will be introduced during the credit and savings group (CSG) meetings that will occur twice per month.
88044|NCT03498755|Behavioral|Market price information|Average market prices for fresh and processed fish at community, district, and regional markets will be disseminated via audio message calls (using Viamo's Infoline platform) to the mobile phones of women with the price information in their preferred language. These market prices will be collected twice weekly by Viamo field enumerators and sent to regional coordinators for validation. A second, independent validation will be carried out to ensure that there are no discrepancies.
88045|NCT03498755|Behavioral|Improved smoke ovens|Local private sector artisans will construct and serve as suppliers of the new ovens. The promotion, uptake and impact of these improved Ahotor ovens will be tested among study participants. Awareness-raising workshops held in each community will promote the Ahotor in concert with a public retrofitting of a Chorkor stove. Immediately following this event, one month later, and three months later, study participants will receive additional one-on-one counseling to provide further support on the proper use of the smoke oven, as well as on optimal handling and smoking practices to enhance product quality.
88046|NCT03498742|Other|NO Intervention|Routine clinical data; asthma control test and spirometry
88047|NCT03498729|Other|Peripheral Blood Sample|30mL peripheral whole blood sample
88048|NCT03498716|Drug|Atezolizumab|"Atezolizumab will be administered by IV, 840 mg every 2 weeks, for 10 doses.~Atezolizumab maintenance will be administered by IV, 1200 mg every 3 weeks to complete 1 year"
88049|NCT03498716|Drug|Paclitaxel|Paclitaxel will be administered by IV, 80 mg/m^2 every week for 12 weeks.
88050|NCT03498716|Drug|Dose-dense Doxorubicin or dose-dense Epirubicin|"Dose-dense doxorubicin will be administered by IV, 60 mg/m^2 every 2 weeks for a total of 4 doses.~Or~Dose-dense epirubicin will be administered by IV, (90 mg/m^2) every 2 weeks for a total of 4 doses"
88051|NCT03498716|Drug|Cyclophosphamide|Cyclophosphamide will be administered by IV, 600 mg/m^2 every 2 weeks for 4 doses
88052|NCT03498703|Drug|Azathioprine Pill|Azathioprine increase pregnancy rate in cases with recurrent implantaion failure
88053|NCT03498703|Drug|Placebo Oral Tablet|Placebo tablets
88054|NCT03498690|Behavioral|Integrative|Stakeholder groups: a-b
88055|NCT03498690|Behavioral|Role specific|Stakeholder groups: a or b
88056|NCT03498690|Behavioral|Consecutive|Stakeholder groups: a=> b
88057|NCT03498677|Behavioral|presentation order|section presentation one
88058|NCT03498677|Behavioral|alternative presentation order|section presentation two
88059|NCT03498664|Device|cap for mucosectomy|endoscopic mucosal resection of colonic lesions with a plastic cap for mucosectomy
88060|NCT03498664|Device|standard snare for polypectomy|endoscopic mucosal resection of colonic lesions with standard inject and cut mucosectomy
88061|NCT03498651|Behavioral|Cognitive Bias Modification - Interpretation training|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will typically then assign a benign (rather than threatening) meaning to the scenario.
88062|NCT03498651|Behavioral|Coaching|Participants identified as high risk for attrition will receive low-intensity coaching, which includes a mix of brief phone calls, texts, and/or emails with a trained member of the study team to help address challenges with adherence to and application of the training.
88063|NCT03498651|Behavioral|Online psychoeducation about anxiety|Participants will review webpages that describe information about symptoms and causes of anxiety, including the nature of biased thinking in anxiety.
88064|NCT03498638|Behavioral|Couples Therapy|Couples in the intervention group will receive couples therapy for 8 weekly sessions. Each therapy session will last approximately an hour. All therapies will be conducted by the PI, Dr. Gunnur Karakurt. Dr. Karakurt is a Licenced Marriage and Family Therapist and AAMFT (American Association of Marriage and Family Therapy) approved clinical supervisor. All therapies will be conducted as a couple. Training on stress management and safety planning will be performed as individuals. There will not be any group sessions. The goal of couple therapy is to help and improve couples' capacity to regulate emotions, solve problems, and communicate through therapy with the couple together.
88065|NCT03498638|Other|Control|Couples in the control group will be taught safety planning, given information on local resources to help victims of violence, and will be instructed in stress and anger management strategies. Following this 8 week period, they will receive 8 weeks of couple therapy unless they choose not to.
88066|NCT03498625|Diagnostic Test|Colonoscopy|Colonoscopy for CD patients in clinical remission
88067|NCT03498612|Other|Laboratory Biomarker Analysis|Correlative studies
88068|NCT03498612|Biological|Pembrolizumab|Given IV
88069|NCT03498599|Behavioral|Novelty facilitated extinction|In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.
88070|NCT03498599|Behavioral|Standard Extinction|During standard fear extinction the expected aversive outcome is omitted.
88071|NCT03498586|Drug|Half-normal saline|Use of half-normal saline as an irrigant for open-irrigated ablation catheters
88072|NCT03498586|Drug|Normal saline|Use of normal saline as an irrigant for open-irrigated ablation catheters
88073|NCT03498573|Other|tunneling surgical technique|sticky bone prepared by centrifuge patient blood and mixing with xinograft
88074|NCT03498560|Device|PSG|PSG data to be collected on the night before surgery to establish level of preexisting sleep disturbance.
88075|NCT03498547|Procedure|caudal block|For the caudal block, sacral horns are palpated and sacral hiatus and epidural area will be determined at S4-S5 level through ulştrasonography. The 20 G adult caudal needle will then be placed to the caudal epidural space and 25 mL bupivacaine at a concentration of 0.5% will be applied in the prone Jack-Knife position with resistance loss.
88076|NCT03498547|Procedure|saddle block|In the saddle block group hyperbaric bupivacaine at a dose of 7 mg will be given to the intrathecal space after a 25 G quincke spinal needle is inserted with ultrasonographyguidance between L4-L5 vertebral disc and clear cerebrospinal fluid is seen. The patient will be placed in sitting position for 5 minutes.
88077|NCT03498534|Drug|Isoniazid 300Mg Tab|-TST tests will receive isoniazid 300Mg Tab for 6 months
88078|NCT03498534|Drug|Isoniazid 300 MG|+ TST test will receive isoniazid 300MG Tab for 6 months
88079|NCT03498534|Drug|Isoniazid 300 MG|HIV positive patient will receive isoniazid 300MGTab for 6 months
88080|NCT03498521|Drug|Alectinib|Alectinib will be administered orally at the label-recommended dose (600 mg) twice daily until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months).
88081|NCT03498521|Drug|Vismodegib|Vismodegib will be administered orally at the label-recommended dose (150 mg) once daily until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months).
88082|NCT03498521|Drug|Ipatasertib|Ipatasertib will be administered orally at the label-recommended dose (400 mg) once daily on Days 1-21 of each 28-day Cycle in combination with paclitaxel until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months).
88083|NCT03498521|Drug|Olaparib|Olaparib will be administered orally at the label-recommended dose (400 mg) twice daily until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months).
88084|NCT03498521|Drug|Erlotinib|Erlotinib will be administered orally in combination with Bevacizumab at the label recommended dose (150 mg) once daily until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months)
88085|NCT03498521|Drug|Bevacizumab|Bevacizumab will be administered intravenously at 15mg/kg every 3 weeks in combination with Erlotinib until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months)
88086|NCT03498521|Drug|Vemurafenib|Vemurafenib will be administered orally, 960 mg twice daily, in combination with Cobimetinib, until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months)
88087|NCT03498521|Drug|Cobimetinib|Cobimetinib will be administered orally, 60mg once daily, in combination with Vemurafenib, on Days 1-21 of each 28-day Cycle, until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months)
88088|NCT03498521|Drug|Trastuzumab Subcutaneous (SC)|Trastuzumab will be administered subcutaneously, 600 mg every 3 weeks, in combination with Pertuzumab and chemotherapy, until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months)
88089|NCT03498521|Drug|Pertuzumab|Pertuzumab will be initially be administered intravenously, 840 mg, followed by 420 mg every 3 weeks, in combination with Trastuzumab and chemotherapy, until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months)
88090|NCT03498521|Drug|Atezolizumab|Atezolizumab will be administered intravenously at the label-recommended dose (1200 mg), alone or in combination with chemotherapy, every 3 weeks until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months).
88091|NCT03498521|Drug|Carboplatin|Carboplatin will be administered intravenously at the area under the curve (AUC) dose once every 3 weeks for up to 9 Cycles (Cycle = 21 days) in some combination with the following: Paclitaxel, Gemcitabine, Atezolizumab, Pertuzumab, and Trastuzumab SC.
88092|NCT03498521|Drug|Paclitaxel|Paclitaxel will be administered intravenously, 175 mg/m^2, once every 3 weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Carboplatin, Ipatasertib, Atezolizumab, Pertuzumab, and Trastuzumab SC
88093|NCT03498521|Drug|Cisplatin|Cisplatin will be administered intravenously, 60-75 mg/m^2, once every three weeks, for up to 9 cycles (Cycle = 21 days) in some combination with the following: Gemcitabine, Paclitaxel, Atezolizumab, Pertuzumab, and Trastuzumab SC.
88094|NCT03498521|Drug|Gemcitabine|Gemcitabine will be administered intravenously, 1000 mg/m^2, twice every three weeks for up to 9 cycles (Cycle = 21 days) in some combination with the following: Cisplatin, Carboplatin, Atezolizumab, Pertuzumab, and Trastuzumab SC.
88095|NCT03498521|Drug|Entrectinib|Entrectinib will be administered orally at the label-recommended dose (600 mg) once daily until disease progression or unacceptable toxicity, through the end of the study (approximately 48 months).
88096|NCT03498495|Behavioral|Self-Monitoring Activity-restriction and Relaxation Training (SMART)|SMART integrates real-time self-monitoring of symptoms and activities with interactive modules designed to increase self-efficacy through psychoeducation and training in problem solving/problem-focused coping strategies.
88097|NCT03498482|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehabilitation (FORNET)|FORNET aims to reduce trauma-related symptoms and aggressive behavior via narrative exposure of traumatic and violent life events.
88098|NCT03498469|Behavioral|Standardized reintegration package|Participants assigned to this comparison arm will receive a standardized reintegration package that includes individualized case management support and a reunification cash grant Individualized case management will consist of a caseworker-developed individualized care plan with routine caseworker visits at the household level. Home visitation will begin during the family assessment and preparation stages and continue throughout the 15-month post-reunification follow-up period. For the cash grant, the family of each enrolled child will receive a reunification cash grant in the Ugandan Shilling equivalent of $125, administered in two equal disbursements. It is designed to offset the cost of child care.
88099|NCT03498469|Behavioral|Enhanced reintegration package|Participants assigned to this arm will receive an enhanced reintegration package that consists of the parenting program, individualized case management, and the reunification grant. will be delivered at the household level by project trained parenting facilitators. The program will consist of approximately 13 bi-weekly sessions, which will be delivered over the course of 7 months. The individualized case management and the reunification grant will be similar to those in the comparison arm.
88100|NCT03498456|Drug|Tegoprazan/Amoxicillin/Clarithromycin|Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
88101|NCT03498456|Drug|Lansoprazole/Amoxicillin/Clarithromycin|Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
88102|NCT03498430|Drug|Copanlisib (Aliqopa, BAY80-6946)|Copanlisib will be administered intravenously on 60mg once in a 3 weeks-on/1 week-off dose regimen (on Days 1, 8 and 15)
88103|NCT03498417|Diagnostic Test|Serum antibodies against the IGF-1R|Measurement of antibodies against the IGF-1R in serum samples by ELISA
88104|NCT03498404|Radiation|Photodynamic Therapy|After the sites are indicated for surgical therapy, they receive surgical access therapy associated with scaling and root planing and TfdA using the treatment protocol during periods of 0, 7, 14 and 30 postoperative days, or only surgical access therapy associated with scaling and root planing. As protocol, TfdA will be used laser light source 660nm wavelength in combination with phenothiazine, a photosensitizer with 10 seconds of exposure per site during surgery and 60 seconds in other applications.
88105|NCT03498404|Other|scaling and root planing|Scaling and root planing, also known as conventional periodontal therapy, or deep cleaning, is a procedure involving removal of dental plaque and calculus (scaling or debridement) and then smoothing, or planing, of the (exposed) surfaces of the roots, removing cementum or dentine that is impregnated with calculus, toxins, or microorganisms, the etiologic agents that cause inflammation. This helps to establish a periodontium that is in remission of periodontal disease. Periodontal scalers and periodontal curettes are some of the tools involved.
88106|NCT03498391|Drug|Propofol|Titration of propofol to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
88107|NCT03498391|Drug|Ketamine Injectable Product|Titration of ketamine to minimal and moderate sedation as measured by Richmond Agitation-Sedation Scale with behavioral task performance over several hours.
88108|NCT03498378|Drug|Avelumab|Avelumab (IV on days 1 and 15 of 28 day cycle)
88109|NCT03498378|Drug|Palbociclib|"Palbociclib (PO daily, days 1-21 of 28 day cycle)~Palbociclib will be administered in capsules of 125 mg, 100 mg, and 75 mg, depending on dosage. Patients will be instructed to take their assigned dose once daily with food for 21 days followed by 7 days off therapy. Patients will be encouraged to take their dose at approximately the same time each day."
88110|NCT03498378|Drug|Cetuximab|"Cetuximab (IV 400 mg/m2 x 1, then weekly)~Cetuximab is administered intravenously once weekly via infusion pump or syringe pump with infusion rate not to exceed 10 mg/min."
88111|NCT03498365|Behavioral|MCDA|Experimental decision support
88112|NCT03498365|Behavioral|Delphi|Standard support
88113|NCT03498352|Procedure|Thoracic surgery|Lung resection surgery
88114|NCT03498326|Drug|Gemcitabine|One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.
88115|NCT03498326|Drug|Gemcitabine|the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.
88116|NCT03498313|Drug|Transdermal Estradiol + Placebo|.1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test, plus twice daily placebo pills during the same time frame.
88117|NCT03498313|Drug|Oral Micronized Progesterone + Placebo|100mg oral micronized progesterone twice daily for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
88118|NCT03498313|Drug|Placebos|Twice daily placebo pills for 14 days starting day 7 after positive urine luteinizing hormone test, plus weekly application of a placebo patch during the same time frame.
88119|NCT03498300|Biological|Tdap vaccine|A single dose of Tdap vaccine at GA 27 - 36 weeks
88120|NCT03498287|Device|Study Device|Real study device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks).
88121|NCT03498287|Device|Sham Device|Sham device applied to affected wrist (or higher CTS severity wrist if patient has bilateral CTS) for 8-10 hours daily for 56 days (8 weeks). *Note: participants in the sham group are given the real study device at the end of the Post-Treatment/Follow-up Phase.
88159|NCT03497988|Drug|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
88122|NCT03498274|Device|Fitting System|End users will drive the screening and fitting flow; however, a trained professional is intended to assist them and help with explanations and the actual fitting of the hearing aids on the person. For a first time user the physical act of placing the hearing aid in/on the ear may create confusion. Therefore, the software is designed for an assistant to guide the user through the process and help with specific parts of the fitting or any questions in general.
88123|NCT03498274|Device|Traditional Fitting System|The trained professional will fit the hearing aids with the traditional software that is currently used on the market. They will not involve the patient except to play demonstration tones.
88124|NCT03498261|Drug|Gabapentin|Gabapentin has been commonly used as an adjuvant in the treatment of neuropathic pain.
88125|NCT03498261|Drug|Placebos|Placebo
88126|NCT03498248|Drug|lenograstim|injection of lenograstim in patients with neutropenia after cytotoxic chemotherapy
88127|NCT03498235|Drug|Sevoflurane|In Team Sevoflurane,patients undergo sevoflurane.
88128|NCT03498235|Drug|Propofol|In Team Propofol ,anesthesia is maintained with propofol
88129|NCT03498222|Drug|Atezolizumab|Administered at a fixed dose of 1200 mg (equivalent to an average body weight-based dose of 15mg/kg) by intravenous (IV) infusion every 3 weeks (21 days).
88130|NCT03498222|Drug|Pemetrexed|Administered at a fixed dose of 500mg/m2 by IV infusion every 3 weeks.
88131|NCT03498222|Drug|Carboplatin|Administered at a fixed dose of AUC5 by IV infusion every 3 weeks.
88132|NCT03498222|Drug|ADI PEG20|Administered by intramuscular (IM) injection to patients once weekly.
88133|NCT03498196|Drug|Avelumab|avelumab 10 mg/kg intravenously every 2 weeks for 3 cycles or 42 days.
88134|NCT03498183|Drug|MIBI-Tc99m/Iodine-123|Following the injection of MIBI-Tc99m/Iodine-123 , the patients will have a scintigraphy.
88135|NCT03498170|Drug|BCT197|Single dose of BCT197
88136|NCT03498170|Drug|Itraconazole 200 mg|Single dose of itraconazole
88137|NCT03498157|Behavioral|Exercise|The exercise intervention is an at least 2 weeks lasting (till the day surgery is taking place) 5-times weekly resistance training intervention combined with aerobic exercise (mostly walking).
88138|NCT03498157|Behavioral|Prehabilitation Education|Participate will receive a 2 hour group-based prehabilitation class which will be held at the Penn State Cancer Institute, Hershey
88139|NCT03498144|Device|Anterior segment OCT|lower punctum examination by AS-OCT
88140|NCT03498131|Drug|3 mg Melatonin|3 mg melatonin once each day
88141|NCT03498131|Drug|5 mg Melatonin|5 mg Melatonin once each day
88142|NCT03498118|Drug|20 mL of bupivacaine 0.25%|"In the infiltration group, at the end of surgery, 30 mL of bupivacaine 0.25% was injected subcutaneously in the surgical wound (15 mL in each of the upper and lower sides) by the obstetrician before skin closure. Sam procedure was performed by the primary investigator after completion of surgery by pressing a covered spinal needle on both sides of the patient`s abdomen.~In the TAP group, after completion of surgery, 20 mL of bupivacaine 0.25% was injected under direct visualization in the plane between the transversus abdominis muscle and the fascia deep to the internal oblique muscle on each side."
88143|NCT03498092|Drug|Bupivacaine-Dexmedetomidine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline and 1 micro gram/kg dexmedetomidine in a volume of 0.5 ml/kg
88144|NCT03498092|Drug|Bupivacaine|isobaric bupivacaine 2.5 mg/ml plus 5 micro gram/ml adrenaline in a volume of 0.5 ml/kg
88145|NCT03498092|Drug|General anesthesia|Normal saline in a volume of 0.5 ml/kg
88146|NCT03498079|Diagnostic Test|3D ultrasound|3D ultrasound will be done to females complaining from primary infertility with mullerian anomalies
88147|NCT03498066|Drug|Beta-blockers withdrawal|withdrawal of all type of betablockers
88148|NCT03498066|Drug|Continuation of the Betablockers (βB) treatment|Use Betablockers treatment
88149|NCT03498053|Behavioral|Marlboro|Participants smoke Marlboro during the first experimental day, ad libitum.
88150|NCT03498053|Behavioral|Marlboro Prime|Participants smoke Marlboro Prime during the second experimental day, ad libitum.
88151|NCT03498053|Behavioral|Marlboro Prime (ventilation holes taped)|Participants smoke Marlboro Prime (filter ventilation holes taped) during the third experimental day, ad libitum.
88152|NCT03498040|Other|Study of the occurrence of Carcinoid Heart Disease|"Patient at high risk of Carcinoid Heart Disease (metastatic ileum or bronchial well-differentiated neuroendocrine tumors, patients with high level of urinary 5HIAA or with carcinoid syndrome) are followed with annual echocardiography to detect the occurrence of carcinoid heart disease.~In case of documented Carcinoid Heart Disease, a six or three months' cardiac follow-up is necessary to evaluate the progression and the severity of the disease.~Investigators collect the data of clinical parameters (flushes, diarrhea, …) biological parameters (urinary 5HIAA, NT-ProBNP …) and cardiac parameters that may influence the occurrence, severity and progression of Carcinoid Heart Disease."
88153|NCT03498027|Device|TaqMan Bacillus anthracis Detection Kit|The TaqMan® Bacillus anthracis Detection Kit is composed of the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software, secondary interpretative software, and lyophilized reagents for the detection of gene targets for B. anthracis. The test assay is a multiplexed assay targeting gene targets for B. anthracis, in addition to an internal positive control. Reagents are lyophilized as a fully formulated Mastermix and are stable at room temperature for up to two years. The kit is specifically designed for performing real-time PCR using the Applied Biosystems® 7500 Fast Dx Real-Time PCR Instrument with SDS Software , with nucleic acids extracted from clinical specimens using Qiagen's QIAamp® Blood Midi Kit manual extraction or Roche MagNAPure automated extraction methods.
88154|NCT03498014|Other|Pharmacogenetic analysis allowing personalized opioid prescription|Genotypic of patient to determine optimal opioid treatment (tramadol, codeine or oxycodone)
88155|NCT03498014|Other|Standard opioid prescription|Opioid prescription made without reference to patient genetic profile (tramadol, codeine or oxycodone)
88156|NCT03498001|Drug|Liraglutide|6 mg/ml
88157|NCT03498001|Procedure|Cardiac MRI|T3 myocardial MRI (total acquisition time : 1h) performed before initiation of treatment and measuring the concentration of intramyocardial triglycerides ([TG] by NMR spectroscopy, parameters of cardiac morphology (myocardial mass, (epicardial fat surface, pericardial fat surface), function (LVEF, SV, TDV, PFR, TPFR) and tissue parameters (extracellular volume, left myocardial fibrosis volume).
88158|NCT03498001|Other|Follow up by phone|at 2 and 4 mois
88160|NCT03497988|Drug|Placebo|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
88161|NCT03497975|Drug|Nalbuphine ER Tablets|Active Nalbuphine ER Tablets
88162|NCT03497975|Other|Matching Placebo Tablets|Matching Tablets with no active substance
88163|NCT03497962|Procedure|Venepuncture|Taken from established arterial or central lines in critical care setting or by experienced clinicians if no line available and in healthy volunteers.
88164|NCT03497962|Procedure|Bronchoscopy|Broncho-alveolar lavage to obtain alveolar macrophages
88165|NCT03497936|Behavioral|Women's Stories|Women's Stories is a brief, HPV vaccination promotion intervention. It presents vaccine information and videos of HPV vaccine decision making. It also includes follow up vaccine reminder text messages.
88166|NCT03497923|Drug|Magnesium Sulfate|After reversal the obention of a TOF ratio of 0.9 is avaited. 10 minutes later patients will receive a perfusion of magnesium 60 mg kg-1 over 5 minutes.
88167|NCT03497897|Drug|LYS006|Oral administration
88168|NCT03497897|Drug|Placebo|Oral administration
88169|NCT03497884|Device|rTMS|For the l-Hz sessions (low frequency), stimulation is delivered at 100% of the subject's resting motor threshold at 1 Hz continuously over 30 min for a total of 1,800 pluses. The 10-Hz stimulation (high frequency) is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses per train).
88170|NCT03497871|Device|HeartMan system|The HeartMan system uses wristband sensors to monitor patients' physical activity and physiological parameters. These data are connected to a decision support system, providing medical advice to patients concerning physical exercise, nutrition, medication intake, clinical measurements, environment management, and mental support. The decision support system is based on predictive models, clinical care guidelines and expert knowledge. The advice will be personalized according to each individual patient's medical and psychological profile, and will be presented to the patient through the user interface of a mobile application on a smartphone.
88171|NCT03497858|Other|Coconut Water|participants will consume coconut water and complete a simulated basketball game
88172|NCT03497858|Other|Placebo - water|participants will consume Placebo - water and complete a simulated basketball game
88173|NCT03497858|Other|Sports drink|participants will consume a sports drink and complete a simulated basketball game
88174|NCT03497845|Biological|VN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
88175|NCT03497845|Biological|IN|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
88176|NCT03497845|Biological|dk/BANG|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
88177|NCT03497845|Biological|gf/WA|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
88178|NCT03497845|Biological|bhg/QL|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
88179|NCT03497845|Biological|AS03 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
88180|NCT03497845|Biological|MF59 adjuvant|0.5 mL vaccine (H5 vaccine antigen plus adjuvant) per dose
88181|NCT03497832|Other|magnetic resonance spectroscopy (MRI)|Each healthy subject will get 3 MRI examinations at 7:30, 13:30 and 18:00. Each MRI scan lasts an average of 20 minutes.
88182|NCT03497819|Biological|CARTmeso CART19|Autologous chimeric antigen receptor T cells with murine scFv, 41BB co-stimulatory domain and CD3ζ signaling domain targeting mesothelin or CD19
88183|NCT03497806|Biological|CP101|Study drug will be administered at Treatment (Day 1) as an oral dose after cessation of standard-of-care CDI antibiotic treatment of the current episode of recurrent CDI.
88184|NCT03497793|Other|SNUBY|Following written informed consent, mother will be issued with an appropriate sized SNUBY® for her use only. The infant will be placed in skin-to-skin in SNUBY®, infant chest to mother's chest whilst the mother is seated on a reclining chair, allowing the infant to be further stabilised by gravity. Monitor wires, IV lines and/or ventilation tube will be secured using the ties on the SNUBY®. The infant's temperature, pulse and SaO2 will be recorded prior to skin-to-skin, repeated as required for the infant's clinical condition or at 30min intervals for the duration of skin-to-skin. Maternal and infant behaviour will be recorded, including spontaneous breastfeeding. The time taken to put the infant into skin-to-skin care, time in skin-to-skin care and time to return to cot will be recorded.
88185|NCT03497780|Procedure|Anterior cruciate ligament reconstruction|Primary surgical reconstruction of the rupture anterior cruciate ligament
88186|NCT03497767|Drug|Osimertinib|All participants will receive a dose of Osimertinib 80mg once daily
88187|NCT03497767|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation depend on lesion size. All SRS must be completed within 14 days of randomisation and all lesions are to be treated within 7 days.
88188|NCT03497754|Device|Probefix|A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.
88189|NCT03497741|Diagnostic Test|procalcitonin measurement|For each patient were blood cultures were taken, a procalcitonin level was determined
88190|NCT03497715|Drug|Ibuprofen lysine|Test 1
88191|NCT03497715|Drug|Ibuprofen Sodium|Test 2
88192|NCT03497715|Drug|Ibuprofen|Test 3
88193|NCT03497715|Drug|Ibuprofen (Nurofen)|Reference 1
88194|NCT03497715|Drug|Ibuprofen (Wockhardt)|Reference 2
88195|NCT03497702|Drug|Doxorubicin|60mg/m2 IV every 3 weeks for 4 cycles
88196|NCT03497702|Drug|Cyclophosphamide|600mg/m2 IV every 3 weeks for 4 cycles
88197|NCT03497702|Drug|Docetaxel|75mg/m2 IV every 3 weeks for 4 cycles
88198|NCT03497702|Drug|Letrozole|2.5 mg once daily preoperably
88199|NCT03497702|Drug|leuprorelin|3.75 mg SC every 4 weeks for premenopausal patients
88200|NCT03497689|Drug|Intravenous/Subcutaneous Treprostinil; Oral Treprostinil|Short term course of IV/SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release tablets taken three times daily
88201|NCT03497676|Drug|Oral Cabotegravir (CAB)|30 mg tablets administered orally
88202|NCT03497676|Drug|Oral Rilpivirine (RPV)|25 mg tablets administered orally
88203|NCT03497676|Drug|Long-Acting Injectable Cabotegravir (CAB LA)|Administered by intramuscular (IM) injection
88204|NCT03497676|Drug|Long-Acting Injectable Rilpivirine (RPV LA)|Administered by intramuscular (IM) injection
88205|NCT03497676|Drug|Combination Antiretroviral Therapy (cART)|Participants will continue their pre-study cART regimen. The antiretroviral drugs in participants' cART regimens will not be provided through the study.
88206|NCT03497663|Other|VIA Family intervention|Family based intervention
88207|NCT03497663|Other|Treatment As Usual|Treatment As Usual
88208|NCT03497650|Device|Mirror Therapy|Mirror Therapy involved the patient sitting on a chair with a standard mirror placed between both legs with the reflective side of the mirror facing the non-affected leg. The patient is instructed to observe the reflection of the non-affected limb during the sessions. The patient was not given any instruction on the use of the affected limb.
88209|NCT03497650|Other|Cross-Education of Strengthening.|Cross-education of strengthening involves training one side of the body with the intention of producing strengthening gains on both sides of the body. In this case the strengthening was done on the non-affected leg of each stroke patient.
88210|NCT03497637|Diagnostic Test|measurement of FFR|use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses
88211|NCT03497637|Diagnostic Test|measurement of Pd/Pa|use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses
88212|NCT03497624|Other|Biospecimens collection|Collection of tumor tissue when a participant is having a clinically-indicated biopsy or surgery for their ROS1-fusion cancer.
88213|NCT03497611|Procedure|transcatheter valve implantation|aortic transcatheter valve implantation using Edwards SAPIEN 3 valve
88214|NCT03497598|Drug|Mannose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
88215|NCT03497598|Drug|Lactose|The powder is dispensed in 2g neutral sticks and ready to be dissolved in 100ml of water for daily oral ingestion.
88216|NCT03497585|Behavioral|Activity pacing framework|The activity pacing framework will be used to structure and standardise the instructions of pacing in existing rehabilitation programmes for adult patients with chronic pain/fatigue. The activity pacing framework has been developed in Stages I and II of this research. Stage I involved an online survey of activity pacing across healthcare professionals in England. The survey findings, together with existing research were used to develop the first draft of the framework. The framework was refined in Stage II: Nominal group technique (consensus method). The activity pacing framework describes the aims, facets and stages of pacing, together with how pacing relates to different behavioural typologies and other pain management strategies.
88217|NCT03497559|Other|Music|Classical music
88218|NCT03497546|Other|Exercise|Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
88219|NCT03497533|Biological|TriCAR-T-CD19|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 0.5-1 x 10^6 CAR+ T cells/kg
88220|NCT03497520|Behavioral|asymmetric spinal stabilization exercise|"The patients were educated to strengthening weakness side of spinal muscle, as asymmetric spinal stabilization exercise(ASSE)~before teach ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity~after perform ASSE, the investigators will evaluate Cobb angle, Apical vertebral rotation in Adam's test, surface EMG, Scoliosis Research Society-22(SRS-22) quastionnaire for evaluation of scoliosis severity"
88221|NCT03497507|Device|Sham bracelet|Patients will wear bracelets on both hands
88222|NCT03497507|Device|Acupressure bracelet|Patients will wear bracelets on both hands.
88223|NCT03497494|Procedure|2 cm away from the pylorus edge|2 cm away from the pylorus edge
88224|NCT03497494|Procedure|4 cm away from the pylorus edge|4 cm away from the pylorus edge
88225|NCT03497494|Procedure|6 cm away from the pylorus edge|6 cm away from the pylorus edge
88226|NCT03497494|Procedure|LRYGB|laparoscopic Roux-en-Y gastric bypass
88227|NCT03497481|Biological|Samples|Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
88228|NCT03497468|Other|Combined exercise training|Aerobic training with cycle ergometer %60-80 of maximal Heart Rate, submaximal level, strengthening of the major muscles of upper and lower extremities
88229|NCT03497468|Other|Task-oriented training|Functional reaching, walking on different obstacles and floor,sitting and standing on different levels and surface,walking around obstacle, climbing stairs with different height and surface
88230|NCT03497455|Device|Barco NV Digital Dermatoscope device images|Images taken by Clinician in consultation OR in Dermatology department theatres OR images taken in medical photography suite - in the latter case, images can be taken by medical photographer or Research nurse or Dermatologist
88231|NCT03497455|Device|Standard medical photographs including dermoscopy images|Images taken by medical photographer as part of standard care in the medical photography suite.
88232|NCT03497455|Other|Clinic proforma completion|This is part of standard care and will be undertaken by the clinician who is responsible for the patient
88233|NCT03497442|Drug|Brimonidine Tartrate|Topical brimonidine tartrate will be applied to one half of each participant's face. A randomization process will be used to determine which side of the face each participant will apply treatment to. The untreated side of the face will receive a placebo vehicle. Patient and clinician will be blinded to treatment side.
88234|NCT03497442|Drug|Placebo Vehicle Gel|Vehicle Gel
88235|NCT03497429|Drug|Niraparib|Niraparib capsule
88236|NCT03497416|Other|No intervention|No intervention
88237|NCT03497403|Procedure|Socket preservation control|After a tooth was extracted, the adjacent gum tissue was fully reflected, bone graft (FDBA) and non-cross-linked barrier membrane (Bio-Gide) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
88238|NCT03497403|Procedure|Socket preservation experimental|After a tooth was extracted, the adjacent gum tissue was minimally reflected, bone graft (FDBA) and cross-linked barrier membrane (OssixPlus) were applied to the defect. The site was stabilized with sutures. Patients were followed for 6 months post operatively.
88333|NCT03496662|Drug|Nab-paclitaxel|Nab-paclitaxel will be given as per routine care from commercial supply.
88239|NCT03497390|Other|EMERALD intervention|EMERALD consists of a 1-year multi-component structured program led by nurses and held 4-weekly for the first 3 months, followed by maintenance program, peers support and telephone calls.
88240|NCT03497390|Other|Usual care|Usual care without any workshop or program
88241|NCT03497377|Drug|18F-DCFPyL Injection|
88242|NCT03497377|Drug|18F-NaF|
88243|NCT03497364|Drug|bupivacaine|0.5 % bupivacaine (0.75% bupivacaine (2 ml) + cerebrospinal fluid (1 ml)) was injection according to the height of subjects (1.7 ml for 173~174cm, 1.65 ml for 170~172cm, 1.6 ml for 168~169cm, 1.55 ml for 165~167cm, 1.5 ml for 163~164cm, 1.45 ml for 160~162cm, 1.4 ml for 158~159cm, 1.35 ml for 155~157cm, 1.3 ml for 153~154cm, 1.25 ml for 150~152cm, 1.2 ml for 148~149cm)，1.15 ml for 145~147cm).
88244|NCT03497364|Drug|ropivacaine|0.5 % ropivacaine (1% ropivacaine (1.5 ml) + cerebrospinal fluid (1.5 ml)) was injection according to the height of subjects (2.300 ml for 173~174cm, 2.225 ml for 170~172cm, 2.15 0ml for 168~169cm, 2.075 ml for 165~167cm, 2.000 ml for 163~164cm, 1.925 ml for 160~162cm, 1.850 ml for 158~159cm, 1.775 ml for 155~157cm, 1.700 ml for 153~154cm, 1.625 ml for 150~152cm, 1.55 0ml for 148~149cm, 1.475 ml for 145~147cm)
88245|NCT03497351|Drug|Nicardipine|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Nicardipine was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
88246|NCT03497351|Drug|Urapidil|The patients in Group N were infused the 130/0.4 hydroxyethyl starch and sodium chloride injection ( 7 ml/kg, 0.4 ml/kg/min) after anesthesi induction and before skin incision. Then the HR, SAP, DAP, MAP, CO, CI, SV, SVI, PPV and SVV were recorded. When the circulation was stability, Urapidil was given, and the the 130/0.4 hydroxyethyl starch and sodium chloride injection was infused again.
88247|NCT03497325|Drug|autologus platelet rich plasma|55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
88248|NCT03497325|Drug|placebo|55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
88249|NCT03497312|Procedure|full mouth rehabilitation|full mouth rehabilitation under general anesthesia
88250|NCT03497299|Device|Active rTMS (20Hz)|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
88251|NCT03497299|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) Procedures: On Day 1, participants will be randomly assigned to receive active or sham rTMS using the MagProX100/R30 stimulator equipped with the B65 active/ placebo coil for DLPFC stimulator (MagVenture, Farum, Denmark) for a period of 28 days.
88252|NCT03497286|Behavioral|Text-based mentorship|The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.
88253|NCT03497286|Behavioral|Control text messaging|Control participants will receive periodic texts from NurturePA with information about child safety and health.
88254|NCT03497273|Drug|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
88255|NCT03497273|Drug|Corticosteroid|Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
88256|NCT03497260|Dietary Supplement|Fructose|Intake of 20 g of fructose dissolved in 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
88257|NCT03497260|Other|Plain water|Intake of 200 ml of tap water within 5 minutes 30 minutes prior to exercise.
88258|NCT03497247|Behavioral|Mindfulness-Based Cognitive-Behavioral Therapy|Both arms have the same intervention techniques (relative intervention, stimulus control and others) except relapse prevention sessions. In the experimental arm, these sessions are carried out from Mindfulness, and in the active comparator is the usual relapse prevention.
88259|NCT03497234|Diagnostic Test|Perilynx Analyzer to measure AF and VF fluid|Hologic developed a rapid in-vitro diagnostic system composed of an analyzer and cassettes to identify women with intra-amniotic infection.
88260|NCT03497221|Behavioral|Education intervention|The same description of arm Education intervention.
88261|NCT03497221|Behavioral|Visual identity campaign|The same description of arm Visual identity campaign.
88262|NCT03497208|Procedure|Microneedling|The technique is about applying a dermaroller equipped with 0.25 mm needles over the vitiligo area.
88263|NCT03497208|Procedure|Cell suspension|The technique involves preparation of a cell suspension (keratinocyte/melanocyte) prepared by trypsinization from a non-lesioned part of a patient's scalp skin and transepidermal delivery using a dermarollerequipped with 0.25 mm needles.
88264|NCT03497208|Radiation|Phototherapy|The patient will receive phototherapy UVB-NB in the lesions of vitiligo after 15 days of the surgical procedure.
88265|NCT03497195|Diagnostic Test|Screening at community level|comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening
88266|NCT03497182|Device|Breath sample collection|Subject exhales into breath collection container.
88267|NCT03497169|Drug|Lisdexamfetamine Dimesylate|Patients are tested for their normal prescription lisdexamphetamine medication
88268|NCT03497156|Drug|Lercanidipine|Patients are tested for their normal prescription lercanidipine medication
88269|NCT03497143|Drug|Lamotrigine|Patients are tested for their normal prescription lamotrigine medication
88270|NCT03497130|Other|skin care regimen|These participants will be asked to apply skin care regimen, the Vaseline® Moisturizer twice a day and use Dove® Soap daily for 2 weeks.
88271|NCT03497117|Device|Lung Clearance Index|To assess the efficiency of ventilation distribution and gas mixing by measuring the rate of clearance of an inert gas (nitrogen) from the lungs.
88464|NCT03495648|Behavioral|Drive|Subjects will drive to a local farmer's market.
88272|NCT03497117|Drug|MRI with PFP|"Description: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
88273|NCT03497104|Other|Surplus blood tests|Surplus blood donation
88274|NCT03497091|Other|Enteral Formula|Enteral Feeding with an amino acid-based formula
88275|NCT03497078|Other|Bone scintigraphy|Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
88276|NCT03497065|Procedure|non-surgical periodontal treatment|scaling, root planing, polishing, and oral hygiene education was performed
88277|NCT03497052|Other|In vitro culture in medium 1|Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
88278|NCT03497052|Other|In vitro culture in medium 2|Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
88279|NCT03497039|Drug|Diclofenac Diethylamine (DDEA) gel|Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at subject's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the subject should be withdrawn from the study.
88280|NCT03497039|Other|Placebo gel|Placebo gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at subject's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of placebo gel will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery. If surgery is delayed by up to 7 days dosing with placebo gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the subject should be withdrawn from the study.
88281|NCT03497026|Device|Robotic Bronchoscopy Platform|Eligible patients will undergo the robotic bronchoscopy for evaluation of suspected lung nodules.
88282|NCT03497013|Device|Active tDCS|All patients received 2-mA anodal left/cathodal right prefrontal tDCS treatment (fifteen 30-minutes sessions: Monday to Friday once daily, every other week to do a group of treatment).
88283|NCT03497013|Device|Sham tDCS|For sham stimulation, the device was set to turn off after 30 seconds(study model).
88284|NCT03497000|Procedure|OCTA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of OCTA
88285|NCT03497000|Procedure|ICGA-guided Photodynamic therapy|Half-dose photodynamic therapy using verteporfin under the guidance of ICGA
88286|NCT03496987|Device|Vacuum Bottle Drainage|Patients undergo drainage via vacuum bottles
88287|NCT03496974|Drug|Bermekimab Monoclonal Antibody 200 mg|200 mg subcutaneous injection
88288|NCT03496974|Drug|Bermekimab Monoclonal Antibody 400 mg|400 mg subcutaneous injection
88289|NCT03496961|Behavioral|Yan Nian Jiu Zhuan Fa|Yan Nian Jiu Zhuan Fa are the kneading methods while cognitive behavior education is the psychological education
88290|NCT03496948|Behavioral|TeGeCoach|"12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription."
88291|NCT03496935|Device|Tunneled versus non-tunneled dialysis catheter insertion|The study participants will be randomized either to tunneled or non-tunneled dialysis catheter insertion to commence renal replacement therapy for an acute kidney injury requiring either continuous or intermittent dialysis in the ICU.
88292|NCT03496922|Behavioral|Experimental Tobacco Marketplace|See arm group description.
88293|NCT03496909|Behavioral|Standard OT|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include manual therapy, education, and active and passive range-of-motion, etc.
88294|NCT03496909|Behavioral|PhysioTouch|12 weekly sessions of occupational therapy tailored to patients with RFS secondary to breast cancer treatment. Sessions can include use of the PhysioTouch electronic massager in lieu of manual therapy, education, and active and passive range-of-motion, etc.
88295|NCT03496896|Other|TARGET|The pre-discharge component includes mainly patient information, medication reconciliation, patient education, planning of a first post-discharge primary care physician visit with a timely discharge summary sent to the primary care physician. Two follow-up phone calls are made by a nurse, at D3 and D14, and include the assessment of the general health condition, the verification of the follow-up care plan, a reinforcement of the patient education, and review with the patient of the medication list with assessment of potential adverse drug events.
88296|NCT03496883|Biological|Recombinant Activated Factor VII (rFVIIa)|Investigators will randomize participants in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Subjects in both arms will receive best medical therapy as per published AHA Guidelines for ICH, including a target blood pressure of 140 mm Hg.
88297|NCT03496883|Drug|Placebos|Investigators will randomize participants in a double-blinded fashion to rFVIIa 80 µg/kg dose (maximum 10 mg dose) or matching placebo. Subjects in both arms will receive best medical therapy as per published AHA Guidelines for ICH, including a target blood pressure of 140 mm Hg.
88298|NCT03496870|Drug|Opicapone|catechol-O-methyltransferase (COMT) inhibitor
88299|NCT03496870|Drug|Carbidopa Levodopa|Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor
88637|NCT03494101|Other|Blood samples|Blood samples will be collected and analyzed at different study time points
88300|NCT03496857|Device|Light emitting diode|Three 10-min LED applications will be performed when the patient has a cervical dilatation of 4-5, 6-7, and 8-9 cm. Data on the level of pain, characteristics of the membrane (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after each intervention.
88301|NCT03496857|Other|Bath Therapy|The method of analgesia with the bath therapy will be performed using a hot shower at 37°C for 10 min. After showering the entire body or the back for 5 min, the participants will be allowed to direct the water flow to any area of the body that feels the most comfortable and to adjust the temperature themselves for improved comfort. Bath therapy will be performed at three time points during labor: at cervical dilatation of 4-5 cm, 6-7 cm, and 8-9 cm. Data on the level of pain, membrane characteristics (intact or damaged), heart rate, cardiotocography, and uterine dynamics will be collected after the bath therapy by performing the same measurements used in the intervention group.
88302|NCT03496844|Diagnostic Test|F-18 fluciclovine-PET/CT scan|PET/CT imaging with F-18 fluciclovine
88303|NCT03496831|Drug|Biologic Agents|
88304|NCT03496805|Drug|MGE|The patients will take 4 capsules by mouth BID (twice daily).
88305|NCT03496805|Other|Placebo|The patients will take 4 capsules by mouth BID (twice daily).
88306|NCT03496805|Other|ADT|Androgen deprivation therapy (ADT) is to be started within 60 days prior to initiation of MGE.
88307|NCT03496792|Other|Tilt + external pressure|In Visit 1, the anti-shock trousers will be inflated to 20, 40, or 60 mmHg. BP will be measured 3 times from the brachial artery. Then the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals. The tilt table is returned to 0o and the resting supine baseline BP will be collected. Then, the anti-shock trousers will be inflated to a different pressure (20, 40, or 60 mmHg) and the head up tilt will be repeated. Repetitions at the various pressures will be performed in a random order with suitable resting intervals in between the tilting bouts.
88308|NCT03496792|Other|Tilt + no external pressure.|In Visit 1, the anti-shock trousers will NOT be inflated. Auscultatory BP will be measured 3 times from the brachial artery. Thereafter, the table will be tilted head up to a maximum of 70o for up to 10 min, while BP will be measured from the brachial artery at 1 min intervals.
88309|NCT03496792|Other|Limb occlusion + negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. After the cuff is inflated to 250 mmHg, the pressure in the tank will be reduced to -100mmHg for 2 minutes. The application of negative pressure creates a suction effect on the leg, and leads to an overall increase in pressure gradient across the blood vessel wall and induces vascular distension.
88310|NCT03496792|Other|Limb occlusion + no negative pressure|In Visit 2, a cuff will be placed on the thigh of a leg that is sealed in an airtight pressure tank. The cuff is inflated to 250 mmHg for 2 minutes, but the pressure in the tank is not changed.
88311|NCT03496779|Drug|Brentuximab Vedotin - induction|Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
88312|NCT03496779|Drug|Gemcitabine|Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy
88313|NCT03496779|Drug|Brentuximab Vedotin - maintenance|"Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.~Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy"
88314|NCT03496779|Procedure|autologous or allogeneic stem cell transplantation|Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation
88315|NCT03496766|Drug|Tipifarnib|Tipifarnib 600 mg will be administered until progression
88316|NCT03496753|Device|Led Therapy|The following will be the phototherapeutic parameters: total spot area: 1.44 cm²; continuous emission mode; output power: 10 mW; infrared wavelength (880 to 904 nm); fluence: 4 J/cm²; and application time: 10 minutes/session. Sessions will be held three times a week on alternating days for six consecutive weeks, totaling 18 sessions.
88317|NCT03496740|Procedure|Penile Block|Ultrasound guided dorsal penile nerve block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
88318|NCT03496740|Procedure|Pudendal Block|Nerve stimulation guided bilateral pudendal block will be done to this group of patients preoperatively, under general anesthesia. 0,25% Bupivacaine 0,5ml/kg (max. 20ml)
88319|NCT03496740|Drug|Bupivacaine (Block Drug)|Block drug
88320|NCT03496727|Procedure|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
88321|NCT03496727|Procedure|Patient controlled analgesia|Patient-controlled analgesia
88322|NCT03496714|Behavioral|Psychoeducation on trauma reactions|The psychoeducation handout and video on trauma symptoms will discuss reactions that are common after experiencing a trauma.
88323|NCT03496714|Behavioral|Psychoeducation on safety behaviors|The psychoeducation handout and video on safety behaviors will discuss safety behaviors that are common in PTSD and tips for how to eliminate them.
88324|NCT03496701|Device|stenfilcon A test lens|contact lens
88325|NCT03496701|Device|stenfilcon A control lens|contact lens
88326|NCT03496688|Procedure|Sinus floor augmentation|
88327|NCT03496675|Behavioral|Group Music Therapy|The core intention of GMT is to meet the psychosocial needs of each person living with dementia, which in turn is thought to reduce depressive symptoms and anxiety and to stimulate overall social and emotional wellbeing. It includes active, reciprocal music making with the use of singing and musical instruments. GMT is provided by a trained music therapist, highly skilled as a musician, and registered with the appropriate professional association in his or her country.
88328|NCT03496675|Behavioral|Recreational Choir Singing|RCS is intended to foster connectedness in a group, wellbeing, and enjoyment of music making in a group. It includes singing familiar songs and providing a familiar musical environment for participants. RCS is provided by a musician with choir leading skills.
88329|NCT03496675|Other|Standard care|May include pharmacological and non-pharmacological interventions as locally available
88330|NCT03496662|Drug|BMS-813160|BMS-813160 will be supplied by Bristol Myers Squibb
88331|NCT03496662|Drug|Nivolumab|Nivolumab will be supplied by Bristol Myers Squibb
88332|NCT03496662|Drug|Gemcitabine|Gemcitabine will be given as per routine care from commercial supply.
88334|NCT03496662|Procedure|Biopsy|Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery
88335|NCT03496662|Procedure|Peripheral blood|-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)
88336|NCT03496649|Drug|Dysport 500 Unit Powder for Injection|Dysport administered by intramuscular injection
88337|NCT03496636|Procedure|Ovarian tissue transplant|Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
88338|NCT03496623|Drug|Inhaled treprostinil solution|Treprostinil inhalation solution
88339|NCT03496623|Drug|Placebo solution|Placebo solution
88340|NCT03496610|Drug|Liposomal Bupivicaine|Patient will receive liposomal bupivicaine mixed with non-liposomal bupivicaine directly to wound
88341|NCT03496610|Procedure|QL Block|Patient will receive ultrasound guided QL Block
88342|NCT03496597|Procedure|Retinal imaging assessment|"OCT-angiography~Automated measurement program: size of the avascular zone and perifoveolar vascular density of the superficial capillary plexus~Eye fundus photography: macular image~Measurement of the fractal dimension of the retinal foveolar retina from photographs of the fundus"
88343|NCT03496597|Procedure|blood glucose holter|for 40 subjects, implantation of a blood glucose holter monitor for 7 days
88344|NCT03496584|Other|Pomegranate Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of pomegranate juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
88345|NCT03496584|Other|Placebo Juice|After the one week run-in period of consuming an ellagitannin-free diet, participants will undergo the skin testing followed by the postprandial meal test with a high fat (HF) test meal consumed with the first dose of the intervention (Pom J or placebo). For the next 12 weeks, participants will consume a daily dose of placebo juice 1x/day. During week 4 participants will undergo another skin testing. During week 12 participants will undergo another skin testing and postprandial meal challenge. Stool will be collected at week 1, 4 and 12.
88346|NCT03496571|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
88347|NCT03496571|Other|Placebo|Placebo
88348|NCT03496558|Other|Variability of the lipid profile in pregnant women|"The women participants will be divided into two groups. Group 1 comprised of healthy women and group 2 by pregnant women with a history of risk. A personal, family history and a detailed medical history will be taken in each group. We will proceed to see all possible variables that influence the level of biomarkers (lipids and prolactin).~At least 60 healthy pregnant women and 60 pregnant women with a history of risk (20 for each risk) x 2 series (three years) will be tried, a total of 240-300 women to whom 5 analytical tests would have to be performed."
88349|NCT03496545|Drug|Bromocriptine|bromocriptine 5mg every 4 hours PO/NG/FT and acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours
88350|NCT03496545|Drug|Acetaminophen|acetaminophen 650mg every 4 hours PO/NG/FT for 48 hours
88351|NCT03496532|Device|biphasic stimulation|Fixed 70Hz symmetrical biphasic pulses
88352|NCT03496532|Device|standard stimulation|Fixed 70Hz pseudo-monophasic pulses
88353|NCT03496532|Device|Uniform distribution|Uniform distribution 70Hz Biphasic pulses
88354|NCT03496532|Device|Poisson distribution|Poisson distribution 70Hz Biphasic pulses
88355|NCT03496532|Device|Recordings of LFP oscillations|"Two minutes of recordings of LFP oscillations will be performed from the contacts of the implanted electrode.~Recordings of the depth of anaesthesia (BIS) all along the measurements performed under general anaesthesia.The correlation between the depth of anaesthesia and the cerebral oscillations recorded at the site of subthalamic nucleus will be studied."
88356|NCT03496519|Drug|Dose Escalation of Durvalumab and Trabectedin|"There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be an increase in Trabectedin for each cohort, given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.~Cohort -1: Durvalumab 1125mg with Trabectedin 0.5mg/m2~Cohort 1: Durvalumab 1125mg with Trabectedin 0.75mg/m2~Cohort 2: Durvalumab 1125mg with Trabectedin 1.0mg/m2~Cohort 3: Durvalumab 1125mg with Trabectedin 1.2mg/m2~Cohort 4: Durvalumab 1125mg with Trabectedin 1.5mg/m2"
88357|NCT03496519|Drug|Dose Expansion of Durvalumab and Trabectedin|There will be a fixed dosage of Durvalumab, 1125mg, given intravenously over 60 minutes on Day 2 every 21 days. There will be a fixed dosage of Trabectedin for each cohort, whatever was determined to be the safest dose during the Dose Escalation Phase, and it will be given through intravenous infusion over a 24 hour period on Day 1 every 21 days as an outpatient.
88358|NCT03496506|Drug|Selexipag|Each film-coated tablet contains 200 microgram (mcg) of selexipag (oral use)
88359|NCT03496506|Drug|Clopidogrel|Each film-coated tablet containing 75 mg of clopidogrel (oral use)
88360|NCT03496493|Device|All patients|Peripheral arterial oxygen saturation recording with both study devices
88361|NCT03496480|Diagnostic Test|Questionnaires|Psychological questionnaires: BTQ, IES-R, 7-items-short Screening scale, BDI, SF-36
88362|NCT03496467|Combination Product|Nepafenac PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that contains nepafenac, a nonsteroidal anti-inflammatory drug.
88363|NCT03496467|Combination Product|Placebo PPDS|A punctal plug delivery system (PPDS) is being developed as a device that can deliver a sustained release of a drug to a specific eye. The PPDS is made up of a medical grade silicone punctal plug which holds an insert (core) that does not contain nepafenac.
88364|NCT03496454|Other|PfSPZ Challenge|The administration of an injection PfSPZ Challenge in Gambian adults
88465|NCT03495635|Behavioral|Big Brothers Big Sisters Community-Based Mentoring Program|One-to-one mentoring provided by an adult volunteer with training and ongoing monitoring and support from program staff.
88365|NCT03496441|Other|Fecal sample collection for analysis|Fecal sample analysis will consist of the following procedure : Microbial DNA extraction, amplicon library construction, sequencing and analysis; Clustering MiSeq reads into operational taxonomic units (OTUs); Iron and heme measurements in the samples.
88366|NCT03496428|Device|Dental implant impressions- Different Techniques|Assessment of soft tissues changes with different techniques
88367|NCT03496415|Device|remote ischemic conditioning|Remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mm Hg during the ischemic period (Patent No. CN200820123637.X, China)
88368|NCT03496415|Device|sham remote ischemic conditioning|sham remote ischemic conditioning is performed by using an electric autocontrol device with cuffs that inflated to a pressure of 60 mm Hg
88369|NCT03496402|Other|Sampling on blood, bone marrow and cerebrospinal fluid|biological sampling during treatment and follow-up
88370|NCT03496389|Drug|Gabapentin|Gabapentin 300mg daily
88371|NCT03496389|Drug|Tramadol|Tramadol 50mg QID
88372|NCT03496389|Drug|Panadol|Panadol 500mg QID
88373|NCT03496376|Other|Kinesio Taping|The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
88374|NCT03496376|Other|Deep Breathing Exercises|Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
88375|NCT03496363|Diagnostic Test|TSH , T4|Thyroid stimulating hormone
88376|NCT03496350|Behavioral|Internet-delivered CBT|Culturally adapted transdiagnostic internet-delivered CBT in Arabic
88377|NCT03496337|Other|Assessment of motor and process skills test|At baseline and follow-up (after 8-10 weeks) all patients are assessed with AMPS in addition to the standard test of Canadian Occupational Performance Measure (COPM) hand grip strength and joint range of motion.
88378|NCT03496324|Drug|Nurofen for Children®|Nurofen for Children® 400 mg/10 ml
88379|NCT03496324|Drug|Algifor® Junior|Algifor® Junior 400 mg/20 ml
88380|NCT03496311|Diagnostic Test|Acid - Base characterization|Samples of cerebrospinal fluid and arterial blood will be collected anaerobically to measure acid-base variables, electrolytes, albumin, progesterone and copeptin levels
88381|NCT03496298|Drug|Efpeglenatide (SAR439977)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
88382|NCT03496298|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
88383|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for anorexia nervosa patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
88384|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for obsessional compulsive disorder patient|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
88385|NCT03496285|Radiation|Multimodal MRI with diffusion sequence for healthy volunteer|Multimodal MRI with diffusion sequence, resting state, T2, T1 without gadolinium contrast
88386|NCT03496259|Device|On-Q pump|Type of pain control device used
88387|NCT03496259|Device|Epidural catheter|Type of pain control device used
88388|NCT03496246|Diagnostic Test|serum total 25 hydroxycholecalciferol 25(OH) vitamin D|Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.
88389|NCT03496246|Diagnostic Test|complete blood count (CBC)|for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils
88390|NCT03496246|Diagnostic Test|serum calcium level|measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level
88391|NCT03496246|Diagnostic Test|erythrocyte sedimentation rate (ESR)|it is an indicator of activity in inflammatory bowel disease
88392|NCT03496246|Diagnostic Test|C-reactive protein (CRP)|it is an indicator for increased possibility of infections
88393|NCT03496246|Diagnostic Test|serum creatinine|for assessment of renal function
88394|NCT03496246|Diagnostic Test|serum albumin level|for possibility of malabsorbtion in patients with inflammatory bowel disease
88395|NCT03496246|Diagnostic Test|seum alanine aminotransferase|for assessment of liver function
88396|NCT03496246|Diagnostic Test|serum potassium level|indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
88397|NCT03496246|Diagnostic Test|serum phosphurus level|measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
88398|NCT03496233|Drug|Elbasvir 50 MG / Grazoprevir 100 MG Oral Tablet [Zepatier]|Treatment with EBR/GZR Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients, with non- severe fibrosis, with or without IR and/or DM
88399|NCT03496220|Device|Angulus|Feedback on patient recumbency
88400|NCT03496207|Drug|Placebo|Placebo
88401|NCT03496207|Drug|Sotatercept|Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1
88402|NCT03496181|Behavioral|Multilingual Aphasia Examination|"For patients only prior to MRI scans.~The MAE contains eleven subtests in five categories which may be used to assess both languages in bilinguals and the participant's primary language in monolinguals: Oral Expression, Spelling, Oral Verbal Understanding, Reading, and Rating Scales. Subtests are scored for accuracy of individual items on a three-point scoring system (0, 1, 2). Contained within these domains are The Token Test, Aural Comprehension of Words and Phrases and Visual Naming which naturally parallel fMRI and direct cortical stimulation behavioral assays already in place for clinical use (phonemic fluency, auditory responsive naming and confrontation naming respectively). The MAE is expected to take under 50 minutes."
88529|NCT03495063|Dietary Supplement|Synthetic Caffeine|Consumption of 400mg of synthetic caffeine
88403|NCT03496181|Diagnostic Test|Language paradigms + RS fMRI|10 monolingual patients: 2 language paradigms + RS fMRI = 7x3 = 21 minutes 10 early bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes 10 late bilingual patients: 2 language paradigms+ RS fMRI = 7x3 = 21 minutes
88404|NCT03496181|Diagnostic Test|Language paradigms + RS fMRI + one anatomical sequence|"10 monolingual English volunteers: 2 task language paradigms* + 1 Resting State fMRI + one anatomical sequence for a total of approximately 25 minutes.~10 late bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes.~10 early bilingual volunteers: 4 language paradigms (2 English + 2 Spanish) + 1 Resting State fMRI + one anatomical sequence for a total of approximately 39 minutes."
88405|NCT03496168|Drug|mavacamten|mavacamten capsules
88406|NCT03496155|Behavioral|Build and Support Your Teen's Strengths|"This is a clinic based psychoeducational intervention for adolescent patients and their parents to improve parent-teen communication about teen strengths. The intervention is designed, if possible, to coincide with the adolescent patients' well-child visits and consists of the following components: (1) In-person or over the phone orientation session with a trained health coach and parent, (2) Distribution of psychoeducational materials to the parent, (3) Endorsement and delivery of key messages from the health care provider, and (4) Booster phone call placed by the health coach."
88407|NCT03496142|Procedure|Transperineal prostate biopsy|Puncture of 12 to 30 percutaneous prostate core biopsies through the perineum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
88408|NCT03496142|Procedure|Transrectal prostate biopsy|Patient would undergo 12 to 30 transrectal prostate core biopsies through the rectum with a transrectal ultrasound probe guidance. The procedure would be performed with the Artemis (Eigen) device allowing topographic recording of the puncture and MRI / ultrasound image fusion in order to target the MRI suspected lesion.
88409|NCT03496129|Behavioral|Personalized feedback|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).
88410|NCT03496129|Behavioral|Personalized feedback and text messages|Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.
88411|NCT03496129|Behavioral|Information Only|Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
88412|NCT03496116|Other|ECIG Session|Participants will complete four sessions using an e-cigarette, including a 10-puff product use bout followed by a 60-minute ad lib bout over an approximately 4-hour period. The study conditions for each session (i.e., heater resistance and nicotine combinations) will be Latin-square ordered.
88413|NCT03496103|Biological|ragweed pollen|three hours ragweed pollen in a allergen exposure chamber
88414|NCT03496090|Other|Free diet|Free diet or free demand, being comparable to the normal or zero hospital diet
88415|NCT03496090|Other|Progressive diet|Progressive diet for 7 days, liquid diet for the first three days and soft diet without waste, from the 4th to the 7th day.
88417|NCT03496064|Other|Successful reperfusion|Defined as modified Thrombolysis in Cerebral Infarction 2b/3
88418|NCT03496038|Procedure|L-PRF|The use of the L-PRF as graft material for sinus augmentation procedure will be analysed
88419|NCT03496038|Procedure|DBBM|The use of bovine xenograft as graft material for sinus augmentation procedure will be analysed
88420|NCT03496025|Device|Electrical muscle stimulation|The intervention consists of activating paralyzed facial muscles with electrical stimulation.
88421|NCT03496012|Genetic|AAV2-REP1|Sub-retinal injection of AAV2-REP1 after vitrectomy.
88422|NCT03495999|Diagnostic Test|hyperuricemia|serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
88423|NCT03495986|Device|Functional Electrical Stimulation Leg Cycle Ergometry|Exercise training will consist of three to five, 40-67 minute sessions (200 minutes at target intensity) each week for a total of 16 weeks at 70% maximal heart rate; 10-minute warm-up and cool-down sessions will accompany each exercise session.
88424|NCT03495986|Behavioral|Diet|An individualized, detailed dietary plan consistent with My Healthy Plate Dietary Guidelines of America will be followed under supervision of Registered Dietitian with weekly telemedicine conferences and monitored dietary intake via MyFitnessPal.
88425|NCT03495973|Drug|Ustekinumab|Participants that are initiated on treatment with ustekinumab and are registered in Swibreg will be recruited into the cohort. All aspects of treatment and clinical management of participants will be in accordance with local clinical practice and applicable local regulations, and at the discretion of the participating physician.
88426|NCT03495960|Drug|Rituximab|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Rituximab is given 375 mg/m2 as standard infusion at days -6, 1, 15 & 29. Rituximab on day -6 will be delivered only during the first course; it will be delivered between day -6 and day 0 according to clinical requirements and patient's conditions. Some patients would need for a fast chemotherapy starting.~PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Rituximab is given 375 mg/m2 in 4 weekly doses, starting on day 2 of radiotherapy."
88530|NCT03495050|Device|Transcatheter Aortic Valve Implantation|Transcatheter treatment of bicuspid aortic stenosis with the Evolut Pro/XL platform
88427|NCT03495960|Drug|Methotrexate|During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Methotrexate is given 3 g/m2 as infusion (0.5 g/m2 in 15 min. + 2.5 g/m2 in 3-hr infusion) on days 2, 16 & 30
88428|NCT03495960|Drug|Procarbazine|"PART A - INDUCTION PHASE During the primary chemo-immunotherapy (PRIMAIN regimen, 2 courses; every 43 days) administered as induction in the PART A of the study, Procarbazine is given oral 60 mg/m2/d from days 2 to 11~PART A - MANTEINANCE PHASE (control arm) Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Procarbazine represents the control arm and is given oral 100 mg/d from day 1 to 5 for 6 courses, every 4 weeks."
88429|NCT03495960|Drug|Lenalidomide|"Patients responsive or with stable disease after two courses of PRIMAIN regimen (the induction treatment) will be randomly allocated to receive two different maintenance therapies. Maintenance will start on day 60 of the 2nd PRIMAIN course.~Lenalidomide represents the experimental arm and is given oral 25 mg/d from day 1 to 21 for 24 courses; every 4 weeks."
88430|NCT03495960|Radiation|Radiotherapy|Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the eyes. Photons of 4 - 10 MeV, 180 - 200 cGy per day, 5 weekly fractions will be employed
88431|NCT03495960|Drug|Temozolomide|"PART B - INDUCTION PHASE Patients ineligible for high-dose methotrexate, will be assigned to receive concomitant whole brain radiotherapy-temozolomide-rituximab (Induction Part B). Temoyolomide is given 75 mg/m2/d, every day for the whole duration of radiotherapy.~PART B - MAINTENANCE PHASE Temozolomide is also given as maintenance in Part B. The treatment consists of 12 courses where temozolomide is administered on days 1-5, every 4 weeks at a dose of 150 mg/m2/d at the first course, and of 200 mg/m2/d at the subsequent courses,"
88432|NCT03495947|Behavioral|high flow nasal cannula|24 hours of continuous use in the immediate post-extubation period.
88433|NCT03495934|Drug|pracinostat|[14C]-pracinostat
88434|NCT03495921|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms.
88435|NCT03495921|Drug|Irinotecan|Irinotecan injectable formulation will be obtained. This will be drawn up into oral syringes (1 cycle of 5 doses) and dispensed to the subject with instructions to refrigerate until administration. Irinotecan may be mixed with cranberry-grape juice immediately before administration to mask the bitter flavor and administered once daily on Days 1 through 5 of each 3-week cycle.
88436|NCT03495921|Drug|Temozolomide|Temozolomide capsules may be opened and mixed in apple sauce or juice if unable to swallow whole capsules. Temozolomide is administered on Days 1 through 5 of each 3-week course and given at least 1 hour before Irinotecan.
88437|NCT03495908|Device|VGo|Eligible subjects will be randomized to either stay on RAI delivered by V-Go or randomized to switch to U-100 RHI delivered by V-Go.
88438|NCT03495895|Behavioral|Minding the Baby|Visits are carried out on an alternating basis by a team made up of a nurse practitioner (NP) and social worker.
88439|NCT03495895|Behavioral|Usual Care|Usual care condition
88440|NCT03495882|Drug|AGEN1884 + AGEN2034|AGEN1884 + AGEN2034 according to protocol design
88441|NCT03495856|Behavioral|Mindfulness Training For Chronic Pain|4-week group Mindfulness training program for adults with chronic pain
88442|NCT03495843|Diagnostic Test|Spinal stiffness|Spinal stiffness will be assessed with a device, which measures tissue compliance according to the concept of impulse-response
88443|NCT03495830|Procedure|Carotid endarterectomy|Exploration of carotid bifurcation. Clamping of carotid artery and plaque removal with endarterectomy. Plaque is stored. Suture of artery with direct suture or patch.
88444|NCT03495817|Drug|ATI-50002|ATI-50002 Topical Solution
88445|NCT03495804|Drug|polyethylene glycol|Experimental group was given polyethylene glycol as oral contrast agent.
88446|NCT03495804|Drug|mannitol|Active comparator group was given mannitol as oral contrast agent.
88447|NCT03495791|Other|YouTube Video|Educational Video
88448|NCT03495778|Other|Test Granola|50.5 Test Granola
88449|NCT03495778|Other|Control Granola|54.3 Control Granola
88450|NCT03495765|Drug|Ranibizumab|Ranibizumab 0.5mcg via intravitreal injection to study eye up to monthly
88451|NCT03495752|Other|Bruce Fatigue Protocol|Participant will perform the Bruce protocol as a fatigue stimulus to examine the impact of fatigue on the FSDT
88452|NCT03495739|Drug|RDG-17012 Capsule|Dabigatran Etexilate tosylate 150mg
88453|NCT03495739|Drug|Dabigatran Etexilate Mesylate 150 MG Oral Capsule|Dabigatran Etexilate mesylate 150mg
88454|NCT03495726|Behavioral|Headspace app|Headspace is a Contemplative Application (App) for Well-being (CAW). Participants will be provided initial instructions for downloading and using the Headspace app. The Headspace app includes guided meditations, articles and videos. Participants will be asked to engage in meditation practice for an average of 10 minutes a day during the 6-week training period.
88455|NCT03495713|Drug|Nivolumab|Nivolumab 3 mg/kg will be administered on day 1 (pre-response assessment week 0) and on day 1 and continued per standard of care and institutional practices. A
88456|NCT03495700|Procedure|L-PRF block|The use of the L-PRF block as graft material for sinus augmentation procedure will be analysed
88457|NCT03495700|Procedure|DBBM|The use of bovine xenograft will be analysed
88458|NCT03495674|Behavioral|Exercise Intervention|Complete cycling classes
88459|NCT03495674|Other|Informational Intervention|Receive information about exercise guidelines
88460|NCT03495674|Device|Monitoring Device|Wear Fitbit
88461|NCT03495674|Other|Questionnaire Administration|Complete questionnaire
88462|NCT03495661|Procedure|Decompression|Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
88463|NCT03495648|Behavioral|walking group led by a community organizer|Subjects will walk 1 kilometer from a pre-determined point to a local farmer's market.
88466|NCT03495622|Behavioral|Motivational Interviewing/Text messaging|"The intervention is a multi-component one that is tailored to the individual and will target smoking cessation. The CHW, after identifying the individual's stage of behavior change, will provide motivational interviewing and set up an automatic text messaging system with their mobile phones that are structured around a quit date chosen by the participant.~The CHW visits are pre-determined and she monitors the progress of the individual regularly. She may restart the process of determining the stage of behavior change for those who relapse or quit the intervention midway thereby reassigning them to the appropriate phase of the trial"
88467|NCT03495609|Drug|Ovitrelle|Ovitrelle will be injected in 35 asymptomatic women with BRCA1 or BRCA2 mutation during 90 days (an extra 4 weeks in a subgroup). The gene expression of the breast epithelial cells will be characterized and compared to the gene expression of the breast epithelial cells before ovitrelle injection.
88468|NCT03495596|Device|Videolaryngoscopy|Videolaryngoscopy device type
88469|NCT03495583|Other|Early introduction|Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
88470|NCT03495570|Diagnostic Test|blood draw|single one time blood draw to measure lymphocyte panels included activated lymphocytes using remnant sample from a full blood count
88471|NCT03495557|Procedure|Control|Fascial closure with simple polydioxanone suture 2/0 stitches
88472|NCT03495557|Device|Experimental|Onlay polypropylene mesh placement (MN mesh)
88473|NCT03495544|Diagnostic Test|PD-L1 expression|IHC testing of PD-L1 expression level in tumor tissue samples
88474|NCT03495531|Device|Virtual Reality|Virtual Reality headset with calming scenery
88475|NCT03495518|Other|Symptom feedback to Health Care Provider|"These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical"
88476|NCT03495518|Other|Standard of care|A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
88477|NCT03495505|Device|WiSE-CRT|Intervention will involve placement of the WISE-CRT system which consists of a transmitter, battery and electrode.
88478|NCT03495492|Device|Dermal Chelation|Dermal chelation with Aqua DetoxTM system for one or more hours one or more times each week.
88479|NCT03495492|Dietary Supplement|Nutritional Therapy|Vitamins and minerals that will be taken one or more times a day.
88480|NCT03495479|Drug|OMN54|Twice daily, self administered, oral dosing of OMN54. A daily diary log will be prepared by each participant and reviewed by the Investigator.
88481|NCT03495466|Procedure|Local only anesthesia vs Local with sedation anesthesia|The investigators are comparing two approved sedation types that are using during carpal tunnel surgery.
88482|NCT03495453|Device|Percutaneous Revascularization of the Femoropopliteal Arteries using a DAS|"Diamondback 360 Peripheral Orbital Atherectomy System (OAS) is a small catheter with a diamond crown. The doctor inserts it at the groin and advances into the leg.The OAS works by spinning around inside the artery to sand down the buildup of material along the artery walls while leaving the healthy vessel behind."
88483|NCT03495453|Device|Percutaneous Revascularization of the Femoropopliteal Arteries using a OAS device|HawkOne Directional Atherectomy System (DAS) also is the small catheter with cutting device. Doctor slowly and smoothly advances it across the blockage in your artery and shaves the plaque from the vessel wall and collects it in the reservoir.
88484|NCT03495440|Behavioral|Center Sessions|Program to support relationships and communication between parents and typically developing adolescent siblings of individuals with intellectual and/or developmental disabilities.
88485|NCT03495440|Behavioral|At-home|Self-study resources paired with regular contact with study personnel.
88486|NCT03495427|Drug|F-DCFPyL Injection|F-DCFPyL Injection is a radioactive diagnostic imaging agent indicated for imaging of patients with recurrent prostate cancer.
88487|NCT03495427|Diagnostic Test|PSMA PET|PSMA PET imaging (for men with high GC >0.45) will be done after 2 years post-treatment, then yearly up to 5 years.
88488|NCT03495414|Other|Brain Imaging|"Structural MRI (T1 weighted)~Diffusion Tensor Imaging (DTI)~resting state functional MRI (rs-fMRI)~functional MRI (fMRI): Brain activity will be measured in response to sexual images (visually evoked sexual arousal; processing of sexual stimuli), and importantly during a phase when these stimuli are anticipated (neural correlates of wanting and desire; reward anticipation)."
88489|NCT03495414|Other|Cognitive testing|"We will administer neuropsychological tests assessing objective measures for~intelligence (Ravens Matrices)~impulsivity and risk-taking behavior (Balloon Analogue Risk Task)~inhibitory control (Stop Signal Task)."
88490|NCT03495414|Other|Psychometric|Administered questionnaires include anxiety and depression symptoms (MADRS, HADS, GAD), drug use (AUDIT, DUDIT), attention deficits (ASRS), impulsivity (BIS-11), reward seeking behavior (BIS/BAS), sexual orientation, (hyper)sexual behavior, desire and compulsivity aspects (HDSI, HBI, SCS, SDI, SIS/SES).
88491|NCT03495414|Other|Blood test|Blood samples will be taken for routine health assessment, measurement of sex hormonal levels, HPA-axis function test (dexamethasone suppression), and potential DNA extraction and (epi)genetic profiling.
88492|NCT03495401|Dietary Supplement|fortified synbiotic milk|100 ml fortified (7,47 mg ferrous sulphate and 4,33 mg zinc acetate) synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
88493|NCT03495401|Dietary Supplement|non-fortified synbiotic milk|100 ml non-fortified synbiotic milk containing 7 billion CFU Lactobacillus plantarum Dad13 in combination with 4 g prebiotic fructooligosaccharides
88494|NCT03495375|Dietary Supplement|Treatment with a probiotic|All participants will take the probiotic once daily for 10 weeks in the form of a powder that can be spread on top of cold foods such as muesli, salad, or yogurt.
88495|NCT03495375|Other|Treatment with placebo|All participants will take the placebo once daily for 10 weeks.
88496|NCT03495362|Dietary Supplement|Yeast Beta-glucan|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
88497|NCT03495362|Other|Placebo|Twice a day, 1 capsule each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
88635|NCT03494127|Device|Use of SQUISHINS FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF SQUISHINS FITTED MODULAR CUSHION for 2 weeks
88498|NCT03495349|Other|safety and effectiveness of the usual treatments of diabetic foot infections|clinical and biological follow-up necessary to assess the safety and effectiveness of the medical treatments, MOS-SF survey (36-Item Short Form Survey) to study the quality of life.
88499|NCT03495336|Other|coffee abstention phase|no coffee consumption for 2 weeks
88500|NCT03495336|Other|LR Coffee consumption|for 4 weeks participants consumed only LR Turkish coffee
88501|NCT03495336|Other|DR Coffee consumption|for 4 weeks participants consumed only DR Turkish coffee
88502|NCT03495323|Drug|LY3300054|LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
88503|NCT03495323|Drug|Prexasertib|Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
88504|NCT03495310|Behavioral|Mindfulness|Mindfulness is a method based on the concentration of attention, awareness and meditation, which has been used successfully to reduce stress, depression and anxiety in individuals with some pathology in the short term
88505|NCT03495297|Procedure|ommitence of defibrillation testing|Induction of a ventricular arrhythmia to test proper arrhythmia detection and termination by the implanted device is omitted
88506|NCT03495284|Dietary Supplement|Potato-based side dish|Daily consumption of a potato-based side dish equivalent to one medium size potato for 4 weeks
88507|NCT03495284|Dietary Supplement|Refined grain-based|Daily consumption of an isocaloric refined grain-based side dish for 4 weeks
88508|NCT03495258|Procedure|Clarion Evolve Laser Vaporization System|
88509|NCT03495258|Procedure|Olympus TURis Plasma Vaporization|
88510|NCT03495232|Device|Zimmer Biomet Persona total knee system|Product manufactured by Zimmer Biomet used to replace the knee joint.
88511|NCT03495219|Procedure|Esophageal Manometry|A catheter inserted through the nares, post appropriate anesthetization. The subject is then given 8 - 10 sips of water or semi viscous fluid during the routine study. At the conclusion of the clinical portion of the examination the manometer catheter is typically removed by the technician at that point. For the purposes of this research study the catheter will remain in place to examine pressures specifically at the lower end of the esophagus during various breathing patterns and training activities to see if pressures can be increased with instruction.
88512|NCT03495206|Drug|Y-2(adaravone And Borneol) Sublingual Tablet|Y-2 sublingual tablet at single ascending doses of one tablet , two tablets, three tablets, four tablets
88513|NCT03495193|Other|Exercise training|Exercise training will be performed 3x/week. After 2 sessions, training volume and intensity will progress over the first 4 sessions ramping up the number of sets to increase the volume. The full volume prescription will consist of: 1) 5 movements to improve strength and muscle mass (leg press, knee extension, chest press, overhead press, pull down), 3 sets each of 8-12 repetitions (~30 total repetitions); 2) trunk exercises to improve postural stability (trunk extension and flexion); 3) 3-4 bodyweight exercises (selected from a menu) to improve power and balance (e.g. step up, squat, jump squat, lunge, side lunge, push-up, assisted pull-up, assisted dip). Bodyweight movements will be modified as necessary to match abilities.
88514|NCT03495193|Behavioral|Sleep hygiene|Subjects randomized to the no-exercise group will receive a handout with tips for improving sleep. Additionally, study staff will provide the title page for a book on sleep relaxation techniques that is recommended for persons with sleeping difficulty. Dr. Amara will review the sleep tips with the subjects and make recommendations for improving current sleep habits. Subjects will be contacted by telephone every 4 weeks during the 16-week intervention period.
88515|NCT03495180|Other|Standard EEG or SSEP|The gamma frequency range (30 -100 Hz) of standard EEG or somatosensory evoked potential (SSEP) correlate with intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
88516|NCT03495167|Drug|SyB C-1101|SyB C-1101 (rigosertib sodium) will be administered to two cohorts of patients; each receives either twice daily (560 mg before breakfast and 560 mg before dinner) or twice daily (840 mg before breakfast and 280 mg before dinner. SyB C-1101 will be administered orally twice daily for 21 consecutive days, followed by a 7-day observation period. The treatment period of 28 days (21 days of administration + 7 days of observation) constitutes 1 cycle.
88517|NCT03495154|Device|Parietene DS Composite Mesh|All subjects enrolled will receive the Parietene DS Composite Mesh
88518|NCT03495141|Behavioral|Supervision/Coaching|Supervision involves coaching the trainee on insertion and withdrawal technique in a standard colonoscopy in a novice trainee
88519|NCT03495128|Other|Bed Rest|3 days of head down tilt (-6 degrees) bed rest
88520|NCT03495128|Other|Reconditioning|daily resistance training (for 3 days) on one leg
88521|NCT03495115|Device|MRI|A MRI uses a strong magnet to produce detailed pictures of the inside of your body.
88522|NCT03495115|Device|RSI|RSI is a technique that aims to improve the pictures produced during a MRI exam.
88523|NCT03495102|Drug|Dulaglutide|Administered SC
88524|NCT03495089|Diagnostic Test|dermal electrochemical conductance (DEC)|The patient will undergo DEC quantification using the Sudoscan® device.(Sudoscan®, Impeto Medical, France)
88525|NCT03495089|Diagnostic Test|Monofilament testing|Monofilament testing by Semmes-Weinstein 5:07 MFT (10 g),
88526|NCT03495076|Other|Saline injection|In the saline injection condition, acute neck pain will be induced via 0.5 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute pain. Saline will be injected into the right (or left) trapezius muscle at the level of C7 cervical level. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at the same depth. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster to ensure blinding.
88527|NCT03495076|Other|Sham injection|In the sham-injection condition (nocebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin without piercing the skin. A stimulus of 512 millinewtons (mN) will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided. The stimuli will be applied in exactly the same spot as the real injection in previous experimental condition.
88528|NCT03495063|Dietary Supplement|Natural Caffeine|Consumption of 400mg of natural caffeine
88531|NCT03495037|Behavioral|Real World Strategy Training|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
88532|NCT03495037|Behavioral|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sodoku puzzles. Homework will consist of reading assignments related to the session topics.
88533|NCT03495024|Drug|Varenicline|Oral medication approved to facilitate smoking cessation
88534|NCT03495011|Diagnostic Test|Breast MRI|Breast MRI prior to clinical breast biopsy
88535|NCT03495011|Other|Laboratory Biomarker Analysis|Oncotype Dx testing will be done on surgical specimen of pure DCIS
88536|NCT03494998|Diagnostic Test|PAT-POPS|Emergency Department-specific screening tool
88537|NCT03494985|Device|Experimental Oralbalance Moisturizing Gel|Participants placed approximately a half inch length of the gel onto the tongue and spread thoroughly using their tongue. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
88538|NCT03494985|Device|Biotene Original Oral Rinse|Participants rinsed their mouth with 15 milliliters (mL) of oral rinse for 30 seconds and spat out. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
88539|NCT03494985|Device|Biotene Moisturizing Mouth Spray|Participants sprayed one jet directly into their mouth. Participants used their assigned treatment products for 28 days as specified on their diary/instructions, at least twice and no more than 5 times daily.
88540|NCT03494985|Other|Water|Participants were allowed to take only one measured sip of water (15 mL) 30 minutes before the supervised product use. After the supervised treatment at the site, participants assigned to the water only treatment were allowed to sip water as often as required.
88541|NCT03494972|Drug|Tetracyclin ointment|During 3rd molar surgery
88542|NCT03494959|Drug|Pentaglobin|Antimicrobial treatment active against the multidrug-resistant strain should be started in case of neutropenic fever (oral temperature ≥38.3°C or temperature ≥38.0°C sustained over a one-hour period). Patients should receive the best available first-line therapy, usually a combination therapy, based on the in vitro susceptibility results of the pre-treatment screening swab in combination to Pentaglobin 5ml/kg over a 12h i.v. infusion for 3 consecutive days. Empirical treatment should be subsequently streamlined according to microbiological results (both positive and negative). Pentaglobin should be started within 12h from the onset of fever, regardless of the presence of hemodynamic stability.
88543|NCT03494946|Procedure|Liver transplantation|
88544|NCT03494946|Drug|Chemotherapy|May include chemotherapy, TACE, SIRT or other available treatment options.
88545|NCT03494933|Procedure|CRT-P implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-P device.
88546|NCT03494933|Procedure|CRT-D implantation|Patients will be treated according to Optimal Medical Therapy defined by ESC Guidelines for treatment of patients with heart failure and will receive on top a CRT-D device.
88547|NCT03494920|Other|Direct endovascular clot retrieval|Direct endovascular clot retrieval within 4.5 hours of stroke onset
88548|NCT03494920|Other|Bridging thrombolysis followed by ECR|Bridging thrombolysis followed by ECR within 4.5 hours of stroke onset
88549|NCT03494907|Drug|Seltorexant|Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
88550|NCT03494907|Other|Placebo Matched to Seltorexant|Participants will be administered matching placebo to seltorexant tablets on Day 1.
88551|NCT03494907|Other|Placebo Matched to Moxifloxacin|Participants will be administered oral dose of moxifloxacin placebo tablet on Day 1.
88552|NCT03494907|Drug|Moxifloxacin Dose 1|Participants will be administered oral dose 1 of moxifloxacin on Day 1.
88553|NCT03494894|Diagnostic Test|Middle meatus aspirations and sputum|Bacterial genotype sequencing analysis will be performed in patients with bacteriological concordance between upper and lower airways.
88554|NCT03494881|Drug|Nucala|All study participants will receive Nucala (2) 100mg SQ injections administered at two different anatomical sites at week zero, 2,4,6, and 8 for a total of 5 doses.
88555|NCT03494868|Dietary Supplement|Carbohydrate Drink|2 - 12 oz drinks
88556|NCT03494855|Device|SyMRI Software|The MDME sequence aims to provide whole absolute quantification of T1, T2, PD and B1 inhomogeneity in 5 minutes at typical clinical resolution (0.8 x 0.8 x 5mm). SyMRI software then allows a user to synthesize any almost image contrast (T1, T2, PD, FLAIR, IR, DIR, etc) by adjusting imaging parameters after the fact.
88557|NCT03494842|Device|Transcutaneous nerve stimulation (TENS)|The active TENS unit (delivers electrical stimulation) with indicator light
88558|NCT03494842|Device|Placebo Transcutaneous nerve stimulation (TENS)|the placebo TENS unit (delivers no electrical stimulation) with indicator light
88559|NCT03494816|Drug|Axitinib Oral Tablet|"Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
88636|NCT03494114|Drug|Ga-EC2115|Ga-EC2115 will be administered by IV injection prior to PET/CT imaging.
89649|NCT03486223|Drug|Placebo oral capsule|Placebo will be taken daily by mouth for 7 days.
88560|NCT03494777|Behavioral|Incentivization based on high adherence|When a participant comes for a regular clinic visit, s/he will have the MEMS data extracted, and if adherence over the previous month >=90%, will participate in a prize drawing.
88561|NCT03494777|Behavioral|Incentivization based on timely clinic visit|When a participant comes for a regular clinic visit on the day s/he is scheduled, s/he will participate in a prize drawing.
88562|NCT03494777|Behavioral|Annual adherence prize drawing|Participants will have a chance to take part in an annual drawing where eligilbity is based on the average adherence during that year.
88563|NCT03494777|Behavioral|Annual viral suppression-based prize drawing|Participants will have a chance to take part in an annual drawing where eligibility is based on showing viral suppression.
88564|NCT03494777|Behavioral|Year 2 booster|Those participants not showing viral suppression at month 12 will be randomized in a 1:1 fashion to receive an additional intervention component or continue receiving the same intervention arm as in Year 1.
88565|NCT03494764|Other|Hyperbaric Oxygen Therapy|Hyperbaric oxygen (HBO) provides 100% oxygen at a pressure above atmospheric pressure (typically twice to three times standard sea level pressure (2.0-3.0 ATA)). This dramatically increases the amount of oxygen dissolved in blood plasma, which in turn increases oxygen delivery to tissues. This effect of hyperbaric oxygen is used clinically to treat acute hypoxia in crush injuries, severed limbs, and failing skin grafts
88566|NCT03494751|Device|Heart monitor|Use of heart monitor device in the patients after acute myocardium infarct.
88567|NCT03494751|Device|No heart monitor|Standard monitoring by nurses.
88568|NCT03494725|Dietary Supplement|Lpc-37|Lactobacillus paracasei Lpc-37 at 1 x 10^10 colony forming units (CFU) per day, Microcrystalline cellulose, Magnesium stearate, silicon dioxide
88569|NCT03494725|Dietary Supplement|Placebo|Microcrystalline cellulose, Magnesium stearate, silicon dioxide
88570|NCT03494712|Drug|S 95010|Single administration of S 95010 in healthy volunteers
88571|NCT03494712|Other|Placebo|Single administration of placebo in healthy volunteers
88572|NCT03494699|Behavioral|Multidisciplinary prevention|group cognitive training (every month) App-based Cognitive Training at Home (using smartphone application) physical activity/body weight/smoking & alcohol cessation monitoring and feedback
88573|NCT03494686|Procedure|LLETZ under local anaesthesia|Conization will be performed under local anaesthesia
88574|NCT03494686|Procedure|LLETZ under general anaesthesia|Conization will be performed under general anaesthesia
88575|NCT03494673|Diagnostic Test|BOLD MRI|"Prospective End-tidal targeting RespirAct device(A specially designed gas blender and sequential rebreathing circuit) will be used to implement the gas targeting method which involves precise elevations in End-tidal PCO2 while maintaining a fixed End-tidal PO2~BOLD MR images will be obtained by using a T2*-weighted two-dimensional gradient-echo sequence with echoplanar readout."
88576|NCT03494660|Device|Subchondroplasty Procedure with AccuFill|Injection of the commercially available flowable calcium phosphate (CaP) synthetic bone-void filler, AccuFill®, into subchondral bone defects in the hip (Subchondroplasty (SCP) Procedure).
88577|NCT03494647|Device|Cheetah Heel Cup|At 1, 2, and 3 months, a study team member will email the subject's parent the OxAFQ-C and Visual Analog Scale (VAS). A reminder phone call will be made if the questionnaires have not been completed within 5 days.
88578|NCT03494647|Device|The X Brace|At 1, 2, and 3 months, a study team member will email the subject's parent the OxAFQ-C and Visual Analog Scale (VAS). A reminder phone call will be made if the questionnaires have not been completed within 5 days.
88579|NCT03494634|Drug|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
88580|NCT03494621|Behavioral|Protecting Babies While they Sleep Curriculum|The intervention curriculum derives from information gathered at previously conducted focus groups and interviews, which aimed to ascertain the role of caregiver knowledge, beliefs, and access to resources in implementation of infant safe sleep practices. .
88581|NCT03494595|Procedure|Pediatric Liver transplantation|Pediatric Liver transplantation
88582|NCT03494582|Procedure|Sacral Hysteropexy|Abdominal approach for uterine suspension
88583|NCT03494582|Procedure|sacrospinous Hysteropexy|Transvaginal approach for uterine suspension
88584|NCT03494569|Drug|Fludarabine|Given IV
88585|NCT03494569|Other|Laboratory Biomarker Analysis|Correlative studies
88586|NCT03494569|Drug|Melphalan|Given as per City of Hope Standard Operating Procedure
88587|NCT03494569|Radiation|Total Marrow Irradiation|Undergo TMLI
88588|NCT03494556|Other|Data Collection|Paramedic will use data collected during routine care to complete four risk stratification tools.
88589|NCT03494543|Procedure|Endoscopic Papillectomy|Endoscopic resection of ampullary of Vater neoplasms
88590|NCT03494517|Drug|Magnesium Sulfate|Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
88591|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered once.
88592|NCT03494504|Drug|Reproxalap Ophthalmic Solution (0.5%)|Reproxalap Ophthalmic Solution (0.5%) administered once.
88593|NCT03494504|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered once.
88594|NCT03494491|Dietary Supplement|Chitin-glucan|Second test day (D2), subjects will received 4.5g of chitine-glucan
88595|NCT03494491|Dietary Supplement|Maltodextrin|First test day (D0), subjects will received 4.5g of maltodextrin.
88596|NCT03494478|Other|Neuropsychological testing|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up
88597|NCT03494478|Other|Actimetry|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
88598|NCT03494478|Other|Self-questionnaires on emotional topics|The assessment will will be done at the time of the initial evaluation (undiagnosed / untreated patients), then at one year of follow-up.
88599|NCT03494465|Procedure|PHACOEMULSIFICATION|"Standard phacoemulsification with intraocular lens implant will be perform within 60 days after allocation. If IOP target is not achieve, patients will be treated as in medical treatment group"
88600|NCT03494465|Drug|MEDICAL GLAUCOMA TREATMENT|The escalation of topical hypotensive medications will be carried out with the following sequence: 1. single topical medication; 2. double topical therapy; 3. triple topical therapy. Beginning, with the exception of individual contraindications, with prostaglandin analogs, followed by topical beta-blockers, carbonic anhydrase inhibitors and finally alpha-agonists.Target IOP will be used in both groups to inform the need of escalation of therapy; in patients with ocular hypertension the target IOP will be 21 mmHg. In patients with mild glaucoma target IOP will be 18 mmHg, and in patients with moderate glaucoma the target IOP will be 15 mmHg.
88601|NCT03494452|Other|No intervention|There is no intervention in this cross-sectional study
88602|NCT03494426|Procedure|radiofrequency thoracic sympathectomy|"Under fluoroscopic guidance thoracic sympathectomy will be done as follow~antroposterior view of upper thoracic vertebrae ,cephalo-caudal adjustment of C - arm until aliment of endplates of T2 and T3~oblique view 20 degree under tunnel view RF 10cm 20G 1mm active tip needle is introduced intimately related to vertebral margin~the depth of the needle will be determined under lateral fluoroscopic view the needle is advanced step by step hugging the lateral vertebra l margin until the tip of the needle situated at the middle of the vertebral body . RF lesion 2min 80c will be done and needle is rotated 90 degree on both sides and another two lesions will be done at the end of the procedure 2ml of lidocaine and 20mg of triamcinolone will be injected at each level Post procedure analgesic protocol consisted of either increase or decrease, according to intensity of pain by 50 mg pregabalin and 50 mg tramadole and 25 mg tryptazole, individualized for each patient."
88603|NCT03494426|Drug|pregabalin ,tramadol,and tricyclic antidepressants|patient will receive anti neuropathic medications
88604|NCT03494413|Diagnostic Test|Transpharyngeal Doppler sonography (TPS)|Usage of transpharyngeal Doppler to assess cerebral perfusion during cardiovascular surgery
88605|NCT03494413|Diagnostic Test|Conventional colour-coded Duplex sonography (CDS)|Usage of conventional colour-coded Duplex sonography (CDS) to assess cerebral perfusion during cardiovascular surgery
88606|NCT03494400|Other|Aerobic Training Presential|The intervention will last 24 weeks, in which the presential training group will undergo aerobic training three times a week on interspersed days.
88607|NCT03494400|Other|Aerobic Training Home-based|The intervention will last 24 weeks, the group accompanied by the distance will carry out the activities in their preferred place under the distance supervision of professionals and every 14 days must attend the UNESP to adjust the intensity and verification of attendance to the proposed activities
88608|NCT03494387|Drug|Oxygen|80% versus 30% inspiratory oxygen concentration
88609|NCT03494387|Drug|Antioxidants|Antioxidants versus placebo
88610|NCT03494374|Device|UCBL orthosis|toe walking exercise
88611|NCT03494348|Device|Medial Congruent Polyethylene (MC)|One group receives the conventional CR surface and the other the new MC articular surface
88612|NCT03494335|Other|Online surveys|We are targeting health care providers for these surveys that are involved in or use imaging.
88613|NCT03494322|Drug|Avelumab|Avelumab 10 mg/kg given IV
88614|NCT03494322|Drug|Cetuximab|"Cetuximab 500* mg/m2 given IV~*Cetuximab dose will be dependent on outcome of safety run-in."
88615|NCT03494309|Procedure|Open Reduction & Internal Fixation|Patients underwent surgery and the fractures were reduced under direct vision followed by internal fixation with titanium plates and screws
88616|NCT03494309|Procedure|Closed Reduction & External Fixation|Patients underwent closed reduction of the fracture and external fixation by arch bars & guided elastics
88617|NCT03494296|Drug|patients received D-COP regimen chemotherapy|patients received D-COP regimen chemotherapy
88618|NCT03494283|Behavioral|Practice Behaviour|Improve and modify practice of the practicers and of the professionals who are framing to decrease the injury incidence.
88619|NCT03494270|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe 10mg
88620|NCT03494270|Drug|Monorova|Rosuvastatin 20mg
88621|NCT03494257|Drug|Brinzolamide-Brimonidine fixed combination|Simbrinza 0.2%-1% Ophthalmic Suspension
88622|NCT03494244|Procedure|Direct-to-implant breast reconstruction|Terminal prosthetic implanted at the time of mastectomy.
88623|NCT03494244|Device|Acellular dermal matrix|Banked tissue used to support the directly implanted breast prosthesis.
88624|NCT03494231|Drug|HLX06|recombinant fully human anti-VEGFR2 monoclonal antibody against cancers
88625|NCT03494218|Diagnostic Test|Nociception Coma Scale (NCS)|Patients have been assessed with both the Nociception Coma Scale (NCS) and the FLACC.
88626|NCT03494205|Drug|Urtica comp. gel|"Urtica comp. gel is a Swissmedic registered medication. The scope of application of Urtica comp. is an imbalanced, affected process of skin-regeneration, in particular when stemming from an overdose of heat or light.~It is applied in first and second-degree burn and scalding, sunburn, allergic and hyperergic (excessive) skin conditions (dermatoses), insect bites, abrasions and ulcers."
88627|NCT03494205|Drug|"institutional standard skin care Excipial-Hydrolotion"|"The institutional standard skin care Excipial-Hydrolotion is available to all patients"
88628|NCT03494192|Other|scapula based|physiotherapy program consists of cold pack, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions
88629|NCT03494192|Other|scapula&rotator cuff based|physiotherapy program consists of cold pack, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions
88630|NCT03494179|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
88631|NCT03494166|Behavioral|Telephone Interpersonal Counseling (TIP-C)|See arm/group descriptions
88632|NCT03494153|Other|Non applicable - Non interventional study|Non interventional study
88633|NCT03494140|Device|Viscontour® Serum Med|Viscontour® Serum Med is a CE-certified preservative-free isotonic solution containing 5.0 mg sodium hyaluronate.
88634|NCT03494127|Device|Use of GEL BALL FITTED MODULAR CUSHION|DAILY COMMUNITY USE OF GEL BALL FITTED MODULAR CUSHION for 2 weeks
88638|NCT03494101|Other|Stool samples|Stool samples will be collected and analyzed at different study time points
88639|NCT03494101|Other|Clinical information|Clinical information will be collected at different study time points using questionnaires
88640|NCT03494062|Behavioral|Exercise|Home-based exercise training
88641|NCT03494049|Procedure|Veil sparring HoLEP|"Early mucosal incision lateral to the Veru followed by early separation of the adenoma from the sphincter ring after identification of the plane of enucleation, this minimizes sphincter stretch.~Furthermore, more proximal incision of the 12 O`clock mucosal strip sparring a veil of mucosa covering the sphincter ring."
88642|NCT03494049|Procedure|Standard HoLEP|Holmium laser enucleation of the prostate in the standard approach described by Elhilali et al 2010
88643|NCT03494036|Dietary Supplement|Synbiotic|capsule
88644|NCT03494036|Dietary Supplement|Placebo|capsule
88645|NCT03494023|Diagnostic Test|Endoscopic ultrasound|Measurement of the common bile duct diameter
88646|NCT03494010|Other|Observation|There is no intervention. Patients will receive the HCL system as part of their clinical care.
88647|NCT03493997|Combination Product|Radiotherapy+IAluril®+Ialuril Soft Gels®|Radiotherapy+IAluril®+Ialuril Soft Gels®
88648|NCT03493997|Radiation|Radiotherapy only|Radiotherapy only
88649|NCT03493984|Other|Ginger exosomes|Naturally occurring plant exosomes from ginger
88650|NCT03493984|Other|Aloe exosomes|Naturally occurring plant exosomes from aloe
88651|NCT03493984|Other|Placebo|Exosome placebo tablet
88652|NCT03493971|Procedure|Carotid revascularization performed using CAS|Carotid artery stenting (CAS) is an endovascular stent procedure used to treat narrowing of the carotid artery and decrease the risk of stroke
88653|NCT03493971|Procedure|Carotid revascularization performed using CEA|Carotid endarterectomy (CEA) is a surgical procedure used to correct stenosis in the common carotid artery or internal carotid artery and reduce the risk of stroke
88654|NCT03493958|Behavioral|SHUTi|The SHUTi program is an automated, interactive, internet-based intervention based on well-established face-to-face CBT-I components including sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. It consists of six core areas of focus that include interactive educational content and case studies about insomnia and its precipitating factors. These cores are designed to parallel traditional (in-person) CBT-I sessions and are metered; that is, new cores are available seven days after completion of the previous core. The program includes a variety of interactive features, including goal-setting, feedback based on user-identified symptoms, animations, quizzes, vignettes, and video-based expert explanations. SHUTi was developed based on the Model for Internet Interventions (a-Ritterband, et al., 2009). SHUTi users must fill out at least five daily sleep diaries for each core in seven days in order to access subsequent cores.
88655|NCT03493958|Other|insomnia education web-based program|Education/control
88656|NCT03493945|Biological|M7824|1,200 mg IV once every 2 weeks
88657|NCT03493945|Drug|ALT-803|8-15 mcg/kg subcutaneous every 2 weeks
88658|NCT03493945|Biological|MVA-BN-Brachyury|MVA-BN-Brachyury will be administered subcutaneously (2 doses 2 weeks apart).
88659|NCT03493945|Biological|FPV-Brachyury|FPV-Brachyury will be given 2 weeks after second dose of MVA- BN-Brachyury, then every 4 weeks until 6 months, then every 3 months for 2 years, then every 6 month.
88660|NCT03493945|Drug|Epacadostat|100 mg orally twice daily (200 total)
88661|NCT03493932|Drug|Nivolumab|OPDIVO is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
88662|NCT03493932|Drug|BMS-986016|Anti-Lymphocyte Activation Gene-3 antibody undergoing clinical evaluation by Bristol-Myers Squibb
88663|NCT03493919|Biological|Bexsero|Two doses of Bexsero will be administered on a 0,2-month schedule (Day 1 and Day 61) intramuscularly in the upper deltoid of the non-dominant arm.
88664|NCT03493919|Biological|Menveo|One dose of Menveo vaccine will be administered intramuscularly in the upper deltoid of the non-dominant arm, at Day 1.
88665|NCT03493906|Other|Patient Ambassador Support|Patient Ambassador Support, with former patient treated for acute leukaemia being ambassadors for newly diagnosed patients for a period of 12 weeks.
88666|NCT03493893|Device|Intermedullary nail|investigate the clinical effects of these design changes from the use of three different IM nail designs in the management of extracapsular hip fractures.
88667|NCT03493867|Device|Vitaliti|Measurements recorded by the Vitaliti device will be compared to the recordings from the arterial catheter.
88668|NCT03493854|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of ddAC Q2W or AC Q3W) for Cycles 1-4.
88669|NCT03493854|Drug|Doxorubicin|Doxorubicin 60 mg/m2 will be administered IV on Day 1 of each cycle of treatment (as part of either ddAC Q2W or AC Q3W) for Cycles 1-4.
88670|NCT03493854|Drug|Docetaxel|As part of one of the two investigator's choices of chemotherapy (AC followed by docetaxel), docetaxel 75 mg/m2 will be administered IV on Day 1 of Cycle 5 and then 100 mg/m2 IV at the discretion of the investigator for Cycles 6-8 (Q3W), if no dose-limiting toxicity occurs.
88671|NCT03493854|Drug|Paclitaxel|As part of one of the two investigator's choices of chemotherapy (ddAC followed by paclitaxel), paclitaxel 80 mg/m2 will be administered IV QW for 12 weeks.
88672|NCT03493854|Drug|Pertuzumab IV|Pertuzumab will be administered as a fixed non-weight-based dose of 840-mg IV loading dose and then 420-mg IV maintenance dose Q3W.
88673|NCT03493854|Drug|FDC of Pertuzumab and Trastuzumab SC|The FDC of pertuzumab and trastuzumab will be administered SC at a fixed non-weight-based dose. A loading dose of 1200 mg SC pertuzumab and 600 mg SC trastuzumab is then followed by a maintenance dose of 600 mg SC pertuzumab and 600 mg SC trastuzumab Q3W.
88674|NCT03493854|Drug|Trastuzumab IV|Trastuzumab will be administered as an 8-mg/kg IV loading dose and then 6 mg/kg IV maintenance dose Q3W.
88675|NCT03493854|Drug|Trastuzumab SC|After surgery (from Cycle 9 onwards), participants in Arm A will be allowed to switch from trastuzumab IV to trastuzumab SC, at the discretion of the investigator, in the countries where trastuzumab SC is routinely used. For participants who switch, a fixed dose of 600 mg trastuzumab SC (irrespective of the patient's weight) will be administered in the adjuvant phase.
88676|NCT03493854|Procedure|Surgery|Participants in both cohorts are scheduled to undergo surgery after 8 cycles of neoadjuvant therapy. Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice.
88677|NCT03493854|Radiation|Post-operative Radiotherapy|If indicated, radiotherapy is given after chemotherapy and surgery, during adjuvant HER2-targeted therapy and hormone therapy (for hormone-receptor positive disease).
88678|NCT03493854|Drug|Hormone Therapy|For hormone receptor positive breast cancer, tamoxifen or aromatase inhibitors will be allowed as adjuvant hormone therapy for postmenopausal participants and with ovarian suppression or ablation for premenopausal participants in countries where it has been registered for this indication. Its use must be consistent with the registered label. Hormone therapy is given after chemotherapy and surgery during adjuvant HER2-targeted therapy.
88679|NCT03493841|Drug|Alpha Lipoic Acid|Lipoic acid is an over the counter supplement. Two different forms, R and racemic are available. R-lipoic acid is the naturally occurring form. Racemic lipoic acid is the most commonly available supplement.
88680|NCT03493828|Procedure|TAP block using Bupivacaine 0.5%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.5% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
88681|NCT03493828|Procedure|TAP block using Bupivacaine 0.25%|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of Bupivacaine 0.25% was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
88682|NCT03493828|Procedure|TAP block using Normal Saline|Following completion of the Cesarean delivery, the abdomen was aseptically prepped with ChloraPrep®. A Sonosite ultrasound machine (S-nerve) with a 14-8 MHz linear probe was used to visualize the lateral abdominal wall muscles and transversus abdominis plane. A 2 or 4 inch stimuplex (Braun) needle was advanced under ultrasound guidance to the transversus abdominis plane. After negative aspiration, 15 ml of normal saline was incrementally injected on each side. The spread of solution within the transversus abdominis plane was visualized with the ultrasound.
88683|NCT03493815|Procedure|Transabdominal Ultrasound Guided IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
88684|NCT03493815|Procedure|Traditional Blind IUD Insertion|Comparing the utility of ultrasound-guided intrauterine device (IUD) insertion compared to traditional blind insertion
88685|NCT03493789|Drug|Fludeoxyglucose F-18|Given IV
88686|NCT03493789|Procedure|Positron Emission Tomography (PET)|Undergo FDG-PET
88687|NCT03493789|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
88688|NCT03493776|Biological|VZV subunit vaccine|VZV subunit vaccine
88689|NCT03493763|Diagnostic Test|5hmC profile in plasma cell-free DNA after liver resection|Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).
88690|NCT03493750|Other|Oral and dental evaluation|Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
88691|NCT03493737|Behavioral|Quality of life surveys|Quality of life surveys by EQ-5D and QLQ-C30
88692|NCT03493724|Other|telemedecine|to evaluate the diagnostic performance of the photographs made by Smartphone, during requests for emergency dermatological advice
88693|NCT03493698|Drug|Midazolam|Midazolam
88694|NCT03493698|Drug|Inarigivir|Inarigivir
88695|NCT03493685|Drug|sparsentan|target dose of 800 mg daily
88696|NCT03493685|Drug|irbesartan|target dose of 300 mg daily
88697|NCT03493672|Diagnostic Test|Objective measurement of physical activity and fitness|Physical activity and fitness will be assessed objectively with a smartphone
88698|NCT03493659|Behavioral|Standing during Concept Test|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test.
88699|NCT03493659|Behavioral|Standing during regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during their regular tutorial sessions.
88700|NCT03493659|Behavioral|Standing during Concept Test and regular tutorial session|The participants will stand with a standing desk at an ergonomically correct height during the administration of the Concept Test and during their regular tutorial sessions.
88701|NCT03493646|Drug|Azacitidine|75mg/m2 per day for 7 days of each 28 day cycle. Cycles 1-6
88702|NCT03493646|Drug|CC-486|100 mg BID for the first 21 days of each 28-day treatment cycle (cycles 7-8). The dose should be increased from cycle 9 onwards to 150mg BID for the first 21 days of each 28-day treatment cycle (cycles 9-12) in the absence of Grade 3 or 4 AE. If 2 or more cycles are tolerated at this dose, further increments are permitted for patients with Stable Disease or if clinically indicated in consultation with the coordinating investigator as per the study dose modification schedule.
88703|NCT03493633|Device|EzyGain|"Each patient performs a minimum of 3 sessions per week with the investigator / APA investigator, for 4 weeks, each walk for a few minutes (<60 min).~Evaluation of the spontaneous physical activity of the patient by actimetry for seven days QAPPA (questionnaire of physical activity for elderly person) a week and a month after the training phase of four weeks"
88704|NCT03493620|Procedure|Device arm|Make a gastric tube (endoscopic sleeve gastroplasty) using the Apollo Overstitch suturing device through endoscopy.
88705|NCT03493620|Procedure|Sham arm|Group II will be conducted identically to Group I except for the procedure itself, and only the endoscopist, that is the researcher, will be aware of which group each patient belongs to.
88706|NCT03493607|Drug|AMO-01|Subjects will receive a single 6-hour intravenous infusion for a total dose administration or 120 mg/m2 of AMO-01.
88707|NCT03493594|Other|Nutrition education program|online platform support, workshop, seminar and cooking demo etc
88708|NCT03493581|Procedure|BIOPSY|re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
88709|NCT03493581|Diagnostic Test|blood-sampled|"after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),~after 6 weeks (V2),~after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),~and after 12 weeks of treatment (V4)."
88710|NCT03493581|Other|feces samples|If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and after the 2nd (V2 - 6 weeks or V3- 8 weeks), depending on courses timelines.
88711|NCT03493568|Drug|Genvoya 150Mg-150Mg-200Mg-10Mg Tablet|switch to Genvoya 150Mg-150Mg-200Mg-10Mg Tablet in patients virologically suppressed HIV-1 infected patients.
88712|NCT03493568|Drug|Dolutegravir 50 mg plus one RTI|Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)
88713|NCT03493555|Behavioral|Peer Health Navigator for PrEP|Peer health systems navigator to improve adherence to PrEP
88714|NCT03493542|Biological|V501|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6
88715|NCT03493516|Diagnostic Test|PET scan quantifying sympathetic denervation using [18F]-LMI1195|A cardiac PET scan will be obtained to quantify the percentage of the left ventricle that is denervated and has reduced uptake of the sympathetic nerve tracer [18F]-LMI1195
88716|NCT03493503|Drug|Salbutamol|Intravenous Salbutamol loading dose
88717|NCT03493503|Drug|Sodium Chloride 0.9%|10 ml of Sodium Chloride 0.9% in 10 minutes intravenous
88718|NCT03493490|Drug|Neodolpasse|Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
88719|NCT03493490|Drug|Diclofenac|Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
88720|NCT03493490|Drug|Placebo|Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
88721|NCT03493477|Other|exposure will be abnormal skeletal jaw relations|Class II skeletal jaw relation or class III skeletal jaw relation based on lateral cephalometric radiograph
88722|NCT03493464|Drug|BR55|A novel targeted ultrasound contrast agent
88723|NCT03493451|Drug|BGB A317|BGB A317 200 mg IV on Day 1 of each 21-day cycle.
88724|NCT03493438|Other|exercise|A hot pack and conventional transcutaneous electrical stimulation (TENS) will be applied with a Chattanoga Intelect® stimulator for 20 minutes at a frequency of 100 Hz and a transition time of 60 μs. The duration of application was 3 days per week and six weeks for each of the four groups. These practices were also applied to individuals in all four groups.
88725|NCT03493425|Drug|Carboplatin|Given IV
88726|NCT03493425|Drug|Cisplatin|Given IV
88727|NCT03493425|Drug|Docetaxel|Given IV
88728|NCT03493425|Radiation|Image Guided Radiation Therapy|Undergo image guided IMRT
88729|NCT03493425|Radiation|Intensity-Modulated Radiation Therapy|Undergo image guided IMRT
88730|NCT03493425|Other|Laboratory Biomarker Analysis|Correlative studies
88731|NCT03493425|Other|Questionnaire Administration|Ancillary studies
88732|NCT03493425|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
88733|NCT03493412|Drug|Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin)|5 mg/kg will be used as the dose of BH4
88734|NCT03493412|Drug|Placebo|Placebo
88735|NCT03493399|Behavioral|Interference|"The principle of interference-based techniques is to move the resources allocated to the elaboration of intrusive desire thoughts to a competing task (e.g., clay modelling, competitive mental imagery, Tetris) in order to monopolize the resources underlying craving, thus preventing its elaboration and reducing its vividness and overwhelming nature. Several studies (Andrade, Pears, May, & Kavanagh, 2012; May, Andrade, Panabokke, & Kavanagh, 2010; Skorka-Brown, Andrade, Whalley, & May, 2015) have shown the efficacy of such techniques to reduce substance-related craving. Yet, data obtained on clinical samples remain scarce.~Due to the flexibility of the single case design towards each participant, the list of interference-based techniques that will be used in this study cannot be exhaustive. However, the following will be proposed to participants: Tetris (smartphone version), manipulation of a bunch of keys, manipulation of a fidget, mental imagery, reading and memorizing a text."
88736|NCT03493386|Drug|Daprodustat 2 mg tablet|Daprodustat is available as 2 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 2 tablets of 2 mg daprodustat will be administered in a fasted state during Part 1 of the study.
88737|NCT03493386|Drug|Daprodustat 4 mg tablet|Daprodustat is available as 4 mg tablet. Subjects will receive daprodustat orally as tablet. A single dose of 4 mg daprodustat will be administered in a fasted state during Part 1 and in fed and fasted state in Part 2 of the study.
88738|NCT03493373|Other|Exercise|The exercise program will consist of: 1) warm up - consisting of stretches of large muscle groups of the upper limbs, lower limbs and trunk and by general mobility exercises; 2) strength training of moderate intensity; 3) balance training; 4) Cooling - will consist of performing overall stretching combined with deep breathing.
88739|NCT03493373|Other|Neural mobilization|Neural gliding mobilization will target mainly the lower limb nerves and will be performed in series of 10 repetitions with 1 minute interval between series.
88740|NCT03493360|Other|Visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at their back in a mirror for visual feedback.
88741|NCT03493360|Other|No visual feedback|Participants will be asked to perform 10 repetitions of low back flexion, extension and lateral side-flexions while looking at a mirror that is covered and no visual feedback is provided.
88742|NCT03493347|Behavioral|Equine-assisted Occupational Therapy|Occupational therapy provided in an equine environment that includes activities such as groundwork, grooming, tacking, mounting, and riding horses
88743|NCT03493334|Other|Visual feedback|Visual feedback of the neck will be given to participants using two mirrors while performing neck movements.
88744|NCT03493334|Other|No visual feedback|Participants will be asked to perform active movements of their neck with the mirrors covered.
88745|NCT03493321|Other|PRF with Theracal|using the PRF which is a new technique with an bioactive material which is the Theracal to evaluate its effect upon the radicular pulp tissue
88746|NCT03493308|Other|Pain neuroscience education|PNE will be conducted in line with international guidelines and will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
88747|NCT03493308|Other|Exercise|Exercise will be provided in different formats including general exercise, strengthening, dance.
88748|NCT03493295|Drug|Levonogestrel IntraUterine System (LNG-IUS)|At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
88749|NCT03493282|Drug|Active Treatment- CT1812 100 mg|Active Study Drug
88750|NCT03493282|Drug|Placebo|Non-active study drug
88751|NCT03493282|Drug|Active Treatment- CT1812 300 mg|Active Study Drug
88752|NCT03493269|Drug|BAY1834845|Orally administered.
88753|NCT03493269|Other|Matching Placebo|Orally administered.
88754|NCT03493269|Drug|Midazolam|Part 1: Orally administered 1mg as a single dose.
88755|NCT03493256|Other|exposure to type 2 neurological complications|exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
88756|NCT03493243|Other|Questionnaires|2-hour clinical observation
88757|NCT03493230|Biological|quantification of BRAF and NRAS mutation|Quantification of cell-free BRAF and NRAS mutations with digital PCR
88758|NCT03493217|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
88759|NCT03493204|Other|Meal delivery|The food will be pre-packaged for storage and patient will prepare these meals at home
88760|NCT03493204|Other|Standard pamphlet with Dietary Advice|Explains how to maintain a low-sodium diet
88761|NCT03493191|Drug|0.5μg/kg SHR0410|a single dose of 0.5μg/kg SHR0410
88762|NCT03493191|Drug|1μg/kg SHR0410|a single dose of 2μg/kg SHR0410
88763|NCT03493191|Drug|2μg/kg SHR0410|a single dose of 2μg/kg SHR0410
88764|NCT03493191|Drug|5μg/kg SHR0410|a single dose of 5μg/kg SHR0410
88765|NCT03493191|Drug|10μg/kg SHR0410|a single dose of 10μg/kg SHR0410
88766|NCT03493191|Drug|20μg/kg SHR0410|a single dose of 20μg/kg SHR0410
88767|NCT03493178|Dietary Supplement|N- acetylcysteine plus Glycine v Placebo (alanine)|Dietary Supplement: Cysteine (as n-acetylcysteine) and glycine, or alanine. Subjects will receive 12wks of supplements.
88768|NCT03493165|Drug|Everolimus|mTOR inhibitor
88769|NCT03493152|Drug|Everolimus|mTOR inhibitor
88770|NCT03493139|Behavioral|Physical Activity Across the Curriculum|Activity breaks will be designed for delivery in the classroom without reconfiguration of the classroom space. Activities will emphasize whole body movements, using large muscle groups. Each break includes multiple activities. Each activity lasts about 2 minutes. There will be a total of about 20 minutes of physical activity done each school day.
88771|NCT03493126|Drug|Estradiol|17β-estradiol vaginal cream
88772|NCT03493126|Other|Placebo|Compounded placebo cream
88773|NCT03493113|Diagnostic Test|EEG|
88774|NCT03493100|Dietary Supplement|oral nutritional supplementation|The intervention group will receive optimized nutritional support, by ONS. While hospitalized each patient receives 2 portions of oral supplementation per day. For remaining days supplementation is calculated individually according to a sarcopenia/energy balance schema resulting in none or maximum 2 portions per day.
88775|NCT03493100|Other|Usual care|The control group will receive treatment according to usual care.
88776|NCT03493087|Dietary Supplement|Menakinon 7|Menakinon 7 - One tablet a day against vitamin K deficiency
88777|NCT03493087|Dietary Supplement|Diet rich in vitamin K|Diet with large content of vegetables and dairy products
88778|NCT03493074|Diagnostic Test|Noninvasive pulse wave analysis sensor, ECG-sensor|The sensors are noninvasively attached
88779|NCT03493061|Drug|Irinotecan|Irinotecan 150 mg/m2 IV over 90 minutes on Day 1, 15
88780|NCT03493061|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.
88781|NCT03493061|Drug|Floxuridine|0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
88782|NCT03493048|Drug|Irinotecan|Irinotecan 130 mg/m²
88783|NCT03493048|Drug|Cetuximab|Cetuximab, iv, 500mg/m2
88784|NCT03493048|Drug|5-fluorouracil|5-FU 2400 mg/m² cont. inf.
88785|NCT03493048|Drug|Oxaliplatin|oxaliplatin 85 mg/m²
88786|NCT03493048|Drug|Leucovorin|leucovorin 200 mg/m²
88787|NCT03493035|Diagnostic Test|Computed tomography angiography (3D CTA)|CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.
88788|NCT03493035|Diagnostic Test|Transcranial color-coded sonography (TCCS)|TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
88789|NCT03493022|Other|Test Granola|50.5 Test Granola
88790|NCT03493022|Other|Control Granola|54.3 Control Granola
88791|NCT03493009|Device|Pure-Vu System|The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.
88792|NCT03492996|Drug|LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose|To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose to healthy subjects
88793|NCT03492983|Dietary Supplement|Intervention group|10 g/day of high cocoa content chocolate for six months.
88794|NCT03492970|Biological|Hourly dosing of the nychtemeral secretion of melatonin|Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
88795|NCT03492957|Other|Physical activity|A tailored, person-centred, 12-week, chair-based exercise intervention to increase physical activity and fitness. Dose: one face-face session with a qualified physiotherapist plus two independent sessions per week. This is combined with education on self-management, self-efficacy and lifestyle change.
88864|NCT03492463|Other|Non-nicotine e-cigarettes|Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
88796|NCT03492944|Drug|Ultrasound Microbubble Contrast Agent|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
88797|NCT03492944|Device|Ultrasound Imaging|Patients undergoing a clinically ordered CT or MRI Enterography for Crohn disease will be recruited to undergo a contrast enhanced ultrasound study of the bowel
88798|NCT03492931|Drug|Ticagrelor|Patients will receive a single dose of ticagrelor
88799|NCT03492918|Drug|Pembrolizumab|"Trial treatment should be administered on Day 1 of each cycle after all procedures/assessments have been completed as detailed on the Trial Flow Chart. Trial treatment may be administered up to 3 days before or after the scheduled Day 1 of each cycle due to administrative reasons.~All trial treatments will be administered on an outpatient basis. Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min)."
88800|NCT03492905|Behavioral|Internet-based Cognitive Behaviour Therapy (iCBT)|Guided self-help for 7 weeks. Contact with therapist 2 times per week.
88801|NCT03492892|Device|Acupuncture|Stimulate acupoint with filiform needles to restore the healthy condition of patients
88802|NCT03492892|Device|Sham Acupuncture|Stimulate non-acupoint with filiform needles to treat the condition of patients
88803|NCT03492879|Device|EIT Technology|Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
88804|NCT03492866|Drug|Gentamicin Sulfate|Topical treatment of 1 side of the scalp twice daily during 6 months
88805|NCT03492853|Genetic|DNA extraction and sequencing|DNA extraction from peripheral blood and KASP sequencing
88806|NCT03492840|Drug|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 2-16 sites (0.1mL per site) into the subcutaneous fat.
88807|NCT03492827|Drug|chlorhexidine acetate gargle|observe whether it can achieve the effect of preventing postoperative infection
88808|NCT03492814|Procedure|partial wound closure|3 sutures distal to second molar and leaving the vertical releasing incision open without any sutures.
88809|NCT03492814|Procedure|total wound closure|5 interrupted sutures with 2 sutures closing the vertical releasing incision and 3 sutures distal to second molar leading to a complete hermetic closure of the wound.
88810|NCT03492801|Procedure|Biospecimen Collection|Undergo collection of blood samples
88811|NCT03492801|Other|Laboratory Biomarker Analysis|Correlative studies
88812|NCT03492788|Other|ECGI-optimized VV-offset|ECGI guided optimization of VV offset programming of CRT device
88813|NCT03492788|Other|Zero VV-offset|Standard-of-care nominal (zero VV-offset) programming of CRT device
88814|NCT03492775|Drug|Obinutuzumab|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
88815|NCT03492775|Drug|Bendamustine|Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
88816|NCT03492762|Drug|64Cu-DOTA-ECL1i|Radiolabeled probe called 64Cu-DOTA-ECL1i that recognizes CCR2 and propose to image CCR2 in the lung to ultimately guide diagnosis and therapy.
88817|NCT03492749|Diagnostic Test|Saliva monitoring|The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT
88818|NCT03492736|Dietary Supplement|Melatonin|30 days 10mg Melatonin taken nightly 1 hour before bed
88819|NCT03492736|Other|Placebo|30 days placebo taken nightly 1 hour before bed
88820|NCT03492723|Dietary Supplement|Aged Garlic Extract|NR
88821|NCT03492710|Biological|Immunoglobulin|Administer volume of IGIV-SN to maintain a trough level of of 5g/L or more
88822|NCT03492697|Drug|PF-06882961 Immediate Release Tablet|Immediate Release Tablet
88823|NCT03492697|Drug|PF-06882961 Controlled Release Tablet (long)|Controlled Release tablet (long)
88824|NCT03492697|Drug|PF-06882961 Controlled Release Tablet (short)|Controlled Release tablet (short)
88825|NCT03492697|Drug|PF-06882961 Immediate Release Solution|PF-06882961 Immediate Release solution
88826|NCT03492684|Procedure|total hip arthroplasty|total hip arthroplasty and EMG
88827|NCT03492671|Drug|Gemcitabine 1000 mg|Pre-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 1000 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
88828|NCT03492671|Drug|nab-paclitaxel|Pre-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 4 cycles) Post-Operative: 125 mg/m2 IV on days 1, 8, 15 (28 days cycles times 2 cycles)
88829|NCT03492671|Radiation|Stereotactic Body Radiation Therapy|Standard Stereotactic Body Radiation Therapy (SBRT) fractionation of 6 Gy per day will be used for all patients to a total dose of 30 Gy.
88830|NCT03492658|Drug|Abatacept|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
88831|NCT03492658|Drug|Methotrexate|Patients will be randomized to treatment with either methotrexate monotherapy (10 - 25 mg once weekly) or a combination therapy of methotrexate (10 - 25 mg once weekly) and abatacept (125 mg subcutaneously once weekly) for 6 months, followed by methotrexate monotherapy (10 - 25 mg once weekly) in both groups for another 6 months.
88860|NCT03492476|Device|Short-stretching Bandage (Reference treatment)|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night"
88861|NCT03492463|Drug|Nicotine patch|Participants will wear the nicotine patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
88832|NCT03492645|Behavioral|Telephone-and technology-facilitated treatment protocol|"8 video or telephone counseling sessions targeting PTSD symptoms related to smoking lapse. The first of these sessions will last approximately 45-60 minutes, and the remaining 7 sessions will last 20-30 minutes.~Use of the Stay Quit Coach (SQC) app between sessions. SQC is a public domain, no-cost mobile app designed by our co-investigators at the National Center for PTSD to complement the IC protocol with evidence-based tools to support smoking cessation, such as motivational messaging and coping tools for managing PTSD symptoms associated with smoking lapse.~Use of the Covita Bedfont iCO Smokerlyzer, a mobile carbon monoxide (CO) monitor, compatible with iOS and Android smartphones, that provides CO readings to the user at any time in order to self-monitor progress in quitting. The Covita iCO mobile app is used with the iCO Smoerlyzer to display CO readings."
88833|NCT03492645|Behavioral|Office-based treatment protocol|Weekly face-to-face sessions using the unmodified treatment manual developed by McFall and Saxon, a protocol combining office-based therapy plus evidence-based pharmacotherapies for smoking cessation that doubled quit rates in veteran smokers with PTSD.
88834|NCT03492632|Other|Hormone panel|Blood sampling on the 3rd day of menstrual cycle for the measurement of serum FSH,LH,PRL,E2 and AMH hormone levels.
88835|NCT03492619|Behavioral|Intensive Intervention|an intervention focused on alleviating discouragement, food insecurity, and excess weight in women and targeted at the individual, family, and community levels
88836|NCT03492619|Behavioral|Non-Intensive Intervention|Group sessions for healthy lifestyle
88837|NCT03492606|Procedure|Samples|lumbar puncture, blood and CSF samples, SNPs analysis
88838|NCT03492593|Other|lycopene|A tomato oleoresin containing lycopene
88839|NCT03492593|Other|beta-carotene|13C beta-carotene
88840|NCT03492593|Other|control|emulsified liquid meal alone
88841|NCT03492580|Drug|Canagliflozin|No intervention or treatment assignment imposed by this study. Participants received canagliflozin as a part of routine clinical practice.
88842|NCT03492580|Drug|Empagliflozin|No intervention or treatment assignment imposed by this study. Participants received empagliflozin as a part of routine clinical practice.
88843|NCT03492580|Drug|Dapagliflozin|No intervention or treatment assignment imposed by this study. Participants received dapagliflozin as a part of routine clinical practice.
88844|NCT03492580|Drug|Dipeptidyl Peptidase-4 (DPP-4) Inhibitors|No intervention or treatment assignment imposed by this study. Participants received DPP-4 inhibitor as a part of routine clinical practice. DPP-4 inhibitors includes: alogliptin, linagliptin, saxagliptin, sitagliptin, vildagliptin.
88845|NCT03492580|Drug|Glucagon-like Peptide-1 (GLP-1) Agonist|No intervention or treatment assignment imposed by this study. Participants received GLP-1 agonist as a part of routine clinical practice. GLP-1 agonists includes: albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide.
88846|NCT03492580|Drug|Anti-hyperglycemic Agents (AHA)|No intervention or treatment assignment imposed by this study. Participants received other selected AHA as a part of routine clinical practice. Other select AHAs includes: acarbose, bromocriptine, miglitol, nateglinide, repaglinide.
88847|NCT03492580|Drug|Thiazolidinediones (TZD)|No intervention or treatment assignment imposed by this study. Participants received TZD as a part of routine clinical practice. TZDs includes: pioglitazone, rosiglitazone, troglitazone.
88848|NCT03492580|Drug|Sulfonylureas (SU)|No intervention or treatment assignment imposed by this study. Participants received SU as a part of routine clinical practice. SUs includes: glipizide, glyburide, glimepiride, chlorpropamide, tolazamide, tolbutamide, acetohexamide
88849|NCT03492580|Drug|Insulin|No intervention or treatment assignment imposed by this study. Participants received Insulin as a part of routine clinical practice.
88850|NCT03492567|Biological|Blood test|Blood draw (max 15 ml)
88851|NCT03492554|Other|1-Lead ECG|All participants will record three single-lead ECGs
88852|NCT03492554|Device|12-Lead ECG|All participants will simultaneously record three 12-lead ECGs
88853|NCT03492541|Other|Propylene glycol-based eye drops|Nano-emulsion ocular lubricant
88854|NCT03492528|Biological|blood samples|blood samples
88855|NCT03492515|Drug|recombinant human thrombopoietin|If platelet count <30×10^9/L and with haemorrhage or risk of bleeding,the patients began to receive subcutaneous injection of TPO with the dose of 300 Unit/kg qd,duration ≤14 days;If platelet count is between 30×10^9/L and 50×10^9/L, the dose will be 300 Unit/kg qod;If platlet count ≥100×109/L, stop this treatment;After delivery, if platelet count <30×10^9/L and with haemorrhage or risk of bleeding,subcutaneous injection of TPO with the dose of 300 Unit/kg qd or qod will be given at a duration ≤14 days;If platelet count is between 30×10^9/L and 50×10^9/L, the dose will be 300 Unit/kg qw;If platlet count ≥100×109/L, stop the treatment.
88856|NCT03492515|Drug|Platelet Concentrate|according to the their conditions, use if necessary
88857|NCT03492502|Biological|Autologous Fecal Microbiota Transplantation|"Consenting allo- SCT patients with acute steroid-resistant GI-related GVHD grade III-IV will receive autologous FMT by nasogastric tube. Standardized stool suspension will be given once a day for two consecutive days.In order to prevent aspiration, patients will be kept in a 45ᵒ upright position for four hours. Participants will fast the night before and be treated with proton pump inhibitors prior to each FMT.~In cases where complete response was not obtained within 7 days after autologous FMT, patients may be eligible for another trail of autologous FMT or to switch to other pharmacological interventions. Stool samples will be collected before and after the intervention for microbial analyses."
88858|NCT03492489|Drug|cemiplimab|Intravenous (IV) administration
88859|NCT03492476|Device|Circaid|"Three observation periods were defined with the following products:~D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system"
88862|NCT03492463|Other|Placebo patch|Participants will wear the placebo patch daily while switching from cigarette use to use of e-cigarettes for eight weeks.
88863|NCT03492463|Other|E-cigarettes|Participants will use e-cigarettes containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
88975|NCT03491644|Drug|Titrated Oxygen|Restrictive treatment with oxygen.
88865|NCT03492450|Other|Treadmill training|Tailored treatment comprising of: 1) aerobic exercises with the aim of increasing fitness 2) task-oriented balance exercises on the treadmill to improve balance and 3) cognitive behavioral interventions to improve balance and gait during dual task activities.In accordance with the literature (Langeskov-Christensen, 2015, Latimer-Cheung, 2013) the treadmill training will be carried out without body weight support, but the participants will be allowed to use the handrails for balance support if needed. The training consists of three different walking sessions, each lasting for 10 minutes: 1) preferred walking speed at an increased slope; 2) walking doing dynamic balance exercises (for example walking with feet in tandem) 3) fast gait speed defined as a 10% increase in walking speed relative to preferred speed with dual task exercises. During the 8-week intervention, walking speed in session 3 will be gradually increased with 10% to 40% of preferred speed.
88866|NCT03492437|Drug|Dabigatran Etexilate|Participants will receive single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.
88867|NCT03492437|Drug|Tepotinib|Participants will receive single oral dose of Tepotinib for 8 days in Treatment period 2.
88868|NCT03492424|Device|cryotherapy|Subjects will receive focal cryotherapy for treatment of prostate cancer
88869|NCT03492411|Other|eHealth Breastfeeding Co-parenting Resource|The eHealth breastfeeding co-parenting resource was designed using a participatory model in partnership with the target population. It contains extensive information about breastfeeding and co-parenting. The topics include not only the importance of breastfeeding and technique but also information on how to manage common issues during breastfeeding establishment as well as over the child's first years, since breastfeeding is recommended to two years and beyond. Interactive learning elements, videos, and links to additional resources are included in the resources.
88870|NCT03492398|Drug|HY209|6 subjects will be assigned to HY209 0.05% gel and 2 subjects will be assigned to placebo.
88871|NCT03492398|Drug|HY209|6 subjects will be assigned to HY209 0.1 % gel and 2 subjects will be assigned to placebo.
88872|NCT03492398|Drug|HY209|6 subjects will be assigned to HY209 0.3% gel and 2 subjects will be assigned to placebo.
88873|NCT03492398|Drug|HY209|6 subjects will be assigned to HY209 0.5% gel and 2 subjects will be assigned to placebo.
88874|NCT03492398|Drug|HY209|6 subjects will be assigned to HY209 0.05% gel and 2 subjects will be assigned to placebo. The trial drug or placebo will be applied on the back of each subject once a day from Day 1 to Day 28.
88875|NCT03492398|Drug|HY209|6 subjects will be assigned to HY209 0.1% gel and 2 subjects will be assigned to placebo. The trial drug or placebo will be applied on the back of each subject once a day from Day 1 to Day 28.
88876|NCT03492398|Drug|HY209|6 subjects will be assigned to HY209 0.3% gel and 2 subjects will be assigned to placebo. The trial drug or placebo will be applied on the back of each subject once a day from Day 1 to Day 28.
88877|NCT03492385|Drug|PB2452 Infusion|30 minute - 12 hour infusion
88878|NCT03492385|Drug|Placebo - Sodium Chloride|30 minute - 12 hour infusion
88879|NCT03492385|Drug|Ticagrelor Oral Tablet - Pre-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo
88880|NCT03492385|Drug|Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment|Ticagrelor 180 mg + 90 mg BID for 5 doses prior to MEDI2452 (PB2452) or Placebo and Ticagerlor 180 mg 24 hours following MEDI2452 (PB2452) or Placebo
88881|NCT03492372|Other|Waste tissues are collected at the time of spinal surgery.|This is a single visit study. Waste tissues are collected at the time of spinal surgery.
88882|NCT03492359|Device|Thora-3Di|Device that uses a grid of structured light to measure chest and abdominal wall movement
88883|NCT03492359|Device|Body Plethysmography|A pulmonary function test (PFT) for measuring total lung volume.
88884|NCT03492359|Device|Spirometry|A pulmonary function tests (PFT) for measuring maximal forced expiratory flow and volume.
88885|NCT03492333|Other|Gluten free diet|Gluten-free diet- Instructions provided by a dietitian
88886|NCT03492320|Other|Health Quality of Life Questionnaire Assessment|Western Ontario and McMaster University Osteoarthritis Index (WOMAC), Self-Rated Questionnaire SF36 and Health Related Quality of Life (HRQoL) 15D questionnaire were used as outcome measurement for functionality and disability assessment.
88887|NCT03492307|Other|Weight-Based Flow for High Flow Nasal Cannula (HFNC) (2L/kg/minute)|A weight-based flow for HFNC.
88888|NCT03492307|Other|Standard Flow for HFNC (Maximum 8L/minute)|Maximum flow of 8L/minute.
88889|NCT03492294|Diagnostic Test|functional magnetic resonance imaging|Patients with disorders of consciousness were assessed by functional magnetic resonance imaging while they were exposed under the condition of music.
88890|NCT03492281|Drug|vibegron|single daily oral dose of vibegron 75mg for 12 weeks
88891|NCT03492281|Drug|Placebos|placebo to match vibegron (experimental drug) and tolterodine (active comparator)
88892|NCT03492281|Drug|Tolterodine Tartrate ER|active comparator
88893|NCT03492268|Biological|BCMA-CART|After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
88894|NCT03492255|Drug|Cyclophosphamide|Patients in both EUROLUPUS group and CYCLONES Group will receive for 3 months Cyclophosphamide (6 doses of 500mg/biweekly)
88895|NCT03492255|Drug|Methylprednisolone|"Patients in EUROLUPUS group will receive Methylprednisolone [750 mg for three consecutive days).~Patients in CYCLONES Group will receive Methylprednisolone [500 mg (day 0 and day 15), 250 mg (day 30 and day 45) and 125 mg (day 60 and day 75)."
88896|NCT03492255|Drug|Prednisone|Patients in EUROLUPUS group will receive oral prednisone ≤ 30 mg/day with a reduction of 5mg/month until complete withdrawal.
88897|NCT03492255|Drug|Mycophenolate Mofetil|From the third month of protocol, patients in both EUROLUPUS group and CYCLONES Group will receive mycophenolate mofetil (2-3 g/day) until the sixth month of study.
88898|NCT03492242|Drug|Immune checkpoint inhibitor|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification) as a monotherapy or in combination: Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
88899|NCT03492229|Other|tDCS|1 mA of tDCS
88900|NCT03492229|Other|AMT|Ankle motor training
88901|NCT03492229|Behavioral|Treadmill training|High intensity treadmill training
88902|NCT03492216|Behavioral|Incentives for negative EtG test|Economic incentives are given to the study participant contingent on point-of-care (POC) urine ethyl glucuronide (EtG) <300 ng/mL with the amount of the incentive escalating with each subsequent negative EtG test.
88903|NCT03492216|Behavioral|Incentives for positive IsoScreen test|Economic incentives contingent on POC (IsoScreen) INH urine positive tests with the amount of the incentive escalating with each subsequent positive IsoScreen test.
88904|NCT03492203|Behavioral|Active Cognitive Remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.
88905|NCT03492203|Behavioral|Cognitive Remediation Control|The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.
88906|NCT03492203|Behavioral|Online computer exercises|There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.
88907|NCT03492203|Behavioral|Strategy monitoring|Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.
88908|NCT03492203|Behavioral|Bridging strategies|The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).
88909|NCT03492177|Drug|selexipag (Uptravi)|Film-coated tablets for oral administration
88910|NCT03492164|Drug|[18F]FluorThanatrace ([18F]FTT)|1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one also known as [18F]FluorThanatrace or [18F]FTT is a positron emitting radiopharmaceutical that has been studied in animals for selective measurement of the in vivo inhibition of the PARP-1 nuclear enzyme with positron emission tomography (PET/CT).
88911|NCT03492138|Drug|ONC201|625mg
88912|NCT03492138|Drug|Ixazomib|Dose to be determined in Phase 1 of study
88913|NCT03492138|Drug|Dexamethasone|40mg
88914|NCT03492125|Drug|MS-533|MS-553
88915|NCT03492112|Device|HCV RNA Point of Care|Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.
88916|NCT03492112|Drug|Sofosbuvir/velpatasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
88917|NCT03492112|Drug|Glecaprevir/pibrentasvir|Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
88918|NCT03492099|Drug|buprenorphine|Patients in this study will receive dosages to be determined by a physician that are specific to each patient.
88919|NCT03492086|Dietary Supplement|Dietary supplementation with capsules containing rosemary and alkylglycerol|
88920|NCT03492086|Dietary Supplement|Dietary supplementation with control capsules|
88921|NCT03492073|Behavioral|Emotional Supportive Mindfulness-based Program|Mindfulness training
88922|NCT03492073|Behavioral|Emotional Supportive Program|Narrative-orientated therapy.
88923|NCT03492047|Dietary Supplement|low dose N-acetylcysteine|N-acetylcysteine 600mg twice daily
88924|NCT03492047|Dietary Supplement|high dose N-acetylcysteine|N-acetylcysteine 1200mg twice daily
88925|NCT03492047|Drug|Paclitaxel|Paclitaxel 80mg /m2 IV
88926|NCT03492034|Device|IUD during CS|IUD insertion during CS
88927|NCT03492034|Device|IUD after puerperium|IUD after puerperium
88928|NCT03492021|Other|Diet Intervention_AP-CPT|Adequate Protein_Carbohydrate Post Therapy (AP-CPT) where protein intake will be 1 g/kg/d for the duration of the study .
88929|NCT03492021|Other|Diet Intervention_PP-PPT|Optimal Protein_Protein Post Therapy (OP-PPT) with protein intake set at 2.0 g/kg/day for the duration of the study
88930|NCT03492008|Other|Conventional technique|Nasogastric tube insertion with patient's head in neutral position
88931|NCT03492008|Other|Contralateral cricothyroid pressure|Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.
88932|NCT03492008|Other|Ipsilateral head turning|Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
88933|NCT03491995|Drug|Quadruple therapy|Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
88934|NCT03491995|Drug|Classic treatment|Omeprazole, amoxycillin, clarithromycin
88935|NCT03491982|Device|Remote Cardiac Rehab|Remote Cardiac Rehab
88936|NCT03491969|Drug|Alpha-Lipoic Acid(α-LA)|200 mg, po, tid
88937|NCT03491969|Drug|Placebos|200 mg, po, tid
88938|NCT03491956|Device|DFPP|Lipid levels,platelet function，and platelet RNA sequencing in hyperlipidemia patients before and after DFPP
88939|NCT03491943|Procedure|ultrasound-assisted midline approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via midline approach.
88940|NCT03491943|Procedure|ultrasound-assisted paramedian approach|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
88941|NCT03491930|Device|VA MOVE! Coach app|The VA MOVE! Coach app promotes weight loss through positive feedback, nutritional education, calorie counts, graphs, charts, and encourages increased activity. Efforts will be supported through weekly phone coaching.
88942|NCT03491930|Behavioral|Telephone Coaching|Weekly Telephone Coaching
88943|NCT03491930|Behavioral|Standard of Care for weight loss.|"Standard of Care for weight loss (2013 American College of Cardiology/American Heart Association Task Force and The Obesity Society (AHA/ACC/TOS) Report,PubMed Identification: 24222017).~To include:~Vioscreen food frequency assessment and bionutritionist consult.~Healthy eating nutritional pamphlets (during consult)~Decrease daily caloric intake by 500 cal/day~Increase in physical activity (goal: 10,000 steps per day - measured by pedometer.)~Dietary counseling by Clinician (monthly)"
88944|NCT03491917|Device|DBT plus S-View|DBT plus S-View images
88945|NCT03491917|Device|FFDM alone|FFDM alone images
88946|NCT03491904|Drug|Fasinumab AI|Self-administered with auto injector
88947|NCT03491904|Drug|Fasinumab PFS|Prefilled syringe administered by study staff
88948|NCT03491878|Procedure|Three dimensional laparoscopic|Three dimensional laparoscopic cholecystectomy including segments IVB and V
88949|NCT03491878|Procedure|Open|Open cholecystectomy including segments IVB and V
88950|NCT03491865|Behavioral|REAL media Plus curriculum|REAL media Plus is a 7-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth smoking and vaping use.
88951|NCT03491852|Behavioral|BOOST Intervention|A cognitive and behavioural group therapy designed to reduce self-stigma and promote effective communication skills for adults (16-65 years old) experiencing a first episode of psychosis.
88952|NCT03491852|Behavioral|Waitlist Control|Participants on the waitlist will still receive treatment as usual, which includes medical, psychosocial, and occupational interventions to help maximize patients' integration within the community and support recovery from a first episode of psychosis.
88953|NCT03491826|Biological|rupture of membrane|
88954|NCT03491813|Device|oscillometric device|"The blood pressure will be measured by the Automatic blood pressure monitor(Oscillometric) named the OMRON M2 basic® device was provided by Omron Healthcare company.~This monitor uses inflation by Fuzzy-Logic controlled by electric pump and an automatic rapid pressure release valve for the deflation , its cuff allows BP measurements in arm circumference of 22-42 cm. The device measure BP and pulse rate with a pressure range of 0-299 mmHg and pulse rate range of 40-180 beats/min."
88955|NCT03491800|Behavioral|Question/Topic Prompt List|A written document containing suggested questions that the family member and/or patient may want to ask the health care provider during the visit. A section is included for the patient to check which behaviors they would like for their family member to engage in during the visit and space is provided for the family member to check which behaviors they are willing to perform during the visit.
88956|NCT03491787|Device|Ultrasound guidance|The ultrasound guidance was used to obtain intraosseous access
88957|NCT03491774|Behavioral|Montessori Intervention|The Montessori method is a system of teaching developed by Maria Montessori based on principles to promote learning and independence in children. In the context of dementia care, this method has been tried in research settings in older people and was found to be effective in improving certain behavioral outcomes such as eating behaviors, agitation, and mood. The intervention is based on designing and offering activities that take into consideration the interests, needs, past experiences and preferences of participants. Importantly, participants demonstrating positive engagement with the intervention, suggesting that this may be a promising form of support to investigate and develop further for the care of people with dementia.
88958|NCT03491761|Biological|PRP Treatment|PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
88959|NCT03491761|Biological|HA Treatment|Euflexxa will be used for treatment. It will be prepared according to the package insert.
88960|NCT03491748|Drug|ETX0282|Oral Gelatin capsules
88961|NCT03491748|Drug|Cefpodoxime proxetil|Oral tablets
88962|NCT03491748|Drug|Placebo|Oral Gelatin capsules
88963|NCT03491735|Other|collection of data from patient files|recording of patient data and its input into an excel sheet from which statistics will be derived
88964|NCT03491722|Other|risk factors and revascularization procedures|arterial revascularizations needed since index procedure
88965|NCT03491709|Drug|anti-EGFR monoclonal antibody|Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
88966|NCT03491709|Drug|Cetuximab injection|Cetuximab injection
88967|NCT03491696|Drug|Metyrapone|Association of Selective Serotonin Reuptake Inhibitor or Serotonin and Norepinephrine Reuptake Inhibitor and METYRAPONE. Duration of the association : 28 days.
88968|NCT03491683|Biological|INO-5401|INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of each plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by immunotherapy Response Assessment in Neuro-Oncology (iRANO), unacceptable toxicity, withdrawal of consent, or death.
88969|NCT03491683|Biological|INO-9012|INO-9012 is a DNA plasmid for expression of human interleukin-12 (IL-12). Starting on Day 0 one mg plasmid will be delivered IM followed by EP using the CELLECTRA® 2000 EP device every three weeks for four doses, and then every 9 weeks until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
88970|NCT03491683|Biological|Cemiplimab|Cemiplimab is an antibody to programmed death-1 (PD-1) protein. Starting on Day 0 cemiplimab will be administered intravenously (IV) every three weeks at a dose of 350 mg per dose in the absence of dose holding, until disease progression as defined by iRANO, unacceptable toxicity, withdrawal of consent, or death.
88971|NCT03491683|Radiation|Radiation Therapy|Radiation therapy (RT) will begin no later than 42 days after surgical intervention, and should start approximately 2 weeks after Day 0. RT will be given for three weeks.
88972|NCT03491683|Drug|Temozolomide|Temozolomide (TMZ) will be given daily during radiation therapy (RT) at a dose of 75 milligrams per square meter (mg/m^2).
88973|NCT03491657|Behavioral|virtual reality distraction (Yes VR)|
88974|NCT03491657|Behavioral|music distraction (No VR)|
88977|NCT03491631|Drug|SHR9146+SHR-1210|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W
88978|NCT03491631|Drug|SHR9146+SHR-1210+Apatinib|SHR9146: Initial dose of 100mg BID with escalation planned to 600mg BID; SHR-1210: 200mg Q2W Apatinib:250mg QD
88979|NCT03491618|Other|PAIN REDUCTION ON VAS/NRS|Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
88980|NCT03491605|Other|peripheral EBV-DNA load|No intervention
88981|NCT03491592|Behavioral|Enhanced Physical Activity Intervention|Participants in the Enhanced Intervention arm will receive all the intervention components of the Original Intervention described above plus: 1) text messages and adaptive goal-setting to drive participants back to the website and keep them there longer, and 2) data-driven, technology supported enhanced intervention content targeting theoretical constructs that influenced PA behavior in Latinas from the parent study.
88982|NCT03491592|Behavioral|Original Physical Activity Intervention|Participants in the Original Physical Activity intervention arm of the study will receive the original Spanish language, motivationally-tailored, Internet-based physical activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
88983|NCT03491579|Drug|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Cladribine and Cytarabine)
88984|NCT03491579|Drug|Cladribine|Standard chemotherapy
88985|NCT03491579|Drug|Cytarabine|Standard chemotherapy
88986|NCT03491566|Other|Clinic Pilates Group|"Clinical Pilates exercises include Hundreds, One Leg Stretch, Shoulder Bridge, One Leg Kick, Swimming , Double Leg Stretch, Swan Dive Circle , Arm Opening , Spine Twist , Roll Down exercises."
88987|NCT03491566|Other|Aerobic Exercise Group|Aerobic exercise with using an elliptical bike, or bike or treadmill under supervision of a physiotherapist.
88988|NCT03491566|Other|Control Group|"30-minutes training session was organized including topics such as What is physical activity, what are the effects of physical activity on health, factors that blocking physical activities and ways of overcoming obstacles, and recommending physical activity appropriate to their ages."
88989|NCT03491553|Drug|selgantolimod|Tablet(s) administered orally once weekly
88990|NCT03491553|Drug|Placebo|Placebo to match (PTM) selgantolimod tablet(s) administered orally once weekly
88991|NCT03491553|Drug|OAV Therapy|Commercially available HBV OAV treatment(s)
88992|NCT03491540|Drug|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
88993|NCT03491540|Drug|Oral Gentamycin|"Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials"
88994|NCT03491540|Drug|Oral Ornidazole|"Oral ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
88995|NCT03491540|Drug|Oral Placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
88996|NCT03491540|Drug|Oral Placebo Ornidazole|"Placebo for oral ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablets per day) on day -2 and day -1"
88997|NCT03491527|Procedure|Absolute isolation|Absolute isolation with rubber dam
88998|NCT03491527|Procedure|Manipulation of the resin cement with MTA|Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
88999|NCT03491527|Procedure|Manipulation of the resin cement without MTA|Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
89000|NCT03491527|Procedure|Fiber Post cimentation|Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.
89001|NCT03491527|Procedure|Dental Prepare|Confection of a indirect crown prepare with diamand burs.
89002|NCT03491527|Procedure|Dental impression|Dental impression whith silicone.
89003|NCT03491527|Procedure|Crown cimentation|Insertion of the cement on the inner surface of the crown. Light-cured for 40 seconds on each surface.
89004|NCT03491527|Procedure|Occlusal adjustment|Analysis of the occlusion with carbon paper.
89005|NCT03491514|Other|Test Granola|51 g Test Granola
89006|NCT03491514|Other|Control Granola|54.1 Control Granola
89007|NCT03491501|Other|Ergonomic evaluation using questionnaires|Employees will be provided with questionnaires such as the 'Rapid Entire Body Assessment' and NIOSH to obtain information regarding ergonomic working situations
89008|NCT03491488|Other|Brain Games|The Brain Games intervention package is used as a tool to improve children's self-regulation and executive function skills. Brain Games were developed as part of larger behavioral intervention package in the US, and are designed to build the fundamental self-regulation skills that children need to be successful in school as well as later in life. The games are designed to be played in the classroom between regular activities.
89009|NCT03491475|Drug|Ajmaline test|Administration of Ajmaline
89010|NCT03491462|Drug|Arimoclomol|Active treatment
89011|NCT03491462|Drug|Placebo oral capsule|Matching placebo capsule
89012|NCT03491449|Procedure|Group A|Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.
89013|NCT03491449|Procedure|Group B|Maintaining a systolic blood pressure <185mm Hg for 72 hours.
89014|NCT03491436|Device|iHealth Align|remote monitor glucometer
89015|NCT03491423|Other|Short and fast step test without measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
89016|NCT03491423|Biological|glucose meter|glucose meter to measure lactatemia
89017|NCT03491423|Other|ECG / heart rate|ECG and heart rate (HR) collection by telemetry
89018|NCT03491423|Other|questionnaires|VAS pain assessment and evaluation of effort perception according to Borg's scale
89019|NCT03491423|Other|Short and fast step test with measurement of pulmonary gas exchange|For one minute, the patient should climb up and down a 17.5 cm high step as quickly as possible while holding onto a bar in front of the step.
89020|NCT03491410|Drug|Aspirin Low Dose|Low-Dose Aspirin is to be added in the standard patient´s treatment
89021|NCT03491410|Drug|Placebo Oral Tablet|Placebo is to be added in the standard patient´s treatment
89044|NCT03491215|Drug|Ruxolitinib|Ruxolitinib taken orally (5mg tablets) or oral pediatric formulation and dosage based on age group
89022|NCT03491397|Device|Embozene MicroSpheres|Embozene is a medical device made by Boston Scientific approved in the United States for the treatment of hypervascular tumors and arteriovenous malformations. It consists of thousands of microscopic spheres that are injected into the artery in the knee going to the region of pain. One of the causes of pain in the setting of knee arthritis is increased blood flow going to the specific area of pain. The goal of this procedure is to decrease the blood flow (embolize) to the specific region of the knee that is causing your pain. This is done by infusing Embozene particles into the specific blood vessel (genicular artery) supplying the area of pain in the knee.
89023|NCT03491384|Drug|Cannabis (smoked flower, ingested edible)|Self-Directed Use (ad-libitum)
89024|NCT03491371|Drug|Methylsulfonic apatinib|Anti-angiogenesis Tyrosine kinase inhibitor which specifically inhibits VEGFR-2.
89025|NCT03491358|Device|Wright jet nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
89026|NCT03491358|Device|Aerogen Solo|Aerogen Ltd., Galway, Ireland
89027|NCT03491345|Drug|Avelumab|avelumab 10mg/kg, IV, q 2 weeks
89028|NCT03491332|Device|conventional circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
89029|NCT03491332|Device|conventional humidification circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
89030|NCT03491332|Device|new humidifaction heat circuit|"The patient enters the operating room without any pretreatment and attaches a standard patient monitoring device. Anesthesia was performed by intravenous anesthesia. After induction of anesthesia, alveolar recruitment is performed in supine position in all groups with 30 cmH2O for 5 seconds. Mechanical ventilator was set with tidal volume of 8 ml / kg, the inspiratory/ expiratory ratio of 1: 2 and respiratory rate was adjusted for targeting EtCO2 around 35mmHg. Keep the fresh air flow of the ventilator at 3 L / min and set the temperature to 37 ° C for the heating circuits of group H and group SH. An arterial cannulation and subclavian jugular vein catheter is inserted.~The circuits were applied to each group as follows; conventional circuit or group C, conventional humidification circuit for group H and new humidification heat circuit for group SH, respectively. All other conditions were same among three groups."
89031|NCT03491319|Procedure|Group X - head low tilt|spinal anaesthesia was given with table in neutral positon. 10 degree head low position was maintained for 10 minutes following spinal anaesthesia
89032|NCT03491319|Procedure|Group Y - head low tilt|the table was put in 10 degree head low position before proceeding to give spinal anaesthesia. Head low position was maintained for 10 minutes following spinal
89033|NCT03491319|Procedure|Group C - neutral|spinal anaesthesia was given with table in neutral positon. Patient was maintained in supine position for 10 minutes following spinal anaesthesia
89034|NCT03491306|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
89035|NCT03491306|Other|Breflex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
89036|NCT03491293|Behavioral|Behavioral Weight Loss + Text|Participants will attend weekly one hour classes on line. They will type their input and responses within the chat room. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide feedback to reinforce or shape new behaviors and to identify high risk situations for problem solving.
89037|NCT03491293|Behavioral|Behavioral Weight Loss + Video|Participants will attend weekly one hour classes on line. They will have audio and video within the chat room, and will talk with their facilitator and classmates during their weekly meeting. They will record their calorie and fat intake daily and weigh themselves daily. Interventionists will review the diaries weekly and provide
89038|NCT03491280|Genetic|NGS Diagnostic|Blood take for genetic diagnostic.
89039|NCT03491267|Drug|Retinoic acid|The study team will treat skin with topical retinoic acid
89040|NCT03491267|Device|Laser|The study team treat skin with a surface laser.
89041|NCT03491267|Drug|Sham treatment|No drug will be given
89042|NCT03491267|Device|Sham treatment|No laser treatment will be given
89043|NCT03491241|Dietary Supplement|hypocaloric diet therapy|all patients will receive an hypocaloric diet, with low carboidrates (<50%) overload.
89051|NCT03491163|Diagnostic Test|Syndecan-1 concentration evaluation|Blood sample will be taken and analysed using ELISA method.
89052|NCT03491150|Drug|Crenezumab (RO5490245)|Crenezumab will be administed by IV, 60 mg/kg every 4 weeks.
89053|NCT03491124|Other|Auricular Acupuncture|Up to five small ASP needles placed in each ear until pain is reduced to 1/10.
89054|NCT03491124|Other|Sham Treatment|Laser pointer pointed at the ear, but not turned on.
89055|NCT03491111|Other|Respiratory muscle training for EMT+IMT|2 times per day and 5 day per week, 6 weeks, training with breathing trainer.
89056|NCT03491111|Other|Regular Rehabilitation|Regular Rehabilitation: 2-3 times a week, 6 weeks.
89057|NCT03491111|Other|Respiratory muscle training for EMT|5 sets, 5 repetition with one or two minute of rest between sets, twice per day, 5 days per week, training with breathing trainer.
89058|NCT03491098|Drug|Mometasone Furoate spray|"Mometasone Furoate spray one puff in each nostril daily for 8 weeks~hypertonic sea water solution spray one puff in each nostril daily for (8) weeks."
89059|NCT03491098|Drug|prednisolone sodium phosphate 15mg|three times per day for 1 week then gradual withdrawal over 2 weeks
89060|NCT03491098|Drug|hypertonic sea water solution spray|one puff in each nostril daily for 8 weeks
89061|NCT03491085|Drug|Amoxicillin/clavulanate|after tonsillectomy half of our patients will receive Amoxicillin /clavulanate for one week and the other half will not receive it.
89062|NCT03491072|Device|Transcutaneous electrical nerve stimulation|Patients will receive IV fentanyl 1µg /Kg with the application of conventional TENS in which constant mode will be chosen. Assessment of pain will be done using visual analogue scale (VAS), every 10 minutes. If VAS ≥ 3 this indicates giving IV increments of 20µg of fentanyl.
89063|NCT03491072|Drug|Fentanyl|Patients will receive IV fentanyl
89068|NCT03491033|Drug|chemotherapy|All of the patients in this study underwent NAC regimens consisting of taxane and platinum combination chemotherapy. After NAC, all of the patients underwent interval debulking surgery. Subsequently, additional cycles of chemotherapy were administered after IDS to complete a total of 6 cycles at the discretion of the treating physician.
89069|NCT03491007|Drug|DHEA|Subjects will be randomized to receive a one-time oral dose of DHEA (400mg) or PBO and sustained administration of the study drug for 6 weeks. There will be a 2 week placebo lead-in period [all participants], followed by subjects continuing in the randomization block of DHEA or placebo for 6 weeks following acute administration).
89070|NCT03490994|Drug|Rivaroxaban|Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
89071|NCT03490994|Drug|Warfarin + LMWH|dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
89072|NCT03490981|Other|TAU|Participants assigned to TAU will receive standard medical care from their primary care provider including pain medications, brief advice (e.g., use of relative rest, application of heat or ice, other self-care strategies), or referral to pain-related adjunctive interventions (e.g., physical therapy), as indicated.
89073|NCT03490981|Behavioral|Brief CBT-CP|Brief CBT-CP is a manualized protocol that includes six, 30-minute sessions over the course of 6 weeks. Brief CBT-CP session outlines and patient handouts are included in the appendix. Session one focuses on foundational pain education and the development of treatment goals. Session two emphasizes balanced engagement in physical activity and pleasurable events. Session three emphasizes skills training for easily implemented relaxation techniques. Sessions four and five focus on recognizing and modifying unhelpful thoughts that negatively impact pain. Session six focuses on relapse prevention and independent implementation of CBT-CP skills following treatment.
89074|NCT03490968|Behavioral|Supervised Exercise|Subjects will have 3 visits per week for 12 weeks.
89075|NCT03490968|Behavioral|Vascular Assessment|"Screen: Subjects will undergo a H&P, ankle brachial index, ECG, CBC, CMP, lipid panel, HgA1C, and urinalysis. A urine pregnancy test will be performed on women of childbearing age.~Testing Visit 1: MRI, IV in common femoral vein with phlebotomy (60 cc total) before and after sphygmomanometric cuff occlusion of lower limb, 6-minute walk test, 4-meter walk speed test, walking impairment questionnaire, and muscle biopsy.~Supervised exercise and leg bypass surgery patients will return in 12 weeks and have the testing visit repeated."
89076|NCT03490955|Other|salad dressing and black pepper|Subjects will consume a vegetable salad with black pepper and dressing one time in the morning
89077|NCT03490955|Other|salad dressing|Subjects will consume a vegetable salad with dressing one time in the morning
89078|NCT03490955|Other|black pepper|Subjects will consume a vegetable salad without dressing but with black pepper one time in the morning
89079|NCT03490955|Other|salad|Subjects will consume a vegetable salad without dressing and without black pepper one time in the morning
89080|NCT03490942|Drug|Glucagon|CSI-Glucagon is a room temperature stable, non-aqueous, liquid formulation of glucagon.
89081|NCT03490942|Drug|Placebo|The placebo solution is a non-active formulation containing excipients only.
89082|NCT03490929|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|injection of Lumason (ultrasound contrast agent)
89083|NCT03490929|Device|contrast-enhanced ultrasound|ultrasound of the abdomen after injection of ultrasound contrast agent (Lumason)
89084|NCT03490916|Drug|Acetazolamide|Administration of Acetazolamide
89085|NCT03490916|Drug|Placebo|Administration of Placebo
89086|NCT03490903|Device|Virtual Reality|Subjects undergoing the Virtual Reality Intervention will be fitted with a VR headset and headphones, and undergo an immersive meditation experience provided by AppliedVR, Inc. The headphones will not be noise-cancelling, and the subject will be able to communicate with the physician or circulating nurse if needed.
89087|NCT03490903|Drug|Fentanyl Injection|Fentanyl is commonly administered to treat pain during invasive procedures such as coronary angiography. Intravenous fentanyl injection dosages are determined by the physician operator, and administered by the circulating nurse.
89088|NCT03490903|Drug|Midazolam injection|Midazolam is commonly administered to treat anxiety during invasive procedures such as coronary angiography. Intravenous midazolam injection dosages are determined by the physician operator, and administered by the circulating nurse.
89089|NCT03490890|Other|Microwave ablaton|Patients with pathology verified GGO were treated with MWA.
89090|NCT03490864|Dietary Supplement|Melatonin 1 mg|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
89091|NCT03490864|Dietary Supplement|Placebos|Melatonin (1mg) or placebo will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
89092|NCT03490864|Other|Meal Timing|Subjects are instructed to maintain an extended overnight fasting period of 12-14 hours.
89093|NCT03490864|Other|NON Meal Timing|Subjects are instructed to maintain their habitual meal timing.
89094|NCT03490851|Other|Oatmeal + OatWell28CF Int 1|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
89095|NCT03490851|Other|Oatmeal + OatWell28CF Int 2|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
89096|NCT03490851|Other|Oatmeal + OatWell28CF Int 3|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
89097|NCT03490851|Other|Cream of Rice|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence.
89098|NCT03490838|Drug|177Lu-PSMA-R2|radio-ligand therapy
89099|NCT03490825|Dietary Supplement|Melatonin 1 mg|Melatonin (1mg) will be administered daily during the intervention. Melatonin capsules will be obtained from Life Extension (Ft. Lauderdale, FL). The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the melatonin pills so the placebo (lactose) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
89100|NCT03490825|Dietary Supplement|Placebos|Placebo will be administered daily during the intervention. The investigational drug pharmacy (IDP) at Northwestern Memorial Hospital will encapsulate the pills so the placebo (lactose/starch) and melatonin pills appear identical. We have worked with this IDP on other projects. The investigators on this study have experience in administering melatonin for investigational and clinical purposes.
89101|NCT03490825|Other|Meal timing|Subjects are instructed to maintain an extended overnight fasting period of 12-14 hours.
89102|NCT03490825|Other|Non-Meal timing|Subjects are instructed to maintain their habitual meal timing.
89105|NCT03490786|Drug|GT-001|PK, PD Study to Determine Safety of Escalating Doses of GT-001
89106|NCT03490760|Drug|Durvalumab|Durvalumab 1500 mg (or 20 mg/m2 if <30 kg) IV every 4 weeks
89107|NCT03490760|Radiation|Radiation Therapy|24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.
89108|NCT03490747|Behavioral|Physical activity referral scheme|An 18-week physical activity referral scheme co-developed by a local multidisciplinary stakeholder group. Behaviour change support underpinned by Self-Determination Theory (Ryan & Deci, 2000) will be provided by an exercise referral practitioner at weeks 1,4,8,12 and 18 to facilitate increased physical activity levels. Patients will be supported to develop a tailored programme of physical activity that may involve use of the fitness centre facilities (e.g. swimming, group classes, gymnasium use), participation in community-based initiatives, and changes to habitual physical activity. Focus on promoting patient autonomy and tailoring activities to patient's preferences and needs. Subsidised access to fitness centre facilities for first 12 weeks.
89109|NCT03490747|Behavioral|Usual care exercise referral scheme|A comparative usual care exercise referral scheme that includes fitness centre based activities (e.g. swimming, group classes, gymnasium use). Patients meet an exercise referral practitioner at their induction (week 1) and week 12 (post scheme). Patients are typically prescribed a gym-based, 12-week programme. Subsidised access to fitness centre facilities for 12 weeks.
89110|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage with added sugar|10 oz daily for three weeks
89111|NCT03490734|Dietary Supplement|Strawberry Kiwi &Lemonade Flavored Beverage with added sugar|10 oz daily for three weeks
89112|NCT03490734|Dietary Supplement|Black Cherry and Orange Flavored Beverage no added sugar|10 oz daily for three weeks
89113|NCT03490734|Dietary Supplement|Strawberry Kiwi & Lemonade Flavored Beverage no added sugar|10 oz daily for three weeks
89114|NCT03490734|Other|Tasteless Beverage|A solution of water, potassium chloride, and sodium bicarbonate. Three mL administered per associated logo presentation only during MRI procedure.
89115|NCT03490721|Other|Clustering care|During 20 minutes, preterm infants will receive a cluster care with 2 minutes of hand containment.
89116|NCT03490708|Drug|Tranilast|Subjects will be treated with tranilast
89117|NCT03490695|Other|Practice Facilitation|Community health nurses trained in implementing the evidence-based TASSH protocol will be employed as Practice Outreach Facilitators (POF) to train the CHPS community health officers to deliver TASSH. The POFs will be required to complete an intensive 12-week training course focused on adoption of TASSH protocol to identify patients at risk for uncontrolled HTN, initiate behavioral lifestyle counseling, and Refer patients to the community health centers for drug therapy. Over the course of 12 months, the POFs will provide support to their assigned CHPS zones to implement TASSH as part of routine patient care.The POFs will also work with CHPS directors to review current work flow and develop a plan of action for TASSH uptake at the CHPS zones.
89118|NCT03490695|Other|Usual Care|Provide Ghana's National Health Insurance, behavioral counseling and referral for care through the usual care system for 12 months.
89119|NCT03490682|Other|Ultrasound assessment of gastric emptying of a flavoured yoghourt.|Each participant will be placed on a table, in the semi-recumbent position with elevation of the head at 45° and a first ultrasound examination will be performed. After that, the participant will be invited to eat a test meal (flavoured yoghurt) in 5 minutes. An ultrasound examination of the antrum allowing measurement of the antral area will be performed at 15, 60, 90 and 120 minutes after the end of the ingestion of the test meal. The participant must stay in the semi-recumbent position during the total duration of the study. The non-invasive ultrasound measurement, of the antral cross-sectional area is performed using a Sonosite ultrasound equiped with a 2 -5.5MHz probe. The diameters (longitudinal D1 and anteroposterior D2) of the antrum are measured in the sagittal plane passing by the abdominal aorta and the left lobe of the liver. The value of the antral cross-sectional area is given by the formula : Antral area = π x D1 x D2 / 4.
89120|NCT03490669|Biological|MSC-1|humanized monoclonal antibody for intravenous administration
89123|NCT03490643|Other|Postural Analysis|posture and plantar pressure analysis
89124|NCT03490643|Other|plantar pressure analysis|posture and plantar pressure analysis
89125|NCT03490617|Drug|Vaginal misoprostol|To determine effectiveness of vaginal misoprostol to facilitate IUD insertion in nulligravida women
89126|NCT03490604|Device|wrist-worn accelerometer|accelerometer worn on the patient's wrist, changed every 15 ± 7 days for 6 months when the patient comes for a chemotherapy session
89127|NCT03490604|Other|Auto-questionnaires|Questionnaire regarding physical activity over the previous 7 days, questionnaires EORTC QLQ-C30 and EORTC QLQ-PAN26
89128|NCT03490591|Behavioral|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of warm-up exercise and 40 minute of robot-assisted hand exercise intervention. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task, robot-assisted task, and game task.
89129|NCT03490578|Device|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The gait robot provides an auditory feedback according to gait cycle and a visual feedback on the patient's active participation. If the patient can tolerate, the gait robot may control the walking speed automatically according to the patient's participation. The treatment time per session is 45 minutes including don and doff time. Total 12 sessions are provided for 4 weeks.
89130|NCT03490578|Device|Intensive treadmill training|Patients exercise on the treadmill. The initial walking speed starts at 1.0 km/h and can be increased gradually to 3.0 km/h. The therapist provides appropriate visual and auditory instructions to allow the patient to participate in the treadmill training. The treatment time per session is 45 minutes including warm-up and cool-down. Total 12 sessions are provided for 4 weeks.
89131|NCT03490565|Behavioral|Exercise training|Structured, supervised, high-intensity combined aerobic and resistance exercise. Based on patients' individual capacity (Wattmax and 1RM), a personalized exercise program will be prescribed. Following a 5 minutes warm up, the patients will perform 21 min of aerobic interval training on a stationary bicycle consisting of three 4 minute high intensity intervals (85-95% HRmax) with 3 minutes of active pause between each interval. The resistance training comprises 4 functional exercises by performed using bodyweight, elastic resistance bands or kettlebells followed by resistance exercises in machines for the major muscle groups: chest press, leg press, seated rows, and leg extension with 1 warm-up set followed by 3-4 sets of 8 to 12 repetitions.
89132|NCT03490552|Procedure|mechanical thrombectomy|Mechanical thrombectomy whatever it type ( SRT , ASPT or Mixed )will be used to extract the thrombi from stroke causing occlusion to be preserved biologically for genomic lab. transfer to be processed by RNA sequencing analysis technique for identifying markers for its composition pointing to its source.
89133|NCT03490539|Drug|Mycophenolate Mofetil|oral tablets
89134|NCT03490539|Drug|Azathioprine|oral tablet
89135|NCT03490526|Device|Root canal disinfection with XP-endo Finisher|The XP-Endo® finisher will be used next to the X-Smart Plus endodontic motor, with speed settings at 800rpm and torque at 1 N.cm. Irrigation with 17% EDTA and 2.5% NaOCl will be performed in three cycles of one minute each. In each cycle the XP-Endo will be used in the working length in continuous and slow movements of entrance and exit, with amplitude of 5mm, for a period of 1 minute, followed by new irrigation with 2.5ml of EDTA solution or hypochlorite of sodium 2,5%. Finally, the channel will be completely dry with absorbent paper tips
89136|NCT03490526|Device|Root canal disinfection with passive ultrasonic irrigation|For cleaning using passive ultrasonic irrigation, the E1 Irrisonic tip (Helse Ultrasonic, Ribeirão Preto, SP), will be used with Jetlaxis Sonic BP LED (Schuster, Santa Maria, RS). The insert has a diameter equivalent to a manual file 20, with reduced taper (0.01). The power used will be 10%. With root canals flooded with 17% EDTA, the irrigation tips will be coupled to the ultrasound and 1mm shorter than the working length. These tips will be kept in the center of the canal avoiding contact with the dentin walls. The irrigation will be performed in three cycles, and in each cycle the irrigation tips will be activated for 1 minute followed by new irrigation with 2.5ml EDTA. The same procedure will be repeated with 2.5% NaoCl. Finally, the channel will be completely dry with absorbent paper tips.
89137|NCT03490513|Drug|anastrozole (1 mg/day)|Participants will take Anastrozole 1mg per day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
89138|NCT03490513|Drug|Placebo|Participants will take a placebo tablet every day, attend behavioral classes conducted by a dietitian, receive instruction on how to loss 10% of their body weight and participate in a supervised exercise training program.
89139|NCT03490487|Drug|conventional antiepileptic drugs|will receive conventional antiepileptic drugs only. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
89360|NCT03488576|Procedure|Macular Peeling with Foveal Sparing|A partial peeling of the internal limiting membrane was performed, sparing the fovea.
89140|NCT03490487|Drug|oral steroid|will receive oral steroid for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
89141|NCT03490487|Drug|Diazepam|will receive oral diazepam for 3 months beside conventional antiepileptic drugs. EEG, attention deficit hyperactivity disorder test and intelligence quotient will be done before and 3 months after treatment.
89142|NCT03490474|Other|Pain Inducing Massage|Participants will receive 60 seconds of manual pressure applied to one myofascial trigger point so the participant rates the pain = 5/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
89143|NCT03490474|Other|Pain Free Massage|Participants will receive 60 seconds of light touch applied to one myofascial trigger point so the participant rates the pain = 0/10 on a scale from 0 to 10. This will be followed by 30 seconds of complete pressure release. This will occur 4 times.
89144|NCT03490474|Other|Coldpressor|Participants will place their non-dominant hand into water cooled by a refrigeration unit temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times.
89145|NCT03490461|Drug|Statin|Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.
89146|NCT03490448|Behavioral|aerobic exercise and appropriate caloric control|The dietary was designed on the basis of ensuring the daily energy physiological requirement, and basal metabolic rate (BMR) was calculated to formulate diet project according to Harris-Benedict formula. The diet was composed of 20% protein, 30% fat and 50% carbohydrates.In the exercise, heart rate was monitored to ensure the small-medial load aerobic exercise. All kinds of sports were conducted indoor, twice per day, 6 days per week, and lasted for 2 hours every time.
89147|NCT03490435|Diagnostic Test|Tests for diagnosis of intestinal parasitic diseases|"Feces testing:~fresh fecal samples will be used to preparing direct (saline and iodine wet) mounts using supplementary techniques (flotation, sedimentation), as well as temporary mounts (hematoxylin and trichrome staining). Other technique of fresh fecal samples examination will be ParaSys™~A non-preserved stool samples will be stored below -20°C. Defrosted fecal specimen will be subjected to enzyme-linked immunosorbent assays (ELISA) - Giardia antigen test (coproantigens)"
89148|NCT03490422|Procedure|Pulpotomy|Pulpotomy in mature carious permanent teeth
89149|NCT03490409|Device|Thigh compression stocking|Thigh compression stocking
89150|NCT03490396|Device|Gelclair|Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel
89151|NCT03490396|Combination Product|First® Mouthwash BLM|Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash
89152|NCT03490370|Device|Electro-muscular stimulation using NeuroTrac MyoPlus 2/4|In this pilot study we aim to determine if change in the muscle metabolism can resolve insulin resistance in NAFLD through muscle stimulation by using electro-stimulation. We hypothesise that 6x35 minute sessions per week over a 12 week time scale would mimic effects of resistance exercise on metabolic parameters associated with NAFLD and hepatic steatosis. All 20 participants will have the electro-stimulation intervention.
89153|NCT03490357|Procedure|Control - Transversus Abdominus Plane Block|Abdominal fascial plane block - regional anesthesia
89154|NCT03490357|Procedure|Quadratus Lumborum Block|Abdominal fascial plane block - regional anesthesia
89155|NCT03490344|Drug|Daratumumab|"Cycles 1 and 2: Daratumumab 16mg/kg weekly per cycle (28 days) as intravenous infusion (total duration: 8 weeks)~Cycles 3-6: Daratumumab 16mg/kg once every 2 weeks per cycle (28 days) as intravenous infusion (total duration: 16 weeks)"
89156|NCT03490344|Drug|Lenalidomide|Lenalidomide maintenance therapy to be administered as standard treatment to all participants. This is administered as 5-15 mg daily 21-28/28 day cycle.
89157|NCT03490331|Other|Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)|Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
89158|NCT03490305|Procedure|Exploratory laparotomy|Findings and procedures done at exploratory laparotomy
89159|NCT03490292|Combination Product|Avelumab combined with Chemoradiation|Co-administration of avelumab with chemoradiation in pre-operative period.
89160|NCT03490292|Drug|Carboplatin|Weekly Carboplatin (AUC2) [intravenous infusion on days 1, 8, 15, 22, & 29]
89161|NCT03490292|Drug|Paclitaxel|Weekly paclitaxel [intravenous infusion on days 1, 8, 15, 22, & 29]
89162|NCT03490292|Radiation|Radiation|Radiation therapy [23 fractions, M-F, estimated completion day 35]
89163|NCT03490279|Dietary Supplement|Lactoferrin CRX|Patients will be asked to take lactoferrin CRX as already mentioned (blindly).
89164|NCT03490279|Other|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
89165|NCT03490266|Procedure|Robotic Repair|The surgeon will be utilizing a robotic system to repair the hernia.
89166|NCT03490266|Procedure|Laparoscopic Repair|The surgeon will be repairing the hernia laparoscopically.
89167|NCT03490253|Behavioral|DIAMANTE Adaptive|In a three arm randomized controlled trial we will examine the effect of a text-messaging smartphone application to encourage physical activity in low-income ethnic minority patients with comorbid diabetes and depression. The adaptive intervention group receives messages chosen by a reinforcement learning algorithm.
89168|NCT03490253|Behavioral|DIAMANTE Static|The static intervention group receives health information text-messages, typical of existing text-messaging interventions for diabetes and depression.
89230|NCT03489746|Other|ICS withdrawal protocol|A primary care intervention to support switch from ICS containing regimen to non-ICS containing regimen in appropriate patients.
89231|NCT03489746|Other|Standard care|Normal clinically indicated inhaled therapy
89232|NCT03489733|Other|Hydrolyzed Formula|Infant formula with extensively hydrolyzed proteins and pre- and probiotics.
89233|NCT03489733|Other|Control formula|Infant formula with intact proteins and pre- and probiotics.
89169|NCT03490240|Behavioral|BIPAMS|"The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention."
89170|NCT03490240|Behavioral|WELLMS|The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
89171|NCT03490214|Device|Multispectral Optoacoustic Tomography|Non-invasive transcutaneous imaging of subcellular muscle components
89172|NCT03490201|Device|Market Approved RF Ablation System|Subjects receive ablation using an FDA approved ablation system.
89173|NCT03490201|Device|FlexAbility SE Ablation Catheter|Subjects receive ablation treatment using an ablation system that is not FDA approved.
89174|NCT03490188|Behavioral|Discharge Mentoring|Phone Conversations on the importance of complying to discharge instructions delivered before discharge
89175|NCT03490162|Drug|DM1157|DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
89176|NCT03490162|Other|Placebo|Placebo
89177|NCT03490149|Device|Electroconvulsive Therapy|Series of electroconvulsive therapy for major depressive disorder
89178|NCT03490149|Drug|Medication - Treatment as usual|Medication only sample - Treatment as usual
89179|NCT03490123|Drug|R1-Total community treatment with azithromycin|At month 0, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
89180|NCT03490123|Drug|R2-Total community treatment with azithromycin|At month 6, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
89181|NCT03490123|Drug|R3-Total community treatment with azithromycin|At month 12, all study participants (regardless of their yaws status) will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
89182|NCT03490123|Drug|R2-Total targeted treatment with azithromycin|At 6 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
89183|NCT03490123|Drug|R3-Total targeted treatment with azithromycin|At 12 months, study participants will be screened for active yaws. Participants with yaws and their contacts will receive 30 mg/Kg (maximum 2 g) of azithromycin orally under direct observation. Benzathine benzylpenicillin will be reserved as a backup for patients who cannot be treated with AZI, and who are not allergic to penicillin.
89184|NCT03490110|Behavioral|State regulation skill training|Participants will complete seven training sessions. Training sessions last 2 hours, and participants are requested to complete approximately 2.5 hours of additional skill practice over the course of each week outside of session (total ~4.5 hours per week).
89185|NCT03490110|Other|Treatment-as-usual|Participants will receive clinical care as usual in VA clinics.
89186|NCT03490097|Drug|Simvastatin 10mg|tablets
89187|NCT03490097|Drug|sofosbuvir plus daclatasvir|sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.
89188|NCT03490084|Other|Association of day hospitalization with hospital-at-home|Patients receive the first administration of chemotherapy through day hospitalization in the hematology department, then 3 weekly administrations of chemotherapy at home.
89189|NCT03490084|Other|Day hospitalization exclusively|Patients receive 4 weekly administrations of chemotherapy through day hospitalization in the hematology department.
89190|NCT03490058|Drug|Truvada|A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
89191|NCT03490045|Other|Diaper Incentive|A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.
89192|NCT03490045|Other|Conditional Cash Transfer Condition|Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.
89193|NCT03490032|Drug|68Ga-PSMA-R2|radio-labelled PSMA ligand
89194|NCT03490019|Drug|Metformin|500, 850 or 1000 mg depending on body weight once daily for 24 weeks
89262|NCT03489460|Behavioral|Specialized sleep-related message interventions|Over the course of 2 weeks' participants will receive specialized sleep-related message interventions to encourage sleep awareness via the smartphone application.
89195|NCT03490006|Procedure|Erector Spinae Plane Block|A relatively recent alternative to the paravertebral block is the thoracic erector spinae plane block, which involves the ultrasound-guided injection of local anesthetic into the interfascial plane deep to the erector spinae muscle at the level of the transverse process. It results in a loss of somatic sensory sensation across multiple unilateral dermatomes due to local anesthetic mediated blockade of the dorsal and ventral rami of the spinal nerve roots. It is increasingly being used due to ease of placing the block and a perception of greater safety. It has been shown to provide pain relief from rib fractures, thoracotomy, and chronic neuropathic pain of the chest wall. However, to date, erector spinae plane block has not been compared with paravertebral block in regards to analgesia with mastectomy surgery, which has been extensively studied.
89196|NCT03490006|Procedure|Paravertebral Block|Paravertebral block is a classic regional anesthesia technique that has been in use for over 100 years. It is performed by the injection of local anesthetic into the space between the costotransverse ligament and parietal pleura resulting in blockade of ipsilateral intercostal nerves. It results in a loss of somatic sensation over multiple unilateral dermatomes.
89197|NCT03489993|Diagnostic Test|Ang II and Ang-(1-7)|Measured in plasma and urine using radioimmunoassays.
89198|NCT03489993|Diagnostic Test|FGF23 and klotho|Measured using ELISA's.
89199|NCT03489980|Other|coloring-type artistic task of a complex form|coloring-type artistic task of a complex form
89200|NCT03489967|Other|Induced-hypoglycemia test|Participants will be admitted at the research center at 7:00 after an overnight fast. A venous catheter will be inserted into an arm vein for blood sampling purposes. A subcutaneous insulin bolus will be administered to induce hypoglycemia. Oral treatment (16g of carbohydrates or 32g of carbohydrates) will be given when plasma glucose levels are at the target threshold of < 3.0 mmol/L or 3.0-3.5 mmol/L. Hypoglycemia symptoms will be assessed every 10 minutes by the participant using a validated scale starting from the time of insulin bolus until hypoglycemia recovery. One hour after hypoglycemia recovery, a standardized meal will be given.
89201|NCT03489954|Other|Evaluation|Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
89202|NCT03489941|Drug|EM-100|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
89203|NCT03489941|Drug|Zaditor®|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
89204|NCT03489941|Drug|Vehicle|Subjects will receive one drop in one eye only based on the randomization list, one time over the course of the trial.
89205|NCT03489928|Drug|Oral Misoprostol|Prostaglandin E1 - 100ug tablet, divided in half by pharmacy staff to be administered by mouth.
89206|NCT03489928|Drug|Vaginal Misoprostol|Prostaglandin E1 - 100ug oral tablet, divided in quarters by pharmacy staff, vaginal placement of one or two quarters as needed every 6 hours
89207|NCT03489928|Drug|Dinoprostone|Prostaglandin E2 - 1-2mg gel manufactured for vaginal use; placed vaginally every 6 hours as needed.
89208|NCT03489915|Device|OCT|Assessment of macular edema secondary to retinal vein occlusion usin optical coherence tomography and its correlation with visual acuity
89209|NCT03489902|Procedure|Transobturator Paravaginal Repair|Transobturator application of sutures to the white line in cases needing paravaginal repair
89210|NCT03489902|Procedure|traditional transvaginal Paravaginal Repair|traditional transvaginal application of sutures to the white line
89211|NCT03489889|Drug|Ursodeoxycholic Acid 300mg tablet|Cross-over study: Ursodeoxycholic Acid 300mg tablet and after Ursodeoxycholic Acid 300mg capsule
89212|NCT03489889|Drug|Ursodeoxycholic Acid 300mg capsule|Cross-over study: Ursodeoxycholic Acid 300mg capsule and after Ursodeoxycholic Acid 300mg tablet
89213|NCT03489876|Device|Synthetic Cartilage Implant|The Synthetic Cartilage Implant will be implanted in to the first metatarsal head according to the manufacturer's recommendations.
89214|NCT03489876|Procedure|Osteochondral Autograft Transfer|The osteochondral autograft transfer will be harvested from the ipsilateral lateral femoral condyle (or contralateral if a previous ipsilateral total knee anthroplasty or trauma) and the graft will be transferred to the first metatarsal head.
89215|NCT03489863|Drug|Prasugrel|Maintenance dose will be maintained for 10±3 days.
89216|NCT03489863|Drug|Ticagrelor|Maintenance dose will be maintained for 10±3 days.
89217|NCT03489850|Drug|Ibudilast|Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor.
89218|NCT03489850|Other|Placebo|Placebo is matched to ibudilast active medication.
89219|NCT03489837|Drug|Levotuss|oral taken
89220|NCT03489824|Procedure|modified- WIM colonoscopy|Modified-water immersion method of colonoscopy refers to the freely episodic suction of the infused-water during colonoscopy insertion phase at a moment to negotiate the angulated colon to facilitate cecal intubation but not suction the mucosa. The original water immersion method only suctions the water when the colon is over-distended or it is dirty and exchanges it with the new cleans water during insertion then evacuates all of the water during withdrawal
89221|NCT03489811|Other|Test Essential Oil Blend|The test essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
89222|NCT03489811|Other|Active Essential Oil Blend|The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
89223|NCT03489811|Other|Control Blend|The control blend consists of inert vegetable oils which are produced from plant matter.
89224|NCT03489798|Procedure|6 misoprostol|Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
89225|NCT03489798|Procedure|3 misoprostol|Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score > 6.
89226|NCT03489772|Drug|ITI-214|Oral
89227|NCT03489772|Drug|Placebo|Oral
89228|NCT03489759|Device|ViE15-A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be ViE15-A.
89229|NCT03489759|Device|REXEED-15A|The type of dialytic treatment that will be used during the study will be continuous venous hemofiltration (CVVH-Continuous veno-venous hemofiltration). The filter will be REXEED-15A.
89361|NCT03488563|Biological|B244|B244 Suspension
89234|NCT03489720|Behavioral|Prescribed Exercise Program|"Brief cardiovascular exercise training (>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~Walking quickly or running up and down stairs~Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~Walking up an incline on a treadmill~Jogging or running on a treadmill or elliptical~Stationary cycling or rowing"
89235|NCT03489720|Behavioral|Usual Exercise Program|Usual exercise activity for 8 weeks
89236|NCT03489707|Behavioral|Home-based human papillomavirus (HPV) DNA screening|Men randomized to arm 1 will receive an HPV DNA home-based collection kit in the mail at 0 and 12 months.
89237|NCT03489707|Behavioral|Clinic-based human papillomavirus (HPV) DNA screening|Men randomized to arm 2 will attend a clinic where a clinician will collect the DNA specimen at 0 and 12 months.
89238|NCT03489694|Procedure|Skin test endpoint titration|An allergen that is suitable to cause skin reactions when introduced to the forearm through pricking will be administered in doubling concentrations.
89239|NCT03489681|Device|acupuncture|"Low dose group:~Twenty patients will assign for low dose group treatment; as six acupoints as Shensu (BL 54), Huantiao (GB 30), Weizhong (BL 40), Yanglingquan (GB 34), Kunlun (BL 60), Juegu (GB 39).~High dose group:~Twenty patients will assign for high dose group treatment. These acupoints contains of eighteen acupoints, as Shenshu (BL 54), Dachangshu (BL 25) , Xiaochangshu (BL 27), Huantiao (GB 30), Yinmen (BL 37) , Zhibien (BL 54), Chengfu (BL 36), Fengshi (GB 31), Weizhong (BL 40), Zusanli (ST 36) Yanglingquan (GB 34), Yinlingquan (SP 9), Feiyang (BL 58), Sanyinjiao (SP 6), Juegu (GB 39), KunLun (BL 60), , Taixi (KI 3), Shenmai (BL 62)."
89240|NCT03489668|Drug|MetFORMIN 500 Mg Oral Tablet|metformin administration 1500mg per day
89241|NCT03489655|Behavioral|Maintenance Phase Intervention|The CHW will utilize motivational interviewing techniques over phone calls to reinforce all asthma education provided in the AI phase, including asthma basics, triggers and reduction strategies, purpose of medications, and steps for proper medication use. The CHW will identify barriers the participant is facing in management of their asthma and set goals to overcome them. The CHW will encourage regular visits with the Primary Care Physician and assist with referrals for other medical and social services, as needed. CHWs will check-in with participants via phone, monthly for the first 6 months and bi-monthly in the remaining 6 months Participants will receive bi-monthly data collection follow-up phone calls by a Research Assistant.
89242|NCT03489642|Behavioral|Telehealth Program|Telehealth program delivered remotely to study participants. Program developed by Cambium Technologies.
89243|NCT03489629|Drug|Trimethoprim Sulfamethoxazole (TMP/SMX)|"Dosing if < 40 kg: 8 mg/kg trimethoprim/40 mg/kg trimethoprim sulfamethoxazole given twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing is ≥ 40 kg: 320 mg/1600 mg twice daily for 14 days during Days 1-14 and Days 29-42."
89244|NCT03489629|Drug|Minocycline|"If a subject has an allergy to or intolerance to TMP/SMX, they may be treated with minocycline provided they are 8 years of age or older.~Dosing if < 50 kg: 2 mg/kg orally twice daily for 14 days during Days 1-14 and Days 29-42.~Dosing if ≥ 50 kg: 100 mg twice daily for 14 days during Days 1-14 and Days 29-42."
89245|NCT03489629|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 5 days during Days 1-5 and Days 29-33.
89246|NCT03489629|Drug|Chlorhexidine Gluconate|For subjects able to swish without swallowing, 0.12% chlorhexidine gluconate oral rinse will be used twice daily for 14 days during Days 1-14 and Days 29-42.
89247|NCT03489629|Behavioral|Environmental Decontamination|"Subjects will be instructed to wipe down all high touch surfaces and medical equipment with surface disinfection wipes daily during Days 1-21 and Days 29-49.~Subjects will also be instructed to wash all linens and towels in hot water once weekly during weeks 1-3 and weeks 5-7."
89248|NCT03489616|Biological|rhGM-CSF|rhGM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils. rhGM-CSF can promote the maturation of dendritic cells and macrophage, increase their antigen presentation ability.
89249|NCT03489616|Drug|Pemetrexed|Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
89250|NCT03489616|Radiation|Local Radiotherapy|Radiotherapy promotes the release of tumor antigen
89251|NCT03489616|Drug|Single agent|Other chemotherapy drugs,such as Docetaxel, gemcitabine
89252|NCT03489590|Drug|PFP|"Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
89253|NCT03489564|Behavioral|Active|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Active group will be categorized by their own routine physical activity levels.
89254|NCT03489564|Behavioral|Sedentary|No behavioral intervention included but the exposure is level of physical activity. Individuals in the Sedentary group will be categorized by their own routine physical activity levels.
89255|NCT03489551|Drug|Haldol|
89256|NCT03489538|Procedure|laparoscopic long limb roux-en-Y gastric bypass|standard laparoscopic roux-en-Y gastric bypass (biliopancreatic limb 40 to 60 cm, alimentary limb 150 cm)
89257|NCT03489525|Biological|Dose Escalation, MEDI2228, ADC (antibody drug conjugate)|Single agent MEDI2228 will be administered to adult subjects with R/R MM. The study aims to evaluate up to 9 planned, sequentially ascending main dose levels
89258|NCT03489525|Biological|Dose Expansion, MEDI2228, ADC (antibody drug conjugate)|Adult subjects with R/R MM with measurable disease will be enrolled in the dose-expansion cohort at the dose selected for evaluation in the dose-expansion phase.
89259|NCT03489512|Drug|A (Chloraprep)|Chloraprep will be used for the insertion and maintenance of the intravascular device while it is in use (Chlorhexidine 2% + alcohol 70%)
89260|NCT03489512|Drug|B (Clorhexidine 2%)|Aqueous clorhexidine (2%) will be used for the insertion and maintenance of the intravascular device while it is in use
89261|NCT03489473|Diagnostic Test|18F-FES PET CT scan|PET CT scan with estrogen tracer
89362|NCT03488563|Biological|Vehicle|Vehicle Suspension
89263|NCT03489460|Behavioral|GAD|Survey responses will be merged with objective GAD data (sleep time, time in deep sleep, physical activity) which will assist in developing message design formats for message testing.
89264|NCT03489447|Other|ICU care|exposure to ICU treatment with or without diagnosed sepsis
89265|NCT03489434|Behavioral|Intervention|Preliminary prevention program component content is based on evidence-based prevention programs and will integrate prevention content for substance use, sexual assault, and sexual risk behaviors.
89266|NCT03489408|Device|Conventus Cage™ PH|Proximal humeral fracture fixation
89267|NCT03489395|Drug|Edoxaban|Edoxaban 60 mg once a day for 4 weeks. Edoxaban 30 mg/day in patients with body weight ≤60 kg, or with concomitant therapy with verapamil/quinidine/dronedarone.
89268|NCT03489382|Other|Smartphone Assisted PST|"Emergency Departments randomized to the study intervention will receive:~Staff education incorporated into regular teaching rounds at least twice a year about the management of self-harm in the Emergency Department. This will include the dissemination of guidelines on how to ask questions about suicide, assessment of suicide risk, the creation of a management plan and how to refer patients to local mental health resources, including the study.~Written materials developed by service users for men who self-harm that outline local resources, distress centre helplines, and follow-up arrangements.~The option to refer men who self-harm to a service that will deliver smartphone-assisted PST specifically designed for men."
89269|NCT03489369|Drug|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
89270|NCT03489356|Behavioral|Addressing Behavior Change (ABC)|The ABC is a 3-minute brief, dermatologist delivered intervention for dermatological patients that takes place during a skin examination. During the ABC intervention, dermatologists specifically assess patients' UV risk behaviors, discuss patients' motivation to use UV protection, and explore solutions to patient-reported barriers interfering with effective sunscreen use. Based on our previous research, the ABC intervention does not add additional time to the visit, but rather replaces treatment as usual conversations about sun protection.
89271|NCT03489343|Drug|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
89272|NCT03489317|Drug|Metformin|Participants with high glucose levels will usually be prescribed Metformin 250 mg three times daily. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
89273|NCT03489317|Behavioral|lifestyle modification|Participants with metabolic syndrome will be offered advice on modifying their diets and exercise regimes. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
89274|NCT03489317|Drug|Simvastatin 10mg|Participants with elevated lipid levels will usually be prescribed simvastatin 10 mg at night. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
89275|NCT03489317|Drug|Amlodipine 5mg|Participants with high blood pressure could be prescribed antihypertensive medicine such as Amlodipine. Can be prescribed to either metabolic syndrome-partial or full groups depending on their metabolic syndrome conditions.
89276|NCT03489304|Drug|Zaleplon|non-benzodiazepine hypnotic agent
89277|NCT03489291|Genetic|AAV5-hFIXco-Padua (AMT-061)|Single intravenous infusion of AAV5-hFIXco-Padua (AMT-061)
89278|NCT03489265|Drug|Eluxadoline 100 mg|100 mg capsule-shaped tablet by mouth taken twice per day
89279|NCT03489265|Other|Placebo|Matching capsule-shaped placebo tablets taken by mouth twice per day
89280|NCT03489252|Device|Monitoring Device|Wear Fitbit Charge 3
89281|NCT03489239|Drug|Tenofovir Alafenamide|subjects switching from Entecavir to single arm TAF 25mg
89282|NCT03489226|Dietary Supplement|Capsimax|Capsimax
89283|NCT03489226|Dietary Supplement|Placebo|Placebo
89284|NCT03489226|Other|Meal|Meal
89285|NCT03489213|Other|Dietary Intervention|Participants randomized to the DGA/AICR group will receive plant-based diet education, garden access and health coaching for 5 months. The sessions are offered every other week.
89286|NCT03489213|Behavioral|Exercise Intervention|Participants will wear a FitBit every day and monitor daily physical activity.
89287|NCT03489213|Other|Laboratory Biomarker Analysis|Correlative studies
89288|NCT03489213|Dietary Supplement|Nutritional Intervention|Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
89289|NCT03489213|Other|Questionnaire Administration|Ancillary studies
89290|NCT03489200|Other|EH301|1-(beta-D-Ribofuranosyl)nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene
89291|NCT03489200|Other|Placebo|No intervention- placebo
89292|NCT03489187|Device|Visualase Thermal Therapy System|Patients who have previously received treatment with VTTS when used as intended.
89293|NCT03489174|Other|Monthly Pregnancy Screening|Pregnancy test will be administered once per month during weekly urine testing for drug levels.
89294|NCT03489174|Other|Usual Care|Usual care.
89295|NCT03489161|Drug|Buprenorphine|buprenorphine/naloxone 4mg/1 mg for Clinical Opioid Withdrawal Scale (COWS) scores between 8 and 12, or 8mg/2mg S/L ≥ 12 by the sublingual route
89296|NCT03489148|Behavioral|Tamarkoz®|Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
89297|NCT03489148|Behavioral|Stress management resources|Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
89298|NCT03489135|Device|Vetex Thrombectomy Device|Endovascular treatment of an acute iliofemoral DVT
89299|NCT03489122|Behavioral|yoga|The yoga intervention consists of Iyengar yoga method and coherent breathing sessions for 90 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
89300|NCT03489122|Behavioral|walking|The walking intervention consists of walking sessions at 2.5 miles an hour on a flat surface for 60 minutes twice a week or a maximum of 24 interventions over the 12 week intervention.
89363|NCT03488550|Biological|ANX007|Single ascending dose
89364|NCT03488537|Device|AeonoseTM|Breath test
89301|NCT03489109|Behavioral|Intermittent fasting|Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
89302|NCT03489096|Device|Cryoballoon Ablation: PVI + substrate modification|Standard pulmonary vein isolation using cryoballoon ablation, followed by left atrial fibrosis substrate modification using cryoballoon ablation
89303|NCT03489083|Other|Strength training|Strength training was performed three times per week for twelve weeks. Supervised (by qualified sport and exercise scientists) exercise was performed in a gym on three non-consecutive days of the week. Each session lasted ~60 min and consisted of a warm up, the resistance exercise training and a cool down. The training programme consisted of a combination of upper and lower body exercises using gym equipments, free weights and body weight as the primary resistance. The twelve weeks of strength training were divided into three mesocycles of four weeks each. The resistance training was performed using two to three sets per exercise at intensities between 12-15 repetition maximum-RM.
89304|NCT03489083|Other|No Training|"Control group performed a placebo stretching/relaxing session once a week (for adherence purposes) for twelve weeks. To avoid any significant adaptation, all stretching exercises (for large muscle groups only) were performed at very low intensity without any significant discomfort."
89305|NCT03489070|Combination Product|Traumastem®|Intraoperative application as secondary hemostatic treatment
89306|NCT03489070|Combination Product|Surgicel®|Intraoperative application as secondary hemostatic treatment
89307|NCT03489057|Behavioral|Prostate Cancer Education and Resources for Couples (PERC)|PERC uses mHealth technologies to dramatically increase couples' accessibility to posttreatment supportive care whenever and wherever they feel comfortable accessing it. PERC aims to improve QOL for both patients and partners by enhancing positive appraisals of illness and boosting self-efficacy, social support from multiple sources, and healthy behaviors for symptom self-management at home.
89308|NCT03489057|Behavioral|usual care plus NCI website|The usual care plus NCI website provides generic information about prostate cancer treatment options, research, causes, and statistics; coping resources that are not prostate cancer-specific; support from non-providers via a toll free phone and LiveHelp Online Chat about cancer-related questions, clinical trials, and quitting smoking.
89309|NCT03489044|Drug|Levetiracetam|To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
89310|NCT03489044|Drug|Placebo Oral Tablet|To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
89311|NCT03489018|Biological|PCV10|Experimental arms will receive a lower dose of the intervention than the marketed dose.
89312|NCT03489018|Biological|PCV13|Experimental arms will receive a lower dose of the intervention than the marketed dose.
89313|NCT03489005|Drug|BIA 5-1058|"Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~1200 mg BIA 5 1058, as 12 × 100 mg tablets"
89314|NCT03489005|Drug|Placebo Oral Tablet|"Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets"
89315|NCT03489005|Drug|Moxifloxacin 400 mg|"Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet"
89316|NCT03488992|Dietary Supplement|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 8 weeks
89317|NCT03488992|Dietary Supplement|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
89318|NCT03488979|Other|educational interventional group|• Patient Education Tool (Appendix 3) and the patient's own IVC images will be shared with each patient in the intervention group in real time. If feasible, each intervention patient will also receive a printed copy of his or her IVC image.
89319|NCT03488966|Behavioral|Mindfulness Based Eating and Awareness Training|Eight sessions of Mindfulness Based Eating and Awareness Training (MB-EAT) will be delivered once per week over the course of 8 weeks, following an introductory session. The treatment uses general mindfulness meditation and eating meditation to help participants bring greater awareness and understanding to their relationship with food. Homework consists of weekly mindfulness exercises.
89320|NCT03488953|Procedure|Living donor liver transplantation with two-staged hepatectomy.|Two-stage hepatectomy combined with transplantation of left-lateral lobe from a living donor.
89321|NCT03488940|Device|24-hours group|"Daily amount of feeding were continuously pumped for 24 hours. Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes(GRV) is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
89322|NCT03488940|Device|16-hours group|"Daily amount of feeding were continuously pumped for 24 hours.Enteral nutrition preparations pumping scheme: the initial pumping speed is 40ml/h, and gastric residual volumes is checked every 4 hours. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
89323|NCT03488940|Device|intermittent group|"Daily amount of feeding were divided into four meals, each meal are pumped within 60mins through stomach tube.~Enteral nutrition preparations pumping scheme: the initial pumping speed is 200ml/h, and gastric residual volumes is checked before each intermittent feeding. If it can be tolerated, the velocity of the pumping can be increased by half of the original speed.If it is not tolerable, the speed of the pumping is reduced by half on the original speed.~GRV<200 mL were considered markers of good tolerance. Feeding intolerance was defined as GRV>200 mL.~Enteral nutrition preparation are Enteral Nutritional Suspension(TPF-FOS) which were producted by ABBOTT LABORATORIES B.V.. The feeding pump are Infusion pump P-600 which were producted by Atom Medical Corporation."
89365|NCT03488524|Drug|AMX0035|A combination therapeutic of TUDCA and Sodium Phenylbutyrate
89324|NCT03488927|Behavioral|Supporting Survivors and Self: An Intervention for Social Supports of Survivors of Partner Abuse and Sexual Aggression (SSS)|The SSS intervention consists of a two-hour session followed by a 90-minute booster session a month following the initial program session. The SSS intervention is delivered in groups of approximately 20 students facilitated by peer educators. The SSS intervention provides participants with specific information on the reasons why positive social reactions are important and negative social reactions can be harmful, examples of what to say and what not to say (including ways to promote healthy coping and discourage unhealthy coping, e.g., drinking to cope), opportunities for roleplay, and an emphasis on the importance of self-care and ways in which self-care can be balanced with the needs of IPV and SA victims.
89325|NCT03488914|Behavioral|YMHP Intervention|
89326|NCT03488914|Behavioral|Enhanced Treatment as Usual|
89327|NCT03488901|Other|chemoresistance signature|to study the predictive value of a tissue transcriptomic profile (=chemoresistance signature) in the chemoresistance to single or multiagent chemotherapy
89328|NCT03488888|Drug|Normal Saline 0,9%|Ultrasound-guided PEC II block with 30 mL of Normal Saline 0,9%
89329|NCT03488888|Drug|Bupivacaine|Ultrasound-Guided PEC block with 30 mL of 0.25% bupivacaine solution
89331|NCT03488836|Procedure|reciproc|rotary reciprocating protocol
89332|NCT03488836|Procedure|race rotary|race rotary group protocol
89333|NCT03488823|Dietary Supplement|with Flavanol|Patient will get twice daily drink rich on flavanols (400 mg) since one week before catheterization till one week after catheterization.
89334|NCT03488823|Dietary Supplement|without Flavanol|Patient will get twice daily drink without flavanols since one week before catheterization till one week after catheterization.
89335|NCT03488810|Other|Radiation Therapy|Dose escalated Intensity-Modulated Radiation therapy (IMRT) with conventional fractionation, hypofractionation and prostate brachytherapy are allowed.
89336|NCT03488810|Drug|Apalutamide|240 mg PO daily, started the same day as the first LHRHa injection, for 6 months
89337|NCT03488810|Drug|Luteinising Hormone Releasing Hormone analog agonist (LHRHa)|2 injections of a three-monthly LHRH agonist depot
89338|NCT03488810|Drug|Non-steroidal anti-androgen|Non-steroidal anti-androgen (e. g. flutamide, bicalutamide) PO daily for 4 weeks, started 2 weeks before the first LHRH agonist injection
89339|NCT03488797|Behavioral|Supervised web- and home-based exercise intervention|"The intervention group gets access to a training platform. Every week, 3 training videos of 20 minutes each will be released on that platform with the aim to perform those during the ongoing week.~Each exercise session is arranged in a video session with child friendly instructions and executions for the different exercises. The videos serve as a virtual training partner and exercise will be performed simultaneously while watching the video~The overall training volume is 72 session calculated from 3 sessions per week over a duration of 24 weeks (6 month)"
89340|NCT03488758|Other|CMF|Taking a infant formula based on cow milk protein fractions, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
89341|NCT03488758|Other|GMF|Taking a infant formula based on whole goat milk, 4-5 feeds per day given by bottle, 180-210 ml/feed, total 800-900ml per day for one mounth
89342|NCT03488745|Behavioral|IntelliCare + Phone Coaching|IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
89343|NCT03488732|Device|Transcatheter valvular repair or replacement|Transcatheter valvular repair (predominantly MitraClip for mitral regurgitation) or replacement (predominantly transcatheter aortic valve implantation for aortic stenosis)
89344|NCT03488719|Drug|Metoprolol Succinate 25 MG|Metoprolol 25mg
89345|NCT03488719|Drug|Metoprolol Succinate 50 MG|Metoprolol 50mg
89346|NCT03488719|Drug|Metoprolol Succinate 100 MG|Metoprolol 100mg
89347|NCT03488693|Radiation|Radiation|Radiotherapy given
89348|NCT03488693|Other|No Radiation|No radiotherapy given
89349|NCT03488680|Behavioral|Behavior change communication|Behavior change communication about optimal complementary feeding
89350|NCT03488667|Drug|Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
89351|NCT03488667|Drug|Adjuvant Treatment - mFOLFOX & Pembrolizumab|Pembrolizumab, mFOLFOX Chemotherapy
89352|NCT03488654|Diagnostic Test|Cardiovascular magnetic resonance|CMR including cine, late gadolinium enhancement (LGE) and stress perfusion sequences
89353|NCT03488641|Diagnostic Test|ex-vivo drug response assay|drug sensitivity testing of primary patient derived cancer cells
89354|NCT03488628|Other|Noninvasive ventilation|Noninvasive ventilation delivered through a face mask, in alternace with satandard nasal oxygen therapy over the first 24 hours
89355|NCT03488628|Other|High-Flow Nasal Oxygen therapy|High-Flow Nasal Oxygen therapy delivered continuously over the first 24 hours by the AIRVO2® device (Fisher & Paykel Healthcare,New Zealand) through nasal canula.
89356|NCT03488602|Behavioral|F-SPS+UC|"Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks.~Participants will continue to receive usual care."
89357|NCT03488602|Behavioral|EUC|"Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed.~Participants will continue to receive usual care."
89358|NCT03488589|Diagnostic Test|serum samples for HEV RNA PCR|serum samples HEV RNA PCR
89359|NCT03488576|Procedure|Complete Macular Peeling|A complete peeling of the internal limiting membrane was performed
89366|NCT03488511|Other|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
89367|NCT03488498|Other|questionnaires|Examination of the spinal mobilization in cm. The pain and quality of life assessment of functional status through questionnaires.
89368|NCT03488485|Drug|Direct Acting Antivirals|DAAs given in patients with viremic chronic hepatitis C
89369|NCT03488472|Device|NovoTTF-200A|Begins within 7 days of SRS and continues until progression, death, or unacceptable toxicity.
89370|NCT03488472|Radiation|Stereotactic Radiosurgery (SRS)|SRS will begin within 21 days of study enrollment for 5-6 Gy per fraction for a total of 25 or 30 Gy.
89371|NCT03488459|Behavioral|Routine preoperative information from a nurse|Routine preoperative information from a nurse.
89372|NCT03488459|Behavioral|Additional information support from a psychologist|Routine preoperative information from a nurse + additional information support from a psychologist.
89373|NCT03488433|Device|Abduction brace|Donjoy Ultrasling IV
89374|NCT03488433|Device|Antirotation sling|Donjoy shoulder immobilizer
89375|NCT03488420|Drug|Edoxaban Pill|Subjects will be taking edoxaban 30 or 60 mg
89376|NCT03488394|Genetic|Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the α-L-iduronidase cDNA, in their final formulation medium.|"The drug product target dose is more or equal to 8x10^6 CD34+ cells/Kg, with a minimum dose of 4x10^6 CD34+ cells/Kg and a maximum dose of 35x10^6 CD34+ cells/Kg.~The product will be injected intravenously."
89377|NCT03488381|Device|Soccer Heading|"Soccer Heading: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer headings, separated by one minute intervals.~Soccer Kicking: Subjects stood approximately 40 feet away from a JUGS soccer ball launcher and participated in 10 consecutive soccer kicks, separated by one minute intervals."
89378|NCT03488368|Other|observation|Observation of renal outcome parameters and adverse events in the follow-up beyond the 3-year trial phase of the original STOP-IgAN trial.
89379|NCT03488355|Other|Modified laboratory report|"Report from microbiology laboratory: This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."
89380|NCT03488342|Procedure|Repair for primary inguinal hernia|Repair for primary inguinal hernia
89381|NCT03488329|Dietary Supplement|Individual nutritional therapy|"Guidance from a clinical dietician.~Individual nutrition plan~A package containing foods and drinks, which will cover their nutritional needs the first day after discharge.~A goodiebag containing samples on protein-rich milk-based drinks.~Telephone follow-up after 4 and 30 days and the possibility to call the dietician in case of questions about nutrition."
89382|NCT03488316|Procedure|Carie removal|Carie removal with a low speed handpiece
89383|NCT03488316|Procedure|Absolute isolation|Absolute isolation with rubber dam
89384|NCT03488316|Drug|Manipulation of the temporary filling material based on Calcium Hydroxide|Manipulation of the temporary material based on Calcium Hydroxide according to the manufacturer's recommendations.
89385|NCT03488316|Drug|Manipulation of the temporary filling material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations.
89386|NCT03488316|Procedure|Material insertion on the root canal|Material insertion on the root canal according to the manufacturer's recommendations
89387|NCT03488316|Procedure|Material re-insertion on the root canal accordging to the infection needs.|Material re-insertion on the root canal according to the manufacturer's recommendations
89388|NCT03488316|Procedure|Definiteve canal root obturation|Definiteve canal root obturation with gutta-percha and definitive cement.
89389|NCT03488316|Procedure|Definitve restoration|Definitve restoration confecction.
89390|NCT03488290|Behavioral|LTP Plus TF-CBT|Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning
89391|NCT03488290|Other|Treatment as Usual|The Treatment as Usual group will receive routine care
89392|NCT03488277|Other|leg elevation|intra operative position that consists in leg elevation with a 30 cm height pillow under the patient's heels
89393|NCT03488251|Drug|MT-3724|Experimental treatment with MT-3724 in combination with GEMOX therapy.
89394|NCT03488225|Drug|Cyclophosphamide|Given IV
89395|NCT03488225|Drug|Cytarabine|Given IT or IV
89396|NCT03488225|Drug|Dexamethasone|Given IV or PO
89397|NCT03488225|Drug|Doxorubicin Hydrochloride|Given IV
89398|NCT03488225|Biological|Inotuzumab Ozogamicin|Given IV
89399|NCT03488225|Other|Laboratory Biomarker Analysis|Correlative studies
89400|NCT03488225|Drug|Leucovorin Calcium|Given IV
89401|NCT03488225|Drug|Mercaptopurine|Given PO
89402|NCT03488225|Drug|Methotrexate|Given IT, IV or PO
89403|NCT03488225|Biological|Ofatumumab|Given IV
89404|NCT03488225|Drug|Prednisone|Given PO
89405|NCT03488225|Biological|Rituximab|Given IV
89406|NCT03488225|Drug|Vincristine Sulfate|Given IV
89407|NCT03488212|Behavioral|Training to Identify Eligible Patients and Direct them to Online Obesity Treatment Program|Primary care clinic staff are trained to identify patients who meet study inclusion and exclusion criteria. They are then trained to provide patients with the information necessary to enroll in the study and access the online behavioral obesity treatment.
89408|NCT03488212|Behavioral|Training to Motivate and Support Patients' Weight Loss|Primary care clinic staff are trained in psychological and behavioral strategies for: talking to patients about weight and weight loss in a way that patients find acceptable and helpful, increasing motivation for weight loss, overcoming common barriers to weight loss, and persevering with a weight loss attempt. They are trained in strategies to provide this support by telephone in addition to during clinic visits.
89500|NCT03487432|Device|Super High-Pressure NC PTCA Balloon (OPN NC)|Strategy of Super High-Pressure NC PTCA Balloon (OPN NC) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
89409|NCT03488212|Behavioral|Online Behavioral Weight Loss Intervention|For 3 months, participants receive: a weekly online lessons for training in behavioral skills for losing weight; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record.
89410|NCT03488212|Behavioral|Control Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online newsletters with educational information pertaining to healthy weight, diet, and physical activity habits.
89411|NCT03488212|Behavioral|Monthly Lessons and Feedback Intervention for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive 9 months of: monthly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; monthly feedback on the self-monitoring record.
89412|NCT03488212|Behavioral|Refresher Courses for Weight Loss Maintenance and Weight Gain Prevention|After completing the 3-month Online Behavioral Weight Loss Intervention, participants receive two month-long refresher courses with weekly online lessons for training in behavioral skills for maintaining weight loss and preventing weight gain; online self-monitoring of daily weight, diet, and physical activity; weekly feedback on the self-monitoring record; weekly challenges focuses on specific behavior change and weight loss goals.
89413|NCT03488199|Device|Stent Acculink ™|Carotid Artery Revascularization using Stents
89414|NCT03488199|Device|CGuardTM™|Carotid Artery Revascularization using Stents
89415|NCT03488186|Drug|Lansoprazole Capsules|24 healthy volunteers will be recruited and randomized into 2 groups (12 for each). During the study session, subjects will receive T drug in group A or R drug in group B for 7 days in fasted condition.
89416|NCT03488173|Drug|Lansoprazole capsules|"Test 1: 30 healthy volunteers will be included and randomized into 3 groups (10 for each). During the study session, subjects will receive a single dose of Lansoprazole capsules 30 mg in sequence of T-R-R in group A; R-T-R in group B; and R-R-T in group C.~Test 2: 12 healthy volunteers will be recruited and randomized to 2 groups (6 for each). Subjects in group A will receive a single dose of experimental drug in sequence of fast-fed condition; while in group B, subjects will receive the same dose and drug but in fed-fast order."
89417|NCT03488160|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
89418|NCT03488147|Drug|Esomeprazole|20 mg esomeprazole tablet
89419|NCT03488147|Drug|Placebo Oral Tablet|resembling esomeprazole tablet
89420|NCT03488121|Behavioral|Poster|Posters contain inspirational messages and pictures highlighting the important and unique roles that patients and physicians can play in reducing unnecessary care and health care costs. These posters will be placed in physician offices.
89421|NCT03488121|Behavioral|Thank-you Letter|Physicians will be sent thank-you letters containing changes in the rates of antibiotics and serum ferritin tests ordered since introduction of Choosing Wisely NL and a thank-you message from the NL Medical Association.
89422|NCT03488108|Other|Platelet Rich Plasma|Autologous Platelet Rich Plasma (PRP) will be isolated from blood collected from each subject at each treatment time point. 100 cc of PRP will be injected with a 30-gauge needle over the affected part of the scalp, approximately 1/10 cc/injection site. Treatments will take place every 4 weeks for a total of 3 treatments over 12 weeks.
89423|NCT03488108|Drug|Minoxidil Foam|Minoxidil 5% topical foam will be applied once daily following manufacturer's instructions for a total of 12 weeks.
89424|NCT03488095|Behavioral|BCI for SLT and BQ Use in Adolescents: A CRT|BCI for SLT and BQ Use in Adolescents: A CRT is aimed towards changing Adolescenst behaviors regarding their SLT and BQ use to as to reduce Oral cancer Burden within population because of this.
89425|NCT03488082|Behavioral|fMRI|saccadic adaptation (target presentations, with or without target jump) during fMRI exam
89426|NCT03488069|Other|Survey|Submission of survey answers
89427|NCT03488056|Other|ICCMS|"The patient's caries risk assessment, Diagnosis of caries lesion and activity assessment~-Intraoral risk assessment, Decide on a personalized care plan for patient and clinical interventions.~After asses all the factors and defining the patient's individual risk, the system presents a personalized treatment plan, indicating the appropriate home care instructions, clinical interventions and specific treatment for each caries lesion categories.~The treatment is divided into Non-Operative Care and Tooth-Preserving Operative Care (restorations with minimal intervention to preserve maximum dental structure).~The return intervals will be scheduled according to the risk: low risk (return of 1 year), moderate risk (6 months) and high risk (3 months)"
89428|NCT03488056|Other|SESC standard care|Standard care related to: Caries Diagnosis, operative and non-operative treatments, Indication of recall interval according to the dentist opinion
89429|NCT03488043|Procedure|Needle lung biopsy|Needle lung biopsy
89430|NCT03488017|Device|Ocular Coil|Non-invasive ocular device
89431|NCT03487991|Behavioral|Personalized sleep intervention|Personalized feedback and recommendations based on study observations of sleep behavior and how participants cope with potentially sleep disruptive cognitions on their frequency and impact and on sleep efficiency. A written report is provided to participants and their initial modifications are monitored.
89432|NCT03487978|Diagnostic Test|resting-state functional MRI|"To ensure inter-ictal fMRI, confirm that the subject has no migraine for at least 48 hours before the procedure.~Record the time difference between the date on the day of fMRI and the date of the last headache attack and record whether the headache on the day of fMRI is absent or not.~On the third day after MRI, examine whether the subject has headache or not."
89433|NCT03487965|Dietary Supplement|Low dose Polyphenol|botanical supplement with 25 mg polyphenol
89434|NCT03487965|Dietary Supplement|High dose Polyphenol|botanical supplement with 13 mg polyphenol
89435|NCT03487965|Dietary Supplement|Placebo Control|inert tablet made to mimic the experimental tablets
89436|NCT03487952|Other|Questionnaire Administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.
89437|NCT03487939|Drug|FOLFOXIRI|IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
89438|NCT03487926|Radiation|[18F]FEPPA|up to 3 PET Scans ([18F]FEPPA PET scans done 3 to 6 months apart, and one [11C]SL2511.88 PET scan) and 1 MRI
89439|NCT03487913|Drug|Lixivaptan|Oral vasopressin V2 receptor antagonist
89440|NCT03487900|Diagnostic Test|Colonoscopy|Colonoscopy for CD patients in clinical remission
89441|NCT03487887|Device|continuous glucose monitoring (CGM) iPro™2 Medtronic|A CGM device is to be set and take off by the diabetologist. Before the study start all diabetologist not familiar to the method will have a short education on CGM device. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard SMBG along with the data on eating, physical exercise, drugs. On Day 7, CGM device is taken off and the data from iPro2 is uploaded to PC. At the end, each patient fills a short query on satisfaction while wearing CGM.
89442|NCT03487874|Procedure|Conventional interscalene block|Under ultrasound guidance, the 5th to 7th cervical nerve roots are blocked.
89443|NCT03487874|Procedure|Interscalene block with C8 root block|Under ultrasound guidance, the 5th to 8th cervical nerve roots are blocked.
89444|NCT03487874|Drug|0.75% ropivacaine|Placement of 25 to 30 ml of 0.75% ropivacaine around the cervical nerve roots
89445|NCT03487861|Diagnostic Test|observational(urinary biomarker for kidney allograft fibrosis)|After an informed consent is obtained, urine specimens will be collected prospectively before kidney transplantation (if available) and 3rd and 7th day, 1st, 3rd, and 6th month post-transplant. About 35~50ml of urine sample is collected from each patient. For each urine specimen, 0.5 ml of a protease inhibitor mixture (5mM 4-(2-animoethyl) benzensulfonyl fluoride hydrolchloride, 2 μM Leupeptin-hemisulfate, and 3.3 mM Sodium azide) is added. To remove urinary sediments including whole cells, large membrane particles, and other debris, urine specimens are centrifuged at a rate of 4000 rpm for 15 minutes at 4 ℃. An aliquot of supernatant is stored at -80 ℃ until use. Urinary biomarkers including transglutaminase 2 are quantified using ELISA or CBA. In addition, urinary exosomes are isolated and analyzed. When a for-cause biopsy is done for some patients, the correlation between biomarkers and pathologic diagnosis will be assessed.
89446|NCT03487848|Drug|Daclatasvir|Daily oral administration
89447|NCT03487848|Drug|Sofosbuvir|Daily oral administration
89448|NCT03487835|Other|Kinesiotape|
89449|NCT03487835|Other|No application|This group have no application during study time
89450|NCT03487822|Behavioral|Path Pain|The intervention examines the effects of PATH-Pain on emotion regulation to improve self-management of pain and pain-related disability in older adults with chronic pain, negative emotions, and cognitive impairment. This intervention consists of 8 weekly therapy sessions by a licensed clinician trained in Path Pain, 4 monthly boosters upon completion of therapy, and optional monthly group educational sessions.
89451|NCT03487809|Drug|Budesonide/Cisclesonide|One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
89452|NCT03487796|Behavioral|MySTYLE|Youth and parents will receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
89453|NCT03487796|Other|Waitlist Control|Youth and parents will not receive intervention materials for the first four months of participation. At the completion of the 4-month follow-up assessment, youth and parents will be eligible to receive two secure texts or emails to their cell phone or preferred device weekly (for eight weeks). Each text/email will contain a link to new media content designed to (1) improve sexual health knowledge surrounding HIV/AIDs and sexually transmitted infections, (2) increase acceptance of young Black men of all backgrounds (sexual, economic, and family), and (3) improve parent and adolescent relationships and communication.
89454|NCT03487783|Drug|Aripiprazole Oral Solution|Aripiprazole 2-20 mg/day (2-20 mL/day)
89455|NCT03487783|Drug|Placebo Oral Solution|Placebo 2-20 mg/day (2-20 mL/day)
89456|NCT03487770|Drug|Aripiprazole Oral Solution|Aripiprazole 2~15 mg/day (2~15 mL/day)
89457|NCT03487770|Drug|Placebo Oral Solution|Placebo 2~15 mg/day (2~15 mL/day)
89458|NCT03487757|Other|Core Stabilization Exercises|Jeffrey's core stabilization exercise training protocol will be performed to the training group. This protocol includes exercises progressing gradually from level 1 to level 3. Level 1; static contraction training on a stable surface, level 2; dynamic training on a stable surface, level 3; dynamic and resistant training on an unstable surface.
89459|NCT03487757|Other|No Intervention|Since no training is given to the control group during the study period, it is ethically necessary to give the same training to the control group if the benefit is achieved when the study is completed.
89460|NCT03487744|Other|Osmolite 1.5|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
89461|NCT03487744|Other|Promote without fiber|Continuous enteral tube feeding according to a standardized calculation via nasojejunal tube.
89462|NCT03487731|Biological|Allogeneic Human Mesenchymal Stem Cells (hMSCs)|A single administration of 20 million allogeneic mesenchymal stem cell delivered intra-facet via 6 injections of 1.5 mL per injection, total of 9 to 12ml.
89463|NCT03487731|Drug|Placebo|A single administration of 1 cc of 1% lidocaine with 1 cc of 2% Ropivicaine and 0.5 cc of betamethasone soluspan (celestone) solution delivered via intra-facet injection.
89464|NCT03487718|Biological|Leukocyte platelet rich fibrin plug + d-PTFE membrane|Following tooth extraction, an autologous leukocyte platelet rich fibrin plug will be placed in the socket and covered with a d-PTFE membrane
89465|NCT03487718|Biological|d-PTFE membrane|Following tooth extraction, the socket will be covered with a d-PTFE membrane
89466|NCT03487705|Other|electromyographic essential tremor|Making a recording electromyographic essential tremor in each child
89467|NCT03487692|Other|Diabetes MESSAGES Program|Health centers in the 2018 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
89468|NCT03487692|Other|Diabetes MESSAGES Program (second trial)|During the first trial period, health centers in the 2020 Training Cohort will collect data on patients receiving usual care. After the first trial period, health centers in the 2020 Training Cohort will enroll groups of 10-15 patients to attend 6 monthly diabetes group visits consisting of group education, social support, goal setting, and an individual medical visit for each patient. At the same time, patients will be enrolled in a 6-month interactive diabetes text messaging program. Patients will receive quarterly booster sessions for 1-2 years after the 6-month intervention period.
89469|NCT03487679|Other|Fasting|Participants will undergo one day of habitual eating followed by 36 hours of water-only fasting and final day of habitual eating consuming the exact same diet consumed on the first eating day. Blood draws will be performed on Day 1 in a 10-12 hr fasted state and 2 hour postprandial state and again on Day 3 in a 36hr fasted state and a 2 hour post prandial state. Microbiome samples and blood glucose data will be collected throughout the course of the study.
89470|NCT03487666|Drug|Nivolumab|Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
89471|NCT03487666|Drug|Capecitabine|Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
89472|NCT03487653|Biological|microbiology:Blood culture and sensitvity test .Serology|Gram stain ,Blood culture ,sensitivity test ,biochemical reactions and serological study will be done
89473|NCT03487640|Procedure|TARMR|Transanal resection of rectal mucosa for at least 5cm in length.
89474|NCT03487640|Procedure|LARSC|We are going to suspend the rectum and to resect rigmarole hidgut Laparoscopically
89475|NCT03487627|Behavioral|mHealth and Care Support Manager Service|This intervention will consist of electronic and Care Support Manager (CSM) contacts with parents from the first week following their adolescent's discharge from hospitalization through the first 3-6 months after discharge. The mHealth electronic application content will be accessible and delivered to parents weekly. Parents will also be able to enter a keyword on their electronic device to access content and material in real time. The CSM contacts will supplement the informational content delivered electronically by providing opportunities to ask questions about the electronic application material, and by checking on progress toward treatment follow through for their youth, identifying and problem solving any difficulties and concerns, and addressing health needs of each parent.
89476|NCT03487627|Behavioral|Enhanced Treatment-as-usual (TAU)|TAU typically involves a discharge planning session by unit staff with the adolescent and their parent(s) to discuss safety monitoring and referrals for mental health services following discharge from psychiatric hospitalization. Investigators will augment this usual care by providing written materials to families outlining some of the key considerations for caring for their adolescent. These written materials will include brochures with information for parents following adolescent suicidal behavior, a listing of resources including instructions for when to call 911 or go to the emergency room, and information regarding the National Suicide Prevention Lifeline. Written materials will be provided to both the enhanced TAU participants as well as participants receiving the mHealth and CSM intervention.
89477|NCT03487614|Behavioral|Behavior-based parental intervention|Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
89478|NCT03487601|Other|transcranial direct current stimulation|Active treatment will consist of a mild electrical current (2mA) administered via saline-soaked sponge electrodes placed along the intact scalp for 30 minutes a day for five days.
89479|NCT03487601|Other|sham transcranial direct current stimulation|Sham stimulation will involve brief delivery of current in a manner that does not result in changes in neuronal firing patterns, but that is perceived as active treatment by participants.
89480|NCT03487588|Drug|A-101 Topical Solution|A-101 Topical Solution applied Day 1, Day 15 and Day 29
89481|NCT03487575|Behavioral|Open trial|Integrated mHealth and support care managers
89482|NCT03487562|Drug|DWP14012 Amg|DWP14012 Amg
89483|NCT03487562|Drug|DWP14012 Bmg|DWP14012 Bmg
89484|NCT03487562|Drug|Clarithromycin|Clarithromycin 500 mg
89485|NCT03487562|Drug|Amoxicillin|Amoxicillin 1 g
89486|NCT03487562|Drug|Lansoprazole|Lansoprazole 30 mg
89487|NCT03487549|Drug|VP-102-cantharidin topical film forming solution|VP-102 cantharidin topical film forming solution.
89488|NCT03487549|Device|VP-102 Applicator|The applicator is used to apply the Study drug.The product is a combination therapy which includes the drug VP-102 and the applicator which is the device.
89489|NCT03487536|Other|Nutritional assessment|BMI and cholesterol levels evaluation
89490|NCT03487523|Behavioral|Text Message|As already stated
89491|NCT03487510|Other|NO interventions apply|does not apply
89492|NCT03487497|Procedure|Lateral column lengthening osteotomy|Lengthening osteotomy of the lateral column of the foot
89493|NCT03487484|Behavioral|Quality of Life Questionnaire for gastrointestinal tract|To assess quality of life, the GIQLI questionnaire (Gastrointestinal Quality of Life Index) will be applied
89494|NCT03487484|Behavioral|Quality of Life Questionnaire|To assess quality of life, the SF-36 questionnaire will be applied
89495|NCT03487484|Behavioral|Faecal Incontinence Score|To assess faecal incontinence, the Vaizey Wexner questionnaire will be applied
89496|NCT03487471|Diagnostic Test|Real-time elastography|Breast ultrasound with real-time elastography
89497|NCT03487471|Diagnostic Test|Shear wave elastography|Breast ultrasound with shear wave elastography
89498|NCT03487458|Procedure|Rib Fixation Surgery|Rib Fixation Surgery
89499|NCT03487445|Drug|ACT-246475|ACT-246475 for s.c. administration will be available as sealed glass vials in 20 mg strength
89781|NCT03485144|Biological|TV003|Live attenuated virus vaccine-TetraVax-DV
89501|NCT03487432|Device|Scoring PTCA Balloon (NSE Alpha)|Strategy of Scoring PTCA Balloon (NSE Alpha) after unsuccessful lesion preparation with conventional NC balloon angioplasty.
89502|NCT03487406|Drug|Ticagrelor|One 90 mg tablet, oral, twice daily for 6 months.
89503|NCT03487406|Drug|Aspirin|One 75 mg tablet, oral, once a day, for 6 months.
89504|NCT03487406|Drug|Placebo Aspirin|Sugar tablet to mimic Aspirin 75 mg tablet One 75 mg tablet, oral, once a day, for 6 months.
89505|NCT03487406|Drug|Placebo Ticagrelor|Sugar tablet to mimic Ticagrelor 90 mg tablet. Once 90 mg tablet, oral, twice daily for 6 months.
89506|NCT03487393|Device|magnetic facial nerve stimulation|Magnetic stimulation of facial nerve.
89507|NCT03487380|Procedure|Fecal sample collection|Fecal sample collection
89508|NCT03487354|Drug|Misoprostol|Misoprostol
89509|NCT03487341|Other|Cord drainage|Cord drainage
89510|NCT03487341|Other|Cord clamping|Cord clamping
89511|NCT03487328|Procedure|Sacrospinous-Sacrotuberous fixation|Sacrospinous-Sacrotuberous fixation
89512|NCT03487315|Diagnostic Test|immunoblot|immunoblot
89513|NCT03487302|Other|Brain MRI|Acquisition of 3D T1-weighted, 3D FLAIR and GRE brain MRI scans
89514|NCT03487302|Other|Neuropsychological test battery|"Mini Mental State Examination (MMSE), Measso et al. (1993);~Frontal Assessment Battery (FAB), Appollonio et al. (2005);~Symbol Digit Test, Amodio et al. (2002);~Digit Cancellation Test, Della Sala et al. (1992);~Trial Making Test (TMT A-B), Giovagnoli et al. (1996);~Weigl's Sorting Test, Laicona et al. (2000) and Inzaghi (2010);~Digit Span, Orsini et al (1987);~Corsi block-tapping test, Orsini et al. (1987);~Babcock story recall test, Carlesimo et al. (2002);~Phonemic verbal fluency in MDB, Caltagirone and Carlesimo (2010);~Semantic verbal fluency, Novelli (1986);~Imitating gestures, De Renzi et al. (1980);~Coloured Progressive Matrices (CPM47), Measso et al. (1993)."
89515|NCT03487289|Procedure|natural orifice|laparoscopic right colon surgery and patients who are removed from the natural orifice and conventional will gather
89516|NCT03487276|Drug|IFX-1|Single IV infusions of IFX-1 diluted in sodium chloride.
89517|NCT03487276|Drug|Placebo|Placebo
89518|NCT03487263|Biological|IC14|chimeric monoclonal antibody against human IC14
89519|NCT03487250|Device|TenJet System|Percutaneous ultrasound guided medial and lateral tenotomy using the TenJet HydroSurgery System
89520|NCT03487237|Biological|Ddimer testing|Included patients will undergo a formal work up for pulmonary embolism: Ddimer testing, followed if positive by a computed tomography pulmonary angiogram or V/Q scan.
89521|NCT03487224|Device|MRI with fMRI frequency|Functional magnetic resonance imaging or fMRI measures brain activity by detecting changes in blood flow. Participants will do cognitive tasks during fMRI.
89522|NCT03487211|Drug|Duloxetine|Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
89523|NCT03487211|Drug|Escitalopram|Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
89524|NCT03487198|Drug|Brexpiprazole|Brexpiprazole 2-3mg/day
89525|NCT03487198|Drug|Placebo|Placebo 2-3 mg/day
89526|NCT03487185|Device|Continuous Positive Airway Pressure|Autotitrating CPAP with weekly contact, incentives for compliance and initial sleep hygiene counseling
89527|NCT03487185|Other|Sleep Hygiene Control|Initial sleep hygiene counseling alone
89528|NCT03487172|Device|poly-L-lactic acid to right knee|Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
89529|NCT03487172|Device|poly-L-lactic acid to left knee|Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
89530|NCT03487159|Device|MRE (Magnetic Resonance Elastography)|The device is using to evaluate liver fibrosis stage
89531|NCT03487146|Device|hemoperfusion(HP)|These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
89532|NCT03487133|Drug|bortezomib/dexamethasone|"Induction therapy ->1cycle=28 days 1,2,3week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 4week : none maintenance therapy ->1cycle=28 days~1week : bortezomib 1.6 mg/m2 SC(subcutaneous), dexamethasone 40mg IV 2,3,4week : none"
89533|NCT03487120|Procedure|facet joint denervation|Bipolar electrocautery
89534|NCT03487107|Drug|SOF|400 mg tablet administered orally once daily
89535|NCT03487107|Drug|DAG181|100 mg capsule administered orally once daily
89536|NCT03487094|Other|Infant formula|Multi-centered, prospective, randomized clinical trial
89537|NCT03487081|Behavioral|Social regulation|Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.
89538|NCT03487081|Behavioral|Self regulation|Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.
89539|NCT03487068|Device|The FibroScan device|The Fibroscan device (Echosens) works by measuring shear wave velocity. In this technique, a 50-MHz wave is passed into the liver from a small transducer on the end of an ultrasound probe. The probe also has a transducer on the end that can measure the velocity of the shear wave (in meters per second) as this wave passes through the liver. The shear wave velocity can then be converted into liver stiffness, which is expressed in kilopascals. Essentially, the technology measures the velocity of the sound wave passing through the liver and then converts that measurement into a liver stiffness measurement; the entire process is often referred to as liver ultrasonographic elastography.
89540|NCT03487055|Biological|TK006|Subcutaneous injection in the upper arm
89577|NCT03486795|Device|PMC stimulation|stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
89578|NCT03486795|Device|Sham stimulation|sham stimulation over both primary motor cortex and premotor cortex
89579|NCT03486782|Device|IFG stimulation|stimulating inferior frontal cortex with transcranial direct current stimulation for 30 minutes
89782|NCT03485144|Biological|Placebo for TV003|Placebo
89541|NCT03487042|Drug|Bimatoprost 0.03% ophthalmic solution|"Each patient will be subjected to the following:~One side will be treated by narrow band ultraviolet rays B sessions twice weekly for 3 months + topical bimatoprost 0.03% solution twice daily ( 1 drop for each 2 cm2 ) and the other side will be treated by topical bimatoprost 0.03% twice daily ( 1 drop for each 2 cm2 ) + narrow band ultraviolet rays B sessions twice weekly for 3 months + 10.600-nm fractional carbon dioxide laser sessions twice monthly for 3 months.~Patients' Evaluation:~The recruited patients will be subjected to:~A) Full history taking. B) General clinical examination. C) Dermatological examination of the skin lesions. D) Vitiligo area scoring index score will be calculated for each patient E) Clinical photographs will be taken at baseline, after each month during treatment and after the end of treatment by 3 months.~F) A skin biopsy from the treated lesions for histochemical examination. F) Dermoscopic evaluation of the treated sites every 2 weeks."
89542|NCT03487029|Other|Short duration|exercise Short duration high intensity training
89543|NCT03487029|Other|Long duration|exercise Long duration high intensity training
89544|NCT03487016|Drug|Gemcitabine|Arm A
89545|NCT03487016|Drug|Nab-paclitaxel|Arm A
89546|NCT03487016|Drug|5-FU|Arm B Arm C
89547|NCT03487016|Drug|Irinotecan Liposomal Injection|Arm B Arm C
89548|NCT03487016|Drug|Oxaliplatin|Arm C
89549|NCT03487003|Drug|rocuronium|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.
89550|NCT03487003|Drug|saline|After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
89551|NCT03486990|Drug|TIMP-GLIA|intravenous infusion
89552|NCT03486977|Procedure|Evaluation of disease and follow-up|Correspondence medical consultation with specific device
89553|NCT03486964|Drug|DPP-4 inhibitors|Patients will be retrospectively evaluated after the addition of a DPP-4 inhibitor to previously taken anti-diabetic therapy
89554|NCT03486951|Procedure|Orthognathic Surgery:|maxillary/mandibular osteotomies for orthognathic purposes for the treatment of a dento-maxillary dysharmony The choice between outpatient procedure or hospitalization is decided by the surgeon on a case-by-case basis according to data relating to the general state of the patient, the type of surgery, the social context, the distance from the patient's home. a medical center in accordance with the usual and legal standards of outpatient surgery
89555|NCT03486938|Drug|Placebo Oral Tablet|Placebo oral tablet
89556|NCT03486938|Drug|AGB101 220 mg tablet|220 mg AGB101 active compound
89557|NCT03486925|Drug|oxytocin treatment|intranasal administration of oxytocin (24IU)
89558|NCT03486925|Drug|placebo treatment|intranasal administration of placebo
89559|NCT03486912|Drug|BMS-986036|Specified dose on specified days.
89560|NCT03486912|Other|Placebo|Specified dose on specified days.
89561|NCT03486899|Drug|BMS-986036|Specified dose on specified days.
89562|NCT03486899|Other|Placebo|Specified dose on specified days.
89563|NCT03486886|Diagnostic Test|PSMA -PET/CT scanning|"PET/CT scanning is performed on hybrid PET/CT scanners. Patients should fast for at least 4 hours to facilitate transit of oral contrast into the distal small bowel. An oral contrast product can be administered and [18F]-DCFPyL is injected by IV rapid bolus followed by saline flush. 80-100 minutes following [18F]-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the upper thighs. An MRI of the questioned lesion sites may be performed.~Uptake of lesions is measured with SUVmax. Hepatic and blood pool SUV is determined for the computation of tumor-to-liver and tumor-to-blood ratios.~15 patients max will undergo a second PSMA-PET scan on the same camera with the same protocol using a different tracer batch within 2 weeks of the initial PSMA-PET evaluation in order to determine test-retest repeatability of the imaging procedure using a Bland-Altman analysis (per lesion analysis)."
89564|NCT03486873|Biological|Pembrolizumab|200 mg IV infusion
89565|NCT03486873|Drug|Standard of Care (SOC)|IV infusion or oral tablets
89566|NCT03486860|Behavioral|Parent Psychoeducation|6-session parent psychoeducation group on child anxiety, following their children's lead, and encouraging approach behaviors.
89567|NCT03486860|Behavioral|Turtle Program|The Turtle Program involves a child social and emotional skills group (Social Skills Facilitated Play) and a modification of Parent-Child Interaction Therapy in which parents are provided in-vivo coaching in following their children's lead and encouraging approach behaviors within the peer context. The child group provides a forum of same-age peers to learn to develop social and emotion regulation skills. The Turtle Program is administered over an 8-week period.
89568|NCT03486847|Procedure|Repetitive recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before suegery and once an hour during surgery. PEEP is set to 7 cmH2O.
89569|NCT03486847|Procedure|One recruitment with PEEP|Apply sustained airway pressure of 30-40 cmH2O for 10-20 seconds before surgery. PEEP is set to 7 cmH2O.
89570|NCT03486834|Biological|V160|V160 administered as a 0.5 mL (100 Units) IM injection containing Merck aluminum phosphate adjuvant (MAPA)
89571|NCT03486834|Drug|Placebo|Saline solution administered as a 0.5 mL IM injection
89572|NCT03486821|Radiation|Hypofractionated Radiation|All patients on this study will receive the same type of therapy, 2 treatment hypofractionated radiation therapy.
89573|NCT03486808|Device|IFG stimulation|stimulating left inferior frontal cortex with transcranial direct current stimulation for 30 minutes
89574|NCT03486808|Device|DLPFC stimulation|stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
89575|NCT03486808|Device|Sham stimulation|sham stimulation over both left inferior frontal cortex and dorsolateral prefrontal cortex
89576|NCT03486795|Device|M1 stimulation|stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
89580|NCT03486782|Device|DLPFC stimulation|stimulating dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes
89581|NCT03486782|Behavioral|aphasia therapy|aphasia therapy for 30 minutes during transcranial direct current stimulation
89582|NCT03486769|Device|M1 stimulation|stimulating primary motor cortex with anodal transcranial direct current stimulation
89583|NCT03486769|Device|PMC stimulation|stimulating premotor cortex with anodal transcranial direct current stimulation
89584|NCT03486769|Device|aIPS stimulation|stimulating anterior intraparietal sulcus with anodal transcranial direct current stimulation
89585|NCT03486769|Behavioral|hand motor task|hand motor task for 30 minutes during transcranial direct current stimulation
89586|NCT03486756|Behavioral|Internet-CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
89587|NCT03486743|Behavioral|Educational video on LARC|Participants will watch a short educational video on long acting reversible contraceptive or LARC
89588|NCT03486730|Drug|BT1718|Dose escalation will consist of Stage 1 and 2. Stage 1 patients will receive BT1718 intravenously twice a week (D: 1,4,8,11,15,18) for 3 out of 4 weeks. Starting dose will be 0.6mg/m2. Single patient cohorts will be explored, but it will change to 3 to 6 patients cohorts. Stage 2 patients will receive BT1718 intravenously once a week (D: 1,8,15) for 3 out of 4 weeks. Starting dose will be less than the total weekly dose from Stage 1. This stage will have 3 to 6 patient cohorts until the recommended dose is established. Expansion phase has four sub-parts: Part A, B, C, D. Part A will commence at the twice weekly recommended dose established in Stage 1. This phase may run in parallel to the 'Dose escalation phase', Stage 2. Part B will commence at the once weekly recommended dose established in Stage 2. This phase may run in parallel to the 'Dose escalation phase', Stage 1. C&D will commence once the data from A and B are reviewed.
89589|NCT03486717|Device|Virtual reality goggles|Patients will act as their own control over two different dental appointments. One appointment will consist of wearing the virtual reality googles, the other appointment will be conducted without them. The goggles have a small screen inside of them along with headphones. This device will play an a movie or cartoon that will immerse the patient during treatment.
89590|NCT03486704|Behavioral|Face to Face VRRS and telerehabilitation|"Face to Face cognitive training using VRRS plus telerehabilitation. Participants will receive 12 sessions of an individualized Face to Face cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based VRRS cognitive training, three sessions for week.~Cognitive training will initially be tailored to the patient's baseline characteristics. The exercise program will be charged by therapist on the patient's computer before the beginning of the at-home treatment. Each patient's performed session will be reviewed by the therapist.~The group will receive a kit home-based (a tablet home, access to a daily individualized cognitive training program)."
89591|NCT03486704|Behavioral|Usual rehabilitation program|The usual rehabilitation group will receive 12 sessions of face-to-face usual cognitive training program.
89592|NCT03486704|Behavioral|FTF VRRS plus unstructured CS|"Face to Face cognitive training using VRRS plus at-home unstructured cognitive stimulation.~Participants will receive 12 sessions of an individualized Face to Face (FTF) cognitive training using VRRS over 4 weeks followed by 36 sessions of home-based unstructured cognitive stimulation (CS), three sessions for week."
89593|NCT03486691|Other|Routine measurement of left lobe|Routine preoperative measurement of left lobe
89594|NCT03486691|Other|control group|no routine preoperative measurement of left lobe
89595|NCT03486678|Drug|SHR-1210+GEMOX|28 days as a treatment cycle, SHR-1210 3mg/kg and Gemcitabine 800 mg/m2 will be administered IV Q2W (D1 and D15 of a treatment cycle),and Oxaliplatin 85mg/m2 will be administered IV Q2W (D2 and D16 of a treatment cycle). PD-1 antibody combined chemotherapy used up to 6 cycles.SHR-1210 3mg/kg IV Q2W will be administered beyond chemotherapy until the disease progression or untolerable toxicity.
89596|NCT03486665|Other|Blood Sampling|Blood samples will be taken from all patients and healthy volunteers.
89597|NCT03486665|Other|CSF Sampling|CSF sample will be taken from hospitalized newly diagnosed patients only.
89598|NCT03486639|Other|IPSS questionnaire|IPSS is an 8 question (7 symptom questions + 1 quality of life question) written screening tool used to screen for, rapidly diagnose, track the symptoms of, and suggest management of patients with lower urinary tract symptoms. It was validated for both genders.
89599|NCT03486626|Drug|Metformin|Metformin to increase pregnancy rate in polycystic ovarian syndrome patients
89600|NCT03486613|Other|PROM registration via the DANBIO App on a smartphone|PROM data is reported through the DANBIO smartphone app
89601|NCT03486613|Other|PROM registration via the touch screen solution|PROM data is reported through the touch screen solution
89602|NCT03486600|Other|Fluid Resuscitation|Patients will be evaluated and the bleeding site to be investigated and hemorrhagic shock confirmed and there is an expected delay in blood and blood products transfusion for more than 40 minutes. 6% HES 130/0.4 (Voluven®) will be administered intravenously to maintain or restore hemodynamic stability up to a maximum dose of 50 mL/kg body weight.
89603|NCT03486587|Drug|Bacillus Cereus tablets|Bacillus Cereus tablets was taken two tablets three times a day.
89604|NCT03486574|Diagnostic Test|Positive result from pathological test|Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test
89605|NCT03486561|Drug|Ranolazine|Ranolazine inhibits sodium and potassium ion channel currents. Inhibition of the late phase of the inward sodium current during cardiac repolarization has been well studied4. In disease states, enhanced sodium-calcium exchange due to augmented late phase of the inward sodium current activity leads to increased cytosolic calcium concentration. Intracellular calcium overload is believed to be critical to the mechanism of decreased left ventricular relaxation caused by ischemia and reperfusion. Elevated left ventricular diastolic wall tension compromises myocardial blood flow even further.
89606|NCT03486548|Drug|bupivacaine and dexamethasone|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound guided popliteal sciatic block with 0.125% bupivacaine 20 ml and dexamethasone 5 mg
89607|NCT03486548|Drug|bupivacaine and lidocaine|adductor canal block with 0.33% bupivacaine 15 ml with ultrasound at popliteal sciatic area and subcutaneous infiltration popliteal area with 2% lidocaine 1 ml
89608|NCT03486548|Device|Ultrasound|ultrasound
89648|NCT03486223|Drug|GSK2256294|Drug will be taken daily by mouth for 7 days.
89609|NCT03486535|Drug|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Diabetic patients.
89610|NCT03486535|Drug|Infraclavicular Brachial Plexus Blocks|All patients will receive Infraclavicular Brachial Plexus Blocks with the mixture of lidocaine and bupivacaine. This is an observational study, because all patients will receive the same blocks with the same doses of the local anesthetics. The only difference between groups is including patients with or without Diabetes Mellitus diagnosis. The intervention is the same and these patients cannot be randomized. The aim is investigating the effect of this local anesthetic mixture in Nondiabetic patients.
89611|NCT03486509|Drug|Afatinib|afatinb 40mg po bid
89612|NCT03486496|Drug|gefitinib|Patients will be treated with gefitinib, 250 mg p.o., daily
89613|NCT03486496|Drug|Berberine|Patients will be treated with Berberine, 50 mg p.o., tid
89614|NCT03486483|Other|Exercise|Intervention included 18 slackline rehabilitation sessions for 6 weeks: 3 sessions per week on non-consecutive days, 30 min each one.
89615|NCT03486470|Diagnostic Test|Ultrasound examination of radial arteries|Measuring the diameter and the depth of two radial segments on both arms
89616|NCT03486457|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
89617|NCT03486457|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
89618|NCT03486457|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
89621|NCT03486431|Radiation|Stereotactic Ablative Radiotherapy (SABR)|A minimum of thirty patients will be included for each dose level. An interval of at least 24 weeks from the first patient treatment to the next patient treatment at each dose level will be respected. In the meantime, more patients will be included in the previous dose level, in an effort to establish the secondary endpoints. In case 1-5 patients present with dose-limiting toxicity (DLT) at 6 months after SABR, thirty additional patients will be included at the same dose level. The maximal tolerated dose will be defined as the dose level below which at least 10 patients present with a dose-limiting toxicity at 6 months after SABR.
89622|NCT03486405|Other|Control group|Control group runners will receive the same graduated return to run intervals and 4-week home exercise program. However, they will receive no video education during the initial 10 weeks.
89623|NCT03486405|Other|Intervention group|Runners randomized to the intervention group will receive additional video tele-health instruction on how to transition to a non-rearfoot strike (NRFS) running pattern. Runners in the intervention group will have additional tele-health follow-ups at weeks 1, 2, 4,6, 8, and 10 using a tele-conferencing program and the Hudl Technique application. At each tele-health video follow-up participants will be emailed a questionnaire assessing their progress and function. At month 6 a final data collection session to include video analysis will be performed.
89624|NCT03486392|Drug|JNJ-64565111 Dose Level 1|Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.
89625|NCT03486392|Drug|JNJ-64565111 Dose Level 2|Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.
89626|NCT03486392|Drug|JNJ-64565111 Dose Level 3|Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.
89627|NCT03486392|Drug|Liraglutide|Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.
89628|NCT03486392|Drug|Placebo|Participants will receive matching placebo SC once-weekly until Week 26.
89629|NCT03486366|Other|non interventional trial|other
89630|NCT03486353|Drug|FF-10501-01|FF-10501-01 round film-coated tablets are immediate release and come in 3 dosage strengths: 50 mg (tan), 100 mg tablets (red) and 200 mg (yellow). Each tablet contains the active ingredient (FF-10501-01 white crystalline powder) and other excipients. All dosage strengths are packaged 32 tablets to a bottle. FF-10501-01 should be stored at room temperature (20 - 25 °C).
89631|NCT03486353|Drug|Azacitidine|azacitidine at a dose of 75 mg/m2 either subcutaneously (SC) or intravenously (IV) x 7 days every 28 days
89632|NCT03486340|Procedure|Cardiologic assessment|Aggressive ischemic risk factor management
89633|NCT03486327|Drug|BR55|A novel targeted ultrasound contrast agent
89634|NCT03486314|Drug|Pevonedistat|Pevonedistat intravenous infusion.
89635|NCT03486314|Drug|Rifampin|Rifampin capsules.
89636|NCT03486314|Drug|Docetaxel|Docetaxel intravenous infusion.
89637|NCT03486314|Drug|Carboplatin|Carboplatin intravenous infusion.
89638|NCT03486314|Drug|Paclitaxel|Paclitaxel intravenous infusion.
89639|NCT03486301|Drug|BDB001|BDB001 is an immunotherapy agent.
89640|NCT03486301|Drug|Pembrolizumab|Pembrolizumab is a potent humanized monoclonal antibody with high specificity of binding to the PD 1 receptor. Pembrolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
89641|NCT03486275|Device|Hygie|Prototype video game called Hygie, accessible on the Internet, on the 5 most common reasons of consultation in general practice using 9 articles from independent journals based on evidence (reviews by Prescrire and Minerva).
89642|NCT03486275|Device|Source articles|9 articles from independent journals based on evidence (reviews by Prescrire and Minerva), about the 5 most common reasons of consultation in general practice, accessible on the Internet.
89643|NCT03486249|Other|Repetition of medical examinations performed as part of the care|Cardiac echo, diaphragm ultrasound and phrenic nerves stimulation performed before the spontaneous breathing trial.
89644|NCT03486236|Drug|VX-440|VX-440 was administered in TC with TEZ and IVA.
89645|NCT03486236|Drug|TEZ|TEZ was administered as part of a fixed-dose combination (FDC) tablet (TEZ/IVA)
89646|NCT03486236|Drug|IVA|IVA was administered as part of a FDC tablet (TEZ/IVA) and as a mono tablet
89647|NCT03486236|Drug|Matched Placebos|Placebos matched to VX-440, TEZ, and IVA.
89650|NCT03486210|Behavioral|Food preference|The study will take place in two phases. A first phase will consist in the validation of translations and the selection of images on 20 healthy volunteers and 20 health professionals specialized in nutrition. They will have to fill a form with images of food and evaluate to what extend they think the pictures represent what we can eat in France. This step will adapt the questionnaire to our country.
89651|NCT03486210|Other|Psychological assesment|"Phase performed with patients fasting for at least 2 hours before the different tests. The FLPQ will be compared between a group of patients suffering from unoperated obesity (OCt), a group of patients operated on a sleeve gastrectomy (OSl) and a group operated by a bypass (OBy) between 6 and 24 months post-surgery, randomized for the 6 combined tests (2 categories). The award can be made in 2 sessions of at least 3 of the 6 tests combined. Each test combines 2 of the 11 categories. The test will consist of 96 pairs of 16 food images presented on a computer screen in color. Participants will be invited to choose the food they most want to eat, by pressing the corresponding computer button (choices saved by counting the frequency scores in E-prime).~The level of hunger will be evaluated by an Analogical Visual Scale, ranging from 0 to 10.~Patients should also complete 3 self-questionnaires used routinely (Binge Eating Scale, The Yale Food Addiction Scale, The UPPS-P short version)."
89652|NCT03486197|Other|Laboratory Biomarker Analysis|Correlative studies
89653|NCT03486197|Biological|Pembrolizumab|Given IV
89654|NCT03486197|Radiation|Radiation Therapy|Undergo neutron radiation therapy
89655|NCT03486184|Diagnostic Test|Cystatin-C|"Laboratory values will be obtained, including level of preoperative serum creatinine, complete blood count, coagulation profile and Cystatin-C (5 ml. venous sample).~Serum creatinine and hemoglobin will be measured after operation, and thereafter at least once a day as a part of routine clinical care. Postoperative serum Cystatin-C will measured only once."
89656|NCT03486158|Device|CalproSmart™ system|Home test kit for measurement of calprotectin in fecal samples. A new clinical tool for monitoring patients with inflammatory bowel disease, enabling measurement of calprotectin level of rapid test through a specially developed Smartphone application (platforms such as Android o Iphone)
89657|NCT03486145|Dietary Supplement|fruit and vegetable juice supplement|"FVS was provided by Isagenix International LLC in identically sealed bottles labeled labeled B. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
89658|NCT03486145|Dietary Supplement|Placebo|"PRU was provided by Isagenix International LLC in identically sealed bottles labeled labeled A. Subjects were not told which supplement they received. Each bottle contained one serving (two ounces) of the supplement."
89659|NCT03486132|Procedure|repair of episiotomy|Different techniques for repair of episiotomy incsicion
89660|NCT03486119|Other|nivolumab|Subjects will be treated with 3mg/kg in nivolumab IV every 2 weeks for a maximum of 12 months.
89661|NCT03486106|Other|Music|Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
89662|NCT03486106|Other|Headphones|All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
89663|NCT03486106|Drug|Propofol|All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
89664|NCT03486093|Device|"Training and retraining to GAVECELT bundle recommendations plus port protector"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed.~After the first training meeting, the use of Curos® Disinfecting Port Protector for needleless valves port-protector has been introduced."
89665|NCT03486093|Behavioral|"Training and retraining to GAVECELT bundle recommendations"|"Physicians and nurses of RICU have been trained and retrained to GAVECELT bundle recommendations concerning the management of CVC. The bundle includes: hand hygiene and precautions for protection and safety, adequate insertion site, echo-guided placement of central venous line, use of clorexidine 2% for skin disinfection of insertion site chosen and subsequent continuous or discontinuous disinfection of exit site, use of suture-less devices, use of transparent semi-permeable dressing whenever applicable and immediate removal of catheter when no longer needed."
89666|NCT03486080|Drug|Dutogliptin Tartrate|Active treatment
89667|NCT03486080|Drug|Filgrastim Injectable Product|Active treatment
89668|NCT03486080|Drug|Placebos|placebo control
89669|NCT03486067|Drug|CC-93269|CC-93269
89670|NCT03486054|Device|INTERCEPT|The pathogen reduction process begins with a unit of whole blood collected according to local standards and procedures at the blood center. The blood unit is treated with amustaline and glutathione (INTERCEPT blood system for whole blood) according to manufacturer's instructions. The INTERCEPT blood system is performed on a single unit of not leuco-reduced whole blood treated with amustaline and glutathione in CPD
89671|NCT03486054|Device|Standard of Care|The control article is Standard of Care, either RBC or whole blood collected by the Centre National de Transfusion Sanguine (CNTS), processed according to the local procedure and in compliance with quality criteria defined by the manufacture regarding the volume, hemoglobin content, hematocrit, storage temperature, age of blood and storage in the predefined anticoagulant solution.
89672|NCT03486041|Behavioral|Comprehensive Behavior Modification|Behavior therapy approach to BFRBs involving targeted intervention tactics chosen in accordance with the modality of functioning (ex: Sensory, Cognitive.....) seeming to cause the most frequent and problematic urges to engage in the BFRB. Therapist and client work together, using careful assessments including detailed self-monitoring, to determine what behavioral methods will suffice for lasting change.
89673|NCT03486041|Behavioral|Attention|Weekly brief calls from therapist to check on safety and clinical status. No focus on TTM.
89734|NCT03485495|Drug|Divaza|"Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).~Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before eating)"
89674|NCT03486028|Other|Adherence to ASAM protocols|ASAM Counties. These counties are requiring their providers to use ASAM criteria to assess patients and to determine level of care. These counties also use ASAM to determine the ongoing need for high-intensity services, such as residential, and approve those services for Medicaid payment.
89675|NCT03486028|Other|Non-adherence to ASAM protocols|These counties are not implementing the ASAM criteria to assess patients and determine the level of care.
89676|NCT03486015|Drug|Sterile water|2 ml of sterile water
89677|NCT03486015|Drug|30% glucose|2 ml of 30% glucose
89678|NCT03486002|Device|Cleansweep|The Cleansweep closed suction system
89679|NCT03486002|Device|Halyard|Halyard Closed Suction System
89680|NCT03485989|Other|Hazelnuts|Dry roasted, individually packaged hazelnuts provided from the Hazelnuts Marketing Board of Oregon
89681|NCT03485976|Drug|Ixekizumab|Treatment at the FDA-approved psoriasis dosing
89682|NCT03485963|Biological|HST-NEETs|The primary objective of this study is to evaluate the safety and tolerability of expanded HIV-specific T cell therapy (HST-NEETs) in HIV-infected individuals suppressed on cART. Patients with a partial response or stable disease 8 weeks after T-cell infusion were eligible to receive additional T-cells, consisting of the same number of cells as their second injection.
89683|NCT03485950|Drug|Cefepime|Given IV
89684|NCT03485950|Drug|Ceftolozane|Given IV
89685|NCT03485950|Other|Laboratory Biomarker Analysis|Correlative studies
89686|NCT03485950|Drug|Meropenem|Given IV
89687|NCT03485950|Drug|Piperacillin-Tazobactam|Given IV
89688|NCT03485950|Drug|Tazobactam|Given IV
89689|NCT03485937|Behavioral|Pre-Operative Videos|Videos will be created by the study team to ensure that the content coincides with what is delivered in the standard-of-care verbal and written instructions. The videos will be split into two modules: 1) preparing for Mohs Surgery 2) Mohs Surgery Walk through. The intervention, in the form of a video walk through, will be provided to the patient via email prior to their surgical procedure once they schedule an appointment with the Mohs clinic for their surgery day.
89690|NCT03485937|Behavioral|verbal instructions|As part of the standard of care for patients receiving Mohs surgery, patients are told about the day of their surgery and what to expect
89691|NCT03485937|Behavioral|written instructions|As part of the standard of care for patients receiving Mohs surgery, patients receive written material about the day of their surgery and what to expect
89692|NCT03485924|Diagnostic Test|EUS-FNA with ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
89693|NCT03485924|Diagnostic Test|EUS-FNB without ROSE|EUS-FNA with ROSE vs EUS-FNB without ROSE
89694|NCT03485911|Drug|BCX7353 capsules|BCX7353 oral capsules administered once daily
89695|NCT03485911|Drug|Placebo oral capsule|Matching oral capsules administered once daily
89696|NCT03485885|Dietary Supplement|Standardized maqui berry extract enriched in anthocyanins|Single oral intake of 1000mg standardized maqui berry extract (in 4 capsules - 250mg each) with 200ml still water
89697|NCT03485872|Other|Self-Screening and Referral Information|Urinary incontinence self-screening questionnaire, fact sheet and self-referral information will be provided by mail or email.
89698|NCT03485872|Other|Standard Care|Demographic and quality of life questionnaires; standard care provided by participants' GPs
89699|NCT03485859|Device|Experimental group|In subjects allocated to the abdominal binder group, the abdomen binder with a standard height of 22 cm (Sejung Korea, Seoul, Republic of Korea) was applied before leaving the operating room. The binder was placed on the abdomen across the laparoscopic incision, with the upper border not higher than the lower margin of the rib cage, ensuring minimal restriction of lateral costal expansion and diaphragmatic excursion. Subjects were carefully instructed to use the abdominal binder during at least the first 2 consecutive days and night, and to reposition the abdominal binder correctly when needed.
89700|NCT03485859|Device|Control group|In subjects allocated in the control group, subjects were not given any opportunity to ware an abdominal binder.
89701|NCT03485846|Drug|Narlaprevir|100 mg, oval shaped, concave, yellow film-coated, tablets taken as 200 mg per os daily
89702|NCT03485846|Drug|Ritonavir|100 mg, tablets, taken as 100 mg per os daily
89703|NCT03485846|Drug|Daclatasvir|60 mg, tablets, taken as 60 mg per os daily
89704|NCT03485833|Diagnostic Test|EEO and EIO test|velocity time integral of the aorta measured by transesophageal echocardiography after end-expiratory and end-inspiratory occlusion test
89705|NCT03485820|Behavioral|COMPASS|The data from the baseline assessment will be used to develop an environmental modification intervention plan. Environmental modifications will be installed before discharge if possible. Problem areas addressed are participant specific (tailored), but the process to identify and address the target area is systematic. All participants will receive identical intervention components. The standardized components include assessment, identification of problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
89706|NCT03485820|Behavioral|Stroke education|The control group will experience the same effects of time and attention in the home but no effect on the outcome of interest.
89707|NCT03485807|Behavioral|Mindfulness Training (MT)|2 week SmartPhone-based mindfulness training
89708|NCT03485807|Behavioral|Active Coping Training (CT)|2 week SmartPhone-based structurally equivalent coping training
89709|NCT03485794|Procedure|Biospecimen Collection|Undergo collection of blood
89710|NCT03485794|Other|Laboratory Biomarker Analysis|Correlative studies
89735|NCT03485495|Drug|Placebo|"Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).~Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before eating)"
89736|NCT03485482|Drug|Bisoprolol|bisoprolo 5 mg tablets
89737|NCT03485482|Drug|Ivabradine|Ivabradine 10 mg tablet
89738|NCT03485482|Drug|combination of Ivabradine and bisoprolol|combination of 10 mg ivabradine and 5 mg bisoprolol
89783|NCT03485131|Device|Transcranial direct-current stimulation (tDCS)|Stimulation sessions will be conducted twice a day on 5 consecutive weekdays. The twice daily sessions will be separated by at least 3 hours (one in the morning and the other one in the PM). The duration of treatment will be 4 weeks
89711|NCT03485768|Procedure|percutaneous disc decompression with coblation nucleoplasty|PDCN was performed using the COBLATION Perc-DC SpineWand surgical device (ArthroCare System 2000, ArthroCare corporation, Heredia, Costa Rica, USA) under local anesthesia. The introducer cannula was then pierced into the target intervertebral disc through an anterior lateral approach. The tip of the cannula stylet was aimed for the center of the nucleus in both the coronal and sagittal planes. The stylet was withdrawn from the introducer cannula and replaced with the Perc-DC SpineWand. The wand was advanced until its tip extended approximately 5 mm beyond the tip of the cannula. A short initial coagulation was performed upon wand insertion to ensure correct placement, if stimulation or movement was detected, the wand was repositioned. As the wand was drawn back out through the disc, ablation energy was set to level three and three ablation cycles of 5-12soconds each were performed, rotating the wand tip 180 degree each time to form three consecutive pockets within the disc.
89712|NCT03485768|Procedure|Manual Therapy (SNAGs plus PJMs)|"(1) sustained natural apophyseal glides (SNAGs): Use the methods described in Mulligan BR. Manual therapy NAGS, SNAGS, MWMS etc. 5th ed. Wellington, New Zealand: Plane View Services; 2004. Three sessions per week and for a total of four to six weeks according to the patients' condition, they were asked to continue the self-SNAG once daily until the last follow-up, and recorded in a diary. (2) passive joint mobilisations (PJMs): Use the methods described in Maitland G. Vertebral manipulation. 6th ed. Oxford: Butterworth Heinemann; 2001. For three repetitions weekly and for a total of four to six weeks according to the patients' condition, then once a day were commenced as a home exercise to be continued until the last follow-up, and recorded in a diary."
89713|NCT03485742|Other|No intervention|No intervention. Collection of data on statin eligibility in patients admitted with MI
89714|NCT03485729|Drug|ONC201|ONC201
89715|NCT03485716|Other|running on a treadmill under normoxia or hypoxia|"30 min running (60% VO2max) on a treadmill under hypoxia (O2: 14%)~30 min running (60% VO2max) on a treadmill under normoxia (O2: 20%)"
89716|NCT03485703|Drug|Azithromycin|the newborn group will receive intravenous azithromycin 10 mg / kg / day once daily for 5 days
89717|NCT03485703|Drug|Placebo|the group of newborns will receive 0.9% saline once daily for 5 days
89718|NCT03485677|Drug|Eliglustat GZ385660|"Pharmaceutical form: Capsule, Liquid~Route of administration: Oral"
89719|NCT03485677|Drug|Imiglucerase GZ437843|"Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous"
89720|NCT03485664|Procedure|tooth extraction|tooth extraction
89721|NCT03485625|Drug|Lidocaine|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
89722|NCT03485625|Drug|Ketorolac|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
89723|NCT03485625|Drug|paracetamol|Two cannulae were placed, one in a vein on the dorsum of the operative hand and the other on the non operative hand for i.v fluids. The operative arm was elevated for 2 min and was then exsanguinated with an elastic bandage. A pneumatic tourniquet was then placed around the upper arm, and the cuff was inflated to 100 mm Hg above systolic BP. Circulatory isolation of the arm was verified by inspection, absence of a radial pulse, and a loss of the pulse oximetry tracing in the ipsilateral index fingers The solutions were prepared by an anesthesiology assistant not involved in any part of the study. The solutions were injected over 90 s by an anaesthesiologist.
89724|NCT03485612|Diagnostic Test|Change of Optic Nerve Sheath Diameter|In patients, the optic nerve sheath width (ONSD) examination will be performed twice: for the first time immediately after general anesthesia and again after surgery after placing the patient in a position on the back.
89725|NCT03485599|Diagnostic Test|ELIZA , Westron blot|Blood sample will be taken then rapid test by ELIZA will be done if positive then confirmatory test by Westron blot will be done
89726|NCT03485586|Device|Traditional ultrasound biometrics|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
89727|NCT03485586|Device|Lenstar|To evaluate the clinical feasibility of using a new optical coherence interferometry ( lenstar ),comparing with traditional ultrasonic biometry and keratometry in the accuracy and characteristics for intraocular lens calculation of cataract after PPV
89728|NCT03485560|Combination Product|ACE CSD|Topical application of the ACE CSD 4 times daily.
89729|NCT03485547|Drug|Venetoclax|VENCLEXTA targets BCL-2 in order to help restore the process of apoptosis. Through apoptosis, your body allows cancer cells and normal cells to self-destruct
89730|NCT03485534|Drug|Tenofovir Disoproxil Fumarate|Viread 300mg
89731|NCT03485534|Drug|Tenofovir Disoproxil|Virehepa 245mg
89732|NCT03485521|Procedure|The tracheobronchial aspiration|"Reading of the procedures of the tracheobronchial aspiration (legislative framework, rules of hygiene, procedures, undesirable effects) The Practical Group participates in a practical work lasting two hours and the Stimulation Group is in simulation with a procedural practice of tracheobronchial suction as part of a simulation sequence. This group benefits from the methodology of the simulation with a part of briefing, a part simulated session and to finish the debriefing.~The experiment finished with a real activity on patients with tracheotomy with in this environment the reproduction of the procedure"
89733|NCT03485508|Diagnostic Test|Transthoracic echocardiography|Transthoracic echocardiography Blood sample with assessment of biomarkers
89779|NCT03485157|Biological|Micronized DHACM|Injection of 40 mg micronized dehydrated human amnion chorion membrane (dHACM) suspended in 1 mL 0.9% Sodium Chloride, USP
89739|NCT03485469|Behavioral|Hypnosis|"There ar 10 hypnosis sessions :~1st session of hypnosis : relaxation and orientation towards emotional cleansing.~2nd session of hypnosis: oriented towards digestion, physical and psychological~3rd session of hypnosis: oriented towards the feeling of security.~4th session of hypnosis: self-esteem oriented.~5th hypnosis session: oriented towards emotional management.~6th hypnosis session: oriented towards self-confidence.~7th hypnosis session: oriented towards the completion of the projects.~8th, 9th and 10th sessions: concern the learning of self-hypnosis and autonomy. A USB key containing the induction of a session of autohypnosis will be given to the subject to promote the continuation of home-made auto-hypnosis."
89740|NCT03485469|Behavioral|Standard Care|The dietary advice given during these dietary consultations is part of the standard care adapted to patients who have undergone bariatric surgery while increasing the frequency of consultations (Fractionation of meals, Volume of meals, Taking meals, Drinks, Food diversity)
89741|NCT03485456|Drug|Tobramycin|Tobramycin dry powder inhalation with 30, 60 and 90 mg. Nebulisation with 300 mg tobramycin
89742|NCT03485443|Drug|%0.9 NaCl 10ml/kg|Fluid administration
89743|NCT03485443|Drug|%0.9 NaCl 20ml/kg|Fluid administration
89744|NCT03485430|Behavioral|Tapering|Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering may also be conducted in inpatient setting. Follow-up to doctor after four months.
89745|NCT03485417|Drug|Aripiprazole|for oral or depot preparation
89746|NCT03485417|Drug|Paliperidone|for oral or depot
89747|NCT03485417|Other|Treatment as Usual|to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone
89748|NCT03485404|Drug|methylcobalamin|methylcobalamin tablets, 0.5mg/tablet, 3 tablets/day.
89749|NCT03485404|Drug|Folic Acid|folic acid tablets, 5mg/tablet, 1 tablet/day
89750|NCT03485404|Other|Placebo for methylcobalamin|orange tablets that looks exactly like methylcobalamin
89751|NCT03485404|Other|Placebo for folic acid|yellow tablets that looks exactly like folic acid
89752|NCT03485404|Procedure|non-cardiac surgery|patients elective for non-cardiac surgery will undergo scheduled surgery after 7 days of intervention
89753|NCT03485404|Behavioral|NPB test|participants will accept Mini-Mental State Examination (MMSE), Patient Health Questionnaire (PHQ-9), ADL, and NPB test before intervention, and NPB by discharge or similar time intermittent after the first assessment for non-surgical controls. Also ADL will be tested again through telephone interview at 3 months after discharge.
89754|NCT03485391|Behavioral|Prolonged Exposure|Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
89755|NCT03485378|Radiation|Stereotactic Ablative Radiotherapy|Stereotactic ablative radiotherapy for early non-small cell lung cancer and interstitial lung disease
89756|NCT03485365|Drug|GSK3858279 IV|GSK3858279 will be available as a brown to yellow solution for injection to be administered via IV route.
89757|NCT03485365|Drug|GSK3858279 SC|GSK3858279 will be available as a brown to yellow solution for injection to be administered via SC route.
89758|NCT03485365|Drug|Placebo matching GSK3858279 IV|Placebo is 0.9 percent sodium chloride solution which will be administered via IV route.
89759|NCT03485365|Drug|Placebo matching GSK3858279 SC|Placebo is 0.9 percent sodium chloride solution which will be administered via SC route.
89760|NCT03485339|Diagnostic Test|genome testing|blood sampling via venipuncture
89761|NCT03485300|Diagnostic Test|Liver and kidney function tests for patients with chronic liver or kidney diseases|Tests will be done to patients with history suggestive of chronic liver or renal diseases or for patients clinically suspected
89762|NCT03485300|Behavioral|Non compliance of the patient|I will order all my patients to take the drug at 10 am and assure the daily in taking of the dose and they will be followed up
89763|NCT03485300|Drug|Drug or food interactions|The patient will be in contact with the researcher for any drug added with warfarin in case of other co morbidity conditions and follow up his/her CBC and INR for measuring its effect on warfarin finding out the effect of food on warfarin therapeutic outcome
89764|NCT03485287|Drug|MDMA|Three sessions of MDMA-assisted psychotherapy with flexible dose of MDMA from 100 to 125 mg and optional supplemental dose half that of initial dose 1.5 to 2 hours later
89765|NCT03485287|Behavioral|Psychotherapy|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
89766|NCT03485274|Drug|Vortioxetine|oral medication taken once daily
89767|NCT03485274|Other|Treatment as Usual|Any pharmacological or non-pharmacotherapy modalities other than use of vortioxetine
89768|NCT03485248|Dietary Supplement|Beetroot Juice|140ml of Beetroot Juice containing on avarege 9 mmol of nitrate
89769|NCT03485248|Dietary Supplement|Placebo|140ml of Beetroot Juice (nitrate free)
89770|NCT03485235|Procedure|D&C|Dilatation and curettage
89771|NCT03485235|Procedure|ICSI|Intra Cytoplasmic Sperm Injection
89772|NCT03485222|Drug|Empagliflozin|6 months
89773|NCT03485222|Drug|Placebos|placebo equivalent for 6 months
89774|NCT03485209|Drug|tisotumab vedotin|Intravenous (IV) infusion [2.0 mg/kg] every 3 weeks
89775|NCT03485196|Other|Microsatellite instability|The microsatellite instability status are definite to three type:MSI-H, MSI-L,and MSS. The gastric cancer patients who received D2 resection were included in 3 groups：MSI-H group， MSI-L group，and MSS group. All patient must be accept fluorouracil(5-FU) based adjuvant chemotherapy. We will analyze the relationship between MSI status and efficacy of 5-FU based adjuvant chemotherapy by observing the survival period of patients with different MSI status.
89776|NCT03485183|Device|White/Pink Noise|White and/or pink noise will be played from 2200 to 0700 using the PicTek® white noise machine.
89777|NCT03485183|Other|Control Group|Standard of care including lights on during the day and off at night, getting the patient out of bed for meals, presence of a large wall clock in the room, updating the whiteboard with current day, consistent reorientation of patient, geriatrician consults as needed, and pain management.
89778|NCT03485170|Diagnostic Test|18F-FDG PET/CT|glucose analogue fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography scan
89784|NCT03485131|Device|Placebo|Placebo/sham stimulation: After 40 seconds of real stimulation of 2 mAmp to simulate the tDCS induced skin sensation, only a small current pulse is delivered every 550 msec (110 mAmp over 15 msec) through the remainder of the 20-minute period
89785|NCT03485118|Drug|HS006+CHOP|"Drug:HS006 HS006 375 mg per square meter (mg/m^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
89786|NCT03485118|Drug|HS006+CHOP|"Drug:HS006 HS006 500 mg per square meter (mg/m^2),administered intravenously(IV) on Day1 of each 21-day cycle for 6 cycles. During cycle 1,HS006 also infused on Day 8 and 15.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 1-5 of each 21-day cycle."
89787|NCT03485118|Drug|Rituximab+CHOP|"Drug:Rituxan Rituxan 375 mg per square metre (mg/m^2), administered by intravenous (IV) on Day 1 of each 21-day cycle.~Drug :Cyclophosphamide Cyclophosphamide 750mg per square metre(mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Doxorubicin Doxorubicin 50mg per square metre( mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug :Vincristine Vincristine 1.4mg(maximum 2.0mg) per square metre (mg/m^2),administered intravenously(IV) on Day 2 of each 21-day cycle.~Drug: Prednisone Prednisone 100 mg administered orally on Days 2-6 of each 21-day cycle."
89788|NCT03485092|Drug|Empagliflozin 10 MG|Empagliflozin 10mg tablets for oral self administration once a day
89789|NCT03485092|Drug|Placebo Oral Tablet|placebo tablets for oral self administration once a day
89790|NCT03485066|Behavioral|Tetris|The video game Tetris is a cognitively challenging task, which requires mental rotation, problem solving and fast visuo-spatial and motor coordination.
89791|NCT03485053|Drug|IOP Injection / MPB-1514|Dilute with 5% Dextrose solution (D5W)
89792|NCT03485027|Drug|XELOX regimen|reintroduction of the XELOX regimen in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
89793|NCT03485027|Drug|FOLFOX regimen|reintroduction of the FOLFOX regimen in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
89794|NCT03485027|Drug|FOLFIRI regimen|reintroduction of the FOLFIRI regimen in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
89795|NCT03485027|Drug|IRI regimen|reintroduction of the irinotecan single agent in the third or later line treatment after the same chemotherapy to which tumor has already proved to be resistant
89796|NCT03485014|Drug|Exparel|EXPAREL 4 mg/kg
89797|NCT03485001|Other|Sham|This group will not receive argon laser medical treatment; instead, they will be only exposed to the slit lamp light.
89798|NCT03485001|Procedure|Argon Laser Treatment|This group will receive argon laser medical treatment to the body and head of pterygium
89799|NCT03484988|Dietary Supplement|Placebo oil|The participants were asked to take corn oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
89800|NCT03484988|Dietary Supplement|Echium oil|The participants were asked to take echium oil capsule twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
89801|NCT03484988|Dietary Supplement|Mixed oil|The participants were asked to take mixed oil(echium oil,camelina oil,safflower oil) twice a day, 4 capsules (500mg/capsules) each time. The intervention period is about 3 months. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
89803|NCT03484962|Biological|Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
89804|NCT03484962|Procedure|cryotherapy|the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
89805|NCT03484949|Diagnostic Test|pre-endoscopic screening risk assessment|pre-endoscopic screening risk assessment
89806|NCT03484936|Procedure|Remote ischemic conditioning|Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.
89807|NCT03484936|Procedure|Sham remote ischemic conditioning|Sham remote ischemic conditioning (Sham RIC) is simulated by the measurement of blood pressure twice daily for 7 days.
89808|NCT03484923|Drug|Spartalizumab|400 mg every 4 weeks intravenously (i.v)
89809|NCT03484923|Drug|LAG525|Taken intravenously (i.v)
89810|NCT03484923|Drug|Capmatinib|Taken orally
89811|NCT03484923|Drug|Canakinumab|Taken subcutaneusly (s.c)
89812|NCT03484923|Drug|Ribociclib|Taken orally
89813|NCT03484910|Other|Exercise therapy|Six-week training program of stationary cycling with / without a real-time visual EMG biofeedback
89814|NCT03484897|Other|P927 - LICHTENA DermAD CREMA CORPO|The study cream was applied once a day (at the morning or at the evening), preferentially always at the same hour, with a mild massage, for an uninterrupted period of 1 month
89815|NCT03484884|Diagnostic Test|Cerenkov luminescence imaging.|Cerenkov luminescence imaging will be obtained from MSKCC patients who are scheduled for routine FDG PET scan or 131I therapy that emit a continuum of ultraviolet and visible light from the decay of certain radionuclides.
89816|NCT03484858|Other|High glycaemic index meal and exercise|
89817|NCT03484858|Other|High glycaemic index meal and rest|
89818|NCT03484858|Other|Low glycaemic index meal and exercise|
89819|NCT03484858|Other|Low glycaemic index meal and rest|
89820|NCT03484845|Drug|Lactoferrin and ferrous fumarate|"Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .~Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .~Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily ."
89821|NCT03484832|Device|Walter Ritter Ethyl Chloride Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
89822|NCT03484832|Other|Placebo Spray|Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
89823|NCT03484832|Other|Placebo Cream|Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
89824|NCT03484832|Drug|EMLA Cream|Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
89825|NCT03484819|Drug|Copanlisib|Given IV
89826|NCT03484819|Drug|Copanlisib Hydrochloride|Given IV
89827|NCT03484819|Biological|Nivolumab|Given IV
89828|NCT03484793|Other|AESOP service system|Investigators develop an electronic reminder in CPOE system which notifies physicians when there appears to be an inappropriate prescription. At the time, a physician saves a typed prescription, our system analyzes the patient's medications, diseases and uses the knowledge base to determine whether a medication is uncommonly prescribed to all diseases in a given prescription. If the system detects the common associations of medications and diseases in a given prescription, it considers an appropriate prescription, and, if not, an actionable reminder is shown onscreen. To the right of each suggested uncommon medication is a reason why the reminder is appearing. Physicians can accept the reminder or ignore the reminder.
89829|NCT03484780|Device|VisONE ADS|VisONE stimulator and leads for delivering continual Asymptomatic Diaphragmatic Stimulation
89830|NCT03484754|Biological|botulinum toxin|injection of botulinum toxina in two different facial sites
89831|NCT03484741|Biological|MSC and PRP|MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.
89832|NCT03484728|Behavioral|placebo manipulation|application of nonactive body cream on forearm
89833|NCT03484715|Behavioral|Physical Activity Intervention|A physical activity programme will be developed by the researcher for each participant. Integral to each physical activity programme will be a walking component (i.e. structured and gradual increases in daily walking time) and sit-to-stand exercises (i.e. a specified number of repeated rises from a chair). The rest of the physical activity programme will be tailored around each participant's specific functional goal and will be based on repeating particular functional activities. This programme will take place on 3 days per week in month 1, 4 days per week in month 2 and 3, and 5 days a week in month 4.
89834|NCT03484702|Drug|JCAR017|JCAR017
89835|NCT03484689|Behavioral|Mindfulness-based cognitive therapy MBCT|8-week mindfulness-based cognitive therapy
89836|NCT03484676|Device|Titinium|custom made plate at one point after 3D virtual simulation and reduction of the complex using Mimics software.
89837|NCT03484663|Device|central venous catheter (small catheter drainage)|Insertion central venous catheter ( small catheter drainage ) after uniport vats to decrease hospital stay and to easy drainage after procedure
89838|NCT03484650|Drug|Lidocaine Hydrochloride|Lidocaine bolus to be given 1 hour pre-operatively
89839|NCT03484650|Drug|Lidocaine Hydrochloride|Lidocaine infusion will be started after the bolus and be continued for 24 hours post-operatively
89840|NCT03484650|Other|Placebo|Control patients will receive a placebo bolus and infusion of saline to match the experimental arm.
89841|NCT03484637|Other|Lifestyle-medicine intervention|
89842|NCT03484624|Device|Treadmill walking|All subjects underwent measurements of muscle fatigue and respiratory metabolism energy during treadmill walking at a comfortable speed for 6 minutes and measured by three conditions (①NoGEMS-free gait, ②Torque off with GEMS, and ③Torque on with GEMS)
89843|NCT03484611|Drug|GnRH antagonist|0,25mg s.c, cetrotide, serono laboratories, Aubonne Switzerland) is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
89844|NCT03484611|Drug|Gonadotropins|started on day 2 of the menstrual cycle until the day of HCG administration(choriomon,IBSA10000IU)with starting dose 300IU to 450IU
89845|NCT03484611|Drug|Human chorionic gonadotropin|10000 IU is given to induce final oocytes maturation when at least 2 follicles reached 14 mm or more
89846|NCT03484611|Procedure|Embryo transfer|0ne to three grade 1 or 2 embryos were transferred on day 3 after oocyte retrieval. Embryo transfer was performed with a Wallace catheter (Smith Medical International Ltd, Hythe, Kent, UK)
89847|NCT03484611|Drug|Progesterone|vaginal prontogest 400 mg twice daily
89848|NCT03484598|Device|SPEAC System|A lightweight, non-invasive monitor that is placed on the belly of the biceps muscles to analyze surface electromyography (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures. It provides an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
89849|NCT03484585|Drug|Rogaratinib (BAY1163877)|Single dose, intake orally, 200 mg
90557|NCT03478774|Drug|oxygen 0.25l/min|0.25l/min of oxygen via an endotracheal tube
89850|NCT03484572|Diagnostic Test|Anthropometric measures|Weight (kg),Height (cm)Body mass index(kg/m²),Mid-upper arm-circumference(cm), tricipital skinfold (cm)
89851|NCT03484546|Procedure|laparoscopic endometrioma cyst excision|laparoscopic resection of ovarian endometrioma
89852|NCT03484533|Behavioral|HIV self-test kit|We will conduct a randomized trial to evaluate whether provision of oral HIV self-test kits to HIV-positive pregnant women overcomes their male partners' reluctance to be tested in PMTCT clinics. Pregnant women who are randomized to the HIVST arm will be trained in the use and interpretation of HIVST, and given two oral fluid-based HIVST kits to use with or give to their partners, along with information about HIV testing and prevention and care services. We will offer men confirmatory testing regardless of their HIV test result through HIVST, counseling, and if negative, PrEP and if positive, ART.
89853|NCT03484533|Behavioral|Standard of Care|In the standard of care arm, we will give women invitation letters to deliver to their male partners to come to the ANC clinic for fast-tracked HIV testing. We will offer men counseling and if negative, PrEP and if positive, ART.
89854|NCT03484520|Drug|Venetoclax|tablet, oral
89855|NCT03484520|Drug|Dinaciclib|intravenous
89856|NCT03484507|Drug|Chlorhexidine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
89857|NCT03484507|Drug|Povidone-Iodine|1 drop half-hourly for days 1-2, then hourly for days 3-6, then 8 times daily until the 4-week visit
89858|NCT03484507|Drug|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
89859|NCT03484507|Drug|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-9, then 2 times daily for weeks 10-11
89860|NCT03484507|Drug|Prednisolone Sodium Phosphate|1 drop 4 times daily for weeks 6-9, then 2 times daily for weeks 10-11
89861|NCT03484507|Drug|Hydroxypropyl Methylcellulose|1 drop 4 times daily for weeks 4-5
89862|NCT03484494|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
89863|NCT03484481|Dietary Supplement|Oral Nutritional Support; Nutrena|Patients in group 1 and 3 take ONS 200 ml/day twice a day at home. Patients in group 2 and 3 received IDPN administrations. ]. Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
89864|NCT03484481|Dietary Supplement|Intradialytic Parenteral Nutrition; Kabiven central|Patients in group 2 and 3 received IDPN administrations Its infusion was started 30 minutes after initiation of HD via the venous port of the bubble trap on the HD tubing and continued throughout the entire HD procedure at a rate of 150 ml/h for 30 min and consisted of 300 ml for 3 hour.
89865|NCT03484468|Device|anterior segment Ocular Coherence Tomography|anterior segment OCT (Ocular Coherence Tomography) a device shows imaging of anterior segment of the eye and able to show corneal layers and measures its thickness.
89866|NCT03484455|Device|Hypothermic machine perfusion|LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
89867|NCT03484455|Device|Static cold storage|Static cold storage (standard of care)
89868|NCT03484429|Device|Peripheral nerve stimulation|Up to 60 days of peripheral nerve stimulation
89869|NCT03484429|Other|Standard Medical Therapy|Medications, physical therapy, or other pain treatments
89870|NCT03484416|Drug|Calcium Carbonate 1500 Mg with Vitamin D|Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
89871|NCT03484403|Other|Lumbar back brace|A brace that supports the lumbar region of the spine.
89872|NCT03484403|Behavioral|Back school|Back school consists of patient education physical therapy exercise instruction.
89873|NCT03484390|Behavioral|Mindfulness-based stress reduction|
89874|NCT03484390|Behavioral|Wellness Group|
89875|NCT03484377|Device|Anodal tDCS|The experimental condition will use a constant current of 2mA for 20 minutes, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively.
89876|NCT03484377|Device|Sham tDCS|The anodal electrode will be placed over the supreorbital ridge. The current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The session will last for 20 minutes.
89877|NCT03484364|Behavioral|ENACTS|Peer-facilitated, self-care BP education delivered weekly for 8 weeks emphasizing healthy diet, traditional NHPI foods, adherence to medication, and encouragement to increase physical activity and stop smoking, with text messaging to boost adherence. $30 of groceries for 8 weeks.
89878|NCT03484351|Other|Fall Monty Activity Programme (FallMAP)|The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing & falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
89879|NCT03484338|Behavioral|Accelerated Resolution Therapy|ART is an evidence-based therapy for the treatment of depressive symptoms and trauma and stress-related disorders that includes the core components of trauma-focused therapy including imaging rescripting, voluntary image replacement, guided visualization with use of eye movements, desensitization and processing of distressing memories, and in-vitro exposure to future feared triggers
89880|NCT03484299|Procedure|Irreversible Electroporation (IRE)|Non-thermal ablation of tumor
89881|NCT03484299|Drug|Gemcitabine|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
89882|NCT03484299|Drug|FOLFIRINOX|25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
89917|NCT03484039|Behavioral|Memory Improvement|Some subjects will be enrolled in a memory improvement course.
89918|NCT03484039|Behavioral|Stress Management|Some subjects will be enrolled in a stress management course.
89883|NCT03484286|Device|OPTILOGG|"OPTILOGG is a CE marked class 1m medical device. It consists of a tablet computer and a wirelessly connected weight scale. The system will have some patient specific information regarding the flexible (loop-) diuretics scheme.~The patient will be asked to step on the weight scale daily, and will be shown to some brief information on how to live better with HF, as well as the recommended dose of diuretics that specific day. Every five days the patient will answer three questions about his/her symptoms, namely shortness of breath, fatigue and peripheral edema. The system also contains information that the patient can study at his/her leisure. If the system detects a deterioration in HF status, the patient is encouraged to contact his/her health care provider via telephone."
89884|NCT03484286|Other|Standard care|Patients in the control group will be subject to standard heart failure care.
89885|NCT03484273|Device|LifeWrap Compression Garment|Non-Pneumatic Anti-Shock (NASG) compression garment comprised of neoprene with velcro closures.
89886|NCT03484260|Drug|Testosterone Product|Men used testosterone product following prescription
89887|NCT03484247|Other|Infraclavicular brachial plexus block|Infraclavicular block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration, via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
89888|NCT03484247|Other|axillary brachial plexus block|Axillary nerve block will be performed with ultrasound guidance and peripheric nerve stimulator. Local anesthetic will be administered after aspiration via peripheric nerve needle according to mentioned technique ( https://www.nysora.com/)
89889|NCT03484234|Device|Ultimaster stent|Percutaneous coronary intervention with Ultimaster stent for long lesion
89890|NCT03484234|Device|Xience alpine stent|Percutaneous coronary intervention with Xience alpine stent for long lesion
89891|NCT03484221|Drug|FOLFOXIRI|IRINOTECAN 150 mg/m^2 IV over 1-h, day 1 + OXALIPLATIN 85 mg/m^2 IV over 2-h, day 1 + L-LEUCOVORIN 200 mg/m^2 IV over 2-h, day 1 + 5-FLUOROURACIL 2800 mg/m^2 IV 48-h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months).
89892|NCT03484221|Radiation|Short-Course Radiation Therapy(5Gy*5)|Patients received a short-course radiation therapy(5Gy*5) after 4 cycles of FOLFOXIRI.
89893|NCT03484221|Drug|XELOX|OXALIPLATIN 130 mg/m^2 IV over 2-h, day 1 Capecitabine 1000 mg/m^2 twice daily days 1-14 every 3 weeks for 4 cycles.
89894|NCT03484208|Other|osteoporotic fracture liaison service|a specific nurse calls patient and propose them to follow the osteoporotic fracture liaison service
89895|NCT03484195|Drug|FOLFOXIRI|Irinotecan 150 mg/m^2 IV over 1h, day 1 + Oxaliplatin 85 mg/m^2 IV over 2h, day 1 + L-Leucovorin 200 mg/m^2 IV over 2h, day 1 + 5-Fluorouracil 2800 mg/m^2 IV 48h continuous infusion, starting on day 1 administered every two weeks for 4 cycles (2 months)
89896|NCT03484182|Behavioral|Web-based Home Exercise Program|Home exercises that are guided by a web-based program
89897|NCT03484182|Behavioral|Standard Home Exercise Program|Standard paper-based home exercise program
89898|NCT03484169|Other|intervention group|"The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;"
89899|NCT03484156|Device|Installation of 3PEGASE Sensor|Volunteers will be equipped with the 3-PEGASE solution to monitor clinical indicators at home : By assessing older person's autonomy at home and detecting early infra-clinical indicators, the solution could provide relevant clinical parameters to the caregivers and healthcare professionals in order to support the patient's follow-up, and support the detection of preliminary signs of functional loss
89900|NCT03484143|Device|Active Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
89901|NCT03484143|Device|Sham Neuro RX Gamma device|Twenty minute treatment session, 6 days a week for 24 weeks
89902|NCT03484130|Dietary Supplement|Sodium loaded diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The diet will consist of >180 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.
89903|NCT03484130|Dietary Supplement|Restricted sodium diet|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium restricted diet. The diet will consist of <40 mmol/day of sodium, ~50 mmol/day of potassium, and 600mg/d of calcium.
89904|NCT03484130|Drug|Angiotensin II|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. The dynamic testing will include a one hour infusion of angiotensin II (3 ng/kg/min) which will permit assessments of angiotensin II stimulated blood pressure, renal blood flow, and adrenal aldosterone secretion.
89905|NCT03484130|Drug|Para-Aminohippurate|At baseline, and annually, participants will undergo aldosterone dynamic testing after ~5 days of a sodium loaded diet. This dynamic testing will include assessment of renal blood flow measured via para-aminohippurate clearance.
89906|NCT03484117|Behavioral|Community Health Worker|Participants will receive 5 one-on-one sessions with a CHW over 24 weeks.
89907|NCT03484104|Diagnostic Test|Measurement of tissue oxygenation index (TOI)|TOI and Vmca measurement during cardiac surgery with hypothermic circulatory arrest
89908|NCT03484091|Drug|Hyruan-One|single dose intra-articular injection
89909|NCT03484091|Drug|Hylan G-F 20|single dose intra-articular injection
89910|NCT03484091|Drug|Normal saline|single dose intra-articular injection
89911|NCT03484078|Device|Vibration Platform|The vibration platform will emit a mild vibration when the participant stands on it 10 minutes per day for 6 months.
89912|NCT03484078|Device|Placebo Platform|The placebo platform will not vibrate when the participant stands on it 10 minutes per day for 6 months.
89913|NCT03484065|Other|Questionnaire quality of life|
89914|NCT03484052|Other|Jugular ultrasound|Performing a jugular ultrasound by 2 operators before and after transfusion
89915|NCT03484039|Behavioral|Medication Adherence|Some subjects will be enrolled in a medication adherence course.
89916|NCT03484039|Behavioral|Seizure Documentation|Some subjects will be enrolled in a seizure documentation course.
89919|NCT03484026|Dietary Supplement|BioFe|BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
89920|NCT03484000|Behavioral|Online Mindfulness Based Cancer Recovery (MBCR)|MBCR is a group behavioral treatment that trains participants in mindfulness techniques through meditation and gentle mindful movement
89921|NCT03483987|Drug|Sof+Ledi+R arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
89922|NCT03483987|Drug|Sof+Ledi+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus ledipasvir 90 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
89923|NCT03483987|Drug|Sof+Dacla+R arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
89924|NCT03483987|Drug|Sof+Dacla+R+Peg-IFN arm|Sofosbuvir 400 mg once daily plus daclatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
89925|NCT03483987|Drug|Sof+Velpa+R arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses
89926|NCT03483987|Drug|Sof+Velpa+R+Peg-IFN arm|Fixed dose combination of sofosbuvir 400 mg plus velpatasvir 100 mg once daily plus ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight =>75 kg) daily in two divided doses plus pegylated interferon alpha 2b @ 1.5 microgram/kg subcutaneously once in a week
89927|NCT03483974|Diagnostic Test|hyperspectral imaging|using hyperspectral detector for evaluation excreta pattern
89928|NCT03483961|Biological|CHIKV VLP/unadjuvanted|Vaccine consists of virus-like particles of chikungunya virus antigens
89929|NCT03483961|Biological|CHIKV VLP/adjuvanted|Adjuvanted formulation includes Alhydrogel
89930|NCT03483961|Biological|Placebo|Placebo is vaccine diluent alone
89931|NCT03483948|Drug|HMPL-523|HMPL-523 tablet
89932|NCT03483948|Drug|Azacitidine|Azacitidine Injection
89933|NCT03483935|Other|Microwave treatment|Microwave energy delivered using the microwave instrument, SWIFT, manufactured by Emblation and CE marked for dermatology applications.
89934|NCT03483922|Diagnostic Test|ctDNA methylation in and it's Correlation wth Development and prediction of HCC|Blood sample from patients with HCC, healthy individuals and individuals with hepatitis B will be collected, and DNA will extracted from PBMC and circulated tumor DNA will be subjected to bisulfite conversion. DNA from PBMC DNA will be analyzed with primers developed for the AHNAK-STAP1 genes. Plasma samples will be subjected to EZ direct DNA extraction and bisulfite conversion kit and will be amplified with primers developed to amplify the target regions. DNA will be used for the subsequent PCR amplification with specific primer to generate PCR amplicon for sequencing using a double PCR procedure. The product of PCR reaction will be subjected to indexed MiSeq Next-Generation sequencing that will allow us quantify DNA methylation level.
89935|NCT03483909|Device|left IFG iTBS|15 daily sessions of intermittent theta burst stimulation at 80% resting motor threshold, total duration of 190 s, localization using EEG 10/20 system at F3/F4
89936|NCT03483909|Device|right IPL cTBS|15 daily sessions of continuous theta burst stimulation at 100% resting motor threshold, total duration of 45 s, localization using EEG 10/20 system at F3/F4
89937|NCT03483909|Device|Placebo|rTMS with a placebo coil that looks identical and makes identical noises for 180 s, localization over left IPL
89938|NCT03483896|Other|Daylight Intervention|Staff increased the daylight exposure of participants by taking them to the perimeter zone of a daylit room from 8:00 to 10:00 AM for socialization over a period of 12 weeks. The perimeter zone was defined to be the region of the room within 3 meters from windows. The intervention was administered each day (7 days / week) over the duration of the study.
89939|NCT03483883|Drug|Avelumab|Avelumab IV 10 mg/kg every 2 weeks
89940|NCT03483883|Drug|Gemcitabine|Dose Level 1: Gemcitabine 1250 mg/m2 IV every 2 weeks Dose Level 2: 1500 mg/m2 IV every 2 weeks
89941|NCT03483870|Drug|Morphine Sulfate|200 ug morphine sulphate will be injected intrathecally
89942|NCT03483870|Drug|Placebo|2 mL of normal saline 0.9% IV injection
89943|NCT03483870|Drug|Granisetron|2 mL of 2 mg granisetron IV injection
89944|NCT03483857|Behavioral|Peer Navigation|Utilizing Peer Navigators for HIV-Positive MSM for increase in uptake along the continuum.
89945|NCT03483844|Diagnostic Test|GE CT 750 HD|Low-dose dual-energy CT imaging
89946|NCT03483831|Behavioral|Intervention group|Refillable water dispensers will be placed in each class of the intervention group to facilitate water access: every class will receive 5 bottles (18 Liters/each) per week for a total of 5 months. Every student will receive a re-usable water bottle.
89947|NCT03483818|Procedure|Assessment & Treatment of HCV infection with oral antivirals|This is a cluster randomised trial of directly observed anti HCV therapy versus conventional care in HCV positive patients, who are in a pharmacist delivered OST program, where the patients attending an individual pharmacist are the cluster. Pharmacies participating in the trial will be allocated to conventional care pathway or the pharmacist-led pathway.
89948|NCT03483805|Dietary Supplement|Protalsafe|mix of prebiotic, probiotic and plant extract in powder form, to be diluted in water
89949|NCT03483805|Dietary Supplement|Placebo|maize maltodextrin in powder form, to be diluted in water
89950|NCT03483792|Biological|Plasma dosage|4 x 7 ml of blood punction at each control visit of the three trimesters of pregnancy
89951|NCT03483792|Genetic|placental biopsy|Immediately following delivery (<12h postpartum), placental biopsies (Collection of 4 placental fragments)
89952|NCT03483779|Drug|Ginkgo biloba pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
89953|NCT03483779|Drug|placebo pills|Each N-of-1 trial will consist of 6 treatment periods, of which 2 treatment periods are in one group, including 8 weeks of placebo treatment and 8 weeks of ginkgo biloba pills.
90012|NCT03483376|Procedure|Dental prophylaxis|Determining the effectiveness of dental prophylaxis alone in eliminating dental black stain.
89954|NCT03483766|Device|Robotic Functional Rehabilitation system|The tailored-made EMG driven soft-robotic hand prosthesis for tetraplegia individuals may help to preserve the residual function and to enhance the functional recovery.
89955|NCT03483753|Drug|Vasopressin|"Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.~Continuous infusion of the drug at doses ranging from 0.01 U / min to 0.06 U / min"
89956|NCT03483753|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
89957|NCT03483740|Behavioral|CRGT|Cognitive remediation group therapy (CRGT) will be comprised of 1/3 brain training exercises on tablets using PositScience software by BrainHQ and 2/3 mindfulness-based stress reduction (MBSR) involving various activities such as meditation, breathing exercises, etc. Intervention will comprise of 8 weekly 3-hour sessions.
89958|NCT03483740|Behavioral|HIV group therapy|These groups use a model of mutual aid to encourage peer-based discussion on the effects of living with HIV. Topics are determined by the group; facilitators ensure that safety is maintained throughout and make connections between participants as appropriate. Intervension will comprise of 8 weekly 3-hour sessions.
89959|NCT03483727|Device|SIMMAXMARCHERYAN|Digital cognitive aid during the management of simulated combat wounded.
89960|NCT03483714|Procedure|Spinal Manipulation|HVLA (High Velocity Low Amplitude) spinal manipulation directed at the lumbar spine and sacroiliac (SI) joints
89961|NCT03483701|Behavioral|Cognitive Remediation Therapy|The intervention of interest for participants in the experimental group is the addition of up to 5 hours per week of computerized cognitive exercises. Cognitive training can be done at home on a computer. For participants without access to a computer, a laptop/tablet computer with the necessary software will be provided for the duration of training. Participants will be able to complete the cognitive exercises on their own schedule, with participation verified by the software. Participants will also receive 1 hour/week of individual coaching to discuss cognitive remediation progress, e.g. to learn about different cognitive domains and develop ways to generalize their cognitive remediation gains.
89962|NCT03483688|Biological|CD19-directed CAR-T cells|CD19-directed CAR-T cells single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
89963|NCT03483675|Biological|Immunosuppressive Therapy|Discontinued IST
89964|NCT03483675|Biological|Immunosuppressive Therapy|Continued IST
89965|NCT03483675|Other|Survey Administration|Ancillary studies
89966|NCT03483662|Behavioral|Multicomponent Intervention|The core component of the intervention is protocol-based treatment using the SPRINT BP management algorithm. The following implementation strategies are adaptable components that will be modified to fit specific federally-qualified health center (FQHC) settings: dissemination of SPRINT study findings among provider-teams, patients, and administrators, team-based collaborative care, BP audit and feedback, home BP monitoring, and health coaching on antihypertensive medication adherence and lifestyle modification.
89967|NCT03483662|Behavioral|Enhanced Usual Care|The investigators will provide an up-to-date clinical guideline for hypertension management to providers. A webinar education session on the new American College of Cardiology (ACC)/American Heart Association (AHA) hypertension guideline and findings from the SPRINT trial will be conducted. Otherwise, the investigators will not conduct any active intervention and all control clinics will follow their routine clinic practice in the management of hypertensive patients
89968|NCT03483649|Drug|HLX04|HLX04: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
89969|NCT03483649|Drug|US-Avastin®|US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
89970|NCT03483649|Drug|EU-Avastin®|EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
89971|NCT03483649|Drug|CN-Avastin®|CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.
89972|NCT03483636|Drug|Lemborexant|Film-coated oral tablet
89973|NCT03483636|Drug|Alcohol|0.6 g/kg (female) or 0.7 g/kg (male) of 40% ethanol (volume per volume) vodka diluted in a low-calorie beverage (e.g., cranberry beverage), for a total volume of 300 mL (approximately 150 mL per aliquot).
89974|NCT03483636|Drug|Placebo|Film-coated oral tablet
89975|NCT03483623|Other|NATO WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
89976|NCT03483623|Other|NATO FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
89977|NCT03483623|Other|RAVEN WELP combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
90177|NCT03482037|Drug|Rec 0/0438 1 mg or 2 mg|Each vial content will be administered via the catheter used for the self-catheterization
89978|NCT03483623|Other|RAVEN FIS combination|Interface pressure will be measured using the XSensor X3 Pressure Mapping System. Transducers and probes will be placed near both scapula. Measures will be obtained in upright (baseline) and supine positions on 4 randomly assigned litter mattress combinations. Constant TCPO2 and Doppler measures, as well as peak pressures and total body surface area exposed to skin will be measured for the occiput, sacrum, both scapula, buttocks and heel areas. It will take about 20 minutes for each combination. The session is complete after all measures have been obtain for all litter/mattress combinations.
89979|NCT03483610|Behavioral|Provider Referral|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. At the end of the study they will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
89980|NCT03483610|Behavioral|Text Messaging|Participants will be asked if they are up-to-date on their cervical cancer screening. If not they will be referred to a provider. They will also receive a total of 3 text messages at 30-day intervals encouraging follow-up for cervical cancer screening. They will receive a 10 minute follow up telephone survey to collect data screening status and views on cervical cancer screening.
89981|NCT03483597|Other|TSQM-II|Treatment Satisfaction Questionnaire for Medication (TSQM Version II) will be used in all groups
89982|NCT03483558|Other|Control|A standardized diet without any vegetables was provided.
89983|NCT03483558|Other|Spinach|A standardized diet with 200g spinach was provided.
89984|NCT03483558|Other|Celery|A standardized diet with 200g celery was provided.
89985|NCT03483558|Other|Onion|A standardized diet with 200g onion was provided.
89986|NCT03483558|Other|Mixed Vegetables|A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
89987|NCT03483545|Combination Product|Follitropin delta and HP-hMG|Follitropin delta dose will be determined by AMG and weight in Kg. Highly purified human menopausal gonadotrophin will be determined by follitropin delta dose and body weight in Kg
89988|NCT03483532|Dietary Supplement|Lit Control pH Up|dietary supplement based on citrate, saponins, magnesium, zinc and vitamin A
89989|NCT03483532|Dietary Supplement|dry cocoa extract|(Theobroma cacao, fruit), 2 capsules of 750 mg per individual, dosed at a rate of one during the breakfast and another during dinner.
89990|NCT03483519|Other|Rehabilitation|Patients randomized to the Experimental Group will undergo a 6 Week Exercise Program plus Standard of Care
89991|NCT03483519|Other|Standard of Care|Patients randomized to the Active Comparator Group will not undergo an exercise program, patients will receive the standard of care used at The Ottawa Hospital for hip and knee surgeries. Standard of care protocol will be explained by each individual surgeon.
89992|NCT03483506|Drug|BI 1467335|Film-coated tablet
89993|NCT03483506|Drug|BI 1467335 (C-14) intravenous solution|Intravenous solution
89994|NCT03483493|Behavioral|Exposure Response Prevention for tics|The intervention consists of evidence-based interventions adapted from previously published treatment manuals on Exposure and Response Prevention (ERP) and established behavioural intervention for tics protocols. Each of the 10 modules includes age-appropriate texts, animations and exercises. Prticipants are instructed to practice suppressing their tics, this is known as 'response prevention'. Then, with the help of their parent/carer, the participant is instructed to provoke premonitory urges (the urge to tic often felt before the tic is expressed) and try to supress the need to express/demonstrate the tic, this known as 'exposure'.
89995|NCT03483493|Other|Psychoeducation for tics|The comparator intervention reviews the definition of tics, natural history, common presentations, prevalence, aetiology, risks and protective factors and strategies for describing tics to other people etc. Problem-solving and development of expertise in tic disorders is emphasised. The intervention includes strategies for promoting positive behaviours which will be rewarded by a parent as a parallel element to the tic control practice in the behavioural therapy arm. There is no information on tic control within the management package.
89996|NCT03483480|Procedure|NPWT for Pilonidal Surgery|After excision of pilonidal sinus Non powered-NPWT will be applied to the area
89997|NCT03483480|Procedure|Excision of Pilonidal sinus with normal dressing|After excision of pilonidal sinus normal dressing will be applied to the area of surgery
89998|NCT03483467|Other|Omnigen|For those randomised onto the investigational arm, a dual layer of the Omnigen product will be applied at baseline and at every fortnightly trial visit until healing or the end of the 12 week period whichever occurs first, according to the standard study procedure.
89999|NCT03483467|Other|Dummy Packaging|For those randomised into the control arm, dummy packaging will be opened at the time of application of standard of care, to ensure the same experience is received to those on the experiential arm.
90000|NCT03483454|Other|Exercise class|Same as above.
90001|NCT03483454|Other|Home exercise|Same as above.
90002|NCT03483441|Other|Placebo pill|An inert placebo pill will be taken for several days prior to PDT
90003|NCT03483441|Dietary Supplement|Vitamin D|10,000 units of cholecalciferol will be taken for several days prior to PDT
90004|NCT03483441|Drug|PDT|Levulan (5-aminolevulinic acid) is applied to tumors for 4 hr, then illuminated with blue light
90005|NCT03483428|Behavioral|Interventionist training and supervision|"Online and in-person training and weekly supervision with licensed clinical social worker while delivering the Family Check-Up to 5 families."
90006|NCT03483428|Behavioral|Behavioral parent training|"Up to 6 sessions of the Family Check-Up program, involving discussions, assessments, feedback, and skills training with a parent coach."
90007|NCT03483415|Drug|Morphine Sulfate|Intravenous morphine infusion with PCA: Solution was concentration of 0.5 mg/mL. Loading dose of 1 mg, 0.5 mg of bolus dose and 20 min of locking time.
90008|NCT03483415|Drug|Bupivacaine|Ultrasound guided Long thoracic nerve blockage with 5 ml % 0.25 bupivacaine
90009|NCT03483402|Procedure|Micropulse laser trabeculoplasty|Micropulse laser trabeculoplasty is performed using the Iridex IQ 532 laser system (Iridex Corporation, 1212 Terra Bella Avenue, Mountain View, CA, USA) and 532 nm (green) wavelength MLT is applied with confluent applications to pigmented trabecular meshwork over 360 degrees using a 300 µm spot size, 300 ms duration, 1000 mW power and 15% duty cycle.
90010|NCT03483389|Drug|Alcohol, Ethyl|Randomized within-subjects design
90011|NCT03483389|Other|Alcohol, Ethyl - placebo|Randomized within-subjects design
90013|NCT03483376|Device|Antimicrobial photodynamic therapy (aPDT)|Establishing the effectiveness of dental prophylaxis combined with antimicrobial photodynamic therapy using blue light and curcumin as the photosensitizing agent in eliminating dental black stain.
90014|NCT03483363|Drug|topical irrigation with the antibiotic bacitracin|Fractures will be irrigated with Bacitracin topical antibiotic (50,000 units) prior to closure.
90015|NCT03483363|Drug|topical irrigation with sterile normal saline (NS)|Fractures will be irrigated with sterile normal saline prior to closure. All groups with receive standard parenteral (IV) prophylactic antibiotic.
90016|NCT03483363|Drug|intravenous (IV) prophylactic antibiotic|All groups with receive standard parenteral (IV) prophylactic antibiotic.
90017|NCT03483350|Drug|Granisetron|Ampoule
90018|NCT03483350|Drug|Midazolam|Ampoule
90019|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
90020|NCT03483337|Other|MRI examinations|Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
90021|NCT03483324|Biological|Unmanipulated Umbilical Cord Blood (UCB)|Human leukocyte antigen (HLA) matched umbilical cord blood
90022|NCT03483324|Biological|AB-110|Expanded cord blood stem cells and engineered human endothelial cells
90023|NCT03483311|Other|skin biopsy before and after NB-UVB phototherapy|skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1
90024|NCT03483298|Other|ICSI|The cryopreserved pre-TESA ejaculate and TESA specimen will be thawed on the day of oocyte retrieval per protocol for ICSI
90025|NCT03483285|Device|airtraq|airtraq videolaryngoscope
90026|NCT03483285|Device|storz|storz videolaryngoscope
90027|NCT03483259|Drug|Sulfatinib T capsule|Sulfatinib T capsules were produced by Hutchison Whampoa Pharmaceutical (Suzhou) Co., Ltd. production.
90028|NCT03483259|Drug|Sulfatinib R capsule|Sulfatinib R capsules were produced by Beijing Yiling Bioengineering Technology Co., Ltd.
90029|NCT03483246|Drug|Fecal Microbiota Transplantation (FMT)|"The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum."
90030|NCT03483246|Drug|Sham-transplantation Placebo|"The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum."
90031|NCT03483233|Other|fMRI and EEG study|fMRI and EEG study
90032|NCT03483220|Diagnostic Test|MRI brain|"Addiction severity index 4th version for assessment of addiction pattern.~UPPS-P Impulsive Behavior Scale is a 59-item inventory designed to measure five distinct personality pathways to impulsive behavior: Negative Urgency, Lack of Perseverance, Lack of Premeditation, Sensation Seeking, and Positive Urgency.~Iowa gambling task computerized version: The task involved drawing one card per trial from one of four decks (labeled as A, B, C, and D). Each deck contained 40 cards in a ﬁxed sequence which is unknown to participants at the start of the task. Next, participants are asked to select cards from the four decks to gain as much money as possible. The task ends when the 100th card is drawn, although subjects do not know this in advance.~MRI brain examination:~Voxel based morphometry through analysis of 3D T1 weighted sequence in order to assess total intracranial volume.~Resting state functional MRI."
90033|NCT03483207|Drug|Warfarin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
90034|NCT03483207|Procedure|MVT with failure of anticoagulation therapy|"patients managed conservatively with anticoagulation will be monitored for the progress of response of therapy , failure to improve or worsening in condition,will be an urgent indication for surgical intervention with resection of the infarcted bowel segment .If there is suspicion about the viability of remaining bowel intraoperative or later on based on clinical evidences,then second look laparotomy will be performed .The mortality and all complications associated with surgery will be recorded."
90035|NCT03483207|Drug|Heparin|Patients with confirmed diagnosis of acute MVT but having no signs of bowel infarction will be treated conservatively with anticoagulation (heparin &warfarin) In addition to usual care intravenous low molecular weight heparin will be started (IV bolus of 5000 IU followed by 1000 IU/hour with infusion pump) and the dose is adjusted to maintain APTT levels at 2-2.5 times the normal. followed by oral anticoagulation (warfarin) for 6 months or for life in the presence of coagulation abnormality. patients will be critically monitored for the progress of response of therapy .
90036|NCT03483194|Device|Virtual Reality|Bliss is a 3D Interactive application designed to meet the needs of escape and relaxation of people in isolation and / or stress and / or during painful care here osteo-medullary biopsy
90037|NCT03483194|Drug|Kalinox|Usually take care of by a gas mixture composed of 50% Nitrous Oxide, 50% Oxygen for the medical procedure (osteo-medullary biopsy)
90038|NCT03483181|Drug|Xarelto (rivaroxaban)|An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.
90039|NCT03483181|Drug|Lovenox (enoxaparin)|An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
90040|NCT03483168|Behavioral|Culturally sensitive pain education|The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.
90041|NCT03483168|Behavioral|Standard pain education program|"For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators."
90042|NCT03483142|Drug|Misoprostol|( 25 patient): who will receive 400 microgram (tablet 200mcg X 2) misoprostol rectally one hour before operation
90043|NCT03483142|Drug|Placebos|( 25 patient): who will receive placebo . two rectal placebo tablet of the same size and shape as the misoprostol
90044|NCT03483129|Behavioral|Consultation|15 minute, one to one consultation with a trained practice nurse at a GP surgery. Participants will have the opportunity to discuss pre-diabetes, the risks of developing diabetes and the steps that can be taken to improve lifestyle behaviors and reduce the risk of diabetes development.
90045|NCT03483116|Biological|RV3-BB|Oral administration
90046|NCT03483116|Biological|Placebo|Oral administration
90047|NCT03483103|Biological|lisocabtagene maraleucel|lisocabtagene maraleucel
90048|NCT03483090|Dietary Supplement|Swisse High Strength Deep Sea Krill Oil|Krill oil is sourced sustainably from the Southern Ocean and is extracted from the Antarctic Krill, the most abundant marine biomass. Krill oil is a source of omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) for the maintenance of good health. Omega-3, EPA and DHA are also found in phospholipid form which are much easier absorbed than triglyceride form of omega-3 which is found in fish oil. Omega-3 supports cardiovascular health, brain health and eye health. Preliminary research suggests krill oil can provide temporary relief from symptoms of mild arthritis, help reduce joint inflammation and increase joint mobility.
90049|NCT03483090|Other|Placebo|No therapeutic effect
90050|NCT03483077|Drug|BI 730460|tablets
90051|NCT03483077|Drug|Placebo|tablets
90052|NCT03483064|Other|Interferential current|interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
90053|NCT03483051|Drug|Potassium Nitrate|Potassium nitrate capsules will consist of potassium nitrate (KNO3-) crystals [610 mg, corresponding to 6.03 mmoles of NO3-] with 190mg of lactose monohydrate, spray dried, NF. The dose for this trial will be 18 mmoles of NO3-per day, given as one capsule (6 mmoles) three times a day.
90054|NCT03483051|Drug|Potassium Chloride|Potassium chloride capsules will consist of potassium chloride (KCl), granular, USP (450mg) plus lactose monohydrate, spray dried, NF (300mg). The dose for this trial will be 18 mmoles of KCl per day, given as one capsule (6 mmoles) three times a day.
90055|NCT03483038|Drug|Liposomal Irinotecan|Subjects will receive 60 mg/m2 intravenously on Day 1 of each 14 day cycle.
90056|NCT03483038|Drug|FOLFOX regimen|Subjects will receive FOLFOX (oxaliplatin 60 mg/m2 IV, leucovorin 400 mg/m2 IV, and 5-fluorouracil 2400 mg/m2 IV) on Day 1 of each 14 day cycle.
90057|NCT03483025|Other|Skin Testing of Hair cleansing products|6 different commercially available shampoos
90058|NCT03483012|Drug|Atezolizumab|Atezolizumab is a protein that affects your immune system by blocking the PD-L1 pathway
90059|NCT03483012|Procedure|Stereotactic radiosurgery (SRS)|Stereotactic radiosurgery (SRS) is a standard procedure used to treat patients with cancer in the brain. SRS uses many precisely focused radiation beams to treat tumors
90060|NCT03482999|Device|TissuGlu Surgical Adhesive|
90061|NCT03482986|Behavioral|Dietary habits plan|Patients will be given a personalized plan regarding their diet.
90062|NCT03482973|Drug|Bupivacaine Group|20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).
90063|NCT03482973|Other|Placebo|20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
90064|NCT03482960|Drug|Hyperpolarized Xenon gas|"Hyperpolarized Xenon gas~Hyperpolarized mixture (750ml HP 129Xe and 250ml nitrogen)~Administration: By mouthpiece attached to a single use Tedlar bag.~Dosage: 750 mL of the 129Xe mixture up to, but not exceeding, four doses of the 129Xe.~Frequency: 10-minute interval between doses."
90065|NCT03482960|Drug|PFP|"Inhaled PFP, a gaseous contrast agent (79% PFP; 21% O2, pre-mixed, medical grade gas)~Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.~Dosage: Two controlled breaths of the contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.~Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred."
90066|NCT03482947|Drug|ultrasonography-guided TAP block|(0.3 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine).
90067|NCT03482947|Drug|Caudal epidural block|(1 mL/kg of bupivacaine 0.25% plus 1 μ/kg dexmedetomidine)
90068|NCT03482934|Device|sphygmomanometer|device used for measurement of brachial blood pressure
90069|NCT03482934|Device|mobilogragh|device used for measurement of central blood pressure
90070|NCT03482934|Diagnostic Test|ECG|Electrocardiogram
90071|NCT03482934|Diagnostic Test|Echocardiography|Echocardiography
90072|NCT03482908|Behavioral|Early healthy lifestyles|Patient reported data to identify parenting practices and child behaviors associated with child's obesigenic risk in the future
90073|NCT03482908|Behavioral|Responsive parenting curriculum|Information from the American Academy of Pediatrics Healthy Active Living for Families (HALF) program supplemented with messages from the INSIGHT study, that were written at the 5th grade reading level, with messages focused on 4 categories: 1) feeding the baby 2) soothing the baby 3) sleep health and 4) playing with the baby
90074|NCT03482908|Behavioral|Data sharing/coordination|Data integration into child's electronic health record that is shared between settings (WIC and GHS PCPs) with display and documentation features that informs counseling.
90075|NCT03482895|Biological|Blood sampling|Quantitative analysis of enterohormones, citrulline and ApoB48
90076|NCT03482895|Biological|Feces sampling|Intestinal absorption assessment
90077|NCT03482882|Drug|Pimavanserin|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)
90078|NCT03482869|Diagnostic Test|walking ability|Included patients will perform a 6 min walk test
90079|NCT03482856|Behavioral|MNA plus CBT-I|MNA plus CBT-I includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, 6 individual sessions of CBT-I and 9 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. CBT-I is the standard evidence-based care for treating chronic primary insomnia and typically includes changing negative thoughts about sleep, sleep hygiene, sleep restriction therapy, and teaching relaxation skills. The 18 sessions will be spread over a period of 14 weeks.
90080|NCT03482856|Behavioral|MNA alone|MNA alone includes 3 sessions (1 group, 1 online and 1 individual session) of therapeutic pain neuroscience education, and 15 individual sessions of time-contingent dynamic and functional cognition-targeted exercise therapy, combined with home exercises. The 18 sessions will be spread over a period of 14 weeks.
90081|NCT03482830|Procedure|Major emergency gastrointestinal surgery|"Open, laparoscopic, or laparoscopically-assisted procedures~Procedures involving the stomach, small or large bowel, or rectum for conditions such as perforation, ischaemia, abdominal abscess, bleeding or obstruction"
90082|NCT03482817|Drug|Ze 117|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
90083|NCT03482817|Drug|Probe drug cocktail|Subjects will be hospitalized to receive a probe drug cocktail alone and in combination with Ze 117.
90084|NCT03482804|Other|Questionnaires|"Parents will be interviewed before being seen in consultation in the emergency room. The reason for consultation will not be taken into account, the only criterion being the age of the child. There will be no sign in the waiting room, the study will be proposed to them by the principal investigator.~The questionnaires will be collected on live paper. The answers will be transferred in a second time on an Excel database protected by a password."
90085|NCT03482791|Radiation|Proton beam therapy|"The daily prescription dose will be 1.8 or 2 Gy RBE (Relative Biologic Equivalence) to be delivered to the periphery of the planning target volume (PTV).~The Mevion S-250 Proton Radiation Beam Therapy System will be used."
90086|NCT03482791|Other|Patient-Reported Outcome Measures|-Prior to start of therapy, end of chemoradiation (day of end of treatment or up to 1 week after), 2, 4, 6, 9, and 12-months following end of chemoradiation
90087|NCT03482765|Dietary Supplement|Probiotic 1|The product under investigation is a unique probiotic.
90088|NCT03482765|Dietary Supplement|Probiotic 2|The product under investigation is a unique probiotic.
90089|NCT03482765|Other|Placebo|Microcrystalline Cellulose
90090|NCT03482752|Drug|Molgramostim|300 µg inhaled molgramostim in cycles of once daily administration for 7 days, then 7 days off treatment.
90091|NCT03482726|Behavioral|Cycling Cadence Modulation|6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
90092|NCT03482713|Drug|Gefapixant 45 mg|Gefapixant 45 mg (film-coated tablet) to be administered orally BID
90093|NCT03482713|Drug|Placebo|Placebo (film-coated tablet) matching gefapixant to be administered orally BID
90094|NCT03482700|Behavioral|Intervention Arm|The intervention group will have their usual annual COPD review performed by a specialist respiratory doctor at baseline and 12 months. The patients will receive care using our local COPD guidance which has been accepted by all local commissioning groups and secondary care organisations.
90095|NCT03482700|Behavioral|Control Arm|Usual standard of care
90096|NCT03482687|Behavioral|Me & You: Building Healthy Relationships|Me & You: Building Healthy Relationships is a classroom- and computer-based healthy relationships curriculum for middle school students. It consists of thirteen 25-minute lessons: 5 classroom, 5 computer-only, and 3 classroom-computer hybrid. The curriculum integrates group-based classroom activities (e.g., role-plays, group discussion, and other skill-building activities) and computer-based activities, some of which are individually tailored. The curriculum was adapted from an existing effective sex education and relationship curriculum, It's Your Game…Keep it Real (IYG), which was enhanced to more explicitly address teen dating violence (TDV).
90097|NCT03482674|Behavioral|DIMINI lifestyle intervention|DIMINI lifestyle intervention consists of the DIMINI-kit which contains health information, a list of food recommendations with additional information on calories, serving size and weight (traffic light rating system), a nutrition and an exercise diary. Participants in the intervention group can choose between a paper-based version or an app-based version of the DIMINI-kit. In addition, the kit includes an elastic exercise band with exercise poster, a measuring tape for self-control of the waist size and a pedometer.
90098|NCT03482661|Other|magnetic steering|The capsule was controlled to pass through the pylorus by magnet steering.
90099|NCT03482648|Drug|BBT-401-1S, Single dose|Single dose of BBT-401-1S, 7 dose levels, oral capsule
90100|NCT03482648|Drug|BBT-401-1S, Multiple doses|Multiple doses of BBT-401-1S, 7 days, 3 dose levels, oral capsule
90101|NCT03482648|Drug|Placebo|Placebo matched to BBT-401-1S, oral capsule
90104|NCT03482622|Diagnostic Test|Fast Raman|Fast Raman uses Raman spectroscopy to measure chemical profiles of tissue and provide a diagnostic map identifying BCC within 30 minutes.
90105|NCT03482596|Behavioral|Reducing/breaking prolonged sitting|"The participants will be encouraged to reduce prolonged sitting by at least 60 minutes per day by introducing light upright movement breaks spread throughout their day. The frequency and duration of these breaks will be tailored to each participant to suit their individual circumstances.~The intervention will involve education regarding the health implications of prolonged sitting, personalised goal setting, behavioural feedback and self-monitoring of behaviour."
90106|NCT03482583|Drug|Nicotine Replacement Therapy|Participants in CBT group will also be offered Nicotine Replacement Therapy if they are interested. NRT is the same regimen followed in AHEC and Quitline. In addition, weekly counseling will be provided to the participants remotely via vidyo, a video based platform.
90107|NCT03482583|Other|Referral to AHEC/Quitline|Participants will be referred to local AHEC/Quitline for treatment
90108|NCT03482570|Device|ActiGraph|Activity behaviours will be objectively assessed by 7-day triaxial accelerometer assessment (ActiGraph GT3X+ Pensacola, FL, USA). Participants will be asked to wear an accelerometer around their waist, 24 hours a day for 7 days.
90178|NCT03482037|Drug|placebo|Each vial content will be administered via the catheter used for the self-catheterization
90179|NCT03482024|Drug|Tirzepatide|Administered SC.
90109|NCT03482557|Device|CESM|Contrast enhanced mammography is a new type of mammogram. It uses contrast material combined with the mammogram to highlight areas that might be breast cancer and that could be missed on the mammogram alone
90110|NCT03482557|Device|MRI|MRI uses magnets to create a detailed image of the tissues and bones inside of the body
90111|NCT03482544|Drug|Pragabalin|pregabalin 150 mg will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Pregabalin Group.
90112|NCT03482544|Other|Placebo|empty capsule will be given orally, 1 day and 1 hour before surgery (totally two times), patients in Control Group.
90113|NCT03482531|Other|mathematical model|mathematical model: regression equation that calculates the mean time from insert placement to delivery for each patient, based on every patient's characteristics (parity, BMI, cervical dilation and state of membranes)
90114|NCT03482518|Other|custom slippers with perforated synthetic leather cover.|the intervention group volunteers will receive a pair of custom slippers with perforated synthetic leather cover.
90115|NCT03482505|Device|INVSENSOR00004|The INVSENSOR00004 will be placed on the subject's neck or chest to provide acoustic respiration rate.
90116|NCT03482492|Drug|Tramadol|Tramadol iv
90117|NCT03482492|Drug|Paracetamol|Paracetamol iv
90118|NCT03482479|Drug|Naltrexone Hydrochloride|Naltrexone Hydrochloride will be taken daily (dose 4.5 mg) for six weeks
90119|NCT03482479|Other|Placebo Comparator|A placebo tablet which matches the drug will be taken daily for 6 weeks.
90120|NCT03482466|Behavioral|Neurofeedback|Patients will be inside an MRI machine. They will be trained using real time feedback from brain imaging to learn personal strategies to bring their brain to the CALM state.
90121|NCT03482453|Drug|TAK-788|TAK-788 capsules.
90122|NCT03482453|Drug|Placebo|TAK-788 placebo-matching capsules.
90123|NCT03482453|Drug|Drug: TAK-788|TAK-788 DiC.
90124|NCT03482440|Drug|Salsalate Oral Tablet|1500mg twice daily for 5 days prior to experimental testing
90125|NCT03482440|Drug|Placebo Oral Tablet|Placebo oral table twice daily for 5 days prior to experimental testing
90126|NCT03482427|Behavioral|Healthy Heart Score|Educational materials based on each component of the Healthy Heart Score and other lifestyle behaviors will be provided to the participants that include the following topics: Fruit and vegetable consumption, Whole grain consumption/ limiting refined grains, Healthy protein choices, Healthy dietary fats, Limiting Sugar-sweetened beverages, Importance of physical activity, Proper hydration, Stress management, Adequate Sleep, Smoking Cessation, Weekly menu example, Recipe Cards following the Mediterranean diet principals, Interactive weekly checklist to encourage participants to meet their weekly goals for consumption of fruits, vegetable, nuts and seeds. Participants will receive a check-in email or phone 6 weeks after the baseline visit. A Registered Dietitian is also available to speak with patients.
90127|NCT03482414|Other|traditional wooden checkerboard|upper limb training with traditional wooden checkerboard
90128|NCT03482414|Other|gaming board with single-player games|upper limb training with a LED-based interactive gaming board equipped with single-player games
90129|NCT03482414|Other|gaming board with two-player games|upper limb training with two LED-based interactive gaming boards equipped with two-player competitive games
90130|NCT03482401|Dietary Supplement|Polyphenol|Patients consume 3 capsules/day (474 mg phenolics/day) from the biopsy-confirmed breast cancer diagnosis to the surgery
90131|NCT03482388|Behavioral|Crowdsourced materials|Among participants randomized to the intervention arm, intervention images and videos promoting HBV and HCV testing will be delivered through the WeChat platform. Men will also be invited to submit suggestions for how to improve intervention videos and images.
90132|NCT03482388|Other|Control|Participants will not view any images or videos promoting HBV and HCV testing.
90133|NCT03482362|Drug|Vinorelbine Tartrate|Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2. One treatment cycle is 21 days.
90134|NCT03482349|Procedure|Total Knee Robotically-Assisted|The surgeon digitizes the shape of the joint and the computer transfers the planned surgical strategy to a dedicated surgical robot. Resections are performed by the surgeon on a constrained guide held by the robot.
90135|NCT03482336|Other|Four FOP label designs|"Color (present and absent) were crossed with facial icon (present and absent) for a total of four FOP label treatments. For each trial, both packages had the same FOP treatment, but one appeared at a healthy level while the second unhealthy. Subjects were asked to choose the healthier option as quickly as possible. Accuracy and speed to correct selection both served as dependent variables."
90136|NCT03482323|Behavioral|Exercise|Our exercise class intervention is based on current best evidence and will be tailored for each participant's ability for exercise. The exercise classes is also designed to fit into the guidelines for exercise in adults aged 18 years and above with a long term health condition. During the 12 weeks in the training, exercises will be varied (mixing up time spent on bikes and walking) along with the intensities of exercise varied to keep the classes more engaging for participants and maintaining compliance to the programme.
90137|NCT03482323|Behavioral|Tai-Chi|Our tai-chi classes will be based on a 24-form Yang style of tai-chi exercise set.
90138|NCT03482310|Device|Using the Neuroport cortical recording array to determine the desired grasp pattern for a functional electrical stimulation (FES) system|Participants will be asked to think about holding different shaped objects, and the recorded cortical signal patterns will be decoded to match those grasp shapes
90139|NCT03482284|Other|Dietary Intervention|Participants receive different monosaccharides for a defined number of days.
90140|NCT03482271|Other|No intervention - data collection only|No intervention - data collection only
90141|NCT03482258|Dietary Supplement|Prebiotic|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This equates to 10g GOS (VGOS is primarily 69% GOS, 23% Lactose).
90142|NCT03482258|Dietary Supplement|Maltodextrin|A daily dose for 3 weeks -14.5g per day in powder form dissolved in 200ml water. This will be matched to VGOS for lactose (3.3g per dose of maltodextrin will be lactose).
90180|NCT03482011|Drug|Mirikizumab|Administered SC
90181|NCT03482011|Drug|Placebo|Administered SC
90182|NCT03481998|Drug|SHR6390|SHR6390 150 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
90481|NCT03479450|Drug|surfactant|surfactant is given when neonatal respiratory distress syndrome is diagnosed
90143|NCT03482245|Other|Blue Light|"Subjects that are to be exposed to blue light will be provided by the research personnel with a Day-Light Classic 10,000 lumen SAD light, a device that has been used in many of the previously listed published studies (Epilepsy Behav. 2012 Jul;24(3):359-64. doi: 10.1016/j.yebeh.2012.04.123. Epub 2012 May 30.) The light is small (4 X 16 X 21 inches) and weights less than a pound. It is UV filtered and glare free. There is a single On/Off switch. It will be attached to a rolling stand.~This light is fitted with a blue spectrum filter (peak 441 nm) such that it produces 1000 Lux of blue spectrum lighting when positioned at a distance of 12 inches from the subject."
90144|NCT03482232|Drug|Benzodiazepines|Benzodiazepines for insomnia, agitation or delirium in people older than 65
90145|NCT03482232|Drug|Non-steroidal anti-inflammatory drugs|Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
90146|NCT03482232|Drug|paracetamol|paracetamol 1g for more than 3 days
90147|NCT03482232|Drug|Antimicrobial agent|antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
90148|NCT03482232|Drug|Lipid-lowering drug|Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
90149|NCT03482232|Diagnostic Test|Prostate cancer|Screening for prostate cancer in asymptomatic patients
90150|NCT03482232|Radiation|Lumbago|image tests in non-specific lumbago
90151|NCT03482232|Drug|Antimicrobial agent|antibiotics for pharyngitis (infants)
90152|NCT03482232|Drug|Mucolytic|mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
90153|NCT03482232|Drug|Ibuprofen and paracetamol|treatment with ibuprofen and paracetamol (infants)
90154|NCT03482219|Other|Occupational therapy|The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.
90155|NCT03482219|Other|Home app intervention|The app consists of videos depicting each exercise and ability to track adherence to exercises.
90156|NCT03482206|Device|Automated extracranial internal carotid artery ultrasound sensor|The investigators' goal is to develop a wearable noninvasive, continuous, automated ultrasound sensor to accurately measure arterial blood flow volume outside of the head. Ultrasound uses sound waves to create a picture. In doing so, the investigators hope to detect CBF compromise early, preventing secondary injuries in TBI patients.
90157|NCT03482180|Drug|KI1106 4g, QD|KI1106 4 Capsules
90158|NCT03482180|Drug|Atorvastatin Calcium 20mg, QD|Atorvastatin Calcium 20mg
90159|NCT03482167|Drug|Niagen®|250 mg capsules (4 capsules daily)
90160|NCT03482167|Other|Placebo|placebo
90161|NCT03482154|Procedure|Hematopoietic Stem Cell Transplant|Allogeneic and autologous stem cell transplants covering both malignant and non-malignant diagnoses.
90162|NCT03482141|Device|Whole Exome Sequencing (WES)|The Investigators will enroll pregnant women with fetal anomalies detected by ultrasound. Patients will be approached by a maternal-fetal specialist, who has counseled the patient regarding the fetal anomaly that has been detected. Written informed consent will be obtained by the study prenatal genetic counselor. Many patients will have undergone prenatal diagnostic testing in an outside laboratory; in such cases, cells or extracted DNA from the original fetal sample will be used for the purpose of this study. The consent process for prenatal WES will include pre-test counseling and the option of choosing whether or not to receive uncertain results and secondary findings. After conducting whole exome sequencing, the findings will be shared with the parent(s). Routine medical care will be provided to patients. The research will study the effectiveness of sequencing as a tool for providing genetic information to parents when a prenatal study reveals a fetus with a structural anomaly.
90163|NCT03482128|Device|Coagulation management guided by SONOCLOT|Application of blood products guided by SONOCLOT measurements
90164|NCT03482128|Device|Standard coagulation management|Application of blood products based on clinical experience of the anesthesiologist in charge
90165|NCT03482115|Radiation|PET examination with radiopharmaceutical drug [18F] DPA-714|Using a Biograph 6 Truepoint device. Establishment of a venous route. It will be injected 4 MBq / kg of 18F-DPA714 by the venous route with a maximum dose of 280 MBq. The patient will be placed along the orbito-meatal line. Brain acquisition will begin 60 minutes post-injection
90166|NCT03482115|Diagnostic Test|MRI examination|MRI device Philips Achieva - 3Tesla. The acquisition of the data will include different sequences (anatomical MRI, diffusion MRI, resting fMRI) and will last a total of one hour (installation and removal of the patient in the machine included).anatomical MRI associated with FLAIR (Fluid Attenuation Inversion Recovery) and diffusion tensor (tractography).
90167|NCT03482115|Biological|Blood samples|Characterization of the TSPO phenotype (mitochondrial translocase) for tracer affinity
90168|NCT03482102|Drug|Tremelimumab|Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
90169|NCT03482102|Drug|Durvalumab|Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system
90170|NCT03482102|Radiation|Radiation|Radiation therapy is used to shrink cancer cells.
90171|NCT03482089|Procedure|Cystoprostatectomy|Patients with bladder infiltrating T4 prostate cancer receive cystoprostatectomy with urinary diversion surgery and extended pelvic lymph node dissection
90172|NCT03482089|Radiation|external beam radiotherapy|Patients with bladder infiltrating T4 prostate cancer are treated with adjuvant androgen deprivation therapy
90173|NCT03482076|Diagnostic Test|transferrin receptor concentration|Sandwich radio-imunoassay
90174|NCT03482063|Dietary Supplement|Swisse Ultiboost Memory + Focus|"B vitamins help energy release, help with metabolism of food into energy, assist energy production and vitality.~Vitamin B5 helps support normal mental performance. Brahmi, Ginkgo, Vitamin B12 and B3 help support brain function. Ginkgo helps maintain healthy circulation and delivery of oxygenated blood to the brain.~Brahmi supports memory function and recall. Vitamin B5, B6 are important for adrenal function, assist adrenal glands during stress periods.~Vitamin B2, B3, B5, B6, B12 help relieve tiredness and fatigue."
90175|NCT03482063|Other|Placebo|riboflavin (2.2mg)
90176|NCT03482050|Biological|AstroRx|Astrocytes derived from human embryonic stem cells
90210|NCT03481777|Device|Sham Remote Ischemic Conditioning|Sham Comparator (Sham-RIC)
90183|NCT03481998|Drug|Letrozole or anastrozole or Fulvestrant|Letrozole 2.5mg or anastrozole 1mg, orally once daily (continuously)， or Fulvestrant 500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
90184|NCT03481985|Other|Fenestration status|The exposure variable will be status of the Fontan fenestration
90185|NCT03481972|Drug|Doxycycline and tauroursodeoxycholic acid|doxycicline and tauroursodeoxycholic acid
90186|NCT03481972|Drug|Standard of care|Standard of care
90187|NCT03481959|Drug|Methylphenidate|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
90188|NCT03481959|Other|Matching Placebo|"Methylphenidate delay shape, 10 and 30 mg and matching Placebo capsules. Treatment should be started at a dose of 10 mg per day or 20 mg/d (depending on the weight of patients), with increasing weekly, according to the clinical tolerance, in order to get an effective dose on the symptoms of ADHD to S4, not more than 1 mg/kg/d (capped at 60 mg/d).~This gradual dose treatment will be resumed in the same manner in M3 at the beginning of the phase in open, allowing the respect of the average of the ADHD support (no), without loss of chance for the Group at 3 months, because it is customary to discontinue treatment during holiday periods)."
90189|NCT03481946|Drug|BAY1093884|0.3 mg/kg given intravenously
90190|NCT03481946|Drug|BAY1093884|1 mg/kg given intravenously
90191|NCT03481933|Device|Transcranial stimulation|"10 days of stimulation (20min, 1.59mA) in double-blind sham-controlled. 3 arms (N=20 in each arm):~left-excitatory tDCS (N=20)~right-inhibitory tDCS (N=20)~sham tDCS (N=20)~4 language/semantic evaluations: base-line; 3 days; 2 weeks; 4 months post-tDCS~2 MRI/PET acquisitions: pre-stimulation (base-line); 2 weeks post-tDCS"
90192|NCT03481920|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.
90193|NCT03481920|Drug|Avelumab|Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
90194|NCT03481907|Device|Nuvagen Collagen Powder|Daily application of Nuvagen collagen powder for 2 to 4 weeks following wounding
90195|NCT03481894|Drug|Kabiven®|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
90196|NCT03481894|Drug|Compounded standard parenteral nutrition|"Infusion should start at a low dose (i.e., 12.5 to 25 mL/kg, corresponding to 10.6 to 21.2 kcal/kg/day, 0.49 to 0.98 g lipids/kg/day, 0.41 to 0.83 g amino acids/kg/day and 1.2 to 2.4 g dextrose/kg/day) followed by stepwise increase to the individual target for PN calories.~The daily dose of the study PN should be infused at a constant rate over 20 to 24 hours.~Route of Administration: Infusion into a central vein. Duration of Treatment: Study treatment will last for a minimum of 5 and a maximum of 8 consecutive days. Study treatment will be stopped if oral and/or enteral intake covers 80% or more of caloric requirements. If the indication for PN continues after 8 study days, PN will continue per normal institution policy."
90197|NCT03481881|Drug|Standard of care drug|This study is collecting PK data on children prescribed the following drugs of interest per standard of care: dexmedetomidine, bosentan, furosemide, chlorothiazide, ethacrynic acid, bumetanide, hydromorphone, tacrolimus, ampicillin, gentamicin, caffeine, fentanyl, midazolam, foscarnet, hydroxychloroquine, and moxifloxacin.
90198|NCT03481868|Biological|Collection of blood and bone marrow|Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment
90199|NCT03481855|Device|Lower-body-low-pressure chamber|The lower-body-low-pressure chamber administers a negative pressure to the lower part of the body (below the waist) to induce a central hypovolaemia by pooling of blood in the legs according to Tymko, M. FACETS, Bd. 1, Nr. 1, S. 225-244, März 2017 and Esch, B.T.A. et al. AJP Adv. Physiol. Educ., Bd. 31, Nr. 1, S. 76-81, März 2007.
90200|NCT03481842|Biological|Linifanib|in a minimally sufficient therapeutic dose
90201|NCT03481842|Drug|BIBW2992|in a minimally sufficient therapeutic dose
90202|NCT03481842|Drug|Axitinib|in a minimally sufficient therapeutic dose
90203|NCT03481816|Biological|ETBX-071; adenoviral PSA vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
90204|NCT03481816|Biological|ETBX-061; adenoviral MUC1 vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
90205|NCT03481816|Biological|ETBX-051; adenoviral brachyury vaccine|5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
90206|NCT03481803|Drug|MS1819-SD|Patient will receive increasing doses from the lowest dose of MS1819-SD to a maximum dose of MS1819- SD. The total treatment phase will range from 48 days to 60 days.
90207|NCT03481790|Drug|Lactoferrin|(Pravotin sachets, Hygint, Egypt): 100 mg in 1/4 glass of water before meals twice a day for 4 weeks.
90208|NCT03481790|Drug|ferrous sulphate + folic acid (vitamin B9)|(Ferrofol capsules, Eipico, Egypt): Dried ferrous sulphate 150 mg + Folic acid (Vitamin B9) 150 mg at least 1 hour before or 2 hours after meals three times a day for 4 weeks.
90209|NCT03481777|Device|Remote Ischemic Conditioning|RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion.
90211|NCT03481764|Genetic|HRC-test|"Using HRC-test we analyze 20 selected genetically controlled morphophysiological traits among FS children and control.Homozygous-recessive traits in the region of human head are: attached ear lobe,continuous frontal hair line,blue eyes straight hair,soft hair and blond hair,double hair whorl,hair whorl orientation-opposite from clock-wise,as well as an inability to roll,fold and curve the tongue,a guttural r and Daltonism.HRC trait expressed in human arms and legs, such as distal or proximal hyper-extensibility of the thumb,index finger shorter than the ring finger,left-handedness, hand clasping pattern.In order to achieve high level of objectivity during the process of data gathering, the same person conducting all testing.Inside the group of charcteristics which show high level of variability,only the extreme phenotypes were considered recessive.For the purpose of testing the color blindness in examinees,the Pseudoisochromatic plates test was used."
90212|NCT03481751|Diagnostic Test|Diagnostic test: Ultrasound|Transabdominal ultrasound of the bowel for categorization of disease activity
90213|NCT03481725|Device|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio)|ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that generates electric current for 14 days
90214|NCT03481725|Device|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable SHAM stimulator (SPR Therapeutics, Cleveland, Ohio)|SHAM peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator (SPR Therapeutics, Cleveland, Ohio) that does not generate electric current for 14 days
90215|NCT03481712|Diagnostic Test|Diagnostic tests|"Head-to-head comparison between:~CADScor and Diamond-Foster score~Rb PET and 3T CMRI~QFR and ICA-FFR"
90216|NCT03481699|Behavioral|Incremental theory of personality|"The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance."
90217|NCT03481699|Other|Educational Intervention|The educational intervention involved scientific information about the human brain. It was designed to be parallel to the experimental intervention and, hence, it has also three main parts. First, participants are asked to read scientific information about the different areas of the brain and their specialties. Second, participants read several testimonials written by upperclassmen about their transition to high school and how their brains help them to adapt to the new space and all the physical differences of the building and the classes. Finally, participants are asked to write a letter to another student explaining the main things he or she has learned about the brain and thinks are important for adapting to the new physical environment in high school.
90218|NCT03481686|Device|Patients with injections of ESA|Patients will perform ASE injections themselves or by their spouses
90219|NCT03481673|Behavioral|COPE for Asthma|The intervention will consist of 7 weekly sessions (30 minutes each). COPE for Asthma is a manualized, cognitive behavior skills-building intervention to improve the physical and mental health outcomes of children with asthma and elevated symptoms of anxiety or depression.
90220|NCT03481660|Drug|Brolucizumab|Intravitreal injection
90221|NCT03481660|Drug|Aflibercept|Intravitreal injection
90222|NCT03481647|Procedure|Oral care programme|Professional oral care (dental hygienist), intensified oral care measures by the patient
90223|NCT03481634|Drug|Brolucizumab|Intravitreal injection
90224|NCT03481634|Drug|Aflibercept|Intravitreal injection
90225|NCT03481621|Device|Acupuncture|Needle size: #32(0.22 mm), 1-1.5 inch(30-40 mm long); Acupuncture time and frequency: 45 min per session, once or twice per week, for 6-12 sessions total (in 6 weeks).
90226|NCT03481621|Other|Standard care|PT, pain medications, nerve block, etc
90227|NCT03481608|Other|Lauric acid (coconut oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of coconut oil.
90228|NCT03481608|Other|No Lauric acid (olive oil)|A breakfast shake made from a complete meal shake will be prepared with water and supplemented with 2 tablespoons of olive oil.
90229|NCT03481595|Device|HealthLoop mobile application|Patients will utilize the HealthLoop mobile application on their mobile device during the post-operative period in addition to standard, routine medical care.
90230|NCT03481582|Drug|Nitroglycerin|(nitrodermal®) 5 mg (patch)as a source of Nitric oxide from 2nd day of cycle till maturation of the follicles ≥ 18 mm just for one cycle.
90231|NCT03481582|Device|Three dimensional power doppler|Once the follicle reached ≥18 mm 3D power Doppler will be used to assess the uterine and subendometrial blood flow
90232|NCT03481569|Other|Blood and cerebrospinal fluid pharmacocinetic samples on one of the seven antibiotics prescribed in routine use|Blood and cerebrospinal fluid pharmacocinetic samples at different time point
90233|NCT03481556|Drug|Melflufen|Intravenous infusion
90234|NCT03481556|Drug|Dexamethasone|Oral tablets
90235|NCT03481556|Drug|Bortezomib|Subcutaneous administration
90236|NCT03481556|Drug|Daratumumab|Intravenous infusion
90237|NCT03481543|Procedure|In-line nebulization through NIV mask|In-line nebulization will be given through NIV circuit.
90238|NCT03481543|Procedure|Off-NIV nebulization|Bronchodilator nebulization is given during which NIV mask is taken off for a short time and reapplied when nebulization is finished..
90239|NCT03481530|Device|Continuing Glucose Monitor System|glucose monitoring
90240|NCT03481517|Drug|Bupivacaine|Bupivacaine 5 mL subcutaneous injection to surgical wound during operation.
90241|NCT03481504|Behavioral|Acceptance & Commitment Therapy-Exposure and Perspective Taking|To increase patients' participation by improving their level of coping with chronic pain.
90242|NCT03481491|Other|transcranial magnetic stimulation of the cerebellum|The intervention will consist in a continuous theta burst stimulation of the cerebellum under neuronavigation.
90243|NCT03481478|Diagnostic Test|CT and MRI|For such patients, using CT and/or MRI to find if existing humeral surgical neck fractures.
90244|NCT03481452|Behavioral|psychotherapy|NBO is an infant-focused, family relationship-based intervention measure, which aims to exhibit to parents infants' surprised ability, understand infants' strength and aspects needed to be improved, strength parents' parenting confidence, and promote sound development of infant-mother relationship.
90245|NCT03481439|Other|Collection of a Pharmaceutical intervention|collection of pharmaceutical interventions carried out by the pharmaceutical team in the care uni in Primary and secondary cohort
90246|NCT03481426|Other|Workplace intervention|The study contains normal services of occupational health. Both intervention groups are based on voluntary will, and the normal care and services are guaranteed. In the intervention group new working method which improve co-operation between occupational health services and workplaces.
90247|NCT03481413|Device|Ablation|Ablation therapy for cardiac arrhythmias
90248|NCT03481400|Drug|Calcitonin Gene-Related Peptide|Calcitonin gene-related peptide intravenous infusion (1.5 micrograms/min for 20 mins)
90249|NCT03481400|Other|Placebo|Isotonic saline
90250|NCT03481387|Device|prosthetic aortic valve (PERCEVAL S valve)|The PERCEVAL S heart valve (PERCEVAL S valve) is a bioprosthesis manufactured with bovine pericardium and assembled on a Nitinol stent. The PERCEVAL S valve is designed to offer an alternative to surgically implanted flexible prostheses (stented and stentless biological valves). A special feature of the device is that it is self-anchoring and does not require sutures to be fixed to the implant site.
90251|NCT03481374|Diagnostic Test|autonomic function testing|"autonomic function testing, ergospirometry, three questionnaires~Other Names:~The autonomic function tests consist of five tests:~The Valsalva maneuver~The isometric handgrip test~The deep breathing test~The cold pressor test~A short head-up tilt test~A maximal ergospirometry~Three questionnaires:~EQ-5D-3L: quality of life~IPAQ: capacity to do physical activities"
90252|NCT03481348|Device|Pharyngeal Electrical Stimulation|Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
90253|NCT03481335|Other|CHAP-P Sessions|Residents of intervention communities (barangays) aged 40+ are openly invited to attend CHAP-P sessions. At CHAP-P sessions, trained local volunteers (Barangay Health Workers, or BHWs) collect consent, measure blood pressure, collect other physical measurements, and conduct a survey to determine clients' risk of diabetes. Based on the findings, BHWs provide education and/or referrals. CHAP-P sessions are held twice a month, and clients are encouraged to continuing attending for ongoing follow-up and monitoring.
90254|NCT03481322|Dietary Supplement|Cooked diet with controlled amount of salt|Cooked diet with controlled amount of salt by nutritionist - 2 grams of salt per patient
90255|NCT03481309|Device|anodal tDCS|The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
90256|NCT03481309|Device|cathodal tDCS|The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
90257|NCT03481309|Device|sham tDCS|The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
90258|NCT03481296|Behavioral|Advanced Control|Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.
90259|NCT03481296|Behavioral|Culturally-Adapted Decision Support Navigation Intervention|Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
90260|NCT03481270|Behavioral|Concordant|We will be randomizing across providers - we are particularly interested in racial concordance.
90261|NCT03481218|Other|The World Health Organization Quality of Life (WHOQOL) -BREF|The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
90262|NCT03481218|Other|The Satisfaction With Life Scale - SWLS|The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
90263|NCT03481218|Other|Big Five Inventory - BFI; John in Srivastava, 1999|The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
90264|NCT03481205|Device|Ischemic conditioning device|RLIC will be done using a specialized blood pressure device ( Doctormate) that inflates to 200 mm HG for 5 minutes followed by 5 minutes deflation.
90265|NCT03481192|Behavioral|Two visits for evaluation|"Visit 1:The first evaluation (E1) of cognitive functions will take place directly following the psychiatric interview (T1), in order to better reflect the cognitive abilities at the time of the proposal of the care project.~This will include the Memory Functioning Questionnaire (MFQ), the five words of DUBOIS, the TMT-A and B, the WAIS code test, and the BADDELEY door test. An intercurrent type ringing event of the phone will take place during this evaluation.~Visit 2: At 24h-48h of the psychiatric evaluation (T2), a second evaluation (E2) will take place.~An episodic memory score will be determined by asking the patient to recall,as precisely as possible the evaluation E1. At first the reminder will be free,the data can be completed, if necessary, with an indication, a recognition."
90266|NCT03481179|Device|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
90410|NCT03479970|Other|GNPT+ Social Cognition|Aplication of a computer based treatment focused on attention, memory, executive functions and social cognition.
90411|NCT03479970|Other|GNPT|It's a computeritzed program of cognitive telerehabilitation
90267|NCT03481179|Other|Physical therapy|The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM & JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
90268|NCT03481166|Other|Education on breastfeeding pain|A Registered Nurse with specialization in antenatal and postpartum care will deliver a one-hour, group-based educational session specifically on breastfeeding-related pain, including: common causes of nipple pain, prevalence of nipple pain, impact of pain on milk ejection reflex, and common approaches to prevention and management of nipple pain.
90269|NCT03481153|Device|Transcranial direct current stimulation (tDCS)|tDCS is a safe, non-invasive neurostimulation technique that can modulate neural excitability in the brain to positively impact cognition, behaviour and mood, particularly when combined with a behavioural intervention
90270|NCT03481140|Device|TissuGlu Surgical Adhesive|lysine-derived urethane adhesive
90271|NCT03481127|Behavioral|Integrated psychological care|Additional possible strategies used may include supportive or validating interventions, increasing/introducing/reinforcing coping strategies, psychoeducation; distress tolerance skills; brief cognitive behavioral therapy; cognitive restructuring; activity scheduling; acceptance; and relaxation/mindfulness.
90272|NCT03481127|Other|Surveys|"NCCN Distress Thermometer~PROMIS Depression & Anxiety~Quality of Life (SF-12)~Brief COPE~Patient awareness and satisfaction survey"
90273|NCT03481127|Procedure|Blood draw|"For patients with ovarian, fallopian tube, or primary peritoneal cysts~Optional~Enrollment, 3 months after enrollment, and 6 months after enrollment"
90274|NCT03481127|Procedure|Fresh tissue from ovary|"For patients with ovarian, fallopian tube, or primary peritoneal cysts~Optional~At time of standard of care surgery"
90275|NCT03481114|Combination Product|PET-based, dose-painted, accelerated chemoradiotherapy|Patients in this arm will receive a more personalized and shorter radiation therapy treatment course utilizing PET imaging.
90276|NCT03481101|Device|PET/CT|3 extra scans with FDG-PET/CT and 4 blood samples
90277|NCT03481088|Procedure|Functional appliance therapy|"All records, including MRI scans will be collected at three stages and will be traced for various angular and linear measurements to document the alterations within the condyle glenoid fossa complex.~Stage- I (pre-treatment),~Stage- II (after pre-functional therapy)~Stage-III (After 6-8 months of functional appliance therapy that is after correction to Class I molar relation)"
90278|NCT03481075|Other|Biomechanical computer program|Fusion assisting software for image-guided intervention
90279|NCT03481049|Behavioral|Usual CM|Behavioral reinforcement for alcohol abstinence
90280|NCT03481049|Behavioral|High-Magnitude CM|Behavioral reinforcement for alcohol abstinence
90281|NCT03481049|Behavioral|Shaping CM|Behavioral reinforcement for alcohol abstinence
90282|NCT03481036|Drug|Direct Acting Antivirals|Sofosbuvir and Daclatasvir
90283|NCT03481036|Drug|DAAs in Cirrhotics Genotype 2/3|Sofosbuvir and Daclatasvir with weight based ribavirin
90284|NCT03481036|Drug|DAAs in Cirrhotics Genotye 1,4,5,6|Sofosbuvir and Ledipasvir with weight based ribavirin
90285|NCT03481023|Device|EnsoETM|Use of esophageal thermal regulation device during radiofrequency ablation.
90286|NCT03481023|Procedure|Conventional Care|Use of luminal esophageal temperature monitoring during radiofrequency ablation procedure.
90287|NCT03481010|Procedure|PAO with hip arthroscopy|Participants who are randomized to the Scope-PAO group will receive central compartment hip arthroscopy in addition to the PAO.
90288|NCT03481010|Procedure|PAO without hip arthroscopy|"Participants who are randomized to the PAO-only group will receive a Bernese Periacetabular Osteotomy (PAO) for treatment of hip dysplasia."
90289|NCT03480997|Combination Product|Albuterol Sulfate and Ipratropium Bromide|
90290|NCT03480997|Combination Product|Albuterol Sulfate|
90291|NCT03480984|Other|Programmed Intermittent Bolus|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via an hourly programmed bolus
90292|NCT03480984|Other|Continuous Infusion|6 mL 0.2% ropivacaine hourly, starting on arrival to PACU, given via continuous infusion
90293|NCT03480971|Drug|Tempol|Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
90294|NCT03480971|Drug|Placebo Solution|The placebo contains the same excipients as the active product plus FD&C Yellow #6 for color matching.
90295|NCT03480958|Device|Intravenous morphine patient controlled device|24 hour morphine consumption will be recorded
90296|NCT03480958|Other|Erector Spinae Plane Block|erector spinae plane block will be administered before the surgery
90297|NCT03480958|Other|Thoracic Paravertebral Block|thoracic paravertebral block will be administered before the surgery
90298|NCT03480945|Diagnostic Test|serotonin|Endothelium-dependent dilatation
90299|NCT03480932|Drug|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
90300|NCT03480932|Drug|Daclatasvir|Direct acting antiviral agent used for the treatment of hepatitis C
90301|NCT03480932|Drug|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
90302|NCT03480919|Device|Shen Men acupuncture|20-minute acupuncture session
90303|NCT03480919|Procedure|Epidural injection|Epidural injection for the relief of back pain
90304|NCT03480906|Drug|Latanoprost|Latanoprost ophthalmic solution administered as a microdose spray
90305|NCT03480906|Drug|Latanoprost|Latanoprost ophthalmic solution administered as an eyedrop
90306|NCT03480893|Procedure|small size interarcuair decompression|A median lumbar incision is made and the paravertebral muscles are dissected subperiosteally and retracted unilaterally or bilaterally. Decompression will be applied via decompression of the ligamentum flavum. The lateral recess will be opened bilaterally and a medial facetectomy will be performed in order maintain stability of the segments. Posterior ligaments will be spared. The wound will be closed in layers with or without a suction drain. Patients will be operated with a loupe magnification or microscope depending on the surgeon's preference.
90479|NCT03479476|Drug|Metformin|Active medication.
90482|NCT03479424|Other|Observational|The MYIA in-home suite of devices.
90307|NCT03480893|Procedure|Laminectomy|A median lumbar incision is made over the spinous processes, the laminae of the affected level(s) are exposed subperiosteally, and the supraspinous ligament will be incised. The spinous process is removed. The supra and interspinous ligament of the affected level is removed by drill or Kerrison punches. The lamen is removed of the affect level, leaving the facet joint intact. The lateral recess will be opened bilaterally and medial facetectomy will be performed in order to maintain stability of the segments. When a single level stenosis is present (e.g. L4-L5) both laminae L4 and L5 will be removed. The wound will be closed in layers with or without a suction drain. Patients will be operated with loupe magnification or microscope depending surgeon's preference.
90308|NCT03480880|Device|Bispectral Index|Thiopentone was administered in 50 mg boluses during induction of anaesthesia, until reduction of Bispectral Index value to less than 50, and total dose of thiopentone recorded.
90309|NCT03480867|Drug|Temozolomide|Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
90310|NCT03480867|Radiation|Pre-Operative Radiation|Radiation is given with Temozolomide for 7 days before surgery
90311|NCT03480854|Other|Quality Improvement|Randomly selected sites will receive one of two system level improvement approaches; 1) patient centered specialty medical home certification 2) IHI Breakthrough Series improvement approach with professional improvement coaching.
90312|NCT03480841|Behavioral|Language ENhancement Assessment/intervention system|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
90313|NCT03480828|Diagnostic Test|comparaison between DE and DTF in prediction of extubation success|diaphragm ultrasound and measurement of DE and DTF in patients meeting all extubation criteria during spontaneous breathing trial
90314|NCT03480815|Device|Nocturnal Temperature Controlled Laminar Flow Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
90315|NCT03480815|Other|None Device|Record of the time to first asthma exacerbation, lung function and exhaled NO level
90316|NCT03480802|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
90317|NCT03480802|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
90318|NCT03480802|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
90319|NCT03480789|Drug|Dexmedetomidine|given dexmedetomidine to meet RASS -1 from 22:00 to 6:00 of the next day
90320|NCT03480789|Device|eye patch|wearing the eye patch from 22:00 to 6:00 of the next day
90323|NCT03480763|Biological|V114|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
90324|NCT03480763|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 ml dose
90325|NCT03480763|Biological|PNEUMOVAX™23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose
90326|NCT03480750|Drug|trientine dihydrochloride|trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
90327|NCT03480750|Drug|pegylated liposomal doxorubicin|pegylated liposomal doxorubicin 40mg/m2 IV D1
90328|NCT03480750|Drug|carboplatin|carboplatin AUC 4 IV D1
90329|NCT03480737|Device|Magstim Super Rapid2 stimulator, 10 Hz condition|10 Hz (2,000 pulses) at left DLPFC
90330|NCT03480737|Device|Magstim Super Rapid2 stimulator, Sham condition|sham
90331|NCT03480737|Device|Magstim Super Rapid2 stimulator, iTBS condition|50 Hz, iTBS (600 pulses) at left DLPFC
90332|NCT03480724|Other|Google Cardboard VRA|Intervention was randomized and shuffled.
90333|NCT03480724|Other|Oculus Rift VRA|Intervention was randomized and shuffled.
90334|NCT03480711|Procedure|SST in group (A)|group (A) single surgeon, using retrobulbar anaesthesia with 2% lidocaine, will be performed in all surgeries. Following insertion of a lid speculum, a 10/0 silk bridle suture is inserted at superior limbus if required. In group (A) a conjunctival incision is made at the limbus to create a fornix-based conjunctival flap. A half thickness scleral flap (4 × 4 mm) are created and dissected into the clear cornea. A cellulose microsponge soaked in 0.3 mg/ml MMC solution (Mitomycin-C) is applied to the under surface of the scleral flap over a wide posterior area for 2 ml
90335|NCT03480711|Procedure|trabeculectomy with ESST in group (B)|group (B), another longitudinal scleral groove will be created in the center of the deep scleral bed area measured about 1.5 × 6 mm.In both groups, standard trabeculectomy of equal size (two bites aside) is created by a Kelly punch ( 1 mm)
90336|NCT03480698|Drug|Cerebrolysin|Dosage, frequency, duration and mode of administration of Cerebrolysin follow the local hospital practice in accordance with the terms of the local marketing authorization and is not amended or influenced by the study. Prescribed Cerebrolysin will be used as solution for injection/concentrate for solution for infusion.
90337|NCT03480685|Device|diagnostic imaging|Use of an imaging catheter
90338|NCT03480672|Drug|Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]|intravenous application, 12 months, in 3-week cycle (q3w) 200 mg
90339|NCT03480672|Other|adjuvant radiochemotherapy|adjuvant radiochemotherapy with cisplatin
90340|NCT03480646|Drug|CPI-1205|Administered orally
90341|NCT03480646|Drug|Enzalutamide|Administered orally
90342|NCT03480646|Drug|Abiraterone/Prednisone|Administered orally
90343|NCT03480620|Other|Online Telerehabilitation Platform Access|Participants will have 24/7 access to a standardized set post-discharge exercise videos and self-management instructions across multiple internet connected devices (e.g. computer, tablet, smartphone). Standardized exercises include a flexibility routine that participants learned and performed with a physical therapist while in the pain management program. Self-management instructions are also written versions of concepts learned and practiced with a member of the multidisciplinary team during the pain management program.
90344|NCT03480620|Other|Usual care|Participants are given a DVD of the standardized post-discharge exercise videos and a written copy of the self-management instructions as described in the experimental group.
90345|NCT03480607|Drug|Dexmedetomidine group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
90346|NCT03480607|Drug|Dexamethasone group|0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
90347|NCT03480594|Drug|Hyperpolarized [13C] Pyruvate Injection|HP Pyruvate Injection two times during MRI with 45 minute rest period between in Fatty Liver Patients and Healthy Control Subjects
90348|NCT03480581|Behavioral|Forward First ICARE Training|Participants will engage in 12-sessions in forward direction, followed by 12-sessions in the reverse direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
90349|NCT03480581|Behavioral|Reverse First ICARE Training|Participants will engage in 12-sessions in reverse direction, followed by 12-sessions in the forward direction. Sessions will be scheduled 3 times/week with training parameters adjusted to progressively increase challenge as tolerated.
90350|NCT03480568|Drug|Alirocumab 150 MG/ML [Praluent]|Cholesterol-lowering therapy
90351|NCT03480555|Dietary Supplement|Replenish Protein|Subjects randomized to this group will receive 2 g of protein/kg/day (acceptable range as 1.8 - 2.2 g of protein/kg/day) for day 6-14.
90352|NCT03480555|Dietary Supplement|Standard protein|Subjects randomized to this group will receive 0.8 - 1 g of protein/kg/day for day 6-14
90353|NCT03480529|Drug|drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom|Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
90354|NCT03480516|Device|SDF|38% silver diamine fluoride solution
90355|NCT03480516|Device|Fluoride varnish|5% sodium fluoride varnish
90356|NCT03480490|Diagnostic Test|Pleural fluid C-reactive protein|"C-reactive protein is an acute phase protein that is synthesized by the liver in response to various stimuli.~The pleural fluid c-reactive protein levels are likely to reflect the serum levels because the presence of c-reactive protein in the pleural fluid may be due to increased diffusion from the blood as a result of inflamed capillary leakage.~Pleural c-reactive protein has been proposed as a specific biomarker for the differential diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity than serum c-reactive protein.~c-reactive protein can be considered a good candidate due to its 1000-fold elevation in response to infection and the positive correlation between the serum and pleural c-reactive protein levels.~Pleural fluid c-reactive protein level was significantly higher in exudates than that in transudative effusion."
90357|NCT03480477|Other|ACE questionnaire|No intervention is performed, patients will complete BRFSS Adverse Childhood experiences questionnaire
90358|NCT03480464|Behavioral|App-technology to increase physical activity|The application will send daily reminders to register and notices with information about the health benefit of physical activity, medication, supplementary vitamins and diet after surgery
90359|NCT03480451|Other|Multi-Disciplinary Patient Centered Rehab and Education|"This project is being withdrawn. No revisions to Intervention is available.~Patients will undergo consultation and education by members of a pre-determined multi-disciplinary team that aims to bring a predetermined set of services to the patient in a coordinated and scheduled manner in order to facilitate a comprehensive and through approach to the patient's entire well being"
90360|NCT03480438|Drug|Blinatumomab|Patients will receive standard of care chemotherapy before blinatumomab, between blinatumomab cycles and after blinatumomab.
90361|NCT03480425|Procedure|Tugging Endotracheal Tube|Intubation of the esophagus of anesthetized participants who are having planned endotracheal intubate for surgery; inflation of the cuff; attachment of a force transducer to the tube connector; and gently tugging the tube out of the mouth. Then intubating the esophagus and repeating the tugging procedure. Meanwhile, the force of resistance to tugging is measured with a force transducer.
90362|NCT03480412|Procedure|Follicular Phase|The follicular phase stimulation is conduced according to a standardized Antagonist protocol or Short protocol (with GnRH agonist) using recombinant or urinary gonadotropins (starting dose 300 or 450 UI) or a long lasting recombinant gonadotropin (Corifollitropin alfa 150 mcg) from the second day of the menstrual cycle. When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
90363|NCT03480412|Procedure|Luteal Phase|Two - six days after the first oocyte retrieval a second gonadotropin stimulation will be started with a GnRH antagonist protocol (the stimulation will be started with 250 UI of human menopausal gonadotropin (hMG) and a GnRH antagonist (GnRH-an) 0,25 mg\die will be administered when the leading follicle is ≥ 14 mm until hCG criteria are met). When at least two follicles had reached 17-18 mm in diameter, ovulation will be triggered with a single subcutaneous bolus of urinary human chorionic gonadotropin (10.000 UI ) and oocyte retrieval will be performed after 35 hours.
90364|NCT03480386|Behavioral|Home Based Pulmonary Rehabilitation|The intervention consists of doing 12 weeks of exercises at home, with a weekly call from a health coach.
90365|NCT03480360|Drug|Cyclophosphamide|14.5 mg/kg for 2 days (days -6, -5) and then 50 mg/kg for two days (days 3, 4)
90366|NCT03480360|Drug|Fludarabine|30 mg/m2 daily for 5 days
90367|NCT03480360|Radiation|Total Body Irradiation|200 centigray (cGy) for one day (day -1)
90368|NCT03480360|Drug|Tacrolimus|1 mg IV daily, (or the oral equivalent) adjusted to achieve a level between 5 and 15 ng/ml. If there is no evidence of GVHD, discontinue Tacrolimus by Day 180.
90369|NCT03480360|Drug|cellcept|dose at 15 mg/kg po three times per day (maximum dose of 3 grams/day). Stop Cellcept at Day 35 following transplantation.
90370|NCT03480360|Drug|g-csf|5 mcg/kg/d starting day 5 and continue until Absolute Neutrophil Count (ANC) > 1000/mcL for 3 days.
90371|NCT03480360|Procedure|Peripheral Blood Transplant|cell dose goal: < 5 x 106 Hematopoietic progenitor cell antigen CD34+ cells/kg recipient weight
90372|NCT03480334|Other|Nivolumab plus radiotherapy|Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
90373|NCT03480321|Drug|Cilostazol 100 mg|One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
90374|NCT03480321|Drug|PMR 150 mg|Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
90375|NCT03480321|Drug|PMR 200 mg|Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
90376|NCT03480308|Drug|Fentanyl|Patients will receive bupivacaine (0.5%) 20 ml , fentanyl 1 μg/kg in paravertebral block
90377|NCT03480308|Drug|Dexamethasone|Patients will receive bupivacaine (0.5%) 20 ml , Dexamethasone 4mg in paravertebral block
90378|NCT03480308|Drug|Bupivacaine|Bupivacaine
90379|NCT03480295|Device|Hyaluronic acid 0.4% and Taurine 0.5%|4 drops /day in addition to the ongoing glaucoma treatment
90380|NCT03480295|Device|Hyaluronic acid 0.2%|4 drops /day in addition to the ongoing glaucoma treatment
90381|NCT03480282|Other|Prognosis information and Provider Scripts|An individualized report including each patient's prognosis will be calculated by the Lee-Schonberg and will include information on patient life expectancy from Cho et al.'s US life tables. This report will be sent to the PCP three days before the patient visit. Example scripts for PCPs to use with patients when discussing life expectancy and stopping cancer screening will be sent with the patient prognostic information.
90382|NCT03480256|Drug|SHR6390|SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer
90383|NCT03480243|Drug|Padsevonil (UCB0942)|"Pharmaceutical Form: film-coated tablet~Route of Administration: Oral use"
90384|NCT03480243|Drug|Erythromycin|"Pharmaceutical Form: film-coated tablet~Route of Administration: Oral use"
90385|NCT03480230|Drug|Compound 121564|Compound 121564 10 mg/Kg administered over 60 minutes given intravenously every 2 weeks for 4 doses plus chemotherapy depending on tumor histology.
90386|NCT03480217|Behavioral|Multifaceted Implementation Strategy|"Key components include:~educational presentations to primary care providers at grand rounds~patient information materials on ABPM and HBPM~training registered nurses to assist providers with teaching patients to conduct HBPM~information on how to order ABPM and HBPM to clinicians, nurses and front desk staff via huddles, emails, and other electronic communications~a computerized EHR-embedded clinical decision support tool that prompts providers to recall the USPSTF hypertension guidelines and facilitates ordering of HBPM and ABPM for guideline-eligible patients~periodic feedback to primary care providers about clinic-level success with appropriately ordering ABPM and HBPM for eligible patients~an accessible, culturally-adapted and locally tailored ABPM service"
90387|NCT03480191|Drug|Daptomycin|Daptomycin will be given by intravenous infusion and administered over a 30 minutes infusion, daily, for 8 days and at the dosis of 10mg/kg/day.
90388|NCT03480165|Drug|Parecoxib 20 MG/ML|1 ml of injectable parecoxib (Dynastat®, Pfizer) at a concentration of 20 mg/mL is given concurrently with 19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)
90389|NCT03480165|Drug|Ropivacaine|19 ml of 0.75% ropivacaine (Naropin®, Astra Zeneca)) is given concurrently with 1 ml of normal saline
90390|NCT03480152|Biological|NCI-4650, a mRNA-based, Personalized Cancer Vaccine|Patients will receive a mRNA-based vaccine intramuscularly at two-week intervals for four cycles (one course of treatment). Patients may be vaccinated with a second and final course of treatment using the same vaccine dose. The second course may start approximately four weeks (plus or minus 2 weeks) from the last vaccine dose of the first course.
90391|NCT03480126|Dietary Supplement|Herbal Teas|Organic caffeine-free herbal tea
90392|NCT03480113|Behavioral|Mindfulness-based Intervention|mindful breath, body scan, sitting meditation and walking meditation and so on.
90393|NCT03480113|Behavioral|Physical fitness intervention|giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.
90394|NCT03480100|Drug|Xylometazoline Nasal Spray|Application of Xylometazoline Nasal Spray in accordance with the instructions for use
90395|NCT03480100|Device|Ectoin Nasal Douche|Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
90396|NCT03480074|Procedure|Staple Ligation|Using a stapler that staples the DVC and then cuts it.
90397|NCT03480074|Procedure|Selective Suture Ligation|Suture the DVC, suspend it to the pubic bone, and then cut.
90398|NCT03480074|Procedure|Single Suture Ligation|Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
90399|NCT03480061|Drug|Dexmedetomidine Hydrochloride Group|Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
90400|NCT03480048|Behavioral|Breastfeeding and weight loss support|The intervention is based on the Loving Support peer counseling breastfeeding model developed by the Special Supplemental Program for Women Infants and Children (WIC) with added components to promote postpartum weight loss.
90401|NCT03480035|Procedure|lightwand intubation|intubation using lightwand
90402|NCT03480022|Drug|Liraglutide Pen Injector [Saxenda]|daily sc injection of liraglutide with final dose of 3mg daily
90403|NCT03480022|Drug|Placebo Liraglutide Pen Injector|daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
90404|NCT03480009|Drug|Dextromethorphan Hydrobromide|Dextromethorphan capsule
90405|NCT03480009|Drug|Avicel PH101 (Microcrystalline Cellulose NF) for Compounding|Placebo capsule
90406|NCT03480009|Drug|Oxycodone|Participants may opt for the narcotic receiving arms of the study, before being randomized to dextromethorphan/placebo.
90407|NCT03479996|Drug|Marcaine 0.5 % Injectable Solution|Intra -operative injection into obturator membrane
90408|NCT03479983|Dietary Supplement|AMX160|500 mg Phyllanthus emblica L. fresh fruit extract capsules
90409|NCT03479983|Dietary Supplement|Placebo|500 mg roasted rice powder in visually identical capsules
90552|NCT03478774|Drug|Oxygen 70l/min|HFNCT will be provided using OptiFlow by Fisher&Paykel.
90412|NCT03479957|Behavioral|REMOTE-CR|The patients randomized to remotely monitored exercise can either work out with self-selected activities e.g. Nordic-walking, cycling, skiing or participate in supervised exercise session via video link. Remotely monitored exercise training sessions will be offered monday-friday 13.00-16.00.
90413|NCT03479957|Other|Control|The patients randomized to be controls will receive individualized information and instructions regarding current exercise recommendations but will not be monitored or coached during their exercise sessions (usual care)
90414|NCT03479944|Procedure|FLACS|Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
90415|NCT03479944|Procedure|Manual conventional surgery|Removal of cataractous lens by phacoemulsification
90416|NCT03479944|Device|CENTURION® Vision System|Phacoemulsification aspiration platform for use during cataract surgery
90417|NCT03479944|Device|LenSx®|Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
90418|NCT03479931|Procedure|Without placement of a catheter|Elective cesarean section without preoperative placement of a urinary catheter.
90419|NCT03479931|Procedure|With placement of a catheter|Elective cesarean section with preoperative placement of a urinary catheter.
90420|NCT03479918|Drug|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
90421|NCT03479918|Drug|R-BL-M-04|R-BL-M-04 treatment without auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
90422|NCT03479918|Drug|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
90423|NCT03479918|Drug|R-BL-M-04 + auto-SCT|R-BL-M-04 treatment with auto-SCT for HGBL DH and HGBL NOS patients younger than 60 years. Courses are repeated every 21 days.
90424|NCT03479905|Other|Salter nasal cannula|Oxygen will be delivered by using standard nasal cannula
90425|NCT03479905|Other|Face mask|Oxygen will be delivered via face mask during colonoscopy
90426|NCT03479905|Device|High Flow Nasal Cannula|A high flow nasal cannula will be placed on the patient at a setting of FiO2 100% and titrated up to 60L/min depending on patient tolerance. 60 L/min is the max flow rate and will be used as tolerated for maximum benefit.
90427|NCT03479892|Drug|NNC0194-0499|"Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
90428|NCT03479892|Drug|Placebo|Participants will receive once weekly injections of NNC0194-0499 matched placebo.
90429|NCT03479879|Drug|Estradiol|Estradiol
90430|NCT03479879|Drug|Placebo Oral Tablet|Placebo
90431|NCT03479879|Drug|Misoprostol|Misoprostol
90432|NCT03479866|Other|Dietary intervention|To carry out an interventional dietary study using standardised meals to predict for an individual their metabolic response to certain foods using the gut microbiome and their metabolic profile. Responses will include post-prandial appetite, levels of satiety, circulating glucose, insulin, ketone bodies and lipid levels.
90433|NCT03479853|Procedure|Ophthalmologic examination and meibographic and interferometric evaluation (Lipiview device)|Classic ophthalmologic examination with visual acuity measurement and slit lamp examination of both eyes and eyelids. Then, meibographic and interferometric evaluation of his two inferior eyelids with the Lipiview device.
90434|NCT03479840|Procedure|PCI|treatment of coronary arteries and evaluation of SYNTAX score pre and post (to quantify severity of disease)
90435|NCT03479827|Device|Monofocal Contact Lens|A monofocal contact lens will be used for this measurement.
90436|NCT03479827|Device|Bifocal Contact Lens|A bifocal contact lens will be used for this measurement.
90437|NCT03479814|Radiation|IMRT-SIB plus sequential IG-RT boost|
90438|NCT03479801|Procedure|Thyroid Surgical Methods|Different methods of thyroid surgery, including conventional open thyroidectomy, transoral endoscopic thyroidectomy via vestibular approach, and endoscopic thyroidectomy via breast approach.
90439|NCT03479762|Drug|Liraglutide|No treatment given
90440|NCT03479749|Device|RegenoGel-OSP, RegenoGel|RegenoGel-OSP (A) and RegenoGel (B) are visco-supplements intended for the intra-articular treatment of OA.
90441|NCT03479736|Drug|Oral Fluoroquinolones (FQ)|Participants will not receive any intervention as a part of this study. The FQ include all oral forms of FQ (24-hours extended release tablets, extended release tablets, oral solution, oral suspension, oral tablet, pack). The drugs included are ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin.
90442|NCT03479736|Drug|Other Antibiotics|Participants will not receive any intervention as a part of this study. Other antibiotics include amoxicillin, azithromycin, trimethoprim and trimethroprim/sulfamethoxazole.
90443|NCT03479736|Other|Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure|Febrile illness not treated with antibiotics is defined as: concurrent diagnoses of viral disease with concurrent fever, and no concurrent prescription for any antibiotic during the 60-day period before and after the first date of viral disease diagnosis; or a diagnosis of influenza with no concurrent inpatient admission during the 60-day period pre- or post-influenza diagnosis, and no prescription for any antibiotics during the 60-day period pre- or post-influenza diagnosis.
90444|NCT03479710|Biological|FMT infusion|Fecal microbiota transplantation via OGD
90445|NCT03479697|Device|HIRREM|Technology
90446|NCT03479697|Other|Continued Current Care|Continue their current clinical care.
90447|NCT03479684|Other|Gene-directed dosage of warfarin|the first day given model prediction dose * 1.5 times（＜6mg）；the second day given model prediction dose；adjusted dose based on INR from the third day
90448|NCT03479684|Other|standard dosage of warfarin|the first day given 4.5mg; adjusted dose based on INR from the second day
90449|NCT03479671|Drug|Intralipid, 20% Intravenous Emulsion|Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr)
90480|NCT03479463|Biological|Dehydrated human amnion/chorion membrane|Laryngectomy/pharyngectomy patched with dehydrated human amnion chorion allograft
90867|NCT03476317|Drug|Polyethylene Glycol 3350|Dissolved in Gatorade on day 2
90450|NCT03479658|Behavioral|High intensity interval training|Two schools with four classes/groups of 4th degree of children will participate in the pilot study (i.e., age of children 9-10 years old). One of them has two physical education (PE) sessions per week and the other has only one PE session per week. In the school with two PE sessions, two classes will be randomly assigned to HIIT (2 sessions/week) +nutrition group, and two to the nutrition group. Similarly, in the school with one PE session per week, two classes will be randomly assigned to HIIT (1 session/week) + nutrition and two classes to the nutrition goup. Both HIIT and nutritional education sessions will be integrated integrated into the physical education and sciences sessions of the schools. The duration of the intervention will be of eight weeks.
90451|NCT03479658|Behavioral|Nutritional education|School-based nutritional education on healthy dietary habits
90452|NCT03479645|Behavioral|Serial text messages and mailed FIT kit|"Pre-alert SMS offering Opt-out of mailed FIT kit~Mailed home FIT kit~SMS A - Reciprocity message~SMS B - Offer for second FIT kit if lost/did not receive~Plus SMS A + C if second mailed FIT is requested.~SMS C - Salience message"
90453|NCT03479632|Behavioral|Aerobic walking program|Participants will make 24 visits over an 8 week period, having 3 sessions per week. Each session will last about one hour.
90454|NCT03479632|Behavioral|Standard physical therapy|Participants will receive standard care they normally would after a stroke.
90455|NCT03479619|Device|Lancing device A|Glucoject Dual Plus lancing device
90456|NCT03479619|Device|Lancing device B|Droplet lancing device
90457|NCT03479619|Device|Lancing device C|Commercially available lancing device
90458|NCT03479619|Device|28 G lancet|Droplet 28 G
90459|NCT03479619|Device|30 G lancet|Droplet personal lancet 30 G
90460|NCT03479619|Device|33 G lancet|Droplet personal lancet 33 G
90461|NCT03479619|Other|Lancing depth setting (1)|The lowest depth setting (1)
90462|NCT03479619|Other|Lancing depth setting (5)|The highest depth setting (5)
90463|NCT03479606|Behavioral|Online Emotion Regulation Skills-training|Emotion Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. The intervention is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the intervention, to increase their familiarity with the terminology, and to the emotion regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotion regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
90464|NCT03479593|Diagnostic Test|CMR and OCT in NSTEMI patients with MVD|Lesions >50% stenosis i patients with NSTEMI are examined by OCT. All patients will have CMR performed prior to angiography
90465|NCT03479580|Other|Patients with a cardiomyopathy|Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.
90466|NCT03479567|Other|Gait accelerometry|accelerometric assessment of gait (Dynaport Hybrid): 7m walk in 3 conditions (normal pace, fast, double task)
90467|NCT03479567|Other|balance accelerometry|accelerometric assessment of balance (Dynaport Hybrid) during 10 seconds trial in 3 conditions (side-by-side, semitandem, tandem)
90468|NCT03479567|Other|Fine motor skill test|assessment of fine motor skills with Purdue Pegboard, with dominant hand, non-dominant hand and bimanual
90469|NCT03479567|Diagnostic Test|Paratonia Assessment Instrument (PAI)|diagnosis of paratonia based on passive movement of the four limbs
90470|NCT03479567|Other|myotonometric measurement of muscle tone|MyotonPRO measurement of muscle tone
90471|NCT03479554|Other|Early antihypertensive treatment|"The CATIS 2 trial is designed to test BP reduction strategies‒early antihypertensive treatment vs. delayed antihypertensive treatment‒rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~Step 2 (within 5 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward."
90472|NCT03479554|Other|Delayed antihypertensive treatment|All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP <140 mmHg (but not lower than 120 mmHg) and diastolic BP <90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
90473|NCT03479541|Behavioral|Rehabilitation|"Participants will see a physiotherapist one-on-one twice per week for 2 weeks and once per week for 4 weeks for a total of 6 weeks. These sessions will consist of cardio, cervical flexion exercises and vestibule-ocular exercises for one hour. Participants will also have similar daily home exercises to complete for approximately 30 minutes. Both the one-on-one physiotherapy and home exercises will be individualized and progressive in the sense that each exercise can increase in the level of difficulty at the discretion of the physiotherapist depending on the performance of the participant.~For the group allocated to home monitoring, they will perform the vestibular exercises while wearing one wireless sensor on the head and one on the sternum. When the participant brings the sensors in to the physiotherapy session each week, the physiotherapist will examine the home data and likely make a more informed decision as to whether or not to increase the level of difficulty of the task."
90474|NCT03479515|Device|Ultrasound|Ultrasound, ADP, bioimpedance measurements
90475|NCT03479502|Drug|Methylprednisolone Injectable Product|3 intra-articular injections of Methylprednisolone Injectable Product spaced every two weeks
90476|NCT03479502|Drug|Doxycycline Injection|3 intra-articular injections of Doxycycline Injection spaced every two weeks
90477|NCT03479489|Other|Human dehydrated amnion chorion allograft|Closed hemorrhoidectomy patched with dehydrated human amnion chorion allograft
90478|NCT03479476|Drug|Placebo Medication|Placebo liquid or capsules given in parallel to active medication.
90483|NCT03479411|Drug|Itraconazole Powder|Itraconazole administered as a dry powder for inhalation (PUR1900)
90484|NCT03479411|Drug|Itraconazole 200 mg|Sporanox® Oral Solution
90485|NCT03479398|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is an evidence-based psychotherapy that treats a variety of disorders. In this study, clinicians will be enrolled who use types of CBT for anxiety disorders, depression and PTSD in their routine clinical practice. CBT is usually a 12-16 session treatment that focuses on intervening on disorders cognitively and behaviorally through the use of worksheets during session and outside of session.
90486|NCT03479385|Behavioral|Integrative Medicine Intervention|Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.
90487|NCT03479385|Behavioral|Health Education Intervention|Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
90488|NCT03479372|Drug|PAN-90806 Ophthalmic Suspension|PAN-90806 provided in single-use dropper bottles for topical ocular administration
90489|NCT03479359|Behavioral|Routine review of DRE results by attending doctors|Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.
90490|NCT03479346|Drug|GGT|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
90491|NCT03479346|Drug|Placebo|Usage: 3g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
90492|NCT03479333|Device|Short implant|Short implant will be placed depending on the previous randomization. For that, a surgical access will be done, and the implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
90493|NCT03479333|Device|Standard implant with sinus lift|First, a surgical access will be performed, followed by sinus lift procedure. Next, a standard implant will be placed, cover screw will be installed and the access closed. The patient will receive the definitive crown after five months after the short implant installation.
90494|NCT03479320|Drug|Lidocaine|Postoperative analgesic effects will be compared between lidocaine and normal saline group
90495|NCT03479320|Drug|Placebo|Postoperative anlagesic requirements will be calculated and compared with experimental group
90496|NCT03479307|Drug|Bilastine Ophthalmic Solution 0.6%|1 drop in each eye at 2 separate times during an 8 day period.
90497|NCT03479307|Drug|Ketotifen Ophthalmic Solution 0.025% (Zaditen)|1 drop in each eye at 2 separate times during an 8 day period.
90498|NCT03479307|Drug|Vehicle of Bilastine Ophthalmic Solution|1 drop in each eye at 2 separate times during an 8 day period.
90499|NCT03479294|Drug|Shenlingcao Oral Liquid|Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
90500|NCT03479268|Drug|Ibrutinib|Given PO
90501|NCT03479268|Other|Laboratory Biomarker Analysis|Correlative studies
90502|NCT03479268|Drug|Pevonedistat|Given IV
90503|NCT03479268|Other|Pharmacokinetic Study|Correlative studies
90504|NCT03479268|Other|Pharmacological Study|Correlative studies
90505|NCT03479255|Behavioral|Smartphone-enabled structured exercise therapy (SE-SET)|The SE-SET program lasts a total of 12 weeks per participant. During this time, the application will automatically track physical activity (steps) and subjects will be prompted to enter other health data such as blood pressure and weight, and watch brief educational videos on topics such as smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. Patients will be contacted by a member of the study team weekly via phone call in order to identify barriers to patient compliance (issues related to exercise tracking, medication issues that prevent patient from being active, high BP/weight issues) and help patients navigate those barriers. Movn participants can also send direct messages to the study team to ask about non-urgent issues related to their care.
90506|NCT03479255|Behavioral|Standard exercise therapy|The Standard exercise therapy lasts a total of 12 weeks per participant. Participants will be counseled by the physician to perform exercise at home, including 3 times per week of walking 30+ minutes; if applicable, the physician will also counsel on smoking cessation, low sodium diet, high fruit/vegetable intake, and medication adherence/education. These patients will be given a fitness band, which will be set up by the study team using a de-identified study account that will provide additional data on their progress over time.
90507|NCT03479242|Other|no interventions|no interventions are planned
90508|NCT03479229|Device|Geneveve Treatment|The active treatment group will receive a treatment dose of 90 J/cm^2
90509|NCT03479229|Device|Sham Treatment|The sham group will receive a sub-therapeutic dose of ≤ 1 J/cm^2.
90510|NCT03479216|Drug|Precedex|10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
90511|NCT03479216|Drug|Magnesium Sulfate|10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
90512|NCT03479203|Drug|Electronic Cigarette Aerosol|16 two-second-long puffs from a non-nicotinized electronic cigarette.
90513|NCT03479190|Procedure|ultrasound guided injection of Platelet rich plasma|Platelet rich plasma (PRP) injection into trochanteric area under ultrasound guidance
90514|NCT03479190|Procedure|ultrasound guided injection of Normal Saline|ultrasound guided injection of Normal Salineinto trochanteric area under ultrasound guidance
90515|NCT03479177|Behavioral|High Intensity Interval Training|The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
90516|NCT03479164|Other|Ultra Low-Dose CT|Ultra Low-Dose CT
90553|NCT03478774|Drug|Oxygen 10 l/min|Medium flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
90554|NCT03478774|Drug|Oxygen 2l/min|Low flow will be applied with a humidifier (Hudson RCI) and a standard nasal cannula.
90555|NCT03478774|Procedure|Jaw thrust|Continuous
90556|NCT03478774|Procedure|Videolaryngoscopy|Continuous
90517|NCT03479151|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|MRgHIFU treatment will be delivered using a Philips Sonalleve system, which integrates a high intensity phased array focused ultrasound transducer with our Philips 3T Achieva imaging system. An electromechanical transducer positioning system is used to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively. The MR system is used to provide images to plan the therapy, and to guide and monitor the thermal ablation with thermal imaging during the treatment.
90518|NCT03479138|Diagnostic Test|Induced sputum|Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome
90519|NCT03479125|Diagnostic Test|Ultrasound|Subjects will be observed to estimate the adjusted event rate for hepatocellular carcinoma with or without cirrhosis previously treated with emricasan or placebo.
90520|NCT03479112|Behavioral|Flashcards|Participants will be provided with Flashcards depicting how to correctly apply a tourniquet to an extremity wound.
90521|NCT03479112|Behavioral|Audio-kit|Participants will be provided with an audio-kit with accompanying visual cues describing and depicting how to correctly apply a tourniquet to an extremity wound.
90522|NCT03479112|Behavioral|B-Con training|Participants will undergo the Bleeding control for the injured (B-Con) basic course.
90523|NCT03479112|Behavioral|B-Con training retention|Evaluation of retention of Bleeding Control for the injured basic course
90524|NCT03479086|Drug|Topiramate|200mg/day 100mg b.i.d
90525|NCT03479086|Drug|Naltrexone|50mg/day
90526|NCT03479060|Procedure|Wet Cupping|cupping technique procedure was conducted in five phases:Primary suction,Area disinfection,Scarification,Bloodletting and secondary suction and Removing and dressing
90527|NCT03479047|Diagnostic Test|assess diaphragmatic displacement (DD) using ultrasonography|During a spontaneous breathing trial (SBT) we will simultaneously, for all included patient, assess diaphragmatic displacement (DD) using ultrasonography, respiratory rate (RR) and tidal volume (VT) on ventilator screen.
90528|NCT03479034|Other|ScalaMed ePrescription application|Mobile phone application (Android and Apple) for storing electronic prescriptions
90529|NCT03479021|Diagnostic Test|Welch-Allyn Spot Vision Screener|photograph of the eye
90530|NCT03479008|Diagnostic Test|Therapeutic Vibration Device|The Therapeutic Vibration Device is capable of applying force through the axial skeletal spine, through bidirectional compression loading (or prestressing) between the shoulder and the plantar surfaces of the feet. It is placed around the body like a mobile frame so that the applied vibration can affect the whole body. The vibration actuators (drivers) are mobile and can vary in size, frequency response, and force. The design minimizes the possibility of mechanical interference for ventilated/intubated patients.
90531|NCT03478995|Drug|GX-I7|GX-I7 25mg/ml/vial
90532|NCT03478982|Drug|Staccato Alprazolam|single dose for inhalation
90533|NCT03478982|Drug|Placebos|single dose for inhalation
90534|NCT03478969|Device|Accu-Chek® Solo micropump system|Medical device for subcutaneous delivery of insulin in a personalized way.
90535|NCT03478969|Device|mylife™ OmniPod® Insulin Management System|A patch pump system delivering insulin.
90536|NCT03478969|Other|Multiple Daily Injections (MDI) therapy|Injecting insulin as per participant's need.
90537|NCT03478956|Drug|Etrolizumab|"For Low Frequency Etrolizumab will be administered by SC injection 3mg/kg at week 0 and week 8 for a period of 16 weeks.~For High Frequency Etrolizumab will be administered by SC injection 1.5mg/kg at week 0,4,8 and 12 for a period of 16 weeks."
90538|NCT03478930|Drug|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection Q2W or Q4W.
90539|NCT03478930|Drug|Placebo|Participants will not be receiving placebo in this OLE study. Participants who were randomized to the placebo arms for 24 weeks in studies GA39688/GA39855 and then enter this OLE study will receive omalizumab, but they will be placed in separate analysis cohorts.
90542|NCT03478891|Biological|VRC-EBOMAB092-00-AB (MAb114)|VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
90543|NCT03478878|Drug|Vitamin A Palmitate|Softgels
90544|NCT03478865|Drug|Vitamin A palmitate|vitamin A palmitate 16,000 IU daily by mouth for two months
90545|NCT03478826|Other|ILD|100 cc of blood collected from a total of 250 ILD patients. This includes IPF (n=100), fibrotic NSIP (n=50), chronic hypersensitivity pneumonia (n=20), sarcoidosis(n=50), progressive rheumatoid lung disease (n=10) and scleroderma lung disease (n=20)), 10 patients with other fibrosing disease (fibrosing mediastinitis), and 50 patients with lymphangioleiomyomatosis
90546|NCT03478826|Other|Healthy|100 cc of blood collected from a total of 25 healthy volunteers in order to compare with the ILD participants.
90547|NCT03478826|Other|Pneumonia|100 cc of blood collected from a total of 100 participants with a diagnosis of pneumonia in order to compare with the ILD participants.
90548|NCT03478813|Behavioral|Voiding school|Children are educated on the kidneys, bladder and bowel function, the importance of regular voiding and drinking habits, and avoidance of constipation. Balloons, books, videos, animations, the pictures of a satisfied and irritated bladder and a poo-cars formula track are used to exemplify the function of urinary and defecation systems. During toilet visits children are given advise about an adequate and relaxed toilet posture with the help of little bench under the feet if needed. Each child also make their own timetable for peeing, pooing, and water drinking times, which they then should learn to follow in day-care, pre-school and at home. At the end of each session child, parent and public health nurse/urotherapist discuss any individual advice and the homework for the next time.
90549|NCT03478800|Procedure|Acupuncture|Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
90550|NCT03478787|Drug|risankizumab|Subcutaneous (SC) injection.
90551|NCT03478787|Drug|secukinumab|Subcutaneous (SC) injection.
90558|NCT03478748|Other|Dental health education|Anticipatory guidance given to mothers to promote their children's oral health.
90559|NCT03478735|Procedure|Ultrasound Guided Greater Occipital Nerve Block at C2|Ultrasound guided injection
90560|NCT03478735|Procedure|Landmark-Based Greater Occipital Nerve Block|Traditional landmark-guided technique at the superior nuchal line. This approach relies solely on superficial bone-based anatomic landmarks to infiltrate local anesthetic and corticosteroid around the nerve at the level of the superior nuchal line.
90561|NCT03478722|Other|Protein Meal|Ingestion of mixed meal containing 20 g of dietary protein
90562|NCT03478722|Other|Stable Isotope Amino Acid Infusion|Continuous infusion of L-[1-13C]leucine (0.13 μmol⋅kg⋅min) and L-[ring- 2H5]phenylalanine (0.05 μmol⋅kg⋅min)
90563|NCT03478709|Other|volume expansion|Volume expansion when the patient has a dependent preload evaluated by a positive leg lever test (variation of more than 10% of the VES). It corresponds to the intravenous administration of 500 ml of Ringer lactate over 10 min.
90564|NCT03478709|Other|norepinephrine|Vasopressor agent when the patient has persistent arterial hypotension related to postoperative vasoplegia syndrome. Norepinephrine is administered during persistent hypotension (MAP <60mmHg) despite volume expansion. It corresponds to continuous intravenous norepinephrine administration to obtain a MAP of more than 70 mmHg
90565|NCT03478696|Drug|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
90566|NCT03478696|Drug|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
90567|NCT03478696|Drug|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
90568|NCT03478696|Drug|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
90569|NCT03478696|Drug|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
90570|NCT03478696|Drug|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
90571|NCT03478696|Drug|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
90572|NCT03478696|Device|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
90573|NCT03478696|Device|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
90574|NCT03478696|Device|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
90575|NCT03478683|Drug|budesonide/formoterol|Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily
90576|NCT03478683|Drug|albuterol/salbutamol|Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
90577|NCT03478683|Drug|FF/UMEC/VI|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
90578|NCT03478683|Drug|Placebo to match budesonide/formoterol|Subjects will be administered two inhalations of matching placebo twice daily via MDI
90579|NCT03478683|Drug|tiotropium|Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
90580|NCT03478683|Drug|Placebo to match FF/UMEC/VI|Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
90581|NCT03478683|Drug|placebo to match tiotropium|Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning
90582|NCT03478683|Device|ELLIPTA|Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.
90583|NCT03478683|Device|MDI|Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.
90584|NCT03478683|Device|HandiHaler|Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.
90585|NCT03478670|Genetic|Strimvelis|Strimvelis is a CD34+ cell enriched dispersion of human autologous bone marrow derived hematopoietic stem/progenitor cells transduced with a retroviral vector containing the human ADA gene. It will be administered as an intravenous infusion once only.
90586|NCT03478657|Drug|Placebo DPI|Subjects will receive placebo via oral inhalation route using ELLIPTA once daily. Placebo DPI will be available in two strips of 30 blisters per strip. First strip will contain lactose monohydrate and second strip will have lactose monohydrate blended with magnesium stearate.
90587|NCT03478657|Device|ELLIPTA DPI|Subjects will receive placebo DPI via ELLIPTA. ELLIPTA is trademark of GSK
90588|NCT03478657|Other|Ease of use questionnaires|Subjects from both stratum after use of ELLIPTA DPI will be randomized to receive either version A or B of the questionnaires. Subjects will be asked questions on ease of use of ELLIPTA. Parent/guardian will also complete a questionnaire about the ELLIPTA DPI.
90589|NCT03478644|Device|Experimental Denture Wipe|Participants were instructed to use the experimental wipe to clean their dentures, external to their mouth, up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days. Participants were instructed to use one wipe per denture.
90590|NCT03478644|Other|Tap Water|Participants were instructed to use running tap water to clean their dentures up to 4 times daily (once after completion of each of their three main meals and once at any other time) for 14 days.
90591|NCT03478631|Other|High-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
90592|NCT03478631|Other|Low-nitrate dehydrated vegetable powder|A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
90593|NCT03478618|Drug|Lactated Ringer|"Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia.~Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups"
90594|NCT03478605|Drug|Olanzapine|Olanzapine 5 mg/day will be administered orally on days 0-4 of chemotherapy cycle (before bedtime)
90595|NCT03478605|Drug|Aprepitant Pill|Aprepitant 125 mg orally will be administered on day 1 of chemotherapy cycle; 80 mg - on days 2 and 3.
90596|NCT03478605|Drug|Ondansetron|Ondansetron 16 mg IV on day 1 of chemotherapy cycle (as standard component of antiemetic therapy)
90597|NCT03478605|Drug|Dexamethasone|Dexamethasone 8 mg IV on day 1 of chemotherapy cycle; 8 mg IV or orally on days 2-3 (as standard component of antiemetic therapy)
90598|NCT03478592|Other|reference technique|Slow-freezing procedure is the reference technique, actually use at the Toulouse hospital, to cryopreserve embryos. Embryon are frozen with a slow freezing.
90599|NCT03478592|Other|vitrification technique|Vitrification is the new technique to freeze embryons. In this study, the GAVI system will be use for for embryos automatically vitrification
90600|NCT03478579|Other|observational|No intervention, it is observational study
90601|NCT03478566|Device|Transcutaneous CO2 monitoring|The aim is to assess the accuracy of ambulatory, at home, transcutaneous CO2 monitoring in pediatric Neuromuscular Disease (NMD).
90602|NCT03478553|Other|High Resolution CT scan of the chest|High Resolution CT scan of the chest
90603|NCT03478553|Other|Blood draw|Blood draw
90604|NCT03478553|Other|Questionnaire|Pulmonary Fibrosis Questionnaire
90605|NCT03478540|Drug|Anti-Retroviral Agents|First line antiretroviral therapy as recommended in China, e.g. tenofovir lamivudine and efavirenz
90606|NCT03478527|Dietary Supplement|Vivomixx® powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
90607|NCT03478527|Other|Placebo powder|Participants will take in a daily dose of 4.4g for 28 consecutive days
90608|NCT03478514|Drug|Palbociclib|Taken at 100 mg once daily for 21 days, followed by 7 days off
90609|NCT03478514|Drug|Ibrutinib|560 mg taken orally all patients throughout the study
90610|NCT03478501|Behavioral|Decision Aid|This intervention is a tablet based Lethal Means Decision Aid with proposed use to augment lethal means counseling in emergency departments for patients at risk of suicide.
90611|NCT03478488|Drug|KN035 plus Gemcitabine & oxaliplatin|KN035 a programmed death ligand immune check inhibitor Per Investigator decision
90612|NCT03478488|Drug|Gemcitabine & oxaliplatin|The standard of care for the patients with unresectable/metastatic biliary tract cancer
90613|NCT03478475|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|
90614|NCT03478475|Other|Placebo|Placebo pill (microcrystalline cellulose 66.3%, starch 33.2%, magnesium stearate 0.5%)
90615|NCT03478462|Drug|CLR 131|IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
90616|NCT03478449|Procedure|lymph node sorting for pathological examination|In this study, intervention methods include two kinds of lymph node sorting for pathological examination in gastric cancer samples after curative surgery. One is the fine sorting lymph nodes, representing the lymph nodes should be sorted one by one from the tissues around the stomach, celiac axis, and the main brunches of celiac axis. The other is the group sorting lymph nodes, representing the lymph nodes should be simply sorted in the soft tissues around the stomach, celiac axis, and the main brunches of celiac axis.
90617|NCT03478436|Drug|Doxycycline|Doxycycline 40 mg capsules
90618|NCT03478423|Drug|Codeine|30mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
90619|NCT03478423|Drug|Oxycodone|5mg tablets. Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
90620|NCT03478423|Drug|Hydromorphone|1mg tablets.Patients will be instructed to take 1 tablet every 4 hours as needed for moderate to severe pain if you continue to have pain despite taking acetaminophen.
90621|NCT03478410|Procedure|Epicardial fat biopsy|A 1 cm (~0.5 g) of epicardial pat biopsy from the area of the pulmonary artery
90622|NCT03478397|Other|Multicomponent mHealth Intervention|Women with HPV self-collected tests will receive a multicomponent intervention which includes SMS text messages to remind them to attend triage. In addition, CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage
90623|NCT03478384|Behavioral|Patient coaching|Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
90624|NCT03478371|Device|tampon D|regular absorbency tampon
90625|NCT03478371|Device|tampon M|regular absorbency tampon
90626|NCT03478371|Device|tampon T|regular absorbency tampon
90627|NCT03478371|Device|tampon V|regular absorbency tampon
90628|NCT03478358|Drug|177Lu-DOTA-EB-TATE 1|The patients were intravenously injected with single dose 0.37GBq-0.74GBq (10-30 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
90629|NCT03478358|Drug|177Lu-DOTA-TATE|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
90630|NCT03478358|Drug|177Lu-DOTA-EB-TATE 2|The patients were intravenously injected with single dose 1.85GBq (50 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
90631|NCT03478358|Drug|177Lu-DOTA-EB-TATE 3|The patients were intravenously injected with single dose 3.7GBq (100 mCi) of 177Lu-DOTA-EB-TATE and underwent 68Ga-DOTATATE PET/CT scans before and after the treatment.
90632|NCT03478345|Behavioral|endocrine disruptor chemical reduction intervention|Participants will take part in a 4-week intervention consisting of a modified (shortened) version of the Diabetes Prevention Program diet and physical activity group education program, with instructions to reduce endocrine disruptor chemical exposure through changes in food handling and personal care products.
90633|NCT03478332|Drug|Yangxinshi pill|0.6g/tablet
90634|NCT03478332|Drug|conventional coronary heart disease medicine|the conventional treatment includes medicines treating coronary heart disease
90635|NCT03478332|Drug|Placebos|Yangxinshi simulant
90636|NCT03478319|Drug|ACE-2494 or placebo|Recombination fusion protein
90637|NCT03478306|Drug|Melatonin 4 mg Tablet|Participants are randomized into arm 1 or arm2, recieving melatonin or placebo, respectively, for 21 days, followed by 1 week of washout, and then swichting to the contralateral treatment arm.
90638|NCT03478293|Device|iStent inject surgery|Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
90639|NCT03478280|Drug|Brodalumab|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
90640|NCT03478280|Drug|Placebos|Subjects with moderate-to-severe psoriasis are enrolled consecutively and randomly assigned to either active treatment with brodalumab or placebo during the treatment period
90641|NCT03478267|Diagnostic Test|AChE levels|AChE levels in peripheral blood tests from maternal blood, fetal umbilical cord and placenta.
90642|NCT03478254|Biological|Influenza vaccination|"Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year."
90643|NCT03478254|Biological|Pneumococcal vaccination|"Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~One PPSV 23 dose in the last 5 years.~One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year."
90644|NCT03478254|Biological|Hepatitis B Virus (HBV) vaccination|"Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months."
90645|NCT03478241|Device|Group 1: single file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
90646|NCT03478241|Device|Group 2: multiple file rotary motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
90647|NCT03478241|Device|Group 3: single file reciprocal motion|after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
90648|NCT03478228|Other|Multi-Sensory Training|
90649|NCT03478215|Biological|Mesenchymal Stromal Stem Cells (MSCs) Infusion|"Investigational infusion bag containing autologous mesenchymal stromal cells wrapped to cover contents to maintain the blind.~Mesenchymal Stromal Stem Cells Infusion."
90650|NCT03478215|Other|Normal Saline (Placebo) Infusion|"Matching infusion containing normal saline wrapped to cover contents to maintain the blind.~Normal Saline (Placebo) Infusion."
90651|NCT03478202|Dietary Supplement|GOLO RELEASE|GOLO RELEASE plus Diet
90652|NCT03478189|Procedure|use of O-arm surgical imaging|during acetabular fracture surgery , use of O-arm surgical imaging with
90653|NCT03478163|Drug|CeFAZolin 1000 MG|Cefazolin 1000 mg every 8 hours for 3 doses
90654|NCT03478163|Drug|Clindamycin 900 MG in 6 ML Injection|Clindamycin 900 mg every 8 hours for 3 doses
90655|NCT03478150|Other|zinc oxide nano-particles|The zinc oxide nano-powder will be mixed with ethanol
90656|NCT03478150|Device|laser diode|The laser light is transferred through a 600µm flexible fiber optic tip by a special hand piece. the output power will be adjusted at 1.5W.
90657|NCT03478137|Behavioral|CPAP intervention|Participants who agree to participate will be evaluated by a sleep specialist who will confirm eligibility for CPAP treatment.Eligible participants will be referred to VitalAire for initiation of treatment following a standard protocol for CPAP use at home. CPAP treatment will continue until the next visit for the main study, between 4-7 months, based on the timing of the evaluations, after which the study will end.
90658|NCT03478124|Behavioral|Cognitive evaluation|An extensive battery of neuropsychological and motor tests was assessed: MMSE, FAB, MoCA, WCST, Stroop Test, TMT-A and B, Verbal fluency Test, ROCF copy and delayed recall, RAVLT, 6MWT, TUG, BBS.
90659|NCT03478111|Drug|CMAB008|the study drug
90660|NCT03478111|Drug|MTX|basic therapy drug
90661|NCT03478111|Drug|Remicade|active comparator
90662|NCT03478098|Other|Low GI mealtest|Meal with low glycaemic index (GI) is consumed over 20 min
90663|NCT03478098|Other|Low GI mealtest and subsequent exercise|Meal with low glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
90664|NCT03478098|Other|High GI mealtest|Meal with high glycaemic index (GI) is consumed over 20 min
90665|NCT03478098|Other|High GI mealtest and subsequent exercise|Meal with high glycaemic index (GI) is consumed over 20 min and the subject postprandially exercises for 30 min
90666|NCT03478085|Other|Oxygen guided exercise therapy|Subjects exercise to a certain intensity based on 15% muscle oxygen desaturation.
90667|NCT03478072|Device|trichoscopy|hair and scalp dermoscopy) is a non-invasive technique in which either a handheld dermoscope or a digital videodermoscope can be used to visualize hair and scalp structures
90668|NCT03478059|Behavioral|Cognitive and Motor Dual-task Intervention|The intervention will take place 3 times per week for 6 weeks (60 minutes/session) and employs motor and cognitive challenges. It is based on known motor and cognitive deficits after mTBI and is structured using a theoretical framework published in another domain of neurologic disease. The intervention will consist of 6 stations that target known motor and cognitive impairments after mTBI. Each station will have 3 levels of difficulty with optional cognitive progressions. Subjects will spend 8 minutes at each station with a 2 minute transition/rest period between stations and will be progressed in motor and cognitive difficulty as able.
90669|NCT03478046|Other|Weight loss|Compare the total and temporal changes in fetuin-A phosphorylation and insulin resistance that occur with an 8 to 10% weight loss induced by chronic exercise training and dietary modification
90670|NCT03478033|Drug|Rifampicin|Rifampicin capsules, 150mg
90671|NCT03478033|Drug|Rifabutin|Rifabutin capsules, 150mg
90672|NCT03478020|Drug|AQX-1125|Investigational Drug
90673|NCT03478020|Drug|Combined Oral Contraceptive|COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)
90674|NCT03478007|Device|Intervention Technology|Subjects will perform their exercises using the provided monitoring device. They will be able to contact the investigators with questions regarding the use of the monitoring device, however, no encouragement or coaching will be provided
90675|NCT03478007|Device|Intervention Technology Plus Coaching|Subjects will perform their exercises using the provided monitoring device. They will also be coached by a trained health coach through a weekly call.
90676|NCT03477994|Drug|Dexmedetomidine|an infusion of 0.5-0.7 μg/kg/h then 1.4 μg/kg/h if Richmond assessment sedation score from +1 to +4 ,if the heart rate less than 60 per minute or persistent hypotension reduce infusion rate by 0.2 μg/kg/h.
90677|NCT03477994|Drug|Clonidine|an infusion of 0.5μg/kg then 0.1-0.2 μg/kg/h if Richmond assessment sedation score from +1 to +4.
90678|NCT03477981|Other|Alginate bread|White bread with 4% alginate (wet weight of dough) included into the bread.
90679|NCT03477968|Other|Plasma sampling|Additional blood draw or additional volume during blood draw
90680|NCT03477955|Procedure|PEEK interspinous spacer|To study the Adjacent Segment Degeneration incidence in the supradjacent segment following short lumbar fusion between PEEK and Silicon Interspinous spacers.
90681|NCT03477942|Biological|Autologous Mesenchymal Stem Cells|Bone marrow will be harvested from each individual patient's iliac crest, followed by stem cell isolation, expansion and preparation. Stem cell will be injected approximately 3-4 weeks after bone marrow harvest, injecting 50x10^6 MSCs in the knee via a medial parapatellar approach under sterile technique in 8 patients with generalized knee OA or focal chondral defects.
90682|NCT03477929|Drug|Ganirelix Acetate|multiple dose of Ganirelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
90683|NCT03477929|Drug|Cetrorelix Acetate|multiple dose of Cetrorelix acetate (0.25mg) are administered when the lead follicle is ≥ 14 mm until hCG criteria are met
90684|NCT03477916|Biological|FMT|fecal microbial transplantation (FMT)
90685|NCT03477916|Biological|Placebo FMT|Placebo fecal microbial transplantation (FMT)
90686|NCT03477916|Dietary Supplement|Prebiotic Fiber|combined fiber supplement of resistant starch type 4, acacia gum, and soluble corn fiber
90687|NCT03477916|Dietary Supplement|Cellulose|Cellulose
90688|NCT03477903|Drug|TAK-954|TAK-954 infusion
90689|NCT03477903|Drug|Metoclopramide|Metoclopramide infusion
90690|NCT03477903|Drug|Normal Saline|0.9% sodium chloride for injection
90691|NCT03477890|Diagnostic Test|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or no-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
90692|NCT03477890|Diagnostic Test|Stratified medicine involving a diagnostic intervention|"Adjunctive tests of coronary artery lesion severity (fractional flow reserve) and function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with obstructive coronary artery disease (mis-classified by non-invasive CTCA) or non-obstructive coronary disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results).~Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013), Scottish Intercollegiate Guideline Network (SIGN), 2017)."
90693|NCT03477877|Behavioral|Indashyikirwa Couples Training|A training curriculum for heterosexual couples in Rwanda comprising 20 3-hour modules (60 hours total) delivered to groups of 15 couples (30 people). Each module facilitated by male and 1 female facilitator. Curriculum topics include: types and uses of personal and interpersonal power (power within, power over, power with, power to), gender, gender based violence, triggers for intimate partner violence, conflict management, economic development, sexuality, alcohol, social norms and community change. Delivered by RWAMREC.
90694|NCT03477877|Behavioral|Indashyikirwa Activist Training|This training is offered to a subset of individuals who complete the couples curriculum (randomly selected from among those who are are willing and eligible). These individuals are trained to serve as community activists, teach peers about the types of power (power within, power over, power with, power to), and advocate for community change to prevent intimate partner violence. Delivered by RWAMREC.
90695|NCT03477877|Behavioral|Indashyikirwa Opinion Leader Training|"Training delivered to opinion leaders (political office holders, religious leaders, service providers), in intervention communities. Training comprised 8 x 3 hour sessions (24 hours) delivered for groups of up to 40 participants. Introduces Opinion Leaders to the concepts of power (power within, power over, power with, power to) and to essential concepts around women's legal rights. Delivered by Rwanda Women's Network."
90696|NCT03477877|Other|Indashyikirwa Women's Spaces|"Establishment of 1 Women's Space per intervention sector -- a physical space with trained facilitators on duty from which support and referrals for women experiencing IPV could be offered and ad hoc programming responsive to community needs and interest can be run. Typical activities include once-off open trainings for community members on the concepts of power (power within, power over, power with, power to), essential concepts around women's legal rights, conflict management in families, etc. Delivered by Rwanda Women's Network."
90697|NCT03477877|Behavioral|Village Savings and Loan Association (VSLA)|A standard Village Savings and Loan Association program as run nationwide by CARE Rwanda.
90698|NCT03477864|Biological|Ipilimumab|Given via intraprostatic injection
90699|NCT03477864|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
90700|NCT03477864|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
90701|NCT03477864|Biological|Anti-PD-1 Monoclonal Antibody REGN2810|Given IV
90702|NCT03477851|Drug|Tramadol Hydrochloride|Tramadol i.m. simultaneous with sciatic nerve block
90703|NCT03477851|Drug|Placebo|0,9%NaCl i.m. simultaneous with sciatic nerve block
90704|NCT03477838|Device|FreeStyle LibrePro CGM|a professional CGM device will be worn by the participant for up to 14 days
90732|NCT03477552|Device|Accuvein V400 device|Sickle cell patients who need a new vein puncture in order to infuse them will benefit of AccuveinV400 device to illuminate their venous network
90705|NCT03477825|Dietary Supplement|Placebo Oral Tablet|"Group A: Placebo group (n = 10)~Supplement appearing similar to Herbal formulations~Each placebo tablet will contain microcrystalline cellulose, dicalcium phosphate, PVPK30, sodium starch glycolate, magnesium stearate, OpaDry orange coating.~Dose: subjects in this group will take 4 placebo tablets per day"
90706|NCT03477825|Dietary Supplement|Rubia Cordifolia|"Group B: R. cordifolia group (n = 10)~2,000 mg R. cordifolia per day - supplied by Banyan Botanicals and following standard supplementation doses on commercially available supplement (https://www.banyanbotanicals.com/manjistha-tablets/)~Each tablet contains 500 mg of R. cordifolia per tablet."
90707|NCT03477825|Dietary Supplement|Triphala|"Group C: Triphala group (n= 10)~Tablets of Triphala will be supplied from Banyan Botanicals (https://www.banyanbotanicals.com/triphala-tablets-11/)~Each tablet contains mix Emblica officinalis, Terminalia bellerica, and Terminalia chebula~Dose: subjects will take 4 tablets per day, with a total dose of 2,000 mg of total herb."
90708|NCT03477812|Device|Polysomnography (Full sleep registration)|For the healthy children two nights of polysomnography. For the children with nocturnal enuresis one night of polysomnography.
90709|NCT03477799|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a safe method for non-invasively modulating cortical excitability through the use of weak electrical currents (usually of 1-2 mA) circulating between two scalp electrodes (i.e., an anode and a cathode) placed over the target cortical regions. The effects of tDCS on brain activity are polarity-dependent, such that anodal stimulation generally enhances cortical excitability by depolarizing cell membranes and increasing neuronal firing rates, while cathodal stimulation generally results in the opposite effect. Because of its neural effects, tDCS has been increasingly used to gauge the functional relationship between cognitive/behavioural dimensions and putatively relevant neurocircuitry
90710|NCT03477786|Combination Product|drug adjustment and behavioral modification|anti-hypertension drug prescription by physician and case management by health educator
90711|NCT03477773|Other|High-intensity exergaming|Perform high-intensity exercise whilst playing a developed exergame. A full warm-up performed prior to the session was performed (~70% HRmax). Periods of exercise were performed at an intensity >85% HRmax for periods of 10, 20 and 30s, interspersed with periods of rest, for a total of 2-3 minutes per session. Heart rate was monitored throughout the intervention.
90712|NCT03477760|Biological|rectal swab for Multi-Drug resistant bacteria|A rectal swab will be performed at admission of patients to look for intestinal carriage of Multi-Drug resistant bacteria
90713|NCT03477747|Device|Microcurrent|Microcurrent based treatments have been proposed more than 30 years. The manufacturer initially should calibrate the microcurrent devices. There is no physical sensation associated with microcurrent based treatments as the strength of the current is not high enough to stimulate sensory nerve fibres. The application of electric fields and currents similar to those generated within the body can substantially change the cell structure and the metabolic behaviour of cells. For example, the application of microcurrent increases the number of organelles responsible for cellular activities; it increases concentrations of adenosine triphosphate (ATP) and amino acid transport; promotes protein synthesis; fastens regrowth of atrophied soleus muscle and would also activate hormone-sensitive lipase which can increase lipolysis from the internal and external adipose tissue. The microcurrent treatment with training would maximize exercise and recovery outcomes in athletes.
90714|NCT03477734|Device|CS1 & heart monitor|Daily activities while wearing the investigational device as well as the control device
90715|NCT03477695|Device|ambulatory use of the Upright device|Patients will wear the UpRight for a period of two month
90716|NCT03477682|Other|Early ambulation|Patients who are in the experimental arm will have a shorter duration of bedrest restriction following sartorius surgery (1 day) versus the standard group (5 days bedrest).
90717|NCT03477669|Dietary Supplement|chamomile/probiotic arm|Caregivers will administer 5 drops of the study product once a day with a feeding at mid-day.
90718|NCT03477669|Dietary Supplement|Placebo of chamomile/probiotic arm|Caregivers will administer 5 drops of the placebo study product once a day with a feeding at mid-day.
90719|NCT03477656|Procedure|Large volume specific immunoadsorption|1 to 2 sessions of large volume specific immunoadsorption using GLYCOSORB®-ABO column
90720|NCT03477656|Procedure|Double Filtration Plasmapheresis|1 to 5 sessions of double filtration plasmapheresis
90721|NCT03477630|Biological|Platelet Rich Plasma|Infiltration PRP 8cc per session, 4 sessions, 1 session every 15 days.
90722|NCT03477630|Drug|Hyaluronic Acid|Infiltration 6 cc of HA , only once.
90723|NCT03477617|Other|Intraoperative Hemodynamic Algorithm|Anesthesiologists are instructed to use the study`s algorithm to manage intraoperative hypotension in response to the cardiac output monitor values.
90724|NCT03477617|Combination Product|Usual hemodynamic management|Anesthesiologists are instructed to manage intraoperative hypotension based on their usual clinical care, without information from cardiac output monitor
90725|NCT03477604|Device|MicroStent|Self-expanding stent
90726|NCT03477591|Other|Evidence-based information|Evidence-based information on PSA testing such as blog posts, plain language evidence summaries and web resource ratings (quality-appraised online resources).
90727|NCT03477591|Other|Patient Decision Aid|Patient Decision Aid for prostate cancer screening decision
90728|NCT03477591|Other|Sham information|Educational information not specific to PSA testing or cancer screening
90729|NCT03477578|Other|freezers|neuropsychological evaluation
90730|NCT03477578|Other|non freezers|neuropsychological evaluation
90731|NCT03477565|Device|Kinesio tape lymphatic drainage technique application|Kinesio Tex Tape strips are applied following Dr.Kase draining techinique. The choice of tape's length and strips' number is based on the area of breast edema and/or presence of seroma, which must be completely covered. The patch is cut into fan strips. The major base is positioned near the functioning lymph node stations closest to the edema and/or seroma area. The bases and the tails of the fan must be applied with zero tension, while for the central part is reached 15-25% of tension. The first application takes place on the 1st post-operative day, while the second is performed on the 7th post-operative day. In case the tape is detached from one application to another, it is necessary that the patient resume in the clinic for a new application to ensure continuity of the therapeutic effect; otherwise the patient is eliminated from the study. The experimental group also receives the expected standard treatment, consisting in physiotherapeutic evaluation and counselin.
90733|NCT03477552|Other|Routine procedure|In the control group, the nurse proceeds as usual to infuse the patient (visual identification in the light of the chamber and palpation)
90734|NCT03477539|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
90735|NCT03477539|Biological|Daratumumab|Given IV
90736|NCT03477539|Other|Laboratory Biomarker Analysis|Correlative studies
90737|NCT03477539|Drug|Lenalidomide|Given PO
90738|NCT03477539|Other|Pharmacokinetic Study|Correlative studies
90739|NCT03477526|Procedure|Pulmonary rehabilitation program|3 weeks, ...
90740|NCT03477513|Radiation|Radation Therapy|Personalized Radiation Therapy
90741|NCT03477500|Drug|Cyclophosphamide and ATG|Hematopoetic stem cell transplantation
90742|NCT03477500|Drug|Alemtuzumab|Alemtuzumab (Lemtrada)
90743|NCT03477487|Biological|XT-150|Human IL-10 variant transgene in a plasmid DNA vector
90744|NCT03477461|Drug|terlipressin|a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
90745|NCT03477448|Drug|Bleomycin|"an antibiotic derived from Streptomyces verticillus, has an antitumor, antibacterial, and antiviral activity that may be related to its ability to bind with DNA, causing bleomycin strand scission and elimination of pyrimidine and purine bases. The bleomycin hydrolase enzyme, which is known to inactivate bleomycin, is normally found in all body tissues but is present in very small amounts in skin .~Intra-lesional bleomycin injection (IBI) has been used for the treatment of warts."
90746|NCT03477448|Drug|Purified Protein Derivative|"is an extract of Mycobacterium tuberculosis and is used for testing exposure to tuberculin protein, either from a previous vaccination or from the environment. It contains live, attenuated Mycobacterium bovis.~Using this protein derivative for immunotherapy of warts is important for two major aspects. First, because the obligatory immunization program in many developing countries - with high prevalence of wart in many of them - includes BCG vaccination. PPD has a high prevalence of immunity in the general population. Second, although immunotherapy is generally an inexpensive method of treatment in wart patients, PPD, among conventionally used antigens, is the cheapest"
90747|NCT03477435|Behavioral|Staff training and academic detailing|Both arms will receive training at baseline to help their patients quit smoking. The training will be a mix of content and process education. We will provide brief updates to staff every 6 months throughout the intervention period, which will focus primarily on process education. We will monitor which staff attend and reach out separately to staff who did not. During the month after implementation of the clinical reminders, two study investigators will make a brief outreach visit to each staff member. We will follow a script, using the seven steps recommended by the National Resource Center for Academic Detailing: 1) Introduction; 2) Needs Assessment; 3) Key Messages/Features/Benefits; 4) Understanding Barriers and Enablers; 5) Identifying and Handling Objections; 6) Summary; and 7) Close. The key message (Step 3) will include demonstration of the clinical reminder, review of the evidence for telephone counseling and text messaging and how to refer patients.
90748|NCT03477422|Drug|CSE-1034 (Ceftriaxone + Sulbactam + EDTA)|CSE-1034 (Ceftriaxone + Sulbactam + EDTA) was Experimental in this study and is a combination of Ceftriaxone 1000mg, Sulbactam 500mg and EDTA 37mg available as dry powder for reconstitution. Patients were given either CSE-1034 or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Placebo) was given at 8th hour from first dose, third dose (Drug) at 12th hour from first dose and the fourth dose (Placebo) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
90749|NCT03477422|Drug|Meropenem|Meropenem was the Comparator in the study. It was also available as dry powder for reconstitution and contained active ingredient Meropenem 1000mg.Patients were given either Meropenem or placebo through IV route four times daily, strictly adhering to the time interval. Time of the first dose (Drug) was considered 0th hr, the second dose (Drug) was given at 8th hour from first dose, third dose (Placebo) at 12th hour from first dose and the fourth dose (Drug) at 16th hour from first dose. The infusion was initiated within ± 30 min of schedule time.
90750|NCT03477409|Other|plasticizers|The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
90751|NCT03477396|Drug|Aromatase Inhibitor|Aromatase inhibitor per treating investigator's discretion
90752|NCT03477396|Other|Laboratory Biomarker Analysis|Correlative studies
90753|NCT03477396|Other|Pharmacokinetic Study|Correlative studies
90754|NCT03477396|Other|Questionnaire Administration|Ancillary studies
90755|NCT03477396|Drug|Ribociclib|Given PO
90756|NCT03477383|Diagnostic Test|donor-derived cell-free DNA (dd-cfDNA)|Measurement of dd-cfDNA and comparison against grade of rejection as measured by endomyocardial biopsy, taken simultaneously
90757|NCT03477357|Device|Geratherm non Contact thermometer|Temperature taken from subject using non-contact device as per manufacturers instructions
90758|NCT03477344|Drug|Dexmedetomidine|Intravenous infusion with electric syringe of Dexmedetomidine 0,4ug/ml. Rate 0,1ug/kg/h to 1,4ug/kg/h. Nightly infusion from 20:00 to 08:00. The drug is titrated to achieve RASS between -1 and 1. Modification of infusion rate by 0,1ug/kg/h is recommended with stabilization phase of 1 hour before another rate adjustment.
90759|NCT03477344|Drug|Sodium chloride 0.9%|Intravenous infusion with electric syringe of normal saline. Rate modifications follow the same rules as in experimental group.
90760|NCT03477305|Behavioral|Blackberry Consumption|Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
90761|NCT03477292|Drug|Duration of antibiotic|Duration of antibiotic for treatment of VAP
90762|NCT03477279|Behavioral|Enhanced Couple HIV Testing and Counseling|"Participants are provided study-specific partner referral cards and encouraged to bring male partners to antenatal care for a male engagement intervention. Those who do not present on their own are then traced.~Couples will receive three enhanced couple counseling sessions that include: pre-test counseling, return of joint results, and post-test counseling. HIV-infected men will be able to initiate cART at the antenatal clinic and the couple will be offered condoms from the HTC counselor. Between sessions, couple members can pick up condoms and cART for one another."
90763|NCT03477266|Drug|Mosapride|Intake mouthly dissolving mosapride tablets in immediate post cesarean section
90764|NCT03477266|Drug|Placebo Oral Tablet|Dummy identical tablets to mouthly dissolving mosapride tablets
90765|NCT03477253|Device|Laparoscopic cholecystectomy|The use of laparoscopy in management of acute calculous cholecysitits
90766|NCT03477227|Device|Short stocking|Patients in the experimental group will be asked to wear new type of compression stockings for four weeks post-operatively
90767|NCT03477227|Device|Usual stocking|Patients in the control group will be asked to wear usual type of compression 2 class stockings for four weeks post-operatively
90768|NCT03477214|Diagnostic Test|Biomechanical and electromyography mapping|The vaginal tactile imaging probe will acquire biomechanical and electromyography high definition measurements for anterior and posterior compartments along entire vagina.
90769|NCT03477201|Procedure|Laparoscopic robotic DaVinci assisted inguinal hernia repair|Laparoscopic inguinal hernia repair using a robotic assisted laparoscopic procedure.
90770|NCT03477201|Procedure|Standard laparoscopic inguinal hernia repair|Laparoscopic inguinal hernia repair, an accepted safe method of repairing inguinal hernia.
90771|NCT03477188|Behavioral|Somatosensorial and Vestibular Exercises|In the experimental group, the subjects who were taken to the somatosensorial and vestibular exercises program after pre- treatment evaluations. The subjects in this group were given classical physiotherapy and somatosensorial combined with vestibular exercise performed 5-7 days a week, 1 set of 10 times with physiotherapist control. In the content of the training, in addition to the general physiotherapy program applied for Brunnstrom and Bobath exercises and spasticity inhibition according to in-bed mobility, Flask and spasticity conditions in the experimental group, a mutual study program was prepared with Cawthorne-Cooksey and Frenkel exercises in the bed, then balance and walking will be performed with the exercises
90772|NCT03477188|Behavioral|Conventional Group|In the control group, The subjects who were taken into the study were taken to the classical physiotherapy based on Bobath and Brunnstrom will be applied to increase the mobilization and spasticity up to the discharge stage known as 5-7 days a week
90773|NCT03477175|Drug|E7080|Oral Administration
90774|NCT03477175|Drug|Comparator Drug|Per parent study
90775|NCT03477162|Drug|Metformin|Metformin will be given to patients prior to surgery.
90776|NCT03477149|Device|Easyx|Embolization will be done with Easyx liquid agent.
90777|NCT03477136|Diagnostic Test|ELISA to evaluate serum and seminal vitamin D level|Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
90778|NCT03477123|Device|Walking therapy with Exo-H2 exoskeleton|
90779|NCT03477110|Drug|Temozolomide|Given PO
90780|NCT03477110|Radiation|Radiation Therapy|Undergo radiation therapy
90781|NCT03477110|Device|NovoTTF-200A Device|Undergo tumor treatment fields therapy using NovoTTF-200A device
90782|NCT03477110|Procedure|Tumor Treating Fields Therapy|Undergo tumor treatment fields therapy using NovoTTF-200A device
90783|NCT03477097|Other|Nutrition, exercise and social network intervention|
90784|NCT03477084|Biological|ESBL-producing enterobacteriaceae carriage|Carriage of ESBL-producing Escherichia coli or Klebsiella pneumoniae
90785|NCT03477071|Procedure|Angioplasty for Transplant Renal Artery Stenosis (TRAS)|The angioplasty is an endovascular treatment for artery stenosis, which could be associated with stenting or not.
90786|NCT03477058|Other|WO 3308 cosmetic product for topical use|Application on the entire body at least once a day over two weeks
90787|NCT03477045|Dietary Supplement|Single dose fish oil|Fish oil consumed within a single high fat test meal
90788|NCT03477045|Dietary Supplement|Repeated dose fish oil|Fish oil consumed daily for 8 weeks
90789|NCT03477045|Dietary Supplement|single dose Camelina seed oil|camelina seed oil consumed within a single high fat test meal
90790|NCT03477045|Dietary Supplement|repeated dose camelina seed oil|camelina seed oil consumed daily for 8 weeks
90791|NCT03477032|Biological|Faecal Microbiota Transplantation|Faeces acquired from a healthy donor
90792|NCT03477019|Drug|SonoVue|"consists of microbubbles containing sulfur hexafluoride stabilized by phospholipids.~Bolus doses à 1,0ml administered every 3.5 minutes , repeated 9 times. Total duration of treatment: 31,5 minutes. This treatment will be repeated maximally 4 times at 2 or 3 week intervals, depending on the patient's diagonse and treatment protocol."
90793|NCT03477019|Procedure|Focused Ultrasound|ultrasound pulses will be generated by a clinically approved ultrasound skanner and probe.
90794|NCT03477006|Biological|Whole blood|Low titer, group O, leukocyte reduced, platelet replete, cold stored whole blood
90795|NCT03476993|Biological|BCD-085|All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.
90796|NCT03476980|Procedure|Randomized to Umbilical Cord Milking at birth|The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.
90797|NCT03476980|Procedure|Randomized to Delayed Cord Clamping at birth|The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
90798|NCT03476967|Procedure|Panretinal photocoagulation|In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
90799|NCT03476954|Other|Respiratory Impedance (RI)|A non-invasive respiratory device is employed to generate resistance during the inspiratory phase of respiration.
90800|NCT03476941|Drug|Gentamicin Sulfate Inj 20mg/2ml vial for injection|Irrigate surgical drain with total amount of 5 mg in 10 ml volume twice/day for 7 days or until drain removal if less than 7 days of therapy.
90801|NCT03476941|Drug|Clindamycin phosphate 6 mg/1ml for injection|Irrigate surgical drain with total amount of 12 mg in 10 ml volume once daily for 7 days or until drain removal if less than 7 days of therapy.
90802|NCT03476941|Other|Placebo|The placebo group will receive drain irrigation twice/day
90804|NCT03476915|Other|ultrasound examination of the hip joint|US examination by US machine , Midray model DP-2200 made in China , with a high frequency (5-10 MHZ) linear transducer using the previously described Graf method for assessment of both hip joints.
90805|NCT03476902|Behavioral|Therapist assisted mobile intervention|Individuals will receive 4 introductory sessions with a therapist followed by weekly phone calls. Participants will utilize nOCD application to assist with treatment protocol adherence.
90806|NCT03476889|Other|Infant formula|Infants are randomized to one of two infant formulas from <14 days of age to 17 weeks of age.
90807|NCT03476876|Device|Dermacell|Subject will receive treatment for deep diabetic foot ulcer using Dermacell acellular matrix. Subject will be followed for 16 weeks post treatment.
90808|NCT03476876|Device|Integra|Subject will receive treatment for deep diabetic foot ulcer using Integra acellular matrix. Subject will be followed for 16 weeks post treatment.
90809|NCT03476863|Procedure|Alveolar Recruitment Maneuver|Patients in the Experimental Group will be submitted to ARM, immediately after abdominal desinflation of the pneumoperitoneum (PNP). The ARM will be performed with PEEP of 15 cmH2O for thirty seconds, 20 cmH2O for thirty seconds, 25 cmH2O for thirty seconds, 30 cmH2O for one minute and a inspiratory plateau pressure of 15 cmH2O above PEEP, totaling two minutes and thirty seconds.The data of the TIE will be continuously recorded and the hemodynamic and respiratory function variables such as heart rate (HR), respiratory rate (RF), mean arterial pressure (MAP), peripheral oxygen saturation (SpO2) and final gas expiratory pressure carbon dioxide (PETCO2) will be recorded in several moments: immediately after the monitoring, and the patient is still on spontaneous ventilation, 5min after orotracheal intubation, after the installation of the pneumoperitoneum, before and after the execution of the MRA and in the Post-OP, in the first 24h, along with new lung function tests.
90810|NCT03476863|Procedure|Conventional mechanical ventilation|Immediately after intubation, patients will undergo mechanical ventilation with the ventilator (Dixtal DX 5020) in volume controlled mode with an ideal tidal volume of 7 ml / kg body weight, a set frequency to maintain a carbon dioxide of 35-42 mmHg, and an inspiratory / expiratory ratio of 1: 2. The inspiratory oxygen fraction (FIO2) will be 0.5.
90811|NCT03476850|Procedure|QL Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
90812|NCT03476850|Procedure|TAP Block|Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
90813|NCT03476837|Behavioral|Treatment|The CHWs will go to the homes of the WCGs who enroll in the study and will use a culturally-adapted motivational interviewing protocol, educational messages pilot tested during the formative research phase, and biofeedback based on the child's saliva sample. Saliva samples will be collect from one child in the home at each assessment and be used to develop feedback that aims to motivate WCGs to implement and sustain comprehensive smoke free policies. The intervention will last 6 months. We will measure changes in primary and secondary outcomes at multiple assessment points.
90814|NCT03476837|Behavioral|Control|Following baseline assessment, at 1, 3, and 6 months, WCGs in the control group will educational materials in the mail. Final follow-up assessments will occur at 12 months.
90815|NCT03476811|Drug|0.25% Marcaine at 2ml/hr and pain medications|Subcutaneous pain control with OnQ Subcutaneous Drug pump
90816|NCT03476811|Device|Placement of OnQ Drug pump|Subcutaneous placement of OnQ drug pump with normal saline infusion
90817|NCT03476798|Drug|Rucaparib|Rucaparib 600mg PO BID daily
90818|NCT03476798|Drug|Bevacizumab|Bevacizumab 15mg/kg IV on day 1 of each cycle
90819|NCT03476785|Behavioral|High intensity exercise|Subjects will perform high intensity aerobic exercise in addition to moderate intensity sessions 4-5 times per week.
90820|NCT03476785|Behavioral|Yoga|Subjects will perform strength and flexibility exercises.
90821|NCT03476772|Drug|Nalbuphine|Children will be randomly assigned into 2 groups of 30 patients each. They will receive caudal anesthesia using bupivacaine 0.25% 1ml/kg plus 2 ml normal saline in the control group, bupivacaine 0.25% 1ml/kg plus nalbuphine 0.1 mg/kg in 2 ml solution in the nalbuphine group.
90822|NCT03476759|Procedure|Tubal adhesiolysis|125 patients will undergo tubal adhesiolysis or tuboplasty
90823|NCT03476759|Drug|IVF/ICSI|125 patients will undergo IVF-ICSI procedures.
90824|NCT03476746|Drug|LEO 90100 foam|A foam formulation of the active comparator Dovobet® ointment
90825|NCT03476746|Drug|Dovobet® ointment|Ointment formulation containing same active ingredients as LEO 90100 foam
90826|NCT03476733|Other|Detection of drug related problem in inpatient|Detection of drug related problem in inpatient
90827|NCT03476720|Device|Pad positioning according to a manufacturer's diagram|Placement of defibrillation pads according to the diagram
90828|NCT03476707|Other|Anemia|Hematocrit less than 0.39
90829|NCT03476694|Procedure|ultra sound guided supraclavicular brachial plexus block|ultra sound guided supraclavicular brachial plexus block , comparing the volume of 0.75 % ropivacine in sucessful block and hemidiaphragmatic motilty.
90830|NCT03476681|Drug|NEO-201|NEO-201 will be given intravenously every 2 weeks.
90831|NCT03476668|Other|MIRT|4-week multidisciplinary intensive rehabilitation treatment
90832|NCT03476655|Drug|Ibrutinib|No study treatment will be administered as a part of this study. Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib treatment before 30 April 2018 in routine clinical practice settings will be observed.
90833|NCT03476642|Drug|Ropivacaine|injection of 20mL of 0.5% Ropivacaine at the left or right T5 transverse process
90834|NCT03476642|Drug|Epinephrine|injection of 20mL epinephrine in combination with ropivacaine at the left or right T5 transverse process
90835|NCT03476629|Other|Physical activity|Effects of different physical activity programs
90868|NCT03476317|Drug|Fluconazole|Orally once daily (Day 1-14)
90869|NCT03476304|Device|Endocrown restoration|The endodontically treated tooth will be impressed, and an endocrown restoration will be manufactured with resin composite in a cast and cemented with self adhesive cement
90895|NCT03476018|Drug|Z-100|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
90896|NCT03476018|Drug|Placebos|Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
90836|NCT03476616|Drug|Eplerenone (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM.
90837|NCT03476616|Drug|Valsartan (-based therapy) arm|At randomization, pts meeting inclusion/exclusion criteria will be randomized (1:1) to either eplerenone (E) 25mg bd or valsartan (V) 160mg od for 8 wks. At 8, 16 and 24 wks, pts at both arms will be evaluated with ABPM primary, as well as home and office BP measurements. At wk 8, pts with controlled hypertension (mean ABPM <130/80mmHg), will continue in monotherapy with eplerenone or valsartan and pts with uncontrolled hypertension (mean ABPM ≥130/80mmHg) will continue with the addition of amlodipine (C) 10mg od. At wk 16, pts achieving BP control will continue in either monotherapy (E), (V) or dual therapy (E+C), (V+C). However, in pts not achieving ABPM target, a third drug, will be added [indapamide (D) 1.25 mg od]. All groups at both arms will be evaluated at 24 wks by ABPM.
90838|NCT03476603|Drug|Irbesartan|Patients are tested for their normal prescription irbesartan medication
90839|NCT03476590|Procedure|new model of ambulatory care with use of of non-invasive vital signs assessment and telemedicine|"The report of symptoms and physical examination will be obligatory performed by the ACP nurse. Self-condition and quality of life assessment at every visit will be based on EQ-5D questionnaire and VAS 10-points scale Hemodynamic assessment - the ACP nurse will perform impedance cardiography (cardiomonitor) and bioimpedance (scale). The parameters measured by ICG and bioimpedance will be assessed with respect to individually defined target values for: heart rate (HR), systolic and diastolic blood pressure (SBP and DBP), thoracic fluid content (TFC) and its change (delta TFC), change of body mass and total body water (delta TBW).~Supervising physician will confront ICG/bioimpedance results with the patient's clinical data and give final remote recommendations."
90840|NCT03476577|Drug|Ibuprofen|Patients are tested for their normal prescription ibuprofen medication
90841|NCT03476564|Drug|pentoxifylline|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
90842|NCT03476564|Drug|Vit E|will be given 2 cycles before starting ICSI cycle and the medication will be continued until the beta-hCG becomes positive or the cycle is cancelled
90843|NCT03476551|Drug|Hydrochlorothiazide|Patients are tested for their normal prescription hydrochlorothiazide medication
90844|NCT03476538|Drug|Gabapentin|Patients are tested for their normal prescription gabapentin medication
90845|NCT03476525|Drug|Fluoxetine|Patients are tested for their normal prescription fluoxetine medication
90846|NCT03476512|Other|Adherence Education|Patients were given adherence education to resolve the identified deficits
90847|NCT03476499|Device|Near Infrared Imaging (NIR) device|Handheld near infrared multispectral imaging device with custom software.
90848|NCT03476486|Procedure|Thread carpal tunnel release|Ultrasound-guided percutaneous minimally invasive thread carpal tunnel release using a looped thread technique
90849|NCT03476460|Drug|Oral sodium chloride|Patients will receive capsules of sodium chloride and free water ingestion (for each capsule of sodium chloride, with 250 ml of water, assuring a minimum ingestion of 750 ml of water) in the 48 hours prior contrast injection. Patients will take capsules of sodium chloride at a dose of 100 mg/kg during 48 hours previous the injection of contrast (48, 40, 32, 24, 16, and 8 hours), at the moment of contrast injection and 12 hours after the injection of contrast.
90850|NCT03476460|Drug|Intravenous sodium chloride|Patients will receive at hospital 3 ml/Kg of sodium chloride 0.9%, one hour previous contrast injection and 2 ml/kg during the 4 hours after contrast injection.
90851|NCT03476447|Other|B. infantis EVC001|A once-daily oral feeding of B. infantis EVC001 will be mixed with breast milk and provided to infants for 28 consecutive days.
90852|NCT03476447|Other|Lactose|A once-daily oral feeding of a lactose placebo will be mixed with breast milk and provided to infants for 28 consecutive days.
90853|NCT03476434|Device|chromoendoscopy with indigo carmine|the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
90854|NCT03476421|Procedure|Hepatic resection|Surgery of the liver; removal of a part of the liver
90855|NCT03476408|Other|Correlation / Observational|correlation between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia
90856|NCT03476395|Other|shoulder range of motion in IR/ER, strength of the IR/ER muscles and Scapular Dyskinesis Test. Core endurance test.|Passive shoulder range of motion using a digital application Clinometer. Isometric strength of the shoulder IR/ER using a HHD measured. Scapular Dyskinesis Test uses a visual scoring system. Core Endurance is teste by measuring the time (s).
90857|NCT03476382|Device|Ultrasound Bone Growth Stimulator|Active device emits ultrasound signals.
90858|NCT03476369|Drug|Fentanyl|Premedicated with Fentanyl (at least 25mcg by IV)
90859|NCT03476369|Drug|Ticagrelor 90Mg Tablet|Ticagrelor administered crushed vs non-crushed
90860|NCT03476356|Drug|oral clomiphene citrate|oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
90861|NCT03476356|Drug|oral carnitine supplementation|oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
90862|NCT03476343|Device|GE OPTIMA MR430s with HDx/GE Electronics|MRI scan
90863|NCT03476330|Drug|Quercetin (dietary supplement)|Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
90864|NCT03476317|Drug|Vancomycin|Oral suspension 4 times daily (Day 1-14)
90865|NCT03476317|Drug|Neomycin|Oral three times daily (Days 1-3)
90866|NCT03476317|Drug|Ciprofloxacin|Oral twice daily (Days 4-14)
90870|NCT03476304|Device|Post retained composite restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a semi direct composite restoration will be cemented with self adhesive cement.
90871|NCT03476304|Device|Post retained ceramic restoration|The endodontically treated tooth will receive a fiber post cemented with self adhesive cement and after this, the tooth will be impressed and a ceramic restoration will be cemented with self adhesive cement.
90872|NCT03476278|Other|Questionnaire|Postoperative questionnaire, and records of complications in the peri-operative period
90873|NCT03476265|Device|Electrical Stimulation of the Lower Esophageal Sphincter|Laparoscopic implantation of an electrical stimulation device to perform an electrical sphincter augmentation for the treatment of GERD.
90874|NCT03476252|Diagnostic Test|pentraxin 3|serum pentraxin 3 level will be assessed using ELISA kits
90875|NCT03476239|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A cycle = 6 weeks (4 weeks of blinatumomab treatment, 2-week treatment-free). Treatment will consist of up to 5 cycles of blinatumomab Subjects who have achieved a bone marrow (BM) response or CR/CRh*/CRi within 2 induction cycles of treatment may continue to receive up to 3 additional consolidation cycles of blinatumomab. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.
90876|NCT03476226|Other|Cognitive Dysfunction Coping Strategy Teaching Sheet|Demographic sheet, Fact-Cog3, and teaching tool at baseline then week 4 and 8 Fact Cog3 and reinforcement of tool, at week 16 evaluation and Fact-Cog3
90877|NCT03476213|Procedure|Group TCI|Induction and anesthesia will be done by using Gepth model for sufentanil and Schnider effect model for propofol. Anesthetics will be aplicated using infusion pump Agilia (Fresenius Kabi). Another titration will be according to target value of entropy between 40 and 60 and surgical pleth index below 35.
90878|NCT03476213|Procedure|Group TIVA|Induction of anesthesia will be done by titrating of propofol to the dose of 1.2 mg/kg and sufentanil 5-10 ug according to body weight, maintaining of anesthesia using continuous infusion of propofol 5 mg/ kg/hour and sufentanil 35 ug/hour to reach the target value of entropy between 40 and 60 and surgical pleth index below 35.
90879|NCT03476200|Behavioral|Cognitive Behavioral Therapy|The intervention consist of 14 weekly group meetings lasting 1.5 or 2 h. Groups are made up of 10 patients. Each group session follow a structured format and consisted of the following elements: introduction to the session, discussion of homework, group discussion and the development of new coping skills. The sessions deal with the following: concept of stress, cognitive restructuring, alternative thought control strategies, relaxation techniques, training in social skills, training in social skills and humour and optimism as coping strategies.
90880|NCT03476187|Device|µCor|Monitor with µCor
90881|NCT03476174|Drug|Pembrolizumab|Subjects will receive 200 mg pembrolizumab every 3 weeks for two cycles. Cycle length is 21 days (i.e., 3 weeks). On the last day of Cycle 2 (+/- 3 days), disease status will be assessed via imaging.
90882|NCT03476174|Drug|Interleukin-2|Following the pembrolizumab treatment, HD IL-2 treatment will commence. After completing the 2 cycles of pembrolizumab, High Dose Interleukin-2 (HD IL-2) will be administered. This will require a hospital stay of at least 5 days for each treatment cycle. Established guidelines will be followed for safely administering HD-IL-2 and managing toxicities from this treatment. Two treatment cycles will be administered, Cycle 2 being separated from Cycle 1 by approximately 9 days after completion (assuming subject has recovered from Cycle 1 adequately to proceed with Cycle 2). Four weeks after completion of the 2 cycles (called a course of HD IL-2 therapy), disease status will be monitored via CT of the chest and abdomen/pelvis using revised RECIST guidelines
90883|NCT03476161|Device|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
90884|NCT03476161|Device|3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ II Adhesive. 3069-6103 / 3069-6114 / 3069-6203 / 3069-6214|One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
90885|NCT03476148|Device|Home Rehabilitation using Interactive device|Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
90886|NCT03476148|Other|Inpatient Rehabilitation|Patients are given the exercises in the setting of inpatient rehabilitation
90887|NCT03476135|Biological|MenACYW conjugate vaccine|Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
90888|NCT03476109|Drug|Randomisation to omalizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
90889|NCT03476109|Drug|Randomisation to mepolizumab|The only intervention will be that allocation of patients to omalizumab or mepolizumab (to both of which patients will be eligible) will be randomized, to avoid that the initial decision is biased by confounding factors that are likely, but unproven, to affect the treatment response. Then, in case of non-response, patients will be switched to the other drug, as routine clinical practice would indicate.
90890|NCT03476083|Drug|Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.|All mothers will receive TDF therapy. However, group A will initiate TDF at the gestational week of 14-16, while group B will initiate TDF at the gestational week of 28. All infants will receive a series of three hepatitis B vaccines (at birth, age of weeks 4 and 24). In addition, the infants in the group B will receive HBIg injection at birth.
90891|NCT03476057|Diagnostic Test|Device： NGS sequencing cfDNA|NGS sequencing cfDNA and Tumor Burden
90892|NCT03476044|Drug|Placebo|40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia
90893|NCT03476044|Drug|Selenium|40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
90894|NCT03476031|Diagnostic Test|renal biopsy|needle biopsy will be taken from the kidney tissue then, diagnosed
91341|NCT03472612|Other|CPAP withdrawal|Short-term withdrawal of CPAP therapy in moderate to severe OSA
90897|NCT03476005|Behavioral|proficiency based progression training|proficiency based progression training supported by technology enhanced learning
90898|NCT03475992|Device|Low-power microwave breast imaging system|Investigate the capacity of microwave imaging to detect and characterise diagnosed palpable breast lump
90899|NCT03475966|Other|Exercise|A kinesiologist will provide each patient wih an individualized home-based exercise program including aerobic, resistance and stretching exercises. Patients will also exercise at our clinic once per week under the supervision of the kinesiologist (prehabilitation arm only)
90900|NCT03475966|Other|Nutrition|Patients will be asked to fill in a 3-day food diary. A registered dietitian (RD) will review this diary, provide a full nutritional assessment, and ensure patients are following a high-protein diet (1.5 g of protein/kg/day). A whey-protein supplement may be provided to patients, should they require it. The RD will also ensure adequate calorie consumption for weight maintenance and will provided advice to help ease any GI issues the patients may be experiencing.
90901|NCT03475966|Behavioral|Relaxation techniques|Patients will see a psychologist who will provide relaxation techniques (eg. imagery, visualization, deep breathing exercises) to help patients manage anxiety prior to surgery.
90902|NCT03475953|Drug|Phase 1 : Regorafenib|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
90903|NCT03475953|Drug|Phase 1 : Avelumab|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
90904|NCT03475953|Drug|Phase 2 : Regorafenib|Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
90905|NCT03475953|Drug|Phase 2 : Avelumab|Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
90906|NCT03475927|Other|Concerning and knowledge about radiation hazard questionnaire|Concerning and knowledge about radiation hazard questionnaire to determine the concerning and knowledge of radiation hazard among surgeon and anesthesiologist
90907|NCT03475901|Other|Virtual Reality App|Virtual reality app produced by KindVR played via a stereoscopic head mounted display (Samsung GearVR) and headphones that the patient will wear over their eyes and ears.
90908|NCT03475888|Device|Medtronic Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Implantation of Medtronic Reveal LINQ™ ICM
90909|NCT03475875|Device|senofilcon A TEST Lens|senofilcon A with new UV blocker investigational process
90910|NCT03475875|Device|senofilcon A CONTROL Lens|senofilcon A with new UV blocker standard process
90911|NCT03475862|Drug|PTI-821 capsule Manipulated|PTI-821 (oxycodone) 40 mg extended release capsule
90912|NCT03475862|Drug|PTI-821 Non-manipulated|PTI-821 (oxycodone) 40 mg capsule extended release capsule
90913|NCT03475862|Drug|OxyContin|Crushed OxyContin (oxycodone) extended-release 40 mg tablet
90914|NCT03475862|Other|Placebo|Matching placebos for PTI-821 and oxycodone IR
90915|NCT03475862|Drug|Oxycodone|Crushed oxycodone 40 mg immediate release tablet
90916|NCT03475836|Dietary Supplement|Mentha piperita|Commercially available essential oil suspended in an off-the-shelf vegetable oil.
90917|NCT03475836|Dietary Supplement|Placebo|Inert placebo control in the form of vegetable oil. This matches the vegetable oil in the active intervention condition.
90918|NCT03475823|Dietary Supplement|Sideritis Scardica|Sideritis Scardica is a popular, naturally un-caffeinated Eastern European tea extract derived from the ironwort plant
90919|NCT03475823|Dietary Supplement|Ginkgo biloba|Ginkgo biloba is an extract from the ginkgo tree comprising ginkgolides and bilobalide. In this trial Ginkgo acted as an active control.
90920|NCT03475823|Dietary Supplement|Placebo control|An inert encapsulated powder provided by Finzelberg.
90921|NCT03475810|Device|Virtual Reality|Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.
90922|NCT03475810|Drug|Midazolam|1-2 mg midazolam will be administered before spinal punction performed.
90923|NCT03475797|Device|Occipital nerve stimulation|Occipital nerve stimulation with percutaneous or surgical lead
90924|NCT03475797|Other|Optimal Medical Management|Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.
90925|NCT03475784|Drug|Restrictive fluid therapy|This group will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 2 mL/Kg/hour.
90926|NCT03475784|Drug|Liberal fluid therapy|This group will receive crystalloid preload of 5 mL/Kg, then will receive intraoperative crystalloids at rate of 10 mL/Kg/hour followed by postoperative crystalloids at rate of 6 mL/Kg/hour.
90927|NCT03475758|Drug|Goserelin|adding goserelin with chemotherapy
90928|NCT03475732|Drug|XueBiJing injection|100mL XueBiJing injection (dissolved with 100 mL of 0.9% normal saline),intravenous infusion for 1.25 h, q12h for 5 days
90929|NCT03475719|Drug|HUG186-B and HUG186-D|Bazedoxifene acetate 22.6mg, Cholecalciferol 8.0mg(=800IU)
90930|NCT03475719|Drug|HUG186|Combination of Bazedoxifene acetate 22.6mg and Cholecalciferol 8.0mg(=800IU)
90931|NCT03475706|Drug|Solabegron immediate release tablets, low dose|twice daily for 12 weeks.
90932|NCT03475706|Drug|Solabegron immediate release tablets, high dose|twice daily for 12 weeks.
90933|NCT03475706|Drug|Matching Placebo|twice daily for 12 weeks.
90934|NCT03475693|Drug|Magnesium Oxide|400 mg Magnesium oxide tablet given once in the ED, and prescribed to take BID for 5 days total after discharge
90935|NCT03475693|Drug|Acetaminophen|500 mg tablets given once in the ED, and prescribed to take BID for 5 days total after discharge.
90936|NCT03475693|Drug|Zofran ODT 4 MG Disintegrating Oral Tablet|Given once in the Emergency department
90937|NCT03475680|Drug|Sennosides colonic preparation|"Mechanical bowel preparation :~Sennosides colonic preparation (X-PREP)~1 per day, on day -2 and day -1"
90938|NCT03475680|Drug|Oral Gentamycin|Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
90939|NCT03475680|Drug|Oral Ornidazole|"Oral Ornidazole :~Ornidazole~1 g per day (2 tablet per day), on day -2 and day -1; In tablets"
90940|NCT03475680|Drug|Oral placebo Gentamycin|"Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1"
90941|NCT03475680|Drug|Oral placebo Ornidazole|"Placebo for oral Ornidazole :~Same presentation as oral ornidazole~1g per day (2 tablet per day) on day -2 and day -1"
90942|NCT03475654|Behavioral|Technology-assisted rehabilitation|The Jintronix software platform, coupled with the Microsoft Kinect for movement capture, contains individualized exercise modules to increase ROM, endurance and strength. Within this PRCT, online monitoring of activity and actigraphy measurements through a wearable device and completion of an online diary will provide enhanced monitoring of home activities.
90943|NCT03475654|Behavioral|Usual care|The control group will receive treatment as usual, which includes a personalized home exercise program prescribed by a burn therapist, prior to hospital discharge.
90944|NCT03475641|Drug|Femoral nerve blockade|The femoral nerve blockade with lidocain is combined to the tumescent anesthesia.
90945|NCT03475641|Procedure|The current standard treatment|Tumescent anesthesia.
90946|NCT03475628|Drug|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications prior to Daratumumab infusion to mitigate potential IRRs and post- infusion medications after Daratumumab infusion for the prevention of delayed IRRs
90947|NCT03475615|Drug|Oxaliplatin|130mg/m2, d1, q3w
90948|NCT03475615|Drug|Paclitaxel|40mg/m2 ip，d1、8 ,q3w
90949|NCT03475615|Drug|S-1 (Tegafur, Gimeracil and Oteracil Porassium Capsules)|40mg/m2 Bid po，d1-14,q3w
90950|NCT03475602|Diagnostic Test|PLA2R|Determination of serum concentration of anti PLA2R antibody
90951|NCT03475602|Diagnostic Test|TSHD7A|Determination of serum concentration of anti TSHD7A antibody
90952|NCT03475589|Drug|apatinib|Patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer will be included in this study to receive apatinib treaetment starting from 250 mg Qd and closely monitored for ADRs during apatinib treatment, with dosage adjustment performed as needed to make the treatment tolerable to the patients.
90953|NCT03475576|Other|Keuzewijzer|"The intervention, offered to the older civilians and their informal care groups will consist of a updated version of the 'Keuzewijzer'. This is a self-management tool which stimulates the communication within the informal care groups to make behaved choices concerning the care for the older civilian, taking into account the standards, values, concerns and needs of every informal caregiver and older civilian. The most important value of this intervention is the approachability and the structured, but adjusted manner of support, focused on the individual context of care with their specific needs.~The 'Keuzewijzer' is an online tool whereby, in conversation with the informal care group and older civilian, the following aspects will be discussed in the context of the care for the older civilian: 1) analyzing the problem, 2) detection of possibilities or alternatives, 3) clarifying of motives and feelings and 4) weighting between values."
90955|NCT03475550|Other|Standard of Care|The intervention involves clinician-provided information to patients receiving a new medication as part of their standard medical care. Intervention 1 includes more detailed information compared to Intervention 2.
90956|NCT03475537|Device|transcranial direct current stimulation|the treatment of transcranial direct current stimulation
90957|NCT03475524|Drug|MetFORMIN 1000 Mg Oral Tablet|oral tablet 1ooomg systemic metformin will be given to group
90958|NCT03475524|Drug|Placebos|oral placebos will be given to control beside trichloracetic acid peeling
90959|NCT03475524|Drug|Trichloroacetic Acid Peeling|Trichloroacetic acid peeling to the three groups
90960|NCT03475524|Drug|MetFORMIN 500 Mg Oral Tablet|oral tablet 500 mg
90961|NCT03475485|Device|ID-Capsule- Active|A standard gelatin or HPMC capsule with an embedded ingestible wireless sensor.
90962|NCT03475485|Device|Wearable Sensor|Subjects will wear an ID-Reader
90963|NCT03475485|Device|Placebo|A standard gelatin or HPMC capsule without an embedded ingestible wireless sensor.
90964|NCT03475459|Drug|NPC-15 and/or Placebo|The dosage and regimen of the study drug in each period is the following. Period I : NPC-15 placebo granules 8 g Period II : NPC-15 placebo granules 4 g + NPC-15 granules 0.2% 4 g (melatonin 8 mg) Period III : NPC-15 granules 0.2% 8 g (melatonin 16 mg)
90965|NCT03475446|Device|real anodal tDCS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the group of healthy elderly.
90966|NCT03475446|Device|real tACS healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the group of healthy elderly.
90967|NCT03475446|Device|sham tES healthy elderly|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the group of healthy elderly.
90968|NCT03475446|Device|real anodal tDCS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the MCI group.
90969|NCT03475446|Device|real tACS MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the MCI group.
90970|NCT03475446|Device|sham tES MCI|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the MCI group.
90971|NCT03475446|Device|real anodal tDCS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real anodal tDCS in the AD group.
90972|NCT03475446|Device|real tACS AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the real tACS in the AD group.
90973|NCT03475446|Device|sham tES AD|A neuroConn DC-Stimulator PLUS (neuroCare Group, Ilmenau, Germany) will be used for the sham tES in the AD group.
90974|NCT03475433|Device|Actigraphy device|Both groups will receive an actigraphy device that will passively measure their movement data.
91032|NCT03475017|Dietary Supplement|Active Comparator: Supplement A|The patients will receive 3 capsules per day containing 500mg of curcumin and 5mg of piperine for 4 weeks
90975|NCT03475407|Drug|Ozurdex intravitreal injection|"Ozurdex intravitreal injection and Antreior Chamber(AC) paracentesis at baseline~AC paracentesis at 6 wk~intravitreal Ozurdex injection and AC paracentesis at 18wk or 24wk"
90976|NCT03475394|Other|Chlorhexidine gel|0.1 ml of Chlorhexidine gel was administered into the periodontal pocket followed by Coe- pack application.
90977|NCT03475394|Other|Morus alba gel|0.1 ml of Morus alba gel was administered into the periodontal pocket followed by Coe- pack application.
90978|NCT03475381|Drug|Ivacaftor+lumacaftor|1 year follow-up after initiation of ivacaftor+lumacaftor
90979|NCT03475368|Other|Vegetarian diet|People randomized to this interventional group will take a vegetarian diet (i.e. without animal products, except milk and eggs).
90980|NCT03475368|Other|Low carbs diet|People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
90981|NCT03475368|Other|Mediterranean diet|People randomized to this interventional group will take a traditional Mediterranean diet.
90982|NCT03475355|Behavioral|Live movement observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the upper limbs. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to look carefully at the therapist who shows 20 different daily routine activities (actions) performed with the upper limb."
90983|NCT03475355|Behavioral|Video Observation (Upper Limbs)|"All participants will be subjected to two 15-minute sessions per day of the video observation of upper limbs movements. The activities of the upper limbs will be based on some relevant activities of daily life such as drinking from a glass, combing, opening a box or eating an apple. The tasks will be both unimanual and bimanual.~Every day, before starting the physical training, the patient will be asked to carefully watch a video showing 20 different daily routine activities (actions) performed with the upper limb."
90984|NCT03475355|Behavioral|Live Movement Observation (Lowe Limbs)|"All participants will be subjected to two 15-minute sessions per day of the Live movement observation of the lower limbs. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking.~Every day, before starting the physical training, the patient will be asked to carefully watch the therapist who will show 20 different movement strategies to avoid episodes of freezing the pace (FOG)."
90985|NCT03475355|Behavioral|Video Observation (Lower Limbs)|All participants will be subjected to two 15-minute sessions per day of the video observation of lower limbs movements. Tasks to avoid freezing will be based on strategies such as touching the thigh, taking side or back steps, counting out loud while walking. Every day, before starting the physical training, the patient will be asked to carefully watch a video that will show 20 different movement strategies to avoid episodes of freezing the pace (FOG).
90986|NCT03475355|Behavioral|Static Picture Observation and Upper Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of upper limbs, and simulating that performed by the experimental groups."
90987|NCT03475355|Behavioral|Static Picture Observation and Lower Limbs Exercise|"Participants will watch for 3 minutes 5 static images that expose objects, none will represent animals or people.~The participant's attention will be kept high through a cognitive task. The patient will be presented a sequence of images for 3 minutes, the images will be displayed separately, each for 30 seconds, and then during the last 30 seconds, they will be displayed together with an intrusive image (intruder) that the patient you will be asked to identify so that your attention span can be controlled in real time. Participants will then be invited to perform limb movements as far as possible for 2 minutes according to a standard sequence involving joint mobilisations of lower limbs, and simulating that performed by the experimental groups."
90988|NCT03475342|Drug|Tranexamic Acid|Ampoules and packaging for both arms will be identical in appearance.
90989|NCT03475342|Other|Placebo|Ampoules and packaging for both arms will be identical in appearance.
90990|NCT03475329|Other|adenotonsillectomy|adenoidectomy with bilateral tonsillectomy versus adenoidectomy with unilateral complete tonsillectomy
90991|NCT03475316|Behavioral|Social Dancing|90-min dance sessions twice weekly for 6-months. The session includes warm-up, dance and cool down.
90992|NCT03475316|Behavioral|Treadmill Walking|Each session starts with 5-10 minutes of warm-up walking at comfortable speed. Speed is gradually increased to the level at which participants felt it is 'somewhat hard' for two 35 minute sessions with breaks in between followed by 5-10 minute cool down period (total 90 min to match dance group).
90993|NCT03475303|Behavioral|early hospital discharge|early hospital discharge at 8-12 hours for women undergone elective cesarean section
90994|NCT03475290|Behavioral|Personal resources' enhancement: self-efficacy and perceived social support|The condition reflects cultivation hypothesis and consists of 2 sequential modules with self-efficacy enhancement module (SE) preceding perceived social support enhancement module (SS). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SE: mastery experience, vicarious experience, and action planning, 2) SS: received support & cognitive distortions, social skills & peer support, action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
90995|NCT03475290|Behavioral|Personal resources' enhancement: perceived social support and self-efficacy|The condition reflects enabling hypothesis and consists of 2 sequential modules with perceived social support enhancement module (SS) preceding self-efficacy enhancement module (SE). Each module is comprised of 3 evidence-based, CBT-framed exercises: 1) SS: received support & cognitive distortions, social skills & peer support, and action planning, 2) SE: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 6 weeks, 1 week per exercise.
90996|NCT03475290|Behavioral|Personal resources' enhancement: self-efficacy|The condition consists of self-efficacy enhancement module (SE) and is comprised of 3 evidence-based, CBT-framed exercises: mastery experience, vicarious experience, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
90997|NCT03475290|Behavioral|Personal resources' enhancement: perceived social support|The condition consists of perceived social support enhancement module (SS) and is comprised of 3 evidence-based, CBT-framed exercises: received support & cognitive distortions, social skills & peer support, and action planning. Participants will have an option to engage in one or more out of four additional modules: relaxation, cognitive reconstruction, mindfulness, and lifestyle. The condition takes 3 weeks, 1 week per exercise.
90998|NCT03475277|Drug|Ketamine|Acute administration
90999|NCT03475264|Diagnostic Test|Lung MRI|Participants will be undergoing hyperpolarized xenon and proton lung MRI
91000|NCT03475251|Biological|CS1003|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the dose expansion part, patients will be assigned to different groups based on their tumor type.
91001|NCT03475238|Procedure|Nursing care|The nursing care will be defined as a lateral mobibization and a length of care superior or equal to 10 min
91002|NCT03475225|Drug|Cholecalciferol|Cholecalciferol delivery
91003|NCT03475225|Drug|Placebo Oral|manufactured to mimic Cholecalciferol
91004|NCT03475212|Biological|Virus Specific T-cell (VST) infusion|Patients will receive partially HLA-matched VSTs as a single infusion. Patients who have a partial response (>1 log decrease in viral load without clearance) or no response and do not have treatment-related dose-limiting toxicities are eligible to receive up to 3 additional doses from day 30 after the initial infusion and at 2 weekly intervals thereafter. The viral load of the virus (or viruses) that patients are initially treated for are monitored by viral PCR.
91005|NCT03475199|Device|FabLife|"A personnalized dietary program depending on the patient's phenotype and genotype~The daily intake of a dietary supplement, developped in the context of male infertility."
91006|NCT03475186|Drug|Ramipril|2.5 - 5 mg oral, 1x daily for 22 weeks
91007|NCT03475173|Device|LSFG-NAVI|laser-speckle blood flow of ocular arteries and veins
91008|NCT03475160|Drug|Sildenafil Citrate vaginal suppositories|Sildenafil citrate vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
91009|NCT03475160|Drug|Placebo vaginal suppositories|Placebo vaginal suppositories. Uterine artery Doppler before treatment. Uterine artery Doppler after treatment.
91010|NCT03475160|Procedure|Uterine artery Doppler before treatment|Uterine artery Doppler before treatment: Uterine artery Doppler indices; PI and RI at cycle days 21-23 of the cycle preceding the pregnancy
91011|NCT03475160|Procedure|Uterine artery Doppler after treatment|Uterine artery Doppler after treatment: Uterine artery Doppler indices; PI and RI at the twelfth week of gestation
91012|NCT03475147|Device|eyeFusion|Smartphone app based flicker fusion test.
91013|NCT03475134|Other|TIL|Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes
91014|NCT03475134|Drug|Cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
91015|NCT03475134|Drug|Fludarabine|Fludarabine will be administered as an intravenous (IV) infusion for five days.
91016|NCT03475134|Drug|Interleukin-2|After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.
91017|NCT03475134|Drug|Nivolumab|Nivolumab (3mg/kg) will be administered every two weeks for maximum 24 months.
91018|NCT03475121|Combination Product|Combination Chemotherapy plus Intrathecal Topotecan|Adjuvant chemotherapy with a reduced dose (compared to GALOP I protocol) of carboplatin
91019|NCT03475121|Combination Product|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan
91020|NCT03475121|Combination Product|Higher Dose Combination Chemotherapy plus Intrathecal Topotecan and Orbital Radiotherapy|GALOP I-based systemic adjuvant therapy plus intrathecal topotecan and orbital radiotherapy (45 Gy) up to chiasm
91021|NCT03475121|Other|No Adjuvant Therapy|Patients will not receive any adjuvant therapy after enucleation of the affected eye.
91022|NCT03475108|Other|Community Health Worker added to diabetes team|A Community Health Worker will be added to the diabetes team caring for a child with type 1 diabetes over 1 year. The intervention includes social determinants of health screening and goal setting, with home visits.
91023|NCT03475095|Other|Tuina|Patients will receive Tuina therapies tiwce per week in one month.each time lasts about 20 minutes,a total of 4 weeks.
91024|NCT03475082|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous electrical nerve stimulation (TENS) is utilized clinically by a variety of health care professionals for the reduction of pain. The mechanisms by which TENS produces analgesia or reduces pain are only recently being elucidated. TENS is a non-invasive modality that is inexpensive, safe and easy to use with relatively few contraindications. Frequency of stimulation is broadly classified as high frequency (>50Hz), low frequency (<10Hz) TENS. Intensity is determined by the response of the patient as either sensory level (low-intensity) TENS strong but comfortable. With sensory level TENS, the voltage (i.e. amplitude) is increased only until the patient feels a comfortable tingling (perceived with high frequency) or tapping (perceived with low frequency) sensation without motor contraction. With strong but comfortable TENS the intensity is increased to a strong but comfortable level which may include muscle contraction.
91025|NCT03475069|Other|Custom Designed Exercises|
91026|NCT03475069|Other|Plates Exercises|
91027|NCT03475069|Other|Calisthenics Exercises|
91028|NCT03475056|Biological|cAd3-Marburg vaccine|The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, VRC-MARADC087-00-VP (cAd3-Marburg) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP).
91029|NCT03475043|Behavioral|Auditory training: temporal contrasts|Behavioral training for 9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
91030|NCT03475030|Other|pre-filled medication trays|
91031|NCT03475030|Other|automated medication reminders|
91238|NCT03473431|Other|control|physiological solution at 0.9 % with the same physical characteristics of ketamine solution,
91033|NCT03475017|Dietary Supplement|Placebo Comparator: Supplement B|The patients will receive 3 capsules of placebo per day containing 500mg of maize starch for 4 weeks
91034|NCT03475004|Drug|Pembrolizumab, Bevacizumab, and Binimetinib|"Cohort A: binimetinib 45mg, orally, twice a day, for 7 days. This will be followed by bevacizumab 7.5mg/kg on day 1 every 21 days and pembrolizumab 200mg on day 1 every 21 days. Binimetinib, 45mg, PO BID, should be taken on a continuous dosing schedule.~Cohort B: bevacizumab 7.5mg/kg on day 1 every 21 days and pembrolizumab 200mg on day 1 every 21 days. Binimetinib, 45mg, PO BID, should be taken on a continuous dosing schedule."
91035|NCT03474991|Drug|Celestamine®|Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
91036|NCT03474978|Device|Peripherally Inserted Central Venous Cather (PICC)|Location of the PICC insertion will be randomized and compared
91037|NCT03474965|Drug|Crizanlizumab|Crizanlizumab (SEG101) is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab.
91038|NCT03474952|Procedure|remote ischemic preconditioning (RIPC)|remote ischemic preconditioning consists of 4 cycles of 5-min ischemia and subsequent 5-min reperfusion using pneumatic cuff applied to upper arm
91039|NCT03474952|Procedure|sham-RIPC|ischemia pressure less than 10 mmHg (sham-RIPC)
91040|NCT03474939|Drug|Midazolam Oral Tablet|Midazolam Oral tablet
91041|NCT03474939|Other|Placebo Oral Tablet|Glucose 1000mg tablet night before surgery and 60 minutes before surgery
91042|NCT03474926|Procedure|Routine Template-based lymphadenectomy|"Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue."
91043|NCT03474926|Procedure|LND only for lymph nodes enlargement found in preoperative image or during surgery|LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
91044|NCT03474913|Device|Upright MRI|Indomitable Magnetic Resonance Imaging Scanner, magnetic resonance imaging using 0.6 T strength
91045|NCT03474913|Device|standard MRI|standard of care closed 3T MRI
91046|NCT03474900|Device|PLGA implant, Bioretec ltd. Finland|The investigational implant is an ultra-high-strength biodegradable intramedullary (IM) nail of poly(lactide-co-glycolide) (PLGA)/tricalcium-phosphate (β-TCP) which was manufactured by Bioretec Ltd. (Hartmaninkatu 2, Tampere, Finland)
91047|NCT03474900|Device|Titanium elastic stable nail|Elastic stable intramedullary nail to stabilize unstable forearm shaft fractures in children
91048|NCT03474887|Other|Physical Consultation|Regular physician consultation at the primary care clinic.
91049|NCT03474887|Other|Online Consultation|An online platform for communicating with a physician digitally. Patients answer a series of algorithm-based questions after specifying chief complaint, after which contact is established with a physician who can communicate through short messages. The physician can then order labs, prescribe relevant medication or book the patient for a physical consultation if need be.
91050|NCT03474874|Device|NeoMatriX Collagen Dressing|Collagen wound dressing
91051|NCT03474861|Biological|anticancer medication A01; immune cells IC01|"The administration of the anticancer medication A01 and immune cells IC01 will be performed in The Second Hospital of Jiaxing, Zhejiang, China.~The subjects will be observed for any side effects during this time and all the adverse events will be recorded."
91052|NCT03474848|Other|HABIT|Provision of individualized bimanual activities, individually chosen according to the child´s abilities, impairments and improvements in order to achieve success and to encourage bimanual use. Task difficulty is graded, focusing on enhancing the level of difficulty or speed, according to child's improvements. We use whole task practice (sequencing successive movements in the context of activities), part task practice (practice of specific components of the task in a repetitive sequence of time) and individualized functional goal training.
91053|NCT03474848|Other|Conventional Occupational Therapy (OT)|Children will maintain the occupational therapy sessions with their therapists, without any change in their routine at the rehabilitation center. Strategies such as functional training, stretching and sensory stimulation are used.
91054|NCT03474835|Diagnostic Test|ISCHEMIC HEART DISEASE diagnostic|ISCHEMIC HEART DISEASE diagnostic
91055|NCT03474822|Biological|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
91056|NCT03474809|Device|Blood sampling|Daily blood samples which will be taken for the PSP measurement using the AbioScope as well as another daily sample taken for central analysis of biomarkers of inflammation, infection and/or sepsis (including but not limited to C-reactive protein [CRP] and Procalcitonin [PCT]).
91057|NCT03474796|Behavioral|Eye-tracking|Visualisation of 4 photographic scenarios (surgical situations), questionnaire, eye-tracking
91058|NCT03474783|Behavioral|Health education|Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
91059|NCT03474770|Drug|BIS-001ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
91060|NCT03474757|Other|Data Collection|Data will be extracted from July 2009 to the last available database extraction
91061|NCT03474744|Drug|Copanlisib|"Induction Phase Cycle 1-6 (28 days cycle):~Copanlisib:~60 mg i.v. fixed dose days 1, 8, 15.~Rituximab:~375 mg/m2 day 1 i.v."
91085|NCT03474510|Drug|local infiltration of liposomal bupivacaine|Those patients randomized to receive LIA of EXPAREL will have 266mg EXPAREL diluted to 100mL, and drawn into (5) 20mL syringes affixed with (5) 22-gauge needles. Investigators will administer the syringes to the tissue in small increments with the plunger held steady while withdrawn from the tissue to avoid saturating the area around the needle sticks since EXPAREL doesn't readily travel through the tissue.
91062|NCT03474731|Behavioral|Diabetes Self Management Program|"Diabetes Self Management Program (DSMP) in a group setting: The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.).~Groups randomized to one of two arms (DSMP only and CCN) will receive the DSMP. The DSMP has demonstrated significant improvements in communication with physicians, healthy eating, and hypoglycemia at six and twelve months. The DSMP and other self-management programs have been shown to increase self-efficacy, knowledge, and skill building; ensure accountability/monitoring; improve patient-provider interaction; leverage local assets; address sustainability, and be cost effective."
91063|NCT03474731|Behavioral|Tailored Patient Navigation (PN) only|Tailored Patient Navigation (PN) only: The goal of this arm of the project is to try to get participants to attend their recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs. We will have to add an additional eligibility criterion for this group—they have to be out of compliance with medical appointments. Most participants will need PN services, owing to missed, rescheduled, or infrequent appointments. This means not attending their office visits, as recommended, which typically is every 3 months. We will interact with them to verify attendance and, at times, to access patient medical records if needed.
91064|NCT03474731|Behavioral|DSMP AND Tailored Patient Navigation|DSMP AND Tailored Patient Navigation : Both group education classes and patient navigation
91067|NCT03474705|Device|Eccentric Training Protocol|A custom-built dynamic shoulder dynamometer (Aalborg University, Aalborg, Denmark) will be used. Participants will be seated with back support and no feet support. The maximal voluntary contraction (MVC) of the painful side will be assessed. Sessions will start with a 5-min warm-up. After that, participants will sit in the dynamometer, and the range of shoulder elevation (highest and lowest vertical position) will be measured for the affected side. During training, subjects will have to counteract a dynamometer vertical force from the highest to the lowest shoulder position at a force equal to 60% (training sessions 1-3), 70% (training sessions 4-6), and 80% (training sessions 7-10) of the MVC recorded during baseline. Three bouts of 10 repetitions (sessions 1-3), 8 repetitions (sessions 4-6) and 6 repetitions (sessions 7-10) will be performed, with a 3-second rest between contractions and a 2-minute break between bouts.
91068|NCT03474679|Drug|Ibrutinib|Participants will receive 420 mg (3 * 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
91069|NCT03474666|Procedure|Strict Glycemic Control Group|The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.
91070|NCT03474666|Procedure|Standard Glycemic Control Group|"The targeted blood glucose range is 130-180 mg/dL~Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU"
91071|NCT03474640|Biological|Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody|Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
91072|NCT03474627|Device|Non-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft
91073|NCT03474627|Device|PLGA-coated HA/TCP particles|Maxillary sinus floor elevation and bone grafting with the use of biphasic hydroxyapatite and beta-tricalcium phosphate bone graft with PLGA coating
91074|NCT03474614|Drug|Propranolol|The medication will be administered so that patient receives a minimum of 7- days and maximum of 10-days of treatment with propranolol prior to planned surgical resection of CCM (routine care)
91075|NCT03474614|Genetic|DNA and RNA Analysis|During the operative procedure, a small sample of the patient's blood will be obtained and small (1 to 2cc) tissue sample from the resected cavernous malformation will be collected. The blood and tissue samples will be labeled and stored for subsequent DNA and RNA analysis
91076|NCT03474601|Other|Dynamic hormone study and Magnetic resonance imaging|"Medical history~Imaging examination including brain magnetic resonance imaging~Blood (Basal hormone study and follow-up study) and pituitary tumor tissue"
91077|NCT03474588|Behavioral|Standard treatment (ST) PLUS web-based CBT4CBT|Participants will have access to the CBT4CBT website in Spanish as an add-on to treatment. In this treatment participants will work with a computerized program that teaches skills for stopping alcohol use and increasing coping skills, such as how to understand patterns of alcohol use, how to cope with cravings for alcohol, how to refuse offers of alcohol, and so on
91078|NCT03474588|Behavioral|Standard Treatment (ST)|ST includes individual and group therapy sessions and regular urine monitoring. Sessions will generally last for 1 hour one time per week for 8 weeks
91079|NCT03474575|Other|Prevention|The purpose is to establish a safe and effective way of discharging COPD patients from emergency department by providing enhanced home care.
91080|NCT03474562|Drug|Duowell®|Telmisartan/Rosuvastatin 40/20mg (increased to Telmisartan 80mg if SBP > 140mmHg or DBP > 90mmHg at week 12)
91081|NCT03474562|Drug|Monorova® + Amlopin®|Rosuvastatin 20mg + Amlodipine 5mg (increased to Amlodipine 10mg if SBP > 140mmHg or DBP > 90mmHg at week 12)
91082|NCT03474549|Device|Tigertriever revascularization device|Mechanical Thrombectomy
91083|NCT03474523|Other|Experimental group|"Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
91084|NCT03474523|Other|Control group|"Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9"
91086|NCT03474510|Other|continuous infusion of ropivacaine interscalene nerve block|"All patients will receive a single injection of 30mL, 0.5% preservative-free ropivacaine.~Those patients randomized to receive CINB will then have an indwelling catheter placed and held in place by Dermabond and Tegaderm. Placement will be confirmed by ultrasound. Patients will then receive 0.2% preservative-free ropivacaine at 8mL/hr beginning at the conclusion of surgery and delivered for approximately 50 hours (or finish of 400mL) via elastomeric infusion system (OnQ Pain Relief System: Select A Flow, Kimberly-Clark Corporation, Roswell, Georgia). Patients are instructed prior to discharge how to pull the catheters at home. Patients may also return to surgeon's office for catheter removal once the pain ball is empty if they prefer."
91087|NCT03474497|Drug|IL-2|• A total of four interleukin-2 treatments will be delivered into the treatment lesion by intralesional injection biweekly (at least 48 hours apart) starting 24-96 hours after the completion of radiotherapy and to be completed during the second on-trial cycle of Pembrolizumab. Intralesional injections will be performed by direct visualization and/or palpation of the lesion or under ultrasound or CT guidance as indicated.
91088|NCT03474497|Drug|Pembrolizumab|Pembrolizumab will be delivered at 200 mg in three week cycles per standard protocol.
91089|NCT03474497|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the second cycle of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1-2 of cycle 2 and will not be repeated in future cycles.
91090|NCT03474471|Behavioral|Pulmonary rehabilitation|Following a PR program
91091|NCT03474471|Device|EBV treatment|Bronchoscopic lung volume reduction using endobronchial valves (EBV)
91092|NCT03474458|Drug|Doxycycline|Doxycycline
91093|NCT03474458|Drug|Standard of care therapy|Standard of care therapy
91094|NCT03474445|Procedure|Volar Plate Osteosynthesis Aptus 2.5|Volar plating of distal radius fracture. Device: Aptus 2.5
91095|NCT03474445|Procedure|Volar Plate Osteosynthesis Inteos 2.5|Volar plating of distal radius fracture. Device: Inteos 2.5
91096|NCT03474432|Device|Optical Coherence Tomography|OCT will be performed with the St. Jude OCT system. Detection of metallic stent struts will be performed automatically with manual adjustments made as necessary. Stent area tracings will be automatically performed by interpolated contours connecting the center point of the luminal surface of each detected metallic strut. Stent expansion will be determined as the minimum stent area divided by the average reference lumen area and presented as a percentage. Neo-intimal hyperplasia (NIH) area will be determined in follow-up examinations as the area between the stent and lumen contours. Incomplete stent apposition (ISA) area will be determined as the area between the stent contour and the lumen contour at the site of malapposed struts, in a region not overlying a side branch ostium.
91097|NCT03474419|Procedure|laser surgery|laser surgery
91098|NCT03474406|Other|follow up system and multimodality approach|To provide a new service system for cancer pain in pain clinic by early detecting red flag sign to consult other departments, early alleviating severe pain, following patients intensively by telephone call and giving pain education
91099|NCT03474393|Other|systematic intensive therapy|intensive telephone och internet Contact with diabetes nurse for coaching and guidance over 4 months and 4 Control visits
91100|NCT03474380|Behavioral|iHI-FIVES|Implementation of iHI-FIVES caregiver skills training
91101|NCT03474354|Device|chemoembolization|correlation of necrosis with the deposition of beads
91102|NCT03474341|Diagnostic Test|MRI|"Anatomical (T2W) and functional MRI (DWI and DCE) at a 1.5T Siemens or Philips scanner~DWI series: sagittal (sIVIM) and high-resolution transversal (HR tDWI)~DCE serie: dynamic20~In total, three MRI scan series (before, during, after nCRT)~Measurements: i.a. change in apparent diffusion coefficient (ADC) or area-under-the-gadolinium-concentration time curve (AUC) within tumor delineation over time, radiological (qualitative) assessment of residual disease"
91103|NCT03474341|Diagnostic Test|PET-CT|"According to European Association of Nuclear Medicine (EANM) Research Ltd guidelines (EARL)~In total one additional PET-CT (during nCRT) for study purposes. A PET-CT scan at diagnosis and after nCRT are included in the standard diagnostic work-up for esophageal cancer.~Measurements: i.a. change in TLG (Total Lesion Glycolysis), SUVmax (Standardized Uptake Value) or Ktrans within tumor delineation over time"
91104|NCT03474341|Diagnostic Test|Endoscopy|Additional endoscopy and/or endoscopic ultrasonography (EUS) with biopsies of the primary tumor site and other suspected lesions in the esophagus after completion of nCRT and prior to surgery
91105|NCT03474341|Diagnostic Test|Blood samples|"Blood samples at three different time points (before, during and after nCRT) will be collected~Blood will be collected in cell-free DNA collection tubes~Purpose: isolation of ctDNA and subsequent mutation analysis by means of Next Generation Sequencing~Measurements: the presence of, and changes in, ctDNA during nCRT"
91106|NCT03474328|Device|AlcoChange|Smartphone app and breathalyser
91107|NCT03474315|Diagnostic Test|Multivariate assessment|Patient's status assessment according to clinical evaluation and data acquired from the implanted device.
91108|NCT03474302|Behavioral|Physical Activity|Aerobic, strength training, balance, flexibility
91109|NCT03474302|Other|Successful Aging|Healthy aging education
91110|NCT03474289|Drug|SHR-1316|Monotherapy
91111|NCT03474276|Drug|Azythromycin|Administration of azythromycin to the child at inclusion (3 days) 20 mgs/kgs/day : three days
91112|NCT03474276|Dietary Supplement|Inuline and fructo-oligosaccharides|Administration of inuline and fructo-oligosaccharides (Synergy1) 2g/day, mixed with the fortified blend flour given to the child through the whole intervention.
91113|NCT03474276|Drug|Albendazole|Administration of Albendazole at inclusion of the child : 200mgs, one administration
91114|NCT03474276|Dietary Supplement|Fortified blend flour|"Children from 6 to 11 months : 200 grams / day Children from 12 to 24 months : 300 grams / day~Compostion of the fortified blend flour per 100 grams : either :~Mil (whole grains): 58,56 g/100g, Soybeans (fat meal): 16,54g/100g Peanuts (roasted seeds): 8,75g/100g, Cane sugar: 7,35 g/100g Whole milk (Powder): 7,56g/100g, MSV MAM: 0,28g/100g, iodized salt :0,45g/100g, CaC03: 0,48g/100g,Amylase BAN: 0,03g/100g OR Corn (whole grains): 53,29g/100g, Soybeans (dry seeds): 17,82g/100g, Peanuts (roasted seeds): 9,00 g/100g, Cane sugar: 11,00 Whole milk (Powder): 5,00g/100g, Soybean Oil (Purified): 1,24g/100g, Peanut oil (Purified): 1,13g/100g, MSV MAM: 0,27g/100g, iodized salt: 0,53 g/100g, Ca3(PO4)2: 0,62g/100g, KCl: 0,09g/100g"
91239|NCT03473418|Drug|Ketoconazole|Ketoconazole as a topical vaginal gel
91115|NCT03474263|Biological|Biologic: IC14 (monoclonal antibody against human CD14)|IC14 intravenous infusion daily for four days on two successive weeks then MR-PET Scan evaluation for impact on glial activation.
91116|NCT03474250|Diagnostic Test|Magnetic Resonance test for kidney|Magnetic Resonance test for kidney
91117|NCT03474237|Other|Hormone study and Imaging study|"Blood (basal hormone and follow up hormone study)~Imaging examination including computed tomography scan or magnetic resonance imaging"
91118|NCT03474224|Device|Ev1000 Clinical Platform from Edwards Lifesciences|The EV1000 Hemodynamic monitoring platform will be used to guide fluid administration following a volume-based parameter such the stroke volume.
91119|NCT03474198|Drug|Rifampicin|10mg/kg
91120|NCT03474198|Drug|Isoniazid|5mg/kg
91121|NCT03474198|Drug|Pyrazinamide|25mg/kg
91122|NCT03474198|Drug|Ethambutol|15mg/kg
91123|NCT03474198|Drug|Linezolid|600mg
91124|NCT03474198|Drug|Clofazimine|200mg
91125|NCT03474198|Drug|Rifapentine|1200mg
91126|NCT03474198|Drug|Levofloxacin|1000mg
91127|NCT03474198|Drug|Bedaquiline|400mg once daily for 2 weeks then 200mg 3x a week
91128|NCT03474198|Drug|Rifampicin|35mg/kg
91129|NCT03474185|Behavioral|Taking Charge of your Heart Health patient education classes|"Taking Charge of your Heart Health patient education classes held at TotalCardiology cardiac rehabilitation in Calgary, Canada. Consists of four, 2.5-hour long group-based classes focused on focused on physiology, risk factors, medications, nutrition, exercise, and stress management"
91130|NCT03474172|Device|Cloak Shape Device for Sham Tuina|The Cloak Shape Device for Sham Tuina is exactly the same as the real one, which is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a sham Tuina will be manipulated
91131|NCT03474172|Device|Cloak Shape Device for Real Tuina|The Cloak Shape Device for Real Tuina is opaque and big enough to cover the whole body and arms of a child who is under 6 years old. Two narrow holes are required on the cover, so that the therapist's hands can touch the child through these holes and a real Tuina will be manipulated.
91132|NCT03474159|Device|Magnetic Resonance Imaging|Aortic distensibility measured in MRI at the Valsalva sinus and at the ascending tubular aortic level
91133|NCT03474159|Device|Transthoracic echocardiography|Aortic distensibility measured in TTE of the same segments in TM and in B mode
91134|NCT03474159|Device|Echography UltraFast|Carotid pulse rate measured on carotid arteries by UF
91135|NCT03474146|Other|Ocimum sanctum|Ocimum sanctum (known as Tulsi, Holy basil) is natural herb which is known for its broad spectrum medicinal properties. Ocimum sanctum is one of the best examples of Ayurveda's holistic lifestyle approach to health. It is also been well practiced in traditional medicine in India and south Asian region. Literature showed that Ocimum sanctum extract have significant anti-gingivitis and anti-inflammatory effect as mouthrinse.
91136|NCT03474146|Other|Chlorhexidine Gluconate|Chlorhexidine Gluconate (C34H54Cl2N10O14) is a bisbiguanide formulation with cationic properties. Chlorhexidine over a period of over 40 years has been thoroughly investigated and successfully used as plaque control agent in dental practice. A literature review, highlighting chlorhexidine as not only a plaque control agent but also as an effective antimicrobial agent and its wider application in variety of oral disorders in various formulations.
91137|NCT03474146|Other|Propylene Glycol|Propylene glycol or 1,2-dihydroxypropane or 1,2-propanediol, is a clear, colourless, viscous, practically odourless liquid with a density of 1.038 g/cm³ at 20 °C and a molecular weight of 76.095. It is miscible with water, acetone and chloroform. It is miscible in water. Propylene glycol is commonly used as an excipient in a variety of drugs and it is also authorised in food products and cosmetics.
91138|NCT03474133|Drug|Brentuximab Vedotin|brentuximab vedotin 1,8 mg/kg, intravenous infusion every 21 days, up to 16 infusions per patient during study period
91139|NCT03474120|Procedure|IVF treatment|Relationship between IVF treatment outcome and genotypes in POI//DOR/ovarian dysgenesis patients
91144|NCT03474094|Combination Product|Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery|"W1,W2, W3, W4 & W5: RADIOTHERAPY. A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6 and W9: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W11: SURGERY. Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent"
91145|NCT03474094|Combination Product|2 cycles of atezolizumab followed by surgery then post-operative radiotherapy|"W1 and W4: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W7, W8, W9, W10 & W11: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized."
91146|NCT03474094|Combination Product|Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.|"W1,W2, W3, W4 & W5: RADIOTHERAPY A 3-dimensional conformal RT (3D-CRT) with photons ≥ 6MV will be realized based on the acquisition of a CT-scan performed in treatment position. Intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT) and tomotherapy are authorized.~W6: SURGERY Surgery should be performed as per Institutional practice by a surgeon with appropriate training in the treatment of sarcoma. The primary aim of surgery is to completely excise the tumor with a margin of normal tissue commonly accepted as 1 cm soft tissue, or equivalent~W11 and W14: ATEZOLIZUMAB IV INJECTION. 2 injections of 1200 mg of atezolizumab with a 3-week interval"
91240|NCT03473418|Drug|Terconazole|Terconazole 80 mg as a topical vaginal cream
91584|NCT03470688|Biological|Originator|Originator anti-TNF agents
91147|NCT03474081|Drug|FF/UMEC/VI|A single inhaler triple therapy of FF/UMEC/VI will be provided via ELLIPTA DPI. FF/UMEC/VI will be available as dry white powder with dosing strengths of 100/25/62.5 mcg per blister.
91148|NCT03474081|Drug|Tiotropium|Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
91149|NCT03474081|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
91150|NCT03474081|Drug|Placebo to match FF/UMEC/VI|Placebo matching FF/UMEC/VI will be available as a dry white powder of lactose or magnesium stearate, administered via ELLIPTA DPI.
91151|NCT03474081|Drug|Placebo to match tiotropium|Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
91152|NCT03474081|Device|ELLIPTA inhaler|ELLIPTA DPI will contain two individual blister strips with 30 blisters per strip. FF/UMEC/VI and placebo to match FF/UMEC/VI will be administered to the subjects using ELLIPTA DPI.
91153|NCT03474081|Device|HANDIHALER|Tiotropium and placebo to match tiotropium will be administered to the subjects using HANDIHALER DPI.
91154|NCT03474081|Device|MDI|Albuterol/salbutamol will be provided as a rescue medication throughout the study using MDI.
91155|NCT03474055|Biological|Liquid Rotavirus Vaccine|Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine
91156|NCT03474042|Drug|GLPG2737|GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
91157|NCT03474042|Drug|Placebo|Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
91158|NCT03474029|Drug|Rifapentine daily for 6 weeks|600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
91159|NCT03474029|Drug|Rifapentine and Isoniazid weekly for 12 weeks|"Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).*~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing > 50 kg. For persons weighing < 50 kg, the following doses will be given: weight > 25-32 kg - RPT 600 mg; weight > 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max)."
91160|NCT03474029|Drug|Rifampin and Isoniazid daily for 12 weeks|"Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)*.~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing < 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max)."
91161|NCT03474029|Drug|Rifampin daily for 16 weeks|"Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).*~*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing > 50 kg. For persons weighing < 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg."
91162|NCT03474016|Diagnostic Test|Mammography-Histopathological examination of breast mass specimens- polymerase chain reaction|Mammography-Histopathological examination of breast mass specimens-Detection of long and short DNA fragments in serum using real-time quantitative polymerase chain reaction
91163|NCT03474003|Other|No intervention|Kidney recipients aged over 18 and of all sexes recruited from 2002 in European and North American centers, who have e-GFR follow-up and data from protocol and for cause biopsies available for trajectories and allograft survival assessment; RCT conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.
91164|NCT03473990|Other|High-intensity interval training|2 minute warm up, followed by 5x1min HIT intervals separated by 90 seconds active recovery (walking on the spot) and then a 2 minute recovery period. The high intensity bouts will be a pyramid of exercises (star jumps, mountain climbers and on-the-spot sprints)
91165|NCT03473977|Biological|Benralizumab|Monoclonal antibody originally developed for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125). Either Benralizumab or Placebo will be injected in 3 monthly doses of 30 mg, to examine the decrease in blood and tissue eosinophil counts in subjects with Eosinophilic Gastritis. This will be followed by an optional OLE period.
91166|NCT03473977|Biological|Placebo|Placebo will be injected in 3 monthly doses of 30 mg, as a comparator to injection with Benralizumab to examine the decrease in blood and tissue eosinophil counts in subjects with Eosinophilic Gastritis.
91167|NCT03473964|Drug|H.P. Acthar gel|"H.P. Acthar gel:~Injection 40 mg twice weekly"
91168|NCT03473951|Diagnostic Test|Hyperuricemia|Hyperuricemia vs. normouricemia
91169|NCT03473938|Device|Spatz3 AIGB|Implantation of Spatz3 AIGB balloon.
91170|NCT03473925|Drug|Navarixin|Oral capsules
91171|NCT03473925|Biological|Pembrolizumab|Intravenous infusion
91172|NCT03473899|Device|rESWT|"rESWT will be performed as follows:~Nine rESWT sessions~Three sessions per week~rESWT device: Swiss DolorClast (Electro Medical Systems, Nyon Switzerland), EvoBlue handpiece, 15 mm applicator~2500 rESWs per session, with energy density between 0.12 and 0.16 mJ/mm^2, depending on what the patient tolerates~rESWs applied at 15 Hz~Application of rESWs in prone position, with the patient lying on an examination table~Exact location of the application of rESWs determined by clinical and ultrasonographic examinations~Treatment of both the side of injury and the entire affected muscle (from distal to proximal in order to relax the affected muscle)~No use of local anesthesia.~In addition, patients will receive a specific rehabilitation program."
91173|NCT03473899|Device|Sham-rESWT|"Sham-rESWT will be performed as rESWT described in Arm rESWT + RP, but with a specially designed placebo EvoBlue handpiece that looks and sounds like the EvoBlue handpiece of the Swiss DolorClast, but does not generate radial shock waves. This is achieved by blocking the projectile shortly before it strikes the metal applicator. The placebo EvoBlue handpiece will not emit any radial shock wave energy.~In addition, patients will receive a specific rehabilitation program."
91174|NCT03473886|Behavioral|Intervention arm: PP-MI|The positive psychology exercises include gratitude-based activities, strengths-based activities, and meaning-based activities. The physical activity goal setting exercises include the following topics: health benefits, social resources, and neighborhood walkability.
91201|NCT03473717|Device|classic method|"Put the Pozzi forceps to draw the uterus by the cervix to horizontalize it and align uterine cavity in the direct axis of cervix.~Insert the hysterometer to measure the uterus depth.~Locate the uterine depth on the inserter tube."
91585|NCT03470688|Biological|Biosimilar|Biosimilar anti-TNF agents
91175|NCT03473873|Other|Measures of muscle function|The participants will be assessed with various measures of muscle function at baseline and at follow up including: Isokinetic knee muscle strength, Isometric strength of trunk and lower extremity, single-leg hop for distance (SLHD), side hop, postural orientation errors (single leg-squat, stair descending, forward lunge, SLHD), hip and ankle range of motion, and muscular activation patterns.
91176|NCT03473847|Device|ArcScan Insight 100 very high-frequency digital ultrasound|The ArcScan Insight 100 VHF digital ultrasound scanner can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris. The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath.
91177|NCT03473847|Device|Carl Zeiss Meditec Cirrus HD OCT 5000|The Cirrus HD OCT 5000 uses high definition spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
91178|NCT03473847|Device|Optovue RTVue OCT|The Optovue RTVue OCT uses high definition Fourier/spectral domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them.
91179|NCT03473847|Device|CSO MS-39 OCT|"The CSO MS-39 OCT uses high definition Fourier domain optical coherence tomography (OCT) to measure anatomical structures of the eye. OCT is non-contact and uses light, rather than ultrasound, to obtain cross-sectional images. The MS-39 also includes a Placido topographer within the device to simultaneously obtain a measurement of the shape (curvature) of the front surface of the cornea, which is then combined with the OCT thickness measurement to generate the shape of the back surface of the cornea.~An OCT scan involves the patient sitting in front of the device, placing their chin on a chin-rest and fixating on a light source. Nothing comes into contact with the eye and the patient is only aware of the instrument rotating in front of them."
91180|NCT03473834|Other|Modified exercise programme|The exercise will be modified from the standardized exercise program (Schenkman, 1998) includes a series of exercises based on the concept that muscle length and coordination.
91181|NCT03473834|Behavioral|Medication|The control group will be received the normal medication from their doctor.
91182|NCT03473821|Behavioral|MOTIFS|o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
91183|NCT03473808|Behavioral|task-practice therapy|Standardized hand therapy program
91184|NCT03473808|Other|Vibration|Peripheral vibration applied to the wrist skin at an imperceptible level
91185|NCT03473795|Behavioral|Questionnaire forms|The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
91186|NCT03473795|Other|Bio-specimen samples|Samples can include tissue, blood, urine, saliva, hair and nail clipping.
91187|NCT03473782|Other|Voiding Diary|A log kept by each patient to record frequency and volume of urine output and fluid input.
91188|NCT03473782|Other|Urodynamics Correlation Study|Provides patho physiological data by assessing bladder sensation, bladder capacity, the presence of involuntary bladder contractions, bladder compliance and bladder outlet obstruction.
91189|NCT03473769|Other|Vital Signs at 2 Hours|Patients vital signs assessed at 2 hours of arrival at ICU
91190|NCT03473769|Other|Confusion Assessment method for the ICU (CAM-ICU)|patient must have altered mental status/fluctuating course and inattention, and either disorganized thinking or altered level of consciousness to be CAM positive; these features are determined by observing the patient during bedside cognitive testing.
91191|NCT03473756|Drug|Rogaratinib (BAY1163877)|"Part A:Rogaratinib will be administered orally until disease progression, unacceptable toxicity or consent withdrawal. The starting dose of 800 mg b.i.d. will be confirmed using a dose selection design.~Part B:Rogaratinib will be administered orally b.i.d. at the RP2D that was selected in Part A of Study 19131 on all 21 days in each cycle until centrally confirmed radiological disease progression, unacceptable toxicity or consent withdrawal"
91192|NCT03473756|Drug|Atezolizumab|Part A & Part B: A fixed dose of 1200 mg atezolizumab will be administered through intravenous (i.v.) infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity or consent withdrawal.
91193|NCT03473756|Drug|Placebo|Part B: Rogaratinib matching placebo will be administered orally b.i.d. at the RP2D that was selected in Part A of Study 19131 on all 21 days in each cycle until centrally confirmed radiological disease progression, unacceptable toxicity or consent withdrawal
91194|NCT03473743|Drug|Erdafitinib|Participants will receive erdafitinib orally.
91195|NCT03473743|Drug|Cetrelimab|Participants will receive cetrelimab by intravenous infusion.
91196|NCT03473730|Procedure|Biopsy|Undergo biopsy
91197|NCT03473730|Biological|Daratumumab|Given IV
91198|NCT03473730|Other|Laboratory Biomarker Analysis|Correlative studies
91199|NCT03473730|Procedure|Metastasectomy|Undergo metastasectomy
91200|NCT03473730|Procedure|Nephrectomy|Undergo nephrectomy
91202|NCT03473717|Device|direct method|"Place the ring on the inserter tube 3 to 4 cm from the end as a marker.~Insert the tube into the cervix until you feel the passage of the internal orifice of the cervix or until the ring is in contact with the external orifice of the cervix, the tube does not enter the uterine cavity"
91203|NCT03473704|Behavioral|Treatment group (TG)|The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.
91204|NCT03473704|Behavioral|Control group (CG)|For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
91205|NCT03473691|Drug|Glembatumumab Vedotin|Standard neo-adjuvant dose-dense doxorubicin 60 mg/m2 and Cytoxan 600 mg/m2 IV every 14 days for 4 cycles followed by GV 1.9 mg/kg IV every 21 days for 4 cycles.
91206|NCT03473678|Dietary Supplement|Nitrate-rich beetroot juice|concentrated beetroot juice
91207|NCT03473678|Dietary Supplement|Nitrate-depleted beetroot juice|concentrated beetroot juice
91208|NCT03473665|Drug|Indomethacin|Indomethacin Extended Release Oral Tablet 75mg every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
91209|NCT03473665|Drug|Diclofenac|Diclofenac Delayed Release Oral Tablet 25mg tablets x 3 tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
91210|NCT03473665|Drug|Meloxicam|meloxicam 7.5mg tablets every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
91211|NCT03473665|Drug|Celecoxib|Celecoxib 200mg capsule every 12 hours for 6 weeks; omeprazole 20mg daily for 6 weeks
91212|NCT03473652|Other|Adapted walking platform|The walking sessions will be carried out on a suitable walking platform, including a connected play tablet.
91213|NCT03473639|Drug|Entinostat|In metastatic breast cancer patients, entinostat will be taken orally starting at 3 mg per week and will increase to 5 mg per week in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
91214|NCT03473639|Drug|Capecitabine|In metastatic breast cancer patients, capecitabine will be taken by mouth starting at 800 mg/m2 twice a day for 14 days per cycle and increase to 1000 mg/m2 (for 14 days per cycle) in the absence of unacceptable side effects. The safe dose (when combined with capecitabine) will be confirmed in additional metastatic breast cancer patients and breast cancer patients with residual invasive disease following neoadjuvant chemotherapy and surgery.
91215|NCT03473626|Drug|Alicaforsen|Alicaforsen tablet
91216|NCT03473613|Drug|Oral Cabergoline|Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days
91217|NCT03473613|Drug|Calcium Gluconate|Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days
91218|NCT03473600|Procedure|Cryotherapy|Liquid Nitrogen spray
91219|NCT03473600|Drug|Triamcinolone acetonide injection|Intralesional Triamcinolone Acetonide injection
91220|NCT03473587|Behavioral|Motivational interview|A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening
91221|NCT03473587|Behavioral|Standard of care|A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
91222|NCT03473574|Biological|Durvalumab|immune checkpoint inhibitor
91223|NCT03473574|Drug|Gemcitabine|standard chemotherapy
91224|NCT03473574|Drug|Cisplatin|standard chemotherapy
91225|NCT03473574|Biological|Tremelimumab|immune checkpoint inhibitor
91226|NCT03473561|Drug|Racecadotril plus ORS|Racecadotril plus ORS
91227|NCT03473548|Device|Portable sleep monitor|Type III portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis and determination of an apnea hypopnea index (AHI), average SPO2, and SPO2 nadir.
91228|NCT03473535|Combination Product|Smartphone Assisted PST|"6 sessions of face-to-face PST delivered by a trained Research Therapist and access to the BEACON Suicide Prevention smartphone application, as well as a booster session of PST at six months."
91229|NCT03473522|Device|tDCS|Transcranial direct current stimulation is a modulation technique of neuronal excitability which has very promising results in Parkinson's disease. In addition to the possibility of increasing the excitability of areas to tDCS, it can also facilitate the execution of the exercises by increasing the excitability of the primary motor cortex and changing the recruitment strategies of the motor units.
91230|NCT03473522|Behavioral|Exercise Therapy|Therapeutic exercises will be based on the literature (O'Sullivan and Schmitz 2004, Klamroth et al 2016, Reynolds et al., 2016, Pérez et al 2016, Smania et al., 2010, Pastor et al., 1993, Traub et al., 1980, Schoneburg et al., 2013) Each session will be divided into warm-up exercises; balance and relaxation, with a duration of 50 minutes and a frequency of 3 times a week. Training progresses and intensifies every two weeks. The subjects will perform five repeated movements of each exercise, evolving according to the condition of each patient (according to the Hoehn and Yahr staging scale).
91231|NCT03473509|Other|CKD Registry|Health Service intervention
91232|NCT03473496|Biological|CART therapy in Relapsed/Refractory multiple myeloma|one kind of BCMA/CD138/CD38/CD56-CART therapy in Relapsed/Refractory multiple myeloma
91233|NCT03473483|Other|SREC|"The Standardized Research E-Cigarette (SREC) was developed by NIDA to help researchers assess uncertainties in electronic nicotine delivery devices.~Tank:~Sealed and disposable~Minimum 350 puffs per tank~Volume of e-liquid per tank ~ 3ml~E-Liquid Characteristics:~Tobacco flavored~Nicotine concentration: 15 mg/ml~Propylene Glycol:~ 50% (wt / wt)~Glycerin: ~ 50% (wt / wt)~Cotinine: <1 μg/g~Nornicotine: 5 μg/g~Myosmine : 3 μg/g~Anabasine: <1 μg/g~Anatabine: <1 μg/g~Beta:nicotyrine: <1 μg/g~Diacetyl: <2 μg/g~2,3:Pentanedione: <1 μg/g~Arsenic: <0.1 μg/g~Cadmium: <0.1 μg/g~Chromium: <0.1 μg/g~Lead: <0.1 μg/g~Nickel: <0.1 μg/g~Mercury: <0.05 μg/g"
91234|NCT03473470|Device|forced air warming and warmed intravenous fluids|Use of warming system (forced air)
91235|NCT03473470|Device|warmed intravenous fluids|Use of warming system to have warmed intravenous fluids
91236|NCT03473457|Biological|CART therapy in Acute myeloid leukemia(AML)|one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
91237|NCT03473431|Drug|Ketamine|single infusion of 0.5 mg / kg ketamine
91241|NCT03473405|Device|Air Barrier System|The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.
91242|NCT03473405|Other|Control|The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
91243|NCT03473366|Device|Tao Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Tao Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
91244|NCT03473366|Device|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).Mask ventilation will be scored before and after the standard administration of paralytic medication.
91245|NCT03473353|Other|Medical Scribe|Trained Medical Scribes will be present in the exam room to take notes on the the electronic medical record so that clinicians can focus all their attention to the interaction with the patient and parent.
91246|NCT03473340|Drug|Pirfenidone Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
91247|NCT03473340|Drug|Placebo Capsule|"Dosing:~Days 1 through 7, 267 mg three times daily;~Days 8 through 14, 534 mg three times daily;~Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks"
91248|NCT03473314|Drug|Nitric Oxide gas at 160ppm|Nitric oxide gas at 160 ppm inhaled three times daily for 50 min delivered with air as the carrier via inhalation for a maximum total of 90 days. Total dose of 6000 ppm hours per day.
91249|NCT03473301|Biological|Infusion of allogeneic umbilical cord blood|Subjects will receive a single infusion of allogeneic umbilical cord blood at the baseline visit.
91250|NCT03473301|Biological|Infusion of MSCs|Subjects will receive 3 infusions of MSCs (baseline, 3 months and 6 months).
91251|NCT03473288|Behavioral|Exercise|Participants will undergo supervised exercise 3 times a week for 10-12 weeks.
91252|NCT03473288|Behavioral|Sedentary|Participants will be asked to maintain the sedentary lifestyle that they already have for 10-12 weeks.
91253|NCT03473275|Diagnostic Test|Cold Pressor test|Ice-cold gel-packs around both feet during BOLD fMRI
91254|NCT03473249|Drug|Contrast-Enhanced Ultrasound using Lumason|Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
91255|NCT03473236|Drug|PK10571 or Placebo|Inhaled PK10571 or Placebo
91256|NCT03473236|Device|Generic Dry Powder Inhaler|Dry Powder Inhaler used for inhalation of active drug or placebo
91257|NCT03473223|Biological|Apolipoprotein A-I [human] (apoA-I)|Apolipoprotein A-I [human] (apoA-I) purified from human plasma for intravenous administration
91258|NCT03473223|Other|Placebo|25% albumin solution diluted to 4.4%
91259|NCT03473210|Drug|Antibiotics|ampicillin 2g IV every 6hours for 48 hours, followed by erythromycin 250mg every 6hours for 5days
91260|NCT03473210|Drug|Corticosteroid|dexamethasone 8mg intramuscular every 12hours for 48 hours i.e. in four divided doses
91261|NCT03473210|Procedure|Amniopatch|a total of around 60-80 mL of platelets, 100-150 mL of FFP and 100-150 mL of amnioinfusion fluid was used throughout the procedure
91262|NCT03473197|Drug|CCP-020 Diacerein 1% topical ointment and vehicle ointment|During the 3-week Induction Phase, 0.2 mL of each study product will be applied to 2 sites twice each week (Monday and Thursday) for approximately 24 hours (±4 hours) under occlusive patch conditions (6 applications).
91263|NCT03473184|Drug|CCP-020 Diacerein 1% topical ointment|A total of 4 application sites (2 cm x 2 cm each) will be marked on the subject's lower thoracic area of the back: 2 sites on each side of the back - 2 sites for CCP-020 (Diacerein 1%) Topical Ointment.
91264|NCT03473184|Drug|Vehicle|A total of 4 application sites (2 cm x 2 cm each) will be marked on the subject's lower thoracic area of the back: 2 sites on each side of the back - 2 sites for CCP-020 (Diacerein 1%) Vehicle.
91265|NCT03473171|Device|Nasal non-invasive ventilation with RAM cannula|Pediatric Pulmonary Team will be consulted on inpatient or outpatient patients that fail to wean from chronic respiratory support (CPAP, BiPAP, High flow Nasal Cannula) in whom long-term ventilation is considered. Pediatric Pulmonary Team, as a consultant, will consider patient history, physical examination, previous imaging and laboratories and previous attempts to wean from respiratory support and causes of failure to wean. The Pulmonary team will determine which patients would potentially benefit from use of NIV/RAM-NC for long-term respiratory support and will recommend initiation of NIV/RAM-NC.
91266|NCT03473158|Device|Transvaginal ultrasound|using the 6.5mHz intra-cavitary probe (65EC10EA) of ultrasound machine DP-50 (Shenzhen Mindray Bio-Medical Electronics Co., Ltd., P.R.China) to determine the number, site, size and cardiac activity of the fetuses, and monitor the fetal reduction procedure
91267|NCT03473158|Procedure|Mechanical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by mechanical disruption of the fetal heart till asystole is achieved, and may be aided by partial or total suction of the fetus, using suction device attached to the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
91268|NCT03473158|Procedure|Chemical fetal reduction|under transvaginal ultrasound guidance, fetal reduction will be achieved by injecting 0.5 mL of potassium chloride (Potassium Chloride® 15% , EIPICO, Egypt) into the cardiac region through the embryo reduction needle (Cook® Ireland Ltd., Limerick, Ireland)
91269|NCT03473145|Behavioral|Health Coaching|Health Coaching sessions will be aimed at goal setting, implementing strategies, overcoming barriers, & relapse prevention.
91270|NCT03473145|Device|ActivPAL inclinometer|Participants in the intervention study arms (B & C) will wear the ActivPAL device for the first 6 weeks of the program. The device will monitor their sitting and standing time and will allow Health Coaches to provide feedback and will assist the participant in developing an action plan.
91271|NCT03473145|Other|Tools to Prompt Standing or Prompt Sit-to-Stand Transitions.|Participants in the intervention study arms (B & C) will receive tools to prompt standing or sit-to-stand transitions such as wearable wrist devices, standing desks or tables (Group B only), mechanical and/or electronic timers, or access to mobile apps or computer programs.
91272|NCT03473132|Drug|four factor prothrombin complex concentrate|After treatment with 4F-PCC, coagulation factor levels will be assessed. Time to return to anticoagulation target INR will also be determined.
91273|NCT03473106|Device|Pneumatic tourniquet use|Surgery requiring a pneumatic tourniquet on the thigh
91274|NCT03473093|Drug|Pregabalin 150mg|One group will receive oral pregabalin with morphine infusion
91275|NCT03473093|Drug|Morphine|One group will receive morphine infusion 20 microgram/kg/h
91276|NCT03473080|Behavioral|Internet CBT|The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
91277|NCT03473067|Behavioral|Social Norms Marketing Campaign|This poster based marketing campaign is designed to correct inaccurate perceptions of norms regarding violence.
91278|NCT03473067|Other|Capacity Building|Schools will participate in teacher training and parent training.
91279|NCT03473054|Other|Web-based Mindfulness Course|"The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources."
91280|NCT03473041|Procedure|Hybrid sling|sling formed of surgeon tailored autologous rectus sheath and polypropylene arms
91281|NCT03473041|Procedure|TVT-O|midurethral transobturator vaginal tape
91282|NCT03473028|Procedure|transabdominal ultrasound guided embryo transfer|400 female with body mass index more than 35 undergo transabdominal ultrasound guided embryo transfer
91283|NCT03473028|Procedure|transvaginal ultrasound guided embryo transfer|400 female with body mass index more than 35 undergo transvaginal ultrasound guided embryo transfer
91284|NCT03473015|Device|PICSO|The PICSO Impulse catheter is a 8F double lumen catheter with a 15.5x20mm long balloon at the distal end. The balloon inflates and deflates cyclically once deployed in the coronary sinus, leading to intermitted coronary sinus pressure increase. The catheter is connected to the console through two pneumatic tubes in which helium is shuttled to and from the balloon. In addition, the coronary sinus pressure is monitored through the center lumen of the catheter.
91285|NCT03473002|Other|Placebo|0.9% Sodium Chloride
91286|NCT03473002|Biological|SeVRSV Vaccine|Recombinant Sendai virus vectored respiratory syncytial virus (SeVRSV) vaccine. SeVRSV is a replication-competent Sendai virus that carries the RSV F gene produced by reverse genetics technology.
91287|NCT03472989|Device|Radial extracorporeal shock wave|"Patients will receive treatment once a week for 3 weeks. Treatment will be administered by using the rESWT device named Swiss DolorClast (EMS). 2000 impulses are implied via the power hand piece to the area of max tenderness at the insertion of the plantar fascia, with a pressure of 1.5-3 bars depending on what the patient tolerates. The treatments will be given by a trained physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
91288|NCT03472989|Device|Sham-radial extracorporeal shock wave|"Patients will receive the same treatment as the patients in the group receiving real shock waves, but no real shock waves are conducted. The probe is similar in design, sound and shape.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
91289|NCT03472989|Behavioral|Standardized high-load exercise program|"Patients will be instructed to do 2 exercises: Unilateral heel raise and unilateral leg squat three times a week for 12 weeks. The patients will have a total of 8 sessions supervised by a physiotherapist at our Department.~Patients will also receive standardized information at baseline, and will get custom made foot orthosis."
91290|NCT03472989|Behavioral|Usual care|Patients will get standardized information as in the other three intervention groups with information on pathogenesis, etiology and prognosis, and they will get custom made foot orthosis
91291|NCT03472976|Other|Aqueous Cream B.P.|Aqueous Cream B.P. will be used as the control cream. An equivalent of 250mg of the cream will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
91292|NCT03472976|Drug|Imiquimod|Aldara (imiquimod 5%) cream is an immune response modifier for topical administration. 250 mg of the cream, equivalent to 12.5 mg of imiquimod will be applied and rubbed into the skin until it vanishes, on the deltoid area 5-15 minutes prior to vaccine administration.
91293|NCT03472976|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04|Inactivated monovalent subvirion H5N1 vaccine containing hemagglutinin (HA) of A/Vietnam/1203/04
91294|NCT03472963|Drug|Single dose of Genvoya® and a single 800 mg dose of Darunavir®|Men will be instructed to take Single dose of Genvoya® and a single 800 mg dose of Darunavir® per oral
91295|NCT03472950|Drug|Ranolazine 500 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
91296|NCT03472950|Drug|Ranolazine 1000 MG|Ranolazine is an FDA approved drug for angina (ongoing chest pain or pressure that is felt when the heart does not get enough oxygen).
91297|NCT03472937|Procedure|Transcervical Foley catheter placement for cervical ripening|Subjects will be randomized have cervical ripening with a transcervical Foley catheter in either the inpatient or outpatient setting.
91298|NCT03472924|Device|Kinesiotaping|The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
91299|NCT03472911|Other|minimum effective volume|The determination of MEV50 and its 95% confidence interval (CI) was based on the staircase up-and-down method by Dixon and Massey.
91300|NCT03472885|Drug|ACH-0144471|All patients will receive a daily oral dose of ACH-0144471 TID during the treatment period.
91301|NCT03472885|Drug|Eculizumab|All patients will receive intravenous (IV) eculizumab administered at the patient's usual dose and schedule.
91302|NCT03472872|Drug|Ketorolac|15mg ketorolac in 100mL 0.9% normal saline IVPB 1,000mg acetaminophen in a 100ml IVPB
91303|NCT03472872|Drug|Acetaminophen|1,000mg acetaminophen IVPB
91304|NCT03472859|Device|PHOTOLASE|This is the investigational yellow laser (PHOTOLASE)
91305|NCT03472859|Device|KTP|This is the traditional green laser (KTP)
91306|NCT03472846|Drug|Prolia, 60 Mg/mL Subcutaneous Solution|antiresorptive treatment with Prolia
91307|NCT03472846|Drug|Teriparatide|osteoanabolic treatment with Forsteo
91308|NCT03472833|Drug|High-dose|Patients will receive a high dose - 180.000 I.U. (1 drop equals 400 I.U.) of Vitamin D3 orally on day 1, and then 4000 I.U. for 60 days
91309|NCT03472833|Drug|Standard dose|Patients will receive a standard dose - 800 I.U. (equals 2 drops) of Vitamin D3 orally for 60 days
91310|NCT03472820|Other|Diet Recommendations|Specific dietary guidelines will be outlined for participants.
91311|NCT03472820|Other|Lifestyle Recommendations|Participants are encouraged to average a minimum of 7 hours of sleep per night.
91312|NCT03472820|Other|Exercise Recommendations|Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.
91313|NCT03472820|Other|Stress Management Recommendations|Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.
91314|NCT03472820|Other|PhytoGanix (tropical fruit flavor)|Organic Superfruits & Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.
91315|NCT03472820|Other|UltraFlora Intensive Care|Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
91316|NCT03472807|Other|Collection of blood sample or saliva|at Inclusion
91317|NCT03472807|Other|Collection of a tumor sample taken before the participation of the patient in study|at Inclusion
91318|NCT03472807|Other|Collection of blood sample if tumor sample is not available|at Inclusion
91319|NCT03472794|Other|"web portal:  Mon réseau cancer du sein  (My Breast cancer Network)"|"web portal:  Mon réseau cancer du sein "
91320|NCT03472781|Other|No intervention. A retrospective case review|No intervention. A retrospective case review on demographics, etiology, clinical features, diagnosis, secondary complications, treatment and outcomes of intraocular inflammation in children aged 16 years and below that presented to uveitis clinic in Singapore National Eye Centre from January 1989 to January 2017.
91321|NCT03472768|Diagnostic Test|Plasma Haptoglobin Concentration|N/A, comparison of haptoglobin concentration between groups
91322|NCT03472755|Other|The posterolateral approach|The posterolateral approach was used for implantation among patients in lateral position. This approach goes through the gluteus maximus, the piriformis and superior gemeli muscles are detached and later reattached to bone
91323|NCT03472755|Other|Direct anterior technique|patients were fixed in a supine position, a small entry incision was made in the vessel free interval between the tensor fasciae latae and the sartorius muscles and the prosthesis socket were put in place. Via a second dorsal incision, after releasing the external rotators, the prosthesis stem and ball were implanted and the two parts of the prosthesis were attached
91324|NCT03472742|Drug|Mesenchymal Stem Cell|As this is a follow-up and an observation study, ADR-001 was administered in the previous study, not in this study.
91325|NCT03472729|Other|AGE-ON Workshop|Series of workshops to reduce social isolation through technology use.
91326|NCT03472716|Procedure|Biological Samples|"5 ml blood sample and one tumoural sample (either a fresh biopsy or the initial diagnosis biopsy).~In case of relapse, new samples will be performed (blood and tumoral samples)"
91327|NCT03472703|Other|Break-Lunch time|The time for the break and lunch will be contrary, depending on their visit/session
91328|NCT03472690|Biological|QBECO-SSI|Subcutaneous injection
91329|NCT03472690|Other|Placebo|Subcutaneous injection
91330|NCT03472677|Other|Ice Pack and Cooling Device|A comparison of two cooling methodologies in healthy volunteers after single intra-articular (IA) injection (15 mL) of 2% lidocaine (without epinephrine).
91331|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling wrap vs ice pack cooling after single IA injection of 1 mg CNTX-4975-05 in each arm after single IA (15 mL) injection of 2% lidocaine (without epinephrine).
91332|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling parameters will be determined after evaluation of data from prior Cohort(s) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
91333|NCT03472677|Drug|CNTX-4975-05 (trans-capsaicin)|Controlled cooling with knee device vs no cooling (determined after evaluation of data from previous cohorts) after single IA injection (15 mL) of 2% lidocaine (without epinephrine) and single IA injection of 1 mg CNTX-4975-05.
91334|NCT03472677|Drug|Capsaicin|Four intradermal injections of capsaicin, two on each forearm.
91335|NCT03472664|Other|low carbohydrate/high fat diet|Modified Mediterranean-Ketogenic Diet is a low carbohydrate/high fat diet.
91336|NCT03472664|Other|low fat/high carbohydrate diet|American Heart Association Diet is a low fat/high carbohydrate diet.
91337|NCT03472651|Drug|test treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, film-coated tablet, single dose
91338|NCT03472651|Drug|reference treatment: flupentixol/melitracen|0.5 mg flupentixol and 10 mg melitracen, coated tablet, single dose
91339|NCT03472638|Device|Dorsomedial prefrontal rTMS|Active or sham rTMS targeting the dorsomedial prefrontal cortex, 20 Hz stimulation, 120% resting motor threshold, 1500 pulses per hemisphere, using a MagVenture R30 stimulator and Cool-DB80 coil.
91340|NCT03472625|Diagnostic Test|Screening and diagnosis of aphasia, dysarthria, dysphagia|"Screening (day 2 +/- 1; day 7 +/-1): NIHSS (National Health Institute Scale) 9 and 10 scores, dysphagia screening (nurse), speech-, and language screening (speech therapist)~Diagnostic assessment (day 2 +/-1-):~Dysphagia: MASA (Mann Assessment of Swallowing Abilities), FOIS (Functional Oral Intake Scale) Dysarthria: perceptual assessment, NSVO-Z (Nederlands spraakverstaanbaarheidsonderzoek - zinnen) Aphasia: ScreeLing, BNT (Boston Naming Test)"
91342|NCT03472599|Other|Genital Nerve Stimulation|Genital nerve stimulation activates sensory afferents that travel through the pudendal nerves and enters the spinal cord through the sacral dorsal root ganglia. Inhibitory spinal reflex pathways are activated, causing increased sympathetic outflow through the inferior mesenteric ganglion and hypogastric nerve and also decreased parasympathetic efferent drive through the pelvic nerve, resulting in inhibited bladder contractions.
91343|NCT03472586|Biological|Ipilimumab|Given IV
91344|NCT03472586|Biological|Nivolumab|Given IV
91345|NCT03472586|Drug|Embolization Therapy|Undergo immunoembolization
91346|NCT03472573|Drug|Palbociclib|Given PO
91347|NCT03472573|Drug|Dexamethasone|Given PO
91348|NCT03472560|Drug|Avelumab (MSB0010718C)|IV treatment: Avelumab administered at 800 mg IV every two weeks
91349|NCT03472560|Drug|Axitinib (AG-013736)|Oral treatment: Axitinib given 5 mg PO BID
91350|NCT03472547|Drug|diacerein 1% ointment|All subjects were exposed to diacerein 1% ointment, vehicle ointment, and 0.9% saline (negative control) at 3 randomly assigned, adjacent skin sites on the infrascapular area of the back 3 times weekly for 3 weeks (9 applications) during the Induction Phase, and one time during the Challenge Phase (10 times in total).
91351|NCT03472534|Drug|Diacerein 1% topical ointment and Vehicle|CCP-020 (Diacerein 1%) topical ointment, approximately 0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks Vehicle, approximately 0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks
91352|NCT03472521|Drug|Gabapentin|Treatment with analgesic adjutant commonly used for post-operative pain, titrated to effect by chronic pain specialist compared to placebo titration.
91353|NCT03472521|Drug|Placebo|Placebo to match gabapentin
91354|NCT03472508|Drug|Folic Acid|Folic acid used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
91355|NCT03472508|Drug|Enalapril Maleate and Folic Acid Tablets (Yiye)|Enalapril Maleate and Folic Acid Tablets (Yiye) have been approved for listing by the China Food and Drug Administration. Approval number: Zhunzi H20103723.All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
91356|NCT03472508|Drug|Enalapril|Enalapril used in this study are listed products. All drugs used in the double-blind treatment period of this study will be loaded into safety capsules with the same outer appearance; all parties involved in the trial will be unaware of the contents of the capsules.
91357|NCT03472495|Drug|Diltiazem Oral Product|Diltiazem Immediate Release 60 MG PO Q6H (30 MG PO Q6H if patient is <60 kg)
91358|NCT03472495|Drug|Diltiazem Injectable Product|Diltiazem Continuous Infusion Titrated
91359|NCT03472482|Diagnostic Test|non-invasive retinal imaging|
91360|NCT03472469|Drug|Acetaminophen IV/PO|Acetaminophen 1g IV/PO every 6 hours
91361|NCT03472469|Drug|Acetaminophen PO|Acetaminophen 1g PO every 6 hours
91362|NCT03472469|Drug|Ketorolac|Ketorolac 30mg IV once
91363|NCT03472469|Drug|Celebrex|Celebrex 200mg PO every 12 hours
91364|NCT03472469|Drug|Naproxen|Naproxen 500mg PO every 12 hours
91365|NCT03472469|Drug|Tramadol|Tramadol 100mg PO every 6 hours
91366|NCT03472469|Drug|Pregabalin|Pregabalin 100mg PO every 8 hours
91367|NCT03472469|Drug|Gabapentin|Gabapentin 300mg PO every 8 hours
91368|NCT03472469|Drug|Lidocaine|Lidocaine patch every 12 hours
91369|NCT03472469|Drug|Opioids|Opioids
91370|NCT03472469|Drug|Regional anesthesia|Regional anesthesia
91371|NCT03472456|Drug|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne|Implementation of a pulp medication in compliance with the dental emergency management protocol: articaïne
91372|NCT03472456|Drug|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol|Implementation of a pulp medication in compliance with the dental emergency management protocol: eugenol
91373|NCT03472443|Other|acupuncture|Subjects will receive Sinew Acupuncture 2-3 times in two weeks, a total of 5 sessions. Needles will be inserted into the Sinew Acupoints on the affected wrist and forearm. Needles will be inserted along the subcutaneous level, nearly parallel to the skin, and the tip of needles pointing towards the painful spot at the radial styloid. 4-6 sinew acupoints will be used.
91374|NCT03472430|Device|Transcutaneous electrical nerve stimulation|The TENS machine used in the study will be the Endomed 482 that delivers biphasic pulsed currents using pulse duration of 400 µs and pulse frequencies between 80-100 pulses.
91375|NCT03472430|Device|TENS machine with electrodes not emitting any impulses.|TENS machine with electrodes not emitting any impulses.
91376|NCT03472417|Device|Active partial rebreathing device|
91377|NCT03472417|Device|Dummy partial rebreathing device|
91378|NCT03472404|Procedure|Internal Brace augmented ankle Ligament reconstruction|internal brace augmented ankle ligament reconstruction and an accelerated revalidation protocol.
91379|NCT03472404|Procedure|Brostrom-Gould ankle Ligament reconstruction|Brostrom-Gould and standard revalidation including 6 weeks immobilisation.
91380|NCT03472391|Behavioral|Physical Therapy|A 4-week (2 exercise session af week, of 40 minutes )tailored physiotherapeutic exercise program. The sessions are individually and supervised by physical therapist and tailored to patients with severe anorexia nervosa. The exercise program mainly consist of strength training exercises without any equipment other than a floor mat.
91381|NCT03472378|Drug|DFN-15|Oral Solution of 4.8 mL containing 120 mg of DFN-15
91382|NCT03472378|Other|Placebo|Oral Solution of 4.8 mL containing 0 mg of DFN-15
91383|NCT03472365|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
91384|NCT03472365|Drug|Capecitabine|1000 mg/m^2 administered as continuous oral twice daily (BID) of each 3-week cycle.
91385|NCT03472365|Drug|Oxaliplatin|130 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle.
91386|NCT03472365|Drug|Apatinib|500 mg administered as continuous oral once daily (QD) of each 3-week cycle.
91630|NCT03470311|Biological|Placebo|Matched placebo (1mL) in pre-filled syringe
91387|NCT03472352|Biological|An anticancer medication (A01) and immune cells (IC01)|The administration of A01 and IC01 will be performed in the Second People's Hospital of Yibin, Sichuan, China. The subjects will be observed for any side effects during this time and all the adverse events will be recorded.
91388|NCT03472339|Drug|Diclofenac Sodium|Group A-Intramuscular diclofenac sodium+oral placebo Group B-Oral diclofenac sodium+ intramuscular placebo
91389|NCT03472326|Drug|GS-9131|Tablet(s) administered orally once daily. Dose for the open-label extension will be determined following review of the safety, efficacy and available PK data of the Randomized Cohort in Part 1 from Part 2.
91390|NCT03472326|Drug|Placebo|Placebo-to-match (PTM) GS-9131 tablets
91391|NCT03472326|Drug|BIC|30 mg tablet(s) administered orally once daily
91392|NCT03472326|Drug|TAF|25 mg tablet(s) administered orally once daily
91393|NCT03472326|Drug|ART regimen|ART regimen may consist of the current failing antiretroviral agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)
91394|NCT03472326|Drug|DRV|800 mg tablet(s) administered orally once daily
91395|NCT03472326|Drug|RTV|100 mg tablet(s) administered orally once daily
91396|NCT03472313|Drug|[18F]MNI-958|Healthy Volunteers recruited for the study will undergo a single [18F]MNI-958 injection and PET scan.
91397|NCT03472300|Other|Survey about knee pain and treatment|All citizens are surveyed to describe the prevalence of knee pain in a danish community.
91398|NCT03472287|Drug|CCP-020 (Diacerein 1% Ointment)|Diacerein 1% Ointment administered topically
91399|NCT03472274|Drug|Durvalumab|Durvalumab 1500 mg every 4 weeks x 3 cycles
91400|NCT03472274|Drug|Tremelimumab|Tremelimumab 75 mg every 4 weeks x 3 cycles
91401|NCT03472274|Drug|Cisplatin-based neoadjuvant chemotherapy|"Regimen 1: 21-day treatment cycle x 3 cycles.~Gemcitabine 1,000-1,200 mg/m2 intravenously on days 1 and 8 every 21 days.~Cisplatin 70 mg/m2 intravenously on day 1 every 21 days. Regimen 2: ddMVAC 14-day treatment cycle x 4 doses.~Methotrexate 30mg/m2 intravenously on day 1~Vinblastine 3mg/m2 intravenously on day 2~Doxorubicin 30mg/m2 intravenously on day 2~Cisplatin 70mg/m2 intravenously on day 2 Granulocyte colony-stimulating factor (G-CSF) for 7 consecutive days (days 4 through 10).~Regimen 3: 21-day treatment cycle x 3 cycle~Gemcitabine 1,000 mg/m2 intravenously on day 1 and 8~Paclitaxel 80 mg/m2 intravenously on day 1 and 8~Cisplatin 70mg/m2 intravenously on day 1"
91402|NCT03472261|Drug|Botulinum toxin type A|Dysport
91403|NCT03472261|Other|Upper extremity orthoses|Twister
91404|NCT03472261|Other|Home exercise program|Specific exercises for pronation deformity
91405|NCT03472248|Behavioral|Acceptance and Commitment Therapy|Eight weeks of smartphone delivered Acceptance and Commitment Therapy for the adolescent and eight weeks of internet delivered parental support to one or two parents of the adolescent.
91406|NCT03472235|Device|Microneedle|"TCA peeling session: Facial skin will be cleansed with tap water and degreased by rubbing with an alcohol sponge .~Then TCA 25% will be applied to the whole face by cotton tipped applicator or gauze pad. The entire face will be treated until complete frosting occur.~The patients will be instructed to wash their faces to decrease the burning sensation.~Combined session: starts with microneedle using microneedle device (Derma pen) The skin of each patient is cleaned with anti septic solution and anesthetic cream may be applied to lessen discomfort.~(Dermapen) will be applied on the lesional skin in four direction, vertical, horizontal and in the two diagonal until pin point bleeding occur which will be gently massaged .~After 10 minutes TCA peeling will be applied TCA peeling will be done for 8 session with 2 weeks interval between each session.~Microneedle will be done for 4session with 4 weeks interval between each session."
91407|NCT03472222|Behavioral|Arsha Vidya program|Integrated intervention program includes counselling and supportive care with the support of Arsha Vidya program
91408|NCT03472196|Device|EndoZip System|"The Nitinotes EndoZip system is designed to allow for the creation of multiple internal gastric segmentation (4-8) in the stomach by using an endoscopic approach. The system allows the forming of wall-to-wall longitudinal attachments of the anterior and posterior stomach walls, creating multiple strictures within.~Creation of this segmentation may significantly reduce gastric volume, may affect gastric motility and consequently, reduce weight."
91409|NCT03472183|Other|biopsies of colon|Removal of additional biopsies of colon during the course of a colonoscopy planned for usual medical follow-up of patient
91410|NCT03472170|Dietary Supplement|Enteral administration of bovine lactoferrin (bLf)|The pharmacy service of the hospital will provide the established dose of lactoferrin, according to the regimen of administration of 150 mg / kg / day (maximum 300 mg / day), as well as that of placebo. Both treatments will be administered in liquid form, in the least amount possible. Both the administration of lactoferrin and placebo will be carried out enterally, orally or by nasogastric tube. The intervention will be done in the first 72 hours of life, once a day, and for 4 weeks, extending to 6 weeks in the newborns with EG ≤ 28 weeks and / or birth weight ≤ 1000 gr, or until discharge if this happens before.
91411|NCT03472170|Other|Enteral administration of placebo|Enteral administration of placebo with similar visual and gustatory characteristics in the first 72 hours of life, and for 4 weeks (6 weeks in the RN ≤ 1000 gr and / or EG ≤ 28 weeks).
91412|NCT03472157|Other|Lifestyle therapy|Lifestyle habits (caloric intake and exercise) + pedometer
91413|NCT03472157|Procedure|Bariatric surgery|Two different types of bariatric surgery can be proposed: laparoscopic Roux-en-Y Gastric Bypass or a Laparoscopic sleeve gastrectomy
91414|NCT03472144|Drug|gel loaded with steroids (momentasone)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local corticosteroids (momentasone) after balloon sinuplasty for chronic sinusitis patients.
91415|NCT03472144|Drug|gel loaded with antibiotic (Levofloxacin)|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
91416|NCT03472144|Drug|gel loaded with both steroids and antibiotic|One of the purpose of this study is to evaluate the efficacy of a gel that actively releases local both steroids (momentasone)and antibiotic(levofloxacin) after balloon sinuplasty for chronic sinusitis patients.
91417|NCT03472131|Procedure|Unilateral Posterolateral Approach and Debridement|
91418|NCT03472131|Other|Titanium cage insertion supplemented by screw fixation|
91419|NCT03472118|Device|Nasal High Flow Oxygen|Nasal High Flow Oxygen during apnoea using Optiflow device of Fisher and Paykel
91420|NCT03472105|Dietary Supplement|New Nordic Renal Diet|One week ingesting a phosphorus reduced diet containing a total of 850 mg of phosphorus/day compared to one week of a habitual diet
91421|NCT03472092|Behavioral|Cognitive Behavioral Therapy (CBT)|This intervention will consist of 8 weekly sessions. The duration of each session is about 45 minutes and will be led by a psychologist/therapist using a manualized protocol. About half of the sessions will be conducted in person and the remaining sessions will be offered via telehealth (Skype or phone).
91422|NCT03472092|Drug|Placebo|The placebo pill will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study.
91423|NCT03472092|Drug|Amitriptyline|Amitriptyline will be administered once a day at home for 8 weeks, to be taken by mouth with or without food under the supervision of the participant's parent or guardian. To maintain blinding, all participants will receive 1 matching capsule as a daily dose to be taken each evening during the study. For this study, a dose of 0.25 mg/kg/day will be provided for the 1st 2 weeks, followed by a dose of 0.5 mg/kg/day for 2 weeks, 0.75 mg/kg/day for 2 weeks and a maximum dose of 1.0 mg/kg/day for 2 weeks based on tolerability. Participants experiencing tolerability issues, may be held a current dose rather than titrated to the next dosage if deemed appropriate by the study doctor.
91424|NCT03472066|Other|Previous conization|a group of women who have been conized,
91425|NCT03472066|Other|no previous conization|group with asymptomatic patients on routine second trimester echography
91426|NCT03472053|Drug|BIO-11006 plus standard of care|BIO-11006 is administered 125mg BID plus standard of care.
91427|NCT03472053|Drug|Standard of Care|Pemetrexed (500 mg/meter square) and Carboplatin (AUC6, Calvert's formula) are administered every three weeks for three months.
91428|NCT03472040|Drug|BCX7353|BCX7353 mg oral capsules administered once daily
91429|NCT03472027|Biological|BCD-145|Anti-CTLA-4 monoclonal antibody, IV infusion
91430|NCT03472014|Biological|IMVAMUNE®|IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose
91431|NCT03472001|Other|Reflection and feedback|2-hour training involving 10 written clinical cases to encourage students to practice thinking like a dermatologist in their clinical reasoning, and to help students build adequate illness scripts of skin diseases
91432|NCT03472001|Other|Lecture|Traditional didactic lecture which uses the same clinical cases
91433|NCT03471988|Drug|AK1820|"Only a switch from IV infusion (vial) to oral administration (capsule) will be permitted; a switch from oral administration to IV infusion will not be possible.~372.6 mg of AK1820 (isavuconazonium sulfate) is equivalent to 200 mg of isavuconazole.~Other Names: Cresemba, BAL8557"
91434|NCT03471988|Drug|Voriconazole|"Only a switch from IV infusion (vial) to oral administration (tablet) will be permitted; a switch from oral administration to IV infusion will not be possible.~Other Name : VFend"
91435|NCT03471975|Procedure|direct laryngoscope|the trainee use McGrath video laryngoscope as direct laryngoscope the trainee is not allowed to watch the screen.
91436|NCT03471975|Procedure|video laryngoscope|the trainee use McGrath video laryngoscope both trainee and trainer can watch the screen.
91437|NCT03471962|Other|surgery|Indirect measurement of RQ was performed by anesthesia ventilator and compared to marker of anaerobic metabolism (arterial lactate, venoarterial PCO2 gradient, venoarterial PCO2 gradient/ arteriovenous O2 content difference, ScVO2) at different time of the srugery (every hours). In post-operative time, complications and hospital's length of stay were recorded.
91438|NCT03471949|Other|CGM in a population with normal OGTT|The population with normal OGTT will use CGM and document their values as well as be documenting a capillary blood glucose value
91439|NCT03471936|Diagnostic Test|Acquisition of pressure-volume-loops|Diagnostic workup including cardiac MRI, Echocardiography and cardiopulmonary exercise test (CPET) followed by invasive acquisition of RV and left ventricular (LV) pressure-volume-loops
91440|NCT03471923|Diagnostic Test|Neurological Examination|The family members and healthy volunteers will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of cervical dystonia and other sensory abnormalities. If the subject is found to have cervical dystonia or any other sensory abnormalities, the subject will be excluded from the study.
91441|NCT03471923|Diagnostic Test|Assessment of Non-Motor Features|All subjects will be assessed for four non-motor symptoms, including (1) spatial discrimination threshold, (2) temporal discrimination threshold, (3) vibration-induced illusion of movement, and (4) kinesthesia.
91442|NCT03471910|Drug|Diosmin|Diosmin 600mg tablet, once daily
91443|NCT03471910|Drug|Diosmin / Hesperidin|Diosmin 900 mg / Hesperidin 100mg tablet, once daily
91444|NCT03471897|Diagnostic Test|Glycosaminoglycan plasma score|A score was calculated using a formula that factors in measurements of plasma glycosaminoglycan. A score higher than a here-determined threshold is deemed diagnostic of RCC.
91445|NCT03471884|Procedure|Nonintubated thoracoscopic lobectomy|Nonintubated general anesthesia using fentanyl, target-controlled infusion of propofol to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a spontaneous breathing due to iatrogenic pneumothorax.
91446|NCT03471884|Procedure|Intubated thoracoscopic lobectomy|Intubated general anesthesia using 2%-3% sevoflurane and rocuronium to achieve a bispectral index value between 40 and 60. One-lung ventilation will be achieved via a endobronchial tube or blocker with use of mechanical ventilation.
91447|NCT03471871|Drug|Placebo|HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
91448|NCT03471871|Drug|Lemborexant 10 mg|HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
91449|NCT03471871|Drug|Lemborexant 25 mg|HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
91450|NCT03471871|Drug|Placebo|OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
91586|NCT03470675|Drug|Epidural saline + IV saline|Sterile saline injection in the epidural catheter and in the intravenous catheter
92026|NCT03467373|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle
91451|NCT03471871|Drug|Lemborexant 10 mg|OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
91452|NCT03471858|Device|Cervical balloon|To assess if a cervical balloon catheter (foleys catheter) for mechanical induction of labour is comparable to prostaglandin usage for induction of labour in women who have had a previous caesarean section.
91453|NCT03471858|Drug|Prostaglandins|Prostin will be used in the control arm.
91454|NCT03471845|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
91455|NCT03471819|Diagnostic Test|Serum serotonin level|blood sample will be obtained to evaluate serum level of serotonin
91456|NCT03471806|Behavioral|Food reward at baseline|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
91457|NCT03471806|Behavioral|Food reward after treatment|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
91458|NCT03471780|Diagnostic Test|ultrasound|Transperineal us are made to pregnant ladies in labour
91459|NCT03471767|Drug|AXS-05|Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
91460|NCT03471767|Drug|Bupropion SR|Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal.
91461|NCT03471754|Device|TESA-HB Transcranial Electronic Stimulation Device|Duration of treatment: 50 Minute Therapy sessions administered one time each day, for two 5-day cycles
91462|NCT03471741|Radiation|IMRT with concomitant boost|
91463|NCT03471741|Radiation|3D-RT with sequential boost|
91464|NCT03471728|Drug|linaclotide|Oral
91465|NCT03471702|Device|Smart External Drain - SED|Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
91466|NCT03471689|Behavioral|Mindfulness meditation|Participants will be trained to use mindfulness meditation to reduce pain perception.
91467|NCT03471689|Behavioral|Positive reappraisal|Participants will be trained to use positive reappraisal to reduce pain perception.
91468|NCT03471676|Other|Muscular oximetry|6 minutes walking test performed in the routine medical care with muscle oximetry recording
91469|NCT03471663|Drug|D-0502|oral tablets
91470|NCT03471663|Drug|palbociclib|standard dose of palbociclib
91471|NCT03471650|Drug|18F-DCFPyL Injection|A bolus of ~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.
91472|NCT03471637|Other|Compassion-Focused Therapy|"Compassion-Focused Therapy 11 weeks of Compassion-Focused Therapy [based on Compassion-Focused Therapy for Dummies (Welford, 2016)]"
91473|NCT03471624|Drug|Tenofovir Alafenamide|Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
91474|NCT03471611|Drug|Autologous CD34+ Cells|The dose will be 1x10^5 cells/kg, injected at the rate of 10 ml/min
91475|NCT03471611|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5mg/kg twice daily
91476|NCT03471585|Drug|THC|A capsule that contains 15 mg of THC as well as dextrose filler administered 2 hours prior to memory testing.
91477|NCT03471585|Drug|Placebo oral capsule|A capsule that contains only dextrose filler administered 2 hours prior to memory testing.
91478|NCT03471559|Drug|Cannabidiol|single or multiple dosing
91479|NCT03471546|Behavioral|Palliative Care|Initial consultation and follow-up with a palliative care provider
91480|NCT03471533|Dietary Supplement|nutraceutical: experimental product|84 days of consumption
91481|NCT03471533|Dietary Supplement|placebo|84 days of consumption
91482|NCT03471520|Behavioral|Earplugs and eye masks|Patients in this study will be given earplugs and eye masks to be worn during sleep
91483|NCT03471507|Drug|Bonipar|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
91484|NCT03471507|Drug|Diclofenac sodium gel 1%|Apply 2 pumps 2 times a day to be applied topically on the affected area during a two week treatment period.
91485|NCT03471494|Other|Exposure: human development index of country|Primary comparison: Between country groups defined by human development index.
91486|NCT03471481|Other|No Intervention. Study is Cross Sectional in nature|No Intervention. Study is cross sectional in nature
91487|NCT03471468|Procedure|kinetics of microparticles under chemotherapy|Blood samples done before chemotherapy and 6 hours later for each of six chemotherapies required by the protocol.
91488|NCT03471455|Drug|Isotretinoin|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
91489|NCT03471455|Drug|Terbinafine|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
91490|NCT03471455|Drug|Itraconazole 200 mg|Patients of recurrent dermatophytosis will receive terbinafine or itraconazole , either alone or in combination with oral isotretinoin
91491|NCT03471442|Procedure|Paravertebral block|Ultrasound-guided paravertebral block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
91492|NCT03471442|Procedure|Erector spinae plane block|Ultrasound-guided erector spinae plane block performed pre-operatively in the anesthesia block room with 20ml of a ropivacaine / bupivacaine mixture.
91493|NCT03471442|Drug|General anesthetic|General anesthesia administered as per preference of intra-operative attending anesthesiologist
91587|NCT03470675|Drug|Epidural morphine 3 mg + IV saline|Morphine 3 milligrams injection in the epidural catheter and sterile normal saline intravenous catheter
91588|NCT03470675|Drug|Epidural morphine 3 mg + IV ketamine 0.3 mg/kg|Morphine 3 milligrams injection in the epidural catheter and 0.3 milligrams per kilogram weight infused in the intravenous catheter
91494|NCT03471442|Drug|Opioids|Intra-operatively, opioids will be titrated to heart rate and spontaneous respiration rate e.g. fentanyl, morphine, hydromorphone. Post-operatively in post anesthesia care unit, morphine and hydromorphone will be titrated to effect as necessary. After discharge from post anesthesia care unit, oral analgesia will be administered on an as required basis e.g. acetaminophen, non-steroid anti-inflammatory medications, acetaminophen / codeine and acetaminophen / oxycodone.
91495|NCT03471442|Drug|Anesthetics, Local|Weight-based dosing of this local anesthetic mixture.
91496|NCT03471390|Other|ProQuaS 2 Intervention|Training and implementation of facility pain champions, comprehensive training of all care workers in pain assessment and management, implementation of pain management policies
91497|NCT03471377|Other|standard scheduling process|Scheduling office assigns start time and room for case and places case on schedule. At this point a default case duration is evaluated by the scheduling office, to see if the value is considered excessively short or excessively long. Depending on the assessment, the scheduling office will either keep the default value, use the value that the surgeon placed in the notes (if available), or the scheduling office provides their own estimation.
91498|NCT03471377|Other|assigned a planned case duration value from predictive model|"Predictive model calculates new duration for case at 3AM the day before surgery, and the predictions are made available on a SecureShare-site.~Model predictions are then read by scheduling manager sometime between 7am-10am from the SecureShare site, and the scheduling manager will in EPIC/OpTime, overwrite the current estimate with the new duration value that was generated by the predictive model."
91499|NCT03471364|Drug|Ketoconazole|Applied topically
91500|NCT03471364|Other|Laboratory Biomarker Analysis|Correlative studies
91501|NCT03471364|Other|Placebo|Applied topically
91502|NCT03471364|Other|Quality-of-Life Assessment|Ancillary studies
91503|NCT03471364|Other|Questionnaire Administration|Ancillary studies
91504|NCT03471351|Drug|Tenalisib|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
91505|NCT03471351|Biological|Pembrolizumab|Tenalisib, BID, orally and Pembrolizumab 200 mg IV Q3W
91506|NCT03471338|Behavioral|Cognitive rehabilitation|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): The patient performs the program (PRESCO software) on his computer autonomously at home at a rate of 3 sessions per week. A neuropsychologist performs at-home visits and weekly phone meetings to train the patient to the software, to encourage him to do exercises and to answer any software use-related questions.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
91507|NCT03471338|Behavioral|Standard Psychological care|"At-site inclusion visit: assessment of patient's eligibility by cognitive complaint questionnaire and BCcogSEP, VAPS and multiple errands test conducted by neuropsychologist.~At-site baseline visit: assessment of quality of life (MUSIQOL), self-esteem (SEI), depression (MADRS), anxiety (HAMA), BICAMS: SDMT, CVLT-II, BVMTR, metacognition (MCQ-30), fatigue (EMIF-SEP), subjective sleep quality (PSQI) conducted by a neuropsychologist.~At-home neuropsychological management (9 weeks): A neuropsychologist performs at-home visits and weekly phone meetings consisting in discussion of the patient's cognitive disorders.~At-site follow-up visits: short and long-term retest of assessments performed in inclusion visit."
91508|NCT03471325|Procedure|Plaque disclosed with air flow|air polishing with prior plaque disclosing
91509|NCT03471325|Procedure|Plaque disclosed with rubber cup|rubber cup polishing with prior plaque disclosing
91510|NCT03471325|Procedure|Non plaque disclosed air flow|air polishing with no prior plaque disclosing
91511|NCT03471325|Procedure|Non plaque disclosed rubber cup|rubber cup polishing with no prior plaque disclosing
91512|NCT03471312|Drug|Magnesium|magnesium therapy
91513|NCT03471286|Drug|Epacadostat|Drug is taken orally two times per day for 14 days, prior to surgical resection of tumor.
91514|NCT03471273|Procedure|endoscopic management, surgery and follow up|endoscopic management, surgery and follow up
91515|NCT03471260|Drug|Azacitidine|Given IV or SC
91516|NCT03471260|Drug|Ivosidenib|Given PO
91517|NCT03471260|Other|Pharmacokinetic Study|Correlative studies
91518|NCT03471260|Drug|Venetoclax|Given PO
91519|NCT03471247|Device|In-Bed Cycle Ergometer|Physiotherapists will place the patient's legs in a specialized in-bed cycle ergometer allowing for gentle leg exercise. Exercise can performed in passive, active-assisted, or active mode.
91520|NCT03471247|Other|Routine PT|Includes, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out- of bed mobility, ambulation, and assistance with optimizing airway clearance and respiratory function.
91521|NCT03471234|Device|Angioplasty|Inspiron Drug Eluting stent implantation
91522|NCT03471221|Behavioral|Therapy Dog Visit|"Animal Assisted Activities (AAA) provide opportunities for motivational, educational, recreational, and/or therapeutic benefits to enhance quality of life. AAA are delivered in a variety of environments by specially trained professionals, paraprofessionals, and/or volunteers, in association with animals that meet specific criteria.~Key features of AAA are as follows:~Specific treatment goals are not planned for each visit.~Volunteers and treatment providers are not required to take detailed notes.~Visit content and activities are spontaneous.~Visit length can be as long or as short as needed."
91523|NCT03471208|Device|Dynamic Navigation Assisted Implant Surgery|Implant surgery using dynamic navigation assistance
91524|NCT03471208|Procedure|Freehand Implant Surgery|Dental implant surgery via conventional freehand
91525|NCT03471195|Diagnostic Test|Total Salivary Cytokine profile|Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
91526|NCT03471182|Behavioral|Psychiatric and Cognitive Testing|Interviews, questionnaires, and computer testing.
91527|NCT03471182|Drug|Cocaine Self-adminstration|The intervention will include a training and safety session that consists of physician/nurse-administered cocaine followed by a self-regulated cocaine administration period under carefully controlled and closely monitored conditions.
91589|NCT03470662|Other|Care bundle|Care bundle
91528|NCT03471182|Radiation|Positron Emission Tomography|PET scans will be performed on a High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available. Antecubital venous catheters will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter may also be inserted by an experienced physician before the PET scan. At the beginning of each scan, the participants's head will be immobilized and a 6-minute transmission scan, using an orbiting 137Cs point-source, is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of [18F]FPEB.
91529|NCT03471182|Other|Magnetic Resonance Imaging|Structural and functional MRI data will be acquired using a Siemens Trio TIM 3.0T system at the Yale Magnetic Resonance Research Center. High-resolution structural MRI data will be acquired to facilitate analysis of PET data and may be used in additional analysis of tissue volume and brain structure. Resting-state and task-based functional MRI data will be acquired using state-of-the-art multiband echo-planar imaging (EPI) gradient-echo sequences. Diffusion-weighted MRI data will also be acquired using multiband imaging sequences to investigate anatomical connectivity.
91530|NCT03471169|Drug|Desirable TEG|"Change the type and dose of antithrombotic therapy and obtain desirable TEG results.~Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol."
91531|NCT03471169|Drug|Undesirable TEG|Don't change the type and dose of antithrombotic therapy and obtain undesirable TEG results. Antithrombotic drugs inclued Bayaspirin®，Plavix ® and Cilostazol.
91532|NCT03471143|Drug|2-Hydroxypropyl-Beta-Cyclodextrin|"VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV VTS-270 for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg"
91533|NCT03471130|Drug|MT-8554 Low dose|Oral, 7 days
91534|NCT03471130|Drug|MT-8554 High dose|Oral, 7 days
91535|NCT03471130|Drug|Placebo|Oral, 7 days
91536|NCT03471117|Drug|Pioglitazone|Pioglitazone 15mg daily for 1 month
91537|NCT03471117|Other|Placebo|Placebo sugar pills for 1 month
91538|NCT03471104|Other|PAID in clinical diabetes consultations|"The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician."
91539|NCT03471091|Device|NIV with the integrated tele-monitoring management program|Noninvasive positive pressure ventilation with the integrated tele-monitoring management will provide regular health report, and once an alert is generated due to the abnormality in NIV usage or vital sign data etc., physicians will take action accordingly.
91540|NCT03471078|Drug|Avatrombopag|Oral avatrombopag tablet
91541|NCT03471078|Drug|Placebo Oral Tablet|Placebo comparator tablet
91542|NCT03471065|Device|TAVR|Implantation of the SAPIEN 3 Ultra THV using the SAPIEN 3 Ultra Delivery System
91543|NCT03471052|Procedure|Radiofrequency ablation (RFA)|"Ablation using the Barrx RFA System is a new technique for field ablation in the oesophagus. It has been used for eradication of diseased epithelium of all three subclasses of Barrett's oesophagus (non-dysplastic Intestinal metaplasia (IM), Low grade dysplasia (LGD) and High grade dysplasia (HGD). The BarrxTM RFA System uses ultra short pulse RF energy delivering 40Watts/cm2 power density and 12Joule/cm2 energy density, and affects the mucosa whilst preserving the submucosa.~Clinical trials have suggested that it is safe and effective for treating non-dysplastic IM, LGD and HGD in Barrett's oesophagus . Long term data show the effect to be durable over 5 years."
91544|NCT03471039|Drug|PACAP27|Infusion of PACAP27 over 20 minutes.
91545|NCT03471039|Drug|Saline|Infusion of Saline over 20 minutes.
91546|NCT03471026|Diagnostic Test|Advanced MRI sequences|Structural, diffusion and perfusion MRI sequences
91547|NCT03471000|Other|Short implants Treatment|Short implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
91548|NCT03471000|Other|Regular implants Treatment|Sinus lift procedure is done and regular implants are placed in the alveolar bone and a clinical Ostell and Periotest evaluation of the implants after a period of time is done. Analysis of periapical radiographs and CBCT images after a period of time. Bone around the implant was measured, marginal bone level loss is determined.
91549|NCT03470987|Procedure|Phase I Periodontal therapy|Oral hygiene instuction, scaling and root planning
91550|NCT03470987|Dietary Supplement|Metabolic control|Calorie restricted diet
91551|NCT03470974|Behavioral|Self-titration strategy|The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
91552|NCT03470961|Drug|Anti-Tlymphocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
91553|NCT03470961|Drug|Anti-Thymocyte Globulins|Induction therapy regimen in simultaneous pancreas kidney transplantation
91554|NCT03470948|Other|Observe postoperative complications|The aim of this study is to confirm the utility of a 10-point Surgical Apgar Score to rate surgical outcomes in Whipples procedure in patients with pancreatic cancer.
91555|NCT03470922|Biological|Relatlimab|Specified dose on specified day
91556|NCT03470922|Biological|Nivolumab|Specified dose on specified days
91590|NCT03470649|Drug|Iron Isomaltoside 1000|Iron Isomaltoside 1000 would be intravenously administrated to treatment group after main procedure of total knee arthroplasty.
91591|NCT03470636|Device|HeartLight X3|Pulmonary vein isolation
92300|NCT03465280|Procedure|Plasma coagulation|Removal of lesions via plasma coagulation
91557|NCT03470909|Procedure|Skin-Sparing Mastectomy (SSM)|"For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
91558|NCT03470909|Procedure|Nipple-Sparing Mastectomy (NSM)|"For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented."
91559|NCT03470896|Procedure|preanesthesia teleconsultation|According to his allocated group, patient will have a teleconsultation at home/at work with an anaesthesiologist.
91560|NCT03470896|Procedure|preanesthesia traditional consultation|According to his allocated group, patient will have a traditional consultation with an anaesthesiologist in the surgical center Emile Galle.
91561|NCT03470883|Other|Evaluation of the long-term complete remission rate (> 12 months)|Evaluation of the long-term complete remission rate (> 12 months)
91562|NCT03470870|Other|Comparative analysis of the characteristics|"Predictive nomogram of short-term hospitalization (less than two days after surgery)~Factors influencing the variations of average stay lenght~Morbidity of the ERAS program"
91563|NCT03470857|Diagnostic Test|Patients|The FDG PET/CT imaging will be performed as part of typical medical procedures related to the diagnosis and monitoring of cancers at the Oncology Center in Bydgoszcz, Poland
91564|NCT03470844|Behavioral|Face-to-face neurocognitive tests|Assessment of attention, processing speed, working memory and executive function
91565|NCT03470844|Behavioral|Psychological screening|Screening for the symptoms of depression, anxiety and post-traumatic stress disorder
91566|NCT03470844|Other|fMRI|Brain volume, chemical markers, functional outcome
91567|NCT03470844|Behavioral|Quality of Life Self-Assessment data|EQ-5D will be converted into a utility score using standard EQ-5D UK tariffs
91568|NCT03470818|Other|Preparatory instructional videos (flipped classroom model)|"The intervention consists in the provision of preparatory instruction about the medical knowledge required to complete the task work of the upcoming simulated acute care clinical situation. The format used to convey this off-loaded educational content will be short (approximately 15 minutes) narrated video PowerPoint presentations; every relevant medical situation incorporated in the simulation case will have a dedicated video presentation.~These videos will be available to the intervention group participants on a web-based platform one week prior to the simulation session"
91569|NCT03470818|Other|Sham video|"Participants in the control group will be called to watch an online video prior to the simulation activity. However, this video presentation will not have any form of information regarding the upcoming simulation case; it will be an introductory video discussing the capacities of the simulation facility. This will limit any unwanted snowball effect where discussion between research participants could lead the control group participants to inquire about a video presentation that they would not exposed to."
91570|NCT03470805|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until disease progression, unacceptable toxicity, withdraws from the study or closure of the study
91571|NCT03470792|Device|Microcirculation examination|Sublingual microcirculation images were recorded using an incident dark-field video microscope
91572|NCT03470779|Other|Physiotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
91573|NCT03470779|Other|Psychotherapy|Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
91574|NCT03470766|Device|Nevro Senza System (HF10 Therapy)|Nevro 10kHz High Frequency Spinal Cord Stimulation
91575|NCT03470753|Other|Number of Exercises|Subjects will receive either 2 or 4 exercises to evaluate the short-term recall and performance.
91576|NCT03470753|Other|Type of Instruction|The type of instruction in phase 1 will be compared: Instruction by providing a handout only vs being instructed by a provider and practiced by the patient with provider feedback.
91577|NCT03470753|Other|Delivery Type|In phase 2 subjects will be provided 4 exercises using only a handout vs delivered to them electronically with the addition of a video.
91578|NCT03470753|Other|Mobile Reminder|A text-message based mobile reminder tool will be utilized to engage with subjects via texting on a daily basis to provide reminders and encouragement to perform their home exercises.
91579|NCT03470740|Behavioral|rheumatoid arthritis self-management program|The intervention group received the rheumatoid arthritis self-management program which was based on Bandura's theory of self-efficacy and proposes that self-efficacy is influenced by four information sources: mastery of experience, social modeling, social persuasion and one's physical and emotional states. To enhance participants' self-management skill, the following strategies were employed: peer story-telling, assessment, family involvement, goal setting, self-monitoring, self-evaluation, and phone calls consultation.
91580|NCT03470727|Device|Citrate dialysate|Change form acetate to citrate dialysate
91581|NCT03470714|Other|Force Irradiation|For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
91582|NCT03470714|Other|Kinesiotaping|For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
91583|NCT03470701|Other|Mailed Urinalysis Smartphone Kit|Patients who fail to complete albuminuria screening after the initial reminder to do so, will be contacted by phone and offered a mailed smartphone urinalysis kit. Agreeable patients will then receive the mailed kit and instructions to use their smartphone camera to analyze a urine dipstick.
91592|NCT03470623|Device|bioabsorbable screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the bioabsorbable screw
91593|NCT03470623|Device|steel screws|Hallux valgus are treated with a distal chevron osteotomy of first metatarsal and fixed using the steel screw
91594|NCT03470610|Drug|Progesterone|6 mg estradiol and vaginal and rectal progesterone
91595|NCT03470597|Other|dietary iodine restriction on subjects with iodine overload|In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.
91596|NCT03470584|Other|Diet Exposure|Vegetarian diet vs nonvegetarian diet
91597|NCT03470571|Diagnostic Test|CMR|Outcome analysis of CMR features in suspected myocarditis patients
91598|NCT03470558|Other|Dietary habits|Sleeve gastrectomy patients will be asked to monitor dietary habits for 1 week before surgery and at 2, 6, and 12 months after surgery.
91599|NCT03470545|Drug|mavacamten|mavacamten capsules
91600|NCT03470545|Drug|Placebo|placebo oral capsule
91601|NCT03470532|Drug|buccal infiltration of 4% Articaine with Epinephrine|Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
91602|NCT03470532|Drug|buccal infiltration of 2% Mepivacaine with Epinephrine|Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
91603|NCT03470506|Other|Stool Samples|Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
91604|NCT03470493|Diagnostic Test|ApneaLink Air|ApneaLink Air to be used on each participant undergoing PSG
91605|NCT03470480|Device|Real Repetitive transcranial magnetic stimulation|A real magnet will be used during rTMS treatments, which will look identical to the sham magnet. The participants and treatment facilitator will be blinded to which magnet will be used. High frequency repetitive transmagnetic stimulation (rTMS) will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
91606|NCT03470480|Device|Sham Repetitive transcranial magnetic stimulation|A sham magnet will be used during rTMS treatments, which will look identical to the real magnet. The participants and treatment facilitator will be blinded to which magnet will be used. The sham rTMS treatments will be directed at left dorsolateral prefrontal cortex (DLPFC) during 10 daily treatments within two weeks then 6 more treatments during the following month.
91607|NCT03470480|Behavioral|Methamphetamine visual cues|Just before each rTMS session, participants will be shown methamphetamine-related pictures
91608|NCT03470480|Behavioral|Neutral visual cues|Just before each rTMS session, participants will be shown neutral pictures
91609|NCT03470467|Other|No intervention|No intervention planed
91610|NCT03470454|Drug|Linagliptin Oral Tablet|Linagliptin for blood glucose control
91611|NCT03470441|Drug|FDY-5301|FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
91612|NCT03470441|Other|Placebo|Placebo will be administered intravenously by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
91613|NCT03470402|Other|RealRisks|RealRisks is a web-based patient decision aid with modules on risk assessment, family history and breast cancer, genetic testing, and prevention options. Participants enter family history data into RealRisks, and RealRisks calculates 5-year breast cancer risk, lifetime breast cancer risk, and the probability of carrying a BRCA mutation. This information is then interactively presented to the participant. RealRisks facilitates the participant in identifying their intention to undergo BRCA genetic testing and the factors that are important to the participant in making this decision. RealRisks produces a summary of all of this information that the participant can print and take with her to a health care appointment.
91614|NCT03470402|Other|BNAV|BNAV is a web-based decision support tool for healthcare providers with educational modules on genetic testing, chemoprevention, patient-centered care, and screening. BNAV also provides providers with a table outlining their enrolled patients' breast cancer risk, eligibility for genetic testing, and stated preferences.
91615|NCT03470402|Other|iNYP|Enrolled patients will have their eligibility for BRCA genetic testing flagged in iNYP, the hospital's portal for visualizing EHR data (standard practice).
91616|NCT03470402|Other|Standard Educational Material|Enrolled patient participants will be sent standard educational brochures on genes and breast cancer and the CUMC breast cancer prevention clinic
91617|NCT03470402|Other|High-Risk Message|Enrolled patient participants will receive a letter that informs them that they meet eligibility criteria for BRCA genetic testing, outlines prevention options, and recommends discussing genetic counseling referral with their health care provider (standard practice).
91618|NCT03470389|Procedure|HVPG measurement|Each patient's computed tomography, blood tests, Doppler ultrasound and HVPG measurement will be performed within 30 days and treatments that may affect HVPG value will be avoided during this period.
91619|NCT03470376|Dietary Supplement|Nutraceutical combination (NC)|An oral NC (red yeast rice-derived monacolin K 3 mg, berberine 500 mg, policosanol 10 mg, astaxanthin 0.5 mg, folic acid 0.2 mg and coenzyme Q10 2 mg) one pill/day was administered for 3 months along with prosecution of standardized diet regimen
91620|NCT03470376|Behavioral|No nutraceutical combination (noNC)|Prosecution of standardized diet regimen for 3 months
91621|NCT03470363|Drug|Sevoflurane Volatile Liquid|
91622|NCT03470363|Drug|Bupivacaine / SUFentanil|
91623|NCT03470350|Drug|Galunisertib|treatment with capecitabine and galunisertib
91624|NCT03470337|Drug|Phlogenzym|Bromelain / Trypsin / Rutoside
91625|NCT03470337|Other|Placebo|
91626|NCT03470324|Device|[standard STN]|standard stimulation on subthalamic (STN) contacts High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
91627|NCT03470324|Device|[STN+SNr]|Combined stimulation of the subthalamic nucleus (STN) and the substantia nigra pars reticulata (SNr) high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
91628|NCT03470324|Behavioral|Swallowing therapy|Swallowing therapy with speech therapist
91629|NCT03470311|Biological|Benralizumab|30mg in 1mL pre-filled syringe
91631|NCT03470298|Procedure|Endometrial scratching|The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
91632|NCT03470285|Procedure|Multiparametric MR imaging (mpMRI)|The main objective of the study is to assess the diagnostic accuracy of mpMRI in small renal tumors. The study characteristics will comply with recommended methods (Quadas, Stard). The population to be included will be representative of patients who would benefit from mpMRI if it is demonstrated to be accurate. In this project, the MR protocol will used the conventional MR sequences either on 1.5 or 3T systems and do not require development. Each center may use their own protocol as long as it includes the mandatory sequences.
91633|NCT03470272|Device|FB Professional LED Red light therapy|FB Professional LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs. Measure before and after effects of device unit. Three measurements before of circumference of abdomen area and three measurements after comparing the results.
91634|NCT03470272|Device|Effects of Red Light LED Therapy on Body Contouring|Intervention is to take a sample and measure before and after using a sham unit (placebo) and take three measurements of abdominal before treatment and three measurements after sham treatment and compare to controlled treatment.
91635|NCT03470259|Drug|IV adminstration of EMI-137|Intravenous administration of the fluorescent tracer EMI-137 approximately two hours before incision. Thereafter will be an observational period of an hour.
91636|NCT03470259|Device|Multispectral Fluorescence Reflectance Imaging|A multispectral Near Infrared Fluorescence (NIRF) camera system sensitive for EMI-137 fluorescence will be used for only ex-vivo Multispectral Fluorescence Reflectance Imaging (MFRI) of the thyroid gland and/or lymph node compartment.
91637|NCT03470259|Device|Spectroscopy|A spectroscopy system sensitive for EMI-137 fluorescence will be used for only ex-vivo spectroscopy of the thyroid gland and/or lymph node compartment.
91638|NCT03470246|Behavioral|PACO intervention for CABG patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from coronary artery bypass grafting (CABG). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
91639|NCT03470246|Behavioral|PACO intervention for AVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from aortic valve replacement (AVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
91640|NCT03470246|Behavioral|PACO intervention for MVR patients|The PACO intervention is based on post-operative guidance to replace prolonged SB with PA in the rehabilitation of patients recovering from mitral valve repair (MVR). The guidance will be provided to the patients with the combination of ExSed smart phone application, accelerometer and cloud system. In addition, exercise guidance (short video files) and regular mobile phone contacts from physiotherapist will be provided to the intervention patients.
91641|NCT03470207|Procedure|Post-pulmonary embolism follow up protocol|Structured post-pulmonary embolism follow up protocol (outlined in Aim 1)
91642|NCT03470194|Other|Interpretation Modality: In Person|Use of In-Person interpretation support for LEP participant during clinical appointment
91643|NCT03470194|Other|Interpretation Modality: Telephonic|Use of telephonic interpretation support for LEP participant during clinical appointment
91644|NCT03470181|Dietary Supplement|Ensure|Participants will perform a Nutrient Drink Test. This consists of drinking 125mL of liquid Ensure four times, at five-minute intervals.
91645|NCT03470168|Device|Hyperbaric Oxygenation Therapy|Received the Hyperbaric Oxygen therapy treatment at 2.4 ATA for 90 minutes each day.
91646|NCT03470168|Device|Normobaric Oxygenation therapy|Received the Normobaric Oxygen therapy treatment at 1 ATA for 90 minutes each day.
91647|NCT03470155|Procedure|mitral valve repair|operative reconstruction
91648|NCT03470142|Procedure|traditional laparoscopy-assisted surgery|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The traditional laparoscopic operation undergo and then a small incision(5cm) is made in the middle of the lower abdominal wall to trim the mesangial membrane and remove the specimen. At last the anastomosis operation undergo by the laparoscopic operation.
91649|NCT03470142|Procedure|total laparoscopic surgery with no incision (natural orifice transluminal endoscopic surgery, NOSES)|All surgical procedures will be performed by the surgery team ,which is leaded by professor Sun Dong-Hui and Wang Quan. The whole procedures undergo by total laparoscopic surgery with no incision in the abdominal wall. The specimen then will be removed through natural orifice (anal).
91650|NCT03470129|Device|fissure sealing|sealing of occlusal fissures with either the conventional sealant, Helioseal F, or the new sealant, Helioseal F Plus, which provides an additional feature and an improved formulation
91651|NCT03470116|Device|Laryngoscopy with Mac Grath|Patients of this group will benefit MacGrath MAC video laryngoscopy for intubation after curarization
91652|NCT03470116|Device|direct laryngoscopy|Patients of this group will benefit direct laryngoscopy for intubation after curarization
91653|NCT03470103|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Use of intravitreal aflibercept in routine clinical practice in Latin America
91654|NCT03470090|Behavioral|Neuromuscular Exercises|In the experimental group, the subjects who were taken into the study were taken to the neuromuscular exercise (NME) program after the pre-treatment evaluations. The subjects in this group were given classical physiotherapy and NME performed 6 days a week, 1 set of 10 times physiotherapist control. NME was including warming, neuromuscular exercises (balance, muscle strengthening, proprioception, sensorimotor system training, joint stabilization and postural control exercises) and cooling periods.
92301|NCT03465280|Procedure|Other|Removal of lesions via other methods
91655|NCT03470090|Behavioral|Conventional Group|In the control group, the subjects who were taken into the study were taken to the classical physiotherapy (hotpack (HP), ultrasound (US), transcutaneous electrical stimulation (TENS)) and conventional exercises program after the pre-treatment evaluations.
91656|NCT03470077|Drug|IV nalbuphine 0.1 mg/kg with induction of anesthesia.|"Group A: 40 patients will receive IV nalbuphine 0.1 mg/kg with induction of anesthesia.~."
91657|NCT03470077|Drug|IV nalbuphine 0.1 mg/kg at the end of surgery.|Group B: 40 patients will receive IV nalbuphine 0.1 mg/kg at the end of surgery just before discontinuation of anesthesia.
91658|NCT03470051|Diagnostic Test|QT Ultrasound|All subjects will be asked to agree to an ultrasound-guided breast needle biopsy by a qualified radiologist experienced in this procedure if not already completed prior to study entry.
91659|NCT03470038|Drug|NGF|Intramuscular injection
91660|NCT03470038|Drug|Isotonic saline|Intramuscular injection
91661|NCT03470025|Other|Psychological Intervention|"F-TPI group will be followed for a period of six months with a telephone-based and a face to face psychological intervention, performed by a clinical psychotherapist .~TPI group will be followed for a period of six months with a TPI characterized by 10 telephone clinical interviews, performed by a clinical psychotherapist.~CTRL group with COPD SoC without PI will follow the standard follow-up program for COPD patients after PR."
91662|NCT03470012|Device|Multi-Purpose Gentle Tape|The Multi-Purpose Gentle Tape is a general purpose medical adhesive tape for medical applications used primarily to secure dressings, lightweight tubing, and devices to skin.
91663|NCT03469999|Drug|Dysport Injectable Product|All participants will receive Dysport injection at multi levels in the spastic lower limb(s)
91664|NCT03469986|Device|Marcus Autism Center Investigational Device|This trial will ascertain whether the binary results of autism or not-autism as determined by the Marcus Autism Center Investigational Device match expert clinical diagnostic opinion. The investigational device is designed to measure visual attention to social information in the environment relative to normative, age-specific benchmarks; these measurements assess presence (primary efficacy outcome) and severity (secondary outcomes) of autism spectrum disorder in 16- to 30-month-old children.
91665|NCT03469973|Procedure|Partial adenoidectomy|"The procedure will be completely visualized with a 45 degrees, 4- mm nasal endoscope; the upper part of the adenoid will be removed using the microdebrider, while the lower part will be preserves to maintain the velopharyngeal competence.~• Adenoid enlargement causing Obstructive Sleep-Disordered Breathing (OSDB) with velopharyngeal insufficiency (proved or suspected)."
91666|NCT03469960|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
91667|NCT03469960|Drug|Nivolumab|Nivolumab 3 mg/kg every 2 weeks
91668|NCT03469947|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
91669|NCT03469934|Drug|ANB020|ANB020
91670|NCT03469934|Drug|Placebo|Placebo
91671|NCT03469921|Drug|administered therapeutic regimens|administered therapeutic regimens
91672|NCT03469895|Drug|ibrutinib ou idelalisib|treatment by ibrutinib or idelalisib for autoimmune cytopenia
91673|NCT03469882|Dietary Supplement|High protein nutrition|Patients in the HPE group will be submitted to nutritional support preferably through the enteral route. Energy expenditure will be determined by indirect calorimetry. They will receive 2.0 to 2.5 grams/kg/day of protein.
91674|NCT03469882|Device|Cycle ergometry exercise|Patients will be submitted to two daily sessions of exercise (cycle ergometry) 15 minutes duration each, during the 7 days of the week. The intervention will be maintained exclusively duting the patient's stay in the ICU. The cycle ergometer will be the MotoMed Letto II (Reck Technik, Germany).
91675|NCT03469882|Other|Usual care group|Participants randomized to the usual care group will receive usual care protein and exercise.
91676|NCT03469869|Other|balanced and sustainable diet|"the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp.~the intervention group will get menu recommendation of restriction calorie balanced and sustainable diet for 8 weeks. the other group will get menu recommendation of balanced diet for 8 weeks. these menus are given in the apps named EatsUp."
91677|NCT03469856|Drug|Prasugrel monotherapy|A multicenter, single arm, open-label trial of in patients with chronic stable angina
91678|NCT03469843|Other|Non intervention|patients without intervention
91679|NCT03469830|Other|SSCP|Insert
91680|NCT03469830|Other|SPMS|Pressure therapy
91681|NCT03469817|Diagnostic Test|MRI|"Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit."
91682|NCT03469804|Drug|Pembrolizumab|Route: intravenous infusion Dose regimen: 200 mg per infusion every 3 weeks Duration of treatment: 6 months (8 cycles)
91683|NCT03469791|Procedure|Surgical treatment of Degenerative Spondylolisthesis|
91684|NCT03469778|Device|Robotic Therapy|Robotic Therapy
91685|NCT03469765|Other|does not apply|biological sample taking: urine, blood
91686|NCT03469752|Behavioral|Parent education classes|8 weekly classes for fathers and youth (10-14 years) at community centers focused on improving parenting skills, youth energy balance related behaviors and weight status
91687|NCT03469726|Diagnostic Test|Contrast-enhanced Diffusion-weighted MRI|An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values
91688|NCT03469713|Drug|Nivolumab|"Hypofractionated radiation will be administered to a metastatic disease site at a dose and schedule of 30 Gy in 3 consecutive fractions. The day of first administration of Nivolumab will be designated as Time 1. Nivolumab will be given as flat dose of 240 mg in intravenous infusion beginning on day 1 every 14 days for 6 months, than switch to 480 mg q4-weekly in responding (CR, PR, SD) patients until PD or unacceptable toxicity .~SRT will be administered between the first and second administration of Nivolumab (7 days after the first infusion of Nivolumab)."
91689|NCT03469700|Other|general anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation. General anesthesia is induced with 0.5-1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.6 mg/kg/h rocuronium, 60% nitrous oxide and 40% oxygen with Ultiva (Remifentanyl) 0.1-0.2 μg/kg/hr
92027|NCT03467373|Drug|Vincristine|Vincristine 1.4 mg/m^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg
91690|NCT03469700|Other|Paravertebral block|Bilateral paravertebral block guided by a nerve stimulator will be performed by injecting local anesthetic mixture from levels T11 to T6. Each 20 ml of the mixture will contain: 6 ml lidocaine 2%; 6 ml lidocaine 2% with adrenaline 5 μg /ml; 5 ml bupivacaine 0.5%; 50μg fentanyl (1 ml); and 2 ml saline 0.9%
91691|NCT03469700|Other|Placebo PVB|Placebo bilateral paravertebral block guided by a nerve stimulator will be performed by injecting normal saline from levels T11 to T6.
91692|NCT03469687|Device|Symax uncemented hip stem|
91693|NCT03469674|Radiation|Vaginal brachytherapy|Internal radiation of the vaginal vault using a vaginal cylinder, 21 Gy in 3 out-patient sessions over 2 weeks
91694|NCT03469674|Radiation|External beam radiotherapy|External beam pelvic radiotherapy on a linear accelerator, 48.6 Gy in 27 out-patients sessions over 5.5 weeks
91695|NCT03469674|Other|Observation|No radiation therapy, but active follow-up and quality of life questionnaires as in the groups who have adjuvant treatment
91696|NCT03469648|Procedure|Air-Test|The Air Test simply consisted in breathing room air for 5 min during anesthesia while measuring peripheral oxygen saturation by Pulse oximetry
91697|NCT03469635|Other|Nutritional deficiencies in pregnant women after bariatric surgery|compare maternal nutritional parameters and neonatal outcomes after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) and to assess the impact of nutritional alterations on fetal growth.
91698|NCT03469622|Device|EndoRings|EndoRings-assisted colonoscopy
91699|NCT03469622|Device|Standard colonoscopy|Standard colonoscopy without any additional devices
91700|NCT03469609|Other|mucous fistula refeeding|Transfer of infants' own stool
91701|NCT03469596|Diagnostic Test|MRI sequence|several MRI sequence before and after contrast product injection.
91702|NCT03469583|Drug|EYP001|EYP001 self administered capsules, morning, with non carbonated water
91703|NCT03469583|Drug|Entecavir 1 MG|Entecavir self administered tablets, morning, with non carbonated water
91704|NCT03469570|Device|EV1000 Clinical Platform with Assisted Fluid Management (AFM) Feature|Subjects enrolled in the validation study will have their fluid management decisions guided by the AFM Feature.
91705|NCT03469557|Drug|BGB-A317|Subjects will be treated with BGB A317 200 mg IV on Day 1 during each 21-day cycle. BGB A317 will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
91706|NCT03469557|Drug|Cisplatin|Subjects will be treated with cisplatin 80 mg/m² IV on Day 1 during each 21-day cycle. Cisplatinwill be given for up to 6 cycles.
91707|NCT03469557|Drug|5-FU|Subjects will be treated with 5-FU 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle. 5-FU will be given for up to 6 cycles.
91708|NCT03469557|Drug|Oxaliplatin|Subjects will be treated with oxaliplatin 130 mg/m² IV on Day 1 during each 21-day cycle. Oxaliplatin will be administered for up to 6 cycles.
91709|NCT03469557|Drug|Capecitabine|Subjects will be treated with capecitabine 1000 mg/m² orally twice daily (bid) Days 1 through 14 (14 days total) during each 21-day cycle. Capecitabine will be administered until disease progression, intolerable toxicity, or treatment discontinuation for any other reason.
91710|NCT03469544|Other|complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body specific test Real time polymerase chain reaction|"complete blood picture ,serum urea and creatinine,liver function test,T3,T4,thyroid stimulating hormone,thyroglobuline and thyroglobuline anti body .~specific test is quantitation of long non coding RNA HOTAIR by Real time polymerase chain reaction in peripheral blood,Enzyme linked Immunosorbent Assay for serum midkine level"
91711|NCT03469531|Drug|Nimotuzumab|Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
91712|NCT03469531|Drug|Cisplatin|Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
91713|NCT03469531|Radiation|external-beam radiation|Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy
91714|NCT03469531|Radiation|brachytherapy|high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy
91715|NCT03469518|Dietary Supplement|β-Cx plus PS plus GOS|
91716|NCT03469518|Dietary Supplement|β-Cx plus PS|
91717|NCT03469505|Behavioral|COPES|Cooperative Pain Education and Self-Management for chronic pain therapy.
91718|NCT03469505|Behavioral|CBT-CP|Cognitive Behavioral Therapy for Chronic Pain
91719|NCT03469492|Drug|Insulin|Insulin regimens will be adjusted on a weekly basis as needed to achieve a target blood glucose level.
91720|NCT03469492|Behavioral|exercise|Exercise in accordance to the guidelines established by the American Diabetes Association.
91721|NCT03469492|Dietary Supplement|Dietary counseling|Dietary counseling in accordance to the guidelines established by the American Diabetes Association.
91722|NCT03469479|Drug|FOLFOX|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
91723|NCT03469479|Procedure|Hepatic resection|R0 resection
91724|NCT03469466|Diagnostic Test|bedside ultrasound|bedside ultrasound imaging of the lungs
91725|NCT03469453|Behavioral|Internet-Delivered Cognitive Behavioral Therapy|Therapist-supported CBT delivered online.
91726|NCT03469440|Other|Continuous central venous oxygenation monitoring|"Central venous oxygen saturation will be targeted higher than 65% in non-cyanogenic patients and 55% in cyanogenic.~First, isotonic crystalloid, 10 up to 20 mL/kg, will be administered in boluses to achieve continuous central venous oxygen saturation higher than 65% in non-cyanogenic and 55% in cyanogenic.~Second, if not achieved with fluid administration, will be targeted by initiating and titrating inotropics (dobutamine or milrinone). If the mean arterial pressure is lower than 50 mm Hg will be associated epinephrine.~If the ScvO2 is lower than 65% in non-cyanogenic and 55% in cyanogenic and the hemoglobin was lower than 8g/dl, red blood cells (20mL/Kg) will be transfused to achieve a hemoglobin level of at least 8g/dL."
91727|NCT03469440|Other|Standard protocol|The control group will keep the standard therapy to achieve mean arterial pressure higher than 50mmHg, central venous pressure 8 to 12 mmHg, urinay debit higher than 0,5ml/kg/h, hemoglobin higher or equal than 8g/dL, arterial oxygen saturation higher or equal than 92% in non-cyanogenic and 80% cyanogenic, central venous oxygen saturation higher or equal than 65% in non-cyanogenic and 55% in cyanogenic.
92104|NCT03466762|Other|Non applicable|Non applicable
91728|NCT03469414|Other|Life Space Assessment Scale|This nine question survey asks participants where they have gone in the last week, frequency of those visits, and how independently they went there.
91729|NCT03469414|Other|6-Minute Push Test|The 6 Minute Push Test is a measure of endurance, and requires that the participant wheel themselves around two pylons that are located 15 meters apart for 6 minutes.
91730|NCT03469414|Other|Forward Push Test|This measure of wheelchair propulsion speed asks patients to propel themselves as fast as they can over 20 meters. This task is performed twice, and the average time is used for the score.
91731|NCT03469414|Other|Wheelchair Slalom Test|In this measure, participants propel themselves through an 18 meter slalom course at their maximum self-selected speed, wheeling around seven cones, separated by three, two, or one meter.
91732|NCT03469414|Other|Craig Handicap Assessment and Reporting Technique|A measure of social participation in individuals with SCI.
91733|NCT03469414|Other|PART-O|The PART-O is a community participation measure.
91734|NCT03469414|Other|GPS Tracking|A GPS tracker will be attached to the wheelchairs of a subset of participants for one week. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
91735|NCT03469401|Other|Intervention|Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture
91736|NCT03469388|Diagnostic Test|Pulse wave analyses; central blood presaure parameters|Pulse wave analyses; central blood presaure parameters
91737|NCT03469375|Drug|modified-FOLFIRINOX|LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
91738|NCT03469362|Behavioral|Activities of Daily Living|Quality of Life questionnaire administered at Baseline and post-operatively per protocol.
91739|NCT03469362|Behavioral|Instrumental Activities of Daily Living|Quality of Life questionnaire administered at Baseline and post-operatively per protocol.
91740|NCT03469362|Other|Hand Grip Strength Test|Administered at Baseline and post-operatively per protocol.
91741|NCT03469362|Other|Timed Up and Go Walking Test|Administered at Baseline and post-operatively per protocol.
91742|NCT03469362|Behavioral|SF-8|Quality of Life (QOL) Questionnaire administered at Baseline and post-operatively per protocol.
91743|NCT03469362|Behavioral|FACT-VCI|Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) Quality of Life (QOL) Questionnaire administered at Baseline and post-operatively per protocol.
91744|NCT03469349|Drug|Actovegin|Actovegin intravenous infusion and tablets.
91745|NCT03469349|Drug|Placebo|Actovegin placebo-matching intravenous infusion and tablets.
91746|NCT03469336|Drug|PF-06763809|Three different concentrations will be administered to three different treatment fields: 2.3%, 0.8% and 0.23%
91747|NCT03469336|Other|Vehicle|Vehicle matching PF-06763809.
91748|NCT03469336|Drug|Calcipotriene/calcipotriol|Calcipotriene/calcipotriol 50 ug/mL solution
91749|NCT03469336|Drug|Betamethasone|Betamethasone 1 mg/g solution
91750|NCT03469323|Drug|Succinylcholine|Giving mini-dose succinylcholine to facilitate lung collapse during nonintubated VATS.
91751|NCT03469323|Drug|Placebo|Giving placebo (normal saline) to facilitate lung collapse during nonintubated VATS.
91752|NCT03469310|Drug|Acetaminophen 500Mg Cap|non-narcotic medication first with narcotic as second choice
91753|NCT03469310|Drug|Tylenol #3 Oral Tablet|Narcotic medication first
91754|NCT03469310|Drug|Tramadol|non-narcotic medication first with narcotic as second choice
91755|NCT03469297|Device|Brown Glaucoma Implant|The Brown Glaucoma Implant (BGI) is an implantable device designed to lower intraocular pressure (IOP) in glaucoma patients by shunting aqueous humor from the anterior chamber of the eye to the surface of the eye. Because there are no physiologic sources of outflow resistance, the device can be engineered to target an IOP that is low enough to halt the progression to blindness in a patient suffering from glaucoma.
91756|NCT03469284|Other|Best Practice|Given standard of care therapy
91757|NCT03469284|Drug|Methylene Blue|Given lower dose PO
91758|NCT03469284|Drug|Methylene Blue|Given medium dose PO
91759|NCT03469284|Drug|Methylene Blue|Given higher dose PO
91760|NCT03469271|Drug|1,25 (OH)2 D3|0.25 micrograms, taken daily for eight weeks, orally
91761|NCT03469271|Other|Inspiratory isometric resistance training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.Participants in the active groups will breathe against a resistance set to generate 30% of maximal inspiratory pressure (PImax).
91762|NCT03469271|Drug|Oral Placebo|Placebo will be created to mimic the appearance of the study drug
91763|NCT03469271|Other|Sham Inspiratory Isometric Resistance Training|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles. Participants in the sham group will train daily against a resistance set to only 15% PImax.
91764|NCT03469271|Device|Threshold Inspiratory Muscle Trainer (IMT)|A small hand-held reusable device to increase muscle strength and endurance through inhalation therapy. Participants will inhale through a valve which provides resistance that increases the work of breathing and exercises the respiratory muscles.
91765|NCT03469258|Drug|Pancrelipase|Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
91766|NCT03469245|Other|numerical simulation|After patients have been treated by fenestrated endovascular of society Vascutek data will be collected by society Vascutek and send to Predisurge society. They will perform numerical simulation and compare with the method of Vascutek.
91767|NCT03469232|Drug|Huanglian-Jiedu Decoction|Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
92105|NCT03466749|Device|Paclitaxel Eluting Balloon Catheter|Paclitaxel Eluting Balloon Catheter
91768|NCT03469206|Procedure|intra-arterial thrombectomy|It is the emergency surgical removal of emboli which are blocking blood circulation. It usually involves removal of thrombi (blood clots)
91769|NCT03469206|Drug|Intravenous thrombolysis|alteplase is used in the intravenous thrombolysis. It catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.
91770|NCT03469193|Procedure|internal PUC implanted with mechanical ancillary|The control group consists of patients operated with a mechanical ancillary (reference surgery in our department). In this technique, bone sections are made with a standardized ancillary (manually adjusted bone cutting guides), according to preoperative radiological planning. The positioning of the implants is done manually and controlled by the placement of test implants.
91771|NCT03469193|Procedure|Internal PUC implanted with robotic assistance|Patients are operated by robotics (surgery that we want to develop systematically in our service). 3D modeling of the knee allows the operator to perform a dynamic planning taking into account the reducibility of the deformation and the model of the implant. The operator can position the implants in three dimensions of the space without difficulty. This makes it possible to visualize, before the bone resections, the angular correction obtained between 0 and 130° flexion and alignment of the prosthesis by visualizing the contact points between the two implants. Bone resections will be performed using a guided retro bone drill. The system retracts more or less the cutter according to the bone thickness to be removed. This technique requires the insertion of two threaded plugs in the tibia and two in the femur to position the sensors that will allow the acquisition of anatomical landmarks of the lower limb and then 3D modeling
91772|NCT03469180|Other|Treadmill training|Treadmill training Each season will be supervised and last 45 minutes. Treadmill speed will be adjusted to the child's maximal heart rate (MHR) (between 65 to 75 percent of the MHR).
91773|NCT03469180|Other|Whole body vibration training|Whole body vibration training whole body vibration frequence will be 50 Hertz and childrens will be standing position on vibration platform .
91774|NCT03469167|Device|CEGP003|Application of CEGP003 to peptic ulcer bleeding
91775|NCT03469167|Device|Injection Tx|Injection of epinephrine to peptic ulcer bleeding
91776|NCT03469154|Other|Dyad training method|The training model for paediatric basic life support for laypersons involves a course based on pairs training together guided by instructional videos and with hands-on practice on resuscitation manikins.
91777|NCT03469154|Other|Instructor led training method|The training model for paediatric basic life support for laypersons involves a course led by an instructor including hands-on practice on resuscitation manikins.
91778|NCT03469141|Device|Pressure Relief Monitoring System|Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
91779|NCT03469128|Other|Cognitive processing therapy|Psychological treatment for patients suffering from post traumatic symptoms.
91780|NCT03469128|Drug|Disulfiram|Medicine for the treatment of post traumatic stress disorder
91781|NCT03469128|Other|Waiting list|The control group was selected from the Hospital waiting list of patients
91782|NCT03469115|Diagnostic Test|Serum blood|Serum blood test for laboratory analysis to determine level of alpha defensin
91783|NCT03469089|Drug|Ketamine 0.58|Ketamine (0.23 mg/kg bolus + 0.58 mg/kg/h)
91784|NCT03469089|Drug|Ketamine 0.31|Ketamine (0.12 mg/kg bolus + 0.31 mg/kg/h)
91785|NCT03469089|Drug|Modafinil|Modafinil tablet 100 mg placed in a capsule
91786|NCT03469089|Drug|Placebo for ketamine|0.9 % NaCl infusion solution
91787|NCT03469089|Drug|Placebo for modafinil|Placebo capsule for modafinil capsule
91788|NCT03469076|Other|YUN ACN Cream|YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
91789|NCT03469063|Dietary Supplement|AferBio|Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
91790|NCT03469050|Drug|Rifaximin delayed released 400mg Tablet|Rifaximin delayed released
91791|NCT03469050|Other|Placebo|Placebo BID + Placebo BID
91792|NCT03469037|Device|Optiflow with an inspired fraction of oxygen of 100%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 100%
91793|NCT03469037|Device|Optiflow with an inspired fraction of oxygen of 21%|Respiratory gaz heated and humidified system of delivery with a fraction of oxygen inspired of 21%
91794|NCT03469024|Other|Home Rehabilitation Program|It consists in a home rehabilitation program performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
91795|NCT03469024|Other|e-Health program|It consists in an e-Health rehabilitation program through a web platform performing electroanalgesia and an exercise program following the Mckenzie method. Patients will be instructed in the use of the TENS device using 5x9cm electrodes at the bilateral paravertebral level, the patients that present radicular pain, the electrodes will be placed in the path of the affected nerve. The realization of exercises will be through the application of an Mckezie protocol. The duration will be the same as that used to carry out the Mckenzie protocol. Mckenzie exercises are designed to make changes in the internal components periarticular of the spine.
91796|NCT03469011|Drug|Imatinib Oral Tablet|3+3 trial design. Cohorts of 3-6 patients with escalating imatinib doses. No intra-patient dose escalation allowed.
91797|NCT03468998|Device|Socket Grafting with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm placed in extraction socket
91798|NCT03468998|Device|Socket Grafting with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm placed in extraction socket
91799|NCT03468998|Device|Lateral ridge augmentation with small particle allograft|Small Particle Bone Allograft of 0.25-1.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
91800|NCT03468998|Device|Lateral ridge augmentation with large particle allograft|Large Particle Bone Allograft of 1.0-2.0 mm used in lateral ridge augmentation (Guided Bone Regeneration) and covered with a collagen membrane
91801|NCT03468985|Drug|Cabozantinib|Given PO
91802|NCT03468985|Drug|Cabozantinib S-malate|Given PO
91803|NCT03468985|Biological|Ipilimumab|Given IV
91804|NCT03468985|Other|Laboratory Biomarker Analysis|Correlative studies
91805|NCT03468985|Biological|Nivolumab|Given IV
91806|NCT03468985|Other|Questionnaire Administration|Ancillary studies
91807|NCT03468972|Drug|Immunosuppressive treatment|At 3 months after randomization, patients in the corticosteroid arm who have persistent proteinuria of ≥ 1.0 g/g creatinine, or fast decline in eGFR ≥ 15% from the baseline value, will additionally receive cyclosphosphamide during the following 3 months. Patients who have substantial decreased amount of proteinuria < 1.0 g/g creatinine at 3 months will continue protocol-based corticosteroids during the same period. At 6 months after randomization, patients who receive add-on cyclophosphamide will switch to azathioprine as a maintenance therapy and those who receive corticosteroids alone will discontinue the treatment and will be followed up during 24 months thereafter. Assessment of outcome will be done at 6 months and at 36 months.
91808|NCT03468972|Other|intensive supportive care|During 3-6 months before the enrollment, all patients will receive maximal supportive care including the use of RAS blockers, blood pressure control with a target of <130/80 mmHg, and protein restriction diet. If proteinuria does not decrease < 1.0 g/g creatinine, patients will be randomly assigned to continue supportive care, or to receive corticosteroids.
91809|NCT03468959|Behavioral|Maternal Supplemental PUFA Intake|Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
91810|NCT03468946|Other|salty taste perception|"salty taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate salty taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors(high caries risk, medium caries risk, low risk )."
91811|NCT03468946|Other|bitter taste perception|"bitter taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate bitter taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
91812|NCT03468946|Other|sour taste perception|sour taste perception in high caries risk, medium caries risk, low caries risk. The aim of this study was to evaluate sour taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk ).
91813|NCT03468946|Other|sweet taste perception|"sweet taste perception in high caries risk, medium caries risk, low caries risk.~The aim of this study was to evaluate sweet taste perceptions of school children and compare them with demographic, clinical, microbiologic and biochemical caries-risk factors (high caries risk, medium caries risk, low risk )."
91814|NCT03468933|Drug|tissue plasminogen activator (tPA) and human recombinant deoxyribonuclease (DNase)|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 dose
91815|NCT03468933|Procedure|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
91816|NCT03468920|Drug|IV Acetaminophen|IV Acetaminophen 1000mg in 100mL normal saline once pre-operatively
91817|NCT03468920|Drug|PO Acetaminophen|Acetaminophen PO 1000mg once pre-operatively
91818|NCT03468920|Drug|PO Placebo|PO placebo capsule compounded to match PO Acetaminophen capsule
91819|NCT03468920|Drug|IV Solution Placebo|This will serve as the placebo for the IV Acetaminophen intervention
91820|NCT03468907|Drug|Telbivudine 600mg|Pregnant mothers who opted for antiviral therapy would start on oral LDT 600 mg daily between gestational weeks 24 and 28.
91821|NCT03468907|Drug|Tenofovir disoproxil fumarate 300mg|Pregnant mothers who opted for antiviral therapy would start on oral TDF 300 mg daily between gestational weeks 24 and 28.
91822|NCT03468894|Behavioral|Treadmill desk walking|See intervention arm description
91823|NCT03468881|Other|Communication Skills Training Package (KEW)|A training package (called KEW: Know, Encourage and Warm-up) for therapeutic radiographers to manage emotional talk with breast cancer patients in treatment.
91824|NCT03468868|Behavioral|Exercise program for people with MS|The intervention consists of 30 minutes of resistance training and 30 minutes of cardio three times per week for 16 weeks.
91825|NCT03468855|Drug|ATI-50002 topical solution|Topical Solution administered twice daily
91826|NCT03468842|Biological|Probiotic|Already described
91827|NCT03468842|Biological|Placebo|Placebo
91828|NCT03468829|Biological|ALX-0171 Dose 1|Oral inhalation of ALX-0171 Dose 1 once daily for a maximum of 14 days
91829|NCT03468829|Biological|ALX-0171 Dose 2|Oral inhalation of ALX-0171 Dose 2 once daily for a maximum of 14 days
91830|NCT03468829|Biological|Placebo|Oral inhalation of Placebo once daily for a maximum of 14 days
91831|NCT03468816|Device|Sensor activation (DryMax Extra Softs)|Study profile of sensor activation
91832|NCT03468803|Diagnostic Test|Beta D Glucan test|Measurement of BDG before, during and after surgery
91833|NCT03468790|Drug|CMAB007|the study drug
91834|NCT03468790|Drug|Symbicort|asthma-controlled drug
91835|NCT03468790|Drug|Seretide|asthma-controlled drug
91836|NCT03468790|Drug|Ventolin|asthma rescue drug
91837|NCT03468790|Drug|placebo|No active components
91838|NCT03468777|Drug|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
91839|NCT03468777|Drug|Lansoprazole|Participants will receive single oral dose of 30 mg lansoprazole capsule as per assigned treatment sequence.
91840|NCT03468777|Drug|Ranitidine|Participants will receive single oral dose of 150 mg ranitidine as per assigned treatment sequence.
91914|NCT03468114|Behavioral|Safe Start|Participant households will receive four visits over a 10 week period from health extension workers promoting safe food preparation, storage and feeding, and will be provided with products to support these practices (a bowl, spoon, cup, hand washing station, liquid soap dispenser).
91915|NCT03468114|Behavioral|Active Control|Participant households will receive 4 visits by health extension workers delivering standard care
91841|NCT03468764|Procedure|Vigileo monitoring during lung recruitment maneuver|"Standard monitoring parameters, invasive blood pressure and hemodynamic values (SVV and CO, through Vigileo device) will be monitored. With the patient in a supine position and as SVV reaches a value of 12-15%, a LRM is performed, consisting in the application of 30 cm H2O continuous positive airway pressure for 30 seconds.~The alterations in the above mentioned parameters will be registered before and after the maneuver.~The same procedure will be performed after a 8 ml/kg crystalloids fluid challenge, as soon as SVV reaches the value of 10%."
91842|NCT03468751|Drug|HLX10|recombinant humanized anti-PD-1 monoclonal antibody against solid cancers
91843|NCT03468738|Other|Blood transfusion|Transfusion of blood products in the perioperative period in patients undergoing major surgery
91844|NCT03468725|Drug|XPF-008|Capsule filled with XEN1101
91845|NCT03468725|Drug|Microcrystalline Cellulose|Placebo capsule
91846|NCT03468712|Procedure|Laparoscopic D2 distal gastrectomy|Laparoscopic D2 distal gastrectomy after 3-Cycle XELOX neo-adjuvant chemotherapy
91847|NCT03468699|Combination Product|Autologous BMMC transplantation|Stem cell transplantation
91848|NCT03468686|Device|Bilateral rTMS|The coil will locate on F3 and F4 in accordance with the 10-20 international system. bilateral rTMS include stimulate the right DLPFC at 1 Hz for a 10 seconds train of stimulation, 2 seconds inter-train interval, and a total of 150 pulse trains. Immediately after that, the stimulation was carried out on the left DLPFC at 10 Hz, 5 seconds of stimulation, with 10 second inter-train interval and 75 pulse trains.
91849|NCT03468686|Device|Sham rTMS|The same parameters will use in the sham rTMS. However, the coil adjust at an angle of 90º vertically on the skull in a way that one wing place on the head.
91850|NCT03468660|Behavioral|Auditory training with feedback|Experimental group receives phoneme-level and sentence-level training with feedback
91851|NCT03468660|Behavioral|Listening paradigm with no feedback|Active controls listen to acoustic stimuli with no feedback
91852|NCT03468647|Other|soles|Volunteer must walk this this connected seamless to measure different walking parameters
91853|NCT03468647|Other|weighting machine|This weighting machine measure weight evolution and equilibrate of volunteers
91854|NCT03468647|Other|gripping force|this machine measure the gripping force of volunteer
91855|NCT03468634|Diagnostic Test|endoscopy|Oesophageal endoscopy with biopsy
91856|NCT03468621|Procedure|Wound closure|Method of wound closure
91857|NCT03468595|Device|ultrasonic (Piezon Master 700) performed with Listerine|
91858|NCT03468595|Device|ultrasonic (Piezon Master 700) performed with CHX|
91859|NCT03468595|Device|ultrasonic (Piezon Master 700) performed with serum|
91860|NCT03468582|Combination Product|123I radiolabeled 3BNC117|123I radiolabeled 3BNC117
91861|NCT03468569|Other|Functional Movement Screen|
91862|NCT03468556|Drug|SNP-610|Subjects will take 2 tablets once a day orally for 12 weeks
91863|NCT03468556|Drug|Placebo Oral Tablet|Subjects will take 2 tablets once a day orally for 12 weeks
91864|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation A|Memantine HCl MR capsule formulation will be administered orally in a single dose
91865|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation B|Memantine HCl MR capsule formulation will be administered orally in a single dose
91866|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation C|Memantine HCl MR capsule formulation will be administered orally in a single dose
91867|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation D|Memantine HCl MR capsule formulation will be administered orally in a single dose
91868|NCT03468543|Drug|Memantine Hydrochloride MR Prototype Capsule Formulation E|Memantine HCl MR capsule formulation will be administered orally in a single dose
91869|NCT03468543|Procedure|Magnetic Resonance Imaging|MRI will be performed on specified days according to protocol
91870|NCT03468530|Procedure|Transurethral ablation|transurethral resection and/or coagulation with a bipolar loop under spinal or general anesthesia
91871|NCT03468517|Other|Bathe method:|BATHE technique, on the other hand, is one of the short therapeutic consultation techniques that strengthen the doctor-patient relationship. BATHE stands for the initials of the questions that include the titles for Background, Affect, Trouble, Handling and Empathy. It allows evaluating the physiological stress of the patients quickly. BATHE method necessitates an empathetic expression that includes the view of the patient in addition to asking the key questions by the doctor doing the interview
91872|NCT03468504|Device|Mirror Therapy|Participants view the reflective side of a simple mirror which is placed in their mid-sagittal plane to view a mirror reflection of their non-affected limb for 30 mins per day, 3 days per week, for four weeks.
91873|NCT03468504|Device|Placebo Mirror Therapy|"Placebo Mirror Therapy: Participants view the reflective side of a simple mirror which is placed forward/ahead of them in their mid-sagittal plane, and thus cannot see a reflection of either lower limb as their leg does not pass in front of the mirror for 30 mins per day, 3 days per week, for four weeks.~Treadmill Training: Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks."
91874|NCT03468504|Device|Treadmill|Participants will walk on a treadmill at their comfortable walking speed for 30 mins per day, 3 days per week, for four weeks.
91875|NCT03468491|Other|combined training|The whole intervention period will last for 6 weeks, 2 visits per week, 1 hour per visit in the Research Building Room 630 of National Yang Ming University. All programs will be under the supervision of a physiotherapist with 2-year experience individually. 1. Hallux valgus correction: 1.1 Joint alignment correction (Grade II joint mobilization, 10 times/set, 3 sets/visit) - 1st MTP joint distraction - Proximal talofibular joint anteroposterior glide - (Grade III joint mobilization if any restriction being found) 1.2 Biomechanical taping (using Dynamic taping, 1 time/ visit, keep the taping for 2 days minimum) 1.3 Foot intrinsic muscle strengthening (10 times/set for each exercise, 3 sets/visit): - Short foot exercise - Toespread out exercise - Heel-rise exercises 2. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 2.1 Single lunge 2.2 Stepping down 2.3 Vertical squat 2.4 Vertical jumping
91916|NCT03468101|Other|Pulmonary Function Testing|Pulmonary Function Testing, Cardiopulmonary exercise testing, 6 Minute walk test, Thoracic CT
92106|NCT03466736|Diagnostic Test|[18F]flutemetamol PET scan|Each subject will receive an amyloid PET scan with [18F]flutemetamol
91876|NCT03468491|Other|Proximal training|1. Lower extremity neuromuscular exercises: (10-15 times/set, 3 sets/visit) 1.1 Single lunge 1.2 Stepping down 1.3 Vertical squat 1.4 Vertical jumping All exercises will first start on firm surface without additional resistance/weight. Later, settings will be gradually shifted into on firm surface with resisted band from random direction, on a cushion with/ without resisted band, on a BOSU balance trainer. Progression are made every 2 weeks ideally, while adjustments may be taken into concern due to individual differences.
91877|NCT03468478|Drug|Sirolimus|sirolimus combined to reduced dose of tacrolimus
91878|NCT03468478|Drug|Everolimus|everolimus combined to reduced dose of tacrolimus
91879|NCT03468478|Drug|Mycophenolic acid|Control arm: mycophenolate combined to regular tacrolimus
91880|NCT03468465|Drug|Solifenacin Succinate|10 mg tablet daily during 75 days maximum
91881|NCT03468465|Device|Neuro-Muscular Stimulators (NMS)|Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
91882|NCT03468452|Other|extubation|Time of extubation
91883|NCT03468439|Other|Femoral nerve block with phenol|
91884|NCT03468426|Drug|BI 836880|intra-venous infusion
91885|NCT03468426|Drug|BI 754091|intra-venous infusion
91886|NCT03468413|Drug|CP1050 or Placebo|Randomised, double-blinded, placebo-controlled
91887|NCT03468387|Procedure|Primary realignment|Endoscopic realignment of rupture urethra over a urethral catheter
91888|NCT03468387|Procedure|Suprapubic cystostomy|Percutaneous cystostomy catheter will be inserted under sonographic guidance
91889|NCT03468374|Device|lymphoscintigraphy|Nuclear Medicine diagnostic device using radioactive material
91890|NCT03468374|Device|Single Photon Emission Tomography|Nuclear Medicine diagnostic device using fusion technique between SPECT and CT
91891|NCT03468361|Other|Natural Product Petroselinum crispum (Parsley)|Parsley herb, in fresh form will be obtained from the local market available. The herb will be properly washed with distilled water and dried properly for 10 to 15 days under shade in the lab. Soft gelatin capsules will be filled with parsley powder (dried herb) in amount normally recommended in daily routine (1g) will be administered to patients once daily.
91892|NCT03468361|Other|Placebo|Soft gelatin capsules will be filled with 1 gram of lactose (inert pharmaceutical ingredient) and will be administered to patients once daily.
91893|NCT03468348|Drug|Duloxetine|patients scheduled for mastectomy and axillary evacuation for cancer breast will receive orally, 2 hours before the operation either, placebo capsule, duloxetine 30 mg,duloxetine 60 mg or duloxetine 90 mg capsule.
91894|NCT03468335|Drug|Irinotecan Liposomal Injection [Onivyde]|"Cancer treatment for PDAC:~Nal-IRI 80 mg/m2 as 1.5 hour infusion~5-FU 2400 mg/m2 as 46 hour infusion~Folinic acid 400 mg/m2 as 0.5 hour infusion~all on D1 of each cycle; Cycle q2w ± 5 days~Treatment until progressive disease or intolerable toxicity or withdrawal of consent."
91895|NCT03468322|Drug|AC-203|The investigational product is formulated as 1% topical ointment
91896|NCT03468322|Drug|Vehicle|Vehicle-only control study medication is the same formulation as investigational product without active ingredient
91897|NCT03468309|Genetic|Genecept Assay and G-DIG decision tool|Participating providers will review results of the Genecept Assay using a secure web-based program and will utilize the G-DIG tool in order to determine the optimal medication regime for the patient, based on their individual genetic profile. Genomind will provide training to all investigators prior to the study start regarding the interpretation of the pharmacological assay and the use of the G-DIG tool. Genomind representatives will be available throughout the duration of the study for consultation regarding the interpretation and implementation of the testing results. All final decisions about changing dosage, adding medications, or removing medications will be determined by the provider.
91898|NCT03468296|Drug|Intravitreal Aflibercept Injection 2mg|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.
91899|NCT03468283|Other|mobile application for diabetes|Intervention was mobile application and individualized regular message feedback sent by healthcare professionals.
91900|NCT03468257|Behavioral|Pavlovian Conditioning|Imagining a stressful event, engaging in progressive muscle relaxation, and eating fruit
91901|NCT03468244|Biological|Personalized mRNA Tumor Vaccine|subcutaneous injection with personalized mRNA tumor vaccine at least four times
91902|NCT03468231|Drug|Sorafenib|Oral Sorafenib, 400mg, Bid
91903|NCT03468231|Drug|HAIC of FOLFOX|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
91904|NCT03468231|Drug|HAIC of OXA|administration of Oxaliplatin via the tumor feeding arteries
91905|NCT03468218|Drug|Cabozantinib|Given PO
91906|NCT03468218|Biological|Pembrolizumab|Given IV
91907|NCT03468192|Other|Non-precaution group|Patients in the NPG had no restrictions on mobility, i.e. they were encouraged to move freely during the recovery phase and assistive equipment were prescribed only if needed
91908|NCT03468179|Dietary Supplement|Oatmeal|Subjects will be fed a calculated serving of oatmeal.
91909|NCT03468166|Other|Chronic stroke|The data for motor function and gait pattern analysis was obtained.
91910|NCT03468153|Biological|Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy|Patient-derived dual specificity CD19 and CD22 CAR-T Cells
91911|NCT03468140|Drug|Eculizumab|Eculizumab will be given at a dose of 1200mg diluted in 0.9% sodium chloride (NaCl) to 5mg/mL for a total volume of 240 mL administered by IV infusion over 25-45 minutes in the anhepatic-phase during the transplant procedure, and a second dose of 900mg diluted in 0.9% NaCl to 5mg/mL for a total volume of 180 mL administered by IV infusion over 25-45 minutes will be given 24 hours following the first dose.
91912|NCT03468140|Other|No intervention|Historical control arm
91913|NCT03468127|Other|Soy foods|Isolated soy protein, soy protein, soybean products, soy milk
91981|NCT03467659|Other|Refined wheat flour porridge,coarse bran|Small particle refined wheat porridge with large particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
91917|NCT03468088|Behavioral|Hand grip strengthening|Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction & with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.
91918|NCT03468088|Behavioral|Conventional treatment|Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
91919|NCT03468075|Drug|Ascorbate|Following 15g test dose, 75g administered on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
91920|NCT03468075|Drug|Gemcitabine|Administered on Days 1, 8 and 15, after the infusion of ascorbate
91921|NCT03468062|Drug|Dexmedetomidine|Patients assigned in Dexmedetomidine or Placebo group are given Dexmedetomidine or normal saline after induction of anesthesia.
91922|NCT03468049|Biological|Topical App. of Allium Cepa Extract|Topical Application of Allium Cepa Extract (oil)
91923|NCT03468049|Biological|Phonophoresis of Allium Cepa Extract|Phonophoresis of Allium Cepa Extract (oil)
91924|NCT03468049|Biological|Raw Mashed Allium Cepa Application|Raw Allium Cepa (onion bulb) Mashed
91925|NCT03468049|Other|Standard Physiotherapy Group (SPG)|This will consist of Massage and therapeutic exercise for the management of shoulder pain post stroke
91926|NCT03468036|Other|none, does not apply|none: does not apply
91927|NCT03468023|Procedure|Short arm cast|Application of a below-elbow cast
91928|NCT03468023|Procedure|Long arm cast|Application of an above-elbow cast
91929|NCT03468010|Radiation|chemoradiation|radiation with concurrent ciplatin
91930|NCT03468010|Drug|Paclitaxel, Cisplatin|The regimen of additional adjuvant chemotherapy following radiation is Paclitaxel, Cisplatin once 3 weeks.
91931|NCT03467997|Behavioral|Trier social stress test|Subjects are asked to give a 5 minute speech on a topic selected by the investigator. Then they are asked to subtract 7 from 758.
91932|NCT03467997|Other|Diesel exhaust|Diesel exhaust is an air pollutant found in the environment and produced by cars, trucks and other transportation modes (e.g. trains, planes).
91933|NCT03467984|Biological|LBVE|Multivalent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
91934|NCT03467984|Biological|Prevnar13|13-valent pneumococcal conjugate vaccine be administered by Intramuscular injection into the thigh
91935|NCT03467971|Drug|Metformin/Gliclazide Fixed Combination|Participants will receive single oral dose of Metformin 1000 mg and Gliclazide 30 mg fixed combination tablet in fasting or fed state.
91936|NCT03467958|Drug|Ozanimod|Ozanimod
91937|NCT03467945|Drug|Metformin/Gliclazide Fixed Combination|Participants received single oral dose of Metformin and Gliclazide fixed combination tablet in treatment period 1, 2, 3 or 4.
91938|NCT03467945|Drug|Metformin|Participants received single oral dose of Metformin tablet in treatment period 1, 2, 3 or 4.
91939|NCT03467945|Drug|Gliclazide|Participants received single oral dose of Gliclazide tablet in treatment period 1, 2, 3 or 4.
91940|NCT03467932|Drug|Cohort A: ORMD-0801|"Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
91941|NCT03467932|Drug|Placebo oral capsule|Placebo provided QHS, BID, TID
91942|NCT03467932|Drug|Cohort B: ORMD-0801|"Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia."
91943|NCT03467919|Procedure|Stem Cell injection|Harvesting of adipose-derived stem cells with intra-articular injection
91944|NCT03467919|Procedure|Corticosteroid injection|Sham harvesting of adipose tissue without intra-articular injection. Intra-articular injection of corticosteroid.
91945|NCT03467906|Other|In-laboratory assessment|Participants will stay in the laboratory for two days during which they will complete questionnaires, have blood drawn, and have other measurements taken.
91946|NCT03467893|Drug|Antacids|number aof antacids treatment after PPI stop
91947|NCT03467880|Other|Clinical Observation|No treatment given but observation with IOS
91948|NCT03467867|Drug|Venetoclax|Venetoclax will be administered as described in the reporting arm.
91949|NCT03467867|Drug|Rituximab|Rituximab (IV) will be administered as described in the reporting arm.
91950|NCT03467867|Drug|Rituximab/Hyaluronidase Human|Rituximab/Hyaluronidase Human (SC) ill be administered as described in the reporting arm.
91951|NCT03467841|Device|CMV IgM, IgG in blood real time PCR for serum CMV DNA .|Colonoscopic examination will be done for all studied patients after standardbowel preparation using a Pentax videoscope to= Assess the endoscopic lesions using Mayo endoscopic subscore
91952|NCT03467828|Genetic|polymorphism analyzing|Blood samples will be taken to EDTA containing tubes and then will be analyzed for genetic polymorphisms.
91982|NCT03467646|Procedure|Sleeve Gastrectomy|The patients undergo a Sleeve Gastrectomy as bariatric procedure
91983|NCT03467646|Procedure|Roux-en-Y gastric bypass|The patients undergo a Roux-en-Y gastric bypass as bariatric procedure
91984|NCT03467646|Procedure|One-Anastomosis Gastric Bypass|The patients undergo a One-Anastomosis Gastric Bypass as bariatric procedure
91953|NCT03467802|Biological|enamel matrix derivative|Enamel matrix derivative (EMD), sold under the brand name Emdogain®, is an amelogenin derivative of embryonal porcine enamel and is FDA approved for application to root surfaces to treat recession defects. Amelogenins comprise the majority of the proteins in EMD while others such as tuftelin, ameloblastin and amelin make up the remainder. EMD is thought to mimic the role of proteins crucial to cementogenesis and root development, which may promote new gingival attachment to exposed roots. The properties of EMD may favor early healing of the soft tissue and stimulate angiogenesis.
91954|NCT03467802|Device|Porcine collagen matrix|Mucograft® is a bi-layered grafting material composed of Type I and III collagen. It is derived from veterinary certified pigs, sterilized by gamma irradiation and has a low antigenicity in conjunction with good biocompatibility. The material is approximately 2.5-5mm thick and is indicated for root coverage, increasing keratinized tissue, covering of implants placed immediately and alveolar ridge reconstruction. A compact outer layer contributes to protection, structure and allows for better control during suturing; while the inner layer is thick, porous and spongy in nature, providing a suitable environment for early vascularization and promotion of cellular in-growth.
91955|NCT03467789|Dietary Supplement|Vitamin D3 prior to first visit|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Patients with VD deficiency will take 14 days of neoadjuvant D3, vs. only 5 days if the initial VD level is normal.
91956|NCT03467789|Dietary Supplement|Vitamin D3 prior to second visit|The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Patients with VD deficiency will take 14 days of neoadjuvant D3, vs. only 5 days if the initial VD level is normal.
91957|NCT03467789|Radiation|Photodynamic therapy|Photodynamic Therapy (PDT) is an experimental technique that works by combining a photosensitizing topical agent and an intense light source to kill tumor cells.
91958|NCT03467789|Dietary Supplement|Maintenance Vitamin D3|2,000 IU/d for adults, 1,000 IU/d for children taken after third visit.
91959|NCT03467763|Drug|Metformin Extended Release Oral Tablet|Metformin hydrochloride extended release tablets in dosages of 250 mg, 500 mg, 750 mg, and 1,000 mg. Individual encapsulations of metformin will contain dosages of 250 mg or 500 mg.
91960|NCT03467763|Drug|Placebo oral capsule|Placebo capsule
91961|NCT03467750|Drug|Ketorolac|Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
91962|NCT03467750|Drug|Standard of Care|"All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered."
91963|NCT03467737|Other|Normal sorghum porridge, algal starch|Normal sorghum porridge with 13C-labeled algal starch was fed, breath tested, as the first arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
91964|NCT03467737|Other|Normal sorghum porridge, algal dextrins|Normal sorghum porridge with 13C-labeled starch limit dextrins was fed, breath tested, as the second arm of an alpha-amylase sufficiency assessment in healthy and moderately malnourished children.
91965|NCT03467737|Other|Normal sorghum porridge, labeled flour|Normal sorghum porridge with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
91966|NCT03467737|Other|Modified sorghum porridge, labeled flour|Modified sorghum porridge with shear stirring to reduce viscosity with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
91967|NCT03467737|Other|Thinned sorghum porridge, labeled flour|Thinned sorghum porridge treated with an alpha-amylase liquifying enzyme with a portion of 13C-labeled sorghum flour was fed, breath tested, for starch digestibility assessment in healthy and moderately malnourished children.
91968|NCT03467737|Other|Modified sorghum porridge, octanoic acid|Modified sorghum porridge with shear stirring to reduce viscosity with addition of 13C-labeled octanoic acid was fed, breath tested, for gastric emptying assessment in healthy and moderately malnourished children.
91969|NCT03467724|Device|fractional radiofrequency|Fractional radiofrequency will be delivered to the area of the surgical scar identified to receive the study treatment.
91970|NCT03467711|Other|tidal volume challenge|transiently increasing tidal volume from 6 to 8 mL/kg predicted body weight (tidal volume challenge)
91971|NCT03467711|Other|volume expansion|give 6ml/kg (predicted body weight) volulyte for 10min
91972|NCT03467698|Device|Active tDCS|Real stimulation
91973|NCT03467698|Device|Sham tDCS|Sham stimulation
91974|NCT03467685|Device|Vibratory Anesthetic Device (VAD)|This is a handheld ~10cm long tool, battery operated, which provides vibration at a rate of ~150 Hz
91975|NCT03467672|Other|Diagnosis of bacterial infection|use of eosinopenia in the diagnosis of bacterial infection
91976|NCT03467659|Other|Cracked whole wheat porridge|Large particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
91977|NCT03467659|Other|Semolina wheat porridge|Large particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
91978|NCT03467659|Other|Whole wheat flour porridge|Small particle whole wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
91979|NCT03467659|Other|Refined wheat flour porridge|Small particle refined wheat porridge was tested for gastric emptying rate, glycemic response and appetitive response.
91980|NCT03467659|Other|Refined wheat flour porridge,fine bran|Small particle refined wheat porridge with small particle bran was tested for gastric emptying rate, glycemic response and appetitive response.
91985|NCT03467633|Behavioral|High-intensity interval training|Participants in the HIIT group will receive 3-weeks of tri-weekly supervised exercise sessions at the UOHI prior to their scheduled electro-cardioversion. The session will last 23 minutes in duration and consist of a 2-minute warm-up at 50% of peak power output (PPO), 2 x 8-minute interval training blocks of 30 seconds at 80-100% of PPO interspersed with 30-seconds of active recovery and a 1-minute cool down at 25 % of PPO. The sessions will be lead by a Registered Kinesiologist.
91986|NCT03467620|Drug|Cannabidiol|Administration of one oral 25-mg capsule of Cannabidiol daily for a duration of 12 weeks
91987|NCT03467620|Drug|Placebo oral capsule|Administration of one oral placebo capsule daily for a duration of 12 weeks
91988|NCT03467607|Procedure|tidal volume ventilation|low tidal volume ventilation
91989|NCT03467594|Behavioral|High-intensity interval training|• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
91990|NCT03467568|Dietary Supplement|Sodium Chloride|300mg sodium chloride will be provided in a capsule
91991|NCT03467568|Other|Placebo capsule|A capsule of identical appearance to that providing salt, but not containing electrolytes, will be consumed
91992|NCT03467568|Dietary Supplement|Water|Twice during the morning a drink of 150ml of water will be consumed
91993|NCT03467568|Biological|No water consumed|No water will be consumed during the monring
91994|NCT03467555|Device|Class II correction using zygomatic miniplates|
91995|NCT03467542|Device|PHIL® Liquid Embolic System|The PHIL Embolic System is indicated in the treatment of dural arteriovenous fistulas (DAVF)
91996|NCT03467529|Other|Non interventional study|Non interventional study
91997|NCT03467516|Biological|Tumor Infiltrating Lymphocytes (TIL)|TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.
91998|NCT03467503|Dietary Supplement|Blueberry fiber|Dietary frozen blueberries and soluble fiber for 20 weeks
91999|NCT03467490|Behavioral|DED self-management|This an educational intervention. The interventional will include watching a series of short videos and a DED handbook. The short videos will address the following topics: anatomy of the eye, pathophysiology of DED, treatment options for DED, management of DED with allergies/glaucoma/ computer use, and new developments in treatment and research of dry eye disease. The handbook will include tools and resources for self management of DED.
92000|NCT03467477|Drug|18F-AV-1451|Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451
92001|NCT03467464|Other|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of 10 weekly EMDR sessions of 60 minutes and targets stressful daily life (i.e. a situation that caused anger, fear or confusion) events rather than traumatic images from the past. For each session, a standardised EMDR protocol is used that consists of the following consecutive steps: 1) determining and visualising a confusing and/or stressful daily life event that occurred during the past week; 2) formulating a negative and a positive thought based on the chosen event; 3) determining the amount of stress that is evoked by the chosen event; 4) patient focuses on the chosen event while being presented with a distracting stimulus; 5) evaluating the amount of stress that is caused by the chosen event; 6) linking positive thoughts to the negative one when the stress caused by the chosen event does no longer exist; 7) evaluation and closure of session.
92002|NCT03467451|Procedure|Endoscopic Mucosectomy|Endoscopic Mucosectomy with anchorage of the tip of the loop
92003|NCT03467438|Drug|Zinc-l-carnosine|Patients will be asked to take the investigational product as already mentioned (blindly).
92004|NCT03467438|Other|Placebo|Patients will be asked to take placebo as already mentioned (blindly).
92005|NCT03467425|Drug|FF/UMEC/VI|FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
92006|NCT03467425|Drug|Inhaled Corticosteroid|Inhaled Corticosteroid (ICS) as prescribed by the physician.
92007|NCT03467425|Drug|LAMA|LAMA as prescribed by the physician.
92008|NCT03467425|Drug|LABA|LABA as prescribed by the physician.
92009|NCT03467425|Drug|COPD rescue medications|Rescue medications for COPD will be prescribed and obtained according to usual practice.
92010|NCT03467412|Drug|FOL-005|intradermal injection
92011|NCT03467412|Drug|Placebo|intradermal injection
92012|NCT03467399|Device|Nucleus 7 Cochlear Implant System|A new cochlear implant sound processor system.
92013|NCT03467386|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|undergo alloHCT
92014|NCT03467386|Drug|Cyclophosphamide|Given IV
92015|NCT03467386|Biological|Filgrastim|Administer according to City of Hope standard operating procedures
92016|NCT03467386|Other|Laboratory Biomarker Analysis|Correlative studies
92017|NCT03467386|Other|Quality-of-Life Assessment|Ancillary studies
92018|NCT03467386|Other|Questionnaire Administration|Ancillary studies
92019|NCT03467386|Drug|Tacrolimus|Given CIV
92020|NCT03467386|Radiation|Total Marrow Irradiation|Undergo TMLI
92021|NCT03467373|Drug|RO7082859|RO7082859 will be administered intravenously (IV) as a step-up dose for Cycle 2 on Days 8 and 15, and as a single dose from Cycle 3 onwards.
92022|NCT03467373|Drug|Obinutuzumab (G)|Obinutuzumab 1000 mg single dose IV infusion on Day 1 of Cycle 1 only
92023|NCT03467373|Drug|Rituximab (R)|Rituximab will be administered as an IV infusion at a dose of 375 mg/m^2 on Day 1 of each 21-day cycle starting from Cycle 1 to Cycle 6 (Part 1) or from Cycles 1-6 (up to 8) (Part 2: DLBCL R-CHOP).
92024|NCT03467373|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents. Tocilizumab will be given as rescue medication.
92025|NCT03467373|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 administered IV on Day 1 of each 21-day cycle
92028|NCT03467373|Drug|Prednisone|Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle
92029|NCT03467360|Drug|acetazolamide in combination with platinum and etoposide-based radiochemotherapy|Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
92030|NCT03467347|Drug|VR: 200 mg DPV + 320 mg LNG|One silicone elastomer vaginal ring (VR) containing the active ingredients dapivirine (DPV) and levonorgestrel (LNG), formulated as IPM VR: 200 mg DPV + 320 mg LNG (Ring-102)
92031|NCT03467334|Dietary Supplement|B. breve|Bifidobacterium probiotic strain at 1E+08 cfu/day
92032|NCT03467334|Dietary Supplement|B. breve plus L. fermentum|Probiotic combination at 2E+08 cfu/day
92033|NCT03467334|Drug|Simethicone 20 MG|Standard treatment for infant colic
92034|NCT03467321|Other|Physical characteristic assessment|Physical characteristics related to balance, pulmonary function and low back pain were evaluated
92035|NCT03467308|Genetic|Markers in tissue samples: (TIGAR , TRIM59, P53, AKT, GSH)|"The followings markers will be investigated in tissue samples:~TIGAR expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~TRIM59 expression using quantitative real-time polymerase chain reaction (q Rt PCR) and immunohistochemistry.~P53 expression using immunohistochemistry. P53 nuclear localization is essential for its normal function in growth inhibition or induction of apoptosis.~Akt expression using western blot.~GSH using chemical methods."
92036|NCT03467295|Procedure|Surgery|For patient in surgically treated group, surgical removal of intracerebral CMs by craniotomy is performed according to the principles as follows: less transgression of normal brain tissue; identification and protection of eloquent brain tissue; sparing associated developmental venous anomaly; hemosiderin rim resection for non-eloquent and superficial CMs and sparing yellowish tissue for eloquent and deep ones; Extended resections (mesial resection, standard temporal lobe resection) are recommend for epileptogenic CMs based on intra-operative EEG.
92037|NCT03467295|Procedure|Observation|Observation is performed in conservatively treated patients with best medicine and supportive treatment, such as antiepileptic drugs, analgesic drugs and neurotrophic drugs. For patients with underlying diseases such as hypertension, hyperlipidemia or diabetes mellitus, after consulting with the relevant experts, the patients can be treated accordingly.
92038|NCT03467282|Dietary Supplement|Probiotic|1g probiotic mix (twice day): Lactobacillus acidophilus 1x109 CFU + Bifidobacterium lactis 1x109 CFU + Lactobacillus rhamnosus 1x109 CFU + Lactobacillus paracasei 1x109 CFU
92039|NCT03467282|Dietary Supplement|Placebo|1g polydextrose/maltodextrin - twice day
92040|NCT03467269|Diagnostic Test|Brush sign|presence of a brush sign in MRI image in acute cerebral ischaemia
92041|NCT03467256|Biological|Chimeric Antigen Receptor T-Cell Therapy|anti-CD19 chimeric antigen receptor - transduced T-cell given IV
92042|NCT03467256|Drug|Fludarabine|given IV
92043|NCT03467256|Drug|Cyclophosphamide|given IV
92044|NCT03467256|Drug|Tocilizumab|given IV
92045|NCT03467243|Behavioral|Cognitive Behavioral Social Skills Training|CBSST is a more recovery-oriented psychosocial rehabilitation intervention that helps Veterans with SMI set goals, correct errors in thinking, and build communication skills to improve social functioning
92046|NCT03467243|Behavioral|Social Skills Training|SST is an evidence-based, manualized, goal setting curricula that teaches social skills, for example: communication skills and listening skills for Veterans with Serious mental Illness.
92047|NCT03467243|Behavioral|Treatment as usual|TAU is when Veterans continue to receive their usual care.
92048|NCT03467230|Device|NoL Index|Use of the PMD-200 in an observational study
92049|NCT03467217|Drug|Losartan potassium|Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype
92050|NCT03467217|Drug|Placebo losartan capsule|Matching placebo losartan oral capsule
92051|NCT03467191|Drug|Alcohol|target BAC .08%
92052|NCT03467191|Other|Placebo|placebo beverage
92053|NCT03467178|Drug|Decitabine|Nucleic Acid Synthesis Inhibitor
92054|NCT03467178|Drug|Carboplatin|Chemotherapy medication
92055|NCT03467178|Drug|Pegylated Liposomal Doxorubicin|Chemotherapy medication
92056|NCT03467178|Drug|Gemcitabine|Chemotherapy medication
92057|NCT03467178|Drug|Paclitaxel|Chemotherapy medication
92058|NCT03467165|Device|MRgFUS treatment|MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)
92059|NCT03467165|Device|MRgFUS treatment|MRgFUS treatment of pain caused by hip OA
92060|NCT03467152|Drug|E2027|Oral hypromellose capsules.
92061|NCT03467152|Drug|Placebo|Oral hypromellose capsules
92062|NCT03467139|Other|Abdominal breathing exercise|Deep Breathing Exercise
92063|NCT03467113|Drug|ZX008 0.2 and 0.8 mg/kg/day|ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.
92064|NCT03467100|Drug|XEN901|Capsule filled with XEN901
92065|NCT03467100|Drug|Inert Ingredients Oral Product|Placebo capsule
92066|NCT03467087|Device|Myopuls 2000D|Device: Myopuls 2000D (Curatec Services GmBH, 47443 Moers, Germany)
92067|NCT03467074|Biological|influenza A/B vaccine|Regardless of the study enrollment, a two-time influenza vaccination at the start of the flu season is recommended every 4 weeks for all patients after stem cell transplantation. The vaccine is a trivalent inactivated non-adjuvanted influenza virus vaccine containing two influenza A viruses: pandemic H1N1, and H3N2, and an influenza B virus
92068|NCT03467061|Dietary Supplement|Nitrate-rich beetroot juice|concentrated beetroot juice
92069|NCT03467061|Dietary Supplement|Nitrate-depleted beetroot juice|concentrated beetroot juice
92070|NCT03467061|Other|Mouthwash|2 x 10 mL antibacterial mouthwash per day for 14 days
92071|NCT03467048|Device|McGrath videolaryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
92072|NCT03467048|Device|Direct laryngoscopy|"Intubations will be performed with a regular endotracheal tube of adequate diameter, usually 7.5 mm or 8.0 mm. Endotracheal tubes will be equipped with a hockey-stick-shaped stylette, which will be prepared by the anesthesiologist in advance.~The McGrath or the Macintosh blade will be introduced into oral cavity according to manufacturer recommendations and clinical practice. Minor airway manipulation procedures including BURP or Sellick maneuvers will be allowed to improve visualization of the vocal cords."
92073|NCT03467035|Other|Inflammasone|Serum level of cytokine and RT-PCR for PBMC
92074|NCT03467022|Drug|Vitamin C|Patients depleted or deficient in vitamin C by blood test were supplemented orally in vitamin C 1 gram per day for three months
92075|NCT03467009|Behavioral|iPACT Intervention|Brief in-person + tailored, daily 8-week text-message secondary prevention intervention.
92076|NCT03467009|Other|Control: Enhanced Usual Care (EUC)|EUC group participants will receive standardized information on cyberbullying.
92077|NCT03467009|Behavioral|iPACT Intervention- app|Brief in-person + tailored, daily 8-week message secondary prevention intervention delivered via app.
92078|NCT03466996|Behavioral|Intervention group|More frequent follow up with face to face interaction.
92079|NCT03466996|Behavioral|Standard of care group|Transition goal setting during annual follow up.
92080|NCT03466983|Drug|Iron Isomaltoside|administered IV
92081|NCT03466983|Drug|Ferric Carboxymaltose|administered IV
92082|NCT03466957|Other|3D printed applicator|add-on cap for oblique needles, 3D printed Vienna-like applicator, individual vaginal cylinder for intracavitary/interstitial application
92083|NCT03466931|Other|Milk|Meals containing Milk and Milk
92084|NCT03466918|Device|SAPIEN 3 THV|Edwards SAPIEN 3 Transcatheter Heart Valve along with the Commander delivery system
92085|NCT03466905|Other|Ambulant assessment|
92086|NCT03466892|Other|Questionnaires and computer paradigm|Patients will complete different scales and also the visual probe task. First, we hypothesize the attention bias for pain-related information in the FM group is correlated with the level of negative repetitive thinking in the maintained attention phase. Second, we hypothesize the attention bias is more important in the attention maintenance phase (1250 ms) than in the attention orientation phase (500 ms).
92087|NCT03466879|Device|SYNUS Pain Relief device|SYNUS Pain Relief is a handheld micro-current TENS device used for the temporary relief of sinus pain.
92088|NCT03466866|Behavioral|COPDE|Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
92089|NCT03466866|Behavioral|Intensive Diabetes Education|In-home diabetes education
92090|NCT03466853|Diagnostic Test|Clinical assessment of nutritional status (CANS) score|Systematized inspection and estimation of loss of SC tissues and muscles of nine superficial physical parameters including hair and buccal fat in the cheeks, chin and neck, arms, back, inter or subscapular skin, buttocks, legs, chest, and abdominal wall skin. These signs will be rated from 1 (worst, severe FM) to 4 (best, well nourished), and the highest and lowest total scores are 36 and 9, 3respectively. A total score of <25 is considered as fetal malnutrition.
92091|NCT03466853|Diagnostic Test|Anthropometric indices|weight, length and head circumference
92092|NCT03466853|Diagnostic Test|Proportionality indices|MAC/HC ratio (Calculation for each infant and value will be plotted on and compared with a standard curve). Ponderal index . A PI <2.2 is considered as malnutrition). Body mass index (BMI= weight (kg) / length2 (m). A BMI <11.2 kg/m2 is considered as malnutrition)
92093|NCT03466840|Procedure|The coronally advanced lingual flap|": A full-thickness crestal incision is performed from the distal surface of the more distal tooth to retromolar pad and finishing with releasing incision. On the lingual side, a full-thickness muco-periosteal flap was elevated until reaching mylohyoid line. Then using a blunt instrument, it was localized a connective tissue band continuing with the epimysium of the mylohyoid muscle. It is inserted into the inner part of the lingual flap about 5mm from the crest in an apical direction. The blunt instrument is inserted below the connective band, and with gentle traction in the coronal direction, this muscular insertion was detached from the lingual flap. Using a periodontal probe, the amount of advancement is measured."
92094|NCT03466840|Procedure|Modified periosteal releasing Incision|"A full-thickness muco-periosteal flap is reflected on the buccal side. Near the base of muco-periosteal flap, the periosteum is incised less than 0.5mm in depth, creating two segments, coronal segment and apical segment, of the periosteal flap. The flap is pulled with a pair of periodontal forceps laterally. Subsequently, the lateral stretching of the coronal segment of the flap is performed by applying pressure using the blunt face of scalpel blade, or a blunt instrument, with sweeping motion. This motion helps stretching the flap over the submucosa, thereby permitting the flap to be mobile.Using a periodontal probe the amount of advancement is measured."
92095|NCT03466827|Drug|Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off Schedule.
92096|NCT03466814|Other|Non-Interventional|Non-Interventional
92097|NCT03466801|Drug|Prednisone|Prednisone was taken for oral administration with dosage of 1mg/kg/d (maximum 60mg/d) by 8 weeks to start.Then reduced Gradually until the end of the experiment.
92098|NCT03466801|Drug|MP and CTX|Methylprednisolone(MP) was injected for 3 day(if weight >60kg ,500mg/d<60kg,300mg/d ), methylprednisolone was 0.4mg/kg/d for 27 day.Cyclophosphamide(CTX) orally was 100mg/ d for 1 month.And repeated for six months.
92099|NCT03466788|Other|Self questionnaires of quality of life and living conditions|Patients will complete self-questionnaires of living conditions and quality of life (QLQ-C30; EN24; CIPN20; IPAQ; HADS)
92100|NCT03466775|Diagnostic Test|Anti-angiotensin II type 1 receptor antibody measurement|Anti-angiotensin II type 1 receptor antibodies are assessed using quantitative ELISA in stored serum samples obtained within the first year after transplantation
92101|NCT03466775|Diagnostic Test|Measurement of ENDAT expression level allograft|Endothelial-associated transcript expression level is assessed using microarray in stored kidney allograft biopsies obtained within the first year after transplantation
92102|NCT03466775|Other|Allograft survival|
92103|NCT03466775|Other|Allograft rejection appearance|
92107|NCT03466723|Genetic|biomarker identification in Parkinson disease|circulating miRNAs profiling by NGS analysis functional miRNA characterization association of miRNA levels with genetic variants
92108|NCT03466710|Procedure|Colposcopy|"Women will undergo colposcopy at 6 and 12 months after randomization. Those with CIN II will be managed according to standard of care. Those with CIN 1 6 months post randomization will have a second exam 6 months later and if still CIN I will have an exit colposcopy 6 months later.~All women in the Pap and HPV testing policies as well as all women in the colposcopy policy with CIN 1 after 2 exams will have an exit colposcopy 18 months after randomization. The exit colposcopy is a safeguard against the possibility of any false negatives in the follow up policies. The exit colposcopy will also establish the true numbers of CIN lesions in the 3 policies in order to determine their sensitivities and specificities. At the exit colposcopy,all will have an endocervical curettage,and either a minimum of 2 directed biopsies of any mucosal abnormality or in the event no abnormality is identified,2 random biopsies from the cervix."
92109|NCT03466710|Other|Pap test|"Women will receive Pap tests at 6 and 12 months after randomization. The Pap test will be prepared using the Thinprep® system which is the standard at Calgary Laboratory Services. Women with a Pap test result of malignant, HSIL, AIS, AGC, ASC-H, or LSIL-H (>LSIL) at 6 or 12 months post randomization will be referred for colposcopic examination. Women with an ASC-US or LSIL result (</=LSIL) will have a second follow up Pap test 6 months later (12 months post randomization). Those with a persistent result of ASC-US or LSIL or >LSIL at 6 or 12 months will be referred for colposcopic examination. Outcome in the Pap policy is positive when the histopathology is >/=CIN II. Results of </=CIN I equal a negative outcome.~All other Pap test results will have an exit colposcopy 6 months later (18 months post randomization)."
92110|NCT03466710|Diagnostic Test|HPV test|Women will have an HPV test performed on a cervical scrape sample 12 months after randomization. Women with a positive result will be referred for colposcopy. Outcome in the HPV testing policy is positive when histopathology obtained at the colposcopic exam shows CIN II. All other results equal a negative outcome. HPV negative women will have an exit colposcopy 18 months post randomization. HPV testing will be performed using Cervista™HPV HR(Third Wave Technologies Inc./Hologic Inc, Madison, WI, USA).This HPV DNA test identifies 14 high risk types (16,18,31,33,35,39,45,51,52,56,58,59,66,68). Testing will be performed on the residual cervical scrape sample which is fixed in the PreservCyt® solution of the Thinprep® liquid based system(Hologic Inc, Marlborough, Ma, USA). Cervical samples may be held for up to 24 wks at room temperature before DNA extraction.This allows time for transportation without refrigeration.The samples will be sent by overnight express delivery to the laboratory.
92111|NCT03466697|Other|Glucose injection/Normal saline injection|Before each PET scan, subject will be injected either glucose or normal saline.
92112|NCT03466684|Other|BIA-guided fluid resuscitation protocol|"In both groups, a multi-frequency BIA with eight tactile electrodes (Inbody S10 Biospace, Biospace Co. Ltd., Seoul, Korea) was used to assess body fluid status every 6h within the first 72h after admission to the ICU and daily for a period of 4 days.~BIA recording was not adjusted by clinicians in fluid restrict, pharmacological and mechanical means of therapy.~In contrast, in group BIA, fluid resuscitation protocol with adjustment determined according to HL measured by BIA."
92113|NCT03466684|Other|Traditional fluid resuscitation protocol|Traditional fluid resuscitation strategy determined by treating clinicians according to usual clinical parameters.
92114|NCT03466671|Drug|TTA-121|A nove intranasal spray of oxytocin and placebo
92115|NCT03466658|Device|JumpStart Antimicrobial Wound Dressing|A novel, wireless, low-level microcurrent-generating antimicrobial device (JumpStart) is a sterile single layer dressing consisting of a matrix of alternating silver (Ag) and zinc (Zn) dots that are held in positions on a polyester substrate with biocompatible binder. Dressing is then activated in the presence of a conductive fluid, which may come from wound exudate or exogenous fluids, such as saline. It has been observed, in vitro, to exhibit electricidal effect in the presence of antibiotic and multidrug resistant clinical wound isolates.
92116|NCT03466645|Drug|Vancomycin|The 1st group receives vancomycin an hour before craniotomy
92117|NCT03466645|Drug|Cefazolin|The 2nd group receives cefazolin an hour before craniotomy
92118|NCT03466632|Drug|Propofol|propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure.
92119|NCT03466632|Drug|Dexmedetomidine|dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure
92120|NCT03466619|Device|inflatable penile prosthesis (IPP)|inflatable penile prosthesis (IPP)
92121|NCT03466606|Behavioral|pre-habilitation|Personalized supervised resistance training and program to promote physical activity and healthy lifestyles
92122|NCT03466593|Other|Prehabilitation|Prehabilitation concerning eating, smoking, drinking and physical activity
92123|NCT03466593|Other|Routine care|Preoperative information
92124|NCT03466593|Other|Extra early mobilization|Mobilization the day of surgery
92125|NCT03466593|Other|Standard mobilization|Mobilization the day after surgery
92126|NCT03466580|Behavioral|The Carer Support Needs Assessment Tool (CSNAT) intervention|The CSNAT intervention is a caregiver-led approach where the caregiver first identifies his/her needs of support in the CSNAT, which consists of 14 support domains. Then the practitioner facilitates the intervention where the caregiver prioritizes which domains to discuss. In the conversation, the caregiver's domain priorities and subsequently identified support needs are discussed with the practitioner to agree on actions/solutions and a shared action plan. The intervention will be offered each caregiver twice: the first time between 0 and 13 days after enrollment, and the second time between 15 and 27 days after enrollment.
92127|NCT03466567|Drug|Semaglutide|A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
92128|NCT03466567|Drug|Probenecid|A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
92157|NCT03466372|Behavioral|biofeedback|treadmill walking with biofeedback regarding propulsion and other gait parameters
92326|NCT03465020|Other|Observation|Safety and efficacy outcomes of patients on different treatments
92129|NCT03466567|Drug|Ciclosporin|A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
92130|NCT03466554|Device|Hyperbaric oxygen-90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes|60 daily HBOT sessions will be administrated 5 days per week. comprise of 90 minutes exposure to 100% oxygen at 2 ATA, with 5-minute air breaks every 20 minutes.
92131|NCT03466541|Behavioral|Riskbruk|The Riskbruk model incorporates alcohol screening through a widely employed alcohol screening questionnaire, the Alcohol Use Disorders Identification Test (AUDIT) and a standard alcohol biomarker, carbohydrate-deficient transferring in serum (CDT), with brief consultations using the motivational interviewing (MI) technique. MI is a collaborative conversation style used to increase awareness and reflection around one's own drinking habits, as well as strengthening the person's motivation for a lifestyle change. The conversation style includes expressing empathy through reflective listening, communicating respect and acceptance of the participants and their feelings, and open up for self-reflection and exploration around the drinking behaviour.
92132|NCT03466541|Behavioral|Balance|Balance is a new Norwegian eHealth programme, and incorporates two approaches to behaviour modification interventions: a brief interventions and an intensive self-help programme. The intervention is based on cognitive-behavioural and self-help principles, and is given to the participants through multiple interactive sessions.
92133|NCT03466528|Drug|Magnesium Sulfate|Intravenous (Magnesium Sulphate) MgSO4 2 grams IV over 20 minutes
92134|NCT03466528|Drug|Pabrinex|standard treatment
92135|NCT03466515|Procedure|stem cells injection|two surgical interventions as day-surgery, starting with liposuction from the abdomen (about 200-300 ml), and fistula tract debridement and closure of internal opening. The external opening is excised. About 30-40 ml fresh harvested patients own fatty tissue are then injected with large needle around the fistula from internal til external opening.The resting harvested fatty tissue will be sent to stem cells (Adipose Derived Regenrative Cells ADRCs) isolation, using Cytori Celusion system®. When the stem cells isolation is completed, 4ml concentrated stem cells ( contains around 20-40 millions cells ) will be injected around the prepared fistula tract, the same site where the fresh harvested fatty tissue injected before.
92136|NCT03466502|Drug|Oral Vancomycin|Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
92137|NCT03466489|Device|Floraseal|FloraSeal is a cyanoacrylate-based sealant used in the prevention of surgical site infections.
92138|NCT03466476|Device|Consensus TracPatch|The information gained by the TracPatch wearable technology will be readily available via a HIPAA secure system to the surgeon and patient in order to monitor post-operative recovery and signal to both parties if any intervention is indicated. The device also monitors for rapid acceleration events which may indicate a traumatic injury. Additionally, the temperature sensor may help detect sub-clinical infection.
92139|NCT03466463|Genetic|GNT0003|Intravenous infusion, single dose
92140|NCT03466450|Drug|PF-04449913|"Glasdegib (3 dose levels will be evaluated: 100mg QD, 150mg QD and 200mg QD, or 75-50mg) will be administered:~During concurrent phase concomitantly with radiation and Extended to the resting period (glasdegib will not be stopped in the 4 weeks of radiotherapy resting period).~During adjuvant therapy with Temozolomide Oral Capsule. Additional treatment with glasdegib beyond 6 sequential TMZ cycles will continue until progression, unacceptable toxicity, non-compliance, consent withdrawal and/or 2 years of glasdegib administration."
92141|NCT03466450|Drug|Temozolomide Oral Capsule|"During RT, patients will receive Temozolamide (TMZ). All patients will be given TMZ at 75 mg/m2~/d concurrently with RT for a maximum of 42 days. At 4 weeks after RT completion, patients will start taking TMZ at 150 mg/m2/d for the first 5 days of a 28-day cycle. If first cycle is well tolerated, patients will receive TMZ at 200 mg/m2/d for the first 5 days of every subsequent 28-day cycle for another 5 cycles."
92142|NCT03466437|Device|Glass-fiber post and composite resin restoration|Patients will receive a glass-fiber and composite resin restoration followed by removable partial denture fabrication
92143|NCT03466437|Device|Glass-fiber post and metalceramic crown|Patients will receive a glass-fiber and metalceramic crown followed by removable partial denture fabrication
92144|NCT03466437|Device|Cast-metal post and metalceramic crown|Patients will receive a cast-metal post and metalceramic crown followed by removable partial denture fabrication
92145|NCT03466424|Radiation|preoperative short-course radiotherapy|Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
92146|NCT03466411|Drug|Guselkumab Dose 1|Guselkumab will be administered by IV infusion.
92147|NCT03466411|Drug|Guselkumab Dose 2|Guselkumab will be administered by SC injection.
92148|NCT03466411|Drug|Guselkumab Dose 3|Guselkumab will be administered by IV infusion.
92149|NCT03466411|Drug|Guselkumab Dose 4|Guselkumab will be administered by IV infusion.
92150|NCT03466411|Drug|Guselkumab Dose 5|Guselkumab will be by SC injection.
92151|NCT03466411|Drug|Guselkumab|Guselkumab will be administered by IV infusion and SC injection.
92152|NCT03466411|Drug|Ustekinumab|Ustekinumab will be administered by IV infusion and SC injection.
92153|NCT03466411|Drug|Placebo|Placebo will be administered as IV infusion.
92154|NCT03466398|Behavioral|Vivify Health RPM Protocol|The Vivify RPM Protocol includes a wireless tablet and glucometer/Bluetooth device that can directly upload blood glucose readings to the tablet. Patients will daily Care Plan questionnaires on the tablet, as well as upload blood glucose readings twice a day. The tablets will also be used for weekly video conferences with study investigators.
92155|NCT03466385|Device|Nasal High Flow|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NHF it will be commence immediately with pre-defined settings
92156|NCT03466385|Device|Non-Invasive Ventilation|Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NIV it will be commence immediately with pre-defined settings
92293|NCT03465280|Procedure|Microdebrider|Removal of lesions via microdebrider
92158|NCT03466359|Behavioral|DEF-EI : Energy restriction induced energy deficit|DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
92159|NCT03466359|Behavioral|DEF-EX : Exercise induced energy deficit|DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
92160|NCT03466346|Drug|Fluoxetine|Fluoxetine is a selective serotonin reuptake inhibitor that is FDA approved for the treatment of depression. Compared to placebo, fluoxetine is more likely to produce symptom response for MDD. Despite the interim development of many other antidepressants since the development of fluoxetine, it remains a first line treatment for depression.
92161|NCT03466346|Behavioral|Interpersonal Psychotherapy|PT was developed in the 1980s by Gerald Klerman and Myrna Weissman to address interpersonal issues in depression. IPT is now considered evidence-based, first-line treatment for depression. IPT improves symptoms by addressing problems in social relationships. IPT is traditionally delivered as weekly one-hour sessions over 12 weeks, focused on one interpersonal problem area.
92162|NCT03466333|Drug|Enalapril Maleate|Enalapril maleate will be encapsulated; participants will take the drug once a day for 6 months following delivery.
92163|NCT03466333|Drug|Placebo oral capsule|The placebo will be encapsulated; participants will take the drug once a day for 6 months following delivery. It will be identical in appearance to the IMP.
92164|NCT03466320|Biological|NKR-2|This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
92165|NCT03466307|Device|Ultrasonography|Ultrasonographic examination of shoulder
92166|NCT03466294|Drug|Azacitidine and Venetoclax|Azacitidine will be given at dose of 75mg/m2 in Cycle 1 days 1-7; repeat in cycle 2 and 3 if no response. Starting on day 2 of cycle 1, venetoclax will be administered orally with doses increased to a target dose of 600 mg (administer 100 mg on day 2, 200 mg on day 3, 400 mg on day 4 and 600 mg on day 5), then 600 mg daily.
92167|NCT03466281|Behavioral|Structured patient group education|Patient education in a group setting
92168|NCT03466281|Behavioral|Education via Internet|Patient education via the internet
92169|NCT03466268|Drug|Glumetinib for tablet|Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
92170|NCT03466255|Other|Ultrasound|Contrast-enhanced ultrasound (CEUS)
92171|NCT03466242|Drug|Dexmedetomidine|Evaluate sedative and analgesic effects of Intranasal Dexmedetomidine
92172|NCT03466242|Drug|Ketamine|Evaluate sedative and analgesic effects of Intravenous Ketamine
92173|NCT03466229|Dietary Supplement|Androferti|
92174|NCT03466229|Dietary Supplement|Placebo|
92175|NCT03466216|Drug|AlphaMedix|There is only a single treatment intervention.
92176|NCT03466203|Biological|LLF580|LLF580 300mg
92177|NCT03466203|Drug|Placebo|Placebo to LLF580
92178|NCT03466190|Procedure|Titanium plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using conventional titanium plates will be performed.
92179|NCT03466190|Procedure|Custom made PEEK plate fixation|Under General Anesthesia, exposure of the fractured mandibular body segments will be done using a standardized surgical approach. Open Reduction Internal Fixation using custom made PEEK plates will be performed.
92180|NCT03466177|Diagnostic Test|Non-invasive, multimodal retinal imaging|Ocular exam including the application of different non-invasive ocular imaging techniques
92181|NCT03466177|Diagnostic Test|Cerebral imaging|amyloid-PET and MRI
92182|NCT03466177|Diagnostic Test|Neuropsychiatric testing|neuropsychiatric test battery
92183|NCT03466177|Diagnostic Test|Venous blood sampling|fasting laboratory tests and apoE genotyping
92184|NCT03466164|Behavioral|Mindfulness Based Stress Reduction Program|8 week, 10-session course of mindfulness training
92185|NCT03466151|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
92186|NCT03466151|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|Treatment of subjects eligible for percutaneous transluminal coronary angioplasty (PTCA) as per study requirements
92187|NCT03466138|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
92188|NCT03466125|Procedure|Cardiac surgery|Retrospective cohort study
92189|NCT03466112|Other|endurance training|endurance training with stationary bicycles
92190|NCT03466112|Other|balance and tone program|flexibility, core strength, balance, relaxation
92191|NCT03466099|Drug|KVD001 Injection|Intravitreal KVD001 Injection
92192|NCT03466099|Other|Sham Procedure|Sham Procedure
92193|NCT03466086|Device|Test Eye Drops|blink® intensive TRIPLE ACTION 3 in 1 eye drops
92194|NCT03466086|Device|Control Eye Drops|Systane® BALANCE eye drops
92195|NCT03466073|Drug|Recombinant Human Plasma Gelsolin|Recombinant Human Plasma Gelsolin Lyophilized for Reconstitution, reconstituted in sterile water
92196|NCT03466073|Other|Normal Saline Placebo|Normal saline in volume equivalent to drug
92197|NCT03466060|Device|Opti-Free : RevitaLens / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92198|NCT03466060|Device|Opti-Free : RevitaLens / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92199|NCT03466060|Device|Clear Care : RevitaLens/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92200|NCT03466060|Device|Clear Care : RevitaLens / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92201|NCT03466060|Device|RevitaLens : Clear Care/ Opti-Free : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92202|NCT03466060|Device|RevitaLens : Clear Care / RevitaLens : Opti-Free|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92203|NCT03466060|Device|RevitaLens : Opti-Free / Clear Care : RevitaLens|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92204|NCT03466060|Device|RevitaLens : Opit-Free / RevitaLens : Clear Care|Subjects between the ages of 18-69 will be randomized to 1 of 3 lenses. Solutions will be administered contralaterally with 1 test solution and 1 of 2 control solutions prior to the subjects' follow-up visits.
92205|NCT03466047|Dietary Supplement|A single macronutrient captured in microcapsules|Encapsulated macronutrients in a drink
92206|NCT03466021|Drug|Liraglutide|Initially 0.6 mg daily, increasing weekly with 0.6 mg, until 3.0 mg is reached.
92207|NCT03466021|Drug|Placebo|Matching injection
92208|NCT03466008|Behavioral|Whole-Body Cryotherapy|10 sessions of WBC were performed (in addition to usual care) in a standard cryotherapy room over a duration of 8 days.
92209|NCT03465995|Device|NKI i-PAS Diagnostic Protocol|"The NKI i-PAS:~The NeuroKinetics i-PAS system is a mobile assessment device with an integrated display for eye tracking with the following properties: a head mounted display, a sampling rate of 100 frames per second, eye tracking in the horizontal, vertical and torsional axes, and pupil area measurement with a spatial resolution less than 0.1 o. The testing protocol includes: optokinetic tracking, smooth pursuit horizontal, smooth pursuit vertical, saccade random horizontal, saccade random vertical, saccade predictive horizontal, antisaccade (horizontal), self-paced saccade, saccade and reaction times, visual reaction time, auditory reaction time, gaze horizontal, light reflex, subjective visual (vertical) and subjective vertical horizontal. Several quantitative measures are computed from the data acquired in each test, and these measures are then employed in a multivariate diagnostic assessment."
92210|NCT03465982|Procedure|Surgery after 8 weeks from chemoradiation treatment|Minimally invasive surgery after 8 weeks from chemoradiation treatment
92211|NCT03465982|Procedure|Surgery after 12 weeks from chemoradiation treatment|Minimally invasive surgery after 12 weeks from chemoradiation treatment
92212|NCT03465969|Drug|tacrolimus|oral
92213|NCT03465956|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy using the gastro-intestinal anastomosis stapler.
92214|NCT03465943|Drug|Ringer|1L of Ringer's solution as a preload in one group.
92215|NCT03465943|Drug|Voluven|500 ml of voluven will be given in combination with 500 ml Ringer's solution as a preload in the other group.
92216|NCT03465930|Procedure|Supermicrosurgical lymphatico-venous anastomoses|Supermicrosurgical lymphatico-venous anastomoses (sLVA) require an accurate visualization of the lymphatic vessels that are still functional. Lymphatic vessels are visualized with lymphography using a fluorescent dye, indocyanine green. Adjacent superficial veins mapping is obtained with Accuvein device.
92217|NCT03465917|Combination Product|Renal Denervation|Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
92218|NCT03465904|Device|Verum Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Verum Cefaly® Abortive Program device will deliver verum external trigeminal nerve stimulation.
92219|NCT03465904|Device|Sham Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS). The Sham Cefaly® Abortive Program device will deliver sham external trigeminal nerve stimulation.
92220|NCT03465891|Drug|atezolizumab|1200mg IV on day 1 of a 21-day cycle for a planned total of 17 cycles of therapy (1 year).
92221|NCT03465891|Radiation|Low- Dose, Local Radiotherapy|4Gy will be administered in 2 fractions to a single nodal site amenable to radiation as identified by the radiation oncologist on day 2 and day 3 of Cycle 1 (over the two days following to the first dose of atezolizumab ).
92222|NCT03465878|Drug|LY900014|Administered via SC injection
92223|NCT03465878|Drug|Insulin Lispro|Administered via SC injection
92224|NCT03465865|Device|optical coherence tomography|optical coherence tomography enables diagosis of macular structures and therefore provides information on macular hole closure.
92225|NCT03465852|Behavioral|ChiCAS|Promotes access to and participation by HIV negative Hispanic/Latina transgender women who have sex with men in PrEP, medically supervised hormone therapy, and consistent condom use.
92226|NCT03465839|Behavioral|Education for improving handovers quality|Specific education on the importance of handovers quality will be provided. The educational session will last 4 hours. The program will be divided into the following sections: 1) a structured survey on the perception of the participants on the handovers importance; 2) Key theoretical concepts on the relevance of handovers with case studies of errors related to this critical moment; 3) showing movie clips of nursing handovers to critically interpret the clips by the participants; 4) presentation of the SBAR method recommended by WHO; 5) general presentation of the nursing delivery assessment project of the Valduce Hospital.
92294|NCT03465280|Procedure|Cold-steel surgery (forceps)|Removal of lesions via forceps
92295|NCT03465280|Procedure|Carbon dioxide laser|Removal of lesions via carbon dioxide laser
92296|NCT03465280|Procedure|Potassium titanyl phosphate (KTP) laser|Removal of lesions via KTP laser
92297|NCT03465280|Procedure|Pulsed dye laser|Removal of lesions via pulsed dye laser
92227|NCT03465839|Behavioral|Education for improving bedside handovers|In addition to the education for improving handovers quality, the following intervention will be implemented for nurses assigned to the study department. The course will be supplemented by a section of the duration of an hour, containing 1) information on the principles underlying bedside handovers; 2) how to handle information in front of the patient and on his / her direct involvement; 3) role-playing of the bedside handover will be performed, assigning the roles of nurse and patient among the participants to bring out impressions linked to the functions.
92228|NCT03465826|Behavioral|PainCOACH Pain Coping Skills Training|Migraineurs will participate in 4 weeks of daily headache monitoring, baseline questionnaires, followed by 8 weeks of the PainCOACH migraine mHealth Pain Coping Skills Training program (developed by Drs. Keefe and Rini based on social cognitive theory and in-person pain coping therapy sessions). Following the 8 week mHealth intervention, participants will immediately complete post-treatment assessments and later will complete follow-up assessments at 3 and 6 months.
92229|NCT03465826|Behavioral|Treatment as Usual|Participants will keep headache diaries for 4 weeks, followed by baseline assessments + 8 weeks of daily headache monitoring (as a parallel to the PainCOACH intervention). Post-assessments will immediately follow, and participants later will complete follow-up assessments at 3 and 6 months.
92230|NCT03465813|Behavioral|CaringGuidance After Breast Cancer Diagnosis|CaringGuidance After Breast Cancer Diagnosis, psychoeducational, Internet-accessible program
92231|NCT03465800|Behavioral|self-monitoring|self-monitoring of physical activity
92232|NCT03465800|Behavioral|daily incentives|daily incentive payments for physical activity
92233|NCT03465800|Behavioral|delayed lump sum incentives|delayed lump sum payments for physical activity
92234|NCT03465787|Drug|Lurasidone HCL 160 mg|Lurasidone HCL 2 80mg tablets, QD
92235|NCT03465787|Drug|Quetiapine XR 600 mg|Quetiapine XR 2 300 mg tablets, QD
92236|NCT03465774|Drug|Doxycycline|Receive via IPC
92237|NCT03465774|Device|Indwelling Catheter|Receive IPC
92238|NCT03465774|Procedure|Quality-of-Life Assessment|Ancillary studies
92239|NCT03465774|Other|Questionnaire Administration|Ancillary studies
92240|NCT03465774|Other|Survey Administration|Ancillary studies
92241|NCT03465761|Device|ExAblate|Bilateral side treatment of Essential Tremor
92242|NCT03465748|Device|OrthoK|orthok (orthokeratology) is the science of changing the curvature or shape of the cornea to change how light is focused on the retina at the back of one's eye. Specially designed molding retainer contact lenses are placed on the eye at night and are removed upon awakening.
92243|NCT03465735|Combination Product|Vascular Boot|The Vascular Boot is one size fits all, insulated fleece padding, and cell foam to enhance and maintain lower limb warmth while maintaining no pressure points on the lower extremity.
92244|NCT03465735|Drug|Standard of Care|Anticoagulant therapy will be decided by physician and patient.
92247|NCT03465709|Drug|APL-2|Study Drug
92248|NCT03465696|Behavioral|Group #2 (Intervention)|"Group #2 (Intervention)~Survey 2 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
92249|NCT03465696|Behavioral|Group #3 (Intervention)|"Group #3 (Intervention)~Survey 3 will be administered, and patients will be asked the following primer:~Stelara® inhibits interleukin 23, one of the immune signaling molecules involved in psoriasis. People who are born with a genetic deficiency in the immune signal interleukin-23 are generally healthy, but also have a LOWER risk of getting immune diseases like psoriasis.~What do you think would be the best way to describe this to a patient?~Stelara® acts in an almost all-natural way to help control psoriasis.~Stelara® blocks one of the genetic causes of psoriasis.~Stelara® makes psoriasis better by blocking the overactive signal that gets the immune system out of balance~Stelara® blocks interleukin-23, an important immune system signaling molecule involved in psoriasis~How willing would you be to take Stelara® to treat your psoriasis, on a scale of (1 = definitely willing, 2 = probably willing, 3 = probably not willing, 4 = definitely not willing)"
92250|NCT03465683|Other|ESBL-producing Enterobacteriaceae|Data and biological sample collection
92251|NCT03465670|Device|CHX|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
92252|NCT03465670|Device|CHX+HA+ADS|Patients received a 21-day supply of 0.2% chlorhexidine (CHX) containing 0.2% hyaluronic acid (HA) and Anti-Discoloration System (ADS) according to the randomization list, and were instructed to use 10 ml of the assigned mouthrinse for 1 minute, t.i.d. for 21 days. After rinsing, patients were asked to avoid washing their mouth or drinking for 30 minutes. Patients were asked to return the mouthrinse bottles (either empty of filled) at the end of the experimental period (day 21), in order to assess the level of patient compliance with the assigned CHX regimen.
92253|NCT03465644|Drug|Tailored antithrombotic strategy|Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
92254|NCT03465644|Drug|Conventional antithrombotic strategy|Clopidogrel + aspirin for 12months
92255|NCT03465631|Device|SMART Glove system with tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
92256|NCT03465631|Device|SMART Glove system with sham-tDCS|combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
92298|NCT03465280|Procedure|Radiofrequency ablation|Removal of lesions via radiofrequency ablation
92299|NCT03465280|Procedure|Monopolar suction diathermy|Removal of lesions via monopolar suction diathermy
92257|NCT03465618|Drug|89Zr-DFO-cRGDY-PEG-Cy5-C' dots PET Imaging|A low dose spiral CT is performed first per the standard procedure. These images will be used for both attenuation correction and registration of the serial image set. The initial PET brain scan will be acquired up to about 24 hours post injection. Based upon the discretion of the physician, non-surgical patients have the possibility of a second scan and third up to about 48 hours post injection. The times per bed position may be adjusted after the first patient is imaged, and his/her scans evaluated. Additional low dose CT scans will be performed at the image session for attenuation correction and image registration. PET study may be done on a PET-MR scanner for ease.
92258|NCT03465618|Other|Blood and Urine samples|Venous blood and urine samples will be obtained at approximately 0.5 hours post injection at the end of each scan
92259|NCT03465605|Diagnostic Test|frailty test|questionnaire
92260|NCT03465592|Drug|Nivolumab|Administered IV
92261|NCT03465579|Diagnostic Test|pelvic MRI|multi-parametric pelvic MRI
92262|NCT03465579|Diagnostic Test|68Ga-PSMA PET/CT|68Ga-PSMA PET/CT
92263|NCT03465566|Diagnostic Test|IDS;MMSPE;CDI 2;CBCL;tests of facial expression evaluation|Five pictures (including nonfacial features; i.e., hairs) were used for each emotion, giving a total of 25 trials.Stimuli consist of pictures of facial affect taken from the Ekman and Friesen series.
92264|NCT03465553|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with advanced thoracic cancer
92265|NCT03465540|Drug|AMG 397|potent and selective inhibitor of protein-protein interactions between myeloid cell leukemia sequence 1 and pro-apoptotic members of the lymphoma/leukemia 2 family
92266|NCT03465527|Drug|PrednisoLONE 50 MG|Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
92267|NCT03465501|Radiation|Brachytherapy|Brachytherapy
92268|NCT03465488|Drug|Albendazole Pill 400mg (GSK)|One single dose of 400mg Albendazole is provided at baseline.
92269|NCT03465462|Dietary Supplement|group/arm C (control group)|Group C in the third stage (30 days) continued drug use with no change in diet and no mineral supplementation.
92270|NCT03465462|Dietary Supplement|group/arm D (diet group)|Group D in the third stage (30 days) received an optimal-mineral-content properly balanced diet enriched in food with high zinc content.
92271|NCT03465462|Dietary Supplement|group/arm S (supplementation group)|Group S in the third stage (30 days) received zinc supplementation as one capsule containing 15 mg of Zn taken orally once a day in the morning, two hours after antihypertensive drug administration with no change in diet.
92272|NCT03465449|Behavioral|CKD-EDU|Palliative Care based coaching intervention for support with dialysis-related decision making.
92273|NCT03465449|Other|usual care|Nephrologist based usual care
92274|NCT03465436|Drug|Lasmiditan|Administered orally.
92275|NCT03465436|Drug|Moxifloxacin|Administered orally.
92276|NCT03465436|Drug|Placebo for Lasmiditan|Administered orally.
92277|NCT03465436|Drug|Placebo for Moxifloxacin|Administered orally.
92278|NCT03465423|Procedure|Not applicable (measuring subject's effect site concentration of propofol during the induction of general anesthesia)|The patients of two cohort group will undergo general anesthesia in the same way and therefore there is no intervention in this study.
92279|NCT03465410|Drug|Standard dosage of Tacrolimus|Immediate release Tacrolimus (Prograf/Adoport)
92280|NCT03465410|Drug|Bayesian Prediction Tacrolimus dosage|Immediate release Tacrolimus (Prograf/Adoport)
92281|NCT03465397|Diagnostic Test|biomarkers driven immunosuppressive therapy|the immunosuppressive treatment of the patients is determined according to the result of 2 biomarkers of immunological risk
92282|NCT03465384|Behavioral|Comet|The intervention is a behaviorally based and manualized parent training program.
92283|NCT03465371|Other|CSC OnDemand Training Intervention|"Level 1: Readiness~Online readiness tool~Level 2: Core Knowledge~Week 1—self-paced core curriculum, totaling 8 hours of instruction~Level 3: Going Deeper~Week 2—instructor-led, role-specific, and advanced topics, totaling 12 hours of instruction~Level 4: Sustainability~9 months of online community of practice support; a discussion forum; open office hours with experts; multisite case conferencing; access to online materials"
92284|NCT03465371|Other|InPerson Intervention|"Level 1: Readiness~Telephone conversations with program leaders to determine structures, roles, staffing, recruitment~Level 2: Core Knowledge~1 day of in-person training on FEP basics and CSC components~Level 3: Going Deeper~1.5 days of in-person training on how the team works, followed by breakout sessions by role~Level 4: Sustainability~9 months of monthly implementation coaching calls with team leads; monthly telephone case conferences; monthly care coordination calls split out by role"
92285|NCT03465358|Other|Items completion|"Patients will complete his Motor Function Measure in the usual way, except items 18, 19 and 22 which will be completed twice: once using conventional material and once on a digital tablet.~The order of completion between conventional material or digital tablet will be allocate randomly."
92286|NCT03465345|Drug|Metformin|Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.
92287|NCT03465345|Drug|Oligomeric Procyanidin Complex|OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
92288|NCT03465332|Other|Doctor's questionnaire|The survey of physicians will be performed using doctor's questionnaire, which will be developed by lung specialists who are not participating in the survey.
92289|NCT03465332|Other|Subject file|All subject-based data will be obtained by retrospective evaluation of subject files available at the treating lung specialist.
92290|NCT03465306|Behavioral|Cognitive Behavioral Therapy|Cognitive-behavioral therapy is a psycho-social intervention that is the most widely used evidence-based practice for improving mental health and requires active interactions between the participants and a therapist or coach.
92291|NCT03465306|Device|Self-guided|Self-guided refers to any contact between the participants and a therapist or coach.
92292|NCT03465293|Other|Bacterial composition and activity after bowel preparation|Bacterial composition and activity and patient's symptoms will be assessed pre and post bowel preparation taken as part of the preparation to have a pre-planned colonoscopy
92302|NCT03465267|Device|Armeo power|"Intervention with Armeo power rehabilitation robot for upper extremity (made by Hocoma), which provide assistive force.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
92303|NCT03465267|Device|Armeo spring|"Intervention with Armeo spring rehabilitation robot for upper extremity (made by Hocoma), which is operated only by participants, without any assistive force from robot.~The intervention was done 4 weeks, 5 times/week, 30 minutes/day."
92304|NCT03465241|Diagnostic Test|the ctDNA dynamic monitoring|To detect ctDNA in patients using the second generation of high-throughput gene sequencing (NGS)
92305|NCT03465228|Device|Training and LED group|The LED application will be performed before GTL training sessions and will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
92306|NCT03465228|Device|Training group|The training sessions will be monitored based on the subjective perception of exertion of the session (PSESession) (FOSTER, 1998), and heart rate. There will be two types of training: continuous and interval training. The sessions of the training group (GT) and group training + LED (GL) will be preceded by a warm-up of 15 minutes. Participants in the two training groups will undergo weekly training twice weekly on non-consecutive days during four weeks. Continuous training will be 30 minutes at 70% to 80% of maximum heart rate, and interval training will be performed 30 minutes at 100% maximum heart rate of laced racing with fixation of an elastic tube in the floating vest, 30 seconds of intense running and 30 seconds interval. The LED off will be performed before training sessions.
92307|NCT03465228|Other|LED group|This group will be applied through the spot method with direct contact of the equipment over the irradiated site for 30 seconds. The application will be in four points in the lumbar region, above the gluteal region, with an angle of 90 ° in relation to the cutaneous surface. A wavelength of 660 to 850nm will be used with a frequency of 0 to 1500 Hz and energy irradiated of 0.9 J of each diode totaling 43.2J (48 diodes).
92308|NCT03465215|Device|Digital holographic microscopy|Tissue obtained from CD patients will be analyzed using digital holographic microscopy. Results will be compared between non-stenotic and stenotic tissue of the intestinal wall of CD patients.
92309|NCT03465202|Drug|Capecitabine|
92310|NCT03465189|Device|Medtronic LINQ Device|Using two LINQ devices that are fixed to scalp to record EEG (in addition to the standard scalp EEG).
92311|NCT03465176|Other|Aromatherapy Blend|The essential oil intervention is a blend of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
92312|NCT03465176|Other|Placebo|The placebo substance is an odorless vegetable oil derived from avocados.
92313|NCT03465163|Device|Deep Brain Stimulation|The device is called the Medtronic Activa PC+S system. Two devices will be implanted per participant. The electrodes will be surgically implanted bilaterally into the hippocampus and anterior nucleus of the thalamus.
92314|NCT03465150|Other|acne|Patient with acne
92315|NCT03465137|Behavioral|Coordinated Anxiety Learning and Management (CALM)|Exposure-focused cognitive behavioral therapy
92316|NCT03465124|Device|Femtosecond Laser|Femtosecond Laser assisted Cataract Surgery will be performed unilateral in randomized order. Contralateral eye will receive conventional cataract surgery
92317|NCT03465124|Other|Manual Cataract Surgery|conventional cataract surgery as control
92318|NCT03465111|Drug|ACTH (adrenocorticotropic hormone) gel|The dose of H.P. Acthar Gel is 80 Units administered subcutaneously
92319|NCT03465098|Other|Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT|The patients will receive 2 PET/CT , first exam with standard diet and 12h fasting and second exam preceded by 3 meals strict low diet and 12h fasting
92320|NCT03465085|Drug|Unfractionated heparin|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
92321|NCT03465085|Drug|Streptokinase|Heparin or Streptokinase were nebulized by Aeroneb Pro@ Lab mesh nebulizer (Aerogen Limited, Galway, Ireland) which is incorporated within GE Healthcare's Engström Carestation ventilator (General Electric Company, Finland). Aeroneb nebulizer is a palladium vibrating mesh nebulizer. The central aperture plate of the nebulizer is 5mm in diameter and is perforated with 1000 precision formed holes, that vibrate at 128,000 times per second, to produce the particles with size 1-5 micron in diameter with average MMAD (Mean Mass Aerodynamic Diameter) is 2.1 microns. The nebulized medication (either streptokinase 250,000 IU or heparin 10.000 IU) was prepared in 3 ml volume of distilled water and nebulized for a period of 15 minutes every 4 hours.
92322|NCT03465072|Other|Exercise training|8 weeks, 3 times per week, 30-40 minutes
92323|NCT03465059|Drug|Zanubrutinib|A single oral dose of 80 mg Zanubrutinib will be administered.
92324|NCT03465046|Combination Product|intensive therapies(CIMT/BIT): protocol 1 or protocol 2|"The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family"
92325|NCT03465033|Other|Early Physiotherapy|"From T1 to T2 patients will perform 3 daily repetitions of active exercises:1 5 repetitions of oral opening exercises and bilateral manual progressive stretching, protrusion and maximum lateralization of the jaw on both sides, holding each movement for 5s and a session of cryotherapy applied to the masseter, temporal and suprahyoid muscles for 120s in two 60s sessions. They will also perform 30 repetitions of exercises aimed at improving the labial seal (inflate cheeks) and the symmetry of the upper lip (broad smile). From T2 to T3 30 repetitions of the same exercises will be performed and passive progressive opening will be implemented by clamping Patients will also perform isometric contraction exercises in opening, closing, laterotrusion, protrusion and retrusion. Each movement will be repeated 5 times and it will remain for 5s."
92327|NCT03465007|Drug|Hydrocortisone|we will give IV Hydrocortisone 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD treatments.
92328|NCT03465007|Drug|Normal saline|we will give IV normal saline 100 mg prior to HD to the patients who developed intra-dialytic hypotension and monitor their BP response during the HD
92329|NCT03464994|Diagnostic Test|ophthalmological examination|"Refraction~Best corrected visual acuity~Intraocular pressure~Slit lamp examination with vital dye (Oxford grading)~Tear break-up time (TBUT)~Schirmer I testing~Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch & Lomb) corneal videotopographies~Pachymetry~Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25)~questionnaire about ichthyosis severity~questionnaire about life quality specifically for patient presenting ichthyosis"
92330|NCT03464968|Drug|Oxaliplatin,5FU, leucovorin|mFOLFOX
92331|NCT03464968|Drug|irinotecan,5FU, leucovorin|mFOLFIRI
92332|NCT03464955|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
92333|NCT03464942|Radiation|SABR|Single Dose Group: this group will receive 20 Gy of radiation in a single dose within 10 days of randomisation Fractionated Dose: Participants in this dose will receive a total of 24Gy of radiation given as 3 separate fractions of 8 Gy each.
92334|NCT03464942|Drug|Atezolizumab|All participants will commence atezolizumab (within 5 days of last SABR dose) 1200 mg every 3 weeks for 24 months
92335|NCT03464929|Device|Airtraq indirect laryngoscopy|Attempt to intubation using the Airtraq device
92336|NCT03464929|Device|King Vision indirect laryngoscopy|Attempt to intubation using the King Vision device
92337|NCT03464916|Biological|CAR2 Anti-CD38 A2 CAR-T Cells|Autologous IV infusion; dose-escalation
92338|NCT03464890|Other|P926 - LICHTENA DermAD CREMA VISO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
92339|NCT03464890|Other|P927 - LICHTENA DermAD CREMA CORPO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
92340|NCT03464890|Other|P926 - LICHTENA DermAD CREMA VISO - PLACEBO|The study product was applied on a skin areas of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
92341|NCT03464890|Other|Untreated control area|Untreated skin area of about 14 cm2 of the forearm, defined turning on the right and left side in accordance with a randomization list, on which an erythema has been experimentally induced by repeated tape stripping.
92342|NCT03464877|Other|Multi-station full-body supervised exercise program|The exercise program was 6-week duration, 2-3 visits per week. It was composed of 7 stations, each consisting of numerous exercises of increasing difficulty. The exercises were grouped together as follows: Hip strengthening and control (Station 1); The squat and its variants (Station 2); Elastic bands and the Bodyblade (Station 3); Abdominal planks and their variants (Station 4); Abdominal strengthening (Station 5); Back extensor strengthening (Station 6); and Lifting techniques (Station 7).
92343|NCT03464864|Drug|Treprostinil Inhalation Powder|Single ascending dose
92344|NCT03464851|Diagnostic Test|Carotid Stenotic Scan (CSS)|"Placement of the CSS instrument on the carotid arteries to measure degree of stenosis~of the carotid artery. The CSS scan takes about 1-2 minutes to gather data for real-time analysis by the processor on the device cart."
92345|NCT03464838|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a form of noninvasive brain stimulation that applies a very low electrical current to the scalp. tDCS will be applied with intensity of 1.8 milliamps in real stimulation condition and 0 milliamps in sham condition, during 20 minutes, using a high density (HD) tDCS montage over the Prefrontal Cortex (PFC). Electroencephalography (EEG) resting state activity will be measured before and after tDCS.
92346|NCT03464838|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is the current treatment available for disordered gamblers at the UK National Problem Gambling Clinic. During the therapy sessions patients acquire learning strategies, cognitive and motivational elements, and develop personal skills to help them improve the understanding of their problems.
92347|NCT03464825|Other|Specific and progressive balance training|Specific and progressive balance training for the intervention group
92348|NCT03464812|Behavioral|DSMES|It is primarily an educational intervention that is focused on assisting patients improve their management and coping with type 2 diabetes.
92349|NCT03464799|Other|immunohistochemical staining|immunohistochemical staining
92350|NCT03464786|Device|Lando® absorbable collagen membrane|Subjects who are fit for the study will be randomized to either intervention arms.
92351|NCT03464786|Device|Geistlich Bio-Gide resorbable bilayer membrane|Subjects who are fit for the study will be randomized to either intervention arms.
92352|NCT03464773|Other|PIUO Pathway|See arm descriptions
92353|NCT03464760|Dietary Supplement|3.5g of spirulina per day in 1% silicone|5 tablets of 700mg per day
92354|NCT03464760|Dietary Supplement|placebo|5 tablets per day of potato-based placebo
92355|NCT03464747|Device|EIRUS system (Maquet Critical Care AB, 17154, Solna, Sweden)|continuous measurement of venous lactate through a central venous catheter by microdialysis
92356|NCT03464734|Drug|Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel|At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.
92357|NCT03464721|Device|issued with SMART ANGEL device|patients will use the technology at home to record and transmit data for blood pressure and oxygen saturation
92358|NCT03464708|Dietary Supplement|HMB|Powder form
92359|NCT03464708|Other|Lactose (placebo)|Powder form
92360|NCT03464695|Device|O2matic|Continous measurement of SpO2 during an admission with COPD, and closed-loop control of oxygen-delivery to maintain SpO2 within a target interval.
92361|NCT03464682|Drug|HS-25 10mg|HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet
92362|NCT03464682|Drug|HS-25 10mg combination with Atorvastatin|HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet
92363|NCT03464682|Drug|HS-25 20mg combination with Atorvastatin|HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet
92364|NCT03464682|Drug|Atorvastatin 10mg|Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets
92365|NCT03464682|Drug|HS-25 20mg|HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet
92366|NCT03464682|Drug|Placebe of HS-25 and Atorvastatin|Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
92367|NCT03464669|Other|Prenatal education|Observational study : natural distribution of participants between groups
92368|NCT03464656|Drug|Fairhaven Pro for men|"Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~B12 (1000 mcg)~Zinc (30 mg)~Selenium (140 mcg)~Arginine (350 mg)~L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~CoQ10 (200 mg)~Vitamin C (120 mg) and Vitamin E (200 IU)"
92369|NCT03464656|Diagnostic Test|Semen analysis|"Full semen analysis according to WHO semen laboratory manual 5th edition will be done pre and 3 months post-treatment.~After complete liquefaction, each sample was evaluated for both macroscopic parameters such as color, pH, ejaculate volume, age of the sample and viscosity. An aliquot of the sample was examined for sperm concentration, total sperm count, total and progressive motility and sperm morphology using the WHO fifth edition guidelines (WHO, 2010). Semen analysis was done manually using a hemocytometer. Sperm motility was assessed and categorized as progressive or non-progressive. Morphology was assessed by a single experienced technician using the Diff-Quik staining protocol. Kruger's strict criteria were used for morphology assessment with 4% normal morphology as a cut-off (WHO, 2010)."
92370|NCT03464656|Diagnostic Test|Sperm DNA fragmentation|Sperm DNA fragmentation was evaluated using the Halosperm kit from Halotech DNA, S.L. (Madrid, Spain) as per manufacturer instructions. The method is based on the sperm chromatin dispersion test (Fernández et al., 2003). A minimum of 500 spermatozoa were scored and reported as percentage of sperm with spermatozoa with fragmented DNA. Normal value is measure at a cut-off value of more than 30%
92371|NCT03464656|Diagnostic Test|Static Oxidation reduction potential in semen|Oxidative stress was assessed by measuring the static oxidation-reduction potential (sORP) of neat liquefied semen samples using the MiOXSYSTM System (Aytu Bioscience, Inc., Englewood, USA). This is a galvanostatic measure of the electron transfer from reductants (antioxidants) to oxidants under a steady low voltage reducing current. Thus, providing an aggregate measure of all current oxidant activity and antioxidant activity in a sample. Higher sORP values (millivolts, mV) indicate a higher oxidant activity relative to the antioxidant activity and therefore greater state of oxidative stress.
92372|NCT03464643|Other|embryo culture|Single embryo culture means only one embryo is cultured in one drop, and the group culture refers to culture of 2-5 embryos in one drop. The main advantage of group culture may be secreting some paracrine cytokines by embryos and benefit each other; and the possible disadvantage of group culture is that embryo secreting of some harmful substances which accumulated to a certain extent will damage the developmental potential of embryos. The advantages and disadvantages of single embryo culture are contrary to group culture.
92373|NCT03464630|Behavioral|Mom & Baby Net|Skills based maternal depression treatment and targeted infant social-communication promotion
92374|NCT03464630|Behavioral|Developmental Awareness System|Depression and infant develop awareness
92375|NCT03464604|Diagnostic Test|active|Pre-screening for melanoma by qualified nurse
92376|NCT03464578|Procedure|Therapy of proximal humeral fractures (irrespective conservative or operative)|
92377|NCT03464565|Device|Penumbra System|Penumbra System
92378|NCT03464552|Drug|Celecoxib 200mg|oral capsule 3 hours before procedure
92379|NCT03464552|Procedure|Colposcopic guided biopsy|Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
92380|NCT03464552|Drug|Placebo oral capsule|oral capsule 3 hours before procedure
92381|NCT03464539|Dietary Supplement|PG low molecular weight chitosan|The product 1000 mg of Polyglucosamine was administered three times per day before and in between main meals
92382|NCT03464526|Drug|Orvepitant|Tablet, once daily, oral
92383|NCT03464526|Drug|Placebo|Tablet, once daily, oral
92384|NCT03464513|Device|Multislice CT Angiography|Multislice CT angiography (MSCTA) provides a relatively non-invasive and effective way of localising the source of bleeding, especially in patients with continuous bleeding.
92385|NCT03464500|Dietary Supplement|AMAZ-02 Low dose|AMAZ-02 containing softgels
92386|NCT03464500|Dietary Supplement|AMAZ-02 High Dose|AMAZ-02 containing softgels
92387|NCT03464500|Dietary Supplement|Placebo|Placebo containing softgels
92388|NCT03464487|Dietary Supplement|Low Glycemic Index Therapy Diet|Low Glycemic Index Therapy Diet allows only carbohydrates with Glycemic Index less than 50 and also restricts daily carbohydrate intake to less than 40-60 gram per day.
92389|NCT03464474|Device|digital holographic microscopy|Colonic biopsies from all patients will be assessed using digital holographic microscopy in comparison to the existing Goldstandard (histopathological analysis).
92390|NCT03464461|Drug|Ketorolac|IV drug
92391|NCT03464448|Drug|Teriflunomide|AUBAGIO® (teriflunomide) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), which inhibits pyrimidine de novo synthesis by blocking the enzyme dihydroorotate dehydrogenase.
92392|NCT03464435|Drug|Tacrolimus|All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. 0.1% tacrolimus will be continued for the last 5 months.
92393|NCT03464422|Behavioral|ESTEEM conneCT|"Thirty participants will be assigned to one of two groups according to their HIV status. Twelve group sessions will take place at regular times once per week over the course of four months. The group will be closed, in that no new members will be allowed to join after the first week in order to promote open self-disclosure and trust among group members."
92394|NCT03464409|Other|Semi-structured interview|Semi-structured interviews to be conducted by a study team member.
92395|NCT03464409|Other|Spinal Cord Independence Measure (SCIM-SR)|The Spinal Cord Independence Measure - Self Report (SCIM-SR) is a self-report instrument for assessing functional independence of persons with spinal cord injury.
92396|NCT03464409|Other|SF-36|A health-related quality of life (QoL) self-reported survey.
92397|NCT03464396|Other|Bedside Physiology study|A 90-minute recording in conjunction with the respiratory evaluations using standard recording equipment that includes a conventional pulse oximeter, an EEG, an airflow sampling catheter near the nose, and respiratory inductance plethysmography (RIP) bands. Standard clinical bedside monitoring will continue during the respiratory evaluations.
92398|NCT03464396|Other|Carotid Body Function Test|Infants without nasal cannula will have a nasal cannula placed in their nares. After a 15-minute baseline period and during quiet sleep, the infant will then be exposed to 30 seconds of 100% O2 by increasing FiO2. This test will be repeated 3 times, with at least 3 minutes between tests to allow for return of SpO2 to baseline values. If oxygen saturations increase to 99% for 15 seconds or the infant is apneic for greater than 5 seconds following initiation of 100% O2, the test will be stopped and FiO2 brought back to baseline. Infants in the NICU will be monitored continuously with heart rate, respiratory rate, and SpO2% for 12 hours after Carotid Body Function Test according to NICU standards. Infants discharge who return for Carotid Body Function Test at 40 and 52 weeks PMA will be monitored continuously for 1 hour after the test is finished.
92399|NCT03464396|Other|Room Air Challenge|Infants receiving nasal cannula high flow support 3 liters per minute (LPM) or less with or without supplemental O2 at 36 weeks PMA will be eligible. After a 15-minute quiet sleep period, infants' FiO2 will be weaned, in 0.20 decrements for 5 min intervals. Flow then decreased in 10 min intervals, initially in 1 LPM decrement until nasal cannula flow is 1LPM, and then decreased by 50% decrements to 0.125 LPM then off. If the infant is weaned to room air alone for 15 minutes, not meeting failure criteria, he/she has passed the RAC. Failure of the RAC is defined as occurring when SpO2% falls below 80%, even briefly, or remains less than 90% for 5 consecutive minutes any time during the test, bradycardia (HR < 80 bpmx 10 sec) or persistent apnea despite stimulation. Infant is returned to the level of support provided before the RAC begun if meets any failure criteria.
92400|NCT03464396|Other|Hypoxia Challenge Test|Infant's breathing room air alone at 36 weeks PMA are eligible. A nasal cannula will be placed prior to a 15-minute period of quiet sleep. During the 15 minutes of quiet sleep, the infant is required to maintain a SpO2 of > 92% in order to undergo the HCT. After the15-minute baseline recording, HCT will begin using FiO2 = 0.18 for 5 minutes. If infant does not meet failure criteria, infant will be given FiO2 0.15 for 10 minutes. Failure criteria is SpO2% < 80% even briefly, or SpO2% 80% to 85% for 30 seconds, bradycardia (HR < 80 bpmx 10 sec) or persistent apnea despite stimulation. If an infant meets criterion for failure, supplemental O2 with FiO2 100% will be started until SpO2% is sustained between 90% and 95%. At that time, the infant will be returned to RA.
92401|NCT03464396|Other|Effects of Nasal Cannula Flow|"Infants will have a standard nasal catheter in place at time of testing (NeoTech Premature RAM Cannula). A 15-minute baseline recording of all physiologic study parameters prior to initiation. Tested in three groups of infants.~28 and 32 weeks PMA flow rates increased after a 15-minute baseline period to 3LPM, or by 1LPM to a max of 5LPM for duration of 15 minutes.~Infant's that fail the RAC or HCT at 36 weeks with periodic breathing will have high flow at 3LPM started for 2 minutes or until periodic breathing stops.~Breathing room air alone at 40 and 52 weeks PMA will have a high flow catheter inserted in their nares. If they have periodic breathing lasting longer than 1 minute during the 15-minute baseline period, flow at 3LPM will be started and maintained for 2 minutes or until periodic breathing stops."
92402|NCT03464396|Diagnostic Test|Magnetic Resonance Imaging|A non-sedating MRI scan will be performed on 3 subsets of infants at 37-40 weeks PMA, or when infant is within one week of discharge from the NICU. Standard images as well as research images will be obtained. The research images use the same MRI scanner and collection techniques as standard clinical imaging, but provide a more detailed examination of brain anatomy and injury. Collection of these sequences using our standard non-sedated acquisition practices for infants is well tolerated. Infants will be placed in scanner by registered nurse accompanied by radiology technician to assure infants' comfort during scan. Infant will remain on cardio-respiratory monitor during MRI via a pulse oximetry probe. It will take no longer than one hour to complete MRI scan including transportation to radiology unit.
92403|NCT03464396|Diagnostic Test|Echocardiogram|An echocardiogram (referred to as an ultrasound of the heart on the consent form) will be performed to assess cardiac structure and function. Echocardiograms are performed routinely in premature newborns in the NICU. The Echocardiogram will be performed at the infant bedside and will be coordinated with bedside nurse. The infant will remain on a cardio-respiratory monitor during the echocardiogram for approximately 15 minutes.
92404|NCT03464396|Other|Blood Sample|Infants that have echocardiograms will have a blood sample collected near the time the echocardiogram is obtained, 3-blood samples total. The blood sample will only be collected with parental permission on an opt-in or out-basis and collected only with routine clinical labs.
92405|NCT03464383|Drug|Escitalopram 10mg|Participants will be given escitalopram 10mg by mouth daily and will be followed up with at 2, 4, 6, 8, and 10 weeks. Medication will be adjusted if side effects occur. If unable to tolerate escitalopram, then venlafaxine XR (Effexor XR) 37.5mg will be substituted.
92406|NCT03464383|Other|Referral to Psychiatry|Participants randomized to control will have a psychiatry referral order placed by the treating epileptologist under typical care circumstances. This will be an internal or external referral order based on patient preference. If external, the order will be printed along with instructions for the patient to follow to find a provider covered by insurance.
92407|NCT03464383|Other|Survey only|One time survey will be offered to individuals who are found to have anxiety or depression symptoms on screening but who are ineligible for the treatment component of the study, or who decline the treatment study.
92408|NCT03464370|Other|Measure of emotional stressors|"For the Epileptic Group~Rapid interrogation, completing the clinical data~A scale of impact of the precipitating factors of crises~An emotional Stroop~A task of detecting emotional targets against threatening information~A measure of the perception of emotions using film clips~A scale of measurement of perceived stress~The transfer of psychiatric scales~For the healthy volunteers group :~A rapid interrogation, gathering the possible medical history, the level of studies, the manual laterality~An emotional Stroop~A task of detecting emotional targets against threatening information~A scale of measurement of perceived stress~A measure of the perception of emotions using film clips~A rapid neuropsychological assessment"
92478|NCT03463928|Biological|donor-derived CD19/22 bispecific CAR-T cells or CD19-directed CAR-T cells; donor-derived-HSCT|The allo-CAR-T cells will be infused in a fractionated manner, 1/3 on day 0, 2/3 on day 1.The allo-HSCT will be infused on day 2.
92409|NCT03464357|Radiation|fMRI|"The BOLD (Blood-Oxygen-Level Dependent) signal obtained by fMRI reflects the rate of oxygenation of the blood in the brain. However, the hemodynamic response that corresponds to an inflow of oxygenated blood increases in regions that consume energy. Thus, it is possible, by the study of the BOLD signal, to know with a great precision the regions of the brain specially active during a given task.~The recorded signals reflect a neuronal activation. For each eye, recordings with and without flash visual stimulation are performed alternately."
92410|NCT03464344|Other|neurological, neuropsychological and MRI evaluation|neurological, neuropsychological and MRI evaluation
92411|NCT03464331|Behavioral|Zero-time exercises|The Investigators/research staff (RS) will help EXP download, operate the Zero-time exercises (ZTE) app and ZTE e-diary. The EXP can enter their goal for the chosen exercise by setting the target duration or number of completed repetitions, review their previous record, and compare their exercise frequency and time ranking with those of the other EXP. After the EXP uploads the goal and results to the ZTE e-diary, the data will be automatically sent to the ZTE app database for data analysis. The EXP will be given a paper diary to record their Zero-time exercises (ZTE). Twenty-five EXP will be given activity trackers (e.g. Fitbit) to record their steps/motion throughout the 3 months.
92412|NCT03464331|Behavioral|relaxation exercises and deep-breathing exercises|The Investigators/RS will teach the CON group (CON) to do relaxation exercises (RE) and deep-breathing exercises (DBE) for at least 30 mins every day. They will be helped download and use the electronic diary (CON_e-diary) to record their RE and DBE. The CON will also be given a paper diary to record RE and DBE they have done if they prefer to use paper diary.
92413|NCT03464305|Drug|acetylsalicylic acid|Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy
92414|NCT03464305|Drug|Placebo|Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.
92415|NCT03464292|Drug|Capsaicin Patch 8% or 0.1% Capsaicin Cream|0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
92416|NCT03464292|Other|Vehicle Patch|Control patch will be the same topical solution but will not contain capsaicin.
92417|NCT03464279|Behavioral|Nudge using Behavioral Economic Interventions|
92418|NCT03464279|Behavioral|Standard Practices to Reduce Health System Antibiotic Prescription|
92419|NCT03464266|Combination Product|FTC/TDF and DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
92420|NCT03464266|Drug|FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
92421|NCT03464266|Drug|DMPA|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
92422|NCT03464266|Other|Neither DMPA nor FTC/TDF|The primary analysis will be separate comparisons of the annualized rates of change in BMD and TBS of the spine and hip between women using PrEP and DMPA concurrently versus women using DMPA only (comparison 1), women using PrEP only (comparison 2), and women using neither (comparison 3). Analyses will account for baseline BMD.
92423|NCT03464253|Device|Performance of the transcranial Doppler (TCD)|Within 24 hour before the operation, TCD is performed using Siemens Acuson X300 machine with ultrasound frequency is 1 - 5 MHz probe to measure Mean Velocity and Pulsatility Index in the right middle cerebral artery.postoperatively, TCD study is performed twice at 24h and 48h after spinal anesthesia. For 5 days postoperatively, the Patients are assessed clinically for the occurrence of headache. Patients who developed PDPH will be identified and their pre and post puncture measurements will be compared with the corresponding measurements of PDPH free patients.
92424|NCT03464240|Dietary Supplement|Glucose|glucose drink
92425|NCT03464240|Dietary Supplement|Water|control
92426|NCT03464227|Drug|UCB0107|"Pharmaceutical form: solution for infusion~Route of administration: intravenous use"
92427|NCT03464227|Other|Placebo|"Pharmaceutical form: intravenous infusion~Route of administration: intravenous use"
92428|NCT03464214|Device|Neck Muscle Vibration|Local vibration device applied on neck muscles for 8 weeks
92429|NCT03464214|Behavioral|Cervical Stabilization Exercises|Cervical stabilization exercises performed by healty individuals for 8 weeks
92430|NCT03464201|Drug|Enzalutamide 40 MG|Enzalutamide 160 mg p.o. every day
92431|NCT03464188|Behavioral|Project Cornerstone|"Project Cornerstone basic elements are:~The intervention is lay navigator-led with regular supervision by a specialist palliative care clinician;~6 base telephone/in-person sessions: Sessions cover specific topics (every 1-2 weeks, 20-60 minutes/session; by phone or in-person), followed by monthly follow-up and additional coaching sessions as needed;~Regular caregiver distress thermometer screening and problem support and self-care coaching.~Caregivers receive a Project Cornerstone Family Supporting Family (FSF) Binder that organizes intervention materials and contains educational information pertaining to the 6 base coaching sessions. Project Cornerstone begins within 60 days of a care recipient being diagnosed with advanced cancer and ends 1 year after care recipient death."
92432|NCT03464175|Device|Aerogen Solo®|Aerosol particles are generated by a vibrating-mesh nebulizer specifically designed for mechanical ventilation
92433|NCT03464175|Device|Heated-humidified circuit|It will be left on during the transfer and the nebulization in group 1
92434|NCT03464175|Device|Heated-humidified circuit|It will be turned off 15 minutes before the transfer in the Nuclear Medicine Department in group 2 (nebulization performed 30 minutes after turning off the heated-humidifier).
92435|NCT03464175|Device|Dry ventilator circuit specific for aerosol therapy|Streamlined components, integrated T-piece for the nebulizer at 15 cm of the Y piece
92436|NCT03464175|Device|Conventional dry ventilator circuit with HME filter|The nebulizer is placed between the filter and the endotracheal tube.
92520|NCT03463642|Dietary Supplement|vitamin D3|100,000IU
92437|NCT03464162|Behavioral|Social Network Meetings|Social Network Meetings are a type of family therapy that includes clients and members of their social network.The social network may include family members, friends or anyone else that clients believe can help them move toward recovery. The meetings will focus on improving communication within the social network.
92438|NCT03464149|Diagnostic Test|One armed study, blood from each patient is analysed by four assays ( two 3rd generation and two 2nd generation assays)|Intact PTH Assay (Siemens Healthcare Diagnostics Inc); LIAISON 1-84 PTH Assay (Diasorin); PTH (1-84), biointact (Roche Diagnostics); PTH, intact (Roche Diagnostics)
92444|NCT03464123|Other|Standard cardiopulmonary resuscitation|Standard Advanced Life Support based on guidelines 2015, including mechanical chest compression device
92445|NCT03464110|Behavioral|Communication Intervention|. The intervention will contain elements of Motivational Interviewing coaching but also will teach providers how to address patient emotion and increase the efficiency of their visits. Clinicians randomized to the intervention will receive a tailored communication coaching intervention that includes didactic elements, audio recording encounters and providing feedback, and role-playing.
92446|NCT03464097|Drug|Ozanimod|Ozanimod
92447|NCT03464097|Other|Placebo|Placebo
92448|NCT03464084|Drug|placebo|Capsules containing microcrystalline cellulose
92449|NCT03464084|Dietary Supplement|melatonin|5 mg of melatonin per os.
92450|NCT03464084|Other|bright light|room light will be bright
92451|NCT03464084|Other|dim light|room light will be dim
92452|NCT03464071|Device|Hyperinflation with mechanical ventilator|increase in initial positive inspiratory pressure until reaching a peak pressure of 40 cmH2O and PEEP equal to 7 cmH2O
92453|NCT03464071|Device|Manual hyperinflation|the manual resuscitation bag will be connected to the oxygen system at five liters per minute. The participant will be disconnected from the ventilator and then initiate a slow inspiration with inspiratory pause followed by abrupt expiration, totaling twelve (12) cycles / minute.
92454|NCT03464058|Drug|BOS172767 tablets|Oral tablets
92455|NCT03464058|Drug|BOS172767 liquid capsules|Oral capsules
92456|NCT03464058|Drug|BOS172767 micronized capsules|Oral capsules
92457|NCT03464058|Drug|BOS172767 immediate release capsules|Oral capsules
92458|NCT03464058|Drug|BOS172767 matching placebo capsules|Oral capsules
92459|NCT03464058|Drug|BOS172767 matching placebo tablets|Oral tablets
92460|NCT03464058|Drug|Rabeprazole|Oral tablets
92461|NCT03464045|Drug|empagliflozin|drug
92462|NCT03464045|Drug|DPP-4 inhibitors|drug
92463|NCT03464045|Drug|SGLT-2 inhibitors|drug
92464|NCT03464032|Drug|BCD-135|Monoclonal anti-PD-L1 antibody
92465|NCT03464019|Drug|Etripamil|Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.
92466|NCT03464019|Drug|Placebo|Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System.
92467|NCT03464019|Device|Aptar Pharma Nasal Spray|Study drug and placebo will be administered via the Aptar Pharma Nasal Spray.
92468|NCT03464006|Other|Online Support Module|The online support module is a computer software program which helps patients monitor factors related to their peripheral artery disease
92469|NCT03464006|Other|Standard of Care|The normal care that patients receive at the institution.
92470|NCT03463993|Drug|Tranexamic Acid|TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.
92471|NCT03463993|Drug|Oxytocin|5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section.
92472|NCT03463980|Behavioral|Compassion meditation (CM)|CM session: 30 minute check-in regarding the participants' levels of suicidal ideation, as well as a discussion of current life stress and weekly meditation practice; a 30 minute didactic session that will describe the meditative technique introduced during the week; and a 30 minute guided meditation session. Participants are also encouraged to meditate at least 30 minutes a day.
92473|NCT03463980|Behavioral|Support group (SG)|SG session: 90 minutes to talk about current concerns and to receive support and guidance from other group members and the leaders.
92474|NCT03463967|Dietary Supplement|Lycopene-enriched tomato juice|Energy-restricted diet supplemented with Lycopene-enriched tomato juice
92475|NCT03463967|Other|Energy-restricted diet|
92476|NCT03463954|Device|Novilase Laser ablation|Image-guided, percutaneous laser ablation of breast tumors
92477|NCT03463941|Behavioral|Peer Support Dyad Intervention|"Phase I: At baseline and at post-intervention, participant height, weight, BMI, fruit and vegetable intake and exercise habits will be measured. Participants will complete surveys and meet each week to learn about nutrition and exercise.~Phase II: Dyads will attend a communication training session to discuss 1) benefits of working with a partner; 2) supportive communication tips; and 3) expected activities for the next 8 weeks, including filling out daily logs. After the training session, the dyads will work together to achieve their health goals. The dyads will return to the church for two check in sessions. At these sessions, participants will turn in their logs, and be weighed. At the end of the intervention, BMI will be reassessed, and surveys and interviews will be completed."
92521|NCT03463642|Dietary Supplement|Pill|Dicalcium phosphate, microcrystalline cellulose, silicium dioxide, magnesium stearate
92522|NCT03463642|Dietary Supplement|orange syrup|100 drops orange syrup
92479|NCT03463915|Drug|Bladder instillation WITH triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), 0.5% bupivacaine (10 mL of 5 mg/mL) plus triamcinolone acetonide (1 vial, 40 milligrams (mg)/1 milliliters (mL).
92480|NCT03463915|Drug|Bladder instillation WITHOUT triamcinolone acetonide|Bladder instillation mixture of heparin (10,000 units), 2% viscous lidocaine (10 mL), 8.4% sodium bicarbonate (15 mL of 1 mEq/mL), and 0.5% bupivacaine (10 mL of 5 mg/mL).
92481|NCT03463902|Device|left IFG anodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG anodal stimulation~2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
92482|NCT03463902|Device|left IFG cathodal|"Single session of transcranial direct current stimulation (tDCS) over left IFG cathodal stimulation~2 mA Stimulation of 10 min, cathodal electrode over left IFG, anodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop"
92483|NCT03463902|Device|left IPL anodal|Single session of transcranial direct current stimulation (tDCS) over left IPL anodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IPL, cathodal electrode over right IPL, 30 sec ramp to start and 30 sec ramp to stop
92484|NCT03463902|Device|left IPL cathodal|Single session of transcranial direct current stimulation (tDCS) over left IPL cathodal stimulation 2 mA Stimulation of 10 min, anodal electrode over left IFG, cathodal electrode over right IFG, 30 sec ramp to start and 30 sec ramp to stop
92485|NCT03463902|Device|Placebo|Single session of placebo tDCS over left IFG 10 min duration, 30 sec ramp during start and end
92486|NCT03463889|Drug|Gallium Ga 68-labeled PSMA-11|Given IV
92487|NCT03463889|Procedure|Magnetic Resonance Imaging|Undergo MRI in combination with PET
92488|NCT03463889|Procedure|Positron Emission Tomography (PET)|Undergo PET in combination with MRI
92489|NCT03463876|Drug|SHR 1210+apatinib|SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
92490|NCT03463863|Procedure|rectus sheath midurethral sling|
92491|NCT03463850|Radiation|Dual Energy CT (DECT)|Dual Energy CT (DECT)
92492|NCT03463850|Radiation|DEXA|Dual-energy x-ray absorptiometry for measurement of bone mineral density
92493|NCT03463837|Device|Treatment with JUUL 5%, Virginia Tobacco|JUUL 5%, ENDS for 5-days in confinement
92494|NCT03463837|Device|Treatment with JUUL 5%, Cool Mint, ENDS|JUUL 5%, ENDS for 5-days in confinement
92495|NCT03463837|Device|Treatment with JUUL 5%, Mango, ENDS|JUUL 5%, ENDS for 5-days in confinement
92496|NCT03463837|Device|JUUL 5%, Creme Bruele, ENDS|JUUL 5%, ENDS for 5-days in confinement
92497|NCT03463837|Other|Combustible cigarette|Exclusive use of combustible cigarette for 5 days in confinement.
92498|NCT03463837|Other|Smoking Cessation|No smoking for 5-days in confinement.
92499|NCT03463824|Behavioral|Experimental Group 1|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
92500|NCT03463824|Behavioral|Experimental Group 2|Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
92501|NCT03463811|Diagnostic Test|Lactate concentration in vaginal fluid|Lactate concentration in vaginal fluid
92502|NCT03463798|Device|Sonar|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
92503|NCT03463798|Device|Structured light plethysmography (SLP)|Measurements of chest wall and abdominal wall movement will be performed while subjects are breathing quietly
92504|NCT03463785|Other|cone beam computed tomography|The CBCT data sets of both the Chinese and Dutch OSA patients will be obtained using a NewTom 5G CBCT system (QR systems, Verona, Italy), according to the standard imaging protocol.
92505|NCT03463772|Procedure|standard IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
92506|NCT03463772|Drug|In vitro maturation|Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
92507|NCT03463746|Device|LYRA® gait trainer|The EG will get standard individual physical therapy (5x/week, 45min) whereby three sessions of electromechanical-assisted gait training on LYRA® gait trainer.
92508|NCT03463746|Device|Standard individual physical therapy|The CG will get standard individual physical therapy (5x/week, 45min) without any instrument-based locomotion therapy (i.e. treadmill training, electromechanical/robot-assisted gait training).
92509|NCT03463733|Drug|Hydroxyurea|147-94-4/HYDROXYCARBAMIDE/HYDROXYCARBAMIDE/based on myeloproliferative disorders (MPD) record: SUB08076MIG
92510|NCT03463733|Drug|Temozolomide|85622-93-1 /TEMOZOLOMIDE/TEMOZOLOMIDE/based on myeloproliferative disorders (MPD) record: SUB10889MIG
92511|NCT03463720|Other|Infected|Extremity wound, infected
92512|NCT03463720|Other|Not infected|Extremity wounds, non-infected
92513|NCT03463707|Drug|BP101|Investigational product BP101, nasal spray
92514|NCT03463707|Drug|Placebo|Placebo to Investigational product BP101, nasal spray
92515|NCT03463694|Other|Na Cl solution|~2.6% NaCl solution prepared from sea salt
92516|NCT03463681|Drug|Cabometyx|cabozantinib 60 mg orally once daily
92517|NCT03463668|Device|uncovered metal duodenal prosthesis|Implantation of an uncovered metal duodenal prosthesis for symptomatic tumor stenosis
92518|NCT03463655|Diagnostic Test|cirrhotic albumin|Ascites puncture
92519|NCT03463655|Diagnostic Test|serum albumin|blood punctures
92523|NCT03463642|Other|mineral oil|Paraffinum Liquidum,Isopropyl Palmitate,Parfum
92524|NCT03463642|Dietary Supplement|Penetrator|Tangerine essential oil (10ml)
92525|NCT03463629|Other|Specialized multidisciplinary diabetes team (SMDT) approach|"The implementation of the pilot study will consist of a specialized multidisciplinary diabetes team care (SMDT) that includes endocrinologists, a nurse practitioner, dieticians, pharmacists and a licensed professional counselors (LPCs) to collaborate and coordinate care. Subjects in the pilot study will follow a multidisciplinary team approach process with the following team members: pharmacist, LPC, and dietician.~There will be 3 individualized visits: 1 visit with the counselor (LPC), 1 visit with the Pharmacist, and 1 visit with the Dietician.~In addition, a follow up phone call post visit, that can range from 5 to 30 minutes, will be scheduled from each of the team members during the study. Also, throughout the pilot study participant's blood glucose readings will be monitored weekly via a transmittable wireless patient transmission monitor."
92526|NCT03463629|Other|Traditional model of care|Receive the traditional model of care, but will not receive diabetes education by pharmacists or counseling services
92529|NCT03463590|Device|Bilateral surgical implantation of DBS system to habenula|The DBS device utilized in the present study may include the Medtronic, PINS and SceneRay DBS device depending on patients' choice.
92530|NCT03463564|Device|Insulin pump|Continuous subcutaneous insulin infusion consisting of the delivery of insulin lispro as basal rate and boluses administered before meals.
92531|NCT03463564|Drug|Insulin injections|Four injections of insulin daily consisting in three bolus of a rapid-acting analog lispro or aspart before breakfast, lunch and dinner and one injection of insulin glargine or degludec at bed-time of basal insulin
92532|NCT03463551|Drug|ABL-101|ABL-101 is provided as a sterile phospholipid-based emulsion for intravenous administration.
92533|NCT03463551|Other|0.9% NaCl|Placebo
92534|NCT03463538|Procedure|arthroscopic capsular release|surgical release of shoulder joint capsule
92535|NCT03463538|Procedure|Hydro-dilatation|dilatation of shoulder joint capsule using water pressure under local anesthetic
92536|NCT03463525|Drug|Osimertinib|Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.
92537|NCT03463525|Drug|[11C]osimertinib|Patients will receive 3 single IV microdose administrations of [11C]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.
92538|NCT03463512|Drug|Racecadotril plus ORS|Racecadotril plus ORS
92539|NCT03463512|Drug|ORS|ORS
92540|NCT03463499|Drug|Hyaluronic Acid and Chondroitin Sulfate|Intravesical instillation of Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients.
92541|NCT03463486|Behavioral|Physical activity|50min of endurance training combined with 50min of calisthenics; 1-3x/wekk; 6weeks up to 1year
92542|NCT03463473|Drug|MSB2311 Injection|An intravenous infusion with concentration from 0.3 mg/kg to 20 mg/kg every 3 weeks (Q3W).
92543|NCT03463460|Other|Laboratory Biomarker Analysis|Correlative studies
92544|NCT03463460|Biological|Pembrolizumab|Given IV
92545|NCT03463460|Drug|Sunitinib Malate|Given PO
92546|NCT03463447|Device|Electronic Dynamometer|Mensuration of the handgrip strength of each volunteer using an electronic dynamometer.
92547|NCT03463447|Device|Hydraulic dynamometer|Mensuration of the handgrip strength of each volunteer using a hydraulic dynamometer.
92548|NCT03463434|Device|Air Fluidized Therapy|AFT bed used for pressure injury treatment
92549|NCT03463434|Device|Continuous Low Pressure-LAL|Continuous Low Pressure/Low Air Loss Mattress for Pressure injury treatment
92550|NCT03463408|Drug|nivolumab|240 mg every 2 weeks
92551|NCT03463408|Drug|ipilimumab|1 mg/kg every 6 weeks
92552|NCT03463395|Device|Reza band|Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
92553|NCT03463382|Procedure|Erector Spinae Plane Block|Erector Spinae Plane block will be administered under general anesthesia before the surgery
92554|NCT03463382|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block will be administered under general anesthesia before the surgery
92555|NCT03463382|Drug|Bupivacaine (Block Drug)|0,25% Bupivacaine was used 0,5ml/kg (max. 20cc) for block performances
92559|NCT03463356|Behavioral|Shame Intervention|In the Shame Intervention, participants will meet with a therapist and learn to: 1) Recognize the experience of shame, 2) Understand the connection between shame and social anxiety, 3) Identify shame triggers and vulnerabilities, 4) Identify the thoughts and behaviors that keep participants stuck in shame, and 5) Learn how to use new, healthier thoughts and behaviors that will help participants move through and decrease shame.
92560|NCT03463343|Other|Cervical spine manual manipulation|In the Manual manipulation group, the thrust was applied in the right side of C3/C4 with neutral flexion/extension, ipsilateral side bending and contralateral rotation. Then, a low amplitude, high velocity thrust in rotation was delivered.
92561|NCT03463343|Other|Cervical spine mechanical manipulation|In the Mechanical manipulation group, the Activator instrument was applied on the right transverse apophyses of C3.
92562|NCT03463343|Other|Placebo intervention|The subjects were positioned in the same pre-manipulative position as the manual manipulation group, but the thrust didn't occur. Instead, the position was hold for 3 seconds and then the subject's head returned passively to neutral position.
92563|NCT03463330|Behavioral|Qigong exercise|The Qigong exercise is a series of mild exercise movements.
92564|NCT03463330|Behavioral|Mild body exercise|Participants will be taught of series of similar movements to the Qigong exercise.
92565|NCT03463317|Device|CE-mark approved LAA closure devices|LAA closure with post procedure treatment
92566|NCT03463317|Drug|Acetylsalicylic acid|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulations are not prescribed in this group
92567|NCT03463317|Drug|Clopidogrel|post procedure treatment according to the physicians (recommendation are made in the protocol); oral anticoagulations are not prescribed in this group
92568|NCT03463317|Drug|Dabigatran|Patients allocated to the best medical care group receive either NOAC therapy or VKA
92569|NCT03463317|Drug|Rivaroxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
92570|NCT03463317|Drug|Apixaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
92571|NCT03463317|Drug|Edoxaban|Patients allocated to the best medical care group receive either NOAC therapy or VKA
92572|NCT03463317|Drug|Phenprocoumon|Patients allocated to the best medical care group receive either NOAC therapy or VKA
92573|NCT03463317|Drug|Warfarin|Patients allocated to the best medical care group receive either NOAC therapy or VKA
92574|NCT03463291|Device|MRI|"T1 weighted image.~Fast spin-echoT2 weighted image.~Short inversion recovery (STIR).~T1-fat suppressed images.~Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values."
92575|NCT03463278|Diagnostic Test|Pregnancy Rate|The pregnancy and live birth rate according to number of blastocysts formed in our three groups
92576|NCT03463265|Drug|ABI-009|ABI-009 as single agent or in combination with other agents
92577|NCT03463265|Drug|Bevacizumab|bevacizumab
92578|NCT03463265|Drug|Temozolomide|temozolamide
92579|NCT03463265|Drug|Lomustine|lomustine
92580|NCT03463265|Radiation|radiation|radiation
92581|NCT03463252|Drug|Progesterone|MPA oral 250mg-500mg qd for 3 months per cycle
92582|NCT03463252|Device|Mirena®|levonorgestrel intrauterine sustained release system (LNG-IUS) placed in uterus for 3 months per cycle
92583|NCT03463252|Drug|GnRH agonist|GnRH-a intramuscular injection 3.75mg once a month for 3 months per cycle
92584|NCT03463239|Biological|Autologous tissue engineered corpora|penile tissue construct
92585|NCT03463226|Diagnostic Test|Cardiopulmonary exercise test|Oxygen consumption (VO2) and carbon dioxide output (VCO2) were measured by means of gas exchange on a breath-by-breath basis. The patients were initially monitored for 2 minutes at rest when seated on the ergometer, after that they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue.
92586|NCT03463226|Diagnostic Test|Muscle Sympathetic Nerve Activity|Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 seconds) to obtain a mean voltage display of sympathetic nerve activity.
92587|NCT03463226|Diagnostic Test|Dual-energy X-ray absorptiometry|Dual-energy X-ray absorptiometry (DXA) scan was used to measure total lean mass, body fat and bone mineral content.
92588|NCT03463226|Diagnostic Test|Venous occlusion plethysmography|Venous occlusion plethysmography was used to assess non-invasively blood flow.
92589|NCT03463226|Diagnostic Test|Blood sample collection|Blood samples were drawn in the morning after 12h overnight fasting.
92590|NCT03463226|Diagnostic Test|Dynamometers for Handgrip Strength|Muscle strength was assessed by handgrip dynamometer using the mean value of three attempts.
92591|NCT03463213|Behavioral|SHE Tribe|Social network-based peer-facilitated intervention to promote adoption of health behavior
92592|NCT03463200|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
92593|NCT03463200|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
92594|NCT03463200|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
92595|NCT03463187|Biological|SHR-1314|Administered subcutaneously
92596|NCT03463187|Drug|Placebo|Administered subcutaneously
92597|NCT03463174|Procedure|Mandibular overdenture|Placement of an implant in the mandibular midline.
92598|NCT03463174|Other|Mandibular complete denture|No intervention.
92599|NCT03463161|Drug|Pembrolizumab|Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.
92600|NCT03463161|Drug|Epacadostat|Epacadostat (100mg) taken by mouth twice a day.
92601|NCT03463135|Drug|Glucopyranosyl Lipid A (GLA)|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
92602|NCT03463135|Drug|Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Pharmaceutical form:Solution Route of administration: Sublingual
92603|NCT03463135|Drug|Placebo for GLA|Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual
92604|NCT03463135|Drug|Placebo for SLIT PE|Pharmaceutical form:Solution Route of administration: Sublingual
92605|NCT03463122|Device|field of regard-focused visual exploration therapy|field of regard-focused visual exploration therapy in addition to conventional therapy
92606|NCT03463122|Other|conventional therapy|conventional therapy for stroke rehabilitation
92607|NCT03463109|Other|Electrocutaneous stimulation|Painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the participants' back. Participants will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation.
92608|NCT03463109|Other|Assessment + Electrocutaneous stimulation|"Patients will be asked to provide information about their lifestyle, level of disability, actual pain and general pain, assessment of kinesiophobia and health status.~Subsequently, painful electrocutaneous stimuli will be randomly delivered to electrodes positioned in a random order on the patients' back. Patients will be instructed to draw with a stylus pen on a digital body chart displayed on a tablet where they will perceive each painful stimulation."
92609|NCT03463096|Other|High G acceleration on a long-arm human centrifuge|Gx (chest-to-back) and Gz (head-to-toe)
92610|NCT03463083|Drug|Dexmedetomidine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgery an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
92611|NCT03463083|Drug|Bupivacaine|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
92612|NCT03463083|Drug|Fentanyl|"All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~The pain score, by using VAS~Onset of analgesia (fall of VAS<4 ).~Peak level of analgesia ( VAS score 0).~Duration of analgesia (once the patient asks fwith VAS>4).~Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale>1 Also deep sedation Ramsay sedation scale>3 , And shivering and hypotension."
92613|NCT03463070|Drug|rectal misoprostol 600mg|70 women who received 600 mg misoprostol postoperatively at operating theatre
92614|NCT03463057|Drug|Atezolizumab|Intervention Atezolizumab starts after 6 - 8 R-CHOP induction cycles (Rituximab, Cyclophosphamide, Hydroxo-doxorubicin, Vincristine and Prednisone (R-CHOP)); 18 cycles Atezolizumab followed by 12 months of observation
92615|NCT03463044|Drug|nangibotide|Continous i.v. infusion
92616|NCT03463044|Drug|Placebo|Placebo
92617|NCT03463031|Drug|GSP 301 NS|1 spray in each nostril twice daily for 14 days
92618|NCT03463031|Drug|GSP 301 Placebo NS|1 spray in each nostril twice daily for 14 days
92619|NCT03463018|Dietary Supplement|Echinacea angustifolia|20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
92620|NCT03463018|Dietary Supplement|Placebo|Placebo tablet containing matching excipients to the active intervention
92621|NCT03463005|Other|Royal jelly|The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
92622|NCT03463005|Procedure|IUI|Subjects in IUI group received 75 units of FSH from the second day of the cycle.
92623|NCT03462992|Diagnostic Test|MonoMark|MonoMark (also known under the registered trademark ColonoKit), is a monocyte-based test using a transcriptomic signature and a mathematical predictive model aimed at discriminating between healthy individuals and CRC patients.
92624|NCT03462979|Device|Immunochromatographic lateral flow test|The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
92625|NCT03462966|Drug|Rifaximin|Rifaximin will be administered to patients diagnosed with IBS-D or IBS-M to evaluate whether the medication is effective in decreasing rectal hypersensitivity. The secondary objective of the study is to assess the role of SIBO in rectal sensitivity.
92626|NCT03462953|Procedure|Gingival tissue samples will be harvested|"Gingival tissue samples will be harvested during the premolar extraction (Orthodontic ttt) or third molar extraction for the healthy controls and during periodontal surgery or extraction of hopeless teeth with periodontal disease ..~The dissected gingival samples will be washed in saline solution and fixed in 4% buffered formalin for 48 hours, dehydrated in ascending grades of ethyl alcohol, cleared in xylene and embedded in paraffin and will be subjected to the following:.~Sections of 4-5 µm in thickness will be obtained, deparaffinized, rehydrated and subjected to histological staining and histomorphometric analysis.~Real time- PCR for TGF-B1 ,Vimenten , E-Cadherin ."
92627|NCT03462940|Dietary Supplement|Tauroursodeoxycholic acid|Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
92628|NCT03462927|Drug|MC2-01 Cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%)
92629|NCT03462927|Drug|CAL/BDP combination|Calcipotriene/betamethasone (calcipotriene/ betamethasone dipropionate, w/w 0.005%/0.064%)
92630|NCT03462901|Procedure|Percutaneous intramedullary fixation of displaced midshaft clavicular fractures .|A group of 15 patients admitted to Assiut university with midshaft clavicular fractures treated by operative fixation of the fracture by single elastic rod through medial approach under image intensifier
92631|NCT03462862|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
92632|NCT03462862|Other|Bre-Flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, poly-amide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon removable denture is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
92633|NCT03462849|Other|increase in positive end expiratory pressure|increase in positive end expiratory pressure from 5 to 10 then 15 cmH2O then at the value for trans pulmonary end expiratory pressure amounting to 3 cmH2O
92634|NCT03462836|Drug|IV ketamine/lidocaine/IV PCA apply|In the MA group, 1.0 mg / kg of ketamine is diluted to a total volume of 10 ml. Slowly apply for 1 minute during surgical drape. 1 mg / kg of Lidocaine is loaded at the beginning of surgery. Lidocaine 1.5 mg / kg / hr is administered until the end of the operation.
92635|NCT03462836|Drug|IV PCA only apply|IV PCA (fentanyl 10mcg/kg + nefopam (Acupan®) 80mg + Ramosetron (Nasea®) ) apply 30min before end of surgery.
92636|NCT03462823|Device|Osteoconductive scaffold-hamstring tendon composite repair|The device under study is a composite bone substitute composed of a natural mineral matrix of bovine origin, reinforced with biodegradable synthetic polymers and natural collagen derivatives of bovine origin (smartbone, IBI S.A., Switzerland).
92637|NCT03462823|Device|Hamstring tendon-only repair|ACL-reconstruction using hamstring autograft with hybrid fixation in accordance with in-house standard of care.
92638|NCT03462810|Drug|cabotegravir, CAB|open label investigational product
92639|NCT03462784|Other|Demographic, physical examination, data will becollected .|"Demographic data collected includ clinical diagnosis, sex, race, genotype, and phenotype.~Historical data included information regarding immunizations, infection exposures, surgical procedures, organ dysfunction(Organ dysfunction was defined as a history of requiring medical treatment for heart disease, diabetes (Type 1 or 2), hypoparathyroidism, hypothyroidism, growth hormone deficiency, or gonadal failure) age at transfusion initiation, chelation therapy, type of RBC product, transfusion reactions, and antigen matching. Data will be collected from chart review, patient interviews, blood banking records, and laboratory"
92640|NCT03462771|Drug|Fish oil|4g of fish oil daily for 14 weeks
92641|NCT03462771|Drug|sunflower oil|4g of sunflower oil daily for 14 weeks
92642|NCT03462758|Device|IUD|Postpartum IUD placement
92643|NCT03462745|Device|AccuVein AV 300|Assess the effectiveness of the AccuVein AV300 device over the standard technique in increasing the ﬁrst-time success rate (SR) for pediatric patients who needed IV cannulation
92644|NCT03462732|Device|Endotracheal tube|Nasotracheal intubation will be done with endotracheal tube
92645|NCT03462732|Device|Nelaton catheter|plus nelaton catheter
92646|NCT03462719|Drug|Ibrutinib|Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
92647|NCT03462719|Drug|Venetoclax|Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
92648|NCT03462719|Drug|Chlorambucil|Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
92649|NCT03462719|Drug|Obinutuzumab|Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
92650|NCT03462719|Drug|Ibrutinib (as Subsequent Therapy)|Participants will receive ibrutinib 420 mg orally once daily till disease progression or unacceptable toxicity during the subsequent therapy phase.
92651|NCT03462706|Procedure|Cold Snare|Subjects randomized to Cold Snare Intervention will have any polyps sized 6mm to 15mm removed using cold snare techniques (no electrocautery, no submucosal injection.)
92652|NCT03462706|Procedure|Hot Snare|Subjects randomized to Hot Snare Intervention will have any polyps sized 6mm to 15mm removed using hot snare techniques (with electrocautery, no submucosal injection.)
92653|NCT03462706|Procedure|Cold EMR|Subjects randomized to Cold EMR will have any polyps sized 6mm to 15mm removed using cold EMR techniques (no electrocautery, with submucosal injection.)
92654|NCT03462706|Procedure|Hot EMR|Subjects randomized to Hot EMR will have any polyps sized 6mm to 15mm removed using hot EMR techniques (with electrocautery, with submucosal injection.)
92655|NCT03462693|Other|Dry needling|The DNHS® dry-puncture technology is specifically marked for stroke patients. the muscle to be treated is placed in a submaximal position; the needle is inserted into the present tense bandage and mobilized in the inside and outside for about 1 minute or until the reaction of global spasm ceases
92656|NCT03462680|Dietary Supplement|niacin|Niacin or nicotinic acid 250 mg tablets
92657|NCT03462680|Other|placebo|placebo tablet
92658|NCT03462667|Behavioral|Stoma Boot Camp|Educational session designed to prepare people for living life with a stoma.
92659|NCT03462667|Other|Standard of Care|Patients receive normal pre-surgery standard of care.
92660|NCT03462654|Behavioral|iLiFE|In the individual LiFE (iLiFE), the program is taught in seven visits in the individuals' homes within eleven weeks. Participants are supervised in a face to face situation by one qualified trainer (physiotherapist or sports scientist). Each home visit takes between 1 and 1.5 hours. A total of five balance exercises, seven strength exercises for the lower extremities, and two exercises to increase physical activity are taught. In addition to the home visits, all participants receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
92661|NCT03462654|Behavioral|gLiFE|The group-based LiFE (gLiFE) program consists of seven group sessions (n = 8-12 participants) which are held over the course of eleven weeks, with a maximum duration of 2 hours per session. Each session is led by two qualified trainers (physio therapists or sports scientists), i.e., one main and one co-trainer. In all group sessions, trainers will teach the participants how to perform and integrate the LiFE program, i.e., LiFE balance and strength activities into their daily routines. After the group sessions have ended, participants will receive two 'booster telephone calls' within the remaining weeks until the 6-month follow-up assessments.
92662|NCT03462641|Drug|Flumazenil|1mg in 10cc normal saline
92663|NCT03462641|Drug|Placebo|10 cc normal saline
92664|NCT03462628|Procedure|PVI|CPVI plus low-voltage substrate modification in the left atrium during SR and CPVI alone
92665|NCT03462615|Diagnostic Test|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
92666|NCT03462602|Procedure|NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was retained until the return of bowel function (passage of flatus or passage of stool) in the patients assigned to the NGT group.
92667|NCT03462602|Procedure|non-NGT group|After induction of anesthesia, a 14- or 16-Fr single-lumen NGT was placed in all patients. Its intragastric position was confirmed by intraoperative palpation. Randomization to the NGT or non-NGT group was performed on completion of surgery by computer-generated randomization provided by the supervision department.The NGT was removed in the operation room immediately after the surgery in those assigned to the non-NGT group.
92668|NCT03462589|Drug|SY-008|The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
92669|NCT03462563|Device|INTERCEED™|when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo). In subjects assigned to the treatment arm, the INTERCEED™ must be applied beneath the target incision site (the midline incision mainly for the removal specimen)
92670|NCT03462563|Device|Placebo|During the Phase 1 operation, when the definite decision to create a temporary ostomy is made, patients will be randomized in 1:1 ratio to either the treatment arm (INTERCEED™) or the control arm (standard of care treatment: no adhesion barrier, no placebo).
92671|NCT03462550|Device|Laryngeal mask|LMA insertion
92672|NCT03462537|Device|Low level laser therapy|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
92673|NCT03462537|Device|Aerobic Exercise|Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
92674|NCT03462537|Device|Low level laser therapy without power|Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
92675|NCT03462524|Procedure|Esophagectomy|FEV1, FVC and DLCO will be assessed at baseline and one month post induction therapy. Radiation induced lung injury (RILI EORTC grade≥2), CCI, Clavien-Dindo, and pulmonary complications will be monitored. Changes in pulmonary function will be compared with cardiorespiratory symptoms and HR-QL among disease-free survivors.
92676|NCT03462511|Behavioral|HABIT Intervention|In addition to standard care and education handouts, dyads randomized to the intervention group will receive the HABIT intervention, which includes CHW support and tailored text messages.
92677|NCT03462498|Drug|1-months DAPT|1-month DAPT followed by 59-month monotherapy
92678|NCT03462498|Drug|12-month DAPT|12-month DAPT followed by 48-month monotherapy
92679|NCT03462485|Other|Golf|Eight weeks of twice-daily golf training
92680|NCT03462472|Behavioral|Lower leg heating|Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius
92681|NCT03462472|Behavioral|Lower leg transcutaneous electrical nerve stimulation (TENS)|Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
92682|NCT03462459|Drug|Vancomycin|Vancomycin capsule, 125 mg
92683|NCT03462459|Drug|Placebo|Capsule containing inert (nonactive) material to mimic 125 mg vancomycin capsule
92684|NCT03462446|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
92685|NCT03462446|Drug|Vitamin K antagonists (VKAs)|As prescribed by treating physicians. VKAs are Acenocoumarol and Warfarin.
92686|NCT03462420|Other|Physical Therapy program|The physical therapy program will be chosen by the treating therapist. However, the most common physiotherapy interventions include therapeutic exercises, joint mobilization techniques and electrotherapy.
92687|NCT03462407|Behavioral|DAID|"The DAID intervention group will engage in imitation based dog training, using positive reinforcement training (operant conditioning) to teach their dog to copy the physical actions they demonstrate on the command Do it."
92688|NCT03462407|Behavioral|Dog walking|Children will participate in dog walking. Trained assistants will teach the children to teach their dog basic commands. Dog walking will occur during the intervention phase and children will be encourage to walk their dogs at home.
92689|NCT03462394|Other|Current Script|This is the version of the phone call script currently used at NYU Langone Health.
92690|NCT03462394|Other|Alternate Script Iterations|Intervention includes various iterations of the phone call script (different wording or script structure).
92691|NCT03462381|Dietary Supplement|Protein|Three endurance training sessions weekly with protein supplementation post-exercise and before sleep.
92692|NCT03462368|Procedure|Control|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.
92693|NCT03462368|Procedure|antimicrobial photodynamic therapy|In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)
92694|NCT03462368|Procedure|Photobiomodulation|After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
92695|NCT03462342|Drug|Olaparib Pill|"Women with Pt-sensitive or Pt-resistant high grade serous cancer are eligible to enroll.~Patients will be given Olaparib to be taken orally on all 28 days of the cycle and investigational AZD 6738 to be taken orally on days 1-7 of each cycle."
92696|NCT03462329|Drug|Antibiotics (preferentially oral doxycycline 100 mg bid)|Patients will be treated with antibiotics for Lyme disease.
92697|NCT03462316|Biological|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）|NY-ESO-1（TCR Affinity Enhancing Specific T cell Therapy）
92698|NCT03462303|Combination Product|Sham tDCS and tyrosine depleted drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a tyrosine and phenylalanine free product.
92699|NCT03462303|Combination Product|Anodal tDCS and tyrosine depleted drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a tyrosine and phenylalanine free product.
92700|NCT03462303|Combination Product|Sham tDCS and balanced drink|Transcranial direct current stimulation (sham) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
92701|NCT03462303|Combination Product|Anodal tDCS and balanced drink|Transcranial direct current stimulation (anodal) of the dlPFC in combination with a drink containing both tyrosine and phenylalanine.
92702|NCT03462290|Drug|botulinum toxin type A|Botulinum toxin type A, powder for solution, 25 international units (IU), injected towards the sphenopalatine ganglion using MultiGuide
92703|NCT03462290|Drug|placebo|solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
92704|NCT03462264|Device|Scoliogold App|The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
92705|NCT03462264|Other|Pre-Formatted Diary|The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
92706|NCT03462251|Combination Product|Ribociclib and aromatase inhibitor or fulvestrant|Combination of ribociclib and aromatase inhibitor or fulvestrant
92707|NCT03462251|Combination Product|Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab|Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
92708|NCT03462238|Procedure|Blood collection for Ppi assay|A 4.5 ml blood sample will be taken with a citrate vacuum tube.
92709|NCT03462238|Radiation|CT Scan|A scanner will be performed
92710|NCT03462212|Drug|Carboplatin|chemotherapy medication
92711|NCT03462212|Drug|Paclitaxel|chemotherapy medication
92712|NCT03462212|Drug|Bevacizumab|Angiogenesis inhibitor
92713|NCT03462212|Drug|Rucaparib|PARP inhibitor
92714|NCT03462199|Dietary Supplement|Actazin (green kiwi powder) High Dose|Participants will consume 4 capsules (600 mg green kiwi powder) daily for 28-days
92715|NCT03462199|Dietary Supplement|Actazin (green kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg green kiwi powder) daily for 28-days
92716|NCT03462199|Dietary Supplement|Control Formula (Actazin green kiwi powder + PreticX prebiotic)|Participants will consume 4 capsules (150 mg green kiwi powder + 250 mg PreticX prebiotic) daily for 28-days
92717|NCT03462199|Dietary Supplement|Livaux (gold kiwi powder) High Dose|Participants will consume 4 capsules (600 mg gold kiwi powder) daily for 28-days
92718|NCT03462199|Dietary Supplement|Livaux (gold kiwi powder) Low Dose|Participants will consume 4 capsules (150 mg gold kiwi powder) daily for 28-days
92719|NCT03462199|Dietary Supplement|Placebo (microcrystalline cellulose)|Participants will consume 4 capsules containing no active ingredients daily for 28-days
92720|NCT03462186|Other|Healthfinder invitation|Invitation to use healthfinder (healthfinder.gov/myhealthfinder
92721|NCT03462173|Drug|yimitasvir|Capsule administered orally once daily
92722|NCT03462173|Drug|placebo|Matching Placebo Capsule
92723|NCT03462160|Other|Placebo control group|Placebo will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal. The placebo appearance will be similar to the probiotic.
92724|NCT03462160|Dietary Supplement|Probiotic experimental group|Probiotic UroLact containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 will be administered orally, after dissolving the sachet in lukewarm water, every evening during the meal.
92725|NCT03462147|Device|Spinal cord stimulation|Spinal cord stimulation will be given according to the arms of the group (no stimulation, high density stimulation of conventional stimulation)
92726|NCT03462134|Other|Survey|Survey amongst orthopaedic surgeons
92727|NCT03462121|Drug|RPh201|RPh201 is a well-defined extract from a botanical source
92728|NCT03462121|Other|Placebo|Inactive placebo consisting of the therapeutic vehicle
92729|NCT03462108|Biological|Rotavirus (Bio Farma) Vaccine|Rotavirus (Bio Farma) Vaccine
92730|NCT03462108|Other|Placebo|Placebo contains 30% sucrose in DMEM
92731|NCT03462095|Procedure|Autologous HSCT|After the 3rd consolidation, T-cell ALL patients, randomized to auto-HSCT will be mobilised by G-SCF and harvested disregarding MRD-status. After completing the 5th consolidation T-ALL patients will be transplanted after non-myeloablative CEAM (CCNU, Ethoposide, ARA-C, Melphalan) conditioning, and after reconstitution will continue 2-years maintenance
92732|NCT03462082|Other|Asymmetric STN-DBS|Asymmetric deep brain stimulation
92733|NCT03462069|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
92734|NCT03462069|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
92735|NCT03462069|Drug|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
92736|NCT03462069|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
92737|NCT03462056|Dietary Supplement|Cystic Fibrosis Ready to Use Supplemental Food|Specially formulated for use by children with Cystic Fibrosis
92738|NCT03462043|Combination Product|ND0612|s.c. infused
92739|NCT03462043|Combination Product|CLES|Carbidopa-Levodopa Enteral Suspension.
92740|NCT03462030|Drug|Baked non-fat cow's milk powder|Oral immunotherapy with increasing quantities of baked milk.
92741|NCT03462030|Drug|Placebo: Tapioca Powder|Placebo control.
92742|NCT03462017|Drug|SAR247799|Pharmaceutical form:Capsule Route of administration: Oral
92743|NCT03462017|Drug|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
92744|NCT03462017|Drug|Sildenafil|Pharmaceutical form:Encapsulated tablet Route of administration: Oral
92745|NCT03462017|Drug|Acetylcholine|Pharmaceutical form:Solution Route of administration: Transdermal
92748|NCT03461991|Device|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
92749|NCT03461978|Device|Ultrahigh resolution Spectral Domain OCT|A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed.
92750|NCT03461965|Behavioral|3D printed model|A printed 3D model of Mohs Micrographic Surgery will be created showing a model of skin, and a tumor to visually depict the surgery
92751|NCT03461965|Behavioral|Verbal Counselling|patients will be educated with a standardized script on skin cancer, risks for skin cancer, treatment options, and Mohs Micrographic Surgery
92752|NCT03461952|Drug|Nivolumab|240mg
92753|NCT03461952|Drug|Ipilimumab|1mg/kg
92754|NCT03461939|Other|ePRIME symptom monitoring tool|ePRIME is an online system for patients to self-report symptoms and AE during cancer treatment. ePRIME allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating notifications for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
92755|NCT03461926|Behavioral|(SB-related planning + daily text messages)|Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
92756|NCT03461913|Procedure|Cesarean section|Lower segment elective Cesarean section
92757|NCT03461900|Other|Minifluid challenge|Pragmatic optimization fluid management protocol based on Mini-Fluid Challenge (MFC) in treating an acute circulatory failure. MFC consist of an infusion of 100 ml of colloid solution (4% human serum albumin) during 1 minute via a separate venous line. Before and after each MFC and depending on the hemodynamic device used, the attending physician will perform a first set of hemodynamic measurements, including cardiac index (CI) or cardiac output (CO); stroke volume (SV), indexed stroke volume (iSV) or velocity time index (VTI). If the variation in measurement is superior to 10%, the attending physician will infuse 400 ml of buffered crystalloid solution or saline solution. After an infusion of 500 ml, fluid responsiveness will be evaluated with CI or CO measurement. For non-responders, fluid challenge must be stopped and other therapeutics should be considered. For responder, another MFC should be consider if hemodynamic status is not stabilized.
92758|NCT03461900|Other|Usual practice|Patients included in control group will be managed according to the last surviving sepsis recommendations edited in 2017.
92759|NCT03461887|Behavioral|Exercise|"Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention."
92760|NCT03461874|Behavioral|Education of patients|"During withdrawal treatment, patients are given recommendations on the approach to the use of drugs for acute treatment of migraine headache and on lifestyle issues. With regard to drugs, patients will be encouraged to restrict use of acute medications to headaches with severe pain; i.e., those rated as 8 or greater on a 0-10 (no pain - pain as bad as it could be). In these instances, patients will be instructed to take Eletriptan (40 mg) and/or Almotriptan (12.5 mg) as the first-line treatment, indomethacin (50 mg) as the second line, and will be specifically urged to avoid opioids. With regard to healthy lifestyle issues, patients will be encouraged to engage in moderate physical activity (i.e., 45 minutes twice per week of aerobic exercise), remain well hydrated, consume 3 meals per day, and maintain a regular sleep/wake pattern with at least 7-8 hours of sleep per night."
92954|NCT03460340|Device|prefrontal deep rTMS of H1 Coil|prefrontal deep rTMS of H1 Coil
92761|NCT03461874|Behavioral|ACT|"ACT consists in 6 weekly sessions, 90 minutes each, and 2 supplementary booster sessions, at two and four weeks after the conclusion of the weekly session. The main focus of the six ACT session will be the following: 1) Creative helplessness: the problem of control; 2) Indentifying values: introduction to Mindfulness; 3) Actions guided by values: working with thought; 4) Working with Acceptance and Willingness; 5) Committed Actions: self-as-context; 6) Integration: working with obstacles - wrap-up. The booster session starts with a mindfulness exercise, followed by a review of the contents covered across the ACT program.~Patients will be trained in small groups (5-7 patients each) and guided by a specifically trained therapist. They will be educated to practice at home according to the instructions given by the therapist during the sessions."
92762|NCT03461874|Drug|Pharmacological prophylaxis|Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or Flunarizine. Doses will depend on patients' features, and the doses herein reported are to be intended as approximate ones: Topiramate at the dose of 50mg/day; Propanolol at the dose of 20mg/day; Amytriptiline at the dose of 10mg/day; Flunarizine at the dose of 5mg/day.
92763|NCT03461861|Drug|AGB101 220 mg|AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.
92764|NCT03461861|Other|Placebo|Placebo, oral capsule given once-daily.
92765|NCT03461848|Other|CYPHP Evelina London Model of care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Targeted services offered dependent on need. Children with any of the tracer conditions will be offered pathway based care including early intervention for physical and related mental health needs, paediatric nursing support, care plans shared with schools, medication reviews, and peer-led parenting support. Self-management support, social support signposting, and safety-netting are offered to all.
92766|NCT03461848|Other|Enhanced Usual Care|Universal services offer, Paediatric hotlines, Education and training for health professionals, Online decision support tools and guidelines, Young people-friendly access to primary care, and Resilience training in schools, Self-management support, social support signposting, and safety-netting are offered to all.
92767|NCT03461835|Diagnostic Test|Risk classification of PUL by M4|High or low risk of being an ectopic pregnancy
92768|NCT03461835|Diagnostic Test|Risk classification of PUL by NICE|High or low risk of being an ectopic pregnancy
92769|NCT03461809|Other|Ocular acupuncture|Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
92770|NCT03461783|Device|Zorflex Activated Carbon Dressing|Antimicrobial dressing
92771|NCT03461783|Device|Standard of Care|foam, calcium alginate, hydrogel, or compressive dressings
92772|NCT03461770|Other|CPAP|Patients will receive general anesthesia induction with CPAP at 5 cmH20 via face mask with a circular system. CPAP will use before extubation.The air-test will perform during anesthesia with transitory decreases inspired fraction of oxygen to 0.21 over a 5 min period. Recruitment maneuver will be perform if the air test is positive, ( SpO2 is ≤ 96%)
92773|NCT03461757|Drug|Rimegepant|BHV-3000 (rimegepant) 75 mg (ODT)
92774|NCT03461757|Drug|Placebo|75mg matching placebo ODT
92775|NCT03461731|Device|Control|laser beam only
92776|NCT03461731|Device|800 nm laser|800 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
92777|NCT03461731|Device|combination laser|800 nm and 905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
92778|NCT03461731|Device|905 nm laser|905 nm laser applied to forearm at 4.4 Joules per square cm during 40 hand grips
92779|NCT03461718|Drug|Ketamine|Experimental arm for sedation.
92780|NCT03461718|Drug|Midazolam injection|Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
92781|NCT03461718|Drug|Fentanyl|Part of standard sedation regimen
92782|NCT03461705|Device|Volcano Verrata Pressure Wire|"Steerable guidewire with a pressure transducer mounted 3cm proximal to the tip. The guidewire has a diameter of 0.014.~and is packaged preconnected to the connector with a torque device to facilitate navigation through the vasculature."
92783|NCT03461705|Device|St. Jude Medical (SJM) Aeris Pressure Wire System|The pressure wire is a 0.014'' guidewire with a pressure and temperature sensor integrated into the tip to enable measurements of physiological parameters.
92784|NCT03461692|Drug|patients under 14 years of age using Reduning injeciton|To assess in patients using Reduning injection's clinical features and drug adverse reaction during patients' hospital stay. The registry procedure will only for patients under 14 years of age using Reduning injection,observed from February 2018 to December 2018.
92785|NCT03461679|Procedure|Adductor canal block|Single shot block with 0.5% bupivacaine 10mls
92786|NCT03461679|Procedure|Femoral triangle block|Single shot block with 0.5% bupivacaine 10mls
92787|NCT03461666|Behavioral|Cognitive Behavior Therapy-Insomnia|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
92788|NCT03461666|Behavioral|Focus of Attention|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
92789|NCT03461666|Behavioral|Combined-CBT-I and FOA Group|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
92790|NCT03461666|Behavioral|Sleep Hygiene|Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
92791|NCT03461653|Other|Telemedicine counselling|women on web counselling
92792|NCT03461640|Other|Community-based doula support for labour|CBDs will be recruited, trained and employed by non-profit organization MIRA. Women allocated to receive CBD support will be contacted by an either a Somali, Arabic-, Russian- or Tigrinya-speaking CBD as appropriate, and arrangements made for them to meet twice prior to the birth to get to know each other and discuss the woman's wishes regarding support in labour and what the CBD can offer. Each woman will then contact her CBD when she goes into labour and the CBD will attend hospital with her and stay with her throughout her labour and birth, in addition to any other support people she may have, such as her partner.
92793|NCT03461640|Behavioral|Standard labour support|"Standard labour support by health care providers only. Women allocated to the comparison arm of the trial will receive standard intrapartum care as provided at their chosen hospital of birth. That is emotional, information and instrumental support from a helping nurse or a midwife or in some cases a doctor. The support includes caring actions, such as comforting, massage, information and presence.~Note: Women partner and/or other support people to accompany throughout her childbirth will be allowed, regardless of their trial allocation."
92794|NCT03461627|Drug|Salmeterol Xinafoate and Fluticasone Propinate Powder|50ug/250ug 1 puff twice a day for 4 weeks
92795|NCT03461627|Drug|Seretide|50ug/250ug 1 puff twice a day for 4 weeks
92796|NCT03461614|Other|Exercise group|Exercise group mainly conducted the 5 core stabilization exercises as described by McGill. These include the curl-up, side bridge, trunk extension, double leg lifts and bird-dog exercises that support respiratory functions. In other words, every single training session consisted of frontal, dorsal, and lateral core exercise. In general, participants always exercised in group so that for integration and motivation. During training weeks 1-2, participants exercises with 3 sets per exercise and 10 s contraction time and 10 repetitions. During training weeks 3-4, contraction times and repetitions were increased to 15 s and 15 repetitions. Additionally, increasing the complexity of exercises, adding opposite limb movements and increasing the lever arm of the exercises were done.
92797|NCT03461614|Other|Control group|In addition to the service routine rehabilitation program mentioned above, participants in the Control group participated in leisure activities such as table tennis/basketball under service staff supervision for 45-60 minutes, 2 times a week, 6 weeks similar time period of Exercise group.
92798|NCT03461601|Procedure|HCG Uterine flushing|HCG Uterine flushing was done one day before IUI with HCG (500 IU) in 10 ml of saline.
92799|NCT03461601|Procedure|IUI|Intrauterine insemination (IUI)
92800|NCT03461601|Procedure|Vaginal flushing with 10 ml normal saline|Flushing of the vagina with 10 ml of saline
92801|NCT03461588|Radiation|free-breathing|patients are irradiated to whole breast +- regional nodal areas with free-breathing technique after breast conserving surgery
92802|NCT03461588|Radiation|deep inspiratory breath-holding|patients are irradiated to whole breast +- regional nodal areas with deep inspiratory breast-holding technique after breast conserving surgery
92803|NCT03461575|Drug|HU007|cyclosporine 0.02%, trehalose 3%
92804|NCT03461575|Drug|Restasis|cyclosporine 0.05%
92805|NCT03461575|Drug|Moisview|trehalose 3%
92806|NCT03461562|Other|Aerobic Exercise|Aerobic exercise wil be held for 40 minutes. Dynamic exercises will be accompanied by physiotherapist on the vibration platform for 15 minutes. Same excercises will be held stable platform (when the devices turned off) by control group for 15 minutes.
92807|NCT03461549|Device|Pressure and Temperature Sensor|This device includes pressure and temperature sensor embedded within silicone and applied to the skin with a medical grade adhesive.
92808|NCT03461536|Behavioral|Ultrasound-first Clinical Decision Support tool|"Intervention: The intervention is the CDS tool, which consists of 4 components:~Four questions which assess the appropriateness of ultrasound for this patient~A link to the evidence~Buttons to remove CT scan and order ultrasound~If the CT scan order is kept, reasons why ultrasonography is not appropriate The CDS tool will be placed or integrated into EPIC, at the point of order entry. The tool will be triggered by an order for CT scan for kidney stone.~Appropriateness criteria for ultrasound:~Adults aged >18 and < 76~Non-obese (men < 285lbs, women < 250lbs)~Low risk of Stone Emergency (Obstructing stone and any of the following: urosepsis, renal deterioration, post kidney transplant, solitary kidney, intractable symptoms)~Low risk of clinically significant alternative diagnosis (e.g. appendicitis, cholecystitis, AAA, ovarian torsion) If all responses are affirmative, then the subject should receive US, and US order is provided."
92809|NCT03461510|Procedure|Hyperglycemic clamp|Subjects with T2D will receive IV Dextrose infusion to maintain plasma glucose at ~250 mg/dL during fMRI.
92810|NCT03461510|Procedure|Hyperinsulinemic Euglycemic clamp|Subjects with T2D will receive IV Dextrose and Insulin infusion to maintain plasma glucose at approximately 90 mg/dL during fMRI.
92811|NCT03461471|Behavioral|Exercise Intervention|Exercise intervention
92812|NCT03461458|Drug|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose-derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Immune Progenitor and Cell Therapeutics Laboratory using current good manufacturing practices (cGMPs).
92813|NCT03461445|Drug|Envarsus|Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
92814|NCT03461445|Drug|IR Tacrolimus|Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
92815|NCT03461432|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a psychological therapy that has been developed with a general immediate focus on improving impaired cognitive domains but ultimately aimed at improving social and functional outcomes.
92816|NCT03461419|Procedure|Microcannula Harvest Adipose Stroma|Use of Disposable, Closed Syringe Microcannula Harvest Autologous Adipose Stroma and Stem/Stromal Cells
92817|NCT03461419|Device|Centricyte 1000|Centricyte 1000 closed system digestion of stromal vascular fraction to isolate and concentrate stem/stromal cells associated with microvasculature
92818|NCT03461419|Procedure|Sterile Normal Saline IV Deployment of cSVF|Sterile Normal Saline Suspension cSVF in 500 cc for Intravenous Delivery Including 150 micron in-line filtration
92819|NCT03461406|Biological|Fibrin Sealant Grifols|human fibrinogen (component 1: 80 mg/mL solution) and human thrombin (component 2: 500 IU/mL solution) solutions filled in syringes and assembled on a syringe holder
92820|NCT03461406|Biological|EVICEL|1 vial of Biological Active Component 2, a frozen, sterile solution consisting of a concentrate of human fibrinogen (55-85 mg/mL) and 1 vial of thrombin (800-1200 IU/mL)
92861|NCT03461029|Device|BIS monitor|The investigators placed on the forehead of all patients the sensor BIS quatroTM, that connects with the monitor, and they registered sedation and recorded the values obtained.
92955|NCT03460327|Drug|Candesartan|Patients are tested for their normal prescription candesartan medication
92956|NCT03460314|Drug|Buprenorphine|Patients are tested for their normal prescription buprenorphine medication
92983|NCT03460002|Biological|Oral polio vaccine|A bivalent oral polio vaccine prequalified by the World Health Organization will be administered in one or two doses directly into the mouth of the vaccinee with two drops per dose by a local nurse.
92821|NCT03461393|Device|Medical-Eye-Trainer (MET)|In order to provide a high contrast, dynamic visual stimulus to the patients, we developed an app that allowed the patients to regularly train with this stimulus. The app runs on Android (version 4.2 or later). The display of the screen is divided into 4 rows. In each row, a pattern of black and white squares is moving in one direction. The directions in subsequent rows are opposite to each other. Through the movement in the opposite direction a changing pattern is achieved in vertical and horizontal extension, the pattern alternates between continuous beams and a checkered pattern. The speed of the display on the monitor is 2 cm per second. In a comfortable viewing distance (ca. 40 cm), this leads to an angular velocity of approximately 3°/sec.
92822|NCT03461380|Dietary Supplement|Menopause Relief EP-40|Fixed combination of black cohosh and Rhodiola rosea
92823|NCT03461380|Dietary Supplement|Low Dose Black Cohosh|6.5 mg black cohosh
92824|NCT03461380|Dietary Supplement|High Dose Black Cohosh|500 mg black cohosh
92825|NCT03461380|Dietary Supplement|Placebo|600 mg excipient
92826|NCT03461354|Drug|MucoLox|MucoLox formulation, with MucoLox as the delivery vehicle, combined with preserved water, beta-glucan, dexpanthenol, and glutamine
92827|NCT03461354|Drug|Sodium Bicarbonate|Sodium bicarbonate oral rinse
92828|NCT03461341|Other|High intensity postoperative oncologic surveillance|High intensity surveillance protocol using routine cross-sectional imaging (computed tomography or positron emission tomography with computed tomography).
92829|NCT03461328|Drug|Magnesium Sulphate|intra-operative infusion of of 10% MgSO2 , stating by a laoding dose of 30be used, a loading dose of 30 mg/kg over 20 min followed by continuous infusion of 10 mg/kg/hr accomplish the total laryngectomy.
92830|NCT03461315|Other|Functional assistance model|Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
92831|NCT03461302|Drug|Topical coal tar|Solution carbonis detergens 10% in cremor vaselini lanette FNA and pix lihantracis 3% in zinc oxide paste
92832|NCT03461302|Drug|Topical corticosteroids|Clobetasone butyrate 0.05% ointment
92833|NCT03461289|Biological|Onasemnogene Abeparvovec-xioi|Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).
92834|NCT03461276|Biological|ABvac40|ABvac40 consists in a conjugate of Aβx-40 with a carrier protein (KLH) vehiculated in phosphate buffer containing 0.35% aluminium hydroxide as adjuvant.
92835|NCT03461276|Biological|Placebo|Placebo consists in the vaccine's vehicle (phosphate buffer containing 0.35% aluminium hydroxide) without the conjugate.
92836|NCT03461263|Other|phonophoresis treatment using pumpkin seeds oil|phonophoresis treatment using pumpkin seeds oil
92837|NCT03461250|Diagnostic Test|HCV serology|Apply CRF to identify risk factors for HCV infection. In patients with positive HCV serology measure the level of viral load and HCV genotype by PCR Abbott-real time and determine the stage of liver fibrosis by elastography (Fibroscan)
92838|NCT03461224|Radiation|accelerated hypofractionated RT|
92839|NCT03461224|Radiation|conventional fractionated RT|
92840|NCT03461211|Biological|Teprotumumab|Approximately 50 participants will receive 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
92841|NCT03461198|Device|Restylane® Silk|Restylane® Silk to a defined area of mid to low cheeks
92842|NCT03461185|Drug|EGFR-TK Inhibitor|EGFR-TKIs include but are not limited erlotinib, gefitinib
92843|NCT03461185|Drug|Anti-Angiogenic Drugs|Anti-Angiogenic Drugs contain endostatin, apatinib and anlotinib
92844|NCT03461172|Procedure|Surgery of breast cancer|Surgery of breast cancer
92845|NCT03461172|Other|Clinical data collection|The collection centralizes the main characteristics of the patients, the tumor and the treatments. Also included are the date of first recurrence, the localization (local, regional or distant) as well as the death or the date of the latest news.
92846|NCT03461159|Other|Operant conditioning of H-reflexes|Spinal reflex responses will be elicited in a wrist flexor muscle using a peripheral nerve stimulator. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to decrease the size of the H-reflex response over successive trials. Responses that are below a threshold will be rewarded and those above will not.
92847|NCT03461159|Other|Operant conditioning of motor evoked potentials|Motor evoked potentials will be elicited in a wrist flexor muscle using transcranial magnetic stimulation. During training trials, the size of the participant's response will be shown on a screen and the participant will be asked to increase the size of the MEP response over successive trials. Responses that are above a threshold will be rewarded and those below will not.
92848|NCT03461146|Drug|MT-6548|Oral tablet
92849|NCT03461133|Other|Intervention|The emergency notification system is linked to a paging system to the surgeon in charge and to the Hospital Medical Emergency Team. Depending on individual Multiparameter Early Warning Score communication protocols are activated.
92850|NCT03461120|Drug|Experimental continuous peripheral nerve blocks|Bupivacaine 0.3% infusions for 7 days via femoral and sciatic perineural catheters
92851|NCT03461120|Drug|Control continuous peripheral nerve blocks|Bupivacaine 0.1% infusions for 1 day followed by normal saline for a total of 7 days via femoral and sciatic perineural catheters
92852|NCT03461107|Other|No intervention|
92853|NCT03461094|Device|Preload assessment and volume expansion|Fluid therapy perform
92854|NCT03461081|Drug|telmisartan/amlodipine and atorvastatin|Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
92855|NCT03461068|Dietary Supplement|Ketone monoester|Acute ingestion of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate prior a 2-hour oral glucose tolerance test.
92856|NCT03461068|Dietary Supplement|Placebo|Acute ingestion of a taste-matched placebo prior a 2-hour oral glucose tolerance test.
92857|NCT03461055|Other|Lavender|Lavender aromatherapy
92858|NCT03461055|Other|Water|Water
92859|NCT03461042|Drug|Ramelteon 8mg|Ramelteon 8mg once daily before bedtime for 12 weeks since informed consent
92860|NCT03461042|Drug|Placebo|Placebo capsule once daily before bedtime for 12 weeks since informed consent
92862|NCT03461016|Behavioral|Exposure Therapy|"Exposure therapy is a form of behavior therapy that is widely used to treat anxiety disorders, including specific phobia. It involves systematic and repeated confrontation with a feared stimulus. It works by (a) implosive therapy, habituation, in which repeated exposure reduces anxiety over time by a process of extinction; (b) disconfirming fearful predictions; and (c) increasing feelings of self-efficacy and mastery. In vivo exposure [is] a type of exposure therapy, generally used for treating individuals with phobias, obsessive compulsive disorder, and other anxiety disorders, in which the client directly experiences anxiety-provoking situations or stimuli in real-world conditions. (VandenBos, 2015)"
92863|NCT03461003|Other|NICHE method|Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.
92864|NCT03461003|Other|Usual care|Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.
92865|NCT03461003|Drug|Amlodipine|Calcium-channel blocker; antihypertensive
92866|NCT03461003|Drug|Lisinopril|Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive
92867|NCT03461003|Drug|Hydrochlorothiazide|Thiazide diuretic; antihypertensive
92868|NCT03461003|Drug|Losartan|Angiotensin II receptor blocker (ARB); antihypertensive
92869|NCT03460990|Drug|VX-659/TEZ/IVA|Participants received VX-659/TEZ/IVA orally once daily in the morning.
92870|NCT03460990|Drug|TEZ/IVA|Participants received TEZ/IVA orally once daily in the morning.
92871|NCT03460990|Drug|IVA|Participants received IVA orally once daily in the evening.
92872|NCT03460990|Drug|Placebo|Participants received placebo matched TEZ/IVA orally once daily in the morning.
92873|NCT03460990|Drug|Placebo|Participants received placebo matched to VX-659/TEZ/IVA orally once daily in the morning.
92874|NCT03460977|Drug|PF-06821497|Oral continuous (Part 1)
92875|NCT03460964|Device|Adhesive glucose sensor|"Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat"
92876|NCT03460964|Drug|Pilocarpine|Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
92877|NCT03460951|Diagnostic Test|cervical MRI|Cervical MRI will be performed in all of the patients and controls on a 3.0-T scanner (Discovery MR750, General Electric (GE) Medical Systems, Milwaukee, WI, USA)
92878|NCT03460938|Procedure|Remote ischemic preconditioning|RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery.
92879|NCT03460925|Radiation|SBRT plus chemotherapy|Neoadjuvant stereotactic body radiotherapy (SBRT, 30 Gy in 5 fractions) plus chemotherapy with Folfirinox
92880|NCT03460912|Device|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.|Bipolar and monopolar probes (SPESS MEDICA S.r.l. Via Buccari 16153 Genova (GE), Italy) administered to all participants.They compared each others(bipolar vs monopolar) via amplitudes and latency values.
92881|NCT03460899|Other|Euglycaemic Clamp|All 14 subjects will undergo an euglycaemic clamp at Visit 2 with a plasma Glucose target of 5.5 mmol/L +/- 10% (4 timepoints for platelet activity parameter blood sampling)
92882|NCT03460899|Other|Hyperinsulinaemic/Hypoglycaemic Clamp|All 14 subjects will undergo a hypoglycaemic/hyperinsulinaemic clamp at Visit 3 with 4 timepoints for platelet activity Parameter blood sampling 30 minutes after reaching certain plasma glucose plateaus (5.5 mmol/L; 3.5 mmol/L; 2.5 mmol/L; after recovery again at 5.5 mmol/L)
92883|NCT03460886|Device|Ipsilesional stimulation|anodal stimulation on Ipsilesional leg area of primary motor cortex and supplementary motor area for 30 minutes
92884|NCT03460886|Device|Contralesional stimulation|anodal stimulation on contralesional leg area of primary motor cortex and supplementary motor area for 30 minutes
92885|NCT03460886|Other|Walking on treadmill|walking on treadmill for 10 minutes
92886|NCT03460873|Procedure|holmium laser enucleation of the prostate|undergo holmium laser enucleation of the prostate
92887|NCT03460860|Dietary Supplement|Astaxanthin (2mg)+Lycopene (1.8mg)+D-Alpha-Tocopherol (10IU)|The intervention is to be taken once daily, for 12 weeks.
92888|NCT03460860|Dietary Supplement|Placebo|The intervention is to be taken once daily, for 12 weeks.
92889|NCT03460847|Drug|Steroids|Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.
92890|NCT03460808|Drug|atorvastatin|Atorvastatin was used in combination with acetylcysteine and danazol.
92891|NCT03460808|Drug|Acetylcysteine|Acetylcysteine was used in combination with atorvastatin and danazol.
92892|NCT03460808|Drug|Danazol|Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
92893|NCT03460795|Biological|MSC|conventional plus MSC or placebo treatment
92894|NCT03460782|Biological|Ipilimumab|"Each patient receives Ipilimumab in regimen and dose according to the official manufacturer's instructions (IV 1 mg / kg every 6 weeks for maximum of 4 doses).~Participation of the patient in the program must necessarily be agreed with the current treatment and contain a written agreement with the attending physician.~This program is not covered by health insurance. For patients in the postoperative period to provide a mandatory conclusion of histology and molecular-genetic for the identified mutations and the type of tumor."
92895|NCT03460769|Other|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
92896|NCT03460756|Drug|Ganaxolone|Oral
92897|NCT03460756|Drug|Placebo|Oral
92947|NCT03460405|Biological|Vi-DT Vaccine|1 dose of Vi-DT Vaccine
92898|NCT03460743|Biological|Study group - quadrivalent recombinant hemagglutinin influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
92899|NCT03460743|Biological|Control group - quadrivalent inactivated influenza vaccine|Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
92900|NCT03460730|Biological|Pneumovax|23-valent pneumococcal polysaccharide vaccine
92901|NCT03460717|Other|Peripheral Nerve Field Stimulation by Thermal Micro-Cautery|The most painful points over the knee received an intense heat by a metal rod for 0.5 seconds.
92902|NCT03460704|Drug|Colistimethate sodium|Inhaled colistimethate sodium twice daily
92903|NCT03460704|Drug|Saline Solution|Inhaled placebo twice daily
92904|NCT03460691|Procedure|Bariatric surgery|Bariatric surgery will done to the patients who were morbid obesity
92905|NCT03460678|Drug|Pemetrexed|Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium) administered as 500mg/m2 IV over 10 minutes on the first day of each 21‐day cycle, until disease progression or unacceptable toxic effects
92906|NCT03460678|Drug|Erlotinib|Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride) administered once daily until disease progression or unacceptable toxic effects
92907|NCT03460665|Procedure|Arteriography|knee arteriography
92908|NCT03460652|Drug|KP415 oral capsule|Daily dose
92909|NCT03460639|Radiation|Active laser|Three points on the masseter muscle (upper, middle and lower portions) and one point on the anterior temporal on each side of the face will be irradiated with a wavelength of 780 nm, radiant exposure of 134 J/cm2, power of 50 mW and irradiance of 1.675 W/cm2 for 80 seconds per point, resulting in an energy of 4 J per point and total energy of 32 J per volunteer.20,21 Point application will be performed with a conventional tip in contact with the skin (beam spot: 0.04 cm2).
92910|NCT03460639|Radiation|Sham laser|The same procedures will be performed in the sham group, but the device will be switched off and a recording of the emission sounds will be used to give the volunteer the auditory sensation of laser therapy.
92911|NCT03460639|Diagnostic Test|Control group|In this group, we will only induce fatigue.
92912|NCT03460626|Drug|Lavender Oil|The oil used in this study will be lavender oil with a final concentration of 3% using almond oil (90%) as diluent. The oil after dilution and final preparation will be converted to proper clean vial in a fix amount (10 ml) and given to the students.
92913|NCT03460626|Other|Placebo|an odorless oil without any therapeutic effect
92914|NCT03460613|Other|FODMAP diet|Patients with a diagnosed FODMAP intolerance (and a control with no FODMAP intolerance) by prior nutrient challenge testing are going on a FODMAP diet. In a first nutritional visit a specialized nutritionist will inform the patients about FODMAP containing foods and illustrate a FODMAP elimination diet. After 3 weeks of elimination diet another visit will take place and a stepwise reintroduction diet is initiated after successful elimination diet.
92915|NCT03460600|Other|Optical Coherence Tomography (OCT)|Optical Coherence Tomography is a fairly new imaging technique in ophthalmology
92916|NCT03460587|Device|Telerehabilitation|The Telerehabilitation system will deliver rehabilitation treatment sessions via an in-home internet-connected computer. A major component of the system is the use of games to promote therapeutically relevant movements. The subject will perform daily assigned home-based telerehabilitation games and exercises and 5 minutes of stroke education, all guided by the telerehabilitation system.During some of the sessions, therapists will initiate a videoconference with the subject's telerehabilitation system to discuss progress, issues, and revise treatment plans as needed.
92917|NCT03460574|Behavioral|INFORMATION|After receiving expectation-disconfirming positive performance feedback, participants receive standardized information that stresses the relevance of this experience. In particular, participants are told that the performance test they worked on is highly relevant for both professional success and personal life satisfaction.
92918|NCT03460574|Behavioral|SALIENCE|After receiving expectation-disconfirming positive performance feedback, partcipants in this condition are instructed to remember how well they performed on the performance test. Using a visual analogue scale, they were asked to specify how they performed relative to the other participants.
92919|NCT03460574|Behavioral|ATTENTION|Before working on the performance test, participants are instructed to pay attention to the feedback they receive. In particular, they are asked to enter what would be a personally good result for them. It is supposed that this shift of attention increases the salience of the expectation-disconfirming feedback.
92920|NCT03460574|Behavioral|CONTROL|This group does not receive any further intervention. Instead, participants of this group pass through the standard procedure of the EXPEC paradigm.
92921|NCT03460561|Procedure|Thoracic epidural block (TEA)|Under complete aseptic precautions and before induction of GA, thoracic epidural catheter was inserted using a 17 gauge, Tuohy epidural needle by a midline approach. T9-T10 interspace was chosen for the injection after skin infiltration by 5 mL of lidocaine 1%. The epidural space was identified by the loss of resistance technique then the catheter was introduced 2 cm into the epidural space, and epidural test dose of 3 mL of lidocaine 2% with 1:200,000 adrenaline was injected to exclude vascular or subarachnoid position.
92948|NCT03460405|Biological|Vi Polysaccharide Vaccine|1 dose of Vi Polysaccharide Vaccine
92949|NCT03460405|Biological|IPV Vaccine|1 dose of IPV Vaccine
92950|NCT03460392|Drug|Antibiotic therapy|To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
92951|NCT03460379|Drug|Escitalopram|Patients are tested for their normal prescription escitalopram medication
92952|NCT03460366|Drug|Enalapril|Patients are tested for their normal prescription enalapril medication
92953|NCT03460353|Drug|Dexamphetamine|Patients are tested for their normal prescription dexamphetamine medication
92922|NCT03460561|Procedure|Rectus sheath block (RSB)|"Under aseptic technique, the rectus muscle was imaged with the ultrasound probe, A broadband (5-12 MHz) linear array probe of Sonosite ™ 3000 ultrasound (FUJIFILM, Sonosite EDGE II -UAS) in a transverse orientation at or immediately above the level of the umbilicus, with an imaging depth of 4-6 cm.~Inserting the needle: An 18G Tuohy needle was introduced few millimeters from the probe using an in plane technique in an angle of 45 degrees to the skin. (posterior rectus sheath and fascia transversalis). Under direct vision, the needle tip was advanced to the desired position where 20 mL of (levo-bupivacaine 0.25% Fentanyl 30 μg) were injected causing hydro dissection of the rectus muscle away from the posterior rectus sheath. The technique is repeated on the opposite side."
92923|NCT03460548|Device|Remogen|instil 1 drop of the product in each eye, 4 times per day
92924|NCT03460548|Device|Cationorm|instil 1 drop of the product in each eye, 4 times per day
92925|NCT03460522|Drug|Inotuzumab ozogamicin|Patients will receive standard of care chemotherapy (consolidation and maintenance) after Inotuzumab Ozogamicin.
92926|NCT03460509|Drug|Sugammadex|Dose-response
92927|NCT03460496|Behavioral|neonatologists|will continue to be contact persons for the APN, even after hospital discharge, and will be available for 3 fixed outpatient consultations with the APN and families that have difficulty getting to a paediatrician, because they live in a rural area with no paediatrician.
92928|NCT03460496|Behavioral|psychological support|Psychological support will be standard for all families. In a first consultation, psychologist and family will decide about long-term psychological support. They will have at least 3 follow-up consultations during hospital stay and one before discharge; specific psychological interventions will be provided. The aim of the interventions is to re-establish emotional stability and improve the ability of parents to cope with the situation, to prevent parental and family adaptive disorders and child developmental disorders. Support focus on screening for psychological disorders. Techniques include family-centred, holistic interventions (e.g. activating parental resources and coping, crisis intervention, stabilization techniques etc.). Parents will receive outpatient psychological support.
92929|NCT03460496|Behavioral|lactation consultant|during hospitalization, the lactation consultant will be involved more frequently than during standard care. Breastfeeding support will take a structured approach and will be performed in close collaboration with both parents. The main aims of structured breastfeeding support are strengthen parent-child bonding. Infants will be breastfed according to their needs. Parents will become competent in meeting their child's nutritional needs. After discharge, parents may schedule outpatient breastfeeding consultations.
92930|NCT03460496|Behavioral|physiotherapeutic interventions|physiotherapeutic interventions will also be structured. The physiotherapist will make an assessment during hospitalization, and decide which physiotherapeutic interventions are necessary. Each family will learn how to handle their premature child in everyday life, based on the child's developmental stage, in a single consultation.
92931|NCT03460496|Behavioral|social workers|social workers will closely collaborate with the APN within the transitional model. They will be involved with every family and will assist the APN in establishing a network with social and medical services within and outside the clinic. They will also support families in coping with daily life and with their integration into society, family and work. Furthermore, they will give advice on social security issues and on asserting claims as well as clarify financial possibilities.
92932|NCT03460496|Behavioral|music therapy|music therapy with premature infants and their parents creates a new dimension of contact, and helps stabilize the child and supports their development through music. It also reduces the anxiety of parents, and enhances self-efficacy and makes them more sensitive to their child 74,75, thus enhancing the parent-child relationship. In standard care, music therapy is offered only during hospitalization. In the new model of care, after NICU discharge, the program will offer 10 follow-up sessions at the family's home or in the music therapists' private practice.
92933|NCT03460496|Behavioral|other health care professionals|the APN will contact and involve other health care professionals, like the family's paediatrician, the outpatient midwife, the community health care nurse or the mother and father counselling as soon as need becomes evident. The APN will help set up meetings between health care professionals and the family, and will keep them up-to-date on the family's situation.
92934|NCT03460496|Behavioral|interprofessional roundtable meetings|interprofessional roundtable meetings with health care professionals involved in the care of a specific family will be held every two weeks. The meeting is aimed at developing consensus on the best possible support in the care of preterm infants and their families. Parents will be invited to participate in these meetings, led by the APN. The meeting will focus on two family situations, and then determine and initiate supportive interventions in collaboration with the parents.
92935|NCT03460496|Behavioral|Advanced practice nurses' interventions|The APN will participate in comprehensively planning individual discharge, coordinating services, consulting with other healthcare professionals, assessing needs on a case by case basis, and coaching the family from birth to 6 months after discharge from the NICU. The APN will provide the Newborn Behavioral Observation (NBO), an infant-centred and family-focused method for building relationships, to parents and children, during and after hospitalization. The NBO helps sensitize parents to their infant's competencies and capabilities, teaching them to read their infant's signals and understand their behaviours. It promotes positive interactions between parent and preterm infant. The APN will also offer telephone support and follow-up Visits at home after discharge.
92936|NCT03460483|Other|Genetic Counseling|Undergo genetic counseling
92937|NCT03460483|Other|Genetic Testing|Undergo genetic testing
92938|NCT03460483|Other|Laboratory Biomarker Analysis|Correlative studies
92939|NCT03460483|Procedure|Mutation Carrier Screening|Undergo tumor screening via next-generation sequencing
92940|NCT03460470|Drug|Sildenafil|PDE5 Inhibitor
92941|NCT03460470|Drug|Placebo oral capsule|Placebo for Sildenafil
92942|NCT03460457|Drug|TQB2450|Pharmacokinetics/Dynamics Study
92943|NCT03460444|Dietary Supplement|MCT Oil Supplementation|Participants consume MCT oil (97-99% octanoic acid) twice per day for 14 days. Dosing will begin at 5ml/dose for Days 1-2, 10ml for Days 3-4, and 15ml for the remainder of the intervention.
92944|NCT03460431|Device|fractional CO2 laser 10,600nm|fractional CO2 laser 10,600nm session, every month for 4 months
92945|NCT03460431|Device|Nd YAG laser1064 nm|Nd YAG laser1064 nm laser session, every month for 4 months
92946|NCT03460418|Other|Phone contact|Assessment of the different outcomes by means of a phone contact
92957|NCT03460288|Behavioral|Retraining (AAT)|The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
92958|NCT03460275|Drug|Osimertinib Mesylate Tablets|Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
92959|NCT03460262|Device|Standard cutiplast®|Our standard dressing consists in a usual ready-to-use Smith and Nephew Cutiplast®. This dressing is open 48 hours after the operation (CDC recommendation) for the first time and then changed every day after wound disinfection.
92960|NCT03460262|Device|PICO®|PICO® is a negative pressure wound therapy consisting in a 4 layers ready-to-use dressing connected to a small console, responsible for the aspiration. The system is canister free. The fluid drained from the wound is lost by evaporation for 80% of it and only 20% remains in the dressing. This permits to the dressing to be kept in place for maximum 7 days. The wound is not checked during the hospital stay, allowing the patient to leave the hospital earlier after the operation.
92961|NCT03460249|Other|BP measurement|the BP will be measured in the chair position followed by the table position and also in the reverse sequence
92962|NCT03460223|Biological|MSC|conventional plus MSC or placebo treatment
92963|NCT03460210|Drug|Atomoxetine|Patients are tested for their normal prescription atomoxetine medication
92964|NCT03460197|Procedure|Endoscopic Ultrasound-Guided Fine-Needle Aspiration|Patients will be submitted to both techniques of tissue acquisition in the same procedure of endoscopic ultrasound. Capillarity technique, requires not remove the stiletto from the needle until the punctures are done for the biopsy sampling. Wet suction technique, requires saline solution to replace the air column. Samplings will be placed in two different jars, where Jar 1 corresponds to Capillarity Technique sampling and Jar 2 to Wet Technique. Once the sampling preparation is concluded will be send to the Pathology Department to be subsequently blindly analyzed by two independent pathologists, that means they would not be aware of the tissue acquisition method used in each of the microscopic slides to analyze.
92965|NCT03460184|Diagnostic Test|G.A Group A:|"G.A will be conducted After pre-oxygenation for 3-5 minutes. thiopental (5 mg/kg) will be administered I.V, followed by succinylcholine 1.5 mg/kg. After tracheal intubation, the patients will be ventilated with 100% oxygen. isoflurane 0.8% will be added, to maintain the anesthesia. Further neuromuscular block will be maintained by using atracurium . After delivery of the fetus, fentanyl IV will be given 1ug/kg as analgesia and 20 IU oxytocin will be given by I.V infusion .Reverse neuromuscular blockade as necessary at completion of surgery. Extubate when the patient is awake~In the sitting position and after complete asepsis , 2-3 ml of Lidocaine will be injected subcutaneously, spinal anesthesia will be performed at interspace L3-4 or L4-5, midline approaches using 22 guage Quinke needle . 2.5 ml of hyperbaric bupivacaine 0.5% in addition to 25 μg fentanyl will be injected into the subarachnoid space after successful dural puncture and confirmation by barbotage."
92966|NCT03460158|Drug|Restylane-L®|Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
92967|NCT03460158|Drug|Restylane-L® Lyft|Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
92968|NCT03460158|Drug|Restylane Silk®|Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
92969|NCT03460145|Other|Lavender Oil on Nasal Strip (Lx)|Usage of Aromatherapy for Preoperative Anxiety
92970|NCT03460145|Other|Strip without Lavender Oil (Px)|Strip without Lavender Oil (Px)
92971|NCT03460145|Drug|Propofol 1 % Injectable Suspension|Propofol 1% (10mg/mL)
92972|NCT03460132|Device|Tomas® Anchorage System - DENTAURUM|self drilling, bone inserted, screw like device used for anchorage preparation during orthodontic treatment.
92973|NCT03460119|Device|High Flow Nasal Cannula Oxygen|The high flow device that we used was an air oxygen blender (Whisper FlowⓇ), which allows FiO2 adjustment between 0.30 and 1.0 and can deliver a gas flow from 10 to 150 l/min. The gas mixture was routed from a heated humidifier (MR850 with MR 290 chamber) through a one line heated inspiratory circuit (RT241) to the subject at a temperature of 37°C via a nasal cannula (OptiflowⓇ).
92974|NCT03460080|Diagnostic Test|AFP-L3 and PIVKA-II in HCC|"Serum samples are tested for tumor markers including PIVKA-II, AFP, AFP-L3% and biochemical tests.~Imaging: CT or MRI"
92975|NCT03460067|Radiation|Omission of Radiation|No Radiation will be given. 1 year of trastuzumab +/- pertuzumab treatment will be given with 5 years of follow up occurring every 3 months to check for recurrence
92976|NCT03460041|Drug|Magnesium Sulfate|caudal magnesium sulphate added to bupivacaine for pain management
92977|NCT03460041|Drug|Dexmetedomedine|Caudal dexmetedomedine added to bupivacaine for pain management
92978|NCT03460041|Drug|Bupivacaine|Caudal bupivacaine for pain management
92979|NCT03460028|Behavioral|Yoga Condition|Participants randomized to the Yoga Condition will participate in an integrated yoga program consisting of yoga postures, breathing exercises, and concentration/meditation practices.
92980|NCT03460015|Drug|Sevoflurane|"During the first 30 minutes after randomization, patients will be treated with propofol (same dosage as the propofol group).~Once the AnaConDa® system is installed, sevoflurane administration will begin (propofol is stopped)."
92981|NCT03460015|Drug|Propofol|"In the control group, sedation will be maintained with the above objective (RASS between -4 and -5, BIS between 40 and 60) until the patient is extubated.~In the sevoflurane group, propofol is administrated during the first 30 minutes after the randomization and when the AnaConDa® system is installed propofol is stopped."
92982|NCT03460002|Biological|Measles vaccine|A measles vaccine prequalified from the World Health Organization will be administered in one dose by deep subcutaneous injection into the left subscapular region by a local nurse.
92984|NCT03459989|Diagnostic Test|Ultrasound|Samsung H60 Ultrasound
92985|NCT03459976|Diagnostic Test|evaluate serum level HE4 in endometrial cancer|"HE4 in beignin endometrial diseases~HE4 in endometrial cancer"
92986|NCT03459963|Device|indwelling urinary catheter|85 women undergoing first elective CS will be catheterized immediately preoperatively using Foley's catheter by applying catheterization precautions.
92987|NCT03459937|Behavioral|Hatha Yoga Intervention|Hatha Yoga will focus on a restorative style of Hatha yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
92988|NCT03459937|Behavioral|Vinyasa Yoga Intervention|Vinyasa Yoga will focus on a more vigorous form of yoga. Total duration will begin at 100 minutes per week and will gradually progress in 4-week intervals until achieving the prescribed dose of 300 min/wk (5 days per week for 60 minutes per day). While attending the behavioral group sessions the participants will also engage in a supervised yoga session with a trained yoga instructor. To facilitate the additional 4 days of unsupervised yoga, we will provide yoga videos that mimic the asanas (poses) and flow patterns that are taught in the supervised yoga sessions. The intervention includes prescribed dietary recommendations based on the participants' baseline body weight, and self-monitoring diaries, meal plans, and sample recipes will be provided. Intervention lessons will also include information related to behavior strategies for achieving the recommended calorie and fat intake goals. Participants will also be provided weekly group intervention sessions across the study period.
92989|NCT03459911|Drug|Cozaar 100mg Tablet|Cozaar® ( Losartan potassium) 100 mg Tablets(Merck Sharpe & Dohme B.V. , Haarlem, the Netherlands)
92990|NCT03459911|Drug|Losartan potassium 100mg|Losartan potassium 100 mg Tablets ( Pharmtechnology LLC, Republic of Belarus)
92991|NCT03459898|Device|AlignRT system (VisionRT Ltd., London, UK)|To review our institutional clinical experience of applying the AlignRT system to monitor patient setup and reproducibility when using ABC and DIBH techniques in the treatment of left-sided breast cancer patients.
92992|NCT03459885|Device|Paired associative stimulation (with eXimia magnetic stimulator and Dantec Keypoint® electroneuromyography device)|Paired associative stimulation (PAS) administered several times per week for 8 weeks to lower limbs. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
92993|NCT03459872|Procedure|Acupuncture|Alternative medicine therapeutic intervention
92994|NCT03459872|Device|RU-Fit|FDA approved medical device for the measurement of fine motor control
92995|NCT03459859|Drug|Pevonedistat|Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.
92996|NCT03459859|Drug|Cytarabine|Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
92997|NCT03459846|Drug|Durvalumab|Durvalumab 1500 mg IV q4w
92998|NCT03459846|Drug|Olaparib|Olaparib PO 300 mg BID adjusted based on patient's creatinine clearance.
92999|NCT03459846|Drug|Placebo|Matching placebo for oral tablet BID
93000|NCT03459833|Drug|Hyaluronic Acid|Glans penis augmentation using multiple puncture technique as described by Abdallah et al. (2012) with minor modifications. HA is injected at two circular levels: one at the level of corona of glans penis and a second circular level is mid-way between the corona and urethral meatus. Six injections are injected at coronal level and four are injected in the second level, each injection is of 0.2 ml and is injected into deep dermis.
93001|NCT03459820|Diagnostic Test|18F-DCFPyL PET/CT|18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
93002|NCT03459807|Drug|Anti-Hypertensive medications|Use of standard Anti-Hypertensive medications
93003|NCT03459807|Procedure|Dry Weight Adjustment|The participant's target post-dialysis dry weight is adjusted
93004|NCT03459794|Drug|Ivermectin|150 mcg/kg ivermectin, by mouth.
93005|NCT03459794|Other|Placebo|An oral placebo will be administered, once
93006|NCT03459781|Behavioral|Cognitively-Based Compassion Training|CBCT® was designed at Emory University by Lobsang Tenzin Negi. CBCT® is a secular adaptation of techniques derived from traditional Tibetan Buddhist methods for cultivating compassion known as lo-jong. Over the course of 8 weeks there will a total of 8 CBCT® sessions, one session per week, led by the CBCT® instructor. Dyads will attend the weekly CBCT® classes together. Each weekly session will last for 90 minutes and will begin with brief meditation to focus attention. The instructor will then articulate content and goals of the current week, after which a group discussion led by the instructor will take place. A session will end with a 20-30 minute meditation. Dyads will be encouraged to practice a minimum of 10 minutes per day at home, and together as a dyad if possible.
93007|NCT03459781|Behavioral|CHE (Cancer Health Education)|The cancer health education (CHE) intervention is an adaptation of the in-person program called Health Discussion, a protocol used by our group previously. The CHE will focus on relevant topics to health and cancer including 1) cancer advocacy, 2) health and cancer biology, 3) nutrition, 4) lifestyle interventions such as physical activity and goals for physical activity, 5) the importance of good sleep, 6) the impact of stress, and 7) mental health and social support. CHE will also discuss current events related to cancer. Over the course of 8 weeks there will be a total of 8 sessions, one session per week. Each session will last for approximately 90 minutes.
93008|NCT03459755|Behavioral|Physical Activity|"Patients will have a baseline assessment by undergoing a maximal exercise testing protocol.~For 12 weeks, patients will participate in an exercise session 3 days per week~The patient will then enter a 12 week Step Down program in which the number of sessions is decreased to every week, then every 3 weeks.~After the second 12-week period, the patient will enter a 28-week follow up period of unsupervised exercise."
93261|NCT03457753|Drug|Riluzole Oral Soluble Film|Riluzole Oral Soluble Film (ROSF) containing Riluzole 50mg .
93009|NCT03459742|Behavioral|Gamification strategy|"The intervention is a gamification strategy, including game elements such as points, levels and rewards. Points are scored by completion of healthy challenges, i.e. a healthy snacks challenge, a steps challenge and activity challenge. Intervention takes place for 8 months from Mar to Nov. There will be three levels. Level 1 at baseline, level 2 expected at month 4 by 100% of participants and level 3 expected in month 8 by 70% of participants. A new cycle will start in 2019.~Rewards include an initial reward (Starting Kit), a structural reward and an activity reward. The Starting Kit is a box with souvenirs, information for students and teachers. A structural reward, at level 2, will be achieved collectively by all participating classes in one school. It consists of school infrastructure improvements to promote a healthy nutrition and PA (eg. climbing wall, shared bicycles, sports equipment). An activity reward (AR), when reaching level 3, consists of a fun and healthy activity."
93010|NCT03459729|Drug|Antitumor B|Study participants will take the natural botanical compound ATB during a short window (seven to 28 days). It will be administered at a dose of 1200 mg three times per day (roughly spaced every 8 hours).
93011|NCT03459716|Other|No intervention|No intervention
93012|NCT03459703|Behavioral|Early Time-Restricted Feeding|Eat all meals between 7 am - 3 pm for an average of ≥6 days per week.
93013|NCT03459703|Behavioral|Control Schedule|Eat all meals over a 12-hour or longer period for an average of ≥6 days per week.
93014|NCT03459703|Behavioral|Structured Weight Loss Program|A structured weight loss program with physical activity recommendations and dietary counseling.
93015|NCT03459690|Behavioral|Meditation|. IK is a meditation that can be learned quickly and requires approximately 12 minutes, twice a day of practice. This regimen was chosen because of its simplicity making it an excellent way to introduce meditation to beginners. IK does not incorporate a spiritual or religious focus
93016|NCT03459690|Device|Enobio 32- EEG machine|The ENOBIO 32 EEG device is an investigational device under US federal law which is a 24-bit EEG data reader which is a wearable wireless device
93017|NCT03459677|Behavioral|Back2School|Modular Trans-diagnostic Cognitive Behavioral Therapy treating school absenteeism in youths
93018|NCT03459677|Other|Treatment As Usual|Aarhus municipality's treatment as usual for youths presenting school absenteeism
93019|NCT03459664|Behavioral|RECOVER|"For each patient baseline assessment and individual support by a diagnostic and crisis resolution home treatment team is available. In addition, patients will be treated with specific interventions based on their severity grade:~Grade 1 (mild): social support, information about mental disorder, e-therapy, consultation, self help, peer-support, supported employment.~Grade 2 (medium): psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 3 (medium to severe): case management, psychotherapy (stepped short-term and group therapy), if applicable medical treatment, e-therapy, peer-support, supported employment.~Grade 4 (severe): assertive community treatment, psychotherapy, medical treatment, e-therapy, peer-support, supported employment."
93020|NCT03459664|Behavioral|Treatment as usual|"For each patient all common care options within the German health care system are available, depending on the severity grade 1 to 4.~This includes the following options: hospital based in-patient, out-patient treatment and day care, community based health care services, general practitioners, private psychiatrists and psychotherapists, self help."
93021|NCT03459651|Behavioral|ANS training|In-home computer-based ANS training
93022|NCT03459638|Other|Screening for DM, ASCVD, MetS and OSAS|Finger stick analysis, questionnaires and clinical measurements
93023|NCT03459625|Behavioral|Mindfulness-Based Stress Reduction (MSBR)|MBSR includes eight weekly 2.5-hour group sessions, a day-long (6hr) meditation retreat on the weekend during week six, 45 minutes of daily home practice guided by instructional audio CDs, and an MBSR parent workbook. Formal mindfulness exercises aim to increase the capacity for mindfulness and include a body scan, mindful yoga, and sitting meditation. Participants are also taught to practice mindfulness informally in everyday activities. In session, didactic instruction on stress physiology and using mindfulness for coping with stress in daily life is provided. Participants practice formal mindfulness exercises, break into dyads to discuss their daily homework practice, and meet as a larger group to ask questions related to the practice of mindfulness in everyday life.
93024|NCT03459625|Behavioral|Psychoeducational Support Group (PE)|The PE consists of 8-weekly 2.5-hour sessions, a day-long (6hr) Family Resource Fair during week six, daily homework that includes monitoring progress on goals identified at the end of each session, and a workbook for parents of children with special needs that provides parents with information regarding their child's development, disability, and associated considerations. Weekly topics for discussion include Preparing for Individualized Education Plan (IEP) meetings, Communicating with Teachers, Advocacy, Sibling Issues, and Community Resources.
93025|NCT03459612|Drug|Lasmiditan|Administered orally
93026|NCT03459612|Drug|Placebo|Administered orally
93027|NCT03459612|Drug|Diphenhydramine|Administered orally
93028|NCT03459599|Drug|Prophylactic antibiotics|Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week
93029|NCT03459599|Other|No prophylaxis (Amox-clav withheld)|Withholding Amox-clav, which is the current local practice for women with ragged placental membranes. This was replaced with appropriate counselling on signs and symptoms of endometritis, when and where women should present if the symptoms above occur. A follow up phone call was performed at 2 weeks and 6 weeks postpartum to ascertain well-being of patients
93030|NCT03459586|Other|9zest app facilitated exercise|The purpose of this study is to determine if the 9zest app for Parkinson's disease is feasible, safe, and efficacious when used independently by individuals with Parkinson's disease
93031|NCT03459573|Behavioral|"One Drop | Experts On Track"|Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
93032|NCT03459573|Behavioral|"One Drop | Experts On Call"|Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
93033|NCT03459573|Behavioral|"One Drop | Experts Revive"|Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
93034|NCT03459560|Drug|PolyPill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, enalapril 5 mg
93574|NCT03455218|Device|INOmax|All patients will have the INOmax device connected to the oxygenator
93035|NCT03459547|Device|dental implant|Local anesthesia, flap preparation, dental implant insertion, flap suture, healing abutment insertion. Peri-implant soft tissue samples taken prior to implant placement and 24 hours after.
93036|NCT03459534|Drug|Radotinib HCl|"Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~Storage conditions: Store in an airtight light proof container at room temperature."
93037|NCT03459521|Biological|Fendrix|Administer hepatitis B virus vaccine (Fendrix®) at standard doses (0,1, 2 and 6 months) in patients with chronic liver disease that have not been vaccinated previously and not immunised
93038|NCT03459508|Diagnostic Test|Ophthalmological examination|Detailed anterior segment examination using slit-lamp biomicroscopy for signs of anterior uveitis, and detailed fundus examination using slit-lamp fundus biomicroscopy with + 90 diopter lens searching for signs of vasculitis and posterior uveitis.
93039|NCT03459495|Device|therapeutic ultrasound|Patients in the ultrasound group will be administered to the posterior neck region for 5 minutes in pulsed mode (pulse rate 1: 1) at 1 MHz, 1.5 W / cm2. The treatment will be done 5 days a week for a total of 10 days
93040|NCT03459495|Device|placebo ultrasound|When the ultrasonic device is in the closed position, the ultrasonic probe will be applied for 5 minutes in the posterior neck region of the patients. The treatment will be done 5 days a week for a total of 10 days.
93042|NCT03459469|Drug|Tegavivint|This is an Investigational drug
93043|NCT03459456|Behavioral|Provocation OC task (Provoc)|used to evoke OC-related distress
93044|NCT03459456|Behavioral|Trier Social Stress Test (TSST)|used to evoke anxiety unrelated to OCD (e.g., performance anxiety)
93045|NCT03459456|Behavioral|Exposure provocation task|used to elicit overt OCD rituals
93046|NCT03459443|Drug|ACH-0144471|All participants will receive ACH-0144471 oral tablets at an individually selected starting dose, with the opportunity for dose adjustment over the first two weeks.
93047|NCT03459430|Other|Core stability training|Effect of different core stability programs using diverse training intensities
93048|NCT03459417|Procedure|intrathecal morphine+LA|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage. patients will receive intrathecal LA 15 mg (3 mL) (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 100 mg.
93049|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 50|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal +0.5 mg preservative free morphine + magnesium sulphate 50 mg.
93050|NCT03459417|Procedure|intrathecal morphine+LA+ Mg sulp. 100|Lumbar puncture will be performed in the sitting position. A 25 gauge (pencil point, Braun, Melsungen, Germany) spinal needle will be introduced into the subarachnoid space at the L3-L4 lumber level midline approach with the needle orifice cephalad. Cerebrospinal fluid will be aspirated and the ready mixture will be injected to subarachnoid space over the period of 15 s, with barbotage.patients will receive intrathecal 15 mg (3 mL) of hyperbaric bupivacaine 0.5% intrathecal with 0.5 mg preservative free morphine + magnesium sulphate 100 mg.
93051|NCT03459404|Combination Product|Sufentanil NanoTab PCA System|15 mcg Sufentanil NanoTab self-administered sublingually up to every 20 minutes as needed for pain for at least 48 hours and up to 72 hours
93052|NCT03459391|Drug|XC221 60 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
93053|NCT03459391|Drug|XC221 200 mg|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
93054|NCT03459391|Drug|Placebo|The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
93055|NCT03459378|Other|no intervention - retrospective analyses|retrospective data examination, there are no study related interventions
93056|NCT03459365|Device|Euflexxa|Aspirations performed before each injection and at six weeks.
93057|NCT03459352|Other|ePRO|"Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction."
93058|NCT03459339|Device|Tethered Capsule Endomicroscopy (TCE)|Tethered Capsule Endomicroscopy will be used to detect Barrett's Esophagus
93059|NCT03459326|Other|IIEF (International Index of Erectile Function questionnaire )|"The questionnaire is presented and answered without help. Answers to the IIEF Questionnaire will be collected in order to obtain the following scores (the total score is of no interest):~Erectile function (score 1 to 30)~Orgasmic function (score 0 to 10)~Desire (score 2 to 10)~Sexual satisfaction (score 0 to 15)~Overall satisfaction (score 2 to 10)"
93060|NCT03459313|Other|Active group|For this study, the Frisk.Friidrott (Healthy.Athletics/Track&Field) website has been developed. The purpose of the website is to provide an easy-to-use tool that can assist coaches and parents involved in youth athletics with information how to structure training and recovery planning, provide guidance on possible injuries, and provide other information on health for youth athletes.
93061|NCT03459287|Device|INTERCEPT|Pathogen reduced RBCs
93062|NCT03459287|Device|Control|Conventional RBCs
93150|NCT03458598|Drug|Patient controlled opioid analgesia (PCA)|Patients in both groups will have PCA dilaudid or morphine prescribed for the post-operative period.
93063|NCT03459274|Device|VR-Biofeedback|The intervention uses a smart phone with a virtual reality app; a headset that connects to the phone and has goggles that contribute to the 3 dimensional, interactive, and surrounding aspects of the experience; headphones through which subjects hear calming sounds and guiding voices from the experience; an attached microphone that allows subjects to monitor their breathing and interact with their environment through their breath; and a heart rate monitor whose realtime data on variability has an affect on the virtual environment. The virtual reality experience guides subjects through deep breathing exercises. Subjects will attempt to match a certain slow breathing rate, and pulse and breathing rate will cause non-stressful changes to the environment.
93064|NCT03459261|Diagnostic Test|blood sample on admission (ADD), first postoperative day (POD1) and fourth postoperative day (POD4)|Laboratory analyses of peripheral venous blood on admission (blood sample ADD), 24 hours after surgery (blood sample POD1) and fourth-day after surgery (blood sample POD4) included biochemical analysis, complete blood count, C-reactive protein (CPR), procalcitonin (PCT), albumin/protein level, prothrombin time and international normalized ratio (INR) (only on admission) and for determination of cytokines: tumor necrosis factor alpha (TFN-α), interleukin-6 (IL-6), interleukin-10 (IL-10).
93065|NCT03459248|Other|Dual therapy|combination of 10 mg metoclopramide with 4 mg ondansetron
93066|NCT03459248|Other|Monotherapy|10 mg metoclopramide
93067|NCT03459248|Other|General anesthesia|Induction of general anesthesia will be performed followed by endotracheal intubation.
93068|NCT03459235|Other|quality of life|Assessment of the impact of digestive sequelae (LARS score) and genitourinary sequelae (score IPSS, USP, FSFI et IIEF) in Patients With Rectal Cancer using validated questionnaires on quality of life (EORTC QLQ-C30 et QLQ-CR 29).
93069|NCT03459222|Biological|Relatlimab|Specified dose on specified days
93070|NCT03459222|Biological|Nivolumab|Specified dose on specified days
93071|NCT03459222|Drug|BMS-986205|Specified dose on specified days
93072|NCT03459222|Biological|Ipilimumab|Specified dose on specified days
93073|NCT03459209|Other|tube feeding|The obtained milk aliquots undergo in vitro administration through three different tube feeding techniques.
93074|NCT03459196|Device|THERMOCOOL SMARTTOUCH SF-5D Catheter|radiofrequence ablation with THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode
93075|NCT03459183|Device|Infrasound (85 dB; 6Hz) source|the infrasound source will emit inaudible 6Hz sound for 8 consecutive hours during participant's night sleep, local sound pressure (at participants head) will be calibrated at 85 dB
93076|NCT03459183|Device|Ultrasound (10dB below hearing threshold; 22.4 kHz) source|the ultrasound source will emit inaudible 22.4 kHz sound for 8 consecutive hours during night sleep
93077|NCT03459183|Device|Infrasound dummy source|the infrasound dummy source looks exactly like the according verum infrasound source but produces absolutely no sound
93078|NCT03459183|Device|Ultrasound dummy source|the ultrasound dummy source looks exactly like the according verum ultrasound source but produces absolutely no sound
93079|NCT03459170|Biological|BPX-501 T cells|Biological: T cells transduced with CaspaCIDe® safety switch
93080|NCT03459170|Drug|rimiducid|administered to kill BPX-501 cells in the event of GVHD
93081|NCT03459157|Drug|HIV prevention package including PrEP|All MSM enrolled will benefit from a comprehensive HIV prevention package including quarterly clinical examinations, screening and treatment of STIs, screening of HIV, PrEP (TDF 300 mg + FTC 200 mg), daily or on-demand, according the participant's choice, immunisation against hepatitis B, individualised peer-led support (for adherence and prevention), group discussions, condoms, and lubricants.
93082|NCT03459144|Drug|verteporfin|Participants will receive the intravitreal ranibizumab treatment (0.05mg) at baseline and additional intravitreal ranibizumab(0.05mg) will be given to the participants when necessary（every three months）.
93083|NCT03459144|Drug|verteporfin and ranibizumab|Participants will be given the standard verteporfin photodynamic therapy followed by intravitreal ranibizumab (0.05mg) 72h after the PDT treatment at baseline. Additional verteporfin photodynamic therapy and intravitreal ranibizumab (0.05mg) will be given to the participants when necessary.
93084|NCT03459131|Device|Comfilcon A with Digital Zone Optics™ contact lenses|Silicone hydrogel spherical contact lenses with Digital Zone Optics™
93085|NCT03459131|Device|Comfilcon A contact lenses|Silicone hydrogel spherical contact lenses
93086|NCT03459118|Behavioral|Function Focused Care|The intervention in the parent study involves the use of a participatory implementation approach as delineated in the Evidence Integration Triangle. Prior to implementation, we meet with the administrator, service coordinator, delegating or oversight nurse or setting contact designee to identify the setting champion and stakeholder team members. In addition to the champion, we recommend the following individuals be included in the stakeholder team: an administrator in a leadership position (e.g. assisted living manager, delegating/overseeing nurse); a direct care worker; a family member; an activity staff member if available; and a resident. FFC-AL-EIT is implemented by a Research Nurse Facilitator working with the stakeholders using our four step approach: (I) Environment and Policy Assessments; (II) Education; (III) Establishing Resident Function Focused Care Service Plans; and (IV) Mentoring and Motivating.
93087|NCT03459105|Procedure|Ultrasound-assisted paramedian spinal anesthesia|A preprocedural ultrasound scanning will be done, and skin marking will be made. The needle entry point and insertion angle will be determined based on ultrasound scanning. Spinal anesthesia will be performed via paramedian approach.
93088|NCT03459105|Procedure|Landmark-guided spinal anesthesia|Spinal anesthesia will be done using conventional landmark-guided technique.
93089|NCT03459105|Drug|0.5% heavy bupivacaine|0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
93090|NCT03459092|Drug|Botulinum toxin type A|Botulinum toxin injection in the horizontal extraocular muscles.
93091|NCT03459092|Procedure|Strabismus surgery|Strabismus surgery on the horizontal extraocular muscles
93092|NCT03459079|Drug|Lanifibranor|The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day
93262|NCT03457740|Dietary Supplement|Formula 1|Dietary supplement for strength, testosterone, sexual function, quality of life
93093|NCT03459079|Other|Placebo|Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.
93094|NCT03459066|Diagnostic Test|Institution-Group|"The study includes three measurement times:~Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization.~Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement.~Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement.~The evaluations will be tone, functionality and quality of life."
93095|NCT03459053|Behavioral|CBART|Cognitive Behavioral protocol that uses art-making for stress reduction and cognitive interventions
93096|NCT03459040|Drug|Alpha 1-Antitrypsin|AAT will be given either in the hospital or the outpatient clinic two times per week.
93097|NCT03459027|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g) acutely
93098|NCT03459027|Dietary Supplement|Beetroot powder|Nitrate devoid beetroot powder (10g) acutely
93099|NCT03459014|Other|Stimulus rich VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
93100|NCT03459014|Other|Stimulus poor VE|Participants will walk in the Lokomat with the VR for 21 minutes. After every 7 minutes, the speed of the OF will change (2 times the comfortable walking speed, equally to the comfortable walking speed, and 0.5 times the comfortable walking speed).
93101|NCT03459001|Other|Tube Feeding Product|a high calorie, high protein tube feed product consumed sole source per their physician's recommendation and per standard of care
93102|NCT03458988|Device|Blood-pressure measuring (Nellcor™ Adult SpO2 Sensor)|Data will be acquired for 10 minutes with a reusable off the shelf adult SpO2 sensor. The Nellcor™ Adult SpO2 Sensor, model DS-100A, is indicated for use when continuous noninvasive arterial oxygen saturation and pulse rate monitoring are required for patients weighing greater than 40 kg.
93103|NCT03458975|Radiation|MRI|Magnetic Resonance Imaging
93104|NCT03458975|Radiation|Perfusion CT scan|Perfusion Computerized tomography scan
93105|NCT03458975|Other|Contrast enhanced ultrasound|Contrast enhanced ultrasound
93106|NCT03458975|Drug|Sonoporation|Gaseous microbubbles (Sonovue) combinated with Ultrasounds
93107|NCT03458962|Genetic|Genetic Enrollees|Identification of new genetic diagnoses in children with multiple congenital anomalies, developmental delay, autism, seizures, intellectual disabilities, neurodegenerative disorders and metabolic illness. Samples and data will be stored in a pediatric biorepository. A subset of samples will undergo genetic/genomic analysis.
93108|NCT03458949|Other|awareness campaign|awareness campaign for colorectal cancer screening in the workplace
93109|NCT03458923|Drug|Diclofenac Sodium 0.1 ml containing 500µg|15 eyes will receive intravitreal 0.1 ml containing 500µg of Diclofenac Sodium monthly for three months
93110|NCT03458923|Drug|Ranibizumab 0.5 mg Solution for Injection|15 eyes will receive intravitreal 0.5 mg of Ranibizumab monthly for three months
93111|NCT03458910|Behavioral|HRV training|Participants will be asked to undergo daily practice to regulate (either increase or decrease) HRV for 5 weeks.
93112|NCT03458897|Diagnostic Test|serial functional magnetic resonance imaging (MRI)|All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.
93113|NCT03458884|Other|Cardiorespiratory interval training|A structured cardiorespiratory interval training program on an ergometer cycle 3 days a week for 8 weeks.
93114|NCT03458871|Device|4-week TTNS home-based protocol|"4-week TTNS home-based protocol. Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is not contraction seen, maximal tolerable intensity will be used.~In addition, if the patient perceives pain, the intensity will be lowered until comfortable.~Stimulation frequency of 10 Hz and pulse width of 200ms in continuous mode will be used."
93115|NCT03458858|Other|Mixed Berry Diet|Mixed Berry Treatment
93116|NCT03458858|Other|Carbohydrate Control Jello|Carbohydrate Control
93117|NCT03458858|Other|Fiber Enriched Jello|Fiber Control
93118|NCT03458858|Other|Low Fiber Mixed Berry Juice|Anthocyanin Control
93119|NCT03458845|Diagnostic Test|Computed Tomography Scan|The results of the CT scan and the hand-grip test will be used for diagnosis of sarcopenia. The Royal Free Hospital-Global Assessment (RFH-GA) results will classify the nutritional status of the patient.
93120|NCT03458832|Diagnostic Test|FSHD-specific functional rating scale|The FSHD-COM is composed of disease-relevant functional tasks such as leg function; shoulder and arm function; trunk function, hand function, and balance.
93121|NCT03458832|Device|Electrical Impedance Myography|EIM is a non-invasive, painless, and fast technique for obtaining information on how a patient's muscle structure is changing. EIM uses a small electrical current to measure the health of the underlying muscle. The patient will be asked to lie down and a trained clinical evaluator will perform testing on 16 total muscles (8 on each side) on your arms and legs.
93122|NCT03458819|Diagnostic Test|Isolation of peritoneal mesothelial cells|HPMCs will be isolated and stored at -80 degrees until analysis. Changes in the protein expression of EMT markers such as E-cadherin, a- SMA, Snail, and fibronectin in the HPMCs will be evaluated by Western blot analysis.
93123|NCT03458806|Diagnostic Test|AS Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
93124|NCT03458806|Diagnostic Test|AS Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.
93125|NCT03458806|Diagnostic Test|MR Algorithm 1|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
93126|NCT03458806|Diagnostic Test|MR Algorithm 2|Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.
93127|NCT03458793|Behavioral|Group walking and group educational workshops|"The experimental group will take part in 12 week intervention consisting of group walking and group educational workshops.~Group walking sessions will run once weekly for up to 45 minutes each in small groups (up to 8-9 people per group) and will be delivered by a trained walk leader once weekly for duration up to 45 minutes per session.~Group educational workshops will be delivered in the form of a group presentation once weekly for up to 45 minutes by the research team (i.e. the PhD student) on a variety of topics focused on the healthy ageing, such as eye hygiene, mental health and well-being, preventing falls, social support, nutritional guides, physical activity recommendations for older adults and other topics"
93128|NCT03458780|Drug|Yellow Fever Vaccine|Yellow Fever Vaccine .5 ml
93129|NCT03458767|Behavioral|Eight weekly 90-minute group educational sessions|Eight weekly 90-minute group educational sessions, originally developed for the MAPSS-MS intervention, adapted for remote web-based delivery.
93130|NCT03458741|Other|Glycogen Supercompensation|The subjects arrived in the morning in the overnight fasted state at day 1, day 2 and day 5. Upon arrival in the morning the subjects were given a meal corresponding to 5% of their daily energy intake (~600-800 kJ). During the 5 day supercompensation regime the subjects were provided a predefined isocaloric diet containing 80% carbohydrates, 10% fat and 10% proteins. All food items were handle out to the subjects and compliance of the diet regime was ensured by survey.
93131|NCT03458728|Drug|BAY806946|Copanlisib will be dosed on Day 1, Day 8, and Day 15 of every 28-day cycle. Phase 1: 2 or 3 dose cohorts may be evaluated in phase 1 of the study. Phase 2: RP2D for copanlisib in pediatric patients, as defined in the Phase I part of the study, will be used.
93132|NCT03458715|Drug|SGLT2 inhibitor (Empagliflozin 25 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
93133|NCT03458715|Drug|DPP4 inhibitor (Linagliptin 5 MG)|We randomized add SGLT2 inhibitor (Empagliflozin 25 MG) or DPP4 inhibitor (Linagliptin 5 MG) to type 2 diabetes patient poorly controlled with premix insulin therapy.
93134|NCT03458702|Behavioral|YogaFit|For YogaFit Vinyasa Flow (referred to as YogaFit in this manuscript)], participants followed, via digital versatile disc, a standardized YogaFit format choreographed by an American Council of Exercise Certified and Registered Yoga Teacher (RYT). YogaFit was performed in the same laboratory setting and lasted 30 min. YogaFit is a westernized version of yoga that does not use Sanskrit terms (Shaw 2009). Breath was an integral part of every movement with specific breath rates for each phase of the session. The objective was to move the body with intention and purpose and be present in the body.
93135|NCT03458702|Behavioral|Quiet Rest|Participants completed 30 min of quiet rest
93136|NCT03458689|Procedure|Left hemicolectomy, laparoscopic technique|Left hemicolectomy, Laparoscopic technique
93137|NCT03458676|Procedure|Advanced Magnetic Resonance Imaging Scan|"AMRI scan performed within 2 weeks before standard of care brain biopsy and tumor removal surgery.~AMRI scan should take less than 1 hour to complete"
93138|NCT03458676|Procedure|Standard of Care Brain Biopsy and Tumor Removal|"During the surgery, the neurosurgeon(s) uses the information collected from the AMRI to decide what area of the brain tumor will be biopsied.~Biopsies from up to 5 locations taken before the tumor is surgically removed."
93139|NCT03458663|Device|Prevena™ og ACTIV.A.C™ Therapy System.|A vacuum assisted (negative pressure) system, Prevena ™ and ACTIV.A.C ™ therapy system have been developed to maintain drainage on closed incisions. The system also works by altering the cytokine profile locally so that it functions anti-inflammatory, by increasing local growth factors and promoting angiogenesis19. Negative pressure wound management (NPWM) such as Prevena ™ and ACTIV.AC ™ is a widely used tool with many different variations, but the evidence of effect remains sparse and more studies are required20. We believe that in a dry and closed incision such as the one after BCL surgery, in an area exposed to stretching during healing, it must be an advantage of maintaining drainage, reducing the anti-inflammatory response and increasing angiogenesis.
93140|NCT03458650|Drug|LXI-15028 50mg|In escalated single-dose study, the subjects in each dose group will receive single oral dose of 50 mg LXI-15028 tablet or 1 matching placebo tablet at fasted state,
93141|NCT03458650|Drug|LXI-15028 100mg|100 mg LXI-15028 tablet or matching placebo 1 tablet at fasted state, In multiple-dose study, the subjects who administered 100mg single dose will continuously receive oral 100 mg LXI-15028 tablet or 1 matching placebo tablet once daily (QD) for 10 times.
93142|NCT03458650|Drug|LXI-15028 200mg|single oral dose 2 100 mg LXI-15028 tablets or 2 matching placebo tablets at fasted state
93143|NCT03458650|Drug|Placebo|matching placebo tablets
93144|NCT03458637|Behavioral|LITE Program and Usual Care|Family based lifestyle Intervention
93145|NCT03458637|Behavioral|Usual Care|Usual care consisting of 3 visits to weight management clinic
93146|NCT03458611|Behavioral|Active Intervention|An audiovisual expanding (looming) stimulus is presented repeatedly to patients during the intervention (Dent & Humphreys, 2011). During the game a disk is presented to the player. This disk expands and contracts in size. The presentation of the disk coincides with the presentation of a sound that matches in frequency. The disk predicts the location where the next target will be presented. The player must discriminate between two types of target stimuli that are presented at the center of the disk. To discriminate between the two targets, the player receives a limited time window. The location of the disk and target stimuli are adjusted in real-time as a function of the player's performance. The primary goal of this algorithm is to present the multisensory looming stimuli more frequently in the contralesional field than in the ipsilesional field.
93147|NCT03458611|Behavioral|Placebo Intervention|The active and placebo intervention are identical in all aspects except for the fact that stimulus presentation will be located in the center of the visual field.
93148|NCT03458598|Procedure|Rectus sheath block|Rectus sheath block under ultrasound
93149|NCT03458598|Procedure|Bilateral rectus sheath catheter|A nerve block catheter known as a continuous rectus sheath block is inserted by the surgeon at the end of the operation. An infusion of 0.2% ropivacaine is delivered through this for up to 48 hours post-operatively.
93263|NCT03457740|Dietary Supplement|Formula 2|Dietary supplement for strength, testosterone, sexual function, quality of life
93151|NCT03458598|Procedure|Subcutaneous injection saline placebo|Subcutaneous injection of 1ml of normal saline under ultrasound guidance at the same site bilaterally as rectus sheath blockade is performed
93152|NCT03458585|Other|Self-administered questionnaire|Self-administered questionnaire
93153|NCT03458572|Device|Seirin Pyonex press needle acupuncture|Acupuncture
93154|NCT03458559|Drug|Radium-223 chloride|Intravenously 50 kBq/kg every 4 weeks. Total: 6 administrations
93155|NCT03458559|Drug|Rhenium-188-HEDP|Intravenously 40 MBq/kg every 8 weeks. Total: 3 administrations
93156|NCT03458546|Drug|Roflumilast|All patients will receive R-CHOP therapy at standard doses according to the standard preparation and infusion procedures of each investigational site, which is to be repeated every 21 days for a total of 6 cycles. All patients will receive a fixed oral dose of one 500 microgram (μg) tablet per day with or without food for all 21 days of each cycle, which will amount to a total of 126 doses of roflumilast.
93157|NCT03458533|Procedure|Bariatric surgery|
93158|NCT03458533|Behavioral|Diet and lifestyle changes|
93159|NCT03458520|Diagnostic Test|PET/MR imaging|undergo PET/MR imaging
93160|NCT03458520|Diagnostic Test|MR imaging|Undergo MR imaging
93161|NCT03458520|Diagnostic Test|PET/CT imaging|Undergo PET/CT imaging
93162|NCT03458507|Device|Switch of nocturnal NIV interface|"test the alternative interfaces (either a nasal mask for the patient used to oronasal mask or inversely an oronasal mask if the usual mask is nasal) during a one-hour diurnal NIV session. SpO2 (polygraphy), PtcCO2 will be monitored continuously during this diurnal session. Patients will use their usual NIV device prescribed at home. NIV settings will be adapted if needed.~Interface switch~unattended nocturnal polygraphy under NIV (cf details below) will be performed at home with SomnoHolter® (Nomics, Liege, Belgium), synchronized with transcutaneous partial pressure in CO2 (PtcCO2) monitoring by SenTec V-Sign™ System.~The PtcCO2 device will be calibrated before and at the end of each night to allow drift correction."
93163|NCT03458494|Other|Mediterranean Diet|Participants will receive meals traditionally consumed in Mediterranean countries
93164|NCT03458494|Other|Low-fat diet|Participants will receive meals with a low content of total fat.
93165|NCT03458481|Drug|SOF|400 mg tablet administered orally once daily
93166|NCT03458481|Drug|DAG181|Capsule administered orally once daily
93167|NCT03458468|Drug|Tranexamic Acid|1g Tranexamic acid prior to skin incision
93168|NCT03458468|Drug|Saline|Equivalent volume of saline prior to skin incision
93169|NCT03458455|Diagnostic Test|Magnetic Resonance Imaging|Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.
93170|NCT03458455|Radiation|Stereotactic Radiosurgery|A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
93171|NCT03458455|Drug|Ipilimumab, nivolumab or pembrolizumab|A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
93172|NCT03458442|Other|Simulation-based surgical training|"Those in the intervention group will be introduced to a variety of simulation-based surgical training techniques. Specifically, this will involve breaking down the SICS cataract surgery procedure into stages, and practicing each stage repeatedly using simulation. This sustained deliberate practice will be integrated into the six-week course, as an enhancement to the course, and not as a replacement of any part of the educational content. Within the last three weeks of the course, 'intervention' arm participants will be introduced to the artificial eyes, the Simulation-OSSCAR rubric, and be provided with ongoing feedback.~All participants in both intervention and control arms will undertake the six-week Orbis-COS training course."
93173|NCT03458442|Other|Standard surgical training|Standard surgical training (without bespoke training scheme using simulation and model eye). All participants in both intervention and control arms will undertake the existing six-week Orbis-COS training course, which includes 2-4 weeks of didactic lectures, surgical observation, and wet lab training with a minimum of 50 pig eye wet lab simulations per trainee. After observed mastery of wet lab pig eyes, trainees then perform hands-on training in county level hospitals. The hands-on training pairs a surgeon from the training centre to mentor the trainee through a minimum of 30 assisted surgeries and 50 independent surgeries under supervision.
93174|NCT03458429|Drug|GMFFP|Granulocyte-Colony Stimulating Factor (G-CSF) Mobilized Fresh Frozen Plasma
93175|NCT03458416|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
93176|NCT03458403|Procedure|Motions during gastroscopy|Recording of endoscopist and endoscope motions right after the endoscopic exam the patient came for. The endoscope is removed halfway up the esophagus and inserted into the pylorus to the descending duodenum. The gesture is repeated three times.
93177|NCT03458390|Device|HyGIeaCare colon irrigation|PillCam COLON for visualization of bowel lining
93178|NCT03458377|Other|Educational telephone call|Explanation of the importance of making the test. Guidelines for the usual medication of the patient. Definition of fasting, explanation of colon cleansing adjusted to the presence of predictors of poor basic preparation. Explanation of the endoscopic procedure with the elimination of erroneous concepts of the patient with respect to the procedure. Explanation of norms of action subsequent to the endoscopy. Management of scheduling, destined to improve the adherence of the patient for the test.
93179|NCT03458364|Device|High flow nasal cannula|High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
93219|NCT03458117|Genetic|Talimogene Laherparepvec (T-VEC)|a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)
93220|NCT03458104|Other|Cone Beam Computed Tomography|Cone Beam CT of the larynx
93264|NCT03457740|Dietary Supplement|Placebo|Placebo comparison
93180|NCT03458364|Device|Noninvasive ventilation|Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
93181|NCT03458351|Device|Remote ischemic preconditioning|Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.
93182|NCT03458351|Device|Sham control|The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
93183|NCT03458338|Diagnostic Test|estimated glomerular filtration rate and albuminuria|chronic kidney disease according to KDIGO
93184|NCT03458325|Combination Product|Furoscix Infusor|Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
93185|NCT03458312|Behavioral|Family and Network Consultations|"Family and Network Consultation' (FNC) seek to identify and address patients' symptoms/concerns and caregiver burden on one side and identify the resources and opportunities to ease their burdens on the other side.~Intervention: FNC IG will receive four family consultations over 52 weeks relying on the Calgary model and Patient-reported outcome on symptom management and concerns."
93186|NCT03458299|Behavioral|Motivational Interviewing|2 hours of motivational interviewing
93187|NCT03458299|Behavioral|Psychoeducation|2 hours of DVD viewing and discussion
93188|NCT03458286|Device|BRH-A2 wound healing device|Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
93189|NCT03458273|Procedure|Zero fluoroscopy ablation|Catheter ablation for the treatment of atrial and ventricular arrhythmia - no fluoroscopy guidance
93190|NCT03458273|Procedure|Conventional ablation without 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance only. 3D system (Every Ensite/Carto) is not allowed
93191|NCT03458273|Procedure|Conventional ablation with 3D|Catheter ablation for the treatment of atrial and ventricular arrhythmia - fluoroscopy guidance + 3D system support (Ensite/Carto)
93192|NCT03458260|Drug|Pixantrone|6 cycles - dose = 80mg/m²
93193|NCT03458260|Other|Ifosfamide|6 cycles - 1500 mg/m2
93194|NCT03458260|Other|Etoposide|6 cycles - 150 mg/m2
93195|NCT03458260|Other|Rituximab|6 cycles - 375 mg/m2
93196|NCT03458260|Procedure|Transplant|after 2 or 6 cycles
93197|NCT03458247|Drug|Abiraterone acetate standard dose|1000 mg/day
93198|NCT03458247|Drug|Abiraterone acetate escalated dose|2000 mg/day
93199|NCT03458234|Device|16 French Foley Catheter|"A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex."
93200|NCT03458221|Drug|Itraconazole|based on the predominant Signal transduction pathway analysis 'targeted therapy' will be administered
93201|NCT03458208|Drug|Metformin|"First aIntervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fasting condition"
93202|NCT03458208|Drug|Glucophage®|"Second Intervention Period:~Single administered dose of Glucophage® (1 000 mg tablet immediate release) in a fasting condition"
93203|NCT03458208|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
93204|NCT03458208|Drug|Glucophage®|"Fourth Intervention Period:~Single administered dose of Metformin (1 000 mg tablet immediate release) in a fed condition"
93205|NCT03458195|Other|bio-banking collection|blood samples, biopsies, and surgical specimen collected in addition to usual practice
93206|NCT03458182|Other|Added exercise|After completion of the standard exercise test, an intervention period of 2 minutes of low intensity exercise is added.
93207|NCT03458169|Device|Therapist LEAP session feedback|A standard therapy session is being performed with a participant with the LEAP body-weight support robot. Subsequently, the therapist is answering a questionnaire to assess the clinical applicability of the robot. An observer will assess with a questionnaire whether use errors occurred during the session.
93208|NCT03458169|Device|Participant LEAP session feedback|A standard therapy session is being performed with a participant inside the LEAP body-weight support robot. Subsequently, the participant is answering a questionnaire to assess the comfort of the robot.
93209|NCT03458169|Device|LEAP risk control validation|The therapist rates the risk control measurements of the LEAP robot with a questionnaire, during a session with a member of the investigational team.
93210|NCT03458156|Biological|SLE group|The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.
93211|NCT03458156|Biological|LN group|The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.
93212|NCT03458156|Other|the control group|The patients will be assigned to the control group.
93213|NCT03458143|Drug|Ketamine 150 ng/ml|conscious sedation in TCI-mode
93214|NCT03458143|Drug|Remifentanil|conscious sedation in TCI-mode
93215|NCT03458143|Procedure|Oocyte retrieval|Oocyte retrieval for In Vitro Fertilization
93216|NCT03458143|Drug|Ketamine 200 ng/ml|conscious sedation in TCI-mode
93217|NCT03458130|Drug|AG10|TTR stabilizer
93218|NCT03458130|Drug|Placebo Oral Tablet|Nonactive control
93260|NCT03457766|Device|HIFU|Ultrasound (Esaota MyLabSeven) imaging system using (SL2325) probe with (6-19 MHz) frequency
93221|NCT03458104|Diagnostic Test|Acoustic/Auerodynamic testing|Records and displays real-time sound pressure level intensity, intraoral pressure, airflow rate, and fundamental frequency
93222|NCT03458104|Diagnostic Test|Laryngovideostroboscopy|Visualization of vocal cords in slow motion. It uses a stroboscopic lamp, which generates regular flashes of light. A flexible tube is inserted in the back of the mouth or through the nose and into the throat. Video pictures are then recorded while patients are making sound.
93223|NCT03458091|Device|THRIVE|Oxygenation during apnea using transversal humidified oxygen
93224|NCT03458091|Device|Endotracheal intubation|Ventilation during the procedure is governed by an endotracheal tube in the trachea and mechanical ventilation
93225|NCT03458078|Drug|Saline Solution|Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.
93226|NCT03458078|Drug|Magnesium Sulfate|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).
93227|NCT03458078|Drug|Midazolam 5 MG/ML Injection|Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
93228|NCT03458065|Device|ICD|Implantable Cardioverter Defibrillator
93230|NCT03458026|Other|Connected object use combined with SMS (text messages) of physical activity reminders|Watch connected used and receipt of SMS (text messages)
93231|NCT03458026|Other|Without connected object|Any intervention except follow-up visit
93232|NCT03458013|Behavioral|Mindfulness Meditation|Guided using an mp3 player and noise cancelling headphones, participants will be led through a series of mindfulness meditations lasting approximately 20 minutes each.
93233|NCT03458000|Device|PillCam UGI|An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.
93234|NCT03457974|Other|saliva|salivary secretion rate, salivary buffering capacity, pH, protein levels, superoxide dismutase (SOD), ferric reducing antioxidant power (FRAP), the thiobarbituric acid reactive substances (TBARS), protein carbonyl, protein thiols, total sialic acid.
93235|NCT03457961|Drug|Perampanel|This study collects clinical information during the first 16 weeks after the first dose of AMPA/NMDA receptor antagonist. Subjects or caregivers shall provide seizure diary which documents seizure type and seizure frequency as per usual medical care. The final visit will be based on the week-16 visit.
93236|NCT03457948|Procedure|Arterial Embolization|Undergo TAE
93237|NCT03457948|Procedure|Cryoablation|Undergo CT-guided cryoablation
93238|NCT03457948|Biological|Pembrolizumab|Given IV
93239|NCT03457948|Biological|Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate|Given IV
93240|NCT03457948|Device|Yttrium-90 Microsphere Radioembolization|Undergo yttrium-90 microsphere RE
93241|NCT03457935|Other|blood samples|Blood samples
93242|NCT03457909|Device|DS-MCE|During the DS-MCE examination,the capsule is allowed to travel down into gastric cardia,from where the string is slowly pulled to allow the capsule to view the esophagus retrogradely.
93243|NCT03457896|Drug|Trastuzumab|Patients with HER2 amplified tumors with prior anti-EGFR therapy and/or HER2 mutated colorectal cancer with/or without prior anti-EGFR therapy will receive 4 mg/kg IV loading dose; then 2 mg/kg IV weekly until disease progression. Neratinib: 240 mg taken by mouth daily until disease progression.
93244|NCT03457896|Drug|Cetuximab|Patients with HER2 WT or HER2 amplified with no prior anti-EGFR therapy: 400 mg/m2 IV loading dose; then 250 mg/m2 IV weekly. Neratinib 240 mg taken by mouth daily until disease progression.
93245|NCT03457896|Drug|Neratinib|240 mg taken by mouth daily until disease progression.
93246|NCT03457896|Diagnostic Test|Guardant360 Diagnostic Test|Prior to assignment to Arm 1, the Guardant360 diagnostic test will be conducted in blood to confirm known HER2 status for select patients.
93247|NCT03457883|Device|herniamesh|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
93248|NCT03457883|Device|biological graft|Patients were randomly assigned in a ratio of 1:1,by using SPSS19.0 statistical software, to either trocar-guided transvaginal mesh(herniamesh, group A) or biological graft (cook, group B)repair.
93249|NCT03457870|Behavioral|Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet.
93250|NCT03457870|Behavioral|Chewing|Asked to chew 1 piece of gum for 10 minutes 3 times a day.
93251|NCT03457870|Behavioral|Chewing + Intermittent Energy Restriction|Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
93252|NCT03457857|Other|Cleanser|Cosmetic Baby Cleanser/Shampoo
93253|NCT03457857|Other|Cleanser and Lotion|Cosmetic Baby Cleanser/Shampoo and Baby Lotion
93254|NCT03457844|Drug|Anlotinib|Anlotinib is followed Day 1 to day 14 by 7 days off treatment in a 21-day cycle） and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
93255|NCT03457818|Drug|Denosumab 60 mg/ml [Prolia]|Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
93256|NCT03457818|Other|Placebo|Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
93257|NCT03457805|Device|Prostatic Artery Embolization|PAE is performed under local anesthesia using commercially available and approved microspheres (study is not limited to a specific manufacturer or product).
93258|NCT03457792|Drug|Abatacept|Subcutaneous (SC) or intravenous (IV) administration
93259|NCT03457779|Dietary Supplement|Glucose|"The first 4 patients enrolled on trial will undergo the research core biopsies of their TNBC without the 13C glucose infusion; these samples will serve as control tissue that will be processed identically to the tissues obtained from patients who received the glucose isotope.~The following 12 patients will receive 6 grams (g) of [1,2-13C] glucose as an IV"
93265|NCT03457727|Drug|Danirixin|Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
93266|NCT03457727|Drug|Omeprazole|Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
93267|NCT03457714|Behavioral|Guided ICBT for persons with Spinal Cord Injury|An 8-week guided internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants who have sustained a spinal cord injury. In addition to the online program, a guide with experience delivering ICBT will provide support by email or telephone once a week. The guide will spend approximately 15 minutes per week/per client.
93268|NCT03457714|Other|Survey|Caregiver burden and mental health will be assessed through online questionnaires.
93269|NCT03457701|Drug|Daprodustat|Daprodustat will be available as 1 milligram (mg), 2 mg and 4 mg tablets strengths. One tablet to be taken daily without regard for food.
93270|NCT03457701|Drug|rhEPO|rhEPO (epoetin alfa OR darbepoetin alfa) is commercially available in various single dose vials and single-dose prefilled syringes. It will be given as subcutaneous injection.
93271|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (57Fe)|57Fe will be available in ascorbic acid oral solution. An oral solution (10 mL) will be administered containing 10 mg of 57Fe as ferrous sulfate (2 mg/mL stock solution) in 5 mL of 2.3 mg/mL ascorbic acid (1:1 molar ratio solution).
93272|NCT03457701|Drug|Ferrous sulfate containing the stable iron isotope (58Fe)|58Fe will be available in ascorbic acid oral solution. An oral solution (10 mL) will be administered containing 1 mg of 58Fe as ferrous sulfate with 9 mg ferrous sulfate (natural abundance Fe) (2 mg/mL stock solution) in 5 mL of 2.3 mg/mL ascorbic acid (1:1 molar ratio solution).
93273|NCT03457688|Dietary Supplement|prebiotic inulin-type fructans|
93274|NCT03457688|Dietary Supplement|placebo maltodextrin|
93275|NCT03457675|Device|Activa PC+S DBS implant for OCD|"DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna"
93276|NCT03457675|Other|One Month Blinded Discontinuation Period|"The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline."
93277|NCT03457662|Combination Product|OMC and pseudo-SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
93278|NCT03457662|Combination Product|OMC and SDT|OMC is established according to the 2016 ACC-AHA Guidelines for the Management of Patients with PAD. SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml.DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site of each lesion.
93279|NCT03457649|Biological|ARGX-113|
93280|NCT03457649|Biological|Placebo|
93281|NCT03457636|Drug|Doxycycline Anhydrous 40 MG|One Oracea Capsule (40 mg) should be taken once daily in the morning on an empty stomach, preferably at least one hour prior to or two hours after meals
93282|NCT03457636|Drug|Adapalene/Benzoyl Peroxide Gel 0.3-2.5%|Epiduo Forte should be applied in a thin layer to affected areas of the face and/or trunk once daily after washing, with care taken to avoid the eyes, lips, and mucous membranes
93283|NCT03457623|Other|Innovative Supported|addition of connected tools and stronger accompaniment to improve quality of life
93284|NCT03457610|Behavioral|Speech and language intervention|Speech therapy includes education about cough and vocal hygiene, teaching strategies to reduce cough, breathing and vocal exercises. The whole therapy consists of eight sessions once a week.
93285|NCT03457597|Drug|Midazolam hydrochloride|Midazolam hydrochloride 2.5 mg
93286|NCT03457597|Drug|Metoprolol tartrate|Metoprolol tartrate 100 mg
93287|NCT03457597|Drug|Pioglitazone hydrochloride|Pioglitazone hydrochloride 15 mg
93288|NCT03457597|Drug|Tolbutamide|Tolbutamide 500 mg
93289|NCT03457597|Drug|Omeprazole|Omeprazole 20 mg
93290|NCT03457597|Drug|Relacorilant|Relacorilant 350mg
93291|NCT03457584|Procedure|air arm|epiretinal membranes are excised during membrane peeling and air-tamponade is left in the eye
93292|NCT03457584|Procedure|BSS arm|epiretinal membranes are excised during membrane Peeling and BSS is left in the eye
93293|NCT03457545|Behavioral|Home-based pulmonary rehabilitation|Pilot study of a home-based pulmonary rehabilitation study for lung transplant candidates at the University of California San Francisco
93294|NCT03457545|Other|Aidcube|Participants will be testing and giving feedback on the use of the Aidcube platform in being able to deliver their home-exercise prescription
93295|NCT03457532|Drug|Glumetinib for tablet|25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
93329|NCT03457259|Device|PVC and/or PICCline|Pt. will receive PVC and/or PICCline
93330|NCT03457259|Device|Midline|Pt. will receive midline
93331|NCT03457246|Other|D-Pigment rich texture|
93332|NCT03457246|Other|Hydrance optimale riche|
93296|NCT03457519|Device|Children's Automated Respiration Monitor (ChARM)|The Philips CHARM (children's automatic respiratory monitor) is specifically designed to detect pneumonia in low resource areas. The lightweight measuring device sits on a child's or infant's chest, secured by a strap and measures respiration rate (fast breathing) through an ingenious algorithm. In this study ChARM will be used as a self monitoring and teaching aide by the CHWS.
93297|NCT03457506|Diagnostic Test|Digital PET/CT scan|The digital PET/CT scan will be acquired before or after the conventional PET/CT scan.
93298|NCT03457493|Drug|DPA-714-PET/MRI|DPA-714-PET/MRI
93299|NCT03457480|Behavioral|Focus Group|"Participants take part in a focus group about their opinions about different tobacco products.~Focus group lasts about 2 hours."
93300|NCT03457480|Behavioral|Focus Group Questionnaires|Participants answer brief questionnaires related to tobacco products, their demographic background, health literacy, and questions about the text messages themselves.
93301|NCT03457480|Behavioral|Health Communication Student Review - Text Messages|Participants review a series of text messages. The text messages contain information about both conventional and new and emerging tobacco products.
93302|NCT03457480|Behavioral|Youth Perceptions of Tobacco - Text Messages|Participants receive 2 text messages a day for 30 days. After the 3-month post-test, participants again receive 2 text messages a day for 30 days. The text messages are related to tobacco products and tobacco use. There are 8 different type of messages.
93303|NCT03457480|Behavioral|Youth Perceptions of Tobacco - Questionnaires|"While receiving the text messages, participants receive a link to a short survey at the end of each week.~7 days and 3 months after the 30-day text messaging period and after the second 30-day text messaging period, participant asked to answer more questions on smartphone using a link the study team sends."
93304|NCT03457480|Behavioral|Surveys|Surveys completed about basic demographics (such as age and race), tobacco use, opinions about cigarettes and opinions about hookah. The surveys should take about 30 minutes total to complete.
93305|NCT03457480|Behavioral|Text Messages with Pictures|Participants will read a series of 64 messages for up to 30 minutes. These images will have pictures.
93306|NCT03457480|Behavioral|Text Messages without Pictures|Participants will read a series of 64 messages for up to 30 minutes. These images will NOT have pictures.
93307|NCT03457467|Drug|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity
93308|NCT03457467|Radiation|SBRT|according to the different treatment sites given the corresponding dose: 1200cGy × 4 times or 800cGy × 7 times, or according to the specific situation dose adjustment
93309|NCT03457454|Other|Informational Intervention|Receive low-literacy educational and instructional brochures
93310|NCT03457454|Other|Colonoscopy scheduling assistance|-Clinics will receive prompts to engage participants to schedule a colonoscopy
93311|NCT03457441|Other|Standards vision tests|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
93312|NCT03457441|Device|OdySight medical application assessment|Subjects vision : near visual acuity, contrast sensitivity and scotoma and metamorphopsia detection will be assessed by gold-standard tests and with the OdySight medical application
93313|NCT03457402|Behavioral|Shaping Delay Tolerance|Participants will be introduced to an adaptive tablet-based application that asks the child to choose between two options: 1) a shorter duration of game play that begins immediately, or 2) a longer duration of game play that begins after a delay. Depending on the child's choices, the application alters the pre-reward delay with the intent of training the child to tolerate longer delays for larger rewards (i.e., more game play). Children may participate in up to 25 approximately 30-minute training sessions over 3-6 weeks.
93314|NCT03457389|Drug|Cabergoline|Cabergoline tablet
93315|NCT03457376|Diagnostic Test|Hand Grip Force|Hand Grip Force
93316|NCT03457376|Diagnostic Test|Maximal Inspiratory Pressure|Maximal Inspiratory Pressure
93317|NCT03457376|Diagnostic Test|Maximal Expiratory Pressure|Maximal Expiratory Pressure
93318|NCT03457363|Device|DTM will be add above NC|After oxygenation by classical nasal cannula, the DTM will be place above NC
93319|NCT03457350|Procedure|cervical negotiation|trial to bypass severe cervical stenosis
93320|NCT03457337|Drug|S-1 plus Gefitinib|S-1: According to the body surface area (BSA) to determine the dose, twice daily, after breakfast and dinner orally Gefitinib: 250mg, 1 day, orally, fasting or with the same service
93321|NCT03457337|Drug|Gefitinib|Gefitinib: 250mg, 1 day, orally
93322|NCT03457324|Drug|JCM-16021|This prescription with seven ingredients.
93323|NCT03457324|Drug|Placebo|Placebo
93324|NCT03457311|Drug|G.S.P. Oral Solution 400 mg/ml|Oral 1.25 ml/kg BW G.S.P. oral solution after fasting for 6 hours.
93325|NCT03457298|Device|Ossix Volumax|Ossix Volumax is intended to be used for Lateral ridge augmentation
93326|NCT03457298|Device|FDBA with collagen membrane|freeze-dried bone allograft (FDBA) with collagen membrane
93327|NCT03457285|Other|Physiotherapy|"Participants, with a confirmed diagnosis of AS, will be invited to participate. Once participants have provided informed consent, they will be required to complete the outcome measures provided. Participants will be set up to use the online exercise application and educated on its use.~Participants will then have access to videos of suitable exercises or exercise classes to follow and education material on their condition to read. Participants will be able to complete AS specific outcome measures and record their progress. Participants will also have a monthly video call with the senior rheumatology physiotherapist to discuss their exercise programme, symptoms and management. The participants will also record their compliance with their exercise programmes.~After the 6 month pilot period, participants will be required to complete the same outcome measures completed at the start of the study."
93328|NCT03457272|Other|New risk assessment|"Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles."
93333|NCT03457233|Drug|Gonadotropins|1) Gonadotrophines is started on day 2 with HMG(merional, IBSA) ,until the day of HCG administration
93334|NCT03457233|Drug|GNRH antagonist|cetrorelix 0,25mg s.c is given using flexible protocol, it is given when at least one follicle reaches size 14 mm to prevent premature lutenization ,until the day of hCG administration
93335|NCT03457233|Drug|Human chorionic gonadotropin Chorimon|10000 IU of HCG are given intramuscular when 2 or more mature follicles reach 18 - 20 mm
93336|NCT03457233|Drug|Natural progesterone|400 mg vaginal tablets twice daily from the day of ovum pick up till HCG tesing
93337|NCT03457207|Procedure|Combined minilaparotomy- laparoscopy approach|Laparoscopic aspiration of cyst then guided its extracorporeal cystectomy then reposition and evaluation by laproscopy
93338|NCT03457194|Biological|Quadrivalent Influenza Vaccine|Inactivated quadrivalent influenza vaccine that is used for active immunisation against influenza A, B virus strains (contained in vaccine). Single dose administration by intramuscular injection to all enrolled pregnant women as part of routine antenatal care.
93339|NCT03457194|Biological|DTP Vaccine (Multiple Actives)|Pertussis vaccine acellular combined with diphtheria and tetanus toxoids. Single dose administration by intramuscular injection, to all enrolled pregnant women who are 28 weeks or greater gestation at time of enrolment, as part of routine antenatal care.
93340|NCT03457181|Other|music|effect of music on anxiety scores
93341|NCT03457181|Other|operating room noise|effect of operating room noise on anxiety scores
93342|NCT03457168|Procedure|Treatment of elevated asleep SBP mean|To reduce asleep SBP mean determined by 48h ambulatory blood pressure monitoring up to the randomly assigned target by hypertension treatment intensification when required
93343|NCT03457155|Other|VS-I dosing in plasma samples|"VS-I dosing in plasma samples using ELISA protocol :~At intensive care admission time~24h after admission time~In case of FA occurrence~In case of sinusal rhythm recovery (in patients with new onset FA)"
93344|NCT03457142|Biological|Abatacept|Given IV and SC
93345|NCT03457142|Drug|Dexamethasone|Given PO
93346|NCT03457142|Drug|Ixazomib Citrate|Given PO
93347|NCT03457142|Other|Laboratory Biomarker Analysis|Correlative studies
93348|NCT03457129|Drug|Perampanel Oral Tablet|Perampanel is an AMPA receptor blockade, that has shown to be efficacious for seizure reduction in both partial onset seizures and generalized tonic-clonic seizures. Perampanel was approved by the FDA in October 2012 as adjunctive treatment in patients with partial onset seizures. Additionally, in June 2015, Fycompa was approved as adjunctive therapy in patients with primary generalized tonic clonic seizures.
93349|NCT03457116|Drug|Norco|20 tablets of Hydrocodone 5mg-Acetaminophen 325mg (Norco)
93350|NCT03457116|Drug|NSAID|Ibuprofen 400mg for post-operative pain
93351|NCT03457103|Device|Capnometry-Assisted Training for COPD to Slow the Breath (CATCH)|Tailored intervention emphasizing slow, quiet, regular nasal breathing pattern.
93352|NCT03457103|Device|Pulmonary Rehabilitation (PR)|Patients in both treatment groups will participate in a 10 week (16-20 sessions) comprehensive PR program. The control group will receive the 10-Week PR program with traditional breathing training sessions (without biofeedback). The program comprises 2 or 3 exercise training sessions per week by physical therapists (each 1 hour duration).
93353|NCT03457090|Other|Examination : a TCD and Trans-Thoracic Echocardiography|"Examination that involves the completion of a TCD and an TTE (Trans-Thoracic Echocardiography) :~To reports clinical parameters at the time of the examination : ECG data: sinus rhythm, atrial or ventricular arrhythmia, state of consciousness, heart rate, O2 saturation~To review of pharmacological parameters at the time of the examination : presence of sedation; presence, type and dose of catecholamines.~To collect biological data from the day of the examination : Partial Pressure of O2, PaCO2 (partial pressure) and hematocrit~To collect possible additional examinations : brain scan, EEG. These are non-invasive exams that do not require patient displacement. Only the samples taken by the medical team as part of the treatment will be analyzed."
93354|NCT03457077|Behavioral|Brief intervention|A brief motivational intervention with feedback about drinking levels compared to norms
93355|NCT03457064|Behavioral|PA+Social Adherence Intervention(PASAI)|While both physical activity programs were tailored to match participants' physical needs and abilities, the PA+Social Adherence Intervention(PASAI) introduced elements to promote and strengthen self-efficacy and social interaction among participants.
93356|NCT03457051|Procedure|Total Knee Arthroplasty (TKA)|In total (complete) knee arthroplasty (TKA), the orthopaedic surgeon removes the damaged areas of the knee and replaces the components with an artificial joint. The device that will be used is: Stryker TKA Triathlon system implant Cruciate retaining radius femur design. This device has been approved for use by Health Canada.
93357|NCT03457051|Procedure|Unicompartmental Knee Arthroplasty (UKA)|Unicompartment (partial) knee arthroplasty (UKA) has been available for over 40 years and differs from TKA in that only the most affected and symptomatic compartment (most commonly medial, but occasionally lateral and patella femoral) are replaced. The device that will be used is: Stryker PKR implant cemented and fixed bearing design. This device has been approved for use by Health Canada.
93358|NCT03457038|Biological|Blood Test|"Addition to the current care but during the normal follow-up visit :~At the entrance to the service: search for bacterial 16S RNA in the blood~Additional blood tests (4) at T6-12-18 and 36h~At each visit: Sampling of an additional heparinized blood tube for the assay PAMPs.~1 time per day: Assay of CRP and PCT from samples taken in common practice~J30: Assessment of the vital status of the patient"
93359|NCT03457025|Drug|Oral Corticosteroids|Prednisone 10 day taper: 60mg for 5 days, then taper for five days to 0mg
93360|NCT03457025|Drug|Oral antivirals|acyclovir 400mg: one pill 4 times daily for 7 days
93361|NCT03457025|Device|Hyperbaric Oxygen Therapy|2.4atm administered for twice daily dives for 5 days, 10 dives total. To be begun in the first 1 week after onset of paralysis.
93362|NCT03457012|Drug|Semaglutide|Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
93363|NCT03456999|Biological|MAU868|MAU868 infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses.
93364|NCT03456999|Biological|Placebo|Solution containing no active excipients, infused i.v. over 1 hour. One dose will be administered monthly for a total of 6 doses
93365|NCT03456986|Behavioral|PATH neurotraining|Tunes up the center of the motion discrimination working range
93366|NCT03456986|Behavioral|Brain HQ Target Tracker|Tunes up the limits of the motion discrimination working range
93367|NCT03456973|Behavioral|Nurse AMIE|Supportive care software platform
93368|NCT03456960|Drug|TAK-438ASA|TAK-438ASA tablet.
93369|NCT03456960|Drug|TAK-438|TAK-438 tablet.
93370|NCT03456960|Drug|Aspirin|Aspirin enteric-coated tablet.
93371|NCT03456947|Drug|Pregabalin|the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
93372|NCT03456934|Other|Modified infant formula|Test formula with lower protein content than standard formula
93373|NCT03456934|Other|Standard infant formula|Standard infant formula
93374|NCT03456921|Other|"End-of-life conversation game called Hello"|To play 'Hello', players are provided 32 open-ended questions in a prearranged order and an equal number of game chips. A player reads aloud the first question. Players then individually write down their answers, and take turns sharing answers with the group (players can opt to pass). Players control how long they share, what they share, and when they are ready to proceed to the next question. During the conversation, players may choose to acknowledge others for a particularly thoughtful, poignant, or even funny comment by giving them a chip. A simple pre-game coin flip determines whether the player with the most chips 'wins' the game ('heads'), or the player with the least amount of chips wins the game ('tails').
93375|NCT03456908|Combination Product|18F-TFB-PET|Infusion of F-18 TFB and PET / CT imaging
93381|NCT03456882|Drug|RNS60|normal saline plus oxigen in nanobubble
93382|NCT03456869|Device|Patient Specific Implant|The patient specific implant is used to simultaneously complete the reposition and fixation of the chin.
93383|NCT03456856|Drug|5mg Ivabradine|"On day 15, the 5mg dose will be titrated according to HR :~HR ≥ 60 bpm 7.5 mg BID HR ≥ 50 bpm, < 60 bpm 5.0 mg BID HR < 50 bpm and/or signs or symptoms of bradycardia 2.5 mg BID~Ivabradine dose levels can be adapted to HR at any clinical visit if necessary."
93384|NCT03456843|Drug|Antiandrogen Therapy|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
93385|NCT03456843|Drug|Docetaxel|To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.
93386|NCT03456843|Other|Laboratory Biomarker Analysis|Correlative studies
93387|NCT03456843|Procedure|Quality-of-Life Assessment|Ancillary studies
93388|NCT03456843|Other|Questionnaire Administration|Ancillary studies
93389|NCT03456843|Procedure|Radical Prostatectomy|Undergo cytoreductive radical prostatectomy
93390|NCT03456830|Drug|ALLN-177|ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
93391|NCT03456830|Drug|Placebo|Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
93392|NCT03456817|Drug|Treatment Arm - high dose ATG|Patients agreeing to 10 mg/kg ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 & -2, ATG will be infused after fludarabine & busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 & over at least 4 hrs on days -3, -2, -1 & 0. Dose is based on actual body wt, & rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in >5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone 40 mg IVPB, acetaminophen 1000 mg PO & diphenhydramine 50 mg IVPB. Acetaminophen 1000 mg PO & diphenhydramine 50 mg IVPB can be repeated in 4-6 hrs PRN for flu-like symptoms/fever/chills. Meperidine 25-50 mg IVPB given PRN every 4 hrs for rigors. MTX is given 15 mg/m2 IV on day +1 & 10 mg/m2 on days +3, +6 & +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.
93393|NCT03456817|Drug|Control Arm - standard of care|The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).
93394|NCT03456804|Drug|ESK981|Treatment with ESK981 for patients with metastatic castrate resistant prostate cancer
93395|NCT03456791|Diagnostic Test|Human epididymis protein 4|Human epididymis protein will be quantitatively assayed using the enzyme immunometric assay (EIA) method
93396|NCT03456778|Procedure|Platelet-Rich Plasma Injection|7 cubic centimeters (cc) of blood will be collected and processed for the PRP injection. The site to be injected will be prepared with isopropyl alcohol and then sprayed with ethyl chloride to achieve cutaneous anesthesia. Next, with continuous sonographic visualization, the skin and subcutaneous tissues overlying the posterior mid-Achilles tendon will be infiltrated with 0.5% bupivacaine and 1% sodium bicarbonate (50 milliequivalents (mEq)/50 mL) via a 25-gauge hypodermic needle. Once adequate anesthesia is achieved, a 20-gauge needle will be used to repeatedly fenestrate the tendinotic portion of the tendon along the long plane. Any calcifications within the substance of the tendon will be mechanically fragmented. When the region of interest has been treated, a PRP injection (5 cc) will be delivered. Each patient will then be provided a post-procedure care form with specific information regarding initial physical activity limitation and return to normal activity.
93397|NCT03456765|Diagnostic Test|Ultrasound|US will be made to assess kidneys
93398|NCT03456752|Drug|Dexamethasone|Dexamethasone 8mg intravenously prior to induction of anesthesia.
93399|NCT03456752|Drug|Normal saline|Normal saline 1.6ml intravenously prior to induction of anesthesia.
93400|NCT03456726|Drug|Tazemetostat|Tazemetostat will be provided as a 200 mg oral tablet.
93401|NCT03456713|Biological|LY3074828|Administered SC
93402|NCT03456700|Drug|Auranofin|Given PO
93403|NCT03456700|Other|Laboratory Biomarker Analysis|Correlative studies
93404|NCT03456700|Drug|Sirolimus|Given PO
93405|NCT03456687|Drug|Exenatide|Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
93406|NCT03456674|Device|LaseMD System|A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
93407|NCT03456661|Drug|Levobupivacaine|Infiltration with 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml), US guided, using pectoralis block technique.
93408|NCT03456661|Drug|Levobupivacaine + Dexmedetomidine|Infiltration with chirocaine 0.25% 29,5ml + 0,5ml dexmedetomidine (50µg) (total volume 30ml), US guided, using pectoralis block technique.
93409|NCT03456648|Drug|apixaban|non-vitamin K oral anticoagulant (NOAC)
93410|NCT03456635|Other|guided antimicrobial prophylaxis|During the intervention period, antimicrobial prophylaxis decisions will be guided by a computerized program
93411|NCT03456609|Drug|shenqifuzheng injection|500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.
93412|NCT03456609|Drug|Sodium Chloride Injection 0.9%|500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
93413|NCT03456596|Other|ENABLE|This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
93414|NCT03456583|Device|Brevera Breast Biopsy System|The Brevera Breast Biopsy System with CorLumina imaging technology is a vacuum-assisted biopsy device, which is used to remove breast tissue in a minimally invasive manner using stereotactic or tomosynthesis imaging. A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
93415|NCT03456570|Drug|Dydrogesterone 10 mg|Dydrogesterone 10 mg twice daily
93416|NCT03456570|Drug|Placebo Oral Tablet|oral tablets twice daily
93417|NCT03456557|Radiation|Perfusion computed tomography.|Using specific post treatment imaging software ( Olea® ) we will calculatell permeability parameters : the pancreatic blood flow and the k-trans, capillary membrane permeability factor.
93418|NCT03456544|Drug|Vancomycin|Patients who have vancomycin associated acute kidney injury will be in the Van-AKI group, and those who don't have vancomycin associated acute kidney injury will be in the none VAN-AKI group.
93419|NCT03456531|Device|pulsed radiofrequency|The patient will have pulsed radiofrequency to suprascapular nerve for 6 minutes
93420|NCT03456531|Drug|"NSAIDs ibubrofen,Aspirin"|"medical treatment as NSAIDs ibubrofen,Aspirin"
93421|NCT03456505|Behavioral|Mindfulness Meditation Training|A researcher will guide participants through 5 mindfulness meditations, each lasting 11 minutes in length.
93422|NCT03456505|Behavioral|Active Listening|A researcher will read participants 5 selections from The Natural History of Selborne, each lasting 11 minutes in length.
93423|NCT03456492|Diagnostic Test|serum sodium|Serum sodium will be measured on admission, day before surgery, day after and at discharge
93424|NCT03456479|Diagnostic Test|skin prick test - specific serum IgE|The study will assess the diagnosis of Cow's milk protein allergy (CMPA) among infant and children in Assiut University Children Hospital using skin prick test and specificserumIgE
93425|NCT03456466|Drug|TQB2303|375mg/m2 ，iv
93426|NCT03456466|Drug|Rituximab|375mg/m2 ，iv
93427|NCT03456453|Behavioral|NIDA Standard for HIV Prevention|The NIDA Standard is a manualized, HIV prevention education intervention focused on reducing risky sexual and drug use practices. It will be adapted for Facebook in this pilot trial.
93428|NCT03456440|Diagnostic Test|MRI|MRI scan of the patients liver with DWI and acquisition of ADC value.
93429|NCT03456427|Device|Patient-Assisted Compression (PAC)|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views Craniocaudal (CC) & Mediolateral Oblique (MLO).
93430|NCT03456427|Device|Technologist-Controlled (TC) Compression|TC compression will be conducted per standard of care practices at the site.
93431|NCT03456414|Other|Virtual reality exercise during hemodialysis|Subjects will play a virtual reality game specially adapted for subjects undertaking hemodialysis treatment
93432|NCT03456401|Drug|Sorafenib or Sunitinib|After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
93499|NCT03455842|Drug|placebo|Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week
93500|NCT03455829|Drug|G1T38|CDK 4/6 inhibitor
93433|NCT03456388|Drug|Ammoxetine Hydrochloride Enteric-coated Tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
93434|NCT03456388|Drug|placebo enteric-coated tablets|There will be 7 ascending cohorts. The first cohort will be administered 2.5 mg once. The second cohort will be administered 7.5 mg. The third cohort will be administered 15 mg once. The forth cohort will be administered 30 mg once. The fifth cohort will be administered 45 mg once. The sixth cohort will be administered 65 mg once.The seventh cohort will be administered 100 mg once. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested.
93435|NCT03456362|Device|REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION|theta burst stimulation (TBS) is a novel form of repetitive transcranial magnetic stimulation that mimics protocols inducing long-term potentiation (LTP) or long-term depression (LTD) in animal models. Whereas continuous TBS (cTBS) induces long-lasting inhibition of cortical areas, iTBS exerts the opposite effect, increasing cerebellar excitability
93436|NCT03456349|Drug|HTL0018318|HTL0018318
93437|NCT03456349|Drug|Placebo|Placebo
93438|NCT03456336|Other|Active Treatment|Infants assigned to the active treatment group will receive indomethacin or ibuprofen per their local site usual care dosing and schedule if the infant has a sPDA. The choice of indomethacin or ibuprofen will be left to the center, however, infants may only receive one or the other. If the infant receives both, it will be considered a protocol violation.
93439|NCT03456336|Other|Expectant Management|Infants assigned to the expectant management group will receive indomethacin or ibuprofen if cardiopulmonary compromise occurs.
93440|NCT03456323|Behavioral|Palliative Care Consultation|The palliative care consultation team will be led by one of the board-certified palliative care physicians at Columbia University Medical Center. Over one or more visits, the palliative care consultation team will first review intervention participants' medical records and baseline Edmonton Symptom Assessment System (ESAS) scores. They will also directly assess participants' physical and psychological symptoms. They will provide supportive counseling, make treatment recommendations for burdensome symptoms to the primary team of physicians, and will address goals of care. They will document these activities in structured electronic medical record consultation notes.
93441|NCT03456323|Other|Usual Care|Patient-surrogate pairs randomized to usual care will not have a palliative care consultation intervention offered, and will receive care by their primary physicians. However, if a palliative care consultation is requested after randomization to usual care by the primary team of physicians and/or the patient/surrogate, it will be provided.
93442|NCT03456310|Diagnostic Test|transperineal ultrasound|"trans-perineal US: B mode capable 2D ultrasound system with cine loop function, a 3.5-6.0 MHz curved array transducer. A mid-sagittal and axial views is obtained by placing a transducer on the perineum (Parting of the labia can improve image quality).~Dynamic MRI:~Magnetic resonance (MR) imaging of the pelvic floor is a two-step process that includes:~analysis of anatomic damage on axial fast spin-echo (FSE) T2-weighted images. then sagittal and coronal (FSE) T2-weighted are obtained.~functional evaluation using sagittal dynamic single-shot T2-weighted sequences during straining and defecation."
93443|NCT03456297|Other|Web-based clinical pedagogy program (WCP)|The nurse preceptors in the experimental cluster will be given access to download the WCP on mobile devices. The unique interactive features provide continuous support and allow preceptors to discuss the clinical encounters with their peers and consult experts for advice.
93444|NCT03456284|Device|Normothermic Liver perfusion|The liver grafts will be preserved and evaluated at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase
93445|NCT03456258|Diagnostic Test|Complete blood count|To measure hemoglobin difference and serum ferritin levels .
93446|NCT03456245|Device|Vision device validation|Group members had their vision tested with the following devices/methods: D-EYE Portable Retinal Imaging System, Eyenetra NETRA, PlenOptika Quicksee, Right Manufacturing Retinomax K Plus 3, and standard eyesight tests using eye charts, phoropters, and slit lens lamp imaging.
93447|NCT03456232|Other|High-flux hemodialysis|High-flux hemodialysis using diffusion, ultrafiltration and convection principle to remove harmful substances in the blood and excessive water.
93448|NCT03456232|Other|Hemodiafiltration|Hemodiafiltration is a combination of hemodialysis and hemofiltration with two modes of treatment advantages, both by diffusion and convection principle to remove harmful substances in the blood.
93449|NCT03456219|Other|Normal protein diet|The intervention with the control diet was composed of 65% of carbohydrates, 15% of proteins and 20% of lipids.
93450|NCT03456219|Other|High-protein diet|The intervention with the higher-protein diet was composed of 45% of carbohydrates, 35% of proteins and 20% of lipids.
93451|NCT03456206|Other|Intake of red and processed meat and fibres|The intention is to analyse exposure groups in tertiles: 1) Upper tertile (33.3% of the total sample) based on the ratio: meat/fibre intake is associated with higher risk of CID. 2) Low intake of fibre (defined as below the lower tertile [33.3% of the total sample]) and high intake of red and processed meat (defined as those above the upper tertile [33.3% of the total sample]) are independently associated with higher risk of CID, and their synergy (interaction between the factors meat and fibres) gives the highest risk outcome.
93452|NCT03456206|Other|Lifestyle factors independently or combined|Lifestyles factors are defined as: red and processed meat, vegetables, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/fat, protein/fat from red and processed meat, glycemic index.
93453|NCT03456193|Procedure|LA transplant|"The proposed study treatment will include three central components:~Harvest of the left atrium and pulmonary veins from a suitable donor~Excision of the left atrium and portions of stenotic pulmonary veins from the patient with pulmonary vein stenosis~Implantation of the donor posterior left atrium and portions of pulmonary veins into the patient."
93454|NCT03456180|Device|Haemoadsorption with Cytosorb cartridge|microcirculatory monitoring in septic shock patients requiring renal replacement therapy for acute renal failure and haemoadsorption with Cytosorb cartridge
93501|NCT03455829|Drug|Osimertinib|EGFR TKI; 80 mg
93455|NCT03456167|Other|RecoverWell mobile app for follow-up care|The mobile app follow-up care is an application that can be loaded onto a smartphone. It allows the patient to submit photos of their surgical site, QoR15 scores, and EORTC selected adverse events scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 6 weeks following surgery.
93456|NCT03456154|Drug|Botox Injectable Product|60u will be used at 3 sites of masseter muscle, on each side of the face
93457|NCT03456154|Device|Occlusal splint|In this group patients will receive an occlusal splint which will be worn everyday for 6 months at night.
93458|NCT03456141|Procedure|third molar surgery|The patient is asked to complete the diary each post-surgery day for 14 days. Recovery is organized into three QOL domains: lifestyle, oral function, and pain.
93459|NCT03456128|Other|CAPABLE|It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
93460|NCT03456115|Device|Mechanical nasal dilator|Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
93461|NCT03456102|Drug|Pravastatin|"Phase IIB clinical trial: A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated.~A two-week safety/PK study to determine pravastatin exposures over 24 hours when given together with first-line treatment (HRZE) and ensure the combination is safe and well-tolerated."
93462|NCT03456089|Diagnostic Test|Urodynamics Testing|Urodynamics utilizes a small catheter to fill the bladder and continuously measure pressure and volume giving information on bladder function and compliance
93463|NCT03456076|Drug|Alectnib|Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
93464|NCT03456076|Drug|Cisplatin|"Participants will receive Cisplatin 75 milligrams per square meter (mg/m^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
93465|NCT03456076|Drug|Vinorelbine|Participants will receive Vinorelbine 25 mg/m^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
93466|NCT03456076|Drug|Gemcitabine|Participants will receive Gemcitabine 1250 mg/m^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.
93467|NCT03456076|Drug|Pemetrexed|"Participants will receive 500 mg/m^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."
93468|NCT03456076|Drug|Carboplatin|For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
93469|NCT03456063|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase"
93470|NCT03456063|Drug|Placebo Comparator|Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
93471|NCT03456063|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
93472|NCT03456063|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
93473|NCT03456063|Drug|Carboplatin|Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
93474|NCT03456063|Drug|Cisplatin|Cisplatin 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
93475|NCT03456063|Drug|Gemcitabine|Gemcitabine 1250 mg/m^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
93476|NCT03456050|Behavioral|FRC exercise|The program will consist of hip joint controlled articular rotations (CARs) in standing position for 3 - 5 repetitions. Then, the participant will sit on the floor in what is called 90/90 position which is sitting in hip and flexion in 90 degrees for both the lead (front) and trail (side) leg. The participant will perform a Progressive and regressive angular isometric loadings (PAILs and RAILs) for the trail leg to increase the range of internal rotation, the contraction will be performed three times and the holding of the position will be for two minutes. After expanding the range, the participant will perform Progressive and regressive angular loadings (PALs and RALs) isometric contractions in form of a passive range hold for internal rotation and abduction, for 3 - 5 times.
93477|NCT03456050|Behavioral|Conventional Exercise|The conventional training program in this study will be the routine training for increasing the hip rotation. By screening the scientific literature, the conventional training found to consists of static stretching and strengthening using body weight and/or a band and the time of holding a stretch is about 30 seconds. For that the flexibility exercise will consist of progressive stretching from a prone position (leg fall in a stretch), the participant will perform 3 - 5 repetitions with 30 seconds hold or as tolerated. The strengthening exercise consists of hip abduction (hip opening) using a band or ankle weight from side lying for 10 - 12 repetitions 3 times.
93496|NCT03455855|Device|Jetstream System|including Atherectomy Console (Jetstream Console) and Atherectomy Catheter(Jetstream Catheter), intended for use in atherectomy of the peripheral vasculature and to break apart and remove atherosclerotic disease, debris, and thrombus from the SFA and/or PPA.
93497|NCT03455842|Biological|BCD-089, 162 mg, s/c, qw|Subcutaneous injections of anti-IL6R every week
93478|NCT03456037|Other|hepatitis viruses|There are 5 main hepatitis viruses, referred to as types A, B, C, D and E. These 5 types are of greatest concern because of the burden of illness and death they cause and the potential for outbreaks and epidemic spread. In particular, types B and C lead to chronic disease in hundreds of millions of people and, together, are the most common cause of liver cirrhosis and cancer.The aim is to investigate incidence of HBsAg, anti-HCV in serum samples and evaluation of biomarkers taken from patients who were followed the intensive care unit of Sakarya University Training and Research Hospital.
93479|NCT03456024|Other|Questinnaire|
93480|NCT03456011|Other|Battlefield Acupuncture|Battlefield Acupuncture gold semi permanent needles
93481|NCT03455998|Other|questionnaires|
93482|NCT03455985|Other|Discharge Order Set (DOS)|In addition to the elements in ESC, for the DOS group the primary team will be contacted to complete the Diabetes Discharge order set, which will be pre-populated into the electronic discharge navigator. Follow-up phone calls in the DOS group will also assess and reinforce insulin dose self-titration.
93483|NCT03455985|Other|Enhanced Standard Care (ESC)|Patients in the ESC group will receive hospital discharge instructions using current best practices within the overall functionality of the electronic medical record, which facilitates medication reconciliation and use of a patient care resource manager. Phone calls are information gathering only in the ESC group, and questions related to care will be referred to the usual provider.
93484|NCT03455972|Biological|CART-anti-CD19/BCMA|Participants will get auto-HSCT. 14 and 20 days after auto-HSCT, participants will get the anti-CD19 T cells (1×10e+7/kg on d0) and anti-BCMA T cells as split-dose (total (2-6)×10e+7/kg, 40% on d1 and 60% on d2)
93485|NCT03455959|Procedure|Bronchoscopy/BAL|Participants will receive 2-3 inhalations(90 ug ea)of albuterol to minimize bronchoconstriction.Medication includes midazolam by intravenous injection, and fentanyl by intravenous injection as judged necessary.4% lidocaine is delivered via atomizer spray to the oral pharynx for local anesthesia.1% lidocaine is delivered through the bronchoscope to the vocal cords and lung segments for local anesthesia.The bronchoscope is then passed through the vocal cords into the trachea.Throughout the procedure,all participants will have continuous blood pressure,heart rate,and oxygen saturation monitoring.Participants will be instructed to relate any discomfort or problems through a series of standardized hand signals.Once in the lung, aliquots of sterile saline are instilled into a subsegment of the lingula of the left lung and withdrawn into a trap by gentle suction. Then,the bronchoscope is passed into a subsegment of the right upper lobe and the right middle lobe where the lavage is repeated.
93486|NCT03455959|Procedure|Airway Brushing|After completion of the BALs, endobronchial brushing of the airways will be performed using the airway brushings with a Conmed Harrell™ 4 mm unsheathed cytology brush. Upon completing the brushing the investigators remove the bronchoscope with the brush in place to avoid shearing off isolated cells. The brush will be gently glided back and forth on the airway epithelium 10 times in 2 different locations within the same airway. The brush is then placed in media and flicked to remove the cells. There is some airway bleeding caused by the procedure, and participants are made aware that they may cough up small amounts of blood for 24-48 hours following the procedure.
93487|NCT03455959|Procedure|Endobronchial Biopsy|In some subjects, after completion of the BALs, endobronchial biopsies of the airways will be performed to compare and contrast the findings on Trm from the bronchial brushings. For the biopsy, the investigators will use a standard alligator jaw forceps that effectively samples the airway wall. The forceps will be placed into the lavaged segments of the lung only (lingula or right middle lobe) and then six biopsies will be taken at the segmental and subsegmental levels. Tissue pieces will be immediately placed into 4% freshly defrosted paraformaldehyde for tissue processing.
93488|NCT03455946|Behavioral|DASH cloud with Alexa|"Participants will download and install the Alexa and Nutritionix application (app) onto their smartphone and study staff will setup the study-specific account to send data to Duke's software system called Prompt. Participants will be instructed to invoke through voice their dietary intake daily for three months using the Nutritionix app through the Amazon Alexa personal assistant. DASH Cloud will access participant's dietary intake data through the Nutritionix application programing interface (API) for three months. Participants' data will automatically be uploaded from the Nutritionix app via the API that links the device with DASH Cloud. DASH Cloud will run an algorithm and send a daily or weekly feedback text message with a score reflecting DASH adherence for the prior days or week's food consumption using a previously validated scoring system."
93489|NCT03455933|Other|Sham Comparator|The investigators will apply a light intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 3/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (3/10 in VAS).
93490|NCT03455933|Other|Experimental Intervention|The investigators will apply a moderate intensity shockwave in the lateral epicondyle with the portable SHOCKMASTER 300 at a 8Hz frequency and 2000 impulses. The intensity will be regulated to reach a 6/10 in the VAS scale, depending on the tolerance of the subject. Each patient will receive between 5 and 10 impulses starting with the lower intensity of the device (middle energy: 1 bar) and will go up towards the target (6/10 in VAS).
93491|NCT03455933|Other|Control Group|Patients will place their hand, wide open and up to the wrist, into the inner part of the container and will keep it under water for a maximum time of 2 minutes. If pain is unbearable before the time ends, the participant will be able to withdraw the hand.
93492|NCT03455920|Other|Clinical nurse (supernurse) evaluation|The first evaluation of the patient refered to the sleep clinic will be performed by the clinical nurse then discussed with the pulmonologist in charge.
93493|NCT03455920|Other|Pulmonologist evaluation|The first evaluation of the patient refered to the sleep clinic will be performed only by the pulmonologist.
93494|NCT03455894|Device|DETECT'CHUTE CLINIBED|The DETECT'CHUTE carpets will be positioned at night at the foot of the bed and set in motion by the nursing staff as soon as the elderly person goes to bed for the night. They will be withdrawn the next morning after the resident's rise. Each patient will benefit from the mat for 1 month.
93495|NCT03455868|Procedure|Bariatric surgery|Sleeve gastrectomy, Roux-in-Y gastric bypass or biliopancreatic diversion with duodenal switch
93498|NCT03455842|Biological|BCD-089, 162 mg, s/c, q2w|Subcutaneous injections of anti-IL6R every other week
93573|NCT03455218|Drug|Placebo|INOmax device connected to oxygenator, but no gas is delivered
93502|NCT03455816|Device|Social Diabetes App|"Social diabetes is an app for diabetes, free with CE mark, that by means of the incorporation of a glucometer (glucomen Areo) allows through NFC technology the automatic introduction of data in the application"
93503|NCT03455816|Device|Usual clinical monitoring group (Control group)|Active Comparator: Usual clinical monitoring group (control group) This group does not use the App. This group have an intermediate visit at 3 months with de doctor to see blood glucose self-monitoring and propose adjustments
93504|NCT03455803|Device|CPAP|Continuous positive airway pressure
93505|NCT03455790|Diagnostic Test|Aerobic Capacity|"Upper limb muscle strength assessments of the athletes will be performed with the ISOMED 2000® isokinetic device and the grip strength with the Jamar® dynamometer. The aerobic capacity values will be measured using the Cosmed K5® instrument and the TS in the Cosmos-Saturn brand running band. Anaerobic capacity will be measured by Wingate anaerobic power test (WanT) for 30 seconds in standard laboratory conditions for TS basketball athletes using Monark 894 E model ergometer developed by Monark for upper extremity anaerobic capacity and power measurement. The sporty performances will be evaluated with the 20 m Sprint test, Slalom Test and Zone Shot tests."
93506|NCT03455777|Drug|AKCEA-ANGPTL3-LRX|Single open-label cohort
93507|NCT03455764|Drug|MCS110|MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.
93508|NCT03455764|Drug|Dabrafenib|Dabrafenib attack different proteins that promote the growth of cancerous cells
93509|NCT03455764|Drug|Trametinib|Trametinib attack different proteins that promote the growth of cancerous cells
93510|NCT03455751|Genetic|PGx-guided post-operative pain management|Post-operative pain management as indicated by pharmacogenomic testing results.
93511|NCT03455738|Other|vasoplegic syndrome|Patients with vasoplegic syndrome for whom the intensive care physician planned to decrease the norepinephrine dosage were included. Hemodynamic and uncalibrated pulse contour analysis (Volume view, FloTrac, Edwards Lifescience, Irvine) values were obtained before and after decreasing the norepineprhine dosage. Responders were defined by a >10% decrease in mean arterial pressure (MAP).
93512|NCT03455725|Device|CardiAMP Cell Therapy System|The CardiAMP Cell Therapy system consists of the CardiAMP Potency Assay, the Helix/Morph intramyocardial delivery catheter system, and the CardiAMP Cell Separator. The system allows the investigator to identify patients with a high chance to respond to im autologous stem cell therapy (using the CardiAMP Cell Potency Assay), to isolate the stem cells from a bone marrow harvest at the point of care (using the CardiAMP CS system), and to percutaneously inject the autologous cells into the myocardium using the Helix/Morph delivery catheters.
93513|NCT03455725|Other|Sham Treatment|Patients will receive sham bone marrow procedure and a ventriculogram. A scripted sham percutaneous procedure will be performed
93514|NCT03455712|Behavioral|Gestational Weight Gain Card|The Gestational Weight Gain Card is designed to be an educational and weight gain tracking tool. Study subjects will be highly encouraged to use the GWG card to gain both important clinical information and to document weight measurements throughout their pregnancy.
93515|NCT03455699|Device|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
93516|NCT03455699|Device|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
93517|NCT03455699|Device|Roll-In (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
93518|NCT03455686|Other|Hyperpolarized 129Xe MRI|Magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas is a research approach for the non-invasive visualization and measurement of lung structure and function.
93519|NCT03455673|Diagnostic Test|ATE score|"The Atrial Thrombus Exclusion (ATE) combine thromboembolic risk factors (hypertension, cardiac insufficiency, history of stoke) and d-dimer level for the prediction of intra-atrial thrombus :~Hypertension = 1 Heart failure = 1 History of stroke = 1 High plasma d-dimer level (> 270 ng/ml) = 1"
93520|NCT03455660|Other|no intervention|no intervention
93521|NCT03455647|Behavioral|ASF promotion plus Girinka|Behavior change communication promoting the consumption of milk produced in the household and other optimal maternal and child nutrition practices. The intervention will be implemented by government of Rwanda Community Health Workers.
93522|NCT03455634|Device|Twin Block|functional appliances for the stimulation of the mandibular growth
93523|NCT03455634|Device|Sander bite jumping appliance|functional appliances for the stimulation of the mandibular growth
93524|NCT03455621|Procedure|Toothbrushing|Toothbrushing with different amounts of fluoride toothpaste (or a non-fluoride toothpaste as a control)
93525|NCT03455608|Behavioral|RE-ACTIVE|Reactive intervention started promptly if/when dysphagia is identified
93526|NCT03455608|Behavioral|PRO-ACTIVE EAT|Early low intensity proactive intervention started before RT commences
93527|NCT03455608|Behavioral|PRO-ACTIVE EAT + EXERCISE|Early high intensity proactive intervention started before RT commences
93528|NCT03455595|Procedure|Endoscopic exams|Coloscopy
93529|NCT03455582|Other|Clinical assessment|Expanded Disability Status Scale (EDSS), ambulation test and Multiple Sclerosis functional composite (MSFC). Medications will be recorded.
93530|NCT03455582|Other|Ecological evaluation|Virtual reality task and Actual reality
93531|NCT03455582|Other|Neuropsychological evaluation|cognitive tests exploring information processing speed, attention/concentration, working and episodic memories and executive function
93532|NCT03455582|Other|Psychological evaluation|questionnaires for depression, anxiety and fatigue
93533|NCT03455582|Device|MRI Evaluation|morphological MRI and resting state functional MRI (fMRI)
93534|NCT03455569|Behavioral|Behavioral sleep education|This group will receive manual-based sleep hygiene recommendations and a behavioral sleep intervention including sleep compression therapy
93535|NCT03455569|Behavioral|Education only|This group will receive information about sleep, aging, and dementia, but without specific or individualized recommendations
93536|NCT03455556|Biological|Anetumab Ravtansine|Given IV
93537|NCT03455556|Biological|Atezolizumab|Given IV
93538|NCT03455556|Other|Laboratory Biomarker Analysis|Correlative studies
93539|NCT03455543|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
93540|NCT03455543|Device|Inactive (sham) Provant Therapy System|Treatment with inactive Provant Therapy System
93541|NCT03455530|Other|Industrial Hygiene-Enhance Community Health Worker Intervention|The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
93542|NCT03455517|Drug|Venetoclax|Venetoclax and rituximab association
93543|NCT03455517|Drug|Rituximab|Venetoclax and rituximab association
93544|NCT03455504|Drug|Venetoclax|Venetoclax add in combination with fludarabine, cyratabine and idarubicine
93545|NCT03455491|Drug|XC221 100 mg|once daily during 3 days.
93546|NCT03455491|Drug|XC221 200 mg|once daily during 3 days.
93547|NCT03455491|Drug|Placebo|once daily during 3 days.
93548|NCT03455478|Device|spectacles|dispending spectacles for uncorrected refractive error
93549|NCT03455465|Other|Community Health Worker Assessment|Participants will be approached by a community health worker who will ask them to complete an assessment of needs and offer to enroll them in post-discharge services to help address the needs identified.
93550|NCT03455452|Other|Non-interventional|Non-interventional
93551|NCT03455439|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
93552|NCT03455426|Drug|letrozole|Women will be randomizedfor ovarian stimulation with letrozole or to natural cycle IUI.
93553|NCT03455413|Device|Swisstom BB2 EIT device|Swisstom BB2 EIT device and NeoSensor Belts will be used to assess lung aeration, ventilation distribution and strech during invasive ventilation in perioperative care.
93554|NCT03455400|Device|Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.
93555|NCT03455387|Diagnostic Test|sampling of the serum marker sFlt1 and PlGF|sampling of the serum markers sFlt1 and PlGF , every 3 days,until delivery
93556|NCT03455374|Device|Treatment with CSI atherectomy device|Following peripheral angiography, patients with significant SFA or below the knee artery disease (≥ 50%) or total occlusions (100%) will have a baseline OCT imaging of the target vessel and the lesion be treated with proper size CSI burr. Repeat OCT imaging will be performed after CSI. Drug eluting balloon angioplasty may be performed in discretion of the operator. If DEB is used, a final OCT imaging will be performed to assess lesion expansion and possible dissections. Balloon sizing will be based on 1:1 vessel ratio with the length covering from minimally diseased distal segment to minimally diseased proximal segment. We will try to avoid use of stents.
93557|NCT03455361|Procedure|Stark Implant with low primary stability|
93558|NCT03455348|Other|catheter insertion|catheter insertion one to less than 4 four centimeters to the wrist joint (Group A) and the other, to more than four centimeters to the wrist joint. (Group B)
93559|NCT03455335|Drug|20 million hMSCs|
93560|NCT03455335|Drug|40 million hMSCs|
93561|NCT03455335|Drug|80 million hMSCs|
93562|NCT03455322|Drug|norepinephrine versus midodrine & octreotide|either intravenous infusion (IVi) norepinephrine in a dose of 0.05-0.3ug/Kg/min. to keep mean arterial pressure ≥ 80-100mmHg & continued either until HRS reversal or for maximum 10 days or oral midodrine 5mg three times/day & can be increased every 24h up to 12.5mg three times daily plus octreotide 100ug/ 6h subcutaneous & if needed increased to 200ug/6h.
93563|NCT03455309|Biological|NDV-3A|Single dose administered by intramuscular injection
93564|NCT03455309|Biological|Placebo|Single dose administered by intramuscular injection
93565|NCT03455296|Other|fluid therapy; crystalloid|maintenance fluid e.g. Ringer or Ringer acetate plus replacement fluid with crystalloids e.g. Ringer,or Ringer acetate or saline 0.9%, 500ml / 30 min. guided by ScVO2 with target value ≥ 70% versus lactate clearance (LCR) with target value ≤ 2mmol/L (or decline ≥ 10%) by the end of the study in group A & group B respectively. Maintenance fluid without replacement will be initiated if ScVO2 or lactate value normalized.
93566|NCT03455283|Drug|Clariscan|Clariscan 0.5 mmol/ml solution for injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
93567|NCT03455283|Other|Gadolinium-Based Contrast Agents|All GBCAs will be selected by the sites and recorded as by the brand names.
93568|NCT03455270|Drug|G1T48|oral SERD
93569|NCT03455257|Behavioral|Cash Transfer|The heads of households will receive a cash transfer for up to 7 family members in the home every quarter. Head of households will be expected to attend meetings every 4 months at their local community health centers led by Community Health Workers (CHW). Meetings will have 2 components: 1) children under 5 will be measured to identify children at risk of malnutrition and 2) group education sessions. There will also be monthly growth monitoring and education sessions led by CHW for a subgroup of head of households with children identified as risk of malnutrition with rapid referrals to regional tertiary clinics for any children with health problems that cannot be addressed by CHW.
93570|NCT03455244|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
93571|NCT03455231|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with complicated bone metastases
93572|NCT03455218|Drug|Nitric Oxide|20 ppm of Nitric Oxide gas delivered to the oxygenator for the duration of cardiopulmonary bypass
93575|NCT03455205|Drug|shenqifuzheng|500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
93576|NCT03455205|Drug|0.9%sodium chloride|500ml sodium chloride（0.9%）daily（at day 1-7 and day22-28）through intravenous infusion.
93577|NCT03455192|Drug|Synbiotic Supplement|
93578|NCT03455192|Drug|Placebo Oral Tablet|
93579|NCT03455179|Other|Slow-speed traditional resistance training|The training session will consist in a general warm-up, 6 resistance exercises, including 2 upper limb exercises (elbow curl and chest press), 2 lower limb exercises (lunge and standing hip abduction), and 2 exercises combining both upper and lower limbs at the same time (squat plus upright rowing and squat plus shoulder press) and finally the cooldown routine.The participants will perform in each training session 6 submaximal repetitions equivalent to 85% of the one-repetition maximum (1RM) and 3-4 sets per exercise (high intensity training sessions).
93580|NCT03455179|Other|High-speed resistance training|The participants will perform the same exercises than the TRADICIONAL group with12 submaximal repetitions equivalent to 40-50% 1RM (low-intensity) and 3-4 sets per exercise.
93581|NCT03455179|Other|Multicomponent training|Participants will perform, in this order, balance exercises followed by resistance/coordination, aerobic/coordination and flexibility exercises in each session. The balance training will consist in static, dynamic and proactive balance exercises. In the resistance training block, the participants will perform 3-4 sets of 15 submaximal repetitions Participants will perform 2 resistance exercises (squat plus upright rowing and lunge) at traditional slow-speed (2s of concentric contraction and 2s of eccentric contraction).The intensity of the aerobic block will progress from 65 to 85% of the maximum heart rate over the training weeks.
93582|NCT03455166|Diagnostic Test|Serum Markers|Serum Markers
93583|NCT03455153|Other|Physical activity monitoring|COPD patients will wear an accelerometer and complete questionnaires related to daily physical activity levels for 7 days before returning for a clinic visit.
93584|NCT03455140|Drug|PEG- BCT-100|PEGylated recombinant human arginase 1
93585|NCT03455127|Other|FSI ECD|Households will be visited by a trained community based lay worker on a weekly to biweekly basis to deliver the 15 module curriculum covering a range of topics from nutrition, water and sanitation, hygiene, early stimulation, conflict management, to good communication. The intervention seeks to promote healthy child development via active coaching to individual beneficiary households, delivering modules on a one on one basis and engaging all family members.
93586|NCT03455114|Device|AssiAnchor|"The novel device, the capsular Anchor, was designed to secure the capsular bag to the scleral wall. The device is a one-piece, one-plane intraocular implant . It works like a paper clip; holding the anterior capsule between a central rod, placed in front of the capsule, and the two lateral arms, inserted through the eye surgery and placed behind the capsule."
93587|NCT03455101|Other|There is no intervention.|There is no intervention.
93588|NCT03455088|Behavioral|Dialectical Behavioral Group Therapy|DBT is based on the model for the development of emotion regulation, designed for teaching how to regulate their adaptive emotions and behaviors cased by mood disorders , so it is valid for BN patient.
93589|NCT03455088|Drug|Drug: fluoxetine|Antidepressant fluoxetine can reduce binge eating and purging behaviors in BN patients in a short time.
93590|NCT03455075|Drug|Dimethandrolone-Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate administered in 100 mg capsules.
93591|NCT03455075|Drug|Levonorgestrel 0.03 MG|Single doses of LNG administered in 30 mcg capsules.
93592|NCT03455075|Drug|Placebo oral capsule|Placebo capsules that look like DMAU and LNG capsules but with no active ingredients.
93593|NCT03455062|Other|Questionnaire about fertility|"Recruitment of participants through the list of cardiac, renal, hepatic, pancreatic or pulmonary transplant patients collected from the the Organ Transplant Unit.~A letter from the the Organ Transplant Unit will initially be sent to patients informing them of the study and if they do not wish to participate they can report their opposition by email.~A fertility questionnaire will be send and that will have to be returned by the patient in order to be included in the study.~The questionnaires, anonymous, will be numbered according to their order of return."
93594|NCT03455049|Other|Andrographis Paniculata Ext|Give the Androgaphis paniculata in prediabetes and normal subject for 14 days.
93595|NCT03455036|Other|Whole body vibration training|10 x 1 min whole body vibration exposure
93596|NCT03455023|Other|pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
93597|NCT03455010|Other|Increased load|Participants walk with 120% body weight achieved with a weight vest
93598|NCT03455010|Other|Reduced load|Participants walk with 80% body weight achieved by a dynamic unloading system
93599|NCT03454997|Other|training including in-person and online|training, motivational interviewing practice
93600|NCT03454997|Other|organizational strategy meetings|meetings with leadership to optimize implementation of evidence-based practices
93601|NCT03454997|Other|performance coaching|to enhance ability to deliver the weight management intervention
93602|NCT03454984|Drug|Guadecitabine|30/m2/day SubCutaneous for 5 days (Cycle = 28 days). total of 10 cycles
93603|NCT03454971|Other|MinOS protocol|"At Day 1, Cycle 1 and 2 of the patient's oral therapy :~Consultation with a hospital pharmacist~Consultation with a nurse care coordinator~Consultation with the patient's oncologist/hematologist~During this multidisciplinary consultation, will be reviewed :~potential medical interactions,~possible adverse effects of therapy,~information on the prescribed drug,~informations on the patient's lifestyle, ...~At day 8 and 15, cycle 1 and 2 :~Phone call from the nurse care coordinator during which will be reported the adverse effects and adherence issues. If needed, the nurse care coordinator can provide complementary information about the treatment.~The MINOS protocol follow up will end with a consultation with the patient's oncologist/hematologist, at day 1 cycle 3."
93604|NCT03454958|Other|Measurements of body composition|Body weight (SECA digital weighing scale), height (SECA stadiometer), body composition (TANITA Bioelectrical Impedance Analyzer & skin fold thickness measurements at the biceps, triceps, subscapular and suprailiac sites) and waist circumference (Cescorf measuring tape) will be objectively measured.
93605|NCT03454945|Drug|Vibramycin|Antibiotic
93606|NCT03454945|Device|Phototherapy|UVA+Psoralen
93607|NCT03454932|Other|Blood sampling|
93608|NCT03454919|Drug|Palbociclib|"Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance."
93609|NCT03454893|Drug|AVR-RD-01|AVR-RD-01 Drug Product (autologous CD34+ cell-enriched fraction that contains cells transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence
93610|NCT03454867|Device|Hemofiltration|
93611|NCT03454867|Procedure|Standard acute ischemic stroke treatment|
93612|NCT03454854|Device|intelligent terminal APP|Applications(APP) support patients to upload the primary data contain pictures and wearable devices data. When risk-rating changes or serious adverse events(SAE) take place, APP will alert patients to seek medical advice or make a call with the doctor. Beside, terminal of patients furnishes functions like answering frequently asked questions,self-assessment of physical condition,push rehabilitation knowledge etc.
93613|NCT03454841|Drug|Prasugrel|Patients with myocardial infarction will receive a 60 mg prasugrel loading dose, followed by a maintenance dose of 10 mg once daily
93614|NCT03454841|Drug|Ticagrelor|Patients with myocardial infarction will receive a 180 mg ticagrelor loading dose, followed by a maintenance dose of 90 mg twice daily
93615|NCT03454828|Dietary Supplement|obese carbohydrate diet|The experimental diet will consist of 30% carbohydrates (CHO), 35% protein, and 35% fat. Since the experimental diet is lower in CHO, the fiber and sugar content will be calculated based on total CHO in the same percentage as the control (0.25 g fiber per each kcal of CHO and 18.2% sugar for total CHO).
93616|NCT03454828|Dietary Supplement|lean carbohydrate diet|The control diet composition will follow the American Dietary Guidelines of 55% carbohydrates (CHO), 15% protein, and 30% fat. CHO content will be primarily complex CHO of high quality (14 g fiber/1,000 kcals and <10% of total kcals in the form of sugar).
93617|NCT03454815|Procedure|Apical patency|Apical patency was maintained by passing a #10 K file 1 mm beyond working length between every instrument change while doing chemomechanical preparation
93618|NCT03454802|Diagnostic Test|Passive Leg Raising|See above
93619|NCT03454789|Drug|brachial plexus block for LB Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
93620|NCT03454789|Drug|brachial plexus block for BS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
93621|NCT03454789|Drug|brachial plexus block for LS Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
93622|NCT03454789|Drug|brachial plexus block for BL Group|Standardized UG AX-SC approach to the BP was performed under sterile conditions by the same anesthesiologist. SC block was performed with the traditional in-plane, single injection cluster approach, then AX approach was performed in the supine position, with a standardized dose of 0.4 ml/kg BW
93623|NCT03454776|Device|Unloader One brace|A knee brace used to unload affected compartments in osteoarthritic knees
93624|NCT03454776|Device|Placebo brace|A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
93625|NCT03454763|Drug|PRRT every 5 weeks|PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles
93626|NCT03454763|Drug|PRRT every 8-10 weeks|PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles
93627|NCT03454750|Drug|177Lu-PSMA|177Lu-PSMA 3.7-5-5 GBq Intravenous Slowly in 15-30 ' Day 1/ every 8-12 weeks Four cycles every 8-12 weeks
93628|NCT03454737|Procedure|mesenchymal stem cells|"Autologous bone marrow aspiration is used as a cellular source to obtain MSVs and is subjected to the protocolized anticoagulant procedure. After checking the perfect condition of the shipment and the correct completion of the documentation that accompanies it, the processing of the bone marrow will be carried out.~The processing of the bone marrow will be done in the Cell Therapy Unit of the IBGM under NCF, within 24 hours of the completion of the aspiration"
93629|NCT03454737|Procedure|Pure platelet-rich plasma|"Under aseptic conditions, in surgical medium, 6 ml of P-PRP will be obtained from 36 ml of autologous peripheral venous blood sample.~The plasma coagulation will be activated by the addition of Cl2Ca at a concentration of 5%."
93630|NCT03454724|Device|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System|MeRes100 Sirolimus-Eluting BioResorbable Vascular Scaffold System used in the treatment of patients with coronary artery disease along with standard percutaneous angioplasty procedure.
93631|NCT03454724|Device|Xience EES Everolimus Eluting Coronary Stent System|Xience EES Everolimus Eluting Coronary Stent System indicated for the treatment of coronary artery disease along with standard percutaneous angioplasty procedure.
93632|NCT03454711|Device|fMRI|Brain MRI
93633|NCT03454711|Device|Indirect calorimetry|Resting energy expenditure
93634|NCT03454711|Device|Bioimpedance|Measurement of body composition
93635|NCT03454711|Biological|Lipid profile, glucose, HBA1c, metabolomic analysis|Blood sample
93636|NCT03454711|Behavioral|YFAS questionnaire, Binge Eating Scale, Hospital Anxiety and Depression (HAD) scale, hedonic evaluation test (liking)|Questionnaires to characterize eating habits and depression
93637|NCT03454698|Other|Education|"Usual care as described for the CG also applies to the IG. The intervention will consist of giving patients an opportunity to learn about the use of compression bandages, wearing and putting on compression stockings, physical activity, good skin care, and a high-protein, vitamin-rich diet. This group will be supervised by a study nurse, who will not be identical with the nurse in charge of the control group."
93638|NCT03454685|Other|without intervention type|Without intervention,this study is just an observational study.
93639|NCT03454659|Procedure|Craniotomy|Extracting the part of the sculpt
93671|NCT03454399|Procedure|Suction orogastric tube which is attached to TEE probe|Suction orogastric tube which is attached to TEE probe
93640|NCT03454646|Drug|cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)|"The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as non-responders or responders.~Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months."
93641|NCT03454633|Procedure|the temperature of hypothermic circulatory arrest|Different temperature (mild 30 degree or moderate 25 degree) employed during the hypothermic circulatory arrest on aortic surgery.
93642|NCT03454620|Drug|irinotecan|GC1118 combination with irinotecan
93643|NCT03454620|Drug|FOLFIRI|GC1118 combination with FOLFIRI
93644|NCT03454607|Device|FREE robot|FREE robot to hold endoscope
93645|NCT03454594|Device|low level laser hemotherapy|semiconductor laser therapeutic instrument irradiate the circulating blood in the vessels of left hand acupoint and the mucosal tissue in the nasal cavity
93646|NCT03454581|Procedure|Photobiomodulation|PBM was applied, three times a week for four consecutive weeks at 5 points in the TMJ region: superior, anterior, lateral, posterior and postero inferior to the condyle. In addition, all patients received laser application in the temporal muscle (anterior, middle and posterior), in the masseter (upper, middle and lower portion) and insertion of the medial pterygoid.
93647|NCT03454581|Procedure|Manual Therapy (MT)|Patients were submitted to MT at temporal, masseter and pterygoid medial from both sides, during 3 minutes each muscle group (Extraoral) and at masseter and lateral pterygoid (Intraoral) for 3 minutes, each total 21 minutes. MT on the TMJ region was performed for 1 minute and 3 repetitions during three times a week .
93648|NCT03454555|Behavioral|Shared Decision Making|The Shared Decision Making (SDM) intervention is a behavioral intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision. The intervention will have both clinician and patient components. The content of the clinician component will be based on the AHRQ (Agency for Healthcare Research and Quality) SHARE Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient (Agency for Healthcare Research and Quality, 2017) . Patients randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice.
93649|NCT03454555|Behavioral|Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain|The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain intervention is an empirically based behavioral pain management behavioral therapy intervention (Monticone et al., 2015), including MI to enhance motivation for opioid dose reduction or cessation and CBT-CP for pain coping skills enhancement. We anticipate one MI session that will focus on engaging, focusing, evoking, and planning. We anticipate 8 sessions of CBT-CP, as is standard, delivered in a group setting.
93650|NCT03454542|Device|Menicon Modified Lens Design|Randomized in a daily wear, single day (6 hours or more) evaluation
93651|NCT03454529|Other|Laboratory Biomarker Analysis|Correlative studies
93652|NCT03454529|Drug|Simvastatin|Given PO
93653|NCT03454516|Other|telemonitoring|the follow-up of the patient will be performed with Telemonitoring
93654|NCT03454503|Drug|Imatinib|Film coated tablet contains 400 mg imatinib (as mesilate)
93655|NCT03454490|Procedure|Postoperative pseudoaneurysm of the greater palatine artery|Patients had an autogenous connective tissue gingival graft.
93656|NCT03454477|Procedure|conventional open surgery|conventional open surgery
93657|NCT03454477|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy
93658|NCT03454477|Device|robotic thyroidectomy|robotic thyroidectomy
93659|NCT03454464|Procedure|Conventional|Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure
93660|NCT03454464|Procedure|central neck dissection first|central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
93661|NCT03454451|Drug|CPI-006|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.
93662|NCT03454451|Drug|CPI-006 + CPI-444|Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.
93663|NCT03454451|Drug|CPI-006 + pembrolizumab|Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.
93664|NCT03454451|Drug|CPI-006|Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.
93665|NCT03454451|Drug|CPI-006 + CPI-444|Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.
93666|NCT03454451|Drug|CPI-006 + pembrolizumab|Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.
93667|NCT03454438|Procedure|Referral strategies|Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
93668|NCT03454425|Device|Exablate Subthalamotomy|ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
93669|NCT03454425|Device|Sham Exablate Subthalamotomy|Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features
93670|NCT03454412|Procedure|Intensive Neurophysiological rehabilitation|Intensive Neurophysiological rehabilitation system (INRS) is a combination of different treatment modalities that complement and reinforce each other. It includes spinal manipulative therapy, physical therapy, occupational therapy, joints mobilization techniques, special massage therapy, mechanotherapy, computer games therapy and other treatments with daily duration up to 4 hours.
93672|NCT03454386|Behavioral|Stress Management and Resilience Training Program|"This program targets attention and interpretation of events, people and the world through the skills of gratitude, compassion, acceptance, forgiveness and understanding of a higher meaning. The program involves two phases. The 4 week training phase begins with a group session that discusses the practices that can be used to enhance awareness and engagement through the principles listed above. Participants will receive twice weekly emails with videos that described a different practice for participants to use in their daily lives. The second phase is the sustain phase that is 8 weeks in duration. Participants are expected to continue using the daily practices learned during the training phase. Weekly emails will be sent with ways to incorporate these practices into their daily lives."
93673|NCT03454386|Behavioral|Self-Management Stress Reduction Program|Program participants will be given a popular stress reduction book to read over a 12 week period. Upon completion of this, they will be enrolled in the online SMART program for 12 weeks.
93674|NCT03454373|Behavioral|Incentive for linkage to care|"Participants who were found to have been lost to care will receive standard of care plus a one-time re-start incentive of 22,500 TZS to return to care"
93675|NCT03454360|Device|ACURATE neo™ Aortic Bioprosthesis|TAVI; Transcatheter Aortic Valve Replacement. Transapical Access.
93676|NCT03454347|Dietary Supplement|Profile Perform|The dietary supplement includes 1.5 grams of fat, 19 grams of carbohydrate, and 25 grams of protein per serving. Participants in the experimental group will consume 3 servings per day.
93677|NCT03454347|Other|Lower Limb Suspension|This group will complete two weeks of lower limb suspension.
93678|NCT03454334|Device|multifocal intraocular lens IOLs|clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
93679|NCT03454321|Other|Infiltration|The subacromial injection will be performed under ultrasound guidance to accurately inject the subacromial bursae. After skin disinfection with povidone, the injection will be performed with a 21G needle. The bursae will be injected with 2 ml of lidocaine 2% and 1 ml of betamethasone.
93680|NCT03454308|Behavioral|SMASH|Auditory and visual reminders are active on Pill device will alert subject each time their medication dose is due. Pill device will transmit dose taken time stamps to researchers. Text message the following morning with tailored motivational messages that reflect the medication dose adherence from the preceding day. Subjects will monitor their BP at home at least every third day using Bluetooth monitor linked to smartphone to transmit encrypted readings to researchers.
93681|NCT03454308|Behavioral|Enhanced SC|Auditory and visual reminders are inactive on Pill device. Pill device will transmit dose taken times to researchers. Healthy lifestyle test messages as attention control.
93682|NCT03454295|Behavioral|Focus Group|Participants will be asked to reflect on their caregiving experience and specifically, when the receipt of a supportive intervention that addresses existential distress would have been most appropriate and well received.
93683|NCT03454295|Behavioral|Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|MCP-C is structured as a 7-session (1-hour weekly or biweekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and cancer caregiving
93684|NCT03454295|Behavioral|Enhanced Usual Care / EUC|"The enhancement to usual care in this study involves the inclusion of screening and targeted referral components as suggested by Reynolds et al. [79]. Research study assistants conducting the screening and providing feedback and referrals will be trained in the NCCN guidelines for distress management and will discuss the screening results and associated recommendations with the study PI (NCCN) [63]. As of November, 2017, ICs of patients seen in the Neurology Service at MSKCC are not consistently screened for distress and offered targeted referrals. Participants randomized to EUC will receive feedback about their level of distress (based on the Distress Thermometer administered at screening) after randomization. Within a week of randomization, and post-baseline, the study RSA will send EUC participants appropriate targeted referrals based on levels of distress and problem areas endorsed."
93685|NCT03454282|Other|FMD|The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
93686|NCT03454269|Diagnostic Test|Optical Coherence Tomography|The Optical Coherence Tomography is a painless analysis without contact with the eye. Patients are sitting in front of the machine. Each eye is analyzed. By a laser scanning system, longitudinal sections of the retina are made at the level of the macula and the optic nerve. The device automatically segments the different layers which are then measurable (in microns) by the ophthalmologist (duration of the analysis: 3 minutes).
93687|NCT03454256|Device|Virtual Reality|Virtual Reality Rehabilitation System
93688|NCT03454243|Drug|RXDX-106|Patients will receive continuous daily oral doses of RXDX-106 in 21 day cycles. To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), study drug will be administered in an escalated fashion starting at dose of 10 mg/day and will proceed at the dose levels prespecified by the dose escalation schema. Once daily dosing for RXDX-106 will initially be tested. However, other dosing schedules (eg, every other day, weight based, etc) may be tested based on safety and PK data to optimize drug exposure.
93689|NCT03454230|Procedure|Positioning schedule|"Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections."
93690|NCT03454217|Drug|Oxycodone|Postoperative pain treatment with oxycodone
93691|NCT03454217|Drug|Tramadol|Postoperative pain treatment with tramadol
93692|NCT03454204|Other|Pharmacokinetic|Analysis of blood samples
93693|NCT03454191|Procedure|Erector spinae plane block|Injection of local anaesthetics below the erector spinae muscle after induction of anaesthesia
93694|NCT03454191|Procedure|No injection|No injection
93695|NCT03454178|Diagnostic Test|WatchBP Office (BP measurement machine)|BP measurement: The nurse or assistant will leave the room after confirmed validity and the WatchBP will automatically measure BP for the participant at 1-minute intervals for 3 more readings; previous research showed that accurate BP readings could be obtained using 1-minute intervals. This is also the measuring method suggested by the manufacturer. The machine will automatically calculate the mean BP using the 3 readings. The mean BP value will be used for analysis. The diagnostic cutoff for diagnosing HT will be ≥135/85 for AOBP
93696|NCT03454165|Combination Product|BNC105P|BNC105P is the phosphate ester of BNC105, a small molecule tubulin polymerization inhibitor.
93697|NCT03454165|Combination Product|Ibrutinib|A novel BTK inhibitor.
93698|NCT03454139|Procedure|Subcostal transversus abdominis plane block|Ultrasound guided Subcostal transversus abdominis plane block is performed after anesthesia induction and endotracheal intubation , to the side where kidney stone is. A composition of 10 ml Lidocaine %1 plus 10 ml physiologic saline solution plus 10 ml Bupivacaine %0,5 , total of 30 ml of local anesthetic mixture is administered into the area between internal oblique muscle fascia and transversus abdominis muscle fascia.
93699|NCT03454126|Drug|BIIB095|Administered as specified in the treatment arm.
93700|NCT03454126|Drug|Placebo|Administered as specified in the treatment arm.
93701|NCT03454113|Device|Ellipsys Vascular Access|The Ellipsys Vascular Access System comprises the Ellipsys Catheter, Ellipsys Crossing Needle and Ellipsys Power Controller. The Ellipsys Crossing Needle is used to facilitate access between the artery and the vein. The Ellipsys Catheter is placed percutaneously into the selected vein in close proximity to the selected artery. The Ellipsys Catheter is actuated at the selected anastomosis site, and the vein and artery are approximated. Once the vessels are in the appropriate relative positions the catheter is connected to the Ellipsys Power Controller to create the anastomosis after which the Ellipsys Catheter is removed, and the access site is closed using standard percutaneous closure techniques.
93702|NCT03454100|Behavioral|multisectoral package of activities|A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
93703|NCT03454087|Other|Enteral Dextrose Infusion|A standard solution of 50% Dextrose (0.85 kcal/mL) will be infused via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
93704|NCT03454087|Other|Free Water Infusion|An infusion of free water will be initiated via enteral route at a rate of 10 mL per hour for a duration of 24 hours.
93705|NCT03454074|Behavioral|Problem-solving|Individualized goal-setting and group problem-solving to help older adults effectively integrate realistic, healthy behavioral changes into their everyday lives
93706|NCT03454074|Behavioral|Education|Education about healthy brain aging behaviors provided.
93707|NCT03454061|Other|physical activity|Physical education program (PEP) of 16-week length
93708|NCT03454048|Drug|Piperaquine (low dose)|subcurative regimen (480 mg)
93709|NCT03454048|Drug|Piperaquine (high dose)|Curative regimen (960mg)
93710|NCT03454048|Drug|Sulfadoxine pyrimethamine|Curative regimen (1000mg/50mg)
93711|NCT03454048|Drug|Atovaquone Proguanil|Curative regimen (1000/400 mg, for 3 days)
93712|NCT03454048|Other|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
93713|NCT03454048|Other|Blood stage malaria challenge infection, P. falciparum 3D7|P. falciparum 3D7-infected human erythrocytes administered intravenously for the purpose controlled human malaria infection.
93714|NCT03454035|Drug|Ulixertinib|Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
93715|NCT03454035|Drug|Palbociclib|Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
93716|NCT03454022|Behavioral|DART|A one-hour long web-based decision-aid program that explains treatment options for end-stage renal disease, including the benefits and risks of each treatment option.
93717|NCT03454022|Behavioral|Choosing a Treatment for Kidney Failure|This is an educational pamphlet published by the National Kidney Foundation.
93718|NCT03454009|Behavioral|Multimodal hygiene intervention|hygiene supplies including hand sanitizer, hand sanitizer surface disinfectant wipes and tissues, along with the following educational materials: a 2-minute electronic educational video; weekly 30-second electronic videos; and an educational flyer.
93719|NCT03453996|Other|Intervention|"Computerized clinical decision support intervention. This intervention consists of 2 decision support components for CI-AKI prevention:~Estimation of safe contrast limit to reduce the relative risk of CI-AKI by 20% (ePRISM Acute Kidney Injury Model with Contrast Sensitivities and Dialysis Risk software from Health Outcomes Sciences)~Patient weight and left ventricular end diastolic pressure (LVEDP) based intravenous crystalloid fluid recommendation."
93720|NCT03453996|Other|Control|Usual procedural care provided by cardiologist without introduction of the computerized clinical decision support information.
93721|NCT03453983|Device|Transcrainial Direct Current Stimulation (tDCS)|Transcranial direct current stimulation (tDCS) is a safe non-invasive form of brain stimulation, which modulates, through the application of weak direct current, cortical excitability. The applied subthreshold current passes through two externally placed electrodes, an anode and cathode.
93722|NCT03453970|Behavioral|Therapeutic Education Program|The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
93723|NCT03453957|Other|Professional development program|Professional development program consists of training including workshops and consultation sessions to enhance therapists ability to detect and repair alliance ruptures in active community based psychotherapy.
93819|NCT03453112|Drug|Foster 100/6mg pMDI|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA_134a propellant
93724|NCT03453944|Device|VentFree prototype (VF03-K) active stimulation|Abdominal wall muscle stimulation synchronised with mechanical ventilation. Stimulation frequency: 30 Hz, pulse width: 352us, max. intensity: 100mA (threshold intensity determined using ultrasound)
93725|NCT03453944|Device|VentFree prototype (VF03-K) sham stimulation|Abdominal wall muscle sham-stimulation synchronised with mechanical ventilation. Stimulation frequency: 10 Hz, pulse width: 352us, intensity: 15 mA.
93726|NCT03453931|Drug|Corticosteroid injection|Intravenous high dose corticosteroids
93727|NCT03453918|Dietary Supplement|polyphenols|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
93728|NCT03453918|Other|Placebo|"After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~Starter: duck gizzard salad.~Main course: black pudding and pasta.~French cheese.~Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic."
93729|NCT03453905|Diagnostic Test|CTFEA|CT scans are used to generate a finite element model of patient-specific long bones. The bone model is loaded in stance position. Load based on patient's weight and the mechanical response, including the risk of fracture, is computed.
93730|NCT03453905|Other|Conventional decision algorithm|Decision on surgery vs follow-up will be based on expert opinion and Mirels' score
93731|NCT03453892|Drug|Nivolumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
93732|NCT03453892|Drug|Pembrolizumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
93733|NCT03453892|Radiation|Radiotherapy|The normal clinical treatment-plan of the underlying disease remains unchanged.
93734|NCT03453892|Drug|Ipilimumab|The normal clinical treatment-plan of the underlying disease remains unchanged.
93735|NCT03453879|Other|no intervention|No intervention - only observation of teams delivering acute obstetric care
93736|NCT03453866|Procedure|Warmed Arthroscopic Fluids|Warmed Arthroscopic Fluids
93737|NCT03453866|Procedure|Room Temperature Arthroscopic Fluids|Room Temperature Arthroscopic Fluids
93738|NCT03453853|Device|Mitral Loop Cerclage Annuloplasty|Atrial Functional mitral regurgitation Response In mitral loop Cerclage Annuloplasty
93739|NCT03453840|Drug|Artemether-lumefantrine|Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: <15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; >=35kg, 4 tablets.
93740|NCT03453827|Other|no intervention|no intervention
93741|NCT03453814|Other|Music Therapy|Subjects will receive one hour of music twice a day for three days.
93742|NCT03453801|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
93743|NCT03453801|Biological|FluMist®|FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
93744|NCT03453788|Device|LETSGO app|LETSGO pilot test Group will test LETSGO app and partially nurseled follow-up
93745|NCT03453775|Device|Ultrasound guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
93746|NCT03453775|Device|Fluoroscopy guided periradicular lumbar infiltration|Once position of the needle is confirmed, the mixture Depomedrol 40mg + Lidocaine 2% (1ml) is injected, under neurostimulation with an intensity of 0.2 milliampere (identifies a distance of 1mm from the nerve root allowing the protection of the root of a lesion by the needle).
93747|NCT03453762|Procedure|recruitment maneuver|Recruitment maneuver is provided with positive pressure of 30 cmH2O for 10 seconds.
93748|NCT03453762|Procedure|ultrasonography-guided recruitment maneuver|Recruitment maneuver is guided by ultrasonography.
93749|NCT03453749|Dietary Supplement|Salovum|Salovum is freeze dried egg yolk, highly enriched with anti-secretory factor. Salovum is registered as a medical food by the EU
93750|NCT03453736|Other|No intervention|This is a qualitative study involving staff interviews and observations. No intervention is being applied.
93751|NCT03453723|Procedure|Magic glove hypnosis technique|Realization of the magic glove hypnosis technique by an expert physician trained in hypnosis, according to a classic discourse before : intravenous infusion with 1% propofol (3 mg/kg with 600 ml / h electric syringe pump). Use and dose in accordance with the SPC.
93752|NCT03453723|Drug|lidocaine|intravenous infusion with an extemporaneous mixture of 18 volumes 1% propofol (180mg) for 2 volumes of 1% lidocaine (2ml) with 600 ml / h electric syringe pump. Use and dose in accordance with the SPC.
93753|NCT03453710|Procedure|Bankart Repair plus Remplissage|"Arthroscopic Bankart repair with a minimum of 3 anchors~1 or 2 anchor Remplissage subsequently performed with percutaneous anchor insertion in the base of the Hill-Sachs defect, and sutures passed in a horizontal mattress configuration 1 cm apart, tied in the subacromial space."
94057|NCT03451045|Drug|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
93754|NCT03453710|Procedure|Latarjet coracoid transfer|Coracoid transfer performed via deltopectoral approach with horizontal subscapularis split. Graft placed in the conventional orientation, secured with 2 screws, ensuring the graft is not lateral to the glenoid rim.
93755|NCT03453697|Device|acute intermittent hypoxia|Adjust the proportion of nitrogen and oxygen, through increasing the suction nitrogen concentration, the subject's blood oxygen saturation could decrease to 80%~90% within 30 seconds and also lasts 30 seconds; then quickly reduce the concentration of nitrogen gas suction to make the subject's blood oxygen saturation gradually return to normal level (consistent with the air inhalation), and then continue breathing air about 60 seconds to enter the next round of hypoxic state.
93756|NCT03453684|Drug|Administration of Vancomycin|Intravenous Vancomycin Administration
93757|NCT03453671|Behavioral|Mindfulness|Participants will use mindfulness techniques while exercising
93758|NCT03453671|Behavioral|Distraction|Participants will distract themselves while exercising
93759|NCT03453671|Behavioral|Self-monitoring|Participants will use associative attentional focus while exercising
93760|NCT03453658|Procedure|Manual instrumentation|Manual conventional files will be used in endodontic treatment of primary teeth
93761|NCT03453658|Procedure|Reciprocating Instrumentation|Reciprocating files system will be used in endodontic treatment of primary teeth.
93762|NCT03453645|Procedure|ventricular tachycardia ablation|The usual organization of hospitalization of the patients addressed for ventricular tachycardia ablation and his follow-up are not modified by the protocol. .
93763|NCT03453632|Drug|Botulinic toxin|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of botulinic toxin (200 UI) on right or left foot"
93764|NCT03453632|Drug|Placebo|"Clinical photographs of the soles Standardized anesthesia protocol (lidocaine, prilocaine on soles, cryo-spray, oral administration of paracetamol and only if necessary oxycodone and hydroxyzine).~Cleaning and antiseptic on the soles Injections of physiological serum (200 UI) on right or left foot"
93765|NCT03453619|Drug|APL-2|APL-2 administered as a daily subcutaneous infusion for 48 weeks
93766|NCT03453606|Other|Home respiratory rehabilitation|Home care is individual (often with the spouse or the carer), during 1h30, one visit per week for 8 weeks, after completion of the educational diagnosis, under direct supervision of a member of the team, with continued physical activities in autonomy the others days of the week, according to a personalized action plan. No visit is scheduled in the pulmonologist, the general practitioner or in the rehabilitation center. The team includes pulmonologist, nurses, dietician, socio-medical beautician and a administrative assistant.
93767|NCT03453606|Other|Center respiratory rehabilitation|"In an outpatient setting, the course is performed in groups of 6 to 8 patients, during sessions from 3 to 7 am, under the direction of health professionals, 3 to 5 times a week, for 4 to 6 weeks, for a total of 20 to 24 sessions. Internally, patients come to complete hospitalization for 4 weeks. This duration can be modulated according to the evolution of the patients.~Supervision is carried out by the entire team including pulmonologists, nurses, physiotherapists, psychologists, activity professors adapted physicists, dietician"
93768|NCT03453593|Other|No intervention|No intervention
93769|NCT03453580|Radiation|multislice computed tomography portography|imaging modality
93770|NCT03453567|Procedure|Valve Replacement|Aortic valve replacement
93771|NCT03453554|Other|Digital Notebook app|Training in use of Digital Memory Notebook app
93772|NCT03453554|Other|Smart Home Prompting|Smart-home sensor based activity-aware prompting to support digital memory notebook app use
93773|NCT03453541|Drug|Ketorolac Tromethamine|Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
93774|NCT03453541|Drug|0.9% Normal Saline|0.9 % Normal saline 1ml/60kg up to a maximum dose of 1ml IV bolus (an equivalent volume as per kg Ketorolac Trimethamine dose) at the completion of the tonsillectomy in the operating room.
93775|NCT03453528|Drug|68Ga-PSMA|68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).
93776|NCT03453515|Behavioral|HEART|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
93777|NCT03453515|Behavioral|Growing Minds|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
93778|NCT03453502|Behavioral|Quality improvement of breast milk feeding|During the Intervention phase and Sustainability phase ,The NICUs will receive training of multiple evidence based quality improvement methods.
93779|NCT03453489|Other|Carbon C 11 Alpha-methyltryptophan|Undergo AMT-PET
93780|NCT03453489|Other|Laboratory Biomarker Analysis|Correlative studies
93781|NCT03453489|Procedure|Positron Emission Tomography|Undergo AMT-PET
93782|NCT03453489|Drug|Telotristat Etiprate|Given PO
93783|NCT03453476|Device|SRP and Fotosan 630|After isolating the test quadrants with cotton roll, toluidine blue was applied into the deep pockets (PD ≥ 4mm) at the test quadrants for 10 seconds, followed by inserting a perio tip (15 or 21 mm depending on the depth of the pocket) that connected to a LED emitting device, and light was emitted for 20 seconds. Toluidine blue in the deep pocket was removed by injecting normal saline into the pocket.
93784|NCT03453463|Other|exercise|3x week predominately resistance exercise for 18 months
93785|NCT03453437|Behavioral|Mindful Self-Compassion|Mindful self-compassion is a course developed by Kristin Neff and Christopher Germer designed to cultivate self-compassion as measured by three subcategories: self-kindness, mindfulness, and a sense of common humanity. This study will shorten the original 8-week course to 5 sessions, and will include interventions and lectures aimed directly toward addressing evaluative concerns perfectionism.
93855|NCT03452826|Device|Antibiotic therapy according to the result of mPCR (device)|"Phone call at D28 and D90, unless the patient is still hospitalized;~Collection of a respiratory tract sample (either distal, i.e. tracheal aspirate or bronchoalveolar lavage, or proximal, i.e. sputum) for broad panel respiratory mPCR in the intervention arm.~Collection of an additional respiratory tract sample for biological banking in both arms."
93786|NCT03453424|Procedure|TEA+DEX|intra and post operative TEA infusion of (bupivacaine +fentanyl 2 mic/ ml+ dexmedetomidine 0.5 mic/ ml) Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 inter space was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.
93787|NCT03453424|Procedure|TEA|"Under strict aseptic precautions thoracic epidural was performed using a 16 gauge,Tuhy epidural needle by a paramedian approach. T8-T9 interspace was chosen for the injection. Skin at insertion site was anesthetized by 3 ml of lidocaine 1%, the epidural space was identified by the loss of resistance technique, the catheter was introduced approximately 2-4 cm into the epidural space, epidural test dose consisted of 3 ml of lidocaine 2 % with 1: 200,000 adrenaline.~then, intra and post operative TEA infusion of bupivacaine 0.125%+fentanyl 2 mic/ ml."
93788|NCT03453411|Other|Non interventional study|Non interventional study
93789|NCT03453398|Other|Shifts working hours with different schedules|"Workers in Group 1, 2, and 3 will undergo three different shift work modalities presenting different schedules.~Importantly, as an inclusion criteria, workers have to be involved in the same shift modality for at least one year at the time at the beginning of the study."
93790|NCT03453385|Behavioral|Electronic Cigarette|An e-cigarette and four weeks of e-liquid provided to participants.
93791|NCT03453372|Device|MRgFUS Treatment|Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
93792|NCT03453372|Other|Placebo|Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
93793|NCT03453359|Device|BIS monitor|The investigators will place on the forehead of all patients the sensor BIS quatroTM, that connects with this monitor, and they will guide sedation and will record the values obtained.
93794|NCT03453359|Device|Ramsay scale|In this group, sedation is guided by the Ramsay monitoring scale. The investigators will talk with the patients and will determine the corresponding level of sedation.
93795|NCT03453346|Drug|Sofosbuvir|Generic sofosbuvir tablet 400 mg
93796|NCT03453346|Drug|Ribavirin|Ribavirin was provided in 100-mg tablets.
93797|NCT03453333|Procedure|3D laparoscope|For laparoscopic camera system, a 10-mm ENDOEYE FLEX 3D Deflectable Videoscope (Olympus Corp., Germany) was used in the 3D group.
93798|NCT03453333|Procedure|2D laparoscope|For laparoscopic camera system, a 10-mm 30º IDEAL EYES Laparoscope (Stryker, Kalamazoo, MI, USA) camera was used in the 2D group.
93799|NCT03453320|Drug|Albumin solution|Infusion rate and effects
93800|NCT03453294|Device|Apnoeic oxygenation using THRIVE|Apnoeic oxygenation using THRIVE
93801|NCT03453294|Device|Endotracheal intubation and mechanical ventilation|Endotracheal intubation and mechanical ventilation
93802|NCT03453281|Drug|Aflibercept Injection [Eylea]|Intravitreal Aflibercept injections were performed by vitreoretinal consultant at the place of study.
93803|NCT03453268|Other|STEP DOWN strategy|"reduction of the number of antihypertensive medication according to:~the systolic blood pressure levels,~co-morbidities"
93804|NCT03453268|Other|Control|usual treatment
93805|NCT03453255|Drug|Chemotherapy|chidamide, decitabine, homoharringtonine, cytarabine
93806|NCT03453242|Other|Bone measurement by HR-pQCT and ultrasound|Measurement will be performed at radius and at tibia (ultra-distal and distal). For all the sites one measurement will be performed by HR-pQCT to get reference values of thickness and BMDs. For the distal positions and additional measurement will be performed by an innovative ultrasound device that estimates cortical thickness and porosity.
93807|NCT03453216|Behavioral|neuropsychological tests|"Part 1: to determine the cognitive capacity, the subjects undergo different neuropsychological tests To determine individual characteristics children, adolescents and adults complete self-assessment questionnaires .~Adults spend a semi-directive interview. Part 2: while the subject 1 (S1) is installed in the MRI, he perform behavioral tasks with the subject 2 (S2) (familiar peer of the same age ± 2 years) installed in an adjacent room, alternating periods when S1 is observed by S2 (condition Social) and periods when S1 is not observed by S2 (condition Alone)."
93808|NCT03453203|Other|Osteopathic Manipulative Treatment Using Counterstrain|Described in arm/group descriptions
93809|NCT03453190|Combination Product|Apremilast and Clobetasol|Patients will receive apremilast and clobetasol with tapering dosages over 16 weeks.
93810|NCT03453177|Drug|Standard of Care + Fosfomycin|Fosfomycin will initially be administered IV for at least 48 hours together with standard care (ampicillin + gentamicin). Then, once babies are tolerating oral feeds and clinically improved, fosfomycin will be changed to oral administration to complete a total of 7 days of fosfomycin (or until the baby is discharged).
93811|NCT03453177|Procedure|PK|Two PK samples will be taken after each of the first IV and oral doses, with sampling times allocated within possible early (5, 10 or 60 minutes) and late (2, 4 or 8 hours) time-points after starting the IV and PO formulations; then again together with biochemistry after 7 days for those babies whom remain as inpatients.
93812|NCT03453177|Procedure|Analysis of Bacterial Isolates|For assessment of susceptibility patterns in bowel flora, we will systematically assess all admission and discharge nappy swabs.
93813|NCT03453164|Radiation|Radiotherapy + Nivolumab|Radiotherapy of 22.5 Gy/5 fractions/5 days will be given to a symptomatic lesion or the largest asymptomatic lesion suitable for irradiation from Day 1. Nivolumab will be administered intravenously starting on Day 15-22 at a dose of 3 mg/kg (body weight) every 2 weeks to a total of 6 courses of administration.
93814|NCT03453151|Drug|splanchnic nerve anesthesia with a local anesthetic|regional nerve block with a local anesthetic (Lidocaine/Bupivacaine)
93815|NCT03453138|Device|LMA Protector|LMA Protector will be inserted by a blind researcher after standart anesthesia induction. The view of the larynx will be assessed using fiberoptic grading scale
93816|NCT03453138|Device|Tracheal Intubation|tracheal intubation will be perform after standart anaesthetic induction and heamodynamic variables including blood pressure heart rate and possible complications will be observed
93817|NCT03453125|Behavioral|Spanish modified Story Memory Technique (mSMT)|
93818|NCT03453112|Drug|Foster 100/6mg NEXThaler|Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler
93820|NCT03453099|Other|Preoperative Questionnaires|"The participants will be asked to complete 5 questionnaires:~An abbreviated version of the Caffeine Assessment Tool (CAT)~Sleep Questionnaire (SQ)~Surgical Fear Questionnaire (SFQ)~WHO Alcohol AUDIT Tool~WHO Smoking Questionnaire~They will also be asked to complete a demographics sheet~All participants will undergo standard anaesthetic induction, a research participant will observe the dose of propofol and time taken for loss of consciousness"
93821|NCT03453099|Other|Postoperative Subjective Pain Scores|After the operation, participants will be provide with a scale from 1-10 in which to rate their pain at rest and whilst coughing. This will be undertaken at 1hr and 3hrs postoperatively.
93822|NCT03453086|Procedure|Thoracic paravertebral block(TPVB) group|"Thoracic paravertebral block group (TPVB) group: The midpoint of the transducer is to be placed in a longitudinal paramedian plane between two transverse processes.Tuohy needle will be introduced in a cephalad direction. The tip of the needle will be advanced under direct visualization until it pierces the superior costo-transverse ligament. When the needle tip is located immediately above the pleura, the needle is aspirated to confirm the absence of blood or air.~Serratus anterior plane block group (SAP) group: The US probe will be placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The ribs will be counted until the 5th rib is identified in the midaxillary line. The latissimus dorsi, teres major and serratus muscles will be then easily identifiable by US overlying the fifth rib. The needle will be introduced in-plane with respect to the US probe from supero-anterior to postero-inferior"
93823|NCT03453073|Behavioral|chocolate consumption level|level of consumption of 1 oz. of chocolate, as assessed at baseline
93824|NCT03453073|Other|physician diagnosis of first occurrence of serious chronic disease|
93825|NCT03453060|Drug|E-WE Thrombin- Dose 1|Participants received a single intravenous dose of 0.5 mcg/kg E-WE Thrombin.
93826|NCT03453060|Drug|E-WE Thrombin- Dose 2|Participants received a single intravenous dose of 1.0 mcg/kg E-WE Thrombin.
93827|NCT03453060|Drug|E-WE Thrombin- Dose 3|Participants received a single intravenous dose of 2.0 mcg/kg E-WE Thrombin.
93828|NCT03453060|Drug|E-WE Thrombin- Dose 4|Participants received a single intravenous dose of 4.0 mcg/kg E-WE Thrombin.
93829|NCT03453060|Other|Placebo|Participants received a single intravenous dose of placebo.
93830|NCT03453047|Diagnostic Test|S100β and Neuron specific enolase (NSE)|S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
93831|NCT03453034|Drug|TQ-B3233|QD or BID in different stage of this research
93832|NCT03453021|Drug|Mepolizumab|
93833|NCT03453008|Other|elbow extension, electromyography|"Two evaluations before the toxin injection (T0 and T1), to quantify cocontractions and to determine the toxin injection pattern.~The first evaluation (T0) will be carried out within a period of between 1 month and 15 days before the injection. This evaluation makes it possible to pose the indication for the realization of injection of Botulinum Toxin A (TBA).~The second evaluation (T1) will be performed on the day of the injection to specify the muscle targets to be injected.~The first evaluation is a Clinical evaluation and second is Instrumental evaluation"
93834|NCT03452995|Procedure|PHYSIOTHERAPY|Lymphodreinage and kinesiotaping are current methods of treatment of edema, pain and indirectly recovery of the knee ROM in TKA. Edema, pain and knee ROM are strictly corelated and, by reducing edema, we reduce the pressure by relieving pain, and allowing an improvement in movement.
93835|NCT03452982|Other|sentinel node technique|Injection of a tracer in the stump of the infundibulo-pelvic ligament and uterus-ovary for sentinel node detection.
93836|NCT03452969|Other|Implantation of multifocal intraocular lens|"Procedure/Surgery:~Bilateral implantation of a segmental refractive multifocal intraocular lens (MIOL) following cataract surgery."
93837|NCT03452956|Other|None-Observation Only|No intervention-this is an observational study
93838|NCT03452943|Drug|TEV-50717|6, 9, 12, 15, and 18 mg oral tablets
93839|NCT03452943|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks.
93840|NCT03452930|Radiation|Radiation Therapy|Undergo RT
93841|NCT03452930|Drug|Tinostamustine|Given IV
93842|NCT03452917|Drug|Placebo|500 patients will 2 ml of normal saline
93843|NCT03452917|Drug|sodium nitrite 45 mg|500 patients will receive 45 mg IV sodium nitrite
93844|NCT03452917|Drug|sodium nitrite 60 mg|500 patients will receive a dose of 60 mg IV sodium nitrite
93845|NCT03452904|Device|Drug-coated balloon|Treatment of in suit coronary lesions with drug-coated balloon
93846|NCT03452904|Device|Drug-eluting stent|Treatment of in suit coronary lesions with drug-eluting balloon
93847|NCT03452891|Other|Methylcellulose|Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
93848|NCT03452891|Drug|Simvastatin-Methylcellulose|Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
93849|NCT03452878|Behavioral|Aggressive behavior|Aggressive Behavior Scale, Quality of Life (SF-36) and Agitated Behavior Scale, measurement of thyroid-stimulating hormone (TSH), T4, T3, Cortisol, Luteinizing Hormone (LH), Estradiol, Prolactin, Progesterone, testosterone, and sex hormone-binding globulin (SHBG) and Resonance Magnetic Imaging.
93850|NCT03452865|Drug|Esomeprazole|"160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml."
93851|NCT03452865|Drug|Placebo|0.9% sodium chloride (same ml of the study drug)
93852|NCT03452852|Device|PICO|NPWT with PICO (Smith and Nephew)
93853|NCT03452852|Other|Coban 2 lite|Compression bandaging with Coban 2 lite
93854|NCT03452839|Drug|Meropenem|Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
93891|NCT03452397|Drug|OC-02|OC-02
93892|NCT03452397|Drug|Placebos|Placebo
93856|NCT03452787|Other|None, cohort studies|this is a metanalysis of previously obtained observational data. there is not intervention on any of the cohorts.
93857|NCT03452774|Other|Clinical Trial Matching|Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
93858|NCT03452761|Dietary Supplement|Ketone Salts|Subjects will take 2 servings of ketone salts daily for 6 weeks
93859|NCT03452748|Device|FTIR spectroscopy|FTIR spectroscopy examines collagen fibers in the excised membranes
93860|NCT03452735|Other|Questionnaire about fertility|Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.
93861|NCT03452722|Drug|intraventricual recombinant tissue plasminogen activator application|
93862|NCT03452709|Behavioral|therapeutic exercise|The duration of the groups is planned to be from 12 weeks with 3 programmed sessions per week. physical activity programmed by an instructor in patient with high risk of cardiovascular.
93863|NCT03452709|Device|ABPM ambulatory blood pressure monitoring|Arterial pressure is a biological variable which fluctuates over a 24 hour period depending on the period of activity/rest, which is known as circadian the BP rhythm. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) vary, on average, more than 50 mm Hg throughout the day in a normotensive adult.
93864|NCT03452696|Dietary Supplement|Calcium supplement|Calcium supplement for low contribution of elemental calcium in the daily diet
93865|NCT03452683|Behavioral|Movn Mobile App|Movn is a mobile application that is downloaded to a cell phone where participants can enter their weight and symptoms every day.
93866|NCT03452670|Behavioral|Active Group|Participants will be provided with a contemplative well-being application (CWA) which will facilitate meditation for 10 minutes daily during the 8 week study period.
93867|NCT03452670|Other|Waitlist Group|The waitlist group will be maintained as a control group throughout all assessments and will be provided enrollment in CWA at the end of the 8 week study period.
93868|NCT03452657|Drug|Ranibizumab|Participants in arm Ranibizumab will receive ranibizumab injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year
93869|NCT03452657|Procedure|No drug|Participants in arm Sham-injection will receive sham injection every 4 weeks for the first 3 months, followed by re-injections every 3 months until 1year.
93870|NCT03452618|Diagnostic Test|diagnosis variables|"The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~Age of the patient~Sex~Presence of bulbar involvement or not~Time from onset of first symptoms to diagnosis of ALS~Score ALSFRS-R~Presence of another underlying respiratory pathology (COPD, asthma ...)~FVC measurement (Forced vital capacity)~PaCO2 measurement~Measure SNIP (Sniff nasal inspiratory pressure)~Measure of Pimax (Pressure inspiratory maximal)~Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)"
93871|NCT03452605|Dietary Supplement|cocoa flavanol supplementation|cocoa flavanols (containing 196 mg epicatechin)
93872|NCT03452592|Drug|Alflutinib|Patients take Alflutinib orally once per day at dose of 80 mg or 160 mg
93873|NCT03452579|Drug|Nivolumab|240mg
93874|NCT03452579|Drug|Standard Dose Bevacizumab|10mg/kg
93875|NCT03452579|Drug|Reduced Dose Bevacizumab|3mg/kg
93876|NCT03452566|Drug|Ingenol mebutate gel|3+3 phase 1 design as described above. After the maximum tolerated dose is defined, the phase 2 segment of the study will take place. Simon's Phase 2 study design tool was used, reinforced by Jung's admissible study designs for phase 2 clinical trials. Considering the margin of error of 0.05 and study power of 80%, and estimating the probability of placebo partial response of 15% and partial response to ingenol mebutate in 45%, the optimized number of patients to be recruited is 19. Six patients will be seen in the first stage of this segment of the study, and if only one patient or none has a partial response, the study will be promptly discontinued. Otherwise, the second and final stage of segment of the study will include an additional thirteen patients who will be treated.
93877|NCT03452553|Device|LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin|Drug Eluting Beads loaded with chemotherapy
93878|NCT03452540|Drug|DS102|Participants will receive 1000mg DS102 capsules twice per day.
93879|NCT03452540|Other|Placebo|Participants will receive placebo capsules twice per day.
93880|NCT03452527|Biological|ICON-1|ICON-1 0.6 mg by intravitreal injection
93881|NCT03452527|Biological|aflibercept|aflibercept 2 mg by intravitreal injection
93882|NCT03452501|Drug|Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
93883|NCT03452488|Drug|BIO101|Oral capsules containing the BIO101 active principle is 20-hydroxyecdysone (20E), which is found and extracted by purification from the edible plant Stemmacantha carthamoides Component : 251 mg per capsule including 175 mg of active principle 20E containing also the following compendial excipients: colloidal silica, microcrystalline cellulose and magnesium stearate.
93884|NCT03452488|Drug|Placebo oral capsule|Oral capsules containing Microcrystalline cellulose, Colloidal anhydrous silica
93885|NCT03452475|Drug|Arterolane-piperaquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
93886|NCT03452475|Drug|Arterolane-piperaquine+mefloquine|Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
93887|NCT03452475|Drug|Artemether-lumefantrine|Artemether-lumefantrine tablets (20 mg/120 mg)
93888|NCT03452462|Device|Pacing|Programming of either Direct His Bundle pacing or biventricular pacing
93889|NCT03452449|Procedure|planned lumbar spine surgery|planned lumbar spine surgery including decompression, discectomy, foraminotomy, laminectomy
93890|NCT03452423|Procedure|ACRFP|Arthroscopic cartilage regeneration facilitating procedure (ACRFP) is a set of surgical procedures that combines resection of medial plica, medial and lateral capsular release, synovectomy of focal synovitis, and chondroplasty of loosened cartilage flaps as a rationale for the deliberate arthroscopic management of osteoarthritic knee.
93893|NCT03452384|Other|Acupuncture|For real acupuncture, disposable acupuncture needles (0.22 x 30-mm sterile stainless needles) were inserted into acupoints for a depth of 10-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, the inserted needles were affixed with adhesive tapes so that real acupuncture procedure will be identical to control acupuncture procedure. For sham acupuncture procedure, Streitberger's noninvasive placebo acupuncture needles will be used. Its validity and credibility have been well demonstrated (Streitberger and Kleinhenz, 1998).
93894|NCT03452371|Behavioral|Patient Navigation|Navigators will also screen participants for barriers to smoking cessation. Patient navigation intervention calls will use motivational interviewing (MI) strategies to: (1) Assess stage of change; (2) Assess and reinforce any prior abstinence from smoking and/or any efforts made to reduce/quit smoking; (3) Explore motivation to quit smoking, drawing on recent illness, financial/family situations as appropriate; advise about the risks of smoking and benefits of quitting (4) Discuss past experience with utilizing cessation support; (5) Explore potential barriers to using smoking cessation medications; (6) Brainstorm strategies to address identified barriers; (7) Elicit commitment to accept another patient navigation counseling call, discuss timing.
93895|NCT03452371|Behavioral|Enhanced Traditional Care|Enhanced traditional care will include a resource card with information on quitlines, BMC's Tobacco Treatment Center Program number, and websites for smoking cessation.
93896|NCT03452358|Procedure|Partial Ceramic Indirect restoration|Placement of an partial ceramic indirect restoration with the use of immediate dentin sealing as an adjunct to adhesive cementation.
93897|NCT03452345|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
93898|NCT03452345|Drug|Placebo|Placebo (Normal saline)
93899|NCT03452332|Biological|Durvalumab|Given IV
93900|NCT03452332|Other|Laboratory Biomarker Analysis|Correlative studies
93901|NCT03452332|Radiation|Stereotactic Radiosurgery|Undergo SABR
93902|NCT03452332|Biological|Tremelimumab|Given IV
93903|NCT03452319|Other|Pretraining|Increased physical activity, and daily strength training and breathing exercises.
93904|NCT03452319|Other|Usual care|Preoperative information
93905|NCT03452306|Drug|Metformine|"First aIntervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fasting condition"
93906|NCT03452306|Drug|Glucophage® Long|"Second Intervention Period:~Single administered dose of Glucophage® (750 mg tablet extended-release) in a fasting condition"
93907|NCT03452306|Drug|Metformin|"Third Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
93908|NCT03452306|Drug|Glucophage® Long|"Fourth Intervention Period:~Single administered dose of Metformin (750 mg tablet extended-release) in a fed condition"
93909|NCT03452293|Device|Stent Peripheral System|Peripheral PTA with Supera Stent implantation
93910|NCT03452267|Drug|Metformin|oral, 850 mg twice daily
93911|NCT03452267|Drug|Pioglitazone|oral, 45 mg daily
93912|NCT03452267|Drug|Placebo|oral, once daily
93913|NCT03452254|Device|Active Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Active tDCS: The anodic electrode will be put on affected M1. The cathodic electrode will be put on contralateral M1. We will apply a constant current of 2mA of intensity during 20 minutes while the patient performs the occupational therapy session."
93914|NCT03452254|Device|Sham Bihemispheric Transcranial direct current Stimulation|"The session will start with the application of the with a couple of surface sponge electrodes (25-35 cm2) on the scalp. The treatment modality will be as follows:~Sham tDCS: We will use the same place and parameters of stimulation applied for the active group, but the stimulator will deactivate after 30 seconds of stimulation. This will ensure that the patient will feel the initial tingling sensation at the beginning of the tDCS which is a requisite for blinding. The occupational therapy session will last one hour."
93915|NCT03452254|Other|Modified Constraint Induced Movement Therapy|"Both groups will perform the mCIMT during a period of seven consecutive days. This protocol consists of two elements:~Restriction of the movements of the non-affected hand by wearing a mitt during six hours a day: we will use a mitt that limits the movement of the fingers but allows the free movements of the wrist, elbow, and shoulder.~Intensive and individualized training of the affected arm during 2 hours a day guided by an occupational therapist: the two hours training will be divided into two sessions of one hour each. Sessions will be organized in three blocks: preparation, activation, and function. In the third block, devoted to function, the patient has to choose one activity of daily living that he wants to improve."
93916|NCT03452241|Other|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.BI refers to a standard 15-30 minute intervention that includes a series of standard models that stimulate knowledge, motivation and behavior that reduce substance abuse.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
93917|NCT03452241|Other|Control Group|The participants only receive the materials about the harm of substance use.the harm of substance use is a dedicated paper publicity handbook, written by the SHMC, detailing the hazards of substance abuse.
93918|NCT03452228|Drug|evinacumab|Administered by Intravenous (IV)
93919|NCT03452228|Drug|Placebo|Administered by Intravenous (IV)
93920|NCT03452215|Behavioral|Mobile Phone Application Educational Resources|Mobile Phone Application Educational Resources
93921|NCT03452215|Behavioral|Mobile Phone Application GWG Tracker|Mobile Phone Application GWG Tracker
93922|NCT03452202|Device|Soterix 1x1 line tDCS low-intensity stimulator|Introduction of the independent variable (treatment) across three different points in time. Participants will be randomly assigned to have each treatment phase begin after 3, 4, or 6 baseline sessions. This current stimulates the cortex, with anodal stimulation leading to a depolarized state in which neurons are more likely to fire.
93923|NCT03452202|Device|Sham|Patients will have two electrodes applied (one anode, one cathode) administering no stimulation
93924|NCT03452189|Drug|Vancomycin|Oral vancomycin 250mg capsules
93925|NCT03452189|Other|Placebo|"Placebo Pills distributed by Research Pharmacy labeled placebo."
94058|NCT03451045|Drug|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
93926|NCT03452176|Device|Scrambler|Scrambler is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of nociceptive fibers with the intent of re-organizing maladaptive signaling pathways which has been investigated for treatment of peripheral neuropathy.
93927|NCT03452176|Device|Scrambler Sham Control|Sham control should be indistinguishable to the participants from experimental Scrambler therapy.
93928|NCT03452163|Device|PMD-200|"the patients will be monitored by PMD-200. The technology consists of measurements of a number of nociception-related physiological parameters that corresponds with the autonomic nervous system's response to noxious stimuli, and using the company's proprietary algorithms, 'translating' these measurements into an index that represents the nociceptive response, the NoL™ (Nociception Level) Index. The NoL index is a relative index from 0 to 100, while 0 is no pain/nociception and 100 is extreme pain/nociception."
93929|NCT03452163|Device|EEG monitor|An EEG device will be connected to the patient and display the Spectral Edge Frequency (SEF) signals and values on the subject monitor.
93930|NCT03452150|Drug|D-0316|If initial dosing of D-0316 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
93931|NCT03452137|Drug|Atezolizumab|Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
93932|NCT03452137|Drug|Placebo|Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
93933|NCT03452124|Device|I quit ordinary smoking (IQOS)|I quit ordinary smoking (IQOS) assisted cessation program
93934|NCT03452124|Other|Conventional cigarette|Conventional cigarette smoking continuation
93935|NCT03452111|Drug|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied daily for 52 weeks to a male subject's arms and shoulders. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62 mg of T that will deliver approximately 6 mg T to the body per day. This gel volume will also contain 8 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 62 mg/d (NES8/T62) gel).
93936|NCT03452085|Device|artificial saliva spray (AS)|cross over design
93937|NCT03452085|Other|maritime throat spray (TT)|cross over design
93938|NCT03452072|Drug|0.25% Timolol gel with paraffin gauze dressings|Timolol 0.25% gel will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply 0.25% topical timolol gel (1 drop = 0.1ml for each cm2 of wound area), and re-cover wound with clean dressing
93939|NCT03452072|Other|Vaseline dressing|Vaseline will be applied to wound bed immediately after surgery before dressing is applied. Starting the day after surgery: each day, the patient will cleanse the surgical site, apply Vaseline, and re-cover wound with clean dressing
93940|NCT03452059|Device|AiLegs, AiWalker and HKAFO|5 days. Using their own control method, each morning using AiLegs, AiWalker AiWalker and HKAFO for 6 minutes walk test, three kinds of appliance between at least 30 minutes to determine heart rate, blood pressure and breathing back to quiet level. Repeat the same procedure in the afternoon ，the order is also random. Each participant will complete 10 groups of lower limb exoskeleton rehabilitation Training robot (including AiLegs, AiWalker two models) and HKAFO 6 minutes walking test
93941|NCT03452046|Other|IVC diametres|
93942|NCT03452033|Drug|H-1337 Placebo|H-1337 Placebo
93943|NCT03452033|Drug|H-1337 [1]|H-1337 Ophthalmic Solution Concentration 1
93944|NCT03452033|Drug|H-1337 [2]|H-1337 Ophthalmic Solution Concentration 2
93945|NCT03452033|Drug|H-1337 [3]|H-1337 Ophthalmic Solution Concentration 3
93946|NCT03452020|Device|Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer|Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
93947|NCT03452007|Device|Epidural Stimulation|Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of [5-6-5]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
93948|NCT03451994|Other|Breath test|Breath samples taken from all participants, analyzed with gas chromatography mass spectrometry (GC/MS), no treatment given.
93949|NCT03451981|Procedure|mechanical debridement and chemical decontamination|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with chlorhexidine.
93950|NCT03451981|Procedure|Er:YAG laser|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Chlorhexidine. Furthermore, Er:YAG laser treatment will be provided on the implant surface.
93951|NCT03451981|Procedure|Air Powder|mechanical debridement and chemical decontamination: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments and the implant surface will be cleaned by copious irrigation with Clorhexidine. Furthermore, an Air-Powder treatment will be provided on the implant surface.
93952|NCT03451968|Other|amino acid tracer injection for metabolism analysis|"the intervention includes injecting stable amino acid tracers in order to evaluate differences in processing of amino acid in critically ill patients compared to a normal population.~after injection 5 ml of blood will be drawn at time 0, 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180 minutes from the start of the study, a total of 14 blood samples (70 cc)."
93953|NCT03451955|Other|Gluten-free diet|Participants in the intervention group abstain from gluten for 6 months.
93954|NCT03451942|Drug|FLOT regimen chemotherapy|FLOT regimen chemotherapy
93955|NCT03451942|Procedure|D2 gastric and imaging metastases resection|After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery)
93956|NCT03451916|Drug|PLX-PAD|PLX-PAD (120 subjects): 150×106 PLX-PAD cells (10×106 cells/mL) in a mixture containing 10% DMSO (v/v), 5% HSA (w/v) and PlasmaLyte
93957|NCT03451916|Drug|Placebo|Arm 2 Placebo (120 subjects): Placebo (solution comprised of 10% DMSO [v/v], 5% HSA [w/v], and PlasmaLyte, without cells).
93958|NCT03451903|Drug|Actilyse|Actilyse is the intra-venous agent used for intra-venous thrombolysis in the acute phase of cerebral infarction.
93959|NCT03451903|Procedure|Mechanical thrombectomy|Mechanical thrombectomy is an endovascular procedure by which an arterial clot is retrieved, in order to reperfuse the brain.
93960|NCT03451890|Drug|E2730|oral capsule
93961|NCT03451890|Drug|Placebo|oral capsule
93962|NCT03451877|Genetic|TGFB1 AND LAMA1 GENE POLYMORPHISMS|we evaluated polymorphisms in the LAMA1 (rs2089760) and TGFB1 (rs4803455) genes in children younger than 13 years of age with ≥6 D myopia in an attempt to further elucidate the genetic basis of high myopia.
93963|NCT03451864|Procedure|Vaginal delivery|classic vaginal delivery
93964|NCT03451864|Procedure|Cesarean Section|routine lower segment cesarean scetion
93968|NCT03451838|Diagnostic Test|Ultrasound|Ultrasound will be done to every pregnant lady
93969|NCT03451838|Diagnostic Test|HbA1c level in blood|a blood sample will be taken to measure HbA1c level
93970|NCT03451825|Drug|Avelumab|Subjects will receive avelumab administered intravenously (IV) once every 2 weeks.
93971|NCT03451825|Drug|Avelumab|Subjects will receive avelumab at a recommended phase II dose (RP2D) adjudicated by a safety monitoring committee (SMC) from phase I part of the study.
93972|NCT03451799|Other|Ketogenic Diet|A 4-month ketogenic diet will be supervised and monitored by the study investigators. Study dietitians will create personalized meal plans for each patient with the goal of achieving and maintaining metabolic ketosis.
93973|NCT03451799|Radiation|Standard-of-care radiation|Patients will receive standard-of-care radiation. Radiation is not protocol directed.
93974|NCT03451799|Drug|Standard-of-care Temozolomide|Patients will receive standard-of-care temozolomide. Temozolomide is not protocol directed.
93975|NCT03451773|Drug|M7824|1,200 or 500mg every 2 weeks by IV infusion
93976|NCT03451773|Drug|Gemcitabine|Standard (1,000 mg/m2) or reduced (600 mg/m2 for 4 doses) IV once a week for first 4 weeks. Then, once weekly for 3 weeks with one week rest. Gemcitabine will be discontinued after 6 months of therapy
93977|NCT03451760|Drug|Feru-guard 100M|Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
93978|NCT03451760|Other|Feru-guard 100M Placebo|In order to conduct a double-blind, controlled trial, the placebo will be contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding. The placebo study drug will be matched to the Feru-guard 100M in terms of appearance, smell, and taste.
93979|NCT03451734|Drug|Olanzapine|Antipsychotic drugs
93980|NCT03451734|Drug|Risperidone|Antipsychotic drugs
93981|NCT03451734|Drug|Aripiprazole|Antipsychotic drugs
93982|NCT03451734|Drug|Ziprasidone|Antipsychotic drugs
93983|NCT03451734|Drug|Amisulpride|Antipsychotic drugs
93984|NCT03451734|Drug|Haloperidol|Antipsychotic drugs
93985|NCT03451721|Device|ImageReady™ MR Conditional Defibrillation System|Subject will receive an ICD or CRT-D pulse generator in the left or right pectoral region ICD
93986|NCT03451708|Device|OKS|Optokinetic stimulation will be displayed on a see-through liquid crystal display lens placed in front of the subjects.
93987|NCT03451695|Drug|Morphine|Morphine group will receive intrathecal 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and 100 μg of preservative free morphine (0.1 ml).
93988|NCT03451695|Drug|Placebo|Placebo group will receive 11 mg of hyperbaric bupivacaine (2.2 mL 0.5%), 10 μg of fentanyl (0.2 ml) and normal saline (0.1ml)
93989|NCT03451682|Dietary Supplement|procyanidine|Natural antioxidant
93990|NCT03451643|Procedure|ENDOSCOPIC PLACEMENT OF EXPANDABLE STENT|PLACEMENT OF AN ENDOSCOPIC SELF EXPANDABLE METAL STENT
93991|NCT03451630|Behavioral|High-Touch|Includes a personalized service design that includes payer-employed registered nurses and social workers to provide intensive, in-person support and resources for eligible patient participants in their homes and/or communities for approximately four months following initial engagement.
93992|NCT03451630|Behavioral|High-Tech|The High-Tech intervention uses less in-person resources by leveraging telehealth and remote monitoring technology to support self-directed care management in real time for approximately four months following initial engagement. Mobile devices, applications, and the Internet are used to provide innovative approaches to inform and communicate with patients including: virtual video visits, appointment and medication reminders, and access to mobile applications for managing individual health and health care.
93993|NCT03451630|Behavioral|Usual Care/Optimal Discharge Planning|After initial engagement in the hospital or in the community, CT staff will have a single home visit with each individual to provide evidence-based support, including: detailed disease management and medication education; confirmation of and connection to family/caregiver support and resources; scheduling an ambulatory follow-up appointment within five days of discharge; and a hand-off to a health plan-based telephonic nurse care manager as needed.
93994|NCT03451617|Device|Stent delivery with Xpedition|Use of Xpedition stent delivery system to implant the XIENCE stent
93995|NCT03451617|Device|Stent delivery with Alpine|Use of Alpine stent delivery system to implant the XIENCE stent
94059|NCT03451045|Other|Placebo|Subjects will receive placebo twice daily.
93996|NCT03451604|Other|preoperative assessement|All data concerning study, involved in normal care of patient for his anesthesia (non interventional study), where included in anonymous computerized database by anesthesiologist during pre operative clinic.
93997|NCT03451591|Drug|Isosorbide Mononitrate XL (ISMN)|Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
93998|NCT03451591|Drug|Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models.
93999|NCT03451591|Drug|ISMN XL and Cilostazol|Cilostazol is a phosphodiesterase 3-inhibitor (PDE3-inhibitor) that enhances the PGI2-cAMP system. It has weak antiplatelet effects (so low bleeding risk), reduces infarct size and reduces ageing-related decline in myelin repair in experimental models. Isosorbide mononitrate (ISMN), is an NO donating organic nitrate that enhances vasodilation, is widely used in ischaemic heart disease, and has no antiplatelet activity.
94000|NCT03451591|Other|Neither ISMN nor cilostazol|Neither isosorbide mononitrate nor Cilostazol administered for the entire duration of the study.
94001|NCT03451578|Device|Alpha MSH assay|Assay to detect levels of alpha MSH in intraocular fluid.
94002|NCT03451552|Behavioral|Patient Navigator|Navigators will support patients to access community based resources for healthy living and self-management, rather than providing specific information about health issues. Navigators will teach patients how to identify available and relevant programs to meet their health-related goals, in their language of choice. The navigator will ensure that the individual understands the reason for referral and potential benefits. They will discuss social barriers potentially affecting patients' access to community health resources, and assist patients to prioritize their health goals and relevant resources to achieve these. The navigator will then assist patients to access the community-based services in the language of their choice to which they have been referred. The navigator may assist the patient in making appointments, coordinating transportation, and/or accompaniment to resources as required).
94003|NCT03451526|Procedure|Surgeries|Surgeries plus adjuvant chemotherapies or perioperative chemotherapies
94004|NCT03451513|Behavioral|Pride Body Project|"PBP is a 2-session eating disorder prevention program. Each session is 2 hours, and separated by a week. Groups have 4 to 7 participants and are led by a peer and a clinician. This program allows a forum for young men to critique the appearance ideal. These exercises should induce cognitive dissonance, which subsequently lead to a reduction of internalization of the ideal. In session 1, participants: (1) define the ideal body type in the gay community, (2) discuss its origin and perpetration, (3) brainstorm its costs, (4) participate in a verbal challenge where they counter the ideal, and (5) are asked to complete three assignments. In session 2, participants: (1) review homework, (2) engage in role-plays to counter pursuit of the ideal, (3) discuss ways to challenge body talk statements, (4) list ways to resist the pressure to pursue this ideal (body activism), (5) discuss barriers to body activism and how to overcome those barriers, and (6) select an exit activity."
94005|NCT03451513|Behavioral|Media Advocacy|We will use a media advocacy (MA) intervention as an active, time- and attention-matched control. MA is a 2 session, group-based program with co-leaders (1 peer and 1 clinician). The MA content centers on acknowledging and discussing the role the media has on shaping body image ideals. In session 1, there is a discussion on describing the ideal body in the gay community and how the media impacts this ideal. Following this, participants will watch a video on how the media influences body image among gay men, and the consequences of internalizing these messages. In session 2, participants will watch a second video. Next, the group discusses other forms of media (e.g., pornography, social media) and how it impacts body image.
94006|NCT03451500|Drug|carbidopa-levodopa|See previous
94007|NCT03451487|Drug|Panadol®|Acetaminophen 500mg Tablet
94008|NCT03451487|Drug|SafeTynadol®|Acetaminophen 500mg Tablet
94009|NCT03451474|Procedure|Upper extremity nerve transfer surgery|Upper extremity nerve transfer surgery is a surgical procedure where axons from an intact, functioning upper extremity peripheral nerve are moved to a target muscle that demonstrates significant weakness or paralysis as a result of spinal cord injury. After allowing time for recovery from surgery and for nerve growth to occur, the patient undergoes hand/occupational therapy in order to retrain motor skills.
94010|NCT03451461|Other|No intervention|Observational study. Clinical data recorded
94011|NCT03451448|Diagnostic Test|PET/MRI|PET/MRI with USPIO contrast
94012|NCT03451448|Diagnostic Test|MRI|MRI with USPIO contrast
94013|NCT03451435|Drug|N acetyl cysteine|N acetyl cysteine at 20mM will be utilized as the final stage of irrigation prior to induction of bleeding during endodontic revascularization procedure.
94014|NCT03451422|Drug|AMG 592|For both the phase 1b and phase 2a part of the study, AMG 592 or placebo will be administered by SC injection in the abdomen, thigh or upper arm
94015|NCT03451422|Drug|Placebo|For both the phase 1b and phase 2a part of the study, AMG 592 or placebo will be administered by SC injection in the abdomen, thigh or upper arm
94016|NCT03451409|Other|Tasked based functional MRI (fMRI)|2-3 brief computer tasks while brain activity is being measured. The tasks performed will involve making button press responses to letters, numbers or shapes on the computer screen.
94017|NCT03451409|Other|Eye Tracking Device|Camera aimed at eyes to record eye movements during tasks
94018|NCT03451396|Drug|Lifitegrast|All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID
94019|NCT03451370|Drug|Capecitabine|"750 mg/sqm/bid, day 2 to 15; if toxicities grade ≥2 do not occur, pts may subsequently receive capecitabine 1000 mg/sqm/bid, day 2 to 15 starting the second cycle based on investigator's choice.~To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal."
94020|NCT03451370|Drug|Oxaliplatin|100 mg/sqm iv over 2 hours, day 1 To be repeated every 3 weeks (21 days), for a maximum of 8 cycles.
94055|NCT03451084|Drug|ASLAN003|Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.
94056|NCT03451071|Drug|Gardasil9|Gardasil 9
94021|NCT03451370|Drug|Bevacizumab|"7.5 mg/kg iv over 90 minutes, day 1; if the first infusion is tolerated, then subsequent infusions may be administered in 30 minutes.~If no progression occurs, pts will receive maintenance capecitabine (starting at the same dose used at the last cycle of the induction treatment) plus bevacizumab every 3 weeks (21 days), until disease progression, unacceptable toxicity or patient's refusal. To be repeated every 3 weeks (21 days), for a maximum of 8 cycles."
94022|NCT03451357|Diagnostic Test|Dependence degree already certificated by Dependence Law.|The European Council defines dependence as the state in which people, due to causes linked to the lack or loss of physical, psychological, or intellectual autonomy, are in need of assistance and/or significant help to carry out common activities of daily life. In primary care, the nurses in charge are trained of data collection. This situation needs of formal care provided by health or/and social workers, private or public.
94023|NCT03451344|Other|Integrated rehabilitation group|Participant in integrated rehabilitation group needs to visit their corresponding social worker and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary. The integrated rehabilitation group received the standardized community-based rehabilitation described above and simultaneously received a 6-month integrated rehabilitation based on CAREs (Community-based Addiction Rehabilitation Electronic System).CAREs was developed by the department of addiction research in Shanghai Mental Health Center(SMHC), with functions including education, support, psychological intervention and other functions.
94024|NCT03451344|Other|Community-based rehabilitation group|Participant in community-based rehabilitation group needs to visit their corresponding social worker for six months and accept illicit drug test every two months. Social worker will help their corresponding client to apply for social benefits accordingly, and provide counseling irregularly if necessary.
94025|NCT03451331|Drug|Nivolumab|Nivolumab 360mg (and/or) Maintenance Single Agent Nivolumab 480mg (starting ~ 2-4 weeks after completing combination chemotherapy plus nivolumab)
94026|NCT03451331|Drug|Gemcitabine|1000 mg/m^2
94027|NCT03451331|Drug|Carboplatin|AUC 4.5 (based on the Calvert formula)
94028|NCT03451331|Drug|Oxaliplatin|130 mg/m^2
94029|NCT03451318|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray NASONEX
94030|NCT03451318|Procedure|tonsillar adenoidectomy|tonsillar adenoidectomy
94031|NCT03451318|Procedure|Maxillary expander plus Twin-Block|Twin-block appliance combined with maxillary expander
94032|NCT03451305|Other|Pillow|A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
94033|NCT03451292|Drug|Albutein 20% Injectable Solution|Within 96 hours after discharge and following randomization, subjects will receive the first Albutein 20% infusion at the dose of 1.5 g/kg body weight (maximum 100 grams per subject). Thereafter, subjects will receive Albutein 20% infusions at the dose of 1.5 g/kg body weight (maximum 100 grams per subject) every 10 ± 2 days for the rest of the study (up to a maximum of 12 months). Subjects in this treatment group will also receive SMT.
94034|NCT03451292|Other|Standard medical treatment|Subjects will receive SMT according to published guidelines for the management of decompensated cirrhosis.
94035|NCT03451266|Drug|Vitamin C|1,5g of IV vitamin C in 100 ml 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
94036|NCT03451266|Drug|placebo|100 ml of IV 0.9% NaCl within 30 min of delivery and then every 6 hours for the first 72 hours post-partum.
94037|NCT03451253|Other|amino acid mixture beverage|commercially available amino acid mixture. Contains 5 amino acids, electrolytes and natural flavoring.
94038|NCT03451253|Other|glucose-based sports drink|Commercially available glucose-based sports drink, contains electrolytes, sugar and artificial flavoring.
94039|NCT03451240|Behavioral|Corporate Athlete® Resilience|"The product Corporate Athlete® Resilience Training Program (CAR Training), is a one day training program aimed to educate participants about stress management and stress recovery techniques.~The content of the training program is divided into two parts:~Introduction to stress and resilience: an overview of stress and its impact on wellbeing, combined with the definition of resilience and its linking to daily performance.~Introduction and implementation of stress management and resilience techniques: an overview of applicable stress management and resilience tools, combined with real time application methods. These activities aim to help individuals recover and grow from a stressful state into meaningful life engagement. The desired overall effect is better performance at home and at work."
94040|NCT03451227|Drug|Dexmedetomidine group|The study drug dexmedetomidine (PrecedexTM) will be infused at 0.2-1mcg/kg/hour from the start of the case. The dexmedetomidine infusion will stop at completion of the procedure.
94041|NCT03451227|Drug|Remifentanil Group|Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
94042|NCT03451214|Other|Diet Zinc|4 mg zinc from zinc biofortified wheat, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period
94043|NCT03451201|Behavioral|High Intensity Interval Training|High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks
94044|NCT03451201|Behavioral|Moderate Continuous Exercise Training|Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity
94045|NCT03451201|Other|Non-exercise|Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
94046|NCT03451188|Device|Cerecare compression garments|all Cerecare compression garments
94047|NCT03451162|Drug|DHES0815A|DHES0815A will be administered via intravenous (IV) infusion on Day 1 of each 21-day cycle.
94048|NCT03451149|Device|Radiofrequency wire (Powerwire)|Using a radiofrequency wire in lieu of a needle for penetrating the liver during transjugular intrahepatic portosystemic shunt creation.
94049|NCT03451123|Drug|FET PET/MRI|FET PET/MRI scan before and after surgery
94050|NCT03451110|Drug|lemborexant|oral tablet
94051|NCT03451110|Drug|Loestrin|oral tablet
94052|NCT03451110|Drug|famotidine|oral tablet
94053|NCT03451110|Drug|fluconazole|oral tablet
94054|NCT03451097|Radiation|echocardiography|cardiac ultrasound
94061|NCT03451019|Drug|Sevelamer Hydrochloride|Single oral doses of lanthanum (1000 mg) or Sevelamer (2400 mg) were administered in random order 15 minutes after 5 g calcium carbonate with standardized meal
94062|NCT03451019|Drug|Lanthanum Carbonate|Single oral doses of lanthanum (1000 mg)
94063|NCT03451006|Drug|Metformin|Oral metformin (up to 2gm) will be given in divided doses
94064|NCT03451006|Drug|Placebo|Oral Placebo will be given in divided doses
94065|NCT03450993|Other|SMART Program|This is an 8-week, multimodal resiliency program that targets stress with 4 main components: mind-body skills (participants learn a variety of meditation techniques, mini relaxations, walking meditation, and yoga), traditional stress management techniques, healthy lifestyle behaviors (sleep, exercise, nutrition, and social support), and cognitive reappraisal and adaptive coping skills (borrowed from cognitive behavioral therapy, acceptance and commitment therapy, and positive psychology)
94066|NCT03450980|Other|EyeTurn App|App software which analyzes the position of ocular surface reflections in a photograph to quantify eye misalignment (strabismus)
94067|NCT03450967|Drug|Durvalumab Plus Tremelimumab|Durvalumab 1500mg plus tremelimumab 75mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination until progression.).
94068|NCT03450954|Procedure|Amniotic membrane transplant|Amniotic membrane graft was transplanted onto the bullous cornea by the inlay technique
94069|NCT03450928|Procedure|Peroral Endoscopic Myotomy (POEM)|"Peroral endoscopic myotomy (POEM) is a minimally invasive intervention for the treatment of esophageal achalasia.~POEM includes different steps:~Lifting of the esophageal mucosa, with the injection of saline solution, and mucosal incision on the esophageal body (approximately 12 or 7 cm above the esophagogastric junction, for about 1-2cm)~Advance of the endoscope into the submucosa, repeated submucosal injection and dissection of a submucosal tunnel into the distal esophagus up to 3 cm into the gastric wall.~Myotomy of the distal esophagus, cardia and gastric wall, starting 3 cm below the mucosal incision~After the completion of myotomy, and check for mucosal integrity, the mucosal incision is closed using endoscopic clips"
94070|NCT03450915|Biological|M-001|A recombinant protein containing 9 conserved epitopes from Influenza A and B that are common to the vast majority of influenza viruses.
94071|NCT03450915|Biological|Saline|0.9% sodium chloride (NaCl)
94072|NCT03450902|Combination Product|Chinese herb & acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
94073|NCT03450902|Combination Product|Chinese herb & sham acupuncture|Participants will take Chinese herbal formula, Yiqi Suoquan granule, which is composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g and prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
94074|NCT03450902|Combination Product|Placebo & acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive acupuncture, three times a week. The selected acupoints include bilateral BL33, BL35, SP6, and ST36.
94075|NCT03450902|Other|Placebo & sham acupuncture|Participants will take Chinese herbal placebo which is prepared by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences. Besides, Participants will receive sham acupuncture, three times a week. The sham BL33, BL35, SP6, and ST36, which are 25 mm outward to BL33, BL35, SP6, and ST36, will be inserted with a depth of 2 to 3 mm.
94076|NCT03450889|Procedure|Colonoscopy|"Patients will undergo surveillance colonoscopies, with intervals of 1 or 2 years depending on the amount and type of polyps resected during last colonoscopy.~In case patients underwent subtotal colectomy, the term 'colonoscopy' should be replaced with 'sigmoidoscopy'."
94077|NCT03450876|Other|Non-Interventional|Non-Interventional
94078|NCT03450863|Drug|Fast-acting insulin aspart|Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection [MDI]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion [CSII]). Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
94079|NCT03450850|Device|NOVOTTF-200A|NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate >= 75% (>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
94080|NCT03450837|Diagnostic Test|Coronary Computed Tomography Angiography|To assess coronary artery plaque and calcification, all participants underwent coronary computed tomography angiography according to the guidelines of the Society of Cardiovascular Computed Tomography (SCCT). All CT scans were acquired in a 320-row detector scanner (AquillionOneTM - Toshiba Medical Systems Corporation, Otawara, Japan) with 0.5-mm thick slices. Acquisition protocol included coronary artery calcium scoring (CACS) and coronary CTA. CACS protocol utilized a 370-ms tube rotation, 120-kV tube voltage, 300-mA tube current, and 320x0.5-mm collimation with 3-mm slice thickness reconstructed images, one heart beat acquisition during diastole.
94081|NCT03450837|Diagnostic Test|Macrophage cholesterol efflux mediated by HDL|Macrophages were incubated with DMEM (Low Glucose, Gibco, Grand Island, New York, USA) containing 1 mg fatty acid free albumin (FAFA) (Sigma-Aldrich, Steinheim, Germany) plus 50 μg acetylated LDL/mL and 0.3 μCi 14C-cholesterol/mL (Amersham Biosciences, UK) for 48h. After washing with PBS/FAFA, cells were incubated in the presence or absence of HDL (50 µg/mL) for 8h. The amount of radioactivity present in the medium at the end of the HDL incubation period will indicate albumin-mediated cholesterol efflux with albumin alone and total efflux with albumin + HDL. Thus, specific HDL-mediated efflux will be calculated, subtracting the albumin-mediated efflux from total efflux
94082|NCT03450824|Other|No intervention|The standardized standing whole-lower-extremity radiographs, the knee lateral view and skyline view of the participants will be taken.
94083|NCT03450811|Procedure|Inguinal hernia repair|Lichtenstein procedure or laparoscopic method (Total extraperitoneal) inguinal hernia repair
94084|NCT03450798|Device|SOFT block group|needle will be introduced medial to the femoral vein and 3 cm below the skin where 15 mL of bupivacaine 0.25% injected. the obturator nerve, the probe shifted medially, superior to the needle, and directed cranially to the pectineus muscle . Needle withdrawn to the subcutaneous tissue and redirected using out-of-plane toward the deep surface of pectineus, 10 mL of bupivacaine 0.25%will be injected. The sciatic nerve, we use the curvilinear probe, inferior to the needle, and tilted the probe to get the clearest image of the sciatic nerve.The needle will be inserted then withdrawn subcutaneously and directed by an in-plane toward the sciatic nerve deep to the inferior border of the quadratus femoris muscle.20 mL of bupivacaine 0.25% will be injected
94085|NCT03450798|Device|spinal anesthesia group|patients will receive spinal anesthesia with hyperbaric bupivacaine 0.5% (7.5-10mg). This will be administered via a 25-G spinal needle at L4-L5 or L3-L4 with the patient in the sitting position under complete aseptic conditions.
94086|NCT03450785|Other|ultrasound examination|Doppler ultrasound examinations from the thyroid cartilage level to the supraclavicular region were used after CVC placement and on each of the following days until the catheter was removed.
94087|NCT03450772|Drug|Creon® 25000|Experimental drug
94088|NCT03450772|Drug|Creon® 10000|Active comparator
94089|NCT03450759|Drug|AZD9977 Oral suspension (reference)|Randomized subjects will receive single oral dose of AZD9977 oral suspension 15 mg/mL on Days 1, 3, 5 and 7 in Part A.
94090|NCT03450759|Drug|AZD9977 capsule|Randomized subjects will receive single oral dose of AZD9977 capsule 65 mg on Days 1, 3, 5 and 7 in Part A.
94091|NCT03450759|Drug|AZD9977 ER capsule (fastvrate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (fast rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
94092|NCT03450759|Drug|AZD9977 ER capsule (Int. rate)|Randomized subjects will receive single oral dose of AZD9977 ER capsule (Int rate) 65 mg on Days 1, 3, 5 and 7 in Part A.
94093|NCT03450733|Device|Wright Medical Technology Metal-on-Metal Total Hip System|Subjects in Group 1 previously implanted between 4 and 8 years prior to the study start date will be identified from Investigator records. Collected data will be evaluated in aggregate and cross-sectioned by year of implantation. Subjects will be cross-sectioned by the time that has elapsed between implantation and the initial visit (e.g. 4 years, 5 years) using contiguous visit windows (number of years + 6 months). There will be 15 THAs collected for the Year 4 intervals and 35 THAs collected for the remaining intervals.
94094|NCT03450720|Drug|GLPG2737 single dose|GLPG2737 oral suspension, single dose
94095|NCT03450707|Drug|Thiamine 500 mg IV|Thiamine hydrochloride (vitamin B1) 500mg IV will be given every 12 hours for 5 doses in the experimental arm.
94096|NCT03450707|Other|Placebo|100mL of intravenous normal saline will be given every 12hours for 5 doses in the placebo arm
94097|NCT03450694|Device|ultrasound|ultrasound is a non-invasive and not expensive method, availiable at almost all institutions.
94098|NCT03450681|Procedure|Pulsed radiofrequency of the saphenous nerve before knee replacement surgery|A trained anesthesiologist and pain clinician performs ultrasound guided pulsed radiofrequency on the saphenous nerve of a patient undergoing knee replacement surgery, prior to the beginning of the surgical act.
94099|NCT03450681|Procedure|Mock incision|A trained anesthesiologist and pain clinician performs a mock incision on the pulsed radiofrequency needle insertion site
94100|NCT03450668|Device|mOm incubator|24 hour usage of test incubator
94101|NCT03450668|Device|standard incubator|standard incubator
94102|NCT03450655|Other|10-week aerobic exercise program|An aerobic exercise program consisting of 45-60 minute sessions 3 times a week for 10 weeks.
94103|NCT03450642|Other|Observational|Complement cascade components C3, C4, iC3b and TCC serum concentrations were measured over the time course from t= admission, 4,8,12,23,47,71 hours or until discharge.
94104|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Suspension|Brimonidine Tartrate Ophthalmic Suspension
94105|NCT03450629|Drug|Brimonidine Tartrate Ophthalmic Solution|Three Times Brimonidine Tartrate Ophthalmic Solution
94106|NCT03450616|Device|PICO Negative Pressure Wound Therapy|Negative Pressure Wound Therapy Device
94107|NCT03450616|Procedure|Compression Dressing|Standard of Care Compression Dressing
94108|NCT03450577|Procedure|PCI of bifurcation lesions|Different approaches for treatment of bifurcation coronary artery disease.
94109|NCT03450564|Behavioral|Women Education|This intervention intends to provide health education message for women enhance FP utilization in pastoralist community. It was cognizant that, Ethiopia is the second most populous country in Africa. And there is a great discrepancy between contraceptive use, unmet need for FP and maternal and child morbidity and mortality between the pastoralist and agrarian community. Pastoralist community in the country expressed as low contraceptive users, a high unmet need for FP and highest maternal and child morbidity and mortality. The previous study indicates that only 5.4% of the women use contraceptive. The most common reason mentioned for not using of contraceptive are lack of awareness, demand for a large number of children and male dominance in all decision making power in general and FP in particular. In light of this, the study hypothesized that working with men and educating women towards the use of FP could enhance the use of family planning utilization.
94110|NCT03450564|Behavioral|Male Involvement|Male involvement was a feature of intervention in this arm. Comprehensive health education about FP was given in addition to the video message about FP. In pastoralist community the most reason mentioned for not using of FP are husband objection and religion influence. And most of the decisions are in the palm of husband to seek care for reproductive, maternal and neonatal health in general and FP in particular. Besides, the pastoralist community manifested by high total fertility rate and maternal and child morbidity and mortality.
94111|NCT03450564|Other|Control group|The third group in this community based intervention was following the community without provision of male iand married women education. In this group there was no intervention by the researchers. However, the activities performed by the government about family planning provision was maintained.
94140|NCT03450200|Other|exercises for diabetic peripheral neuropathy|Hands, fingers, and foot exercises for diabetic peripheral neuropathy to improve activities of daily living, and decreases the signs and symptoms of DPN
94112|NCT03450551|Device|Twin Block, Herbst, Frog distalising appliance|To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
94113|NCT03450525|Other|No intervention|No intervention
94114|NCT03450512|Other|prospective study on digestive affections in an homogeneous cohort of hematological patients|"Systematic realization during the induction and/or every consolidation of a CTscan with injection, at the same time as the thoracic CTscan (to research an invasive fungal bronchopulmonary infection), in front of a febrile neutropenia with persistent fever after 5 days of antibiotics and presence of digestive signs.~Statement of the information characterizing the digestive affection: clinical symptoms, microbiological, characteristic, realized additional explorations, infectious complications and specific therapeutics.~The abdominal scanner will be repeated in case of suspicion of complication or clinical worsening. In case of EC, the abdominal scanner will be realized before beginning the next cycle of AML treatment to evaluate digestive remission. Finally, a CT scan, will be performed when digestive disease, digestive neoplasia or digestive symptoms are noted at AML diagnosis."
94115|NCT03450499|Drug|Ketamine|the analgesic affects of ketamine will be compared between the experimental and placebo group.
94116|NCT03450499|Drug|Placebo|the analgesic requirement will be calculated in placebo group.
94117|NCT03450486|Other|exercise|one 30 minute bout of mild exercise
94118|NCT03450473|Device|SurgiMend® MP|SurgiMend MP® is an acellular dermal tissue matrix derived from bovine dermis. The device is supplied sterile in a variety of sizes to be trimmed by the surgeon to meet the individual patient's needs. SurgiMend MP® will be used for abdominal wall reinforcement in patients with complex ventral hernia repair.
94119|NCT03450460|Behavioral|Peer support|The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
94120|NCT03450434|Drug|XC8 Oral Tablet|1 tablet of XC8 in a dose according to the treatment group + 2 tablets of placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
94121|NCT03450434|Drug|Placebo Oral Tablet|Placebo (in total 3 tablets) once daily in the morning during 12 weeks of treatment period.
94122|NCT03450421|Device|Actamax™Adhesion Barrier|Actamax™Adhesion Barrier is a degradable hydrogel to be sprayed directly on surgically traumatized tissue. The aim of using the Actamax™ Adhesion Barrier (AB) in this way is to allow damaged and apposing tissue surfaces the opportunity to heal separately without becoming abnormally attached.
94123|NCT03450408|Procedure|Method of placement of Foley bulb transcervical dilator|This trial will assess two methods used to place a Foley bulb transcervical dilator.
94124|NCT03450395|Other|Hot Cereal|Intervention involves consumption of one hot cereal in the beginning of each day
94125|NCT03450382|Other|Hans Kai Education|9 weeks of health education classes preceding social group formation into Hans Kai. Peer led support focused on behavioural change.
94126|NCT03450369|Biological|NB01|Use an existing therapy designed to kill existing facial bacterial followed by populating facial skin with a single application of NB01
94127|NCT03450343|Drug|Oral azacitidine|Azacitidine can be taken with or without food at the same time every day.
94128|NCT03450343|Drug|R-ICE|R-ICE is approved for the treatment of NHL before ASCT for relapsed or primary refractory diffuse large b-cell lymphoma. R-ICE consists of rituximab, etoposide, carboplatin and ifosfamide. R-ICE will be administered per institutional guidelines.
94129|NCT03450330|Drug|AZD4205|Daily dose of AZD4205, followed by daily dose of AZD4205 and Osimertinib 80 mg. Starting dose of AZD4205 at 75 mg, administered once daily. If tolerated, subsequent cohorts will test increasing doses of AZD4205, and in combination with Osimertinib 80 mg.
94130|NCT03450317|Drug|Aspirin 80mg|No treatment
94131|NCT03450291|Other|Volatility task|Participants complete a volatility task, with pupillometry; and a Wisconsin Card Sort Task.
94132|NCT03450278|Procedure|micro-osteoperforation|Minor surgical procedure including performance of limited and shallow perforations of the cortical plate of bone to increase the expression of inflammatory cytokines, hence accelerating orthodontic tooth movement.
94133|NCT03450265|Device|Hemopatch|Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
94134|NCT03450265|Device|Tachosil|Applied according to the current instruction for use (IFU).
94135|NCT03450252|Device|Active pacing|Ventricular pacing via the invasive haemodynamic study-defined optimal pacing site in order to relieve pressure gradient across the mid-cavity obstruction in mid-cavity obstructive variant hypertrophic cardiomyopathy.
94136|NCT03450252|Device|Back-up pacing|Back-up pacing. The pacemaker is set-up to sense and pace only in the right atrium (AAI) without any pacing capacity in the ventricle.
94137|NCT03450239|Other|MRI|MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
94138|NCT03450226|Drug|stellate ganglion block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
94139|NCT03450213|Device|Pentacam|Pentacam will be used to measure the magnitude and axis orientation of anterior and posterior corneal astigmatism.
94141|NCT03450200|Other|Health education for diabetic foot care|Health education for daily diabetic foot care to prevent diabetic foot ulcer was provided.
94142|NCT03450187|Drug|TP-271|multiple oral doses of TP-271 or placebo, randomized 6:2, doses escalating 50 mg, 100 mg, 200 mg, 300 mg, 400 mg once daily for 7 days.
94143|NCT03450174|Dietary Supplement|Placebo|In control group, participants will receive only a placebo product
94144|NCT03450174|Behavioral|Formative messgaes|In this group, participants will only receive daily formative messages
94145|NCT03450174|Dietary Supplement|Fortified product|In this group, participants will receive fortified product on alternate day up till 8 months
94146|NCT03450174|Combination Product|Fortified product plus|In this group participants will receive fortified product on alternate day and formative messages up till 8 months
94147|NCT03450161|Drug|Fentanyl dosing schemes|We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
94148|NCT03450148|Device|Pavlok wristband with electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Device has maximum voltage of 0-500 volts, delivers a electric stimulus for a maximum of 1 sec and average duration of 0.2 secs
94149|NCT03450148|Device|Pavlok wristband without electric stimulus|it is a device for various behavior modifications in the form of wristband which participants will wear on the wrist. Participants will not receive any electric stimulus since this feature will be turned off.
94150|NCT03450135|Behavioral|Trier Social Stress Test|Participants will perform an acute psychosocial stress manipulation (Trier Social Stress Test) involving a speech task and challenging mental arithmetic.
94151|NCT03450135|Behavioral|Emotional go/no-go task|Participants will perform an emotional go/no-go paradigm to examine electrophysiological (EEG) correlates of cognitive and affective processing.
94152|NCT03450122|Biological|Aldesleukin|Given SC
94153|NCT03450122|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
94154|NCT03450122|Drug|Cyclophosphamide|Given IV
94155|NCT03450122|Biological|Dendritic Cell-targeting Lentiviral Vector ID-LV305|Given ID
94156|NCT03450122|Drug|Immunotherapeutic Combination Product CMB305|Given IM
94157|NCT03450109|Drug|LY01005|One gluteal IM injection
94158|NCT03450109|Drug|Zoladex|One Subcutaneous injection in the abdominal wall
94159|NCT03450096|Other|LPB|A bolus injection for LPB of 0.5 ml/kg ropivacaine 3.75 mg/ml (max 40 ml will be performed and the catheter will be placed before surgical interventions. A continuous perineural infusion of 0.2 ml/kg/h ropivacaine 0.2%, starting immediately after initial bolus injection will be then administered
94160|NCT03450083|Drug|Benralizumab|30mg Benralizumab will be delivered subcutaneously
94161|NCT03450083|Drug|Placebo|Subcutaneous placebo injection
94162|NCT03450070|Device|Light Therapy Mask Cream|test panel
94163|NCT03450057|Drug|Daratumumab|"Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs~Drug: Dexamethasone~Dexamethasone will be administered at 40 mg (20 mg for patients >75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle"
94164|NCT03450044|Biological|Dendritic cells|Adoptive transfer of autologous DCs
94165|NCT03450031|Other|NAC (no drug/no device)|Nasal allergen challenge (NAC) with mixed grass pollen: a bolus NAC with mixed grass pollen will be conducted
94166|NCT03450018|Drug|SLC-0111|Oral SLC-0111
94167|NCT03450018|Drug|Gemcitabine Injection|1000 mg/m^2 IV
94168|NCT03449992|Dietary Supplement|nitrate-rich beetroot juice|Nitrate-rich beetroot juice supplementation was administered for 15 consecutive days to participants in this arm
94169|NCT03449992|Dietary Supplement|Placebo|Placebo drink
94170|NCT03449979|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
94171|NCT03449979|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
94172|NCT03449966|Device|Confocal group|Under pCLE, target biopsy at cancer lesion will be done. 5 pieces of forcep biopsy will be obtained.
94173|NCT03449966|Device|Control group|Random biopsy around cancer lesion will be done under WLE. 5 pieces with forcep biopsy will be obtained.
94174|NCT03449940|Procedure|Immediate repair|
94175|NCT03449940|Procedure|Delayed repair|
94176|NCT03449940|Drug|Lidocaine|10cc of Lidocaine 1% is used to inject at the base of the penis for a dorsal penile nerve block for the localized repair.
94177|NCT03449940|Drug|Ceftriaxone|Pre-operative antibiotic given to all patients. Ceftriaxone 1g is administered intravenously.
94178|NCT03449940|Drug|Diclofenac Sodium|Oral Diclofenac Sodium 50mg tablet is prescribed to be taken as needed up to a maximum of three times daily until the penis is repaired.
94179|NCT03449927|Other|Specialized menu|-Specialized menu that will guide participant food choices if the participant experiences nausea or diarrhea
94180|NCT03449927|Other|Standard of care menu|-Standard registered dietitian support
94181|NCT03449927|Other|Self report dietary intake worksheet|-Self report nausea and diarrhea
94182|NCT03449927|Other|Post study questionnaire|-Completed upon count recovery and prior to discharge
94183|NCT03449901|Drug|pegylated arginine deiminase|-Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
94184|NCT03449901|Drug|Gemcitabine|-Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
94256|NCT03449446|Drug|SEL|18 mg tablet administered orally once daily without regard to food
94185|NCT03449901|Drug|Docetaxel|-Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.
94186|NCT03449901|Procedure|Tumor biopsy|"Day -7 (pre-treatment) and Day -1 prior to the start of Cycle 1~Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only"
94187|NCT03449901|Procedure|Research blood draw|-Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
94188|NCT03449888|Procedure|Regadenoson myocardial perfusion imaging stress test|Best fit model of pharmacologic myocardial perfusion imaging data, including summed stress and difference scores, gated left ventricular ejection fraction, transient ischemic dilatation, and heart rate response to regadenoson data.
94189|NCT03449888|Procedure|Arm exercise electrocardiographic stress test|Published arm exercise score and best fit model of arm exercise ECG stress testing data.
94190|NCT03449888|Procedure|Treadmill electrocardiographic stress test|Duke Treadmill Score and best fit model of treadmill exercise ECG stress testing data.
94191|NCT03449888|Procedure|Coronary artery calcium score and cardiac computed tomographic angiography|Coronary artery calcium score by Agatston criteria and severe obstructive coronary artery disease > 70% by cardiac computed tomographic angiography or invasive coronary arteriography.
94192|NCT03449875|Device|TREOVANCE® Stent-Graft with Navitel® Delivery System|Endovascular repair of abdominal aortic aneurysms.
94193|NCT03449862|Other|Simulation-based clinical decision on brain CT ordering|Clinicians asked to make decision on medical imaging for their simulated patient after presentation of clinical case then additional information. At each presentation of new information the clinician may modify their image order.
94194|NCT03449849|Other|Base Diet|Base Diet
94195|NCT03449849|Other|Kale Treatment|Base Diet plus Kale
94196|NCT03449836|Combination Product|Streptococcus salivarius 24SMBc + Strept. oralis 89a|nasal spray based on Streptococcus salivarius 24SMBc + Strept. oralis 89a
94197|NCT03449836|Combination Product|fluticasone + mometasone|nasal spray based on fluticasone + mometasone
94198|NCT03449836|Other|placebo|nasal spray based on isotonic solution
94199|NCT03449823|Diagnostic Test|Doppler ultrasound of fetal renal artery|Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.
94200|NCT03449810|Procedure|Muscles Energy Technique (MET)|In MET the patient is asked to lie supine on a couch with the hip at the edge and both lower limbs freely off the couch. The patient will then place one of his legs over the therapist's shoulder and push up with the opposite leg into therapist's hand. A total of four contractions will be resisted by force equal to the patient's, held for 5sec with 5sec rest b/w each contraction. Also, restriction barrier (i.e. where movement is not possible due to impairment resulting from LBP) will be identified and the patient will be instructed to make a contraction of about 20-30% 0f maximal voluntary isometric contraction, held for 8-10secs, relaxed for 2-3secs and the limb will be moved to a new barrier. The procedure is repeated for about 4-6 times.
94201|NCT03449810|Procedure|Core Stability Exercise (CSE)|This Involves four type of exercises viz; 1)Upper-body rollout. 2) Inclined press-up. 3)Contralateral single-leg hold. 4) Quadruped exercise.
94202|NCT03449810|Procedure|MET plus CSE|This intervention is a combination of both Muscles Energy Technique and Core Stability Exercises administered to participants in group C.
94203|NCT03449810|Behavioral|Patient Education and Counselling|This involves Educating participant in-home care treatment program and Recommendation of strategies to prevent recurrent problems e.g. Functional movement training/re-education, this commonly involves identifying movements that are associated with low back pain, such as excessive flexion of the lumbar spine when rising from a chair instead of utilizing flexion of the hip for executing the movement, then providing cuing and education on movement options that enable the activity to be performed with fewer, or no, symptoms.
94204|NCT03449797|Procedure|AVS performed with no intraprocedural rapid cortisol assay|AVS performed plus intraprocedural rapid cortisol assay
94205|NCT03449797|Procedure|AVS performed plus intraprocedural rapid cortisol assay|Adrenal vein sampling performed according to usual clinical practice without intraprocedural rapid cortisol assay
94206|NCT03449784|Other|Detection of patients with dyslipidemia|Detection of patients with dyslipidemia
94207|NCT03449771|Other|self-administered questionnaire|The newsletter and a self-questionnaire will be systematically given in the waiting room to any PrEP consultant to evaluate the consumption of psychoactive substances (ASSIST questionnaire) and to identify anxio-depressive disorders (HAD questionnaire - Hospital Anxiety and Depression). scale).
94208|NCT03449758|Drug|SARILUMAB|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
94209|NCT03449758|Drug|Azathioprine|Pharmaceutical form:Tablet Route of administration: Oral
94210|NCT03449758|Drug|Chloroquine|Pharmaceutical form:Tablet Route of administration: Oral
94211|NCT03449758|Drug|Hydroxychloroquine|Pharmaceutical form:Tablet Route of administration: Oral
94212|NCT03449758|Drug|Leflunomide|Pharmaceutical form:Tablet Route of administration: Oral
94213|NCT03449758|Drug|Methotrexate|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
94214|NCT03449758|Drug|Sulfasalazine|Pharmaceutical form:Tablet Route of administration: Oral
94215|NCT03449732|Device|PDR measurement|"PDR measurement at two standardized times perioperatively:~Anesthetized subject by sevoflurane sedation until a minimum alveolar concentration (MAC) of at least 1,5 is reached~Administration of fentanyl 2µg/kg, in the absence of adjustments in sedation depth"
94216|NCT03449719|Radiation|SBRT - Ablative radiation Therapy|"The current phase II randomized trial,Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer (ARTO trial) aims to evaluate the difference in PSA response rate between the experimental arm (AA+SBRT) and control arm (AA) in metastatic castration-resistant prostate cancer patients."
94217|NCT03449719|Drug|Abiraterone Acetate|systemic treatment with abiraterone acetate 1000 mg daily and prednisone 10 mg daily, plus GnRH agonist or antagonist
94218|NCT03449706|Drug|Early combination anti-retroviral treatment|Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.
94219|NCT03449693|Dietary Supplement|Magnesium Oxide Supplement|Magnesium Oxide tablet
94220|NCT03449680|Procedure|Femoral Articular Branch Block|Slow injection (3mL aliquots) of local anesthetic solution (20ml of Ropivacaine 0.5%) into the fascia above the iliopsoas muscle (located in the groove between the two bony landmarks - (1)anterior inferior iliac crest and (2)iliopubic eminence).This is done by ultrasound guidance.
94221|NCT03449680|Procedure|Placebo Block|Subcutaneous injection of 1ml normal sterile saline
94222|NCT03449667|Device|Cryoneurolysis|Cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
94223|NCT03449667|Device|Sham Comparator|Sham cryoneurolysis of the femoral and sciatic nerves (or their distal counterparts) in the residual limb: The cryoneurolysis device will be triggered using 3 cycles of 2-minute gas activation separated by 1-minute defrost periods. However, for sham probes, the nitrous oxide is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
94224|NCT03449654|Drug|Liraglutide|Liraglutid
94225|NCT03449654|Drug|Placebo (for liraglutide)|Placebo (for liraglutide)
94226|NCT03449641|Device|Positive airway pressure (PAP)|Positive airway pressure (PAP) is a mode of respiratory ventilation used in the treatment of sleep apnea.
94227|NCT03449628|Dietary Supplement|L.casei DG|"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"
94228|NCT03449628|Dietary Supplement|PLACEBO|1 capsule, b.i.d. for 12 weeks
94229|NCT03449602|Device|Mini-thoracoscopy|Thoracoscopic pleural biopsy with the mini-thoracoscope
94230|NCT03449602|Device|Conventional rigid thoraoscopy|Thoracoscopic pleural biopsy with the conventional rigid thoraoscope
94231|NCT03449576|Other|Trauma Management Therapy|Trauma Management Therapy (TMT) consists of a combination of 15 sessions of individualized exposure therapy and 14 sessions of group-based social and emotion rehabilitation.
94232|NCT03449576|Other|Exposure Therapy with Psychoeducation|Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 15 sessions of individualized exposure therapy and 14 session of group-based psychoeducation.
94233|NCT03449563|Combination Product|Open TPVB|In Group E,the thoracic paravertebral block was performed under the direct vision with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
94234|NCT03449563|Combination Product|Ultrasound-guided TPVB|In Group U, thoracic paravertebral block was performed on the operated side under ultrasound guidance with 0.25% ropivacaine 30 ml,and the Patient-controlled intravenous analgesia was administer after the surgery.
94235|NCT03449563|Other|placebo|In Group G,patients were just received Patient-controlled intravenous analgesia after the surgery.
94236|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing to start with home respiratory polygraphy
94237|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
94238|NCT03449550|Other|Home Respiratory Polygraphy (HRP)|Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
94239|NCT03449550|Other|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
94240|NCT03449537|Dietary Supplement|extensively hydrolyzed casein formula + LGG|Hypoallergenic formula based on extensively hydrolyzed casein supplemented with the probiotic Lactobacillus rhamnosus GG
94241|NCT03449537|Dietary Supplement|Hypoallergenic formula based on amino-acid based formula|Hypoallergenic formula for cow milk allergy treatment based on amino acids
94242|NCT03449524|Drug|75mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
94243|NCT03449524|Drug|150mg CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
94244|NCT03449524|Other|Placebo|Placebo
94245|NCT03449511|Other|Ginger aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
94246|NCT03449511|Other|Orange aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
94247|NCT03449511|Other|Lavender aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
94248|NCT03449511|Other|Jojoba aromatherapy|Three sniffs of aromatherapy inhaler four times daily for seven days.
94249|NCT03449498|Other|Qualitative functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Six functional activities focusing on lower limbs and trunk are performed: walking, stair climbing, balance, transfers, trunk control, and Wii (combination of functional activities in sitting and/or standing). A group of clinical experts composes a set of exercises for each of these activities, however individual adaptations according to the needs and abilities of the child can be still be done. Quality of movement (alignment, weightshift, dissociation, coordination and stability) is hereby very important. The theme 'circus' is used to enhance the motivation of the children.
94250|NCT03449498|Other|Functional therapy|Camps fot children with spastic CP are organised. Each camp consists of 10 days of 6 hours therapy per day. Goals are set with the parents and the children. During the camp children work on obtaining these goals in a exclusively functional way.
94251|NCT03449485|Drug|Chlorprothixene|Patients are tested for their normal prescription chlorprothixene medication
94252|NCT03449472|Drug|Quetiapine|Patients are tested for their normal prescription quetiapine medication
94253|NCT03449459|Dietary Supplement|oral probiotics|"Culturelle™ DIGESTIVE HEALTH 30 CT(VCAP)(10 Billion Claim) which consists of 100% Lactobacillus rhamnosus GG, 1 tablet, q.d., for 3 months.~Subjects will take conventional therapy at the same time."
94254|NCT03449459|Drug|aerosol inhaled amikacin|"0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 5-7 days per month, for 3 months.~In order to observe and cope with adverse events timely, subjects will be admitted to the ward during the course of medication.~Subjects will take conventional therapy at the same time."
94255|NCT03449459|Biological|combined vaccination|"Influenza Vaccine recommended by World Health Organization(WHO) in that year and imported 23-Valent Pneumococcal Polysaccharide Vaccine approved by China Food and Drug Administration(CFDA) are vaccinated at different body sites by professional nurses.~The interval between two vaccinations is 3-5 days to avoid the overlap of adverse events.~Subjects will take conventional therapy at the same time."
94257|NCT03449446|Drug|Firsocostat|20 mg tablet administered orally once daily without regard to food
94258|NCT03449446|Drug|Cilofexor|30 mg tablet administered orally once daily without regard to food
94259|NCT03449446|Drug|SEL Placebo|Tablet administered orally once daily without regard to food
94260|NCT03449446|Drug|Firsocostat Placebo|Tablet administered orally once daily without regard to food
94261|NCT03449446|Drug|Cilofexor Placebo|Tablet administered orally once daily without regard to food
94262|NCT03449433|Drug|LY900014|Administered SC
94263|NCT03449433|Drug|Insulin Lispro|Administered SC
94264|NCT03449433|Drug|Insulin Aspart|Administered SC
94265|NCT03449433|Drug|Insulin Aspart|Administered SC
94266|NCT03449420|Diagnostic Test|thromboelastography|TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample
94267|NCT03449394|Other|Metacognitive Training|4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases
94268|NCT03449381|Drug|BI 907828|Film-coated tablet
94269|NCT03449342|Drug|turoctocog alfa|Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
94270|NCT03449329|Procedure|SIP|The intervention group will receive a SIP block
94271|NCT03449316|Behavioral|Inhaler technique education|Teaching of inhalers use with placebo devices in real training
94272|NCT03449303|Other|EOI|Topically-applied oil
94273|NCT03449303|Other|Placebo|Topically-applied oil
94274|NCT03449290|Other|Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles with muscle technique
94275|NCT03449290|Other|Sham Kinesio taping|Kinesio taping was applied on both sides of rectus abdominus, obliquus internus, obliquus externus and sacrospinalis muscles without any technique
94276|NCT03449277|Drug|Oral Tablet|oral labetalol tablets and oral nifedipine tablets
94277|NCT03449264|Biological|biological collection|"Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery.~Blood samples taken at different times. During the blood samples taken for diagnosis and / or treatment, additional samples for research purposes will be carried out."
94278|NCT03449251|Drug|Apelin|Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
94279|NCT03449251|Drug|Relaxin|Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.
94280|NCT03449251|Drug|Normal saline|Vehicle
94281|NCT03449251|Diagnostic Test|Verapamil|NO independent challenge agent
94282|NCT03449251|Diagnostic Test|LN Monomethyl arginine|Basal NO synthase inhibitor
94283|NCT03449238|Drug|Pembrolizumab|pembrolizumab will be infused the day before SRS, at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
94284|NCT03449225|Other|Computer-Aided Genetic Education Module|Subjects will be provided with an electronic device to view Computer-Aided Genetic Education Module (CAGEM) software. This is an interactive software designed to provide subjects with tailored information regarding prenatal screening options for carrier status and aneuploidy.
94285|NCT03449199|Drug|TMX-049|A certain dose of TMX-049 to be taken orally, once daily
94286|NCT03449199|Drug|Placebo|Matching placebo to be taken orally, once daily
94287|NCT03449186|Other|Saliva collection|
94288|NCT03449186|Other|GCF collection|
94289|NCT03449173|Drug|Sunitinib|small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor
94290|NCT03449160|Device|UPRIGHT|A small externally wearable device that is placed on the back, which gently vibrates when correct posture is not maintained. The device is removable, and used for only portions of the day
94291|NCT03449160|Other|physical therapy|routine physical therapy
94292|NCT03449147|Drug|Gefapixant 45 mg BID|Gefapixant 45 mg tablet to be administered orally BID
94293|NCT03449147|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet to be administered orally BID
94294|NCT03449147|Drug|Placebo|Placebo tablet administered orally BID
94295|NCT03449134|Drug|Gefapixant 45 mg BID|Gefapixant 45 mg tablet administered orally BID
94296|NCT03449134|Drug|Gefapixant 15 mg BID|Gefapixant 15 mg tablet administered orally BID
94297|NCT03449134|Drug|Placebo|Placebo tablet administered orally BID
94298|NCT03449121|Behavioral|Slow breathing techniques|8 sessions of instruction in slow breathing exercises over 12 weeks of study
94299|NCT03449108|Biological|Aldesleukin|Given IV
94300|NCT03449108|Biological|Autologous Tumor Infiltrating Lymphocytes LN-145|Given IV
94301|NCT03449108|Drug|Cyclophosphamide|Given IV
94302|NCT03449108|Drug|Fludarabine|Given IV
94303|NCT03449108|Drug|Fludarabine Phosphate|Given IV
94304|NCT03449108|Other|Quality-of-Life Assessment|Ancillary studies
94305|NCT03449108|Other|Questionnaire Administration|Ancillary studies
94306|NCT03449095|Drug|Alcohol|Alcohol Target BAC .08%
94307|NCT03449082|Biological|High concentration of Allo-ASC|10 million cells of Allo-ASC 0.5cc
94308|NCT03449082|Biological|Low concentration of Allo-ASC|1 million cells of Allo-ASC 0.5cc
94309|NCT03449082|Drug|Fibrin glue|Fibrin glue 0.5cc
94310|NCT03449082|Drug|Normal saline|Normal saline 0.5cc
94311|NCT03449069|Drug|MSC-AFP|Patients will have a mesenchymal stromal cell coated anal fistula plug placed in their Crohn's perianal fistula tract.
94312|NCT03449056|Drug|salbutamol|T2 - T1+1h30: High-nasal flow and salbutamol nebulization
94313|NCT03449043|Other|Real care course|Evaluate the rate of adequacy between the request made by the general practitioner and the response to emergencies
94314|NCT03449030|Drug|TAK-164|TAK-164 intravenous infusion.
94315|NCT03449030|Drug|89Zr-TAK-164|89Zr-TAK-164 intravenous infusion
94316|NCT03449017|Behavioral|E-cig use|Self-administration of e-cig (10 puffs in 5 minutes) prior to lab task, self-administration of e-cig (10 puffs in 5 minutes) prior to ad lib alcohol, and ad lib e-cig use throughout ad lib alcohol paradigm.
94317|NCT03449004|Other|Validation of the OPSI questionnaire|A questionnaire to measure satisfaction with online information for patients with low back pain
94318|NCT03448978|Biological|Descartes-08|autologous CD8+ T-cells transiently expressing an anti-BCMA chimeric antigen receptor
94319|NCT03448978|Drug|Fludarabine|intravenous fludarabine
94320|NCT03448978|Drug|Cyclophosphamide|intravenous cyclophosphamide
94321|NCT03448965|Diagnostic Test|random blood sugar|do random blood sugar at 0 hour - 2 hours- 4 hours and after 6 hours
94322|NCT03448939|Drug|S5G4T-1|once a day topical cream
94323|NCT03448939|Drug|S5G4T-2|once a day topical cream
94324|NCT03448926|Diagnostic Test|DCISionRT Test|The Prelude DCISionRT Test was developed by Prelude Corporation and is performed at its CLIA laboratory facility. The biomarkers used to evaluate the biologic signature of DCIS tissue are based on over a decade of research including the University of California, San Francisco, Yale University as well as Prelude Corporation. The test is prognostic for 10-year recurrence risk and predicts RT treatment benefit for invasive breast cancer. The laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing and is accredited by the College of American Pathologists (CAP).
94325|NCT03448913|Procedure|PECS block|It consists in injection of 20-30 ml of local anesthetic between pectoral minor, pectoral major, and serratus muscles.
94326|NCT03448900|Behavioral|Multicomponent intervention|Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
94327|NCT03448900|Behavioral|Brief advice|Brief advice (5-10minutes) and a self-help pamphlet
94328|NCT03448887|Device|Theranova|Extended HD with theranova
94329|NCT03448887|Device|Online hemodiafiltration|Online hemodiafiltration
94330|NCT03448874|Device|Seal-G MIST System|Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
94331|NCT03448861|Device|Polso Wearebale watch|The objective of the Polso™ feasibility study is to demonstrate the suitability of Polso™ as a data acquisition and processing platform by comparison with the conventional British version of EWS (UK-NEWS) on aggregate and on each individual parameter score. Although in a full NEWS system, the frequency of testing is determined by the score itself, this aspect will not be evaluated, in the event that a divergence of scores would complicate clinical evaluation and correspondence of readings. In addition, good clinical practice calls for patient care to be fully motivated by the NEWS currently in use, as opposed to the experimental Polso™. Therefore, this compromise will be made, which will still permits system evaluation.
94332|NCT03448848|Drug|BCAA preparation Intravenous infusion|BCAA IVi in a dose 0.5-1 gm/Kg/day for 2-5 days post liver surgery versus sterile normal saline in a volume equal to the study drug
94333|NCT03448848|Drug|sterile normal saline|sterile normal saline in a volume equal to the study drug
94334|NCT03448835|Drug|Atezolizumab|atezolizumab 1200 mg 5 cycles
94335|NCT03448835|Drug|Capecitabine|capecitabine 850 mg /m2 4 cycles
94336|NCT03448835|Drug|Oxaliplatin|oxaliplatin 100 mg/m2 4 cycles
94337|NCT03448835|Drug|Docetaxel|docetaxel 50 mg/m2 4 cycles
94338|NCT03448822|Procedure|sentinel node procedure|a robot-assisted laparoscopic sentinel node procedure to detect occult lymph node metastasis
94339|NCT03448809|Behavioral|Mind My Mind|An individual, modular and flexible cognitive and behavioural therapy
94340|NCT03448809|Behavioral|TAU (Treatment as Usual)|The children were offered anonymous counselling, supportive talk therapy, pedagogical advice, network meetings, and/or individual support in the school setting. A few were offered group-based CBT-programs for selected problems, but the access to manualized treatment was generally very restricted.
94341|NCT03448796|Procedure|HTO|Group that receives high tibial osteotomy combined with supervised physiotherapy as treatment.
94342|NCT03448796|Other|Supervised physiotherapeutic program|Group that receives only supervised physiotherapy as treatment.
94343|NCT03448783|Drug|Apixaban|Patients are tested for their normal prescription apixaban medication
94344|NCT03448770|Drug|PEG- 17 gm sachet|PEG- 17 gm sachet 3-4 times per day
94345|NCT03448770|Drug|Lactulose : 20-30gm|Lactulose : 20-30gm
94346|NCT03448757|Other|measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure|"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.~Patients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma."
94347|NCT03448744|Drug|Thymosin Alpha1|Thymosin Alpha1 (1.6 mg subcutaneously injection twice a week) plus ETV (0.5 mg orally, daily) for 24 weeks, and followed by continuous ETV for at least 48 weeks
94348|NCT03448744|Drug|Entecavir|ETV (0.5 mg orally, daily) for 72 weeks
94349|NCT03448731|Drug|Doxycycline 50Mg Tablet|Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
94350|NCT03448718|Drug|Olaparib|1 cycle = 28 days. Subject's with calculated creatinine clearance (CrCl) of ≥ 40 mL/min will start at a dose of olaparib tablets of 300 mg twice a day. Subjects with a CrCl of > 30 to < 40 mL/min will start at a dose of olaparib tablets 200 mg twice a day.
94351|NCT03448705|Biological|4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 1 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
94352|NCT03448705|Biological|4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intradermal, Dosage: 2 μg HA/strain / 0.1 ml, Package: 0.5 ml in one ampoule from which 0.1 ml is equal to a single dose, Dosage regimen: 1 x 0.1 ml, Treatment duration: single dose.
94353|NCT03448705|Biological|3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)|Route of administration: intramuscular, Dosage: 6 μg HA/strain / 0.5 ml, Package: 0.5 ml in one ampoule from which a total of 0.5 ml is equal to a single dose, Dosage regimen: 1 x 0.5 ml, Treatment duration: single dose.
94355|NCT03448666|Combination Product|Pembrolizumab|Electrochemotherapy will be performed with the CLINIPORATOR™ after the first treatment of Pembrolizumab
94356|NCT03448653|Other|Colonoscopy with NBI|Colonoscopy with NBI
94357|NCT03448640|Drug|Drug used in the examination of premature infants.|to investigate side effects of eye drops used
94358|NCT03448601|Other|Non-tailored intervention group|Alzheimer's Disease and precision medicine brochure
94359|NCT03448601|Other|Culturally tailored intervention group|Alzheimer's Disease and precision medicine enhanced brochure
94360|NCT03448588|Diagnostic Test|detection of serum selenium|For this case-control study, no intervention will be administered to participants, only serum sample will be collected for selenium assessment
94361|NCT03448575|Other|Control - Provider Medication Alert Only|Simple text medication alert referencing Choosing Wisely guidelines.
94362|NCT03448575|Other|Intervention - Alert + CAP Review AND Enhanced BH Access|Interactive medication alert referencing SUAY Clinical Guidelines and offering options to keep/remove orders for the antipsychotic, virtual CAP consult, BH navigation for the patient, and access to bridging therapy for the patient.
94363|NCT03448562|Procedure|CPVI|ablate around the pulmonary vein orifice
94364|NCT03448562|Procedure|STABLE-SR|homogenization of the low voltage zones and elimination of the complex electrograms from the transitional zones during sinus rhythm
94365|NCT03448549|Drug|Oxaliplatin|adjuvant chemotherapy
94366|NCT03448549|Drug|Tegafur，gimeracil and oteracil potassium|adjuvant chemotherapy
94367|NCT03448549|Drug|Xeloda|adjuvant chemotherapy
94368|NCT03448536|Drug|Naproxen Sodium, (Aleve, BAY117031)|220 mg *2 tablets, orally, single dose
94369|NCT03448536|Drug|Acetaminophen (Tylenol Extra Strength)|500 mg *2 caplets, orally, single dose
94370|NCT03448523|Behavioral|Right To Play's Positive Child and Youth Development program|"Right To Play's Red Ball Child Play manual provided for 60 hours per annum for two years~Training of junior leaders~Related play-based activities such as sports days~Quarterly awareness sessions with community groups and parents~Summer camps for children~training of teachers on Right To Play's foundational resources, positive disciplining, and gender and child protection"
94371|NCT03448510|Device|Irreversible electroporation|The subject will receive Irreversible electroporation procedure which is a novel ablation modality using electric pulses to create nanoscale defects in the cell membrane.
94372|NCT03448510|Drug|Standard Medication|The subject will be prescribed with α-blocker or/and 5α-reductase inhibitors.
94373|NCT03448497|Other|Non-interventional|Non-interventional
94374|NCT03448484|Dietary Supplement|Intervention (integrated package)|"Provided to all intervention households:~Soap (for daily hand washing)~Chlorine solution (for daily drinking water treatment)~8 birds of chicken (child consumes 1 egg/day)~Vegetable seeds (red onion, indigenous managu and sukuma)~Monthly trainings to all farmers on nutrition and WASH~Micronutrient powder (MixMe, 1g sachet every third day)~Oral rehydration solution (ORS) + zinc (to be used to treat acute diarrhoea: 20 mg zinc tablets; ORS sachets (10.3 g/sachet))~All families in the intervention group will receive the same agriculture-focused package (see section 'control intervention' below) as those in the control group."
94375|NCT03448484|Other|Control|"Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. The control intervention is the same for study 1 and study 2. This agriculture-focused package consists of:~Agricultural training (every 2 weeks on average) for all~Free to enrol for the following products on credit:~Compost boosters~Cook stoves~Seeds (onions, maize, indigenous greens, beans)~Maize storage bags~Drying tarps~Trees~Solar lights~Fertilizer~Actellic dust (insecticide)~Re-usable sanitary pads"
94376|NCT03448458|Procedure|CT (Computed Tomography)|Undergo PET/CT
94377|NCT03448458|Drug|Gallium Ga 68-DOTATATE|Given IV
94378|NCT03448458|Procedure|Positron Emission Tomography|Undergo PET/CT
94379|NCT03448445|Other|Usual care setting|usual care settings without any intervention
94380|NCT03448419|Drug|Empagliflozin|Film-coated tablet
94381|NCT03448419|Drug|Placebo|Film-coated tablet
94382|NCT03448406|Drug|Empagliflozin|Film-coated tablet
94383|NCT03448406|Drug|Placebo|Film-coated tablet
94384|NCT03448393|Biological|CD19/CD22 CAR T-Cells|CD19/CD22 cells will be infused on Day 0 after induction chemotherapy regimen.
94385|NCT03448393|Drug|Fludarabine|Fludarabine is administered as an IV infusion in an appropriate solution over 30 minutes. To prevent undue toxicity the dose will be based on BSA (25 mg/m2/dose)
94386|NCT03448393|Drug|Cyclophosphamide|Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
94387|NCT03448380|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
94388|NCT03448367|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will utilize capillary SMBG for managing diabetes for 6 months (control phase) followed by diabetes management using FreeStyle Libre for 6 months (intervention phase).
94389|NCT03448354|Procedure|HIPEC|HIPEC(paclitaxel 175mg/m2, 90min; open or closed technique) after IDS . IDS is recommended within 4 weeks after the 3rd NAC cycle. HIPEC procedure is allowed only in case of residual disease less than 5mm.
94390|NCT03448328|Dietary Supplement|NUTRALYS pea protein supplement|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
94391|NCT03448328|Dietary Supplement|Whey Protein|0.3 grams of protein per kilogram of body weight before and after eccentric exercise, and each of 4 mornings of recovery
94392|NCT03448328|Dietary Supplement|Apple juice|1.2 calories per kilogram body weight before and after eccentric exercise, and each of 4 mornings of recovery
94393|NCT03448315|Device|tDCS|motor cortex stimulation (2 mA, 20 min for 4 sessions)
94434|NCT03448016|Drug|NOP-1A|Tracer
94435|NCT03448003|Other|Cancer Prevention|Attend IO prevention program
94436|NCT03448003|Other|Questionnaire Administration|Ancillary studies
94394|NCT03448302|Radiation|Computed tomography perfusion|Pre-contrast images will be obtained to identify the colorectal tumor location. Then Fifty milliliters of iopromide (Ultravist ) will be injected intra-venously at rate of 5 milliliter per second via an automatic pump injector for computed tomography perfusion scans. Computed tomography perfusion scans will be performed at the mid-portion of the tumor for 60seconds beginning 5 seconds after contrast injection. Then arterial input will be defined by using the mouse to place a circular region of interest and the tumor region of interest will be placed on the most enhanced area of the tumor. Tumor blood flow, blood volume, mean transient time & permeability surface measurements will be obtained.
94395|NCT03448289|Behavioral|RLPT|The Reproductive Life Plan Tool (RLPT) will be self-administered. Pediatricians will use the RLPT to assess women's need for well-woman primary care.
94396|NCT03448276|Other|Training in the vibrating platform|20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
94397|NCT03448276|Other|Walk|Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.
94398|NCT03448263|Procedure|Balanced Force technique|Flex-R files sizes 15-45 taper .02 were used according to the technique on each tooth
94399|NCT03448263|Procedure|WaveOne technique|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
94400|NCT03448263|Procedure|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
94401|NCT03448250|Behavioral|Optimune|Optimune is a web-based psychological intervention developed for women with breast cancer.
94402|NCT03448250|Other|Care-As-Usual|Participants are free to continue to engage with any treatment they require (i.e., CAU).
94403|NCT03448237|Other|Speech Therapy|Speech therapy adapted to the child, at least 25 sessions over 9 months.
94404|NCT03448237|Other|Proprioceptive treatment|"Proprioceptive treatment adapted to the child.~This treatment aims to stabilize a central reference instability revealed to Maddox Postural by the use of neurosensory decoys::~Proprioceptive stimulation of oculomotor muscles (active prisms).~Oral somatosensory stimulation (ALPH).~Proprioceptive antigravity stimulation (proprioceptive sole).~Proprioceptive reprogramming exercise.~Following the teaching of the University Diploma: Perception-Action, Learning Disorders (University of Bourgogne, France)"
94407|NCT03448211|Drug|Para-toluenesulfonamide Injection (PTS)|Intratumoral injection
94408|NCT03448198|Procedure|Total knee replacement|Primary knee gonarthrosis treated with navigated total knee replacement and computer-assisted patellar replacement.
94409|NCT03448185|Behavioral|High intensity exercise|Subjects will be randomized to the exercise groups will undergo 1 year aerobic exercise training comprised of high intensity exercise sessions 2-3 days per week. Sessions will be supervised remotely via heart rate monitors.
94410|NCT03448185|Dietary Supplement|Omega-3 fish oil|Subjects randomized to omega-3 fatty acids will take 2 grams total of omega-3 per day for 1 year.
94411|NCT03448185|Behavioral|Yoga|Subjects randomized to yoga will undergo yoga training as a control to those randomized to high intensity aerobic exercise.
94412|NCT03448185|Dietary Supplement|olive oil capsules|Subjects randomized to receive olive oil placebo will take 1 gram total of olive oil capsule per day.
94413|NCT03448172|Drug|[14C]PF-05221304|a single oral dose of [14C]PF-05221304 (50 mg/100 µCi liquid formulation)
94414|NCT03448159|Drug|Fluoxetine Hydrochloride|Half of the participants will take fluoxetine for a period of 15-17 weeks (depending on ramp-up period).
94415|NCT03448159|Other|Placebo|Half of the participants will take the a placebo for a period of 15-17 weeks (depending on ramp-up period).
94416|NCT03448159|Behavioral|Exercise Program|All participants will take part in a 12-week exercise program. The program will run 3 times/week, 1 hour/class.
94417|NCT03448146|Drug|Para-Toluenesulfonamide|
94418|NCT03448133|Device|Magstim rTMS|The device is made in London,UK
94419|NCT03448120|Procedure|Acupuncture|Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
94420|NCT03448120|Procedure|Dry needling|Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
94421|NCT03448107|Device|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
94422|NCT03448107|Device|Fluoride Varnishes|Fluoride varnish (FV)
94423|NCT03448107|Device|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
94424|NCT03448094|Dietary Supplement|Resveratrol|Participants will consume one of the treatment types daily for a period of three months.
94425|NCT03448094|Dietary Supplement|Placebo|Participants will consume one of the treatment types daily for a period of three months.
94426|NCT03448081|Drug|SNA-120|SNA-120 (0.5%) active ointment
94427|NCT03448081|Drug|Placebo|Vehicle Ointment
94428|NCT03448081|Drug|Calcipotriene|Calcipotriene ointment (0.005%)
94429|NCT03448068|Drug|Ketamine|"Ketamine 0.3 mg/kg (IBW) bolus with induction. Ketamine infusion 0.2mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~Ketamine infusion not titrated."
94430|NCT03448068|Drug|Standard therapy|"Pre-op dexamethasone 4mg IV and midazolam 1-2mg IV Anesthesia Induction - Propofol 2-3mg/kg IV, Fentanyl 1mcg/kg IV, neuromuscular block w/succinylcholine and/or rocuronium, orotracheal intubation Anesthesia maintenance - Sevoflurane/rocuronium, fentanyl 0.5-1mcg/kg Anesthesia emergence - Acetaminophen 1g, ketorolac 30 mg IV, ondansetron 4mg IV, sugammadex 2mg/kg or 4 mg/kg dose depending on twitch Post-op anesthesia - Hydromorphone patient-controlled analgesia (PCA) 0.2 mg/8 min, acetaminophen 1 g IV Q8 around the clock (ATC) x 3 addl. doses, ketorolac 15 mg IV Q6 ATC x 3 addl. doses.~Other standard surgical post-op care"
94431|NCT03448055|Dietary Supplement|Immunocal|cysteine-rich whey protein isolate
94432|NCT03448042|Drug|BTRC4017A|BTRC4017A will be administered via IV infusion from until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
94433|NCT03448016|Radiation|[C-11]|Radiolabel
94442|NCT03447964|Other|dosing of sphingolipids|- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
94443|NCT03447951|Drug|Para-Toluenesulfonamide|A total dose of PTS100 in this study, the expected accumulated dose in the treatment duration, depends on the patient's tumour size. For each patient, up to 4 tumors, each not exceeding 8.8 cm in diameter, are selected for treatment by the joint decision of the investigator and the radiologist. The total dose is defined as the accumulated dose in treatment duration. The total dose is randomly assigned as either 20% or 30% of TTV for each patient and maximum TTV should be less than 366 cm3.
94444|NCT03447938|Procedure|MICS CABG|Coronary artery bypass grafting performed through small incisions between the ribs.
94445|NCT03447938|Procedure|Conventional CABG|Coronary artery bypass grafting performed through an incision through the sternum or breastbone.
94446|NCT03447925|Drug|Medicinal Plant|Medicinal Plant Extract with vaseline cream
94447|NCT03447925|Drug|Salicylate|Salicylate 10% with vaseline cream
94448|NCT03447925|Drug|Vaseline|Vaseline cream
94449|NCT03447912|Behavioral|Intervention Condition|The intervention approach will be informed by the Community Coalition Action Theory (CCAT) developed by Butterfoss and Kegler. CCAT posits that coalitions form due to a threat, opportunity, or mandate. Public health center staff will form a coalition by recruiting partner organizations from civil society and other government sectors (e.g., health care, education), conduct situational assessment, and develop and implement action plans to promote the adoption and enforcement of smoke-free policies in worksites and restaurants.
94450|NCT03447899|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|Attachment and Biobehavioral Catch-up (ABC) is an in-home, 10-session, manualized parent-training program for children ages 6 months through 2 years who have experienced early adversity. ABC utilizes parent-child interactions to enhance positive interactions with the child through live coaching with particular focus on nurturing behaviors, following the child's lead, non-frightening behaviors. These behaviors include appropriate soothing and comforting when a child is distressed, responding to or imitating a child in a contingent way, and displaying warmth.
94451|NCT03447886|Other|Phone interview|Collecting clinical and socio-demographic information.
94452|NCT03447873|Drug|Continue with triple therapy|To continue with triple therapy
94453|NCT03447873|Drug|Switch to DTG + 3TC|Switch to dolutegravir + lamivudine once daily
94454|NCT03447873|Drug|Switch to DRV/cobicistat + 3TC|Switch to darunavir/cobicistat + lamivudine once daily
94455|NCT03447860|Behavioral|PAACC|Mindfulness based caregiver intervention that includes education , problem solving, skill building, stress management and mindfulness to help enhance compassion and acceptance of self and others
94456|NCT03447860|Behavioral|REACH-VA|A cognitive-behavior based multi-component caregiver intervention to reduce caregiver stress
94457|NCT03447847|Other|Water|1 liter of water in meals; 1 liter out of meals
94458|NCT03447834|Other|Selective intracoronary hypothermia + PPCI|Selective intracoronary hypothermia is a new technique, recently tested for safety and feasibility in the SINTAMI trial. The procedure starts by advancing a guidewire beyond the occlusion in the culprit artery, followed by an OTWB that is inflated at the location of the occlusion, at a low pressure (4 atm), to prevent reperfusion. After that, a pressure/temperature wire will be advanced along the inflated OTWB and is placed in the distal coronary artery. Then the guidewire is removed and the lumen is used for infusion of saline. During the 'occlusion phase', saline at room temperature is infused for 10 minutes with distal coronary temperature 6-8°C below body temperature. After that, the balloon of the OTWB is deflated. Simultaneously, infusion is started with saline of 4°C, the so called 'reperfusion phase'. This is continued for 10 more minutes. After that, the OTWB can be retracted and the procedure can continue not different from routine PPCI.
94459|NCT03447834|Other|Standard PPCI|PPCI per routine
94460|NCT03447821|Drug|400 mg Rifamycin SV dosage|
94461|NCT03447821|Drug|800 mg Rifamycin SV dosage|
94462|NCT03447821|Drug|1200 mg Rifamycin SV dosage|
94463|NCT03447808|Biological|Daratumumab|Given IV
94464|NCT03447808|Drug|Ibrutinib|Given PO
94465|NCT03447808|Other|Laboratory Biomarker Analysis|Correlative studies
94466|NCT03447808|Other|Pharmacological Study|Correlative studies
94467|NCT03447795|Procedure|Alveolar ridge preservation|grafting procedure using autogenous tooth.
94468|NCT03447782|Drug|Naltrexone HCl (Bulk) Powder|For the NDPH Persistent group, patient will take naltrexone, 4.5 mg, po 1 time/day for three months-Naltrexone will be compounded from Naltrexone HCL powder
94469|NCT03447769|Drug|Canakinumab|Canakinumab will be administered periodically for approximately 54 weeks.
94470|NCT03447769|Drug|Placebo|Placebo will be administered periodically for approximately 54 weeks.
94471|NCT03447756|Drug|ABX-1431|Capsules of either 2mg, 10mg, or 50mg
94472|NCT03447756|Drug|Placebo oral capsule|placebo to match
94473|NCT03447743|Drug|XR-NTX community location|XR-NTX will be administered in both conditions, but the location of on-going injections will vary
94474|NCT03447730|Drug|SYNB1020|SYNB1020 (5 × 10 to the 11th CFU, TID)
94475|NCT03447730|Other|Placebo|Placebo 100 mL masking solution
94476|NCT03447717|Device|ActiGait|implanted device for peroneal nerve stimulation
94477|NCT03447704|Drug|BCD-085|120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week
94478|NCT03447704|Other|placebo|2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week
94479|NCT03447691|Drug|Des (volatile anesthetic-desflurane)|Inducing unconciouness with 1.5 to 2 mg/kg of propofol, Intubation is performed 3 minutes after administration of remifentanil 1-2 mcg / kg and rocuronium 0.6 mg / kg. Desflurane concentration is maintained 3-7% (0.7-1.1 MAC) and remifentanil continuous infusion (0.02-0.2 mcg / kg / min).
94480|NCT03447691|Drug|TIVA (Total intravenous anesthesia with propofol and remifentanil)|TIVA group is administered with intravenous anesthetic using commercial target controlled infusion (TCI) pump. Anesthesia is induced and maintained with 2-6 mcg / ml propofol and 2-6 ng / ml remifentanil, which are converted to the effect site concentration. After administrating rocuronium 0.6mg/kg, intubation is performed.
94481|NCT03447678|Drug|Pembrolizumab|humanized antibody used in cancer immunotherapy
94482|NCT03447665|Behavioral|Bedtime routine|Tailored bedtime routine
94483|NCT03447665|Behavioral|Sleep schedule|Tailored sleep schedule, including morning rise time, cut-off for last nap of the day, and bedtime.
94484|NCT03447665|Behavioral|Intervention (bedtime)|Parents implement behavioral sleep intervention at bedtime.
94485|NCT03447665|Behavioral|Intervention (after night wakings)|Parents implement behavioral sleep intervention following each night waking.
94486|NCT03447652|Other|Resistance Band Ankle Rehabilitation|Resistance Band - uses a tension band to provide resistance during ankle motion
94487|NCT03447652|Other|Biomechanical Ankle Platform System Rehabilitation|Biomechanical Ankle Platform System Board Group - uses different levels of half spheres to increase the amount of motion allowed at the ankle.
94488|NCT03447652|Other|Combination Rehabilitation|Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
94489|NCT03447639|Drug|Povidone-iodine irrigation|Single dose, 60 cc of 2% povidone-iodine indwelling for 10 minutes prior to catheter removal using aseptic technique
94490|NCT03447626|Device|MAKO Robotic UKA|Prospective UKA patient receiving unilateral knee arthroplasty using the MAKO robotic machine
94491|NCT03447613|Procedure|surgery|All participants were scheduled to have elective total hip or knee replacement surgery, ureteroscopic lithotripsy and transurethral resection of the prostate under spinal anesthesia at the Shanghai 10th People's Hospital. After 5 years, the investigaors will follow up the participants including cognitive functions, PET-CT, thickness of Retinal Nerve Fiber Layer.
94492|NCT03447600|Behavioral|Alternate Day Fasting|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
94493|NCT03447600|Behavioral|Continuous dietary restriction|25% daily energy requirements every other day until study completion at >/=5% weight loss which is an average of 12 weeks.
94494|NCT03447587|Other|Electroacupuncture|Each subject will be treated with predefined acupoints including bilateral Ear-Shenmen, Touwei (ST8), Sishencong (EX-HN1), and unilateral Yintang (EXHN3) and Baihui (GV20) on the head (total 8 needles). Subject's current symptoms will be ascertained using a Traditional Chinese Medicine symptom checklist and eight additional acupoints will therefore be selected and needled based on their clinical judgements. The acupuncture treatment will consistent of two sessions per week (30 minutes) for 4 consecutive weeks.
94495|NCT03447587|Other|Sham acupuncture|Subjects will be treated at 1 cm posteriorly and laterally adjacent to the same acupoints as the traditional acupuncture group using validated non-invasive sham needles. Subjects will also be assessed with Traditional Chinese Medicine checklist. The acupuncturist, setting, treatment frequency, and duration of the treatment course will be the same as in the traditional acupuncture group.
94496|NCT03447574|Other|ethanol dilution|Ethanol has been validated against deuterium oxide, the invasive gold standard for determining totally body water
94497|NCT03447561|Behavioral|Anticipatory + consummatory food reward|Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake).
94498|NCT03447561|Behavioral|Consummatory food reward|Exposure to consummatory food reward (drinking sips of chocolate milkshake).
94499|NCT03447548|Behavioral|Neurofeedback processing speed training|Processing speed training on tablets that incorporates changes in pupil size to titrate the learning algorithm
94500|NCT03447548|Behavioral|Active control|Commercially available games on tablet
94501|NCT03447535|Other|Semi-directive interview (Kiddy Sads)|semi-directive interview (Kiddy Sads) conducted as part of the care
94502|NCT03447535|Other|SDQ questionnaires (strenghs and difficulties questionnaire)|SDQ questionnaires (strenghs and difficulties questionnaire) conducted as part of the care
94503|NCT03447509|Device|iTMS|small magnetic pulse will be given to the brain in a non invasive manner
94504|NCT03447509|Other|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
94505|NCT03447509|Device|Sham iTMS|Sham or fake stimulation will be given to the brain in a non invasive manner
94506|NCT03447509|Other|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm or hand. This is called training.
94507|NCT03447496|Procedure|Closed reduction|The children were treated with closed reduction.
94508|NCT03447496|Procedure|Open reduction|The children were treated with Open reduction.
94509|NCT03447483|Other|Patients starting a treatment by ICI|"Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30) before treatment administration and during the 12 months of treatment period, at the following time points:~every 6 weeks for treatment regimen administered every 2 or 3 weeks~at Weeks 6, 12, 20, 24 for treatment regimen administered every 4 weeks"
94510|NCT03447470|Drug|RXC004|RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway
94511|NCT03447457|Device|High-flow oxygen|HFNC is continuously applied via large-bore nasal prongs with a gas flow rate of 50 L/min and a FiO2 adjusted to maintain a pulse oxymetry at least 92%
94512|NCT03447457|Device|Standard oxygen|nasal cannula, face mask or non-rebreathing reservoir mask
94513|NCT03447444|Other|music and physical activity|This feasibility study focus on promoting a combination of music therapy and physical activity with the primary goal to describe the influence on restlessness, irritability, and aggression in persons with severe stage of dementia with a mixture of symptoms including frontal lobe problems in institutional care. A secondary goal is to investigate the treatment fidelity.
94514|NCT03447418|Procedure|Multiple breath nitrogen washout|Lung Clearance Index (LCI) will be performed in healthy volunteers with a multiple breath nitrogen washout device.
94515|NCT03447405|Device|Dino Egg|DINO EGG speakers, a NICU-safe and developmentally appropriate music player that delivers parent's voice to the bedside of NICU infants. The device passed NCH NICU-safe products committee and has been used in the clinical setting delivering clinical music therapy services (available at bedside to play parents' voice).
94516|NCT03447392|Behavioral|Discharge Education of Chinese Medicine|Discharge Education of Integrated Traditional and Western Medicine
94517|NCT03447379|Drug|1. P2Y12 inhibitor monotherapy after 3 months of DAPT|"P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day)~DAPT(Aspirin 100mg + Clopidogrel 75mg/day or Aspirin 100mg + Ticagrelor 180mg/day) for a year"
94518|NCT03447366|Diagnostic Test|mitral doppler|Mitral doppler before and after vascular filling
94519|NCT03447353|Drug|Xanax 1Mg Tablet|Single dose on two of four visits, one in conjunction with 1 tab of 10mg/325mg Norco
94520|NCT03447353|Drug|Norco 10Mg-325Mg Tablet|Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
94521|NCT03447353|Drug|Placebo Oral Tablet|Single dose on two of the four study visits, double dose on one of the four study visits
94522|NCT03447340|Behavioral|Canteen and Behavior intervention|"canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.~Behavioral : 16 core classes and 8 maintenance classes"
94523|NCT03447340|Other|Canteen Only|canteen intervention: (a) form and train a canteen improvement team; (b) train canteen staff on healthy cooking; (c) add healthy food and remove unhealthy food; (d) information and communication of canteen changes to employees; (e) monitoring of the interventions.
94524|NCT03447327|Procedure|single burr hole|patients with CSDH operated by single burr hole craniostomy under local anaesthesia
94525|NCT03447314|Drug|GSK1795091|GSK1795091 will be available as solution for injection
94526|NCT03447314|Drug|GSK3174998|GSK3174998 will be available as lyophilized powder to be reconstituted for infusion.
94527|NCT03447314|Drug|GSK3359609|GSK3359609 will be available as solution for infusion.
94528|NCT03447314|Drug|Pembrolizumab|Pembrolizumab will be available as solution for infusion or lyophilized powder for reconstitution.
94529|NCT03447301|Dietary Supplement|Extra virgin olive oil (30mL daily)|Intervention arm will take 30 mL of Extra virgin olive oil daily.
94530|NCT03447275|Other|Type 2 diabetes|Test if patients with diabetes have different blood concentrations of vitamin biomarkers compared with control subjects and if vitamin levels in the patients will differ according to renal damage.
94531|NCT03447262|Drug|VX-659|Fixed-dose combination (FDC) tablets (VX-659/TEZ/IVA)
94532|NCT03447262|Drug|TEZ|FDC tablets (VX-659/TEZ/IVA)
94533|NCT03447262|Drug|IVA|FDC tablets (VX-659/TEZ/IVA)
94534|NCT03447262|Drug|IVA|IVA tablet
94535|NCT03447249|Drug|VX-659|Fixed-dose combination (FDC) tablet (VX-659/TEZ/IVA)
94536|NCT03447249|Drug|TEZ|FDC tablet (VX-659/TEZ/IVA)
94537|NCT03447249|Drug|IVA|FDC tablet (VX-659/TEZ/IVA)
94538|NCT03447249|Drug|Matched Placebos|Placebo will be used as a comparator.
94539|NCT03447249|Drug|IVA|IVA tablet
94540|NCT03447236|Behavioral|Feuerstein Program|Mediated learning cognitive enhancement program
94541|NCT03447210|Behavioral|Assisted Partner Services|Contact tracing for sexual and drug-sharing partners to notify about exposure to HIV and offer HIV and hepatitis C testing with linkage to care and partner services for those who test positive.
94542|NCT03447197|Procedure|The use of extracorporeal circulation|The use or not of extracorporeal circulation during the coronary artery bypass procedure.
94543|NCT03447184|Drug|Androgen priming|"Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor"
94544|NCT03447171|Device|App Vision Screening|Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
94545|NCT03447158|Procedure|15% Dextrose|inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance
94546|NCT03447158|Procedure|Normal saline|inject normal saline and xylocaine into subacrominal bursa under sonographically guidance
94547|NCT03447145|Drug|TQ-B3203|dose escalation, 2/4/6/10/14/18mg/m2
94548|NCT03447132|Drug|Fulvestrant 500mg|All patients in all arms will receive Fulvestrant 500mg
94549|NCT03447132|Drug|Palbociclib 125mg|Dose reduction to 100 mg and 75 mg
94550|NCT03447132|Drug|Goserelin 3.6 MG|Only for pre or peri menopausal patient
94551|NCT03447132|Drug|Placebos|Placebo
94552|NCT03447119|Behavioral|Living Well with a Disability|Implementation of an adapted health promotion program.
94553|NCT03447106|Procedure|laparotomy|This is a kind of traditional surgical method.
94554|NCT03447106|Procedure|Laparoscopic|laparoscopic surgery
94555|NCT03447106|Procedure|Robotic|the Da Vinci robot assisted gastric resection
94556|NCT03447093|Drug|Methimazole Pill|Patients who developed GD received methimazole treatment
94557|NCT03447093|Drug|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
94558|NCT03447080|Other|Control|White Bread containing 50g carbohydrate
94559|NCT03447080|Other|Control|White Bread containing 50g carbohydrate
94560|NCT03447080|Other|Ricebran soybean milk|White Bread with rice bran soybean milk
94561|NCT03447080|Other|Soybean milk|White Bread with soybean milk
94562|NCT03447067|Procedure|computer guided surgical|has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
94563|NCT03447067|Procedure|Conventional surgery|Low speed motor with surgiacl round burs and surgical fissure for removal a covering bone with decapitation and guttering formation
94564|NCT03447067|Device|CBCT|For measuring the bone removeal
94565|NCT03447067|Device|CBCT|for identifed the nerve
94566|NCT03447054|Behavioral|Combined TDCS active and ICT active|Five 20-minute long sessions including TDCS (2 MicroAmperes during 20 minutes) and ICT, 5 consecutive days
94567|NCT03447054|Behavioral|Combined TDCS sham and ICT active|Five 20-minute long sessions including TDCS sham (non active) and ICT, 5 consecutive days
94568|NCT03447054|Behavioral|Combined TDCS active and ICT inactive|Five 20-minute long sessions including TDCS sham and no-cue inhibition training, 5 consecutive days
94569|NCT03447054|Behavioral|Combined Sham TDCS and inactive ICT|Five 20-minute long sessions including TDCS and no-cue inhibition training, 5 consecutive days
94570|NCT03447041|Procedure|keratoplasty|"Mark the center of the host cornea with a Sinskey hook. Use calipers to measure the corneal diameter to determine the appropriate size for donor trephine.~Trephine the donor tissue, typically aiming for 0.25 or 0.5 mm larger than the planned host trephination.~Trephinate the host cornea to approximately 90% depth.~Create a paracentesis in the trephination groove or the corneal periphery, and inject Healon into the anterior chamber to preserve anterior chamber depth and stability.~After using a blade to enter the eye through the trephination groove, resect the host cornea tissue using curved corneal scissors.~Secure the donor graft to the host corneal tissue using interrupted and/or running 10-0 nylon sutures."
94571|NCT03447015|Other|ambulation|"Ambulation during labour here will refer to moving from place to place during the first stage of labour that reduces the amount of time a woman spends laying down during this stage (measured by recording the number of minutes spend on walking)."
94572|NCT03447002|Diagnostic Test|24 hours urine levels metanephrine and normetanephrine|24 hours rhythm recording and 24 hours urine measurement
94573|NCT03446989|Behavioral|Case management|completing assessment, detecting the presence of RA complications, consultation about taking medications and exercise, education for patients and their family, assist in formulating a management, and providing a basis for continuing care for each patient. Additionally, the management plan was rationally modified in accordance with the individualized therapeutic alliance of the patient, his/her family, the physician or other members of the medical team.
94574|NCT03446976|Biological|CT-P13 SC Auto-injector|Each subject may receive single dose by subcutaneous administration using Auto-Injector
94575|NCT03446976|Biological|CT-P13 SC Pre-filled Syringe|Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
94576|NCT03446963|Behavioral|Groups for Health|Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
94577|NCT03446950|Procedure|Vaginal Surgery|Patients will undergo elective surgery on vagina or bladder
94578|NCT03446937|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone sodium phosphate injection 12 mg X doses to be given 12 hours apart
94579|NCT03446937|Drug|Betamethasone Sodium Phosphate Injection (Medication)|betamethasone sodium phosphate injection12mg X 2 doses given 12 hours apart
94580|NCT03446937|Drug|Water for injection|Two doses of intramuscular injection of water for injection given 12 hours apart
94581|NCT03446924|Dietary Supplement|Phosphatidic Acid|To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).
94582|NCT03446924|Dietary Supplement|Rice flour|Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
94583|NCT03446911|Radiation|SABR|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy.
94584|NCT03446911|Combination Product|SABR + pembrolizumab|Prior to surgery (lobectomy), patients receive stereotactic ablative radiotherapy + 2 rounds of pembrolizumab
94585|NCT03446898|Other|Chronic hypoxic environment|Chronic hypoxic environment. Since the partial pressure of oxygen in inspired air falls with increasing terrestrial elevation above sea level, many physiological variables in adults would be affected by the chronic hypoxia environment.
94586|NCT03446885|Drug|Lisdexamfetamine Dimesylate 40 MG|Lisdexamfetamine Dimesylate 40 MG administered orally
94587|NCT03446885|Drug|Placebo|Placebo capsule administered orally
94588|NCT03446872|Drug|ONIVYDE|irinotecan liposome injection
94589|NCT03446872|Drug|5-fluorouracil|a nucleoside metabolic inhibitor
94590|NCT03446872|Drug|Leucovorin|an active metabolite of folic acid
94591|NCT03446859|Other|TENS|"First, there was explanation of the overall test procedure. The subject was placed in supine lying in a comfortable position.A pair of electrodes (inactive electrodes) was placed a little below the umbilicus (Right and Left) and the other pair (active electrode) along the inguinal region at the level of pubic symphysis (Right and Left) according to (Akinbo et al 2000).~The TENS equipment was switched on and the intensity was set at a level tolerable by each participant's. The treatment period lasted for 30 minutes for each treatment sessions and the procedure was carried out once a day on the 1st, 3rd and 5th days (Akinbo et.al 2000). Pain intensity was measured pre treatment and post treatment each day of treatment using the visual analogue scale (VAS)."
94592|NCT03446846|Drug|MIN-117 2.5 mg|2.5 MIN-117 capsules administered as a single dose once daily
94593|NCT03446846|Drug|MIN-117 5.0 mg|5.0 MIN-117 capsules administered as a single dose once daily
94594|NCT03446846|Drug|Placebo|Placebo oral capsules administered as a single dose once daily
94595|NCT03446833|Device|The LFP Beta aDBS System|The LFP Beta aDBS System is intended for use in patients receiving DBS for Parkinson's Disease where LFPs may be recorded and analyzed.
94596|NCT03446820|Other|hygro cotton sheets|hygro cotton sheets will be utilized to impact microclimate
94597|NCT03446807|Drug|Droxidopa|Droxidopa in 100, 200, and 300mg capsules. Maximum dose to be used in this study is 600mg.
94598|NCT03446807|Drug|Placebo Oral Tablet|Placebo capsules to match Droxidopa 100, 200, and 300mg capsules.
94599|NCT03446794|Other|Non Intervention|To assess the procedural safety and efficacy on stroke and bleeding prevention of LAAC in patients with NVAF and ESCKD on HD
94600|NCT03446781|Biological|EN3835|Collagenase clostridium histolyticum
94601|NCT03446781|Biological|Placebo|Placebo
94602|NCT03446768|Other|Peer support|Access to educational and informational support by a trained peer coach
94603|NCT03446768|Other|Online platform|An online platform that provides educational, informational and access to several therapeutic device metrics
94604|NCT03446768|Other|Respiratory Therapist support|Limited medical support provided by trained Respiratory Therapists.
94605|NCT03446755|Device|intra uterine Cook balloon|An intra uterine Cook balloon will be placed after adhesiolysis to prevent recurrent adhesions after adhesiolysis by hysteroscopy.
94623|NCT03446625|Drug|Resveratrol|Resveratrol treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
94624|NCT03446625|Drug|Placebo|Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
94625|NCT03446612|Drug|Daprodustat|Daprodustat will be available as 1 mg, 2 mg and 4 mg oral tablets. Daprodustat will be administered once daily by oral route without regard for food.
94606|NCT03446742|Other|Cardiovascular rehabilitation|The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
94607|NCT03446729|Behavioral|Guided Self-Help Behavioral Weight Loss|Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
94608|NCT03446716|Behavioral|Sleep Extension|Child attempted to go to bed 90 mins in advance of their normal bedtime.
94609|NCT03446703|Behavioral|SCIT|SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.
94610|NCT03446703|Behavioral|TAR|TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
94611|NCT03446690|Drug|MI Varnish|MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
94612|NCT03446690|Other|Control group|Participants received routine treatment and oral hygiene regimes. No intervention for this group.
94613|NCT03446677|Other|Postural Stability Testing|Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks. Data of center of pressure, antero-posterior sways and medial-lateral sways were collected in each of the conditions. Each task took 30 seconds to be performed. The first 4 tasks were performed with the mat on the hard surface of the floor. These 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving head upward and downward, and standing with eyes closed and the head actively moving upward and downward. The subjects were asked to perform four more tasks while standing on a thick piece of balance foam that was placed on top of the MatScan®. The remaining 4 tasks are as follows: standing with eyes open, standing with eyes closed, standing with eyes open looking and actively moving the head upward and downward, and standing with eyes closed with head actively moving upward and downward.
94614|NCT03446664|Device|Microburst Stimulation|Implantable generator with new stimulation feature under study to determine the safety and effectiveness of device stimulation on different seizure types.
94615|NCT03446651|Drug|Lysine Chloride|Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride & the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
94616|NCT03446651|Other|Placebo|Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride & the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
94617|NCT03446638|Drug|FDA-approved drug or combination of drugs|Patients assigned to this arm will receive an FDA-approved drug or combination of drugs. Dosing and treatment schedule will follow the package insert for the selected drug(s).
94618|NCT03446638|Drug|FLAG induction|Patients will receive 30 mg/m2 per day intravenously of fludarabine for 5 days and 2000 mg/m2 per day intravenously of cytarabine for 5 days. 5 mg/kg per day of granulocyte colony stimulating factor (G-CSF) may be given subcutaneously beginning on Day 1 of each treatment until absolute granulocyte count > 500/ microliter for 3 days.
94619|NCT03446638|Drug|7 + 3 induction|Patients will receive 100-200 mg/m2 per day intravenously of cytarabine for 7 days, plus either 45-60 mg/m2 per day intravenously of daunorubicin or 9-12 mg/m2 per day intravenously of idarubicin for 3 days.
94620|NCT03446638|Drug|Low-dose cytarabine|Patients will receive 20 mg/m2 per day subcutaneously of cytarabine for 10 days every 28 days.
94621|NCT03446638|Other|Supportive care alone|Patients will receive one or more of the following: blood product transfusions, antibiotics, granulocyte colony-stimulating factor (G-CSF), erythropoietic stimulating factors, and iron chelation.
94622|NCT03446638|Device|Computational biology simulations software|Genetic testing results for each patient randomized to this arm will be used by a computational biology simulations software program to generate a personalized map of dysregulated metabolic pathways contributing to the patient's disease. This map will then be used to digitally screen for potentially therapeutic FDA-approved drugs or drug combinations to target the dysregulated metabolic pathways.
94626|NCT03446612|Drug|Darbepoetin alfa (Aranesp)|Darbepoetin alfa will be given as solution for injection for subcutaneous administration every 2 weeks.
94627|NCT03446612|Drug|Acetylcholine|Acetylcholine will be used as a challenge agent and will be infused at 7.5, 15 & 30 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
94628|NCT03446612|Drug|Sodium nitroprusside|Sodium nitroprusside will be used as a challenge agent and will be infused at 3 and 10 micrograms/minute each for 6 minutes per infusion into the brachial artery of the test arm.
94629|NCT03446612|Drug|L-N-monomethyl arginine citrate (L-NMMA)|L-N-monomethyl arginine citrate will be used as a challenge agent and will be infused at a doses of 2 and 8 micromoles/minute for 6 minutes into the brachial artery of the test arm.
94630|NCT03446599|Drug|Hydroxocobalamin|One intravenous dose of 5mg hydroxocobalamin, which is the current FDA-approved adult dose for carbon monoxide poisoning, reconstituted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
94631|NCT03446599|Drug|Methylene Blue|One intravenous dose of methylene blue 2mg/kg, which has been the accepted dose for vasoplegia, diluted in 200ml normal saline will be administered over 10-15minutes at the time of initiation of cardiopulmonary bypass.
94632|NCT03446599|Drug|Normal saline|200ml normal saline will be administered intravenously over 10-15minutes at the time of initiation of cardiopulmonary bypass.
94633|NCT03446573|Drug|DTG + 3TC|DTG+3TC is supplied as white, oval, film-coated, fixed dose combination tablet. The tablets will be available in packed high density polyethylene (HDPE) bottles with induction seals and child-resistant closures.
94634|NCT03446573|Drug|TAF based regimen (TBR)|Subjects will continue to receive their TBR.
94635|NCT03446560|Device|CPAP, conventional follow up|Positive airway pressure to splint the airway and to prevent apneas during sleep. Follow up of patients after initiation of treatment according to clinical routine at the study site. Patients are informed to call or visit the sleep center in case of problems with the CPAP device. At 3 months a follow up visit is scheduled at the sleep center. CPAP compliance data will be downloaded and all patients fill in a number of questionaires related to the CPAP treatment effects on sleep apnea symptoms and health related quality of Life. Mask fitting will be tested.
94636|NCT03446560|Device|CPAP, telemedicine based follow up|Follow up of patients by means of a telemedicine solution for surveillance of CPAP treatment, Compliance with and efficacy of CPAP can be followed up by the sleep center personnel on a regular basis. Patients with low compliance and mask fitting problems will be contacted by phone. At the end of the 3 months period a visit at the sleep center will be scheduled only for patients with low compliance, low treatment efficacy, or high mask leakage. All patients will be asked to fill in a number of questionaires related to CPAP treatment effects on sleep apnea symptoms and health related quality of Life.
94637|NCT03446547|Drug|Durvalumab|durvalumab 1500 mg i.v. every fourth week for 12 months
94638|NCT03446534|Drug|Amoxicillin|Imacillin mixture
94639|NCT03446534|Drug|Placebos|Placebo manufactured to mimic amoxicillin mixture (Imacillin)
94640|NCT03446508|Device|Active frontal|1) active HD-tDCS will be administered
94641|NCT03446508|Device|Active parietal|2) active HD-tDCS will be administered
94642|NCT03446508|Device|Sham|3) sham HD-tDCS - no current
94643|NCT03446495|Drug|Trabectedin + PLD|Combination of Trabectedin + PLD: PLD 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks.
94644|NCT03446482|Other|observation of differents tasks|Evaluation by an external observer (nurse student in research stage or clinical research technician) of the distribution of medical time for the performance of the different tasks of anesthesiologist (in minutes)
94645|NCT03446469|Other|Fascial Manipulation|Myofascial release of densified centers of coordination
94646|NCT03446456|Drug|Arginine vasopressin|Intranasal vasopressin will be administered shortly before the fMRI experiment.
94647|NCT03446456|Other|Saline|Intranasal saline will serve as a placebo for participants in the Saline Arm
94648|NCT03446443|Drug|Honghe Fujie lotion|Before application，wash the vaginal area with water and dry it. Take10ml Hong He Fujie into dilution bottles，added to 100ml with warm boiled water, using diluted lotion for the rinse of vulva and vagina, twice daily for 7days.
94649|NCT03446443|Drug|Metronidazole Suppositories|Before bedtime，wash the vaginal area and put 0.5g Metronidazole Suppositories into posterior vaginal fornix，once daily for 7days.
94650|NCT03446430|Device|PWV measurement by LDV|PWV measurement by LDV : carotid-femoral, carotid and chest-carotid
94651|NCT03446417|Drug|ZN-e4|Oral dose, tablet, daily dosing
94652|NCT03446404|Diagnostic Test|Standing Computed Tomography|Provides weight bearing 3D view of knees.
94653|NCT03446391|Procedure|Kinematic alignment|The principle for kinematically aligning the femoral component is to remove the correct amount of bone and cartilage from the distal and posterior femur after accounting for wear and saw blade kerf, so that the total thickness of the missing and removed tissue matches the thickness of the femoral component.
94654|NCT03446391|Procedure|Mechanical alignment|Classic mechanical alignment (MA) in total knee arthroplasty (TKA) is meant to co-align the prosthetic components to the mechanical axes of the femur and tibia and restore neutral overall limb alignment
94655|NCT03446391|Device|GMK Sphere®|The GMK Sphere® is a total knee prosthesis . The design of the GMK Sphere® is characterized by a spherical medial femoral condyle and an asymmetrical fixed tibial UHMWPE polyethylene insert with a concave spherical medial compartment.
94656|NCT03446378|Device|Anodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
94657|NCT03446378|Behavioral|Physical therapy|all patients will be submitted to a protocol of exercise with differents levels according with motor learing and neuroplasticity principles. All physical therapists were trained before the study.
94658|NCT03446378|Device|Cathodal tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
94659|NCT03446378|Device|Sham tDCS|tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability questionnaire will be applied
94660|NCT03446365|Behavioral|ASMAS|A high school peer led group intervention for middles school students targeting asthma education and asthma management practices.
94661|NCT03446365|Behavioral|Asthma education plus child health|Health educator led intervention focused on asthma education and other child health topics.
94662|NCT03446352|Other|Psychomotor exercise program|"Each session includes: beginning ritual (5 min), warm-up (15 min), main section comprising the multimodal exercises (40 min), cool-down (10 min), and finishing ritual (5 min).~At the initial stage, the activation of different muscle groups will be performed, providing an elevation of the neurophysiological parameters. The main section (multimodal exercises) will be focused on the specific objectives through sensorimotor and neurocognitive activities. This section includes periods ranging 10-15 min of exercises mainly focused on motor stimulation- physical performance (cardiovascular, strength, balance, flexibility, agility and movement accuracy)- alternating with exercises mainly focused on cognitive stimulation- executive functions (planning ability, information processing speed, attention and dual-task performance).~At the cool-down the participants will normalize their physiological parameters. Finally, at the finishing ritual the participants share their sensations experienced."
94663|NCT03446352|Other|Combined exercise program|"The EG2 intervention combines the psychomotor exercise program with a WBV program. The program integrates 3 sessions / week of 75 minutes (including the 6 minutes of WBV) on alternated days.~The WBV will integrate 3 sessions / week of 6 minutes each, with programed increased exercise time, series, and frequencies throughout the intervention."
94664|NCT03446326|Device|Pacing|Assess the non-invasively determined stroke volume and cardiac output response at different paced heart rates in patients with a cardiac pacemaker or implanted defibrillator with preserved ejection fractions (LVEF≥50%)
94665|NCT03446313|Behavioral|Movn Mobile App|The Movn app will have each participant's personalized instructions for post-cardiac rehab integrated into it including medication reminders, physical activity prompts, educational materials, and patient-reported outcomes.
94666|NCT03446274|Drug|Evenamide|This is an orally available small molecule that potently blocks voltage-gated sodium channels (VGSCs) in vitro and is indicated for the treatment of patients with schizophrenia, mania, and bipolar disorder.
94667|NCT03446261|Drug|Rosuvamibe® Tab|Rosuvastatin 5mg/ezetimibe 10mg qd for 8 weeks
94668|NCT03446261|Drug|Monorova® Tab|Rosuvastatin 10mg qd for 8 weeks
94669|NCT03446248|Device|Corometrics-146 device|Fetal vibroacoustic stimulation with the Corometrics-146 fetal acoustic stimulator will be performed by placing the device on the maternal skin halfway between the pubic symphysis and the umbilicus and activating the device for 3 seconds.
94670|NCT03446248|Device|Mobile phone application|Fetal vibroacoustic stimulation with the mobile phone will be performed by placing and iPhone on the maternal skin halfway between the pubic symphysis and umbilicus and using the application to activate for 3 seconds the phone's built in vibration along with a 2,000 Hz tone at a sound level of 74 decibels when measured at 1 meter.
94671|NCT03446235|Behavioral|Exercise instruction with motivational interview|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. In addition to the basic instruction of exercise and nutrition, an exercise physiologist provides individualized exercise instruction with a motivational interviewing skill, which is a different style from traditional persuasive style of communication between the healthcare professionals and patients.
94672|NCT03446235|Behavioral|Self-monitoring|An activity tracker and a heart rate monitor to track the participants activity and exercise records will be used. Basic instruction about exercise and nutrition is provided at the initial visit.
94673|NCT03446222|Procedure|Catheter ablation|Catheter based radiofrequency ablation with wide antral circumferential PVI and isolation of posterior wall will be performed. Mitral and cavo-tricuspid isthmus ablation will be done only if such isthumus dependent flutters are documented prior to / during the procedure.
94674|NCT03446222|Procedure|Mini-maze surgical procedure|Wolf Mini-maze surgical ablation along with left atrial appendage ligation will be performed.
94675|NCT03446209|Drug|Tocilizumab Infusion RoAcemtra (EU)|Experimental arm's patients will obtain TCZ intravenously once every 4 weeks for 28 weeks
94676|NCT03446209|Drug|0.9% physiological saline|"Experimental arm's patients will obtain saline intravenously once every 4 weeks for 16 weeks. If necessary, patients will get rescue medication after week 16 to week 28."
94677|NCT03446196|Device|Fluid replacement based on MOSTCARE up|Clinician will be able to read MOSTCARE parameters and to choose the best treatment to adequate hemodynamics considering that current literature suggests a fluid IV expansion only if PPV > 12%
94678|NCT03446183|Behavioral|Smoking cessation workshops|All the participants took part in smoking cessation workshops. The comparison of metabolic aspects was made between the smokers and non-smokers
94679|NCT03446170|Behavioral|Graphic cigarette warning labels, plain packaging|This study tests the effects of graphic cigarette warning labels that include pictures and text, and plain or standardized packaging
94680|NCT03446157|Drug|Cetuximab|Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib
94681|NCT03446157|Drug|Palbociclib|125 mg taken orally once daily on days 1-21, then 7 days off
94682|NCT03446144|Drug|IONIS-FB-Lrx|Single Dose of IONIS-FB-Lrx administered once weekly for weeks 1-3, and every other week or less frequently until week 70
94683|NCT03446144|Drug|Placebo (sterline saline 0.9%)|Calculated volume to match active comparator. Administered subcutaneously weekly for weeks 1-3, and every other week or less frequently until week 70
94684|NCT03446118|Device|MRI to detect inflammation and fibrosis in subjects with EoE|MRI will be performed on a 1.5T magnet. Patients will be scanned in an oblique prone position similar to how esophageal distention is assessed at barium fluoroscopy
94685|NCT03446105|Behavioral|App-based behavioral intervention|Achieving Wellness After Kancer in Early life (AWAKE) is a behavioral intervention that includes a smartphone app and coaching. AWAKE contains eight modules, and participants will complete the one module every week. App functioning will facilitate weekly homework assignments and include health education messaging, the ability to track progress toward goals over time via self-monitoring and graphical depictions of progress, audio-recordings of guided imagery exercises and relaxation exercises (e.g., progressive muscle relaxation), videos of topic-related inspirational material, and a portal for interacting with the coach. The coach will call each intervention participant weekly. Each coaching session will last roughly 30 minutes and involve four segments that will correspond to the module for the week. The coach will send daily text messages to participants encouraging their goal pursuits and providing other sources of support related to that week's homework.
94686|NCT03446105|Behavioral|Attention control group|The attention control group will receive the same components as the intervention group, but the educational modules will contain different content than those receiving the AWAKE intervention.
94687|NCT03446092|Behavioral|Mindfulness for health|A course of mindfulness using the mindfulness for health programme.
94688|NCT03446079|Other|Topical Anti Aging Cream|Primary Subjects will take a saliva based genetic test and apply a topical anti aging cream for 6 weeks.
94689|NCT03446053|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
94690|NCT03446053|Other|INT200-Placebo|Formulation buffer except active ingredient for continuous intravenous infusion over 60 minutes
94691|NCT03446040|Biological|BMS-986258|Specified dose on specified day
94692|NCT03446040|Biological|Nivolumab|Specified dose on specified day
94693|NCT03446040|Drug|rHuPH20|Specified dose on specified days
94694|NCT03446027|Device|NMES|NMES device to be used for up to 3 hours daily in 30 minute sessions for 3 months.
94695|NCT03446014|Device|Fitbit Sub-Study|
94696|NCT03446001|Drug|TRx0237 16 mg/day|Oral TRx0237 4-mg tablets administered twice daily
94697|NCT03446001|Drug|Placebo|Oral placebo tablets (some of which contain a urinary discolorant) administered twice daily
94698|NCT03446001|Drug|TRx0237 8 mg/day|Oral TRx0237 4-mg tablet administered twice daily
94699|NCT03445988|Behavioral|Cognitive Behavioral Therapy|A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.
94700|NCT03445988|Behavioral|Chronic Pain Self Management Program|The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session
94701|NCT03445988|Other|Usual Care|Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
94702|NCT03445975|Procedure|3-in-1 perineal care washcloths|The 3-in-1 washcloth was used for daily routine perineal skin hygiene and after each diaper/underpad change. This procedure was intended for cleansing, moisturizing, and application of a barrier protection (dimeticone 3%). 3-in1 washcloths pH range is 3.5 to 5.0.
94703|NCT03445962|Diagnostic Test|Assessment of OSAS predictive factors|"All subjects of the two groups realized the same assessment:~Anthropometric evaluation~biological examination (hormonal, inflammatory and complete blood count, and lipidic profile)~rest electrocardiogram~motor assessment (strenght, flexibility and balance)~actigraphy~Autonomic nervous system assessment during sleep~Autonomic nervous system assessment during head up tilt test before and after physical exercise~maximal treadmill test (VO2 max measure)~polysomnography~seismocardiography~questionnaires :sleep and physical activity"
94704|NCT03445949|Drug|short postimplantation dual antiplatelet therapy|continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet
94705|NCT03445949|Drug|extended postimplantation dual antiplatelet therapy|stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months
94706|NCT03445936|Device|Parietene Macro|Parietene Macro is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
94707|NCT03445936|Device|Permacol|Permacol biologic implant is placed and sutured on retro muscular space on closed posterior rectus sheath to prevent incisional hernia.
94708|NCT03445923|Other|Time lapse monitoring (KID Score)|The unique information that is obtainable from taking Pictures each 10 minutes throughout the development of the embryos will be used in the form of a special score (KID score). The score is comprised out of several key developmental parameters.
94709|NCT03445910|Drug|Human chorionic gonadotropin|intrauterine injected of 500 IU of hCG on the day of ovum pick-up and
94710|NCT03445897|Drug|miltefosine plus intralesional pentamidine|miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 ug/mm2 lesion area on days 1, 3, and 5).
94711|NCT03445884|Drug|68Ga-NODAGA-E[c(RGDyK)]2|200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 administered IV.
94712|NCT03445871|Biological|Blood sample|Blood samples will be collected for measuring PG-MTX blood concentration.
94713|NCT03445871|Diagnostic Test|CRQ|Compliance Rheumatology Questionnaire (CQR) is a self-administered questionnaire for to evaluate therapeutic observance during rheumatoid arthritis.
94714|NCT03445858|Drug|Pembrolizumab|Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
94715|NCT03445858|Drug|Decitabine|Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
94716|NCT03445858|Radiation|Hypofractionated Index Site Radiation|Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
94717|NCT03445845|Drug|Secukinumab|Secukinumab : 150 mg per week for 5 weeks, and then every month by subcutaneous injection
94718|NCT03445845|Drug|TNF blocker|"TNF blocker (originator or biosimilar) :~infliximab: 5mg/kg per IV infusion at weeks 0, 2, 6, and then every 6 weeks,~etanercept: 50mg per week in subcutaneous injection,~adalimumab: 40mg every other week in subcutaneous injection,~certolizumab: 400mg every other week 3 times, and then 200mg every other week or 400mg per month in subcutaneous injections,~golimumab: 50mg every month in subcutaneous injection, in case of overweight (>100kg) an inadequate response, 100mg every month is allow."
94719|NCT03445845|Biological|blood specimen|Blood specimen at each visits for measurement of bDMARS blockers concentration and anti-drug antibody concentration
94720|NCT03445819|Procedure|Group A: Surgical Treatment|Open reduction and internal fixation (ORIF) of the patellar fracture will be performed using screws, wires, pins, or plate fixation at the discretion of the treating surgeon
94721|NCT03445819|Other|Group B: Conservative Treatment|Patients randomized to non-operative treatment will receive identical treatment to the operative group, minus the surgery.
94722|NCT03445780|Drug|Ethyl chloride spray|Skin cooling with ethyl chloride spray 5 seconds prior to injection
94723|NCT03445780|Procedure|Pinching|Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection
94724|NCT03445780|Procedure|No Site of Procedure|Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
94725|NCT03445767|Other|MedSafer|An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
94726|NCT03445754|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
94727|NCT03445754|Device|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
94728|NCT03445741|Other|Supervised treadmill group (%70 VO2 max) (group 1)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 70% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 3 days in a week and 20 minutes per day walking program was applied.
94729|NCT03445741|Other|Supervised treadmill group (%50 VO2 max) (group 2)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target heart rate (HR) corresponding to values of 50% VO2max were determined by the submaximal treadmill test. The participants were instructed walking at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port, Washington, NY). During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
94730|NCT03445741|Device|ECE PEDO pedometer group (%50 VO2 max) (group 3)|Target heart rate (HR) corresponding to values of 50 % VO2max were determined by the submaximal treadmill test. The number of steps taken in a minute corresponding to target HR was determined by a criterion pedometer and group 3 was instructed walking in this step range recorded to ECE PEDO giving audible feedback. During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
94731|NCT03445728|Drug|Nicorandil|After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
94732|NCT03445728|Other|Placebo|After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
94733|NCT03445715|Genetic|ART-I02|Single Intra-articular injection in the wrist joint
94734|NCT03445702|Drug|Metformin|Metformin 1000mg once
94735|NCT03445702|Drug|Placebo|Sugar pill manufactured to mimic metformin 1000mg
94736|NCT03445689|Other|Assessment of oxygenation instability|Recordings of SpO2 and heart rate will be analyzed by dedicated software to obtain frequency, duration and severity of episodes of hypoxemia and hyperoxemia.
94737|NCT03445689|Other|Determination of mechanisms of hypoxemia episodes|Recordings of SpO2, heart rate, esophageal pressure, tidal volume, minute volume, respiratory rate and transcutaneous PCO2 will be analyzed to determine the prevalence, severity and duration of hypoxemia episodes produced by the different mechanisms.
94738|NCT03445689|Other|Assessment of respiratory instability|Recordings of tidal volume, minute volume and respiratory rate will be analyzed to determine frequency of apnea, periodic breathing, distribution of inter-breath intervals.
94739|NCT03445689|Other|apneic threshold of CO2|In mechanically ventilated infants the apneic threshold of CO2 will be measured by transcutaneous PCO2 following a step wise increase in ventilator rate until spontaneous breathing ceases transiently. In spontaneously breathing infants the apnea threshold of CO2 will be measured during episodes central apnea.
94740|NCT03445689|Other|Assessment of peripheral chemoreceptor function|The Dejours test will be used to assess peripheral chemoreceptor function by measuring the immediate ventilatory response to high-inspired oxygen.
94741|NCT03445689|Other|Assessment of central chemo-receptor function|Central chemo-receptor function will be assessed by measuring the ventilatory response to inspired CO2.
94742|NCT03445676|Behavioral|ABHR directly on gloves|HCW will be directed by study personnel to use alcohol-based hand rub (ABHR) to cleanse gloves at each hand hygiene opportunity
94744|NCT03445650|Drug|ADX-102 1% Topical Dermal Cream (reproxalap)|ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months in Part 1 and Part 2.
94745|NCT03445650|Drug|Vehicle of ADX-102 Topical Dermal Cream|Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months in Part 1 and Part 2.
94746|NCT03445624|Drug|Infliximab|follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy
94747|NCT03445611|Drug|corticosteroid solution with lidocaine containing parabens.|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
94748|NCT03445611|Drug|corticosteroid solution with lidocaine containing no paraben|To identify whether corticosteroid use with anesthetics containing parabens reduces clinical effectiveness relative to para-free preparations.
94749|NCT03445598|Behavioral|Interactive and personalized CCBT|Participants will go through an automated program. Participants will learn and practice the techniques of CBT through multimedia elements along with personalized content and interactive features in the program
94750|NCT03445598|Behavioral|Feature-limited CCBT|Participants will be going through an automated program. Participants will learn and practice the techniques of CBT in a plain-text format with reduced features.
94751|NCT03445598|Other|Waitlist control|Participants will be put on a waitlist for a period of 6 weeks.
94752|NCT03445572|Other|Best Practice|Receive standard supportive care
94753|NCT03445572|Procedure|Meditation Therapy|Perform MSB
94754|NCT03445572|Procedure|Meditation Therapy|Perform IK meditation
94755|NCT03445572|Other|Questionnaire Administration|Ancillary studies
94756|NCT03445559|Behavioral|Clinical Order Check|A Clinical Order Check is an evidence-based, systems-level method to affect significant behavior change. It addresses the intervention functions of education, enablement and incentivization which are effective methods to change behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. All VA facilities currently use locally adapted clinical reminders. This strategy is technologically simple, straightforward, and is considered to be a best practice within the VA IT community. The reminder will be self-explanatory and non-intrusive to workflow.
94757|NCT03445559|Behavioral|Academic Detailing|Academic detailing is an individual and facility-level intervention consistently shown to improve provider behavior. This strategy addresses the intervention functions of persuasion, coercion, modeling, and education which are effective methods for affecting behaviors driven by beliefs about capabilities, knowledge, social influences, beliefs about consequences, and environmental context and resources. During the meeting, the detailer will follow a script explaining that the visit is part of an experimental program to provide physicians with up-to-date, unbiased information about imaging to stage prostate cancer.
94758|NCT03445559|Behavioral|Audit and Feedback|Audit and feedback is an effective, individual-level intervention for changing healthcare provider behavior, resulting in small but potentially clinically important benefits. Audit and feedback addresses the intervention functions of education, persuasion and incentivization, all of which are important for addressing beliefs about capabilities and consequences, knowledge, and social influence.
94759|NCT03445546|Diagnostic Test|diagnostic test of platelet function|Light transmittance aggregometry and VerifyNow
94763|NCT03445520|Behavioral|Intervention Coaching Group|Parents in this group receive six, 1 hour, coaching sessions with a research staff coach, to discuss key information about transitions (knowing parent's rights about special education services, communicating effectively with school staff, knowing the roles of the school team members, how to develop and share your Snapshot, and what to do with your child over the summer to help with the transition). The coach will encourage the parent to identify a school staff member to help with preparing for the transition. If the post transition school team is not able to participate in a pre-transition meeting, then the coach will encourage the parent to share the Student Snapshot with the post-transition teacher(s) and school team when the new school year begins in the Fall.
94764|NCT03445507|Other|Chat bot|Patients in intervention arm will use an evidence-based chat bot as an aid for smoking cessation
94765|NCT03445507|Other|Usual care|Usual care given by their usual general practitioners and nurses of primary care health centres, as defined in Public Health System Portfolio.
94766|NCT03445494|Procedure|Brace|A brace to be weared according to protocol
94767|NCT03445494|Procedure|Normal sling|A normal sling to be weared according to protocol
94768|NCT03445481|Device|Medacta femoral prosthesis|patients' treatment with a new implant prosthesis
94769|NCT03445468|Biological|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
94770|NCT03445468|Biological|IL-YANG Flu Vaccine Pre-filled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
94771|NCT03445455|Device|Tidal volume measurement|"Recording of thoracic impendance variations during different non-invasive oxygenation techniques.~Conversion to Tidal volume after calibration using the airway flow signal recorded during the NIV with bucco-nasal mask."
94772|NCT03445442|Procedure|SCP|Sacrocolpopexy (SCP) aims to secure the anterior vaginal wall, the uterus more or less the posterior vaginal wall using polypropylene prostheses and to secure them to the presacral ligament to restore the patient's anatomical features and improve pelvic symptoms
94773|NCT03445442|Procedure|NTR|Native tissue repair surgery (NTR) consist of site-specific surgical repair of the existing defect (anterior and/or posterior) using non-absorbable sutures. Specifically, anterior and/or posterior colporrhaphy for cystocele and rectocele respectively after adequate hydrodissection of the vesicovaginal or rectovaginal space.
94774|NCT03445442|Procedure|VMR|Vaginal mesh repair surgery (VMR) is performed using a single-incision mesh system. A single vertical incision is made in the anterior and/or posterior vaginal wall. A full-thickness dissection is performed laterally and apically to the ischial spine.
94775|NCT03445429|Other|3D-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 3D-display system means that the training-set up is performed first with 3D-display system an after that with the 4K-display system.
94776|NCT03445429|Other|4K-display system|The subjects will perform tasks on a minimal-invasive/laparoscopic training set-up. They will perform the tasks with a 3D-display system or a 4K-display system. The intervention type 4K-display system means that the training-set up is performed first with 4K-display system and after that with the 3D-display system.
94777|NCT03445416|Behavioral|POL arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
94778|NCT03445416|Behavioral|Comparison arm|A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
94779|NCT03445403|Other|Offset analgesia|Exposure to a moderate heat-pain stimulus applied for 5 seconds, raised by 1 degree C for 5 seconds, reduced by 1 degree C, and held for 20 seconds using a computerized paradigm in order to evoke endogenous pain modulation.
94780|NCT03445390|Drug|Acetaminophen|Acetaminophen 1 g intravenous given at the beginning and end of surgery.
94781|NCT03445390|Drug|Placebo|Placebo to match acetaminophen given at the beginning and end of surgery.
94782|NCT03445377|Device|Real-time continuous glucose monitoring|Subjects randomised to Real-time continuous glucose monitoring will be given a Dexcom G5 or similar, training on its use, and HbA1c measurements taken at the start and end of the study. They will also be given validated questionnaires to complete.
94783|NCT03445377|Device|Self-monitoring of blood glucose|Subjects randomised to self monitoring of blood glucose will be given a masked CGM which will be applied for one week, during Week 1, 4 and 8. HbA1c measurements will be taken at the start and end of the study. They will also be given validated questionnaires to complete.
94784|NCT03445364|Other|Use of different injection pressure during primary PCI|Using ACIST injector during the PCI it is possible to change injection pressure - in one arm low pressure of 200psi, and in the second arm average pressure of 550psi
94785|NCT03445351|Other|Aerobic, resistance and concorrent.|All protocols followed the American College of Sports Medicine (ACSM) guidelines , with frequency of three times per week, duration between 40-50 minutes, low to high intensity, modified according to the physical needs of each participant, respecting the physical training principles.
94786|NCT03445338|Drug|K0706|Study
94787|NCT03445338|Drug|K0706|Study
94788|NCT03445338|Drug|K0706|Study
94789|NCT03445325|Behavioral|LiGHT v2.1|"The LiGHT mobile program strives to support youth and their families to adopt lifelong healthy behaviours in four areas - eating, physical activity, recreational screen time and sleep - to foster healthy growth and development, to prevent chronic diseases and manage unhealthy weights.~The program includes content that involve the family, and focus on behavioural therapy as well as dietary and physical activity patterns. LiGHT is intended to be engaging and fun, provide virtual and tangible rewards, and interact with participants multiple times per day. In addition, it will feature a mobile social support network and interaction with a live coach with specialized training in motivational interviewing to support youth/families in changing their health behaviours through messaging and phone calls."
94790|NCT03445312|Behavioral|not processing urine cultures|microbiology lab will not process culture unless called
94791|NCT03445299|Behavioral|Music|Listening to music for 30 minutes at bedtime
94792|NCT03445286|Device|Silver Diamine Fluoride|Silver Diamine Fluoride (Advantage Arrest) for the experimental group
94793|NCT03445286|Other|Normal Saline|Normal Saline for the control group
94794|NCT03445260|Other|Nutritional Supplements|PreCovery is a carbohydrate loading nutritional supplement, INergy FLD is an immunonutrition formulated liquid diet, and ISOlution is a protein supplement.
94795|NCT03445260|Other|Placebo|Each placebo is composed of a collagen-based filler with exactly the same taste and texture as the intervention.
94796|NCT03445247|Other|Extracorporeal low-intensity shockwave|Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.
94797|NCT03445234|Dietary Supplement|Blueberry|26 g/day freeze-dried powder, 2 weeks duration
94798|NCT03445234|Dietary Supplement|Placebo|Placebo powder
94799|NCT03445234|Dietary Supplement|banana|Acute ingestion of bananas 0.2 g carb/kg every 15 min exercise with water
94800|NCT03445234|Dietary Supplement|No banana|water only
94801|NCT03445221|Dietary Supplement|Oral Immunonutrition|patients will take preoperative oral immunonutrition in form of glutamine, Omega-3 fatty acid, multivitamins and trace elements (2KCAL FIBRE DRINK product) once daily for 5 days before surgery in addition to a conventional diet.
94802|NCT03445221|Dietary Supplement|Conventional Diet|patients will continue preoperative oral conventional diet.
94803|NCT03445208|Drug|BMS-986036|Crossover administration to abdomen then upper arm
94804|NCT03445195|Drug|Sulbactam-ETX2514|The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
94805|NCT03445195|Drug|Placebo|Matching 1g IV solution.
94806|NCT03445195|Drug|Imipenem-cilastatin|All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
94807|NCT03445182|Procedure|Local anaesthesia with conventional syringe|"Buccal infiltration in posterior maxillary region with traditional technique. A 27 gauge short needle is inserted in the mucobuccal fold above the tooth to be anesthetized.~Local anaesthetic infiltration speed 1ml/min. Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
94808|NCT03445182|Device|Local anaesthesia with conventional syringe + Dentalvibe|"Buccal infiltration in posterior maxillary region. The tip of the DentalVibe device is placed in the mucobuccal fold above the tooth to be anesthetized. The device is activated for 5 s. A 27 gauge short needle is inserted as close as possible to the inner side of the prong while the vibration is still on.~Local anaesthetic infiltration speed 1ml/min. After injection the needle is withdrawn and vibration continues for another 5 s.~Drug: Local anaesthetic - Ubistesin - 4% Articaine with adrenaline 1: 200 000 1.7 mL"
94809|NCT03445169|Drug|PT2977|PT2977 Tablets
94810|NCT03445156|Behavioral|Video game|Participants played either a violent shooting game or nonviolent shooting game in the pilot study, and either either a violent shooting game, nonviolent shooting game, or nonviolent non-shooting game in the experiment proper.
94811|NCT03445156|Behavioral|Controller|Participants used either a gun-shaped or regular controller to play the violent and nonviolent shooting video games.
94925|NCT03444272|Drug|Sofosbuvir and Daklatasuvir|HCV Treatment (Sofosbuvir and Daklatasuvir)
94812|NCT03445130|Other|Lavandula Angustifolia oil (LO)|two drops on the inside of an oxygen face mask for 15 minutes.
94813|NCT03445130|Other|Michelia Alba Leaf oil (MA)|two drops on the inside of an oxygen face mask for 15 minutes.
94814|NCT03445130|Other|Almond oil (AO)|two drops on the inside of an oxygen face mask for 15 minutes.
94815|NCT03445130|Other|Water|two drops on the inside of an oxygen face mask for 15 minutes.
94816|NCT03445117|Other|Educational intervention|a) The educational intervention comprises putting up posters on vaccination in the clinic, as well as provision of a specially designed flyer to the clinic, which will be handed out by the clinic assistants to all patients 65 years and above, at the point of registration. The poster and flyer content will provide simple messaging to encourage patients to receive influenza and pneumococcal vaccinations and inform them of available healthcare subsidies. b) Reminders to physicians: The flyers will also serve as physical prompts to physicians to encourage vaccination for their patients. Doctors and clinic staff will also be updated on the study protocol and the recommended adult vaccination schedule before commencement of the study.
94817|NCT03445104|Other|Huperzine A|During one of the two experimental sessions, participants will be given huperzine A.
94818|NCT03445104|Other|Placebo|During one of the two experimental sessions, participants will be given a placebo.
94819|NCT03445091|Device|SANKOM Patent Socks|Using compression socks to ease symptoms of patients with chronic venous insufficiency
94820|NCT03445078|Dietary Supplement|selenium supplementation|administration of selenium-rich corn powder 20g/d offering selenium 100μg/d
94821|NCT03445078|Dietary Supplement|ordinary corn powder|ordinary corn powder,20g/d(selenium contain <0.5ug/20g).
94822|NCT03445065|Device|Eversense XL|Implantable continuous glucose monitoring (CGM) sensor inserted under the skin.
94823|NCT03445065|Device|Usual SMBG or FGM device used by participants|Commercially available products for self-monitoring of blood glucose (SMBG) or flash glucose monitoring (FGM)
94824|NCT03445052|Behavioral|XPAND|The intervention is personalised to the psychosocial factors influencing poor photoprotection for each person. These factors could include beliefs that reduce motivation to protect as well as factors that prevent intentions being translated into action. The facilitator will use behaviour change techniques to target the factor most important for each person. Standardised content related to habit formation will be received. The intervention will be delivered via 7 1:1 sessions with a facilitator (psychologists or clinical nurse specialist). Sessions 1 (1.5 hours maximum) and 6 (45 minutes) will be delivered face to face in the home of the participant and the remaining sessions will be conducted via telephone calls or skype sessions.
94825|NCT03445039|Device|traditional TSFE|The TSFE procedure is performed by osteotomes (Straumann AG, Basel, Switzland) and mallet as the traditional ways.
94826|NCT03445039|Procedure|bone grafting materials|The bone substitute is placed into the siuns under the membrane before the implant placement
94827|NCT03445039|Device|TSFE by DASK drills|The TSFE procedure is performed by DASK(Dentium Advanced Surgical Kits) drills (Dentium, Korea), the residual cortical plate of the sinus floor is grinded by the drills.
94828|NCT03445039|Procedure|without bone grafting materials|The bone substitute will not be placed into the sinus before the implant placement.
94829|NCT03445026|Diagnostic Test|dental panorama|radiographic examination
94830|NCT03445013|Drug|SB414 6%|Twice daily
94831|NCT03445013|Drug|Vehicle|Vehicle Comparator
94832|NCT03445000|Drug|Alectinib|"Alectinib is administered orally 600mg (4x150mg capsules), twice per day (8 capsules, total 1200mg daily). The appropriate number of alectinib capsules will be provided to patients to be self-administered at home.~Alectinib capsules must be taken at the same time each day with food. If a planned dose of alectinib is missed, patients can take the missed dose up until 6 hours before the next dose."
94833|NCT03444987|Genetic|Measurement of protein expression in tissue and /or blood samples.|"The followings markers will be estimated in tissue, and/ or blood samples:~Fibroblast activation protein (FAP) will be measured by quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level).~Circulating (cFAP) will be measured using ELISA in blood of UF patients and healthy controls.~Autophagy markers level (LC3 and p62) will be measured by qRTPCR (mRNA level) and by immunohistochemical analysis in both UF tissue samples and normal myometrial tissues.~Phosphorylated protein kinase B (pAKT) level will be measured by western blot analysis."
94834|NCT03444974|Other|adapted treatment according to the MATRIX-A therapy|cognitive and behavioral treatment of drug abuse/dependency issues, as well as connected parameters
94835|NCT03444961|Device|CAREN system training|CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
94836|NCT03444948|Device|EUS-RFA using Habib Tm as a probe|3 course of EUS-RFA
94837|NCT03444948|Drug|Standard therapy|Standard therapy
94838|NCT03444935|Behavioral|Follow-up phone call|Please see arm/group description.
94839|NCT03444922|Other|Placebo|Ingestion of Placebo
94840|NCT03444922|Other|BPA 4 ug/kg BW|Oral BPA ingestion of 4 ug/kg BW
94841|NCT03444922|Other|BPA 50 ug/kg BW|Oral BPA ingestion of 50 ug/kg BW
94842|NCT03444909|Device|cardiotocograph|Monitoring of 20 min with the cardiotocograph
94843|NCT03444909|Device|Toconaute|Monitoring of 20 min withToconaute
94844|NCT03444909|Device|electrophysiological device (Micromed)|Monitoring of 20 min with the cardiotocograph
94845|NCT03444896|Device|Acupuncture group|Acupuncture needles were placed at acupoints Baihui (DU20), Shenting (DU24), Fengfu (DU16), Fengchi (GB20), Danzhong (RN17), Zhongwan (RN12), Qihai (RN6), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Xinshu (BL15), Yixi (BL45), Tongli (HT5), and Zhaohai(KI6). Electrodes were attached the needle holders of the Baihui (DU20) and Shenting (DU24). The acupuncture needles are inserted through the adhesive pads and are retained for 20 minutes in every course. Treatment will be conducted over a period of 3 months, at a frequency of two times per week.
94884|NCT03444558|Dietary Supplement|Natural supplement containing chlorogenic acid and luteolin|50 eligible subjects will receive natural supplement as the oral pills at a fixed dose of 1 pill/day (450 mg/day) for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
94922|NCT03444298|Drug|Placebo|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
94923|NCT03444285|Other|Warm Up|Run on a treadmill during 10 minutes without fatigue of the participant after this time.
94846|NCT03444896|Device|Sham acupuncture group|Sham acupoint (SA) 1 located in the midpoint of Shuaigu and Touwei. SA2 located in the midpoint of Touwei and Yangbai. SA3 located in the midpoint of Tianyou and Tianrong. SA4 located in 4 cun above umbilicus and 1 cun right of umbilical midline (UM). SA5 located in 2 cun below umbilicus and 1 cun right of UM. SA6 1 cun outside the point 1/4 of the line between Shenmen and Shaohai. SA7 located in 1 cun outside the midpoint of Shaohai and Tongli. SA8 located in 6 cun above mediosuperior border of the patella. SA9 located in 3 cun below the Yanglingquan and middle of the gallbladder and bladder channels. SA10 located in midpoint between Jiexi and Qiuxu. SA11 and SA12 located in 2 cun from the lower border of spinous process of fifth or sixth thoracic vertebra. Electrodes were attached the needle holders of the bilateral SA 2. Procedures, and other treatment settings were the same in the acupuncture group but with no skin penetration, electricity output, or needle manipulation for de qi.
94847|NCT03444883|Drug|Ilaprazole|10mgx2 tablet once daily for weeks
94848|NCT03444870|Drug|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
94849|NCT03444870|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
94850|NCT03444857|Device|Continuous positive airway pressure|The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
94851|NCT03444844|Drug|Ga-68 P16-093 PET/CT scan|IV injection followed by PET/CT scanning
94852|NCT03444831|Drug|Buspirone|Buspirone 5mg used QID a day after meal plus 20mg omeprazole before breakfast.
94853|NCT03444831|Drug|Placebo Oral Tablet|Buspirone placebo QID after meal plus 20mg omeprazole before breakfast.
94854|NCT03444818|Drug|[14C]-E6007|Oral administration
94855|NCT03444805|Procedure|Autologous HSCT|1st AHSCT
94856|NCT03444792|Procedure|mechanical dilatation of the cervix|"the surgeon will perform the cervical dilatation by inserting the double-gloved index ﬁnger into the cervical canal of the patients after the extraction of placenta and membranes. The outer glove will be removed after this procedure.~- If failed the surgeon will use artery forceps to dilate cervix"
94857|NCT03444779|Device|Tibial Tuberoplasty|Kyphoplasty ballon
94858|NCT03444779|Device|Open technique|Cutaneous incision with submeniscal arthrotomy under guidance of a fluoroscope.
94859|NCT03444766|Drug|Nivolumab|specified dose on specified days
94860|NCT03444753|Drug|BMS-986299|Specified dose on specified day
94861|NCT03444753|Biological|Nivolumab|Specified dose on specified day
94862|NCT03444753|Biological|Ipilimumab|Specified dose on specified day
94863|NCT03444740|Other|ICIQ-FLUTS, ADMN-20|Questionnaire
94864|NCT03444727|Other|Ice Pre-treatment|Topical application of ice prior to local anesthetic injection.
94865|NCT03444727|Other|Room Temperature Water Pre-treatment|Topical application of room-temperature water prior to local anesthetic injection.
94866|NCT03444714|Drug|RiMO-301|"Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection~Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks"
94867|NCT03444701|Drug|E7130|Starting dose of 25 μg/m^2 on Day 1 and Day 15 of Cycle 1
94868|NCT03444688|Other|Conventional Gait Training|Subjects allocated to the CT group will first perform active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. They will then perform conventional gait and balance therapy based on the proprioceptive neuromuscular facilitation (PNF) concept for 15 minutes. They will be given a 5 minutes rest. Finally, the CT subjects will undergo the over-ground gait training with or without aid or orthoses and with manual assistance from senior physiotherapist for 15 minutes, depending on the individual subject's abilities.
94869|NCT03444688|Device|Gait rehabilitation with walker|For WT group, subjects will first go through active assisted or passive range of motion of the lower limbs including ankle, knee, and hip joint in the supine position for 10 minutes. The main therapy consists of 2 parts with 5 minutes rest in between. During part 1, subjects will be trained on the robotic walker with the help of active body weight support (BWS) and functional electrical stimulation (FES) for 15 minutes with pelvic motion support function and lateral balance function being continuously provided. During part 2, subjects will also receive resistance/assistance forces on top of the BWS and FES training for 15 minutes.
94870|NCT03444662|Dietary Supplement|Placebo supplement|Cellulose and Sunflower oil
94871|NCT03444662|Dietary Supplement|Citicoline and Omega-3 supplement|Citicoline and Omega-3
94872|NCT03444662|Dietary Supplement|Omega-3 supplement|Cellulose and Omega-3
94873|NCT03444649|Drug|Epacadostat|Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
94874|NCT03444649|Drug|Idarubicin|Standard chemotherapy d1-d3 cycle 1
94875|NCT03444649|Drug|Cytarabine|Standard chemotherapy d1-d7 cycle 1 and 2
94876|NCT03444649|Drug|Daunorubicin|Standard chemotherapy d1-3 cycle 2
94877|NCT03444636|Drug|Ropivacaine/Fentanyl|Ropivacaine 0.2% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
94878|NCT03444636|Drug|Bupivacaine/Fentanyl|Bupivacaine 0.125% with Fentanyl 5 µg/ml; flow rate of 0.1 ml/kg/hr
94879|NCT03444610|Biological|Blood transfusion escalation rate|3+3 dose escalation (3 patients/cohort) each started on a fixed rate (standard is 5 ml/kg/ hr).1st cohort start at 6ml/kg/hr till complete prescribed volume. Rate escalation by 1ml/kg/each cohort until dose limiting toxicities (DLTs) or max of 10ml/kg/hr. If no DLTs new cohort enrolled at the next planned rate. If DLTs seen in 1 patient in the cohort, another 3 patients treated with the same dose level.1ry phase I end point is maximum-tolerated rate (MTR) of blood transfusion that can be infused safely ( max rate at which 1 or fewer of 3 patients experienced DLT) or dose of 10ml/kg/hr. DLT is transfusion related adverse event lead to stop of transfusion. MTR is highest dose at which no more than 1of 6 patients experienced a DLT.15 additional patients enrolled at MTR to confirm safety.
94880|NCT03444584|Biological|MEDI0382|Solution for injection
94881|NCT03444584|Biological|Placebo|Solution for Injection
94882|NCT03444584|Drug|Dapaglifozin|10 mg Tablet
94883|NCT03444571|Procedure|revision surgery|If DNA based diagnosis detects infection, standard revision surgery will be conducted
94921|NCT03444298|Drug|Gamma Tocopherol|Each dose consists of two (700 mg) capsules by mouth once daily for a total of 7 days.
94885|NCT03444558|Other|Placebo (without any active ingredients)|50 eligible subjects will receive placebo (without any active ingredients) at a fixed dose of 1 pill/day for 6 months, as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study.
94886|NCT03444545|Device|Capnodynamic method|"Expired carbon dioxide is measured with a mainstream infrared sensor (Capnostat-3, Respironics Inc, Wallingford, CT, USA) and gas flow analysed with the flow sensor incorporated in the ventilator (Servo-i, Maquet Critical Care, Solna, Sweden) which was connected to a computer where all the mathematical analysis is carried out with a software written in Matlab™ (The Mathworks Inc, Natick, MA, USA).~Instead of a fixed ratio between inspiration and expiration, three breaths out of every nine are prolonged with a 3-4 seconds longer expiration creating small changes in end- expiratory CO2"
94887|NCT03444545|Device|Transpulmonary thermodilution|Each cardiac output measurement comprises an average of three thermodilutions performed successively one after another. TPTD is performed with a PiCCO2 monitor (Pulsion Medical Systems SE, Feldkirchen, Germany)
94888|NCT03444532|Behavioral|12-week aerobic exercise and cognitive-behavioral therapy|12-week intervention of aerobic exercise training and four session of cognitive-behavioral therapy
94889|NCT03444519|Drug|Mannitol|This drug is in our routine use of neuroanesthesia, are given for facilitate brain relaxation
94890|NCT03444506|Drug|Molo 1 (also referred as GSP 301-2 NS)|
94891|NCT03444506|Drug|Molo 2 (also referred as GSP 301-1 NS)|
94892|NCT03444506|Drug|Placebo nasal spray|
94893|NCT03444506|Drug|DYMISTA nasal spray|
94894|NCT03444506|Drug|PATANASE nasal spray|
94895|NCT03444493|Other|Exercise|Exercises were basically performed in 3 phases in this study. In the first phase; effectively and correctly contraction of TrA and multifidus muscles and how the patients adapted to daily life activities was taught. In the second phase; was aimed that the protection of stabilization by counteracting more muscle activation, in the third phase neutral position along with the activities required high level control.
94896|NCT03444480|Drug|Remimazolam Tosylate|Initial dose plus supplemental doses
94897|NCT03444467|Drug|NNC9204-1513|"Participants will receive NNC9204-1513 subcutaneous (s.c., in to a skin fold on the stomach) injection as single increasing doses of 0.01 mg, 0.04 mg, 0.10 mg, 0.25 mg, 0.50 mg, 1.0 mg or 2.0 mg. Each participant will only be given one dose.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group."
94898|NCT03444467|Drug|Glucagon|Participants will receive single dose of 1 mg glucagon s.c. injection.
94899|NCT03444467|Drug|Placebo|Participants will receive single dose of placebo (for double dummy injections).
94900|NCT03444454|Behavioral|VRRS Khymeia|"Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes.~Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions."
94901|NCT03444454|Behavioral|Usual care program|The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
94902|NCT03444441|Procedure|Foot or ankle surgery|Surgery for foot or ankle
94903|NCT03444428|Other|Non Invasive Ventilation|Assessments for those participants who are being set up onto NIV
94904|NCT03444428|Other|Without Non Invasive Ventilation|Assessments for those participants who are not being set up onto NIV
94905|NCT03444415|Other|Motivational interviewing in groups|Intervention consists of six 90 minutes workshops, two of those during pregnancy and the other four within the following two years after the birth of the children.
94906|NCT03444415|Other|Usual care|Parents will receive information about height, weight, and BMI percentile provided by a health professional during usual well child visits
94907|NCT03444402|Drug|CKD-381(formulation I)|1 tablet administered before the breakfast during 7 days
94908|NCT03444402|Drug|CKD-381(formulation II)|1 tablet administered before the breakfast during 7 days
94909|NCT03444402|Drug|D026(Nexium 40mg)|1 tablet administered before the breakfast during 7 days
94910|NCT03444376|Drug|GX-188E|GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using Ichor TDS-IM device
94911|NCT03444376|Drug|Keytruda|pembrolizumab(100mg/4mL/vial), Intravenous administration
94912|NCT03444363|Device|Laser group|Laser application in addition to SRP
94913|NCT03444363|Device|Control group|Placebo laser application in addition to SRP
94914|NCT03444350|Device|Gaseous ozone|SRP plus gaseous ozone
94915|NCT03444350|Device|SRP plus placebo|only SRP
94916|NCT03444337|Device|Catheter Ablation|
94917|NCT03444324|Biological|BT524|BT524 is administered intravenously, patient specific dosage calculated based on body weight and fibrinogen level.
94918|NCT03444324|Biological|FFP|FFP is administered intravenously; dosage according to local standards in mL per kg body weight.
94919|NCT03444311|Dietary Supplement|A: 1 dosis|"1 dosis (3E+09 cfu/d + 6 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
94920|NCT03444311|Dietary Supplement|B: 2 dosis|"1 dosis (3E+09 cfu/d + 12 g of fiber) Two different combinations of fibers (formula A and B) will be tested with the following administration pattern for both groups.~Week 1: Formula A Week 2: Formula A Week 3: Formula B Week 4: Formula B~Composition of an envelope of formula A:~Formula A Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1.75 Inulin of low degree of polymerization 1,5 Polydextrose 1 Guar gum partially hydrolyzed 0,5 TOTAL 6~Composition of an envelope of formula B:~Formula B Composition (g) Pectin 1 B-glucan oatmeal 0.25 High-grade polymerization inulin 1 Inulin of low degree of polymerization 0.75 Polydextrose 2.5 Guar gum partially hydrolyzed 0,5 TOTAL 6"
94927|NCT03444246|Dietary Supplement|Iodine free diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
94928|NCT03444246|Dietary Supplement|Normal iodine diet group|120 patients with hyperthyroidism relapsed after new diagnosis or treatment were enrolled. They were randomly divided into iodine free diet group and normal iodine diet group. The two groups were treated with routine antithyroid drugs, followed up for 6 months.
94929|NCT03444233|Other|Diet|7 days fruit-rich diet, 7 days HFCS-rich diet
94930|NCT03444220|Biological|Anaerobically Cultivated Human Intestinal Microbiota|30ml ACHIM will be administrated at week 0 and 2 with 14 days apart
94931|NCT03444220|Biological|Anaerobically Cultivated medium|30ml medium will be administrated at week 0 and 2 with 14 days apart
94932|NCT03444207|Behavioral|Endurance training|The women in group A underwent endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA). Exercise sessions consisted of a five-minute warm-up (stretching exercise) at low intensity (50%-60% of maximum heart rate), a 45-minute exercise (at 50%-80% of maximum heart rate), five minutes of cycling without a load, and five minutes of closing stretching and breathing exercise of low intensity.
94933|NCT03444207|Behavioral|Endurance-strength training|Group B performed endurance-strength exercise consisting of a five-minute warm-up (stretching exercises) of low intensity (50%-60% of maximum heart rate), a strength component, an endurance component, 5 minutes cycling without a load, and a 5 minutes closing stretching and breathing exercise of low intensity. The 20-minute-long strength component was performed using a neck barbell and a gymnastic ball. Directly after the strength exercise, the women took part in a 25-minute endurance exercise on cycle ergometers (Schwinn Evolution, Schwinn Bicycle Company, Boulder, Colorado, USA) at 50%-80% of maximum heart rate.
94934|NCT03444194|Procedure|liver biopsy|Liver biopsy of neoplastic tissue and normal liver tissue.
94935|NCT03444181|Behavioral|Music lessons|Also described as neurocognitive music therapy. Singing lessons will be provided once a week for a period of 12 months by a person with a qualification in music therapy, or by a person with a different relevant qualification (e.g. psychology and music teaching) under the supervision of a music therapist. Additionally, participants will have the opportunity to meet regularly (1-2 times per month) as a choir to sing the song they have learned together in a group.
94936|NCT03444181|Behavioral|Training intervention|Cognitive training that is comparable in scope and extent to the music lessons, but not using music. Group training sessions will be provided once a week for a period of 12 months by a person with a qualification in physiotherapy or occupational therapy. Group activities may include group tours such as mountain hikes and the like (about 2 times per month) and will follow an established program for the elderly.
94937|NCT03444155|Dietary Supplement|Panmol-B-Complex|B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
94938|NCT03444155|Dietary Supplement|Synthetic Vitamin B-Complex|B1 (2,77mg), B2 (3,53mg), B3 (40,32mg), B5 (15,12mg), B6 (3,53mg), B7 (0,13mg), B9 (0,50mg), B12 (6,3µg) daily for 6 weeks.
94939|NCT03444142|Drug|Exenatide LAR|2 mg, once weekly subcutaneously before breakfast during 4 weeks.
94940|NCT03444142|Drug|Dulaglutide|.75 mg once weekly subcutaneously before breakfast during 4 weeks.
94941|NCT03444129|Behavioral|Healthy eating workshop and interactive health game|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop and interactive health game. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
94942|NCT03444129|Behavioral|Healthy eating workshop|The intervention sessions will be weekly for 6 weeks and will involve participation in health education workshop. Sessions may last up to 2 hours and will be held at designated times/days at a Chicago Church.
94943|NCT03444116|Diagnostic Test|Motion Analysis|Gait and Motion Analysis, comprised of 3-dimensional kinematics and kinetics, electromyography, energy expenditure, and physical exam (range of motion, strength, spasticity, etc.)
94944|NCT03444116|Diagnostic Test|sterEOS Imaging of Lower Extremities|Bi-planar imaging of the lower extremities to evaluate femoral anteversion and hip dysplasia and subluxation.
94945|NCT03444116|Behavioral|Surveys|9 surveys assessing function, activity, participation, pain, quality of life, and treatment history.
94946|NCT03444103|Drug|Clazakizumab / Clazakizumab|Humanized monoclonal anti-IL-6 antibody
94947|NCT03444103|Drug|Placebo / Clazakizumab|0.9% Saline
94948|NCT03444090|Procedure|Colon polypectomy|"For participants assigned into the experimental group, colon lumen is washed and the debris is suctioned as the colonoscopy is slowly inserted from rectum to cecum. Deliberate and systematic inspection of the mucosa is performed with adequate insufflation during both the insertion and withdrawal phases. Colon polyps with size <10 mm are removed as they are identified on insertion and withdrawal. Polyps with size >10 mm are removed only during withdrawal.~For participants assigned into the control group, deliberate inspection and polyp removal are performed exclusively on colonoscopy withdrawal.During insertion, minimal mucosal inspection and insufflation are applied to efficiently advance the instrument into cecum."
94949|NCT03444077|Diagnostic Test|Use of the Trauma Induced Coagulopathy Clinical Score (TICCS) as a diagnostic tool.|The TICCS will be calculated on the site of injury for the patients taken in charge in the intervention group. Those patients will be classified in two categories regarding their TICCS value. Patients with TICCS ≥ 10 will be classified as in need for DCR; while patients with TICCS < 10 will be classified as not in need for DCR.
94950|NCT03444077|Diagnostic Test|Regular care|Patients from the control group will be evaluated by clinicians using the local usual clinical Tools.
94951|NCT03444077|Other|STTTOPPP the bleeding|"Surgical team pre-activation~Trauma team pre-activation~Transfusion team pre-activation~Tranexamic acid (administration of 1 gram of TXA if documented hyperfibrinolysis)~O negative RBC transfusion as soon as possible~Plasma and Platelets transfusion as soon as possible~Permissive hypotension (restrictive use of crystalloids: no more than 500 milliliters before definitive control of the bleeding is achieved)~Prophylaxis (initiate antithrombotic prophylaxis as soon as the bleeding is under control and coagulation tests are normal, first evaluation before the 24th hour after trauma)"
94952|NCT03444077|Other|Regular Care|Regular local pre-hospital care.
94993|NCT03443778|Drug|Bupivacaine 0.5% , Dexamethasone|Bupivacaine 0.5% , Dexamethasone
94953|NCT03444064|Biological|PolyTregs|Treatment group receive PolyTregs 6 weeks after islet transplantation as immunotherapy to improve islet survival and reduce the need for immunosuppression drugs.
94954|NCT03444051|Procedure|EUS-FNB with 20-gauge Procore® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 20-gauge Procore® needle
94955|NCT03444051|Procedure|EUS-FNB with 22-gauge Acquire® needle|Puncture of a pancreatic or peripancreatic mass under Endoscopic Ultrasonography, with a 22-gauge Acquire®
94956|NCT03444038|Drug|NBI-98854|vesicular monoamine transporter 2 (VMAT2) inhibitor
94957|NCT03444025|Drug|Goserelin|Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
94958|NCT03444012|Drug|ticagrelor 90 mg|persistence and adherence on ticagrelor in ACS patients
94959|NCT03443999|Device|Supraflex Sirolimus-eluting Coronary Stent System|Patient implanted with at least one Supraflex sirolimus-eluting stent as a part of planned clinical care
94960|NCT03443986|Other|Resistance training associated with vibration|The workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration and 5 minutes of slowdown.
94961|NCT03443986|Other|Resistance training associated with vibration sham|"he workout will be held three times a week and will last a total of 12 weeks (3 months) for 45 minutes, where there will be 5 minutes of heating, 19 minutes of exercise with load, 16 minutes of vibration sham and 5 minutes of slowdown."
94962|NCT03443973|Drug|Gantenerumab|Gantenerumab will be administered as per the schedule specified in the respective arm.
94963|NCT03443973|Drug|Placebo|Placebo matching to gantenerumab will be administered as per the schedule specified in the respective arm.
94964|NCT03443960|Drug|TNX-102 SL 5.6 mg|Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
94965|NCT03443960|Drug|Amrix 30 mg|Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
94966|NCT03443947|Device|Tongue depressor group|using a tongue depressor to assess airway score without tongue protrusion
94967|NCT03443947|Procedure|control group|airway assessment after tongue protrusion
94968|NCT03443921|Procedure|Artery Divestment Technique|Tunica adventitia was pick up by forceps and opened by electrocoagulation at 1 cm distal from tumor-artery contact. Space between tunica adventitia and external elastic lamina (EEL) were blunt lifting tumor-invaded adventitia by angled clamp. Adventitia was then sectioned to show EEL. Loose dissect space could be achieve along long the plane between EEL and adventitia as long as tumor invasion outside EEL. Tumor and invaded adventitia were further cut open by electrocoagulation proximally. Circumferentially, separation could be done by blunt dissection around EEL. Nourishing blood vessels of the artery would be secured by electrocoagulation or ultrasonic scalpel while major branch would be ligated or transfixed.
94969|NCT03443921|Drug|Nab-paclitaxel|After eligibility testing as blood tests, contrast-enhanced CT and MRI scan, 3 cycles were administered (1,000 mg/m2 of gemcitabine and 125 mg/m2 of nab-paclitaxel on days 1, 8, and 15 every 28 days).Patients will be reevaluated and curative operation would be attempted if without disease progression.
94970|NCT03443908|Device|CPAP|CPAP therapy 3-4 weeks
94971|NCT03443895|Drug|AEF0117 oral capsule|0.6, 2 and 6mg of AEF0117
94972|NCT03443895|Drug|Placebo oral capsule|Matching placebo capsule
94973|NCT03443882|Dietary Supplement|Astaxanthin|an oral dose form
94974|NCT03443869|Drug|Letermovir|LET 480mg (or 240 mg when co-administered with cyclosporin A) once daily for 28 weeks
94975|NCT03443869|Drug|Valganciclovir|900 mg VGCV tablet orally, once daily for 28 weeks
94976|NCT03443869|Drug|Acyclovir (ACV)|400 mg over-encapsulated ACV tablet orally, every 12 hours for 28 weeks
94977|NCT03443869|Drug|Placebo to ACV|Over-encapsulated placebo tablet orally, every 12 hours for 28 weeks
94978|NCT03443869|Drug|Placebo to LET|Placebo to LET tablet orally, once daily for 28 weeks
94979|NCT03443869|Drug|Placebo to VGCV|Placebo to VGCV tablet orally, once daily for 28 weeks
94980|NCT03443856|Drug|Nivolumab and Ipilimumab|Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year
94981|NCT03443856|Other|chemotherapy|Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
94982|NCT03443843|Drug|loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D)|Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
94983|NCT03443843|Drug|Placebo tablet|Placebo tablet orally
94984|NCT03443843|Drug|Fluticasone Propionate|Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
94985|NCT03443843|Drug|Placebo spray|Placebo Nasal Spray, 2 sprays per nostril
94986|NCT03443830|Drug|Tyzivumab|Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb) Infused over 30 minutes
94987|NCT03443817|Behavioral|Tele rehab|"Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time."
94988|NCT03443804|Drug|Test(DW1401)|DW1401+Placebo of Stillen tab.
94989|NCT03443804|Drug|Reference(Stillen tab.)|Stillen tab.+Placebo of DW1401
94990|NCT03443791|Diagnostic Test|Women Enrolled|Diagnostic Testing will be performed. Results of individual test results will determine the degree of intervention offered.
94991|NCT03443791|Diagnostic Test|Newborns of Female Study Participants|Newborns will be tested after birth as soon as possible for CMV positivity.
94992|NCT03443778|Drug|Bupivacaine 0.5%|Marcaine 0.5% Injectable Solution
94995|NCT03443765|Diagnostic Test|Detection of Plasma levels of 25(OH) vitamin D by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at −20°C maximum of 30 days. Plasma levels of 25(OH) vitamin D will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
94996|NCT03443765|Diagnostic Test|Detection of Total serum immunoglobulin E by ELISA technique|Five milliliters of peripheral venous blood sample will be taken (after 8-12 hours of fasting) from each participant and will be collected into HumaTube Serum Gel - C/A for ELISA. Serum will be appropriately obtained and stored at −20°C maximum of 30 days. Total serum immunoglobulin E will be detected by enzyme-linked immunosorbent assay (ELISA) technique.
94997|NCT03443752|Other|Shotokan-Karate|The Shotokan-Karate training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
94998|NCT03443752|Other|Tai-Chi|The Tai-Chi training program will be ran over a period of 12 weeks. Classes will be conducted 3 times per week at the Movement Disorders Rehabilitation Centre in Waterloo, Ontario. The program will be conducted by a trained professional (principal investigator), and there will be volunteers who ensure the safety and well-being of participants.
94999|NCT03443739|Other|Intermittent Fasting|Intermittent Fasting with abstinence from food and drink daily from sunrise to sunset for nineteen consecutive days in March 2018
95000|NCT03443726|Procedure|Nerve block technique|Inferior alveolar nerve block with 1.8 cc of 4% articaine 1:100.000 epinephrine and 1.8 cc of the same anesthetic for the buccal nerve for third molar extraction.
95001|NCT03443726|Procedure|Infiltrative technique|Infiltrative anesthesia buccally between first and second mandibular molar with 3.6 cc of 4% articaine 1:100.000 epinephrine and 0.6 cc lingually to the third molar using the same anesthetic solution.
95002|NCT03443726|Drug|4% articaine 1:100.000 epinephrine|Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
95003|NCT03443726|Procedure|Third molar extraction|Third molar extraction under local anesthesia.
95004|NCT03443713|Device|Dexcom G6 CGM|Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
95005|NCT03443700|Device|EKSO-GT|Each rehabilitation session with EKSO-GT will last (operating time) 30-40 minutes. Such training will be carried out for 3 sessions per week, during the first 4 consecutive weeks of the study period (i.e. 12 total sessions per patient).
95006|NCT03443700|Procedure|Standard neurorehabilitation locomotor training|Neurorehabilitation locomotor training will be performed according to standardized protocols shared within the scientific community, during the whole 8-week study period, 5 times per week, twice a day, for a total of about 2,5 hours per day.
95007|NCT03443687|Behavioral|Pelvic Floor Physical Therapy|Pelvic floor exercises for 3 months under instruction of physical therapist
95008|NCT03443687|Device|Home Biofeedback|Pelvic floor exercises for 3 months using biofeedback device
95009|NCT03443674|Drug|SCB-313|3 intraperitoneal injections of SCB-313 on Days 1, 2 and 3
95010|NCT03443661|Drug|FOLFOXIRI|oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals
95011|NCT03443648|Procedure|External fixator assisted plaing|The plate length is marked on the skin. Limb reconstruction system (LRS) with one swivel clamp or Taylor Spatial frame (TSF) is used in all cases. The fixator is put in a plane parallel to that of the deformity. Two tapered pins are placed on either side of the planned osteotomy site and passed at a distance from the osteotomy so that they will not impede the subsequent internal fixation. Swivel clamps or the struts of the TSF are aligned in such a way that full correction is achieved. After osteotomy, swivel clamp is loosened and angular correction is achieved. Translation is carried out according to preoperative planning. If readjustment is required the swivel clamps or TSF struts are loosened and further correction is carried out. Once desired correction is achieved, the clamps or struts are tightened. Definitive internal fixation is carried out while external fixation holds the fragments. For internal fixation, locked T plate will be used.
95012|NCT03443635|Behavioral|Treatment|The intervention educates subjects through the hands-on cooking and nutrition education classes how to buy, cook, store, and consume healthy foods as an adjunct to healthy activity levels and avoidance of such health risks factors as smoking, excessive alcohol intake, and drug use.
95013|NCT03443622|Drug|SC-43 Oral Solution|SC-43 Oral Solution has drug substance of 1-[4-chloro-3(trifluoromethyl)phenyl-3-[3-(4-cyanophenoxy)] urea, or SC-43. SC-43 inhibits tumor growth through the activation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and the repression of p-STAT3 signalings. As a result of STAT3 inhibition by SC-43 treatment, decreased cell viability and enhanced apoptosis have been observed in cancer cells. The anti-tumor activity of SC-43 was also investigated in a variety of xenograft tumor models. Administration of SC-43 provides the tumor-bearing animals survival benefits, including the reduction of tumor volume and prolonged lifespan. SC-43 has been proposed to be evaluated as an anticancer therapeutic in in subjects with refractory solid tumors in the phase I trial.
95014|NCT03443609|Diagnostic Test|68Ga-HBED-CC-PSMA PET / CT|Patient will receive a specific PET / CT with PSMA
95015|NCT03443596|Biological|Early intensive BP control|Participants in the early intensive BP control arm are treated with BP lowering medications, with an aim to bring the systolic BP to 140-160mmHg and maintain this level for 72 hours post-ictus
95016|NCT03443583|Other|Immediate Dentin Sealing or Delayed Dentin Sealing|The main difference between the IDS and DDS technique lies in the fact that in IDS, a thin layer of bonding resin is applied immediately after tooth preparation and prior to impression taking, whereas in DDS this layer is applied immediately before cementation of the restoration.
95017|NCT03443570|Drug|Rituximab|given with a fixed dose of 500 mg administered as an intravenous infusion every two weeks, for 2 times totally
95018|NCT03443570|Drug|Bortezomib|given subcutaneous injection at a fixed dose of 2.0 mg weekly, for 4 times totally
95019|NCT03443557|Other|oral nutrition supplement|receiving prescription of oral nutrition supplement during hospitalization
95020|NCT03443544|Procedure|Aggressive debridement|Aggressive debridement of the tissues undergoing fascitis
95116|NCT03442751|Drug|Paracel Placebo|Two drops of Paracel Placebo every 60 seconds for 4 minutes followed by two drops every 30 seconds for 6 minutes
95021|NCT03443531|Drug|Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
95022|NCT03443531|Drug|Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
95023|NCT03443531|Drug|Placebo Bufei Huatan granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of qi deficiency of lung and phlegm-turbidity obstructing the lung will be given placebo Bufei Huatan granule, twice daily for 24 weeks for lower dosage.
95024|NCT03443531|Drug|Placebo Yifei Qinghua granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of Qi and Yin deficiency of the lung and the phlegm-heat obstructing the lung will be given placebo Yifei Qinghua granule, twice daily for 24 weeks for lower dosage.
95025|NCT03443518|Procedure|Psoas Compartment Block (PCB)|30 ml of bupivacaine 0.25% will be infused over 3 minutes at the anatomical landmark for Psoas Compartment Block (PCB)
95026|NCT03443518|Procedure|Local Anesthesia infiltration|Lidocaine 5 ml of 2% will be injected subcutaneous as local infiltration.
95027|NCT03443518|Drug|Normal saline 0.9% IV infusion|Normal saline 0.9% IV infusion at the same rate of the Remifentanil infusion(0.05-0.1 μg/ kg/min).
95028|NCT03443518|Drug|Remifentanil infusion|Remifentanil infusion with rate 0.03-0.1 μg/ kg/ min to achieve Visual Analog Scale (VAS) 3 or less
95029|NCT03443505|Diagnostic Test|Neural respiratory drive measurement|"Neural respiratory drive (NRD) has been validated as an objective physiological biomarker in acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Change in NRD during hospital admission has been demonstrated to be a marker of physician-defined clinical deterioration. NRD is a non-invasive measurement that involves skin preparation with a gel and alcohol wipe before placing 3 surface electrodes on the chest wall and collar bone to perform electromyography (EMG) of parasternal muscles. Electrodes are connected to an automated EMG analysis system to derive a measurement of NRD. Measurements take approximately 10 minutes with subject being monitored during normal (tidal) breathing and performing maximal sniff manoeuvres."
95030|NCT03443492|Drug|S-1|Intervention is administered to patients in this Arm.
95031|NCT03443492|Drug|Leucovorin(oral )|Intervention is administered to patients in this Arm.
95032|NCT03443492|Drug|Gemcitabine|Intervention is administered to patients in this Arm.
95033|NCT03443492|Drug|Oxaliplatin|Intervention is administered to patients in this Arm.
95034|NCT03443492|Drug|Irinotecan|Intervention is administered to patients in this Arm.
95035|NCT03443492|Drug|5-FU|Intervention is administered to patients in this Arm.
95036|NCT03443492|Drug|Leucovorin(IV)|Intervention is administered to patients in this Arm.
95037|NCT03443479|Device|Non-Invasive Ventilation|Treatment with Non-Invasive Ventilation by BiPAP. Different BiPAP models are in use. Ventilation parameters set at the discretion of the treating physician.
95038|NCT03443479|Device|High-Flow Nasal Cannula|Treatment with a High-Flow Nasal Cannula. The Optiflow device by Fisher&Paykel used in all cases. Flow and fraction of inspired oxygen (FiO2) parameters at the discretion of the treating physician.
95039|NCT03443466|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
95040|NCT03443466|Device|Loss of resistance (LOR)|Using loss of resistance technique only
95041|NCT03443453|Drug|MIV-711|MIV-711 administered as tablets and capsules at four occasions
95042|NCT03443440|Other|Neurocognitive Testing|neurocognitive testing, computerized
95043|NCT03443427|Biological|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm and a third dose administered at either Day 181 or Day 361, according to each vaccination scheduling defined per protocol.
95044|NCT03443427|Biological|Placebo|One dose administered intramuscularly at either Day 181 or Day 361 in the deltoid region of the non-dominant arm.
95045|NCT03443414|Drug|RPL554 suspension|A dual PDE3/PDE 4 inhibitor
95046|NCT03443414|Drug|Placebo|Placebo solution
95047|NCT03443401|Procedure|Standard physical therapy care|standard plan of care delivered to patient with chronic low back within scope of licensure
95048|NCT03443388|Device|Hövding inflatable helmet|The Hövding inflatable helmet is designed for cyclists as a collar with a deployable airbag that inflates when a sensor detects rapid changes in acceleration. The inflated helmet wraps the back and sides of the user's head in inflated nylon fabric which then slowly deflates after deploying.
95049|NCT03443375|Other|Physical exercise|The interventions proposed in the present trial were based on a safe and well-established exercise training program
95050|NCT03443362|Procedure|Punch Biopsy|A 3 mm punch biopsy will be taken from lesional and non-lesional skin as a routine procedure.
95051|NCT03443362|Procedure|Blood sampling|Blood sampling
95052|NCT03443349|Device|Vibwife One|"Vibwife One is a powered rotation bed intended to be used to assist in active mobilization of delivering women. Vibwife One imitates manual mobilization and position techniques. It is integrated in the mattress and fixed to the pelvis area of the birthing bed. Vibwife One can be used, when manual mobilization and position techniques are deemed appropriate.~The device with all its functions is controlled over a remote control."
95053|NCT03443323|Behavioral|Organizational Skills Training - School Based (OST-S)|OST-S is a small group skills training intervention, with parents and teachers supporting children's use of new skills. The program manual includes strategies for training and coaching school staff, referred to as school partners, to effectively implement OST-S and guidelines to modify the program for implementation in diverse schools with diverse students. Each student session includes: (a) homework review to assess completion of between-session skills implementation; (b) skill-building activities, which include the use of modeling, shaping, guided practice, and reinforcement for organized behavior; and (c) activities to promote generalization of skills. Sessions address four organizational challenges: (a) tracking assignments, (b) managing materials, (c) managing time, and (d) planning for long term assignments.
95054|NCT03443310|Procedure|Ultrasound assessment of DVT|Using Ultrasound in assessing DVT in high-risk patients following hip fracture and major arthroplasty before the patients become symptomatic.
95055|NCT03443297|Other|breast milk|Feeding with breast milk will be started in early feeding group from 24 to 48 hours of age or in late feeding group, from 48 to 72 hours of age. Initially 4 hourly feeding will be started with 0.5ml and 1 ml expressed breast milk in babies with birth weight <1200 grams and >1200 grams respectively. gradually volume of milk should be increased
95056|NCT03443284|Behavioral|Health Partner|Health Partner is a combination of an iPhone or iPod Touch Operating System mobile application and a health care provider portal.
95057|NCT03443284|Behavioral|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Providence Health & Services.
95058|NCT03443271|Procedure|TAP Block with Bupivicaine|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.25 % Bupivicaine on each side.
95059|NCT03443271|Procedure|TAP Block with Placebo drug|Ultrasound guided TAP block will be performed and patient will be administered 20 ml of 0.9% Saline on each side.
95060|NCT03443258|Other|Needs assesment tool integrated in nursing consultation.|Needs assessment tool consisting of 57 items related to functional, emotional, social and existential areas guide follow-up care and referral to multidisciplinary team rehabilitation e.g. dietician; speech-pathologist; psychologist, etc
95061|NCT03443232|Procedure|Cryoballoon ablation|Cryoablation is performed using a single cryoballoon.In general, the cryoablation of each pulmonary vein is carried out twice. According to the objective condition, the operator determine whether or not to carry out an additional cryoablation. Then we will applicate electrophysiological substrate mapping for guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
95062|NCT03443232|Procedure|Radiofrequency ablation|Each patient randomly allocated into the radiofrequency ablation group receives circumferential pulmonary vein isolation(CPVI),The default strategy is to create a circle surrounding the two ipsilateral pulmonary veins.We will mapping the left atrial subtrate. If mapping system detect a poor substrate,we should continue to ablate for left atrial roof and posterior line.
95063|NCT03443219|Device|Spritztube®|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,Spritztube® was inserted and both cuffs inflated
95064|NCT03443219|Device|LMA Supreme™|After preoxygenation, anaesthesia was induced with midazolam, propofol, and fentanyl,LMA Supreme™ was inserted and both cuffs inflated
95065|NCT03443206|Other|anonymous social support|Participants randomized to the intervention condition will be able to communicate with one another and offer social media-based forms of support (e.g., post music, photos, etc).
95066|NCT03443206|Other|psychoeducation|educational materials related to mental health
95067|NCT03443206|Other|online resources|links to online mental health resources
95068|NCT03443193|Other|Exercise training|Patients will undergo three weekly exercise training sessions with periodized high-intensity interval training and resistance training for a period of 12 weeks.
95069|NCT03443180|Other|Gluten and Amylase Trypsin Inhibitors (ATI)-free diet|Participants will be asked to avoid foods containing gluten and ATI (a similar protein found in grains) for 4 weeks.
95070|NCT03443167|Behavioral|Training on emergency telephone numbers and mnemonics|"The intervention will consist in carrying out an initial theoretical training on how to act in case of attending an emergency, with graphic support of slides (power-point) during 5 minutes, followed by a practical part with the projection of the video of a song and with a role play activity for 15 minutes, to remember the helpline number for emergencies (112) and relate it to the mnemonic mouth-nose-eyes. At the beginning and at the end of the theoretical-practical activity, the evaluation questionnaires will be administered to each one of the students."
95071|NCT03443167|Behavioral|Sham generic formation on the cardiopulmonary arrest.|The sham intervention for the control group will consist in providing a generic formation on the cardiopulmonary arrest, with graphic support of slides (power-point) during 10 minutes, without specifying the telephone number of assistance for emergencies or the mnemonics mouth-nose-eyes. At the beginning and at the end of the theoretical activity, the evaluation questionnaires will be administered to each one of the students.
95072|NCT03443154|Diagnostic Test|VF-Test|A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).
95073|NCT03443141|Drug|Vitamin E|The applied dressing will be embebbed in Vitamin E
95074|NCT03443141|Drug|Standard dressing|The applied dressing is a normal one without adding any product to it.
95075|NCT03443128|Drug|Vinorelbine|During each course, patients will be treated with vinorelbine (25mg/m2/week on weeks 1-3). After 1 course(4 weeks) of vinorelbine, response will be evaluated by simple assessment: clinical symptoms, signs, B ultrasound, chest X-ray, peripheral blood test and bone marrow smear(if needed). After 2 courses, response will be evaluatedy by simple assessment, CT and FDG-PET. The CR/CRu was defined by anatomic tumour shrinkage more than 75% after 2 courses based on CT with negative PET assessment, with negative bone marrow PCR(if needed) and without CNS involvement. Patients who achieved a CR/CRu after two courses either will proceed to stem cell transplantation (SCT) or will receive additional courses of therapy while awaiting SCT. Response was re-evaluated at the end of every 2 courses. Patients with progressive disease at any time during treatment will be removed from protocol therapy.
95076|NCT03443089|Drug|Test formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
95077|NCT03443089|Drug|Reference formulation|Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
95078|NCT03443076|Dietary Supplement|EPA + DHA in SMEDS Formulation|A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
95079|NCT03443076|Drug|Lovaza|A single dose of 840 mg EPA + DHA administered as Lovaza
95080|NCT03443063|Drug|Lemborexant|oral tablet
95081|NCT03443050|Other|Unstable|This group will train over unstable surfaces to enhance balance abilities
95082|NCT03443050|Other|Stable|This group will train over stable surface to enhance balance abilities
95083|NCT03443037|Drug|amantadine sulphate|
95084|NCT03443024|Biological|Lebrikizumab|Sterile liquid solution injected subcutaneously
95085|NCT03443024|Drug|Placebos|Solution injected subcutaneously
95086|NCT03443011|Radiation|Low dose CT without intravenous contrast|participants will receive an extra radiation dosage of about 3 milli Sievert (mSv) depending on patients height and weight. This is the radiation amount from the low dose CT protocol without intravenous contrast.
95087|NCT03442998|Other|Suburban walk|Each subject is tested under the 'suburban' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
95088|NCT03442998|Other|Nature walk|Each subject is tested under the 'nature' condition. We will compare the stress response and working memory response to walking in the two experimental conditions ((1)response to walking on a nature path and (2) response to walking on an urban sidewalk).
95089|NCT03442985|Drug|Palovarotene 2.5 mg|Subjects will receive a weight-adjusted dose equivalent of 2.5 mg palovarotene, once daily, for up to 24 months.
95090|NCT03442985|Drug|Palovarotene 5.0 mg|Subjects will receive a weight-adjusted dose equivalent of 5.0 mg palovarotene, once daily, for up to 24 months.
95091|NCT03442985|Other|Placebo|Subjects will receive placebo, once daily, for up to 24 months.
95092|NCT03442972|Drug|Teduglutide|Teduglutide
95093|NCT03442972|Drug|Placebo|Placebo
95094|NCT03442959|Other|Data record|characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
95095|NCT03442933|Other|3 hours Road Cycling Time Trial|The road itinerary is a mixed route profile of 90 km, an elevation gain of 900 m, with mixed sections, flat, uphill and down over roads with little traffic.
95096|NCT03442933|Other|3 hours Mountain Biking Time Trial|The mountain itinerary, is a mixed route of 55 km, an elevation gain of 600 m, with sections of wide tracks and trails, flat, uphill and down, with a medium technical difficulty.
95097|NCT03442920|Other|Exercise|This group made exercise for 12 week/3 times a week.
95098|NCT03442907|Procedure|24 hour blood pressure measurement, fluids, vasopressors|Targeting individual blood blood pressure values during surgical procedures
95099|NCT03442907|Procedure|Standard of Care|Treatment according to Standard of care at the Department of Anaesthesiology, University Medical Centre Hamburg Eppendorf
95100|NCT03442894|Procedure|Standard Physical Therapy Treatment|All three groups will receive manual therapy and exercise interventions provided by their physical therapist. The exact dosage and choice of exercise and manual therapy techniques will not controlled in the study. Documentation of dosage and utilization rates of each will be captured for each patient session in order to determine if these variables influence outcomes. A full shoulder exam will be conducted per standard of care at this time as well. Manual therapy and exercise interventions will be selected to address impairments uncovered in the shoulder exam.
95101|NCT03442894|Procedure|Dry Needling|In addition to the standard PT interventions, the Dry Needling (DN) group will receive 6 DN sessions as part of their rehabilitation visits (they will occur at the same time). In 6 of the scheduled 10 visits, dry-needling intervention will be performed. They will have one DN session per week, which is consistent with typical clinical practice. After they complete their standard PT treatment, and while still in the clinic, the rotator cuff and periscapular muscles will be evaluated for the presence of MTrPs. Once located, the MTrPs will be treated with DN technique, as this is consistent with routine clinical practice. Potential muscles to receive TPDN treatment include the following: suprapsinatus, teres minor, infraspinatus, deltoid, upper trapezius, middle trapezius, levator scapula, pec major and pec minor.
95102|NCT03442894|Procedure|Sham Dry Needling|In addition to the standard PT treatment, patients in the sham DN group will receive what appears to be a DN treatment, but it will not be done with the acupuncture needles and the skin will not be punctured. The Sham DN procedure will be performed over the site of identified MTrPs using a guide tube and a toothpick. A guide tube is positioned firmly over the area to be treated and a toothpick is inserted in the guide tube. The clinician taps the toothpick to mimic the skin prick from a needle and the guide tube is removed. The clinician maintains pressure on the end of the toothpick and moves the end furthest from the skin in different directions to mimic the pistoning and changes in needle angle that occur in actual dry needling. Care will be taken to treat from 1-3 muscle groups for 5-10 seconds per MrTP identified.
95103|NCT03442881|Procedure|Excision of adnexal mass through laprotomy|Through laparotomy incision, the adnexal mass will be excised
95104|NCT03442868|Device|high frequency rTMS|Participants receive 16 minutes (5Hz, 24 10-second trains with a inter-train interval of 30s) of high frequency rTMS applied to either primary motor cortex, supplementary motor areas and dorsolateral prefrontal cortex at different sessions. Walking performance is evaluated before and after the brain stimulation.
95105|NCT03442829|Behavioral|Sweet food consumption|Sweet food consumption at breakfast
95106|NCT03442829|Behavioral|Non-sweet food consumption|Non-sweet food consumption at breakfast
95107|NCT03442816|Device|MHRC Camera|Evaluate the technical capabilities of the device to obtain quality images in reflectance and fluorescence imaging modes in a diverse population.
95108|NCT03442803|Device|Target-Controlled Infusion|Propofol Target-Controlled Infusion
95109|NCT03442790|Procedure|Agitated Saline Method|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using agitated saline under ultrasound vision.
95110|NCT03442790|Procedure|chest x-ray|All patients in the study who have undergone a central venous line placement will undergo a confirmation of the accurate or inaccurate placement of central venous lines using chest x-ray obtained in supine position as an active comparator
95111|NCT03442777|Device|Allevyn® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Smith&Nephew (Allevyn® brand).
95112|NCT03442777|Device|Mepilex® brand silicone adhesive multilayer foam dressings|Skin sites (restricted to sacrum, heel right/left and greater trochanter right/left) will be treated with silicone adhesive multilayer foam dressings by Mölnlycke Health care (Mepilex® brand).
95113|NCT03442764|Drug|mavacamten|MYK-461
95114|NCT03442764|Drug|Placebo|Placebo
95115|NCT03442751|Drug|Paracel 1|Two drops every 60 seconds for 4 minutes
95117|NCT03442751|Drug|Paracel 2 R0185|Two drops every 30 seconds for 6 minutes
95118|NCT03442751|Device|KXL High Power System (2 J)|6 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 2 J/cm2)
95119|NCT03442751|Device|KXL High Power System (10 J)|30 mW/cm2 for 11 minutes 6 seconds with an on/off cycle of 1 second UVA on/1 second UVA off (total UVA does of 10 J/cm2)
95120|NCT03442738|Procedure|Endocuff group|Endocuff Vision cap on Standard colonoscope
95121|NCT03442725|Drug|Telotristat etiprate|Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
95122|NCT03442712|Other|Auricular acupressure plus smartphone App|Semen Vaccaria laccaria will be kept in place by a piece of adhesive patch. Seeds will be applied on one ear only, and seed plasters will be changed every 3 days to 4 days to the opposite ear, that is, we will meet the subjects twice per week. Subjects will be requested to apply pressure on the acupoints thrice per day, preferably within 30 min before eating, pressing for 20 times using a constant rhythm to each point. Coaching on how to self-administer AA on the acupoints will be given to the subjects, and a return demonstration from the subjects will be required to ensure the skills are performed properly. The subjects will install the smartphone App specifically designed for this study. The App will send out regular AA reminders to the subjects. In addition, the subjects will be asked to input the number of bowel open and compliance with AA performance per day into the App. The total treatment period will be 8 weeks.
95123|NCT03442712|Other|Auricular acupressure|The participants will receive AA treatment and are required to perform daily self-administered seeds pressing, but no smartphone App will be provided, but a booklet containing relevant information will be provided to the subjects.
95124|NCT03442699|Behavioral|Cognitive Behavioral Therapy|Up to 10 daily sessions of brief cognitive behavioral therapy for suicidal inpatients for about an hour each day.
95125|NCT03442686|Behavioral|Compass Course|An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
95126|NCT03442673|Drug|Vinorelbine|Stimulation with vinorelbine together with G-CSF for mobilization of autologous stem cells
95127|NCT03442673|Drug|Gemcitabine|Stimulation with gemcitabine together with G-CSF for mobilization of autologous stem cells
95128|NCT03442673|Drug|G-CSF|Cytokine stimulation with G-CSF for mobilization of autologous stem cells
95129|NCT03442660|Other|Data collection|Subjects will be treated in accordance with usual medical practice during their participation in this study. No additional diagnostic or treatment procedures will be required. Subjects will be asked to complete electronic (or on paper when it's not possible to use electronic version) questionnaires.
95130|NCT03442647|Diagnostic Test|sinistrin clearance dynamic measurement|sinistrin clearance measurements will be performed before and 90 min after oral protein load
95131|NCT03442634|Other|Early Hydration|this group will start oral hydration within 1 hour after cesarean section
95132|NCT03442634|Other|Traditional Oral Hydration|this group will start oral hydration 6 hours after cesarean section
95133|NCT03442621|Drug|Relacorilant Fasted|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10.5 h fast
95134|NCT03442621|Drug|Relacorilant with a high fat breakfast|Relacorilant presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a high fat breakfast
95135|NCT03442621|Drug|Relacorilant with a moderate breakfast|Relacorilant, presented as 7 x 50-mg white, hard gelatin capsules for oral administration, given following a 10 h fast and 0.5 h after the start of a moderate breakfast
95136|NCT03442608|Procedure|Zoll 2000 and/or CureWrap 3500 cooling system|Device(Zoll 2000 and/or CureWrap 3500 cooling system),lasting 5 to 7 days, the core temperature will be controlled in 33-35 degree.
95137|NCT03442595|Other|Intensive diabetes education and medication management|Patients receive intensive knowledge based diabetes education and algorithm driven medication management over a period of 12 weeks.
95138|NCT03442582|Biological|Afluria Influenza Vaccine|"Afluria is a seasonal influenza vaccine~Vaccine exposure in routine care (no vaccination per protocol)"
95139|NCT03442569|Drug|Panitumumab|6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab
95140|NCT03442569|Drug|Nivolumab|240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab
95141|NCT03442569|Drug|Ipilimumab|1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab
95142|NCT03442556|Drug|Carboplatin|Given IV
95143|NCT03442556|Drug|Docetaxel|Given IV
95144|NCT03442556|Other|Laboratory Biomarker Analysis|Correlative studies
95145|NCT03442556|Drug|Rucaparib Camsylate|Given PO
95146|NCT03442556|Drug|Rucaparib|Given PO
95147|NCT03442543|Device|preoperative localization of SLN detected by CTLG by either methods|50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel & traditional method was performed.
95148|NCT03442530|Behavioral|ToPIC|Expanded tobacco cessation counseling for pregnant women.
95149|NCT03442530|Behavioral|Tobacco Treatment As Usual (TTAU)|Standard of care tobacco cessation counseling for pregnant women
95150|NCT03442517|Behavioral|Behavior Lifestyle Intervention|Participants will be involved in group-based counseling. Sessions will be about 1 hour each and comprise up to 10 people. The sessions will be led by a trained health educator. The calls will be a chance for participants to discuss challenges with breastfeeding, problem solving skills, educational information, and discuss balanced diet topics.
95236|NCT03441854|Device|HFNC group|Application of HFNC oxygen delivery after extubation.
95151|NCT03442517|Other|Usual prenatal care|Participants will receive the standard education given by their OBGYN or other healthcare provider. No additional breastfeeding, nutrition or postpartum weight loss education will be provided to participants by the investigators during pregnancy. After delivery, participants will follow normal pediatric visit schedule.
95152|NCT03442504|Diagnostic Test|FES PET/CT|"There will be no premedication or other treatment before and after PET FES. PET / CT will be performed at the center level on a hybrid PET camera.~The first TEP FES acquisition begins at the time of injection and continues for 30 minutes,~The second acquisition of 20 minutes takes place 60 minutes after the injection is a total of 50 minutes of imaging and 1:30 in the service."
95153|NCT03442491|Procedure|Hayman's Haemostatic Suture|After the uterus is exteriorised, bimanual compression is applied to check whether this stopped the bleeding, before the suture is applied. A number 2 polyglactin suture on a straight needle is used to transfix the uterus from front to back, just above the reflection of the bladder, and is then tied above the fundus of the uterus, while an assistant applies bimanual compression.
95154|NCT03442478|Other|2D/3D Tomosynthesis|
95155|NCT03442465|Behavioral|Toronto Extremity Salvage Score|Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
95156|NCT03442465|Behavioral|Musculoskeletal Tumor Society Score|Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
95157|NCT03442465|Behavioral|Timed Get Up and Go Test|Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
95158|NCT03442465|Diagnostic Test|Orthogonal Radiographs|The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
95159|NCT03442465|Diagnostic Test|Weight Bearing for lower extremities only|As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
95160|NCT03442465|Diagnostic Test|Range of Motion|As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
95161|NCT03442465|Diagnostic Test|Osteocalcin|This lab assesses bone metabolism and require 5 mL of blood
95162|NCT03442465|Diagnostic Test|Amino terminal propepetide of type 1 collagen|This lab assesses bone metabolism and require 5 mL of blood
95163|NCT03442465|Diagnostic Test|N-telopeptide of type 1 collagen|This lab assesses bone metabolism and require 5 mL of blood
95164|NCT03442452|Other|Electronic Decision Aid Tool|The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
95165|NCT03442439|Behavioral|Nutrition and Play Intervention|Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.
95166|NCT03442439|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
95167|NCT03442426|Other|Integrated model of primary care|Intervention includes: 1) consistent risk screening and assessment; 2) care coordination and system navigation; 3) patient/caregiver engagement and shared decision-making; and 4) enabling technology supports.
95168|NCT03442413|Drug|2-[18F]-FA PET/CT|2-[18F]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
95237|NCT03441841|Drug|Lidocaine + Prilocaine|Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
95169|NCT03442413|Drug|I.V. Nicotine|Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
95170|NCT03442400|Device|Volcano iFR/FFR Verrata Plus coronary pressure/flow wire|We will measure the degree of flow-limitation of intermediate severity coronary steonses using the iFR/FFR Verrata Plus coronary pressure/flow wire before and after transcatheter aortic valve replacement.
95171|NCT03442387|Other|Frame of numerical information|Each group received only one frame of information.
95172|NCT03442374|Other|Exercise|The exercise protocol consists of 1 set of 20 repetitions (range 15-25 reps) at a rate of 5 seconds/repetitions with a starting weight of 60-80% of their computerized strength score. Patients will be instructed to target an exertion level of 7/10 on the Borg Rate of Perceived Exertion (RPE) scale within their available passive ROM range into flexion-extension
95173|NCT03442348|Dietary Supplement|Omega 3 fatty acid|Participants in the bottom median of dietary fibre intake (<15 g per day) will be randomised into one of two arms. Participants in the second arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
95174|NCT03442348|Dietary Supplement|Inulin fibre|The participants in the control arm (N>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
95175|NCT03442335|Diagnostic Test|Chromohysteroscopy|Standard hysteroscopy followed by injection of a dye, in this case iodine.
95176|NCT03442335|Diagnostic Test|Endometrial biopsy (Pipelle)|A narrow plastic tube (Pipelle) is passed through the cervix to aspirate a sample of endometrial tissue.
95177|NCT03442322|Other|transdisciplinary approach|This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
95178|NCT03442322|Other|multidisciplinary approach|This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
95179|NCT03442309|Device|Silver Diamine Fluoride|Silver diamine fluoride (SDF)
95180|NCT03442309|Device|Fluoride Varnishes|Fluoride varnish (FV)
95181|NCT03442309|Device|Glass Ionomer|Glass Ionomer Sealants (GC Fuji IX)
95182|NCT03442296|Behavioral|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner (if applicable)
95183|NCT03442296|Device|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
95184|NCT03442283|Dietary Supplement|Vitamin mineral supplementation|supplementation with a vitamin or mineral: vitamin A, β-carotene, B1, B2, B3 (niacin), B6, B10 (folic acid), C, D and E, calcium, iron, zinc, magnesium and selenium. Also, multivitamins, antioxidants, B-complex and the combination of calcium and vitamin D.
95185|NCT03442270|Other|No Intervention|This is an observational study, so standard of care will be followed.
95186|NCT03442257|Behavioral|SMS|The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
95187|NCT03442244|Drug|LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
95188|NCT03442244|Drug|Vehicle of LEO 90100 foam|Each subject has each of the 2 treatments applied at the same time on 2 different sites on the back
95189|NCT03442231|Device|Journey UNI Unicompartmental Knee System|Lateral or medial knee compartment replacement
95190|NCT03442218|Drug|Clorhexidine|Vaginal wash with clorhexidine solution previous to cesarean section in patients with premature rupture of membranes.
95191|NCT03442218|Drug|Saline solution|Vaginal wash with saline solution previous to cesarean section in patients with premature rupture of membranes.
95192|NCT03442205|Procedure|LC + LCBDE + ENBD + primary closure of CBD|LC + LCBDE + ENBD + primary closure of CBD
95193|NCT03442205|Procedure|ERCP technique + LC|ERCP technique + LC
95194|NCT03442205|Procedure|LC + LCBDE + primary closure of CBD|LC + LCBDE + primary closure of CBD
95195|NCT03442192|Other|PrEP Care Anywhere Services|"PrEP Virtual Clinic Visits. PrEP clinical care will follow guidelines as established by the CDC for PrEP clinical evaluation and follow-up. Appointments will be set up in the same process as any practice visit and require the same clinical documentation and billing requirements, but will have a separate clinic designation for the visit type. At any time during the study, a patient can request a face-to-face visit with the provider. The provider may also request a face-to-face visit based on patient presentation and/or laboratory results.~The typical visit options will include:~On demand peer interim visits- participants can text, chat (via PrEPme app) or call to access an on demand virtual support visit with a peer Case Manager (CM).~HIV and Sexually Transmitted Infection (STI) at Home Self-Testing"
95196|NCT03442179|Device|EEG|the anesthesiologists (attending faculty, residents, and CRNAs) in the treatment group use the unprocessed EEG waveforms and EEG spectrogram to maintain appropriate levels of unconsciousness for general anesthesia while avoiding burst suppression. The presence of slow (0.1-1 Hz) and frontal alpha (8-12 Hz) oscillations on EEG time trace and spectrogram will be used as indicators of anesthesia-induced unconsciousness in these patients who are receiving propofol and sevoflurane for induction and maintenance of general anesthesia, respectively.
95197|NCT03442166|Radiation|LED group|The patients (n=17) will receive daily intra and extra oral LED applications from the immediate postoperative period up to 7 days after the surgical procedure. The LED irradiation will be performed in two areas, one intra and one extra oral. The LED to be used in the intraoral site will be red, 660+/-20nm wavelength, 5 mW power, 2.7J/cm2 energy density for 7 min, 2J energy per point, knowing that the 6 irradiated spots will have 12J in total. In the extra oral site the infra-red LED will be used, 850+/-20nm wavelength, power of 5mW, 3.8J/cm2 of energy density for 10 min, 3J of energy per point, knowing that 36 will be irradiated, so we will have 108J in total.
95238|NCT03441841|Drug|Lidocaine|Single topical dose of 2g lidocaine 2.5 % formulation.
95198|NCT03442166|Radiation|Sham group|Patients will be treated in the same way as the LED group. The person in charge of the application will simulate the intraoral and extraoral irradiation by positioning the LED in the same locations described for the LED group, but the equipment will be kept off. So that the patient does not identify the sound of activation of the device (beep), it will be recorded, and connected at the time of application.
95199|NCT03442153|Dietary Supplement|Solgar No7 Complex|Solgar No7 Capsules
95200|NCT03442153|Dietary Supplement|placebo|Placebo tablets Cellulose
95201|NCT03442140|Other|Harmonica playing|Patients will play the harmonica for up to 6 months
95202|NCT03442127|Behavioral|CaringGuidance™ After Breast Cancer Diagnosis|Web-based, psychoeducational, self-management tool
95203|NCT03442114|Behavioral|Hydroxyurea SDM Toolkit|Implementation tools and visit decision aids
95204|NCT03442114|Behavioral|Clinician Pocket Guide|current hydroxyurea protocol and ASH pocket guide
95205|NCT03442101|Drug|Patients with psychosis will be treated with known antipsychotic medication|Subjects with first episode psychosis will be treated with risperidone, the most frequently used antipsychotic drug (APD) for 32 weeks. The study will follow a rigorous longitudinal design to capture treatment response whereby those without an adequate response after 16 weeks of treatment will be switched to aripiprazole, another APD for 16 weeks. All patients will be scanned four times: at baseline and after 6, 16, and 32 weeks of treatment.
95206|NCT03442088|Drug|Apremilast|Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.
95207|NCT03442062|Other|Assessment Feedback Incentives and eXchange|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
95208|NCT03442062|Other|Physician-to-physician engagement|Physician-to-physician engagement is a quality improvement strategy in which trained physician educators deliver a 60 minute consultation via interactive webinar. The consultations will be delivered to providers in primary care clinics and will include didactic instruction on HPV-related cancers, HPV vaccination, communication training, and assessment and feedback about each clinics' vaccination coverage.
95209|NCT03442062|Other|Active Intervention Control|Active Intervention Control will be a remotely delivered quality improvement strategy on a clinical topic other than HPV vaccination.
95210|NCT03442049|Other|Physiotherapy - Study group|Study group : In addition to home program spinal stabilization exercises
95211|NCT03442049|Other|Physiotherapy - control group|Home exercise program
95212|NCT03442036|Device|Suture-Method Technique|Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve
95213|NCT03442036|Device|Through-the-Needle Technique|Perineural catheters are inserted through a straight hollow-bore needle
95214|NCT03442023|Drug|Chlorhexidine gluconate at 2%|Mouth Rinse with Chlorhexidine gluconate at 2% every 12 hours, one week.
95215|NCT03442023|Drug|Chlorhexidine gluconate at 0.12%|Mouth Rinse with Chlorhexidine gluconate at 0.12% every 12 hours, one week.
95216|NCT03442010|Other|Detection of adverse drug events|Detection of adverse drug events
95217|NCT03441997|Other|Mind-body exercise|Exercise program.
95218|NCT03441997|Other|Light mobility exercises|Modified mind-body program.
95219|NCT03441984|Drug|Treatment A|TRIUMEQ (Adult) administered as a, single dose, fixed dose combination (FDC) tablet - DTG 50 mg/ABC 600 mg/3TC 300 mg as 1 conventional tablet, orally as direct-to-mouth.
95220|NCT03441984|Drug|Treatment B|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/ 3TC 30 mg, orally as 10 dispersible tablets
95221|NCT03441984|Drug|Treatment C|TRIUMEQ (Pediatric) administered as a, single dose, FDC tablet - DTG 5 mg/ABC 60 mg/3TC 30 mg, orally as direct-to-mouth.
95222|NCT03441984|Drug|Treatment D|"DTG and 3TC (Adult), administered as a, single dose, Single dose, 1 tablet DTG (50 mg) and~1 tablet 3TC (300 mg), orally as direct-to-mouth."
95223|NCT03441984|Drug|Treatment E|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as 10 dispersible tablets.
95224|NCT03441984|Drug|Treatment F|DTG and 3TC (Pediatric) administered as a, single dose, FDC tablet single dose, FDC tablet - DTG 5 mg/3TC 30 mg, orally as direct-to-mouth.
95225|NCT03441958|Biological|ECT-001 (UM171) expanded cord blood|ECT-001 expanded cord-blood will be produced and infused on site
95226|NCT03441945|Other|magnetic steering|magnetic steering
95227|NCT03441932|Procedure|Fiberoptic endoscopic evaluation of swallowing (FEES)|"Subjets within the two groups will after than have FEES with videotaping of pharyngeal phase after giving subjects a standardised food consisting of thin Puree."
95228|NCT03441919|Radiation|PET-CT (positron emission tomography - computer tomography)|PET-CT to determine vascular inflammation
95229|NCT03441919|Diagnostic Test|Blood drawn|Blood drawn
95230|NCT03441893|Diagnostic Test|parasitological diagnostics (coproscopy)|Three stool samples for parasitological examination will be taken from ulcerative colitis patients at 1-2 days interval.
95231|NCT03441893|Drug|Nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (two pills) twice over orally for 14 consecutive days
95232|NCT03441893|Drug|Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet|Tab. nitazoxanide by a 1.0 g/day (one pill - 500 mg) twice over orally and mesalazine 1.5 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
95233|NCT03441893|Drug|Mesalazine 250Mg|Tab. mesalazine ≥3 g/day (one pill - 500 mg) three times a day orally for 14 consecutive days
95234|NCT03441867|Behavioral|Cognitive Behavioral Therapy for Seizures|CBT-informed psychotherapy for patients with PNES and PTE
95235|NCT03441867|Other|Standard Medical Care|Observational - standard medical care
95239|NCT03441841|Drug|Prilocaine|Single topical dose of 2g prilocaine 2.5 % formulation.
95240|NCT03441828|Procedure|Quality of surgical field conditions|evaluation of the intraoperative surgical conditions assessed by the surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point) given by deep vs moderate neuromuscular block
95241|NCT03441828|Drug|Deep Neuromuscular Block|maintenance of a deep neuromuscular block by infusion of rocuronium
95242|NCT03441828|Drug|Moderate Neuromuscular Block|maintenance of a moderate neuromuscular block.
95243|NCT03441815|Drug|XC8|
95244|NCT03441815|Drug|Placebo|
95245|NCT03441802|Other|High quality extra virgin olive oil|Cases and controls were given 40 g/die high quality extra virgin olive oil
95246|NCT03441789|Drug|Enstilar|Enstilar foam applied to affected areas daily
95247|NCT03441789|Drug|Vehicle|vehicle foam applied to affected areas once daily
95248|NCT03441789|Drug|Otezla|Otezla 30mg
95249|NCT03441776|Other|Generalized Vestibular Rehabilitation Treatment|These treatment visits are available twice a week and each visit lasts 45 minutes. Individuals receiving GVRT are allowed to choose the frequency at which they want to attend and the program is designed for each subject to complete 8 visits within a period between 4 and 8 weeks. The ideal number of patients receiving treatment at each class is from 3 to 6 but the system has capacity for a maximum of 8. GVRT is a standard of care treatment option and is not considered research.
95250|NCT03441776|Other|Individualized Vestibular Rehabilitation Treatment|Individuals receiving IVRT are scheduled depending on their individual needs and PT availability. These visits require one-on-one time with a PT. Individuals are commonly seen by the PT 3 times at two week intervals. These visits last 30 minutes and include PT evaluation designed to instruct patients on exercises for them to perform on their own. IVRT is a standard of care treatment option and is not considered research.
95251|NCT03441763|Device|Emed foot device|foot pressure will be measure by using emed foot pressure system
95252|NCT03441750|Drug|metformin|Metformin tablets will be administrated in the experimental arm.
95253|NCT03441750|Other|Standard lifestyle intervention|"Standard lifestyle advice will be united for all subjects by providing special booklet.~All participants will receive 20-30 minutes individual or group session with assigned nurse addressing the harm of prediabetes and the importance of a healthy lifestyle for preventing Diabetes.~The amount of energy intake of the participants will be calculated based on the ideal body weight and physical activity levels. The sample recipe will be explained by the nurse and provided in the diet instruction.~Moderate intensity physical activity (150 minutes per week) is recommended.~Smoking cessation is encouraged for the smoker.~Excessive alcohol intake is encouraged to avoid."
95254|NCT03441737|Behavioral|Exercise|20 minutes of aerobic exercise (walking on a treadmill) at 2/3 of participant's maximum heart rate (maximum heart rate calculated as 220-age).
95255|NCT03441737|Behavioral|Non-Exercise|20 minutes of sitting in the laboratory with access to magazines and the internet.
95256|NCT03441724|Diagnostic Test|Mechanocardiography|Mechanocardiographic recording
95257|NCT03441698|Device|Genuine acupuncture (A)|A) Acupuncture is administered bilaterally to the acupuncture point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpii radialis. Sharp acupuncture needles were inserted into a depth of a half body-inch. The needles are manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
95258|NCT03441698|Device|Sham acupuncture (B)|B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device was used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist give an illusion of manipulating the needle by turning it three times until it touched the skin, but no deqi occurs. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
95259|NCT03441698|Other|Rest|C) Rest means resting for 30 minutes, either sitting or lying down. Within the groups A, B and C, the participants are randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected relaxing effects of their treatment, using a standardized communication model.
95260|NCT03441685|Behavioral|Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues|"Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures."
95261|NCT03441672|Behavioral|Meaning of Screening|Interactive technology game providing education about prenatal screening and what the results may mean.
95262|NCT03441659|Procedure|ACL reconstruction|Surgical ACL reconstruction
95263|NCT03441633|Drug|apixaban|current or new medication
95264|NCT03441633|Drug|dabigatran|current or new medication
95265|NCT03441633|Drug|VKA|current or new medication
95266|NCT03441633|Drug|rivaroxaban|current or new medication
95267|NCT03441620|Dietary Supplement|strawberries|Freeze-dried strawberry powder
95268|NCT03441620|Other|Control powder|Control powder matched for fiber and strawberries
95269|NCT03441607|Drug|mHACMb|Active ingredient
95270|NCT03441607|Other|placebo|inactive ingredient
95271|NCT03441581|Drug|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
95272|NCT03441568|Device|BAY987534|The modified Diprobase formulation will be applied topically twice daily over 14 days on the whole body and face.
95273|NCT03441555|Drug|Venetoclax|tablet, oral
95274|NCT03441555|Drug|Alvocidib|Intravenous
95275|NCT03441542|Behavioral|Data-assisted Case Navigation|"The researchers will develop a monthly task list for the patient navigator with patient by patient care cascade and treatment milestones that need to be accomplished per patient in the case group. The researchers will deliver the spreadsheet and the task list to the Grady Liver Clinic Director who will use it to direct and supervise the activities of the patient navigator.~Patient navigators will be responsible for reaching out to patients in only the intervention arm about their next step in the HCV care cascade."
95276|NCT03441542|Behavioral|Standard of Care|Patients will be recruited into the study by the patient navigator, be provided information about HCV infection, and will be informed that treatment is freely available should they seek it. Patients will also be provided contact and address information for the treatment clinic.
95277|NCT03441529|Drug|Lumicitabine|Participants will receive single oral dose of 1000 mg lumicitabine as per assigned treatment sequence.
95278|NCT03441529|Drug|Piperacillin/Tazobactam|Participants will receive three IV infusions of piperacillin/tazobactam combination product (4 g of piperacillin and 0.5 g of tazobactam) every 6 hours on Day 1.
95279|NCT03441516|Drug|Alfoatirin® Tab. + Aripezil® Tab.|Choline Alphoscerate 400 mg Oral Tablet bid + Donepezil 10 mg Oral Tablet qd for 24 weeks
95280|NCT03441516|Drug|Aripezil® Tab.|Donepezil 10 mg Oral Tablet qd for 24 weeks
95281|NCT03441503|Other|Child HCAHPS: Automated day-of-discharge survey|Child HCAHPS surveys will be administered on the day of discharge via an electronic interactive patient care system on inpatient televisions.
95282|NCT03441490|Behavioral|Guided-ICBT for adolescents with anxiety|Internet-based cognitive behavioural therapy with therapeutic guidance through mail, 8 weeks.
95283|NCT03441490|Behavioral|Guided-ICBT with chat|Internet-based cognitive behavioural therapy with therapeutic guidance through chat, 8 weeks.
95284|NCT03441490|Behavioral|Guided-ICBT with learning support|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.
95285|NCT03441490|Behavioral|Guided-ICBT with learning support and chat|Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
95286|NCT03441464|Combination Product|LUM Imaging System|Patients will be injected with one of 3 study doses of LUM015, or have no LUM015 intervention, and resected tissue will be imaged ex vivo with the LUM imaging device.
95287|NCT03441438|Dietary Supplement|Water|Serum and urine markers will be obtained after drinking 5 oz of water
95288|NCT03441438|Dietary Supplement|Red wine|Serum and urine markers will be obtained after drinking 5 oz of water
95289|NCT03441438|Dietary Supplement|Polyphenolic Compounds|Serum and urine markers will be obtained after consuming 100 mg of provinols powder
95290|NCT03441425|Other|Unexpected death|
95291|NCT03441412|Drug|Ticagrelor 90mg|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg−1 min−1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
95292|NCT03441412|Drug|Epinephrine|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg−1 min−1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
95293|NCT03441412|Drug|Metoprolol|"2 x 90 mg of ticagrelor will be administered orally to the subjects. Two hours after administration, the registrations and blood sampling are repeated after which an infusion of epinephrine diluted in glucose solution (5%) is started at a weight-adjusted rate of 0.01, 0.05, 0.10 and 0.15 μg kg−1 min−1. Each infusion will be maintained for 15 minutes.~After the measurement at the highest dose of epinephrine, 5 mg metoprolol (Abcur, Haelsingborg , Sweden) will be given intravenously to the study subject and thereafter registrations and blood sampling will be repeated."
95294|NCT03441399|Other|Financial incentives|Providing money for taking antidepressant medication
95295|NCT03441386|Behavioral|Physical Exercise Session|
95296|NCT03441373|Drug|XC8 20 mg|once daily during 5 days.
95297|NCT03441373|Drug|XC8 100 mg|once daily during 5 days.
95298|NCT03441373|Drug|XC8 200 mg|once daily during 5 days.
95299|NCT03441373|Drug|Placebo|once daily during 5 days.
95300|NCT03441360|Drug|Eribulin mesylate|Intravenous infusion
95301|NCT03441347|Behavioral|Specific rehabilitation program|17-week specific and personalised rehabilitation program. The program starts with a visit to the Plexus out patient clinic in week 1. During this visit, the patient will be examined by a multidisciplinary team, consisting of a rehabilitation physician, neurologist, physical therapist and occupational therapist, which will form a rehabilitation treatment plan. This treatment plan is implemented through 4 weekly sessions in week 2-5, 2 biweekly sessions in week 6-9 and 2 monthly sessions in week 10-17 . Each treatment session involves one hour of physical- and one hour of occupational therapy.
95302|NCT03441347|Other|Usual Care|Participants will receive their usual care for 17 weeks, which may vary for each individual
95303|NCT03441334|Device|High Frequency rTMS|Participants in the intervention group will receive 1200 stimuli at the intensity of 90% of resting motor threshold via an air-filmed coil placed on the vertex. The stimulation will be delivered across 24 sessions (in 10 weeks). Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
95304|NCT03441334|Device|Sham rTMS|Participants in the sham group will receive the same duration of stimulation via a sham coil placed on the vertex.Right after each session, participants will receive a 45-minute structured body weight supported treadmill training.
95950|NCT03436173|Drug|Fluoxetine|Fluoxetine 10 mg/2.5 ml mixed with water
95305|NCT03441321|Other|Media Intervention|Participate in Facebook group focusing on avoiding indoor tanning and promoting healthy body image
95306|NCT03441321|Other|Media Intervention|Participate in Facebook group focusing on other health topics
95307|NCT03441321|Other|Survey Administration|Ancillary studies
95308|NCT03441308|Behavioral|Educational method of group treatment|
95309|NCT03441295|Procedure|Dynamic Intraligamentary Stabilization|DIS, Ligamys
95310|NCT03441295|Procedure|Internal Brace Ligament Augmentation|IBLA
95311|NCT03441295|Procedure|ACL Reconstruction|Conventional
95312|NCT03441282|Drug|Fentanyl|"After the patient is attached to an ASA non-invasive monitor, a dose (2mcg/kg) of Fentanyl will be administered.~Groups compared would include patients experiencing respiratory depression vs those not experiencing respiratory depression after fentanyl administration. Their samples would be evaluated for any differences in genetic make-up concerning selected, known sequences affecting opioid-induced analgesia."
95313|NCT03441269|Drug|Oral Ibuprofen|Oral Ibuprofen will be given to all the arms; only the dosage will be different: 400mg vs. 600mg vs. 800mg
95314|NCT03441256|Device|LION procedure|Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.
95315|NCT03441256|Device|NMES|Conventional neuromuscular electrical stimulation via surface electrodes.
95316|NCT03441230|Device|Balloon characteristics|Different size balloon
95317|NCT03441217|Drug|Hyoscine Butylbromide 20Mg/1mL Injection|Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
95318|NCT03441217|Drug|Saline Solution|Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
95319|NCT03441204|Drug|LTOT 24 h/day|LTOT prescribed for 24 h/day.
95320|NCT03441204|Drug|LTOT 15h/day|: LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
95321|NCT03441191|Device|Audiovisual Stimulation|A commercially available AVS device (MindPlace Procyon) modified for use in the current study will be used to deliver the AVS programs in this study
95322|NCT03441178|Device|ENSEAL X1|ENSEAL X1 is used for transecting and sealing vessels according to instructions for use.
95323|NCT03441165|Procedure|ligament reconstruction and meniscus transplantation|ACL reconstruction ACL revision MAT
95324|NCT03441152|Device|tDCS|Transcranial direct current stimulation
95325|NCT03441139|Other|Cryotherapy + Medical analgesics|"Percutaneous cryotherapy: A complete cycle of treatment will require 2 freezing 10-minutes periods, separate by a 9-minutes passive and 1-minute active thaw, with the cryoablation system. Dimension of the iceball coverage above the tumor will be monitored by non-contrast CT or MRI during the freezing cycle.~Medical supportive care: Best analgesic therapy at investigator's discretion"
95326|NCT03441139|Drug|Medical Analgesics|Best analgesic therapy at investigator's discretion
95327|NCT03441126|Other|Multicenter Quality Improvement program|Participating institutions will not participate in an intervention study. Sites will design and implement local QI programs to improve care within their unit. Local healthcare teams, who are interested in directly and immediately improving patient outcomes, will devise customized tools. The Bright STAR Team will assess the impact of these local QI initiatives on patient health outcomes, using data that are collected as part of the QI programs or through routine clinical care.
95328|NCT03441113|Drug|MMB|Tablet(s) administered orally once daily
95329|NCT03441100|Drug|IMA202 Product|Four dose levels (DL) of IMA202 product will be evaluated. The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
95330|NCT03441100|Device|IMA_Detect|IMA_Detect is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials. IMA_Detect is intended for investigational use only.
95331|NCT03441087|Device|Transvaginal ultrasound|
95332|NCT03441087|Device|Hysteroscopy|
95333|NCT03441074|Behavioral|enhanced olfactory stimuli|Patients in intervention group will get enhanced olfactory stimuli during perioperative period (7 days before and after the surgery), by using portable scented sachets.
95334|NCT03441061|Biological|Inotuzumab Ozogamicin|Given IV
95335|NCT03441048|Drug|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of relapsed/refractory acute myeloid leukemia. Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
95336|NCT03441048|Drug|Cladribine|Cladribine 5mg/m2/day IV over two hours on days 2-6.
95337|NCT03441048|Drug|Cytarabine|Cytarabine 2 gm/m2/day IV over four hours on days 2-6.
95338|NCT03441048|Drug|Mitoxantrone|Mitoxantrone 10mg/m2/day IV on days 2-4.
95339|NCT03441048|Drug|G-csf|G-CSF at a dose of 300 µg on days 1-6.
95340|NCT03441035|Other|General anesthesia and surgery (liver transplantation)|The effects of general anesthesia and surgery under the hospital routine of albumin administration during and after liver transplantation is studied with the mass balance of albumin method.
95341|NCT03441022|Device|Amiigo Watch Only|Subjects will be asked to wear a wrist band with capabilities to detect their heart rate or rhythm on the basis of PPG on either wrist around the time of their cardioversion procedure. Data will be acquired from the wrist band at the same time as the electrocardiogram (ECG) monitor to which subjects are hooked up for the purposes of the cardioversion.
95342|NCT03441022|Device|Amiigo Watch + BodyGuardian|Subjects will be sent home after the cardioversion with a 30 day heart monitor called the BodyGuardian. This device continuously monitors their heart rate and rhythm and they will wear this on the chest. Subjects will also wear the wrist monitor over the same 30 day period.
95343|NCT03441009|Other|Physio-/occupational therapy|Physio-/occupational therapy, ADL
95379|NCT03440736|Behavioral|Life-style intervention|A structured program to guide weight loss and increased physical activity
95380|NCT03440723|Device|DilaCheck|Measuring device for the measurement of cervical dilation
95381|NCT03440723|Diagnostic Test|Cervical dilation examination|Sterile vaginal examination using subjective methods for measurement of cervical dilation
95382|NCT03440710|Procedure|BET|Balloon Eustachian Tuboplasty
95344|NCT03440996|Other|Clinpro™ 5000|Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
95345|NCT03440996|Other|Clinpro™ Tooth Crème|Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.
95346|NCT03440996|Other|MI-Paste Plus|MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
95347|NCT03440983|Device|MRI data acquiring in healthy volunteers|The quality of the images, cartographies or spectres will be compared to standard acquisitions. This evaluation will be based on qualitative visual criteria assessed by expert radiologists or on quantitative criteria assessed by data processing tools
95348|NCT03440970|Drug|Lysine Chloride|Patients will receive the study drug twice a day for 5 days.
95349|NCT03440970|Other|Placebo|Patients will receive the placebo twice a day for 5 days.
95350|NCT03440957|Other|Osteopathic treatment|The patients meeting the inclusions criteria will be informed of the study and an osteopathic treatment holistic ,involving all the body will be applied, three time with 2 days between the treatments .Each meeting with the practitioner will last around 40 minutes. The pain and symptoms assessment will be done before and after the treatment .
95351|NCT03440944|Device|Ultrasound Guided Peripheral IV Catheter|Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
95352|NCT03440944|Device|Midline Catheter|Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
95353|NCT03440931|Diagnostic Test|Ultrasound scan|Transvaginal ultrasound scan to assess ovaries
95354|NCT03440918|Other|Procalcitonin-Guided Antimicrobial Stewardship|In addition to baseline audit of antimicrobial orders, the stewardship team will additionally recommend procalcitonin (PCT) testing and treatment per algorithm. PCT will be used in conjunction with clinical status and exam, and results of radiographic and laboratory studies, to make medical decisions about antibiotic therapy.
95355|NCT03440918|Other|Baseline Antimicrobial Stewardship|Baseline audit of antimicrobial orders with feedback to providers by the antimicrobial stewardship team.
95356|NCT03440892|Drug|methotrexate|folate antagonist
95357|NCT03440892|Drug|sulfasalazine|Immunomodulatory
95358|NCT03440892|Drug|abatacept|Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
95359|NCT03440892|Drug|tocilizumab|IL-6 receptor antagonist
95360|NCT03440892|Drug|tofacitinib/baricitinib|JAK inhibitor
95361|NCT03440879|Drug|Zoladex|Patients currently treated with Zoladex
95362|NCT03440866|Drug|Administration of drugs concomitantly.|Administration of oral Mifepristone 600 mg and oral Misoprostol 400 mcg concomitantly.
95363|NCT03440853|Behavioral|TASCCI|TASCCI is a stepped-care collaborative care approach of pharmaco- and/or behavioral-therapy for a 12 week period. The intervention will target 1 or more symptoms based on patients' report of clinical levels of each symptom and patient preference. A trained behavioral therapist will deliver weekly video conferencing sessions during dialysis treatment.
95364|NCT03440853|Other|Technology Delivered Health Education Intervention|The Technology Delivered Health Education Intervention will deliver weekly video conferencing sessions to deliver online educational material from the National Kidney Foundation. These sessions will be delivered by a care coordinator.
95365|NCT03440840|Procedure|Transcranial Direct Current Stimulation (tDCS)|Application of a small electrical current (1-2 mA) across the head.
95366|NCT03440840|Behavioral|Computer-based Cognitive Training|Use of computer-delivered games or exercises with the goal of improving cognitive performance.
95367|NCT03440840|Behavioral|Watching Educational Videos|Watching educational videos and answering questions about them
95368|NCT03440827|Behavioral|Focus Group|First (phase 1), collect experiences, perceptions, difficulties, needs and expectations of patients with slow-flow malformations (for the age group of 11 to 15 years-old), carried out with 3 categories of participants and then (phase 2) development and validation of the specific scale of life's quality of slow-flow vascular malformation in children aged 11 to 15 years-old.
95369|NCT03440814|Drug|DCCR|Once daily oral administration
95370|NCT03440814|Drug|Placebo for DCCR|Once daily oral administration
95371|NCT03440801|Device|Synergy|Biodegradable-polymer everolimus-eluting stent Synergy
95372|NCT03440801|Device|Xience|Durable-polymer everolimus-eluting stent Xience
95373|NCT03440788|Drug|Brentuximab Vedotin|Brentuximab vedotin (BV) will be prescribed to patients in accordance with indication for treatment as second or subsequent line therapy after failure of at least one type of first-line therapy for patients with relapsed or refractory HL who are not candidates for ASCT, or for patients with relapse after ASCT within routine hematological practice. Dose, preparation, administration etc - as in Instruction for use (Prescribing information).
95374|NCT03440775|Behavioral|Digital stories|Digital story telling videos
95375|NCT03440775|Behavioral|Informational videos|Informational videos
95376|NCT03440762|Behavioral|AF awareness education|Participants will receive education about a description of AF, complications, recognition of signs and symptoms of AF, pulse taking, and how to recognize an irregular pulse
95377|NCT03440749|Other|luminous stimuli|The child is placed in front of a screen on which 4 luminous stimuli are presented on a horizontal plane. Four buzzers are placed in front of him, each buzzer corresponds to the position of a stimulus. Child had to push the buzzer corresponding to the place of the luminous stimuli.
95378|NCT03440736|Drug|Secukinumab|Secukinumab 300 mg s.c., which consists of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection is performed at week 24)
95383|NCT03440684|Other|Exercise|"At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program."
95384|NCT03440671|Biological|Hutox Inj|Hutox Inj(Clostridium botulinum type A)
95385|NCT03440671|Biological|Botox Inj|Botox Inj(Clostridium botulinum type A)
95386|NCT03440645|Other|Family-oriented primary cardiovascular prevention|An initial screening visit including a targeted history, physical exam, and investigations as per the Canadian Cardiovascular Society's recommendations for cardiovascular primary prevention. Counselling and informational handouts on improved cardiovascular risk factor and lifestyle habits. All family and household members, as well as the cardiovascular disease proband, are encouraged to attend and participate in all healthcare visits.
95387|NCT03440632|Device|FES|Functional electrical stimulation of the ankle dorsiflexors during walking, using a (superficial) neurostimulator with tilt sensor.
95388|NCT03440619|Device|INVSENSOR00013|Investigational pulse oximeter device that will be placed on the subject's finger. This will be used as a spotcheck device
95389|NCT03440606|Behavioral|Mindful-Compassion Art Therapy Supervision|"Each Mindful-Compassion Art Therapy Supervision group will focus on 3 major areas that cultivate self-care, resilience and communal support. The specific structure include: (1) Self-care and Stress Management in Week 1 and 2 (i.e., concept of mindfulness and art, the symbol of the mandala and its use in self-care, mindfulness practice and art); (2) Sharing of Clinical Expertise and Experiences in Week 3 and 4 (i.e., Create mindful art about one meaningful and one challenging patient/client interaction with small group discussion); and (3) Understanding Grief and Meaning-Making in Week 5 and 6 (i.e., Create mindful art representing a clinical encounter of mortality, and meaning-making from reflection on grief)."
95390|NCT03440593|Other|Caloric delivery will target results of IC measurement.|The prescribed calories to be delivered will be set to target the measurement obtained from performing indirect calorimetry (IC). IC measures the gas exchange of oxygen consumption and carbon dioxide production to determine the true metabolic needs for cellular respiration. The expenditure of calories will be measured utilizing the gas module incorporated within the General Electric Carescape R860 ventilators.
95391|NCT03440580|Device|BOOSTH|BOOSTH as a serious game is used as a tool to motivate children to perform more PA. BOOSTH uses the combination of a smartphone game and a pedometer that assesses daily PA by measuring steps/day. The BOOSTH activity monitor is a wrist-worn activity monitor that is able to provide online feedback on the child's PA levels. Moreover, BOOSTH is a reward-based game as a child is given incentive to increase their PA level, in order to acquire activity points which later can be used to unlock levels and progress in the BOOSTH game.
95392|NCT03440567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplantation
95393|NCT03440567|Drug|Avelumab|Given IV
95394|NCT03440567|Drug|Carboplatin|Given IV
95395|NCT03440567|Drug|Etoposide Phosphate|Given IV
95396|NCT03440567|Drug|Ibrutinib|Given PO
95397|NCT03440567|Drug|Ifosfamide|Given IV
95398|NCT03440567|Other|Laboratory Biomarker Analysis|Correlative studies
95399|NCT03440567|Biological|Rituximab|Given IV
95400|NCT03440567|Biological|Utomilumab|Given IV
95401|NCT03440554|Diagnostic Test|Whole Body Non-Contrast MRI|Whole Body Non-Contrast MRI in Prostate Cancer Patients
95402|NCT03440541|Combination Product|REGE pro|REGE pro is a patch of human amniotic membrane sterilized by gamma radiation
95403|NCT03440515|Drug|Prednisone|Prednisone treatment for severe skin rash induced by imatinib
95404|NCT03440502|Procedure|spinal anaesthesia|Intrathecal block under strict aseptic conditions will be performed by median approach (L3-4 or L4-5) under sitting position by anesthesiologists . 25 Gauge sprotte spinal needles and 2-3 mLof 0.5% hyperbaric bupivacaine
95405|NCT03440489|Diagnostic Test|Six-minute walking test|physical performance of the muscle measured by these tests
95406|NCT03440489|Diagnostic Test|30 seconds chair stand test|physical performance of the muscle measured by these tests
95407|NCT03440476|Behavioral|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
95408|NCT03440476|Behavioral|Feedback-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The content is clearly automatically generated.
95409|NCT03440476|Behavioral|Feedback-plus-personal-contact booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and reminders of strategies they can use to protect themselves from alcohol-related harm. The email is sent from an individual on the research staff.
95410|NCT03440463|Behavioral|e-checkup to go|The e-checkup to go substance program is designed to motivate individuals to reduce their consumption using personalized information about their own use and risk factors. The program is a combination of several components including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It is self-guided and requires no face-to-face time with an administrator. It provides tailored feedback regarding quantity and frequency of alcohol use, normative comparisons, physical health information, amount and percent of income spent on alcohol, negative consequences feedback, explanation and advice for how to reach their goals, and resources.
95411|NCT03440463|Behavioral|Norms-only booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare.
95412|NCT03440463|Behavioral|Norms-plus-Strategies booster|Booster emails will contain normative feedback indicating average consumption for students at the same institution by sex, their perceptions of student drinkers at the same institution, their own reported consumption, and how they compare. These booster emails will also contain reminders of strategies they can use to protect themselves from alcohol-related harm, both ones they've reported using in the past and others they might consider using in the future.
95413|NCT03440450|Drug|FF-10832 Gemcitabine Liposome Injection|FF-10832 to be diluted in dextrose 5% in water (D5W) and intravenously infused at a continuous rate over 60 minutes
95414|NCT03440437|Drug|FS118|Dosing of patients will occur intravenously (IV) weekly in 3-week treatment cycles until iCPD (ie, immune confirmed progressive disease) (or progressive disease [PD] per the Lugano classification for patients with lymphoma), unacceptable toxicity, or discontinuation.
95415|NCT03440424|Drug|Lemborexant|oral tablet
95416|NCT03440411|Drug|Pomalidomide|4 mg/daily as oral administration (PO) on days 1-21.
95417|NCT03440411|Drug|Cyclophosphamide|50 mg every other day as oral administration (PO) on days 1-28
95418|NCT03440411|Drug|Dexamethasone|40 mg as oral administration (PO) on days 1, 8, 15, 22.
95419|NCT03440398|Procedure|Robotic NSM|Surgical technique conducted using robot to perform nipple sparing mastectomy and breast reconstruction
95420|NCT03440398|Procedure|Open NSM|Open nipple-sparing mastectomy and immediate breast reconstruction with implant
95421|NCT03440385|Drug|Ozanimod|Ozanimod
95422|NCT03440385|Other|Placebo|Placebo
95423|NCT03440372|Drug|Ozanimod|Ozanimod
95424|NCT03440372|Other|Placebo|Placebo
95425|NCT03440359|Drug|Progesterone Vaginal Gel 8%|progesterone supplementation for luteal phase support administered with vaginal applicators and used instead of progesterone intramuscular injections or progesterone vaginal suppositories.
95426|NCT03440359|Drug|Letrozole Oral Tablet|letrozole oral tablet 2.5 mg or 5 mg administered cycle day 3-7 for ovulation induction
95427|NCT03440359|Diagnostic Test|pelvic ultrasound|pelvic ultrasound performed at cycle day 11 or 12 and repeated as necessary until leading follicle size is >17 mm in diameter
95428|NCT03440359|Drug|Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe|ovidrel 250 mcg given when leading follicle size is > 17 mm in diameter
95429|NCT03440359|Other|Intrauterine insemination or timed intercourse|Intrauterine insemination or timed intercourse (depending on semen parameters) performed 36-40 hours after Ovidrel
95430|NCT03440346|Other|Few-foods diet|The few-foods diet (FFD) is followed for 5-weeks preceded by a 1-week transition period during which the child's eating pattern will be gradually adjusted. The diet consists of rice, meat (turkey and lamb), a range of vegetables, pear, rice milk with added calcium and water, and is complemented with foods such as potatoes, fruits, corn, some sweets and wheat, which are allowed in small quantities only. Normal quantities of vegetables, rice and meat are allowed every day. If necessary the diet will be adjusted to avoid foods that the child dislikes or has cravings for. If the child does not respond to the initial FFD, i.e. no change in behaviour after the first two weeks, interim adjustments to the FFD will be made in consultation with the parents.
95431|NCT03440333|Drug|surfactant|Pulmonary surfactant was administrated if the baby was diagnosed with respiratory distress syndrome
95432|NCT03440320|Behavioral|MY-SKILLS|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of yoga and an hour of self-management designed to meet the needs of a caregiving dyad with chronic pain
95433|NCT03440320|Behavioral|MY-SKILLS control|Participants will complete an 8-week, 16 session class. Each class will consist of approximately an hour of exercise and an hour of education designed to meet the needs of a caregiving dyad with chronic pain..
95434|NCT03440307|Behavioral|Face-to-Face Meetings|Participants received health and fitness education, and a face-to-face 3-week intervention to reduce bisphenol exposure.
95435|NCT03440307|Behavioral|Email Only|Participants received health and fitness education.
95436|NCT03440294|Diagnostic Test|resting standard spirometry|The subject (seated, bust straightened) should perform, after a slow and maximum inspiration, a forced and complete exhalation followed by a new inspiration to the total lung capacity.
95437|NCT03440294|Diagnostic Test|maximum exercise testing|Incremental exercise on cycle ergometer with 100W start for men (80W for women) for 4 minutes as part of the warm-up. Then, step increment of a 50W power for men (40W for women) lasting 2 minutes each.
95438|NCT03440281|Diagnostic Test|Uterine artery doppler|Uterine artery Doppler pulsatility indices
95439|NCT03440281|Diagnostic Test|Maternal serum homocysteine estimation|
95440|NCT03440268|Drug|N Acetyl Cysteine|Administrate NAC in the pre operatory and intra operatory moments and assess the influence in the outcomes
95441|NCT03440268|Drug|Placebos|These participants will receive a saline solution in pre operatory with the same volume as the experimental group, and this solution will be administrated in 2 hours. During the surgery they will receive a new solution with the same volume of the experimental group, and this solution will be administrated in 6 hours too. The solutions will be covered by an opaque bag, so the participant will not see what is being administrated
95442|NCT03440255|Device|Transcutaneous Vagus Nerve Stimulation|"TaVNS will be applied by the TENS 7000 device. The stimulation was set according the group of treatment: (GAD: 20Hz-80µs), (CP: 5Hz-200 µs), (IBS: 3Hz-250µs).~The current intensity was individually established under the pain threshold .The stimulus generates an continous asymmetric biphasic waveform. Ear clip electrodes were plugged in the concha area of the left ear. The stimulation will last 30 min per session (total=8)"
95443|NCT03440242|Device|JJVC Contact Lens|etafilcon A with PVP DD
95444|NCT03440242|Device|Marketed Contact Lens|nelfilcon A DD
95478|NCT03439943|Drug|Lixisenatide|Patients randomized in the Lixisenatide group will receive 10μg/day for 14 days and then 20μg/day administered by once-daily subcutaneous injections during 12 months. If patients are unable to tolerable the dose of 20μg/day, this dose can be reduced to 10μg/day
95479|NCT03439943|Drug|placebo|Patients randomized in the placebo group will receive the corresponding placebo administered subcutaneously (once daily subcutaneous injection).
95445|NCT03440229|Other|Emulsifier-containing diet|CMC is one of many synthetic dietary emulsifiers that are incorporated into a variety of processed foods. We have recently shown that, in mice, consumption of P80 and CMC, alters microbiota composition, have pro-inflammatory potential and promote microbiota encroachment into the colonic mucosa, low-grade inflammation, and metabolic syndrome. However, it is not known whether these compounds have similar effects in humans. We would like to study these effects in the human gut microbiota.
95446|NCT03440216|Drug|blood sampling|"temocillin: blood sampling every day for 7 days~ceftriaxone: blood sampling 12h after administration for 7 days~meropenem: blood sampling at 1h, 3h, 5h and 8h after initiation of the administration at days 1 and 2; one sampling at 8h on days 3 to 7"
95447|NCT03440216|Drug|Tissue sampling (lung)|Sampling of tissue (lung) when possible during treatment for measurement of the content in antibiotic (temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient)
95448|NCT03440216|Drug|Collection of fluid samples|Collection of fluid samples (bronchoalveolar lavage, drainage fluid) for determination of antibiotic ((temocillin, ceftriaxone, or meropenem, depending on the drug received by the patient) concentration when possible during treatment
95449|NCT03440203|Other|difficult activities of daily living in each group|Compare the severity of pain by the severity of diabetic peripheral neuropathy. Compare the difficulties in ADLs in three group of diabetic patients
95450|NCT03440190|Drug|Methylphenidate|Patients are tested for their normal prescription methylphenidate medication
95451|NCT03440177|Drug|Ramipril|Patients are tested for their normal prescription ramipril medication
95452|NCT03440164|Other|Sylimarin and Sylibin|We compared the plasma levels of Silibinin after a dosage of Silibinin-phosphatidylcholine complex, equivalent to 45 mg Silybin oily-medium soft-gel capsules after the conventional 70-mg Silymarin tablets, in 23 healthy volunteers
95453|NCT03440151|Procedure|contralateral submental flap for tongue cancer defect|"Tumor resection will be star first this accomplish with 1- 2 cm safety margin, Simultaneous neck dissection will be performed in all patient.~Flap dissection begins from the opposite side of the pedicle in the subplatysmal plane. Then the level 1a is dissected, the distal facial artery and facial vein to the branching point of the submental pedicle are ligated. The anterior belly of the digastric muscle on ipsilateral to the pedicle and strip of mylohyoid muscle will dissected off the mandible and the hyoid bone and included with the flap. This results in complete mobilization of the flap.A tunnel will be created between the defect and the donor site and the skin paddle of the flap will be transported through it intraorally and the flap is insetted."
95454|NCT03440151|Procedure|primary closure for tongue cancer defect|Under general anesthesia the tumor will be resected with Preserving floor of mouth mucosa as much as possible to avoid restriction of tongue mobility. After Obtaining meticulous hemostasis, the tongue defect will be closed in layers.
95455|NCT03440138|Procedure|bariatric surgery (RYGB or SG)|laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy for severe obesity
95456|NCT03440125|Drug|Cayenne Pepper topical|20min topical Cayenne Pepper Cataplasm application containing 5% Cayenne Pepper nd 95% Kaolin mixed with water
95457|NCT03440125|Device|Electrical stimulation|Electrical stimulation 10min 60Hz biphasic rectangular neuromuscular electrical Stimulation (NMES)
95458|NCT03440125|Procedure|Massage|10 minutes of classical massage of low back pain area.
95459|NCT03440112|Drug|Clarithromycin|Clarithromycin (generic) capsule 250mg each
95460|NCT03440112|Drug|Placebo|Lactose in a gel capsule
95461|NCT03440099|Other|Resistance exercise training|16-week exercise training program, wherein one leg undergoes traditional low-velocity, high-load resistance training and the other leg undergoes high-velocity, low-load power training.
95462|NCT03440086|Device|abdominal Jackson-Pratt drain|One-hour application of abdominal Jackson-Pratt drain at the end of laparoscopic procedure.
95463|NCT03440073|Other|Mulligan Concept Intervention|The concept is a manual therapy paradigm that includes a clinician applying joint mobilizations and having the patient perform concurrent active, pain free, movement.
95464|NCT03440073|Other|Sham Mulligan Concept Treatment|The treating clinician will ask the participant to perform the movements associated with the Mulligan Concept technique. The clinician will have her hands on the participant during the movement but will not apply any pressure or force.
95465|NCT03440060|Diagnostic Test|procalcitonin|procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only
95466|NCT03440047|Device|Fuji Flim Processor VP-7000, Light Source BL-7000|Fujifilm's Digital Video Processor VP-7000 and LED Light Source BL-7000 is a class II Endoscopic Video Imaging System under 21 C.F.R. 876.1500. It is the next generation of Fujifilm's VP-4440HD Digital Video Processor with Flexible-spectral Imaging Color Enhancement (FICE) and Light Source (K140149).
95467|NCT03440034|Drug|Pioglitazone|Pioglitazone comes as a tablet to take by mouth and can be taken with or without food.
95468|NCT03440021|Drug|ORM-12741|Novel selective alpha2c adrenoceptor antagonist
95469|NCT03440021|Drug|Placebo|Identical in appearance to experimental drug, not psycho-active
95470|NCT03440008|Other|Dynamic 3D bone motion capture|Two x-ray systems will image the subjects ankle while they walk, allowing us to calculate ankle joint angle and alignment
95471|NCT03440008|Device|wedged insole|medial or lateral wedge (appropriate for varus or valgus misalignment) will be applied during 1 data collection session to evaluate effect of wedging on misalignment
95472|NCT03439995|Other|Open lung protective ventilation|Higher PEEP, lower tidal volume mechanical ventilation
95473|NCT03439995|Other|Conventional ventilation|Lower PEEP, standard tidal volume mechanical ventilation
95474|NCT03439982|Biological|FMT|FMT processed from routinely screened donors
95475|NCT03439969|Device|Mobile Text Messages|Dental inter-proximal control with floss holder and receiving 16 SMS during 4 months.
95476|NCT03439969|Device|Intra Oral Camera|"SPT - Appointment with Intra-Oral Camera~Examination and diagnosis (15 min) using Intra-oral camera.~Motivation, discussion about desired outcomes and treatment needs (using Intra-oral camera) followed by instrumentation (scaling, polishing) (30 min)."
95477|NCT03439956|Procedure|Transvaginal specimen extraction|Previous transvaginal specimen extraction through posterior colpotomy.
95480|NCT03439930|Other|Balance training|6 weeks lasting balance training program
95481|NCT03439917|Dietary Supplement|L-Carnitine tartrate|2g L-Carnitine tartrate as a powder consumed twice a day
95482|NCT03439917|Dietary Supplement|Meal Replacement Drink|325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
95483|NCT03439917|Dietary Supplement|Maltodextrin|2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day
95484|NCT03439904|Other|Pharmaceutical care|Patients receive pharmaceutical care including individualized evaluation and intervention of adherence, efficacy and safety in cancer pain treatment.
95485|NCT03439891|Other|Laboratory Biomarker Analysis|Correlative studies
95486|NCT03439891|Biological|Nivolumab|Given IV
95487|NCT03439891|Drug|Sorafenib|Given PO
95488|NCT03439878|Dietary Supplement|Galactose|Co-ingestion of d-galactose with a high-fat meal
95489|NCT03439878|Dietary Supplement|Glucose|Co-ingestion of d-glucose with a high-fat meal
95490|NCT03439865|Drug|Ivacaftor|150 mg tablet PO BID x 14 days
95491|NCT03439865|Drug|standard of care treatment|topical nasal steroid spray and culture-directed antibiotics x 14 days
95492|NCT03439852|Behavioral|Light-to-Moderate Physical Activity / Sedentary Time|12 weeks of telephone counseling -motivational interviewing designed to increase leisure-time physical activity and decrease amount of sitting each day
95493|NCT03439839|Drug|LNP023|LNP023 bid
95494|NCT03439813|Behavioral|TASK-CBT|.Web and telephone-delivered cognitive behavioural therapy designed for anxiety after stroke and TIA. Six personalized telephone CBT sessions, one week apart by a trained and supervised medical professional using the TASK Therapist's Manual. Treatment website contains multimedia content to cover key CBT skills with weekly online tasks.
95495|NCT03439813|Behavioral|TASK-Relax|Web and telephone-supported relaxation therapy. Treatment website contains five relaxation exercises: i) audio- and visually-guided breathing exercise, ii) relaxing imagery and sounds, iii) music for relaxation, iv) audio-guided progressive muscle relaxation, and v) a selection of sounds of nature. Telephone instruction given and treatment website contains multimedia content to explain to participant how to practice relaxation regularly during the trial period.
95496|NCT03439800|Other|Mental and Physical Practice|"Subjects will see a video of the typical gait and will attempt to analyze the sequence of the gait cycle.~They will imagine themselves walking in the first-person perspective (kinesthetic) using the gait of the non-pathological pattern during 2 minutes.~From the 1st to 4th session, the subjects will perform gait with corrections identified in previously in the video for 2 minutes.~From 5th to 8th session: the subjects will do the protocol already described, however, the imagined gait will be in an environment with obstacles, also for 2 minutes. They will continue with the physical practice of the gait with obstacles.~From 9th to final training session: both mental and physical practice of the dual task gait."
95497|NCT03439800|Other|Physical Practice|"Subjects will see a video about PD which does not mention physiotherapy treatments related to gait and they will explain their understanding about the theme.~Then, the patients will make the physical gait protocol. Patients will be invited to perform the gait, in flat and firm ground with a length of 60 meters. The execution will be carried out for 10 minutes.~From the 5th to 8th session, the subjects will do the physical practice of the gait with obstacles (which will be: going through 2 cones zigzag, going up and down 1 step, going through a narrow door, going up and down 1 ramp, going over 1 box of shoes, climbing a ramp, going down 1 step) for 2 minutes.~From the 9th to the final training session, the subjects will do physical practice of the dual task gait."
95498|NCT03439787|Drug|Bupivacaine-EPINEPHrine 0.5%-1:200,000 Injectable Solution|10 ml
95499|NCT03439787|Other|Sodium Chloride 0.9 %|10 ml
95500|NCT03439774|Device|Topcon CT-800|tonometer
95501|NCT03439774|Device|Topcon TRK-2P|tonometer, pachymeter
95502|NCT03439761|Drug|PT-112 Injection|PT-112 Injection 28 days constitute a period. The drug is intravenously dripped for 60 minutes at the 1st, 8th and 15th day of each period.
95503|NCT03439748|Behavioral|Positive Affect Treatment|Sessions 1-7: Planning for engagement in pleasurable activities and reinforcement of positive mood effects of those activities Sessions 8-10: Exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.
95504|NCT03439748|Behavioral|Negative Affect Treatment|Sessions 1-7: Exposures to avoided scenarios Sessions 8-10: Cognitive restructuring Sessions 11-14: Normalization of arousal response to exposure Session 15: Relapse prevention
95505|NCT03439735|Drug|Aromatase Inhibitor and Palbociclib|Participants that are initiating treatment with an AI and Palbociclib.
95506|NCT03439722|Other|Polysomnography|Participants will be admitted for 1 night at the Danish Center of Sleep Medicine for polysomnography.
95507|NCT03439709|Radiation|Gamma knife radiosurgery|Minimum 25 Gy of marginal dose is applied for residual tumor or resection cavity. Depending on the size of tumor, the dose can be varied.
95508|NCT03439709|Drug|Lanreotide 60Mg Solution for Injection|Lanreotide injection.
95509|NCT03439696|Procedure|Thoracoscopic surgery|Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
95510|NCT03439683|Other|Survey about patient-ventilator asynchrony|Participants will fill an online survey that asks multiple-choice questions related to knowledge, attitudes and practice related to patient-ventilator asynchrony and also have images of ventilator waveforms wth asynchrony, where they need to identify the type of asynchrony
95511|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for the duration of the study.
95512|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
95513|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
95514|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for the duration of the study.
95515|NCT03439670|Drug|Prednisone|Oral administration of 0.75 mg/kg/day for 24 weeks.
95516|NCT03439670|Other|Placebo|Oral administration of placebo daily for 24 weeks.
95517|NCT03439670|Drug|Vamorolone|Oral administration of 2.0 mg/kg/day for 20 weeks.
95518|NCT03439670|Drug|Vamorolone|Oral administration of 6.0 mg/kg/day for 20 weeks.
95519|NCT03439657|Biological|HZ/su vaccine GSK1437173A|2 doses of 0.5 mL of the vaccine in a 0,2 Months schedule. Administered by intramuscular injection into the deltoid muscle of the non-dominant arm.
95520|NCT03439657|Biological|Prevenar13|1 dose of 0.5 mL of the vaccine. Administered by intramuscular injection into the deltoid muscle of the dominant arm.
95521|NCT03439644|Other|Measurement of the upper eyelid laxity|Measurement using a soft slider of the distance between our 2 marks The difference obtained between the measurement and the initial 10 millimeters corresponds to the tarsal laxity.
95522|NCT03439631|Other|Patient satisfaction questionnaire|Patient satisfaction questionnaire
95523|NCT03439618|Other|time-restricted feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group. In continuous feeding group, the enteral nutritional suspension was fed at constant speed for 24h.In the time restricted feeding, feeding time should be at 7:00-9:00, 11:00-13:00 and 17:00-19:00 at constant feeding speed.
95524|NCT03439618|Other|continuous feeding|At the beginning, all enrolled patients were fed by continuous feeding. When the amount calorie of feeding enteral nutritional suspension increased to 80% target calorie (target calorie: 25kilocalorie/kg.d), the patients was randomly into continuous feeding and time-restricted feeding group.In the continuous feeding, the total amount of every days' Enteral Nutritional Suspension was fed at constant speed for 24h.
95525|NCT03439592|Diagnostic Test|collection of fecal material|in study population we will collect fecal material to analyze the microbiotic flora by genetic techniques.
95526|NCT03439579|Behavioral|Home weight loss program|Patient remote self-monitoring of diet, activity, and weight with clinician feedback provided remotely based on self-monitored data.
95527|NCT03439553|Behavioral|Ads display with target websites|Ads are shown, but users are referred to control websites.
95528|NCT03439553|Behavioral|Ads display with control websites|Ads are shown, but users are referred to control websites.
95529|NCT03439540|Dietary Supplement|Plantago major|Individuals receive Plantago major daily, for 2 months
95530|NCT03439540|Dietary Supplement|Placebo|Individuals receive placebo daily, for 2 months
95531|NCT03439527|Other|Muscle Precursor Cells (MPCs), ATMP|The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.
95534|NCT03439501|Drug|avelumab|"Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~Dosage: 10 mg per body weight (kg) of a subject every two weeks~One cycle consists of two injection of avelumab (28 days).~The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle."
95535|NCT03439488|Drug|JNJ-440|JNJ-440 will be administered as oral tablets in Parts 1, 2 and 3. JNJ-440 may be provided as oral solution in a cohort in Part 1.
95536|NCT03439488|Drug|Placebo|Matching placebo as oral tablets will be administered in Parts 1, 2 and 3.
95537|NCT03439475|Biological|AMG 714|
95538|NCT03439462|Drug|ABI-009; nab-rapamycin; albumin-bound rapamycin|albumin-bound rapamycin
95539|NCT03439449|Device|CLEOS software program|Computer-assisted history taking program
95540|NCT03439449|Procedure|Physician taken history|Conventional history taking by physicians
95541|NCT03439436|Drug|xylo+dex nasal spray (0.1 mg+5 mg/dose)|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
95542|NCT03439436|Drug|Nasic|Xylometazoline+Dexpanthenol metered nasal spray (0.1 mg+5 mg/dose) for nasal congestion. One spray into each nostril, 3 times daily for max 5 days.
95543|NCT03439423|Radiation|CT with contrast agent|
95544|NCT03439423|Diagnostic Test|MR without contrast agent|"on 1.5-T unit, with the following sequences:~steady-state free-precession (true-FISP)~half-Fourier single shot spin-echo (HASTE)"
95545|NCT03439423|Diagnostic Test|Color-Doppler Ultrasound|
95546|NCT03439423|Other|Questionnaire|regarding their perception of examinations
95547|NCT03439410|Other|Clinical Complexity Index|Clinical Complexity Index (CCI) will be administered at the time of admission to the ward.
95548|NCT03439397|Device|Ballon Technique|Ballon Technique
95549|NCT03439397|Device|SOAI|SOAI
95550|NCT03439384|Device|Home Telemonitoring|Patients will monitor their weight, blood pressure, oxygen saturation and symptoms with sensors and a tablet computer provided to them. Patients are asked to do this everyday for 60-days. A monitoring nurse will be receiving the data electronically and reviewing on a daily basis.
95551|NCT03439371|Other|HLA-mismatched micro-transplantation after induction chemotherapy|HLA-mismatched micro-transplantation after induction chemotherapy
95552|NCT03439358|Drug|Magnesium Sulfate|Bolus infusion: 100mL normal saline with 4g MgSO4 over 30 minutes Maintenance infusion: 25mL normal saline per hour with 1g MgSO4
95553|NCT03439358|Other|Normal Saline|Bolus infusion: 100mL normal saline over 30 minutes Maintenance infusion: 25mL normal saline per hour
95554|NCT03439345|Drug|Fenofibrate 145 mg|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
95555|NCT03439345|Drug|Placebo Oral Tablet|One tablet (taken daily with normal renal function, taken every second day with chronic kidney disease)
95556|NCT03439319|Device|MyndMove®|This FES therapy can be used as a short-term therapeutic intervention to help improve voluntary grasping function
95557|NCT03439319|Other|Conventional Therapy|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
95558|NCT03439306|Device|Pulse Oximeter|The Pulse Oximeter are placed on the left and right Index fingers of each subject of the healthy adult volunteer group to evaluate the SpO2 accuracy performance.
95559|NCT03439293|Drug|Ixazomib|Ixazomib capsule.
95560|NCT03439293|Drug|Daratumumab|Daratumumab IV infusion.
95561|NCT03439293|Drug|Dexamethasone|Dexamethasone tablets.
95562|NCT03439280|Drug|TAK-079|TAK-079 subcutaneously.
95563|NCT03439280|Drug|Pomalidomide|Pomalidomide orally.
95564|NCT03439280|Drug|Dexamethasone|Dexamethasone orally.
95635|NCT03438747|Device|P-15L Bone Graft|The investigational group will be treated with P-15L in an instrumented TLIF
95565|NCT03439267|Combination Product|Coronary Artery Calcium Screening and Statin Treatment|Will undergo coronary artery calcium screening and will receive statin treatment based on the cardiovascular risk algorithm.
95566|NCT03439267|Other|Standard Treatment|Patients will be managed following the AHA/ACC guidelines for statin initiation and follow-up.
95567|NCT03439254|Drug|Obeticholic acid (10 mg)|Tablets administered orally once daily.
95568|NCT03439254|Drug|Obeticholic acid (10 mg to 25 mg)|Tablets administered orally once daily.
95569|NCT03439254|Drug|Placebo|Tablets administered orally once daily.
95570|NCT03439241|Device|Coloplast ostomy device|the test product is a newly developed Coloplast ostomy device
95571|NCT03439228|Device|Lumbar brace|3 months of lumbar brace wear
95572|NCT03439215|Drug|Lorlatinib|Lorlatinib is a novel small-molecule ROS1/ALK inhibitor that was optimized for robust brain penetration.
95573|NCT03439202|Other|Hypoxia|Subject will conduct low-intensity exercise on a bike in different hypoxic conditions.
95574|NCT03439176|Other|Standard adhesive 1|This strip contains a standard hydrocolloid adhesive found in ostomy devices
95575|NCT03439176|Other|Standard adhesive 2|This strip contains a standard hydrocolloid adhesive found in ostomy devices
95576|NCT03439176|Other|PL4|This strip contains a new adhesive
95577|NCT03439176|Other|PL16-L|This strip contains a new adhesive
95578|NCT03439163|Device|MRI scan|All participants underwent the MRI scan
95579|NCT03439150|Diagnostic Test|Absolute flow and resistance measurement|Absolute flow and resistance measurements immediately after PPCI of the culprit vessel (in a STEMI setting) and repeated absolute flow and resistance measurements after 3-7 days
95580|NCT03439137|Drug|MT-6548|Oral tablet
95581|NCT03439137|Drug|Darbepoetin alfa|Intravenous administration
95582|NCT03439137|Drug|MT-6548-matching placebo|Oral tablet
95583|NCT03439137|Drug|Darbepoetin alfa-matching placebo|Intravenous administration
95584|NCT03439124|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril 10 to 20 mg/kg (age-adjusted) IV q8h
95585|NCT03439124|Drug|Ceftazidime|Ceftazidime 50 mg/kg IV q8h, up to a maximum of 6 g/day
95586|NCT03439124|Drug|Ceftriaxone|Ceftriaxone 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day
95587|NCT03439111|Dietary Supplement|Standardized Lycium chinense Fruit Extract (LCF) capsules|All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
95588|NCT03439098|Dietary Supplement|Fermented Codonopsis lanceolata 525mg|Fermented Codonopsis lanceolata 525mg daily for 8 weeks
95589|NCT03439098|Dietary Supplement|Fermented Codonopsis lanceolata 1050mg|Fermented Codonopsis lanceolata 1050mg daily for 8 weeks
95590|NCT03439098|Dietary Supplement|Placebo|Placebo daily for 8 weeks
95591|NCT03439085|Biological|DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457|Given IM and via electroporation
95592|NCT03439085|Biological|Durvalumab|Given IV
95593|NCT03439072|Drug|G-Pen|1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
95594|NCT03439072|Drug|Lilly Glucagon|1 mg subcutaneous injection of Lilly Glucagon (glucagon injection [RNDA Origin])
95595|NCT03439059|Behavioral|Reducing Sedentary Behaviour Group|Participants will be prompted to perform 10min of light physical activity (>1.5 METS) 3x/day for 6 weeks
95596|NCT03439046|Drug|Ribociclib|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
95597|NCT03439046|Drug|Letrozole|Ribociclib oral (3weeks on/1week off) in combination with oral once daily letrozole: 600mg tablets ribociclib QD + 2.5 mg tablets letrozole QD
95598|NCT03439046|Drug|Alpelisib|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
95599|NCT03439046|Drug|Fulvestrant|Alpelisib 300 mg oral daily on a continuous dosing schedule in combination with fulvestrant 500 mg intramuscular on Days 1 and 15 of Cycle 1, and on Day 1 of each cycle thereafter in a 28 days cycle
95600|NCT03439033|Drug|PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
95601|NCT03439033|Drug|Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC|Subjects have two visits (the second visit being optional) within two years. During each visit, they will undergo one PET/MRI with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
95602|NCT03439033|Drug|PET/CT with Gallium-68 labeled PSMA-HBED-CC|Subjects have one visit, during which they will undergo one PET/CT with the study drug, Gallium-68 labeled PSMA-HBED-CC, a radiopharmaceutical
95603|NCT03439020|Procedure|Plastic stent anchoring|Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
95604|NCT03439020|Procedure|FCSEMS|Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
95605|NCT03438994|Diagnostic Test|Play.Care|iPad based game to assess movement as the player interacts with the screen
95606|NCT03438968|Behavioral|Exercise training|Cardiac Rehabilitation exercise training
95607|NCT03438955|Drug|Omacor|Omacor soft capsule 4000mg for 16days
95608|NCT03438955|Drug|Pritor|Pritor tablet 40mg for 7days
95609|NCT03438955|Drug|Omacor + Pritor|Omacor soft capsule 4000mg + Pritor tablet 40mg for 7days
95610|NCT03438955|Drug|Pritor + Omacor|Pritor tablet 40mg + Omacor soft capsule 4000mg for 16dyas
95611|NCT03438942|Dietary Supplement|Folic acid and iron supplementation|Individuals with low level of blood folic acid and iron- will receive folic acid and iron supplementation daily, for 3 months
95612|NCT03438942|Dietary Supplement|Control group|Individuals with proper level of blood folic acid and iron- will not receive folic acid and iron supplementation daily, for 3 months
95613|NCT03438929|Device|Diode laser|Diolaze XL blended modes diode laser
95614|NCT03438903|Device|Repeat exams of OCT device|All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
95615|NCT03438890|Device|Warm saline|In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
95616|NCT03438890|Device|anti-fog agent|In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
95617|NCT03438890|Device|chlorhexidine|In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
95618|NCT03438877|Procedure|Intensive dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 3.5. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 24-36L/day of dialysate, 1.5-2L/exchange, and 16 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
95619|NCT03438877|Procedure|Regular dosage of PD|Within the first month since PD initiates, PD prescription will be adjusted to achieve the minimum target of 2.1. It's anticipated to prescribe the dosage with automatic PD (APD) or manual PD as 9-12L/day of dialysate, 1.5-2L/exchange, and 6 cycles. Anyway, it depends on the characteristics of the patients, including residual renal function, peritoneal memberane properties. The Kt/V goal will be compromised by clinical assessment for the patient, which means PD will not induce additional treatment, such as fluid infusion.
95620|NCT03438864|Device|Electrotherapy, interferential current|Interferential current, entry frequencies and beat frequencies were set differently in 2 groups, amplitude was individualized and increased until patients felt a comfortable tickling sensation.
95621|NCT03438864|Other|Control|No current except for first 5 seconds, device open but does not appy electrotherapy.
95622|NCT03438851|Device|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
95623|NCT03438838|Procedure|Laparoscopic Heller's myotomy|"Laparoscopic Heller's myotomy:~Anterior wall of esophagus is exposed by opening peritoneum and minimal dissection of fat over it. Myotomy is started at 2 cm above the esophago- gastric junction. Initial plane is created using dissector and further muscles are split using pair of dissector or bowel holding forceps for length of 7 to 8 cm with 2 cm over stomach"
95624|NCT03438838|Procedure|Anterior Fundoplication|The Fundus was sutured with 3 stitches on either side of the esophagus to right and left crus of diaphragm using ethibond(1-0) beside intervening stitch over esophagus. Width of fundoplication is kept approximately at 2cm. The proximal short gastric vessels were divided only if the fundus is insufficiently mobile
95625|NCT03438825|Procedure|Mitral valve replacement/repair|Mitral valve replacement/repair: standard of care operation of the mitral valve due to severe insufficiency
95626|NCT03438812|Dietary Supplement|dehydroepiandrosterone (DHEA)|Participants take DHEA 90 mg daily for two months at least before in vitro fertilization cycles.
95627|NCT03438799|Device|Cordio System|App, cloud and web device
95628|NCT03438786|Procedure|Trans-inguinal Pre-peritoneal Hernioplasty|"patients were catheterised pre-operatively, to prevent any injury to the bladder and aid in preperitoneal dissection. The catheter was removed after 48 hours post-operatively.~Incision of TIPP is same as that of Lichtenstein technique . After dissection of the sac, the transversalis is fascia is incised to enter the preperitoneal space. The preperitoneal space is developed by dissection with index finger. The space extends from rectus muscle medially, arcuate line cranially, a little beyond the anterior superior iliac spine over the psoas muscle laterally and the lilipubic tract caudally. A 15 cm x 15 cm polypropylene mesh, cut into dimension 15 cm x 12 cm, the inferior medial angle of the mesh is trimmed in a semicircular fashion to prevent trauma to the bladder neck. The mesh is placed in the preperitoneal space and anchored to the Cooper's ligament with a single 2-0 interrupted prolene suture"
95629|NCT03438786|Procedure|Lichtnestein's hernioplasty|incision 1 cm above and parallel to inguinal ligament,Opening subcutaneous fat ,Opening Scarpa fascia to external oblique aponeurosis ,visualization of external ring and lower border of the inguinal ligament,Opening deep fascia of the thigh,checking for a femoral hernia ,Division of external oblique aponeurosis from external ring laterally for 5 cm, safeguarding ilioinguinal nerve ,Mobilization of superior and inferior flaps of external oblique aponeurosis exposing underlying structures ,Mobilization of spermatic cord along with the cremaster, including (ilioinguinal ,genitofemoral) nerves, and spermatic vessels; all of these structures may be encircled in a tape ,Opening of the coverings of spermatic cord, identification and isolation of the hernia sac ,Inversion, division, resection, or ligation of the sac ,Placement and fixation of mesh to edges of the defect or weakness in the posterior wall of inguinal canal creating artificial internal ring,Closure
95630|NCT03438773|Drug|Envarsus|Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
95631|NCT03438773|Drug|Tacrolimus|Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
95632|NCT03438760|Behavioral|Science + Phonological Awareness|The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
95633|NCT03438760|Behavioral|Science + Grammar Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
95634|NCT03438760|Behavioral|Science + Vocabulary Intervention|The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
95636|NCT03438747|Other|Local autologous bone in a TLIF with Instrumentation|The active control group will be treated local autologous bone in an instrumented TLIF
95637|NCT03438734|Device|Regional cerebral oxygen saturation|Regional cerebral oxygen saturation is a useful clinical research tool for noninvasive and continuous monitoring of hemodynamic and brain oxygenation. Regional cerebral oxygen saturation (Near-infrared spectroscopy system, NIRS, Cerebral Oximeter) monitoring was performed to all patients.
95638|NCT03438734|Device|Bispectral Index (BIS)|The most effective method for depth of anesthesia and assessment of sedation is bispectral analysis of mean frequency of electroencephalography. The values of BIS decreases with the deepening of anesthesia.
95639|NCT03438721|Behavioral|Infant obesity prevention|Parents will receive education on infant feeding, sleep, and screen time practices just after well-child visits in the first year of life. The education will be provided by a lay health educator. Parents will also receive text messages to reinforce the intervention content
95640|NCT03438721|Behavioral|Financial coaching|Parents randomized to the financial coaching arm will receive basic education on financial topics including budgeting, savings, and managing debt as well as coaching on these topics just after well-child visits in the first year of life. Coaching will be provided by lay health educators trained in financial coaching. Parents will also receive text messages reinforcing the information learned.
95641|NCT03438708|Drug|Axitinib Oral Tablet [Inlyta]|Axitinib 5 milligrams (mg) administered orally (po) twice daily (BID) for 8 weeks (with titration to 7 mg BID as tolerated at 4 weeks)
95642|NCT03438695|Procedure|Motorized Spiral Enteroscopy|Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
95643|NCT03438682|Device|Essure|Essure hysteroscopic sterilization
95644|NCT03438682|Procedure|Laparoscopic sterilization|Laparoscopic sterilization via electrocautery, ring, or clip.
95645|NCT03438682|Device|Intrauterine Device (IUD)|Intrauterine Device (IUD)
95646|NCT03438669|Other|no intervention|no intervention
95647|NCT03438656|Behavioral|Behavioral Activation|The Adolescent Behavioral Activation Program (ABAP) will be used as the BA protocol. ABAP was developed and validated by McCauley, Dimidjian et al. to adapt BA to adolescents. ABAP is a 12-week protocol that utilizes an idiographic approach to foster rewarding experiences, effective problem solving, and goal attainment, and decrease avoidance, barriers to activation, and depressive rumination that may be contributing to depression severity and maintenance.
95648|NCT03438643|Diagnostic Test|Blood samples|Blood samples (42mL) will be taken before and during treatment.
95649|NCT03438643|Diagnostic Test|skin biopsy|skin biopsy will be taken before and during treatment.
95650|NCT03438617|Behavioral|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
95651|NCT03438604|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
95652|NCT03438591|Device|Medtronic 4196 lead|Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)
95653|NCT03438578|Device|Efficacy Safety Score monitoring|According to data gathered from ESS and monitoring, the patients will receive needed care.
95654|NCT03438565|Device|Asahi Chikai Black 18 neurovascular guidewire|"The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback."
95655|NCT03438552|Radiation|Stereotactic Body Radiotherapy|This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.
95656|NCT03438539|Behavioral|Normative Feedback|Subjects assigned to normative feedback will be directed to a statement standardized based on subjects' reported average number of standard drinks per week, age, and gender.
95657|NCT03438539|Behavioral|Inhibitory Control Training|The inhibitory control training task is a modified version of the Cued Go/No-Go tasks (Weafer and Fillmore, 2012; Miller et al. 1991) and is based on a task currently used in our laboratory targeting cocaine inhibitory control.
95658|NCT03438539|Behavioral|Working Memory Training|A battery of working memory tasks will be used during the intervention period. These tasks were selected from previous research evaluating working memory training in substance use disorder (Bickel et al., 2011b; Houben et al., 2011b). Tasks will include visuospatial working memory task, digit span task, letter span task, and the n-back task.
95659|NCT03438526|Drug|Melatonin (Circadin ®)|4 mg of oral melatonin at 8 p.m. for the length of the duration of the hypoactive delirium
95660|NCT03438526|Drug|Placebo|Lactose monohydrate, cellulose powder, magnesium stearate (Ph. Eur.), mocrocristalline cellulose
95661|NCT03438513|Behavioral|Occupational Therapy Assessment|The occupational therapy assessment includes a functional evaluation of the disorders impact (activities of daily living)
95662|NCT03438513|Behavioral|Psychological Assessment|It consists of a detailed history of the patient's experience, an evaluation with the patient (cognitive, emotional, motivational ...), an interview with the caregiver to see the repercussions of the disorders on a daily basis, how they are managed, and how they cope in order to give information and advice.
95663|NCT03438513|Behavioral|Problem Solving Therapy|Problem-solving learning program for all situations of daily living, done in groups (10 people per group)
95664|NCT03438513|Behavioral|Speaking group|Intervention, carried out in groups (10 people per group) which will consist of sharing experiences, sufferings, exchange and allow people who attend to share their experiences.
95665|NCT03438500|Device|Cardiac Extracorporeal Shockwave Therapy (Modulith SLC)|40 - 60 spots per visit (200 shots/spot) at Energy Level 3
95666|NCT03438487|Biological|Flucelvax Trivalent Influenza Vaccine|"Flucelvax is a cell culture seasonal trivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage or B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
95667|NCT03438487|Biological|Flucelvax Quadrivalent Influenza Vaccine|"Flucelvax Quadrivalent is a cell culture seasonal quadrivalent influenza vaccine that contains the following influenza hemagglutinin antigens: 1) A/H1N1-like virus, 2) A/(H3N2)-like virus, 3) B/Yamagata lineage, 4) B/Victoria lineage~Vaccine exposure in routine care (no vaccination per protocol)"
95668|NCT03438474|Procedure|Standard surgical procedure for endometrial cancer|total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
95669|NCT03438474|Procedure|systematic lymphadenectomy (LNE)|systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels
95670|NCT03438461|Drug|Seltorexant 40 mg|Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.
95671|NCT03438461|Drug|Seltorexant 20 mg|Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
95672|NCT03438448|Other|High sensitive Troponin T monitoring|Three determinations of Roche high-sensitive troponin T (99th percentile (14 ng/L) for each patient: preoperative (during the preoperative visit or just before surgery), 48h, and 72h after surgery. If a rise and/or fall of hs-cTnT with at least one value above the 99th percentile upper reference is detected, a clinical evaluation and a 12-lead ECG will be performed. If no ECG changes, ischemic symptoms, or pulmonary edema to fulfill the diagnostic for PMI the patients will undergo an echocardiographic study.
95673|NCT03438435|Drug|QRH-882260 Heptapeptide|Imaging agent
95674|NCT03438422|Dietary Supplement|Pollen extract|1 tablet a day
95675|NCT03438409|Other|Robotic gait training|Robotic gait training
95676|NCT03438396|Drug|tisotumab vedotin|All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity
95677|NCT03438383|Device|Bi-PAP|The Bi-PAP system combines inspiratory support-IPAP (inspiratory positive airway pressure) with expiratory support-EPAP (expiratory positive airway pressure) and has been used, with good results, in a number of different clinical conditions such as COPD, respiratory failure due to neuromuscular disease, cardiogenic pulmonary edema and immediately post-operatively with pro-phylactic purpose.
95678|NCT03438383|Device|Sham Bi-PAP|"Sham Bi-PAP was created by introducing a hole at the connection of the mask with the spiral tube of the conventional Bi-PAP system. By doing so, the applied pressure by sham Bi-PAP was constant and equal to 2 cm H2O."
95679|NCT03438370|Other|Three monthly ART supply at CAGs|Sites where three monthly ART supply will be provided at outreaches
95680|NCT03438370|Other|Six monthly ART supply at outreaches|Sites where six monthly ART will supply will be provided at outreaches
95681|NCT03438357|Other|Analysis of cerebral MRI with automatic segmentation software|Pixyl.Neuro software versus manual analysis of lesions
95682|NCT03438344|Biological|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
95683|NCT03438344|Other|Laboratory Biomarker Analysis|Correlative studies
95684|NCT03438344|Other|Placebo|Given IM
95685|NCT03438331|Behavioral|Cognitive Behavioural Therapy for Insomnia (CBT-I)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-I delivered within a 10-week window. The treatment components in the CBT-I aim to address the behavioural, cognitive and physiological perpetuating factor of insomnia and include: psycho-education about sleep and sleep hygiene, stimulus control, sleep restriction, relaxation training, structured worry time, cognitive restructuring (targeting sleep-related dysfunctional cognitions), and relapse prevention.
95686|NCT03438331|Behavioral|Cognitive Behavioural Therapy for Depression (CBT-D)|The intervention will consist of 8 weekly group sessions (90-min, 5-8 adolescents in each group) of CBT-D delivered within a 10-week window. The main treatment elements of CBT-D include: psycho-education about depression, self-monitoring, behavioural activation, improving social skills, communication skills and problem solving skills, cognitive restructuring (addressing negative and irrational thoughts often associated with depression in adolescents), relaxation techniques, and relapse prevention.
95687|NCT03438318|Drug|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
95688|NCT03438318|Drug|Atezolizumab|Atezolizumab will be administered as per the approved label and according to the schedule specified in the respective arms.
95689|NCT03438318|Radiation|Radiation Therapy|Radiation therapy will be administered using either 3-dimensional (3D) conformal radiotherapy or intensity-modulated radiation therapy (IMRT) to non-target node or metastatic lesion as per the dose and schedule specified in the respective arms.
95690|NCT03438305|Other|sonar assessment of gastric volume in Diabetic patients|assessment of gastric volume in Diabetic Patients
95691|NCT03438305|Other|sonar assessment of gastric volume in Non Diabetic patients|assessment of gastric volume in Non- Diabetic Patients
95692|NCT03438292|Dietary Supplement|Berberine|Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
95693|NCT03438292|Dietary Supplement|TPGS emulsified berberine|Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
95694|NCT03438292|Dietary Supplement|Quillaja extract emulsified berberine|Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
95695|NCT03438279|Other|Non-Interventional|Non-Interventional
95696|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with cannula|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with cannula.
95697|NCT03438266|Device|JUVÉDERM VOLUMA® XC injectable gel with needle|Participants had 1 cheek treated with JUVÉDERM VOLUMA® XC injectable gel with a needle.
95698|NCT03438253|Procedure|spinal anaesthesia|
95699|NCT03438240|Drug|Bupivacaine|patients will receive combined general anesthesia / epidural analgesia with 15 ml bupivacaine 0.20%
95700|NCT03438240|Drug|Fentanyl|Plus 50 µg fentanyl
95701|NCT03438240|Drug|Dexmedetomidine|Plus 50 µg dexmedetomidine
95702|NCT03438227|Drug|Iron dextran|Single intravenous infusion of iron dextran 1000mg.
95733|NCT03437915|Procedure|Partial mastectomy|4-12 weeks post NIBB
95703|NCT03438227|Drug|Ferrous sulfate 325mg|Oral iron supplementation with ferrous sulfate 325mg one to three times daily
95704|NCT03438214|Drug|Vancomycin Continuous infusion|Will be administered a loading dose of 25mg/kg followed of 2g infused in 24h. Serum levels will be measured after the end of the loading dose (peak) and after 24 hours (steady state). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and area under curve (AUC) /MIC≥400mg.h/L
95705|NCT03438214|Drug|Vancomycin Intermittent infusion|Will be administered a loading dose of 25mg/kg followed of 1g every 12h. Serum levels will be measured after the end of the loading dose (peak) and one hour before the next dose (trough). The doses will be adjusted according to serum levels (between 15 and 20 mg / L) and AUC/MIC≥400mg.h/L.
95706|NCT03438201|Dietary Supplement|Intervention|Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
95707|NCT03438201|Dietary Supplement|Control|Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day
95708|NCT03438188|Other|Practice Quit Attempt|Smokers will be studied under 2 conditions: smoking as usual and during a 4 day practice quit attempt.
95709|NCT03438175|Behavioral|Enhanced communication by brochure, website and posters|Several instruments to improve communication toward ICU patients' families were prepared for this study: a brochure of 12 pages, a website with 80 webpages, 8 posters for the waiting room, 1 sign for the ICU door. All these instruments are made to have more correct comprehension and to legitimize emotions of ICU patients' families.
95710|NCT03438162|Behavioral|Education|Patients randomized in the intervention group received pre-discharge pharmacotherapeutic education. The education was conducted by a qualified physician.
95711|NCT03438136|Behavioral|Adult Broad Learning Experiment (ABLE)|"This intervention implements six factors from early childhood experiences: individualized scaffolding (having a responsive teacher), forgiving environment (allowing the learner to make and learn from mistakes), growth mindset (believing that abilities can develop with effort), open-minded learning (exploring new experiences), serious commitment to learning (adopting a learning lifestyle), and learning multiple skills simultaneously."
95712|NCT03438123|Device|CZT SPECT imaging|Acquisition of SPECT (single photon emission computed tomography) imaging utilising a camera system with solid-state cadmium zinc telluride (CZT) detectors to visualise injected, or otherwise introduced, radioactivity in the human body.
95713|NCT03438084|Dietary Supplement|Interesterified fat|50 g fat provided as commercially available interesterified fat.
95714|NCT03438084|Dietary Supplement|Non- interesterified fat|50 g fat provided as commercially available non-interesterified fat.
95715|NCT03438084|Dietary Supplement|Rapeseed oil|50 g fat provided as commercially available rapeseed oil.
95716|NCT03438084|Dietary Supplement|Butter|50g fat provided as commercially available spreadable butter
95717|NCT03438071|Other|Videoconferencing|Daily videoconference updates using Skype between parents of preterm infants hospitalized in NICU and the nurse taking care of their child, lasting 5 to 10 minutes, to check with her for the daily news and then see their child through the camera.
95718|NCT03438058|Other|Graft survival and/or Rejection appearance|
95719|NCT03438045|Behavioral|Partnered intervention|CHWs will provide dental education and counseling, lead interactive demonstrations of brushing with fluoride toothpaste and flossing, and improve access to dental care through dental coverage enrollment and linkage to local dentists.
95720|NCT03438032|Diagnostic Test|Bronchoscopy with lavage|During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.
95721|NCT03438019|Device|PrO2|The PrO2 device is linked to a tablet via Bluetooth and provides the user with a graphic representation of their inspiratory effort throughout all of inspiration and real-time biofeedback. This device incorporates a standard 2mm leak to avoid glottal closure during maximal inspiration. The PrO2 provides measures of MIP (cmH2O), SMIP (PTU) and ID (seconds).
95722|NCT03438019|Device|Threshold Inspiratory Muscle Trainer|The Threshold incorporates a flow-independent one-way valve to ensure consistent resistance and features an adjustable specific pressure setting to be set based on MIP values of each subject.
95723|NCT03438006|Other|Safety data collection (following routine vaccination)|"This study assesses the safety of GSK Biologicals' Human papillomavirus (HPV) vaccine when administered routinely according to the Prescribing Information in female Chinese subjects aged between 9 and 45 years.~The intervention consists in the active surveillance of adverse events following immunization and pregnancy outcomes if the vaccine is administered inadvertently during pregnancy. Information of potential adverse events and pregnancy outcomes will be collected at immunisation visits, telephone contacts and through spontaneous reporting by the patient/LAR/physician."
95724|NCT03437993|Other|Recollect, the game|"Recollect is a working memory training game"
95725|NCT03437993|Other|Tetris|App-based video game where shapes are rotated and placed to fit a grid
95726|NCT03437980|Drug|propofol|A bolus of 0.7 mg/kg will be given initially, additional incremental doses of 20 mg propofol will be given if the patient complained of pain or moved arms towards the back. Patients will be sitting on the middle of the operating table facing towards the table's foot. The table's foot will be dropped 45 degrees for a comfortable chair position, Monitoring through pulse oximeter (SaO2), non-invasive blood pressure (NIBP) adjusted every 2 minutes automatic measuring and capnography tube in contact with nostrils.
95727|NCT03437967|Device|LightForce EXPi|LASER photobiomodulation therapy of 15-25 watts of coherent infrared light to affected area for 10 minutes using wand-type probe.
95728|NCT03437954|Other|Diet modification|Patients will be randomized to follow the standard post-tonsillectomy diet at our institution, which consists of soft foods for ten days, or will be in the non-restricted diet group following surgery.
95729|NCT03437941|Drug|CORT125281|CORT125281 is supplied as capsules for oral dosing
95730|NCT03437941|Drug|Enzalutamide (Xtandi)|Enzalutamide will be taken orally
95731|NCT03437928|Device|Directional Deep Brain Stimulation|Boston Scientific Vercise DBS leads and 16-channel implanted pulse generators (IPGs) will be implanted to control the shape and size of stimulation
95732|NCT03437915|Radiation|NIBB: accuboost|28.5 Gy delivered in 5 daily fractions
95734|NCT03437902|Dietary Supplement|Rutin in combination with Vitamin C|Rutin and Vitamin C will be supplied as tablets containing 60 mg Rutin and 160 mg Vitamin C. The use of Rutin and Vitamin C will be under the trade name of RUTA C 60 ® manufactured by KAHIRA PHARM.& CHEM. IND. Company
95735|NCT03437902|Dietary Supplement|Vitamin C|Vitamin C will be supplied as capsules containing500 mg of Vitamin C. The use of Vitamin C will be under the trade name of C-Retard ® manufactured by HIKMA Quality Company.
95736|NCT03437889|Other|Cold Stimulus (Ice)|The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen between 10 and 30 minutes after the epidural catheter is inserted.
95737|NCT03437876|Other|intestinal microbiota transplant|All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
95738|NCT03437863|Device|Mobile application|Use of a mobile application (on a borrowed device) with following features: 1) strengths reflection and identification, 2) summary of registered strengths, 3) defining goals, and 4) linking strengths to goals.
95739|NCT03437850|Other|Usual care|Care as usual, in terms of processes and outcomes, will be collected for all participants in both cohorts
95740|NCT03437824|Drug|Cyanocobalamin|1,000 mg, Once
95741|NCT03437824|Drug|Placebo|0.9% Sodium Chloride, Once
95742|NCT03437811|Device|Electro Flo Percussor, Model 5000|FDA 510K K031876 Regulation Number: 21 CFR 868.5665 Regulation Name: Percussor, Powered-Electric Regulation Class: II Product Code: BY1
95743|NCT03437798|Other|Disease status|Women who reported periodontal disease diagnosis/condition
95744|NCT03437785|Drug|CKD-495 75mg|CKD-495 75mg Tab.
95745|NCT03437785|Drug|CKD-495 150mg|CKD-495 150mg Tab.
95746|NCT03437785|Drug|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg|Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.
95747|NCT03437785|Drug|Rebamipide 100mg|Rebamipide 100mg Tab.
95748|NCT03437785|Drug|Placebo of the CKD-495 75mg|Placebo of the CKD-495 75mg Tab.
95749|NCT03437785|Drug|Placebo of the CKD-495 150mg|Placebo of the CKD-495 150mg Tab.
95750|NCT03437785|Drug|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg|Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.
95751|NCT03437785|Drug|Placebo of the Rebamipide 100mg|Placebo of the Rebamipide 100mg Tab
95752|NCT03437772|Behavioral|Mindfulness Cognitive Behavioral Therapy program|16 simultaneous-but-separate therapy sessions for parents and children.
95753|NCT03437759|Biological|exosomes derived from mesenchymal stem cells (MSC-Exo)|After air-liquid exchange, 50μg or 20μg MSC-Exo in 10μl PBS was dripped into vitreous cavity around MH, leaving 20% SF6 or air as tamponade .
95754|NCT03437746|Drug|injection of methylprednisolone at anesthetic induction|intravenous administration : 20 mg/kg, over 30 minutes at anesthetic induction
95755|NCT03437746|Biological|Blood samples|Blood samples (D0, D1, D2, D3, D4)
95756|NCT03437733|Device|Radiofrequency Ablation|RF ablation using multi-electrode radiofrequency balloon catheter and multi-electrode circular diagnostic catheter
95757|NCT03437720|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
95758|NCT03437720|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous injection"
95759|NCT03437707|Drug|Morphine Sulfate|Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
95760|NCT03437707|Drug|Intravenous paracetamol|1 g paracetamol will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
95761|NCT03437707|Drug|Intravenous ibuprofen|800 mg ibuprofen (diluted with 250 ml saline) will be administered 30 minutes before the end of surgery. All administrations will be applied through IV infusion over 30 minutes. Patients will be received morphine with intravenous patient controlled analgesia (IV PCA) device during postoperative 24 hours. The PCA solution will be prepared with 100 mg morphine in 200 mL of saline (0.5 mg/ml). The PCA device was adjusted as infusion: 0 ml/h, bolus: 1 ml, lockout period: 7 min.
95762|NCT03437694|Other|Medication optimization intervention|Pharmacists will engage participants in medication therapy management either with access to the medical records (intervention) or without access (control).
95763|NCT03437681|Behavioral|Insufficient sleep|Four days of insufficient sleep
95764|NCT03437668|Drug|WSE|WSE tablets
95765|NCT03437668|Drug|Placebo Oral Tablet|Placebo tablet
95766|NCT03437655|Procedure|Carie removal|Carie removal with a low speed handpiece
95767|NCT03437655|Procedure|Relative isolation|Relative isolation with cotton and gauze.
95768|NCT03437655|Procedure|Manipulation of the temporary material based on Zinc Oxide and Eugenol|Manipulation of the temporary material based on Zinc Oxide and Eugenol according to the manufacturer's recommendations
95769|NCT03437655|Procedure|Manipulation of the temporary material based on Mineral trioxide aggregate|Manipulation of the temporary material based on Mineral trioxide aggregate according to the manufacturer's recommendations
95770|NCT03437655|Procedure|Material insertion on the cavity|Material insertion on the cavity according to the manufacturer's recommendations
95771|NCT03437655|Procedure|Finishing the temporary direct restoration|Excess cement removal; Occlusal Adjustment; Finishing and polishing.
95772|NCT03437642|Behavioral|Short Term Psychotherapy|Humanistic-existential psychotherapy derived from ontopsychological method and specifically adapted to public health systems. Individual and group sessions to be tailored to individual needs
95773|NCT03437629|Procedure|Temporary cement based on Calcium Hydroxide|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Calcium Hydroxide; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
95828|NCT03437200|Drug|Ipilimumab|Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
95774|NCT03437629|Procedure|MTA temporary cement|Confection of a temporary crown with acrylic resin; Finishing and polishing; relative isolation with cotton and gauze; Manipulation of the temporary cement based on Mineral trioxide aggregate; Cement insertion on the internal surface of the temporary crown; Excess cement removal; Occlusal Adjustment.
95775|NCT03437616|Behavioral|Tulppa rehabilitation|The intervention includes health education on e.g. healthy diet, weight management, physical activity and psychosocial coping as well as peer discussions and physical exercises.
95776|NCT03437603|Drug|Eltrombopag|Starting Eltrombopag daily on empty stomach (2 hour before breakfast) for 8 weeks.
95777|NCT03437590|Drug|JNJ-55308942|JNJ-55308942 will be administered as oral solution.
95778|NCT03437590|Drug|[18F]-JNJ-64413739|[18F]-JNJ-64413739 fluid for injection administered intravenously.
95779|NCT03437577|Drug|immediate-release tacrolimus|Standard of care for transplant patients
95780|NCT03437577|Drug|extended release tacrolimus|Experimental care
95781|NCT03437564|Drug|Vortioxetine|Vortioxetine tablet
95782|NCT03437551|Other|cross-sectional observation|cross-sectional ophthalmic examination
95783|NCT03437538|Device|MCO-HD|Measurements will be done during a single hemodialysis session with Medium Cut-Off filter
95784|NCT03437538|Device|High-flux HDF|Measurements will be done during a single hemodiafiltration session with standard high-flux filter
95785|NCT03437525|Behavioral|Peer Support|The intervention involves monthly education/support groups co-led by a CHC doctor / nurse and peer coaches. These meetings will begin with a general discussion about participants' previous month, what they had been doing, any special events etc. Meetings will devote time to identifying goals and specific plans for reaching them, rehearsal and/or discussion of specific behaviors to execute plans and ways in which the group members can be helpful to each other. This will be organized around a Diabetes Action Plan. Peer coaches will provide education and support for insulin therapy to help reduce barriers around insulin use. Peer coaches will also organize activities to promote healthy lifestyles, such as walking groups, to promote informal contacts among peer supporters and participants.
95786|NCT03437512|Device|Anodal tDCS|20 minutes of 2mA anodal stimulation.
95787|NCT03437512|Behavioral|Fluency training|Speaking along with a metronome and/or speaking along with another person (choral speech) for 20 minutes
95788|NCT03437512|Device|Sham tDCS|For sham stimulation, current is ramped up and back down over 30 seconds.
95789|NCT03437499|Procedure|Sustained Inflation|Application of positive pressure by face mask with T-piece resuscitator for a prolonged period of 15 seconds at a peak pressure of 25 cmH20 followed by PEEP set at 5 cmH2O
95790|NCT03437499|Procedure|Positive Pressure Ventilation|Application of positive pressure by face mask with T-piece resuscitator at a peak pressure of 25 cmH20, PEEP set at 5 cmH2, for 40 inflations/minute
95791|NCT03437473|Device|SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System|Active Implantable Vagus Nerve Stimulation device.
95792|NCT03437460|Drug|Ibuprofen 600 mg|The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
95793|NCT03437460|Dietary Supplement|Prenatal vitamins|The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
95794|NCT03437447|Drug|Cisticid|Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).
95795|NCT03437447|Drug|Biltricide|Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
95796|NCT03437434|Other|Visual Acuity|Ocular Examination
95797|NCT03437421|Dietary Supplement|Vitamin D3 (cholecalciferol)|"Patients with 29≤ 25-OH-D3 ≥20 ng/mL will receive 200 000 UI orally the first month (100 000 UI at T0 + 100 000 UI at T0+15 days, UVEDOSE™ Laboratoires Crinex, Montrouge, France) followed for the last 2 months by one daily dose (5 drops orally = 1 000 UI/day, DÉDROGYL™ , DB Pharma, La Varenne-Saint-Hilaire, France).~Patients with : 19≤ 25-OH-D3 ≥10 ng/mL will receive orally 300 000 UI (100 000 UI at T0 + 100 000 UI at T0+23days + 100 000 UI at T0+45days; UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™ ).~Patients with : 25-OH-D3 <10 ng/mL will receive orally 400 000 UI (100 000 UI at T0 + 100 000 UI at T0+15days + 100 000 UI at T0+30 days + 100 000 UI at T0+45days, UVEDOSE™) followed for the last month by one daily dose (5 drops orally =1 000 UI/day, DÉDROGYL™)."
95798|NCT03437408|Device|Mapping and ablation|High density substrate map. Data collection during ablation
95799|NCT03437395|Device|Balloon Brachytherapy|The balloon brachytherapy catheter method uses one tube with a small balloon on the end placed where the tumor had been. The balloon is filled with salt water so it fits this space. The end of the tube will extend from the side of the breast and will be connected to a special machine for treatments. The RT dose is delivered by a radioactive seed that travels through the tube into the center of the balloon. The seed will be removed at the end of each treatment. The tube and the balloon filled with salt water will stay in the breast until the 10 RT treatments are done. The radiation oncologist will decide if this type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10-15 minutes.
95800|NCT03437395|Radiation|3D Conformal External Beam Irradiation|3D conformal external beam irradiation uses a beam of radiation to deliver the radiation therapy dose to the place in the breast where the cancer was removed. The Radiation Oncologist will decide which type of treatment is most appropriate for the patient. The treatment will be given 2 times a day, about 6 hours apart, on 5 days. Each treatment lasts for 10 to 15 minutes.
95801|NCT03437382|Device|Quirem Medical Holmium-166 radioembolization microspheres|radioembolisation as adjuvant treatment to RFA
95802|NCT03437369|Drug|Ivabradine Oral Tablet|The target dose is 10 to 15 mg / day, administered orally in two doses
95803|NCT03437369|Other|Standard of Care treatment|The study drug will be compared with the standard of Care treatment
95804|NCT03437356|Other|Pulmonary vein isolation using CLOSE protocol|'CLOSE' protocol: Ablation index > 400 at the posterior wall (reduce to 300 if esophagus temperature rise), ablation index > 550 at the anterior wall, and inter-lesion distance < 6.0mm
95805|NCT03437356|Drug|Antiarrhythmic drug therapy (ADT)|"During the first 3 months after PVI, patients continue oral anticoagulants and antiarrhythmic drug therapy (ADT). ADT is a continuation (or restart) of previously ineffective Class IC and III ADT. At the time of discharge, dosage is optimized according to the 2016 ESC guidelines on AF management.~Preferred dosages:~Flecainide: Tambocor or Flecainide EG 100mg b.i.d., Apocard R 100 to 200mg overdose (OD) Propafenone: Rytmonorm or Propafenone EG 300 mg b.i.d., except 225 mg b.i.d. if ≥70 years or <70 kg Sotalol: Sotalex or Sotalol EG 80mg b.i.d., Except 80mg t.i.d. if men < 70 years, Cr <1.5mg/dl, >70kg, except 80 mg OD if female >70 years or Cr >1.2mg/dl~In case of amiodarone intake before PVI, amiodarone is switched to sotalol or class IC ADT."
95806|NCT03437343|Procedure|Hip arthroplasty|
95807|NCT03437330|Drug|Empagliflozin (Jardiance®)|Empagliflozin Dose/frequency: 25 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs) FBG > 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia < 3.9 mmol/L occurs)
95808|NCT03437317|Behavioral|Perceptual Retraining|"Participants viewed faces varying in their expression of anger and were asked to identify if the face was angry or neutral via button press. Participants were provided with feedback if their categorization of the face as neutral or angry was correct. Each participant was assigned 4 levels of angry faces based on their decision point of anger detection in faces. Faces were selected based on the closest existing anger morph to the category boundary; for example, a decision point of 40% anger was closest to the 38% anger face, and so the faces used would have been 17%, 31%, 45%, and 59% anger. For this example, responses of neutral to the 31% angry face would be marked as correct, whereas a similar response to the 45% angry face would be incorrect, as it was above their decision point."
95809|NCT03437317|Behavioral|Gender Discrimination|Participants viewed faces varying in their expression of anger and were asked to identify if the face was male or female via button press.
95810|NCT03437304|Biological|Immunose™ FLU 1%|Quadrivalent influenza vaccine with 30 μg HA/strain and 1% Endocine™, dosing volume 200 μl, intranasal administration x 2
95811|NCT03437304|Biological|Immunose™ FLU 2%, 200 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 200 μl, intranasal administration x 2
95812|NCT03437304|Biological|Immunose™ FLU 2%, 300 μl|Quadrivalent influenza vaccine with 30 μg HA/strain and 2% Endocine™, dosing volume 300 μl, intranasal administration x 2
95813|NCT03437304|Biological|Influenza antigen|Quadrivalent influenza vaccine with 30 μg HA/strain, dosing volume 200 μl, intranasal administration x 2
95814|NCT03437304|Drug|Placebo|NaCl dosing volume 200 μl, intranasal administration x 2
95815|NCT03437304|Biological|i.m comparator|Quadrivalent influenza vaccine containing 15 μg HA/strain, 500 µl for intramuscular administration x 1
95816|NCT03437291|Procedure|Cesarean section|Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion
95817|NCT03437291|Device|Transabdominal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
95818|NCT03437291|Device|Transvaginal ultrasound|loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
95819|NCT03437278|Drug|Ligelizumab|Ligelizumab comes in 120 mg per 1 mL liquid in vial. If the patient is on the high or low dose of ligelizumab, the patient will receive 1 injection of ligelizumab every 4 weeks from Day 1 to Week 20 (inclusive).
95820|NCT03437278|Drug|Placebo|Placebo comes in 00 mg per 1 mL liquid in vial. The patient will receive 1 injection of placebo at Day 1, Week 4, Week 8; followed by one injection of ligelizumab at Week 12, Week 16 and Week 20
95821|NCT03437265|Drug|NER1006 powder for oral solution|NER1006 Dose 1 (1 sachet) and NER1006 Dose 2 (2 sachets)
95822|NCT03437239|Device|Delfi PTS II Portable Tourniquet System|This is a portable tourniquet system that allows for occlusion of venous outflow without inhibiting arterial blood flow. This portable tourniquet system allows for rapid cuff inflation and deflation with a battery. The Delfi PTS is a purpose-built system that allows for precise control of pressure throughout training, despite the natural changes in muscle shape and length. The device has advanced pressure leak detection that monitors the tourniquet cuff, tubing, and connectors for air leaks and safely alerts staff to hazards or follow-up actions required. The device has visual and audio alarms for over and under pressure and elapsed time as well as a large, easily visible display of tourniquet pressure and elapsed time. The Delfi PTS II calibrates and self-tests on startup. It has a safety interlock that limits the normal maximum pressure and integrated tourniquet cuff testing as recommended in current AORN Standards and Recommended Practices
95823|NCT03437226|Drug|Levosimendan 2.5 MG/ML|Levosimendan Arm: 1 x 5 ml (1 vial) of levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
95824|NCT03437226|Drug|Placebos|Placebo Arm: 1 x 5 ml (1 vial) of placebo levosimendan infusion concentrate is added to one 250 ml infusion bag of 5% glucose or 0.9% NaCl in diabetic patients.
95825|NCT03437213|Drug|Total intravenous anesthesia group|Induction of general anesthesia with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg), intubation. Anesthesia maintained using Propofol (4-6) mg/kg/h, fentanyl (0.5-1) μg/kg/h. to be modified according to analgesic needs and hemodynamics. 10mg atracurium when the 2nd twitch of train of four appears.
95826|NCT03437213|Drug|Total intravenous plus block group|Ultrasound guidance identifies the paravertebral space using a linear high-frequency (10-12 MHz) probe in the transverse plane in the midline, rotate the probe to the longitudinal plane, and scan in a medial-to-lateral direction. Locate the desired segment shift from the cephalad aspect of the sacrum. The transverse scan will show a hyperechoic outline of the vertebral spinous and transverse processes. Use the loss of resistance technique. Bilaterally inject (5ml) bupivacaine 0.5% for each segment. Induction of anesthesia after 30 minutes with fentanyl, (1mcg / kg), propofol (1-2 mg / kg), atracurium (0.5 mg / kg),then prone position.
95827|NCT03437200|Drug|Nivolumab|Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
95829|NCT03437200|Other|Chemoradiation|All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.
95830|NCT03437187|Procedure|Cholecystectomy|Laparoscopic technique
95831|NCT03437161|Radiation|Radiation Therapy (RT)|Undergo RT either in the supine position with DIBH or in the prone position.
95832|NCT03437148|Device|Innocor®|Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)
95833|NCT03437148|Device|Physioflow®|Bioimpedance cardiograph: Physioflow® (Manatec, France)
95834|NCT03437135|Diagnostic Test|Glasgow Hearing Status Inventory questionnaire|"This is a questionnaire of the hearing quality presenting eleven questions. This is allows to determine the quality of the hearing status of the patients. It is enough to answer the various questions yes or no."
95835|NCT03437122|Procedure|Bronchoscopy|Multiple level sampling of the respiratory mucosa (cytology brush and biopsies forceps)
95836|NCT03437109|Diagnostic Test|Laboratory tests|Testosterone HSBG Hb1Ac LH
95837|NCT03437096|Other|venipuncture pain|postoperative sleeve gastrectomy patients pain
95838|NCT03437083|Drug|Eribulin mesylate|intravenous infusion
95839|NCT03437070|Drug|Trabectedin|Administered intravenously per protocol on Day 1 for 21-day cycles.
95840|NCT03437070|Drug|Doxorubicin|Administered intravenously per protocol on Day 1 for 21-day cycles.
95841|NCT03437070|Drug|Olaratumab|Administered intravenously per protocol
95842|NCT03437057|Other|KARGEGIC 75mg|Prospective single-arm study to estimate the risk of renal hematoma when performing a session of lithotripsy for renal lithiasis, on a 15-day scanner, in patients treated with KARDEGIC 75mg No suspended.
95843|NCT03437044|Drug|Ticagrelor|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
95844|NCT03437044|Drug|Clopidogrel|After providing written informed consent and following diagnostic angiography, patients meeting study entry criteria undergoing PCI will be randomly assigned in a 1:1 ratio to treatment with either ticagrelor or clopidogrel. Randomized treatment will be maintained for 30±3 days.
95845|NCT03437031|Device|Virtual Reality device|For those patients randomized to VR, the study staff member will explain the use of the Samsung VR goggle set, and thereafter will allow the patient to use the device freely for up to 30 minutes. Intervals of 2-5 minutes is suggested for first-time use, and patients will be to allowed to discontinue it at any time as long as they are not experiencing any discomfort or side effects (dizziness, motion sickness, etc.). The study staff member will be present at all times, and will work with hospital staff as necessary to ensure the patient is receiving appropriate clinical care throughout the duration of the intervention.
95846|NCT03437018|Other|moderate diabetic retinopathy follow-up by tele-expertise|"Consultation by an orthoptist to measure visual acuity, eye tone by pulsed air tonometer, and retinography images after pupillary dilatation (9 photographs: one of the posterior pole and 8 of the peripheral retina) and optical coherence tomography (OCT).~The results are immediately evaluated on site by an ophthalmologist. The results are sent through a secure online medical application to a diabetic retinopathy specialist ophthalmologist for evaluation."
95847|NCT03437005|Drug|Desonide 0.05%|Desonide 0.05% ointment topically twice daily for two weeks
95848|NCT03437005|Drug|Ketoconazole 2%|Ketoconazole 2% cream topically twice daily for two weeks
95849|NCT03436992|Dietary Supplement|Antioxidant Cocktail|Vitamin C, Vitamin E, alpha lipoic acid
95850|NCT03436992|Dietary Supplement|Resveratrol|1500 mg trans-resveratrol
95851|NCT03436992|Other|Placebo|placebo
95852|NCT03436979|Device|NeuGuide™ System|The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
95853|NCT03436966|Device|MULTI SLICE CT|Positive enteric contrast, can, however, obscure IV contrast enhancement of the bowel wall. In addition, positive oral contrast agents opacify but do not always well distend the bowel. IV contrast is administered and images are acquired in the portal venous phase, which is optimized for visceral organ evaluation.
95854|NCT03436953|Drug|CX-8998|T-type calcium channel blocker
95855|NCT03436953|Drug|Placebo|Placebo comparator
95856|NCT03436940|Other|On Demand Discharge Planning (DDP)|Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
95857|NCT03436940|Other|Routine Discharge Planning (RDP)|All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)
95858|NCT03436927|Other|Nintendo Wii Fit Balance exercises|Nintendo Wii Fit' training protocol consisted of 'Penguin Slide', 'Table Tilt', 'Ski Slalom', 'Heading' and 'Balance Bubble' games that selected from the Wii Fit Plus balance games section
95859|NCT03436927|Other|Balance Trainer Balance Exercises|Balance Trainer' training protocol consisted of 'Collect Apples', 'Outline', 'Paddle War' and 'Evaluation of Movement' games which were included in the device software and allowed the patients to done balance exercises in different directions.
95860|NCT03436914|Drug|PPI|After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
95861|NCT03436901|Diagnostic Test|MRI with DWI vs CT|MRI with diffusion weighted imaging of thorax, abdomen, and pelvis without contrast agent vs. CT of thorax, abdomen, and pelvis with contrast agent
95897|NCT03436654|Procedure|Extended Pelvic lymphadenectomy|To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes
95898|NCT03436654|Drug|GnRH agonist/antagonist|Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
95899|NCT03436641|Other|No intervention|No intervention
95900|NCT03436628|Device|MyT1DHero|A mobile phone application
95862|NCT03436875|Diagnostic Test|Mixed meal challenge|"We will conduct a traditional oral glucose tolerance test (OGTT), and compare microvascular and metabolic responses with mixed meal challenge (MMC). The procedures between the two are identical except for what is being consumed. In brief, the OGTT will be 75 g of glucose, and the MMC will be a protein shake consisting of 30g of protein, 5 g of fat, and 35g of carbohydrate.~A fasting sample of blood will be collected, and the test drink (either OGTT or MMC) will be given. We will collect blood to measure glucose at: 15, 30, 60, 90, and 120 min post-drink consumption. We hypothesize that, like in Caucasians (under review), healthy Hispanics will have greater microvascular blood flow in skeletal muscle with the MMC than with OGTT, and this increased blood flow will result in greater substrate oxidation switching (metabolic flexibility)."
95863|NCT03436862|Drug|Nivolumab|Nivolumab 240 mg IV infusion over 60 minutes given every 2 weeks for up to 6 months.
95864|NCT03436849|Drug|ESN364|ESN364 will be administered orally.
95865|NCT03436849|Drug|Placebo|Placebo will be administered orally.
95866|NCT03436836|Drug|Nalbuphine|"Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe.~If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study.~After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery"
95867|NCT03436836|Drug|lidocaine, bupivacaine, hyaluronidase , saline|lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).
95868|NCT03436836|Drug|lidocaine, bupivacaine , hyaluronidase|2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)
95869|NCT03436823|Other|nurse semi-structured interview|The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up
95870|NCT03436823|Other|Music & Relaxation with eyes closed|The first session of rTMS is D1. From the first meeting to D14 music & relaxation with eyes closed sessions are set up
95871|NCT03436810|Procedure|Motor imagery|Motor imagery (MI) will be trained for the individuals by imagination of the movement. Program of MI includes 1) body relaxation and awareness 2) visual imagery 3) kinesthetic imagery and 4) refocusing of body and environment.
95872|NCT03436810|Procedure|Health education|Topic of Health education (HE) consists of 1) Changes caused by stroke 2) Complications after stroke 3) Emotional changes after stroke 4) Living at home after stroke 5) High blood pressure and stroke and 6) Preventing recurrent stroke.
95873|NCT03436810|Procedure|Task-Oriented Circuit Class Training|Program of Task-Oriented Circuit Class Training (TOCCT) consists of warm up and perform tasks 1) Stepping forward-backward onto block 2) Stepping sideway onto block 3) Heel lifts in standing to strengthen affected planter-flexor muscles 4) Standing with a decreased base and reach for object 5) Standing up from chair, walking a short distance, and returning to chair 6) Symmetrical walking and 7) Walking at fast speed.
95874|NCT03436797|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
95875|NCT03436784|Behavioral|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
95876|NCT03436771|Genetic|JCAR017|No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
95877|NCT03436771|Genetic|JCARH125|No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
95878|NCT03436745|Drug|Zolpidem|In men with prostate cancer, males (precastration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach <50 ng/dL (postcastration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at predose and 0.5, 1, 2, 4, and 8-hours post-dose.
95879|NCT03436732|Drug|LMB-100|administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles
95880|NCT03436732|Drug|SEL-110|administered on day 1 of each cycle for up to 4 cycles
95881|NCT03436719|Drug|Oral antibiotic|Metronidazole - 500 mg and Erythromycin - 500 mg per os *3 times at 5 p.m.; 8 p.m., 11 p.m. in a day before surgery
95882|NCT03436719|Drug|Intravenous antibiotic|Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
95883|NCT03436719|Drug|Mechanical Bowel Preparation|Beginning of MBP at 4 p.m. in a day before surgery
95884|NCT03436706|Other|exposure|exposure to chronic stress
95885|NCT03436693|Drug|Canagliflozin|Canagliflozin 100mg orally once daily
95886|NCT03436693|Drug|Placebo|Placebo orally once daily
95887|NCT03436680|Other|Best Practice|Receive standard of care
95888|NCT03436680|Behavioral|Neurofeedback|Complete neurofeedback training sessions
95889|NCT03436680|Other|Quality-of-Life Assessment|Ancillary studies
95890|NCT03436680|Other|Questionnaire Administration|Ancillary studies
95891|NCT03436667|Diagnostic Test|Spirometry|Lung volumes will be measured using spirometry.
95892|NCT03436667|Diagnostic Test|Reaction Time|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
95893|NCT03436654|Drug|Apalutamide|240mg daily orally
95894|NCT03436654|Drug|Abiraterone Acetate|1000mg daily orally
95895|NCT03436654|Drug|Prednisone|5mg BID orally
95896|NCT03436654|Procedure|Radical Prostatectomy|A laparoscopic, robotic-assisted, or open approach to RP is permitted at the discretion of the operating surgeon.
95901|NCT03436615|Drug|SB206 4%|Twice daily
95902|NCT03436615|Drug|SB206 8%|Twice daily
95903|NCT03436615|Drug|SB206 12%|Once or twice daily
95905|NCT03436589|Behavioral|Indiana SNAP-Ed|First four Indiana SNAP-Ed nutrition education lessons served as the intervention
95906|NCT03436576|Drug|Autologous Serum 20%|Instillation of 1 drop of Autologous Serum 20% four times a day
95907|NCT03436576|Drug|Autologous Serum 50%|Instillation of 1 drop of Autologous Serum 50% four times a day
95908|NCT03436563|Biological|Anti-PD-L1/TGFbetaRII Fusion Protein M7824|Given IV
95909|NCT03436550|Procedure|mpMRI|Multiparametric MRI
95910|NCT03436550|Procedure|ARFI US|Acoustic radiation force impulse is a type of ultrasound elastography
95911|NCT03436537|Other|Periodontal Aesthetic Perception Scale|Patients answered the self-reported 7-item questionnaire for Periodontal aesthetic perception scale
95912|NCT03436498|Drug|Insulin aspart SAR341402|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
95913|NCT03436498|Drug|Insulin aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
95914|NCT03436485|Drug|ODM-208|co-administered with glucocorticoid and fludrocortisone, orally daily
95915|NCT03436472|Drug|dexmedetomidine|low-dose dexmedetomidine infusion
95916|NCT03436472|Drug|placebo|normal saline infusion
95917|NCT03436459|Device|Extracorporeal Shock Wave Therapy|shock wave therapy once a week for three weeks, total of 1000 shock waves for each treatment at the frequency of 10Hz, with 2 Bar pressure and energy flux density (EFD) of 0.25 mJ/mm2 per minute using a BTL-6000 SWT Topline Power® device
95918|NCT03436459|Device|Low Level Laser Therapy|LLLT once a day for three weeks (altogether 15 working days) using a PR999 4W scanning laser device; around trigger points with 3 J/cm2, power 800 mW, frequency 2000Hz, on trigger points with 9 J/cm², power 2000mW, frequency 5000Hz for total of 2 minutes on each spot
95919|NCT03436446|Other|Interview|Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
95920|NCT03436433|Drug|Lacosamide|LCM 100mg twice a day.
95921|NCT03436433|Drug|Levetiracetam|LEV 1000mg twice a day.
95922|NCT03436420|Drug|Gemcabene|Participants will take 300 milligrams (mg) of gemcabene, once per day for 12 weeks.
95923|NCT03436394|Drug|Evobrutinib|Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
95924|NCT03436381|Other|Questionaire|We will provide two sleep apnea screening questionnaire, Stop-bang questionnaire and Epworth sleepiness scale
95925|NCT03436368|Procedure|Continuous spinal anesthesia|Continuous spinal anesthesia will be performed for patients of the CSA group at the L3-L4 intervertebral space using Spinocath (B. Braun, Melsungen, Germany). After the cerebrospinal fluid is aspirated, 7.5 mg hyperbaric Bupivacaine 0.5% (1.5 ml) together with 25 micrograms Fentanyl (0.5 ml) will be injected intra-thecally. Supplemental injections will be given in aliquots of 5 mg hyperbaric Bupivacaine 0.5% (1 ml) if the sensory block is lower or reseeds, during surgery, below T6 dermatome.
95926|NCT03436368|Procedure|General anesthesia|Anesthesia will be induced with intra-venous administration of Fentanyl (2 micrograms/kg), Ptopofol (1-2 mg/kg) and Atracurium (0.5 mg/kg). Maintenance will be achieved with 0.8-1.5% Isoflurane in an O2 / air mixture, an Atracurium infusion at 0.5 mg/kg/hr and a Fentanyl infusion at 1 micrograms/kg/hr.
95927|NCT03436355|Behavioral|Physical activity|"The Active school study was a 10-month randomized controlled trial.The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework."
95928|NCT03436342|Drug|68Ga-Pentixafor|Intravenous injection of one dosage of 74-148 MBq (2-4 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga-Pentixafor will be used to image lesions of MM and lymphoma by PET/CT.
95929|NCT03436329|Procedure|Vein ligation first|During this procedure, patients undergo lobectomy with the pulmonary vein ligated first.
95930|NCT03436329|Procedure|Artery ligation first|During this procedure, patients undergo lobectomy with the pulmonary artery ligated first.
95931|NCT03436316|Drug|AZD8154|SAD Part 1; 6 cohorts which receive single dosing. One cohort is invited back for large particle administration. Part 2; 1 cohort which receives IV dose and then inhaled administration of AZD8154. MAD Part 3; 3 cohorts will receive inhaled multiple dosing. Additional doses are provisional and could be adjusted based on the emerging data from the previous dose by the safety review committee (SRC).
95932|NCT03436303|Drug|CEE 0.625 mg/MP 100mg|CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
95933|NCT03436303|Drug|CEE 0.3 mg/MP 100mg|CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
95934|NCT03436303|Drug|CEE 0.625mg/dydrogesterone|CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years
95935|NCT03436290|Behavioral|Palliative Care Intervention|These patients will receive the palliative care intervention.
95936|NCT03436277|Drug|L-Carnitine|L-Carnitine oral solution 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
95937|NCT03436277|Dietary Supplement|Sucralose|Sucralose 1.5 g diluted in 250 ml of water, before crossfit training, 5 times a week for 8 weeks
95938|NCT03436264|Other|MRI|fMRI
95939|NCT03436251|Device|Local Hyperthermia at 37℃|As a control, for patients with HPV+/CIN-1 or HPV+ with normal cytology, hyperthermia at 37℃ is applied
95940|NCT03436251|Device|LEEP or cold knife|For patients with HPV+ / CIN-2
95941|NCT03436251|Device|Local Hyperthermia at 44℃|As an experimental arm, for patients with HPV+/CIN-1/CIN2 or HPV+ with normal cytology
95942|NCT03436225|Drug|Dexamethasone orally.|Administered orally (0.15mg /kg / dose) twice daily for 3 to 5 days.
95943|NCT03436225|Drug|Dexamethasone parenteral.|Administered parenteral (0.15mg /kg / dose) twice daily for 3 to 5 days.
95944|NCT03436225|Drug|Inhaled nebulized Budesonide.|Administered for inhalation (1 mg/ 2ml) twice daily for 3 to 5 days.
95945|NCT03436225|Drug|Inhaled nebulized salbutamol.|Administered for inhalation (0.15mg /kg / dose) daily every 6-8hrs
95946|NCT03436212|Device|Continuous Glucose Monitoring (CGM)|DEXCOMG4 device
95947|NCT03436199|Drug|ADS-5102, 137 mg|Oral capsules to be administered once daily at bedtime
95948|NCT03436199|Drug|ADS-5102, 274 mg|Oral capsules to be administered once daily at bedtime
95949|NCT03436199|Other|Placebo|Oral capsules to be administered once daily at bedtime
95951|NCT03436173|Other|Peppermint syrup|Liquid peppermint syrup measured to the equivalent volume and mixed with water
95952|NCT03436160|Drug|WR826647|100 mcg Carbon-14 radio labeled WR826647 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
95953|NCT03436160|Drug|WR909388|100 mcg Carbon-14 radio labeled WR909388 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
95954|NCT03436160|Drug|WR909390|100 mcg Carbon-14 radio labeled WR909309 at an exposure no greater than 250 nCi per dose, administered both IV (bolus) and PO with a six half-life wash-out period between IV and PO administration. Interim analyses will be done at Day 14 following the IV dosing groups in order to assess half-lives of the three compounds to ensure the wash-out period between IV and PO dosing is at least six half-lives long.
95955|NCT03436147|Other|POP-Q|Pelvic Organ Prolapse Quantification
95956|NCT03436134|Other|Sessions of conventional apheresis|"Patient receiving sessions of Plasma exchange as treatment of chronic antibody mediated rejection.~The plasma exchange uses a single filter to remove whole plasma and the volume is replaced with a matched volume of blood products +/- saline.) 8 sessions plasma exchange.Patients will have one session per day, 4 consecutive days and then three days without, then one session per day for 4 consecutive days. That's 11 days of treatment at all. The fourth and eighth sessions will be followed by an infusion of Rituximab 375 mg / m2.~At the beginning and at the end of each session, the patients will have a blood test to measure the parameters of the routine care and the analyzes, collection of biological samples planned for the study."
95957|NCT03436134|Other|Sessions of news apheresis with double filtration|"Patient receiving DFPP as treatment of chronic antibody mediated rejection. 8 sessions~A Double filtration plasmapheresis (DFPP) is a variation of plasma exchange. The circuit contains two plasma filters : the first is a standard plasma filter and the second is a high molecular weight filter that primarily removes immunoglobulins. The depleted plasma is returned to the blood circuit and then to the patient."
95958|NCT03436121|Drug|Ketamine|"Ketamine is a medication approved by the US Food and Drug Administration (FDA) for anesthesia, sedation, and post-surgical pain treatment. It is not approved for emergency patients complaining of pain but is often used off-label. Ketamine may be useful for acute pain management and in treatment of depressed mood. The purpose of this study is to determine whether a single low dose of ketamine can relieve pain and reduce negative mood for 2 weeks after emergency department (ED) treatment."
95959|NCT03436121|Drug|Midazolam|In this study, all patients will also receive midazolam. Midazolam is a sedative that typically makes people feel relaxed and is intended to increase comfort with ketamine and reduce anxiety.
95960|NCT03436121|Drug|Placebo|In this study, patients in the active comparator group will receive midazolam first, then placebo. A placebo is an inactive solution that looks like the study drug, but contains no active ingredients.
95961|NCT03436108|Diagnostic Test|Measurement of Bisphenol in blood|to see level of this material in blood of women
95962|NCT03436095|Other|bundle measures|Implementation of bundle measures to improve the successful rate of weaning ventilator
95963|NCT03436082|Device|A mobile health platform|Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.
95964|NCT03436069|Other|Conventional treatment protocols of breast cancer|
95965|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 30 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 30 Gy in 3 fractions (#) in week 3
95966|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) 54 Gy 3 fractions (#)|Stereotactic Body Radiotherapy (SBRT) dosed at 54 Gy in 3 fractions (#) in week 3
95967|NCT03436056|Radiation|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose|Stereotactic Body Radiotherapy (SBRT) dosed at the maximum tolerated dose (MTD) determined in Part A in week 3
95968|NCT03436056|Drug|Pembrolizumab|Pembrolizumab in week 1 dosed at 200 mg (prior to SBRT) and then treatment with pembrolizumab will be continued dosed at 200 mg given every 3 weeks.
95969|NCT03436043|Device|Transmural Plastic stenting|After metal stent removal in patients of disconnected pancreatic duct syndrome, transmural plastic- double pig tail stent will be placed into the residual necrotic cavity with the standard duodenoscope.
95970|NCT03436030|Other|Simple breathing manuevers during brief echocardiographic imaging|Valsalva, Muller, light mask CPAP, leg raising, hand grip.
95971|NCT03436017|Other|Metabolomic approach|Biological samples (blood and urine) for a multimodal metabolomic approach
95972|NCT03436004|Device|Colonoscopy|Patients undergoing screening colonoscopy
95973|NCT03436004|Device|Colonoscopy with specific device (Endocuff Vision)|Patients undergoing screening colonoscopy using the Endocuff Vision device
95974|NCT03435991|Other|Validation Experience Sampling Method 'Uromate'|In a period of 7 days, participants will fill out an electronic ESM assessment at 10 random moments during the day. Moreover, they will fill out a sensation-related bladder diary (SR-BD) during the last three consecutive days of filling out the ESM and several symptom questionnaires at the end of the study period.
95975|NCT03435978|Behavioral|MetS+|
95976|NCT03435978|Other|MetS-|Data processing from Patient Medical Files
95977|NCT03435965|Diagnostic Test|AmnioQuickDuo+|AmnioQuickDuo+ kit for detection of PROM
95978|NCT03435952|Drug|Pembrolizumab|200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
95979|NCT03435952|Biological|Clostridium Novyi-NT|"Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10^4 spores followed by dose escalation."
95980|NCT03435952|Drug|Doxycycline|Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
95981|NCT03435939|Drug|Losartan|50 mg/day for 7 days followed by 100 mg/day for 12 weeks
95982|NCT03435913|Other|Standard PEEP ventilation|During mechanical ventilation a fixed PEEP (5 mcH2O) is set at all IAP levels during pneumoperitoneum insufflation
95983|NCT03435913|Other|Matched PEEP ventilation|During mechanical ventilation PEEP is matched to IAP level
95984|NCT03435900|Drug|Combination of fosfomycin, metronidazole and rhGM-CSF (administered together intraperitoneally) and three days of antibiotics p.o.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed. Hereafter, the intervention group will receive three days of orally administered antibiotics: 500 mg amoxicillin combined with 125 mg clavulanic acid and 500 mg metronidazole. These doses will be administered three times daily.
95985|NCT03435900|Drug|Standard antibiotics intravenously|4 g piperacillin/500 mg tazobactam and 1 g metronidazole administered intravenously during surgery followed by 4 g piperacillin/500 mg tazobactam and 500 mg metronidazole administered intravenously three times daily for three days.
95986|NCT03435887|Behavioral|Alere q HIV-1/2 Detect for point of care infant testing|The investigators will pilot the Alere q HIV-1/2 Detect mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4-8 weeks postnatal) for analysis with Alere q HIV-1/2 Detect, with results available within 1-2 hours to enable mother notification at the same clinic visit.
95987|NCT03435887|Behavioral|GeneXpert HIV-1 Qual for point of care infant testing|The investigators will pilot the GeneXpert HIV-1 Qual mobile system for point of care (POC) infant testing at two of the study hospitals. A blood sample will be collected from each HIV-exposed infants at birth (before discharge from Maternity or at first follow-up MCH visit within 14 days postnatal) and at 6-week EID visit (4 to <24 weeks postnatal) for analysis with GeneXpert HIV-1 Qual, with results available within 1-2 hours to enable mother notification at the same clinic visit.
95988|NCT03435887|Behavioral|HIV DNA PCR testing (Standard of Care)|This is the standard of care for infant HIV testing. A dried blood spot sample will be collected from the infant and shipped to a central laboratory for HIV DNA PCR testing. Results will then be returned to the hospital.
95989|NCT03435874|Biological|ChAd63 RH5|Vaccine
95990|NCT03435874|Biological|MVA RH5|Vaccine
95991|NCT03435874|Biological|Rabies Vaccine|Vaccine
95992|NCT03435861|Drug|VX-745|active drug capsules
95993|NCT03435861|Drug|placebo|placebo capsules
95994|NCT03435848|Drug|BST-236|1 to 4 courses
95995|NCT03435835|Device|Control/Sham Treatment|Thermoneutral water (33ºC) will be circulated through water-circulating trousers to maintain skin temperature at baseline levels.
95996|NCT03435835|Device|Heat Therapy (HT)|Water at 42-43ºC will be circulated through the water-circulating trousers.
95997|NCT03435822|Other|asthma action plan management group|Patients will follow the directions in asthma action plan when their asthma get worse.
95998|NCT03435822|Other|conventional management group|Patients will follow the directions in conventional strategy when their asthma get worse.
95999|NCT03435809|Procedure|Intrauterine insemination|Obligatory use of a Pozzi forceps tenaculum during intrauterine insemination
96000|NCT03435796|Genetic|Gene-modified (GM) T cell therapy|Gene-modified (GM) T cell therapy
96001|NCT03435783|Behavioral|Brief Electronic Intervention|The brief electronic intervention will allow users to receive normative feedback based on their alcohol use and sexual activity. Users who show interest in changing their behavior will also be asked to create a plan to do so.
96002|NCT03435783|Behavioral|Attention-Matched Control|Participants will view a video clip on general health promotion that is a similar length as the intervention arm.
96003|NCT03435770|Device|EUSRA RFA needle|A 19-gauge RFA electrode and a RF generator with a electrode that is needle-shaped and echogenic that allows EUS guided puncture of the target lesion. The active electrode tip is 1 cm in length. During ablation, the RF electrode is cooled and perfused internally with circulating chilled saline solution (0°C) delivered via a pump to maintain a constant temperature. A setting of 50W energy would be used for RFA and the duration of application is 10 seconds. Sequential applications of up to 7 times per session are allowed for complete ablation of the lesions.
96004|NCT03435757|Procedure|OFD+IMP+CPS|open flap debridement (OFD) and intramarrow penetration (IMP) plus calcium phosphosilicate putty
96005|NCT03435757|Procedure|OFD+IMP|open flap debridement (OFD) and intramarrow penetration (IMP)
96006|NCT03435744|Drug|Simvastatin 20 mg|Simvastatin 20 mg added to TAU for 3 months.
96007|NCT03435744|Other|Placebo Oral Tablet|Matched placebo added to TAU for 3 months
96008|NCT03435731|Combination Product|Dual Therapy|Concomitant use of Continuous Positive Airway Pressure (CPAP) and Mandibular Advancement Splint (MAS) therapeutic devices.
96009|NCT03435718|Drug|Oxfendazole|oral suspension
96010|NCT03435718|Drug|Albendazole|tablet
96011|NCT03435705|Behavioral|maintaining of occupational therapy|8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
96012|NCT03435692|Procedure|Lumbar Plexus Catheter|lumbar plexus catheter placed intraoperatively for perioperative pain control
96013|NCT03435692|Procedure|Lumbar Epidural Catheter|lumbar epidural catheter placed intraoperatively for perioperative pain control
96014|NCT03435692|Procedure|Patient Controlled Analgesia|A PCA started post operatively for perioperative pain control
96015|NCT03435692|Drug|Fentanyl|IV fentanyl was administered in the OR for induction of anesthesia. Subsequent doses in the OR were standardized to be given only for heart rate or blood pressure increases > 20% above baseline and occurring more than 30 minutes after the block (if applicable).
96016|NCT03435692|Drug|Morphine|In the OR patients, IV morphine was administered if patients had a failed block and standardized to be given only for heart rate or blood pressure increases > 20% above baseline and after fentanyl had been administered. IV Morphine was also administered in the OR if the patient was randomized to the PCA arm of the study. Post operatively IV Morphine was administered as needed for severe pain.
96017|NCT03435692|Drug|Lorazepam|IV Lorazepam was administered PRN for muscle spasm post operatively.
96018|NCT03435692|Drug|Ondansetron|IV Ondansetron was administered PRN for nausea and vomiting post operatively.
96019|NCT03435692|Drug|Diphenhydramine|IV Diphenhydramine was administered PRN for itching postoperatively.
96020|NCT03435692|Drug|Acetaminophen|PO Acetaminophen was administered PRN for pain in the PACU and then scheduled for 72 hours.
96021|NCT03435692|Drug|Oxycodone|PO Oxycodone was administered PRN for breakthrough pain post operatively.
96022|NCT03435692|Drug|Ropivacaine|IV Ropivacaine was administered as part of the initial bolus after placement of the lumbar epidural or lumbar plexus catheter and then as a continuous infusion post operatively.
96023|NCT03435679|Procedure|one-stage|one-stage surgery
96024|NCT03435679|Procedure|two-stage|two-stage surgery
96025|NCT03435666|Drug|Capecitabine|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
96026|NCT03435666|Drug|XELODA|Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
96027|NCT03435653|Other|OFD with DFDBA|Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.
96028|NCT03435653|Other|OFD with decortication and DFDBA|Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
96029|NCT03435640|Drug|NKTR-262|"During Phase 1 Doublet: Patients will receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients will receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients will receive the RP2D of NKTR-262."
96030|NCT03435640|Drug|bempegaldesleukin|"During Phase 1 Doublet (Cohort A), and Phase 2 Doublet: Patients will receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients will receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles."
96031|NCT03435640|Drug|nivolumab|During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients will receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
96032|NCT03435627|Drug|Somatropin|Participants will be treated with commercially available Norditropin® (somatropin) according to routine clinical practice at the discretion of the treating physician.
96033|NCT03435614|Drug|Opioids|Once an opioid dose reduction of 10% or greater is achieved, a daily assessment will be conducted by a physician using the DSM-5 criteria for opioid withdrawal. In addition, signs and symptoms of withdrawal will be collected daily by a blinded investigator.
96034|NCT03435601|Drug|Anifrolumab|"IV Administration of Anifrolumab 300 mg every 4 weeks from week 0 to week 20 for a total of 6 doses.~At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
96035|NCT03435601|Drug|Placebos|"Placebo IV administration Q4W, a total of 6 doses At week 24 patients will continue the current study for another 8 weeks to complete a 12-week safety follow-up after the last dose of investigational products (last dose of investigational product will be given at week 20).~The total study duration could be up to approximately 36 weeks (including the screening period)."
96036|NCT03435588|Procedure|EUS|Radial endoscopic ultrasound. A special endoscope uses high-frequency sound waves to produce detailed images of the lining and walls of the digestive tract , and allows to take samples from abnormal areas.
96037|NCT03435588|Procedure|FNA with ROSE|Endoscopic ultrasound guided biopsy of the pancreas with the traditional fine needle aspirate needle with the addition of rapid on-site cytopathology (cytopathologist looking at each biopsy samples as they are taken): The sampling is done with a small needle called fine needle aspiration needle or FNA. FNA alone is sometimes limited due to inadequate acquisition of cells for proper diagnosis under the microscope, which can lead to need for repeat endoscopic procedures and delay in diagnosis and possibly treatment. Rapid on-site evaluation of cytopathology (ROSE) is where a cytopathologist is next to the physician doing the endoscopic procedures and evaluates each sampling performed.
96038|NCT03435588|Procedure|FNB alone|Endoscopic ultrasound guided biopsy with a novel core biopsy needle without on-site cytopathology: New needles called core needles (fine needle biopsy, FNB) have recently been developed which not only acquires cells but also the entire tissue structure (histology).
96039|NCT03435575|Device|Boosth|Boosth activity tracker which measures steps
96040|NCT03435562|Other|JUUL electronic cigarette|Effects of JUUL electronic cigarette use.
96041|NCT03435562|Other|IQOS electronic cigarette|Effects of IQOS electronic cigarette use.
96042|NCT03435562|Other|Own Brand cigarette|Effects of own brand cigarette use.
96043|NCT03435549|Behavioral|Remote monitoring|Patients given an activity tracker to wear for 6 weeks after LEJR replacement surgery. For 2 weeks after surgery, they will also receive a daily text messages asking what their pain is on a scale of 0 to 10. They will be asked to reply to the text with their pain score. They will also be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days.
96044|NCT03435549|Behavioral|Remote monitoring plus goal setting and social support|Patients given activity tracker to wear for 6 weeks after LEJR surgery. For 2 weeks after surgery, they will receive a daily text messages asking what their pain is on a scale of 0 to 10 and asked to reply by text. They will be sent occasional messaging about their recovery, tips of what to do, and feedback on their progress. They will also also be sent a text message if they stop using their activity tracker for 3 days. Patients will be asked to identify a a friend or family member to act as support partner. The study will share progress updates with support partner and contact this individual if patient stops wearing the activity tracker for over 3 days. This partner will also be able to provide supportive messages to help encourage them to reach their activity goals.
96045|NCT03435536|Other|Blood samples|Blood samples will be taken to analyze the circulating tumor DNA rate by NGS
96074|NCT03435328|Device|TENS|"Duration of stimulation: 5 minutes.~Frequency: will be fixed at 50 Hertz.~Pulse duration: 250 µs.~Intensity: optimal intensity of TENS (amplitude will be gradually increased to the maximum intensity that the subject will be comfortable and tolerate it).~Sessions: only one session"
96338|NCT03433326|Drug|Elbasvir/Grazoprevir|Administration of MK-8742 (Elbasvir)/MK-5172 (Grazoprevir) for 12 weeks
96046|NCT03435523|Procedure|Recruitment maneuver|"the ventilator was switched to pressure-control ventilation with a driving pressure of 20 cmH2O. After a 3 min equilibration, PEEP was applied in steps of 5,10,15 and 20 cmH2O every five respiratory breaths; subsequently, after setting a driving pressure of 15 cmH2O, PEEP was stepwise reduced, starting from 15 cmH2O, by 2 cmH2O every 2 minutes. The recruiting pressure of 20/20 was applied for six breaths. During the decremental PEEP trial, CRS was measured at every step. The PEEP level corresponding to highest CRS during the decremental trial was identified as the best PEEP. Subsequently, the lungs were recruited again and the best PEEP was applied."
96047|NCT03435510|Behavioral|Live Donor Champion Program|Even with adequate education of live donation, many KT candidates still feel ill equipped to ask others to consider donating. Friends and family are often eager to help and may not be able to serve as donors themselves, but might be able to provide substantial instrumental support. An LDC is a friend or family member who serves as an advocate for the candidate in their pursuit of live donation. The Johns Hopkins Comprehensive Transplant Center has developed a 6-month program that provides education and advocacy training to waitlist candidates and their LDCs. The instrumental support provided by the LDC bridges a critical link between education and action.Using LDCs to increase live donation is a novel approach that has garnered widespread enthusiasm.
96048|NCT03435497|Behavioral|Game Changers|Game Changers is an intervention that aims to empower and mobilize PLHA to be agents for HIV prevention and behavioral change in their social networks.
96049|NCT03435484|Other|Current Instructions|Participants will receive a verbal reminder to complete the Health Assessment Questionnaire from the intake personnel, as part of usual care.
96050|NCT03435484|Other|Additional Instructions|Intervention includes various iterations of instructions for completing the Health Assessment Questionnaire. Participants will receive these instructions in addition to the verbal reminder from the intake personnel (usual care).
96051|NCT03435471|Other|Prophylactic Swallowing Home Exercise Program|The home exercise program will consist of six exercises that are recommended to be practiced three times per day. Subjects will complete a weekly exercise log to track compliance.
96052|NCT03435471|Other|Penetration/Aspiration Scale|Assessed by standard Videofluoroscopic Swallowing Assessment. Scores will be determined based on the Penetration/Aspiration Scale (PAS), which is an 8-point equal-appearing interval scale to describe the depth to which material passes in the airway and by whether or not the material entering the airway is expelled. This scale is from least (1) to most severe (8).
96053|NCT03435471|Other|Functional Oral Intake Scale|Subject's current nutritional level will be assessed by a study speech pathologist using the FOIS scale, which provides a diet level of safe oral intake meeting nutritional and hydration needs. Diet levels include from most restrictive (1) to least restrictive (7). FOIS to be assessed at baseline, 4 weeks and 26 weeks post-treatment, per protocol.
96054|NCT03435471|Behavioral|Eating Assessment Tool-10|Each subject will complete the EAT-10 to document swallowing function. This is a patient completed questionnaire that includes 10 items related to their perceptions of their swallowing ability, to be assessed at baseline, 4 weeks and 26 weeks post-treatment, per protocol.
96055|NCT03435471|Behavioral|University of Washington Quality of Life|Each subject will complete the UW-QOL to assess the physical, functional, and emotional quality of life assessment at baseline, 4 weeks and 26 weeks post-treatment, per protocol.
96056|NCT03435471|Other|Performance Status Scale for Head and Neck Cancer Patients|Assessed by speech pathologist to rate the subject's normalcy of diet, whether the subject eats in public, and the understandability of speech through use of an unstructured interview format at baseline, 4 weeks and 26 weeks post-treatment, per protocol.
96057|NCT03435471|Other|Clinician-Directed Prophylactic Swallowing Exercises|Once weekly face-to-face meetings with a study speech pathologist for a total of six sessions, to participate in active swallowing exercises
96058|NCT03435458|Combination Product|Balloon catheter + oral misoprostol|The pharmacological cervical ripening will be administered just after the balloon catheter insertion (after coming back in her room) and will consist of misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
96059|NCT03435458|Drug|Oral misoprostol alone|Patients will receive a pharmacological cervical ripening alone that consist of Misoprostol 25 micrograms given orally (oral prostaglandin E1). The same dose will be given every 2 hours until beginning of labor with a maximum of 8 administrations.
96060|NCT03435445|Behavioral|Online platform group|The online platform has social network, gamification and short-text sessions.
96061|NCT03435445|Behavioral|Online dietitian coaching|Dietitian coaching refers to individual online sessions between a dietitian and participants to strengthen dietary recommendations
96062|NCT03435445|Behavioral|Control group|Minimal intervention with four videos with diet, physical activity and behavior change recommendations
96063|NCT03435432|Dietary Supplement|Glucose|Glucose drink
96064|NCT03435432|Dietary Supplement|Water|Control
96065|NCT03435419|Diagnostic Test|LoopampTM Leishmania Detection Kit|LoopampTM Leishmania Detection Kit is a diagnostic test for Leishmania DNA detection
96066|NCT03435419|Diagnostic Test|CL DetectTM Rapid Test|CL DetectTM Rapid Test is a diagnostic test for Leishmania antigen detection
96067|NCT03435393|Procedure|Catheter ablation|Mapping of the epicardium and ablating areas of long fractionated potentials
96068|NCT03435380|Behavioral|Patient activation|Smartphone-based materials including text messages and supplemental short videos focusing on how to find a primary care doctor, the importance of medical screening, and how to talk to a doctor about medical screening. Guidelines for monitoring and maintaining health, such as a survivorship care plan, will also be included in the smartphone-based materials.
96069|NCT03435380|Behavioral|Primary care physician activation|Mailed educational print materials sent to the participants' primary care doctors about health risks and recommendations for medical screening for adult women who were treated for a childhood cancer with chest radiation.
96070|NCT03435380|Behavioral|Control|Mailed educational materials.
96071|NCT03435367|Device|Virtual Reality Program|VR with head mounted display (HMD) and headphones.
96072|NCT03435367|Device|iPad Tablet|iPad with headphones
96073|NCT03435354|Behavioral|Physical activity counselling|Clinician counselling about physical activity using standardized tools to promote daily physical activity.
96075|NCT03435315|Other|Treadmill Exercise- behavioral approach|16-session, 8-week treadmill exercise program utilizing behavioral techniques while walking
96076|NCT03435315|Other|Treadmill Exercise- traditional approach|16-session, 8-week traditional treadmill exercise program
96077|NCT03435302|Drug|Temozolomide Plus Cisplatin|"Temozolomide is the oral analog of dacarbazine (DTIC), shows potential advantages over dacarbazine.~Cisplatin is an agent that can potentially enhance the activity of temozolomide."
96078|NCT03435302|Drug|High-Dose IFN-a2b|Interferon belongs to the large class of glycoproteins known as cytokines.
96079|NCT03435289|Drug|CPI 613 in Combination With Gemcitabine and Nab-paclitaxel|"Day 1,15 CPI-613: IV infusion at a rate of 4 mL/min via a central venous catheter starting at 500 mg/m2 (with concurrent D5W infusing at a rate of 125-150 cc/hr). The CPI dose will be determined based on cohort. Day 2,16 Neulasta as clinically indicated~Nab- paclitaxel 125mg/m2 iv over 30 min followed by Gemcitabine 1000mg/m2 iv over 30 min"
96080|NCT03435276|Drug|AZD9977|Randomized subjects will receive AZD9977 oral suspension at a dose of 50 mg in Cohort 1, 150 mg in Cohort 2 and 300 mg in Cohort 3
96081|NCT03435276|Other|Placebo|Randomized subjects will receive orally AZD9977 matched placebo in Cohorts 1, 2 and 3
96082|NCT03435263|Other|home management|pregnant women presented with PROM will be randomized into 2 groups group a will be discharged home after initial assessment and group B will be admitted to hospital as usual
96083|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
96084|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
96085|NCT03435250|Drug|AG-270|AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
96086|NCT03435250|Drug|docetaxel|Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
96087|NCT03435250|Drug|nab-paclitaxel|Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
96088|NCT03435250|Drug|gemcitabine|Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
96089|NCT03435198|Diagnostic Test|Collect exhaled breath during low and normal blood sugar|Collect exhaled breath during low and normal blood sugar to determine if there are any differences between the two in people with type 1 diabetes.
96090|NCT03435185|Procedure|Lidocaine injections|Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.
96091|NCT03435185|Procedure|Saline injections|Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve
96092|NCT03435172|Device|Device-ADRCs intravenously infusion|Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
96093|NCT03435159|Diagnostic Test|Doppler Ultrasonography|GE LOGIQ S8 ultrasound machine was used to measure blood flow parameters in right and left a. carotis communis, a. carotis interna and a. vertebralis. All vessels were examined in the axial plane through their traces in the B-mode with a C6-15 MHz curvilinear matrix probe. Flow patterns and directions of vessels were then examined with Colour Doppler and it was determined whether there was any stenosis. Intimal thickness of a. carotis communis was measured by spectral doppler method. Measurements were recorded by visualizing the CCA at the supraclavicular level, the ICA carotid sinus (C4 level), and the VA at the V2 segment (C3-4 level), with less angle at 60 degrees. All measurements before and after the application were made at the same level. Immediately after manipulation, blood flow parameters were recorded as numerical data by the same physician again with Doppler USG of the relevant arteries.
96094|NCT03435159|Procedure|Manual Chiropractic Spinal Manipulation|"Manipulation procedures were applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Manual chiropractic manipulation for C1 vertebra was applied in sitting position, using the digit / atlas pull technique. This technique is applied with the contact of practitioner's middle finger to the posterior part of transverse process of atlas, and generate a rotation force between C1 and C2 vertebrae.~The procedure was applied to C2 vertebra using the index / facet push technique in the supine position. This technique places pushing force in the direction of rotation between the C2-C3 vertebrae, placing the practitioner's index finger in contact with the posterior surface of the C2 facet joint."
96095|NCT03435159|Device|Instrumental Chiropractic Spinal Manipulation|"Activator technique was applied to C1 or C2 (atlas and axis) vertebrae once in each participant. The application to which vertebrae were applied was determined by the palpation method applied by the physiotherapist. Instrumental spinal manipulation was applied with Activator V chiropractic instrument. For C1 vertebra, the procedure was applied in supine position, by placing the Activator device horizontally on the participant's atlas transverse process of the affected side and applying a pushing force in the medial direction.~For C2 vertebra, the procedure was applied in prone position, by placing the Activator device in the relevant C2 pedicle-lamina junction of the participant's affected side and applying a pushing force in the anterior, superior and mild medial direction of movement of the facet joint."
96096|NCT03435146|Combination Product|3HP plus DTG +2NRTIs|"HIV treatment: DTG will be dosed as described above and will be given with daily TDF/FTC.~LTBI treatment: 3HP will be given once-weekly for a total of 12 doses, with doses as follows:~Rifapentine: 900 mg; Isoniazid: 900 mg"
96097|NCT03435133|Drug|Prasugrel|60 mg oral bolus plus oral 10 mg once daily
96098|NCT03435133|Drug|Ticagrelor|180 mg oral bolus plus oral 90 mg every 12 hours daily
96099|NCT03435120|Other|No intervention|No intervention
96191|NCT03434483|Other|Clinical evaluation|Clinical evaluation including hemostasis and biochemical studies and questionaries for diet and exercice registration
96192|NCT03434444|Drug|Oxytocin|Oxytocin in solution, ranging from 10 -15M to 10 -5M
96193|NCT03434444|Drug|Propranolol|Propranolol in solution, 10-7M
96194|NCT03434431|Other|Reverse dieting|
96195|NCT03434418|Drug|osimertinib|80 mg oral administration daily
96100|NCT03435107|Drug|Durvalumab|"Study treatment consists of durvalumab 1500 mg Q4W for patients > 30 kg, and will be repeated every 4 weeks. For patients ≤ 30 kg, weight based dosing of 20 mg/kg durvalumab Q4W will be used.~Response evaluation will be performed every 8 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
96101|NCT03435094|Drug|Binosto 70Mg Effervescent Tablet|Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
96102|NCT03435094|Drug|Fosamax 70Mg Tablet|Assess the effect of alendronate 70mg tablet on bone turnover markers and patient reported outcomes.
96103|NCT03435081|Drug|Baricitinib|Administered orally
96104|NCT03435081|Drug|Placebo|Administered orally
96105|NCT03435068|Device|Ceramic rotary bur|Gingivoplasties were performed with the same ceramic burs to easily provide a knife-edge appearance with ceramic rotary bur
96106|NCT03435068|Device|Diode laser|The fiber optic laser tip had a 320-μm diameter with a 2.8 W output power were used in the study.
96107|NCT03435068|Device|Scalpel|Scalpel surgery were performed as control group (conventioanl group).
96108|NCT03435055|Drug|Nitrous Oxide Gas for Inhalation|Each volunteer will participate in one scanning visit in which simultaneous fMRI/EEG data will be collected wherein they receive placebo (20 minutes) followed by inhaled nitrous oxide at subanesthetic levels (35% inhaled concentration) over 40 minutes.
96109|NCT03435042|Behavioral|Self care + Hypnosis group|Our groupal intervention is divided into 6 monthly 2-hour sessions in which some self-hypnosis exercises are proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
96110|NCT03435029|Behavioral|Cognitive Remediation Program (REHACOP)|The REHACOP group received cognitive remediation sessions 3 times per week for 3 months in 60 minute per session. The rehabilitation consisted of 39 sessions divided into: attention and concentration unit (sustained, selective, alternating, and divided attention) 4 weeks; learning and memory unit (verbal and visual memory and learning strategies) 3 weeks; language (verbal fluency, syntax, grammar, vocabulary, and comprehension) 3 weeks; and executive functioning (objectives planning and attainment, verbal reasoning, categorization, and conceptualization). In addition, processing speed was trained transversely during all the sessions.
96111|NCT03435029|Other|Occupational Therapy|The control group received occupational group activities (reading the newspaper, drawing, singing or doing crafts) with the same frequency and format as the experimental group.
96112|NCT03435016|Diagnostic Test|Diagnostic work-up|Patients are examined with all modalities. MR enterocolonography, ultrasound, and small bowel capsule endoscopy are compared against ileocolonoscopy (gold standard).
96113|NCT03435003|Drug|Aprepitant 80Mg Oral Capsule|aprepitant 80 mg orally one hour prior to scheduled surgery
96114|NCT03435003|Drug|scopolamine transdermal|scopolamine transdermal patch one hour prior to scheduled surgery
96115|NCT03435003|Procedure|Total intravenous anesthesia|Maintenance of anesthesia without the use of inhaled anesthetics.
96116|NCT03435003|Drug|Dexamethasone|Dexamethasone 8 mg intraoperatively
96117|NCT03435003|Drug|Ondansetron|Ondansetron 4 mg intraoperatively. Ondansetron will be given twice. Once intraoperatively and then post- operatively.
96118|NCT03435003|Drug|Reglan|Postoperatively scheduled Reglan
96119|NCT03435003|Drug|Ondansetron|Postoperatively scheduled ondansetron
96120|NCT03435003|Drug|Compazine|Postoperatively as needed compazine for breakthrough PONV
96121|NCT03435003|Drug|Sugammadex|Reversal with sugammadex
96122|NCT03435003|Drug|Propofol|Intravenous anesthesuia will be maintained through IV propofol
96123|NCT03435003|Drug|dexmedetomidine|maintainance of anesthesia in the intervention arm
96124|NCT03435003|Drug|Fentanyl|intermittent bolus dosing of fentanyl will be used after induction for anesthesia maintenance
96125|NCT03435003|Drug|Sevoflurane|inhalational anesthesia
96126|NCT03435003|Drug|Desflurane|inhalational anesthesia
96127|NCT03434990|Other|Spinal manipulation/myofascial release|The protocol will be composed by myofascial release followed by spinal manipulation. Paravertebral muscles and gluteus maximus and piriform muscles will be manually checked for tension, stiffness, spasm and painful points. The intervention will be composed by: trigger points release, release of muscle fascia and active release technique. The myofacial release will be done with a constant pressure during 30 seconds, 3x in each point. After this procedure, the spinal manipulation will be performed in high velocity and low amplitude thrust technique, on the lumbar spine and sacroiliac joint.
96128|NCT03434990|Other|Spinal manipulation|The sacroiliac joint will be test and manually verified for any dysfunction, and the lumbar spine will be also assessed to verify any hypomobility and vertebral rotation. The segments with alterations will be manipulated with a high velocity and low amplitude thrust technique.
96129|NCT03434977|Drug|TAK-536|TAK-536 granule formulation
96130|NCT03434964|Diagnostic Test|the intraoperative effectiveness of the AIFIB software in real time in the detection of atrial fibrillation drivers during an ablation procedure.|Real-time validation by an expert operator of the correct detection of atrial fibrillation driver
96131|NCT03434951|Drug|Bupivacaine Hydrochloride, Spinal|Intrathecally administered 12,5mg bupivacaine for spinal anaesthesia
96132|NCT03434951|Drug|Morphine hydrochloride, Spinal|Intrathecally administered morphine 0,2mg (2mg/ml, 0,1ml)
96133|NCT03434951|Drug|Placebo - Concentrate|Intrathecally administered saline solution 0,9% 0,1ml to match morphine volume
96196|NCT03434405|Behavioral|SocialMind|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
96197|NCT03434405|Behavioral|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
96198|NCT03434405|Drug|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
96134|NCT03434938|Behavioral|Motivational interviewing|"MI sessions' goals will to obtain patients' collaboration, creating a shared tailored approach to complement the individual geriatric rehabilitation plan, and reinforcing engagement and adherence at 3 months.~All 20-minutes sessions will follow the logical sequence of MI by Rollnick and Millner (engaging, focusing, evoking and planning) in a semi-structured format to ensure homogeneity. Content will include: 1) Creating engagement with patients by exploring their preferences, values, goals, and their knowledge and expectations about rehabilitation and recovery, 2) enhancing motivation by evoking patients' strengths and abilities, 3) follow-up and reinforcement, and 4) adapting the plan to the improved abilities and to home setting after discharge."
96135|NCT03434925|Genetic|Multi-targeted next generation sequencing|Study directed at finding molecular predictors of recurrent colorectal adenomas also taking into account the intrinsic level of heterogenity imprinted in the internal differences in molecular profiles
96136|NCT03434899|Behavioral|Physical exercise and online support|Person-centered design of a health care plan including individually adjusted physical exercise. Online support for management of health care plan.
96137|NCT03434899|Behavioral|Physical exercise|Person-centered design of health care plan individually adjusted physical exercise.
96138|NCT03434886|Other|CFView|Registry patient portal
96139|NCT03434886|Other|CF educational videos|CF educational videos
96140|NCT03434873|Other|magnetic stimulation|Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks
96141|NCT03434860|Dietary Supplement|probiotic|"The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day."
96142|NCT03434860|Dietary Supplement|placebo|Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
96143|NCT03434847|Other|Education|Participants who receive perioperative educational to address their expectation about their postoperative pain will have improved pain-related postoperative outcomes.
96144|NCT03434834|Device|optical coherence tomography|OCT measurements of 5 locations in the esophagus
96145|NCT03434808|Other|Whole Blood Donation|Study subjects will provide 250ml whole blood donation for the manufacture and banking of iPS cells.
96146|NCT03434782|Drug|In-office dental bleaching|The group will receive in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 3 sessions, with a 7-day interval.
96147|NCT03434782|Drug|Low Level Laser Therapy|It will be used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and apical region of the incisors, canines and premolars.
96148|NCT03434782|Drug|5% potassium nitrate / 2% sodium fluoride gel|5% potassium nitrate / 2% sodium fluoride gel will be applied for 10 minutes on the vestibular surface of all pre-bleached dental elements, following the manufacturer`s protocol.
96149|NCT03434769|Drug|Cyclophosphamide|Cyclophosphamide 60mg/Kg on day -6
96150|NCT03434769|Drug|Fludarabine|Fludarabine 25mg/m^2 IV on days -5 to -3
96151|NCT03434769|Biological|CAR-T Cells|Chimeric antigen receptor T cells on day 0
96152|NCT03434756|Other|Propioceptive training of the abdominal wall muscles|At the beginning, patients will be in a supine position, the lower edge of the StabilizerTM will be placed between the posterior superior iliac spines, aligned with the sacral base. Abdominal manoeuvre will be developed by the patients until they reach 40 mmHg and hold steadily for 10 seconds. Prior the examination, each subject practiced the abdominal manoeuvre three times with an ultrasound image feedback.
96153|NCT03434743|Other|Rehabilitative|Non-nutritive sucking on emptied breast
96154|NCT03434743|Other|Active Comparator|Non-nutritive sucking on pacifier
96155|NCT03434730|Radiation|Total Body Irradiation|Participants will receive a total dose of 400 cGy on day -2 and day -1 as 2 fractions (200 cGy x 2). Participants receiving total body irradiation (TBI) are treated in a standing position, and the treatment takes about 20 to 30 minutes.
96156|NCT03434730|Drug|Cyclosporine|Dilute in D5W or NS to make a 2.5 mg/ ml solution. Infuse slowly over approximately 1-4 hours (intermittent infusion) or 24 hours for continuous infusion.
96157|NCT03434730|Drug|Mycophenolate Mofetil|A 1000 mg dose should be placed in 140 ml of D5W. Administer only with D5W, over at least 2 hours.
96158|NCT03434730|Drug|Tocilizumab|For participants < 30kg, dilute with 50mL 0.9% sodium chloride. For participants ≥ 30kg, dilute to 100ml with 0.9% sodium chloride. Administer infusion over 60 minutes with infusion set.
96159|NCT03434730|Drug|Filgrastim|The single use prefilled syringes contain either 300 mcg or 480 mcg Filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. For the prevention/treatment of chemotherapy induced neutropenia, the dose of filgrastim is standardized per body weight: ≤ 60 kg = 300 mcg daily subcutaneously; > 60 kg = 480 mcg subcutaneously daily.
96160|NCT03434717|Other|Individualised rehabilitation|Patients will get access/support to individualised rehabilitation based on their needs identified through the distress thermometer
96161|NCT03434717|Other|Care as usual|Patients will get care as usual
96162|NCT03434704|Drug|"Conditioning treatment Thiotepa-Treosulfan-Fludarabine"|Thiotepa iv 5 mg/kg/bid (total dose TD 10 mg/kg) day -3,-2; Treosulfan iv 14g/mq/day (TD 42 g/mq) as a single daily dose day -6, -5, -4; Fludarabine iv 30 mg/m2 (TD 150 mg/m2) day -6, -5, -4, -3, -2. Thiotepa TD 5 mg/kg and treosulfan TD 36 g/mq dose reduction according to age > 65 years.
96163|NCT03434704|Procedure|PBSC graft|(target 4-8 × 106 CD34+ cells/kg patient body weight)
96164|NCT03434704|Drug|GvHD prophylaxis|"Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.~Mycophenolate 15 mg/kg bid i.v. or per os day +5 through +28. Cyclophosphamide 50 mg/kg i.v. day +3+4. Mesna: >80% of the cyclophosphamide dose in 3 divided doses from day +3 daily through day +5."
96165|NCT03434704|Drug|Primary antifungal prophylaxis|Posaconazole delayed-release tablet [available in 100 mg tablets]: 300 mg twice daily on the first day followed by a maintenance dose of 300 mg once a day, starting on the day 0 to day 85.
96272|NCT03433859|Other|Topical Aluminium Chloride (cosmetic product)|Topical Aluminium Chloride (cosmetic product) : 1 quantity sufficient on the lower limb
96166|NCT03434691|Device|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
96167|NCT03434691|Drug|remifentanyl|Only the dose of remifentanyl (initial infusion of 6 µg/kg/h) can be changed to achieve a Goal of sedation: Richmond agitation-sedation scale 0 to -2.
96168|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl 2 mcg/kg+ Inhalational Agent, Bupivacaine 0.125% + Fentanyl 5 mcg/ml|Patient will have their epidural started at the beginning of the surgery and receive fewer opioid drugs. The epidural is continued into the recovery room.
96169|NCT03434678|Drug|Propofol+ Rocuronium+ Fentanyl + Inhalational|Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
96170|NCT03434678|Procedure|Open Pancreaticoduodenectomy|Whipple' Procedure
96171|NCT03434665|Procedure|Transradial celiac artery angiography|"After completion of transradial diagnostic coronary angiography and/or PCI, before removal of the radial arterial sheath, selective angiography of the celiac artery will be performed.~Technically, a 0.35-inch wire is advanced into the descending aorta. A 125 cm 5-French Judkins right catheter is inserted over this wire, which is then removed. The distal tip of the catheter is brought in front of the ostium of the celiac artery and positioning is confirmed with angiography of the celiac artery. Two or three views will be obtained to determine the optimal view to visualize the left gastric artery anatomy. All material is removed and hemostasis is obtained as per clinical routine for coronary angiography."
96172|NCT03434652|Device|Percutaneous neurostimulation|Auricular percutaneous neurostimulation
96173|NCT03434639|Diagnostic Test|Spectroscopic gut permeability test|"The spectroscopic gut permeability test first involves patients receiving an oral dose of one or more fluorescent dyes. A wearable sensor will then be attached to the patients' skin and this will be used to monitor the leakage of the fluorescent dyes from the intestine into the blood stream in a non-invasive manner. In this way, a measure of the permeability of the intestine will be obtained.~Note that patients in Group 1 (ophthalmology patients) will not receive oral doses of contrast agents. Instead, the wearable sensor will simply be used to detect the presence of fluorescent dyes that were administered intravenously as part of planned ophthalmic procedures.~Complete details of the spectroscopic gut permeability test can be found in the attached protocol."
96174|NCT03434626|Behavioral|ACP Education|Decision aid and Goals of Care Designation form information administered by Navigator
96175|NCT03434626|Other|Usual care|Usual care includes reviewing Goals of Care Designation form and Greensleeve with physician
96176|NCT03434613|Drug|Rosuvastatin|Rosuvastatin 5mg 1T daily for 6 months
96177|NCT03434613|Drug|Rosuvastatin/ezetimibe combination|Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
96178|NCT03434600|Other|Oxford UKA vs Sigma UKA|
96179|NCT03434587|Procedure|Syndactyly|Syndactyly
96180|NCT03434587|Procedure|Reduction and inmobilization|Closed reduction and inmobilization with splint
96181|NCT03434574|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
96182|NCT03434574|Dietary Supplement|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa).
96183|NCT03434535|Device|Technology Intervention|A combination of existing technology and a new app developed by InHealth Measurement Corp to (1) remotely monitor a participant's activity level and weight and (2) remotely provide updates to the participants regarding their progress towards the goals established in the Prostate Cancer Foundation Health and Wellness guidelines.
96184|NCT03434522|Device|vBloc Maestro Rechargeable System|vBloc therapy consists of a neuromodulation device that delivers intermittent, controllable electrical blocking algorithms, to the intra-abdominal vagus nerve for the treatment of obesity.
96185|NCT03434509|Other|Continuous Tai Chi and Mindful Movement classes|"Participants will be enrolled in ongoing Tai Chi and mindful movement classes throughout the year, for 1 hour twice a week.~Class sessions will consist of warm up (yoga- and mindfulness-based practices), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing)."
96186|NCT03434496|Device|Gait Trainer 3|With the BIODEX Gait Trainer 3, patients acquire a smooth gait pattern. In addition, balance, coordination, endurance and the cardiovascular system are trained. Work on the treadmill strengthens the leg muscles. On the screen or via an audio message, the patients and therapists receive direct feedback on the smoothness of the gait pattern. The therapists can then make corrective interventions if necessary and the patients are motivated.
96187|NCT03434483|Procedure|Assessment of the atherosclerotic plaque in a moderate lession.|"In patients who have been successfully revascularized the artery responsible for AMI and also present an intermediate lesion (40-80%) in another coronary territory, the clinical care protocol of the Cardiology Service stipulates the need for a physiological assessment with guidance of pressure (FFR).~The thickness of the fibrous cap shall be measured using optical coherence tomography.~In addition to the FFR measurement, a complete physiological assessment with a Doppler-pressure guide. This will allow the procedure to be performed without additional risk to the patient. The physiological study will include the analysis of endothelium-dependent vascular function and endothelium-independent vascular function."
96188|NCT03434483|Genetic|Gene variants in atherosclerosis|From the blood samples of the patients, the total DNA will be extracted and the main functional variants identified in the literature will be genotyped
96189|NCT03434483|Other|Microbiota analysis|From the samples of blood, feces, oral cavity and blood, the DNA of the microbiota will be extracted using specific extraction kits and the microbiome will be analyzed through the study of 16S ribosomal RNA amplicons.
96190|NCT03434483|Other|Immunological analysis|A study of immunological cell populations and cytokines will be carried out from fresh blood samples using antibody panels and flow cytometry
96199|NCT03434392|Diagnostic Test|Quantitative Sensory Test 1|Subject will give pain rating (on Visual Analogue Scale (VAS) 0-10) of single as well as multiple stimulation with round-tip non-invasive pin-prick device. Difference is recorded as Temporal Summation Score.
96200|NCT03434392|Diagnostic Test|Quantitative Sensory Test 2|Subject will state when they first detect pain and pain detection threshold in response to pressure administration with pressure algometer. Pressure threshold recorded in kilopascals(kP). Stimulation will be repeated in pancreatic and control dermatomes. Subject will then state pain tolerance threshold at same locations. Sensitization will be characterized by ratio of pancreatic vs. control dermatome scores.
96201|NCT03434392|Diagnostic Test|Quantitative Sensory Test 3|Subject will apply dominant hand to ice-chilled water bath (36F) for up to 2 minutes. Pain score (VAS 0-10) will be assessed each 10 seconds. Pain tolerance threshold (in kP) will be assessed with algometer on non-dominant thigh before and after water bath to determine change in threshold. Difference in pain tolerance recorded as Conditioned Pain Modulation Score.
96202|NCT03434379|Drug|Atezolizumab|Atezolizumab will be administered by IV, 1200 mg on day 1 of each 21 day cycle
96203|NCT03434379|Drug|Bevacizumab|Bevacizumab will be administered by IV, 15 mg/kg on day 1 of each 21 day cycle
96204|NCT03434379|Drug|Sorafenib|Sorafenib will be administered by mouth, 400 mg twice per day, on days 1-21 of each 21-day cycle
96205|NCT03434366|Drug|ketamine and dexmedetomidine|intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
96206|NCT03434366|Drug|ketamine|intranasal ketamine for treatment for autism spectrum disorder
96207|NCT03434366|Drug|Saline|intranasal saline for treatment for autism spectrum disorder
96210|NCT03434340|Biological|Peppermint essential oil|2 drops applied on a nasal strip
96211|NCT03434340|Drug|Granisetron|1mg intravenous injection
96212|NCT03434340|Drug|Dexamethasone|4mg intravenous injection
96213|NCT03434327|Other|Strength Training|Eleven resistance training exercises performed on pneumatic resistance training machines using 2 second concentric and 3 second eccentric contractions at 75-80% of each subjects maximal strength. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
96214|NCT03434327|Other|Power Training|Eleven resistance training exercises performed on pneumatic resistance training machines using maximum speed concentric and 3 second eccentric contractions at the load that produces the highest power for the individual. Subjects will perform 3 sets per exercise, two times per week for 12 weeks.
96215|NCT03434314|Procedure|Minimally-Invasive Segmental Artery Coil-Embolization|During one single MISACE session 3-7 segmental arteries will be occluded. The procedure is conducted through a peripheral artery access in local anaesthesia. Microcoils or vascular plugs will be used for the occlusion itself.
96216|NCT03434301|Device|ReliaTack™|Absorbable tack (ReliaTack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
96217|NCT03434301|Device|Protack™|Non-absorbable tack (Protack™) to fixate Symbotex™ composite mesh in the elective repair of incisional hernia.
96218|NCT03434288|Other|Bone sampling|Bone biopsy in Diabetic patients with foot osteomyelitis
96219|NCT03434275|Drug|N1539|Once Daily
96220|NCT03434275|Drug|Placebo|Once Daily
96221|NCT03434262|Drug|Gemcitabine|Given intravenously (IV).
96222|NCT03434262|Drug|ribociclib|Given orally (PO).
96223|NCT03434262|Drug|sonidegib|Given PO.
96224|NCT03434262|Drug|trametinib|Given PO.
96225|NCT03434262|Biological|filgrastim|Given subcutaneously (SQ).
96226|NCT03434249|Dietary Supplement|Bifidobacterium, BB-12® (Bifidolactis Infant)|
96227|NCT03434249|Dietary Supplement|Bifidolactis Infant Placebo|
96228|NCT03434236|Dietary Supplement|low dose Lipinova (30 mL daily)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
96229|NCT03434236|Dietary Supplement|Placebo|Placebo will have a similar appearance, smell and taste as the nutritional supplement
96230|NCT03434236|Dietary Supplement|high dose Lipinova (60mL)|Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
96231|NCT03434210|Other|LAT-treated Community Model|The subjects in experimental group is on 'LAT-treated Community Model'. which means,beside care as usual, subjects will be treated by paliperidone palmitate, Psychiatrists will guide community mental health professinals about the treatment and management. Psychiatrists will give community mental health professinals and patients/ caregiver long acting injection related education information.
96232|NCT03434210|Other|care as usual|Control group will get usual community care, the treatment is identified by doctors, patients and care-giver as usual.
96233|NCT03434197|Drug|Esflurbiprofen|A plaster containing 40 mg of Esflurbiprofen and 36.2 mg of Japanese Pharmacopoeia mentha oil per patch (10 × 14 cm)
96234|NCT03434197|Drug|Diclofenac diethylamine|A gel containing 11.6 mg of Diclofenac diethylamine (equivalent to 10 mg of diclofenac sodium) per 1 g (1 tube contains 20 g)
96235|NCT03434171|Behavioral|Aerobic excercise|practiced treadmill exercise program for 30 minutes at 60% to 70% of maximum heart rate. The treatment sessions will be repeated 3 times per week for 12 weeks
96236|NCT03434171|Dietary Supplement|soy products|diet modification contains soy products (phytoestrogen) such as soy milk and soy beans every day for 12 weeks only
96237|NCT03434158|Drug|Olaparib|300 mg twice a day
96238|NCT03434145|Other|ophthalmologic exams|ophthalmologic exams such as vision, intraocular pressure, axial length and optical coherence tomography
96273|NCT03433833|Drug|Digoxin|Digoxin oral route once daily for 24 weeks.
96274|NCT03433820|Other|Observation of wound healing|Observation of wound healing after skin biopsy
96275|NCT03433807|Drug|Idebenone|900 mg idebenone/day (2 tablets to be taken 3 times a day with meals)
96300|NCT03433599|Other|Normal Room Air|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of normal room air (with tubing attached to the mask) and 60-90 sec of normal room air (without the tubing attached to the mask).
96239|NCT03434132|Procedure|Open or robotic radical cystectomy|"ORC and orthotopic ileal neobladder is performed as previously described. A separate package PLND is performed as in open as in robotic surgery. RARC is performed replicating open surgical procedure.~The orthotopic ileal neobladder model used is the 'vescica ileale padovana' as previously described. An ileal segment, approximately 42 cm long, is chosen at a minimum distance of 20cm far from ileo-cecal valve. A latero-lateral ileal anastomosis is performed with staplers to restore bowel continuity.~For ileal conduit, a 20cm ileal segment (approximately 20 cm long) at a minimum distance of 20 cm from ileo-cecal valve is isolated and transected with staplers. Bowel continuity is restored as previously described. The ileal loop on its distal edge is extracted through abdomen wall at the previously identified stoma point and fixed to abdomen fascia. The ureters are spatulated and a latero-lateral anastomosis according to Wallace 1 technique is performed."
96240|NCT03434119|Drug|INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
96241|NCT03434119|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
96242|NCT03434106|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatmen
96243|NCT03434106|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
96244|NCT03434093|Device|Transcranial Magnetic Stimulation (TMS)|Description: This will comprise single and repeated paired-pulses delivered over motor and non-motor areas.
96245|NCT03434093|Behavioral|Working Memory Task|This will consist in remembering an item presented 1 to 5 steps before the inquiry. This task will span the whole duration of the functional MRI acquisition.
96246|NCT03434054|Drug|Losartan|blood pressure medication
96247|NCT03434054|Other|Placebo|non-active sham intervention
96248|NCT03434041|Drug|Esketamine 56 mg|Participants will self-administer 56 mg of esketamine as intranasal spray.
96249|NCT03434041|Drug|Esketamine 84 mg|Participants will self-administer 84 mg of esketamine as intranasal spray.
96250|NCT03434041|Drug|Placebo|Participants will self-administer matching placebo as intranasal spray.
96251|NCT03434041|Drug|Duloxetine (Oral Antidepressant)|Duloxetine can be selected as the oral antidepressant medication based on investigator's discretion. The minimum therapeutic dose is 60 milligram per day (mg/day).
96252|NCT03434041|Drug|Escitalopram (Oral Antidepressant)|Escitalopram can be selected as the oral antidepressant medication based on investigator's discretion. Escitalopram will be started at a dose of 10 mg/day and up-titrated to a maximum dose of 20 mg/day.
96253|NCT03434041|Drug|Sertraline (Oral Antidepressant)|Sertraline can be selected as the oral antidepressant medication based on investigator's discretion. Sertraline will be started at a dose of 50 mg/day and up-titrated to a maximum dose of 200 mg/day.
96254|NCT03434041|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine XR can be selected as the oral antidepressant medication based on investigator's discretion. Venlafaxine XR will be started at a dose of 75 mg/day and up-titrated to a maximum dose of 225 mg/day.
96255|NCT03434028|Drug|Early Vasopressors|"Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. Rescue fluids may be administered as 500ml boluses if predefined rescue criteria are met."
96256|NCT03434028|Drug|Early Fluids|"Additional 2 liter intravenous fluid bolus upon enrollment. Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. Rescue vasopressors may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted."
96257|NCT03434002|Other|Training by Virtual Reality Simulation|Those Randomized 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by Virtual Reality simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
96258|NCT03434002|Other|Training by Mannequin Based Simulation|Randomized other 15 residents will be receive Local Anesthetic Systemic Toxicity simulation training by mannequin based simulation and after two weeks, they will be evaluated by investigators by using the same performance evaluation tool.
96259|NCT03433989|Diagnostic Test|telephone interview|questionnaire PDEQ et IES-R
96260|NCT03433976|Drug|spinal anesthesia|spinal anesthesia for planned cesarean sections
96261|NCT03433963|Dietary Supplement|L-Arg supplement|L-Arg supplement will be prepared as pills, administered 9g each day in 3 times for 2 weeks.
96262|NCT03433963|Dietary Supplement|Placebo|Placebo will be prepared as pills (the same size, color and shape as of L-Arg), administered 3 times daily for 2 weeks.
96263|NCT03433950|Other|No Intervention|Observational
96264|NCT03433937|Device|Negative pressure wound therapy|Wound dressing
96265|NCT03433937|Other|Micropore tape|Wound dressing
96266|NCT03433911|Device|FemBloc|Treatment with FemBloc for women who desire permanent birth control (female sterilization)
96267|NCT03433911|Procedure|Laparoscopic bilateral tubal sterilization|Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
96270|NCT03433872|Other|We Grow Together: The Q-CCIIT Professional Development System|We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
96271|NCT03433859|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA in intradermal Injections on residual lower limb : 100 Units - 1 dose
96339|NCT03433313|Drug|EG12014|EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
96276|NCT03433794|Behavioral|Alcohol 101 Plus (TM)|It is a combination of several intervention components, including alcohol education, personalized feedback, attitude-focused strategies, and skills training. It also included a virtual bar, where participants provide information such as sex, weight, and state so that the program can provide tailored information on blood alcohol content (BAC) as well as state regulations regarding legal limits. The program provides updated BACs based upon choices about what to consume and how quickly to consume it. The intervention is highly interactive, with text, photos, videos, and narratives for fictional students with decision points where the participant chooses what the fictional student should do. It is a non-linear environment, where participants choose which sections of the website to explore.
96277|NCT03433794|Behavioral|Booster|Personalized feedback was emailed to participants. Content included sex-specific descriptive normative information (i.e., drinks per week typically consumed by males and females at the same institution), as well as reminders of harm reduction strategies (i.e., techniques the participant reported using in their last survey, versus techniques not used).
96278|NCT03433794|Behavioral|Lilly for Better Health|This is an online education session directed at other health behaviors besides alcohol. The site provides practical tips on general well-being such as healthy eating, physical activity, and stress management, as well as provides information on managing health conditions such as diabetes, heart disease and depression. It was not expected to influence alcohol use.
96279|NCT03433781|Drug|50 gm CIVI/24 hours x 5 days every 4 week|Each one ml solution will contain 500 mg ascorbic acid in the addition of disodium edetate 0.25mg, sodium hydroxide 110 mg in water with a pH in the range of 5.5 to 7.0 adjusted with sodium bicarbonate and sodium hydroxide. Vitamin C will be dispensed continuously by a computerized ambulatory drug deliver (CADD) pump, which will bereplaced every 24 hours.
96280|NCT03433768|Genetic|Real time PCR|We take peripheral blood sample at day one, six and ten of ovarian stimulation and measure mRNA expression of androgen receptor.
96281|NCT03433755|Drug|Evolocumab 140 mg SC Q2W|Investigational product and placebo will be administered per pre-filled auto-injector pen (AI/Pen). Subjects will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously. In addition, all eligible subjects must be taking a maximum appropriate dose of an approved statin, not requiring up titration.
96282|NCT03433755|Drug|Evolocumab 420 mg SC QM|Investigational product and placebo will be administered per pre-filled auto-injector pen (AI/Pen). Subjects will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously. In addition, all eligible subjects must be taking a maximum appropriate dose of an approved statin, not requiring up titration.
96283|NCT03433755|Other|Placebo SC Q2W|Investigational product and placebo will be administered per pre-filled auto-injector pen (AI/Pen). Subjects will receive placebo every 2 weeks or monthly subcutaneously. In addition, all eligible subjects must be taking a maximum appropriate dose of an approved statin, not requiring up titration.
96284|NCT03433755|Other|Placebo SC QM|Investigational product and placebo will be administered per pre-filled auto-injector pen (AI/Pen). Subjects will receive placebo every 2 weeks or monthly subcutaneously. In addition, all eligible subjects must be taking a maximum appropriate dose of an approved statin, not requiring up titration.
96285|NCT03433742|Other|Blood levels drawn|The patients will have their bloods drawn at the Hospital for Special Surgery during their regular, standard of care visit. The laboratory at the Hospital for Special Surgery will then test their bloods to determine the metal ion levels.
96286|NCT03433729|Other|Patient agenda form|On arrival at the clinic patients are given an agenda form to prompt them to think about what issues they wished to discuss with their doctor. The form contains a prompt list of items they can tick, free space to write their own items, and a prompt to consider what is the most important issue for them and what they would like to happen before they leave their clinic appointment.
96287|NCT03433716|Other|Ultrasound-guided Percutaneous Neuromodulation|It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
96288|NCT03433703|Drug|Lenvatinib|"Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW <60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)"
96289|NCT03433690|Behavioral|HIIT|High Intensity Interval Training for twelve weeks
96290|NCT03433690|Behavioral|Moderate training|Moderate training for twelve weeks
96291|NCT03433677|Drug|LY900014|Administered by CSII
96292|NCT03433677|Drug|Insulin lispro|Administered by CSII
96293|NCT03433664|Device|CO2 laser|Fractional CO2 laser treatment using the DeepFX setting hand piece (Ultrapulse, Lumenis), performed under general anaesthetic at 4-6 week intervals. All treatments consisted of a single pass of 300Hz, 5% density and 50mJ energy with minimal overlapping
96294|NCT03433651|Drug|Creatine monohydrate|Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
96295|NCT03433651|Drug|Placebo|Subjects will take by mouth 5 grams a day of placebo powder.
96296|NCT03433625|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|CBT
96297|NCT03433612|Other|Classic Intercristal Line Technique|"Researcher will use the classic technique to estimate the L4-L5 interspace. The classic technique begins by palpating both the right and left posterior iliac crests and following the imaginary line that intersects each (intercristal line) with the non-dominant hand to the spine where it is estimated to intersect the L4 spinous process or L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
96298|NCT03433612|Other|Novel SAIL Technique|"Researcher will use the novel technique to estimate the L4-L5 interspace. The SAIL technique begins by palpating the sacrum and the researcher sliding the non-dominant hand up the dorsal surface of the sacrum to the first interspace (L5-S1) and then up one more interspace to estimate the L4-L5 interspace. A marker pen will mark an X lateral to the estimation, opposite side from the estimation of the other technique."
96299|NCT03433599|Other|Daily Acute Intermittent Hypoxia|Participants will be fitted with a mask that will be placed over mouth and nose. Tubing will be attached to the front of the mask. The session will last approximately 30-45 minutes with 60-90 seconds of lower oxygen (tubing attached, 9-10% oxygen level), alternating with 60-90 sec of normal room air (no tubing attached).
96337|NCT03433339|Device|transcutaneous spinal direct current stimulation|Anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
96520|NCT03431948|Drug|Nivolumab|Nivolumab 240 mg given by intravenous infusion every 2 weeks
96301|NCT03433599|Other|Training by Research Staff|Training sessions will last for approximately 45 minutes, with additional time for set up. During these sessions, participants will be asked to complete a variety of tasks related to general arm/hand movement, pinch, and grip. The number of repetitions will be monitored and adjust the difficulty to ensure appropriate task difficulty.
96302|NCT03433599|Other|Training with an Exoskeleton Rapael glove|These training sessions will last approximately 45 minutes, with additional time for set up of the device. During these sessions, the participant will be asked to complete a variety of activities related to arm, pinch, and grip function. The activities will be made more or less difficult based on the ability of the participant to successfully complete the activity.
96303|NCT03433599|Other|No training|The participants will not be receiving any training.
96304|NCT03433586|Drug|Aspirin 81 mg|81mg of aspirin for 10+/-3 days
96305|NCT03433573|Device|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring System and will be asked to perform 4 blood glucose tests per day (pre-meal and before bedtime). Subjects will be asked to scan the sensor when each blood glucose test is performed.
96306|NCT03433547|Procedure|Buckle|Surgical procedures of macular buckling
96307|NCT03433547|Procedure|Vitrectomy|Surgical procedures of small gauge vitrectomy
96308|NCT03433547|Other|Limbal paracentesis|Drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis
96309|NCT03433547|Other|Gas injection|Inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous cavity through pars plana.
96310|NCT03433547|Other|Peeling internal limiting membrane|Peeling internal limiting membrane with forceps
96311|NCT03433547|Other|Gas tamponade|Filling the vitreous cavity with gas (C3F8, 14%)
96312|NCT03433534|Other|Pharmacokinetic of Nivolumab|Nivolumab residual concentration is measured 14 days after administration of nivolumab 3 mg/kg as an intravenous infusion just before the new administration.
96313|NCT03433508|Biological|Liberal|2 PRBC /day to maintain the target of Hemoglobin 10 to 11 gm/dL. PRBC will be given intravenously at least for 28 days
96314|NCT03433508|Other|Restrictive|To maintain the target Hemoglobin of 7 to 8 gm/dL.
96315|NCT03433495|Other|Melodic Intonation Therapy|
96316|NCT03433482|Biological|MenACWY liquid|At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.
96317|NCT03433482|Biological|MenACWY|At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
96318|NCT03433469|Other|Laboratory Biomarker Analysis|Correlative studies
96319|NCT03433469|Drug|Osimertinib|Given PO (orally)
96320|NCT03433469|Procedure|Therapeutic Conventional Surgery|Undergo surgery
96321|NCT03433456|Behavioral|Home visitation + HABITS program|The HABITS program will target 5 key behaviors (physical activity, increasing fruit and vegetable consumption, decreasing sugary beverages, decreasing fried foods, and encouraging regular self-monitoring and self-weighing) aimed at reducing obesity risk in mothers or primary caregivers and children.
96322|NCT03433456|Behavioral|Standard home visitation program|Treatment in the control arm includes the content and services typically provided by the home visitation partner, which is focused on promoting caregiver and child health by providing screenings and referrals, encouraging smoking cessation, promoting safe sleep practices, and strengthening children's school readiness and achievement, social/emotional and physical development.
96323|NCT03433443|Behavioral|Case manager assisted rehabilitation|In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.
96324|NCT03433443|Behavioral|Usual physical rehabilitation|The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
96325|NCT03433430|Device|truSculpt|Subjects will receive up to three treatments and will be followed at 12 weeks post the first and final treatment.
96326|NCT03433417|Device|Cutera truSculpt|one truSculpt treatment before scheduled Abdominoplasty on tissue to be removed during abdominoplasty
96327|NCT03433404|Procedure|Soft Tissue Mobilization|The technique has been described previously in other descriptions. However, the main goal of this treatment is to address the LDSIL in the manner described previously in order to mobilize the soft tissue in the area.
96328|NCT03433404|Procedure|Soft Tissue Massage|For sMass, the subject will be positioned on her side opposite to the most painful side of the lumbosacral spine with the hips flexed to 45 degrees and knees flexed to 90 degrees (with a pillow positioned between them). The investigator will perform superficial (light stroke) massage to the painful side of the lumbosacral region for 5 minutes
96329|NCT03433391|Device|Oxiplex|Oxiplex is a clear, viscoelastic gel that is applied to operative site during lumbar spine surgery in order to coat the nerve root with a protective barrier.
96330|NCT03433391|Other|Surgery Only|Single level partial discectomy as per standard of care procedures.
96331|NCT03433378|Drug|Tretinoin cream, 0.05%|Tretinoin cream, 0.05%
96332|NCT03433378|Drug|RETIN-A® (tretinoin) cream, 0.05%|RETIN-A® (tretinoin) cream, 0.05%
96333|NCT03433378|Drug|Vehicle of the test product|Vehicle of the test product
96334|NCT03433365|Other|MRD analysis|To collect 2 samples for MRD analysis in patients treated with Lenalidomide
96335|NCT03433352|Drug|Methimazole Pill|Patients who developed GD received methimazole treatment
96336|NCT03433352|Drug|Propylthiouracil Pill|Patients who developed GD received propylthiouracil treatment
96340|NCT03433313|Drug|Herceptin|Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
96341|NCT03433300|Device|Ottobock Kenevo/C-Leg|Microprocessor-controlled prosthetic knee
96342|NCT03433300|Device|Ottobock 3R60/3R62|Nonmicroprocessor-controlled knee
96343|NCT03433287|Diagnostic Test|18F-NaF-PET/MRI|PET/MRI scan after injection of 18F-labelled sodium fluoride
96344|NCT03433274|Device|Tendyne Mitral Valve System|Mitral valve replacement
96345|NCT03433274|Device|MitraClip System|Percutaneous mitral valve repair using the MitraClip system.
96346|NCT03433261|Dietary Supplement|Ketogenic Diet|Eat a ketogenic diet (low carbohydrate, high fat diet) for 72 hrs prior to the experiment and consume a dietary ketone supplement 60 minutes before the experiment.
96347|NCT03433248|Drug|EMPA/LINA 10/5 mg QD (n=22)|Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
96348|NCT03433248|Drug|LINA/EMPA 5/10 mg QD (N=22)|Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg
96349|NCT03433248|Drug|Gliclazide 30 mg QD/BID (N=22)|Once daily or twice daily treatment with oral glicazide MR 30mg
96350|NCT03433235|Drug|Edoxaban|"1-3-6-12 rule*~Anticoagulation in patients with acute ischemic stroke and atrial fibrillation can be initiated from the following days after stroke event.~After 1 day: transient ischemic attacks~After 3 days: mild ischemic strokes (NIHSS <8)~After 6 days: moderate ischemic strokes (NIHSS 8−16)~After 12 days: severe ischemic strokes (NIHSS >16)~- NIHSS: National Institute of Health Stroke Scales"
96351|NCT03433222|Device|HF-LED-RL Phototherapy|"The starting dose of 480 J/cm2 will be administered to Group 1's HF-LED-RL phototherapy randomized subjects and the HF-LED-RL dose will be escalated in the subsequent group to 640 J/cm2. Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity in 2 or more subjects and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
96352|NCT03433222|Device|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit. The mock therapy unit only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
96353|NCT03433209|Device|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy
96354|NCT03433209|Device|Articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy
96355|NCT03433196|Drug|HS-25 and Atorvastatin|HS-25 20mg (2 tablets), Atorvastatin 10mg, Placebo of Atorvastatin 1 tablet oral, once daily
96356|NCT03433196|Drug|Atorvastatin|Atorvastatin 20mg (2 tablets), Placebo of HS-25 2 tablets, oral, once daily
96357|NCT03433183|Drug|Selumetinib|Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
96358|NCT03433183|Drug|Sirolimus|Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
96359|NCT03433170|Procedure|Quadrupled semitendinosus graft|Quadrupled ST graft as unique graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
96360|NCT03433170|Procedure|ST-Gracilis graft|Use of both semitendinosus and gracilis graft for the ACL reconstruction. Fixation with cortical button in femur and interference screw in tibia.
96361|NCT03433157|Device|Hall technique|Metal Stainless stain crown placed with Hall technique
96362|NCT03433157|Device|Traditional technique|Metal Stainless stain crown placed with Traditional technique
96363|NCT03433144|Drug|Tranexamic Acid Injectable Solution|the drug will be given to patients intravenously at a dose of 10mg/kg pre-operatively after induction on general anesthesia
96364|NCT03433144|Other|Placebo (normal saline 0.9%)|An equivalent amount of normal saline (0.9%) will be given to the patient pre-operatively after induction of general anesthesia. The amount of saline given will correspond to the same amount of fluid which would have been given had the patient been in the intervention group.
96365|NCT03433131|Drug|Pitolisant|Tablets
96366|NCT03433118|Device|Acupuncture|Acupuncture administered by specially-trained therapeutic radiographers
96367|NCT03433092|Other|serum carotenoids|In each study, the serum concentrations of carotenoids were detected by high performance liquid chromatography
96368|NCT03433079|Diagnostic Test|Neutrophil gelatinase-associated lipocalin (NGAL)|Blood neutrophil gelatinase-associated lipocalin (NGAL) test was performed in all patients.
96369|NCT03433079|Diagnostic Test|Arterial lactate|Arterial lactate level was assessed in all patients.
96370|NCT03433079|Diagnostic Test|Interleukin-6 (IL-6)|The level of interleukin-6 was assessed in all patients.
96371|NCT03433079|Diagnostic Test|Procalcitonin (PCT)|The level of procalcitonin (PCT) was assessed in all patients.
96372|NCT03433079|Diagnostic Test|Myoglobin|The level of myoglobin was assessed in all patients.
96373|NCT03433066|Procedure|Advanced platelet-rich fibrin mixed with biphasic alloplast|mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
96374|NCT03433066|Procedure|Biphasic alloplast mixed with saline|mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
96375|NCT03433053|Behavioral|HIV Testing Message Intervention|The Health Belief Model will be utilized as the primary theoretical framework in guiding the development of a tailored HIV testing message for young African American women in this intervention. Two conditions will be developed and compared as outlined below. Condition 1 participants will be exposed to an HIV testing message inclusive of culturally tailored information that addresses both culturally specific barriers and facilitators of HIV testing (as identified in Study 1). The message will be brief (will take less than 3 minutes to present/read).
96376|NCT03433053|Behavioral|Control|Condition 2 (generic message) participants will be exposed to a simple HIV educational message only, consisting of HIV statistics for women in the United States, information on how HIV is transmitted, where to get tested, and the benefits of HIV testing. The statistics on HIV and where to get tested will be taken directly from the CDC's website. The message will be brief (will take less than 3 minutes to present/read).
96377|NCT03433040|Drug|17-Hydroxyprogesterone Capronate|17-Hydroxyprogesterone Capronate 250mg versus 500mg
96378|NCT03433027|Drug|BB-401|BB-401 1.92ug/mL Intratumoral Injections, every week for up to 8 weeks
96379|NCT03433014|Procedure|0.5% Levobupivacaine|The infiltration group will receive local infiltration with 0.5% Levobupivacaine. The trocar insertion sites are infiltrated before the skin incision is made. Using the Lap-Assist Transversus Abdominis Plane Block Technique, the total volume of infiltrated 0.5% Levobupivacaine is 20 ml, divided proportionally according to the length of the skin incision (2 ml for the 5-mm trocar and 3 ml for the 10-mm trocars, and 10 mL for specimen retrieval incision). The specimen retrieval incision will be performed in one of two techniques, depending on the surgeon's preference, a 4-6 cm length midline incision (extending from the Hasson trocar incision) or a 4-6 cm length Pfanensteil incision.
96380|NCT03433014|Other|Control|No infiltration
96381|NCT03433001|Drug|Ixazomib|Ixazomib capsules
96382|NCT03433001|Drug|Lenalidomide|Lenalidomide capsules
96383|NCT03433001|Drug|Dexamethasone|Dexamethasone tablets
96384|NCT03432988|Behavioral|Nursing Solution-Focused|Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
96385|NCT03432975|Drug|Povidone-Iodine 10%|The side of the mouth receiving the subgingival irrigations of povidone iodine 10% (test group)
96386|NCT03432975|Drug|Saline Solution|The other side of the mouth will be irrigated with a sterile saline solution (control group)
96387|NCT03432962|Other|no intervention - recoding of food recall only|recoding of food recall
96388|NCT03432949|Drug|Dexamethasone plus Radium-223|Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
96389|NCT03432936|Device|MRI guided procedure software evaluation|MRI guided ablation/biopsy using standard MR imaging along with Philips Interventional iSuite software tools.
96390|NCT03432923|Drug|Benzocaine 8 mg|Benzocaine 8 mg, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
96391|NCT03432923|Drug|Placebo|Placebo, oval, white to slightly beige to yellow film coated tablet. One lozenge to be dissolved slowly in the mouth every 2 hours. Max 6 per day, max treatment 5 days.
96392|NCT03432910|Other|CPAP Titration using a Bilevel S/T mode with minimal pressure support and background rate|The study performs within clinical routine with this exception that instead of the usually applied CPAP mode a modified BiLevel S/T mode is used. The modified BiLevel S/T mode meets the same requirements as the CPAP mode while providing the Forced Breath Technique to classify apneas as central or obstructive.
96393|NCT03432897|Drug|Olaparib Pill|300 mg BID
96394|NCT03432897|Procedure|Prostatectomy|22-42 days post Olaparib patients will undergo surgery
96395|NCT03432884|Drug|BGB-3111|Subjects will receive BGB-3111
96396|NCT03432884|Drug|Placebo|Subjects will receive Placebo
96397|NCT03432884|Drug|Moxifloxacin|Subjects will receive Moxifloxicin
96398|NCT03432871|Dietary Supplement|Nicotinamide Riboside|Nicotinamide Riboside is a member of the Vitamin B family which acts as a precursor to NAD+, an enzyme involved in energy production.
96399|NCT03432858|Drug|Vancomycin|Vancomycin - 1-gram dosing
96400|NCT03432858|Drug|Cefazolin|2-gram dosing for patients <120 kg 3-gram dosing for patients 120 kg or greater
96401|NCT03432858|Drug|Saline Solution|Placebo
96402|NCT03432845|Other|compare reversal agents|compare effect of two different approved reversal agents on postoperative and post-discharge nausea and vomiting
96403|NCT03432832|Behavioral|EASE|Weekly behavioral sessions with therapist to work on emotional control through measures such as mindfulness.
96404|NCT03432832|Behavioral|Supportive Therapy|Weekly behavioral sessions with a therapist to work on emotional control
96405|NCT03432819|Behavioral|Siempre Seguiré|A culturally congruent CBT group intervention for HIV-positive LMSM, to include strategies for ART adherence and retention in HIV care.
96406|NCT03432806|Other|blood draws|Three peripheral venous blood draws (10 mL per draw): in the operating room prior to incision, upon completion of the surgical procedure (within 6hours), and first postoperative clinic visit.
96407|NCT03432806|Procedure|colectomy or hepatectomy|"Three small pieces of otherwise normal-appearing liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D)."
96408|NCT03432806|Diagnostic Test|Fibroscan test|This may be done either at a preoperative clinic setting or immediately prior to surgery.
96409|NCT03432793|Drug|TD-9855|oral tablet, QD
96410|NCT03432793|Drug|Fluvoxamine|oral tablet, QD
96411|NCT03432793|Drug|Itraconazole|oral tablet solution, QD
96412|NCT03432793|Drug|Caffeine|oral solution, single dose
96413|NCT03432780|Drug|Docetaxel|
96414|NCT03432780|Biological|Hormone and radiation therapy|
96415|NCT03432780|Radiation|Radiation therapy|
96416|NCT03432767|Device|Non-invasive hemoglobin monitor|
96417|NCT03432754|Behavioral|Mindfulness-Based Attention Training|The mindfulness-based attention training is closely modeled after the traditional mindfulness-based stress reduction (MBSR) protocol, it incorporates formal MBSR practices such as breath exercises, body scans and long sitting meditations. Specifically, MBAT is an abbreviated version of MBSR with a focus on the cognitive components.
96521|NCT03431948|Drug|Cabiralizumab|Cabiralizumab 4 mg/kg given by intravenous infusion every 2 weeks
96418|NCT03432754|Behavioral|Lifestyle Education|"The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning and mind wandering in older adults, will comprise of scientific health and lifestyle information. Lectures will be focused on concepts presented in the book The Culprit and the Cure: Why lifestyle is the culprit behind America's poor health and how transforming that lifestyle can be the cure. Meetings will cover how to begin and maintain a more nutritious diet, classifying healthy choices across food groups, completing stretching/toning exercises, and reviewing homework."
96419|NCT03432741|Drug|Belinostat|Given intralesionally
96420|NCT03432741|Drug|Carfilzomib|Given intralesionally
96421|NCT03432741|Biological|Daratumumab|Given intralesionally
96422|NCT03432741|Drug|Fludeoxyglucose F-18|Undergo FDG-PET
96423|NCT03432741|Drug|Gemcitabine Hydrochloride|Given intralesionally
96424|NCT03432741|Other|Laboratory Biomarker Analysis|Correlative studies
96425|NCT03432741|Biological|Nivolumab|Given intralesionally
96426|NCT03432741|Biological|Obinutuzumab|Given intralesionally
96427|NCT03432741|Biological|Pembrolizumab|Given intralesionally
96428|NCT03432741|Procedure|Positron Emission Tomography|Undergo FDG-PET
96429|NCT03432741|Biological|Rituximab|Given intralesionally
96430|NCT03432741|Drug|Romidepsin|Given intralesionally
96431|NCT03432741|Other|Saline|Given intralesionally
96432|NCT03432741|Biological|Trastuzumab|Given intralesionally
96433|NCT03432728|Procedure|Dental rehabilitation under general anesthesia|Dental treatment of all teeth affected by dental caries in a single visit under general anesthesia
96434|NCT03432715|Behavioral|Student Wellness Champions|"Student Wellness Champions participate in a training to, develop a rapport, and build trust with the wellness specialist. SWCs will meet once/week during lunch. The SWC's will receive a health education/ health literacy curriculum in order to be well-versed on the importance of being active and eating healthy foods and how to communicate health information to key stakeholders to enact policy change and to fellow students to enact behavior change. These students will work with the Wellness Specialist and Wellness Champion to implement wellness policies and practices.~Target policies/practices will be presented as a menu of options. The mechanisms used to enact change are based in the tenets of health literacy anchored in nutrition and PA promotion. Components of the curriculum include raising awareness of school system's local wellness policies and improving student skills surrounding the five standards of health literacy, using examples/activities linked to the local wellness policy."
96435|NCT03432715|Behavioral|Teacher Wellness Champions|"Schools will be asked to identify a Wellness Champion (WC), someone at the school who is passionate about creating a healthy school environment. All WC's will be asked to attend a Wellness Champions for Change (WCC) training, led by a Wellness Specialist (health educator part of our study team). The WC's will learn about the skills necessary to make health promoting changes to the School Environment.~Following the WCC training, the Wellness Champion will receive technical assistance from the Wellness Specialist. The Wellness Specialist will work with the Wellness Champion and the school's Wellness Team to conduct a needs assessment, and develop and implement a school action plan. The Wellness Specialist will provide support and resources to the Wellness Champion and the school to help them work towards their goals. All Wellness Champions in a given school system will meet monthly, as a group, with their Wellness Specialist to discuss progress, pitfalls, and successes."
96436|NCT03432702|Procedure|Horizontal ridge augmentation|Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
96437|NCT03432689|Device|Transcranial Magnetic Stimulation|Single-pulse transcranial magnetic stimulation and theta-burst stimulation
96438|NCT03432689|Drug|Cycloserine|Cycloserine 100mg
96439|NCT03432689|Drug|Placebo Oral Tablet|Placebo capsule matched to cycloserine capsule
96440|NCT03432676|Drug|Epacadostat|Given PO
96441|NCT03432676|Biological|Pembrolizumab|Given IV
96442|NCT03432663|Drug|Intravenous amiodarone(1)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg until 24 h was reached
96443|NCT03432663|Drug|Intravenous amiodarone(2)|Intravenous amiodarone infusions at doses of 5 mg/Kg for over 30 min, followed by 20 mg/Kg every 24 h for up to 72 h or until sinus rhythm was reached
96444|NCT03432650|Drug|Bupivacaine + dexamethasone|Anesthetic that will help treat pain and sensation after hip arthroscopy
96445|NCT03432650|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the nerve block
96446|NCT03432637|Procedure|spontaneous ventilation|thoracoscopic lobectomy under spontaneous ventilation
96447|NCT03432637|Procedure|intubated anesthesia with single-lung mechanical ventilation|undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation
96448|NCT03432624|Diagnostic Test|Serum MicroRNA-25 detection|The level of microRNA-25 in serum of patients will be detected using the MicroRNA (microRNA-25) Qualitative Detection Kit (Fluorescent PCR Method) and following the manufacture's instruction.*all arms are given the same intervention.
96449|NCT03432611|Other|Self-care information feature|The self-care feature offers information on self-care for menstrual pain. The following topics are shown: exercise, dietary supplementation, heating pad/hot water bottle, yoga, and information on when to consult a doctor and how primary dysmenorrhoea is often treated. Notifications from the app which can be deactivated remind women of surveys and activities.
96450|NCT03432611|Other|Self-acupressure feature|The acupressure feature offers detailed written and multimedia descriptions of an acupressure used for menstrual pain. Three acupressure points are described, which should be massaged bilaterally twice a day up to five times a day on the 5 days before menstruation and during menstruation. Each point should be massaged for 2 minutes. A timer for the acupressure and notifications from the app which can be deactivated remind women of surveys and acupressure.
96451|NCT03432598|Drug|BGB-A317and Pemetrexed plus cisplatin (or carboplatin)|In the non-squamous NSCLC cohort, subjects will be treated with the following on Day 1 of each 21-day (3 weeks) cycle: BGB A317 200 mg IV, pemetrexed 500 mg/m² IV, and cisplatin 75 mg/m²/day IV (or carboplatin AUC 5). Pemetrexed plus cisplatin (or carboplatin) should be given for up to 4 cycles. Following either completion of or discontinuation from chemotherapy, BGB-A317 will be continued as scheduled, if clinically appropriate. Pemetrexed maintenance after completion of doublet chemotherapy is permitted.
96452|NCT03432598|Drug|BGB-A317 and Paclitaxel plus cisplatin (or carboplatin)|BGB A317 200 mg IV every 3 weeks (Q3W), paclitaxel 175 mg/m² IV, and cisplatin 75 mg/m²/day IV (or carboplatin AUC 5), Q3W:. Paclitaxel plus cisplatin (or carboplatin) will be administered for 4-6 cycles. Following either completion of or discontinuation from chemotherapy, BGB-A317 will be continued as scheduled, if clinically appropriate.
96453|NCT03432598|Drug|BGB-A317 and Gemcitabine plus cisplatin (or carboplatin)|BGB A317 200 mg IV Q3W on Day 1, gemcitabine 1250 mg/m² IV on Day 1 and Day 8, and cisplatin 75 mg/m²/day IV (or carboplatin AUC 5) on Day 1. Gemcitabine plus cisplatin (or carboplatin) will be administered for 4-6 cycles. Following either completion of or discontinuation from chemotherapy, BGB-A317 will be continued as scheduled, if clinically appropriate.
96454|NCT03432598|Drug|BGB-A317 and Etoposide and cisplatin (or carboplatin)|BGB A317 200 mg IV Q3Won Day 1, etoposide 100 mg/m2 on Days 1, 2, and 3, and cisplatin 75 mg/m²/day IV (or carboplatin AUC 5) on Day 1. Etoposide and cisplatin (or carboplatin) will be administered for 4-6 cycles. Following either completion of or discontinuation from chemotherapy, BGB-A317 will be continued as scheduled, if clinically appropriate.
96455|NCT03432585|Behavioral|Applicant Survey|This survey will ask a few brief demographic questions and will assess feedback from participants about preferences and barriers to conference attendance.
96459|NCT03432559|Diagnostic Test|endoscopy|endoscopy of pharynx, upper esophagus, mid esophagus, cardia, gastric fundus, und gastric body
96460|NCT03432546|Other|Non-interventional|Non-interventional
96461|NCT03432533|Drug|HCP administration with PFS|subjects will receive 210 mg romosozumab SC QM either by HCP administration with 2 PFS
96462|NCT03432533|Device|Subject self-administration with AI/Pen|subjects will receive 210 mg romosozumab SC QM either by self-administration with 2 AI/Pens
96463|NCT03432520|Genetic|SPK-8011|Observational long-term safety follow-up study of subjects previously treated with SPK-8011 in any Spark-sponsored SPK-8011 study
96464|NCT03432507|Other|PCR|PCR for proinflammatory cytokines (IL-1b, IL-6, IL-8, IL-17, TNF-a, INF-g) and bacteria
96465|NCT03432494|Device|Transcaval closure device (TCD)|This is an early feasibility study (EFS) evaluation of a purpose-built closure device for transcaval access. The device, the Transcaval closure device(TCD) will be evaluated for safety and performance to close transcaval access sites in patients ineligible for femoral artery access for TAVR
96466|NCT03432481|Procedure|Unicompartmental Knee Arthroplasty Surgery|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
96467|NCT03432481|Device|Bodycad Unicompartmental Knee System (BUKS)|Unicompartmental Knee Arthroplasty Surgery using the Bodycad Unicompartmental Knee System (BUKS)
96468|NCT03432468|Drug|Valsartan 1|the high dose of valsartan
96469|NCT03432468|Drug|Valsartan 80 mg|a single dose of valsartan
96470|NCT03432442|Drug|Ivermectin|Ivermectin once every 24 hours for three administrations
96471|NCT03432429|Other|REIMS iKnife|Use of REIMS iKnife in breast conserving surgery
96472|NCT03432416|Drug|NES-E2 CVR|NES-E2 CVR
96473|NCT03432403|Device|Ambu LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
96474|NCT03432403|Device|Gastro LMA|Will be randomized to either the new Gastro LMA or old Ambu LMA for EGD procedure and the intracuff pressure will be measured
96475|NCT03432390|Device|Continuous Positive Airway Pressure|A continuous positive airway pressure will be delivered to the patients during the induction of general anesthesia through the anesthesia work station
96476|NCT03432390|Device|Open system ventilation|Facemask ventilation adapted to the anesthesia work station
96477|NCT03432364|Genetic|ST-400 Investigational product|Single dose of ST-400 following chemotherapy conditioning with busulfan
96478|NCT03432338|Other|inquiries|Inquires reported to clinician.
96479|NCT03432325|Device|Neural Enabled Prosthesis|Surgically implanted neural enabled prosthesis
96480|NCT03432312|Drug|Nicotine lozenge|Nicotine mint lozenge, 4 mg
96481|NCT03432312|Drug|Nicotine lozenge|NiQuitin mint lozenge, 4 mg
96482|NCT03432299|Procedure|RFA for PTMC|Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.
96483|NCT03432286|Drug|Galcanezumab|Administered SQ
96484|NCT03432286|Drug|Placebo|Administered SQ
96485|NCT03432273|Drug|Nicotine lozenge|Nicotine mint lozenge, 2 mg
96486|NCT03432273|Drug|Nicotine lozenge|NiQuitin mint lozenge, 2 mg
96487|NCT03432260|Drug|DUR-928|Dose escalation including 3 doses: 30mg, 90 mg and 150 mg
96488|NCT03432247|Behavioral|Interactive Music Therapy|Six 45-minute individual interactive music therapy (IMT) sessions delivered by a board-certified music therapist. Sessions start with music-guided breathing, imagery, or humming. The music therapist then engages the participant in singing of familiar songs and co-created vocal or instrumental music improvisations based on patient needs. Discussion about the meaning assigned to songs and emotions expressed through the improvisations follow. The IMT experiences are aimed at facilitating emotional expression, offering support through interactive music making, and strengthening inner resources of creativity. In addition, each week the participant learns music-based techniques for self-management of anxiety, stress, mood, and pain.
96489|NCT03432247|Behavioral|Verbal support|Six 45-minute individual sessions delivered by a master's level clinician with training in counseling. The sessions are focused on patient-initiated conversations about their pain, life stressors and the impact on their daily life. The intervener provides nondirective, supportive care by offering supportive, validating statements and reflective listening. The intervener refrains from employing active suggestion, problem-solving or behavioral or cognitive therapy techniques. The verbal support sessions are aimed at providing an empathic, therapeutic environment to facilitate emotional expression and sharing of worries and fears.
96490|NCT03432234|Other|Biomarkers|This is an observational study, there is no intervention
96517|NCT03431974|Drug|Placebo oral capsule|Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
96518|NCT03431961|Drug|Triamcinolone Acetonide|220 mcg administered twice daily for 14 days
96491|NCT03432221|Drug|Desvenlafaxine|Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
96492|NCT03432208|Procedure|GI consult|
96493|NCT03432195|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
96494|NCT03432182|Diagnostic Test|electroencephalography|Sleep states definition by electroencephalograpy
96495|NCT03432169|Other|Yoga (stretching plus mindfulness)|Stretching plus mindfulness
96496|NCT03432169|Other|Stretching|Stretching alone
96497|NCT03432156|Biological|Autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells in peripheral blood and then given back to the patient after amplified in vitro.
96498|NCT03432143|Other|Community Reviewers|Intervention manuscripts will be reviewed by both a trained community member and scientific reviewers. Community reviewers will follow each journal's instructions regarding electronic access to manuscripts, use of drop-down menus and free-text boxes to address specific aspects of the review, and completion within the time frame specified by the journal.The journal editorial team will use all reviews to make decisions about acceptance, revision, or rejection of manuscripts.
96499|NCT03432130|Other|Structural training program|15-week experimental structural training protocol
96500|NCT03432117|Other|Fixed respiratory rehabilitation|There are 6 step-exercise presented in the application and initial target of exercise will be set according to subject condition. After subject completes targeted exercise, next step will be started.
96501|NCT03432117|Other|Responsive respiratory rehabilitation|The application provide responsive exercise program by changing type and numbers of exercise according to subject condition and exercise ability (This will be assessed with monitored O2 saturation, symptom of dyspnea and pulse rate during exercise)
96502|NCT03432104|Dietary Supplement|Oxxynea®|Oxxynea® is a blend of polyphenol-rich extracts from olive, grape, pomegranate, green tea, grapefruit, orange and blueberry. Dosage is 1 x 450 mg-capsule.
96503|NCT03432104|Dietary Supplement|Placebo|Placebo product is 100% maltodextrin. Dosage is 1 x 450 mg-capsule of identical appearance than the verum capsule.
96504|NCT03432091|Drug|melatonin|Ramelteon RMT (RMT, Rozerem®), a novel MT1 and MT2 agonist, has been approved for treatment of insomnia, and provides a strong phase shift signal to the circadian timing system. Melatonin receptor agonists have recently become available for treatment of sleep and psychiatric disorders
96505|NCT03432078|Other|Hypnotherapy|Non-pharmacological treatment
96506|NCT03432065|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial. During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
96507|NCT03432052|Procedure|centralization|Wrist centralization involves aligning the distal ulna with the middle finger metacarpal and passing a large Kirschner wire or a small Steinmann pin through the middle finger metacarpal, carpus, and ulna for temporary stability. This is followed by soft tissue balancing in order to counteract the volar and radial directed force vectors consisting of reefing the ulnocarpal wrist capsule and transferring the extensor carpi ulnaris muscle distally and flexor carpi ulnaris muscle dorsally on the wrist.
96508|NCT03432039|Behavioral|Psychoeducation|This intervention has three phases occurring the same time as the Psychoeducation intervention. Phase I provides verbal and written information about the paediatric acute care unit services and policies. Phase II consists of: (a) verbal and written information about the general paediatric unit and its policies, and (b) a parent-child activity having ''control'' activities like reading a story not related to hospital stay. Phase III of the control program consists of a telephone call 2-3 days after discharge during which time mothers were informed that they should contact their primary healthcare providers if their children were having any problems or unusual symptoms. They also were asked to comment on their children's hospital stays during this telephone call.
96509|NCT03432039|Behavioral|Behavioral|This is an educational-behavioural intervention that educates the parent about the children's likely emotional and behavioural problems that may result from ICU admission. Phase I will be delivered within 6 to 16 hours of admission to the hospital where caregivers are provided with information about the child's likely emotional reactions during admission in hospital. Phase II will be delivered within 2 to 16 hours of transfer to the general ward and will consist of: (a) verbal and written information to reinforce information provided in Phase I and (b) a parent-child skills building activities. Phase III of the COPE intervention program will occur 2 to 3 days after hospital discharge and will consist of a telephone call during which a 5 minute script will be read that reinforces young children's typical post-discharge emotions and behaviours and parenting behaviours which would continue to facilitate positive coping outcomes in their children.
96510|NCT03432026|Device|High resolution computed tomography scan of the chest.|High resolution computed tomography scan of the chest & pulmonary function tests will be done for every patient to classify them.
96511|NCT03432013|Behavioral|CUD-AMT|Participants will be trained to manage their negative thoughts and emotions while also receiving treatment for cannabis misuse
96512|NCT03432013|Behavioral|SUD-CBT|Participants will receive traditional cognitive behavioral therapy for substance use disorder
96513|NCT03432000|Other|Performances of patients and controls on temporal task|To carry out this work, we will rely on an experimental paradigm (derived from Michotte's paradigm) which makes it possible to explore the links between temporal sequencing and perception of causality, validated in the normal subject. subjective consequences of these alterations will be explored using a phenomenological-inspired clinical scale (EAWE time-scale items)
96514|NCT03431987|Drug|One day with a dose of placebo cannabis paired with alcohol|Vaporized placebo marijuana with little to no THC paired with drinking alcohol to BrAC of 0.05%
96515|NCT03431987|Drug|One day with a dose of active THC cannabis paired with alcohol|Vaporized marijuana with active THC paired with drinking alcohol to BrAC of 0.05%
96516|NCT03431974|Drug|Aminopterin oral capsule|anti-folate treatment
96519|NCT03431961|Drug|Placebo|twice daily for 14 days
96522|NCT03431948|Drug|Urelumab|Urelumab 8 mg given by intravenous infusion every 4 weeks
96523|NCT03431948|Radiation|Stereotactic Body Radiation Therapy|Radiation to metastatic lesion(s) given at assigned dose levels based on lesion location and dose level being tested at time of enrollment. Doses range from 30 - 50 Gy.
96524|NCT03431922|Device|endovascular denervation|multi-electrode catheter-based endovascular denervation
96525|NCT03431909|Drug|Human urinary kallidinogenase (HUK)|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
96526|NCT03431909|Drug|aspirin® , clopidogrel® , atorvastatin®|Patients in control group will receive foundation treatment, including aspirin® (100 mg/d), clopidogrel® (75 mg/d), and atorvastatin® (20 mg/d) for 14 days
96527|NCT03431870|Other|Trans-esophageal echocardiography|Perform a trans-esophageal echocardiography before and after anesthesia.
96528|NCT03431857|Device|TESS V2|Patients requiring the TESS V2 prosthesis.
96529|NCT03431831|Behavioral|Intervention Control|diet recommendations of 1200 calorie limit for women daily and 1400 limit for men daily. Decreased foods that are high sugar, highly processed, low nutrient simple carbohydrates. Increased foods that are whole foods, lean proteins, complex carbohydrates and healthy fats. Switch from high calorie drinks to water for beverages.
96530|NCT03431831|Behavioral|Counselling|Usual care as listed in comparator intervention plus motivational interviewing to identify areas of barriers and how to overcome them, to help patient set achievable food, physical activity and beverage goals for themselves weekly and monthly. To identify whether knowledge or confidence counseling is more important for each participant and follow up with them. To help them learn self-management techniques for overeating.
96531|NCT03431831|Drug|Contrave|In addition to usual care as described in the comparator intervention, these participants will be prescribed Contrave and raised to the therapeutic dosage within one month. They will be monitored closely for side effects and meds adjusted accordingly.
96532|NCT03431831|Drug|Contrave and Counseling|This group of participants will receive a combination of all the above interventions including diet/physical activity prescription, motivational interviewing and Contrave.
96533|NCT03431818|Other|Nasal cannula flow rate|This is a crossover study where observations will be obtained at five nasal cannula flow rates: 0.5, 1, 2, 4 and 6 liters per minute.
96534|NCT03431805|Drug|Tranexamic Acid Injectable Solution|After the routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the woman within 3 minutes after birth, slowly (over 30-60 seconds), once the cord has been clamped.
96535|NCT03431805|Drug|Sodium Chloride 0.9%|After a routine and prophylactic administration of a uterotonic , the intervention will be the IV administration of a 10-ml blinded ampoule of the study drug (either TXA or placebo according to the randomisation sequence) to the patient within 3 minutes afterbirth), slowly (over 30-60 seconds), once the cord has been clamped.
96536|NCT03431792|Device|Long Tail Balloon|s. description of experimental Arm
96537|NCT03431779|Procedure|Adipose derived stem cell transplantation via lipofilling|Liposuction of 60cc abdominal fat with its adipose derived stem cells which will be reinjected (10-20 cc) in the vestibular area after centrifugation for 3 minutes at 1000 rpm and decantation of oil and red blood cells.
96538|NCT03431779|Procedure|Surgical excision|Excision of painful areas
96539|NCT03431766|Device|placebo gel|On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
96540|NCT03431766|Device|0.20% chlorhexidine gel|On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
96541|NCT03431753|Diagnostic Test|PSA, STHLM3 and mpMRI for PC detection|"Men who request a prostate specific antigen test from their general practitioner will be offered study participation.~Men with increased PC risk as judged from the STHLM3 test and/or an elevated PSA test will be offered an mpMRI examination."
96542|NCT03431714|Drug|Artesunate amodiaquine|Drugs were administered under observation of the study nurse for three days
96543|NCT03431701|Other|Chlorhexidine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
96544|NCT03431701|Other|Iodine|Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds
96545|NCT03431701|Other|Antibiotics|All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
96546|NCT03431688|Drug|PAM|treatment with PPI, metonidazole, amoxicillin
96547|NCT03431688|Drug|PBMT|treatment with PPI, metonidazole, bismuth, tetracyclin
96548|NCT03431675|Drug|Ciprofloxacin|Single-dose oral ciprofloxacin
96549|NCT03431662|Procedure|Ellipse IM HTO Nail|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
96550|NCT03431662|Procedure|TomoFix|A CT scan will be performed at 3 and 6 months postoperatively to assess the healing of the osteotomy site. Endpoint is 6 months.
96551|NCT03431649|Drug|Beraprost Sodium|1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
96552|NCT03431649|Drug|Sildenafil Citrate|0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
96553|NCT03431636|Other|immersion|cold water immersion
96554|NCT03431636|Other|ice pack|ice packs through the body
96555|NCT03431636|Other|rest|seated rest
96556|NCT03431623|Biological|CKD-11101(Darbepoetin alfa)|
96557|NCT03431623|Biological|NESP(Darbepoetin alfa)|
96558|NCT03431610|Drug|SB414 2%|Twice daily
96559|NCT03431610|Drug|SB414 6%|Twice daily
96560|NCT03431610|Drug|Vehicle|Placebo comparator
96592|NCT03431337|Drug|Amoxicillin 875 mg|Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
96561|NCT03431597|Dietary Supplement|novel micronutrient|The supplements will be supplied to participants on a daily basis. The novel micronutrient supplement will be provided in powder form with instructions to dissolve one sachet in 250ml of clean water
96562|NCT03431597|Dietary Supplement|existing micronutrient supplement, UNIMMAP|UNIMMAP will be provided in tablet form and given one daily
96563|NCT03431584|Drug|infiltration of corticosteroids|infiltration of corticosteroids
96564|NCT03431584|Drug|infiltration of corticosteroids and hyaluronic acid|infiltration of corticosteroids and hyaluronic acid
96565|NCT03431571|Procedure|ReLEx SMILE|the VisuMax femtosecond laser is used to cut a thin layer of corneal tissue that is removed through a small cut in the cornea
96566|NCT03431558|Combination Product|bLF (Bovine lactoferrin)|BLF administration in two different strengths (150 & 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
96567|NCT03431558|Drug|Glucon-D 99.4% (Placebo)|This group will be given 100mg Glucon-D (99.4% glucose) placebo which will be similar in shape, color to the bLF.
96568|NCT03431545|Behavioral|PALS and|"Play and Learning Strategies (PALS) include web-based parent training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Parents will begin their 11 week (infant) or 14 week (toddler) parenting program in October and complete it by April. There will be monthly Parent Meetings related to the content they are learning online. Post-assessments will occur in late April and May. Each weekly online parent session will take approximately 30 minutes to complete with a 40 - 60 minute weekly remote coach call."
96569|NCT03431545|Behavioral|BEECH|"Beginning Education: Early Childcare at Home (BEECH) includes web-based teacher training courses with remote coaching and in-person meetings that support the adults' developing a set of core behaviors that comprise a responsive interactive style including responses contingent to children's needs and interests with rich language input.~Teachers will complete the 20 online sessions weekly, except for planned center closings due to holidays or agency-related events. The three in-person trainings will occur before Session 1 and after Sessions 8 and 14. Each weekly online teacher session will take approximately one-hour for a teacher to complete with a 30 minute weekly remote coach call. Each in-person teacher training will be 6-hours in duration."
96570|NCT03431545|Behavioral|Control condition|Parents and teachers conduct business as usual in regards to care-giving in the school and at home.
96571|NCT03431519|Procedure|VP|Percutaneous Injection of Strontium Containing Hydroxyapatite versus Polymethacrylate plus Short Segment Pedicle Screw Fixation
96572|NCT03431506|Behavioral|Vestibular rehabilitation|Vestibular Rehabilitation Exercises
96573|NCT03431493|Behavioral|Behavioral Activation - Rehabilitation|"Participants will first receive a home visit from a physical therapist (PT) who will evaluate home safety and establish/verify the participant's exercise prescription. Within 1 week, an occupational therapist (OT) will visit the home to: 1) explain the purpose of behavioral activation (BA); 2) help the participant identify long-term recovery goals regarding valued activities; and 3) then, using the principles of BA, identify short-term goals for the next week and an action plan. The OT will then call the participant weekly (weeks 2-5) to review the status of the prior week's goals and use BA to set new goals for the upcoming week. The PT and OT will repeat home visits at week 6 to assess the participant's progress, and the OT will conduct phone calls every 2 weeks for weeks 8-12."
96574|NCT03431480|Biological|Autologous Human Placental Cord Blood Mononuclear Cells|Autologous human placental cord blood mononuclear cells are infused into the coronary artery during the Norwood heart operation
96575|NCT03431467|Device|Impella-CP LV Vent|Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
96576|NCT03431454|Procedure|trained to do the pencil push-ups procedure|15 minutes per day, five days a week
96577|NCT03431454|Procedure|using a major amblyoscope twice weekly with additional home orthoptic therapy|60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
96578|NCT03431454|Procedure|using three diopter over-minus lenses and a base out prism|For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
96579|NCT03431441|Device|JJVC Marketed Contact Lens|Female subjects that are habitual contact lens wearers between the ages of 18 to 39 will be dispensed 1 treatment of the JJVC Marketed Contact Lens during the 2-visit study.
96580|NCT03431428|Procedure|transanal surgery|Transanal surgery could Preserve anus to reduce trauma and improve the quality of life
96581|NCT03431428|Procedure|Miles surgery|Miles surgery cut off the anus, enlarge the trauma and reduce the quality of life.
96582|NCT03431428|Drug|Preoperative chemoradiotherapy|After preoperative radiochemotherapy, two cycles of XELOX were given at the interval of waiting operation.
96583|NCT03431415|Procedure|Anatomical Segmentectomy, Lobectomy or Bilobectomy|Lung Cancer Anatomical Resection
96584|NCT03431415|Radiation|Stereotactic Body Radiation Therapy|SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
96585|NCT03431402|Drug|Hyperbaric oxygen|- HBOT group will receive 10 sessions of HBOT at 2.0 Atmosphere absolute (ATA) for one hour in a hyperbaric chamber pressured with compressed air, whereby patients will breath 100% oxygen to 2 ATA started within 3-5days after the onset of stoke plus conventional therapy as antiplatelets therapy, correction of hypovolaemia , hypoxia and adequate nutrition
96586|NCT03431389|Device|Tracheostomy tube|Tracheostomy done to all patients by open surgical technique and was done in ICUs without need to transfer to theatre.
96587|NCT03431350|Drug|Niraparib 200 mg|Participant will receive niraparib 200 mg orally once daily.
96588|NCT03431350|Drug|JNJ-63723283 240 mg|Participants will receive JNJ-63723283 240 mg IV every 2 weeks.
96589|NCT03431350|Drug|JNJ-63723283 480 mg|Participants will receive JNJ-63723283 480 mg IV every 4 weeks.
96590|NCT03431350|Drug|Abiraterone Acetate|Participants will receive 1000 mg (4*250 mg tablets) once daily orally.
96591|NCT03431350|Drug|Prednisone|Participants will receive 10 mg (2*5 mg tablets twice daily).
97123|NCT03427060|Drug|Coversin|Coversin - 22.5mg followed by 45mg for 6 months.
96593|NCT03431337|Dietary Supplement|Placebo (lactase)|Placebo (in place of additional amoxicillin in experimental arm)
96594|NCT03431324|Behavioral|Episodic Future Thinking about Mating Opportunities|"Participants who complete the mating-EFT intervention will be instructed to write about three positive mating-related events that would occur within the course of one year if you successfully quit smoking now. Participants will then be asked to close their eyes and imagine the events that they listed as specifically and vividly as possible (e.g., to imagine the setting and the sequence of the events, as well as the persons and objects that would be present. A period of one minute will be allotted for participants to mentally pre-experience each event.~The general-EFT intervention will be structured similarly to, with the key exception of being instructed to write about and imagine three positive life events."
96595|NCT03431324|Behavioral|Targeted Mating-EFT Intervention|"This intervention is identical to the Episodic Future Thinking about Mating Opportunities intervention with the exception that in Arm 2 the aim will be to determine whether the Mating-EFT intervention is especially effective when administered to individuals who are single or highly motivated to seek a mate."
96596|NCT03431311|Biological|Adoptive Cell Therapy (ACT)|T cell receptor based therapy of metastatic colorectal cancer with mRNA-engineered T cells targeting mutant transforming growth factor beta receptor type II (TGFβII)
96597|NCT03431298|Behavioral|Aerobic exercise & movement control|"The aerobic exercise content is no different between the experimental group and the active comparator group.~The movement control is individual training which divided into fourths progressing sessions.~First, lumbo-pelvic and hip dynamic direction control.~Second, trunk muscle groups, hip muscle groups and thigh muscle groups extensibility control.~Third, trunk muscle groups and hip muscle groups through range control.~Fourth, functional movement control training"
96598|NCT03431298|Behavioral|Aerobic exercise|"The aerobic exercise will organized in groups. Each group has 6-8 persons. The exercise form is fixed at each time.~The description of exercise form is as below:~10 min Warm up~40 min Aerobic exercise (which focus on lower extremity muscle strengthening and increasing muscle endurance)~10 min Cool down"
96599|NCT03431285|Drug|Morphine Group|Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.
96600|NCT03431285|Drug|Ketamine Group|Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration
96601|NCT03431285|Other|standard IV hydration|IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)
96602|NCT03431272|Drug|Lifitegrast|Eye drop
96603|NCT03431259|Other|Patient Gateway|Patients will be enrolled in the Patient Gateway app.
96604|NCT03431246|Biological|Gardasil and Gardasil-9|All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.
96605|NCT03431233|Dietary Supplement|Protein-enriched bar, commercial cereal bar, or water|Protein enriched bar, commercial cereal bar, or water will be provided 15 minutes before breakfast.
96606|NCT03431220|Device|RENASYS® TOUCH Negative Pressure Wound Therapy (NPWT) Device|NPWT applied to Grade 1 or Grade 2 open abdomen wounds for temporary abdominal closure for up to 14 days, with a 21 day post study initiation follow-up assessment.
96607|NCT03431207|Other|Standardized video recording for behaviors|"A standardized apparatus, scenario, and procedure was applied to record all the behavioral phenotypes with minimized background interference and stimulation.~For each standardized procedure, the guardian sits in the chair, holding the infant facing the stage. Each infant is given a few minutes to adapt to the surroundings and to be calm before recording. No hints or simulations are permitted during the entire process. The recording process lasted for over 5 minutes to ensure that behavioral phenotypes could be completely recorded."
96608|NCT03431194|Drug|midodrine|oral midodrine tablets 5 mg
96609|NCT03431181|Behavioral|MAP target 60-65 mmHg|Treating teams will adjust vasopressors to a target MAP range of 60 to 65 mmHg, avoiding vasopressor-induced MAP above this range.
96610|NCT03431181|Behavioral|Usual care|Patients in the control arm will receive usual care (as per local practices).
96611|NCT03431168|Drug|Azithromycin/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
96612|NCT03431168|Drug|Placebo/TMPS|2 tabs po daily x 3 days at enrollment and at each monthly follow up visit
96613|NCT03431155|Other|Nursing intervention|Nursing Intervention: This intervention planned based on Mishel's Uncertainty in Illness Theory. So it contains individual counseling and education.
96614|NCT03431142|Drug|Clopidogrel|Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)
96615|NCT03431142|Drug|Clopidogrel+aspirin|Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)
96616|NCT03431129|Diagnostic Test|Hyperpolarized gas and proton lung MRI|Lung MRI for participants undergoing radiation therapy (RT)
96617|NCT03431116|Radiation|ultrasound|to detect the placental site
96618|NCT03431103|Behavioral|Exercise|12 week home exercise program
96619|NCT03431090|Device|CliniMACS® TCRαβ/CD19 Combined Depletion System|The mobilized peripheral blood cell collection (apheresis product) will be processed using a Miltenyi CliniMACS device according to the manufacturing instructions. The processing will deplete the αβTCR+ cells and CD19+ cells from the apheresis product to formulate the graft.
96620|NCT03431077|Drug|Angiotensin II|Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption. LJPC-501 (angiotensin II) is being developed for the treatment of hypotension in patients who do not respond to fluids and vasopressor therapy.
96621|NCT03431064|Other|Lung Recruitment Maneuver|Lung Recruitment Maneuver by Anesthesiologist
96622|NCT03431064|Other|Fluid Administration|Administration of IV Fluid by Anesthesiologist
96623|NCT03431051|Other|Healthy Beverage Initiative|A Healthy Beverage Initiative will be instituted at two hospital campuses.
96624|NCT03431025|Device|Wearable sensors and biofeedback|Participants in the Experimental Arm will wear sensors to monitor their upper limb movement and will receive feedback from these sensors to encourage usage of the impaired limb during activities of daily living.
96805|NCT03429764|Procedure|VIMS|internal mattress suture will be placed with minimum two intact contact points at the surgical site
96625|NCT03431012|Other|Agency Assignment framing|Linguistic framing used in written health messages. Each version of the messages described the pandemic flu and the efficacy of the antivirals using linguistic expressions that assigned transmission to either humans (HA: 'You can contract the virus when you touch…') or the pandemic flu virus itself (VA: 'It can infect you when you touch…')
96626|NCT03431012|Other|Attribute framing|Linguistic framing used in written health messages. Each message described the side effects of the antivirals in terms of chances of either experiencing (negative framing: 'Uncommon side effects (10% of people will be affected)') or not experiencing side effects (positive framing: 'Uncommon side effects (90% of people will not be affected)') after using them.
96627|NCT03430999|Drug|Calmangafodipir|Single ascending doses of 2 μmol/kg, 5 μmol/kg, and 10 μmol/kg
96628|NCT03430999|Drug|Placebo|Placebo
96629|NCT03430986|Device|VOLUMA With Lidocaine|Participants will be treated with Voluma with Lidocaine injectable gel during the control period. Participants are eligible for touch-up treatment at day 29.
96630|NCT03430986|Other|No-treatment control|No treatment during the control period. Optional treatment with VOLUMA with Lidocaine during the Post-Control period.
96631|NCT03430973|Behavioral|Videos|Videos depicting various aggressive driving and road rage behaviors.
96632|NCT03430973|Behavioral|Bumper stickers|Bumper stickers hypothesized to increase or decrease aggressive driving.
96633|NCT03430973|Behavioral|Alcohol-related cues|Case of beer or water on passenger seat.
96634|NCT03430973|Behavioral|Music|Lyrics and tempo of music will be manipulated to increase or decrease aggressive driving.
96635|NCT03430973|Behavioral|Roadside vegetation|The roadside will contain trash to increase aggressive driving, or vegetation to decrease aggressive driving. There is also a control group.
96636|NCT03430973|Behavioral|Video game|Participants will play a racing or neutral video game before driving in the simulator.
96637|NCT03430960|Other|Phone Call|Participants will be followed-up via phone call by Acute Pain Research Nurse
96638|NCT03430960|Other|Mobile App Survey|Participants will be followed-up via mCare mobile app
96639|NCT03430947|Drug|Vemurafenib|Vemurafenib (960 mg twice a day) will be taken on days 1 - 28 of each 28-day treatment cycle.
96640|NCT03430947|Drug|Cobimetinib|Cobimetinib (60 mg once a day) will be taken on days 1 - 21 of each 28-day treatment cycle.
96641|NCT03430934|Combination Product|NAVI mapping with Indocyanine green|Moh's tumor imaging with Indocyanine green
96642|NCT03430921|Device|Enlighten™ Laser and a MLA Attachment|Subjects will receive up to six treatments with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment, and may undergo a 2mm punch biopsy before, immediately after, and up to 72 hours after treatment. Subjects may receive a biopsy per Investigator discretion either at one of the follow-up visits (6 weeks or 12 weeks) or 3 months post initial treatment.
96643|NCT03430908|Other|Blind Gastric Tube Placement|The provider will be blinded to the ultrasound imaging throughout the entire insertion. This blind insertion process is the standard of care currently practiced at MSKCC. After the provider verbalizes that they have completed the insertion the investigators will stop the ultrasound imaging and complete the data form. No information will be given to the provider about the location of the gastric tube as to not deviate from the standard of care. The only time that information will be provided to the practitioner inserting the tube will be if the tube is positioned in any of the following positions that are thought to be potentially injurious if unrecognized. These positions include intrapulmonary, cranial, nasal or oral pharyngeal placements and diverticular or hiatal hernia sac coiling and remain unrecognized by the practitioner. These are considered positions that have the potential for injury and therefore will be divulged to prevent ensuing injury.
96644|NCT03430895|Drug|durvalumab and tremelimumab|Patients will receive durvalumab 1500 mg and tremelimumab 75 mg IV Q4W for up to 4 doses/cycles, then durvalumab 1500 mg Q4W starting 4 weeks after the last combination treatment for up to 9 doses.
96645|NCT03430882|Drug|Carboplatin|Given IV
96646|NCT03430882|Drug|Paclitaxel|Given IV
96647|NCT03430882|Drug|Sapanisertib|Given PO
96648|NCT03430869|Drug|F-18 AV-45|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by F-18 AV-45 PET.
96649|NCT03430869|Drug|F-18-THK-5351|In the present project, the investigators will recruit 40 patients with lifetime major depressive disorder, and 20 non-depressed cognitively normal comparison subjects. All subjects will further undergo F-18-THK-5351 image study to detect underlying tau pathology. By doing this, the investigators will elucidate the neurodegenerative pathophysiology behind the link between depressive disorder and the subsequent development of dementia.
96650|NCT03430856|Drug|Insulin Tregopil|Drug: Insulin Tregopil (IN-105) Mode of Administration: To be administered orally 10 ± 2 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit.
96651|NCT03430856|Drug|Insulin Aspart|Drug: Insulin Aspart Mode of Administration: To be administered within 5 minutes prior to each major meal (breakfast, lunch and dinner) starting at the Randomization visit
96652|NCT03430843|Drug|BGB-A317|Anti-PD-1 ANTIBODY
96653|NCT03430843|Drug|Paclitaxel, or Docetaxel, or Irinotecan|One of the following three single-agent chemotherapies as determined by the Investigator Paclitaxel, or Docetaxel, or Irinotecan
96654|NCT03430830|Drug|Ravidasvir 50mg|50mg, Tablet
96655|NCT03430830|Drug|Ravidasvir 200mg|200mg, Tablet
96656|NCT03430817|Drug|Citicholine|Patients will receive 1 gram (2 vials of citicholine; each 500 mg) every 12 hours given slowly intravenous over 10 minutes for 7 days then oral form of the drug will be used. Participants who can swallow will receive 500-mg (5ml volume; 100mg/ml) oral drops (syrup) twice a day. Participants who cannot swallow will receive the same dose as oral drops syrup of citicoline through a nasogastric (NG) tube or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for the remainder of the 30 days study period.
96710|NCT03430375|Device|Alternating air wheelchair cushion|The Ease alternating air cushion has longitudinal air bladders which alternately inflate and deflate at 3 minutes intervals in order to change the areas of pressure to the skin for areas in contact with the wheelchair cushion/seat (buttock and posterior thighs). The Ease Alternating Pressure wheelchair cushion is 510(k) exempt.
96657|NCT03430817|Drug|Amantadine|Patients will receive 200 mg of amantadine sulphate in a 500 ml solution every 12 hours by slow intravenous infusion over a period of 4 hours for 7 days then oral form will be used. Participants who can swallow will receive two 100-mg tablets twice a day. Participants who cannot swallow will receive the tablets of amantadine through a NG tube or PEG tube as 400 mg via crushed tablets with a 25-mL saline or water flush for the remainder of the 30 days study period.
96658|NCT03430804|Other|Bishop score calculation of modified Bishop score in numbers by digital vaginal examination|Measurement of cervical length by transvaginal ultrasound and digital examination of Bishop score in 320 parturients undergoing labour induction at term
96659|NCT03430791|Drug|Nivolumab 240 mg IV|Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.
96660|NCT03430791|Drug|Nivolumab 3 mg/kg|Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.
96661|NCT03430791|Drug|Ipilimumab 1 mg/kg|Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.
96662|NCT03430791|Device|NovoTTF200A (Optune)|A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.
96663|NCT03430778|Other|High end-tidal CO2|maintaining of end-tidal CO2 with the range of 40-45 mmHg
96664|NCT03430778|Other|Low CO2 group|maintaining of end-tidal CO2 with the range of 30-35 mmHg
96665|NCT03430765|Behavioral|Acceptance and Commitment Therapy|Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
96666|NCT03430752|Other|questionnaires|Participants were asked to respond to the questionnaires including the Chinese version of the Paediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0), the Chinese version of the Center for Epidemiological Studies Depression Scale for Children (CES-DC), the Chinese version of Rosenberg self-esteem scale, the Chinese version of the Herth Hope Index (HHI) and the Chinese version of Resilience Scale for Children (RS10).
96667|NCT03430739|Other|No intervention|No intervention
96668|NCT03430726|Other|Probiotic yogurt drink|Food product; yogurt drink containing a multi-strain probiotic.
96669|NCT03430713|Procedure|Measure of tooth color|Evaluation of agreement about measure of tooth color between clinicians using two dental shade guides and two spectrophotometers in the determination of the color of maxilary central incisors and canines.
96670|NCT03430700|Drug|Pembrolizumab|Intravenous infusion
96671|NCT03430687|Other|Laboratory Biomarker Analysis|Correlative studies
96672|NCT03430687|Biological|Talimogene Laherparepvec|Given intravesically
96673|NCT03430674|Behavioral|Exercise|Exercise, questionnaires and blood draws.
96674|NCT03430661|Drug|ACT-246475|Lyophilized ACT-246475A to be reconstituted with 1 mL of water for injection
96675|NCT03430661|Drug|Clopidogrel|Tablet for oral administration (300 or 600 mg)
96676|NCT03430661|Drug|Prasugrel|Tablet for oral administration (60 mg)
96677|NCT03430661|Drug|Placebo|Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
96678|NCT03430661|Drug|Ticagrelor|Tablet for oral administration (180 mg)
96679|NCT03430635|Procedure|Hepatectomy|Surgery of the liver: removal of a given part of the liver affected by hepatocellular carcinoma
96680|NCT03430622|Behavioral|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Interpersonal Psychotherapy (IPT). The LTP Plus is a low-literacy; sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Interpersonal Psychotherapy (IPT) intervention is comprised of a supportive element, an educational element, a parenting element and an interpersonal relationship element. Intervention goals include helping mothers feel supported, empowered and confident about their parenting abilities, which would directly influence reduction in depressive symptoms as well as resolution of interpersonal conflicts.
96681|NCT03430622|Other|TAU|This group will be on their routine care and will not be given any intervention
96682|NCT03430609|Procedure|Laparoscopic treatment for endometrioma Astus©|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
96683|NCT03430609|Diagnostic Test|AMH Level|"The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery."
96684|NCT03430609|Diagnostic Test|Transvaginal ultrasound for antral follicle count|The participants will be subjected to transvaginal ultrasound for antral follicle count before surgery (1 month before surgery) and 1, 3 and 6 months after surgery. This test will be performed during the early proliferative stage (days 3 to 6 of the menstrual cycle); the size of the endometrioma and the ovary volume will be recorded, and functional cysts or suspected malignant cysts will be ruled out. For measurement of cysts, the average diameter of the three perpendicular ovary dimensions will be considered. For antral follicle count, the total number of follicles with diameters under 9 mm will be considered.
96685|NCT03430609|Procedure|Laparoscopic treatment for endometrioma Vicryl®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will perform suture with 2-0 Vicryl® in this group.
96769|NCT03430050|Drug|Progesterone|Progesterone capsule
96770|NCT03430050|Drug|Placebo|Placebo capsule. Manufactured to mimic progesterone 200mg capsule.
96686|NCT03430609|Procedure|Laparoscopic treatment for endometrioma Surgicel®|Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In this group, for hemostasis , the investigators will use matrix Surgicel®
96687|NCT03430596|Drug|Pramipexole|The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
96688|NCT03430596|Drug|Trihexyphenidyl hydrochloride|he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
96689|NCT03430583|Drug|MZ101|Drug
96690|NCT03430570|Behavioral|Tablet TRAC Emotion Regulation Intervention|The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
96691|NCT03430557|Procedure|PRP|platelet rich plasma
96692|NCT03430557|Procedure|periapical surgery without PRP|retrograde MTA filling will be done after apicectomy and flap will be closed without filling anything in the bony lesion.
96693|NCT03430544|Drug|Cariprazine Oral Capsule [Vraylar]|Cariprazine Groups (1.5 or 3mg/d): Cariprazine (VRAYLAR) capsules will be administered orally, once per day. Subjects in the 1.5mg group will receive 1 VRAYLAR capsule containing 1.5 mg cariprazine each day that study drug is administered. Subjects in the 3 mg group will be gradually titrated up to full dose: they will receive 1 VRAYLAR capsule containing 1.5mg cariprazine on the first and second days that study drug is administered and will receive 1 VRAYLAR capsule containing 3mg cariprazine each day for the rest of the medication period. The study medication period begins during the inpatient/induction phase and ends on the last day of outpatient treatment week 8 (approx. 10 weeks total). All VRAYLAR capsules will be over-encapsulated by the University of Pennsylvania Investigational Drug Services (IDS).
96694|NCT03430544|Drug|Placebo oral capsule|PLACEBO Group: Visually identical placebo capsules will be supplied by the University of Pennsylvania Investigational Drug Service, with a dosing regimen matching the cariprazine groups.
96695|NCT03430531|Drug|Lidocaine|Lidocaine 2% viscous (0.5ml) will be squirted on two cotton swab sticks and one will be gently inserted into each nostril, along the floor of the nose. Slight rotatory motion of the stick will be used to insert it as far as it goes with the intention to reach the nasopharyngeal wall (posterior wall of the nose). At that position the swab sticks will be left undisturbed for 5 minutes. The swabs will be taken out and this will be repeated twice more, using fresh swabs and 0.5ml of 2% lidocaine. The block would take about 30 minutes.
96696|NCT03430518|Drug|Durvalumab|1.12g given IV on day 1 every 21 day cycle
96697|NCT03430518|Drug|Eribulin|1.1 mg/m2 IV on day 8 of every 21 day cycle in the first 3 patients, then increased to 1.4mg/m2 IV on day 1 and day 8 of every 21 day cycle. If significant toxicity occurs in patients given the 1.1mg/m2 IV dose, then subsequent patients with receive eribulin 0.7mg/m2 IV on day 1 and day 8 of every 21 day cycle.
96698|NCT03430505|Device|Bilevel|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, IPAP 12 and EPAP 8 bilevel applied for 10 minutes, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
96699|NCT03430505|Drug|Albuterol|Basal respiratory mechanics in spontaneous breathing will be analyzed by optoeletronic plethismography (OEP), followed by bronchial provocation with hypertonic saline solution 4.5%, another 45-second OEP uptake, 400 micrograms inhaled Albuterol, and a new uptake. All abstractions are preceded by a forced and slow spirometry maneuver. The entire procedure takes 1 hour.
96700|NCT03430479|Drug|Cohort A|Radiation + Nivolumab + hormone therapy
96701|NCT03430466|Drug|Durvalumab,Tremelimumab,Fulvestrant|
96702|NCT03430453|Procedure|Measure of the minimal intensity of stimulation during ultrasound guided peripheral nerve blockade|A needle is placed at the target under ultrasound guidance, the nerve stimulator is turned on and the intensity increased until motor response is observed. The Minimal Intensity of Stimulation is recorded before injection of local anesthetic
96703|NCT03430440|Device|Apply CIPKA mode|The newly developed computer-integrated patient-controlled analgesia (CIPCA) mode increases or decreases the basal infusion rate with the use of the patient's bolus button. Compared with the conventional mode in which only the basal infusion rate is set to be fixed, the CIPCA mode sets the basal infusion rate, the increase / decrease rate of basal rate, and the increment / decrement interval.
96704|NCT03430440|Device|Conventional mode|PCA pumps typically set a fixed basal infusion rate to set the analgesic to enter at a constant rate every hour (conventional mode).
96705|NCT03430414|Diagnostic Test|Transcriptome Analysis|Transcriptome Analysis of Formalin Fixed Paraffin Embedded biopsies
96706|NCT03430401|Behavioral|Perceptual-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
96707|NCT03430401|Behavioral|Semantic-based memory encoding|"It will run for 12 weeks with a 1-hour training session each week, supervised by a rehabilitation professional.~In addition, two 30-minute home-based training sessions will be completed by participants. In the home training session, participants will practice specific daily tasks that are covered in the previous professional-led session through the use of the computer-based intervention."
96708|NCT03430401|Behavioral|Cognitive stimulation|The frequency, duration and the number of sessions will be consistent with the experimental interventions.
96709|NCT03430388|Biological|Yellow Fever vaccine (17D)|Vaccination against Yellow Fever, fractional dose (0,1mL) of 17D vaccine
96711|NCT03430375|Device|Static air cushion|The Roho static air cushion is composed of multiple air bladders that are inflated to proper levels according to the individual's weight. This cushion is commonly used for individuals post spinal cord injury and sometime for individuals post stroke. The Roho wheelchair cushion is 510(k) exempt.
96712|NCT03430362|Drug|Hyoscine N Butylbromide|7. Group A will receive injection Hyoscine butyl bromide 20 mg first dose at the time of amniotomy, and second dose after 2 hours
96713|NCT03430362|Drug|Normal Saline 0.9%|Group B, will receive normal saline same volume first dose at the time of amniotomy, and second dose after 2 hours
96714|NCT03430349|Biological|vaccination with novel OPV2 candidate vaccines|oral administration of 1 dose of nOPV2 candidate vaccine 2 to participants in group 1, and oral administration of nOPV2 candidate vaccine 1 to participants in group 2.
96715|NCT03430336|Other|CDSS provides drug-therapy relevant information|External computerized decision support system (CDSS: RpDoc® eMMa Software, RpDoc® Solutions GmbH, Saarbruecken) provides drug-therapy relevant information about participating patients with polypharmacy on demand to the general practitioners (GPs) such as data about diagnoses and treatments. The information is based on claims data gathered from all health care professionals involved in the care of the patient (e.g. specialized physicians, other GPs, psychotherapists as well as data about hospital stays and prescription data from pharmacies).
96716|NCT03430336|Other|Modification of medication|GPs can add and modify patient's data within the CDSS (e.g. remove drugs which are not taken by the patient anymore, add most recent laboratory findings about kidney function etc.) to enrich and update claims data based information.
96717|NCT03430336|Other|Assessment of medication appropriateness|GPs systematically assess the appropriateness of the medication supported by the CDSS, which will alert in case of drug-drug, drug-disease, and drug-age interactions as well as other inappropriateness, such as prescriptions with regard to incorrect dosage or Dear Doctor letters.
96718|NCT03430336|Other|Medication plan|GPs print out the updated medication plan including also recommendations for medication use and reasons for prescription in lay language (also available in foreign languages for patients with migration background) as well as recommendations on drugs to use / to avoid including over-the-counter drugs (OTC) (optional) and hand it out to the patient.
96719|NCT03430336|Other|Guidance in medication process|GPs receive guidance via the CDSS (e.g. recommendations addressing certain types of medication errors and high risk prescribing, developed by the German Society for Internal Medicine in collaboration with other scientific medical societies).
96720|NCT03430310|Other|Low Glycemic Diet|The investigators will use a Low Glycemic Load Diet (LG Diet), which emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary (e.g., for vegetarians). Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included. Saturated fat from red meat will be limited to less than 10% of daily caloric intake. The participants will obtain the majority of their fat intake from mono-unsaturated fatty acids (e.g. olive oil), and medium-chain triglycerides (e.g., coconut oil and cream); from nuts and nut butters; and from fresh fish.
96721|NCT03430310|Other|Control Diet|The Control diet will be compatible with both the American Diabetes Association and The United States Department of Agriculture guidelines. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide <2300 mg/day sodium. Saturated fat will be limited to less than 10% of total energy, and all dairy products will be fat-free (or low-fat). Although the Control diet will be a healthful diet, it will include a greater amount of carbohydrate foods from such sources as bread, potatoes, and pasta that will distinguish it qualitatively from the LG diet. In addition, it will have quantitatively more total energy from carbohydrate than the LG diet.
96722|NCT03430297|Biological|JS001 240mg Q2W|"recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) will be provided by the sponsor. Strength: 240mg/6ml/vial. 240mg, once every two weeks.~Control drug: dacarbazine (1000mg/m2, d1, intravenously, once every three weeks). The dose will be given intravenously over 180 minutes (the infusion time can be prolonged according to the institutional criteria), starting from Week 1, once every 3 weeks, until progression of disease."
96723|NCT03430297|Drug|Dacarbazine 1000mg/m2 Q3W|"The dose of DTIC will be calculated according to the following formula, where the 'X' represents the total mg dose of DTIC: X (mg) = [body surface area (BSA) x (1000mg/m2)].~The body surface area (BSA) is defined by Dubois formula: BSA (m2) = 0.007184* (cm0.725) * (kg0.425)"
96724|NCT03430284|Behavioral|Lifestyle therapy|The key components of lifestyle therapy include medical nutrition therapy, regular physical activity, sufficient amounts of sleep, behavioral support, and smoking cessation and avoidance of all tobacco products.
96725|NCT03430284|Drug|Pharmacotherapy|"Pharmacological therapy is individualized. 1.Glucose-lowering agents:~Oral antihyperglycemic agents:Biguanides;Sulfonylureas;Thiazolidinediones;Glinides;a-Glucosidase inhibitors;DPP-4 inhibitors;Sodium-glucose cotransporter 2 inhibitors~GLP-1 receptor agonist~Insulin:Rapid-acting analogs;Short-acting analogs;Intermediate-acting analogs;Basal insulin analogs;Premixed insulin products~2.Blood pressure-lowering agents~(1)ACE inhibitor;(2)Angiotensin receptor blockers (ARBs);(3)Calcium channel blockers (CCB);(4)Diuretics;(5)β-blockers;(6)α1-blockers~3.Lipid-modifying agents~(1)Statins;(2)Fibrates;(3)Others: Nicotinic Acid, Ezetimibe,Probucol,Bile Acid Sequestrants,Policosanol,etc.~4.Medications for weight management~(1)Glucose-lowering agents associated with weight loss;(2)Orlistat;(3)Metabolic Surgery~The above medications are individualized to maintain the risk factors (blood glucose, serum lipid profiles, blood pressure and weight) at appropriate levels."
96726|NCT03430284|Other|Monitoring and management|Before follow-up, patients are divided into low, moderate or high risk for diabetic vascular complications. During follow-up, frequencies of interview and risk factor monitoring are formulated based on the risk stratification.
96727|NCT03430284|Other|General treatment|General treatment is carried out based on the device from the general practitioners at present.
96728|NCT03430271|Other|Physical Activity Intervention|Participants in this arm will complete exercise sessions 1 time per week for 24 weeks. An optional, second PA session will also be offered to PA participants. The exercise sessions will be multimodal and involve walking, lower extremity strengthening exercises, flexibility and balance training.
96729|NCT03430271|Other|Healthy Aging Intervention|Participants will attend health education workshops on topics of relevance to older adults. Workshops will be offered weekly in a group setting, and participants will be required to attend biweekly.
96730|NCT03430258|Device|high-flow nasal cannula|high flow of air with supplemental oxygen was delivered by an Optiflow cannula interface using an AIRVO 2 blower humidifier
96731|NCT03430258|Device|Conventional oxygen therapy|Conventional oxygen therapy
96732|NCT03430245|Device|VelaShape III|"The VelaShape III, the newest generation VelaShape, is a device based on the CE-cleared VelaShape II and FDA-cleared Transcend device (K120510). All devices combine controlled infrared (IR) light and conducted bipolar radiofrequency (RF) energies with vacuum. The VelaShape III device is indicated for relief of minor muscle aches and pain, relief of muscle spasm, temporary improvement of local blood circulation, temporary reduction in the appearance of cellulite, and for temporary reduction of thighs and abdomen circumference.~The VelaShape III device has 150W RF energy."
96733|NCT03430245|Device|UltraShape Power|The newest generation UltraShape device, UltraShape Power, includes a small transducer (U-Sculpt Power), and is FDA-cleared (K170370) for lipolysis (breakdown of fat) to provide a non-invasive approach to achieve a desired aesthetic effect. It is intended for non-invasive reduction in abdominal circumference and fat reduction in the flanks and thighs.
96734|NCT03430232|Drug|Placebo|Short infusion of the solution for intravenous administration, Sodium Chloride 0.9%
96735|NCT03430232|Drug|STR-324 Dose Level 1|Short infusion of a solution for intravenous administration
96736|NCT03430232|Drug|STR-324 Dose Level 2|Short infusion of a solution for intravenous administration
96737|NCT03430232|Drug|STR-324 Dose Level 3|Short infusion of a solution for intravenous administration
96738|NCT03430232|Drug|STR-324 Dose Level 4|Short infusion of a solution for intravenous administration
96739|NCT03430232|Drug|STR-324 Dose Level 5|Short infusion of a solution for intravenous administration
96740|NCT03430232|Drug|STR-324 Dose Level 6|Short infusion of a solution for intravenous administration
96741|NCT03430232|Drug|STR-324 Dose Level 7|Short infusion of a solution for intravenous administration
96742|NCT03430232|Drug|STR-324 Dose Level 8|Short infusion of a solution for intravenous administration
96743|NCT03430232|Drug|STR-324 Dose Level A|Long infusion of a solution for intravenous administration
96744|NCT03430232|Drug|STR-324 Dose Level B|Long infusion of a solution for intravenous administration
96745|NCT03430232|Drug|STR-324 Dose Level C|Long infusion of a solution for intravenous administration
96746|NCT03430232|Drug|Placebo|Long infusion of the solution for intravenous administration, Sodium Chloride 0.9%
96747|NCT03430219|Device|Subchondroplasty Procedure|AccuFill is an injectable, self-setting, macro-porous, osteoconductive, calcium phosphate bone graft substitute material that is intended for use to fill bony voids or gaps of the lower extremities (pelvis through foot) that are not intrinsic to the stability of the bony structure
96748|NCT03430206|Device|High-flow nasal cannula|While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
96749|NCT03430193|Other|FIRM|"FIRM program consisted of total 10 days session including PT, in two times twenty-minute sessions per day and 4 times OT during admission initiated before transfer to rehabilitation ward.~PT (Weight bearing exercise, strengthening exercise, gait training, aerobic exercise and functional training) progressed gradually based on individual functional level and OT of activities of daily life (ADL) training (transfer, sit to stand, bed mobility, dressing, self-care retraining and using adaptive equipment) was provided."
96750|NCT03430193|Other|Conventional rehabilitation|Conventional rehabilitation program consisted of total 10 days session of PT focused on simple standing and gait training, in one time twenty-minute sessions per day.
96751|NCT03430180|Drug|Naloxone hydrochloride|Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
96752|NCT03430180|Drug|Placebo|One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
96753|NCT03430167|Other|home therapy|Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
96754|NCT03430167|Other|formal therapy|Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises
96755|NCT03430154|Other|No treatment given|No treatment given
96756|NCT03430141|Other|Nutritarian Diet-style|Nutritarian Diet-style: Daily consumption of greens, beans/legumes, a variety of other vegetables, fresh or frozen fruits, nuts, seeds and whole grains. Participants are encouraged to minimize consumption of refined grains, vegetable oils, processed foods, and to limit animal products.
96757|NCT03430128|Dietary Supplement|IMPACT immunotherapy|Powdered formula that is pre-packaged in individual packets which the patients will be instructed to mix with water before consumption.
96758|NCT03430128|Dietary Supplement|ENSURE|Liquid milk formula available over the counter
96759|NCT03430102|Diagnostic Test|Indicor|Calculation of LVEDP via analysis of PPG waveform with Valsalva
96760|NCT03430089|Biological|Shz QIV 0.25 mL, 2 doses|Administered intramuscularly in the anterolateral aspect of the thigh in infants (aged 6 to 12 months) or into the deltoid muscle (participants aged more than 12 months), 28 days apart.
96761|NCT03430089|Biological|Shz QIV 0.5 mL, 2 doses|Administered intramuscularly into the deltoid muscle, 28 days apart
96762|NCT03430089|Biological|Shz QIV 0.5 mL, single dose|Administered intramuscularly into the deltoid muscle.
96763|NCT03430076|Procedure|revascularization|open revascularization for below-knee popliteal in the absence of an suitable autologous vein with PTFE.
96764|NCT03430076|Device|Propaten®|Propaten®
96765|NCT03430076|Device|Crude PTFE|Crude PTFE
96766|NCT03430063|Drug|SDREGN2810|Standard dose intravenous (IV) infusion
96767|NCT03430063|Drug|SDREGN2810/ipi|Combination therapy dose IV
96768|NCT03430063|Drug|HDREGN2810|High dose IV
96773|NCT03430024|Other|Association of Myosin VI with oestrogen receptor|"Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues."
96775|NCT03429998|Drug|evolocumab|evolocumab 140 mg/biweekly
96776|NCT03429998|Drug|evolocumab and LDL apheresis|evolocumab 140 mg/biweekly LDL-apheresis monthly
96777|NCT03429998|Procedure|LDL apheresis|LDL apheresis biweekly
96778|NCT03429985|Behavioral|FRRM Intervention|Fathers Raising Responsible Men (FRRM) is designed to facilitate important paternal parenting behaviors that influence adolescent decision-making. FRRM incorporates a novel, theoretically-based intervention highlighting the important and influential role that fathers have on the development of adolescent males.
96779|NCT03429972|Device|Elasto-Gel™|Elasto-Gel™ hypothermia mitts and slippers contain glycerine, which has thermal properties, allowing use for cold therapies.
96780|NCT03429972|Drug|Paclitaxel|80mg/m^2 of Paclitaxel is administered by infusion for 60 mins once a week, for a total of 12 cycles
96781|NCT03429959|Device|SOCKNLEG|Donning and doffing success compared with the two study stockings, wearing the assigned study stocking for a day, Patient Quesationnaire on donning and doffing success and wearing comfort of each study stocking
96782|NCT03429959|Device|SIGVARIS Cotton|SIGVARIS Cotton
96783|NCT03429946|Drug|Spironolactone|Participants will receive spironolactone 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
96784|NCT03429946|Drug|Placebo|Participants will receive placebo 12 hours and 3 hours before the initiation of the hyperinsulinemic clamp treatment.
96785|NCT03429946|Other|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute hypoglycemic (50 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit. Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
96786|NCT03429946|Other|Euglycemic Hyperinsulinemic Clamp|Participants undergo two 120-minute euglycemic (90 mg/dL) hyperinsulinemic clamps - an AM clamp from about 9 am to 11 am and a PM clamp from 1 pm to 3 pm on Day 2 of a 3-Day study visit.Modified Oxford Procedure is performed in duplicate at six time points - on Day 1, before the AM hyperinsulinemic clamp, during the AM hyperinsulinemic clamp, before the PM hyperinsulinemic clamp, during the PM hyperinsulinemic clamp, and on Day 3. The Modified Oxford procedure is performed to calculate baroreflex sensitivity.
96787|NCT03429933|Drug|BMS-986278|Specified dose on specified days
96788|NCT03429933|Other|Placebo|Specified dose on specified days
96789|NCT03429920|Dietary Supplement|Q CAN PLUS|Active powder with fermented soy , 2 pouches per day, each pouch contains 12-15 gms of fermented soy
96790|NCT03429920|Dietary Supplement|Placebo|Sprouted brown rice protein with flavor (provided by BESO Biological Research, Inc.)
96791|NCT03429907|Behavioral|Mind-Body Exercises|Participants do daily mind-body exercises for 14 days before starting chemotherapy. The exercises are about 10 minutes per day.
96792|NCT03429907|Behavioral|Questionnaires|Questionnaires completed at baseline, at third and at last cycle of chemotherapy, and 6 months after chemotherapy.
96793|NCT03429894|Device|Percutaneous Coronary Intervention|Drug eluting stent implant
96794|NCT03429881|Procedure|Stripping versus laser CO2|Patients were randomly selected to undergo either CO2 laser vaporization (L group) or laparoscopic stripping (S group) of OE.
96795|NCT03429868|Device|integrated PET/MRI|"The enrolled subjects receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan."
96796|NCT03429855|Other|trunk training|Bobath based trunk training
96797|NCT03429855|Other|physiotherapy|conventional physiotherapy
96798|NCT03429829|Device|Flairesse varnish|Flairesse is applied to enamel and dentine as protective varnish in order to prevent caries formation and to promote remineralization of initial caries. It is also used in the treatment of hypersensitive teeth by sealing dentin tubules and hypersensitive areas at the neck of the tooth and exposed root dentine. Flairesse varnish contains xylitol and fluoride (22,600 ppm). Both components have been well established for oral health by reducing caries prevalence and incidences.
96799|NCT03429816|Procedure|Biopsy|Patients with locally advanced, resectable gastric or esophagogastric junction adenocarcinoma will receive a biopsy of the primary tumor, followed by standard-of care neoadjuvant systemic treatment; after neoadjuvant therapy tumor biopsies will be taken from different sites of the resection specimen.
96800|NCT03429803|Drug|TAK-580|28 day cycle, oral, once per week
96801|NCT03429790|Combination Product|intra-operative cell salvage|intra-operative cell salvage collects the patient's blood lost during an operation, processes it and returns it to their own circulation.
96802|NCT03429790|Combination Product|allogeneic blood transfusion|transfuse allogeneic blood to patients if blood transfusion is needed.
96803|NCT03429777|Device|HearMe Smartphone Application|The HearMe smartphone application is a digits-in-noise test that can be used to digitally quantify speech reception thresholds.
96804|NCT03429764|Procedure|CISS|continuous independent sling sutures will be placed with minimum two intact contact points at the surgical site
96806|NCT03429751|Drug|30 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
96807|NCT03429751|Drug|10 ml/Kg/h crystalloid|Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
96808|NCT03429738|Drug|Ibuprofen/Pseudoephedrine HCl 200/30 mg Film-Coated Tablets|Experimental drug
96809|NCT03429738|Drug|RhinAdvil Rhume 200 mg/30 mg Film-Coated Tablets|Active Comparator
96810|NCT03429725|Other|Online prime (statements writing)|Participants to write statements describing themselves or their similarities to their community.
96811|NCT03429725|Other|Online prime (circling)|Participants to circle either pronouns denoting themselves or pronouns denoting others.
96812|NCT03429725|Other|Online prime (Sumarian Warrior)|Participants read a passage which described the factors that led to his success in a war.
96813|NCT03429725|Other|Online prime (all)|Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.
96815|NCT03429699|Behavioral|Stage-based Lifestyle Modification Intervention for the Management of Childhood Obesity|The participants will receive treatment based on nutrition clinical practice guideline for the management of childhood obesity. Participants in IG will be received a nutrition clinical practice guideline for the management of childhood obesity that comprised several activities, including nutrition counselling, aerobic sessions, a hands-on activity (healthy food preparation) and 'Sharing is Caring'. The Nutrition Practice Guideline for the Management of Childhood Obesity that comprised recommendations for assessment of nutritional status, determination of energy requirement, dietary prescriptions and physical activity modifications will be used. Participants' SOC for dietary and physical activity behaviors will be determined before any information was given to ensure that the selected educational topic will be tailored to the participant's current SOC.
96816|NCT03429699|Behavioral|Existing practice for the management of childhood obesity|The participants will receive treatment based on the existing practice for the management of childhood obesity. Only nutritional counseling will be received by CG and standard treatment based on current practices by most dietitians in Malaysia for weight management of obese children will be used.
96817|NCT03429686|Other|DRT Intervention|The digital reminiscence therapy intervention will run 12 sessions twice per week, for six weeks, for up to an hour at a time (this will depend on the participant's ability and willingness to participate). The sessions of reminiscence therapy will be culturally appropriate and based on the key stages in the life which most people will have experienced. These sessions are individual, face-to-face sessions.
96818|NCT03429673|Procedure|Surgeries|Lobectomy or segment/wedge dissection
96819|NCT03429660|Other|Medical information|"The information collected are about :~Introduction or non-introduction of treatment~Cumulative dose of treatment~Drug dispensation and withdrawal~Hospitalization reason~Safety information~Demographic data (date of death)"
96820|NCT03429647|Diagnostic Test|visible light spectroscopy|Sigmoid perfusion was assessed using visible light spectroscopy
96821|NCT03429634|Procedure|Balloon-Stent Kissing technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment,Balloon-Stent Kissing Technique (BSKT)for the interventional treatment of coronary bifurcation lesion
96822|NCT03429634|Procedure|Jailed Wire technique|All patients underwent coronary angiogram that confirmed true bifurcation lesions, and received PCI treatment, Jailed Wire technique(JWT) for the interventional treatment of coronary bifurcation lesion
96823|NCT03429621|Drug|Simethicone 80 MG|Simethicone (Air-X®; 80 mg) 2 tablets chewing with water 50 ml at 2-8 hours before surgery
96824|NCT03429595|Drug|ATx201|ATx201 GEL
96825|NCT03429595|Other|ATx201 GEL Vehicle|Vehicle
96826|NCT03429582|Device|Standard C02 Cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
96827|NCT03429582|Device|Single Tip Thermoablation|Thermoablator outfitted with a 19mm conical tip
96828|NCT03429582|Device|Multiple Tip Thermoablation|Thermoablator outfitted with detachable probes
96829|NCT03429569|Drug|Cross linking|Accelerated cross-linking procedure: (Total duration: 40 minutes)
96830|NCT03429556|Biological|Botulinum Neurotoxin Serotype E|Single botulinum neurotoxin serotype E injection into RA muscles during abdominoplasty surgery.
96831|NCT03429556|Drug|Placebo|Placebo (sterile saline solution 0.9% Sodium Chloride Injection) injected into RA muscles during abdominoplasty surgery.
96832|NCT03429543|Drug|Linagliptin|Film Coated Tablet
96833|NCT03429543|Drug|Empagliflozin|Film Coated Tablet
96834|NCT03429543|Drug|Placebo|Film Coated Tablet
96835|NCT03429517|Diagnostic Test|Lipogram|liporgram samples
96836|NCT03429491|Dietary Supplement|Placebo|Protein-free, LC n-3 PUFA-free juice based supplement
96837|NCT03429491|Dietary Supplement|Leucine-enriched protein|Leucine-enriched whey protein
96838|NCT03429491|Dietary Supplement|LC n-3 PUFA|LC n-3 PUFA
96839|NCT03429478|Other|Preoperative application of a bluetooth enabled Headphones.|A Bluetooth enabled Headphones device which is worn overhead and music can be played through it.
96840|NCT03429465|Other|EVO Cognitive Remediation Game|EVO (formerly called Neuroracer) is a neuroscience-inspired plasticity trainings in the form of a video driving game that uses adaptive algorithms and dual-tasking paradigms to target the CCN. Work from our group (Project:EVO) recently showed that 4 weeks of EVO training is associated with increased neural recruitment in brain regions associated with CNN, superior improvement in cognitive control performance (i.e., working memory, sustained attention) when compared to an evidence-based psychotherapy (Problem-Solving Therapy), and improved depression outcomes similar to Problem-Solving Therapy among older adults (Areán, Hallgren, Jordan, Gazzaley, Atkins, Heagerty, & Anguera, 2016; Journal of Medical Internet Research).
96841|NCT03429439|Other|intestinal microbiota transplant|Participants in experimental group take 6 times IMT with 2-week intervals.
96842|NCT03429439|Drug|Antiviral Agents|All participants continue present antiviral therapy over 12 months.
96843|NCT03429413|Behavioral|Protect Me 4 Application + External Quality Improvement Support|Participants will be asked to interact with the Protect Me 4 application, using an iPad tablet. During the implementation period (months 4-6), intervention clinics will receive the Protect Me 4 app and External Quality Improvement Support (practice facilitation and external and internal provider peer opinion leaders and provider incentives). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates with the assistance of the practice facilitator. Providers at the intervention clinic will complete a pre-intervention survey to obtain background information (demographics, approximate HPV vaccination rates, comfort with the use of technology etc.)
96844|NCT03429413|Behavioral|Protect Me 4 Application Alone|During the maintenance period (months 7-9), intervention clinics will receive Protect Me 4 without external support (practice facilitation and external provider peer opinion leaders). Providers from intervention clinics will complete audit and feedback reports to assess HPV vaccination rates without the assistance of the practice facilitator. Providers at the intervention clinic will complete a post-intervention survey to gain provider feedback regarding the feasibility of Protect Me 4 and changes in perceptions regarding the use of technology.
96845|NCT03429400|Drug|Morphine Sulfate|Morphine every 4 hours as needed for up to a maximum of 5 days
96846|NCT03429387|Diagnostic Test|FDG-PET/CT|FDG-PET performed with low dose CT
96847|NCT03429387|Diagnostic Test|Conventional CT|HRCT and CT of sinuses +/- other regions as per clinician's discretion
96848|NCT03429374|Device|Liquiband Fix8|LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.
96849|NCT03429374|Device|Absorbable tack|Absorbable tack
96850|NCT03429361|Other|Health by Mindstrong|Health by Mindstrong is a smartphone application that collects data on a participant's smartphone usage patterns.
96851|NCT03429348|Other|Sauna Rehabilitation|Firefighters selected for sauna rehabilitation will spend time in a sauna
96852|NCT03429335|Behavioral|Teaching session|The cardiology nurse (RN) will have an hour long one-on-one teaching session prior to their pediatric cardiology clinic visit. The RN will go over the youth's cardiac history including the chronic heart disease diagnoses, names and dates of cardiac surgical procedures and cardiac catheterizations, and current cardiac medications and doses. She will also discuss transitioning from pediatric to adult care and healthy lifestyle choices.
96853|NCT03429335|Behavioral|Just TRAC It!|Just TRAC It! (Transitioning Responsibly to Adult Care) is a mobile health intervention that encourages youth to use existing functions on their personal phones to track their health information. The use of Just TRAC It! allows youth to electronically document all medical information that would previously be printed on their MyHealth Passport, but may offer additional functionality in terms of learning to manage their health.
96854|NCT03429335|Behavioral|MyHealth Passport|"MyHealth Passport is a customized, wallet-size card that includes the youth's important medical information. The RN will help the youth create a MyHealth Passport online, and print out the card for them.~The same educational intervention will be completed by cardiology nurse using a MyHealth Passport to track their medical information instead of the electronic Just TRAC It!"
96855|NCT03429322|Behavioral|Medical Care and Resource Facilitation|The intervention expands on an established web-based platform and uses other information and communication technology (ICT) devices, incorporating synchronous direct clinical care and asynchronous intervention. Participants will use their own devices and internet access for any and all interactions with Mayo Clinic providers. The specific ICT modes used and services provided to interact with participants will be determined by clinical need, individual preference, and technological capacity.
96856|NCT03429322|Other|Usual Care|Participants will receive and provide usual and customary care in their communities.
96857|NCT03429309|Drug|Propofol|Anesthesia was induced by intravenous infusion of propofol via the syringe pump at a rate of 30 mg/kg/h.
96858|NCT03429296|Other|Autohypnosis learning|Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
96859|NCT03429283|Other|descriptive retrospective epidemiological study|descriptive retrospective epidemiological study
96860|NCT03429270|Device|TDOC 5Fr|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
96861|NCT03429257|Other|Exposures of interest: Maternal EED and Aflatoxin Exposure|Maternal EED, measured via lactulose: mannitol (L:M) ratios and serum concentrations of antibodies to the bacterial components flagellin and lipopolysaccharide (LPS); Maternal aflatoxin exposure, measured via serum concentration of AFB1-lysine adduct
96862|NCT03429244|Diagnostic Test|68Ga-PSMA-11 PET-MRI|Patients will undergo injection of 68Ga-PSMA-11 at the time of pre-treatment MRI scan and followed until biopsy and/or surgical resection.
96863|NCT03429231|Dietary Supplement|Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol|Patients in the active group will take one tablet a day orally
96864|NCT03429218|Drug|TP-0184|Oral daily dose
96865|NCT03429205|Other|No external heating used during surgery|Deviation from external heating for all surgery standard
96866|NCT03429205|Other|External heating blanket used during surgery|Standard external heating plan used in all surgery types
96867|NCT03429192|Procedure|Surgery|Surgeries plus dissection of lymph nodes
96868|NCT03429179|Drug|Butorphanol|intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
96869|NCT03429179|Other|Physiological saline|intravenous infusion of the same volume of 0.9% saline
96870|NCT03429166|Behavioral|STAIR|A non-trauma-focused treatment
96871|NCT03429166|Behavioral|PCT|A non-trauma-focused treatment
96872|NCT03429140|Drug|Gel-One|an injection of Gel-One® (hyaluronan, 3 mL) 1-2 weeks after ACL surgery
96873|NCT03429140|Other|Saline Placebo|a placebo injection (saline, 3 mL) 1-2 weeks after ACL surgery
96874|NCT03429127|Other|Normal saline|Plasma osmolality, acid base status and electrolytes after application up to 2000 ml of normal saline during neurosurgical operation
96952|NCT03428529|Drug|Capecitabine Oral Product|Neoadjuvant Capecitabine concomitant to external beam radiotherapy
96875|NCT03429127|Other|Balanced fluid|Plasma osmolality, acid base status and electrolytes after application of up to 2000 ml balanced fluids during neurosurgical operation
96876|NCT03429114|Other|Magnetic resonance imaging|We will conduct MRI and fMRI brain scans to compare brain function between groups.
96877|NCT03429101|Drug|Poziotinib|Poziotinib is a tablet for oral administration.
96878|NCT03429101|Drug|T-DM1|T-DM1 (ado-trastuzumab emtansine) is a HER2-targeted therapy for I.V. administration.
96879|NCT03429088|Behavioral|Motivational interviewing telephone counseling|
96880|NCT03429075|Drug|Psilocybin + Placebo|Multiple dosing days psilocybin vs 6 weeks of daily placebo
96881|NCT03429075|Drug|Psilocybin + Escitalopram|Multiple dosing days psilocybin vs 6 weeks of daily escitalopram
96882|NCT03429062|Other|Personal training exercises|Personal training: strengthening, stretching, endurance, balance Whole body vibration: strengthening, balance, stretching, endurance, balance
96883|NCT03429049|Drug|CNTX-4975-05 (trans-capsaicin)|Receiving CNTX-4975-05 injection
96884|NCT03429049|Drug|Placebo|Receiving Placebo injection
96885|NCT03429010|Procedure|"New guideline anesthesia strategy team"|"New guideline anesthesia strategy team"
96886|NCT03428997|Device|Lotion|Formulated Lotion F# 13451-131 was applied on an occlusive patch and placed on a test site on each subjects back three times a week for four weeks.
96887|NCT03428997|Other|Negative Control|Control. An undosed occlusive patch was placed on a test site on each subjects back three times a week for four weeks.
96888|NCT03428984|Drug|EXPAREL|EXAPREL 266 mg in 20 mL
96889|NCT03428971|Procedure|cardioversion|Direct current (DC) cardioversion for sinus rhythm restoration
96890|NCT03428958|Drug|NUC-3373 + leucovorin|NUC-3373 + leucovorin
96891|NCT03428958|Drug|NUC-3373|NUC-3373
96892|NCT03428958|Drug|NUC-3373 + oxaliplatin|NUC-3373 + oxaliplatin
96893|NCT03428958|Drug|NUC-3373 + oxaliplatin + bevacizumab|NUC-3373 + oxaliplatin + bevacizumab
96894|NCT03428958|Drug|NUC-3373 + oxaliplatin + panitumumab|NUC-3373 + oxaliplatin + panitumumab
96895|NCT03428958|Drug|NUC-3373 + irinotecan|NUC-3373 + irinotecan
96896|NCT03428958|Drug|NUC-3373 + irinotecan + cetuximab|NUC-3373 + irinotecan + cetuximab
96897|NCT03428945|Drug|Hydroxychloroquine|Hydroxychloroquine for oral administration, dosed by weight
96898|NCT03428945|Drug|Placebo|Placebo tablet identical to active drug
96899|NCT03428932|Device|Closed Loop (Medtronic 670G)|A loaner Medtronic 670G insulin pump, Enlite 3 sensor and GST3C Guardian transmitter will be utilized
96900|NCT03428919|Procedure|ICSI|In ICSI group, insemination will be performed by using ICSI, 3 - 4 hours after oocyte retrieval. OCCs will be stripped by using hyaluronidase. Only matured oocytes will be inseminated.
96901|NCT03428919|Procedure|IVF|In IVF group, insemination will be performed by conventional IVF. Two hours after retrieval, collected OCCs will be inseminated for another 2 hours, at a concentration of 100,000 motile sperm/ml. Inseminated OCCs will be cultured overnight in culture medium.
96902|NCT03428906|Drug|Oxytocin|intranasally administrated
96903|NCT03428906|Drug|Placebo|intranasally administrated
96904|NCT03428893|Device|Mobile Application|Participants will receive usual care physical therapy guided by Clinical Practice Guidelines and based on individual symptoms and need over 7 in-person visits. Measures will be collected by the physical therapist related to leg strength, balance, fitness, and mobility as part of the usual care physical therapy evaluation and follow-up. The treating physical therapist will negotiate the physical therapy intervention based on patient preferences and goals and assessment findings. Using clinical practice guidelines, the intervention for the research participants is expected to address deficits in strength, mobility, balance, and cardiovascular endurance. Exercise prescription will be provided using the Wellpepper physical therapy exercise prescription mobile app.
96905|NCT03428880|Drug|Morphine|spinal morphine is done before cesarean section
96906|NCT03428880|Drug|Quadratus lumborum block|a US Block QLB is done after surgery
96907|NCT03428854|Drug|LNG-IUS|Levnorgestrel containing IUD
96908|NCT03428841|Procedure|Audiometry|
96909|NCT03428828|Behavioral|Amygdala Neurofeedback|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
96910|NCT03428828|Behavioral|Parietal Neurofeedback|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
96911|NCT03428815|Device|Prosthesis suspension liner|Liners out of phase change material will be fitted
96912|NCT03428802|Other|Laboratory Biomarker Analysis|Correlative studies
96913|NCT03428802|Biological|Pembrolizumab|Given IV
96914|NCT03428789|Procedure|Sensory nerve coaptation|A recipient sensory nerve of the abdomen was reattached to a donor nerve in the chest area. The sensory branch of usually the 11th intercostal nerve was used as recipient nerve for nerve coaptation and the anterior cutaneous branch of the third intercostal nerve was used as donor nerve. Direct, end-to-end nerve coaptation was performed with two stitches.
96915|NCT03428776|Behavioral|Standard Compliance-linked incentives|Standard mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
96916|NCT03428776|Behavioral|Intelligent Compliance-linked incentives|Intelligent mobile-phone reminders and compliance-linked incentives Electronic immunization records on cloud-based software platform and use of biometric identification
96917|NCT03428776|Other|Record keeping|Electronic immunization records on cloud-based software platform and use of biometric identification
96953|NCT03428529|Drug|5Fluorouracil|Neoadjuvant bolus 5-Fluorouracil concomitante to external beam radiotherapy
96954|NCT03428516|Device|Fixed CPAP|CPAP is a device that applies continous fixed positive pressure to the airways in order to keep them opened during sleep
96955|NCT03428516|Device|Auto-adjusting CPAP|Auto-adjusting CPAP is a device that applies auto-adjusting continous positive pressure to the airways in order to keep them opened during sleep
96956|NCT03428503|Drug|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
96918|NCT03428763|Device|Homebased disease monitoring (eHealth)|"Participants allocated to the intervention group will be trained in self-monitoring (assessment of tender of swollen joints). Further they will be instructed in using a point-of-care CRP-measuring device to measure blood concentrations of C-reactive protein at their home, and to submit the self-monitoring results on a dedicated internet platform. These procedures represent a virtual visit.~The participants are instructed to have virtual visit (self-monitoring) every month from allocation. The scheduled virtual visits include~Joint score by the patient~Patient global disease activity measured on a 0-100 mm visual analogue scale.~CRP measurement on home-based device Based on the submitted data a DAS28-CRP is calculated and recorded in the eCRF."
96919|NCT03428763|Other|Standard clinical disease monitoring|Those allocated to the control arm of the study will continue usual clinical care (i.e. they will not self-monitor or have access to the eHealth solution). No other medication changes will be mandated and participating investigators will be asked to manage all other care according usual clinical practice. Individuals in the control group will not be given the option to self-monitor.
96920|NCT03428750|Biological|EN3835|Collagenase clostridium histolyticum
96921|NCT03428750|Biological|Placebo|Placebo
96922|NCT03428737|Procedure|Nocturnal controlled pressure control ventilation|use of an inspiratory pressure of 20 cm of H2O and an respiratory frequency chosen to stop all spontaneous breathing activity during the night
96923|NCT03428737|Procedure|Pressure support ventilation|use of a pressure support level identical during the night to the pressure support level at the end of the day.
96924|NCT03428724|Drug|Standard Preparation|standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
96925|NCT03428724|Drug|Individualized Preparation|individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age>65, neurologic comorbidities)
96926|NCT03428711|Drug|Mesoglycan Oral Tablet|"Experimental drug: mesoglycan, already used in the treatment of chronic venous ulcers, is a complex mucopolysaccharide, composed of a mixture of glycosaminoglycans (mainly heparan-sulphate, dermatan sulfate), inhibitors of thrombin and of Factor Xa and active in restore flow-mediated vasodilation.~Used in oral formulation, hard capsules, 50 mg, twice-a-day, for 12 months. Reference therapy: placebo, organoleptically indistinguishable from the experimental drug, twice-a-day, for 12 months."
96927|NCT03428711|Drug|Placebo Oral Tablet|Indistinguible placebo tablet
96928|NCT03428698|Device|Aminogam|A lower third molar was extracted. All the surgical tools and materials as well as the surgical field were sterile. A full-thickness flap was raised and, if necessary, osteotomy and tooth sectioning were performed using a straight handpiece with dedicated burs under copious irrigation with sterile saline solution. The extraction was completed with curved and straight extractors, the socket was closely inspected and the dental follicle was removed. Depending on the group to which the patient was assigned, one of the following procedures was carried out.
96929|NCT03428685|Drug|Dydrogesterone Oral Tablet|Oral dysdrogesteone 10mg tds will be prescribed from 12 - 36+6 weeks.
96930|NCT03428685|Drug|Placebo Oral Tablet|Placebos will be prescribed from 12 - 36+6 weeks.
96931|NCT03428672|Procedure|total hip arthroplasty|Bone samples from Hip fracture were collected from the femoral head which has been replaced
96932|NCT03428659|Other|Data acquisition of functional abilities in sub-acute stroke|MRI data, motor evoked potentials, gait function and behavior data acquisition
96933|NCT03428646|Drug|Dupilumab|In addition to (or substituting for) DUPIXENT®, participants may receive marketed drugs as deemed necessary by their physicians for the treatment of AD or comorbid conditions.
96934|NCT03428633|Drug|Ropivacaine|Paravertebral block using ropivacaine preoperatively and postoperatively
96935|NCT03428633|Drug|Morphine|Morphine intraoperatively and postoperatively
96936|NCT03428620|Other|High Velocity Low Amplitude mobilization|Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
96937|NCT03428620|Other|Exercise protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
96938|NCT03428607|Drug|AZD6738|AZD6738 160mg QD
96939|NCT03428607|Drug|Olaparib|Olaparib 300mg BID
96940|NCT03428594|Biological|CKD-11101|
96941|NCT03428594|Biological|NESP|
96942|NCT03428581|Procedure|ALND with ARM +/- LVB|"Subjects will undergo removal of the lymph nodes in the underarm or axilla area. This is referred to as an axillary lymph node dissection (ALND). The procedure for identifying the drainage of the arm lymphatics during an axillary dissection has been coined axillary reverse mapping (ARM). Lympho-venous bypass (LVB) is a technique incorporated along with the ARM procedure that allows preservation of the lymphatics draining the arm while removing the standard lymph nodes and not compromising the extent of the axillary dissection."
96943|NCT03428581|Procedure|ALND|Prospective and retrospective subjects undergoing an ALND.
96944|NCT03428568|Other|Herbal Melanin|Herbal melanin extracted from Nigella sativa seeds
96945|NCT03428568|Drug|Nexium|omeprazole
96946|NCT03428568|Drug|Amoxil|Antibiotic
96947|NCT03428568|Drug|Clarithromycin|Antibiotic
96948|NCT03428555|Behavioral|Integrated Care Pathway|The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
96949|NCT03428555|Behavioral|Treatment As Usual|Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
96950|NCT03428542|Behavioral|Yin yoga|Yin yoga 2 times per week for 5 weeks. Daily breathing assignments.
96951|NCT03428542|Behavioral|YOMI|"30 minutes of psychoeducation combined with mindfulness practice followed by 60 minutes of Yin yoga allowing the psychological theme to be further explored, aided by verbal instructions of the yoga teacher. 2 times per week for 5 weeks.~Daily breathing assignments."
96957|NCT03428503|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
96958|NCT03428490|Behavioral|Fully integrated treatment|Clinicians will be delivering CBT for Social Anxiety Disorder directly into the context of the Matrix's evidence-based treatment for substance use disorders (i.e., The Matrix Model).
96959|NCT03428490|Behavioral|Stand-alone Intensive Outpatient Program|Evidence-based treatment for substance use disorders (i.e., The Matrix Model).
96960|NCT03428477|Drug|Icosapent Ethyl|Composition: soft amber to light yellow, oblong gelatin capsules. One capsule contains 1g pure EPA-EE Dose: 4 capsules per day
96961|NCT03428477|Other|Placebo|"Composition: soft, amber to light yellow, oblong gelatin capsules containing light mineral oil:~Dose: 4 capsules per day"
96962|NCT03428464|Drug|Sodium Bicarbonate|Participants will take ½ the daily dose of sodium bicarbonate in the morning and the other ½ in the evening.
96963|NCT03428464|Other|Placebo|Participants will take ½ the daily dose of a placebo in the morning and the other ½ in the evening.
96964|NCT03428451|Drug|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.
96965|NCT03428451|Drug|NaCl 3% HS|Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.
96966|NCT03428451|Drug|NaCl 0.9% NS|Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
96967|NCT03428438|Other|Rehabilitation at home via SMS|Cardiac rehabilitation
96968|NCT03428425|Drug|paclitaxel apatinib S-1|"HIPEC: 43℃, 60min. the drug is paclitaxel : 70mg/m2 d1 d3 d5, The interval is not less than 24h , A total of three times.~apatinib：500mg qd po, 28 days is a cycle.preoperative 2 cycles, 2 cycles after surgery.~S-1： According to the body surface area, BSA <1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA >1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery"
96969|NCT03428412|Drug|TCM and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
96970|NCT03428412|Drug|TCM placebo and conventional drug|"All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days."
96971|NCT03428399|Other|Psychosocial variables|The investigators will assess mental health history and self-reported psychosocial variables as hypothesized risk and protective factors for body image and depression severity in breast reconstruction patients, before and after their mastectomy and breast reconstruction surgery. Mastectomy and breast reconstruction will be received in the context of routine medical care. Thus, this is not a psychological intervention, but rather observational measures assessed pre- and post routine care for breast reconstruction patients.
96972|NCT03428386|Procedure|Gastric plication ileal bypass|laparoscopic plication of the greater curvature of the stomach then the duodeno-jejunal junction is identified and 300 cm is measured downwards. The selected loop will be ascended without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just 3 cm away from the pylorus with a linear stapler charged with a green cartridge, the diameter of ileal antrum anastomosis is not exceeding 3 cm in diameter. The staple defect is closed with a two-layer running 3/0 polyglactin suture
96973|NCT03428373|Drug|Rivaroxaban|Rivaroxaban 10mg daily
96974|NCT03428373|Drug|ASA|ASA 81mg
96975|NCT03428360|Drug|Diazepam Buccal Soluble Film 5, 7.5,10, 12.5, and 15 mg|The subjects in this study will be administering DBSF themselves or with the help of a caregiver, (trained by the study site staff in study drug administration and documentation) in the same setting as they typically use the diazepam rectal gel or other rescue medication, without the presence of study staff.
96976|NCT03428347|Biological|GamEMab|drug for emergency prevention of Ebola based on recombinant monoclonal antibodies
96977|NCT03428334|Drug|Oral roflumilast|Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor is approved worldwide (including Hong Kong) for treatment of severe chronic obstructive pulmonary disease (COPD) with frequent exacerbations. Roflumilast has been shown to have anti-inflammatory effect in patients with COPD, with significant reduction of sputum absolute neutrophil count, IL-8 and neutrophil elastase compared with placebo treatment. Roflumilast can also improve the lung function parameters in patients with COPD and reduce the rate of moderate-to-severe exacerbations.
96978|NCT03428308|Other|Screening|Each individual general practitioner reviews his/her record system and detects patients who meet the inclusion criteria. Patients who meet these criteria will be invited to participate in the project.
96979|NCT03428308|Other|Treatment|Patients who are diagnosed with one or more of the selected somatic diseases receive an individualized course of treatment in general practice, primarily focusing on initiation and maintenance of medical treatment, and complying with current clinical guidelines and course programmes. Treatment goals are set in active co-operation with the patient and his/her family and with supervision and support from the Mental Health Centre Copenhagen, clinical pharmacologists and relevant staff from the municipality in terms of contact/support persons.
96980|NCT03428295|Device|Dose Safety AP system|Device will be used to automatically dose insulin
96981|NCT03428282|Procedure|VR Box|Distraction will be made during the injection of the drug using this method.
96982|NCT03428282|Procedure|Tablet Device|Distraction will be made during the injection of the drug using this method
97369|NCT03425162|Procedure|Group P|Group P:patient-controlled analgesia (PCA) morphine
96983|NCT03428282|Drug|Anesthesia|Anesthesia will be obtained by injecting the drug into the oral mucosa before performing the dental treatment.
96984|NCT03428269|Other|simulation by gaming (LabForGames Warning)|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
96985|NCT03428269|Other|traditional education|comparison of the efficacy of two educational methods to improve the clinical reasoning skills of nursing students facing patient deterioration
96986|NCT03428256|Device|Optiflow and THRIVE technique|Nasal high flow humidified oxygen
96987|NCT03428256|Device|Standard anaesthetic face mask|Oxygen delivery via an anaesthetic facemask
96988|NCT03428243|Device|truSculpt|Device comparison of Circumference measurement at Baseline vs 18 months post treatment
96989|NCT03428230|Drug|30 mg Paracetamol 3% (1 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injection will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
96990|NCT03428230|Drug|60 mg Paracetamol 3% (2 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
96991|NCT03428230|Drug|90 mg Paracetamol 3% (3 mL)|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
96992|NCT03428230|Drug|Placebo, 0.9% saline solution|Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
96993|NCT03428230|Drug|NIMP: Chloroprocaine HCl 1% (10 mg/mL), solution for injection|Immediately after intrathecal administration of the Paracetamol dose or Placebo, all patients will receive a single intrathecal dose of Chloroprocaine HCl 1% according to the Summary of Product Characteristics indications. Time interval between the 2 administrations should not exceed 2 min.
96994|NCT03428217|Drug|CB-839|Oral glutaminase inhibitor
96995|NCT03428217|Drug|Cabozantinib|Oral receptor tyrosine kinase inhibitor
96996|NCT03428217|Drug|Placebo|Placebo tablets
96997|NCT03428204|Procedure|Balloon dilation during 180 seconds|Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
96998|NCT03428204|Procedure|Balloon dilation during 300 seconds|Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
96999|NCT03428191|Drug|Remifentanyl+Dexmedetomidine|In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
97000|NCT03428178|Drug|rAAV2-ND4|rAAV2-ND4 of vitreous cavity injection
97001|NCT03428165|Other|HCG|250 μg/0.5ml choriogonadotropine alpha, Ovitrelle, Merck Serono
97002|NCT03428152|Procedure|superior hypogastric block|superior hypogastric blockade during surgery
97003|NCT03428139|Procedure|pulsed radiofrequency|Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
97004|NCT03428139|Drug|pulsed radiofrequency plus alpha lipoic acid|Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
97005|NCT03428126|Drug|Durvalumab|Dose Escalation and Dose Expansion Dose: 1500 mg by vein every 4 weeks in a 28 day cycle.
97006|NCT03428126|Drug|Trametinib|"Dose Escalation Starting Dose: 2mg by mouth daily in a 28 day cycle.~Dose Expansion Dose: MTD from Dose Escalation."
97007|NCT03428113|Other|Bladder Volume Measurement bladder scanner RN|Measure Urine Volume with Bladder Scanner by RN
97008|NCT03428113|Other|Bladder Volume Measurement Ultrasound APRN|Measure Urine Volume with Point of Care Ultrasound by APRN
97009|NCT03428113|Other|Bladder Volume Measurement bladder scanner APRN|Measure Urine Volume with Bladder Scanner by APRN
97010|NCT03428113|Other|Bladder Volume Measurement Ultrasound MD|Measure Urine Volume with Point of Care Ultrasound by MD
97011|NCT03428113|Other|Intermittent Straight Catheterization|Measure Urine Volume with Intermittent Straight Catheterization
97012|NCT03428100|Drug|Baricitinib|Administered orally.
97013|NCT03428100|Drug|Placebo|Administered orally.
97014|NCT03428100|Drug|Topical corticosteroid|Administered topically.
97015|NCT03428074|Procedure|Surgeries|Minimally invasive surgeries of Ivor-Lewis and Mckeown
97016|NCT03428061|Other|Integrated care for cardiovascular risk management|Disease management program for the prevention of cardiovascular diseases
97017|NCT03428035|Other|Package Insert|Modified package insert of Ibuprofen given postprocedural as pain medication
97018|NCT03428022|Drug|Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）|Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
97019|NCT03428009|Other|Magnetic Resonance Imaging|Study interventions are minimal risk.
97020|NCT03427996|Procedure|Rotational atherectomy|Percutaneous coronary intervention with rotational atherectomy
97021|NCT03427983|Procedure|Hydrodissection|Additional 3cc's of saline is used to establish an increase in hydrodissection during routine treatment.
97022|NCT03427983|Procedure|Regular Injection|Corticosteroid and lidocaine injection without additional saline is used as routine treatment.
97023|NCT03427970|Behavioral|observation|Control group will receive the standard of care according to the Scoliosis Research Society criteria: observation for patients with curves between 10°- 25°.
97024|NCT03427970|Behavioral|three-dimensionally integrated exercise for scoliosis|Experimental group will receive a modified physiotherapeutic scoliosis specific exercises ——the three-dimensionally integrated exercise for scoliosis program, which include auto-correction in 3D, postural correction, breathing training, resistance training, muscle fascia releasing, functional activities, balance training, core stability training, proprioceptive input exercises and patient education. Auto-correction exercise in 3D will combine with specific breathing mode, isometric training to correct abnormal spinal physiological curvatures in sagittal plane, and accompany with wedge pad to modify humpback, waist asymmetry, pelvic rotation in horizontal. While in coronal plane, longitudinal axial stretching, pelvic adjustments will be conducted to reduce the lateral curvature.
97025|NCT03427957|Diagnostic Test|Endometrial biopsy|"Endometrial biopsy performed through hysteroscopy:~Patients included in the Experimental Arm (New hysteroscopic grasper) will undergo hysteroscopic endometrial biopsy through the new grasper with knurled terminal end and cutting jaws.~Patients included in the Active Comparator Arm (Classic spoon grasper) will undergo hysteroscopic endometrial biopsy through the classic spoon grasper."
97026|NCT03427944|Drug|Calcium Dobesilate group|Calcium dobesilate was used to treat patients with chronic renal failure on the basis of conventional treatment.
97027|NCT03427944|Drug|Conventional Treatment group|Conventional treatment were used to treat patients with chronic renal failure.
97028|NCT03427931|Other|Continuous Glucose Monitor (CGM)|Study subjects will collect Continuous Glucose Monitor data for a minimum of 28 days but may continue for up to 3 months.
97029|NCT03427918|Behavioral|Mindfulness-Based Sex Therapy|Mindfulness-Based Sex Therapy in an integration of psychoeducation, sex therapy, and mindfulness-based skills.
97030|NCT03427905|Procedure|Lipoaspiration|Procedure: Lipoaspiration of fat and processing for the isolation of SVF Procedure: Transplantation
97031|NCT03427905|Procedure|Transplantation|Procedure: Lipoaspiration of fat and processing for the isolation of SVF and culture for the obtention of ADSCS Procedure: Transplantation
97032|NCT03427892|Drug|Brexpiprazole|Brexpiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders.
97033|NCT03427879|Drug|Low flavonoid beverage|A low flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), placebo blueberry powder (2.4%), alkalized cocoa powder (1.6%), and whey protein isolate (0.6%). The beverage will contain approximately 5mg flavonoids per serving.
97034|NCT03427879|Drug|High flavonoid beverage|A high flavonoid, sports nutrition recovery beverage will be prepared from milk (78%), sugar (8.6%), maltodextrin (8.6%), blueberry powder (2.4%), cocoa powder (1.6%), green tea extract (0.1%) and whey protein isolate (0.6%). The beverage will contain approximately 620 mg flavonoids per serving.
97035|NCT03427866|Drug|Ruxolitinib|Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The JAK2 pathway is over active in the disease, acute myeloid leukemia.
97036|NCT03427853|Drug|LY06006|LY06006 18mg, 60mg, 120mg subcutaneous injection
97037|NCT03427853|Drug|Placebos|Placebo subcutaneous injection
97038|NCT03427840|Procedure|Procedure/Surgery: superior hypogastric block|superior hypogastric blockade during surgery
97039|NCT03427827|Drug|Camrelizumab|Camrelizumab is an antibody targeting PD-1 developed by Jiangsu Hengrui Medicine, China.
97040|NCT03427814|Drug|BGB-290|60 mg PO BID
97041|NCT03427814|Drug|Placebo|60 mg PO BID
97042|NCT03427801|Drug|Erythropoiesis-Stimulating Agent|erythropoiesis-stimulating agent: Mircera or Darbepoietin
97043|NCT03427788|Drug|BAY2328065|Doses from 2.25-700 mg once daily in an escalating manner as liquid service formulation (LSF) or tablets
97044|NCT03427788|Drug|Placebo|Matching placebo, once daily in an escalating manner as LSF or tablets
97045|NCT03427775|Combination Product|multimodal perioperative pain protocol (MP3)|administration of gabapentionoid, acetaminophen, non steroidal anti-inflammatory drugs around the clock in addition to the peripheral nerve block offered before surgery
97046|NCT03427762|Other|Rehabilitation|"Healthy cycling group: The group participates in 5 weeks of intensive cycling therapy.~Healthy xbox group: The group participates in 5 week intensive xbox therapy Healthy controll group: The group does not take any kind of therapy. PD group: We have already analyzed the results of our group, and we will compare their results with the results of healthy groups."
97049|NCT03427723|Device|Accuvein®400|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
97050|NCT03427723|Other|Standard care|The intervention comes down to the randomization of the standard treatment versus Accuvein for peripheral intravenous cannulation
97051|NCT03427710|Drug|CiVi007|cholesterol lowering drug
97052|NCT03427710|Other|Placebo|matching placebo to CiVi007
97124|NCT03427047|Device|MyKnee with single use Efficiency Instrument|Total Knee Arthroplasty utilizing a CT scan for customization of cutting blocks with single use instrumentation
97053|NCT03427697|Device|Virtual reality and accommodation relax techniques in combination|The children will be given head-mounted video display to watch video at break of classes, 40 minutes per day in total. The video will be shown by virtual reality and accommodation relax techniques in combination.
97054|NCT03427684|Radiation|Hypo-fractionated radiotherapy|Hypo-fractionated radiotherapy with fraction >2Gy .
97055|NCT03427684|Drug|S1|S-1 80mg/m2/day, orally intake on radiotherapy days.
97056|NCT03427671|Device|Occlusin 500 Microspheres|Occlusin 500 microspheres will be administered using a catheter directed to the uterine vasculature using fluoroscopy. The microsphere suspension will be administered to a near-stasis endpoint.
97057|NCT03427658|Behavioral|Sweet food consumption|Comparison of the impacts of sweet and non-sweet food consumption
97058|NCT03427645|Behavioral|Decision tool|A tailored web-based stroke decision support intervention. This web-based tool will be developed for use by the surrogate decision maker during the acute stroke hospitalization and will be designed to facilitate high quality patient-centered decisions and minimize adverse effects on the surrogate.
97059|NCT03427632|Drug|Bone Cements|patents in PVP group will get injected with bone cement inside the collapsed malignant vertebra
97060|NCT03427619|Drug|OK432|OK432 will be injected at dosage of .1mg-.2mg 6-12 weeks apart up to 4 injections total.
97061|NCT03427606|Procedure|Continuous Locked Suture vs Traditional 5-points suture for Laparoscopic Sacral Colpopexy|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using continuous locked suture vs traditional 5-points suture for mesh fixation
97062|NCT03427593|Genetic|FACS analyses|FACS analyses
97063|NCT03427593|Genetic|Target Sequencing by NGS ( Next-generation sequencing)|Target Sequencing by NGS ( Next-generation sequencing)
97064|NCT03427593|Genetic|Whole Exome Sequencing|Whole Exome Sequencing
97065|NCT03427580|Behavioral|MERIT|Metacognitive Reflection and Insight Therapy
97066|NCT03427567|Procedure|Sublobar dissection|Sublobar dissection plus lymphadenectomy
97067|NCT03427554|Drug|Tretinoin cream 0.1%|Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
97068|NCT03427554|Drug|RETIN-A® Cream|RETIN-A® (Tretinoin) Cream (Valeant)
97069|NCT03427554|Drug|Vehicle of the test product|Vehicle for Tretinoin cream 0.1% (Taro Pharmaceuticals Inc.)
97070|NCT03427541|Procedure|Surgeries|Surgeries
97071|NCT03427528|Behavioral|Fathers and Babies (FAB)|Partners of female clients will receive the FAB texts that align with the original MB 1-on-1 intervention. The female partners will receive MB-TXT curriculum (i.e., MB 1-on-1 plus MB-TXT) and their male partners will receive the Home visitors will be responsible for sending texts to both their female clients and the clients' male partners.
97072|NCT03427528|Behavioral|MB 1-on-1 plus TXT|Female clients will receive the MB-TXT curriculum (i.e., MB 1-on-1 plus MB-TXT) and their male partners will receive the FAB texts that align with the original MB 1-on-1 intervention.Home visitors will be responsible for sending texts to both their female clients and the clients' male partners.
97073|NCT03427515|Dietary Supplement|Lactobacillus rhamnosus GG (ATCC 53103)|30 days of supplementation, 6x10^9 CFU/day
97074|NCT03427515|Dietary Supplement|Saccharomyces boulardii (CNCM I-1079)|30 days of supplementation, 5x10^9 CFU/day
97075|NCT03427515|Dietary Supplement|Placebo|30 days of supplementation
97076|NCT03427502|Drug|Bupivacaine-epinephrine|10 ml of 0.5% bupivacaine with 1:2,00,000 adrenaline. For children less than 12 years of age, 0.25% bupivacaine with 1:2,00,000 adrenaline
97077|NCT03427502|Drug|normal saline|normal saline
97078|NCT03427476|Drug|CTT1057|"Cohort A: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort A will undergo metastatic lesion biopsy (plus lymph node dissection) within 12 weeks after CTT1057 PET.~Cohort B: Single IV dose (370 MBq, or 10 mCi). Combined PET/MR or PET/CT imaging (kidney + whole body) will be performed following tracer injection. Patients in cohort B (renal cell carcinoma) will have nephrectomy within 12 weeks of CTT1057 PET imaging."
97079|NCT03427463|Drug|receiving 0.1 mg IT morphine|Patients will receive the standard of care dose 0.1 mg of intrathecal morphine
97080|NCT03427463|Drug|recieving 0.05 mg IT morphine|Patients will receive 0.05 mg of intrathecal morphine
97081|NCT03427450|Diagnostic Test|Blood draw|Blood collected will be processed on Parsortix PC1 system for capture and harvest of circulating tumor cells to be used in subsequent evaluations.
97082|NCT03427437|Drug|Bupivacaine|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
97083|NCT03427437|Drug|Adrenalin|caudal block was performed by conventional and ultrasound method with %0,25 bupivacaine + 1/200000 adrenalin
97084|NCT03427437|Device|Ultrasound|caudal block was performed by ultrasound method
97085|NCT03427411|Drug|M7824|Flat dose of 1,200 mg IV once every 2 weeks
97086|NCT03427385|Drug|Ropivacaine 0.5%|The volume of local anesthetic Ropivacaine 0.5% will be determined by the response (success or failure of block, 30 minutes after local anesthetic injection) of the previous patient in that group. Block success is defined as an absence of ice sensation in the knee within 30 min of ropivacaine administration accompanied by tolerance to tetanic electrical stimulation (TES) at 60 mA(milliamp) for 5 seconds.
97087|NCT03427372|Behavioral|anxiety scale, depression scale|post spinal puncture headache and backache will be assess by using visual analogue scale, anxiety will assess by beck anxiety scale, depression mood will assess by beck depression scale
97088|NCT03427359|Drug|cisplatin, capecitabine|Experimental arm patients received 3 cycles of induction chemotherapy (cisplatin 80mg/m2, day 1; oral capecitabine 1000mg/m2 twice daily from day1-14, repeated every 3 weeks) followed by concomitant cisplatin (100mg/m2,day1,every 3 weeks) for a total of 2 cycles with radiotherapy.
97117|NCT03427112|Device|Xin1 Humerus System|"Retrospective assessment of the surgical handling and performance of the X-ray-based tracking and navigation system Xin1 Humerus system evaluated from 10 proximal humerus plate fixations"
97118|NCT03427099|Behavioral|Rehabilitation with a biopsychosocial focus|Rehabilitation with a biopsychosocial focus
97119|NCT03427099|Behavioral|Control group|usual care
97120|NCT03427086|Drug|Biotin|High dose biotin
97121|NCT03427086|Drug|Placebo Oral Tablet|Placebo tablet similar in shape and size to the biotin tablet
97089|NCT03427346|Procedure|Endoscopic mucosal resection|Endoscopic resection is carried out using a double-channel scope. The lesion borders are marked with a coagulator. Saline liquid and sometimes epinephrine are injected into the submucosal layer to swell the area containing the lesion and elucidate the markings. The resected mucosa is lifted, then trapped and strangulated with a snare, and subsequently resected by electrocautery. Another method of EMR employs the use of a clear cap and prelooped snare inside the cap. After insertion, the cap is placed on the lesion and the mucosa containing the lesion is drawn up inside the cap by aspiration. The mucosa is caught by the snare and strangulated, and finally resected by electrocautery.
97090|NCT03427346|Procedure|Endoscopic submucosal dissection|After circumferential cutting of the surrounding mucosa of the lesion, fluid is injected into the submucosa to elevate the lesion from the muscle layer, and the connective tissue of the submucosa beneath the lesion is dissected subsequently.
97091|NCT03427333|Device|The Rook® Epicardial Access Kit|Use of the Rook Epicardial Access Kit to gain access to the normal, non distended pericardial space.
97092|NCT03427320|Drug|[131]I-IAZA|Injection of a single dose of 185MBq ( range 150-220MBq) of [131]I-IAZA prior to whole body imaging acquisition at 0-1 hrs,1-3 hrs , 4-8 hrs,19-36 hrs,41-72 hrs and 6-8 days post-injection. SPECT CT of target lesion(s) will be acquired at 19-36 hrs post injection.
97093|NCT03427294|Other|Delphi study|Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
97094|NCT03427281|Behavioral|questionnaire|questionnaire to assess the patterns of postoperative bracing use by spinal surgeons in Belgium
97095|NCT03427268|Drug|PM060184|"PM060184: 9.3 mg/m2 PM060184 i.v. as a 30-minute infusion via a central or peripheral venous catheter.Dose can be rounded to the first decimal point.~PM060184 will be administered on Day 1 and Day 8 q3wk. (Three weeks=one treatment cycle)."
97096|NCT03427255|Behavioral|CBT group treatment-plus|The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
97097|NCT03427255|Other|Waiting-list control condition|Waiting-list control condition during length of active treatment (6 months).
97098|NCT03427242|Drug|Apatinib|oral apatinib 750mg qd
97099|NCT03427229|Biological|Single-infusion FMT|Patients will receive a single fecal infusion by colonoscopy
97100|NCT03427229|Drug|Vancomycin (before randomization)|Vancomycin is administered in all patients for 3 days before randomization. Then vancomycin is stopped and patients are randomized to single-infusion FMT or multiple-infusion FMT.
97101|NCT03427229|Biological|multiple-infusion FMT|Patients will receive multiple fecal infusions by colonoscopy
97102|NCT03427216|Drug|Baclofen/diazepam|Vaginal suppository placed once daily, patients will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weekly
97103|NCT03427216|Drug|Vaginal placebo|Vaginal suppository placed once daily, patient will record pelvic pain daily on a VAS scale, sexual satisfaction and quality of life on a standardized questionnaire weeky.
97104|NCT03427203|Device|SenSura Mio|SenSura Mio is a marked ostomy device which is used as the comparator in this study
97105|NCT03427203|Device|Coloplast Ostomy device 1|Coloplast Ostomy device 1 a newly developed ostomy device
97106|NCT03427203|Device|Coloplast Ostomy device|Coloplast Ostomy device 2 a newly developed ostomy device
97107|NCT03427203|Device|Coloplast Ostomy device 3|Coloplast Ostomy device 3 a newly developed ostomy device
97108|NCT03427190|Other|APSOM vs Control|In complement to actions described in the control arm, the patient's general practitioner (GP) and the patient him/herself will be contacted within 21 days of hospital discharge in order to organize an appointment between them two; this consultation is expected to take place between day 22 and day 45 after hospital discharge. If the patient does not have a GP, a health-care professional (HCP) will be provided. .GP (or HCP) will also be contacted at 6 and 13 months.
97109|NCT03427177|Behavioral|mychoice|The mychoice communication tool begins to prepare patients to participate in a personal and tailored discussion with their provider about clinical trials as a potential treatment option. It is also customized to address the concerns of those least likely to participate, instead of providing a more general look at clinical trials- a common trait of other available tools.
97111|NCT03427151|Drug|IPP-201101|200 mcg of IPP-201101 will be administered subcutaneously every 4 weeks for 24 weeks.
97112|NCT03427138|Behavioral|Jasper|Families in the joint attention intervention will receive 10 weeks of the JASPER (Joint Attention Symbolic Play Engagement Regulation) protocol. JASPER is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari at the Center for Autism Research and Treatment, at University of California, Los Angeles. Our research staff will be trained on the specific techniques of JASPER guided by Connie Kasari (consultant on project) and her colleagues The study's intervention involves 2 days/week of 60-minute sessions with a trained experimenter (which may take place in the lab or home, depending on the needs of the family). The primary goal for the intervention will be to increase the frequency and range/variety of joint attention and to advance the child to higher levels (e.g., from requesting to initiating joint attention acts).
97113|NCT03427138|Behavioral|Parent Education|Families in the parent education intervention. Parent education will be provided in group sessions. During the sessions information is presented about ASD, how to deal with behavioral difficulties and available services, and parents are given an opportunity to share experiences. Parents will attend a weekly session for 10 weeks. 10 different topics will be discussed, which include: causes and symptoms of autism, diagnosis process, treatment options, enhancing communicative abilities in children with autism, emotion regulation, dealing with distress, correcting behavior difficulties, applying structure and routines.
97114|NCT03427125|Drug|Tenapanor|Active Drug
97115|NCT03427125|Drug|Placebo|Inactive Drug
97116|NCT03427125|Drug|Sevelamer Carbonate|Active control
97122|NCT03427073|Drug|ALM201|Drug: ALM201 administered subcutaneously
97125|NCT03427047|Device|Stryker Navigational with conventional metal instruments|Total Knee Arthroplasty without customization of cutting blocks using conventional metal instruments.
97126|NCT03427034|Device|BladderLight®|Using a cell collection device to look for the presence of bladder cancer cells
97127|NCT03427021|Drug|Oxaliplatin|Infusion
97128|NCT03427008|Other|mHealth Intervention|The mHealth app will allow transplant recipients to see their medication regimen, record themselves taking every dose, report side effects or symptoms, visualize their treatment progress, access educational content, and track appointments. This information is encrypted and transmitted to a HIPAA-secure web portal for providers to review.
97129|NCT03426995|Drug|Placebo|Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
97130|NCT03426995|Drug|GSK3358699|GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
97131|NCT03426995|Biological|GM-CSF|The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
97132|NCT03426995|Biological|LPS|LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
97133|NCT03426995|Other|Cantharidin|This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
97134|NCT03426982|Drug|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by APTT
97135|NCT03426982|Drug|Unfractionated heparin|Infusion dose of unfractionated heparin was adjusted by anti-Xa
97136|NCT03426969|Drug|Cyclophosphamide|Given IV
97137|NCT03426969|Biological|Filgrastim|Given SC
97138|NCT03426969|Drug|Fludarabine Phosphate|Given IV
97139|NCT03426969|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
97140|NCT03426969|Drug|Melphalan|Given IV
97141|NCT03426969|Drug|Mycophenolate Mofetil|Given PO
97142|NCT03426969|Drug|Tacrolimus|IV or PO
97143|NCT03426969|Radiation|Total-Body Irradiation|Undergo TBI
97144|NCT03426956|Dietary Supplement|Glucose|Ingestion of glucose (50 g) dissolved in 200 ml water.
97145|NCT03426956|Dietary Supplement|Glucose + Canagliflozin|Ingestion of glucose (50 g) dissolved in 200 ml water combined with the SGLT-1/SGLT-2 inhibitor canagliflozin.
97146|NCT03426943|Biological|Arterial blood sampling|All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels
97147|NCT03426943|Biological|Ultrafiltrate sampling|All patients will have ultrafiltrate sampling to assess cytokine levels
97148|NCT03426943|Device|CVVH using oXiris™ filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter
97149|NCT03426943|Device|CVVH using PrismafleX HF1400 filter|Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter
97150|NCT03426930|Other|self-evaluation of the Body Mass Index|Evaluation of the Body Mass Index before and after the treatment
97151|NCT03426930|Other|Cognitive-behavioral psychotherapies|Cognitive-behavioral psychotherapies before and after the treatment
97152|NCT03426904|Drug|Neoadjuvant FOLFOX|4 cycles of FOLFOX neoadjuvant chemotherapy and 8 cycles of postoperative chemotherapy
97153|NCT03426904|Drug|Conventional adjuvant FOLFOX|12 cycles of postoperative FOLFOX chemotherapy
97154|NCT03426891|Drug|Pembrolizumab|200 mg intravenously (IV) every 3 weeks. The dose of pembrolizumab will remain the same throughout study treatment. During the maintenance phase, participants will receive pembrolizumab (for 12 months).
97155|NCT03426891|Drug|Vorinostat|Dose Escalation Level -1 vorinostat 100 mg/day by mouth on days 1-5 every week during radiotherapy starting on first day of radiotherapy and 300 mg/day 1 week on 1 week off after radiotherapy. Level 1:vorinostat 200 mg/day by mouth on day 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 300 mg/day 1 week on 1 week off after radiotherapy. Dose Escalation Level 2: vorinostat 300 mg/day by mouth on days 1-5 every week during radiotherapy, starting on first day of radiotherapy; and 400 mg/day 1 week on 1 week off after radiotherapy. Dose Expansion:all participants will receive the same dose of vorinostat that was determined to be most tolerated dose. During the maintenance phase, participants will receive vorinostat (for 12 months).
97156|NCT03426891|Drug|Temozolomide|All participants will receive standard Temozolomide: Temozolomide (chemotherapy) 75 mg/m^2/day by mouth administered during the course of radiotherapy. Temozolomide will be administered continuously from Day 1 of radiotherapy to the last day of radiation. Maintenance Phase: temozolomide will start 4 weeks (+/- 3 days) after last dose of radiotherapy and will continue for 6 cycles post radiotherapy (150-200 mg/m^2/day, days 1-5 every 4 weeks) as per standard of care. During the maintenance phase, participants will receive Temozolomide (for the first 6 months).
97157|NCT03426891|Radiation|Radiotherapy|All participants will receive standard radiotherapy: a total dose of 60 Gy administered in daily doses of 2 Gy, typically on a 5 days on / 2 days off schedule over 6 - 7 weeks.
97158|NCT03426878|Other|Modified genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive modified genetic counseling to help them understand the results.
97159|NCT03426878|Other|Traditional genetic counseling|After participants at high risk for a hereditary cancer syndrome receive exome sequencing, they will receive traditional genetic counseling to help them understand the results.
97160|NCT03426865|Drug|Axumin PET scan|PET scan prior to RPLND
97161|NCT03426852|Other|No intervention|No intervention
97162|NCT03426839|Diagnostic Test|Coagulation tests|
97163|NCT03426826|Biological|FMT versus placebo|"Biological/Vaccine: Fecal Microbial Transplant versus placebo Fecal Transplant via endoscopy.~Other Names:~FMT"
97164|NCT03426813|Other|Historical control group for early mobilization|
97165|NCT03426800|Other|Acupuncture and training|Acupuncture twice in the week in 3 weeks combined with training in 6 weeks
97413|NCT03424772|Diagnostic Test|Whole genome sequencing|WGS will be performed for the trio
97166|NCT03426787|Behavioral|Decision Aid|Participants will have the option to view a web or paper-based version of the decision aid.
97167|NCT03426774|Device|Gentle Jogger|Passive Simulated Jogging device (Gentle Jogger)
97168|NCT03426774|Device|Gentle Jumper|Passive Simulated Jumping Device ( Gentle Jumper)
97169|NCT03426761|Drug|Dalbavancin|Dalbavancin 1,500mg intravenously every fourteen days for two to four infusions
97170|NCT03426761|Drug|Vancomycin|Examples of standard of care arm; infusions one to three times per day depending on the antibiotic for a total of three to eight weeks
97171|NCT03426748|Radiation|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
97172|NCT03426748|Radiation|High dose rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
97173|NCT03426735|Other|Dry heat|Dry heat will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
97174|NCT03426735|Other|Dry cold|Dry cold will be applied in the extravasation zone for 10 minutes. Let it rest for 20 and proceed to make a second application of dry cold for another 10 minutes. The control is after 24 hours.
97175|NCT03426722|Drug|L-carnitine|"L-carnitine VS Placebo is randomized (1:1)~L-carnitine 500mg TID(PO),~First evaluation will be performed at 8 weeks and then unblinding will be done. If symptoms continue after treatment, dose escalation in L-carnitine group by 1000mg TID (PO). If symptoms continue after treatment in Placebo group, L-carnitine 500mg TID(PO) will be given."
97176|NCT03426722|Drug|Placebo|Placebo 500mg TID(PO)
97177|NCT03426709|Behavioral|Low intensity Internet-delivered psychotherapy|The online intervention will be individual and interactive, which will be supported by multimedia material (videos, sound recordings, etc.) and will have internet support. The estimated duration of the program is 8 weeks. Low Intensity Internet-delivered psychotherapy: Psychoeducation, Healthy living habits, Behavioral activation, Positive Psychology, Mindfulness and Compassion
97178|NCT03426696|Behavioral|psychological condition|Graves ́ ophthalmopathy quality of life questionnaire, Symptom checklist 90(SLC-90), Hamilton anxiety scale(HAMA), Somatic self-rating scale(SSS), MATRICS Consensus Cognitive Battery (MCCB), Hamilton depression scale(HAMD)
97179|NCT03426683|Other|Intestinal Microbiota Transplantation|the bacteria will be transplanted to mid-gut by nose-jejunum nutrition tube. Patients in this study will be assigned to receive standardized IMT three times or traditional medicine and would be followed up for at least 3 year.
97180|NCT03426670|Device|OraQuick HIV Self-Test|OraQuick® HIV Self-Test is an in-vitro diagnostic medical device that is used for self-testing of antibodies for HIV-1 and HIV-2 in oral fluid. This test is intended as an aid to detect antibodies to HIV-1 and HIV-2 from infected individuals.
97181|NCT03426657|Combination Product|Durvalumab + Tremelimumab + RT|Patients with an increased CD8+ tumor infiltrating immune cell density and at least clinically stable disease will receive radioimmunotherapy with the PD-L1 Inhibitor Durvalumab and the CTLA4-Inhibitor Tremelimumab (altogether 4 doses q4w including the induction dose) followed by maintenance therapy with Durvalumab (8 additional doses q4w).
97182|NCT03426644|Behavioral|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
97183|NCT03426631|Drug|Placebo oral capsule|Placebo capsule 30 minutes before sleep
97184|NCT03426631|Drug|DAW1033B2 oral capsule|DAW1033B2 capsule 30 minutes before sleep
97185|NCT03426618|Other|Non-interventional|Non-interventional
97186|NCT03426605|Drug|Open Label LAM-003|LAM-003
97187|NCT03426592|Drug|Vitamin D3, 10000 Intl Units Oral Capsule|"Vitamin D capsule. Over-encapsulated to mimic placebo oral capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
97188|NCT03426592|Drug|Placebo oral capsule|"Capsule containing oleic acid. Over-encapsulated to mimic vitamin D3 capsule.~Eligible study participants will be randomized 1:1 to vitamin D or placebo one capsule daily from week 0 to week 24. All participants will be advised to achieve 1 gram daily dietary calcium intake whilst on study.~Blood and urine will be taken at 0, 12, 24 and 36 weeks to evaluate the primary and secondary endpoints.~Rectal swabs will be taken at 0, 24 and 36 weeks.~All participants will continue antiretroviral therapy throughout the study."
97189|NCT03426579|Device|NeuroSENSE ®in children|Before induction of anesthesia NeuroSENSE ® monitoring will be applied to all subjects.General anesthesia with dexmedetomidine and remifentanil is titrated based on the evaluation of respiratory clinical signs (cough, spasm, movement) and immobility of the vocal cords. The anesthesiologist performing anesthesia will be blinded for the Wavelet-based Anesthetic Value for Central Venous System (WAVCNS) index assessed by NeuroSENSE ® and will adjust dexmedetomidine according to clinical signs, which is standard of care. Retrospectively data obtained by NeuroSENSE ® will be compared to evaluate whether they are useful in predicting upcoming unwanted airway reflexes.
97190|NCT03426566|Other|retrospective observational study with no intervention|no intervention
97191|NCT03426553|Biological|Riboflavin+UV RBC|35 patients who met all inclusion and exclusion criteria received transfusion with RBC suspension from whole blood, treated with riboflavin and ultraviolet pathogen reduction technology
97192|NCT03426553|Biological|irradiated RBC|35 patients who met all inclusion and exclusion criteria received transfusion with irradiated RBC suspension
97193|NCT03426540|Drug|Conbercept|Three-port 25-G PPV was performed in all patients using a Constellation system. Patients in the treatment group received an intravitreal injection of conbercept (10 mg/mL, 0.5 mg) using a sterile technique after 25-G vitrectomy.
97194|NCT03426527|Drug|Levobupivacaine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine
97370|NCT03425162|Procedure|Group A|Group A:Ultrasound guided unilateral anterior Quadratus Lumborum block with 20 ml %0.25 Bupivacaine
97195|NCT03426527|Drug|Levobupivacaine-Dexmedetomidine|Following induction of anaesthesia, patients will receive ultrasound guided bilateral superficial cervical plexus block with levobupivacaine in conjunction with dexmedetomidine
97196|NCT03426527|Other|General Anaesthesia|Using propofol, fentanyl and atracurium
97197|NCT03426514|Procedure|Three-port Laparoscopic Surgery|Patients undergo three-port laparoscopic surgery. The surgery will be completed by a surgeon and a camera-person without another assistant. The surgeon will adjust surgical position to expose the operative field with the help of gravity. All the orther operative procedures are the same as conventional laparoscopic surgery.
97198|NCT03426514|Procedure|Conventional Laparoscopic Surgery|Patients undergo conventional laparoscopic surgery（4 or more ports）.The surgery will be routinely completed by a surgeon，a camera-person and another assistant to provide counter-traction.
97199|NCT03426488|Behavioral|VIP - Västerbotten Intervention Programme|Intervention on CVD (cardiovascular disease) and diabetes
97200|NCT03426475|Procedure|interprof ACT measures|Definition of common goals between general practitioner and nursing staff, appointment of a contact person, support in assigning medication, use of name badges worn by GPs and nurses during visits, mandatory availability of contact person, standardized procedures for GPs home visits
97201|NCT03426462|Drug|Propofol|Induction of anesthesia and two further deepening episodes will be performed whilst recording the electroencephalogram.
97202|NCT03426449|Procedure|posterolateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 5 o'clock position for 8-10 mm
97203|NCT03426449|Procedure|lateral sphincterotomy|Fissurectomy and limited division of internal anal sphincter at 3 o'clock position for 8-10 mm
97204|NCT03426436|Diagnostic Test|Two consecutive 15-lead ECGs|The 15-lead ECG consists of a traditional 12-lead ECG and an additional three leads on the right side of the body. The first 15-lead ECG will have an additional three electrodes/stickers on the right side of the chest and the second 15-lead ECG will have an additional three electrodes/stickers on the posterior side.
97205|NCT03426423|Other|Behavioral smoking cessation intervention|"The intervention consists in a behavioral smoking cessation intervention combined with pharmacotherapy. The intervention is tailored it to specificities of participants based on findings from the previous phase of our study (DISCGO-MIX, Swissethics ID PB_2016-01459).~Counseling will cover topics such as assessing ambivalence and enhancing motivation with motivational interviewing methods, identifying barriers to quit, coping with cravings and intensive relapse prevention strategies. Participants will be advised to use over the counter nicotine replacement bi-therapy (NTR). A 2-week starting kit, consisting of nicotine transdermal patch and a short acting NRT (lozenge, gums, inhaler or mouth spray) will be provided to participants for free, if they wish to take NRT.~The behavioral intervention will last 30-45 minutes, and will be conducted by a research nurse using an interview guide."
97206|NCT03426423|Other|Control|"Participants assigned to the control group will receive a less intensive and non-tailored intervention for smoking cessation.~For this arm the structured 3 steps AAR approach will be used:~Ask for smoking status. Advise to quit in a clear manner. Refer to external help: participants will receive a booklet with information on smoking cessation (non specific to diabetes and gender) and links to support facilities (national quitline, smoking cessation clinic, websites, self-help).~This unique intervention of 5-10 minutes will be performed by the research nurse."
97207|NCT03426410|Other|Survey|Electronic survey containing a questionnaire regarding knowledge and use of national guidelines of low back pain rehabilitation, type and frequency of cross sectional communication, attitudes and beliefs about back pain and two patient vignettes.
97208|NCT03426384|Behavioral|Mymee Program|A combination of digital therapeutics and telephonic health coaching is used to identify and test dietary, lifestyle, and environmental triggers in order to reduce symptoms of auto-immune disease.
97209|NCT03426371|Drug|KL-140|"KL-140 will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to KL-140.~Drug: Oxaliplatin Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m^2/day intravenously followed by 2400 mg/m^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
97210|NCT03426371|Drug|Placebo|"Placebo will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity Drug: Oxaliplatin Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: Folinic Acid FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.~Drug: 5Fluorouracil 5-FU as a bolus of 400 mg/m^2/day intravenously followed by 2400 mg/m^2/day infusion over 48 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity."
97211|NCT03426358|Device|LSM assessed by Elastographic Techniques|Performing Transient Elastography, ARFI or 2D-SWE on patients at baseline (within 1 month before HSCT) and after HSCT on days +9/10, +15/17, +22/24
97212|NCT03426345|Drug|Relamorelin|Relamorelin 10μg injected twice daily for 12 weeks.
97213|NCT03426345|Drug|Placebo|Placebo injected twice daily for 12 weeks
97214|NCT03426332|Other|No intervention|No intervention
97215|NCT03426319|Diagnostic Test|Cardiovascular evaluation|Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
97216|NCT03426306|Diagnostic Test|4DCT-Ventilation|4DCT-ventilation is an imaging modality that provides superior image quality, reduced cost, and a faster imaging procedure compared to nuclear medicine VQ scans.
97217|NCT03426293|Other|Measuring the ACT to determine effect of heparin|Measuring the ACT to determine effect of heparin during non-cardiac arterial procedures
97371|NCT03425149|Biological|VLA1601|purified inactivated ZIKV vaccine candidate adsorbed on alum
97218|NCT03426280|Device|Apple Watch Series 1|Clinic pharmacists will issue Apple Watches to study arm patients and teach them the usage of the Activity app. In addition to usual care, these patients will each receive an in-person 3-minute coaching session during clinic visit at 2, 4, 6 and 12 months.
97219|NCT03426267|Drug|SDN-037|twice daily
97220|NCT03426267|Drug|Placebo|twice daily
97221|NCT03426254|Biological|Injections Subcutaneously Talazoparib|Patients receive per day single dose of subcutaneous Injection contains 1 mg Talazoparib on days 1-28
97222|NCT03426254|Drug|Oral capsules Talazoparib|Patients receive 1 mg of Talazoparib PO QD on days 1-28.
97223|NCT03426241|Other|no intervention|this is cross-sectional study
97224|NCT03426228|Diagnostic Test|HbA1C|"After overnight fasting, 10 ml of blood will be collected at four different timings during the IVF protocol:~At baseline (second day of the menstrual period)~Triggering phase (post-egg retrieval procedure)~Embryo transfer phase (post-transfer procedure)~Week 4 (positive bHCG)~4. Week 8 of pregnancy"
97225|NCT03426215|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
97226|NCT03426202|Drug|Modafinil Oral Tablet|modafinil 200mg
97227|NCT03426202|Drug|Placebo Oral Tablet|placebo 200mg
97228|NCT03426189|Procedure|Leukapheresis|Blood will be taken by a needle inserted into a vein in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out of the machine for purposes of this research. The rest of the blood will be returned through a needle in the other arm.
97229|NCT03426189|Procedure|Lymph node biopsy|Ultrasound will be used to localize the position of one lymph node in the groin. Under a light general anesthetic, one lymph node will be removed.
97230|NCT03426176|Drug|oxytocin nasal spray|intranasal administration of oxytocin (24 IU)
97231|NCT03426176|Drug|intranasal placebo treatment (placebo-control for oxytocin)|intranasal administration of placebo nasal spray
97232|NCT03426176|Drug|ATD treatment|oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
97233|NCT03426176|Drug|oral placebo treatment (placebo-control for ATD)|oral administration of a tryptophan-balanced mixture (78.2g)
97234|NCT03426163|Device|Virtual reality|Application of knee MRI transformed virtual reality system
97235|NCT03426150|Drug|CPP-ACP|The surfaces of specimens were pretreated with CPP-ACP for 3 min
97236|NCT03426150|Drug|Placebos|The surfaces of specimens were pretreated with deionized water for 3 min
97237|NCT03426137|Drug|Oxycodone|5mg Oxycodone in oral solution given every 3 hours
97238|NCT03426137|Drug|Ketorolac|toradol intravenous (IV) 30mg. Maintain toradol IV every 8 hours, round the clock. For patients with renal insufficiency, decrease toradol dose to 15mg every 8 hours. For patients over 65 years old, decrease toradol dose to 15 mg every 8 hours. After 24 hours, start oral NSAIDS every 8 hours round the clock when tolerating pain.
97239|NCT03426137|Other|Placebo|Oral solutions containing only the carrier vehicle - a flavored syrup called OraSweet
97240|NCT03426124|Device|EkoSonic Endovascular System with thrombolytic|The device uses ultrasonic waves in combination with clot-dissolving thrombolytic drug to effectively dissolve clots.
97241|NCT03426111|Device|Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA)|This endoscopic technique is defined as a gastric restriction by means of sutures of the entire gastric wall, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
97242|NCT03426111|Behavioral|Lifestyle modification|Hypocaloric diet and moderate physical exercise
97243|NCT03426098|Device|Secret RF|A series of 3 facial treatments with the Secret Micro-Needle Fractional RF System® at 4 week intervals.
97244|NCT03426085|Drug|Liraglutide 6 mg Solution for Injection|
97245|NCT03426085|Other|Placebo|
97246|NCT03426072|Other|modified IHI breakthrough series|"There are five main elements to the intervention:~Establishment of the team and set up~Establishing baseline performance and knowledge~Ongoing developmental support~Learning sessions (3)~Action periods (3)~The actual facilitative actions (e.g., coaching, guiding, mentoring, supporting) occur in combination with limited teaching, largely during telephone conferences but also in any visit, which may occur up to quarterly.~5. The concluding session is an opportunity for networking, sharing successes and making plans for the continuation of project work following the end of formal support"
97247|NCT03426059|Other|No Intervention|No Intervention. This is an observational study.
97248|NCT03426046|Procedure|Partial Pulpotomy|Partial removal of inflamed pulp tissue in cariously exposed teeth
97249|NCT03426046|Drug|Pulp Capping Agents|Biocompatible materials
97250|NCT03426033|Drug|ISIS 681257|Xmg dose administered as a subcutaneous injection
97251|NCT03426033|Drug|Warfarin|25mg tablet administered orally
97252|NCT03426020|Other|Oral midazolam|0.5 mg/kg oral midazolam administered 20 minutes before induction
97253|NCT03426020|Other|Film http://www.animaturk.com/animasyon/suko-ameliyat-oluyor|patients will be watched a short movie (at URL: http://www.animaturk.com/animasyon/suko-ameliyat-oluyor ) 20 minutes before induction.
97254|NCT03426020|Other|Play game (PC fishing game)|Patients will be played a simple PC game (a fishing game) 20 minutes before induction
97255|NCT03426007|Procedure|Uterine lavage|embryo recovery from the uterus following either natural cycle (NC)/intrauterine insemination (IUI), or controlled ovarian hyperstimulation (COH)/intrauterine insemination (IUI).
97256|NCT03425994|Drug|Elvitegravir/Cobicistat/Emtricitabine|Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide 150mg/150mg/200mg/10mg (Genvoya) film coated tablet
97277|NCT03425838|Drug|Non-Steroidal Aromatase Inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
97257|NCT03425981|Other|Whole-Body Electromyostimulation Training|"The WB-EMS training program consisted of six WB-EMS training sessions (one per week) and six running training sessions (also one per week).~This intervention programme followed a within-day undulating periodization model. The training sessions were divided into four parts: warm up (A), strength (B), high intensity interval power training (c), and high intensity interval training (HIIT) (D)."
97258|NCT03425955|Device|SUNEKOS ® 200|"4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days. Two different injection techniques were carried out mono-laterally on the left or right face side randomly: interstitial fluid technique (IFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
97259|NCT03425955|Device|"SUNEKOS® 1200 and SUNEKOS® 200"|"5 micro-injection sessions (one of the product SUNEKOS® 1200 and four of SUNEKOS® 200. SUNEKOS® 1200 was injected bi-laterally on the face with cushion technique. 24 hours after the SUNEKOS® 1200 treatment, 4 micro-injection sessions of SUNEKOS® 200 with an interval of 10 days were performed . SUNEKOS® 200 was injected with two different techniques, carried out mono-laterally on the left or right face side randomly: retrograde interstitial fluid technique (RIFT) on one face side; bolus technique on five pre-determined face points (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) on the contralateral face side."
97260|NCT03425942|Behavioral|Internet Cognitive Behavioral Therapy for insomnia (ICBT-i)|This intervention lasts for five weeks. The intervention is internet-based and mainly consists of the most potent CBT technics i.e. sleep restriction and stimulus control. Weekly feedback is provided by master students supervised by clinical psychologists.
97261|NCT03425942|Behavioral|Internet Applied Relaxation Techniques (IART-i)|This intervention lasts for five weeks. The intervention is internet-based and consists of different common applied relaxation exercises and treatments. Weekly feedback is provided by master students supervised by clinical psychologists.
97262|NCT03425929|Drug|Oxytocin|Intranasal administration, 24 international units (IU) oxytocin.
97263|NCT03425929|Drug|Placebo|The placebo nasal sprays contain identical ingredients except for the peptide itself.
97264|NCT03425916|Other|Physical therapy intervention|Primiparous women start a physical therapy intervention in week 6 after normal one-child delivery, based on abdominal and pelvic floor exercises, education and behavior advices. Abdominal muscle condition and activation are measured by transabdominal ultrasound and surface electromiography. This group is going to be examined after treatment and 6 and 12 months after treatment.
97265|NCT03425903|Device|Whole body cryotherapy sessions|Whole body cryotherapy (WBC) 10 sessions of 3 minutes at a temperature of -196ºC (point of evaporation of liquid nitrogen), on the basis of three sessions a week.Fills in questionnaires.
97266|NCT03425890|Behavioral|SURE program|SURE program is a self-exercise program which aims to empower people with stroke and their caregivers to increase early UL practice outside therapy
97267|NCT03425877|Device|MS Band 2|Before starting the experiments, the subjects will be helped to wear the Microsoft® Band 2 bracelet (a smartwatch capable of recording data from over 12 sensors, including a heart rate sensor and a skin conductance sensor) and a session will be recorded Of 10 minutes at rest. After the rest period and always wearing the Microsoft® Band 2, the subjects will perform the other session of the procedure.
97268|NCT03425877|Behavioral|Emotion Assessment|The subjects will be subjected to the viewing of 21 video clips depicting 6 different emotional states belonging to the FilmStim database validated by Schaefer's studio and collaborators (Schaefer, Nils, Sanchez, & Philippot, 2010). When viewing the clip, subjects will wear the Microsoft ® Band 2 .and after each movie clip of an evaluation of the stimulus value and activation level perceived by the Self-Assessment Manikin (Bradley & Lang, 1994) questionnaire). The presentation of movie clip is randomized and does not follow a fixed effect. Between the presentation of each clip a fixed interval of 15 seconds has been inserted in order to induce artifacts and overlap of physiological signals among different emotional valence video clips.
97269|NCT03425877|Behavioral|Single Task|The section includes three tasks which involve upper and lower extremities, and cognitive functions, associated with low cognitive and motor load for their execution. Subjects are required to perform a single task, i.e. without the simultaneous execution of other tasks. Grasping(Motor Upper Limbs): The subject is required to reach an object's dominant limb and grab it. Walking(Motor Lower Limbs): It is required to carry 10 feet of walk. Attention(Cognitive): Signal detection task. The subject is required to detect acute sound between a series of serious sounds (Oddball Paradigm).
97270|NCT03425877|Behavioral|Dual Task|This section includes three tasks of different types (upper limb motor, lower limb motor, cognitive) that will be performed with a greater cognitive load. Elbow N-back (Dual Task Motor upper limbs): The subject is required to reconfigure the arrangement of the floppy disks on a different blade, by moving only one disk at a time and by putting a disk on another bigger disk, never on a smaller one. Walking + Nback (Dual Task Motor lower limbs): The subject is required to walk while subtracting from 100 to 3 in 3. Problem Solving (Dual Task Cognitive): The subject is subjected to a deductive logic puzzle.
97271|NCT03425877|Behavioral|Rest|At this stage, the HR and GSR signals will be recorded during a period of rest of 10 minutes. The subjects wear a pair of headphone for reducing the environmental sound noise. Through the headphones a sound indicates to the subject when recording starts and stops. Two separate recording of 5 minutes are performed, the first is performed while keeping eyes closed The two session are presented randomly to each different subject in order to prevent a bias due to order effect .
97272|NCT03425864|Biological|connective tissue graft|patient will receive immediate implant and connective tissue graft
97273|NCT03425864|Device|immediate implant|patient will receive immediate implant with connective tissue graft.
97274|NCT03425851|Other|Diapers|Receive 600 diapers.
97275|NCT03425851|Other|Resources of diaper banks|Caregivers will receive resources of diaper banks.
97276|NCT03425838|Drug|CDK 4/6 inhibitor|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
97325|NCT03425500|Device|GRAFTJACKET™ allograft|The acellular human dermal allograft in used in the bridging rotator cuff reconstruction
97372|NCT03425149|Biological|Placebo|Phosphate buffered saline (PBS)
97278|NCT03425838|Drug|Fulvestrant|Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
97279|NCT03425825|Other|Non-interventional|Non-interventional
97280|NCT03425812|Drug|To withdraw NSAIDs therapy|NSAIDs therapy will be withdrew after washout period.
97281|NCT03425812|Drug|To continue NSAIDs therapy|NSAIDs therapy will be continued.
97282|NCT03425799|Drug|Sodium Chloride 0.9% Inj|Inactive ingredient mixture for injection without drug, intravenous infusion bags containing normal saline, manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
97283|NCT03425799|Drug|Tranexamic Acid|Tranexamic Acid Intravenous Infusion Bags (10 mg/mL), manufactured and provided by Exela Pharma Sciences, LLC from a single batch / lot.
97284|NCT03425786|Behavioral|Diagnostic training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV.
97285|NCT03425786|Behavioral|Diagnostic and treatment training|Training in the Dix-Hallpike maneuver and the supine head roll test to diagnose BPPV. Training in the Epley and Barbecue maneuvers to treat BPPV.
97286|NCT03425773|Biological|BVAC-B|Autologous B cell and monocyte presenting HER2/neu antigen
97287|NCT03425747|Drug|Calcium Carbonate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
97288|NCT03425747|Drug|Calcium Citrate|subjects will be assigned to a calcium supplement (Carbonate or Citrate) at the same total amount of elemental calcium that they had taken before the study enrolment.
97289|NCT03425734|Drug|Dexmedetomidine|The drug will be prepared in 50 ml saline 0.5 ml DEX (100mc/ml +49.5 cc saline 1ml=1mg), and the dose will be calculated according to body weight.
97290|NCT03425721|Other|No Intervention|No Intervention is administered in this study.
97291|NCT03425708|Drug|20mg Febuxostat|Participants take 20mg febuxostat pill once a day for at least six months.
97292|NCT03425708|Drug|40mg Febuxostat|Participants take 40mg febuxostat pill once a day for at least six months.
97293|NCT03425695|Device|CheseeTM Diode Laser|low level laser therapy was utilized adjunct with free gingival graft.
97294|NCT03425695|Other|Clinical examination|"The shrinkage of the graft area was calculated according to the differences between the graft area at baseline, 1st, 3rd, and 6th months.~Epithelization was determined via bubbling test by using 3% hydrogen peroxide (H2O2) at 7, 14, 21, and 28 days after surgery."
97295|NCT03425682|Other|ViBone|Viable Bone Allograft
97296|NCT03425669|Device|Stochastic Vestibular Stimulation|Stochastic vestibular stimulation will be given by electric stimulation through electrodes place over the mastoid processes behind each ear. Auditory stimulation with stochastic white noise will be administrated through ear phones.
97297|NCT03425669|Device|Sham stimulation|Patients will receive sham stimulation in place of active vestibular stimulation.
97298|NCT03425669|Drug|Active medication|Patients will be examined with and without medication.
97299|NCT03425656|Drug|Trastuzumab plus docetaxel (for 4 21-day cycles) after four 14-day cycles of Doxorubicin plus cyclophosphamide|Trastuzumab (8 mg/kg IV loading doseat cycle 1, followed by 6 mg/kg at subsequent cycles) is given concomitantly with docetaxel (100 mg/m2 IV) for 4 21-day cycles after four 14-day cycles of Doxorubicin (60 mg/m2 IV) plus cyclophosphamide (600 mg/m2 IV)
97300|NCT03425643|Biological|Pembrolizumab|200 mg by IV infusion every 3 weeks (Q3W), given on cycle day 1.
97301|NCT03425643|Drug|Placebo|Normal saline by IV infusion Q3W, given on cycle day 1.
97302|NCT03425643|Drug|Cisplatin|75 mg/m^2 by IV infusion Q3W, given on cycle day 1.
97303|NCT03425643|Drug|Gemcitabine|1000 mg/m^2 by IV infusion Q3W, given on cycle days 1 and 8. Given only to participants with squamous NSCLC.
97304|NCT03425643|Drug|Pemetrexed|500 mg/m^2 by IV infusion Q3W, given on cycle day 1. Given only to participants with nonsquamous NSCLC.
97305|NCT03425630|Dietary Supplement|Argicolina|8 weeks
97306|NCT03425630|Dietary Supplement|Normolip|8 weeks
97307|NCT03425617|Drug|Tiotropium + Olodaterol|tiotropium 5 mcg plus olodaterol 5 mcg via Respimat® single dose
97308|NCT03425617|Other|PLACEBO|PLACEBO via Respimat® single dose
97309|NCT03425604|Procedure|Intrauterine insemination|
97310|NCT03425591|Drug|Ibrutinib|Participants in this observational study with confirmed diagnosis of CLL and MCL receiving ibrutinib in routine clinical practice settings will be observed for 5 years.
97311|NCT03425578|Dietary Supplement|MSG|150 mg/kg body mass monosodium glutamate (MSG).
97312|NCT03425578|Dietary Supplement|CHO|75g CHO (i.e. dextrose)
97313|NCT03425578|Dietary Supplement|Placebo A|A non-caloric placebo composed of table salt (NaCl) and sucralose (Splenda).
97314|NCT03425578|Dietary Supplement|Placebo B|A non-caloric placebo composed of flavoured water.
97315|NCT03425565|Drug|Pembrolizumab|3 weekly cycles of Pembrolizumab administered by IV
97316|NCT03425552|Drug|Paliperidone|Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)
97317|NCT03425552|Drug|Paliperidone|Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension
97318|NCT03425539|Drug|Lucerastat|Hard gelatin capsules containing 250 mg of lucerastat and inactive excipients; 1000 mg (4 capsules) b.i.d.; dose adjusted for renal function.
97319|NCT03425539|Drug|Placebo|Placebo capsules are identical in appearance to the lucerastat capsules, and contain inactive excipients; 4 capsules b.i.d.; dose adjusted for renal function.
97320|NCT03425526|Biological|Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes|Given IV
97321|NCT03425513|Diagnostic Test|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg and anti-HBc antibodies).
97322|NCT03425513|Other|Questionnaire|Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
97323|NCT03425500|Procedure|Bridging Rotator Cuff Reconstruction|Bridging Rotator Cuff Reconstruction of massive rotator cuff tear using a GRAFTJACKET™ allograft
97324|NCT03425500|Procedure|Superior Capsular Reconstruction|Superior Capsular Reconstruction of massive rotator cuff tear
97326|NCT03425487|Behavioral|Mindfulness based Intervention|MBSR consists of 8 weekly groupal sessions of 150 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months
97327|NCT03425487|Behavioral|Compassion based Intervention|ABCT consists of 8 weekly groupal sessions of 120 minutes/session (10-16 people). Written material and sound recordings will be offered as support elements. The estimated duration of the program is two months.
97328|NCT03425487|Other|TAU|Usual specialized treatment in mental health (psychological or/and psychiatric)
97329|NCT03425474|Drug|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary
97330|NCT03425474|Drug|Propofol|Initial dose plus supplemental doses as necessary
97331|NCT03425461|Biological|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
97332|NCT03425461|Biological|Ipilimumab|Given IV
97333|NCT03425461|Other|Laboratory Biomarker Analysis|Correlative studies
97334|NCT03425461|Biological|Nivolumab|Given IV
97335|NCT03425461|Other|Pharmacological Study|Correlative studies
97336|NCT03425448|Drug|Heparin|Heparin hemodialysis catheter lock solution
97337|NCT03425448|Device|Neutrolin|Neutrolin hemodialysis catheter lock
97338|NCT03425435|Other|QoL and developed questionnaires for healthcare research|Questionnaires
97339|NCT03425422|Device|VITARIA System|Chronic stimulation of the right cervical vagus nerve
97340|NCT03425409|Device|Integra Pulse Portable- Continuous flow|4 liters per minute oxygen flow
97341|NCT03425409|Device|Integra Pulse Portable- Pneumatic pulsed flow|Oxygen flow determined by test device
97342|NCT03425396|Drug|Omadacycline; po tablets|Oral Omadacycline
97343|NCT03425396|Drug|Nitrofurantoin, po capsules|Oral Nitrofurantoin
97344|NCT03425383|Diagnostic Test|FMD and c-IMT|"The diameter of the target artery (right brachial artery) will be measured from two- dimensional ultrasound images, with a 70 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA).~c-IMT will be assessed by M-mode ultrasonography via a vivid 7 MHz linear array transducer and a standard 128XP/10 system (Acuson, Mountain View, California, USA) with participants in the supine position."
97345|NCT03425370|Procedure|Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.|Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
97346|NCT03425357|Other|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
97347|NCT03425344|Diagnostic Test|Diagnostic|No traditionally intervention will be given but participants will be exposed to shoulder- MRI, ultrasound and sonoelastography..
97348|NCT03425331|Drug|Ipilimumab|Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
97349|NCT03425331|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells
97350|NCT03425318|Device|CNAP|Application of CNAP in patients with ARDS
97351|NCT03425292|Drug|Temozolomide|concomitant and 5-day adjuvant temozolomide
97352|NCT03425292|Radiation|conformal brain radiation therapy|standard radiation therapy for newly diagnosed glioblastoma
97353|NCT03425292|Drug|Nivolumab|nivolumab 300 mg IV every 2 weeks
97354|NCT03425292|Drug|Ipilimumab|ipilimumab 1 mg/kg IV every 6 weeks
97355|NCT03425292|Drug|Bevacizumab|bevacizumab 5 mg/kg IV every 2 weeks
97356|NCT03425292|Drug|Metronomic Temozolomide|50 mg/m^2 once daily
97357|NCT03425279|Biological|CAB-AXL-ADC|Conditionally active biologic anti-AXL antibody drug conjugate
97358|NCT03425266|Other|Interactive decision support tool|PainApp 1) assesses patient treatment goals (a structured values clarification exercise) and preferences, including decision making and communication preferences; 2) presents structured educational modules tailored to the user's stated goals and preferences; 3) presents educational information addressing identified gaps in care and communication; 4) assesses pain, pain interference, function, and other clinical factors; 5) generates succinct individualized summaries of patient treatment preferences and medical history, tailored to different clinical settings; 6) generates a personalized report for the patient, based on their goals and interests; 7) transmits the clinical summary to the patient and their provider(s), with patient permission.
97361|NCT03425240|Device|Nerve Stimulation|Acute placement of electrodes on the pelvic plexus to apply electrostimulation during open radical prostatectomy.
97362|NCT03425227|Other|FRED EXERGAME|biofeedback with physiological constants as follows: systolic blood pressure, diastolic blood pressure, heart rate and blood oxygen saturation
97363|NCT03425214|Other|fMRI|"Session will be of about 45 minutes. The reward system will be explore using an experimental task during functional Magnetic Resonance Imaging (fMRI). The name of this task is themonetary incentive delay task."
97364|NCT03425214|Other|Videopolysomnography|Video polysomnography will be perform in the sleep center during one night if patient did not have vPSG for 1 year.
97365|NCT03425214|Other|NC (narcolepsy-cataplexy)|The investigators hypothesize that NC patients with RBD have a more severe dysfunction of the reward system (hypoactivation of the meso-cortico-limbic pathway) than patients without RBD.
97366|NCT03425201|Drug|Niraparib plus Cabozantinib|Non-randomized trial will comprise 2 stages. A dose escalation phase will characterize the safety, tolerability, DLTs and MTD, of oral niraparib plus cabozantinib in patients with urothelial or renal cell carcinoma. Subsequently, the phase II will further evaluate the safety and antitumor activity of this combination in patients with urothelial carcinoma.
97367|NCT03425175|Other|Audio-recoring|Recording of audio through microphone carried bu surgeon and assistant surgeon
97368|NCT03425162|Drug|Morphine Sulfate|patient-controlled analgesia (PCA) morphine
97373|NCT03425136|Other|Systems Analysis and Improvement Approach (SAIA)|Five-step systems analysis and iterative improvement cycles applied by district maternal and child health supervisors to subordinate health facilities providing prevention of mother-to-child HIV transmission services at the facility level.
97374|NCT03425123|Other|Regenerative Endodontic Procedure (REP)|Regenerative Endodontic Procedure (REP) involves disinfection of the root canal with the use of acombination of three antibiotics including ciprofloxacin, metronidazole, minocycline. At the second visit, the patient is evaluated for resolution of signs or symptoms of an acute infection and if none then bleeding is induced, the site covered with a plug and the patient is evaluated at follow up.
97375|NCT03425110|Other|Modified Ketogenic Diet|
97376|NCT03425097|Drug|Fexofenadine|Fexofenadine 180 mg in the morning
97377|NCT03425097|Drug|Placebo - Cap|Placebo cap in the morning
97378|NCT03425084|Drug|Morphine|The study was designed as an open, non-controlled drug trial, with scientists and participants blinded to the patients OCT1 status. Morphine will be given as a single dosis (0,15 mg/kg) at the end of the Surgery and later as boluses of 0,04mg/kg administrated by patient-controlled analgesia, (PCA). Blood samples with drug concentrations will be used to determine a difference in morphine AUC due to the patients OCT1 status. Questionnaire answers will be used to determine the effect of morphine due to the patients OCT1 status
97379|NCT03425045|Procedure|Repetitive Transcranial Magnetic Stimulation|Patients randomised in Arm 1 will receive stimulation of the dorsolateral prefrontal cortex (frequency 25 Hz; 300 pulses; 80% resting motor threshold=RMT) and primary auditory cortex on both sides (1 Hz; 1000 pulses; 110% RMT) will be stimulated in patients in rTMS stimulation group for 5 consecutive days. No medication therapy will be provided for patients in this arm.
97380|NCT03425045|Procedure|Sham stimulation|Sham stimulation will be performed in patients randomised in Arm 2 of the study for 5 consecutive days. No medication therapy will be provided for patients in this arm.
97381|NCT03425045|Drug|Ginkgo Biloba Extract|Patients randomised in Arm 3 of the study will receive medication therapy with Ginkgo biloba extract EGb 761 once a day for 6 months.
97382|NCT03425032|Device|CT scanner|Regular CT imaging of the abdomen and pelvis
97383|NCT03425019|Device|Soterix 1x1 tDCS mini-CT Stimulator device|Transcranial Direct Current Stimulation (tDCS) involves the application of weak direct electric current to the head in a noninvasive and painless manner. tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device. Participants will self-administer tDCS at their home or a private room for two weeks (Mondays-Fridays) under real-time supervision by the research staff.
97384|NCT03425006|Drug|Itacitinib|a JAK 1 selective small molecule inhibitor
97385|NCT03425006|Biological|Pembrolizumab|a highly selective humanized monoclonal antibody (mAb)
97386|NCT03424993|Other|Dietary Sodium Restriction|A registered dietician will counsel participants to reduce daily habitual dietary salt intake below 2000mg over 4 weeks
97387|NCT03424993|Other|Control|Participants will consume their routine habitual dietary sodium intake > 3400mg per day with regular pre determined check in phone calls from a registered dietician.
97388|NCT03424980|Combination Product|Tyrosine kinase inhibitors|Tyrosine kinase inhibitors only or combinations therapies of tyrosine kinase inhibitors
97389|NCT03424967|Behavioral|ABM|Participants are trained with a dot-probe task including angry-neutral faces. In 80% of trials the probe appears in place of the neutral face, and in 20% of trials in place of the angry face.
97390|NCT03424954|Behavioral|EpxOstomy|A 30-day post-operative automated text-messaging intervention for home monitoring of ileostomy output
97393|NCT03424928|Drug|Pomalidomide 4 MG Oral Capsule|per os,capsule,4mg,1 capsule per period
97394|NCT03424928|Drug|Pomalidomide 4 MG Oral Capsule-Pomalyst|per os,capsule,4mg,1 capsule per period
97395|NCT03424915|Behavioral|Harvard Health Professionals survey|Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.
97396|NCT03424915|Other|Blood draw|Participant will provide a blood sample
97397|NCT03424915|Other|CPET Procedures|CPET with 12-lead ECG
97398|NCT03424915|Other|stool sample|Research stool sample (within ±1 week of surgery), if possible
97399|NCT03424902|Diagnostic Test|cardiac computed tomography and cardiac catheterization|assesment of certain predictors with CT and fluroscopy for paravalvular leakage
97400|NCT03424889|Drug|Xylometazoline|Nasal administration of Xylometazoline
97401|NCT03424889|Drug|Saline|Nasal administration of 0.9% Saline
97402|NCT03424876|Drug|Imatinib 400mg|exposure 400 mg/day or 600mg/day,
97403|NCT03424876|Drug|Sunitinib 37.5Mg Oral Capsule|exposure 37.5 mg/day, continuous taking, or 50 mg/day (4/2)
97404|NCT03424863|Other|Moderate Intensity Muscle Strengthening|1 session of lower extremity muscle strengthening at moderate intensity (60% of estimated maximal muscle strength). The exercise is performed on one single day.
97405|NCT03424850|Radiation|HDR brachytherapy|"-Dose constraints are as follows:~Bladder and rectum: V65 < 1 cc~Urethra: V105 < 1 cc~V125: 0%"
97406|NCT03424837|Behavioral|ASCENT|"ASCENT includes the following components:~Survivorship care plan created through the ASCENT tool~Online tool which assesses health care needs and facilitates receipt of care~A national-level navigator who helps the participant to access support services~Periodic reminders for the participant to pursue recommended survivorship care"
97407|NCT03424824|Drug|BP1.3656 low dose|Tablet, once daily oral administration at the low dose
97408|NCT03424824|Drug|BP1.3656 intermediate dose|Tablet, once daily oral administration at the intermediate dose
97409|NCT03424824|Drug|Placebo|Tablet, once daily oral administration
97410|NCT03424811|Device|Mobile Health Intervention|Mobile health intervention to promote healthy eating.
97411|NCT03424798|Device|Inspiwave|patients are monitored with the Inspiwave device. A low dose inert tracer gas is added to the inspred air
97412|NCT03424785|Other|drug, stent, surgical treatment|drug, stent, surgical treatment
97414|NCT03424759|Drug|AZD9291|Patients will be treated 80 mg/day of AZD9291 orally (1 cycle for 21 days).
97415|NCT03424746|Drug|disodium EDTA|Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
97416|NCT03424733|Drug|Plegridy|Self injection into area of high adipose content. Injections include 63 and 94 microgram titration doses, and the full 125 microgram dose
97417|NCT03424733|Drug|Prednisone|Take one 20 milligram prednisone tablet four to five hours prior to injections two through six of the full 125 microgram Plegridy dose.
97418|NCT03424733|Drug|Tylenol Pill|Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
97419|NCT03424720|Device|PLE and BIS|Investigators attach the PLE and BIS sensors on the forehead of the patients undergoing facial nerve integrity monitoring during general anesthesia using total intravenous anesthetics
97420|NCT03424707|Drug|DW340(pelubiprofen/eperisone)|DW340
97421|NCT03424707|Drug|Pelubi(pelubiprofen)|pelubiprofen
97422|NCT03424707|Drug|Placebo Oral Tablet|Placebo Oral Tablet
97423|NCT03424694|Radiation|HDR brachytherapy as monotherapy|
97424|NCT03424681|Drug|Modafinil|Modafinil 300 mg by mouth daily
97425|NCT03424681|Other|Placebo|Placebo
97426|NCT03424668|Behavioral|diet|lifestyle factors
97427|NCT03424655|Procedure|Twisted File Adaptive|Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.
97428|NCT03424655|Procedure|Balance Force|Flex-R files sizes 15-45 taper .02 were used according to the technique
97429|NCT03424655|Procedure|WaveOne|"WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL."
97430|NCT03424655|Procedure|Reciproc technique|Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
97431|NCT03424642|Behavioral|Interactive 4D-ultrasound examination|Randomized controlled trial
97432|NCT03424629|Biological|Low-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
97433|NCT03424629|Biological|High-dose UC-MSCs|Participants will receive 6 times UC-MSCs infusions (each time 3×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks（week 0,1,2,3）, then the last two times will be given once every two weeks（week 5,7）.
97434|NCT03424629|Drug|Methotrexate|Participants will be administered Methotrexate (each time 5-25mg) orally once a week for successive 16 weeks(week 0-15).
97435|NCT03424616|Device|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations.
97436|NCT03424603|Drug|STRO-001|intravenous antibody drug conjugate
97437|NCT03424590|Device|Clearblue Connected Ovulation Test System|Urinary LH test to predict ovulation
97438|NCT03424577|Drug|H3B-6527|Oral capsule
97439|NCT03424564|Drug|Perampanel|Oral Tablet
97440|NCT03424551|Device|vibrator|Local or whole body vibration was applied at six different frequencies
97441|NCT03424538|Other|Neurorehabilitation|5-week-long intervention, administered daily, targeted postural instability, balance and mobility using at-limit intensity sensorimotor and visuomotor agility training
97442|NCT03424538|Other|Physiotherapy|5-week-long intervention, physiotherapy, stretching, walking preparation, strengthening
97443|NCT03424525|Drug|11C-Trimethoprim|[11C]TMP is a radiolabeled imaging agent for positron emission tomography (PET/CT). Most relevant to this protocol, it is for imaging bacterial infection in human subjects. TMP is well-known, safe, broad-spectrum, synthetic, small molecule antibiotic that has been used clinically for over 50 years for the treatment of acute bacterial infection and has been combined with sulfa-based antibiotics (Bactrim/Septra) for bacterial infection prophylaxis especially in the lung and bladder.
97444|NCT03424512|Behavioral|Group Metacognitive Therapy|Group MCT is based on a manualised protocol and is structured in the following way. In session 1, idiosyncratic case formulations based on the generic metacognitive model are developed for each participant. Socialization helps patients to understand that worry/rumination and unhelpful coping strategies are maintaining emotional distress. Patients are then introduced to, and practice well established treatment techniques to modify negative beliefs about uncontrollability of rumination/worry. Later sessions address relapse prevention and involves modifying remaining use of the 'cognitive attentional syndrome', reviewing residual conviction in positive and negative beliefs and consolidating and strengthening alternative ways of responding to negative thoughts.
97445|NCT03424499|Procedure|Single-use catheter|Each urethral catheterization will be done with a new sterile catheter in a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
97446|NCT03424499|Procedure|Reused catheter|Each catheter is programmed to last 1 week. Evaluation will last a period of 8 weeks. Frequency of urethral catheterization will depend of the conditions of each patient (from 3-5 per day). after catheterization, PVC catheter was washed with water and soap, and stored in a container with 0.5% benzalkonium chloride. Each catheter was programmed to last a week. Patients and parents were instructed to use clean technique by hand washing with water and soup, and penis/vulva cleansing with antiseptic wipes. Researchers reinforced the intermittent catheterization technique before the trial.
97492|NCT03424122|Drug|Rituximab|Rituximab administered intravenously at the protocol-defined dose regimen according to treatment group.
97447|NCT03424499|Diagnostic Test|Urine culture|A midstream urine sample will be obtained using sterile catheterization for urine culture performed by health provider. Urine cultures will be done in days 0, 7, 14, 28, 42 and 56.
97448|NCT03424486|Other|Questionnaires|Evaluation of the prevalence of anxiety, depression and quality of life
97449|NCT03424473|Drug|Tucatinib|
97450|NCT03424460|Biological|Haemostasis tests|Venipuncture of 30 milliliters of blood. The following tests will be performed: thromboelastography (TEG®), standard tests of coagulation, genetic thrombophilia, lupus anticoagulant, fibrinolysis markers (Alpha-2-antiplasmin, amidolytic activity, plasmin anti-plasmin complexes, Plasminogen Activator Inhibitor-1 (PAI-1) antigen, plasminogen amydolytic activity), and a global test of fibrinolytic activity.
97451|NCT03424460|Biological|Monocytes and megacaryocytes culture and RNA extraction|Venipuncture of 60 milliliters of blood. Monocytes and megacaryocytes culture. RNA extraction from monocytes and megacaryocytes.
97452|NCT03424460|Genetic|RNA extraction|RNA extraction from liver tissue
97453|NCT03424447|Procedure|efferent limb stimulation|
97454|NCT03424434|Other|Survey diffusion|The study consists in a survey diffusion during several weeks by emailing each practitioner and resident and inviting them to participate to a questionnaire about occupational blood exposure. This survey is strictly anonymous. No identity data is required, only age, gender, function, surgical or medical specialty, work quota and hospital group they belong. This survey is diffused in four UHC (Lyon, Grenoble, Clermont-Ferrand and Saint-Etienne) in France.
97455|NCT03424421|Procedure|subscapular sling|semitendinosus subscapular sling procedure
97456|NCT03424408|Drug|Aspirin 81 mg|Healthy volunteers will receive 5 days of aspirin 81 mg daily. Following cessation of aspirin, daily blood samples will be collected for serum thromboxane B2 measurement
97457|NCT03424395|Other|Personalized dietary and wellness program|Single arm intervention containing three periods: (1) run-in (control), (2) personalized advice/counseling and meals, (3) personalized advice/counseling only
97458|NCT03424369|Procedure|Tympanoplasty|Tympanoplasty
97459|NCT03424356|Drug|Rocuronium Bromide|0.15 mg/kg rocuronium bromide
97460|NCT03424356|Drug|Saline Solution|1-2 ml saline solution
97461|NCT03424356|Drug|Fentanyl|1mcg/kg for induction
97462|NCT03424356|Drug|Propofol|2-3mg/kg for anaesthetic induction
97463|NCT03424356|Procedure|cystoscopy|patients will treated with this surgical procedure
97464|NCT03424343|Other|Questionnaire bundle|Questionnaires on identity formation and psychosocial functioning, assessed and reported at baseline, one year later, two years later, and five years later.
97465|NCT03424343|Other|Obtaining information from survivors' medical file|After obtaining informed consent, we will access the medical file of participants to obtain information on the diagnosis, time of diagnosis, treatment duration, type of treatment, and relapse (when applicable).
97466|NCT03424330|Device|ReX-C intervention|Patients receive medication by the ReX-C device
97467|NCT03424330|Other|Standard of Care|Patients receive medication as usual
97468|NCT03424317|Behavioral|Sodium intake reduction|Provide materials to reduce sodium intake and educate how to reduce sodium intake effectively
97469|NCT03424317|Behavioral|Exercise|Provides materials on exercise methods to reduce blood pressure and educates how to perform exercise effectively
97470|NCT03424304|Device|Excel V™ Laser With Green Genesis|Subject(s) will receive 3 to 5 treatments with a Cutera Excel V™ Laser
97471|NCT03424291|Drug|Apatinib plus chemoradiation|Apatinib 500 mg qd po Taxus + platinum or 5FU + platinum (drug dose reference to clinical) palliative radiotherapy dose ≥ 40Gy and radical radiotherapy dose (60-70Gy)
97472|NCT03424278|Other|Motor control exercises|Motor control exercises for the deep trunk muscles in patients with chronic low back pain is based on evidence of motor control dysfunction, including delayed onset of activity in the transversus abdomens and internal oblique abdominal muscles and segmental hypertrophy of the lumbar multifidus muscle.
97473|NCT03424278|Other|Resistance training exercises|A type of strength-building exercise program that requires the body muscle to exert a force against some form of resistance, such as weight, stretch bands, water, or immovable objects. Resistance exercise is a combination of static and dynamic contractions involving shortening and lengthening of skeletal muscles.
97474|NCT03424265|Dietary Supplement|EAA mixture|Dietary supplement intervention for 12-weeks
97475|NCT03424265|Dietary Supplement|Placebo (whey protein)|Dietary supplement intervention for 12-weeks
97476|NCT03424252|Drug|FDL169|Cystic Fibrosis Transmembrane Regulator (CFTR) corrector
97477|NCT03424239|Drug|Zoledronic Acid|5mg zoledronic acid
97478|NCT03424239|Dietary Supplement|Calcium citrate + vitamin D|Chewable 500mg calcium citrate with 500IU Vitamin D3
97479|NCT03424239|Dietary Supplement|Vitamin D3|1000IU Vitamin D3 gummy
97480|NCT03424226|Drug|Acetazolamide|a diuretic and commonly used medication for prevention and treatment of acute mountain sickness
97481|NCT03424213|Other|No interventions - retrospective data collection|No new patients will be consented to this study. Only retrospective data will be collected on prostatectomy specimens and correlated with health data
97482|NCT03424200|Behavioral|Routine care|Participants will receive routine care
97483|NCT03424200|Other|Coaching plus routine care|Participants will receive coaching plus routine care
97484|NCT03424187|Dietary Supplement|chickpea|"all three meals are isocaloric but different in the chickpea structure( physical form):~• Whole chickpea, flour chickpea, intact cell flour chickpea"
97485|NCT03424174|Device|Coated Total Knee Arthroplasty|Implantation coated Total Knee Arthroplasty
97486|NCT03424174|Device|Standard Total Knee Arthroplasty|Implantation StandardTotal Knee Arthroplasty
97487|NCT03424161|Device|Secret RF|Subjects may receive up to 4 treatments
97488|NCT03424148|Device|Excel V™ Laser & Micro-Lens Array Attach|Subjects will receive up to 6 laser treatments
97489|NCT03424135|Drug|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
97490|NCT03424135|Drug|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
97491|NCT03424122|Drug|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks followed by once weekly.
97493|NCT03424122|Drug|Bendamustine|Bendamustine administered intravenously on Days 1 and 2 of each cycle for up to 6 cycles.
97494|NCT03424122|Drug|Ibrutinib|Ibrutinib administered orally once daily.
97495|NCT03424109|Behavioral|healthcare service utilization in the six months following the ED visit|The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
97496|NCT03424070|Other|Shoulder Roll|The POGO score assesses the percent of the glottic opening that can be seen with and without the shoulder roll.
97497|NCT03424070|Other|No shoulder roll (placebo)|Placebo
97498|NCT03424057|Procedure|Asymmetric Primary Closure and Additional Skin Excision Technique|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method, but an advancement tissue flap was performed using additional skin excision, in order to reduce the dead-space volume.
97499|NCT03424057|Procedure|Standard Karydakis technique.|In this new technique, following total sinus excision, the excision defect was closed with the standard Karydakis method
97500|NCT03424044|Device|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The algorithm has 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to two Omnipod insulin pumps, one filled with insulin and one with glucagon.
97501|NCT03424044|Device|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod pump filled with insulin.
97502|NCT03424044|Device|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. The Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G5 sensor and sending delivery commands to one Omnipod insulin pump filled with insulin.
97503|NCT03424044|Drug|XeriSol glucagon|XeriSol glucagon is an investigational drug that is a stable, soluble liquid glucagon formulation that can be injected or administered through an insulin pump. XeriSol glucagon will be used to fill the Omnipod to deliver glucagon for the Artificial Pancreas Controller in Dual Hormone mode.
97504|NCT03424031|Procedure|Verticalization|To allow the verticalization of hemiplegic patients, we will use a device commonly used in rehabilitation: the standing (or standing) brand Thera Trainer . This device makes it possible to keep the patient standing despite the motor and postural deficits thanks to knee, buttocks and an anterior support for the upper limbs. Verticalization with this device requires the presence of one or two caregivers (including at least one re-educator), depending on the possibilities of participation of the patient.
97505|NCT03424018|Drug|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
97506|NCT03424005|Drug|Capecitabine|Capecitabine will be administered 1250 mg/m2 orally twice daily on Days 1−14, of each 21 day cycle
97507|NCT03424005|Drug|Atezolizumab|"For Atezolizumab + SGN-LIV1A, Bevacizumab, Capecitabine, RO6874281 or Chemo arms: Atezolizumab will be administered by IV, 1200 mg, on Day 1 of each 21-day cycle.~For Atezolizumab + Bevacizumab+ Cobimetinib, + Selicrelumab + Bevacizumab, or + Ipatasertib arms: Atezolizumab will be administered by IV, 840 mg on Days 1 and 15, of each 28 day cycle"
97508|NCT03424005|Drug|Ipatasertib|Ipatasertib will be administered by mouth 400 mg once a day, on Day 1-21 of each 28 day cycle
97509|NCT03424005|Drug|SGN-LIV1A|SGN-LIV1A will be administered by IV, 2.5 mg/kg (maximum calculated dose 250 mg), on Day 1 of each 21 day cycle
97510|NCT03424005|Drug|Bevacizumab|When given as a doublet combination, Bevacizumab will be administered by IV, 15 mg/kg, on Day 1 of each 21 day cycle. When given as a triplet combination, Bevacizumab will be administered by IV, 10 mg/kg, on Days 1 and 15 of each 28 day cycle.
97511|NCT03424005|Drug|Cobimetinib|Cobimetinib will be administered orally, once per day, 60 mg, on Days 1-21 of a 28-day cycle.
97512|NCT03424005|Drug|Chemotherapy (Gemcitabine + Carboplatin or Eribulin)|"Gemcitabine will be administered by IV, 1000 mg/m2, along with Carboplatin, by IV, AUC 2, on Days 1 and 8 of each 21 day cycle~Or~Eribulin will be administered by IV, 1.4 mg/m2 on days 1 and 8 of each 21 day cycle"
97513|NCT03424005|Drug|RO6874281|RO6874281 will be administered at a fixed dose of 10 mg IV on Day 1 of each 21 day cycle.
97514|NCT03424005|Drug|Selicrelumab|Selicrelumab will be administered by SC injection at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (cycle = 28 days).
97515|NCT03423992|Biological|chimeric antigen receptor T cells|chimeric antigen receptor T cells expressing receptors specific for EGFRvIII, IL13Rα2, Her-2, CD133, EphA2, GD2, respectively
97516|NCT03423979|Device|Optilume™ BPH Prostatic DCB Dilation Catheter|BPH Prostatic DCB treatment - The Optilume BPH Prostatic DCB Dilation Catheter System should be prepared per the Instructions for Use (IFU).
97517|NCT03423979|Drug|Paclitaxel|paclitaxel will release to adjacent tissue after the balloon inflated in the urethra
97518|NCT03423966|Device|Smartphone Pedometer App|Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
97519|NCT03423953|Device|Comprehensive Nano|Patients requiring the Comprehensive Nano shoulder system.
97724|NCT03422458|Device|Alveolar Ridge Preservation|Insertion of a bone substitute material (BioOss Collagen) within the bony envelope at least to the level of the palatal/ lingual bone plate. Adaptation of a collagen matrix (Mucograft Seal) to the soft tissue borders.
97520|NCT03423940|Behavioral|Functional communication training|"During functional communication training (FCT), the social consequence (e.g., attention, toys, breaks from instructions) that heretofore reinforced destructive behavior (i.e., as determined through a functional analysis) is delivered contingent on an appropriate communication response, while destructive behavior is on extinction (i.e., reinforcers are no longer provided). For example, if a functional analysis shows that aggression is reinforced by escape from demands, FCT would typically involve (a) teaching the child to access breaks from demands via a functional communication response (FCR; e.g., saying, Break, please) and (b) placing destructive behavior on extinction (i.e., continuing with scheduled demands independent of destructive behavior)."
97521|NCT03423940|Behavioral|RaC-enhanced functional communication training|We will use the quantitative predictions of Resurgence as Choice (RaC) Theory to tailor a set of reinforcement-schedule thinning steps for each subject. This quantitative prediction will allow for dynamic decisions regarding how to conduct upcoming treatment sessions, as based on both the subject's recent response to treatment and the RaC equation.
97522|NCT03423927|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 6 monthly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, selfrespect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
97523|NCT03423914|Behavioral|Expressive writing|The emotional or expressive writing therapy developed by James Pennebaker has been used as a method of self-understanding in people with high levels of stress, chronic diseases, sexual and physical abuse, natural disasters and job loss, among others. Expressive writing allows and implies revealing the deepest thoughts and feelings of the person about a stressful or traumatic event in life translate emotions into words, and with that, reduce mental stress (decrease in levels of depression, stress and anxiety), strengthen self-esteem and even strengthen the immune system
97524|NCT03423914|Other|Only Writing|Participants write about knowledge related to infant care during four days
97525|NCT03423901|Other|Blood sampling|Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
97526|NCT03423888|Device|high-flow nasal cannula oxygen therapy (HNFC)|"Set up of high-flow nasal oxygen for patient with dyspnea for a respiratory disease without possibility of curative care. Patients who require a treatment by oxygen are included.~After 7 days of treatment, acceptability is evaluated by the duration of use of HNFC."
97527|NCT03423875|Diagnostic Test|PrEDICT game score|PrEDICT game score will be shared with the emergency physicians and health care professionals
97528|NCT03423862|Other|Mixed Meal Tolerance Test|"After a 10-hour overnight fast (not eating or drinking anything except water), participants will complete a mixed meal tolerance test (MMTT):~This involves participants drinking a Boost drink, like a milkshake, which will raise participants' blood sugar.~The amount of Boost will be based on participants body weight, up to a maximum of 360 mL or about 1 ½ cups, and should be consumed within 5 minutes.~An IV will be placed in participants arm and blood will be drawn from it. Blood will be drawn from the IV before and then 6 times over the next 2 hours after participants drink the Boost."
97529|NCT03423849|Drug|Vinorelbine|25mg/m2,day 1 and day 8, every 3 weeks
97530|NCT03423849|Drug|Gemcitabine|1250mg/m2,day 1 and day 8, every 3 weeks
97531|NCT03423849|Drug|Cisplatin|25mg/m2,day 1,every 3 weeks
97532|NCT03423849|Drug|Capecitabine|1250mg/m2,day 1 to day 14, every 3 weeks
97533|NCT03423823|Drug|Ziv-Aflibercept 25 MG/ML [Zaltrap]|Anti-VEGF injection
97534|NCT03423823|Drug|Ranibizumab|Anti-VEGF standard of care injection
97535|NCT03423810|Drug|Hydralazine|Participants will be asked to take pills two times per day for 6 weeks. This is a dose increasing study with potential doses ranging from 5 mg two times per day to 50 mg two times per day.
97536|NCT03423797|Drug|25% AgNO3 solution followed by 5% NaF|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF: 11.6mg (F-)/0.5ml (max dose).
97537|NCT03423797|Drug|25% AgNO3 solution followed by 5% NaF with fTCP|Dosage: 25% AgNO3 solution 7.9mg(Ag+)/0.05ml (max dose), 5% NaF with fTCP: 11.6mg (F-)/0.5ml (max dose).
97538|NCT03423784|Device|HA BPX V3.3|medical device containing HA
97539|NCT03423784|Other|Dentinox-Gel N|Anaesthetic gel
97540|NCT03423771|Drug|NPF-08|Drug: NPF-08 Arms: NPF-08 oral sulfate solution
97541|NCT03423758|Other|Blood sample|Blood sample
97542|NCT03423732|Drug|CardioCell|"Patients in the N-O CLI trial will receive a full dose of IMP three times during the trial: at baseline, after 45 days post index administration and after 3 months post index administration.~IMP will be administered into femoral artery and intramuscularly with 50:50 proportion. The intramuscularly dose will be administered into muscles above and below the knee in 50:50 proportion."
97543|NCT03423732|Drug|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
97544|NCT03423719|Dietary Supplement|Fiit-ns®|Fiit-ns® is a blend of polyphenol-rich extracts from grapefruit, grape, green tea, guarana and black carrot. It also provides Vitamin B3. Daily dosage is 900 mg in two 450 mg-capsules for 16 weeks.
97545|NCT03423719|Dietary Supplement|Placebo|Placebo product is 100% maltodextrin. Daily dosage is 900 mg in two 450 mg-capsules of identical appearance than the supplement capsule for 16 weeks.
97546|NCT03423706|Procedure|the new model of haplo-HSCT for r/r B-ALL|take advantage of high-dose CTX、CD19-CART、donor CD34+HSC and Tregs to create a new model of haplo-HSCT for the patients in r/r B-ALL,to improve the quality of HSCT.
97547|NCT03423693|Other|No any intervention|No any intervention is applied to any groups in this study
97548|NCT03423680|Drug|Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
97725|NCT03422445|Drug|Apatinib|Apatinib：500mg/d，qd，po，d1-28
97726|NCT03422445|Drug|Temozolomide|Temozolomide：300mg/d，qd，po，d1-5
97549|NCT03423680|Drug|Placebo of Abilify 2, 5, 10, 15mg (Tablet)|Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
97550|NCT03423667|Drug|N-acetylcysteine|N-acetylcysteine (1200 mg) administered twice a day during 5 days
97551|NCT03423667|Drug|Lactose powder|Placebo comparator.
97552|NCT03423654|Other|Spatial Training|Spatial Training using a 5x5 grid
97553|NCT03423654|Other|Letter number matching|Letter number matching
97554|NCT03423641|Drug|Direct Acting Antivirals|The time period during which a patient is dispensed the medication and for up to 180 days after initiation of the medication.
97555|NCT03423628|Radiation|Radiation Therapy|"Arm A: 35 Gy of Intensity-modulated radiation therapy (IMRT) administered at daily fractions of 3.5 Gy over 10 fractions (2 weeks) Arm B: 30 Gy of whole brain radiation therapy (WBRT) or partial brain radiation therapy (PBRT) administered at daily fractions of 3 Gy over 10 fractions (2 weeks).~Arm C: 60 Gy of intensity-modulated radiation therapy (IMRT) administered at daily fractions of 2 Gy over 30 fractions (6 weeks)"
97556|NCT03423628|Drug|AZD1390|"AZD1390 Administered in 3 Cycles:~Cycle 0: 1 dose prior to Radiation Therapy Cycle 1: Intermittent or continuous dosing during Radiation Therapy (except for first 2 cohorts of Arm A) Cycle 2: 2 weeks adjuvant treatment after Radiation Therapy"
97557|NCT03423615|Behavioral|Comprehensive Health & Hygiene Improvement Program (CHHIP)|CHHIP is an intense, multi-component holistic school health program based on the WHO Health Promoting School framework and designed for implementation by lay fieldworkers.
97558|NCT03423602|Device|PerQseal®|Large hole closure system
97559|NCT03423589|Dietary Supplement|VSL#3|VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.
97560|NCT03423576|Behavioral|comprehensive patient-centered outpatient health service with multiple components|Individualized multi-component education and counselling program coordinated by a case Manager.
97561|NCT03423563|Device|Flexible fiberoptic bronchoscopy|Flexible fiberoptic bronchoscopy versus flexible intubation video endoscope regarding intubation time in obese patients
97562|NCT03423563|Device|Fexible intubation video endoscopy|Fexible intubation video endoscopy
97563|NCT03423537|Drug|hCG|the addition of hCG (Pregnyl®, MSD Greece) will begin with the administration of gonadotrophin at a dose of 100 IU per day, administered subcutaneously, and will continue until the administration of hCG for follicular maturation.
97564|NCT03423537|Drug|Placebo|100IU per day containing N/S 0.9% will be injected
97565|NCT03423524|Device|Micropure 1.2.3.|"Implantation of intraocular lens (IOL). Name: MicroPure 1.2.3. It is a monofocal intraocular lens consisting of hydrophobic acrylic material. One IOL per eye will be implanted"
97566|NCT03423511|Device|MiStent II coronary artery stent|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
97567|NCT03423511|Device|Xience or Promus coronary artery stents|Implantation of a coronary stent patient with stable and unstable coronary artery disease including non-ST-Elevated Myocardial Infarction
97568|NCT03423498|Other|toe-spread-out exercise|The therapeutic intervention lasted 14 days and focused on doing the TSO exercise. This exercise was performed unilaterally under the supervision of a qualified physiotherapist. The starting position of the TSO exercise was the sitting position with the knee joint and hip bent at 90 degrees. The exercise consisted of 3 consecutive phases: dorsiflexion of the toes keeping the metatarsal heads and the heel on the ground, moving the fifth toe down and in a lateral direction, moving the big toe down and abduction. The final position needs to be maintained for 5 seconds. The whole sequence was repeated 200 times a day.
97569|NCT03423485|Device|CG-100 Intraluminal Bypass Device|Intended to reduce contact of fecal content with an anastomotic site , following colorectal surgery.
97570|NCT03423472|Behavioral|Orange Fleshed Sweet Potato (OFSP) agriculture promotion and nutrition education on vitamin A intake|Support to farmers to grow and store OFSP in the form of agricultural extension, community based trainings and supplies, while simultaneously increasing community demand for OFSP through community-based Healthy Living Clubs. The Clubs promote OFSP, provide nutrition education, and conduct community mobilization events and social marketing of OFSP and OFSP-based processed products. Special emphasis is on women and children < 2y; especially diet diversity and vitamin A intake.
97571|NCT03423472|Behavioral|Healthy Baby Toolkit|The toolkit consists of a demarcated bowl, a slotted spoon, and a counseling card. The demarcations on the bowl guide caregivers on age-specific meal volume and frequency. The slotted spoon promotes thicker food consistency - and therefore nutrient density - by cuing caregivers when food drips through the slots. The counseling card relies on images rather than text to reinforce messages of the previous two instruments, promote dietary diversity, and promote hygienic food preparation.
97572|NCT03423472|Behavioral|Standart of care|Government standard of care for nutrition education through the Health Development Army
97573|NCT03423459|Device|TAVR|Transcatheter Aortic Valve Replacement
97574|NCT03423446|Drug|Telotristat Ethyl|Telotristat ethyl (TE) 250 mg (1 x 250-mg tablet), single dose
97575|NCT03423433|Behavioral|Heel raise intervention|A daily heel-raise programme for ten weeks to determine any chronic effects of heel raises on the previously mentioned variables.
97576|NCT03423407|Device|Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|FDA approved scanner
97672|NCT03422783|Biological|Biomarkers|Some biomarkers of inflammation and endogenous opioids are associated with post-operative pain. Blood samples will be withdrawn at D0 before surgery starts, D1 (H24) and D2 (H48) after surgery to see if they correlate with NOL changes after the stimulus described in intervention 1 above
97727|NCT03422432|Procedure|HIPEC|All HIPEC will be with Mitomycin C and given at a dose of 10mg/body surface area.
97728|NCT03422419|Drug|Heparin|The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.
97577|NCT03423394|Behavioral|Motivational Enhancement Therapy|The MET intervention will consist of three 45-90 minute telephone delivered sessions that will be staggered to occur 1 week, 1 month, and 2 months after the baseline assessment. The first MET session intervention will involve a counselor using motivational interviewing (MI) strategies to establish an empathic therapeutic relationship and focus learning about the PTSD symptoms the participant is experiencing and exploring ambivalence about seeking treatment services. MET sessions 2 and 3 will focus on identifying and responding to risk factors for dropping out of treatment (increases in ambivalence, avoidance behavior, concerns about stigma, life chaos), identifying and responding to barriers to participant's active engagement in treatment, and facilitating enrollment in alternate therapeutic resources if necessary.
97578|NCT03423394|Behavioral|Treatment as Usual|TAU will include a written referral list comprised of PTSD resources including information on in-person treatments, self-help, web-based and bibliotherapy options. At the completion of the study, participants in the TAU condition will be offered the MET intervention.
97579|NCT03423381|Other|Cereal product 1|Cereal products based on rye, barley, wheat, oat, and corn
97580|NCT03423381|Other|Cereal product 2|Cereal products based on rye, barley, wheat, oat, and corn
97581|NCT03423381|Other|Cereal product 3|Cereal products based on rye, barley, wheat, oat, and corn
97582|NCT03423381|Other|Cereal product 4|Cereal products based on rye, barley, wheat, oat, and corn
97583|NCT03423381|Other|Cereal product 5|Cereal products based on rye, barley, wheat, oat, and corn
97584|NCT03423381|Other|Control product|A cereal based product with low concentrations of df
97585|NCT03423368|Device|Libramed|Policaptil Gel Retard
97586|NCT03423368|Device|Placebo|Placebo-comparator
97587|NCT03423355|Drug|Dapagliflozin 10mg|10mg p.o. daily
97588|NCT03423355|Drug|Hydrochlorothiazide 25 mg|25mg p.o. daily
97589|NCT03423342|Dietary Supplement|nicotinamide riboside|nicotinamide riboside capsule
97590|NCT03423342|Drug|Placebo|matching placebo capsule
97591|NCT03423329|Drug|Brufen|Brufen Syrup
97592|NCT03423329|Drug|Cital|Cital Cyrup
97593|NCT03423329|Drug|Placebo for Brufen|Sansovit Syrup
97594|NCT03423316|Behavioral|Supervised exercise therapy|The therapy will be conducted three times each week for 12 weeks. Each session takes 1 hour, consisting of 5 minutes of warmup activities, 50 minutes of intermittent exercise, and 5 minutes of cool-down activities. Exercise consists of walking on a treadmill initiated at 2 mph and 0% grade, until claudication pain becomes moderately severe. After claudication pain subsides, the subject will restart the walk. At the end of the session, the total exercise duration will be recorded. After a patient is able to walk 8-10 minutes at the initial workload, the grade is increased by 1-2%, or the speed is increased by 0.5 mph as tolerated.
97595|NCT03423303|Diagnostic Test|Prostate cancer screening|Depending on each diagnostic test result the participants in the screening arm will undergo PSA-testing, 4Kscore determination, MRI, and MRI/US fusion biopsy only.
97596|NCT03423290|Device|FRED and FRED Jr|Flow Re-Direction Endoluminal Device
97597|NCT03423277|Device|Easy Stretch Toolkit|Study the use of novel intraoral tools for management of facial burns and other facial disorders
97598|NCT03423264|Drug|Gabapentin|"Gabapentin taken as follows:~Day 1 (evening): 600 mg Day 2 (morning): 600 mg Day 2 (evening): 600 mg Day 3 (morning): 600 mg Day 3 (evening): 900 mg Day 4 (morning): 900 mg Day 4 (evening): 900 mg Day 5 (morning): 900 mg Day 5 (noon): 900 mg Day 5 (evening): 900 mg"
97599|NCT03423238|Other|Exercise|Each exercise session lasts for 60 to 90 minutes and consists of 5-10 minutes of warm-up and cool-down activity; up to 30 minutes of aerobic exercise using a variety of modalities (e.g., walking laps on a track, cycle ergometry, treadmills, stair climbers); and 15-20 minutes of upper and lower body resistance exercises using Thera-Bands. An exercise physiologist creates an individualized plan
97600|NCT03423238|Behavioral|Health Education|Group education classes conducted by an exercise physiologist and/or dietitian are designed to provide support and general information on healthy lifestyle behaviors. Topics include risk factor control, diabetes, hypertension, lipids, medications, aerobic exercise, strength training and flexibility, weight control, reading food nutrition labels, eating out, holiday eating, intimacy, stress, relaxation, cardiac symptoms, and cardiac interventions.
97601|NCT03423238|Other|Exercise Compliance|Multiple behavioral management strategies to create a positive exercise environment and promote adherence and retention will be utilized. These include promptly contacting participants who miss a session, scheduling makeup sessions, and offering individual counseling sessions to discuss strategies to promote attendance and limit obstacles to participation.
97602|NCT03423238|Dietary Supplement|Calorie-Restricted Diet|Diet plans will provide a caloric deficit of 500 kcals per day. The lowest calorie level permitted will be 1,100 kcals for women and 1,200 kcals for men. The calorie distribution goal will be 15-20% from protein, <30% from fat, and 45-60% from carbohydrates. Participants will consume 2 meal replacements per day (Premier Protein shakes and bars); provided by the study)), along with one meal composed of traditional foods (500-750 kcals, low in fat, high in vegetables), and 1-3 snacks as needed (e.g., cereal bar, fruit, or vegetable, providing 100-150 kcals each). For the meal, patients will follow a weekly menu plan and recipes provided by the study. The food plan will be tailored to individual preferences and energy needs.
97603|NCT03423238|Behavioral|Behavioral Modification|During months 1-3, participants will attend weekly individual behavioral counseling sessions with the study registered dietitian (RD); individual sessions will be held twice per month during months 4-6. The sessions will focus on self-monitoring, portion control, mindful eating, coping with negative thoughts, eating at regular times, and stress management. The RD will review individual progress, solve problems, answer questions, and set weight loss goals. At the end of the 6-month weight loss intervention, the RD will meet with participants to devise a weight maintenance strategy, including sample meal plans.
97604|NCT03423238|Other|Weight-Loss Compliance|Participants will be asked to record their food and beverage intake in daily logs which will be reviewed weekly by the RD to verify compliance to the diet. Body weight will be measured weekly to ensure that participants are losing weight at an appropriate rate. If a participant is not meeting weight loss goals, energy intake will be modified accordingly to produce the desired rate of weight loss.
97605|NCT03423238|Other|Dietary Counseling|Participants have one meeting with the Rehab dietitian upon starting.
97721|NCT03422497|Other|Female sex|Male sex-as listed in the discharge abstract database
97606|NCT03423225|Drug|ADVAGRAF®|"Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~Duration of treatment The investigational product will be administered for 24 weeks."
97607|NCT03423212|Behavioral|Just Do You|Just Do You is an intervention designed to keep young adults connected to their professional behavioral health treatments. It is a brief two-module engagement program that utilizes a hybrid provider team of a licensed clinician and peer to increase young adult engagement in adult outpatient day programs (i.e., New York State Personalized Recovery Oriented Services). The first session consists of the following components: 1) Welcome; Group Guidelines, Purpose, 2) Discuss Recovery Principles; Narrative of Role Model; 3) Video of Celebrity Service User and Discussion, and 4) Recovery Goals (and role of services in that). The second session consists of: 1) What are services & how can they help? 2) Visual art exercise -- Cause of SMI and validation, 3) Maintaining my Medicaid Insurance, and 4) Discussion of Systemic Barriers.
97608|NCT03423212|Behavioral|Active Control|The active control condition will receive the PROS program that is standard in the agencies, and a two-session curriculum on maintaining healthy relationships, which is an identified issue for the population.
97609|NCT03423199|Drug|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
97610|NCT03423199|Drug|Placebo|Placebo, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
97611|NCT03423199|Drug|Tamoxifen|Tamoxifen, 20mg, orally once daily (continuously)
97612|NCT03423199|Drug|Goserelin|For pre/perimenopausal patients only: Goserelin, 3.6 mg, subcutaneously every 4 weeks; or 10.8 mg, subcutaneously every 12 weeks
97613|NCT03423186|Drug|SOBI003|Weekly i.v.infusion
97614|NCT03423173|Biological|TAK-003 (DENVax)|TDV subcutaneous injection
97615|NCT03423173|Biological|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
97616|NCT03423160|Other|None--observational|Observational study of behavior and electrical brain activity
97617|NCT03423147|Drug|2% chlorhexidine gluconate cloth|applied to their abdomen
97618|NCT03423147|Drug|4% Chlorhexidine gluconate vaginal scrub|applied as a vaginal cleanse in the operating room prior to cesarean section
97619|NCT03423134|Other|New adhesive strip|This is a strip made of a newly developed adhesive
97620|NCT03423121|Drug|Tauroursodeoxycholic Acid|Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
97621|NCT03423121|Drug|Placebo oral capsule|Participants will be given four capsules of the placebo twice daily.
97622|NCT03423108|Behavioral|G150|This group will receive 150 min/week of combined exercise training, structured and supervised.
97623|NCT03423108|Behavioral|G300|This group will receive 300 min/week of combined exercise training, structured and supervised.
97624|NCT03423095|Behavioral|Active Jaw Exercise with Relaxation|This is the control group that will complete exercises unrelated to the primary outcome measures.
97625|NCT03423095|Behavioral|Active Tongue Exercise|This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
97626|NCT03423095|Behavioral|Active Tongue Exercise + Mental Practice|This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
97627|NCT03423095|Behavioral|Mental Practice Tongue Exercise|This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
97628|NCT03423082|Drug|18F fluciclovine|Each subject will receive one IV dose of 18F fluciclovine for PET scanning
97629|NCT03423082|Device|18F fluciclovine PET|Each subject will undergo one 18F fluciclovine PET scan on a hybrid PET/MRI scanner
97630|NCT03423069|Dietary Supplement|Diet low in FODMAPs|A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.
97631|NCT03423069|Dietary Supplement|Specific dietary advice for IBS|Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
97632|NCT03423056|Other|Preoperative exercise program|Individualized aerobic training program developed by physical therapist using Karvonem's equation . It will programmed in 3 sessions/week (not in row) during 4 weeks. Each 50-minutes session will be organized in three phases: warm up, central and back to calm. The heart rate target will be prescribed between 50 to 70% of the maximum heart rate and will be carried on a treadmill or in a stationary bicycle.
97633|NCT03423043|Radiation|Low Dose CT Scan of the Wrist|A low dose CT scan will be obtained in patients with a distal radius fracture of the wrist.
97634|NCT03423030|Drug|PBTZ169 Formulation|PBTZ169 Formulation supplied as powder for oral solution
97635|NCT03423030|Drug|Placebo|matching placebo supplied as powder for oral solution
97636|NCT03423030|Drug|PBTZ169 NCP|PBTZ169 NCP supplied as powder for oral solution
97637|NCT03423017|Other|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life and one hospitalization of 24 hours between 6 and 10 months of life~General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs : first and second visit~Respiratory rate, respiratory signs, stridor : first and second visit~24h holter-ECG : first and second visit~24h impedance pH-metry : first visit~Nocturne polysomnography : 50% prone position, 50% supine : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram) : first and second visit~24 h gaz exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index : first and second visit"
97722|NCT03422484|Other|Detection and correction of medication error at hospital admission|Detection and correction of medication error at hospital admission
97638|NCT03423017|Other|Recording of data|"Recording during one hospitalization of 48 hours between birth and 2 months of life~General data: age, term of birth, birth weight, gender, diseases, weight and size at recording, cranial perimeter, food, drugs~Respiratory rate, respiratory signs, stridor~24h holter-ECG~24h impedance pH-metry~Nocturne polysomnography : 100% supine position : sleep analyze, obstructive apnea hypopnea index (OAHI), central apnea index (CAI), periodical breathing, micro arousals index, non-nutritive swallowing analyze,(mental region electromyogram)~24 h gas exchanges : mean, maximal PtcCO2 and % of time spent above 50 mmHg , SpO2 under 90%, 85% et 80% and desaturations index"
97639|NCT03423004|Procedure|Biopsy|the sample will be taken by superficial cutaneous biopsy in psoriasic patients
97640|NCT03422991|Other|Blood sampling and Quality of life questionnaire.|Blood sampling and Quality of life questionnaire.
97641|NCT03422978|Drug|Dexmedetomidine|Single dose dexmedetomidine administered over 60 seconds post-induction.
97642|NCT03422978|Drug|Normal saline|Single dose normal saline administered over 60 seconds post-induction.
97643|NCT03422965|Diagnostic Test|Optical Coherence Tomography Angiography|Optical Coherence Tomography Angiography images capture.
97644|NCT03422965|Diagnostic Test|Blood test|Blood test, systemic markers
97645|NCT03422965|Diagnostic Test|Urine test|Urine test, systemic markers
97646|NCT03422939|Other|there was no intervention, only separate analyses|We only conducted separate analyses to see if responses differed according to level of experience.
97647|NCT03422926|Behavioral|Social marketing campaign|Messaging campaign designed to help mothers in choosing healthful options when dining out.
97648|NCT03422913|Procedure|controlled low central venous pressure|Anesthesiologists will control the amount of fluid input and the use of composite intravenous anesthesia to make CVP at 0~5cm H2O, if CVP is still >5cm H2O, intravenous infusion of nitroglycerin will be used to reduce CVP. Maintaining arterial systolic blood pressure (SBP) > 90 mmHg, urine output more than 1ml/kg/h, and CVP was continuously monitored. Arterial pressure, pulse oxygen saturation ( SPO2), PaCO2 and electrocardiogram (II and V5 leads) were continuously monitored by radial artery cannulation. CVP will Returned to normal level (6 ~ 12 cmH2O) after resection to observe the wound if active bleeding still exist. Intraoperative hepatic blood flow blocking intermittent Pringle block method also required during surgery, 10-15 minutes for once, and more than 5 minutes interval can be repeated.
97649|NCT03422900|Dietary Supplement|Diabetes-Specific enteral formula|Complete enteral formula normocaloric hyperproteic with fiber (80% SOLUBLE)
97650|NCT03422900|Dietary Supplement|Standard formula|Complete enteral formula normocaloric hormoproteic without fiber
97651|NCT03422887|Drug|Nalbuphine|Nalbuphine administration during surgery
97652|NCT03422887|Drug|Flurbiprofen Axetil|Flurbiprofen axetil administration during surgery
97653|NCT03422887|Drug|Nalbuphine and Flurbiprofen Axetil|Nalbuphine and Flurbiprofen Axetil administration during surgery
97654|NCT03422874|Drug|MLN9708|MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
97655|NCT03422874|Drug|Nelfinavir|Nelfinavir is an oral HIV protease inhibitor approved by FDA in 1997, now available in generic form. It has a well established safety profile in HIV patients when administered at the recommended dose of 1250 mg PO BID. Nelfinavir was shown to induce ER stress in cancer cell lines and xenograft tumors leading to apoptosis and tumor growth inhibition.
97656|NCT03422861|Drug|Nabilone|Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours
97657|NCT03422861|Drug|Placebos|Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
97658|NCT03422848|Dietary Supplement|Water|Increased daily water intake with 1.5 L of water on top of habitual water intake.
97659|NCT03422848|Behavioral|general life style advice|oral and written advice on diet and physical activity
97660|NCT03422835|Procedure|R-TME|Conventional Robotic Total Mesentery Excision
97661|NCT03422835|Procedure|R-TaTME|Robotic Transanal Total Mesentery Excision
97662|NCT03422822|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for up to 92 weeks.
97663|NCT03422822|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for up to 92 weeks
97664|NCT03422822|Drug|Placebo|For subjects whose dose was changed from 100 mg PF-04965842 to placebo, one tablet will be administered to be taken orally once daily for the remainder of the study.
97665|NCT03422822|Drug|PF-04965842 100 mg|For subjects whose dose was changed from 200 mg PF-04965842 to 100 mg PF-04965842, one tablet will be administered to be taken orally once daily for the remainder of the study.
97666|NCT03422796|Drug|Cilostazol 200mg|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
97667|NCT03422796|Drug|SUMAtriptan 6 MG/ML|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
97668|NCT03422796|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
97669|NCT03422783|Device|Standardized tetanic stimulation|"The intervention is not a drug, but it is standardized electrical stimulus applied with a muscle relaxation monitor on the forearm of the anesthetized patient. The NoL index is registered in response to this stimulus in an observational manner.~Device: Device PMD200TM offering intraoperative NoL Index"
97670|NCT03422783|Diagnostic Test|Catastrophizing score|Pre-operative catastrophizing score is correlated with post-operative pain and opioid consumption
97671|NCT03422783|Diagnostic Test|Nociceptive threshold|Nociceptive threshold for pressure, heat and electrical stimulation are associated with post-operative pain and will be assessed preoperatively to see if there is correlation between them and the NOL index response to the nociceptive stimulus (see intervention 1)
97723|NCT03422471|Other|Hyperinsulinemic Hypoglycemic Clamp|Participants will receive two 90 minute sessions of hypoglycemia. Baroreflex sensitivity will be assessed before, after, and during the sessions.
97673|NCT03422770|Diagnostic Test|Echocardiography|Conventional transthoracic echocardiography will be performed, in addition 3D-imaging and acquisitions with high frame rate. The data from these patients will be anonymized and transferred for post-hoc analysis in dedicated computer software (GE Vingmed, EchoPac 2.0) and in validated machine learning algorithms.
97674|NCT03422770|Diagnostic Test|MRI|Cardiac MRI will be performed. In all patients without contraindications a gadolinium-based contrast agent will be given.
97675|NCT03422770|Diagnostic Test|Blood test|Conventional brachial venous blood samples will be drawn. Blood samples will be analyzed for markers of myocardial fibrosis at Oslo University Hospital.The findings will be related to imaging findings.
97676|NCT03422770|Diagnostic Test|ECG and Holter-ECG|ECG/Holter-ECG will be performed, and the findings will be related to the imaging findings.
97677|NCT03422770|Diagnostic Test|6 min walking test|6 MWT will be performed, and the findings will be related to findings from MRI/echocardiography.
97678|NCT03422757|Device|adaptive Deep Brain Stimulation|"The investigational medical device (AlphaDBSvext) is a portable, external, dual mode stimulator that can deliver adaptive DBS or conventional DBS for the treatment of PD.~In the adaptive mode, the device records Local Field Potential activity from the implanted DBS electrode and simultaneously delivers stimulation through the same electrode based on the recorded signal."
97679|NCT03422757|Device|conventional Deep Brain Stimulation|"The same investigational medical device (AlphaDBSvext) is used to deliver conventional DBS for the treatment of PD. In the conventional mode it delivers constant stimulation."
97680|NCT03422744|Procedure|trans bronchial biopsy guided by echo-endoscopic miniprobes|We get a sample trough transbronchial biopsy guided by echo-endoscopic miniprobe.
97681|NCT03422744|Procedure|if first one negative: samples under fluoroscopic control|If no diagnosis with first intervention we get a second sample by cytological smear, fine needle biopsy and transbronchial biopsy under fluoroscopic control
97682|NCT03422731|Procedure|Biospecimen Collection|Undergo collection of bone marrow and blood samples
97683|NCT03422731|Procedure|Dual-Energy Computed Tomography|Undergo DECT
97684|NCT03422731|Other|Fluorothymidine F-18|Undergo FLT PET
97685|NCT03422731|Other|Laboratory Biomarker Analysis|Correlative studies
97686|NCT03422731|Procedure|Magnetic Resonance Imaging|Undergo water-fat MRI
97687|NCT03422731|Procedure|Positron Emission Tomography|Undergo FLT PET
97688|NCT03422718|Behavioral|Healthy Behavior Texts|Participants receive motivational health behavior texts
97689|NCT03422718|Behavioral|No healthy behavior texts|Participants do not receive healthy behavior texts
97690|NCT03422718|Behavioral|BP Monitoring Daily Via Text Messaging|Daily text messages will prompt participants for BP by home cuff
97691|NCT03422718|Behavioral|BP Monitoring Weekly Via Text Messaging|Weekly text messages will prompt participants for BP by home cuff
97692|NCT03422718|Behavioral|Physician appointment and transportation scheduling|Participants receive assistance scheduling physician appointment and transportation to those appointments
97693|NCT03422718|Behavioral|No physician appointment and transportation scheduling|Participants do not receive assistance scheduling physician appointment or transportation
97694|NCT03422705|Device|Optimised programming|Optimised programming to avoid RV pacing when possible.
97695|NCT03422705|Drug|Lisinopril|Uptitration of lisinopril
97696|NCT03422705|Other|Standard care|No pacemaker adjustment or medical therapy
97697|NCT03422692|Biological|BioXclude amnion-chorion membrane|BioXclude will be used for the prevention of alveolar ridge resorption via socket bone graft and amnion-chorion membrane closure
97698|NCT03422692|Biological|Mem-Lok collagenous membrane|Mem-Lok will be used for the prevention of alveolar ridge resorption via socket bone graft and collagenous membrane closure
97699|NCT03422679|Drug|CB-103|Capsules, taken once daily during treatment period A and B. Treatment cycle is 28 days.Starting dose is 15 mg.
97700|NCT03422666|Drug|Teduglutide|Teduglutide
97701|NCT03422666|Drug|Placebo|Placebo
97702|NCT03422653|Drug|CR845 0.5 mcg/kg|IV medication delivered three times/week
97703|NCT03422653|Drug|Placebo|IV medication delivered three times/week
97704|NCT03422640|Drug|Apremilast|Open label treatment with apremilast
97706|NCT03422614|Diagnostic Test|Diagnostic Test|Characterisation of cellular and functional phenotype in different PIDs
97707|NCT03422601|Diagnostic Test|Immunoscore test|To identify patients with high risk (IS 0-1) of relapse or death under oxaliplatin-based adjuvant therapy.
97708|NCT03422588|Procedure|Laparoscopic right colectomy|Laparoscopic right colectomy for colorectal cancer with a standard vascular dissection, performing the anastomosis with a side-to-side mechanical anastomosis fashioned intracorporeally versus extra corporeally
97709|NCT03422575|Drug|Etoricoxib 120Mg Film-coated Tablet|One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
97710|NCT03422575|Drug|Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)|One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
97711|NCT03422562|Dietary Supplement|Florababy|Probiotic supplement
97712|NCT03422549|Device|Drager VN500 Ventilator|This ventilator is capable of providing both CPAP and NHFOV support.
97713|NCT03422536|Biological|Cetuximab|Given IV
97714|NCT03422536|Drug|Ficlatuzumab|Given IV
97715|NCT03422523|Drug|Atezolizumab|Intravenous drip
97716|NCT03422523|Drug|Rituximab|Intravenous drip/or Subcutaneous from cycle 2
97717|NCT03422523|Drug|Gemcitabine 1000 mg|intravenous drip
97718|NCT03422523|Drug|Oxaliplatin 100 MG|intravenous drip
97719|NCT03422510|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitro-oleic acid (OA-NO2)
97720|NCT03422497|Other|Male sex|Male sex-as listed in the discharge abstract database
97729|NCT03422419|Device|TIPS|transjugular intrahepatic portosystemic shunt deployment
97730|NCT03422406|Other|Dietary iodine intake restriction|All subjects with excessive iodine load were recommended by nutritionists to restrict dietary iodine intake, and resume iodine-containing supplements and foods until their iodine status return to normal. However, in this observational study, the intervention was a regular management in prenatal care, and not assigned by investigator of the study.
97731|NCT03422393|Drug|Venetoclax|On cycle 1, day 1, patients will initiate venetoclax. The dose of venetoclax will ramp-up from 20 mg PO daily to 400 mg PO daily over a 5 week period.
97732|NCT03422393|Drug|Ibrutinib|"During the screening period, patients will continue on ibrutinib at their previous tolerated dose, unless required to stop (e.g.: by a preceding clinical trial).~On cycle 1, day 1, the dose of ibrutinib will be assigned based on the dose cohort. Patients in cohort 1 will receive ibrutinib 420 mg PO daily. Patients in cohort 2 will receive ibrutinib 560 mg PO daily. Cohort 3 will be 840 mg PO daily."
97733|NCT03422367|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
97734|NCT03422354|Procedure|Ultrasound guided PVB with General Aneasthesia|An 18G Tuohy needle was inserted perpendicularly at L1,2 to hit the transverse process via an out-of-plane approach. This then directed over the top of the bony structure. The deviation of the needle was kept at 15°. The space was identified using loss of resistance without U/S After negative aspiration, Transverse process visualisation was possible. Distances measured using U/S correlated well with needle depth. Injection of local anaesthetic was visualised as turbulence at L1,2 in all patients. The onset time for this block is 15-25 min
97735|NCT03422354|Device|Ultrasound|Ultrasound
97736|NCT03422354|Drug|Paravertebral block|Patients will receive single shot L1-L2 PVB before undergoing GA
97737|NCT03422354|Drug|General Aneasthesia|General Aneasthesia
97738|NCT03422341|Device|Comparison between GenePOC CR and Reference Method|The collected swab will be tested with both the GenePOC Strep A, C/G assay and the Reference Method defined as standard microbiology culture and strain identification using a MALDI TOF.
97739|NCT03422328|Drug|macitentan|macitentan 10 mg, film-coated tablet, oral use
97740|NCT03422315|Drug|Propofol|injection;2mg/kg;single-dose
97741|NCT03422302|Device|Biphasic Positive Airway Pressure|Receive BiPAP
97742|NCT03422302|Procedure|Computed Tomography|Undergo CT simulation scans
97743|NCT03422302|Procedure|Continuous Positive Airway Pressure|Receive CPAP
97744|NCT03422302|Procedure|Deep Inspiration Breath Hold|Complete DIBH
97745|NCT03422302|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo CT simulation scans
97746|NCT03422302|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
97747|NCT03422289|Dietary Supplement|myo-inositol plus folic acid|this treatment is made in the first phase of the study for three months
97748|NCT03422289|Dietary Supplement|myo-inositol plus folic acid plus alpha-lactalbumin|this treatment is made in the second phase of the study and it has a new molecule added to the previous ones administered in the first phase of the study
97749|NCT03422276|Other|Rehabilitation Discharge Plan|"CARF standards for discharge following an inpatient rehabilitation stay for a traumatic brain injury. This approach may include the following:~patient and family education about TBI, both general and individualized to each person's symptoms and level of function, as well as education on medications and symptoms to monitor following discharge;~written discharge care instructions, including recommended appointments with primary care, rehabilitation medicine and outpatient therapies, and medication list which are reviewed with the patient and family prior to discharge; and~a phone call from an inpatient care provider within a few days of discharge to address any immediate problems and ensure that equipment has arrived, medications are being taken, etc."
97750|NCT03422276|Other|Rehabilitation Transition Plan|"Participants and their caregivers (if applicable) randomized to the Rehabilitation Transition Plan group will receive up to 12 scheduled contacts 6 months post-discharge from a TBI care manager familiar with the care and resource networks at the respective sites. The contacts will at minimum be by telephone, although a HIPAA-compliant video conferencing option will also be available.~The content of these contacts will include:~Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans;~Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population."
97751|NCT03422250|Device|transcranial direct current stimulation (tDCS)|10 daily 25-minutes tDCS sessions over two weeks. AD: Anodal tDCS of the default mode network (inferior parietal cortex). bvFTD: Anodal tDCS of the salience network (prefrontal cortex).
97752|NCT03422250|Device|transcranial direct current stimulation (tDCS)|10 daily 25-minutes tDCS sessions over two weeks. AD: Cathodal tDCS of the salience network (prefrontal cortex). bvFTD: Cathodal tDCS of the default mode network (inferior parietal cortex).
97753|NCT03422237|Biological|RSV ΔNS2/Δ1313/I1314L|10^6 plaque-forming units (PFU); administered as nose drops
97754|NCT03422237|Biological|RSV 276|10^5 PFU; administered as nose drops
97755|NCT03422237|Biological|Placebo|Administered as nose drops
97756|NCT03422224|Diagnostic Test|Mixed lymphocyte reaction|Assessment of alloreactive T cell repertoire
97757|NCT03422211|Other|Questionnaire|Will ask patients questions in regards to how many narcotics they have taken and what their pain level has been.
97758|NCT03422198|Radiation|Vaginal Cuff Brachytherapy|Undergo standard of care vaginal cuff brachytherapy
97759|NCT03422198|Radiation|Short course vaginal cuff brachytherapy|Undergo short course vaginal cuff brachytherapy
97760|NCT03422185|Other|No intervention|No intervention
97761|NCT03422172|Drug|Oral CAB|CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.
97762|NCT03422172|Drug|CAB LA|CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
97763|NCT03422159|Drug|Ascorbic Acid|Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
97764|NCT03422159|Drug|Thiamine|Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
97765|NCT03422159|Drug|Hydrocortisone|Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
97766|NCT03422159|Drug|Sodium Chloride 0.9%|"Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days)."
97767|NCT03422146|Other|Tea Tree Oil (TTO)|Participants will use the Cliradex® eyelid hygiene lid wipe / towelette for BID for 2 weeks
97768|NCT03422146|Other|I-Lid'n Lash® Hygiene|Patients will use the I-Lid'n Lash® Hygiene lid wipe / towelette for BID for 2 weeks
97769|NCT03422133|Other|Patient-oriented, personalized risk communication eHealth application|The application features simple and consistent design, large well-lit buttons that tolerate tremor, and simple language. The process will be applied in preoperative clinics at The Ottawa Hospital (TOH), where patients will be asked to provide their personal health history through a series of questions already used on our TOH preoperative health screener. These values will then populate the NSQIP Universal Risk Calculator, which we have calibrated to TOH data, to generate personalized risks of mortality, serious complications, and hospital length of stay. These risk estimates will be communicated directly to the patient using absolute risk estimates represented pictorially (best practice for risk communication to patients). Risk estimates will also be provided to the patient's clinician.
97770|NCT03422120|Other|Natural Killer Cell Activity Assay|Subjects had a blood test to measure NK cell activity (NKA) at different time points
97771|NCT03422094|Biological|NeoVax|At each vaccination time point, patients will receive up to 20 synthetic long peptides co-administered with 1.5 mg of poly-ICLC divided into a maximum of four injections (pools). Each pool (of vaccine + poly IC:LC) will be administered to one of the four limbs (right axilla, left axilla, right inguina, left inguina) by subcutaneous injection.
97772|NCT03422094|Biological|Nivolumab|Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
97773|NCT03422094|Biological|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
97774|NCT03422094|Procedure|Research blood draw|-Baseline, cycle 2 day 1, cycle 4 day 1, and time of progression or discontinuation of treatment
97775|NCT03422094|Procedure|Leukapheresis for research|-Baseline, cycle 4 day 1, and time of progression or discontinuation of treatment
97776|NCT03422081|Diagnostic Test|arterial doppler ultrasound|doppler ultrasound
97777|NCT03422068|Drug|BI 1015550|Tablet formulation
97778|NCT03422068|Drug|Placebo|Tablet formulation
97779|NCT03422055|Drug|99mTc-Fucoidan SPECT|Intravenous administration of 99mTc-Fucoidan on healthy volunteers.
97780|NCT03422042|Other|Short duration of antibiotic|Patient will received intravenous antibiotic until the body temperature is less than 37.8 c fir 72, then antibiotic is discontinued.
97781|NCT03422042|Other|Standard treatment of antibiotic|Patient will received intravenous antibiotic for 7 days, followed by oral antibiotic for 7 days, regardless of the body temperature.
97782|NCT03422029|Drug|177Lu-Dotatate PRRT|"PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT"
97783|NCT03422016|Diagnostic Test|electroretinogram (ERG)|an ERG is a measure of the eyes response to a flash of light
97784|NCT03422003|Radiation|Radiation Therapy|"For the conventional fractionation arm: Each fraction will consist of 200 cGy per day. Total dose = 5000 cGy to the chest wall and 4600‐5000 cGy to the lymph nodes.~For the hypofractionation arm: Each fraction consists of 266 cGy per day. Total dose = 4256 cGy to the chest wall and 3990 cGy to the lymph nodes."
97785|NCT03421990|Procedure|General anesthesia|general anesthesia and regional anesthesia techniques are used
97786|NCT03421977|Biological|Onasemnogene Abeparvovec-xioi|Patients received treatment with onasemnogene abeparvovec-xioi in the parent study, AVXS-101-CL-101
97787|NCT03421964|Behavioral|Resilience/Adjustment Counseling|The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. During the first session, participants will receive an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
97788|NCT03421964|Behavioral|Resilience/Adjustment Counseling with Booster Sessions|"The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. During the first session, participants will receive an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists."
97789|NCT03421938|Other|Walking Exercise|Group 1 will have downhill walking exercises with %10 slope; group 2 uphill walking exercises on the treadmill with %10 slope..
97790|NCT03421925|Procedure|Laparoscopic totally extraperitoneal procedure for inguinal hernia|Laparoscopic totally extraperitoneal procedure for inguinal hernia is a technique that is done by not entering the peritoneal cavity
97791|NCT03421912|Other|Cicaplast Balm B5|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
97792|NCT03421912|Other|Dexeryl|The patients have to do 2 to 3 applications per day on the face, on lesions and in poultice in the evening in case of painful crack on the fingers
97825|NCT03421639|Drug|Aromatase inhibitor plus GnRH analog|1mg/day of Anastrazole plus 3.6mg/monthly for 3 months
97826|NCT03421626|Device|Xpert BCR-ABL Ultra|Semi-quantitation of BCR-ABL transcript in patients that have been previously diagnosed with CML
97827|NCT03421613|Drug|3VM1001|Self treatment 3 times daily for 10 days
97828|NCT03421613|Other|Placebo|Cream without investigational drug. Self treatment 3 times daily for 10 days
97793|NCT03421886|Device|Aerodentis system|The Aerodentis system is intended for the treatment of tooth malocclusion and is treated by applying force, over time, to teeth requiring alignment. It is an individually-fitted, plastic dental mouthpiece that is inserted and worn by the patient according to the dental practitioner's treatment plan. The Aerodentis system is comprised of a plastic mouthpiece containing an inflatable balloon that provides pressure (force) on the selected teeth designated to be moved to a final treated state. The inflatable balloon is inflated to the desired pressure using an electrical air pump unit that is programmed by the dental practitioner using Dror Orthodesign proprietary software; thus creating a course treatment specially designed for each patient.
97794|NCT03421886|Device|Invisalign clear aligner system|Clear aligners are used for the treatment of tooth malocclusion. In these devices, a series of mouthpieces are used, where the force created by each mouthpiece on the treated teeth is designed to push the teeth in small, one step increments, toward the desired result.
97795|NCT03421873|Other|0h/1h hs-cTnT protocol|Implementation of a 0h/1h hs-cTnT protocol in routine care
97796|NCT03421860|Drug|"cardiac output changes with ephedrine"|measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
97797|NCT03421860|Drug|"cardiac output changes with phenylephrine"|measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
97798|NCT03421860|Drug|"cardiac output changes with ondansetron"|measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
97799|NCT03421860|Drug|"cardiac output changes with nor-epinephrine"|measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
97800|NCT03421847|Diagnostic Test|Rotatory vestibular test|We will measure Depression and Healthy subjects vestibular activity by Rotatory Vestibular tests
97801|NCT03421834|Procedure|Catheter ablation of ventricular tachycardia|Catheter ablation with a uniform mapping system, procedural endpoint, and definition of acute procedural success.
97802|NCT03421834|Drug|Optimal medical treatment|Optimal guidelines-based heart failure treatment and antiarrhythmic drugs. Antiarrhythmics will be avoided if possible in the ablation group.
97803|NCT03421821|Drug|Ropivacaine|Subfascial injection OR extrafascial injection
97804|NCT03421808|Device|Transcranial Magnetic Stimulation (TMS)|TMS
97805|NCT03421795|Other|Let's Talk About Pain Training|See arm/group descriptions.
97806|NCT03421795|Other|Family Centered Care Training|See arm/group descriptions.
97807|NCT03421782|Behavioral|Cognitive Behavior Therapy|Undergo PROSPECT internet-based CBT
97808|NCT03421782|Behavioral|Exercise Intervention|Undergo POWER exercise intervention
97809|NCT03421769|Procedure|EA and AMLK|A 7-9mm diameter corneal epithelial tissue will be obtained from the fellow eye using femtosecond laser technology. This epithelial autograft (EA) is then ready for transplantation on the disease eye, following the procedure of allogeneic middle lamellar keratoplasty (AMLK).
97810|NCT03421769|Procedure|LA and AMLK|A 3-clock-hour limbal autograft (LA) will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following the procedure of AMLK.
97811|NCT03421756|Drug|Alemtuzumab|Alemtuzumab is a non-myeloablative pre-transplant conditioning regimen. Non-myeloablative therapy uses doses of chemotherapy and radiation to weaken (but not destroy) the patients bone marrow and immune system, while still allowing their body will accept the donor's stem cells. Alemtuzumab will be given 7 days prior to stem cell infusion at 0.03 mg/kg IV, 6 days prior to stem cell infusion at 0.1 mg/kg IV, and 5 thru 3 days prior to stem cell infusion at 0.3 mg/kg IV.
97812|NCT03421756|Radiation|Total Body Irradiation|300 cGy will be administered in a single fraction on Day - 2. TBI is used commonly as part of pre-transplant conditioning in a variety of settings.
97813|NCT03421756|Drug|Sirolimus|Sirolimus will be used for the prevention of graft-verus-host disease and will begin on Day - 1.
97814|NCT03421743|Drug|Inhaled molgramostim|300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
97815|NCT03421730|Combination Product|VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System|The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
97816|NCT03421730|Combination Product|1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer|Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
97817|NCT03421717|Device|Chitosan brush|If inflammation (Bleeding on probing) and deep pockets (4 mm or more) is present at the control - maintenance is performed according to allocation
97818|NCT03421704|Device|DreamStation BiPAP autoSV|Philips Respironics DreamStation BiPAP autoSV (PR DS-autoSV) is designed to deliver pressure support for patient ventilatory assistance
97819|NCT03421691|Device|excel V Laser|excel V Laser Genesis procedure utilizing 1064 nm Nd:YAG laser
97820|NCT03421678|Diagnostic Test|Urine Sample|One to two home visits where tobacco use and medical history and biological samples will be collected including blood, buccal cells and urine
97821|NCT03421665|Device|Titan 3D Wedge System|Each subject will undergo an LCL procedure and/or medial cuneiform osteotomy with one or more TITAN 3-D™ Wedges. Ancillary fixation should be used in conjunction with each TITAN 3-D™ Wedge used. This surgical procedure will be performed as standard of care and is not part of the research procedures. Post-operative care and weight-bearing/activity restrictions will be at the discretion of the surgeon as part of their standard of care for the procedure.
97822|NCT03421652|Drug|Nivolumab|Patients receive nivolumab IV over 30 minutes on day 1. Treatment repeats every 14 days (2 weeks) for up to 14 courses (6 months) in the absence of disease progression or unacceptable toxicity. Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
97823|NCT03421652|Radiation|Radiation|Beginning 3 days of course 1, patients undergo radiation therapy over 32-35 on weeks 1, 3, 5, 7 and 9.
97824|NCT03421639|Drug|Ulipristal acetate|5.0mg/day of Ulipristal acetate for 3 months
97829|NCT03421600|Device|blue laser imaging|blue laser imaging
97831|NCT03421587|Behavioral|Processing of social olfactory and tactile stimuli|Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
97832|NCT03421574|Device|MR-guided Focused Ultrasound|Focused Ultrasound allows for non-invasive thermal ablation of soft tissue virtually anywhere in the body. Treatment begins by acquiring a series of magnetic resonance (MR) images of the target tissue. The physician then reviews the images on the system workstation, identifies the target, delineates treatment contours, and reviews the treatment plan. Therapy planning software calculates the parameters required to effectively treat (e.g. ablate) the defined region. During treatment, the patient wears a helmet equipped with multiple sources of ultrasound which generate a point of focused energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, causing a thermal coagulation effect.
97833|NCT03421561|Device|"Stellarex 0.035 OTW Drug-coated Angioplasty Balloon"|"The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm."
97834|NCT03421561|Device|EverCross™ 0.035 PTA Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
97835|NCT03421548|Device|EyeMate|Patients will undergo implantation BKPro with concomitant implantation of the EyeMate pressure sensor. The surgical approach will involve a trephination of the central recipient cornea of adequate size. In subjects with adequate capsular support, the sensor device will be placed in the sulcus space by grasping the sensor's silicone sleeve at approximately the 3 and 9 o'clock positions and sliding it into the sulcus space. In subjects in whom capsular support is inadequate, the Eyemate implant will be sutured to the sclera. This is performed by placing an 8-O Gortex suture or 9-O prolene on CIF-4 needles around the antenna at the 2 and 7 o'clock positions and suturing the device to the sclera using an ab-interno technique.
97836|NCT03421535|Procedure|Sleeper Stretch|Internal Range of motion of dominant shoulder
97837|NCT03421535|Procedure|Opposite SI joint Stretch|Internal range of motion of dominant shoulder
97838|NCT03421522|Other|ICBN preservation surgery|"For participants randomized to the ICBN preserving technique, surgeons will perform axillary dissection in which the second ICBN, just inferior to the axillary vein, will be preserved. Surgeons will be asked to indicate whether the ICBN nerve was fully preserved, partially preserved, or sacrificed.~All study participants will receive anesthetic management at the discretion of the attending physician, which will be documented."
97839|NCT03421509|Other|cutaneous silent period|In the upper limb the cutaneous silent period (CSP) is a brief transient suppression of the voluntary muscle contraction that follows painful stimulation applied to the finger (digits II-V, C6-C8 dermatomes)
97840|NCT03421496|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
97841|NCT03421496|Drug|Placebo|Matching oral solution
97842|NCT03421496|Drug|Vigabatrin|Powder suspension
97843|NCT03421483|Dietary Supplement|Folic Acid supplementation|Participants receive a 400 microgram Folic Acid supplement
97844|NCT03421483|Dietary Supplement|Adult Multivitamin|Participants will receive an adult multivitamin supplement
97845|NCT03421457|Procedure|Uterus-preserving laparoscopic lateral suspension with mesh|V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.
97846|NCT03421457|Procedure|Uterus-preserving laparoscopic sacrocervicopexy with mesh|The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.
97847|NCT03421444|Other|No intervention|No intervention
97848|NCT03421431|Drug|EDP-305 Dose 1|Two tablets daily for 12 weeks
97849|NCT03421431|Drug|EDP-305 Dose 2|Two tablets daily for 12 weeks
97850|NCT03421431|Drug|Placebo|Two tablets daily for 12 weeks
97851|NCT03421418|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
97852|NCT03421405|Device|NeuroCatch Platform™|NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.
97853|NCT03421392|Other|non interventional study|non interventional study
97854|NCT03421379|Drug|Glucagon Nasal Powder|Administered intranasally
97855|NCT03421379|Drug|Glucagon Hydrochloride Solution|Administered IM
97856|NCT03421366|Drug|Posaconazole|A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
97857|NCT03421353|Drug|AZD9150|"AZD9150 will be administered as a 1-hour intravenous infusion either weekly (QW) or every two weeks (Q2W), depending on which arm the patient is enrolled in.~AZD9150 will be provided as a liquid drug product in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
97858|NCT03421353|Drug|Durvalumab|"Durvalumab will be administered as a 1-hour intravenous infusion either every three weeks (Q3W) or every four weeks (Q4W), depending on which arm the patient is enrolled in.~Durvalumab will be provided as a solution in clear glass vials. Each vial will be labelled in accordance with GMP Annex 13 and per country regulatory requirement."
97859|NCT03421353|Drug|Cisplatin|Cisplatin will be infused over 30-60 minutes on Day 1.
97860|NCT03421353|Drug|5-Flourouracil|5-flourouracil will be continuously infused over Days 1 to 4 every three weeks for up to 18 weeks.
97861|NCT03421353|Drug|Carboplatin|Carboplatin will be infused over 30 to 60 minutes on Days 1, 8, and 15, depending on which arm the patient is enrolled in, for up to 18 weeks.
97862|NCT03421353|Drug|Gemcitabine|Gemcitabine will be infused over 30 minutes on Days 1 and 8 for up to 18 weeks.
97863|NCT03421353|Drug|Nab-paclitaxel|Nab-paclitaxel will be infused over 30 to 40 minutes on Days 1, 8, and 15 for up to 18 weeks.
97864|NCT03421340|Device|DSC|Stone removal without fluoroscopy using the SpyGlass device.
97865|NCT03421340|Device|ERC|Standard of care stone removal with fluoroscopy.
97866|NCT03421314|Dietary Supplement|Zinc gluconate and/or Selenium yeast|30 mg dose of zinc gluconate and/or 200 mcg of selenium yeast
97867|NCT03421301|Dietary Supplement|dietary portfolio|The dietary intervention was a combination of functional foods (dehydrated nopal, chia seed, soy protein and inulin) that was provided in dehydrated form in packages of 17.3 g dissolved in 250 ml water for breakfast and 34.7 g in 300 ml water for dinner.
97868|NCT03421288|Drug|Atezolizumab|Day 1 q2w: 840 mg IV over 1 hour (4 cycles perioperative with FLOT) + Day 1 q3w: 1200 mg IV over 1 hour (8 additional cycles monotherapy)
97869|NCT03421288|Drug|5-Fluorouracil|Day 1 q2w: 2600 mg/m² IV over 24 hours
97870|NCT03421288|Drug|Calciumfolinat|Day 1 q2w: 200 mg/m² IV over 1 hour
97871|NCT03421288|Drug|Oxaliplatin|Day 1 q2w: 85 mg/m² IV over 2 hours
97872|NCT03421288|Drug|Docetaxel|Day 1 q2w: 50 mg/m² IV over 1 hour
97873|NCT03421275|Drug|Esketamine|anesthetic used as analgetic in subanesthetic doses given intranasally
97874|NCT03421275|Drug|Fentanyl Citrate|intravenous fentanyl given intranasally
97875|NCT03421275|Drug|Saline Nasal|intravenous saline given intranasally as placebo
97876|NCT03421262|Diagnostic Test|IADPSG Criteria|One-step: 2 hr 75 gr OGTT
97877|NCT03421262|Diagnostic Test|NDDG Criteria|Osullivan test + 3 h 100 g OGTT
97878|NCT03421249|Other|Exercises|Muscle strengthening exercises of the hip and knee muscles
97879|NCT03421249|Other|Electromagnetic field therapy|Electromagnetic field therapy with Magnetron®
97880|NCT03421236|Biological|Ty21a|intravesical administration of Ty21a
97881|NCT03421223|Other|No intervention|No intervention
97883|NCT03421197|Drug|PPC-06 400 mg QD|Tepilamide Fumarate 400 mg tablet once per day
97884|NCT03421197|Drug|PPC-06 400 mg BID|Tepilamide Fumarate tablets 400 mg twice per day
97885|NCT03421197|Drug|PPC-06 600 mg|Tepilamide Fumarate tablets 600 mg twice per day
97886|NCT03421197|Drug|Placebo|white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
97887|NCT03421184|Other|blood sample|25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
97888|NCT03421184|Other|urine sample|10 ml
97889|NCT03421184|Other|food questionnaire|dietary habit enquiry and a 48h dietary
97890|NCT03421184|Other|hair|lock of hair
97891|NCT03421171|Other|no intervention|Qualitative research through semi-structured interviews
97892|NCT03421158|Behavioral|breastfeeding|Newborns were breastfed during the procedure
97893|NCT03421158|Dietary Supplement|oral sucrose|Newborns were given oral sucrose during the procedure
97894|NCT03421158|Behavioral|Skin-to-Skin contact|Newborns were placed in direct contact with their mothers during the procedure
97895|NCT03421158|Behavioral|Non-nutritive sucking|newborns were given a pacifier to suck on during the procedure
97896|NCT03421119|Drug|Liraglutide 6 MG/ML Pen Injector|Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
97897|NCT03421119|Drug|Metformin|Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
97898|NCT03421119|Drug|Sulfonylurea/non-sulfonylurea insulin secretagogues|Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
97899|NCT03421106|Behavioral|Intervention Food Pantries|Food pantries will receive consulting services to transform their food offerings and environment in order to influence client health behaviors.
97900|NCT03421106|Other|Control Food Pantries|Normal food pantry use
97901|NCT03421093|Procedure|Surgeries|Surgeries or surgeries plus adjuvant therapies
97902|NCT03421080|Behavioral|MoodGYM|The MoodGYM Internet intervention will employ the latest version of MoodGYM (Mark 4) which has been updated to support mobile devices. The core design and function of the program has not been altered. A major focus of this intervention is to provide individuals with behavioral and cognitive strategies to improve depression symptoms.
97903|NCT03421080|Behavioral|Check Your Drinking|Internet intervention designed to assess and provide feedback on hazardous alcohol use. The CYD has been subjected to seven randomized trials from two independent research groups, all of which displayed a significant impact of the CYD to reduce hazardous alcohol consumption compared to controls.
97904|NCT03421054|Dietary Supplement|patients assuming nutraceutical containing HA|pain reduction of the affected knee in the patients assuming nutraceutical containing HA
97905|NCT03421041|Drug|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet，0.75mg/tablet
97906|NCT03421028|Device|Functional Electrical Stimulation Biofeedback|Functional Electrical Stimulation (FES) is a method in which the device is delivering small electrical pulses through electrodes situated on the surface of the skin to exert specific effect. In case of this study to relax masseter muscles.
97907|NCT03421028|Device|Electromyography Biofeedback|EMG-Biofeedback- assisted training is a method in which electrodes situated on the surface of the skin detect small voltage changes which arise from the working muscles (in this case masseter muscles). The voltage is transformed into a visual or sound time-variable signal which gives the patient feedback as he willingly tries to change the muscle tension (in this case to lower the excessive masseter tension)
97908|NCT03421002|Drug|Micafungin|Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
97909|NCT03420989|Other|Active snack food|snack enriched with seaweeds and carob
97910|NCT03420989|Other|Control snack food|the same snack food without seaweeds and carob
97911|NCT03420976|Dietary Supplement|Novel Supplement Based Therapy|"Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term"
97912|NCT03420963|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
97913|NCT03420963|Drug|Cyclophosphamide|Given IV
97914|NCT03420963|Drug|Etoposide|Given IV
97915|NCT03420950|Other|Rapid sequence intubation: sedative first|Sedative first
97916|NCT03420950|Other|Rapid sequence intubation: paralytic first|Paralytic first
97917|NCT03420937|Drug|Sugammadex|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
97918|NCT03420937|Drug|Neostigmine, Atropin Biotika|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
97919|NCT03420924|Device|Thermal suit|Forced-air warming device will be connected to the trouser legs of the thermal suit.
97920|NCT03420924|Device|Conventional hospital clothes|The warming mattress and a forced-air warming blanket for the lower body will be used intraoperatively.
97921|NCT03420911|Drug|dexketoprofen trometamol|
97922|NCT03420911|Drug|Midazolam|
97923|NCT03420898|Other|Quality Improvement Intervention, prescription reduction|The intervention is a quality improvement education aimed at reducing sedative prescriptions and implementing safe sleep environments.
97924|NCT03420885|Behavioral|Ba Duan Jin|Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.
97925|NCT03420885|Behavioral|Health Education|Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
97926|NCT03420872|Other|Nutrient mixtures|consumption of a mixture of beneficial nutrients
97927|NCT03420859|Diagnostic Test|qPCR for abnormal vaginal microbiota|qPCR for A.vaginae and/or G.vaginalis as developed in the pilot study (Hum Reprod. 2016 Apr;31(4):795-803. doi: 10.1093/humrep/dew026. Epub 2016 Feb 23.)
97928|NCT03420846|Other|OCT Mapped|Presurgical mapping of Basal Cell Carcinoma margins
97929|NCT03420833|Device|Cardiac resynchronization therapy pacemaker (CRT-P)|A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
97930|NCT03420820|Biological|Bacterial Culture Swab|Culture swabs will be obtained before application of PI and after injection.
97931|NCT03420807|Device|MHRC|Evaluate the feasibility of detection of beta-amyloid plaques by using their spectral signature in autofluorescence or reflectance.
97932|NCT03420794|Other|Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy|Patients will be screened, enrolled, consented, and randomized during the preoperative office encounter, typically occurring within the 30 days prior to surgery. Patients randomized to pre-admission administration (study group) will be provided with a prescription for a one-time dosing of routine oral non-narcotic analgesic medications to be filled at the Cleveland Clinic outpatient pharmacy. Both the study and the control groups will receive written pre-operative instructions. Those patients randomized to the standard practice of administration in the pre-anesthesia unit (control group) will be administered the same medications in the same doses by the nursing staff. Patients in both groups will undergo general anesthesia, orogastric tube placement, and minimally invasive hysterectomy (MIH). Postoperatively, these patients will be observed for differences in PACU narcotic uptake, pain scores, patient satisfaction, and surgical recovery.
97933|NCT03420781|Drug|Relamorelin|Relamorelin 10 μg injected twice daily for 6, 40 or 46 weeks.
97934|NCT03420781|Drug|Placebo|Placebo injected twice daily for 6 weeks or 40 weeks.
97937|NCT03420755|Behavioral|Mothers and Babies 1-on-1|MB 1-on-1 is a 12-session intervention divided into five modules. An introductory 2-session module establishes key concepts related to stress, monitoring of one's mood, and ways in which one's mood influences one's internal thoughts and external environment; three 3-session modules correspond with key cognitive-behavioral elements: pleasant activities, thoughts, and social support/contact with others; a 1-session summary reviews content and identifies areas for future use of MB skills. Throughout MB, mood management skills are integrated using psycho-educational activities that encourage participants to understand connections between their mood and their activities, thoughts, and contacts with others.
97938|NCT03420755|Behavioral|Mothers and Babies Plus Text|MB 1-on-1 along with text enhancements, both in English and Spanish. These texts focus on: a) skill reinforcement (e.g., Some thoughts just come to us, but we can make a conscious effort to think of positive thoughts.); b) homework reminders (e.g., What pleasant activity will you try today?), and c) self-monitoring (e.g., On a scale of 1-9, how would you rate your mood?). These texts will be linked with the 12 MB sessions. Specifically, after completing each in-person session, 3 texts will be sent by a home visitor to her client; one text will focus on skill reinforcement, one will be a homework reminder, and one will focus on self-monitoring.
97939|NCT03420742|Drug|Midazolam|Midazolam syrup.
97940|NCT03420742|Drug|Brigatinib|Brigatinib tablets.
97941|NCT03420729|Procedure|gastroscopy|a thin, flexible tube called an end oscope is used to look inside the oesophagus (gullet), stomach and first part of the small intestine (duodenum)
98064|NCT03419728|Behavioral|Healthy Families, Healthy Futures|Home visiting program for pregnant and parenting teens
97942|NCT03420729|Device|magnetic assisted capsule endoscopy|The patient will be given 500 to 1000mls of water with 6 drops of simethicone added to drink. This is to enable adequate distension of the stomach. The patient then swallows the capsule in the presence of the PI. MACE of the oesophagus and stomach will be carried out by the PI. Once the PI is satisfied that an adequate examination has been completed the capsule will be allowed to pass into and through the small bowel.
97943|NCT03420716|Dietary Supplement|yogurt|
97944|NCT03420703|Other|erector spinae plane block|ultrasound guided erector spinae plane block will be administered to this group.
97945|NCT03420703|Device|Intravenous morphine patient controlled analgesia device|Intravenous morphine patient controlled analgesia device will be given to the patients postoperatively and 24 hour morphine consumption will be recorded
97946|NCT03420690|Other|satisfaction questionnaire after art therapy session|After the administration of art therapy sessions (>1) and the death of patients (> 1 month), the intervention consists in submitting to families of patients a satisfaction questionnaire intended to evaluate the impact of art therapy session and in particular about their relationships.
97947|NCT03420677|Device|Application of tones|During NREM sleep, tones (max. 60 dB) will be played using a portable, safe, in-home device. This device records biosignals (e.g. brain activity) and precisely times the tones during NREM sleep. It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
97948|NCT03420677|Device|No application of tones|This is the sham-control intervention; The device will only record biosignals but will not play tones.
97949|NCT03420664|Device|Orthosis VACOped|Orthosis for lower limb immobilisation
97950|NCT03420664|Device|Below knee cast|Below knee cast for lower limb immobilisation
97951|NCT03420651|Other|Peak Expiratory Flow Rate (PEFR)|PEFR values and the National Asthma Prevention and Education Program guidelines will be used by providers in the management of these patients.
97952|NCT03420651|Other|Standard Clinical Judgement|Providers will use physical exam and standard clinical judgement to guide management.
97953|NCT03420638|Drug|Adjunct Exparel (bupivacaine liposome suspension 1.3%)|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication—bupivacaine HCl 0.25% (2.5 mg/mL) with epinephrine (5 mcg/mL) i.m.—into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side. Following the standard medication, the principal investigator will infiltrate 0.5 mL of adjunct Exparel (bupivacaine liposome suspension 1.3% [13.3 mg/mL] i.m.) into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine liposome injectable suspension 1.3% (13.3 mg/mL) on each side.
97954|NCT03420638|Other|Standard Care|After removal of the tonsils and before extubation, the principal investigator will infiltrate 0.5 mL of the standard of care medication—bupivacaine HCl 0.25% (2.5 mg/ mL) with epinephrine (5 mcg/mL) i.m.—into the upper and lower poles of the anterior and posterior tonsillar pillars on the right and left side of the oropharynx for a volume of 2 mL of bupivacaine HCl on each side.
97955|NCT03420625|Device|Foot IPC|Intermittent pneumatic compression in the foot using the A-V Impulse™, Covidien®, New Haven, CT, USA
97956|NCT03420625|Device|Rapid calf IPC|Intermittent pneumatic compression in the calf using the VenaFlow® Elite, DJO Global, USA
97957|NCT03420625|Device|Slow calf IPC|Intermittent pneumatic compression in the calf using the Kendall SCD™ 700, Covidien, Medtronic, USA
97958|NCT03420625|Device|Calf NMES|Neuromuscular electrical stimulation in the calf using the DJOTM, CefarCompex Mi-Theta 500 stimulator
97959|NCT03420599|Procedure|splenectomy|Traumatic patients who performed total splenectomy
97960|NCT03420586|Drug|Nitrous Oxide|The nitrous oxide group (GN2O) will receive 70% N2O in 30% O2 at the end of surgery.
97961|NCT03420560|Behavioral|warmer temperature|Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
97962|NCT03420547|Behavioral|RISE|Intervention will consist of 3 sessions over 6 weeks. Each session will last 2 hours and be conducted with a clinical psychologist or medical social worker. The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.The intervention content include psycho-education, communication training between the couple, and exercises to foster intimacy. A therapy manual will be developed to ensure program delivery fidelity. A folder with session summaries will be provided to the participants.
97963|NCT03420534|Drug|Iloperidone 1 MG|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
97964|NCT03420534|Drug|Placebo|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
97965|NCT03420534|Dietary Supplement|fasting|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
97966|NCT03420534|Dietary Supplement|postprandial|An open, random, two-period and two-sequence cross-test design was adopted for the fasting and postprandial groups, and the randomization method was adopted for each subject to randomly take the subjects or reference preparations.
97967|NCT03420521|Drug|Nivolumab|240mg IV over 60 minutes Q2W
97968|NCT03420521|Drug|Ipilimumab|1mg/kg IV over 30 minutes Q6W
97969|NCT03420508|Drug|Ensartinib|Ensartinib will be given at a dose of 225mg daily in the form of 100mg and 25mg capsules. Patients will receive treatment continuously in 28 day cycles. Patients will then have the same tumor specimen biopsied again at day 15. Treatment will continue until disease progression, unacceptable toxicity, or patient choice to discontinue therapy.
97970|NCT03420508|Diagnostic Test|ALKATI by Customized Nanostring Assay|a custom chip with probes targeting the ATI site in ALK, providing a reproducible, quantitative measure of ALKATI
98065|NCT03419715|Drug|Bimatoprost Topical Solution|One drop of bimatoprost topical solution is applied daily to the lunula region of the fingernail bed
97971|NCT03420495|Behavioral|Decision-Making Tasks|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors, decision-making styles, and anxiety/mood symptoms. They then will be guided through three judgment and decision-making (JDM) paradigms (the Risk and Ambiguity Task, the Beads Task, and the Balloon Analogue Risk Task), each of which each has been modified to differ by whether the likelihood of potential adverse outcomes is provided (or whether it remains ambiguous).
97972|NCT03420482|Drug|Fecal Microbiota Transplant (FMT) oral capsules|Donors will be healthy individuals, selected through a previously published, rigorous screening process. Elizabeth Hohmann M.D. of MGH has demonstrated the safety and therapeutic efficacy of oral frozen FMT capsules in Clostridium difficile infection, and her lab will produce the capsules for this study.
97973|NCT03420482|Drug|Placebo oral capsule|Oral placebo capsules filled with glycerol and cocoa powder. These capsules are identical in appearance to FMT capsules.
97974|NCT03420469|Drug|Bupropion|Phase 1: Baseline CYP2D6 activity, using dextromethorphan (30 mg single dose PO) as a probe drug Phase 2: Single dose bupropion pharmacokinetics and its effect on CYP2D6 activity (determined by dextromethorphan 30 mg single dose PO) Phase 3: Bupropion treatment to steady state (150 mg twice daily for 14 days PO) Phase 4: Steady state disposition of bupropion and its interaction with CYP2D6 activity (30 mg single dose PO)
97975|NCT03420456|Device|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
97976|NCT03420456|Device|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
97977|NCT03420443|Dietary Supplement|Oat bran|45 g oat bran.
97978|NCT03420443|Dietary Supplement|Oat bran and blueberry husks|13 g freeze dried blueberry husks and 22 g oat bra + probiotic bacteria.
97979|NCT03420443|Dietary Supplement|No oral supplementation|No oral supplementation.
97980|NCT03420430|Biological|GL-ONC1|
97981|NCT03420417|Device|Esophageal pressure measurement|Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
97982|NCT03420404|Other|TCM physician involved collaborative care model (TCMCMC)|"TCM physician delivered acupuncture as well as history taking, physical examination, non-pharmacological advice and communications with rheumatologists.~Acupuncture procedures: After eliciting the deqi sensation, the needles will be left in place for 30 minutes. The acupuncture treatment will be done 2-3 times a week, with 5 sessions constituting a treatment course. There will be a break of 1 week in between each acupuncture course. Patients in the intervention arm will undergo 2 treatment courses (or 10 sessions) in total."
97983|NCT03420391|Device|Photobiomodulation Therapy (PBMT)|Phototherapy device - Multi Radiance Medical® (Solon, OH, EUA)
97984|NCT03420378|Dietary Supplement|vitamin D|Vitamin D replacement
97985|NCT03420365|Behavioral|Aerobic exercise|30 minutes of either aerobic, or balance and coordination, or reading magazines
97986|NCT03420352|Diagnostic Test|Thromboelastography|paired TEG analysis undertaken from participants with the two different needles
97987|NCT03420339|Drug|Stimulant|The stimulants used must meet FDA dosage guidelines for age.
97988|NCT03420326|Behavioral|Frailty status assessment|The Edmonton frail scale and Frailty criteria by Dr. Fried would be used to assess participants frailty status
97989|NCT03420313|Drug|Buprenorphine/naloxone sublingual tablets|24-week maintenance with buprenorphine/naloxone sublingual tablets (plus other technology-assisted components described previously)
97990|NCT03420300|Drug|EBR/GZR|Elbasvir/grazoiprevir (EBR/GZR 50mg/100mg fixed dose combination [FDC]): 1 table per os per day for 12 weeks
97991|NCT03420287|Combination Product|MPM Prepared From Allogenic Bone Graft|patients will receive a sticky bone which prepared by mixing the the growth factors of the patient with allogenic bone graft for cleft closure
97992|NCT03420287|Other|Autogenous bone|patients will receive an autogenous bone graft from anterior iliac crest for cleft closure
97993|NCT03420274|Behavioral|NEST|This is a point-of-care shared decision-making instrument.
97994|NCT03420274|Behavioral|Usual care|This group will utilize usual care with respect to healthcare provider practice for education and counseling.
97995|NCT03420261|Biological|0.9% saline|Fluid administration
97996|NCT03420261|Biological|HES 130/0.4|Fluid administration
97997|NCT03420248|Device|Non-spherical polyvinyl alcohol particle or Tris-acryl gelatin microsphere|One of non-spherical polyvinyl alcohol particle or tris-acryl gelatin microsphere is used for embolic materials. All other processes are same.
97998|NCT03420235|Other|Home monitoring program|The home monitoring program consists of 1) the use of an interactive internet tool to coach patients and enhance self-management 2) home-based pulmonary function testing with a handheld spirometer and 3) recording of patient-reported outcomes (PROs).
97999|NCT03420222|Drug|AVP-786|oral capsules
98000|NCT03420222|Drug|Placebo|oral capsules
98001|NCT03420209|Behavioral|Group applying PNF technique|
98002|NCT03420196|Other|Supervised exercise program|"It will consist in a supervised exercise program, including the following exercises:~Diaphragmatic breathing.~Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~Pelvic swing.~Gluteus bridge.~Spinal mobility.~Spinal extensor muscles strengthening~Frontal plank~Side plank.~Lateral leg raise for gluteus medium"
98003|NCT03420196|Other|Non supervised exercise program|"It will consist in a non supervised exercise program, including the following exercises:~Diaphragmatic breathing.~Transverse abdomLateral leg raise for gluteus mediuminis muscle activation.~Pelvic swing.~Gluteus bridge.~Spinal mobility.~Spinal extensor muscles strengthening~Frontal plank~Side plank.~Lateral leg raise for gluteus medium"
98035|NCT03419949|Drug|oral pregabalin 150 mg|Pain relief using drug Pregabalin is a structural analogue of the inhibitory neurotransmitter gama-aminobutyric acid (GABA), with anticonvulsant, antihyperalgesic, and anxiolytic properties
98063|NCT03419741|Device|Transcranial Magnetic Stimulation Clinical Research System|Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
98004|NCT03420170|Other|Graded Exercise Integrated Education|"Aerobic exercise Wheelchair propelling, boxing, hand cycling (2 rounds)~3 mins. exercise and 2 mins. rest~Increased to 4.5 mins. and 30 sec. rest~Strengthening exercise:~Vertical chest press, butterfly press; vertical row and wide lattissimus pull down 3 sets, 10 reps. and 2 min rest between sets, moderate to vigorous intensity (50% of 1 RM)~Educational intervention:~The educational intervention for exercise self-efficacy and physical activity level (2 hours a week for 8 weeks during in rehabilitation and once a month for 8 weeks after discharge from rehabilitation)"
98005|NCT03420170|Other|Conventional Physical Therapy|Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
98006|NCT03420157|Other|Focus Group|Focus Group of 2 hours. Women will be asked to give their opinion about the communication media of the vaginal self-sampling kit.
98007|NCT03420144|Drug|Standard Medical Therapy|Standard Medical Therapy will include nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics as required
98008|NCT03420144|Drug|Growth Hormone|GH therapy is initiated at a low dose of 1U/day and titrated slowly upward to a maximum dose of 3U/day (depending on IGF-1 levels) subcutaneously for 1 year.
98009|NCT03420131|Diagnostic Test|QFR and iFR|"iFR® (CE-Marked) is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option.~QFR® (CE-Marked) is an angio-based FFR estimation using the analytical Software QAngio XA 3D from Medis medical imaging B.V., The Netherland"
98010|NCT03420118|Procedure|Tumor tissue collection|"Depending on the status of disease when participants join the study, a sample of tumor tissue may be collected from:~A previous surgery for the disease,~A biopsy for diagnosing the disease,~Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~At anytime participants require a biopsy as a part of their cancer care, a sample of that tumor tissue will be collected.~New biopsies will be done to collect fresh tumor tissue each time participants' disease worsens."
98011|NCT03420118|Procedure|Blood draws|"Blood samples will be collected at the following different times points:~Before starting a new line of treatment for the disease,~One week after starting a new line of treatment for the disease,~During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~At the time the disease worsens or relapses (comes back)~During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease"
98012|NCT03420105|Other|Neuropsychological, psycho-pathological and quality of life assessments|Patients and Healthy volunteers perform neuropsychological, psycho-pathological and quality of life assessments, and sleep tests
98013|NCT03420105|Drug|Hormonotherapy|Adjuvant hormone therapy
98014|NCT03420092|Drug|Form 1 of AZD5718 tablets|The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
98015|NCT03420092|Drug|Form 2 of AZD5718 tablets|The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
98016|NCT03420092|Drug|Form 3 of AZD5718 tablets|The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
98017|NCT03420092|Drug|Form 4 of AZD5718 tablets|The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
98018|NCT03420092|Drug|Form 5 of AZD5718 tablets|The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
98019|NCT03420092|Drug|Selected form (Form 2 - 5) of AZD5718 tablets|The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
98020|NCT03420079|Drug|FCN-411|This is a five parts study to determine the pharmacokinetics of FCN-411 administered orally at five dose levels (4 mg Cohort 1、8mg Cohort 2、 16mg Cohort 3、24mg Cohort 4 and 32mg Cohort 5) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
98021|NCT03420066|Other|Retrospective data collection|Retrospective collection of data recorded as standard of care for patients that were implanted with the Nexus device as part of Compassionate Use duly authorized according to country specific regulations.
98022|NCT03420053|Biological|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating, radiation-attenuated, cryopreserved Pf sporozoites.
98023|NCT03420053|Other|Normal Saline Placebo|0.9% sodium chloride solution
98024|NCT03420053|Biological|PfSPZ Challenge|Aseptic, purified, live, infectious, cryopreserved Pf sporozoites.
98025|NCT03420040|Device|QS-M Needle Free Injector|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
98026|NCT03420040|Device|Glargine pen|The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
98027|NCT03420027|Other|questionnaire to be filled in by investigators|A simple seven-item questionnaire will be filled in by the investigator before performing urgent tracheal intubation. This intubation, which will be performed as done in routine care, does not constitute a study specific intervention
98028|NCT03420014|Drug|Doxorubicin|75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
98029|NCT03420014|Combination Product|L19TNF plus doxorubicin|13 μg/kg L19TNF will be administered on day 1, 3 and 5 of every 21-days cycle in combination with 60 mg/m2 doxorubicin on day 1 of every 21-days cycle.
98030|NCT03419988|Behavioral|Exercise Intervention|24 sessions of aerobic exercise
98031|NCT03419975|Drug|TJO-002|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
98032|NCT03419975|Drug|Latanoprost|Administrate the drugs for clinical trial one drop once daily at the same time (9 p.m. ± 1 hour) for a study eye
98033|NCT03419962|Drug|MaxSpiolto® Respimat® 160 Characters...|as per the approved SmPC
98034|NCT03419949|Drug|oral lamotrigine 100 mg|Pain relief drug Lamotrigine inhibits the voltage-gated sodium and calcium channels. Inhibition of the voltage-gated sodium channel stabilizes the presynaptic neuronal membrane, thus preventing the release of excitatory neurotransmitters such as glutamate and inhibiting sustained repetitive neuronal firing
98293|NCT03418038|Biological|Rituximab|Given IV
98036|NCT03419936|Diagnostic Test|Endoscopic biopsy|"Pre-operation (initial diagnosis) Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~Post-subtotal gastrectomy (After 6 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~Post-subtotal gastrectomy (After 12 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy.~Post-subtotal gastrectomy (After 24 months) Assess the distribution of helicobacter pylori after subtotal gastrectomy."
98037|NCT03419923|Drug|two stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow(3/4 x 1.2 x blood flow)ml/h,and at the venous bubble trap at a rate according to the blood flow(1/4 x 1.2 x blood flow)ml/h.
98038|NCT03419923|Drug|one stage regional citrate|4% trisodium citrate was infused at the arterial bubble trap at a rate according to the blood flow( 1.2 x blood flow)ml/h.
98039|NCT03419910|Drug|BMS-986165|Specified dose on specified days
98040|NCT03419910|Drug|Cyclosporine|Specified dose on specified days
98041|NCT03419897|Drug|BGB-A317|Anti-PD-1 ANTIBODY
98042|NCT03419871|Other|Monitoring Sleep|An accelerometer will be placed on the wrist or ankle of the child while the child sleeps in their home. Caregivers will be instructed to keep the accelerometer on their toddler's ankle to measure sleep duration, latency and sleep efficiency. Seven nights of data will be obtained because actigraphy is most reliably measured in young children over this time frame.
98043|NCT03419871|Other|stress biomarkers|"Salivary and hair cortisol measurements were used to obtain a change in baseline from 12 to 24 months. Data on the timing of the saliva collection will be collected using a Medical Electronic Monitoring System (MEMScapTM) - a digital memory cap that records the timing and frequency of opening.~Cortisol will be measure in the morning and bedtime samples. A small amount of hair (30mg) will be cut from the posterior vertex of the child's head. Due to the expected variability in hair length of toddlers, documentation of hair length will be completed. Each centimeter represents 1 month history of stress and ideally 3 cm of hair length will be collected to provide a three month history of stress."
98044|NCT03419858|Behavioral|Mindfulness Meditation|A well-validated brief mindfulness-based mental training regimen [four sessions; 20 min/session] was used to teach patients to independently practice mindfulness meditation.
98045|NCT03419858|Behavioral|Placebo Meditation|A well-validated brief meditation-based mental training regimen [four sessions; 20 min/session] was used to teach patients to independently practice closing their eyes and take a deep breath every few minutes.
98046|NCT03419858|Behavioral|Slow-Breathing|Study volunteers practiced lowering their breathing rate, across four, 20 minute training sessions, in response to a fluctuating light with the guidance of a trained facilitator.
98047|NCT03419858|Drug|Naloxone|A 0.15 mg/kg bolus dose of naloxone (Naloxone Hydrichloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion ceased till the end of the experiment.
98048|NCT03419858|Other|Saline|A 0.15 mg/kg bolus dose of saline in 25ml normal saline was administered over 10 minutes. We also administered a supplementary IV infusion dose of 0.1mg/kg/hour saline immediately after bolus infusion ceased till the end of the experiment.
98049|NCT03419845|Device|Step Right Buddy|The Step Right Buddy, which is under investigation in this clinical study, is an elasticated band that attached by Velcro to the back legs of a standard walking frame. The purpose of the Step Right Buddy is to provide sensory feedback to standard walking frame users of how far to step in to the frame and to encourage them to move the frame forward.
98050|NCT03419832|Other|NEAT Form|The NEAT form consists of a clear and concise overview document containing information satisfying all elements of consent. This is made up of IRB-approved wording from the regular consent form. More detailed information, such as specific clinic measures are provided as additional material and are discussed during the consent process after the general overview has been provided with the NEAT form.
98051|NCT03419832|Other|Standard Form|The regular IRB approved version.
98052|NCT03419819|Dietary Supplement|PKU Sphere|PKU Sphere is a glycomacropeptide based alternative to amino-acid based products for the dietary management of phenylketonuria.
98053|NCT03419806|Drug|Infudopa i.v.|Infudopa i.v. infusion will be given through an indwelling catheter placed in the arm. Infudopa i.v. will be delivered in 75% of the subject's individual pre-study dosing of Duodopa, administered as a morning rapid i.v. constant rate administration followed by continuous i.v. infusion up to 16 h. The subject's usual morning dose will be administered to rapidly achieve the therapeutic dose level. The maximum daily dose levodopa during i.v. administration should normally not exceed 2513 mg, and is not allowed to exceed 3000 mg (equal to 75% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
98054|NCT03419806|Drug|Infudopa s.c.|A suitable infusion needle will be placed laterally on the abdomen for the s.c. infusion of Infudopa. Infudopa s.c. will be delivered in the same dosage as the subject's individual pre-study dosing of Duodopa, also administered as a morning rapid s.c. constant rate administration followed by continuous s.c. infusion up to 16 h. The maximum daily dose levodopa during s.c. administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg (equal to 100% of the maximum allowed daily dosage for Duodopa that is 4000 mg).
98055|NCT03419806|Drug|LCIG (Duodopa)|Duodopa will be administered directly to the proximal small intestine via a PEG-J tube connected to a portable infusion pump. Individually optimized dosing of Duodopa will be administered as a morning rapid constant rate administration followed by continuous infusion and, if needed, intermittent extra doses (subject-initiated based on symptom experience). The maximum daily dose levodopa during Duodopa administration should normally not exceed 3350 mg, and is not allowed to exceed 4000 mg.
98056|NCT03419793|Device|segmental vibration device|segmental vibration device
98057|NCT03419793|Other|physical therapy exercises|
98058|NCT03419780|Biological|Blood Transfusion|Patients are randomized to receive 1 or 2 units of packed red blood cells for initial transfusion.
98059|NCT03419767|Drug|Melatonin|Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
98060|NCT03419767|Other|blank|Patients under carotid revascularization surgery without taking melatonin
98061|NCT03419754|Dietary Supplement|Glucose|Glucose
98062|NCT03419754|Behavioral|Fidgetting|low intensity physical activity (fidgetting)
98066|NCT03419715|Drug|Control|One drop of saline solution is applied daily to the lunula of the fingernail bed on one hand.
98067|NCT03419702|Dietary Supplement|Almonds|During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
98068|NCT03419689|Procedure|Tumour tissue collection|"Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:~At the time of diagnosis or progression~Any surgical procedures for management of tumour related medical conditions~At each subsequent relapse or disease progression"
98069|NCT03419689|Procedure|Blood sample collection|"Blood samples will be taken:~At the time of first diagnosis~About 1 week after starting any treatment~At each radiological response assessment~At each subsequent relapse or disease progression"
98070|NCT03419689|Procedure|Ascites Collection|"Ascites will be collected if paracentesis is required during any of the following time points:~At the time of diagnosis or progression~Any surgical procedures for management of tumour related medical conditions~At each subsequent relapse or disease progression"
98071|NCT03419689|Procedure|Fluid Collection|Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
98072|NCT03419676|Device|Hemopatch|Collagen patch derived from bovine dermis, coated with NHS-PEG, applied covering the pancreaticojejunostomy after pancreatoduodenectomy once the anastomosis is completed.
98073|NCT03419663|Dietary Supplement|cereal or grain consumption|intake of cereal, whole grain, refined grain, and other grain of every day
98074|NCT03419650|Drug|ACTHar|Acthar™ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.
98075|NCT03419637|Other|Mobile app|The mobile app, or app, is installed on the patient's mobile device and is used to document the surgical procedure with before and after photographs, including pre- and post-surgery diagnosis. The app allows patients to view a skin history summary report and a reference on their skin ﬁndings and procedures.
98076|NCT03419624|Drug|Dapagliflozin 10mg|Dapagliflozin 10 mg tablet once daily
98077|NCT03419624|Drug|Exenatide 2 mg [Bydureon]|Exenatide 2 mg injection once weekly
98078|NCT03419624|Drug|Placebo Oral Tablet|Placebo oral tablet once daily
98079|NCT03419624|Drug|Placebo injection|Placebo injection once weekly
98080|NCT03419624|Drug|Insulin|daily Insulin injections
98081|NCT03419624|Drug|Metformin, if taken before|If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
98082|NCT03419611|Behavioral|Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.
98083|NCT03419611|Other|Treatment as Usual|Teacher provided with word list and teacher intervening as usual.
98084|NCT03419611|Behavioral|High Intensity Multi-Modal|Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
98085|NCT03419598|Procedure|Opening wedge high tibial osteotomy|Realignment of knee by creating an opening wedge osteotomy in the upper part of the tibia
98086|NCT03419598|Device|ToKa subject specific custom HTO plate|Subject specific custom plate for stabilizing an open wedge HTO
98087|NCT03419598|Device|Generic HTO plate|Generic plate for stabilizing an open wedge HTO
98088|NCT03419585|Device|Intervention systematic light exposure|30 minutes of intervention systematic light exposure daily
98089|NCT03419585|Device|Comparison systematic light exposure|30 minutes of comparison systematic light exposure daily
98091|NCT03419559|Biological|LN-145|adoptive cell therapy (ACT) with autologous TIL therapy
98092|NCT03419559|Drug|Durvalumab|PD-L1 antagonist monoclonal antibody
98093|NCT03419520|Behavioral|Nutritional counseling|Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
98094|NCT03419507|Device|Endotracheal tube introducer|The doctors that drawed envelop number 2 will be asked to intubate with laryngoscope by the adult size, endotracheal tube introducer with using No. 3 Macintosh blade
98095|NCT03419507|Device|Macintosh laryngoscopy|The doctors who drawed envelope number 1 will asked to intubate with using No. 3 Macintosh blade
98096|NCT03419494|Drug|PLD|PLD36mg/m2.d d1、d15，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
98097|NCT03419494|Drug|DNR|DNR 45mg/m2.d d1～3，ivdrip，1h，VCR 1.4mg/m2.d d1，d8，d15，d22 iv，CTX 800mg/m2.d d1 ivdrip，L-asp 6000u/m2.d d19～28 ivdrip，Dex10mg.d d1～28 ivdrip
98098|NCT03419481|Drug|pembrolizumab|200mg every 3 weeks infusion
98099|NCT03419468|Other|Self Geriatric Assessment Measure (SGAM)|Self Geriatric Assessment Measure
98100|NCT03419455|Other|Trajectories of body fatness and diet|There is no intervention. This is an observational study with trajectories of body fatness and diet as main exposure.
98101|NCT03419442|Drug|Xofigo|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injection
98102|NCT03419442|Drug|Taxotere|Docetaxel injection 75mg/m2 every 3 weeks
98103|NCT03419442|Drug|Jevtana|Cabazitaxel injection 25mg/m2 intravenously once every 3 weeks
98104|NCT03419429|Drug|Simvastatin|Simvastatin is a drug used orally for treatment of hypercholesterolemia. It assists in bone regeneration and has anti-inflammatory effect when applied locally in intrabony defects for periodontal therapy.
98105|NCT03419429|Other|EDTA|EDTA is a demineralizing agent used for root surface conditioning.
98106|NCT03419429|Device|Occlusive membrane|Occlusive membrane is the traditional collagen resorbable membrane used in guided tissue regeneration.
98107|NCT03419429|Device|Modified perforated membrane|Modified perforated membrane is the traditional collagen resorbable membrane but modified to be perforated. It is used in guided tissue regeneration
98108|NCT03419416|Other|Kangaroo mother care (KMC)|Skin to skin contact of newborns with mothers and exclusive breast feeding
98109|NCT03419403|Drug|Steroid eye drop|solution, eye drop
98110|NCT03419403|Drug|Ophthalmic steroid ointment|ointment
98111|NCT03419403|Radiation|Radiation|radiation
98112|NCT03419403|Drug|Temozolomide|oral
98113|NCT03419403|Drug|depatuxizumab mafodotin|infusion
98114|NCT03419403|Other|cold compress|cold compress
98115|NCT03419403|Drug|Vasoconstrictor eye drop|solution, eye drop
98116|NCT03419390|Device|combined Coaxial Optical Coherence Tomography (OCT) System|The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel
98117|NCT03419377|Other|Standard care and sexological counseling|6-8 sexological consultants in a period of six months
98118|NCT03419364|Drug|nicotinamide|2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
98119|NCT03419351|Diagnostic Test|Smartphone|Smartphone based measurement of refractive error and visual acuity testing using these measurements.
98120|NCT03419351|Diagnostic Test|Autorefractor|Autorefractor based measurement of refractive error and visual acuity testing using these measurements.
98121|NCT03419351|Diagnostic Test|Individual|Individual, human measurement of refractive error and visual acuity testing using these measurements.
98122|NCT03419338|Procedure|Sinus lift|Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.
98123|NCT03419338|Procedure|Surgical alveolus|Using a round diamond bur, a surgical alveolus will be created on an toothless ridge region.
98124|NCT03419338|Procedure|Inorganic bovine bone + newly forming bone|Maxillary sinus lift will be done with inorganic bovine bone associated with newly forming bone. The newly forming bone will be collected from surgical alveolus previous prepared.
98125|NCT03419338|Procedure|Inorganic bovine bone|Maxillary sinus lift will be done with inorganic bovine bone.
98126|NCT03419338|Device|Collagen membrane|At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.
98127|NCT03419325|Genetic|CYP2C19 test|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
98128|NCT03419325|Diagnostic Test|P2RY12 assay|Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
98129|NCT03419312|Device|Proclaim™ Elite 5: Burst - Washout - Sham|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
98130|NCT03419312|Device|Proclaim™ Elite 5: Sham - Washout - Burst|"All implanted hardware manufactured by S:t Jude Medical/Abbot:~Implantable Pulse Generator (IPG): Proclaim™ Elite 5 IPG, model 3660. Electrode: Octrode percutaneous lead, 60 cm, model 3161. Anchor: Long lead anchor, model 1106."
98131|NCT03419299|Other|Tube Feeding Application|A smart device application was developed and used to help residents determine the best enteral nutrition prescription for patients admitted to the ICU
98132|NCT03419273|Procedure|bariatric surgery|We are recruiting only those going through bariatric surgery
98133|NCT03419260|Other|Clinically indicated EEG monitoring.|Children enrolled in the study will be undergoing clinically indicated EEG monitoring. Some children will undergo clinically indicated electrographic seizure management.
98134|NCT03419247|Procedure|Fresh tumor tissue biopsy|A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
98135|NCT03419247|Procedure|Blood draw|Blood will be taken by a needle from a vein.
98136|NCT03419247|Procedure|Archival tumor tissue collection|A sample of tumor tissue that was taken by biopsy or surgery before agreeing to take part in this study will be collected.
98137|NCT03419234|Drug|Abiraterone Acetate|Given PO
98138|NCT03419234|Drug|Antiandrogen Therapy|Receive standard of care antiandrogen therapy with either LHRH agonist or antagonist
98139|NCT03419234|Drug|Cabazitaxel|Given IV
98140|NCT03419234|Other|Laboratory Biomarker Analysis|Correlative studies
98141|NCT03419234|Procedure|Orchiectomy|Undergo standard of care surgical castration with bilateral orchiectomy
98142|NCT03419234|Other|Pharmacological Study|Correlative studies
98143|NCT03419234|Drug|Prednisone|Given PO
98144|NCT03419221|Procedure|PET/CT Positron emission tomography (PET) using small radiotracers, a special camera and a computer to evaluate organ and tissue functions|"Open-label randomized controlled superiority trial in patients with SAB without infective endocarditis at the time of inclusion comparing whole-body PET/CT in arm A and routine care with performance of imaging studies according to anamnesis and clinical symptoms in arm B. To demonstrate that PET/CT is associated with a 20% higher frequency of detection of DFI during SAB, the inclusion of 145 patients in each arm is required.~Randomization will be stratified on centre and SAB setting of acquisition (healthcare vs community)."
98145|NCT03419221|Other|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms|Patients' routine care with performance of explorations based on anamnesis and clinical symptoms
98146|NCT03419208|Other|SPIN-HAND Program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
98147|NCT03419195|Other|Cardiovascular exercise training|Following the completion of baseline testing, both subject groups will undergo supervised cardiovascular exercise training 3 times per week for 3 months (plus a 3 week ramp-up). Exercise training will take place on a treadmill, stationary bicycle, elliptical, rowing machine, or combination of machines. Each session will last 1 hour, which includes a 5 minute warm-up, 50 minutes of exercise, and a 5 minute cool down.
98148|NCT03419182|Procedure|Open Reduction internal Fixation|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture.
98149|NCT03419182|Procedure|Open Reduction Internal Fixation with Total Hip Arthroscopy|A surgeon uses hardware, such as plates and screws, to restore structural integrity and alignment of an acetabular fracture, and replaces the cartilage and bone of the greater trochanter with prosthetic components.
98150|NCT03419169|Device|Light load BFR resistance training|A novel training light load resistance training modality.
98151|NCT03419169|Procedure|Heavy load resistance training|A common form of resistance training used for rehabilitation within the National Health Service.
98152|NCT03419156|Other|Text Message Arm Intervention|Patients in the Text Message Arm will receive a weekly set of text messages inquiring about the patients' symptoms instead of a weekly phone call from the nurse team (standard of care). Potentially harmful symptoms identified by the automated system will generate an alert that will be sent to the medical team. The alert will be immediately sent via email to the nursing team. The nurse will be able to contact the patient to decide the best further treatment. The nurses will check patient response rates daily. If a patient does not respond to their weekly message, then the patient will be called.
98153|NCT03419143|Other|Non-interventional|Non-interventional
98154|NCT03419130|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
98155|NCT03419130|Other|Laboratory Biomarker Analysis|Correlative studies
98156|NCT03419130|Biological|Pembrolizumab|Given IV
98157|NCT03419130|Radiation|Radiation Therapy|Undergo conventionally fractionated RT
98158|NCT03419117|Procedure|ESP block|An ESP block will be performed prior to surgery for postoperative pain control
98159|NCT03419117|Procedure|Placebo|A sham ESP block will be performed before surgery in the placebo group
98160|NCT03419104|Diagnostic Test|preoperative walk test|Patients undergoing bariatric surgery who will complete a preoperative 60 meters 60 seconds walk test.
98161|NCT03419091|Device|single-use flexible digital ureteroscope|Device being tested.
98162|NCT03419091|Device|Reusable Ureteroscope|Comparative device.
98163|NCT03419065|Behavioral|Relaxation Intervention|Relaxing Music combined with Progressive Muscle relaxation and guided imagery
98164|NCT03419052|Behavioral|Speed of processing|"All interventions are conducted through applications running on a tablet computer device that we will provide to all participants for the study duration.~Speed of processing training is provided by the Internet-based BrainHQ program from Posit Science, Inc. BrainHQ contains five different speed training modules (Hawk Eye, Visual Sweeps, Fine Tuning, Eye for Detail, Sound Sweeps) tap time-order judgment, visual discrimination, spatial-match, forward-span, instruction-following, and memory.(93) The Posit program systematically reduces stimulus presentation time to maintain an 85% accuracy rate and launches each new session based on the stopping point of the preceding session. Participants receive performance ratings relative to their prior trial upon completion of each exercise. Participants will be incentivized to train 15 minutes (minimum), 5 days per week for 12 weeks."
98165|NCT03419039|Dietary Supplement|Anthocyanins|Medox tablet containing 80 mg anthocyanins.
98166|NCT03419039|Dietary Supplement|Placebo|Identically appearing capsules.
98167|NCT03419013|Other|New adhesive strip|This strip is made of a newly developed adhesive
98168|NCT03419000|Genetic|blood sample|Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
98169|NCT03418987|Other|Medical File data analysis|Analysis of the 2D/3D spine images (performed with the sterEOS software and the MATLAB software)
98170|NCT03418974|Drug|Pitavastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
98171|NCT03418974|Drug|Atorvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
98172|NCT03418974|Drug|Rosuvastatin|Capsule/Tablet, oral, follow the doctor's advice Participants will receive rosuvastatin treatment for 3 or 12 weeks.
98173|NCT03418961|Drug|Carvedilol|Given PO
98174|NCT03418961|Other|Laboratory Biomarker Analysis|Correlative studies
98175|NCT03418961|Other|Patient Observation|Undergo observation
98176|NCT03418948|Device|CC followed by EC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
98177|NCT03418948|Device|EC followed by CC|CC = conventional colonoscopy EC = endocuff assisted colonoscopy
98178|NCT03418948|Device|2x EC|EC = endocuff assisted colonoscopy
98179|NCT03418948|Device|2x CC|CC = conventional colonoscopy
98180|NCT03418935|Drug|Remaxol (succinate + methionine + inosine + nicotinamide)|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
98181|NCT03418935|Drug|Ringer's Solution|Intravenous infusion, 400 or 800 ml
98182|NCT03418922|Drug|Lenvatinib|Specified doses will be administered orally on specified days.
98183|NCT03418922|Drug|Nivolumab|Specified doses will be administered intravenously on specified days.
98184|NCT03418896|Drug|human chorionic gonadotropin|a single injection of a standard dose
98185|NCT03418883|Other|Mirror therapy|
98186|NCT03418870|Behavioral|Family Integrated Care|Parents of infants assigned to mFI-Care will be trained and treated as primary caregivers for their infants and participate in daily medical rounds, with mFI-Care-trained nurses serving as teachers and coaches.
98187|NCT03418857|Drug|Yogurt smoothie with BB-12|During the one month intervention period, the participants will consume one yogurt smoothie with BB-12 daily.
98188|NCT03418857|Drug|Yogurt smoothie|During the one month control period, the participants will consume one yogurt smoothie daily.
98294|NCT03418025|Behavioral|Exercise Intervention|Undergo Exercise Together intervention
98295|NCT03418025|Other|Questionnaire Administration|Ancillary studies
98189|NCT03418844|Other|Self-questionnaires of living conditions and quality of life|Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
98190|NCT03418844|Diagnostic Test|Cardiac, pulmonary, auditory and biological assessment|"Patients will perform :~Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~Blood tests"
98191|NCT03418831|Drug|Raloxifene Hydrochloride|60 mg per capsule (1 tablet daily) for 12 weeks
98192|NCT03418831|Other|Placebo|1 tablet daily for 12 weeks
98193|NCT03418818|Drug|18F-FAZA|18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after their radiation treatment.
98194|NCT03418805|Drug|Advil Ibuprofen table 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
98195|NCT03418805|Drug|Motrin IB Ibuprofen Tablets 200 mg|"Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration."
98196|NCT03418805|Drug|Ibuprofen CR Tablets 600 mg|"Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively"
98197|NCT03418792|Other|Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography|Head & neck radiation with parotid sparing. Parotid sparing will be facilitated by avoidance of salivary ductal structures and stem cells, as identified by the pre-treatment MRI sialogram, in the radiation treatment plan.
98198|NCT03418779|Drug|The Yi-Qi-Qing-Jie Herbal Compound|Patients will receive granular infusion of Yi-Qi-Qing-Jie herbal compound twice a day which composed of astragalus, angelica root, lonicera, rheum palmatum, etc, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid for the duration of the treatment and follow-up phases.
98199|NCT03418779|Drug|Immunosuppressive Agents|Patients will receive prednisolone 0.5-0.8mg/kg/d (up to a maximum of 60mg/day) for 8 weeks and then the dose is tapered by 20% every 4 weeks until the course is completed (28-32 weeks), plus intravenous cyclophosphamide (0.8-1g/4w, total dose 8-10g) for the duration of the treatment and follow-up phases.
98200|NCT03418779|Other|Optimized Supportive Care|"The optimized supportive care included:~Lifestyle: low-salt, restricted protein dietary with sufficient calorie supply, smoking cessation, moderate alcohol consumption and keeping a healthy weight~The use of renin-angiotensin system blockade: lowering blood pressure to a target below 130/80 mmHg, during which treatment was adjusted to ensure that patients were receiving the maximum labelled or tolerated dose of RAS blockade~Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c<7.0%~Received uricosuric agents or xanthine oxidase inhibitors as necessary to achieve serum uric acid <6 mg/dL"
98201|NCT03418779|Other|Yi-Qi-Qing-Jie herbal compound placebo|Patients will receive Yi-Qi-Qing-Jie herbal compound placebo instead for the duration of the treatment and follow-up phases. Placebo contained ingredients with no therapeutic effects (e.g., coke malt) that looked, smelled and tasted like Yi-Qi-Qing-Jie herbal compound.
98202|NCT03418753|Diagnostic Test|EyeBOX for ICP|non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time
98203|NCT03418727|Drug|Brimonidine|Two products delivered in sequence twice daily.
98204|NCT03418727|Drug|Brimonidine Mono Therapy|Brimonidine given twice daily along with placebo drops
98205|NCT03418727|Drug|sodium carboxymethylcellulose|Placebo given twice daily.
98206|NCT03418727|Drug|Corticosteroid Eye Drop|Eye drop to be administered after Briomonidine in treatment arm 1
98207|NCT03418714|Drug|Salvinorin A|Salvinorin A, blinded doses
98208|NCT03418701|Behavioral|Health Smart for Weight Loss|We will test the effectiveness of a culturally sensitive, evidence-based, multi-component, behavioral program for treating obesity called Health-Smart. This program will be implemented for 6 months in 20 UF Health Jacksonville primary care clinics by Community Health Workers (CHWs) with Black women patients who have obesity, and followed by either of two physician-implemented behavioral counseling weight loss maintenance programs that are applied quarterly over 12 months to prevent weight gain. Specifically, we will compare the effects on weight-loss and weight-loss maintenance of (1) Health-Smart plus the Patient-Centered, Culturally Sensitive Weight Loss Maintenance Program (PCS-WLM), and (2) Health-Smart plus the Standard Behavioral Weight Loss Maintenance Program (SB-WLM).
98209|NCT03418688|Drug|COR388|COR388 administered for 10 or 28 days.
98210|NCT03418688|Drug|Placebo|Placebo administered for 10 or 28 days.
98211|NCT03418675|Drug|Rexulti|Atypical antipsychotic
98212|NCT03418675|Drug|Placebo|Pill that contains no medicine
98213|NCT03418662|Device|EndoRings device|Subjects randomized to undergo a colonoscopy procedure with the EndoRings device will have the device placed on the colonoscope that will be used during their procedure.
98214|NCT03418649|Drug|Eplerenone 50 Mg Tab|50 mg PO per day for 10 days
98215|NCT03418649|Drug|Placebo Oral Tablet|PO once daily for 10 days
98216|NCT03418636|Behavioral|Staying Safe (Ssafe)|Staying Safe motivates and teaches young people who inject drugs (PWID) planning skills and drug use management strategies to enable long-term risk avoidance and the implementation of healthy protective behaviors. Content is presented through guided discussions and role playing exercises, and relies heavily on interactive participation by group members to foster peer-based learning and social reinforcement processes.
98217|NCT03418636|Behavioral|Healthy Living|The content of the Healthy Living intervention is based on the DHHS' Eat Healthy, Be Active Community Workshop curriculum, supplemented with basic sleep hygiene education. Science-based dietary and light physical activity guidelines are demonstrated and promoted to help participants develop and maintain a healthy lifestyle.
98218|NCT03418623|Drug|GET73|GET73 300 mg oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
98219|NCT03418623|Other|Placebo|Placebo oral capsules, administered three times a day on Visit 2 and 4, and twice a day on Visit 3 and 5.
98220|NCT03418610|Drug|Azelaic Acid foam 15%|mild to moderate rosacea
98296|NCT03418025|Other|Survey Administration|Ancillary studies
98221|NCT03418597|Procedure|Deep local anesthesia + Virtual reality|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne). Patient will have a 3-D immersive experience, created using a visual and audio headset and a software labelled as medical device.
98222|NCT03418597|Procedure|Deep local anesthesia alone|Biopsy performed according to current practice (deep local anesthesia with premedication and lidocaïne).
98223|NCT03418584|Device|HybridAPC|HybridAPC is a device which combines submucosal fluid injection with APC
98224|NCT03418571|Biological|ALX-0171 1.5 mg/kg|ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.
98225|NCT03418571|Other|Placebo|Placebo was administered via a single inhalation once daily for 3 consecutive days.
98226|NCT03418558|Drug|Trastuzumab emtansine|
98227|NCT03418532|Combination Product|MP0250 DARPin® drug candidate, Osimertinib|Number of Cycles: until progression, unacceptable toxicity or other reasons for withdrawal
98228|NCT03418519|Other|Constraint Induced Movement Therapy|Constraint-induced movement therapy (CIMT) is a high-dosage, efficacious, rehabilitation approach used for children with hemiplegic cerebral palsy
98229|NCT03418506|Behavioral|SMOKELESS TOBACCO AWARENESS PROGRAM|A SMOKELESS TOBACCO AWARENESS PROGRAM was conducted for 2 consecutive weeks in all the selected schools. The intervention programme comprised of health education sessions that emphasized on the hazard of betel quid, areca-nut and smokeless tobacco. The sessions included 30 minutes power point presentation, posters, one pictorial booklets on the hazards of use of various tobacco products. Moreover we played a 30 minutes game show at follow-up visit. After completion of 2 weeks intervention programme, the same group of students completed the post-test questionnaire. Educational materials about hazards of betel quid, areca-nut and smokeless tobacco were distributed to both intervention and control groups.
98230|NCT03418493|Drug|LY3316531 - IV|Administered IV.
98231|NCT03418493|Drug|LY3316531 - SC|Administered SC.
98232|NCT03418493|Drug|Placebo - IV|Administered IV.
98233|NCT03418493|Drug|Placebo - SC|Placebo - SC.
98234|NCT03418480|Drug|HPV vaccine|Intradermal vaccine
98235|NCT03418454|Diagnostic Test|Buccal mucosa samples for Extraction of BACTERIAL DNA|"Sampling of the buccal mucosa after informed consent and prior to routine treatment. Similar sampling on follow up after 3,6,9,12 months.~Extracted BACTERIAL DNA (and not human DNA) from clinical samples will be sequenced and analyzed for the 16s rRNA (BACTERIAL ribosome)."
98236|NCT03418441|Other|Community-acquired CNS infections|Prospective observational registration of clinical characteristics and outcome
98237|NCT03418415|Device|Renal denervation|multi-electrode catheter-based renal denervation
98238|NCT03418402|Device|Airseal®|Total laparoscopic hysterectomy: Approach according to the Open-Laparoscopy technique and use of the insufflation system.
98239|NCT03418402|Device|Standard insufflator|Standard insufflator
98240|NCT03418376|Dietary Supplement|Beta-alanine supplementation|The supplementation protocol of β-alanine (Etixx® Omega Pharma Belgium NV) involves oral intake of 4 x 800mg (3.2g/day29, 43) daily with at least 2h apart of slow-release β-alanine during the first 12 weeks. After this loading period, subjects will receive a maintenance dose of 2 x 800mg (1.6g/day) β-alanine for the remaining study duration.
98241|NCT03418376|Other|Exercise intervention|The exercise training program (6 months) involves 3 week cycles (week I-III). During week I, subjects will perform high volume moderate intensity cardiovascular cycle training (3x/week). Twice a week, subjects perform 3h training sessions (70-80% HRmax*) and once a week a 1.5h session will be executed (80-90% HRmax). During week II, subjects will perform low volume maximum intensity interval cycle training (3/w). High intensity interval cycle training (HIIT) will consist of 3x maximal sprints (90-100% HRmax) of 1.5min, interspersed with 3min rest intervals. A 5min standardized warming up and 5min cooling down will be performed. Week III involves a recovery week where subjects will perform one training session of 1.5h at an exercise intensity of 70-80% HRmax and one session of HIIT.
98242|NCT03418363|Dietary Supplement|DHEA Oral Capsule|Daily 100mg DHEA supplement
98243|NCT03418363|Other|Placebo Oral Capsule|Daily oral capsule
98244|NCT03418337|Drug|dexilansoprazole (Dexilant 60 mg)|evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group
98245|NCT03418337|Drug|lansoprazole (Takepron OD 30 mg)|lansoprazole group
98246|NCT03418324|Drug|TRC105|Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks
98247|NCT03418324|Drug|Abiraterone|Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.
98248|NCT03418324|Drug|Enzalutamide|Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
98249|NCT03418311|Device|Cervical Pessary-Group|Placement of the cervical pessary (non-invasive) at enrolment including a transvaginal ultrasound to verify its correct fit. Removal of the cervical pessary (non-invasive) in a regular preventive examination at week of gestation 37+0. Except for placement/removal of cervical pessary the pregnant women will receive the usual care.
98250|NCT03418298|Behavioral|Prehabilitation group|Subjects will performed an internet-based exercise program before surgery
98251|NCT03418272|Diagnostic Test|Culture/PCR Analysis|"Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~Staphylococcus aureus (MSSA, MRSA)~Pseudomonas aeruginosa~Haemophilus influenza~Streptococcus pneumonia~Streptococcus Pyogenes Group B streptococci,~Klebsiella pneumonia~Moraxella catarrhalis"
98252|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
98253|NCT03418259|Device|KCS Medical Device|Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
98254|NCT03418246|Device|GIC|tooth colored filling
98255|NCT03418246|Device|Biodentine|White filling -Biodentine
98334|NCT03417661|Drug|Placebos|Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
98335|NCT03417648|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
98256|NCT03418233|Drug|CardioCell|"Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system, Balton, Poland) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties."
98257|NCT03418233|Drug|Placebos|Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
98258|NCT03418220|Other|blood and aqueous humor sampling|The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
98259|NCT03418207|Procedure|trans-perineal template-guided mapping biopsy|new super saturation of prostate biopsy technique
98260|NCT03418194|Procedure|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
98261|NCT03418194|Procedure|sham transcutaneous acupoint electrical stimulation|Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
98262|NCT03418181|Procedure|Standard Haemodialysis|Thrice weekly dialysis.
98263|NCT03418181|Procedure|Incremental dialysis|Individualised dialysis dose according to native kidney function.
98264|NCT03418168|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
98265|NCT03418155|Drug|Treatment of TongBi Capsule|TongBi Capsule:0.31g,3times a day, oral, for 4 weeks.
98266|NCT03418155|Drug|Treatment of TongBi placebo|TongBi placebo:0.31g,3times a day, oral, for 4 weeks.
98267|NCT03418142|Behavioral|Priovi|Priovi is an Internet intervention for people with BPD. Content is continuously adapted to patients' concerns and needs. Priovi is a comprehensive program, which is conceptually and substantially based on the schema therapeutic approach used in BPD patients. It contains interactive dialogues that can be accessed via computer or smartphone, illustrations, audios and motivating text messages. Techniques to cope with borderline symptoms (e.g., psychoeducation about modes, schemas and basic emotional needs in addition to relevant strategies to weaken, reduce and/or heal maladaptive schemas and modes) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 365 days after registration.
98268|NCT03418142|Other|CAU|Care as Usual: In the CAU/wait list control group, participants are free to continue to engage with any treatment they require (i.e., CAU). However, they will receive access to Priovi after 12 months post-baseline (i.e., wait list with respect to Priovi access).
98269|NCT03418129|Device|Mindfulness|Neromodulatory intervention for pain management
98270|NCT03418129|Device|Neurofeedback|Neuromodulatory intervention for pain management
98271|NCT03418129|Device|Relaxation|Neuromodulatory intervention for pain management
98272|NCT03418116|Device|Argus II Retinal Prosthesis|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
98273|NCT03418103|Device|Thermal imaging analysis of participant position in a hospital bed|The SAFE sensor system will use thermal imaging to detect and identify a participant's position relative to the edges of the hospital bed. If a dangerous position is identified, an alarm notification will be sent to the ward staff to allow them to take pre-emptive action to prevent the participant's situation from evolving into a fall event.
98274|NCT03418090|Drug|129Xe MRI|Evaluation of pulmonary function
98275|NCT03418090|Drug|133XE scintigraphy|Evaluation of pulmonary function
98276|NCT03418077|Dietary Supplement|Energy Drink|Participants will consume 24 ounces of energy drink within 30 minutes.
98277|NCT03418064|Device|Fanfilcon A toric lens|Contact lens
98278|NCT03418064|Device|Lotrafilcon B toric lens|Contact lens
98279|NCT03418051|Other|Joint Mobilization|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of Grade II anterior to posterior ankle joint mobilizations with 1-minute between sets. Mobilizations will be large-amplitude, 1-s rhythmic oscillations from the mid- to end range of arthrokinematic motion.
98280|NCT03418051|Other|Massage|Participants will receive 6, 5-minute treatment sessions over 2-weeks. Each session will consist of 2, 2-minute bouts of plantar massage with 1-minute between sets. The massage will be a combination of petrissage and effleurage to the entire plantar surface.
98281|NCT03418038|Dietary Supplement|Ascorbic Acid|Given IV
98282|NCT03418038|Drug|Carboplatin|Given IV or PO
98283|NCT03418038|Drug|Cisplatin|Given IV or PO
98284|NCT03418038|Drug|Cytarabine|Given IV or PO
98285|NCT03418038|Drug|Dexamethasone|Given IV or PO
98286|NCT03418038|Drug|Etoposide|Given IV or PO
98287|NCT03418038|Drug|Gemcitabine Hydrochloride|Given IV or PO
98288|NCT03418038|Drug|Ifosfamide|Given IV or PO
98289|NCT03418038|Other|Laboratory Biomarker Analysis|Correlative studies
98290|NCT03418038|Drug|Oxaliplatin|Given IV or PO
98291|NCT03418038|Other|Placebo|Given normal saline IV
98292|NCT03418038|Other|Questionnaire Administration|Ancillary studies
98297|NCT03418012|Device|cervical pessary|Intervention: Device: Cervical pessary: After Having excluded a vaginal infection insertion of the cervical pessary (silicone ring) directly after enrollment. After insertion verification of correct fit of the cervical pessary by transvaginal ultrasound. Removal of the pessary at 37+0 weeks of gestation, or before if any unexpected event occurs. Except for the insertion of the pessary the obstetrical management during the remainder of the pregnancy will be usual management.
98298|NCT03418012|Other|Control-Group|Intervention: Other: expectant management: expectant management is usual care; interventions only in terms of a tertiary prevention of PTB according to guidelines for premature rupture of membranes, premature labour or other pregnancy complications
98299|NCT03417999|Drug|Dexmedetomidine|Dose-escalation of atomized intranasal dexmedetomidine
98300|NCT03417986|Drug|TEP|"For safety reasons the clinical trial will first enroll 14 subjects (7 patients and 7 healthy volunteers) for Group 1a receiving 26 mg TEP daily for 4 days with subsequent safety evaluation, based on adverse events and the safety parameters discussed in the protocol. A second set of patients (Group 1b), which will receive a higher dosage of 52 mg per day for 4 days will be enrolled optionally after recommendation to continue and subsequently treatment Group 2 with a treatment paradigm of 26 mg TEP daily for 54 days will start.~Subjects eligible for participation are subjects with newly diagnosed (within last 12 month) early-to-mild dementia due to AD and healthy volunteers who fulfill all inclusion criteria and have none of the exclusion criteria present at screening."
98301|NCT03417973|Device|dorsal root ganglion neuromodulation|stimulation for neuromodulation of the dorsal root ganglion
98302|NCT03417960|Device|iTBS|The investigators will treat post-partum depressed subjects with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro100 and Cool-B65 coil. The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. The accelerated paradigm will consist of 6 such sessions separated by 30 minutes. Treatments will be delivered at the 10-20 EEG coordinate for F3 (approximating the left DLPFC), and will be found using the Beam-F3 method.
98303|NCT03417947|Dietary Supplement|Vitamin D bolus|One single oral liquid vitamin D3 supplement of 300 000 IU
98304|NCT03417947|Dietary Supplement|Placebo|Placebo identical in taste and appearance to the vitamin D bolus
98305|NCT03417934|Procedure|Hip Arthroscopy Procedure|The purpose of this pilot study is to evaluate the effects of hip distraction without a perineal post on the lower extremity during hip arthroscopic procedures by peri-operative monitoring of various prognostic markers for venous, nerve and tissue injury.
98306|NCT03417921|Drug|ABTL0812|ABTL0812 in combination with gemcitabine and nab-paclitaxel
98307|NCT03417921|Drug|Gemcitabine and nab-paclitaxel|Gemcitabine and nab-paclitaxel as standard pattern
98308|NCT03417908|Procedure|PNF|The contract-relax method of proprioceptive neuromuscular facilitation (PNF) technique will be used for stretching of ESC, ECM and external intercostals muscles. The contraction of agonist muscles against the resistance imposed by the physiotherapist (isometric contraction) will be maintained for 6 seconds. After that, the patient is oriented to relax the muscles for 6 seconds without losing range of motion, and then the muscle will be lengthened. This procedure is repeated until the maximum amplitude of motion of the neck and upper limb is reached. The stretching will be performed on the right and left sides of the body.
98309|NCT03417908|Procedure|Sham|Isotonic concentric contraction of the biceps (two sets of five push-ups elbow in both arms) with the individual sitting in a chair with back support.
98310|NCT03417895|Drug|SHR-1210|A humanized anti-PD-1 monoclonal antibody
98311|NCT03417895|Drug|Apatinib|A tyrosine kinase inhibitor selectively targeting VEGFR-2
98312|NCT03417882|Biological|GRN-1201 + Pembrolizumab|GRN-1201 will be administered in combination with Pembrolizumab
98313|NCT03417869|Device|QuickVue Influenza A+B|Rapid diagnostic test with IVD, QuickVue Influenza A+B
98314|NCT03417843|Device|EUSRA RF electrode|"At the tip of the needle there is a probe that releases the peripheral energy in a continuous and continuous manner. The method is a long 50W power release for 10 seconds or 40W until white bubbles appear in a sonographic image.~Materials that come into contact with the body: electrode and grounding surfaces"
98315|NCT03417830|Drug|GSK2315698 (CPHPC)|GSK2315698 will be administered as 20 milligrams per hour (20 mg/hour) IV infusion (in the vein) for up to 72 hours followed by 60 milligrams (mg) three times daily as SC injection for 8 days. Dose level and frequency will be adjusted according to renal function.
98316|NCT03417830|Drug|GSK2398852 (unlabeled anti-SAP mAb)|Subjects will be administered up to 490 mg of GSK2398852, IV. Dose level will be adjusted based on emerging imaging data.
98317|NCT03417830|Drug|89Zr-GSK2398852 (89Zr-labeled anti-SAP mAb)|89Zr-GSK2398852 will be available as solution containing 10 mg 89Zr-GSK2398852 for Infusion. Subjects will be administered 37 (Megabecquerel) MBq radioactive dose of 89Zr-GSK2398852 by the IV route at each dosing session.
98318|NCT03417817|Device|Bravo|wireless pH monitoring over 96 hours
98319|NCT03417791|Other|no intervention|no intervention
98320|NCT03417778|Drug|Filgotinib|100 mg tablet administered orally
98321|NCT03417765|Drug|FE 203799|GLP-2 analogue, once weekly, subcutaneous administration
98322|NCT03417752|Other|Exposure to firearm safety PSA|Exposed to firearm safety PSA
98323|NCT03417752|Other|Exposure to health promotion PSA|Exposed to general health promotion PSA
98324|NCT03417739|Drug|BVD-523|In the laboratory BVD-523 works against proteins called ERK to decrease tumor growth
98325|NCT03417713|Device|Fluoroscopic imaging with the OEC Elite Device|Vascular, gastrointestinal (GI), urology or pain management procedures for which use of the OEC Elite system in the vascular configuration would be prescribed.
98326|NCT03417700|Dietary Supplement|NW training|NW training
98327|NCT03417700|Dietary Supplement|Placebo|training with placebo
98328|NCT03417700|Dietary Supplement|HICT|Training and vitamin D
98329|NCT03417687|Drug|129Xe MRI|Evaluation of pulmonary function
98330|NCT03417687|Drug|133 Xe scintigraphy|Evaluation of pulmonary function
98331|NCT03417674|Combination Product|Lifestyle intervention|Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
98332|NCT03417661|Drug|HEXI-PREP By Clinell Wipes|Sterile single sachet wipe containing 3ml solution.
98333|NCT03417661|Drug|Chloraprep|Sterile applicator containing 3ml solution.
98336|NCT03417648|Other|Supplement|unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
98337|NCT03417635|Behavioral|Guided focused attention|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The focused attention practice itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
98338|NCT03417635|Behavioral|Acoustic music|Participants will meet for 20 minute group sessions with 6-10 participants in each group. There will be three meetings a week for a four week period. The acoustic music track itself will last for 20 minutes with instructions being given during the 20 minute period. All sessions will occur in the retirement home in a community room to ensure the sessions are easily accessible to the participants.
98339|NCT03417622|Procedure|Bracketing|At the beginning of therapy, ultrasonographic examination is used to measure the tumor in three dimensions and bracket the tumor using 4-6 metal clips which will serve as markers for the initial tumor extent in case of tumor shrinkage in response to systemic treatment.
98340|NCT03417622|Drug|Neoadjuvant therapy|All patients will receive primary systemic therapy according to the current institutional guidelines. Drugs include cytotoxic chemotherapy, hormonal therapy and/or anti-HER2/neu therapy as indicated.
98341|NCT03417622|Procedure|Post-treatment volume margin resection|The lumpectomy resection margin is planned according to the identifiable tumor at operation. The initial extent of the tumor at diagnosis is not taken in account. If there is complete clinical response to systemic therapy (i.e. no identifiable tumor), the center of the bracketed tissue is biopsied.
98342|NCT03417622|Procedure|Pre-treatment volume margin resection|The lumpectomy includes the whole bracketed tissue to take in account the initial tumor extent before systemic therapy.
98343|NCT03417609|Device|Tongue strength measurement|The Iowa Oral Performance Instrument is a validated device for assessing the strength of the tongue. This involves placing the tip of a tube in the mouth and asking the patient to exert pressure on it.
98344|NCT03417609|Procedure|Blood sampling|Blood sampling
98345|NCT03417609|Diagnostic Test|Mini Mental State Examination (MMSE)|Also called Folstein test, it is an assessment of the patient cognitive and memory functions. It detects cognitive disorders or dementia. The MMSE is quickly realizable and explores several cognitive functions through 30 questions divided into 7 items.
98346|NCT03417609|Diagnostic Test|Minimal nutritional assessment (MNA-SF)|The minimal nutritional assessment - short form is a simple, non - invasive and validated scale for the detection of malnutrition in the elderly patient.
98347|NCT03417609|Diagnostic Test|Dual-energy x-ray absorptiometry (DEXA)|Dual-energy x-ray absorptiometry (DEXA) is the imaging technique recommended for the diagnosis of sarcopenia.
98348|NCT03417609|Device|Dynamometer (Hand grip )|By placing a dynamometer in the patient's hand and asking him to apply maximum pressure to it, the muscular strength of the extremities of the limbs is estimated.
98349|NCT03417609|Diagnostic Test|Walking speed|Walking speed evaluates the muscular performance. The seated patient must get up and walk a distance of 6 meters as quickly as possible without the help of a third party.
98350|NCT03417596|Other|Control|Routine treatment
98351|NCT03417596|Behavioral|Vestibular Rehabilitation|Exercise and rehabilitation programme was individualized
98352|NCT03417583|Other|Protocol Intervention Group|For neuropsychiatric symptoms identified by the clinician, the treatment protocol, based on clinical standard of care, will be implemented. This protocol includes directions for multidisciplinary treatment of 7 neuropsychiatric symptoms: depression, apathy, anxiety, agitation/irritability, obsessive compulsive behaviors, delusions/hallucinations, and sleep dysfunction. These treatment recommendations differ according to symptom but include provision of additional information to patients and caregivers, psychotherapy/counseling, and pharmacotherapeutic treatment options including recommended agents and follow-up schedule.
98353|NCT03417570|Procedure|Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI)|-The second endoscopist will be blinded to the results of the initial exam.
98354|NCT03417570|Device|Olympus Disposable Distal Attachment Cap|-The second endoscopist will be blinded to the results of the initial exam.
98355|NCT03417544|Drug|ATEZOLIZUMAB|(IV) every 3 weeks
98356|NCT03417544|Drug|PERTUZUMAB|Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV
98357|NCT03417544|Drug|TRASTUZUMAB|Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks
98358|NCT03417531|Dietary Supplement|Protein Supplement|Predosed protein powder; can be added to various dishes and drinks
98359|NCT03417531|Dietary Supplement|Protein-free Supplement|Predosed protein-free powder; can be added to various dishes and drinks
98360|NCT03417531|Procedure|Active Exercise|Program includes five strength exercises that can be easily performed at home
98361|NCT03417531|Procedure|Control Exercise|Program includes five flexibility exercises that can be easily performed at home
98362|NCT03417518|Drug|Desflurane Inhalant Product|General anesthesia will be induced with sufentanyl (0.2µg/kg) and thiopental (5mg/kg) and maintained by desflurane
98363|NCT03417518|Drug|Propofol|General anesthesia will be induced with propofol (2mg/kg) and sufentanyl (0.2µg/kg) and maintained by propofol in a target-controlled infusion mode
98364|NCT03417505|Device|Scleral lenses treated with Tangible Hydra-PEG|Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.
98365|NCT03417505|Device|Untreated scleral lenses|Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.
98366|NCT03417492|Drug|Sildenafil Citrate|Three 20 mg capsules for the single dose studies. For the 5-week treatment phase, subjects will be assigned to a titration of doses for the 5 week duration of the study. Subjects will be instructed to take 20mg twice per day for 3 days, then 40mg twice per day for 3 days, and then 80mg twice per day for 4 weeks.
98367|NCT03417479|Other|Gabapentin|
98368|NCT03417466|Device|Enlite 1 connected to iPro2 recorder|Use Enlite Sensor over 144 hours (6 days) when inserted in the abdomen and used with the iPro2 in subjects age 14 - 75 years.
98487|NCT03416491|Drug|KW-136|KW-136 30 mg was provided in 3 capsules, 10 mg each, and KW-136 60 mg in a single capsule of 60 mg.
98369|NCT03417453|Device|Eye Drop Dispenser TYPE Opticare|"Subject will apply normal saline eye drops to them-self with various eye drop dispensers.~Assessment of ease of use will be conducted by questioners."
98370|NCT03417453|Device|Eye Drop Dispenser Autodrop|Eye Drop Dispenser Autodrop
98371|NCT03417440|Other|Physical Activity (PA) Tracker App|This PA tracker app auto-monitors PA and provides a text-based summary of goal progress, thereby targeting self-regulation and outcome expectation.
98372|NCT03417440|Other|On Your Feet|On Your Feet is a specialty app feature designed to be paired with a PA tracker app and reduce sedentary activity—a health risk factor largely independent of insufficient PA. This feature utilizes self-regulatory and behavior change techniques including goal-setting, progress feedback, and prompting. Accumulated sedentary activity time is displayed alongside self-selected goals; reminders to stand are sent at a user-specified frequency; and general tips and previously compiled, older adult-identified strategies to reduce sedentary activity are texted. Additionally, messages about the benefits of reducing sedentary activity and overcoming barriers are sent.
98373|NCT03417440|Other|Coach Me|Coach Me is a specialty app feature designed to be paired with a PA tracker app and includes daily messages that assist older adults in discovering practical ways to integrate PA into their daily routines and overcoming PA barriers. Blending PA with productive activity facilitates PA engagement in older adults. In Coach Me, suggestions on how to intensify daily activities are tailored based on user selections from an activity inventory. This app feature helps older adults become more active in a minimally intrusive way, while allowing for engagement in productive and meaningful activities. Coach Me asks users to select obstacles to PA encountered in the previous week. Based on those selections, the app sends strategies on how to overcome those barriers, thereby targeting self-efficacy.
98374|NCT03417440|Other|Proof Positive|"Proof Positive is a specialty app feature designed to be paired with a PA tracker app and capitalizes on the beneficial effects that exposure to positive aging messages and stereotypes has on health and PA. When activated, users (a) receive texts describing how old age does not equate to physical inability, (b) obtain information about the benefits of growing older, and (c) are presented with a weekly positive aging stereotype task modeled after a computerized series. This last function exposes users to blocks of positive priming words. Primers are quickly flashed to allow perception without awareness while users focus on a simple icon that represents PA. Icons are intended to provide an additional PA cue, maintain user interest, and increase the external validity."
98375|NCT03417427|Drug|Decitabine and Ara-C|Decitabine in combination with high-dose of Ara-C is used to improve the effect of consolidation chemotherapy. It is expected to make minimal residual disease (MRD) become negative in more patients with intermediate-risk AML.
98376|NCT03417427|Drug|Ara-C|Intermediate-risk AML patients with hematological complete remission and positive minimal residual disease (MRD) will receive high-dose of Ara-C (2g/m2 d4-6) consolidation chemotherapy.
98377|NCT03417401|Procedure|Vitrectomy with retinal vein cannulation and intravenous rtPA (Actilyse) infusion up to 1mg.|Standard 3-port pars plana vitrectomy with surgical stabilizer assisted (mynutia surgical robot) retinal vein cannulation with recombinant tissue Plasminogen Activator (Actilyse-0.25mg/ml) infusion with a maximal dose of 1mg..
98378|NCT03417401|Drug|Intravenous Infusion|Intravenous infusion in a retinal vein with rtPA (Actilyse 0.25mg/ml).
98379|NCT03417388|Drug|High dose potent statin|The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.
98380|NCT03417388|Drug|ACE-I (lisinopril) or ARB (losartan)|Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.
98381|NCT03417388|Drug|Aspirin|Will be recommended to IMT women without contraindications or bleeding risk.
98382|NCT03417388|Behavioral|Lifestyle Counseling|The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.
98383|NCT03417388|Behavioral|Quality of Life Questionnaires|Quality of Life Questionnaires will be obtained.
98384|NCT03417375|Procedure|Bilateral Sinus Augmentation|Lateral window sinus augmentation with core samples harvested from the window following 4 months of healing.
98385|NCT03417362|Other|Animation|3 minute video describing and explaining early medical abortion, followed by questionnaire
98386|NCT03417349|Device|Sofia|The SOFIA™/ SOFIA™ PLUS Catheter will be used in removal/aspiration of emboli and thrombi following the CE marked Instructions For Use. Enrollment into the study does not change the routine care at the site provided to the patient requiring mechanical thrombectomy treatment.
98387|NCT03417336|Radiation|prostatic boost in brachytherapy with high dose rate (HDR)|prostatic boost in brachytherapy with high dose rate (HDR)
98388|NCT03417323|Other|Compression|Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
98389|NCT03417310|Device|"H joystick"|A joystick that corrects lateral displacement and angulation for multi-direction reduction
98390|NCT03417310|Procedure|Common reduction methods|Manual reduction methods without the assistance of any devices
98391|NCT03417297|Device|high intensity focused ultrasound|high intensity focused ultrasound
98392|NCT03417284|Drug|Evomela|"Group 1 Evomela Starting Dose: 200 mg/m2 by vein for 30 minutes on Day -2.~Group 2 Evomela Starting Dose: 200 mg/m2 by vein for 12 hours on Day -2.~Phase II starting dose is maximum tolerated dose from Phase I."
98393|NCT03417284|Procedure|Autologous Stem Cell Infusion|Autologous Stem Cell Infusion on Day 0.
98394|NCT03417284|Drug|G-CSF|G-CSF 5 mcg/kg/day (rounded up to the nearest vial, max dose of 600 mcg) given subcutaneously on Day +5, continuing until evidence of an absolute neutrophil count (ANC) of 0.5 x 109/L.
98395|NCT03417284|Drug|Palifermin|Palifermin 60 microgram/Kg by vein over about 30 seconds on Days -5, -4, -3, +1, +2, and +3.
98396|NCT03417271|Device|Deep brain stimulation|The different stimulation pulse widths are made possible by the use of a Medtronic XBP flashcard used with the conventional Medtronic 8840 programmer.
98397|NCT03417245|Drug|fitusiran|by subcutaneous (SC) injection
98398|NCT03417245|Drug|factor VIII or factor IX|by intravenous (IV) injection
98434|NCT03416933|Other|Blood sampling|2x10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.
98435|NCT03416920|Other|Wellframe|Wellframe mobile phone app
98399|NCT03417232|Procedure|CAF|The design of the flap consisted of two horizontal beveled incisions (3mm in length) and two slightly oblique beveled incisions. The resulting trapezoidal-shaped flap was elevated in the coronal-apical direction. The suture of the flap started with two interrupted periosteal sutures performed at the most apical extension of the vertical releasing incisions; afterwards, it proceeded coronally with other interrupted sutures, each of them directed, from the flap to the adjacent buccal soft tissue, in the apical-coronal direction. The last sling suture allowed for the stabilization of the surgical papillae over the inter-dental connective tissue bed and allowed for a precise adaptation of the flap margin over the underlying convexity of the crown.
98400|NCT03417219|Behavioral|Education and Skill Building Rehabilitation-mobile (ESBR-m)|Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
98401|NCT03417219|Behavioral|Usual Care (UC)|"Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss)."
98402|NCT03417206|Drug|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes until PRD decreases below 5%
98403|NCT03417206|Device|pupillary dilatation reflex|PRD value will me measured before the start of FESS after 5 minutes of remifentanyl infusion, when PRD sensitivity > 5% , infusion of remifentanyl will be increased by 50% until PRD sensitivity <5% and FESS will be started ; intraoperatively infusion of remifentanyl will be increased by 50% until PRD sensitivity <5%
98404|NCT03417193|Drug|opioid free Anesthesia vs Opioid based Anesthesia|Compare the opioid based anesthesia with Fentanyl and Remifentanyl to opioid free anesthesia with dexmedetomidine and lidocaine and their effect on postoperative pain.
98405|NCT03417180|Drug|Remifentanil|a rate of infusion of reminfentanil will be increased by 50% every 5 minutes, until SPI value decreases back to baseline level
98406|NCT03417180|Device|surgical pleth index|every time SPI value increases by 15 a rate of infusion of reminfentanil will be increased by 50% every 5 minutes
98407|NCT03417167|Other|US-guided synovial biopsy|Needle Synovial biopsy performed using a Tru-cut® device.
98408|NCT03417154|Drug|Nivolumab|3mg/kg IV (or if prior alloHSCT, 1 mg/kg) over 30 minutes every 14 days on Days 1 and 15 for up to four 28-day courses.
98409|NCT03417154|Drug|Stage 1 Arm 1: Low dose Cyclophosphamide (CTX)|Oral cyclophosphamide 50mg + nivolumab 3 mg/kg IV every 2 weeks for up to 4 courses of treatment
98410|NCT03417154|Drug|Stage 1 Arm 2: Low dose Cyclophosphamide (CTX)|Oral cyclophosphamide 350 mg every 7 days + nivolumab 3mg/kg IV every 2 weeks for up to 4 courses of treatment
98411|NCT03417154|Drug|Stage 2: Low dose Cyclophosphamide (CTX)|Stage 2: Oral cyclophosphamide as assigned for up to 4 treatment courses with each treatment course equal to 28 days.
98412|NCT03417141|Drug|Valchlor|Assess the potential effectiveness of once daily application of Valchlor in decreasing disease activity in patients with Lichen Planopilaris.
98413|NCT03417128|Behavioral|Peer support|Participants residing in the location selected to be intervene will to form at minimum 4 peer groups. This group will receive a continuous three-months, peer-led nutrition and lifestyle behaviour intervention through a series of peer gathering. Two participants from each peer group will be selected as the peer leader (PL). PL will be trained to deliver the content of PERSUADE modules and will be responsible to run a weekly peer gathering with their respective groups for the following three months.
98414|NCT03417102|Drug|fitusiran|by subcutaneous (SC) injection
98415|NCT03417102|Drug|recombinant Factor VIIa and FEIBA|by intravenous (IV) injection
98416|NCT03417089|Procedure|Falciform ligament suspension|routine of falciform ligament suspension during Mini gastric bypass
98417|NCT03417089|Procedure|no suspension|working without of falciform ligament suspension during Mini gastric bypass
98418|NCT03417076|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg, and bexagliflozin by IV
98419|NCT03417050|Other|No intervention will take place for this retrospective and observational study.|No intervention will take place for this retrospective and observational study.
98420|NCT03417037|Drug|BMS-986205|Administered orally daily, 100 mg
98421|NCT03417037|Biological|Nivolumab|Specified dose on specified days
98422|NCT03417037|Drug|Chemotherapy|Platinum-based doublet chemotherapy
98423|NCT03417024|Device|Automated Breast Ultrasound|The ABUS system is designed to methodically scan a breast and capture multiple ultrasound images that can be rendered and reviewed in three dimensions.
98424|NCT03417024|Device|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) systems are designed to collect 3-dimensional x-ray images of breast tissues.
98425|NCT03417011|Device|Medtronic CoreValve™ Evolut™ PRO System (Evolut™ PRO System)|Transcatheter Aortic Valve Replacement with Medtronic Evolut PRO system
98426|NCT03416998|Other|phototherapy|Phototherapy will be performed using clusters of 12 diodes (Table 1); four 905 nm diodes (mean power of 0.3125 mW and peak power of 12.5 W for each diode; 250 Hz), four 875 nm diodes (mean power of 17.5 mW for each diode) and four 640 nm diodes (mean power of 15 mW for each diode). The device manufactured by Multi Radiance Medical® (Solon, OH, USA) will be used due to its high quality, ample use in clinical practice and due to the fact that no national companies manufacture diode clusters with the characteristics required for the proposed project.
98427|NCT03416985|Device|Oral B Healthy Clean Manual Toothbrush|Manual Toothbrush
98428|NCT03416985|Device|BURST Sonic Oral Care|Electric sonic toothbrush
98429|NCT03416985|Device|Philipps Sonicare DiamondClean 300 Series|Electric pulsating toothbrush
98430|NCT03416972|Radiation|Standard platinum-based chemoradiotherapy|Stage III patients: Standard platinum-based chemotherapy, total radiation dose 60 Gy in 30 fractions. Stage I/II patients: Standard radiotherapy, total radiation dose of 54 Gy in 3 fractions (peripheral), 55 Gy in 5 fractions (near chest wall), or 60 Gy in 8 fractions (central).
98431|NCT03416959|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment for long bone metastases with intramedullary nail or endoprosthetic reconstruction
98432|NCT03416946|Device|Visionaire|Custom cutting block using MRI to create patient specific instrumentations
98433|NCT03416946|Other|Traditional|Traditional cutting method
98436|NCT03416907|Behavioral|Original consent form|Participants will review the full-length, original consent form for the clinical trial.
98437|NCT03416907|Behavioral|Shortened consent form|Participants will review a shortened consent form for the clinical trial, which includes only material indicated as important by 2/3 of participants from a previous study.
98438|NCT03416907|Behavioral|Reordered, shortened consent form|Participants will review a reordered, shortened consent form. This form is based on the shortened consent form, but the sections are reordered based on a previous study, such that sentences previously rated as more likely to impact a participant's decision is more likely to be presented first (except for an initial introductory section).
98439|NCT03416907|Behavioral|Shortened consent form with a highlights box|Participants will review a shortened consent form with a highlights box, where the highlights box includes the 10 sentences rates as most likely to impact a participant's decision from a previous study.
98440|NCT03416907|Behavioral|Interactive, shortened consent form|Participants will review an interactive, shortened consent form, where hyperlinks to different sections of the consent form are provided. The landing page includes the introductory section.
98441|NCT03416894|Device|Deep Brain Stimulation|DBS offers the opportunity to insert electrodes into deep brain structures and electrically stimulate them in a titratable and ultimately reversible manner
98442|NCT03416868|Behavioral|Ambulatory voice biofeedback|Patients will be provided cues regarding their vocal behavior in daily life. Depending on the result of Study 1 in this IRB protocol/NIH grant, The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
98443|NCT03416855|Drug|Insulin degludec /insulin aspart|Commercially available Insulin degludec /insulin aspart (Ryzodeg® FlexTouch®) according to routine clinical practice at the discretion of the treating physician.
98444|NCT03416842|Device|Training with 4D Motion Capture Device|Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
98445|NCT03416829|Behavioral|Ambulatory voice biofeedback|Subjects will be provided cues regarding their vocal behavior in daily life. The cues will either be: 100% feedback = a vibrotactile cue on a smartwatch every time the patient voices incorrectly... 25% feedback = a vibrotactile cue on a smartwatch every 4th time the patient voices incorrectly... Summary feedback = the patient's overall compliance (percentage of voiced time within desired limits) will be presented via a smartwatch every 2 minutes of voicing.
98446|NCT03416816|Drug|DSP-0337|DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.
98447|NCT03416803|Radiation|Radiotherapy|Radiotherapy
98448|NCT03416777|Behavioral|Meat-based diet|Diet including 4 servings per week of red meat (1 serving = 150 g), 3 servings per week of processed meat (1 serving = 50 g), and 1 servings per week of poultry (1 serving = 150 g), for a total amount of 900 g per week of meat.
98449|NCT03416777|Dietary Supplement|Meat-based diet supplemented with alpha-tocopherol (MBD-T)|Dietary intervention like the MBD with supplementation of alpha-tocopherol at a dosage of 100 mg/die. Available evidence suggests that alpha-tocopherol may help prevent colon cancer by decreasing the formation of mutagens arising from the oxidation of faecal lipids, by decreasing oxidative stress in the epithelial cells of the colon and by molecular mechanisms that influence cell death, cell cycle and transcriptional events (Pierre 2013, Bastide 2016, Bastide 2017, Diallo 2016). It is important to note that 200 mg/day of tocopherol was administered to 20,000 women for 10 years without side effects (Lee et al.,2005).
98450|NCT03416777|Behavioral|Pesco-vegetarian diet|Diet excluding fresh and processed meat, poultry but including 3 servings per week of any type of fish, excluding shellfish (1 serving = 150 g), for a total amount of 450 g per week. Diet will contain other sources of proteins (e.g. eggs, dairy, legumes/beans). There is suggestive evidence that fish and vegetable consumption has protective effects against CRC (Vieira et al., 2017).
98451|NCT03416764|Device|EFP-NF training|Experimental groups (among participants with and without steady menstrual cycle) will receive a total of 10 training sessions during 10 weeks. In addition to EFP-NF training, participants in the experimental groups will continue to be treated as usual at Clinic for Sexual Assault.
98452|NCT03416751|Biological|Fecal Microbial Transplant|Fecal transplant from a donor in the OpenBiome Registry
98453|NCT03416751|Other|Placebo|Placebo enemas
98454|NCT03416738|Behavioral|Semantically focused treatment|"Tasks are as follows:~Semantic feature analysis (SFA): For each pictured stimulus the patient is prompted to name the picture, and then to produce related words that represent features similar to the target word.~Semantic barrier task: The goal is for one participant (e.g., patient) to describe each card so that the other participant (e.g., clinician) can guess the picture on the card. Participants are only allowed to describe the semantic features of the target and the clinician models the kinds of cues that are allowed.~Verb network strengthening treatment (VNeST): This treatment targets lexical retrieval of verbs and their thematic nouns. The objective of VNeST is for the patient to generate verb-noun associates with the purpose of strengthening the connections between the verb and its uses.~These are tasks used in clinical aphasia rehabilitation."
98455|NCT03416738|Behavioral|Phonologically focused treatment|"Tasks are as follows:~Phonological (sound) components analysis task: Participants are to name a given picture and then to identify the sound features of the target words (e.g., first sound, last sound, and rhyme).~Phonological production task: This tasks asks participants to sort and identify the sounds that make up a word. Various stages include identifying first sounds, last sounds, etc. Participants also work on blending sounds together to form words.~The phonological judgment task: A computerized presentation of verbs and nouns where participants are required to judge whether pairs of words include similar phonological features.~These are tasks used in clinical aphasia rehabilitation."
98456|NCT03416725|Device|Otoscope|Otoscopic examination will be done to find the presence or absence of perforation, granulation tissue and cholesteatoma.
98457|NCT03416712|Other|Screening survey and accompanying handout for resources|Intervention group will be completing a survey of social determinants of health and providing resources based on caregiver responses.
98458|NCT03416686|Device|Radiofrequency (RF star electrode electrode_Fixed)|"The radiofrequency will be performed under ultrasound control after local anesthesia by a trained operator, after finding the lesion to be treated by the operator.~Medical device used: RF star electrode electrode_Fixed (Starmed Co,Gyeonggi-do, Korea, French representative Cosysmed)."
98459|NCT03416673|Procedure|peCTG+CAF|A connective tissue graft will be reshaped to have extensions mimicking the papillae to augment the inter-dental papillae recessed
98460|NCT03416673|Procedure|CTG+CAF|A connective tissue graft harvested from the palate will be sutured to the gingival recession site and covered with a coronally advanced flap
98461|NCT03416660|Device|Fractional Carbon Dioxide laser|
98462|NCT03416647|Procedure|Duodenojejunostomy|Duodenojejunostomy with or without duodenal resection
98463|NCT03416634|Behavioral|App|The Microsoft Band app can be installed for free on compatible smartphones. The app can be used to track steps while the phone is with the participant (such as in a pocket). Participants can synchronize their device with the study app to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
98464|NCT03416634|Behavioral|Wearable Device|A Garmin vivofit 3 fitness device will be provided for free to participants randomized to this study arm. This wearable device tracks daily activity and gives reminders to move after an hour of inactivity. The battery lasts for one year and the device is water resistant. Participants can synchronize their device with the study App to give permission to share physical activity level with the study team. Daily physical activity will be tracked for 24 weeks.
98465|NCT03416634|Behavioral|Automated Motivational Message|An automated behavioral intervention will be delivered once weekly via an in-app motivational message, over the 12-week intervention period.
98466|NCT03416634|Behavioral|Personalized Motivational Message|A behavioral intervention will be delivered once weekly via an in-app motivational message adapted to each patient's personalized PA goal progression based on the previous week data from the smartphone activity app (Microsoft band) or the Garmin wearable device over a 12-week intervention period.
98467|NCT03416621|Other|Cognitive behavioral cessation counseling|Standard smoking cessation plus support text messages
98468|NCT03416621|Drug|Counseling and placebo drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + DCS placebo
98469|NCT03416621|Drug|Counseling and active drug intervention|Enhanced cue exposure treatment (lab-based + interactive SMS texting) + active DCS. In addition to an in-person screening visit, we will conduct three in-person treatment visits and an in-person follow-up visit.
98470|NCT03416595|Dietary Supplement|N1115 Probiotic Supplement|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
98471|NCT03416595|Dietary Supplement|placebo|Participators will receive a sachet each day during 8 weeks. The contents of the sachet should be added to warm water or milk, mixed until fully dissolved and served within 15 minutes.
98472|NCT03416582|Behavioral|Symptom Management Education and Nurse Coaching|"The registered nurse (RN) will teach good mouth care and management of sore mouth or throat (mucositis) symptoms to the patient for self-management at home. The RN will then call the patient twice every week to continue educating and coaching the patient about the mucositis self-management. The patient will receive the Symptom Management (SxM) Toolkit which is a written educational guide known as the Cancer Treatment Symptom Management Education Toolkit geared to help the patient manage their symptoms of sore mouth and throat at home in order to prevent dehydration."
98473|NCT03416582|Behavioral|Drinks Diary|The patient will complete the Drinks Diary daily by recording the all oral fluid ingested and also record the number of times the bathroom is used.
98474|NCT03416569|Drug|Placebo|placebo skin patch + placebo capsule
98475|NCT03416569|Drug|Nicotine|nicotine patch (7 mg/24 hrs) + placebo capsule
98476|NCT03416569|Drug|Prazosin|placebo patch (7 mg/24 hrs) + prazosin capsule (1 mg)
98477|NCT03416569|Drug|Nicotine + Prazosin|nicotine patch (7 mg/24 hrs) + prazosin capsule (1 mg)
98478|NCT03416556|Procedure|Mobilization to the glenohumeral joint|The treatment condition consisted on the application of a passive rhythmic AP mobilization to the glenohumeral joint of the affected shoulder. In particular, a Grade III AP glide to the humeral head with the arm positioned in 90º of glenohumeral abduction and full internal rotation was used. The posterior gliding force to the humeral head was applied maintaining the glide at right angles to the plane of movement and at a frequency of 2 Hz which was controlled by means of a metronome. The arm was returned to its original position between each set.
98479|NCT03416556|Procedure|The manual contact condition|During the manual contact condition the therapist positioned the patient in a mid-range position of glenohumeral abduction and internal rotation and applied the hands to the same contact point as in the treatment condition. However, a simulated posterior glide was performed but with minimal pressure actually applied. The number of repetitions and sets were as per the treatment condition.
98480|NCT03416556|Other|No-contact condition|During the no-contact condition, the subject remained in the initial starting position thorough the entire session but there was no manual contact between the therapist and the participant. The total treatment time was the same as per the other conditions.
98481|NCT03416543|Other|Puncture|Puncture necessary for daily practice in patients with acute arthritis of RA or Gout or osteoarthritis
98482|NCT03416530|Drug|ONC201|ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
98483|NCT03416517|Drug|Anlotinib|Anlotinib 12 or 8 mg/d po D1-14 q3w
98484|NCT03416517|Drug|Irinotecan|Irinotecan 20 or 15mg/m^2/d IV over 60 minutes on days 1-5 and 8-12, q3w
98485|NCT03416504|Behavioral|Gradual Exposure (EXP-G)|In EXP-G, exposure proceeded hierarchically from mildly, to moderately, to highly intense stimuli so that exposure intensity gradually built between (but not within) sessions.
98486|NCT03416504|Behavioral|Variable Exposure (EXP-V)|In EXP-V, exposure stimuli were chosen at random (i.e., pieces of paper with exposure stimuli written on them were pulled randomly from an opaque container) so that mild, moderate, and high intensity exposures could occur in any order during any of the sessions (the participant was not informed which level was coming next). This aimed to maximize (a) uncertainty, (b) variability in exposure intensity, and (c) variability in corresponding physiological arousal.
98488|NCT03416491|Drug|Sofosbuvir|Sofosbuvir was provided in a single tablet of 400 mg.
98489|NCT03416478|Diagnostic Test|ctDNA test|ctDNA test to find some possible mutation.
98490|NCT03416465|Behavioral|medical questionnaire|The patient will complete a questionnaire of 10 questions before leaving hospital. This questionnaire concerns the care pathway for hospitalized patients.
98491|NCT03416452|Device|vibratory cueing device|ankle brace with vibrator that provides electric stimulus
98492|NCT03416452|Device|Mobile Gait Trainer|standard rolling walker that has a battery operated sensor attached to the side, designed to detect footsteps
98493|NCT03416439|Other|lifestyle intervention|lifestyle intervention program carried out by trained professionals
98494|NCT03416426|Device|Amplatzer® PFO occluder or Gore® Septal Occluder|The closure procedure was performed under general anesthesia. After achieving femoral venous access, the PFO was crossed with a 5F multipurpose catheter, which was advanced into the left upper pulmonary vein and then exchanged over a 0.035 inch J-tipped stiff guidewire for an 8F or 9F guiding sheath. Procedural anticoagulation was initiated with 5000 units of intravenous heparin. After then additional heparin was administrated throughout procedure to maintain an activated clotting time of ≥250 seconds. Device size was selected based on TEE measurements of the distance between the PFO and the aortic root.
98495|NCT03416413|Procedure|Ambulatory phlebectomy|Minor surgery to remove varicose vein tributaries
98496|NCT03416413|Drug|Foam sclerotherapy|Injection of foam sclerosant into varicose vein tributaries
98497|NCT03416400|Other|Oocyte vitrification|Immature oocytes were collected from patients (≤37 years old, without endometriosis, Polycystic syndrome or other ovulatory desease) who underwent to ICSI. In addition, immature oocytes collected from patient diagnosed with cancer will be included in this study. Oocytes were matured in vitro with IVM medium and vitrified in closed system (Vitrolife). Kinetic of maturation were analyzed by Primovision (Vitrolife) and actin, and spindle organization were studied by microscopy, immunostaining techniques and quantitive analysis.
98498|NCT03416387|Device|3D PRINTING|A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.
98499|NCT03416374|Drug|Ixazomib|Ixazomib capsules
98500|NCT03416374|Drug|Bortezomib|Bortezomib injections
98501|NCT03416374|Drug|Carfilzomib|Carfilzomib intravenous infusions
98502|NCT03416374|Drug|Lenalidomide|Lenalidomide capsules
98503|NCT03416374|Drug|Dexamethasone|Dexamethasone tablets
98504|NCT03416361|Dietary Supplement|4000IU Vitamin D3|Chewable blackcurrant flavoured tablets (two per day)
98505|NCT03416348|Drug|Aluminum Chloride 20% (deodorant)|Aluminum Chloride (deodorant)
98506|NCT03416348|Drug|Alcohol|Placebo
98507|NCT03416335|Drug|DSP-0509|DSP-0509 will be administered as an IV bolus injection over 3 minutes at one of the 5 dose levels being explored in dose escalation (Part A), then at the RP2D in dose expansion (Part B) as well as in maintenance dose schedule evaluation (Part C). The schedule for dosing is DSP-0509 once a week (q1w) for 4 weeks during the induction treatment period (study Day 1 29) followed by dosing every 2 weeks (q2w) during the maintenance treatment period (study Day 30 onwards) with the exception for Part C where the maintenance schedule is changed to every 3 weeks (q3w) in dose-expansion phase.
98508|NCT03416335|Drug|DSP-0509, Pembrolizumab|DSP-0509 will be administered as an IV bolus injection over 3 minutes at one of the 5 dose levels being explored in dose escalation (Part A) and is given in combination with pembrolizumab which should be administered following the dosing schedule of the approved label (200 mg IV q3w)
98509|NCT03416322|Other|Water exchange|Infusion and remove water during inertion and withdrawal of colonoscope
98510|NCT03416283|Behavioral|Remote Monitoring|Remote BP monitoring and medication adherence
98511|NCT03416283|Behavioral|Remote Monitoring + Social Support|"Remote BP monitoring and medication adherence with enhanced support from a support partner (facilitated cheerleading)"
98512|NCT03416270|Drug|Ertugliflozin|Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks
98513|NCT03416270|Drug|Placebo|Placebo once daily for 12 weeks
98514|NCT03416257|Other|No intervention|
98515|NCT03416244|Drug|Nivolumab|Nivolumab 240 mg IV fixed dose every two weeks
98516|NCT03416244|Drug|Ipilimumab|Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
98517|NCT03416231|Drug|Apatinib|apatinib, at a dose of 250 mg daily,Treatment was continued until disease progression.
98518|NCT03416231|Drug|Docetaxel|Docetaxel, at a dose of 75mg/m2 on days 1 and 22, repeat every 4 weeks for 4~6 cycles.
98519|NCT03416218|Behavioral|Prognosis|Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
98520|NCT03416205|Device|Erbao electric knife|Erbao electric knife is used to cut the Duodenal sphincter
98521|NCT03416205|Device|Three-cavity incision knife|Three-cavity incision knife is used to cut the Duodenal sphincter
98522|NCT03416205|Device|Columnar expansion balloon|Columnar expansion balloon is used to expand the the Duodenal sphincter
98523|NCT03416192|Device|MCO-HD|Measurements will be done after 0,4,8 and 12 weeks of hemodialysis with Medium Cut-Off filter.
98524|NCT03416192|Device|high-flux HDF|Measurements will be done after 0,4,8 and 12 weeks of hemodiafiltration with standard high-flux filter
98525|NCT03416179|Drug|glasdegib|"Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
98618|NCT03415555|Drug|paracetamol|Paracetamol will be given i.v. every 6 hours.
98619|NCT03415542|Behavioral|Exercise Promotion|Evidence-based techniques (goal-setting, reduced barriers) for increasing exercise behavior
98620|NCT03415516|Device|Gluma Universal|Adhesive systems
98526|NCT03416179|Drug|daunorubicin + cytarabine|"'7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');"
98527|NCT03416179|Drug|azacitidine|Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
98528|NCT03416179|Drug|Placebo|"Matching placebo (PO) given on Day 1 and is to continue up to 2 years post randomization. Following consolidation therapy, placebo will be administered daily for up to 2 years after randomization or until they have MRD negative disease, whichever comes first.~Daily placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy."
98529|NCT03416179|Drug|Placebo|Matching placebo (PO) is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment. Subjects will continue placebo until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
98530|NCT03416179|Drug|glasdegib|"Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first."
98531|NCT03416179|Drug|cytarabine|Consolidation with single agent cytarabine 3 g/m2 IV for adults <60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
98532|NCT03416179|Procedure|HSCT|If required, and done per standard of care post Induction(s).
98533|NCT03416166|Device|Transcatheter Tricuspid Intervention|Any available transcatheter tricuspid valve intervention
98537|NCT03416140|Other|Therapeutic Exercise|30 minutes per day of therapeutic exercise
98538|NCT03416127|Drug|Propolis|300 mg, two times per day before break-fast and dinner during 12 weeks.
98539|NCT03416127|Drug|Metformin|850 mg, two times per day before break-fast and dinner during 12 weeks.
98540|NCT03416127|Drug|Placebo|Two times per day before break-fast and dinner during 12 weeks.
98541|NCT03416101|Procedure|Total Gastrectomy|The esophagus was resected at the arch level of the azygos vein, a frozen section of the resection margin was routinely performed to achieve a proximal clean resection margin. The surgical specimen was comprehensive of distal esophagus, stomach and omentum. Digestive tract continuity was established with Roux-en-Y esophagojejunostomy. Lymphadenectomy was extended to the thoracic stations R 2-4, 7-8-9, and L 4, numbered according to the Mountain's classification [39] (Suppl. File 2 Figure A) and to the abdominal stations 1-12, numbered according to the Japanese Research Society for Gastric Cancer (JRSGC) 1998 classification.
98542|NCT03416088|Dietary Supplement|water deprivation,water,wine,coffee|The participants drink 300ml wine (alcohol concentration:13%)or 300ml coffee (caffeine concentration 1.2%).
98543|NCT03416075|Device|Mechanical ventilation|Noninvasive and/or invasive mechanical ventilation were performed when patients had respiratory failure.
98544|NCT03416062|Drug|Remaxol®|Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle
98545|NCT03416062|Drug|Ringer's Solution|Solution for intravenous infusion, 400 or 800 ml
98546|NCT03416049|Device|PEMF therapy with a high-power PEMF device|The 20 participants assigned to a high-power PEMF device will treat each Venous Stasis Leg Ulcer (VSLU) area for 10 minutes twice a day.
98547|NCT03416049|Device|PEMF therapy with a medium PEMF power device|The 20 participants assigned to a medium-power PEMF device will treat each VSLU area for 15 minutes twice a day.
98548|NCT03416049|Device|PEMF therapy with a low-power PEMF device|The 20 participants assigned to a low-power PEMF device will treat each VSLU area for 30 minutes twice a day.
98549|NCT03416049|Device|PEMF therapy with the sham PEMF device|The 20 participants assigned to the sham PEMF device will treat each VSLU area for 15 minutes twice a day.
98554|NCT03416023|Device|TIES® (Transcutaneous Implant Evacuation System)|Transcutaneous Implant Evacuation System
98621|NCT03415516|Device|All Bond Universal|Adhesive systems
98622|NCT03415516|Drug|Single Bond2|Adhesive systems
98623|NCT03415503|Drug|Medox® Anthocyanin capsules|Subjects were orally administered Medox® capsules daily for 12 weeks.
98700|NCT03414931|Drug|NMDA|Use of an NMDA enhancer for the treatment of MDD in late life
98701|NCT03414931|Drug|Sertraline|Use of SSRI as an active comparator
98702|NCT03414931|Drug|Placebo - Cap|Use of placebo as a comparator
98555|NCT03416010|Behavioral|COPE-P|"Session 1 ABCs (A=Antecedent or Activator event, B=Belief that follows the event, C=Consequence: how you feel and how you behave).~Session 2 self-esteem and positive self-talk, including ways to build self-esteem and the group provides examples of how to change unhealthy habits into healthy ones.~Session 3 stress/coping during pregnancy. Physical and emotional responses to stress are discussed along with healthy snacking and healthy ways to cope with typical stresses.~Session 4 planning, goal setting and the 4-step problem solving process. Session 5 dealing with emotions in healthy ways through positive thinking and effective communication.~Session 6 coping with stressful situations encountered during pregnancy while continuing to reinforce the thinking-feeling-behaving triangle."
98556|NCT03415997|Drug|Iohexol|Iodinated contrast media
98557|NCT03415984|Diagnostic Test|Color retinography|Color retinography
98558|NCT03415984|Diagnostic Test|Optical coherence tomography|Optical coherence tomography
98559|NCT03415984|Diagnostic Test|Fundus autofluorescence imaging|Fundus autofluorescence imaging
98560|NCT03415971|Procedure|EMG befor denture treatment|
98561|NCT03415971|Procedure|EMG in a month after termination of treatment|
98562|NCT03415971|Procedure|EMG in a 3 months after termination of treatment|
98563|NCT03415945|Device|Cardiac resynchronization therapy (CRT)|All study participants have a clinical indication for CRT and will receive CRT implantation as part of their routine medical care. Additionally, participants will receive temporary left and right ventricular septal pacing electrodes and a temporary PressureWire to investigate the acute hemodynamic effect of left ventricular septal pacing, using patients as their own controls.
98564|NCT03415932|Behavioral|health education|Health information by a multimodal team
98565|NCT03415919|Other|no intervention will be given to patients.|samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
98566|NCT03415906|Combination Product|sacubitril+valsartan|Combined angiotensin receptor + neprilysin inhibition
98567|NCT03415906|Drug|valsartan|Angiotensin receptor inhibition alone
98568|NCT03415880|Behavioral|Interactive workshops LiPAT intervention group|Workshops include practical behavior change strategies and address barriers to movement, awareness of the immediate benefits of movement and implementation-intentions. Participants will be encouraged to cultivate a learning mind-set in order to better tolerate potential set-backs and to apply strategies such as pre-planning their week to incorporate physical activity, engaging their social network, and setting up systems and habits. Participants' progress in changing their physical activity patterns which will be compared and discussed.
98569|NCT03415880|Device|Wrist-worn feedback physical activity monitor|Participants receive the feedback monitor (i-Health Wave ®; commercially available consumer product (www.ihealthlabs.com)
98570|NCT03415880|Device|Smartphone application LiPAT|With a cloud-based platform the iHealth data is synchronized with a mobile phone app developed by the research team. The app is designed to help the participant to self-monitor their physical activity levels and includes information on total activity and number of steps taken.
98571|NCT03415880|Behavioral|Telephone Coaching|participants in the intervention group will receive telephone coaching during the first 3 months of the intervention. Telephone coaching will be conducted twice in the first month and once each in months two and three. The researcher will enquire about the progress with increasing LiPA, about the experiences of applying the strategies discussed during workshops, and about the experience with iHealth Wave ® and the corresponding app. If needed, the coach will offer suggestions to improve goal adherence.
98572|NCT03415880|Behavioral|Workshops control group LiPAT|During the first 6 months of the study (the intervention period) participants in the control group will attend 4 workshops in which the benefits of physical activity and the health-risks of sedentary behavior will be discussed. Additionally, information will be provided on healthy lifestyle for patients with type 2 diabetes.
98573|NCT03415867|Drug|Glasdegib|A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
98574|NCT03415854|Drug|Paricalcitol (Zemplar)|combination therapy
98575|NCT03415841|Device|mHealth remote monitoring devices|"Blood Pressure and wearable vital signs monitor, Biovotion and Kardia mobile application"
98576|NCT03415828|Device|Ethanol gel|Intradiscal injection of ethanol gel
98577|NCT03415828|Drug|Prednisolone acetate|Intradiscal infiltration of steroids
98578|NCT03415815|Procedure|Surgeries|Radical resection of esophageal cancer
98579|NCT03415802|Drug|Nab-paclitaxel and S-1|Nab-paclitaxel 120 mg/m2 (D1, D8, q3w) and S-1 (40mg BID for body surface area < 1.25 m2; 50mgBID for body surface area of 1.25-1.5 m2; and 60mg BID for body surface area >1.5 m2; D1-14, q3w)
98580|NCT03415789|Diagnostic Test|Doppler echocardiogram exam|A complete echocardiographic study will be performed at enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
98581|NCT03415789|Diagnostic Test|Cardiac Magnetic Resonance|"A cardiac MR will be acquired within 10 days after the enrollment. The protocol includes the following sequences: cine mode of short axis from LV base to apex and 2-3-4 chambers. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 3 min and 10 min of the administration of a total of 0.2 mmol / kg of Prohance®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ) and sphericity index will be measured."
98624|NCT03415490|Other|Folded technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. Then, after the second circuit, the bandage is brought on the cheek and up over the eye to the forehead, where it was passed between the eyebrows but not wrapped around the head. Instead, the bandage is folded and then first passed back on the cheek of the affected side then back to the forehead a total of four times. Finally, the bandage is wrapped completely around the head once
98582|NCT03415789|Diagnostic Test|Brain Magnetic Resonance|A brain MR will be acquired within 10 days after the enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
98583|NCT03415789|Diagnostic Test|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment.
98584|NCT03415776|Procedure|Hemodialysis|Renal replacement therapy
98585|NCT03415763|Drug|Capecitabine|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
98586|NCT03415763|Drug|mFOLFOX6 or CAPOX|According to the postoperative pathological stage, the present study was designed as a non-inferiority trail for patients with pathological complete response or yp stage I to compare the long-term outcomes of observational group and those receiving 5-fluorouracil. For patients with yp stage II or III, the study aims to compare the effect of oxaliplatin combined with 5-fluorouracil and 5-fluorouracil alone.
98587|NCT03415750|Drug|Everolimus|Conversion from Mycophenolate mofetil to Everolimus
98588|NCT03415750|Drug|Mycophenolate mofetil|Patients will remain in Tacrolimus + Mycophenolate mofetil
98589|NCT03415750|Drug|Tacrolimus|
98590|NCT03415737|Other|Questionnaire|Profile Fitness Mapping Neck Questionnaire
98591|NCT03415724|Procedure|Inferior alveolar nerve block|Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars
98592|NCT03415711|Dietary Supplement|VSL#3®|VSL#3® 450 billion sachets
98593|NCT03415711|Drug|Mesalamine|Mesalamine 2.4 g/day in once daily administration.
98594|NCT03415711|Drug|Placebo|sachets with maltose, cornstarch and dioxide
98595|NCT03415698|Drug|G-CSF|G-CSF will be administered at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days. four such cycles will be administered at three monthly intervals.
98596|NCT03415698|Drug|Standard Medical Therapy|Nutritional support, rifaximin, lactulose, bowel wash, albumin, diuretics, multivitamins and antibiotics.
98597|NCT03415685|Device|PicoPlus laser system|Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
98598|NCT03415672|Biological|HBVaxPro|Three doses of HBVaxPro-10μg at 0, 1, and 2 months. The HBVaxPro-10μg vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
98599|NCT03415672|Biological|HBAI20|Three doses of HBAI20 at 0, 1, and 2 months. The HBAI20 vaccines are administered strictly intramuscularly in the deltoid muscle and must not be injected intravascularly.
98600|NCT03415659|Drug|HWH340 tablet|"single escalating dose study starts from 20 mg as the initial dose until the maximum dose group (520mg) or maximum tolerated dose (MTD) has been reached.~multiple-dose study conducted on oral HWH340 tablet BID. The dosing period is 4 weeks and the safety evaluation period is 2 weeks."
98601|NCT03415646|Other|Erector Spinae Plane Block|erector spinae plane block with double level injection will be administered before the surgery
98602|NCT03415646|Device|Intravenous Morphine patient controlled analgesia device|24 hour morphine consumption will be recorded
98603|NCT03415633|Other|Home Respiratory Polygraphy (APNIA)|Randomizing to start with home respiratory polygraphy (APNIA)
98604|NCT03415633|Other|Standard Polysomnography (PSG)|Randomizing to start with Standard Polysomnography (PSG)
98605|NCT03415633|Other|Home Respiratory Polygraphy (APNIA)|Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA)
98606|NCT03415633|Other|Standard Polysomnography (PSG)|Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
98607|NCT03415620|Procedure|Music listening|Patient is given an ipod with earphone and with saved playlist of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
98608|NCT03415594|Drug|FE203799 GLP-2 analogue|FE203799 5 mg subQ once weekly
98609|NCT03415594|Drug|FE203799 Placebo GLP-2 analogue|Placebo subQ once weekly
98610|NCT03415594|Drug|FE203799 GLP-2 analogue|FE203799 10 mg subQ once weekly
98611|NCT03415581|Drug|Intranasal Oxycodone|Under each doxazosin maintenance condition the effects of intranasal oxycodone will be assessed in order to determine if doxazosin reduces dependent measures assessing its abuse potential.
98612|NCT03415581|Behavioral|Cue Session|During the cue exposure session participants are presented with neutral cues followed by drug-related cues. This procedure will allow the investigators to determine whether the study medication affects reactivity to drug-related cues.
98613|NCT03415568|Dietary Supplement|LCT oil|LCT muffin was provided to the study participants. The LCT muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was LCT.
98614|NCT03415568|Dietary Supplement|MCDG oil|MCDG muffin was provided to the study participants. The MCDG muffin was consumed within 15 min, and then 6-h meal tolerance test was conducted. The muffin had approximately 465 kcal, 8.36 g of protein, 17.24 g of fat, and 69.0 g of carbohydrate; among the 17.24g of fat, 15g of fat was MCDG.
98615|NCT03415555|Procedure|Erector Spinae Plane blockade|Before the beginning of the procedure, ESP blockade will be performed under ultrasound control. A single-shot technique will be used with 0.375 % solution of ropivacaine: 0.2 mL per patients' KG. The maximum dose is 40 mL.
98616|NCT03415555|Drug|Oxycodone|Each patient, before the end of surgery, will be administered i.v. 0.1 mg of oxycodone. PCA with oxycodone (1mg/mL) will be utilized during the postoperative period: 5-minute interval.
98617|NCT03415555|Procedure|general anesthesia|Each patient will generally anesthetized and endotracheal tube will be inserted
98625|NCT03415490|Other|Classic technique of self-adherent wrap|Wrapping a piece of self-adherent wrap around the patient's head starting with the opened end on the forehead above the affected eye.The bandage is then firmly but not tightly wrapped around the head twice. After the second circuit, the bandage was brought below the ear, up over the eye and around the head of the non-affected side and then wrapped around the head in the same manner four times. The bandage is then brought around the head once.
98626|NCT03415477|Drug|Denosumab (Xgeva)|Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
98627|NCT03415464|Other|Exercise|neuromuscular training
98628|NCT03415451|Device|Fiberscope-Guided Nasogastric tube insertion|Fiberscope-Guided Nasogastric tube insertion
98629|NCT03415438|Diagnostic Test|Visual Analogue Scale|intensity of pain perception patients feel
98630|NCT03415438|Diagnostic Test|posterior capsule tightness|tape measurement for posterior capsule tightness with patients lying at side and horizontally adducting their shoulder.
98631|NCT03415438|Diagnostic Test|shortness tests for lumbar movements|tape measurement for lumbar movements
98632|NCT03415438|Diagnostic Test|range of motion tests for lumbar movements|range of motion measurements for lumbar flexion, extension and lateral flexion with goniometer.
98633|NCT03415438|Diagnostic Test|The thoracolumbar fascia length test|patient sitting straight with shoulders at horizontal plane, both the arms are asked to rotated with primarily spinal rotation. the degree of rotation gives idea about the thoracolumbar fascia length
98634|NCT03415438|Diagnostic Test|Modify Schober test|tape measurement of spinal flexion between designated regions
98635|NCT03415425|Other|Current Version of the Influenza Alert|Intervention includes the current version of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination, as part of usual care.
98636|NCT03415425|Other|Alternate Modifications of the Influenza Alert|Intervention includes various iterations of the Influenza Alert that fires in the electronic medical record if the patient has not received the flu vaccination.
98637|NCT03415412|Device|Clearfil Univesal Bond|Adhesive systems
98638|NCT03415412|Device|IBond Universal|Adhesive systems
98639|NCT03415412|Device|G-Premio Bond|Adhesive systems
98640|NCT03415399|Biological|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct
98641|NCT03415386|Drug|Combination of antiplatelet drugs and anticoagulants for at least one month|Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.2), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.2), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.
98642|NCT03415373|Device|Microneedle Adapter (Model UAR-2S)|Investigational device
98643|NCT03415373|Device|Hypodermic needle + syringe|Control device
98644|NCT03415360|Procedure|cryoablation|cryoablation of nerve responsible for phantom limb pain
98645|NCT03415347|Procedure|Abscess de-roofing and curettage|Abscess de-roofing and curettage
98646|NCT03415347|Procedure|Abscess wide local excision|Abscess wide local excision
98647|NCT03415334|Behavioral|behavioral development for change|"Social Marketing Principles (4 Ps) Product, price, place and promotion~Communication for Behavior Development Approach 1. Interpersonal communication campaigns (IPC) 2. Mass media and public gathering awareness campaigns 3. Public health awareness campaigns 4. A village hotline and local satellite channel 5. School awareness raising events"
98648|NCT03415321|Device|Postpartum Mobile Support Application|"Women in the experimental group will use the Postpartum Mobile Support Application during six weeks after birth.~Women will be evaluated three times in total, one for the first day after birth, second for the seventh day after birth and the last for the sixth week after birth.~Short messages and calls will be remind of women's Postpartum Mobile Support Application use"
98649|NCT03415308|Other|Focus Groups|Investigators will use qualitative methods to gather data on the elements associated with the patient perception of implicit bias (e.g. communication, respect, patient-centeredness) to ensure that our selected outcomes reflect the breadth of patients' concerns.
98650|NCT03415308|Other|Cognitive Interviews|To gather insights from stakeholders regarding how to best refine the design of our existing implicit bias intervention to ensure that we have addressed potential facilitators and barriers to uptake, use, and sustainability
98651|NCT03415308|Other|Pilot Testing of Implicit Bias Training|Determine the feasibility of delivering the refined implicit bias reduction intervention and assessing patient centered outcomes by giving providers a refined implicit bias training.
98652|NCT03415295|Other|Plasma TMAO concentration|Plasma TMAO concentrations were determined by stable isotope dilution liquid chromatography with online electrospray ionization tandem mass spectrometry on an AB SCIEX 4500 triple quadrupole mass spectrometer
98653|NCT03415282|Drug|RVT-501 0.5% topical ointment|RVT-501 0.5% topical ointment twice daily (BID) for 4 weeks.
98654|NCT03415269|Drug|Ambroxol Hydrochloride|single lozenge of 20mg ambroxol
98655|NCT03415256|Other|passive vibration|The passive vibration is delivered using a Physio Plate (Domino S.R.L, San Vendemiano, Italy). The frequency delivered is 50 Hz for a total number of ten cycles for a period of ten minutes approximately (one cycle= 60seconds working time with 2 seconds rest time).
98656|NCT03415256|Other|no passive vibration|The control group will not receive any treatment and continue their usual lifestyle.
98697|NCT03414970|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RT
98698|NCT03414957|Diagnostic Test|Hormonal and biochemical blood tests and ultrasound scanning|Subjects undergo clinical assessment, blood tests and a pelvic ultrasound scan, to determine if they have either PCOS or Metabolic Syndrome or both
98699|NCT03414944|Radiation|SMART-Brain|"Prescription dose: Gross tumor (PGTV) 40-50 Gy/10 fractions/2 weeks + EBI (PCTV) 30 Gy/10 fractions/2 weeks.~OARs dose limits: Hippocampus D100%≤10Gy, Dmax≤17Gy,Inner ear: Dmean ≤15Gy."
98657|NCT03415243|Drug|Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg|Contents of the sachet will be emptied into a glass bottle and 225 mL of hot, but not boiling water (approximately 90-95°C), will be added to the container and mixed to dissolve the contents of the sachet. The dissolved solution will be allowed to cool to approximately 40 - 50 degree Celsius (°C). After cooling, a small volume (1 to 10 microliters [mcL]) of 99mTc-DTPA (Technetium-99m-diethylene-triamine-pentaacetate will be added to the drug solution in to achieve a maximum of 108 curie(mcCi) i.e.4 megabecquerel [MBq] per individual dose at the time of dosing. The container will be capped and maintained at a temperature between 35-45°C at time of dosing and then participants will be instructed to consume the hot drink entirely within 30 seconds.
98658|NCT03415243|Drug|Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg|Caplet doses will be prepared by drilling hole of approximately(app.)1millimetre(mm)diameter and app.2-2.5mm deep into individual caplets.99mTc-DTPA(dissolved in normal saline)will be added into hole of each caplet as low volume liquid(0.5-2.0mcL)to achieve maximum of 54 mcCi(2MBq)per caplet at time of dosing(2caplets=108 mcCi[4MBq]dose per assessment visit).Applied liquid will be allowed to air dry,hole to be filled with equivalent powder blend from crushed caplet so drug content will remain constant for all caplets.Caplet will be sealed with appropriate material.Radiolabeled caplets will be packaged as unit doses(2 caplets per container)and maintained at room temperature until administration.Caplets will be swallowed with 225mL of noncarbonated room temperature water within 30 seconds.
98659|NCT03415230|Other|Therapeutic massage|Massage therapy involves the administration of combinations of specific physical manipulations applied in a systematic way, with varying intensity, direction, rate, and rhythm, to the soft tissues of the body.
98660|NCT03415230|Other|Sham massage|Sham massage involves only light touch massage in a non systematic way
98661|NCT03415217|Other|Neighbourhood Team Development Program|The Neighbourhood Team Development Program aims to both enhance team development and resident centredness in LTC. The Program has three components, designed to modify the physical environment, the organization and delivery of services, and the alignment of staff members, to function independently and collaboratively in providing resident-centred care.
98662|NCT03415204|Other|acupuncture|acupuncture for post operative pain
98663|NCT03415191|Drug|Ketamine|A bolus dose of ketamine 1 mg/kg intravenously five minutes before surgical incision
98664|NCT03415191|Drug|Normal Saline|A bolus dose of normal saline 1 mg/kg intravenously five minutes before surgical incision
98665|NCT03415178|Drug|Alirocumab SAR236553|Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
98666|NCT03415178|Device|Current auto-injector device (AI)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
98667|NCT03415178|Device|New auto-injector device (SYDNEY)|"Pharmaceutical form:~Route of administration: Subcutaneous self-administration of alirocumab"
98668|NCT03415178|Drug|Atorvastatin|Pharmaceutical form:tablet Route of administration: oral
98669|NCT03415178|Drug|Rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
98670|NCT03415165|Drug|green tea buccal tablet|buccal tablet for 8 hrs 3 times aday
98671|NCT03415165|Drug|Corticosteroids Topical|kenacort in orabase 4 times aday
98672|NCT03415152|Drug|Omacor (Omega-3-acid ethyl esters)|Observational study without intervention, Omacor is prescribed in routine manner in accordance with clinical practice and the valid Instruction for Medical Use regarding the dose, duration of therapy, patient population, and therapeutic indication.
98673|NCT03415139|Drug|Oral Glucose Tolerance Test (OGTT)|A standard OGTT will be performed. During OGTT 75gm of glucose will be given followed by phlebotomy.
98674|NCT03415139|Drug|2 OGTTs with and without GLP-1|A standard OGTT will be performed and a second OGTT procedure will be repeated on a different day with exogenous GLP-1 infusion.
98675|NCT03415139|Drug|Hyperglycemic clamp procedure|During the hyperglycemic clamp procedure, D20 will given, followed by phlebotomy.
98676|NCT03415126|Drug|ASN007: ascending doses|Oral drug for the treatment of advanced solid tumors
98677|NCT03415126|Drug|ASN007 RD|Oral drug for the treatment of advanced solid tumors
98678|NCT03415100|Biological|CAR-NK cells targeting NKG2D ligands|The infusion of CAR-NK cells will be performed in the Third Affiliated Hospital of Guangzhou Medical University. Following infusion of CAR-NK cells, interleukin-2 (IL-2) will be injected subcutaneously into some patients to support the in vivo survival of CAR-NK cells. The subject will be observed for any side effects during this time and all the adverse events will be recorded.
98679|NCT03415087|Procedure|sequential intrathecal injection|intrathecal injection of fentanyl and hyperbaric bupivacaine
98680|NCT03415087|Drug|hyperbaric bupivacaine|intrathecal injection of intrathecal bupivacaine
98681|NCT03415087|Drug|fentanyl|intrathecal injection of fentanyl
98682|NCT03415074|Behavioral|Protein restriction|In both arms the dietary protein intake will be reduced. In the sLPD arm, the protein restriction is more severe and ketoanalogues of the essential aminoacids are offered.
98683|NCT03415061|Drug|Regular Insulin, Human 100 UNT/ML|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
98684|NCT03415061|Drug|Normal Saline Flush, 0.9% Injectable Solution|Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
98685|NCT03415048|Other|No Intervention|
98686|NCT03415022|Behavioral|computer-based treatment|30 minute sessions of free viewing of faces and listening to music
98687|NCT03414996|Other|Exercise training|Patients will undergo two weekly exercise training sessions with high-intensity interval training or moderate-intensity continuous exercise training for a period of 12 weeks.
98688|NCT03414983|Biological|Nivolumab|Specified dose on specified days
98689|NCT03414983|Drug|Oxaliplatin|Specified dose on specified day
98690|NCT03414983|Drug|Leucovorin|Specified Dose on specified days
98691|NCT03414983|Drug|Fluorouracil|Specified dose on specified days
98692|NCT03414983|Drug|Bevacizumab|Specified dose on specified days
98693|NCT03414970|Radiation|Radiation Therapy|Undergo RT
98694|NCT03414970|Other|Questionnaire Administration|Ancillary studies
98695|NCT03414970|Other|Quality-of-Life Assessment|Ancillary studies
98696|NCT03414970|Other|Laboratory Biomarker Analysis|Correlative studies
98703|NCT03414918|Drug|Clarithromycin|Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
98704|NCT03414905|Device|Aspira Catheter|-15.5Fr catheter
98705|NCT03414905|Procedure|Ultrasound|Standard of care
98706|NCT03414892|Drug|Globalagliatin Hydrochloride|once daily, oral
98707|NCT03414892|Drug|Placebo|once daily, oral
98708|NCT03414879|Drug|Ketamine|While in the semi-setting position, patients will receive nebulization with ketamine 3 mg/kg to be completed with normal saline solution to reach a volume of 6 ml (K group; n=30) for 15 minutes before commencing the awake fiberoptic intubation..
98709|NCT03414879|Drug|Lidocaine|While in the semi-setting position, patients will receive nebulization with lidocaine 4% 6 ml (L group; n=30) for 15 minutes before commencing the awake fiberoptic intubation
98710|NCT03414866|Behavioral|EQ-5D-5L QOL questionnaire|Written questionnaire
98711|NCT03414853|Diagnostic Test|Free text prediction algorithm for appendicitis|A free-text prediction software that predicts the probability of acute appendicitis
98712|NCT03414840|Drug|Atorvastatin|Patients diagnosed with coronary artery disease by CCTA be enrolled. Among enrolled patients, patients who is indicated to statin treatment according to the current ACC/AHA guideline will be treated with atorvastatin.
98713|NCT03414814|Drug|Osimertinib 80 MG [Tagrisso]|Osimertinib 80mg once daily until disease progression
98714|NCT03414801|Other|Allergen Exposure|Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
98715|NCT03414788|Biological|PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and [124I]IB PF 06687234 simultaneously
98716|NCT03414788|Biological|[124I]IB PF 06687234|Subjects will be given single, intravenous dose of PF 06687234 and [124I]IB PF 06687234 simultaneously
98717|NCT03414775|Other|Nourish|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
98718|NCT03414775|Other|Pediasure|The effects of Nourish on the gastrointestinal microbiome will be compared to the the effects of Pediasure on the gastrointestinal microbiome
98719|NCT03414762|Device|PICO Negative Pressure Wound Therapy|The PICO unit is a single patient use, battery-powered, disposable unit that can provide continuous 80 - 125 mmHg negative pressure over a 5 to 7-day therapy period.The dressing is applied to the wound and extra strips are placed over the outside edge to help hold the dressing in place. When the pump is turned on, air is pulled out of the dressing and excess fluid from the wound will start to enter the dressing.
98720|NCT03414762|Device|Standard Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing
98721|NCT03414749|Procedure|Lower Extremity First (LEF)|The intervention for the LEF group was a non-specific long-axis distraction to the ankle, knee, and hip or shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
98722|NCT03414749|Procedure|Upper Extremity First (UEF)|The intervention for the UEF group was a non-specific long-axis distraction to the shoulder, elbow and wrist provided was at the discretion of the clinic doctor (over 25 years experience).
98723|NCT03414736|Drug|SAR425899|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
98724|NCT03414723|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
98725|NCT03414723|Drug|Ramipril|"Pharmaceutical form: tablets~Route of administration: oral"
98726|NCT03414710|Behavioral|Health education booklet plus video plus brief counseling|Participants in the intervention group will receive a health education booklet, watch a 10-minute video and receive counseling provided by the clinicians
98727|NCT03414710|Behavioral|Health education booklet only|Participants in the intervention group will only receive a health education booklet
98728|NCT03414697|Other|Control group|The control group received routine rehabilitation treatments including acupuncture, massage, Bobath therapy, and Vojat therapy.
98729|NCT03414697|Procedure|UC-MSCs|Injection of umbilical cord-derived mesenchymal stem cells (UC-MSCs) (at least 1×10^7), once every 2 weeks, one course of treatment including two injections within 4 weeks, a total of two courses of treatment.
98730|NCT03414684|Drug|Carboplatin|Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.
98731|NCT03414684|Drug|Nivolumab|Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
98732|NCT03414658|Drug|Vinorelbine|work by interfering with cell division, which leaves the tumor unable to grow and spread
98733|NCT03414658|Drug|Trastuzumab|trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2.
98734|NCT03414658|Drug|Avelumab|monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein
98735|NCT03414658|Drug|Utomilumab|Utomilumab is an antibody designed to stimulate the body's immune system to fight cancer cells
98736|NCT03414645|Biological|CAM-101 10%|fibrinogen-depleted human platelet lysate
98737|NCT03414645|Biological|Vehicle Control|PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
98738|NCT03414645|Biological|CAM-101 30%|fibrinogen-depleted human platelet lysate
98739|NCT03414632|Drug|99mTc-PYP|Radioisotope used in the SPECT/CT imaging
98768|NCT03414307|Device|Robot-assisted intracerebral catheter|ROSA is a robotic device with trajectory planning software that can be used to aid in planning multiple trajectories to large, irregular clots, and aids in navigating into and out of the cerebral hematoma with minimum human error.
99806|NCT03406143|Procedure|Control|Saline will be injected into expanded skin
98740|NCT03414619|Behavioral|Cognitive Control Tasks and Script Driven Imagery|All participants will receive a structured diagnostic assessment and complete self-report questionnaires about cognitive factors and anxiety/mood symptoms. They then will complete a battery of neuropsychological executive functioning tasks on the computer, each of which measures a different facet of cognitive control (i.e., response inhibition, cognitive flexibility, and attentional control). Finally, they will be guided through a standardized script-driven imagery paradigm that involves generating and listening to an individualized imaginal script associated with a moderately distressing intrusive thought. Self-report and psychophysiological data will be collected during this exercise.
98741|NCT03414593|Drug|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivcaine|Ultrasound guided popliteal sciatic nerve block with 0.2% ropivacaine 20ml
98742|NCT03414580|Procedure|Breath sampling for volatile organic compounds|Acquisition of exhaled breath sample in exhaled air to be analysed by gas chromatography-mass spectrometry
98743|NCT03414541|Drug|DS102|DS102
98744|NCT03414541|Other|Placebo|Placebo
98745|NCT03414528|Diagnostic Test|Diagnostic Test|Analysis of DNA samples of patients with molecularly undetermined PID by whole exome/genome sequencing Transcriptome analysis of patients with molecularly undetermined PID
98746|NCT03414515|Device|Endovascular intervention|Endovascular treatment with stent or balloon according to current practice
98747|NCT03414502|Drug|Methotrexate|Starting dose of Methotrexate of 15 mg once a week plus folic acid 1mg. daily.
98748|NCT03414489|Drug|ABC294640|
98749|NCT03414476|Other|Hair follicles sampling|The follicles will be collected by lock of 10 hair on the scalp (centro-parietal part), to obtain 40 follicles with epithelial sheath
98750|NCT03414463|Behavioral|TREAT|A 4-week one-to-one intervention between the clinical RA (cRA) and participant. Comprised of eight sessions, it involves psycho-educational lessons and skill-building exercises to achieve objectives based on the characteristics of alexithymia.
98751|NCT03414450|Drug|ETC-1907206|ETC-1907206 gelatin capsules will be dosed every other day (EOD) and contain 10 mg or 50 mg of ETC-1907206.
98752|NCT03414450|Drug|dasatinib|dasatinib tablets at 140 mg will be dosed every day
98753|NCT03414424|Device|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
98754|NCT03414424|Device|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
98755|NCT03414385|Other|Exercise|Acute bout of aerobic exercise at moderate intensity for 2 hours
98756|NCT03414372|Behavioral|Tough Talks Online|Those randomized to the online condition will receive information about how to access Tough Talks online and be given their unique log-in and password information and information on how to contact study personnel for any technical issues. Arm 1 participants will have 24-hour access to all of the intervention features and will be able to access the program for additional sessions at any time. Study staff will provide reminders using text or email (participant preference) if they have not accessed the intervention at the specified time intervals.
98757|NCT03414372|Behavioral|Tough Talks Clinic|Those randomized to the in-clinic condition (Arm 2) will immediately begin the Tough Talks intervention. Study staff will ensure participants are logged on and will also be available to answer technical issues should they arise. After completion, those in this arm will have an in-person follow-up visit scheduled for approximately two weeks.
98758|NCT03414372|Behavioral|Standard of Care|Those randomized to the control arm (SOC) will receive a paper-based disclosure informational packet based on available Centers of Disease Control (CDC) guidance. At one-month, all participants will complete an online survey to assess intervention acceptability as well as to assess Social Cognitive Theory (SCT model) constructs.
98759|NCT03414359|Drug|2% Lidocaine|2% Lidocaine using a combined spinal-epidural (CSE)
98760|NCT03414359|Drug|3% Chloroprocaine|3% Chloroprocaine using a combined spinal-epidural (CSE)
98761|NCT03414346|Other|Exclusively ice pack|Each subject will receive an experimental intervention of exclusively 500 grams of crushed ice. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
98762|NCT03414346|Other|Ice pack added 10% of water|Each subject will receive an experimental intervention of ice pack added to 50 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
98763|NCT03414346|Other|Ice pack added 100% of water|Each subject will receive an experimental intervention of ice pack added to 500 mL of water. The intervention will last 20 minutes, and the order of application, expressed in % of water X ice, will be according to the randomization (realized in the first day). The pack will be wrapped in a band for improvement of the contac area. The subject will be asked to mark his pain level on the visual analogue scale (no pain score of 0 and pain as bad as it could be score of 10) every minute until the total time of the intervention.
98764|NCT03414333|Procedure|RYGB|RYGB is associated with a increase of circulating GLP-1 (up to ten-fold) especially in response to meal ingestion. This increased availability of GLP1 has been claimed to contribute to restoration of some of the beta-cell function.
98765|NCT03414333|Drug|GLP-1|GLP-1 is an hormone secreted by gut in response to nutrients ingestion.
98766|NCT03414320|Other|Gathering data|Gathering data about sleep, heart rate, carbohydrate intake, insulin pump, continuous glucose sensor, meals.
98767|NCT03414307|Procedure|Intracerebral catheter placement|Image guided stereotactic placement of intra-hemorrhage catheters to evacuate intra-cerebral hemorrhage
98769|NCT03414294|Drug|K-755 Part A (SAD)|Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
98770|NCT03414294|Drug|Placebo Part A (SAD)|Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
98771|NCT03414294|Drug|K-755 Part B (MAD)|Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
98772|NCT03414294|Drug|Placebo Part B (MAD)|Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
98773|NCT03414294|Drug|K-755 Part C (FE)|Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
98774|NCT03414294|Drug|K-755 Part D (FE)|Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
98775|NCT03414294|Drug|K-755 Part E (MAD)|Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
98776|NCT03414294|Drug|Placebo Part E (MAD)|Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
98777|NCT03414281|Procedure|TMQLB group 1|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
98778|NCT03414281|Procedure|TMQLB group 2|"The patient is placed in the lateral position. The curved (C1-5) probe of Philip CX50 Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
98779|NCT03414281|Procedure|TPVB|"The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The linear(L12-3) probe of Philips CX50 is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine with 1: 200,000 adrenaline is injected into the paravertebral space of T10.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine."
98780|NCT03414268|Other|Micronized dHACM|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
98781|NCT03414268|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
98782|NCT03414255|Biological|Micronized DHACM|1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).
98783|NCT03414255|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
98784|NCT03414242|Other|Cervical spine musculature|Previously established cervical spine musculature training methodology will be utilized to develop a concussion prevention training program.
98785|NCT03414229|Drug|Epacadostat|100mg bid days 1-21
98786|NCT03414229|Drug|Pembrolizumab|200mg/dose Day 1, Q 3 weeks
98787|NCT03414216|Procedure|Group 1 early offloading surgery|As above.
98788|NCT03414216|Procedure|Group 2 - off-loading in fiberglass cast|As above.
98789|NCT03414203|Other|tDCS|Transcranial Current Stimulation equipment consists of an ammeter (measured with current intensity), a potentiometer (voltage controller between the electrodes), a generator (two 9-volt batteries) and two electrodes (anode and cathode). The direct low-amplitude currents released by the electrodes reach the cortex and modify the neuronal potentials.
98790|NCT03414190|Behavioral|Mobile phone text message|The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order. The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. They will also receive simple and short text messages related to the importance of trial participation.
98791|NCT03414177|Other|Asthma Subspecialty Follow-up Visits|Pediatric patients with persistent asthma will be recruited to compare outcomes among patients with follow-up visits managed via telemedicine vs. in-person visits.
98792|NCT03414164|Dietary Supplement|procyanidine|natural antioxidants
98793|NCT03414151|Other|Observation|No intervention administered.
98794|NCT03414138|Behavioral|Mindfulness Training|A well-validated brief mindfulness-based mental training regimen [four sessions; 20 min/session] will be used to teach patients to independently practice mindfulness meditation.
98795|NCT03414138|Behavioral|Book Listening Control|Study volunteers will listen to four 20 minute blocks of The Natural History and Antiquities of Selborne throughout their interventions.
98796|NCT03414125|Other|FIT Screening Strategy|"Mailed outreach invitation to complete FIT. FIT Strategy invitation includes: 1) invitation letter, 2) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
98838|NCT03413735|Other|Placebo|Confections containing no green tea extract that will be ingested daily for 4 weeks
98839|NCT03413722|Drug|Tacrolimus|The patient's physician will prescribe drug according to standard practice.
98840|NCT03413722|Drug|Everolimus|The patient's physician will prescribe drug according to standard practice.
98797|NCT03414125|Other|Choice Screening Strategy|"Mailed outreach invitation offering patients the choice to complete either a FIT or schedule a colonoscopy.~Letter will discuss advantages and disadvantages of FIT vs. colonoscopy but will not recommend a particular test, allowing patients to choose a screening option based on their own preferences. Outreach includes: 1) invitation letter, 2) choice grid 3) telephone number for scheduling colonoscopy, and 4) test kit (1-sample FIT, simplified instructions on how to perform the test and return mailer with prepaid postage).~Up to three live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow-up."
98798|NCT03414112|Biological|Intranasal oxytocin|oxytocin is a peptide hormone that influences social affiliation
98799|NCT03414099|Drug|Ketum|Ketum (Mitragyna speciosa) is an indigenous plant of Southeast Asia reported to have medicinal value in traditional culture
98800|NCT03414099|Drug|Placebo|Placebo drink matched for taste and appereance
98801|NCT03414086|Other|Healthy Control|Ten healthy adult patients evaluating serum, PBMC's, and RNA.
98802|NCT03414086|Other|Myositis in Remission|Ten patients (four who have polymyositis, six dermatomyositis) from our database who are followed in the Myositis Center. We will collect serum, PBMC's, and RNA samples will be obtained at baseline and at six months. Remission is defined as a global myositis disease activity score less than or equal to 1 on the MDAAT assessments with no new immunosuppressive drug or glucocorticoid use and no increase in dose of either in the preceding year.
98803|NCT03414073|Device|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
98804|NCT03414073|Device|Conventional flossing technique|"The subject will wrap the floss around their middle or index finger and gently slide the floss between the teeth and move it along the gum margin, curved into C shape. After this, they will have to move the floss up and down several times between each tooth without using excessive pressure, finally allowing it out through embrasure."
98805|NCT03414073|Device|Conventional Interdental Brushing|The subject will gently insert the interdental brush into the interdental area with an inclination akin to the angle of the interdental gums (gingiva), and perform to and fro buccal to lingual movements and a little apico-coronal movement such that the gingiva is not impinged, and finally removing the brush out buccally.
98806|NCT03414060|Device|Menstrual Cup|
98807|NCT03414047|Drug|Prexasertib|Administered IV
98808|NCT03414034|Drug|Onvansertib|Onvansertib orally
98809|NCT03414034|Drug|Abiraterone|Abiraterone orally
98810|NCT03414034|Drug|Prednisone|Prednisone orally
98811|NCT03414021|Diagnostic Test|SPECT-CT Scan|Injection of a Tracer and SPECT-CT Scan
98814|NCT03413995|Drug|Rucaparib|Continuous dosing
98815|NCT03413982|Other|Registry|Patient registry
98816|NCT03413969|Behavioral|CREATION|The physician-oriented intervention will consist of a two-day weekend retreat that focuses on the application of CREATION Health principles in order to reduce burnout and perceived stress and improve well-being and empathy. There will be one four-hour session about each of the following CREATION Health principles: Choice, Trust, Interpersonal Relationships, and Outlook.
98817|NCT03413956|Procedure|Surgeries|Surgeries
98818|NCT03413943|Other|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
98819|NCT03413930|Procedure|Transanal total mesorectal excision|Patients undergo transanal total mesorectal excision.（assisted by laparoscopy to control the IMA）
98820|NCT03413930|Procedure|Laparoscopic total mesorectal excision|Patients undergo Laparoscopic total mesorectal excision.
98821|NCT03413917|Other|Analysis of genomic markers in uterine atony|No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
98822|NCT03413904|Procedure|transanal TME|transanal approach to TME in rectal cancer
98823|NCT03413904|Procedure|laparoscopic TME|laparoscopic approach to TME in rectal cancer
98824|NCT03413891|Drug|Tranexamic Acid|Mouthwash
98825|NCT03413891|Other|Placebo|Mouthwash
98826|NCT03413878|Other|Breathing in the simulated avalanche snow|Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
98827|NCT03413865|Other|Visits conducted via Telemedicine|Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
98828|NCT03413852|Device|SQUID non-adhesive liquid embolic agent|AVM embolization using SQUID non-adhesive liquid embolic agent
98829|NCT03413839|Behavioral|Physiotherapeutic Scoliosis Specific Exercises (PSSE)|Exercises with emphasis on trunk extensor strengthening, and teaching patient better postural strategies in supine, sidelying, sitting, standing, and dynamic movements (walking, squatting), led by a PSSE-trained physical therapist.
98830|NCT03413839|Behavioral|Conventional Physical Therapy (PT)|Conventional PT includes generalized pelvis, and trunk strengthening, lower extremity (LE) stretching, and use of modalities (ice and heat), iontophoresis and E-Stim.
98831|NCT03413826|Behavioral|Exercise|The intervention groups will perform aerobic exercise for 12 weeks, expending 3,000 kcal of energy per week.
98832|NCT03413813|Device|Magmaris|Severe stenosis de novo, in native coronary arteries, treated with percutaneous coronary intervention with scaffold implantation.
98833|NCT03413800|Drug|Lenalidomide-Dexamethasone-DLI|Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)
98834|NCT03413774|Procedure|vaginal swab|high vaginal and Endocrvical swabs for bacterial, protozoal and chlamydial infection- examined by PCR
98835|NCT03413748|Procedure|Elective Cesarean Section|lower segment cesarean section
98836|NCT03413748|Other|Peritoneal irrigation|Irrigation of peritoneal cavity with 500 - 1000 ml of warm normal saline
98837|NCT03413735|Other|Green Tea Extract|Confections containing green tea extract that will be ingested daily for 4 weeks
98841|NCT03413709|Other|Family Formation Program|The sample for the treatment group for the impact evaluation will only include fathers who are receiving the full 240 hour FFP program (and not the abbreviated 80 hour program). The treatment group will receive FSC's Family Formation Program, which is a six week, 240 hour program implementing a set of curricula focusing on responsible parenting, healthy relationships, and economic stability and mobility.
98842|NCT03413657|Procedure|Increase in intrathoracic pressure|Will transiently increase intrathoracic pressure for 60 seconds and monitor for changes in hemodynamics during this time.
98843|NCT03413644|Diagnostic Test|Flow Cytometry|Immunophenotyping of residual clinical samples tested with ClearLLab diagnostic reagent on a specified Flow Cytometer
98844|NCT03413631|Behavioral|Prenatal mentalization intervention|
98845|NCT03413631|Other|Prenatal obstetric treatment as usual|
98846|NCT03413618|Drug|Rivaroxaban|15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
98847|NCT03413618|Drug|Diosmin|600 mg q.d. for 12 month
98848|NCT03413618|Other|compression stockings|above knee stocking for 12 month
98849|NCT03413605|Behavioral|A Multilevel CBPR Intervention|The intervention will be implemented through a group-based education workshop. The education session is a curriculum-based group education; each group will be having about 15-20 participants. All group education sessions will take place at collaborating Viet community partners sites, and delivered in Vietnamese language, with offering of refreshment. We will allow 5-7 minutes for participants to get to know each other and to get comfortable talking to the group. Education will have two major topics--- (a) CDC's standard Clinical Preventive Services Guidelines for adults 50+ (CPS). (b) culturally tailored CRC information discussion.
98850|NCT03413592|Other|Road-tracking test|Driving with simulator program for SDLP measurement
98851|NCT03413592|Other|Car-following test|Driving with simulator program for DCV measurement
98852|NCT03413592|Other|Harsh-braking test|Driving with simulator program for BRT measurement
98853|NCT03413579|Biological|Nimotuzumab ( h-R3)|Humanized monoclonal antibody
98854|NCT03413579|Other|Placebo|
98855|NCT03413566|Other|Clinical diagnosis|A clinical diagnosis of cerebral palsy given by a pediatrician at a habilitation center in Norway.
98856|NCT03413553|Device|immediate implant|Patient will receive immediate implant alone.
98857|NCT03413553|Biological|connective tissue graft|patient will receive immediate implant with connective tissue graft and platelet rich fibrin
98858|NCT03413553|Biological|platelet rich fibrin|patient will recieve immediate implant combined with connective tissue graft and platelet rich fibrin
98859|NCT03413540|Other|Jump|Drop jump from step
98860|NCT03413527|Device|rTMS|rTMS Treatment
98861|NCT03413514|Drug|NACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for n courses.(0<n<8)
98862|NCT03413514|Procedure|SDM|Making the decision about the cycle of neoadjuvant chemotherapy with shared decision making
98863|NCT03413514|Procedure|Surgery|Radical surgery with D2 lymph node dissection
98864|NCT03413514|Drug|ACT|SOX: Oxaliplatin 130mg/m2,iv.,d1; S-1 60mg,po.,Bid,d1-14; Repeat every 21 days for 8-n courses.(0<n<8)
98865|NCT03413514|Other|Questionnaire|MAPPIN'SDM questionnaire, the control performance card, the care questionnaire, the decisional conflict questionnaire, the decisional regret questionnaire, the questionnaire of the reason for stopping neoadjuvant chemotherapy
98866|NCT03413501|Behavioral|MUD-PI|
98867|NCT03413488|Other|kinesio taping|Apply exercise and kinesio taping for intervention
98868|NCT03413488|Other|exercise|Apply only exercise intervention
98869|NCT03413475|Behavioral|quality of life|
98870|NCT03413462|Drug|HS-25|HS-25 10mg/tablet, 20mg,once daily,for 12 weeks, and then HS-25 20mg once daily for 40 weeks.
98871|NCT03413462|Drug|Placebo of HS-25|Placebo HS-25 10mg/tablet, 20mg,once daily,for 12 weeks,and then HS-25 20mg once daily for 40 weeks.
98872|NCT03413449|Diagnostic Test|Frailty model|"Grip strength~30 second chair sit stand test~Psoas muscle area~Six minute walk"
98873|NCT03413436|Drug|Lobaplatin|at least one cycle adjuvant chemotherapy after esophagectomy
98874|NCT03413436|Drug|Cisplatin|at least one cycle adjuvant chemotherapy after esophagectomy
98875|NCT03413423|Behavioral|BAT-CS|All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
98876|NCT03413423|Behavioral|Smoking Cessation and Health & Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
98877|NCT03413410|Drug|Metoprolol|Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
98878|NCT03413384|Drug|Ceftriaxone|1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
98879|NCT03413384|Other|Placebo|Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle
98880|NCT03413371|Drug|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
98881|NCT03413371|Drug|0,5 % bupivacaine with of 2% lidocaine|in group BL patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
98882|NCT03413371|Drug|1 % ropivacaine with of 2% lidocaine|in group RL patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
99005|NCT03412396|Other|Quality-of-Life Assessment|Ancillary studies
98883|NCT03413371|Drug|1 % Ropivacaine|in group R patients will receive regional peribulbar block using a solution of 0,75 % ropivacaine (5 ml)
98884|NCT03413371|Drug|0,5 % bupivacaine|in group B patients will receive regional peribulbar block using a solution of 0,5% bupivacaine (5 ml)
98885|NCT03413358|Drug|Sheng Bai oral liquid|"Drug: Sheng Bai oral liquid 40 mL, oral use, thrice daily after screening on the same day in the second course of the chemotherapy.~Subjects will be treated for 2 courses"
98886|NCT03413358|Drug|Platinum-based two medicine (carboplatin / cisplatin) .|Using Platinum-based two medicine (carboplatin / cisplatin)
98887|NCT03413332|Other|E-Talkcare|Women in the intervention group will receive the E-Talkcare web address, a user name, and a temporary password. The participant will be able to read or listen (through audio narration) to instructions on how to complete the intervention in order, though she can freely navigate between web modules. Each module will have an ever-present indicator (showing users' progress) and a link to for users to continue navigating through modules.We will ask participants to complete the full intervention within 3 months after intervention delivery and then complete a 3-month post-randomization interview (T1). The website will remain open for six months after intervention delivery to allow participants to use QPL if they wish. A 6-month post-randomization interview (T2) will then be administered.
98888|NCT03413332|Other|Usual Care|Survivors randomized to the usual care group will receive care from their doctors as usual, allowing us to compare the intervention against real-world practice to inform next steps. Since we do not know if the intervention will be efficacious, we decided not to provide a delayed intervention to control participants.
98889|NCT03413319|Drug|ABBV-8E12|Solution for infusion
98890|NCT03413306|Drug|Eltrombopag|Eltrombopag is an oral mimetic thrombopoietin selectively binding transmembrane and juxtamembrane domains of the thrombopoietin receptor different from the binding site of thrombopoietin. Therefore it does not compete for binding with the native molecule. It is promoting thrombopoiesis and release platelets from mature megakaryocytes. Also it promotes more primitive multilineage progenitors and hematopoietic stem cells to proliferate and differentiate into thrombocytes, erythrocytes and leukocytes.
98891|NCT03413306|Drug|IST (ATG + CsA)|
98892|NCT03413293|Diagnostic Test|Diagnosis of bacterial infections|Cultures
98893|NCT03413280|Drug|Ultrasound guided Rectus sheath block|Ultrasound guided rectus sheath block with 0.25% ropivacaine 34ml around umbilicus
98894|NCT03413280|Drug|Intercostal nerve block|Ultrasound guided intercostal nerve block with 0.25% ropivacaine 6ml in 7,8,9 th intercostal space
98895|NCT03413267|Other|Custard|Food matrix: custard (liquid emulsion)
98896|NCT03413267|Other|Flan|Food matrix: flan (soft gel)
98897|NCT03413267|Other|Sponge cake|Food matrix: sponge cake (porous and spongy)
98898|NCT03413267|Other|Biscuit|Food matrix: biscuit (thick and crunchy)
98899|NCT03413254|Other|Routine follow-up|Patients visit the outpatient clinic twice a year during the first two to three years and annually thereafter, until five years postoperative. CEA-levels are determined at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 48 and 60 months after primary resection. Detection of liver metastases with ultrasound or CT is performed at 12, 24, 36, 48 and 60 months postoperative. At 6 and 18 months postoperative, a CT-scan is part of the study protocol, but ultrasound of the liver is allowed for other time intervals during follow-up. Colonoscopy is performed at 12 and 48 months postoperative.
98900|NCT03413254|Procedure|Second look DLS|Second look DLS is performed within one month from negative CT at 6-9 months (depending last date of adjuvant chemotherapy) and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
98901|NCT03413254|Procedure|Third look DLS|Third look DLS is performed within one month from negative CT at 18 months and normal CEA. Laparoscopic access to the abdominal cavity is obtained under general anaesthesia, followed by adhesiolysis if necessary. Complete staging is performed, with biopsy of any lesion suspicious of PM, and determining the peritoneal cancer index (PCI) in case of PM. Conversion to laparotomy not allowed for better exposure, but only for intra-operative complications.
98902|NCT03413228|Other|Questionnaire|An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
98903|NCT03413215|Behavioral|Intensive|"Patients are provided with a BP machine, glucometer and test strips, and instructed how to use either a written or smartphone logbook, photograph their meals and use smartphone apps to measure daily activity. DNEs will contact patients in between visits to reinforce adherence and self-monitoring.~MSWs will conduct at least 6 face-to-face sessions, at 3 weeks then less frequently, on essential self-care behaviours in people with diabetes: healthy eating; being physically active; monitoring of blood sugar; compliance with medications; problem-solving; healthy coping skills; and risk-reduction behaviour.~Renal pharmacists will see patients at 2-4 week intervals for 3 months after the first clinic visit, and subsequently every 3-6 months. They will review patient's compliance, laboratory results and home BP, educate patient and titrate antihypertensives to meet BP goal. Physician referrals will be made for severe hypertension or hypotension, or intolerable side effects."
98904|NCT03413202|Drug|butylphthalide(NBP)|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 25mg butylphthalide(NBP) injection, and 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, butylphthalide(NBP) capsule for 76 days.
98905|NCT03413202|Drug|placebo|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2014), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.In addition, 100ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, infusion for 14 days, then, starch capsule for 76 days.
99006|NCT03412396|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
99007|NCT03412383|Drug|Pyrotinib|Pyrotinib 400mg/day
98906|NCT03413189|Other|Review of medical records|Medical records of patients will be reviewed to establish the median and highest level of functional achieved in Intensive Care (intensity) and the percentage of exercise sessions performed (frequency)
98907|NCT03413189|Other|Assessment of physical and cognitive function|This will be performed in person through the Function Independence Measure (FIM), grip strength, functional reach, 6-minute walk test (6MWT) and Montreal Cognitive Assessment (MoCA-Blind).
98908|NCT03413189|Other|Interview of patients, carers and/or family members|Questions will be asked to participants regarding their recovery from Intensive Care to establish themes
98909|NCT03413176|Drug|Cardiac complication induced by VEGF/VEGFR inhibitor|Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity
98910|NCT03413163|Drug|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
98911|NCT03413163|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
98912|NCT03413150|Drug|Amiodarone|Data were extracted from the files of 80 consecutive critically ill patients who had received at least one dose of amiodarone to treat or prevent AT during their hospitalization in the ICU.
98913|NCT03413137|Procedure|Transperineal mpMRI-US Fusion prostate biopsy|mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).
98914|NCT03413137|Procedure|Transrectal mpMRI-US Fusion prostate biopsy|using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.
98915|NCT03413124|Drug|MGL-3196 Tablet|MGL-3196 in Tablet form
98916|NCT03413124|Drug|MGL-3196 Capsule|MGL-3196 in Capsule form
98917|NCT03413111|Procedure|Modified double wire technique|For experimental arm, a tiny cut of papilla orifice, with the length of 5mm, was performed by sphincterotome before the double wire cannulation.
98918|NCT03413098|Device|Nasal CPAP mask|Investigative Nasal Mask to be used for OSA therapy
98919|NCT03413085|Device|soft contact lens|"Group A~Group B"
98920|NCT03413059|Drug|Morphine Sulfate|Thoracic Epidural morphine
98921|NCT03413059|Drug|Triamcinolone Acetonide|thoracic epidural triamcinolone acetonide
98922|NCT03413046|Diagnostic Test|Peripheral and bone marrow sampling|We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.
98923|NCT03413033|Other|Resonance tube|Participants will phonate into a tube (10cm length 4mm inner diameter) during 5 minutes. They will produce series of the vowel /u/ into the tube. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
98924|NCT03413033|Other|Tongue trill|Participants will produce series of a similar /r/ Spanish sound during 5 minutes. They will be asked to maintain the same pitch and loudness as they did in the baseline samples. They will be perceptually controlled by experimenters. When performing the exercise, the participants will be instructed to phonate with ease voice and to sense vibrations in the anterior face and the mouth.
98925|NCT03413020|Drug|esomeprazole|proton pump inhibitor
98926|NCT03413020|Drug|bismuth Potassium Citrate|gastric mucosal protective drug with anti-H. pylori effect
98927|NCT03413020|Drug|amoxicillin|antibiotic for H. pylori eradication
98928|NCT03413020|Drug|clarithromycin|antibiotic for H. pylori eradication
98929|NCT03413020|Drug|metronidazole|antibiotic for H. pylori eradication
98930|NCT03413020|Drug|levofloxacin|antibiotic for H. pylori eradication
98931|NCT03413007|Diagnostic Test|Immune compleX Predictive Index|iXip is an algorithm thant integrates PSA, PSA-IgM, prostate volume and age of the patient in order to provide the probability of prostate cancer
98932|NCT03412994|Drug|Apatinib|Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer
98933|NCT03412994|Drug|standard second-line chemotherapy|The second line standard chemotherapy regimen recommended by the NCCN
98934|NCT03412981|Other|pregnant mothers|we will be collecting data on a cohort of pregnant mothers
98935|NCT03412968|Procedure|Polysulfone Filter|The intervention for this group consisted using a Polysulfone filter in order to hemofiltration in the procedure involving Cardiopulmonary Bypass (CPB).The perfusionist's role is essential during the procedure, as they control both Cardiac Output (CO) and gas exchange, depending on their action, will affect blood lactate levels.
98936|NCT03412968|Procedure|Procedure/ Surgery: without Polysulfone Filter|In this group, no intervention is performed during the procedure involving Cardiopulmonary Bypass (CPB)
98937|NCT03412955|Drug|Eribulin Mesylate|1.4mg/m2/dose on days 1 and 8 of a 21-day treatment cycle.
98938|NCT03412942|Device|FISH SP|The device will be used to close the femoral artery after angiogram and/or endovascular procedure.
99008|NCT03412370|Other|Cognitive Assessment|Complete cognitive assessments
99009|NCT03412370|Other|Questionnaire Administration|Complete questionnaires
98939|NCT03412929|Device|Honey Impregnated Dressing|The investigational product being examined contains 100% Manuka honey and is ideal for difficult to dress wounds. The dressing provides a moist wound environment to help promote autolytic debridement. The dressing is ideal for partial or full thickness wounds with moderate-to-heavy drainage.
98940|NCT03412916|Behavioral|GetActive|GetActive is a comprehensive, multimodal treatment that was designed to increase quality of life, resiliency and ability to cope with medical symptoms and stress. This program is rooted in the elicitation of the relaxation response, a non-judgmental state of focused attention and increased awareness.
98941|NCT03412916|Behavioral|Get Active with Fitbit|The GetActive Program for Pain with a Digital Monitoring Device (GetActive Fitbit) is identical to the GetActive with the addition of a FitBit for recording of physical activity.
98942|NCT03412890|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
98943|NCT03412890|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
98944|NCT03412877|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
98945|NCT03412877|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
98946|NCT03412877|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in cohort 3 may receive 72,000 IU/kg IV.
98947|NCT03412877|Biological|Individual Patient TCR-Transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes.
98948|NCT03412851|Other|A Direct Aspiration First Pass Technique|Distal aspiration technique
98949|NCT03412851|Other|Stentriever Thrombectomy|Thrombectomy with stent retriever
98950|NCT03412838|Procedure|graft surgery|A graft surgery using bone allogenic blocks that are screwed over the atrophic sites of the maxilla to obtain bone augmentation to support dental implants
98951|NCT03412825|Dietary Supplement|Egg supplementation|Participants will required to consume 2 eggs per day, 5 days a week (a total of 10 eggs per week).
98952|NCT03412812|Radiation|Dose Escalated Five Fraction Stereotactic Radiosurgery|As focal radiation techniques are utilized more frequently in the treatment of brain metastases, there is increasing need to accurately define the appropriate patient and tumor characteristics for focal therapy. Unfortunately, not all patients are good candidates for single fraction stereotactic radiosurgery (SRS) since large tumors and those in unfavorable locations have been associated with unacceptable rates of treatment-related toxicity. Five fraction stereotactic radiation has proven to be a more effective treatment for these patients that aren't good candidates.
98953|NCT03412799|Drug|SBP-101|Administered as subcutaneous (SC) injection, escalating dose cohorts
98954|NCT03412799|Drug|nab-paclitaxel|Administered as intravenous (IV) infusion
98955|NCT03412799|Drug|Gemcitabine Injection|Administered as intravenous (IV) infusion
98956|NCT03412786|Biological|Bcl-Xl_42-CAF09b vaccine|The vaccine consists of 0.05 mg peptide (bcl-xl_42) and 625 μg DDA, 125 μg MMG og 31 μg Poly I:C (CAF09b) mixed in a 0.5 ml emulsion
98957|NCT03412773|Drug|BGB-A317|BGB-A317: 200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
98958|NCT03412773|Drug|Sorafenib|Sorafenib: 400 mg twice daily (BID), oral dosing
98959|NCT03412760|Diagnostic Test|Trio whole exome sequencing|Expansive genetic test performed for affected fetus as well as for both biological parents where possible (or for only one parent where applicable).
98960|NCT03412747|Drug|Bimekizumab|Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2.
98961|NCT03412747|Drug|Adalimumab|Adalimumab will be administered according to the labeling recommendations.
98962|NCT03412747|Other|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP).
98963|NCT03412734|Drug|Chlorhexidine|Chlorhexidine preparation solutions
98964|NCT03412734|Drug|Iodine|Iodine-based preparation solutions
98965|NCT03412721|Procedure|Laser analgesic procedure|"Water mist spray set to maximum, non-contact handpiece with sapphire tip. Tip-to-tissue distance 10 mm from the tooth neck, achieved by using a spacer. Energy is delivered to the enamel above the gingival margin adjacent to the cemento-enamel junction (perpendicularly towards the dental pulp) on each of the four line angles of the tooth for 30s, moving the laser handpiece in a sweeping action. Pulse energy - 0.2 W/ 10 Hz/ 20 mJ. Follows increase of energy and repetition of protocol - 0.6 W/ 15 Hz/ 40 mJ. Total duration of LA-induction - 240s."
98966|NCT03412721|Procedure|Placebo analgesic procedure|Performing imitation of laser analgesic procedure. No pulse energy applied, non-contact handpiece with sapphire tip. Moving the laser handpiece in a sweeping action towards the cemento-enamel junction (pointing perpendicularly towards the dental pulp) on each of the four line angles of the tooth. Total duration of placebo analgesia induction - 240s.
98967|NCT03412708|Other|Vestibular Rehabilitation supported with Virtual Reality|Patients will perform the supervised vestibular exercises in virtual reality environment using a virtual reality goggle (Samsung Gear VR SM323) and a smartphone (Samsung Galaxy S7). The virtual environments consist of 2 media provided by the videos taken with a 360 camera (Samsung Gear 360). 1) A square with people moving, noise and traffic and 2) A supermarket where the shelves are full.
98968|NCT03412695|Device|MyFood|Patients included in the intervention group will use the MyFood app to record their dietary intake. Nurses will use the report and recommendations in the MyFood tool to follow up the nutritional treatment of the patients.
98969|NCT03412682|Drug|Budesonide (6 mg)|Budesonide (6 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
98970|NCT03412682|Drug|Budesonide (9 mg)|Budesonide (9 mg) administered once a day along with three mesalazine placebo three times a day, over an 8-week treatment period.
98971|NCT03412682|Drug|Mesalazine (3,600 mg)|Mesalazine (3,600 mg) administered once a day plus three mesalazine 400 mg three times a day, over an 8-week treatment period.
98972|NCT03412669|Other|Supporting Addiction Affected Families Effectively|Counselling
98973|NCT03412669|Other|Enhanced Usual Care|Information sheet
99165|NCT03410979|Drug|GLPG2737 multiple dose|GLPG2737 oral suspension, multiple ascending doses, daily for 14 days.
98974|NCT03412656|Device|SHPro with CUFF|Participants will complete various movement and activity of daily living (ADL) assessments to test the effectiveness of the CUFF device in combination with the Soft Hand Pro (SHP) in conveying haptic force feedback to patients with transradial limb loss, and to assess the extent to which the grip force feedback improves the embodiment of the prosthetic device.
98975|NCT03412630|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
98976|NCT03412604|Device|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
98977|NCT03412591|Drug|Suvorexant 20 mg|Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
98978|NCT03412578|Procedure|Massage Therapy|Massage therapy was started at corrected gestational age of 35 weeks and continued for 5 consecutive days. The protocol of massage therapy was performed as been described by Tiffany Field (Field, Schanberg et al. 1986). Three consecutive, 15 minutes, sessions were performed daily after the noon feeding. Each treatment session was divided into 5 minutes of tactile stimulation, followed by 5 minutes of kinaesthetic stimulation, and then another 5 minutes of tactile stimulation (Field, Diego et al. 2006).
98979|NCT03412565|Drug|Daratumumab|Daratumumab will be administered at a dose of 1800 mg by SC injection in Cycles 1 to 4 in D-VRd cohort and until documented progression of disease, unacceptable toxicity, or end of study for D-VMP, D-Rd and D-Kd cohorts.
98980|NCT03412565|Drug|Bortezomib|Bortezomib will be administered as 1.3 mg/m^2 SC injection in Cycles 1 to 4 in D-VRd cohort and in Cycles 1 to 9 in D-VMP cohort.
98981|NCT03412565|Drug|Lenalidomide|Lenalidomide will be administered as 25 mg capsule orally in Cycles 1 to 4 in D-VRd cohort and in all Cycles until documented progression of disease, unacceptable toxicity, or end of study in D-Rd cohort.
98982|NCT03412565|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg orally or intravenously in Cycles 1 to 4 in D-VRd cohort; 40 mg orally or intravenously in all cycles and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Rd and D-Kd cohort.
98983|NCT03412565|Drug|Melphalan|Melphalan will be administered as 9 mg/m^2 orally in Cycles 1 to 9.
98984|NCT03412565|Drug|Prednisone|Prednisone will be administered as 60 mg/m^2 orally in cycles 1 to 9.
98985|NCT03412565|Drug|Carfilzomib|Carfilzomib will be administered as 20 mg/m^2 IV on Day 1 of Cycle 1 only then 70 mg/m^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or end of study in D-Kd cohort.
98986|NCT03412552|Drug|MgSO4|Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
98987|NCT03412526|Drug|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)
98988|NCT03412526|Radiation|Radiation|Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day
98989|NCT03412526|Biological|TIL administration|TIL Administration
98990|NCT03412526|Drug|IL-2|bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.
98991|NCT03412513|Drug|Mirabegron|Mirabegron 50mg po daily for 12 weeks to Active Comparator group, and 4 weeks(from visit 4 to visit 5) to Placebo comparator group.
98992|NCT03412513|Drug|Placebo|Placebo po daily for 8 weeks to Placebo comparator group.
98993|NCT03412500|Drug|Vancomycin equation-based method|Vancomycin dosage will be adjusted according to the equation-based method
98994|NCT03412500|Drug|Vancomycin trough concentration method|Vancomycin dosage will be adjusted according to the trough concentration method
98995|NCT03412487|Procedure|laparoscopy|under general anesthesia. CO2 pneumoperitoneum, the laparoscope inserted through the umbilicus and a thorough evaluation of the abdominal cavity and pelvis was performed. a grasper was inserted; the utero-ovarian ligament was stabilized with the round biopter will be introduced. The tip of the biopsy instrument was placed on an area of the ovary free of cysts; the hilar area was avoided because it is deficient in small follicles. After correct placement was verified, the inner protecting trocar was removed to expose the sharp leading edge of the round sheath. Gentle circular movements were made cutting through the ovarian cortex to produce a 5-mm disk of 2-3 mm in thickness.
98996|NCT03412474|Drug|Bupivacaine|"The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%)."
98997|NCT03412474|Drug|Dexmedetomidine|Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
98998|NCT03412474|Drug|paracetamol|paracetamol
98999|NCT03412461|Other|Thought Spot|Thought Spot is a mobile app and website. This digital platform was designed and produced in partnership with transition aged youth in post-secondary education. The platform maps out wellness and mental health services across the Greater Toronto Area.
99000|NCT03412461|Other|Resource Pamphlet|The resource pamphlet that participants will be given will include information on the mental health and wellness services available at their respective post-secondary institution.
99001|NCT03412448|Other|observation|Observation,
99002|NCT03412422|Diagnostic Test|fluid responsiveness assessment|During the procedure, the investigator will be imaging one of the carotid arteries with ultrasound. In expiratory phase, four sets of three video loops will be recorded: before and after PLR and then before and after fluid challenge. There also will be noted hemodynamic parameters measured with PiCCO monitor. The fluid challenge is defined as administration of 500ml of crystalloid in less than 10 minutes. Later, another investigator, who will be blinded to other data, will measure the maximal and minimal diameter of CCA in each loop. The measurements will be averaged and eventually two values (maximal an minimal) from each set will be obtained.
99003|NCT03412409|Drug|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days −10 to −9), busulfan (3.2 mg/kg/day on days −8 to −6), cyclophosphamide (1.0 g/m2/day, days −5 to −4), fludarabine (30 mg/m−2/day, days −6 to −2), semustine (250 mg/m−2, day −3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days −5 to −2; Sanofi, France).
99004|NCT03412396|Drug|Apalutamide|Given PO
99010|NCT03412357|Procedure|pleurectomy/decortication|"VAT-PD is a type of keyhole surgery performed under general anaesthesia using a telescope and instruments put inside the chest. Through small incisions, or keyholes made between the ribs, the thoracic surgeon removes the hard rind of the tumour over the surface of the lung, thereby allowing the 'trapped' lung to fully expand again. Simultaneous removal of mesothelioma from the outer pleural membrane allows pleurodesis to occur."
99011|NCT03412357|Procedure|indwelling pleural catheter|A soft silicone catheter (IPC) with a one-way valve at the end is inserted a few centimetres under the skin under local anaesthesia. The inside end of the catheter is inserted into the pleural space and the outside end is connected to a vacuum drainage bottle. The IPC permits regular fluid drainage.
99012|NCT03412331|Device|Ultrasonic|Cavitron® BOBCAT® Pro, Dentsply International, USA
99013|NCT03412331|Device|Hand Instruments|Gracey, SG 5/6, 7/8, 11/12, 13/14, Hu-Friedy Ins. Co., USA
99014|NCT03412331|Device|LED Source|LED source (625-635 nm wavelength) (FotoSan®, CMS Dental, Denmark)
99015|NCT03412318|Device|Twisted file|Use of twisted file during cleaning and shaping of root canals
99016|NCT03412318|Device|Mpro|Use of Mpro during cleaning and shaping of root canals
99017|NCT03412305|Drug|Amoxicillin|Antibiotic prophylaxis consisting of 4 amoxicillin tablets, totally 2 g, orally 1 hour before implant placement
99018|NCT03412305|Other|Placebo|Placebo consisting of 4 tablets, orally 1 hour before implant placement
99019|NCT03412292|Drug|MAX-40279|"MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses."
99020|NCT03412279|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of Hausa ODI, NPRS, RMDQ, SF-12, PCS, GROC, BBQ, VAS for pain and disability, and FFD.
99021|NCT03412279|Behavioral|Final application of instruments|Application of the Hausa versions of ODI, NPRS, RMDQ, SF-12, PCS, GROC and BBQ one week after initial evaluation
99022|NCT03412266|Drug|Cytarabine|RIC preconditioning regimen consisted of cytarabine (2 g/m2/day, days −10 to −9), busulfan (3.2 mg/kg/day on days −8 to −6), cyclophosphamide (1.0 g/m2/day, days −5 to −4), fludarabine (30 mg/m−2/day, days −6 to −2), semustine (250 mg/m−2, day −3), and rabbit antithymocyte globulin (thymoglobulin, 2.5 mg/kg/d, days −5 to −2; Sanofi, France).
99023|NCT03412253|Procedure|Single-Anastomosis Gastric Bypass surgery (SAGB).|We checked the effect of SAGB on patients suffered from T2DM with BMI 25-30
99024|NCT03412240|Procedure|Induced pacing of the heart|Once the defibrillator leads have been inserted or, in the case of a box change, the old leads have been tested as per routine procedure, these pacing leads will be connected to an external pacing stimulator. The test involves electrically pacing your heart at different rates and we will be constantly monitoring you under close clinical supervision. During the test, your heart will be electrically stimulated to beat at a faster rate.
99025|NCT03412227|Behavioral|Individual Behavioral Activation Therapy (IBAT)|IBAT is a manual-based, individual behavioral activation plus exposure therapy aimed at treating youth with anxiety, depression, and anger. The program consists of 10-14 weekly 60 minute sessions. It uses behavioral activation (BA) strategies to target avoidance by helping youth identify stuck points in their lives through functional assessment of numerous life domains, including family and peer interactions, school, extracurricular activities, and health and self-care.
99026|NCT03412227|Behavioral|The PASCET Program for Youth Depressive Disorders|The Primary and Secondary Control Enhancement Therapy (PASCET; Weisz, Southam-Gerow, Gordis, & Connor-Smith, 2003; Weisz, Southam-Gerow et al., 2009; Weisz, Thurber, Sweeney, Proffitt, & LeGagnoux, 1997) is a brief (usually 11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of, and beneficial treatments for, youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b).
99027|NCT03412227|Behavioral|The Coping Cat Program for Youth Anxiety Disorders|"The Coping Cat program (Kendall & Hedtke, 2006; Kendall, Choudhury, Hudson, & Webb, 2002) has received substantial empirical support for its efficacy in both children (9-13 years old) and teens (12 - 17 years old) (Kendall, 1994; Kendall et al., 1997; Kendall et al., 2008) and involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward."
99028|NCT03412227|Other|14-week waitlist (WL) condition|Youth assigned to the 14-week WL will receive no specific therapeutic services from study therapists during the 14-week WL period. However, participants will be assigned a WL Liaison whom families can contact in the event of clinical deterioration. The Liaison will also be responsible for sending links to, and monitor completion of, weekly and mid-WL online surveys (Qualtrics). Independent Evaluators will conduct post-WL diagnostic interviews at the completion of the 14-week WL. WL participants will receive compensation for completion of assessments. After completion of the WL, participants will be invited to continue in the study and be randomly assigned to one of the three behavioral treatments (IBAT, PASCET, or Coping Cat).
99029|NCT03412214|Device|Perfusion index detected by pulse oximeter|Perfusion index detected by pulse oximeter
99030|NCT03412214|Device|AAI|The AEP Monitor/2 (Danmeter A/S, Odense, Denmark), a commercialized system for depth of anesthesia monitoring, extracts the middle latency auditory evoked potentials (MLAEP) from the EEG-signal by using an autoregressive model with an exogenous input adaptive method.
99031|NCT03412201|Other|Usual Care|Follow-up and management of heart failure medications provided by the patient's general physician and/or cardiologist according to local medical standards
99032|NCT03412201|Other|High Intensity Care|Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 2 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
99033|NCT03412188|Drug|Eltrombopag|Patients who showed no response (platelet count ≤ 20x109/L) initially for 3 months or relapse after 6 months after at least one prior ITP therapy will receive a total daily dose of eltrombopag of (25-50mg/d)
99034|NCT03412188|Drug|conventional|Patients who are currently receiving conventional lines of treatment (steroids, IVIG, azathioprine, and rituximab, Mycophenolate mofetil) will continue on the same line of treatment
99035|NCT03412175|Behavioral|Behavioral Intervention|The CREATION Health Specialist (CHS) will review with the participant his/her biometrics, assessments, and surveys. The CHS will identify the participant's strengths and weaknesses thereby tailoring the intervention care plan to the participant. Together the participant and CHS will work on goal-setting, action plans, self-monitoring, identification of personal and social barriers to change, and self-regulatory techniques.
99036|NCT03412162|Behavioral|Ethnic and Racial Identity Promotion|See arm description
99037|NCT03412162|Behavioral|Academic Skills Promotion|See arm description
99038|NCT03412149|Procedure|Mini Gastric Bypass|"Standardization of the techniques will be guaranteed:~Mini Gastric Bypass Arm~Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
99039|NCT03412149|Procedure|Roux en Y Gastric Bypass|"Standardization of the techniques will be guaranteed:~Mini Gastric Bypass Arm~Roux en Y Gastric Bypass arm All patients will have intraoperative measurement of the whole length of bowel from Treitz ligament to the ileocecal junction (expected range 6-8 m).The common limb will be therefore about 2/3 of total small bowel length."
99040|NCT03412136|Dietary Supplement|Control|Participants were given 5 minutes to ingest the non-caloric beverage which contained 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water and sweetened with 0.2g sucralose (Tate & Lyle, Stoney Creek, Ontario, Canada) in order to match sweetness with the glucose beverage.
99041|NCT03412136|Dietary Supplement|Glucose|Participants were given 5 minutes to ingest the beverage which contained either 1g of protein (plain whey-protein isolate; BiPro USA., Eden Prairie, Minnesota, U.S.A) per kg of bodyweight and was flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
99042|NCT03412136|Dietary Supplement|Protein|Participants were given 5 minutes to ingest the beverage which contained 1g of glucose monohydrate (BioShop Canada Inc., Burlington, Ontario, Canada) per kg of bodyweight and flavoured with 1.5ml of chocolate extract (Vanilla Food Company, Markham, Ontario, Canada) to account for the flavor differences and mixed with 500ml of water.
99043|NCT03412123|Behavioral|group lifestyle-integrated functional exercise|Manualized teaching of balance and strength principles and integration of exercises and physical activity into daily routine during 7 sessions in a group of 8 to 10 participants with 2 trainers. The pilot intervention group will undergo the same strength and balance exercises and learn about the same physical activity enhancement strategies as described in the LiFE programme by Clemson et al. (BMJ 2012;345:e4547). However, instead of 7 home visits, gLiFE participants will attend seven group sessions (1 session/week). In these, LiFE contents are adapted to the group setting and enhanced by health psychological and behaviour change strategies fitting to the social structure and modalities of a group.
99044|NCT03412110|Other|active surveillance: electronic platform|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
99045|NCT03412097|Other|active surveillance|Provides a structure to systematically gather adverse event information from healthcare providers and sometimes directly from patients.
99046|NCT03412084|Behavioral|Stand up and move more|4 week behavioral intervention involving the development and implementation of action plans
99047|NCT03412071|Drug|Oral Tinidazole|Please see description under arms
99048|NCT03412071|Drug|Topical metronidazole|Please see description under arms
99049|NCT03412071|Drug|Topical Clindamycin|Please see description under arms
99050|NCT03412071|Drug|Topical Hydrogen Peroxide|Please see description under arms
99051|NCT03412058|Procedure|Biopsy|To be performed prior to anti-PD1/PD-L1 treatment initiation
99052|NCT03412058|Procedure|Biopsy|To be performed after 42 (±3) days of anti-PD1 or PD-L1 treatment in consenting patients
99053|NCT03412058|Procedure|Biopsy|To be performed at disease progression if medically feasible
99054|NCT03412045|Device|hyperbaric oxygen therapy|hyperbaric oxygen therapy applied to patients in vaso-occlusive crisis
99055|NCT03412032|Other|assessment|different assessments in both arms
99056|NCT03412019|Other|Music|Selections of Mozart piano sonatas
99057|NCT03412006|Drug|Fulacimstat (BAY1142524)|25 mg BAY1142524 are given twice daily over a treatment period of 6 months
99058|NCT03412006|Drug|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
99059|NCT03411993|Diagnostic Test|Focused cardiac echography|All pregnant women attending antenatal care will be eligible to undergo focused cardiac echo to identify underlying cardiac disease
99060|NCT03411980|Drug|Vilaprisan (BAY1002670)|Single oral dose (1 x 2 mg immediate-release, film-coated tablet)
99061|NCT03411967|Drug|Apatinib|apatinib mesylate tablets 500mg, po, qd, continued until the next cycle, taking on an empty stomach (daily taken at the same time), every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment, apatinib has been taken until the disease progresses, intolerable toxicity.
99062|NCT03411967|Drug|Docetaxel|Docetaxel, 60 mg / m2, d1, iv ,every 3 weeks For one cycle, a total of 4 to 6 cycles of treatment
99063|NCT03411941|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|IVT(Intravitreal) aflibercept treatment in routine clinical practice.
99064|NCT03411928|Device|Tracheolator|'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
99065|NCT03411915|Biological|XmAb18087|monoclonal bispecific antibody
99066|NCT03411902|Drug|Risedronate Sodium 150 MG|Subjects randomized to the Risedronate group will take a 150 mg capsule of oral Risedronate once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
99166|NCT03410979|Drug|GLPG2737 multiple dose|Placebo, oral suspension, daily for 14 days
99067|NCT03411902|Other|Placebo|Participants randomized to the placebo group will receive 150 mg placebo capsule once every 4 weeks for 24 weeks (6 doses), beginning 1 week prior to surgery and dispensed in blinded capsules from the WFSM research pharmacy.
99068|NCT03411889|Diagnostic Test|MRI scanning|MRI scanning during tear drainage
99069|NCT03411876|Device|Oxymizer® pendant nasal cannula|Supplemental oxygen is provided by an Oxymizer pendant nasal cannula.
99070|NCT03411876|Device|conventional nasal cannula|Supplemental oxygen is provided by a conventional nasal cannula.
99071|NCT03411863|Device|CES at rest|"CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits."
99072|NCT03411863|Device|CES plus active hand or wrist movements|"CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function."
99073|NCT03411850|Biological|Orencia|FDA approved biologic
99074|NCT03411850|Other|Placebo|
99075|NCT03411837|Biological|Dupilumab|Biologic (monoclonal antibody)
99076|NCT03411824|Other|no intervention|Non applicable
99077|NCT03411811|Other|Usual Care|Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
99078|NCT03411811|Procedure|Dextrose|Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.
99079|NCT03411798|Drug|Yisaipu®|Yisaipu® was introduced only during the active state and was switched to DMARDs, methotrexate(MTX), sulfasalazine(SSZ) and hydroxychloroquine(HCQ), after disease remission (ESR & CRP reduce to normal and BASDAI＜4) maintenance.
99080|NCT03411785|Other|CPC+ model|CPC+ practices receive a monthly care management fee and prospective performance-based incentive payment on top of traditional payments. Some practices will also receive some payment that shifts away from fee-for-service. In addition, CPC+ practices will receive learning and health IT support and data feedback to implement processes to meet care delivery requirements and achieve five primary care functions.
99081|NCT03411772|Procedure|TAP block|Injection of 20 mL of 0.25% bupivacaine in the transversus abdominis plane under ultrasound guidance after performing bariatric surgery
99082|NCT03411772|Procedure|Bariatric surgery|Bariatric surgery will be conducted
99083|NCT03411746|Other|Subarachnoid haemorrhage|Data on the type of patients enrolled have been described already in other sections.
99084|NCT03411733|Other|Blood and stool samples collection|Collection of blood and stool samples from each participants for H.pylori antigen/ antibody detection
99085|NCT03411720|Other|FES Row Training|Hybrid FES Row Training using voluntary upper body and electrically-stimulated lower body
99086|NCT03411707|Diagnostic Test|Stool DNA test|Stool DNA test could detect specific gene methylation in stool DNA. Blood mRNA test could detect specific set of gene expression in blood.
99087|NCT03411694|Other|Survey|Survey in patients from the Jessa Hospital that are planned for elective surgery, both ambulatory and inpatient.
99088|NCT03411681|Other|Resistance Exercise|Participants will perform 4 sets of 12 repetitions of moderate intensity leg extension
99089|NCT03411668|Other|EBP Educational Programme|The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
99090|NCT03411655|Device|Ambu Aura GainTM|Time and success rate
99091|NCT03411655|Device|Ambu® Aura-ITM|Time and success rate
99092|NCT03411603|Other|Diet and socio-demographic questionnaires|24-hr recall or food diary questionnaires; socio-demographic questionnaires
99093|NCT03411590|Other|Fortified milk Powder|Toddlers will be allocated to the 200 ml group and will receive on a daily basis 32g of growing up milk powder respectively, in doses of 16 g, which can be reconstituted with 180 ml water to a final volume of about 200 ml of milk. The intervention period will last for 6 months. For the 200 ml test group, this translates into 32 g of growing up milk powder supply as one dose per day (in the morning)
99094|NCT03411577|Other|Behavioral Intervention|
99095|NCT03411564|Other|Filming Together to See Ourselves in a New 'Present'|"PHASE 0. PRIOR TRAINING 1) Promoting protective assets related to violence together. 10-hour training session with 10-15 secondary school teachers; 2) Identifying our own protective assets against violence. This training activity will be addressed to targeted students. The activity will be carried out in four sessions of 1 hour in duration.~PHASE 1.PRE-PRODUCTION. 1) Participant activity on building story arguments; and 2) Construction of a technical and literary guide to the video capsules.~PHASE 2: PRODUCTION.- 1) Rehearsal of the script developed by each group; 2) Preparation and selection of environment, wardrobe and characterization of the roles and, 3) Filming of the video capsules.~PHASE 3: POST-PRODUCTION.- This phase consists of putting together the short film using the various video capsules.~PHASE 4: DISSEMINATION. A short film exhibition to provide a space where participants can present their video capsules and briefly explain the production process."
99096|NCT03411551|Procedure|regional anesthesia|The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
99097|NCT03411538|Other|Collect data on clinical history|Collect data on clinical history, clinical manifestation, comorbidity, admission data, use of invasive medical intervention, history of antibiotic treatment and antibiotic susceptibility test results
99098|NCT03411525|Behavioral|Commitment Invitation for Clinicians (Clinician Intervention)|Clinicians will be invited to commit to follow 3 Choosing Wisely® recommendations. Those that choose to commit will sign a written document, appear on in-clinic posters along with their colleagues who have committed to the recommendations, have access to point-of-care Choosing Wisely® patient education handouts, and receive weekly emails with decision support resources.
99167|NCT03410966|Procedure|trans cateheter ablation|All AF patients will receive trans catheter ablation by radiofrequency, to destroy arrhythmic atrial cells, and to isolate arrhythmic atrial firing around pulmonary veins' ostia.
100107|NCT03403946|Device|Intubation|Intubation with C-MAC PM in combination with D-Blade
99099|NCT03411525|Other|Health Education Materials to Patients (Patient Intervention)|During the intervention period, the letter and study information sheet that eligible patients will receive in advance of a scheduled appointment with a participating clinician will also be accompanied by a patient education handout from Consumer Reports that is publicly available and may be relevant to their health and health care. Specifically, patients with type 2 diabetes who are 65 and older will receive a handout about diabetes overtreatment, patients with insomnia or anxiety who are 65 and older will receive a handout about overuse of benzodiazepines and sedative-hypnotics, and male patients who are 75 and older with no history of prostate cancer will receive a handout about overuse of PSA tests to screen for prostate cancer.
99100|NCT03411499|Procedure|Early surgery|Surgery within 72 hours from endocarditis diagnosis
99101|NCT03411499|Procedure|Conventional therapy|Delayed surgical intervention or medical treatment according to the current guidelines
99102|NCT03411473|Biological|AGEN1884 in combination with pembrolizumab|AGEN1884 in combination with pembrolizumab in subjects with stage IV NSCLC whose tumors have high PD-L1 expression and no EGFR or ALK genomic tumor aberrations
99103|NCT03411460|Device|FreeStyle Libre™ system|Measured non-invasively via scanner
99104|NCT03411460|Procedure|Finger prick|Blood test
99105|NCT03411447|Other|Parenteral nutrition|
99106|NCT03411447|Other|Enteral nutrition|
99107|NCT03411434|Drug|Methylphenidate Oral Tablet|cf arm group description
99108|NCT03411421|Drug|AL-794|AL-794 will be administered as tablets orally on Day 1 to Day 5.
99109|NCT03411421|Drug|Placebo|Matching placebo tablets will be administered.
99110|NCT03411408|Device|HBO|"Hyperbaric oxygen is administrated in a multiplace hyperbaric chamber according to the following schedule:~Ten minutes of compression with a Fraction of inspired oxygen (FiO2) more than 90% from 152 to 253 kilopascal, 60 minutes of Fraction of inspired oxygen (FiO2) more than 90% at 253 kilopascal (three breathing cycles in oxygen for 22 minutes each, with two intervals breathing air for 2 minutes each) and 10 minutes of decompression with a Fraction of inspired oxygen (FiO2) more than 90% from 253 to 152 kilopascal."
99111|NCT03411408|Radiation|RT|tomotherapy (within 60 minutes from completion of decompression of hyperbaric chamber) with 3-5 consecutive sessions- one fraction per day, 5 Gy / die .
99112|NCT03411395|Dietary Supplement|5AA+CrPic Water|Dietary supplement drink with carbonation, aroma, amino acids and chromium picolinate
99113|NCT03411395|Other|Placebo drink|Placebo water with carbonation and aroma
99114|NCT03411382|Other|Sit muscle strength training|Sit muscle strength training using a sand bag grip ball conducted twice a week. Each exercise session will begin and end with a 5-15 minute warm-up and cool-down routine. The exercise program consists of 20-40 minute chair-based resistance exercises.
99115|NCT03411382|Other|Game training|Game training (including ball activities, clay courses, massage, puzzles, painting conducted four times a week). Each section 30-60 minutes.
99116|NCT03411382|Other|Sitting strength + game training|Sitting strength training (using sandbag training conducted twice a week) and game training (such as ball activities and clay courses) conducted twice a week).
99117|NCT03411382|Other|Health education|Health education (conducted once a month). Each section 50-60 minutes. The topics are oral hygiene, medicine safe, living safe, food safe.
99118|NCT03411369|Dietary Supplement|Creatine, D-Ribose, B1 Vitamin, and B6 vitamin|The treatment will consist of taking 2 sachets / day for the first two weeks, and then continuing with 1 sachet/day for the next month.
99119|NCT03411369|Other|Placebo|Water-soluble powder in sachets of 4 grams containing inert product consisting of starch powder.
99120|NCT03411356|Behavioral|Daily Caloric Restriction (DCR)|Participants in this group will be given a calorie goal designed to produce a 34.3% energy deficit from estimated baseline weight maintenance energy requirements. Participants in this group will also receive a 12 month comprehensive group-based behavioral weight loss program and will be instructed in specific strategies to support DCR. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
99121|NCT03411356|Behavioral|Intermittent Fasting (IMF)|Participants in this group will be instructed to limit energy intake to 20% of estimated baseline energy requirements on three non-consecutive days per week, and to eat ad libitum the other 4 days per week. Participants in this group will also receive a 12 month comprehensive group based behavioral weight loss program and will be instructed in specific strategies to support IMF. Randomized groups will meet separately. Participants in this group will also be asked to increase moderate intensity physical activity to a target of 300 minutes per week.
99122|NCT03411343|Procedure|Interscalene Block|Injection with ultrasound guidance of 20mL of levobupivacaine 0.5% with 5 micrograms of epinephrine per mL in the interscalene groove of the brachial plexus.
99123|NCT03411343|Procedure|Costoclavicular Infraclavicular Block|Ultrasound guided brachial plexus block injecting 20mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in between the cords of the brachial plexus at the costoclavicular infraclavicular space.
99124|NCT03411330|Drug|Hyaluronidase|Scalp nerves block will be done using lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%) with maximum allowed dose 175 mg in group A, Hyaluronidase will be added in group H in a dose of 1500 IU (The minimum and maximum effective doses of hyaluronidase are not known. The doses used range from0.75 IU/ml to 300 IU/ml
99125|NCT03411330|Drug|Lidocaine|lidocaine (2%) in a maximum dose of 300 mg and bupivacaine (0.5%)
99126|NCT03411330|Drug|Bupivacaine|bupivacaine (0.5%)
99127|NCT03411291|Device|MRI, MR Spectroscopy, MR Perfusion|One brain MRI/MR Spectroscopy/MR Perfusion at baseline and one brain MR/MR Spectroscopy/MR Perfusion at 3 months.
99128|NCT03411278|Device|Deep Oscillation (DO)|"DO self treatment with the device mobile (Physiomed, Laipersdorf, Germany; U.S. patent 7,343,203 B2).The device produces an alternating electrostatic field, which results in a low-frequency vibration penetrating the tissue. The Field is pulsed at a frequency of 90 Hz. For self-treatment, each volunteer is given an apparatus to take home. An applicator with a diameter of 9 cm is used. The treatment will be carried out in the morning and evening for 15 minutes each in supine position on a sofa. In accordance with the technique of classical manual lymphatic drainage, stroking and circular movements in the upper and lower leg and the inguinal area take place in a fixed order."
99193|NCT03410784|Drug|Carboplatin|Carboplatin (AUC 5) i.v. on Day 1 every 3 weeks for up to 6 cycles
99129|NCT03411265|Other|self-administered, e-health application|"RETAIN is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT and its benefits when they started treatment. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
99130|NCT03411252|Drug|Mirabegron 50 MG|Myrbetriq (Mirabegron) tablet
99131|NCT03411252|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron
99132|NCT03411239|Device|Adult esophageal balloon catheter (obc)|Using OBC to determine airway pressure changes in patients undergoing general anaesthesia for laparoscopic surgery
99133|NCT03411226|Procedure|re-TREPP|repeated hernia repair via the TREPP technique
99134|NCT03411213|Device|diffuse optical tomography|Optical tomography is a form of computed tomography that creates a digital volumetric model of an object by reconstructing images made from light transmitted and scattered through an object.
99135|NCT03411200|Behavioral|Multimodal and exercise-based intervention|"The multimodal and exercise-based intervention is comprised of:~Supervised and group-based exercise two times a week (60 minutes per session). The program consists of warm-up, exercises for balance and flexibility, progressive resistance training, and stretching and relaxation.~Individualized activity program based on step counts (with activity tracker). Based on each participant's starting point, preferences and motivation, an individualized program will be composed. Evaluation and goal-setting will be conducted once weekly.~Nurse-led supportive and motivational counseling; each participant will be invited to two sessions of counseling (in week 1 + 6). Each session will be based on a holistic assessment of each participant's life situation. Advice and counseling will be provided based on identified problems and needs.~A nutritional supplement (protein bar or drink) will be served to participants immediately after the supervised exercise session."
99136|NCT03411187|Device|used of the Pressure adjustable foot-control method|Whether The Pressure adjustable foot-control method is used.
99137|NCT03411187|Device|direct exhaust|direct exhaust through the trocar.
99138|NCT03411174|Radiation|hypofractionated partial breast irradiation|deliver 40Gy/15Fx to tumor bed areas
99139|NCT03411161|Drug|Combination therapy (S81694 + paclitaxel) phase I|Dose escalation S 81694 (IV); paclitaxel started at 80 mg/m²,(IV)
99140|NCT03411161|Drug|Paclitaxel|Paclitaxel (IV) at 80 mg/m²/week
99141|NCT03411161|Drug|Combination therapy (S81694 + paclitaxel) phase II|S 81694 (IV) at RP2D; paclitaxel (IV) at 80 mg/m²/week
99142|NCT03411148|Behavioral|Weekly exercise sessions with physical therapist and psychologist|Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.
99143|NCT03411148|Behavioral|Home-based exercises|Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
99144|NCT03411135|Other|VES and VASI scores as assessment methods for vitiligo|compare VES and VASI scores as assessment methods for vitiligo
99145|NCT03411122|Drug|napabucasin|Napabucasin will be administered at dose of 240 mg twice daily, every 12 hours (BID) on days 1-2 in period 1, and on days 1-11 in period 3.
99146|NCT03411122|Drug|cytochrome P450 (CYP450) probe drugs or BCRP transporter substrate|CYP450 probe drugs or BCRP transporter substrate will be administered once every period during days 1-4 in period 2, and days 6-9 in period 3.
99147|NCT03411109|Drug|Hydromorphone Hydrochloride|All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
99148|NCT03411096|Procedure|Quadratus lumborum block using ropivacaine|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with 0.75% ropivacaine (20cc) under ultrasound guidance.
99149|NCT03411096|Procedure|Quadratus lumborum block with normal saline|After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with normal saline (20cc) under ultrasound guidance.
99150|NCT03411083|Procedure|Total or unicompartmental knee replacement|Fast-track Knee replacement surgery.
99151|NCT03411070|Device|Implanted Medical Device|Undergo SCOUT reflector placement
99152|NCT03411070|Procedure|Therapeutic Conventional Surgery|Undergo surgery
99153|NCT03411057|Behavioral|Mindfulness Based Stress Reduction (MBSR)|An interactive form of meditation that includes gentle yoga.
99154|NCT03411057|Other|Control|Standard of care including an educational video.
99155|NCT03411044|Device|Fitmore Hip Stem|
99156|NCT03411031|Drug|Elotuzumab|Elotuzumab according to dosing schedule outlined in treatment arms.
99157|NCT03411031|Drug|Lenalidomide|Lenalidomide according to dosing schedule outlined in treatment arms.
99158|NCT03411031|Drug|Dexamethasone|"Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert."
99159|NCT03411018|Other|Mechanical ventilation exposure|
99160|NCT03411005|Dietary Supplement|Metabolic availability of lysine in sorghum|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from sorghum and 1 level from sorghum with lentils.
99161|NCT03410992|Drug|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
99162|NCT03410992|Other|Placebo|Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.
99163|NCT03410979|Drug|GLPG2737 single dose|GLPG2737 oral suspension, single ascending doses
99164|NCT03410979|Drug|Placebo single dose|Placebo, oral suspension.
99168|NCT03410953|Biological|Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).|"The primary immunisation consists of 4 separate 0.5 ml doses administered at the following schedule:~1 month, 2 months and 6 months from the date of the first dose. Once initiated, the primary course of vaccination at 0, 1, 2 and 6 months should be completed with Fendrix, and not with other commercially available HBV vaccine"
99169|NCT03410940|Device|CLS Brevius stem with Kinectiv technology|
99170|NCT03410927|Drug|TAS0728|TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
99171|NCT03410914|Device|Hemopatch|Application of hemopatch to the divided end of the pancreas during surgery.
99172|NCT03410901|Biological|Anti-OX40 Antibody BMS 986178|Given IV, intratumoral
99173|NCT03410901|Other|Laboratory Biomarker Analysis|Correlative studies
99174|NCT03410901|Radiation|Radiation Therapy|Undergo radiation therapy
99175|NCT03410901|Drug|TLR9 Agonist SD-101|Given intratumorally
99176|NCT03410888|Procedure|Popliteal approach|"Popliteal approach:~Under ultrasound guidance a 50 to 90 mm 22 G needle is inserted in and advanced to contact the target nerve until nerve movement is detected. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
99177|NCT03410888|Procedure|Infragluteal approach|Infragluteal approach: The patients in this group will receive sciatic bock according to the approach described by Chan et al. Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter. The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve.
99178|NCT03410875|Drug|Vemurafenib|Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.
99179|NCT03410875|Drug|Obinutuzumab|Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
99180|NCT03410862|Drug|Elderberry Extract|Thick reddish-brown liquid of Sambucus Nigra (Black Elderberry)
99181|NCT03410862|Drug|Placebos|Thick reddish-brown liquid similar in appearance and taste to Elderberry Extract not containing elderberry
99182|NCT03410849|Diagnostic Test|Gastroscopy|in both arms intervention 'gastroscopy' will be carried out
99183|NCT03410836|Drug|intravenous lidocaine (IVL)|lidocaine 2% will be used for induction (1 syringe of 5 ml, administered dose of 1.5 mg / kg) and for intra-operative infusion (1 syringe of 30 ml, infusion dose of 1.5 mg / kg / h). Lidocaine syringes and placebo will be prepared on a blinded manner so that the investigating anesthesiologist in charge of the patient in the operating room, as well as the respiratory therapist and the recovery room nurse and the floors do not know what the patient received during the anesthesia (whether IVL or placebo).
99184|NCT03410836|Other|Placebo|Group Control will receive (double blinded) an infusion of saline at the same volume and regimen than the lidocaine 2% group (IVL).
99185|NCT03410823|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
99186|NCT03410823|Dietary Supplement|Protein|Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
99187|NCT03410823|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
99188|NCT03410810|Diagnostic Test|MRI|MRI analysis
99189|NCT03410810|Diagnostic Test|Neurodevelopmental/Neuropsychological Assessment|Standardized Cognitive and Developmental Tests
99190|NCT03410797|Device|Inclusion of semi occluded facemask to voice therapy|Patients will be given a facemask with a semi-occlusion (SOMask) for use in clinic and with a home practice program. Therapy will include speaking into mask during home practice between therapy sessions as well as during clinical voice therapy sessions as specified.
99191|NCT03410784|Drug|Pembrolizumab|Pembrolizumab 200 mg i.v. on Day 1 every 3 weeks up to 22 cycles
99192|NCT03410784|Drug|Paclitaxel|Paclitaxel 175 mg/m2 i.v. on Day 1 every 3 weeks up to 6 cycles
99194|NCT03410771|Drug|Monitor antibiotic exposure (PK profile)|several plasma samples to measure drug exposure
99195|NCT03410771|Device|Bioelectrical impedance analysis to measure body composition|non invasive analysis (electrodes) to measure extra- and intracellular, and total body water.
99196|NCT03410745|Behavioral|Exercise.|Moderate to heavy intensity resistance exercise consisting of leg press.
99197|NCT03410732|Biological|activated DCs|autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
99198|NCT03410732|Procedure|radical surgery only|Only radical surgery is given to the control group
99199|NCT03410719|Other|Hi GI|subjects will consume the same quantities of metabolizable CHOs (270 g/d) with 135 g of CHOs assigned to the GI intervention foods. The 135 g of CHOs will be distributed as 35 g GI breakfast product, 40 g GI lunch product, and 60 g GI dinner product. Assuming an average 2400 kcal/d total energy requirement among subjects, the 270 g/d metabolizable CHO equates to 40% of total energy intake (1080 kcal/d). One-half of daily CHO intake (135 g/d) will be the same between the Hi-GI and Low-GI groups, including CHOs in fruits, vegetables, and other foods that all subjects will consume. The other one-half of daily CHO intake (135 g) will be different between the Low-GI and Hi-GI groups. Specifically, the GI values of these foods will either be <55 (Low-GI group) or >70 (Hi-GI group).
99200|NCT03410706|Drug|Rivaroxaban(Xarelto, BAY 59-7939)|The dosage and the anticoagulation duration is decided by investigators. As list in product information, the PE treatment dosage of rivaroxaban is 15mg bid for first 21 days and then 20mg qd. If CrCl is 30-49 ml/min and bleeding risk is over VTE recurrence risk, 20mg qd can be replaced with 15mg qd.
99203|NCT03410680|Behavioral|FUERTES|The intervention focuses on antiretroviral therapy habit-formation among MSM living with HIV
99204|NCT03410667|Behavioral|Phase One: Exploration|"Spina Bifida patients from the pediatric urology clinic at Riley Hospital and their caregivers will participate in discussions of UI goals. These patients will self report their experiences and perspectives using a Day in the Life diary tool-kit."
99205|NCT03410667|Behavioral|Phase Two: Creation|Patients, caregivers and providers will work to create a goal setting tool to help patients and physicians appropriately address the issue of UI in patients with spina bifida.
99206|NCT03410667|Behavioral|Phase Three: Reflection|This is a validation step to test whether the goal-setting tool is widely applicable and functional in a clinic setting. There will be cognitive interviews after the tool is completed to gather patient impressions.
99207|NCT03410667|Behavioral|Aim 2|This will be a large scale validation of the tool.
99208|NCT03410654|Drug|Tacrolimus, Extended Release, (Envarsus Xr)|After conversion of tacrolimus immediate release to tacrolimus extended release.
99209|NCT03410641|Behavioral|Diet and antismoking advice|Dietary advice with the aim of reducing participant's serum cholesterol levels, including reduction in the intake of saturated fat and cholesterol, and increased intake of polyunsaturated fat, fish, vegetables and fruit. Weight reduction was recommended for overweight men, as well as reduced consumption of sugar rich foods and drinks, and alcoholic beverages. Smokers were advised to stop smoking. The advice was given both individually and in group sessions during a five-year time period from 1972/3 until 1977/8.
99210|NCT03410628|Device|gammaCore|Non-invasive vagal nerve stimulator
99215|NCT03410602|Procedure|Full-mouth supragingival scaling|Control group comprised of 15 patients who were treated with routine full-mouth supragingival scaling.
99216|NCT03410602|Procedure|Subgingival scaling|Test group comprised of 15 patients who were treated with subgingival scaling only around all banded first molars.
99217|NCT03410602|Drug|Subgingival irrigation|Test group comprised of 15 patients who were treated with subgingival irrigation only around all banded first molars with 0.2% chlorhexidine gluconate solution (Trade name: HEXIDINE), an antiseptic - antiplaque agent.
99218|NCT03410589|Other|Sinlge arm|application of scales for evaluation of sleep, fatigue and quality of life - Observational study
99219|NCT03410576|Procedure|Carotid artery stenting|Patient undergo elective carotid artery stenting. In this patient group blood sampling was performed at three time points: T1, at the time of the insertion of the arterial line; T2, 60 min after stent insertion; and T3: the first postoperative morning.
99220|NCT03410576|Procedure|Carotid endarterectomy|Patient undergo elective carotid endarterectomy. Group samples were collected at the following four time points: T1, at the time of the insertion of the arterial line; T2, 60 min after cross-clamp release; T3, the first postoperative morning; and T4, the third postoperative morning. A matched subgroup of patients from the previously obtained data served as a historical control.
99221|NCT03410563|Behavioral|Auditory inputs|Three different auditory inputs
99222|NCT03410550|Device|Exoskeleton Training|Twenty subjects will participate in a powered exoskeleton (EKSO) for one or twice a week for 12 weeks. The program will involve walking with the robotic suits for 1 hour for persons with complete (n=10) and persons with incomplete (n=10).
99223|NCT03410537|Drug|Taurine|
99224|NCT03410537|Drug|Placebo|
99225|NCT03410524|Drug|Simethicone Solution|200 mg of Simethicone in 3 mL of Simethicone Solution Formulation
99226|NCT03410524|Drug|Water|3 mL of water as placebo added to the bowel preparation
99227|NCT03410511|Other|Nicotine free intake|The participant will wean off nicotine during five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
99293|NCT03409965|Device|Lutronic LaseMD System|A fractional thulium laser device
99228|NCT03410511|Other|Nicotine intake|The participant will pursuit his regular nicotinic propylene/glycerol intake five days before the experimental session. At the start of the experimental session, participants will be exposed to acute propylene glycol/glycerol (mix 50:50) intake.
99229|NCT03410511|Other|Cessation intake|The participant will completely stop his regular nicotinic propylene/glycerol intake during five days before the session. At the start of the experimental session, participants will mimick intake with the device turns off.
99230|NCT03410498|Other|Incremental shuttle walk test|"In the incremental shuttle walk test, participants will have to walk between two cones (10m distance) several times. The time they will have to cover the distance between the two cones (signified by 'bleeps') will become increasingly shorter, until they cannot get to the next cone before the next 'bleep'. This test will last a maximum of 20 minutes.~In the Stroop test, the words of four colours, but written with a different colour, will be projected on the wall in front of participants and they will need to identify the colour of the text and ignore the word itself."
99231|NCT03410485|Device|BIS index/NoL index|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a NoL index between 10-20.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then adapted to the BIS between 45-55."
99232|NCT03410485|Device|Variation of baseline mean arterial pressure|"Remifentanil i.v. infusion will be run between 0.03 and 0.15 mcg/kg/min and boluses (0.4mcg/kg) will be given to keep a baseline mean arterial pressure between 10% of variation.~Once intubated, the maintenance of anesthesia will be achieved with: desflurane set at 1 MAC to start, then ajusted to 0.8 MAC."
99233|NCT03410472|Behavioral|Web based diet application|This group will be asked to record their diets for 8 weeks after being told an approximate calorie goal. This group will receive weekly emails with tips on how to eat healthy
99234|NCT03410459|Diagnostic Test|DEXA (= Dual-energy x-ray absorptiometry)|measurement of vertebral bone and hip bone mineral density
99236|NCT03410433|Device|Silk 4.0|Silk suture 4.0
99237|NCT03410433|Device|PG 910 4.0|PG 910 4.0
99238|NCT03410433|Device|PP 4.0|PP 4.0
99239|NCT03410433|Device|Silk 5.0|Silk 5.0
99240|NCT03410433|Device|PG910 5.0|PG910 5.0
99241|NCT03410433|Device|PP 5.0|PP 5.0
99242|NCT03410433|Device|APG 5.0|APG 5.0
99243|NCT03410433|Device|ePTFE 5.0|ePTFE 5.0
99244|NCT03410420|Drug|Pimonidazole hydrochloride|administration of pimonidazole-HCl
99245|NCT03410407|Other|Observation of CNS involvement|AML patients with CNS involvement defined by the confirmation of leukemic blast cells in the centrifuged cerebrospinal fluid (CSF) with the presence of more than five WBCs in the CSF or the detection of a CNS granulocytic sarcoma using computed tomography or magnetic resonance imaging.
99246|NCT03410381|Other|Application EMMA|Emma proposes four types of assessments during 6 months:1) 5 times a day during 3 days, every month (5 minutes): patients can assess their emotions, their thoughts, their behavior and their occurrence context. 2) Weekly (7 minutes): consists of a summary of the week, about their emotions, thoughts, behavior, their relationships (family, work, friends, and their quality of life.3) Monthly (5 minutes): assessment of the usefulness and satisfaction about the application.4) Assessment available at any time An action plan is designed to support the participants, to help them facing difficult emotions and feelings, and to encourage them to ask for help. They can contact a relative or call the psychiatric emergency service directly by clicking on a button.
99247|NCT03410368|Biological|NK cells|Autologous peripheral blood mononuclear cells (PBMCs) are collected by apheresis on D0, then induced into NK cells and infused into the patients 14 days later (D14) as the initial transfusion. There are 3 consecutive transfusion days (D14-D16). The second course of PBMCs collection started D14 before infusion. A total of 6 courses will be completed unless progression or unacceptable adverse events.
99248|NCT03410355|Procedure|BMAC/PRP Injection|Patients will be placed on an office procedure under local anesthesia. The investigators will harvest 60 cm3 of bone marrow from posterior iliac crest and centrifuged obtaining approximately 3 cm3 of autologous bone marrow-mesenchymal stem cells concentrate. At the same time, 60cm3 of peripheral blood will be taken and centrifugated once, to obtain approximately 3 cm3 of PRP. After activation of platelet rich plasma cells they will be mixed in one syringe with the concentrated BMaC and both will be injected in the hip joint under ultrasound.
99249|NCT03410355|Procedure|Cortisone Injection|An intraarticular injection of 1cm3 with 80mg of methylprednisolone combined with 3cm3 of 0.25% bupivacaine will be injected in the hip joint under ultrasound.
99250|NCT03410342|Other|LFV|1 apple/banana/small bunch of grapes per day plus 1 portion of carrot/pepper/tomato per day
99251|NCT03410342|Other|HFV|4 portions of fruits (apples, bananas, grapes, pears) plus 4 portions of vegetables (carrots, cucumber, sweet peppers, tomatoes), of commonly consumed types per day excluding citrus fruits, cruciferous and allium vegetables.
99252|NCT03410342|Other|CC|4 portions of citrus fruits (clementines, grapefruits, lemons, oranges) plus 4 portions of cruciferous vegetables (broccoli, brussels sprouts, cauliflower, kale, savoy cabbage) per day.
99253|NCT03410329|Other|Resistance training|Physical activity
99254|NCT03410316|Other|No intervention|
99255|NCT03410303|Diagnostic Test|Intraoperative ultrasound and 2 months post-operative ultrasound ( ± 1 month)|An ultrasound of the position of the prosthesis during surgery, under general anesthesia, is performed. A follow-up visit will be carried out 2 months (± 1 month) after the surgery as part of the usual care. An ultrasound of the position of the prosthesis is performed without anesthesia, either as part of the treatment or as part of the research. This measurement is performed without the intraoperative measurement by an independent sonographer.
99256|NCT03410290|Other|Online Questionnaire|The online questionnaire includes questions about factors that impacted a patients diagnosis of vasculitis.
99257|NCT03410277|Other|Experimental hypoglycemia|Experimental hypoglycemia with and without MRI
99258|NCT03410264|Behavioral|CR-EXP|See arm/group descriptions
99259|NCT03410264|Behavioral|EXP-CR|See arm/group descriptions
99260|NCT03410264|Behavioral|Stress Management|See arm/group descriptions
99334|NCT03409679|Drug|Two anti-pseudomonal antibiotics|Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin
99261|NCT03410251|Procedure|Socket preservation|"Teeth were extracted atraumatically and without flap release in patients who have received prophylactic antibiotherapy and local anaesthesia. After checking the integrity of the buccal and palatal bone plate, biomaterial (Bio-Oss®) was introduced into the socket. A connective tissue graft harvested from the palate was inserted and sutured in buccal and palatal pouches in order to cover the socket.~chlorhexidine spray (0.12%) twice a day and Ibuprofen 600 mg three times/ day were prescribed whereas antibiotics were continued for 5 days. Tooth brushing was banned at the extraction site for 10 days and sutures were removed 10 days after surgery."
99263|NCT03410225|Behavioral|CAMI-TPP|The TPP group will receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; the sessions will be guided by personalized feedback aimed at increasing condom use, supporting female partners in contraceptive use, and obtaining reproductive health services and STI testing. MI counseling sessions will be conducted by phone or video call.
99264|NCT03410225|Behavioral|CAMI-Fitness|The Fitness group will also receive four 30-minute sessions of one-on-one coaching over 12 weeks with a MI coach; these sessions will be guided by personalized feedback aimed at healthy diet, physical activity and tobacco avoidance. MI counseling sessions will be conducted by phone or video call.
99265|NCT03410212|Drug|Ketorolac Tromethamine|The 30mg/mL vial of Ketorolac will be injected as second inferior alveolar nerve block and the success of anesthesia will be evaluated using visual analog scale.
99266|NCT03410212|Behavioral|Sham injection|In the control group, the sham injection will be provided at the same place of the first inferior alveolar nerve block but any injection would be done.
99267|NCT03410173|Drug|Taurine|
99268|NCT03410173|Drug|Placebo|
99269|NCT03410160|Diagnostic Test|Clinical and biochemical examination.|Patients with chronic adrenal insufficiency were assessed by clinical and biochemical examination as well as questionnaire to evaluate the quality of hormone replacement therapy with glucocorticoids, education status, cortisol-metabolism, catecholamine deficit, chronic inflammation and variations of the glucocorticoid receptor.
99270|NCT03410147|Diagnostic Test|13C-octanoate breath test for gastric emptying|"The 13C-octanoate breath test for gastric emptying will be performed to assess gastric emptying rate of a liquid meal that is infused continuously over a period of 8 hour.~13C-labeled sodium octanoate (food adjective) is mixed with liquid nutrients used for enteral feeding. The concentration of 13C-labeled sodium octanoate is according to the randomized treatment order. This mixture is infused at 20 ml/h for 8 hours (hourly dose of 13C-octanoate differs between treatment arms). In order to estimate gastric emptying rate quantitatively throughout the infusion period, the appearance of 13CO2 in the breath, relative to 12CO2, will be monitored by sampling the exhaled breath at a 15 minute interval.~The aim is to induce a steady state hourly 13C-recovery. This would allow to implement the prolonged breath test protocol in future clinical investigations."
99271|NCT03410134|Device|NeoMTA|NeoMTA™ Plus® root and pulp treatment material is a powder/gel system with no resin. The components are an extremely fine powder primarily tricalcium and dicalcium silicate plus a water-based gel.
99272|NCT03410121|Device|IPolysite ® Mini série 3108 or Polysite ® Standard, série 4108.|Implantation of intravenous medical device in thoracic location
99273|NCT03410121|Device|Vital Port®Minititanium|Implantation of intravenous medical device in humeral location
99274|NCT03410108|Drug|Brigatinib|Brigatinib tablet
99275|NCT03410095|Diagnostic Test|Brain MRI, cognitive testing, bloodwork|"Participants will undergo 3-Tesla MRI. Scan time will be about 1 hour and 15 minutes per subject per session at the Sunnybrook site. The protocol is designed to image SVD burden by quantifying PVS and WMH volumes, and image various physiological estimates on the brain.~Participants will undergo the following cognitive tests: Behavioural Neurology Assessment‐R (BNA-R), Montreal Cognitive Assessment (MOCA), Center for Epidemiologic Studies Depression Scale (CES-D), and BrainScreen.~Blood samples will be assayed for inflammatory and endothelial function. Classical vascular risk factors will also be assessed. Once data collection is complete, DNA will be extracted from the frozen PBMC fraction and will be genotyped for APOE genotype and a panel of other single nucleotide polymorphisms known to be associated with cognition and cerebrovascular disease."
99276|NCT03410082|Device|Titration under the guidance of BIS|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if BIS is greater than 80; The infusion rate is decreased by 0.1mcg/kg/h if BIS is less than 60.
99277|NCT03410082|Diagnostic Test|Titration under the guidance of OAA/S|The infusion rate of dexmedetomidine is increased by 0.1mcg/kg/h if OAA/S is greater than 3; The infusion rate is decreased by 0.1mcg/kg/h if OAA/S is less than 3.
99278|NCT03410069|Device|IKORUS UP system|Continuous assessment of the urethral microcirculation
99279|NCT03410056|Drug|AMG 592|AMG 592
99280|NCT03410056|Drug|Placebo|Placebo
99281|NCT03410043|Drug|Osimertinib|Given PO
99282|NCT03410043|Radiation|Radiation Therapy|Undergo radiation therapy
99283|NCT03410043|Procedure|Therapeutic Conventional Surgery|Undergo surgery
99284|NCT03410030|Drug|Ascorbic Acid|combination therapy
99285|NCT03410030|Drug|Paclitaxel protein-bound|combination therapy
99286|NCT03410030|Drug|Cisplatin|combination therapy
99287|NCT03410030|Drug|Gemcitabine|combination therapy
99288|NCT03410017|Other|Functional Listening Index|Functional Listening Index questionnaire to assess acquisition of listening skills.
99289|NCT03410004|Drug|Chidamide|Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
99290|NCT03409991|Behavioral|Opening Doors|This project is designed as a three-stage mixed methods study to test the efficacy of a career guidance intervention for individuals with psychiatric disabilities. We are using both a randomized clinical trial design coupled with a small qualitative sub-study.
99291|NCT03409978|Device|in-Motion app|mobile phone application for recording fidgety movements at home
99292|NCT03409965|Device|Lutronic Infini System|A microneedle radiofrequency device
99294|NCT03409952|Device|LaseMD and DUAL 1927nm Laser|Laser treatment of benign pigmented lesion based on photothermolysis whereby the target molecule, the chromophore, absorbs a delivered wavelength of light over a period of time to damage the target while limiting collateral damage to adjacent structures, leading to pigmentary clearance.
99295|NCT03409952|Device|LaseMD|Laser treatment of benign pigmented lesion using optimized treatment settings.
99296|NCT03409939|Dietary Supplement|Aromatic Amino Acid Intake|Intakes will be randomly chosen from a list of 8 doses of aromatic amino acids. Each intake will will be repeated approximately 4 times.
99297|NCT03409926|Dietary Supplement|Acacia Gum|dietary supplement will be added to the participant's usual diet
99298|NCT03409913|Radiation|FDG PET/CT|Conventional FDG PET/CT including head in order to asses cranial arteries.
99301|NCT03409887|Procedure|Intraorifice barrier of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
99302|NCT03409887|Procedure|Base of GIC|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
99303|NCT03409887|Procedure|Direct composite restoration|After primary root canal treatment, Glass Ionomer Cement (KetacTM Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
99304|NCT03409874|Other|Dry Needling|Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
99305|NCT03409874|Other|Spinal manipulation|Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
99306|NCT03409874|Other|Interocclusal Appliance|Interocclusal appliance worn every nights for 4 weeks.
99307|NCT03409874|Drug|NSAIDs|diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
99308|NCT03409874|Other|TMJ Mobs|Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
99309|NCT03409848|Drug|Nivolumab|Addition of Nivolumab to Standard therapy (chemotherapy and Trastuzumab)
99310|NCT03409848|Drug|Nivolumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
99311|NCT03409848|Drug|Ipilimumab|Chemo-free immunotherapy with Nivolumab, Ipilimumab, Trastuzumab
99312|NCT03409835|Drug|Ramosetron|Ramosetron 0.3 mg is administered after induction of general anesthesia.
99313|NCT03409835|Drug|Normal saline|Normal saline 2 ml is administered after induction of general anesthesia.
99314|NCT03409822|Device|Masimo SpHb™ monitor|Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
99315|NCT03409809|Behavioral|Training|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide and facilitator support website.
99316|NCT03409809|Behavioral|Training and Technical Assistance|Level of Support: Intensive 2-day train-the-trainer workshop, facilitator guide, and facilitator support website, plus half-day implementation training to further define goals, needs, leadership structure and strategy for adoption and recruitment.
99317|NCT03409809|Behavioral|Training, Tech. Assistance, Quality Assurance/Improvement|"Level of Support: As for Training and Technical Assistance arm, plus 1-year of technical assistance, coaching, and quality assurance to enhance skills for implementation and sustainability."
99318|NCT03409796|Dietary Supplement|Gluten|Gluten powder
99319|NCT03409783|Device|ENSO Device|An active ENSO device that delivers neuromodulation therapy.
99320|NCT03409783|Device|Sham Device|Sham Device
99321|NCT03409770|Other|Therapeutic hypothermia|Whole body cooling using a servo controlled device
99322|NCT03409757|Drug|Velphoro|4 weeks
99323|NCT03409757|Other|saliva collection|2 samples
99324|NCT03409757|Other|Supragingival biofilm collection|2 samples
99325|NCT03409757|Other|stool collection|2 samples
99326|NCT03409757|Other|blood collection|2 samples
99327|NCT03409744|Drug|evinacumab|Intravenous (IV) administration
99328|NCT03409731|Device|ABSORB GT1 BVS|Patients receiving Absorb GT1 BVS
99329|NCT03409718|Device|Biomet Comprehensive Shoulder System|Total shoulder system designed to provide intraoperative flexibility for surgeons with unmatched humeral stem options, and infinite humeral head offset possibilities while meeting the growing demand for ease of glenoid preparation through a streamlined, low-profile, cannulated instrument platform
99330|NCT03409705|Dietary Supplement|Skate Skin group|2,000 mg of low-molecular collagen peptide was orally administered per day for 12 weeks.
99331|NCT03409705|Dietary Supplement|Control group|2,000 mg of starch was orally administered per day for 12 weeks.
99332|NCT03409692|Diagnostic Test|Gene Expression Profiling|SkylineDx has previously developed the MMprofiler, a microarray-based diagnostic test that can subtype MM patients and reliably predict MM patient survival (prognosis). In this project, the test's clinical value will be expanded to include the prediction of treatment effectiveness in individual patients based on Gene Expression Profiling.
99333|NCT03409679|Drug|Murepavadin|Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic (Piperacillin-tazobactam, ceftazidine, cefepime, meropenem, amikacin, ciprofoxacin, levofloxacin, colistin)
99335|NCT03409666|Device|Taperloc Complete Microplasty stem|Total hip replacement with Taperloc Complete Microplasty stem and G7 acetabular shell with E1 liner
99336|NCT03409666|Device|Taperloc Complete Reduced Distal stem|Total hip replacement with Taperloc Complete Reduced Distal stem and G7 acetabular shell with E1 liner
99337|NCT03409627|Biological|INXN-4001|Retrograde coronary sinus infusion of triple effector plasmid (INXN-4001)
99338|NCT03409614|Drug|REGN2810|REGN2810 plus Platinum-based doublet chemotherapy Part 1 and Part 2
99339|NCT03409614|Drug|REGN2810/chemo/ipi|REGN2810 plus abbreviated chemotherapy plus Ipilimumab Part 1
99340|NCT03409614|Other|Chemotherapy|Platinum-based doublet chemotherapy Part 1
99341|NCT03409614|Drug|Placebo|Matching placebo Part 2
99342|NCT03409601|Other|100% Portion Size|Meal portion size at baseline
99343|NCT03409601|Other|125% Portion Size|Meal portion size 125% of baseline
99344|NCT03409601|Other|150% Portion Size|Meal portion size 150% of baseline
99345|NCT03409601|Other|175% Portion Size|Meal portion size 175% of baseline
99346|NCT03409588|Drug|Adempas|After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
99347|NCT03409575|Other|5 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 5 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 5 minutes of NMES will be made in 4 sets. Fifteen contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
99348|NCT03409575|Other|10 minutes stimulation|Before the NMES application, warming exercises will be performed on the lower extremity muscles for 5 minutes. NMES will be administered through Compex device (Physio, Chattanooga Corporation, Chattanooga, U.S.A.). Quadriceps will be stimulated bilaterally for 3 sessions per week for 6 weeks (totally 18 sessions). Four electrodes will be used on the femoral nerve, and motor points of the rectus femoris, vastus medialis, lateralis.The biphasic, symmetrical waveform will be used. The 100 Hz current will be applied for 10 minutes by 5 sec on: 15 sec off and than the muscle will be rested for 10 minutes. 10 minutes of NMES will be made in 2 sets. Thirty contractions will be received at each set. The intensity of the current will be increased until the visible contraction is taken.
99349|NCT03409562|Behavioral|motor control training|Exercises to strengthen the lumbar musculature and control the posture.
99350|NCT03409562|Behavioral|pain neurophysiology education|Educational sessions to improve patient's neurophysiology of pain knowledge.
99351|NCT03409549|Radiation|Fluciclovine PET/CT|Fluorine-18 Fluciclovine PET/CT scan of the brain
99352|NCT03409536|Device|SSEP monitoring|Participants will be monitored using the SSEP device both before and after induction of a brachial plexus block.
99353|NCT03409510|Radiation|UVB radiation|"UVB treatment regimen:~Week 1-2: 0.85 kilo Joule/m2 twice per week Week 3-7: 0.85 kilo Joule/m2 three times per week Week 8-9: 1.4 kilo Joule/m2 three times per week"
99354|NCT03409497|Other|Concord Grape Juice|Concord Grape Juice
99355|NCT03409497|Other|Low flavonoid low essence beverage|Low flavonoid low essence beverage
99356|NCT03409497|Other|Low flavonoid beverage|Low flavonoid beverage
99357|NCT03409484|Other|Concord Grape Juice|Concord Grape Juice
99358|NCT03409484|Other|Low flavoniod low essence beverage|Low flavoniod low essence beverage
99359|NCT03409484|Other|Low flavonoid beverage|Low flavonoid beverage
99360|NCT03409471|Device|Flocked Swab|At the colposcopy clinic, vaginal self-sample will be collected with the Flocked Swab (Noble Bioscience, Inc., Korea).
99361|NCT03409471|Device|Cervical Brush|Physician collected cervical sample will be collected also at the colposcopy center with the Cervical Brush (Noble Bioscience, Inc., Korea).
99362|NCT03409471|Diagnostic Test|HPV assay|The hrHPV assay used, will be the Roche Cobas® 4800 HPV test, Anyplex™ II HPV HR detection kit and Realtime HPV HR-S Detection kit.
99363|NCT03409458|Drug|PT-112|The MTD and RP2D of PT-112 when used in combination with avelumab will be determined during dose escalation.
99364|NCT03409458|Biological|avelumab|Avelumab will be administered at a fixed dose of 800 mg.
99365|NCT03409445|Other|no intervention|no intervention (observational study)
99366|NCT03409432|Drug|Brentuximab Vedotin|Given IV
99367|NCT03409432|Other|Laboratory Biomarker Analysis|Correlative studies
99368|NCT03409432|Drug|Lenalidomide|Given PO
99369|NCT03409419|Drug|[18F] CFA|pilot study to evaluate the bio-distribution of [18F] CFA, a new tracer for imaging the purine nucleoside biosynthetic pathway, before and after immunotherapy treatment in patients with metastatic or recurrent advanced melanoma.
99370|NCT03409406|Behavioral|Caregiver Intervention|This intervention is a 3-month (or 12 weeks) sequenced mobile health intervention provided to the parent/caregiver to use at home with the child. It supplements the 30 minute speech and language therapy session provided to the child at the hospital once a month
99371|NCT03409406|Behavioral|ST Intervention|This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
99372|NCT03409393|Other|The COPUS intervention|The COPUS intervention consists of 8 weeks of High-Intensity Functional Training (HIFT). The frequency of the training is 3 sessions per week and the duration is one hour per session. The intervention is group-based and supervised. Each training session includes warm-up (15 min), followed by 30 minutes of HIFT based on a range of varied functional exercises, including elements of strength training and aerobic exercise. The sessions are supervised by a trained physiotherapist and exercise physiologist supported by 2 two trained bachelor students in Sports Science.
99478|NCT03408691|Other|Acidified dairy drink without ferment|Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
99373|NCT03409393|Other|Usual Care (OPUS treatment)|Usual care include specialised early intervention treatment (OPUS treatment) and consists of three main pillars: modified assertive treatment, family involvement, and social skill training. OPUS treatment is delivered via multidisciplinary teams include psychiatrists, psychologists, nurses, social workers, physiotherapists, and vocational therapists. All team members, except for the psychiatrist, function as case managers. The ratio of patients to case managers must not exceed 12:1.
99374|NCT03409380|Dietary Supplement|Arginine Drink|10 g of arginine in a formulated drink
99375|NCT03409380|Dietary Supplement|Plain Drink|formulated drink
99376|NCT03409367|Other|Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream|Lipid-rich emollient serving as skin barrier
99377|NCT03409354|Behavioral|Tele-rehabilitation|There are five different categories of exercise in the rehabilitation program, which combines both physiotherapy (Category 1 to 4) and occupational therapy components (Category 5). Each tele-therapy session could cover all five categories of exercises. Progression of levels within each exercise within each category should be determined by the tele-therapist and in consultation with the participant.
99378|NCT03409354|Behavioral|Usual care|Usual rehabilitation care (e.g., PT, OT and ST), prescribed by rehabilitation therapists at participating centers and performed by participants at participating centers.
99379|NCT03409341|Other|Blood and tumor tissue analysis, Clinical response.|DNA sequencing and functional testing of peripheral blood mononuclear cells. DNA and RNA sequencing and immune cell analysis of tumor. Clinical response at 12 months.
99380|NCT03409328|Behavioral|HIV and substance use prevention|The intervention content will be developed through formative research during the initial phase of the study. However, the intervention will address: bisexual-inclusive sexual health education, unique influences of risk behavior among bisexual adolescents, and skills to cope with bisexual stigma and to increase acceptance of one's bisexual identity.
99381|NCT03409315|Procedure|Centralized Therapeutic Drug Monitoring|Plasma samples will be drawn at peripheral centres en shipped to a central laboratory for analysis. Results and dosing advice will be returned by email to local physician.
99382|NCT03409302|Behavioral|ALGEApp (Brief iACT intervention)|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The i-ACT intervention participants will be encouraged to login the website platform with their credentials and to complete 4 weekly sessions (1 session per week) which lasts about 1 hour each. Participants will be guided by a 3D- animated Avatar who adopts the role of a facilitator.
99383|NCT03409302|Behavioral|Active control group|Participants will be randomly assigned to one of the two groups: brief i-ACT intervention or active control group. The active control group will have access, through the same platform. only to limited online psycho-educational information regarding pain. Active control group will complete pre-treatment and post-treatment questionnaires in parallel with the intervention group.
99384|NCT03409289|Device|RUSH Exam|Within two hours of return of spontaneous circulation, the following elements of the RUSH exam will be performed: focused evaluation of the heart, inferior vena cava, abdomen and aorta with the addition of evaluation for DVT and ocular ultrasound.
99385|NCT03409276|Biological|env (A,B,C,A/E)/gag (C) DNA Vaccine|Administered by intramuscular injection in the deltoid.
99386|NCT03409276|Biological|gp120 (A,B,C,A/E) Protein Vaccine|Administered by intramuscular injection in the deltoid.
99387|NCT03409276|Biological|Placebo|Sodium Chloride for Injection, USP 0.9%; Administered by intramuscular injection in the deltoid.
99388|NCT03409276|Biological|GLA-SE adjuvant|Administered by intramuscular injection in the deltoid.
99389|NCT03409263|Other|Observational study|Not applicable (observational registry study)
99390|NCT03409250|Drug|Ranibizumab, Lucentis|Intravitreal injection with Lucentis (Ranibizumab)
99391|NCT03409237|Drug|Mannitol|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity <320.
99392|NCT03409237|Drug|Hypertonic saline solution|Therapy is administered according to the clinical gold standard and until reaching and maintaining serum sodium levels between 145 e 155 meq/l and an osmolarity <320.
99393|NCT03409211|Dietary Supplement|PEVCO|All subjects will receive PEVCO for 6 more weeks.
99394|NCT03409211|Dietary Supplement|Dietary Supplement Capsules without Coconut Oil|All subjects will receive placebo (PBO) for 3 weeks
99395|NCT03409198|Drug|Ipilimumab|Ipilimumab blocks CTLA-4 and may deplete regulatory T cells
99396|NCT03409198|Drug|Nivolumab|Nivolumab blocks PD-1 and thereby enhances the effector phase of the immune reaction, by enabling T cells to kill tumor cells and engage effectively with other PD-L1 expressing targets.
99397|NCT03409198|Drug|Pegylated liposomal doxorubicin|Chemotherapy
99398|NCT03409198|Drug|Cyclophosphamide|Chemotherapy
99399|NCT03409185|Device|Alcon 1 piece SA60AT lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-absorbing Acrylate/Methacrylate Copolymer
99400|NCT03409185|Device|AMO 1-piece AABOO lens|Optic Diameter: 6.0 mm, Overall length: 13.0 mm, Material: Ultraviolet-blocking hydrophobic acrylic
99401|NCT03409172|Other|CTR|no counseling or nutritional therapy and no exercise
99402|NCT03409172|Other|MICT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based moderate continuous intensity training (MICT).
99403|NCT03409172|Other|HIIT|no counseling or nutritional therapy. 8 weeks of individualized and supervised ergometer-based high intensity interval training (HIIT)
99404|NCT03409159|Device|LAAC|Left atrial appendage closure
99405|NCT03409146|Device|Monica Novii Wireless Patch System|The Monica Novii Wireless Patch System is a transabdominal fetal/maternal recorder that provides fetal heart rate, maternal heart rate and maternal uterine activity contractions.
99406|NCT03409133|Device|Multi contact electrode implant|See Arm Description
99407|NCT03409120|Device|Boston Scientific Vercise PC IPG with directional DBS lead|We will contrast the effects of omnidirectional versus directional STN DBS on dystonia symptoms in patients with PD.
99408|NCT03409107|Drug|Daprodustat (GSK1278863)|Daprodustat will be available as 9 millimeter (mm) or 7 mm film-coated tablets. Daprodustat will be administered once daily via oral route and can be taken without regard to food.
99479|NCT03408665|Radiation|SBRT|3 sessions at least, up to 6. Neither specifc device is imposed.
99409|NCT03409107|Drug|Placebo|Daprodustat matching placebo will be available as 9 mm or 7 mm film coated tablets. Placebo will be administered once daily via oral route and can be taken without regard to food.
99410|NCT03409107|Drug|Iron therapy|Iron therapy will be administered if ferritin is <50 Nano gram per milliliter and/or TSAT is <15 percent.
99411|NCT03409081|Drug|gilteritinib|oral
99412|NCT03409068|Procedure|C2-C4 compartment anesthetic block|C2-C4 compartment anesthetic block is performed by injecting levobupivacaine 0.375% 20 mL between the posterior face of the middle scalenus muscle, the anterior face of the posterior scalene muscle and the lower plane of the sternoscleidomastoid muscle.
99413|NCT03409068|Procedure|Costagliola block|Costagliola block is performed by injected by injecting levobupivacaine 0.375% 20 mL along the anterior and the posterior border of sternocleidomastoid muscle
99414|NCT03409042|Behavioral|Caloric compensation|The investigators have adapted an established within-subject preload paradigm to assess infant's short term caloric compensation. At each studied age, the measure of caloric compensation required two visits at the laboratory on two non-consecutive days. On the first visit, the infants received a fixed amount of a food preload either low or high in energy density. The order of the two preloads was counterbalanced. After a delay (ranging from several hours in the 3-4 months old infants to 25 min in 10.5- and 14.5-month-old infants), the infants were served an ad libitum meal. Weight intakes (g) were assessed by weighing each bottle/bowl before and after consumption.
99415|NCT03409029|Diagnostic Test|MRI Scan|Additional imaging using MRI scan
99416|NCT03409016|Other|Blood Testing|Patients will undergo therapy per standard protocol. There are no study-related medications or interventions beyond blood testing.
99417|NCT03408977|Other|probe meal|The probe meal will be served in 150 Kcal portions (10 g foie, 10 g cheese, 5 g chips, 2 g peanuts, 3 g toast, and 27 mL soft drink) up to the level of maximal satiation.
99418|NCT03408964|Other|biological samples collection and analysis|Participants to the study will be assigned to 4 cohorts according to the stage of disease and planned antitumor treatment at time of study entry; they will be followed up and sampled according to a defined time schedule
99419|NCT03408951|Other|Recording|The patient cutaneous ECG is recorded, to later be comparatively analysed by an expert and by the ISSD detection algorithm
99420|NCT03408938|Device|of Masimo Radical-7¿ Pulse CO-Oximeter|"The Masimo pulse oximetry model:~The pulse oximetry model which Masimo developed accounts for saturation values contributed by the true arterial signal, and by one or more motion or noise signals. lt is assumed that under conditions of motion, the detected IR and RD signals comprise both the true arterial saturation signal and a venous (or non-arterial) motion noise signal. Masimo uses a highly sophisticated adaptive filter with, Discrete saturation transform (DST) four other parallel engines, to leverage each algorithm's unique strengths to ensure accurate readings through all patient conditions. Masimo SET's most powerful algorithm is Signal extraction technology (SET). All algorithms depend upon assumptions. The more assumptions, the weaker the algorithm. DST makes only one assumption -that arterial blood has a higher oxygenation than venous - making it the most powerful pulse oximetry algorithm"
99421|NCT03408925|Other|Exercise program|The orienteerers are asked to perform specific exercises four times a week throughout the entire study period. The exercises are heel rises, runners pose, single leg stance and one-leg jumps with three difficult levels aiming to mainly improve lower extremity strength and neuromuscular function. Each second week the exercises' difficulty level is increased.
99422|NCT03408912|Diagnostic Test|FFR|FFR from CMR compared to invasive FFR
99423|NCT03408899|Drug|PC-1005 gel|PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.
99424|NCT03408886|Drug|Vancomycin|Oral vancomycin is administered to reduce pathogenic bacteria.
99425|NCT03408886|Drug|MoviPrep|MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota
99426|NCT03408886|Biological|Full Spectrum Microbiota|Gut bacteria from healthy human donors are administered orally in a pill form
99427|NCT03408873|Drug|Abilify Maintena|Drug is in an injectable form and will be administered approximately every four weeks through Week 24 of the study. Dosage is per package insert or at the discretion of the psychiatrist.
99428|NCT03408873|Behavioral|Customized Adherence Enhancement (CAE)|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
99429|NCT03408860|Other|Countering Emotional Behaviors Module from Unified Protocol|This is a 4-week behavioral treatment that teaches patients to counter problematic emotional avoidance by approaching behaviors and situations that may bring up strong emotions in the short-term, but prevent interfering emotional difficulties in the long-term.
99430|NCT03408847|Combination Product|Beclomethasone dipropionate in addition to MC-EVOO|Oral beclomethasone dipropionate at dose of 10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks plus MC- EVOO for 12 weeks at a dose of 2 tablespoons per day (1 before lunch and 1 before dinner). Each spoon will contain 10 grams of oil containing 5 mg of biophenols.
99431|NCT03408847|Combination Product|Beclomethasone dipropionate in addition to refined oil|Oral beclomethasone dipropionate (10 mg / day for the first 4 weeks, 5 mg / day for the second 4 weeks) plus placebo consisting of refined olive oil with low biophenols.
99432|NCT03408834|Other|pulse variability index|fluid management with pulse variability index or conventional
99433|NCT03408821|Other|Problem Solving Therapy (PST)|Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
99434|NCT03408808|Procedure|Platelet rich plasma|Aspiration of ganglion and injection with platelet rich plasma.
99435|NCT03408808|Procedure|Aspiration alone|Aspiration of the ganglion
99436|NCT03408795|Procedure|Laparoscopic distal gastrectomy|Sequential validating Global Operative Assessment of Laparoscopic Skills-Distal Gastrectomy
99437|NCT03408782|Procedure|Insertion of drainage|
99438|NCT03408769|Other|Medical questionnaire|"Brief Index of Sexual Functioning for Women questionnaire~Quality of life questionnaire (EORTC QLQ-BR23)~Partnership questionnaire (partnerschaftsfragebogen; PFB)~Short interview about their sexual intimacy"
99439|NCT03408756|Drug|methotrexate|Participants will receive methotrexate through oral or subcutaneous route of administration
99440|NCT03408743|Behavioral|Knowledge Alone|Increase knowledge relate d STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
99441|NCT03408743|Behavioral|Self-efficacy alone|Increase self-efficacy to us e protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99442|NCT03408743|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
99443|NCT03408743|Behavioral|Benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99444|NCT03408743|Behavioral|Injunctive norms alone|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
99445|NCT03408743|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99446|NCT03408743|Behavioral|Injunctive norms and benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99447|NCT03408743|Behavioral|Injunctive norms, benefits, self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99448|NCT03408743|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
99449|NCT03408743|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99450|NCT03408743|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
99451|NCT03408743|Behavioral|Descriptive norms, benefits, self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99452|NCT03408743|Behavioral|Descriptive norms and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
99453|NCT03408743|Behavioral|Descriptive and injunctive norms, self-efficacy|orrect misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99454|NCT03408743|Behavioral|Descriptive and injunctive norms, and benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
99455|NCT03408743|Behavioral|Descriptive & injunctive norms, benefits, efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99456|NCT03408743|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
99457|NCT03408743|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99458|NCT03408743|Behavioral|Expectancies and perceived benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
99459|NCT03408743|Behavioral|Expectancies, benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99460|NCT03408743|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
99670|NCT03407144|Drug|cyclophosphamide|500 mg/m^2 IV on days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)
99461|NCT03408743|Behavioral|Expectancies, injunctive norms, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99462|NCT03408743|Behavioral|Expectancies, injunctive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
99463|NCT03408743|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99464|NCT03408743|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
99465|NCT03408743|Behavioral|Expectancies, descriptive norms, & self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99466|NCT03408743|Behavioral|Expectancies, descriptive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
99467|NCT03408743|Behavioral|Expectancies, descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99468|NCT03408743|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
99469|NCT03408743|Behavioral|Expectancies, descriptive & injunctive norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99470|NCT03408743|Behavioral|Expectancies, descriptive & injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
99471|NCT03408743|Behavioral|Expectancies, descriptive & injunctive, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
99472|NCT03408730|Biological|Hepatitis B Vaccination|Hepatitis B Vaccination
99473|NCT03408717|Other|Questionnaires|Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
99474|NCT03408717|Procedure|Mechanical Temporal Summation assessment|A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
99475|NCT03408717|Procedure|Pain threshold assessment|Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure ~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
99476|NCT03408704|Other|ASP|"It consists of one educational session where doctors and staff at the center discuss current guidelines around management of patients attending for a sore throat. At the education the following is discussed:~The Swedish guidelines~Example of cases~Statistics from previous 6 month showing how well this clinic adheres to the Swedish guidelines."
99477|NCT03408691|Dietary Supplement|Fresh fermented dairy drink containing probiotic strain|Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.
100486|NCT03400839|Diagnostic Test|Symptoms - mMRC|"Assessment of symptoms by the modified Medical Research Council (mMRC) scale"
99480|NCT03408652|Drug|denosumab|Single subcutaneous injection of denosumab 120 mg every 4 weeks One intravenous infusion of zoledronic acid 4 mg every 4 weeks, according to labelled use.
99481|NCT03408639|Drug|CinnaPoietin®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
99482|NCT03408639|Drug|Eprex®|The starting dose of Erythropoietin is 60 (50-100) IU/kg body weight/week for naïve patients. Administration dose for patients who are treated with erythropoietin is similar dose of previously administered amount (IV or SC without any change). After then, dose adjustment will be done based on patients' response.
99483|NCT03408639|Drug|Nephrovit|Nephrovit tablet is daily administered to all the patients.
99484|NCT03408639|Drug|Vitamin B12 Injection|Vitamin B12 is monthly injected to all the patients.
99485|NCT03408626|Drug|Papain-based Chemo-mechanical caries removal agent|Birx 3000 and the exclusive Encapsulating Buffer Emulsifier (EBE) technology claim it has effective and selective proteolytic action to remove collagen fiber in the carious tissue. It has an antibacterial and antifungal power, thus it has an antiseptic power at the tissue level .furthermore, this gel does not contain chloramines in its formula, which enhances its toxicological safety feature.
99486|NCT03408626|Device|conventional rotary|traditional rotary method
99487|NCT03408613|Procedure|Positive Airway Pressure|See arm/group description
99488|NCT03408613|Procedure|Supplemental Oxygen|See arm/group description
99489|NCT03408613|Procedure|Sham|See arm/group description
99490|NCT03408600|Other|Management|To evaluate vital signs in a global cohort of patients with acute peritonitis, determining which parameters are statistically significant to predict in-hospital mortality and ICU admission.
99491|NCT03408587|Biological|CVA21|Oncolytic virus
99492|NCT03408587|Biological|Ipilimumab|Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.
99493|NCT03408574|Drug|Nicotine patch, oral mecamylamine, placebo|Each participant randomly receives one active drug or placebo on each of three study days.
99494|NCT03408561|Other|Internet-Based Intervention|Receive message via Twitter
99495|NCT03408561|Other|Survey Administration|Ancillary studies
99496|NCT03408548|Procedure|Scaling root planning|Periodontal treatment
99497|NCT03408548|Dietary Supplement|Probiotic|two lozenge per day containing Bifidobacterium animalis lactis HN019
99498|NCT03408548|Other|Placebo|two lozenge per day not containing Bifidobacterium animalis lactis HN019
99499|NCT03408535|Other|Eriksholm Guide to Better Hearing|Online rehabilitation program.
99500|NCT03408509|Behavioral|Computerized cognitive training|Posit Science Inc. will supply the software for the computerized cognitive training through the platform BrainHQ, which is available on line. The training program consists of a set of computerized exercises designed to improve the speed and accuracy of sensory information processing while engaging neuromodulatory systems involved in attention and reward. The rationale is that, in order to understand and remember information, the brain must first generate precise and reliable neurological responses that represent the sensory stimuli. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations. The goal is to increase the effectiveness with which these stimuli engage and drive plastic changes in brain systems. Engagement is monitored by electronic data upload following each training session.
99501|NCT03408496|Other|Myofascial release|Manual therapy
99502|NCT03408496|Other|Muscle stretching|Muscle stretching
99503|NCT03408496|Other|Control|Medical appointment
99504|NCT03408483|Drug|Quadratus Lumborum Block (QLB)|Under ultrasound guidance, the needle will be advanced to the posterior border of the quadratus lumborum muscle. After negative aspiration, a bolus of 40 mL of 0.25% bupivacaine with 1:400,000 epinephrine will be injected in 5 mL aliquots, ensuring proper placement of needle tip and appropriate spread of local anesthetic.
99505|NCT03408483|Drug|Standard of Care|This is currently the standard of care, no local anesthetic will be injected. Pain will be managed with parenteral and oral medication.
99506|NCT03408470|Drug|TD-1473 oral capsule|(Intervention description included in arm description)
99507|NCT03408470|Drug|[14C]-TD-1473 IV bolus|(Intervention description included in arm description)
99508|NCT03408470|Drug|[14C]-TD-1473 Oral Capsule|(Intervention description included in arm description)
99509|NCT03408457|Procedure|Blood sampling after antibiotic administration|Sampling of 6 x 8 mL (in sum 48 mL) via the central venous line (established for the surgical procedure) until postoperative day 2
99510|NCT03408431|Device|Ambu® AuraGain™|Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
99511|NCT03408431|Procedure|neck extension|Patients' neck will be maximally extended (~60°) during blind intubation.
99512|NCT03408418|Procedure|Platelet-rich fibrin|The use of autologous platelet-rich fibrin after tooth extraction to promote bone healing and alveolar ridge preservation
99513|NCT03408405|Drug|Acthar Gel 80 UNT/ML Injectable Solution|Participant will self inject 'Acthar Gel 80 UNT/ML Injectable Solution' 2 x per week for six months.
99514|NCT03408392|Drug|Test formulation A|Test formulation: SKF101804 will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a fruit flavor and odor.
99515|NCT03408392|Drug|Reference formulation B|Reference formulation will be available as oral suspension supplied as powder for reconstitution (Off-white to cream coloured powder). Subjects will receive single dose of 5 mL of suspension thus receiving 200 mg dose of cefixime. The suspension is a white to off white viscous suspension with a strawberry flavor and odor.
99598|NCT03407729|Other|Magnetic Resonance Imaging|MRI uses a strong magnetic field and radio waves to create detailed images of the brain while the person's head is positioned inside a round tunnel.
100487|NCT03400839|Diagnostic Test|Sleep quality|"Assessment of sleep by the Pitsburg Sleep Quality Index (PSQI)"
99516|NCT03408379|Other|Collection of blood sample in aneurysm|"In case of an endovascular treatment :~A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the procedure, an intra aneurysmal blood sample (1mL) will be taken during the procedure and a blood sample (arterial) of 1 mL will be taken at the end of the procedure.~Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit.~In case of a surgery treatment :~A blood sample (venous or arterial) of 10 ml will be taken at the beginning of the surgery.~A Tissue sample will be taken during the surgery~Iterative blood samples (arterial) of 10 mL will be taken at each follow up visit."
99517|NCT03408366|Procedure|Laparotomy|Laparotomy via vertical midline incision and after the planned surgical procedure is complete.
99518|NCT03408366|Other|ICG|ICG will be injected intravenously ICG is a fluorescent iodide dye.
99519|NCT03408366|Other|Spectrum NIR imaging system|The Spectrum NIR imaging system uses a handheld camera that emits light in the NIR range.
99520|NCT03408353|Behavioral|Questionnaire|Baseline questionnaire and annual follow up questionnaires that collect data on personal and family history of cancer, health status, breast cancer risk factors, diet, weight gain, and physical activity
99521|NCT03408353|Other|Health Measurements|During the annual screening visit, staff will also record health measurements (weight, height, and waist/hip circumferences), record recent food/drink consumption, and will administer a 30-second sit-to-stand test to the participants.
99522|NCT03408340|Procedure|Paravertebral Nerve Block|Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established. A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry. The patient will be intubated, and then will be positioned laterally for the nerve block at approximately the left T3-4 level. A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block. The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
99523|NCT03408340|Drug|Standard of Care Anesthesia|Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established. The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery. Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane. The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
99524|NCT03408327|Device|Wearable technology|Fitness wristband & APP
99525|NCT03408327|Behavioral|LINE group|Promote social interaction
99526|NCT03408327|Behavioral|Group activities|Which was developed by applying social cognitive theory
99527|NCT03408327|Device|Health promotion manual|Which was about general physical activity promotion content
99528|NCT03408314|Other|PediQUEST Response|PediQUEST Response consists of regular feedback of electronic patient reported outcomes (child symptoms and quality of life) to providers and families coupled with involvement of the palliative care team, who will meet with families and providers within three weeks of randomization and follow-up at least monthly as deemed necessary based on PediQUEST feedback reports and other clinical indications.
99529|NCT03408314|Other|Usual Cancer Care|Patients assigned to the usual cancer care arm, will receive the standard care provided by participating sites + be required to complete PediQUEST surveys (but no reports will be generated).
99530|NCT03408301|Procedure|Tourniquet deflation|Tourniquet deflation
99531|NCT03408288|Other|Hemapoche|Use of Hemapoche scale to assess hematuria in reference samples
99532|NCT03408288|Other|Hemastick|Use of Hemastick scale to assess hematuria in reference samples
99533|NCT03408288|Other|Color description|Describe color of reference sample
99534|NCT03408275|Other|None - observational|None - observational
99535|NCT03408262|Biological|Ad4-EnvCN54|Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
99536|NCT03408262|Biological|MVA-CN54|Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54
99537|NCT03408262|Biological|CN54gp140/MPLA|Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant
99538|NCT03408249|Diagnostic Test|IBDoc calprotectin test|Patients are asked to perform a single IBDoc calprotectin home test.
99539|NCT03408249|Other|questionnaire|Patients evaluate the ease-of-use of the test, clearness of test results and comprehensiveness of the instructions for use through a specific questionnaire implementing Likert scales.
99540|NCT03408236|Drug|Botulinum toxin type A|Experimental
99541|NCT03408236|Drug|Botulinum toxin type A|Active Comparator
99542|NCT03408223|Radiation|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
99543|NCT03408223|Radiation|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12-20 Gy TMLI (fraction size of 4 Gy given once a day).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
99544|NCT03408210|Radiation|total body irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Body Irradiation Dose of 10 Gy TBI (fraction size of 5 Gy given once a day on days -2 and -1).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
99545|NCT03408210|Radiation|total marrow and lymphoid irradiation|"Drug: Cyclophosphamide 60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg~Drug: Cyclosporine or tacrolimus Beginning on Day -1 pre-transplant maintaining a level of 150-250 ng/ml or 5-10 ng/ml respectively. Cyclosporine or tacrolimus dosing will be monitored and altered as clinically appropriate by physician, and discontinue at approximately day + 180 post-transplant.~Drug: Methotrexate 15 mg/m2 intravenous on days 1, 10 mg/m2 intravenous on days 3, 6 and 11 after transplantation.~Intervention: Total Marrow and Lymphoid Irradiation Dose of 12 Gy TMLI (fraction size of 4 Gy given once a day on days -6, -5 and -4).~Procedure: Peripheral blood stem cell transplantation product will be infused via intravenous drip on Day 0."
99546|NCT03408197|Device|EasyWarm|Perioperative warming with EasyWarm to prevent inadvertent hypothermia during anaesthesia
99547|NCT03408197|Device|BairHugger|Perioperative warming with BairHugger to prevent inadvertent hypothermia during anaesthesia
99548|NCT03408184|Drug|Lumbar paravertebral group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
99549|NCT03408184|Drug|The field block group|A mixture of 0.5 ml /kg bupivacaine (0.25%), and 0.5µg/Kg dexmedetomidine and Epinephrine 5 microgram/ ml.
99550|NCT03408171|Device|19-gauge FNA needle|A 19-gauge FNA needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNB needle.
99551|NCT03408171|Device|19-gauge FNB needle|A 19-gauge FNB needle will be used to obtain liver tissue during an endoscopic-ultrasound guided liver biopsy. Tissue yield and diagnostic accuracy will be assessed and compared to that of the 19-gauge FNA needle.
99552|NCT03408158|Procedure|same type infusion of main HPA antigen|Compare the differences of platelet count between participants with same type infusion of main HPA antigen and not
99553|NCT03408145|Device|Hyaluronic Acid|Injection of 3x 2.5ml of Hyaluronic Acid
99554|NCT03408145|Device|Amniotic Tissue Allograft|Injection of 1x 1ml of Amniotic Tissue Allograft
99555|NCT03408145|Drug|Saline|Injection of Saline
99556|NCT03408132|Drug|FE203799|FE203799 5 mg subcutaneous once weekly
99557|NCT03408119|Dietary Supplement|Dried Plum|Dried plum fruit, 100g or 50g depending on treatment group randomized to
99558|NCT03408119|Dietary Supplement|800 IU vitamin D and 450mg elemental calcium|Supplemental vitamin D and calcium to protect against further bone loss
99559|NCT03408093|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (INFb-1b) was used at the standard dose of 250 mg/ml.
99560|NCT03408080|Drug|BHV-4157|BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
99561|NCT03408054|Drug|Oxytocin|Oxytocin 10-5M solution
99562|NCT03408054|Drug|Nitroglycerin|Nitroglycerin 25-1000mcg
99563|NCT03408041|Other|Medical file data extraction|Medical file data extraction
99564|NCT03408028|Other|Medical File consultation|Medical File consultation
99565|NCT03408015|Drug|Lifitegrast|Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
99566|NCT03408002|Behavioral|Psychological intervention|"The intervention aims to increase self-efficacy perception in managing pre-operative anxiety. The intervention is based on one single psychological consultation adopting the Four elements technique elaborated by Shapiro"
99567|NCT03407976|Drug|Apatinib|Apatinib oral daily at starting dose 1, Dose Level 2 or Dose Level 3 in phase I, and then whichever is the maximum tolerated dosage will be used for all Phase II patients.
99568|NCT03407976|Drug|Pembrolizumab|200 mg Q3 weeks IV
99569|NCT03407963|Procedure|Embolization|Embolization by microparticles (300-500 microns)
99570|NCT03407950|Behavioral|IPT+|Integrated Psychological Treatment and cognitive remediation and relaxation and Mindfulness : IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
99571|NCT03407950|Behavioral|Treatment as usual|no specific therapy but same number and duration of each sessions than IPT+. A blind evaluation will be realized thanks to questionnaires of the current practice to compare the IPT+ versus treatment as usual (TAU).
99572|NCT03407937|Behavioral|Hypnosis|Hypnosis is a therapeutic method in which the experimenter or therapist make suggestions to individuals after they have undergone a hypnotic induction. This induction is a relaxation procedure designed to focus one's mind and to induce a hypnotic trance in individuals. The hypnotic trance consists in a state of deep absorption, concentration and altered sensations, cognitions and behaviors. Hypnosis can be used for pain control in experimental and clinical settings. In this study, standardized hypnosis including a relaxation technique for the hypnotic induction and a direct hypnotic analgesia technique for the hypnotic suggestions will be used.
99573|NCT03407937|Behavioral|Meditation|Meditation is a relaxation method that can be used to reduce pain symptoms and pain perception in clinical and experimental situations. In this study, a standardized mindfulness meditation session of 20 minutes will be used to induce a relaxation and an analgesic effect in participants. Mindfulness meditation is a practice intended to increase mindfulness and awareness of the self and the environment by techniques of controlled breathing, focus on neutral elements, and observation of one's thoughts and emotions without judgment.
99599|NCT03407729|Other|Electroencephalography|EEG tracks and records brain wave patterns. A head cap with small discs and thin wires (electrodes) is placed on the scalp, and then send signals to a computer.
99633|NCT03407417|Other|virtual technology - tailored minimally|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Minimally tailored patient reminders will be customized using 4 randomly selected constructs.
99574|NCT03407937|Other|Conditioned pain modulation|Conditioned pain modulation (CPM) is a pain inhibition mechanism that is used to assess endogenous analgesia capacity. The method to evaluate CPM in healthy individuals and patients with pain includes both a conditioning stimulus (a noxious stimulus that induces CPM) and a test stimulus (a noxious stimulus used to evaluate the analgesic response to the conditioning stimulus). In this study, the conditioning stimulus will be a cold pressor test (two-minutes immersion of one hand in ice water) and the test stimulus will be a two-minutes thermal noxious stimulus delivered by a contact thermode.
99575|NCT03407937|Drug|Placebo Oral Tablet|A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
99576|NCT03407924|Other|Aerobic Exercise (AER)|Aerobic exercise will be performed with a treadmill or stationary tandem bike 3 times per week. Each exercise session will take about 30 minutes plus 5 to 10 min of warm-up and cool-down. Participants will wear a safety harness.
99577|NCT03407924|Other|Rehabilitation|Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
99578|NCT03407911|Other|Harvested|Metagenomic exam of Gingival crevicular fluid harvested by adsorbent paper point around periodontal teeth and implant affected by peri-implantitis
99579|NCT03407898|Other|intubation time|intubation attempt number and intubation time
99580|NCT03407885|Other|Bundled payments for knee and hip replacement|"The bundled payment model holds acute care hospitals (ACHs) financially responsible for the spending and quality of an entire episode of care for two types of hospital admissions: MS-DRG 469 and 470. An episode begins with an ACH stay that results in a discharge in one of the two DRGs, and ends 90 days after discharge. Before each performance year begins, hospitals receive target prices from CMS, determined by historical hospital and regional episode expenditures. Hospitals are eligible for reconciliation payment from CMS if they spend less than the target prices for an episode, provided that they met an acceptable quality standard. Conversely, they are responsible for paying the difference if they spend more than the target prices."
99581|NCT03407872|Drug|Esketamine DPI|Participants will receive different number of consecutive Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts.
99582|NCT03407872|Drug|Esketamine DPI|"Participants will receive different dosing sequences of Esketamine DPI inhalations, consider as a single dose. There will be dose escalation between cohorts. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A of the study.~Dose: very low, low, medium, high."
99583|NCT03407872|Drug|Esketamine DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. There will be dose escalation between cohorts. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio. Number of Esketamine DPI inhalations within a dosing sequence will be defined based on results from PART A and PART B of the study.~Dose: very low, low, medium, high."
99584|NCT03407872|Drug|Placebo DPI|"Participants will receive different cycle of treatment consisting of 4 dosing sequences administered within 2 weeks. Participants in this part will be randomized to receive Esketamine DPI or placebo in 3:1 ratio.~In each cohort, number of placebo inhalations within a dosing sequence will correspond to number of Esketamine DPI inhalations."
99585|NCT03407859|Biological|Sequential Treatment With different CART|Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL
99586|NCT03407846|Procedure|Hystrectomy|Total laparscopic hystrectomy versus total abdominal hystrectomy
99587|NCT03407833|Other|Endoscopy biopsy|Tissue samples will be collected from the jejunum, duodenum, and colon during the subject's standard of care procedure.
99588|NCT03407833|Other|Surgical biopsy|Biopsy of the liver is standard of care for diagnosing NAFLD. Biopsy of omentum, skeletal muscle and subcutaneous adipose (the latter two tissues taken at the site of trocar placement) will be collected intraoperatively at the time of Roux-en-Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
99589|NCT03407833|Other|Mixed-meal tolerance test|The mixed meal tolerance test (MMTT) shows how much insulin your body is making after drinking a liquid meal beverage that contains fats, protein and carbohydrates (sugar). Glucose, C-peptide, free fatty acids, triglycerides, incretins, pancreatic polypertide, bile aceis, and fatty acid amides can also be measured. A total of 9 tablespoons of blood is taken over a 255 minute period.
99590|NCT03407820|Procedure|Absorbable Chromic gut sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received absorbable Chromic sutures are treated recording to the standard protocol and they are advised that they can start to gently rub the scab and suture line to encourage the sutures to fall off starting 10-14 days postoperatively.
99591|NCT03407820|Procedure|Non-absorbable Nylon sutures|In this group interrupted simple or horizontal mattress skin sutures are used for wound closure per surgeon preference. Standardized wound care instructions will be given to all patients. Those who received Nylon sutures are treated recording to the standard protocol and sutures are removed after the usual time (10-14 days) of the received procedure.
99592|NCT03407794|Other|Fermented vegetable|The intervention is to consume 1/2 cup fermented vegetables every day for 6 weeks
99593|NCT03407794|Other|Non-fermented vegetable|The intervention is to consume 1/2 cup of non-fermented vegetables every day for 6 weeks
99594|NCT03407781|Drug|68Ga-BBN-IRDye800CW|PET/NIR fluorescent imaging-guided surgery
99595|NCT03407768|Behavioral|Individualized interventions|"A participant will be able to select one or more (or no intervention) based on her preferences.~Individualized exercise program Yoga and mindfulness Massage therapy Acupuncture Others: Women who are not interested in any above intervention but like to explore other interventions will be offered material pertinent to their choice of complimentary techniques."
99596|NCT03407755|Procedure|Intraocular gas|Participants randomized to either air or SF6 gas in the anterior chamber.
99597|NCT03407742|Behavioral|CAPAS Youth|9-week parenting intervention
99600|NCT03407729|Other|Cognitive Performance Testing|"For the Verbal n-back: During the fMRI scan, children will respond to a letter displayed on a small screen and indicate (by pushing a button) whether the letter shown is the same as a previously displayed letter. Children will repeat this test during the EEG.~For the Grooved Pegboard task: After the MRI scan, children will be timed as they place pegs into holes with randomly positioned slots."
99601|NCT03407716|Drug|American Ginseng|Given PO
99602|NCT03407716|Other|Laboratory Biomarker Analysis|Correlative studies
99603|NCT03407716|Other|Placebo|Given PO
99604|NCT03407716|Other|Questionnaire Administration|Correlative studies
99605|NCT03407703|Drug|Elbasvir / Grazoprevir Oral Tablet [Zepatier]|HCV treatment
99606|NCT03407690|Other|nasal swab|collection of nasal swab to allow carriage of pneumococci to be assessed
99607|NCT03407677|Device|ROTO track®|An electronic injection form and injection log for keeping track of injection sites in the abdominal region. The device attaches directly to the insulin pen and activates whenever the insulin pen is picked up.
99608|NCT03407664|Other|this field is not applicable|We will not be testing an intervention. Only the long term outcomes of men screened for AAA in England.
99609|NCT03407651|Biological|Coagulation Factor VIIa variant|Single intravenous injection of MarzAA, followed by single subcutaneous injection of MarzAA, followed by daily subcutaneous injection of MarzAA for 50 days at final dose level required.
99610|NCT03407638|Other|PROUD Intervention|The PROUD intervention includes 3 strategies used to implement the MA Model: 1. Clinic leadership receives funding for a 1.0 full time equivalent NCM for 2 years after randomization and technical support for recruiting and hiring the NCM. Once hired for the study, the NCM will receive technical assistance (TA) from experts at Boston Medical Center (BMC) supported by PROUD, but NCMs will be employed and supervised by the health system. 2. Experts at BMC who originally developed and disseminated the MA Model will: provide intervention clinics with a Manual; train PROUD NCMs at BMC; and provide the ongoing TA for 2 years after randomization. 3. At least 3 primary care providers in the PROUD intervention clinic will obtain DEA waivers to prescribe buprenorphine for OUDs, if not already waivered, and work closely with the NCM to offer high quality primary care for OUDs (e.g. medication treatment with buprenorphine or naltrexone with close follow-up to maximize retention in treatment).
99611|NCT03407625|Other|Foley bulb plus Oral Misoprostol|"Although labeled experimental for comparison purposes, this is not an experimental intervention, as the method is a currently accepted standard of care for cervical ripening and labor induction in the United States."
99612|NCT03407625|Other|Oral Misoprostol|Patients will receive standard oral misoprostol 100mcg according to current Labor Induction Protocol.
99613|NCT03407612|Device|Continuous Passive Motion|CPM devices are used in postoperative rehabilitation and are throughout to reduce joint stiffness.
99614|NCT03407599|Drug|Faster aspart|An injection of fast-acting insulin aspart 0.2 U/kg body weight under the skin just prior to a standard meal.
99615|NCT03407599|Drug|Insulin aspart (NovoRapid®)|An injection of insulin aspart (NovoRapid®) 0.2 U/kg body weight under the skin just prior to a standard meal.
99616|NCT03407586|Diagnostic Test|Point-of-care STI testing|All participants underwent point-of-care STI testing (GeneXpert), and if diagnosed with a STI were offered immediate therapy, and expedited therapy, if indicated.
99617|NCT03407573|Biological|Administration of Red Cell|Transfusion of red cells dependent on haemoglobin level. Either transfused at haemoglobin of 7 or 9.
99618|NCT03407560|Device|SintLife|"Patients will be treated for degenerative diseases of the spine, such as lumbar stenosis, spondylolysis and spondylolisthesis, degenerative disc disease.~The fusion technique used will be the posterolateral arthrodesis of one or more vertebral levels included in the lumbosacral region (L1-S1), obtained by screws and bars, together with a preparation of the transverse processes treated with bone substitute in order to Sintlife obtain new bone formation and then spinal fusion. It is also possible to associate interbody fusion with the use of a cage."
99619|NCT03407547|Diagnostic Test|Electroencephalography|EEG is a device to measure brain activity via surface electrodes
99620|NCT03407521|Drug|Misoprostol|induction of abortion using misoprostol
99621|NCT03407521|Drug|isosorbide mononitrate|isosorbide mononitrate
99622|NCT03407521|Drug|Placebo|Placebo
99623|NCT03407508|Dietary Supplement|Comparison of Diets|Okinawan-based Nordic Diet and Control Diet
99624|NCT03407495|Drug|IOP Injection (MPB-1523)|one dose, once IV injection at Day 1
99625|NCT03407482|Drug|GDC-0853|Participants will receive 4 tablets of GDC-0853 orally BID.
99626|NCT03407469|Behavioral|Questionnaires|Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
99627|NCT03407456|Other|Gastroesophageal reflux symptoms questionnaire|Reflux Symptom Questionnaire, 7-day recall (RESQ-7).
99628|NCT03407443|Other|Exposure to Make the Connection messages|Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
99629|NCT03407443|Other|Active Control Group|Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
99630|NCT03407430|Drug|Pregabalin|During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.
99631|NCT03407430|Drug|Placebo|During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
99632|NCT03407417|Other|virtual technology - highly tailored|The app will first ask participants a short series of questions designed to assess their baseline risk for colon cancer. Highly tailored patient reminders will be customized using all 12 constructs.
99634|NCT03407404|Combination Product|Ketamine-Midazolam|Continous intravenous sedation with 36mg of Midazolam and 900mg of Ketamine mixed in 50ml syringes as long as patient still requires sedation.
99635|NCT03407404|Combination Product|Morphine -Midazolam|Continous intravenous sedation with 54mg of Morphine Sulphate and 36mg of midazolam mixed in 50ml syringes as long as participant still requires sedation.
99636|NCT03407391|Other|None - observational|No intervention - observational only
99637|NCT03407378|Drug|IPT803|Administration of IPT803 three times a day for 12 weeks as add-on therapy to patient regular PD medication(s) or as a new therapy for drug naïve patients.
99638|NCT03407378|Genetic|Optional pharmacogenetic assessment|Blood sample of 3 milliliters for genotyping assessment (according to patient consent).
99639|NCT03407378|Other|Questionnaires|Personality, Health and Disease questionnaires completion during the study (Visits 1, 2, 3 and 4)
99640|NCT03407378|Other|Optional Blood-Oxygen-level Dependent functionalMRI|BOLD fMRI performed in a sub-group of patients, depending of randomization (exploratory)
99641|NCT03407378|Other|Motor Assessments before taking regular PD treatment|Regular PD treatment stopped 12 or 24 hours prior to Visits 2, 3 and 4 depending on the drug form (extended vs standard release). Motor assessments using UPDRS Part III are performed when patients are OFF regular PD treatment. Regular PD treatment is taken on site during the visit after the motor assessments are performed.
99642|NCT03407378|Other|Motor Assessments on regular PD treatment|Regular PD treatment is not modified before the visits. The motor assessments using UPDRS Part III are performed while the patient is on regular PD treatment.
99643|NCT03407365|Behavioral|10 Week Exercise Program|Subjects will complete a 10 week exercise program using DVD with instructions provided. Participants will have to do one session of exercise on 5 different days each week for a total of 5 sessions per week, for 10 weeks.
99644|NCT03407365|Behavioral|DVD Program After 10 Weeks|If the DVD program shows to help participants in Group 1, the program and DVD will be provided to Group 2 participants
99645|NCT03407352|Behavioral|Active Video Game Play|60 minutes of active video game play at a moderate intensity
99646|NCT03407352|Behavioral|Passive Video Game Play|60 minutes of passive video game play
99647|NCT03407339|Other|Shared Oral Care intervention|"One hour of teaching in oral hygiene and oral diseases to health care professionals at the intervention nursing homes.~The dentists will make an assessment of the elderly's oral hygiene at baseline, after three and six months using a mucosal and plaque score. During the six months, a dentist will be doing ward rounds at each nursing home in a specific time interval. In dialog with the resident and the healthcare professional, the dentist will present individual advice on how to perform oral care based on the resident's oral care routines, oral hygiene status, and the resident's physical and cognitive function level."
99648|NCT03407326|Dietary Supplement|Alternative RUTF|The alternative RUTF contains oat, peanuts, sugar, milk powder, vegetable oil as well as premix containing concentrated minerals and vitamins and emulsifier.
99649|NCT03407326|Dietary Supplement|Standard RUTF|Standard RUTF contains peanut paste, sugar, non-fat dried milk (NFDM), vegetable oil, a premix containing concentrated minerals and vitamins, and emulsifier.
99650|NCT03407313|Device|Rotational fractional resection|Single treatment of skin resection and focal lipectomy (removal of loose skin and fat)
99651|NCT03407300|Drug|Docetaxel|To evaluate the safety and efficacy of Docetaxel alone in stage III-IV NSCLC patients
99652|NCT03407300|Drug|Chinese traditional medicine XH1|To evaluate the safety and efficacy of Docetaxel combined with Chinese tradition medicine XH1 in stage III-IV NSCLC patients
99653|NCT03407287|Procedure|Peripheral Intravenous Analysis (PIVA)|Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV
99654|NCT03407287|Procedure|Standard of care invasive vascular monitoring|Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.
99655|NCT03407287|Procedure|Standard noninvasive vascular monitoring|Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.
99656|NCT03407261|Procedure|micro-osteoperforations|Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
99657|NCT03407235|Device|Computerized Laparoscopic Trainer|Gold standard laparoscopic trainer using simulated computerized equipment.
99658|NCT03407235|Device|Box trainer with eye patch|Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
99659|NCT03407222|Other|Text messages|Text messages which encourage the increment of daily step count
99660|NCT03407209|Other|consumption of local anesthetic measurement|consumption of local anesthetic measurement in both groups
99661|NCT03407196|Drug|Forxiga|Oral antidiabetics
99662|NCT03407183|Procedure|intradetrusor injection of botulinumtoxinA (Botox)|intradetrusor injection of botulinumtoxinA (Botox®, Allergan, Irvine, USA) to assess the efficacy of Botox in treatment of neurogenic bladder.
99663|NCT03407170|Biological|pembrolizumab|200 mg by IV infusion Q3W for up to 24 months
99664|NCT03407157|Dietary Supplement|Probiotic supplementation|Participants will take two capsules daily of Urex Plus VCap-5 (each containing 2.5 billion CFUs of L. rhamnosus and L. reuteri) and one lozenge of Blis K12 (1 billion CFUs of streptococcus Salivarius)
99665|NCT03407157|Other|Placebo|Participants will be asked to take 2 placebo capsules and 1 placebo lozenge daily from 25 weeks pregnancy
99666|NCT03407144|Biological|pembrolizumab|2 mg/kg intravenous (IV) up to a max of 200 mg (3 to 17 years of age) or 200 mg IV (18 to 25 years of age); cycle frequency Q3W
99667|NCT03407144|Drug|doxorubicin|"25 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~40 mg/m^2 IV on Days 1 and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~25 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
99668|NCT03407144|Drug|vinblastine|"6 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~6 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)"
99669|NCT03407144|Drug|dacarbazine|"375 mg/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)~375 mg/m^2 IV on Days 1 and 15 as part of AVD chemotherapy (cycle frequency: Q4W, Group 1)~250 mg/m^2 IV on Days 1 to 3 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
99671|NCT03407144|Drug|vincristine|"1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1, 8, and 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~1.5 mg/m^2 IV with maximum single dose 2 mg on Days 1 and 8 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
99672|NCT03407144|Drug|prednisone/prednisolone|"60 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)~40 mg/m^2/day orally divided in 3 doses on Days 1 to 15 as part of COPDAC-28 chemotherapy (cycle frequency: Q4W, Group 2)"
99673|NCT03407144|Drug|bleomycin|10 units/m^2 IV on Days 1 and 15 as part of ABVD induction therapy (cycle frequency: Q4W, Group 1)
99674|NCT03407144|Drug|etoposide|125 mg/m^2 IV on Days 1 to 5 as part of OEPA induction therapy (cycle frequency: Q4W, Group 2)
99675|NCT03407144|Radiation|Radiotherapy (RT)|RT administered daily, dose dependent on randomization group and disease response.
99676|NCT03407131|Procedure|Joint replacement surgery|Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
99677|NCT03407131|Procedure|Intramedullary nail fixation|Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
99678|NCT03407118|Drug|LY900014|Administered SC.
99679|NCT03407118|Drug|Insulin Lispro|Administered SC.
99680|NCT03407105|Biological|MDX-010|Specified dose on specified days
99681|NCT03407092|Other|ADAPT cohort|Thrombectomy with distal aspiration technique
99682|NCT03407092|Other|Stentriever Cohort|Thrombectomy with stent retriever
99683|NCT03407079|Other|Sucralose|Sucralose is an organochlorine and is approximately 600 times sweeter than sucrose. Participants will receive sucralose (approximately 4mg/kg/day) or placebo by mouth in a capsule for 28 days. This dose corresponds to the amount of sucralose contained in approximately 3 or 4 twelve ounce cans of commercially-available diet soda for a 70 kg adult.
99684|NCT03407079|Other|Placebo|Placebo capsule will be taken orally for 28 days
99685|NCT03407027|Drug|Quadratus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
99686|NCT03407027|Drug|Gluteus triamcinolone|40mg of triamcinolone and 10ml of levobupivacaine 0,25%.
99687|NCT03407027|Drug|quadratus without triamcinolone.|10ml of levobupivacaine 0,25%.
99688|NCT03407001|Procedure|Contrast-Enhanced Ultrasound|Undergo CEUS
99689|NCT03407001|Drug|Sulfur Hexafluoride Lipid Microspheres|Given IV
99690|NCT03407001|Procedure|Ultrasound|Undergo non-contrast US
99691|NCT03406988|Procedure|Autologous fat grafting|Implantation of small amount of autologous adipose tissue at the base of the finger to induce a rapid healing of the distally located DU
99692|NCT03406988|Procedure|Sham procedure|Local injection of 0.5ml saline solution after a simulated liposuction procedure.
99693|NCT03406975|Device|Overstitch|Endoscopic sleeve gastroplasty
99694|NCT03406962|Drug|MGTA-456|Hematopoietic stem cell transplantation will be done with the cell therapy product MGTA-456.
99695|NCT03406949|Biological|MGD009|B7-H3 x CD3 DART protein
99696|NCT03406949|Biological|MGA012|anti-PD-1 antibody
99697|NCT03406936|Drug|Daily interruption of midazolam|daily at 7 am midazolam infusion will be stopped spontaneous breath trial will be done
99698|NCT03406923|Other|Health literacy-psychosocial support|The intervention is based upon enhancing patient health literacy-related attributes by (1) addressing the barriers to patients' self-efficacy by working with the patient to minimize the barriers (2) clarifying the patient beliefs about diabetes and diabetes medications, and (3) developing personalized action plans. We will tailor the intervention to each patient, so, the details of the content of each session will depend on the individual's self-efficacy, beliefs in illness and medicines, and health literacy level obtained at baseline. In addition to the 45-minute scheduled sessions, patients will be able to call the clinical pharmacist on the phone during the 6-week session at their discretion, for patient-driven support for self-management of goals and skills.
99699|NCT03406897|Drug|Cholecalciferol|Oral Administration
99700|NCT03406897|Drug|Omega 3 fatty acid|Oral Administration
99702|NCT03406871|Drug|Regorafenib|One course will last 28 days. Oral administration at a dose of 80 mg/day, 120mg/day or 160 mg/day for 21 consecutive days, with a 1-week washout period.
99703|NCT03406871|Drug|Nivolumab|One course will last 28 days. Given once every 2 weeks at a dose of 3.0 mg/kg.
99704|NCT03406858|Biological|HER2Bi-Armed Activated T Cells|Given IV
99705|NCT03406858|Other|Laboratory Biomarker Analysis|Correlative studies
99706|NCT03406858|Biological|Pembrolizumab|Given IV
99707|NCT03406845|Behavioral|Chair-side mindfulness intervention|"Tailored mindfulness intervention to chair-side type, based from Mindfulness Based Cognitive Therapy (MBCT).~Health promotion based on the Health Enhancement Program (HEP)."
99708|NCT03406832|Drug|Nitroprusside Sodium|Intracoronary infusion 50~100μg each time (repeated)
99709|NCT03406832|Drug|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
99710|NCT03406832|Drug|Heparinized saline|Intracoronary infusion 2ml for single time
99711|NCT03406819|Drug|Nitroprusside Sodium|Intracoronary infusion 50~100μg each time (repeated)
99712|NCT03406819|Drug|Tirofiban Hydrochloride|Intracoronary infusion 10μg/kg for single time
99713|NCT03406819|Drug|Heparinized saline|Intracoronary infusion 2ml for single time
99768|NCT03406429|Device|SHAM rTMS|All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of 20Hz SHAM rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
99769|NCT03406416|Device|44Ch Bionic Eye Device|Prototype wide view suprachoroidal retinal prosthesis
99866|NCT03405623|Procedure|Dynamic needle tip positioning under ultrasound-guidance|The tip of needle is positioned under ultrasound-guidance using dynamic short-axis view.
99867|NCT03405623|Procedure|Conventional long-axis view|The tip of needle is positioned under ultrasound-guidance using conventional long-axis in-plane view.
99714|NCT03406806|Other|Gaitbox|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
99715|NCT03406806|Other|SprintSystem device|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
99716|NCT03406806|Other|NIH toolbox 4 meter walk|"The walking path will be set according to the directions of the NIH toolbox 4 meter clinic walk test which includes marking the beginning and end of the walking path. A standard manual stopwatch will be used to record time. The examiner will demonstrate the task then instruct the participant to Walk at a comfortable pace and count down by saying: 3, 2, 1, go. The stop watch will be used to time the amount of time it takes to walk between the cones. Subjects will complete 3 timed trials. The time will be recorded in the log. Simultaneously, the Sprint System [6] will be operated according to manufacturers instructions. The Gaitbox will be set up at the end of the 4 meter walking path at a height of 4 feet from the floor. Times/speeds will be recorded on log sheet."
99717|NCT03406793|Dietary Supplement|Standard MNP|Standard MNP, 15 micronutrients (Vitamin A 400 µg, vitamin D 5 µg, vitamin E 5 mg, vitamin C 30 mg, thiamine 0.5 mg, riboflavin 0.5 mg, niacin 6 mg, pyridoxine 0.5 mg, vitamin B12 0.9 mg, folate 150 µg, iron 10 mg, zinc 4.1 mg, copper 0.56 mg, selenium 17.0 µg and iodine 90 µg). Daily supplementation for 24 weeks.
99718|NCT03406793|Dietary Supplement|High zinc, low iron MNP|Same as group 1, except with 10 mg zinc instead of 4.1 mg and 6 mg iron instead of 10 mg. Daily supplementation for 24 weeks.
99719|NCT03406793|Dietary Supplement|High zinc, low/no iron on alternating days|Same as study group 1, except with 10 mg zinc instead of 4.1 mg, and 6 mg iron and no iron on alternating days instead of 10 mg. Daily supplementation for 24 weeks.
99720|NCT03406793|Dietary Supplement|Dispersible zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 24 weeks.
99721|NCT03406793|Dietary Supplement|Intermittent zinc supplement|10 mg zinc in a dispersible tablet. Daily supplementation for 14 days at baseline and 3 months, placebo tablet on all other days.
99722|NCT03406793|Dietary Supplement|Placebo powder|Daily provision of a placebo powder for 24 weeks.
99723|NCT03406780|Biological|CAP-1002|The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic and regenerative.
99724|NCT03406780|Drug|Placebo|Placebo
99725|NCT03406767|Other|GLA:D Canada Program|The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
99726|NCT03406767|Other|JointEffort Program|The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
99727|NCT03406754|Behavioral|rehabilitation programs|an 8-week multidisciplinary inpatient rehabilitation program
99728|NCT03406741|Behavioral|psychometric evaluation|Wechsler type composite scales (WISC)
99729|NCT03406741|Behavioral|neuropsychological evaluation|Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
99730|NCT03406728|Other|PDSAFEX|PDSAFEX is a week by week, progressive, exercise protocol that is followed. It lasts 12 weeks.
99731|NCT03406728|Other|CONTROL|Participants will be asked to maintain their day to day life as consistently as possible for the 12 week duration of the study.
99732|NCT03406728|Device|VIRTUAL REALITY|WorldViz Oculus Rift Move package (headset and software).
99733|NCT03406715|Drug|Nivolumab|Nivolumab (BMS-936558) is an anti-PD-1 antibody. It works by attaching to and blocking a molecule called PD-1. Induction Immunotherapy Phase (4 x 21 days cycles): Nivolumab on Day 1 of each cycle for 4 cycles. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: Nivolumab only on Day 1 of every 4 week period. Participants will continue to receive Nivolumab only on Day 1 of each additional 4 week period that they take part until their disease progresses. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
99734|NCT03406715|Drug|Ipilimumab|Ipilimumab is an antibody (a type of human protein) that is approved to treat patients with metastatic melanoma. In this study, the use of ipilimumab is investigational. Induction Immunotherapy Phase (4 x 21 days cycles): Ipilimumab on Day 1 of each cycle for 4 cycles. The Retreatment phase of the study may be available to participants whose doctor feels they would benefit from retreatment and if they qualify for this retreatment.
99804|NCT03406156|Drug|Venetoclax|tablet
99805|NCT03406143|Procedure|CGF injection|CGF injection subdermally to expanded skin at the density of 0.02ml/cm2.
99735|NCT03406715|Biological|Dendritic Cell based p53 Vaccine|Dendritic Cell based p53 Vaccine (Ad.p53-DC). The p53 vaccine will be made by inserting the p53 gene (a gene is a hereditary unit of all living organism within a cell) into a subset of the participant's own white blood cells. The insertion of the gene into their white blood cells will occur in the laboratory, after their cells have been extracted from their body through a procedure called leukopheresis (similar to dialysis). Induction Immunotherapy Phase (4 x 21 day cycles): Participants will receive the p53 vaccine on Days 1 and 15 of cycle 1 and then again on Day 8 of Cycle 2. Maintenance Immunotherapy beginning on Day 1 of Cycle 5: p53 vaccine three additional times (every 4 weeks over a 12 week period).
99736|NCT03406702|Drug|CX-8998|T-type calcium channel blocker
99737|NCT03406689|Drug|Nepafenac 0.1% Oph Susp|One drop of Nepafenac 0.1% will be instilled 45' prior to the IVI.
99738|NCT03406689|Drug|Nepafenac 0.3% Oph Susp|One drop of Nepafenac 0.3% will be instilled 45' prior to the IVI.
99739|NCT03406689|Drug|Artificial tear|One drop Artificial Tears will be instilled 45' prior to the IVI.
99740|NCT03406676|Drug|Methylene Blue|2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.
99741|NCT03406663|Behavioral|Group 1|"Patients will be instructed to daily adjust their dose of Gla-300 based on fasting SMPG values. Fasting SMPG will be measured daily by the patient before breakfast and any intake of antihyperglycemic agents.~Fasting SMPG in the range of~≥ 5.6 mmol/L, increase 1 unit of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change, < 4.4 mmol/L, reduce 1 unit of Gla-300 dose"
99742|NCT03406663|Behavioral|Group 2|"Fasting SMPG (median of the last 3 days including current day) in the range of~7.8 mmol/L, increase 6 units of Gla-300 dose, > 5.6 and < 7.8 mmol/L, increase 3 units of Gla-300 dose, > 4.4 and ≤ 5.6 mmol/L, no change,~3.3 and < 4.4 mmol/L, reduce 3 units of Gla-300 dose, < 3.3 mmol/L or occurrence of ≥ 2 symptomatic or 1 severe hypoglycemic episode in the preceding week, reduce 3 units of Gla-300 dose or at the discretion of the investigator"
99743|NCT03406650|Drug|Neoadjuvant and adjuvant durvalumab|Neoadjuvant durvalumab 1500 mg q3w for 4 cycles Adjuvant durvalumab 1500 mg q4w for 10 cycles
99744|NCT03406637|Device|BPK-S Integration|primary total knee endoprosthesis
99745|NCT03406624|Procedure|Biopsy|Biopsies will be taken from disc and / or bone during elective lumbar fusion surgery or disc herniation surgery
99746|NCT03406611|Drug|OT-58|OT-58 sterile solution for subcutaneous injection
99747|NCT03406611|Drug|Placebo|Normal saline for subcutaneous injection
99748|NCT03406598|Other|Patients in shock|Analysis of sublingual microcirculation by nurses in ICU patients in shock to predict needs for fluid challenge, vasopressors or transfusion.
99749|NCT03406585|Drug|ProTrans: Allogeneic transplantation with WJMSCs|The IP is a cell suspension with MSC's procured from donated Wharton's Jelly from umbilical cord tissue and expanded in adherent culture over maximum of 3 passages. The treatment is allogenic.
99750|NCT03406585|Drug|Placebos|Placebo treatment
99751|NCT03406572|Device|HFHO Group|"Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~Brand name: Airvo 2"
99752|NCT03406572|Device|Standard O2|Standard oxygen therapy
99753|NCT03406559|Other|orthodontic treatment|fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion,
99754|NCT03406546|Drug|Dexmedetomidine|Dexmedetomidine was used as a sedation agent with less side effect on respiratory system.
99755|NCT03406546|Drug|Remifentanil|Remifentanil was used to prevent cough induced by bronchoscopy.
99756|NCT03406546|Device|Laryngeal mask|Laryngeal mask was used to ensure respiration function during general anesthesia.
99757|NCT03406533|Drug|Midazolam|Midazolam is used as a common medication for sedation in all groups.
99758|NCT03406533|Drug|Dexmedetomidine|Dexmedetomidine is used for sedation in bronchoscopy with less impact on respiration.
99759|NCT03406533|Drug|Remifentanil|Remifentanil is used for analgesia to prevent bronchoscopy induced cough.
99760|NCT03406533|Drug|Fentanyl|Fentanyl is another opioid drug used for analgesia to prevent bronchoscopy induced cough.
99761|NCT03406533|Drug|Propofol|Propofol is used for sedation with high efficacy but more side effect on respiration than dexmedetomidine.
99762|NCT03406520|Device|Chlorhexidine-impregnated disk|The chlorhexidine-impregnated sponge, named biopatch, is a protective disk (2.5 cm x 0.7 cm), which is hydrophilic polyurethane absorptive foam with chlorhexidine gluconate, in average of 86.8mg per disk
99763|NCT03406507|Biological|ALXN1210|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
99764|NCT03406494|Other|Early multicomponent physical therapy program|"Positioning (upright bed standing; turning, moving on bed).~Peripheral muscle strength training (active or passive full range of motion, lower extremities ergometer cycling).~Respiratory muscle training (supine abdominal breathing training).~Neuromuscular electrical stimulation (NMES) on target muscles (bilateral bicipital muscles, quadriceps femoris muscles and rectus femoris).~Gut rehabilitation (midfrequency NMES; abdominal manual or vibration massage)."
99765|NCT03406468|Radiation|Radiotherapy|Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS (stereotactic radiosurgery)) are allowed if these are standard for a certain location or palliative indication in the body.
99766|NCT03406442|Procedure|Transpterygoid approaches|All patients will be operated by transpterygoid approaches which is classified into 5 major types.Type A involves thinning of the pterygoid process to access to Pterygopalatine fossa. Type B involves the removal of the medial and anterior aspect of the base of the pterygoid process to access the lateral recess of sphenoid sinus. Type C involves removing the base of the pterygoid plates to reach the petrous apex, Meckel's cave, or cavernous sinus. Type D requires removal of the pterygoid plates to access the infratemporal fossa. Type E requires the removal of the medial pterygoid plate or the entire pterygoid process, and the medial third of the Eustachian tube to acessof the lateral nasopharynx
99767|NCT03406429|Device|Active rTMS|All study participants will receive one block of active rTMS. Each block will consist of daily sessions of 20Hz active rTMS delivered to the left dorsolateral prefrontal cortex (dlPFC) over five days (Monday through Friday).
99770|NCT03406403|Device|Laryngeal mask airway|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
99771|NCT03406403|Drug|Magensium sulphate|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
99772|NCT03406403|Other|Control group (closure of anesthetics)|After obtaining approval of the ethics committee of Kasr Al Ainy Hospitals and informed written consents from the patients, this study will be performed on 20 patients in Kasr Al Ainy Hospitals with ASA physical status I, II and ages between 18 and 60 years undergoing undergoing supratentorial tumours excision under general anesthesia
99773|NCT03406390|Procedure|Pterygium surgery|The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
99774|NCT03406377|Drug|OPK-88003|OPK-88003 subcutaneous injection
99775|NCT03406377|Drug|Placebo|Placebo subcutaneous injection
99776|NCT03406364|Drug|MG005|"Phase I:~Eligible patients will receive different dosages of GW5074 in 1 of the 3 dose cohorts plus 200 mg of sorafenib. Dose cohorts will be escalated sequentially from Cohort 1 at 750 mg QD GW5074 plus 200 mg QD sorafenib to Cohort 2 at 1500 mg QD GW5074 plus 200 mg QD sorafenib, and Cohort 3 at 750 mg BID GW5074 plus 200 mg QD sorafenib. Owing to the fact that there is no previous human experience for GW5074, Cohort 1 will include a monotherapy stage with 750 mg QD GW5074 prior to administration of the GW5074 and sorafenib combination to initially assess the safety of GW5074 monotherapy.~Phase IIa:~Following the MTD level determined at Phase I, the efficacy and safety profiles will be investigated in approximate 15 patients to achieve at least 12 evaluable patients. The enrolled patients at Phase IIa will be instructed to follow the chosen dosage regimen of MG005 for ≥168 days. Concurrent administration with 200 mg of sorafenib once daily will be implemented for each patient."
99777|NCT03406351|Other|Observational|Observational deep phenotyping physiological readouts
99778|NCT03406338|Procedure|Fasciectomy|Surgical excision of Dupuytren cords causing finger joint contractures. Surgery done under regional or general anesthesia. Additional procedures (such as capsulotomy or skin graft) done if surgeon deemed necessary.
99779|NCT03406338|Drug|Collagenase Clostridium Histolyticum|Injection of Collagenase into the Dupuytren cord after local anesthesia (nerve block) followed 24-48 hours later by finger manipulation after local anesthesia
99780|NCT03406312|Diagnostic Test|Post Prandial Hypoglycemia test|three test assessing hypoglycemia will be used: liquid mixed meal tolerance test, solid mixed meal tolerances test, continuous glucose monitoring
99781|NCT03406299|Drug|Tegafur|Tegafur(S-1) 35 mg/m2/b.i.d., day 1 - 7 (maximum dose: 120 mg/day)
99782|NCT03406299|Drug|Leucovorin|Leucovorin 30 mg/b.i.d., day 1-7
99783|NCT03406299|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 in 250 mL of 5% Glucose, given as 2-hour intra- venous infusion, day 1
99784|NCT03406299|Drug|Gemcitabine|"Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate (, 10 mg/m2/min) infusion, day 1; After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin. in SLOG arm.~Gemcitabine 1000 mg/m2 in 100 mL of normal saline, IV drip for 30 mins on D1 and D8 ，in GC arm"
99785|NCT03406299|Drug|Cisplatin|Cisplatin 25 mg/m2 in 250ml of normal saline, IV drip for 2 hours on D1 and D8
99786|NCT03406286|Drug|Tolvaptan|
99787|NCT03406273|Radiation|Cerebral Spinal (CS) radiation|Surgery plus Cerebral Spinal (CS) radiation
99788|NCT03406273|Radiation|Focal radiotherapy (SRS)|Surgery plus focal radiotherapy (stereotactic radiosurgery to the tumor bed [SRS])
99789|NCT03406260|Drug|Lasmiditan|Administered orally.
99790|NCT03406260|Drug|Placebo|Administered orally.
99791|NCT03406247|Drug|Nivolumab|"Patients in cohorts 1 and 1bis will be administered Nivolumab 240 mg every 2 weeks during 3 first months and then 480 mg every 4 weeks during 3 months Patients in cohorts 2 and 2bis will be administered~- nivolumab 240 mg every 2 weeks during 6 months"
99792|NCT03406247|Drug|Ipilimumab|"Patients in cohorts 2 and 2bis will be administered~- ipilimumab 1mg/kg IV every 6 weeks during 6 months"
99793|NCT03406234|Other|No intervention.|Cross-sectional observation without interventions.
99794|NCT03406221|Behavioral|Information Communication Technology Continuum of Care Service|Mobile phones were made available to community health workers in the intervention arms that integrated a comprehensive set of functions to assist them in their duties, including registration and tracking of beneficiaries, automated scheduling of home visits, provision of health information through videos, guided protocols for conducting home visits through checklists, a feature to track child immunizations, and supervisory tools.
99795|NCT03406221|Other|Control Condition|Standard of care
99796|NCT03406208|Behavioral|Stress and Symptom Management Program 1|The Stress and Symptom Management Program 1 (SMP1) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
99797|NCT03406208|Behavioral|Stress and Symptom Management Program 2|The Stress and Symptom Management Program 2 (SMP2) introduces and reinforces stress and symptom management skills. The program consists of 8 weekly sessions (90 minutes each), delivered through live videoconferencing.
99798|NCT03406195|Device|Transcranial magnetic stimulation (TMS)|TMS paradigm called theta burst stimulation
99799|NCT03406169|Drug|Sildenafil 25 MG Oral Tablet|twice a day dosing
99800|NCT03406169|Drug|Pentoxifylline|400mg twice a day
99801|NCT03406169|Other|Placebo|placebo twice a day
99802|NCT03406156|Drug|Obinutuzumab|intravenous
99803|NCT03406156|Drug|Bendamustine|intravenous
99807|NCT03406130|Procedure|Orthodontic Procedure|"Damon self-ligating systems (Ormco) were used for all patients. The patients were allowed to choose between clear and metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in. copper nickel-titanium Damon arch forms were placed. The subjects returned every 2 wk, and the archwires were changed only when full bracket engagement were achieved. The sequence of archwires was the following: 0.018-in., 0.014 × 0.025-in., and 0.018 × 0.025-in. copper nickel-titanium archwires were used for alignment, while 0.019 × 0.025-in. stainless-steel archwires were used for fine-tuning. Following the alignment steps, impressions were taken, and a blinded senior orthodontist validated appliance removal or provided advice regarding further adjustments.~Alginate impressions were taken after the removal of the appliances, and fixed and removable retainers were placed."
99808|NCT03406130|Procedure|Piezocision surgery|The piezocision surgery was performed 1 week after orthodontic appliance placement. The surgical protocol was performed as described by Dibart and al. (Dibart et al. 2009). However, to avoid bias, hard and soft tissue augmentations were not considered. The patients received local anesthesia in both arches; vertical interproximal microincisions were created below each interdental papilla. In cases of root proximity (i.e., <2 mm of interdental bone), this procedure was not performed. These incisions were kept to a minimum (varying from 5 to 8 mm). Next, with a vertical piezoelectric device, 5-mm-long and 3-mm-deep corticotomies were made, and no subsequent sutures were required. The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intake for 1 wk. Anti-inflammatories were prohibited to avoid interference with the RAP.
99809|NCT03406117|Drug|HAT1|All the participants will have the test product applied to the appropriate test sites by trained study staff. The study was conducted on a mixed population comprising of normal subjects, and patients with atopic dermatitis and active plaque psoriasis.
99810|NCT03406117|Other|Saline Solution|Only for CIT portion of the study. Participant will have product applied topically on site by the trained study staff.
99811|NCT03406104|Genetic|GS010|Different procedures will be performed in order to assess the safety and efficacy of GS010 up to 5 years post-treatment
99812|NCT03406104|Other|Sham Intravitreal Injection|Different procedures will be performed in order to assess the safety and efficacy of GS010 up to 5 years post-treatment
99813|NCT03406091|Drug|Plerixafor|Plerixafor (AMD3100) is a selective, reversible inhibitor of the receptor chemokine (C-X-C motif) receptor 4 (CXCR4) and prevents binding of its cognate ligand stromal cell derived factor-1α (SDF-1α), also known as chemokine (C-X-C motif) ligand 12 (CXCL12) [3]. CXCR4 is a co-receptor, along with CD4, for the binding of human immunodeficiency virus, type 1 (HIV-1) to its receptor cells.
99814|NCT03406078|Biological|Tezepelumab|Tezepelumab subcutaneous injection
99815|NCT03406078|Other|Placebo|Placebo subcutaneous injection
99816|NCT03406065|Dietary Supplement|Sodium bicarbonate supplementation|The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 25 to 100 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
99817|NCT03406065|Dietary Supplement|Placebo treatment|The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
99818|NCT03406052|Behavioral|Smartphone-Assisted MB-CBT|Experimental subjects will receive a mindfulness-based CBT online software program workbook (in collaboration with Nex J Systems, Inc.) accessible online. Exposure to and interaction with the online workbook is combined with health coaching (duration of 24 total hours) primarily delivered in phone and software interactions. In addition, each participant will be given a Fitbit-HR Charge, a wearable bracelet that assesses physical steps and 24 hour heart rate in 5 second (averaged) durations (with related access to software that permits daily tracking).
99819|NCT03406039|Behavioral|Integrated Online CBT and MI|The treatment condition will have access to 12 treatment modules and have 8-weeks to complete them. The content of all modules is derived from Cognitive Behavioural Therapy and Motivational Interviewing. Through module engagement, young adults will identify goals related to alcohol use and mood, learn strategies to cope with alcohol cravings, triggers, and social pressures, and learn how to prevent relapse. There will also be several modules to target anxiety and depression, focusing on strategies designed to help reduce negative thinking and worry, increase behavioural activation, and increase self-care (e.g., sleep hygiene).Participants will have immediate access to all modules, and it will be recommended that they work through the modules sequentially.
99820|NCT03406026|Other|Balance System Protocol Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.
99821|NCT03406026|Other|Control Stroke|This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
99822|NCT03406013|Behavioral|Written Information|Receive written information on diet and exercise relevant to older men with prostate cancer
99823|NCT03406013|Behavioral|Prescription|Participants receive tailored exercise prescription and tailored diet recommendations
99824|NCT03406013|Behavioral|Technology|Participants receive motivational text messages and can electronically log and track their exercise and diet habits
99825|NCT03406013|Behavioral|Coaching|Participants receive access to an exercise and diet coach to provide advice by phone and/or email
99826|NCT03406000|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: Solution for Injection~Route of administration: Subcutaneous injection"
99827|NCT03405987|Diagnostic Test|Strain analysis by CMR|Strain analysis by CMR will be performed
99828|NCT03405974|Drug|Aspirin|Aspirin (acetylsalicylic acid)
99829|NCT03405974|Drug|Placebo|Placebo
100488|NCT03400839|Diagnostic Test|Sleepiness|"Assessment of sleepiness by the Epworth Sleepiness Scale"
99830|NCT03405961|Device|Carestream 3600 intra oral scan|"Carestream 3600 is CE marked intra oral scanner manufactured by Carestream Dental. It is already licensed for use in dentistry to produce digital study models. The scanner is 220 x 38 x 58 mm large and operates using video capture technology. It emits no radiation.~Carestream 3600 is connected to a computer via a USB port and a computer software (CS Model +) converts the scan into digital study models using trigonometric calculations. The software is then used to take measurements on the digital models and calculate PAR scores"
99831|NCT03405948|Drug|Intra muscular injection of Botulinum toxin|posture and gait analysis were performed before injection and 4 to 6 weeks after injection
99832|NCT03405935|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food.
99833|NCT03405922|Drug|Placebo 40 mL Saline 0.9%|Injection of 40 mL 0.9% saline
99834|NCT03405922|Drug|40 mL Ropivacain 0.5%|Ropivacaine Hcl 0.5% Injection 40 mL
99835|NCT03405909|Diagnostic Test|contrast enhanced ultrasound (CEUS)|CEUS with SonoVue following standardized protocol
99836|NCT03405909|Diagnostic Test|MRI|CE-MRI following standardized protocol
99837|NCT03405909|Diagnostic Test|Histology|diagnostic liver biopsy
99838|NCT03405896|Other|Turning|start to walk with normal speed, and then turn to approach the terminal under different angle.
99839|NCT03405883|Other|Vaginal swab + endometrial biopsy|In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.
99840|NCT03405870|Drug|Smoflipid|Administration of lipid injectable emulsion
99841|NCT03405857|Other|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
99842|NCT03405831|Drug|Ivabradine|Ivabradine, oral tablets, 5 mg, coated in gelatine capsules to ensure blinding, 1 capsule twice a day, for a period of 12 weeks
99843|NCT03405831|Drug|Placebo|Placebo, gelatine capsules to ensure blinding, 1 capsule twice daily, for a period of 12 weeks
99844|NCT03405818|Drug|Tavaborole 5% Topical Solution|topical solution for application to toenails
99845|NCT03405805|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|Vaccination with PCV13
99846|NCT03405792|Drug|Temozolomide (TMZ)|Patients will begin treatment with adjuvant TMZ at least 4 weeks but no more than 6 weeks from last dose of concomitant temozolomide or radiation therapy (the latter of the two). A minimum of 6 and maximum of 12 cycles of adjuvant TMZ will be given depending on tolerability and toxicity.
99847|NCT03405792|Device|Optune System|Patients will undergo 24-months of planned treatment with Optune therapy.
99848|NCT03405792|Drug|Pembrolizumab|Pembrolizumab will be given intravenously every 3 weeks beginning on Day 1 of Cycle 2 of adjuvant TMZ. Treatment with pembrolizumab every 3 weeks until first disease progression or unacceptable toxicities or 2 years, whichever comes first.
99849|NCT03405779|Procedure|Lung ultrasonography|Mechanically ventilated patients suffering from pulmonary diseases will undergo a lung ultrasonography during their stay in the intensive care unit (ICU)
99850|NCT03405753|Dietary Supplement|Aronia, washout and then placebo|Three tablets three times à day for three months then washout for three months, then three placebo tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
99851|NCT03405753|Dietary Supplement|Placebo, washout and then aronia|Three tablets three times à day for three months, then washout for three months, then three aronia tablets three times à day for three months. Blood samples and semen samples collected before and after each period of tablet intake.
99852|NCT03405740|Device|Remote Patient Management|"Transmissions will occur at three monthly intervals, with no in-clinic visits. If there is an actionable event on the remote transmission, patients will be seen at their closest community clinic. If this is a hub site, any device programming would be performed as per usual.~All patients will be required to follow up with their family physician at least annually, and their cardiologist at least every 2 years."
99853|NCT03405740|Device|Standard of Care|No intervention
99854|NCT03405727|Dietary Supplement|Oral dietary supplements|Protein enriched diet
99855|NCT03405714|Drug|Brivaracetam|"Pharmaceutical form: Solution for iv injection~Route of administration: intravenous use~Concentration: 10 mg/ml"
99856|NCT03405701|Procedure|IVM|Patients in IVM group will receive FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and the ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
99857|NCT03405701|Procedure|IVF|Patients in IVF arm will undergo controlled ovarian hyperstimulation with recombinant FSH (Menopur, Ferring) in GnRH antagonist protocol, treatment monitoring using ultrasound scans and blood tests. GnRH agonist will be used for final oocytes maturation. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
99858|NCT03405688|Procedure|Blood sampling|Extra blood samples taken for laboratory analysis
99859|NCT03405675|Other|SLAS 1|NA. Observational study, no interventions administered.
99860|NCT03405675|Other|SLAS 2|NA. Observational study, no interventions administered.
99861|NCT03405662|Device|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
99862|NCT03405662|Other|Sham Vielight Neuro Gamma|The Sham Vielight Neuro Gamma headset is identical to the active Vielight Neuro Gamma headset and intranasal light emitting diode (LED) except it has a power output of 0.
99863|NCT03405649|Behavioral|Group A|Muscle conditioning exercise for postpartum women and infants less than 20 weeks of age.
99864|NCT03405649|Behavioral|Group B|Muscle conditioning exercise for postpartum women and infants more than 20 weeks of age.
99865|NCT03405636|Device|Xeltis Pulmonary Valved Conduit|RVOT reconstruction
99868|NCT03405610|Behavioral|The Toolkit for Optimal Recovery after Injury|The Toolkit for Optimal Recovery after Injury (ToR) is a skills based mind body program that was designed to prevent the development of chronic pain and disability following an acute musculoskeletal injury (e.g., fracture). The program has 4 sessions and it is delivered via live video. Patients learn myth about recovery after injury, false and real pain alarms, the fear avoidance model and how to prevent the disability spiral, mindfulness based exercises and activity pacing.
99869|NCT03405597|Drug|Commercial Hepatitis B vaccine|Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6
99870|NCT03405597|Other|Standard Treatment|HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
99871|NCT03405584|Drug|Esomeprazole|Proton pump inhibitor
99872|NCT03405584|Drug|Amoxicillin|Antibiotic for H. pylori eradication
99873|NCT03405584|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
99874|NCT03405571|Other|No intervention|No intervention
99875|NCT03405558|Other|No intervention|As this is an observational study, we will only supervise testing and training sessions which were performed anyway during first rehabilitation as daily therapeutic routine
99876|NCT03405545|Behavioral|High-intenstiy interval training|High-intensity interval training is a training of 30 minutes involving 10 bouts of 1 minute high intensity cycling (80-90% of maximum heart rate) interspersed by 2 minutes rest.
99877|NCT03405545|Dietary Supplement|Insulinogenic, carbohydrate-rich drink|Subject will consume a hydrolyzed casein-based drink co-ingested with maltodextrin, during and post-exercise
99878|NCT03405532|Diagnostic Test|DM-ECC|Diabetes mellitus CPB
99879|NCT03405519|Procedure|Radiotherapy planning using both CT and MRI scans|Patients' radiotherapy will be planned using CT and MRI scans in order to establish the best methodology for planning of radiotherapy for nodal disease
99880|NCT03405506|Device|Quantitative Flow Ratio (QFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
99881|NCT03405493|Behavioral|Wake and Light Therapy|Participants will be helped to change the pattern sleep by depriving participants of sleep for one night. On Day 1 participants will be supported to stay up all night and the following day at the Hospital. Participants can go to bed by 5pm at home on Day 2. Participants will need to get up by about 1am and return to the hospital to be supported to stay awake. Participants will then go to bed at 7pm on Day 3. Participants will be asked to sleep until 3am and then stay awake at home until bed at 9pm on Day 4. Participants will then get up by 5am on Day 5 and stay awake until 11pm to resume a normal sleep routine waking by 7am on Day 6. Participants will also be given a light box to use each morning. For the light box, participants will be asked to sit about one foot away from a light box. You will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes. Participants may continue to have treatment as usual.
99882|NCT03405493|Behavioral|Sleep and Light Therapy|Participants will be given information and advice on how to get a good night's sleep. Participants will be also given a light box to use in the morning for 1 week. For the light box, participants will be asked to sit about one foot away from a light box. Participants will be free to have breakfast, read or use a computer while facing towards the light. Treatment with a light box will last 30 minutes when you get up. Participants may continue to have any treatment as usual (for example medication or talking therapies).
99883|NCT03405480|Other|Rehabilitation|Rehabilitation
99884|NCT03405467|Other|general and specific data|General and specific data collected
99885|NCT03405454|Drug|durvalumab|Durvalumab will be given at 1500mg fixed dose every 4 weeks for 24 months or until the appearance of significant treatment-related toxicity or disease progression
99886|NCT03405454|Drug|standard chemotherapy|chemotherapy treatment will be administered as per local institutional guidelines
99887|NCT03405441|Drug|JNJ-55375515 Dose Level 1|Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.
99888|NCT03405441|Drug|JNJ-55375515 Dose Level 2|Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.
99889|NCT03405441|Drug|JNJ-55375515 Dose Level 3|Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.
99890|NCT03405441|Drug|JNJ-55375515 Dose Level 4|Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.
99891|NCT03405441|Drug|JNJ-55375515 Dose Level 5|Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.
99892|NCT03405441|Drug|JNJ-55375515 Dose Level 6|Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.
99893|NCT03405441|Drug|Placebo|All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
99894|NCT03405441|Drug|JNJ-55375515|Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
99895|NCT03405428|Other|Allen test|Before induction, with firm occlusive pressure held on both the radial and ulnar arteries, the patient is asked to clench his or her fist several times until the palmar skin is blanched. The patient is then instructed to unclench the fist, and then ulnar artery pressure is released while maintaining occlusion of the radial artery. Overextension of the hand and wide spreading of the fingers should be avoided because it can lead to falsely abnormal results. The time required for palmar capillary refill is noted. An abnormal Allen test result was defined as a recovery time of more than 10 seconds.
99896|NCT03405428|Other|Radial artery diameter measurement by ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the radial artery will be scanned. The diameter of the radial artery will be measured and recorded.
99897|NCT03405428|Other|Ulnar artery doppler ultrasonography|Ultrasonography measurements will be performed with a linear probe before and after induction. The non-dominant hand of the patient will be fixed in the anatomical position on the arm chair. The wrist joint of patient will be extended to 30 degrees with a wrist pad. The USG probe will be transversally placed 2 cm proximal to the styloid process and the short axes of the ulnar arter will be scanned. The blood fow of ulnar artery will be measured and recorded.
99965|NCT03404960|Drug|Niraparib + Nivolumab|Niraparib 200mg PO daily on days 1-21 of each 21 day cycle Nivolumab 240mg IV days 1 and 15 of odd-numbered cycles; day 8 of even numbered cycles
99898|NCT03405415|Device|Blood glucose monitoring system and continuous interstitial glucose monitoring system|"At enrolment, participants are provided with BGM (Blood Glucose Monitoring) and CGM (Continuous Glucose Monitoring) systems. They will use the systems throughout the study. Participants will visit the study site three times. During the first visit, a standardized oral glucose tolerance test will be performed to ensure that participants do not have diabetes mellitus and to obtain glucose concentration data from people without diabetes mellitus during a glucose challenge. On another two days, participants will visit the study site for standardized breakfast and lunch meals to provide glucose concentration data under standardized conditions.~Outside of the study site visits, participants are asked to eat similar meals on two days to obtain glucose concentration data under repeated conditions that represent daily life.~During the study, participants are asked to document meals, physical activity and addition comments to provide context to the recorded glucose concentration data."
99899|NCT03405402|Procedure|Blood sampling|Extra blood sampling at the time of a blood transfusion in order to perform the laboratory analysis
99900|NCT03405389|Procedure|MatrixWAVE MMF System|Standard of care treatment of the injury and use of the MatrixWAVE MMF system to establish occlusion
99901|NCT03405376|Drug|Intravitreal aflibercept injection|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30G needle-attached syringe for branch retinal vein occlusion.
99902|NCT03405350|Procedure|Redon-sulfide baths|Encompassing whole body or isolated limbs - upper and/or lower limbs - temperature: 37-38 degrees Celsius, duration: 20 minutes.
99903|NCT03405350|Procedure|Partial Mud Baths|duration: 20 minutes, temperature 40-42 degrees Celsius
99904|NCT03405350|Procedure|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min.
99905|NCT03405350|Procedure|Terrain Therapy|walking, outdoors physical activities,
99906|NCT03405350|Procedure|Dry Massage|Depending on the needs of each patient it involved cervical (CC), thoracic (TH), or lumbar spine (LS).
99907|NCT03405350|Procedure|Laser Therapy|treatment parameters: sweeping, continuous, wavelength 808 nm, power 12 J, 400mV, duration 30s,
99908|NCT03405350|Procedure|Low-frequency Magnetic Field|duration 20 minutes, impulse shape - rectangular, induction 5 mT, frequency 20-50Hz,
99909|NCT03405350|Procedure|Ultrasonotherapy|treatment parameters: 800kHz/6cm2 head, ultrasound impulse wave: 2ms - impulse, 9ms - break, dose 0.5-0.6 W/cm2 over 6 minutes,
99910|NCT03405350|Procedure|Cryotherapy|ventilator, treatment duration 2-3 minutes, temperature - 80 to - 110 degrees Celsius,
99911|NCT03405350|Procedure|Electrotherapy|Bernard's diadynamic currents - treatment parameters: DF1 CP4 LP4, Nemec interference currents (frequency range 0-100Hz), percutaneous electrostimulation (TENS) - rectangular impulse currents, impulse duration 0.2ms, frequency 40Hz, regulated current 0-100mA,
99912|NCT03405350|Procedure|Light Therapy|blue filter Sollux lamp, radiation distance 30-40 cm, duration 15 minutes, Bioptron lamp - radiation distance 10 cm, duration 5-10 minutes
99913|NCT03405337|Drug|FVIII products|Adynovate, Eloctate, Afstyla, Kovaltry
99914|NCT03405337|Drug|Conventional FVIII replacement therapies|Advate, Kogenate FS, Helixate, Novoeight, Nuwiq, Recombinate, Xyntha
99915|NCT03405324|Device|tDCS|a single session of tDCS over the primary motor cortex with constant current of 2mA intensity will be applied for 20 minutes with a 5-second ramp phase at the beginning.
99916|NCT03405324|Device|sham tDCS|sham tDCS
99917|NCT03405311|Device|Rivanna Accuro 3D Ultrasound Device|The treatment group (Group 1: Ultrasound and Epidural) will receive epidural analgesia using ultrasound pre-procedural scan with the ACCURO device
99918|NCT03405311|Other|Palpation|The control group (Group 2: Epidural) will receive the 'Blind approach/palpation', which is using palpation in administering labor epidural analgesia. Additionally, anesthesiologist will scan patient's back with Accuro device in turned off mode
99919|NCT03405298|Behavioral|Educational Material|Educational material is in the form of a brochure
99920|NCT03405298|Behavioral|Supplemental Collaborative Care|Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider
99921|NCT03405285|Device|Connected Catheter|The Connected Catheter is a fully internal, urethral-indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization, including neurogenic lower urinary tract dysfunction (NLUTD - e.g. due to spinal cord injury). The CoCath is a sterile, single-extended-use device that resides fully internally to the male lower urinary tract (urethra + bladder neck) for an intended service life of up to 29 days per Catheter.
99922|NCT03405272|Biological|Recombinant Anti-EGFR Monoclonal Antibody（SCT200）|Experimental: recombinant anti-EGFR monoclonal antibody（SCT200） Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
99923|NCT03405259|Device|Super Seal® Desensitizer|Single dose professional application.
99924|NCT03405259|Device|Acclean® Fluoride Varnish|Single dose professional application.
99925|NCT03405246|Behavioral|KIDFIT HEALTHY|KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.
99926|NCT03405246|Behavioral|KIDFIT SAFE|KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
99927|NCT03405233|Procedure|Double vein cuffed ePTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around both ends of PTFE Graft
99928|NCT03405233|Procedure|single vein cuffed eTFE graft both at the inflow and outflow ends|Vein cuff is obtained from a segment of one of the arm veins (cephalic or basilica) after incising it longitudinally and wrapped around the venous end of PTFE Graft
99929|NCT03405233|Procedure|ePTFE graft without any cuff|anastmosis between arterial and venous side usinf non cuffed ePTFE graft
100033|NCT03404492|Other|Stress echocardiography|A stress echocardiography will be performed in addition to the traditional patient care
99930|NCT03405220|Behavioral|Self affirmation, 10 items, written examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
99931|NCT03405220|Behavioral|Self affirmation, 10 items, no examples|"Participants will complete the 10 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
99932|NCT03405220|Behavioral|Self affirmation, 10 items, imagined examples|"Participants will complete the 10 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
99933|NCT03405220|Behavioral|Self affirmation, 5 items, written examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
99934|NCT03405220|Behavioral|Self affirmation, 5 items, no examples|"Participants will complete a 5 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
99935|NCT03405220|Behavioral|Self affirmation, 5 items, imagined examples|"Participants will complete a 5 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
99936|NCT03405220|Behavioral|Self affirmation, 3 items, written examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to provide written examples for each item they respond yes to."
99937|NCT03405220|Behavioral|Self affirmation, 3 items, no examples|"Participants will complete a 3 item self-affirmation kindness quiz and will not be asked to provide examples for any items they respond yes to."
99938|NCT03405220|Behavioral|Self affirmation, 3 items, imagined examples|"Participants will complete a 3 item self-affirmation kindness quiz and will be asked to imagine examples for each item they respond yes to."
99939|NCT03405207|Drug|Vitamin D3 50000 UNT Oral Capsule|Holick's protocol of treating vitamin D deficiency lasting for 8 weeks
99940|NCT03405207|Drug|Placebo oral capsule|identical as active drug providing by pharmaceutical company unless it is placebo
99941|NCT03405194|Drug|Elvitegravir, Cobicistat, TAF, FTC|Started on day of HIV diagnosis
99942|NCT03405194|Drug|Efavirenz, TDF, and 3TC|Started on day of HIV diagnosis
99943|NCT03405181|Other|Training with additional weight|The infants will be positioned in a reclined position. A bracelet with an additional weight (20% of the total mass of the upper limb) will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches it. After reaching, the object will be carefully removed and resubmitted in order to elicit a new movement. The interval between each presentation will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
99944|NCT03405181|Other|Training without additional weight|The infants will be positioned in a reclined position. A bracelet without the additional weight will be placed on both wrists. The training will happen 2x/week, during 4 weeks (8 sessions). An object will be used to stimulate the reaching behavior, which will be displayed by the examiner (positioned in front of the infant), and presented in the midline at shoulder height, considering the distance from the arm's length of the infant to the height of the wrist. The physiotherapist will draw the attention of the infant to the object, moving it momentarily so that the infant perceives it and reaches the object. After reaching, the object will be carefully removed (or picked up) and resubmitted in order to elicit a new movement. The interval between each presentation of the object will be of approximately 5 seconds. At least 10 movements will be stimulated. If the infant does not achieve the 10 reaches within the maximum interval of 15 minutes, the session will be terminated.
99945|NCT03405168|Drug|Moxifloxacin Hydrochloride 400mg Tablet|Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.
99946|NCT03405155|Biological|Nivolumab|Given IV
99947|NCT03405142|Drug|Panitumumab-IRDye800|50 mg infusion
99948|NCT03405142|Drug|Lymphoseek|2 mCi, infusion
99949|NCT03405129|Behavioral|Phoenix|Phoenix cessation app
99950|NCT03405129|Behavioral|NRT order button|Ability to order NRT through smartphone app
99951|NCT03405129|Behavioral|Factoid|Factoid app
99952|NCT03405103|Behavioral|Striving|
99953|NCT03405103|Behavioral|Boning-Up|
99954|NCT03405103|Behavioral|Personal Choice|
99955|NCT03405090|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer
99956|NCT03405090|Drug|Combivent|0.5 mg ipratropium bromide + 2.5 mg salbutamol will be inhaled via nebulizer
99957|NCT03405077|Behavioral|IPT Online Training|"First, college mental health clinicians will complete baseline online questionnaires and deliver their usual treatment to 1 or 2 clients with symptoms of eating disorders. Then, they will complete the guided online training program and post-training assessments. Next, they will treat 1 or 2 different clients with eating disorders and complete post-training assessments. As part of the baseline and post-training assessments, clinicians will complete a telephone-based simulation assessment with staff raters, in which the investigators will recreate a client session and rate how well the clinicians adhere to IPT in treating the simulated client. The guided on-line training program will ultimately be compared to the gold standard training."
99958|NCT03405064|Drug|Oral Levonadifloxacin/Linezolid Tablet|oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)
99959|NCT03405064|Drug|Intravenous Levonadifloxacin/Linezolid Infusion|IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)
99960|NCT03405025|Procedure|Endoscopic ultrasound guided radiofrequency ablation|To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.
99961|NCT03405025|Device|ultrasound|ultrasound
99962|NCT03404999|Other|clinical decision support|Decision support system (see description of hypertension decision support system alerts and order sets for details)
99963|NCT03404986|Procedure|ureteroscopy|The patients will be subjected to rigid ureteroscopy
99964|NCT03404986|Radiation|Ultrasonography|The patients will be subjected to Ultrasonography
99966|NCT03404960|Drug|Niraparib + Ipilimumab|Niraparib 200mg PO daily on days 1-21 of each 21 day cycle Ipilimumab 3mg/kg IV day 1 of each cycle, for the first 4 cycles only
99967|NCT03404947|Dietary Supplement|Ethanol|For one exercise session, participants will be asked to ingest a quantity of ethanol (in the form of vodka) sufficient to maximally stimulate liver alcohol metabolism.
99968|NCT03404934|Device|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
99969|NCT03404921|Procedure|ESTD|During the ESTD procedure,after marking and submucosal injection, incisions were made at both the anal and oral sides of the lesion, and the submucosa under the lesion was then dissected to create a tunnel between the distal and proximal incisions. When the endscope reached the lower incision, the distal end of the esophageal lumen could be visualized , then two lateral mucosal incisions were made, thus completing the ESD procedure.
99970|NCT03404921|Procedure|ESD|The ESD procedure involved marking,injection,circumferential cutting, submucosal dissection.
99971|NCT03404908|Procedure|TAP (transversus abdominis plane block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).
99972|NCT03404908|Procedure|QL (quadratus lumborum block)|the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
99973|NCT03404908|Drug|Ropivacaine|In both groups (TAP&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)
99974|NCT03404908|Device|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
99975|NCT03404908|Drug|paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
99976|NCT03404908|Drug|metamizole|Intravenous metamizole will be used (1.0 gram), up to 4 grams per day
99977|NCT03404908|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
99978|NCT03404908|Drug|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
99979|NCT03404895|Device|Conventional Therapy|Local wound care consists of at least once daily dressing Occasionally, a limited bedside debridement is indicated to excise small quantity of devitalized tissues and to provide better drainage. Antibiotic therapy including both gram-positive and gram-negative coverage when the DFU appears infected is guided by wound cultures and when necessary, Infectious Disease consultation. Debridement and amputation will be performed as clinically indicated. To promote healing after the more acute processes have been addressed, pressure offloading is frequently helpful in the healing of DFU. Pressure offloading treatment ranges from special dressings and devices to special diabetic foot wares. Offloading will be utilized as indicated.
99980|NCT03404895|Device|Venous Stent(s)|After PVOO is confirmed by venography and IVUS, and patient subject is randomized to conventional therapy and stent placement, stent placement is performed immediately at the same sitting.
99981|NCT03404882|Behavioral|Supportive/reminder text messaging plus peer support|Regular supportive/reminder text message will be delivered to patients who will also receive face to face and interactive text message support from peer support workers
99982|NCT03404882|Behavioral|Supportive/reminder text messaging|Regular supportive/reminder text message will be delivered to patients who will NOT receive any face to face or interactive text message support from peer support workers
99983|NCT03404882|Behavioral|Peer support only|face to face support from peer support workers but no interactive or daily supportive/reminder text messages
99984|NCT03404869|Drug|ORL-1M - D-mannose|Oral ORL-1M
99985|NCT03404856|Drug|ORL-1G - D-galactose|Oral ORL-1G - D-galactose
99986|NCT03404843|Drug|Fasudil Hydrochloride|10 mg/mL vial of fasudil hydrochloride. 6 mL (60 mg) of fasudil hydrochloride are added to a 100 mL saline bag for delivery to subjects.
99987|NCT03404843|Other|Saline|100 mL saline bag.
99988|NCT03404830|Other|HIIT group, MICT group|"The HIIT program training:~5 minutes of heating will be done. The intervention will consist of a training in suspension (TRX) performing squats. The session will be divided into four four-minute intervals at an intensity of 90-95% of the maximum heart rate, followed by three-minute active rest intervals of 50-70%. This intensity will be assigned to each subject individually. After the training, there will be a return to calm of 10 minutes of exercises of joint range. There will be 2 weekly training, with three days between both training, for a period of 12 weeks.~The training of the MICT program:~5 minutes of heating will be done. Subsequently, participants will perform a squat training with the Suspension Training System (TRX) with an intensity close to 70% of their maximum heart rate maintained for 40 minutes. The session will conclude with a return to calm of 10 min of joint width and stretching."
99989|NCT03404817|Drug|Original formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
99990|NCT03404817|Drug|New formulation EMB-001|Single oral dose (720 mg metyrapone/24 mg oxazepam)
99991|NCT03404804|Drug|Amoxicillin|Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
99992|NCT03404791|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 will be placed for 21-day dosing cycles, with up to 7 doses per subject.
99993|NCT03404778|Device|Biomet Comprehensive Reverse Shoulder|Designed to eliminate the potential for scapular notching, this reverse shoulder system combines a a true locking mechanism that minimized wear and oxidative breakdown with a modular central screw for secure fixation.
99994|NCT03404765|Behavioral|Tai Chi|
99995|NCT03404752|Drug|Peg-Filgrastim|
99996|NCT03404739|Drug|Saline Solution|These patients will be given only one dose of ceftazidime at the start of POEM plus 2 doses of saline solution every 12 hours after the procedure.
99997|NCT03404739|Drug|Ceftazidime|These patients will be given ceftazidime 2g at the start of POEM plus additional 2 doses given every 12 hours after the procedure.
100034|NCT03404479|Drug|Diacerein|For 12 weeks, administered twice a day by oral.
100035|NCT03404479|Drug|Celecoxib|For 12 weeks, administered twice a day by oral.
100036|NCT03404466|Drug|Hypidone Hydrochloride tablets|Hypidone Hydrochloride tablets 10 or 20mg/day Study drug is to be given orally, twice daily, for 6 weeks
99998|NCT03404726|Drug|BAY2402234|BAY2402234 is a potent and selective small molecule inhibitor of dihydroorotate dehydrogenase. A solution of BAY2402234 will be available to initiate the trial and there are plans to transition to a tablet form of BAY2402234 once it becomes available. Both liquid and tablet formulations of BAY2402234 will be continually administered once daily by mouth in 28 day cycles.
99999|NCT03404713|Behavioral|Pathways to Health|Manualized sessions will follow an acceptance based behavioral weight loss treatment approach, including guided goal-setting and self-monitoring, identifying barriers and solutions, contingency management, stimulus control, dealing with setbacks and relapse prevention. Daily food and physical activity are logged and monitored. Parents learn strategies to support and facilitate their child's weight management via family-based change.
100000|NCT03404713|Behavioral|Be4U|This intervention is grounded in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), and Acceptance and Commitment Therapy (ACT). The core elements include regulating eating patterns, self-monitoring, developing openness to an acceptance perspective, fostering a willingness to accept distress, teaching defusion from distressing thoughts and feelings, practicing mindful awareness, fostering self-as-context, and directing patients towards clarifying and focusing on life values. Self-monitoring of eating behaviors and emotions are encouraged using a free app that facilitates electronic self-monitoring of eating patterns and symptoms. For participants who elect not to use this app, paper self-monitoring records are provided.
100001|NCT03404700|Behavioral|Egg breakfast|"Containing:2 Scrambled Eggs, 120 mL Skim Milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 30g Margarine, 18g Smuckers Strawberry Jam~10 g of Margarine, 18 g of Smuckers® Strawberry Jam"
100002|NCT03404700|Behavioral|Egg breakfast with high saturated fat|Containing:2 Scrambled Eggs, 120 mL 2% milk, 2 Slices Nature's Own Double Fiber Wheat Bread, 15 g Butter, 15g Smuckers Strawberry Jam
100003|NCT03404700|Behavioral|Cereal breakfast|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1 Slice Mrs. Bairds Extra Thin Bread, 35g Margarine, 10 g Smuckers Sugar Free Strawberry Jam
100004|NCT03404700|Behavioral|Cereal breakfast with high saturated fat|Containing: 1c Special K ready-to-eat (RTE) High Protein Cereal, 200 mL Silk Original Soy milk, 1/2 Slice Arnold Double Protein Whole Grain Bread, 15 g Butter
100005|NCT03404687|Radiation|ultrasound|for assessment of adnexal masses size and pattern
100006|NCT03404687|Diagnostic Test|cancer antigen 125 level|for prediction of malignancy
100007|NCT03404687|Radiation|Doppler|for detection of blood flow
100008|NCT03404674|Biological|CssBA|recombinant ETEC CssBA protein
100009|NCT03404674|Biological|dmLT|double mutant heat labile toxin
100010|NCT03404661|Drug|Synthetic Human Secretin|Subjects will receive a dose of 0.2ng/kg while the endoscope is positioned in the second portion of the duodenum.
100011|NCT03404648|Drug|C-11 choline PET tracer|C-11 choline PET tracer, One dose, totally 12-14 millicurie (mCi), intravenous administration while patient is lying on the table.
100012|NCT03404648|Drug|Gadobutrol|Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
100013|NCT03404648|Device|PET/MR scanner|C11-PET/MR and pelvic mpMRI scan for prostate cancer.
100014|NCT03404635|Drug|Apixaban|Apixaban as standard of care for VTE
100015|NCT03404622|Drug|IUCD|IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
100016|NCT03404609|Device|MagPro X100 by MagVenture|Participants in the rTMS group will receive MagPro X100 by MagVenture cortical stimulation condition.
100017|NCT03404596|Drug|Nicotine Patch|Nicotine patches and thorough education of the indications for the patch will be provided to all participants.
100018|NCT03404596|Behavioral|Counseling|Brief counseling sessions, 10-15 minutes each.
100019|NCT03404596|Behavioral|Smartphone|Ecological momentary assessment (EMA) assesses participants' moment-to-moment subjective experiences via self-report assessments on a smart phone. Participants will receive mindfulness strategies for 10 days pre- and post-quit via smart phone to aid in their cessation attempt. Text messages will be sent to provided study phones throughout the day. These messages will be short (1-3 minutes long) and will ask participants to do things like focus on the present moment, pay attention to their breathing, and be aware of their current thoughts.
100020|NCT03404596|Other|AutoSense|Participants will be asked to wear equipment throughout the day that will measure their physiology and smoking behavior. AutoSense unobtrusively and objectively collects physiological and behavioral data (i.e., negative affect (NA), self-regulatory capacity (SRC), and smoking) via wearable chest and wrist sensors.
100021|NCT03404583|Behavioral|Person-centred care at distance through an eHealth platform|Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
100022|NCT03404570|Drug|Dexmecamylamine HCl|Investigational drug
100023|NCT03404570|Other|Placebo|Oral tablet containing no active drug.
100024|NCT03404557|Other|Proteomic analysis|Proteomic analysis of Crohn's disease macrophages in response or not to Adherent-Invasive Escherichia coli
100025|NCT03404544|Drug|Carbetocin bolus|Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
100026|NCT03404544|Drug|Carbetocin infusion|Carbetocin 100 mcg intravenous as a 10 minutes infusion
100027|NCT03404531|Behavioral|Social Media Messages Intervention Group|The Social Media Messages Intervention Group will receive theoretically-grounded messages through social media in order to encourage participants to regularly access the newly developed, culturally-tailored website that includes information about treatment as prevention and pre-exposure prophylaxis.
100028|NCT03404531|Behavioral|Website Only Group|The Website Only group will have access to the newly developed, culturally-tailored website but will not receive social media messages.
100029|NCT03404518|Drug|Norco|Hydrocodone/Acetaminophen as first line therapy every 6 hours as needed for pain control
100030|NCT03404518|Drug|Ibuprofen|Ibuprofen as first line therapy every 6 hours as needed for pain control
100031|NCT03404505|Behavioral|Infant Achievements|Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.
100032|NCT03404505|Behavioral|Caregiver Education (CE)|Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
100037|NCT03404453|Diagnostic Test|Difficult airway incidence and prediction|Paediatric patients scheduled for surgery under general anaesthesia will be examined and a set up of airway prediction tests will be performed to predict the possibility of difficult airway
100038|NCT03404440|Other|L.Reuteri|
100039|NCT03404427|Behavioral|Normal sleep night|Usual hours of sleep
100040|NCT03404427|Behavioral|Sleepless night|Total sleep deprivation the first night
100041|NCT03404414|Drug|18F-FDG|"Single-dose 18F-FDG were injected into the patients before the PET/MR or PET/CT scans.~patients before the PET/CT scans"
100042|NCT03404401|Drug|BLI4700|Oral bowel preparation
100043|NCT03404401|Drug|Polyethylene glycol bowel preparation|Oral bowel preparation
100044|NCT03404388|Behavioral|Balance Training|4 days of a challenging balance training task
100045|NCT03404375|Device|Gauss Triton system|"The Triton system (Gauss Surgical, Inc., Palo Alto, CA) is a novel mobile monitoring platform that combines mobile computing with Gauss Feature Extraction Technology (FET) to directly assess Hb mass (mHb) absorbed by surgical sponges from an image. The device is an iPad like imaging device that will assess blood loss via imaging of the surgical sponges used in the surgery.~The device will be used to calculate blood loss on every patient enrolled in the study."
100046|NCT03404362|Procedure|Bone Metastases Pain treatment|Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
100047|NCT03404349|Behavioral|Mindfulness for Adolescence Course|There are 6 topics that will each be presented over 2 weeks for the 12 week intervention. Individuals will participate in a one to 1.5 hours, once a week intervention for 12weeks. Mindfulness is the practice of becoming aware of one's present-moment experience with compassion and openness as a basis for wise action. This curriculum is intended to strengthen attention and emotion regulation, cultivate wholesome emotions like gratitude and compassion, expand the repertoire of stress management skills, and help participants integrate mindfulness into daily life. Each lesson includes age-appropriate discussion, activities, and opportunities to practice mindfulness in a group setting.
100048|NCT03404336|Behavioral|Well-Being Therapy|Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.
100049|NCT03404336|Other|Control condition|Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.
100050|NCT03404310|Dietary Supplement|Zinc Sulfate|Participant will take one 220mg tablet twice daily for three months.
100051|NCT03404310|Other|Placebo (Gelatin Tablet)|Participant will take one tablet twice daily for three months.
100052|NCT03404297|Other|Locally sourced compression therapy|The dressing is made up of a zinc oxide impregnated compression wrapping
100053|NCT03404284|Behavioral|Family planning and infant immunization service integration|The approach involved integration of services through health surveillance assistant (HSA) outreach as well as through the health facility platform. The HSAs provided door to door FP services in their designated communities as well as provided integrated FP and Immunisation services at village clinics and outreach sessions. At outreach sessions, mothers were offered both routine infant immunization and family planning services (pills, condoms, injectables plus referrals for other methods). At health facilities, mothers who sought routine infant immunization services were offered same-day family planning services and those who seek family planning services are also screened for infant immunization schedule completion / need for infant immunization services. HSAs and health facility providers were trained on FP-immunization service integration and were monitored through regular supportive supervision visits.
100054|NCT03404271|Dietary Supplement|Beta-hydroxy beta-methylbutyrate|3 grams per day of the calcium salt form of beta-hydroxy beta-methylbutyrate (HMB).
100055|NCT03404271|Other|Resistance Training|Performing supervised resistance training three times per week.
100056|NCT03404271|Dietary Supplement|Protein Supplementation|Consuming a protein supplement daily.
100057|NCT03404271|Behavioral|Time-Restricted Feeding|Consuming all calories within a specified 8-hour period of time each day.
100058|NCT03404258|Other|Research Blood Sampling|Blood samples will be collected at specified time points and research assays will be performed.
100059|NCT03404245|Behavioral|Education, Fitbit/self-management app, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex paired with a self-management app, and remote counseling by a PT. Intervention will be received immediately.
100060|NCT03404245|Behavioral|Same intervention with a 6 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 6 month delay.
100061|NCT03404232|Device|Dynesys DTO device (Zimmer Spine, Inc.)|All patients receive posterior hybrid instrumentation.
100062|NCT03404219|Behavioral|Motivation and Skills Support (MASS)|Mobile phone-based application to support social skills and social motivation
100063|NCT03404206|Drug|Naproxen Sodium (Aleve, BAY117031)|220 mg x 2 tablets, oral, single dose
100064|NCT03404206|Drug|Ibuprofen (Advil)|200 mg x 2 tablets, oral, single dose
100065|NCT03404206|Drug|Placebo|Matching placebo, 2 tablets, oral, single dose
100066|NCT03404193|Drug|Decitabine|20 mg/m2 by vein over approximately 1 hour daily x 10 days on days 1-10 of each treatment cycle.
100067|NCT03404193|Other|Laboratory Biomarker Analysis|Correlative studies
100068|NCT03404193|Drug|Venetoclax|400 mg by mouth on Days 1-28 of the first cycle and Days 1-21 of all other cycles.
100105|NCT03403946|Device|Macintosh blade|Laryngoscopy with C-MAC PM in combination with Macintosh blade
100106|NCT03403946|Device|D-Blade|Laryngoscopy with C-MAC PM in combination with D-Blade
100069|NCT03404180|Procedure|Peripheral nerve block|All enrollees will have ultrasound-guided femoral and sciatic nerve blocks placed per current practice at research site. Single-injection obturator and lateral femoral cutaneous nerve blocks will also be performed.
100070|NCT03404180|Drug|Intravenous Sedatives|Intravenous sedation using propofol or dexmedetomidine will be administered.
100071|NCT03404180|Procedure|Lateral femoral cutaneous nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
100072|NCT03404180|Procedure|Obturator nerve blocks|After administration of intravenous sedation, lateral femoral cutaneous and obturator nerve blocks (in addition to the femoral and sciatic catheters) will be performed under ultrasound guidance.
100073|NCT03404167|Drug|AZD0914|Zoliflodacin (also known as AZD0914 and ETX0914), is a spiropyrimidinetrione antibacterial agent
100074|NCT03404154|Diagnostic Test|3D ultrasound|it describes the diagnostic test which is 3D us to diagnose the cause of postmenopausal bleeding
100075|NCT03404154|Procedure|Dilatation and curretage|it describes the surgical maneuver that will be made to diagnose cause of bleeding
100076|NCT03404141|Other|Parent craft|Midwife-guided classes for pregnant women about pregnancy and childbirth
100077|NCT03404141|Behavioral|Cognitive-Behavioral Therapy|Cognitive-Behavioral Therapy to reduce stress levels among pregnant women
100078|NCT03404128|Other|Questionnaires|Questionnaire for patient: satisfaction regarding rechargeable DBS battery Questionnaire for neurologist: seizure frequency, satisfaction regarding rechargeable DBS battery
100079|NCT03404115|Drug|Reproxalap Ophthalmic Solution (0.25%)|Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.
100080|NCT03404115|Drug|Reproxalap Ophthalmic Solution (0.1%)|Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.
100081|NCT03404115|Drug|Vehicle Ophthalmic Solution|Vehicle Ophthalmic Solution administered for approximately twelve weeks.
100082|NCT03404102|Device|Cu-IUD|Copper Intra-uterine device used as contraceptive method
100083|NCT03404089|Device|pharmacokinetic device|MON4STRAT system: bed-side pharmacokinetic device for drug concentration measurement
100084|NCT03404089|Device|pharmacokinetic device|High performance liquid chromatography, (HPLC), the reference methods HLPC tandem mass spectrometry or Ultraviolet are using
100085|NCT03404076|Diagnostic Test|Dual Energy CT|Dual Energy CT is performed for diagnostic evaluation in gastrointestinal stromal tumor (GIST) patients undergoing tyrosine kinase inhibitor (TKI) treatment
100086|NCT03404063|Drug|Cardiac Drug|"Patients in the AMI trial will receive one dose of IMP during the index procedure. The IMP administration will be performed by dedicated catheter into infarct related artery.~Active IMP consist of 30 000 000 of Wharton's jelly mesenchymal stem cells (WJMSCs) in each IMP dose prepared for patients randomized into active treatment group."
100087|NCT03404063|Drug|Placebos|"Patients randomized to the control group will receive 0.9% NaCl and 5% albumin injections (in the same volume as CardioCell) in the same manner.~Control group will receive the same amount of fluid used for WJMSCs preparation, without cells."
100088|NCT03404050|Other|Music and dance movement therapy|Theoretically, the intervention adopts a humanistic approach of person centred care highlighting the importance of maintaining and enhancing personhood for older people with dementia.
100089|NCT03404037|Diagnostic Test|serum endostatin level|"An oral (metoprolol 20 mg) was given to the patients with heart rates > 60 beats/minute and had no contraindications to beta-blockers, one hour before the scan. Sublingual nitroglycerin was given to all patients before CT examination. A 64-slice CT scanner (Sensation 64; Siemens Medical System, Germany) was used for imaging all subjects. All CT examinations were done during inspiratory breath holding.~Endostatin levels were measured using a sandwich ELISA kit according to the manufacturer's instructions endostatin ELISA kit (R&D Systems, Minneapolis, Minnesota, USA"
100090|NCT03404024|Biological|Stage 1-Low dose VM202RY|Day 0: 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY)
100091|NCT03404024|Biological|Stage 1-Middle dose VM202RY|Day 0: 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY)
100092|NCT03404024|Biological|Stage 1-High dose VM202RY|Day 0: 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY)
100093|NCT03404024|Drug|Stage 2-Placebo|Day 0: 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl)
100094|NCT03404024|Biological|Stage 2-Low dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY)
100095|NCT03404024|Biological|Stage 2-High dose VM202RY|Day 0: 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
100096|NCT03404024|Device|C-Cathez® Catheter|Day 0 (Stage 1-Low dose VM202RY): 1mg of VM202RY (4 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-Middle dose VM202RY): 2mg of VM202RY (8 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 1-High dose VM202RY): 3mg of VM202RY (12 sites of 0.25mg/0.5mL VM202RY) Day 0 (Stage 2-Placebo): 6mL of VM202RY vehicle (12 sites of 0.5mL 1.1% sucrose/0.9% NaCl) Day 0 (Stage 2-Low dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, low dose candidate-0.5mg VM202RY, 1mg VM202RY, 1.5mg VM202RY) Day 0 (Stage 2-High dose VM202RY): 6mL of VM202RY and VM202RY vehicle (total 12 site injections, high dose candidate-1mg VM202RY, 2mg VM202RY, 3mg VM202RY)
100097|NCT03404011|Other|Propylene glycol and Glycerol intake|Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.
100098|NCT03404011|Device|Mimicking intake|Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
100099|NCT03403998|Other|Exercises|The treatment will consist of an 8-week progressive exercise program of neck flexors and extensors exercises supervised by a physical therapist for 30-45 min twice a week per 8 weeks as described in Arm/group descriptions.
100100|NCT03403998|Other|Placebo|The placebo treatment will be for 30-45 min twice a week for 8 weeks, as for the intervention group. ( see details in arm description)
100101|NCT03403985|Drug|Calcium Hydroxide (Ca(OH)2)|Ca(OH)2 will be used in this group
100102|NCT03403985|Drug|Mineral Trioxide Aggregate|MTA will be used in this group
100103|NCT03403972|Drug|Vancomycin 250Mg Capsule|Investigators will compare simavastatin pharmacokinetics before and after the vancomycin PO multiple administration.
100104|NCT03403959|Device|light therapy|6 weeks morning treatment with bright light therapy in own home.
100108|NCT03403933|Drug|Didrogyl|"Calcifediol will be administered at a dose of 10 drops per day (as indicated for use) for 6 months or until vitamin D levels> 30 ng / ml are obtained.~Once these values have been obtained, the dosage can be reduced to a dosage of 4/5 drops of calcifediol (1 drop contains 5mcg of calcifediol) with the aim to maintain the plasma values of 25 (OH) D in a optimal range between 30-60 ng / ml during the 6 month of the duration of the study."
100109|NCT03403920|Other|Questionnaire|Profile Fitness Mapping Low Back Questionnaire
100110|NCT03403907|Other|Probiotic|twice a day for 4 months (Streptococcus thermophilus, Lactobacillus acidophilus, L.plantarum, L. paracasei, L. delbrueckii subs bulgaricus, Bifidobacterium breve, B.longus y B.infantis. y CD2).
100111|NCT03403894|Behavioral|Asking caregivers in their practice|A questionary is given to caregivers
100112|NCT03403881|Behavioral|Physical activity promotion + TAU|"Pedometer:~Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial.~The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial.~Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient.~All patients were receiving treatment as usual"
100113|NCT03403881|Behavioral|Control|Weekly call on general health aspects + treatment as usual
100114|NCT03403868|Diagnostic Test|conductance catheter|pressure volume loops are assessed via a special catheter (Conductance catheter)
100115|NCT03403855|Device|Rocket® IPC- Long External Length|Rocket® IPC- Long External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
100116|NCT03403855|Device|Rocket® IPC- Short External Length|Rocket® IPC- Short External Length Intervention. Evaluation of Long and Short External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions
100117|NCT03403842|Device|Sublingual sufentanil tablet system|Administration of sublingual sufentanil with a PCA
100118|NCT03403842|Device|Peridural catheter|Positioning of a peridural catheter with a continuous infusion of ropivacaine 0,2% 99 ml+sufentanil 50 mcg
100119|NCT03403842|Drug|PCA Morphine|Administration of endovenous morphine with a PCA
100120|NCT03403829|Drug|Gemcitabine|Gemcitabine maintenance chemotherapy
100121|NCT03403829|Radiation|standard chemoradiotherapy|standard chemoradiotherapy
100122|NCT03403816|Behavioral|Before School Physical Activity Program|BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
100123|NCT03403803|Device|Optune|"Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.~TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme."
100124|NCT03403790|Drug|Quetiapine|Oral (extended-release tablet)
100125|NCT03403777|Drug|Avelumab|AVELUMAB will be administered intravenously 10mg/kg every 2 weeks.
100126|NCT03403764|Other|Wellness Intention|
100127|NCT03403751|Drug|Reltecimod|Single IV administration of 0.5 mg/kg Reltecimod (at a concentration of 1 mg/mL)
100128|NCT03403751|Drug|0.9% Sodium Chloride Injection|Single IV administration of 0.5 mL/kg of 0.9% saline (volume equivalent with Reltecimod dosing schema)
100129|NCT03403738|Behavioral|Bounce Back Now|web/smartphone-based intervention for disaster victims
100130|NCT03403738|Behavioral|enhanced usual care|enhanced usual care with list of resources
100131|NCT03403725|Drug|MEN1309|MEN1309 solution for intravenous infusion once every 3 weeks
100132|NCT03403712|Drug|fosnetupitant/ palonosetron|intravenous fosnetupitant/ palonosetron (260 mg/0.25 mg) fixed-dose combination
100133|NCT03403712|Drug|netupitant/palonosetron|oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination
100134|NCT03403712|Drug|dexamethasone|Oral dexamethasone (12 mg)
100135|NCT03403699|Biological|Generation of inducible pluripotent stem cells|Generation of inducible pluripotent stem cells from peripheral blood cells.
100136|NCT03403686|Biological|blood draw|Blood sample will be obtained and CD34+ cells will be isolated for functional testing.
100137|NCT03403673|Other|Frailty assessment tools|There is evidence to suggest that patients who are frail have a higher risk of developing complications after major surgery. Our aim is to ask you simple questions about your physical ability to perform daily life activities, assess your general health condition and ask you to do simple tasks such as drawing a clock or walking for a short distance to assess your speed of walking. Our main aim is to identify a tool that will assist us to identify patients who are at risk of frailty
100138|NCT03403660|Other|non White coat|Postpartum patients are randomized to either arm of the study (white coat or standard scrub suit only) by location. All the obstetric physicians associated with patient's postpartum care should use or not use white coat in every single encounter with patient.
100139|NCT03403647|Dietary Supplement|Vitamin D|Oral daily vitamin D
100140|NCT03403634|Drug|Celecoxib|Given PO
100141|NCT03403634|Other|Laboratory Biomarker Analysis|Correlative studies
100142|NCT03403634|Biological|Recombinant Interferon Alfa-2b|Given IV
100143|NCT03403634|Drug|Rintatolimod|Given IV
100144|NCT03403621|Drug|Pentamidine Isethionate|Pentamidine isethionate prepared in a silicone base will be applied topically
100145|NCT03403621|Drug|Silicone Gels|Silicone base will be applied topically
100146|NCT03403595|Drug|177Lu-EB-PSMA-617|accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
100147|NCT03403582|Other|Raspberries|250g frozen whole red raspberries
100572|NCT03400215|Diagnostic Test|Research Scan for Gradient-echo Spectroscopic Imaging (GSI)|15-min research MRI scan
100148|NCT03403569|Drug|Triptolide Wilfordii|In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.
100149|NCT03403569|Drug|Placebo Oral Tablet|In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
100150|NCT03403556|Drug|Rosuvamibe|Rosuvastatin 10mg/Ezetimibe10mg qd for 24 weeks
100151|NCT03403556|Drug|Monorova|Rosuvastatin 20mg qd for 24 weeks
100152|NCT03403530|Drug|IgM rich Immunoglobin|the 'IgM rich immunoglobn' is the normal human immunoglobin containing Human plasma protein 50mg/ml of which immunoglobin is atleast 95% Immunoglobin M (IgM) 6mg Immunoglobin A (IgA) 6mg Immunoglobin G (IgG) 38mg
100153|NCT03403517|Drug|Methylprednisolone|10 mg/kg methylprednisolone mixed in 100 ml NaCl (sodium chloride), infusion over 30 minutes, prior to surgery
100154|NCT03403517|Drug|Dexamethasone|Dexamethasone mixed in 100 ml NaCl, infusion over 30 minutes, prior to surgery
100155|NCT03403504|Drug|Oxycodone Tamper Resistant|Orally administered Oxycodone Tamper Resistant 10mg
100156|NCT03403504|Drug|OXYCONTIN®|Orally administered OXYCONTIN® Tablet 10 mg
100157|NCT03403491|Other|patientMpower application|electronic health journal for patient to record weight, blood pressure, medication adherence and symptoms
100158|NCT03403491|Other|sham application|dummy application which does not allow recording of weight, blood pressure, medication adherence and symptoms
100159|NCT03403478|Other|LICE|No specific exercise will be performed. The participant will walk into the pool accompanied with a researcher for 45 minutes.
100160|NCT03403478|Other|MICE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
100161|NCT03403478|Other|HIIE|"The following exercises will be carried out: a) jumping jacks (shoulder abduction and adduction); b) horizontal adduction and abduction of the shoulder; c) stationary running with knee elevation; d) pull and push horizontally with upper limbs; e) pull and push vertically with upper limbs.~Note: For exercises 'a' and 'b', the legs alternated in movements in the sagittal plane to provide greater stability to the participant's movement. For exercises 'd' and 'e', the legs simulates a stationary running."
100162|NCT03403478|Other|Aquatic exercise training|"The sessions of the aquatic exercise training will be divided into 3 phases: warm-up (10 minutes), main part (40 minutes) and cool down.~In order to increase intensity to aquatic exercise, the training program will carried out as follows:~From week 1 to 4 the instructors will use a 128 bpm musics in both warm-up and cool down. In main part, will be used a 130 bmp musics.~From week 5 to 8 the instructors will use a 130 bpm musics in both warm-up and cool down. In main part, will be used a 132 bmp musics.~From week 9 to 12 the instructors will use a 132 bpm musics in both warm-up and cool down. In main part, will be used a 135 bmp musics."
100163|NCT03403465|Other|FDG PET scan|At radiation planning subjects will have a PET-CT. The CT scan — also called computerized tomography or just CT — combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
100164|NCT03403452|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
100165|NCT03403439|Drug|BI 1015550|Reference and Test Treatment
100166|NCT03403439|Drug|itraconazole|Test treatment
100167|NCT03403426|Device|Wingman Crossing Catheter|Endovascular CTO crossing
100168|NCT03403413|Device|muscle vibration during walking|Baseline assessment of gait followed by 12 sessions (3/week for a month) of gait training with cyclic muscle vibration during walking emulating normal muscle activity of lower extremities in treatment group and gait training without muscle vibration during walking in control group and repeat gait assessment after gait training.
100169|NCT03403400|Behavioral|VRWP Group|The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
100170|NCT03403400|Behavioral|VRW Group|The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
100171|NCT03403387|Dietary Supplement|GlutenShield|combination probiotic, prebiotic, and enzyme supplement
100172|NCT03403387|Other|Placebo|Avicel (cellulose) and bentonite powder
100173|NCT03403374|Drug|Repatha® (evolocumab)|Administered of Repatha by subcutaneous injection via autoinjector(AI)/pen
100174|NCT03403361|Device|Siemens Somatom Definition Edge|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
100569|NCT03400228|Dietary Supplement|Probiotic|The probiotic is composed of a combination of Lactobacillus acidophilus (LA-5®) and Bifidobacterium lactis (BB-12®).
100175|NCT03403361|Device|Philips Brilliance Big Bore CT/simulator|In addition to acquiring medically-routine datasets, each patient subject will be scanned sequentially at two or three different beam energies (80 or 90 kVp, 100 kVp, 120 kVp, and 140 kVp) as part of this research study. These additional scans will be acquired utilizing the FDA-approved workflow and scanner operating modes. Sinogram data will be exported in raw, minimally processed form utilizing proprietary data export and processing tools provided to the investigators by the scanner vendors. In no case, will the additional local imaging dose (in terms of CTDIvol) given to the patients by the two or three additional scans exceed 6 cGy per session
100176|NCT03403348|Drug|JNJ-64417184|Participants will receive JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
100177|NCT03403348|Drug|Placebo|Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
100178|NCT03403335|Behavioral|Mindfulness Based Practices for Health Care Professionals in Training|Eight weekly sessions including didactic lecture, discussion, homework, gentle yoga, and meditation and mindfulness exercises
100179|NCT03403322|Other|Kinesio taping|An experienced physiotherapist placed the base of the Kinesio taping strip, over rectus femoris muscle, 3cm bellow the anterior iliac spine, without tension. From this point, the Kinesio taping was placed up to the upper edge of the patella and stretched to 100% tension. It was, then, bi-sectioned, circled the patella and ended in the tuberosity of the femur, without tension. In order to avoid interference in the electromyography signals, a section was held at Kinesio taping at the point where the electrode was placed.
100180|NCT03403322|Other|Without taping|Children performed functional activities without tape
100181|NCT03403309|Drug|1) Inosine 5'-monophosphate|1) Subjects are initiated with 1 tablet (500mg of inosine 5'-monophosphate per one tablet) two times per day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL, so that reducing dose of administration may be considered in case of being way over the top of limited level.
100182|NCT03403309|Drug|Placebo|2) Subjects are initiated with 1 tablet (500mg of placebo tablet with inactive therapeutic effect) two times a day, and then titrated up by 1 tablet per every visit up to visit 2, i.e. increased up to 2 tablets two times a day by week 6. A maximum limit of elevated serum uric acid level is 9 mg/dL.
100183|NCT03403296|Genetic|nProfiler I Stomach Cancer Assay Kit|qPCR by nProfiler I Stomach Cancer Assay Kit
100184|NCT03403283|Other|15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy|
100185|NCT03403283|Other|Healthy Controls 15 age matched control subjects|
100186|NCT03403270|Other|ENCOURAGE App|Users will have an opportunity to engage with the app as described for the duration of the study period.
100187|NCT03403257|Other|No interventions|No intervention
100188|NCT03403244|Procedure|US-MR image fusion-guided PTED|patients diagnosed with lumbar disc herniation undergoing US-MR image fusion-guided PTED
100189|NCT03403244|Procedure|fluoroscopy-guided PTED|patients diagnosed with lumbar disc herniation undergoing fluoroscopy-guided PTED
100190|NCT03403231|Behavioral|INVENT Secure Messaging Intervention|We are proposing a 12 week schedule of weekly Secure Messages and monthly mailings for this intervention. Each study arm represents different combinations of messages a participant will receive.
100191|NCT03403218|Behavioral|Case group|assessment of quality on posture, transfers and displacement
100192|NCT03403205|Drug|ALXN1840|ALXN1840 administered orally in 15 mg tablets
100193|NCT03403205|Drug|SoC Therapy|Depending on the site/region,subjects randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
100194|NCT03403192|Device|EZ-Blocker|"The EZ-Blocker essentially functions as a bronchial blocker with a 7-Fr shaft with two separate occlusive balloons coming off this shaft in a Y configuration designed to rest on the carina. Once anchored in place the operator can choose to inflate one of the two occlusive balloons to isolate one main stem bronchus or the other. According to the manufactures recommendations the EZ-blocker is placed through a Y-piece adaptor included with the blocker kit. A flexible fiberoptic bronchoscope (FFB) is placed in a separate limb of this Y-piece and this fed through along side the EZ-blocker to visualize and confirm placement of the of the BB. The balloon is then inflated typically under direct vision to occlude that bronchus thus isolating that lung hopefully achieving full lung isolation."
100195|NCT03403192|Device|DLT|A Double Lumen Tube (DLT) is made of two small-lumen endotracheal tubes of unequal length fixed side by side. The shorter tube ends in the trachea while the longer tube is placed in either the right or left bronchus to ventilate the right or left lung.
100196|NCT03403179|Other|Functional Remediation|Functional Remediation: The functional remediation program consists of 21 weekly sessions, each lasting 90 min. This intervention addresses neurocognitive issues such as attention, memory and executive functions, but it focuses even more on enhancing functioning in daily routine. The content of the intervention is based on ecological tasks to be performed in two settings, in the clinic as well as at home. Participants will be trained with exercises for memory, attention, problem solving and reasoning, multitasking and organization in order to improve their functional outcome. Most of the techniques are based on paper-and-pencil tasks and group activities.
100197|NCT03403166|Behavioral|DASH diet|Diet intervention
100198|NCT03403166|Behavioral|Fruits and vegetables diet|Diet intervention
100199|NCT03403166|Behavioral|Control diet|Diet intervention
100200|NCT03403153|Behavioral|SAHP|"Aim 1: To obtain and incorporate expert clinician and Veteran feedback on credibility, acceptability, and satisfaction with the intervention to ensure Veteran-friendly intervention manual, materials, and processes. Aim 1 will be accomplished through two rounds of expert panel review of treatment/MIA manual and two rounds of pilot testing of the treatment for Veteran Feedback in 16 female and 16 male Veterans.~Aim 2: To evaluate feasibility of study recruitment, retention, assessment procedures and proposed methods of the intervention. Preliminary examination of whether the intervention results in improvements to parenting behaviors, parenting satisfaction and overall family functioning."
100201|NCT03403140|Drug|Etanercept|"Enerceptan®. Injectable Solution in prefilled syringes~Source: GEMABIOTECH S. A. Formulation per unit:~1,0 ml of Enerceptan® contains 50 mg solution of Etanercept /Once a week Methotrexate 15 to 25 mg / Once a week"
100570|NCT03400228|Dietary Supplement|Maltodextrin|Maltodextrin is a supplement feed based carbohydrate powder and tasteless.
100202|NCT03403127|Diagnostic Test|PET/CT Scans|PET Imaging requires the use of an investigational drug, a radioactively-labelled sugar called 18F-Fluorodeoxyglucose (FDG). FDG is glucose labelled with a radioactive fluorine atom. It is given by intravenous injection and is particularly absorbed by cancer cells. The radioactive signal given off by the FDG can then be detected by the PET scanner providing an image of the cancer (or tumour).
100203|NCT03403114|Behavioral|Questionnaire|a 15min questionnaire
100204|NCT03403101|Drug|S1|"Patients are planned to receive the SIRIOX regimen including S-1 (BSA < 1.2m2, 40 mg/day; BSA = 1.2~1.4 m2, 60 mg/day; BSA = 1.4~1.6 m2, 80 mg/day; BSA > 1.6 m2, 100 mg/day; oral twice daily on days 1-7, days 15-21）of every cycle.~• 28 days a cycle."
100205|NCT03403101|Drug|Oxaliplatin|"Patients are planned to receive the SIRIOX regimen including Oxaliplatin (OXA, 85 mg/m2; d1,d15) of every cycle.~• 28 days a cycle"
100206|NCT03403101|Drug|Irinotecan|"Patients are planned to receive the SIRIOX regimen including Irinotecan (IRI, 180mg/m2; day 1,day 15) of every cycle.~• 28 days a cycle"
100207|NCT03403088|Device|Experimental: • Group LA|to apply Laser (780 nm and 70mW) at the cementum-enamel junction fat the teeth affected by sensitivity
100208|NCT03403088|Device|Placebo Comparator: • Group LA-P|to apply Laser (780 nm and 70mW) at the cementum-enamel junction at the teeth affected by sensitivity with the laser device having no effective laser emission, only guided by light
100209|NCT03403088|Other|Experimental: • Group DE|to brush teeth with a blinded dentifrice with 0,45% of stannous fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
100210|NCT03403088|Other|Placebo Comparator: • Group DE-P|to brush teeth with a blinded dentifrice with 1500 ppm of available fluoride and a soft-bristled manual toothbrush (Johnson & Johnson®).
100211|NCT03403088|Other|Experimental: • Group RGI|to apply a thin layer of resin based glass-ionomer product on the cervical surface of the affected teeth affected by sensitivity following the manufacturer instructions.
100212|NCT03403088|Other|Experimental: Group RX|to apply Adper Single Bond Plus Adhesive in accordance with the manufacturer instructions, at the teeth affected by sensitivity product for 20 seconds.
100213|NCT03403075|Behavioral|ETAF|Therapeutic education and Physical activity
100214|NCT03403075|Behavioral|Usual care|Usual care
100215|NCT03403049|Radiation|Carbon Ion|Study subjects will receive carbon ion radiotherapy (CIRT), with daily fraction sizes of 3 GyE. The total CIRT dose will increase with each dose level. Subjects in dose level 1 and 2 will receive photon radiotherapy as well.
100216|NCT03403049|Drug|Gemcitabine + Cisplatin|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
100217|NCT03403049|Drug|Gemcitabine + Capecitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
100218|NCT03403049|Drug|Gemcitabine + Erlotinib|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
100219|NCT03403049|Drug|Gemcitabine|"Combined chemotherapy regimen before/after radiotherapy: gemcitabine-based chemotherapy regimen.~All patients will have received 2-4 cycles of gemcitabine-based chemotherapy prior to study registration, with post-chemotherapy imaging demonstrating locally-advanced disease without evidence of distant metastatic disease spread. Patients who received chemotherapy regimens other than those listed above may be considered for study enrollment at the discretion of the lead investigators, provided that all other eligibility criteria are satisfied. Gemcitabine-based chemotherapy will be continued starting 3-5 weeks after completion of radiotherapy until disease progression, intolerability, or the patient's decline of chemotherapy."
100220|NCT03403049|Radiation|Photon|During this study, the prescribed dose shall be administered according to the dose escalation shown in the table, starting with dose level 1. The carbon ion dose shall be gradually escalated while gradually reducing the dose of photons until eventually administering a full dose of 56 GyE/14 Fx carbon ions (fractional dose of 4 GyE). Dose escalation will be performed in parallel for two patient groups: patients whose pancreatic tumors are greater than 5 mm from the duodenum (Group A) and those whose tumors are within 5 mm of the duodenum (Group B). Enrolled patients will be monitored for 90 days after radiotherapy starts for any acute toxic reaction and to explore the maximum tolerated dose, in addition to being observed for any related long-term toxic reactions in accordance with the protocol.
100221|NCT03403036|Drug|Brodalumab|Weeks 0, 1, 2, and every 2 weeks thereafter through and including Week 16.
100222|NCT03403023|Device|Tear Film Imager|The TFI is an imaging device based on standard camera that uses white light to image the tear film in an ultra high resolution. DES patients in this study will be imaged before and 3 months after initiation of treatment with Restasis (the treatment indicated for their condition).
100223|NCT03403023|Drug|Restasis|Restasis therapy is given to all of the patients as indicated for moderate-severe DES. TFI imaging is performed before and 3 months after initiation of therapy.
100745|NCT03399019|Drug|Propofol|continuous infusion (0.75-3mg/kg/hr)
100224|NCT03403010|Other|Rehabilitation-specific gaming platform|The rehabilitation specific gaming software was developed as part of the ICT4rehab project with partners from the Vrije Universiteit Brussel and the University Libre de Bruxelles. The ICT4Rehab puts several ICT tools supporting 2/3D user interaction into place. The games can be controlled using a Kinect camera system (Microsoft(®) (Redmond, WA) Kinect™) or a Wii balance board (® NintendoTM, Japan), depending on the choice of the therapist and the needs of the child.
100225|NCT03402997|Diagnostic Test|Resistivity measurement|To measure and compare the tissue impedance values obtained by analysing ex vivo non-neoplastic (healthy and peritumoral) and neoplastic breast tissues
100226|NCT03402984|Drug|Acotiamide|Acotiamide treatment, 100 mg, t.i.d. for three week. Intake 10 minutes before meal.
100227|NCT03402984|Drug|Placebo Oral Tablet|Placebo treatment, t.i.d. for three week. Intake 10 minutes before meal.
100228|NCT03402971|Diagnostic Test|echocardiography|echocardiography focused on right heart: Parameters include RV enddiastolic diameter basal, mid-cavity and longitudinal, RVOT distal, pulmonal outflow AT and AT/ET, endsystolic RA area. RV wall thickness, TAPSE, S', tricuspidal E/A, E/e', RIMP. V. Cava to estimate CVP and sPAP.
100229|NCT03402945|Device|Prevena|Negative-Pressure Wound Management System
100230|NCT03402945|Drug|Cefazolin|antibiotic
100231|NCT03402945|Drug|Vancomycin|antibiotic
100232|NCT03402945|Other|standard wound dressing|Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
100233|NCT03402932|Other|Auditory amplified|The cognitive test will be administered using a computer-based signal processing to amplify the instruction. The presentation level is customized to the individual's hearing thresholds.
100234|NCT03402932|Other|Visual|The cognitive test will be administered visually by using timed computer slides.
100235|NCT03402932|Other|Auditory unamplified|The cognitive test will be administered by using a generic presentation level that simulates a normal conversational level.
100236|NCT03402906|Behavioral|Family-Clinician Collaboration Program|Family-mediated treatment activities and collaboration between clinician and family members
100237|NCT03402906|Behavioral|Standard Care at KIR|Participants will receive the standard care provided at Kessler Institute for Rehabilitation.
100238|NCT03402893|Drug|ONEXTON Topical Gel|Onexton gel applied once daily to face
100239|NCT03402880|Biological|Pembrolizumab|Given IV
100240|NCT03402880|Drug|Epacadostat|Given PO
100241|NCT03402880|Other|Laboratory Biomarker Analysis|Correlative studies
100242|NCT03402867|Procedure|Deep dry needling|Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
100243|NCT03402854|Device|active transcranial direct current stimulation|Participants will receive 20 min of tDCS over the scalp during the first 20 min of bimanual training.
100244|NCT03402854|Behavioral|bimanual training|Participants will engage in movements that use both hands, by playing with toys and games.
100245|NCT03402841|Drug|Olaparib|300 mg twice daily - oral
100246|NCT03402828|Drug|Any topical drug treatment|Any treatment strategy used to prevent relapse of psoriasis symptoms
100247|NCT03402815|Drug|Maraviroc 300 mg|Patients were randomly allocated with an AB/BA cross over design to either maraviroc 300 mg/day to current ART for 24 weeks (A) or no additional treatment (B). At the end of the first 24-week period patients were switched to the alternative arm.
100248|NCT03402802|Drug|monitoring of adherence with medication|persons taking routine postoperative eye drops will have their frequency of drop taking monitored
100249|NCT03402789|Drug|Docosahexaenoic Acid|Docosahexaenoic acid 1,200mg daily plus 2 hours of eye patching daily
100250|NCT03402789|Drug|Placebo Oral Tablet|Placebo tablet daily plus 2 hours of eye patching daily
100251|NCT03402776|Drug|4th dose of hexavalent vaccine 1 month after the 3rd dose|4th dose of hexavalent vaccine 1 month after the 3rd dose
100252|NCT03402763|Behavioral|Educational Video|The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.
100253|NCT03402763|Behavioral|Primary Care Provider Email|For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
100254|NCT03402750|Behavioral|Meds to Beds|Medications will be delivered to patient bedside before discharge
100255|NCT03402750|Behavioral|Electronic Prescription|Patient or surrogate can pick up medication from pharmacy
100256|NCT03402737|Radiation|Stereotactic body radiotherapy|"The range of dose-painting will be escalated in following levels:~2x 6-8Gy (day 1-4)~3x 6-8Gy (day 1-4-7)~3x 6-10Gy (day 1-4-7)~3x 6-12Gy (day 1-4-7)~Patients will take cyclophosphamide orally 50 mg tablets, 1 tablet a day from the first day of irradiation for 8 consecutive weeks.~Nivolumab will be considered as standard therapy in patients with cisplatin refractory locoregional disease recurrence. Nivolumab will be administered as per current standard of care. In case patients that are treated with nivolumab will be included in the trial, they will not be treated with cyclophosphamide."
100257|NCT03402724|Other|echographic|Patients are called for an echographic evaluation in the implanting center in case of the usual care
100258|NCT03402698|Dietary Supplement|cholecalciferol|supplementation at a dose 1000 IU/d
100259|NCT03402685|Device|ClearSight|Patients in the intervention group receive management of volume and vasopressor settings according to the non-invasive ClearSight system.
100260|NCT03402672|Other|self-administered, e-health application|"AWAITS is a self-administered, e-health application and includes short videos in which patients who are successfully engaged in MAT discuss what they wish they had known about MAT when they were actively using. The intervention is designed to maximize scalability - the administration would entail handing an electronic device (e.g., tablet, laptop, etc.) to an individual who would then self-administer the intervention."
100261|NCT03402659|Drug|neflamapimod|40 mg neflamapimod capsule
100262|NCT03402659|Other|placebo|matching placebo capsule
100263|NCT03402646|Behavioral|Reminder module (SMS and Phone call)|Same as described under arm/group descriptions
100264|NCT03402646|Behavioral|Photovoice|Same as described under arm/group descriptions
101179|NCT03395457|Drug|Care as usual|Application of usual pharmacological care for chronic migraine
100265|NCT03402633|Other|Examination of leukotrichia in vitiligo patients|Examination of leukotrichia will be enhanced by wood's light and dermoscopy for better enhancing of the lesions and good magnification
100266|NCT03402620|Drug|Gonadotropins|Human menopausal gonadotropin 75 IU ampoules start at cycle day 2
100267|NCT03402607|Procedure|Percutaneous Local Abalation|Microwave Ablation (MWA) is a form of percutaneous localized ablation using thermal ablation techniques to treat cancer via direct coagulative necrosis. Microwaves can generate high temperatures in a short period of time; MWA has the potential to improve treatment efficacy over radiofrequency ablation as it can be used to treat larger lesions and has less susceptibility to heat-sink due to vessel proximity. MWA uses electromagnetic waves (300 MHz to 300 GHz) to produce oscillation of polar molecules within tissue; this generates tissue necrosis through frictional heating. For HCC, one or more microwave antennae are inserted into the liver, usually under the guidance of ultrasonography or computed tomography (CT). Frequency and length of treatment is determined on a case by case basis depending on tumor size and proximity to vessels or other organs at risk.
100268|NCT03402607|Radiation|Hypofractionated Image Guided Radaition Therapy|HIGRT represents the only non-invasive curative modality in the management of HCC. HCC patients typically have a host of other medical comorbidities complicated by underlying liver dysfunction that makes the implementation of liver-directed therapy challenging. Presently HIGRT is typically offered only after alternative surgical (transplantation/hepatectomy) and non-operative approaches (PLA/embolization) have been exhausted.
100269|NCT03402594|Device|High flow oxygen|Heated humidified high flow oxygen cannula (Optiflow; temperature of 34°C and fractional inspired oxygen of 0.24) with a flow rate of 20 liter/minute
100270|NCT03402594|Device|Low flow oxygen|Oxygen cannula with a flow rate of 2 liter/minute
100271|NCT03402581|Device|c-mac laryngoscope|type of laryngoscopes
100272|NCT03402555|Other|Stool pattern|Collection of stool images
100273|NCT03402542|Procedure|Cholecystectomy|Cholecystectomy
100274|NCT03402529|Diagnostic Test|Contrast Enhanced Spectral Mammography|Pilot study
100275|NCT03402516|Device|18.5 resector|hysteroscopic myomectomy with a 18.5 Fr resector after cervical dilatation until Hegar bougie number 7
100276|NCT03402516|Device|26Fr resector|hysteroscopic myomectomy with a 26Fr resector after cervical dilatation until Hegar bougie number 10
100277|NCT03402503|Drug|Montelukast buccal film|Film with active investigational product (montelukast) inserted and applied on inner cheek
100278|NCT03402503|Other|Placebo buccal film|Film with placebo (no active drug) inserted and applied on inner cheek
100279|NCT03402490|Behavioral|Motivational interviewing|
100280|NCT03402464|Drug|Icotinib combined dihydroaremisinin|Icotinib should be taken by the patients continuously until disease progressed or intolerable toxicity. On day 1-3, oral dihydroaremisinin was given at 20mg per day, the dose of dihydroaremisinin is increased to 40mg daily on day 4 to 6, and 80mg twice daily until disease progressed or intolerable toxicity.
100281|NCT03402438|Drug|Fulacimstat (BAY1142524)|single oral dose of 25 mg immediate-release tablet BAY1142524
100282|NCT03402425|Diagnostic Test|18F-FET PET|Patient are investigated with an 18F-FET PET
100283|NCT03402412|Other|narrow-band UVB|Standard established treatment for atopic dermatitis with narrow-band UVB will be used in this study but initially only on a small amount of skin to assess what changes takes place in the skin.
100284|NCT03402399|Other|Molecular analysis|Blood test
100285|NCT03402386|Drug|MT-6548|Oral tablet
100286|NCT03402373|Dietary Supplement|Lycoderm|soft gel contains nutritional supplement
100287|NCT03402373|Dietary Supplement|Placebo|soft gel without active ingredients
100288|NCT03402360|Other|Virtual Reality rehabilitation group|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: virtual reality upper extremity motor rehabilitation~1 hour: virtual reality neurocognitive training"
100289|NCT03402360|Other|Control group rehabilitation|"Three hours rehabilitation sessions every day that will consist in two hours of physiotherapy and one hour of neurocognitive rehabilitation, for 15 consecutive working days (3 weeks).~1 hour: conventional physiotherapy~1 hour: upper extremity motor rehabilitation~1 hour: neurocognitive training"
100290|NCT03402347|Radiation|Non-ionising radiation|Laser regimes will be applied to ex vivo skin samples.
100291|NCT03402334|Behavioral|Patient counseling for HCV associated CVD risk factors|Patients will be counseled for cardiovascular disease risk factors associated with Hepatitis C infection. Such risk factors include atherosclerosis, heart attack, and stroke. Cardiovascular risk factors can be managed through connection with primary care and reduced through curative HCV treatment.
100292|NCT03402321|Drug|Gelatin Sponge Sheet|sheets act as a mechanical barrier used to protect the denuded area of the palatal donor site
100293|NCT03402321|Drug|Alvogyl|paste form with analgesic action to protect the palatal donor site and help to relief pain
100294|NCT03402308|Dietary Supplement|Schisandra chinensis extract|Schisandra chinensis extract 1,000 mg/day for 12 weeks
100295|NCT03402308|Dietary Supplement|Placebo|Starch placebo 1,000 mg/day for 12 weeks
100296|NCT03402295|Drug|Bortezomib, cyclophosphamide, thalidomide, dexamethasone|Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
100297|NCT03402282|Procedure|embolization|upper rectal artery embolization with coils
100298|NCT03402282|Procedure|surgical repair|surgical repair through the classic technique (Milligan and Morgan technique)
100299|NCT03402269|Other|Clavicle fracture injury- observation|The study is an observational study with assessments at 1 month, 3 months, 6 months and 1 year following injury. Assessments include range of motion, strength, patient reported outcomes and radiographic healing
100338|NCT03401970|Behavioral|Cellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 1 E% added sugar), 38 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
100300|NCT03402256|Behavioral|Text Message|In addition to the SC interventions, participants in the Text Message condition received text messages. Participants received 3 text messages per day for the first four weeks of the study and 3 messages per week for the last four weeks. Participants will receive messages targeting known predictors of alcohol abstinence and relapse, including (1) craving, (2) identification of high-risk situations, (3) identification of triggers, (4) stress level, (5) coping skills, and (5) quality of life. The text messages will include motivational messages and behavior-change techniques (e.g. coping with cravings and urges to drink, trigger identification, high-risk situation identification). Messages will encourage participants to continue with sobriety and focus on the success they have achieved so far.
100301|NCT03402243|Other|Menthol ban on cigarettes|Participants will have menthol and tobacco flavored e-cigarettes available but only non-menthol cigarettes
100302|NCT03402243|Other|Menthol ban on cigarettes and e-cigarettes|Participants will have neither menthol flavored cigarettes or e-cigarettes available
100303|NCT03402243|Other|No menthol ban|Participant will have menthol and tobacco flavored cigarettes and e-cigarettes available
100304|NCT03402230|Drug|Broccoli Sprout/Broccoli Seed Extract Supplement|Given PO
100305|NCT03402230|Other|Laboratory Biomarker Analysis|Correlative studies
100306|NCT03402230|Other|Questionnaire Administration|Ancillary studies
100307|NCT03402217|Behavioral|Patient Centered Postpartum Contraception App|This is a theory-based smart phone-based application designed to provide immediate postpartum contraception information to young women aged 15-25.
100308|NCT03402204|Drug|Simvastatin 10 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
100309|NCT03402204|Drug|Simvastatin 40 mg|"Simvastatin is a cholesterol-lowering medication that blocks the production of cholesterol (a type of fat) in the body.~Simvastatin reduces low-density lipoprotein (LDL) cholesterol and total cholesterol in the blood. Lowering your cholesterol can help prevent heart disease and hardening of the arteries, conditions that can lead to heart attack, stroke, and vascular disease."
100310|NCT03402191|Drug|L-arginine|l-arginine for thalassemia with pulmonary hypertension
100311|NCT03402191|Drug|Sildenafil|Sildenafil for thalassemia with pulmonary hypertension
100312|NCT03402178|Drug|E2082|Solution (0.2 mg) or tablet (0.5 mg and 5 mg).
100313|NCT03402178|Drug|Placebo|Solution (0.2 mg) or tablet (0.5 mg and 5 mg) matched to E2082.
100314|NCT03402165|Drug|Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir|Response to DAAD's and developing HCC
100315|NCT03402152|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
100316|NCT03402152|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
100317|NCT03402152|Drug|Placebo|Placebo oral capsule
100318|NCT03402126|Other|TPD RAMWare|TPD RAMWare injected into enrolled subject's device.
100319|NCT03402113|Drug|Dexmedetomidine|consistent infusion at a loading dose of 0.15ug/kg/h, increased by 0.15ug/kg/h, with a maximum dose of 1.5ug/kg/h.
100320|NCT03402113|Drug|Midazolam|consistent infusion at a loading dose of 1mg/h, increased by 1mg/h, with a maximum dose of 10mg/h.
100321|NCT03402100|Drug|eye drops|children who received daily eye drops for myopia
100322|NCT03402087|Drug|Methotrexate|Specified dose on specified days
100323|NCT03402087|Drug|Leucovorin|Specified dose on specified days
100324|NCT03402087|Drug|BMS-986165|Specified dose on specified days
100325|NCT03402074|Behavioral|Group hypnosis|5 session of group hypnosis, each 90 minutes, to reduce subjective stress and increase relaxation. Additional auditapes of hypnosis sessions as hoemwork
100326|NCT03402061|Dietary Supplement|nutrient enhanced recipes|normal ingredients will be substituted to promote nutrient density of products
100327|NCT03402048|Drug|Carboplatin|
100328|NCT03402048|Drug|Gemcitabine|
100329|NCT03402048|Drug|Pemetrexed|
100330|NCT03402048|Drug|Docetaxel|
100331|NCT03402048|Drug|Vinorelbine|
100332|NCT03402009|Behavioral|Apps|Apps and weblinks to coach self-guided meditation.
100333|NCT03402009|Behavioral|EEG neurofeedback|Device provides feedback based on EEG readings.
100334|NCT03401996|Device|1 mA tDCS over bilateral SMA|"A 1mA direct current will be delivered through two 5cm x 5cm saline-soaked surface sponge electrodes by a battery-driven, constant-current stimulator (Neuroconn DC stimulator). First, the SMA will be identified based on the guidelines of the international 10-20 electrode system. The tDCS will then be applied using the following procedure:~The head of participants will be measured to find the 'vertex' (top) of the head. This point will be used as a landmark to locate the SMA. This region corresponds to the FCZ (e.g., Legon et al., 2013).~The return electrode will be placed over the mastoids. Once the electrodes are in position, cathodal tDCS will be applied at 1mA for 15 minutes, 2 times a day with a resting period of 20 minutes in between treatment periods, for 5 consecutive days."
100335|NCT03401983|Other|Pelvic Floor Muscle Training and Abdominal Training|Pelvic Floor Muscle Training + Abdominal Training program was used in the study. The follow-up measurements of the PFMT+AT group were obtained in the 0th, 4th, and 8th weeks.
100336|NCT03401983|Other|Pelvic Floor Muscle Training|Pelvic Floor Muscle Training program was used in the study. The follow-up measurements of the PFMT group were obtained in the 0th, 4th, and 8th weeks.
100337|NCT03401970|Behavioral|Acellular carbohydrate diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 45 energy percent (E%) carbohydrate (up to 5 E% added sugar), 30 E% fat (10-12 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
100374|NCT03401723|Other|3D-Colonoscopy Retraction Score|3D-Colonoscopy Retraction Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
100375|NCT03401710|Drug|Erythropoietin|Erythropoietin 4000 UI will be administered every other day subcutaneously
100339|NCT03401970|Behavioral|Low-carbohydrate high-fat diet|Participants will be asked to consume 2,000 - 2,500 kcals, thereof 10 energy percent (E%) carbohydrate (up to 1 E% added sugar), 73 E% fat (30 E% saturated fatty acids and 7-10 E% polyunsaturated fatty acids) and 17 E% protein. They will use an original online/smartphone application that provides choices of meals/food combinations/recipes corresponding to their prescribed macronutrient profile and dietary pattern. Participants are asked to complete 3-day dietary records every 14 days throughout the study, and to report any deviations from the planned interventions.
100340|NCT03401957|Drug|Cetuximab|Cetuximab-based infusional 5-FU regimen as the 1st line treatment.
100341|NCT03401957|Diagnostic Test|liquid biopsy|The blood samples taken from subjects will be evaluated for RAS genotype using MassARRAY technique.
100342|NCT03401944|Drug|TPN|
100343|NCT03401944|Other|Control|
100344|NCT03401918|Diagnostic Test|Uterine ERA and microbiome testing|Uterine fluid and endometrial biopsy collection to test uterine endometrial receptivity array and microbiome.
100345|NCT03401918|Drug|Oral antibiotics and vaginal probiotics|For subjects with abnormal microbiome results, oral antibiotics and vaginal probiotic treatment will be offered followed by a repeat uterine microbiome biopsy.
100346|NCT03401905|Procedure|Low frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a low frequency TENS is applied, at 2 Hz frequency and 120 microseconds of pulse width.
100347|NCT03401905|Procedure|High frequency|A dry needling on trapezius muscle is performed, until two local twitch responses are obtained. The needle is kept inside the trigger point, as it will be the negative electrode, and an adhesive electrode will be added as the positive one. After that, a high frequency TENS is applied, at 12o Hz frequency and 200 microseconds of pulse width.
100348|NCT03401892|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
100349|NCT03401892|Device|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
100350|NCT03401892|Device|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
100351|NCT03401879|Device|Dynamic Vessel Analyzer (DVA)|Retinal vessel diameters and oxygen saturation will be measured with the DVA device.
100352|NCT03401879|Device|Fourier Domain Doppler Optical Coherence Tomography (FDOCT)|Retinal blood flow will be assessed using FDOCT.
100353|NCT03401879|Device|Optical coherence tomography (OCT)|Nerve fiber layer thickness and central retinal thickness will be measured using OCT.
100354|NCT03401879|Device|Optical coherence tomography angiography (OCTA)|Retinal microvasculature will be assessed using OCTA.
100355|NCT03401866|Diagnostic Test|DSC-MRI|"The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes."
100356|NCT03401853|Other|Laboratory Biomarker Analysis|Correlative studies
100357|NCT03401853|Biological|Pembrolizumab|Given IV
100358|NCT03401853|Biological|Rituximab|Given IV
100359|NCT03401840|Radiation|postoperative hypofractionated stereotactic radiotherapy|total dose of 36Gy in 6 fractions over 11-13 days
100360|NCT03401827|Drug|Chemotherapy (Gemcitabine + nab-paclitaxel)|"Nanoparticle albumin-bound paclitaxel (125 mg/m2) miv over 30 min, Day 1,8,15~Gemcitabine (1,000mg/m2) and N/S 150mL miv over 30 min, Day 1,8,15"
100361|NCT03401814|Other|Magnetic Resonance Elastography|rapidly developing technology for quantitatively assessing the mechanical properties of tissue, using externally applied mechanical waves
100362|NCT03401801|Procedure|Stellate ganglion block|Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
100363|NCT03401788|Drug|PT2977|HIF-2α Inhibitor
100364|NCT03401775|Other|Cognitive rehabilitation program|Cognitive rehabilitation programs have been developed to improve the cognitive functions of the elderly or patients with cognitive impairments. The program includes sub-categories such as attention, working memory, memory and executive functions with various levels of difficulty.
100365|NCT03401762|Behavioral|MCI|EMG-controlled game
100366|NCT03401762|Behavioral|Sham MCI|Sham control game
100367|NCT03401749|Drug|Chlorhexidine Gluconate 2% Wipe|Patients will be instructed to use CHG wipes after showering the night before surgery and again on the morning of surgery.
100368|NCT03401749|Other|Theraworx Bath Wipes|Theraworx TM is a cosmetic product that is a non-rinse skin formulation that combines multiple ingredients, including Aloe Concentrate, Allantoin, Tego Betaine F 50, Tego Betaine L-7, Lauryl Glucoside, Abil 8852, Vitamin E, Natural Fragrances, Methyl paraben, Propyl paraben, EDTA, Antimicrobial Preservative, Colloidal Silver, and Beta Glucan, in preoperative disposable bath wipes. The main proposed antimicrobial mechanism of action involves the local reduction in skin pH to around 4.6.
100369|NCT03401736|Device|Mechanical Ventilation|Whether midazolam and dexmedetomidine have an effect on the diversity of intestinal microbiota or not is still unknown，especially the patient who requires the mechanical ventilation.
100370|NCT03401736|Drug|Midazolam|The impact of Midazolam on the diversity of intestinal microbiota.
100371|NCT03401736|Drug|Dexmedetomidine|The impact of dexmedetomidine on the diversity of intestinal microbiota.
100372|NCT03401723|Other|3D-Colonoscopy Progression Score|3D-Colonoscopy Progression Score is a computerized analysis of the movement of the colonoscope based on data from coils within the colonoscope.
100373|NCT03401723|Other|Endoscopy Training System|"The Endoscopy Training System is based on the Colonoscopy Training Model platform and includes four different performance metrics and a scoring system.~Scope Manipulation - The use of torque and tip deflection to move a shape in the colon~Tool Targeting - 10 targets located around the colon must be found. With a biopsy forceps, each target has to been touched.~Loop Management - The management of a standard alfa-loop.~Mucosal Inspection - Randomly placed polyps inside the rubber colon have to be found during withdrawal."
100376|NCT03401684|Behavioral|Resilient Minds|The program is designed: 1) to decrease the risk of developing a stress disorder or other mental illnesses due to workplace incidents and/or unhealthy stress; 2) to mitigate the negative impacts of mental illness and trauma through early recognition and early intervention; 3) to support the public while on the frontline; and 4) to improve the psychological health of fire staff while cultivating resilience and enhancing quality of life.
100377|NCT03401671|Drug|Lanadelumab|SC injection of 300mg in 2mL (150 mg/mL) solution of lanadelumab will be administered as a single dose injection in the abdomen.
100378|NCT03401658|Device|Sensor light detector|The intervention is based on a sensor technology that gathers data and transmit it to another location for processing. The monitoring utilises an LED light source, an integral detector set which has variance from device to device and chromatic based algorithms for extraction of information from the detectors. The integration of these components into a system provides robustness and stability for operation. The availability of smartphones which possess high quality cameras and constant internet connectivity provides an ideal platform for multimedia clinical data collection and real-time patient-provider communication.
100379|NCT03401645|Other|Wrist Alarm|Wrist device with alarm timer
100380|NCT03401645|Behavioral|Home-based Arm and Hand Exercise|Repeated visuomotor tasks, unilateral arm and hand movements, bilateral arm and hand movements
100381|NCT03401632|Other|Enteral nutrition|Enteral nutrition support
100382|NCT03401619|Combination Product|Exercise，Nutrition，Bisphosphonates，Statins，Calcitonin,Vitamin D，et al.|The long-term effect of comprehensive treatment on health, especially for osteoporosis and neurodegenerative diseases, we hope to find association from epigenetics and provide clues for further exploration of its pathogenesis.
100383|NCT03401606|Drug|remifentanil|remifentanil, 0.25 ng/mL, given intravenous, infusion, until surgery finished
100384|NCT03401606|Drug|Dexmedetomidine|dexmedetomidine, 0.125 mcg/kg/hour, given intravenous, infusion, until surgery finished
100385|NCT03401593|Drug|midazolam with fentanyl|Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
100386|NCT03401580|Drug|Viena II 160/10|once daily
100387|NCT03401580|Drug|Viena II 190/10|once daily
100388|NCT03401580|Drug|Viena II 160/12|once daily
100389|NCT03401580|Drug|Viena II 190/12|once daily
100390|NCT03401567|Other|Exercise group|Elbow bending exercises with blood flow restriction will be performed to the exercise group during 6 weeks for 3 times a week. The first set of exercises will be 30 repetitions then 3 sets of 15 repetitions. Totally 75 repetitions will be performed. 30 seconds rest interval between sets will be given.
100391|NCT03401554|Procedure|titanium mesh|closing the lateral window for maxillary sinus floor elevation with titanium mesh
100392|NCT03401554|Procedure|collagen membrane|closing the lateral window for maxillary sinus floor elevaion with collagen membrane
100393|NCT03401541|Drug|Calcifediol|One capsule of 900 micrograms of 25(OH)D
100394|NCT03401541|Drug|Calciferol|One capsule of 900 micrograms of Vitamin D
100395|NCT03401528|Drug|AVB-S6-500|AVB-S6-500 is an investigational drug.
100396|NCT03401528|Other|Placebo|Matching placebo
100397|NCT03401515|Drug|Propranolol Hydrochloride 1 MG/ML|Propranolol 1 mg every 6 hrs in the first 24 hrs after isolated blunt traumatic brain injury
100398|NCT03401515|Other|Normal saline|Normal Saline 1 ml every 6 hrs
100399|NCT03401502|Drug|Ranolazine|Oral, b.i.d
100400|NCT03401502|Drug|Placebos|Oral, b.i.d
100401|NCT03401489|Device|PACESETTER|Patients will be given a Viaca electronic pill tray & blue-toothed UA-767 Plus BT BP device and the PACESETTER app installed on their smart phone for automatic relay of BP data. The Vaica tray emits a blinking light for 30 minutes when it is time to take the meds. If the compartment is not opened and emptied, an intermittent chime ensues for 30 minutes. If the compartment is not opened and emptied, the subject /caregiver receives an automated SMS or email. PACESETTERs will be given a questionnaire. Responses will be used to generate personalized motivational & reinforcement messages guided by self-determination theory constructs of competence & autonomous regulation. In addition, PACESETTERs will receive 30-45 second auditory or text messages 2 times per week on HTN/stroke facts, importance of med adherence, tips on expressing questions/concerns with physician. We will calculate medication possession ratios, on all subjects' HTN medications at each evaluation.
100402|NCT03401476|Drug|Morphine Sulfate|Morphine Sulfate Tablets
100403|NCT03401463|Other|traning seminar|There will be provided 30 min training seminar on the function of endotracheal cuff and cuff pressure.
100404|NCT03401450|Drug|ACB within true AC with bupivacaine 0.5% 20cc|The adductor canal block (ACB) is more commonly being used to provide post-operative analgesia since it provides a sensory block with minimal motor block.
100405|NCT03401450|Drug|ACB proximal to true AC with bupivacaine 0.5% 20cc|Patients will receive ultra-sound guided single femoral triangle block injection with 20 mL of 0.5% bupivicaine
100406|NCT03401437|Behavioral|SF-36|Evaluation of the quality of life with an auto-questionnaire validated, with 8 dimensions: physical activity ; limitations due to physical condition; physical pain; perceived health; vitality; life and relationship with others; limitations due to physical condition; psychic health as well as the assessment of perceived health compared to a year ago. Evaluation done pre-operatively, at M1 and M3
100407|NCT03401437|Behavioral|HAD|Evaluation of anxiety and depression with a scale validated with 14 items assess between 0 and 3. Evaluation done pre-operatively and at M3.
100408|NCT03401437|Other|ANSM|Additional information requested by the ANSM (french National Agency for Medicines and Health Products Safety) following a materiovigilance report. Evaluation done pre-operatively and at M3.
100409|NCT03401424|Procedure|improved Warren-type style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision plus modified Warren cholangiobiliary reconstruction.
100410|NCT03401424|Procedure|Roux-en-Y style|Select 60 cases of biliary dilatation in patients undergoing laparoscopic cyst excision Roux-en-Y cholangiobiliary reconstruction.
100411|NCT03401411|Behavioral|Survey|Survey of 15 fictional patient case scenarios to be assessed by participant using the standard prioritization or modified SCCMP to prioritize each patient scenario into one of a 5-point likert-scale categories for ICU admission. SCCMP scale categorized as 1-Critically ill to 4-Less likely to require ICU.
100412|NCT03401411|Behavioral|Algorithm-based Triage Tool|Newly designed flowchart-based triage guide to prioritize each patient case scenario into one of the 5-point likert-scale categories, used in conjunction with SCCMP for ICU admission.
100415|NCT03401385|Drug|DS-1062a|A total anti-TROP2 antibody and MAAA-1181a
100416|NCT03401372|Drug|Doxycycline|Oral doxycycline 100mg twice daily
100417|NCT03401372|Drug|Bortezomib|1.3mg/m2 of intravenous bortezomib on days 1, 8, 15 and 22 of a 35-day cycle
100418|NCT03401372|Drug|Cyclophosphamide|300mg/m2 cyclophosphamide on days 1, 8 and 15 of a 35-day cycle
100419|NCT03401372|Drug|Dexamethasone|40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle
100420|NCT03401359|Genetic|tissue biopsy, blood sample|At baseline, 100 tumor/blood samples will be banked. Only ~60 will be profiled if the paired samples are acquired post-progression or on-treatment. On-treatment blood samples will be serially collected and banked from all consenting patients.
100421|NCT03401346|Combination Product|INP104|Dihydroergotamine Mesylate (DHE) administered via I123 Precision Olfactory Delivery (POD) Device
100422|NCT03401346|Drug|Dihydroergotamine Mesylate (DHE)|Dihydroergotamine Mesylate (DHE) injection (intravenous)
100423|NCT03401346|Combination Product|Migranal Nasal Spray|Dihydroergotamine Mesylate (DHE) delivered via Migranal Nasal Spray pump
100424|NCT03401333|Behavioral|Text Messaging and Brief Negotiation Interview|An in-person brief motivational intervention coupled with 4 weeks of motivational text messages
100425|NCT03401320|Drug|Letrozole ISM|2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
100426|NCT03401294|Drug|FOLFOXIRI and Bevacizumab|Every 2 week for a total of 12 cycles
100427|NCT03401281|Other|Coconut oil|50g extra virgin coconut oil daily for four weeks
100428|NCT03401281|Other|Butter|50g butter daily for four weeks
100429|NCT03401281|Other|Olive oil|50g extra virgin olive oil daily for four weeks
100430|NCT03401268|Drug|subcutaneous immunoglobulin|24 patients demonstrating hypogammaglobulinemia post allogeneic HCT will be started on ScIG for a total of 6 months. Tolerability of the intervention will be assessed with qualitative questionnaires, as well as a financial analysis regarding the intervention.
100431|NCT03401255|Other|Partosure test|To perform the analysis, a sample of cervicovaginal secretions is collected using a vaginal swab provided in the PAMG-1 Detection Test Kit.After removing the swab from its packaging, hold the swab in the middle of the stem and carefully insert the end of the swab into the vagina over a length of 5-7cm (using a speculum). Is not necessary for sampling), when the patient is lying down.Remove the swab from the vagina after 30 seconds. Once the swab has been removed, immediately place the end in the solvent vial provided for this purpose, then rinse the swab by repeating several rotations for 30 seconds. The strip is removed as soon as two bands are clearly visible in the test area, or after 5 minutes.Two bands in the test area indicate a positive result, while a line in the test area indicates a negative result. It is not recommended to read or interpret results beyond 10 minutes of immersion.
100432|NCT03401229|Biological|Benralizumab 30 mg SC + Mometasone Furoate|"Benralizumab injection is 30mg/ml SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Benralizumab 30 mg SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
100433|NCT03401229|Biological|Matching placebo SC + Mometasone Furoate|"Matching placebo injection is SC clear to opalescent, colourless to yellow solution in accessorized pre-filled syringe.~Matching placebo SC will be injected every 4 weeks for the first 3 doses - Weeks 0 , 4 and 8 and every 8 weeks thereafter - Weeks 16, 24, 32, 40 and 48. Total of 8 doses.~Mometasone Furoate Nasal Spray (MFNS) - intranasal corticosteroid - 2 doses (1 dose = 50 micrograms/actuation) in each nostril twice daily. Total daily dose of 400mcg. MFNS will be used for a minimum of 4 weeks prior to randomization and will be continued throughout the study."
100434|NCT03401216|Device|SYNERGY 48 mm|Material: Platinum-Chromium alloy. Stent strut thickness: 0.0029-0.0032 inches. Polymer carrier composed of PLGA (poly(DL-lactide-co-glycolide)). Drug product: Everolimus, 1µg per 1 mm2. Stent diameters available: 2.25; 2.50; 2.75; 3.00; 3.50; 4.00 mm. Stent length: 48 mm. Nominal balloon pressure: 11 atm. (1117 kPa). Manufacturing company: Boston Scientific Corporation (USA)
100435|NCT03401216|Procedure|PCI|Standard PCI procedure
100436|NCT03401216|Procedure|3 month OCT follow-up|Optical coherence tomography imaging of target vessel within 3 month after PCI
100437|NCT03401216|Procedure|6 month OCT follow-up|Optical coherence tomography imaging of target vessel within 5 month after PCI
100438|NCT03401203|Procedure|Rotational atherectomy followed by balloon angioplasty|Percutaneous coronary intervention
100439|NCT03401203|Procedure|Balloon angioplasty|Percutaneous coronary intervention
100440|NCT03401190|Drug|CM4620 Injectable Emulsion (Low Dose)|CM4620-IE 1.0 mg/kg on Day 1 and then 1.4 mg/kg on Days 2-4, during the first phase of the study (Cohorts 1 and 2). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
100485|NCT03400839|Diagnostic Test|Anxiety and depression|"Assessment of anxiety and depression by the Hospital Anxiety And Depression (HADS) Scale"
101257|NCT03394885|Drug|Atezolizumab|1200mg IV q3weeks
100441|NCT03401190|Drug|CM4620 Injectable Emulsion (High Dose)|CM4620-IE 2.08 mg/kg on Days 1 and 2 and then 1.6 mg/kg on Days 3 and 4, during the second phase of the study (Cohorts 3 and 4). All doses of CM4620-IE will be administered intravenously (IV) over 4 hours.
100442|NCT03401177|Drug|Naproxen 500 Mg|Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
100443|NCT03401177|Drug|Placebo Oral Tablet|Placebo is used, to provide a control to the active group.
100444|NCT03401177|Other|Heavy resistance training|Heavy slow resistance training - used in both groups subsequent to the initial week of NSAID or placebo treatment.
100445|NCT03401138|Other|Preoperative Stroke Volume(SV)-guided fluid optimization|"Preoperative SV-guided hemodynamic optimization will be commenced with patients receiving 250ml fluid challenges over five minutes aiming to maximize SV. Maximal SV is defined as absence of a sustained rise in SV by at least 10% in response to a fluid challenge.~PPI will be obtained from the Masimo Radical 7 (Masimo, Irvine, CA, USA) and NIRS from Invos 5100C (Medtronic, Minneapolis, MN, USA).~BV measurements will use pulse dye densitometry (PDD) with Indocyanine Green (ICG). We will use the Dye Densitogram 3300 analyser Nihon Kohden (Tokyo, Japan) for registration of the spectrophotometrical absorption of ICG and calculation of BV."
100446|NCT03401125|Other|Medical file data collection|The information described in the 'outcome measures' section will be collected from the medical files of the patients.
100447|NCT03401112|Drug|IMR-687|Oral administration of once daily IMR-687
100448|NCT03401099|Procedure|Radiofrequency ablation of CTI|Delivery of radiofrequency energy to the cavotricuspid isthmus (region of right atrial tissue between the tricuspid annulus and the inferior vena cava) until bidirectional block is achieved
100449|NCT03401099|Procedure|Cryoballoon PVI|Cryoballoon application to the pulmonary veins aiming for Pulmonary Vein Isolation
100450|NCT03401086|Other|Kinesio Taping|Kinesio Taping
100451|NCT03401073|Drug|Intravenous immunoglobulin|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
100452|NCT03401073|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
100453|NCT03401060|Drug|Denosumab|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
100454|NCT03401060|Drug|Placebo|Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
100455|NCT03401047|Drug|Estradiol|Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
100456|NCT03401021|Other|Questionnaires set|Participants will be asked to respond to the demographic information sheet, Smoking characteristics sheet, the Fagerstrom Test of Nicotine Dependence, the Transtheoretical Model (TTM) variables, Smoking Self-efficacy Questionnaire (SEQ-12), Family Adaptation, Partnership, Growth, Affection, and Resolve (Family APGAR), and a smoking hazard questionnaire.
100457|NCT03401008|Other|Oral manifestations|To do the most accurate clinical and radiological state of oral manifestations in the series of prevalent acromegaly patients followed in the endocrinology service of the CHU of Clermont-Ferrand.
100458|NCT03400995|Drug|AK0529|A solution containing 300 mg radiolabelled AK0529.
100459|NCT03400982|Diagnostic Test|Bone densitometry measurement|Bone densitometry and measurement of body composition
100460|NCT03400969|Device|Glycerol 17%|Glycerol will be applied, using gauze on a lockable tweezer, at the end of the oral care procedure performed by a dentist.
100461|NCT03400969|Device|Aequasyal (OGT)|Aequasyl (OGT) will be sprayed on the mucosa, at the end of the oral care procedure, preformed by a dentist.
100462|NCT03400969|Device|Salient (new product)|Salient (new Product) will be applied/given on a spoon, at the end of the oral care procedure, preformed by a dentist.
100463|NCT03400956|Drug|Vilaprisan (BAY1002670)|Orally, coated tablet 2 mg, once daily
100464|NCT03400956|Drug|Placebo|Orally, coated tablet, once daily
100465|NCT03400943|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily up to 2 x 12 weeks
100466|NCT03400943|Drug|Placebo|Matching placebo is administered to group B1 and B2.
100467|NCT03400930|Other|Severe Acute Malnutrition|
100468|NCT03400917|Biological|AV-GBM-1|Investigational treatment with AV-GBM-1
100469|NCT03400904|Other|Patients with brain injury and mechanical ventilation exposed to extubation/tracheostomy|Extubation and/or tracheostomy if applicable
100470|NCT03400891|Behavioral|Program based on the theory of planned behaviour|14 sessions of one hour to work TPB constructs: attitude, subjective norms, perceived behavioural control and intention.
100471|NCT03400878|Biological|BCG-Japan|One dose of 0.05 ml BCG-Japan vaccine applied to the left deltoid region.
100472|NCT03400878|Biological|BCG-Russia|One dose of 0.05 ml BCG-Russia vaccine applied to the left deltoid region.
100473|NCT03400865|Drug|HCQ/CQ and CAB combined treatment|Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
100474|NCT03400852|Drug|Cosyntropin|Suspension administered subcutaneously 2X week
100475|NCT03400852|Other|Placebo|Suspension administered subcutaneously 2X week
100476|NCT03400839|Diagnostic Test|Daily physical activity levels|Objectively measured physical activity using activity monitors.
100477|NCT03400839|Diagnostic Test|6-minute walk test|Assessment of functional exercise capacity.
100478|NCT03400839|Diagnostic Test|Cardiopulmonary exercise testing|Assessment of maximal exercise capacity.
100479|NCT03400839|Diagnostic Test|Muscle Function|Assessment of muscle force, muscle endurance and muscle fatigability
100480|NCT03400839|Diagnostic Test|Lung Function|Assessment of whole-body plethysmography and spirometry.
100481|NCT03400839|Diagnostic Test|Body composition|Assessment of bioelectrical impedance.
100482|NCT03400839|Diagnostic Test|HRQoL - SGRQ-I|"Assessment of Health-related quality of life by the Saint-George Respiratory questionnaire (SGRQ-I)"
100483|NCT03400839|Diagnostic Test|Symptoms - UCSD/SOBQ|"Assessment of symptoms by the UCSD Short of breath questionnaire"
100484|NCT03400839|Diagnostic Test|HRQoL - SF36|"Assessment of Health-related quality of life by the SF-36 questionnaire"
100489|NCT03400839|Diagnostic Test|Inflammatory markers and oxidative stress|"blood assessment of inflammatory markers: IL-2, IL-10, IL-6, IL-4 e IL-17A, TNF, Interferon-γ, CK and CRP.~Blood assessment of oxidative stress: TRAP, SH, SOD, CAT, PON 1, Gpx, MDA, NOx, FOX and AOPP."
100490|NCT03400826|Drug|Simvastatin 40mg|The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
100491|NCT03400826|Drug|Placebo 40 mg|The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
100492|NCT03400813|Behavioral|R-TEP EMDR|Recent Traumatic Episode Protocol Eye-Movement Desensitization and Reprocessing is a early and short adaption protocol of EMDR developed by Shapiro E. EMDR is a psychotherapeutic approach that can rapidly process disturbing experiences adaptively together with the aid of eye movements or other forms of bi-lateral stimulation.
100493|NCT03400800|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
100494|NCT03400800|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
100495|NCT03400787|Device|Latera Implant|Treatment
100496|NCT03400774|Other|Stair-climbing|Short bouts of moderate intensity stair-climbing
100497|NCT03400748|Device|RF Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radio-frequency energy.
100498|NCT03400735|Combination Product|Cefdinir/clavulanic acide 300/125 mg film-coated tablets|Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.
100499|NCT03400735|Drug|Cefdinir 300Mg Capsule|Cefdinir is used as comparator
100500|NCT03400722|Drug|Pergoveris|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
100501|NCT03400722|Drug|Clomiphene|Two controlled ovarian stimulation within the same menstrual cycle. It will be followed by ovarian puncture, fertilisation of oocyte by IVI or ICSI, blastocyst vitrification. If there are 3-5 blastocysts, the embryo accumulation process will be completed and the unfrozen embryos transferred.
100502|NCT03400709|Drug|N Acetylcysteine|Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.
100503|NCT03400709|Drug|Placebo Oral Tablet|Placebo treatment
100504|NCT03400696|Behavioral|Lower carbohydrate diet|Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity
100505|NCT03400696|Behavioral|Higher fiber diet|Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity
100506|NCT03400696|Behavioral|Physical activity focused|Focused on aerobic and resistance exercise, while following dietary guidelines <https://www.choosemyplate.gov>
100507|NCT03400683|Drug|Misoprostol|200 microgram misoprostol in sublingual every four hours for a maximum of five doses
100508|NCT03400683|Drug|Letrozole|15mg( letrozole 2.5mg) on three successive day
100509|NCT03400683|Procedure|Foley's catheter|transcervical 16F Foley's catheter with 30 ml balloon capacity inserted under aseptic conditions
100510|NCT03400670|Device|ventilator NCPAP|infants will be randomized into two different NCPAP groups
100511|NCT03400657|Procedure|Multi-disciplinary Treatment|due to suggestion of Multi-disciplinary Treatment ,the patients would be suggested to chemotherapy or surgery.
100512|NCT03400644|Device|Cervical collar|Cervical neck collar which is routinely made for post-laminoplasty patients
100513|NCT03400631|Drug|Dextrose 0|Dextrose injection at time 0
100514|NCT03400631|Drug|Aspiration 0|Aspiration only at time 0
100515|NCT03400631|Drug|Dextrose 1|Dextrose injection at week 1
100516|NCT03400631|Drug|Aspiration 1|Aspiration only at week 1
100517|NCT03400618|Other|Moderate carbohydrate diet|30 E % carbohydrates included in the diet
100518|NCT03400618|Other|Higher carbohydrate diet|50 E % carbohydrates included in the diet
100519|NCT03400605|Other|Infant feeding questionnaire|Prospective infant feeding questionnaire administered over the telephone or in-person at 2 weeks and at 2, 4 and 6 months postpartum
100520|NCT03400592|Drug|Irinotecan|180 mg/m2 IV once every 2 weeks until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
100521|NCT03400592|Drug|nimotuzumab|400mg IV once weekly until radiographically documented tumour progression, unacceptable toxicity, or withdrawal of consent by the patient
100522|NCT03400579|Device|autoRIC® device|The autoRIC® automatically delivers four RIC cycles of five minutes of pressure at 200 mm Hg followed by five minutes of no pressure for a total 40-min treatment period
100523|NCT03400566|Behavioral|Narrative|Children will be read a story book featuring vegetables for a minimum of 7 times (including twice during the familiarization phase).
100524|NCT03400566|Behavioral|Experiential|Children will receive hands on experience with the vegetable. They will get to listen, see, feel, touch and smell the actual vegetable during the two familiarization phases.
100525|NCT03400553|Diagnostic Test|Blood analysis|The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).
100526|NCT03400540|Diagnostic Test|verbal instruction|Verbal instruction for pelvic floor contraction will be given to participants. Ultrasound examination will be conducted to asses urinary bladder displacement being a marker for pelvic floor muscle function.
100527|NCT03400527|Other|Exercise|Participants will pedal on a stationary bicycle up to 25 minutes 2-3 times a week for 4 weeks at a self directed pace and intensity
100528|NCT03400501|Drug|Insulin Degludec|Single daily dose of insulin degludec based on their fasting blood glucose levels and current long acting insulin dose
100529|NCT03400501|Drug|Insulin Glargine|Single daily dose of insulin glargine based on their fasting blood glucose levels and current long acting insulin dose
100571|NCT03400215|Diagnostic Test|Diagnostic Breast Cancer Scan|clinically indicated diagnostic breast MRI scans
100530|NCT03400488|Drug|AZD5718 oral suspension|In all cohorts, randomized subjects will receive orally AZD5718 oral suspension SAD (60 mg) on Day 1 and MAD (180 mg, 360 mg and 600 mg) from Days 3 to 10. On Day 2, no dose will be given. In total each subject will receive 9 doses of AZD5718.
100531|NCT03400488|Other|Placebo matching AZD5817 oral suspension|In all cohorts, randomized subjects will receive orally placebo matching AZD5718 oral suspension on Day 1 and from Days 3 to 10. On Day 2, no dose will be given.
100532|NCT03400475|Drug|Simvastatin|One topical application in peri-implant gingival crevice
100533|NCT03400475|Other|Placebo|One topical application in peri-implant gingival crevice
100534|NCT03400462|Drug|NSAID|Nimesulide has anti-inflammatory and analgesic properties. Like other NSAIDs it inhibits the action of COX . If prostaglandins can not be further synthesized, so there is no factor able to excite local nociceptors. According to t must be taken regularly for a minimum 2 weeks to achieve appropriate blood concentration.
100535|NCT03400462|Device|oral appliance|The stabilization appliance used in this study was a removable device for maxillary arch, made of hard acrylic. Appliance was fitted over occlusal and incisal surfaces of the teeth and precisely contacted with the teeth of opposing arch. It provided canine disocclusion of the posterior teeth during eccentric movements.
100536|NCT03400462|Other|dry needling|Equipment: acupuncture needle 0,6*13 e.g. Dragon Medical Device, Visits schedule:( 1st visit - Day 1st , 2nd visit- 7 days after the 1st, 3rd visit- 7 days after the 2nd)
100537|NCT03400449|Other|Video counseling|Video counseling
100538|NCT03400449|Other|Conversational counseling|Conversational counseling
100539|NCT03400436|Other|No intervention in observational studies|No intervention in observational studies
100540|NCT03400423|Drug|Caffeine|Oral administration of 1.2mg/kg of powdered caffeine with water.
100541|NCT03400423|Behavioral|Moderate Intensity Exercise|Moderate intensity exercise conducted on a treadmill. Moderate intensity exercise defined as (220-age)*0.6.
100542|NCT03400410|Behavioral|Education Arm|The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
100543|NCT03400397|Other|Cool Kids programme|A manualised cognitive behavioural treatment programme that consists of 10 session within 12-16 weeks each lasting 2 hours.
100544|NCT03400384|Other|Direct-to-consumer educational brochure|The intervention arm will be mailed an evidence-based, theory-driven direct-to-consumer educational brochure, highlighting the potential benefits and harms of opioids when used to treat chronic non-cancer pain.
100545|NCT03400371|Other|Blood draw|Participation includes one visit for one blood draw per recruited patient. 10-20ml peripheral venous blood will be taken from the antecubital fossa. The DNA from the blood sample will then be extracted and resequenced for analysis.
100546|NCT03400371|Other|Existing samples|Control DNA samples will be used that have been previously acquired in other studies.
100547|NCT03400358|Other|uterocervical angle|the angle between cervical canal and anterior uterine wall is measured sonographically.
100548|NCT03400332|Drug|BMS-986253|Specified dose on specified days
100549|NCT03400332|Biological|Nivolumab|Specified dose on specified days
100550|NCT03400306|Drug|Veliparib, capsule|capsule; 50 mg or 100 mg
100551|NCT03400306|Drug|Veliparib, tablet|tablet; 400 mg
100552|NCT03400306|Drug|Carboplatin|Intravenous
100553|NCT03400306|Drug|Paclitaxel|Intravenous
100554|NCT03400293|Other|Functional Assessment of HIV Infection|Functional Assessment of HIV Infection will be used to assess HRQoL of subjects. This will include 47 items.
100555|NCT03400293|Other|Patient Satisfaction Questionnaire|Patient Satisfaction Questionnaire will be used to assess burden and HRQoL in subjects. This will include 18 items.
100556|NCT03400293|Other|Symptom Distress Module|Symptom Distress Module will be used to assess burden and HRQoL in subjects. This will include 20 items.
100557|NCT03400293|Other|Patient Health Questionnaire|Patient Health Questionnaire will be used to assess burden and HRQoL in subjects. This will include 2 items.
100558|NCT03400293|Other|Internalized Stigma of AIDS Tool|Internalized Stigma of AIDS Tool will be used to assess burden and HRQoL in subjects. This will include 10 items.
100559|NCT03400293|Other|Medication adherence visual analogue scale|Medication adherence visual analogue scale will be used to assess burden and HRQoL in subjects. This will include 1 item.
100560|NCT03400280|Other|Best practice algorithm for postoperative care|See arm/group description
100561|NCT03400267|Drug|Paracetamol|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
100562|NCT03400267|Drug|Fentanyl|Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
100563|NCT03400254|Drug|Hydroxychloroquine (HCQ)|All patients will receive HCQ at a dose of 600 mg orally twice daily. This dose is the same in both phase Ib and phase II portions of the protocol. Capsules of HCQ are available in 200 mg strength, thus patients will initially start with 3 capsules twice daily for a total of 6 capsules per day. HCQ will be administered in divided doses (BID). When taking HCQ twice daily, the two daily doses should be taken 12 hours apart as close to 9am and 9pm as possible. Patients receiving antacids, sucralfate, cholestyramine, and/or bicarbonate should have the HCQ drug dose administered at least 1 hour before or 2 hours after these medications. Hydroxychloroquine will be obtained from the UPENN Investigational Drug Service (IDS).
100564|NCT03400254|Drug|Gedatolisib|"Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC >1.0 x 109/L and platelet count > 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to <grade 1 then any further treatment with GED should be stopped."
100565|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product A
100566|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product B
100567|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Tiotropium Easyhaler 10 mcg/dose Product C
100568|NCT03400241|Drug|Tiotropium Bromide Monohydrate|Spiriva 18 Mcg/capsule inhaled via HandiHaler
100573|NCT03400202|Device|Skin imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Ox Optical Coherence Tomography (OCT).
100574|NCT03400202|Other|Facial cleanser|Facial cleanser prior to procedures.
100575|NCT03400189|Drug|Sulthiame|Single dose (50, 100, 200 mg)
100576|NCT03400176|Drug|VAY736|Experimental
100577|NCT03400176|Drug|ibrutinib|Approved medication
100578|NCT03400163|Drug|BMS-986036|BMS-986036 20 mg QD
100579|NCT03400163|Drug|Placebo|Placebo QD
100580|NCT03400150|Device|ProSpace|ProSpace balloon implantation
100581|NCT03400150|Other|Control|Control - Marking & IMRT are standard of care for prostate cancer - there is no study-specific intervention
100582|NCT03400137|Diagnostic Test|Increasing of intraocular pressure (IC)|intraocular pressure will be increased using an ophthalmodynanometer
100583|NCT03400124|Procedure|ISBCS|The intervention group will undergo cataract surgery in both eyes on the same day (ISBCS)
100584|NCT03400124|Procedure|DSBCS|The usual care / control group will undergo cataract surgery in both eyes on separate days, with a time period of at least two weeks between surgeries.
100585|NCT03400111|Radiation|low-level laser therapy|low-level laser therapy will be used to relieve pain and discomfort during orthodontic treatment at specific time points.
100586|NCT03400111|Drug|Panadol-extra|Tablets of 565-mg Panadol-extra will be used at specific time points to control pain and discomfort
100587|NCT03400098|Drug|Inotersen|Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm
100588|NCT03400085|Other|mHealth application|The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
100589|NCT03400072|Other|Unsupervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.
100590|NCT03400072|Other|Supervised APA program|Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.
100591|NCT03400059|Device|Chordate System S211 in treatment mode|Chordate System S211 in treatment mode
100592|NCT03400059|Device|Chordate System S211 in placebo mode|Chordate System S211 in placebo mode
100593|NCT03400046|Drug|Nutritional Product Supplementation|Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
100594|NCT03400033|Drug|Daprodustat tablets|Round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
100595|NCT03400033|Drug|Matching placebo tablets|Matching placebo to daprodustat tablets supplied as round, biconvex, white, film-coated tablet in unit dose strengths 2 and 4 milligrams (7 millimeter tablets), 6, 8 and 10 milligrams (9 millimeter tablets) administered by the oral route.
100596|NCT03400033|Drug|Epoetin alfa vials|Single-dose, preservative-free vials in unit dose strengths of 2000, 3000, 4000 and 10,000 Units/milliliter administered by the IV route.
100597|NCT03400033|Drug|Saline vials or bags|0.9% sodium chloride saline vials or bags administered by the IV route.
100598|NCT03400020|Other|Ascorbic acid|Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.
100599|NCT03400020|Other|Normal Saline|Normal saline IV two hours before the operation and thereafter for three days.
100600|NCT03400007|Device|Dynamic floor magnetic resonance imaging|Dynamic floor magnetic resonance imaging (MRI)
100601|NCT03400007|Device|Colpocystodefecography|Colpocystodefecography (CCD)
100602|NCT03399994|Device|device implantation during coronary angioplasty|device implantation during coronary angioplasty
100603|NCT03399981|Biological|Tysabri|Administered as specified in the treatment arm.
100604|NCT03399968|Device|ESWT|at low energy, shockwaves are applied non-invasively at the injury level and 5 segments up and down of the spinal cord paravertebrally left and right
100605|NCT03399968|Device|Placebo ESWT|the ESWT therapy head is positioned at the level of injury and is moved up and down identically as described in the Verum intervention group (ESWT) but without application of shockwaves. The sound which is normally produced by shockwave generation is played by high quality sound recordings in the same amount as in the Verum group
100606|NCT03399955|Drug|Paromomycin|Paromomycin (20 mg/kg/d) IM for 14 days
100607|NCT03399955|Drug|Ambisome|AmBisome® (20 mg/kg total dose) IV over 7 days
100608|NCT03399955|Drug|Miltefosine|Miltefosine oral (allometric dosing) for 42 days (arm 1) or 28 days (arm 2)
100609|NCT03399942|Procedure|Deep brain Stimulation of cingulum anterior|The Deep brain Stimulation of cingulum anterior is alternatively ON and OFF while Thalamic stimulation is ON
100610|NCT03399929|Other|Post Acute Rehabiltation|
100611|NCT03399916|Behavioral|Prompt sent|
100612|NCT03399903|Drug|Pentasa vs Align|We will examine the safety and possible effectiveness of Pentasa® and Align in reducing markers of immune activation believed to be important reflectors of risk for cardiovascular disease and ongoing immune damage in people with chronic treated HIV-1 infection.
100613|NCT03399890|Diagnostic Test|Neurological physical exam|Neurological physical exam is performed in all patients at the OR table, immediately after the operation.
100614|NCT03399877|Biological|Combining electromyography with uroflowmetry (group A)|Children who assigned group A perform uroflowmetry-electromyography for the first and subsequently perform uroflowmetry-electromyography again.
100615|NCT03399877|Biological|Uroflowmetry(Group B)|Children who assigned Group B perform uroflowmetry-electromyography for the first, and subsequently perform sole uroflowmetry.
100616|NCT03399877|Biological|Uroflowmetry-Combining electromyography with uroflowmetry (Group C)|Children who assigned Group C firstly perform sole uroflowmetry and subsequently perform uroflowmetry-electromyography.
100617|NCT03399864|Behavioral|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for 52 weeks.
100618|NCT03399864|Other|usual care|The subjects in the control group will receive usual care, such as medical follow-up according to the schedule of the oncology units.
100619|NCT03399851|Device|Amplatzer Amulet for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Amplatzer Amulet will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
100620|NCT03399851|Device|Watchman/FLX for left atrial appendage closure|The closure of the left atrial appendage (LAAC) is performed percutaneously. Implantation of the Watchman/FLX will be performed according to device specific instruction for use, based on both TEE guidance and angiography, femoral venous access and inter-atrial septum crossing.
100621|NCT03399838|Drug|Dexmedetomidine|IN Dex for pediatric procedural sedation at the emergency department
100622|NCT03399838|Drug|Midazolam|po/pr midazolam as active comparator to dexmedetomidine for pediatric procedural sedation at the pediatric emergency department
100623|NCT03399825|Device|OCT-A|"optical coherence tomography angiography~Imaging with optical coherence tomography angiography"
100624|NCT03399812|Dietary Supplement|Animal protein|The animal protein intervention is a smoothie containing 40 grams of whey protein isolate.
100625|NCT03399812|Dietary Supplement|Plant protein|The animal protein intervention is a smoothie containing 40 grams of pea protein isolate.
100626|NCT03399799|Drug|JNJ-64407564|Participants will receive IV infusion or SC injection of JNJ-64407564.
100627|NCT03399786|Drug|evinacumab|IV administration of evinacumab
100628|NCT03399786|Drug|Placebo|IV administration of placebo
100629|NCT03399773|Biological|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
100630|NCT03399773|Drug|Cyclophosphamide|Given IV
100631|NCT03399773|Drug|Fludarabine|Given IV
100632|NCT03399773|Drug|Thiotepa|Given IV
100633|NCT03399773|Radiation|Total-Body Irradiation|Undergo TBI
100634|NCT03399773|Procedure|Umbilical Cord Blood Transplantation|Given IV
100635|NCT03399760|Biological|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
100636|NCT03399760|Procedure|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
100637|NCT03399747|Drug|Abb-R-CHOP|"Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma~3 Cycles(1 Cycle:4weeks) of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy"
100638|NCT03399734|Drug|Perampanel|Single oral dose of 1 x 4-mg perampanel tablet
100639|NCT03399734|Drug|Perampanel|Single 4-mg dose of perampanel fine granules
100640|NCT03399721|Device|Chordate S101|Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
100641|NCT03399708|Drug|Apremilast 30mg|Apremilast will used in line with its license. This includes the standard dose titration scheme (see section 6) and then the usual maintenance dose of 30 mg twice daily orally.
100642|NCT03399695|Procedure|preoxygenation|spontaneous breathing
100643|NCT03399682|Diagnostic Test|cystography|observationnal study
100644|NCT03399669|Drug|gefitinib|Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
100645|NCT03399656|Dietary Supplement|Avmacol tablets|The active components of Avmacol® are ground broccoli seeds that provide glucoraphanin and freeze-dried broccoli sprouts that provide a stabilized form of the enzyme myrosinase, which converts glucoraphanin to sulforaphane.
100646|NCT03399656|Dietary Supplement|Placebo tablets|MCC 90M Emcocel
100647|NCT03399643|Drug|Atezolizumab|Atezolizumab is administered via IV 1200 mg every 3 weeks
100648|NCT03399630|Other|Injection of Autologous Adipose Tissue|Injection of Autologous Adipose Tissue to study the safety and efficacy of treating osteoarthritis
100649|NCT03399630|Other|Injection of lactated ringers|Injection of placebo lactated ringers to compare against the injection of autologous adipose tissue.
100650|NCT03399617|Dietary Supplement|Micronutrient Powders|Micronutrient powders (5 nutrient formulation) are currently provided by the Guatemalan Ministry of Health to children between 6-24 months of age.
100651|NCT03399617|Behavioral|SPOON behavioral change strategy|An innovative behavioral change strategy designed using ethnographic and marketing methods to promote adequate infant and young child feeding practices and the use of SQ-LNS. The strategy will be delivered to mothers or caregivers through individual home-visits, group sessions, and community mobilization activities.
100652|NCT03399617|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based ready to use home fortification product to improve diet quality in children 6-24 months of age. It includes peanuts and other ingredients such as vegetable fat, powdered milk and several micronutrients. The formulation designed for this study does not include sugar.
100653|NCT03399604|Drug|LIQ861 Inhaled Treprostinil|LIQ861 bulk powder is generated from a treprostinil/excipient matrix from which particles of precise size and shape are created and filled into a hydroxypropyl methylcellulose (HPMC) capsule (size 3). LIQ861 capsules are provided in capsule strengths of 25 μg, 50 μg, 75 μg and 100 μg treprostinil.
100654|NCT03399578|Biological|ChAdOx1 MERS|The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
100655|NCT03399552|Drug|Avelumab|10mg/kg delivered by IV infusion
100656|NCT03399552|Radiation|Stereotactic Body Radiation Therapy|short course of SBRT after the first two doses of avelumab
100657|NCT03399539|Drug|Dexamethasone|Given PO
100658|NCT03399539|Drug|Ixazomib Citrate|Given PO
100659|NCT03399539|Other|Laboratory Biomarker Analysis|Correlative studies
100660|NCT03399539|Drug|Venetoclax|Given PO
100661|NCT03399526|Drug|Mapracorat (ZK 245186, BAY 86-5319)|0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
100662|NCT03399526|Drug|Prednicarbate 0.25% ointment|0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
100663|NCT03399526|Drug|Clobetasol 0.05% ointment|0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
100664|NCT03399526|Drug|Calcipotriene 0.005% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene as ointment
100665|NCT03399526|Drug|Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment|0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
100666|NCT03399513|Drug|Ibrutinib Oral Capsule [Imbruvica]|Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)
100667|NCT03399513|Drug|R-CHOEP chemotherapy|Immunochemotherapy
100668|NCT03399500|Behavioral|In-Person Case Management at Homeless Recovery Program|In-Person Case Management at Homeless Recovery Program
100669|NCT03399500|Behavioral|Unlimited Smartphone|Smartphone with unlimited calls, texts, and data plan
100670|NCT03399500|Behavioral|Smartphone Based Case Management (SPCM) app|Smartphone Based Case Management app
100671|NCT03399487|Drug|LDK378(Ceritinib)|"This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.~This clinical study is targeted for the patients who harbor ROS1 rearrangement and all patients will be treated with LDK378 750mg daily. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days."
100672|NCT03399474|Drug|Dexmedetomidine Injection 0.25 ug/kg|Dexmedetomidine 0.25 ug/kg
100673|NCT03399474|Drug|Lidocaine|Lidocaine
100674|NCT03399474|Drug|Nalbuphine|Nalbuphine
100675|NCT03399474|Drug|Paracetamol|paracetamol
100676|NCT03399474|Drug|Diclofenac sodium (Voltaren®)|Diclofenac sodium (Voltaren®)
100677|NCT03399474|Drug|Dexmedetomidine Injection 0.5ug/kg|Dexmedetomidine 0.5ug/kg
100678|NCT03399461|Other|Patient Interview guide|The interviewer will conduct the interview for subjects with WAS using a semi-structured patient interview guide.
100679|NCT03399461|Other|Caregiver interview guide|The interviewer will conduct the interview for caregivers of subjects with WAS using a semi-structured caregiver interview guide.
100680|NCT03399461|Other|Sociodemographic questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of country-specific sociodemographic questionnaire.
100681|NCT03399461|Other|Pediatric quality of life (PedsQL) questionnaire|The PedsQL is a validated generic measure of health-related quality of life (HRQOL) in children, adolescents, and young adults with acute and chronic health conditions. At the end of interview, subjects will be required to complete subject or caregiver versions of PedsQL questionnaire.
100682|NCT03399461|Other|Clinical questionnaire|At the end of interview, subjects will be required to complete subject or caregiver versions of clinical questionnaire.
100683|NCT03399448|Biological|NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1|Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRα, TCRβ and PD-1 (NYCE T Cells).
100684|NCT03399448|Drug|Cyclophosphamide|a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
100685|NCT03399448|Drug|Fludarabine|a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
100686|NCT03399448|Device|NY-ESO-1 expression testing|Testing to determine if NY-ESO-1 is expressed on tumor tissue.
100687|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low and epinephrine (T1)|A single injection: Neosaxitoxin from 1.25 to 60 µg. Bupivacaine 40 mg. Epinephrine 100 µg.
100688|NCT03399435|Combination Product|Bupivacaine low combined with epinephrine (C1)|A single injection: Bupivacaine 40 mg. Epinephrine dose 100 µg.
100689|NCT03399435|Combination Product|Bupivacaine high combined with epinephrine (C2)|A single injection: Bupivacaine 100 mg. Epinephrine 100 µg.
100690|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low (T2)|A single injection: Neosaxitoxin from 1.25 to 60 μg. Bupivacaine from 10 to 80 mg.
100691|NCT03399435|Drug|Bupivacaine low (C3)|A single injection: Bupivacaine from 10 to 80 mg.
100692|NCT03399435|Drug|Bupivacaine high (C4)|A single injection: Bupivacaine 100 mg.
100693|NCT03399435|Drug|Neosaxitoxin (T3)|A single injection: Neosaxitoxin will be between 1.25 and 60 µg.
100694|NCT03399435|Combination Product|Neosaxitoxin combined with epinephrine (T4)|A single injection: Neosaxitoxin will be between 1.25 and 60 μg. Epinephrine 100 µg.
100695|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low and epinephrine|A single injection: Neosaxitoxin will be between 1.25 to 60 µg. Bupivacaine dose based on results from Part B (10 to 80 mg). Epinephrine 100 µg.
100696|NCT03399435|Combination Product|Neosaxitoxin combined with bupivacaine low|A single injection: Neosaxitoxin will be between 1.25 to 60 μg. Bupivacaine dose based on results from Part B (10 to 80 mg).
100697|NCT03399422|Biological|i-PRF|i-PRF (injectable platelet rich fibrin) assisted upper canine retraction
100698|NCT03399422|Procedure|canine retraction|upper canine retraction will be performed in one side of patients with Class II Division 1 malocclusion patients requiring therapeutic extraction of the maxillary first premolars
100699|NCT03399409|Behavioral|Motivational Interviewing|Motivation techniques
100700|NCT03399409|Behavioral|Anti-inflammatory Information|Provision of information on anti-inflammatory products
100701|NCT03399396|Behavioral|Practice facilitation for HPV vaccine|The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
100702|NCT03399383|Other|Patient education|Participation in the standardized education program (90min patient education). During sessions of 90-120 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings. Participants are provided with emergency cards and sets and are trained in self-injection of glucocorticoids.
100703|NCT03399370|Drug|Inclisiran Sodium|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
100704|NCT03399370|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
100705|NCT03399357|Biological|Influenza Vaccine|Inactivated Trivalent Influenza Vaccine (IIV3) 2017 containing: A (H1N1): an A/Michigan/45/2015 (H1N1) - like virus (new strain); A (H3N2): an A/Hong Kong/4801/2014 (H3N2) - like virus; B/Brisbane/60/2008 - like virus
100706|NCT03399344|Other|MRI|In addition to the standard diagnostic work-up patients will receive an additional MRI scan 0-21 days prior to their scheduled surgery.
100707|NCT03399331|Dietary Supplement|Manuka honey|5 for children or 10cc of honey for adults was ordered directly from a New Zealand company
100708|NCT03399331|Dietary Supplement|olive oil|5 cc of extra virgin olive oil for adults and 2 cc for children directly from a local distributor in south Lebanon will be given.
100709|NCT03399331|Combination Product|Control group|Control at our institution is 5cc sodium bicarbonate, 5cc rinsidin and 5cc of mycostatin 4 times daily for children. For adults it is Caphosol in the BMT unit and in the Basile inpatient unit it is the magic solution (without xylocaine).
100710|NCT03399318|Drug|Acetaminophen|30 mg/kg load then 15mg/kg
100711|NCT03399318|Drug|Ibuprofen|10 mg/kg
100712|NCT03399318|Drug|placebo for acetaminophen|placebo for acetaminophen
100713|NCT03399318|Drug|placebo for ibuprofen|placebo for ibuprofen
100714|NCT03399292|Drug|Cationorm MD sine eye drops|studyparticipants receive lipidbased eye drops once only in the study eye
100715|NCT03399279|Procedure|Open flap debridment|Full mucoperiosteal flap reflected+ Debridement of infrabony defect
100716|NCT03399279|Other|Perforated collagen membrane|Membrane perforations using dental needle
100717|NCT03399279|Other|Occlusive membrane|Biotech collagen membrane
100718|NCT03399279|Other|Nanohydroxyapetite|Nanbone Particles
100719|NCT03399266|Device|Double Balloon catheter for induction of labor|With the patient in lithotomy position or lying supine in bed, a speculum is inserted to visualise the cervix. The device is inserted into the cervix using long forceps until both balloons enter the cervical canal. Then, the uterine balloon is inflated with 20 ml of saline (by means of a 20 ml syringe). The device is then pulled out until stopped by the uterine balloon covering the internal cervical os. At this point the cervico-vaginal balloon located at the external os is inflated with 20 ml of saline and the speculum is removed. Then both balloons are additionally inflated with alternate increments of 20 ml normal saline to a total volume of 80 ml in each balloon. The device is loosely taped to the patient's inner thigh.
100720|NCT03399253|Procedure|surgery|D2 gastrectomy + metastasectomy
100721|NCT03399253|Drug|chemotherapy|capecitabine and oxaliplatin (eight 3-week cycles of oral capecitabine 1000 mg/m² twice daily on days 1-14 plus intravenous oxaliplatin 130 mg/m² on day 1) for 6 months or progress of disease
100722|NCT03399240|Device|Vitasitiq device|Participant uses Vitastiq device for about 2 months to perform Vitastiq readings every day, preferably in the morning. On day 1, 29 and 57 participants' blood sampling is collected and analysed, and measurements using Vitastiq device are performed.
100723|NCT03399214|Drug|IOP Injection|T1 and T2
100724|NCT03399201|Procedure|General anesthesia|induction with the intravenous anesthetic (Propofol) and maintenance with the inhalational anesthetic (Sevoflurane)
100725|NCT03399201|Procedure|Neuraxial anesthesia|Spinal anesthesia will be applied via the local anesthetic ( Bupivacaine).
100726|NCT03399201|Diagnostic Test|Spirometer|Pulmonary function will be evaluated via the portable spirometer (MIR Spirodoc, Spirodoc®, Roma, Italy)
100727|NCT03399188|Procedure|Fecal microbiome transplantation|Fecal microbiota transplantation will be performed through colonoscopy to the IBD patients. Donor feces will be extensively screened for other diseases. Colonoscopy will be done at FMT center of Severance Children's Hospital twice with a month of duration. Recipients will be admitted the day before colonoscopy, and they will be discharged after a day of observation.
100728|NCT03399175|Drug|Early high-dose corticosteroid and immunosuppressive therapy|Early high-dose corticosteroid and immunosuppressive therapy
100729|NCT03399162|Behavioral|PREHAB Workshop|PREHAB workshop/education session in the Prevention and Rehabilitation Centre regarding nursing, nutrition, physiotherapy, psychology, and diabetes.
100730|NCT03399162|Behavioral|PREHAB Exercise Program|An 8-week program that consists of: (1) 2x/week 60-minute supervised exercise sessions; and (2) 3x/week 30-minute home-based exercise sessions.
100731|NCT03399149|Other|Systematic evaluation by an intensivist|
100732|NCT03399136|Behavioral|Exercise training|Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
100733|NCT03399123|Other|Tidal volume|After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
100734|NCT03399110|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
100735|NCT03399110|Drug|Capecitabine|Capecitabine 1000mg/m2
100736|NCT03399084|Drug|Ferric carboxymaltose|750 mg/15 mL
100737|NCT03399071|Drug|FLOT-A|This is a single-arm study with all patients receiving combination FLOT-A
100738|NCT03399058|Other|Group 1 5+5+5 (Control)|The standard of care in Cambodia is known as the basic health and nutrition service package or 5+5+5. The participants in the first group will be the control group and will only be implementing the standard of care, 5+5+5 package (Group 1).
100739|NCT03399058|Behavioral|Group 2: 5+5+5 & PDH|The participants in the second group will receive contextualized Hearth messages through on-going PDH programs in addition to the basic standard of care (Group 2).
100740|NCT03399058|Behavioral|Group 3: 5+5+5 & PDH lite+mHealth|The participants in the third group will receive a PDH lite program and receive follow-up through mobile support phone calls (Group 3).
100741|NCT03399045|Procedure|9-minute withdrawal|Patients in 9-minute withdrawal group will be carefully observed for 9 minutes during the colonoscopy withdraw
100742|NCT03399045|Procedure|6-minute withdrawal|Patients in 6-minute withdrawal group will be carefully observed for 6 minutes during the colonoscopy withdraw
100743|NCT03399032|Drug|Caspofungin|"Each patient will receive: caspofungin i.v. once daily ( 70 mg on the first day, 50 mg on the 2 and 3 day~Blood samples (3 mL) will be collected 2, 4, 8, 12 and 24 hours after each dose of caspofungin for 3 consecutive days."
100744|NCT03399019|Drug|Dexmedetomidine|initial loading dose (0.5 ~ 1㎍/kg for 10 minutes) and maintenance infusion (0.2-0.7㎍/kg/hr)
100746|NCT03399019|Drug|Midazolam|0.05mg/kg bolus injection and if not OAA/S ≤ 3 within 5 minutes, add 0.01mg/kg at intervals of 1~2 minutes
100747|NCT03399006|Device|2D ultrasound|Trans-abdominal ultrasound examination was performed with the woman placed in a recumbent or semi recumbent position & carried out for measurement of fetal CRL and diagnosis of any major fetal defects
100748|NCT03399006|Device|Doppler Ultrasound|"measurement of UtA-PI & UtA-RI. A sagittal section of the uterus was obtained For the Doppler studies, and the cervical canal and internal cervical os were identified. The transducer was gently tilted from side to side and color flow mapping was used to identify each UtA along the side of the cervix and uterus at the level of the internal os.~When three similar consecutive waveforms had been obtained the UtA-PI and UtA-RI were measured, and the mean UtA-PI and UtA-RI of the left and right arteries were calculated."
100749|NCT03399006|Device|3D ultrasound|"3D transabdominal ultrasound of the Placental volume: the transducer with a full bladder and the transducer placed perpendicular to the placenta to see the entire placenta. The adjustments to 3D placental scan were an angle of 70° and a maximum region of interest that allowed the full placental surface. The external limits of the placenta were defined by the basal plate and the chorionic plate excluding the myometrium. Another acquisition was done, if the quality criteria were not attained.~After sonography, the placental volume was calculated with 4D View software (GE Healthcare) by a single operator. The calculation was done twice using the same image, and the time spent was recorded. The VOCAL mode with an angle of rotation of 30° was chosen; the axial plane was the reference; and the calipers were placed on either side of the placenta. With 6 planes, it was possible to reconstruct the volume measured in cubic centimeters."
100750|NCT03398993|Drug|Clomiphene Citrate|50 mg twice daily from3rd day of cycle till 7th day of cycle
100751|NCT03398993|Drug|Human chorionic gonadotropin|75 IU dail;y from 6th day of cycle till 8th of cycle once daily
100752|NCT03398993|Device|Endometrial scratch|"The procedure was carried out in preovulatory day (known when dominant follicle reached 18_20 mm in diameter), usually, done around day 14-day of the cycle.~In the theatre, Patients put in a lithotomy position, sterilization was performed with the presence of good source of light., the procedure was carried out using a thin pipelle tube as follow :- A cuscoe's speculum was inserted into the vagina in order to visualize the cervix.~Cervix was grasped by vollselum upwards backwards, then pipelle tube passed through the cervix and uterine cavity, then moved up and down to make a single induced scratch two times in the lining endometrium of posterior wall of uterus.~The procedure took approximately 15minutes to complete"
100753|NCT03398980|Radiation|survivors treated with CRT|Radiotherapy technology included conventional radiotherapy (CRT) and intensity-modulated radiotherapy (IMRT).
100754|NCT03398967|Biological|Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells|"Biological: Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells~Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose~Other: Laboratory Biomarker Analysis"
100755|NCT03398941|Drug|Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide|Long-Period Octreotide 20mg one week before operation combine Short Period Octreotide 0.3mg during postoperative five days.
100756|NCT03398928|Other|Acupuncture|
100757|NCT03398928|Other|Sham procedure|Ear stimulation with plastic tape
100758|NCT03398915|Procedure|Transpedicular Instrumentation|Transpedicular screw placement and instrumentation
100759|NCT03398902|Behavioral|Sleep extension|Based on CBTI principles, the instructor will prescribe bed times and wake times each week to allow for gradual increases in sleep opportunity.
100760|NCT03398902|Other|Habitual sleep|The study team member will monitor and encourage participants to keep bedtimes and wake times that matched their baseline bedtimes and wake times.
100761|NCT03398889|Diagnostic Test|Plasma levels of metabolites|plasma levels of metabolites
100762|NCT03398889|Behavioral|Dietary questionnaire|Harvard food frequency questionnaire
100763|NCT03398889|Diagnostic Test|Intestinal microbiome|amplification and sequencing of 16S rRNA gene variable regions in stool samples
100764|NCT03398876|Drug|Oromucosal Nicotine Spray (ONS)|Participants will receive oral dose of oromucosal nicotine spray (ONS).
100765|NCT03398876|Drug|Nicotine Gum|Participants will chew nicotine gum for 30 minutes.
100766|NCT03398876|Other|Cigarette|Participants will smoke one cigarette as 10 puffs for 3 minutes.
100767|NCT03398863|Procedure|Cleaning of uterine cavity|Procedure: Cleaning the uterine cavity These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
100768|NCT03398837|Drug|Lenabasum 5 mg|Subjects will receive lenabasum 5 mg twice daily.
100769|NCT03398837|Drug|Lenabasum 20 mg|Subjects will receive lenabasum 20 mg twice daily.
100770|NCT03398837|Other|Placebo oral capsule|Subjects will receive placebo twice daily.
100771|NCT03398824|Drug|metformin HCl|Receive metformin HCl
100772|NCT03398811|Drug|Depot medroxy-progesterone acetate|Injection every 3 months
100773|NCT03398811|Drug|Etonogestrel|68 mg implant
100774|NCT03398811|Drug|Levonorgestrel Acetate|one pill every day for 35days without pill-free interval.
100775|NCT03398798|Device|".014"|".014 CuNiTi orthodontic arch wire"
100776|NCT03398798|Device|".016"|".016 CuNiTi orthodontic arch wire"
100777|NCT03398798|Device|Twin brackets|Ormco Insignia Metal Twin brackets
100778|NCT03398798|Device|Self-ligating brackets|Ormco Insignia SL brackets
100779|NCT03398785|Procedure|Endovascular chemical Ablation of Adrenal Gland|Patients in this group will be treated with partial ablation of adrenal gland by endovascular injection of dehydrated alcohol.
100780|NCT03398772|Behavioral|Comprehensive Health Coaching Program|Comprehensive Health Coaching Program: included physical activity and motivational interviewing techniques, participants were encouraged to set goals with decision-making, self-management and self-monitor their progress, and received support from researcher.
100781|NCT03398759|Drug|Butorphanol|Butorphanol IV injection
100782|NCT03398746|Procedure|LOOP Technique|Placement of subcutaneous loop drain
100783|NCT03398746|Procedure|Standard incision and drainage|Incise and drain with placement of packing
100784|NCT03398733|Device|continuous positive airway pressure|The CPAP treatment group received both baseline and CPAP treatment for 7 days preoperatively. The non-CPAP treatment group only received baseline treatment.
100785|NCT03398720|Drug|HTI-1066 dose level 1|Starting dose level
100786|NCT03398720|Drug|HTI-1066 dose level 2|2nd dose level
100787|NCT03398720|Drug|HTI-1066 dose level 3|3rd dose level
100788|NCT03398720|Drug|HTI-1066 dose level 4|4th dose level
100789|NCT03398694|Procedure|Radiosurgery|Stereotactic radiosurgery will be delivered on all patients utilizing gamma knife technique based on tumor diameter with the exception that the largest lesion diameter to be treated with 15 Gy will be 5 cm. All apparent, previously untreated brain metastases will be treated with radiosurgery at this time. Radiosurgery will be performed 1-3 days prior to surgical resection.
100790|NCT03398681|Drug|Ferric carboymaltose|Ferric Carboxymaltose solution [Ferinject® (FCM), Vifor Pharma (Glattbrugg, Switzerland)]
100791|NCT03398681|Drug|Placebo (Normal saline)|Normal saline (0.9% weight/volume (w/v) NaCl)
100792|NCT03398681|Diagnostic Test|Cardiac magnetic resonance|Cardiac magnetic resonance including T2* and T1-mapping sequences
100793|NCT03398668|Device|Relievion device- Treatment stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
100794|NCT03398668|Device|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
100795|NCT03398655|Drug|VB-111 + Paclitaxel|VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
100796|NCT03398655|Drug|Placebo + Paclitaxel|Placebo will be administered intravenously every 2 months Paclitaxel will be administered intravenously at a dose of 80mg/m2 every week
100797|NCT03398642|Behavioral|French Lifestyle Redesign|Lifestyle Redesign® is a preventive occupational therapy intervention designed to promote meaningful and healthy activities. The French-Canadian Lifestyle Redesign® intervention was led by an occupational therapist (OT) who took the University of Southern California 6-hour online introductory training course and was supervised on a weekly basis. Weekly 2-hour group sessions were held over a six-month period.These sessions were based on 12 modules (e.g. occupation, health and aging; transportation and occupation) from the 2nd edition of the Lifestyle Redesign® Manual and involved didactic presentations, peer exchanges, reflective exercises, direct experience and personal exploration. Every month, one group outing was targeted and individual meetings with the OT were planned.
100798|NCT03398603|Procedure|blood sample and ultrasound|When included in the study blood samples and ultrasound are taken every second day of the first and third menstrual cycle after inclusion.
100799|NCT03398590|Behavioral|self-regulation theory-based mHealth behavior intervention|Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
100800|NCT03398577|Drug|Dapagliflozin 10 MG [Farxiga]|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
100801|NCT03398577|Drug|Placebo Oral Tablet|Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
100802|NCT03398564|Procedure|Erector Spinae Plan Block|The trocar site incision was done 15 minutes after the block in the three groups. The skin was disinfected with chlorhexidine solution, and the high-frequency transducer was isolated with a sterile disposable plastic cover and gel. The patient was placed in lateral position. A high-frequency linear ultrasound probe was placed longitudinally lateral to the T8 spinous process by 3 cm. After identification of the 3 muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The needle was introduced in a cephalo-caudal orientation. The needle tip was positioned fascial plane between rhomboid major and erector spinae muscles. Hydrodissection by 1-2 ml of normal saline to visualize the plan, then deposition of local anesthetic was done. A total of 20 mL of 0.25% bupivacaine was injected here. The same procedure was repeated on the other side.
100803|NCT03398564|Procedure|Oblique subcostal TAP|ultrasound-guided bilateral oblique subcostal TAP block with bupivacaine 0.25% (20ml on each side)
100804|NCT03398538|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment, or total contact cast if patient cannot be fit with diabetic offloading boot
100805|NCT03398538|Other|Additional (outer) Dressing Application|Application of outer a moisture retentive dressing, and a multi-layer compression dressing.
100806|NCT03398538|Other|Mirragen Wound Matrix Dressing|Application of Mirragen to wound site along with standard of care treatment
100807|NCT03398538|Other|Fibracol Wound Dressing|Application of Fibracol Alginate along with standard of care treatment
100808|NCT03398525|Other|usual care|usual care following local standard operational procedures
100809|NCT03398525|Other|Musical intervention|Musical intervention using a marketed music program validated for music therapy
100810|NCT03398512|Procedure|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical colorectal resection and cytoreductive surgery
100811|NCT03398512|Procedure|HIPEC|Normal saline 3000ml-4000ml, Raltitrexed 4mg, 43°C, 60min.
100812|NCT03398512|Drug|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. Capecitabine: 1500mg, twice daily for two weeks, and then suspend for one week
100813|NCT03398499|Device|VIOFOR (Med & Life)|Device: VIOFOR (Med & Life) Magnetic-light applicators, generating a slow-changing electromagnetic field and light ener-gy (830 nm and 640 nm), emitted from LEDs during a physiotherapeutic treatment application parameters: frequency of basic field pulses: 180-195 Hz frequency of packet the field pulses: 12.5 Hz-29 Hz magnetic induction: 15 μT wavelength of light: 830 nm and 640 nm Duration: 10 min number of treatments: 10
100875|NCT03398044|Drug|Placebo|Placebo will be administered to patients randomised into the control group arm.
101258|NCT03394885|Drug|Carboplatin|5-6mg/ML IV q3 weeks
100814|NCT03398486|Diagnostic Test|Kinesiotaping|Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
100815|NCT03398486|Diagnostic Test|inactivation of trigger points (TrP)|A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
100816|NCT03398473|Drug|Epoetin Hospira SDV|Epoetin Hospira Single Dose Vial
100817|NCT03398473|Drug|Epoetin Hospira MDV|Epoetin Hospira Multi-Dose Vial
100818|NCT03398460|Diagnostic Test|Survey|Burnout rates before and after the introduction of a bereavement card Burnout rates before and after an ICU rotation for physicians
100819|NCT03398447|Procedure|High Definition colonoscopy|Colonoscopy without EndoCuffVision
100820|NCT03398447|Diagnostic Test|High Definition colonoscopy with Endocuff Vision|Endocuff Vision is an FDA approved device that fits over the end of a colonoscope and has flexible soft fingers that project from the sides. These fingers can be used to pull back the folds in the colon and expose mucosa on the proximal sides.
100821|NCT03398434|Drug|MAA868|3 MAA868 doses, single administration, subcutaneous,
100822|NCT03398434|Drug|Apixaban|Apixaban 5 mg b.i.d
100823|NCT03398421|Drug|Nemiralisib|Nemiralisib will be given as 100 mcg via ELLIPTA Dry Powder Inhaler with 30 doses per inhaler/ 100 mcg total dose. ELLIPTA® is a registered trademark of GlaxoSmithKline group of companies.
100824|NCT03398421|Drug|Itraconazole|Itraconazole will be given as 100 mg per capsule per day administered orally with water
100825|NCT03398408|Behavioral|Training|The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
100826|NCT03398395|Procedure|endocrown restoration|a cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
100827|NCT03398395|Procedure|90° shoulder endocrown restoration|a 90°cervical margin in the form of a butt joint and a preparation of the pulp chamber that does not extend into the root canals.
100828|NCT03398382|Dietary Supplement|Magnesium tablet group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-artikain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected, the patient will receive magnesium citrate tablets. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
100829|NCT03398382|Dietary Supplement|Placebo tablets group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected , the patient will receive placebo tablets which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo tablets. 200 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
100830|NCT03398382|Dietary Supplement|Magnesium lozenge group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX..) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive magnesium citrate lozenge.The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and magnesium citrate lozenges. 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
100831|NCT03398382|Dietary Supplement|Placebo lozenges group|Before the anaesthesia, all principles of surgical sterility and asepsis with oral cavity flushing for 1 min. ( 15 ml. 0.12% CHX.) will be performed. Operative side will be anaesthetized with the same anaesthetic 3M ESPE, Ubistesin-articain. The surgeon, assistant, surgical approach, surgery technique and instruments will be the same in all subjects. For one side which will be randomly selected patient will receive placebo lozenges which will be identical to the right drug. The same analgesics will also be prescribed: Ibuprofen tbl 400 mg which will be taken as needed, and placebo lozenges 100 mg. After the surgery, all patients will be given the same written and oral instructions for postoperative care.
100832|NCT03398369|Procedure|MRI-Guided CRT|MRI-Guided CRT
100833|NCT03398356|Drug|Metformin|"for group A: 12 weeks metformin treatment in a final dose 3 x 500 mg~for group B: 3 weeks metformin treatment in a dose 3 x 500 mg, next: 3 weeks metformin treatment in a final dose 3 x 1000mg, next: 3 weeks metformin treatment in a dose 3 x 500 mg."
100834|NCT03398330|Drug|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fed state
100835|NCT03398330|Drug|OxyContin®|Orally taking OXYCONTIN® 40mg in fed state
100836|NCT03398317|Other|PICSI|sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
100837|NCT03398317|Other|MACS|sperm selection using MACS for selecting sperm with lower DNA fragmentation index
100838|NCT03398304|Other|Exercise|The participant will exercise for 60 minutes at the Vanderbilt Orthopedics fitness center at moderate intensity (running, goal 70-80% maximum HR).
100839|NCT03398291|Procedure|Synchronous resection of primary pancreatic cancer and liver oligometastasis|Patients undergo surgical exploration. If no extensive metastatic sites are found, the synchronous resection of primary pancreatic cancer and liver metastatic sites will be performed. Adjuvant chemotherapy was recommended, and the regimen selection is recommended to be based on the preoperative chemotherapy.
100980|NCT03397017|Other|Transfusion|
100840|NCT03398291|Drug|Standard chemotherapy|Patients continue to receive standard chemotherapy including folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX), gemcitabine plus nab-paclitaxel, or gemcitabine plus S-1
100841|NCT03398278|Drug|Oxycodone Tamper Resistant|Orally taking Oxycodone Tamper Resistant 40mg in fast state
100842|NCT03398278|Drug|OXYCONTIN®|Orally taking OXYCONTIN® 40mg in fast state
100843|NCT03398265|Behavioral|Treatment Navigation (Intervention)|Subjects in the intervention arm will begin a discussion with the interventionist about whether they are interested in treatment and medication choices for opioid use disorder. The interventionist will use a decision tool informed by the Substance Abuse and Mental Health Services Administration (SAMSHA) guide to medication assisted treatment in order to help make an informed decision about treatment choices. Once a decision is reached, the Treatment Navigator will communicate with the subject periodically to assist with entering treatment and help with locating other social services as needed within the community. The Treatment Navigator will emphasize getting into treatment as quickly as possible once a decision is made. The Treatment Navigator and the subject will continue communicating throughout the 6 month study period. Subjects will also receive overdose education and be offered take-home naloxone.
100844|NCT03398265|Other|Control|Subjects in the control arm will receive referrals from Department of Corrections (DOC) staff for treatment per DOC protocols. Subjects will not receive any treatment navigation or treatment decision making. Subjects will also receive overdose education and be offered take-home naloxone.
100845|NCT03398252|Drug|Doxazosin XL|Participants will be randomized to receive increasing doses of doxazosin XL (0, 4, and 8 mg).
100846|NCT03398252|Drug|Placebo|Participants will be randomized to receive a placebo for doxazosin XL.
100847|NCT03398239|Device|Noninvasive mechanical ventilation|
100848|NCT03398213|Other|Acupuncture|Acupuncture
100849|NCT03398213|Other|Sham procedure|Ear stimulation with plaster
100850|NCT03398200|Biological|Hyperbaric Oxygen Therapy|The intervention consists of exposure to hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours, in a single see-through hyperbaric chamber, breathing 100% oxygen for 90 minutes while subjects are resting in supine position. During the 2 hours, there will be compression and decompression phases for 15 minutes each in which subjects will be breathing compressed environmental air (21% oxygen).
100851|NCT03398200|Other|No Hyperbaric Oxygen Therapy|The reference arm will not receive hyperbaric oxygen therapy prior to hematopoietic stem cell transplant.
100852|NCT03398187|Device|cardiac catheterization|diagnostic and interventional cardiac catheterization
100853|NCT03398174|Behavioral|Motor Control Exercise|"Exercise aiming at improving function of specific muscles of the lumbopelvic region and the control of posture and movement.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
100854|NCT03398174|Behavioral|Patient Education|"Patient education to enable patients to better understand their pain, change any unhelpful beliefs about LBP, and integrate self-management and active coping strategies that deals with fear avoidance behavior and catastrophic thought.~In addition, participants will perform stretching exercises aiming at targeting the postural muscles and connective tissue around the lower back, pelvis and lower limb that tend to get shortened in chronic LBP, and they will be advised to perform aerobic exercise in the form of overground walking at desirable speed at home."
100855|NCT03398161|Other|Quality-of-Life Assessment|Ancillary studies
100856|NCT03398161|Other|Questionnaire Administration|Ancillary studies
100857|NCT03398161|Radiation|Radiation Therapy|Undergo ultra low dose radiation therapy
100858|NCT03398148|Drug|risankizumab IV|risankizumab intravenous (IV) infusion
100859|NCT03398148|Drug|placebo for risankizumab|placebo for risankizumab
100860|NCT03398148|Drug|risankizumab SC|risankizumab subcutaneous (SC) injection
100861|NCT03398135|Drug|risankizumab|subcutaneous (SC) injection
100862|NCT03398135|Drug|placebo for risankizumab|subcutaneous (SC) injection
100863|NCT03398122|Procedure|TACE|epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
100864|NCT03398122|Drug|Apatinib|a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor
100865|NCT03398109|Device|Customized toric IOL for post-DALK atigmatism|
100866|NCT03398096|Device|Cardiac shock wave therapy|Ultrasound guided cardiac shock wave therapy (CSWT) is a new treatment method offering an alternative to revascularization by stimulating angiogenesis. Subsequent clinical trials showed that CSWT could reduce symptoms of myocardial ischemia and improve cardiac function in patients with severe coronary artery disease.
100867|NCT03398083|Drug|THC|THC capsule
100868|NCT03398083|Drug|Alprazolam|Alpraxolam capsule
100869|NCT03398083|Drug|Placebo oral capsule|Sugar pill capsule
100870|NCT03398083|Drug|CBD|CBD capsule
100871|NCT03398070|Other|Standard of Care|"The standard of care interventions for Functional Neurological Disorders (FND) include:~delivery of a rule-in diagnosis~providing educational materials~referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~referring to FND-related cognitive behavioral therapy (CBT)~psychotropic medication management based on standard psychiatric care"
100872|NCT03398057|Other|Health education|SHEP included a comprehensive lecture about BC, with a generally deep focus on detection and screening tools, which were illustrated by a PowerPoint presentation with pictures and videos. The program also included a practical session about BSE (on breast silicon model). At the end of SHEP, a focused group discussion was conducted to answer participants' questions, and to discuss important barriers regarding BSE practice and visiting primary health care centers or clinics to undergo CBE and mammography. Different scientific and administrative solutions were discussed. SHEP materials were distributed as a hard copy (booklet) and in electronic format (CD) for all participants in the health education group at the end of training.
100873|NCT03398057|Other|Control group|Placebo health education (pamphlets) will be applied to this group participants during study.
100874|NCT03398044|Drug|Dexamethasone|Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.
100876|NCT03398031|Drug|Magnesium Oxide|After biochemical diagnosis of pregnancy each participant will receive magnesium plus 500 mg tablet once daily till the end of the 1st trimester
100877|NCT03398031|Drug|Placebo Oral Tablet|After biochemical diagnosis of pregnancy each participant will receive placebo tablet once daily till the end of the 1st trimester
100878|NCT03398018|Drug|repository corticotropin injection|80 units twice per week as a subcutaneous injection
100879|NCT03398005|Drug|CaPre|4 x 1 g capsules administered orally once a day for 26 weeks
100880|NCT03398005|Drug|Placebo|4 x 1 g capsules administered orally once a day for 26 weeks
100881|NCT03397992|Other|Changing dialysate temperature|Patients had SLED with low dialysate temperature (around 35°C) compared with high dialysate temperature (around 37°C)
100882|NCT03397979|Behavioral|Infrequent versus Frequent Soaking Baths|Submersion of skin, affected by atopic dermatitis, in a bathtub filled with luke-warm water, where the frequency and duration of these baths are varied, to look for any differential effect.
100883|NCT03397966|Drug|recombinant human BNP (1-32)|Subjects will receive an IV infusion of recombinant human BNP1-32 (6 mcg BNP/ml saline) for 240 minutes.
100884|NCT03397966|Drug|normal saline (placebo)|Subjects will receive an IV infusion of normal saline for 240 minutes.
100885|NCT03397953|Drug|Vinorelbine|Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
100886|NCT03397927|Device|orthosis|
100887|NCT03397914|Drug|Colistimethate Sodium|Intravenous injection of colistimethate Sodium 2.5 mg/kg or 5 mg/kg for Multidrug-resistance gram negative infections
100888|NCT03397901|Procedure|Transverse colostomy|Transverse double-cavity colostomy
100889|NCT03397888|Drug|Betrixaban|80 mg capsule
100890|NCT03397875|Procedure|Zinc oxide based sealer|After root canal treatment obturation will be done using zinc oxide eugenol based sealer.
100891|NCT03397875|Procedure|Epoxy resin based sealer|After root canal treatment obturation will be done using epoxy resin based sealer.
100892|NCT03397875|Procedure|Bioactive silicone based sealer|
100893|NCT03397862|Drug|Donepezil TDS|Donepezil patch
100894|NCT03397862|Drug|Vehicle TDS|Placebo patch
100895|NCT03397849|Behavioral|Intervention using mobile technology|Each study patients that are randomized to IMT plus usual care group will receive a group of smart devices including mobile phone (Vestel Venus e2) (Vestel, Manisa, Turkey), wristband (Xiaomi band 2) (Beijing Xiaomi Technology Co., Beijing, China), weight scale (Bluecat, Yongkang Tiansheng Electronic Co., Zhejiang, China) and blood pressure monitor (Clever Chek TD-3250) (TaiDoc Technology Co., Taipei County, Taiwan)
100896|NCT03397836|Other|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers who will collect information electronically using a tablet computer. The volunteers will collect information about the client's health goals, health risks, and needs using a specifically designed application (TAP-App). Once the data is gathered, it is summarized into a report (TAP-report) which is securely and electronically sent to the health care clinic (TAP huddle). The team can leverage clinic supports and/or community supports as they deem appropriate to help clients reach their health goals and address any needs and risks which were reported during the volunteer visits.
100897|NCT03397836|Other|Usual Care|Usual care while waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
100898|NCT03397810|Radiation|low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
100899|NCT03397797|Drug|Rocuronium|In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
100900|NCT03397771|Drug|Litoxetine|oral study medication provided in a dose titration manner
100901|NCT03397771|Drug|placebo|placebo medication provided in a dose titration manner
100902|NCT03397758|Device|Study population|First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
100903|NCT03397745|Device|BIS|All patients applied BIS on both side (Left and Right)
100904|NCT03397732|Procedure|aorto-bifemoral bypass and aorta stentgraft|Surgical implantation of aorto-bifemoral bypass or aorta stentgraft under general and/or regional anaesthesia.
100905|NCT03397719|Behavioral|Treatment Condition|This group will receive three hours of parent coaching per week, one hour per week will involve feedback on parent usage of coached strategies based on parent recorded interactions with their children.
100906|NCT03397719|Behavioral|Control Group|This group will receive in-vivo parent coaching three hours per week.
100907|NCT03397706|Drug|VRx-3996|capsules taken orally once or twice daily
100908|NCT03397706|Drug|Valganciclovir|tablets taken orally once or twice daily
100909|NCT03397680|Diagnostic Test|13C Urea Breath Test|After the H.pylori eradication treatment course completed, participants then was tested with 13C Urea Breath Test to confirm treatment effectiveness at least after ceasing PPI and antibiotics for 4 weeks.
100910|NCT03397667|Other|ABC ANSWERS|Primary Care plus ABC ANSWERS
100911|NCT03397667|Other|Control|Primary Care as usual
100912|NCT03397654|Drug|Pembrolizumab|Pembrolizumab solution
100913|NCT03397654|Combination Product|Trans-arterial chemoembolization|Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
100914|NCT03397641|Drug|HBI-3000|Small molecule, multi-ion channel blocker
100915|NCT03397641|Other|Placebo|Normal Saline
100916|NCT03397628|Other|FIFA 11 for health|
100917|NCT03397615|Behavioral|Betadine douches|subjects received a vaginal preparation with povidone-iodine solution immediately prior to caesarean delivery
100918|NCT03397602|Behavioral|standard care + moderate-intensity continuous exercise training|Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
100919|NCT03397602|Behavioral|standard care + high-intensity interval training|Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
100920|NCT03397589|Behavioral|Community Health Worker (CHW) services|CHWs are non-clinical people who provide education, care coordination, and support to families.
100921|NCT03397576|Behavioral|ATHENA|Adherence Through Home Education and Nursing Assessment (ATHENA), is an evidence-based ART adherence intervention delivered in the patient's home by nurses and peer educators working in teams.
100922|NCT03397563|Device|Continuous Positive Airway Pressure|standard automatic CPAP machine set on optimal automatic pressure
100923|NCT03397563|Device|sham Continuous Positive Airway Pressure|CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask
100924|NCT03397550|Other|salt restriction education|Salt intake target：＜5g/d Method：the standard salt restriction education will be lasting for 10-15 minutes by oral explanation at baseline.
100925|NCT03397537|Drug|Letrozole 2.5Mg Tablet|letrozole 2.5mg p.o.qd
100926|NCT03397537|Drug|GnRH analogue|3.75 mg triptorelin im. q28d
100927|NCT03397524|Other|optima4BP|optima4BP will provide the treating physician with a treatment action recommendation for consideration.
100928|NCT03397511|Behavioral|Financial Incentives|Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month
100929|NCT03397498|Behavioral|CogniFit™|The program utilizes 21 tasks, which may develop 14 cognitive domains: awareness, inhibition, spatial perception, visual short term memory, working memory, hand-eye coordination, visual scanning, response time, divided attention, time estimation, visual perception, shifting, naming, and planning.
100930|NCT03397498|Behavioral|Control-games|The program utilizes classic computer games, which may develop cognitive domains. Games will be used over 8 weeks. The participants will use the program 3 days a week, with one rest day between each session. Each session lasts approximately 20 minutes. The participant will use the program for a total number of 24 sessions.
100931|NCT03397485|Dietary Supplement|Growing milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
100932|NCT03397485|Dietary Supplement|Fortified milk|Intervention Milk powder was prepared and reconstituted every weekday at each day-care center according to WHO and Day Care guidelines. Trained personnel prepared the milk according to the color-coding assigned to each child. Bottles were used to facilitate measuring in milliliters. Each bottle was weighted before and after preparing milk in a diet measuring scale (OHOUSE, model CS5000, capacity 5000gx2g).Each children received an individual bottle or cup with its own milk (240ml). Once each bottle or cup was prepared it was given to the child. After the child finished drinking the milk, leftovers were weighted and recorded.
100933|NCT03397472|Device|magnetic field modulation device|use the device with magnetic field modulation to treat insomnia
100934|NCT03397472|Device|placebo device|use the sleep pillow without magnetic field modulation treatment
100935|NCT03397459|Diagnostic Test|Spine teleradiography EOS|
100936|NCT03397446|Drug|Lisdexamfetamine dimesylate|50mg or 70mg oral capsules taken once-daily for to 2 months. The trial will begin with a 4-week titration phase, where patients will titrate up to a dose of 50mg/day or 70mg/day, followed by a 4-week maintenance phase. No dose changes will be permitted during the maintenance phase.
100937|NCT03397433|Other|Information Technology physician assist|The intervention hospitals will have a progress note placed in the electronic health record by a reviewing Infectious Disease specialist that comments on the initial antibiotic choice. The comment is based on an electronic prediction tool (Information Technology physician assist) as to what the best therapy is for the individual patient whose health record is reviewed.
100938|NCT03397420|Other|FAM-CARE|Family-centered care, where all HIV-positive family members are seen together as a unit and receive HIV care and treatment services together, for HIV-positive children and their caregivers
100939|NCT03397407|Other|No intervention|
100940|NCT03397394|Drug|Rucaparib|Rucaparib will be administered daily.
100941|NCT03397368|Diagnostic Test|Transperineal Ultrasound -|Every women with stress incontinence witll be subjected to urodynamics to confirm genuine stress incontinence then will be subjected Transperineal US
100942|NCT03397342|Device|CPAP machine|Use of CPAP machine during MRI
100943|NCT03397329|Drug|AG-348 Sequence A|"Treatment Period 1 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)~Washout Period 7 days~Treatment Period 2 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)"
100944|NCT03397329|Drug|AG-348 Sequence B|"Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~Washout Period 7 days~Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)"
100945|NCT03397316|Procedure|xenograft placement .|immediate implant placement in upper esthetic zone with xenograft placement between residual labial bone and implant surface.
100946|NCT03397303|Other|elastography measurements|elastography measurements
100947|NCT03397290|Device|Ultrasound (US) Imaging|Ultrasound (US) Imaging will be compared to the chest X-ray for diagnostic accuracy (sensitivity and specificity) in diagnoses of pneumothorax post transthoracic lung biopsy
100948|NCT03397277|Behavioral|Safety behaviour promoting video|A 7 min. video which teaches 15 different safety behaviours to reduce violence or the effect of violence
100949|NCT03397277|Behavioral|Control video|A 7 min. video which teaches women about safety regarding food, alcohol, smoking, medication and physical activity during pregnancy
100950|NCT03397264|Biological|Aflibercept|Intravitreal injection
100951|NCT03397264|Biological|OPT-302|Intravitreal Injection
100952|NCT03397264|Other|Sham intravitreal injection|Sham (mock) intravitreal injection
100953|NCT03397251|Device|Ascyrus Medical Dissection Stent placement|The study is a prospective, non-randomized, non-blinded, single-arm, single center study evaluating the feasibility and safety of this new design of stent. The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
100954|NCT03397225|Behavioral|Lifestyle intervention|The educational sessions and individual sessions including dietary management and physical activity advices.
100955|NCT03397212|Other|NADA acupuncture|Ear acupuncture protocol described by National Acupuncture Detoxification Association
100956|NCT03397212|Other|Sham acupuncture|Ear acupuncture using inactive sham points
100957|NCT03397199|Drug|Apatinib + S-1|Apatinib 250mg/d,q.d.,p.o. A course of treatment need 21days. S-1 40-60mg（40mg bid BSA <1.4, 60mg bid BSA>1.4），bid,from day1-day 14.
100958|NCT03397186|Procedure|Biopsy|Undergo biopsy
100959|NCT03397186|Other|Laboratory Biomarker Analysis|Correlative studies
100960|NCT03397186|Drug|Trabectedin|Given as standard of care
100961|NCT03397173|Drug|Azacitidine|Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
100962|NCT03397173|Drug|Ascorbic acid|Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
100963|NCT03397160|Behavioral|Decision Support Intervention (DSI)|"A question list (QL) that includes areas of patient concern are created by the health coach for use by the patient and the urologist at their first consultation visit where they discuss the extent of their cancer and consider treatment options. The coach uses the Prostate Cancer SCOPED model to complete a Prostate Cancer SCOPED Model Form. The SCOPED model uses concepts such as the situation, choices (treatment), objectives (personal goals and priorities), people (involved in supporting a treatment decision), evaluation and decisions (clarifying which choice is best and next steps)."
100964|NCT03397147|Behavioral|Sleep Coach Jr.|A brief sleep education program for parents of school-aged children with type 1 diabetes, with a focus on resolving sleep disturbances with parent education and positive bedtime routines.
100965|NCT03397134|Drug|Placebo Oral Tablet|Placebo administered as a single dose once daily
100966|NCT03397134|Drug|Roluperidone 32 mg|Roluperidone administered as a single dose once daily
100967|NCT03397134|Drug|Roluperidone 64 mg|Roluperidone administered as a single dose once daily
100968|NCT03397121|Drug|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
100969|NCT03397121|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
100970|NCT03397095|Combination Product|CSWT+BMMSCs|All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
100971|NCT03397095|Device|CSWT+Sham operation|Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
100972|NCT03397082|Drug|Lidocaine gel|5mL of lidocaine gel applied topically to cervix previous to clamping and paracervical blockade.
100973|NCT03397082|Drug|Placebo|5mL of sterile gel applied topically to cervix previous to clamping and paracervical blockade.
100974|NCT03397069|Procedure|Peribulbar block (control)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
100975|NCT03397069|Procedure|Peribulbar block(M1)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 50 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
100976|NCT03397069|Procedure|Peribulbar block(M2)|"The Peribulbar block was performed by inserting the needle percutaneously at the area bounded by 1- The imaginary perpendicular line joining inferior lacrimal papilla to the inferior margin of the orbit, laterally 2- Lateral border of the nose, medially 3- Inferior lacrimal canaliculus, superiorly and 4- Inferior orbital margin, inferiorly. The needle was introduced in an anteroposterior direction to its half-length and then in an oblique direction to the optical foramen.~After negative aspiration, 6-8 ml of local anesthetic solution (lidocaine 2%, hyaluronidase 15 IU / ml. plus midazolam 100 µg/ml ) was injected slowly over about 40 seconds or until the appearance of lid fullness. This was followed by a gentle digital massage to the eyeball to facilitate diffusion of the local anesthetic mixture."
100977|NCT03397056|Other|Questionnaire|The Questionnaire is provided in the links at the end of the declaration.
100978|NCT03397043|Other|Protein intake (dose)|Protein intake, in the form of crystalline amino acids, will range between 0.2-3.0 g/kg/d
100979|NCT03397030|Other|Home-Based Exercise Program|The intervention will include a combination of both aerobic and body-weight based exercises. The aerobic portion of the intervention will include 5 days of light to moderate intensity walking for 30 mins. Intensity will be set at 40-60% of the individual's heart rate reserve. The body-weight based exercises will be done 3 times a week and will consist of 3 sets of 15 reps of bodyweight squats, incline push-ups, and hip thrusts. If these exercises cannot be performed, lower intensity exercises such as sit-to-stand, wall push up and pelvic tilt can be replaced. Individuals in this group will be given a pocket guide with instructions on how to safely perform the exercises and document their completion.
100981|NCT03397004|Drug|Doxycycline Hyclate|Doxycycline will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
100982|NCT03397004|Drug|Placebo|Placebo will be given for 6 months, followed by a washout period for 6 months (pre or post a crossover intervention)
100983|NCT03396978|Other|GnRHag|Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
100984|NCT03396965|Other|Mini-c-arm|Fluoroscopy used to aid reduction of distal radius fracture
100985|NCT03396952|Drug|Aspirin|Given PO
100986|NCT03396952|Biological|Ipilimumab|Given IV
100987|NCT03396952|Other|Laboratory Biomarker Analysis|Correlative studies
100988|NCT03396952|Biological|Pembrolizumab|Given IV
100989|NCT03396939|Device|Orthosis|All participants in the experimental group will be given an orthotic device for a 12-week period to use alongside their functional goal- and task-oriented training program.
100990|NCT03396926|Biological|Bevacizumab|Given IV
100991|NCT03396926|Drug|Capecitabine|Given PO
100992|NCT03396926|Other|Laboratory Biomarker Analysis|Correlative studies
100993|NCT03396926|Biological|Pembrolizumab|Given IV
100994|NCT03396913|Device|IPL|Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
100995|NCT03396913|Device|Sham IPL|Sham intense pulsed light (IPL) will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of10-15 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
100996|NCT03396913|Procedure|MGX|Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps
100997|NCT03396900|Drug|RhBMP-2 Protein, Recombinant|Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
100998|NCT03396900|Other|Conventional Corticotomy|A conventional PAOO Surgical procedure will be performed for individuals in this arm
100999|NCT03396887|Other|U Control Drink Smartphone Application|The smartphone application comprises five recovery focused features: supportive messages, Computerised-Cognitive Behavioural Therapy, a drinking log, craving management and gamification.
101000|NCT03396887|Other|Control group|The control group will receive treatment as usual.
101001|NCT03396874|Drug|68Ga-PSMA|"PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi)."
101002|NCT03396861|Drug|Aflibercept|Subconjunctival aflibercept
101003|NCT03396848|Other|SHAReClinic|Online clinic with educational modules
101004|NCT03396835|Device|INVSENSOR00009|All subjects who are enrolled into the test group and participate in data collection receive both the INVSENSOR00009 and the control sensor simultaneously on the forehead.
101005|NCT03396822|Drug|Gadoteridol|gadolinium MRI contrast
101006|NCT03396809|Device|Punctal plug|Punctal plugs are FDA approved for the treatment of dry eye. They increase lubrication of the eye by blocking the drainage of tears into the lacrimal sac. The nose portion of the plug has a larger diameter which is designed to fit in the canaliculum in order to retain the plug in the punctum. The plugs will be used on-label, as it is FDA approved in the treatment of dry eye. The purpose of punctal plugs are to increase tear volume by preventing drainage of tears into the lacrimal sac. The plugs are removable if necessary. Investigators are not testing this device for effectiveness or safety.
101007|NCT03396796|Procedure|Vagus nerve-preserving group|The modified vagus nerve-preserving procedure was performed in the following order: (1) left gastroepiploic vein along greater curvature; (2) the posterior surface of stomach, including the posterior gastric veins; (3) the left lateral surface of the distal esophagus; (4) the left inferior phrenic veins; (5) the posterior surface of the distal esophagus;(6) the anterior surface of the distal esophagus; and (7) the right lateral surface of the distal esophagus. The hepatogastric ligament was conserved. the adherent junction between visceral peritoneum and the right crural diaphragm, and divided it into the lesser omental sac. The left gastric artery and vein and the posterior gastric veins were transected en bloc using a linear laparoscopic vascular stapler.
101008|NCT03396783|Biological|blood test|during the visit, nurse will make a blood test for biological and immunological analysis
101009|NCT03396783|Other|electromyogram and walk test|during the visit, measuring the amount of functional motor units at the muscular level and the distance traveled during a 2 minute walk
101010|NCT03396770|Procedure|Standard clinical routine|Patient management is carried out according to the usual service protocol
101011|NCT03396770|Procedure|Nephrocheck test|"Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~If the test is negative, patient management is carried out according to the usual protocol.~A second test is realized 6 hours after the first test whatever the result of it."
101012|NCT03396757|Procedure|Standard strategy|"RRT is initiated within 12 hours after documentation of serum urea concentration >40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),"
101037|NCT03396575|Drug|Cyclophosphamide + Fludarabine Lymphodepletive Conditioning|Subjects in Group B, however, will receive lymphodepletion with cyclophosphamide + fludarabine after DC vaccination and prior to the intravenous infusion of ex vivo expanded tumor-reactive lymphocytes.
101013|NCT03396757|Procedure|Delayed strategy|"RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice."
101014|NCT03396744|Device|Light|Placebo light (50 Lux) during 1 week and then active bright light with glasses using a dosage escalation (inter- and intra-subject) of 7.5, 10, 15, 30 and 45 min
101015|NCT03396731|Device|geko™ medical device|The geko™ device, manufactured by Firstkind Ltd (High Wycombe, United Kingdom), is a small disposable, battery powered CE marked medical device.
101016|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 1|54/ 59,4 Gy
101017|NCT03396718|Radiation|De-escalation radio(chemo)therapy - Level 2|48,8/ 55 Gy
101018|NCT03396718|Radiation|Standard radio(chemotherapy)|60/ 66 Gy
101019|NCT03396705|Procedure|Liver Biopsy|liver tissue will be collected via core biopsy during liver resection surgery and post-operatively by fine needle aspiration biosy
101020|NCT03396692|Procedure|Intravenous morphine patient-controlled analgesia (PCA)|"Group 1 control:~Morphine titration at 0.1 mg/kg~Establishment of PCA morphine:~concentration 1mg/ml~1ml bolus~refractory period of 7 minutes~no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg"
101021|NCT03396692|Procedure|Block of the posterior exo-thoracic fascia with Ropivacaine|"Group 2 PEF block:~Establishment of PCA morphine:~concentration 1mg / ml~1ml bolus~refractory period of 7 minutes~no maximum dose per day.~Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia."
101022|NCT03396692|Procedure|Block of paravertebral space with Ropivacaine|"Group 3 paravertebral block:~Establishment of PCA morphine:~concentration 1mg / ml~1ml bolus~refractory period of 7 minutes~no maximum dose per day.~Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse."
101023|NCT03396679|Other|Ultrasound examination|Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
101024|NCT03396666|Other|Telemouv|Telemouv telerehabilitation solution Patients will receive telerehabilitation solution during three months
101025|NCT03396653|Behavioral|Peer-delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month patient-delivered behavioral weight maintenance intervention. Specifically, group sessions will be delivered by a mentor (i.e., successful weight loser) and weekly coaching will be delivered by a peer (other member of their weight maintenance group).
101026|NCT03396653|Behavioral|Professionally-Delivered Weight Maintenance|Contingent upon participants losing 5% of body weight or more in Phase I (weight loss) of this trial, participants will receive an 18-month reduced intensity behavioral weight maintenance intervention, delivered by a professional. The intervention will consist of 24 group sessions.
101027|NCT03396640|Procedure|Unicondylar Knee Arthroplasty|"Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not."
101028|NCT03396640|Procedure|Total Knee Arthroplasty|Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
101029|NCT03396627|Diagnostic Test|pathological examination|fresh MM specimens from patients undergoing Müllerectomies will undergo histologic examinations
101030|NCT03396614|Diagnostic Test|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram|CTTC scan, cardiac MRI, ECG, 6 minute walking test, echocardiogram
101031|NCT03396601|Drug|Ketamine Hydrochloride|Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes
101032|NCT03396601|Drug|Placebo|Normal Saline placebo will be infused IV over 40 minutes
101033|NCT03396588|Drug|Clonidine|1mcg/kg/dose (with a dosing interval of 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
101034|NCT03396588|Drug|Morphine|Starting dose is 0.06 mg/kg/dose (every 3 or 4 hours), increases by 25% of initial dose every 12-24 hrs. Decrease by 10% of max dose every 24 hrs.
101035|NCT03396575|Biological|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
101036|NCT03396575|Biological|TTRNA-xALT|During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
101105|NCT03396081|Behavioral|No intervervention Usual Care|Advices about the care pathway, provided by care givers. Prescription of home nurse's visits if needed.
101259|NCT03394885|Drug|Paclitaxel|70-80 mg/m2 IV q1 week
101038|NCT03396575|Drug|Dose-Intensified TMZ|After chemoradiation, subjects in Group A will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
101039|NCT03396575|Drug|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
101040|NCT03396575|Biological|Autologous Hematopoietic Stem Cells (HSC)|During Cycle 4, all patients will receive HSCs prior to xALT infusion and DC vaccine #6.
101041|NCT03396562|Other|Assessments of Development and Growth|Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years.
101042|NCT03396549|Device|new sham tDCS|1 ch TCT transcranial stimulator
101043|NCT03396549|Device|real tDCS|1 ch TCT transcranial stimulator
101044|NCT03396536|Other|Evaluation of KM|"KM will be evaluated. The alveolar mucosa will be stained with Lugol's solution, by means of a cotton swab. A cotton roll will be soaked in the solution and gently applied on the mucosa around the implant. Since Lugol's solution is selective to the glycogen present in AM, the muco-gingival junction as the borderline between the blue-stained alveolar mucosa and KM can be easily identified.~A manual periodontal probe with 1 mm markings will measure the distance from the peri-implant margin and the muco-gingival junction.~Mucosal thickness (MT) will be measured after topical application of the anesthetics. MT will be evaluated inserting a 27G needle with a rubber stop 1 mm below the peri-implant mucosal margin at the mid-buccal aspect, until the abutment is engaged. The needle will be removed and the distance between the rubber stop and the point of the needle will be measured with a manual periodontal probe."
101045|NCT03396523|Drug|Losartan|administration of losartan (50 mg) (oral)
101046|NCT03396523|Drug|Placebo Oral Tablet|administration of placebo (oral)
101047|NCT03396510|Other|IMPROVED intervention|Patients randomized to IMPROVED will self-report their symptoms each day using a tablet computer. If any patient refuses or is unable to complete the symptom assessment on the computer, the investigators will permit them to use paper versions. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden. Patients randomized to IMPROVED will have their symptoms presented to their inpatient oncology team, but the investigators will not provide guidance about what actions to take in response to patients' symptoms.
101048|NCT03396497|Drug|LYC-55716|Continuous twice daily administration of LYC-55716 in 28 day treatment cycles.
101049|NCT03396497|Drug|Pembrolizumab|Pembrolizumab administered every 3 weeks as prescribed as standard of care by the investigator in accordance with the package insert.
101050|NCT03396484|Drug|Methyldopa|Tablet for oral dosing
101051|NCT03396484|Drug|Placebo|Tablet for oral dosing
101052|NCT03396471|Drug|Pembrolizumab|200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 35 cycles.
101053|NCT03396471|Radiation|External Beam Radiation Therapy|20-30 Gy over five fractions for up to two cycles.
101054|NCT03396458|Diagnostic Test|Hepatitis B serology|A serum specimen will be taken and assessed for hepatitis B serology (HBsAg, anti-HBs and anti-HBc).
101055|NCT03396458|Other|Questionnaire|Participants will be asked to fill in a questionnaire regarding sociodemographic factors, migration history, risk factors for HBV infection (e.g. sharing toothbrushes, HBV infected family member) and HBV vaccination status.
101056|NCT03396445|Drug|MK-5890|IV infusion
101057|NCT03396445|Biological|Pembrolizumab|IV infusion
101058|NCT03396445|Drug|Pemetrexed|IV infusion
101059|NCT03396445|Drug|Carboplatin|IV infusion
101060|NCT03396432|Device|Video Laryngoscopy for ET placement|Tracheal intubation performed with the Storz C-Mac Video Laryngoscope
101061|NCT03396432|Device|Direct Laryngoscopy for ET Placement|Tracheal Intubation performed with the Miller Blade
101062|NCT03396406|Device|Pulsed radiofrequency (PRF)|received PRF at 42°C for 8 minutes followed by CRF at 60°C for 270s
101063|NCT03396406|Device|thermocoagulation|received sole CRF at 70°C for 270 s
101064|NCT03396393|Drug|Dihydroartemisinin tablet|DHA tablet
101065|NCT03396393|Drug|Placebo tablet|Placebo tablet
101066|NCT03396380|Drug|Vitamin D with calcium and clomiphene citrate|"Vitamin D ( ossofortin®, EVA PHARMA) 10000 IU twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~Induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily) starting from the third day of menstrual cycle and for five days ."
101067|NCT03396380|Drug|Placebo Oral Tablet with calcium and clomiphene citrate|"The placebo tablet twice weekly and calcium (calciprex®, Marcyrl Pharmaceutical Industries ) 1250 mg twice daily which provide elemental calcium 500 mg/tablet for one month before induction of ovulation and both will be continued during the 3 induction cycles in the same regimen.~induction of ovulation by clomiphene citrate (Clomid®, Aventis) 50 mg tablet twice daily 12 hours apart (total dose 100 mg daily)starting from the 3rd day of menstrual cycle and for five days"
101068|NCT03396367|Behavioral|PARTNER|The PATRNER intervention addresses, drug use, PrEP uptake/adherence, and HIV transmission risk by enhancing communication skills by integrating motivational interviewing and video-based communication skills training.
101069|NCT03396367|Behavioral|Education Intervention|The Education intervention consists of a 4-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format.
101070|NCT03396354|Procedure|Integrated robotic surgery|Robotic gastrectomy using Single-Site and Firefly technology will be performed. Specifically, two-port surgery using the Single-Site port and an independent trocar along the right flank (for harmonic scalpel) will be used, along with peritumoral injection of indocyanine green via endoscopy the day before surgery to completely visualize the entire lymphatic channel.
101071|NCT03396354|Procedure|Conventional laparoscopic surgery|conventional laparoscopic gastrectomy will be performed.
101072|NCT03396341|Other|Salvia sample|salvia sample
101106|NCT03396068|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
101107|NCT03396068|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
101073|NCT03396341|Behavioral|Questionnaires|Participants will complete Assessment #1 questionnaires. Participants will be contacted 1 week later (+/- 1 week) to complete Assessment #2 questionnaires. Participants will be contacted 6 months (+/- 3 weeks) following the receipt of their genetic risk modifier results to complete Assessment #3 questionnaires. Participants will be encouraged to complete Assessments #2 and #3 via email using the secure, approved REDCap system
101074|NCT03396328|Behavioral|conventional low salt education|conventional low salt education
101075|NCT03396328|Behavioral|Intensive low salt dietary education by smartphone application|Participants are provided with information on food and recipe, which allows them to record daily meals in their applications. Through the mobile application, the participants receive information on daily salt intake. Based on this information, the clinical nutritionist coach sets a goal for low salt diet and provides feedback to the patients through the mobile application. The clinical nutritionist coach checks the activity of the user more than twice a week and sends in-app messages to maintain compliance.
101076|NCT03396315|Drug|Alendronate|oral alendronate 70 mg weekly for 12 months will be given for the prevention of osteoporosis
101077|NCT03396315|Drug|Zoledronic Acid|single intravenous dose of zoledronic acid 5 mg will be given for the prevention of osteoporosis
101078|NCT03396302|Other|Educational intervention|The self-applied on-line intervention will comprise a three months behavioural intervention composed by 8 modules seeking to develop gradually achieving the goals of changing eating and physical activity habits.
101079|NCT03396289|Other|Conventional physiotherapy including balance exercises|Programme will include balance exercises with balance board and swiss ball, weight shifting exercises on board, one-legged balance, balance on unstable surface, balance on tilting surface and balance with Biodex Balance System. Biodex Balance System Biodex will only be used during sessions under physiotherapist supervision.
101080|NCT03396289|Other|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
101081|NCT03396276|Drug|Suboxone|8mg of buprenorphine/2mg of naloxone
101082|NCT03396276|Behavioral|Brief counseling in the ED|"Patients will receive brief counseling from ED physician prior to discharge about the options for outpatient treatment, as well as opioid dependency.Consented patients will be provided with a pamphlet from the Substance Abuse and Mental Health Services Administration called Facts About Buprenorphine, as well as an information packet for study contact information for the opioid recovery network providers."
101083|NCT03396276|Behavioral|Referral to outpatient treatment|A referral will be made to one of the affiliated MAT clinics.
101084|NCT03396276|Behavioral|Follow-up coaching|A designated paramedic with the Houston Fire Department (called the navigator or care coordinator) will work with UTHealth to jointly follow-up on patients both telephonically and in-person. The Houston Fire Department paramedic will provide brief information sharing and assist with coordination in scheduling or registering with MAT clinics or recovery coaching.
101085|NCT03396263|Behavioral|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalised dietary advice for improved food choice based on standard population health guidelines.
101086|NCT03396263|Behavioral|Online personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
101087|NCT03396263|Behavioral|Face-to-face personalised advice|Provision of face-to-face personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
101088|NCT03396250|Drug|Naproxen sodium and diphenhydramine hydrochloride soft capsules|Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
101089|NCT03396250|Drug|Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve, PMBAY98-7111)|Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
101090|NCT03396211|Drug|Apatinib (also known as rivoceranib)|Oral daily doses of apatinib (as its mesylate salt)
101091|NCT03396211|Drug|Nivolumab|Fixed dose of nivolumab given intravenously every 2 weeks
101092|NCT03396185|Drug|Icotinib|Patients who have EGFR-mutant stage IIIA-IIIB and unresectable lung adenocarcinoma will receive Icotinib with a dose of 125 mg three times per day orally till progressive disease or unaccepted toxicity as consolidation therapy after synchronous or sequential chemoradiotherapy.
101093|NCT03396172|Other|Control|The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria
101094|NCT03396172|Device|FreeDom|Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation
101095|NCT03396159|Diagnostic Test|mini fluid challenge|mini fluid challenge will be given to diagnose if patient is need fluid resuscitation or not
101096|NCT03396146|Other|12 ml total blood tubes volume|12 ml total blood tubes at 0, +60, + 90, + 120 minutes before and after a mixed meal
101097|NCT03396146|Other|Fecal sample|Fecal sample at inclusion
101098|NCT03396133|Diagnostic Test|Snap|screen, transmission, and analysis ECG automated
101099|NCT03396120|Diagnostic Test|Pulmonary function test|forced vital capacity and diffusing capacity
101100|NCT03396107|Drug|Dexamethasone|Dexamethasone 6mg, IM, 48 hours before cesarean section
101101|NCT03396107|Drug|Placebo|Placebo 6mg, IM, 48 hours before cesarean section
101102|NCT03396094|Device|High-flow nasal cannulae (HFNC) oxygenation|Delivery of 60L/min of supplemental oxygen for pre-oxygenation and apnoeic oxygenation during rapid sequence intubation using the AIRVO™ 2 Humidifier with Integrated Flow Generator (Fisher & Paykel Healthcare, Auckland, New Zealand)
101103|NCT03396094|Device|Non-rebreather mask and standard nasal cannula|Pre-oxygenation using non-rebreather mask and apnoeic oxygenation via nasal cannulae at 15L/min
101104|NCT03396081|Behavioral|PRADO-IC|"Help of administrative employees to schedule the first medical visits after an hospitalization for heart failure.~Home nurse's visiting program, during 2 to 6 months after the hospitalization for heart failure."
101108|NCT03396055|Other|specific rehabilitation exercise|specific rehabilitation exercise for patients with cervical myelopathy
101109|NCT03396029|Behavioral|Individually tailored lifestyle feedback|The written, standardized individually tailored lifestyle feedback includes feedback on consumption of fruit, berries and vegetables and alcohol, physical activity, smoking and body mass index.
101110|NCT03396029|Behavioral|Standard leaflet|The leaflet is The Norwegian Cancer Society's one-page information brochure on healthy lifestyle behaviours for low cancer risk, including non-smoking, healthy body weight, physical activity, diet, moderate alcohol consumption, moderate sun exposure etc.
101111|NCT03396003|Device|GALILEI G6 Lens Professional|Eight measurements of the eye using the GALILEI G6 Lens Professional will be taken using two different devices and 2 different operators
101112|NCT03396003|Device|Oculus Pentacam AXL|A single measurement of the eye will be taken using the Oculus Pentacam AXL
101113|NCT03395990|Procedure|Active comparator: chloroprocaine|15 ml of 2% chloroprocaine was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
101114|NCT03395990|Procedure|Sham comparator: saline|15 ml of normal saline was placed under ultrasound guidance adjacent to the femoral nerve in the operative limb.
101115|NCT03395977|Drug|Placebos|Lactose placebo for pills and saline for perfusion.
101116|NCT03395977|Drug|Febuxostat|Febuxostat tablet.
101117|NCT03395977|Drug|Rasburicase|Rasburicase injectable solution.
101118|NCT03395964|Procedure|Hybrid Dyna-CT guided localization|We will perform intraoperative lung tumor localization in CGMH hybrid operation room(Room 51) equipped with the Siemens Artis Zeego system with DynaCT imaging capabilities. The system provides images equivalent to a 16-slice spiral CT scanner in a single 6-s sweep.
101119|NCT03395964|Procedure|Preoperative CT scan-guided localization|Preoperative localization of the lung nodule will be carried out in the radiology department on the day of surgery using local anesthesia. CT-guided hook-wire or methyl blue dye will be placed percutaneously through a 22-gauge needle with the distal end deep to the nodule. The patient will then be taken to the operating room, where under general anesthesia with lung isolation, the nodule will be removed by wedge excision with endostaplers (Endo GIA II, United States Surgical,Norwalk, Conn; Echelon Endostapler, Ethicon Endo-Surgery, Cincinnati,Ohio) under the guidance of preoperative lung marking. If the lesion could not be excised using the VATS technique, the patient underwent an open thoracotomy.
101120|NCT03395951|Drug|Diuretics|Observation of hemodynamics during diuretics treatment within clinical indication.
101121|NCT03395938|Behavioral|Proactive engagement|The engagements would include (1) a sealed envelope containing a cancer information sheet and an invitation letter directed towards siblings for them to contact the research team, (2) weekly phone reminders to the participants for a total of 4 weeks in a bid to remind participants of the need to convey the screening message to their siblings. The envelope will contain information on the various means for the siblings to contact the research team. These include communication means such as electronic mails (emails), telephone, hard copy returned mails through pre-paid envelopes, short messaging services (SMSs) or clinic consult.
101122|NCT03395938|Behavioral|Current practice|This intervention depicts current practices by having the research team educate the participants on the Ministry of Health Singapore screening guidelines akin to counselling sessions carried out during the patient's clinical consultation. The research team would highlight that we would be happy to assist if necessary. The research team would then contact the patients in 4 weeks to check if they have communicated with their siblings and if they have gone for screening. We would also find out which method did they adopt to communicate with their siblings.
101123|NCT03395925|Device|Celon Pro Surge|bipolar coagulation electrode intended for tissue heating
101124|NCT03395912|Drug|Intervention|After closing the fascia above the rectus muscles, and before closing the skin, the subcutaneous layer will be infiltrated on both sides of the incision (top and bottom) by 30 ml of 0.25% BUPIVACAINE and ADRENALIN at 1: 200,000 concentration and then closing the skin.
101125|NCT03395899|Drug|Atezolizumab|PD-L1 antibody
101126|NCT03395899|Drug|Cobimetinib|Highly selective small-molecule inhibitor of MEK1 and MEK2
101127|NCT03395899|Drug|Ipatasertib|Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt
101128|NCT03395899|Drug|Bevacizumab|Highly specific humanized monoclonal antibody that targets VEGF
101131|NCT03395873|Drug|Avelumab|"Decitabine 20mg/m2 IV day 1-5, every 28 days~Avelumab 10mg/kg IV, day 1, every 14 days"
101132|NCT03395860|Drug|ATG|group A:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-3-d-2 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3 group B:low dose antithymocyte globulin rATG(2.5mg/kg/d) used at d-2-d-1 low dose post-transplant cyclophosphamide PTCy (50mg/kg/d) use at d+3
101133|NCT03395847|Biological|Pembrolizumab|Given IV
101134|NCT03395834|Device|O3|O3 TM and INVOS® monitoring simultaneously in single patient during 3 min of vascular occlusion test
101135|NCT03395821|Behavioral|Conventional training|traditional training according to residency program
101136|NCT03395821|Behavioral|Virtual Reality+conventional training|virtual reality training+traditional training using virtual reality
101137|NCT03395808|Drug|Tramadol|IV; 50 mg given at Hours 0, 2, 4, 8 and every 4 hours thereafter, for a total of up to 43 doses
101138|NCT03395795|Device|NAVA|"The study has 3 phases:~Phase 1:~The patient is connected to the SERVOi® ventilator in classic VNI mode, which is parameterized according to the patient's needs and then maintained for 30min for measurements.~Phase 2:~Switch to NAVA mode (1h).~Definition of NAVA parameters: The positive expiratory pressure will not be modified. The NAVA level (the proportionality factor that converts the EADi (microV) to the pressure level in cmH2O was first adjusted according to the actual assisted pressure in the patient in the normal VNI mode.~NAVA period: The ventilatory pressure, as well as the EADI is recorded continuously for 30min after a NAVA adaptation period of about 30min.~Phase 3:~The patient returns to classic VNI mode with Phase 1 ventilatory settings for a 30 minute recording."
101139|NCT03395769|Biological|AB-SA01|AB-SA01 is an investigational bacteriophage therapeutic for treatment of Staphylococcus aureus infections
101177|NCT03395470|Drug|Placebo|MAD
101178|NCT03395470|Drug|Rosuvastatin|DDI
101140|NCT03395756|Drug|Depot-Medroxyprogestereone Acetate|Administration of 150 mg intramuscular depot medroxyprogesterone acetate
101141|NCT03395743|Biological|AB-PA01|AB-PA01 is an investigational bacteriophage therapeutic for treatment of Pseudomonas aeruginosa infections
101142|NCT03395730|Drug|Intraumbilical vein injection oxytocin|intraumbilical vein injection of oxytocin 20 units diluted in 20 ml of 0.9% saline solution immediately after delivery of the baby, clamping and cutting the cord.
101143|NCT03395730|Procedure|placental cord drainage|placental cor drainage immediately after delivery. This scenario will include placental cord clamping and cutting after delivery of the baby followed by immediately unclamping of the maternal side, allowing the blood to drain freely for a duration of three minutes.
101144|NCT03395730|Procedure|Expectant managment of 3rd stage of labour|Placenta will be delivered spontaneously after appearance of clinical signs of placental separation, which include strong uterine contraction, vaginal bleeding, and descending of umbilical cord through the vulva. This scenario will include placental cord clamping and cutting after 2 minutes of delivery of the baby.
101145|NCT03395717|Device|Exoskeleton-Assisted Gait Training|
101146|NCT03395704|Drug|LJPC-401|LJPC-401 subcutaneous injection, up to 20 mg weekly for 16 weeks. The minimum weekly dose will be 5 mg and the maximum weekly dose of LJPC-401 will be 20 mg.
101147|NCT03395704|Drug|Placebo|0.9% Sodium Chloride Injection, USP, or equivalent
101148|NCT03395691|Procedure|The distal approach|The first two attempts via the distal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the proximal approach
101149|NCT03395691|Procedure|The proximal approach|The first two attempts via the proximal approach will be performed . If the first two attempts failed, the subsequent attempts of venipuncture were performed using the distal approach.
101150|NCT03395678|Device|Microneedling|The exact microneedling settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
101151|NCT03395678|Device|Fractional non-ablative 1,540nm laser|The exact laser settings will be tailored to each patient based on skin type, photodamage, skin thickness based on area of the face. Settings will be adjusted to deliver similar endpoints among all patients. Each participant will receive 5 treatments a month apart.
101152|NCT03395665|Other|Estradiol level|Estradiol level measured at previous day of embryo transfer procedure
101153|NCT03395665|Other|Progesterone level|Progesterone level measured at previous day of embryo transfer procedure
101154|NCT03395665|Other|Endometrial thickness|Endometrial thickness measured at previous day of embryo transfer procedure
101155|NCT03395639|Drug|Edoxaban|Edoxaban 15 mg or 30 mg tablets for participants 12 to <18 years of age, or 60 mg edoxaban suspension (dosed as mg/kg) for participants under 12 years of age (and optionally, 12 or older), for oral administration
101156|NCT03395639|Drug|Standard of Care (SOC)|Standard of care could include low molecular weight heparin (LMWH) and/or VKA according to the clinical site's SOC treatment regimen
101157|NCT03395626|Dietary Supplement|ID-JPL934|probiotics
101158|NCT03395626|Dietary Supplement|Placebo|corn starch
101159|NCT03395613|Device|NPWT|Negative pressure wound thearpy on closed surgical wounds
101160|NCT03395600|Drug|B1S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
101161|NCT03395600|Drug|B125S5|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 5µg sufentanyl along with 5 ml bupivacaine 0.125% as the test dose. After 3 min, 10 ml of 0.125% bupivacaine epidural was injected
101162|NCT03395600|Drug|B1S10|Women were then placed supine with left uterine displacement. Epidural labour analgesia was initiated with 10µg sufentanyl along with 5 ml bupivacaine 0.1% as the test dose. After 3 min, 10 ml of 0.1% bupivacaine epidural was injected
101163|NCT03395587|Biological|Autologous, tumor lysate-loaded, mature dendritic cells (DC)|Advanced therapy medicinal product (ATMP) produced at the University Hospital Düsseldorf according to Good Manufacturing Practice (GMP) with production permission according §13 AMG (German Drug Law) of the local authorities (Bezirks¬regierung Düsseldorf)
101164|NCT03395587|Drug|standard therapy|temozolomide, fractionated radiochemotherapy
101165|NCT03395574|Drug|Terlipressin|drug will be given after 30 minutes of induction of anesthesia
101166|NCT03395574|Drug|Normal saline|drug will be given after 30 minutes as placebo in control group
101167|NCT03395561|Dietary Supplement|green coffee|2 capsuls
101168|NCT03395561|Other|control|2 capsuls
101169|NCT03395548|Drug|Macrogol|Used drug: Macrogol (osmotic laxative)
101170|NCT03395535|Procedure|Primary Selective Laser Trabeculoplasty Treatment Pathway|"Primary Selective Laser Trabeculoplasty Treatment (followed by medications as required) Pathway.~First treatment is SLT, 100 shots of laser over 360 degrees. If this does not reach the target IOP then repeat laser (once only) is given. If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
101171|NCT03395535|Drug|Primary Medical Treatment Pathway|"Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary."
101172|NCT03395522|Device|iTind|device implanted for 5-7 days
101173|NCT03395496|Drug|Biodentine|Biodentine pulpotomy agent
101174|NCT03395496|Drug|ProRoot (Aggregate)|ProRoot MTA pulpotomy agent
101175|NCT03395483|Other|Haemodynamic monitoring|see Group description
101176|NCT03395470|Drug|PXL770|MAD
101180|NCT03395457|Other|Manual Therapy|5 sessions of manual therapy over 12 weeks
101181|NCT03395444|Device|pulsed shortwave therapy|Pulsed shortwave therapy us the RecoveryRx device. Emits a pulsed signal a the 27.12Mhz wavelength
101182|NCT03395431|Other|Fingerprick autologuos blood (FAB)|Intervention involves the instillation of whole blood obtained from the prick of a clean finger 4 times a day.
101185|NCT03395392|Drug|NRX-101|NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth
101186|NCT03395392|Drug|Lurasidone HCl|Lurasidone HCl will be given twice a day by mouth
101187|NCT03395379|Procedure|RFA|Radiofrequency ablation (RFA) is a medical procedure in which part of the electrical conduction system of the tumor is ablated using the heat generated from medium frequency alternating current.
101188|NCT03395366|Other|Multifaceted Educational / Cognitive Behavioral Intervention|The intervention includes 8 to 12 one-on-one sessions over a 12-week period, run by a licensed social worker (LSW) with experience delivering therapy. Curriculum will introduce education relevant for self-management and consists of prepared slides, handouts & worksheets. The education was designed based on slides developed and published online by the national kidney foundation and the national kidney disease education program. The curriculum was designed to be understandable by all potential subjects, including those with low literacy levels. Sessions will incorporate behavior-based activities designed to deliver education about and improve upon medication adherence, diet, exercise, and coping. These activities, based around CB strategies such as cognitive restructuring and behavior shaping, will include review of self-management logs, goal setting, creation of treatment plan, problem-solving techniques, reinforcing techniques, and coping with ESRD.
101189|NCT03395353|Drug|Duloxetine Hydrochloride|Administered orally
101190|NCT03395340|Drug|Ruxolitinib 1.5% cream|Ruxolitinib cream 1.5% applied as a thin film twice daily (BID)
101191|NCT03395340|Drug|Vehicle cream|Matching vehicle cream applied as a thin film BID
101192|NCT03395327|Other|quality of life questionnaire|QLQ-C30 and BR23 (Quality of Life Questionnaire and Breast 23) Questionnaire FSFI (Female Sexual Function Index)
101195|NCT03395301|Device|Coil|Fiber platinum coil were inserted into the interstitial part of the tubes of patients in hydrosalpinx through hysteroscopy
101196|NCT03395288|Drug|D-Mannose|A total of 2 g D-mannose daily
101197|NCT03395275|Behavioral|Quantitative Sensory Tests|"Three testing modalities will be utilized for this study:~Hot threshold test: The hot threshold method we will be utilizing has been described in the literature with good reproducibility and reliability. We will be using a similar system and have reproduced the program using a non-invasive device.~Cold threshold test: the same non-invasive device will be used to test cold detection and pain threshold levels. This method is previously described.~Pressure threshold: Mechanical testing (pressure pain threshold) will be assessed utilizing an algometer. We have used this method in a previous study and published results."
101198|NCT03395275|Behavioral|surveys|surveys including anxiety, depression, pain behavior, fatigue, pain interference, physical function, sleep disturbance, self-efficacy, satisfaction roles
101199|NCT03395262|Dietary Supplement|Active with caffeine|Novel formula with caffeine
101200|NCT03395262|Dietary Supplement|Active without caffeine|Novel formula without caffeine
101201|NCT03395262|Dietary Supplement|Placebo|Dextrose placebo
101202|NCT03395249|Drug|SPR994|"SAD: Double-blind dosing will occur in all SAD Cohorts except for Cohort 12. In each cohort, six subjects will receive one of five different timed release formulations of SPR994 and 2 subjects will receive placebo. Subjects in SAD Cohorts 2, 3, 6, 16 and 17 will receive a single dose following a 10-h fast. Subjects in SAD Cohorts 1, 8-15 will receive one dose of SPR994 or placebo following a 10-h fast on Day 1 and a second dose following consumption of a standardized meal on Day 7. The dose escalation steps may be altered following review of the safety data of each cohort.~MAD: Double-blind dosing will occur in all MAD Cohorts. Subjects will receive multiple doses of an optimal timed release formulation of SPR994 in MAD Cohort 4 (300 mg) and Cohort 5 (600 mg) or placebo for 14 consecutive days at either BID or TID dosing beginning on Day 1."
101203|NCT03395249|Drug|Placebo Oral Tablet|Mannitol 200SD SAD: Two subjects in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
101204|NCT03395249|Drug|Orapenem®|Tebipenem pivoxil granules
101205|NCT03395236|Combination Product|"StellarexTM 0.014 Over-The-Wire Drug-coated Angioplasty Balloon"|"The Stellarex balloon (0.014) is indicated for the treatment of de-novo or re-stenotic lesions in the lower extremities to establish blood flow and to maintain vessel patency."
101206|NCT03395223|Drug|Methylene Blue|Administration of Methylene Blue to treat acquired methaemoglobinaemia
101207|NCT03395210|Drug|PRN1008|BTK inhibitor
101208|NCT03395197|Drug|Talazoparib with enzalutamide|Talazoparib 0.5 mg/day plus enzalutamide 160mg/day
101209|NCT03395197|Drug|Placebo with enzalutamide|Placebo plus enzalutamide 160 mg/day
101210|NCT03395184|Drug|Placebo PF-06651600|12 weeks, followed by PF-06651600, 50 mg QD for 52 weeks
101211|NCT03395184|Drug|Placebo PF-06700841|12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks.
101212|NCT03395184|Drug|PF-06651600|200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
101213|NCT03395184|Drug|PF-06700841|60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
101214|NCT03395171|Dietary Supplement|Cholecalciferol (Vitamin D3)|Supplementation of subjects who meet the inclusion criteria and test to have below the threshold of vitamin D in their blood.
101215|NCT03395158|Diagnostic Test|Implementation of new alert criteria|The intervention is when the prior alert criteria are replaced by the present alert criteria
101216|NCT03395145|Device|Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal|Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation after tooth extraction
101217|NCT03395132|Drug|Fucicort® Lipid cream|The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
101260|NCT03394885|Drug|Bevacizumab|15 mg/kg IV q3 weeks
101218|NCT03395132|Drug|Fucidin® cream|The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
101219|NCT03395132|Drug|Fucicort® Lipid cream vehicle|The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
101220|NCT03395132|Drug|betamethasone (Lianbang Beisong®) cream|The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
101221|NCT03395119|Drug|Ozone|After the four-week supplementation period, each subject will be blindly exposed on consecutive days to filtered air for 2 hours and to 0.3 ppm ozone for 2 hours, while undergoing intermittent moderate exercise (minute ventilation of 20 L/min/m²).
101222|NCT03395119|Dietary Supplement|Fish Oil|3 (1-gram) soft-gels daily Commercially available, enteric-coated, soft-gels formulated to deliver >60% eicosapentaenoic/docosahexaenoic acids (EPA/DHA)
101223|NCT03395119|Dietary Supplement|Olive Oil|3 soft-gels daily Commercially available soft-gels containing 1 gram of USDA organic certified, cold pressed, extra virgin, olive oil
101224|NCT03395106|Behavioral|Parent source|Having a parent feature prominently in a news story
101225|NCT03395106|Behavioral|Doctor source|Having a doctor feature prominently in a news story
101226|NCT03395106|Behavioral|Deliberative content|News story content includes process of weighing the risks/benefits of vaccinating, the importance of vaccines for community protection, and concludes with a recommendation to vaccinate.
101227|NCT03395106|Behavioral|Intuitive content|News story content focuses on the consequences of not vaccinating (including vaccine preventable diseases) and the decisional regret.
101228|NCT03395093|Drug|Fentanyl|Five minutes before the patients is done the flexible bronchoscopy, fentanyl will be intravenous injected.
101229|NCT03395093|Drug|Midazolam|Five minutes before the patients is done the flexible bronchoscopy, midazolam will be intravenous injected.
101230|NCT03395093|Drug|Propofol|Propofol will be intravenous injected as soon as the flexible bronchoscopy begins.
101231|NCT03395093|Device|Bispectral Index monitoring|Bispectral Index monitoring will be used in the process of the flexible bronchoscopy.
101232|NCT03395080|Drug|Paclitaxel|Administered by IV infusion
101233|NCT03395080|Drug|300mg DKN-01|Administered by IV infusion
101234|NCT03395080|Drug|600mg DKN-01|Administered by IV infusion
101235|NCT03395067|Behavioral|Intervention group|Lifestyle counseling coupled with psychotherapeutical intervention
101236|NCT03395054|Other|cervical stabilization exercises|cervical stabilization exercises
101237|NCT03395054|Other|conventional exercises|conventional exercises
101238|NCT03395041|Diagnostic Test|cardiac imaging tests|cardiac computed tomography, echocardiography, intravascular ultrasound, optical coherence tomography
101239|NCT03395028|Drug|Granulocyte Colony-Stimulating Factor|G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) produced by recombinant DNA technology with NEUPOGEN® as the Amgen Inc. trademark for filgrastim. G-CSF regulates the production, proliferation and differentiation of neutrophils and hematopoietic stem cell precursors within the bone marrow leading to dose-dependent increase in circulating neutrophils and hematopoietic stem cells in the blood. It is indicated to reduce the incidence of infection in patients with severe neutropenia, for neutrophil recovery in neutropenic patients with bone marrow depletion, to mobilize hematopoietic progenitor stem cell for collection by leukapheresis in hematopoietic stem cell transplantation.
101240|NCT03395015|Other|VAS scale (from 1 to 10) esthetic assessment of facial 3-D images|The rating process is biphasic: firstly a 3-D model is showed to the raters, who can orientate the vultus, familiarize with the 3-D technology and have a first glance evaluation. Secondly, the judges are asked to rate each of the following patient views: right profile, left profile, frontal, neck hyperextension and hyperflexion views Two weeks after the first assessment, the same judges assessed the same number of pictures, once again in random order.
101241|NCT03395002|Drug|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder|Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder (1 puff) twice daily via Discair® for two days.
101242|NCT03395002|Drug|Tiotropium 18 mcg Inhalation Powder|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler® for two days.
101243|NCT03395002|Drug|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for two days
101244|NCT03394989|Drug|Fluticasone propionate/salmeterol 100/50 µg|Test Arm: Dry powder inhaler
101245|NCT03394989|Other|Placebo|Placebo
101246|NCT03394989|Drug|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Comparator Arm: Dry powder inhaler
101247|NCT03394976|Diagnostic Test|No intervention|No intervention
101248|NCT03394963|Behavioral|Food-based dietary guidelines for healthier diet|Develop and validate food-based dietary guideline and a healthy eating index
101249|NCT03394950|Drug|Butyphthalide combined with rtPA|Intravenous treatment with 25mg butyphthalide, followed by intravenous throbolysis with 0.9mg/kg rtPA. Next day, intravenous treatment with 25mg butyphthalide 2 times/day for 14 days, followed by oral butyphthalide capsule (0.2g 3 times/day) to 90 days after thrombolysis. Other treatments were done according to guidelines.
101250|NCT03394950|Drug|rtPA|Intravenous thrombolysi with 0.9mg/kg rtPA, followed by other treatments according to guidelines
101251|NCT03394937|Biological|ECI-006|ECI-006 consists of TriMix and 5 tumor associated antigens mRNA. TriMix is a mixture of mRNAs that encodes potent immune stimulating molecules
101252|NCT03394924|Drug|EDP-305 Dose 1|Two tablets daily for 12 weeks
101253|NCT03394924|Drug|EDP-305 Dose 2|Two tablets daily for 12 weeks
101254|NCT03394924|Drug|Placebo|Two tablets daily for 12 weeks
101255|NCT03394911|Biological|250mg healthy adult male facial skin surface lipid liquid pheromone|Human Pheromone provided p.o. to tox-screen verified opioid drug addict
101256|NCT03394898|Other|body mass index, eating behaviour|The patients' weights and heights will be measured and the body mass index will be calculated from the measured values.Patients' eating behaviour will be questioned with Three Factor Eating Questionnaire. The 18-item Three-Factor Eating Questionnaire is a scale that measures three domains of eating behavior: cognitive restraint , uncontrolled eating and emotional eating.
101262|NCT03394846|Behavioral|Prototype Movement Integration Product|A movement integration product prototype based on the findings from Aim 1 will be developed. Teacher will test the prototype Movement Integration Product in their classrooms for four weeks.
101263|NCT03394833|Other|gelofusine|Preoperative colloid fluid bolus 6ml/kg ideal body weight
101264|NCT03394820|Drug|Dexamethasone|The intervention is the time when dexamethasone is administered
101265|NCT03394807|Drug|Levobupivacaine|Levobupivacaine injection to Transversus abdominis plane and rectus sheath
101266|NCT03394807|Drug|Placebo|Saline injection to Transversus abdominis plane and rectus sheath
101267|NCT03394794|Device|Pelvic floor rehabilitation|The aim is to compare how each treatment improves symptoms and quality of life and which physiologic mechanisms affects. The basal treatment which other therapies are compared to is Kegel.
101268|NCT03394781|Drug|DUR-928|oral suspension daily for 28 days
101269|NCT03394768|Other|No additional intervention|Patients will be treated as per department protocols and no additional intervention will be performed
101270|NCT03394755|Biological|Thrombosomes|Freeze-dried platelets
101271|NCT03394742|Behavioral|Peer support|Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
101272|NCT03394729|Drug|Propolis tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days
101273|NCT03394729|Drug|Xilytol tablet to limit dental biofilm|The tablets will be offered in an exact number of days of use. Collection of total stimulated saliva and dental biofilm will be performed at the beginning of the study (before tablet consumption) and 7 days after the intervention. Saliva samples from each individual will be collected in separate containers as well as the biofilm samples, both at baseline and after 7 days.
101274|NCT03394716|Radiation|Radiotherapy|standard radiotherapy treatment with 1-3 extra MRIs
101275|NCT03394690|Dietary Supplement|green coffee|2 capsuls
101276|NCT03394690|Other|control|2 capsuls
101277|NCT03394677|Drug|RVT-501 0.5% ointment|Patients will receive RVT-501 0.5% ointment twice daily (BID) for 4 weeks.
101278|NCT03394677|Drug|Vehicle ointment|Placebo comparator - ointment twice daily (BID) for 4 weeks.
101279|NCT03394664|Behavioral|Feeding Study|Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
101280|NCT03394651|Drug|Oral medications to treat lower urinary tract symptoms|Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
101281|NCT03394651|Procedure|Minimal invasive transurethral prostate procedures|Patients in this group will receive surgical treatment.
101282|NCT03394638|Other|Access to online eLearning module|Patients enrolled in the Online group have access to an online platform called BePatient. Patients are given the ability to access the platform and do eLearnings; watch videos about the operation and recovery; do quizzes, see dietary advices; see news about obesity and our department; read patients' stories. They are also able to chat with other patients.
101283|NCT03394638|Other|Access to measurement devices|Patients in the device group have, in addition to patients in the Online group, access to 4 measuring devices, including: weight scale, oximeter, activity bracelet and blood pressure device. Those devices are connectable to their mobile phones where patients can view their own progress.
101284|NCT03394638|Procedure|Conventional group|All patients undergo the standard of care which included: the bariatric procedure and several outpatient visits including consultation with their surgeon, obesity nurses, dieticians and (if indicated) psychologists.
101285|NCT03394625|Procedure|Socket shield technique|Socket shield technique is a recent technique which is by sectioning the root and extraction of palatal part and leaving buccal part of the root with its attachment of periodontal ligament and vascularization still intact then placing implant in palatal socket.
101286|NCT03394625|Procedure|using Xenograft material|placing xenograft material in gap between the implant and the buccal plate of bone
101287|NCT03394612|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
101288|NCT03394612|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
101289|NCT03394599|Device|TheraTrainer + Motiview|TheraTrainer will be used in conjunction with Motiview.
101290|NCT03394599|Device|TheraTrainer Only|TheraTrainer will be used.
101291|NCT03394586|Drug|Exposure to golimumab|retrospective chart review to assess patient related outcomes and objective measures of inflammation at baseline, 6-10 weeks, 6 months, 12 months.
101292|NCT03394573|Other|OCT guided treatment arm|Intravitreal injection of Aflibercept for DME OCT guided
101293|NCT03394573|Other|VA guided treatment arm|Intravitreal injection of Aflibercept for DME VA guided
101294|NCT03394560|Device|High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
101325|NCT03394287|Drug|SHR-1210|SHR-1210 200mg (3mg/kg for patient whose weight is below 50kg) will be administered as an intravenous infusion over 30 minutes every two weeks until unacceptable toxic effects or disease progression or other termination criteria appeared.
101326|NCT03394287|Drug|Apatinib|Apatinib 250mg will be taked daily/intermittent dosing until unacceptable toxic effects or disease progression or other termination criteria appeared.
101359|NCT03393975|Biological|BAX930|A recombinant human disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13
101295|NCT03394560|Device|Sham High frequency repetitive transcranial magnetic stimulation|Gait training with body weight support will be performed through Biodex Rehabilitation treadmill. It will performed for 20 minutes and researchers will assist the patient in placing the foot on the ground, in the extension of the knee and in the alignment of pelvis and trunk. The percentage of body weight support and speed of treadmill will be modified based on the performance of each patient. Repetitive transcranial magnetic stimulation will be applied by an eight-shaped coil positioned on the patient's scalp and performed according to the 10-20 international system (primary motor cortex). In sham rTMS two coils will be used: (i) a coil connected to the stimulator will be positioned behind the patient (away from the scalp) to generate characteristic stimulus sound, and (ii) another coil will be disconnected from the stimulator and positioned on the scalp individual. The active and sham stimulation will last 20 minutes.
101296|NCT03394547|Device|Allay|pulsed shortwave therapy treatment for painful periods
101297|NCT03394547|Device|Placebo|A placebo device is given which is identical to the Allay device but emits no pulsed shortwave therapy.
101298|NCT03394534|Other|CGA group|CGA Plus Individualised Care and Support Plan delivered by Advanced Clinical Practitioner (ACP)
101299|NCT03394521|Other|Routine clinical practice|This is an observational study
101300|NCT03394508|Drug|ALK Alutard birch or 5-grasses|Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval
101301|NCT03394508|Drug|ALK diluent 0,3% human albumin|Intralymphatic injection with 1000 units. 3 injections with 4-5 weeks interval
101302|NCT03394495|Other|BCE Combination group|The combination intervention programme consists of a weekly exercise training sessions and 6 sessions of Behavioral Change Enhancement (BCE) programme.
101303|NCT03394482|Drug|Lu AF35700 5 mg clinical formulation|Lu AF35700 tablets 5 mg oral single dose
101304|NCT03394482|Drug|Lu AF35700 5 mg commercial formulation|Lu AF35700 tablets 5 mg oral single dose
101305|NCT03394482|Drug|Lu AF35700 10 mg clinical formulation|Lu AF35700 tablets 10 mg oral single dose
101306|NCT03394482|Drug|Lu AF35700 10 mg commercial formulation|Lu AF35700 tablets 10 mg oral single dose
101307|NCT03394482|Drug|Lu AF35700 20 mg clinical formulation|Lu AF35700 tablets 20 mg oral single dose
101308|NCT03394482|Drug|Lu AF35700 20 mg commercial formulation|Lu AF35700 tablets 20 mg oral single dose
101309|NCT03394469|Other|collection|Blood, urinary and faecal samples
101310|NCT03394456|Other|diabetes program|Comprehensive diabetes program (weekly to bimonthly CHW mHealth contact (phone, text) for 12-months and monthly diabetes group visits for 6-months)
101311|NCT03394456|Other|telehealth training and support for Community Health Workers|weekly 1-hour diabetes training and patient support for CHWs via telehealth i.e., ZOOM technology for the study duration
101312|NCT03394443|Behavioral|Semi-structured interviews|"Semi-structured interviews of the parents of preterm infants. 3 weeks after their child has left hospital. They will be made either at the University Hospital of Besançon. They will take place in a dedicated hospital ward to ensure the confidentiality of the statements made between the investigator and the parent.~They will follow a predefined questionnaire. They will be fully recorded on a dictaphone with note taking during the interview by the investigator and will be transcribed in writing anonymously and confidentially on Word.~The content of the interviews will be analyzed:~As a first step, it will be a vertical analysis of the thematization of each interview~Then, in a second step, a transversal analysis between the contents of the different interviews."
101313|NCT03394430|Drug|Placebos|Patients in Group A receive intranasal normal saline before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
101314|NCT03394430|Drug|Midazolam|Patients in Group B receive intranasal 0.25mg/kg midazolam before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
101315|NCT03394430|Drug|Dexmedetomidine|Patients in Group C receive intranasal 1μg/kg dexmedetomidine before anesthesia. Anaesthesia was induced with 8% sevoﬂurane initially. Sevoflurane concentration decreased to 2% after intubation. An electroencephalogram was recorded before and during induction up to 10 min after the start of induction.
101316|NCT03394417|Device|StrataXRT|randomized patient allocated to this group will receive 2 50g tubes of StrataXRT for application during the treatment and 4 weeks further after the treatment ends.
101317|NCT03394404|Device|ECG-I mapping and PVI|ECG-I mapping and PVI
101318|NCT03394391|Behavioral|Daily ART-adherence SMS reminder|Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.
101319|NCT03394391|Behavioral|Standard Adherence Counselling/Patient experience group chat|"All the participants will receive the standard adherence counselling by trained counsellors at each visit.~All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges."
101320|NCT03394365|Biological|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
101321|NCT03394352|Other|Activity on Board|During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.
101322|NCT03394352|Other|Usual Diabetes Care|Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
101323|NCT03394326|Behavioral|family-based obesity prevention lifestyle intervention|A family-based obesity prevention lifestyle intervention is based on the combination of behavioral therapy strategies, a physical activity prescription and a dietary prescription. Both the parent and child will be working to achieve the same behavioral targets.
101324|NCT03394300|Other|iol power calculation|iol power calculation in high myopia
101360|NCT03393975|Biological|Standard of care|Investigator-recommended Standard of care (SoC)
101327|NCT03394274|Other|restrictive and liberal transfusion|hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
101328|NCT03394261|Behavioral|Patient Decision Aid|PtDA-MAT will provide information on MAT treatment options and pros and cons of each treatment option, and will assess patients' preferred options.
101329|NCT03394248|Device|Vector Mouthguard|The mouthguard will be used by athletes to measure the magnitude and number of impacts throughout one season.
101330|NCT03394235|Device|Long-pulsed, 1064nm Nd-YAG laser|This long-pulsed Nd-YAG laser is commonly used for laser hair removal and vascular lesions, but in this study it is used to reduce the size of the hair shaft at the occipital area.
101331|NCT03394222|Drug|preoperative budesonide inhalation|
101332|NCT03394222|Drug|preoperative normal saline inhalation|
101333|NCT03394209|Drug|Favipiravir|"In first step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1600 mg twice daily. Starting from the second day, the dosage is 600 mg twice daily.~In second step: favipiravir tablet is orally administered. This drug will be given twice daily for a 10-day period. For the First day, the dosage is 1800 mg twice daily. Starting from the second day, the dosage is 800 mg twice daily."
101334|NCT03394209|Drug|Oseltamivir 75Mg Capsule|oseltamivir will be administered at 75mg twice daily orally for 10 days
101335|NCT03394196|Diagnostic Test|HIV-2 Genotypic Drug Resistance Testing using DBS|Real time HIV-2 genotypic drug resistance testing using dried blood spots and consensus sequencing.
101336|NCT03394196|Drug|2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID)|1. No resistance: Continue Current ART: Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID (AZT/3TC or TDF/3TC or TDF/FTC + LPV/r) + Enhanced Adherence Counseling
101337|NCT03394196|Drug|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID )|2. NRTI resistance only: Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID (TDF/FTC or TDF/3TC + LPV/r + RAL) + Enhanced Adherence Counseling
101338|NCT03394196|Drug|2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID)|3. NRTI-PI resistance: Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID (TDF/FTC or TDF/3TC +DRV/r2 + RAL) + Enhanced Adherence Counseling
101339|NCT03394183|Other|Cardiac Rehabilitation|Cardiac rehabilitation is a 6 month program in which patients enrolled attend weekly classes which consist of individualized exercise and risk factor education lectures. This intervention is consistent with standard care procedures for the Cardiovascular Prevention and Rehabilitation Program at the Toronto Rehabilitation Institute Rumsey Centre.
101340|NCT03394170|Other|Collection of specimens prior to and during surgery|Collection of specimens prior to and during surgery
101341|NCT03394157|Other|metabolic surgery|operation to cure type2 diabetes
101342|NCT03394144|Drug|AZD9150, Durvalumab|After confirmed safety with Cohort 1, Cohort 2 will open. Patients allocated in each cohort will be evaluated for DLT
101343|NCT03394131|Drug|Hylase|hydro-dissection injection of median nerve inside carpal tunnel using hyalase and 10 cc saline
101344|NCT03394131|Drug|Insulin|hydro-dissection injection of median nerve inside carpal tunnel using 10 IU insulin and 10 cc saline
101345|NCT03394131|Other|saline|hydro-dissection injection of median nerve inside carpal tunnel using 10 cc saline
101346|NCT03394118|Drug|Osimertinib|A cycle of study treatment is defined as 28 days. Each subject will continue the study drug(Osimertinib) until disease progression or manifestation of unacceptable toxicity during the study period. The study drug will be administered orally as one 80 mg tablet once a day. The initial dose of the study drug 80 mg daily can be reduced to 40 mg once daily.
101347|NCT03394105|Drug|intrapleural docetaxel administration|intrapleural docetaxel administration using medical pleuroscopy in malignant effusion with lung cancer
101348|NCT03394092|Diagnostic Test|Quantitative measurements the changes of IgG glycosylation|Serum (50 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture.Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to assess the quantitative changes of IgG glycosylation by HPLC-MRM at 0 , 3 and 7 days after admission.
101349|NCT03394079|Procedure|PCI|Percutaneous Coronary Intervention
101350|NCT03394066|Device|TMS|Transcranial Magnetic Stimulation device
101351|NCT03394027|Drug|ONC201|625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
101352|NCT03394014|Procedure|sciatic nerve block|blocking sciatic nerve either at the subgluteal area or the popliteal region for effective anesthesia and analgesia during below knee amputation
101353|NCT03394001|Procedure|Wound infiltration|Before skin closure,the subcutaneous tissue and skin all around the wound will be infiltrated by 20 mL of the drug then closure of the skin will be done.
101354|NCT03394001|Drug|Lidocaine Hydrochloride|20 ml of 1% Lidocaine solution
101355|NCT03394001|Drug|Ketorolac tromethamine|20 mL of saline with 30 mg ketorolac
101356|NCT03393988|Drug|Fentanyl infusion|After induction of general anesthesia; Fentanyl infusion (0.5 µg/kg/hr) will be started (which will be afterwards adjusted intraoperatively according to the hemodynamics and Bispectral Index (BIS) reading).
101357|NCT03393988|Procedure|Ultrasound guided TAP block|After induction of general anesthesia; Patients will receive ultrasound guided subcostal oblique TAP block with 0.25 % bupivacaine 40 ml on each side resulting in a total volume of 80 ml, subcostal TAP block was given twice, at the beginning and at the end of the surgery.
101358|NCT03393988|Drug|Dexmedetomidine|Dexmedetomidine (200 µg in 2 ml diluted in 48 ml of saline) will be started in a dose of 1 μg/kg over 10 min then maintenance dose as continuous infusion between 0.2 and 0.8 μg/ kg/h through infusion pump (which will be adjusted according to the hemodynamics and BIS reading)
101361|NCT03393962|Biological|OC-EIEs|2 to 4 infusions, once a week, 0.1~4x10^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
101362|NCT03393949|Drug|Methylprednisolone 1 mg•kg-1|Patients in Group M received methylprednisolone 1mg•kg-1
101363|NCT03393949|Drug|Methylprednisolone 0.5mg•kg-1|Patients in Group C received methylprednisolone 0.5mg•kg-1
101364|NCT03393936|Biological|CCT301-38|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-38. During CCT301-38 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-38 by intravenous (IV) injection.
101365|NCT03393936|Biological|CCT301-59|Subjects will undergo blood draw to isolate peripheral blood mononuclear cells (PBMCs) for the production of CCT301-59. During CCT301-59 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocyte depletion. After lymphodepletion, subjects will receive one dose treatment with CCT301-59 by intravenous (IV) injection.
101366|NCT03393923|Other|Application of the anterior wedge|Application of anterior wedge in tennis
101367|NCT03393910|Diagnostic Test|Experimental Pelvic Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the standard group. In the Experimental group the pelvic exam will be done with external xam, bimanual exam then speculum exam."
101368|NCT03393897|Other|Trans oesophageal echocardiography|Transoesophageal echocardiography : it's a standard practice for this patient
101369|NCT03393897|Other|Trendelenburg test|Trendelenburg test : it's a standard practice for this patient
101370|NCT03393884|Biological|GEN-1|IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
101371|NCT03393884|Drug|Carboplatin|AUC 6 IV over 1 hour on Day 1 of each cycle
101372|NCT03393884|Drug|Paclitaxel|175 mg/m2 IV over 3 hours on Day 1 of each cycle
101373|NCT03393871|Diagnostic Test|absolute blood flow measurement|Absolute maximum flow will be measured, using the RayFlow® multifunctional monorail infusion catheter. (This measurement takes a few minutes per artery, does not require any additional drug, but only 50-100 ml of saline per artery, and is not associated with any additional risk for the patient compared to the regular invasive procedure.
101374|NCT03393858|Drug|Anti-PD-1 antibody|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
101375|NCT03393858|Biological|DC-CIK Immunotherapy|Mononuclear cells were collected from 50ml peripheral blood , and cultured DC-CIK cells for 15-20 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
101376|NCT03393858|Device|Thermotron RF-8EX|Hyperthermia for 40 minutes, with maximum temperature setted on 42℃ ± 0.5℃ as upper limit, twice a week since the 1st week of pembrolizumab for a total of 10 times.
101377|NCT03393845|Drug|Pembrolizumab|Pembrolizumab 200mg IV, 21 day cycles
101378|NCT03393845|Drug|Fulvestrant|Fulvestrant, 500mg IM, 28 day cycles.
101379|NCT03393832|Other|Oral Care with sterile water|Administration of 0.2 ml of sterile water to buccal mucosa, every 3-4 hours for 4 weeks beginning within 72 hours of birth.
101380|NCT03393832|Other|Oral Care with all breast milk|Administration of 0.2 ml of breast milk (either mother's milk or pasteurized donor breast milk) to buccal mucosa, every 3-4 hours for 4 weeks beginning within 72 hours of birth.
101381|NCT03393819|Drug|DuraPrep|DuraPrep surgical solution
101382|NCT03393819|Drug|ChloraPrep|ChloraPrep surgical solution
101383|NCT03393806|Drug|GSK3772847|GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.
101384|NCT03393806|Drug|Placebo|Commercially sourced sterile normal saline will be provided as Placebo
101385|NCT03393780|Drug|Follitropin Delta|The Intervention (solution for injection) is delivered with an injection pen. The REKOVELLE® dose will be based on recent determination (within the last 12 months) of AMH (anti- müllerian hormone) measured by the following diagnostic test from ROCHE: ELECSYS AMH Plus immunoassay.
101386|NCT03393767|Drug|Ranibizumab|Intravitreal injection
101387|NCT03393754|Biological|Hepatitis B Vaccination|Prophylactic Hepatitis B Vaccination
101388|NCT03393741|Drug|Taxane|Taxane is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
101389|NCT03393741|Drug|Vinorelbine|Vinorelbine is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
101390|NCT03393741|Drug|Ixabepilone|Ixabepilone is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
101391|NCT03393741|Drug|Eribulin|Eribulin is a chemotherapeutic agent and a standard drug for treatment in breast cancer targeting microtubules. This drug is typically infused as a single agent for breast cancer therapy.
101392|NCT03393741|Drug|Chemotherapy|Chemotherapy is used to treat various stages of breast cancer.
101393|NCT03393728|Drug|Propanolol|72-hour propanolol before specific treatment of hyperthyroidism
101394|NCT03393715|Drug|Perindopril Oral Tablet|Perindopril oral tablet morning versus evening
101395|NCT03393702|Drug|Gabapentin|"Patients in this arm of the study receive identical capsules, containing 15 mg/kg of oral gabapentin.~Patients after surgery receive identical capsules, containing 7,5 mg/kg of oral gabapentin 2 times per day."
101396|NCT03393702|Drug|Placebo|"Patients in this arm of the study receive identical placebo capsules 1 hour before surgery.~Patients after surgery receive identical placebo capsules 2 times per day."
101397|NCT03393689|Drug|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E[c(RGDyK)]2
101398|NCT03393663|Other|CKD-related outcomes|the study is observational
101399|NCT03393650|Other|Exercise + Placebo group|1/2 of the subject will follow a mixed power training: 4 power exercises + 6 functional exercises combined to a placebo
101971|NCT03389152|Device|Elastography|liver stiffness measurements by shear wave-based elastography
101400|NCT03393650|Other|Exercise + Protein group|1/2 of the subject will receive 30 g/ d of protein (leucine+ vitD; divided in three equal doses: morning, afternoon and evening) + will follow a mixed power training: 4 power exercises + 6 functional exercises.
101401|NCT03393637|Behavioral|Mentors Offering Maternal Support (M-O-M-S)|10, 1 hour, structured classes meeting every-other-week in person beginning in the first trimester of pregnancy and unlimited access to mentor support.
101402|NCT03393611|Drug|CPX-351|Salvage Chemotherapy: CPX-351 at 120 u/m2 on Days -21, -19, and -17
101403|NCT03393611|Drug|Fludarabine|Fludarabine 150 mg/m2 (30 mg/m2/day x 5 days, Day -7 to Day -3)
101404|NCT03393611|Drug|Melphalan|Melphalan 140 mg/m2 (Day -2)
101405|NCT03393611|Drug|Rabbit Anti-Human T-Lymphocyte Globulin|Rabbit ATG (rATG)-thymoglobulin 4.5 mg/kg (1.5 mg/kg/day x 3 days)
101406|NCT03393611|Biological|Haplo-Cord Stem Cell Transplantation|Allogeneic stem cell transplantation using a haploidentical donor and umbilical cord blood unit.
101407|NCT03393598|Device|pre-expansion using Kiwi® VAC-6000M.|The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.
101408|NCT03393598|Device|pre-heating using Hilotherm Calido®.|The pre-heating will be performed with Hilotherm Calido®.
101409|NCT03393598|Device|pre-expansion-heating|Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
101410|NCT03393585|Other|touchless vital signs monitoring|We measure Respiratory Rates in the Triage of Patients entering an Emergency Department by three different methods.
101411|NCT03393572|Drug|Bupivacaine 0.25%|Patients will receive 30 mL of intraperitoneal bupivacaine 0.25%
101412|NCT03393572|Drug|Magnesium sulphate.|Patients will receive intraperitoneal 30 mg/kg of magnesium sulphate.
101413|NCT03393572|Drug|nalbuphine|Patients will receive intraperitoneal 5 mg nalbuphine
101414|NCT03393559|Procedure|leg elevation|Patients' leg will be raised by a pillow under both legs and the hip and knee joints will be flexed 45 degrees to position both knees at the heart level.
101415|NCT03393546|Behavioral|Auricular Point Acupressure|It includes 4 weekly auricular point acupressure treatment.
101416|NCT03393546|Behavioral|Education Control|It includes 4 weekly education counseling.
101417|NCT03393533|Procedure|Group I|Extraction third molar without the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
101418|NCT03393533|Procedure|Group II|Extraction third molar with the application of therapeutic bandaging in the face and with evaluation of edema, pain and trismus
101421|NCT03393507|Drug|Apatinib|500mg,po, adjusted to 250mg if cannot tolerate, 3 weeks a cycle for a total of 6 cycles
101422|NCT03393507|Drug|Taxus + platinum|Taxanes are paclitaxel or docetaxel, and platinum is carboplatin or cisplatin. Docetaxel injection dose size of 60-75mg / m2, infusion time of 1 hour; paclitaxel injection dose size 135-175mg / m2, infusion time> 3 hours; injection of carboplatin dose according to the standard formula Calculated, AUC = 4-5, continued intravenous infusion the next day; cisplatin injection dose size of 75-100mg / m2.
101423|NCT03393494|Drug|Adapalene and Benzoyl Peroxide Topical Gel|Test product
101424|NCT03393494|Drug|Epiduo Topical Product|RLD product
101425|NCT03393494|Drug|Placebo|Placebo gel
101426|NCT03393481|Drug|MAA868|MAA868 dose 1 and dose 2, single administration, subcutaneous,
101427|NCT03393481|Drug|Enoxaparin|Enoxaparin 40 mg, o.d X 10 days
101428|NCT03393468|Drug|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
101429|NCT03393455|Other|not accurate|not accurate
101430|NCT03393442|Diagnostic Test|Brain MRI scan|Diagnostic brain MRI scan with the purpose to detect signal changes due to brain deposits of Gd.
101431|NCT03393429|Other|DAVID assisted training|DAVID device assisted training under supervision
101432|NCT03393429|Other|training recommendation|"training recommendation to stay active"
101433|NCT03393416|Biological|MASCT-I|The final products of MASCT-I(Multiple-antigen specific cell therapy) technology are dendritic cells (DC) and effector T cells.Treatment with MASCT-I alone, conducted until disease progression, intolerance or end of study.
101434|NCT03393416|Drug|PD1 antibody|"Drug: PD1 antibody~1mg/kg or 3mg/kg. Administration is conducted in Day1 and Day15. Conducted until disease progression, intolerance or end of study."
101435|NCT03393403|Drug|Dexmedetomidine|0.5mcg/kg intravenous(IV)continuous infusion for 30 minutes, or 0.5mcg/kg adding to local anesthetic for subcostal TAP block
101436|NCT03393403|Drug|0.9% Sodium-chloride|0.125ml/kg intravenously infusion in Dexmedetomidine_adj group and control group
101437|NCT03393390|Diagnostic Test|Clinical Assessment Visit|Subjects will meet with a clinician who will determine if they meet diagnostic criteria for an externalizing disorder.
101438|NCT03393390|Other|fMRI scan|Subjects will undergo an fMRI scan where images will be taken for observational purposes only, not as a means of diagnosis.
101439|NCT03393377|Drug|fluvastatin 10 mg and valsartan 20 mg|
101440|NCT03393377|Drug|placebo|
101441|NCT03393364|Drug|Oxycodone|Patients receive oxycodone for pain control after outpatient urologic surgery.
101442|NCT03393364|Drug|Ketorolac|Patients receive ketorolac for pain control after outpatient urologic surgery
101443|NCT03393351|Other|Shared decision-making program|"The intervention is shared decision-making. The implementation strategy to foster shared decision-making in routine cancer care is a multicomponent implementation program. The implementation program consists of the following components:~shared decision-making trainings for health care professionals,~individual coaching for physicians,~patient activation strategy,~provision of patient information material and decision aids,~revision of the clinics quality management documents, and~critical reflection of current organization of multidisciplinary team meetings.~Implementation: after baseline assessment (t0) for clinic 1, after assessment at t1 for clinic 2, after assessment at t2 for clinic 3."
101444|NCT03393351|Other|Usual Care|No specific study related intervention. Treatment decisions are made according to current routine practice at the comprehensive cancer center in Germany.
101478|NCT03393000|Other|Standard of Care (SOC)|Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
101445|NCT03393338|Behavioral|DM I-TEAM|DM I-TEAM is a home-based behavioral intervention that involve 9 treatment visits with a community health worker (CHW) over 12 months. During the treatment visits, the CHW provides culturally-relevant diabetes education, and facilitates telehealth visits with a diabetes nurse educator and participants' primary care physicians (PCPs). In addition, a clinical pharmacist reviews participants' medication regimens to identify potentially inappropriate medications (PIMS), and to simply regimens when indicated to facilitate medication adherence.
101446|NCT03393325|Other|Observation of treatment with Tadalafil-Delivra|Tadalafil 2% in a Delivra base (Transdermal Application)
101447|NCT03393312|Device|Transcranial direct current stimulation (tDCS)|Electric current
101448|NCT03393299|Procedure|STOPP/START criteria|software which helps to do the drug reconciliation
101449|NCT03393273|Drug|Elotuzumab|"Induction 4 cycles of 28 days Elotuzumab IV, 10 mg/Kg, D1, 8, 15, 22 Dexamethasone PO, 40 mg/d, D1, 8, 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, 11 Thalidomide PO, 100 mg/d, D1 to 21~melphalan 140-200 mg/m2 one day followed by autologous hematopoietic stem cell transplantation~Consolidation 2 cycles of 28 days (2 to 3 months after autograft) Elotuzumab IV, 10 mg/Kg, D1, 8, 15 and 22 Dexamethasone PO, 40 mg/d, D1, 8 and 15 Velcade® IV, 1,3 mg/m2/d, D1, 4, 8, and 11 Thalidomide® PO, 100 mg/d, D1 to 21"
101450|NCT03393247|Drug|infliximab and azathioprine combination at week 0|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Experimental group will receive azathioprine at week 0.
101451|NCT03393247|Drug|infliximab and azathioprine combination at week 14|All enrolled CD patients will schedule on IF X (week 0, 2, 6 and then every 8 weeks at 5mg/kg).Control group will receive azathioprine at week 14.
101452|NCT03393234|Radiation|Interoperative radiation by INTRABEAM using low energy X-ray|Intrabeam is a mobile Platform for Intraoperative Radiotherapy (IORT) produced by the ZEISS company in Germany.Interoperative radiation by INTRABEAM using low energy X-ray.The Intrabeam PRS appears to be a safe technique for delivering IORT in rectal cancer patients.
101453|NCT03393221|Behavioral|ER|Emotion regulation content
101454|NCT03393221|Behavioral|SBWC|
101455|NCT03393208|Drug|Test GIR|Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
101456|NCT03393208|Drug|Reference GIR|Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
101457|NCT03393195|Behavioral|Time-restricted Eating plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study. The eating plan will consist of eating during a specified 8 hour window and fasting for the remaining 16 hours of the day.
101458|NCT03393195|Behavioral|Consistent Meal timing plan|Research team will prescribe an eating plan for the participant to follow for the 12 week study.The eating plan will consist of eating three structured meals each day during three specified meal windows.
101459|NCT03393182|Procedure|TLDG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)
101460|NCT03393182|Procedure|LADG arm|After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)
101461|NCT03393156|Behavioral|Internet-based metacognitive therapy|Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
101462|NCT03393130|Diagnostic Test|APOE genotyping|APOE genotyping and broad cognitive assessment expressed as a median T-score of the following tests (with cognitive domains assessed in brackets) Trail Making Part A (processing speed), Trail Making Part B (executive function), One Back test (working memory), List Learning Task (Immediate recall, visual learning, delayed recall and recognition discrimination).
101463|NCT03393117|Drug|Liposomal Bupivacaine|20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.
101464|NCT03393117|Drug|Bupivacaine|20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.
101465|NCT03393117|Drug|Patient-Controlled Analgesia Pump|The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.
101466|NCT03393117|Drug|Oral Narcotic|Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.
101467|NCT03393104|Behavioral|Motor Control Exercise|Activation of specific muscles of the lumbopelvic region responsible for providing stability or control of posture and movement.
101468|NCT03393104|Behavioral|Patient Education|Education aiming to change unhelpful beliefs about LBP, decrease fear avoidance behavior and catastrophic thought, promote positive attitude, self-management, and active coping strategies.
101469|NCT03393078|Device|transcranial magnetic stimulation with real coil|TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
101470|NCT03393078|Device|transcranial magnetic stimulation with sham coil|TMS with sham coil is a placebo
101471|NCT03393065|Other|Fluid management guided by BLS|We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
101472|NCT03393052|Procedure|Coronary Angiography|Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
101473|NCT03393039|Behavioral|Negative Affect Task|fMRI stress task
101474|NCT03393026|Drug|Lurasidone|Lurasidone 40-160 mg/day for 6 weeks
101475|NCT03393013|Drug|KZR-616|Subcutaneous Injection of KZR-616
101476|NCT03393013|Drug|Placebo|Subcutaneous injection of matching placebo
101477|NCT03393000|Drug|Trans Sodium Crocetinate plus SOC|Trans Sodium Crocetinate (TSC) plus the Standard of Care (SOC): SOC composed of radiation and temozolomide for 6 weeks followed by 4 weeks of rest followed by six (6) 28-day cycles of temozolomide
101514|NCT03392779|Drug|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition
101479|NCT03392987|Genetic|OTL-200|OTL-200 is an autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human ARSA cDNA sequence
101480|NCT03392974|Biological|Valoctocogene Roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
101481|NCT03392961|Drug|IN-105 (Insulin Tregopil)|15 mg strength tablets for oral use used at a dose of 30 mg
101482|NCT03392961|Other|Placebo comparator|Placebo tablet for oral use
101483|NCT03392935|Device|1540 nanometer Erbium glass laser|Subjects will receive laser treatment by dermatologist at week 0 and week 4.
101484|NCT03392922|Device|Uniblocker|The BBs have more advantages than DLT: easier insertion especially in patients with difficult airway18 and no need to exchange the tube when mechanical ventilation is required after surgery.
101485|NCT03392922|Device|Left-sided Double-lumen Tube|the double-lumen tube (DLT) is the most commonly used device for OLV
101486|NCT03392909|Drug|Gentamicin|Short-term intravenous gentamicin therapy should have the advantage of treating all of the patient's multiple skin wounds simultaneously. Six patients (three adults and 3 children) will receive intravenous gentamicin (7.5 mgs/kg) daily for 14 days and then stopped. Three adult patients will receive intravenous gentamicin (7.5mg/kg) biweekly for three months and then stopped.
101487|NCT03392896|Drug|DCR-PHXC|DCR-PHXC is a novel, potent, and long-acting small interference ribonucleic acid (siRNA) molecule conjugated to N-acteylgalactosamine (GalNAc) that is designed to decrease liver oxalate production. DCR-PHXC is delivered via subcutaneous (SC) injection.
101488|NCT03392896|Drug|Placebo|Single SC administration of placebo, which will be a sterile, preservative-free normal saline 0.9% solution for SC injection, which is of similar osmolality to the DCR-PHXC formulation.
101489|NCT03392883|Behavioral|Laddr|Laddr is a mobile behavioral health technology that offers science-based self-regulation monitoring and health behavior change tools via an integrated platform to a wide array of populations. Specifically, the core functionality of Laddr (e.g., problem-solving therapy) will be structured to focus on an end user's management of depression and its impact on their functioning and quality of life. The program will secondarily focus on problematic alcohol use and its relationship to depression management.
101490|NCT03392870|Other|Integrative interventional programme|The active condition includes specialized, multidisciplinary and intensive individual (weekly to monthly) or group interventions (weekly). Only high-functioning subjects will be considered for group interventions.
101491|NCT03392870|Other|As usual|The control group will follow treatment as usual, consisting in conventional general psychiatrist/psychologist clinical follow-up. The frequency varies between 3-6 months or 15-21 days if worsening of symptoms or comorbid conditions.
101492|NCT03392857|Other|Assessment by caregivers of the quality of the end of life in intensive care units|Quality of the end of life in intensive care units perception will be explore from the side of the caregivers, trough the CAESAR scale.
101493|NCT03392844|Other|Beds for Kids program|"The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes."
101494|NCT03392831|Other|Peripherally inserted central catheter (PICC)|The peripherally inserted central catheter with different sizes (French scale). Trained vascular access nurses will perform the insertion of the PICC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established. In the case of children the procedure may be performed at the Ambulatory Surgical Center
101495|NCT03392831|Other|Central venous catheter|The central venous catheter with different sizes (French scale). Trained doctors will perform the insertion of the CVC, guided by ultrasound at bedside using the Seldinger technique. A suitable sterile field will be established.The decision of the caliber depends on the clinical evaluation and need for multiple infusional therapy.
101496|NCT03392818|Other|The measured distance|To measure the distance between the upper edge of the thyroid cartilage to the upper edge of the sternum add the distance from the upper edge of the sternum to the carina calculated according to the chest CT scans as a guide to the placement of Uniblocker without the aid of Fiberoptic bronchoscope.
101497|NCT03392818|Other|formula|Calculate the depth of intubation according to the formula of 0.1977* patient's height - 4.2423
101498|NCT03392818|Device|Fiberoptic bronchoscope|The intubation of Uniblocker under the guidance of Fiberoptic bronchoscope
101499|NCT03392805|Behavioral|physical activity|beginning of regular physical activity under the supervision of a coach
101500|NCT03392792|Drug|tissue plasminogen activator|role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
101501|NCT03392792|Procedure|thrombectomy|role of thrombectomy in patient with acute ischemic stroke
101502|NCT03392779|Drug|ZSP1601 25 mg|ZSP1601 tablet administered orally once daily under fasted condition
101503|NCT03392779|Drug|Placebo 25mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
101504|NCT03392779|Drug|ZSP1601 50 mg|ZSP1601 tablet administered orally once daily under fasted condition
101505|NCT03392779|Drug|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
101506|NCT03392779|Drug|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily in the fasting state
101507|NCT03392779|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
101508|NCT03392779|Drug|ZSP1601 175 mg|ZSP1601 tablets administerekd orally once daily under fasted condition
101509|NCT03392779|Drug|Placebo 175 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
101510|NCT03392779|Drug|ZSP1601 275 mg|ZSP1601 tablets administered orally once daily in the fasting state
101511|NCT03392779|Drug|Placebo 275 mg|Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state
101512|NCT03392779|Drug|ZSP1601 350 mg|ZSP1601 tablets administered orally once daily under fasted condition
101513|NCT03392779|Drug|Placebo 350mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition
101515|NCT03392779|Drug|Placebo 100mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition
101516|NCT03392779|Drug|ZSP1601 50 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
101517|NCT03392779|Drug|Placebo 50 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
101518|NCT03392779|Drug|ZSP1601 100 mg|ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
101519|NCT03392779|Drug|Placebo 100 mg|Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).
101520|NCT03392766|Device|single lumen tube and bronchial blocker|neck collar apply. fibreoptic intubation with single lumen tube and bronchial blocker.
101521|NCT03392766|Device|double lumen tube|neck collar apply. fibreoptic intubation with double lumen tube.
101522|NCT03392753|Procedure|Mechanochemical ablation|Treatment of incompetent saphenous veins using mechanochemical ablation (Clarivein)
101523|NCT03392753|Procedure|Cyanoacrylate adhesive|Treatment of incompetent saphenous veins using cyanoacrylate (VenaSealTM)
101524|NCT03392740|Drug|Lisinopril|Patients will be given lisinopril once a day prior to starting an anthracycline chemotherapy regimen and titrated up in a stepwise fashion, as allowed by patients blood pressure, to a target dose of 20mg daily.
101525|NCT03392740|Drug|Placebo Oral Tablet|Patients will be given a look-alike placebo medication once a day prior to starting an anthracycline chemotherapy regimen. They will be given a new placebo medication in a step-wise fashion over period of 1 to 3 weeks.
101526|NCT03392727|Device|Study Box|Baby box (bassinet) with infant items
101527|NCT03392727|Device|Community Box|Baby box (bassinet)
101528|NCT03392727|Behavioral|Education Session|Face to face education and baby box orientation session
101529|NCT03392727|Behavioral|Online Education|Online baby box education
101530|NCT03392714|Drug|R-B(O)AD|rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
101531|NCT03392701|Biological|LPS infusion|infusion of LPS 2 ng/kg over 5 minutes
101532|NCT03392688|Other|kujala patellofemoral pain scale|Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.
101533|NCT03392688|Diagnostic Test|Surface EMG|The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.
101534|NCT03392688|Other|Q angle measurement|Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
101535|NCT03392675|Behavioral|Self-monitoring of BF and intervention|"Self-Monitoring: At discharge, mothers will complete daily diaries for self-monitoring to stimulate cognitive reframing on the occurrence, duration, and characteristics of nipple and breast pain, infants' latch and sucking pattern, positioning, length of each BF session, and the MAIBB.~Self-Regulation: To support self-regulation skills, mothers will be provided with several 5-minute video modules on pain and BF pain SM with additional resources links. After discharge mother will receive text message from a nurse 2X/week for BF support. Mothers may text the nurse for emergent BF support."
101536|NCT03392662|Device|Hemopatch|Patients received product at the discretion of their surgeon.
101537|NCT03392649|Device|Parasym|Tragus stimulation will be done using the Parasym device.
101538|NCT03392636|Procedure|Herniotomy|In Mitchell Banks Herniotomy, one of investigators will do herniotomy without opening inguinal canal and in Ferguson Gross Herniotomy , one of investigators will do herniotmy by opening inguinal canal.
101539|NCT03392623|Drug|Retinoic acid|topical administration in melasma lesions
101540|NCT03392623|Device|colorimetry measurement|Measurement of erythema and luminosity through a colorimeter
101541|NCT03392623|Drug|sunscreen|topical administration in melasma lesions
101542|NCT03392623|Drug|Niacinamide|topical administration in melasma lesions
101543|NCT03392597|Behavioral|Brothers as Allies|Strengths-based group approach to promote boys' and young men's safe and healthy passage through the pre-teen and adolescent years.
101544|NCT03392597|Behavioral|Programming-as-Usual|Usual afterschool programming.
101545|NCT03392571|Drug|NGC-Triple regimen|gemcitabine 800 mg/m2; Abraxane (nab-paclitaxel 100 mg/m2; cisplatin 25 mg/m2
101546|NCT03392558|Other|Burt's Bees Skin Care Regimen|Burt's Bees Facial Cleanser (twice daily), Burt's Bees Sensitive Daily Moisturizing Cream (morning), Burt's Bees Sensitive Night Cream (at bedtime)
101547|NCT03392558|Other|Control Regimen|Cetaphil Gentle Skin Cleanser (twice daily), Cetaphil Moisturizing Lotion (twice daily)
101548|NCT03392545|Combination Product|Combined immune adjuvants and radiation|24 hours before the radiation, patients will be administrated poly I:C or CAR-T or TCR-T intratumorally and receive granulocyte macrophage colony stimulating factor 5 days after the radiation.
101549|NCT03392532|Device|Lotrafilcon B toric contact lenses with HYDRAGLYDE|Silicone hydrogel soft contact lenses for astigmatism
101550|NCT03392532|Device|Lotrafilcon B toric contact lenses|Silicone hydrogel soft contact lenses for astigmatism
101551|NCT03392519|Other|Chronic stroke|MRI data acquisition and behavioral test
101552|NCT03392506|Device|EBUS-TBNA-RTE|Every patient will do CT、 PETCT and EBUS-TBNA-RTE.These three kind of examination will have their own result.The three methods of inspection will be compared by diagnostic rate
101553|NCT03392493|Behavioral|Robot-assisted hand rehabilitation|Robot-assisted hand rehabilitation: 20 minute of worm-up exercise and 40 minute of robot-assisted hand exercise. Robot-assisted hand exercises include passive range of motion of hand, bilateral hands task and robot-assisted task.
101876|NCT03389958|Other|Counseling and provision of contraception|Provider training, availability of contraceptive methods
101554|NCT03392493|Behavioral|Standard treatment|Standard treatment only group: 60 min standard treatment. 20 minute of worm-up exercise and 40 minute of traditional occupational therapy. Traditional occupational therapy include spasticity-reducing activity, bilateral hands activity and hand training task.
101555|NCT03392467|Biological|PNEUMOSTEM|human umbilical cord blood-derived mesenchymal stem cells
101556|NCT03392467|Other|Placebo|normal saline
101557|NCT03392454|Procedure|T+LRTI|T+LRTI is the most commonly used procedure, it removes the entire trapezium
101558|NCT03392454|Procedure|PT+TI|The PT+TI is less invasive than the T+LRTI as only part of the trapezium is removed
101559|NCT03392441|Other|Insulin Deprivation in Type 1 Diabetic Patients|Type 1 Diabetic Patients requiring insulin will have insulin stopped for a short period of time (4-6 hours)
101560|NCT03392428|Other|177Lu-PSMA617|"Patients randomised to the 177Lu-PSMA617 arm will receive 6-8.5GBq of 177Lu-PSMA617 by intravenous injection once every 6 weeks until progressive disease, prohibitive toxicity or a maximum of 6 cycles.~The first dose will be administered at 8.5GBq, reducing by 0.5GBq with every cycle given (i.e. to 6.0GBq on the sixth cycle, if reached). In some patients who have an exceptional response, treatment will be paused but can be re-commenced up to the maximum of 6 cycles upon progression."
101561|NCT03392428|Drug|Cabazitaxel|"Patients randomised to the Cabazitaxel arm will receive 20mg/m2 Cabazitaxel by intravenous infusion once every 3 weeks until progressive disease, prohibitive toxicity or a maximum of 10 cycles.~Patients in this arm will also receive prednisolone 10mg orally per day for the duration of their cabazitaxel treatment."
101562|NCT03392415|Procedure|CTO PCI|attempted percutaneous coronary intervention of the chronic total coronary occlusion
101563|NCT03392389|Biological|mRNA-1653|Escalating dose levels
101564|NCT03392389|Other|Placebo|Saline
101565|NCT03392376|Drug|Haloperidol Injection|ICU patients with diagnosed delirium are treated with 2,5mg haloperidol x 3 daily intravenously with additional as needed doses to a maximum of 20mg/daily.
101566|NCT03392376|Other|Saline (0,9%)|ICU patients with diagnosed delirium are treated with 0,5ml isotonic saline x 3 daily and as needed doses to a maximum of 4ml/daily, corresponding to the algorithm in the experimental arm.
101567|NCT03392363|Device|Recordings of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease.
101568|NCT03392350|Behavioral|Physician Body Scan Consultation with Behavioral Intervention|The RENEW™ program consisted of 7 bi-monthly face-to-face web sessions over 16-18 weeks followed by an average of 15 monthly check-in sessions (maintenance) over 80 weeks.This included modules on responding to stress, enhancing effects of relaxation, nourishing theimmune system, physical activity, and social support.
101569|NCT03392337|Device|Narrowband UVB phototherapy|Ultraviolet B phototherapy
101571|NCT03392311|Drug|Calcipotriol ointment|The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
101572|NCT03392311|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
101573|NCT03392298|Drug|Colla corii asini|15g Colla corii asini granule, once daily for 4 weeks
101574|NCT03392285|Device|Internal fixation or hip arthroplasty|Patients treated according to the routine at the orthopedic department with screw fixation of an undisplayed femoral neck fracture or hip arthroplasty for a displaced femoral neck fracture.
101575|NCT03392272|Device|Using of Tisseel fibrin glue|Using of Tisseel fibrin glue instead of sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
101576|NCT03392272|Other|Using sutures|Using sutures in Müller's Muscle-Conjunctival Resection (MMCR) surgeries
101577|NCT03392259|Behavioral|Smartphone app|Installment and use of smartphone app
101578|NCT03392246|Drug|Osimertinib|"may stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
101579|NCT03392246|Drug|Selumetinib|"may enhance the effect of osimertinib to stop (or inhibit) the growth of a cancer with a mutation in the EGFR gene"
101580|NCT03392233|Radiation|Stereotactic Body Radiation Therapy|Eligible patients will receive Stereotactic body radiation therapy (SBRT) for spinal metastatic lesion in 24Gy/3f(cervical vertebra) or 30Gy/3f (thoracic vertebra/lumbar vertebra) every other day and receive relevant system treatment at same time
101581|NCT03392220|Procedure|Unilateral Neck Dissection|patient undergo unilateral (affected side) neck dissection, along with the excision of the laryngeal primary tumor
101582|NCT03392220|Procedure|Bilateral Neck Dissection|patient undergo bilateral neck dissection, along with the excision of the laryngeal primary tumor
101583|NCT03392207|Biological|Seasonal Influenza Vaccine|Trivalent, Fragmented, Inactivated Seasonal Influenza Vaccine (2018 Southern Hemisphere Season) produced at Butantan Institute
101584|NCT03392194|Behavioral|Sleep hygiene intervention|The community-adapted SH intervention includes 2 group sessions. (1) teach the importance of sleep and the core components of SH; distribute and explain the daily sleep log (2) facilitate an open discussion where participants share challenges and experiences implementing a SH goal.
101585|NCT03392194|Behavioral|Yoga intervention|Following the SH intervention, participants randomized to the SH+Y arm will participate in 8 weekly beginner level yoga classes. Classes will increase participants' skill and comfort with yoga postures and relaxing breathing exercises so that participants can adopt an evening yoga practice (10 weeks).
101586|NCT03392181|Drug|18F-DCFPyL|To determine whether PET/MR utilizing PYL improves pre-operative staging of prostate cancer prior to radical prostatectomy compared to MRI alone.
101587|NCT03392168|Drug|ARQ-151 cream 0.5%|0.5% active concentration
101588|NCT03392168|Drug|ARQ-151 cream 0.15%|0.15% active concentration
101589|NCT03392168|Drug|ARQ-151 cream placebo|Cream vehicle
101590|NCT03392155|Behavioral|Training & Nutrition|Exercise at moderate to high intensities and diet education/counseling
101591|NCT03392142|Biological|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
101592|NCT03392129|Other|Ai Chi|Children in the intervention group will perform 12 sessions (twice a week 40 minutes each session) of treatment with the Ai Chi Method, and educational intervention in relation to asthma.
101593|NCT03392129|Other|Asthma education|Children assigned to the control group will receive, along with their parents, educational interventions in relation to asthma.
101594|NCT03392116|Biological|NGM120|Subcutaneous Injection
101595|NCT03392116|Other|Placebo|Subcutaneous Injection
101596|NCT03392103|Drug|Raltitrexed|concurrent chemotherapy
101597|NCT03392103|Radiation|postoperative radiotherapy|concurrent postoperative radiation therapy
101598|NCT03392090|Other|More Good Days video&brief questionnaire|Help patients with advanced cancer think about what a good day means to them and to help them think about questions they may have for their physicians when discussing treatments
101599|NCT03392077|Procedure|Caesarean section|Caesarean section will be done to deliver the baby
101600|NCT03392077|Other|cervical dilatation|Cervical dilatation will be done by double gloves digital dilatation postpartum
101601|NCT03392077|Other|No cervical dilatation|after delivery of the baby cervix will be remain closed
101602|NCT03392064|Biological|AMG 119|Investigational, adoptive cellular immunotherapy for the treatment of small cell lung cancer
101603|NCT03392051|Drug|ISIS 681257|Xmg dose administered as a subcutaneous injection
101604|NCT03392051|Drug|Clopidogrel|75mg tablet administered orally
101605|NCT03392038|Procedure|Thin ADM|Use of soft tissue allograft for root coverage
101606|NCT03392038|Procedure|Thick ADM|Periodontal surgical procedure to coronally position the tissue over the ADM allograft
101607|NCT03392025|Other|Flaxseed|Daily consumption of 30 grams flaxseed in adjunct to medical treatment for 3 months
101608|NCT03392025|Other|the Mediterranean-like diet|Weekly Mediterranean-like diet menu in adjunct to medical treatment for 3 months
101609|NCT03392025|Dietary Supplement|Placebo|Daily consumption of one capsule of wheat fiber as placebo in adjunct to medical treatment for 3 months
101610|NCT03391999|Other|A questionnaire; CHU9D|Measuring Health Related Quality of Life
101611|NCT03391986|Device|SEIRIN® Pyonex™ Acupuncture Needles|Needles will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix
101612|NCT03391986|Procedure|12 mm Plasters|"12 mm (0.5). Latex-free Adhesives will be placed on the right and left ear. Right ear - cingulate gyrus, thalamus, Point Zero, Shen Men, uterus. Left ear - cingulate gyrus, thalamus, Point Zero, Shen Men, cervix"
101613|NCT03391973|Drug|Pembrolizumab Injection|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion Q3W.
101614|NCT03391960|Device|Passive disinfection device|Add use of passive disinfection cap to existing central line needleless connector infection control procedure
101615|NCT03391947|Procedure|semilunar coronally positioned flap|The description of this intervention has been already given before
101616|NCT03391947|Procedure|coronally advanced flap|The description of this intervention has been already given before
101617|NCT03391934|Drug|Cetuximab + FOLFIRI|Cetuximab 400 mg/m2 will be administered in the first dose and 250 mg/m2 will be administered in the next doses every week. Irinotecan will be administered 180 mg/m2 biweekly. Leucovorin will be administered 400 mg/m2 biweekly.Fluorouracil will be administered 400 mg/m2 push, and 2400 mg/m2 as 46-h infusion biweekly.
101618|NCT03391921|Biological|Vaccine|All patients will receive the 9-valent vaccine against HPV (Gardasil9) intramuscularly: After a first open phase evaluating tolerability of Gardasil9, women will be randomized between two different doses schedules: in the first schedule, women will receive 2 doses at time 0 and 6 months and a third dose between 18-48 months if their antibody levels are insufficient; the second schedule will be 3 doses at 0, 2 and 6 months.
101619|NCT03391908|Diagnostic Test|cardiac imaging tests|Patients will undergo non-invasive Cardiac Computed Tomography for assessment of coronary plaques and myocardial perfusion, and invasive intracoronary imaging tests (coronary angiography, Intravascular ultrasound, optical coherence tomography and FFR). If imaging will reveal existence of a significant coronary plaque, a percutaneous coronary intervention (PCI - stenting) will be performed.
101620|NCT03391895|Other|Home based exercise program|Program will include deep diaphragmatic breathing exercises, local expansion exercise on the collapsed areas in scoliosis concave sides with elastic exercise bands, dynamic lumber stabilization exercises for core stabilisation, strengthening of interscapular muscles with elastic bands and stretching exercises for lumbar extensor, hip flexor and hamstring muscles. Exercises will be applied 2 sets of 10 repetitions and once a day.
101621|NCT03391895|Other|Inspiratory Muscle Training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure after assessment of respiratory muscle strength for each patient every week.
101622|NCT03391882|Drug|APL-130277|APL-130277: Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
101623|NCT03391882|Drug|subcutaneous apomorphine|subcutaneous apomorphine Part A- determine the dose; Part B- 28-day repeat dosing at the dose determined in Part A
101624|NCT03391869|Biological|Ipilimumab|Given IV
101625|NCT03391869|Procedure|Local Consolidation Therapy|Undergo radiation and/or surgery
101626|NCT03391869|Biological|Nivolumab|Given IV
101627|NCT03391869|Other|Quality-of-Life Assessment|Ancillary studies
101628|NCT03391869|Radiation|Radiation Therapy|Undergo radiation
101629|NCT03391869|Procedure|Therapeutic Conventional Surgery|Undergo surgery
101630|NCT03391856|Drug|N-acetyl-L-cysteine (NAC)|NAC treatment for PT: 400mg p.o tid from day 60 to 90 post transplant
101631|NCT03391856|Other|supportive therapy|prophylactic platelet transfusion was given when platelet count <20000/ul
101632|NCT03391843|Drug|FOLFOXIRI+Cetuximab regimen|FOLFOXIRI+Cetuximab Irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h +Cetuximab 500mg/m²,all on day 1 of each 2 weeks cycle
101633|NCT03391830|Drug|Atorvastatin-Ascorbic acid|atorvastatin (80-mg loading dose given a mean 24 hours before procedure with another 40-mg dose approximately 2 hours before the procedure and for 3 days) plus ascorbic acid 500mg
101634|NCT03391830|Drug|Placebo|Placebo
101635|NCT03391817|Other|Fecal microbiota transplantation|Fecal microbiota transplantation administered in gastroscopy
101636|NCT03391804|Drug|ALLN-177|ALLN-177 7,500 units (2 capsules) with each meal/snack by mouth 5 times per day for 12 weeks
101637|NCT03391791|Genetic|Genetically engineered T Cell Receptors|No study drug is administered in this study. Subjects who received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial will be evaluated in this trial for long-term safety and efficacy.
101638|NCT03391778|Genetic|GSK3377794 (NY-ESO-1ᶜ²⁵⁹ T)|No study drug is administered in this study. Subjects who received NY-ESO-1ᶜ²⁵⁹T in a previous trial will be evaluated in this trial for long-term safety and efficacy.
101639|NCT03391765|Drug|ABBV-8E12|ABBV-8E12 solution for IV infusion
101640|NCT03391752|Combination Product|Integrated Nutrition Pathway for Acute Care|algorithm to guide care processes with respect to nutrition e.g. screening on admission, diagnosis with subjective global assessment, early treatment with medication pass of oral nutritional supplement
101641|NCT03391739|Biological|CART-19 cells|CART-19 cells treat
101642|NCT03391726|Other|CART-19 cells|CART-19 cells treat
101643|NCT03391713|Behavioral|Poster|The poster includes the FAST symptoms but translated to the Malay language (Ce.P.A.T) Cakap tak jelas (slurred speech - Speech slurring) Perubahan muka (face changes - Face drooping) Anggota lemah (weak limbs - Arm weakness) Terus ke Hospital (straight to the hospital - Time to call 911
101644|NCT03391700|Drug|Rocuronium(deep)|In the group with deep relaxation during surgery, rocuronium is given by continuous infusion (0.6 mg/kg/h).
101645|NCT03391700|Drug|Rocuronium(moderate)|In the group with deep relaxation during surgery, rocuronium is given by bolus dose(0.15mg/kg) induced a train of four count of 1-2.
101646|NCT03391687|Diagnostic Test|Amylase Test|body fluid amylase will be tested after radical gastrectomy in scheduled interval
101647|NCT03391674|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation through oral capsules after omeprazole pre-treatment
101648|NCT03391661|Behavioral|Pain neuroscience education patient exercise|Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.
101649|NCT03391661|Behavioral|Health behavior control intervention|Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.
101650|NCT03391648|Other|Observation|Observation only
101651|NCT03391635|Device|Electroacupuncture|Participants will receive electroacupuncture at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
101652|NCT03391635|Device|TranscutaneousElectricNerveStimulation|Participants will receive transcutaneous electric nerve stimulation at bilateral ST25, SP14 and ST37 for 30 minutes each time，3 times a week for 8 weeks.
101653|NCT03391622|Device|Calibrated Automated Thrombogram|blood samples will be collected . Thrombin generation in platelet-poor plasma will be measured by means of the Calibrated Automated Thrombogram (CAT).
101654|NCT03391609|Drug|placebo infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative saline infusion (placebo) in the same rate as dexmedetomedine starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
101655|NCT03391609|Drug|Dexmedetomidine infusion|Caesarian section will be performed under standard general anesthesia plus pre and intra operative Dexmedetomidine infusion in a dose of 0.5mic/kg/hour starting 15 minutes before induction of general anesthesia and continue till peritoneum closure.
101656|NCT03391596|Behavioral|Internet-based ACT intervention|The Internet-based ACT intervention is a 12-week program based on the processes of Acceptance and Commitment Therapy.
101657|NCT03391596|Behavioral|Standardized rehabilitation|Standardized institutional rehabilitation in a rehabilitation center
101658|NCT03391596|Behavioral|Support by voluntary caregiver associations|Support given by voluntary caregiver associations
101659|NCT03391583|Other|Education|Participants in the education arm of the study will be provided with three PowerPoint presentations. Material for these slides has been adapted from material developed by the Ontario Neurotrauma Foundation. Topics to be addressed will surround post-traumatic headache and will include information regarding common symptoms, timeline for improvement, red- flags and when to seek medical attention
101660|NCT03391570|Drug|COX-2 inhibitor|Celebrex 200mg/1cap 2 tablets, take medication an hour before surgery
101661|NCT03391570|Drug|Placebo Oral Tablet|Ramnos 250mg/1cap 2 tablets, take medication an hour before surgery
101662|NCT03391570|Procedure|Preoperative peritoneal biopsy|Preoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
101663|NCT03391570|Procedure|Single-port laparoscopic surgery|Single-port laparoscopic surgery with CO2 gas
101664|NCT03391570|Procedure|Postoperative peritoneal biopsy|Postoperative peritoneal biopsy (1x1cm sized peritoneal tissue)
101665|NCT03391557|Diagnostic Test|UE|All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
101666|NCT03391544|Procedure|V4c toric ICL implantation surgery|The size and power of the V4c toric ICL were determined following the manufacturer's guidelines using a modified vertex formula. Emmetropia was the target refraction following surgery in all cases. Before surgery, three centration points were marked using the slit lamp while the patient, in sitting position, fixated on the center of the slit-lamp beam, which was narrowed as much as possible.
101667|NCT03391531|Procedure|Bilateral subcostal TAP block|Echo-guided infiltration of a local anesthetic solution in the plane located between the transversus abdominis muscle and the rectus abdominis muscle
101668|NCT03391518|Procedure|Water drinking test|Ingestion of 800 ml water in less than 5 minutes.
101669|NCT03391505|Behavioral|Small-sided soccer game|The small-sided soccer game consists of a single bout (two times ten minutes) of small-sided soccer game (3v3) interspersed with a five minutes break.
101670|NCT03391505|Behavioral|Walking soccer game|The walking soccer game consists of a single bout (two times ten minutes) of small-sided walking soccer game (3v3) interspersed with a five minutes break.
101671|NCT03391505|Behavioral|Rest group watching soccer|The rest group watching soccer consists of watching a soccer game on a laptop (two times ten minutes) interspersed with a five minutes break.
101672|NCT03391479|Drug|Avelumab|Avelumab is a fully human monoclonal antibody (mAb) of the immunoglobulin (Ig) G1 isotype. Avelumab selectively binds to programmed death-ligand 1 (PD-L1) and competitively blocks its interaction with programmed death protein 1 (PD-1).
101673|NCT03391479|Other|Best Supportive Care|As required.
101674|NCT03391466|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously following a conditioning chemotherapy regimen of fludarabine and cyclophosphamide
101675|NCT03391466|Drug|Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.|Platinum-containing salvage chemotherapy (R-ICE, R-DHAP, R-ESHAP, or R-GDP as selected by treating investigator) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.
101676|NCT03391466|Drug|Cyclophosphamide|Administered intravenously
101677|NCT03391466|Drug|Fludarabine|Administered intravenously
101678|NCT03391440|Drug|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 14 days) with levofloxacin hydrochloride and sodium chloride injection (500 mg intravenous, once daily for the first week) sequential of levofloxacin hydrochloride tablets (500 mg (500 mg orally, once daily for the second week)
101679|NCT03391427|Drug|Lidocaine|This group will receive lidocaine infusion
101680|NCT03391427|Drug|Ketamine|This group will receive Ketamine infusion
101681|NCT03391427|Drug|Lidocaine+ketamine|This group will receive mixture of ketamine and lidocaine infusion
101682|NCT03391427|Drug|Saline|This group will receive saline infusion
101683|NCT03391414|Drug|hypertonic bicarbonate|8.4% sodium bicarbonate inhaled
101684|NCT03391414|Drug|sodium chloride|7% sodium chloride inhaled
101685|NCT03391401|Procedure|Bariatric surgery|Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
101686|NCT03391388|Radiation|3-Dimensional Conformal Accelerated Partial Breast Irradiation|Undergo 3D-CRT, catheter-based brachytherapy, or proton APBI
101687|NCT03391388|Procedure|Interstitial Radiation Therapy|Undergo catheter-based brachytherapy APBI
101688|NCT03391388|Other|Laboratory Biomarker Analysis|Correlative studies
101689|NCT03391388|Radiation|Photon Beam Radiation Therapy|Undergo 3D-CRT APBI
101690|NCT03391388|Radiation|Proton Beam Radiation Therapy|Undergo proton APBI
101691|NCT03391388|Other|Quality-of-Life Assessment|Ancillary studies
101692|NCT03391375|Biological|DNA-HIV-PT123 & AIDSVAX B/E|DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant
101693|NCT03391362|Radiation|Stereotactic Radiation|Stereotactic radiation involves using a high dose of radiation that only targets the specific metastases
101694|NCT03391323|Device|Medacta GMK Sphere® Medial-Pivot Knee Prosthesis|
101695|NCT03391323|Device|Medacta GMK PS Posterior Stabilized Knee Prosthesis|
101696|NCT03391310|Other|Honey (medicated)|Honey (medicated) dressing will be used in the experimental group
101697|NCT03391297|Behavioral|Prolonged Exposure Therapy|PE consists of 10-15 treatment sessions. Treatment includes psychoeducation, in vivo exposure (i.e., confronting trauma-related situations and objects that are being avoided), imaginal exposure (i.e., revisiting and recounting traumatic memory) followed by processing (discussing the experience of revisiting the trauma memory, with a focus on new learning and changed beliefs or perspectives).
101698|NCT03391284|Drug|acetominophen|INTRAVENOUS
101699|NCT03391284|Drug|Acetaminophen|ORAL
101700|NCT03391271|Other|photobiomodulation therapy (PBMT)|"Multiwave Locked System® (M6 laser, ASA srl, Arcugnano (VI), Italy)~• The PBMT-group will receive twice-weekly laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy)"
101701|NCT03391271|Other|sham laser sessions|• The control group will undergo twice-weekly sham laser sessions starting at first until the last week of chemotherapy (9-12 weeks depending on the type of chemotherapy). The laser device will be placed on the same manner and for the same period of time on the identified body sites, but the device will not be switched on.
101702|NCT03391258|Procedure|Bone Regeneration with GLAM technique|Bone regeneration with GLAM technique in full arch implant supported rehabilitation
101703|NCT03391245|Diagnostic Test|3- Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique|Serum 25-Hydroxy Vitamin D level will be measured by Competitive ELISA technique using CALBIOTECH (A life science company) kit, Catalog No.: VD220B
101704|NCT03391232|Biological|PolyPEPI1018 CRC Vaccine|Colorectal Cancer Vaccine
101705|NCT03391219|Drug|injection bevacizumab|1.25 mg/0.05 cc bevacizumab
101706|NCT03391219|Drug|injection Combined Bevacizumab and Fasudil|1.25 mg/0.05 cc bevacizumab and 0.15mg/0.05 cc fasudil
101707|NCT03391206|Diagnostic Test|Inbody 720|We investigated the diagnostic accuracy of breast cancer related lymphedema diagnosed by bioimpedance analysis (Inbody 720) and arm circumference measurement..
101708|NCT03391193|Biological|Multi-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
101709|NCT03391193|Biological|Single-dose Quadrivalent Influenza Vaccine|0.5 mL, intramuscular
101710|NCT03391180|Drug|ICON Remineralization|A material used for the Remineralization of white spot lesions.
101711|NCT03391180|Drug|CPP-ACPF|Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
101712|NCT03391167|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).
101906|NCT03389685|Biological|Platelet Rich Plasma|Pure PRPII®, leukocyte-poor, platelet rich plasma
101907|NCT03389685|Other|Saline Placebo|saline solution
101713|NCT03391167|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
101714|NCT03391154|Drug|levothyroxin|100 female will receive levothroxine
101715|NCT03391154|Drug|Placebo Oral Tablet|100 female will receive placebo
101716|NCT03391115|Behavioral|Storytelling Intervention for Patient Participants|The storytelling intervention consists of an audio-recorded interview with each patient participant prompted the participant to share their story with questions such as: tell me about your illness, tell me how your illness has affected your emotions, relationships, and spirituality. The interview transcripts will be used to co-create a 1 page patient story using these criteria:1) written in the first person; 2) nonjudgmental; 3) captures the participant's voice; 4) accurately reflects content of the interview; and 5) non-labeling. Once the story has been approved by the participant, I will upload it to the EHR.
101717|NCT03391115|Behavioral|Storytelling Intervention for Nurse Participants|"Once the patient's story is uploaded to the EHR, automatic alerts will be sent to the participant's EHR-assigned nurses. For usability testing, nurse participants will 1) provide content expertise of the workflow processes, and 2) put the storytelling intervention through in-house usability testing to check the strength of EHR features and user-friendliness. Data will be collected with exit interviews and completion of a questionnaire: the System Usability Scale which asks them to rank their satisfaction with specific elements such as: how the story is labeled and presented in the EHR, any technical navigation EHR difficulties, and use of the material."
101718|NCT03391102|Other|Observational study|
101719|NCT03391089|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system.
101720|NCT03391076|Diagnostic Test|FilmArray Respiratory Panel|An Multi-PCR method which can detect 20 pathogens in 45 minutes.
101721|NCT03391063|Other|polyamide|metal reinforced polyamide denture base material
101722|NCT03391063|Other|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
101723|NCT03391050|Drug|APR-246|Intravenous infusion
101724|NCT03391050|Drug|Dabrafenib|Oral administration
101725|NCT03391037|Diagnostic Test|Internal Jugular Vein Distensibility|. 40 donor candidates for right lobe hepatectomy for living donor liver transplantation were enrolled. During period of hypovolemia (T0) left IJV scanned and measured. After a given fluid bolus in the form of ringer acetate 5 ml / Kg. ultrasonic and hemodynamic measurements were reassessed 10 minutes (T 10) after the fluid resuscitation
101726|NCT03391024|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while navigated with clinically approved system.
101727|NCT03391011|Device|BBL Experimental Navigation System|Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
101728|NCT03390972|Drug|Placebo|Placebo (NaCl 0.9%) TCI infusion
101729|NCT03390972|Drug|Dexmedetomidine|Dexmedetomidine TCI 0.6 ng/ml and 1.2 ng/ml
101730|NCT03390959|Other|Proprioceptive Training|"Individuals in the Trained Group will perform the training twice a week for 45 minutes and perform for a period of 12 weeks.~The training is divided into a pre-training phase where general hip dissociation exercises and simple stretching of the hip flexor and extensor muscle groups, knee, foot and paravertebral are performed.~The second phase is the proprioceptive training, where it will involve training of balance, sensitivity and proprioception, being used a circuit composed of 15 stations, whose time of stay in each station is 2 minutes.~And finally the third stage are relaxation exercises, performed with breathing exercises associated with slow active movements of the joints."
101731|NCT03390959|Other|Control Group|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
101732|NCT03390946|Drug|Poor responder group adjuvant chemotherapy|"Poor responder group (necrosis ≤ 90%)~: week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~B. Resection of tumor~C. Adjuvant chemotherapy~Poor responder group (necrosis ≤ 90%)~week 0, 7 and 14, doxorubicin; week 2, 9 and 16, ifosfamde, week 4, 11, 18 and 19, methotrexate; wk 5, 12 and 20~Good responder group (necrosis > 90%)~week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
101733|NCT03390946|Drug|Good responder group adjuvant chemotherapy|"Good responder group (necrosis > 90%)~: week 0 and 8, doxorubicin; week 2 and 10, ifosfamide; week 4, 5, 12 and 13, methotrexate; week 6 and 14, cisplatin"
101734|NCT03390933|Drug|Fluoxetine|Patients enrolled into Phase II will be prescribed 2 weeks of short-acting fluoxetine 20 mg and will be instructed to take the prescription daily for 2 weeks. Then patients will be prescribed 10 additional weeks of 90 mg (weekly) fluoxetine and will be observed taking it once weekly at the dialysis unit. At the end of the 12 week study period, participants will be provided 4 additional weeks of 90 mg fluoxetine in order to provide sufficient time to follow up with their primary care physician or nephrologist.
101735|NCT03390920|Biological|Amniotic|The amniotic product is regulated by the FDA as a biologic and comes from a lab that is FDA registered/certified.
101736|NCT03390907|Device|Hybrid APC|Following standard EMR Hybrid Argon Plasma Coagulation (APC) of the base and edges of the polypectomy site to fulgurate any potential microscopic residual disease.
101737|NCT03390881|Other|Fasting condition|Subjects will fast over the whole experimental period (480 min)
101738|NCT03390881|Other|Sugar condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% carbohydrate, 15% fat and 15% protein and providing 1.5 X hourly resting energy requirement.
101739|NCT03390881|Other|Fat condition|After a 2-h fasting state, subjects will ingest every hour a drink containing 70% fat, 15% carbohydrate and 15% protein and providing 1.5 X hourly resting energy requirement.
101853|NCT03390166|Biological|Licensed influenza vaccine|The comparator licensed influenza vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
101740|NCT03390868|Behavioral|Web-based training for staff|This web-based training program is focusing on strengthening the carers' communication skills. Video lectures on the definitions, characteristics and causes of challenging behavior will be given. Video lectures will also be given on the importance of the carers' views on their values, emotions, abilities and attitude towards people with intellectual disabilities and on the impact that workplace culture and environmental factors have on the quality of interactions. The program also includes written cases that gives the participants opportunities to reflect upon approaches supporting a successful interaction. It also covers factors to consider when mental illness and challenging behavior occur. The time to complete the web-based training program is estimated at approximately ten hours.
101741|NCT03390855|Other|Broccoli sprouts|
101742|NCT03390842|Drug|TRC101|Oral suspension
101743|NCT03390842|Drug|Placebo|Oral suspension
101744|NCT03390829|Other|semi-directed interviews|semi-directed interviews
101745|NCT03390816|Other|Nutritional assessment|Observational
101746|NCT03390803|Other|effect of hemifacial spasm on intraocular pressure|To evaluate the effect of Hemifacial spasm on Intraocular pressure measurement.
101747|NCT03390790|Drug|Lidocaine gel 2%|If assigned to this intervention via randomization, participants will receive lidocaine (numbing) gel prior to their urodynamics procedure.
101748|NCT03390790|Other|Standard lubricant gel|If assigned to this intervention via randomization, participants will receive standard lubricant gel prior to their urodynamics procedure.
101749|NCT03390777|Procedure|surgery|surgery without the use of prgf
101750|NCT03390777|Device|PRGF after surgery|surgery and application of PRGF
101751|NCT03390764|Procedure|4:1 closure group|In this arm the incisions are closed by the 4:1-technique
101752|NCT03390764|Procedure|RTL plus 4:1 closure group|In this arm the incisions are closed by a reinforced tension-line suture in addition to the 4:1-technique
101753|NCT03390751|Other|Data collection|The collection of data will be done by interrogation of the patient and his family / entourage and rereading of medical records
101754|NCT03390738|Drug|Nivolumab|Intravenous nivolumab 240mg every 2 weeks until radiologically-documented disease progression, unacceptable toxicity as judged by investigators or patient withdrawal
101755|NCT03390725|Behavioral|A Healthy School Start Plus intervention|Intervention for prevention of childhood overweight and obesity in disadvantaged areas through parental support in the school setting
101756|NCT03390712|Drug|Paliperidone Palmitate|Monthly injections
101757|NCT03390712|Drug|Risperidal Consta|Bi-weekly injection
101758|NCT03390712|Drug|Antipsychotic|Any oral antipsychotic prescribed to be taken on a regular basis prior to the initiation of a long-acting injectable antipsychotic.
101759|NCT03390699|Diagnostic Test|Microbial profile|microbiological testing
101760|NCT03390686|Drug|Bevacizumab|15 mg/kg IV every 3 weeks on Day 1
101761|NCT03390686|Drug|HD204|15 mg/kg IV every 3 weeks on Day 1
101762|NCT03390686|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
101763|NCT03390686|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
101764|NCT03390673|Drug|HD204|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
101765|NCT03390673|Drug|Avastin|Single-Dose 1mg/kg body weight by 90 minute intravenous infusion
101766|NCT03390660|Other|WIC program participation|WIC program is a welfare program in the U.S. to provide nutritional supplements to low-income women, infants, and children.
101767|NCT03390647|Drug|E6130|Oral dose
101768|NCT03390647|Drug|Placebo|E6130-matched placebo
101769|NCT03390634|Other|Gastroesophageal reflux symptoms questionnaires|Reflux Disease Questionnaire (RDQ) Reflux Symptoms Index (RSI) Gastroesophageal Reflux Disease Health-Related Quality of Life (GORD-HRQL)
101770|NCT03390608|Drug|Endocrine therapy|Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).
101771|NCT03390608|Radiation|Radiotherapy|Radiotherapy versus no radiotherapy.
101772|NCT03390608|Drug|Herceptin|Trastuzumab versus no trastuzumab (in women with HER2-positive disease).
101773|NCT03390608|Drug|Chemotherapy|Chemotherapy versus no chemotherapy.
101774|NCT03390608|Procedure|Type of breast cancer surgery|Type of surgery (partial mastectomy, mastectomy, other).
101775|NCT03390608|Other|Age at diagnosis|Age at diagnosis (<35, 35-<50, 50-<70, ≥70).
101776|NCT03390608|Other|Screen detected tumor|Screening detected tumor (yes, no).
101777|NCT03390608|Other|Menopausal status at diagnosis|Menopausal status (premenopausal, postmenopausal).
101778|NCT03390608|Other|Tumor size|Tumor size (≤5 mm, 6-≤10 mm).
101779|NCT03390608|Other|Estrogen receptor (ER) status|ER-status (positive, negative).
101780|NCT03390608|Other|Tumor grade|Tumor grade (1, 2, 3).
101781|NCT03390608|Other|HER2-status|HER2-status (positive, negative).
101782|NCT03390608|Other|Intrinsic subgroups of breast cancer|Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).
101783|NCT03390608|Other|Nodal status|N-status (N0, N1).
101784|NCT03390595|Combination Product|avelumab 10mg/kg with carboplatin/gemcitabine|"Dosage and schedule:~Avelumab 10mg/kg will be administered over 60 minutes in the experimental arm as follows:~Intravenously every 2 weeks for two cycles.~During carboplatin-gemcitabine treatment, on day +15 (carboplatin will be administered on day 1; gemcitabine on days 1 and 8), for six cycles. Intravenously every 2 weeks until progressive disease o intolerance.~Intravenously every 2 weeks until progressive disease or intolerance.~Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
101785|NCT03390595|Combination Product|carboplatin/gemcitabine alone|"•Carboplatin-gemcitabine will be administered for six cycles, every three weeks, with the following posology, according to the SmPC~Carboplatin 5AUC day +1.~Gemcitabine 1000mg/m2 day +1 and +8."
101786|NCT03390582|Drug|Methimazole Pill|Hyperthyroidism patients are treated with Methimazole Pill according to the guidelines
101787|NCT03390569|Behavioral|Exercise|The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
101788|NCT03390556|Other|Nurse-delivered education|"The nurse will:~Give the caregiver and child an overview of asthma, and discuss asthma control, triggers, and medications.~Give caregivers information about asthma management written at or below 6th grade reading levels.~Provide colored medication labels to distinguish controller from rescue medications following the action plan color scheme (green for controller medications, red for rescue medications). Teach-back methods will be used to elicit understanding of correct indications of use.~Demonstrate MDI/spacer technique with teach-back.~Discuss age-appropriate caregiver and child responsibility for asthma management within the family, with an overview of transitioning responsibility.~Ask patients to make a 1 month follow-up appointment for asthma care."
101789|NCT03390543|Device|Sono with Device|In Group D, simple needle guide device was attached to the sono probe. Device was designed to assist the detection of the puncture site. After induction of anesthesia, both the device and sono-guided internal jugular vein catheterization was performed.
101790|NCT03390543|Device|sono only|In Group S, simple needle guide device was not attached to the sono probe. After induction of anesthesia, only sono-guided internal jugular vein catheterization was performed.
101791|NCT03390530|Drug|Thyroxine|8 µg/kg/day divided into two doses intravenous every 12 hours
101792|NCT03390530|Drug|Placebo|Placebo
101793|NCT03390517|Device|Fluorescence angiography with indocianyne green|The fluorescence angiography was performed after mobilization of the bowel, transection of the rectum, division of the rectal and colon mesentery and central vessels, before specimen extraction or resection and creation of the anastomosis. This site was selected by the surgeon using his or her best judgment and typical standard of care assessment. After this selection, the anesthesiologist administered a bolus of 1 to 2 ml indocianyne green intravenously. Perfusion of the colon was visualized and assessed via fluorescence angiography and the line of demarcation between perfused and nonperfused tissue was noted and compared with the initial planned transection point.
101794|NCT03390504|Drug|Erdafitinib|Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.
101795|NCT03390504|Drug|Vinflunine|Participants will receive vinflunine 320 mg/m^2 as a 20-minute intravenous infusion.
101796|NCT03390504|Drug|Docetaxel|Participants will receive docetaxel 75 mg/m^2 as a 1 hour intravenous infusion.
101797|NCT03390504|Drug|Pembrolizumab|Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.
101798|NCT03390504|Device|Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)|FGFRi CTA will be used to determine molecular eligibility.
101799|NCT03390491|Behavioral|OnTrack>TheGame (OTG)|OTG clients will be informed that the game can be played on a computer or a tablet and the time estimate for completing the game is approximately 5-8 hours. OnTrack>The Game offers players the opportunity to immerse in a fictional neighborhood that centers around four domains for supportive recovery as defined by SAMHSA: health, home, purpose and community. The player interacts with other game characters including new acquaintances, friends/peers, a family member, and a treatment team, allowing the player to practice social and communication skills, while fostering personal relationships and building a support network. Additionally, the game provides players with helpful resources including psychoeducation materials and videos of real people who have experienced a first episode of psychosis, sharing their stories of hope and recovery. As a whole, the game provides a safe environment to promote goal attainment and recovery.
101800|NCT03390491|Behavioral|Recovery Videos (RV)|As described, RV clients will have access to a website that includes recovery videos and static psychoeducation materials. In this condition, mental health providers will also ask about possible reactions to viewing the recovery videos and information on the website.
101801|NCT03390478|Other|Combined Intervention Group|Experimental: Combined Intervention Program is composed by a Cognitive Stimulation Program (CSP), a Physical Activity Program (PAP) and Animal Assisted Therapy (AAT). During the PAP participants that use rolling-walkers, will do PAP using the Auto-Blocking kit mechanism for rolling walkers (ABMRW).
101802|NCT03390465|Drug|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide|Fimasartan/Amlodipine combination drug, Hydrochlorothiazide
101803|NCT03390452|Behavioral|Mobile Phone Messaging|"Parents of primary school children will receive Mobile Phone Messages regarding their children's oral hygiene maintenance and their positive dietary habits."
101804|NCT03390439|Device|Nd-Yap 1340nm laser|Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
101805|NCT03390439|Device|Microneedling|In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
101806|NCT03390426|Drug|Mepivacaine|An ultrasound guided injection of mepivacaine superomedially to the femoral artery.
101807|NCT03390426|Procedure|Perifemoral Injection of Local Anesthetic|An ultrasound guided injection of mepivacaine superomedially to the formal artery in an effort to numb the nerves that contribute to tourniquet hypertension intraoperatively.
101808|NCT03390426|Drug|Saline|An ultrasound guided injection using a medication that does NOT numb any nerves called saline, or salt water.
101809|NCT03390413|Procedure|Robot|Renal cancer treated with robotic surgery
101810|NCT03390413|Procedure|Cryoablation|Renal cancer treated with cryoablation
101811|NCT03390400|Device|Femtosecondlaser-assisted|Femtosecondlaser-assisted Cataract Surgery will be performed bilateral on the same day with different laser settings.
101812|NCT03390400|Procedure|Anterior Capsulotomy|Cataract Surgery
101813|NCT03390400|Procedure|Lens Fragmentation|Cataract Surgery
101814|NCT03390387|Drug|Dexamethasone continuous|6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.
101815|NCT03390387|Drug|Dexamethasone intermittent|6 mg/m2, per os, in two divided doses per day q12 hours. Days: 1-14 (dose in the first few days is depending on the total tumor mass) and 22-28; days 15-21 - pause. From day 29 the dose of dexamethasone is reducing: days 29-30 - 3 mg/m2, days 31-32 - 1.5 mg/m2, then dexamethasone is discontinued completely.
101873|NCT03389997|Diagnostic Test|nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding
101874|NCT03389984|Diagnostic Test|cutaneous|SKIN BIOPSY
101816|NCT03390387|Drug|Dexamethasone|"Induction: 6 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 3 mg/m2, days 32-34 - 1.5 mg/m2, days 35-36 - 0.75 mg/m2; then dexamethasone is discontinued completely.~Consolidation: 6 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 6 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
101817|NCT03390387|Drug|Methylprednisolone|"Induction: 60 mg/m2, per os, in two divided doses per day q12 hours. 1-28 day (dose in the first few days is depending on the total tumor mass). From day 29 the dose of dexamethasone is reducing: days 29-31 - 30 mg/m2, days 32-34 - 15 mg/m2, days 35-36 - 8 mg/m2; then methylprednisolone is discontinued completely.~Consolidation: 60 mg/m2 per os, in two divided doses per day q12 hours. Weeks 13-14 (days 85-98), weeks 21-22 (days 141-154), weeks 29-30 (days 197-210), weeks 37-38 (days 253-260), weeks 45-46 (days 309-316), weeks 53-54 (days 365-372).~Maintenance therapy: 60 mg/m2, per os, in two divided doses per day q12 hours, for 10 days followed by quick discontinuation during 3 days. Weeks 61-62, 69-70, 77-78, 85-86, 93-94."
101818|NCT03390387|Drug|Daunorubicin|Induction: 45 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 30 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
101819|NCT03390387|Drug|Idarubicin|Induction: 10 mg/m2, intravenously, for 6 hours on days 8 and 22. Consolidation: 8 mg/m2, intravenously, for 6 hours on days 44, 65 (consolidation S1); 107, 121 (consolidation S2); and 163 (consolidation S3).
101820|NCT03390387|Drug|Bortezomib|1.3 mg/м2, intravenously, bolus injection. Days 85, 89, 92, 96 (consolidation S1); 141, 145, 148, 152 (consolidation S2) and 197, 201, 204, 208 (consolidation S3).
101821|NCT03390387|Drug|Second phase of induction|Cyclophosphamide (1,000 mg/m2, intravenously, for 1 hour ‒ days 43 and 71); Cytarabine (75 mg/m2/day, intravenously, bolus injection. Four blocks of 4 days each, days 46-48, 52-55, 59-62, and 66-69); 6-mercaptopurine (60 mg/m2/day, per os, days 43-71); Triple intrathecal therapy (days 52 and 66)
101822|NCT03390387|Drug|Standard induction therapy|Dexamethasone (6 mg/m2, p/o; 1-29 days); Daunorubicin (45 mg/m2, i.v.; day 8 and 22); Vincristine (1.5 mg/m2, i.v.; days 8, 15, 22, 29 and 36); Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone; days 0/1, 8, 15, 22, 29 and 36)
101823|NCT03390387|Drug|Standard consolidation therapy|Consolidation consists of 3 phases: S1, S2 and S3. Each phase is a 6-week therapy with 6-mercaptopurine (50 mg/m2 per day, daily, orally), methotrexate (30 мг/м2, i.m., weekly) and L-asparaginase (10 000 U/m2, i.m., weekly), followed by 2 weeks of re-induction with Vincristine (1.5 mg/m2, i.v., days 1 and 8 of reinduction) plus Dexamethasone (6 mg/m2, p/o, daily, for 10 days followed by quick discontinuation during 3 days). Daunorubicin (30 mg/м2, i.v., N2 during S1, N2 during S2 and N1 during S3). Triple intrathecal therapy (Methotrexate/Cytarabine/Prednisone) N12 (4 injections per each phase)
101824|NCT03390374|Drug|Nystatin Oral|Nystatin oral suspension
101825|NCT03390361|Device|Femtosecond Laser-assisted|Laser cataract surgery will be performed in one eye
101826|NCT03390361|Procedure|Manual Cataract Surgery|Manual cataract surgery will be performed in contralateral eye
101827|NCT03390348|Device|LENA Recorder|Use of the LENA recorder to document crying and fussing
101828|NCT03390335|Other|Pressure|Subjects undergo altitude exposure, diving exposure, and return to altitude. Altitudes: 8,000, 10,000, 12,000, or 15,000 feet Dives: 60 or 100 feet of sea water
101829|NCT03390335|Other|Breathing Gas|Subjects will breathe air, 35% Oxygen, Balance Nitrogen, or 100% Oxygen during the diving exposure
101830|NCT03390322|Device|DiaGone™|Duodenal Glycemic Control™ using the DiaGone™ system
101831|NCT03390309|Other|Partially Hydrolyzed Formula|Partially Hydrolyzed Whey Protein Infant Formula
101832|NCT03390309|Other|Normal Formula|Normal Formula
101833|NCT03390296|Biological|Anti-OX40 Agonist Monoclonal Antibody PF-04518600|Given IV
101834|NCT03390296|Drug|Avelumab|Given IV
101835|NCT03390296|Drug|Azacitidine|Given IV or SC
101836|NCT03390296|Drug|Gemtuzumab Ozogamicin|Given IV
101837|NCT03390296|Drug|Glasdegib|Given PO
101838|NCT03390296|Drug|Glasdegib Maleate|Given PO
101839|NCT03390296|Drug|Venetoclax|Given PO
101840|NCT03390296|Drug|Azacitidine|Given IV or SC
101841|NCT03390283|Other|Survey Administration|Complete online survey
101842|NCT03390270|Other|Admission with NSTEMI|All patients admitted to Duke University Hospital with an NSTEMI
101843|NCT03390257|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during Balloon Sinus Dilation
101844|NCT03390244|Device|Foldable Capsular Vitreous Body Implant|Vitrectomy augmented with the implantation of the FCVB implant
101845|NCT03390231|Combination Product|Stem Cell Educator therapy|It briefly cocultures the patient's lymphocytes with CB-SCs in vitro, induces immune tolerance through the action of autoimmune regulator (AIRE, expressed by CB-SCs), returns the educated autologous lymphocytes to the patient's circulation, and restores immune balance and homeostasis.
101846|NCT03390218|Behavioral|Therapy Assistance Online|protocoled on-line educational modules, with brief therapist interaction and practice support with a mobile app.
101847|NCT03390218|Behavioral|Treatment as usual|Individual and group therapy, generic in nature
101848|NCT03390205|Diagnostic Test|Optical coherence tomography angiography under dark and light adaptation|Optical coherence tomography angiography under dark and light adaptation with pupil dilatation
101849|NCT03390192|Device|Dual-mode stimulation|1Hz rTMS over contralesional primary motor cortex and anodal tDCS over ipsilesional primary motor cortex are simultaneously simulated.
101850|NCT03390192|Device|Single sham stimulation|1Hz rTMS over contralesional primary motor cortex and sham tDCS (no stimulation) over ipsilesional primary motor cortex are simultaneously simulated.
101851|NCT03390179|Drug|Steroid Drug|mesure of the glucose concentration
101852|NCT03390166|Biological|GPO Tri Fluvac vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
101875|NCT03389971|Procedure|catheter-directed thrombolysis|catheter-directed thrombolysis with commercially available multi-sidehole catheter or USAT catheter
101854|NCT03390153|Other|semi flexible socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
101855|NCT03390153|Other|rigid fiber socket|The investigators will analyze the subject's gait by trained visual diagnosis and video gait analysis, to determine comfort and safety. Any modifications will be done at this time. Once the subjects, student, and faculty investigators are satisfied with the overall fit of prostheses, a student investigator will insert force sensors into the socket to evaluate pressure. In the 'Comfort Test', walk at a self-selected pace on a treadmill for 10 minutes. Subjects will then perform a single stance activity on a Balance Master. Investigators will remove the force sensors and do one final safety check of prostheses before each subject takes their definitive socket home. Subjects will be required to wear the prosthesis given to them for one week before returning for a follow up appointment.
101856|NCT03390140|Behavioral|ReInventing Yourself after SCI structured group CBT|ReInventing Yourself after SCI intervention integrates positive psychotherapy concepts into structured group cognitive behavioral therapy (CBT) to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle. The intervention consists of six weekly two-hour facilitator-led sessions that include didactic presentations of eight core skills and related experiential exercises with extensive group discussion.
101857|NCT03390140|Behavioral|ReInventing Yourself after SCI study-specific workbook|A study-specific workbook that incorporates positive psychotherapy concepts to develop optimistic self-efficacy beliefs, thereby strengthening resilience to emotional distress, enhancing a sense of well-being and promoting a more active lifestyle.
101858|NCT03390140|Behavioral|ReInventing Yourself after SCI YouTube videos|YouTube videos containing the content of the ReInventing Yourself after SCI structured group CBT sessions
101859|NCT03390127|Other|PEEP|After LMA Supreme™ insertion, it's proper position is confirmed. Then, PEEP of 7 cmH2O is applied during mechanical ventilation.
101860|NCT03390114|Behavioral|SHUTi|SHUTi consists of six, 40-minute, weekly sessions during which the intervention components of stimulus control, sleep restriction, sleep hygiene, cognitive restructuring, and relapse prevention are delivered. Each SHUTi session has the same structure: the main content, a homework screen with options, and a summary of the main points.
101861|NCT03390101|Drug|BCD-085 Q2W|"In Arm 1, the test drug BCD-085 will be used at a dose of 120 mg given as two SC injections according to the following schedule: once a week for the first 3 weeks (induction treatment) and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label patients will receive BCD-085 through week 50. The follow-up will continue through week 54."
101862|NCT03390101|Drug|BCD-085 Q4W|In Arm 2, and then once every 4 weeks through Week 10. On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 2 will be given BCD-085 once every 4 weeks through week 50. The follow-up will continue through week 54.
101863|NCT03390101|Drug|Placebo|"In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54."
101864|NCT03390062|Drug|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue.
101865|NCT03390049|Device|Fractional CO2 Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the fractional CO2 laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe with the following settings: dot power 26 Watts, dwell time 1000 μs, dot spacing 1000 μm, and smart stack parameter from 1 to 3. Stack 1 is used at baseline; stack 3 is used 6 and 12 weeks after.
101866|NCT03390049|Device|Sham Laser Treatment|After obtaining a negative urine pregnancy test, each subject assigned to the sham laser treatment arm will undergo laser sessions with the fractional microablative CO2 laser system (SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy) using the flat vulvar probe. However, these sham laser sessions will administer no fractional CO2 laser energy. To increase the likelihood that subjects assigned to sham laser remain blinded to treatment arm assignment during the study, MonaLisa Touch will provide a software package with settings that allow for reproduction of the sounds generated during a regular fractional CO2 laser session but using 0 Watts of power.
101867|NCT03390036|Drug|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)
101868|NCT03390036|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
101869|NCT03390036|Drug|Triamcinolone Hexacetonide|20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide
101870|NCT03390023|Behavioral|Focus Group|Groups will last 60 to 90 minutes. Focus groups will be moderated by KUMC Juntos staff who are formally trained to conduct focus groups. General topics to be covered in focus groups include: attitudes, preferences and knowledge about prenatal care, clinical trial participation, and nutritional supplement use. Focus groups will be conducted in Spanish.
101871|NCT03390010|Drug|Misoprostol + syntocinon and methergine drugs|medical prophylaxis against postpartum atony and postpartum hemorage by giving misoprostol plus syntocinon and methergine
101872|NCT03390010|Drug|Syntocinon plus methergine drugs|medical prophylaxis against postpartum atony and postpartum hemorage by giving syntocinon and methergine
101877|NCT03389945|Procedure|25G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 25G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
101878|NCT03389945|Procedure|27G Dural Puncture Epidural Block|"Dural puncture epidural analgesia using a 27G pencil point spinal needle at a lumbar interspace.~Then 20ml of bupivacaine 0.125% + fentanyl 2ug/ml will be injected in the epidural space."
101879|NCT03389932|Behavioral|Patient-Guided|Patients in the ET@Home study condition will receive four modules of video and print transplant education over a 6-month period. After each module is mailed, 3 postcards are mailed weekly that recap important transplant educational content covered within the videos. Patients will have the opportunity to participate in a texting component of ET@Home that also sends small pieces of educational content and learning reminders by phone each week.
101880|NCT03389919|Biological|MSC administration (intraosseal)|MSCs will be administered under local anesthesia to the iliac crests after receiving informed consent from the patient.
101881|NCT03389906|Other|Gold|Approximately 72000, 20-40 my-meter diameter, sterilised gold particles (=20 mg) will be provided in vials (The Berlock® Gold Implants). 5-10 ml of synovial fluid is aspirated (20G needle) from most affected OA-knee. The vial of gold particles are mixed with the synovial fluid, and the mix of gold and synovial fluid is injected intra-articularly into the patients knee.
101882|NCT03389893|Drug|Dupilumab|Dupilumab, an interleukin (IL)-4 receptor alpha (IL-4Rα) antagonist, is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. (FDA approved on March 28, 2017.)
101883|NCT03389893|Drug|Placebo|Placebo will contain the identical formulation as the dupilumab formulation without the active mAb and will be given by exactly the same route and schedule through Day 28.
101884|NCT03389880|Procedure|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
101885|NCT03389880|Procedure|Patellar denervation|circumpatellar electrocautery with monopolar coagulation diathermy
101886|NCT03389867|Dietary Supplement|Kaempferia parviflora extract|
101887|NCT03389854|Device|RestoreX PTT - randomized and open label|Penile traction therapy in the straight and bent positions
101888|NCT03389854|Device|RestoreX PTT - open label phase only|Penile traction therapy in the straight and bent positions
101889|NCT03389841|Other|Education|Education of the caregiver about early symptoms and signs of heart failure
101890|NCT03389815|Drug|WX-0593 Tablets|tablets, dosage ranged from 30 mg to 300 mg, quaque die（QD）
101891|NCT03389802|Biological|APX005M treatment for recurrent or refractory primary malignant CNS tumor patients|"APX005M dosing will begin at 0.1 mg/kg, the APX005M dose may be increased (0.3, 0.45, 0.6 mg/kg) or decreased (0.03 mg/kg) in subsequent cohorts until the MTD is reached or until dose level 3 (0.6 mg/kg) is complete without MTD being defined.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
101892|NCT03389802|Biological|APX005M treatment for newly diagnosed DIPG patients|"The starting dose of APX005M for the DIPG patients will be one dose level below the RP2D determined in Stratum 1 patients. The dose may be decreased or increased to the RP2D established in Stratum 1.~APX005M will be administered at the assigned dose level every 21 days (3 weeks). Patients may continue to receive APX005M for 36 courses (approximately 2 years) or until disease progression, unacceptable toxicity or death, whichever occurs first."
101893|NCT03389789|Other|Oral glucose solution + maternal holding|Infant will receive both the oral glucose solution and the contact with the mother
101894|NCT03389789|Other|Breastfeeding|Infants will be breastfed
101895|NCT03389789|Other|Oral glucose solution|Infant will receive only oral glucose solution without contact with the mother
101896|NCT03389789|Other|Oral expressed breastmilk|Infant will receive only oral expressed breast milk without contact with the mother
101897|NCT03389776|Procedure|Anesthesia|Occurrence and severity of postoperative sore throat could be determined by various factors other than the pressure of the cuff alone. In particular, cuff pressure measurement, duration of anaesthesia, airway manipulations e.g. multiple insertion attempts, could all be factors determining the occurrence of postoperative sore throat.
101898|NCT03389763|Drug|Remifentanil|a rate of infusion will be increased by 50% every 5 minutes
101899|NCT03389750|Drug|Intravenous Challege Drug|Intravenous administration of opioid drugs (oxycodone, oxymorphone, morphine, hydromorphone), for the purpose of comparison of their abuse potential among each other, and in comparison to placebo (saline).
101900|NCT03389737|Behavioral|Counseling|Counseling on healthy behaviors with in person meetings.
101901|NCT03389737|Behavioral|Counseling|Counseling on healthy behaviors with emails.
101902|NCT03389724|Drug|Capoten®|ACE-I (Capoten®) will be given to patients in the Intervention arm with the start of chemotherapy, twice daily at a dose of 0.5 mg/kg/day (divided over 2 doses)
101903|NCT03389711|Combination Product|DMARD´s and multidisciplinary treatment|"At study enrollment, medical history, disease-specific autoantibodies, ACR 1987 classification criteria for RA were applied. Medical evaluations were standardized and included at least 66 swollen and 68 tender joint counts, acute reactant-phase determinations , patient and physician reported outcomes, comorbidity established by record review, and treatment assessments (name, dose and schedule of all drug they were taking) along with an evaluation of persistence, at six-month intervals.~Patients were evaluated by a single rheumatologist every two months during the first two years of follow-up, and every two, four or six months thereafter.~Also the following scores: Michigan Hand Outcome Questionnaire (MHQ), Disabilities of the Arm, Shoulder and Hand Outcome Measure (DASH),Mayor Depressive Episodes (MDE) was defined using the Mini International Neuropsychiatric Interview and the severity of depressive symptoms was assessed with the Beck Depression Inventory (BDI-II)."
101904|NCT03389698|Device|GRASP DCE-MRI|DCE-MRI termed Golden-angle Radial Sparse Parallel (GRASP) significantly improves both spatial and temporal resolution while enabling retrospective reconstruction with flexible temporal resolution.
101905|NCT03389698|Device|3T Brain Scan|up to 60 minutes: 3T brain scan, a portion of which uses the GRASP DCE-MRI sequence (the first 21 minutes of the scan for CN cohorts and the first 9 minutes of the scan for the Amnestic Mild Cognitive Impairment cohort)
101908|NCT03389672|Procedure|spinal anesthesia|For conventional spinal anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
101909|NCT03389672|Procedure|epidural anesthesia|For conventional epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
101910|NCT03389672|Procedure|combined spinal-epidural anesthesia|For conventional combined spinal-epidural anesthesia, injection site was 1 cm lateral and 1 cm caudal to the spinous process, and the needle was directed cephalad and medially to the epidural-subarachnoid space by the operator. For modified method, we reduced the distance from 1cm to 0.5cm in each directions.
101911|NCT03389659|Drug|vitamin D3|vitamin D3 400IU*5pills po. qd continue to disease progression
101912|NCT03389659|Drug|Placebo|placebo 5 pills po. qd continue to disease progression
101913|NCT03389646|Device|CERAMENT G V|"During the removal of hip and knee prostheses usually bone defects occur at the intramedullary canal of the tibia and or / femur and /or acetabulum. These bone defects are filled with CERAMENTTM|G or V during the re-implantation of the cementless or hybrid revision THA or TKA. CERAMENTTM|G or V can be directly injected into the intramedullary canal or bone defect at the acetabulum. Alternatively and preferably, the surface of the prostheses shafts can be used to transfer CERAMENTTM|G or V into the bone defects. For information of handling and mixing please see the attached instructions for use (IFU)."
101914|NCT03389633|Other|rehabilitation|
101915|NCT03389620|Drug|dexamethasone|0.8 mL of dexamethasone (10 mg/mL) will slowly be injected over a period of approximately 30 seconds
101916|NCT03389607|Diagnostic Test|spinal anesthesia|before spinal anesthesia, before 5 min opening of tourniquet and 2 hr after operation SCUBE-1, MDA and TAC will measured from plasma
101917|NCT03389594|Other|Surgical guide|Surgical Guide for this group will designed from 0.4mm voxel size
101918|NCT03389581|Behavioral|awareness and anxiety|before operation awareness and anxiety will recorded with STAIX-I score
101919|NCT03389568|Behavioral|singing-based music therapy program|A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
101920|NCT03389555|Drug|vitamin C, vitamin B1, hydrocortisone|Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.
101921|NCT03389555|Drug|Normal saline|Normal saline (0.9% NaCl solution) volume to match all components
101922|NCT03389542|Procedure|Surgery|Early mitral valve repair
101923|NCT03389542|Other|Clinical interview and echocardiography|Clinical interview and echocardiography every 6 months.
101924|NCT03389516|Other|Polymem|wound care dressings
101925|NCT03389516|Other|Lanolin|wound care oinment
101926|NCT03389503|Procedure|Radial approach|Approach site for coronary angiography and coronary intervention
101927|NCT03389490|Drug|Insulin Glargine 300 UNT/ML|Self titration of insulin glargine U300
101928|NCT03389490|Drug|Neutral protamine hagedorn insulin|Self titration of NPH insulin
101929|NCT03389477|Drug|Palbociclib|Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
101930|NCT03389477|Drug|Cetuximab|-Cetuximab must not be administered as an IV push or bolus
101931|NCT03389477|Drug|Cisplatin|-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
101932|NCT03389477|Radiation|Intensity-Modulated Radiation Therapy|-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
101933|NCT03389477|Procedure|Tumor biopsy|"Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy~If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline."
101934|NCT03389477|Procedure|Peripheral blood draw|Baseline and post-treatment
101935|NCT03389477|Other|European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30|-Baseline, Step One Cycle 2 Day 22, Day 1 of RT, Day 36 of RT, Cycle 1 Day 1 (adjuvant), Cycle 4 Day 1 (adjuvant), EOT (adjuvant), 8 months after completion of chemoradiation therapy (CRT), 12 months after completion of CRT, 18 months after completion of CRT, 24 months after completion of CRT, 30 months after completion of CRT, 36 months after completion of CRT, 42 months after completion of CRT, 48 months after completion of CRT, 54 months after completion of CRT, 60 months after completion of CRT
101936|NCT03389464|Behavioral|computer-based confrontation with dysfunctional beliefs|"Patients will be presented with a virtual agent confronting them with their dysfunctional core beliefs (e.g. You are worthless). Participants will be instructed to contradict these virtual agents (e.g. That's not true, I'm a wonderful person)."
101937|NCT03389451|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
101938|NCT03389438|Biological|autologous Tcm cells immunotherapy|Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
101939|NCT03389425|Behavioral|simplified intervention to modify physical activity, lifestyle, and eating behavior|16 week, behavioural weightloss intervention.
101940|NCT03389412|Drug|Desmopressin|The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
101941|NCT03389412|Device|Conditional alarm|Eight weeks of treatment.
101942|NCT03389386|Diagnostic Test|Blood withdrawal for laboratory analysis|"Participants in this study will have their peripheral blood sampled from the cubital vein and the total volume withdrawn for the purposes of this study will be no more than 22 mL per person.~Parameters of interest in the laboratory analysis will include serum catestatin levels, NT-proBNP levels, hs-cTnI, parameters of inflammation and renal function as well as standard biochemistry and complete blood count (CBC) panels."
101943|NCT03389386|Other|Standard-of-care treatment|Patients diagnosed with chronic heart failure will receive optimal standards of care in terms of pharmacologic management, according to their current clinical condition.
101944|NCT03389386|Diagnostic Test|Transthoracic echocardiography (TTE)|Participants from both groups will undergo transthoracic echocardiography examination that will measure established hemodynamic parameters of systolic and diastolic cardiac function as well as parameters of LV and RV strain in the selected subset of patients.
101945|NCT03389373|Device|GC Strep Mutans Saliva Sampling|Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
101946|NCT03389360|Diagnostic Test|procalcitonin|assessing the frequency of rising procalcitonin associated with infectious complications in immunosuppressed LDLTRx.
101947|NCT03389347|Procedure|Biospecimen Collection|Undergo collection of bone marrow aspirate and blood
101948|NCT03389347|Device|High Throughput Screening|Anti-tumor drugs are tested against myeloma cells in the laboratory, in a high-throughput drug sensitivity assay
101949|NCT03389347|Other|Laboratory Biomarker Analysis|Correlative studies
101950|NCT03389334|Other|massage|The techniques include myofascial release and manual active and passive stretching with the intention to lengthen overly contracted or shortened tissue, increase range of motion, and restore any malpositioning of structural landmarks as defined by its contralateral counterpart. By addressing the symptoms of the somatic dysfunction, you will in turn reduce the overall perceived pain in the body caused in these related tissues. The duration of each massage treatment session will be 45 minutes long and therapists will use a timer to ensure all subjects receive the same length of treatment. Patients will continue to receive treatment from the same therapist to maintain consistency of results.
101951|NCT03389321|Drug|Riociguat (Adempas)|Riociguat film-coated tablets for oral administration at a strength of 1 mg
101952|NCT03389321|Drug|Macitentan (Opsumit)|Macitentan film-coated tablets for oral administration at a strength of 10 mg
101953|NCT03389308|Drug|Diacerein 1% Ointment|"Topically apply study medication to lesions identified by the Investigator that require.~treatment"
101954|NCT03389295|Radiation|Reduced Target Delineation|The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.
101955|NCT03389282|Diagnostic Test|Tear Sampling|comprehensive eye exam, Schirmer test, break-up time, tear sampling
101956|NCT03389269|Other|Meal test|240 min mixed meal test with aspiration using AspireAssist.
101957|NCT03389256|Drug|Apatinib|Apatinib mesylate tablets 250 mg qd po, if the patient can tolerate the toxic side effects, adjust the dose to 500mg qd po after 1 week.
101958|NCT03389256|Drug|EGFR-TKI|Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po
101959|NCT03389243|Drug|Metamizol|in group M patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
101960|NCT03389243|Drug|paracetamol|in group P patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram
101961|NCT03389243|Drug|paracetamol and metamizole|in group PM patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1,25 gram and paracetamol in a dose of 1 gram
101962|NCT03389230|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given via catheter
101963|NCT03389230|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given via catheter
101964|NCT03389230|Other|Laboratory Biomarker Analysis|Correlative studies
101965|NCT03389230|Procedure|Leukapheresis|Undergo leukapheresis
101966|NCT03389217|Device|Real-tDCS + rehabilitation programme|tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
101967|NCT03389217|Device|Sham-tDCS + rehabilitation programme|The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
101968|NCT03389191|Drug|Acyclovir|
101969|NCT03389178|Diagnostic Test|Cohen Perceived Stress Scale-10 (PSS-10)|Participants with a PSS-10 score ≥19 will be categorized as stressed and entered into Phase II. For every consented subject categorized as stressed, the next screened participant matching for maternal and gestational age with a PSS-10 score < 19 will be entered into Phase II as control
101970|NCT03389165|Device|Wearable hip assist robot|All participants climbed stairs from the first basement level to the fourth floor of the Proton Therapy Center, Samsung Medical Center, Korea with and without a wearable hip assist robot. During climbing stairs, the metabolic energy expenditure of all participants was measured using a portable cardiopulmonary metabolic system (Cosmed K4b², Rome, Italy).
101972|NCT03389139|Device|Near infrared spectroscopy (spinal anesthesia)|effect of spinal anesthesia on regional renal and cerebral oxygen saturation in newborns
101973|NCT03389139|Device|Near infrared spectroscopy (general anesthesia)|effect of general anesthesia on regional renal and cerebral oxygen saturation in newborns
101974|NCT03389126|Drug|Avelumab|Avelumab 10 mg/kg intravenous injection every 2 weeks until disease progression or unacceptable toxicity
101975|NCT03389113|Device|Whole body vibration|Whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
101976|NCT03389113|Other|Exersice|Exercise maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees.
101977|NCT03389100|Drug|18F-MK6240 injection|Intravenous injection of 18F-MK-6240, up to 5 mCi (185 MBq), total of one injection per PET scan (2 injections in total with an interval of 18 to 30 months)
101978|NCT03389087|Drug|Apatinib + Etoposide Capsule|Apatinib 250mg/qd，po, A course of treatment need 28 days. Etoposide Capsule 25mg/d，po, from day 1-day 21.
101979|NCT03389074|Procedure|Radiofrequency catheter ablation|minimally-invasive procedure used to remove or terminate a faulty electrical pathway from sections of the hearts of those who are prone to developing cardiac arrhythmias.
101980|NCT03389061|Drug|sofosbuvir/velpatasvir tablet|Single-dose SOF/VEL as a whole tablet in a fasted state.
101981|NCT03389061|Drug|sofosbuvir/velpatasvir crushed|Single-dose crushed SOF/VEL in a fasted state.
101982|NCT03389048|Device|PMD-200|The PMD-200 system is comprised of a console and designated finger probe with 4 sensors. The Sensors are Photoplethysmography (PPG) Galvanic Skin Response (GSR), Accelerometer (ACC) and Thermistor (TMP)
101983|NCT03389048|Diagnostic Test|SLR|With the patient lying down on his/her back, the examiner lifts the patient's leg while the knee is straight.
101984|NCT03389035|Biological|CARCIK-CD19|Allogeneic (donor-derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 Chimeric Antigen Receptor (CAR) gene
101985|NCT03389022|Drug|Ketamine|Intravenous injection 0,15mg/kg (LBM) given pre-incisional in the operating room.
101986|NCT03389022|Drug|Saline|Intravenous injection given pre-incisional in the operating room.
101987|NCT03389009|Diagnostic Test|Ultrasound Biomicroscopy of anterior segment of the eye|5150 Vumax (Sonomed, USA) under standard illumination
101988|NCT03388996|Diagnostic Test|microbiomes|16s RNA analysis and microculture of discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube
101989|NCT03388983|Other|6-week prehabilitation|Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
101990|NCT03388970|Drug|Vitamin K 1|Research group use Vitamin K1
101991|NCT03388970|Drug|normal saline|Placebo group use normal saline
101992|NCT03388957|Drug|Propranolol|This drug will be given before the extraction procedure
101993|NCT03388957|Drug|Midazolam|This drug will be given before the extraction procedure
101994|NCT03388944|Behavioral|PCT group|In this group antibiotic therapy will be stopped based on serial PCT measurements starting from admission.
101995|NCT03388931|Radiation|Radiation Therapy|Increased radiation therapy dose
101996|NCT03388931|Combination Product|Chemotherapy|Standard-of-care chemotherapy with treatment regimen to be determined by the treating physician
101997|NCT03388918|Device|Telerehabilitation|Blood pressure (A&D Medical UA 767PBT), weight (A&D Medical UC-321PBT), step counters(Fitbit Zip & Charge), sleep sensor (Beddit 3), tablet (iPAD Air 2) & transmitter (Qualcomm Life, QWH-HUB-V1.0E)
101998|NCT03388905|Device|Life Vest Wearable defibrilator|The LifeVest is a cardioverter defibrillator worn by a patient at risk for sudden cardiac arrest (SCA). It monitors the patient's heart continuously and, if the patient goes into a life-threatening arrhythmia, can deliver a shock treatment to restore the patient's heart to normal rhythm.
101999|NCT03388892|Device|paclitaxel-coated balloon, IN. PACT(Invatec-Medtronic, Brescia, Italy)|Arteriovenous graft (AVG) dysfunction or acute thrombosis is mainly caused by neointimal hyperplasia. Although endovascular intervention, such as percutaneous transluminal angioplasty (PTA), catheter-based directed thrombolysis with urokinase, mechanical thrombectomy with percutaneous thrombolytic device or even if graft stenting, can salvage the hemodialysis access, the long-term primary and secondary patent rate don't improve due to repeated restenosis from neointimal hyperplasia. Drug eluting balloon is used in reducing neointimal hypoplasia in patients with coronary in-stent restenosis and it's also effective in restenosis of peripheral arterial diseases. It's reasonable to hypothesize that PTA with PCB at venous anastomotic stenosis of AVG could prolong the patency and reduce the acute thrombosis rate.
102000|NCT03388892|Device|Plain Balloon|Traditional Plain Balloon was used to dilate the venous anastomotic stenosis of arteriovenous graft (AVG) as the usual intervention
102001|NCT03388879|Device|Taylor Spatial Frame|Circular external fixator
102002|NCT03388879|Device|Intramedullary nail|Antegrade intramedullary nail
102003|NCT03388866|Drug|Mite extract sublingual immunotherapy (SLIT)|Administration of increasing weekly doses of extracts of mites Dermatophagoides pteronyssinus in the treatment group.
102004|NCT03388866|Other|Placebo|Placebo group will be submitted to administration of increasing weekly doses, but with diluent of the allergenic extract (doubly distilled water solution and glycerin).
102005|NCT03388853|Drug|Acetylcysteine/Doxofylline|Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
102006|NCT03388853|Other|Placebo|Placebo once daily for four weeks.
102007|NCT03388840|Biological|Adipose derived stem cells suspention|application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
102008|NCT03388840|Biological|Platelet rich plasma|application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
102009|NCT03388827|Device|Laminaria tent|Laminaria tent was inserted for 12 hours before Hysteroscopy
102010|NCT03388827|Drug|Laminaria plus Misoprostol|Laminaria plus Misoprostol were inserted for 12 hours before Hysteroscopy
102011|NCT03388814|Drug|Local infiltration of bupivacaine|Patients assigned to the local infiltration with bupivacaine group will receive 30 ml of 0.25% bupivacaine with 1:200,000 epinephrine. These injections will occur at the end of the mastectomy and prior to the insertion of the tissue expander implant. The local anesthetic will be injected into the chest wall and skin flaps. Attending physicians and resident physicians will receive prior instruction regarding correct placement of the local anesthetic so that it will be consistently placed in the same locations with similar volume distribution.
102012|NCT03388814|Drug|Pectoralis Nerve block|Patients assigned to the pectoralis block group will receive a total of 20 ml 0.25% bupivacaine (with 1:200,000 epinephrine and 1.67 mcg clonidine per ml) in the tissue plane between the serratus anterior and the pectoralis minor muscles at approximately the level of the 4th rib and 10 ml of the same solution in the tissue plane between the two pectoralis muscles at approximately the 3rd rib under ultrasound guidance on the surgical side preoperatively.
102013|NCT03388801|Other|Spa therapy|Spa treatment was applied during a session lasting 120 to 150 minutes a day. Spa treatment lasted 3 weeks, including treatments from Monday to Friday (15 days of treatment). As a part of comprehensive spa treatment, all the patients benefited from kinesiotherapy, physical agent modalities (electrotherapy, phototherapy), massage and balneotherapy (peloid therapy, hydrotherapy with mineral waters, crenotherapy).
102014|NCT03388788|Radiation|PET Imaging|Positron Emission Tomography (PET) imaging for research.
102015|NCT03388788|Behavioral|Circadian Study Protocol|5-day circadian study schedule
102016|NCT03388788|Drug|11C-Meta-Hydroxyephedrine (mHED)|11C-meta-hydroxyephedrine will be used during PET imaging to measure cardiac presynaptic norepinephrine transporter function.
102017|NCT03388788|Drug|11C-CGP12177|Cardiac beta adrenergic receptor density will be measured via PET imaging with infusion of 11C-CGP12177.
102018|NCT03388788|Drug|O15-water|Blood flow will be measured via PET imaging with infusion of O15-water.
102019|NCT03388775|Other|deep venous thrombosis|Five-year prospective analysis of deep venous thrombosis performed by the RHEUNI group of five public schools in the State of São Paulo.
102020|NCT03388762|Dietary Supplement|GlucoSupreme™ Herbal|This study will assess changes in glycemic parameters and other biomarkers over a twelve week period, with two blood draws (Baseline and 12 weeks). Additionally, an IRB-approved research associate will call each study participant at the 6-week mid-point of the study to assess compliance and collect data on any adverse events.
102021|NCT03388762|Other|Placebo|The placebo utilized in this clinical trial will be formulated by the manufacturer to be as similar as possible to the active intervention in appearance, odor, and other key characteristics. Packaging for the control will be identical to packaging for the Active Comparator.
102022|NCT03388749|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
102023|NCT03388736|Behavioral|Supplementary Medicine|A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
102024|NCT03388710|Radiation|XRay|Xray to confirm the location of the endotracheal tube
102025|NCT03388697|Diagnostic Test|Quantose IR and Quantose IGT analysis|Testing using Quantose IR and Quantose IGT: The blood draws will be timed to coincide with clinically indicated blood tests as much as possible (e.g. first visit labs, aneuploidy screening, gestational diabetes screening).
102026|NCT03388697|Diagnostic Test|HOMA IR the standard testing for insulin resistance|Testing using HOMA IR: Investigators will be measuring fasting insulin and glucose levels (last meal more than 8hrs before testing i.e. overnight fasting) from EDTA-plasma samples. After collection, the samples will be spun and plasma obtained. Samples will be stored until testing. The investigators will be using the following computation to calculate HOMA.
102027|NCT03388684|Procedure|Conjoined twin separation surgery|This study included 4 case reports on conjoined twins (CT), 2 male and three female patients; 3 of them were parasitic and one was conjoined. We operated upon 2 parasitic and one conjoined. The 1st case died preoperatively.
102028|NCT03388671|Procedure|TAB Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided TAB Block
102029|NCT03388671|Procedure|Psoas Block|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block
102030|NCT03388671|Drug|Bupivacaine|patients will recieve 0.3ml/kg bupivacaine 0.25% on each side for laparoscopically guided Psoas Block or TAB block
102031|NCT03388645|Biological|RSV A2|Each adult volunteer will receive a single intranasal inoculation of RSV A2 administered with a nasal atomizer with subsequent sampling of nasal fluids and blood draws.
102032|NCT03388632|Drug|rhIL-15|IL-15 is a stimulatory cytokine that activates the immune system, inducing proliferation of T lymphocytes and NK cells. Administration of recombinant human IL-15 (rhIL-15) has been shown to result in a dramatic increase of circulating CD8+T cells and NK cells; these changes in immune cell populations suggest potential for anti-tumor activity.
102033|NCT03388632|Drug|Ipilimumab|Ipilimumab is a fully human monoclonal antibody against CTLA-4, a receptor present on the surface of activated T cells that functions as an immune checkpoint. Immune checkpoints pathways typically act to downregulate T cell activity and are co-opted by tumors to allow the malignant cells to evade the immune response. Blocking the engagement of CTLA-4 with ipilimumab allows infiltrating T cells to mount an anti-tumor response. Ipilimumab is approved by the FDA for the treatment of certain patients with melanoma and has shown clinical activity in other tumor types as well.
102034|NCT03388632|Drug|Nivolumab|Nivolumab is a humanized monoclonal antibody against programmed death 1 (PD-1), a receptor present on the surface of activated T cells that functions as an immune checkpoint. One of the ligands for PD-1, PD-L1, is commonly expressed by tumor cells. Similar to inhibition of the CTLA-4 pathway by ipilimumab, blocking of PD-1/PD-L1 signaling by nivolumab allows infiltrating T cells to mount an an immune response against the tumor. Nivolumab is approved as a single agent for several cancer types, as well as for the treatment of advanced melanoma in combination with ipilimumab.
102035|NCT03388619|Radiation|Dose to prostate bed with integrated boost|Radiation will be delivered to an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed
102036|NCT03388619|Radiation|Dose to prostate bed|Radiation will be delivered to the prostate bed only
102037|NCT03388593|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
102038|NCT03388593|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
102039|NCT03388580|Procedure|bronchoalveolar lavage (BAL)|clinically indicated, elective BAL
102040|NCT03388567|Other|Staff pharmacy whith intervention|Pharmacists who will receive continuous education through technology and communication tools, as well as accompaniment and advice from a pharmaceutical chemist
102041|NCT03388554|Device|tDCS|
102042|NCT03388541|Drug|Dexmedetomidine|Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room.
102043|NCT03388541|Drug|Placebo|Placebo
102044|NCT03388528|Dietary Supplement|Low Residue Diet Intervention|All patients will be provided with a LRD plan (< 10g fibre per day) for 12 weeks between visits 2 and 3. They will also be supplemented with multivitamin and mineral tablet or liquid (Forceval) to meet nutrient requirements (prescribed as standard care). The dietitian will provide written and oral information about the LRD and weekly telephone calls to assess patient's progress on the diet.
102045|NCT03388515|Biological|SSS11|IV infusion for 60 min.
102046|NCT03388515|Other|placebo|IV infusion for 60 min.
102047|NCT03388502|Other|Automated Text Messaging (SMS) Bot (intervention group)|Patients will be enrolled in an 'Automated Text Messaging (SMS) Bot (intervention group)' which is a computer program that sends patients timely reminders, instructions, and videos to help them prepare and recover from surgery.
102048|NCT03388502|Other|Routine perioperative education & teaching (control group)|Patients will receive the 'Routine perioperative education & teaching (control group)' and will not be enrolled in the physician-specific SMS bot.
102049|NCT03388489|Behavioral|Mind-Body Walking|walking, breathing, and mindfulness
102050|NCT03388476|Diagnostic Test|Capnography|Measuring of the exhaled air, especially endtidal co2, through capnography.
102051|NCT03388463|Drug|Omeprazole|Omeprazole 80 mg continues infusion
102052|NCT03388463|Drug|Placebo group|Omeprazole 40 mg single daily dose.
102053|NCT03388450|Drug|Omega 3|Enteral 1000 mg omega 3 fatty acid.
102054|NCT03388450|Drug|Placebo|Enteral nutrition without omega 3 fatty acid.
102055|NCT03388437|Device|NI-NAVA|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
102056|NCT03388437|Device|NIPPV|"Enrolled infants will receive Surfactant and loading dose of Caffeine citrate prior to extubation. The criteria for extubation will be as per attending decision.~The device is used Servo-I ventilator (MAQUET). FiO 2 % is adjusted to maintain oxygen saturation between 90-94% on pulse oximetry. The flow rate is 8-10 L/min. NAVA electrodes will be inserted within nasogastric catheter & positioned at the level of diaphragm.Vital signs and ventilatory parameters are monitored hourly. Blood gases will be measured before and one hour after extubation"
102057|NCT03388424|Diagnostic Test|quantification of microbiota|For each group a sample of biological sample will be take and will be analyzed using the n-counter flex platform in order to quantify disbiosis
102058|NCT03388411|Diagnostic Test|Gut microbiome profiling|Gut microbial profiling will be done with next-generation sequencing targeting bacterial 16s rRNA genes.
102059|NCT03388385|Drug|Sodium Chloride 0.9% Intravenous Solution|Physiologic saline infusion will be infused in day 1.
102060|NCT03388385|Drug|Ferinject|Ferric carboxymaltose will be infused in day 2.
102061|NCT03388372|Biological|Nimotuzumab|Nimotuzumab, 200 mg as 1-hour intravenous infusion once weekly, from first week to last week of RT for a total of 6 times.
102062|NCT03388372|Drug|Temozolomide|Temozolomide, 75 mg/m2/d was administered orally from the first to the last day of RT. After 4-week break, individualized adjuvant TMZ was given based on MGMT status. The standard 5-day schedule every 4 weeks for six cycles was given for patients with negative MGMT expression. Dose was 150mg/m2 for the first cycle and 200 mg/m2 from the second cycle. The 7-day on/7-day off schedule every 2 weeks for 12 cycles was given for patients with positive MGMT expression. The dose was 100 mg/m2 for the first two cycles and 150 mg/m2 starting from the third cycle.
102063|NCT03388372|Radiation|Radiotherapy|Fractionated 3D conformal RT was given at 2.0Gy per fraction, 5 daily fractions per week for 6 weeks.
102064|NCT03388359|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen. Measurements of differences in eosinophils activity after allergen challenge.
102065|NCT03388359|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell or pulmonary fibroblast co-culture formation. Bronchial smooth muscle cell and pulmonary fibroblast proliferation, migration, contractillity, differentiation, eosinophil adhesion to the bronchial smooth muscle cells or pulmonary fibroblast.
102066|NCT03388359|Other|Inhibition of Wnt and Smad signaling pathways|Wnt and Smad signaling pathways inhibitors effect on development of airway remodelling processes (extracellular matrix production, bronchial smooth muscle cell and pulmonary fibroblast proliferation, contractillity, differentiation, migration).
102067|NCT03388359|Other|Extracellular matrix turnover and deposition assessment|Eosinophils effect on extracellular matrix proteins (collagen, fibronectin, elastin, versican, decorin, laminin, etc.) and matrix metalloproteinasis (MMP-2,9,12,etc.) production by pulmonary fibroblasts.
102068|NCT03388359|Biological|Dermatophagoides pteronyssinus allergen|Dermatophagoides pteronyssinus allergen is required to perform allergen bronchial challenge test.
102069|NCT03388359|Device|Dosimeter ProvoX (Ganshorn)|Device for allergen bronchial challenge test.
102070|NCT03388359|Biological|Eosinophils|Eosinophils are isolated from peripheral blood
102071|NCT03388359|Biological|Airway smooth muscle cells|Airway smooth muscle cells from healthy subjects (support from the University of Groningen)
102072|NCT03388359|Biological|Fibroblasts|Normal human fibroblast cell lines (commercial fibroblast lines)
102073|NCT03388346|Drug|Ga-68 PSMA-HBED-CC PET|Ga-68 PSMA-HBED-CC is an investigational PET drug (radionuclide), that binds to the prostate specific receptors. The dose will be about 5mCi (range 3-7 mCi) and administered intravenously.
102074|NCT03388333|Procedure|Catheter Ablation|
102075|NCT03388320|Device|A-CHESS|Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
102076|NCT03388307|Procedure|unilateral laminotomy|minimally invasive technique
102077|NCT03388307|Procedure|decompressive laminectomy|classic surgery
102078|NCT03388294|Behavioral|Parents and Infants Engaged|A novel in-home parent coaching intervention addressing transactions between pre-linguistic communication and sensory reactivity in infants at-risk for autism and other NDs on the one hand, and parent responses to infant cues on the other hand, using live coaching and video feedback methods.
102079|NCT03388281|Other|No intervention, retrospective analysis only.|No intervention, retrospective analysis only.
102080|NCT03388268|Drug|Oral Vancomycin|Oral vancomycin 125mg 4 times per day
102081|NCT03388268|Drug|Placebo|Sugar liquid manufactured to mimic oral vancomycin 125mg
102082|NCT03388268|Device|Toxin enzyme immunoassay|EIA assay: Wampole/Tech Lab Tox A/B II
102083|NCT03388268|Device|Nuceleic acid amplification test|NAAT: Xpert C. difficile, Cepheid
102084|NCT03388255|Drug|Polydeoxyribonucleotides|"Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~Follow up period: 3 months after end of active treatment, without study medication."
102085|NCT03388242|Other|No intervention|Patients will be recruited into the study in their initial visit before patients are on any drug treatments for their AD or MCI. The study does not include use of any interventions.
102086|NCT03388229|Behavioral|not an intervention|it was observation not intervention
102087|NCT03388216|Biological|Drug: INM004 Dose 1|Stage I- Cohort I: (2mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo) -
102088|NCT03388216|Biological|Drug: INM004 Dose 2|Stage I- Cohort II: Dose 2 (4mg/kg) administered at a single dose. The ratio is 3:1 (investigational product:placebo)
102089|NCT03388216|Biological|Drug: INM004- Repeated dose|Stage II: Either 3 doses of 2 mg/kg or 4 mg/kg will be administered every 24 hs. The ratio is 5:1 (investigational product : placebo).
102090|NCT03388216|Other|Placebo|A placebo infusion will be administered at the same infusion rate as the Drug arm
102091|NCT03388203|Diagnostic Test|25(OH)D measurement, PTH measurement|25(OH)D analyses by LC-MS/MS were performed as part of our routine clinical work with a commercial kit from Recipe (Munich, Germany) ; PTH was measured in lithium-heparin plasma using the PTH STAT assay from Roche Diagnostics (Mannheim, Germany) on a Cobas 8000 auto-analyzer.
102092|NCT03388190|Drug|Nivolumab|"FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.~Nivolumab: 240 mg flat dose; IV administration every 2 weeks."
102093|NCT03388190|Drug|FLOX|FLOX: Intravenous oxaliplatin 85 mg/m2 on day 1; bolus 5-fluorouracil 500 mg/m2 and bolus Leucovorin on days 1 and 2; IV administration every 2 weeks.
102094|NCT03388177|Behavioral|Yoga-based therapy|
102095|NCT03388177|Other|Treatment as usual|
102096|NCT03388164|Drug|Escitalopram + RT2CK17|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
102097|NCT03388164|Drug|Escitalopram + Placebo|Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.
102098|NCT03388151|Drug|Midazolam|Midazolam 3 mg i.v added to fentanyl 0.5 ug/kg till reaching satisfactory level of sedation
102099|NCT03388151|Drug|Propofol|Propofol 1 mg/kg i.v added to fentanyl 0.5 ug/kg i.v till reaching satisfactory level of sedation
102100|NCT03388125|Drug|Injection Sclerotherapy|5% ethanolamine oleate group
102101|NCT03388125|Drug|N-butyl-2-cyanoacrylate|N-butyl-2-cyanoacrylate injection group
102102|NCT03388112|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics blend of Bifidobacterium longum, Lactobacillus acidophilus, Enterococcus faecalis with does of 1.5*10^7CFU for 2 weeks
102103|NCT03388086|Drug|Injection of Onabotulinum toxin|multiple injections of Onabotulinum toxin into the detrusor muscle
102104|NCT03388073|Other|Berry extract I|Seabuckthorn berry proanthocyanidin extract 250 mg single dose
102105|NCT03388073|Other|Berry Extract II|Seabuckthorn berry proanthocyanidin extract 500 mg single dose
102106|NCT03388073|Other|Berry extract blend|Seabuckthorn berry blend with other berry-based antioxidants
102107|NCT03388073|Other|Placebo|Placebo
102108|NCT03388060|Procedure|Ultrasound guided SWL|Ultrasound guided SWL for radiolucent renal stone
102109|NCT03388060|Procedure|Dissolution therapy|Alkalinization dissolution therapy for radiolucent renal stone
102110|NCT03388060|Procedure|Combined ultrasound guided SWL and dissolution therapy|Combined ultrasound guided SWL and alkalinization dissolution therapy for radiolucent renal stone
102111|NCT03388047|Device|Endoscopy with Polyscope (Polydiagnost TM) coupled with Multi-Spectral Imaging light-source|During surveillance endoscopy procedure, the endoscopist will insert the multispectral endoscopy probe through the working channel and use this to inspect the Barrett's oesophagus segment and any visible lesions
102112|NCT03388034|Procedure|Nasopharyngeal sampling|A nasopharyngeal sample collected from each nostril by swabbing
102113|NCT03388034|Procedure|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
102114|NCT03388021|Procedure|completion angiography followed by endovascular treatment of residual or underlying lesions|completion angiography followed by endovascular treatment as thromboembolectomy under fluoroscopic guidance using Fogarty over the wire, angioplasty, stenting, or Intraarterial thrombolysis to treat residual or underlying lesions
102115|NCT03388008|Drug|Belatacept|Belatacept will be dosed at 10 mg/kg of actual body weight on days 0, 7, 14, 28, 56, and 84 then at 5 mg/kg on day 112 and every 28 days through day 364 (i.e., on days 140, 168, 196, 224, 252, 280, 308, 336, and 364)
102116|NCT03388008|Drug|Tacrolimus|Tacrolimus will be dosed enterally or sublingually within 48 hours of transplantation and the dose will be adjusted to target a trough blood level of 8-15 ng/ml
102117|NCT03388008|Drug|ATG|Anti-thymocyte globulin will be dosed intravenously at 3 mg/kg divided into 3 daily doses starting on day 0 after transplantation
102118|NCT03388008|Drug|Mycophenolate Mofetil|Mycophenolate mofetil will be dosed at 1000 mg twice daily (or if the enteric coated formulation is used, this will be dosed at 720 mg twice daily. In the standard of care arm, mycophenolate mofetil will be initiated on day 0 after transplantation, whereas in the belatacept-based immunosuppression arm, mycophenolate mofetil will be initiated on day 90 after transplantation
102119|NCT03388008|Drug|Methylprednisolone|Methylprednisolone 500 mg will be given intravenously before perfusion of the allograft during the transplant procedure, then methylprednisolone 0.5 mg/kg will be given intravenously twice daily for 6 total doses
102120|NCT03388008|Drug|Prednisone|Prednisone will be dosed at 0.5 mg/kg orally daily through day 14, then 0.2 mg/kg orally daily through day 30, then 0.1 mg/kg daily through day 180, then 5 mg daily through day 365
102121|NCT03387995|Device|LVIS stent|The group has 80 patients.
102122|NCT03387995|Device|Solitire stent|The group has 80 patients.
102123|NCT03387995|Device|Enterprise stent|The group has 80 patients.
102124|NCT03387995|Device|Neuroform stent|The group has 80 patients.
102125|NCT03387995|Device|Pipeline stent|The group has 80 patients.
102126|NCT03387969|Procedure|CSF sample|"for all patient CSF sample obtained for analysis , culture sensitvity and CSF-CRP.~also blood samples will be collected and analyzed for serum procalcitonin"
102127|NCT03387956|Drug|Intrathecal atropine|100ug intrathecal atropine will be injected with spinal anesthesia
102128|NCT03387956|Drug|dexamethasone|intravenous 8 mg dexamethasone (2ml).
102129|NCT03387943|Drug|PLD|intravenous infusion of liposomal doxorubicin 35 mg/m2, d1,once every 21days, for 6 cycles.
102130|NCT03387943|Drug|Cisplatin|cisplatin 75 mg/m2, drip, total dose should be carried out on d1-3; once every 21days, for 6 cycles.
102131|NCT03387917|Drug|TLD-1|TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
102132|NCT03387904|Drug|Anlotinib Plus Irinotecan|Anlotinib QD po.and Irinotecan Day 1,8 ivgtt.
102133|NCT03387904|Drug|Irinotecan|Irinotecan Day 1,8 ivgtt
102134|NCT03387891|Device|Cortrium C3 device|Paired measurements of data from C3 device with golden standard methods or equipment
102135|NCT03387878|Device|Intermittent Catheter|Intermittent urinary catheter for bladder drainage
102136|NCT03387865|Procedure|tissue biopsies|additional biopsies will be performed during a diagnostic or therapeutic procedure, in order to sample tumor tissue and healthy tissue.
102137|NCT03387865|Procedure|blood sampling|additional blood samples will be collected during a SOC sampling procedure (2 EDTA 7.5 ml tubes, 2 SST 7.5 ml tubes and 2 citrate 5 ml tubes)
102138|NCT03387865|Genetic|DNA banking|constitutional and somatic genetic alterations will be analysed for subjects who consent, from either tumor or healthy tissue, or whole blood buffy coat after centrifugation
102139|NCT03387852|Drug|SAR440340/REGN3500|Pharmaceutical form:Solution for Injection Route of administration: Subcutaneous
102140|NCT03387852|Drug|Dupilumab|Pharmaceutical form:Solution for Injection Route of administration: Subcutaneous
102141|NCT03387852|Drug|Fluticasone or Fluticasone/salmeterol combination|Pharmaceutical form:Aerosol, dry powder Route of administration: Inhaled
102142|NCT03387852|Drug|Placebo for SAR440340 (REGN3500)|Pharmaceutical form:Solution for Injection Route of administration: Subcutaneous
102143|NCT03387852|Drug|Placebo for dupilumab|Pharmaceutical form:Solution for Injection Route of administration: Subcutaneous
102144|NCT03387839|Other|Stress X-Ray|Antero-posterior stability of the knee measured with stress x-rays using the TELOS Stress device in 45° and 90° flexion
102145|NCT03387826|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg twice daily
102146|NCT03387826|Drug|Prasugrel 5mg|Prasugrel 5 mg once daily
102147|NCT03387813|Device|CardioMEMS™ HF System|The CardioMEMS™ HF System is comprised of a lead-less, battery-less pressure sensor permanently implanted in the PA, which remotely transmits PA pressure measurements from the patient's home to a secure website. Healthcare professionals are able to access these measurements and associated waveforms to remotely guide individualization of medical management for their patients with chronic HF.
102148|NCT03387800|Behavioral|Basic health education messages|Messages containing basic health education materials, including perceived severity of smoking, perceived benefit of smoking cessation and tips on resisting situational temptations will be sent to the participants of both arms through WeChat after randomization takes place.
102149|NCT03387800|Behavioral|WeChat interactive peer support group|Participants will be grouped together by the researcher to form closed online peer support groups (with group names they choose). Activities on the WeChat groups serve two functions: i) It enhances social support among peer members toward smoking cessation. ii) The online support group also enhances the participants' positive affect.
102150|NCT03387787|Device|GlucoTab|"The GlucoTab® system is a computerized decision support system built of an android based front-end user interface and a backend server including the REACTION algorithm. GlucoTab® is able to process blood glucose data and physiological confounders of glycaemia. Subsequently, GlucoTab® provides patient-specific basal, bolus, and correction insulin doses together with visualization and documentation of relevant data.~Insulin doses of recruited patients will be calculated by the GlucoTab System for at least 48 hours and a maximum duration of 21 days."
102151|NCT03387787|Drug|Insulin Degludec|During the study, patients will be treated with basal Insulin degludec
102152|NCT03387774|Drug|Cisplatin|"Patients in both arms received concurrent cisplatin chemotherapy:~100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy."
102186|NCT03387527|Behavioral|Prostate cancer decision aid|Patients will undergo standardized counseling and individualized counseling with the screening decision aid. The screening decision aid is a computer program that provides individual patients estimates of their risks of prostate cancer diagnosis, prostate cancer related death, or death from any cause
102253|NCT03387111|Biological|N-803|Recombinant human superagonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
102254|NCT03387098|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
102153|NCT03387774|Radiation|Intensity Modulated Radiation Therapy|"Patients in both arms received Intensity Modulated Radiation Therapy:~All target volumes were outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes were defined in accordance with the International Commission on Radiation Units and Measurements Reports 50 and 62. The prescribed dose was 68-72 Gy to PTVnx (Planning target volume of the primary tumor), 64-68 Gy to GTVnd (Gross tumor volume of the cervical lymph node), 60- 64Gy to PTVnd and PTV1 (Planning target volume 1), and 54-58 Gy to PTV2 (Planning target volume 2) in 30-32 fractions. The details of dose limits for organs at risk were based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225)."
102154|NCT03387774|Drug|Ulinastatin|"Patients in the experimental group were received ulinastatin:~Ulinastatin (UTI): ulinastatin was intravenous drip at a dose of one hundred thousand units added to 100 ml of 0.9% normal saline every time, 3 times every radiation day, and until the end of radiotherapy."
102155|NCT03387761|Drug|Ipilimumab|"For Cohort 1:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2a:~Day 1: Ipilimumab 3 mg/kg~Days 22: Ipilimumab 3 mg/kg~For Cohort 2b:~Day 1: Ipilimumab 1 mg/kg~Days 22: Ipilimumab 1 mg/kg"
102156|NCT03387761|Drug|Nivolumab|"For Cohort 1:~Day 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2a:~Days 1 and 22: Nivolumab 1 mg/kg~Day 43: Nivolumab 3 mg/kg~For Cohort 2b:~- Days 1, 22 and 43: Nivolumab 3 mg/kg"
102157|NCT03387748|Behavioral|Gesture elicitation|"Participants are required to gesture with their hands (and not speaking) one by one 30 pictures from the Boston Naming Task which appear on a laptop screen.~Participants retell a cartoon to the researcher~The researcher initiates a 10-min spontaneous conversation.~These three tasks are video-recorded."
102158|NCT03387735|Other|Treatment as usual (TAU) + Internet|Patients in this group will receive TAU+internet and links to helpful websites.
102159|NCT03387735|Behavioral|TAU + C-CHESS|"For the patient, C-CHESS provides tools, motivation, and social support to help them manage their specific set of chronic conditions and communicate with peers and their primary care physician.~For the clinic, C-CHESS has a Clinician Report (CR), a visual dashboard of health-tracking data that can be customized based on the needs of the clinic. The CR provides alerts to the clinician when a patient passes a certain threshold. The dashboard is intended to help clinicians prepare for patient office visits."
102160|NCT03387709|Behavioral|Pistachio-enriched diet|Composition of prescribed diets will be based on individual preferences, with the goal of consuming 1.5 oz of pistachios per day and increased energy expenditure. During the 4-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Pistachios will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
102161|NCT03387709|Behavioral|General dietary guidance diet|During the 4-month group intervention, study subjects will participate group sessions, receive telephone, email and/or text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
102162|NCT03387683|Drug|dapagliflozin|dapagliflozin 10mg
102163|NCT03387683|Drug|placebo|placebo to match dapagliflozin
102164|NCT03387670|Drug|Simvastatin|"One (1 = 40mg) simvastatin tablet once daily at night for 1 month~Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 months"
102165|NCT03387670|Drug|Placebo|"One (1) placebo tablet once daily at night for 1 month~Two (2) placebo tablets once daily at night, for the next 35 months"
102166|NCT03387657|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
102167|NCT03387657|Drug|Hydrochlorothiazide|"Pharmaceutical form: Tablet~Route of administration: Oral"
102168|NCT03387644|Drug|Pregabalin (PG)|Pregabalin 150 mg one hour before the procedure as premedication.
102169|NCT03387644|Drug|Control placebo (C)|Placebo tablets one hour before the procedure as premedication.
102170|NCT03387631|Drug|Artemether-Lumefantrine|
102172|NCT03387605|Drug|Ivabradine|ivabradine or placebo given orally 2 times daily for 72 hours
102173|NCT03387605|Drug|Placebo|matching placebo given 2 times daily for 72 hours
102174|NCT03387592|Drug|CPT-11|180 mg/m2
102175|NCT03387592|Drug|Calcio levofolinate|200 mg/m2
102176|NCT03387592|Drug|5-Fluorouracil|400 mg/m2 + 2400 mg/m2
102177|NCT03387592|Drug|Capecitabine|1500 mg/m2
102178|NCT03387592|Drug|Temozolomide|200 mg/m2
102179|NCT03387579|Drug|Lipid Emulsions, Intravenous|Intravenous lipid containing soy, MCT, olive, and fish oils
102180|NCT03387579|Drug|Intralipid, 20% Intravenous Emulsion|Intravenous lipid emulsion of 20% soy oil
102181|NCT03387566|Drug|HB002.1M|HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
102182|NCT03387553|Biological|Dendritic Cell Vaccine (DC1)|"Study Vaccine:~Lead In Phase - Weekly as outlined in each treatment Arm.~Expansion Phase - At the optimal schedule determined at the end of the Lead In Phase.~Pre-surgery - Booster Vaccine at week 25 prior to receiving surgery.~Post-surgery - Participants will receive a series of 3 booster intranodal study vaccines given once every 6 months."
102183|NCT03387553|Drug|Neoadjuvant Chemotherapy|Upon completion of the 3 week series of vaccinations participants will then undergo neoadjuvant chemotherapy treatment with the TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen given intravenously once every 3 weeks for up to 6 cycles. The treating physician will have the discretion to delay, modify, or shorten the neoadjuvant chemotherapy as per routine practice guidelines and physician discretion.
102184|NCT03387553|Procedure|Curative Surgery|Planned definitive curative surgery at 26 to 28 weeks.
102185|NCT03387540|Drug|ICI|Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
102251|NCT03387111|Drug|Necitumumab|Necitumumab is a recombinant human lgG1 monoclonal antibody.
102187|NCT03387514|Drug|PSMA-based 18F-DCFPyL PET tracer for PET/CT exams|"18F-DCFPyL whole body PET/CT scan administered at the following timepoints:~PET1 - Prior to scheduled nephrectomy~PET2 - to establish a new baseline PET before systemic therapy~PET2A - Post-surgery and prior to start of standard of care systemic therapy~PET2B - 12-16 weeks from start of first line systemic therapy (immune-based or anti-angiogenic)~PET3 - If first line systemic therapy did not include anti-angiogenesis therapy and new systemic therapy does include anti-angiogenesis therapy~PET3A - Prior to start of additional anti-angiogenesis therapy~PET3B - 12-16 weeks from the start of additional anti-angiogenesis therapy~PET4 - obtained at clinical progression or 2 years following initial systemic therapy"
102188|NCT03387501|Drug|Plasma rich in growth factors (PRGF-Endoret)|Intrauterine administration of PRGF
102189|NCT03387488|Device|StingrayTM, Medtronic®|Video- assisted pericardioscopic surgery for implanting epimyocardial pacemaker lead Model 09090, Medtronic®
102190|NCT03387475|Drug|Deferasirox|iron chelation
102191|NCT03387462|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open label daily emtricitabine/tenofovir disoproxil oral tablet
102192|NCT03387462|Other|DOT Diary mobile app|DOT Diary mobile application for tracking medication adherence and sexual activities.
102193|NCT03387449|Device|Bimanual Arm Training|Device-based bimanual-to-unimanual training will be provided with the Bimanual Arm Trainer (BAT, Mirrored Motion Works, NC). The device provides bimanual-to-unimanual training of simultaneous shoulder external rotation and elbow extension, and independent training of pronation-supination and grasp and release of each hand. Range of motion and speed are recorded during training and feedback and motivation are provided through age-appropriate gaming modules.
102194|NCT03387436|Behavioral|Sham-Intervention|The sham intervention does not target the specific topics of the study intervention group (i.e. no special focus an ACP or end of life communication). Supportive therapy uses common factors of psychotherapy such as elicitation of affect, reflective listening, and feeling understood, but provides no explicit theoretical formulation to the patient. The therapist tries to elicit and validate the patients' affect for instance on the realization that there is no curative treatment option. Supportive therapy has been used as an unspecific control condition in several studies (Cohen et al. 2011; Markowitz et al. 1998). Patients of the sham intervention will be informed about the benefits of advance directives in general.
102195|NCT03387436|Behavioral|Study-Intervention|"The design of the study-intervention was influenced by dignity therapy (Chochinov et al. 2005), the End-of-life-Review (Ando et al. 2010) and barriers concerning participation of ACP identified by research (Bollig et al. 2017; Gjerberg et al. 2015). It is the goal of the study-intervention to enhance communication about death related topics of patients and their relatives/caregivers.~Our study intervention extends over six therapeutic sessions. The length of each session will be adjusted to the patients physical condition, it should not exceed 45 minutes in total.~In the first four sessions, patients and relatives will be informed about the relevance of ACP. Potential barriers for an efficient patient-caregiver communication and ACP are discussed. The intervention focuses on encouraging end-of-life communication and on jointly modifying barriers to EOL communication.~The fifth and sixth session focus on ACP based on the standardised concept of beizeiten begleiten."
102196|NCT03387423|Drug|Tofacitinib|Patients who are started on Tofacitinib treatment according to the drug label
102197|NCT03387410|Drug|Intravenous IRDye 800BK|Fluorescence of the ureter using IRDye 800BK
102198|NCT03387384|Other|Non-interventional study|Non-interventional study
102199|NCT03387371|Device|Ultrasonics|ultrasonic scalers
102200|NCT03387371|Device|Gracey Curettes|Spesific gracey curettes
102201|NCT03387371|Device|Er:YAG Laser|2940 nm wavelenght Er:YAG laser
102202|NCT03387358|Device|Nasal bridle securement device for small bore feeding tubes|A Nasal bridle securement device is an alternative method to securing small bore feeding tubes which are most commonly secured with adhesive tape to the nose. A nasal bridle securement device instead secures the feeding tube to a cloth ribbon that is inserted in one nostril, over then nasal bridle and out the other nostril.
102203|NCT03387345|Other|100% steel cut barley|25 g of available carbohydrate was delivered to participants via steel cut Sustagrain barley (Ardent Mills, LLC).
102204|NCT03387345|Other|100% barley flakes|25 g of available carbohydrate was delivered to participants via Sustagrain barley flakes (Ardent Mills, LLC).
102205|NCT03387345|Other|50/50 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 50/50 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
102206|NCT03387345|Other|80/20 rice-barley mix|25 g of available carbohydrate was delivered to participants via a 80/20 mixture (by weight) of Goya medium grain white rice and steel cut Sustagrain barley (Ardent Mills, LLC).
102207|NCT03387345|Other|100% rice|25 g of available carbohydrate was delivered to participants via Goya medium grain white rice
102208|NCT03387345|Other|white bread|25 g of available carbohydrate was delivered to participants via Sara Lee Classic White Bread (Bimbo Bakeries USA, Inc.)
102209|NCT03387332|Drug|APG-1252|Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
102210|NCT03387319|Behavioral|Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, race-related event.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
102211|NCT03387319|Behavioral|Non-Racialized Stressful Event Recall|"Participants will undergo a moderate psychological stress adapted from the Trier Social Stress Test (TSST) where they will be asked to recall a stressful, real-life, event unrelated to race.~After instructions are provided, participants will be given two minutes to prepare their statement, and three minutes to deliver their statement. There will be an 'audience' present at each participant's speaking task which will include two observers who are of same race as the participant (African American), to heighten stress responses."
102212|NCT03387293|Other|LGI-LII Breakfast|This test meal with low GI and low FII amounts were served as a breakfast after 12-hours fasting and participants were asked to consume the meal in full, within 15 min.
102213|NCT03387293|Other|LGI-HII Breakfast|In crossover design, this test meal with low GI and high FII amounts were served as a breakfast to compare the LGI-LII Breakfast.
102214|NCT03387267|Device|Dysphagia Detection System|The Nestle Health Sciences (NHSc) Dysphagia Detection System (DDS) is a portable, non-invasive device designed for use at the bedside. The investigational DDS has 3 basic components: Sensor Unit (suspended on a necklace), Sensor Fixation and a personal computer (PC) for collecting data. The Sensor Unit consists of a dual-axis accelerometer in a plastic housing that is attached to the front of a patient's neck just below the thyroid cartilage by the single-use, disposable fixation unit. The Sensor Unit is connected via a cable to an A/D converter which then connects via cable to the PC. The PC collects the examination data, which is then sent to dedicated application software (installed at the CRO), which interprets the acceleration data and displays the examination result.
102215|NCT03387254|Device|VR + active brain stimulation|Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
102216|NCT03387254|Device|VR + sham brain stimulation|Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
102217|NCT03387241|Drug|Fluticasone/ Formoterol|See above
102218|NCT03387241|Drug|fluticasone/ salmeterol|See above
102219|NCT03387228|Other|Pain education|"Pain education intervention we plan to use is based on Explain Pain developed by Moseley and Butler in 2003. The pain education handout and materials produced in Nepali will be proof-read and pre-tested in 5 - 10 Nepalese with LBP as needed, and corrected, if necessary.~Dosage: A single (approximately) one hour pain education will be delivered to the PEG.~Home advice: A printed handout of the pain education material will be provided only to the study participants in the PEG. Participants will be advised to read them (or have family members read them), followed by walking for 30 minutes."
102220|NCT03387228|Other|Control group|"The control participants will receive physiotherapy care based on the recent clinical practice guidelines. This control group intervention will comprise of: (1) education (advice to remain active); (2) massage to back; (3) superficial heat; and (4) static cycling or (treadmill) walking with the aim to promote physical activity. Although superficial heat is recommended in the acute/subacute LBP, we included this as a common treatment for all types of LBP including chronic LBP, which could be a part of self-management.~Duration of treatment: 1 hour. Home advice: Participants will be advised to self-manage their back pain based on the information provided. Home exercise leaflet with emphasis on the value of exercise to increase strength and endurance, followed by a 30 minutes walking."
102221|NCT03387215|Drug|ITI-214|Oral
102222|NCT03387215|Other|Placebo|Oral
102223|NCT03387202|Procedure|Laparoscopic lateral suspension with mesh|V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level
102224|NCT03387202|Diagnostic Test|Transperineal ultrasound|Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
102225|NCT03387189|Other|Quality Improvement Project|Simulation education conducted at Regions Hospital for a Quality Improvement project on delivery of impacted fetal head at cesarean section. This is a department-wide, simulation-based educational training required for all Regions Hospital Birth Center staff physicians, residents, nursing staff, and surgical techs.
102226|NCT03387176|Other|Implementation of a gluten-free diet|Patients will be placed on gluten free diet for 9-12 months.
102227|NCT03387163|Drug|Sacubitril/Valsartan|commercially available Sacubitril/Valsartan: 24/26; 49/51 ; 97/103
102228|NCT03387150|Biological|VRC07-523LS|Administered by intravenous (IV) infusion, subcutaneous (SC) injection, or intramuscular (IM) injection, depending on which group participants are in
102229|NCT03387150|Biological|Placebo|Sodium Chloride for Injection USP, 0.9%; administered by IM injection
102230|NCT03387137|Biological|RSV 6120/∆NS2/1030s|Delivered as nose drops
102231|NCT03387137|Biological|Placebo|Delivered as nose drops
102232|NCT03387124|Other|Breastfed infants|Breastmilk
102233|NCT03387111|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
102234|NCT03387111|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
102235|NCT03387111|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2
102236|NCT03387111|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
102237|NCT03387111|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
102238|NCT03387111|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
102239|NCT03387111|Biological|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
102240|NCT03387111|Biological|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
102241|NCT03387111|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
102242|NCT03387111|Drug|Avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
102243|NCT03387111|Drug|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
102244|NCT03387111|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
102245|NCT03387111|Drug|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.
102246|NCT03387111|Drug|Cisplatin|cis-diamminedichloroplatinum(II)
102247|NCT03387111|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
102248|NCT03387111|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
102249|NCT03387111|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
102250|NCT03387111|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
102255|NCT03387098|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
102256|NCT03387098|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
102257|NCT03387098|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
102258|NCT03387098|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
102259|NCT03387098|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
102260|NCT03387098|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
102261|NCT03387098|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
102262|NCT03387098|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
102263|NCT03387098|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
102264|NCT03387098|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
102265|NCT03387098|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
102266|NCT03387098|Drug|lovaza|Omega-3-acid ethyl esters
102267|NCT03387098|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
102268|NCT03387098|Procedure|SBRT|Stereotactic Body Radiation Therapy
102269|NCT03387085|Drug|Aldoxorubicin HCl|Aldoxorubicin hydrochloride
102270|NCT03387085|Biological|N-803|Recombinant human super agonist interleukin-15 (IL-15) complex
102271|NCT03387085|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
102272|NCT03387085|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
102273|NCT03387085|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
102274|NCT03387085|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
102275|NCT03387085|Biological|GI-6207|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins
102276|NCT03387085|Biological|GI-6301|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins
102277|NCT03387085|Biological|haNK for Infusion|NK-92 [CD16.158V, ER IL-2]
102278|NCT03387085|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
102279|NCT03387085|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
102280|NCT03387085|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
102281|NCT03387085|Drug|Cisplatin|cis-diamminedichloroplatinum(II)
102282|NCT03387085|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
102283|NCT03387085|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
102284|NCT03387085|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
102285|NCT03387085|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
102286|NCT03387085|Procedure|SBRT|Stereotactic Body Radiation Therapy
102287|NCT03387072|Other|Non interventional study|mental stress test and Blood (or salivary) sample
102288|NCT03387059|Device|Forielle|Participants randomized to receive Forielle endometrial washing (an intrauterine solution) following oocyte retrieval on Study Day 0 (Randomisation).
102289|NCT03387046|Dietary Supplement|D-aspartate|D-aspartate 2660 milligram (mg) once daily in the form of oral solution for 24 weeks.
102290|NCT03387046|Drug|Placebo|Placebo matched to D-aspartate once daily in the form of oral solution for 24 weeks.
102291|NCT03387046|Biological|IFN beta-1a|IFN beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg) three times a week for 24 weeks.
102292|NCT03387046|Drug|Methylprednisolone|Methylprednisolone 1000 mg will be administered intravenously once daily for 5 consecutive days.
102293|NCT03387033|Device|Relaxation response and virtual reality (VR) session|A 10-minute relaxation response (mindfulness and deep breathing) followed by 10-minute immersive VR session.
102294|NCT03387020|Drug|Everolimus|Given PO
102295|NCT03387020|Other|Laboratory Biomarker Analysis|Correlative studies
102296|NCT03387020|Other|Pharmacological Study|Correlative studies
102297|NCT03387020|Drug|Ribociclib|Given PO
102298|NCT03387007|Behavioral|Psychosocial support training for school teachers|The intervention for this study was schoolteachers' training on psychosocial support.A clinical psychologist provided 2-day training (a total of 16 hours) training on psychosocial support for the schoolteachers
102299|NCT03386981|Other|blood and saliva tests|Blood and saliva will be tested for: bone turnover markers, cytokines, chemokines, adipokines, myokines and hormones regulating bone and energy metabolism
102300|NCT03386968|Behavioral|Active video gaming|"Children will visit Blythedale for 8 sessions, one 45-session visit per week, in place of one of the child's typical physical therapy sessions. During each session, children will play a video game on the X-Box Kinect system, using the games Kinect Adventures and Kinect Sports. The child will first play a Kinect Adventures game, which requires ambulating, ducking, and dodging one's way through an obstacle course."
102301|NCT03386968|Behavioral|Usual care physical therapy|Children will attend their usual care physical therapy appointments at Blythedale.
102302|NCT03386955|Drug|BPI-7711 Capsule|Phase I: BPI-7711 capsule(30mg, 60mg, 120mg, 180mg, 240mg...) Phase IIa: BPI-7711 capsule(with recommend phase II dose)
102303|NCT03386942|Drug|MORAb-202|Part 1: MORAB-202 intravenous (IV) infusion administered every 3 weeks. starting at a 0.3 mg/kg dose and successively increasing doses until DLT. Part 2: MORAb-202 administered IV every 3 weeks at a dose determined in Part 1 until any of the criteria for discontinuation are met.
102304|NCT03386929|Drug|Avelumab|A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.
102305|NCT03386929|Drug|Axitinib|A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.
102306|NCT03386929|Drug|Palbociclib|A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
102307|NCT03386916|Procedure|CT scan guide percutaneous biopsy of lytic bone metastases of lung cancer|
102308|NCT03386903|Device|Ture acupuncture|"Patients receive true acupuncture treatment by Zhoushi coordinated points at the Bai-hui (DU20), Shen-ting (DU24), bilateral Ben-shen (BG13), Shen-men (HT7), San-yin-jiao (SP6) with Deqi sensation. The needles are retained for 20 minutes in every course, three times per week and last for 3 months."
102309|NCT03386903|Device|Sham acupuncture|Patients receive sham acupuncture stimulation by non-acupoint points (superficial insertion, 0.2 cun, No needle sensation (de qi) is elicited) at the bilateral mid-point between Shuaigu(GB8) and Touwei(ST8), Touwei(ST8) and Yangbai(GB14), front tibia, the junction of biceps and triceps.
102310|NCT03386877|Procedure|periodontal regeneration|Defects were accessed with the MIST In the test group the obtained micro-grafts enriched in DPSCs were endorsed onto a collagen sponge scaffold (Condress®, Istituto Gentili, Milano, Italy) to form a bio-complex. In the control group the collagen sponge was only hydrated using physiologic sterile solution. The collagen sponge with or without cells was provided to the masked surgeon who filled the intrabony defect. The flaps were repositioned and tension-free primary flap closure was obtained using horizontal internal mattress and interrupted sutures
102311|NCT03386838|Biological|Nivolumab|Specified dose on specified days
102312|NCT03386838|Drug|BMS-986205|Administered 100mg orally once daily for a maximum of 104 weeks
102313|NCT03386838|Biological|Cetuximab|400 mg/m² intravenous administration once only, then 250 mg/m² weekly maintenance until disease progression, unacceptable toxicity, withdrawal of informed consent, or other reason
102314|NCT03386838|Drug|Cisplatin|Cisplatin (100 mg/m2) every 3 weeks (Up to 6 cycles)
102315|NCT03386838|Drug|Carboplatin|Carboplatin (AUC of 5 mg per milliliter per minute) every 3 weeks (Up to 6 cycles)
102316|NCT03386838|Drug|Fluorouracil|1000 mg/m² per day for 4 days, every 3 weeks (Up to 6 cycles)
102317|NCT03386825|Drug|Regorafenib (Stivarga, BAY73-4506)|Antineoplastic agents, protein kinase inhibitor (L01XE21)
102318|NCT03386799|Device|E-motion device|Powered assisted Wheelchair with the E-motion device. Outdoor and indoor runs
102319|NCT03386786|Behavioral|Health Partner|Health Partner is a combination of a mobile application and a web-based portal.
102320|NCT03386786|Behavioral|Standard Care|Patients randomized to Control will receive pre-printed brochures that outline the steps of the care plan for unilateral TKA and THA, as per standard care provided to any unilateral TJA patient receiving care at Princeton Healthcare System (PHCS).
102321|NCT03386773|Behavioral|16-week program|16-week program where patients will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity.
102322|NCT03386773|Behavioral|Patient generated health data|Intervention patients will be asked to track patient generated health data and patient reported outcomes. PGHD elements related to weight management will be collected through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
102323|NCT03386760|Device|Laser Utilisation PicoSecond|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
102324|NCT03386760|Device|Laser Utilisation Nano-second|"Laser utilisation for tattoo depigmentation~1 session every month for a total of 3 sessions"
102325|NCT03386747|Behavioral|Home visits to improve parenting behaviors|Caregivers will be visited twice per month starting from the third trimester in pregnancy up to age three to discuss important health and development behaviors.
102326|NCT03386747|Behavioral|Center based parenting groups|Caregivers will be invited to early childhood development groups. Groups will meet at nearby centers twice per month. Caregivers will be invited to participate starting from the third trimester up to age 3 of the child.
102327|NCT03386734|Procedure|SLN biopsy only|In experimental arm, SLN dissection only. A full lymphadenectomy will not be performed. The radical hysterectomy or trachelectomy will be done.
102328|NCT03386734|Procedure|SLN biopsy + PLN dissection|In active comparator arm, SLN dissection + full lymphadenectomy will be performed.
102329|NCT03386721|Drug|RO6874281|RO6874281 will be administered as per the dosage regimen mentioned in arm descriptions.
102330|NCT03386721|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered as per the dosage regimen mentioned in arm descriptions.
102331|NCT03386721|Drug|Gemcitabine|Single-agent treatment administered as per approved protocol.
102332|NCT03386721|Drug|Vinorelbine|Single-agent treatment administered as per approved protocol.
102333|NCT03386708|Procedure|intrauterine injection|intrauterine injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/ 15 days, total 4 times
102334|NCT03386708|Procedure|intravenous injection|intravenous injection with umbilical cord mesenchymal stem cell (SCLnow 19#); one time/ 15 days, total 4 times
102335|NCT03386708|Biological|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), intrauterine injection: 2 * 10^7 cells (2ml)/ intravenous injection: 4 * 10^7 cells (30ml)
102336|NCT03386708|Drug|Normal saline (NS)|Treat patient with Normal saline (NS): 2ml/30ml
102337|NCT03386695|Other|Education by Pamphlets|Distribution of pamphlets with information of prevention and early detection of cervical cancer and written as well as pictorial depiction on how to collect cervical self sample for HPV detection.
102338|NCT03386695|Other|Health education programme|Health education program explaining about prevention and early detection of cancer and education on method of collection of cervical self sample for HPV.
102339|NCT03386682|Device|ESTYME® MATRIX Breast Implants|Breast implant surgery in breast reconstruction or breast augmentation
102381|NCT03386396|Dietary Supplement|High carbohydrate/low protein|A high carbohydrate/low protein shake will be given to the child
102340|NCT03386669|Drug|F-18|Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
102341|NCT03386656|Drug|Amchafibrin|Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
102342|NCT03386656|Other|Saline Solution|Placebo
102343|NCT03386643|Drug|Bifidobacterium animalis subsp. lactis HN019|The selected patients will receive capsules to be diluted in 15 ml of water containing 6 x 109 CFUs of Bifidobacterium subsp. lactis HN019 for mouthwash twice a day for 4 weeks.
102344|NCT03386643|Drug|Clobetasol propionate 0.05%|The selected patients will receive capsules to be diluted in 15ml of water containing clobetasol propionate 0.05% for mouthwash twice a day for 4 weeks.
102345|NCT03386630|Drug|Hyperbaric bupivacaine+Sufentanil|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: sufentanil (5 mcg)
102346|NCT03386630|Drug|Hyperbaric bupivacaine+Morphine|To evaluate in spinal anesthesia for elective cesarean section what association of hyperbaric bupivacaine 0.5% (0.06 mg Cm-1 in height) plus opioid: morphine (0,01 mg)
102347|NCT03386617|Drug|NEPA|"Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded."
102348|NCT03386604|Dietary Supplement|Whey protein|whey protein 40 g: energy value 160 kcal; carbohydrate 10 g; 25g proteins; total fat 2.3g; saturated fats 1.1 g; trans fat 0 g; dietary fiber 0 g; sodium 157 mg; calcium 264 mg.
102349|NCT03386604|Dietary Supplement|Maltodextrin|Maltodextrin energy value 160 kcal.
102350|NCT03386591|Drug|Naloxone|Comparing pharmacokinetics of naloxone
102351|NCT03386591|Device|Mucosal atomization device and syringe|Injection
102352|NCT03386591|Device|Narcan|Nasal Spray
102353|NCT03386591|Device|Intramuscular Auto Injector|Intramuscular injection
102354|NCT03386578|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily
102355|NCT03386578|Behavioral|Behavioral HIV risk reduction package|HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
102356|NCT03386565|Drug|sodium chloride solution|intraoperative IV infusion
102357|NCT03386565|Drug|Lidocaine|intraoperative IV infusion
102358|NCT03386552|Drug|Isifera+|Pertubation solution of lidocaine 0.5 mg ml in Ringer-Acetate buffer
102359|NCT03386552|Drug|Buffer|Pertubation solution of Ringer-Acetate buffer
102360|NCT03386539|Drug|Everolimus|Everolimus tablet
102361|NCT03386539|Drug|Tacrolimus|Tacrolimus capsule or liquid suspension
102362|NCT03386539|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil capsule or liquid suspension
102363|NCT03386526|Drug|APG-1387 for Injection|Multiple dose cohorts, 30 minute IV infusion, once weekly for 3 weeks of a 21-day cycle
102364|NCT03386513|Drug|IMGN632|CD123-targeted ADC
102365|NCT03386500|Drug|BMX-001|BMX-001 at escalating doses in combination with standard RT, 33 fractions to 59.4 Gy, plus Mitomycin at the standard dosing of 10 mg/m2 administered IV bolus at day 1 and day 29 as well as 5FU 1g/m2/d day 1-4 and 29-32.
102366|NCT03386487|Drug|PF 04457845|Study medication will be administered at 4mg by mouth daily for eight weeks.
102367|NCT03386487|Drug|Placebo Oral Tablet|Placebo comparator will be administered by mouth daily for eight weeks.
102368|NCT03386474|Drug|Brolucizumab 6 mg|Administered as an intravitreal injection to the study eye
102369|NCT03386474|Drug|Aflibercept 2 mg|Administered as an intravitreal injection to the study eye
102370|NCT03386461|Behavioral|Exercise training|Combined aerobic and resistive training 3 times a week for 4 months. The strength training will be performed at moderate intensity (i.e., 50-60% of RM), and moderate volume (i.e., 2 to 3 sets per exercise). Endurance training will be performed at moderate- to high-intensity (i.e., 60-85% of VO2max) in the form of continuous and interval training (for high intensities), respectively. The training intensity will be prescribed individually on the basis of the initial exercise testing. Subjects will be thoroughly instructed on effective home-based exercise and advised to exercise in total 5 days a week.
102371|NCT03386461|Dietary Supplement|omega 3 supplementation|Capsules with high content of omega 3 fatty acids (Calanus oil) will be taken every day with lunch meal. The content of omega-3 fatty acids (EPA, DHA) per day should reach 250 mg.
102372|NCT03386461|Dietary Supplement|placebo|Capsules with content of omega 6 fatty acids (sunflower oil) will be taken every day with lunch meal.
102373|NCT03386448|Drug|Scopolamine and naltrexone|participants will receive scopolamine and naltrexone in buccal drops
102374|NCT03386448|Drug|placebo arm|participants will receive placebo medications
102375|NCT03386435|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning was performed following anesthesia induction in donors. The protocol involves 3 cycles of 5-minute inflation of a blood pressure cuff to 200 mm Hg to one upper arm, followed by 5-minute reperfusion with the cuff deflated
102376|NCT03386422|Behavioral|MSC|Mindfulness and Self-Compassion training
102377|NCT03386422|Behavioral|CBT|Cognitive-behavioural techniques training
102378|NCT03386409|Behavioral|Free safe firearm storage device distribution|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a free device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
102379|NCT03386409|Behavioral|Low cost safe firearm storage device|Participants in the experimental phase of the study receive a safe firearm storage device at the time of study enrollment. They are randomized to receive a low cost ($5) device. Safe firearm storage devices include a California Department of Justice-approved lock box, trigger lock and/or cable lock.
102380|NCT03386396|Dietary Supplement|High protein/low carbohydrate|A high protein/low carbohydrate shake will be given to the child.
102382|NCT03386383|Behavioral|Intervention|Individual session, physical activity tracker, online intervention
102383|NCT03386370|Device|"Indigo Mechanical Thrombectomy System"|"Removal of acute clot (< 14 days) from the artery causing lower limb ischemia, using the Indigo System by Penumbra"
102384|NCT03386357|Combination Product|A (pembrolizumab+RT)|Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
102385|NCT03386357|Drug|B (pembrolizumab)|Pembrolizumab (200mg absolute, q3w)
102386|NCT03386344|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
102387|NCT03386344|Drug|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
102388|NCT03386331|Behavioral|diet and exercise|Diet and lifestyle intervention
102389|NCT03386318|Drug|Oxycodone|Serum concentration per hour from 1 to 5 h
102390|NCT03386305|Drug|EnvarsusXR|Patients randomized to study drug will be converted to EnvarsusXR once daily.
102391|NCT03386305|Drug|Tacrolimus|Patients continue to take Tacrolimus BID, as a part of routine care.
102392|NCT03386279|Drug|PF-04965842|one single dose of 600 mg by mouth
102393|NCT03386279|Drug|Moxifloxacin|one single dose of 400 mg by mouth
102394|NCT03386279|Drug|Placebo|one single dose by mouth
102395|NCT03386253|Device|active tDCS|two 13 minute tDCS sessions separated by 20 minutes in between
102396|NCT03386253|Device|sham tDCS|sham tDCS session given for same length of time as active
102397|NCT03386240|Drug|Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)|The intervention consists of using Plus group (Triclosan-coated Sutures)
102398|NCT03386240|Other|Vicryl, monocryl, PDS (not coated with triclosan)|Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
102399|NCT03386227|Other|Withholding antibiotic prophylaxis|Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
102400|NCT03386214|Drug|Pevonedistat|The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a > 5% change in body weight from the weight used for the most recent BSA calculation.
102401|NCT03386214|Drug|Ruxolitinib|-Standard of care outside of protocol
102402|NCT03386214|Procedure|Peripheral blood draw|"Baseline or Cycle 1 Day 1 (prior to study treatment administration)~Cycle 2 Day 1 (prior to study treatment administration)~Cycle 4 Day 1 (prior to study treatment administration)~End of treatment"
102403|NCT03386214|Procedure|Skin biopsy|A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.
102404|NCT03386201|Drug|Intravenous Methylene blue|Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
102405|NCT03386188|Device|Transcranial Magnetic Stimulation (TMS)|Transitory inactivation of the posterior parietal cortex and measure of sensorimotor integration.
102406|NCT03386188|Device|Electrical Muscle Activity (EMG)|Electrodes for the collection of EMG activity will be glued on the skin next to the first interosseus dorsalis muscle, the Abductor digiti minimi, the Extensor carpi radialis and the Abductor pollicis brevis. EMG signals will be stored on computer for off-line analysis using Signal © software (Cambridge Electronic Design, Cambridge, UK)
102407|NCT03386175|Device|therapy with negative pression and instillation|therapy with negative pression and instillation
102408|NCT03386162|Drug|Alpelisib|fulvestrant (500 mg intramuscular [as two 5 mL injections] every 28 days ± 3 days, with an additional injection on 15 after the first administration + Alpelisib (300 mg by mouth once daily, in a 21-day cycle). Premenopausal women will receive LH-RH analogs in addition every 28 days± 3 days.
102409|NCT03386162|Drug|Chemotherapy|maintenance chemotherapy, meaning the same chemotherapy regimen used during the first 6-8 cycles (investigator's choice) or no antineoplastic treatment in case of toxicity after 4 full cycles.
102410|NCT03386149|Drug|Bosinji|"Product name : Bosinji Granule Manufacturer : Tsumura & Co. Ingredient : Bosinji granule 2.5g (Bosinji extract 1.523g)~Bosinji extract is composed of following proportion of ingredient~Rehmannia Root 1.7g~Achyranthes Root 1.0g~Cornus Fruit 1.0g~Dioscorea Rhizome 1.0g~Psyllium Husk 1.0g~Alisma Rhizome 1.0g~Hoelen 1.0g~Moutan Root Bark 1.0g~Cinnamon Bark 0.3g~Pulvis Aconiti Tuberis Purificatum 0.3g"
102411|NCT03386149|Drug|Loxonine tab.|Product name : Loxonine tab. Manufacturer : Dong Wha Pharm. Co., Ltd Ingredient : Loxoprofen Sodium 68.1mg (Loxoprofen 60mg)
102412|NCT03386149|Procedure|Acupuncture|"Acupuncture treatment will be performed on 20 predefined acupoint using 0.25mm x 40mm acupuncture needle. The time for needle retaining is 15 minutes.~Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints)~Both side BL24, BL25, BL26, EX-B7, BL28 (10 acupoints)~Symptomatic side GB30, GB34, BL57, ST36 (4 acupoints)"
102413|NCT03386136|Drug|100% Oxygen|To provide hospitalized ileus or pseudo-obstruction patient with 100% oxygen via non-rebreather face mask, for 6 hours
102414|NCT03386123|Behavioral|Cognitive Behaviour Therapy for Insomnia|Continuous maintenance of sleep diary, cognitive behaviour therapy, including cognitive restructuring, and behavioural change focusing on sleep restriction and safety behaviours.
102415|NCT03386123|Behavioral|Standard Audiological Care|Maintenance of sleep diary at key times. Psycho-education, provision of bedside sound generator.
102416|NCT03386123|Behavioral|Sleep Support Group|Maintenance of sleep diary at key times. Social support focused on tinnitus and sleep problems.
102417|NCT03386110|Behavioral|Couples Health Project (CHP)|The CHP intervention focuses on addresses drug use and HIV transmission risk by enhancing dyadic communication skills and motivation to work towards shared health goals. The last session of the CHP intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
102418|NCT03386110|Behavioral|Education|The Education intervention consists of a 3-session health education intervention that addresses sexual risk and substance use through a lecture and question and answer format with a male couple. Additionally, the last session of the education intervention consists of a Couples HIV Testing and Counseling (CHTC) session.
102614|NCT03384524|Other|Placebo|Three pills, matching active drugs to be administered daily
102419|NCT03386097|Other|Collection of interstitial fluid, skin biopsies and blood|Collection of interstitial fluid, skin biopsies and blood
102420|NCT03386084|Device|microwave diathermy|Application of microwave diathermy with Monopolar CapacitiveResistive Radiofrequency Therapy (INDIBA)
102421|NCT03386071|Drug|Trametinib 2 mg|The dosage of trametinib for oral administration is 2mg once daily.
102422|NCT03386058|Device|Temporary device deactivation|Patient-controlled, temporary deactivation of implanted device
102423|NCT03386045|Radiation|Optimal SBRT|Two thirds of the participants in this group will get the SBRT (5 treatments) and one third will get standard treatment (60 Gy in 20 treatments)
102424|NCT03386045|Radiation|Optimal Booster|"Two thirds of the participants in this group will get the two high precision radiotherapy plus 20 doses of standard external beam radiotherapy (ie the Booster approach|) and one third will get the standard treatment (60 Gy in 20 treatments)"
102425|NCT03386032|Drug|Investigational OTC Cream|Investigational Over the Counter (OTC) Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as moisturizer.
102426|NCT03386032|Drug|0.05% Desonide|"Rx Steroid applied topically, twice daily, once in the morning and once in the evening, for 8 weeks to all atopic dermatitis lesions.~Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to whole body as body moisturizer, except atopic dermatitis lesions."
102427|NCT03386032|Other|Placebo Cream|Placebo Cream applied topically, twice daily, for 8 weeks, once in the morning and once in the evening, to atopic dermatitis lesions and whole body as body moisturizer.
102428|NCT03386019|Other|Lymphatic massage|One certified physical therapist will perform the massage regimens and techniques adapting from Swedish massage such as effleurage and petrissage that will be used in the massage group. Participants will first lay down in prone position, and the massage leg will be supported on the therapist's leg or on pillows with legs being positioned at approximately 30 degrees of knee flexion. This can promote venous return of the lower legs and also keep the ankle plantar flexors in a relative low muscle tension position. After positioning, long strokes will be applied from the distal to proximal part of gastrocnemius with approximately 20 repetitions and then 20 repetitions of circular strokes would be applied at the popliteal fossa. Finally, therapist will knead around participant's Achilles tendon for 10 repetitions.6 The combination of the techniques mentioned above will repeat 3 times in each subject, and the total duration of massage will be approximately 5 minutes.
102429|NCT03386019|Other|Static stretching|For the static stretching group, participants will perform the standing gastrocnemius stretches. First, participant stands facing a wall and put the stretched leg behind the body. Physical therapist will ask the participant to slightly flex the front leg, and keep back leg extended with heel on the ground. Both toes will be positioned pointing forward. Participant will then be asked to lunge forward slowly until the calf muscles on the back leg feeling stretched. Participant will hold in this position for 60 seconds and repeat 3 times.
102430|NCT03386019|Other|Cold water immersion|In the cold-water immersion group, participant's lower leg will be put in a bucket filled with cold water for 10 minute. The temperature of the water will be kept in 11-15 degrees Celsius.52 The water level should reach participant's fibular head to ensure complete immersion of the lower leg.
102431|NCT03386006|Behavioral|Noom Coach for Bariatric Health|Noom Coach for Bariatric Health offers a sustainable, low-cost, coach-led intervention, and an innovative solution to issues with pre-bariatric surgery weight loss. The intervention will take place over 8 weeks.
102432|NCT03385993|Device|Technology based guided meditation and relaxation|Subjects will be guided through a mediation and relaxation exercise on a tablet or virtual reality headset for up to an hour each day.
102433|NCT03385980|Other|Proteomic analysis|Proteomic analysis of tissues collected from all sites of disease, guided by either imaging performed prior to the patient's death or post-mortem findings. Peripheral blood mononuclear cells (PBMC) will be collected with the purpose of identifying somatic changes occurring specifically in the tumor cells and not in normal DNA of the same patient.
102434|NCT03385967|Drug|Dexmedetomidine|Addition of Dexmedetomidine in block .25mcg/kg of dexmedetomidine
102435|NCT03385967|Drug|ropivacaine|Standard of care 0.5%ropivacaine
102436|NCT03385954|Other|Intervention|The distance eduacation group course has a workload of 8 hours and will be developed over 2 weeks. It is suggested that students have a minimum of 1 hour of study per day. The course will consist of work tips, clarifications and procedures for the prevention of RIS/WRMD physical training tips to improve cardiovascular condition and, of strength and flexibility, available literature and theoretical evidence that should be answered through the knowledge acquired in the EAD course of prevention of LERDORT from the HCPA's Physiatrics and Rehabilitation Service. This Course will be available through moodle.
102437|NCT03385954|Other|Control|will receive a lecture of 30 minutes.
102438|NCT03385928|Drug|Tranexamic Acid|Investigational product given within 2 hours of symptom onset
102439|NCT03385928|Drug|Normal saline|Placebo given within 2 hours of symptom onset
102440|NCT03385915|Procedure|Aortic valve replacement|Transcatheter or surgical aortic valve replacement for severe aortic valve stenosis
102441|NCT03385902|Other|optimal start time|patients will start hemodialysis when their DIFE reach 35, and can not wait if the DIFE decline to 30.
102442|NCT03385902|Other|late start time|patients will start hemodialysis when their DIFE less than 30
102443|NCT03385889|Procedure|Cervical Spine Mobilization|C1/2 graded mobilizations (Grade III/IV) provided to C1/2 segment on ipsilateral side of unilateral headache. Mobilizations will be completed for 3 sets of 30 seconds.
102444|NCT03385889|Procedure|Cervical Spine Manipulation|C1/2 manipulation (Grade V) provided to C1/2 segment on ipsilateral side of unilateral headache. The goal of the manipulation technique is to elicit an audible cavitation. If no cavitation is achieved upon the first attempt, a second and final attempt will be completed. No more than two attempts will be utilized per each subject in this allocated group.
102445|NCT03385876|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic biorepository. A subset of samples will undergo genetic/genomic analysis.
102576|NCT03384745|Drug|Secukinumab|Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
102615|NCT03384511|Drug|Apatinib|Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
102446|NCT03385863|Drug|Surfactant, Pulmonary，Curosurf|All NRDS were given an early endotracheal infusion of Curosuf, with an initial dose of 200mg/kg, and if the condition needed to be repeated. Compare the therapeutic effect of pulmonary surfactant of infants at different gestational ages and to investigate whether exogenous surfactant replacement therapy is effective for all newborns with RDS.
102447|NCT03385863|Other|Perinatal risk factors of NRDS|Compare the perinatal risk factors that were closely related to NRDS between early preterm infants with RDS and near term/term infants with RDS.
102448|NCT03385850|Other|enteral nutrition|early enteral nutrition group or delayed enteral nutrition group
102449|NCT03385824|Behavioral|Self-Advocacy for Independent Life (SAIL)|SAIL program is based on an interactive workshop model. In -person sessions will focus on: enhancement of self-efficacy beliefs; enhancement of knowledge of TBI self-advocacy information; group process to instill hope and universality; and practice of self-advocacy behaviors in a supportive neuro-rehabilitation structured group environment.
102450|NCT03385811|Other|no intervention, only questionnaires survey|questionnaires survey
102451|NCT03385798|Procedure|Endowrist|Anastomosis made by Endowrist
102452|NCT03385798|Procedure|Endo-GIA|Anastomosis made by Endo-GIA
102453|NCT03385772|Procedure|Sphenopalatine ganglion block|The patient will be placed supine, with head in sniffing position. Two long cotton-tipped applicators will be soaked in 4% lidocaine for 30 seconds. An anesthesia provider, after visually inspecting each nostril for any sign of deformity or blockage, will perform the block. A cotton tipped applicator will be inserted into one nostril at an angle perpendicular to the face, and will be advanced to the back of the nasopharynx until resistance is met. The procedure will be repeated in the other nostril. If the patient experiences any pain or discomfort, the physician will stop and redirect the applicator. The applicators will be left in place for 10 minutes, and then removed by the anesthesia provider.
102454|NCT03385759|Procedure|Unicompartmental knee arthroplasty|Implant to replace the medial compartment of a patient with knee osteoarthritis
102455|NCT03385759|Procedure|Total knee arthroplasty|Implant to replace the knee joint of a patient with knee osteoarthritis
102456|NCT03385746|Other|polyamide|metal reinforced polyamide denture base material
102457|NCT03385746|Other|heat cured acrylic resin|conventional heat cured acrylic resin denture base material
102458|NCT03385733|Other|inspiratory muscle training|The treatment group received IMT. Patients were trained using an inspiratory threshold-loading device
102459|NCT03385720|Procedure|modified neck dissection|Modified neck dissection with preservation of submandibular gland. The submandibular gland is preserved during neck dissection.
102460|NCT03385720|Procedure|traditional neck dissection|traditional neck dissection without preservation of submandibular gland
102461|NCT03385707|Device|Dexcom continuous glucose monitor and activity monitor|Participants will wear the Dexcom continuous glucose monitor and activity monitor for two weeks. They will not be able to see sensor glucose values. A stool sample will be collected to determine if there is a relationship between postprandial glycemia patterns and microbiome composition.
102462|NCT03385694|Diagnostic Test|Assessment|Pelvic coronal X-ray, proprioceptive test with Delos system, questionnaires administration, orthopaedic, physiatric and prosthetic assessment
102463|NCT03385681|Other|Tailored Educational Intervention|The intervention will be a one-day seminar for nurses working at the units, with lectures and workshops with main focus on the subjects showing the lowest pediatric pain management competence. In addition, there will be clinical supervision in pediatric postoperative pain management (two or three days per unit). The intervention will be conducted by two experts (nurse and physician) in pediatric postoperative pain management. After the intervention there will be different reminders every week for the first month, and then every month (in different forms) about pediatric pain management during six months of time.
102464|NCT03385668|Drug|Pirfenidone|Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).
102465|NCT03385655|Drug|AZD1775|300mg days 1-5, 8-12 q21 days
102466|NCT03385655|Drug|Savolitinib|600mg once daily, orally.
102467|NCT03385655|Drug|Darolutamide|600mg twice daily, orally.
102468|NCT03385655|Drug|CFI-400945|64mg Daily. Cycle 1 will consist of a 14-day run-in with CFI-400945 at 64 mg/day for 7 days and followed by a 7-day period without CFI-400945 administration.
102469|NCT03385642|Device|ChondroMimetic|ChondroMimetic is a single-use, biphasic implant that serves as an osteochondral scaffold for the repair of cartilage defects in the knee
102470|NCT03385629|Behavioral|CSM theory-based didactic education and skills training|Common-Sense Model of Self-Regulation (CSM) theory-based education and skills training for the provider to teach him/her to communicate core oral health facts to parents, provide a prescription to take their child to the dentist together with a list of Medicaid-accepting dentists in the area, and document the oral health encounter in EMR.
102471|NCT03385629|Other|AAP-based didactic education|American Academy of Pediatrics (AAP) based oral health education and follow the usual care for oral health assessment recommended by AAP guidelines.
102472|NCT03385629|Other|Practice EMR changes|Enhancements to the EMR system to include oral health documentation (four questions) which will be implemented prior to enrolling any parent/caregiver and child participants into the study.
102473|NCT03385616|Device|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
102474|NCT03385603|Device|Dilator|Both groups will have a home program consisting of dilators which are progressive in size. The standard care group will use manufacturer instructions to progress in size of dilators, while the experimental group will use self-reported levels of fear to progress in size of dilators.
102475|NCT03385603|Behavioral|Fear-Based Questionnaires|Series of questionnaires used to facilitate emotional awareness associated with vaginal and decreased sexual arousal.
102476|NCT03385590|Dietary Supplement|Soy-fiber-maize|Two servings of soy-maize porridge fortified with soy fiber (1.3 g per serving) will be consumed by the children each day for a period of six months.
102477|NCT03385590|Dietary Supplement|Maize|Two servings of maize porridge will be consumed by the children each day for a period of six months.
102802|NCT03383068|Drug|Metformin|metformin effective subjects,act as control group
102478|NCT03385577|Behavioral|Stilling the Waters of Uncertainty: A yoga program for women with gynecologic, gastrointestinal (GI), or thoracic cancer|'Stilling the waters,' the prominent theme of this program, is drawn from the core principle in yogic philosophy. It uses breath techniques and physical postures to cultivate inner peace and an ability to live in the present moment. The emphasis on stilling the fluctuations of uncertainty is a direct allusion to the intrusive and inherently unknown future, which characterizes the core experience of Fear of Cancer Recurrence (FCR). This is especially true among gynecologic, gastrointestinal (GI), or thoracic cancer patients for whom the likelihood of recurrence is quite high. An additional motif throughout the program is the lotus flower. The symbolic importance of the lotus in yogic culture is due to its requiring thick muddy waters for ideal growth. The metaphor of cancer as the muddy waters will be used to cultivate benefit-finding and acceptance regarding the mental and physical challenges participants endured during their initial diagnosis and treatment.
102479|NCT03385564|Drug|BI 655064|subcutaneous injection
102480|NCT03385564|Drug|Placebo|subcutaneous injection
102481|NCT03385551|Drug|Estradiol|Estradiol or Promestriene depending on the arm
102482|NCT03385538|Drug|Clopidogrel|increasing doses of clopidogrel depending on PRU values (75-300 mg)
102483|NCT03385525|Drug|BIIB074|Administered as specified in the treatment arm
102484|NCT03385525|Drug|Valproic Acid|Administered as specified in the treatment arm
102485|NCT03385512|Behavioral|OPEN High Touch|This arm will contain three components: (a) a pre-visit questionnaire delivered through the patient portal of the EHR, asking patients what they most want to discuss with their physician in the upcoming visit; (b) an animated video for patients providing coaching on how to best prepare for their upcoming visits and get the most from the visits; and (c) Standardized Patient Instructor (SPI) providing communication coaching for physicians on how to incorporate what matter most to patients in the visit, with empathy, and clarity.
102486|NCT03385512|Behavioral|OPEN High Tech|The patient components of the intervention will be identical to the patient components of the High Touch arm (i.e., the pre-visit survey and patient coaching video). The difference will be in the PCP training: we will replace the in-person SPI with a mobile app program.
102487|NCT03385512|Behavioral|ASK|This arm is intended to activate patients by encouraging them to ask three questions during their primary care visit: (1) What are my options? (2) What are the possible benefits and risks of each option? (3) How likely are the benefits and risks of each option to occur to me? This will involve placing posters with these questions in all exam rooms used by providers in clinics randomized to the ASK arm of the trial.
102488|NCT03385499|Biological|blood additional samples|additional samples of mother's blood and umbilical cord at delivery
102489|NCT03385486|Biological|TBX-3400|Autologous transfusion
102490|NCT03385473|Genetic|Pharmacogenomic index|All patients will have a blood sample drawn at randomization visits for PG analysis. For patients in the PA arm, the sample will be processed immediately to obtain the PG results and the subsequent index within 10 days. As soon as the results are available, the project team will contact the attending physician to propose the dosing adequation according to the pharmacogenomic index. PG analysis will be performed once for each patient.
102491|NCT03385473|Diagnostic Test|Therapeutic drug monitoring|The patients included in the Pharmacological Adequation arm will have a TDM according to this schedule: day +14 (±3), +28 (±3), and +168 (±3). If there is an abnormal value (out of the therapeutic range), we will proceed to adjust the prescription.
102492|NCT03385460|Other|ESWL BOTOX|ESWL after intrravesical BOTOX
102493|NCT03385447|Behavioral|Physical Activity|Participants underwent 12-weeks of exercise prescription aimed at the federal guidelines (3 days/week).
102494|NCT03385434|Device|Endorings-2|292 patients with an indication for screening colonoscopy will be included. 146 patients will receive a standard colonoscopy and 146 patients will receive an Endorings-2 assisted colonoscopy (1:1 standard colonoscopy vs Endorings-2-assisted colonoscopy).
102495|NCT03385408|Device|HIRO® 3.0|Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).
102496|NCT03385408|Device|Sham laser|For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
102497|NCT03385395|Drug|OctaAlpha1|For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
102498|NCT03385395|Drug|Glassia|For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions
102499|NCT03385382|Drug|Dexamethasone intravitreal implant 0.7 mg|Intravitreal Implant of dexamethasone
102500|NCT03385382|Drug|Ranibizumab Injection|Injection of ranibizumab
102501|NCT03385369|Drug|MEDI0382|Single dose of MEDI0382
102502|NCT03385369|Drug|Placebo|Single dose of placebo
102503|NCT03385356|Drug|Vitamin D|Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
102504|NCT03385343|Diagnostic Test|VLE imaging for staging EAC|Volumetric Laser Endomicroscopy (VLE) imaging for staging Esophageal Adenocarcinoma (EAC)
102505|NCT03385330|Other|LOWER oxygen saturation target group|We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
102506|NCT03385330|Other|HIGHER oxygen saturation target group|We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
102507|NCT03385317|Behavioral|Mindfulness|
102508|NCT03385304|Drug|10% povidone-iodine (1% free iodine) in purified water|Participant recruitment will begin with the clinical sites using their assigned pre-operative antiseptic skin solution for all open fracture surgeries for a two-month period.
102609|NCT03384537|Combination Product|Listerine total care zero|reducing intra-oral cariogenic microorganism.
102610|NCT03384537|Combination Product|Chlorhexidine Mouthwash (0.2%).|Chlorhexidine Mouthwash (0.2%).
102509|NCT03385304|Drug|4% chlorhexidine gluconate (CHG) in purified water|Once the first intervention phase is completed, each site will crossover to the opposite study solution. Each site will need to develop local procedures to ensure a successful crossover. They will use the second solution for all open fracture surgeries for a two-month period, and will then crossover back to the solution in the first intervention phase.
102510|NCT03385291|Device|music,name,and noise sound|A 5-minute baseline silence was followed by the presentation of three contrasting auditory stimuli(music,name,and noise), with a 2-minute washout silence separating each stimulus
102511|NCT03385278|Other|rTMS|20HZ Repetitive Transcranial Magnetic Stimulation
102512|NCT03385265|Behavioral|DIPPer Academy|The DIPPer Academy curricula will build on treatment models guided by the Health Beliefs Model (HBM) and Social Cognitive Theory (SCT). The curricula includes video microlectures, personalize progress reports, and other features delivered via the internet.
102513|NCT03385265|Behavioral|Standard of Care|Families in the standard of care control group will be instructed to manage their child's T1D as recommended.
102514|NCT03385252|Other|Eggs|Eggs provided as complementary food for the infant
102515|NCT03385252|Behavioral|Visits|Twice weekly household visits by study staff
102516|NCT03385239|Drug|ISIS 678354|Randomly assigned to one of the dosing cohorts
102517|NCT03385239|Drug|Placebo|Randomly assigned to one of the dosing cohorts. Dose of placebo in each cohort will match volume of active in that cohort.
102518|NCT03385226|Drug|Pembrolizumab|Pembrolizumab is a humanised monoclonal antibody which targets the programmed cell death 1 (PD-1) receptor. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells.
102519|NCT03385226|Radiation|Radiotherapy|12Gy in 3 fractions
102520|NCT03385200|Drug|SonoVue|As part of the study therapy supportive ultrasound will be performed with iv Infusion of the chemotherapeutic agent.
102521|NCT03385187|Device|NightOwl HSAT|Patient wears the NightOwl sensor device
102522|NCT03385174|Other|Carbon monoxide|Carbon monoxide inhalation
102523|NCT03385161|Procedure|Botulinum toxin A|
102524|NCT03385161|Procedure|Ethanol|
102525|NCT03385148|Drug|68Ga-Sgc8|underwent a standard routine 18F-FDG PET/CT first, and then injected 10~20 MBq 68Ga-Sgc8
102526|NCT03385135|Drug|Allopurinol|300 mg for 4 weeks then 600 mg for 4 weeks in the active group
102527|NCT03385109|Device|Surgery|Patients are approached surgically with the Senhance Surgical System
102528|NCT03385096|Drug|Busulfan (BU)|"Busulfan was administered at 3.2 mg/kg/day on days -8 to -6.~−7 to −4."
102529|NCT03385096|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days −3 to −2.
102530|NCT03385096|Drug|Etoposide (VP-16)|"Etoposide was administered at 10 mg/kg/day on days -3 to -2.~−3 to −2."
102531|NCT03385096|Drug|Melphalan|Melphalan was administered at 200mg/m2 on day -2.
102532|NCT03385083|Behavioral|Step count monitoring with consulting|Subject counseled on step counts at initial visit and 2 and 4 weeks
102533|NCT03385083|Behavioral|Step count monitoring without consultation|Subject counseled on step counts at initial visit
102534|NCT03385083|Device|Fitbit tracker|Fitbit tracker given to participant
102535|NCT03385070|Diagnostic Test|Lens examination|The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
102536|NCT03385057|Drug|Ibuprofen|Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
102537|NCT03385057|Drug|Acetaminophen|Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
102538|NCT03385044|Procedure|MOVT|ETT cuff will be inflated till the disappearance of audible air leak on auscultation, while abdominal carbon dioxide (CO2) inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
102539|NCT03385044|Procedure|VE/VI ratio of Spirometer|ETT cuff will be inflated till the VE/VI ratio meets the initial VE/VI ratio, while abdominal CO2 inflation is maintained with peak inspiratory pressure of 25 cm H2O during volume controlled ventilation. The patient will be in the Trendelenburg position.
102540|NCT03385031|Other|CBCT imaging|CBCT imaging at first and last fraction of radiotherapy treatment
102541|NCT03385018|Procedure|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach|"Total gastrectomy with D2(D2-10) lymph node dissection by laparoscopic approach~The number of trocars is 6 or less~Roux-en-Y esophagojejunostomy with any stapling method~Enough(negative) margin from tumor~LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~Washing cytology~Frozen biopsy for surgical margin at surgeons discretion~Complete omentectomy for grossly serosa-involved tumor~Combined organ resection only in cholecystectomy and splenectomy~Indwelling nasogastric tube and drainage catheter at surgeons discretion~D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
102611|NCT03384524|Drug|Bromocriptine 2.5 MG|Administered daily
102612|NCT03384524|Drug|Metoprolol 25 MG|Administered daily
102542|NCT03385018|Procedure|Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach|"Total gastrectomy with D2(D2-10) lymph node dissection by open conventional approach~Roux-en-Y esophagojejunostomy with any stapling method~Enough(negative) margin from tumor~LN station #1, 2, 3, 4d, 4sb, 5, 6, 7, 8a, 9, (10), 11p, 11d, 12a should be examined~Washing cytology~Frozen biopsy for surgical margin at surgeons discretion~Complete omentectomy for grossly serosa-involved tumor~Indwelling nasogastric tube and drainage catheter at surgeons discretion~D2 lymphadenectomy should be performed : dissection of LN stations No.4d, 4sb, 4sa, 2, 10 (splenic hilar LN can be left according to the clinical stage), 6, 5, 12a, 8a, 9, 7, 1, 3, 11p, 11d with prevention of pancreatic injury during suprapancreatic dissection"
102543|NCT03385005|Device|Participants will receive neuromuscular electrical stimulation via an investigational (not FDA approved) neuromuscular stimulator.|The study involves the administration of various electrical pulses being delivered to muscles of the forearm from a neuromuscular stimulator in order to evoke different hand and finger movements. The grip strength and evoked forces at the fingertips will also be measured using sensors.
102544|NCT03384992|Other|Diaphragmatic breathing and relaxation|Education on physiological effects of anxiety, instructions in diaphragmatic breathing and relaxation techniques, and audio-recordings 5-15 minutes in length that provide guided relaxation exercises (autogenic, imagery-based and progressive muscle relaxation).
102545|NCT03384992|Other|Cognitive restructuring|Education on the thought-emotion connection and exercises designed to better understand cognitions associated with increased anxiety and tools to evaluate and replace anxiety-generating cognitions. Includes an interactive tool (thought record) participants complete to facilitate this process.
102546|NCT03384992|Other|Scheduled worry practice|Education on the association between avoidance and increased anxiety, and instructions on actively thinking about feared events to reduce avoidance and engage healthy coping strategies. Interactive tool includes a video-based guided worry practice session and an interactive worksheet and timer.
102547|NCT03384992|Other|Telephone coaching|BCS will receive 5 TeleCoaching calls over a period of 4 weeks, to include one introductory phone call, followed by 4 calls focused each week on the current CSM; if the participant is not randomized to a CSM, TeleCoaching will provide reflective listening and encouragement.
102548|NCT03384992|Other|Usual care|Includes general health, diet-general information and diet-BCSS (breast cancer survivor-specific) information.
102549|NCT03384979|Drug|Iopamidol|Contrast agent will be adrministered intravenously using total body weight or lean body weight, calculated with bioelectrical impedance analysis balance.
102550|NCT03384966|Drug|ACT-246475|ACT-246475 for s.c. administration will be available as sealed glass vials in 20 mg strength.
102551|NCT03384966|Drug|Placebo|Matching placebo for s.c. administration
102552|NCT03384953|Behavioral|Clinical Hypnosis - Group Treatment|group treatment
102553|NCT03384953|Behavioral|Clinical Hypnosis - Individual Treatment|individual treatment
102554|NCT03384940|Drug|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration
102555|NCT03384914|Biological|DC1 Vaccine|"Vaccination Phase: DC1 vaccine will be administered weekly via intranodal injection in weeks 1 to 6 (window 8-21days between vaccines).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
102556|NCT03384914|Biological|WOKVAC Vaccine|"Vaccination Phase: WOKVAC vaccine will be administered via intradermal injection on weeks 1, 4 and 7 (window +21 days).~Booster vaccines will be administered at approximately 3 month intervals on months 6, 9 and 12 (with a window +/- 1 month)."
102557|NCT03384901|Procedure|vitrectomy|Pars plana vitrectomy and ILM (internal limiting membrane) peeling
102558|NCT03384888|Device|Active tDCS|Transcranial direct current stimulation Duration: 20 minutes; Intensity: 2 mA (miliamps); Placement of the electrodes: anode over the left M1 and cathode region over the right supraorbital region.
102559|NCT03384888|Device|Sham tDCS|Sham Transcranial direct current stimulation The procedure is the same as for active tDCS, but the stimulation is non-active / sham.
102561|NCT03384862|Dietary Supplement|Vitamin B12|5 μg/d vitamin B12 to be given orally. This is a standard nutritional supplement commonly used in the US.
102562|NCT03384862|Dietary Supplement|Placebo|Placebo pills, with same appearance as intervention pills.
102563|NCT03384862|Dietary Supplement|Folic Acid|400 μg/d folic acid to be given orally. This is a standard nutritional supplement commonly used in the US.
102564|NCT03384849|Diagnostic Test|MRI examination|The part of the body that is being scanned and the time of the MRI examination are not relevant.
102565|NCT03384836|Other|Laboratory Biomarker Analysis|Correlative studies
102566|NCT03384836|Biological|Pembrolizumab|Given IV
102567|NCT03384836|Drug|Propranolol Hydrochloride|Given PO
102568|NCT03384823|Drug|EDP-938|Subjects will receive either a single dose of EDP-938 on Day 1 only (SAD) or a single dose of EDP-938 starting on Day 1 through Day 7 (MAD).
102569|NCT03384823|Drug|Placebo|placebo to match EDP-938
102570|NCT03384784|Drug|Galantamine|The study will be performed using the 8mg, 16mg and 24mg doses of galantamine hydrobromide-ER. The dosing regimen will be an initial 4 weeks of drug run-up at the lowest 8mg q.d. dose, followed by 16mg q.d. for the following 4 weeks, and the dose will be increased for the last 4 weeks to 24mg. Participants will be instructed to take one 8mg 16mg or 24mg pill (galantamine-ER or placebo) every morning, preferably with food.
102571|NCT03384784|Drug|Placebo|Matched placebo will be made in-house using lactulose filler in gel capsules. Participants will be instructed to take one pills every morning for 12 weeks.
102572|NCT03384771|Behavioral|MBSR|There is no study intervention per se, but participants will be teaching or enrolled in public 8-week MBSR classes.
102573|NCT03384758|Device|Compression Therapy|Therapy of the leg edema with compression stockings class I for three hours, after a short break with compression stocking class II for again three hours.
102574|NCT03384745|Drug|M1095|M1095 is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.
102575|NCT03384745|Drug|Placebo|Placebo contains no active drug.
102613|NCT03384524|Drug|Tamsulosin 0.4 MG|Administered daily
102577|NCT03384719|Dietary Supplement|35 g protein (30% milk + 70% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
102578|NCT03384719|Dietary Supplement|35 g protein (54% milk + 46% rapeseed)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)~Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
102579|NCT03384719|Dietary Supplement|35 g protein (100% milk)|"The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.~Protein powder ingredients (all are food quality):~Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)~Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day."
102580|NCT03384706|Behavioral|Cognitive Processing Therapy (CPT)|"CPT looks at the impact the traumatic event has had on your life and helps you to examine and change unhelpful thoughts and feelings related to the event, yourself, others and the world.~CPT will be conducted in 5-15, 60 minute sessions held once or twice a week."
102581|NCT03384706|Behavioral|Accelerated Resolution Therapy (ART)|"ART, like CPT also involves processing thoughts and feelings related to the event, but does this in a different way relying more on visualization or imagination rather than talking.~ART will be conducted in 5-15, 60 minute sessions held once or twice a week."
102582|NCT03384693|Drug|Defibrotide|Defibrotide is an anticoagulant and fibrinolytic agent that has been shown to be an effective treatment in other endothelial disorders such as hepatic veno-occlusive disease.
102583|NCT03384667|Drug|Maekmoondong-tang|MMDT is a Herbal medicine consist of six herbs.
102584|NCT03384667|Drug|Placebo|The granules do not contain any active ingredients.
102585|NCT03384654|Drug|Daratumumab|Participant will receive daratumumab 16 milligram per kilogram (mg/kg) in cohort 1 and cohort 2.
102586|NCT03384654|Drug|Vincristine|Participant will receive vincristine 1.5 milligram per meter square (mg/m^2) in cohort 1 and cohort 2.
102587|NCT03384654|Drug|Prednisone|Participant will receive prednisone 40 mg/m^2 in cohort 1 and cohort 2.
102588|NCT03384654|Drug|Doxorubicin|Participant will receive doxorubicin 60 mg/m^2 in cohort 2.
102589|NCT03384654|Biological|Peg-asparaginase|Participant will receive peg-asparaginase 2500 units per meter square (U/m^2) in cohort 2.
102590|NCT03384654|Drug|Cyclophosphamide|Participant will receive cyclophosphamide 1 gram per meter square (g/m^2) once in cohort 2.
102591|NCT03384654|Drug|Cytarabine|Participant will receive cytarabine 75 mg/m^2 in cohort 2.
102592|NCT03384654|Drug|6-mercaptopurine|Participant will receive 6-mercaptopurine 60 mg/m^2 orally daily in cohort 2.
102593|NCT03384654|Drug|Methotrexate|Participant will receive methotrexate 5 g/m^2 intravenously (IV) in cohort 2.
102595|NCT03384628|Device|First pair Senofilcon A contact lens|Fit assessment of the first pair contact lenses.
102596|NCT03384628|Device|Second pair Senofilcon A contact lens|Fit assessment of the second pair of contact lenses.
102597|NCT03384628|Device|Third pair Senofilcon A contact lens|Fit assessment of the third pair of contact lenses.
102598|NCT03384615|Behavioral|Compassion-Focused Therapy|CFT for PGD symptoms in the present project is inspired by two well-established CFT treatment manuals. The first is used for treatment of PTSD (Lee & James, 2011) and the other for treatment of anger (Kolt, 2011). The manual for CFT for PGD adopts both structure and techniques from these into an 8-week, group-based program with weekly 2 1/4-hour sessions. Each session contains elements of psychoeducation on uncomplicated and prolonged grief reactions, identifying unhelpful strategies for self-protection and facilitating use of more helpful strategies, and training an open and compassionate management of grief-related distress through CFT exercises. Between the sessions the participant will train the exercises introduced at the previous session.
102599|NCT03384602|Other|Dalcroze Eurhythmics Program|music-based multi-task exercise in group setting
102600|NCT03384602|Other|home exercise strength program|simple strength exercise program to perform individually at home
102601|NCT03384589|Biological|PCV13|Vaccine against pneumococcal disease
102602|NCT03384576|Other|Music intervention|Classical music to be played in the Emergency waiting room
102603|NCT03384576|Other|No music|No music played in emergency waiting room
102604|NCT03384563|Drug|Dexmedetomidine|Dexmedetomidine 9 arms
102605|NCT03384550|Behavioral|Self-regulation coaching|Short (2-5 min.) dialogue with the digital coach who provides information relevant for behavioral self-regulation, such as a goal reminder, the distance between the current step count and the goal and strategies to increase daily steps. Participants are randomized to self-regulation coaching or control (no coaching) on a daily basis.
102606|NCT03384550|Behavioral|Planning|A dialogue with the digital coach who prompts the participant to either formulate action plans (when and where the participant can go for a walk) or coping plans (strategies to respond to barriers for increasing daily steps) for the upcoming week. Participants are randomized on a weekly basis to action planning, coping planning or control (no planning).
102607|NCT03384550|Behavioral|Financial Incentives|Participants receive CHF 1 ($1) for each day they meet a personalized adaptive step goal.
102608|NCT03384550|Behavioral|Charity Incentives|Participants donate CHF 1 ($1) to a charity of choice for each day they meet a personalized adaptive step goal.
102616|NCT03384485|Diagnostic Test|antiphospholipid syndrome|blood test for enzyme test,plasma and Lys-3-3 plasma
102617|NCT03384459|Device|the 308-nm excimer laser|For a total period of 12 months, the 308-nm excimer laser therapy is performed once a month.
102618|NCT03384446|Other|Tooth-borne treatment|Titanium curettes
102619|NCT03384446|Other|Implant-specific treatment|Implant brush
102620|NCT03384433|Biological|exosome|allogenic mesenchymal stem cells derived exosome enriched by miR-124
102621|NCT03384420|Biological|CD34+ cells enriched with MNV-BLD|Transplantation of autologous stem cell enriched with MNV-BLD (blood-derived mitochondria)
102622|NCT03384407|Device|Red cell survival in INTERCEPT treated red cells|Red cell recovery/survival analysis of untreated and INTERCEPT treated RBC concomitantly
102623|NCT03384394|Device|high-flow nasal cannula oxygen|high-flow nasal cannula oxygen
102624|NCT03384394|Device|Conventional oxygen therapy|oxygen by a standard nasal cannula or nonrebreather mask
102625|NCT03384368|Device|fractured level screws-distraction|four pedicle screws were implanted into the upper vertebra and the lower vertebral body of the fractured vertebra. Then, immediate reduction and decompression were achieved by applying distraction of rod. Finally, two additional screws were introduced at fracture level
102626|NCT03384342|Device|Narrow-band UV-B therapy|"Patients treated with NBUVB and showed 75% or more repigmentation rate would be included.~For a total period of 12 months, narrow-band UV-B therapy is performed once a month."
102627|NCT03384329|Drug|Resveratrol Pill|Resveratrol 500 mg
102628|NCT03384329|Drug|Placebos|Placebo Pills
102629|NCT03384316|Biological|ETBX-051; adenoviral brachyury vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
102630|NCT03384316|Biological|ETBX-061; adenoviral MUC1 vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
102631|NCT03384316|Biological|ETBX-011; adenoviral CEA vaccine|immunotherapeutic vaccine administered subcutaneously every 3 weeks for 3 doses, and then every 8 weeks for up to a year
102632|NCT03384303|Other|Standardized meal test|Preoperatively and postoperatively standardized meal test
102633|NCT03384290|Drug|PRS-060|Drug
102634|NCT03384290|Drug|Placebo|PRS-060 Matching Placebo
102635|NCT03384277|Drug|Steroid|Methylprednisolone 0.8 mg/kg/day (or equivalent corticosteroid doses) for 3 weeks（then tapering gradually, 8 weeks in total）
102636|NCT03384277|Drug|Rituximab|375mg/m2 for one dose
102637|NCT03384277|Drug|Cyclophosphamide|cyclophosphamide 2 mg/kg/day until inhibitor negative (no longer than five weeks)
102638|NCT03384264|Other|Physical activity|The suspension device was securely attached to a fixed beam. The suspension programme included an initial 10 min warm-up with very low-intensity joint mobility exercises. The central part of the program had a duration of 40 min and included six exercises in which the level of intensity was based on the inclination of the body. The exercises were performed in a split routine, alternating by segment to prevent joint overload. Finally, participants performed 10 minutes of stretching.
102639|NCT03384251|Behavioral|comprehensive sex education|A comprehensive sex education program to be delivered in approximately six (6) sessions comprising of an introductory lesson on susceptibility and severity of teenage pregnancy, personal and community values, female reproductive system, contraception and decision-making skills.
102640|NCT03384238|Procedure|Fluorescence Imaging|Undergo fluorescence imaging
102641|NCT03384238|Biological|Panitumumab|Given IV
102642|NCT03384238|Drug|Panitumumab-IRDye800|Given IV
102643|NCT03384225|Drug|Cladribine|
102644|NCT03384225|Drug|Fludarabine|
102645|NCT03384225|Drug|Busulfan|
102646|NCT03384225|Drug|Cytarabine|
102647|NCT03384212|Drug|Cladribine|
102648|NCT03384212|Drug|Fludarabine|
102649|NCT03384212|Drug|Busulfan|
102650|NCT03384212|Drug|Cytarabine|
102651|NCT03384199|Radiation|Dose escalation to prostate focal lesion|For each patient the radio-opaque marker (used for treatment verification) will be inserted by ultrasound guidance & local anaesthetic with an 17ga x 30cm brachytherapy needle that has 1.2mm x 3mm one gold marker. The ultrasound probe (as used for transrectal biopsy) will be introduced rectally with the patient in the left lateral position. After measuring the volume of the prostate and determining the desired position (preferably in the corpus of prostate), three gold markers will be inserted as follows: one into right side, one into left side of the base and the third in the apex of the prostate
102652|NCT03384186|Drug|ACH-0144471 Modified Release Prototype 1|400 mg ACH-0144471 Modified Release Prototype 1 in the fasted state
102653|NCT03384186|Drug|ACH-0144471 Modified Release Prototype 2|XXX mg ACH-0144471 Modified Release Prototype 2 in the fasted state
102654|NCT03384186|Drug|ACH-0144471 Modified Release Prototype 3|XXX mg ACH-0144471 Modified Release Prototype 3 in the fasted state
102655|NCT03384186|Drug|ACH-0144471 Modified Release Prototype 4|XXX mg ACH-0144471 Modified Release Prototype 4 in the fasted state, or a prior MR Prototype in the fed state (optional period)
102656|NCT03384186|Drug|ACH-0144471 Modified Release Prototype 5|XXX mg ACH-0144471 Modified Release Prototype 5 in the fasted state, or a prior MR Prototype in the fed state (optional period)
102657|NCT03384173|Device|Near Infrared Spectroscopy|Application of regional NIRS sensors to brain and kidney sites in the first 48 hours after birth to monitor regional tissue oxygenation for the first 7 days of age.
102658|NCT03384160|Diagnostic Test|Group 1 -Pain monitor|Use of the anesthetic Mepivacaine 2% in third molar extraction and evaluation in postoperative
102659|NCT03384160|Diagnostic Test|Group 2 -Pain monitor|Use of the anesthetic Articaine 4% in third molar extraction and evaluation in postoperative
102660|NCT03384147|Dietary Supplement|Drinking|Five different types of alcohol given to participants for 4-5 days in a random sequence for 3 weeks
102661|NCT03384147|Other|Abstaining|Participants are abstaining from all alcoholic beverages for three weeks
102686|NCT03383926|Procedure|4.5cm suture|Suture confection of the Tobacco-pouch of 4.5cm from the anal margin.
102687|NCT03383926|Procedure|6cm suture|Suture confection of the Tobacco-pouch of 6cm from the anal margin.
102803|NCT03383055|Biological|CMV-MVA Triplex Vaccine|"CMV-MVA Triplex vaccine administered on days 28 and 56 post-HCT~TDap administered on Day 56"
102662|NCT03384134|Other|Pain Buddy|Pain Buddy is a user interface (application) which contains a personalized avatar (Pain Buddy) to guide children and parents through daily diary entries using mobile devices. The Pain Buddy application has been designed to be used with children age 8-18, receiving outpatient chemotherapy, as well as their parents. Pain Buddy will capture real time pain data from patients and that will ultimately allow for remote monitoring of patient symptoms. Remote symptom monitoring in real time will provide an opportunity for implementation of appropriate interventions, thereby introducing the potential to decrease pain and symptoms and improve quality of life in children with cancer. The use of symptom monitoring and skills training will further increase patient engagement in healthcare.
102663|NCT03384121|Drug|Rifampin 150 mg, 300 mg capsules and 25 mg/mL oral suspension|Starting Dose (V2): 5 mg/kg/day (max 600mg/day) orally for 2 months followed by a 2 month washout period V4: After washout period, only Non-responders will escalate dose to 10 mg/kg/day (max 600mg/day) orally for 2 months
102664|NCT03384108|Other|5-13C-Glutamine|Intravenous infusion of 5-13C-Glutamine
102665|NCT03384108|Other|Bone marrow aspiration|Bone marrow aspiration of bone marrow aspirate
102666|NCT03384095|Drug|Hyaluronic Acid (HA)|Dosage form: hyaluronic capsules; Dose: 100 mg; Frequency: twice daily; Duration: 26 weeks
102667|NCT03384095|Other|Placebo|Dosage form: microcrystalline cellulose (MCC) capsules; Dose: approx. 100 mg (determined by weight of HA counterpart); Frequency: twice daily; Duration: 26 weeks
102668|NCT03384082|Procedure|hysteroscopic treatment|treatment
102669|NCT03384069|Behavioral|Group-based Cognitive Behavioral Therapy (CBT)|The group-based CBT intervention will include twelve 1-hour group sessions held biweekly for six months. Each sixty-minute session will consist of 15 minutes of Alzheimer's disease (AD) prevention education and approximately 45 minutes of CBT presentations/engagement activities. A physician and a Behavioral Interventionist will collaboratively facilitate the group sessions.
102670|NCT03384069|Behavioral|Phone-based Cognitive Behavioral Therapy (CBT)|Participants in the phone-based CBT will be asked to reserve a 1-hour period for a phone call from the Behavioral Interventionist biweekly for six months. Text reminders will be sent to the participant's prior the sessions. This intervention will follow the same frequency and format as the group-based CBT and will use an established protocol incorporating the same elements of cognitive behavior change as in the group-based CBT, but without the opportunity for group-interaction.
102671|NCT03384056|Device|Self Pressurized Airway Device with Blocker|used in adult low risk females undergoing elective gynecological operations
102672|NCT03384056|Device|Proseal Laryngeal Mask Airway|used in adult low risk females undergoing elective gynecological operations.
102673|NCT03384043|Behavioral|Smartphone Personal Assistant|Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
102674|NCT03384043|Behavioral|Implementation Intention|Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
102675|NCT03384030|Other|adapted STMST|Participants are subjected to the adapted STMST to induce emotional sweating.
102676|NCT03384017|Other|Transcutaneous Spinal Cord Stimulation and Gait Training|"TSCS will be applied using a midline electrode placed on the skin between spinous process T11 -T12 and two electrodes placed symmetrically on the skin over the lower abdomen as anodes. A symmetrical biphasic rectangular waveform, at 50 Hz and 1 millisecond, is used to provide 30 continuous minutes of stimulation.~Subjects will participate in 24 two-hour sessions of physical therapy over eight weeks. In each session, subjects will receive TSCS continuously for 30 minutes, using the parameters outlined above. During stimulation, subjects will participate in strengthening, segmental task practice, and gait-based interventions. Participation in gait training will continue following the stimulation period for the duration of the session."
102677|NCT03384004|Device|Irrigation Technique 1|Irrigation of root canals for this group will be performed using EndoVac Pure, an Apical Negative Pressure Endodontic Irrigation System intended for the delivery and evacuation of endodontic irrigation solutions during root canal procedures. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid). This will be followed by Ultrasonic activation of the sodium hypochlorite solution using Minendo II ultrasonic unit.
102678|NCT03384004|Device|Irrigation Technique 2|Irrigation of root canals for this group will be performed using the EndoVac pure system without Ultrasonic irrigation. The Endovac Pure is a negative pressure system that utilizes negative pressure irrigation so irrigants are suctioned apically from the pulp chamber to the apical terminus and then through the dental office High Volume Evacuation (HVE) valve (Hi-VAC) system. Endovac Pure is designed to be used with Sodium Hypochlorite (NaOCl or bleach) and EDTA (Ethylenediaminetetraacetic acid).
102679|NCT03383991|Procedure|Reverse Total Shoulder Arthroplasty|
102680|NCT03383991|Procedure|Hemiarthroplasty|
102681|NCT03383978|Biological|NK-92/5.28.z|Intracranial application of NK-92/5.28.z, 1x10E7-1x10E8
102682|NCT03383965|Biological|ICAR30 T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
102683|NCT03383952|Biological|ICAR19 CAR-T cells|T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
102684|NCT03383939|Drug|Group A|one nebulization with 250mg alpha-1-antitrypsine diluted in 10ml injectable solution once a day during 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
102685|NCT03383939|Drug|Group B|10ml of 0.9% NaCl saline solution nebulised once daily for 1 month. A CR-60 high flow compressor and Ventstream nebulizer were used for nebulization.
102688|NCT03383913|Behavioral|Heart Rate Variability Biofeedback|Over a period of 4-6 weeks participants in the intervention arm will learn a series of breathing techniques to determine Heart Rate Variability's effects on physical function, anxiety, depression, fatigue, sleep disturbance, participation in social activities, pain interference and intensity.
102689|NCT03383900|Device|Inspiratory muscle training|"The inspiratory muscle training program will be of the strength and endurance type, using the POWERbreathe® device and composed of: daily sessions (3 sets of 15 repetitions -inspiration), 4 days a week for 12 weeks. Participants will begin training breathing with a resistance of 20% of their PImax during the first week. After the first week, the resistance will increase between 5% and 10% in each session until reaching 80% of the PImax, which will be maintained during the first month. Upon completion, the PImax value will be re-evaluated and the player will train 80% of this new value during the second month. At the end of the second month, the PImax is evaluated and the player will train the third month with a resistance of 80% of this new value."
102690|NCT03383887|Drug|Placebo oral capsule|Placebo before sleep
102691|NCT03383887|Drug|DAW1033D oral capsule|DAW1033D before sleep
102692|NCT03383874|Combination Product|Probio-Tec BG-VCap-6.5|"The product under investigation is a probiotic containing two microorganisms (Lactobacillus rhamnosus, LGG® and Bifidobacterium animalis subsp. lactis, BB-12®, referred to as LGG® and BB-12®, respectively) and is offered commercially as Probio-Tec BG-VCap-6.5. This composition is formulated to contain a minimum of 1 billion (1.0 x 10^9) CFU (Colony Forming Units) per dose (capsule), including equal numbers of the two strains; i.e. 0.5 x 10^9 CFU of each of LGG® and BB-12® at the time of manufacture. The product will be administered orally."
102693|NCT03383874|Other|Placebo|This placebo is made almost identically to the Probio-Tec but without active microorganisms.
102694|NCT03383861|Diagnostic Test|Dual-Energy X-ray Absorptiometry (DXA)|BMD t-score derived from DXA scan
102695|NCT03383848|Device|Medication Management Software|"The OnTrack Medication Management Software allows patients to track the amount of fertility medication they have at home. When they check off their to do list of medications, it decrements the amount they have at home. It allows them to see when they will run out of medication depending on their current doses (which can change daily). Daily use of the software will be 5-10 minutes daily for approximately 21 days."
102696|NCT03383835|Dietary Supplement|Omega-3 Supplementation|"DHA 600 milligrams (mg) per day for 6 months~EPA 300mg per day for 6 months"
102697|NCT03383822|Drug|Intranasal insulin|Humalog lispro 40 IU intranasally
102698|NCT03383822|Drug|Intranasal placebo|Diluent intranasally
102699|NCT03383809|Dietary Supplement|Strawberry juice with Inulin|Mixture of polyphenols and non digestible carbohydrates
102700|NCT03383809|Dietary Supplement|Strawberry Juice|Source of Polyphenols
102701|NCT03383809|Dietary Supplement|Inulin|Source of non digestible carbohydrate
102702|NCT03383796|Procedure|Three dimensional laparoscopic resection for pCCA|Three dimensional laparoscopic resection for pCCA
102703|NCT03383796|Procedure|Open resection for pCCA|Open resection for pCCA
102704|NCT03383783|Drug|0 ppm F (placebo, negative control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
102705|NCT03383783|Drug|250 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
102706|NCT03383783|Drug|500 ppm F as NaF (dose-response control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
102707|NCT03383783|Drug|1100 ppm F as NaF (positive control)|Each subject will use this product during one of the four treatment periods in the crossover study design.
102708|NCT03383770|Procedure|Regional Anesthesia Touhy|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.
102709|NCT03383770|Procedure|Regional Anesthesia Facet|The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
102710|NCT03383757|Device|SpO2 Sensor application & blood draw|At the start of the procedure, one to two commercial sensors shall be applied to the subject. Readings will be allowed to stabilize. After at least 10 minutes of data collection, arterial blood will be collected and analyzed blood per hospital's standard procedure. Data collection will continue post blood draw for two minutes.
102711|NCT03383744|Dietary Supplement|vitamin A supplementation|Each child received one capsule of 200,000 IU of vitamin A
102712|NCT03383731|Procedure|Group 1|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + air-fluid exchange + silicone oil infusion
102713|NCT03383731|Procedure|Group 2|the surgical method of standard 3-port 23 gauge pars plana vitrectomy + internal limiting membrane peeling + inverted internal limiting membrane insertion + air-fluid exchange
102714|NCT03383718|Procedure|Revascularisation|Percutaneous coronary intervention or coronary artery bypass surgery
102715|NCT03383718|Other|Optimal Medical Treatment/OMT|Standard of care in stable coronary artery disease or after acute myocardial infarction.
102716|NCT03383705|Device|VBeam Prima|Up to four treatments will be performed every 4-6 (±1) weeks.
102717|NCT03383692|Drug|DS-8201a|DS-8201a is provided as a sterile lyophilized powder of DS-8201a in a glass vial, which will be dissolved and administered as an intravenous (IV) solution
102718|NCT03383692|Drug|Ritonavir|Ritonavir is a OATP1B inhibitor; an antiretroviral tablet for oral administration
102719|NCT03383692|Drug|Itraconazole|Itraconazole is a CYP3A inhibitor; an antifungal tablet for oral administration
102720|NCT03383679|Drug|Darolutamide|treatment with darolutamide
102721|NCT03383679|Drug|Capecitabine|treatment with capecitabine
102722|NCT03383666|Device|PulseRider® Aneurysm Neck Reconstruction Device|Neck Reconstruction Device
102723|NCT03383640|Other|Active exercises|Active flexion movements every waking hour of the replanted digits
102799|NCT03383068|Drug|Acarbose 100 MG|for metformin uneffective subjects, using acarbose for 3 months
102800|NCT03383068|Drug|Exenatide|for metformin uneffective subjects, using Exenatide for 3 months
102724|NCT03383627|Device|Continuous Glucose Monitoring|"The FreeStyle Libre Pro Flash Glucose Monitoring System is a professional continuous glucose monitoring (CGM) device indicated for detecting trends and tracking patterns in persons (age 18 and older) with diabetes. The Freestyle Libre Pro device is FDA approved (PMA# P150021). Participants will use the FreeStyle Libre Pro Flash Glucose Monitoring device according to its approved use, on the back of the arm.~CGM monitoring will be performed on Day 1 by placing the Freestyle Libre Pro on research subjects for intended use of 14 days.~Subjects will be advised to return to the research site on Day 14 to remove the CGM device for analysis."
102725|NCT03383614|Drug|LSF emodepside (BAY 44-4400) oral solution (1mg/mL)|LSF emodepside (BAY 44-4400) oral solution (1mg/mL) or matching placebo
102726|NCT03383601|Other|Heated Tobacco product IQOS/heatstick|Heated Tobacco Products: heatsticks heated by iQOS device
102727|NCT03383601|Other|Smoking combustible cigarettes|Current smoking of combustible cigarettes
102728|NCT03383588|Drug|Bupivacaine|20 ml subcutaneous bupivacaine (Marcaine) 0.25%. Bupivacaine is an anesthetic which can numb an area of the body to relieve pain during surgery or medical procedures, childbirth, and dental work.
102729|NCT03383588|Drug|Morphine|intrathecal morphine (Duramorph) 150mcg. DURAMORPH (morphine injection) is a systemic narcotic analgesic for administration by the intravenous, epidural or intrathecal routes. It is used for the management of pain not responsive to non-narcotic analgesics. DURAMORPH (morphine injection) administered epidurally or intrathecally, provides pain relief for extended periods without attendant loss of motor, sensory or sympathetic function.
102730|NCT03383588|Drug|Fentanyl|intrathecal fentanyl 10 mcg. Fentanyl (also spelled fentanil) is an opioid which is used as a pain medication and together with other medications for anesthesia.
102731|NCT03383588|Drug|Epinephrine|Epinephrine injection is used along with emergency medical treatment to treat life-threatening allergic reactions caused by insect bites or stings, foods, medications, latex, and other causes. Epinephrine is in a class of medications called alpha- and beta-adrenergic agonists (sympathomimetic agents). It works by relaxing the muscles in the airways and tightening the blood vessels.
102732|NCT03383588|Other|Saline solution|20 ml subcutaneous NACL 0.9% - saline solution is the placebo
102733|NCT03383575|Drug|Azacitidine|Given IV or SC
102734|NCT03383575|Drug|Enasidenib|Given PO
102735|NCT03383575|Other|Quality-of-Life Assessment|Ancillary studies
102736|NCT03383562|Procedure|operation in different stages of the day|operation was arranged in the morning ,afternoon or at night
102737|NCT03383549|Other|Tele-rehabilitation|Each subject undergoes a combined rehabilitation protocol, which will be administered on a daily basis, designed to alternate physical exercises and cognitive training. Each daily session lasts between 30 and 45 minutes. The complete protocol lasts 8 weeks.
102738|NCT03383523|Drug|Emodepside (BAY 44-4400)|2 tablets compared to the liquid formulation
102739|NCT03383510|Other|Climate friendly diet|Participants in the 'Climate friendly' group will be assigned a diet generating low emissions of greenhouse gases. The target is to reduce the participants' diet-related carbon dioxide equivalents (CO2e) to 2.5 kg per person and day, which is approximately a reduction by 50% compared the average CO2e, according to a previous study on diet-related CO2e in Sweden. The participants will be instructed to reduce their consumption of beef and dairy products and increase their consumption of plant-foods i.e. fruits, vegetables, legumes and whole-grain cereals.
102740|NCT03383510|Other|Organic diet|Participants in the 'Organic group' will be assigned an organic diet with very low, or no, content of pesticides. The participants will be instructed to replace at least 50% of their food intake with organic foods.
102741|NCT03383510|Other|Climate friendly and organic diet|The participants in the 'Climate friendly and organic diet group' will be assigned a combination of a climate friendly and organic diet generating low emissions of greenhouse gas and having very low levels of pesticides. The target is to reduce the participants' diet-related CO2e to 2.5 kg per person and day. The participants will be instructed to replace at least 50% of their food intake with organic products.
102742|NCT03383510|Other|Control group (Control diet)|"A conventional diet according to the Nordic Nutrition Recommendations (NNR). The participants will get information about the present dietary guidelines and how they can adhere to the guidelines, for example, by implementing the plate model for meals and learning about recommended levels of intake of macronutrients, micronutrients, fiber and energy."
102743|NCT03383484|Other|OMT|Weekly manipulation of Chapman points and rib raising techniques (osteopathic manipulative treatment)
102744|NCT03383484|Other|Yoga|Yoga practice 3 times per week for 1 hour each time; hatha yoga poses, asanas, and breathing techniques
102745|NCT03383471|Biological|Invossa K Inj.|Invossa K Inj.
102746|NCT03383471|Drug|Placebo|Placebo control
102749|NCT03383445|Procedure|Edwards|The TAVR procedure will be performed with the Edwards SAPIEN XT or SAPIEN 3 valve (20 0r 23 mm).
102750|NCT03383445|Procedure|CoreValve|The TAVR procedure will be performed with the CoreValve Evolut R valve system (23 or 26 mm).
102751|NCT03383445|Procedure|Standard|The choice of the type and size of valve, utilization of additional procedures such as root enlargement will be left at the discretion of heart team of the treating the patient.
102752|NCT03383432|Device|Intrauterine device|Copper T 380 A
102753|NCT03383432|Radiation|Ultrasound|Transabdominal ultrasound
102754|NCT03383432|Procedure|uterine sounding sparing technique|we will insert intrauterine device without using the uterine sound and we will replace this step by ultrasound before insertion
102755|NCT03383419|Drug|Epclusa|If and when these recipients develop confirmed viremia by HCV PCR, Epclusa® therapy will be administered for a 12-week course.
102756|NCT03383406|Drug|Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy|"Every cycle(4weeks)~Subject will receive Ifosfamide 1.5 g/m2 over 2 hours for Day1~Day5 by Intravenous infusion, Etoposide 150 mg/m2 over 3 hours on Day1~Day3 by Intravenous infusion, Cytarabine 100 mg/m2 over 1 hour on Day1~Day3 by Intravenous infusion."
102757|NCT03383393|Drug|Intracoronary bolus of adenosine (adenocor), Integrilin (eptifibatide) or nitroglyzerin (nitronal)|intracoronary drugs
102801|NCT03383068|Drug|Orlistat|for metformin uneffective subjects, using Orlistatfor 3 months
102758|NCT03383380|Drug|Rapamycin|Gain-of-function (GOF) PIK3CD mutations lead to PI3Kδ hyperactivity, with the downstream mediators Akt and mTOR hyperphosphorylated. The mammalian/mechanistic target of rapamycin inhibitor rapamycin may be effective to control the progress of this disease.
102759|NCT03383367|Behavioral|Tempo Colo|Reminder letter for people at high risk of colorectal cancer.
102760|NCT03383354|Other|Sleep-related disturbances (exposure)|Sleep-related disturbances such as sleep-disordered breathing (e.g. sleep apnea), sleep fragmentation, abnormal sleep architecture, and periodic limb movements (PLMs)
102761|NCT03383341|Dietary Supplement|Cricket Protein Powder|Cricket powder was supplied by Entomo farms and consists of roasted and milled whole crickets.
102762|NCT03383341|Other|Placebo control|Placebo controls consisted of intervention foods (muffin and smoothie powder packet) that were visually and organoleptically similar to cricket-containing foods but contained no cricket powder.
102763|NCT03383328|Drug|NSAID + prednisolone, preoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
102764|NCT03383328|Drug|NSAID + prednisolone, postoperative|Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
102765|NCT03383328|Drug|NSAID, preoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
102766|NCT03383328|Drug|NSAID, postoperative|Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
102767|NCT03383328|Drug|Drop-less surgery|A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
102768|NCT03383315|Drug|Tramadol|One dose of intravenous tramadol 50mg
102769|NCT03383315|Drug|Metoclopramide|One dose of intravenous metoclopramide 10mg
102770|NCT03383315|Drug|Placebo|Sodium chloride 0.9%
102771|NCT03383302|Radiation|Stereotactic body radiotherapy|Patients will receive a total of 54 Gy if delivered in 3 fractions or 55 Gy if delivered in 5 fractions.
102772|NCT03383302|Drug|Nivolumab|Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody, that binds to the PD-1 receptor and blocks interaction with its ligands PD-L1 and PD-L2. Nivolumab will be given every 14 days at a flat dose of 240 mg, to be administered as a 30 minute IV infusion.
102773|NCT03383289|Other|R-REM training|three training modules for front-line long-term care staff to aid in recognition, management and reporting of R-REM
102774|NCT03383276|Drug|IL-1Ra|custom eye drop to be applied to the left eye.
102775|NCT03383250|Dietary Supplement|Normal meal|
102776|NCT03383237|Drug|Apatinib|500mg/d,q.d.,p.o.
102777|NCT03383224|Other|genotype-guided therapy|treatment based on patient's CHRNA5 rs16969968 genotype
102778|NCT03383224|Drug|Nicotine patch|
102779|NCT03383224|Behavioral|Smoking cessation counseling|
102780|NCT03383211|Other|RNAseq|Transcriptome profiling of peripheral blood using RNA sequencing technology
102781|NCT03383198|Drug|Liposomal bupivacaine right injection|Right side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the left side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
102782|NCT03383198|Drug|Liposomal bupivacaine left injection|Left side will have liposomal bupivacaine ultrasound guided PEC II field block injection ; the right side side will have bupivacaine plus dexamethasone ultrasound guided PEC II field block injection.
102783|NCT03383185|Device|Intrauterine device|Use of Intrauterine device during the follow-up period
102784|NCT03383185|Drug|Combined Oral Contraceptive|Use of combined oral contraceptive during the follow-up period
102785|NCT03383185|Drug|Progestin-only pills|Use of progestin-only pills during the follow-up period
102786|NCT03383185|Drug|Depot-Medroxyprogestereone Acetate|Use of depot-medroxyprogesterone acetato during the follow-up period
102787|NCT03383172|Behavioral|I Can Problem Solve (ICPS) Program|The 59 sessions of ICPS program explicitly promote cognitive regulation, solving social problems, and emotional learning skills.
102788|NCT03383146|Drug|Relamorelin|Relamorelin 10 μg injected twice daily for 52 weeks.
102789|NCT03383146|Drug|Placebo|Placebo injected twice daily for 2 weeks or 52 weeks.
102790|NCT03383133|Drug|SULT Allosteric Inhibition|A single, therapeutic dose of acetaminophen (APAP, 1.0 g)) or dehydroepiandrosterone (DHEA, 75 mg) is taken orally (with 375 ml of water) either alone or simultaneously with a single, oral, therapeutic dose of mefenamic acid (MEF, 0.75 g). In total, 5 experiments will be performed. Each experiment is performed in duplicate. Compounds are taken prior to eating breakfast. One hour later, the patient has a light breakfast and eats normally thereafter. Urine samples are collected at 15', 30', 1 h, 2h, 3h, 4h, 5 h, 6h, 7h, 8h, 9h, 10h, 11h, and 12h intervals following dosing. The samples are weighed. A 10 ml aliquot is taken from each time point and the aliquots are stored at -20 °C. Samples (0.5 ml) are then transferred to NMR tubes spectra are taken to assess drug metabolites in urine.
102791|NCT03383120|Device|Laser treatment|Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.
102792|NCT03383120|Procedure|Surgical treatment with adjunctive systemic antibiotics|Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
102793|NCT03383094|Drug|Pembrolizumab|Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles
102794|NCT03383094|Radiation|Radiation therapy|70 Gy in 33-35 fractions
102795|NCT03383094|Drug|Cisplatin|100 mg/m2 Weeks 1, 4, and 7.
102796|NCT03383081|Biological|Low dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 * 10^7 cells (5ml);
102797|NCT03383081|Biological|High dose mesenchymal stem cells|Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 * 10^7 cells (5ml)
102798|NCT03383081|Procedure|Intraarticular injection|Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
102804|NCT03383042|Drug|Cohort 1 (JP-1366 A mg)|Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg
102805|NCT03383042|Drug|Cohort 2 (JP-1366 B mg)|Drug: JP-1366 B mg or JP-1366 Placebo or Esomeprazole 40 mg
102806|NCT03383042|Drug|Cohort 3 (JP-1366 C mg)|Drug: JP-1366 C mg or JP-1366 Placebo or Esomeprazole 40 mg
102807|NCT03383042|Drug|Cohort 4 (JP-1366 D mg)|Drug: JP-1366 D mg or JP-1366 Placebo or Esomeprazole 40 mg
102808|NCT03383042|Drug|Cohort 5 (JP-1366 E mg)|Drug: JP-1366 E mg or JP-1366 Placebo or Esomeprazole 40 mg
102809|NCT03383042|Drug|Cohort 6 (JP-1366 F mg)|Drug: JP-1366 F mg or JP-1366 Placebo or Esomeprazole 40 mg
102810|NCT03383042|Drug|Cohort 7 (JP-1366 G mg)|Drug: JP-1366 G mg or JP-1366 Placebo or Esomeprazole 40 mg
102811|NCT03383042|Drug|Cohort 8 (JP-1366 H mg)|Drug: JP-1366 H mg or JP-1366 Placebo or Esomeprazole 40 mg
102812|NCT03383042|Drug|Cohort 9 (JP-1366 I mg)|Drug: JP-1366 I mg or JP-1366 Placebo or Esomeprazole 40 mg
102813|NCT03383029|Behavioral|iEAT Program|The iEAT Program is a six-month long behavioral intervention consisting of 10 biweekly outpatient appointments of about 1 hour in length. The iEAT manual will guide behavioral intervention targeting severe feeding disorders and will involve some combination of escape extinction, reinforcement, and antecedent manipulation of food presentation to lessen the aversive quality of the meal.
102814|NCT03383016|Other|Lifestyle questionnaires|
102815|NCT03383016|Diagnostic Test|Prostate Biopsy|Possible follow-up by an urologist at 1 year and 2 years after recruitment. After 2 years, proposal for a 2-year end-of-study prostate biopsy to assess the presence or absence of prostate cancer.
102816|NCT03383003|Drug|Nexium|Esomeprazole ( Nexium )40 mg tid daily for 14 days in the high dose dual therapyarm and 40 mg bid daily for 7 days in the non-bismuth quadruple therapy
102817|NCT03383003|Drug|Amolin|Amoxicillin 750 mg qid daily for 14 days in the high dose dual therapy and amoxicillin 1 g bid daily for 7 days in the non-bismuth quadruple therapy
102818|NCT03383003|Drug|Klaricid|clarithromycin 500 mg bid daily for 7 days in the non-bismuth quadruple therapy
102819|NCT03383003|Drug|Flagyl|Metronidazole (Flagyl) 500 mg tid daily for 7 days in the non-bismuth quadruple therapy
102820|NCT03382990|Device|DES or BMS|DES or BMS placement during the procedure of PCI in patients with AMI is depend on the operator's decision.
102821|NCT03382977|Biological|VBI-1901|The vaccine is formulated with GM-CSF and administered intradermally (ID).
102822|NCT03382964|Biological|VLA1553|I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
102823|NCT03382938|Drug|Dexmedetomidine|WOUND INFILTRATION IN CESAREAN SECTION
102824|NCT03382938|Drug|Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
102825|NCT03382938|Drug|Dexmedetomidine - Ropivacaine|WOUND INFILTRATION IN CESAREAN SECTION
102826|NCT03382938|Other|0,9% saline|placebo WOUND INFILTRATION IN CESAREAN SECTION
102827|NCT03382925|Procedure|cervical interlaminar with lidocaine|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL 1% lidocaine.
102828|NCT03382925|Procedure|cervical interlaminar with normal saline|Interlaminar cervical epidural steroid injection at the C7-T1 level with triamcinolone 80 mg (40 mg/mL) + 2 mL preservative saline
102829|NCT03382925|Drug|Lidocaine|2 mL lidocaine to be used as steroid diluent in group #1 cervical interlaminar procedure.
102830|NCT03382925|Drug|Triamcinolone Acetonide|2 mL of 40 mg/mL will be used as the steroid in group #1 and group #2 cervical interlaminar procedures.
102831|NCT03382925|Drug|Normal saline|2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
102832|NCT03382912|Biological|Pegilodecakin|Pegilodecakin plus Nivolumab
102833|NCT03382912|Drug|Nivolumab|Nivolumab Alone
102834|NCT03382899|Biological|Pegilodecakin|Pegilodecakin plus Pembrolizumab
102835|NCT03382899|Drug|Pembrolizumab|Pembrolizumab Alone
102836|NCT03382886|Drug|Nivolumab|"Nivolumab will be administered as a 240mg IV infusion given once every two weeks (+/- 3 days).~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
102837|NCT03382886|Drug|Bevacizumab|"Bevacizumab will be administered as an IV infusion from 1-10mg/kg in accordance with the appropriate subject cohort being examined as described below:~Dose level 1: 5 mg/kg intravenously once every two weeks Dose level 2: 10 mg/kg intravenously once every two weeks Dose level -1: 1 mg/kg intravenously once every two weeks~Dosing is based on actual body weight. There is no dose adjustment for obese or frail individuals. Dosing is recalculated if patient weight changes by more than 10% as reviewed by the principal investigator.~Subjects will remain on study treatment for up to two years or until progression or excessive toxicity"
102838|NCT03382873|Behavioral|Group Lifestyle Balance (GLB)|"The intervention includes the following key features: 1) individual case managers or lifestyle coaches; 2) frequent contact with participants; 3) a structured, state-of-the-art, 16-session core-curriculum that teaches behavioral self-management strategies for weight loss and physical activity; 4) a more flexible maintenance intervention, combining group and individual approaches and motivational campaigns; 6) individualization through a toolbox of adherence strategies; and 7) tailoring of materials and strategies utilizing a network of training, feedback, and support."
102839|NCT03382873|Behavioral|Group Lifestyle Balance Plus (GLB+)|The GLB+ intervention arm will include participants who did not achieve the targeted percentage of weight loss by week 5, and will add enhanced training to the program that will focus on values clarification, mindful decision making, planning, and problem solving.
102840|NCT03382860|Diagnostic Test|Fundus videos|Recordings of fundus videos
102841|NCT03382847|Combination Product|Transplant with HCV positive donor, followed by surveillance and treatment of viremia|Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
102842|NCT03382834|Drug|Tamoxifen|20 mg orally
102843|NCT03382834|Drug|Vorinostat|400 mg orally
102844|NCT03382834|Drug|Antiretroviral drugs|Participants will receive antiretroviral (ARV) drugs provided by their own doctors. ARV drugs will not be provided by the study.
102845|NCT03382821|Procedure|Transforaminal ESI with dexamethasone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with dexamethasone sodium phosphate 1.5 mL (10 mg/mL) and 1 ml 1% lidocaine (total volume 2.5 mL).
102971|NCT03381781|Drug|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
102846|NCT03382821|Procedure|Transforaminal catheter-targeted ESI with triamcinolone|Catheter-targeted ESI via interlaminar access at the C7-T1 level with triamcinolone acetonide 2 mL (40mg/mL) and 1 ml 1% lidocaine (total volume 3 mL).
102847|NCT03382821|Drug|Dexamethasone Sodium Phosphate 10 MG/ML|Transforaminal ESI with dexamethasone 1.5 mL of dexamethasone sodium phosphate in group #1
102848|NCT03382821|Drug|Lidocaine|1 mL of 1% lidocaine as diluent for the steroid in both group #1 and group #2
102849|NCT03382821|Drug|Triamcinolone Acetonide 40mg/mL|Transforaminal catheter-targeted ESI with triamcinolone acetonide 2 mL in group #2
102850|NCT03382808|Behavioral|SEE Training|Participants are first presented with a fixation cross which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a neutral and a fearful image (face) of the same model identity. The fearful expression is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with neutral and 75% fearful expressions only in the first session; the intensity of the fearful cue is successively decreased by 15% at every subsequent session.
102851|NCT03382808|Behavioral|GAZE Training|Participants are first presented with a fixation cross, which indicates the beginning of a trial and is immediately followed by a bilateral presentation of a direct gaze-image (neutral face) and an image of a neutral face (same model identity) displaying deviated gaze. The averted gaze-face is always replaced by an arrow pointing to the left or the right which remaines active until the participant indicates via button-press which direction the arrow is pointing to. The model identity, the position of the fearful cue and the arrow probe direction are pseudo-randomized across trials with no more than three identical sequential occurrences on each parameter. Each session consists of 360 trials in total, with 120 distinct trial types and three repetitions. Participants are trained with direct and 100% averted gaze images only in the first session; the intensity of the deviated gaze cue is successively decreased by 20% at every subsequent session.
102852|NCT03382795|Drug|EGFR|Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.
102853|NCT03382782|Behavioral|BWLI|"BWLI includes group weight management classes, physical activity classes, individual sessions with a facilitator to address goals and barriers to weight loss, and weigh-ins.~A punch card system will be implemented to incentivize participation for BHL classes. Each participant from the BWLI condition will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in."
102854|NCT03382782|Behavioral|BWLI & Peer Navigator|Participants receive the BWLI condition and partner with a peer navigator. Peer navigators will meet individually and face-to-face with participants to address their health and weight goals (i.e. working on BWLI homework, attending health care appointments, and facilitating diet and exercise activities). A punch card system will be implemented to incentivize participation for BHL classes. Each participant from BWLI & Peer Navigator will be given a punch card, each punch card contains 10 spaces of punches, and will receive a punch at the end of each class (either BHL or physical activity) they attend. No punch will be given if they are more than 15 minutes late for BHL class or more than 5 minutes late for physical activity class. Participants can earn $5 per punch for up to $250. They will be allowed to cash in for $50 Visa gift card every 10 punches. They cannot cash in for a partially filled card. They must have the 10 full punches to cash in.
102855|NCT03382782|Behavioral|Integrated Care|Participants receive integrated physical and mental health care from their usual provider.
102856|NCT03382769|Device|Cochlear implantation|Unilateral implantation with a commercially approved Nucleus cochlear implant
102857|NCT03382756|Dietary Supplement|High fat diet|A diet consisting of more than 900kcal and 35% of fat
102858|NCT03382756|Drug|CKD-337|Test Drug
102859|NCT03382743|Drug|Endocervical Lidocaine spray|5 sprays of endocervical Lidocaine spray (10%) is used 3 minutes before office hysteroscopy
102860|NCT03382730|Other|Chlorhexidine Mouth Rinse|Oral chlorhexidine gluconate oral rinse
102861|NCT03382730|Other|Chlorhexidine Mouth Rinse De-Adoption|Multifaceted education and audit/feedback.
102862|NCT03382717|Device|Excilor Forte|1 application per day during 6 months
102863|NCT03382717|Drug|Loceryl 5%|1 application per week during 6 months
102864|NCT03382704|Diagnostic Test|Examination for presence or absence of lanugo hairs|Pre-operative examination for presence or absence of lanugo hairs
102865|NCT03382691|Device|blood pressure check|Check blood pressure using new device and conventional device alternatively. Compare blood pressure measured with new device and conventional device.
102866|NCT03382639|Drug|TAK-831|TAK-831 tablets.
102867|NCT03382639|Drug|Placebo|TAK-831 placebo-matching tablets.
102868|NCT03382626|Device|anodal tDCS|Anodal tDCS will be applied on the left prefrontal cortex dorsolateral (F3 area using International 10-20 system for EEG electrode placement) with the following parameters: electrode size of 25-35 cm², 2mA, 0.057 mA/cm² and duration of 20 minutes. The cathode will be placed over the supra-orbital region.
102869|NCT03382626|Device|Computer-assisted training|The computer-assisted cognitive training will consist of games with visual and auditory stimuli to improve working memory, attention, and executive function. The games will be Genius and Labyrinth games, reaction time and timing-coincident.
102870|NCT03382626|Device|sham tDCS|Sham tDCS will be applied with the same parameters and electrode placement of active anodal tDCS. However, the current flow will be interrupted by the device after few seconds.
102871|NCT03382600|Biological|Pembrolizumab|200 mg Q3W on Day 1 by IV infusion
102872|NCT03382600|Drug|Oxaliplatin|130 mg/m^2 Q3W on Day 1 by IV infusion
102873|NCT03382600|Drug|TS-1|40 to 60 mg orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
102874|NCT03382600|Drug|Cisplatin|60 mg/m^2 Q3W on Day 1 by IV infusion
102972|NCT03381781|Drug|Cytarabine|15mg/m^2,hypodermic injection,q12h,d1-7
103048|NCT03381144|Drug|Placebo|Participants will receive GDC-0334-matching placebo.
102875|NCT03382587|Drug|Aflibercept (Eylea, BAY86-5321)|"Intravitreal aflibercept injections used in a routine treat and extend regimen, under which the intervals between the injections are extended if disease stability is maintained and no signs of worsening disease are observed on the injection day"
102876|NCT03382574|Biological|Denosumab|Given SC
102877|NCT03382574|Procedure|Salpingo-Oophorectomy|Undergo risk-reducing salpingo-oophorectomy
102878|NCT03382561|Drug|Carboplatin|Given IV
102879|NCT03382561|Drug|Cisplatin|Given IV
102880|NCT03382561|Drug|Etoposide|Given IV
102881|NCT03382561|Biological|Nivolumab|Given IV
102882|NCT03382548|Drug|Reducing Antibiotics treatment duration|Antibiotics should be stopped at day 3 if respiratory cultures are negative and the patients fulfill a set of stringent clinical criteria signifying cardiopulmonary stability for 48 hours. If the respiratory cultures are positive, patients who fulfill the same set of clinical criteria should have their antibiotics stopped from day 5 to 7.
102883|NCT03382548|Drug|Standard Antibiotics treatment duration|Participants in the control (long duration) arm will receive standard care, which is antibiotic treatment for at least 7 days with the exact duration decided by the primary physician.
102884|NCT03382535|Behavioral|Voice therapy|Voice therapy with direct and indirect therapy elements.
102885|NCT03382535|Behavioral|Voice therapy with carryover strategies|Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.
102886|NCT03382535|Other|Control group|No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
102887|NCT03382509|Drug|[14C]BI 1467335|Once Daily
102888|NCT03382509|Drug|BI 1467335|Twice Daily
102889|NCT03382496|Other|Non-Interventional|Non-Interventional
102890|NCT03382483|Device|Low intensity pulsed ultrasound|bone growth stimulator
102891|NCT03382470|Other|Antimicrobial stewardship advice|A basic antimicrobial stewardship team will be created at each site. The team will provide advice on the treatment of urinary tract infections and asymptomatic bacteriuria during the second half of the study.
102892|NCT03382457|Device|Transcatheter Tricuspid Valve Reconstruction|Reconstruction of the tricuspid valve through a transcatheter approach
102893|NCT03382444|Procedure|Cognitive Assessment|Each patient with have a 2 hour cognitive assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therapy
102894|NCT03382444|Diagnostic Test|Depression and Quality of Life Assessment|Each patient with have a 2 hour depression and QOL assessment at baseline, 3months after starting renal replacement therapy and 12 months after starting renal replacement therpay
102895|NCT03382431|Drug|PC786|Repeat doses
102896|NCT03382431|Drug|Placebo/vehicle|Repeat doses
102897|NCT03382418|Biological|gp145 C.6980 Vaccine|Administered by intramuscular injection in the deltoid.
102898|NCT03382418|Biological|Placebo|Sodium Chloride for Injection, 0.9%; Administered by intramuscular injection in the deltoid.
102899|NCT03382418|Biological|Aluminum Hydroxide Adjuvant|Administered by intramuscular injection in the deltoid.
102900|NCT03382405|Biological|mRNA-1647|Escalating dose levels
102901|NCT03382405|Biological|mRNA-1443|Escalating dose levels
102902|NCT03382405|Other|Placebo|Saline
102903|NCT03382392|Other|Assesment of REE in ALS patients compared to control populations and to compare six formulas commonly used to predict REE.|
102904|NCT03382379|Device|Active transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak (2 mAmp) direct current over the skull for 1200 seconds with 30 seconds ramp up to 2 mAmp, and 30 seconds ramp down at the end.
102905|NCT03382379|Device|Sham transcranial Direct Current Stimulation (tDCS)|Sham Transcranial Direct Current Stimulation (tDCS) as a device-based technology is employed by applying a very weak direct current over the skull. Sham mode will have just 30 seconds ramp up to 2 mAmp, 40 seconds on 2 mAmp stimulation and, 30 seconds ramp down with 1160 seconds no stimulation (just impedance control).
102906|NCT03382366|Diagnostic Test|Blood sampling, risk of fall evaluation, and MR acquisition.|Data will be collected on 1) bone/muscle metabolism through blood sampling, 2) risk of fall through OAK device; 3) muscle quality through MR acquisition.
102907|NCT03382353|Dietary Supplement|Nutritional supplementation|Daily consumption of Tramiprosate (100 mg) for 1 year
102908|NCT03382353|Behavioral|Educational training|16 educational lessons (twice a week): basic principles of different cognitive domains (e.g. memory, attention, perception) and educational DVD viewing.
102909|NCT03382353|Behavioral|Counselling on a brain-healthy diet|4 lessons on the principles of Mediterranean Diet lead by a nutritionist, aimed to teach how to include brain-healthy foods in daily diet (e.g. antioxidant, omega-3 fatty acids and vitamins). Each participant will receive the educational material presented.
102910|NCT03382353|Behavioral|Physical exercise training|80 sessions of physical exercise supervised by a Fitness Training Expert with the aim of achieving 150 minutes of moderate-intensity physical activity per week
102911|NCT03382353|Behavioral|Computerized cognitive training|16 cognitive training sessions (twice a week) supervised by a psychologist, aimed to improve Attention, Processing speed, Memory, Social skills and Intelligence using BrainHQ (www.brainhq.com).
102912|NCT03382340|Drug|Imx-110|a nanoparticle encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin
102913|NCT03382327|Procedure|Surgical planning|Two surgical plans will be established preoperatively. The first plan will be based on standard preoperative images (CT-scan, MRI) review. The second plan will be based on the 3D model review. Both will be compared to the actual surgery performed in the operating room.
102914|NCT03382314|Combination Product|HDDO-1614|"Combination drug (Bazedoxifene + Cholecalciferol)~Incrementally modified drug~Not market authorized product"
102915|NCT03382314|Drug|Bazedoxifene / Cholecalciferol|Co- Administration of Bazedoxifene and Cholecalciferol
102916|NCT03382301|Drug|Ciclosporin A preconditioning before renal artery stenosis dilation|Ciclosporin A perfusion (2.5 mg/kg) for 1 hour before renal artery dilation
102917|NCT03382301|Drug|NaCl preconditioning before renal artery stenosis dilation|NaCl perfusion (Saline perfusion) for 1 hour (2.5 mg/kg) before renal artery dilation
102918|NCT03382288|Device|EYESTAR 900|EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The experimental intervention is an optical, non-contact examination with the investigational device EYESTAR 900.
102919|NCT03382275|Drug|Iron Supplement|any oral or intravenous prescription iron supplement
102920|NCT03382262|Drug|FX006 32 mg|Extended-release 32 mg FX006 IA injection
102921|NCT03382262|Drug|TAcs 40 mg|Immediate-release 40mg TAcs IA injection
102922|NCT03382249|Combination Product|Sonodynamic therapy (SDT)|Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
102923|NCT03382249|Combination Product|pseudo-SDT|Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
102924|NCT03382236|Other|osteopathy|osteopathic techniques
102925|NCT03382210|Other|Enhanced recovery protocol|Standardized enhanced recovery protocol including 21 perioperative items.
102926|NCT03382197|Device|Nebulization|For inhalation of the radioaerosol a dose of DTPA-Tc99m (methionine-labeled diethylnitriaminepentaacetic acid) with 1mCi activity, associated with 10 drops of Fenoterol Bromide and 20 drops of Ipatropium Bromide diluted for a total of up to 3 ml of saline solution 0.9%. A MESH vibrating nebulizer (NIVO, Philips Respironics, Murrysville, Pennsylvania) will be used.
102927|NCT03382197|Device|Positive expiratory pressure valve|For nebulization associated with the EPAP valve will be used a non-invasive distribution system consisting of a non-toxic orofacial mask connected to a spring loaded EPAP valve. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
102928|NCT03382197|Device|Nonivasive ventilation|For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
102929|NCT03382184|Device|Fraxel Dual laser|The Fraxel DUAL 1550 nm laser will be used at 7 mJ, 8 pulses, 120 spots/cm2, treatment level 3 (9% coverage) for hair regrowth.
102930|NCT03382184|Device|Halo laser|The Halo hybrid laser will be used per protocol due to its dynamic thermal optimization technology for hair regrowth.
102931|NCT03382171|Other|FoodforCare at home|Five small protein rich meals that will be delivered twice a week for 3 weeks.
102932|NCT03382145|Other|No intervention|No intervention
102933|NCT03382132|Behavioral|momHealth|Mobile health program delivered via an iPad. Program delivers information and support related to breastfeeding education, Ten Steps of the Baby Friendly Hospital Initiative, healthy eating and active living topics, and depression prevention information.
102934|NCT03382132|Behavioral|Standard of Care|Participants will receive standard health care via their prenatal provider, including routine prenatal education and postpartum support.
102935|NCT03382119|Device|Ultrasound with ARFI (acoustic radiation force impulse)|This technology uses sound waves to measure the stiffness of tissue.
102936|NCT03382119|Device|Ultrasound with backscatter imaging|This ultrasound tool gathers data from the waves returning from imaged tissue.
102937|NCT03382106|Drug|Sildenafil 20 MG|Sildenafil, 20mg three times daily for 3 month period.
102938|NCT03382106|Drug|Placebo Oral Tablet|Placebo manufactured to look like Sildenafil 20 MG
102939|NCT03382093|Behavioral|Personalized Feedback Intervention|Personalized Feedback Intervention for smoking and anxiety.
102940|NCT03382093|Behavioral|Smoking Information Control|Smoking Information with no personalized feedback.
102941|NCT03382080|Other|Dream School Program|The Dream School program is a whole school program, involving staff and students, with the aim of creating learning environments where students are confident and experience a sense of belonging, and where mental health is promoted.
102942|NCT03382080|Other|Mental Health Support Team|"MHST is also a whole school project but aimed at specific students at risk of dropping out. It is a systematisation of the student services through~Co-location of services and staff working in services~One open door to increase accessibility to the services and staff for students~Focus on the transition from lower to upper secondary school~Close follow-up of students at risk to ensure tailored help to each student~Early intervention and follow up when students starts being absent from school This work demands cross- and multidisciplinary collaborations within the MHST, between MHST and school leadership, and between lower and upper secondary schools."
102943|NCT03382067|Dietary Supplement|High Epicatechin/ Melissa|Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa
102944|NCT03382067|Other|Low Epicatechin/ Oat bran|Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
102945|NCT03382041|Device|Carbon Fiber Implant|A cannulated rod, made of long carbon fiber reinforced polymer, with interlocking holes at its proximal and distal ends. The Nail provides for a slight bend. A Tantalum radiopaque marker along the Nail longitudinal axis provides for its visualization under fluoroscopy. The Nail proximal end is marked by a tantalum marker.
102946|NCT03382041|Device|Titanium Implant|An intramedullary rod, also known as an intramedullary nail (IM nail) or inter-locking nail or Küntscher nail (without proximal or distal fixation), is a metal rod forced into the medullary cavity of a bone. IM nails have long been used to treat fractures of long bones of the body
102947|NCT03382015|Other|BKR-013 or Placebo|Encapsulated L-glutamine
102948|NCT03382002|Diagnostic Test|TCL|evaluation of oxidative status
102973|NCT03381768|Biological|PD-L2 peptide|100 ug PD-L2 peptide dissolved in DMSO and water mixed with 500ul montanide.
102974|NCT03381768|Biological|PD-L2 and PD-L1 peptide|100 ug PD-L2 peptide and 100ug PD-L1 peptide dissolved in DMSO and water mixed with 500ul montanide.
102949|NCT03381989|Device|ASHI_INTECC Astato XS 20 0.014 guidewire|A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
102950|NCT03381976|Other|Intervention 2X/week (G2X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
102951|NCT03381976|Other|Intervention 3X/week (G3X)|Participants performed resistance training (RT) composed of eight exercises performed for one set of 10-15 repetition maximum (RM). The rest interval between exercises was 2-3 min. Participants were instructed to control the speed of movement in the ratio of 1:2 for concentric and eccentric muscle actions, respectively. The progression of training loads in each exercise occurred, when a participant completed 15 repetitions in two consecutive sessions, with increases of 2-5% in exercises for the upper limbs, and 5-10% in exercises for the lower limbs. At the end of each session, one static stretching exercise at the point of discomfort for 15 seconds was performed for all major muscle groups for a total of exercises. Participants were asked not to perform any other type of organized physical exercise during the entire study period.
102952|NCT03381937|Other|speech trial|speech trial during different ventilation conditions
102953|NCT03381924|Other|Educational programme|In each session, neuroscience-based information on the neurophysiology of pain and migraine were provided with audio-visual support.
102954|NCT03381924|Other|Routine clinical practice|Patients allocated to the control group will only receive the drugs used in the habitual clinical practice
102955|NCT03381911|Other|Embodied Conversational Agent|The Embodied Conversational Agent (ECA) is a computer generated character that can interact with study subjects through a touch screen computer. The ECA is programmed to respond with relevant speech and body language to a subject's responses.
102956|NCT03381898|Behavioral|Telehealth Exercise, speech therapy, medication management|Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
102957|NCT03381885|Behavioral|Gentle Nudge|Clinicians ordering medium or high scoring imaging studies could bypass the usual mandatory phone call to radiology.
102958|NCT03381885|Behavioral|Usual Standard Procedure|Clinicians ordering imaging studies required mandatory phone to radiology
102959|NCT03381872|Procedure|Percutaneous coronary intervention for complex lesion|"In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms~Intravascular imaging arm~Angiography arm~Definition of Complex Lesions~True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size~Chronic total occlusion (≥3 months) as target lesion~PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)~Implanted stent length ≥38mm~Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)~Multiple stent needed (≥3 more stent per patient)~In-stent restenosis lesion as target lesion~Severely calcified lesion (encircling calcium in angiography)"
102960|NCT03381872|Device|Drug-eluting stent|All patient will be received percutaneous coronary intervention with second generation drug-eluting stent.
102961|NCT03381872|Device|Intravascular imaging (IVUS or OCT)|"IVUS Reference site: Largest lumen, Plaque burden <50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter~OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: [1] By measuring vessel diameter at the distal reference sites (in case of ≥180 of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25mm [2] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25mm."
102962|NCT03381859|Drug|Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]|Hepatitis C Virus direct-acting antiviral
102963|NCT03381846|Procedure|MOHS micrographic surgery|Mohs surgery is a precise surgical technique used to treat skin cancer. Thin layers of cancer-containing skin are progressively removed and examined microscopically until only cancer-free tissue remains.
102964|NCT03381846|Procedure|Wide local excision|A surgical technique in which the skin cancer is excised along with 2-3 cm of clinically normal appearing surrounding tissue.
102965|NCT03381833|Drug|LJPC-401|subcutaneous injection, up to 40 mg weekly from week 26 to 52
102966|NCT03381833|Drug|LJPC-401|subcutaneous injection, up to 40 mg weekly from week 1 to 52
102967|NCT03381820|Other|instrumental folk music|The music was composed and edited by a professor of Folk Musical Department, Faculty of Arts, Khon Kaen University. There were total of 6 songs, 32-minute length. The music was slow-instrumental, 60-80 beats per minute and ranged between 40-60 decibel levels.
102968|NCT03381807|Biological|hAECs|100 million hAECs is infused into uterine cavity after TCRA.
102969|NCT03381794|Procedure|Corneal transplantation|PKP: Penetrating Keratoplasty DALK: Deep Anterior Lamellar Keratoplasty DMEK: Descemet Membrane Endothelial Keratoplasty DSAEK: Descemet's Stripping Automated Endothelial Keratoplasty
102970|NCT03381781|Drug|Decitabine|20mg/m^2,d1-5,ivgtt,28days as a duration
102975|NCT03381755|Drug|half-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 45mg bidpo. in Chinese ACS patients undergoing PCI.
102976|NCT03381755|Drug|standard-dose ticagrelor|To observe the effectiveness and safety of ticagrelor 90mg bidpo. in Chinese ACS patients undergoing PCI.
102977|NCT03381742|Drug|Ticagrelor|ticagrelor 45 mg twice daily for 5 consecutive days at least.
102978|NCT03381742|Drug|ticagrelor|ticagrelor 90 mg once daily for 5 consecutive days at least.
102979|NCT03381742|Drug|ticagrelor|ticagrelor 90 mg twice daily for 5 consecutive days at least.
102980|NCT03381742|Drug|clopidogrel|clopidogrel 75 mg once daily for 5 consecutive days at least.
102981|NCT03381729|Biological|Onasemnogene Abeparvovec-xioi|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
102982|NCT03381716|Drug|drug|Application bracket
102983|NCT03381716|Procedure|Surgery|Surgery
102984|NCT03381703|Drug|YH12852|YH12852 administration
102985|NCT03381703|Drug|14C-labeled YH12852|14C-labeled YH12852 administration
102986|NCT03381690|Procedure|Epidural labor analgesia|Epidural catheter was inserted for labor analgesia using an 18-gauge Tuohy needle and a 20 gauge epidural catheter. In our institute, for epidural labor analgesia, 10 ml bolus of 0.075% levobupivacaine mixed with fentanyl 2 μg/ml was administered and same regimen was continuously infused by patient-controlled epidural analgesia (infusion rate : 10 ml/hr, bolus : 4 ml, lockout time: 30 min).
102987|NCT03381677|Device|Pedicle Lengthening Osteotomy with Altum® Device|Decompressive surgery via Pedicle lengthening osteotomy using Altum Device. Altum is intended for pedicle lengthening to correct degenerative lumbar spinal stenosis in the presence of a grade 1 degenerative spondylolisthesis. The Altum bone saw is designed for creating an osteotomy at the base of each pedicle. The Altum implant is designed for distraction of the pedicle osteotomy and for lengthening of the pedicles. Altum is appropriate for skeletally mature adults with symptomatic stenosis at one or two levels between L2-L5.
102988|NCT03381677|Device|Control|"Decompressive surgery via open surgical decompression and Transforaminal Lumbar Interbody Fusion (TLIF) with implantation of bilateral pedicle screws (4 screws) and rods (2 rods) and an interbody fusion cage (1 PEEK fusion cage, coated or uncoated):~DePuy Synthes Expedium® 5.5 System or Medtronic CD Horizon Solera 5.5 System or Innovative Surgical Designs True System for fixation; and~DePuy Synthes TLIF cage, Metronic TLIF cage or Meditech Talos TLIF cage."
102989|NCT03381664|Drug|AVP-923|capsule
102990|NCT03381651|Radiation|Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation|50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
102991|NCT03381651|Radiation|Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation|41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
102992|NCT03381638|Device|Blink Reflexometer|The device uses 5 light puffs of air to the side of the eye causing a blink reflex that is captured by the high-speed camera tracking the eyelids.
102993|NCT03381625|Drug|BMX-010|Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.
102994|NCT03381625|Drug|Placebo|Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
102995|NCT03381599|Drug|Filgrastim Injection|Filgrastim of 10 ug/kg/day will be given for four serial days.
102996|NCT03381586|Drug|ALT-803|Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
102998|NCT03381547|Biological|Pegilodecakin|Pegilodecakin Alone
102999|NCT03381534|Device|stenting with EPD|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
103000|NCT03381534|Device|stent assisted angioplasty|participants will be randomly assigned to control group or experimental group,patients in control group will be undergone stenting of vertebral artery origin without embolic protection device,patient in experimental group will be undergone stenting of vertebral artery origin with embolic protection device
103001|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
103002|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
103003|NCT03381521|Procedure|Ultrasound-guided nerve hydrodissection|Ultrasound-guided nerve hydrodissection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
103004|NCT03381521|Device|Ultrasound|The ultrasound was used to measure cross-sectional area and injection guidance
103005|NCT03381521|Drug|Normal saline|The normal saline was used for injection solution
103006|NCT03381508|Device|Brizzy continuous positive pressure device|Patients are treated with the Brizzy continuous positive pressure device, including pneumotachograph.
103007|NCT03381495|Drug|Ropivacaine Hydrochloride, Sufentanil|In this research one group will receive epidural analgesia(Ropivacaine Hydrochloride, Sufentanil), data will be collected and analyzed between this group and non-epidural analgesia group.
103008|NCT03381482|Diagnostic Test|CSF drawing during spinal anaesthesia|4mL of CSF by lumbar puncture
103009|NCT03381482|Diagnostic Test|Fasting blood sample|6x5 mL of fasting blood sample
103010|NCT03381482|Diagnostic Test|Lumbar puncture|10 mL of CSF by lumbar puncture
103011|NCT03381469|Procedure|Comprehensive periodontal treatment|The Case group participants will receive non-surgical periodontal therapy that will be completed by the end of week 20-21 of gestation. This will consist of oral hygiene instruction with comprehensive periodontal treatment which will include excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth followed by supragingival and subgingival scaling and root planing (SRP) of sites with PDs > 4 mm and polishing of all the teeth. Participants will be offered treatment under local anesthetic when necessary. No limits will be imposed on the number of dental visits needed to accomplish periodontal therapy.
103012|NCT03381469|Procedure|single visit supragingival scaling|The control and Placebo group participants will receive oral hygiene instruction and supragingival cleaning of all teeth at their baseline visit.
103013|NCT03381456|Other|LICI|Paired pulse TMS to measure LICI and late cortical disinhibition
103014|NCT03381443|Other|different assessments|coded survey about NTS and assessment
103015|NCT03381430|Drug|Gefitinib|Gefitinib 250 mg/day oral daily
103016|NCT03381417|Drug|pegcyte|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
103017|NCT03381417|Drug|Neulastim|Eligible patients are scheduled to receive three cycles of chemotherapy every two weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
103018|NCT03381404|Drug|[14C] MT-8554|14-C MT-8554
103019|NCT03381391|Behavioral|Personalized Feedback Intervention|The current intervention included personalized feedback regarding their alcohol consumption, alcohol-related consequences, gender-specific normative drinking comparisons, personal risk factors (e.g., dependence symptoms, family history of alcoholism), and alcohol expectancies. The intervention also included didactic material related to alcohol (e.g., effects at different BAC levels, tolerance) and drinking moderation strategies. The feedback was presented graphically in a feedback report with the individual's information.
103020|NCT03381365|Device|CuraSeal Percutaneous Intraluminal Closure System|
103021|NCT03381352|Radiation|Chemo-radiotherapy with IMRT technique|IMRT radiation technique; 50.4-54Gy/25F
103022|NCT03381352|Drug|Capecitabine|Capecitabine 825mg/m2 PO BID
103023|NCT03381352|Drug|Mitomycin C|Mitomycin C 10mg/m2 D1,29 iv
103024|NCT03381339|Device|Oscillating rotating power toothbrush|a battery powered oscillating rotating toothbrush will be used for twice daily regular home dental hygiene
103025|NCT03381326|Procedure|blood and FFPE sample collection|blood sample and Formalin-fixed paraffin-embedded (FFPE) sample collection
103026|NCT03381313|Behavioral|Conditioned word repetition training|In the classical conditioning training the onset of the visual stimulus preceded that of the auditory stimulus with a short onset asynchrony, and both stimuli co-terminated. By contrast, in the training without conditioning the auditory stimulus was administered first and the visual stimulus appeared short after the off-set of the auditory one.
103027|NCT03381300|Procedure|Ovarian tissue cryopreservation|Laparoscopic unilateral oophorectomy followed by cryopreservation of ovarian cortex tissue
103028|NCT03381287|Drug|HTD1801 Tablets, 500mg|16 participants will be randomized 3:1 to receive 500mg of either HTD1801 or placebo, bid. The treatment duration will be 4 weeks.
103029|NCT03381287|Drug|HTD1801 Tablets, 1000mg|16 participants will be randomized 3:1 to receive 1000mg tablets of either HTD1801 or placebo, bid. The treatment duration will be 4 weeks.
103030|NCT03381287|Drug|HTD1801 Tablets, 2000mg|16 participants will be randomized 3:1 to receive 2000mg of either HTD1801 or placebo, bid. The treatment duration will be 4 weeks.
103031|NCT03381274|Biological|MEDI9447|Subjects will receive MEDI9447 in combination with osimertinib or AZD4635 until disease progression
103032|NCT03381274|Drug|Osimertinib|Subjects will receive osimertinib in combination with MEDI9447 until disease progression
103033|NCT03381274|Drug|AZD4635|Subjects will receive AZD4635 in combination with MEDI9447 until disease progression
103034|NCT03381261|Drug|Botulinum toxin type A|Injection of Botulinum toxin type A in back of head
103035|NCT03381248|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
103036|NCT03381248|Biological|Hyaluronic Acid|Delivery of hyaluronic acid into knee by injection with needle to reduce knee pain
103037|NCT03381235|Other|Spin exercise|Each exercise class will consist of 20 minutes of progressive, interval based Spin exercise 2 times a week for 6 months on stationary exercise cycles and will be led by a qualified instructor. The Duration of each session is lengthened based on the progression of the participant and the recommendation of the instructor by 1-2 minutes as needed to a maximum time of 60 minutes per session. Exercise intensity will begin at low levels (50% of maximal heart rate reserve (HRR) and increase by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
103038|NCT03381222|Diagnostic Test|epiaoryic scan|Epiaortic scan will be performed by use L15-7i Phillips®. Ultrasound probe cover with sterile cover. Five standard epiaortic views will be collected
103039|NCT03381209|Drug|Sugammadex|sugammadex given based on 3 measurements of body weights
103043|NCT03381183|Drug|Durvalumab|Phase 1 and Phase 2: 1500 mg every 4 weeks (Q4wks).
103044|NCT03381183|Drug|IRX-2 Regimen|"Phase 1 and Phase 2 - Every 12 weeks - IRX-2 Regimen:~Cyclophosphamide 300 mg/m^2 - intravenously.~IRX-2: 460 units daily (4 injections of 115 units)."
103045|NCT03381170|Biological|Ublituximab|Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E
103046|NCT03381157|Other|Observational General Movements Assessments|GMs assessment has been increasingly used to predict motor dysfunction, especially the Cerebral Palsy (SP), since its introduction 25 years ago. The GMs assessment is based on the visual holistic perception of normal and abnormal movements of the body. This approach focuses on spontaneous movements of the baby rather than reflexes, tonus, and reactions
103047|NCT03381144|Drug|GDC-0334|Part 1: GDC-0334 given orally with dose escalation between cohorts, based on emerging safety and pharmacokinetic (PK) data. Parts 2 and 3: doses to be based on the safety, tolerability, and PK data generated in the study. The dosing duration in Part 3 is planned to be at least 14 days, but no longer than 28 days.
103049|NCT03381118|Drug|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D-4, -3, -2
103050|NCT03381118|Drug|Nivolumab|Nivolumab 40 mg IV infusion on D+5
103051|NCT03381118|Drug|Cytarabine|Cytarabine 500-1000 mg/m2 bid IV infusion on D+1, +2, +3
103052|NCT03381118|Drug|Nivolumab|Nivolumab 40 mg IV infusion on D+1
103053|NCT03381118|Biological|G-CSF mobilized HLA-haploidentical donor PBSC|G-CSF mobilized HLA-haploidentical donor peripheral blood stem cells IV infusion on D0
103054|NCT03381105|Diagnostic Test|PSA and Stockholm3|The new Stockholm3 test and traditional PSA test
103055|NCT03381079|Procedure|Posterior scleral reinforcement|Posterior scleral reinforcement (pPSR) is a procedure applied with autologous or biological material or synthetic materials reinforcing pole of the sclera after eyeball, in order to prevent or alleviate myopic development.
103056|NCT03381066|Drug|gefitinib, pemetrexed,cisplatin|"Intercalation phase (Duration: 3weeks x 4 cycles = 12 weeks) Pemetrexed 500mg/m2 D1, Cisplatin 75mg/m2 D1, Gefitinib 250mg D5-18, every 3week~Maintenance phase (Duration: 1 year) Gefitinib 250mg D1-2"
103057|NCT03381066|Drug|Vinorelbine, cisplatin|Duration: 3wks x 4 cycles = 12 weeks Vinorelbine 25mg/m2 D1,8, Cisplatin 75mg/m2 D1 q3week
103058|NCT03381053|Drug|Imatinib 400mg|The NIH assessment of patients with surgical excision of GIST with moderate to high risk of recurrence was recommended imatinib 400mg treatment.
103059|NCT03381040|Device|Restylane Lyft|Restylane® Lyft is a sterile gel of hyaluronic acid with lidocaine generated by Streptococcus species of bacteria, chemically cross-linked with BDDE (the cross linker), stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL. Lyft is intended to be used for facial tissue augmentation. It is recommended that the product be used for shaping the contours of the face and the correction of folds using the co-packed needles. Given the very high lift capacity of Lyft, it is often used when the skin envelope is normal or thicker than normal, as the contours of the product may be palpable in the presence of thin skin.
103060|NCT03381040|Device|Restylane Volyme|"Restylane® Volyme is a sterile, biodegradable, viscoelastic, non-pyrogenic, clear, colorless, and homogeneous soft hyaluronic acid gel with a high lifting capacity. Volyme is intended for injection into the supraperiostic zone or subcutis to augment the volume of the cheeks.~Given Volyme's viscoelastic and lifting capacities, it is best used when there is significant loss of volume and a thin skin envelope."
103061|NCT03381027|Procedure|Baby Massage|Structured massage of the baby
103062|NCT03381014|Drug|Chemotherapy, Cancer, Anthracyclines|follow up cardio-toxicity .... by speckle tracking echo and cardiac troponin
103063|NCT03381001|Procedure|embryo transfer after thaw and culture|embryos will be kept in culture after thawing for one day before transfer for the uterus
103064|NCT03381001|Procedure|embryo transfer with no culture|embryos will be transfer with no culture after thaw
103065|NCT03380988|Other|Acute test meal with fiber-enriched buckwheat pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
103066|NCT03380988|Other|Acute test meal with corn pasta|Pasta with tomato sauce (100g tomato sauce, 5g extra-virgin olive oil)
103067|NCT03380975|Drug|Montelukast 10mg|Montelukast is an orally active compound which binds with high affinity and selectivity to the CysLT1 receptor. Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity. As a result, bronchoconstriction is inhibited with decreased airway and blood eosinophil's leading to improved control over asthma and allergic rhinitis. Montelukast should be taken once daily in the evening
103068|NCT03380962|Drug|Clazakizumab|All patients will receive clazakizumab 25 mg subcutaneous injections (monthly) for a maximum of 18 injections.
103069|NCT03380949|Procedure|Opioid administration (remifentanil) in intervention group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by analgesia indices during general anesthesia in the experimental arms.
103070|NCT03380949|Procedure|Opioid administration (remifentanil) in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration (remifentanil) is guided by clinical signs in the control group.
103071|NCT03380936|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|Switching from current version of tacrolimus to the extended release, once a day version (Envarsus) and titrating dose to achieve an optimal trough level. Goal trough tac level > 8 ng/ml, MPA at 720 mg bid unless medically contraindicated, prednisone at current dose (5mg) or continue taper to 5mg per center standard of care protocol.
103072|NCT03380936|Other|Plasma Exchange and IVIG (Intravenous Immunoglobulin )|Plasma exchange x 5 treatments, each followed by IVIG 200 mg/kg except last dose of 1 gm/kg. Rituximab 375 mg/m2 following final plasma exchange treatment.
103073|NCT03380923|Behavioral|Moderate Intensity|Exercise prescription intensity is moderate
103074|NCT03380923|Behavioral|High Intensity|Exercise prescription intensity is high
103075|NCT03380910|Behavioral|Pharmacy and Behavioral Health Team|An interdisciplinary approach using medications through pharmacy support and counseling through behavioral health team members will be used to improve smoking cessation rates.
103076|NCT03380910|Behavioral|Motivational Interviewing|Patients not ready to quit will be offered motivational interviewing to increase readiness to quit.
103077|NCT03380897|Other|Intervention for outpatient group was to go home|Intervention for outpatient group was to go home and assess the the pain
103078|NCT03380897|Other|Intervention for inpatient group was to stay at ward|Intervention for inpatient group was to stay at ward and assess the pain
103079|NCT03380884|Device|Low-magnitude high-frequency vibration (LMHFV)|Low-magnitude high-frequency vibration (LMHFV) is a biophysical intervention that provides non-invasive, systemic mechanical stimulation and has been reported to have no adverse effect.
103085|NCT03380858|Device|colectomy|colectomy resection
103086|NCT03380845|Device|Fraxel Restore|Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.
103087|NCT03380845|Device|Fractora|Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.
103088|NCT03380819|Diagnostic Test|Genome sequencing|Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
103089|NCT03380806|Drug|LHRH agonist|Standard LHRH agonist for 3 years
103090|NCT03380806|Radiation|Pelvic Radiation|Pelvic Radiation
103091|NCT03380806|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT: 19.5 - 21 Gy in three fractions (1 treatment per week - over 22days)
103092|NCT03380806|Radiation|Conventional Radiotherapy (CRT) Prostate Boost|CRT: 33 - 35 Gy in 16 fractions (5 days per week - over 22 days)
103093|NCT03380793|Drug|morinidazole|morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.
103094|NCT03380780|Drug|Emicizumab|Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
103095|NCT03380767|Procedure|Trauma-induced coagulopathy treatment|Transfusion as needed according to the assay methodology
103096|NCT03380754|Dietary Supplement|Nutricia preOp|A clear, non-carbonated lemon-flavored, iso-osmolar carbohydrate drink for preoperative surgical patients. Used in studies supporting the Enhanced Recovery After Surgery (ERAS) Society Consensus Guidelines.
103097|NCT03380754|Other|Nestle Splash Lemon Flavor Water (Placebo)|Placebo control drink. PURIFIED WATER, NATURAL FLAVORS, CITRIC ACID, SODIUM POLYPHOSPHATE, POTASSIUM SORBATE (PRESERVE FRESHNESS), POTASSIUM BENZOATE (PRESERVE FRESHNESS), SUCRALOSE, ACESULFAME POTASSIUM, CALCIUM DISODIUM EDTA, MAGNESIUM SULFATE.
103098|NCT03380741|Diagnostic Test|Tumour markers detection|Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
103099|NCT03380728|Drug|Ibogaine Hydrochloride|The first 3 patients will receive oral doses of 20 to 400 mg of ibogaine in an open-label design. If the 3 higher doses (240, 320 and 400 mg) are well tolerated, the next 9 volunteers will receive these doses or placebo randomly in 3 different groups.
103100|NCT03380715|Device|Nasal nebulisation into the right nostril|400mcl of co-phenylcaine (20mg of lidocaine + 2mg of phenylephrine) is added into the nasal nebuliser device (Rinowash Nebula, Air liquid medical systems) and the solution is diluted with 4.5cc of isotonic normal saline. This Mixture is then nebulised into the right nasal cavity for approximately 3 minutes.The seated patient's head is kept flexed and nebulizer device is kept sealed within the nasal cavity while the nebulisation is done and subsequently checking nasal resistance after nasal nebulisation.
103101|NCT03380715|Device|Nasal Spray into the right nostril|Intervention : Administration of 4 sprays of nasal decongestions(Co-Phenylcaine(400mcl) (20mg lidocaine + 2mg phenylephrine) once into the right nasal cavity using a nasal spray and subsequently checking nasal resistance post nasal spray
103102|NCT03380702|Procedure|whitening photoactivation gel|35 subjects in active comparator group
103103|NCT03380702|Procedure|placebo|35 subjects in placebo comparator group
103104|NCT03380689|Drug|S-1|- S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
103105|NCT03380689|Drug|Irinotecan|- CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.
103106|NCT03380689|Drug|Bevacizumab|- Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.
103107|NCT03380663|Procedure|Remote Ischemic Conditioning (RIC)|"Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.~High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes)."
103108|NCT03380650|Device|directional atherectomy and locol drug delivery|combined use of directional atherectomy and locol drug delivery for the treatment of femoralpopliteal disease
103109|NCT03380650|Device|drug-coated balloon dilation|use of drug-coated balloon dilation for the treatment of femoralpopliteal disease
103110|NCT03380637|Other|ultrasound|Sonosite ultrasound (Sonosite, FUJIFILM M-Turbo, made in USA)
103111|NCT03380624|Drug|Refresh Optive|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose
103112|NCT03380624|Drug|Refresh Optimum OMEGA 3|Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose
103113|NCT03380611|Dietary Supplement|Wakame|Consumption of 4.8 grams wakame per day for 17 days
103114|NCT03380611|Dietary Supplement|Spirulina|Consumption of 4.8 grams spirulina per day for 17 days
103115|NCT03380611|Dietary Supplement|Control|Consumption of microcrystalline cellulose for 17 days
103116|NCT03380598|Behavioral|CLOSS|Usual care plus using mobile application's to register weight and physical activity as well as for communication with the clinic. A web-based system enables health care professionals to follow the the patient's daily weight registration online.
103117|NCT03380598|Behavioral|Usual care|Usual care. The child and parent(s) at regular visits to the nurse at the clinic
103118|NCT03380585|Procedure|Reciprocating single-file system|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.The device in the experimental group moves in CW and CCW direction with different angles. It is a single-file endodontic file system. The intervention is reciprocating single-file system. A Reciproc single-file will be used for enlarging apical foramen. In the active comparator group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
103277|NCT03379376|Other|Questionnaire Administration|Receive questionnaire
103278|NCT03379376|Procedure|Supportive Care|Undergo eHealth mindful moving and breathing
103119|NCT03380585|Procedure|Rotational multi-file system.|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged. In this group, a continuous rotational multi-file system, ProTaper Next, will be used in enlarging apical foramen.
103120|NCT03380572|Device|Senhance Assisted Cholecystectomy|Cholecystectomy performed using Senhance surgical robotic system
103121|NCT03380572|Procedure|Laparoscopic Cholecystectomy|Standard laparoscopic cholecystectomy
103122|NCT03380559|Drug|Injection, botulinum toxin + corticoid|"Intramuscular injection of botulinum toxin (Xeomin® 100 U) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
103123|NCT03380559|Drug|Injection, placebo of toxin + corticoid|"Intramuscular injection of placebo botulinum toxin (2 ml) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of corticoid (2 ml of Hydrocortancyl® 2,5 %)"
103124|NCT03380559|Drug|Injection, botulinum toxin + placebo corticoid|"Intramuscular injection of botulinum toxin (2 ml) under ultrasound control~Subcutaneous injection (lateral epicondylitis side) of placebo of corticoid (2 ml of physiological saline solution NaCL 0.9 %)"
103125|NCT03380546|Drug|Acarbose|Women will receive acarbose at an initial dose of 50 mg once daily in the beginning of the meal for which the postprandial glucose value is the highest, with progressive increase every 2 days or more: adding a pill before another meal, and then increasing dose of acarbose to 100 mg if post-prandial glucose goals are not obtained, with a maximal dose of 3 x 100 mg / day.
103126|NCT03380546|Drug|Prandial insulin|Women will receive prandial fast-acting insulin according to usual practice (routine care according to French recommendations), i.e. one injection before each meal usually.
103127|NCT03380533|Drug|Buprenorphine|Buprenorphine 10mg transdermal patch used during the first five postoperative days after arthroscopic rotator cuff repair
103128|NCT03380533|Drug|Placebo Patch|Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
103129|NCT03380533|Drug|Multimodal Oral Scheme|Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
103130|NCT03380533|Drug|Tramadol|Tramadol 50mg tablet that the patient consumes every 8 hours during the first five days
103131|NCT03380533|Drug|Placebo Tablet|Placebo tablet that the patient consumes every 8 hours during the first five days
103132|NCT03380520|Drug|Ferric Carboxymaltose|Ferric carboxymaltose will be administered according to product specification dosing
103133|NCT03380520|Drug|Placebo|IV nacl 0.9%
103134|NCT03380507|Drug|Triple therapy group|Refer to arms description
103135|NCT03380494|Other|Overhead perturbation training|A specifically chosen weight is attached to a 1m resistance band held above the head, hanging against gravity. The participant is encouraged to sustain a static position, where the weight and band provide variable magnitude perturbations to arm position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
103136|NCT03380494|Other|Non-perturbed training|A weight is grasped by the participant and elevated above head to the same position as the OPT intervention. The participant is encouraged to sustain a static position. The body position of the participant is modified to facilitate greater and lesser perturbations. Bodily movements are prescribed to encourage joint perturbation. The participant undertakes 3 sets of 25 repetitions (60s rest) and continues with variable stimulus until fatigued.
103137|NCT03380481|Other|observational only-no intervention|Observational only and no predesigned interventions in this study.
103138|NCT03380468|Drug|cisplatin plus pemetrexed|cisplatin 75mg/m2 iv; pemetrexed 500mg/m2 iv
103139|NCT03380455|Drug|Lucerastat|Single oral dose of 500 mg lucerastat under fasted conditions
103140|NCT03380455|Drug|Cimetidine|Twice daily oral dose of 800 mg cimetidine under fasted conditions
103141|NCT03380442|Drug|Psilocybin|Psilocybin ingested orally
103142|NCT03380442|Drug|Ketamine (Ketalar)|Ketamine administered intranasally
103143|NCT03380429|Drug|RELVAR/BREO|RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
103144|NCT03380429|Drug|Salbutamol|Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
103145|NCT03380429|Device|Smart phone app|Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth. The data from sensors attached to ELLIPTA DPI and MDI will be fed back to subjects via the app on their smartphone.
103146|NCT03380429|Device|HCP Dashboard|The information from sensors attached to ELLIPTA DPI and MDI will be reviewed by the subjects HCP via an online dashboard.
103147|NCT03380429|Device|Sensors|Clip on sensors will be fitted on to RELVAR/BREO ELLIPTA DPI and salbutamol MDI to electronically record the actuation data.
103148|NCT03380416|Other|Portfolio Diet|Medium-term (8 weeks ) nutritional intervention
103149|NCT03380416|Other|MUFA Diet|Medium-term (8 weeks ) nutritional intervention used as control
103150|NCT03380403|Radiation|PDT|clinical treatment of infected diabetic foot
103151|NCT03380403|Other|Ciprofloxacin|antibiotics and or surgical debridment
103152|NCT03380390|Drug|Oxymetazoline HCL 1.0% Cream|Oxymetazoline HCl cream 1.0% once daily application
103153|NCT03380390|Device|Energy-Based Therapy|Energy-based therapies (Potassium Titanyl Phosphate [KTP], Pulsed Dye Laser [PDL], or Intense Pulsed Light [IPL])
103154|NCT03380377|Drug|Clazakizumab|Clazakizumab 25 mg subcutaneous monthly x 6 doses (or max of 12 doses) will be given to patients who are enrolled in this clinical trial.
103239|NCT03379714|Device|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/ iridium radiopaque markers.
103488|NCT03377556|Other|Laboratory Biomarker Analysis|Correlative studies
103155|NCT03380364|Device|hystroscope|"Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
103156|NCT03380351|Behavioral|SCDIC interventions|The research team will characterize the intervention components and their implementation strategies.
103157|NCT03380351|Behavioral|SCDIC control groups|The research team will characterize the control settings, including patients, providers and organization.
103158|NCT03380338|Behavioral|Combined aerobic and strength exercise|
103159|NCT03380325|Drug|Iloprost infusion|Iloprost is a stable prostacyclin analogue
103160|NCT03380312|Procedure|rTARUP technique|robot-assisted rTARUP technique
103161|NCT03380286|Device|Firehawk|Firehawk stent
103162|NCT03380273|Behavioral|Implementation of the AO Trauma SSI Prevention Bundle|"AOT SSI Prevention Bundle~Preventive measure~Antibiotic prophylaxis~Perioperative antibiotics~Oxygen administration~Patient temperature~Surgeon protective wear~Patient operative skin preparation~Suction drains~Blood glucose level~Red cell transfusion~Dressing changes"
103163|NCT03380260|Behavioral|Paranoia Induction|Behavioral procedure involving social exclusion and negative feedback to induce paranoia
103164|NCT03380234|Other|Worksheets|Worksheets will be distributed to students for them and their parents to complete together. During the first 3 months, the teachers will distribute 1 worksheet every two weeks to the intervention grades, and 1 worksheet in the 4th and 5th months as boosters. The worksheets will deliver information about tobacco smoke, SHS and THS, inviting students and their family members to complete other interesting tasks together.
103165|NCT03380234|Other|Whatsapp messages|A mobile phone number of this study is also provided on the worksheets, through which participants can receive WhatsApp/WeChat/instant messages (1-2 times every week) designed to encourage behavioural change [15]. They can then forward selected messages to other members of their household, especially smokers.
103166|NCT03380234|Other|Online quizzes|At the end of each worksheet, a QR code is inserted. By scanning this code, students or parents will be invited to answer 2-3 simple quizzes which allow us to assess students' knowledge obtained from the intervention materials and their avoidance of environmental tobacco smoke.
103167|NCT03380234|Other|Leaflet|A leaflet on smoking and SHS published by the Department of Health will be mailed to the control grades.
103168|NCT03380221|Other|Watermelon|Participants will consume 100 Kcal of watermelon fruit (2 cups) daily for 4 weeks.
103169|NCT03380221|Other|Low fat cookies|Participants will consume 100 Kcal of low fat cookies daily for 4 weeks.
103170|NCT03380195|Other|Watermelon juice|Subject drinks 355ml of watermelon juice 1 hour prior to submaximal exercise
103171|NCT03380195|Other|Sport drink|Subject drinks 355ml of Gatorade 1 hour prior to submaximal exercise
103172|NCT03380195|Other|Sugar water|Subject drinks 355ml of sugar water (22.5g) 1 hour prior to submaximal exercise
103173|NCT03380195|Other|Water|Subject drinks 355ml of water 1 hour prior to submaximal exercise
103174|NCT03380182|Other|Acupressure Band|These bands use pressure to stimulate the P6 acupuncture point.
103175|NCT03380182|Other|Sham Band|These sham bands are used to make it seem like the band is using pressure to stimulate the P6 acupuncture point.
103176|NCT03380169|Other|Prophylactic advance wound dressing|A combination of dressing including occlusive moist wound dressing to provide a barrier from the external environment and silver-containing dressing to reduce the inflammation of wounds and promotes healing
103177|NCT03380169|Other|Prophylactic conventional wound dressing|Conventional gauze dressing
103178|NCT03380156|Device|TVS|Active TVS will be performed by use of a Tragus stimulator device with electrodes attached to the tragus of the ear. Stimulator will be applied continuously for 1 hour
103179|NCT03380156|Device|Sham TVS|Device will be applied but not to the Tragus of the ear but will be attached to the ear lobule.
103180|NCT03380143|Behavioral|Wellness Landscape Intervention|Community and organization systems intervention targeting youth population physical activity
103181|NCT03380143|Behavioral|Standard Practice|Community development intervention
103182|NCT03380130|Drug|Nivolumab|An anti-programmed death 1 monoclonal antibody
103183|NCT03380130|Device|SIR-Spheres|Resin microspheres labeled with the radioactive isotope yttrium 90 that serves as a source of beta radiation
103184|NCT03380117|Behavioral|eBridge Online Counseling|In eBridge, students take an online screen and receive personalized feedback about their self-reported depression, alcohol/substance use, and level of functioning. Students are randomly assigned to either the eBridge or control condition. In the eBridge condition, personalized feedback is provided in a graphic format that is accompanied by motivational-interviewing-adherent statements. In this condition, students' communications with eBridge counselors will occur via online dialogues, in which students and counselors exchange messages using a secure website. In the control condition, personalized feedback will also be delivered online to students, highlighting their personal data and specify links between key screening variables and negative outcomes. However, in the control condition, this is provided in a straightforward graphic, informational format, which is consistent with standard practice in online screening programs for college students.
103185|NCT03380104|Device|Intradural Spinal Cord Stimulation|The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.
103186|NCT03380104|Behavioral|Administration of Questionnaires|Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
103187|NCT03380091|Drug|Metformin|Oral medication daily
103188|NCT03380091|Drug|Vitamin D|Oral medication daily
103489|NCT03377556|Other|Pharmacological Study|Correlative studies
103189|NCT03380078|Behavioral|Teams Leadership Institute (TLI)|TLI is training for leaders in how to improve implementation of evidence-based interventions in community settings. TLI includes 5 key components : 1. Assessment: The Implementation Leadership Scale (ILS) and Implementation Climate Scale (ICS) will be completed by first-level leaders participating in the intervention, his/her subordinates (i.e. providers) and executive leaders. 2. Initial Training: a 3-hour didactic and interactive session that includes training in implementation leadership Leaders will develop a plan for using specific implementation support strategies. 3. Coaching: Weekly, brief (15-30 min) coaching calls keep leaders on track with goals and plans. Coaching includes review of progress toward goals, updating plan based on emergent issues, and problem solving. 4. Follow up : At month 4, leaders attend a 2-hour booster session . 5. Graduation: TLI programs will have a group-based graduation for the leaders and provider trainees at EBI training completion.
103190|NCT03380078|Behavioral|Motivational Enhancement (TIPS for Training)|The TIPS module applies MI principles and strategies to address attitudinal barriers and improve engagement in training. I AIM HI and CPRT trainers (in the TIPS Conditions ) will incorporate MI during training and ongoing consultation/coaching with providers to increase provider engagement and problem solving throughout training: 1. Providers will receive a call designed to provide information about training and the intervention. 2. During the workshop, trainers will assess concerns about participating and will use reflective problem solving to address barriers . Trainers will work with the provider to develop a plan through the use of Planning Worksheets . 3. During each consultation , planning worksheets will be updated collaboratively with the provider. 4. Providers will receive a weekly motivational text to encourage on-going participation.
103191|NCT03380078|Behavioral|Classroom Pivotal Response Teaching (CPRT)|CPRT is a naturalistic behavioral intervention adapted from pivotal response training (PRT) for use during classroom activities to target social, communication, behavior, and learning skills. CPRT is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. CPRT has an established training plan and the training curricullum that follows the manual. Training and coaching including standard EBI training is conducted by MA or postdoctoral level researchers with extensive training and experience with CPRT.
103192|NCT03380078|Behavioral|An Individualized Mental Health Intervention for ASD (AIM HI)|A package of well-established, evidence-based behavioral strategies designed to reduce challenging behaviors in children served in MH service settings. AIM HI is a manualized program with user-friendly materials for training, intervention planning and fidelity monitoring provided in printed and web-based formats. AIM HI is a package of evidence-based parent-mediated and child focused strategies, designed to reduce behavior problems in children with ASD ages 5 to 13 served in MH programs. AIM HI has an established training plan and the training curriculum follows the manual. Training and coaching is conducted by MA or postdoctoral level researchers with extensive training and experience with AIM HI.
103193|NCT03380065|Device|Late deflation of TR band|"First 3ml of air is removed after TWO hour of sheath removal. Then, 3ml of air is removed every 15minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 3ml of air is pushed back into the device until bleeding stops. Then a gap of 15minutes is observed for the next deflation."
103194|NCT03380065|Device|Early deflation of TR band|"First 2ml of air is removed from the band ONE hour after sheath removal. Then, 2ml of air is removed every 30minutes.~Observe for any bleeding or hematoma. During every deflation, if any bleeding or hematoma is noticed then 2ml of air should be pushed back into the device until bleeding stops. Then wait for another 30minutes for the next deflation."
103195|NCT03380039|Genetic|CAR-BCMA T cells|"Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied."
103196|NCT03380039|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
103197|NCT03380039|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
103198|NCT03380026|Drug|Triamcinolone|Apply up to three times daily on select lesions.
103199|NCT03380026|Drug|Valchlor 0.016 % Topical Gel|Apply valchlor nightly on select lesions.
103200|NCT03380013|Procedure|Osteopathic Manipulative Treatment (OMT)|Each neonate will have a structural exam completed assessing each body region (head, cervical, thoracic, lumbar, sacral, pelvic, rib cage, and abdominal regions) for underlying somatic dysfunctions prior to each treatment. The specific OMT techniques used will be left to the discretion of the treating physician and will not be based on a predetermined protocol. Treatment techniques will consist of myofascial release, balanced ligamentous tension, balanced membranous tension, and osteopathy in the cranial field. Total treatment time will be 15 minutes. The features of the osteopathic structural exam which will be recorded on paper by the treating physician at the time of the evaluation. The paper will be marked only with the research identifier.
103201|NCT03380000|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
103202|NCT03380000|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
103203|NCT03379987|Drug|PVB morphine|The PVB was performed under ultrasonographic guidance in the sitting position. Surgical disinfection of thoracoabdominal paravertebral area was done. A linear high-frequency transducer (10-12 MHz, Sonosite, Bothell, WA, USA) was used. The scanning process (Longitudinal out-of-plane technique) was started at 5-10 cm lateral to the spinous process of thoracic vertebrae to identify the rounded ribs and parietal pleura underneath. The transducer is then moved progressively more medially until the transverse processes are identified as more squared structure deeper to the ribs. A 100 mm needle was inserted out-of-plane to contact the transverse process of thoracic vertebra and then, walked off above the transverse process 1-1.5 cm deeper searching for loss of resistance injecting 10 ml of 0.25% bupivacaine + 3 mg morphine for group PVB morphine in incremental doses of 3 ml.
103204|NCT03379987|Drug|PVB bupivacaine|the same steps mentioned in group PVB morphine but the solution used for paravertebral block contain bupivacaine only 10 ml of 0.25% bupivacaine injected in in incremental doses of 3 ml.
103205|NCT03379974|Drug|DDAVP Inhalant Product|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP. After receiving IN DDAVP, the participant will rest for 30 minutes.
103206|NCT03379974|Behavioral|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
103207|NCT03379948|Diagnostic Test|blood culture|blood culture to diagnose blood stream infection
103208|NCT03379935|Procedure|Type of radial head arthroplasty|Patiens are either treated with a unipolar or a bipolar radial head arthroplasty. At Sundsvall hospital all patients were treated with a unipolar and at Umeå university hospital all patients were treated with a bipolar arthroplasty.
103209|NCT03379922|Behavioral|Stress balls|Squeezing stress balls while receiving ESWL treatment
103210|NCT03379922|Behavioral|Headphones|Listening to music while receiving ESWL treatment
103211|NCT03379909|Drug|Metformin|Metformin orally at doses up to 1500 mg twice daily for 3 months.
103212|NCT03379896|Other|Collect peripheral blood sample|Collect 20 ml heparinized blood from patients and controls strictly abiding by the principle of aseptic manipulation after informed consent.
103213|NCT03379883|Procedure|Pulsed radiofrequency (P-RF)|"Intra articular RF~Insertion of the RF cannula within the joint. The recommended parameters are a pulse width of 20 msec and a rate of 2 Hz at 42°C for 10min.~Genicular nerve RF ablation.~The RF probe will be placed. A 50 Hz-frequency sensorial stimulation will be applied with a threshold of < 0.6 V"
103214|NCT03379883|Procedure|Platelet rich plasma (PRP)|Under ultrasound guidance while the patients in a sitting position. In total, 3 to 8 mL of PRP will be injected via the inta-articular route
103215|NCT03379870|Device|Electric Acoustic Speech Processor: EAS fitting|Electric Acoustic Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or better,
103216|NCT03379870|Device|Electric Acoustic Speech Processor: Electric only fitting|Electric Stimulation for children with post-operative residual low frequency hearing averages of 75 dB HL or poorer and pre-operative low frequency hearing averages of 75 dB HL or better.
103217|NCT03379857|Other|Drug urinal test|Non Applicable
103218|NCT03379844|Device|Holmium-166 radioembolization|An intra-arterial radioembolization procedure will be performed. The hepatic artery catheter is inserted via the femoral or radial artery under x-ray guidance by a trained interventional radiologist. The radiologist must repeatedly check the position of the catheter during the procedure to ensure it remains correctly sited and that reflux of the QuiremSpheres® into other organs does not occur. This is performed by injecting contrast medium. At the conclusion of the procedure, the catheter is removed.
103219|NCT03379818|Behavioral|Shape training intervention|This intervention is based on on a study conducted by Smith and colleagues (2002), where they found that teaching typically developing infants to attend to shape by the end of the second year of life significantly enhances their word learning. Participants will be taught that the significant property they should focus in when learning and extending novel labels is shape. This will be done through play-like sessions.
103220|NCT03379818|Behavioral|Specific word training|"In this intervention, participants will be taught the names of 28 real objects. The target words have been selected from the Wordbank database, which is an open database that lists the proportion of children that know a specific word at a specific age. Twenty-eight words that are understood by 80% of the total child population at 25 months were randomly selected as target words. Techniques such as focused stimulation and modelling target words, which have proved to be useful for word learning, will be used."
103221|NCT03379805|Diagnostic Test|Near Infrared Fluorescence Imaging|The functional state of lymphatics is investigated using near infrared fluorescence imaging, NIRF.
103222|NCT03379805|Diagnostic Test|Non-contrast MRI|The anatomy is described using non-contrast MRI.
103223|NCT03379805|Diagnostic Test|Strain Gauge Plethysmography|The capillary filtration rate is measured using plethysmography
103224|NCT03379792|Other|DEXA|Measurement of body composition by Dual Energy X-ray Absorptiometry (DEXA)
103225|NCT03379792|Other|MRI|Whole body magnetic resonance imaging (MRI)
103226|NCT03379792|Other|CGM|A continuous glucose monitor (CGM) will be placed on the participant and will be used as a safety measure to monitor glucose levels.
103227|NCT03379792|Other|Whole room calorimeters|Whole room indirect calorimetry allows for the simultaneous measure of total energy expenditure and substrate oxidation in a free living environment with multiple activities.
103228|NCT03379792|Other|Dietary counseling|The low carbohydrate diet counseling will be to assist young adult, overweight study participants with Type 1 diabetes in adhering to a lower calorie diet (500 calorie deficit)
103229|NCT03379779|Diagnostic Test|16s RNA sequence of sputum, bronchoalveolar lavage fluid (options), stool|We will check the microbiome in lower respiratory samples (sputum and bronchoalveolar lavage fluid) and stool by using 16S RNA sequencing
103230|NCT03379766|Device|Successor of Phonak Audéo B-Direct|The successor of Phonak Audéo B-Direct will be fitted to the participants indivudal hearing loss.
103231|NCT03379766|Device|Phonak Audéo B-Direct|The Phonak Audéo B-Direct will be fitted to the participants individual hearing loss.
103232|NCT03379753|Other|music and positive images|The diad of misic and positive image will be administered to the standard care by adding a Bluetooth capable speaker with selections of music and a soothing nature landscape into the hospital room.
103233|NCT03379740|Other|E-cigarette|Subject's own e-cigarette
103234|NCT03379740|Other|P4M3-1.7%|P4M3 e-liquid concentration of 1.7% nicotine without lactic acid
103235|NCT03379740|Other|P4M3-1.7%LA|P4M3 e-liquid concentration of 1.7% nicotine with lactic acid
103236|NCT03379740|Other|P4M3-3%LA|P4M3 e-liquid concentration of 3% nicotine with lactic acid
103237|NCT03379740|Other|P4M3-4%LA|P4M3 e-liquid concentration of 4% nicotine with lactic acid
103238|NCT03379727|Drug|Midostaurin|Orally administered inhibitor of multiple tyrosine kinases
103275|NCT03379389|Drug|Methenamine + Methylthioninium + Acriflavine + Atropa belladona|Methenamine + Methylthioninium + Acriflavine + Atropa belladona
103243|NCT03379662|Device|Erchonia HLS Laser|The Erchonia HLS Laser emits a 640 nm (nanometer) wavelength with a tolerance of ±10 nm from each of two 7.5 mw (milliwatt) laser diodes.
103244|NCT03379662|Device|Placebo Laser|The Placebo Laser emit the same visible light output as the active HLS Laser but without therapeutic effect.
103245|NCT03379649|Combination Product|Platelet rich plasma|Patients will have 60ml of blood drawn. Platelet rich plasma will be obtained by placing the blood in the Arteriocyte Magellan device. 0.5ml of Platelet rich plasma will be placed into the uterus at least 48 hours prior to embryo transfer.
103246|NCT03379649|Combination Product|Placebo|Patients will have 60ml of blood drawn. 0.5ml of embryo culture media (the placebo) will be placed into the uterus at least 48 hours prior to embryo transfer.
103247|NCT03379636|Device|kinesiotape|Application of an elastic beige 5-cm width Leukotape®K (BSN medical, Germany). The first strip, a Y-strip, was applied with 10% to 15% of tension over the deltoid muscle, from origin to insertion with the first tail along the anterior deltoid while the arm was externally rotated and horizontally abducted. The second tail was applied along the posterior deltoid with the arm horizontally adducted and internally rotated. A second strip, an I-strip, was applied for mechanical correction, transversally in the sagittal plane over the acromioclavicular joint with a downward pressure applied to the KT, the arm being at trunk side
103248|NCT03379636|Device|sham tape|a rigid Leukotape®Classic (BSN medical, Germany) was used. A 5-cm strip was applied transversally under the deltoid tuberosity with no tension and with no direct influence on shoulder area.
103249|NCT03379623|Other|ESCAPE-pain Programme|The Enabling Self-management and Coping with Arthritic (knee) Pain using Exercise (ESCAPE-pain) is a programme of rehabilitation that integrates educational self-management and coping strategies for people with joint pain with an individualised exercise regimen for each participant. The implementation of the programme will be conducted by the researcher as a certified facilitator by using Clinician's training manual for the ESCAPE-pain programme.
103250|NCT03379610|Diagnostic Test|Nasopharngeal brush|"Baseline nasopharngeal brush before treatment~Post-treatment reassessment of residual NPC"
103251|NCT03379597|Drug|Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)|Bifico 840mg Bid
103252|NCT03379597|Dietary Supplement|Dietary fiber|dietary fiber compound powder 30g bid
103253|NCT03379584|Drug|SGN-CD48A|Intravenous (IV) infusion on days 1, 8, and 15 of a 28-day cycle
103254|NCT03379558|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:as per routine practice Route of administration: subcutaneous
103255|NCT03379545|Diagnostic Test|3-dimensional (3D) magnetic resonance (MR)|MRI is performed using 3T scanners with a dedicated 16-channel shoulder array coils. The MRI sequences include 3-mm slice thickness and 0.5-mm gap width with a field of view of 14 or 15 cm. There were 6 diagnostic sequences with axial, coronal, and sagittal proton density weighting as well as coronal T2 with frequency selective fat suppression and sagittal T1 images.
103256|NCT03379545|Diagnostic Test|3D computed tomography (CT) imaging|The CT protocol consists of 3-mm axial images of the glenoid reconstructed into 1-mm sagittal and coronal 2D reconstructions using the following parameters: 120 kV, 280 mA, and pitch of 0.9. The CT data were also used to produce a 3D reconstruction of each glenoid.
103257|NCT03379532|Device|BCI-NMES|From the recorded brain activity (EEG) subject specific patterns will be extracted with machine learning techniques from recordings where the subject executes movements tasks. Whenever a subject-specific pattern can be identified and detected, this is used for triggering neuromuscular electrical stimulation.
103258|NCT03379532|Device|Sham-NMES|Neuromuscular electrical stimulation is triggered independently of the patient's movement intentions.
103259|NCT03379519|Behavioral|Multi-domain Attention Training (MAT)|The training content emphasis three concept of attention include: intensity of attention, executive attention, and spatial orienting attention.
103260|NCT03379519|Behavioral|Passive information activities (PIA)|The active control group (Passive information activities) training content included reading online e-books and playing online games.
103261|NCT03379506|Drug|EBR/GZR|Ages 12 to less than 18 years will receive oral FDC tablets with EBR 50 mg/GZR 100 mg once daily. Ages 3 to less than 12 years will receive oral granules pediatric formulation in a soft food vehicle once daily with EBR/GRZ not to exceed 50 mg/100 mg.
103262|NCT03379493|Biological|ET190L1 ARTEMIS™ T cells|Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) ARTEMIS™ expression construct, administered by intravenous (IV) infusion
103263|NCT03379480|Behavioral|Yoga arm|Yoga module developed for patients with Schizophrenia
103264|NCT03379467|Other|SMS Reminder|A text message sent as a reminder for immunization on the registered phone number
103265|NCT03379467|Other|Interactive Reminder|A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
103266|NCT03379441|Drug|Pembrolizumab Injectable Product|Pembrolizumab Injectable Product 200 mg Q3W Intravenous
103267|NCT03379428|Drug|Trastuzumab|8 mg/kg loading dose (first dose), followed by 6 mg/kg every 3 weeks, administered intravenously (IV)
103268|NCT03379428|Drug|Ibrutinib 560 mg|560 mg by mouth daily
103269|NCT03379428|Drug|Ibrutinib 840 mg|840 mg by mouth daily
103270|NCT03379428|Drug|Ibrutinib 420 mg|420 mg by mouth daily
103271|NCT03379415|Device|Footwear|Different types of footwear will be tested to see if these can be used to help slow the progression of osteoarthritis in meniscectomy patients or even stop it from occurring.
103272|NCT03379415|Procedure|Gait analysis|Gait analysis will be done during several different tasks wear the footwear
103273|NCT03379402|Other|Specimens collection|"On admission: Blood samples 30.01 mL and other specimens (if available) for culture and other diagnostics tests including sputum, throat swab, urine (midstream urine), and pus which is part of routine practice for patients with sepsis at study site.~Day 3: Blood (15 mL) for culture (10 mL) and PCR (5 mL). There will be no blood collection, if patient is discharged before day 3."
103274|NCT03379389|Drug|Methenamine + Methylthioninium|Methenamine + Methylthioninium
103276|NCT03379389|Drug|Antibiotics|Antibiotics based on individual subjects urine culture / antibiogram
103279|NCT03379350|Procedure|clamping group|Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
103280|NCT03379337|Diagnostic Test|Dental imaging|The target teeth positions for imaging included 4 incisors and all 4 canines. Only the vestibular and interproximal regions were of interest. Images were taken of these target teeth positions regardless of whether or not they exhibited plaque, consisted of full or partial restorations, contained major cracks/fractures, chips, or were missing. Other captured images included any abnormality of the tooth or gum exhibiting red fluorescence physically accessible by the devices.
103281|NCT03379324|Biological|Superiority of augmented repairs|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
103282|NCT03379324|Biological|Fat degeneration of supraspinatus muscle|4cc of FlōGraft® injected into repair subject tissue divided evenly between repair site and muscle body
103283|NCT03379311|Drug|AK002|AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8, a member of the CD33-related family of sialic acid-binding, immunoglobulin-like lectins (Siglecs).
103284|NCT03379259|Drug|BGB-A333|Anti-PD-L1 antibody
103285|NCT03379259|Drug|BGB-A333 and BGB-A317|Anti-PD-L1 and anti-PD-1 antibodies
103286|NCT03379233|Combination Product|Concept2 inhaler|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler
103287|NCT03379233|Combination Product|Concept2 inhaler with patient application|Fixed combination of Indacaterol maleate (QAB149) and glycopyrronium bromide (NVA237), 110/50 μg, capsule added to Concept2 inhaler with application used for monitoring
103288|NCT03379207|Other|Blood samples|Blood samples for research purpose, taken whenever possible during blood sampling for routine purpose
103289|NCT03379207|Other|Tracheal Aspirates|Only for mechanically ventilated participants.
103290|NCT03379207|Other|Surplus of Broncho-alveolar lavage fluid|Only if performed for diagnosis purpose by the treating investigator : indication left at his discretion
103291|NCT03379194|Behavioral|Antibiotic stewardship program|Routine feedback on antibiotic prescriptions in addition to evidence based guidelines for the management of acute respiratory and urinary tract infection and patient leaflets for using antibiotics wisely
103292|NCT03379181|Drug|Propranolol|Patients receive a single dose of 80 mg propranolol p.o.
103293|NCT03379168|Device|Microfragmented Adipose Tissue (Lipogems)|Lipogems is a technique to harvest, process, and inject minimally manipulated adipose tissue. This procedure is enzyme free and requires no clonal expansion or manipulation. Lipoaspirate is harvested most commonly from the abdomen and washed in saline solution, then processed through a closed-system device that micro-fragments the adipose tissue. This mechanical process retains the vascular architecture, mature pericytes, and MSCs for autologous injection. Lipogems is currently FDA-approved for orthopedic and arthroscopic procedures; thus, this would be an on-label use for knee injections.
103294|NCT03379168|Drug|Corticosteroid injection|Cortisone is a standard of care injection to reduce joint inflammation.
103295|NCT03379168|Drug|Saline|Sterile saline injection will act as a placebo group.
103296|NCT03379155|Other|Internet-based self-help program|The intervention provided is based on the principles of cognitive behavioral therapy (CBT) (Bachem & Maercker, 2013). The manual integrates a variety of approaches validated as treatments for PTSD, anxiety disorders, or depression; the selection focuses on exercises which are intended to target the main symptoms of AjD, namely preoccupations (e.g. constant rumination, excessive worry about the stressor) and failure to adapt (e.g. sleep disturbance, difficulties concentrating, loss of interest in previously enjoyable activities).
103297|NCT03379142|Behavioral|Faith-Based messages|We will send out faith based text messages on a weekly basis for the one week prior to the start of Ramadan, then twice a day during the Ramadan period that will encourage smoking cessation and continue to encourage change of behavior. The faith-based messages will be incorporated with messages drawn from the Smokefree.gov Mobile Interventions QuitNowTXT Message Library. These messages will be geared towards reminding the smokers that as Ramadan is coming closer they need to consider the effects that smoking may have on their health and should consider taking steps towards quitting.
103298|NCT03379116|Other|enteral nutrition and parenteral nutrition|In the treatment of the burned patients injured,data on nutritional support and patient's outcomes were collected and analyzed.
103299|NCT03379103|Drug|Sevoflurane|Patients will receive 1 MAC sevoflurane for 15 minutes before the installation of member ischemia by tourniquete
103300|NCT03379103|Drug|Propofol|Patients will receive propofol for 15 minutes before the installation of member ischemia by tourniquete
103301|NCT03379077|Behavioral|LTP Plus|LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
103302|NCT03379064|Behavioral|Culturally adapted Cognitive Behavior Therapy for IBS|Culturally adapted Cognitive Behavior Therapy for IBS
103303|NCT03379051|Drug|Venetoclax|BCL-2 Inhibitor
103304|NCT03379051|Drug|Umbralisib|PI3K-Delta Inhibitor
103305|NCT03379051|Drug|Ublituximab|Glycoengineered Anti-CD20 mAb
103306|NCT03379038|Other|Progressive Physical Therapy|Stretching of the tight muscle, positioning, abdominal co activation; rolling etc to decrease muscle tone and functional independence.
103307|NCT03379038|Other|Maintenance Physical Therapy|Same Physical therapy protocol but aim was to maintain current level of spasticity and functioning
103308|NCT03379025|Other|Electronic cigarette|electronic cigarette and cartridge refills (also known as pods)
103309|NCT03379012|Drug|Testosterone undecanoate and sunitinib or pazopanib|Testosterone undecanoate (Nebido®) 1,000 mg (4 ml) intramuscular deeply, once before targeted therapy (sunitinib 50 mg 4/2 or pazopanib 800 mg daily)
103310|NCT03378999|Dietary Supplement|Rhodospirillum rubrum|Capsules containing oven-dried Rhodospirillum rubrum
103311|NCT03378999|Dietary Supplement|Control|Capsules containing microcrystalline cellulose
103312|NCT03378986|Procedure|Unilateral total hip arthroplasty|Replacement of one hip joint through a mininvasive surgical procedure
103313|NCT03378986|Procedure|Simultaneous bilateral total hip arthroplasty|Replacement of both hip joints through one-stage mininvasive surgical procedure
103314|NCT03378973|Drug|Dexmedetomidine|Patients will randomly assigned to received Arm 1 anesthesia or Arm 2 anesthesia during surgery.
103315|NCT03378960|Drug|Omeprazole 20mg|
103316|NCT03378947|Other|clinical and pathological data EBV-related GZL and DLBCL|"Invesrigators will retrospectively collect clinical and pathological data of all EBV-related GZL and DLBCL in immunocompetent patients diagnosed in the pathology department Centre Hospitalier Lyon Sud.~Investigators will analyze their clinical feature and prognosis."
103317|NCT03378934|Drug|Berberine|Berberine 200 mg twice daily for 4±1 weeks (Stage 1); then, 300 mg twice daily for 4±1 weeks (Stage 2); then, 400 mg twice daily for 4 weeks (Stage 3).
103318|NCT03378934|Drug|Standard treatment|Standard treatment for 12±1 weeks.
103319|NCT03378934|Drug|Aspirin|Aspirin 100 mg once daily for 12±1 weeks.
103320|NCT03378934|Drug|Clopidogrel|Clopidogrel 75 mg once daily for 12±1 weeks.
103321|NCT03378921|Biological|Fecal microbiota transplantation|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 3, 12, 26, and 52.
103322|NCT03378921|Biological|Placebo|Follow up of the patients include a telephone call after 12 and 26 weeks after the FMT, and a clinical control visit 52 weeks after the transplantation. The clinical part of the Pouchitis Disease Activity Index score is assessed during each call and clinical visit. Fecal stool samples for phylogenetic analysis are collected before FMT and on weeks 3, 12, 26, and 52.
103323|NCT03378908|Behavioral|Intervention Treatment|Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
103324|NCT03378895|Behavioral|online questionnaire|Risk assessment identified by online questionnaire
103325|NCT03378882|Biological|Parasitic serologies|"Suspected angiostrongylosis - Angiostrongylus cantonensis:~An aliquot of CSF and an aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies.~A CSF aliquot will be sent to the CDC for PCR.~Suspected angiostrongylosis- Angiostrongylus costaricensis:~- An aliquot of serum will be sent to the laboratory of tropical medicine in Switzerland for research of specific antibodies."
103326|NCT03378882|Procedure|Biopsy|"Suspected angiostrongylosis - Angiostrongylus costaricensis:~- A piece of biopsy or intestinal resection will be sent to the pathology laboratory for parasitic elements suggestive of Angiostrongylus costaricensis infection"
103327|NCT03378869|Procedure|esophagectomy|all the included participants had received esophagectomy, either Ivor Lewis or tri-incision, or more complex procedures.
103328|NCT03378843|Other|Spermidine content of natural diet|The exposure consists in the long-term average dietary intake of the polyamine spermidine
103329|NCT03378817|Procedure|HOPE|HOPE for 2 hours via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
103330|NCT03378817|Other|Conventional cold storage|No intervention
103331|NCT03378804|Procedure|Programmed intermittent epidural bolus application (PIEB)|Instead of a continuous background infusion of 6ml/h, one bolus injection is performed at the same amount per hour.
103332|NCT03378804|Procedure|Continous epidural analgesia|
103333|NCT03378791|Drug|Iron bisglycinate Oral Tablet|
103334|NCT03378791|Drug|Ferrous Fumarate Oral Tablet|
103335|NCT03378778|Procedure|Root canal treatment|Root Canal Treatment followed by Ceramic Onlay restoration
103336|NCT03378765|Behavioral|Diet and physical activity monitoring|Lifestyle monitoring
103337|NCT03378752|Procedure|HFJV|On High frequency jet ventilation, Every 15 minutes, after induction of general anaesthesia, a computed tomography of the lower part of the lungs are taken (10 cm volume, with the top of the right diaphragm as the lower border)
103338|NCT03378739|Procedure|Cardiogenic Shock team activation|Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.
103339|NCT03378726|Dietary Supplement|Micronutrients|Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
103340|NCT03378726|Behavioral|SPOON Group Counseling|SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
103341|NCT03378726|Behavioral|Interpersonal Counseling|SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
103342|NCT03378726|Dietary Supplement|SQ-LNS|SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
103343|NCT03378726|Behavioral|Standard Counseling|Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
103344|NCT03378713|Drug|GROUP 1: Long testosterone|Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
103345|NCT03378713|Drug|GROUP 2: Short testosterone|Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
103346|NCT03378713|Drug|GROUP 3: Control|The COS starts directly on the second day of the cycle without prior medication.
103490|NCT03377556|Drug|Talazoparib|Given PO
103347|NCT03378700|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention, consisting of four sessions: two face-to-face sessions (1-hour) and two telephone follow up sessions (30 minutes) in between.~The facilitator will guide participants to imagine how they navigate themselves to circumvent possible obstacles and accomplished their set goals and experience positive emotions.~A booklet will be given to the participants for reviewing their planned goals, recording achieved targets and successful experiences."
103348|NCT03378700|Other|Pre-dialysis Education Group|Pre-dialysis educational class and standard care such as clinic follow up and normal hospital care will be provided. This session is led by clinicians with renal nursing training. The educational class aims at providing information on the treatment modalities for patients with ESRD, signs and symptoms of their illness and the basic advice on the importance of adherence to healthy lifestyle, nutrition and medications. Logistic call and social communication will be offered and initiated by trained nurses in the second week and the third week
103349|NCT03378674|Drug|Remifentanil Injectable Product|remifentanil: 0,15 mcg/kg/min
103350|NCT03378661|Drug|Benznidazole|Benznidazole tablet
103351|NCT03378661|Drug|E1224|E1224 capsules
103352|NCT03378661|Drug|E1224 Placebo|E1224 matched placebo capsules
103353|NCT03378661|Drug|Benznidazole Placebo|Benznidazole matched placebo tablets
103354|NCT03378648|Drug|CHF6366|"Drug: CHF6366 (Part 1 - SAD) Single doses of CHF6366 at each period (for up to 3 periods per subject)~Drug: CHF6366 (Part 2 - MAD) Once daily doses of CHF6366 for 7 days~Drug: CHF6366 (Part 3) Single dose of CHF6366"
103355|NCT03378648|Drug|Placebo CHF6366|"Drug: Placebo (Part 1 - SAD) Single doses of placebo matching CHF6366 at each period (for up to 3 periods per subjects)~Drug: Placebo (Part 2 - MAD) Once daily dose of placebo matching CHF6366 for 7 days~Drug: Placebo (Part 3) Single dose of placebo matching CHF6366"
103356|NCT03378648|Drug|umeclidinium bromide and vilanterol trifenatate|Part 3 Single dose
103357|NCT03378635|Drug|Dasiglucagon|Glucagon analog
103358|NCT03378635|Drug|GlucaGen|Native glucagon
103359|NCT03378635|Drug|Placebo|Placebo for dasiglucagon
103360|NCT03378622|Other|Anchor|Anchor technique for mesh attachment
103361|NCT03378622|Other|Suture|Suture technique for mesh attachment
103362|NCT03378609|Other|Vocal Fatigue Index (VFI)|collection of 190 consecutive data sets, participants give separate consent for participating a retest or an interview, retest will be realised with the 10 following volunteers
103363|NCT03378596|Dietary Supplement|L-citrulline + L-arginine|L-citrulline + L-arginine - sachet dissolved in water
103364|NCT03378596|Dietary Supplement|L-arginine|L-arginine - sachet dissolved in water
103365|NCT03378596|Dietary Supplement|L-citrulline|L-citrulline - sachet dissolved in water
103366|NCT03378596|Dietary Supplement|Placebo|Placebo (corn starch) - sachet dissolved in water
103367|NCT03378570|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation will be targeted to a location in the left prefrontal cortex and delivered according to FDA-approved parameters for the treatment of major depressive disorder, specifically high-frequency 10 Hz rTMS for 3000 pulses, 5 days per week for a total number of sessions as deemed clinically appropriate by the patient's clinical TMS treatment team but usually on the order of 20-30 treatments.
103368|NCT03378544|Behavioral|mhGAP|The intervention will involve psycho-education to patients on the importance of maintaining interest in activities that they used to do, regular sleep cycles, physical activity and social activity
103369|NCT03378531|Drug|AEB1102|modified human arginase I
103370|NCT03378505|Behavioral|Mobile App|Purposeful Living Mobile App JOOL to be used daily
103371|NCT03378505|Behavioral|Reflection|Bi-weekly online reflection question
103372|NCT03378492|Device|Ultrasound Guided Epidural|Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
103373|NCT03378492|Procedure|Standard Epidural|The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
103374|NCT03378479|Drug|SOC +Posaconazole 18 MG/ML (milligram/milliliter)|.2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days (total 7 days)
103375|NCT03378479|Other|standard of care (SOC)|treatment for influenza pneumonia at the investigators discretion
103376|NCT03378466|Drug|Unfractionated heparin|UFH initiated at 18 IU/kg/hr, dosed according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin (aPTT) of 1.5 to 2.5 times that of the reference aPTT value or anti-Xa values targeted to local practice levels. Duration of study intervention will be a maximum of 5 days (120 hours) or until vasopressors have been discontinued for 24 continuous hours. All participants will then receive venous thromboprophylaxis according to local practice.
103377|NCT03378466|Other|Venous thromboprophylaxis (VTE)|May include subcutaneous heparin or dalteparin, sequential compression device or graduated compression stockings
103378|NCT03378453|Device|PET-scan18F-AV-45|The PET-scan18F-AV-45 is a PET-scan dedicated to analyze the amyloid load in the brain with the AV45 tracer by the measurement of the mean cortical SuVr
103379|NCT03378453|Device|PET-scan18F-AV-45|PET-scan18F-AV-45 already done in another protocol MEMENTO-AMYging
103380|NCT03378427|Drug|Tedizolid Phosphate 200 MG [Sivextro]|Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.
103381|NCT03378414|Procedure|Intravenous infusion|Intravenous infusion of mesenchymal stem cells: 2 * 10^7 cells (30ml)
103382|NCT03378414|Procedure|Intrathecal injection|Intrathecal injection of mesenchymal stem cells: 2 * 10^7 cells (1ml)
103383|NCT03378414|Biological|umbilical cord mesenchymal stem cell|Treat patients with umbilical cord mesenchymal stem cell (SCLnow 19#), the dosage based on different procedure
103384|NCT03378401|Drug|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
103385|NCT03378401|Other|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
103386|NCT03378375|Other|nutritional assessement|
103387|NCT03378362|Procedure|Partial denervation of the wrist joint|Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
103388|NCT03378349|Behavioral|Internet-delivered cognitive behavior therapy|The intervention lasts for 10 weeks and include: Education, Interoceptive exposure, exposure in-vivo, combining in-vivo exposure with interoceptive exposure, behavioral activation and relapse prevention. Include the guidance of a minimum weekly contact with a CBT psychologist.
103389|NCT03378349|Behavioral|Treatment as usual|Consist of standardized AF information that emphasizes that an active physical and social lifestyle is necessary to maintain good health, without the guidance of a psychologist or any CBT interventions.
103390|NCT03378323|Drug|Multiple injection local anesthetic|Multiple injection local anesthetic
103391|NCT03378323|Drug|Single injection local anesthetic|Single injection local anesthetic
103392|NCT03378310|Drug|BMS-986205 reference tablet|Single, 100 mg oral dose.
103393|NCT03378310|Drug|BMS-986205 tablet with free base|Single, 100 mg oral dose.
103394|NCT03378297|Drug|Metformin|Metformin tablets 850 mg x 2 orally
103395|NCT03378297|Drug|Acetylsalicylic acid|Acetylsalicylic acid tablets 160 mg x1 orally
103396|NCT03378297|Drug|Olaparib|Olaparib capsules 300 mg x 2 orally
103397|NCT03378297|Drug|Letrozole|Letrozol tablets 2.5 mg x 1 orally
103398|NCT03378284|Drug|Tegoprazan|Tegoprazan QD for 7 days
103399|NCT03378284|Drug|Revaprazan|Revaprazan QD for 7 days
103400|NCT03378271|Device|Simultanious CGM/FGM|Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
103401|NCT03378245|Behavioral|Behavioral modification and education on pharmacologic treatments.|Education and counseling of care-giving staff on behavioral modification strategies, as well as education about current standard of care best practices for pharmacologic interventions.
103402|NCT03378232|Dietary Supplement|Placebo Olive Oil|Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
103403|NCT03378232|Dietary Supplement|High EPA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
103404|NCT03378232|Dietary Supplement|High DHA Supplement|Each participant was instructed to consume assigned dietary supplement on a daily basis for 12 weeks.
103405|NCT03378219|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:injection Route of administration: subcutaneous
103406|NCT03378206|Device|hinged 8-figure plate|Hinged 8-figure plate has two arms and a built-in hinge. The rotation of the two arms ranged from 155° to 170° to better fit the contour of the physis in all stages of angular correction. That automatic change can also disperse repeated stress on the surface of periosteum and perichondrium during walking.
103407|NCT03378206|Device|conventional 8-figure plate|Conventional 8-figure plate is a widespread device to treat angular deformity of lower limbs with moderate successful rate. The device was designed based on the principle of tension band model. It consists of a plate and two screws (epiphyseal screw and metaphyseal screw).
103408|NCT03378167|Biological|MICROBIOTA|Fecal microbiota enema (RBX2660) infused via colonoscope x 1 + oral microbiota capsules (RBX7455) x 6 weeks. The fecal microbiota enema (RBX2660) prepared by Rebiotix has received Health Canada Clinical Trials Application (CTA), and U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection, and pediatric inflammatory bowel disease. The human-derived fecal oral microbiota capsule (RBX7455) has received U.S. Food and Drug Administration Investigational New Drug Application (IND) approval for clinical trials in patients with recurrent Clostridium difficile infection.
103409|NCT03378167|Biological|PLACEBO|"Placebo enema (Normal Saline) infused via colonoscope x 1 + oral placebo capsules (dextrose-containing capsules) x 6 weeks.~NOTE: Patients randomized to the control group will be given the option of receiving open-label treatment, with the intervention therapy, either: upon completion of the trial, or if they are removed from the trial due to disease exacerbation or other adverse event, at the discretion of their primary gastroenterologist."
103410|NCT03378154|Procedure|Orotracheal intubation in infants with Macintosh|Orotracheal intubation in infants using Macintosh laryngoscope
103411|NCT03378154|Procedure|Orotracheal intubation in infants with King vision|Orotracheal intubation in infants with King vision videolaryngoscope
103412|NCT03378141|Behavioral|Maternal Nutrition Behavior change|Counseling and community mobilization
103413|NCT03378128|Procedure|Diagnostic laparoscopy|The patient will initially undergo a diagnostic laparoscopy by a minimally invasive approach and entry method. The decision of which approach and entry to perform will be dictated by the primary surgeon of record's preference and their assessment of pre-operative patient factors. Once the primary surgeon determines the areas of macroscopic disease, he/she will make an assessment as to the need to convert to a laparotomy or continue laparoscopically. At the completion of the procedure, it will be noted whether an optimal cytoreduction (≤ 1 cm residual disease) or a sub-optimal cytoreduction (>1 cm residual disease) was performed.
103414|NCT03378102|Biological|IFN-gamma-secreting HAdV antigen specific T cells|Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant
103491|NCT03377543|Drug|Aspirin|81mg aspirin pill daily at bedtime over a 25 day period
103492|NCT03377543|Drug|Placebo|81mg non-active pill that looks like aspirin
103848|NCT03374800|Drug|Pantoprazole|40 mg powder for injection reconstituted with 0.9% saline
103415|NCT03378089|Behavioral|Music Therapy|No narcotic or anti-emetic therapy will be administered for at least 2 hours prior to music therapy session. Music therapy sessions will be administered by a board certified music therapist (MT-BC) and last approximately 45 minutes. Involvement in sessions will be based on therapist and patient availability.
103416|NCT03378089|Behavioral|No Music Therapy|Participants will fill the same 45 minute period in any way they choose; however, they will be asked to refrain from listening to recorded music during this time.
103417|NCT03378076|Drug|FX006 32 mg|Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)
103418|NCT03378076|Drug|TAcs 40 mg|Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)
103419|NCT03378063|Drug|transplantation of mesenchymal stem cell|allogeneic human umbilical cord blood (hUCB)-derived mesenchymal stem cell (MSC) transplantation will be given to preterm infants
103420|NCT03378063|Drug|no transplantation of mesenchymal stem cell|MSC transplantation will be not given to preterm infants
103421|NCT03378050|Behavioral|HEART|"The intervention group will receive a multi-component individualized support intervention HEART, which will consist of 12 sessions in four stages. By using a comprehensive assessment targeting five components, an individualized intervention plan will be developed to address identified problems and unmet needs. Those five components consist of: Health, Emotion, Activities, Resources and Training."
103422|NCT03378050|Other|Usual Care|"Caregivers in the control group will receive 12 week follow-up as usual (FU) including two brief check-in calls and an outcome measures call during the study period."
103423|NCT03378037|Procedure|Acupuncture|20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.
103424|NCT03378024|Device|oscillometric (Omron Colin co)|fast measurements of the brachial-ankle pulse wave velocity (baPWV) and the resting ankle-brachial index(ABI) with the oscillometric method (Omron Colin co, Japan)
103425|NCT03378011|Other|phototherapy|phototherapy either UVA1 or topical PUVA on acral vitiligo
103426|NCT03377998|Other|skin biopsy|Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.
103427|NCT03377985|Procedure|brachial plexus block|
103428|NCT03377959|Other|Pilates Mat Classes|The intervention, the exercises, and their progressions were systematized based on protocol proposed by Siler (2008).
103429|NCT03377959|Other|Ballet Classes|The intervention is ballet classes three times a week, 1 hour and 30 min. The ballet classes consists in barre work and center work with specific ballet exercises.
103430|NCT03377946|Biological|probiotics|the probiotics group was taking probiotics 4 packets a day
103431|NCT03377946|Biological|placebo|the placebo group was taking placebo 4 packets a day
103432|NCT03377933|Other|Compound Lactobacillus acidophilus|Compound Lactobacillus acidophilus Tablet
103433|NCT03377920|Device|In-check Dial device (Clement Clarke International Ltd, Harlow, UK)|"pre-bronchodilator spirometry for the measurement of PIFspiro as per ERS/ATS guidelines for standard lung function5 (part of routine clinical follow-up).~5 forced inspiratory manoeuvres using the In-check Dial device G16, set at 5 different resistances (performed in order of increasing resistance), yielding the PIFresist values for the different DPI's"
103434|NCT03377907|Drug|ketamine in hematoma block|ketamine used in local hematoma block only
103435|NCT03377907|Drug|ketamine in local intravenous anesthesia|ketamine will be used with lidocaine in local intravenous anesthesia
103436|NCT03377907|Drug|Lidocaine Hydrochloride|2.5 mg/kg of lidocaine 2% in intravenous regional anesthesia
103437|NCT03377894|Procedure|blunt uterine incision expansion|blunt uterine incision expansion
103438|NCT03377894|Procedure|sharp uterine incision expansion|sharp uterine incision expansion
103439|NCT03377881|Procedure|MRI/Fusion biopsies|The intervention in the experimental arm is an MRI with targeted biopsies using fusion technique to prostate lesions.
103440|NCT03377881|Procedure|Systematic biopsies|The intervention in the control arm is traditional systematic biopsies of the prostate.
103441|NCT03377868|Diagnostic Test|Optic coherence tomography|Optic coherence tomography measures retinal layer thickness, macular volume , and cell inner plexiform layer.
103442|NCT03377868|Diagnostic Test|Pulmonary function test|Pulmonary function test measures forced vital capacity and forced expiratory volume in one second.
103443|NCT03377855|Other|Default Prescribing Change|In the e-prescribing system, the default opioid dosage/duration is changed to the minimum recommended dosage from the CDC guidelines for short acting opioids.
103444|NCT03377842|Drug|FOLFOX regimen|FOLFOX(Oxaliplatin 85 mg/m² IV infusion and leucovorin 200 mg/m² IV infusion， followed by Fluorouracil 400 mg/m² IV bolus , followed by Fluorouracil 600 mg/m²/h IV infusionas a 22-hour continuous infusion). Repeat cycle every 2 weeks for a total of 6 cycl
103445|NCT03377842|Drug|apatinib and FOLFOX regimen|Apatinib, 500mg p.o. qd, Repeat cycle every 2 weeks for a total of 6 cycles. FOLFOX regime, Repeat cycle every 2 weeks for a total of 6 cycles.
103446|NCT03377829|Procedure|PLA|During the PLA, the patient is in supine position with head extended: the physician, ultrasound assistant and trained nurse work within the sterile field. Under constant ultrasound image guidance and after local anesthesia by means of 2% xylocaine infiltration, thin needles (21G) are positioned in the thyroid lesion, within safety distance from the surrounding anatomical structures. A plane-cut tip fiber optics is inserted into the PTMC through the needle. The laser at 1064 nm wavelength is turned on for 10 minutes until the pre-established energy dose is attained. There is usually no pain or very limited pain.
103447|NCT03377829|Procedure|Thyroid Surgery|Patients are routinely disinfected and spread the drapes after general anesthesia. Neck skin, fat, placenta muscle are incised successively. The flap is separated to the upper edge of thyroid cartilage, neck white line is incised and anterior muscle group is separated. Then both sides thyroid lobes are exposed. Cut off the isthmus, ligature the thyroid artery, cut off the upper pole. Ligature and cut off the ipsilateral thyroid vein. Reveal and protect the ipsilateral recurrent laryngeal nerve and the parathyroid gland during the entire process. Finally patient is performed total thyroidectomy or subtotal thyroidectomy.
103493|NCT03377530|Diagnostic Test|Ways to prevent these infections.|"The purpose of this database is to describe the pathogenicity of this germ, the incriminated modes of contamination.~The collaborators studied the factors of poor prognosis and propose ways to prevent these infections."
103448|NCT03377816|Behavioral|Art Therapy|In a group setting participants will be encouraged to engage in art making for increased emotional awareness, expression, and acceptance. The role of the art therapist is to encourage a non-judgmental and exploratory approach to artmaking in which the process is emphasized over product. The art therapist obtains these goals by creating an atmosphere that is calm and by remaining tuned in to the verbalizations and body language of participants. If needed she can provide individual attention that is geared toward neutralizing concerns regarding performance during the art making.
103449|NCT03377816|Behavioral|Sham Art Therapy|In a group setting participants will engage in Mandala coloring
103450|NCT03377803|Drug|VP-102|VP-102 Active will be administered via the applicator to Molluscum lesions
103451|NCT03377803|Drug|Placebo|Placebo to be applied via the applicator to Molluscum lesions
103452|NCT03377803|Device|Applicator|Used to apply the topical film forming Active or Placebo to Molluscum.
103453|NCT03377790|Drug|VP-102|VP-102 Active will be administered via the applicator to Molluscum lesions
103454|NCT03377790|Drug|Placebo|Placebo to be applied via the applicator to Molluscum lesions
103455|NCT03377790|Device|Applicator|Used to apply the topical film forming Active or Placebo to Molluscum.
103456|NCT03377777|Other|No intervention|
103457|NCT03377764|Procedure|Landmark Technique Control group|Spinal Anesthetic
103458|NCT03377764|Procedure|Neuroaxial block using Ultrasound Guidance|Ultrasound guided Spinal Anesthetic
103459|NCT03377751|Procedure|Additional posterior wall isolation|"PVI and additional posterior wall isolation will be performed according to the following protocol which is based on low voltage area.~Proportion of low voltage area to area of left atrium body <10% : PVI only~Proportion of low voltage area to area of left atrium body ≥10% : PVI + Posterior wall isolation~Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
103460|NCT03377751|Procedure|Voltage-guided substrate homogenization|"PVI and additional substrate modification at low voltage areas will be performed according to the following protocol which is based on low voltage area.~Proportion of low voltage area to area of left atrium body <10% : PVI only~Proportion of low voltage area to area of left atrium body ≥10% : PVI + substrate homogenization at low voltage areas~Low voltage area will be measured from more than 1000 points of sampled voltage value during sinus rhythm using PentaRay catheter with 3D mapping system of CARTO (Biosense Webster, CA, USA)."
103461|NCT03377751|Procedure|PVI only group|PVI will be performed in this arm.
103462|NCT03377738|Diagnostic Test|spirometry|All patients will be given an intervention for tobacco cessation which will depend on the individual's cessation phase and will be given a spirometry test as a motivational element for dishabituation.
103463|NCT03377725|Drug|Decitabine|20mg/m^2,d1-5,ivgtt,28days as a duration
103464|NCT03377725|Drug|Arsenic Trioxide|0.16mg/kg,d1-5,ivgtt,28days as a duration
103465|NCT03377712|Device|optoelectronic plethysmography|Evaluates the thoracoabdominal kinematics and the ventilatory pattern of the patient through the filming with cameras, simple and non-invasive examinations
103466|NCT03377712|Device|diaphragmatic ultrasound|Evaluates the diaphragmatic mobility through images, simple and non-invasive use
103467|NCT03377712|Device|Postural evaluation|Evaluates the patient's posture through photos and filming, rapid examination, simple and non-invasive
103468|NCT03377712|Device|Pain evaluation|by means of questionnaires
103469|NCT03377712|Device|Evaluation of the function|through questionnaires
103470|NCT03377712|Device|Functional capacity assessment|Evaluated through the six-minute walk test, where the patient walks along a 30-meter corridor, simple, fast and safe assessment
103471|NCT03377712|Device|Quality of life assessment|through questionnaire
103472|NCT03377699|Drug|Insulin degludec|Injection for subcutaneous (s.c., under the skin) use once daily. The total trial duration for subjects will be maximum 25 months
103473|NCT03377699|Drug|Insulin Aspart|Injection for subcutaneous (s.c., under the skin) use 2-4 times daily with meals. The total trial duration for subjects will be maximum 25 months
103474|NCT03377699|Drug|Insulin detemir|Injection for subcutaneous (s.c., under the skin) use, once daily or twice daily. The total trial duration for subjects will be maximum 25 months
103475|NCT03377686|Diagnostic Test|inflammation markers in exhaled breath|non-invasive, cross-sectional, assessment of inflammation markers in exhaled breath with various techniques (observational)
103476|NCT03377673|Diagnostic Test|CMR|CMR is performed using a 1,5T whole-body system (Siemens Aera, Siemens Medical Solutions; Erlangen, Germany)
103477|NCT03377660|Other|Clinical treatment|Patients undergo clinical treatment as indicated, they are studied before and after.
103478|NCT03377647|Behavioral|Asthma Care Provider Training|In this intervention, asthma care providers will be trained in current, evidence-based guidelines for care of children with asthma, and will be provided with tools that their practice may use to facilitate care improvements.
103479|NCT03377647|Behavioral|School Staff Asthma Education|In this intervention, teachers and other school staff will be provided current, evidence-based training in understanding asthma and will be provided tools to help schools address the special needs of children with asthma.
103480|NCT03377634|Behavioral|MORPH|Participants will engage in 12 weekly group coaching sessions discussion behavioral approaches to pain management, weight loss, and daily physical activity. The first three sessions (i.e., weeks 1 - 3) will occur in-person, and the remaining 9 will take place via telephone. All intervention participants will receive access to an activity monitor, smart scale, and smartphone app that aims to provide support for daily physical activity and weight loss.
103481|NCT03377621|Device|Whole Body Vibration|Whole Body Vibration Machine from the company Confidence Fitness
103482|NCT03377608|Drug|Tenofovir Disoproxil Fumarate|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
103483|NCT03377608|Drug|Depo-Provera|Two cervical biopsies, blood plasma, PBMC, urine, and two cervicovaginal swabs will be collected at a single study visit
103484|NCT03377595|Drug|Exparel|TAP (Transversus Abdominis Plane) block
103485|NCT03377595|Drug|Exparel|Wound infiltration
103486|NCT03377582|Other|Exercise|Both interventions uses exercises
103487|NCT03377569|Other|Sleep, PD and DBS|Sleep, PD and DBS
103494|NCT03377517|Radiation|radiosurgical hypophysectomy|Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
103495|NCT03377504|Behavioral|mirror therapy|Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
103496|NCT03377504|Behavioral|Routine physical therapy and exercise program|Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
103497|NCT03377491|Device|NovoTTF-100L(P)|Patients receive continuous TTFields treatment using the NovoTTF-100L(P) device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
103498|NCT03377491|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered immediately after nab-paclitaxel on Days 1, 8 and 15 of each 28-day cycle.
103499|NCT03377491|Drug|nab paclitaxel|nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on Days 1, 8 and 15 of each 28-day cycle.
103500|NCT03377478|Drug|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
103501|NCT03377465|Diagnostic Test|ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin|ADMA, NTproBNP, IL-6, Adiponectina, Leptine, Syndecan, Resistin
103502|NCT03377452|Behavioral|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
103503|NCT03377452|Behavioral|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided in individual sessions.
103504|NCT03377439|Other|Platelet function tests|Platelet reactivity was measured by flow cytometry, filopodia detection and the platelet aggregation analyzer.
103505|NCT03377426|Drug|LYS228|LYS228 IV infusion
103506|NCT03377426|Drug|Standard of care therapy|IV infusion of standard of care antibiotics
103507|NCT03377400|Drug|Durvalumab|concurrent radiotherapy
103508|NCT03377387|Drug|Capecitabine|Capecitabine will be taken orally in AM and PM (at the assigned dose per cohort) 7 days on and 7 days off. Phase II MD 1000mg BID of capecitabine.
103509|NCT03377387|Drug|Neratinib|Neratinib is given as 240 mg daily continuously without stopping. A cycle is 28 days. Phase II The MD has been determined as 240mg of neratinib
103510|NCT03377387|Behavioral|EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30|Questionnaires Every Cycle (+/- 3 days) (For phase II)
103511|NCT03377374|Dietary Supplement|Probiotic|L. reuteri Prodentis oil drops (L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289) will be given at a dose of 2x108 Colony Forming Units (CFU). Five drops are to be taken twice a day (in the morning and in the evening) giving a daily dose of 4x108 CFU/day.
103512|NCT03377374|Other|Placebo|Five drops of Placebo taken twice a day (in the morning and in the evening).
103513|NCT03377361|Biological|Nivolumab|specified dose on specified days
103514|NCT03377361|Drug|Trametinib|specified dose on specified days
103515|NCT03377361|Biological|Ipilimumab|specified dose on specified days
103516|NCT03377348|Procedure|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision|intraoperative subconjunctival injection of triamcinolone acetonide and limited peritomy during bare scleral pterygium excision
103517|NCT03377335|Drug|Dapagliflozin 10mg|"The subjects in this arm will receive dapagliflozin (10mg daily) as add-on to metformin therapy (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: >87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
103518|NCT03377335|Drug|Metformin|"All the subjects in this arm will be on metformin therapy only (doses ranging from 1500 to 3000 mg daily).~Number of patients to be randomized: 93~Number of patients expected to complete the study: >87~All the other medications (including lipid-lowering, anti-hypertensive and anti-platelet agents) will be maintained at fixed doses during the treatment."
103519|NCT03377322|Drug|Probiotic Capsule|Probiotic - one capsule a day for four weeks
103520|NCT03377322|Drug|Placebo Capsule|Placebo - one capsule a day for four weeks
103521|NCT03377309|Drug|Fycompa|Dose will be increased by 2mg/day increments every one week to reach a maximum dose of 8 mg/day. Treatment phase will be stable dose for 12 weeks then followed by washout period over 2 weeks.
103522|NCT03377296|Other|Plasmodium vivax infection|Two healthy human volunteers are exposed to the bites of five infectious mosquitoes per participant (by placing their forearms over the pot containing mosquitoes) for 5-10 minutes. Fed mosquitoes (as indicated by the presence of a blood meal in the abdomen) are individually dissected and assessed for sporozoite load (graded 0 to +4; a gland rating of +2 or more, representing 10 or more observed sporozoites, qualifies as being infectious). If, by this method the volunteer is found to have been inoculated by less than five infected mosquitoes, further mosquitoes are allowed to feed on the volunteer until a total of 5 appropriately infected mosquitoes have fed. The bite-challenge procedure continues until the subject has been bitten by 5 infectious mosquitoes.
103523|NCT03377296|Procedure|Collection of 250mL blood from each volunteer (N=2)|Collection of 250mL of P. vivax-infected blood from each volunteer when a threshold parasitaemia/ symptoms are met
103524|NCT03377283|Biological|organ perfusion with rabbit anti-thymocyte globulin (rATG)|
103525|NCT03377283|Other|organ perfusion with saline|
103526|NCT03377270|Behavioral|Respiratory Swallow Training|Training in the Optimal Respiratory Swallow Pattern and Lung Volume at Swallow Initiation
103527|NCT03377257|Drug|zolmitriptan by sublingual administration|Experimental group
103528|NCT03377257|Drug|zolmitriptan by oral|Active group
103637|NCT03376477|Drug|Lenalidomide|Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5-25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
103529|NCT03377244|Behavioral|Diabetes Prevention Program Lifestyle Intervention (DPP-LI) with Healthy Bodies Healthy Souls (HBHS)|Diabetes Prevention Program Lifestyle Intervention (DPP-LI) with Healthy Bodies Healthy Souls (HBHS) intervention which includes DPP-LI with the additional enhancement of working with Marshallese churches to implement organizational/institutional level changes to support the individual behavioral intervention of the DPP-LI.
103530|NCT03377231|Device|Stratamark®|Film-forming dressing for the prevention and treatment of stretch marks.
103531|NCT03377218|Dietary Supplement|Iodine|Receiving 150 μg iodine (as potassium iodide) daily
103532|NCT03377218|Dietary Supplement|Iodine + Selenium|Receiving a combination of 150 μg iodine (as potassium iodide) and 100 μg selenium daily
103533|NCT03377205|Device|Compression screws and neutralization plate|Open reduction and internal fixation with screws and plate
103534|NCT03377205|Device|Acumed Fibular Rod System|intramedullary nailing of fibula
103535|NCT03377179|Drug|ABC294640|Two 250 mg capsules of ABC294640 will be taken twice daily
103536|NCT03377166|Diagnostic Test|Bucket test and Smartphone-based evaluation of SVV|Bucket test and Smartphone-based evaluation of SVV
103537|NCT03377153|Dietary Supplement|hesperidin and flaxseed|2 capsuls hesperidin and 30 g flaxseed
103538|NCT03377153|Other|control|no supplementation
103539|NCT03377140|Dietary Supplement|Hesperidin|2 capsuls
103540|NCT03377140|Other|control|2 capsuls
103541|NCT03377127|Behavioral|Pharmacy Managed Diabetes Clinic (PMDC)|The PMDC visit encounters will focus on patient identified goals for the management of their diabetes. Initial visit in the PMDC will be 60-90 minutes with follow up visits lasting 30-45 minutes.
103542|NCT03377127|Other|Standard of Care (SOC)|Standard of care will be delivered at the physician discretion per the current American Diabetes Association recommendations
103543|NCT03377114|Procedure|Neutral|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head and neck in neutral position.
103544|NCT03377114|Procedure|Head tilting|When inserting a tracheal tube to oral cavity via nostril before use of laryngoscope in nasotracheal intubation, clinicians advance the tube with patient' head in head-tilting position.
103545|NCT03377101|Drug|Copanlisib|Given IV
103546|NCT03377101|Drug|Fulvestrant|Given IM
103547|NCT03377101|Other|Laboratory Biomarker Analysis|Correlative studies
103548|NCT03377101|Drug|Palbociclib|Given PO
103549|NCT03377088|Other|Rose oil|Rose oil will be given as the intervention in this study, an over-the-counter agent that can be commonly found in retail stores. It will be delivered as 2 drops 50% rose oil in water on a cotton ball within 20 cm of the patient's face for 30 minutes.
103550|NCT03377088|Other|Almond Oil|Almond Oil has been shown in limited studies to act as a placebo for pain control when compared to Rose Oil. This subtly sweet oil will be used to ensure the patient always receives a smell, and maintains blinding.
103551|NCT03377075|Device|AL measurement|IOL Master 500 (Carl Zeiss AG, Germany)
103552|NCT03377075|Device|OCT|Choroidal and retinal thickness measurement (DRI OCT-1 Model Triton (plus), Topcon, Tokyo, Japan)
103553|NCT03377062|Diagnostic Test|EEG monitoring|Five-minute of EEG monitoring accompanied with auditory stimulation.
103554|NCT03377036|Diagnostic Test|DBT+s2D|Digital breast tomosynthesis plus synthesized 2D mammograms
103555|NCT03377036|Diagnostic Test|2D-FFDM|2D full-field digital mammography
103556|NCT03377023|Drug|Nivolumab|Intravenous nivolumab every 2 weeks.
103557|NCT03377023|Drug|Ipilimumab|Intravenous ipilimumab every 6 weeks.
103558|NCT03377023|Drug|Nintedanib|Nintedanib 100-200 mg capsules by mouth twice daily for two-week cycles.
103559|NCT03377010|Other|Dietary intake -Food Frequency Questionnaire|Dietary intake will be assessed using 2014 full-length food frequency questionnaire. The Block 2014 questionnaire combines a full-length food frequency questionnaire with a brief physical activity screening tool. The food and beverage list includes 127 items in the past 1 month, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
103560|NCT03377010|Other|Receptivity to Participating in Diet Interventions|Study participants will rate their interest in learning more about dietary interventions to stay healthy using items developed specifically for this study. The items will be rated on a 3-point Likert-type scale from 3 (extremely interested) to 1 (not at all interested).
103561|NCT03376997|Drug|Perampanel|IV infusion
103562|NCT03376997|Drug|Perampanel|Oral tablet
103563|NCT03376984|Combination Product|ND and AMOX modified Gutta Percha|Gutta percha reinforced and modified with 5 nm diameter nanodiamonds and amoxicillin
103564|NCT03376984|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
103565|NCT03376971|Procedure|Biopsy|Undergo lung biopsy
103566|NCT03376971|Other|Laboratory Biomarker Analysis|Correlative studies
103567|NCT03376958|Drug|Apatinib|Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
103568|NCT03376945|Drug|trail cohort|"Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid [FA] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
103569|NCT03376945|Drug|control cohort|"Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
103638|NCT03376477|Drug|Prevnar13|Prevnar will be administered at the same time points as the GM-CSF vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine.
103849|NCT03374787|Device|Fusion Sound Processor|Sound Processor
103570|NCT03376932|Drug|FF/UMEC/VI|FF/UMEC/VI will be given as dry white powder delivered via the ELLIPTA DPI once daily in the morning or evening. The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg or 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
103571|NCT03376932|Drug|FP/SAL|FP/SAL will be given as dry white powder delivered via the DISKUS DPI twice daily in the morning or evening. The DISKUS DPI holds a single blister strip with 60 blisters, which contains FP 250 mcg or 500 mcg and SAL 50 mcg per blister.
103572|NCT03376932|Drug|Tiotropium|TIO will be given as clear, colorless, inhalation solution delivered via RESPIMAT inhaler once daily in the morning or evening. The RESPIMAT inhaler will contain 60 puffs with 2.5 mcg TIO per puff.
103573|NCT03376932|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
103574|NCT03376932|Device|ELLIPTA DPI|The ELLIPTA device will be used to administer FF/UMEC/VI once daily. The ELLIPTA DPI is a molded plastic two-sided inhaler that can hold two individual blister strips, which contain powder formulation for oral inhalation.
103575|NCT03376932|Device|DISKUS DPI|The DISKUS device will be used to administer FP/SAL twice daily. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FP/SAL for oral inhalation.
103576|NCT03376932|Device|RESPIMAT inhaler|The RESPIMAT inhaler will be used to administer TIO once daily. The RESPIMAT inhaler has a solution filled into a polyethylene/polypropylene cartridge with a polypropylene cap with integrated silicone sealing ring. The cartridge is enclosed within an aluminum cylinder.
103577|NCT03376932|Device|Metered Dose Inhaler|Albuterol/salbutamol will be delivered as a rescue medication via MDI.
103578|NCT03376932|Device|Connected Inhaler System|The CIS will consist of a sensor, which clips on to the ELLIPTA DPI. This will inform subject's if/when they have taken their medication that is in the ELLIPTA inhaler. The sensor will measure when the ELLIPTA inhaler mouth piece cover is fully opened and closed and this data can be fed back, via the app on a mobile device to the subject. The sensors, app, and provider portal that provide data are subsequently described as the CIS.
103579|NCT03376919|Device|CLs++ gait training|CLs++ gait training
103580|NCT03376906|Procedure|HIIE 1|In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
103581|NCT03376906|Procedure|HIIE 3|In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
103582|NCT03376906|Procedure|Control|In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
103583|NCT03376880|Other|1 year follow-up testing|The approach of the study is not in studying the effectiveness of the intervention stimulus, the dose response of diet and exercise, or the rate of weight loss but only the response to 1) weight loss and regular exercise or 2) continued weight gain.
103584|NCT03376867|Other|Conditioned pain modulation|Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
103585|NCT03376854|Device|Hypothermia|Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.
103586|NCT03376854|Drug|Neuromuscular Blocking Agents|Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.
103587|NCT03376854|Device|Standard of Care|Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature >38°C will receive 650 mg acetaminophen and, if temperature remains >38°C, surface cooling will be initiated to return core temperature to 37-38°C.
103588|NCT03376841|Drug|Cenicriviroc|1 tablet; single-dose oral administration
103589|NCT03376828|Device|Macintosh laryngoscopy|Endotracheal intubation time using the Macintosh laryngoscope
103590|NCT03376828|Device|C-Mac Videolaryngoscope|Endotracheal intubation time using the C-Mac Videolaryngoscope
103591|NCT03376815|Diagnostic Test|landscape sample method|200 cases of different tumor tissues will be compared by traditional sample method and landscape sample method to testify the clinical value and significance of tumor landscape pathological diagnosis .
103592|NCT03376802|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
103593|NCT03376802|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
103594|NCT03376789|Drug|MYL-1501D|Process V or Process VI
103595|NCT03376776|Procedure|Vitrectomy|
103596|NCT03376763|Drug|Abilify maintena|Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)
103597|NCT03376750|Behavioral|CO - OP|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
103598|NCT03376737|Drug|Apatinib|Apatinib (250 mg/d) + Pemetrexed (500 mg/m2)
103599|NCT03376724|Other|Functional Exercise Protocol|Functional exercise protocol. This protocol started with corporal conscience exercise, breathing, abdominal activation, activities such as sitting, getting up, climbing stairs, reaching with arms, moving forward, bodyweight exercises, bridges and boards. This protocol will be performed during 12 weeks, two sessions per week.
103600|NCT03376724|Other|Minimal|Analgesic use when necessary and a single back scholl class
103639|NCT03376477|Other|Placebo Prevnar13|Saline will be used for placebo. Placebo prevnar will be administered at the same time points as the GM-CSF vaccine or Placebo GM-CSF Vaccine (day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months), but on the opposite arm from GM-CSF vaccine or placebo GM-CSF vaccine.
104116|NCT03372629|Drug|Placebo oral capsule|Placebo capsules matching ID-085 capsules
103601|NCT03376711|Behavioral|Online Peer Support Program|"The online peer support program will entail: 1) Informational links; 2) A discussion forum (open to all participants and allowing for asynchronous contact between caregivers & peer mentors); 3) A weekly live chat; 4) Private messaging (audio, video, and text options); and 5) Ask-a-mentor (A short video/blurb profiling each caregiving mentor will be posted including details such as gender, age, duration of care, relationship to care-recipient, and illness that care-recipient suffers from). Caregiving participants can then self-match to a peer mentor they feel is best-positioned to address their support needs."
103602|NCT03376698|Drug|Colchicine 0.5 mg|oral administration of Colchicine 0.5 mg once daily for 12 weeks
103603|NCT03376698|Drug|Colchicine 0.25 mg|oral administration of Colchicine 0.25 mg once daily for 12 weeks
103604|NCT03376698|Drug|Placebo|oral administration of Placebo once daily for 12 weeks
103605|NCT03376685|Behavioral|Endurance Exercise Training (END)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week for 20-25 minutes (Week 1); 30 minutes (Weeks 2-4); or 35 minutes (Weeks 5-6) at 60% VO2 peak.
103606|NCT03376685|Behavioral|Sprint Exercise Training (SIT)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 3 days a week involving a 3-minute warm-up, followed up 4 repetitions (Week 1); 5 repetitions (Weeks 2-4); or 6 (Weeks 5-6) repetitions of 30 seconds at a maximal intensity with 2.5 minutes' rest in between. Exercise will conclude with a 2 minute cool-down.
103607|NCT03376685|Behavioral|Combined Endurance-Sprint Exercise Training (COMB)|Physical activity will be conducted on cycle ergometers under supervision. Participants will exercise 5 days a week alternating between the endurance session (Mon/Wed/Fri) and the sprint session (Tues/Thurs).
103608|NCT03376672|Drug|Ixazomib|All patients will have similar induction and consolidation treatment with the same regimen.
103609|NCT03376672|Drug|Lenalidomide|All patients will have similar induction and consolidation treatment with the same regimen.
103610|NCT03376672|Drug|Dexamethasone|All patients will have similar induction and consolidation treatment with the same regimen.
103611|NCT03376659|Drug|Durvalumab|750mg IV q2 weeks
103612|NCT03376659|Biological|CV301|"MVA-BN-CV301 (prime) - two priming doses of 1.6 x 109 infectious units/0.5 mL (Inf.U) given subcutaneously (s.c.)~FPV-CV301 (boost) - dosed at 1 × 109 Inf.U/0.5 mL given s.c."
103613|NCT03376659|Drug|Capecitabine|1000mg orally twice a day, Monday - Friday Weekly
103614|NCT03376659|Drug|Bevacizumab|5mg/kg IV q2weeks
103615|NCT03376646|Device|Cohort A: Dissolve™|Dissolve™ are to be used in the trial
103616|NCT03376646|Device|Cohort A: Resolute™ Integrity|Resolute™ Integrity are to be used in the trial
103617|NCT03376646|Device|Cohort B: Dissolve™-2.00mm|Dissolve™ are to be used in the trial
103618|NCT03376633|Behavioral|Working on Womanhood (WOW)|A trauma-informed group counseling and clinical mentoring intervention for young women
103619|NCT03376620|Drug|1,4-Diaminobutane|Daily application to surgical breast scars of 1,4 diaminobutane on the active side
103620|NCT03376620|Drug|10% Urea cream|Daily application to surgical breast scars of 10% Urea cream on the sham side
103621|NCT03376607|Other|HBCP programme|The newly-established Home-Based Community Practitioners (HBCPs) programme will enable frontline workers to offer monthly health assessments, disease management and lifestyle advice to diabetic patients, and referral to the district hospitals when needed.
103622|NCT03376607|Behavioral|mobile health application|"HBCPs will actively encourage the use of a mobile app by assisting patients to access it (this process is known as facilitated access). The app will enable: (i) the registration of measurements, such as blood glucose and weight; (ii) the registration of concerns and questions in a diary; (iii) the reception of alerts and notifications for the appointments to the health facilities, and; (iv) access to advice on lifestyle improvement and other patient educational material."
103623|NCT03376594|Drug|Benjakul Extract|30 patients taking Benjakul Extract dosage 100 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
103624|NCT03376594|Drug|Loratadine|30 patients taking Loratadine dosage 10 mg capsule 3 times daily. before Breakfast, lunch and dinner for 42 days.
103625|NCT03376581|Procedure|Platelet rich plasma|Blood drawn from each participant will be spun down to separate platelets. Platelets will be injected into that patient's scalp.
103626|NCT03376555|Drug|Acetylcholine (ACh) Dose Response|Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin
103627|NCT03376555|Drug|Local Heating (LH)|Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin
103628|NCT03376555|Drug|Flow Mediated Dilation with nitroglycerin|"BP cuff on a forearm, gel on the upper arm just above the elbow, and a Doppler ultrasound probe on the gel. The ultrasound measures vessel size and blood velocity. After a 3-minute resting measurement, the cuff inflates for 5 minutes to occlude forearm blood flow (BF). After the cuff deflates, we perform a second reading.~Sublingual nitroglycerin: The subject is supine. We measure blood pressure. Also, we perform ultrasonography at the brachial artery at the elbow during the procedure. Nurse places a 0.4 mg nitroglycerin tablet under the subject's tongue. The subject remains supine for 20 minutes following the nitroglycerin administration."
103629|NCT03376542|Diagnostic Test|Cardiopulmonary Exercise Testing|Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
103630|NCT03376529|Drug|SPR741|400 mg IV over 1 hour
103631|NCT03376529|Drug|Ceftazidime|1.0 gram IV over 1 hour
103632|NCT03376529|Drug|Piperacillin/tazobactam|4.5 grams IV over 1 hour
103633|NCT03376529|Drug|Aztreonam|1.0 gram IV over 1 hour
103634|NCT03376516|Drug|Wilate|von Willebrand factor / Factor VIII (plasma derived)
103635|NCT03376503|Drug|Pegfilgrastim|PK,PD and safety assessment
103636|NCT03376477|Biological|GM-CSF vaccine|Each vaccination will consist of three total intra-dermal injections, on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Vaccine injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each vaccination injection is approximately 0.7-0.8ml.
103640|NCT03376477|Other|Placebo GM-CSF Vaccine|Saline will be used for placebo. Each placebo vaccine will consist of three total intra-dermal injections on day 14 of cycles 1, 2, 3, 6 and annually for a minimum of 36 months in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). In the event that the specified limb is contraindicated, the dominant arm may be used. Placebo injection sites shall be at least 5 cm at needle entry from the nearest neighbor. The approximate volume of each injection is approximately 0.7-0.8ml.
103641|NCT03376464|Device|Xeomin Cosmetic|Xeomin Cosmetic is the purest commercially available botulinum toxin type A available to date. It has been approved by Health Canada since 2012 for the temporary improvement in the appearance of moderate to severe glabellar lines.
103642|NCT03376451|Other|Assessment of endometrium and blood biomarkers for endometriosis diagnosis|Biological samples will be collected from patients, sent to Endodiag, Paris, in France and be processed through IHC and molecular biology techniques to assess the ability of the identified biomarkers signature to diagnose and prognose endometriosis.
103643|NCT03376438|Other|Prospective observational cohorts|Patients with AF or SVT that is significant enough to consider prenatal treatment are eligible for enrollment. Management decisions are made at each patient encounter by the primary physician based on clinical findings and may include: 1) no antiarrhythmic treatment; 2) transplacental antiarrhythmic treatment; 3) direct fetal antiarrhythmic treatment; 4) delivery. Patients enrolled in the FAST Registry will be followed from the time of enrollment until the baby is discharged after birth.
103644|NCT03376412|Device|Raindrop Near Vision Inlay|A maximum of 60 consecutive non-dominant eyes will be implanted with the Raindrop Near Vision Inlay.
103645|NCT03376399|Other|Gastroparesis Cardinal Symptom Index Questionnaire|Patients with an established diagnosis of Diabetic Gastroparesis that are interested in a sleeve gastrectomy for weight loss will be asked to participate in the registry. Once the consent process is complete the patient will be asked to complete the Gastroparesis Cardinal Symptom Index Questionnaire prior to weight loss surgery and 30 days, 3 months, 6 months and 12 months after surgery.
103646|NCT03376386|Radiation|Adaptive dose-Escalated multi-modality image-guided radiotherapy|FDG-PET/CT-scan will be used twice during radiotherapy for a mild dose-escalation to the less-responding parts of the tumor. By adapting the radiotherapy plan, these areas will receive 74-78 Gy.
103647|NCT03376373|Behavioral|neurofeedback|real-time feedback on accuracy of emotion recognition
103648|NCT03376347|Device|FlotracIQ with HPI algorithm|FlotracIQ with hypotension probability indicator (HPI) algorithm connected to arterial line. The treating anesthetist is provided with guidance by means of a flowchart suggesting when to treat and what. Timing of treatment and choice of treatment is then left to the discretion of the attending physician.
103649|NCT03376334|Other|Mental Motor Imagery|
103653|NCT03376308|Diagnostic Test|Pain Score|"Four poin scala 0=No Pain~mild~intermediate~severe"
103654|NCT03376308|Diagnostic Test|Withdrawal movement score|"Withdrawal movements~no movement response~movement limited to the wrist~movement limited to the elbow/shoulder,~generalized movement response."
103655|NCT03376308|Diagnostic Test|hemodynamic response|Hemodynamic data were recorded in the patients taken in the operation room. (T0). Hemodynamic values (T1) measured 1 minute after administration of intravenous propofol were recorded. Hemodynamic values (T2) measured 1 minute after administration of intravenous rocuronium were recorded. Hemodynamic values (T3) measured 1 minute after administration of endotracheal intubation were recorded.
103656|NCT03376295|Drug|LABA and the LAMA tiotropium (LABA-TIO)|combinational drug
103657|NCT03376295|Drug|LABA and an ICS (LABA-ICS)|combinational drug
103658|NCT03376282|Other|Hyperbaric Oxygen oxygen therapy (HBOT)|60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
103659|NCT03376269|Biological|HBOT|•HBOT of 2 ATA for 90 minutes O2 100%, for 60 treatments
103660|NCT03376269|Behavioral|Psychotherapy|creative art psychotherapy which includes self drawing and daily diary alongside professional psychotherapy sessions
103661|NCT03376256|Device|Compuflo Epidural Instrument|Compuflo Epidural Instrument will be used to measure pressure levels in the thoracic epidural space while performing thoracic epidural anesthesia.
103662|NCT03376243|Other|LIPIKAR BAUME AP+ emollient|Structured education on prevention guidelines
103663|NCT03376230|Other|Collect of blood, urines, and intestinal biopsies|
103664|NCT03376217|Other|IPTp delivered by HSAs|Pregnant women will have the option to receive IPTp-SP from Health surveillance assistants (HSAs). SP is recommended in Malawi for prevention of malaria during pregnancy, but currently it is only available at antenatal clinics.
103665|NCT03376204|Other|No intervention|No intervention
103666|NCT03376191|Drug|apatinib|Clinicians chose the initial dose of apatinib according to the patient's physical condition. Besides the clinicians adjusted the dose according to the patient's tolerance during the medication.The dosage was demanded not higher than 750 milligram (mg) per day. The patients received apatinib continuously, 28 days for a period, until intolerance, no longer getting benefits or patient wanted stop.
103692|NCT03375957|Drug|ATx201|two hundred microliters (200 μL) of test article applied to the test site areas of the upper outer arms
103667|NCT03376178|Combination Product|lidocaine and ropivacaine injection through catheters|injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
103668|NCT03376152|Behavioral|Electric Kettle Promotion|Provision of free electric kettles and promotional materials/information
103669|NCT03376139|Drug|Zonisamide|Zonisamide capsules titrated to a maximum tolerated dose of 400 mg/day for 35 days +/- 4 days, followed by a 14 day down-titration period.
103670|NCT03376139|Drug|Placebo Comparator|Encapsulated placebo filler (lactose) for 35 +/- 4 days, followed by a 14 day down-titration period. Placebo will go through a similar perceived titration process to maintain blind.
103671|NCT03376126|Other|Minimal-invasive isolated limb perfusion|Minimal-invasive isolated limb perfusion
103672|NCT03376113|Behavioral|the volitional help sheet|A sheet includes two columns: one shows critical situations that easily trigger self-harm; other one shows appropriate solutions for patients to prevent self-harm.
103673|NCT03376100|Procedure|Ultrasound guided nerve blocks|Ultrasound guided nerve blocks of the radial and median nerves
103674|NCT03376100|Procedure|Hematoma Block|Conventional local anesthetic method using hematoma block
103675|NCT03376074|Device|Hypothermic oxygenated perfusion (HOPE)|25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure < 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa
103676|NCT03376074|Other|Conventional cold storage|75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
103677|NCT03376061|Drug|Tranexamic Acid|Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
103678|NCT03376048|Procedure|Wound infiltration plus TAP|"TAP block: At the beginning of the main surgical procedure the surgeon will perform a TAP with ropivacaine infiltration, bilaterally in the anterior axillary line, between the costal margin and iliac crest in the intermuscular plane between the internal oblique and transversus abdominis muscles, the anesthesiologist under ultrasound guidance, the surgeon under laparoscopic guidance (two pops technique).~Wound infiltration : Wound infiltration of ropivacaine will be performed by the surgeon before skin incision."
103679|NCT03376048|Procedure|Wound infiltration|Wound infiltration of ropivacaine will be performed by the surgeon before skin incision.
103680|NCT03376035|Other|Temperature measurement of breast|Multiple measurements will be obtained from the ear, chest, breast, abdomen, and hands.
103681|NCT03376022|Other|Attitudes, knowledge|To investigate attitudes and knowledge to oral Health and oral care
103682|NCT03376009|Diagnostic Test|Blood sample for serum and plasma biomarkers:|Serum/plasma biomarkers: Approximately 10ml (3 teaspoons) of blood will be extracted to measure pre-specified biomarkers of renal injury including kidney injury molecule-1 (KIM-1), cystatin C and neutrophil gelatinase-associated lipocalin (NGAL). Samples will then be stored to facilitate measurement of additional biomarkers in the future.
103683|NCT03376009|Diagnostic Test|Urine sample for biomarkers|Urinary biomarkers: A random urine sample will be obtained to measure urinary protein to creatinine ratio (uPCR), KIM-1 and liver-type fatty acid binding protein (L-FABP)
103684|NCT03376009|Diagnostic Test|Cardiac bio-impedance (Cardioscreen Medis)|Cardiac bio-impedance - a non-invasive assessment of cardiac output, cardiac index and systemic vascular resistance index using the bio-impedence technique (Cardioscreen 1000 Medis) Cardiac bio-impedance is performed by attaching sticky electrodes to the participant's neck and thorax. These electrodes pass a very low, constant and alternating current (1.5 mA, 86 kHz) across the thorax, which is imperceptible to the patient. This provides beat by beat data on cardiac output and haemodynamic measurements.
103685|NCT03376009|Diagnostic Test|Aortic pulse wave velocity (APWV) (TensioMed and SphygmoCor)|"Aortic pulse wave velocity (APWV) a non-invasive measure of arterial function using oscillometric recordings to detail peripheral and central haemodynamics. This will be measured using two different techniques:~TensioMed Arteriograph: After a rest period a blood pressure cuff inflates and deflates twice on the arm. This takes ~3 minutes and should cause only mild, temporary discomfort. The test will routinely be performed in duplicate to ensure accuracy of results.~SphygmoCor: A pressure sensor is held over the radial pulse at the wrist to analyse the pulse wave. Then held over the carotid artery and/or femoral artery to assess the speed of the pulse wave through the body. The probe is similar to an ultrasound probe and should not cause any discomfort."
103686|NCT03376009|Diagnostic Test|Optical Coherence Tomography (Spectralis OCT)|"OCT is a non-invasive imaging test which uses light waves to take cross sectional images of the back of the eye. Examination of the retinal and retinal nerve fibre layer thickness, macular volume, and choroidal thickness provides an assessment of generalised systemic microvascular injury. A strong correlation between choroidal thickness and renal dysfunction has previously been shown in patients with chronic kidney disease (Balmforth C et al, JCI Insight 2016).~The participant is asked to sit in front of the OCT machine and rest their chin on a support to keep it motionless. The equipment will then scan the eye without touching it. Scanning takes about 5 - 10 minutes."
103687|NCT03376009|Diagnostic Test|Arterial Spin Labelling Magnetic Resonance Imaging|"Magnetic resonance imaging using arterial spin labelling (ASL-MRI) This promising quantitative technique has the potential to identify dysregulated renal perfusion, stratify risk of AKI in pre-OLT patients, and to monitor alterations in renal haemodynamics in the post transplantation setting.~We aim to recruit 5 participants with 'normal' renal function (eGFR≥60ml/min/1.73m2) and a further 5 participants with 'abnormal' renal function (eGFR<60ml/min/1.73m2)~ASL-MRI will be performed in this subgroup during the week of OLT assessment and then repeated at 6-weeks post transplantation in those participants who undergo OLT during the study period."
103688|NCT03375996|Drug|cyclopentolate 0.5% eye drops|cyclopentolate 0.5% eye drops and measurement of the pupillary mydriasis (dilatation)
103689|NCT03375983|Biological|Blood-stage infection of P.vivax|The P. vivax infected blood will be confirmed to follow the national standard of blood donation to ensure that only P. vivax is included, excluding the presence of P. falciparum. Exclude other infectious diseases according to the test of national standard of blood donation.
103690|NCT03375970|Other|TCM|oral chinese herb, chinese topical ointment
103691|NCT03375970|Other|Western medicine|oral steroid, oral antihistamine, topical steroid
103693|NCT03375957|Drug|ATx201 Placebo Gel|two hundred microliters (200 μL) of placebo applied to the test site areas of the upper outer arms
103694|NCT03375944|Other|Rehabilitation|"The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population."
103695|NCT03375931|Behavioral|Prayer|If the patient wishes to pray, the anesthesiologist will pray for one minute before anesthesia.
103696|NCT03375931|Behavioral|non-prayer|If the patient does not want to pray, the anesthesiologist does anesthesia without praying.
103697|NCT03375918|Other|CONSULT-BP Educational Intervention|"The CONSULT-BP intervention includes two, 180-minute, in-persons sessions 5 weeks apart. Each session has 3 parts: 1. Pre-Clinical Practice Simulation Learning; 2. Trainee Self-Assessments of implicit bias; and 3. In-Person Clinical Practice Simulations to practice communication skills, trigger reflection, and frame group-based reflections on bias."
103698|NCT03375905|Device|cNEP|subjects with OSA will be treated with the cNEP device with the goal of reducing the number of apneas and hypopneas
103699|NCT03375892|Other|Deep Inspiration Breath Hold and Free-breathing|The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered. In addition, the patient will be instructed to breathe freely.
103700|NCT03375879|Device|Bandage contact lens|Bandage contact lens
103701|NCT03375866|Other|Pretzels|Subjects consume 240 kcal of pretzels daily for 8 weeks.
103702|NCT03375866|Other|Mixed nuts|Subjects consume 240 kcal of mixed nuts daily for 8 weeks.
103703|NCT03375853|Behavioral|Computer Based Response Training Weight Loss Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
103704|NCT03375853|Behavioral|Generic Response Training Control Intervention|Participants complete four computer based training tasks each visit, over the course of a few lab visits. Participants then perform weekly booster sessions in a more natural home or community environment over the internet using the same computer based training tasks.
103705|NCT03375840|Behavioral|Text-only PWL|Control condition
103706|NCT03375840|Behavioral|Low-emot PWL|Pictorial warning
103707|NCT03375840|Behavioral|High-emot PWL|Pictorial warning
103708|NCT03375840|Behavioral|Immediate posttest|
103709|NCT03375840|Behavioral|delay posttest|
103710|NCT03375827|Other|IGCDG|The IGCDG reviews topics of concern for patients with metastatic breast cancer.
103711|NCT03375814|Drug|Crocin|This group (osteoarthritic patients) can receive crocin with conventional therapy
103712|NCT03375814|Drug|Placebo Oral Tablet|The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
103713|NCT03375801|Other|Decision Aid|This will be an online tool giving evidence based information and explanation on their options.
103714|NCT03375788|Drug|Tesamorelin|Tesamorelin F4 formulation 1.4mg daily
103715|NCT03375788|Drug|Identical Placebo|Placebo injection daily
103716|NCT03375775|Drug|Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy|According to standardized clinical protocol
103717|NCT03375775|Other|No immunotherapy, symptomatic treatment|These patients will only receive symptomatic treatment for their allergic rhinoconjunctivitis.
103718|NCT03375762|Other|Remote ischemic perconditioning|Five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
103719|NCT03375762|Other|Sham remote perconditioning|Sham five 5-minute inflations/deflations of an automatic device placed on the upper non-paretic arm initiated in the ambulance on the way to hospital in the case of stroke code activation and RACE score >0 and RACE motor item>0
103720|NCT03375749|Behavioral|Standing desk intervention|Standing desk converter
103721|NCT03375749|Behavioral|Waitlist control|Control
103722|NCT03375736|Device|whole body vibration|The children and young adults will receive the WBVT when standing still on a vibration platform of 20 Hertz and a peak-to-peak amplitude of 2 mm: sessions will be 18 minutes in length, 4 days per week for 4 weeks. Assessments will be performed at baseline and at completion of the intervention to examine the functional abilities of these children and young adults. The vibration frequency, duration and amplitude will be progressively increased over 2 weeks to the maximum of 3 minutes of 20 Hz with a peak-to-peak amplitude of 2mm.
103723|NCT03375723|Other|Information on anatomy and physiology, and breathing technique|The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.
103724|NCT03375723|Other|Usual care treatment|Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
103725|NCT03375710|Device|Cordella™ Heart Failure System|"The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~myCordella™ Patient Management Portal~myCordella™ Hub~myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)"
103726|NCT03375697|Drug|JNJ-63733657|Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.
103727|NCT03375697|Drug|Placebo|Subjects will receive matching placebo intravenously.
103771|NCT03375346|Other|Exercise|maintain a half-squat position (knee joint angle at 160 degrees) on the tilt table with an incline of 60 degrees
103728|NCT03375684|Other|Conventional chest physiotherapy|Programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage and coughing tecniques.
103729|NCT03375684|Other|Inspiratory muscle training|Threshold IMT device will be used for the training. Training intensity will set at 30% of the maximum inspiratory pressure.
103730|NCT03375671|Drug|Ketalar|single administration of 5 mg/kg, IM
103731|NCT03375671|Drug|Midazolam injection|single administration of 5 mg, IM
103732|NCT03375671|Drug|Haloperidol|single administration of 5 mg, IM
103733|NCT03375658|Other|PDWS Intervension|Patients admitted to the emergency department in the intervention period will have their vital values presented on the PDWS in addition to existing patient monitoring systems
103734|NCT03375645|Drug|Any oral opioid|Emergency department patients who receive a prescription for an oral opioid
103735|NCT03375632|Drug|FYU-981|Oral daily dosing for 14 weeks
103736|NCT03375619|Other|Long-Term Follow-Up of Patients who Received CAR-20/19-T cells|No study drug is administered in this study. Patients who received CAR-20/19-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.
103737|NCT03375606|Biological|CSL730|Solution for IV infusion
103738|NCT03375606|Other|Placebo|Saline solution for IV infusion
103739|NCT03375593|Drug|Hydrocodone 5Mg/Acetaminophen 500Mg Tab|tablet
103740|NCT03375593|Drug|Acetaminophen 500Mg Tab|tablet
103741|NCT03375593|Drug|Ibuprofen 600 mg tab|tablet
103742|NCT03375580|Dietary Supplement|TLC|transform life custom (TLC)
103743|NCT03375580|Drug|metformin|0.5g metformin group，PO tid
103744|NCT03375580|Drug|Compound Zhenzhu Tiaozhi capsule|Compound Zhenzhu Tiaozhi capsules consist of eight Chinese herbal medications, such as Ligustrum lucidum, Atractylodes macrocephala, Radix Salviae Miltiorrhizae, pseudo-ginseng, Astragalus membranaceus.
103745|NCT03375580|Drug|Simvastatin|20mg simvastatin, PO qn
103746|NCT03375567|Procedure|Guided Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
103747|NCT03375567|Procedure|Standard Lesion Biopsies|After patients are treated with Carfilzomib Lenalidomide Dexamethasone (CRD), lesion biopsies will be performed per usual care. Patients will have biopsies performed on lesions using a novel image guided technique.
103748|NCT03375541|Other|Risk Aversion Calculator|The calculator asks the participant to rate their level of aversion to having a set list of potential medication side effects (0 = no concern; 1 = mild concern; 2 = moderate concern; 3 = moderate to severe concern; 4 = severe concern)
103749|NCT03375528|Device|DES implantation|Coronary artery intervention using Drug eluting stent and Intravascular Ultrasound is performed.
103750|NCT03375515|Drug|Hydromorphone|"For opioid-intolerant patients: continuous infusion of hydromorphone 0 mg per hour, and a demand dose of 0.5 mg with a lockout interval of 15 minutes.~For opioid-tolerant patients: basal rate 0 mg per hour, and a demand dose of 10% of the hydrmorphone dose equivalent to the total opioid taken in the previous 24 hrs with a lockout interval of 15 minutes."
103751|NCT03375515|Device|PCA pump|"For opioid-intolerant patients: initia dose 0.5 mg intravenous hydromorphone.~For opioidtolerant patients: intravenous hydromorphone with a initial dose equivalent to 10%(5-15%) of the total opioid taken in the previous 24 hrs."
103752|NCT03375502|Drug|Varicella Vaccine|The subject will receive investigational product or comparator.
103753|NCT03375489|Other|Telehealth|"Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
103754|NCT03375489|Other|In-person PC|"In person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness"
103755|NCT03375476|Diagnostic Test|collection of cardiovascular risk scores and intraoperative cardiovascular parameters|collection of preoperative cardiovascular risk scores and intraoperative cardiovascular parameters
103756|NCT03375476|Diagnostic Test|cardiac troponin assay|plasmatic concentration of high sensitive cardiac troponin will be measured at baseline and on postoperative day 1, 2 and 3
103757|NCT03375476|Diagnostic Test|Electrocardiogram|12 derivations ECG will be made at baseline and on postoperative day 1, 2, and 3
103758|NCT03375463|Drug|Tirzepatide|Administered SC
103759|NCT03375463|Drug|Tirzepatide|Administered IV
103760|NCT03375463|Drug|Placebo|Administered SC
103761|NCT03375450|Other|Standard of Care|Participants will be followed as per local routine primary healthcare practice
103762|NCT03375437|Genetic|Blood and tumor samples|"FFPE tumor block (archival or a dedicated freshly collected tumor biopsy) will be collected for all enrolled patients and centralized.~Blood sampling for Translational Research (optional) (2*10mL EDTA)"
103763|NCT03375424|Biological|vedolizumab|duration of disease and kind of therapy
103764|NCT03375411|Device|Stent INC1|Coronary intervention with conventional angioplasty technique but with a novel bare metal stent.
103765|NCT03375398|Dietary Supplement|Rice|Test food #1: White Rice <63.0 g (dry) Jasmine rice consumed together with 250 mL water
103766|NCT03375398|Dietary Supplement|Sugardown™|Test food #2: White Rice < 63.0 g (dry) Jasmine rice + 3 Sugardown™ tablets consumed together with 250 mL water Test food #3: White Rice < 63.0 g (dry) Jasmine rice + 6 Sugardown™ tablets consumed together with 250 mL water
103767|NCT03375385|Drug|dexmedetomidine/ propofol|The loading and infusion doses of dexmedetomidine hydrochloride and 1% propofol were calculated according to the patient's body weight and diluted to a 10 ml volume (labeled as loading-1 and loading-2) and a 50 ml volume (labeled as infusion-1 and infusion-2).
103768|NCT03375372|Procedure|Scaling and Root Planing (S&RP)|dental Scaling and Root Planing and oral hygiene regimen
103769|NCT03375359|Diagnostic Test|cfDNA screening|cfDNA screening test for aneuploidy risk assessment
103770|NCT03375346|Device|Whole body vibration|whole body vibration exercise is a stimulus that uses vibrations generated on a machine with oscillatory movement determined by the amplitude and frequency of the vibration.
103777|NCT03375294|Drug|Nitrous Oxide|One hour inhalation of 50% nitrous oxide, an odorless, colorless gas FDA approved as an induction agent for dental sedation
103778|NCT03375281|Procedure|RFA|thermal ablation using radiofrequency for HCC
103779|NCT03375255|Drug|SRP-5051|Single dose of SRP-5051 administered as an intravenous (IV) infusion.
103780|NCT03375242|Drug|crizotinib|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
103781|NCT03375229|Other|Dry Needling|"It will be used acupuncture needles, individually packaged and sterilized, with 0.25 mm of thickness and 0.40 mm of length. The therapist will perform the grip in upper trapezius on the site of one of the two previously marked locations, according to the subject group allocation, and will insert the needle in the skin with help of a guide tube and will deepen the needle approximately 10 to 15 mm inside the trigger point. The needle will be moved up and down as in the fast-in and fast-out technique described by Hong and the movement will be repeated during 30 seconds in a cadence of approximately 1 Hz. The protocol will be the same for the groups that will receive the application directly on the trigger point and for the group that will receive the application away from the trigger point"
103782|NCT03375229|Device|Low-Level Laser Therapy|The laser protocol will be performed using an equipment from Ibramed Equipamentos Médicos® of Aluminized Gallium Arsenide (AsGaAl) laser diode, with a wavelength of 830 nm, fluency of 20 J/cm², 30 mW, beam area of 0.116 cm², energy of 2,3 J per point, continuous beam (22). The low-level laser therapy (LLLT) will be applied for 30 seconds at the marked point on upper trapezius, right after the dry needling application.
103783|NCT03375216|Behavioral|sensory testing (Heat, cold, and pressure)|sensory threshold measurement is the point at which the participant feels pain due to either heat, cold, or pressure
103784|NCT03375216|Behavioral|Promis Survey|PROMIS computer adaptive survey in anxiety, depression, pain behavior, fatigue, pian interference, physical function, sleep disturbance, self efficacy
103785|NCT03375203|Drug|Placebo|Placebo (matching to JNJ-42847922 or Zolpidem) will be administered as one or two oral capsules once daily based upon dosing group.
103786|NCT03375203|Drug|JNJ-42847922, 5 mg|JNJ-42847922 will be administered as 5 mg (2*2.5 mg capsule) oral capsules once daily.
103787|NCT03375203|Drug|JNJ-42847922, 10 mg|JNJ-42847922 will be administered as 10 mg oral capsule once daily.
103788|NCT03375203|Drug|JNJ-42847922, 20 mg|JNJ-42847922 will be administered as 20 mg oral capsule once daily.
103789|NCT03375203|Drug|Zolpidem|Zolpidem will be administered as 5 mg or 10 mg (2*5mg capsule) oral capsule once daily based upon the local labeling information.
103790|NCT03375190|Other|Dressing|Transparent film dressing (TegadermTM CHG Chlorhexidine Gluconate IV Securement Dressing, 3M Health Care, St. Paul, MN, USA) alone
103791|NCT03375190|Other|Dressing + adhesive|Transparent film dressing + topical skin adhesive (SwiftSetTM Topical Skin Adhesive, CovidienTM Devon, UK) at insertion site
103792|NCT03375190|Other|Experimental: Dressing + adhesive + strips (parallel)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed parallel to long axis of catheter
103793|NCT03375190|Other|Experimental: Dressing + adhesive + strips (perpend)|Transparent film dressing + topical skin adhesive + reinforced skin closure strips (Steri-StripTM, 3M Health Care, St. Paul, MN, USA) placed perpendicular to long axis of catheter
103794|NCT03375190|Other|Experimental: Dressing + adhesive + strips + benzoin|Transparent film dressing + topical skin adhesive + skin closure strips + topical benzoin (Compound Tincture of Benzoin USP 10%, Professional Disposables International, Inc., Orangeburg, NY, USA) spread in a 12 centimeter by 14 centimeter area around the insertion site
103795|NCT03375190|Other|Experimental: Dressing + adhesive + strips + spray|Transparent film dressing + topical skin adhesive + skin closure strips + medical adhesive spray (AdaptTM Medical Adhesive, Hollister Incorporated, Libertyville, IL, USA) in a 12 centimeter by 14 centimeter area around the insertion site
103796|NCT03375177|Other|Natural history of disease|registry plan
103797|NCT03375164|Drug|rAAVrh74.MHCK7.micro-dystrophin|gene vector
103798|NCT03375151|Device|EEG based feedback|Participants will participate in cognitive training sessions. The therapist will use feedback from the EEG analyzed data to direct the cognitive therapy based on the therapist's guidance to maximize the intensity and duration of the patient's high brain engagement Index (BEI) during exercise.
103799|NCT03375151|Behavioral|Standard practice based feedback|Participants will participate in cognitive training sessions. The therapist will give feedback to the participants during the exercise based on their performance only according to the his therapist standard practice.
103800|NCT03375151|Behavioral|No feedback|Participants will participate in cognitive training sessions. The therapist will not guide them during the sessions.
103801|NCT03375138|Drug|belatacept|Specified dose on specified days
103802|NCT03375125|Dietary Supplement|Probiotic|L. reuteri DSM 17938 & L. reuteri ATCC PTA 5289 ) will be given at a dose of 2x10^8 Colony Forming Units (CFU). One lozenges is to be taken twice per day (one in the morning and one in the afternoon) giving a total daily dose of at least 4x108 CFU/day.
103803|NCT03375125|Other|Placebo|Placebo will have identical appearance, taste, and flavor, except for lacking the bacteria. One lozenges will be taken twice per day (one in the morning and one in the afternoon)
103804|NCT03375112|Procedure|Fascia iliaca compartment block|The patient will be brought to the block room within 30 minutes of arriving in recovery. An injection of local anesthetic into the fascia iliaca compartment using ultrasound guidance will be administered. The patient will then be transported back to recovery.
103805|NCT03375112|Drug|Placebo|The patient will be brought to the block room within 30 minutes of arriving in recovery. An ultrasound probe will be placed to the skin and a blunt needle will be touched to the patient's skin in the area that a fascia iliaca compartment block would be performed. The patient will then be transported back to recovery.
103806|NCT03375112|Drug|Bupivacaine|A one time dose of 40 milliliters of 0.5% bupivacaine will be injected into the fascia iliaca compartment
103807|NCT03375099|Behavioral|Lethal Means Counseling|Single session motivational interviewing based interaction aimed to increase the safe storage of firearms in an effort to reduce suicide risk.
104265|NCT03371563|Drug|Antibiotics|Patients were treated with antibiotics for Lyme disease.
103808|NCT03375099|Behavioral|Health and Stress Reduction|Single session motivational interviewing based interaction aimed to reduce vulnerability to negative outcomes across four domains: sleep, diet, exercise, and stress.
103809|NCT03375086|Drug|APX3330|APX3330 will be supplied as 60 and 120 mg orally administered tablets. Patients will receive a fixed dose of APX3330 twice daily (i.e., bid) each day of a 21-day cycle. The starting dose of APX3330 will be a daily dose of 240 mg (i.e., 120 mg/dose bid). Doses will be increased until identification of a maximum tolerated dose or bio-effective dose, whichever is lower.
103810|NCT03375073|Other|Positive communication during medical transmission|Use of positive communication for medical transmission to the anaesthetic team who takes over the patient.
103811|NCT03375047|Drug|MRT5005|Nebulization of MRT5005
103812|NCT03375047|Drug|Normal saline|Normal Saline for Inhalation
103813|NCT03375034|Drug|NDMC 20mg|Oral administration of one NDMC 20mg capsule and two Placebo capsules
103814|NCT03375034|Drug|NDMC60mg|Oral administration of three NDMC 20mg capsules
103815|NCT03375034|Drug|Clonazepam 1.5mg|Oral administration of three clonazepam 0.5mg capsules
103816|NCT03375034|Drug|Placebo|Oral administration of three Placebo capsules
103817|NCT03375021|Drug|CX717 200 mg|CX717 200 mg capsules BID
103818|NCT03375021|Drug|CX717 800 mg|CX717 4 X 200 mg capsules BID
103819|NCT03375021|Drug|Placebo|Placebo 200 mg or 800 mg capsules BID
103820|NCT03375008|Diagnostic Test|Imaging diagnostic and biopsy|Liver biopsy and MRI scan
103821|NCT03374995|Other|Best Practice|Receive standard of care
103822|NCT03374995|Other|Quality-of-Life Assessment|Ancillary studies
103823|NCT03374995|Drug|Topical Keratin|Given topically
103824|NCT03374982|Device|DentalVibe|The DentalVibe is a handheld device that delivers vibration to the tissue during local anesthetic administration.
103825|NCT03374969|Behavioral|Attachment and Biobehavioral Catch-Up|Attachment and Biobehavioral Catch-up (ABC) is a 10-session, weekly intervention delivered in the family's home. ABC addresses three primary issues. First, young children who have experienced early adversity are especially in need of nurturance and parents who behave in synchronous ways and delight in them. Next, when parents behave in frightening ways, it is difficult for children to look to them for reassurance when distressed. This can be particularly difficult for children who have experienced early adversity. Therefore, this intervention helps parents learn how to: 1) behave in nurturing ways when children are distressed; 2) behave in synchronous, delighted ways when children are not distressed; and 3) avoid behaving in frightening or intrusive ways. Interventionists are provided with a manualized protocol, but tailor specific session content to each family's needs. Sessions are videotaped, both for playback to families, and for supervision.
103826|NCT03374969|Behavioral|Developmental Education for Families|Developmental Education for Families (DEF) is a 10-session, weekly intervention delivered in the family's home. DEF focuses on enhancing gross and fine motor skills, cognition and language development. The age-based protocols (i.e., 6-24 months,) provide information about the developmental themes of focus for each week and suggest activities to enhance the target skills for that week. However, the protocols do not provide a direct script with which to conduct the sessions. Interventionists tailor the developmental program session to the needs of the child and family by considering the child's current gross, fine, cognitive and language skills and creatively preparing several activities that will address the session topics.
103827|NCT03374956|Drug|Phentermine-Topiramate|Extended Release at dose of 7.5/46 mg oral daily
103828|NCT03374956|Drug|Liraglutide|dose of 3 mg subcutaneous daily
103829|NCT03374956|Drug|Naltrexone/bupropion|Oral naltrexone extended-release/bupropion extended-release at dose of 32/360 mg oral daily (divided in 2 tables in morning and 2 tablets in evening)
103830|NCT03374956|Drug|Phentermine|15-37.5 mg oral daily
103831|NCT03374943|Drug|KB004|KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase
103832|NCT03374930|Procedure|Multiple rapid swallows test|Multiple rapid swallows test consists in giving to patient 4 to 6 sips of 2 mL of water, with an interval less than 4 seconds between the different sips.
103833|NCT03374917|Drug|ABBV-951|powder for solution
103834|NCT03374904|Behavioral|Video Feedback|first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.
103835|NCT03374904|Behavioral|Control Group|Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
103836|NCT03374891|Other|Educational video and/or handout|The intervention includes a video and/or handout (whichever is easier for the participant) that will give information about defibrillators and about other patients' experiences with their decisions about defibrillators.
103837|NCT03374878|Other|no oral contraceptive and training|10 weeks of training in a group of oral contraceptive users
103838|NCT03374878|Other|oral contraceptive and training|10 weeks of training in a group of users of oral contraceptives
103839|NCT03374865|Other|Facetalk|Area of interest: communication during Facetalk consultations
103840|NCT03374865|Other|Face-to-face consultation|Area of interest: communication during face-to-face consultations
103841|NCT03374852|Drug|CPI-613|500 mg/m2, IV infusion at a rate of 4 mL/min via a central venous port
103842|NCT03374852|Drug|mFOLFIRNOX|mFOLFIRNOX (given immediately after CPI-613 administration):
103843|NCT03374839|Drug|TIL + IL-2 + Nivolumab|"The patients will receive Nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks from day0 until week52.~Two TIL (Tumor Infiltrating Lymphocytes) injections will be performed: at week 14 and at week 18.~The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days."
103844|NCT03374826|Diagnostic Test|Dedicated axillary hybrid PET-MRI|All clinically node negative patients will undergo a hybrid PET-MRI axilla preoperatively, followed by breast surgery and SLNB.
103845|NCT03374813|Device|MimetikOss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
103846|NCT03374813|Device|Bio-Oss (bone grafting surgery)|Ridge preservation bone grafting after dental extraction.
103847|NCT03374800|Drug|Placebo (0.9% saline)|normal saline
103850|NCT03374774|Drug|BIAsp 30|Participants will receive commercially available BIAsp 30 according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose.
103851|NCT03374761|Other|Families First Home Visiting Program|10 group sessions and 4 home visits with community facilitators emphasizing positive parenting
103852|NCT03374748|Other|N/A - observational study|N/A - observational study
103853|NCT03374735|Device|SETALUM™ Sealant|SETALUM™ Sealant to be applied on the suture line
103854|NCT03374722|Drug|Opioids|Mechanically ventilated critically ill patients who receive continuous opioid infusion for more than 24 hours will be observed for withdrawal symptoms when rate of opioid infusion is disrupted or decreased
103855|NCT03374709|Drug|Oxtellar XR 150Mg Extended Release Tablet|Oxtellar XR
103856|NCT03374696|Behavioral|SAFETY|
103857|NCT03374696|Behavioral|Standard education|
103858|NCT03374683|Behavioral|RR Digital Tool|"Participants proceed through three chapters in the tool: https://outsideplay.ca. Chapter 1: most important attributes they want for their child; their child's favourite play activities; their own childhood play activities; how their child's and their own play activities compare.~Chapter 2: imagining themselves in three video segments where they must decide whether they allow their child to climb a tree, walk home from school, and use box cutters to build a fort. They reflect on their barriers and things that helped them let go.~Chapter 3: revisiting the most important attributes they want for their child and whether there is anything they want to change, setting a realistic goal, outlining steps for attaining that goal, and setting start date."
103859|NCT03374683|Behavioral|RR In-Person Workshop|Participants engage in a 2-hour facilitator guided discussion of the same tasks as the RR digital tool. Participants are taken through each task using PowerPoint slides that include the videos from the digital tool. The facilitator guide contains detailed guidance on discussion for each component and length of time to be dedicated to each slide. Participants are provided with a paper booklet to complete that mimics the online tasks.
103860|NCT03374683|Behavioral|Position Statement Active Outdoor Play|"The position statement summarizes the issues and research regarding children's access to outdoor play and provides recommendations for various stakeholders. It states that access to active play in nature and outdoors - with its risks - is essential for healthy child development and recommends increasing children's opportunities for self-directed play in all settings. The Position Statement includes recommendations for parents, educators, health professionals, administrators and various level of governments to address the barriers to children's outdoor play. It addresses common misconceptions and encourages that danger be differentiated from risk and outdoor play and fun be valued as much as safety (ParticipACTION Canada, 2015; Tremblay et al., 2015)."
103861|NCT03374670|Drug|Zimura|Zimura in combination with Eylea
103862|NCT03374670|Drug|Eylea|Zimura in combination with Eylea
103863|NCT03374657|Biological|CPK850|In one of 5 dose levels administered via subretinal injection under anesthesia
103864|NCT03374644|Device|SentriTM ETCO2 adult nasal cannula|Sentri nasal cannula is the device which designed to sample exhaled ETCO2 in non-intubated patients during the administration of supplementary oxygen. By delivering oxygen through one prong and sampling exhaled gas from the other prong, the nasal cannula can provide end tidal values comparable to those achieved with intubated patients. It is fitted to the patients as same manner as conventional nasal cannula. Furthermore, it consists of curved prong to improve the anatomical fit.
103865|NCT03374631|Device|active anodal tDCS|active anodal tDCS with behavioral tasks and self-report measures to assess paranoid ideation
103866|NCT03374631|Device|sham tDCS|sham tDCS with behavioral tasks and self-report measures to assess paranoid ideation
103867|NCT03374618|Other|Blood sample|Blood sample to quantify and qualify netosis in vivo and ex vivo after different stimulations in SSC, SLA and healthy controls
103868|NCT03374605|Device|active tDCS|15 minutes of active (2mA) high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
103869|NCT03374605|Device|sham tDCS|15 minutes of sham high definition tDCS will be applied to the participant's skull. The anodal electrode will be placed over 10-20 EEG coordinate AF7 and cathodal electrode over coordinate Fz.
103870|NCT03374592|Radiation|Volumetric Intensity-Modulated Arc Therapy|Advanced radiotherapy technique
103871|NCT03374592|Radiation|Conventional Radiotherapy|Conventional radiotherapy technique
103872|NCT03374579|Diagnostic Test|Fluid challenge|Fluid challenge and measure change in co2 gap
103873|NCT03374553|Device|MINIject 636 implant|"MINIject 636 is an integrated system comprising a minimally-invasive Glaucoma Drainage Implant CS636 and a Delivery Tool.~The Delivery Tool is a single-use tool, designed for inserting the CS636 implant into the sub-scleral location through an ab-interno minimally-invasive approach."
103874|NCT03374540|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
103875|NCT03374540|Drug|Vitamin K antagonist(VKA)|Individually adjusted dose
103876|NCT03374527|Other|blood sample collection|Blood samples are collected from patients with psoriasis vulgaris and patients with psoriatic arthritis following the routine procedure. Blood samples will also be collected from healthy control subjects.
103877|NCT03374527|Procedure|Synovial Fluid collection|Synovial fluid is collected when prescribed in patients with psoriatic arthritis
103878|NCT03374514|Drug|Dexamethasone|instilation of the solution in the middle ear
103879|NCT03374514|Drug|Sterile isotonic saline solution|Sterile isotonic saline solution
103880|NCT03374501|Dietary Supplement|Sugardown™|Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)
103881|NCT03374501|Dietary Supplement|Soft drink|Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)
103882|NCT03374488|Drug|Pembrolizumab|Pembrolizumab administered intravenously Day 1 of each cycle every 3 weeks.
103883|NCT03374488|Drug|Epacadostat|Epacadostat administered orally twice daily.
103884|NCT03374488|Drug|Placebo|Matching placebo administered orally twice daily.
103885|NCT03374475|Drug|JNJ-42847922 20mg|Participants will swallow 20 mg (2*10 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
104266|NCT03371563|Other|no intervention|controls were not given antibiotics
103886|NCT03374475|Drug|JNJ-42847922 40mg|Participants will swallow 40 mg (2*20 mg) JNJ-42847922 capsule orally for 5 weeks during treatment period.
103887|NCT03374475|Drug|Placebo|All participants will receive matching placebo capsule during lead in period, treatment period and withdrawal period.
103888|NCT03374462|Behavioral|Telemedicine Intervention|Home-based telemedicine visits
103889|NCT03374449|Procedure|continuation of the RAS-inhibitors|drug intake
103890|NCT03374449|Procedure|discontinuation of the RAS-inhibitors|no drug intake
103891|NCT03374436|Behavioral|High-Carbohydrate Sedentary|Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
103892|NCT03374436|Behavioral|High-Carbohydrate Active|"Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period except that once every hour they will ascend three flights of stairs vigorously (stair climbing sprint snack) for a total of 8 active breaks."
103893|NCT03374436|Behavioral|Low-carbohydrate Sedentary|Three low-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at ~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period. This condition will provide a condition where the blood glucose and insulin responses are relatively low and stable throughout the day.
103894|NCT03374423|Procedure|radiofrequency|"The procedure will be done under propofol sedation, under fluoroscopic guidance. The image intensifier will be rotated in a cephalo-caudal direction until the endplates of the thoracic vertebrae are aligned and the transverse processes became discernable from the ribs.~For the intercostal nerve group, the radiofrequency needle 10 cm with 10 ml active tip will then inserted to contact the lower edge of the transverse process of (T2-T5), the needle is walked off to obtain sensory stimulation between 0.3-0.6 mv and motor stimulation less than 1.2 mv .five cycle of pulsed radiofrequency will be delivered."
103895|NCT03374423|Procedure|radiofrequency|The procedure will be done under propofol sedation, under fluoroscopic guidance.for dorsal root ganglion group, radiofrequency needle 10 cm with 10 ml active tip will inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walked into the thoracic intervertebral foramen. Once correct needle position is confirmed, test stimulation will be performed at 50 Hz, during which time the needles will slightly redirected to optimize stimulation, the point of maximum stimulation will be designated to be the location of the dorsal root ganglion. five cycle of pulsed radiofrequency will be delivered.
103896|NCT03374397|Drug|Surgiguard|Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
103897|NCT03374384|Other|No drug intervention|This study will be performed in Al-Arish Central Hospital and will include all patients from 2 months up to 18 years of age with seizures admitted to Al-Arish Central Hospital
103898|NCT03374371|Diagnostic Test|high-throughput sequencing|technique of high-throughput sequencing of the markers present in the genome of the S. epidermidis strains responsible for infection in order to help to discriminate the true infections of the contaminations
103899|NCT03374358|Drug|Raltegravir|The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .
103900|NCT03374345|Drug|Sipjeondaebo-tang Granule|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
103901|NCT03374345|Drug|Placebo|3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
103902|NCT03374332|Drug|Gemtuzumab Ozogamicin (GO)|"Treatment 1: > or = 70 years old: GO 6mg/m2 (2mg/m2 each dose, capped at 4.5mg)~Treatment 1: < 70 years old: GO 9mg/m2 (3mg/m2 each dose, capped at 4.5mg)~Treatments 2 and 3: 6mg/m2 (2mg/m2 each dose, capped at 4.5mg)~Day 1,4,7"
103903|NCT03374332|Other|Donor Leukocytes|The product will be administered unprocessed on day 8/24 hours post GO (same day as leukapheresis) with a minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg irrespective of the number of CD34+ cells.
103904|NCT03374319|Procedure|Modified amputation procedure|A stair-step (BKA) or fishmouth (AKA) incision will be made. Tibial and fibular or femoral osteotomies will be performed. Segments of the tibialis anterior (TA), peroneus longus (PL), lateral gastrocnemius (LG) and tibialis posterior (TP) muscles will be isolated, as well as the quadriceps (Q) and hamstring (H) groups in the AKA model; if it is not possible to preserve native innervation to these muscles, functional motor units will be constructed from muscle coapted to the appropriate motor nerve endings. The distal tibial and peroneal nerves will be redirected to skin patches in the distal or proximal thigh. Coaptation of the TA/LG, PL/TP and Q/H muscles will then be performed to promote dynamic coupling of these agonist/antagonist pairs. The skin envelope will then be closed in layers over percutaneous drains.
103905|NCT03374319|Procedure|Standard amputation procedure|Amputation is performed via standard techniques at either the BKA or AKA level. No construction of agonist-antagonist muscle pairs will be performed.
103906|NCT03374306|Drug|Atropine (0.01%)|tropical application
103907|NCT03374306|Drug|Artificial tear|tropical application
103908|NCT03374293|Radiation|Radiation|RT to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody .
103909|NCT03374293|Drug|Anti-PD-1 Antibody|Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
103910|NCT03374280|Drug|pemetrexed/cisplatin intercalating gefitinib|
103911|NCT03374280|Drug|pemetrexed/cisplatin|
103912|NCT03374267|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
103913|NCT03374254|Biological|Pembrolizumab|200 mg Pembrolizumab solution for IV infusion Q3W
103914|NCT03374254|Drug|Binimetinib|tablet orally BID at 30 or 45 mg depending upon DLT profile
103915|NCT03374254|Drug|Oxaliplatin|85 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 cocktail. Dose may be de-escalated to 70 mg/m^2 if the standard dose of mFOLFOX7 is deemed too toxic per mTPI, based upon occurrence of DLTs.
103916|NCT03374254|Drug|Leucovorin|400 mg/m^2 as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation.
104118|NCT03372616|Diagnostic Test|Invasive aortic blood pressure measurement|Aortic blood pressure will be measured with polyethylene catheter in aortic root.
103917|NCT03374254|Drug|5-Fluorouracil [5-FU]|2400 mg/m^2 over 46-48 hours as IV infusion. Administered Q2W as part of mFOLFOX7 or FOLFIRI cocktail, depending upon allocation. Dose may be de-escalated to 2000 mg/m^2 if the standard dose of mFOLFOX7 or FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
103918|NCT03374254|Drug|Irinotecan|180 mg/m^2 as IV infusion. Administered Q2W as part of FOLFIRI cocktail. Dose may be de-escalated to 150 mg/m^2 if the standard dose of FOLFIRI is deemed too toxic per mTPI, based upon occurrence of DLTs.
103919|NCT03374241|Biological|HM15211 or Placebo|Long-acting tri-agonist
103920|NCT03374228|Drug|BMS-986205|Specified Dose on Specified Days
103921|NCT03374202|Drug|VRC-HIVAAV070-00-GT (AAV8-VRC07)|AAV8-VRC07 is a recombinant AAV vector expressing a HIV-1 CD4 binding site-specific neutralizing antibody, VRC07.
103922|NCT03374189|Device|EZ close|EZ close used.
103923|NCT03374189|Device|Carter Thomason|Carter Thomason used.
103924|NCT03374176|Drug|Amoxicillin 500 mg / Metronidazole 250 mg|Subjects were instructed to take a capsule three times a day for 7 days
103925|NCT03374176|Drug|Clindamycin 300 mg|Subjects were instructed to take a capsule three times a day for 7 days
103926|NCT03374163|Drug|intralipid 20%|milky soulation for energey supplement.
103927|NCT03374150|Behavioral|diet counseling|Subjects were given nutrition consultation, diet recipes, and logbook. Counseling was performed once weekly. During 8 weeks of diet program, subjects were instructed to reduce their daily caloric intake by 500 - 1000 kcal from their previous usual daily intake with limitation in low calorie diet range (800-1500 kcal.day) of calorie intake.Follow-up for each subject was performed once daily by person-to-person encounter. Besides, subjects were contacted by everyday cellphone texting and telephone twice a week to control subject's compliance. After 8 weeks of intervention, subjects were invited to revisit the clinic for anthropometry and body composition measurement after completing the program.
103928|NCT03374137|Biological|obinutuzumab|Obinutuzumab 1000 mg solution used for infusion according to routine clinical practice.
103929|NCT03374124|Diagnostic Test|sinonasal outcome test-22|Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
103930|NCT03374111|Drug|Colla corii asini|15 g Colla corii asini granule daily for 8 weeks
103931|NCT03374111|Drug|a Simulate Agent of Colla corii asini granule|15 g a Simulate Agent of Colla corii asini granule daily for 8 weeks
103932|NCT03374098|Behavioral|Home Visitiation|"The home visit component of the intervention will involve a visit to participants' homes by a social worker, who will assist patients dealing with other health and social problems. Participants will be followed for a minimum of 10 weeks, and additional follow-up visits will be at the discretion of the social worker. They will work with community partners and refer patients when appropriate.~Community partners could include: Domestic violence services, employment placement, benefit enrollment, community action agency (bill pay, utilities), ACA enrollment, homeless shelter, housing authority, re-housing program"
103933|NCT03374098|Behavioral|Education|"The education component of the intervention will include attending a class once per week for 3 weeks. Classes will be led by a dietician, and may also involve other members of an interdisciplinary team including nurse practitioners, health educators, and community members. Education sessions will be held at 5:30pm on Mondays or Tuesdays, and participants will be provided with a meal. Topics will include:~Week 1 (5:30-6:30pm): Importance of self-management of disease, glucometer testing for blood sugars and using home blood pressure monitors, diabetes medication review~Week 2 (5:30-7:00pm): Diabetes and Healthy Eating and Exercise - carbohydrate counting, portion control, lifestyle activity, and exercise demonstration activity~Week 3 (5:30-6:30pm): Grocery shopping guidelines, label reading, hands on cooking demo"
103934|NCT03374085|Drug|CC-92480|CC-92480
103935|NCT03374085|Drug|Dexamethasone|Dexamethasone
103936|NCT03374072|Behavioral|Siblings FORWARD program|Siblings will participate in a program developed by the researchers designed to engage adult siblings with their brother or sister with ASD and other family members to plan for the future. The Siblings FORWARD program will be implemented by community service providers already working with adults with ASD. The program will involve a series individual and joint sessions with siblings and adults with ASD using videoteleconferencing software.
103937|NCT03374072|Behavioral|Information Only Condition|Siblings will be provided with written information about services for adults with ASD and future planning.
103938|NCT03374059|Other|Exercise program|
103939|NCT03374059|Other|Life modification|
103940|NCT03374046|Procedure|Apneic Oxygenation|Supplemental oxygen will be provided via nasal cannula during intubation attempt
103941|NCT03374033|Dietary Supplement|NUTR +|one extra g/kg/d of protein and lipids starting before 48 hours after birth until 36 weeks postmenstrual age
103942|NCT03374033|Behavioral|STIMUL +|Physical activity stimulation consists in flexion/extension of the 4 limbs and other motion exercises of the shoulder girdle and of the hips. This stimulation will take place before the feed for a mean of 30 times a week (minimum 24- maximum 36 times a week, 10 minutes each time) and will start within the 10th day of life until 36 weeks postmenstrual age
103943|NCT03374020|Device|Notal OCT|Imaging using Notal OCT
103945|NCT03373994|Diagnostic Test|18F-FDG PET/CT initial-time imaging|18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.
103946|NCT03373994|Diagnostic Test|18F-FDG PET/CT balanced-time imaging|18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.
103947|NCT03373981|Device|rTMS|repetitive transcranial magnetic stimulation
103948|NCT03373968|Drug|Givinostat|suspension of givinostat (10 mg/mL)
103949|NCT03373955|Drug|pembrolizumab|anti-programmed death 1 (PD-1) antibody
103950|NCT03373942|Other|Choroidal thickness measurements with SD-OCT device|
103951|NCT03373929|Device|PFO Closure Rate|Suture Mediated PFO Closure and Septal Repair
103952|NCT03373929|Device|Published PFO Device Closure|Suture Mediated PFO Closure and Septal Repair
104161|NCT03372239|Drug|Indoximod HCL (salt) formulation|Specified dose on specified days
104162|NCT03372239|Other|Placebo|Specified dose on specified days
103953|NCT03373916|Behavioral|Peer mentorship|The peer mentor will meet with the participant for the first time while the participant is still in the hospital. Sessions will be scheduled according to the participant's preferences, with a suggested maximum frequency of twice weekly for the first two weeks, weekly for weeks 3 to 8, and then every other week for the last month. Allowable meeting locations include public places in the community (e.g., coffee shop, park), the participant's home, or a research clinic space or by phone. Session content is flexible and allows for the peer mentor to provide general supportive listening, validation, and sharing. Session duration is on average 1 hour with at least 15 minutes discussing hope or belongingness according to semi-structured conversation guides. The session structure and content are intentionally highly flexible to allow for genuineness in the peer relationship, thereby increasing acceptability and implicit belongingness.
103954|NCT03373916|Behavioral|Enhanced Usual Care|"The EUC condition will consist of a caring message from the study team via e-mail or text message (based on the participant's preference) 24-72 hours after discharge. An example message is, We hope things are going well for you since you left the hospital. If you wish to reply, we'd be glad to hear from you. A list of local mental health resources will be available if participants reply and during the 3 and 6-month follow-up assessments. The EUC condition is modeled on prior studies of caring letters and brief contacts by health professionals after suicidal crisis and national recommendations to provide post-crisis follow-up contacts."
103955|NCT03373903|Other|Placebo|oral
103956|NCT03373903|Drug|BEZ235|oral
103957|NCT03373903|Drug|BEZ235 plus everolimus (RAD001)|Oral
103958|NCT03373890|Behavioral|Short Burst Interval Locomotor Treadmill Training (SBLTT)|SBLTT consists of interval training consisting of short-bursts (30 seconds) of vigorous intensity locomotor treadmill training (LTT) alternating with low to moderate intensity LTT.,
103959|NCT03373877|Drug|PU-H71|PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
103960|NCT03373877|Drug|Ruxolitinib|Dosing will be in accordance with current package insert and dose subject was on during study entry.
103961|NCT03373864|Procedure|Unilateral spinal anesthesia|Unilateral spinal anesthesia with hypobaric local anesthesia allowing a lateralized anesthesia of the fractured limb.
103962|NCT03373864|Procedure|General anesthesia|General anesthesia following the latest recommendations for elderly patients (SFAR 2017)
103963|NCT03373851|Device|Zalviso Device|"The Zalviso device will be provided immediately before the Post anesthesia care unit (PACU) discharge. Patients will be queried every day during three postoperative days for the ability to use the device, their satisfaction, the level of pain, and the incidence of side effects. There will be no changes in usual care.~In the end of this study ward nurses carrying Zalviso patients will be asked to provide their usability and satisfaction evaluation for Zalviso device management. Physical therapist will be asked to provide their satisfaction regarding patients' ability to follow physical therapy program."
103964|NCT03373838|Other|Census|Survey and interview
103965|NCT03373825|Behavioral|Take home rapid drug test|The Rapid Response fentanyl test strips will be offered as take-home rapid drug tests to all participants to assess the willingness to use take-home rapid drug tests and the feasibility of using such an intervention at home. Arm 1 will be offered one method of using the take-home rapid drug test (urine testing). Arm 2 will be offered a second method of using the take-home rapid drug test (testing drug residue).
103966|NCT03373812|Procedure|Blepharoptosis repair|levator advancement or mullerectomy
103967|NCT03373799|Other|Video-Based Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. A video record was made by the physiotherapist to a patient where each exercise was described in detail and the patient correctly performed the exercises according to the verbal and visual commands of the physiotherapist. This video record watched by the patients who come to the clinic and patients were asked to do the exercises in the video. Patients did the exercises under control of the physiotherapist in the clinic.
103968|NCT03373799|Other|Physiotherapist-Supervised Rehabilitation Program|In both groups, a program consisting of exercises used in conservative treatment of rotator cuff tears was performed. Program was carried out by teaching the same exercises individually by the physiotherapist.
103969|NCT03373786|Drug|RG012|RG012 in 0.3% sodium chloride
103970|NCT03373773|Device|Foley catheter|After reinsertion of the Foley catheter, both groups of women will be given instructions on urinary catheter and bag management, this will be done by an RN as per standard protocol. Prior to discharge, every subject from the home removal group as well as their significant other/caregiver/family member will receive a standardized education session and written and illustrated instructions on Foley catheter removal from RN, per standard protocol. They will be provided with the syringe for catheter removal, urine collection pan, and a diary to record their voiding quality and quantity. Both groups of women will have the catheter removal in 2 days.
103971|NCT03373760|Biological|Durvalumab|Given IV
103972|NCT03373760|Other|Laboratory Biomarker Analysis|Correlative studies
103973|NCT03373760|Biological|Tremelimumab|Given IV
103974|NCT03373747|Diagnostic Test|Reliability of IET|The participants will be do three sessions: familiarization, test and retest to assess the reliability inter and intra rater of the test.
103975|NCT03373747|Diagnostic Test|Physiological analysis of IET|The participants will be submitted two sessions, familiarization session and test session. In the test session there will be the physiological analysis by means of gas analysis, blood lactate concentrate and activation muscular percentage.
103976|NCT03373734|Device|Enjoy Your Bump|Online life skills course based on Cognitive Behavioural Therapy Principles.
103977|NCT03373708|Drug|Epirubicin|100mg/m2
103978|NCT03373708|Drug|Cyclophosphamide|600mg/m2
103979|NCT03373708|Drug|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
103980|NCT03373708|Drug|Goserelin acetate|3.6mg every month
103981|NCT03373708|Drug|Tamoxifen|10mg twice daily oral
103982|NCT03373708|Drug|Letrozole|2.5mg every daily oral
103983|NCT03373695|Device|Dissolve™|Dissolve™ are to be used in the trial
103984|NCT03373695|Device|SeQuent®Please|SeQuent®Please are to be used in the trial
104117|NCT03372616|Diagnostic Test|Invasive left ventricular diastolic function assessment|Left ventricular (LV) polyethylene catheter was inserted into left ventricular to directly measure LV filling pressure.
103985|NCT03373669|Biological|Oral Cholera Vaccine|Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
103986|NCT03373669|Biological|Adjusted Dose Oral Cholera Vaccine|The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
103987|NCT03373656|Biological|Vaccination|"Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study:~hepatitis B vaccine measles-rubella combined vaccine"
103988|NCT03373656|Other|No Vaccination|Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
103989|NCT03373643|Diagnostic Test|OSA screening|Full night polysomnography
103990|NCT03373630|Device|Midline catheter|The catheter will be inserted according to usual practices, after the enrollment of the patient in the study. The follow-up will last until the removal of the catheter, which will also be done according to usual practices. Following the removal, bacteriologic analyses will be performed in order to diagnose any prospective infection.
103991|NCT03373604|Drug|18F-MK-6240|18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
103992|NCT03373604|Procedure|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
103993|NCT03373591|Drug|Liposomal Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
103994|NCT03373591|Drug|Bupivacaine TAP block|Infiltration of the transverse abdominis peritoneum by a local anesthetic under laparoscopic visualization.
103995|NCT03373578|Device|earmuffs|to compare the neonate's sleep with and without earmuffs during Quiet time at the NICU
103996|NCT03373565|Procedure|Radial|Coronary angiography using radial approach
103997|NCT03373565|Procedure|Palmar|Coronary angiography using radial approach
103998|NCT03373552|Diagnostic Test|Platelet function assay|Platelet function assay
103999|NCT03373526|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training will be perform using using the Power Breathe® device, during 20 minutes daily, five times a week. The protocol will be performed in the sitting position with an established load of 40% of maximal inspiratory pressure.
104000|NCT03373526|Other|Aerobic Training|The aerobic physical training will be perform using a cycle ergometer, during 20 minutes daily, five times a week, with moderate intensity (50-70% of reserve heart rate).
104001|NCT03373513|Procedure|Robotic single-site Hysterectomy|Robotic assisted Periumbilical single incision hysterectomy
104002|NCT03373513|Procedure|Laparoscopic hysterectomy|Multiport laparoscopic hysterectomy
104003|NCT03373500|Other|Dietary salt reduction|Patients will be given intensive dietary advice to achieve a low salt diet, targeting a dietary salt intake of less than 5g per day (80 mmol/day).
104004|NCT03373487|Behavioral|The cognitive rehabilitation program ReMind|Cognitive rehabilitation, i.e. psychoeducation, strategy training & retraining
104005|NCT03373474|Other|local distribution points association|"Participants will receive acupuncture treatments using the local points set plus the local-addition points set (local distribution association) described below. Warming acupuncture will be applied at HT2, LI11, and TE9 if permitted.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Local-addition points set: LU5, PC3, SI7, TE4, TE3, HT2, TE10, LI15, and 2 other points according to the symptom on the affected arm."
104006|NCT03373474|Other|local-distal points association|"Participants will receive acupuncture treatments using the local points set plus the distal points set (local-distal association) described below. Warming acupuncture will be applied similarly to the local distribution group, with the addition of Ren6, Ren9, bilateral SP9, and LI11 on the unaffected arm.~Local points set: TE5, LI11, TE9, HT3, TE13, and Xiajiquan on the affected arm. Distal points set: TE5, LI11, HT3, TE13 on the unaffected arm; CV4, CV6, CV9, CV12, bilateral SP6 and SP9."
104007|NCT03373461|Drug|LNP023|LNP023 b.i.d. Dose 1, Dose 2 and Dose 3
104008|NCT03373461|Drug|Placebo|Placebo to LPN023 b.i.d
104009|NCT03373448|Device|Labrida BioClean|The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
104010|NCT03373448|Other|Titanium curettes|Peri-implant pockets will be debrided using titanium curettes.
104011|NCT03373435|Drug|exendin 9-39|Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
104012|NCT03373435|Other|Placebo|Placebo solution is identical to the active drug product except for the absence of the active ingredient, Exendin 9-39.
104013|NCT03373422|Drug|BAY1128688|Various dosing OD (once daily) and BID (twice daily)
104014|NCT03373422|Drug|Placebo|Matching placebo tablets
104015|NCT03373409|Drug|Albuterol DPI 90mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
104016|NCT03373409|Drug|Albuterol DPI 180mcg|Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
104017|NCT03373409|Drug|Albuterol HFA MDI|Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
104018|NCT03373396|Diagnostic Test|Blood samples|Collected data will contain epidemiological and biological data, blood samples with chlordecone dosage.
104019|NCT03373383|Drug|Padsevonil|Padsevonil in different dosages.
104020|NCT03373383|Other|Placebo|Placebo will be provided matching Padsevonil.
104021|NCT03373357|Other|Patient not SAHOS|"Phone consultation in 1 month, 3mois, then every 6 months, and an annual visit.~Cardiovascular events arisen during the duration of the study~Modifications of the lifestyle: alcohol, physical activity~Weight~Clinical measure of the PA~Clinical examination~The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
104022|NCT03373357|Other|Patient SAHOS sailed by the ventilation in PPC and not sailed|"Questionnaire of subjective evaluation of diurnal slumber: scale of Epworth and search for appearance of at least 2 of the following symptoms: sleep not salvage dealer, night-breathlessnesses, multiple awakenings, fatigue, disordersconfusions, nycturie, snore.~Questionnaire of evaluation of the global quality of life of the SAHOS~Appearance of new cardiovascular risk factors~Cardiovascular events arisen during the duration of the study~Modification of the current treatments~Modifications of the lifestyle: alcohol, physical activity~Weight~Clinical measure of the PA~Clinical examination~The collection of the cardiovascular events arisen during the duration of the study will be realized for all the inclusive patients"
104023|NCT03373344|Behavioral|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
104024|NCT03373344|Behavioral|Placebo control exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
104025|NCT03373331|Behavioral|Emotional Processing Training|Participants in the experimental group will receive computerized exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
104026|NCT03373331|Behavioral|Placebo Control Exercises|Participants in the control group will receive computerized control exercises administered on a laptop computer. They will undergo 12 sessions of 45-60 minutes each (twice a week for 6 weeks).
104027|NCT03373318|Drug|Human albumin|Single dose as a primer for the CEC, in sufficient quantity to reach a concentration of 4% of the total volume of priming.
104028|NCT03373318|Drug|Plasmalyte|The dose and the speed of administration depend on the age, weight, clinical and biological status of the patient and the concomitant treatment. The recommended dose for adults, the elderly and adolescents: from 500 ml to 3 liters / 24 hours.
104029|NCT03373305|Drug|Brentuximab Vedotin|Given IV
104030|NCT03373305|Drug|Lenalidomide|Given PO
104031|NCT03373305|Other|Laboratory Biomarker Analysis|Correlative studies
104032|NCT03373292|Procedure|Venous stenting for internal jugular vein stenosis|"After confirming the diagnosis of IJVS by Jugular Vein Doppler Ultrasound, Magnetic Resonance Venography (MRV) and/or Computed Tomography Venography (CTV), and excluding external compression-induced stenosis as well as other causes of intracranial pressure elevation, patients will be divided into two groups randomly (30 for each group: group-1 and group-2).~Patients in Group-1 will receive Digital Subtraction Angiography (DSA) immediately after enrollment, and trans-stenotic pressures (∆MPGs) will be measured, balloon angioplasty bridging venous stenting will be performed when their ∆MPGs of jugular veins are equal to or greater than 5.44 cmH₂O (4 mmHg)."
104033|NCT03373292|Procedure|One-month routine medical treatment followed by venous stenting for internal jugular vein stenosis|"Patients in Group-2 will receive routine medical treatment for one month. Afterwards, they will undergo DSA (the procedure is the same as that in Group-1).~Notably, patients in Group-2 with medical uncontrolled intracranial hypertension will be provided stenting of their jugular veins at any time during the one-month routine medical treatment, in attempt to reduce their intracranial pressure and ameliorate visual damages in time."
104034|NCT03373266|Drug|Sevoflurane|anesthesia was maintained with Sevoflurane 1-2%.
104035|NCT03373266|Drug|Isoflurane|anesthesia was maintained with isoflurane 1-2%.
104036|NCT03373240|Behavioral|TAU plus Cognitive Remediation Program|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.
104037|NCT03373240|Behavioral|TAU plus Control Tasks|Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
104038|NCT03373227|Drug|Envarsus|Patients will take once daily Envarsus
104039|NCT03373214|Biological|Na-GST-1|Na-GST-1/Alhydrogel®
104040|NCT03373214|Biological|CPG 10104|CPG 10104
104041|NCT03373201|Drug|Tasimelteon|Oral capsule
104042|NCT03373201|Drug|Placebo|Oral capsule
104043|NCT03373188|Biological|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
104044|NCT03373188|Biological|Ipilimumab|Given IV
104045|NCT03373188|Biological|Nivolumab|Given IV
104046|NCT03373188|Procedure|Surgery|Undergo therapeutic conventional surgery
104047|NCT03373175|Device|Basal record|Basal EMG record will be performed during 5 minutes. This record must be the same in both ventilators.
104048|NCT03373175|Device|PS 10 record|PS 10 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
104049|NCT03373175|Device|PS 15 record|PS 15 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
104050|NCT03373175|Device|PS 20 record|PS 20 EMG record record will be performed during 5 minutes. First with ventilator 1 and then with the other. The patient must be rest at least 5 minutes to recover basal record
104051|NCT03373162|Drug|onabotulinumtoxinA|This study is a pre- and post-design. One scan will be collected prior to BOTOX injection and the second will be collected 14-21 days post-injection. BOTOX injections will be limited to 20 units in the glabellar area, as approved by the FDA .
104083|NCT03372902|Device|Breast Mammogram|State-of-the-art full-field digital mammography (FFDM) and or digital breast tomosynthesis (DBT) comprising both raw and post-processed images as well as ultrasound and MRI images from the initial screening study will be collected and sent to the MSKCC Breast Radiology Department.
104084|NCT03372902|Other|Blood draw|Participants will donate approximately 60ml of peripheral blood. Mononuclear cells from peripheral blood will be used to extract germline DNA. Germline genomic testing will be employed as a matched control for tumor sequencing and for germline breast cancer susceptibility testing.
104052|NCT03373149|Drug|Growth hormone/HPuFSH/GnRH antagonist|"Growth hormone (Somatropin, Sedico, Egypt) [4 IU/day] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) [300 IU/day] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
104053|NCT03373149|Drug|HPuFSH/GnRH antagonist|"Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) [300 IU/day] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration."
104054|NCT03373136|Device|Polypectomy|Polypectomy during colonoscopy is considered effective to reduce the incidence and mortality of colorectal cancer
104055|NCT03373123|Procedure|Endoscopy|Endoscopy
104056|NCT03373123|Procedure|CTA|Radiomic features were extracted from CTA images.
104057|NCT03373110|Behavioral|Online Mindfulness Based Cognitive Therapy|see arm description
104058|NCT03373110|Behavioral|Online Cognitive Behavioral Therapy|see arm description
104059|NCT03373110|Behavioral|Fitbit Alone|see arm description
104060|NCT03373097|Biological|GD2-CART01|Following a lymphodepleting treatment with conventional chemotherapy, patients will be treated with 1.0 to 10.0 x 10⁶/kg GD2 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
104061|NCT03373084|Other|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
104062|NCT03373084|Other|ultrasound|Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
104063|NCT03373084|Other|Self-questionnaire|Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
104064|NCT03373071|Biological|CD19-CAR T cell|"Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 0.5 to 3.0 x 10⁶/kg CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.~In case of toxicity, the patient will receive the dimerizing drug activating the suicide safety switch in order to improve the safety of the treatment"
104065|NCT03373058|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m^2 and cisplatin 75 mg/m^2, respectively, 43°C, 90min.
104066|NCT03373058|Procedure|cytoreductive surgery|Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.
104067|NCT03373058|Drug|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
104068|NCT03373032|Other|Stiper|"Stiper silicon tablets, for stimulation of meridian points of acupuncture, the chemical composition of the Stiper is nothing more than SiO 2 - (silicon dioxide) the shape of the quartz stone (silicon rich).They will perform the treatment with the Stiper silicon inserts, which will be applied and fixed by plasters at the acupuncture points."
104069|NCT03373032|Other|acupuncture|Treatment with a systemic needle to stimulate meridian acupuncture points, treatment begins with asepsis with 70% alcohol-soaked cotton in the region of the acupoints and then sterile and disposable needles (0.25 mm x 30 mm) will be inserted in both limbs, will be placed in the following regions: shoulders, thorax, legs and feet with the puncture order from bottom to top.
104070|NCT03373032|Other|Control|Will perform pre-defined kinesiotherapy based on stretching of the cervical musculature and scapular waist, lumbar spine and lower limbs with exercises for WM and upper limb (MS) and lower limb (MI) strength with a duration of 30 minutes.
104071|NCT03373019|Drug|Chidamide combined with R-GDP|Chidamide: 30mg,PO,biw one week before cycle 1 treatment rituximab 375 mg/m2,ivgtt D0 gemcitabine 1000mg/m2 iv D1,8 dexamethasone 40mg, iv D1-4, cisplatin 25mg/m2 iv D1-4 chidamide :20mg PO Biw, 2 week on , 1 week off
104072|NCT03373006|Drug|Axumin PET/CT|Synthetic amino acid uptake agent injection followed by imaging
104073|NCT03372967|Biological|Vaccine administration by a pharmacist|Administration, number and types, of vaccines by a pharmacist
104074|NCT03372967|Behavioral|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
104075|NCT03372967|Behavioral|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
104076|NCT03372954|Drug|BMAC|retrograde administration on non-selected BMAC via coronary sinus
104077|NCT03372941|Drug|Dalbavancin|Dalbavancin, a lipoglycopeptide antibiotic, has been approved by the FDA for the treatment of ABSSSI caused by Gram-positive bacteria. A single dose of dalbavancin will be administered in the Emergency Department followed by discharge with close outpatient infectious disease clinic follow-up.
104078|NCT03372928|Dietary Supplement|Low EAA|EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation
104079|NCT03372928|Dietary Supplement|High EAA|EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
104080|NCT03372915|Behavioral|Standard Exposure|Exposure therapy conducted according to standard clinical care practices
104081|NCT03372915|Behavioral|Exposure + Inhibitory Learning|Exposure therapy conducted according to practice recommendations based derived from research on inhibitory learning theories of fear extinction
104082|NCT03372902|Device|Breast MRI|Participants with dense breast tissue will get a mammogram and MRI
104085|NCT03372902|Procedure|Breast Biopsy|Tissue specimens from the biopsy of the BI-RADS 4 mammographic lesion and (among women undergoing surgical excision) the surgical specimen(s) will be subjected to genomic profiling at GRAIL, Inc. or MSKCC. The tumor specimens from the participants diagnosed with cancer during the follow-up period will also undergo molecular profiling.
104086|NCT03372902|Behavioral|online participant reported questionnaire|Participants will be asked to complete a questionnaire that covers the topics of breast health, general health and lifestyle, genetic testing, personal, and family history of cancer.
104087|NCT03372889|Behavioral|Patient educaiton materials - Print based|Print (paper) based materials
104088|NCT03372889|Behavioral|Patient educaiton materials - Media based|Media (electronic) based materials
104089|NCT03372876|Dietary Supplement|Protein and carbohydrate supplementation|Participants were randomly assigned to protein-carbohydrate group (PC) (n=17), that ingested 30 g of whey protein immediately after exercise and 30 g of maltodextrin in the afternoon; and to carbohydrate-protein group (CP) (n=17), that ingested 30 g of maltodextrin immediately after exercise and 30 g of whey protein in the afternoon. Both groups performed the same resistance training protocol in the morning, 3 times a week, at 70% of 1-maximum repetition (1-RM) during 8 weeks.
104090|NCT03372850|Drug|HIP1601|Test Drug
104091|NCT03372850|Drug|HGP1705|Reference Drug
104092|NCT03372837|Drug|Rituximab|The administration of rituximab at 375 mg/m^2/day by intravenous infusion on Day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
104093|NCT03372811|Drug|TC cream|A well-characterized botanical drug for topical treatment of psoriasis vulgaris
104094|NCT03372811|Drug|Vehicle|Vehicle
104095|NCT03372798|Procedure|ICE/IVUS imaging during atrial fibrillation ablation|Intravascular ultrasound imaging of the left atrial wall thickness with ICE/IVUS during atrial fibrillation ablation
104096|NCT03372785|Drug|aspirin, betaloc, atorvastatin, rosuvastatin, clopidogrel, ticagrelor|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
104097|NCT03372785|Device|coronary wires. stents or coronary balloons|all species of drug-eluting stent ((such as Xience, Endeavor, Resolute) implantation or balloon expansion (POBA)
104098|NCT03372772|Drug|Levocarnitine|Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks
104099|NCT03372759|Procedure|airtamponade|airtamponade is applicated in the study group air
104100|NCT03372759|Procedure|saline|saline is left in the study Group saline
104101|NCT03372733|Drug|control olive oil (COO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
104102|NCT03372733|Drug|palmitoleate-rich oil (PLO)|2 capsules, 2 times a day after meals in a total of 4 capsules a day
104103|NCT03372720|Procedure|Laser Therapy|Undergo fractional CO2 laser therapy
104104|NCT03372720|Other|Questionnaire Administration|Ancillary studies
104105|NCT03372720|Procedure|Sham Intervention|Undergo sham laser therapy
104106|NCT03372707|Diagnostic Test|Cuff Leak Test|The Respiratory Therapist (RT) will perform the CLT on all enrolled patients. The patients will first be switched to volume assist-control (V-AC) with a respiratory rate of 10 breaths/min (to allow patient assist), constant flow of 60 l/min, and tidal volume set to match the average tidal volume currently being delivered during supportive ventilation. The RT will document the average exhaled volume over 3-5 breaths after switching to V-AC. The test will be performed by deflating the ETT balloon cuff with a 10 cc syringe, and: a) auscultation with a stethoscope to identify audible air leak around the ETT, and b) measuring the difference between the average exhaled volume prior to cuff deflation and the average exhaled volume over 3-5 breaths after cuff deflation.
104107|NCT03372694|Behavioral|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training will be carried out between every two cycles of chemotherapy. Rehabilitation training is mainly composed of gymnastics qigong, which has long been regarded as a form of rehabilitation in Traditonal Chinese Medicine. According to the poor pulmonary function of patients with lung cancer after operation, Liu Zi Jue lung exercise is chosen to strengthen the pulmonary function of the human body in Chinese traditional health culture. Liu Zi Jue lung exercise intervention will be lead by an expert instructor, five times a week, 15 min/time.
104108|NCT03372694|Drug|TCM|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe. Each package contained 20g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (Tian Jiang Ltd, Jiangyin, China). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number.
104109|NCT03372694|Other|Rehabilitation Education|General health education
104110|NCT03372694|Drug|placebo|four types with functions such as benefiting Qi recipe, benefiting Yin recipe, harmonizing stomach recipe and detoxication and resolving masses recipe，with the same color, smell，taste, weight and package
104111|NCT03372681|Procedure|Isoperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with Isoperistaltic Billroth II + Braun reconstruction
104112|NCT03372681|Procedure|Antiperistaltic Billroth II + Braun anastomosis|Laparoscopic distal gestrectomy will be applied with antiperistaltic Billroth II + Braun reconstruction
104113|NCT03372668|Other|massage therapy combined with components of mirror therapy|"Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb."
104114|NCT03372642|Device|Subtalar endorthesis|Subtalar arthroereisis with endorthesis for pediatric flexible flat foot
104115|NCT03372629|Drug|ID-085|Hard gelatin capsules for oral administration formulated in strengths of 10 mg, 100 mg, and 200 mg
104119|NCT03372616|Diagnostic Test|Non-Invasive left ventricular diastolic function assessment|Echocardiography will be performed in all participants to assess left ventricular diastolic function non-invasively.
104120|NCT03372616|Diagnostic Test|Non-Invasive aortic blood pressure measurement|Three devices (Sphygmocor [AtCor Medical, Australia], PulsePen [DiaTecne SRL, Italy], and Mobil-O-Graph [IEM, Germany] ) will be used to assess aortic blood pressure non-invasively when participants are undergoing invasive aortic blood pressure measurement.
104121|NCT03372603|Drug|GSK2798745|GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient [API]) to be taken with a glass of water (approximately 240 mL).
104122|NCT03372603|Drug|Placebo|Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).
104123|NCT03372590|Other|NICU-based rehabilitation bundle|Maternal-driven gestational age-appropriate intervention/activity bundle, including the evidence-based elements of vocal soothing, comforting touch, scent exchange, kangaroo care, and infant massage
104124|NCT03372590|Other|Standard of care|Standard NICU care
104125|NCT03372577|Behavioral|Mindfulness-Based Sex Therapy|It is based on an integration of psychoeducation, sex therapy, and mindfulness-based skills. the intervention will be delivered by a group of facilitators on a group based weekly.
104126|NCT03372577|Other|Treatment as usual|Routine discharge counseling
104127|NCT03372564|Procedure|Hip Capsule Repair|In the central compartment, significant and obvious pathologies will be addressed accordingly. Following addressing central compartment pathologies, cam impingement type lesions in the peripheral compartment will be treated. Once all pathologies are addressed, the interportal capsulotomy10 will be repaired by using simple interrupted sutures with absorbable suture (Number 1 Vicryl).
104128|NCT03372551|Device|somofilcon A 1 day test lens|Contact lens
104129|NCT03372551|Device|somofilcon A 1 day control lens|Contact lens
104130|NCT03372538|Procedure|cesarean section or cesarean hysterectomy|upper segment cesarean section and or cesarean hysteroctomy
104131|NCT03372525|Device|HFOV|Infants were randomized to HFOV
104132|NCT03372525|Device|CMV|Infants were randomized to CMV
104133|NCT03372512|Diagnostic Test|Bioimpedance spectroscopy|Fluid overload will be assessed by bioimpedance spectroscopy
104134|NCT03372499|Dietary Supplement|diet management strategy for encephalopathy|diet management strategy for encephalopathy means diet management strategy from the nutritional management consensus of hepatic encephalopathy.
104135|NCT03372486|Drug|Bupivacaine plus naloxone|Patients received 20 mL bupivacaine 0.5% plus 100 ng naloxone (1ml) in 2ml saline.(naloxone ampoule 0.4mg will dilute in 400ml of saline then 1ml of it will dilute in 10 ml saline, so each ml will have 100ng naloxone)
104136|NCT03372486|Drug|Bupivacaine|Patients will be injected ultrasound guided in their brachial plexus by 20 mL bupivacaine 0.5% plus 3 ml of saline
104137|NCT03372473|Drug|Montelukast mixed with Loratadine|Montelukast 5mg mixed with Loratadine 5mg, one dose per day
104138|NCT03372473|Drug|Montelukast|Montelukast 5mg
104139|NCT03372460|Device|Active stimulation|For active tDCS, the investigators will use a 1x1 configuration with the anode placed over EEG coordinate AF7 (using the 10-20 EEG convention) and the cathode over Fz. The investigators will use 3x3 cm sponge covered electrodes and a 2mA current for 25 minutes per session.
104140|NCT03372460|Device|Sham stimulation|For sham tDCS, the investigators will use the same configuration of active tDCS, with the anode over AF7 and the cathode over Fz. The investigators will use 3x3 cm sponge covered electrodes and 1mA for 30 seconds, with a ramp up/down over 30 seconds per session.
104141|NCT03372460|Other|Virtual Reality (VR)|Participants will undergo VR exposure to trauma-related context.
104142|NCT03372447|Drug|Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg|Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
104143|NCT03372421|Other|Social Story|A short story written in the third person about what it's like to attend an assessment for ASD.
104144|NCT03372421|Other|Standard Information|Information the host site currently sends out to patients informing them about what to expect from the assessment
104145|NCT03372408|Other|Chart review|Retrospective chart review of program participation and socio-demographic & psychosocial characteristics
104146|NCT03372395|Other|Lactobacillus rhamnosus BMX 54|Given once a day for 10 days, once every 3 days for 20 days and then once every 5 days for other 2 months in all patients (probiotics implementation for 3 months comprehensively).
104147|NCT03372382|Drug|Ibuprofen|NSAID
104148|NCT03372382|Drug|Acetaminophen|analgesic
104149|NCT03372382|Drug|Norco|acetaminophen plus opioid
104150|NCT03372369|Other|View CDC Poster|The poster designed by the CDC to explain contraceptive effectiveness.
104151|NCT03372369|Other|View Patient-Centered Poster|The poster designed by the research team to explain contraceptive effectiveness. This poster was developed through cognitive interviews with 26 North Carolina women, and the final version of this poster was found to be more useful, acceptable, and attractive than the CDC poster by the majority of women participating.
104152|NCT03372330|Drug|Standard care for sepsis and PAD|The standard medications care for the patient with PAD included antiplatelet agents.
104153|NCT03372330|Drug|Standard care for sepsis|The standard care for the patient with sepsis.
104154|NCT03372317|Drug|18F-MK-6240|Results of the 18F-MK-6240 PET scan will be correlated with other observations.
104155|NCT03372304|Drug|Ropivacaine 0.2%|Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
104156|NCT03372291|Other|Usual Care|Usual leukemia care with all the supportive care measures instituted by the leukemia team
104157|NCT03372291|Other|Psychological intervention|Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
104158|NCT03372265|Drug|Ropivacaine 0.2%|Perineural infusion using a peripheral nerve block catheter and a portable infusion pump.
104159|NCT03372252|Device|Electroencephalography|Simplified electroencephalography using three electroencephalogram electrodes and two electro-oculogram electrodes for the measurement of central respiratory control through the inspiratory premotor potentials.
104160|NCT03372239|Drug|Indoximod base formulation|Specified dose on specified days
104163|NCT03372226|Behavioral|Online self-help program|The program consists of 10 modules with many interactional exercises and homework-sheets. Themes that are addressed in the online-program are for example self-esteem, sleep hygiene, problem solving strategies, mindfulness-based relaxation and attention exercises as well as gambling-specific topics such as money/debt management and impulse control. In addition, the user learns to modify negative and gambling-specific thought distortions, to integrate positive activities into his/her daily routine, strategies to deal with the urge to play as well as ways to regulate debts and to prevent relapse.
104164|NCT03372200|Drug|FYU-981|Oral daily dosing for 14 weeks
104165|NCT03372200|Drug|Febuxostat|Oral daily dosing for 14 weeks
104166|NCT03372187|Behavioral|DIET-MS|Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
104167|NCT03372174|Device|Maintaining mechanical ventilation during surgery|dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
104168|NCT03372174|Device|Absence of mechanical ventilation during surgery|absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
104169|NCT03372161|Drug|SP-102|injection
104170|NCT03372161|Drug|Placebo|injection
104172|NCT03372122|Drug|Chlorhexidine Gluconate|A cloth to cleanse and disinfect the skin
104173|NCT03372122|Combination Product|HUBS with Hibiclens|A dry cloth to be used in combination with water and antimicrobial soap to cleanse and disinfect the skin
104174|NCT03372109|Dietary Supplement|Meal replacement shake|Meal replacement shake taken two days per week during the modified fasting periods
104175|NCT03372109|Dietary Supplement|Multivitamin and mineral capsules|Multivitamin/mineral supplement
104176|NCT03372109|Dietary Supplement|Fish oil with sesame lignans and olive extract softgel|Wild Fish Oil Concentrate 2000mg, Olive Extract 300mg, Sesame seed lignan extract 10mg/2 softgels
104177|NCT03372109|Dietary Supplement|Prebiotic Chewable tablet|Prebiotic Fiber 1,400 mg/tablet
104178|NCT03372109|Dietary Supplement|Clove Extract and Maqui Berry extract capsule|Clove extract 250mg and maqui berry extract 200mg/capsule
104179|NCT03372109|Dietary Supplement|.Whole Food Blend capsule|Whole food blend 1000mg/3 capsules
104180|NCT03372109|Dietary Supplement|Turmeric extract capsule|Turmeric 25:1 extract 400mg/capsule
104181|NCT03372109|Dietary Supplement|European White Kidney Bean capsule|White kidney bean extract 100mg/capsule
104182|NCT03372109|Dietary Supplement|Saffron extract capsule|Saffron extract 88.25mg/capsule
104183|NCT03372109|Dietary Supplement|Ubiquinol with Fulvic acid complex softgel|Ubiquinol 100mg and Fulvic Acid complex 100mg/softgel
104184|NCT03372109|Dietary Supplement|Calcium with Hesperidin and gynostemma extract tablet|Calcium 130mg. hesperidin 500mg and gynostemma extract 450mg/ tablet
104185|NCT03372109|Dietary Supplement|Multivitamin and mineral supplement|Multivitamin and multimineral supplement
104186|NCT03372096|Device|Prostatic Artery Embolization|LC Bead LUMI is a spherical polyvinyl alcohol embolic particle that incorporates radiopaque moieties. Once a catheter has been fluoroscopically guided into the target vessel, the beads are then injected, causing obstruction at the arteriole level until the desired degree of embolization has occurred.
104187|NCT03372083|Drug|Deferasirox|Deferosirox is provided in tablet forms of 90, 180 and 360mg. Tablets must be crushed.
104188|NCT03372070|Device|cNEP|soft silicon collar applied to anterior neck with negative pressure
104189|NCT03372057|Drug|Duvelisib|Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
104190|NCT03372057|Drug|Duvelisib|Duvelisib PO 75 mg BID in 28-day cycles.
104191|NCT03372057|Drug|Duvelisib|Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase)
104192|NCT03372044|Drug|PF-06865571 Immediate release suspension|Suspension
104193|NCT03372044|Drug|PF-06865571 Slow release MR tablets|Modified release tablets
104194|NCT03372044|Drug|PF-06865571 Fast release MR tablets|Modified release tablets
104195|NCT03372044|Drug|PF-06865571 Immediate release tablets|Immediate release tablets
104196|NCT03372031|Behavioral|Piano training (Active)|Piano Curriculum. Participants were all trained on one of four 88-key pianos located in the assisted living facility. Piano instructors were 6 undergraduate Music Education and Music Performance majors. Each lesson of the week had a different focus: right and left hands separately, bimanually coupled, and bimanually uncoupled (Loehrer et al., 2016). Each week of the module had a different focus as well: notes played one step apart, notes played multiple steps apart (intervals), and tones played together (two-note chords) (van Vugt et al., 2016; Villeneuve et al., 2014). Each session began with skill exercises and ended with learning a simple, recognizable song. Two participants with extensive piano experience progressed to playing duets with the instructor and hymns out of a hymnal after mastery of the study curriculum. These training protocols were based on those of Schneider and colleagues' 2007 study.
104197|NCT03372031|Behavioral|Piano Training (Passive)|Participants listened to their research partner complete 8 active piano training sessions across 2 weeks.
104198|NCT03372018|Behavioral|Promotora-led Intervention (PLI)|Behavioral life-style program with cognitive-behavioral content lead by a team of trained community health workers (called promotoras) with the following principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
104199|NCT03372018|Behavioral|Usual care (UC)|Participants in this arm will be given educational materials in spanish discussing mental health and diabetes prevention.
104200|NCT03372005|Behavioral|Floorball|This intervention will have one week of testing before the first 12 weeks of floorball, followed by one week of testing before the last 27 week training period.
104201|NCT03371992|Drug|Nivolumab|Nivolumab, pembrolizumab or atezolizumab will be administered as per the established standard of care for the eligible population.
104202|NCT03371992|Diagnostic Test|3D-EX|Analysis of drug-mediated changes in the tumor microenvironment.
104203|NCT03371992|Other|Evaluation of Response by RECIST|Evaluation of tumor response using the set of published rules to determine if a tumor has responded, is stable or progressed during treatments.
104206|NCT03371966|Dietary Supplement|High Nitrate Beetroot Juice|High nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of low nitrate beetroot juice.
104207|NCT03371966|Dietary Supplement|Low Nitrate Beetroot Juice|Low nitrate beetroot juice (120 ml) will be administered for 7 days consecutively followed by a 7 day washout period then 7 consecutive days of high nitrate beetroot juice..
104208|NCT03371953|Drug|Vecuronium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
104209|NCT03371953|Drug|Atracurium|A top-up dose of vecuronium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
104210|NCT03371953|Drug|Vecuronium + Atracurium|A top-up dose of vecuronium + atracurium will be administered when the TOF count is 1 on the accelerometer. However, if there is a diaphragmatic contraction which interferes with surgical procedure then a dose will be given irrespective of the TOF count.
104211|NCT03371940|Behavioral|Program ACTIVE Exercise|Please see the Exercise arm description above.
104212|NCT03371940|Behavioral|Program ACTIVE CBT|Please see the Talk Therapy arm description above.
104213|NCT03371940|Behavioral|Program ACTIVE|Please see the Talk Therapy + Exercise arm description above.
104214|NCT03371940|Behavioral|Usual Care - No intervention|Please see the Usual Care arm description above.
104215|NCT03371927|Other|SINC Feeding Protocol|Safe individualized nipple-feeding competence protocol for premature infants
104216|NCT03371914|Behavioral|Management training and data feedback|The management training will consist of a variety of management topics, such as financial, workplace and staff management. The training will include a number of tools that the managers will be expected to bring back with them and use regularly at their site. There will be monthly refresher trainings for the managers via an online platform, where participants will interact about the topics covered in the training and others relevant to their work as managers. Participants will also receive monthly visualizations that compare the data that they enter via tablet monthly to both (1) their baseline data, and (2) to other sites' data. Outcomes that will be measured and reported back to sites include cost per client tested, number of condoms distributed, and number of FSW reached by educational interventions.
104217|NCT03371901|Other|Physical therapy with BFR-LLST|"The criteria-based rehabilitation protocol for the patients with cartilage or meniscus repair may vary according to the surgical procedures.~Patients will attend 5 individual treatments, and a 6-week supervised group-based rehabilitation program with BFR-LLST (Blood Flow Restriction - Low Load Strength Training) twice a week at the rehabilitation centre. Patient will be instructed to perform BFR-LLST 5 times a week in total (twice supervised, 3 times at home).~During each BFR-LLST session, patients are encouraged to perform 4 sets of 30 repetitions, 15 repetitions, 15 repetitions, and 15 repetitions (or to fatigue in the final set), respectively.~The exercise intervention will adhere to TIDieR (template for intervention description and replication)."
104218|NCT03371888|Biological|Platelet-Rich Plasma intramuscular injections|A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.
104219|NCT03371888|Biological|Placebo Comparator: 0,9% NaCl intramuscular injections|A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
104220|NCT03371875|Behavioral|Automated transition care reminders|The CHICA system will gather the elements of the TRAQ questionnaire and report the specific areas of deficiency to the physician. If a patient reaches the point of care transition (18 years), then an automated email is sent to a clinic nurse.
104221|NCT03371862|Drug|Liraglutide Pen Injector [Victoza]|Pilot study of liraglutide in patients with short bowel.
104222|NCT03371849|Drug|montelukast and levocetirizine FDC|HCP1102
104223|NCT03371849|Drug|Singulair + xyzal|HGP0813 + HGP1408
104224|NCT03371836|Drug|Clobazam|Clobazam is used as an adjunct medicine for all participants.
104225|NCT03371823|Other|Normotensive|FMD is a measure of endothelial function by assessing the degree to which vessel dilates in response to increased flow. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection in all women. Laser Doppler flowmetry is used in combination with cutaneous microdialysis as a minimally invasive technique to examine mechanisms of vascular function. ET-B and ET-A receptor antagonists will be perfused via intradermal microdialysis fibers while measuring cutaneous blood flow. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will also be assessed. Immunohistochemistry will be performed on skin punch biopsy samples to assess for protein expression of ET-A and ET-B receptors.
104226|NCT03371823|Drug|Hypertensives|ANG II increases the synthesis of ET-1 and alters ET-A/B receptor expression, thus affecting ET-1 bioavailability. Losartan is an ANG II receptor antagonist which attenuates ET-1 production. Losartan 50 mg daily is administered for 14 days to hypertensive women. FMD is used to measure endothelial function. Pulse Wave Analysis and Pulse Wave Velocity assesses arterial stiffness and wave reflection. Laser Doppler flowmetry with cutaneous microdialysis is used to examine vascular function when ET-A and ET-B receptor antagonists is perfused via intradermal microdialysis fibers. ET-1 production and ET-B receptor expression in endothelial cells collected from an antecubital vein will be assessed. Skin punch biopsy samples will be used to assess for protein expression of ET-A and ET-B receptors.
104227|NCT03371810|Behavioral|Bright light therapy|Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
104267|NCT03371550|Drug|Docetaxel|Induction chemotherapy
104268|NCT03371550|Radiation|concomitant radiotherapy|Pulmonary and mediastinal radiotherapy
104269|NCT03371550|Drug|Cisplatin|Induction chemotherapy
104270|NCT03371537|Procedure|Liver debit measure|Mesure of liver debit during hepatectomy
104271|NCT03371524|Other|Cardiac Echography|While routine cardiac echography is performed on patients with calcified aortic valve, a 30 second loop is recorded.
104374|NCT03370653|Drug|Odiparcil|Investigational product: odiparcil 250 mg tablets
104228|NCT03371810|Behavioral|Physical exercise|"During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity."
104229|NCT03371797|Drug|Valsartan, Amlodipine -|"Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker."
104230|NCT03371784|Drug|Hydrocortisone|I.V. administration
104231|NCT03371784|Drug|Placebo|I.V. administration
104232|NCT03371771|Behavioral|Volunteer-delivered Behavioral Activation|Behavioral Activation as delivered by trained volunteers
104233|NCT03371771|Behavioral|MSW-delivered Behavioral Activation|Behavioral Activation as delivered by trained MSWs
104234|NCT03371758|Other|skin biopsy|Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.
104235|NCT03371745|Procedure|Trophectoderm biopsy|Biopsy at blastocyst stage of trophectoderm cells for comprehensive evaluation of the eupolid status of the embryo.
104236|NCT03371745|Procedure|Cryopreservation|Rapid freezing using vitrification
104237|NCT03371745|Procedure|Embryo Transfer|Transfer of embryo that has been cultured in vitro into the uterus
104238|NCT03371732|Behavioral|Motivational Intervention group|Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.
104239|NCT03371732|Behavioral|Educational advises group|Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.
104240|NCT03371719|Drug|Apalutamide|Given PO
104241|NCT03371719|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
104242|NCT03371719|Other|Placebo|Given PO
104243|NCT03371706|Behavioral|Evidence-Based Treatment|Evidence-based speech language therapy treatment will be compared and contrasted in the two arms of the study.
104244|NCT03371693|Device|HIPEC|Patients consenting to this protocol will undergo their scheduled surgical procedure. After cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm, a single dose of lobaplatin (30 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 60 minutes in the hyperthermic phase (43℃±0.5℃). And HIPEC will be repeated at the 3 and 5 day after the day of CRS plus HIPEC.
104245|NCT03371693|Device|CRS|cytoreductive surgery (CRS) to a residual disease ≤ 2.5 mm.
104246|NCT03371693|Device|IVCT|platinum-based intravenous chemotherapy
104247|NCT03371680|Drug|Injection of 1-13 Carbon Leucine and deuterated water|All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
104248|NCT03371667|Drug|Methotrexate|"Methotrexate 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Methotrexate will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
104249|NCT03371667|Drug|Placebo|"Placebo 5 mg/m2 will be given once week for 4 weeks, then 3 mg/m2 every two weeks for 12 weeks. Body surface area will be capped at 2 m2.~Placebo will be given as an IV infusion over 15 minutes. All patients will received prednisone 2 mg/kg.day PO (or methylprednisolone 1.6 mg/Kg/day) for 3 days.~For responding patients between day 4 and 28, the dose of prednisone must be at least 0.25 mg/kg/day prednisone (or 0.2 mg/kg/day methylprednisolone).~All patients should receive a folinic acid supplementation 24 hours after each MTX/placebo administration.~Lederfoldin 10 mg po or iv will be administered on days 2, 9, 16 and 23. Lederfoldin 10 mg po or iv will be administered on days 37, 51, 65, 79, 93 and 103."
104250|NCT03371654|Drug|Estradiol|Synthetic estradiol (2mg or 4mg) will be administered
104251|NCT03371654|Drug|Placebo|Placebo will be administered
104252|NCT03371641|Behavioral|ASQ parental questionnaire|ASQ parental questionnaire
104253|NCT03371641|Behavioral|Development scales|WPPSI - IV and NEPSY development scales
104254|NCT03371641|Behavioral|Scale of Conners|Scale of Conners
104255|NCT03371641|Behavioral|SCQ Questionnaire|SCQ questionnaire
104256|NCT03371641|Procedure|Blood sample (mother)|Blood sample (mother) before delivery
104257|NCT03371641|Procedure|Cord blood sample|Cord blood sample after delivery
104258|NCT03371641|Procedure|Placenta sample|Placenta sample
104259|NCT03371628|Device|Non invasive ventilation|Non invasive ventilation is a mode of mechanical ventilation that does not require the use of artificial airway.
104260|NCT03371615|Other|Anti-regurgitation infant formula|Anti regurgitation infant formula
104261|NCT03371602|Procedure|surgery|a diaphragmatic biopsy (100 microgram) and a parietal biopsy will be performed by the surgeon during surgery.
104262|NCT03371602|Procedure|multi-organ sampling|a diaphragmatic biopsy (100 microgram) will be performed by the surgeon during surgery.
104272|NCT03371498|Drug|Methylprednisolone|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
104273|NCT03371498|Drug|Methylprednisolone placebo|Ventilated patients presenting moderate to severe ARDS with a procollagen III alveolar level above 9 µg/L
104274|NCT03371485|Biological|AST-VAC2|"Patients will receive up to a maximum of six vaccinations over six weeks. Each weekly AST-VAC2 vaccination will be administered as a split dose via two intradermal injections at a target dose defined as 1 × 107 viable cells. There is no dose escalation planned during this study; only one dose level will be explored.~Each vial of AST-VAC2 will contain 0.6 mL. For each vaccination, vial contents should be drawn into one needle from the vial and delivered as two separate intradermal injections. Each injection will be a maximum of 0.3 mL each. The injections should be administered to the same body site approximately 1 cm apart.~Patients should receive the intradermal injections in either the deltoid muscle on the arm, the outer thigh surface, anterior abdominal wall or buttock.~Six vaccinations will be scheduled however may stop earlier if unacceptable toxicity develops."
104275|NCT03371472|Device|Visualisation and measuring of paravalvular leak.|Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).
104276|NCT03371459|Drug|AS MDI|AS MDI 1+1+2+4+8 inhalations of 90 μg per inhalation
104277|NCT03371459|Drug|Proventil|Proventil 1+1+2+4+8 inhalations of 90 μg per inhalation
104278|NCT03371446|Genetic|oral epithelial cells obtained by rinsing with 3% sucrose|rinsing with 3% sucrose, for a single time of collection, patients received periodontal treatment after collection and data analysis.
104279|NCT03371433|Other|Soft drinks|Caffeine and Caffeine free soft drinks
104280|NCT03371420|Drug|PU-AD|
104281|NCT03371420|Device|PET Scan|
104282|NCT03371420|Other|Blood Draws|
104283|NCT03371407|Other|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology|Assessment of behavioral performance and the electrophysiological (EEG) activity in PD patients during the early and more advanced stages of the pathology, using an instrumentation, called the Kinarm, which assess objectively sensory, motor and cognitive functions
104284|NCT03371394|Other|no intervention|no intervention
104285|NCT03371381|Biological|JNJ-64041757|Participants will receive intravenous (IV) infusions of JNJ-64041757 over approximately 60 minutes during each treatment cycle.
104286|NCT03371381|Drug|Nivolumab|Participants will receive IV infusions of nivolumab over approximately 60 minutes during each treatment cycle.
104287|NCT03371368|Procedure|Roux-en-Y Gastric Bypass|NOTE: The surgery is NOT paid for by the study
104288|NCT03371368|Procedure|Sleeve Gastrectomy|NOTE: The surgery is NOT paid for by the study
104289|NCT03371368|Behavioral|Very Low Calorie Diet|Weight loss with calorie restricted liquid diet. Subjects will be placed on a 800 kcal/day diet with a meal replacement (Optifast) provided by the investigator for 12 weeks. Then, transitioning to a higher calorie diet intake up to a year. Subjects will be closely monitored by study dietitian
104290|NCT03371355|Drug|ISIS 703802|Randomly assigned to one of the dosing cohorts.
104291|NCT03371355|Drug|Placebo|Randomly assigned to one of the dosing cohorts. Dose of placebo in each cohort will match volume of active in that cohort.
104292|NCT03371342|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
104293|NCT03371342|Drug|Botox|Botox(Botulinum toxin type A)
104294|NCT03371329|Biological|MSC|bone marrow derived cultured MSC (mesenchymal stem cell)
104295|NCT03371316|Biological|ViaShield|Anti-adhesion scores using amnion patch
104296|NCT03371303|Other|collection of prescription data|collection of prescription data before and after a hospitalization
104297|NCT03371290|Other|Mirror Therapy|The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
104298|NCT03371290|Other|Control Intervention|"In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention."
104299|NCT03371277|Other|Medical visit for specific questionnaires|Ambiguous Intentions Hostility Questionnaire (AIHQ) developed by Combs (2007)
104300|NCT03371251|Drug|BOS161721|SC administration
104301|NCT03371251|Drug|Placebo|SC administration
104302|NCT03371238|Behavioral|Floorball|The subjects in this group are set to play floorball three times pr. week for 39 weeks.
104303|NCT03371225|Device|Active tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. 20 minutes of tDCS will be applied.
104304|NCT03371225|Procedure|Active Exercise|Participants will walk briskly in a treadmill (as to keep at 60-70% maximum heart rate) for 30 minutes
104305|NCT03371225|Device|Sham tDCS|Active tDCS: A 1x1 Low-intensity DC Stimulator will be used to deliver direct current through rubber electrodes in saline soaked sponges. The anode will be placed over the left primary motor cortex (M1) while the cathode will be placed over the contralateral supra-orbital area. Only 30 seconds of current will be applied for the sham condition.
104306|NCT03371225|Procedure|Sham Exercise|Participants will walk in a treadmill (as to keep at 5% within their baseline heart rate) for 30 minutes.
104307|NCT03371212|Device|Dual mobility cohort|Patients will receive the Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell.
104308|NCT03371212|Device|Conventional cohort|Patients will receive a Taperloc femoral stem, ceramic femoral head (size 32mm for acetabular components 48/50mm; size 36mm for acetabular components > 52mm), polyethylene bearing, and G7 acetabular shell
104309|NCT03371199|Drug|Sodium chloride|Sodium chloride tablets, 250 mg
104310|NCT03371199|Drug|Placebo Oral Tablet|Starch tablets
104311|NCT03371186|Other|Community Health Worker|The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers
104312|NCT03371186|Other|Continuous Surveillance|Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.
104313|NCT03371186|Other|CB-Integrated Management of Newborn and Childhood Illness|Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
104314|NCT03371186|Other|Group Antenatal and Postnatal Care|The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
104315|NCT03371186|Other|Balanced Post-Partum Contraceptive Counseling|Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care—antenatal care, labor and delivery, postnatal care, and infant care—are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
104316|NCT03371173|Drug|Ferric maltol 30 mg (Feraccru®)|Feraccru® 30 mg hard capsules will be used. Each capsule contains 30 mg iron (as ferric maltol), 91.5 mg of lactose, 0.5 mg of Allura Red AC (E129) and 0.3 mg Sunset Yellow FCF (E110) as excipients with known effects
104317|NCT03371147|Other|CancerLife|CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team.
104318|NCT03371134|Biological|Harvesting of muscular biopsies|Muscular biopsies will be harvested during surgery; them satellite cells will be isolated and characterized in vitro.
104319|NCT03371121|Other|AT-AMIC (arthroscopic talus autologous matrix induced chondrogenesis)|to fill arthroscopically osteochondral talar lesion
104320|NCT03371108|Biological|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
104321|NCT03371108|Biological|Lantus®|Route of administration: subcutaneous injection
104322|NCT03371095|Drug|Infliximab|Use of infliximab instead of cyclophosphamide
104323|NCT03371095|Drug|Cyclophosphamide|Use of cyclophosphamide
104324|NCT03371082|Biological|Gan & Lee Insulin Glargine Injection|Route of administration: subcutaneous injection
104325|NCT03371082|Biological|Lantus®|Route of administration: subcutaneous injection
104326|NCT03371069|Other|users of methylphenidate|Children and adolescents who are users of methylphenidate, 2010 to 2015
104327|NCT03371056|Biological|Bacteriological analyses on clinical samples performed with swabs|Bacteriological analyses will be performed to assess the InSPIRe kit
104328|NCT03371043|Other|users of analgesic medications|Children and adolescents who are users of analgesic medications, 2012 to 2015
104329|NCT03371030|Procedure|Pronatus quadratus reparation|Displaced and intra-articular distal radius fractures treated with volar approach and plate fixation. Pronator Quadratus muscle repair.
104330|NCT03371017|Drug|Atezolizumab|"Atezolizumab will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
104331|NCT03371017|Drug|Placebo|"Placebo will be administered, 1200 mg by IV infusion with :~gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle"
104332|NCT03371017|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
104333|NCT03371017|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle
104334|NCT03371017|Drug|Carboplatin|Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle
104335|NCT03371004|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
104336|NCT03370991|Dietary Supplement|Blueberry Powder|22 g/day freeze-dried blueberry powder for 12 weeks
104337|NCT03370991|Dietary Supplement|Placebo Powder|22 g/day placebo powder for 12 weeks
104338|NCT03370978|Behavioral|Text Messaging|"To communicate with intervention patients after discharge from the ED, we will use a bidirectional text messaging service provided by another physician's research group within the University of Iowa. The nurse navigator will enter the patient's study identification number, first and last name and cell phone onto a secure study website established by this research group.~Patients will, as previously mentioned, have had their cell phone number tested in the text messaging system prior to leaving the Emergency Department (this includes the control group).~Patient's will receive a text message 3 days, and 1 day, prior to their scheduled follow-up appointment with Family Medicine (this appointment having been scheduled through the Emergency Department Nurse Navigators). Each text message will remind the patient of the date/time of their appointment, and provide them a link containing a map with the location of their appointment."
104339|NCT03370965|Diagnostic Test|Neuro-ophtalmology examination|"Patients will first undergo a full neuro-ophthalmic examination which includes visual acuity, contrast vision, color vision, slit-lamp anterior segment and fundus examination as well as automatized visual field and optical coherence tomography of the optic nerves and retina.~Patients will then be admitted to the Neurology and Ophthalmologic Department for optic neuritis emergency treatment, 3-Tesla brain and medullar MRIs, and ancillary testing. Specific NMO antibodies (AQP-4 and MOG) will be tested in all patients. Neuro-ophthalmic examination will be repeated after 3 days of IV steroids in order to decide on further treatment."
104340|NCT03370952|Procedure|laproscopy|laparoscopic ovarian cystectomy
104341|NCT03370952|Procedure|combined laproscopic and minilaparotomy ovarian cystectomy|"Under general anaesthesia, the patient is placed in the modified dorsal lithotomy position a 10-mm umbilical trocar is inserted. A panoramic view of the pelvis was obtained together with full assessment of the ovarian mass(es).~Aspiration of the cyst:Delivery of affected ovary outside the abdominal cavity:~Ovarian cystectomy:~Re-introduction of the ovary to inside the abdominal cavity:"
104342|NCT03370913|Biological|valoctocogene roxaparvovec|Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
104343|NCT03370900|Other|Testing|Participants either received 20 case testing with or without feedback
104344|NCT03370887|Drug|AZD8601|AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
104345|NCT03370887|Drug|Placebo|Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
104346|NCT03370874|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
104347|NCT03370874|Procedure|Vehicle sheet|Application of Vehicle sheet to diabetic foot ulcer
104348|NCT03370861|Biological|Immunotherapy|Medications that increase the activity of the immune system.
104349|NCT03370848|Dietary Supplement|Psyllium|Aspirin 325 mg tablet and two 1.7gm psyllium wafers (3.4gm total) 30 minutes prior to niacin ER
104350|NCT03370848|Drug|Aspirin|Aspirin 325 mg tablet 30 minutes prior to niacin ER
104351|NCT03370835|Drug|Metoprolol succinate ER|Cardioselective beta-blocker
104352|NCT03370835|Drug|Carvedilol|Non-cardioselective beta-blocker
104353|NCT03370822|Device|MONICA AN24 device|Application of MONICA AN24 device and recording for the longest period of fetal heart rate recording possible (limited by battery life)
104354|NCT03370809|Radiation|Brain PET/CT step|a cerebral PET/CT will be registered on the 45th minute after 18F-FDG injection and just before the whole body recording. This recording does'nt need a new injection but needs a low dose scanner
104355|NCT03370796|Other|Reminiscence Therapy Program|The Reminiscence Therapy program is composed of: (i) main strand lasting 7 weeks, with sessions twice a week (total of 14 sessions); (ii) maintenance strand, which runs for 7 weeks, once a week (total of 7 sessions). The duration for each session will be 60 minutes.
104356|NCT03370783|Drug|Ethanol|Moderate alcohol consumption
104357|NCT03370770|Drug|Afatinib|GILOTRIF, GIOTRIF, XOVOLTIB
104358|NCT03370770|Drug|Osimertinib|on T790M resistance mutation was developed
104359|NCT03370757|Other|3-hour bundled care|Infants in the 3-hour bundled care group will receive diaper changes every 3 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 3 times per week.
104360|NCT03370757|Other|6-hour bundled care|Infants in the 6-hour bundled care group will receive diaper changes every 6 hours with observational coding, microbiome samples, skin pH measurements and trans epidermal water loss measurements taken 4 times per week.
104361|NCT03370744|Diagnostic Test|Neuropsychological scale|Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on
104362|NCT03370731|Procedure|adenotonsillectomy|Resection of adenoidal tissue or hypertrophy tonsils by radiofrequency ablation or other methods.
104363|NCT03370731|Other|Nonsurgical management|Nasal Irrigation or inhaled corticosteroids, etc.
104364|NCT03370718|Drug|Cabozantinib|Given PO
104365|NCT03370718|Other|Pharmacogenomic Study|Correlative studies
104366|NCT03370718|Other|Pharmacokinetic Study|Correlative studies
104367|NCT03370705|Drug|Sulodexide|Sulodexide 250 ULS twice daily per oral route
104368|NCT03370705|Drug|Statin|Statin 20mg once daily per oral route,
104369|NCT03370705|Drug|Antiplatelet Agents|Antiplatelet therapy 75mg once daily per oral route
104370|NCT03370705|Drug|ACE inhibitor|ACE inhibitor 20mg once daily per oral route
104371|NCT03370692|Other|Cognitive assesment, Frailty assessment|Asking relatives (using a structured questionaire) about cognitive function at admission , likewise about frailty using the Clinical Frailty Score
104372|NCT03370666|Other|HFNT|High flow nasal therapy
104373|NCT03370666|Other|NIV|Noninvasive ventilation
104375|NCT03370653|Other|Placebo|Comparator: placebo tablets similar to odiparcil 250 mg tablets
104376|NCT03370640|Drug|SEP-363856|An oral 25 or 50mg dose of SEP 363856
104377|NCT03370627|Biological|Monoclonal anti-cd303 antibody|Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.
104378|NCT03370614|Other|IBS Group|Participants will receive approximately 2 months of dietary and nutritional counseling.
104379|NCT03370614|Other|Healthy Control Group|Participants will not receive any dietary or nutritional counseling.
104380|NCT03370601|Drug|Infliximab|Infliximab 10mg/kg every 8 weeks
104381|NCT03370601|Drug|Mercaptopurine|6-mercaptopurine 1 à 1,5 mg/kg
104382|NCT03370601|Drug|Azathioprine|Azathioprine 2 à 2.5mg/kg/j
104383|NCT03370601|Drug|Infliximab|Infliximab 5mg/kg every 8 weeks
104384|NCT03370588|Drug|dexmedetomidine|Group A: dexmedetomidine infusion (0.4㎍/kg/hr) from anesthetic induction until the start of closure of peritoneum. Group B: Saline infusion during same time period.
104385|NCT03370588|Drug|Normal saline|Group B: Saline infusion during same time period.
104386|NCT03370575|Drug|ethiodized poppyseed oil|Hysterosalpingography using ethiodized poppyseed oil
104387|NCT03370575|Drug|the second-generation non-ionic monomer contrast|Hysterosalpingography using the second-generation non-ionic monomer contrast
104388|NCT03370562|Drug|Dexmedetomidine|Administration of 10 mcg intravenous dexmedetomidine
104389|NCT03370562|Drug|Placebo|Administration of normal saline
104390|NCT03370549|Behavioral|AWARE intervention|Group psychotherapy for Asian-American women
104391|NCT03370536|Device|CardioInsight ECGI Mapping System|The CardioInsight mapping system is a noninvasive, single beat cardiac arrhythmia mapping system that provides 3D electroanatomic maps of the heart.
104392|NCT03370536|Procedure|AF ablation|Empiric ablation (CFAE or linear ablation) is not permitted
104393|NCT03370536|Drug|Ibutilide|Progressive doses of Ibutilide administered (0.25mg, then 0.25mg, then 0.5mg)
104394|NCT03370523|Other|No intervention is planned in our study|No intervention is planned in our study
104395|NCT03370510|Drug|Oxytocin|Oxytocin nasal spray.
104396|NCT03370510|Behavioral|Pivotal Response Treatment|An evidence-based manualized treatment for individuals with autism, which was specifically designed to improve social communication.
104397|NCT03370510|Drug|Placebo|Placebo nasal spray.
104398|NCT03370497|Dietary Supplement|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
104399|NCT03370497|Dietary Supplement|Whey Protein Hydrolysate|50 g whey protein hydrolysate
104400|NCT03370484|Dietary Supplement|Control|Water with 80 mg sucralose
104401|NCT03370484|Dietary Supplement|Milk mineral supplement|Water with milk mineral supplement (1000 mg calcium), plus 80 mg sucralose
104402|NCT03370471|Behavioral|Moderate Intensity Exercise|Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning.
104403|NCT03370471|Behavioral|Gentle Stretching|Subject will engage in 30 minutes of gentle upper- and lower- limb stretching prior to word learning.
104404|NCT03370458|Dietary Supplement|Lactobacillus plantarum DR7|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
104405|NCT03370458|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum DR7 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years. Secondary emphases include respiratory and gastrointestinal health
104406|NCT03370445|Behavioral|Control Group|In contrast to the Intervention study, NO training in communication skills will be provided, and NONE of the nutrient/physical activity oriented educational materials will be provided to the Control groups.
104407|NCT03370445|Behavioral|Greenlight Intervention|"The GREENLIGHT Tool Kit will use low-literacy handouts and study-related gifts to assess nutrition and physical activity behaviors, and reinforce evidence-based recommendations about early childhood nutrition and physical activity."
104408|NCT03370432|Other|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
104409|NCT03370419|Behavioral|The Pick Two to Stick To Habit Development Intervention|Lifestyle intervention fostering the development of behavioral automaticity (habit strength) or dietary and physical activity behaviors.
104410|NCT03370406|Drug|5-fluorouracil|Intralesional injections of 50mg/ml over a 3 week period.
104411|NCT03370406|Drug|Imiquimod 5% cream|Topical application of 5% cream over a 3 week period.
104412|NCT03370393|Behavioral|Pathways for African-Americans' Success (PAAS)|PAAS is a 6-week, technology-delivered, family-based youth risk intervention program. PAAS includes 6 sessions for parents and youth, and joint sessions in which they both engage on the same computer to integrate and practice the skills they have just learned in their separate sessions. Each session includes a review, a virtual discussion, and observing and interacting with four parent and four youth Avatars that reflect phenotypes of AAs, with voice-overs by AA parents and youth. Videos portraying family interactions and intrapersonal processes are integrated into each session to convey key points of the intervention along with interactive activities to promote skill-building and to reinforce learning. PAAS also includes a technology tutorial and an introductory session.
104413|NCT03370380|Drug|Aflibercept|Patients are treated according to authorization of Aflibercept
104414|NCT03370367|Drug|13-cis retinoic acid|Taken daily.
104415|NCT03370367|Other|Placebo|Placebo
104416|NCT03370354|Behavioral|Observational|Ask patients about sleep quality and identify reasons of troubled sleeping patterns in the units.
104417|NCT03370341|Device|active anodal tDCS|active anodal tDCS with behavioral tasks to assess IA
104418|NCT03370341|Device|sham tDCS|sham tDCS with behavioral tasks to assess IA
104449|NCT03370055|Device|LeucoPatch®|LeucoPatch® is an elastic membrane produced by the patients own venous blood by centrifugation, and one or two is placed on the wound once a week The LeucoPatch® consist of the fibrin Leucocytes and growth factors from the patients own blood
104419|NCT03370328|Other|Peppermint oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
104420|NCT03370328|Other|Ginger oil|The study product is a commercial essential oil product and nasal inhaler. It is to be prepared by a trained, independent individual who will add 4 drops of one of the three oils/oil combinations. The subject will be instructed to twist off the cap and position inhaler in such a way as to allow the subject to inhale the vapors; it can be reused for multiple administrations. Essential oils have been the subject of other studies in treating nausea. If nausea is unrelieved, treatment will progress to the ordered antiemetic.
104421|NCT03370315|Other|Dance Program|The dance program consists of dance classes inspired by the rhythm of Forró and Samba. The sessions are divided into four stages: 1) stretching and sensitization of the body, with the support of chairs; 2) balance and rhythm exercises, with the support of the bar; 3) dance inspired by the genres worked - Forró and Samba; 4) Fun activities that stimulate socialization or with visual clues, working displacements, motor coordination, rhythm, improvisation and creativity. 24 sessions, twice a week, which session take 60 min.
104422|NCT03370315|Other|Walking Program|The walking program consists of 3 moments: 1) a brief warm-up of free walking for 3 minutes in the comfortable velocity; 2) then walking according to the training cycle, the intensity will be between 60 and 80% of the reserve heart rate; 3) a relaxation. 24 sessions, twice a week, which session take 60 min.
104423|NCT03370302|Drug|TAK-228|TAK-228 Capsules.
104424|NCT03370289|Biological|BLB-750 Vaccine (Qinghai RG strain)|BLB-750 Injection
104425|NCT03370276|Drug|Nivolumab|Nivolumab intravenously (IV) at 240 mg as outlined in the treatment arms.
104426|NCT03370276|Drug|Cetuximab|Cetuximab intravenously (IV) at 500 mg/m^2 or 250 mg/m^2 as outlined in the treatment arms.
104427|NCT03370263|Drug|Benlysta|Benlysta will be administered intravenously or subcutaneously.
104428|NCT03370224|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
104429|NCT03370224|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
104430|NCT03370211|Other|resistance training|Participants from TG performed program, executed in 3 sets of 10-15RM, 3 times per week on Mondays, Wednesdays, and Fridays. The RT program was composed of 8 exercises comprising one exercise with free weights and seven with machines performed in the following order: chest press, horizontal leg press, seated row, knee extension, preacher curl (free weights), leg curl, triceps pushdown, and seated calf raise. All participants were personally supervised by physical education professionals with substantial RT experience to help ensure consistent and safe exercise performance. Participants were instructed to inhale during the eccentric phase and exhale during the concentric phase while maintaining a constant velocity of movement at a ratio of approximately 1:2 seconds (concentric and eccentric phases, respectively). Participants were afforded 1 to 2 min of rest between sets and 2 to 3 min between each exercise. The average duration of each session lasted approximately 50-60 minutes.
104431|NCT03370198|Biological|NKR-2 cells|NKR-2 cells will be administered (hepatic transarterial administration) every 2 weeks (14 days) for a total of 3 administrations within 4 weeks (28 days)
104432|NCT03370185|Drug|Duvelisib|Duvelisib 25 mg orally (PO) twice daily (BID) continuously in 28-day cycles
104433|NCT03370172|Drug|BAX 888|Participants will receive a single peripheral IV infusion of BAX 888 in Cohort 1, 2, 3 on Day 0.
104434|NCT03370159|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
104435|NCT03370159|Drug|Docetaxel|Given IV
104436|NCT03370159|Other|Pharmacological Study|Correlative studies
104437|NCT03370146|Behavioral|Mental training based on Motor Imagery|Patients of the experimental group will be instructed to imagine walking, from a first person perspective, focusing on the kinaesthetic sensations typically associated with the movement. The motor imagery training will be performed using the support of a laptop, on which there will be presented complex static scenes, representing different kind of paths with different landmarks to reach during the mental walking.
104438|NCT03370146|Behavioral|Cognitive training|Patients of the control group 1 will undergo a general cognitive training, not based on motor imagery.
104439|NCT03370146|Behavioral|Evaluation of gait abilities|All the subjects included in the trial will undergo a series of behavioral test for the evaluation of gai abilities
104440|NCT03370133|Drug|Bimekizumab|Bimekizumab will be provided at pre-specified time intervals.
104441|NCT03370133|Drug|Ustekinumab|Ustekinumab will be provided as dose 1 for subjects weighing <=100 kg and as dose 2 for subjects weighing >100 kg at pre-specified time intervals.
104442|NCT03370133|Other|Placebo|Subjects will receive Placebo at pre-specified time points.
104443|NCT03370120|Drug|Padsevonil|"Pharmaceutical Form: film-coated tablet~Route of Administration: Oral use"
104444|NCT03370107|Device|rTMS|Conventional magnetic stimulations will be applied with a MacPROX100 machine using neuronavigation system. H-coil rTMS will be delivered with the Brainsway H-coil (Brainsway, Jerusalem, Israel) applied via a helmet placed on the head corresponding to the primary motor cortex (H10 coil) and connected to a Masgtim Rapid2 stimulatior (Mastim, Whitland, UK), while sham stimulation will be delivered with a sham coil placed in the helmet encasing the active rTMS coil. Active rTMS sessions with H-coil will use exactly the same parameters of stimulation as conventional rTMS.
104445|NCT03370094|Diagnostic Test|Audio-video-streaming of suspected stroke symptoms and signs|The diagnosis based on the patient evaluation by end-to-end encrypted real-time video will be compared to the gold standard, consisting of an in-person neurological examination by a stroke specialist in patients with suspected acute stroke.
104446|NCT03370081|Device|CAPNOGRAPHY|MONITORING OF CAPNOMETRY USING ETCO2 METHOD
104447|NCT03370068|Other|ICSI|Oocytes retrieved from one ovary will undergo insemination by ICSI.
104448|NCT03370068|Other|Conventional IVF|Oocytes retrieved from the second ovary will undergo insemination by conventional IVF
104450|NCT03370055|Other|Control,|Usual wound care in a specialized clinic
104451|NCT03370042|Procedure|semilunar coronally positioned flap with free gingival graft|
104452|NCT03370042|Procedure|semilunar coronally positioned flap alone|
104453|NCT03370016|Procedure|Amount of Pneumoperitoneum Pressure applied during RARP|Patients will be randomly assigned to undergo RARP either at a pneumoperitoneum pressure of 8 mmHg (experimental) or 12mm Hg (standard technique)
104454|NCT03370003|Other|Standard medical care|All children will receive nutritional treatment and standard medical care in accordance with the nutritional guidelines of the national protocol, with the exception of the routine distribution of antibiotics.
104455|NCT03369990|Drug|Botulinum toxin type A|Botulinum toxin type A(DWP450)
104456|NCT03369990|Drug|Placebos|Normal Saline
104457|NCT03369977|Device|BioGlue Surgical Adhesive|BioGlue (produced by CryoLife in Kennesaw, GA) is a surgical adhesive with two components respectively purified bovine serum albumin (BSA) and Glutaraldehyde (their proportions are 4:1). Crosslinked bonds (covalent bonds) of Glutaraldehyde cross-link the protein on the surface of the tissue and the amino residue of the bovine serum albumin. BioGlue also adheres to the synthetic matrix material by a mechanical interlocking mechanism in the space of graft matrix.
104458|NCT03369964|Drug|Atezolizumab|"In Cohort A1, Atezolizumab will be administered, 1200 mg IV, every 3 weeks starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV, starting on Cycle 2; Day 1 of a 21 day cycle~In Cohort A2 , In Cycle 2-8, Atezolizumab will be administered, 1200 mg IV on day 1 of each 21 day cycle~In Cohort A2, Atezolizumab will be administered, 1200 mg IV starting on Cycle 9; Day 1 of each 21 day cycle"
104459|NCT03369964|Drug|Emactuzumab|"In Cohort A1, Emactuzumab will be administered 1000 mg IV, every 3 weeks, starting on Cycle 1; Day 1 of a 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV, starting on Cycle 1 Day 1 of a 21 day cycle.~In Cohort A2, in cycle 2-8, Emactuzumab will be administered 1000 mg IV, on day 1 of each 21 day cycle.~In Cohort A2, Emactuzumab will be administered 1000 mg IV starting on Cycle 9; on Day 1 of each 21 day cycle"
104460|NCT03369964|Drug|Obinutuzumab|"In Cohort A2, Obinutuzumab will be administered 1000 mg IV starting on Cycle 1; Day 1 of a 21 day cycle~In Cohort A2, Obinutuzumab will be administered again on days 8 and 15 (Cycle 1) of a 21 day cycle~In Cohort A2, in cycle 2-8, Obinutuzumab will be administered 1000 mg IV on day 1 of each 21 day cycle"
104461|NCT03369951|Drug|Minocycline|Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
104462|NCT03369938|Other|exercise training intervention|structured aerobic endurance/resistance training on top of usual care for 12 weeks (3x/week)
104463|NCT03369925|Dietary Supplement|Placebo supplement|Cellulose
104464|NCT03369925|Dietary Supplement|Citicoline supplement|Cognizin
104465|NCT03369912|Biological|CSJ148|Active
104466|NCT03369912|Other|Placebo|No Drug
104467|NCT03369899|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
104468|NCT03369886|Diagnostic Test|Optical Coherence Tomography Angiography (OCTA)|The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).
104469|NCT03369873|Other|Guidance Manual|The intervention group received of nursing orientation using a validated guidance manual about cardiac catheterization.
104470|NCT03369860|Behavioral|Interactivity of Experimental Condition|The neurofunctional correlates of motor control will be compared between a collaborative and non-interactive condition.
104471|NCT03369847|Drug|budesonide, beclomethasone|The inhaled corticosteroids we are using for this study are budesonide nebulized solution and beclomethasone metered-dose inhaler. Low-doses for these medications are 0.5mg/day for budesonide and 160 mcg/day for beclomethasone. Patients under 5 years of age will receive low dose budesonide solution 0.25mg/respule to be given twice a day via nebulizer. Budesonide is FDA approved for children under 5 years of age. Patients 5 years and older will receive one beclomethasone metered-dose inhaler (MDI) 40mcg/puff two puffs twice a day via spacer. Beclomethasone is FDA approved for children 5 years and older.
104472|NCT03369834|Device|Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
104473|NCT03369834|Device|Infrared Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
104512|NCT03369457|Biological|Isolation of multipotent cells|Isolation of multipotent cells from patient's cells. Analysis of CFU and differentiation potential
104513|NCT03369444|Biological|FLT180a|FLT180a is a replication-incompetent adeno- associated viral vector. The vector is composed of a DNA vector genome encapsidated in an adeno-associated virus derived protein capsid. The expression cassette contains DNA encoding Factor IX.
104474|NCT03369834|Device|Infrared and Red Light-emitting diode device|"The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
104475|NCT03369834|Device|Sham|LED device off.
104476|NCT03369821|Diagnostic Test|Beta Cell Loss and Immune Function|Beta cell loss (measured by serum/urine C-peptide), islet-specific autoantibodies, T1D risk genes and autoreactive CD8 T cells.
104477|NCT03369821|Other|Immune Function with RNAseq|Immune function (measuring autoantibodies, autoreactive CD8 T cells and RNAseq of immune genes).
104478|NCT03369808|Biological|7.5μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
104479|NCT03369808|Biological|Phosphate Buffer Solution|0.5ml phosphate buffer solution
104480|NCT03369808|Biological|Aluminum Hydroxide Adjuvant|0.5ml aluminum hydroxide adjuvant
104481|NCT03369808|Biological|15μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
104482|NCT03369808|Biological|30μg H7N9 Vaccine|The vaccine was a inactivated, whole virion preparation of the influenza A/Shanghai/2/2013(H7N9) virus, propagated in embryonated chicken eggs，mixed with aluminum hydroxide adjuvant.
104483|NCT03369795|Drug|Methotrexate|Methotrexate 10mg once a week will be given for the first two weeks of the trial, followed by an increase in dose to 15mg or equivalent placebo once a week until week 16.
104484|NCT03369795|Other|Placebo Arm|Pills equivalent to the study drug arm (10mg) will be given once a week for the first two weeks of the trial, followed by an increase in dose to 15mg of equivalent placebo once a week until week 16.
104485|NCT03369782|Drug|Rocuronium|rocuronium is administered in bolus and continuous infusion
104486|NCT03369782|Drug|Sugammadex|Sugammadex is administered just before reduction of the joint
104487|NCT03369782|Drug|Placebo|"Placebo is administered as alternative to rocuronium in a bolus and in a syringe pump.~Placebo is administered as alternative to sugammadex"
104488|NCT03369769|Other|Activity|10 minutes interaction with therapy dog and adult handler in small group (2-4 participants).
104489|NCT03369756|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|Wound cleansing using Prontosan solution and gel
104490|NCT03369717|Drug|Amoxi Clavulanate|Postoperative antibiotics
104491|NCT03369704|Drug|Omalizumab|Omalizumab were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
104492|NCT03369704|Drug|Placebo|Placebo were administered by subcutaneous injection. Dose (75 to 600 mg) and dosing frequency (every 2 or 4 weeks) were determined by serum total IgE level (IU/mL) and body weight (kg) measured at the screening epoch according the dosing table.
104493|NCT03369665|Drug|Mavenclad®|Subjects will receive Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
104494|NCT03369652|Behavioral|Medication review|Conducted by the pharmacist and discussed with hospital physician
104495|NCT03369626|Behavioral|FareWell Program|The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
104496|NCT03369613|Device|transcranial electrical stimulation|The device is a Neoprene headcap that holds an array of padded electrodes close to the scalp to stimulate the underlying brain.
104497|NCT03369600|Device|Supersonic Imagine Aixplorer SWE Ultrasound Imaging|Consented women will attend 2+ sessions where they will be imaged using the Supersonic Imagine Aixplorer for Shear Wave Elastography imaging.
104498|NCT03369587|Behavioral|Handwriting Practice|Self-directed home handwriting practice daily for 6 weeks
104499|NCT03369574|Drug|Reslizumab|reslizumab administration
104500|NCT03369561|Diagnostic Test|Serum urea and creatinine and the calculated e GFR|The primary outcome will be AKI during the 1st 7 days of ICU care, as defined by an increase of ≥ 0.3 mg/dl in serum creatinine within 48 hours of ICU admission, an increase of ≥ 50% within 7 days of ICU admission, or acute dialysis
104501|NCT03369548|Other|Apple|2 Renetta Canada apples and 2 placebo capsules/ day
104502|NCT03369548|Other|Oats|40g jumbo rolled oats with semi-skimmed milk and 2 placebo capsules / day
104503|NCT03369548|Dietary Supplement|Lactobacillus reuteri NCIMB 30242|2 probiotic capsules and 40g cornflakes with semi-skimmed milk / day.
104504|NCT03369548|Other|Cornflakes|40g cornflakes with semi-skimmed milk and 2 placebo capsules/ day.
104505|NCT03369535|Other|CARB rich diet|Consumed CARB rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
104506|NCT03369535|Other|MUFA rich diet|Consumed MUFA rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
104507|NCT03369535|Other|PROT rich diet|Consumed PROT rich diet for 6 weeks with a washout period of at least 2 weeks before the next intervention
104508|NCT03369496|Other|Social capital; Neighborhood environment|Observational study examining the relationship among neighborhood environment, social capital and health among Montreal adults
104509|NCT03369483|Other|Abdominal pressure assessment|We will perform measurements of the abdominal pressure an urinary catheter connected with an intra-abdominal pressure device (Uno-Meter ® - Unomedical) in all patients undergoing on open-surgical procedures after mechanical ventilation withdrawal and extubation, 30 minutes and 4 hours after the application of CPAP.
104510|NCT03369470|Behavioral|App Dexterity|App based dexterity training by means of Finger Zirkus (see for more details: www.fingers-in-motion.de)
104511|NCT03369470|Behavioral|Theraband|Active control being five traditional hand strengthening (Thera-band) exercises, which we published in our previous RCT, being feasible and effective in improving dexterity (for more details see for Kamm et al. 2015).
104514|NCT03369431|Dietary Supplement|Vivomixx|Multi-strain probiotic containing 450 billion lyophilized bacterial cells per sachet belonging to 8 probiotic strains. The probiotic strains contained in the intervention are Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus delbrueckii subsp. bulgaricus.
104515|NCT03369431|Dietary Supplement|Placebo|4.4 grams of maltose and silicon dioxide per sachet
104516|NCT03369418|Device|Alpha-Stim Active|The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia
104517|NCT03369418|Device|Alpha-Stim Inactive|The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
104518|NCT03369405|Other|NO intervention, patient records review only|There is no intervention - the three study groups are created by utilizing three unique sets of search criteria for the patient records review.
104519|NCT03369392|Other|Panda application|A smartphone-based postoperative pain management tool
104520|NCT03369379|Drug|D3 Vitamin|Subjects will receive a capsule of 50,000 units of vitamin D3 echa week for 12 weeks, basal levels of vitamin D will be taken and again at week 12.
104521|NCT03369379|Other|Placebo|Placebo pill
104522|NCT03369366|Device|NobelActive|NobelActive's expanding tapered implant body condenses bone gradually while the apex with drilling blades enables a smaller osteotomy. These features help to achieve high primary stability in demanding situations, such as soft bone or extraction sockets. NobelActive enables immediate implant placement and Immediate Function where it might otherwise be challenging.
104523|NCT03369366|Device|KLS Martin Mandibular Reconstruction Implant|The prefabricated prosthesis will be secured onto the implants using non-engaging multiunit abutments with screws, followed by fixation of the patient-specific plate to the fibula with monocortical screws. The previously used cutting guides are fixated with the screw locations corresponding to the screw locations of the custom plate. This allows for accurate positioning and fixation of the custom construct of the plate and fibula without the need for intermaxillary fixation (IMF).
104524|NCT03369340|Other|P3P 1|Product 1: 2 mg of nicotine; no flavor
104525|NCT03369340|Other|P3P 2|Product 2: 2 mg of nicotine; flavor
104526|NCT03369340|Other|P3P 3|Product 3: 1 mg of nicotine; flavor
104527|NCT03369340|Other|P3P 4|Product 4: 2 mg of nicotine; flavor
104528|NCT03369327|Drug|sofosbuvir and daclatasvir|"Depending on the ART received by each patient one of the fixed-dose combination pills below will be used:~Daclatasvir 30 mg and sofosbuvir 400 mg~Daclatasvir 60 mg and sofosbuvir 400 mg~Daclatasvir 90 mg and sofosbuvir 400 mg"
104529|NCT03369314|Drug|octaplasLG®|Data will be collected in all patients who have received at least one infusion of octaplasLG®
104530|NCT03369301|Drug|Gammanorm|Gammanorm given per standard of care
104531|NCT03369301|Drug|Other Subcutaneous Immunoglobulins|Other Subcutaneous Immunoglobulins given per standard of care
104532|NCT03369288|Diagnostic Test|PET MRI|18F-fluoride PET-MRI
104533|NCT03369275|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Cryopreserved Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
104534|NCT03369275|Other|Placebo|Placebo, with excipients, will be administered intravenously.
104535|NCT03369262|Drug|OBE022|Oral
104536|NCT03369262|Drug|Placebos|Oral
104537|NCT03369262|Drug|Atosiban|I.V.
104538|NCT03369249|Behavioral|Link2CARE|The Link2CARE intervention consists of 4 sessions. Session 1 consists of a one-on-one meeting with a Health Coach, during which participants will be offered an oral rapid HIV test and STI test. Sessions 2, 3, and 4 are group-based. During these sessions, participants will engage in discussions and activities regarding sexual and substance use risk behaviors.
104539|NCT03369236|Drug|ACH-0144471|All participants randomized to the treatment arm will receive 6 months of active study medication ACH-0144471. At the time of treatment completion, drug will be tapered as appropriate.
104540|NCT03369236|Drug|Placebo|All participants randomized to the placebo arm will receive 6 months of placebo medication. At the time of treatment completion, drug will be tapered as appropriate.
104544|NCT03369210|Drug|red blood cell transfusion trigger|patients receive a RBC unit with different target ranges for the post-transfusion Hb levels
104545|NCT03369197|Device|Nasal Mask|Nasal anesthesia mask which covers the nose and attaches to the anesthesia circuit, allowing for variable positive pressure by setting the pop-off valve
104546|NCT03369197|Device|Control: Nasal Cannula|Nasal cannula as per usual care
104547|NCT03369184|Drug|Oxygen gas|The intervention is administered as previously described. The duration of intervention is 10 minutes.
104548|NCT03369184|Other|Ambient air|Administered similarly to treatment arm, via an open face mask and during 10 minutes
104549|NCT03369171|Device|Myo Armband (MYO,Thalamic Labs Inc, Kitchener, ON, Canada)|"MYO armband is a commercialized, gesture control device containing Height Medical Grade Stainless Steel EMG sensors, and an inertial measurement unit (IMU) consisting of a three-axis gyroscope and a, three-axis accelerometer, three-axis magnetometer. MY0 motion data (EMG and IMU) will be recorded during standard motor/neurological evaluation.~The clinical assessment will include standard motor neurological evaluation : EDSS and FS, walking status, foot tapping test, Heel-knee test, finger tapping test, Finger to nose test, Romberg test, timed 25 foot walk test, nine holes peg test. This clinical assessment will be done at the inclusion visit (V1) and at the follow-up visit at one year (V2)."
104550|NCT03369158|Procedure|patient specific pedicle screw positioning guide|
104551|NCT03369158|Procedure|Free hand technique pedicle screw positioning|
104552|NCT03369158|Device|MUST pedicle screw|
104553|NCT03369145|Dietary Supplement|High-fat diet|The high-fat diet will provide 7 days of overfeeding comprising of: +50% extra calories above the daily required intake, 65% of which is fat.
104623|NCT03368664|Drug|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
104554|NCT03369132|Device|Angiflash|throat spray (20 ml) containing hypertonic seawater, vegetable glycerin, natural mint, acacia honey, propolis extract, essential oils of thyme linalool, ravintsara and wintergreen, natural lemon flavor.
104555|NCT03369132|Device|Placebo|water based throat spray matching Angiflash for posology, dispensed volume, shape and size.
104556|NCT03369119|Drug|Montelukast 4 Mg Oral Granule|
104557|NCT03369119|Drug|Placebos|
104558|NCT03369106|Other|Composite severity score calculation|Neurological examination, cognitive testing, and MRI exam
104559|NCT03369093|Drug|Amoxicillin|Twice daily doses of injectable amoxicillin
104560|NCT03369067|Device|Tandem t:slim X2 with Control-IQ Technology + Dexcom G6|Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor [CGM].
104561|NCT03369067|Device|Dexcom CGM G5|"The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes"
104562|NCT03369067|Device|Continuous Subcutaneous Insulin Infusion|Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
104563|NCT03369054|Behavioral|Minority Stress Treatment|"The (MST) condition will include a psychoeducation session on minority stress for all participants during the initial assessment session prior to their first psychotherapy session. Prior to attending each of the 12 psychotherapy sessions during their electronic assessment (filling out the OQ-45 on Qualtrics on a computer provided by the study team), patients will be prompted to report up to three minority stress experiences over the previous week in the survey tool (which the therapists will not see). They will be prompted by their therapist to discuss these experiences within their psychotherapy sessions (for example, Would you like to discuss any of the minority stress experiences you've had over the week?)."
104564|NCT03369054|Behavioral|Treatment As usual|Treatment-as-usual (TAU) will occur as any usual 12-week treatment. The therapists will be encouraged to discuss any of the presenting concerns reported by patients and supervision will include usual care.
104565|NCT03369041|Drug|Irinotecan-Eluting Beads|
104566|NCT03369028|Other|2D and 3D image of infants´ faces|2D and 3D image of infants´ faces
104567|NCT03369015|Drug|10 mg d-amphetamine|10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
104568|NCT03369015|Drug|20mg d-amphetamine|20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
104569|NCT03369015|Drug|Placebo|Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
104570|NCT03369002|Drug|seladelpar|Oral single dose 10 mg
104571|NCT03368989|Drug|Radium-223 dichloride|Previously known as Alpharadin, Radium-223 dichloride is a calcium-mimetic, alpha emitting radiopharmaceutical, which introduces double-stranded DNA breaks in metastatic cancer cells.
104574|NCT03368950|Other|Online Mindfulness Course|An online mindfulness course guiding participants through all elements of Mindfulness-Based Cognitive Therapy (MBCT) and Mindfulness-Based Stress Reduction (MBSR). Ten easy-to-follow sessions with videos and interactive exercises led by leading mindfulness trainers.
104575|NCT03368937|Device|Tandem t:slim X2 with Control-IQ Technology|Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
104576|NCT03368924|Other|SCA patients (SS genotype)|"The clinical data relative to the patients will be collected in each of these stages (CVO, basic state).~Besides, to estimate the severity of the CVO, we shall use an index of severity of the episode ( IS2) adapted from the one who was validated by our group to stratify the severity of vasoocclusifs episodes at the drepanocytic child SS.~Main clinical parameters: taken of analgesic at home (level), temperature in the admission, SaO2 in the admission, number of painful sites, thoracic pain with or without associated cough, score EVA in the entrance, feeling of the patient of bigger gravity of the CVO with regard to its crises previous, heart rate to the admission, … Main biological parameters: rate of leukocytes, of polynucléaires neutrophiles, of réticulocytes, Lactate déshydrogénase, of haemoglobin, C-reactive Protein … The biological data can be studied according to their raw rate or according to their difference with their basic value (in the stable state)."
104577|NCT03368911|Device|Oral/Nasal Endotracheal Tube, Reinforced (Covidien)|Use Oral/Nasal Endotracheal Tube, Reinforced (Covidien) for endotracheal intubation
104578|NCT03368911|Device|TaperGuard oral tracheal tube (Covidien)|Use TaperGuard oral tracheal tube (Covidien) for endotracheal intubation
104579|NCT03368885|Other|Maternal dietary diversity|Counsel pregnant women for proper dietary intake and create awareness among family members and community to support her on maternal nutrition
104580|NCT03368885|Other|Diet diversity in complementary feeding|Counsel mothers of children of 6-23 months on diet diversity in complementary feeding by demonstration during home-visits and seek support from father and family members
104581|NCT03368885|Other|Exclusive Breast Feeding|Counselling on exclusive breast feeding among children under 6 months-Provide information to mothers of children of 3-6 months for exclusive breast feeding through home visits, and mothers meetings
104582|NCT03368885|Other|Community mobilization|Engagement of local/religious leader, husbands to support diet diversity for pregnant women and doctors and fathers to support diet diversity for complementary feeding
104583|NCT03368885|Other|Capacity Building|Capacity Building-Training of Community mobilization coordinator and mentoring for knowledge enhancement on nutrition for pregnant women and children below 2 years
104584|NCT03368885|Other|Use of existing platforms VHSND|Convergence- Strengthen Village Health Sanitation and Nutrition Day for creating awareness on diet diversity for maternal nutrition and complementary feeding
104585|NCT03368885|Other|Strategic use of data|Strategic use of data-Data analysis for concurrent monitoring,planning and decision making to improve the performance of CMCs
104586|NCT03368872|Other|Astaxanthin formulation|Astaxanthin formulation containing AstaReal® astaxanthin (Haematococcus pluvialis algae extract), tocotrienol, and zinc will be orally administered starting on Day 1 until Day 120
104587|NCT03368872|Other|Placebo|Placebo will be orally administered starting on Day 1 until Day 120.
104588|NCT03368872|Other|Exercise training|The subjects will undergo interval treadmill incline protocol (target 85% HR max, 3 times a week for 40 to 60 minutes) starting on Day 31 until Day 120.
104589|NCT03368859|Drug|Leucovorin|Intravenous
104590|NCT03368859|Drug|Fluorouracil - bolus|Intravenous
104591|NCT03368859|Drug|Bevacizumab|Intravenous
104592|NCT03368859|Drug|Fluorouracil - infusion|Intravenous
104593|NCT03368859|Drug|ABT-165|Intravenous
104594|NCT03368859|Drug|Irinotecan|Intravenous
104595|NCT03368846|Drug|Varlitinib|[14C]-Varlitinib
104596|NCT03368833|Diagnostic Test|Electrocardiogram|12-lead ECG will be obtained after induction and at 5, 10, 20, 30, and 60 minutes after the caudal epidural block.
104597|NCT03368820|Other|No intervention|Treatment left at the discretion of the participant
104598|NCT03368807|Device|Continuous Glucose Monitoring|Commercially available
104599|NCT03368807|Drug|Insulin Lispro|As prescribed.
104600|NCT03368794|Behavioral|Active treatment referral of opioid overdose survivors to long-term treatment|Telephone alert and outreach for inclusion, assessment and intake into long-term evidence-based treatment of the substance use disorder.
104601|NCT03368794|Behavioral|Control|Written information from ambulance staff to the patient about how to seek treatment. Patient is able to contact the research treatment facility through a specific phone number, making it possible to study treatment entry in the information-only control condition.
104602|NCT03368781|Device|AcQMap Imaging and Mapping System|3D Cardiac Imaging and Mapping during ablation procedures
104603|NCT03368768|Other|Obtain inform consent via questionnaire of Monkey Survey|This is an internet-based questionnaire study. Therefore, anyone in Thailand can access and answer the questionnaire.
104604|NCT03368755|Diagnostic Test|Cardiopulmonary Exercise Testing|Pimax, Pemax, airway pressure at 100 msec after occlusion (P0.1), and Ti and Ttot will be measured by the Micro 5000 device (Medisoft, Sorinnes, Belgium). TTImus will be calculated as (Pimean / Pimax) x (Ti / Ttot), where Pimean is the mean airway pressure resulting from the formula Pimean = 5 x P0.1 x Ti9. RM function will be determined a) prior to CPET, b) during CPET when the anaerobic threshold (AT) will be reached, and c) after CPET, when heart rate (HR) and oxygen consumption will be normalized.
104605|NCT03368755|Diagnostic Test|Respiratory Muscle Strength and Endurance|CPET will be performed by the Ultima CPX system (Medgraphics, St. Paul, USA), using a cycle ergometer and according to a standardized protocol. The following parameters will be recorded: total work in Watts, maximum HR, maximum oxygen consumption (VO2max), AT indices (work, HR, VO2 ) and duration of recovery.
104606|NCT03368742|Genetic|SGT-001|AAV9 vector containing muscle-specific promoter and microdystrophin construct
104607|NCT03368729|Drug|Niraparib|Niraparib is an oral PARP-1 and -2 inhibitor with high potency.
104608|NCT03368729|Drug|Trastuzumab|Trastuzumab is a commercially available agent administered by intravenous infusion. A loading dose of 8 mg/kg will be given as the first dose followed with all subsequent doses of 6 mg/kg every 3 weeks.
104609|NCT03368716|Behavioral|Acceptance-based Behavioral Treatment (ABBT)|ABBT is rooted in behavioral therapy but also cultivates self-regulation skills including experiential acceptance of potentially uncomfortable internal experiences (e.g., emotions, cravings), mindful awareness of decision making (e.g., mindful eating), and values clarification and behavioral commitment (e.g., practicing daily physical activity to be a contributing member on a sports team). ABBT has been used effectively to help youth and adults manage various medical and psychological problems. Moreover, components of ABBT have been shown to improve child and adult EF including inhibitory control and cognitive flexibility. Recently, ABBT has been integrated with components of standard behavioral treatment of obesity and applied with robust efficacy to weight management in adults.
104610|NCT03368703|Device|Anodal transcranial direct-current-stimulation|2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
104611|NCT03368703|Device|Sham transcranial direct-current-stimulation|"Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions."
104612|NCT03368690|Dietary Supplement|Oligopin®|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
104613|NCT03368690|Other|Placebo|At the treatment period (0th to 4th week of the experiment), subjects with ADHD will receive 1~3 capsules of polyphenolic extract from pine bark (25mg or 50 mg Oligopin per capsule) according to their body weight and age. The 5th to 6th week will be the washout period. The control group and Oligopin group will be cross-over at 7th week to 10th week of the experiment.
104614|NCT03368664|Drug|Alemtuzumab GZ402673|Pharmaceutical form:solution Route of administration: intravenous
104615|NCT03368664|Drug|Glatiramer acetate|Pharmaceutical form:solution Route of administration: subcutaneous
104616|NCT03368664|Drug|Beta-Interferon|Pharmaceutical form:solution Route of administration: subcutaneous / intramuscular
104617|NCT03368664|Drug|Methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
104618|NCT03368664|Drug|Ranitidine|Pharmaceutical form:tablet Route of administration: oral
104619|NCT03368664|Drug|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
104620|NCT03368664|Drug|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
104621|NCT03368664|Drug|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
104622|NCT03368664|Drug|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
104624|NCT03368664|Drug|Diphenydramine|Pharmaceutical form:solution Route of administration: intravenous
104625|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form:solution Route of administration: intravenous
104626|NCT03368664|Drug|Other H1 antagonist|Pharmaceutical form:tablet/pill Route of administration: oral
104627|NCT03368651|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
104628|NCT03368638|Other|Physical therapy intervention|Double knee to chest stretches, hip extension mobilization, neural mobilizations, home exercises program
104629|NCT03368625|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery before surgical resection of brain mets.
104630|NCT03368612|Other|Electronic evaluation system|spirometry, plethysmography, cardiopulmonary exercise test
104631|NCT03368612|Other|Electronic evaluation system|AirGo recording
104632|NCT03368599|Procedure|Bronchoscope guided advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the bronchoscope-guided method. The method is as follows.~Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~Pass the fiberoptic bronschoscope through a bronchial lumen of Lt. DLT.~Secure the pathway into the Lt. main bronchus by advancing the bronchoscope into the Lt. main bronchus.~Lt. DLT can be advanced through the guide of the bronchoscope into Lt. main bronchus.~After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
104633|NCT03368599|Procedure|Conventional advancement|"During the anesthetic induction for thoracic surgery, Lt. DLT is intubated using the conventional method. The method is as follows.~Lt. DLT is intubated through vocal cord using the direct laryngoscopy.~Rotate Lt. DLT 90 degrees to the left side.~Advance Lt. DLT blindly to main bronchus level.~After the advancement, the position of Lt. DLT can be confirmed using the fiberoptic bronchoscope. If necessary, the depth and direction of Lt. DLT should be modified."
104634|NCT03368586|Device|Flash Glucose Monitoring|The camp comprised a structured daily routine with five fixed meals: breakfast, lunch, afternoon snack, dinner and evening snack. Capillary blood glucose (BG) values were measured in parallel with unmasked Flash Glucose (FG) measurements using the FGM reader's built-in glucometer at breakfast, lunch and dinner. Additional measurements were taken before snacks, between the meals or overnight and BG was measured only in cases of low (<4.0 mmol/L) or high (>15.0 mmol/L) FG values or when symptoms were discordant with sensor readings. Sensor-related issues were documented and a questionnaire assessing satisfaction and usability of the FGM was completed by patients and caregivers at study completion.
104635|NCT03368573|Device|QbTest|QbTest is a computerised assessment which takes approximately 20mins. The test combines a continuous performance test alongside an infrared camera which measures the participant's movements. The infrared camera measures motor activity of the participant whilst they undertake the task. During the test, the participant is presented with continuously changing stimuli. Embedded within these stimuli is a given target. Participants have to respond by pressing a hand-held button only when the target appears. Attention is measured through omission errors and reaction time to response. Impulsivity is assessed through commission errors and anticipatory errors. Motor activity is measured through head movements during the task. The test is approved by the FDA (Ref: K133382) and CE marked.
104636|NCT03368560|Other|Sudarshan Kriya Yoga|Sudarshan Kriya Yoga (SKY): A 12-week training course conducted by certified instructors from the Art of Living Foundation. SKY training will take place in group-format (group sizes of 8-15 participants) in an appropriately sized and accessible community hall in London, Ontario.SKY training involves attending a week-long (5 days) course that teaches the basic principles of SKY over 2.5-3 hour daily sessions. This will be followed by once weekly follow up sessions (90 min/wk) for 3 weeks and then bimonthly sessions (every 2 weeks) for the next 8 weeks. In addition, participants will be asked to practice SKY at home daily (25 min/day) throughout the duration of the study period and log practice frequency and any other noteworthy observations in a log sheet that will be provided to them . Nutritional snacks will be provided during the 5 day SKY training course.
104637|NCT03368547|Procedure|Computed Tomography|Undergo PET/CT scan
104638|NCT03368547|Radiation|Gallium Ga 68-labeled PSMA-11|Given IV
104639|NCT03368547|Other|Laboratory Biomarker Analysis|Correlative studies
104640|NCT03368547|Procedure|Positron Emission Tomography|Undergo PET/CT scan
104641|NCT03368534|Device|Autologous Regenerative Technology (ART)|ART device with single-needle, fluid-assisted skin tissue harvesting technology.
104642|NCT03368521|Other|Back pain screening test|The care giver use the screening tool in order to score the back patient to three levels of risk. For each level of risk, one suggested type of care is provided; 1) simple advise; 2) physiotherapy; 3) multimodal rehabilitation. highest risk level includes multimodal intervention.
104643|NCT03368508|Behavioral|Simulating video|A 360-degree simulating video showing physiotherapy assessment in lumbar area
104644|NCT03368508|Behavioral|Conventional video|A conventional video showing physiotherapy assessment in lumbar area
104645|NCT03368495|Biological|Co-administration of MMR/YF|Both MMR & yellow fever vaccines administered on Day 0.
104646|NCT03368495|Biological|MMR followed by YF|MMR vaccine administered on Day 0 and yellow fever vaccine administered on Day 28.
104647|NCT03368495|Biological|YF followed by MMR|Yellow fever vaccine administered on Day 0 and MMR vaccine administered on Day 28.
104648|NCT03368482|Behavioral|Brain Gym Exercises|"Participants in the BrainGym Exercises group performed six of the following BG exercises in every training session they took part in: Cross Crawl, Gravity Glider, Arm Activation, Belly Breathing, Hook-ups, Think of an X, Lazy Eights, Elephant, Space Buttons, The Owl, Energy Yawn, Balance Buttons and The Energizer. All exercises were executed from a sitting position but following the main tenets of the Brain Gym® work routine."
104649|NCT03368482|Behavioral|Standard exercise program for institutionalized older adults.|Participants in the Standard Exercise group took part in a traditional physical exercise program designed for institutionalized elderly people aimed at increasing their range of mobility and coordination, specifically focused on the lower limbs.
104650|NCT03368469|Device|transcranial direct current stimulation|The Soterix Medical 1×1 Low Intensity Transcranial DC Stimulator Model 1300A is an investigational device manufactured by Soterix Medical, Inc. (New York, NY, USA). It is designed for use in noninvasive transcranial stimulation of the brain by delivering low-intensity electrical current to the scalp through two electrodes.
104651|NCT03368456|Behavioral|S4E|S4E application was developed in collaboration with youth in Southeast Michigan. S4E aims to prevent and reduce HIV/STI risk behaviors, including drug use and sexual risk behaviors, and increase HIV/STI testing among youth. Content produced for the application is based on scientific prevention principles in conjunction with youth input. To date, we have developed modules focused on youth alcohol & drug use, HIV & STIs and a forthcoming module on tobacco prevention and cessation.
104652|NCT03368456|Behavioral|Usual Care|Participants in Usual Care (i.e., Control Condition) will not receive the S4E intervention from the study staff. The Clinic's usual care includes a standard risk behaviors intake form, pamphlets highlighting resources, and reproductive and healthcare services.
104653|NCT03368443|Behavioral|treadmill training and overground gait training|The participants will be randomized into three different groups, and they will receive treadmill and overground gait training in one room, two rooms, or three different rooms.
104654|NCT03368430|Dietary Supplement|Melatonin|After performing scaling and root planing (SRP) in the test group, melatonin 10 mg oral capsule was taken once daily at night prior to bedtime for only 2 months during the 6-month study period
104655|NCT03368430|Drug|Placebo|After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
104656|NCT03368417|Other|Usual Care|"Participants will be advised to measure their BP at least 3 times a week and record their results on a form. The participants will be educated on how to interpret their BP according to standard self-monitoring practice guidelines.~As part of the study, participants without a HBPM will be provided with the Omron HEM 7130. Adherence to hypertensive medicines will be monitored using the medication event monitoring system eCAP™. In addition, the participants will be asked to undertake ambulatory blood pressure monitoring (using the Welch Allyn ABPM 7100 monitor) at Baseline and Month 6 for a duration of 12 hours, during their waking hours."
104657|NCT03368417|Other|Wireless HBPM System|"BP will be monitored using the iHealth KN-550BT wireless HBPM and transmitted to the study application via the iHealth mobile application.~The Wireless HBPM System consists of:~i) Instant BP feedback: Classification of each BP reading with feedback SMS. CRC will call the patient in case of alarming BP readings.~ii) Weekly HBPM adherence feedback: Participants receive praise, encouraging, or reminder SMSes.~iii) Continuous assessment: Based on average BP over the last 4 weeks, participants will be categorized and flagged for the CRC to follow clinical protocols. Protocols include asking patients to immediately come to the clinic, checking for alarm symptoms and discussing adherence over the phone, remote titration, and cancelling 1 clinic visit in case of good BP control."
104658|NCT03368417|Behavioral|BP Monitoring Incentives|"Participants will receive an intervention identical to those in the Wireless HBPM System, with financial incentives for BP monitoring. This arm is further randomly subdivided into the Instant Reward and Health Capital arms in a 1:1 ratio.~Instant Reward sub-arm:~Participants receive SGD 3 for each day they measure their BP, up to three times per week.~Participants do not receive financial incentive if they do not measure their BP.~Health Capital sub-arm:~Participants receive an initial health capital of SGD 72~Participants' health capital increases by SGD 6 on each week where they measure their BP on at least 3 different days and decreases weekly by 10% per missing BP reading."
104659|NCT03368404|Device|CBL-102 eye drops|CBL-102 eye drops, 3 to 6 times per day for 3 months
104660|NCT03368404|Device|Vismed Multi eye drops|Vismed Multi eye drops, 3 to 6 times per day for 3 months
104661|NCT03368391|Drug|tetracaine HCl and oxymetazoline HCL|0.4 mL HCl and oxymetazoline HCl administered intranasally
104662|NCT03368391|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
104663|NCT03368391|Drug|3% Mepivacaine with 1:100,000 epinephrine|2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
104664|NCT03368391|Drug|saline intranasal|0.4 mL intranasal saline will be administered as a placebo
104665|NCT03368391|Drug|saline infiltration|2.8 mL of saline will be infiltrated at anterior teeth as a placebo
104666|NCT03368378|Procedure|Early DVC ligation|After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The DVC will be identified and incised. The DVC will be then selectively ligated using a V-lok 3/0 barbed suture. This approach would allow for the preservation of the external urethral sphincter and for the identification and preservation of the neurovascular bundles that are located in the anterolateral aspect of the prostate. After the early DVC isolation, incision and ligation, the bladder neck will be incised and preserved when possible. A posterior nerve sparing approach will be then performed. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
104667|NCT03368365|Device|Ventilotel ®|Using of the spirometer of Aqsitania company, Ventilotel ®, to analyse the respiratory function at rest and to predict unplanned hospitalizations.
104668|NCT03368352|Dietary Supplement|Melatonin|Dietary supplement melatonin
104669|NCT03368352|Other|Hypoxia|Sleep in a hypoxic tent simulating high altitude
104670|NCT03368339|Drug|PR013 (0.045%)|PR013 topical Ophthalmic Drops (0.045%)
104671|NCT03368339|Drug|PR013 (0.06%)|PR013 topical Ophthalmic Drops (0.06%)
104672|NCT03368339|Drug|Placebo|Vehicle
104673|NCT03368326|Diagnostic Test|Critical-Care Pain Observation Tool (CPOT)|The CPOT includes 4 behaviors: (1) facial expression, (2) body movements, (3) compliance with the ventilator, and (4) muscle tension. Each behavior is rated from 0 to 2 for a possible total score ranging from 0 to 8.
104674|NCT03368313|Device|Circaid|Circaid is a velcro compression device for the calf (Circaid Juxtalite® Lower Leg; Medi Gmbh, Bayreuth, Germany), thigh and knee (Circaid Juxtafit; Medi Gmbh, Bayreuth, Germany). The Circaid device will be applied with an average pressure of more than 40 mmHg, verified through a BPS (built-in pressure system).
104675|NCT03368300|Other|Clinical and biological exam|"The study will include a clinical, neuropsychological, oculomotor, food intake and environmental exposure assessment. Blood samples will be taken to constitute a library of plasma, DNA and serum. The harvesting of samples will be part of a subsequent study. Consent for possible post-mortem neuropathological analysis will be proposed.~All the patients accepting it will be followed by a 5-year longitudinal follow-up. The longitudinal follow-up bi-annual and then annual will include a clinical evaluation, a questionnaire of dependence and a questionnaire of monitoring of exposure to certain environmental factors~All controls must answer a questionnaire of environmental exposure factors, oculomotor test, and blood sample (3 collections: DNA, serum, plasma)."
104676|NCT03368287|Device|Fitbit One, the activity tracker|Activity tracker, Fitbit One, will be used for a week to evaluate the steps of daily life before the surgery and at the time of follow up.
104677|NCT03368274|Drug|T 614|Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
104678|NCT03368261|Other|HTAP/ clinical complications in the sickle cell disease|At the inclusion in our study the diagnosis of PAH will be performed by transthoracic Doppler-echocardiograms in a group of 306 children (aged between 8 to 16 years old) with either SS or SC genotype with similar medical caring, to avoid a known selection bias. These patients will be followed during a 3 years longitudinal period. The occurrence of the clinical specific complications associated with SCD (acute chest syndrome, painful vaso occlusive crisis, septicemia and stroke) and the observed mortality rate of our children group, will be compared in patients groups stratified according to the occurrence of PAH. The expression of several molecular and cellular genetic biomarkers potentially associated with this complication will also be studied.
104679|NCT03368248|Other|Survey|A survey was conducted among all professionals in neonatal resuscitation services : doctors (senior and intern), paramedics (managers, pediatric nurses, auxiliaries and nurses, psychomotor therapists) and psychologists. The survey was based on a questionnaire, which was offered to all professionals, both medical and non-medical. All questions were closed, and a free comment area was proposed at the end. The questionnaire was preceded by a comment recalling the objectives of the study, the voluntary and individual nature of participation, and insisted on respect for anonymity. It consisted of 49 questions, allowing 197 possible answers. For most questions, several answers could be chosen.
104680|NCT03368235|Drug|AZD9567|oral OD SGRM administered as suspension
104681|NCT03368235|Drug|Prednisolone|oral capsules of 20 mg prednisolone administered OD for two weeks
104682|NCT03368209|Device|WM3.4|Investigational Medical Device collecting spectral raman data from tissue.
104683|NCT03368196|Drug|DS-8201a|An antibody drug conjugate
104684|NCT03368183|Other|Care delivery algorithim|SCAMP
104685|NCT03368170|Drug|IRL790|IRL790 capsule
104686|NCT03368144|Device|ClearLumen II Peripheral Thrombectomy System|Patients will be treated with the ClearLumen Peripheral Stent Graft System
104687|NCT03368131|Drug|Trastuzumab|intravenously administered with the loading dose of 8 mg/kg followed by maintenance dose of 6mg/kg in day 1 of each cycle
104688|NCT03368131|Drug|Capecitabine|825~1000mg/m2 bid d1-14
104689|NCT03368131|Drug|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
104690|NCT03368131|Radiation|Radiotherapy|45 Gray (unit) Gy/25f （1.8Gy/f/d，5 f/w）
104691|NCT03368118|Drug|ABX464|All subjects will receive ABX464 given at 50 mg o.d for an overall period of 12 months.
104692|NCT03368105|Dietary Supplement|Prevention of C. difficile infections using LP299v strain|"Patients treated with antibiotics and at high CDI risk (patients after organ transplantation or receiving immunosuppressive therapy for any other reason) will be enroll to study.~We will divide participants into two group. Group 1 will receive one capsule of LP299v orally per a day during the entire period of antibiotic therapy. Group 2 will receive one capsule of placebo during the entire period of antibiotic therapy."
104693|NCT03368092|Drug|Dornase Alfa Inhalant Solution [Pulmozyme]|Dornase alfa (Pulmozyme®, Roche 2500U, 2,5mL) given by aerosol in the respiratory circuit (Aerogen solo®) within 6h at day 1 and 24 hours after on day 2.
104694|NCT03368092|Drug|Placebos|NaCl 0,9%, given by aerosol in the respiratory circuit within 6h at day 1 and 24 hours after on day 2.
104695|NCT03368079|Device|Negative Pressure Suction Catheter|The negative pressure suction device to be used in the study will be a Foley catheter. The catheter will be placed through the gastrostomy tube site, directed retrograde through the esophagus, and terminating in the PES.
104696|NCT03368066|Drug|Cosyntropin|Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
104697|NCT03368053|Procedure|Blood sampling|Blood samples will be taken during the single study visit at Year 14 for the assessment of: HIV testing, antibody determination, cell mediated immune (CMI) responses and exploratory characterisation.
104698|NCT03368040|Device|Tcore|Monitoring system to measure body temperature based on heat-flux technology
104699|NCT03368027|Behavioral|A cognitive-behavioral intervention program|In this program, participants receive a training of assertive skills, social skills, acceptance, among other psychological aspects.
104700|NCT03368027|Other|Standard intervention|Participants receive different activities conducted by a psychologist in the association where the attend.
104701|NCT03368014|Behavioral|Lyrics-writing and singing show|"Participants will participate in a Lyrics-Writing and Singing Competition. They will first attend a lyrics-writing workshop and a short talk on SME (Sharing, Mind, Enjoyment) focusing on praising family members and knowledge of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; submit SME (Sharing, Mind, Enjoyment) worksheet, such as Express Your Love to Family Member after the workshops; participate in the SME (Sharing, Mind, Enjoyment) Lyrics-writing and Singing Show and Award Ceremony (sharing) with a live performance by awarded entries and prize presentation ceremony."
104702|NCT03368001|Behavioral|SENSE Theatre|SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).
104703|NCT03368001|Behavioral|Tackling Teenage Together|The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
104704|NCT03367988|Drug|Opioid Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Anesthesia will be induced with rocuronium, propofol, intravenous opioids, and other medication(s)/agent(s) at a concentration range/dose(s) based on the clinical need of the subject.~Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with IV opioids, propofol and/or medication(s)/agent(s), including inhalation anesthetic agents, at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
104705|NCT03367988|Drug|Opioid-free Anesthesia|"Doses/concentration of medications/agents used for the anesthetic management of the subjects enrolled in this trial may be adjusted when necessary to provide optimal subject care. Acetaminophen 1g will be given prior to induction. Anesthesia will be induced with rocuronium 1mg, propofol 3-6 mg/kg, and succinylcholine 1.5 mg/kg Depth of anesthesia will be measured with BIS-monitoring and a standard approaching 50% suppression will be maintained throughout the main duration of surgery. Reversal agent will be administered at a post-tetanic count of 1 or 2.~Anesthesia will be maintained with Sevoflurane, Magnesium, Lidocaine, Ketamine, Decadron, Ondansetron, and Ketorolac at a concentration range/dose(s) based on the clinical need of the subject.~Tracheal extubation will be performed at the end of anesthesia after administration of reversal agent. After extubation, the investigator will determine when the subject is OR discharge ready."
104706|NCT03367975|Other|near infrared spectroscopy|
104707|NCT03367962|Drug|[18F]F-Ara-G|the [18F]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
104708|NCT03367949|Other|Surgical guide designed from Impression inversion with markers|Rather than using optical scan of the cast , We will use impression inversion technique with VPS impression and adding CBCT Markers on the tray
104709|NCT03367936|Behavioral|One-on-one Session|Participants will receive a 45-minute one-on-one behavioral lifestyle program for a healthful lifestyle and weight loss.
104710|NCT03367936|Behavioral|Self-monitoring|Participants will receive an orientation on how to self-monitor using the smartphone and other devises
104711|NCT03367936|Behavioral|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings
104712|NCT03367923|Other|Communication Intervention|Receive email/text
104713|NCT03367923|Other|Counseling|Undergo exercise counseling
104714|NCT03367923|Other|Fitbit tracker|Wear Fitbit tracker
104715|NCT03367923|Other|Quality-of-Life Assessment|Ancillary studies
104716|NCT03367923|Other|Questionnaire Administration|Ancillary studies
104717|NCT03367923|Behavioral|Telephone-Based Intervention|Receive phone call
104718|NCT03367910|Drug|Fecal microbiota transplant|150mL of FMT product RBX2660 delivered via enema
104719|NCT03367884|Procedure|Neck dissection followed by radiotherapy(50Gy) according to risk factors|Neck dissection followed by radiotherapy(50Gy) according to risk factors
104720|NCT03367884|Radiation|Definitive radiotherapy|Definitive radiotherapy (70Gy)
104721|NCT03367871|Drug|Pembrolizumab|IV
104722|NCT03367871|Drug|Paclitaxel|Administered intravenously (IV) on day 1
104723|NCT03367871|Drug|Cisplatin|Administered intravenously (IV) on day 1
104724|NCT03367871|Drug|Carboplatin|Administered intravenously (IV) on day 1
104725|NCT03367871|Drug|Bevacizumab|Administered intravenously (IV) on day 1
104726|NCT03367858|Behavioral|Motivational Interviewing (MI)|
104727|NCT03367858|Behavioral|Brief Adolescent Mindfulness (BAM)|
104728|NCT03367845|Behavioral|Control|Parents receive 8 phone contacts (1 per week) that do not focus on material in the sensitivity and couples communication intervention.
104729|NCT03367845|Behavioral|Sensitivity Intervention|Four home visits take place. Mothers and fathers are video recorded with their infant (separately) for approximate 10-15 minutes at the beginning of each visit. The recorded situations are natural (e.g., playing together, bathing the baby, mealtime, etc.) and the family coach (interventionist) is not actively involved in the parent-child interaction. A different theme is covered across the four intervention sessions: Exploration vs. Attachment Behavior, Speaking for the Child, Sensitivity Chain, and Sharing Emotions. For each parent-infant interaction recording, the family coach reviews the recordings between visits and provides feedback to parents in the following intervention session. The exception to this is that video of parent-child interactions during the lab pre-test is used for material at the first home visit. Each session takes approximately 90 minutes. Visits occur over an 8 week period with phone contacts between each session.
104730|NCT03367845|Behavioral|Couples' Intervention|The psycho-educational inter-parental conflict prevention curriculum is a 4-session program that takes place in the families' homes. Each session lasts approximately 90 minutes and involves discussion and practice of four themes pertinent to improving conflict process, communication, and emotional security in the family: Conflict Overview, Interparental Conflict and Children, Stresses of Parenting, and Emotional Security. The family coach scaffolds and supports the couples' development of constructive conflict behaviors. Visits occur over an 8 week period with phone contacts between each session.
104731|NCT03367845|Behavioral|Sensitivity and Couples' Intervention|This group receives both the Sensitivity and Couples' Intervention in their home. There are 8 home visits (4 for Sensitivity and 4 for Couples Intervention).
104732|NCT03367819|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
104733|NCT03367819|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
104734|NCT03367793|Device|Clinical|Prescription spectacle lenses determined by clinically derived techniques.
104735|NCT03367793|Device|Metric #1|Prescription spectacle lenses determined by metric-derived objective technique #1.
104736|NCT03367793|Device|Metric #2|Prescription spectacle lenses determined by metric-derived objective technique #2.
104737|NCT03367780|Device|PSMA PET/CT-scan|PSMA PET is a new diagnostic instrument which can visualize the presence of vital acinar cells in salivary gland locations throughout the head and neck, with a sensitive and quantitative signal.
104738|NCT03367754|Other|Placebo|Placebo
104739|NCT03367754|Drug|Pembrolizumab|Pembrolizumab, 200 mg, or placebo via intravenous (IV) infusion, single dose.
104740|NCT03367741|Drug|Cabozantinib|Giving PO
104741|NCT03367741|Drug|Cabozantinib S-malate|Given PO
104742|NCT03367741|Other|Laboratory Biomarker Analysis|Correlative studies
104743|NCT03367741|Biological|Nivolumab|Given IV
104744|NCT03367728|Drug|Ropivacaine|TAP and Rectus Sheath Block Injections of Ropivacaine
104745|NCT03367728|Drug|Normal saline|TAP and Rectus Sheath Block Injections of Normal Saline
104746|NCT03367715|Drug|Nivolumab|study treatment on Day 1 with one dose of nivolumab 3 mg/kg
104747|NCT03367715|Drug|Ipilimumab|study treatment on Day 1 with one dose of ipilimumab 1mg/kg
104748|NCT03367715|Radiation|Radiation Therapy (RT)|total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
104749|NCT03367702|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
104750|NCT03367702|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
104751|NCT03367689|Drug|Olaparib|Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
104752|NCT03367676|Drug|Trastuzumab|Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days for 4 cycles.
104753|NCT03367676|Drug|Docetaxel|Docetaxel 100mg/m2，d1，iv，q3w*4
104754|NCT03367663|Drug|Prednisone 20 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
104755|NCT03367663|Drug|Prednisone 40 Mg|Each participant will be randomly assigned to one of two treatment groups, low dose of Prednisone 20mg/d (n=10) and high dose of Prednisone 40 mg/d (n=10). During the experimental periods, the subjects will take either one or two 20mg tablet of Prednisone, according to their assigned group. Subjects will be instructed to take the tablets at home in the mornings after a meal each day for 5 consecutive days. At the baseline visit, a medical history will be documented and a physical examination will be performed. Subjects will be asked to come to the research unit on days 1,2,5 after a 14h fasting where two blood samples (5ml each) will be taken, immediately centrifuged, one for biochemical analysis (Lipid profile, Liver function tests, Glucose, Electrolytes and Renal function tests) and the second will be aliquoted, and stored at -20°C until later analyses.
104756|NCT03367650|Dietary Supplement|Blood sample and environmental survey|The intervention corresponds to a 10 ml of Blood sample and an environmental survey.
104757|NCT03367637|Other|Standard palliative care|Standard care includes regular follow-up phone calls and home visits by the RPCHO staff for all advanced cancer patients at RPCHO, though the timing of these calls is variable and is selected by the discretion of the team. In addition, patients can contact providers on a landline number available during business hours and staffed by an on-call palliative care provider as and when needed. For after-hours emergency assistance, patients have the option of contacting the on-call palliative-care physicians for assistance.
104758|NCT03367637|Other|Smart Phone based symptom evaluation application|In addition to the standard palliative care currently provided at the RPCHO, patients will receive biweekly reminders to fill out the African Palliative Care Outcomes Scale (APCA POS) on the new smartphone application on their phones. It is a short symptom assessment questionnaire with responses on 5-point severity scale. In addition to bi-weekly frequency, patients can complete the symptom assessment at any time they feel their symptoms are poorly controlled. The team at RPCHO will be able to track all enrolled patients on a desktop dashboard. Any score of 2 or higher will be flagged. The providers at RPCHO will respond to such patients during business hours via call or text and will advise the patients as indicated or triage to a fellow team member.
104759|NCT03367611|Diagnostic Test|Immunochemical faecal occult blood test (iFOBT)|All participants in the study will collect a single faecal sample for haemoglobin measurement.
104760|NCT03367598|Genetic|rs662799 (APOA5 -1131T>C)|Among the 349 normal-weight individuals, 168 were homozygous (TT) for the T allele, 155 were heterozygous for the C allele (TC) and 26 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism. Among the 154 overweight individuals, 68 were homozygous (TT) for the T allele, 75 were heterozygous for the C allele (TC) and 11 were homozygous (CC) for the C allele of the APOA5 -1131T>C polymorphism.
104761|NCT03367585|Dietary Supplement|Physical exercise + Vitamin D3|Strength exercise + Supplementation of vitamin D3 50,000 IU / week
104762|NCT03367585|Other|Physical exercise|Strength exercise
104763|NCT03367572|Drug|Dexamethasone|Given PO
104764|NCT03367572|Other|Laboratory Biomarker Analysis|Correlative studies
104765|NCT03367572|Drug|Netupitant/Palonosetron Hydrochloride|Given PO
104766|NCT03367572|Drug|Olanzapine|Given PO
104767|NCT03367572|Other|Placebo|Given PO
104768|NCT03367572|Drug|Prochlorperazine|Given PO
104769|NCT03367572|Other|Quality-of-Life Assessment|Ancillary studies
104770|NCT03367559|Biological|ROTAVAC®|Rotavac® is in frozen form and is thawed till fully liquid prior to administration.
104771|NCT03367546|Procedure|Blood and Marrow Transplant|Reduced intensity conditioning (RIC) with rabbit ATG, fludarabine, cyclophosphamide, thiotepa and low dose (2 Gy) total body irradiation followed by T-cell replete, unmanipulated, haploidentical related donor stem cell transplant (HaploHCT) and post-transplant cyclophosphamide (PTCy)
104772|NCT03367533|Drug|Ketamine|Intravenous ketamine
104773|NCT03367533|Drug|Perampanel|Oral perampanel (6 mg)
104774|NCT03367533|Drug|Placebo|Oral placebo
104775|NCT03367520|Behavioral|StayQuit|StayQuit offers 3 meetings during hospitalization and up 13 telephone calls. StayQuit begins in the hospital with an assessment of motivation to remain quit after discharge and a brief intervention to develop discrepancy between values and behaviors and generate change talk. Participants are also encouraged to try nicotine replacement therapy during the hospitalization and after discharge. Telephone counseling is brief and focused on managing withdrawal from nicotine, coping with cravings, and supporting use of NRT. The investigators will work with hospital staff as needed to ensure that nicotine replacement therapy is offered to participants during the inpatient stay and prescribed at discharge.
104810|NCT03367234|Behavioral|Contingency Management|Rewards for engagement in specified recovery behaviors
104811|NCT03367221|Device|NAVA ventilation|Assisted Ventilation Mode, synchronized, through EAdi catheter, with patient's inspiratory effort and proportional to respiratory drive
104812|NCT03367195|Drug|Omeprazole|1 Omeprazole 20 mg capsules twice daily
104813|NCT03367195|Drug|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
104776|NCT03367507|Behavioral|Sub-symptom aerobic exercise|Both groups will be instructed to perform their respective aerobic exercise program the following day after completing their first treadmill test. Participants will be instructed to exercise at their prescribed intensity for a maximum of 30 minutes a day, 4-5 days a week. They will be asked to postpone the exercise until the next day if they experience significant increases in symptoms from usual resting levels. Exercise type will be the participant's choice, however we will ask the participant refrain from contact/high risk activities including any modalities that might induce rapid and aggressive head movements.
104777|NCT03367494|Diagnostic Test|Measurement of Sweat Chloride and Sweat Bromide|Sweat Chloride comparisons between ion exchange chromatography and fluorescence citrate-based sensors
104778|NCT03367481|Device|Toothbrush type|In this cross-over study, the participants will use either a soft brush (control) and the medium brush (test).
104779|NCT03367468|Other|Exercise|Strengthening exercises ( extrinsic and intrinsic foot muscles) Stretcthing exercises (plantar fascia, plantar flexor muscles)
104780|NCT03367468|Other|Mobilization|Antero-posterior gliding, talocrural traction, metatarsal mobilization
104781|NCT03367442|Other|no intervention|no intervention
104782|NCT03367429|Drug|Botox|Please see arm descriptions for intervention description.
104783|NCT03367416|Behavioral|NIATx model|"The NIATx model engages organizations through a multi-clinic learning collaborative and coaching. NIATx teaches organizations how to implement change by using their own organization as the teaching mechanism. Key components of the model include:~educating executives on how to promote effective process change techniques~training staff teams in the theory and practice of organizational change techniques~training staff to develop and implement a process improvement intervention~implementing a sustainability plan to institutionalize change and avoid reverting to previous methods"
104784|NCT03367403|Drug|LY3002813|Administered IV
104785|NCT03367403|Drug|Placebo|Administered IV
104786|NCT03367390|Device|AID System|AID system
104787|NCT03367390|Drug|Insulin Lispro|Individualized doses of insulin lispro administered via the AID system to maintain glycemic control, except during procedures designed to induce hyperglycemia and hypoglycemia.
104788|NCT03367377|Drug|LY3209590|Administered SC
104789|NCT03367377|Drug|Insulin Glargine|Administered SC
104790|NCT03367364|Behavioral|Patient education bundle (PEB),|A charge nurse will intervene in real-time via an EHR-triggered alert when there is documentation that a dose of VTE prophylaxis medication is not given for any reason. The charge nurse will speak to the bedside nurse and one of them will provide the patient with the education bundle including one-on-one personalized discussion, supplemented by a 2-page paper handout and patient education video.
104791|NCT03367364|Behavioral|Nurse feedback and coaching (NFC)|Nurse leadership (i.e. managers, directors) will provide data to all nurses on their personal clinical effectiveness with the proportion of doses of VTE prophylaxis administered. The data will have comparisons to their nurse peers on the same floor. Coaching for nurses will include one-on-one conversations with bedside nurses with lower performance than their peers.
104792|NCT03367351|Behavioral|Web-Based Education|Completion of a CGM specific web-based educational intervention that includes a series of online learning modules.
104793|NCT03367351|Behavioral|Social Support|Engagement in peer-led CGM specific discussion boards
104794|NCT03367351|Behavioral|Standard of Care|Standard of Care - serves as the control group for the treatment arm
104795|NCT03367338|Other|Low-phosphate diet|Very low-phosphate diet, PPR value of 8 mg/g, vs. low-phosphate diet, PPR value of 10 mg/g
104796|NCT03367325|Device|CDS-NVAF|The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is < 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in > 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
104797|NCT03367312|Drug|Hyperpolarized 129Xenon gas|Hyperpolarized 129Xenon gas XeMRI scans will provide 3D images of ventilation and gas exchange pre, post, and 2-4 hours post inhaled prostacyclin treatment. Subjects will inhale HP 129Xe from the dose delivery bags with each scan and then move into the scanner and undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will undergo several MRI scans after inhalation of HPXe. This will occur as three scans at the three different time points (pre, post, and 2-4 hours post) of inhaled prostacyclin treatment.
104798|NCT03367299|Drug|Chemotherapy + Blinatumomab|Chemotherapy cycles are administered at 21-28 days intervals and each blinatumomab course is 28-day long.
104799|NCT03367286|Other|inspection mode|different inspection modes：Computed Tomography Perfusion (CTP) or Magnetic Resonance Perfusion (MRP)
104800|NCT03367273|Other|skin biopsy|Lesional skin biopsy was taken from every patient. Also a skin biopsy was taken from every control subject
104801|NCT03367260|Other|Preference Elicitation|Survey of patient preferences for treatment
104804|NCT03367234|Behavioral|Individual Therapy Sessions|One-on-one sessions with a counselor
104805|NCT03367234|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive Behavioral Therapy techniques delivered by a behavioral health consultant (BHC)
104806|NCT03367234|Behavioral|Medication-Assisted Treatment|Buprenorphine or Extended-Release Naltrexone
104807|NCT03367234|Behavioral|Peer Recovery Specialist Support|Individual and/or group sessions with a certified peer recovery specialist
104808|NCT03367234|Behavioral|Group Therapy Sessions|Group therapy sessions
104809|NCT03367234|Behavioral|Psychiatric Consultation|Access to psychiatric consultation
104814|NCT03367195|Drug|Placebo capsule of Omeprazole|1 placebo capsule of omeprazole, twice daily
104815|NCT03367195|Drug|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
104816|NCT03367182|Drug|Weekly paclitaxel|Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
104817|NCT03367182|Drug|Topotecan|Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
104818|NCT03367182|Drug|Pegylated liposomal doxorubicin|Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks
104819|NCT03367182|Drug|Bevacizumab|Drug: bevacizumab [Avastin] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
104820|NCT03367169|Procedure|minimally invasive method|type of surgical technique
104821|NCT03367169|Procedure|open reduction method|type of surgical technique
104822|NCT03367156|Drug|Dexamethasone|Given PO
104823|NCT03367156|Other|Placebo|Given PO
104824|NCT03367156|Other|Questionnaire Administration|Ancillary studies
104825|NCT03367143|Drug|Lenalidomide|
104826|NCT03367143|Drug|Ifosfamide|
104827|NCT03367143|Drug|Carboplatin|
104828|NCT03367143|Drug|Etoposide|
104829|NCT03367130|Behavioral|Mobile phone reminder|Intervention described already in arm/group descriptions.
104830|NCT03367104|Device|ECG Belt|Assess electrical dyssynchrony with an anterior-posterior body surface mapping system.
104831|NCT03367091|Other|Ekso GT gait training with high swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance"
104832|NCT03367091|Other|Ekso GT gait training with neutral swing assistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral"
104833|NCT03367091|Other|Ekso GT gait training with high swing resistance|"Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance"
104834|NCT03367078|Device|Anodal tDCS|Anodal tDCS, on L-DLPFC area, is started 2 weeks after admission to the sABI Operative Unit with: one session per day (in the morning), possibly for 5 consecutive days per week (from Monday to Friday), for 2 consecutive weeks. Each tDCS session lasts 20 minutes. Current intensity is 1 mA during the first week, 2 mA in the second week
104835|NCT03367078|Other|Usual care|Usual care of DOC patients
104836|NCT03367065|Radiation|Dynamic contrast enhanced computerised tomography|
104837|NCT03367052|Procedure|Two level Prodisc-C vivo|Two level of Prodisc-C vivo artificial disc replacement will be done in one group of patients.
104838|NCT03367052|Procedure|Hybrid|The hybrid method will be used in one group of patients.
104839|NCT03367039|Procedure|ProDisc-C vivo|Total Disc Replacement using ProDisc-C vivo.
104840|NCT03367039|Procedure|Anterior cervical discectomy fusion|Anterior Cervical Discectomy and Fusion
104841|NCT03367026|Drug|Ivabradine Oral Product|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm"
104842|NCT03367013|Dietary Supplement|Bovine Lactoferrin|Intervention includes a daily dose of 200 mg/kg bovine lactoferrin in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
104843|NCT03367013|Other|No Bovine Lactoferrin added|Control includes daily study feed with no bovine lactoferrin added in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier.
104844|NCT03367000|Dietary Supplement|Ceprolac|The supplement was packed into two ~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.
104845|NCT03367000|Other|Dietary counseling (DC)|Received standard dietary counseling at baseline and month 6.
104846|NCT03366974|Drug|Midazolam|5 mg PO, 1 mg IV
104847|NCT03366974|Drug|Clarithromycin|500 mg bid
104848|NCT03366974|Dietary Supplement|Grapefruit juice|500 mL
104849|NCT03366961|Procedure|Conversion surgery|Palliative chemotherapy followed by radical gastrectomy
104850|NCT03366948|Other|IGDT-10 self-administered questionnaire|"Patients and their parents will answer the French version of the IGDT-10 self-administered questionnaire (IGDT-10-P in the parents 'questionnaire).~The IGDT-10 is a self-administered questionnaire based on DSM-5 internet gaming disorder criteria and the IGDT-10-P is a parental version specially adapted from the IGDT-10 for this study."
104851|NCT03366935|Other|EPL and CEI|"Procedure: Standard epidural placement(EPL)~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
104852|NCT03366935|Other|DPE and CEI|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to continuous epidural infusion(CEI) plus patient-controlled epidural analgesia (PCEA)."
104853|NCT03366935|Other|DPE and PIEB|"Procedure: Dural puncture epidural (DPE) Epidural with spinal needle placed to create a single dural puncture and confirm free flow of cerebral spinal fluid (CSF) , without direct medication administration into the subarachnoid space.~Drug: ropivacaine Drug: sufentani 0.1% ropivacaine + sufentanil 0.3μg/mL~Device: Infusion pump Infusion pump set to programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA)."
104854|NCT03366922|Dietary Supplement|Artemisia Annua, Moringa oleifera|As described above
104855|NCT03366909|Behavioral|Mindfulness based relapse prevention (MBRP)|"These weekly visits include a Mindfulness Meditation session:~The sessions of meditation take place in a dedicated room. The collective sessions owed approximately of 2 hours and will approach the following themes: (1) Autopilot, (2) Facing obstacles, (3) Full awareness of breath, (4) Staying present, (5) Allow, let go (6) Thoughts are not facts, (7) How to take care of oneself, (8) Mindfulness on a daily basis."
105088|NCT03365219|Other|Standard Surgical Retractors|Routine hand-held metal retractors as needed by the surgical team
104856|NCT03366909|Behavioral|classic therapy|These weekly visits include usual addiction care provided during a consultation. This care includes psychotherapeutic management: brief interventions, cognitive-behavioral therapies, motivational interviews; associated with nonsystematic pharmacological management.
104857|NCT03366896|Diagnostic Test|Malay 3D-CAM diagnostic tool 1|Assessor 1 uses Malay 3D-CAM to detect Delirium
104858|NCT03366896|Diagnostic Test|Malay 3D-CAM Diagnostic tool 2|Assessor 2 uses Malay 3D-CAM to detect Delirium
104859|NCT03366883|Combination Product|Paclitaxel, Cisplatin Plus 5-FU (TCF)|preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)
104860|NCT03366883|Radiation|radiochemotherapy|preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
104861|NCT03366870|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
104862|NCT03366870|Behavioral|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform.
104863|NCT03366857|Drug|Oxygen 30 %|The oxygen concentration will be set at 30%.
104864|NCT03366857|Drug|Oxygen 80 %|The oxygen concentration will be set at 80%.
104865|NCT03366844|Drug|Pembrolizumab|checkpoint inhibitor
104866|NCT03366844|Radiation|RT Boost|The second dose of pembrolizumab will be given in conjunction with an RT boost, consisting of 8 Gy for 3 fractions.
104867|NCT03366831|Behavioral|Thirty Million Words Initiative Newborn Intervention|The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
104868|NCT03366818|Device|thrombectomy|mechanical thrombectomy
104869|NCT03366805|Behavioral|Pain Management Patient Education Video|Patient education video that were created in-house specifically for this project.
104870|NCT03366805|Behavioral|Wound Care Patient Education Video|Patient education video that were created in-house specifically for this project.
104871|NCT03366792|Device|Artemis™ software system|Computerized targeting of mpMRI lesions. The computerized co-registration will then be performed by software within the Artemis™ system and will fuse the MR imaging with real-time ultrasound imaging.
104872|NCT03366779|Device|6mm annular closure device|6MM Barricaid annular closure device implantation following standard lumbar discectomy
104873|NCT03366766|Biological|Nivolumab|Given IV
104874|NCT03366766|Drug|Cisplatin|Given IV
104875|NCT03366766|Drug|Pemetrexed Disodium|Given IV
104876|NCT03366766|Drug|Gemcitabine Hydrochloride|Given IV
104877|NCT03366753|Procedure|acute normovolemic hemodilution|acute normovolemic hemodilution (ANH) is performed by using 5 ml/kg of blood salvage and intravenously administering 5 ml/kg of balanced hydroxyethystarch 130/0.42 (Tetraspan™) for 15 min
104878|NCT03366753|Procedure|In-vitro hemodilution|Blood sample after ANH 5 ml/kg undergoes further 30% in-vitro dilution by adding 1-1.5 ml hydroxyethystarch 130/0.42
104879|NCT03366740|Other|GB mixed full strength rice suji|On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn`t resolve, the child will be enrolled in the study and after randomization will get the Green banana mixed full strength rice suji The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure.
104880|NCT03366740|Other|Full strength rice suji Alone|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn`t resolve, the child will be enrolled in the study and after randomization will get full strength rice suji alone.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
104881|NCT03366740|Other|3/4th strength rice suji|"On day 4 (3 days after milk suji) after diagnosis of PD, if PD doesn`t resolve, the child will be enrolled in the study and after randomization will get 3/4th strength rice suji.~The diet will be continued for 7 days and a child will be followed. If there is deterioration of diarrhea (either increased frequency or watery consistency) for 3 days or condition remains static up to 7 days the child will be declared as treatment failure."
104882|NCT03366727|Device|drug-coated balloon catheter （Orchid, Acotec）|After predilation, using drug-coated balloon catheter to cover the whole treated segment
104883|NCT03366727|Device|plain balloon catheter (Admiral, medtronic)|After predilation, using plain balloon catheter to cover the whole treated segment
104884|NCT03366714|Device|nasal CPAP support with RAM cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support RAM cannula.
104885|NCT03366714|Device|nasal CPAP support with Hudson cannula|Patients with respiratory distress syndrome who do not need intubation in the delivery room. This groub will be provided with non-invasive respiratory support Hudson cannula.
104886|NCT03366701|Other|Rehabilitation|The intervention (routine care) correspond to five weeks rehabilitation program
104887|NCT03366688|Drug|IBI306|Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
104888|NCT03366688|Drug|placebo|Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
104889|NCT03366675|Drug|AZD2811|AZD2811 100mg/vial
104890|NCT03366662|Device|Monitoring of frontal electrical muscle activity|Continuous monitoring of frontal electrical muscle activity during general anesthesia simultaneous to burst suppression electroencephalogram
104923|NCT03366415|Drug|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.
105281|NCT03363711|Other|AYA STEPS|a mobile health application
104891|NCT03366649|Procedure|Undersizing Mitral Annuloplasty|Participants will receive a commercially available annuloplasty ring. 10-12 ethicon sutures are placed around the mitral annulus, and the metallic ring is then implanted onto the mitral annulus to reduce it in size. To ensure uniformity between patients, an Edwards Lifesciences Physio II ring will be used in all patients, with a ring size ranging between 26mm-30mm.
104892|NCT03366649|Procedure|Papillary Muscle Approximation|One or two 4-0 pledgeted sutures are used to draw the two papillary muscle tips together to reduce the inter papillary muscle separation (IPMS) before undergoing undersizing mitral annuloplasty.
104893|NCT03366636|Behavioral|Project Legacy|"Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~1. Thinking about the future~2. Present actions to achieve future success~3. Safeguarding one's future~4. Creating a Healthy Life Plan~5. Navigating service systems"
104894|NCT03366623|Behavioral|Hospital clown|Presence of the hospital clown
104895|NCT03366623|Behavioral|No hospital clown intervention|Presence of pediatric nurses and biomedical laboratory technologists in the venipuncture procedure.
104896|NCT03366610|Other|Non-interventional|Non-interventional
104897|NCT03366597|Drug|Sevoflurane|1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
104898|NCT03366584|Dietary Supplement|Beta carotene|Beta carotene 25,000 IU
104899|NCT03366584|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU
104900|NCT03366584|Dietary Supplement|Zinc|Zinc 50 mg
104901|NCT03366584|Drug|Dexamethasone|Dexamethasone 6 mg
104902|NCT03366571|Drug|Nucleos(t)ide Analogues|Entecavir 0.5mg daily for no less than 5 years ;Lamivudine:100mg qd daily for no less than 5 years; Adefovir Dipivoxil:10mg daily for no less than 5; years;telbivudine:600mg qd daily for no less than 5 years; or their combination therapy for no less than 5 years
104903|NCT03366558|Diagnostic Test|UPDRS questionnaires|UPDRS (Unified Parkinson's Disease Rating Scale) questionnaires are utilized for the assessment of the disease stage.
104904|NCT03366558|Diagnostic Test|20-step walking test|20-step walking test is utilized either for assessing the disease stage (subjects having Parkinson disease) or for assessing the normal walking (subjects not having Parkinson disease)
104905|NCT03366545|Device|Cardiac Resynchronization Therapy (CRT)|Observation and documentation of routine care for CRT patients
104906|NCT03366532|Other|Dietary assessments|We use food frequency questionnaires to collect and update intake of foods and nutrients in observational studies. No intervention is involved.
104907|NCT03366519|Procedure|clinical echography (CE)|clinical echography (CE) is performed in the first 24 hours following the diagnosis of PE, in emergency unit
104908|NCT03366506|Other|Observation|
104909|NCT03366493|Combination Product|FRD|The Folate Receptor-Mediated Staining Solution is a dye solution that stains for medical purposes used in staining cells and tissues for detecting neoplastic diseases. After inserting a speculum into your vagina, the FRD™ staining solution will be applied to the cervix using an applicator. After removal of the applicator, the doctor will inspect the applicator for color changes and note any changes. The physician will then remove any excess stain from the cervix using distilled water.
104910|NCT03366493|Other|Cytology|Cytology testing done by collecting samples of cells, and smearing those samples across a glass microscope slide in order to detect abnormal cells that may develop into cervical cancer.
104911|NCT03366493|Other|HPV testing|HPV tests will detect HPV infections, which can lead to cervical cells to become cancer cells.
104912|NCT03366493|Procedure|Colposcopy|During the colposcopic examination, the physician will insert a speculum into the vagina and then apply a vinegar solution to the cervix. The vinegar solution causes any potential abnormal cells to turn white. These white regions are best seen using the colposcope, which magnifiesthe skin.
104913|NCT03366493|Procedure|ECC|If the examination is not satisfactory and the doctor is not able to see the entire cervix, he may perform an endocervical curettage, or ECC. This sample is collected by placing a long, thin instrument into the cervical canal and a sample is scraped from that area. The sample will be sent to the laboratory for a pathologist to review.
104914|NCT03366493|Procedure|Biospy|"According to the colposcopy assessment, if the doctor sees a white area, or an area of abnormal cells, a tiny sample of tissue, called a biopsy will be taken from the cervix. About half of women do not feel the biopsy being taken.~Others may feel a quick pinch. After the biopsy, the wound will be treated to stop bleeding.The biopsy will be sent to the laboratory for a pathologist to review."
104915|NCT03366480|Drug|ABTL0812 in combination with paclitaxel and carboplatin|ABTL0812 in combination with paclitaxel and carboplatin.
104916|NCT03366467|Other|SADE|The SADE: the sensory stimuli addressed are visual and auditory, as follows: (i) Visual sensation. All ceiling fluorescent lighting are removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, in the child's visual field. (ii) Auditory stimuli include rhythmic music, which was heard via loudspeakers.
104917|NCT03366467|Other|RDE|The RDE utilized fluorescent lighting on the ceiling, without special visual effects and without music stimulation.
104918|NCT03366441|Other|Telephone call|From 20 October to 10 November 2016, telephone calls were given to the donors in the phone call group
104919|NCT03366441|Other|SMS|Text messages were sent to an equal number of donors in the SMS group
104920|NCT03366428|Drug|DS-8201a|DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
104921|NCT03366415|Drug|gemcitabine and cisplatin (Induction and adjuvant chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.
104922|NCT03366415|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor
105003|NCT03365843|Other|Conventional Sternal Closure|Closure of sternum with standard wire cerclage.
104924|NCT03366415|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4Gy to the primary tumor, concurrently with cisplatin 30mg/m² every week.
104925|NCT03366402|Diagnostic Test|RT-PCR H1N1|At the first stage an upper respiratory swab was taken to determine the presence of Infuenza A H1N1 (the virus identification was done by RT - PCR). Then the different subtypes of lymphocytes were quantified at different stages of the disease. The identification and quantification of the different cell types were performed by FACS method, the cell receptors that were marked were CD31, CD19, CD4, CD3, CD45, CD8, CD56.
104926|NCT03366376|Radiation|WBRT with hippocampus-sparing and SIB|"Radiotherapy could be delivered in 5, 8, or 10 fractions according to participating investigator's choice. The prescribed doses are as below;~Fractions 5fxs 8fxs 10fxs Whole brain 20 Gy 24 Gy 25 Gy Gross tumor 30 Gy 40 Gy 40 Gy"
104927|NCT03366363|Other|acupuncture|acupuncture is a therapy of traditional Chinese medicine，in which acupuncturist puncture the patient's skin at specific acupoints with needle.
104928|NCT03366350|Procedure|Allogeneic hematological stem cell transplantation|Patients receive allogeneic hematological stem cell transplantation after they achieve MRD- CR through CAR-T therapy.
104929|NCT03366337|Drug|Bardoxolone methyl capsules|Bardoxolone 5 mg capsules
104930|NCT03366324|Genetic|Second generation CAR-T cells|Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.
104931|NCT03366324|Procedure|Hematological stem cell transplantation|Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
104932|NCT03366311|Procedure|holding position|two types of holding positions plus two types of shapes of stylet, with or without epiglottis lift
104933|NCT03366298|Combination Product|Epipen 0.3mg|Epipen 0.3mg auto-injector
104934|NCT03366298|Combination Product|Emerade 300mcg|Emerade 300mcg auto-injector
104935|NCT03366298|Combination Product|Emerade 500mcg|Emerade 500mcg auto-injector
104936|NCT03366285|Diagnostic Test|Attachment story completion taks (ASCT)|Bonding quality
104937|NCT03366272|Drug|Nivolumab|eight cycles of nivolumab (3 mg/kg) plus (R)-GemOx in 2-wk intervals followed by additional 18 infusions of Nivolumab (3 mg/kg) in 2-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first
104938|NCT03366272|Drug|Rituximab|eight cycles of R-GemOx in 2-wk intervals
104939|NCT03366272|Drug|Gemcitabine|eight cycles of (R)-GemOx in 2-wk intervals
104940|NCT03366272|Device|Oxaliplatin|eight cycles of (R)-GemOx in 2-wk intervals
104941|NCT03366259|Drug|Misoprostol 200Mcg Tab|administration of 200 Mcg of misoprotol rectal
104942|NCT03366259|Procedure|elective cesarean section|elective cesarean section for full term patients
104943|NCT03366246|Drug|Lidocaine / Prilocaine Cream|according randomized this side received placebo or active product
104944|NCT03366246|Drug|placebo|according randomized this side received placebo or active product
104945|NCT03366233|Other|Mental fatigue|A modified Stroop task of 90 min, partitioned in 8 blocks of 252 stimuli, will be used as mentally fatiguing task. The Stroop task requires inhibition and sustained attention on controlled processes.
104946|NCT03366233|Other|Control|In the control task subjects will have to watch a documentary on the same computer screen as that used for the experimental trial. These documentaries are chosen based on their emotionally neutral, yet engaging content.
104947|NCT03366220|Drug|Plasma|Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
104948|NCT03366220|Drug|Balanced crystalloids|Usual care using balanced crystalloids (Iso-Lyte or Plasma-Lyte) only will follow Surviving Sepsis Campaign guidelines. Controls will receive 30 mL/kg (2100 mL in a typical 70 kg adult) of crystalloids within the first 3 hours. Subsequent resuscitation with balanced crystalloids will be titrated to the endpoints of resuscitation.
104949|NCT03366207|Drug|Ciprofloxacin|Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
104950|NCT03366181|Device|internal cardioverter defibrillator implant (ICD)|to implant ICD in failing heart subjects with reduced left ventricle ejection fraction (LVEF < 35%).
104951|NCT03366181|Procedure|percutaneous catheter ablation|to perform catheter ablation in patients with heart failure and reduced left ventricle ejection fraction (LVEF < 35%).
104952|NCT03366155|Device|OneRNA|genomic test done on tumor and normal liver biopsy samples taken during baseline and end of treatment
104953|NCT03366155|Drug|FUDR-Dex|HAIP will be filled with mixture of Floxuridine and Dexamethasone. Pump will perfuse drugs to liver for 14 days. Floxuridine (0.12 mg/kg X pump volume X pump flow rate), Dexamethasone (1 mg/day X pump volume (30) X pump flow rate)
104954|NCT03366155|Drug|Oxaliplatin|85 mg/m2, IV
104955|NCT03366155|Drug|5FU|2000 mg/m2, IV 46-hour infusion of 5-Flouroucail + 400mg/m2, IV of Leucovorin
104956|NCT03366155|Drug|Irinotecan|150 mg/m2, IV
104957|NCT03366155|Procedure|HAIP installation|HAIP pump installation
104958|NCT03366155|Drug|cetuximab|500mg/m2,IV
104959|NCT03366155|Device|Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter|implanted Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter
104960|NCT03366142|Drug|Ustekinumab|0.75 mg/kg or 45 or 90 mg via subcutaneous injection for 5 doses (second dose 4 weeks after first, subsequent doses every 12 weeks thereafter).
105004|NCT03365830|Diagnostic Test|FertQol, Beck's Depression Inventory, Beck's Anxiety Inventory|These 3 scale will be given to patients to fill up who takes infertility treatments
105005|NCT03365817|Drug|Opioids taper off|Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
105006|NCT03365817|Drug|Opioid stable treatment|No changes on prescribed opioids and adjuvant medication for the next six months
105007|NCT03365804|Device|3D Printed Brace|All subjects' body shape will be scanned to generate sterolithography (STL) files for 3D printing.
104961|NCT03366116|Drug|aza-TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 5-aza-4'-thio-2'- deoxycytidine (aza-TdCyd) is incorporated into DNA, where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to hypermethylation and silencing of tumor suppressor genes. Aza-TdCyd offers an improvement over traditional DNMT inhibitors via higher incorporation into DNA and lower cytotoxicity; aza-TdCyd has greater antitumor activity than another recently developed DNMT1 inhibitor, TdCyd, in some solid tumor xenograft models. Treatment with aza-TdCyd is anticipated to yield inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
104962|NCT03366103|Biological|Navitoclax|Given PO
104963|NCT03366103|Drug|Vistusertib|Given PO
104964|NCT03366090|Procedure|Biopsies during coloscopy|During standard ileocolonoscopy intestinal biopsy specimens of the macroscopically most inflamed ileal and colonic mucosa will be obtained at the moment of presentation and during follow up.
104965|NCT03366077|Dietary Supplement|Probiotic|Probiotic
104966|NCT03366064|Biological|Pemetrexed and donor-derived NK cell infusion|Patients are administered with donor-derived NK cells one week after pemetrexed infusion
104967|NCT03366051|Procedure|Sentinel Node Mapping|At least one sentinel node should be retrieved in both hemipelvis. If no sentinel node is found in one hemipelvis, a side specific lymphadenectomy will be performed.
104968|NCT03366051|Procedure|Lymphadenectomy|Systematic Pelvic and Para-Aortic Lymphadenectomy
104969|NCT03366038|Procedure|Shark Mouth Modified Pancreaticojejunostomy|"The remnant of jejunum is closed by continuous suture. The transverse incision is made on the posterior wall of the jejunum (5 centimeters distal to remnant）, which starts at 0.2 centimeter to the mesenteric border and should never exceed the anti-mesenteric border . In case of large pancreas remnant, a longitudinal jejunum incision will be done at anterior part of anastomosis.~The posterior part of anastomosis is two layers of intermittent suture, including seromuscular suture layer and full thickness suture layer. The anterior part of anastomosis is a single layer full thickness suture. At last, the seromuscular layer of the proximal jejunum is sutured with the anterior pancreatic capsule to cover the anterior part of anastomosis."
104970|NCT03366025|Diagnostic Test|Serum progesterone measure|Serum Progesterone will be measured in all donors on the day triggering at 8:00 am, 12:00 p, 16:00 pm and 20:00 pm
104971|NCT03366012|Device|Cytosponge|The Cytosponge consists of a 3cm diameter, polyester, medical grade spherical sponge on a string, compressed within a gelatin capsule. The capsule is swallowed while the patient or the research specialist holds onto the string. After 3-5 minutes the gelatin capsule dissolves allowing the spherical sponge to expand. The sponge is then retrieved by gently pulling on the string, thus collecting cells along the passageway through the entire length of the esophagus. The sample is then put into a preservative to be processed for immunohistochemical testing for trefoil factor 3 (TFF3) to determine diagnosis of Barrett's esophagus.
104972|NCT03365999|Drug|Oral Tranexamic Acid|Patients undergoing total knee replacement who will receive three doses of tranexamic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
104973|NCT03365999|Drug|Oral Aminocaproic Acid|Patients undergoing total knee replacement who will receive three doses of aminocaproic acid administered orally (1 prior to surgery and 2 subsequent to surgery).
104974|NCT03365986|Diagnostic Test|genetic screening|Patients receive genetic test to see whether they have germline cancer susceptibility gene mutations
104975|NCT03365960|Dietary Supplement|Watermelon Rind|watermelon rind
104976|NCT03365960|Dietary Supplement|Watermelon Flesh|watermelon flesh
104977|NCT03365960|Dietary Supplement|Watermelon Seeds|watermelon seeds
104978|NCT03365960|Dietary Supplement|Placebo|Control Comparator
104979|NCT03365947|Drug|ARO-HBV Injection|Single or multiple doses of ARO-HBV Injection by subcutaneous (sc) injection
104980|NCT03365947|Other|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
104981|NCT03365934|Device|ADHESIVE BANDAGE #1|Bandage applied daily to wounded site for 14 days
104982|NCT03365934|Device|ADHESIVE BANDAGE #2|Bandage applied daily to wounded site for 14 days
104983|NCT03365934|Device|ADHESIVE BANDAGE #3|Bandage applied daily to wounded site for 14 days
104984|NCT03365934|Device|Antibacterial Bandage with 0.8% BZK|bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days
104985|NCT03365934|Other|Intact and No Bandage|This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.
104986|NCT03365934|Other|Wounded and No Bandage|This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
104987|NCT03365921|Biological|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
104988|NCT03365908|Procedure|Adductor Canal Nerve Block|An adductor canal nerve block with 15 mL of 0.5% ropivacaine will be performed pre-operatively by Anesthesiology.
104989|NCT03365908|Drug|Ropivacaine injection|15 mL of 0.5% ropivacaine will be administered for the adductor canal block
104990|NCT03365895|Procedure|Diffusion Tensor Imaging|Undergo non-enhanced MRI using MRN and DTI
104991|NCT03365895|Other|Laboratory Biomarker Analysis|Correlative studies
104992|NCT03365895|Procedure|Magnetic Resonance Imaging|Undergo non-enhanced MRI using MRN and DTI
104993|NCT03365895|Other|Questionnaire Administration|Ancillary studies
104994|NCT03365882|Biological|Cetuximab|Given IV
104995|NCT03365882|Drug|Irinotecan Hydrochloride|Given IV
104996|NCT03365882|Other|Laboratory Biomarker Analysis|Correlative studies
104997|NCT03365882|Biological|Pertuzumab|Given IV
104998|NCT03365882|Biological|Trastuzumab|Given IV
104999|NCT03365882|Device|HER-2 testing|Central testing of HER-2 for eligibility
105000|NCT03365869|Drug|Sirolimus|Sirolimus or placebo were added to patients every day
105001|NCT03365856|Other|observational study|as clinical practice
105002|NCT03365843|Device|Montage bone putty|Application of bone putty on cut sternal surfaces prior to application of conventional wires for closure of sternum during cardiac surgery.
105008|NCT03365791|Biological|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-programmed death-1 (PD-1) IgG4 antibody that blocks the binding of Programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2) to PD-1.
105009|NCT03365791|Biological|LAG525|LAG525 is a high-affinity, ligand-blocking, humanized anti-LAG-3 IgG4 antibody which blocks the binding of the known LAG-3 ligand MHC class II to LAG-3.
105010|NCT03365778|Other|Educational intervention|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. Then they will receive educational materials including 20 printed slides and view a 3 minute video on safety and efficacy of SLT. If patients agree to SLT, assistance in scheduling will be provided.
105011|NCT03365778|Other|Usual care|Patients will respond to 5 questions regarding selective laser trabeculoplasty (SLT) versus topical medication to lower eye pressure. No other guidance will be provided.
105012|NCT03365765|Drug|Apatinib|Apatinib tablet
105013|NCT03365765|Drug|Oxaliplatin|Oxaliplatin Intravenous
105014|NCT03365765|Drug|5-fluorouracil|5-fluorouracil Intravenous
105015|NCT03365752|Drug|Chloroprocaine|A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
105016|NCT03365752|Drug|Mepivacaine|A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
105017|NCT03365752|Drug|General Anesthetics|General anesthetics will be administered intravenously
105018|NCT03365739|Dietary Supplement|Active Comparator 1|Mango (pulp/flesh) (500 g)
105019|NCT03365739|Dietary Supplement|Active Comparator 2|Mango (500 g) + Vitamin C (100 mg)
105020|NCT03365739|Dietary Supplement|Control Comparator|Vitamin C (100 mg)
105021|NCT03365726|Diagnostic Test|Dobutamine stress test with trans-esophageal echocardiography|"Dobutamine stress echocardiography will be performed: before skin incision and at the end of surgery.~After a TEE evaluation at rest to assess myocardial structure, function and potential regional wall motion abnormalities, dobutamine infusion will be started~If no regional wall motion abnormalities will be detected, a dobutamine stress echocardiography will be started at the range infusion of 50 γ/kg/min (ADST: Accelerated Dobutamine Stress Test). The Test will be continued up to the 85% of maximum heart rate adjusted for the patient age and echo images will be stored.~If regional wall motion abnormalities are present, a gradual dobutamine stress test will be started at the initial dose of 10 mcg/kg/min (GDST: Gradual Dobutamine Stress Test) and it will be increased every 3 minutes until the 85% of maximum heart rate, adjusted for patient's age (maximal dose: 40 mcg/kg/min) and echo images will be stored."
105022|NCT03365700|Procedure|Radiofrequency Ablation|Left atrial catheter ablation with pulmonary vein antrum isolation documented by a circular mapping catheter.
105023|NCT03365700|Procedure|Cryoballoon ablation|Cryoballoon pulmonary vein isolation with the Arctic Front Advance® System or any future development generations of this product line. Additional substrate modification is allowed with the catheter type assigned at the index procedure.
105024|NCT03365687|Dietary Supplement|Vitamin D|2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
105025|NCT03365687|Dietary Supplement|Placebo|2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
105026|NCT03365674|Device|Vibration|Vibration applied with vibrator switch-on state (100Hz)
105027|NCT03365674|Device|Placebo vibration|Vibrator applied with switch-off state
105028|NCT03365661|Biological|ALT-803|A reduced intensity conditioning starts on Day -6, (CY/FLU/TBI/TLI) followed by infusion of a TCRα/β-deplete haploidentical graft on Day 0. Two doses of ALT-803 are given initially (early) 1 week apart to facilitate NK cell expansion. ALT-803 maintenance (late) for immune reconstitution begins at Day 42 and consists of 4 weekly doses, followed by 4 weeks off. Up to four 8 week treatment courses are permitted. No post-transplant GVHD prophylaxis is administered unless the final donor cell product contains > 2 x 105 α/β T cells/kg recipient weight.
105029|NCT03365648|Dietary Supplement|Lertal® + standard therapy|"Lertal® is a novel food supplement. Each tablet contains the following active ingredients:~Quercetin 150 mg: a natural flavonoid that inhibits the release of histamine, leukotrienes, PGD2, IL (IL-6, IL-8, TNF-alpha).~Perilla frutescens 80 mg: A dry extract of the seeds containing rosmarinic acid, luteolin, apigenin and crysoeriol that inhibits the release of histamine and expression of interleukins (IL-6, TNF-alpha).~Vitamin D3 5 mcg (200 IU), which contributes to the normal function of the immune system.~Standard therapy: antihistamine."
105030|NCT03365648|Other|Placebo + standard therapy|"Placebo tablet identical in appearance, size and taste to Lertal® tablets. Standard therapy: antihistamine.~Standard therapy: antihistamine"
105031|NCT03365635|Drug|Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier]|Same as described in arm description
105032|NCT03365622|Drug|acetaminophen|Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.
105033|NCT03365622|Drug|Acetaminophen|500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
105034|NCT03365622|Drug|Placebos|Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.
105035|NCT03365622|Drug|Placebo Oral Tablet|Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
105036|NCT03365609|Drug|triple therapy|Omeprazole+Amoxicillin+Clarithromycin
105037|NCT03365609|Drug|sequential therapy|the first 7 days : Omeprazole+Amoxicillin, the last 7 days: Omeprazole+Clarithromycin+Metronidazole
105038|NCT03365609|Drug|bismuth quadruple therapy|Omeprazole+Amoxicillin+Metronidazole+Colloidal Bismuth Subcitrate
105039|NCT03365609|Drug|concomitant therapy|Omeprazole+Amoxicillin+Clarithromycin+Metronidazole
105040|NCT03365596|Other|Conventional therapy|According to the status of a patient, optimized therapy will be applied.
105041|NCT03365557|Procedure|Airway peak pressure|Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
105042|NCT03365544|Other|Time-restricted eating|Groups will be required to only ingest calories in their designated 8 hour eating window.
105043|NCT03365531|Other|Alternate Daily Fasting (ADF)|See ADF arm for details
105044|NCT03365531|Other|Caloric Restriction (CR)|See CR arm for details
105325|NCT03363321|Biological|PF-06741086|PF-06741086 subcutaneous injection
105045|NCT03365518|Behavioral|Cognitive Behavioural Therapy (CBT)|Sessions consist of CBT tools as well as sex therapy techniques and education. The CBT treatment was adapted from the mindfulness-based treatment, but all mentions of mindfulness have been replaced with CBT principles. The therapeutic content presented in this treatment arm is manualized.
105046|NCT03365518|Behavioral|Mindfulness-Based Therapy|The mindfulness-based treatment was developed based on pre-existing mindfulness-based cognitive therapy treatment groups for sexual dysfunction developed by Dr. Lori Brotto at the University of British Columbia Sexual Health Laboratory, mindfulness in Sex therapy and Intimate Relationships (MSIR) treatment group developed by Kocsis and Newbury-Helps (2016), and expert input. Sessions consist of mindfulness-based training as well as sex therapy techniques and education. The therapeutic content presented in this treatment arm is manualized.
105047|NCT03365492|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
105048|NCT03365479|Drug|Iloprost|Single administration of inhaled iloprost 2.5 μg delivered via Breelib nebulizer
105049|NCT03365466|Drug|Low dose aspirin|LDA 25mg tid
105050|NCT03365466|Drug|Low molecular weight heparin|LMWH 5000u IH qd
105051|NCT03365466|Drug|Low dose aspirin plus low molecular weight heparin|LDA 25mg tid + LMWH 5000u IH qd
105052|NCT03365466|Drug|no treatment|Patients who did not receive any treatment.
105053|NCT03365453|Other|frailty evaluation|frailty and comorbidity scores
105054|NCT03365440|Device|esoECG-3D catheter|Recording of esophageal ECGs with the investigational medical device (IMD). Recording of respiration with a commercial breathing sensor.
105055|NCT03365427|Other|APP|An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
105056|NCT03365414|Biological|Albumin (Human) 5%, USP|Albumin (Human) 5%, USP. Intravenous Solution. Plasma Substitute/Blood Derivative
105057|NCT03365414|Drug|Normal Saline 0.9% Infusion Solution Bag|Placebo Normal Saline 0.9% Infusion Solution Bag.
105058|NCT03365401|Procedure|decompression surgery|undertake decompression surgery
105059|NCT03365401|Procedure|nonsurgical treatment|complete on bed with prevention of complication
105060|NCT03365388|Drug|Sodium Hyaluronate|Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form
105061|NCT03365388|Drug|Aerzhi|Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage
105062|NCT03365375|Behavioral|MBSR Referral|Referral for mindfulness-based stress reduction (MBSR), a structured meditation training program consisting of 8 weekly group sessions.
105063|NCT03365375|Other|Usual Care Referral|Referral to PCP or Psychiatry
105064|NCT03365362|Drug|Long-Term Varenicline|Varenicline tablet x 24 weeks
105065|NCT03365362|Drug|Short-Term Varenicline|varenicline tablet for 12 weeks, followed by placebo tablet manufactured to mimic varenicline 1 mg tablet
105066|NCT03365362|Behavioral|Directly Observed Therapy|Varenicline doses are administered by opioid treatment program nurses
105067|NCT03365362|Behavioral|Self Administered Therapy|Varenicline doses are self-administered
105068|NCT03365349|Other|"participating in a session of living theatre"|"participating to a session of living theatre which consists in writing a story about life with diabetes, which is then transformed to a script to be played by professional actors co-directed by the patient with the support of the Director to create a short play"
105069|NCT03365349|Other|writing workshop|"one session consisting for the patient of writing a Letter to his/her own diabetes and then to read it to the group of patients and the healthcare providers."
105070|NCT03365336|Drug|polyherbal formulation|Each Flu Care consist of 350 mg of polyherbal component
105071|NCT03365336|Drug|Oseltamivir 75mg|All the participant has to take 75 mg of oseltamivir for five days.
105072|NCT03365323|Other|Periprosthetic Joint Infection|Periprosthetic Joint Infection is diagnosed according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
105073|NCT03365323|Other|Non-Periprosthetic Joint Infection|PJI can not be diagnosed for the lack of clinical evidence according to the diagnosing criteria from the Workgroup of the Musculoskeletal Infection Society.
105074|NCT03365310|Drug|C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk|Polyherbal formulation along with standard of care
105075|NCT03365310|Other|Standard of Care|Usual standard of care for consist of exercise, caloric and protein support, vitamin D, reduction of polypharmacy along with medical management of health condition, assessment of care needs and provision of care. These will be determined on case by case basis by research clinician.
105076|NCT03365297|Drug|Apalutamide|240mg (4x60mg) oral tablets daily over a max. of 90 days
105077|NCT03365284|Device|Smart Kneebrace with a smart phone app|Smart Kneebrace will be used during the rehabilitation. Patients wearing the Smart KneeBrace are able to know their daily activity summary and exercise performance during rehabilitation training through a smart phone app.
105078|NCT03365284|Other|regular rehabilitation procedure|regular rehabilitation procedure, especially muscle strengthening exercises
105079|NCT03365271|Procedure|drainage|Applying a drain tube during TKA procedure
105080|NCT03365271|Procedure|non-drainage|No drain tube will be applied during TKA procedure
105081|NCT03365258|Dietary Supplement|Trophic feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition of trophic feeding is continue feeding with feeding rate: 20 kcal/hr.
105082|NCT03365258|Dietary Supplement|volume-based feeding|Non-blind to randomize to trophic feeding group and volume based feeding group in the first six days (Day 0->Day 6). The definition Volume-based feeding also use continue feeding by feeding protocol
105083|NCT03365245|Device|Microperimetry|Microperimetry is performed at three different days
105084|NCT03365245|Device|automated visual field|Automated visual field ist performed at three different days
105085|NCT03365232|Device|non custom base attachment|non custom base attachment
105086|NCT03365232|Device|custom base attachment|custom base attachment
105087|NCT03365219|Device|Alexis O-Ring Wound Retractor|A flexible self-retaining plastic Alexis retractor was used in place of standard surgical retractors.
105089|NCT03365206|Other|Questionnaire on practices and knowledge in terms of oral hygiene|Questionnaire on practices and knowledge in terms of oral hygiene during a dental consultation
105090|NCT03365193|Diagnostic Test|Transesophageal Echocardiography|Standard transesophageal echocardiography will be performed as clinically indicated by treating physicians.
105091|NCT03365180|Device|Starter Kit Algorithm|Long acting insulin titration to target
105092|NCT03365167|Radiation|LANAP (Laser Assisted New Attachment Procedure)|radiation of Nd:YAG laser in periodontal pocket
105093|NCT03365167|Radiation|LANAP off|radiation of Nd:YAG laser in off mode in periodontal pocket
105094|NCT03365154|Device|Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment|Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.
105095|NCT03365154|Device|Balloon Angioplasty|Low pressure balloon angioplasty may be used following atherectomy
105096|NCT03365141|Drug|Triamcinolone acetonide 0.4mg/cc|"Intralesional injection of dilute triamcinolone acetonide with 2% lidocaine (400mg/20 mL) would be performed to reduce pain when injecting the drug.~Once weekly, for a total of 12 weeks"
105097|NCT03365141|Device|Phototherapy (NBUVB or excimer laser)|NBUVB or excimer laser treatment weekly
105098|NCT03365141|Drug|Topical tacrolimus|Application of topical tacrolimus ointment twice a day
105099|NCT03365115|Drug|Intrathecal morphine|Intrathecal morphine 100 mcg will be injected.
105100|NCT03365115|Drug|Intrathecal fentanyl|Intrathecal fentanyl 25 mcg will be injected.
105101|NCT03365102|Device|anodal tDCS over the rIFG,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the right inferior frontal gyrus . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, participants will complete the Stop Signal and Delayed Discounting Task, while EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition. Ordering of tasks will be counterbalanced.
105102|NCT03365102|Device|anodal tDCS over the lOFC,|tDCS at a constant current of 1.5 mA will be applied for one 20-minute session over the left orbitofrontal cortex . Resting-state EEG for 10 minutes will be recorded immediately prior to and after tDCS. After post-tDCS resting state EEG is acquired, participants will complete the Stop Signal and Delayed Discounting Task, while EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition. Ordering of tasks will be counterbalanced.
105103|NCT03365102|Device|sham tDCS stimulation condition|In the sham condition, the current will be ramped up to 1.5mA for 30 seconds and then ramped back down to 0. As this commonly used sham procedure produces a brief tingling sensation, participants are kept unaware of their experimental condition. Resting-state EEG for 10 minutes will be recorded immediately prior to and after the sham tDCS. After post-sham stimulation resting state EEG is acquired, participants will complete the Stop Signal and Delayed Discounting Task, while EEG is recorded to extract Evoked Response Potentials in a single-blind procedure. The participants and assessors will be blind to experimental condition. Ordering of tasks will be counterbalanced.
105104|NCT03365089|Procedure|Collateral vein ligation|Collateral venous flow will be interrupted by ultrasound-guided ligation of venous side branches.
105105|NCT03365076|Other|Physical activity|Aerobic physiocal activity as stated in Arm A
105106|NCT03365063|Other|Active Knowledge Translation|"Integration of the KFRE in the CPCSSN DPT - The DPT will report the output from the KFRE for all patients with CKD Stages G3-G5 from the clinic sites. The risk output will include interpretation and automated categorized risk of progression to kidney failure, and will recommend actions based on the KFRE risk based care pathway.~Audit and Feedback - Providers at CPCSSN clinics receive sentinel feedback reports on a panel of chronic conditions and quality improvement targets. The investigators will add CKD to the feedback report for the intervention sites, and provide detailed feedback on the practices' risk profile.~Medical Detailing - The intervention CPCSSN clinics will receive a standardized presentation to clinic staff by the principal investigator, who will provide the evidence for the accuracy of the KFRE and guidance on implementation of a risk based treatment pathway, as well as describe the supporting visual aids."
105107|NCT03365050|Other|No Intervention Given|No Intervention to be given
105108|NCT03365037|Drug|Electret electrostatic physiotherapyFilm|Patients with acute soft tissue injury treated with electret electrostatic physiotherapyFilm
105109|NCT03365037|Drug|Fracture healing film|Patients with acute soft tissue injury treated with Fracture healing film
105110|NCT03365024|Behavioral|Computerized Cognitive Behavioral Therapy for Insomnia|A computerized insomnia intervention that employs the same behavioral, educational, and cognitive treatment components that underlie non-computerized CBT-I.
105111|NCT03365024|Behavioral|Sleep Education|A web-based program will deliver components of sleep education via an Internet platform
105112|NCT03365011|Drug|Nitrous oxide gas for inhalation|Nitrous oxide gaseous mixture (50% nitrous oxide and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
105113|NCT03365011|Drug|Placebo gas for inhalation|Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
105114|NCT03364998|Drug|Damoctocog (Jivi, BAY94-9027)|60 international units (IU)/kg, given as a 10 minute injection, 1 dose
105115|NCT03364998|Drug|Elocta|60 IU/kg, given as a 10 minute injection, 1 dose
105116|NCT03364985|Drug|DWP16001|DWP16001 tablets
105117|NCT03364985|Drug|Placebo|DWP16001 placebo-matching tablets, Active control placebo-matching tablets
105118|NCT03364985|Drug|Dapagliflozin|Forxiga®
105119|NCT03364972|Device|Cataract surgery|Conventional small-incision phacoemulsification cataract surgery with insertion of intraocular lens implant
105120|NCT03364959|Other|Corticosteroids inhalation|Flixotide inhalation followed by Qvar inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
105121|NCT03364959|Other|Corticosteroids inhalation|Qvar inhalation followed by Flixotide inhalation through a nasal filter and a mouth filter located in a partitioned face mask and delivered to an infant with asthma via a Tipshaler® holding chamber
105122|NCT03364946|Other|No intervention|No intervention, observational study
105123|NCT03364933|Behavioral|Primary intensivist and nurses|"Primary intensivist will have no active role in the daily management of patients. The primary intensivist should facilitate decision-making, be a liaison between the patient/family and PICU team, and be a resource of information for all. Responsibilities of primary intensivist:~Weekly check-in with and availability to patient/family~Attendance at family meetings~Availability to PICU team~Primary nurses will be a team of up to 7 ICU nurses who will provide as much of the bedside care as possible. Responsibilities of primary nurses:~Maintain a primary nurse binder (paper format) for on-going communication about the patient among the team members; it will be their discretion what is information is communicated.~The Primary Nurse or delegate will be involved in all team/family meetings and will be expected/given an opportunity to speak during these meetings."
105124|NCT03364907|Other|HIPEC with flushing afterwards|flushing with saline fluid after HIPEC
105125|NCT03364907|Other|HIPEC without flushing afterwards|NO flushing with saline fluid after HIPEC
105126|NCT03364868|Drug|Oral Insulin|treatment starting at 4 months - 7 months until age 3.0 years; dose escalation scheme: daily treatment with 7.5 mg or placebo for 2 months; increasing to daily treatment with 22.5 mg or placebo for the following 2 months; increasing to daily treatment with 67.5 mg or placebo until the end of the treatment period.
105127|NCT03364868|Other|Placebo|treatment starting at age 4 months - 7 months until age 3.0 years; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
105128|NCT03364855|Other|Star excursion balance test|Star excursion balance test,
105129|NCT03364855|Other|Kinesthetic Ability Trainer 2000|Kinesthetic Ability Trainer 2000
105130|NCT03364855|Other|SEBT and KAT 2000|Star excursion balance test and Kinesthetic Ability Trainer 2000
105131|NCT03364842|Drug|Furosemide|Administering furosemide
105132|NCT03364829|Drug|Indacaterol/Glycopyrronium|
105133|NCT03364816|Procedure|TDR|total artificial disc replacement
105134|NCT03364803|Other|Cushing's QoL (Quality of Life Questionnaire)|Cushing's QoL is a validated disease specific questionnaire consisting of 12 questions on a five-point Likert scale ranging from always to never. The total score ranges from 12 to 60, with a lower score indicating a greater negative impact on health related QoL. This is converted to a 0-100 scale, 0 indicating the worst and 100 indicating the best QoL
105135|NCT03364803|Other|Nottingham Health Profile (NHP)|NHP is used in patients to assess general health and quality of life. This assessment consists of 38 yes/no questions that are subdivided into six scales assessing impairments: pain (eight items), energy level (three items), sleep (five items), emotional reactions (nine items), social isolation (five items) and physical mobility (eight items). A higher score indicates more impairment
105136|NCT03364803|Other|Hospital Anxiety and Depression Scale (HADS)|HADS consists of 14 items pertaining to anxiety and depression, with each item measured on a four-point scale. Total scores for the anxiety and depression subscales range from 0 to 21. A higher score indicates greater symptomatology
105137|NCT03364803|Other|Perceived Stress Scale (PSS)|The PSS predicts both objective biological markers of stress and increased risk of disease in patients with higher stress levels.
105138|NCT03364803|Other|Barratt's Impulsivity Scale (BIS)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
105139|NCT03364803|Other|Beck Depression Inventory (BDI)|BDI and BIS in combination have demonstrated that depression and/or binge eating may be mediating factors for the outcome of obesity
105140|NCT03364803|Other|State-Trait Anxiety Inventory (STAI)|The STAI provides data to help distinguish between anxiety and depression.
105141|NCT03364803|Other|State Food Craving Questionnaire-State (FCQ-S)|The FCQ-S consists of 15 items assessing: desire to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement (reduction of negative affect) from eating, lack of control over eating, and (physiological) hunger; higher scores reflect stronger food craving. Participants respond, using a Likert-type scale, how much each item is true of them right now.
105142|NCT03364803|Other|Trait Food Craving Questionnaire-Trait (FCQ-T)|Trait food craving will be assessed with the Food Craving Questionnaire-Trait (FCQ-T). The FCQ-T consists of 39 items assessing: intentions/plans to eat, anticipation of positive reinforcement from eating, anticipation of negative reinforcement from eating, lack of control over eating, preoccupation with food, (physiological) hunger, emotions preceding or following food cravings or eating, environmental cues that may elicit food cravings, negative emotions including guilt experienced as a consequence of food cravings, and/or indulging such cravings; higher scores again indicate higher trait craving. Individuals are asked to respond, using a Likert-type scale, how much each item is true of them in general.
105143|NCT03364803|Other|Visual Analogue Scale (VAS)|"A validated visual analogue scale (VAS) questionnaire will be completed in the fasting state. The VAS consists of 100-mm lines with words anchored at each end describing extreme sensations of hunger, prospective consumption (How much do you think you can eat?), fullness, and satisfaction, as well as craving (sweet, salty, fatty or savory). Patients will be asked to make a vertical mark across the line corresponding to their feelings. Quantification will performed by measuring the distance from the left end of the line to the mark."
105144|NCT03364803|Other|Sensitivity to Reinforcement of Addictive and other Primary Rewards (STRAP-R) food variant|A validated questionnaire that assesses perceived subjective value attributed to expected/hypothetical foods and other primary reinforcers will be administered. This variant of this questionnaire was initially developed by Dr. Goldstein to assess 'liking' and 'wanting' of expected drug rewards for patients with cocaine addiction. The current assessment uses a modified version to assess 'liking' and 'wanting' for food.
105145|NCT03364790|Procedure|PLIF|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
105146|NCT03364790|Procedure|TKA|Randomly include the 30 participants diagnosed LSS and knee arthritis or limited by knee extension greater than 10 °who need to be operated and then performed PLIF or PLF; include anothr ones of 30 need to be with the implementation of TKA;and another group with the same diagnosis will be underwent both of surgeries in one stage.
105147|NCT03364777|Other|emotional state|anxiety or depression state evaluated by emotional scale
105324|NCT03363334|Drug|Fostamatinib disodium 150 mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
105148|NCT03364764|Drug|Sirolimus|On refractory PRCA patients, sirolimus was tried. Dosage: 2mg QD for the first day, then 1 mg QD. Medication time should last at least 6 months.
105149|NCT03364751|Other|IQOS|Patients will switch from cigarette smoking to ad libitum IQOS use.
105150|NCT03364751|Other|Cigarette|Patients will continue to smoke cigarettes ad libitum.
105151|NCT03364738|Biological|rhPTH(1-84)|Participants will receive rhPTH(1-84) SC injection in the thigh (alternate thigh every day) QD.
105152|NCT03364725|Drug|Glecaprevir-pibrentasvir|Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
105153|NCT03364712|Other|routine medical care, venipuncture|
105154|NCT03364699|Dietary Supplement|dietary supplementation|The volunteers ingested 3 g daily of Soybean lecithin or fish oil rich in docosa-hexanoic acid (DHA) containing 1.5 g DHA and 0.3 g EPA (DHA:EPA = 5:1) or fish oil rich in eicosapentaenoic acid (EPA) containing 1.6 g EPA and 0.3 g DHA (EPA:DHA = 5.4:1) during 60 days.
105155|NCT03364699|Other|Exercise|All volunteers performed two half-marathons. In the first half-marathon, all participants were not supplemented. In the second half-marathon, all participants were supplemented. Blood samples were collected before and after both half-marathon race.
105156|NCT03364686|Biological|Biotin-Labeled Red Blood Cells|We will collect 500 mL of blood. The blood will be processed and split into two bags and labeled with a naturally occurring vitamin, biotin. The blood will then be re-infused back into the same participant at 2 time points (5-7 days and 35-42 days after storage).
105159|NCT03364660|Device|Epidural Stimulation|Eligible participants will be implanted with 16-electrode epidural array and epidural stimulator in the spinal cord.
105160|NCT03364660|Biological|Stand Training|Standing in a body weight support (BWS) harness on a treadmill or standing in a standing frame.
105161|NCT03364647|Other|Arm A - blood flow restriction training|Group receive standard of care plus blood flow restriction training
105162|NCT03364647|Other|Arm B - standard of care|Group will receive standard of care plus a sham version of blood flow restriction training
105163|NCT03364634|Diagnostic Test|Intracranial pressure monitoring|Weekly ICP monitoring sessions beginning at discharge from the neuro-intensive care unit and carried out until 1 month after cranioplasty.
105164|NCT03364608|Drug|AS MDI 90 μg|AS MDI 90 μg (2 actuations of 45 μg/actuation)
105165|NCT03364608|Drug|AS MDI 180 µg|AS MDI 180 μg (2 actuations of 90 μg/actuation)
105166|NCT03364608|Other|Placebo MDI|Placebo MDI (2 actuations)
105167|NCT03364608|Drug|Proventil 90 μg|Proventil 90 μg (1 actuation of 90 μg/actuation)
105168|NCT03364608|Drug|Proventil 180 μg|Proventil 180 μg (2 actuations of 90 μg/actuation)
105169|NCT03364595|Procedure|plate fixation|ORIF of the radial head fracture
105170|NCT03364595|Procedure|replacement|replacement of the radial head fracture
105171|NCT03364582|Other|Observed dietary pattern|No intervention will be used. This is an observational study with dietary patterns as main exposure
105172|NCT03364569|Procedure|Tranexamic acid|Participants with taking tranexamic acid (2 x 1g per day) as a preventive and without adjuvant treatment.
105173|NCT03364556|Other|No intervention|
105174|NCT03364543|Other|Access to the Medical-Legal Partnership Group|The Medical-Legal Partnership Group are lawyers in clinics who address health-harming legal needs.
105175|NCT03364543|Other|Access to social worker and a community worker|Access to social worker and a community worker, but no systematic process for addressing health-harming legal needs.
105176|NCT03364530|Drug|Gemcitabine-Oxaliplatin Regimen|"Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity."
105177|NCT03364530|Procedure|Hepatic intra arterial chemotherapy|"The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor."
105178|NCT03364517|Other|Predictor score of the imminence of a childbirth (SPIA)|The SPIA score is based on the analysis of 6 types of criteria: panic during the call, the possibility of having a telephone contact with the parturient, the urge to push and if so for how long, the rhythm of the CU, some aggravating factors (history of fast delivery or at home, maternal age between 26 and 35 years, lack of follow-up of pregnancy) and 2 minor factors (nulliparity and the taking of a tocolytic treatment). Each criteria is between 0 to 8, except for the 2 minor criteria for which 7 and 3 points are removed if they are present. This gives a score between -10 and +33, which is weighted according to the admission time estimated at the hospital (30 minutes, 1h and 2h).
105179|NCT03364504|Other|urine collection|3 urine collections during 24 hours
105180|NCT03364491|Drug|Tranexamic Acid|A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
105181|NCT03364491|Drug|Placebo|50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)
105182|NCT03364478|Procedure|DML group|The group underwent laparoscopic right hemicolectomy with dorsal and medial hybrid approach.
105183|NCT03364478|Procedure|MLA group|The group underwent laparoscopic right hemicolectomy with traditional medial-to-lateral approach.
105184|NCT03364465|Other|change of ventilatory settings|change of tidal volume during one-lung ventilation
105185|NCT03364439|Drug|Treatment plan|R-CHOP14 or R-CHOP21 for 6 cycles Restaging after 2, 4, 6 cycles Consolidation therapy with RT (36 Gy) if PET positive (PET after 6 R-CHOP cycles)
105186|NCT03364426|Other|No intervention|No intervention - this is was an observational, cross-sectional study to identify potential risk factors associated with stunting
105187|NCT03364413|Other|Chocolate|Participants will be asked to taste commercially available chocolate varying in sugar, fat and percent cocoa (milk, 70%, 85% and 90% cocoa).
105188|NCT03364400|Drug|VT1021|Peptide
105189|NCT03364374|Behavioral|Postural counseling|A therapist will provide verbal/physical cues to improve the participants posture
105190|NCT03364361|Procedure|Acupuncture|Participants will receive a six-point standardized stress acupuncture (SSA) treatment once a week for 4 weeks. The SSA consists of GV- 20, GV-24.5 (Yin Tang), bilateral LI-4, and bilateral LR-3. This acupuncture protocol has been used as an effective treatment for stress-related symptoms in the operational theater.
105191|NCT03364348|Drug|Utomilumab|Given IV
105192|NCT03364348|Drug|Trastuzumab|Given IV
105193|NCT03364348|Drug|Trastuzumab Emtansine|Given IV
105194|NCT03364335|Drug|Leu Sil 1.0mg|Leu 1100 mg + 1mg Sil BID
105195|NCT03364335|Drug|Leu Sil 4.0mg|Leu 1100 mg + 4mg Sil BID
105196|NCT03364335|Drug|Leu Met Sil 1.0mg|Leu 1100 mg + Met 500mg + 1mg Sil BID
105197|NCT03364335|Drug|Leu Met Sil 4.0mg|Leu 1100 mg + Met 500mg + 4mg Sil BID
105198|NCT03364335|Drug|Placebo|Placebo
105199|NCT03364322|Other|Observation|Observation
105200|NCT03364309|Drug|Ixekizumab|Administered SC
105201|NCT03364309|Drug|Placebo|Administered SC
105202|NCT03364296|Other|Blood Samples|Blood sample retrieved for biological assessment and biobanking
105203|NCT03364283|Procedure|Surgical position|
105204|NCT03364270|Drug|PET/CT Imaging with [F-18] RGD-K5|PET Imaging/scan with [F-18] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
105205|NCT03364257|Diagnostic Test|iDTECT Blood|Next generation sequencing-based shot-gun metagenomic test for the diagnosis of viral or bacterial infections using blood samples
105206|NCT03364244|Drug|Sildenafil|"[REVATIO® Tablets / REVATIO® OD Film] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily.~[REVATIO® Dry Syrup for Suspension] Adults Usually, sildenafil 20 mg is orally given three times daily. Children aged 1 year or older In children weighing 8 kg or more but less than 20 kg: Usually, sildenafil 10 mg is orally given three times daily.~In children weighing 20 kg or more: Usually, sildenafil 20 mg is orally given three times daily."
105207|NCT03364231|Drug|Umbralisib|Oral Daily Dose
105208|NCT03364218|Drug|N-Acetyl Cysteine|Nebulized N-Acetyl Cysteine administered every 12 hours
105209|NCT03364205|Behavioral|solution-focused interview technique|This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
105210|NCT03364192|Behavioral|Whole Health Coaching|Veterans Health Administration variation of integrative health coaching.
105211|NCT03364166|Procedure|surgical excision|"Under general anaesthesia, the buccal squamous cell carcinoma which invaded the buccinator muscle will be excised with the skin of the cheek. This will be done by a safety margins in the soft tissue and the mandible may be resected according to the plan and the invasion of the tumour.~A neck dissection will be done in all cases of negative or positive neck lymph node.~Reconstruction of the soft tissue will be done immediately by a major pectorals flap with the skin, also bony reconstruction may be done by a reconstructed plate at the time of surgery then the patients will be prepared for bone graft in another surgery."
105212|NCT03364153|Drug|Zimura|Zimura Intravitreal Injection
105213|NCT03364153|Other|Sham|Sham Intravitreal Injection
105214|NCT03364127|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
105215|NCT03364127|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
105216|NCT03364114|Device|EndoRotor Mucosal Resection System|The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
105217|NCT03364114|Device|Continued Ablation|Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
105218|NCT03364101|Dietary Supplement|Placebo Capsule|Composition of the placebo is 100% organic rice flour, manufactured at a facility New York State licensed to produce pharmaceuticals. Capsules will be instructed to commence on day 7 of the study after baseline appointment.
105219|NCT03364101|Dietary Supplement|POWEROFF Capsule|blend of California Poppy Aerial Part Extract, L-Cystine, L-Theanine,GABA (proprietary Phosphatidylcholine-Palmitic Acid-Oleic Acid Complex), 5-HTP, Magnolia Officinalis Bark Extract, Glycine, Melatonin with 0.5mg of Vitamin B6 (as pyridoxal-5-phosphate).
105220|NCT03364088|Procedure|Spinal anesthesia with tourniquet|Operation is done under spinal anesthesia and surgical tourniquet is used.
105221|NCT03364088|Procedure|Spinal anesthesia without tourniquet|Operation is done under spinal anesthesia and without the use of surgical tourniquet.
105222|NCT03364088|Procedure|General anesthesia with tourniquet|Operation is done under general anesthesia and surgical tourniquet is used.
105223|NCT03364088|Procedure|General anesthesia without tourniquet|Operation is done under general anesthesia and without the use of surgical tourniquet.
105224|NCT03364088|Drug|Oxycodone by patient-controlled analgesia (PCA)|PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
105225|NCT03364075|Drug|Duloxetine|30 mg for seven days, then increased to 60 mg for seven days
105226|NCT03364075|Drug|Propranolol|40 mg for seven days, then increase to 60 mg for seven days
105227|NCT03364075|Genetic|Genotype for SNPs associated to Serotonin and COMT|DNA and RNA extraction from blood samples to identify genetic variants associated to pain pathways
105228|NCT03364075|Drug|Placebo Treatment|1 capsule BID for two weeks
105229|NCT03364062|Procedure|cemented shoulder replacement|proximal humeral fracture receiving hemi-shoulder replacement with cement when inserting the stem
105230|NCT03364049|Drug|MK-7162|oral tablets
105231|NCT03364049|Biological|Pembrolizumab|IV infusion
105232|NCT03364036|Drug|Mavenclad®|Subjects will receive Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
105233|NCT03364023|Device|Neurothrombectomy|Medtronic Market-Released Neurothrombectomy Device
105234|NCT03364010|Behavioral|Evaluation of proprioception|Velocity perception and Position perception
105235|NCT03364010|Behavioral|Evaluation of motor learning|Motor accurancy and State Estimation with visual perturbations
105236|NCT03364010|Behavioral|Evaluation of written language|Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
105237|NCT03363997|Drug|Estriol 0.125 mg/day|Application of one vaginal ring
105238|NCT03363997|Drug|Estriol 0.250 mg/day|Application of one vaginal ring
105239|NCT03363997|Drug|Estriol 0.500 mg/day|Application of one vaginal ring
105240|NCT03363984|Drug|Midazolam|Single oral administration of 2 mg midazolam under fasted conditions/outside of meal times
105241|NCT03363984|Drug|ID-082|Administration of ID-082 under fasted conditions/outside of meal times
105242|NCT03363971|Drug|Zhi Kang Capsule|0.3g/capsule, oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
105243|NCT03363971|Drug|Simulant agent for Zhi Kang Capsule|0.3g/capsule,oral, 4 capsules at a time, 3 times a day, half an hour after dinner, warm water delivery; treatment for 6 weeks.
105244|NCT03363958|Procedure|Remote Ischemic Preconditioning with Postconditioning|Three cycles of 5 minutes of ischemia and 5 minutes of reperfusion of lower leg 24 hours, immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
105245|NCT03363958|Procedure|Sham RIPC procedure|Three cycles of 5 minutes of inflation and 5 minutes of deflation of artificial lower leg immediately before surgery and within 60 minutes after the restoration of coronary blood flow postoperatively.
105246|NCT03363945|Drug|MDR-101|Enriched CD34+ hematopoietic stem cells and defined dose of CD3+ T-cells
105247|NCT03363919|Device|NeuroStar TMS Therapy® System|The NeuroStar TMS Therapy® System is a computerized electromechanical instrument that produces and delivers brief duration, rapidly alternating (pulsed) magnetic fields to induce electrical currents in localized regions of the cerebral cortex. It is a non-invasive tool used for the treatment of Participants with MDD who have not achieved sufficient clinical benefit from antidepressant pharmacotherapy.
105248|NCT03363919|Device|NeuroStar XPLOR®|NeuroStar XPLOR® is a clinical research option for the NeuroStar TMS Therapy System that provides features necessary to conduct randomized controlled trials and other TMS research.
105249|NCT03363906|Drug|Dulaglutide (Reference)|Administered SC
105250|NCT03363906|Drug|Dulaglutide (Test)|Administered SC
105251|NCT03363893|Drug|CT7001|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression
105252|NCT03363893|Drug|CT7001 in combination with fulvestrant|Cyclin-dependent kinase 7 (CDK7) inhibitor given orally once daily until disease progression in combination with fulvestrant given as 2 x 250mg intramuscular (IM) gluteal injections on Day 1, Day 15, Day 28 and every 28 days thereafter
105253|NCT03363880|Other|trauma treatment team|Establishing the trauma management system included a trauma treatment team. The severe trauma treatment team will be composed by the physicians from departments of emergency, orthopedic trauma, urology, cardiothoracic surgery, neurosurgery, general surgery, anesthesiology, and ICU.
105254|NCT03363880|Other|Basic experimental settings|Establishing the trauma management system without a trauma treatment team.
105255|NCT03363867|Drug|Atezolizumab|840mg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion from Cycle 2 onwards.
105256|NCT03363867|Drug|Bevacizumab|5mg/kg every 2 weeks (i.e. Day 1 and Day 15 of each 28 day cycle) via intravenous infusion.
105257|NCT03363867|Drug|Cobimetinib|60mg per day, every day for 21 days (i.e. Day 1 to Day 21 of each 28 day cycle)
105258|NCT03363854|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration.
105259|NCT03363854|Drug|Placebo|Placebo contains the same excipients in the same concentration only lacking tralokinumab.
105260|NCT03363841|Drug|SCY-078|Oral SCY-078
105261|NCT03363828|Drug|Clindamycin Oral Tablet|No intervention
105262|NCT03363815|Drug|CC-90001|CC-90001
105263|NCT03363815|Drug|Omeprazole|Omeprazole
105264|NCT03363815|Drug|Midazolam|Midazolam
105265|NCT03363815|Drug|Warfarin|Warfarin
105266|NCT03363815|Dietary Supplement|Vitamin K|Vitamin K
105267|NCT03363815|Drug|Rosuvastatin|Rosuvastatin
105268|NCT03363815|Drug|Metformin|Metformin
105269|NCT03363815|Drug|Digoxin|Digoxin
105270|NCT03363815|Drug|Nintedanib|Nintedanib
105271|NCT03363789|Biological|Brisement injection|An injection of Lidocaine into the tendon sheath to break up adhesions that could be causing the condition.
105272|NCT03363789|Procedure|Physical Therapy|Patients will receive a prescription for physical therapy.
105273|NCT03363776|Biological|BMS-986277|Specified dose on specified days
105274|NCT03363776|Biological|Nivolumab|Specified dose on specified days
105275|NCT03363763|Drug|Sirolimus 0.2%|Ointment for topical administration hs x 12 weeks
105276|NCT03363763|Drug|Sirolimus 0.4%|Ointment for topical administration hs x 12 weeks
105277|NCT03363763|Drug|Placebo ointment|Placebo ointment comparator for topical administration hs x 12 weeks
105278|NCT03363750|Behavioral|mind-body-skills group|mind-body skills group program incorporates meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement
105279|NCT03363737|Behavioral|Transtheoretical Model|Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).
105280|NCT03363724|Other|HaGuide version 1.0 software module|
105282|NCT03363698|Other|Cough variant asthma treatment|Evaluation of the treatment response to inhaled corticosteroids, long-acting beta-agonists, montelukast, prednisone.
105283|NCT03363659|Drug|Disulfiram|Disulfiram is taken orally, twice daily.
105284|NCT03363659|Dietary Supplement|Copper gluconate|Copper gluconate is taken orally, twice daily
105285|NCT03363659|Drug|Temozolomide|Temozolomide is taken once daily
105286|NCT03363633|Drug|sodium tetradecyl sulfate|Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins
105287|NCT03363633|Device|Compression|20-30 mmHg compression stockings
105288|NCT03363620|Device|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
105289|NCT03363620|Device|Orthodontic Brackets|arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
105290|NCT03363607|Procedure|Digital indirect bonding|Indirect bonding of orthodontic attachments using digital 3D printed transfer tray
105291|NCT03363607|Procedure|Conventional indirect bonding|Indirect bonding of orthodontic attachments using thermoformed transfer tray
105292|NCT03363607|Procedure|Intraoral scanning|Intraoral Scanning of the bonded brackets
105293|NCT03363607|Procedure|Superimposition and evaluation|superimposition of the brackets' positions before and after bonding and evaluation of the transfer accuracy
105294|NCT03363581|Behavioral|Food Preference|Buffet meal to assess food preference
105295|NCT03363568|Behavioral|Adaptive Inhibitory Control Training|Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
105296|NCT03363568|Behavioral|Non-adaptive Inhibitory Control Training|Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
105297|NCT03363555|Drug|SHR-1210|A humanized monoclonal immunoglobulin.
105298|NCT03363542|Dietary Supplement|fruits, vegetables and/or whole grain high fiber rich diet|Dietary education to Increase fruits, vegetables and/or high fiber intake
105299|NCT03363529|Device|Dynamic light|Dynamic lighting is light that changes in intensity and spectral distribution during the day
105300|NCT03363529|Device|Standard|Standard lighting is non-dynamical light corresponding to standard hospital lighting.
105301|NCT03363516|Diagnostic Test|Cerebral 3 Tesla MRI|Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
105302|NCT03363503|Drug|Salmeterol/Fluticasone Capsair®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
105303|NCT03363503|Drug|Salmeterol/Fluticasone Diskus®|Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
105304|NCT03363490|Behavioral|Self-management program|Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
105305|NCT03363490|Behavioral|Neuromuscular exercise therapy|The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
105306|NCT03363490|Behavioral|Health education|All four groups of patient will receive two times of health education in the first week.
105307|NCT03363477|Drug|Enoxaparin|
105308|NCT03363477|Drug|Clexane|
105309|NCT03363464|Drug|Empagliflozin|Empagliflozin
105310|NCT03363464|Drug|DPP-4 inhibitor|dipeptidyl peptidase-4 inhibitor
105311|NCT03363451|Drug|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment
105312|NCT03363438|Other|no intervention survey|there was no intervention this was a survey
105313|NCT03363425|Drug|Lidocaine Iv|Lidocaine Iv
105314|NCT03363425|Drug|Dexmedetomidine|dexmedetomidine iv
105315|NCT03363425|Drug|Normal saline|placebo
105316|NCT03363412|Device|PTFE-covered stent grafts|Creation of a small diameter intrahepatic shunt between portal and hepatic veins.
105317|NCT03363399|Diagnostic Test|Flow cytometry analysis of neutrophil myeloperoxidase expression|"Flow cytometry analysis of neutrophil myeloperoxidase expression in peripheral blood samples will be performed within 24 h of MDS diagnostic evaluation and blinded to the reference standard. Peripheral blood samples will be collected in 5 ml (EDTA) anticoagulant plastic tubes and processed within 24 h maximum of collection. The samples will be stored at 4°C overnight.~Blood samples containing at least 105 neutrophils will be incubated with a panel of antibodies conjugated to fluorochromes, according to the manufacturers' recommendations.~At least 10,000 cell events will be acquired on a 3-laser, 8-color flow cytometer and analyzed using Becton Dickinson (BD) Fluorescence-activated cell sorting (FACS) Diva Software version 6. Each marker will be expressed as median, geometric and arithmetic mean, regular and robust coefficient of variation."
105318|NCT03363386|Procedure|Proprioceptive Exercises|Patients trained for proprioceptive exercises
105319|NCT03363386|Procedure|Resistive Exercises|Patients trained for resistive exercises
105320|NCT03363386|Procedure|Aerobic Exercise|Patients were educated with treadmill walking for 30 minutes of each exercise session
105321|NCT03363373|Biological|GM-CSF + Naxitamab|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
105322|NCT03363347|Drug|Redifferentiation with retinoid acid|In this retrospective study, patients with radioiodine refractory papillary thyroid cancer routinely received (clinical indication, no study medication was given) retinoid acid for redifferentiation prior to further course of radioiodine therapy.
105323|NCT03363334|Drug|Fostamatinib disodium 100 mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
105326|NCT03363308|Behavioral|training for health care workers supplmented by QI teams|Jhpiego will deliver maternal and newborn health and family planning (MNH+FP) training using evidence-based low-dose, high-frequency (LDHF) learning approaches and support hospital staff-led quality improvement efforts to increase the coverage of facility-based high-impact interventions, including care of the mother and newborn on the day of birth and through the first week postpartum and post abortion services.
105327|NCT03363295|Drug|Moxifloxacin Injection|One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
105328|NCT03363282|Procedure|Pterygium Excision|Pterygium excision is the first step for repair
105329|NCT03363269|Drug|ID1201|
105330|NCT03363256|Behavioral|TES-NAV|Internet-delivered psychosocial treatment grounded in the community reinforcement approach plus contingency management adapted for AI/AN
105331|NCT03363256|Behavioral|TAU|Standard outpatient addiction treatment
105332|NCT03363243|Other|STOP Therapy Treatment group|Testing of the STOP Therapy protocol
105333|NCT03363243|Other|Treatment as usual (TAU) group|Treatment as usual in the community through group therapy
105334|NCT03363230|Behavioral|Mindfulness skills training|Mindfulness skills were taught over a 10-week period. Mindfulness skills were delivered in a weekly group-format. Participants were instructed to follow mindfulness practice at home. The treatment was focused on enhancing the patient capacity to defuse from cognitive and emotional content.
105335|NCT03363230|Behavioral|Interpersonal Effectiveness skills training|Interpersonal effectiveness skills were taught over a 10-week period. Skills were delivered in a weekly group-format. The treatment was focused on improving interpersonal effectiveness.
105336|NCT03363217|Drug|Trametinib|Daily administration of oral trametinib at a unique dose of 0.025 mg/kg.
105337|NCT03363204|Device|BRUXENSE occlusal splint|Patients participating will put the BRUXENSE occlusal splint each night. During the night the device will collect data potentially related to bruxism. After each night the device will be cleaned with water and toothpaste and charged. This routine will be conducted over 10 consecutive nights.
105338|NCT03363191|Drug|Fluticasone Furoate/Vilanterol|Fluticasone furoate/vilanterol will be supplied as inhalation powder in ELLIPTA DPI. It will contain 2 strips with 30 blisters per strip. First strip will contain fluticasone furoate 100 mcg dry white powder blended with lactose. Second strip will contain vilanterol 25 mcg dry white powder blended with lactose and magnesium stearate.
105339|NCT03363191|Drug|Fluticasone Furoate|Fluticasone furoate will be supplied as inhalation powder in ELLIPTA DPI. It will contain a single strip with 30 blisters, containing fluticasone furoate 100 mcg dry white powder blended with lactose.
105340|NCT03363191|Drug|Salbutamol/Albuterol|Salbutamol/albuterol will be provided to subjects to use as rescue medication on an as-needed basis.
105341|NCT03363178|Biological|GC3107|BCG Vaccine, 0.1mL
105342|NCT03363165|Drug|VM202|"Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with an ankle brachial index <= 0.90. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have an ABI < 0.90 in only one leg will only receive injections in the leg with ABI < 0.90."
105343|NCT03363165|Other|Placebo|"Participants randomized to placebo will receive bilateral calf muscle injections of placebo (the excipient buffer formulation minus the VM202). Injections of placebo are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Placebo appears identical to the VM202 study drug and is administered in a pattern on the calf identical to that of the VM202 injections.~Note: Participants who have an ABI < 0.90 in only one leg will only receive injections in the leg with ABI < 0.90."
105344|NCT03363139|Drug|Tirosin Kinase Inhibitors|Patients that received Tyrosin Kinase inhibitors and progressed
105345|NCT03363126|Procedure|Endonasal transsphenoidal pituitary tumor removal|Removal of pituitary tumor by transsphenoidal endonasal surgery
105346|NCT03363113|Drug|Botulinum Toxins|Injection of botulinum toxin in the muscles affected by oromandibular dystonia
105347|NCT03363100|Behavioral|Digital health Partnership program|The program pairs patients with their own certified diabetes educator coach who will guide the patient through a personalized program that leverages a proven educational curriculum combined with proven patient engagement methods.
105348|NCT03363087|Device|Mapping and ablation|Ultra high density scar mapping Collection of impedance data during ablation
105349|NCT03363074|Device|Orthotic Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole,and 3mm,15 Shore A hardness ethyl vinyl acetate was used for covering.Orthotic insoles have been emplemented in a pair of sports shoes.
105350|NCT03363074|Device|Low-Level Laser|A low density laser with a power density of 0.05-0.10 (w / cm2), a therapeutic dose of 0.7-7 (j / cm 2) of gallium-arsenic 904 nm will be applied. It will be 3 administered times a week for 5 weeks. Laser treatment will be applied along the tibialis posterior tendon. 3 different point (proximal tibial tendon, distally tibial tendon and posterior medial malleol) applications will be done.
105351|NCT03363048|Behavioral|Restricted|Certain foods and beverages are not allowed to be purchased with food benefit dollars.
105352|NCT03363048|Behavioral|Restriction plus Incentive|Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
105353|NCT03363035|Drug|Rivaroxaban 2.5 mg|One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
105354|NCT03363035|Drug|Rivaroxaban 5 mg|One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
105355|NCT03363035|Drug|Enoxaparin|Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
105356|NCT03363022|Drug|Standard Medical Treatment|Standard Medical Treatment includes antibiotics,CRRT (Continuous Renal replacement Therapy),Liver Dialysis.
105446|NCT03362320|Procedure|single layer fixation|
105357|NCT03363022|Other|Fecal Microbiota Transplant|"Fecal Microbiota Transplant Stool specimen (preferably Bristol Stool Type 3 or 4) with a weight of ∼50 g will be considered adequate.~250 mL sterile normal saline will be added to the stool sample and homogenized with a blender for 2-4minutes in pulses of 30 seconds with 10 seconds wait in between each pulse.~Enema to be held for 30 minutes."
105358|NCT03363022|Other|Placebo|Placebo will be identical and non medicinal to the Fecal Microbiota Transplant
105359|NCT03363009|Device|Optimized group|The data provided by the connected devices is analyzed daily; the patient receives a phone call in case of no realization of the objectives.
105360|NCT03363009|Device|Control group|Data will be recorded but not analyzed daily during the period of participation. The patient receives a phone call one time a week to answer possible questions and modify the prescription of physical activity if need.
105361|NCT03362996|Dietary Supplement|Freshly-Pressed Extra Virgin Olive Oil|Dietary Supplement: Freshly-pressed extra virgin olive oil Freshly-Pressed Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
105362|NCT03362996|Combination Product|extra virgin olive oil|Extra Virgin Olive Oil Aluminum bottle with 500 ml of freshly-pressed extra virgin olive oil 1 bottle per 10 days
105363|NCT03362996|Other|mediterranean diet|50 patients that will have the same dietary habits and a Mediterranean dietary protocol
105364|NCT03362983|Other|CareHND|Multidisciplinary, integrated, person-centered care at the integrated HND-clinic
105365|NCT03362970|Device|BioFire Gastrointestinal Panel FilmArray®|The BioFire Gastrointestinal Panel FilmArray® is a multiplexed nucleic acid (NA) based device that simultaneously identifies 22 enteric pathogens. It specifically tests for the presence of Shiga toxin and for O157. It requires 2 minutes of hands-on-time, returns results in ~2-3 hour, and is Health Canada and Food and Drug Administration approved. The device, which has been validated, hopefully will enable the early identification of infected children and initiation (or withholding) of interventions directed by previously unavailable clinical data. It will enable us to bring a precision medicine approach into ED care.
105366|NCT03362970|Other|Standard of Care|Standard practices for children with hematochezia upon the discretion of the treating physician. If investigations are ordered, results have a turn-around time up to 72 hours.
105367|NCT03362957|Device|Geniculate Artery Embolization|Gel-Bead Microspheres will be used for geniculate artery embolization (GAE) in subjects with knee osteoarthritis.
105368|NCT03362957|Diagnostic Test|Sham Procedure|Patients will receive a sham procedure, which will include a diagnostic angiogram
105369|NCT03362944|Behavioral|Active Music Therapy|The intervention consists of a standardized series of Music Therapy tasks, all based at a constant rhythmic pulse.
105370|NCT03362944|Behavioral|Passive Music Therapy|The intervention consists of a series of recorded listening tracks, matched in style to the active intervention, all based at a constant rhythmic pulse.
105371|NCT03362931|Device|XEN45|XEN45 unilaterally implanted in the study eye
105372|NCT03362918|Behavioral|High Intensity Interval Training|"The exercise prescription is as follows:~Type: High-Intensity Interval Training on a treadmill, elliptical trainer or cycle ergometer.~Intensity: 30 seconds of high-intensity alternating with 90 seconds of low intensity for a total of 10 cycles~High intensity for most individuals will occur at approximately 90% of maximum heart rate. Using the rating of perceived exertion scale, participants should be exercising at a 9/10, which is very difficult to maintain the intensity and results in only being able to speak a few words at a time.~Low intensity is defined as light activity and rated as 2-3/10 on the rating of perceived exertion scale. Participants should be able to carry on a conversation and maintain the pace for hours.~Duration: 30 minutes Frequency: 3 times per week"
105373|NCT03362918|Behavioral|Continuous Aerobic Exercise Training|"The exercise prescription for the continuous aerobic exercise group is as follows:~Type: Aerobic exercise including walking, running, cycling or using the elliptical trainer.~Intensity: Moderate intensity, defined as 50-60% of the participant's maximum heart rate. On the rating of perceived exertion scale, this corresponds with a 4-6/10, which allows participants to hold a conversation while breathing heavily.~Duration: 50 minutes Frequency: 3 times per week"
105374|NCT03362905|Drug|Lidocaine topical|Local anesthetic for reduction of IUD associated pain
105375|NCT03362853|Drug|Nemonoxacin 500Mg Capsule|Receive a single dose in a fasting state
105376|NCT03362853|Drug|Moxifloxacin 400Mg Tablet|Receive a single dose in a fasting state
105377|NCT03362853|Drug|Nemonoxacin 750Mg Capsule|Receive a single dose in a fasting state
105378|NCT03362853|Drug|Placebo oral capsule|Receive a single dose in a fasting state
105379|NCT03362840|Behavioral|Early Start Denver Model|The ESDM is a manualized comprehensive treatment model for young children (12-48 months). In the preschool based ESDM, learning objectives are guided by the ESDM curriculum checklist, which includes developmental skills in language, play, motor skills, personal independence, imitation and cognition. The objectives are monitored for progress during each session The sessions are conducted according to ESDM principles, and include weekly parent-coaching session, in which parents observe the therapist interact with the child while applying various teaching techniques, and then implement these techniques during the interaction with their child. Additionally, parents get acquainted with the daily objective sheet and are encouraged to work on these objectives at home as well. Finally, in this model, therapist adherence to the ESDM practices are monitored according to the ESDM fidelity rating system
105380|NCT03362840|Behavioral|Eclectic preschool intervention|"The eclectic approach consists of a combination of methods from several treatment-models. Individualized educational plans are based on multi-disciplinary assessment, and include objectives in several domains - communication, social-skills, play, emotional adjustment, adaptive daily skills, motor skills and cognition. They are presented to parents at the beginning of the year and are reviewed by the staff three times a year.~Parents attend by-weekly counseling-sessions with a professional in order to receive input regarding their child's progress, and discuss issues concerning their child's functioning. All staff members receive supervision at various intensities. However, these usually do not adhere to a single structure and are not guided by official fidelity criteria."
105381|NCT03362827|Other|Chronic low back pain patients|People must have experienced low back pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
105382|NCT03362827|Other|Subjects without chronic low back pain|These participants must not have presented episodes of low back pain for more than 7 days in the last 12 months.
105383|NCT03362814|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
105384|NCT03362814|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
105385|NCT03362814|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
105386|NCT03362814|Drug|Ribavirin 100 MG|Ribavirin tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(<75kg = 1000mg and ≥75kg = 1200mg)
105387|NCT03362814|Drug|Ravidasvir Placebo|Ravidasvir Placebo tablet administered orally once daily
105388|NCT03362814|Drug|Danoprevir Placebo|Danoprevir Placebo tablet administered orally twice daily
105389|NCT03362814|Drug|Ritonavir Placebo|Ritonavir Placebo tablet administered orally twice daily
105390|NCT03362814|Drug|Ribavirin Placebo|Ribavirin Placebo tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations(<75kg = 5 tablets and ≥75kg = 6 tablets)
105391|NCT03362801|Diagnostic Test|sarcopenia and mobility measurement|"walking speed, grip strength and BIA. QAPPA questionnaire (validated in French in the elderly) and the objective measurement of the time of activity and rest on a week per wrist actimeter.~Comprehensive Geriatric Assessment"
105392|NCT03362788|Drug|VKA|VKA plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
105393|NCT03362788|Drug|NOAC|NOAC plus a P2Y12 inhibitor (clopidogrel 75mg or ticagrelor 90mg twice daily) and/or aspirin ≤100mg daily.
105394|NCT03362775|Drug|Propofol|Target-controlled infusion of propofol with an effect-site concentration of 0.0 µL/mL; 0.5 µL/mL and 1.0 µL/mL.
105395|NCT03362762|Other|Description of plans insuliniques used in Guadeloupe in the type 2 diabetes and the characteristics of the handled patients:|The physician or the endocrinologist will see the patient during his consultation. The pharmacist will see the patient when he goes to the pharmacy for an insulin treatment. In each case, the patient will be informed about the study, about the medical data that will be collected anonymously. The date will be strictly confidential and under medical secrecy. Then the patient will meet the physician during another consultation at the University Hospital Center of Guadeloupe, in order to collect information's on a questionnaire. Otherwise, the physician can meet the patient at his home, in case he can't move to the University Hospital Center of Guadeloupe.
105396|NCT03362749|Other|RFA, MWA, cryo and IRE|local tumor ablation
105398|NCT03362723|Drug|Idasanutlin|Participants will receive one 300-mg dose of each of the four different oral tablet formulations of idasanutlin (tablet A [reference], B, C, D) during Cycle 1, in the order specified for their assigned treatment arm (Treatment Sequence 1-4). Participants who enter the optional treatment extension phase will receive the reference tablet formulation of idasanutlin, as specified in the Optional Treatment Extension Arm description.
105399|NCT03362710|Diagnostic Test|simplified tools|"Skin temperature on the back of the foot with infra-red thermometry~Toe saturometry~ABI with an automatic sphygmomanometry~Skin Recoloration time at the foot"
105400|NCT03362697|Dietary Supplement|Probiotics|The Probiotic group will receive Sachet 1 - contains an instant cranberry drink, consisting of xylitol, monosodium citrate, cranberry aroma, cranberry extract, grape-skin extract, xanthan gum, acesulfame potassium and zinc gluconate and Sachet 2 - contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666/ATCC 55845 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin. Both Sachets should be administered Day 1-14, twice per day This group will also receive for Placebo for Antibiotic treatment day 1-7, twice per day
105401|NCT03362697|Drug|Antibiotics|Patient in this group will receive for 7 days Amoxicillin + clavulanic acid (500 mg twice daily) for seven days in patients with negative nitrites in dipstick or oral nitrofurantoin (200mg twice per day) for patients with positive nitrates in dipstick. This group will also receive for placebo for probiotics 2 sachets for 14 days
105402|NCT03362684|Drug|Cetuximab|Cetuximab every 2 weeks
105403|NCT03362684|Drug|FOLFOX|FOLFOX-4 every 2 weeks
105404|NCT03362671|Device|Implant Supported Mandibular Advancement Oral Appliance|This device is a novel oral appliance that attached to orthodontic mini implants in the jaw and is designed to keep the jaw in an advanced position, opening the upper airway during sleep.
105405|NCT03362671|Device|Orthodontic Mini Implant|Small titanium devices that are fixed to the bone for the purpose of enhancing anchorage of other orthodontic devices.
105406|NCT03362632|Drug|Antibiotics|This is an observation study, no specific antibiotics will be indicated during treatment.
105407|NCT03362619|Biological|CC-EIEs|2 to 4 infusions, once a week, for 1x10^5~1x10^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time
105408|NCT03362606|Biological|OC-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg via IV, abdominal cavity or tumor injection each time
105409|NCT03362593|Drug|MEDI7219|Experimental Drug
105410|NCT03362593|Drug|Placebo|Placebo
105411|NCT03362593|Drug|Formulation without Active Drug|Formulation without Active Drug
105412|NCT03362580|Device|Slit lamp examination|The slit lamp is an instrument consisting of a high-intensity light source that can be focused to shine a thin sheet of light into the eye.Examination performed without pupil dilatation.
105413|NCT03362580|Device|Undilated 7-field color fundus photography|Undilated 7-field color fundus photography with Cobra fundus camera. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp. Two ophthalmologists will assess fundus photos and OCT (Spectral domain optical coherence tomography) frames, to determine whether or not an ERM is present.
105633|NCT03360760|Drug|Ifosfamide|12g/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
105414|NCT03362580|Device|Color scan|Multicolor photo. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.
105415|NCT03362580|Device|Spectral domain optical coherence tomography|Spectral domain optical coherence tomography (OCT) with Heidelberg Retina Tomography device. The examination will be done without pupil dilatation; but in case of very small pupils one drop of tropicamide will be instilled, after anterior segment observation with the slit lamp.Two ophthalmologists will assess fundus photos and OCT frames, to determine whether or not an ERM is present.
105416|NCT03362567|Other|Sustained Natural Apophyseal Glides|Subjects in SNAGS group were treated with sustained natural apophyseal glides, twice weekly for six weeks
105417|NCT03362567|Other|Mechanical Cervical Traction|subjects in MCT received mechanical cervical traction, for 15 minutes each session twice in a week for six weeks
105418|NCT03362554|Behavioral|Controlled diet and exercise.|"The intervention will involve 3 weeks of a diet and exercise program designed to cause a net energy decrease of 7000 kcal/week compared to habitual behaviour. This will be achieved through:~Five exercise sessions per week at 70% VO2 max, using 400 kcal per session.~Reduction of their standard diet by 5000 kcal per week~Before and after this intervention period participants will take part in a trial day which includes measurement of body composition (using DEXA) and blood sugar control (oral glucose tolerance test). Samples of blood, adipose, skeletal muscle and faeces will also be taken."
105419|NCT03362541|Behavioral|MS INFoRm|MS INFoRm incorporates principles of self-management and adult learning theory. The contents address the sources of fatigue, ways of monitoring fatigue, and strategies to reduce fatigue.
105420|NCT03362541|Behavioral|Usual Care Control Group|The usual care webpage will contain content from widely available resources about MS fatigue.
105421|NCT03362528|Device|WM3.4NR|Investigational Medical Device collecting spectral raman data from tissue.
105422|NCT03362515|Drug|Furosemide|furosemide
105423|NCT03362515|Drug|Placebo|placebo
105424|NCT03362502|Genetic|PF-06939926|"Recombinant adeno-associated virus, serotype 9 (AAV9) carrying a truncated human dystrophin gene (mini-dystrophin) under the control of a human muscle specific promoter.~Subjects will receive a single intravenous infusion of one of 2 dose levels."
105425|NCT03362489|Procedure|IVF / IVF-ICSI|"In the IVF arm, oocyte retrieval is performed 36 hours after the HCG injection, in the operating room, under transvaginal ultrasound guidance, under local or general anesthesia. The procedure lasts about 20 minutes and the patients are discharged on the same day. The oocytes retrieved from the follicles are transported immediately to the lab for fertilization with the partner's sperm. Fertilization is done either via conventional IVF, or via ICSI, depending on the indication. Embryos are later transferred into the uterus on day 3 or day 5, under ultrasound guidance, in the outpatient department."
105426|NCT03362489|Procedure|IUI|"In the conversion to IUI arm, IUI is performed 24 to 36 hours after ovulation trigger. The partner provides the sperm on site on the morning of the insemination, which is performed in the outpatient department."
105427|NCT03362476|Behavioral|Computer-based alcohol reduction intervention|Brief computer-based version of cognitive behavioral therapy (CBT) used in conjunction with standard clinical care for current substance users. Modules and follow up assignments focus on key concepts in substance use, including cravings, problem solving and decision making skills. The multimedia presentation, based on elementary level computer learning games, requires no previous experience with computers.The intervention was adapted to be linguistically, gender- and HIV/HCV-appropriate for Russian women living with HIV/HCV.
105428|NCT03362476|Behavioral|Standard-of-care|Routine counseling to avoid alcohol and drugs.
105429|NCT03362463|Other|Non-Interventional Study|Non-Interventional Study
105430|NCT03362450|Other|Fetal ultrasound during the second or third trimester/ Postnatal surgery / Post mortem examination|Fetal ultrasound during the second or third trimester Postnatal surgery Post mortem examination
105431|NCT03362437|Drug|BMS-986177|Form A
105432|NCT03362437|Drug|BMS-986177|Form B
105433|NCT03362424|Biological|Mesenchymal stem cell|Mesenchymal stem cells applies at the end of rotator cuff repair in de active group
105434|NCT03362424|Procedure|Rotator cuff repair|Rotator cuff repair
105435|NCT03362411|Drug|BMS-986205|Single 100 mg dose on Day 1 and Day 15
105436|NCT03362398|Drug|Omarigliptin 25 mg|Once weekly new anti-diabetic drug approved only in Japan
105437|NCT03362398|Drug|Trelagliptin 100 mg|Once weekly new anti-diabetic drug approved only in Japan
105438|NCT03362385|Other|Patients with OSA based on sleep study|Polysomnography or Polygraphy
105439|NCT03362385|Other|Patients without OSA based on sleep study|Polysomnography or Polygraphy
105440|NCT03362372|Behavioral|Mediterranean diet counseling|"The participants of the intervention CAP will enter into an educational program to increase adherence to the DiMet that will integrate three operational components:~Explain the particularities of DiMet and the benefits of its monitoring. It will be an individual visit of 25-30 minutes (V1) where the study variables will be collected and the medical tests will be performed and repeated annually for two years (V3 and V5).~Clarify the doubts of the DiMet monitoring and the advice received. It will be a telephone visit to reinforce the intervention, with annual frequency, for two years (V2 and V4).~Report on DiMet's own foods, cooking habits, adapted recipes and other related topics. It will be for access to an ad hoc designed nutrition blog."
105441|NCT03362359|Drug|Ga-68-PSMA-11|Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
105442|NCT03362346|Device|intracranial pressure monitoring|The patients may have either intracranial pressure (ICP) monitor insertion or external ventricular drainage that can be used as ICP monitor.
105443|NCT03362333|Other|Exercise|Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular stabilizer muscles.
105444|NCT03362333|Other|Pain neuroscience education|Pain neuroscience education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.
105445|NCT03362320|Procedure|double layer fixation|
105447|NCT03362307|Device|Low-Level Laser and Light-Emitting Diodes|Combination of Low-Level Laser and Light-Emitting Diodes were used after dental implant placement for enhancement of stability
105448|NCT03362307|Device|Dental implant placement|A dental implant with 4.8X 10 mm (Zimmer, USA) size was placed at the posterior of the mandible
105449|NCT03362294|Drug|GA Depot 40mg once monthly|Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
105450|NCT03362281|Drug|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
105451|NCT03362281|Drug|Omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
105452|NCT03362281|Drug|Ilaprazole tablet|Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
105453|NCT03362281|Drug|amoxicillin and clarithromycin|The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
105454|NCT03362268|Drug|Ilaprazole|10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling. Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
105455|NCT03362268|Drug|omeprazole|40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min,Since 4th day, those patients were changed to take oral omeprazole tablets 20mg each day till 30th day
105456|NCT03362255|Other|thoracic epidural catheterization|thoracic epidural catheterization with different speed of injection
105457|NCT03362242|Drug|ARO-AAT Injection|Single or multiple doses of ARO-AAT by subcutaneous (sc) injections
105458|NCT03362242|Other|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
105459|NCT03362229|Procedure|Fixation|A well reduced medial malleolus fracture will undergo internal fixation, guided by the surgeon's skill and expertise
105460|NCT03362229|Procedure|Non-fixation|A well reduced medial malleolus fracture will be left without fixation
105461|NCT03362216|Drug|Compound Methyl Salicylate Liniment|Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
105462|NCT03362216|Drug|Diclofenac Sodium Liniment|Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
105463|NCT03362203|Other|Patients with chronic neck pain|Patients,aged 21-80 years, must have experienced neck pain for at least 3 months and have reported a minimal pain level of 30 (pain threshold) on the 0-100 pain numerical rating scale (NRS) in the last 7 days.
105464|NCT03362203|Other|Subjects without chronic neck pain|Subjects,aged 21-80 years, must not have presented episodes of chronic neck pain for more than 7 days in the last 12 months.
105465|NCT03362190|Drug|Zimura|Zimura in combination with Lucentis
105466|NCT03362190|Drug|Lucentis|Zimura in combination with Lucentis
105467|NCT03362177|Biological|Romiplostim|This study is designed to study Romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of gastrointestinal/colorectal cancer.
105468|NCT03362177|Other|Placebo|Placebo Comparator
105469|NCT03362151|Other|Regular pasta|Regular pasta (Approximately 42 grams carbohydrate per meal)
105470|NCT03362151|Other|High protein pasta|High protein pasta (Approximately 38 grams carbohydrate per meal)
105471|NCT03362151|Other|White rice|White rice (Approximately 43 grams carbohydrate per meal)
105472|NCT03362138|Device|dermoscopy|Solely after the dermatologist has decided to biopsy a lesion and sent the patient to biopsy, a dermoscopic image is captured by a camera attached to a dermoscope.
105473|NCT03362099|Drug|Varenicline Tartrate or bupropion|the drug treatment will be chosen related to the polymorphism. If the polymorphism is favorable to varenicline the patient will receive varenicline, If it is favorable to bupropion the patient will receive bupropion, if not favorable to varenicline and bupropion the patient will receive bupropion + varenicline. If the patient has both favorable polymorphisms he will receive bupropion. Bupropiona dosage 150 mg once a day seven days, after twice a day until complete week twelve. Varenicline dosage 0,5 mg once a day for 3 days, after this 0,5 mg twice a day until seven day .At day eight 1 mg twice a day until complete week twelve.
105474|NCT03362073|Drug|Ketamine|"Application of ketamine using continuous intravenous infusion method during 5 days~Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~Dose schedule: 0.05mg/kg/hr -> 0.10mg/kg/hr -> … -> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)"
105475|NCT03362060|Drug|Pembrolizumab|Pembrolizumab is a monoclonal antibody checkpoint inhibitor that blocks a protein in T-cells cells called PD-1, which then allows these cells and other parts of the immune system to attack tumors
105476|NCT03362060|Biological|PVX-410|PVX-410 is a type of vaccine composed of 4 9-amino acid peptides that may help the immune system stimulate immunity against cancer cells
105477|NCT03362047|Drug|Riciguat Group|Patients will be administered 12 weeks Riciguat
105478|NCT03362047|Drug|Macitentan Group|Patients will be administered 12 weeks Macitentan
105479|NCT03362034|Device|double transfer trays|double trays one soft and one hard
105480|NCT03362034|Device|single transfer tray|single soft tray
105481|NCT03362021|Procedure|transvaginal oocyte retrieval|sedation for oocyte retrieval
105482|NCT03362008|Drug|Zeropix|administration of Zeropix
105483|NCT03362008|Drug|Champix®|administration of Champix®
105484|NCT03361995|Device|Cooling Procedure using the ZOLL Proteus IVTM System|Cooling Procedure with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
105485|NCT03361995|Device|PCI Only|Standard of Care for PCI
105486|NCT03361982|Other|Slow Freezing and Thawing|half of the surgically obtained testicular sperm will be frozen for 30 minutes and subsequently thawed prior to performing ICSI
105487|NCT03361969|Drug|Estetrol|estetrol formulated in tablets
105488|NCT03361969|Drug|Placebo Oral Tablet|placebo tablets
105489|NCT03361956|Drug|JNJ-56136379|Participants will receive JNJ-56136379 tablet orally.
105490|NCT03361956|Drug|Placebo|Participants will receive matching placebo tablet orally.
105491|NCT03361956|Drug|NA (ETV or TDF)|Participants will receive NA (ETV or TDF) tablet orally as per approved label.
105634|NCT03360760|Procedure|definitive surgery|Including limb-sparing procedure and amputation
105492|NCT03361930|Device|Ankle-foot orthosis|"Two custom ankle-foot orthoses for the involved lower leg; cast, rectified and fitted by same certified orthotist to reduce clinician variability.~The cast is rectified according to the specifications of Hylton (1987) to produce tone-reducing features in the foot plate; the tone-reducing ankle-foot orthosis is manufactured on this cast. The orthotist then remodels the cast with a flat foot plate; the plain ankle-foot orthosis is then manufactured."
105493|NCT03361917|Device|Endocuff Vision|Subjects that are randomized to undergo their colonoscopy procedure with the Endocuff Vision device will have the device placed on the colonoscope that will be used during their procedure.
105494|NCT03361904|Procedure|Colonoscopy|Total colonoscopy : All consecutive patients who were scheduled for colonoscopy were included. Exclusion criteria were: patients scheduled for partial colonoscopy, interventional colonoscopy (for stent insertion, stenosis dilation).
105495|NCT03361891|Behavioral|WalkMORE Group|Hospitalized Internal Medicine patients will walk with trained volunteer coaches twice daily until hospital discharge
105496|NCT03361878|Drug|Metformin Hydrochloride|Single dose of 500mg oral metformin
105497|NCT03361865|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
105498|NCT03361865|Drug|Epacadostat|Epacadostat administered orally twice daily.
105499|NCT03361865|Drug|Placebo|Matching placebo administered orally twice daily.
105500|NCT03361852|Drug|Rituximab|Rituximab is classified as a monoclonal antibody. It works by targeting the CD20 antigen on normal and malignant B-cells. Then the body's natural immune defenses are recruited to attack and kill the marked B-cells
105501|NCT03361852|Biological|Neo Vax|"Neo Vax is an experimental viral mimic and an activator of immunity."
105502|NCT03361839|Diagnostic Test|endometrial biopsy|endometrial biopsy for genetic study of endometrial receptivity
105503|NCT03361826|Device|MagPro MST with Cool TwinCoil|MST treatments will be administered using the MagPro MST with Cool TwinCoil. The investigators will evaluate the effectiveness of MST for reducing suicidality and depressive symptoms in an open-label clinical trial of up to 15 treatment sessions. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
105504|NCT03361826|Behavioral|DBT|Dialectical behavior therapy (DBT) is a specific type of cognitive-behavioral psychotherapy developed to help better treat borderline personality disorder. Moderate-to-highly suicidal patients with BPD beginning dialectical behavioural therapy (DBT) will be recruited using a case-control design, comparing individuals receiving MST and DBT with matched patient control group receiving DBT alone.
105505|NCT03361813|Other|trans-cutaneous ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a transcutaneous route
105506|NCT03361813|Other|trans-oral ultrasound guided peritonsillar infiltration|Preoperative peritonsillar infiltration of bupivacine in tonsillectomy surgery by using the ultrasound through a trans-oral route
105507|NCT03361800|Drug|Entinostat|oral drug, 5mg tablet given once weekly x 2 doses
105508|NCT03361787|Behavioral|"Parentship- a multi dimensional intervention program to improve parental resilience"|"Parentship is a multi dimensional intervention program to improve parental resilience and adolescent participation using the OPC model."
105509|NCT03361774|Drug|Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).|"Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to."
105510|NCT03361774|Drug|Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).|Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
105511|NCT03361761|Other|Health education program|formalized/official Health education program
105512|NCT03361761|Other|Health education program|non formalized/official Health education program
105513|NCT03361748|Biological|bb2121|: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
105514|NCT03361735|Drug|Leuprolide Acetate|Intramuscular or subcutaneous injection
105515|NCT03361735|Drug|Goserelin Acetate|Subcutaneous injection
105516|NCT03361735|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
105517|NCT03361735|Radiation|Radium Ra 223 Dichloride|Given IV
105518|NCT03361735|Other|Laboratory Biomarker Analysis|Correlative studies
105519|NCT03361735|Drug|Degarelix|Subcutaneous injection
105520|NCT03361709|Drug|Dexamethasone|Dexamethasone will be injected intracamerally at the conclusion of Phacoemulsification
105521|NCT03361709|Drug|Saline Solutions, Intraocular|Only saline will be injected intracamerally at conclusion of Phacoemulsification
105522|NCT03361696|Other|Help to use the Interface System of Communication and Control of the Environment|the occupational therapist and the ergonomics engineers at the rate of 4 sessions per patient for periods of 2 to 3 hours help patient to use use the Interface System of Communication and Control of the Environment
105523|NCT03361683|Device|High-flow nasal oxygen|Randomized patients will receive oxygen through a high nasal flow device capable of delivering humidified, heated air at an output rate of 40 L/min
105524|NCT03361683|Device|Venturi mask|Randomized patients will receive oxygen through a Venturi mask at an air flow of 15 L/min
105525|NCT03361670|Other|Observational Study|
105526|NCT03361657|Device|IAP 8mmHg|The surgical team will perform a laparoscopy using a Hasson technique for the umbilical corkscrew port insertion (a three-port approach), 5-mm instruments. Insufflation pressures will be set at 8 mmHg and continuously measured using the GS 1002 402 Insufflator (ConMed Linvatec, Largo, FL, USA).
105635|NCT03360760|Other|pre surgical chemotherapy|chemotherapy that given before definitive surgery
105636|NCT03360747|Drug|AKCEA-ANGPTL3-LRX|Single open-label cohort
105527|NCT03361657|Device|IAP 10mmHg|The surgical team will perform a laparoscopy using a Hasson technique for the umbilical corkscrew port insertion (a three-port approach), 5-mm instruments. Insufflation pressures will be set at 10 mmHg and continuously measured using the GS 1002 402 Insufflator (ConMed Linvatec, Largo, FL, USA).
105528|NCT03361657|Device|IAP 12 mmHg|The surgical team will perform a laparoscopy using a Hasson technique for the umbilical corkscrew port insertion (a three-port approach), 5-mm instruments. Insufflation pressures will be set at 12 mmHg and continuously measured using the GS 1002 402 Insufflator (ConMed Linvatec, Largo, FL, USA).
105529|NCT03361644|Behavioral|High-Intensity Interval Training|Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
105530|NCT03361644|Behavioral|Moderate-Intensity Continuous Training|Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
105531|NCT03361631|Drug|Autologous Bone Marrow derived Mesenchymal Stem Cells|Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination & Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores & Pharmaco-Doppler
105532|NCT03361618|Dietary Supplement|Zinc Sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
105533|NCT03361605|Drug|Propofol|Propofol administration
105534|NCT03361592|Procedure|Spinal Manipulative Therapy|Lumbar (SMT) was performed using Diversified techniques, aiming to correct vertebral dysfunctional lumbar segments. Participants were asked to lay down prone on, to perform spinal motion palpation analysis was in order to evaluate the presence of dysfunction in vertebral segments of lumbar spine.
105535|NCT03361592|Procedure|SHAM|"The SHAM (pre-load positioning SMT) was performed with participant body positioning in the lateral position, as the SMT intervention. The doctor followed the participant through the same position of (SMT) intervention, using the maintenance of set-up position, but no manipulative thrust was delivered. The therapist applied minimal pressure and slid their hands across the skin to mimic the manipulative trust. The position was maintained 30 seconds on each side, and none of force or researcher body weight were putted in this procedure, only minimal pressure common to stabilize the set up position of (SMT)."
105536|NCT03361579|Other|Education|c.p. intervention description
105537|NCT03361566|Behavioral|physical activity|3 different levels of physical activity
105538|NCT03361566|Behavioral|energy intake|4 different types of energy intake
105539|NCT03361540|Drug|ASP8302|ASP8302 will be administered orally.
105540|NCT03361540|Drug|Placebo|Placebo will be administered orally.
105541|NCT03361527|Other|binaural beamformer|Each study participant will use an Advacned Bionics Naida CI Q90 loaner processor during the course of the study, an Advanced Bionics MyPilot remote control and- if applicable- a SmartPhone. the processors will be programmed with SoundWave and BEPSnet.
105542|NCT03361514|Behavioral|Supported Protocolized Discontinuation (SPD)|Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
105543|NCT03361514|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
105544|NCT03361501|Drug|CaPre|4 x 1 g capsules administered orally once daily for 26 weeks
105545|NCT03361501|Drug|Placebo|4 x 1 g capsules administered orally once daily for 26 weeks
105546|NCT03361488|Other|Trained anesthesiogist|
105547|NCT03361475|Behavioral|SME App|"The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~Express gratitude to family members (sharing)~Deliver positive messages regularly (mind)~Record physical and other joyful activities (enjoyment)~Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)"
105548|NCT03361462|Behavioral|Joyful Adventure Day|"Participants will participate in two joyful adventure days with adventure games and a short talk on SME (Sharing, Mind, Enjoyment) focusing on positive thinking and understanding of adolescent mental health problem (in particular the anxiety disorders) and mental well-being; provide physical activity diary, such as Zero-time Exercise after 1st session of adventure day, and invite family members / peers to join the competition at the 2nd session."
105549|NCT03361449|Other|Flamingo exercise|Flamingo exercise
105550|NCT03361449|Other|training with kinesthetic ability trainer|training with kinesthetic ability trainer
105551|NCT03361436|Drug|Eribulin Mesylate|Given IV
105552|NCT03361436|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
105553|NCT03361436|Other|Laboratory Biomarker Analysis|Correlative studies
105554|NCT03361436|Procedure|Quality-of-Life Assessment|Ancillary studies
105555|NCT03361436|Other|Questionnaire Administration|Ancillary studies
105556|NCT03361436|Procedure|Therapeutic Conventional Surgery|Undergo surgery
105557|NCT03361423|Device|Nerivio Migra-1 active device|"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."
105558|NCT03361423|Device|Nerivio Migra-1 Sham device|The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
105559|NCT03361410|Dietary Supplement|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 12 months
105560|NCT03361410|Dietary Supplement|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 12 months
105561|NCT03361397|Drug|Lidocaine Hydrochloride|Lidocaine hydrochloride will be used via mask nebulizer before LMA insertion
105562|NCT03361397|Drug|Distilled Water|Distilled Water will be used via mask nebulizer before LMA insertion
105563|NCT03361384|Drug|Alcohol|
105564|NCT03361384|Other|Placebo (non-alcoholic beverage)|
105565|NCT03361371|Device|Battery operated nasal aspirator|Suctioning prior to every feed with battery operated nasal aspirator for three days in addition to the routine standard of care.
105566|NCT03361371|Device|Suction bulb|Suctioning prior to every feed with bulb nasal aspirator for three days in addition to the routine standard of care.
105567|NCT03361345|Drug|Tranexamic Acid|Topical tranexamic acid in cream form applied to dark spots on right side of face.
105568|NCT03361345|Drug|Vehicle|The Vehicle is going to be a cream without any active medication that will be applied as a control substance for the topical tranexamic acid cream, and will be applied to the contralateral side of the face.
105569|NCT03361332|Other|Behavioral and fMRI|Subjects and patients will perform temporal-judgment-tasks (considered an indirect measure of the sense of agency) in an event-related fMRI setting. In the first task, they will hear a sound either caused by a voluntary key press or by the passive displacement of the same finger by the experimenter. Following each trial, subjects will estimate the delay between the finger movement and the subsequent sound, which will be presented at variable latencies after the key press. There will be also control-trials characterized by the active or passive movement with a subsequent sound presented with a delay that excludes causality inferences.
105570|NCT03361319|Drug|Vargatef|small molecule triple kinase inhibitor
105571|NCT03361319|Drug|Abraxane|Paclitaxel formulated as albumin bound nanoparticles
105572|NCT03361319|Other|placebo|Placebo in place of Ninedanib
105573|NCT03361306|Drug|Elotuzumab|Experimental
105574|NCT03361293|Device|Active tDCS|Active Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (active mode)
105575|NCT03361293|Behavioral|Cognitive training|BrainHQ Computerized cognitive training
105576|NCT03361293|Device|Sham tDCS|Sham Transcranial Direct Current Stimulation (tDCS) administered with a Neuroelectrics StarStim Enobio cap system (sham mode)
105577|NCT03361280|Drug|Beta blocker|Beta blockers are administered as described in arms.
105578|NCT03361267|Diagnostic Test|Helicobacter pylori PCR test|Clarithromycin resistance (-) Triple therapy (rabeprazole 20 mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid) for 7 days Clarithromycin resistance (+) Bismuth containing quadruple therapy (rabeprazole 20 mg bid, metronidazole 500 mg tid, bismuth 300 mg qid, tetracycline 500mg qid) for 7 days
105579|NCT03361267|Diagnostic Test|CLO test|CLO test : negative --> drop out CLO test : postive --> bismuth containing quadruple therapy
105580|NCT03361254|Biological|cryopreservation|cryopreservation to every patient with an indication of ECP for acute or chronic GVHD in Nancy Hospital for 18 months
105581|NCT03361241|Other|No Physiotherapeutic Intervention|"Experimental group will perform a balance training program in a virtual environment (using a gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) without verbal/manual physiotherapeutic intervention.~Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided.~Then the patient will be invited to start the game, and in the two attempts of the training no manual or verbal assistance will be provided. Physiotherapist participation during training will be restricted to ensuring patient safety, providing motivational verbal stimuli, and replicating the feedback provided by the game at the end of each attempt."
105582|NCT03361241|Other|Physiotherapeutic Intervention|Control group will perform a balance training program in a virtual environment (gaming system with balance board device - eight games of Nintendo Wii Fit®, for 14 sessions) with verbal and manual physiotherapeutic intervention. Initially, instructions about the rules and strategies of how to play the game and control the avatar will be provided. Then the patient will be invited to start the game, and in the first attempt of the training physiotherapist will provide manual and verbal assistance, providing corrections on movement (avoiding compensatory movements). In the second attempt, no manual or verbal assistance will be provided (only ensuring patient safety, providing motivational verbal stimuli), allowing the patient to organize his or her performance.
105583|NCT03361228|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
105584|NCT03361228|Drug|Epacadostat|Epacadostat at the protocol-defined dose administered orally twice daily.
105585|NCT03361228|Drug|Pembrolizumab|Pembrolizumab at the protocol-defined dose administered intravenously every 3 weeks.
105586|NCT03361202|Other|blood sampling|"atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up~control group:before coronary angiography and at hospital discharge."
105587|NCT03361189|Device|Closed loop stimulation|Closed loop stimulation is a physiologic, rate-adaptive pacing algorithm.
105588|NCT03361176|Drug|Injectable sodium deoxycholate|Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
105589|NCT03361176|Combination Product|Injectable sodium deoxycholate with Triamcinolone acetate|Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
105590|NCT03361163|Biological|emm75 Streptococcus pyogenes (GAS M75, strain 611024)|Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
105591|NCT03361150|Procedure|HIT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. HIT alternates a series of high-intensity bouts with relief period. MCT is continuous exercise with a constant intensity below anaerobic threshold.
105592|NCT03361150|Procedure|MCT|Both exercise protocol will be personalized, 3 times per week, 40-min exercise. MCT is continuous exercise with a constant intensity below anaerobic threshold.
105593|NCT03361137|Drug|Emicizumab|Emicizumab via SC injection at a loading dose 3 mg/kg once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly, or by any other approved maintenance regimen, as long as the participant continues to derive sufficient benefit.
105594|NCT03361124|Drug|Oxytocin|Administration of additional 20 mU Oxytocin
105595|NCT03361098|Drug|Dapagliflozin 10mg|Dapagliflozin 10mg oral tablet once daily
105596|NCT03361098|Drug|Exenatide|Exenatide 5 microgram b.i.d. week 1-4 Exenatide 10 microgram b.i.d. week 5-16
105597|NCT03361098|Other|placebo exenatide|placebo b.i.d. exenatide
105598|NCT03361098|Other|placebo dapagliflozin|placebo tablets dapagliflozin
105599|NCT03361085|Procedure|nvHAP Prevention Bundle|oral care, (early) mobilization, diagnosis and treatment of dysphagia, respiratory physiotherapy, stop Proton pump Inhibitors (PPI) if reasonable
105600|NCT03361072|Dietary Supplement|Oral immunotherapy|Milk, peanut or egg oral immunotherapy
105601|NCT03361046|Device|Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)|Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses
105602|NCT03361007|Device|Transcatheter Aortic Valve Implantation (TAVI)|Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
105603|NCT03360994|Other|WATChmAN Active Surveillance|WATChmAN Active Surveillance uses an electronic tool used to provide active surveillance care to testicular cancer patients. This virtual active surveillance care is delivered with an identical schedule to in-person care without the need to come into clinic.
105604|NCT03360994|Other|In-person Active Surveillance|In-person active surveillance is the current recommended management option for all Stage I testicular cancer patients at Princess Margaret. Patients are monitored clinically with imaging and blood work, and active treatment only begins if relapse occurs.
105605|NCT03360981|Drug|Incretins|after CABG, and epicardial tissue biopsy, patients will receive incretin therapy.
105606|NCT03360968|Procedure|Variable-PS|Variable-PS mode switched on for 1 hour
105607|NCT03360968|Procedure|SPN-CPAP/PS|SPN-CPAP/PS mode switched on for 1 hour
105608|NCT03360968|Procedure|Variable-PS|Variable-PS mode switched on for 1 hour
105609|NCT03360955|Procedure|Anesthesia|Different anesthesia technique will be compared to find out which one offers better outcome to perform ultrafast track extubation
105610|NCT03360942|Device|SCC DBS|Deep Brain Stimulator
105611|NCT03360929|Drug|AZD3759|Strength: 50mg/tablet, 100mg/tablet Dosage and administration: Twice daily administration under fasting state.
105612|NCT03360916|Drug|Lipitor 20Mg Tablet|One tablet by mouth every day for 12 weeks.
105613|NCT03360916|Drug|Lipitor 80Mg Tablet|One tablet by mouth every day for 12 weeks.
105614|NCT03360916|Drug|Placebo|One matching placebo tablet by mouth every day for 12 weeks.
105615|NCT03360916|Behavioral|Exercise Program|Exercise program of brisk walking and/or slow jogging on a treadmill for 90 minutes of exercise spread over 3 days during week 1, 150 minutes of exercise spread over 5 days during week 2, 225 minutes of exercise over 5 days during week 3 and for the rest of the study.
105616|NCT03360903|Drug|Placebo|"Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~Saline"
105617|NCT03360903|Drug|Caffeine|"Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~Caffeine citrate"
105618|NCT03360890|Drug|Pembrolizumab|Pembrolizumab will be administered via IV at 200mg every three weeks. Patients will receive pembrolizumab for about 2 years.
105619|NCT03360890|Drug|Docetaxel|Docetaxel will be administered via IV at 75mg/m2 every three weeks for 3 to 6 cycles.
105620|NCT03360877|Other|Health-care associated infection (HCAI)|Cleaning of the child with soap and water administered by the child's accompanying person in a structure or - a cleaning of the child with chlorhexidine gluconate administered by the child's accompanying person in the other structure
105621|NCT03360864|Other|Education program|Patient will participate to a education program.
105622|NCT03360851|Diagnostic Test|low-dose CT|see arm/group description
105623|NCT03360851|Diagnostic Test|PoC-PCR|see arm/group description
105624|NCT03360838|Other|CogCheck|Performance of study participants in the application
105625|NCT03360825|Device|TetraGraph|The TetraGraph is a dedicated neuromuscular stimulator / recorder intended to evoke, record, and analyze muscle action potentials during surgical procedures
105626|NCT03360812|Other|Online training resource|Please see information included in the description of the intervention group.
105627|NCT03360799|Other|Questionnaire Administration|Complete questionnaires
105628|NCT03360786|Other|Specific intervention|Series of progressive exercises targeted at balance, adaptation, dividing attention, head on neck control, visual + education on concussion identification and concussion education
105629|NCT03360786|Other|Control intervention|Education on concussion and concussion identification in addition to typical cardiovascular warmups
105630|NCT03360760|Drug|Doxorubicin|60mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
105631|NCT03360760|Drug|Cisplatin|100mg/m^2, in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
105632|NCT03360760|Drug|Methotrexate|High dose of methotrexate (8-12g/m^2), in the adjuvant chemotherapy regimen for osteosarcoma in PKUPH
105637|NCT03360734|Biological|Gatipotuzumab and Tomuzotuximab|Two monoclonal antibodies, Gatipotuzumab is anti-TAMUC1, Tomuzotuximab is anti-EGFR
105638|NCT03360721|Drug|Abiraterone Acetate 250 MG Oral Tablet [Zytiga]|1,000 mg (4 x 250 mg tablets each) orally each day on empty stomach. Treatment with Abiraterone continues through duration of participation.
105639|NCT03360721|Drug|Apalutamide|240 mg (4 x 60 mg tablets) orally each day with or without food. Apalutamide should be taken as close to the same time each day as possible.
105640|NCT03360721|Drug|Prednisone|5-mg oral, once daily (recommended to be taken with food). Treatment with prednisone will continue throughout the duration of participation.
105641|NCT03360708|Other|Laboratory Biomarker Analysis|Correlative studies
105642|NCT03360708|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
105643|NCT03360695|Other|Proactive Psychiatry Consultation (PPC)|Proactive Psychiatry Consultation and Case Management aims to improve communication among the patient, oncology team, and mental health clinicians, and increase engagement of family and community caregivers, which may help patients to receive the cancer care they need.
105644|NCT03360695|Other|Enhanced Usual Care (EUC)|At enrollment, study staff will inform the treating oncologist of the psychiatric diagnosis and will inform the oncologist, patient, and caregiver of available psychosocial services.
105645|NCT03360682|Drug|Lamivudine 300 MG|Lamivudine 300 MG/day (48 weeks)
105646|NCT03360682|Drug|Abacavir 600 MG|Abacavir 600 MG/day (48 weeks)
105647|NCT03360682|Drug|Dolutegravir 50 mg|Dolutegravir 50 MG/day (48 weeks)
105648|NCT03360682|Drug|Tenofovir Disoproxil 245Mg Tablet|Tenofovir 245 MG/day (48 weeks)
105649|NCT03360682|Drug|Emtricitabine 200 MG|Emtricitabine 200 MG/day (48 weeks)
105650|NCT03360669|Other|Sequence: Clinical/Research|Participants will be assigned to a sequence of: research visit first/clinical visit second.
105651|NCT03360669|Other|Sequence: Research/Clinical|Participants will be assigned to a sequence of: clinical visit first/research visit second.
105652|NCT03360656|Device|Transnasal Thermal Regulating Device|Placement of transnasal thermal regulating device to reduce temperature in febrile patients for a period of 8 to 24 hours
105653|NCT03360643|Diagnostic Test|Point-of-care ultrasound prior to radiology ultrasound|Point-of-care ultrasound performed by pediatric emergency medicine physicians prior to radiology-performed ultrasound
105654|NCT03360643|Diagnostic Test|Radiology-performed ultrasound|Ultrasound performed an ultrasound technician and/or radiologist, and interpreted by a radiologist
105655|NCT03360630|Biological|Anti-PD-1 plus DC-CIK|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal. DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible.
105656|NCT03360630|Biological|Anti-PD-1 alone|Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
105657|NCT03360617|Device|Syringe IV Push over 2-3 minutes|IV antibiotics will be administered by Syringe IV Push over 2-3 minutes
105658|NCT03360617|Device|Piggyback over 30 minutes|IV antibiotics will be administered by IV Piggyback over 30 minutes.
105659|NCT03360604|Dietary Supplement|Low Glycaemic Diet|This intervention is a diet consisting of a Low GI breakfast, lunch and snack meal.
105660|NCT03360604|Dietary Supplement|High Glycaemic Diet|This intervention is a diet consisting of a High GI breakfast, lunch and snack meal.
105661|NCT03360591|Device|Physiologically-guided strategy|"The Angiographically-guided strategy is that of aiming the most complete degree of revascularization based on angiographic evaluation (stenting all coronary stenosis of major branches >2.5mm, with a % coronary stenosis>50% as evaluated by visual estimation.~The Physiologically-guided strategy is that of treating only lesions with FFR ≤0.80, and leaving on optimal medical treatment lesions with FFR >0.80. The iFR values will be recorded in all patients, and verified in the core laboratory to allow a post-hoc analysis correlating the 0.80 FFR cut-off with different iFR cut-off values, and using the same study end-points.~Particular attention will be dedicated to the eventual occurrence of clinical events in patients deferred on the bases of FFR values >0.80 that show a discrepancy with positive (<0.89) iFR values to investigate the reliability of the FFR in the aortic stenosis setting. Both groups will receive the same TAVI strategy and optimal medical therapy"
105662|NCT03360578|Device|Zephyr BioPatch|A physiological Monitoring Device
105663|NCT03360552|Other|Multidimensional fragility index questionnaire RAI-Home Care|Questionnaire for assessing deficits in Alzheimer's disease
105664|NCT03360552|Other|Usual care|Usual clinical evaluation
105665|NCT03360539|Behavioral|Nurse-Family Partnership|
105666|NCT03360526|Device|PICSI|Semen processing is done by double layer density gradient method followed by adding Sperm to the dot of hyaluronan on the PICSI dish, within minutes the bound sperm are attached by their acrosome to the surface of the dot. (Selecting an individual bound sperm with enhanced genetic and developmental integrity ensures that the sperm selected is the optimal sperm from the sample for oocyte injection.
105667|NCT03360526|Procedure|TESA|"Patients will undergo TESA which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure then examine the sample for presence of motile~sperms followed by sample processing and oocyte injection."
105668|NCT03360513|Other|general group|The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
105695|NCT03360318|Device|Removable elbow brace|Removable elbow brace
105783|NCT03359616|Procedure|Laparoscopic total mesorectal excision|Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
105936|NCT03358407|Drug|Placebo|Placebo oral capsules matching GSK2983559 will be available for subjects.
105669|NCT03360500|Other|EXERCISE PROTOCOL + CRYOTHERAPY|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Cryotherapy: Crushed ice inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field."
105670|NCT03360500|Other|EXERCISE PROTOCOL|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises."
105671|NCT03360500|Other|EXERCISE PROTOCOL + PLACEBO|"Protocol: The therapeutic exercise protocol was designed according to the recommendations and guidelines of evidence-based practices and specific randomized clinical trials of physical exercise intervention for Knee osteoarthritis.~The suggested parameters for an adequate prescription of physical exercises include the type, application method, intensity, duration, minimum number of sessions and frequency of exercises.~Placebo: Sand inside two plastic bags. The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sandbags, they will be fixed with an elastic bandage (compression). All the knee surface will be covered with a moistened operative field."
105672|NCT03360487|Radiation|Photobiomodulation in the sublingual region|In the group submitted to sublingual irradiation, disposable plastic wrap will cover the application pen for the purposes of hygiene, and irradiation will take 10 minutes.
105673|NCT03360487|Radiation|Photobiomodulation in the spinal cord|Transcutaneous irradiation of the spinal cord will be performed on segments corresponding to the nerve roots of the lumbosacral plexus (T12-S5) and cervicothoracic plexus (C5-T1-2). Twenty points will be irradiated for 30 seconds (total treatment time: 10 minutes).
105674|NCT03360487|Radiation|Photobiomodulation in the radial artery|Intravascular laser irradiation will be applied to the skin in the region of the radial artery with a specific bracelet of the DMC laser Therapy EC model.
105675|NCT03360474|Behavioral|Delirium Screen|Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
105676|NCT03360461|Drug|EMI-137|EMI-137 - a fluorescent c-Met receptor targeted peptide
105677|NCT03360448|Drug|Ad5.hAC6|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
105678|NCT03360448|Drug|Placebo|1:1 randomization (Ad5.hAC6 : placebo) - intracoronary delivery
105679|NCT03360435|Dietary Supplement|Patch MD MultiVitamin Plus patch|The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
105680|NCT03360422|Other|Survey|Respondents meeting inclusion criteria will be informed they were selected for the longer survey and continue to the survey. Upon completion, the survey will generate a study identification (ID) that respondents will provide to study staff with additional contact information via phone, text or email to be compensated
105681|NCT03360422|Other|Focus Group|After informed consent, participants will complete the web-based intervention component in development. Afterward, participants will be engaged by an experienced facilitator in a discussion of aspects of the intervention they liked and disliked and suggestions they have for enhancing its cultural appropriateness to young MSM.
105682|NCT03360422|Other|Usability study|After informed consent, participants will utilize the mobile intervention in development for 30 days to establish usability, acceptability and correct any functionality issues.
105683|NCT03360409|Procedure|ACD|Undertake anterior cervical discectomy without fusion
105684|NCT03360409|Procedure|ACDF|anterior cervical discectomy with fusion
105685|NCT03360409|Procedure|ACDA|anterior cervical discectomy with arthroplasty
105686|NCT03360396|Device|Endobronchial Coils|Endobronchial Coil implants
105687|NCT03360383|Procedure|percutaneous vertebroplasty|Undertake Percutaneous vertebroplasty with polymethylmetacrylate bone cement.
105688|NCT03360383|Procedure|conservative treatment|complete on bed with prevention of complications
105689|NCT03360370|Other|Ages & Stages Questionnaires, Third Edition in French (ASQ-3™)|"This questionnaire screens 5 neurodevelopmental areas (communication, gross motor, fine motor, problem solving and personal-social); 30 items per questionnaire about the child's abilities are evaluated.~It takes about 15-20 minutes. Data are collecting and a scoring by a professional is provided. Follow-up action is taken for children at risk. Medical and surgical history is also collected to detect risk factors for neurodevelopmental disorders among neonatal data, characteristics of congenital heart disease and first surgery, and other comorbidities."
105690|NCT03360357|Procedure|Guided drills|"These residents will perform 5 set of exercises:~Needle Dance (Learning to manipulate the suture)~Loopy Loop (Learning to place needle through a loop)~Slalom Course (Passing the needle and suture through 5 rings right handed and left handed)~Dense Matter (Passing the needle through dense material without losing control of the needle)~Respect for tissue (Passing the needle through flimsy material without tearing)"
105691|NCT03360344|Device|Kinesio 12 inch Tape|Kinesio Tape approximately 12-inch strip will be applied to the dorsal surface of the forearm of the affected side for three-day increments over three weeks of the study.
105692|NCT03360344|Device|Kinesio 4 inch Tape|Kinesio Tape for the control group will be a 4 inch Kinesio Tape applied to the scapular spine for three day increments over three weeks of the study.
105693|NCT03360344|Device|Cock up Splint and Lumbrical exercises|A general cock-up splint will be supplied, fitted, and checked on each of the four return visits by the researchers. Lumbrical exercises are also used and consist of active joint ranges for the wrist and hand. The exercises will be demonstrated by the researchers for 3-sets of 10 times each, daily, to be recorded in a log by the participants.
105694|NCT03360318|Device|elbow cast|elbow cast
105696|NCT03360305|Behavioral|GAPcare intervention|Subjects will receive PT and pharmacist evaluation. PT will help determine whether subject may benefit from doing exercises to improve strength or balance. PT may also supply subject with an assist device. A pharmacist will ask patient about any medication they are taking and will make recommendations on how their medication could be changed to prevent falls. Pharmacists will communicate this information to subject's doctors. Subjects will receive a fall calendar for home, where they will record any falls they have after their discharge from the ED. They will receive a phone call at home asking about any recent falls and health care interactions. Study personnel will call subjects every 2 weeks for 6 months. Subjects may receive a referral for outpatient or home-based physical and occupational therapy at the end of the visit.
105697|NCT03360292|Other|Higher target range|Intervention is using a higher oxygen saturation target range than in routine practice
105698|NCT03360279|Device|Regular balloon|Randomization: to use regular balloon to treat stent graft restenosis
105699|NCT03360279|Device|DCB (paclitaxel-coated balloon)|Randomization: to use DCB (paclitaxel-coated balloon, Ranger, Boston-Scientific) to treat stent graft restenosis. The paclitaxel dose is 2 ug/mm2 delivered with the Ranger drug-coated balloon.
105700|NCT03360266|Combination Product|Sodium Fluoride with CPP-ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
105701|NCT03360266|Combination Product|sodium fluoride with ACP varnish|for children with ECC, this varnish effectively remineralizes the white spot lesion
105702|NCT03360266|Drug|5% Sodium Fluoride Varnish|ffor children with ECC, this varnish effectively remineralizes the white spot lesion
105703|NCT03360253|Dietary Supplement|L. reuteri DSM 17938 in drops|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
105704|NCT03360253|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
105705|NCT03360227|Device|implantation of cardiac devices|implantation of cardiac devices
105706|NCT03360214|Drug|Bupivacaine Hydrochloride|For active drug, 0.25% marcaine, will be used.
105707|NCT03360214|Other|Placebo Drug|For sham drug, 0.9% saline, will be used.
105708|NCT03360214|Device|Pulsed Electromagnetic Field (PEMF) Device|The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.
105709|NCT03360214|Other|Placebo Device|Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.
105710|NCT03360201|Behavioral|"Tuko Pamoja, We are Together in Kiswahili"|"Tuko Pamoja, We are Together in Kiswahili; This intervention, delivered by lay counselors and through existing community social structures, focuses on improving family relationships and mental health with content derived from evidence-based practices; these include solution-focused family therapy and cognitive behavioral strategies. It is components based, with modules delivered based on need. Tuko Pamoja includes a smart phone component to support psychoeducation components and data collection. The content and structure has been adapted in both content and implementation model based on formative research in this context."
105711|NCT03360175|Other|No intervention - observational study|No intervention - observational study
105712|NCT03360136|Behavioral|Multi-professional CBT-rehabilitation|"See Detailed description"
105713|NCT03360123|Drug|Midazolam Hydrochloride 2Mg/mL Syrup|Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.
105714|NCT03360123|Drug|Triazolam 0.125 MG|Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
105715|NCT03360110|Device|Phoebe test lens|Daily disposable contact lens
105716|NCT03360110|Device|stenfilcon A lens (control)|Daily disposable contact lens
105717|NCT03360097|Procedure|Frozen Embryo Transfer|Patient's embryos are cultured to day 6, vitrified and transferred in a cryo-synthetic cycle
105718|NCT03360084|Procedure|Percutaneous lung biopsy under CT guidance|Percutaneous lung biopsy under CT guidance
105719|NCT03360071|Drug|Allergen Immunotherapy Extract|Allergen Immunotherapy treatment mixture to be delivered subcutaneously
105720|NCT03360071|Drug|Allergen Immunotherapy Control|Allergen Immunotherapy Control Solution to be delivered subcutaneously
105721|NCT03360058|Behavioral|Small Talk Big Difference Immediate access training|Immediate access to 1 hour online training and supporting print materials for implementation in primary care practice
105722|NCT03360058|Behavioral|Small Talk Big Difference delayed access training|Delayed access (by 4 months) to 1 hour online training and supporting print materials for implementation in primary care practice
105723|NCT03360045|Drug|Tranexamic Acid|500mg tranexamic acid is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
105724|NCT03360045|Drug|Normal saline|5 cc normal saline is sprayed in the nose by atomizer spray, and then is applied nasal compression by manually.
105725|NCT03360045|Device|Merocel|Merocel packing is applied.
105726|NCT03360019|Device|Activlink insole|Dementia patients will wear the provided insole inserted into their own shoes. The insole will have a small electronic sensor that measures acceleration, foot force, and/or orientation.
105727|NCT03360019|Other|Activlink Phone Application|Smartphone tool used for monitoring location
105728|NCT03360006|Drug|ABBV-744|Tablet, oral
105729|NCT03359993|Procedure|Premedication of intubation|The umbilical vein is punctured to inject drugs efficiently. The access is simple, the umbilical vein is clearly visible, and a blood reflux can be found easily. We used the same equipment required for a peripheral venous injection: 24 gauge cannula, antisepsis, compress, and a syringe with the prepared anesthetic drugs. We report 5 cases of intubations in the delivery room using this method to administer the premedication.
105730|NCT03359980|Drug|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
105731|NCT03359967|Drug|Entresto tablet|Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
105732|NCT03359954|Radiation|Radiation Therapy|Undergo radiation therapy
105733|NCT03359954|Procedure|Therapeutic Conventional Surgery|Undergo breast surgery
106013|NCT03357718|Drug|Midazolam|0.5 mg/kg
105734|NCT03359941|Procedure|acupuncture|Acupuncture points: Examples of acupuncture points to be used include BL23 (Sinsu, bilateral), BL24(Gihaesu, bilateral), BL25(Daejangsu, bilateral), BL40(Wijung, bilateral), BL60(Gollyun, bilateral), BL65(Sokgol, bilateral), LI11(Gokji, bilateral), LI4(Hapgok, bilateral), ST36(Joksamni, bilateral), GB41(Jogimeup, bilateral), LR3(Taechung, bilateral). Electrical stimulation with alternating frequency of 2-100 Hz will be applied to the selected points (e.g., BL 23-25, bilateral). Treatments will be provided by qualified Korean traditional medicine doctors with more than 2 years of clinical experience.
105735|NCT03359928|Behavioral|Boxing|as already discussed
105736|NCT03359928|Behavioral|Stair stepping|as already discussed
105737|NCT03359928|Behavioral|Stair climbing|as already discussed
105738|NCT03359915|Behavioral|COPD Self-Management Plan|Patient education in use of a COPD self-management action plan supported by monthly visits from, and access to, a CHW who has been trained in the use of a COPD self-management action plan.
105739|NCT03359902|Device|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
105740|NCT03359902|Device|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
105741|NCT03359889|Drug|PraxbindTM|Drug
105742|NCT03359876|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily
105743|NCT03359876|Drug|Warfarin sodium|Individually adjusted dose
105744|NCT03359863|Drug|Pirfenidone|Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily)
105745|NCT03359850|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
105746|NCT03359837|Drug|INSULIN GLARGINE (HOE901)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
105747|NCT03359837|Drug|Insulin Glulisine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
105748|NCT03359837|Drug|Biphasic insulin aspart 30|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
105749|NCT03359837|Drug|Repaglinide|"Pharmaceutical form: tablet~Route of administration: oral administration"
105750|NCT03359837|Drug|Acarbose|"Pharmaceutical form: tablet~Route of administration: oral administration"
105751|NCT03359837|Drug|Metformin|"Pharmaceutical form: tablet or capsule~Route of administration: oral administration"
105752|NCT03359824|Other|Exercise|
105753|NCT03359811|Drug|Local Anesthetic Solution|A bolus or infusion of local anesthetic solution with or without the addition opioids given before surgical incision according to anesthesia provider's clinical judgment.
105754|NCT03359811|Drug|Bupivacaine HCl|30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
105755|NCT03359811|Drug|Liposomal Bupivacaine|65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
105756|NCT03359798|Behavioral|Narcotic counseling script|Script regarding post-cesarean section narcotic use
105757|NCT03359798|Behavioral|Post-partum depression counseling script|Study participants will be read a script of the same length, and much of the same wording as the experimental script. However, this script's content is focused on post-partum depression.
105758|NCT03359785|Drug|TAK-831 500 mg|TAK-831 Tablets.
105759|NCT03359785|Drug|TAK-831 50 mg|TAK-831 Tablets.
105760|NCT03359785|Drug|Matching Placebo|Matching Placebo Tablets.
105761|NCT03359772|Other|Kinesthetic Ability Trainer|Kinesthetic Ability Trainer
105762|NCT03359759|Other|Conected objects|"Every week, each patient report her symptoms and answer ten questions on the i-PAD. The connected watch reports the performance status (activtiy and time spent in bed or sitting), and the falls.~If nurses or doctors detect any problem, they ask the patient for a telemedicine to try to help her. During the same time, nurses or doctors send a message on a secure plateform to the local team (nurse, General Practitioner, and pharmacists) and they reserve a place for an hospitalization if necessary."
105763|NCT03359746|Drug|Grazoprevir/Elbasvir|Medication for treatment of patient
105764|NCT03359733|Drug|TAK-659|TAK-659 tablet.
105765|NCT03359720|Other|no intervention survey|survey
105766|NCT03359707|Other|survey|no intervention just survey
105767|NCT03359694|Drug|DT group|Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
105768|NCT03359694|Drug|ET group|Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
105769|NCT03359694|Drug|NX group|Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
105770|NCT03359681|Drug|Metformin Hydrochloride|metformin 500mg three times a day 20 days before colon cancer surgery and 10 days after.
105771|NCT03359681|Drug|Placebo oral capsule|placebo 500mg three times a day 20 days before colon cancer surgery and 10 days after.
105772|NCT03359668|Diagnostic Test|Use of IV contrast during head and neck CT|Use of IV contrast during head and neck CT
105773|NCT03359655|Drug|Misoprostol|Rectal administration 2 jours before the procedure
105774|NCT03359655|Drug|Hyoscine butyl bromide|Rectal administration 2 jours before the procedure
105775|NCT03359642|Other|blood sample|14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation
105776|NCT03359642|Other|stool samples|Study of the fecal microbiota
105777|NCT03359642|Other|food questionnaire|food questionnaire on the seven days before the collection
105778|NCT03359642|Other|colonoscopy|Only for patients with ulcerative colitis (in routine care)
105779|NCT03359642|Other|VOCs profile|Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
105780|NCT03359629|Device|Spectrophon Glucometry Monitor|Wearable smartwatch with integrated non-invasive glucose detection system
105781|NCT03359629|Device|YSI 2300 Stat Plus|Reference commercial glucometer
105782|NCT03359616|Procedure|Transanally curable surgical resection|Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
106014|NCT03357705|Procedure|alveolar ridge preservation with synthetic bone|after tooth extraction
105784|NCT03359603|Device|Electro-acupuncture|"Patients will be treated by use of 5 obligatory and 3 customized acupoints. Obligatory points (ST35, EX-LE5, LR8, GB33 and Ashi) will be used in all patients. Other 3 customized acupoints should be chosen by the physicians on the basis of traditional Chinese medicine diagnosis for acupuncture channels related to the individual pain area, with the intent of optimizing efficacy. ST34, ST36, ST32, ST40 and EX-LE2 will be used for pain at stomach meridian. GB31, GB36, GB34, GB39 and GB41 will be used for pain at gallbladder meridian. BL39, BL40, BL57 and BL60 will be used for pain at bladder meridian. LR7, SP9, SP10, KI10, SP4, SP6, LR3 and KI3 will be used for pain at three yin meridians of foot. Needles will be stimulated manually for 10 seconds to achieveDe Qi. Paired alligator clips will be attached transversely to the needle holders at LR8-GB33 and two other customized acupoints. Other needles will be manipulated for 10 seconds during the treatments."
105785|NCT03359590|Drug|Sitagliptin 100mg|The treatment consists of sitagliptin 100 mg/day or placebo taken together with a morning dose of metformin during two treatment periods. At the end of each treatment period a 54 hour inpatient period is performed. The duration of each treatment period is planned to be between 1 and 16 weeks. At the discretion of the investigator the treatment period may be increased up to a maximum of 24 weeks.
105786|NCT03359590|Other|Placebo arm|Placebo comparator
105787|NCT03359577|Dietary Supplement|Psorax35|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
105788|NCT03359577|Dietary Supplement|MCT oil|This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis. Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
105789|NCT03359564|Procedure|micro endoscopic discectomy|the patients receive micro endoscopic discectomy surgery therapy
105790|NCT03359538|Drug|Rapamycin|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
105791|NCT03359538|Drug|Placebo Oral Tablet|tablets containing Rapamycin/placebo will be administered based on body surface area and adjusted taking into consideration plasma rapamycin dosage
105792|NCT03359525|Drug|Tranexamic Acid|intravenous versus Intraarticular versus intravenous
105793|NCT03359512|Device|qCON monitor|supervision by qCON monitor of the depth of anesthesia
105794|NCT03359499|Drug|Bacillus clausii|Oral suspension administered BID
105795|NCT03359499|Drug|Trimebutine|One tablet of 200 mg of trimebutine administered BID
105796|NCT03359486|Behavioral|Group problem management plus|Low intensity group psychological intervention including stress management, behavioral activation, problem solving, and strengthening social support
105797|NCT03359486|Behavioral|Enhanced treatment as usual|Referral to primary care workers trained in mental health Gap Action Program Implementation Guide
105798|NCT03359473|Drug|GSK2881078|GSK2881078 will be available as capsules for oral administration. GSK2881078 will be administered once daily by the oral route at a dose of 1 mg and 2mg to post-menopausal female subjects and male subjects, respectively.
105799|NCT03359473|Drug|Matching Placebo|Subjects will be administered two capsules of GSK2881078 matching placebo once daily by the oral route.
105800|NCT03359460|Drug|Ibrutinib|Given PO
105801|NCT03359460|Drug|Lenalidomide|Given PO
105802|NCT03359447|Drug|Weekly Ferrous Sulfate|Drops
105803|NCT03359447|Drug|Daily Ferrous Sulfate|Drops
105804|NCT03359434|Device|Clearsight device (Edwards) around the finger|Continuous measurement of blood pressure with the Clearsight device (Edwards) around the finger, within 24 hours after reperfusion:
105805|NCT03359434|Device|Intermittent blood pressure measurements with cuff.|Standard method: 35 blood pressure measurements with cuff within 24 hours after reperfusion
105806|NCT03359408|Behavioral|Dementia Care Management (DCM)|"A specialised discharge management, based on Dementia Care Management (DCM; Thyrian et al. 2017, Eichler, Thyrian, Fredrich et al. 2014, Eichler, Thyrian, Dreier et al. 2014, Dreier et al. 2016, ) will be applied to subjects with cognitive impairment. Specifically qualified will conduct comprehensive data assessments during the hospital stay, assess recommendations at discharge and assess unmet needs at home. Supported by a a computerized Intervention Management (IMS) and in close cooperation with the discharging hospital, treating physicians and other care providers, they will develop, implement and monitor a treatment and care plan. Interventional home visits will take place at the participants homes."
105807|NCT03359395|Drug|Alfentanil|Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
105808|NCT03359395|Drug|Placebos|Administration of a equidose placebo during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
105809|NCT03359382|Other|Resistance or home exercise combined with eccentric exercise|"First year: Progressive resistance exercise (60-80% RM) combined with low intensity eccentric exercise (10%RM).~Second year: Progressive resistance exercise (60-80% RM) combined with progressive eccentric exercise (10-80% RM).~Third year:Home exercise combined with low intensity eccentric exercise (10% RM )"
105810|NCT03359369|Diagnostic Test|level of serum cholesterol and triglyceride|other
105811|NCT03359356|Drug|Dupilumab|A total of 24 doses
105812|NCT03359356|Drug|Placebos|A total of 24 doses
105813|NCT03359330|Other|Degradable Conduit Small Gap Tublization|Degradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury
105814|NCT03359317|Behavioral|jogging|Jogging as instructed for 1 year
105815|NCT03359291|Drug|Rosuvastatin|Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
105816|NCT03359291|Drug|Macitentan|Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16
105817|NCT03359278|Procedure|open reduction and internal fixation|The volar approach was used for open reduction and internal fixation of distal radius fractures
105818|NCT03359265|Device|underpants|
105819|NCT03359252|Procedure|non-stent assisted coiling|non-stent assisted coiling of unruptured intracranial aneurysm
105820|NCT03359252|Procedure|stent assisted coiling|stent assisted coiling of unruptured intracranial aneurysm
105821|NCT03359239|Drug|Atezolizumab|1200 mg administered by IV infusion every 3 weeks (21 [+/-2] days) for up to 12 months in the adjuvant setting and up to 24 months in the metastatic setting.
105822|NCT03359239|Biological|PGV001|"PGV001: up to ten total doses of PGV001with helper peptides. The product is prepared within the ISMMS . The product consists of two independent preparations of patient specific long peptides mixed with poly-ICLC.~A dose of PGV001 consists of the following:~Up to ten synthetic peptides - 100μg (0.01 mL, 10 mg/mL) per peptide. One tetanus helper peptide - 100μg (0.01 mL, 10 mg/mL)"
105823|NCT03359239|Drug|Poly ICLC|1.4 mg (0.7 mL, 2 mg/mL)
105824|NCT03359239|Drug|Normal saline|0.19 mL
105825|NCT03359226|Procedure|Submandibular gland biopsy|Needle biopsies of the right and left submandibular glands
105826|NCT03359213|Drug|JR-141|IV infusion (lyophilized powder), 1.0 mg/kg/week
105827|NCT03359213|Drug|JR-141|IV infusion (lyophilized powder), 2.0 mg/kg/week
105828|NCT03359213|Drug|JR-141|IV infusion (lyophilized powder), 4.0 mg/kg/week
105829|NCT03359187|Other|Normal saline with salt/Soda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
105830|NCT03359187|Other|Clinacanthus nutans|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
105831|NCT03359187|Other|Boesenbergia rotunda|Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
105832|NCT03359174|Drug|All-trans retinoic acid|Fixed low dose of ATRA 10 mg twice daily for 24 weeks.
105833|NCT03359161|Combination Product|sc2Wear Furosemide Infusor|Subcutaneous furosemide for the treatment of fluid overload
105834|NCT03359148|Device|Disposable ventilator system|
105835|NCT03359148|Device|Conventional reused ventilator system|
105836|NCT03359135|Other|Rehabilitation|Rehabilitation during 4 weeks
105837|NCT03359135|Device|Compression Garment|Rehabilitation associated to wearing CG during 4 weeks
105838|NCT03359096|Device|Therapeutic HGNS|Prior to enrollment in this study, the HGNS will have been implanted as part of clinical care, and a therapeutic voltage setting will have been determined via overnight sleep study The pulse generator, using technology from cardiac pacemakers, utilizes the signal from the pressure sensor for timing of stimulation to the tongue nerve. Patient will undergo activation of the implanted device one month post-operatively. A functional threshold (in volts) is obtained based on tongue motion during device stimulation. For the next month, the patient will have steadily increased stimulation strength by 0.1V every 2-3 nights within the preset range until the upper limit is reached.
105839|NCT03359096|Device|Subtherapeutic 'Sham' HGNS|"Sham threshold determination will be performed as follows. The patient will be in a reclined position with the mouth open while nasal breathing. Stimulation will be increased from 0.1V up by 0.1V until bulk tongue motion is detected without obvious protrusion. This process is repeated twice and the average value is used to determine sham-HGNS. The electrode configuration will remain consistent between the patient's therapeutic and sham thresholds"
105840|NCT03359083|Other|Correlation|Correlation between assesment parameters
105841|NCT03359070|Drug|Dapaconazole|Application of 1 gram on the lesion.
105842|NCT03359070|Drug|Miconazole Nitrate|Application of 1 gram on the lesion.
105843|NCT03359057|Drug|ethinyl estradiol + levonorgestrel + folic acid|One coated tablet of ethinyl estradiol + levonorgestrel + folic acid, 0.02 mg + 0.10 mg + 0.4 mg for 21 days in 3 cycles (12 weeks).
105844|NCT03359057|Drug|Folic Acid|One coated tablet of folic acid 0.4 mg for 7 days in 3 cycles (12 weeks).
105845|NCT03359031|Other|Patient education|This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
105846|NCT03359018|Drug|Apatinib|Every patients will received apatinib 250mg or 500mg orally daily according to their body surface area (BSA) until disease progression or intolerance to side effects.
105847|NCT03359018|Drug|SHR-1210|Every patients will received SHR-1210 3mg/kg (no more than 200mg) iv every 2 weeks until disease progression or intolerance to side effects.
105848|NCT03359005|Drug|Vincristine|vincristine 1.5mg/m2 iv D1,D8
105849|NCT03359005|Drug|Temozolomide|Temozolomide 100mg/m2/d iv on days 1-5.
105850|NCT03358966|Other|Doubly-labelled water technique|
105851|NCT03358966|Other|Resting Energy Expenditure|Resting energy expenditure represents the amount of calories required for a 24-hour period by the body during a non-active period.
105852|NCT03358953|Device|Electron Cigarette|Blended Tobacco flavour, 18mg/ml
105853|NCT03358953|Device|Nicotine Replacement Patch|NiQuitin 21mg
105854|NCT03358940|Other|urine collection|For patient with miscarriage complications or not, or threatened miscarriage there will be a urine collection the day of the inclusion. In case of hospitalization, another urine collection will be done between 12 and 18 hours after the inclusion. For patient coming for voluntary termination of pregnancy using misoprostol, a urine collection will be done the day of the inclusion and another ones 1, 4, 12 and 24 hours after the inclusion.
105855|NCT03358927|Behavioral|Immediate Fast-Track Care|Eligible for fast-track care at enrollment
105856|NCT03358927|Behavioral|Deferred Fast-Track Care|Eligible for fast-track care after 6 months on ART
105857|NCT03358914|Other|No intervention|Completion of surveys
105858|NCT03358901|Drug|YC-6|
105859|NCT03358901|Drug|Vehicle|
105860|NCT03358888|Drug|Multi-modal with as needed opioids|Multi-modal with as needed oxycodone and tramadol provided for break-through pain
105861|NCT03358888|Drug|Multi-modal with one week of opioids offered|Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
105862|NCT03358888|Drug|Standard of Care|This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
105863|NCT03358875|Drug|Intravenous injection BGB-A317|Anti-PD-1 monoclonal antibody
105864|NCT03358875|Drug|Intravenous injection Docetaxel|Antineoplastic, cytotoxic, taxane
105898|NCT03358667|Procedure|augmentation peri-implant soft tissue|the implant was cover with a 2 mm cover screw for a tent effect or with a dermal membrane after implant insertion
106015|NCT03357705|Procedure|alveolar ridge preservation with bovine collagen|after tooth extraction
105865|NCT03358862|Device|NaturalVue Multifocal Contact Lens|NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
105866|NCT03358849|Biological|Natural killer cell|Patients who received natural killer cell injection
105867|NCT03358810|Device|PES|The PES system is a two-part neurostimulation system. It is composed of a durable component called the Base Station and the single-use sterile disposable Phagenyx® Catheter. The Base Station acts as the user interface and provides the means to generate, optimize and monitor the delivery of electrical stimulation.
105868|NCT03358797|Other|Community-based intervention|presented by multiple professionals (nutritionists, exercise trainers, health coaches, and psychotherapists), this intervention will include Mediterranean diet education, social support, food tasting and cooking, goal setting, self-monitoring, emotion regulation, planning, conscious eating, leadership and lay leader training, initiative-taking, group dynamics, project design, community needs assessment, and project evaluation.
105869|NCT03358784|Procedure|Hemi-shoulder Arthroplasty|Hemi-shoulder Arthroplasty treating three or four-part fractures of proximal humerus
105870|NCT03358784|Procedure|PHILOS Plate|PHILOS plate treating three or four-part fractures of proximal humerus
105871|NCT03358771|Other|COPD discharge care bundle|As a part of RHSCN quality improvement initiative, the elements of the COPD discharge bundle were integrated into a standardized COPD admission order set and are being implemented province-wide. The discharging physician/team will complete the COPD bundle (with reminders facilitated by clinical decision support tools) prior to patient discharge. A copy of the bundle is retained in the patient's medical record, and another copy is sent to the patient's primary care provider detailing the components of the bundle that were completed prior to discharge, and those still needing to be addressed. The patient will also receive a patient-focused discharge checklist detailing discharge bundle items
105872|NCT03358771|Other|COPD discharge care bundle & coordinator|The coordinator will be health professional associated with a Primary Care Network, ED or AHS with access to patient information. Patients will be informed that care coordinator may contact them for follow up after discharge. At 48-72 hours after hospital/ED discharge and then at intervals to be determined, the care coordinator will contact the patient by phone. The care coordinator will identify specific needs or problems that patient may have encountered after discharge, which could potentially affect the successful transition from acute to community care setting. Specifically, the care coordinator will seek information on any follow up with family doctor visit, pulmonary rehabilitation and smoking cessation referrals
105873|NCT03358745|Other|Standard meal, bread/butter as starter|Reference lunch. Bread and butter are eaten during the first 15 min. Soup, cheese and salad are eaten within the following 15 min.
105874|NCT03358745|Other|Standard meal with soup as starter|Lunch meal in which soup is eaten during the first 15 min. Bread, butter, cheese and salad are eaten within the following 15 min.
105875|NCT03358745|Other|Standard meal with cheese as starter|Lunch meal in which cheese is eaten during the first 15 min. Bread, butter, soup and salad are eaten within the following 15 min.
105876|NCT03358745|Other|Standard meal with salad as starter|Lunch meal in which salad is eaten during the first 15 min. Bread, butter, soup and cheese are eaten within the following 15 min.
105877|NCT03358732|Device|endometrial navigation one day before the embyo transfer using IUI catheter ,|one day before the actual ET, the participants, in the study group, were taken into the operating room with a moderately full bladder at 10 am. The patient was placed in the lithotomy position and a sterile speculum was inserted into the vagina. The cervix was cleaned with sterile swabs and sterile water, and a mock transfer was performed using a soft catheter (Wallace Intrauterine Insemination Catheter; Sims Portex Ltd., Hythe, Kent, UK). The catheter has an outer sheet with memory , to aid insertion, and a soft inner catheter with atraumatic tip. Under ultrasound guidance, only the soft inner catheter was introduced beyond the internal cervical os till it was 0.5 cm from the fundus. It was, then, gently withdrawn out of the uterus, and the speculum was removed.
105878|NCT03358719|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intracutaneously
105879|NCT03358719|Drug|Decitabine|Given IV
105880|NCT03358719|Other|Laboratory Biomarker Analysis|Correlative studies
105881|NCT03358719|Biological|Nivolumab|Given IV
105882|NCT03358719|Drug|Poly ICLC|Given SC
105891|NCT03358693|Drug|Ustekinumab|Subject receives Ustekinumab open-label as per guidelines
105892|NCT03358693|Drug|Infliximab|Subject receives Infliximab open-label as per guidelines
105893|NCT03358693|Drug|Secukinumab|Subject receives Secukinumab open-label as per guidelines
105894|NCT03358693|Drug|Dupilumab|Subject receives Dupilumab open-label as per guidelines
105895|NCT03358693|Drug|Brodalumab|Subject receives Brodalumab open-label as per guidelines
105896|NCT03358693|Drug|Ixekizumab|Subject receives Ixekizumab open-label as per guidelines
105897|NCT03358680|Device|noninvasive analgesia measurement|noninvasive analgesia measurement using index of consciousness(IOC2)
105899|NCT03358654|Drug|mesenchymal stem cells from umbilical cord|inject mesenchymal stem cells from umbilical cord，and the patients will be followed up at 1, 2, 3, and 6 months after the injection.
105900|NCT03358641|Other|level of physical activity|According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
105901|NCT03358628|Other|Molecular Profiling & In Vivo drug testing in PDX|Molecular profiling of host tumour sample and PDX will be performed and analyzed by an expert panel. In vitro drug testing using organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo PDX drug testing results will be made, if available.
105902|NCT03358615|Procedure|cesarean section|assessment of the indications of cesarean section according to Robson criteria
105903|NCT03358602|Radiation|Radiotherapy|Radiotherapy with a dose of 66-70 Gy is used to manage the cervical lymph nodes
105904|NCT03358602|Procedure|Selective neck dissection|Selective neck dissection, defined as surgical clearance of the upper jugular (leveI II), midjugular (level III) and sometimes submandibular (level I) nodes, is used to manage the cervical lymph nodes
105905|NCT03358589|Diagnostic Test|FDG-PET/CT|Scans
105906|NCT03358576|Drug|Ertapenem|Antibiotic for complicated intra-abdominal infection
105907|NCT03358576|Drug|Sulopenem-Etzadroxil/Probenecid|Antibiotic for complicated intra-abdominal infection
105908|NCT03358576|Drug|Ciprofloxacin|Antibiotic for complicated intra-abdominal infection
105909|NCT03358576|Drug|Metronidazole|Antibiotic for complicated intra-abdominal infection
105910|NCT03358576|Drug|Amoxicillin-Clavulanate|Antibiotic for complicated intra-abdominal infection
105911|NCT03358576|Drug|Sulopenem|Antibiotic for complicated intra-abdominal infection
105912|NCT03358563|Drug|Docetaxel|Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
105913|NCT03358563|Drug|Degarelix|Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
105914|NCT03358563|Drug|Bicalutamide|The dose for bicalutamide tablets therapy in combination with an LHRH analog (in this study, degarelix) is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
105915|NCT03358550|Diagnostic Test|Accommodation Measurement|Accommodation was measured for different distances and light conditions.
105916|NCT03358537|Dietary Supplement|Clear Liquid Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
105917|NCT03358537|Dietary Supplement|Low-residue Diet|Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
105918|NCT03358524|Drug|Vitamin E 400 UNT|Vitamin-E capsule (alpha tocopherol) 400 IU (once per day)
105919|NCT03358524|Drug|Placebo oral capsule|sugar capsule manufactured to mimic vitamin E capsule once per day
105920|NCT03358511|Dietary Supplement|Probiotic|Primal Defense Ultra® Probiotic Formula is an over-the-counter probiotic that provides 15 billion colony forming units of 13 species of beneficial bacteria, including Saccharomyces boulardii, Lactobacillus plantarum, Bacillus subtilis, Bifidobacterium lactis, Bifidobacterium bifidum, Lactobacillus rhamnosus, Bifidobacterium breve, lactobacillus casei, Lactobacillus salivarius, Lactobacillus acidophilus, Lactobacillus brevis, Bifidobacterium longum, and Lactobacillus paracasei.
105921|NCT03358498|Other|The Medical Outcomes Short-Form 36-Item Health Survey (SF-36v2) It|"SF-36v2 is questionnaire comprising 36items measuring eight dimensions of general HRQOL: physical functioning 10 items, physical health problems 4 items, bodily pain 2 items, general health perceptions 5 items, vitality 4 items, social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health 5 items.~."
105922|NCT03358485|Drug|Aolanti Weikang tablets|Aolanti Weikang tablets is a Chinese patent drug designed to treat Functional dyspepsia (FD).
105923|NCT03358485|Other|Placebo|Placebo
105924|NCT03358472|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
105925|NCT03358472|Drug|Epacadostat|Epacadostat administered orally twice daily.
105926|NCT03358472|Drug|Cetuximab|Cetuximab administered intravenously on Cycle 1 Day 1 followed by administration every week.
105927|NCT03358472|Drug|Cisplatin|Cisplatin administered intravenously every 3 weeks for </= 6 cycles.
105928|NCT03358472|Drug|Carboplatin|Carboplatin administered intravenously every 3 weeks for </= 6 cycles.
105929|NCT03358472|Drug|5-Fluorouracil|5-Fluorouracil administered intravenously every 3 weeks for </= 6 cycles.
105930|NCT03358459|Other|non|non
105931|NCT03358446|Other|A group|"The optimal range of leg abduction was defined as the range without overlap in A group and the range presenting that the overlap was less-than half of the diameter of femoral vein in S group.~A1 angle defined the point that the femoral vein and artery started non-overlapping interval when increasing the angle of the leg in the A group and the A2 angle is defined the point that the femoral vein and artery ended non-overlapping interval."
105932|NCT03358446|Other|S group|B1 is the angle at which the overlap starts at the half of the femoral vein radius when increasing the angle of the leg in the S group, B2 is the angle at which overlap starts at half or more of the femoral vein radius again. In the range of B1 and B2 angles, they are overlapped by half or less of the femoral vein radius.
105933|NCT03358433|Other|Exercise|
105934|NCT03358420|Diagnostic Test|Immunohistochemical staining|Pathological liver slides to be immunohistochemically stained for alpha-defensin
105935|NCT03358407|Drug|GSK2983559|GSK2983559 will be available as oral capsules with dose strength of 2-45 milligram (mg), 100 and 114 mg.
105937|NCT03358394|Behavioral|A human-interventional study|"The intervention was developed by Ahmed et al. (2017) and was adapted by the investigators for parents of children with T1D. The researcher has received permission form the author to use the script but, not the audio recordings. As a result, we contacted Saab et al. (2016) to get the permission to use the Arabic audio recording of Mindfulness exercises (i.e., introduction to mindfulness practice and mindfulness breathing).~The mindfulness script to be used in the current study is based on MBPT. In this study, we will be using the MBPT programme, but tailored to the needs of parents of children with T1D. One of the main changes in our study is that it will be delivered via the Internet. Participants in the original MBPT programme attended in-person sessions however, Rayan et al. (2016) delivered only the first two sessions in person and the rest via telephone"
105938|NCT03358381|Procedure|the gap balance type of total knee arthroplasty|A gap balance type of total knee arthroplasty surgery will be performed.The gap balance group will receive this kind of intervention.
105939|NCT03358381|Procedure|the measured resection type of total knee arthroplasty|A measured resection type of total knee arthroplasty surgery will be performed.The measured resection group will receive this kind of intervention.
105940|NCT03358368|Device|Vitalscan|Vitalscan is a magnetocardiograph device
105941|NCT03358355|Drug|unacelyated ghrelin|We will test doses of 10 ug/kg, 20 ug/kg, and 40 ug/kg of unacylated ghrelin on three separate days for each participant.
105942|NCT03358342|Other|ePneumonia CDS|ePneumonia clinical decision support system for community-onset pneumonia
105944|NCT03358303|Device|Medly|Medly) will enable patients with HF to take clinically relevant physiological measurements with wireless home medical devices and to answer symptom questions on the smartphone. The measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated self-care instructions/messages will be sent to the patient based on the readings and reported symptoms. If there are signs of their status deteriorating, an alert will be sent to a clinician that is responsible for the particular chronic condition of concern. The clinicians will have all the relevant patient data sent to them and will be able to access (through a secure web portal) to view historical and trending data for their patients.
105945|NCT03358290|Drug|JTE-051|Active drug tablets containing JTE-051
105946|NCT03358290|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
105947|NCT03358277|Drug|MPH + APZ|MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.
105948|NCT03358264|Dietary Supplement|L-citrulline|Amino acid supplement
105949|NCT03358251|Device|Pocket-X Gel|Pocket-X Gel is a biodegradable in-situ gelling product that is inserted into a pre-cleaned periodontal pocket where it quickly turns into a gel that adheres to the periodontal pocket and acts as a filler and physical barrier against bacterial re-colonization at the site of application. Administration of this product typically causes no discomfort. The product naturally degrades after 1-3 weeks.
105950|NCT03358251|Procedure|Scaling and root planing|Scaling and root planing is a conventional gold-standard treatment for periodontitis. As part of this procedure, subgingival plaque and tartar are removed and root surfaces are planed.
105951|NCT03358238|Behavioral|Weekly review|Each week in the study, an interviewer will review manic and depressive symptoms self-reported by a participant and patterns of activity, sleep, and heart rate collected by the participant's activity tracker.
105952|NCT03358238|Other|No weekly review|An interviewer will not review self-report symptoms and patterns collected from an activity tracker.
105953|NCT03358225|Procedure|anterior cervical discectomy and fusion|The patients undergoing anterior cervical discectomy and fusion sugery
105954|NCT03358225|Procedure|cervical artificial disc replacement|The patients undergoing cervical artificial disc replacement surgery
105955|NCT03358225|Procedure|hybrid surgery|The patients undergoing 1-level C-ADR plus 1-level ACDF surgery
105956|NCT03358212|Drug|Denosumab|Denosumab 120mg was administrated to patients by subcutaneous injection every four weeks, with loading doses on Day 8 and Day 15 of the first cycle.Patients were instructed to take calcium supplements orally every day and avoid any oral operation during treatment
105957|NCT03358199|Procedure|LOD|Women underwent LOD in the preceding 3 months prior to IVF/ICSI
105958|NCT03358186|Procedure|surgically treated periprosthetic femur fracture|patients with surgically treated periprosthetic femur fracture
105959|NCT03358173|Procedure|Conservative Treatment|Conservative Treatment
105960|NCT03358173|Procedure|Operative Plate Fixation|Operative Plate Fixation
105961|NCT03358160|Behavioral|Action discrimination tasks.|The investigators will compare the groups' performance during action discrimination tasks related to movements of the upper vs. lower limbs.
105962|NCT03358147|Drug|GP MDI 28.8 μg|GP MDI (PT001)14.4 μg per actuation taken as 2 inhalations BID
105963|NCT03358147|Drug|GP MDI 14.4 μg|GP MDI (PT001) 7.2 μg per actuation taken as 2 inhalations BID
105964|NCT03358147|Drug|GP MDI 7.2 μg|GP MDI (PT001) 3.6 μg per actuation taken as 2 inhalations BID
105965|NCT03358147|Drug|Placebo MDI|Placebo taken as 2 inhalations BID
105966|NCT03358147|Drug|Spiriva Respimat 2.5 μg|Spiriva Respimat 2.5 μg QD (open-label)
105967|NCT03358134|Drug|Secukinumab|anti IL17 therapy (subcutaneous)
105968|NCT03358121|Diagnostic Test|Clamp study|Clamp study to achieve high, normal, and lower glucose levels to study the dynamics of Asprosin.
105969|NCT03358095|Device|Tannenbaum Fr 10 stent or WallFlex stent|A plastic or metallic endoprosthesis is placed to the biliary ducts.
105970|NCT03358082|Drug|Tacrolimus 0.03% Ointment|topical tacrolimus 0.03% twice daily for 6 months
105971|NCT03358082|Drug|Hydrocortisone Acetate 1% Ointment|hydrocortisone acetate 1% ointment twice daily for 6 months
105972|NCT03358069|Diagnostic Test|Emergence agitation scale|Emergence agitation scale: PAED scale > 10 defined as positive for Emergence agitation (EA) Post hospitalize behavioral questionnaire (PHBQ) positive Post operative behavioral changes defines as 10 % change from sum score of PHBQ
106016|NCT03357692|Procedure|all on four implant rehabilitation|implant insertion after piezoelectric site preparation for trans-sinusal implants
105973|NCT03358056|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-based cognitive therapy (MBCT) is a manualized, 8 weeks-group-based training derived from mindfulness-based stress reduction (MBSR) and cognitive-behavioral therapy (CBT). In MBCT participants are trained in how to be more aware of their bodily sensations, thoughts and feelings associated with negative emotional states. Mindfulness exercises and cognitive-behavioral skills are practiced both during the sessions and through homework assignments. The program is structured in 2.30 h group sessions over 8 consecutive weeks.
105974|NCT03358043|Device|mechanical ventilation|Consecutive intubated pateints receiving mechanical ventilation with a PaO2/FiO2≤300 mmHg on positive end-expiratory pressure (PEEP) of 5 cmH2O or more and FiO2 of 0.3 or more.
105975|NCT03358030|Drug|ISIS 416858|subcutaneous injection
105976|NCT03358030|Drug|Placebo|subcutaneous injection
105977|NCT03358017|Drug|Zoledronate|4 mg i.v. every 3/4 weeks for 6 months
105978|NCT03358017|Drug|Atorvastatin 80mg|80mg /die os for 6 months
105979|NCT03358017|Drug|Standard neoadjuvant cht|Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
105980|NCT03358004|Drug|Vinorelbine Tartrate|Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A
105981|NCT03358004|Drug|Capecitabine 500 MG|Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
105982|NCT03357978|Diagnostic Test|bioelectrical impedance analysis|Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
105983|NCT03357978|Diagnostic Test|blood draw|Blood samples are taken from sober patients
105984|NCT03357978|Diagnostic Test|transient elastography (FibroScan)|FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
105985|NCT03357978|Diagnostic Test|ataxia score|Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
105986|NCT03357978|Diagnostic Test|Five-Times-Sit-to-Stand Test|The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
105987|NCT03357965|Other|Questionnaire|Women who had gave birth in 6 weeks
105988|NCT03357952|Drug|Daratumumab|Participants will receive daratumumab 16 milligram per kilogram (mg/kg) intravenously (IV) once every week for 8 weeks (Weeks 1 to 8); then once every other week for 16 weeks (Weeks 9 to 24); then once every 4 weeks (Week 25 onwards).
105989|NCT03357952|Drug|JNJ-63723283|Participants will receive JNJ-63723283 240 mg IV during Week 1 on Cycle 1 Day 2, Cycle 1 Day 15, then every 2 weeks thereafter.
105990|NCT03357939|Drug|HLX03 Adalimumab Injection|
105991|NCT03357926|Diagnostic Test|24 hour Holter ECG Monitoring|24 hour Holter ECG Monitoring
105992|NCT03357913|Other|Lung transplantation|To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
105993|NCT03357900|Device|Automated titration of propofol and remifentanil|Calculation of Consumption of propofol and remifentanil
105994|NCT03357887|Other|Analysis of cerebrospinal fluid and serum|Analysis of biomarkers in patient biological samples
105995|NCT03357874|Drug|Clopidogrel|600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).
105996|NCT03357874|Drug|Ticagrelor|patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
105997|NCT03357835|Other|Trauma Decision System|At the time of application, color codes indicating the urgency of the patients will be given according to the demographic data of the patients, the type of trauma and the vital signs were directed by the software program. As a result of the software program's direction, patients will be coded as green-yellow-orange-red area and patient care will be made in accordance with these codes.
105998|NCT03357822|Drug|Pegylated interferon|180ug Pegylated interferon is injected subcutaneously once a week
105999|NCT03357822|Drug|Entecavir|0.5mg entecavir is orally taken every day
106000|NCT03357822|Drug|Tenofovir disoproxil fumarate|300mg tenofovir is orally taken every day
106001|NCT03357809|Procedure|Endoscopic mucosal resection|"Mucosectomy performed at day 1. Endoscopic mucosal resection (EMR) and or endoscopic submucosal dissection (ESD), is at least 3 cm long. The mucosal resection is carried out along the side of the small curvature of the stomach, in order to preserve a valve of the cardia at the level of the large curvature of the stomach.~A coloured solution is injected into the submucosa following markers. The correct submucosal injection is confirmed by the lifting of the mucosal surface. A submucosal dissection is carried out using the dual knife. The mucosectomy is repeatedly performed until the mucosal zone is completely resected. The choice of the resection technique will depend on the anatomy of the patient."
106002|NCT03357796|Drug|LY03005|80 mg, oral tablets, single dose
106003|NCT03357796|Drug|Pristiq|50 mg, oral tablets, single dose
106004|NCT03357783|Other|Macroscopic deciduosis|Deciduosis is a benign lesion during pregnancy that is not correlated with obstetrical complications. Our study has shown that this physiological phenomenon is more frequent that originally thought, being present in 10% of the Cesarean sections, and is associated with abdominal pain during pregnancy.
106005|NCT03357770|Drug|mesenchymal stem cells|we will enroll three groups of patients, and they will be therapized by high, medium, and low-dose cytotoxic respectively to evaluate the dose-limiting toxicity (DLT) and establish the maximum tolerated dose (MTD). Dose and cell concentration selection will be based on previous literature [5]. The low-dose is 1 × 10^7cells / 3mL, the medium-dose is 5 × 10^7cells / 3mL and the high dose is 1 × 10^8cells / 3mL
106006|NCT03357757|Drug|Valproic Acid|The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles.
106007|NCT03357757|Biological|Avelumab|10 mg/kg IV
106008|NCT03357744|Other|distress barometer|not applicable, observational study
106009|NCT03357731|Drug|HNO Donor|Infusion
106010|NCT03357731|Drug|Nitroglycerin (NTG)|Infusion
106011|NCT03357731|Other|Placebo|Infusion
106012|NCT03357718|Drug|Precedex|2 µg/kg oral
106017|NCT03357679|Procedure|Tracheal intubation|Intubation of the trachea with endotracheal tube
106018|NCT03357679|Device|Glidescope assisted tracheal intubation|With the use of the Glidescope video laryngoscope, the trachea will be intubated with the endotracheal tube
106019|NCT03357679|Device|Bed up head elevated tracheal intubation|Use of the Macintosh laryngoscope blade size 3
106020|NCT03357666|Drug|HUDC_VT(Glucose 200mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
106021|NCT03357666|Drug|HUDC_VT (Glucose 400mg/Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
106022|NCT03357666|Drug|HUDC_VT (Glucose 400mg)|Vaginal administration, two tablets once a day for 7 days
106023|NCT03357666|Drug|HUDC_VT (Sodium chloride 200mg)|Vaginal administration, two tablets once a day for 7 days
106024|NCT03357666|Drug|Placebo|Vaginal administration, two tablets once a day for 7 days
106025|NCT03357653|Drug|Losartan group|Losartan 50 mg daily
106026|NCT03357653|Drug|Placebo group|Placebo 1 pill daily
106027|NCT03357640|Drug|combined oral contraceptive pills|one package of oral contraception (Cilest containing norgestimate 250 microgram + ethinyl estradiol 35 microgram)
106028|NCT03357627|Drug|TAK-659|TAK-659 tablets.
106029|NCT03357627|Drug|Venetoclax|Venetoclax tablets.
106030|NCT03357614|Drug|Sulopenem|Antibiotic therapy for complicated UTI
106031|NCT03357614|Drug|Sulopenem-Etzadroxil/Probenecid|Antibiotic therapy for complicated UTI
106032|NCT03357614|Drug|Ertapenem|Antibiotic therapy for complicated UTI
106033|NCT03357614|Drug|Ciprofloxacin|Antibiotic therapy for complicated UTI
106034|NCT03357614|Drug|Amoxicillin-clavulanate|Antibiotic therapy for complicated UTI
106035|NCT03357601|Behavioral|HIIT|The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
106036|NCT03357601|Behavioral|MCEET|The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
106037|NCT03357588|Other|Intensified monitoring|Intensified virological monitoring during first-line ART with viral load monitoring at month 6 of ART and 3-monthly thereafter, followed-up consecutively by point-of-care qualitative drug level testing and drug resistance testing in case of a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
106038|NCT03357588|Other|Standard of care monitoring|Standard-of-care virological monitoring during first-line ART as described by WHO and South African National Department of Health ART guidelines, consisting of viral load monitoring at month 6 and 12 of ART and annually thereafter, followed-up by a repeat measurement within 3 months after a viral load >1000 copies/mL, during first-line antiretroviral treatment (ART) for HIV-1 infection as prescribed by South African national guidelines.
106039|NCT03357575|Biological|Mesenchymal Stem Cells from adipose|inject mesenchymal Stem Cells from adipose
106040|NCT03357575|Biological|Hyaluronic Acid|inject hyaluronic acid
106041|NCT03357562|Device|lung MRI|lung MRI without contrast injection
106042|NCT03357549|Other|Brief Motivational Intervention|The Brief Motivational Intervention is an intervention that use strategies are typical of patient-centered interventions. These strategies will help the interviewer to listen, to elicit important information, and to build rapport with the patient and should be used throughout the intervention. The four strategies are Open-Ended Questions, Affirmations, Reflections and Summaries. The objective of de BMI is to increase the client motivation to adopt healthy initiatives, and to increase their self-efficacy to reach their own objectives.
106043|NCT03357549|Other|Breastfeeding education|It's a common educational intervention about breastfeeding. The women will receive the information by a leaflet with information about breastfeeding and community resources and they will receive verbal information during 20-30 minutes to resolve their doubts.
106044|NCT03357536|Procedure|Human biological samples|"Blood sample~Skin biopsy~Saliva"
106045|NCT03357523|Device|Omnilux new-U (Red LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Red LED) light source, while the right wrist will not be illuminated
106046|NCT03357523|Device|Omnilux new-U (Near infrared LED)|The left wrist (including area of radial artery) will be illuminated with the Omnilux new-U (Near infrared LED) light source, while the right wrist will not be illuminated
106047|NCT03357523|Device|RESPeRATE|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm
106048|NCT03357523|Device|Heating bag|Applying a standard 10X13 [cm] heating bag on the surface of the hand at 43-45 degree Celsius for 10 seconds
106049|NCT03357497|Other|Very early mobilization|The patient will be mobilized by a physiotherapist in our postoperative care unit. The intervention uses the SOMS protocol.
106050|NCT03357484|Procedure|Leukocyte- and platelet rich fibrin|Prior to surgery, two 9 ml glass-coated tubes (Intra-Spin, Intra-Lock International, Boca Raton, USA) of patient venous blood were collected. Tubes were transferred to a centrifuge (Andreas Hettich GmbH & Co.KG, Tuttlingen, Germany) and processed for 12 minutes at 2800 rpm to prepare L-PRF.
106051|NCT03357484|Procedure|Blood clot|Natural blood clot formed within extraction socket
106052|NCT03357471|Drug|e-Device|"Active Substance: Certolizumab Pegol~Pharmaceutical form: Solution for injection~Route of administration: subcutaneous injection by e-Device"
106053|NCT03357458|Behavioral|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
106054|NCT03357445|Other|Avantage Reload cup|Patients receiving the Avantage Reload acetabular cup in total hip arthroplasty
106055|NCT03357432|Other|gelatin, collagen, gummy dose|The study is aimed at determining if the same dose of gelatin, hydrolyzed collagen (administered in a beverage form) or a mixture gelatin/hydrolyzed collagen (administered in a gummy form) with a standard dose of vitamin C (50 mg) has a similar effect a marker of collagen synthesis (PINP). In a randomized, crossover design subjects consume 3 different nutritional supplements: (a) 15 of gelatin, (b) 15 hydrolyzed collagen (administered in a beverage form) or (c) 15 g of gelatin/hydrolyzed collagen mixture all with a standard dose of vitamin C (50 mg) 1 hour prior to exercise stimulus (6 minutes of jump rope). A baseline assessment with only the jump rope and no intervention will also be conducted prior to the interventions. Each intervention will be separated by a >24 hr washout. Following completion of exercise, subjects will remain in the lab in a rested state for the subsequent 4 hours. After 4 hours blood samples will be collected. Blood samples will be used for PINP analysis.
106056|NCT03357419|Drug|Cephalexin|"The subjects will be randomized, at the operation day, to one of two treatment groups:~group 1: prophylactic antibiotic~group 2: placebo oral capsule~Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
106057|NCT03357419|Drug|Placebo oral capsule|"The subjects will be randomized, at the operation day, to one of two treatment groups:~group 1: prophylactic antibiotic~group 2: placebo~Sealed envelopes, numbered according to the randomization dose, containing the drug or placebo will be prepared in advance and provided to the patient following randomization.~Each patient will be given the randomized drug on admission, 30-60 minutes before the surgery, by the nurses."
106058|NCT03357406|Procedure|ultrasound implant site preparation|piezoelectric bone surgery will be used to create implant bone ostectomy
106059|NCT03357406|Procedure|conventional implant site preparation|twist drills will be used to create implant bone ostectomy
106060|NCT03357393|Drug|Midazolam|Midazolam is givenas sedation to the Control arm.
106061|NCT03357393|Drug|Propofol-Lipuro|Propofol is given as sedation to both intervention arms.
106062|NCT03357393|Drug|morphine-scopolamine|Given as premedication for the Control arm and one of the interventions arms.
106063|NCT03357393|Drug|Glycopyrrolate|Given as premedication for one of the intervention arms..
106064|NCT03357380|Drug|Semaglutide|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
106065|NCT03357380|Drug|Placebo|Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
106066|NCT03357367|Device|TiVi system|"Device: TiVi system A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by TiVi system 10 minutes later.~Measurement of the value of skin blood flow (by TiVi system) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
106067|NCT03357354|Behavioral|collective workshop|diet, sports games, food budget, feeling of satiety and hunger, self-image
106068|NCT03357341|Device|Mobile spirometer|Mobile spirometer will be used to measure FEV1 values weekly.
106069|NCT03357341|Device|Device sensor|Sensors will be attached to rescue and maintenance inhalers to measure use of rescue medication and maintenance therapy.
106070|NCT03357341|Drug|Salbutamol|Salbutamol MDI will be given as a rescue medication to be used on an as needed basis in this study.
106071|NCT03357341|Device|Activity monitor|Subjects will be required to wear activity monitors daily to record their physical activity.
106072|NCT03357341|Other|electronic diary card|Electronic diary card will be completed daily by subjects in COPD cohort.
106073|NCT03357341|Other|CAT|Subjects will be required to complete CAT monthly.
106074|NCT03357341|Other|ACT|Subjects will be required to complete ACT monthly.
106075|NCT03357328|Other|Therapy light room|See group description
106076|NCT03357328|Other|Standard light|See group description
106077|NCT03357315|Biological|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
106078|NCT03357289|Biological|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
106079|NCT03357276|Biological|Mix vaccine|Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
106080|NCT03357263|Biological|GC3114|High-dose Quadrivalent influenza vaccine
106081|NCT03357263|Biological|GCFLU Quadrivalent|Quadrivalent influenza vaccine
106082|NCT03357237|Other|medical device|"patients will be assigned, following an external randomization, to two groups:~Intervention or experimental group: treatment regimen with oral rehydration solution and xyloglucan~Control or reference group: treatment regimen with oral rehydration solution and placebo"
106083|NCT03357224|Drug|Atezolizumab|Patients will receive atezolizumab 1200 mg IV Q3w for 1 year.
106084|NCT03357185|Procedure|Femoral eversion|"The purpose of this database is to compile the data of patients followed at the René Dubos Hospital Center with symptomatic lower extremity arterial disease (AOMI) (Rutherford 2 to 5) who were operated on by the femoral tripod eversion technique.~The database will include data on the operation, possible complications, clinical course of patients and medical and surgical follow-up."
106085|NCT03357172|Biological|Blood Sample|Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2
106086|NCT03357172|Biological|Bone marrow aspiration|Additional bone marrow aspiration before graft, D30, D90, Y1
106087|NCT03357172|Biological|Blood sample|Before donation
106088|NCT03357172|Biological|Allogeneic hematopoietic stem cell sample|Allogeneic hematopoietic stem cell sample
106089|NCT03357159|Drug|Cyclophosphamide|In the first phase escalated doses of post-transplant cyclophosphamide up to a maximal dose of 50 mg/kg , the second phase will use the MTD cyclophosphamide dose identified in the first phase.
106090|NCT03357159|Drug|anti-human T-lymphocyte immunoglobulin (ATLG)|15mg/kg total (5mg/kg day) on days -3 to -1 pre transplantation
106091|NCT03357146|Device|Optical coherence tomography angiography|OCTA scans per built-in device protocol
106092|NCT03357133|Drug|Tirofiban|Tirofiban Injection after the alteplase intravenous thrombolysis
106094|NCT03357120|Other|Follow-up after neoadjuvant chemotherapy|"Sequential plasma samples for ctDNA mutations analysis will be taken during the post-surgery visit (within 2-5 weeks after surgery) and every 6 months (+/- 1 month) thereafter for 5 years. In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated). Next Generation Sequencing (NGS) analysis will be performed on post-neoadjuvant chemotherapy residual tumor tissue samples. The mutations identified by NGS in residual tumor will be tracked in ctDNA using personalized digital PCR (dPCR) or by an NGS technique whose bioinformatics pipeline is adapted to the analysis of ctDNA.~In case of relapse patients will be proposed to participate to an optional research program with a blood test for ctDNA assessment and biopsies from a metastasis (when these biopsies are clinically indicated)."
106095|NCT03357107|Procedure|Transoral robotic surgery (TORS)|All patients underwent primary tumour resection with transoral robotic surgery (TORS) using the daVinci robot (Intuitive Surgical, Sunnyvale CA)
106096|NCT03357081|Drug|CEUS or Contrast enhanced Ultrasound|Real time contrast enhanced ultrasound with Lumason. CEUS or Contrast enhanced Ultrasound
106097|NCT03357068|Procedure|Control|Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.
106098|NCT03357068|Procedure|Acid|Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
106099|NCT03357055|Drug|Ketamine|IV infusion of 0.25mg/kg of ketamine over 10 minutes before pneumatic tourniquet inflation. Throughout procedure patient will receive 0.25mg/kg of ketamine infusion.
106100|NCT03357055|Drug|Normal saline|Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
106101|NCT03357042|Other|Aerobic exercise and balance retraining|Aerobic and balance exercises that gradually progress in intensity over the course of 8 weeks.
106102|NCT03357042|Other|Standard of care|Normal concussion treatment; physical and cognitive rest
106103|NCT03357029|Device|GammaCore Device|GammaCore will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes.
106104|NCT03357029|Device|Sham Device|Sham device will be administered using a handheld device the size of a mobile phone, which consists of a battery powered portable stimulator with a digital control user interface that controls the stimulation amplitude and two steel contact electrodes. The sham device is identical in appearance, weight, visual and audible feedback, and user application and control but did not deliver electrical stimulations.
106105|NCT03357016|Other|Training programs|High Intensity Interval Training program (HIIT) vs. Moderate Intensity Continuous Training program (MICT) vs. High Intensity Interval Training program + Resistance Training program (HIIT+RT)
106106|NCT03357003|Other|Observational study|Comparison between O-desmethyltramadol/tramadol ratio and tramadol clinical efficiency and tolerance
106107|NCT03356990|Dietary Supplement|Resistant Starch|"Dietary supplement will be taken every day for total of 2 weeks. Each participant will be take half the dose (one bag) of Hi-Maze 260 or High RS Gummy Chews in the morning and the other half dose (one bag) in the evening."
106108|NCT03356977|Drug|Crisaborole ointment 2%|Applied BID
106109|NCT03356964|Drug|follicle stimulating hormone|Follicle stimulating hormone( will be chosen according to ovarian reserve parameters in the study group the dosage will be reduced in the control group it will remain unchanged
106110|NCT03356951|Procedure|TAR through anterior approach and subtalar fusion|Simultaneous total ankle replacement through anterior approach and subtalar fusion
106111|NCT03356951|Procedure|TAR through lateral approach and subtalar fusion|Simultaneous total ankle replacement through lateral approach and subtalar fusion
106112|NCT03356938|Behavioral|Sleep restriction|Restricted sleep to 5 hours / night for 5 days prior to sleep laboratory examination
106113|NCT03356938|Behavioral|Sleep deprivation|Sleep deprivation during first night of sleep laboratory examination
106114|NCT03356925|Diagnostic Test|Xpert Ultra Point of Care testing|The intervention is the point of care Xpert Ultra TB diagnostic compared to the standard of care centralised TB testing at a centralised facility
106115|NCT03356912|Drug|Cabazitaxel|"Cabazitaxel drug products should be administered only by intravenous route.~Prednison should be administered by oral route"
106116|NCT03356912|Drug|Prednisone|Prednisone should be administred by oral route
106117|NCT03356899|Drug|Low dose bupivacaine 0.5% (8mg)|8 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.1 ml
106118|NCT03356899|Drug|High dose bupivacaine 0.5% (10mg)|10 mg hyperbaric bupivacaine with added 25 µg fentanyl to form a total volume of 2.5
106119|NCT03356886|Procedure|Spinal Manipulative Technique|1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
106120|NCT03356886|Behavioral|Pain Neuroscience Education|All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
106121|NCT03356873|Drug|Vitamin D|Vitamin D supplementation
106122|NCT03356873|Other|Placebo|Placebo
106123|NCT03356860|Drug|Paclitaxel|80mg/m2 IV weekly from week 1 to week12
106124|NCT03356860|Drug|Epirubicin|90 mg/m2 IV Q 2 weeks from week 14 to week 20
106125|NCT03356860|Drug|Cyclophosphamide|600 mg/m2 IV Q 2 weeks from week 14 to week 20
106126|NCT03356860|Drug|Durvalumab|Durvalumab 1500 mg IV at week 14 and 18
106127|NCT03356847|Device|Fitting of ocular implant|Removal of natural lens and replacement with a SISA monofocal intraocular implant
106128|NCT03356834|Drug|Tenofovir alafenamide(TAF)|25 mg tablet administered orally once daily
106129|NCT03356834|Drug|Tenofovir disoproxil fumarate(TDF)|300 mg tablet administered orally once daily
106130|NCT03356821|Biological|Mesenchymal Stem Cells|One dose of 50x10^6 bone marrow-derived allogeneic MSCs via the nasal route as soon as possible after confirmation of the stroke (in the middle cerebral artery), but within the first week of onset of presenting clinical symptoms. Within 30 minutes after cleaning the nose with saline, using standard procedures operative at the Neonatal Intensive Care Unit, the MSC will be delivered.
106131|NCT03356808|Biological|Lung cancer-specific T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
106132|NCT03356795|Biological|Cervical cancer-specific CAR-T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
106133|NCT03356782|Biological|Sarcoma-specific CAR-T cells|1 infusion, for 1x10^6~1x10^7 cells/kg via IV
106134|NCT03356769|Drug|Aspirin|low-dose of aspirin, 5mg/Kg/d, once every day, 25mg per tablets
106135|NCT03356769|Drug|AED|maintain the dosages and the drugs throughout the 3-month observation time
106136|NCT03356769|Drug|Placebo|placebo, 5mg/Kg/d, once every day, 25mg per tablets
106137|NCT03356756|Diagnostic Test|simultaneous combined 18F-FDG PET and cardiac MRI imaging|Patients will undergo a research study performed with an integrated whole-body PET/MRI imaging system designed for simultaneous PET and MRI acquisition, immediately after standard of care PET/CT exam.
106138|NCT03356743|Device|Spectrum Analysis|The ultrasound probe will be placed on the lung surface in several different directions to obtain the cross section with maximum diameter. Three spectral parameters including midband-fit (dB), intercept (dB), and slope (dB/MHz) will be calculated and compared between the tumor and the lung.
106139|NCT03356730|Drug|Vitamin D|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This group will receive vitamin D supplementation.~Vitamin D3 - cholecalciferol, oral suspension in drops, will be prescribed as follows:~• 5,000 IU / day - 10 drops per day for two months."
106140|NCT03356730|Other|Placebo|"Only patients with vitamin D deficiency / deficiency will be included in the study. Randomly, they will be divided into two groups. This control group will receive placebo.~Placebo (olive oil mint flavor), oral suspension in drops, will be prescribed as follows:~• 10 drops per day for two months."
106141|NCT03356717|Behavioral|educational intervention with observer tool|To assess if the use of an observer tool by observers during high fidelity simulation improves learning outcomes
106142|NCT03356717|Behavioral|educational intervention|without observer tool
106143|NCT03356704|Other|no intervention|Observational study
106144|NCT03356691|Other|Complementary Spiritist Therapy|"Complementary Spiritist Therapy:~Prayer: for 1 to 2 minutes.~Spiritual education: reading and commentary of the Gospel according to Spiritism, about 7 minutes.~Spiritist passe, for 2-min.~Fluid therapy."
106145|NCT03356691|Other|Prayer|Individuals will receive prayer during 1 to 2 minutes.
106146|NCT03356691|Other|"Spiritist passe"|"Individuals will receive Spiritist passe during 5 to 10 minutes."
106147|NCT03356691|Other|laying on of hands with intent to heal|Individuals will receive laying on of hands with intent to heal during 5 to 10 minutes.
106148|NCT03356691|Other|Fluid therapy.|Individuals will receive fluid therapy.
106149|NCT03356691|Other|No-fluid therapy.|Individuals will receive no-fluid therapy.
106150|NCT03356678|Drug|Pralatrexate|"Patients treated with pralatrexate due to relapse or refractory disease after primary and/or salvage treatment. Relapse following an autologous stem cell transplant allowed.~Patients treated with pralatrexate 30mg/m2 once a week for 6 weeks as part of a 7-week cycle. However, modified dose and/or schedule allowed."
106151|NCT03356665|Diagnostic Test|Rapid diagnostic test (RDT)|The 4 rapid diagnostic tests (RDT) will be carried out on fresh blood from clinical suspects. Only those subjects that are positive in at least 1 RDT will 1) undergo tests on DBS (immune trypanolysis, ELISA and DNA detection); 2) undergo parasitological confirmation (reference standard) at inclusion.
106152|NCT03356665|Diagnostic Test|Serological and molecular tests on DBS|Serological and molecular reference tests on dried blood spots (DBS) are carried out on RDT positive clinical suspects, which also undergo parasitological examination at inclusion (reference standard). If at least one of the serological or molecular reference tests on dried blood spots is positive, parasitological examination is repeated 3 and 6 months after inclusion. The combined results of parasitological examinations (at inclusion and if applicable at 3 and 6 months) serve as reference standard
106153|NCT03356652|Procedure|Noninvasive electrical dyssynchrony study|"Ventricular activation maps will be acquired simultaneously with hemodynamic measurements using noninvasive mapping system (ECVUE, Medtronic Inc, USA). A thoracic computed tomographic scan will be acquired with the electrodes attached to the patient. Local ventricular activation times will be defined as the onset of the QRS complex or the pacing spike to the maximal negative slope of each unipolar electrogram.~Pacing leads will be placed in high right atrium, His-bundle region, right ventricular apex, high septal RV, coronary sinus posterior/lateral branch, coronary sinus anterior branch, lateral and septal region of endocardial LV in order to deliver CRT in 8 different configurations."
106154|NCT03356639|Drug|ASP6981|Oral
106155|NCT03356639|Drug|Placebo|Oral
106156|NCT03356626|Device|ULTRACISION Harmonic Scalpel|to use ULTRACISION Harmonic Scalpel when performing gastrectomy
106157|NCT03356626|Device|Ligasure Maryland|to use Ligasure Maryland when performing gastrectomy
106158|NCT03356626|Device|Thunderbeat|to use Thunderbeat when performing gastrectomy
106159|NCT03356613|Other|Focus group|An researcher in psychology will lead focus group on research views for paramedical staff
106160|NCT03356613|Other|test of the Geni tool|The GenI tool built on paramedic's view will be tested.
106161|NCT03356600|Combination Product|Apatinib plus radiotherapy|"Apatinib:~Within 1 week before radiotherapy, the dose of Apatinib were 500mg/daily .During radiotherapy,the dose of Apatinib were 250mg/daily.~After radiotherapy, if the subject did not have a level 3 or above adverse reaction, investigators consider increasing doses to 500mg.~Radiotherapy:~The subjects with 1 to 4 metastases receive stereotactic radiosurgery or stereotactic radiation therapy ,and the subjects with more than 4 metastases receive stereotactic radiosurgery plus whole-brain radiation therapy"
106162|NCT03356587|Drug|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day
106163|NCT03356574|Procedure|Single-ventricle palliation surgery|Single-ventricle palliation surgery
106164|NCT03356561|Biological|Ad26.ZIKV.001 5*10^10 vp|Participants will receive Ad26.ZIKV.001 at a dose of 5*10^10 vp via IM route.
106165|NCT03356561|Biological|Ad26.ZIKV.001 1*10^11 vp|Participants will receive Ad26.ZIKV.001 at a dose of 1*10^11 vp via IM route.
106166|NCT03356561|Biological|Placebo|Participants will receive placebo via IM route.
106167|NCT03356509|Behavioral|Exercise|Exercise will be performed on a stationary bicycle ergometer.
106168|NCT03356496|Device|AirLife 4000 cc incentive spirometry device|Incentive spirometry device provides improved lung expansion and respiratory muscle strength
106169|NCT03356483|Drug|Psilocybin (0.25mg/kg)|Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic.
106170|NCT03356483|Drug|Niacin (250mg)|A medication used to treat high cholesterol, triglyceride levels, and niacin deficiency.
106171|NCT03356470|Other|F-FDG PET/CT|F-FLT PET uses a thymidine analogue that accumulates in proliferating tissue. Proliferating tissue could include malignant lesions or immune cells. In this study, FLT PET/CT will be utilized as a molecular imaging tool to detect immune activation after administration of immune checkpoint blockade with pembrolizumab or nivolumab.
106172|NCT03356457|Drug|Dichloroacetate|Dichloroacetate is an isoform-unspecific inhibitor of four regulatory pyruvate dehydrogenase kinases, which are able to reduce entry of substrates into mitochondria by reducing the conversion of pyruvate to acetyl-CoA. Drug will be administered to subjects with sever hypoglycemia as well as healthy non-diabetic subjects.
106173|NCT03356457|Drug|Placebo oral capsule|A Placebo oral capsule identical in shape and color to those with active ingredient.
106174|NCT03356444|Drug|Abiraterone Acetate|Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
106175|NCT03356444|Drug|Docetaxel|"Docetaxel: intravenously, 75 mg/m^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd.~Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment"
106176|NCT03356431|Other|Supervised group exercise|"Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~Sit to stand exercise during 1 min.~Dynamic stepping exercise (walking up and down one step/stair during 1 min).~Standing calf stretch 3 x 20 sec.~Standing quadriceps stretching 3 x 20 sec.~Supine hamstring stretching 3 x 20 sec."
106177|NCT03356431|Other|Home-based exercise|"Quadriceps muscle isometric contraction in sitting position 1 set of 3-3 reps × 1 min hold.~Isotonic quadriceps contraction with resistance band 3 sets of 10 reps x 1min hold.~Isotonic hamstring contraction with resistance band 3 sets of 10 reps x 1min hold.~Sit to stand exercise during 1 min.~Dynamic stepping exercise (walking up and down one step/stair during 1 min).~Standing calf stretch 3 x 20 sec.~Standing quadriceps stretching 3 x 20 sec.~Supine hamstring stretching 3 x 20 sec."
106178|NCT03356418|Other|WBV exercise group|The intervention will consist of a half-squat isometric whole-body vibration exercise with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
106179|NCT03356418|Other|Sham WBV exercise group|The intervention will consist of as half-squat isometric exercise , but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
106180|NCT03356392|Other|telephone call d90|telephone call on day 90 to assess the primary outcome (mRs d90)
106181|NCT03356379|Diagnostic Test|Transcutaneous oximetry|Measurement of TcpO2 on calves and chests. Calculation of the DROP index (decrease from rest of oxygen pressure)on both calves
106182|NCT03356366|Other|MRI 3T|Magnetic Resonance Imaging 3 Tesla
106183|NCT03356366|Other|MRI 1,5T|Magnetic Resonance Imaging 1,5 Tesla
106184|NCT03356366|Other|MRI 7T|Magnetic Resonance Imaging 7 Tesla
106185|NCT03356353|Drug|Sildenafil Citrate|20 mg tablets
106186|NCT03356327|Drug|Actitan F|A molecolar complex of Tannins and Flavonoids used for acute diarrhea in children
106187|NCT03356327|Drug|Standard Oral Rehydration|Standard oral rehydration as suggested by ESPGHAN guidelines
106188|NCT03356314|Other|MRI between 30-35 GA|MRI between 30-35 GA
106189|NCT03356314|Other|Pediatric surgeon meeting|Pediatric surgeon meeting
106190|NCT03356314|Other|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal|Postnatal abdominal ultrasound, barium enema and upper gastrointestinal
106191|NCT03356314|Other|+/- prophylactic surgery|+/- prophylactic surgery
106192|NCT03356301|Device|Cardiac MRI|Non injected cardiac MRI exam
106193|NCT03356301|Device|Applanation tonometry|Applanation tonometry and ECG
106194|NCT03356275|Behavioral|Mindfulness for Resilience in Illness: Support for Parents|Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
106195|NCT03356249|Diagnostic Test|Next-Generation Sequencing|In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
106196|NCT03356223|Drug|Abemaciclib|"400mg/day with 2 doses of 200mg 12-hour apart For each 28-day cycle, a total of 56 doses of study drug will be dispensed.~Route of administration : oral~Duration of treatment until the patient experiences an unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent."
106366|NCT03354793|Other|Survey on first pregnancy after endometriosis diagnosis|Obstetric complications were noted
106197|NCT03356210|Behavioral|Neurofeedback|The intervention will consist of 20 sessions of symptom-based NF tailored to the individual patient. Training will be conducted using the Othmer method of NF from EEGinfo, comprising bipolar, infra-low frequency training, with the inclusion of synchrony and alfa-/theta training as needed.
106198|NCT03356184|Device|The Rhea Vital Sign Vigilance Device Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
106199|NCT03356184|Device|The Earlysense System Device Group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
106200|NCT03356171|Procedure|Cardiac Coherence|"10 sessions of HRV-BF (45mn) weekly over 12 weeks. HRV-BF is a cognitive behavioural therapy consisting on stress management training based on breathing. We use the SYMBIOLINE PC software to record the heart rate variability biofeedback, with an infrared plethysmograph sensor. The sensor is put on the finger, and the patient's HRV pattern is displayed in real time.~24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective."
106201|NCT03356171|Procedure|Adapted Physical Activity|- 24 APA sessions (1.5h) bi-weekly over 12 weeks. Each session includes aerobic exercises (walk, step) and resistant exercises (muscular reinforcement). This program is built on previous cancer studies to make it effective.
106202|NCT03356158|Biological|CPGJ602|Injection, q.w., 20 mg: 100 ml
106203|NCT03356158|Biological|Cetuximab|Injection, q.w., 20 mg: 100 ml
106204|NCT03356145|Other|12 mL paracervical block|Injection of 12 mL of lidocaine
106205|NCT03356145|Other|20 mL paracervical block|Injection of 20 mL of lidocaine
106206|NCT03356132|Device|Silimed® Textured Silicone Gel-Filled Breast Implant|Women undergoing primary breast augmentation using Silimed® Textured Silicone Gel-Filled Breast Implant.
106207|NCT03356132|Device|Silimed® Polyurethane Foam Covered Silicone Gel-Filled Breast Implant|Women undergoing primary breast augmentation using Silimed® silicone gel-filled breast implants with polyurethane foam covered surface.
106208|NCT03356119|Device|RemovAid device|The contraceptive implants of the subjects in this arm are removed by the new IMD.
106209|NCT03356106|Device|Continuous positive airway pressure (CPAP)|A non-invasive positive pressure device that is used for the treatment of obstructive sleep apnea by splinting the collapsed upper airway during sleep
106210|NCT03356093|Other|complete questionnaire|Patients were asked to complete a questionnaire at baseline, and week 1, 2, 3, 4, 5 and 6 after starting of radiotherapy.
106211|NCT03356080|Drug|Decitabine|Decitabine,iv,0.1-0.2mg/kg, Day1-Day3 per week,up to 3 weeks
106212|NCT03356080|Drug|Cytarabine|cytarabine, iv,15mg/m2 q12h, Day1-Day10
106213|NCT03356080|Drug|All-transretinoic acid|All-transretinoic acid, 45mg/d Day4-Day6;15mg/d Day7-Day20
106214|NCT03356080|Drug|G-CSF|G-CSF 300ug,sc,Day 0 until CR is achieved
106215|NCT03356067|Procedure|Gastric endoscopic peroral pyloromyotomy|"G-POEM is, in principle, adaptation of POEM (per-oral endoscopic myotomy) in the stomach. The procedure consists of:~Mucosal incision at the greater curvature 3-5 cm from the pylorus~Submucosal tunnelling~Finding pyloric sphincter~Myotomy (2-3 cm) of the pyloric muscle~Incision closure (endoclips or suture device)"
106216|NCT03356067|Procedure|Esophago-gastro-duodenoscopy|Standard endoscopic examination of the upper GI tract with flexible endoscope
106217|NCT03356054|Combination Product|R-DHAP|3 cycles q 3 weeks
106218|NCT03356054|Drug|Brentuximab Vedotin|3 cycles q 3 weeks added to R-DHAP
106219|NCT03356041|Other|Diabetic patients with neuropathy|Lifestyle modification will be assessed using summary of diabetes self-care activity
106220|NCT03356028|Behavioral|Child and adolescent psychiatry and Epidemiology|psychosocial risk assessment questionnaire, structured diagnostic interview, pedopsychiatric questionnaire
106221|NCT03356028|Other|salivary biological collection|Saliva sampling will be done using a specific kit
106222|NCT03356028|Behavioral|qualitative analysis of the discourse|two semi-structured interviews, the first with the teenager alone, the second with the lone parents
106223|NCT03356015|Drug|4L Polyethylene Glycol|4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
106224|NCT03356015|Drug|3L Polyethylene Glycol|3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
106225|NCT03356002|Device|C-Scan System|"Each subject will ingest the capsule within 30 days prior to colonoscopy. The results of the C-Scan review will be compared to the findings of colonoscopy.~To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~To evaluate the safety of the C-Scan Capsule System procedure"
106226|NCT03355989|Other|Conditional Cash Transfer|Conditional cash transfer provided via mobile airtime and easypaisa along with SMS reminders to increase immunization coverage and timeliness
106227|NCT03355989|Other|SMS Reminder|Three SMS reminders for immunization provided before, at and after the due date respectively
106228|NCT03355976|Drug|Nivolumab|240mg flat dose every 2 weeks
106229|NCT03355976|Drug|Ipilimumab|Ipilimumab 1mg/kg every 6 weeks
106230|NCT03355963|Other|saline injection|The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.
106231|NCT03355963|Biological|Botulinum toxin type A 50 units|The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.
106232|NCT03355963|Biological|Botulinum toxin type A 100 units|The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
106233|NCT03355950|Procedure|Lichtenstein Repair|Well defined Lichtenstein Repair for inguinal hernias
106234|NCT03355950|Procedure|TEP Repair|Laparoscopic totally extraperitoneal repair for inguianal hernias
106235|NCT03355937|Procedure|Sperm Chip|Sperm selection using by conventional or with sperm chip
106236|NCT03355872|Drug|HLX01|Biosimilar of Rituximab
106305|NCT03355287|Other|Traditionally Threshed Teff (TTT)|The intervention will take place for 7 months in Debre Zeit where the the arm will be fed injera based on teff that are threshed traditionally
106237|NCT03355859|Biological|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
106238|NCT03355846|Drug|Centella|after meals twice a day for 15 days
106239|NCT03355846|Drug|Proctocella|after hygiene treatment for 4 weeks;
106240|NCT03355846|Drug|Flavonil® cps|after meals twice a day for 15 days
106241|NCT03355846|Drug|Flavonil® Cream|"treatment for 4 weeks;~."
106242|NCT03355846|Drug|Rectalgan Mousse|for 4 weeks
106243|NCT03355820|Procedure|Blood sampling for antibody determination|In order to assess the persistence of immune responses seven to eight years after the last vaccine dose against HPV-16/18, a blood sample (~5 mL) will be taken from all the subjects, at Day 1.
106244|NCT03355807|Drug|Magnesium|The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4
106245|NCT03355794|Drug|ribociclib|Oral capsule or liquid formula
106246|NCT03355794|Drug|Everolimus|Oral tablets or dispersible tablets
106247|NCT03355781|Device|magnetic resonance imaging (MRI)|brain imaging : structural anatomy, emotional congruence, anatomic connectivity, functional connectivity
106248|NCT03355781|Procedure|Blood sample|27,5 ml of blood sample : genetic analysis and biobank
106249|NCT03355781|Other|Clinical psychiatric evaluation|Global Assessment Scale(GAS),Mini International Neuropsychiatric Interview(MINI),Positive and Negative Symptoms Scale(PANSS),Family Interview for Genetic Studies(FIGS),Calgary Depression Scale for Schizophrenia(CDSS),extrapyramidal side effects evaluation or Simpson-Angus scale evaluation(ESRS),Apathy Evaluation Scale(AES-C),State-Trait Anxiety Inventory(STAI),Beck Depression Inventory(BDI-13),Eysenck Personality Questionnaire-Revised(EPQ-R),Assessment of Schizotypal Personality(SPQ),Emotion Regulation Questionnaire(ERQ),Emotional Reactivity Scale(ERS),Toronto Alexithymia Scale(TAS-20),social anhedonia scale(SAS),Childhood Trauma Questionnaire(CTQ),Clinical-administered Post Traumatic Stress Disorder Scale(CAPS),Wechsler Adult Intelligence Scale(WAIS-III),Trail Making Test(TMT),Pen and paper visuospatial working memory(DOT-test),impulsivity test(GoStop),Stroop test,National Adult Reading Test(NART),Wechsler Adult Intelligence Scale(WAIS-III),Facial Emotion Recognition task(FER)
106250|NCT03355768|Drug|Romidepsin|Intravenous administration on a 28 day cycle
106251|NCT03355768|Drug|Pralatrexate|Intravenous administration on a 28 day cycle
106252|NCT03355755|Device|EksoGT with SmartAssist software|Intervention will consist of exercise using the EksoGT exoskeleton for supported walking. The EksoGT is a powered motorized orthosis intended to enable individuals who are experiencing muscular or neurological conditions affecting their lower extremities to perform ambulatory functions such as gait training.
106253|NCT03355742|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
106254|NCT03355742|Drug|DAPT|1-month clear subjects will receive 1 month of P2Y12 inhibitor and 12 months of aspirin after index procedure.
106255|NCT03355716|Drug|bupivacaine|Bupivacaine 25 ml (0.25%)
106256|NCT03355716|Drug|morphine|Morphine (3.0 mg)
106257|NCT03355716|Drug|fentanyl|fentanyl (30.0 Mc)
106258|NCT03355716|Drug|Ketamine:|ketamine (0.5 mg/kg).
106259|NCT03355677|Procedure|Case finding Clinic|Case finding clinic - participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 3 quality of life and functionality questionnaires the MRC dyspnoea score and the COPD diagnostic questionnaire. They will then be asked to perform FeNO CO and spirometry measurements.
106260|NCT03355677|Procedure|At Risk Case Clinics|Complex Case Clinic participants will be reviewed by a respiratory specialist team. Full respiratory history will be taken and physical examination will be preformed. The participant will then complete 6 quality of life and functionality questionnaires . They will then be asked to perform FeNO CO and spirometry measurements. Participants inhaler technique will be checked and any errors corrected. Smoking cessation advice and support will be given if necessary. Each participant will be given an individualised self management plan.
106261|NCT03355677|Other|Usual Care|The control surgeries selected by the HHRA will continue with usual care.
106262|NCT03355664|Drug|ACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus low dose primaquine at hour 24
106263|NCT03355664|Drug|TACT|Artemether-lumefantrine (20/120 mg) as a fixed dose combination twice daily for 3 days according to weight plus Amodiaquine (150mg) twice daily for 3 days according to weight plus low dose primaquine at hour 24
106264|NCT03355651|Dietary Supplement|PROGEN|Dietary supplement based on plasma proteins, hydrolyzed collagen, a complex of Hyaluronic Acid - Chondroitin Sulfate (HC-15), and vitamin C
106265|NCT03355638|Drug|Aflibercept Injection [Eylea]|patients received monthly 0.5 mg aflibercept intravitreal injections for 3 months, after which monthly injections were administered pro re nata
106266|NCT03355638|Drug|Pranoprofen Eyedrops|Patients were given a bottle of eyedrops for self-administration of 0.1% pranoprofen (Pranoflog, Sifi SpA, Aci Sant'Antonio, CT, Italy). Pranoprofen dosage was 1 drop in the study eye, 3 times a day, over the 12-month study period
106267|NCT03355638|Drug|Omega-3 Supplementation|Ppatients were given daily tablets of Omega-3 supplementation provided free of charge by the company (Azyr Mega; Sifi SpA, Aci Sant'Antonio, CT, Italy).
106268|NCT03355612|Drug|Apatinib|Apatinib: 500 mg, qd, po, last 180 days
106269|NCT03355612|Drug|XELOX|Capecitabine:1000 mg/m2 bid d1-14 q3w, Oxaliplatin:130 mg/m2 d1 q3w
106270|NCT03355599|Other|3d camera|3 D camera and associated software that introduces measurement and monitoring of wounds as a specific intervention
106271|NCT03355586|Combination Product|Electromagnetic navigation|Electromagnetic navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
106272|NCT03355573|Drug|Bimekizumab|Bimekizumab at a prespecified dose.
106273|NCT03355560|Drug|Nivolumab|Nivolumab 480 mg IV infusion
106306|NCT03355287|Other|Lab Threshed Teff (LTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher.
106274|NCT03355547|Other|questionnaire about the severity of their symptoms of upper respiratory tract infection|Before the operation, the researcher interviews the parents of the pediatric patients to check whether they have the upper respiratory tract infection and asks them to fill out a questionnaire about the severity of their symptoms. The questionnaire consists of 8 types of symptom about upper respiratory infections and each symptom was checked from 0 to 3 according to severity by their patients.
106275|NCT03355534|Drug|Intravenous dexmedetomidine|drug is intravenously infused to patients
106276|NCT03355534|Drug|nasal dexmedetomidine|drug is nasally given to patients
106277|NCT03355534|Drug|intravenous saline|saline is given to patients intravenously
106278|NCT03355534|Drug|nasal saline|normal saline is given to patients nasally
106279|NCT03355521|Other|Nordic Walking|Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
106280|NCT03355521|Other|Free Walking|Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
106281|NCT03355508|Device|pucture in the arteriovenous fistula|"The compression time will be measured with a stopwatch so that it is objective and accurate, although the compression times range from minute to minute.~An initial 2-week observation phase (phase 1) will establish a reference time for each patient using the most common puncture technique in the department: bevel up.~We will evaluate the patient's reference time by counting the time of compression using a stopwatch for 2 weeks (ie 6 sessions) and we will take an average.~A draw will determine for each patient the order in which the direction of the needles will be used.~After this determination of the reference time, the patient will enter two successive phases where it will be punctured bevel up (phase 2) and then down (phase 3) or vice versa following the draw."
106282|NCT03355495|Procedure|Colonoscopy - Position Change|Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
106283|NCT03355482|Drug|Methylprednisolone|160mg IM at baseline
106284|NCT03355482|Drug|Placebos|IM saline injection at baseline
106285|NCT03355469|Drug|Low Intensity Exercise + Metformin|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with metformin.
106286|NCT03355469|Drug|High Intensity Exercise + Metformin|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with metformin.
106287|NCT03355469|Drug|Low Intensity Exercise + Placebo|Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
106288|NCT03355469|Drug|High Intensity Exercise + Placebo|High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
106289|NCT03355456|Procedure|Radiofrequency ablation|Ablation procedure to eliminate atrial fibrillation
106290|NCT03355443|Procedure|Retroflexion|Retroflexion technique in colonoscopy means turning the colonoscope tip 180 degree in order to look backward in the colon and rectum.
106291|NCT03355443|Procedure|Re-examination|Re-examination in colonoscopy means examining the cecum and ascending colon twice in the routine fashion.
106292|NCT03355430|Procedure|combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
106293|NCT03355430|Procedure|accelerated corneal collagen cross-linking (CXL)|After at least 1 month (average 2.7 ± 1.1 months; range 1 to 4 months), all patients were scheduled for combined corneal wavefront-guided tPRK and accelerated CXL treatment. tPRK between the corneal ring segments was performed using an excimer laser (Amaris 1050 Excimer Laser platform; Schwind eye-tech-solutions GmbH and Co KG, Kleinostheim, Germany).
106294|NCT03355417|Other|OT-SI|Occupational therapy using a sensory integration approach (OT-SI) 3x per week for 10 weeks. A typical session will be 1 hour (total of 3 hours per week).
106295|NCT03355404|Other|standing patient|patient goes standing to the surgery room
106296|NCT03355378|Procedure|gum chewing|chewing gum orally for 30 minutes
106297|NCT03355365|Biological|Intrathecal MSC-NP injection|MSC-NPs represent a neural subpopulation of MSCs from bone marrow with reduced pluripotency and minimized risk of ectopic differentiation, thus are likely to be more suitable for CNS delivery. Importantly, characterization of MSC-NPs demonstrated their immunoregulatory and trophic properties, and MSC-NPs derived from MS and non-MS patients alike were therapeutically viable.
106298|NCT03355365|Other|Intrathecal saline injection|Placebo
106299|NCT03355352|Drug|Sufentanil|Sufentail sublingual 15ug nanopills
106300|NCT03355339|Device|Binasal occlusion|Binasal occlusion glasses
106301|NCT03355339|Device|No binasal occlusion|Non-occluded glasses
106302|NCT03355326|Drug|Glycerin Suppository|Glycerin suppository is given once daily beginning after conditions described are met and continued until discontinue conditions are met.
106303|NCT03355313|Radiation|Low level Light therapy|Laser will be administered for 10 seconds on four intraoral points and four extraoral points in the region of the parotid glands bilaterally as well as one intraoral point and one extraoral point in the regions of the submandibular and sublingual glands.
106304|NCT03355300|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
106307|NCT03355287|Other|Fortified Lab Threshed Teff (FTT)|The intervention will take place for 7 months in Debre Zeit where this arm will be fed injera from teff that is threshed using a modern thresher. In addition, they will receive Ferrous sulfate drops
106308|NCT03355274|Diagnostic Test|Transcutaneous Oximetry|"The examination of transcutaneous Oximetry dynamic measurement with palmar face of both forearms during two consecutive maneuvers known as the candlestick (hands up).~the microcirculation measurement by the tissue vitality (TIVI) system will be performed on the hands during the operation of the candlestick."
106309|NCT03355261|Procedure|complete remission (CR) group|According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).
106310|NCT03355261|Procedure|partial remission (PR) group|According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).
106311|NCT03355261|Procedure|stable disease (SD) group|According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
106312|NCT03355261|Procedure|progressive disease (PD) group|According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
106313|NCT03355248|Other|Oxycodone Acetaminophen|Decrease in opioid prescribing for post-operative cesarean pain management
106314|NCT03355222|Behavioral|Promotion of chicken eggs|Community is provided with chickens and young children are to receive one egg a day; selected mothers will consume eggshell.
106315|NCT03355209|Drug|ZX008 0.2 or 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free and is intended to be compatible with a Ketogenic Diet.
106316|NCT03355209|Drug|Matching Placebo|Placebo will be administered twice a day (BID) in equally divided doses.
106317|NCT03355196|Drug|LRX712|Ascending single dose on Day 1
106318|NCT03355196|Drug|Placebo|Ascending single dose on Day 1
106319|NCT03355183|Other|Isokinetics|Isokinetics, or accommodating resistance, is a form of exercise where a person provides a maximum muscle contraction against a resistance or lever arm, (isokinetic dynamometer) at a fixed speed through a given range of motion. This type of muscle action can be done either concentrically or eccentrically at the given joint.
106320|NCT03355170|Combination Product|Lansoprazole/Domperidone|Experimental
106321|NCT03355170|Drug|Lansoprazole|Active comparator
106322|NCT03355157|Drug|Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)|Drug intervention
106323|NCT03355144|Dietary Supplement|Daily Supplementation with Coffee|"At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener"
106324|NCT03355131|Behavioral|Adapted NASA's Mission X program|8 Weeks Adapted National Aeronautics and Space Administration's (NASA's) Mission X (MX) program
106325|NCT03355118|Other|General anaesthesia and major surgery|The effect of general anaesthesia and surgery on oxygen transport and how it relates to outcome
106326|NCT03355105|Other|Objective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|The exsufflation pressures will be progressively increased starting from -20 cmH2O with 10 cmH2O increments up. 3 coughing operations will be realised for each level, until obtention of 10% of AUC decrease or a PCF collapse of at least 10% over the last 2 levels and without exceeding -70 cmH2O. The selected landing will be the one allowing the largest PCF without presence of collapse. An intermediate bearing between 2 bearings may be tested in order to approach an optimum adjustment threshold less than 5 cmH2O.
106327|NCT03355105|Other|Subjective adjustment of the MI/E exsuflation pressure and evaluation of cough effort|"The exsufflation pressures will be gradually increased from -20 cmH2O, with 10 cmH2O increments up to a maximum of -70 cmH2O. The selected level will be the one selected both by the patient and the clinician therapist and considered as making it possible to obtain the most effective cough according to the return of the patient."
106328|NCT03355092|Device|vBloc Therapy|The vBloc device will be placed using a laparoscopic procedure. The participants will be followed according to standard clinical practice and vBloc therapy protocol under the supervision of study surgeons. . Pre-operative testing will be conducted per surgeon's evaluation. Participants will receive weight management education according to the vBloc Therapy protocol.
106329|NCT03355079|Drug|SmofKabiven® E|In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
106330|NCT03355066|Drug|SM08502|tablet, dosed once daily
106331|NCT03355053|Drug|Dexmedetomidine|See description of study arms
106332|NCT03355040|Other|induction of labour|induction of labour
106333|NCT03355027|Drug|Alirocumab 150 MG/ML|Dosing to be performed by subcutaneous injection in clinic
106334|NCT03355027|Drug|Ezetimibe 10Mg Tablet|Patients will be instructed to take once daily at night.
106335|NCT03355027|Drug|Atorvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR < 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
106336|NCT03355027|Drug|Atorvastatin 80Mg Tablet|Patients will be instructed to take once daily at night. Atorvastatin will be the preferred statin option for those with eGFR < 60 ml/min/1.73m2. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
106337|NCT03355027|Drug|Rosuvastatin 20Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
106338|NCT03355027|Drug|Rosuvastatin 40Mg Tablet|Patients will be instructed to take once daily at night. Rosuvastatin only to be prescribed if atorvastatin and simvastatin are not previously tolerated. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
106339|NCT03355027|Drug|Simvastatin 80mg|Patients will be instructed to take once daily at night. Patient may be required to complete a 4 week run-in period on a statin prior to entering the study (dependent on eligibility)
106340|NCT03355014|Drug|Combination of gemigliptin/metformin HCl sustained release 50/1000mg|Gemigliptin/Metformin HCl extended release 25/500mg 2tablets
106341|NCT03355014|Drug|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg|Zemiglo 50mg 1 tablet Glucophage XR 2 tablets
106342|NCT03355001|Device|Monosyn® Quick|"Mucosal sutures in the facial and oral~Dermal sutures, particularly in pediatrics~Episiotomy~Circumcision"
106343|NCT03354988|Other|Physical exercise group|For the exercise group, systematic physical activity programs consisting of range-of-motion exercises with gentle compression, extension and flexion of all joints of both bilateral upper extremities; including the shoulder, elbow, and wrist and lower extremities; including the hip, knee and ankle, with a total of 12 joints. Each activity was about 10 min a day and was carried out 5 times per week for 4 weeks. This program was started after 1 week of birth. Physical activity continued until discharge from hospital
106344|NCT03354988|Other|Control group|Other routine care activities such as bathing (every day) and kangaroo care (30 minutes/day), will be done for both the control
106345|NCT03354975|Behavioral|Experiential Training|Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
106346|NCT03354975|Behavioral|Training-As-Usual|The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
106347|NCT03354962|Combination Product|Nivolumab + Ipilimumab|Nivolumab + Ipilimumab alone (standard dosage regimen)
106348|NCT03354962|Combination Product|Combined treatment schema|SBRT (recommended optimal dose) with Nivolumab + Ipilimumab (standard dosage regimen)
106349|NCT03354949|Other|Measurement of sitting postural control of the adult (MCPAA)|"The Adult Seated Postural Control Measure 2.0 (MCPAA 2.0) is a clinical evaluation tool for sitting postural control of adult clients using a locomotion aid. It thus allows the evaluation of the two variables inherent to the postural control sit, the alignment of body segments and the influence between movement and posture.~It can also be used to evaluate the changes in seated postural control due to changes over time or to an adaptation of the sitting posture.~Assessment of wheelchair pain in the spine and ischia by a self-evaluation scale (EVA).~the speed of propulsion by a wheelchair."
106350|NCT03354936|Biological|Blood sample|Blood samples will be collected to constitute cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy and possibly for complementary research
106351|NCT03354923|Behavioral|PEERS intervention|PEERS is a 14-week manualized social skills treatment program that targets the friendship skills of adolescents with ASD. In the Israeli adaptation of PEERS, two meeting were extended. An adolescents group will be held concurrently with the parents group in different rooms. Both groups will begin the session with homework review, followed by a didactic social skills lesson, utilizing the teaching methods of modeling and role-playing. In order to practice the newly learned social skills,a behavioral rehearsal interaction will be assigned in the adolescents group. Finally,Socialization homework assignments designed to address further mastery and generalization of newly learned skills within the natural social environment will be assigned too.
106352|NCT03354910|Behavioral|House Call|60 to 90 minute home based educational intervention which will be administered by a health educator.
106353|NCT03354910|Behavioral|Peer Mentorship|A National Kidney Foundation Peer Mentor will be assigned to the participant to provide contact and support to study participants.
106354|NCT03354897|Drug|Torasemide 5Mg Tablet|16 weeks treatment
106355|NCT03354884|Drug|cabozantinib|cabozantinib 60 mg orally once daily
106356|NCT03354858|Procedure|Follicular flushing|Repeated follicle flushing up to 5 times using a double lumen needle for oocyte recovery
106357|NCT03354845|Other|Deprescribing intervention|Pharmacists assessed the appropriateness of target symptomatic medications and potential for discontinuation. After discussion with pharmacists and consideration of patients' and caregivers' preferences regarding discontinuation or dose reduction, doctors would deprescribe these symptomatic medications. Symptom recurrence, adverse drug withdrawal events (ADWEs), and the need for drug re-initiation or initiation of new symptomatic control medications after deprescribing were monitored and documented in the 1st, 2nd and 6th weeks.
106358|NCT03354832|Other|Foetal death|A midwife is in charge to interview the mother during the month following the lost of her infant.
106359|NCT03354832|Other|New-born death|A midwife is in charge to interview the mother during the month following the lost of her infant.
106360|NCT03354832|Other|Birth control for foetal death|A midwife is in charge to interview the mother during her hospital stay
106361|NCT03354832|Other|Birth control for new-born death|A midwife is in charge to interview the mother during her hospital stay
106362|NCT03354819|Behavioral|Modified MBCT|"Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion & allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning"
106363|NCT03354819|Behavioral|SIRE on dementia|"The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~Overview of dementia~Pharmacological and non-pharmacological treatment of dementia~BPSD in dementia care~Person center care~Advance planning in people with dementia~Principle of mindfulness~Non-pharmacological intervention on stress reduction"
106364|NCT03354806|Procedure|Continuous peripheral nerve blocks|6 weeks-ropivacaine treatment delivered by continuous peripheral nerve blocks Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
106365|NCT03354806|Procedure|Analgesic treatment|6 weeks-analgesic treatment according to WHO's pain relief ladder Transcutaneous oxygen measurement is assessed on day 2, week 3 and week 6 under atmospheric and hyperbaric conditions
106367|NCT03354793|Other|Survey on first pregnancy|Obstetric complications were noted
106368|NCT03354780|Other|Survey on first pregnancy after endometriosis diagnosis|rate of miscarriage was noted
106369|NCT03354780|Other|Survey on first pregnancy|rate of miscarriage was noted
106370|NCT03354767|Procedure|Aortic and aortic valve surgery|
106371|NCT03354754|Drug|LYS228|LYS228 IV infusion every 6 hours
106372|NCT03354754|Drug|Standard of care therapy|IV infusion of standard of care antibiotics
106373|NCT03354741|Other|laser therapy|stimulation of the acupuncture point P6 by laser therapy
106374|NCT03354728|Biological|Multi-antigen CMV-Modified Vaccinia Ankara Vaccine|Given IM
106375|NCT03354728|Other|Laboratory Biomarker Analysis|Correlative studies
106376|NCT03354715|Device|Rapid prototyping Denture base|The introduction of rapid prototyping (RP)Stereo lithography (SLA) technology, which mainly depends on addition of layers of materials which would be polymerized using a light curing unit. It consists of a bath of photo polymerized liquid and ultraviolet unit for curing these layers, that would bond to each other till forming the full object. SLA has many advantage as high accuracy, high mechanical strength, smooth surface finish with close tolerance and fine details printing, but it has some limitation as it is only limited Material, in addition to the high material and equipment cost.
106377|NCT03354715|Device|Heat Cured Conventional Complete Denture|it is the main treatment for most of completely edentoulous Cases
106378|NCT03354702|Other|Aerobic|Aerobic exercise Patients performs 8 sessions of aerobic exercise (walking / running),with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
106379|NCT03354702|Other|Stretching|Stretching Patients performs 8 sessions of stretching, with monitoring and 8 sessions without monitoring totaling 16 sessions and patients have medical appointment with psychiatrist and make psychotherapy sessions.
106380|NCT03354689|Radiation|Scintigraphy|Scintigraphy
106381|NCT03354676|Other|MetS+|Data processing from Patient Medical Files
106382|NCT03354676|Other|MetS-|Data processing from Patient Medical Files
106383|NCT03354663|Device|TactiCath SE|Ablation to achieve pulmonary vein isolation.
106384|NCT03354650|Diagnostic Test|blood culture|blood culture to determine causative organisms of neonatal sepsis
106385|NCT03354637|Drug|ATI-50002 high dose|Topical solution
106386|NCT03354637|Drug|ATI-50002 low dose|Topical solution
106387|NCT03354637|Drug|Placebo|Topical solution
106388|NCT03354624|Drug|Sterile solutions of recombinant human nerve growth factor (NGF)|The intramuscular injections of NGF cause muscle soreness.
106389|NCT03354611|Radiation|Contrast Enhanced Cone Beam Breast CT Scan|"Pre-contrast scan~Begin contrast injection (and saline chaser)~Post-contrast Scan. Start time of post-contrast CE-CBBCT scan is 90-200 seconds after start of injection, depending on method of contrast delivery (bolus vs hand injection)"
106390|NCT03354611|Drug|Contrast Dye, Iodinated|"1.5-2ml/kg body weight (100 ml maximum) of a low osmolar, nonionic, 300-350 mgI/ml iodinated contrast agent, will be injected at a rate of ~2.0 ml/s, for a total injection time of 30-60 seconds (for a 50 kg subject). This will be immediately followed by a saline chaser from 20 to 40 ml at ~2 ml/s (20 seconds) to maximize dynamic enhancement."
106391|NCT03354598|Drug|Sulopenem-Etzadroxil/Probenecid|Treatment of uncomplicated urinary tract infection
106392|NCT03354598|Drug|Ciprofloxacin|Treatment of uncomplicated urinary tract infection
106393|NCT03354585|Behavioral|Meditation training|A well-validated brief mindfulness-based mental training regimen [20 min/session(s)] will be used to teach patients to independently practice mindfulness. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
106394|NCT03354585|Behavioral|Meditatin training|A well-validated brief meditation-based mental training regimen [20 min/session(s)] will be used to teach patients to independently practice mindfulness. Participants will be asked to close their eyes acknowledge distracting thoughts and feelings.
106395|NCT03354585|Behavioral|Book Listening Control|Study volunteers will listen to The Natural History and Antiquities of Selborne throughout the intervention.
106396|NCT03354572|Drug|Acetyl cysteine|acetyl cysteine 150 mg/kg prior to surgery
106397|NCT03354572|Drug|Placebos|saline 0.9% prior to surgery
106398|NCT03354546|Diagnostic Test|Frailty index|A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
106399|NCT03354533|Drug|L-fucose|Oral ORL-1F
106400|NCT03354520|Behavioral|Tailored Videos|web-based OSA messages (videos featuring role models and coaching advice using motivational enhancement) addressing OSA barriers within a health literacy framework--to decrease cognitive load and render messages understandable and actionable. OSA messages were tailored based on focus group data in the previous study (group tailoring).
106401|NCT03354520|Behavioral|OSA Treatment|Web-based platform delivering messages promoting OSA self-efficacy. . All patients will view the introductory video, followed by the video cluster: Sleep, Health, and Well-Being; Sleep-Heart Health; Lifestyle Changes; and Sleep Hygiene.
106402|NCT03354520|Behavioral|Standard Videos|Patients in the control arm will also receive an iPad, providing access to standard online OSA health information (e.g., National Sleep Foundation) in an equivalent dose as in the intervention arm using pre-selected automatic alerts to access the website
106403|NCT03354507|Dietary Supplement|Sodium bicarbonate|Sodium bicarbonate. See arms.
106404|NCT03354494|Drug|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa|
106405|NCT03354481|Behavioral|Arithmetic facts solving|The experiment will contain several tasks. The main one will be a computerized task on arithmetic facts where participants will have to solve simple additions. There will also be three additional tasks: a processing speed task where the participant will have to tell the orientation of an arrow as fast as possible, a visuo-spatial task where the participant will have to reproduce a tapping block sequence and an arithmetic task where the participant will try to solve a maximum of operations in a limited time.
106435|NCT03354234|Other|Head up tilt (HUT)|Model of -Gz: HUT up to 75 degrees (maximum)
106436|NCT03354234|Other|Lower body negative pressure (LBNP)|Model of -Gz: LBNP down to -100 mmHg (maximum)
106406|NCT03354468|Behavioral|fall prevention program|fall prevention program in orthopedic department, consisting of 1) Seven examples of risk factors which might cause falls (diseases and medications, movement, cognitive behavior, vision, continence, nutrition, and the room and surroundings), 2) Methods to detect the risk factors, and 3) Measures to avoid falls or protect the patient in case of a fall.
106407|NCT03354455|Device|Repetitive transcranial magnetic stimulation|"Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot."
106408|NCT03354442|Device|Modified Fixed Mandibular Retractor Appliance|All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
106409|NCT03354429|Drug|Ticagrelor|Ticagrelor arm: Day 1, loading dose of ticagrelor followed by daily maintenance dose until Day 30.
106410|NCT03354429|Drug|Placebo|Placebo arm: Day 1, loading dose of placebo followed by placebo daily maintenance dose until Day 30.
106411|NCT03354390|Biological|cell infusion|This is a single-arm, phase 1 trial of HERV-E TCR transduced CD8+/CD34+ T cells in HLAA* 11:01 positive patients with metastatic ccRCC. The study is planned based on a Phase 1 3+3 dose escalation design. The maximum tolerated dose (MTD) is defined as the highest dose at which 0 or 1 patient in six has experienced a dose limiting toxicity (DLT). Patients with evaluable advanced/metastatic ccRCC will be recruited in up to 4 dose levels.
106412|NCT03354377|Behavioral|Dietary Intervention Meetings|Participants will attend classes once per week for the first 6 months, bi-weekly for the next 6 months; then once a month for the last 12 months.
106413|NCT03354377|Behavioral|Physical Activity|Participants will be given the following exercise recommendations: strength training twice per week and ≥75 min of vigorous or ≥150 min of moderate PA per week and will be provided with accelerometers.
106414|NCT03354377|Behavioral|Podcasts/Mailings|Participants with receive additional support delivered remotely months 13-24 in the form of audio podcasts and email newsletters.
106415|NCT03354364|Dietary Supplement|Pea hull fiber|Snacks containing 15 g/day of ground pea hulls.
106416|NCT03354364|Dietary Supplement|Control|Snacks without added fiber.
106417|NCT03354351|Behavioral|Stepped-care model|The intervention proposed in this study is a stepped-care model (comprising 3 steps) integrating cognitive-behavioural therapy or trauma-focused therapy and emotion-focused therapy that involves matching individuals to the most appropriate level of care, based on their specific needs . When patients do not show improvement they move to higher, more intensive levels of care.
106418|NCT03354338|Drug|Amoxicillin|Intensive Periodontal treatment; Pre-medication with 2 gr of oral Amoxicillin 1 hour before treatment
106419|NCT03354338|Other|Placebo|Intensive Periodontal treatment; Pre-medication with 2 gr of Placebo 1 hour before treatment
106420|NCT03354325|Behavioral|Scheduled PCP follow-up|Parents of children randomized to scheduled follow up will be instructed to follow up with their primary care physician within 4 days of discharge regardless of improvement and/or symptom resolution. Research coordinators will verify that the child has a scheduled follow up appointment prior to discharge.
106421|NCT03354325|Behavioral|As needed PCP follow-up|At the time of hospital discharge, parents will be instructed that the child does not need to automatically follow up with his/her primary care physician. Rather, the child should follow up on an as needed basis: if the child does not improve or if new concerns arise.
106422|NCT03354312|Drug|Lidocaine Hydrochloride 1% Gel|Cylinder vials with 1.7 g gel containing 34 mg lidocaine (1 g gel contains 20 mg lidocaine) will be used. Application of the gel into the periodontal pockets or the sulcus according to summary of product characteristics (SmPC). A total dose of 40 mg lidocaine should not be exceeded.
106423|NCT03354312|Drug|Articaine hydrochloride/epinephrine (adrenaline) hydrochloride|Cylinder vials with 1.7 ml solution for injection containing 68 mg articaine and 0.0102 mg epinephrine (1 ml contains 40 mg articaine and 0.006 mg epinephrine) will be used. Infiltration anesthesia for the upper jaw and infiltration or nerve block anesthesia for the lower jaw with articaine solution for injection according to SmPC. Adults can be treated with up to 7 mg articaine per kg of body weight per treatment session.
106424|NCT03354299|Dietary Supplement|coconut milk|50 cc of coconut milk supplementation plus 25 gram sugar (pudding) was given to cirrhosis patients as late night snack
106425|NCT03354286|Behavioral|Developmental & Technological Demands|Education and training related to use of CGM in this age group
106426|NCT03354286|Behavioral|Distress Reduction|Education and training on reducing distress
106427|NCT03354286|Behavioral|Nutrition, Set Point, & C:I Ratio|Education and training on how to use the HCL system to dose for different kinds of foods to improve glycemic control
106428|NCT03354286|Behavioral|Hypoglycemia management|Education and training on reducing worries of hypoglycemia
106429|NCT03354286|Behavioral|Minimal Intervention|Minimal intervention to simulate standard care - serves as the control group
106430|NCT03354273|Drug|PET MPI|Flurpiridaz (18F) Injection. All subjects will receive 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions will not exceed a total of 14 mCi (520 MBq) for an individual subject.
106431|NCT03354273|Drug|SPECT MPI|SPECT imaging must use 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study will be administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All patients will undergo SPECT MPI.
106432|NCT03354273|Drug|Pharmacological stress agents|Pharmacologic stress agents will be restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration will be through an IV line.
106433|NCT03354260|Other|Personalized adapted oral diet and nutritional education|Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
106434|NCT03354247|Behavioral|Lifestyle Intervention|Participants randomized to the Lifestyle Intervention will receive an intensive, state-of-the-art weight loss intervention based on a Mediterranean diet and physical activity. The intervention will focus on changing both eating and exercise habits with a goal of producing a 7-10% weight loss within the first 6 months and then maintaining this weight loss. Participants will be evaluate using validated questionnaires and adherence scores to assess food intake and physical activity, and will then be closely followed during the intervention period.
106437|NCT03354234|Other|Head down tilt (HDT)|Model of +Gz: HDT down to -30 degrees (maximum)
106438|NCT03354234|Device|Tilt table|Range of tilt angles: -45° to +80°, rate of tilt changes: up to 45°/s
106439|NCT03354234|Device|LBNP chamber|Range of generated underpressure: 0 to -100 mmHg, rate of underpressure changes: up to 20 mmHg/s
106440|NCT03354221|Device|Cytosponge|Patients undergoing the six food elimination diet will be monitored during the initial elimination period at 2, 4 and 6 weeks with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
106441|NCT03354221|Other|Diet|During the initial 6 week elimination period, participants will eliminate the 6 most common food allergens from their diet (fish, nuts, eggs, soy, wheat, dairy). Participants will return for the cytosponge during this time at 2, 4 and 6 weeks of elimination.
106442|NCT03354221|Other|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline and during each cytosponge visit during the initial elimination period (2, 4, 6 weeks).
106443|NCT03354221|Other|Likert Scoring Scale|"This is a short questionnaire for patients to compare their experiences swallowing the cytosponge versus completing an upper endoscopy. The scale is rated from worst experience to best experience."
106444|NCT03354208|Other|blood sampling|small volume blood sampling, according to local laws, is not categorized as intervention (observational study)
106445|NCT03354195|Procedure|Unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system.|All patients will receive the RESTORIS MCK (Multicompartmental Knee) Implant System, which is approved for use in unicompartmental knee arthroplasty with the Mako Robotic Arm-assisted system. The femoral component is constructed from cobalt chrome (CoCr) and the tibial component is constructed from an ultra-high molecular weight polyethylene (UHMWPE) insert and titanium (Ti) baseplate. UKA will be facilitated with MAKO Robotic-Arm Assisted Surgery, which has been shown in prior studies to lower pain and result in more accurate implant placement than manual UKA in a randomized controlled trial.(15)
106446|NCT03354182|Procedure|Open flap surgery|Elevation of a flap in order to access the treated furcation
106447|NCT03354182|Device|Bio-oss collagen|Biomaterial for periodontal surgery
106448|NCT03354182|Device|Bio-gide|Biomaterial for periodontal surgery
106449|NCT03354169|Behavioral|Eating Condition|Participants will be randomly assigned to eat per the prescribed eating condition for 8 weeks during eating condition 1. They will complete the alternate eating condition for 8 weeks during eating condition 2.
106450|NCT03354156|Drug|statin treatment|The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
106451|NCT03354143|Drug|Standard Care|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 130 mmHg.
106452|NCT03354143|Drug|Intensive Treatment|Calcium channel blocker (CCB, amlodipine), angiotensin II receptor blocker (ARB, losartan), and other antihypertensive drugs will be used to reduce 24-hour SBP ≤ 120 mmHg.
106453|NCT03354130|Other|Processed meat dietary intervention|Randomized cross-over dietary intervention with 5 different diets
106454|NCT03354117|Drug|Ulipristal Acetate 30 MG Oral Tablet|Each study participant will receive one dose of the study medication (ulipristal acetate 30mg plus meloxicam 15mg) at peak fertility in the treatment cycle.
106455|NCT03354104|Device|The tunnel technique for root coverage with Emdogain|The tunnel technique for root coverage with Emdogain
106456|NCT03354104|Device|The tunnel technique for root coverage without Emdogain|The tunnel technique for root coverage without Emdogain
106457|NCT03354091|Device|FitBit Flex 2|Participants in the intervention Group will wear the FitBit Flex 2 for Three months.
106458|NCT03354078|Procedure|interrupted sutures|The way of closing subcutaneous tissue either by interrupted
106459|NCT03354078|Procedure|continous sutures|The way of closure of subcutanous tissue is by continous sutures
106460|NCT03354065|Dietary Supplement|TIME OF FEEDING|Liquid ( Re Feeding 8 h ) OR Enteral Feeding ( re feeding 48 h)
106461|NCT03354052|Device|Real-rTMS + Gloreha device|The real rTMS will be delivered using a 8-shaped coil placed over the primary motor cortex (M1). The resting motor threshold (RMT) will be assessed at the place of the first dorsal interosseous (FDI) contralateral to the stimulated cortex. RMT of the FDI will be determined as the lowest strength of TMS needed to elicit 5 or more electromyographic responses ≥50 μV within 10 trials. Stimulation will be applied with frequency 10 Hz and intensity of 90% of RMT. Every session will last 15 minutes and includes 3000 pulses (30 trains of 10 seconds, following intertrain interval of 20 seconds). Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
106462|NCT03354052|Device|Sham-rTMS + Gloreha device|The sham rTMS will be delivered using a sham stimulator. All procedures will be performed as for the real treatment. Rehabilitation programme will last 30 minutes and will be delivered using Gloreha® device, a proprioceptive stimulator under visual feedback. All the subjects enrolled will receive treatments for 2 weeks, 5 days per week.
106463|NCT03354039|Drug|Tamoxifen|DMD patients randomised to verum will receive 20 mg (0.6mg/kg) of Tamoxifen daily. Treatment will be given for the total period of 48 weeks.
106464|NCT03354039|Drug|Matching placebo|Patients randomised to placebo will be administered matching placebo. Treatment will be given for the total period of 48 weeks.
106465|NCT03354026|Drug|AICH-PXZY|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
106466|NCT03354026|Drug|AICH-without PXZY|AICH-2(herbal medicine without Hirudo, Tabanus) (6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
106467|NCT03354026|Drug|AICH-placebo|The placebo is made up of Starch, bitter taste and cyclodextrin
106468|NCT03354013|Procedure|AOA|100% ICSI-AOA will be performed in the group with less than 6 mature oocytes; 50% ICSI/50% ICSI-AOA will be performed when 6 or more mature oocytes are retrieved
106469|NCT03354013|Diagnostic Test|Genetic screening|Patients will donate a saliva sample. Genetic screening will take place for PLCzeta (male) and Dux4 (male and female). Also other possible genes involved in embryo development could be tested.
106501|NCT03353818|Behavioral|No intervention|Patients acting as controls will not be restricted in any ways.
106470|NCT03354013|Diagnostic Test|Calcium pattern analysis|Male patients will donate a sperm sample. Calcium pattern analysis will take place by injecting the patients' sperm into mouse and/or human (in vitro matured) oocytes (research-donated control oocytes). This will estimate the sperm capability to induce calcium oscillations in the oocyte.
106471|NCT03354000|Behavioral|Take-home online training|We randomized patients to receive a link to access the online tutorial on their own. Participants in the take-home arm were given a paper handout with a link to the training materials and an outline of the steps for accessing the training curriculum.
106472|NCT03354000|Behavioral|In-person online training|For participants randomized to the in-person training arm, a trained research assistant prompted participants to log into the learning platform and guided them in accessing the training materials for portal features that were of interest to them. The staff member provided further explanation or clarification if participants had questions about the training material.
106473|NCT03353987|Behavioral|Cognitive training|"Procedure~A therapist will go through the daily routine of the participants at home before starting the intervention~Selections of exercise items based on familiar items/ activities at home~Given a memory logbook with list of household items, names and numbers and newspaper cuttings from the previous week~Taught on how to perform the exercises~Perform at least one hour per day~Both spatial and visual memory strategies will be used for memory training: simple mnemonics, associations, visualisations, rhymes~Advised to follow-up with the therapist to review on the progress and compliance of exercises weekly~The difficulty of the exercise will be adjusted weekly~List of exercises:~Memorizing a set of lists, household items, names and numbers~Summarising the contents of newspaper cuttings within a set of time~Searching and listing sets of words from newspaper cuttings"
106474|NCT03353974|Device|Video game therapy|Video game therapy will be delivered with a commercial video game console (X-Box 360 Kinect, Microsoft, Inc., Redmond, WA).
106475|NCT03353974|Device|Balance platform therapy|Balance/rebalancing, postural stability and weight-shifting exercises with and without visual feedback will be administered using a balance platform (Biodex Medical Systems, Inc., Shirley, NY).
106476|NCT03353961|Behavioral|Emotion regulation individual therapy|The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
106477|NCT03353961|Behavioral|Treatment as usual|Treatment as usual as provided in the community.
106478|NCT03353948|Drug|MET|In the MET group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os for 12 weeks. After 1 month IVF was done.
106479|NCT03353948|Drug|COMBI|In the COMBI group the initial dose of MET was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg BID. Liraglutide 1.2 mg QD s.c. was added after first two weeks of monotherapy with MET. After 1 month IVF was done.
106480|NCT03353935|Other|Validated questionnaires|Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
106481|NCT03353922|Drug|Cyclobenzaprine 10 Mg Oral Tablet|cyclobenzaprine 10 mg tablets
106482|NCT03353922|Drug|Placebo Oral Tablet|sugar pill
106483|NCT03353909|Device|new crosslinked hyaluronan gel|At the end of the dilatation and curettage, new crosslinked hyaluronan gel was applied to the uterine cavity.
106484|NCT03353896|Device|Wear novoTTF-200A|Wear novoTTF-200A device
106485|NCT03353896|Procedure|Quality-of-Life Assessment|Ancillary studies
106486|NCT03353883|Drug|Triptorelin SR|GnRH agonist depot( Decapeptyl) will be taken in the previous mid luteal cycle in group A and the first day in group B
106487|NCT03353870|Other|qualitative interview|individual qualitative interview
106488|NCT03353857|Drug|levonorgestrel/ Microlut|In Period 1, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 1, In Period 2, 0.03 mg single dose administered as 1x0.03 mg tablet on Study Day 15 In Period 3, 0.03 mg single dose administered as 1x0.03 mg tablet at Study Day 26
106489|NCT03353857|Drug|Norethindrone/ Noriday|In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
106490|NCT03353857|Drug|Desogestrel/ Cerazette|In Period 1, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 1, In Period 2, 0.075 mg single dose administered as 1x0.075 mg tablet on Study Day 15 In Period 3, 0.075 mg single dose administered as 1x0.075 mg tablet at Study Day 26
106491|NCT03353857|Drug|Dienogest/ Visanne|In Period 1, 2 mg single dose administered as 1x2 mg tablet on Study Day 1, In Period 2, 2 mg single dose administered as 1x2 mg tablet on Study Day 15 In Period 3, 2 mg single dose administered as 1x2 mg tablet at Study Day 26
106492|NCT03353857|Drug|Drospirenone, Ethinylestradiol/ Yasmin|In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
106493|NCT03353857|Drug|Midazolam/ Midazolam-ratiopharm|In Period 1, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 1, In Period 2, 1 mg single dose administered as 1x0.5 ml oral solution on Study Day 15 In Period 3, 1 mg single dose administered as 1x0.5 ml oral solution at Study Day 26
106494|NCT03353857|Drug|Rifampicin|In period 2, 10 mg (suspension, 0.5 ml) for 11 days at 10 mg/day In period 3, 600 mg (film-coated tablets) for 11 days at 600 mg/day
106495|NCT03353844|Behavioral|Intradialytic exercise|intradialytic exercise which start and finish in first hour of hemodiafiltration session
106496|NCT03353831|Drug|Bevacizumab|Bevacizumab will be administered by intravenouse route at a dose of 10mg/kg q14 during the treatment period
106497|NCT03353831|Drug|Atezolizumab|Atezolizumab will be administered by intravenous route at a dose of 840 mg q14 during the treatment period
106498|NCT03353831|Drug|Chemotherapy|Chemotherapy (Paclitaxel or PLD) will be administered by intravenous route at different doses during the treatment period q28
106499|NCT03353831|Drug|Placebos|Placebo will be administered by intravenous route q14 during the treatment period
106500|NCT03353818|Behavioral|Golf|A free golf course and free membership for one year in a golf club will be given to participants.
106503|NCT03353792|Device|CL/AP system|CL/AP system enabled insulin pump/CGM combination
106504|NCT03353792|Device|usual diabetic care|usual diabetic care (insulin pump therapy) along with CGM recording
106505|NCT03353766|Device|Early crossbite correction with Q-H Device|Crossbite treatment in deciduous dentition with Quad-Helix appliance
106506|NCT03353753|Drug|DCC-2618|Oral KIT/PDGFRA kinase inhibitor
106507|NCT03353753|Drug|Placebo Oral Tablet|Placebo
106508|NCT03353740|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
106509|NCT03353727|Other|Orthoptic rehabilitation|Orthoptic rehabilitation using innovative mechanisms (eye tracker and tactile device) for low vision people
106510|NCT03353714|Other|Pudendal block|Pudendal block with normal saline (for control group) and bupivacaine (for intervention group)
106511|NCT03353701|Behavioral|Contingency Management (CM)|A reinforcement delivery method that involves financial incentive to participants for sustained alcohol abstinence. CM will start after the participants complete the baseline measures and last for at least 30 days and up to 90 days.
106512|NCT03353688|Device|Boston Scientific Vercise PC IPG with directional DBS lead|Deep brain stimulation
106513|NCT03353675|Biological|TG4010|1 dose (1x1E+08) Subcutaneous injection/week over 6 weeks then 1 dose/3 weeks
106514|NCT03353675|Drug|Chemotherapy|"Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance"
106515|NCT03353675|Drug|Nivolumab|360 mg IV administration every 3 weeks
106516|NCT03353662|Other|Women of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Gamo Gofa between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
106517|NCT03353662|Other|Children of Gamo Gofa|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Gamo Gofa between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
106518|NCT03353662|Other|Women of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of West Gojjam between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
106519|NCT03353662|Other|Children of West Gojjam|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of West Gojjam between the age of 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
106520|NCT03353662|Other|Women of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the women of Kamashi between 15-49 years by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
106521|NCT03353662|Other|Children of Kamashi|The prevalence of Fe, Zn and vitamin A deficiency will be assessed in the children of Kamashi between 6-59 months by measuring hemoglobin (Hb), plasma ferritin (PF), soluble transferrin receptor (sTfR), C-reactive protocol (CRP), alpha-1-acid glycoprotein (AGP), plasma Zn (PZn), plasma retinol and retinol binding protein (RBP), respectively.
106522|NCT03353649|Behavioral|Now vs. Later Cue|"As we collect data from all participants, we will include manipulations (or motivating operations) meant to modulate putative targets within the self-regulation domain in each clinical group - to assess the extent to which we can shift self-regulatory function both in desired and undesired directions. More specifically, subjects will see a now cue instructing them to think of immediately using/consuming that stimulus or a later cue instruction them to think about the long-term consequences of using/consuming that stimulus. The latter cue is intended to down-regulate desire to use/consume the stimulus, and this down-regulation is measured by a subsequent probe asking subjects the degree to which they want to use/consume that stimulus."
106523|NCT03353649|Device|fMRI|Subjects will complete the tasks inside a functional magnetic resonance imaging device, allowing us to measure brain activity that while completing each task.
106524|NCT03353636|Dietary Supplement|Magnesium|150mg elemental magnesium
106525|NCT03353636|Dietary Supplement|Placebo|Rice flour
106526|NCT03353623|Device|Serious Game|"Serious Game (SG) refers to the use of immersive virtual environments and wearable haptic devices during the treatment. Two SG were specifically developed to allow a playful training of different, targeted Upper Limb (UL) movement based on typical rehabilitation exercises (reach-to-grasp, linear path tracking, hand orientation). The child interacts directly with a virtual environment through haptic feedback provided to his/her fingertips. In particular, moneybox game focused on pincer grasp and reaching tasks with pronation/supination od the hand while marble labyrinth game focused on pointing and tracking movements requiring both eye-hand and upper limb inter-joint coordination."
106527|NCT03353623|Other|Conventional Therapy|Conventional therapy (CONV) refers to the neurocognitive rehabilitation approach, with the purpose of improving pointing, tracking, reaching and grasping, and pronation/supination of the forearm. The therapeutic sessions were performed with the exception of the visual channel to ensure that the child focused his/her attention on tactile/kinesthetic information to complete the task. In particular, five different tasks have been proposed during the sessions: 1) recognize trajectories; 2) arm proprioception; 3) object manipulation; 4) recognize surfaces; 5) forearm orientation.
106528|NCT03353597|Biological|Plasma Transfusion|All subjects will receive monthly, 2-unit transfusions of young healthy male donor plasma for total of 6 treatments. The plasma will be administered at a transfusion services facility in a manner consistent with generally accepted and standard guidelines for plasma transfusions.
106529|NCT03353584|Other|Virtual Reality Therapy|The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
106530|NCT03353571|Device|"C3 UMBRELLA CATHETER"|The C3 is an alternative method to facilitate bladder drainage in the study population which are using either a foley catheter or Clean Intermittent Catheter technique to drain the bladder.
106531|NCT03353558|Device|Actigraph|The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.
106532|NCT03353519|Other|Primary care model|"Specifically, the intervention will comprise the following components:~Structured review of patient needs;~A self-management programme (MLAS) for stroke survivors and their carers;~A direct point of contact for stroke survivors and carers at the GP surgery;~Optimised communication between General Practice staff and specialist services;~Service mapping for stroke related needs;~Training for General Practice staff."
106535|NCT03353493|Behavioral|MBCT|Mindfulness-Based Cognitive Therapy (MBCT) is an 8 week manualised group intervention. MBCT will be delivered according to the manual by Segal, Williams & Teasdale (2013).
106536|NCT03353493|Other|TAU|Treatment as usual (TAU)
106537|NCT03353480|Drug|Azithromycin Tablet manufactured in China|250 mg Azithromycin Tablet manufactured in China
106538|NCT03353480|Drug|Azithromycin Tablet manufactured in US|250 mg Azithromycin Tablet manufactured in US
106539|NCT03353467|Procedure|Endoscopic surgery|Endoscopic nasopharyngectomy included endoscopic resection, with or without posterior pedicle nasal mucoperiosteal flap resurfacing the nasopharyngeal defects.
106540|NCT03353467|Radiation|Intensity-modulated radiotherapy|All of the patients were received irradiation by IMRT. The target volumes were delineated according to a previously described institutional treatment protocol, which is in accordance with the International Commission on Radiation Units and Measurements reports 50 and 62.
106541|NCT03353454|Drug|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
106542|NCT03353454|Drug|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
106543|NCT03353441|Dietary Supplement|Microencapsulated Sublingual Glycine (MSG)|Glycine (MSG) tablet
106544|NCT03353441|Dietary Supplement|Placebo|Lactose tablet manufactured to mimic Glycine (MSG) tablet
106545|NCT03353428|Biological|LC-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg via IV, chest or tumor injection each time
106546|NCT03353415|Device|Dexcom continuous glucose monitor|The CGM will monitor sensor glucose levels in all participants. During the first two weeks of the study, participants will be masked to the sensor glucose levels and will need to use other methods, such as a blood sample from a finger stick, to check their blood sugar. During the second two weeks, participants will be able to see the sensor glucose levels displayed from the CGM. Participants will be instructed to use this information to treat low glucose levels before symptoms or severely low glucose levels develop.
106547|NCT03353402|Procedure|Fecal Microbiota Transplant (FMT)|Patients with metastatic melanoma who responded to immunotherapy will serve as the fecal implant donors. The tested fecal implant will be used for two different products. The first part of the tested stool will be mixed with a saline solution, strained and infused into your bowel using colonoscopy. The second part of the tested stool will be packed into capsules. These stool capsules are at the size of standard drug-containing capsules and can be swallowed in a standard manner. Stool capsules are a common method of FMT and has been used worldwide for several years. After the colonoscopy, you will be asked to swallow the capsules. Swallowing the capsules will be conducted at the clinic, and does not require any additional procedures.
106548|NCT03353389|Other|No AKI|Subjects will be allocated into this group if they did not acquire Acute Kidney Injury during admission.
106549|NCT03353389|Other|CA-AKI|"CA-AKI is defined by any patient who developed AKI (as per definition below) within 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
106550|NCT03353389|Other|HA-AKI|"HA-AKI is defined by any patient who developed AKI (as per definition below) after 48 hours of hospital admission.~Definition of AKI:~i. An increase in serum creatinine of 0.3 mg/dl (26.5 μmol/l) within 48 hours OR ii. An increase in serum creatinine to more or equal to 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days~Definition for baseline creatinine:~i. The baseline creatinine level is defined as the creatinine level at or within 7 days before the hospital admission, OR ii. at the hospital admission OR iii. the lowest creatinine (excluding the post dialysis creatinine if dialysis is initiated) during the index hospitalisation for those whose baseline creatinine were unknown."
106551|NCT03353376|Behavioral|group care with Empowerment model|Patients with type 2 and type 1 diabetes were followed in a tertiary outpatient clinic with group appointment
106552|NCT03353363|Drug|Bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of bupivacaine 0.5% plain will be infiltrated into the wound by the obstetrician team in a standardized fashion.
106553|NCT03353363|Drug|Liposomal bupivacaine|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of one liposomal bupivacaine will be infiltrated into the wound by the obstetrician team in a standardized fashion.
106554|NCT03353363|Drug|Placebos|After patients receive their spinal anesthetic and as the Pfannenstiel incision is being closed, an equal volume (20ml, administered via two 10ml syringes) of normal saline will be infiltrated into the wound by the obstetrician team in a standardized fashion.
106555|NCT03353350|Drug|efpeglenatide (SAR439977)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
106556|NCT03353350|Drug|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
106557|NCT03353337|Behavioral|aerobic exercise|Cycling at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 1 months.
107627|NCT03344640|Other|Placebo|Placebo to match AIN457 subcutaneously for 12 weeks
106558|NCT03353337|Behavioral|Placebo controlled group|General intensity activities of recreation therapy, including Handicraft manufacture, reading activity, singing entertainment, walking.
106559|NCT03353324|Drug|intravitreal injection of bevacizumab|under gone 3 intravitreal injection of bevacizumab monthly and examine monthly for Visual acuity and central macular thickness, if in month four or more the CMT is more than 250 micrometer and the visual acuity is less than 8/10 the injection is repeatet and follow up in this manner is continued until 9 months.
106560|NCT03353324|Radiation|intravitreal injection of bevacizumab+ targeted laser|"patients in this group undergone laser photocoagulation of retinal non perfused areas based on FAG wide field imaging .~After 9 month follow up the outcomes such as Vusal acuity, Central macular thickness, intraocular pressure, neovascular formation are compared"
106561|NCT03353298|Drug|Allopurinol 300 mg|Allopurinol oral tablets 300 mg given to participants once daily for 9 months
106562|NCT03353298|Drug|Placebo Oral Tablet|placebo oral tablets given to participants once daily for 9 months
106563|NCT03353285|Procedure|intracytoplasmic sperm injection (ICSI)|All eggs will be fertilized by ICSI
106564|NCT03353272|Behavioral|Patient Engagement Education and Restructuring of Cognitions|This protocol, informed by principles of CBT, involves three components: 1) engagement, 2) education and 3) cognitive restructuring and behavioral activation. A health coach who is responsible for engaging patients, educating them about pain modulatory mechanisms, and reinforcing cognitive and behavioral coping skills, will deliver the PEERC protocol.
106565|NCT03353259|Combination Product|Tranexamic acid and Tocilizumab|The first intervention is Tranexamic acid, The second intervention is Tocilizumab
106566|NCT03353246|Device|InfraScanner 2000™|The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
106567|NCT03353233|Drug|Ropivacaine|Local anesthetic (numbing drug)
106568|NCT03353233|Procedure|Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block|An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
106569|NCT03353233|Drug|Saline|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
106570|NCT03353220|Drug|Belviq|Belviq is an oral drug
106571|NCT03353220|Drug|Placebo|The placebo is made to mimic Belviq, but does not contain any active drug
106572|NCT03353181|Device|Endoscopic scissors|Application of endoscopic cutting technique following endoscopic nasobiliary drainage in the treatment of malignant hilar biliary strictures.
106573|NCT03353181|Device|Biliary stent|Standard placement of biliary stent
106574|NCT03353155|Behavioral|Usual Care|
106575|NCT03353155|Behavioral|CareHub|
106576|NCT03353142|Other|Equal Breathing|"Blood pressure recorded at baseline, immediately pre- and post-trial~Maximum Tolerable Breathing Ratio: Test run to determine the maximum tolerable time for inhalation and exhalation.~PRESSURE TOLERANCE: Pressure algometer device used to determine pain pressure tolerance. It will be applied to the first dorsal interosseous and deltoid, and pain pressure tolerance will be measured and recorded. Pressure will be applied at 1kg per second until the patient indicates that the pressure has become painful. Pain pressure tolerance will be performed 3 times at each anatomical location and an average will be determined for each location.~TRIAL: Participants will begin 5 minutes of Equal Breathing at their maximum tolerable equal breathing ratio that was previously determined. Immediately after 5 minutes of breathing, the pain pressure tolerance will be measured using pressure algometry"
106577|NCT03353116|Procedure|the mandible first|the mandible osteotomy is going to be done and fixed first
106578|NCT03353116|Procedure|the maxilla first|the maxilla osteotomy is going to be done and fixed first
106579|NCT03353103|Drug|Sodium fluoride F-18 PET imaging|prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
106580|NCT03353077|Device|Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
106581|NCT03353064|Other|Vivify|A telemedicine kit will (Vivify) which will obtain daily biometrics (vital signs) and care plans. These are all monitored by the Pulmonary team remotely via an online portal. The telemedicine system has a set-up for alerts whenever there are clinical concerns (vital signs out of parameters), or non-use of the Non-invasive positive pressure ventilation (NIPPV). This system allows for video conferencing between the Pulmonary team (physician, respiratory therapist, nurse) to troubleshoot issues, and increase NIPPV compliance.
106582|NCT03353064|Other|EMS|Emergency medical service scheduled home visits for face to face troubleshooting of the NIPPV, environmental check and end-tidal CO2.
106583|NCT03353051|Other|Observational study|Observational study
106584|NCT03353038|Device|3D printed pillbox|The research team interviewed the participant about their habits, routines, preferences, medications, and skills and abilities. Based on the interview, the research team designed and printed a customized 3D printed pillbox.
106585|NCT03353025|Procedure|transsphenoidal surgery treatment|transsphenoidal surgery treatment
106586|NCT03353025|Drug|dopamine agonist treatment|Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
106587|NCT03353012|Drug|Etonogestrel Drug Implant|Etonogestrel 68 mg (single rod) is implanted at inner arm of participant.
106588|NCT03353012|Drug|Levonorgestrel Drug Implant|Levonorgestrel 75 mg (2 rods) are implanted at inner arm of participant.
106589|NCT03352999|Procedure|Fast track access to vaECMO|"ROHCA must be witnessed with onset of bystander CPR and an immediate call to Emergency Dispatch. Furthermore, to minimize any loss of time, all qualified geographical locations are directly incorporated in the regulation software of the center for medical emergency control.~Patients suitable for vaECMO implantation were identified as early as possible by the Medical Dispatcher at the Emergency Call Dispatch Center.~Bystanders pursued CPR until Mobile Intensive Care Unit (MICU) arrival. OHCA was considered refractory after 10 min of CPR initiating the transport by MICU to the hospital such that the vaECMO intervention could be performed. The resuscitation was pursued during the transfer to hospital. An automated chest compression device was used in order to minimize interruption periods.~The intensivists and cardiac surgeons stood ready to implant the vaECMO surgically in the catheterization laboratory where a percutaneous coronary intervention was subsequently performed."
106590|NCT03352986|Biological|biological analysis|biological analysis will be performed in the 6 groups of patients
106591|NCT03352986|Other|peripheral arterial tonometry|peripheral arterial tonometry will be performed in the 6 groups of patients
106592|NCT03352973|Other|active tDCS on the dlPFC|During active tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the active tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
106593|NCT03352973|Other|sham tDCS on the dlPFC|During the sham tDCS session, participants will perform the regulation of craving (ROC) and emotion regulation (ER) tasks. In the ROC task, participants will downregulate and upregulate craving elicited by gaming pictures using cognitive reappraisal. In the ER task, participants will downregulate and upregulate aversive feelings by negative pictures using cognitive reappraisal. After the sham tDCS session, participants will complete a cognitive task assessing inhibitory control of attentional bias, in which participants will perform a number classification task with gaming pictures and non-gaming pictures being distractors. During the task, reaction times (RTs) wil be recorded.
106594|NCT03352947|Drug|Dabrafenib|150mg Dabrafenib twice daily day 1-21 of 28 day cycle in intermittent arm Day 1-28 of 28 day cycle in continuous arm
106595|NCT03352947|Drug|Trametinib|Trametinib 2mg once daily Day 1-14 of a 28 day cycle in intermittent arm Day 1-28 of a 28 day cycle in the continuous arm
106596|NCT03352934|Drug|Avelumab|Avelumab will be administered as intravenous infusion at 10 mg/kg once every two weeks until documented disease progression (PD), unacceptable toxicity, or any criterion for treatment withdrawal are met.
106597|NCT03352921|Other|clinical pilates exercises|servikal, deep flexor muscles, posture exercsises
106598|NCT03352921|Other|home exercises program|stretching, strengthening, and posture exercises to reduce functional disability, to relieve the pain and to provide postural straightening.
106599|NCT03352895|Dietary Supplement|resveratrol|Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg
106600|NCT03352895|Dietary Supplement|Placebo|The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
106601|NCT03352882|Diagnostic Test|Ultrasound|Hepatic ultrasound using gray scale, color Doppler, and spectral Doppler imaging to evaluate hepatic vein and portal vein patency, direction and velocity of flow respectively. ARFI will be performed in the right hepatic lobe. Three measurements of stiffness (m/s) will be performed and the mean value recorded.
106602|NCT03352869|Drug|Exenatide|Use Exenatide for 3 months to treat PCOS
106603|NCT03352869|Drug|Metformin|Use Metformin for 3 months to treat PCOS
106604|NCT03352856|Other|Barley starch|Highly purified barley starch
106605|NCT03352856|Other|Maize starch|Maize starch
106606|NCT03352843|Drug|Primaquine|All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
106607|NCT03352830|Behavioral|RANAS Behavior Change Intervention|The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
106608|NCT03352830|Other|Infrastructural Intervention - Direct Delivery|Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
106609|NCT03352817|Other|Cardiac rehabilitation|A questionnaire and an information sheet are provided. The questionnaire had to be completed anonymously and individually by the patient, to avoid any influence.
106610|NCT03352804|Other|Screening of MDR Bacteriae|questionnaire will be filled by every patient
106611|NCT03352791|Behavioral|DSM-H Hospice Edition performance improvement program|Patients in the performance improvement group will receive care from a care team who has received the DSM-H Hospice Edition performance improvement program
106612|NCT03352791|Behavioral|Usual Care|control will receive usual care from a care team who has not received the performance improvement program.
106613|NCT03352778|Radiation|IMRT|66Gy by intensity-modulated radiotherapy
106614|NCT03352778|Radiation|2DRT|66Gy by 2-dimensional radiotherapy
106615|NCT03352765|Drug|rituximab|rituximab 375 mg/m2 on days -11 and -4, The second dose of rituximab (day -4) is administered 7 days after the first dose (day -11), +/- 1 day. Rituximab may be administered by a local oncologist. If the participant has a CD20 negative tumor, rituximab can be omitted from the conditioning regimen.
106616|NCT03352765|Drug|bendamustine|bendamustine 160 mg/m2 intravenously on days -3 and -2
106617|NCT03352765|Drug|melphalan|melphalan 140 mg/m2 intravenously on day -1 before the reinfusion of autologous stem cells on day 0.
106618|NCT03352765|Procedure|Autologous Stem Cell Transplantation (ASCT)|reinfusion of autologous stem cells on day 0.
106619|NCT03352752|Device|HTC Vive|Wearing VR helmet before operation
106620|NCT03352752|Other|Without HTC Vive|Wearing a blindfold before operation
106621|NCT03352739|Device|DBS of the fornix, power on|"DBS of bilateral columns of the fornix is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
106622|NCT03352739|Device|DBS of the NbM, power on|"DBS of bilateral NbMs is performed, with the power of the device on since the 1st month after the implantation. Observations will start at the time when the device is turning on .~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
106623|NCT03352739|Device|DBS of the fornix, power off|"DBS of bilateral columns of the fornix is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
106624|NCT03352739|Device|DBS of the NbM, power off|"DBS of bilateral NbMs is performed, the power of the device is going to keep off during the first 7 months after the implantation. Observations will start after 1 month of the implantation.~DBS system includes:~Pins G102 Implantable Neurostimulator; Pins L301 DBS Electrode； Pins E202 DBS extension lead"
106625|NCT03352726|Drug|DBV712 IHRP|DBV712 Solution for Skin Prick Test
106626|NCT03352713|Behavioral|Laddr|"Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences."
106627|NCT03352700|Drug|3L PEG|Group A patients (n = 300) used only 3L PEG before colonoscopy.
106628|NCT03352700|Drug|3L PEG+Dyclonine Hydrochloride Mucilage|Patients in group B (n = 300) were additionally advised to Dyclonine Hydrochloride Mucilage plus 3 L PEG
106629|NCT03352687|Procedure|anterior SSAX|block of the suprascapular nerve block for shoulder surgery by anterior way
106630|NCT03352687|Procedure|posterior SSAX|block of the suprascapular nerve block for shoulder surgery by posterior way
106631|NCT03352674|Drug|Insulin Glargine Ezelin|Insulin Glargine (Ezelin) once daily at individually adjusted dose
106632|NCT03352674|Drug|Insulin Glargine Pen Injector [Lantus]|Insulin Glargine (Lantus) once daily at individually adjusted dose
106633|NCT03352661|Other|Collect retrospectively data|Collect retrospectively data
106634|NCT03352622|Other|CASES|Patients with RA with methotrexate therapy and inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; That present problems of effectiveness.
106635|NCT03352622|Other|CONTROLS|Patients with RA with methotrexate therapy inhibitors of tumor necrosis factor alpha (TNFα) infliximab, etanercept, adalimumab; No problems of effectiveness
106636|NCT03352609|Device|Active rTMS with MagVenture MagPro double blind rTMS system|5 sessions of rTMS delivered with MagPro (MagVenture) double blind rTMS system delivered at 110% of resting motor threshold with 3000 pulses of 10hz stimulation (5s on, 10s off) per session.
106637|NCT03352609|Device|Sham rTMS|Double blind MagPro system delivers sham condition by mimicking rTMS sound and delivering skin stimulus via TENS pads
106638|NCT03352596|Other|low frutose diet|
106639|NCT03352583|Dietary Supplement|Protein|40g calcium caseinate
106640|NCT03352570|Device|COLOVAC|The intervention consists in the placement of the Colovac device, during the colorectal surgery, Once the colorectal anastomosis has been completed as per standard care and the water-thightness of the anastomosis has been verified.
106641|NCT03352557|Drug|BIIB092|Administered as specified in treatment arm.
106642|NCT03352557|Drug|Placebo|Administered as specified in treatment arm.
106643|NCT03352544|Behavioral|Exercise|Exercise training for 12 weeks (aerobic and resistance training trice a week)
106644|NCT03352531|Biological|AK-105|Anti-PD-1 monoclonal antibody; Subjects will receive AK105 by intravenous administration.
106645|NCT03352518|Device|WM3.4NR|The investigational medical device will collect spectral raman data from tissue.
106646|NCT03352492|Procedure|Superior laser peripheral iridotomy|Iridotomy placement between 11:00 and 1:00 o'clock
106647|NCT03352492|Procedure|Temporal laser peripheral iridotomy|Iridotomy placement at 3:00 or 9:00 o'clock
106648|NCT03352479|Other|Opioid Return|Calculate the percentage of prescribed to returned opioids
106649|NCT03352466|Biological|NasoShield|NasoShield is an adenovirus-vectored anthrax vaccine.
106650|NCT03352466|Biological|BioThrax|Commercially available anthrax vaccine
106651|NCT03352466|Other|Placebo|Normal saline
106652|NCT03352453|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
106653|NCT03352453|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
106654|NCT03352440|Device|Cerebral Palsy - Kinect|Group with Cerebral Palsy that will perform the task on Kinect
106655|NCT03352440|Device|Cerebral Palsy - Touchscreen|Group with Cerebral Palsy that will perform the task on Touchscreen
106656|NCT03352440|Device|Control Group - Kinect|Group with typical development that will perform the task on Kinect
106657|NCT03352440|Device|Control Group - Touchscreen|Group with typical development that will perform the task on Touchscreen
106658|NCT03352427|Drug|Dasatinib|60 mg/m2 orally twice daily
106659|NCT03352427|Drug|Everolimus|3.0 mg/m2, with titration of dosing after first cycle to keep trough level of 5-15 ug/ml
106660|NCT03352414|Drug|Alvimopan|alvimopan pill
106661|NCT03352414|Drug|Placebo|placebo pill
106662|NCT03352401|Other|Ultrasouund assessment of gastric contents|A qualitative and quantitative ultrasound evaluationof the stomach will be performed when the patient arrives in the pre-anesthesia room. The examination will be held in the right lateral decubitus with a low frequency convex ultrasound probe.
106663|NCT03352388|Dietary Supplement|Dairy- and berry-based snacks|High-protein dairy-based products and energy-enriched berry products for three months
106664|NCT03352375|Device|Orotracheally intubation|Interventions used for airway safety and ventilation during surgical procedures
106665|NCT03352375|Device|Laryngeal Mask Airway|Interventions used for airway safety and ventilation during surgical procedures
106811|NCT03351088|Procedure|DVC ligation|Ligation of the dorsal vascular complex during robot-assisted radical prostatectomy
106666|NCT03352362|Drug|ibuprofen (caldolor 10 mg / kg)|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
106667|NCT03352362|Drug|propacetamol (denogan 30 mg / kg)|Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
106668|NCT03352362|Drug|ibuprofen + propacetamol|Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
106669|NCT03352349|Drug|Terlipressinum|If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
106670|NCT03352323|Drug|Oxymetazoline|RLD
106671|NCT03352310|Biological|autologous umbilical cord blood (UCB)|autologous UCB transfusion to the newborn infants presence of HIE and/or anemia within 48 hours after the birth
106672|NCT03352310|Procedure|standard care|standard care procedure to the newborn infants presence of HIE and/or anemia
106673|NCT03352297|Biological|Unfiltered Nanofat Graft|Nanofat created from microfat, skipping the filtration step. Intradermal and subdermal injections in post burn scars on the face.
106674|NCT03352284|Device|Straumann Pure Ceramic Implant|The surgical technique begins with the lift of a vestibular mucoperiosteal flap respecting the papillae of the adjacent teeth. After the alveolar bone is exposed, the sequence of drilling and placement of the intra-bone fixation are carried out. In case of fenestrations or dehiscence, they are treated by xenograft and collagen-absorbable membrane. Once the implant is placed, a healing cap or provisional prosthesis is placed depending on the torque achieved. Finally, the flap is replaced and sutured.
106675|NCT03352271|Procedure|Individualized Incremental hemodialysis|Individualized Incremental hemodialysis program (twice/week, once/week, once/10days or less frequent) will be provided to incident ESRD patients according to their symptom presentation, clinical examination, investigations and daily urine volume measurement.
106676|NCT03352271|Procedure|Conventional thrice weekly hemodialysis|Thrice weekly hemodialysis program, the current standard of care for all patients, as a control
106677|NCT03352258|Radiation|Low dose radiotherapy|10 Gy in 5 fractions of 2 Gy on 5 consecutive days
106678|NCT03352245|Behavioral|Prescribed Activity|Educational session at enrollment, increase subject communication via tailored electronic messaging, and use of a wrist-bound device (FitBit Flex 2)
106679|NCT03352232|Combination Product|HBOT and OMT|Hyperbaric oxygen therapy (HBOT) is defined as breathing 100% oxygen at increased atmospheric pressure. Osteopathic manipulative therapy (OMT) is used for myriad ailments including contractures, pain, spasticity. Patients in intervention arms will receive hyperbaric oxygen therapy at 2ATM (atmospheres) for 90minutes daily for up to 6weeks. In addition, they will receive osteopathic manipulative therapies twice a week during the same treatment phase.
106680|NCT03352219|Behavioral|Reality Check|
106681|NCT03352219|Behavioral|Physical Activity Attention Control|
106682|NCT03352206|Drug|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)
106683|NCT03352206|Drug|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
106684|NCT03352193|Dietary Supplement|Wheat spaghetti|Wheat oral immunotherapy
106685|NCT03352180|Procedure|arthroscopic reapir of subscapularis tendon|arthroscopic reapir of massive rotator cuff tears involving the subscapularis.
106686|NCT03352180|Procedure|arthroscopic debridement of subscapularis tendon|arthroscopic debridement of massive rotator cuff tears involving the subscapularis.
106687|NCT03352154|Diagnostic Test|P300 - Auditory long latency potential|Perform the P300 exams.
106688|NCT03352141|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
106689|NCT03352128|Dietary Supplement|Creatine|Participants will have to supplement themselves with creatine for 7 days (20g/day).
106690|NCT03352128|Dietary Supplement|Calcium lactate|Participants will have to supplement themselves with calcium lactate for 7 days (elemental calcium: 0.780g/day).
106691|NCT03352115|Drug|Prednisolone|5 day course of oral prednisolone
106692|NCT03352115|Drug|Placebos|Placebo syrup
106693|NCT03352102|Procedure|Electrical stimulation|Neuromuscular electrical stimulation therapy was performed
106694|NCT03352076|Drug|Vaginal Danazol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
106695|NCT03352076|Drug|Oral Danatrol|Proof of mechanism study to establish intraperitoneal and serum concentrations of Danazol
106696|NCT03352063|Behavioral|Prolonged sitting with exercise|Subjects will commit to sitting more than 11 hours per day and taking less than 5000 steps per day while participating in exercise training.
106697|NCT03352063|Behavioral|Active walking with exercise.|Subjects will commit to sitting less than 5 hours per day and taking more than 10000 steps per day while participating in exercise training.
106698|NCT03352050|Dietary Supplement|mushroom|
106699|NCT03352050|Other|ground beef|
106700|NCT03352037|Diagnostic Test|PET scan|Patients with known pancreatic cystic lesions requiring MR imaging for lesion characterization for clinical evaluation will be recruited to undergo 18F-FDG PET/MR imaging after written informed consent.
106701|NCT03352024|Other|Relational care|Relational care is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
106702|NCT03352024|Other|Hypno-analgesia|Hypno-analgesia is combined with a cutaneous anesthesia (Transcutaneous device(plan) of lidocaïne-pilocaïne (EMLA®))
106703|NCT03352011|Behavioral|Primary Care Brief Mindfulness Training|Primary Care Brief Mindfulness Training consists of four 90-minute group classes that teach sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go.
106914|NCT03350191|Drug|[68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
106704|NCT03352011|Behavioral|PTSD Psychoeducational Class|"The PTSD Psychoeducational Class is designed to provide a supportive environment for learning about PTSD-related issues and to help Veterans determine what recovery strategies will be most helpful for them. Session themes include Civilian Readjustment and PTSD, Trust, Safety, and Healing and Treatment Strategies."
106705|NCT03351998|Drug|Lipitor 20Mg Tablet|20 mg/day pills.
106706|NCT03351998|Drug|Lipitor 80Mg Tablet|80 mg/day pills.
106707|NCT03351998|Drug|Placebo Oral Tablet|Matching placebo pill.
106708|NCT03351985|Device|quantitative electroencephalogram (qEEG)|the patients receive the quantitative electroencephalogram (qEEG) monitoring within 1 hour when they admitted to ICU
106709|NCT03351972|Drug|Klean Prep|Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
106710|NCT03351972|Other|Clear liquids only|Participants randomised to clear liquids only will receive guidance to only drink clear liquids before their procedure
106711|NCT03351959|Radiation|neo-adjuvant treatment|long-course radio-chemoradiation; short-course radiation with immediate/delayed surgery
106712|NCT03351946|Procedure|ZEEP|Zero positive end-expiratory pressure (ZEEP) during emergence preoxygenation and awakening.
106713|NCT03351946|Procedure|PEEP|Positive end-expiratory pressure remains during emergence preoxygenation and awakening and until the study subject is extubated.
106714|NCT03351933|Biological|Immune Globulin (Human)|A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
106715|NCT03351920|Other|mechanical ventilation|All patients who need an invasive or non invasive mechanical ventilation, initiated in Prehospital or IntraHospital Emergency Department by an emergency Physician
106716|NCT03351894|Procedure|Femtosecond laser assisted cataract surgery|Ziemer Z8 femtosecond laser assisted cataract surgery
106717|NCT03351894|Procedure|Conventional phacoemulsification|conventional phacoemulsification with infinity phaco
106718|NCT03351881|Other|Description of Organ Donation Policy|Participants will read about an organ donation policy type (opt-out, opt-in, or opt-neutral) and rate what they think or feel about it.
106719|NCT03351868|Genetic|Gene-modified autologous stem cells|Infusion for 5x10^6~1x10^7 per kilogram of body weight of gene-modified cells; or more infusions depending on the circumstances
106720|NCT03351855|Biological|HPV-CTLs|2 to 4 infusions, once a week, for 1x10^5~4x10^6 CTLs/kg by IV each time
106721|NCT03351842|Drug|cis Platinum/Carboplatin, Pemetrexed Disodium|Intravenous inject Pemetrexed Disodium for Injection over 10 minutes, waiting for at least 30 minutes, then followed by cis Platinum/ Carboplatin over 2 hours
106722|NCT03351842|Procedure|Undergo surgery|Therapeutic conventional surgery, R0 resection
106723|NCT03351829|Genetic|Gene-modified autologous stem cells|1 infusion for 5x10^6~1x10^7 gene-modified cells; or more infusions depending on the circumstances
106724|NCT03351816|Procedure|Ablation of atrial fibrillation|Pulmonary vein isolation by radiofrequency or cryoablation.
106725|NCT03351816|Procedure|Cardioversion|External electric shock delivery under general anesthesia.
106726|NCT03351803|Other|BFOR Digital Health solution/Web Portal|A digital health solution with Internet-based participant recruitment and ascertainment is a mechanism for distributing access to genetic testing to populations who might not otherwise have access. For this project, LifeLink will build a private web-portal designed by the PI's of the study as described in this protocol, including the wireframes that are in the appendices, that will enable secure contact between study participants and the participating commercial laboratory (Quest Diagnostics) and BFOR researchers, as well as facilitate contacts between study participants and their primary care providers and/or a list of BFOR study centers and BFOR providers.
106727|NCT03351790|Other|Questionniare only|A pre-procedure questionnaire will be completed by all participants
106728|NCT03351777|Drug|PR022|Topical Gel
106729|NCT03351751|Drug|Placebo|Placebo
106730|NCT03351751|Drug|PF-06372865|PF-06372865
106731|NCT03351738|Biological|MEDI5884|Biologic
106732|NCT03351738|Other|Placebo|Placebo
106733|NCT03351725|Device|peripheral venous catheter (PVC)|No intervention is made only in situ swab from the PVC
106734|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITH Feedback|Combining ACT and Behavioral Change
106735|NCT03351712|Behavioral|Gold Standard Intervention + Activity Tracker WITHOUT Feedback|Medical Rehabilitation, Motivational Support and Psycho-Education
106736|NCT03351712|Behavioral|Gold Standard Intervention and Activity Tracker WITH Feedback|Behavioral Change Condition - Activity Tracker
106737|NCT03351712|Behavioral|ACT-Based Intervention and Activity Tracker WITHOUT Feedback|ACT-Based Intervention Standalone
106738|NCT03351699|Drug|MK-4250|MK-4250 tablets for oral administration
106739|NCT03351686|Drug|Tranexamic Acid|Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A. Tranexamic acid injection was prepared by diluting 1g (10 mL) tranexamic acid into 20 ml of 5% glucose.
106740|NCT03351673|Diagnostic Test|endometrial volume 2D TVS|calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
106741|NCT03351660|Diagnostic Test|connected ECG|Cardiosecur allows the realization of a 15 or 22 leads ECG with only 4 electrodes connected to a tablet with an automatic interpretation function
106742|NCT03351647|Biological|Evaluation of biological predictive factors of clinical response to ustekinumab|The clinical response is defined as a decrease in the Crohn's Disease Activity Index (CDAI) score ≥ 100 points or a decrease in the HBI score ≥ 3 points.
106743|NCT03351634|Device|Implantation of ACT balloon, Uromedica (Irvine, CA, USA) periurethrally at the bladder neck|The ACT system is a permanent implant designed for the correction of incontinence in patients.
106915|NCT03350178|Drug|fecal microbiota transfer|transfer of fecal microbiota from healthy donor to the patients
106916|NCT03350165|Drug|K-877|0.2mg tablet
106748|NCT03351582|Behavioral|Grief and Communication Family Intervention|This intervention is an integrative approach which uses techniques from systemic family therapy as well as cognitive behavioral therapy.
106749|NCT03351569|Drug|Intravenous immunoglobulin|Intravenous drip.
106750|NCT03351556|Behavioral|Active Arm 1|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
106751|NCT03351556|Behavioral|Active Arm 2|Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
106752|NCT03351543|Biological|microbial inoculate|volunteers will regularly receive microbial inoculate that they do not use orally
106753|NCT03351517|Drug|Tapentadol 100 MG|100 mg of oral extended release tapentadol will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
106754|NCT03351517|Drug|Placebo Oral Tablet|A matching placebo will be given to the patients undergoing total knee replacement surgery on spinal anesthesia to evaluate its efficacy in the management of post-operative pain.
106755|NCT03351504|Other|Solar lighting system|consisting of a solar panel, rechargeable lead acid battery, charge controller, wiring and switches to 4 lighting points fitted with LED bulbs. This system will include a two-year service warranty.
106756|NCT03351478|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
106757|NCT03351478|Drug|Empagliflozin|"Pharmaceutical form: capsule~Route of administration: oral"
106758|NCT03351478|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
106759|NCT03351478|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
106760|NCT03351465|Behavioral|Coordinated Anxiety Learning and Management|The intervention for this study, CALM Tools for Living-Il, is a computer-assisted cognitive behavioral therapy for anxiety and depression that guides both the patient and CALM specialist. It is a reformulation of CALM Tools for Living42 that directly incorporates our previously optional modules for depression into the main program. The computerized internet format is designed to retain the fidelity of CBT when delivered by novice clinicians. The program is intended to be delivered in 6 to 8 sessions, although flexibility is allowed.
106761|NCT03351452|Device|real anodal transcranial direct current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
106762|NCT03351452|Device|real transcranial alternating current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
106763|NCT03351452|Device|sham transcranial electric current stimulation|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used.
106764|NCT03351439|Drug|Zopiclone|Group 2 - Zopiclone 7.5 mg orally, nightly for 7 days
106765|NCT03351439|Drug|Gabapentin|Group 3 - Gabapentin 600 mg orally, 1 hour pre-operatively and 600 mg orally, 8 hours post-operatively
106766|NCT03351439|Drug|Celebrex|Group 4 - Celebrex 400 mg PO, 1 hour pre-operatively
106767|NCT03351439|Drug|Percocet|Standard of Care
106768|NCT03351439|Drug|Naprosyn|Standard of Care
106769|NCT03351426|Device|Transcranial Direct Current Stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS) is a noninvasive form of neuromodulation that uses constant, low-intensity direct current delivered via electrodes that are placed on the head.
106770|NCT03351413|Other|LIVE-LiFE to Prevent Falls Among Older Fallers|"LIVE-LiFE Intervention: Individually tailored program at the participant's home spaced across 12 weeks including:~Home safety assessment and risk reduction strategies; incorporating strength and balance training into daily habits vision screening and referral; and education about fear of falling and falls~Home repairs, modifications, and low cost assistive devices to address unsafe home environments increasing fall risk~Medication review and feedback concerning medications with increased fall risk~Measurement intervals: Baseline, 4 months, 8 months (with $25 gift card given at each visit for your time)"
106771|NCT03351400|Biological|Stem cells administered to participants|Patients in this arm will receive intracoronary infusion of 1,000,000 autologous c-kit positive cardiac stem cells.
106772|NCT03351387|Combination Product|SPY Intra-operative Angiography|The SPY Intra-operative Angiography Fluorescent Imaging System consists of an imaging head equipped with a charged coupled device (CCD) camera, a laser light source and a distance sensor. The imaging head is attached to an articulating arm on a mobile cart containing the central processing unit, keyboard, monitor, and mouse. SPY is used in tandem with indocyanine green (ICG), a water-soluble tricarbocyanine dye. Once the camera is in place, 5 cc of diluted ICG is pushed through an IV line and is flushed immediately; simultaneously the room lights must be dimmed. Perfusion images will be recorded then the SPY system will be removed from the operating room.
106773|NCT03351374|Other|Software|multi-module system of web software tools
106774|NCT03351361|Drug|Nivolumab + Ipilimumab|Nivolumab dosed intravenously over 30 minutes at 240 mg every 2 weeks combined with Ipilimumab dosed intravenously over 30 minutes at 1 mg/kg every 6 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol.
106812|NCT03351075|Other|Standard physical therapy program|"Mobilisations, stretching, scar tissue treatment and exercises~Start immediately after surgery, sessions are individual and take 30 minutes~Intensive phase (4 months): 1-2x/week~Maintenance phase (8 months, 3 sessions): 6, 8 and 12 months post-surgery"
106775|NCT03351361|Drug|Chemotherapy|Doublet of chemotherapy according to standard of care carboplatin (AUC 5) with a dose that will be capped to 700 mg and pemetrexed (500 mg/m²) over 4 to 6 hours every three weeks (restricted to non-squamous histology) or carboplatin (AUC 6) with a dose that will be capped to 700 mg and paclitaxel (90 mg/m²) D1 D8 D15 over 4 to 6 hours every 4 weeks, with a maximum of 4 cycles of carboplatin based doublet, and the possibility to use maintenance with pemetrexed.
106776|NCT03351348|Drug|Bupivacaine|The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
106777|NCT03351348|Behavioral|patient-reported pain scores|Will be recorded by the nurse in the PACU as per usual practice. Patients will be given a follow-up Brief Pain Inventory (short form) 6 months and 1 year after surgery to assess their level of chronic pain.
106778|NCT03351348|Other|saline|The intervention in this study is the insertion of 20cc of saline via a drain into the mastectomy wound for 2 ± 30 minutes hours postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
106779|NCT03351335|Device|Microfocused ultrasound with visualization|All subjects will receive an Ultherapy® treatment at dual depth using the 4-4.5mm and 7-3.0mm transducers. Treatments will be provided to the lower face, submental (under the chin) and neck area.
106780|NCT03351322|Drug|ENERGI-F701|ENERGI-F701 are applied for treatment of hair loss.
106781|NCT03351322|Drug|Regaine|Regaine are applied for treatment of hair loss.
106782|NCT03351309|Behavioral|Telephone-based Cognitive Behavioral Therapy (CBT)|Four session telephone CBT protocol.
106783|NCT03351296|Drug|LV5FU2|LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
106784|NCT03351296|Drug|Streptozocin|streptozotocin 800 mg/m² day 1 every 14 days
106785|NCT03351296|Drug|Capecitabine|Capecitabine 750 mg/m² twice daily, days 1-14
106786|NCT03351296|Drug|Temozolomide|temozolomide 200 mg/m² once daily, days 10-14, every 28 days
106787|NCT03351296|Drug|Bevacizumab|bevacizumab 5 mg/kg every 14 days
106788|NCT03351283|Other|Severe sodium restriction|Patients will be assigned to a diet with sodium restriction of two grams.
106789|NCT03351283|Other|Moderate sodium restriction|Patients will be assigned to a diet with sodium restriction of three grams.
106790|NCT03351270|Other|Standardized strength, respiratory and motor function assessments|Standardized assessments will be adjusted by the age, the ambulant status and the respiratory status of the patient. The visit frequency will also be adjusted according to the age and to the time spent in the study varying between quarterly to yearly.
106791|NCT03351257|Other|observation of surface patterns and colors of polyps|examination of the surface patterns and colors of polyps using Linked color imaging and white-light
106792|NCT03351244|Drug|BI 409306|28 week treatment period
106793|NCT03351244|Drug|Placebo|28 week treatment period
106794|NCT03351231|Drug|BMS-986242|Specified dose on specified days
106795|NCT03351231|Biological|Nivolumab|Specified dose on specified days
106796|NCT03351218|Behavioral|Behavioral testing - computerized tasks|Cognitive behavioral testing and cerebral MRI
106797|NCT03351205|Device|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
106798|NCT03351205|Procedure|dried biological amnion graft|"Uterine application of dried biological amnion graft following hysteroscopic adhesiolysis.~Other Name: Human amnion membrane"
106799|NCT03351205|Drug|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
106800|NCT03351179|Combination Product|clinical characteristics, previous history, laboratory bio-markers, echocardiographic measurements, angiographic findings,clinical outcomes|The differences of data(clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were conducted. The differences between two groups were compared (clinical characteristics, history, laboratory biomarkers, echocardiographic measurements, angiographic characteristics and clinical outcomes) in two groups were compared, and then found the risk factors. Following,the incidence of clinical outcomes and mortality were compared. Then, univariate logistic regression and multivariate logistic regression analysis adjusted for significant risk factors were performed to find out the independent predictive factors. Finally, the ROC was constructed, and the area was evaluated to assess the predicted probability of regression model.
106801|NCT03351166|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
106802|NCT03351153|Radiation|X-ray|In the X-ray group, the changes in femoral head height were measured with X-ray in an anteroposterior position of the pelvis (healthy and affected sides of the hip) at preoperative 1 week
106803|NCT03351153|Radiation|CT|In the CT group, changes of femoral head height were measured with CT scan on bilateral hips (healthy side and affected side) at preoperative 1 week
106804|NCT03351153|Other|specimen|In the specimen group, femoral head on the affected side was resected during surgery and directly measured with a ruler and vernier caliper.
106805|NCT03351140|Other|Qualitative Interviews|Subjects will participate in a qualitative interview lasting up to 90 minutes. The interviews will include a concept elicitation component to explore details of the subject's perceived disease condition, functional limitations and impacts on daily life and health-related quality-of-life (HRQoL). In addition, a card sorting exercise will be used to evaluate the relevance and comprehension of PROMIS Physical Function items.
106806|NCT03351140|Other|PROMIS Physical Function Items|PROMIS Physical Function Items is a set of self-report measurement tools. The latest version of PROMIS Physical Function Items contains 165 items for self-assessment. PROMIS Physical Function Cancer Item Bank contains a subset of 45 items relevant to cancer subjects. Subjects will complete half of the PROMIS Physical Function Items during their enrollment visit and the other half of items prior to their interview.
106807|NCT03351127|Radiation|Carotid ultrasound examination|Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's Aixplorer ultrasound system.
106808|NCT03351114|Drug|Crisaborole|Apply Crisaborole 2% ointment to affected skin twice per day.
106813|NCT03351075|Other|Modern educational program|"This modern neuroscience educational approach is suited to explain more complex issues associated with pain such as the involvement of peripheral and central mechanisms, neuroplasticity and pain behaviour.~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
106814|NCT03351075|Other|Traditional biomedical educational program|"Traditional educational interventions are applied according to the biomedical model. This means that the patient's pain experience is explained from a tissue (injured versus healthy tissue) and biomechanics perspective~Sessions are individual and take 30 minutes, in addition to the standard physical therapy sessions~3 sessions during week 1-2, 3 booster sessions at 6, 8 and 12 months post-surgery"
106815|NCT03351062|Drug|Tamoxifen|Patients will be given 10mg Tamoxifen twice a day.
106816|NCT03351062|Drug|Toremifene|Patients will be given 60mg Toremifene once a day.
106817|NCT03351049|Device|LAL|Reactive support surface with a low air loss feature
106818|NCT03351049|Device|Non-LAL|Reactive support surface without a low air loss feature
106819|NCT03351023|Other|no intervention-this was an observational study|
106820|NCT03351010|Behavioral|Mindfulness training program|The mindfulness training program is a self-awareness mindfulness training program by performing the 15-position hand movement series
106821|NCT03351010|Device|Cancer pain educational program|A cancer pain education program by using Videos and personalized face-to-face techniques
106822|NCT03350997|Behavioral|Trial 2 Exercise|During the exercise session, subjects will exercise at 65% of VO2peak. One hour after the exercise session, participants will eat a standardized dinner which will NOT include the energy expended from their exercise session (- 350 kcal).
106823|NCT03350997|Behavioral|Trial 1 Exercise|During the exercise session, subjects will use a mouthpiece and nose clip (which will allow all of their expired air to pass through the metabolic cart for analysis of oxygen consumption and carbon dioxide production) for ~5 min at the beginning, middle and toward the end of exercise to verify they are exercising at 65% of VO2peak. This will allow us to accurately measure energy expenditure (kcal) during exercise. One hour after the exercise session, participants will eat a standardized dinner which includes the energy expended from their exercise session (+ 350 kcal).
106824|NCT03350984|Drug|NPH insulin|NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose >180 mg/dL.
106825|NCT03350984|Drug|Glargine and Lispro insulin|Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
106826|NCT03350971|Other|Virtual reality training|training with Wii games, ergometer exercise, ambulation, standing exercises
106827|NCT03350971|Other|Control|chest physical therapy exercises
106828|NCT03350958|Dietary Supplement|Alginate Bread|100g Alginate Bread, toasted with 20g of butter.
106829|NCT03350958|Other|Control Bread|100g standard White Bread (control), toasted with 20g of butter.
106830|NCT03350945|Procedure|Device: tumor localization|At present, three dominant methods can be available to locate tumor: preoperative endoscopic clip placement, intraoperative endoscopy and endoscopic tattooing
106831|NCT03350932|Behavioral|Sensory imagination about foods|In both groups, children will be presented with pictures of items. In the control group, the pictures will represent landscapes at different seasons. In the experimental group, the pictures will represent a variety of foods. In the experimental group, based on the pictures representing a variety of foods, children will have to perform a food sensory imagination task before choosing the portion size of a food.
106832|NCT03350919|Device|Training in the blind field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the blind field. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
106833|NCT03350919|Device|Training in the intact field|A computer software and chin-rest necessary to perform visual training will be loaned to each patient to use at home. They will perform one to two daily training sessions in their home, consisting of 200-300 trials each. The visual task performed repetitively will involve discriminating the direction of motion of a small cloud of dots located at a pre-determined location in the intact field of vision. The computer program will automatically create a record of patient performance during each home training session. They will train daily (about 40-60 minutes total), 5 to 7 days per week, for at least 24 weeks.
106834|NCT03350906|Drug|n3-PUFA|participants will be instructed to swallow 2 softgels twice per day with meals (morning and evening) for a total of 4 softgels per day. The DHA/EPA softgels will each contain ~465mg of EPA and ~375mg of DHA for a total daily dosage of 3.4g/day. Additionally, each capsule will contain SCI's proprietary Advance Lipid TechnologiesTM (ALTTM) containing the surfactants polysorbate 80, NF (~381 mg) and poloxamer 237, NF (~8.8 mg).
106835|NCT03350906|Drug|Placebo|Patients in this group will be supplemented with placebo capsules containing soybean oil. Participants will be instructed to swallow 2 placebo soft gels twice per day with meals (morning and evening) for a total of 4 soft gels per day. The duration of the intervention will be 6 months.
106836|NCT03350893|Combination Product|Emulsion base with probiotics|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide, Heat-killed L. plantarum powders (1x10^9 cells/ g-cream)
106878|NCT03350529|Device|MRI guided transurethral HIFU ablation of prostatic tissue|The technology is developed to ablate targeted benign and malignant prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.
106837|NCT03350893|Other|Emulsion base|Water、Polyglyceryl-3/ Methylglucose Distearate、Triethyl Hexanoin、Macadamia Ternifolia Seed Oil、Propanediol、PEG/PPG/Polybutylene Glycol-8/5/3 Glycerin、Cetyl Alcohol、Myristyl Myristate、Glycerin、Glycosyl Trehalose/Hydrogenated Starch Hydrolysate、Rice Ferment Filtrate(Sake)、Saccharomyces/Daylily Flower Ferment Filtrate、Bis-PEG/PPG-20/5 PEG/PPG-20/5Dimethicone、Methoxy PEG/PPG-25/4 Dimethicone、Caprylic/Capric Triglyceride、Sodium Polyacrylate、Phenoxyethanol、o-Cymen-5-ol、Xanthan Gum、Potassium Hydroxide
106838|NCT03350880|Other|Flexibility training|Flexibility training was carried out over a period of six weeks, with two sessions per week, totaling 12 sessions.
106839|NCT03350867|Other|Personalized Insole Group|Personalized Insole Group
106840|NCT03350867|Other|Placebo Group|Placebo Group
106841|NCT03350854|Behavioral|Patient Preference in Treatment Decision Making|The roles are divided into two active roles, a collaborative (or shared) role, and two passive roles in the Patient Preference scale questionnaire. Once the questionnaire is administered, the patient will then proceed to original surgical appointment. The provider is informed of the patient's preferred role and has a discussion with them patient about this in the intervention group, but not in the control group.
106842|NCT03350841|Procedure|Platelet rich plasma PRP|blood sample is collected to prepare platelet rich plasma injected in the canal
106843|NCT03350841|Procedure|root canal treatment|conventional root canal treatment and obturation with guttapercha
106844|NCT03350815|Drug|150 mg open-label secukinumab|All patients in Treatment Period 1 will receive 150 mg open-label secukinumab.
106845|NCT03350815|Drug|150 mg double-blinded secukinumab|Treatment Period 2
106846|NCT03350815|Drug|300 mg double-blinded secukinumab|Treatment Period 2
106847|NCT03350802|Diagnostic Test|procalcitonin test|All patients enrolled in this cohort undergo procalcitonin test in addition to basic microbiological test.
106848|NCT03350789|Device|Real acupuncture|manual acupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral GB30) + electroacupuncture(0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) (unilateral EX-B2 (L4 & L5), BL25, BL23, BL40, GB34), twice a week, for 4 weeks, common approaches for the treatment of chronic sciatica used by doctors of Korean medicine in Korea today
106849|NCT03350789|Device|Sham acupuncture|sham acupuncture without skin penetration(0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) (unilateral GB30) + placebo electroacupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea) without electrical stimulation (unilateral EX-B2, BL25, BL23, BL40, GB34), twice a week, for 4 weeks
106850|NCT03350776|Behavioral|Care coordination|Care coordination and associated emerging occupations by comparing theoretical expected outcomes to professionals, patients and caregivers representations
106851|NCT03350763|Device|Tannenbaum 10 Fr biliary stent|Tannenbaum 10 Fr biliary stent
106852|NCT03350763|Device|Self-expandable metallic biliary stent|ie WallFlex biliary RX
106853|NCT03350750|Device|programmable CSF shunt valve|Brain shunt surgery using a programmable CSF shunt valve
106854|NCT03350737|Other|Physical rehabilitation|Standard treadmill exercise session
106855|NCT03350737|Drug|Heparin|Heparin i.v.
106856|NCT03350737|Other|Placebo|Sodium Chloride 0.9% i.v.
106857|NCT03350724|Device|episil wound dressing|Episil is a wound dressing material intended for the management of pain and relief of pain by adhering to the mucosal surface of the mouth, soothing oral lesions of various etiologies. episil is an oromucosal liquid that transforms in situ to a bioadhesive oromucosal gel by uptake of small amounts of aqueous fluid.
106858|NCT03350724|Device|PeriAcryl90 wound dressing|PeriAcryl90 is a cyanoacrylate wound dressing.
106859|NCT03350711|Other|Microbiota Enrichment Program (MEP)|"Registry participants will provide demographic and medical information and may take part in general screening procedures to facilitate enrolling into an appropriate FMT study.~Once determined to be eligible for study entry, study-specific screening procedures may include:~Health history and physical examination~Urinalysis~Urine or serum pregnancy test~Blood tests for Hepatitis B, Hepatitis C, HIV, chemistry panel (which includes liver function, kidney function), complete blood count with differential, platelet count, partial thromboplastin time (PTT), international normalized ratio (INR)~Electrocardiogram (EKG or ECG)~Stool studies~Participants will be re-screened every 6 months and will remain in follow-up indefinitely or until they are rendered ineligible, participate in a MEP study, or withdraw consent to be included in the database."
106860|NCT03350698|Biological|Gardasil-9|3 vaccine series
106861|NCT03350672|Drug|FTC/TAF|Participants in cohorts 1a&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
106862|NCT03350659|Drug|Midodrine|Midodrine single 5mg/day
106863|NCT03350659|Drug|Atomoxetine|Atomoxetine single 18mg/day
106864|NCT03350646|Other|Volume of medium during embryo transfer|
106865|NCT03350633|Drug|Tocilizumab Injection|Tocilizumab Injection will be intravenously administered with a dose of 8 mg/kg every 4 weeks.
106866|NCT03350633|Drug|Azathioprine|Azathioprine will be orally given at a dose of 2-3 mg/kg/d
106867|NCT03350620|Drug|NVK-002 Concentration 1|Study medication will be administered, once daily (QD)
106868|NCT03350620|Drug|NVK-002 Concentration 2|Study medication will be administered, once daily (QD)
106869|NCT03350620|Drug|Placebo|Vehicle (placebo) will be administered, once daily (QD)
106870|NCT03350607|Other|Non interventional study|Non interventional study (collect of data)
106871|NCT03350594|Behavioral|Systemic Family Therapy|Patient will have 10 sessions of Systemic Family Therapy during 12 months with his/her family.
106872|NCT03350594|Behavioral|Multiple Family Therapy|Patient and his/fer family will have 10 sessions of Multiple Family Therapy during 12 months.
106873|NCT03350581|Procedure|FAM 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by FAM alone.
106874|NCT03350581|Procedure|FAM-CT 3D map group|Radiofrequency catheter ablation using the 3D map which is constructed by the integration of the FAM with CT or MRI.
106875|NCT03350568|Other|Total dietary NEAC assessed at baseline|
106876|NCT03350555|Device|Additioned Endoscopy|To evaluate the use of additioned endoscopy in ERCP treatment.
106877|NCT03350542|Device|SYNERGY 48 mm|A drug eluting coronary stent system
106879|NCT03350516|Dietary Supplement|Daily 500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
106880|NCT03350516|Dietary Supplement|Daily1500 mg elemental calcium as calcium carbonate|Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.
106881|NCT03350503|Device|AcrySof IQ Toric A-code IOL|Intended to provide visual acuity, including astigmatism correction, over the lifetime of the cataract patient
106882|NCT03350503|Procedure|Cataract surgery|Removal of cataractous lens and implantation of IOL
106883|NCT03350490|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
106884|NCT03350490|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
106885|NCT03350477|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
106886|NCT03350477|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
106887|NCT03350464|Device|Repetitive Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
106888|NCT03350451|Drug|ALN-GO1|Multiple doses of ALN-GO1 by subcutaneous (sc) injection
106889|NCT03350399|Diagnostic Test|placenta growth factor|estimation level of derum placenta growth factor
106890|NCT03350386|Drug|FYU-981|Single administration
106891|NCT03350386|Drug|Oxaprozin|Repeated administration
106892|NCT03350373|Drug|FYU-981|Single administration of FYU-981 under Fasted and fed conditions in the morning.
106893|NCT03350360|Behavioral|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
106894|NCT03350360|Behavioral|Comparison Task|Neutral- neutral stimuli prior to response task
106895|NCT03350347|Drug|Molidustat (BAY85-3934)|Starting dose of 25 mg or 50 mg molidustat once daily (OD) will be titrated based on the subject's Hb response
106896|NCT03350347|Drug|Darbepoetin alfa|Starting dose and frequency of darbepoetin alfa are based on previous ESA. The dose will be titrated based on the subject's Hb response
106897|NCT03350334|Drug|Duloxetine|Peri-operative Duloxetine administration
106898|NCT03350334|Drug|placebo|Placebo administration
106899|NCT03350321|Drug|Molidustat (BAY85-3934)|Starting dose of molidustat once daily (OD) will be titrated based on the subject's Hb (Hemoglobin) response
106900|NCT03350321|Drug|Darbepoetin alfa|Starting dose of darbepoetin alfa once every 2 weeks will be titrated based on the subject's Hb (Hemoglobin) response
106901|NCT03350308|Other|hemodialysis|The main objective is to establish a statistical predictive model of the risk of intradialytic hypotension during hemodialysis (HD) or hemodiafiltration (HDF) sessions based on the measurement of residual blood volume and excess extracellular hydration
106902|NCT03350295|Drug|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
106903|NCT03350282|Dietary Supplement|GAA-creatine|
106904|NCT03350282|Dietary Supplement|Creatine|
106905|NCT03350269|Other|Information provision|Kidney transplant recipients are informed that their donors may be eligible for lost wage reimbursement
106906|NCT03350256|Device|Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.|BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.
106907|NCT03350243|Other|CCENT Intervention|"Mindfulness approach: engaging families through structured individual and group sessions within the NICU and continue this support once discharged.~Care coordination: supporting providers in clear communication when liaising across various levels of care as well as supporting families in system and resource navigation.~Anticipatory guidance: proactive education targeting normal challenges in caring for a child who required intensive care support."
106908|NCT03350217|Drug|Eleview|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
106909|NCT03350217|Drug|Hetastarch|If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
106910|NCT03350204|Procedure|Meniscectomy|This will be to see what occurs in both kinetics and kinematics after you have a surgery and how this links on to osteoarthritis
106911|NCT03350204|Other|Helathy control comparison|This group will be used to get a baseline for normal and natural walking, running and other several tasks which will be used as a comparison for the meniscus injury group.
106912|NCT03350191|Drug|SAR425899|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
106913|NCT03350191|Drug|[68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
106918|NCT03350139|Device|gamma knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
106919|NCT03350126|Drug|Ipilimumab 200 MG in 40 ML Injection|"Induction therapy (12 weeks):~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W"
106920|NCT03350126|Drug|Nivolumab 10 MG/ML|"Induction therapy (12 weeks) :~Nivolumab 3mg/kg intravenously (IV) over 60 minutes and Ipilimumab 1mg/kg (IV) over 90 minutes Q3W~Maintenance therapy (40 weeks):~Nivolumab monotherapy IV over 60 minutes Q2W until iRECIST progression or if no PD for one year."
106921|NCT03350113|Device|Blood sampling for analysis|Blood Sampling for Analysis
106922|NCT03350100|Dietary Supplement|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance|Acute effect of two Saudi cultivars of date fruit on mood and cognitive performance at baseline, 45 post-dose, 90 min post-dose and 135 min post-dose
106923|NCT03350087|Device|intermittent theta burst stimulation|"In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation"
106924|NCT03350087|Device|continuous theta burst stimulation|"In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation"
106925|NCT03350087|Device|iTBS+cTBS group|In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
106926|NCT03350087|Device|sham theta burst stimulation|"In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation"
106927|NCT03350087|Device|VCT|"The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program"
106928|NCT03350087|Device|VCT+optimal rTMS group|In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
106929|NCT03350061|Device|SENSY|The sensory feedback will be delivered by SENSY with or without the leg prosthesis. Benefits connected to the stimulation of sensory nerves will be assessed.
106930|NCT03350048|Diagnostic Test|Trans-Dot point-of-care test|"Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response."
106931|NCT03350035|Drug|Ganaxolone|IV
106932|NCT03350035|Drug|Placebo|IV
106933|NCT03350022|Procedure|Sham Feeding|Sham feeding will be offered to participants.
106934|NCT03349996|Device|LifeStream Peripheral Stent Graft System|Patients will be treated with the LifeStream Peripheral Stent Graft System
106935|NCT03349983|Biological|MVA-BN-Brachyury/ FPV-Brachyury|Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
106936|NCT03349957|Drug|Transarterial chemoembolization using TANDEM and idarubicin|Transarterial chemoembolization using TANDEM and idarubicin
106937|NCT03349944|Behavioral|Training|The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
106938|NCT03349931|Diagnostic Test|DNA extraction and detection of Aspergillus fumigatus in serum samples|Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).
106939|NCT03349918|Behavioral|Mobile Health Monitoring|Use of mobile health application to monitor blood pressure and mood.
106940|NCT03349905|Procedure|fresh transfer|"Women randomized in the non experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of rhCG (Ovitrelle®; Serono, France)~All of their embryo kept in prolonged culture~A fresh single embryo transfer at blastocyst stage (on day 5 or 6 according to blastocyst stage)~Supernumerary blastocysts cryopreserved"
106941|NCT03349905|Procedure|Deferred-frozen embryo transfer|"Women randomized in the experimental group will have:~Antagonist stimulation protocol~Ovarian triggering using a single injection of 0.2 mg of GnRH agonist triptorelin (Decapeptyl® Ipsen France)~All of their embryo cryopreserved at the blastocyst stage after prolonged embryo culture.~A frozen-thawed single embryo transfer at blastocyst stage, is planned 4-5 weeks after cryopreservation"
106942|NCT03349892|Radiation|Stereotactic Ablative Radiotherapy (SABR)|A single fraction of radiation is delivered using a clinical radiotherapy system capable of stereotactic radiotherapy to the chest, with on-board image guided radiotherapy capabilities, respiratory motion management, and Intensity Modulated Radiotherapy Treatment (IMRT) planning.
106943|NCT03349866|Drug|apatinib|apatinib：250mg qd po
106944|NCT03349866|Drug|Capecitabine|1000mg/m2 bid d1-14
106945|NCT03349866|Drug|Oxaliplatin|130 mg/m2 Ivgtt d1 q3w
106946|NCT03349866|Radiation|Radiotherapy|45Gy/25f （1.8Gy/f/d，5 f/w）
106947|NCT03349840|Drug|Insulin Degludec U100|Patients on any basal insulin including insulin glargine will be randomised and converted to basal degludec insulin
106948|NCT03349840|Drug|Insulin Glargine|Patients on any basal insulin including insulin glargine will be randomised and either glargine will be continued or will beconverted to basal glargine insulin
106949|NCT03349827|Procedure|exploratory laparoscopy or laparotomy|Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery
106950|NCT03349827|Procedure|HIPEC|Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.
106951|NCT03349827|Drug|Systemic chemotherapy|Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week
106952|NCT03349827|Drug|Apatinib|500mg, once daily, day 1 to day 21.
106953|NCT03349814|Procedure|Diagnostic laparoscopy without appendectomy|A diagnostic laparoscopy where the appendix is not found to be inflamed, and therefore is not removed.
106954|NCT03349814|Procedure|Diagnostic laparoscopy with appendectomy|A diagnostic laparoscopy where the appendix seems inflamed, and therefore is removed
106955|NCT03349801|Other|No intervention|According to clinical practice.
106956|NCT03349788|Procedure|LCA-nP|The group underwent lapaoroscopic radical rectectomy without preserving left colic artery.
106957|NCT03349788|Procedure|LCA-P|The group underwent lapaoroscopic radical rectectomy with preserving left colic artery.
106958|NCT03349775|Drug|Metformin|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
106959|NCT03349775|Drug|Placebo|One capsule by mouth twice a day, followed by an increase to two capsules by mouth twice a day for a total of 3 months
106960|NCT03349749|Device|LiDCOplus haemodynamic monitor|Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
106961|NCT03349736|Other|Pelvic Floor Muscle Training|All the women will receive information and instruction/guidance exercise individually and in groups on PFMT on the first day of their visit. Following this, the women are advised to perform daily PFMT at home which includes 10 sec hold X 10 times X 3 sets. Women will record their home PFMT using an exercise diary. During the follow-up, women will attend the PFMT in a group or individual led by a Physiotherapists (to motivate and to ensure women are performing the PFMT correctly). Exercise diary will be collected in every follow up so that the information is retained even if the women discontinued or deviate from intervention protocols.
106962|NCT03349723|Drug|BI 1265162|Single rising dose groups
106963|NCT03349723|Drug|Placebo|Single rising dose groups
106968|NCT03349697|Dietary Supplement|Phyllantus amarus|
106969|NCT03349697|Other|Placebo|
106970|NCT03349684|Drug|Acarbose|Acarbose will be started at a lower daily dose of 50 mg, which will be increased to 100 mg at week 2 and to 150 mg at week 3.
106971|NCT03349684|Drug|Metformin|Single tablets of metformin 500 mg tablet will be given three times daily together with main meals (breakfast, lunch, dinner).
106972|NCT03349684|Drug|Placebo|Acarbose placebo tablets will be given at breakfast and lunch during week 1 and at lunch during week 2 in experimental arm; In active comparator arm, Acarbose placebo tablets will be given three times daily together with main meals(breakfast, lunch, dinner)
106973|NCT03349671|Procedure|ultrasound|A 3D volume of the uterus will be acquired by transabdominal sonography. The sweep angle was set at 85º and the probe will be kept perpendicular to the placental plate. The placenta will be examined and the size of the volume box will be adapted in such a way that the placenta fitted into it completely. The volume will then stored for later offline analysis.
106974|NCT03349658|Other|general anesthesia|effect of general anesthesia on transcranial regional cerebral oxygen saturation
106975|NCT03349658|Other|spinal anesthesia|effect of spinal anesthesia on transcranial regional cerebral oxygen saturation
106976|NCT03349645|Biological|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% Human Serum Albumin (HSA), solution, 4 mL
106977|NCT03349632|Device|verofilcon A contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
106978|NCT03349632|Device|senofilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
106979|NCT03349632|Device|stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
106980|NCT03349632|Device|etafilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
106981|NCT03349619|Drug|Resveratrol plus Carboxymethyl-β-Glucan|Patients in this arm will receive Resveratrol plus Carboxymethyl-β-Glucan, two sprays (100µL/spray) per nostril three times/day for 4 weeks
106982|NCT03349619|Drug|Placebo|Patients in this arm will receive nasal saline solution 0.9%, two sprays per nostril, three times/day for 4 weeks
106983|NCT03349606|Drug|d-amphetamine|oral d- amphetamine 0.5 mg/kg is used to stimulate dopamine release in the brain
106984|NCT03349606|Radiation|[C-11]FLB 457|PET radiotracer
106985|NCT03349593|Diagnostic Test|Echocardiography|Preoperative transthoracic echocardiography
106986|NCT03349580|Behavioral|The training group|The training group performed rehabilitation program twice per week over 9 weeks. The group commenced rehabilitation 3 weeks after the surgery. During the phase one training (week 1 to week 5), the isometric exercises were preformed on the trunk extension, flexion and lateral flexion muscles. During the phase 2 (week 6 to week 9), the exercises were performed on the strength machines and duration of the exercises were maintained and prolonged to 30 seconds. The leg adduction and hip extension exercises were added. The patients were instructed to perform abdominal bracing (IAP) and maintain the neutral position of their lumbar spine before and during the exercises.
106987|NCT03349567|Behavioral|Audit-and-feedback|We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.
106988|NCT03349554|Other|body-scan meditation|15 minutes audio-guided body-scan meditation
106989|NCT03349554|Diagnostic Test|Psychological evaluation|"NPI (Neuropsychiatric symptoms Inventory) - PAS (Parkinson's disease Anxiety Screening Questionnaire) - VAS measuring pain, anxiety and discomfort Before and after body-scan meditation"
107091|NCT03348904|Drug|Gemcitabine|Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
106990|NCT03349541|Other|Complex Care Curriculum|"A well-established approach to curriculum development was utilized to develop competency-based objectives aligned with the Canadian CanMEDS Physician Competency Framework, identify appropriate educational strategies and design relevant evaluations."
106991|NCT03349528|Biological|Probiotic Supplement|Probiotic supplement 1 tablet by mouth daily
106992|NCT03349528|Biological|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
106993|NCT03349515|Drug|Provodine-Iodine Solution|Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
106994|NCT03349515|Drug|Group B will receive three drops in each eye of ophthalmic balanced salt solution.|Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
106995|NCT03349502|Drug|MG4101|Administration of study drug (MG4101) for the patients with refractory or relapsed acute myeloid leukemia (Single arm)
106996|NCT03349489|Other|Exercise 1|Participants will be admitted at the research center at 14:00. At 14:30, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
106997|NCT03349489|Other|Exercise 2|Participants will be admitted at the research center at 14:00. At 15:20, participant's insulin basal rate will be reduced by 80%. At 16:00, participants will perform a 60-minute exercise on a stationary bicycle at 60% of their maximal cardiorespiratory capacity (VO2 max). During the exercise period, muscle oxygenation and muscle oxygen extraction will be measure by near infrared spectroscopy. Glucose levels will be measured every 10 minutes during the exercise period. At 17:30, the participant will be discharged.
106998|NCT03349489|Device|Dexcom G4 Platinum|The Dexcom G4 Platinum will be used to measure continuous glucose levels.
106999|NCT03349489|Drug|Insulin|Participant's usual fast-acting insulin analog will be used.
107000|NCT03349489|Device|Insulin pump|Participant's insulin pump will be used to infuse insulin.
107001|NCT03349476|Device|MFAM|"Specifically, the mFAM Workstation accesses stored data of recorded electronic heart activity that has been obtained by conventional electrophysiological methods, using multi-electrode catheters placed in the heart (data inputs) for collection. Using proprietary software algorithms, the mFAM Workstation analyzes these data inputs and generates 3D anatomical structure.~mFAM improves on the FAM functionality by applying a model-based approach for reconstruction of left atrial chamber anatomy"
107002|NCT03349463|Drug|Fluciclovine F18|All study participants will receive 10 mCi of 18F-Fluciclovine (Axumin) one time administered through injection through the catheter into participant's arm immediately before PET/CT scan.
107003|NCT03349450|Biological|DPX-Survivac|DPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
107004|NCT03349450|Biological|Pembrolizumab|Pembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
107005|NCT03349450|Drug|Cyclophosphamide 50mg|Cyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
107006|NCT03349437|Device|Vitabreath Device|The VitaBreath device is designed for non-continuous use only and typical device use is expected to be for 2-3 minutes. The device should only be operated for less than 10 minutes at a time. After such time, the device should be turned off for at least 30 minutes
107007|NCT03349437|Other|Pursed Lip Breathing|Pursed lip breathing (PLB) is the standard of care and will be used as the control condition comparator.
107008|NCT03349424|Drug|Somatostatin|Patients in the Stilamin group will be continuous intravenous infusion with the somatostatin (Stilamin®) of 250μg/h, beginning within 3 hours (Visit 1) after the operation and lasting for 120 hours (each subject will receive the Stilamin of 30mg in total), and other postoperative conventional treatment protocol remain unchanged.
107009|NCT03349411|Diagnostic Test|Confusion Assessment Method|This test is used for delirium assessment. The CAM consists of a series of questions, measuring attention (digits forward and backwards, days of the week and months of the year backwards), orientation (person, place, time), memory (immediate and delayed recall of 3 concrete nouns); and probing for any sleep, perceptual, or thinking disturbances. It was designed to incorporate DSM-III criteria for delirium.
107010|NCT03349411|Diagnostic Test|Behavioral Inattention Test|This test is used for neglect assessment. The BIT consists of 6 tasks: figure and shape copying; line, star, and letter cancellation, and representational drawing. Such tasks were shown to be appropriate in patients within 48 hours of stroke onset. Scoring of each test will include proportion of error responses on each test or deviation from midpoint on line bisection. Figure and shape copying and representational drawing will be scored based on each item completed.
107011|NCT03349411|Diagnostic Test|Magnetic Resonance Imaging|Structural, functional and diffusion weighted scans will be obtained or acquired, depending on the cohort. Subacute sample participants will undergo a research MRI scan, whereas acute sample participants will allow the release of their clinical MRI scans.
107012|NCT03349411|Diagnostic Test|Florida Mental Status Examination|This test is used for mental status assessment, and it will be conducted in our subacute sample only. The FMSE tests memory, attention, language, visuospatial processing, and executive function. It will help to establish patients' mental status profile, including any deficits.
107013|NCT03349411|Diagnostic Test|Montreal Cognitive Assessment|MoCA is a brief cognitive screening tool for individuals with mild cognitive impairment and will be used in the acute sample.
107014|NCT03349411|Diagnostic Test|Geriatric Depression Scale|Because depression has been previously associated with delirium, patients will be evaluated for depression with the GDS. The GDS is a self-report measure consisting of 30 yes/no questions to measure depression in the elderly. It will be used as a covariate in data analysis.
107015|NCT03349411|Diagnostic Test|Kessler Foundation Neglect Assessment Process|This is a 10-category scale for spatial neglect based on observation of activities of daily living (e.g., eating, dressing, grooming, gaze orientation). Thee test is based on the Catherine Bergego Scale (CBS) and administered via the standardized KF-Neglect Assessment Process developed within our program.
107016|NCT03349398|Procedure|Uncut Roux-en-Y reconstruction|Uncut Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
107017|NCT03349398|Procedure|Roux-en-Y reconstruction|Roux-en-Y Reconstruction All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Roux-en-Y construction will be used in this group.
107018|NCT03349372|Procedure|Hematopoietic stem cell transplantation|Hematopoietic stem cell transplantation
107019|NCT03349359|Drug|HIV antiretroviral therapy|HIV patients are receiving an antiretroviral therapy according to the physician's discretion and the availability of drugs
107020|NCT03349346|Drug|Idelalisib|Tablet (s) or dispersible tablets for suspension administered orally twice daily
107021|NCT03349346|Drug|Rituximab|375 mg/m^2 administered intravenously
107022|NCT03349346|Drug|Ifosfamide|3 mg/m^2 administered intravenously
107023|NCT03349346|Drug|Carboplatin|635 mg/m^2 administered intravenously
107024|NCT03349346|Drug|Etoposide|100 mg/m^2 administered intravenously
107025|NCT03349333|Drug|pralatrexate|Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.
107026|NCT03349333|Dietary Supplement|Vitamin B12 and folic acid|The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.
107027|NCT03349307|Device|Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)|Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.
107028|NCT03349281|Drug|Pevonedistat|Administered each cycle on days 1, 3 and 5.
107029|NCT03349281|Drug|Vincristine|Administered each cycle on days 2, 9, 16 and 23.
107030|NCT03349281|Drug|Dexamethasone|Taken orally each cycle on days 2 through 15.
107031|NCT03349281|Drug|PEG-asparaginase|Administered via intramuscular injection (IM) each cycle on days 9 and 23.
107032|NCT03349281|Drug|Doxorubicin|Administered via IV each cycle on day 2.
107033|NCT03349281|Drug|Cytarabine|Administered to all subjects via IT injection on day 1; and on days 9, 16, and 23 to CNS positive subjects.
107034|NCT03349281|Drug|Methotrexate|Administered via IT injection to CNS negative subjects on day 16; and to CNS positive subjects on days 9, 16 and 23.
107035|NCT03349281|Drug|Hydrocortisone|Administered via IT injection to CNS positive subjects on days 9, 16, and 23.
107038|NCT03349255|Biological|autologous ET1402L1-CART cells|Autologous T cells transduced with lentivirus encoding an anti-AFP (ET1402L1)-CAR expression construct
107039|NCT03349216|Procedure|Intravenous Regional Anesthesia|in this research patients will receive intravenous regional anesthesia as infusion of mini dose (that is 1.5 mg/kg ) lidocaine 0.5% and immediately after procedure their torniquettes (A.T.S. 2000, Zimmer, Inc., Bloomfield, CN) will be deflated (hence named Rapid MiniBier's block). the pain score will be assessed by NRS system before during and after the procedure.
107040|NCT03349216|Drug|Systemic Analgesia|in this group the patients will receive ketamine 1-2 mg/kg IV slow ( Bioniche,Ireland Ketamine Hydrochloride 500mg/10cc)and titrated to effect. again here the pain score will be assessed before procedure and after the procedure every 5 minutes until 30 minutes by NRS ( Numerical Rating Score)
107092|NCT03348904|Drug|Paclitaxel|Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
107041|NCT03349203|Drug|Icotinib|Patients with EGFR-mutant stage IIIB or oligometastasis Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day by mouth for 8 weeks as neoadjuvant therapy before surgery and 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
107042|NCT03349190|Drug|ULIPRISTAL ACETATE|Ulipristal Acetate (Esmya) administrated for fibroids indication before surgery and IVF/ICSI procedure(retrospective study)
107043|NCT03349177|Drug|Epirubicin|100mg/m2
107044|NCT03349177|Drug|Fluorouracil|500mg/m2
107045|NCT03349177|Drug|Docetaxel|75mg/m2(TC), 100mg/m2(EC-T)
107046|NCT03349177|Drug|Cyclophosphamide|500mg/m2(FEC), 600mg/m2(EC-T and TC)
107047|NCT03349164|Diagnostic Test|acute PE survivors|Patients from this group will be assessed by cardiologist, echocardiography and VQ scanning
107048|NCT03349151|Behavioral|Early feeding|Feeding on postoperative 2nd hour on return to the ward
107049|NCT03349151|Behavioral|On- Demand feeding|Feeding whenever the patient asks for on return to the ward
107050|NCT03349138|Device|Conventional Therapy|
107051|NCT03349138|Device|Robotic Glove|
107052|NCT03349138|Device|Electrical Stimulation|
107053|NCT03349125|Behavioral|Collar On|
107054|NCT03349125|Behavioral|Collar Off|
107055|NCT03349112|Behavioral|4% Lidocaine Spray|2% Viscous Lidocaine is applied to the nares as standard of care. In this intervention, 4% lidocaine spray is applied additionally.
107056|NCT03349112|Behavioral|2% Viscous Lidocaine|2% Viscous Lidocaine is applied to the nares as standard of care. This intervention is considered as the control group.
107057|NCT03349099|Device|Cook Flexor|ureteral access sheath
107058|NCT03349099|Device|Boston Scientific Navigator|ureteral access sheath
107059|NCT03349086|Behavioral|Voice Exercise|Voice exercise will consist of sustained pitches and pitch glides on a variety of different vocal facilitators.
107060|NCT03349073|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
107061|NCT03349060|Drug|PF-04965842 100 mg|PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 12 weeks
107062|NCT03349060|Drug|PF-04965842 200 mg|PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 12 weeks
107063|NCT03349060|Drug|Placebo|Placebo, administered as two tablets to be taken orally once daily for 12 weeks
107064|NCT03349047|Behavioral|Behavioral intervention group|Patients will hold the peanut or tree nut in a cup and will be asked to touch the nut with their finger.
107065|NCT03349047|Behavioral|Education|The group will be educated about what can occur with contact with or being in proximity of peanuts or tree nuts.
107066|NCT03349034|Drug|Ropivicaine|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.2% Ropivacaine via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
107067|NCT03349034|Drug|Local Saline Infusion|Patients will be randomized to receive a local continuous infusion of 6 ml/hr of 0.9% normal saline via On-Q infusion pump, at the donor site, for the first 48 hours of the postoperative period.
107068|NCT03349021|Device|Bougiecap|Treatment of esophagel Stenosis by Bougiecap
107069|NCT03349008|Drug|Entecavir|Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
107070|NCT03349008|Drug|Magnesium Isoglycyrrhizinate|Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
107071|NCT03349008|Drug|Diammonium Glycyrrhizinate|Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
107072|NCT03349008|Drug|Magnesium Isoglycyrrhizinate Placebo|Magnesium Isoglycyrrhizinate Injection Placebo
107073|NCT03349008|Drug|Diammonium Glycyrrhizinate Placebo|Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
107074|NCT03348995|Device|Bridge-Enhanced ACL Repair (BEAR)|In the BEAR Procedure, surgery is performed to sew the ACL back together and a scaffold is placed between the torn ends at the time of repair.
107075|NCT03348982|Behavioral|Jogging program|The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
107076|NCT03348969|Drug|Mitomycin c|Neoadjuvant Mitomycin C
107077|NCT03348956|Diagnostic Test|EPR Oximetry|Subjects will have up to five EPR oximetry readings at each study visit. Subjects will place the foot with the paramagnetic ink injection between the two magnets of the EPR device. Continuous scans will be acquired for 10 minutes while the subject breathes room air, 10 minutes while the subject breathes enriched 100% oxygen, and 10 minutes while breathing room air again.
107078|NCT03348943|Behavioral|Right hemiparesis, right upper limb.|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
107079|NCT03348943|Behavioral|Right hemiparesis, left upper limb|Individuals with right hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
107080|NCT03348943|Behavioral|Left hemiparesis, left upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the affected upper limb.
107081|NCT03348943|Behavioral|Left hemiparesis, right upper limb|Individuals with left hemiparesis Cerebral Palsy that will perform the tasks with the non-affected upper limb.
107082|NCT03348930|Drug|Tolcapone 200 MG|All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
107083|NCT03348917|Drug|7.5% Povidone-Iodine [PVP-I]|Betadine® 7.5% skin cleanser (PVP-I 7.5%)
107084|NCT03348917|Drug|4% chlorhexidine skin cleanser|Unity antiseptic hand wash (no alcohol)
107085|NCT03348917|Drug|Plain non antibacterial soap|Guardian gel hand wash (not medicated),
107086|NCT03348904|Drug|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
107087|NCT03348904|Drug|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
107088|NCT03348904|Drug|Placebo|Matching placebo for epacadostat administered orally twice daily.
107089|NCT03348904|Drug|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
107090|NCT03348904|Drug|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
107093|NCT03348904|Drug|Pemetrexed|Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
107094|NCT03348891|Other|Tumor biopsy specimens and blood samples|Tumor biopsy specimens (if feasible) and blood samples will be collected at Baseline, Week 6 Day 1 (blood sample only) and Week 12 Day 1.
107095|NCT03348878|Other|assessment of drug compliance|assessment of drug compliance using electronic monitoring devices (2 months duration)
107096|NCT03348865|Behavioral|Fertility Life Counselling Aid (FeLiCiA)|The FeLiCiA study is a pilot randomised control trial study of an intervention that uses cognitive behavioral therapy (CBT) method to provide counselling for infertility patients within low resource settings. this intervention is designed for management of the psychological problems associated with having infertility. It is based on the Thinking Healthy Programme by WHO.
107097|NCT03348852|Device|Transcranial direct current stimulation|Device: Transcranial direct current stimulation Transcranial direct current stimulation over the motor cortex.
107098|NCT03348839|Device|NeLLY service|Telesurveillance and therapeutic support
107099|NCT03348826|Drug|Sodium Bicarbonate 8.4% Solution for Injection|3 mL injection into line with up to 2 injections administered
107100|NCT03348826|Drug|Alteplase Injectable Solution|2 mL injection into line with up to 2 injections administered
107101|NCT03348813|Behavioral|HIV/STI Prevention Intervention|The targeted HIV/STI risk reduction intervention was delivered with groups of up to 8 participants through 8, 45-minute modules equally divided over 2 days (4 modules per session). It was designed to enhance participants' knowledge and ability to reduce their risk of HIV/STIs. Grounded in both social/behavioral and cognitive theories, the intervention includes psychoeducation, and was intended to enhance participants' HIV/STI prevention knowledge, attitudes, beliefs and skills in a manner relevant to Black adolescents.
107102|NCT03348813|Behavioral|General Health Control Intervention|"The original Promoting Health among Teens (PHAT) Project was designed to increase knowledge and motivation regarding healthful dietary practices, aerobic exercise, and breast and testicular self-examination, and to discourage cigarette smoking. The 8-hour, 2-session PHAT intervention was shortened to mirror the Project GOLD HIV/STI risk reduction curriculum. This was done to control for the Hawthorne effect and reduce the likelihood that effects of the HIV/STI risk reduction intervention can be attributed to its nonspecific features, including special attention. From an ethical standpoint, adolescents in both conditions received a valuable and engaging health-risk-reduction intervention as opposed to usual care."
107103|NCT03348800|Procedure|Dental anesthesia|A tooth extraction will be performed
107104|NCT03348787|Behavioral|Behavioral and Cognitive Therapies|"Group intervention of 6 weekly sessions of one hour and 30 minutes based on the psychoeducational therapeutic principles and CBT type 3 wave Accept Voices applied to HAV"
107105|NCT03348761|Device|rTMS group|
107106|NCT03348748|Other|Laboratory Biomarker Analysis|Correlative studies
107107|NCT03348748|Other|Quality-of-Life Assessment|Ancillary studies
107108|NCT03348748|Drug|Stereotactic Body Radiation Therapy|Undergo lowest-dose of SBRT
107109|NCT03348748|Drug|Stereotactic Body Radiation Therapy|Undergo lowest- or higher-dose of SBRT
107110|NCT03348748|Drug|Stereotactic Body Radiation Therapy|Undergo highest-dose of SBRT
107111|NCT03348748|Procedure|Thoracic Surgical Procedure|Undergo thoracic surgery
107112|NCT03348735|Drug|Lidocaine patch 5%|Application of Lidocaine 5% patch for 12 hours.
107113|NCT03348735|Drug|Capsaicin 8% Patch|Application of Capsaicin 8% patch for
107114|NCT03348735|Drug|Pregabalin|Oral treatment with pregabalin (75mg capsules) will be used at optimized doses to best match clinical practice in Europe.
107115|NCT03348722|Other|Active surveillance|PSA testing (every 3 months, then every 6 after 30 months), clinical visit and DRE every 6 months, prostate biopsy after 1, 4 and 7 years
107116|NCT03348722|Procedure|Radical prostatectomy|Radical prostatectomy (open, laparoscopic or robotic)
107117|NCT03348722|Radiation|Radiotherapy|External radical radiotherapy or brachitherapy
107118|NCT03348722|Procedure|Other radical treatments|High intensity focal ultrasound, cryotherapy, others
107119|NCT03348709|Dietary Supplement|Isoosmolar|48 hours, 800 ml per 24 hours
107120|NCT03348709|Dietary Supplement|Hyperosmolar|48 hours, 800 ml per 24 hours
107121|NCT03348696|Drug|Dexamethasone tapering dose|dexamethasone standard of care pre-medication + dexamethasone tapering dose
107122|NCT03348696|Drug|Dexamethasone physician choice|Dexamethasone standard of care pre-medication + dexamethasone physician choice
107123|NCT03348683|Drug|Propranolol|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of the one-time study medication, IV Propanolol.
107124|NCT03348683|Drug|Placebo|After induction is started with Foley or misoprostol placement, 30 minutes will pass before administration of IV Saline
107125|NCT03348670|Drug|Etoposide Capsule + Methotrexate Tablet + Topotecan Capsule|"Etoposide Oral plus Methotrexate Oral plus Topotecan Oral~Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule"
107126|NCT03348670|Drug|Etoposide Capsule + Methotrexate Tablet + Everolimus Tablet|"Etoposide Oral plus Methotrexate Oral plus Everolimus Oral~Etoposide Capsule plus Methotrexate Tablet plus AFINITOR - Everolimus Tablet"
107127|NCT03348657|Other|Music Session|Three to four times a week, volunteer musicians came to the geriatric assessment unit and would provide music sessions (duration of about 60 minutes) to the patients who volunteered to attend.
107128|NCT03348644|Dietary Supplement|Phosphate tablets.|
107129|NCT03348644|Dietary Supplement|High cheese intake.|
107130|NCT03348644|Dietary Supplement|High milk intake.|
107131|NCT03348631|Other|Laboratory Biomarker Analysis|Correlative studies
107132|NCT03348631|Drug|Tazemetostat|Given PO
107133|NCT03348618|Biological|IVIG|Intravenous immunoglobulin
107173|NCT03348267|Dietary Supplement|Milk protein isolate|Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water
107174|NCT03348267|Dietary Supplement|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
107175|NCT03348254|Drug|Single shot antibiotic prophylaxis|single shot preoperative antibiotic prophylaxis
107134|NCT03348605|Device|Phantom Stimulator, Cort X Sensorics, Spaichingen, Germany|"This system consists of a pressure sensing insole connected to regular TENS-Electrode patches which are applied to the receptive fields of the patients (evoking the sensation of heel and forefoot). The individually adjusted stimulation intensity on the systems regulatory box through a socked screw is set at the beginning of the testing phase, and not changed anymore.~The current is applied to mimic the roll-off-sensation while walking. This is done by locating two sets of electrodes on the receptive fields representing the heel and the ball of the foot respectively. Now the current is applied in an alternating manner coordinated with the walking of the participant. The coordination is made able through the pressure sensing insole."
107135|NCT03348592|Dietary Supplement|Oligofructose-enriched inulin (p-inulin)|
107136|NCT03348592|Other|No treatment|Patients do not take a supplement during the first 8 weeks or the last 8 weeks of the study.
107137|NCT03348579|Other|Guidelines publication and application|Passing recommendations on using the guidelines in the intensive care units
107138|NCT03348566|Other|fish|fish intkae
107139|NCT03348553|Dietary Supplement|control group|no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products
107140|NCT03348553|Dietary Supplement|Omega2|2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
107141|NCT03348553|Dietary Supplement|Omega4|4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
107142|NCT03348553|Dietary Supplement|Omega2+OGV|2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
107143|NCT03348540|Behavioral|Attention Control Training|Attention control training teaches participants that the emotional salience of cues (i.e., threatening or neutral) is not related to successful completion of the computerized response task, and thus, teaches participants to ignore irrelevant threat-related contingencies (Badura-Brack et al., 2015).
107144|NCT03348540|Behavioral|Comparison Task|Neutral- neutral stimuli prior to response task
107145|NCT03348527|Drug|2-Hydroxyflutamide Depot|Liproca® Depot is a depot formulation containing a bioresorbable, controlled-release,formulation of the nonsteroidal antiandrogen 2-hydroxyflutamide
107146|NCT03348514|Drug|CPX-POM|CPX-POM
107147|NCT03348501|Other|survey for long-term follow-up of the disease|patients will be regularly asked about their state of health (occurrence of a major health event that required hospitalization, for example ...), and about their living conditions (alcohol and tobacco consumption, socio-economic environment). Questionnaires of quality of life and satisfaction related to care will also be offered at regular intervals to better know the impact of their disease on their daily lives and their perception of their care.
107148|NCT03348488|Procedure|Ultrafiltration dose|Fixed high volume of ultrafiltration over an hour during dialysis
107149|NCT03348475|Behavioral|Binge Focused Therapy (BFT) Intervention|The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
107150|NCT03348462|Drug|ethosomal preparation of anthralin|once daily with short contact topical application
107151|NCT03348462|Drug|liposomal preparation of anthralin|once daily with short contact topical application
107152|NCT03348449|Other|Collection of data|Outcome of patients will be collected from charts to evaluate primary and secondary objectives
107153|NCT03348436|Procedure|radiofrequency ablation|
107154|NCT03348423|Drug|DEX-IN|IN Dexmedetomidine + IV placebo
107155|NCT03348423|Drug|Fentanyl|IN Placebo + IV Fentanyl
107156|NCT03348423|Drug|Placebo|IN Placebo + IV Placebo
107157|NCT03348410|Behavioral|Motivational interviewing|Motivational interviewing with insurance officer
107158|NCT03348397|Procedure|right ventricular outflow tract reconstruction with contegra|Contegra pulmonary valved conduit is an animal jugular vein that contains a valve with three leaflets that are similar to a human heart valve.
107159|NCT03348397|Procedure|right ventricular outflow tract reconstruction with pulmonary homograft|cryopreserved pulmonary homografts
107160|NCT03348384|Radiation|[C-11]|Radiolabel
107161|NCT03348384|Drug|NOP-1A|Tracer
107162|NCT03348371|Other|Ethanol|The intervention is two different administrationforms of ethanol, orally and i.v.
107163|NCT03348358|Behavioral|quiet music|playing quiet music during labor
107164|NCT03348358|Behavioral|Rhythmic music|playing rhythmic music during labor
107165|NCT03348358|Behavioral|control|No music during labor
107166|NCT03348345|Behavioral|Eat Breathe Thrive|Eat Breathe Thrive (EBT) program which was designed to increase positive body image, awareness, self-regulation, and mindful eating habits. This program aims to achieve these things through psychoeducation of cultural influences of beauty standards, the basic neuropsychological systems in the body and how they affect eating habits, creating a community within the group members for support, and finally through the practice of yoga.
107167|NCT03348332|Behavioral|Exercise pregnant women|A supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 10 to 39) was conducted. Each session consisted of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training. Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor during the training sessions to control the intensity.
107168|NCT03348319|Other|radiation|Scanning cadaver organs
107169|NCT03348306|Device|MRI|Brain and cardiac MRI in one time with gadolinium injection.
107170|NCT03348306|Biological|Blood sample collection|A blood sampling is also collected for hematocrit measure.
107171|NCT03348293|Procedure|3D printing|Scope of tumor resection was simulated according to the MR imaging data. After meticulous design, we created the personalized porous biodegradable scaffold and printed by 3D printer, using porous PCL biomaterials. During operation, the biodegradable scaffold was implanted into the defective cavity after tumor resection.
107172|NCT03348280|Diagnostic Test|Blood draw|Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
107176|NCT03348254|Drug|Multiple shot antibiotic prophylaxis|Multiple shot perioperative antibiotic prophylaxis
107177|NCT03348241|Drug|Gum Arabic|Gum acacia, also known as Gum Arabic is exuded from acacia trees; mainly from Acacia Senegal (gum Hashab or Kordofan gum) which was used in this study.
107178|NCT03348241|Drug|Chemotherapy|Patients of control group and study group (Gum Arabic group) received chemotherapy according to type and stage of cancer.
107179|NCT03348241|Behavioral|Lifestyle counseling|Lifestyle counseling pertaining to the optimal nutrition and daily routine for oral hygiene.
107180|NCT03348228|Dietary Supplement|Hydroxycitrate (HCA)|Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. Each subject will be given 42 capsules of Swanson super citrimax (hydroxycitrate) Details of the product are provided above. The subjects will be asked to take the capsules over a seven period (6 capsules per day).
107181|NCT03348215|Other|Enhanced Treadmill Training|6 week programme of treadmill training with addition of an immersive environment (virtual reality projection), body weight support, orthotics and functional electrical stimulation
107182|NCT03348189|Other|Pulse Oximeter|Pulse Oximeter
107183|NCT03348176|Other|Vegetable exposure|Repeated exposure to variety of vegetables
107184|NCT03348176|Behavioral|VIPP-Feeding Infants|Promoting responsive feeding practices
107185|NCT03348176|Other|Control|Phone calls with mother about development of child, no advice on complementary feeding
107186|NCT03348163|Drug|B/FTC/TAF|B/FTC/TAF in one pill (single tablet regimen) for administration to participants in Arm A.
107187|NCT03348163|Drug|Current ART|Comparator arm. Participant continues open label entry ART.
107188|NCT03348150|Procedure|Cytoreductive surgery + Gastrecomy|Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.
107189|NCT03348150|Drug|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
107190|NCT03348137|Other|Questionnaire Administration|Ancillary studies
107191|NCT03348124|Behavioral|"Children - what does it involve?"|"Thirteen educational lessons based on the conversational material Toolkit will be delivered in the classroom at school, two lessons per theme. The themes consists of: 1) a card game: What i wish 2) Time 3) Money 4) Skills 5) Relations 6) Housing. The material is prepared and same for all schools. This intervention will be given 1-2 lessons per week over a period of 8-14 weeks. During this period the students also care for the RCB simulator during three days and nights, but with a break for day care for the simulator which was between 7 am and 5 pm when the students were in school. All students will practice handling the simulator to be familiar with all types of needs: to rock, change diaper, feed and burp and were taught the skills of head support, techniques to avoid rough handling."
107192|NCT03348111|Device|Air-polishing device|Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally
107193|NCT03348098|Drug|Apatinib|500 mg, po, qd. 12weeks
107194|NCT03348098|Drug|Paclitaxel|drug: Paclitaxel ,80mg/m2, d1, Once a week , A total of 12 weeks; 3 weeks as a cycle
107195|NCT03348085|Other|No intervention|No intervention.
107196|NCT03348072|Procedure|Cardiac surgery|Cardiac surgery
107197|NCT03348059|Drug|Direct-acting antiviral therapy|HCV patients received direct-acting antiviral treatment for 12 or 24 weeks
107198|NCT03348046|Drug|Biosimilar Infliximab|A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg
107199|NCT03348033|Biological|Chronic Myeloid Leukemia + NK cell|Patients with chronic phase chronic myeloid leukemia who lost response to the second line of treatment with tyrosine kinase inhibitor with indication of bone marrow transplantation or refractory. Infusion of autologous natural killer cells, expanded in the laboratory, after chemotherapeutic conditioning.
107200|NCT03348020|Procedure|Blood Donation|Subjects will donate blood within ~1 month after their baseline clinical trial. Subjects will report to the Substrate Metabolism Laboratory between 24 and 72 hours following blood donation. A finger-stick will be performed for the measurement of hemoglobin concentration.
107201|NCT03348007|Other|Taking two kinds of mineral water|1.5L of low-mineral water (Vittel Bonne Source, control group) or 1L of Hépar + 0.5L of low-mineral water (Hépar group).
107202|NCT03347994|Drug|Minnelide|Minnelide therapy may be administered for up to 12 cycles of 28 days are planned. If patients are receiving clinical benefit, treatment can continue beyond 12 cycles.
107203|NCT03347981|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
107204|NCT03347981|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
107205|NCT03347968|Biological|MEDI0382|All participants will receive MEDI0382
107206|NCT03347968|Drug|Warfarin|All participants will receive Warfarin
107207|NCT03347968|Drug|Esmolol|All participants will receive Esmolol
107208|NCT03347955|Procedure|Neural implantation group|Cultured mesencephalic tissue from four embryos was implanted into the putamen bilaterally for those receiving the implant
107209|NCT03347955|Procedure|Sham surgery|Steel frame affixed to head and four burr holes drilled into forehead of sham surgery patients
107210|NCT03347942|Behavioral|Intervention group|Wait at least 20 minutes after finishing the first portion of meals previously considered sufficient by the individual before serving again if he or she feels the need. The intervention time will be monitored by the participants themselves, who will be instructed by the researcher when the methodology to be performed.
107211|NCT03347942|Other|Control group|The control group will also serve the dish of the form, but can serve additional portion without waiting.
107212|NCT03347929|Drug|Naproxen 500 Mg|10 days treatment with Naproxen 500 mg twice daily
107213|NCT03347929|Drug|Placebo|10 days treatment with Placebo1 tablet twice daily
107214|NCT03347916|Drug|Strawberry juice as (placebo)|Patients received strawberry juice 5 ml volume, one hour before induction.
107215|NCT03347916|Drug|Gabapentin Oral Solution [Neurontin]|Patients received gabapentin (Neurontin oral solution 250 mg/ml, Pfizer, USA) 5 mg/kg mixed with strawberry juice to constitute 5 ml volume, one hour before induction.
108153|NCT03340649|Other|taking peripheral blood|taking peripheral blood of no more than 3ml
107216|NCT03347890|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo|Patients will be evaluated at baseline and at 16-week (end of study) after daily subcutaneous injections of Saxenda® (liraglutide 3.0 mg) or Placebo by pen injector.
107217|NCT03347877|Procedure|autologous osteo-periosteal cylinder graft transplantation|Autologous osteo-periosteal cylinder graft transplantation is a novel treatment for Hepple V osteochondral lesions of the talus.
107218|NCT03347877|Procedure|autologous osteochondral graft transplantation|Autologous osteochondral graft transplantation is the most common treatment for Hepple V osteochondral lesions of the talus.
107219|NCT03347877|Device|autologous osteo-periosteal cylinder graft|Autologous osteo-periosteal cylinder graft is taken from ilium.
107220|NCT03347864|Drug|68Ga-NOTA-RM26|1.85 MBq per kilogram body weight of 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans
107221|NCT03347851|Other|MRI|Enrolled patients will complete a non-contrast cardiac MRI
107222|NCT03347851|Other|Transthoracic echocardiography exam|Enrolled patients will complete a transthoracic echocardiography exam.
107223|NCT03347838|Drug|Nivolumab|Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
107224|NCT03347825|Procedure|Robotic-assisted lobectomy using da Vinci Surgical System|Robotic-assisted lobectomy
107225|NCT03347825|Procedure|VATS (video assisted thoracic surgery)|VATS (video assisted thoracic surgery)
107226|NCT03347825|Procedure|Open lobectomy|Open lobectomy
107227|NCT03347812|Procedure|Endovascular Aortic Repair|Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
107228|NCT03347812|Procedure|Total Arch Replacement|A kind of open surgery is performed for the replacement of total aortic arch.
107229|NCT03347786|Drug|Verapamil|Intra-arterial delivery of verapamil following mechanical thrombectomy procedure
107230|NCT03347773|Dietary Supplement|ReGen 18%|ReGen 18% is a kind of oral nutritional supplement, designed for patients under regular hemodialysis. One can of ReGen 18% contains 237ml, 425 Kcal, 19.1g protein, 22.7g lipid and 37.9g carbohydrate.
107231|NCT03347760|Drug|DOTATOC-68Ga PET initial|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
107232|NCT03347760|Drug|DOTATOC-68Ga PET at 6 months|DOTATOC is a tracer of high affinity for the type 2 somatostatin receptors and is used for imaging of tumours which are expressing them, including endocrine tumours
107233|NCT03347760|Biological|blood sample|blood tests will be carried out during the control visit to ensure that biological parameters are normalized
107234|NCT03347747|Other|Study Photography + Personal & Medical History Collection|3D facial images taken and complete a detailed study questionnaire
107235|NCT03347734|Behavioral|Eye exercises group|"20 times hot water, 20 times cold water washing face in the morning and evening.~Palming; 2 hands are rubbed together and warmed up, and the eyes are closed, and 8 digits are drawn with eyes in darkness.~20 blinks~Looking at a clock in a circular shape, from 12 to 6, from 6 to 12, from 3 to 9, from 9 to 3, from 2 to 8, from 8 to 2, oblique from 10 to 4, from 4 to 10, and turning the eyes starting from 12 clockwise and counterclockwise. At the end of the exercises, 2-3 minutes of light massage around the eyes and on sunny days, sunbathing was recommended by closing the eyes for 3-5 minutes and swinging to the left and right."
107236|NCT03347734|Behavioral|Convergence exercise group|"Close eyes for 15 s,~Focus on a point 1 to 1.5 ft away for 10 s,~Close eyes for 5 s,~Focus on a point 20 ft away for 10 s,~Close eyes for 5 s,~Focus on a point 1 to 1.5 ft away for 10 s,~Blink for 5 s,~Close eyes for 5 s."
107237|NCT03347734|Behavioral|Oculomotor Exercise Group (OMEG)|"The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes."
107238|NCT03347721|Drug|lidocaine gel|2% lidocaine jelly, injected into the urethra
107239|NCT03347721|Drug|Lubricant Gel|Lubricating gel
107240|NCT03347708|Biological|IDCT|Discogenic Cells + Sodium Hyaluronate Vehicle
107241|NCT03347708|Drug|Saline Solution|Sodium Chloride Solution
107242|NCT03347708|Drug|Sodium Hyaluronate|Sodium Hyaluronate Vehicle
107243|NCT03347695|Procedure|Circumferential resection of a strip for the left atrial|Two circular incisions were performed in the left atrial wall between the pulmonary veins and the mitral annulus. The first one was made in the right atrial free wall, about 5 mm inside the right pulmonary veins an parallel to the interatrial groove, and extended around the pulmonary veins. The second incision was made in the interatrial groove and extended around the posterior mitral annulus(leaving about a 2cm margin from the annulus).
107244|NCT03347682|Other|Satisfaction with Prosthesis -SATPRO|questionnaire 1
107245|NCT03347682|Other|Nottingham Health Profile-NHP|questionnaire 2
107246|NCT03347682|Other|Prosthesis donning and doffing questionnaire|questionnaire 3
107247|NCT03347669|Device|Sudoscan®|Sudoscan® is a new device that provides rapid, non-invasive and reproducible quantitative assessment of sweat function. It makes it possible to measure the ability of the sweat glands to release chloride ions in response to electrochemical activation and thus to detect the presence of a neuropathy with small fibers. This new device therefore makes it possible to detect an SFN in a much simpler and faster way than the technique of ophthalmology, or biopsy. Sudoscan® has been tested to assess the neuropathies of small nerve fibers in several diseases, in particular diabetes, chemotherapy-induced polyneuropathy, familial amyloid polyneuropathy or Fabry disease. The interest of Sudoscan® lies in the fact that this device is non-invasive and rapid. Its diagnostic value has been compared with other neurophysiological tests.
107248|NCT03347643|Device|tDCS with real stimulation|tDCS is a non-invasive brain stimulation. Real stimulation includes 2mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
107360|NCT03346694|Device|Mepilex Border Post-Op Ag|Participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision
107249|NCT03347643|Device|tDCS with sham stimulation|Sham stimulation includes 0mA current for 20 minutes per session. Two sessions a day for 5 consecutive days (Total: 10 sessions) will be applied.
107250|NCT03347630|Diagnostic Test|MRI|Thoraco-abominal MRI
107251|NCT03347617|Drug|Ferumoxytol|Given IV
107252|NCT03347617|Other|Laboratory Biomarker Analysis|Correlative studies
107253|NCT03347617|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol MRI
107254|NCT03347617|Biological|Pembrolizumab|Given IV
107255|NCT03347604|Diagnostic Test|Supine spirometry, MIPs and MEPs|We are going to test spirometry while in supine position , and also test respiratory muscles by measuring the maximum inspiratory and maximum expiratory efforts made by patients.
107256|NCT03347591|Genetic|WES|136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
107257|NCT03347591|Diagnostic Test|Several assays|Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
107258|NCT03347578|Diagnostic Test|Ultrasonography|Diaphragmatic ultrasound was performed to investigate diaphragmatic function after thoracic surgery
107259|NCT03347552|Behavioral|HOME|"Prior to discharge from the inpatient unit, the HOME program provider or another member of the research team, will meet individually with the Veteran to provide further information regarding the HOME program intervention. Efforts are made to schedule the initial phone call and home visit that occur during the first week after discharge. Following the home visit, the HOME provider may continue to have weekly contact with the Veteran via the telephone or in person until he or she is disenrolled following engagement in outpatient care. Engaged in care is defined as attendance at two individual outpatient mental health appointments or engagement in equivalent or elevated care as determined by the PI. All clinical contacts with the Veteran may include the following: suicide risk assessment, review and modification of the Veteran's safety plan, review and modification of the discharge plan, involvement of the Veteran's support system, and facilitation of engagement in outpatient care."
107260|NCT03347539|Device|Nexplaon|This study is an exploratory study of user reasons for Nexplanon implant and removal, and NOT a study on the efficacy or safety of Nexplanon. Nexplanon has already been FDA approved and its efficacy and safety studied.
107261|NCT03347526|Drug|Cosyntropin Injectable Suspension, 1 mg/mL|Injectable
107262|NCT03347526|Drug|Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin|Injectable + oral solution
107263|NCT03347526|Drug|Vigabatrin|oral
107264|NCT03347513|Drug|triple attack therapy|eradication of H-pylori using triple attack therapy.
107265|NCT03347513|Drug|Ferrous(II)-glycine-sulphate complex 567.7 mg capsules|Iron therapy will be given to both groups twice daily for one month.
107266|NCT03347500|Other|use of patient-derived biological samples|We will use biological samples that are routinely collected as waste material from patients undergoing prosthetic surgery at IRCCS Istituto Ortopedico Galeazzi. Peripheral blood will be also collected from patients during the pre-surgery visit and during the post-surgery hospitalization coinciding with routine blood sample collection.
107267|NCT03347487|Procedure|Deep brain stimuation system implantation|All subjects will receive bilateral surgical implantation of DBS system.The Medtronic DBS 3389 electrode is utilized in this study. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller.
107268|NCT03347474|Procedure|Bilateral surgical implantation of DBS system to NAc|The Medtronic, PINS and SceneRay DBS device will be utilized in the present study.
107269|NCT03347461|Drug|Otiprio|Otiprio is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery. Otoprio (6% ciprofloxacin, 60 mg/mL) will be administered through the tube lumen by the otolaryngologist immediately after tympanostomy surgery.
107270|NCT03347461|Drug|Ciprodex|Ciprodex is a combined antibiotic and steroid ear drop used to treat otitis media with tympanostomy tubes. Four drops of Ciprodex (0.14mL) instilled by the otolaryngologist into the affected ear immediately after tympanostomy surgery. Each mL of Ciprodex contains ciprofloxacin hydrochloride 0.3 % (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1 % equivalent to 1 mg dexamethasone
107271|NCT03347435|Genetic|genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435|The CYP2C19*2 (10q24.1-q24.3; rs4244285), CYP2C19*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.
107272|NCT03347435|Other|clinical algorithm|Antiplatelet therapy will be choose on the basis of clinical algorithm alone
107275|NCT03347409|Other|Changes in preoperative care|Optimization of relevant medical uncontrolled situations, avoid fasting, avoid bowel preparation, avoid premedications, nutritional assessment, stop smoking, stop alcohol and appropriate counselling
107276|NCT03347409|Other|Changes in intraoperative care|Blended anesthesia is mostly carried out using Total Intra Venous Anesthesia (TIVA) with loco regional analgesia, in particular Thoracic Epidural Anesthesia (TEA) in open surgery and spinal morphine or Transversus Abdominis Plane (TAP) block or quadratus lumborum block for laparoscopic surgical approach, associated to NSAIDs or acetaminophen; control of deep neuromuscular blocking with Train-of-four (TOF) stimulation avoiding residual paralysis. Multimodal prevention of PONV (according to preoperative assessment of Apfel Score) with a combination of multiple antiemetic drugs.
107496|NCT03345732|Diagnostic Test|ICG and SPY system for wound complications|
107497|NCT03345719|Diagnostic Test|3D Cone-Beam Imaging|
107277|NCT03347409|Other|Changes in postoperative care|Postoperative pain control is obtained with opioid sparing strategies, in order to avoid Post Operative Ileus (POI) and PONV. According to the type of surgery TEA, TAP block , quadratus lumborum block or IT morphine is preferred. Patient is proposed to start drinking clear fluid 4 hours after surgery and to start eating the evening of the surgery, with the introduction of a normal free diet within 24 hours after surgery. It is proposed to chew gum three times daily for at least 15 minutes and eventually to use laxatives to promote a faster bowel function. Early mobilization is started from the evening of surgery.
107279|NCT03347383|Device|Combination therapy DCB + stent|Patients will be treated with the Luminor DCB and iVolution stent
107280|NCT03347370|Drug|SC Peginterferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics [SmPC]).
107281|NCT03347370|Drug|SC interferon beta-1a|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics [SmPC]).
107282|NCT03347370|Drug|SC interferon beta-1b|All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.
107283|NCT03347357|Drug|Tacrolimus|Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
107284|NCT03347344|Drug|Riluzole|50 mg will be administered (per os) twice a day
107285|NCT03347344|Drug|Placebo|50 mg will be administered (per os) twice a day
107286|NCT03347331|Drug|[18F]F13640|"Radiotracer injection and PET scan acquisition of 90 min:~*150 Mbq + 1 MBq/Kg of [18F]F13640 at t=0 min~Arterial Blood Sampling during the 90min acquisition"
107287|NCT03347331|Drug|[18F]F13640|2 Radiotracer injections and PET scan acquisition of 90 min distant from 1 to 3 weeks: For each exam: 150 MBq + 1 MBq/kg of [18F]F13640 at t=0 min
107288|NCT03347305|Behavioral|automated DP|Energy expenditure measurement
107289|NCT03347305|Behavioral|Calorimetric chamber|The main objective is to compare DE and its variations according to the conditions (rest, sleep, meals, physical activity) in patients treated with automated DP compared to controls, in a calorimetric chamber
107290|NCT03347292|Drug|Regorafenib(Stivarga, BAY73-4506)|Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
107291|NCT03347292|Drug|Pembrolizumab|200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
107292|NCT03347279|Biological|Experimental: Tezepelumab|Tezepelumab subcutaneous injection
107293|NCT03347279|Other|Placebo|Placebo subcutaneous injection
107294|NCT03347266|Drug|VVZ-149 injections|•VVZ-149 injection
107295|NCT03347266|Drug|Placebo|water for injection
107296|NCT03347240|Procedure|Brain Lesioning|Stereotactic radiofrequency lesioning of the pallidum or thalamus
107297|NCT03347240|Procedure|Combined anterior and posterior lumbosacral rhizotomy|Combined anterior and posterior lumbosacral rhizotomy
107298|NCT03347240|Device|Deep brain stimulation|Bilateral DBS
107299|NCT03347240|Device|Intra-thecal baclofen infusion|Intra-thecal Baclofen infusion
107300|NCT03347227|Procedure|Catheter ablation|Wide area circumferential catheter ablation for pulmonary vein isolation of persistent atrial fibrillation
107301|NCT03347201|Device|HMS Plus|Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
107302|NCT03347188|Drug|Fremanezumab|1 subcutaneous dose regimen
107303|NCT03347188|Drug|Placebo|1 subcutaneous dose regimen
107304|NCT03347175|Procedure|Volume controlled ventilation|Volume controlled ventilation mode
107305|NCT03347175|Procedure|Pressure controlled ventilation|Pressure controlled ventilation
107306|NCT03347175|Procedure|CPAP mode|CPAP mode only
107307|NCT03347149|Device|Alarm Advisor Software|Providing advice on alarm limits as part of routine medical care
107308|NCT03347136|Device|CPAP|
107309|NCT03347136|Device|NIPPV|
107310|NCT03347123|Drug|Epacadostat|Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
107311|NCT03347123|Drug|Nivolumab|Nivolumab at the protocol-specified dose and schedule.
107312|NCT03347123|Drug|Ipilimumab|Ipilimumab at the protocol-specified dose and schedule.
107313|NCT03347123|Drug|Lirilumab|Lirilumab at the protocol-specified dose and schedule.
107314|NCT03347110|Drug|Bimekizumab|Bimekizumab at a prespecified dose.
107315|NCT03347097|Drug|TIL|
107316|NCT03347084|Device|Excitation|Administration of LIFUP, a method of deep brain stimulation, according to excitation paradigms using the following parameters: Tone Burst Duration = 50ms; Pulse Repetition Frequency = 10Hz; ISPTA = 720 mW/cm2. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
107317|NCT03347084|Device|Inhibition|Administration of LIFUP, a method of deep brain stimulation, according to inhibition paradigms using the following parameters: Tone Burst Duration = 50ms and Pulse Repetition Frequency = 10Hz. Four treatments of thirty seconds each, with two-minute intervals between treatment (20 minutes, approximately)
107318|NCT03347071|Behavioral|Prevention Course Group|The undergraduate prevention course is structured around Eat Breathe Thrive Program curriculum. The course aims to teach somatic practices, provide healthy tools for emotional regulation, allow for the creation of community-based networks of support, foster a sense of meaning and purpose through service activities, and practice these learned skills through yoga.
107356|NCT03346720|Other|Focus group discussions (FGDs)|These will be conducted following an interview guide. FGDs will be conducted in English or Thai. In addition, a note taker will be present to take notes. FGDs will take place at a place convenient and familiar to the participants. It is estimated that each FGD will last between 1 to 1.5 hours. FGDs will typically consist of homogenous groups e.g. study nurses.
107357|NCT03346707|Device|10.5 Tesla|10.5Tesla MR scan
109205|NCT03332628|Device|Microneedle patch|Each patch contains 50 microneedles.
107320|NCT03347045|Combination Product|Trimodal Prehab & ERP|"1-hr daily exercise will be completed a total of 5d/week, of which 2 of these sessions are completed through a community fitness center. Following these sessions, the participant will consume a high-protein oral supplement.~Additionally, during the program, participants will be given the option of attending a stress-reduction group and will receive a take-home anxiety-reduction program. They will have access to a physiotherapist, kinesiologist, registered dietitian, and physician throughout the program.~The total length of this program is 8-weeks and is timed to occur in the waiting period between the consent for surgery and operation date."
107321|NCT03347045|Other|No Prehab; ERP Alone|1-hr daily exercise with a self-completed home-exercise program. The participant will be given nutritional education material and a take-home anxiety-reduction program. They will be responsible for maintaining a journal of their activity.
107322|NCT03347032|Procedure|Remote ischemic preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions
107323|NCT03347032|Procedure|Control|Serial inflations and deflations as detailed in the arm/group descriptions
107324|NCT03347019|Other|Accelerated rehabilitation|advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control
107325|NCT03347019|Other|Delayed rehabilitation|Patients were not allowed to start rehabilitation programme first three weeks after surgery.
107326|NCT03347006|Dietary Supplement|SPM Active|"Supplement or placebo will be administered orally between 9 am to 9:30 am.~Each participant will give a baseline blood sample then they will be given one of the randomly allocated three doses of fish oil supplement, or a matching placebo in one of 8 study groups [this will be on a 1:1:1:1:1:1:1:1 ratio]. Blood will be collected again at 2h, 4h, 6h and 24h after supplementation/placebo, 12ml per time interval."
107327|NCT03346993|Drug|Bupivacaine Hydrochloride 5 MG/ML|Ultrasound guided infraclavicular brachial plexus block with warmed bupivacaine
107328|NCT03346980|Diagnostic Test|Esophagogastroduodenoscopy|All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
107329|NCT03346967|Combination Product|adipose-derived mesenchymal stem cells|Collect adipose-derived mesenchymal stem cells from the patients. Adipose-derived mesenchymal stem cells will be isolated, expanded and characterized in vitro under the GMP- grade procedure
107330|NCT03346954|Other|[11C]-Methionine PET/MRI|Implementation [11C]-Methionine PET/MRI performed for each patient in one place (department of nuclear medicine of the Hospices Civils de Lyon). The [11C]-Methionine PET/MRI will be performed after a pituitary MRI and before a transsphenoidal surgery.
107331|NCT03346941|Drug|DAA treatment|Direct-acting antiviral-based treatment
107332|NCT03346928|Procedure|Head and neck reconstruction|Head and neck free flap reconstruction
107333|NCT03346915|Behavioral|WoW and BNI|The Text/web based health information technology system, WoW, will provide educational resources for participants and their families to learn more about HPV vaccination and cervical cancer screening. WoW will be tailored to the participant and will be based on the participant's cancer screening and HPV vaccine health needs; It will then send custom text messages based their concerns and will remind them to schedule and attend their doctor's appointment. The brief negotiated interview will encourage and empower participants to have positive behavioral changes in regards to their health.
107334|NCT03346902|Drug|EB-001|Injection of EB-001 into area of scarring (forehead)
107335|NCT03346902|Drug|0.9% Sodium Chloride Injection|Injection of Saline into area of scarring (forehead)
107336|NCT03346876|Procedure|Nuss surgery|surgical correction for pectus excacatum
107337|NCT03346850|Device|Nasogastric tube (NGT) feeding|A nasogastric tube goes from the nose to the stomach.
107338|NCT03346850|Device|Nasoduodenal tube (NDT) feeding|A nasoduodenal tube goes from the nose to the duodenum.
107339|NCT03346837|Drug|BMS-986205|BMS-986205
107340|NCT03346837|Drug|Itraconazole|Oral solution
107341|NCT03346837|Drug|Rifampin|Tablet
107342|NCT03346811|Drug|Icotinib|Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity
107343|NCT03346798|Behavioral|Food Photography|Participants will engage in food photography on their smart phones while eating
107344|NCT03346798|Behavioral|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
107345|NCT03346798|Behavioral|No Phone Use|Participants will not use their smart phones while eating
107346|NCT03346785|Behavioral|Food Photography|Participants will engage in food photography on their smart phones while eating
107347|NCT03346785|Behavioral|Non-Food Photography|Participants will engage in non-food photography on their smart phones while eating
107348|NCT03346785|Behavioral|No Phone Use|Participants will not use their smart phones while eating
107349|NCT03346772|Biological|Influenza vaccination|Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.
107350|NCT03346759|Device|Tampon A|24 Tampax Pearl Regular Tampons for use during a single menstrual period.
107351|NCT03346759|Device|Tampon B|24 Playtex Gentle Glide 360 Regular Tampons for use during a single menstrual period.
107352|NCT03346746|Dietary Supplement|Low Glycaemic Diet|This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
107353|NCT03346746|Dietary Supplement|High Glycaemic Diet|This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
107354|NCT03346733|Dietary Supplement|Psyllium Fibre|Viscous soluble psyllium fibre
107355|NCT03346720|Other|Semi-structured interviews|These interviews will be conducted following an interview guide. Interviews will be conducted in English or Thai at a place convenient and familiar to the interviewee. It is estimated that each interview will last between 45 minutes to an hour.
107358|NCT03346694|Device|Standard Island Dressing|participant randomized to control group before end of surgery to be applied on cardiovascular heart surgical sternal incision.
107359|NCT03346694|Device|Prevena Negative Pressure wound dressing|participant randomized to dressing before end of surgery to be applied on cardiovascular heart surgical sternal incision.
107361|NCT03346681|Drug|N-acetyl cysteine|The procedure involved would be the administration of N-acetylcysteine via nebulization, which would be administered to the patient by respiratory therapy in the dosage of 2 mL 20% solution acetylcysteine (or 4 mL of 10% solution) along with inhaled albuterol via endotracheal tube every six hours for 72 hours total. The control arm will have saline administered with the albuterol every six hours. Both arms will have additional bronchodilators administered as indicated clinically (bronchospasm, COPD, peak airway pressure elevation, etc.).
107362|NCT03346668|Drug|Topical gabapentin|topical gabapentin 6% solution
107363|NCT03346642|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and histocompatibility leukocyte antigen (HLA) expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
107364|NCT03346642|Drug|GVD chemotherapy|GVD regimen is a chemotherapy regimen consisted by Gemcitabine, Vinorelbine and Doxorubicine. Patients will be administrated with Gemcitabine 0.8 g/m2, Vinorelbine 30mg and Doxorubicin 20mg/m2 intravenously infusion.
107365|NCT03346642|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
107366|NCT03346629|Drug|Mifepristone + Misoprostol|A single dose of 200 mg mifepristone (one tablet) to be taken orally either at home or at the hospital, followed 24-48 hours later with 400mcg misoprostol (buccal) at home. The participant will return to the hospital one to two hours after taking the initial dose of misoprostol to receive repeated doses of 400 mcg misoprostol until the abortion occurs.
107367|NCT03346616|Other|Texting Group|See above in arm/group description
107368|NCT03346616|Other|Non Texting Group|See above in arm/group description
107369|NCT03346603|Other|urine culture and susceptibility testing|All patients will have a urine culture and susceptibility test ordered per standard care. Results of tests will identify which patients have antimicrobial-resistant organisms.
107370|NCT03346590|Behavioral|Energy metabolism of patients suffering from RA|Energy metabolism of patients suffering from RA
107371|NCT03346577|Device|stent or balloon|Endovascular treatment with stent or balloon according to current practice
107372|NCT03346564|Behavioral|Ritual training program|Ritual training program including education and demonstration
107373|NCT03346564|Behavioral|Routine care|
107374|NCT03346551|Behavioral|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"|"Evaluation of the quality attachment : Adult Attachment Narratives and CaMir scale"
107375|NCT03346551|Behavioral|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"|"Evaluation of the self-defining memories : Specific Questionnaire during an interview"
107376|NCT03346538|Drug|Continuous infusion high-dose MCI-186|intravenous injection
107377|NCT03346538|Drug|Continuous infusion low-dose MCI-186|intravenous injection
107378|NCT03346538|Drug|Continuous infusion placebo|intravenous injection
107379|NCT03346538|Drug|Approved dosing regimen MCI-186|intravenous injection
107380|NCT03346538|Drug|Approved dosing regimen placebo|intravenous injection
107381|NCT03346525|Drug|intramuscular benzathine penicillin G (BPG) prophylaxis|Intramuscular BPG prophylaxis (600,000 IU for children <30kg, 1.2 million IU for children ≥30kg), every 28 days.
107382|NCT03346512|Procedure|Cardiac surgery|Cardiac surgery
107383|NCT03346499|Biological|NK cells and IL-2|Natural Killer Cells
107384|NCT03346486|Other|Control diet|Regular diet
107385|NCT03346486|Other|Intervention diet|Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
107386|NCT03346460|Other|Tongue Scraping|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating.
107387|NCT03346460|Radiation|aPDT|One session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. The excess will be removed with a sucker in order to keep the surface wet with the PS itself, without using water. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
107388|NCT03346460|Radiation|Tongue scraper and aPDT|Tongue scraping will be performed by the same operator in all patients. Posterior-anterior movements will be performed with the scraper over the lingual dorsum, followed by cleaning the scraper with a gauze. This procedure will be performed ten times in each patient, in order to standardize the mechanical removal of the tongue coating. After, one session of aPDT will be performed with the photosensitizer (PS) urucum manipulated at a concentration of 20% (Fórmula e Ação®) in spray, to be applied in sufficient quantity to cover the middle third and back of the tongue (5 sprinkles) for 5 minutes for incubation. Six points with a distance of 1 cm between them will be irradiated, considering the halo of light scattering and effectiveness of aPDT. The apparatus shall be precalibrated at wavelength 440-480nm for 60 seconds per point, irradiance of 450mW/cm and the light shall be irradiated so that a halo of 2cm diameter is formed per point.
107389|NCT03346447|Other|Artificial Fecal Enzyme|Artificial Fecal enzyme Trypsin/Chymotrypsin mixture
107390|NCT03346434|Drug|Dupilumab|Solution for injection, subcutaneous (SC)
107391|NCT03346434|Drug|Matching placebo|Solution for injection, subcutaneous (SC)
107392|NCT03346421|Behavioral|diet and physical activity|
107393|NCT03346408|Behavioral|Questionnaire|patient (self-questionnaire) and algologist physician (questionnaire)
107394|NCT03346395|Behavioral|Problem solving based intervention|Problem solving based intervention
107395|NCT03346395|Behavioral|Care as usual|Medical treatment, or behavioral therapy or a coordination of behavioral therapy and medical treatment. Meeting with a rehabilitation coordinator.
107529|NCT03345407|Drug|Placebo ELLIPTA|Placebo will be administered via oral inhalation route once daily in the morning.
107396|NCT03346369|Drug|Lanthanum Carbonate|Treatment with Lanthanum Carbonate 3 x 250 mg/day with meals during a first 14-day treatment period. Subsequently, treatment with Lanthanum Carbonate 3 x 500 mg/day with meals during a second 14-day treatment period
107397|NCT03346356|Behavioral|Teenagers as cross-age SHCP teachers for younger youth|Implementation of the SHCP using teenagers as cross-age teachers for younger youth
107398|NCT03346343|Device|Non-invasive forced airway oscillometry|This is a non-invasive device will measure lung function in spontaneously breathing infants. Infants will have a cushioned mask placed on his/her face and the device will take measurements as the infant breathes normally.
107399|NCT03346330|Drug|TRK-750|TRK-750 capsule
107400|NCT03346330|Drug|Placebo|Placebo capsule
107401|NCT03346317|Device|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter.
107402|NCT03346317|Procedure|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
107403|NCT03346317|Drug|estradiol valerate tablets+dydrogesterone tablets|oral estradiol valerate tablets+dydrogesterone tablets
107404|NCT03346304|Other|Photodynamic Therapy (PDT)|Photodynamic Therapy (PDT) using photosensitiser drug Fotolon
107405|NCT03346291|Behavioral|counseling|individual, weekly, smoking cessation counseling + over-the-counter nicotine patch
107406|NCT03346278|Behavioral|Text Messaging Intervention|After completing baseline procedures, study staff will activate the intervention in the participant's profile on the text messaging platform if the participant was randomized to the intervention. The text messaging platform will deliver messages by an automated algorithm. Participants will receive 4 messages per week for 6 months.
107407|NCT03346265|Other|Treatment A combined exercise program and gait training with sensory cues|Treatment A consisted in a combined exercise program of 40 min duration RMP
107408|NCT03346265|Other|Treatment B Conventional physiotherapy|Conventional physiotherapy was composed of 4 sections of exercises, chiefly oriented to different body structures appropriate to movement (International Classification of Functioning, Disability and Health code)
107409|NCT03346252|Drug|Botulinum Toxin type A|"All the participants meeting the inclusion criteria will be seen for a total of 4 visits and 3 phone interviews. Participants will complete a set of self-reporting questionnaires, assessing the disability associated with Headaches Attributed to TMD, and other pain-related TMD diagnoses, the impact of headaches on the quality of life, and psychosocial distress questionnaires.~In addition, they will undergo 3 cycles of treatment, each 12 weeks apart."
107410|NCT03346239|Behavioral|Gaze Contingent Music Reward Therapy|Feedback according to participants' viewing patterns, in order to modify their attention.
107411|NCT03346239|Drug|Escitalopram|10-20 mg of Escitalopram
107412|NCT03346239|Behavioral|Waitlist|Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
107413|NCT03346226|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine is given to patients during spinal anesthesia at the dose of 0.5 μg/kg，adjusted the dose to keep BIS between 70-80 until 30 minutes before the end of surgery
107414|NCT03346226|Drug|Propofol|Propofol is given with an initial ratio of 2-10mg/kg/h, when the operation starts，adjust the propofol`s dose to keep BIS between 70-80 before the end of surgery
107415|NCT03346213|Drug|MonoFer|Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
107416|NCT03346200|Drug|Tamoxifen Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
107417|NCT03346200|Drug|Placebo Oral Tablet|Randomised dose of tamoxifen 1 pill/day for 180 days
107418|NCT03346187|Drug|Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)|Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)
107419|NCT03346187|Drug|Test drug(CKD-337)|CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
107420|NCT03346174|Other|AAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of AAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
107421|NCT03346174|Other|BAAD|In this controlled trial with intra-subject design infants will be studied using multichannel intraluminal impedance pH (pH-MII) monitoring , during which they receive one 20 min session of BAAD . The number of reflux episodes (RE) is the outcome measure. The results obtained during and 20 min after the intervention will be compared to a period of 20 min before treatment ( control ).
107422|NCT03346161|Other|"Usual care American Society of Plastic Surgeons booklet Breast Reconstruction"|-Booklet from the American Society of Plastic Surgeons about how to choose a breast reconstruction surgeon, what to expect during surgery, what is breast reconstruction, risks of breast reconstruction, recovery, costs, and questions to ask surgeon about breast reconstruction
107423|NCT03346161|Other|Decision tool|-Interactive web based tool. Provides detail about breast reconstruction, asks participant questions about health and medications to personalize risks for breast reconstruction outcome. The tool also goes into pros/cons of breast reconstruction, talks about differences between types of reconstruction, helps people weigh when to have reconstruction (immediate vs. delayed), shows participants representative photos of breast reconstruction outcomes, and assesses patients' knowledge and preferences
107424|NCT03346161|Other|Usual Care Group - Outcome Measures|"Section 1 Knowledge (primary outcome) - set of multiple choice questions about breast reconstruction, implants, flap surgeries, and side effects~Section 2 Decisional Conflict Scale - 4 questions with yes/no answers dealing with participant's certainty about surgery (it total score less than 4, indicates higher decisional conflict)~Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction~Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appoint answers range from 0=no effort to 9=every effort."
109601|NCT03329781|Dietary Supplement|Placebo|Consuming 1 placebo capsule per day
107425|NCT03346161|Other|Decision Group - Outcome Measures|"Section 1 Knowledge and Values Clarification Questions - set of multiple choice questions about the participants feelings on breast reconstruction, implants, flap surgeries, and side effects~Section 2 Decisional Conflict SURE measure - 4 questions with yes/no answers dealing with participant's conflicts on surgery (if total score less than 4, indicates higher clinical significant decisional conflict)~Section 3 Patient Activation Measures: 3 yes/no questions about participant's knowledge and trust of healthcare provider, sources of info about breast reconstruction, and different options available~Section 4 Breast Reconstruction Decision Quality Instrument: 18 multiple choice questions about thought and processes that went into deciding about breast reconstruction (for those who have a clinical visit)~Section 5 BREAST-Q: 3 questions about the breast reconstruction consultation appointment answers range from 0=no effort to 9=every effort (for those who have a clinical visit)."
107426|NCT03346161|Other|Demographic and Background Questions|"Asks 15 questions~Age, education, ethnicity, race, combined household income, zip code, disease stage, (3) questions about health insurance, (4) questions about participant's ability to work with numbers, heath literacy, health insurance status, and (1) question on if participant spoke to another provider about breast reconstruction decision"
107427|NCT03346135|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo standard of care ASCT with a conditioning regimen of melphalan
107428|NCT03346135|Drug|Melphalan|Undergo standard of care ASCT with a conditioning regimen of melphalan
107429|NCT03346135|Biological|Daratumumab|Given IV
107430|NCT03346135|Other|Laboratory Biomarker Analysis|Correlative studies
107431|NCT03346122|Drug|JNJ-64991524 Dose Level 1|Participants will receive JNJ-64991524 at a Dose Level 1 in SAD Part 1 of study.
107432|NCT03346122|Drug|JNJ-64991524 Dose Level 2|Participants will receive JNJ-64991524 at a Dose Level 2 in SAD Part 1 of study.
107433|NCT03346122|Drug|JNJ-64991524 Dose Level 3|Participants will receive JNJ-64991524 at a Dose Level 3 in SAD Part 1 of study.
107434|NCT03346122|Drug|JNJ-64991524 Dose Level 4|Participants will receive JNJ-64991524 at a Dose Level 4 in SAD Part 1 of study.
107435|NCT03346122|Drug|JNJ-64991524 Dose Level 5|Participants will receive JNJ-64991524 at a dose of Dose Level 5 in SAD Part 1 of study.
107436|NCT03346122|Drug|JNJ-64991524 Dose Level 6|Participants will receive JNJ-64991524 at a Dose Level 6 in SAD Part 1 and MAD part 2 of study.
107437|NCT03346122|Drug|Placebo|Participants will receive matching placebo in all cohorts on Day 1 in Part 1 and Part 2 of the study.
107438|NCT03346122|Drug|JNJ-64991524 Dose Level 7|Participants will receive JNJ-64991524 at a dose of Dose Level 7 in MAD Part 2 of study for 14 days.
107439|NCT03346122|Drug|JNJ-64991524 Dose Level 8|Participants will receive JNJ-64991524 at a Dose Level 8 in MAD Part 2 of study for 14 days.
107440|NCT03346122|Drug|JNJ-64991524 Dose Level 9|Participants will receive JNJ-64991524 at a Dose Level 9 in MAD Part 2 of study for 14 days.
107441|NCT03346109|Radiation|medial group retropharyngeal node（MRLN） sparing|Patients in MRLN sparing group will not routinely receive MRLN irradiation; while patients in MRLN prophylactic irradiation group will always receive MRLN irradiation to 56Gy/33Fr.
107442|NCT03346096|Drug|Thiotepa|fixed dose 5mg/kg on days -7-6
107443|NCT03346083|Drug|Betrixaban|Factor Xa
107444|NCT03346070|Drug|Sugammadex 2 mg/kg ABW|"Following the final administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants will receive a single i.v. bolus of Sugammadex (2 mg/kg by ABW) for NMB reversal.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
107445|NCT03346070|Drug|Sugammadex 2 mg/kg IBW|"Following the final administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants will receive a single i.v. bolus of Sugammadex (2 mg/kg by IBW) for NMB reversal.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
107446|NCT03346070|Drug|Sugammadex 4 mg/kg ABW|"Following the final administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants will receive a single i.v. bolus of Sugammadex (4 mg/kg by ABW) for NMB reversal.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
107447|NCT03346070|Drug|Sugammadex 4 mg/kg IBW|"Following the final administration of NMBA (Rocuronium or Vecuronium) to achieve deep NMB, participants will receive a single i.v. bolus of Sugammadex (4 mg/kg by IBW) for NMB reversal.~Deep NMB is defined as no response to TOF stimulations (TOF=0) and a detection target of 1-2 post-tetanic counts (PTCs)."
107448|NCT03346070|Drug|Neostigmine + Glycopyrrolate|"Following the final administration of NMBA (Rocuronium or Vecuronium) to achieve moderate NMB, participants will receive a single i.v. bolus of Neostigmine (50 µg/kg; 5 mg maximum) and Glycopyrrolate (10 µg/kg; 1 mg maximum), dosed according to participant ABW, for NMB reversal.~Moderate NMB is defined as the reappearance of a second twitch (T2) in response to TOF stimulations."
107449|NCT03346057|Drug|Sugammadex 2 mg/kg|Sugammadex 2 mg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for moderate block and reversal in participants receiving the NMBA rocuronium or vecuronium. Moderate block is a level of NMB in which peripheral nerve stimulation elicits one to four muscle twitches.
107450|NCT03346057|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for deep block and reversal in participants receiving the NMBA rocuronium or vecuronium. Deep block is a level of NMB in which peripheral nerve stimulation elicits no muscle twitches and high-frequency muscle stimulation elicits minimal levels of muscle contraction.
107451|NCT03346057|Drug|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for deep block and reversal in participants receiving the NMBA rocuronium
107452|NCT03346057|Drug|Neostigmine + Glycopyrrolate|Neostigmine 50 μg/kg plus glycopyrrolate 10 μg/kg, administered as a single bolus injection into a fast-running IV line on the day of surgery, for moderate block and reversal in participants receiving the NMBA rocuronium or vecuronium
107453|NCT03346044|Device|Carpentier-Edwards SAV bioprostheses|Performance of these bioprostheses
107454|NCT03346044|Device|Medtronic Mosaic bioprostheses|
107455|NCT03346031|Procedure|music therapy|patients will listen to music with an MP3 headset
107595|NCT03344887|Other|RBC Transfusion from male donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.
107456|NCT03346018|Diagnostic Test|Analysis of aqueous humor and plasma samples|"The collected samples will be analyzed as follow:~Determination of the concentration of various cytokines, chemokines and groeth factors in aqueous humor and in the plasma.~Analysis of the mononuclear cells ( T helper lymphocytes CD3+ and CD4+, T cytotoxic lymphocytes CD3+ CD8+, B lymphocytes CD19+, Natural killer lymphocytes CD56+ and CD3- and monocytes CD14+) present in the aqueous humor by cytofluorimetry.~Evaluation of the presence of anti-human HSP70 antibodies in plasma samples by Western blot immunoprecipitation assays.~Whenever possible (adequate number of cells), in vitro stimulation of mononuclear cells presence in aqueous humor with epitopes from tuberculosis mycobacterium antigens and the analysis of cytokines production in the supernatants."
107457|NCT03346005|Device|Aeonose|An electronic nose device is an artificial olfactory system that analyses volate organic compounds (VOCs) in exhaled breath. The AeonoseTM is a handheld device of 650 gram. A nose clip will be used to prevent the entry of non-filtered air and patients will be instructed to enclose the mouthpiece with their mouth at all times. A measurement cycle lasts for about 15 minutes, of which 5 minutes of in-and exhalation by the patient takes place.
107458|NCT03345992|Drug|Clarithromycin|Clarithromycin two vials of lyophilised powder for reconstitution as solution for IV administration per patient, once daily, for four consecutive days.
107459|NCT03345992|Drug|Water for injection|Water for injection 20 ml will be administered, diluted in D/W 5%, IV, once daily for four consecutive days
107460|NCT03345979|Combination Product|Aripiprazole Lauroxil|Intramuscular injection; study drug provided using a pre-filled syringe
107461|NCT03345979|Drug|Paliperidone Palmitate|Intramuscular injection
107462|NCT03345966|Diagnostic Test|Bmi-1 antibody|B-lymphoma Moloney murine leukemia virus insertion region-1
107463|NCT03345953|Drug|BP 1.4979|Double blind versus placebo
107464|NCT03345953|Drug|Placebo|Double blind versus placebo
107465|NCT03345940|Drug|Fingolimod|Fingolimod is a currently approved oral DMT for the treatment of relapsing remitting MS. It modulates sphingosine-1 phosphate receptors.
107466|NCT03345940|Drug|Dimethyl Fumarate|Dimethyl Fumarate is a currently approved oral DMT for the treatment of relapsing remitting MS. The mode of action comprises immunomodulatory effects and an activation of nuclear (erythroid-derived 2) related factor mediated antioxidative response pathways leading to additional cytoprotective effects.
107467|NCT03345927|Other|no intervention|no intervention
107468|NCT03345914|Drug|Dupilumab|"Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)"
107469|NCT03345914|Drug|Matching Placebo|"Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)"
107470|NCT03345914|Other|Background Treatment: Topical Corticosteroids|All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
107471|NCT03345914|Other|Background Treatment: Moisturizers|All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
107472|NCT03345901|Drug|Pemafibrate|0.2 mg orally BID - twice daily
107473|NCT03345901|Drug|Placebo|orally BID - twice daily
107474|NCT03345888|Other|predictive power of end-tidal carbon dioxide|end-tidal carbon dioxide predicts resuscitation outcomes
107475|NCT03345875|Diagnostic Test|HPV self collection, followed by visual assessment of the cervix for treatment (VAT) and treatment|Women who test HPV positive are offered visual assessment for treatment, with treatment method (cryotherapy, LEEP, or biopsy) based on visual assessment findings.
107476|NCT03345862|Behavioral|non-pharmacological multicomponent|Following the proposal of Nicholson & Shellman, (2013) collected in its CARELINK program, an intervention is proposed that includes: 6 sessions at home [30-60 minutes] for 16 weeks (1 fortnightly session) and 5 telephone sessions [20 min.] That will be intercalated (in the 16 weeks) depending on the particular characteristics of each person. The first visit, aimed at defining objectives and creating a relationship of trust for future visits.
107477|NCT03345849|Drug|Upadacitinib|It will be administered once daily.
107478|NCT03345849|Drug|Placebo for Upadacitinib|This will be orally administered.
107481|NCT03345823|Drug|Upadacitinib|Tablet
107482|NCT03345823|Drug|Placebo for Upadacitinib|Tablet
107483|NCT03345810|Drug|Durvalumab|Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W
107484|NCT03345810|Drug|Vinorelbine|(30 mg/m2 D1 + D8 as infusion) cycle Q3W
107485|NCT03345810|Drug|Gemcitabine|(1000 mg/m2 D1 + D8 as infusion) cycle Q3W
107486|NCT03345810|Drug|nab-Paclitaxel|(100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W
107487|NCT03345810|Drug|Carboplatin|(AUC = 5 mg•min/mL on Day 1) cycle Q3W
107488|NCT03345797|Drug|Testosterone Nasal Gel [Natesto]|nasal gel containing 4.5% w/w testosterone
107489|NCT03345784|Drug|Adavosertib|Given PO
107490|NCT03345784|Drug|Cisplatin|Given IV
107491|NCT03345784|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
107492|NCT03345771|Combination Product|Antimicrobial Barrier Dressing|Ionic Silver is a soft, nonwoven pad or ribbon that features the gelling benefits of Hydrofiber technology plus antimicrobial ionic silver.
107493|NCT03345771|Device|Negative Pressure Wound Therapy (NPWT)|PICO provides suction known as negative Pressure wound Therapy (NPWT) which draws out excess fluid from a wound and protects the injured area from getting dirty to ultimately help promote healing. PICO consists of an nPwT pump connected to an absorbent gentle adhesive dressing
107494|NCT03345758|Other|outcome|telephone to patients to finish SF-36 (the MOS item short from health survey,SF-36)，EQ-5D(EuroQol-5 Dimensions,EQ-5D)， AMT-4（Abbreviated Mental Test-4,AMT-4）and MMSE（Mini-mental State Examination,MMSE） to make assessments of their physical and mental health, cognitive function and social adaptation after discharge
107495|NCT03345745|Diagnostic Test|salivary samples|Salivary Hs-CRP, Fetuin-A and S100A12 levels and salivary flow rates were evaluated at baseline and a month after the treatments
107498|NCT03345706|Procedure|Selective cerebral hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
107499|NCT03345706|Procedure|Regular hypothermia|Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
107500|NCT03345693|Device|MoTrack Therapy|A software that runs on a tablet or computer that reads information from a Universal Serial Bus external sensor and instructs patients in their exercises, giving patients feedback as necessary, and recording patient progress and activity.
107501|NCT03345680|Other|Referred to a specific hospital for treatment|To King Saud University Dental College, treatment will be provided free of charge to the referred participants.
107502|NCT03345667|Drug|lucentis|Use of lucentis and other anti-vegf in patients with diabetic retinopathy
107503|NCT03345654|Other|Toolset-directed hearing aid fit|In the toolset-directed arm, audiogram, age and working memory capacity will be measured and the clinician will then use a touchpad application (an implementation of our individualized prediction programs) to guide hearing aid parameter choices.
107504|NCT03345654|Other|Standard-of-care hearing aid fit|In the standard-of-care fit, working memory capacity will not be measured and no touchpad application will be used. The clinician will select the hearing aid signal processing parameters based on his/her own knowledge and clinical experience
107505|NCT03345641|Other|describe precocious maternal impressions when confronting the premature birth of her infant|
107506|NCT03345628|Drug|Sedatives|sedated group received sedative drugs to tolerated intubation and ventilation
107507|NCT03345615|Diagnostic Test|30-day ambulatory cardiac event monitor|SpiderFlash® 30-day ambulatory cardiac event monitoring will be worn upon discharge.
107508|NCT03345602|Diagnostic Test|serum S100B protein assay measurement|serum S100B protein assay measurement within the 3 hours after head trauma
107509|NCT03345589|Drug|18-22mg/kg/d Ursodeoxycholic|18-22mg/kg/d Ursodeoxycholic
107510|NCT03345589|Drug|13-15mg/kg/d Ursodeoxycholic|13-15mg/kg/d Ursodeoxycholic
107511|NCT03345576|Device|Testosterone and LPWS|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and long pulse width stimulation (LPWS) in persons with denervated spinal cord injury.
107512|NCT03345576|Drug|Testosterone and standard NMES|Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
107513|NCT03345563|Behavioral|Body Mind Training (BMT)|"Participants will practice BMT under the instruction of a BMT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Each session will include both light physical exercise and mind training.~Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period."
107514|NCT03345563|Behavioral|Body Training (BT):|Participants will practice BT under the instruction of a BT instructor. There will be 24 sessions. Each session will last 60 minutes and will occur twice a week for 12 weeks. Sessions will be supplemented with home-based practice using an instructional DVD and handouts. Participants will be instructed to practice at least 30 minutes a day (at least 3 days per week) throughout the intervention and post-intervention period.
107515|NCT03345563|Behavioral|Usual Care (UC)|Participants in the usual care arm will receive care as normal and will not attend classes but will complete the same assessments as participants in the BMT and BT classes.
107516|NCT03345550|Drug|Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules.|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules.
107517|NCT03345550|Drug|Placebo - Cap|Participants will be randomized to receive fish oil 1000 mg (contains 500 mg DHA & 100 mg EPA) or placebo capsules (olive oil capsules that look identical to the intervention DHA+EPA).
107518|NCT03345537|Other|Non interventional study|Non interventional study - only data collected and one blood sample additional
107519|NCT03345524|Other|Peer-Buddy System|"2-4 30-minute in person sessions with Peer Buddy (2 before and 2 after receiving CPAP)~Standard of care CPAP educational training~8-10 phone conversations with Peer Buddy over 3 month period~Subsequent 3 months use of phone system to contact Peer Buddy as needed"
107520|NCT03345524|Other|Usual Care|"Standard of care CPAP educational training~Educational Brochures and DVD videos mailed to participants (12 times)"
107521|NCT03345511|Procedure|Ultrasound Guided Caudal Block|Using an external ultrasound probe, the investigators guided a 18 gauge epidural needle into the caudal space and injected a local anesthetic solution consisting in bupivacaine 0.25%, lidocaine 1% and dexamethasone 8mg in the caudal space.
107522|NCT03345498|Drug|Entecavir|Entecavir is the antiviral drug of choice recommended for hepatitis B virus treatment in presence of decompensated cirrhosis
107523|NCT03345485|Drug|Tinostamustine (EDO-S101)|The study is designed as an open label, Phase 1/2 trial of single agent EDO-S101. The Phase 1 portion of the study is designed to define the MTD by evaluating toxicities during dose escalation until MAD. The Phase 2 portion of the study is designed to evaluate ORR and SD that persists for at least 4 months of the RP2D.
107524|NCT03345472|Device|Spinal Cord Stimulation System|Implanted neurostimulation system (neurostimulator and leads) with high dose stimulation parameters.
107525|NCT03345459|Other|ICare Prevent (internet-based treatment for depression in college students)|ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
107526|NCT03345446|Diagnostic Test|Cardiac MRI|Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
107528|NCT03345420|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
107530|NCT03345407|Drug|Nemiralisib ELLIPTA 50 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 50 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
107531|NCT03345407|Drug|Nemiralisib ELLIPTA 100 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 100 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
107532|NCT03345407|Drug|Nemiralisib ELLIPTA 250 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 250 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
107533|NCT03345407|Drug|Nemiralisib ELLIPTA 500 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 500 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
107534|NCT03345407|Drug|Nemiralisib ELLIPTA 750 µg|Nemiralisib is a potent and highly selective inhaled PI3Kd inhibitor being developed as an anti-inflammatory for the treatment of inflammatory airways disease. Nemiralisib 750 µg will be administered as a dry powder inhaler via oral inhalation route. In addition, subjects will receive SOC therapy for the index acute moderate or severe exacerbation of COPD.
107535|NCT03345407|Drug|Albuterol (Salbutamol) MDI or nebules|Albuterol (Salbutamol) MDI or nebules will be provided to all subjects as a rescue medication.
107536|NCT03345407|Drug|Standard of care therapy|SoC therapy for the index exacerbation is defined as treatment with oral/systemic corticosteroid (prednisone 40 mg/day or equivalent) for 5 days and antibiotic for 7 days. Subjects will receive SoC as prescribed by the Investigator or medically qualified designee. The dose and/or duration of prednisone and/or the antibiotic can be modified according to the Investigator's/medically qualified designee's judgment or according to local country/institution practice.
107537|NCT03345394|Behavioral|Contingency Management|Participants will receive vouchers with monetary value for submitting crack cocaine negative urine samples
107538|NCT03345394|Behavioral|Standard treatment|Participants will receive the standard treatment offered by the 2 treatment facilities where the study is being conducted
107539|NCT03345381|Other|SKY + ASTM + usual care|Sudarshan Kriya Yoga (SKY) followed by Automatic Self Transcending Meditation (ASTM) involves breathing exercise followed by meditation.
107540|NCT03345381|Other|Usual care|Treatment as usual
107541|NCT03345368|Device|rTMS|Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
107542|NCT03345368|Device|sham rTMS|As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
107543|NCT03345368|Other|Diet|This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
107544|NCT03345355|Diagnostic Test|Imaging|Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
107545|NCT03345342|Drug|PP6M|Participants will receive intramuscular injection of PP6M.
107546|NCT03345342|Drug|PP3M 350 mg eq.|Participants will receive intramuscular injection of PP3M 350 mg eq.
107547|NCT03345342|Drug|PP3M 525 mg eq.|Participants will receive intramuscular injection of PP3M 525 mg eq.
107548|NCT03345342|Drug|PP1M|Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.
107549|NCT03345342|Other|Placebo|Participants will receive matching placebo.
107550|NCT03345316|Drug|FFI-1010|Intravenous single dosing
107551|NCT03345303|Drug|Bortezomib|Bortezomib Injectable Solution
107552|NCT03345290|Device|PET with a cerebral step|Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography
107553|NCT03345290|Device|Central blood pressure measurement|Central blood pressure measurement
107554|NCT03345290|Other|Neurocognitive tests|Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
107555|NCT03345277|Other|Continuous Temperature monitoring|Residents in a long term care facility will wear a thermometer continuously for 3 months, measuring their body temperature
107556|NCT03345264|Behavioral|Online, interactive self-help program|Participants will receive access to the program, which provides: In-depth information specific to cancer sites and treatments, guidance on medical options for cancer-related sex or fertility problems, personalized goal-setting with progress tracking and relapse prevention, self-help exercises on overcoming sexual, relationship, and dating problems, videos of survivors' stories, and video vignettes with actors.
107557|NCT03345251|Device|Hydrotubation|
107558|NCT03345238|Procedure|Deep Dry Needling|Deep Dry Needling in the upper trapezious muscle is an invasive technique of Physical Therapy.
107559|NCT03345225|Device|SureFire Infusion System|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
107560|NCT03345225|Device|Standard Endhole Microcatheter|A Microcatheter with a single hole at the end for a infusion.
107561|NCT03345212|Other|Exercise training|The rehabilitation program comprises interval ergometer training, dumbbell training, respiratory therapy, mental training and guided walks for 5-7 times/week.
107626|NCT03344640|Drug|AIN457|AIN457 subcutaneously for 12 weeks
107562|NCT03345199|Other|Inspiratory Muscle Trainer (IMT)|During the 10-week training period, participants will perform exercises using a Threshold Inspiratory Muscle Trainer (IMT) at 3 sets of 15 repetitions per day. The initial resistance of the IMT unit will be at 30% of participants' maximum inspiratory pressure (MIP). Resistance for the IMT unit will be increased progressively and adjusted weekly by a licensed physical therapist based on participant's MIP at baseline, Borg perceived rate of exertion, and symptoms.
107563|NCT03345186|Other|nurse led plus standard of care|structured nurse led patient management programme: Patient education will be done by a specialised nurse and nurse consultations and phone calls will be done.
107564|NCT03345173|Drug|CI-581-a|Two infusions in the context of naltrexone induction protocol.
107565|NCT03345173|Drug|CI-581-b|Two infusions in the context of naltrexone induction protocol.
107566|NCT03345160|Drug|Peanut Flour|open label oral immunotherapy
107567|NCT03345147|Other|High Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
107568|NCT03345147|Other|Normal Vitamin A intake|Total Vitamin A stores will be assessed by isotopic measurement, 13C-Retinol will be given to the subject and blood wil be drawn on Day 4 to assess the isotopic dilution in the plasma. Other biochemical indicators will be assessed too, along with Dietary assessment (Food Frequency, 24 hours recalls).
107569|NCT03345134|Drug|MK-3475 and BCG|combination treatment with MK-3475 and BCG after endoscopic ablation
107570|NCT03345108|Device|Denture Adhesive Cream (Conventional Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
107571|NCT03345108|Device|Denture Adhesive (Continuous Strip Application)|The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
107572|NCT03345108|Other|No Adhesive|No adhesive applied.
107573|NCT03345095|Drug|Marizomib|Intravenous administration of Marizomib
107574|NCT03345095|Drug|Temozolomide|Oral Administration of Temozolomide
107575|NCT03345095|Radiation|radiotherapy|60 Gy in 30 fractions over 6 weeks
107576|NCT03345082|Biological|OPT-302|Intravitreal injection
107577|NCT03345082|Biological|ranibizumab|Intravitreal injection
107578|NCT03345082|Other|sham intravitreal injection|Sham (mock) intravitreal injection
107579|NCT03345056|Procedure|vitrectomy with planned foveal detachment|23 gauge vitrectomy, posterior hyaloid detachment, internal limiting membrane peeling , sub-macular BSS injection using 38 gauge canula
107580|NCT03345043|Biological|VAL-339851|Escalating dose levels
107581|NCT03345043|Other|Placebo|Saline
107582|NCT03345004|Biological|GAD-alum|Alhydrogel®-formulated recombinant human glutamic acid decarboxylase (rhGAD)
107583|NCT03345004|Dietary Supplement|Vitamin D|Oil suspension of Vitamin D
107584|NCT03345004|Biological|Placebo for Diamyd (GAD-alum)|Alhydrogel® only
107585|NCT03345004|Dietary Supplement|Placebo for Vitamin D|Placebo oil suspension for Vitamin D
107586|NCT03344991|Other|Cardboard Cot Care|When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found < 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
107587|NCT03344991|Other|Open Crib|When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found < 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
107588|NCT03344978|Other|Cardboard Cot Care|Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found < 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
107589|NCT03344978|Other|Incubator Care|Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found < 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
107590|NCT03344965|Drug|Olaparib|olaparib tablets bid daily continuously on a 21 day cycle until progression, intolerable toxicity, consent withdrawn, patient noncompliance or death.
107591|NCT03344952|Drug|Botulinum toxin type A|Repeated injections to hypertonic muscles
107592|NCT03344952|Other|Physical therapy|3 weeks intensive program 1 week -10 days after BoNT-A injections
107593|NCT03344926|Behavioral|ACTsmart|"Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.~Treatment content is divided into four modules:~education about pain behaviors, exposure and acceptance and commitment therapy~education about pain physiology~exercises on changing behaviors, acceptance, mindfulness, defusion and exposure~value based exposure in the participant's daily life"
107594|NCT03344913|Behavioral|Walking|walking 30 minutes per day, three days/week for 6 weeks with a member of study team.
107596|NCT03344887|Other|RBC Transfusion from female donor|Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.
107597|NCT03344874|Device|Stethee®|Stethee® is a new wireless digital stethoscope.
107598|NCT03344874|Device|3MTM Littmann® Classic IIITM|3MTM Littmann® Classic IIITM is the conventional stethoscope.
107599|NCT03344861|Drug|Porfimer Sodium|Porfimer sodium (Photofrin®) will be injected intravenously at a dose of 2 mg/kg.
107600|NCT03344861|Device|Fiber optic|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). An optical fiber diffuser length matching the tumor length will be placed in the lesion or adjacent to the lesion under fluoroscopy guidance. After the placement of the optical fiber, the laser light will be applied at a dose of 200 J/cm of diffuser length.
107601|NCT03344848|Device|Orion Visual Cortical Prosthesis System|The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.
107602|NCT03344835|Other|No intervention|
107603|NCT03344822|Diagnostic Test|68Ga-PSMA-11|radioactive tracer for PET-CT (68Ga-PSMA-11)
107604|NCT03344822|Diagnostic Test|18F-Choline PET-CT|radioactive tracer for PET-CT (18F-Choline PET-CT)
107605|NCT03344783|Other|PUFA and R-TFA|PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
107606|NCT03344770|Device|Active rESWT|5,000 pulses of rESWT, with 0.16mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
107607|NCT03344770|Device|Sham rESWT|5,000 pulses of rESWT, with 0.0 mJ/mm2 of energy at a frequency of 20Hz once a week for three weeks.
107608|NCT03344757|Behavioral|Cultural CBT|During each session, participants are taught a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms are used for educational purposes and as catalysts for discussing CBSM techniques. The delivery of the culturally adapted C-CBSM places a greater emphasis on salient sociocultural determinants of symptom burden and HRQoL in Hispanics (e.g., fatalistic attitudes, family interdependence, perceived discrimination, machismo).The investigators allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses with role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
107609|NCT03344757|Behavioral|Standard CBT|During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms are used for educational purposes and as catalysts for discussing CBSM techniques. The investigators allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactic, and contact community resources and other participants in their group.
107610|NCT03344731|Behavioral|Cognitive evaluation|Cognitive task
107611|NCT03344731|Device|Non-invasive brain stimulation|Transcranial Magnetic Stimulation (TMS)
107612|NCT03344705|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.
107613|NCT03344705|Drug|Fludarabine|Two days before cell infusion,all patients will be treated with fludarabine for 3 days
107614|NCT03344705|Drug|Cyclophosphamide|Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
107615|NCT03344692|Drug|Alirocumab|prefilled pen containing 75 mg of Praluent (Alirocumab) in 1 ml of solution
107616|NCT03344692|Other|Placebo|prefilled pen containing 1 ml of solution without Praluent
107617|NCT03344679|Drug|Bupivacaine 0.25%|Bupivacaine 0.25% for PECS block
107618|NCT03344679|Drug|Adenosine 12mg|Adenosine 12 mg for PECS block
107619|NCT03344679|Drug|Magnesium Sulphate 500 mg|Magnesium sulphate 500 mg for PECS block
107620|NCT03344666|Behavioral|Step 1 Treatment BI+HC|Participants in the Brief intervention + Health Coach (BI+HC) will receive a BI in the ED, followed by weekly sessions with the Health Coach for 4 weeks, which will occur by phone or in person. During sessions, the HC will review the prior week's progress, and discuss goals and plans for the following week.
107621|NCT03344666|Behavioral|Step 1 Treatment BI+TM|Participants in the Brief intervention + Text messages (BI+TM) will receive a BI in the ED, followed by daily TMs for 4 weeks. TM's are tailored based on weekly surveys and focus on motives for alcohol and violence and strategies to reduce involvement.
107622|NCT03344666|Behavioral|Step 2 Treatment Responders|"Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM.~Participants in the BI+HC or BI+TM assigned to stepped down control will receive a brochure containing community resources."
107623|NCT03344666|Behavioral|Step 2 Treatment Non-Responders|"Participants in the BI+HC assigned to be stepped up will receive HC+, which will consist of weekly sessions as well as on daily TMs from the HC.~Participants in the BI+HC assigned to stay the course (e.g., continue to receive the HC) will have 4 more weekly sessions with the HC.~Participants in the BI+TM assigned to be stepped up will receive the HC, which consists of 4 weekly sessions with the HC.~Participants in the BI+TM assigned to stay the course (e.g., continue to receive the TM) will receive 4 more weeks of TM."
107624|NCT03344653|Device|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by 1 month DAPT
107625|NCT03344653|Device|Biosensors BioFreedom BA9 Drug Coated Coronary Stent|Biosensors BioFreedom BA9 Drug Coated Coronary Stent Followed by 1 month DAPT
107628|NCT03344627|Drug|Meropenem standard dose|"Empirical with 1 g meropenem intravenous infusion in 30 minutes then 1 g intravenous infusion in 3 hours every 8 hours.~Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection."
107629|NCT03344627|Drug|Meropenem high dose|"Empirical with 2 g meropenem intravenous infusion in 30 minutes then 2 g intravenous infusion in 3 hours every 8 hours.~Dosage is adjusted in case of renal dysfunction. Duration of therapy is varied regarding source(s) of infection"
107630|NCT03344614|Drug|raltitrexed combined with apatinib|raltitrexed, 3 mg/㎡, ivgtt, d1, apatinib 500 mg, QD po, d1-21, Every 3 weeks for 1 cycles
107631|NCT03344601|Behavioral|physical activity|The program will consist of 18 face-to-face coaching sessions (~1 hour) over 12 months. The timing of these sessions will be decided between participant and coach. A coaching manual will be used to provide a structured approach to coaching sessions, focussing on physical activity engagement (specifically aerobic and strengthening exercise) and adherence to exercise. The intervention will take place in the participant's home or in a rehabilitation facility at the research site. Each participant will be provided with a choice of exercise equipment options (e.g. exercise bike, weights, therabands), gym membership or use of online exercise resources. Participants will develop physical activity goals that will be monitored and adjusted throughout the program. Physical activity diaries will be completed to record the amount and type of physical activity involvement. Wearable activity monitors will also be used to facilitate/monitor physical activity and sedentary behaviours.
107632|NCT03344588|Procedure|artery preserving varicocelectomy|During sub-inguinal varicocelectomy, testicular arteries will be spared with aid of by intraoperative Doppler US (VTI intraoperative Doppler system 20 MHz). The arteries will be carefully dissected by a micro-dissector, separated over a vessel loupe, and then the remaining veins will be ligated using vicryl 3/0.
107633|NCT03344588|Procedure|artery ligation varicocelectomy|During sub-inguinal varicocelectomy, all vascular channels will be ligated without identifying or sparing the internal spermatic arteries.
107634|NCT03344575|Procedure|Conventional defect closure|Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh
107635|NCT03344575|Procedure|Peritoneal bridging|Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
107636|NCT03344562|Device|CES|Patients will receive cranial electrical stimulation once a day for 20 minutes over 7 days. They will be allowed to increase the stimulation level on Day 2. A wrist worn actigraph will record sleep. Patients may elect to receive standard of care sleep medication if not satisfied with sleep.
107637|NCT03344562|Device|CES|Patient will receive sham electrical stimulation once a day for 20 minutes over 7 days.
107638|NCT03344549|Behavioral|Renal nutrition teleconsultation|Renal Nutritional teleconsultation for patients with diabetic kidney disease without dialysis, monthly for 4 months.
107639|NCT03344549|Behavioral|Face-to-face consultation of renal nutrition|Face-to-face consultation of renal nutrition for patients with diabetic kidney disease without dialysis, monthly for 4 months.
107640|NCT03344536|Drug|Fulvestrant|Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.
107641|NCT03344536|Drug|Debio 1347|Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.
107642|NCT03344523|Drug|Iron protein succinylate oral solution|Iron protein succinylate oral solution
107643|NCT03344523|Other|standard treatment|standard treatment
107644|NCT03344510|Device|Kinetic Anesthesia Device|A vibrating device held to the skin in close proximity to the lidocaine injection, intended to diminish discomfort by the gate control theory of pain
107645|NCT03344510|Other|Control|One injection will be administered without the kinetic anesthesia device.
107646|NCT03344497|Other|VC Group|VC (Conventional Consultation/Video) Group
107647|NCT03344484|Other|Surgical approach|Comparison of 2 surgical approaches used to treat degenerative spondylolisthesis via one- and two-level fusion
107648|NCT03344471|Other|Passation of questionnaires|Specific questionnaires (Perinatal PTSD Questionnaire evaluating the Post-Traumatic Stress Disorder) and (NEO-FFI evaluating personality)
107649|NCT03344458|Drug|TransCon hGH|Once weekly subcutaneous injection of TransCon hGH
107650|NCT03344445|Other|video-assisted pre anesthesia explain|Anesthesiologist will visit all study patients, and only the experimental group will read the video.
107651|NCT03344432|Diagnostic Test|with intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
107652|NCT03344432|Diagnostic Test|without intraocular pressure high|Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
107653|NCT03344419|Drug|CI-581a|Medication infusion intravenously over 1 hour.
107654|NCT03344419|Drug|CI-581b|Medication infusion intravenously over 1 hour.
107655|NCT03344419|Behavioral|Motivational Enhancement Therapy (MET)|Manualized one on one therapy aimed at mobilizing motivation for change and for goals.
107656|NCT03344419|Behavioral|Mindfulness Based Relapse Prevention|Manualized one on one therapy aimed at mindfulness-based behavioral modification and the cultivation of relapse prevention skils.
107657|NCT03344406|Other|Telephonic interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with asthma.
107658|NCT03344406|Other|E-RS: COPD|E-RS questionnaire will directly measure respiratory symptom severity.
107659|NCT03344406|Other|Supplemental asthma items|Supplemental asthma items will include one question on wheeze and an item on breathlessness with activities to evaluate shortness of breath associated with strenuous activities.
107660|NCT03344406|Other|Daily diary|Subjects will complete a daily diary including the E-RS: COPD and supplemental asthma items for 7 days.
107661|NCT03344406|Other|Sociodemographic questionnaire|Sociodemographic questionnaire will capture subject's demographic characteristics, including age, gender, and the highest level of educational attainment.
107703|NCT03344068|Drug|Chemotherapy|Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
107662|NCT03344406|Other|Clinical questionnaire|Clinical questionnaire will capture subject's clinical characteristics including the number of asthma exacerbations in the past 12 months, absenteeism due to asthma in the past month, and the presence of comorbid conditions.
107663|NCT03344393|Drug|Ketamine Hydrochloride|intravenous ketamine infusion intraoperatively
107664|NCT03344393|Drug|Normal saline|intravenous normal saline infusion intraoperatively
107665|NCT03344367|Biological|JWCAR029|Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.
107666|NCT03344354|Device|Biogel 1|All study surgical gloves will be used during surgical procedures.
107667|NCT03344354|Device|Ansell|All study surgical gloves will be used during surgical procedures.
107668|NCT03344354|Device|Cardinal|All study surgical gloves will be used during surgical procedures.
107669|NCT03344354|Device|Biogel 2|All study surgical gloves will be used during surgical procedures.
107670|NCT03344354|Device|Medline|All study surgical gloves will be used during surgical procedures.
107671|NCT03344341|Drug|Dapagliflozin|Starting dose of dapagliflozin is 5 mg once daily, taken orally in the morning, before or after breakfast. From the third week,the dose can be increased to 10 mg once daily, and last to the end of the study.
107672|NCT03344341|Drug|Acarbose|Acarbose was started from 50 mg once a day at dinner during the first week and titrated up to 50 mg twice a day at lunch and dinner in the second week, 50 mg three times a day at three meals in the third week, and 100 mg three times a day till the end of the study.
107673|NCT03344328|Drug|Bortezomib|The algorithm (computer query) will identify all patients who received bortezomib-based chemotherapy for the multiple myeloma indication between 2008 and 2016. All the questionnaires used are validated in the scientific literature.
107674|NCT03344315|Device|experimental: collagen matrix|Mucograft collagen matrix combined with coronal advanced flap
107675|NCT03344315|Other|Active Comparator: autologous connective tissue graft|Soft tissue harvesting from patient palate with coronal advanced flap
107676|NCT03344302|Drug|Oxytocin|intravenous infusion of oxytocin 30 units over 5 minutes diluted into 500 mL of normal 0.9% sodium chloride
107677|NCT03344289|Diagnostic Test|Colonoscopy|Participants will be randomized towards colonoscopy withdrawal with either LCI or HD-WLE
107678|NCT03344276|Diagnostic Test|Neurocognitive Assessments|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. Prior to surgery patients will undergo a battery of neurocogntive assessments 1 month and 2 months prior to surgery.
107679|NCT03344276|Diagnostic Test|Measurements of inflammatory biomarkers|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis. After surgery, patients will undergo blood draws to measure for inflammatory biomarkers.
107680|NCT03344276|Procedure|Carotid Artery Stenting|Patients will undergo carotid artery stenting for 50-70% carotid artery stenosis.
107681|NCT03344263|Diagnostic Test|tests of attentional performance|tests of attentional performance before and after 6 months of continuous positive airways pressure
107682|NCT03344250|Drug|EGFR BATs with SOC RT and TMZ|"Standard of care portion of study:~6 weeks of RT and TMZ 6 cycles of TMZ (150-200 mg/m2) on days 1-5 of each 28 day cycle EGFR BATs 2 and 3 weeks after completing RT, and then on day 21 of each cycle of TMZ."
107683|NCT03344224|Diagnostic Test|laboratory test|laboratory test
107684|NCT03344211|Drug|Enzalutamide|Given PO
107685|NCT03344211|Other|Laboratory Biomarker Analysis|Correlative studies
107686|NCT03344211|Radiation|Radium Ra 223 Dichloride|Given IV
107687|NCT03344198|Behavioral|Circuit Training exercise & Modified Mediterranean diet|Participants will receive circuit training program and a modified Mediterranean diet program. Educational sessions, serving size training, and portion containers will be provided. Participants will also receive individualized support throughout the 6 week intervention.
107688|NCT03344185|Dietary Supplement|Low Glycaemic Diet|This intervention consisted of three low GI meals.
107689|NCT03344185|Dietary Supplement|High Glycaemic Diet|This intervention consisted of three meals, all with a high GI value.
107690|NCT03344172|Drug|Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab|2 cycles of gemcitabine and nab-paclitaxel (1000mg/m2 & 125mg/m2 - day 1, 8, 15) and hydroxychloroquine (1200mg/day) with Avelumab (days 1 and 15 of each 28-day cycle)
107691|NCT03344172|Drug|Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine|2 cycles of gemcitabine and nab-paclitaxel (1000mg/m2 & 125mg/m2 - day 1, 8, 15) and hydroxychloroquine (1200mg/day)
107692|NCT03344159|Drug|Spironolactone|Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
107693|NCT03344159|Drug|Placebo|Placebo daily for a total of duration of 12 weeks
107694|NCT03344159|Radiation|PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82|At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.
107695|NCT03344159|Diagnostic Test|Cardiac MRI (Gadolinium enhanced)|At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.
107696|NCT03344146|Behavioral|Medication intake reminders|Acoustic and visual alarm at predefined DOAC-intake timepoints.
107697|NCT03344146|Behavioral|Pillbox use and counselling|All patients will be counselled based on their previous electronically recorded adherence data and will be given a multicompartment pillbox für daily use
107698|NCT03344133|Behavioral|Exercise|4-week moderate intensity exercise programme
107699|NCT03344120|Other|Administration of USSQ Symptoms questionnaire after double-J positioning|Administration of USSQ Symptoms questionnaire to patients with two different type of double-J stents after ureteroscopy
107700|NCT03344107|Other|USSQ questionnaire administration after RIRS.|USSQ symptoms questionnaire administration after Vortek double-J stent versus Polaris Loop stent
107701|NCT03344094|Drug|ocrelizumab|FDA-approved MS drugs
107702|NCT03344068|Radiation|Radiotherapy|Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
107704|NCT03344068|Dietary Supplement|Nutren® Optimum|Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
107705|NCT03344055|Device|Endocuff Vision (ECV) second generation|"Colonoscopy performed with the use of Endocuff Vision (ECV) second generation at the tip of the scope"
107706|NCT03344042|Drug|Fentanyl|100mcg Fentanyl
107707|NCT03344042|Drug|Sufentanil|10mcg sufentanil
107708|NCT03344029|Biological|SP Shz TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
107709|NCT03344029|Biological|Hualan TIV|0.5 mL, intramuscular into the deltoid muscle, single injection on Day 0
107710|NCT03344016|Other|Contact by clinical center|Patients will be acitvely contacted by the clinical center for follow-up procedure
107711|NCT03344003|Drug|Wilate or Nuwiq|Wilate or Nuwiq administered via intravenous injection
107712|NCT03343990|Procedure|Interlocking multi-twisted wires in sternal closure|One of many ways in cloure of sternal give more stabilization. At least 6 wires have to be passed. The wirs should run around the sternum in the intercostals spaces except in the manubrium where it has to be passed through the bone . Adjacent wires on the surgeon's side are wrapped around each other. The wires on the surgeon's side are then pulled towards the assistant so that the sternum is re-approximated. Alternatively the surgeon can also pull the wires at the assistant's side towards himself or herself approximating the sternum. Adjacent wires on the assistant's side are then wrapped around each other. The wrapped wires on both sides are then wrapped around each other The wrapped wires are then twisted around with a twister, closing the sternum tightly and the ends of the are burried
107713|NCT03343990|Procedure|Eight Figure techniqe in sternal closure|The figure-eight closure is described as faster, simpler, and more reliable than its trans-sternal counterpart; with only oblique forces sutures are less likely to loosen or fracture the sternum. The advantage of figure-eight closure is that it allows oblique and horizontal angle of shearing forces instead of direct perpendicular forces. Thus these wires are less likely to loosen or fracture
107714|NCT03343977|Drug|docetaxel 50mg/m2|50 mg/m2 of docetaxel will be given on day 1 every 14 days
107715|NCT03343977|Drug|docetaxel 75mg/m2|75 mg/m2 of docetaxel will be given on day 1 every 21 days
107716|NCT03343964|Diagnostic Test|Amplitude-integrated electroencephalography|Amplitude-integrated EEG (aEEG) is a compressed form of real-time conventional EEG monitoring that will be added to cEEG monitoring.
107717|NCT03343951|Other|Examination|"Patients will be examined twice the same day by an extended scope physiotherapist (ESP) and an orthopaedic surgeon (OS) in random order. They will independently and blinded to each other's opinion register~diagnosis and treatment plan (including need for further diagnostic examinations - i.e. imaging)~if the patient needs a new appointment at the shoulder clinic~if they under usual conditions would discuss their results with the opposite health professional before deciding diagnosis and treatment plan.~After the individual examinations the ESP and OS discuss their results and come to an agreement (common decision) regarding the patient's diagnosis, treatment plan and need of a new appointment. Patients will be informed only of the common decision of the ESP and OS."
107718|NCT03343938|Other|Embryo handling in a closed station|Embryo handling is performed inside a closed station with a controlled environment: 6% CO2 and 37 degrees.
107719|NCT03343912|Drug|Estriol 0.400 mg/day and Trimegestone 0.06 mg/day|Vaginal ring with a nominal delivery rate of 0.400 mg/d estriol (E3) and 0.06 mg/d trimegestone (TMG), vaginal application
107720|NCT03343912|Drug|Estriol 0.300 mg/day and Trimegestone 0.12 mg/day|Vaginal ring with a nominal delivery rate of 0.300 mg/d estriol (E3) and 0.12 mg/d trimegestone (TMG), vaginal application
107721|NCT03343912|Drug|Estriol 0.200 mg/day and Trimegestone 0.18 mg/day|Vaginal ring with a nominal delivery rate of 0.200 mg/d estriol (E3) and 0.18 mg/d trimegestone (TMG), vaginal application
107722|NCT03343873|Drug|Midazolam|Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.
107723|NCT03343873|Drug|Propofol|Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;
107724|NCT03343873|Drug|Ketamine|ketamine group with a bolus dose of 1mg / kg intravenous injection , followed by 10μg / kg / min continuous intravenous injection, and maintained to the scanning process;
107725|NCT03343873|Drug|Dexmedetomidine|Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
107726|NCT03343873|Drug|Saline|Saline group at 5ml / kg / h continuous intravenous infusion.
107727|NCT03343860|Procedure|AT case 1.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
107728|NCT03343860|Procedure|AT case 2.1|"In the case of AT at the time of ablation :~In the case of sinus rhythm restoration, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
107729|NCT03343860|Procedure|AT case 1.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
107730|NCT03343860|Procedure|AT case 1.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps"
107731|NCT03343860|Procedure|AT case 1.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
107732|NCT03343860|Procedure|AT case 2.2|"In the case of AT at the time of ablation :~In the case of termination to another AT, ablation of the subsequent AT will be performed until sinus rhythm restoration. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
107733|NCT03343860|Procedure|AT case 2.3|"In the case of AT at the time of ablation :~In the case of AF deterioration, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
107734|NCT03343860|Procedure|AT case 2.4|"In the case of AT at the time of ablation :~In the case of no AT termination, a DCC will be performed. Thereafter, PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 5 consecutive AT)"
107735|NCT03343860|Procedure|SR Case 1|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Inducibility will be tested but no ablation will be carried out and a DCC post AT mapping will be performed if necessary. The procedure will end up after these steps."
107736|NCT03343860|Procedure|SR Case 2|"In the case of SR at the time of ablation:~PV will be re-isolated if necessary and lines (CTI, roof and mitral) already blocked during the first procedure will be re-blocked if necessary. The CTI line will be performed in all patients with a ECG showing a typical counterclockwise flutter. Then inducibility will be tested and all inducible AT will be mapped and ablated (max 10 consecutive AT)"
107737|NCT03343847|Biological|Romiplostim|This trial is designed to study romiplostim for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for the treatment of lymphoma.
107738|NCT03343847|Other|Placebo|Placebo Comparator
107739|NCT03343834|Biological|biological collection|"At D0:~blood samples~saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"
107740|NCT03343821|Other|Balance and daily life questionnaire|Patients complete questionnaire
107741|NCT03343808|Procedure|cooled radiofrequency ablation of genicular nerves|Cooled RF consists of creating an injury in the nerve trough a high frequency flow. Unlike conventional RF, in cooled RF through a closed circuit where intravenous flows, we can create an injury for a longer period of time, at a lower temperature (standard RFA 90º C, cooled RFA 60º C) and within an area 8 times larger. As the lesion is spherical, and larger (about 10-12 mm in diameter), the chances of neurolysis of the nerve increase.
107742|NCT03343795|Drug|oral progesterone|daily
107743|NCT03343795|Drug|intramuscular progesterone|every week
107744|NCT03343782|Combination Product|Expanded autologous bone marrow-derived mesenchymal stem cell|Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure
107745|NCT03343769|Other|BERG scale|Complete the BERG balance scale
107746|NCT03343769|Other|Functional tests|timed up and go, Mini motor test, retropulsion test
107747|NCT03343769|Other|Measurement of balance on a force platform|4 trials of 30 seconds x 2 conditions (eyes open; eyes closed)
107748|NCT03343769|Other|Measurement of maximal moment of the plantar flexor and dorsiflexor muscles|5-second repetitions
107749|NCT03343769|Other|Measurement of the moment of the plantar flexors and dorsiflexors corresponding to RMS activity during balance measurements|3 10-second repetitions
107750|NCT03343743|Other|Oligomineral water|Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C <200 mg/L) for at least 12 months
107751|NCT03343730|Diagnostic Test|Non-mydriatic color fundus photography with the RetinaVue camera|This hand-held device allows the primary care physician to capture an image of the patient's retina and transmit the image to a board-certified ophthalmologist for interpretation.
107752|NCT03343730|Diagnostic Test|Referral for dilated eye exam with an eye care professional|All patients will be given a referral to an eye care professional for a routine, dilated, diabetic eye exam.
107753|NCT03343717|Other|Rehabilitation|physical therapy exercise
107754|NCT03343717|Other|Chest physical therapy|chest physical therapy exercise
107755|NCT03343704|Drug|Idarucizumab|Intravenous
107756|NCT03343691|Diagnostic Test|Screening Population|Blood samples taken from screening population
107757|NCT03343691|Diagnostic Test|Breast Cancer Population|Blood samples taken from Breast Cancer population
107758|NCT03343678|Drug|Venetoclax|Venetoclax given alone and then in combination with BI 836826
107759|NCT03343678|Drug|BI 836826|Venetoclax given in combination with BI 836826
107760|NCT03343665|Drug|Nivolumab 40 mg in 4 ml Injection|40 mg by intravenous (IV) infusion on day 1 Duration of cycle 14 days
107761|NCT03343652|Drug|Nivolumab|3 mg/kg IV infusion on day 1,14 up to 3 cycles
107762|NCT03343652|Drug|Bendamustine Hydrochloride|90 mg/kg IV infusion on day 1 up to 3 cycles
107763|NCT03343639|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
107764|NCT03343639|Drug|Matching Placebo Tablets|Placebo Tablets
107765|NCT03343626|Drug|Placebo|PIZV placebo-matching saline solution.
107766|NCT03343626|Biological|PIZV|Purified inactivated Zika virus vaccine with aluminum hydroxide adjuvant.
107767|NCT03343613|Drug|LY3381916|IDO-1 inhibitor administered orally
107768|NCT03343613|Drug|LY3300054|PD-L1 inhibitor administered IV
107769|NCT03343600|Drug|Imatinib|Imatinib 100 mg/tablet, 2 tablets daily
107770|NCT03343600|Drug|Placebo|Placebos 2 tablets daily
107771|NCT03343587|Drug|LY3375880 IV|administered IV
107772|NCT03343587|Drug|LY3375880 SC|administered SC
107773|NCT03343587|Drug|Placebo IV|administered IV
107774|NCT03343587|Drug|Placebo SC|administered SC
107775|NCT03343574|Other|Abdominal Strengthening Exercise|Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
107776|NCT03343561|Behavioral|Nutrition Advice|Intervention diet for 8 weeks for intervention group. Detailed 30 mins consultation in week 1 (provided by dietitian) and 15 min consultation (provided by RA) in week 4 to enhance subject adherence to the diet for intervention group. Control group subjects will receive 1 detailed 30 mins nutrition consultation from dietitian after the study.
107777|NCT03343548|Drug|magnesium sulfate|2cc of magnesium sulfate ( 50%) will be administered epidurally
107778|NCT03343548|Drug|normal saline|2cc of normal saline will be administered epidurally
107779|NCT03343535|Device|OCS Lung Preservation|OCS Lung Preservation
107780|NCT03343522|Behavioral|Exercise|A multimodal exercise training program (aerobic, strength and flexibility exercises) for 6 months (60-min sessions performed 3 times/week with moderate intensity).
107781|NCT03343509|Drug|Metronidazole Oral|Oral Metronidazole
107782|NCT03343509|Drug|Metronidazole Ointment|Metronidazole Ointment
107783|NCT03343509|Drug|Placebo Oral Tablet|Placebo Tablet
107784|NCT03343509|Drug|Placebo Ointment|Placebo Ointment
107785|NCT03343496|Procedure|Awake fiberoptic intubation (AFOI)|With forty patients (ASA I~II, aged 18~75, simulating cervical instability injury) recruited to be operated on under general anesthesia, two experienced anesthesiologists performed the whole procedures within the study. Pre anesthetic interview was taken to illustrate the procedures of tracheal intubation to the patients. The simplified method consisted of three parts: conscious sedation, regional anesthesia and intubation. The time of AFOI, rate of one-time intubation success, hemodynamic parameters, pulse oxygen saturation (SpO2), rate of amnesia of the intubation, patients' satisfaction, and relative complications were recorded accordingly.
107786|NCT03343483|Behavioral|Volunteering|"Volunteers provide non-medical caregiving for frail seniors—care receivers—to help them maintain their independence and improve their well-being. Friendly visiting is the primary service provided. Structured, intensive training is provided prior to placement. The target expectation is of interactions in person and/or by telephone for at least 16 hours per month. On-going training (booster sessions) as well as volunteer support groups, and educational activities are provided."
107787|NCT03343483|Behavioral|Life Review|Subjects will complete a self-guided life review exercise over 12 months. Subjects will complete one section of the life review (with the self-help book) each month and send 'assignments' once per month to an email 'counselor' who will respond with supportive comments within three days.
107788|NCT03343457|Behavioral|Cognitive therapy|
107789|NCT03343444|Drug|12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 12 weeks
107790|NCT03343444|Drug|8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg)|Single Tablet (Sofosbuvir 400mg/Ledipasvir 90mg) daily for 8 weeks
107791|NCT03343431|Drug|Anti-HBV antiviral prophylaxis|Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum
107792|NCT03343418|Drug|Desmopressin|Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
107793|NCT03343418|Drug|Placebo|0.9% saline is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Patients randomized to the control group will receive the infusion of 100 milliliters (mL) 0.9% saline (SF0,9%). After 0.9% saline infusion, bleeding treatment will follow the predefined standardized treatment regimen.
107794|NCT03343405|Behavioral|Online Mind/Body Program for Fertility|The Mind/Body intervention involves (1) reducing physical symptoms of stress, (2) enhancing lifestyle behaviors related to fertility, (4) self-nurturing and coping skills, and (5) relaxation methods.
107795|NCT03343392|Drug|acetam/ketoro tromet group|One hour before in-office bleaching patients received either the acetaminophen 750 mg (Paracetamol 750 mg, Bioativa compounding pharmacy) and ketorolac tromethamine oral 10 mg (Toragesic® 10 mg, EMS Sigma Farma). The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h to keep a safe maximum daily dosage of 4000 mg of acetaminophen and 40 mg of ketorolac tromethamine.
107796|NCT03343392|Drug|Placebo group|One hour before in-office bleaching patients received either placebo,The operator administered the first dose of drug 1 h before the protocol, and extra doses were administered every 8 h for 48 h.
107797|NCT03343379|Other|Core stability tests|A test battery comprised of field tests to evaluate core stability
107798|NCT03343366|Drug|Metronidazole|Systemic AAT would contain Metronidazole (MET) 400 mg x 3 for 10 days
107799|NCT03343366|Procedure|Scaling Root Planing|SRP will be performed using ultrasonic scaling device at medium intensity. In addition to ultrasonic scalar, hand instrumentation (using sharpened and sterilized curettes) may also be used if required to smoothen certain irregular areas of root surface until the surfaces are smooth.
107800|NCT03343366|Behavioral|Oral Hygiene Instructions|OHI would include brushing teeth using soft bristles toothbrush and fluoridated toothpaste twice daily (morning after breakfast and night before sleeping) using Modified Bass Technique.
107801|NCT03343353|Other|LED (Light Emission Diode)|LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
107802|NCT03343340|Other|Early CRRT|Continous Renal Replacement Therapy
107803|NCT03343340|Other|Late CRRT|Continous Renal Replacement Therapy
107804|NCT03343340|Other|Standard Medical Therapy|Standard Medical Therapy
107805|NCT03343327|Drug|Chronocort®|Single dose of 20mg Chronocort® administered in one treatment period
107806|NCT03343327|Drug|Cortef®|Single dose of 20mg Cortef® administered in one treatment period
107807|NCT03343301|Combination Product|FPA144 + mFOLFOX6|Dose escalation of FPA144 to identify recommended dose in combination with mFOLFOX6
107925|NCT03342352|Drug|Placebo|Matching placebo for epacadostat administered orally twice daily.
107808|NCT03343288|Device|Silver doped hydroxyapatite coated implants|In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.
107809|NCT03343275|Combination Product|Lit control pHDown|Patients within the experimental arm will receive dietary supplement Lit-control®pH Down to help them keep their urinary pH in the adequate levels, being these considered as the preventive ones to avoid stent calcification (pH<6.2) being the 3 capsule per day indication. On the other hand, the control arm will receive a placebo product with similar organoleptic qualities and the same posology characteristics. Both arms wil use Lit-Control® pH Meter device to keep self- control of the urinary pH; also, both will receive the same hygienic-dietary indications about the care of the stent.
107810|NCT03343262|Device|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of IGT.
107811|NCT03343262|Other|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
107812|NCT03343249|Behavioral|Smart Phone Based Smoking Cessation|The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system. The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time. The phone has 4G and is Wi-Fi and GPS capable. Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire. Thus, computer/typing skills are not required. Participants have the ability to call and receive calls from research staff through the smart phone free of charge. All phones will be equipped with Global Positioning Systems (GPS) capability. The smart phones are also equipped with a Secure Digital card to store data as it is collected.
107813|NCT03343236|Radiation|Radiotherapy|All patients will undergo radiotherapy or surgery, or combined modality treatment
107814|NCT03343223|Behavioral|Intervention Group|"The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state (TelePrEP). In brief, PrEP involves daily use of a medication (i.e. Truvada) to prevent HIV infection among people at risk for infection due to sexual exposure or needle sharing."
107815|NCT03343210|Diagnostic Test|quality of life and pain measurement .|comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
107816|NCT03343197|Drug|AG-120|Prior to surgery subjects will receive AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
107817|NCT03343197|Drug|AG881|Prior to surgery subjects will receive AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects without residual disease following surgery will have the option to receive treatment for up to a year, until disease progression or unacceptable toxicity, whichever occurs first. Subjects with residual disease following surgery will have the option to receive treatment, until disease progression or unacceptable toxicity.
107818|NCT03343184|Procedure|SEE Strategy and Incremental Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
107819|NCT03343184|Procedure|SEE Strategy and Bulk Fill Restoration|37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
107820|NCT03343184|Procedure|SET Strategy and Incremental Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Z350XT composite will be used in increments of no more than 2 mm, using the incremental restoration technique, and each increment will be photoactivated for 40 seconds.
107821|NCT03343184|Procedure|SET Strategy and Bulk Fill Restoration|no conditioning, the adhesive system will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and photoactivated during 10 seconds with Light Emission Diode (LED) light. Then, the Filtek Bulk Fill composite will be used in increments of 4 mm, using the bulk restoration technique, and photoactivated for 40 seconds.
107822|NCT03343145|Biological|Leucostim 5µg/kg/day|5µg/kg/day (based on actual body weight) Leucostim®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
107823|NCT03343145|Biological|Neupogen 5µg/kg/day|5µg/kg/day (based on actual body weight) Neupogen®, subcutaneously, once a day, for up to 14 days or until the target ANC of 10,000/mm3 following the expected chemotherapy-induced ANC nadir
107824|NCT03343132|Behavioral|Standard locomotor therapy|Typical clinical therapy.
107825|NCT03343106|Behavioral|ACT plus ERP|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Acceptance and Commitment Therapy plus Exposure and Response Prevention (ACT plus ERP).
107826|NCT03343106|Behavioral|ERP alone|16 twice-weekly sessions of 120-minute individual psychotherapy consisting of Exposure and Response Prevention (ERP alone) monotherapy.
107827|NCT03343093|Behavioral|Restore Rehabilitation Program|Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
107828|NCT03343093|Behavioral|Control|usual care, surveys every 3 months
107829|NCT03343080|Drug|1.8% lidocaine plus 0.76% sodium bicarbonate|At the time of intubation, the endotracheal tube cuff will be inflated with a solution containing 1.8% lidocaine plus 0.76% sodium bicarbonate until loss of air leak at a positive pressure of 20 cm of water. This solution will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
107830|NCT03343080|Other|Air|At the time of intubation, the endotracheal tube cuff will be inflated with air until loss of air leak at a positive pressure of 20 cm of water. The air will remain in situ through the duration of cardiac surgery, transportation to the intensive care unit, and continued to the time of extubation.
107833|NCT03343054|Drug|talazoparib|Talazoparib will be administered orally on a continuous basis. Talazoparib may be taken with or without food. Each cycle will consist of 28 days.
107834|NCT03343041|Dietary Supplement|low-carbohydrate nutrition|low-carbohydrate enteral nutrition
107835|NCT03343041|Dietary Supplement|Standard enteral nutrition|standard enteral nutrition
107836|NCT03343028|Behavioral|Psychotherapy|
107837|NCT03343015|Procedure|complete dentures|therapy with maxilla and mandible dentures
107838|NCT03343002|Drug|fentanyl at 10-15 min before end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
107839|NCT03343002|Drug|fentanyl at end of surgery|Label 2 syringe is filled with 1mcg/kg of fentanyl, label 1 syringe is filled with same amount of saline solution. If the surgeon notifies the anesthesiologist 10-15 minutes before the end of the operation, the syringe drug labeled 1 will be administered intravenously(that is, normal saline ). At the end of the surgery, the syringe drug labeled 2 is administered intravenously((that is, 1mcg/kg of fentanyl)
107840|NCT03342989|Behavioral|Speed of Processing Training|This intervention is based on computer-administered tasks that are used to evaluate Useful Field of View test, which measures discrimination between visually presented stimuli in the presence of distractors
107841|NCT03342989|Behavioral|Internet-Based Contact Control|This intervention provides social contact and mentally stimulating activities that do not target speed of processing
107842|NCT03342976|Other|My-AHA platform|ICT strategy for early detection of frailties
107843|NCT03342963|Drug|ASC-01|Aripiprazole 3 mg/sertraline 100 mg combination drug
107844|NCT03342963|Drug|Aripiprazole and sertraline|Aripiprazole 3 mg and sertraline 100 mg
107845|NCT03342950|Drug|Topical Solution|Topical Solution of Clonidine (0.01%) + Pentoxifylline (5%) in anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
107846|NCT03342950|Drug|Placebos|Topical Solution of anhydrous ethanol (6.5%), polyethylene glycol 400 (20%), propylene glycol (53.5%), and oleyl alcohol (20%)
107847|NCT03342937|Drug|Oxaliplatin+Capecitabine+Pembrolizumab|"For each cycle: Oxaliplatin 130 mg/m2 IV on Day1, Capecitabine 825 or 1000 mg/m2 PO, BID Days on Days1-14, Pembrolizumab 200 mg IV on Day 1.~This study has 2 parts:~Safety validation part: all Cycles are 21 days in length.~Dose Expansion part: Cycle 1 is 28 days in length. Cycle 2 and beyond are 21 days."
107848|NCT03342924|Other|Flanker Test and physical fitness test|Socioeconomic status was determined using a trichotomous index. Inbody was used to assess body composition. To assess physical fitness, certain field tests were implemented using devices to quantify precise actions of physicality. Cognitive control was assessed using a computer-based Flanker Task.
107849|NCT03342911|Drug|Paclitaxel|Given IV
107850|NCT03342911|Drug|Carboplatin|Given IV
107851|NCT03342911|Biological|Nivolumab|Given IV
107852|NCT03342898|Biological|YF-17D|YF-17D subcutaneous injection
107853|NCT03342898|Biological|TAK-003 (DENVax)|TDV subcutaneous injection
107854|NCT03342898|Biological|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
107855|NCT03342885|Behavioral|Specific sleep ergonomics guidance|Participants receive a detailed instruction in sleep ergonomics. Participants are instructed to maintain either side lying or supine sleeping posture, depending on which is less painful. Neutral position of spine supported by specific placement of body pillow. Changing of posture during sleep is prevented. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
107856|NCT03342885|Behavioral|General sleep ergonomics guidance|Participants are instructed find most comfortable sleeping posture by personal preference and to avoid painful posture. The participants are recommended to replace their mattress if they feel that it is too hard or too soft. Instruction is given by a physiotherapist during one personal therapy session and the participants also receive a printed instruction.
107857|NCT03342872|Behavioral|Core Training: FBS System Mapping and MTFS-I Installation|Core Training will be a blended strategy wherein multiple interventions targeting multiple agency roles are combined to help ASU treatment providers increase their FBS quality. Core Training will be conducted with administrators, supervisors, data managers, and clinical staff. It will contain two 3-hour sessions focusing on FBS System Mapping and MTFS-I Installation. FBS System Mapping will focus on process mapping of existing site policies and practices for assessing family functioning at intake, educating families about intervention strategies and activities, including family members in treatment sessions, and hiring and supporting clinicians trained in and routinely delivering FBS. MTFS-Installation will focus on introducing MTFS-I components and integrating principles of DDDM.
107926|NCT03342352|Drug|Carboplatin|Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
107927|NCT03342352|Drug|Cisplatin|Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for 6 cycles.
107928|NCT03342352|Drug|Cetuximab|Cetuximab administered intravenously at the protocol-defined dose weekly.
107858|NCT03342872|Behavioral|Core Training & Facilitation: FBS System Mapping and MTFS-I Installation plus monthly on-site meetings|Facilitation will consist of monthly on-site meetings to review progress toward FBS improvements, discuss MTFS-I feedback reports and online resource use, and provide intensive technical assistance for progressing toward site-selected FBS improvement goals. Meetings will involve a subset of site-delegated participants from Core Training sessions to serve as a local change team (quality improvement team). The efficacy of facilitation-guided change teams has been established. Although there are several models for creating change teams, at least three features are common: (1) members represent multiple organizational roles (supervisors, data managers, line staff); (2) focus on data-driven decisions; and (3) use of external expert advisors.
107859|NCT03342859|Drug|Vilaprisan, BAY1002670|Daily single oral doses of 2 mg vilaprisan over 8-12 weeks
107860|NCT03342859|Drug|Ulipristal|Daily single oral doses of 5 mg ulipristal over 8-12 weeks
107861|NCT03342846|Device|rTMS|the first group received 20 Hz and the 2nd group received 1 Hz rTMS daily for 10 days 5 sessions every week on M1.
107862|NCT03342833|Device|Blood flow restriction|Occlusion of venous flow between bouts of HIIT training exercise
107863|NCT03342820|Procedure|Muscle fatigue|Isokinetic quadriceps muscle fatigue of the paretic lower limb
107864|NCT03342807|Drug|Insulin|Insulin infusion for subjects in Group Insulin.
107865|NCT03342807|Device|Aphesis|Aphesis for subjects in Group Aphesis.
107866|NCT03342794|Procedure|cataract surgery|To diagnose the preexisting posterior capsule defects in congenital cataracts after the cataracts are removed by surgery and observe the characteristics
107867|NCT03342781|Device|high flow nasal oxygen therapy|Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.
107868|NCT03342781|Device|Diffuser oxygen mask|diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
107869|NCT03342768|Other|Smartphone-based messages|"For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research."
107870|NCT03342742|Behavioral|Weight Loss|Weight loss behavioral intervention via one of two strategies.
107871|NCT03342729|Behavioral|Intervention|Participants receive the AMP 10-week program immediately
107872|NCT03342729|Behavioral|Control|Participants will not received the AMP 10-week program immediately, rather will wait 3-months
107873|NCT03342703|Diagnostic Test|Ultrasound|Patients will undergo a standard liver US protocol for approximately 15 minutes.
107874|NCT03342690|Drug|Eplerenone|"In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily.~Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions."
107875|NCT03342677|Diagnostic Test|Primovist MRI|Utility of Gd-EOB-DTPA (Primovist) enhanced Liver MRI in HCC detection and characterization in cirrhotic patients will be studied.
107876|NCT03342664|Device|Artemis + Medical Management|Subject will receive best MM in addition to the MIS procedure with Artemis.
107877|NCT03342664|Other|Best Medical Management Alone (MM)|Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
107878|NCT03342651|Other|Vitamin D|Vitamin D, general anesthesia, respiratory complications
107879|NCT03342638|Drug|Cyclophosphamide|Potent immunosuppressive agent; an alkylating agent
107880|NCT03342638|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
107881|NCT03342638|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
107882|NCT03342638|Drug|Methylprednisolone|Steroid
107883|NCT03342638|Drug|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
107884|NCT03342638|Biological|IVIg|Sterile, purified immunoglobulin G (IgG) products manufactured from pooled human plasma and typically contain more than 95% unmodified IgG, which has intact Fc-dependent effector functions and only trace amounts of immunoglobulin A (IgA) or immunoglobulin M (IgM).
107885|NCT03342638|Biological|Autologous Stem Cells|Infusion of participant's own stem cells
107886|NCT03342625|Device|High Instensity Focused Ultrasound|High Intensity Focused Ultrasound guided by MRI
107887|NCT03342612|Procedure|Brain Magnetic Resonance Imaging (MRI)|
107888|NCT03342599|Dietary Supplement|Alpha Lipoic Acid Supplement|Alpha lipoic acid ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
107889|NCT03342599|Dietary Supplement|Placebo|Cellulose fiber ingestion (600mg/daily) for 8 weeks with no change in lifestyle.
107890|NCT03342586|Diagnostic Test|Resting State fMRI (rsfMRI)|rsfMRI before receiving High-dose chemotherapy with autologous stem cell transplantation/HDC-ASCT (pre-HDC-ASCT), at approximately 3 months (+/- 2 weeks) after HDC-ASCT (early post-HDC-ASCT) and approximately 6months (+/- 2 weeks) after HDC-ASCT (late post-HDC-ASCT).
107929|NCT03342352|Drug|5-Fluorouracil|5-Fluorouracil administered intravenously at the protocol-defined dose on Days 1-4 for 6 cycles.
107930|NCT03342339|Other|cognitive examination|mini mental test of Parkinson, Hospital Anxiety and Depression Scale, 5 words by Dubois, fast test frontal assessment, Trail Making Test
107931|NCT03342339|Other|viewing of video|viewing during 5 minutes scale of differential emotions and Positive and Negative Affect Scale
107932|NCT03342339|Other|Iowa Gambling Task|Test of Iowa Gambling Task
108192|NCT03340285|Dietary Supplement|Placebo|first 2 weeks: Placebo + Diet then 4 weeks placebo two tablet/day before meals + Diet
107891|NCT03342586|Other|Auditory Attention and Executive Functions Test|"Trail Making Test (Parts A & B): Part A is a timed test of visual scanning and graphomotor speed; AT: 3 minutes. Part B is a timed measure of set-shifting; Administration Time (AT): 5 minutes. Test-retest reliabilities=0.64-0.94.~Brief Test of Attention-BTA assesses auditory working memory; AT: 10 minutes. Test-re-test reliability=0.70.~Controlled Oral Word Association Test-COWAT is a timed measure of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S). The subject is allowed 60 seconds per letter, and the resultant score is the total number of words produced. Test-retest reliability=0.88. AT: 5 minutes."
107892|NCT03342586|Other|Memory Test|The Hopkins Verbal Learning Test-Revised (HVLT-R): The HVLT-R is a test of verbal learning and memory.
107893|NCT03342586|Other|Motor Speed Test|Grooved Pegboard Test (GPT)-Dominant Hand and Non-Dominant Hand. It is a timed test of manual dexterity, in which the time to completion is scored separately for each hand.
107894|NCT03342586|Other|Self Reported Quality of Life Questionnaire|The Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR Version 4) consists of 46 questions with five domains assessing physical well-being, social/family well-being, emotional well-being, functional well being, additional concerns. The neuropsychological and QOL assessments will be performed by a neuropsychologist or by a trained RSA under the neuropsychologist's direct supervision.
107895|NCT03342573|Drug|Cosentyx|Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
107896|NCT03342560|Device|Sonographic SWE measurements with 4 different ultrasound systems|Sonographic Shear wave elastography will be performed to quantify liver fibrosis
107897|NCT03342547|Procedure|Duodenal biopsy|Two duodenal biopsy samples will be collected from each participant
107898|NCT03342547|Procedure|Saliva|Saliva (1-2 mL) will be collected from each participant for secretor status testing
107899|NCT03342534|Device|DC-stimulator (Neuroconn, Germany)|A current of 2 mA will be applied for 20 minutes, 3 times per week during 2 weeks, except for the sham tDCS arm.
107900|NCT03342521|Diagnostic Test|optical coherence tomography and VerifyNow|optical coherence tomography Imaging P2Y12 and Aspirin reaction units quantification by the VerifyNow
107901|NCT03342508|Device|Fetal Pillow|see arm description
107902|NCT03342495|Other|Patient Navigator|Social worker/Patient Navigator will be assigned to follow youth in adult care for up to 24 months to assist youth adapt and attach to adult delivered healthcare
107903|NCT03342495|Other|Usual Care|Whatever processes are in place in a variety of clinics to support transfer from pediatric to adult care in the pediatric clinics
107904|NCT03342482|Other|Low-glutamate diet|The dietary intervention consists of a one-month low-glutamate diet, followed by a randomized crossover challenge with MSG and placebo to measure return of symptoms.
107905|NCT03342469|Other|Artificial Food Coloring|Artificial Food Coloring (AFC)
107906|NCT03342469|Other|Placebo|Chocolate cookies with no additives
107907|NCT03342456|Drug|Doxycycline Hyclate Enteric-Coated Capsules|group 1,0.1g*10 capsules/box, produced by Yung Shin Pharm.Ind.(Kunshan) Co.,Ltd.
107908|NCT03342456|Drug|Amoxicillin Capsules|group 2,0.5g*24 capsules/box, produced by United Laboratories（Zhuhai）
107909|NCT03342456|Drug|Ilaprazole Enteric-Coated Tablets|group 1 and group 2,5mg*6 capsules/box, produced by Livzon Pharmaceutical Group Inc
107910|NCT03342456|Drug|Furazolidone Tablets|group 1 and group 2,0.1g*100 tablets/bottle,produced by Shanxi Yunpeng Pharmaceutical co.,Ltd.
107911|NCT03342456|Drug|Potassium Citrate Tablets|group 1 and group 2,110mg*40 tablets/bottle,produced by Livzon Pharmaceutical Group Inc
107912|NCT03342443|Drug|Memantine|Patients receive memantine with a dosage of 5 microgram at 8 am daily for one week (Week 1), then 5 microgram at 8 am and 5 microgram at 5 pm for one week (Week 2), then 10 microgram at 8 am and 5 microgram at 5 pm for one week (Week 3), then 10 microgram at 8 am and 10 microgram at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
107913|NCT03342443|Drug|Placebo|Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
107914|NCT03342417|Biological|Nivolumab|Nivolumab 240 mg administered by IV infusion over 30 minutes
107915|NCT03342417|Biological|Ipilimumab|Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.
107916|NCT03342404|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level every 3 weeks and can be dose escalated up to 1.25 mg/kg.
107917|NCT03342404|Other|Placebo|Placebo, Subcutaneous, every 21 days
107918|NCT03342404|Other|Best Supportive Care (BSC)|Best Supportive Care (BSC)
107919|NCT03342391|Other|Transnasal esophagoscopy|single food antigen introduction OR removal of topical swallowed steroid therapy followed by surveillance utilizing TNE
107920|NCT03342378|Radiation|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) will be delivered over 6.5 weeks in 33 daily fractions. Treatments will be initiated on Monday or Tuesday. Missed treatments will be compensated for by delivering an additional BID treatment during the week given at least 6 hours apart OR treating on the Saturday of that week, OR adding to the end of treatment. Gross disease will receive 70 Gy in 2.12 Gy fractions, areas at high-risk for subclinical disease will receive 60 Gy in 1.82 Gy fractions, and areas at low-risk for harboring subclinical disease will receive 56 Gy in 1.70 Gy fractions.
107921|NCT03342378|Diagnostic Test|PET-MRI|All imaging data will be acquired using a 3.0T PET-MRI scanner with a standard bore size of 60 cm. Patients will be placed in standard non-ferrous head and neck immobilization devices during PET-MRI to simulate their anticipated positioning during subsequent CT simulation and treatment. A head and neck PET-MRI study will be performed with scan sequences tailored for the site of interest. The PET-MRI exam will take approximately 90 minutes to complete.
107922|NCT03342365|Diagnostic Test|Evaluation of microbial translocation and microbiota|Blood test from catheter already in place to determine microbial translocation and stool sample taken for microbiota analysis
107923|NCT03342352|Drug|Nivolumab|Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
107924|NCT03342352|Drug|Epacadostat|Epacadostat administered orally at the protocol-defined dose twice daily.
108042|NCT03341520|Radiation|Low dose radiation Therapy (LDRT)|2 x 2 Gy
107933|NCT03342326|Other|Exposure to familiar songs|3 conditions : a) Words and Music (sing condition), b) Words only (spoken condition) and c) Music only (instrumental condition) After each song : rate the popularity of the song on a scale of 1 to 5.
107934|NCT03342326|Other|Music Experience Questionnaire|questions about the past music training
107935|NCT03342326|Other|Implicit tasks memory|"2 tests : a) Completion of trigrams : freely complete the first 3 letters of a word.~b) lexical decision : judge whether an audibly presented sound sequence is a word existing in the French language or not."
107936|NCT03342326|Other|Questionnaires|Mini Mental State Examination, 5 words by Dubois and fluence verbal test
107937|NCT03342313|Other|Food - Sandwich|Sandwich as a breakfast for testing chewing activities.
107938|NCT03342300|Drug|pegylated liposomal doxorubicin|Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
107939|NCT03342300|Drug|pirarubicin|Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
107940|NCT03342287|Other|questionnaires|Questionnaires rating IBS symptoms, constipation, anxiety and depression
107941|NCT03342287|Other|cognitive evaluation|Administration of online cognitive battery
107942|NCT03342287|Other|Blood|Measurement of cytokines/inflammatory biomarkers
107943|NCT03342287|Other|Fecal sample|Measurement of the gut microbiome
107944|NCT03342274|Behavioral|Lifestyle Program|Participants will receive group weight loss sessions addressing healthy eating, exercise, and weight loss principles adapted from the Diabetes Prevention Program delivered by Community Health Workers.
107945|NCT03342274|Other|Usual Care|Usual care consists of chronic disease management through medication delivery and monitoring of weight, blood pressure, and blood glucose by Community Health Workers.
107946|NCT03342261|Drug|DAA treatment|Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks
107947|NCT03342248|Other|access to the social network|The development of a social network via a digital platform for carers of patients suffering from severe mental illness and study of the impact of its use on the health status of caregivers
107948|NCT03342235|Procedure|Photorefractive Keratectomy (PRK)|Subjects randomized to refractive surgery will be referred to one of six study surgical centers (surgical centers are listed in Appendix B) to have photorefractive keratectomy (PRK) in the affected eye within 60 days after randomization.
107949|NCT03342235|Other|Patching 2 hours per day|Patching prescribed 2 hours per day with continued refractive correction (with spectacles and/or contact lenses) as able.
107950|NCT03342235|Device|VisX STAR S4 IR Excimer Laser System; TECHNOLAS TENEO 317 Excimer Laser|VisX STAR S4 IR Excimer Laser System; TECHNOLAS TENEO 317 Excimer Laser
107951|NCT03342222|Device|Interference Screws|tibial fixation for ACL reconstruction
107952|NCT03342209|Device|Fisher&Paykel AIRVO™ 2 High Flow Nasal Cannula Therapy|"A high flow nasal cannula will be implemented to the CO-poisoned patients. In the meantime, intravenous access and cardiac monitorization will have been establishing. When the high flow nasal cannula becomes ready, the first venous blood sample will be taken and the treatment will be started without any delay. The gas flow rate will be started at the rate of 30 liters per minute and will be increased to the max flow rate which patient can tolerate and FiO2 of 1.0. If the first COHb level is lesser than 10%, the patient will be excluded and will receive standard emergency care.~The blood sample will be drawn from existing IV access every 10 minutes until the COHb levels become %50 or lesser of the initial level.~Once the COHb level becomes 50% of initial measurement, following blood samples will be taken in every 30 minutes."
107953|NCT03342196|Drug|Melphalan|"Alkylating agent which is a derivative of mechlorethamine that inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA; acts on both resting and rapidly dividing tumor cells.~Melphalan may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
107954|NCT03342196|Drug|Thiotepa|"Thiotepa is an alkylating agent which produces cross-linking of DNA strands leading to inhibition of DNA, RNA, and protein synthesis; thiotepa is cell-cycle independent.~Thiotepa may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. It may cause damage to the GI tract causing mouth sores, nausea, vomiting, and diarrhea. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash."
107955|NCT03342196|Drug|Fludarabine|"Fludarabine is an antineoplastic fluorinated nucleoside analog and inhibits DNA synthesis through inhibition of polymoerase alpha after incorporation into DNA.~Fludarabine may cause a lowering of the white blood cell or platelet counts, leading to an increased risk of infection and frequent bruising or bleeding. Other side effects may include loss of appetite, liver abnormalities, hair loss, swelling, fatigue, sleepiness, skin rash, and lower limb weakness."
107956|NCT03342196|Drug|Keratinocyte Growth Factor (KGF)|"Chemoprotective Agent.Recombinant keratinocyte growth factor (KGF) produced in E. coli. KGF binds to the KGF receptor resulting in proliferation, differentiation and migration of epithelial cells in multiple tissues, including (but not limited to) the tongue, buccal mucosa, esophagus, and salivary gland.~Palifermin may cause rash, itching, redness, or discoloration of the skin. It may cause edema, an increase in pancreatic enzymes. It may cause arthralgias. It may cause tongue discoloration or tongue edema."
107957|NCT03342183|Other|Intervention Arm|RIPC stimulus will be applied prior to the first intervention visit, using a previously validated (for cardiac protection in HD patients) standard dose (four cycles of cuff inflation to the lower limb of the patient and inflating at 200mmHg for five minutes, with five minutes' deflation).
107958|NCT03342183|Other|Control Arm|Sham procedure in which the blood pressure cuff will be applied to the lower limb and inflated to 40mmHg for five minutes and deflated for five minutes with the cycle repeated a total of four times prior to dialysis. To be administered on a monthly basis from the baseline visit to the year 1 visit.
107959|NCT03342170|Genetic|G20210A prothrombin gene mutation and Factor 5 Leiden mutation|blood sample
107960|NCT03342157|Drug|senna/docusate|Stimulant laxative
109635|NCT03329508|Drug|Pramipexole ER|Pramipexole ER titrated to optimal dose
107961|NCT03342131|Other|Circulating wnt 2 and wnt 4 concentration|"Blood (150 each group) is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture to explore circulating wnt 2 and wnt 4 concentration by ELISA. Continuous wnt2 and wnt4 concentration are measured in all patients with STEMI at 0 , 7days and 12 months after admission. Other patients with acute syndrome system are measured Wnt 2 and wnt4 only once within 24h after admission.~Wnt2 and wnt4 concentration in Control group will be measured only once with 24h after admission."
107962|NCT03342118|Drug|Phloroglucin(Flospan®)|The experimental group was taken with Phloroglucin(Flospan®) before endoscopy.
107963|NCT03342118|Drug|Normal saline|The control group was treated with normal saline before endoscopy
107964|NCT03342105|Procedure|Cettum|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Moxibustion will be provided at 11 standard acupuncture points: EX-HN3, and both EX-HN8, LI20, LI4, GB2, ST36. A specifically designed device, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea), will be used to treat patients in this group. The expected total time of each treatment session will be 15 min.
107965|NCT03342105|Procedure|Acupuncture|The treatment will be applied in 8 sessions, 2 times per week for 4 weeks. Acupuncture will be provided at same points in the Cettum group. Sterile stainless steel disposable acupuncture needles (0.25X30mm, DongBang Acupuncture Inc, Korea) will be used to treat patients in this group. The needles will be kept in place for 15 min.
107966|NCT03342092|Other|Questionnaire|Questionnaires distributed to the families 15 days before child's medical consultation + anthropometric measures and data collected from the personal interview with school nurse
107967|NCT03342079|Drug|Local Anesthetics,Topical|topical anesthetic
107968|NCT03342079|Drug|Nitrous Oxide|inhaled nitrous oxide
107969|NCT03342079|Drug|Placebos|placebo topical anesthetic
107970|NCT03342066|Diagnostic Test|reproducability of caries risk assessment|reproducability of caries risk assessment CAMBRA verses cariogram
107971|NCT03342053|Drug|RO7234292 (RG6042)|Intrathecal injection
107972|NCT03342040|Procedure|Laparoscopic ventral hernia repair with TAP block|Transverse abdominis plane block is given under ultrasound guidance during laparoscopic ventral hernia surgery
107973|NCT03342040|Procedure|Laparoscopic ventral hernia repair without TAP block|No block administered during Laparoscopic ventral hernia surgery
107974|NCT03342027|Drug|Bupropion|medication for smoking cessation
107975|NCT03342027|Behavioral|Positively smoke free|an 8 session, tailored behavioral intervention for treating tobacco dependence
107976|NCT03342027|Other|Brief advice to quit smoking|Standardized brief advice to quit smoking (standard of care)
107977|NCT03342014|Device|Ultrasound|3DPD and UAD acquisitions (10 min)
107978|NCT03342014|Biological|Blood sample collection|A blood sampling (20 mL) is collected for biomarker analysis (PAPP-A and PlGF) and biological collection.
107979|NCT03342001|Drug|Calcitonin|calcitonin nasal spray
107980|NCT03341988|Drug|Ombitasvir-Paritaprevir-Ritonavir Tab 12.5-75-50 milligram|To asses curability of( Ombitasvir ,Paritaprevir,Ritonavir) in ch HCV infected patients in those with CKD vs ESRD 2- Also assess duration of sustained viral response,treatment, relapse or failure of therapy in CKD vs ESRD
107981|NCT03341975|Behavioral|SexHealth|To enhance and test our ED SexHealth intervention that provides risk reduction counseling and point-of-care services as well as connections to sustainable, non-episodic sources of care.
107982|NCT03341962|Drug|IMU-838|IMU-838 tablet
107983|NCT03341962|Drug|Placebo|Tablets manufactured to mimic IMU-838 tablets
107984|NCT03341949|Biological|Recurring blood sample|An additional tube will be collected for the assay of CD146s as part of the research
107985|NCT03341936|Drug|Nivolumab|Nivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
107986|NCT03341936|Drug|Lirilumab|Lirilumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells
107987|NCT03341923|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily disposable wear
107988|NCT03341923|Device|Etafilcon A multifocal contact lenses|Hydrogel multifocal contact lenses for daily disposable wear
107989|NCT03341910|Drug|Tazarotene Lotion, 0.1%|DFD-03 Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
107990|NCT03341910|Drug|Tazarotene Cream, 0.1%|Tazorac Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
107991|NCT03341910|Drug|Vehicle Lotion 0%|Vehicle Lotion will be applied to the face (avoiding areas around the eyes and mouth) twice daily, approximately 12 hours apart, and washed off after 1 minute.
107992|NCT03341910|Drug|Vehicle Cream 0%|Vehicle Cream will be applied to the face (avoiding areas around the eyes and mouth) once daily in the evening and left on overnight.
107993|NCT03341897|Procedure|endovasculer embolization of varicocele|"Step 1: Vascular Access~Access can be achieved via the internal jugular or femoral veins. Step 2: Left Renal Vein Injection Step 3: Left Spermatic Vein Catheterization Step 4: Spermatic Vein Occlusion Step 5: Right Spermatic Venography POSTPROCEDURE CARE~The patient is kept in bed for 1 hour postprocedure. The patient is advised to take anti-inflammatory agents as needed and to avoid any activity involving the Valsalva maneuver, such as lifting, vigorous, or hitting type sports for 3 full days beginning the day after the proce¬dure. Most patients report a minor dull ache in the back or groin lasting < 2 to 5 days. Fewer than 5% of patients will develop more severe pain lasting up to 14 days, requiring oral analgesics and anti-inflammatory agents and avoidance of vigorous exercise."
107994|NCT03341884|Drug|Ipatasertib|A single oral dose of 100 mg ipatasertib will be administered.
107995|NCT03341858|Other|no intervention-strictly observational|
107996|NCT03341845|Drug|Axitinib|axitinib in combination with avelumab
107997|NCT03341845|Drug|Avelumab|axitinib in combination with avelumab
107998|NCT03341832|Drug|NVP-1203|oral dose for 7 days
107999|NCT03341832|Drug|NVP-1203-R|oral dose for 7 days
108000|NCT03341832|Drug|NVP-1203 placebo|oral dose for 7 days
108001|NCT03341832|Drug|NVP-1203-R placebo|oral dose for 7 days
108002|NCT03341819|Procedure|Total knee arthroplasty|A surgical procedure in which parts of the knee joint are replaced with artificial parts (prostheses)
108003|NCT03341819|Procedure|Urinary Catheterization|Urinary catheterization is a latex, polyurethane, or silicone tube known as a urinary catheter is inserted into a patient's bladder via the urethra. Catheterization allows the patient's urine to drain freely from the bladder for collection.
108004|NCT03341806|Drug|Avelumab|Avelumab will be administered intravenously every 2 weeks at a dose of 10 mg/kg for 2 cycles
108005|NCT03341806|Combination Product|MRI-guided LITT therapy|(Part B) prior to receiving Avelumab 10 mg/kg every 2 weeks + LITT
108006|NCT03341793|Diagnostic Test|Muscle biopsy and blood test|Characterize the changes in muscle secretion induced by bariatric surgery and determine their role in improving the insulin sensitivity of skeletal muscle and insulin secretion by B cell responsible for the remission of diabetes mellitus.
108007|NCT03341780|Procedure|amblyopia therapy|Any of the following amblyopia training activities may be employed during patching: board games, card games, coloring in O's, comic books, craft projects, crossword puzzles, dot-to-dot patterns, drawing, hammering nails, jacks, jigsaw puzzles, lego and other blocks, marbles, mazes, peg-board activities, perceptual materials, pickup sticks, reading, sewing, shooting games, stringing beads, throwing or hitting games, tracing, and video or computer games.
108008|NCT03341767|Drug|Clofazimine|50 or 100 mg micronized Clofazimine suspended in an oil-wax base in a gelatin capsule
108009|NCT03341767|Drug|Placebo|Oil-wax in gelatin capsule
108010|NCT03341754|Biological|D/ChAd63-CA|Priming Component (DNA) = NMRC-M3V-D-PfCA (D-CA) Vaccine Boosting Component = ChAd63-PfCA
108011|NCT03341754|Biological|D/ChAd63-CAT|Priming Component (DNA) = NMRC-M3V-D-PfCAT (D-CAT) Boosting Component = ChAd63-PfCAT
108012|NCT03341754|Other|Infectivity Control (IC) Group|Subjects will be exposed to bites of 5 Anopheles stephensi mosquitoes carrying infectious Pf sporozoites within a controlled clinical environment.
108013|NCT03341741|Drug|Tobramycin Powder|TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);
108014|NCT03341741|Drug|Colistin|Colistin solution 2 x daily 1 Mega continuously
108015|NCT03341728|Behavioral|Optical flow perturbations|Continuous mediolateral (i.e., side-to-side) 20-minute perturbations of optical flow that elicit the visual perception of lateral imbalance via virtual reality during treadmill walking.
108016|NCT03341728|Behavioral|Normal walking|Usual treadmill walking without optical flow perturbations
108017|NCT03341715|Drug|Mavoglurant (AFQ056)|2-100mg tablets of Mavoglurant will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
108018|NCT03341715|Other|Placebo|Two matching tablets of placebo will be administered on the morning of 1 of the 2 experimental days by an RN or the physician investigator.
108019|NCT03341702|Other|penintetiary's incident reports collection|collection of clinical and penitentiary 's data
108020|NCT03341689|Drug|High Dose Psilocybin|0.143 mg/kg psilocybin capsule
108021|NCT03341689|Drug|Low Dose Psilocybin|0.0143 mg/kg psilocybin capsule
108022|NCT03341689|Drug|Placebo|microcrystalline cellulose capsule
108023|NCT03341676|Drug|Dexamethasone|Dexamethasone 3.3 mg/mL solution for injection
108024|NCT03341676|Drug|Placebo|Sodium Chloride 0.9% w/v solution for injection
108025|NCT03341663|Combination Product|Coronary angiography,Canadian Cardiovascular Society angina pectoris classification for the severity of angina and electronic Von Frey instrument for testing the degree of acupoint sensitization|All the interventions were tested for only once
108026|NCT03341650|Behavioral|High Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (at least 5 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
108027|NCT03341650|Behavioral|Low Pasta|Participants received a personalised diet program considering their food preferences and eating behaviour, based on the Italian guidelines for a healthy and Mediterranean diet and were encouraged to maintain their habitual consumption of pasta (no more than 3 times/week). To encourage participants to prepare healthy meals by using high-quality ingredients, participants were provided with a recipe book and dietary guidelines and recommendations.
108028|NCT03341637|Biological|Tetravalent Dengue Vaccine (TDV)|TDV subcutaneous injection
108029|NCT03341637|Biological|Placebo|Normal Saline (0.9% NaCl) subcutaneous injection
108030|NCT03341624|Procedure|cataract surgery cataract extraction and intraocular implantation|
108031|NCT03341611|Behavioral|Neuro-imaging during behavioral decision-making task|All participants will make simple decisions while in a scanner.
108032|NCT03341598|Procedure|CAF|Periodontal surgical technique to treat gingival recessions.
108033|NCT03341598|Procedure|R|Restorative procedure to treat tooth structure loss.
108034|NCT03341598|Procedure|MC|Xenogenous graft placed in the surgical site.
108035|NCT03341585|Other|expiration lente prolongée|l'Expiration Lente Prolongée (ELPr) is a passive technique to enhance the expiration used in infants, obtained by a slow and increasing manual thoraco-abdominal pression applied at the end of a spontaneous expiration till the residual volume. The aim is to obtain a bigger expired volume compared to a normal expiration and drain the mucus out of the airways (Postiaux 2003). This technique has been invented by Guy Postiaux and is used in the Chest Physiotherapy (CPT).
108036|NCT03341572|Other|5,10 and 15cmH2O positive end expiratory pressure|every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
108037|NCT03341559|Device|Spatial Frequency Domain Imaging (SFDI)|Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
108038|NCT03341546|Other|A single measurement of the patient's abdominal depth|A single measurement of the patient's anterior-posterior abdominal depth
108039|NCT03341533|Procedure|Ice packs plus usual post-op analgesia|A 9 inch by 12 inch zip lock bag filled with ice chips, placed inside a cotton pillow case, placed directly on the abdomen. Ice chips will be replaced as they thaw. Monitoring of surgical sites, skin integrity, and comfort with ice pack in place by nursing per current procedural guidelines.
108040|NCT03341533|Other|Usual post-op analgesia|Standard post-operative analgesia orders will be followed.
108041|NCT03341520|Drug|Obinutuzumab Injection [Gazyva]|7x 1000mg flat dose
108043|NCT03341507|Device|classical laryngoscopy|the laryngoscopy with the Mc Coy laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
108044|NCT03341507|Device|rigid tube for laryngoscopy|the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
108045|NCT03341494|Drug|Thalidomide|Gefitinib 250mg Thalidomide 200 MG
108046|NCT03341481|Other|Femaltiker|Patient had taken twice a day the product
108047|NCT03341481|Other|Placebo|Patient had taken twice a day the placebo
108048|NCT03341468|Device|Urethral catheter immobilization|"Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study."
108049|NCT03341455|Behavioral|Capacity building to support families affected by IPV & substance misuse|Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
108050|NCT03341442|Procedure|No hip precautions|No hip precautions practiced after THA surgery
108051|NCT03341429|Drug|Liraglutide Pen Injector [Saxenda]|Daily injection of GLP-1 agonist (liraglutide 3.0 mg) for obese patients presenting poor weight loss (<20%) after bariatric surgery and suboptimal GLP-1 levels.
108052|NCT03341429|Drug|Placebo|Daily subcutaneous injection
108053|NCT03341416|Device|deep brain stimulation on stimulation - active|bilateral deep brain stimulation reaching the dentate nucleus turned ON - phase active
108054|NCT03341416|Device|deep brain stimulation off stimulation - sham|bilateral deep brain stimulation reaching the dentate nucleus turned OFF - phase sham
108055|NCT03341403|Dietary Supplement|Probiotical®|"Probiotical is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill."
108056|NCT03341403|Other|Placebo|pills containing placebo
108057|NCT03341390|Drug|Aspirin|1 x 325 mg tablet of aspirin administered once daily
108058|NCT03341390|Drug|BMS-986177|200 mg of BMS-986177 administered twice daily
108059|NCT03341390|Drug|Placebo|200 mg of Placebo administered twice daily
108060|NCT03341364|Behavioral|ACT-based group therapy|6 group therapy sessions over 6 weeks (one session à 2 hours weekly), plus one follow-up session 6 weeks after last session. The sessions are lead by a psychologist and a social worker. Each session containing discussions, experimental exercises and home-work assignment.
108061|NCT03341364|Behavioral|ACT individual treatment|3-12 individual therapy sessions over 3-16 weeks, plus one follow-up session 6 weeks after last session, lead by a clinical psychologist. Each session containing discussion, experimental exercises and home-work assignment.
108062|NCT03341351|Other|Instructional video|Instructional video using the modified beef tongue model
108063|NCT03341351|Other|Instructional workshop|Instructional workshop using the modified beef tongue model.
108064|NCT03341325|Other|animal-assisted activity|a live animal (small dog and/or rabbit)
108065|NCT03341325|Other|control activity|a stuffed toy animal
108066|NCT03341312|Biological|LY900014|Administered SC
108067|NCT03341312|Biological|Insulin Lispro|Administered SC
108068|NCT03341299|Biological|LY900014|Administered SC
108069|NCT03341299|Biological|Insulin Lispro|Administered SC
108070|NCT03341286|Drug|TK3|Tryptophan and thiamine as on oral supplement
108071|NCT03341273|Drug|Azithromycin|Azithromycin is an azalide antibiotic and is derived from erythromycin used to treat many different types of infections caused by bacteria, such as respiratory infections.
108072|NCT03341273|Other|Placebo|Placebo will be a matching capsule the same size, weight, and color as the capsules containing Azithromycin tablets.
108073|NCT03341273|Device|VIDAS B.R.A.H.M.S Procalcitonin Test (PCT)|The VIDAS B.R.A.H.M.S PCT is an automated test for use on the VIDAS instruments for the determination of human procalcitonin in human serum or plasma using the Enzyme-Linked Fluorescent Assay (ELFA) technique.
108074|NCT03341260|Drug|Diclofenac Potassium 50mg Tab.|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
108075|NCT03341260|Drug|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
108076|NCT03341234|Drug|Bupivacaine|30 ml %0,25 bupivacaine
108077|NCT03341234|Drug|Saline|2 ml saline subcutaneously
108078|NCT03341234|Device|Ultrasound|Ultrasound guided block
108079|NCT03341208|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Cardiac MRI will be performed before and after subject has undergone catheter directed therapy
108080|NCT03341195|Behavioral|SMS messages and automated calls|The intervention consists of SMS and automated calls based messages
108081|NCT03341182|Procedure|Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Lay the subject down on the stomach and hold the pillow on the stomach. The skin of the injection area is sterilized by aseptic method and covered with aseptic pouch. After confirming the level of he vertebrae around the C-arm and aligning the anteroposterior view of the endplate of the vertebral body, rotate the C-arm 20~30 degrees diagonally in the direction to be performed. After confirming the best Scotty dog view, confirm the final target point at 6 o'clock directly below the pedicle. At this position, the skin point is marked on the skin. And then both groups proceed in parallel with the beam direction of the transducer with the tunnel view technique until the needle reaches the back of the vertebral body at the level of the spinal nerve roots. At this time group A uses a mirror and group B dose not. The final reach of the target point (ideal depth) is confirmed through the anterior and posterior views and lateral views.
108082|NCT03341182|Procedure|conventional manner|A portable mirror is located at the side of surgical table and used in this procedure.
108116|NCT03340935|Other|Fasting mimicking diet|Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (600 Kcal on day 1, followed by 300 KCal/day on days 2 to 5), low-protein, low carbohydrate diet
108083|NCT03341169|Drug|N(2)-L-Alanine L-Glutamine dipeptide|:Intravenous infusion of N (2) -L-alanyl-L-glutamine(mixed with normal saline, ratio 1:1) at the dose of 0.25g/kg(body weight) for 8 hours before induction of anesthesia(rate=2.5*weight/8 ml/h) and administration another 0.25g/kg(body weight) of N (2) -L-alanyl-L-glutamine(mixed with 8.5% amino acid solution, ratio 1:5) into the central vein for 10 hours after induction of anesthesia(rate=0.75*weight ml/h)
108084|NCT03341169|Drug|placebo (0.9% NaCl (normal saline))|Intravenous infusion of 0.9% NaCl for 8 hours before induction of anesthesia(rate=2.5*weight/8 ml/h) and administration 0.9% NaCl into the central vein for 10 hours after induction of anesthesia(rate=0.75*weight ml/h)
108085|NCT03341156|Drug|Kcentra|Kcentra will be administered in 2 divided doses; Pre-bypass (5-10 units/kg based on body weight and preoperative INR and post-protamine based of the pre-bypass dose and the preoperative INR; daily maximum dose not to exceed 5000 IU (50 IU/kg)
108086|NCT03341156|Drug|Frozen Plasma Product, Human|If the patient is randomized to receive standard transfusion they will receive 2 U of fresh frozen plasma intravenously before cardiopulmonary bypass and then up to 4-8 U of plasma added to the cardiopulmonary bypass reservoir during rewarming.
108087|NCT03341143|Drug|Fecal Microbiota Transplant with Pembrolizumab|"FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by doing a colonoscopy. The FMT consists of introducing normal bacterial flora contained in stool collected from a donor into your small intestine. In this case, the donor is patient with advanced melanoma who has been treated with a PD-1 inhibitor (nivolumab or pembrolizumab) and has been rendered disease-free as a result. The FMT will be performed on Cycle 1 Day 1.~Pembrolizumab, 200mg, through an IV over 30 minutes on Cycle 1 Day 1 (same day as the FMT, and then again on Day 1 of each 21-day cycle for an additional 3 cycles (Cycles 2 - 4)."
108088|NCT03341130|Device|Mandibular Repositioning Splint|The Morning Repositioner is a hands-free bite deprogrammer designed to help return the patient's jaw back to its pre-treatment centric position.
108089|NCT03341130|Device|Mandibular Advancement Oral Appliance|Mandibular Advancement Oral Appliances are dental splints used to keep the jaw in an advanced position, opening the upper airway during sleep.
108090|NCT03341117|Drug|Acetylsalicylic acid|Acetylsalicylic acid 300 mg per capsule
108091|NCT03341117|Drug|Calcined magnesia|Calcined magnesia 300 mg per capsule
108092|NCT03341104|Drug|Bupivacaine liposome|Replace bupivacaine with bupivacaine liposome
108093|NCT03341091|Other|Tai-chi group|The Tai-chi group received a 16-week 10-step simplified Tai-chi training programme in which additional measures were implemented to enhance participants' engagement.
108094|NCT03341078|Drug|Ibudilast|Ibudilast capsules will be orally ingested twice daily for 6 weeks.
108095|NCT03341078|Drug|Placebo Oral Tablet|Placebo capsules will be orally ingested twice daily for 6 weeks.
108096|NCT03341065|Device|exoskeleton type robot|
108097|NCT03341065|Device|end-effector type robot|
108098|NCT03341052|Other|Normal Diet|The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
108099|NCT03341052|Other|High Fat Diet|The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
108100|NCT03341052|Other|Low Fat Diet|The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
108101|NCT03341026|Other|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 4, 7 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
108102|NCT03341026|Other|Metronom CGM device|Patient receives three Metronom CGM devices on day 1. On day 1, 7, 10 and 14, a hypo- or hyperglycaemic experiment will start according to allocation by randomizer.
108103|NCT03341013|Drug|MEDI0382 Formulation 2|Sequence 1 Period 1 and Sequence 2 Period 2.
108104|NCT03341013|Drug|MEDI0382 Formulation 3|Sequence 1 Period 2 and Sequence 2 Period 1
108105|NCT03341000|Device|DISCSS Device|This pilot feasibility study will explore and help determine optimal settings and configuration of the DISCSS™ System with patients that have completed a percutaneous trial with a commercially available SCS trial system.
108106|NCT03340987|Procedure|vestibular incision subperiosteal tunnel access|vertical vestibular incision will be made down to the periosteum followed by creating a tunnel without reflecting the interdental papilla. Then a free gingival graft will be optained from the palate and de-epithelialized extraorally. The connective tissue graft will then be applied through the tunnel and the gingival margin will be sutured and the sutures will be fixed to the tooth surface by flowable composite. Then the vestibular incision will be sutured.
108107|NCT03340987|Procedure|Coronally advanced flap|Two horizontal incisions will be made mesial and distal to the recession area followed by two oblique incisions extended to the alveolar mucosa and a full-split thickness flap will be elevated. De-epithelialization will be done to receive the connective tissue graft obtained from the palate by de-epithelializing a free gingival graft. Then the flap will be advanced coronally aand sutured without tension
108108|NCT03340974|Drug|GC4419|90 mg GC4419 per day daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level, administered Monday - Friday over one week.
108109|NCT03340974|Drug|Placebo|Placebo daily (60 min IV infusion, prior to SBRT), concurrent with daily fractions of SBRT to assigned dose level, administered Monday - Friday over one week.
108110|NCT03340974|Radiation|Stereotactic Radiation Therapy (SBRT)|Dose-finding will be done using the sequentially adaptive phase I-II Late onset Efficacy-Toxicity (LO-ET) trade-off-based design.
108111|NCT03340961|Drug|DFD-29 Extended Release Capsules (40 mg)|Oral Treatment
108112|NCT03340961|Drug|DFD-29 Extended Release Capsules (20 mg)|Oral Treatment
108113|NCT03340961|Drug|Oraycea® (doxycycline) Capsules|Oral Treatment
108114|NCT03340961|Drug|Placebo Capsules|Oral Treatment
108115|NCT03340948|Behavioral|Mindfulness Based Stress Reduction (MBSR)|An 8-week course in mindfulness meditation, yoga training and weekly group support in the form of weekly 2,5 hour meetings at the hospital.
108149|NCT03340662|Drug|CC-122|CC-122
108150|NCT03340662|Drug|Itraconazole|CYP3A Inhibitor
108117|NCT03340922|Device|Automatic annotation of LAT (WF-method)|Automatic annotation of LAT during PVC activation mapping. Acquisition of points will be automatically performed using the Wavefront (WF) annotation tool integrated into CARTO navigation system.
108118|NCT03340922|Device|Manual annotation of LAT (M-method)|Conventional, manual annotation of LAT during PVC activation mapping. Acquisition of points will be performed using the CARTO navigation system by an expert electrophysiologist.
108119|NCT03340909|Drug|Prednisolone|Prednisolone tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
108120|NCT03340909|Other|Placebo|Placebo tablets initiated at 40 mg for three days, after which it will be phased out within 6 weeks after start
108121|NCT03340896|Drug|Docetaxel|Docetaxel 75 mg / m² administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion of one hour followed by cisplatin 75 mg / m² administered on day 1 hour infusion followed by 5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
108122|NCT03340896|Drug|Cisplatin|Cisplatin: 75 mg/m² for experimental arm and 100mg/m² for comparator arm administered on day 1 of each cycle every 3 weeks as an intravenous (IV) infusion.
108123|NCT03340896|Drug|Fluorouracil|5-FU, 750 mg / m² / day administered in continuous infusion from D1 to D5 (or 120 hours)
108124|NCT03340896|Radiation|radiotherapy|Radiotherapy : 70Gy (2Gy/day) for 7 weeks.
108125|NCT03340883|Biological|BION-1301|a solution for intravenous (IV) administration, diluted and administered Q2W
108126|NCT03340870|Drug|Sonazoid™|Single Dose of Sonazoid™ lipid-stabilised aqueous suspension of perfluorobutane (PFB) gas microbubbles.
108127|NCT03340857|Other|Intelligent electric bicycle (VELIS) sessions|Oncology patients will participate in intelligent electric bicycle (VELIS) sessions twice a week for 6 weeks after their release from a rehabilitation and recuperative care facility
108128|NCT03340844|Procedure|No Touch (NT)|Tumor resection by No-touch technique: dissection of hepatic hilum, dissection of superior mesenteric vein (SMV) in caudal aspect of pancreas, section of antrum, pancreatic neck section. Section-ligation of veins of duodenopancreatectomy part of SMV and portal. Then Kocher-uncrossing maneuver of the jejunal loop and final section of the retro-portal (back of the portal vein) blade.
108129|NCT03340844|Procedure|Superior Mesenteric Artery First (SMA)|Tumor resection by SMA technique: Kocher maneuver extends to the left renal vein (LRV). Dissection above the LRV of the SMA (refer to vessel-loop). Then, SMA will be identified on the caudal side of the pancreas (mesenterial root) and progressive dissection until its origin in the aorta artery (previously referenced with vessel loop).
108130|NCT03340831|Device|Continuous Glucose Monitoring (CGM)|Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)
108131|NCT03340818|Other|Bone Marrow Concentrate|Bone marrow concentrate is bone marrow harvested from the iliac crest and minimally processed in a centrifuge. It is then injected into the suspected painful disc (s) using fluoroscopic guidance
108132|NCT03340818|Other|Placebo|Injection of normal saline dorsal to the transverse process after sham bone marrow aspiration
108133|NCT03340805|Drug|Lactated Ringer|"LR is a sterile, nonpyrogenic balanced solution used for fluid and electrolyte replenishment via intravenous or intraosseous administration. Each 100 mL of LR contains 600 mg sodium chloride (NaCl), 310 mg of sodium lactate (C3H5NaO3), 30 mg of potassium chloride (KCl), and 20 mg of calcium chloride (CaCl2 · 2H20) with an approximate potential of hydrogen (pH) of 6.5 (6.0 to 7.5)."
108134|NCT03340805|Drug|Normal saline|"Normal saline solution is an unbalanced crystalloid solution containing 154 mEq/L of sodium and 154 milliequivalent (mEq/L) of chloride."
108135|NCT03340792|Device|Ambulation training utilizing an exoskeleton robot|Participants undergo 40 hours of ambulation training utilizing an exosksleton robot within 3 months.
108136|NCT03340779|Drug|Norepinephrine|After obtention of a mean arterial pressure (MAP) of 65 mmHg with infusion of norepinephrine, patients with cardiogenic shock receive for 3 hours either increasing doses of norepinephrine (with a maximal MAP of 85 mmHg) or dobutamine. There is a wash-out phase of 30 minutes (decrease of norepinephrine dose or weaning of dobutamine). The third phase of the study is the administration of the comparator treatment during 3 hours. After the 6.5 hours of the study, the hemodynamic management is up to the physician.
108137|NCT03340766|Drug|Blinatumomab|"Up to 2 cycles of Blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion. The dosing given is dependent on the cohort, and is as follows:~Cohort Ia: 9 microgram/day for 7 days followed by 28 microgram/day for the remainder of each cycle.~Cohort IIa: 9 microgram/day for 7 days followed by 28 microgram/day for 7 days followed by 56 microgram/day for the remainder of each cycle.~Cohort IIIa: 9 microgram/day for 7 days followed by 28 microgram/day for 7 days followed by 112 microgram/day for the remainder of each cycle.~The Maximum Tolerated Dose identified through this cohort design will then be tested in the expansion cohort."
108138|NCT03340766|Drug|Pembrolizumab|"One cycle of Pembrolizumab is a 200 milligrams intravenous injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.~Treatment start is dependent on the cohort:~Cohort Ia: Study day 15 (where blinatumomab treatment started on study day 1) Cohort IIa, IIIa: Study day 19 (where blinatumomab treatment stated on study day 1)"
108139|NCT03340753|Drug|KBP-5074 mineralocorticoid receptor antagonist|KBP-5074 (0.5 mg or 1.0 mg) in either capsule or tablet formulation, single dose, in a 2-period crossover design with a 2-week washout/follow-up period
108140|NCT03340740|Drug|Cetirizine Hydrochloride 1 MG/ML|Cetirizine oral suspension
108141|NCT03340740|Drug|Placebo - Concentrate|Similar-appearing liquid to cetirizine oral suspension
108142|NCT03340727|Drug|Caffeine Citrate|The study intervention is caffeine citrate given once daily at 10 mg/kg/day. It is given orally, before hospital discharge and 28 days after discharge.
108143|NCT03340727|Drug|Placebo|The study intervention is placebo given once daily at a volume equivalent to 10 mg/kg of caffeine citrate. It is given orally, before hospital discharge and 28 days after discharge.
108144|NCT03340714|Device|Monitoring Device|Wear ADAMM
108145|NCT03340701|Drug|vaginal progesterone suppository|200mg vaginal suppository micronized progesterone
108146|NCT03340688|Procedure|Cervical cerclage|Cervical cerclage indicated by short cervix ≤15mm
108147|NCT03340675|Drug|Ifetroban|Weight based, once daily oral ifetroban
108148|NCT03340675|Drug|Placebo|Matching oral placebo
108154|NCT03340623|Device|Venous coupler|A coupler can be used to perform a venous anastomosis. It is a double ring with pins on only one of its 2 faces. The technique consists in clamping the two veins, estimating the intima-to-intimal diameter of the vessels, choosing the coupler of the appropriate size, sliding the vein in the ring and evers the edges of the vessel to fix them on the pins, redo the same thing for the other vein and finally bring the two vessels together in order to clip them together.
108155|NCT03340610|Drug|Alflibercept|Intravitreal Injection
108156|NCT03340597|Drug|F901318|F901318 tablet
108157|NCT03340584|Other|the Nine Castle Net Format Taping|The intervention group received traditional rehabilitation and Taping throughout all rehabilitation period.The taping including a Nine Castle Net Format of taping in both side of surgery knee.We will exchange the new taping for every two days， for a week.Traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
108158|NCT03340584|Other|traditional rehabilitation|traditional rehabilitation included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 30 minutes each day, for a week.
108159|NCT03340558|Biological|Atezolizumab|Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1.
108160|NCT03340558|Drug|Cobimetinib|MEK inhibitor
108161|NCT03340545|Other|Custom Magnetic Resonance Elastography Device|Magnetic Resonance Elastography is an imaging method to measure mechanical properties of tissues.
108162|NCT03340532|Other|THE INFORMATION + APPEARANCE VIDEO|THE INFORMATION + APPEARANCE VIDEO which will include the full information video, along with an additional embedded video segment emphasizing negative appearance consequences of UV exposure.
108163|NCT03340532|Other|Information SunSmart video|The INFORMATION SunSmart video providing basic information about UV risks, including secondary skin cancer and the benefits of SP, as well as specific SP recommendations and steps to integrate SP as part of routine self-care for the healthy cancer survivor
108164|NCT03340532|Other|Sleep hygiene video|Contain information on better sleep hygiene
108165|NCT03340519|Device|MR Imaging|Novel MR imaging will be performed to provide bowel anatomic and functional data
108166|NCT03340506|Drug|dabrafenib|dabrafenib is available in capsules (50mg and 75mg) as well as in powder form for Oral Suspension (10 mg/mL dose) and taken twice a day
108167|NCT03340506|Drug|trametinib|trametinib is available in tablet (0.125mg, 0.5mg, 2mg dose) as well as in powder form for Oral Solution (0.05mg/mL dose
108168|NCT03340493|Drug|Tenecteplase|Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
108169|NCT03340480|Drug|NVP-1402|Oral
108170|NCT03340467|Device|CGM patch|Patient receives four CGM patches.
108171|NCT03340454|Other|Test-and-treat EHR-CHW intervention|a health systems-level intervention using electronic health record (EHR)-based tools to facilitate H. pylori test-and-treat strategies
108172|NCT03340454|Other|Usual care of EHR-only intervention|a community-engaged culturally and linguistically adapted CHW-led patient navigation program we are currently pilot testing for feasibility and acceptability.
108173|NCT03340441|Device|Prizma|sensor unit with mobile application installed on smartphone
108174|NCT03340428|Behavioral|Transition Community Adherence Club (TCAC)|A behavioral intervention targeting stigma and care challenges through care delivery, social capital through a group setting, improved job prospects through referrals and training, and substance use through referrals. Participants assigned to this group will meet at least every month in a group of 5-15 members for approximately 2 hours. During the meeting there will be facilitated group discussion, an interactive curriculum including life skills, economic skills, HIV and health, and disclosure and stigma. Individual health screening and distribution of prepackaged medications conclude the session. Individual referrals for specific services (e.g. mental health or substance use management) will be available.
108175|NCT03340415|Other|Accelerated Rehabilitation plan|early weight bearing after surgery
108176|NCT03340402|Radiation|Accelerated Partial Breast Irradiation|Proton radiation
108177|NCT03340402|Device|AlignRT|AlignRTTM uses infrared imaging to capture the 3D data of the patient's position to ensure accuracy of treatment delivery
108178|NCT03340389|Procedure|a ray-tracing aberrometry|The Dysfunctional Lens Index is obtained by a ray-tracing aberrometry
108179|NCT03340376|Drug|Atezolizumab|atezolizumab
108180|NCT03340376|Drug|Doxorubicin|Doxorubicin
108181|NCT03340363|Behavioral|environmental change|"Offer kid-friendly, low-cost recipes in a prominent, high-traffic location.~Offer healthy default ingredients (bundled ingredients promoted with recipes).~Promote recipe ingredients with prominently displayed signage and images.~Promote recipes in multiple locations throughout the store."
108182|NCT03340363|Behavioral|messaging|Short, behavioral messages sent to participants via text message or email each week to promote the in-store environmental changes
108183|NCT03340350|Drug|Minocycline|Minocycline capsule
108184|NCT03340337|Device|Neo-Russian|The subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.
108185|NCT03340337|Device|Aussie|The subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.
108186|NCT03340337|Device|RBS|The subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured.
108187|NCT03340337|Device|Fatigue Test|The subjects will receive a fatigue protocol that consists in 21 reps of electrical stimulation with the three types of current.
108188|NCT03340324|Biological|V-Endo|V-Endo is a tableted immunotherapeutic derived from hydrolyzed, heat-inactivated, pooled blood from women with endometriosis
108189|NCT03340311|Device|iHealth Wireless Smart Gluco- Monitoring System (BG5)|Over the course of 8 weeks, participants collected serum glucose logs (SGL) for 4 weeks using usual care followed by SGL's log for 4 weeks using Bluetooth-enabled glucometers and the iGluco application.
108190|NCT03340298|Dietary Supplement|fiber|the intervention of different sources of dietary fibers
108191|NCT03340285|Dietary Supplement|AkP06|first 2 weeks: Placebo + Diet then 4 weeks AkP06 two tablet/day before meals + Diet
108193|NCT03340259|Procedure|Exposure(s) of interest: enterostomy|Newborn infants with congenital malformations of the gastrointestinal tract, necrotizing enterocolitis, and spontaneous intestinal perforation commonly require surgery and enterostomy. In these infants samples of the enterostomy effluent will be collected and DNA extracted for microbiota identification.
108194|NCT03340246|Procedure|Delayed sclerotherapy|See arm descriptions
108195|NCT03340246|Procedure|Immediate phlebectomy|See arm description
108196|NCT03340233|Diagnostic Test|MRI (cardiac) off-label use gadolinium contrast (IND exempt)|Clinical MRI
108197|NCT03340233|Diagnostic Test|MRI (cardiac)|MRI without contrast
108198|NCT03340220|Drug|XPF-008|Capsule filled with XEN1101
108199|NCT03340220|Drug|Microcrystalline Cellulose|Placebo capsule
108200|NCT03340207|Device|Pneumaglide|The device is designed to facilitate intubation and reduce the time to intubation. It works with traditional glidescope to make the process of intubation easier. In this study patients scheduled for surgery and intubation, will be randomized to two groups. The intervention group will be intubated with the help of the pneumaglide. Yet, the other group will receive standard intubation. We aim to evaluate the efficacy of the Pneumaglide to improve the ease of intubation in unskilled clinicians and skilled clinicians during difficult and routine intubations
108201|NCT03340194|Radiation|Radiography|Radiography of the hand and feet (face incident) the day of the inclusion
108202|NCT03340194|Procedure|Veinous punction|Blood sample to analysis VEGF, endothelin 1, endostatin and P/GF, (ELISA method)
108203|NCT03340181|Other|RIPC|4 cycles of 5-min ischemia(using a blood pressure cuff inflated to 40mmHg over the patient's basic blood pressure) and 5-min repercussion are done on an upper limb before skin incision.
108204|NCT03340168|Other|Bisphenol-S|Oral and dermal exposure in volunteers
108205|NCT03340155|Other|Photo(chemo)therapy|Treatment with photo(chemo)therapy, including UVB, UVA, PUVA and photopheresis
108206|NCT03340142|Device|VIVO™|Diagnose the area of a PVC or VT onset
108207|NCT03340129|Drug|Ipilimumab|Ipilimumab 3mg per kg every 3 weeks for 4 doses
108208|NCT03340129|Drug|Nivolumab|Nivolumab 1mg/kg every 3 weeks for 4 doses, then 480mg every 4 weeks .
108209|NCT03340129|Radiation|Stereotactic Radiotherapy|1 fraction at between 16-22 Gy or 24-30 Gy hypofractionated for larger lesions.
108210|NCT03340129|Other|Salvage therapy|Any form of salvage therapy (surgery or radiotherapy) for intracranial disease progression, further disease control at any site, symptom control or treatment of cerebral haemorrhage or cerebral radionecrosis.
108211|NCT03340116|Procedure|Burn surgery|Burn surgery including wound debridement, skin grafting
108212|NCT03340116|Diagnostic Test|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100|Measurement of RBC volume, plasma volume, and total blood volume using Daxor BVA-100
108213|NCT03340103|Dietary Supplement|LUTEIN ofta 0,5 gocce|LUTEIN ofta 0,5 gocce, containing a solution of 5% Lutein and 2,25% Zeaxanthin with excipients (Corn starch, glucose, potassium sorbate, xanthan gum, citric acid)
108214|NCT03340103|Drug|Placebo|Placebo solution with unique excipients (Demineralised water, potassium sorbate, xanthan gum, citric acid)
108215|NCT03340090|Device|Medical Device Hemopatch-PEG-coated collagen patch|Two pieces of PEG-coated collagen patch Hemopatch will be applied in one patient. One piece to improve hemostasis in the bed of LIMA harvesting and second piece of Hemopatch will be placed beneath the sternum.
108216|NCT03340077|Other|Medicines Optimisation Review toolkit|The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
108217|NCT03340077|Other|Standard of Care|Pharmacist review of ART medications
108218|NCT03340064|Drug|Levetiracetam|Levetiracetam dry syrup 50% for oral administration and Levetiracetam solution for infusion (100 mg/mL).
108219|NCT03340051|Behavioral|Episodic Future Thinking (EFT)|EFT participants will generate positive future events they are looking forward to and that could happen at different future time points (e.g., in 2 weeks, 1 month, 6 months, 1 year). Participants will be instructed to use and think about their episodic cues as they make decisions.
108220|NCT03340051|Behavioral|Episodic Recent Thinking (ERT)|ERT participants will list positive recent events (events that have already happened) that they enjoyed that occurred at different past time points (e.g., 12 hours ago, 24 hours ago, a week ago). Participants will be instructed to use and think about their episodic cues as they make decisions.
108221|NCT03340038|Other|Non-ICU Specialty ward|
108222|NCT03340025|Device|PICO Single Use Negative Pressure Wound Therapy System|Class II negative pressure wound therapy powered suction pump
108223|NCT03340025|Device|xeroform gauze|traditional surgical dressing of xeroform gauze and padding
108224|NCT03340012|Device|GTR + radiation-sterilize allogenic bone graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and radiation-sterilized allogenic bone graft from the Central Tissue Bank in Warsaw
108225|NCT03340012|Device|GTR + xenogenic graft|Guided tissue regeneration of intrabony defects with collagen membrane (Bio-Gide® Perio, Geistlich Biomaterials) and xenogenic graft (Bio-Oss®, Geistlich Biomaterials)
108226|NCT03339999|Drug|AGN-242428|AGN-242428 administered as an oral capsule(s) once daily.
108227|NCT03339999|Drug|Placebo|Placebo administered as an oral capsule(s) once daily.
108228|NCT03339986|Behavioral|Reduction or Replacement|
108229|NCT03339973|Biological|allo-APZ2-PAOD|Suspension of ABCB5-positive mesenchymal stem cells in pre-filled syringe
108230|NCT03339973|Drug|Placebo|Solution for injection in pre-filled syringe
108231|NCT03339960|Other|Ergonomic measurement|Ergonomic measurement of the surgeon and assistant
108232|NCT03339947|Other|Questionnaire|
108233|NCT03339921|Drug|Botulinum toxin injections for chronic compartment syndrome|Botulinum toxin will be injected in the upper and lower portion of the affected area with a syringe
108234|NCT03339921|Procedure|surgical fasciotomy for chronic compartment syndrome|linear incisions will be made into the affected compartment releasing the underlying fascial layer, reducing the pressure of the compartment
108235|NCT03339908|Device|Thalamotomy by gamma Knife radiosurgery|The surgical procedure consists of a very partial radiation of the brain with stereotaxic precision
108236|NCT03339895|Other|pvı-guided|pvı- guided total amount of crystalloid volume of fluid infused during colorectal surgery pvı-guided(according to pvi value) fluid infused during whole procedure 2 ml/kg/h infusion during surgery If PVI value <%13 and if MAP>65mmHg continue with 2 ml/kg/h cristalloid infusion If PVI value <%13 and if MAP>65mmHg 5 mcg efedrin intravenous bolus till MAP>65 mmHg If PVI value >%13 and MAP>65 mmHg infuse 250 ml Gelofusine bolus up to PVI value lowers to %13 every 5 minute If PVI value >%13 and MAP <65 mmHg infuse 250 ml Gelofusine bolus and 5 mcg efedrin intravenous up to PVI value lowers to %13
108237|NCT03339895|Other|traditional-guided|traditional-guided total amount of crystalloid volume of fluid infused during colorectal surgery traditional-guided fluid infused during whole procedure 4-8 ml/kg/h infusion during surgery If MAP <65 mmHg or <30%of basal value, infuse 250 ml Gelofusine bolus and 5 mcg efedrin If MAP>65 mmHg no intervention
108238|NCT03339882|Drug|Remifemin|Remifemin 0.2g po bid*12 weeks at the beginning of the LHRH-a treatment
108239|NCT03339869|Other|Blood sample|The blood samples will be taken from the patient's bed and then sent to the clinical pharmacology laboratory of Prof. Blin (DRC, Bat F, Timone Hospital).
108240|NCT03339856|Device|Selective retina therapy|"The selective retina therapy (SRT) is a laser treatment to the retina using the R:GEN device (Lutronic, Goyang-si, South Korea).~Laser energy began at 80 µJ and was increased in 5-10 µJ intervals until the optimal energy delivery was confirmed by the RFD system. Following confirmation, the optimal laser energy was applied to fluorescein leakages. If the energy was indeed optimal at leakage points, laser shots were administered around the leakages. If the energy was not optimal at the leakage points, laser energy was again increased in 5-10 µJ increments until optimal energy delivery."
108241|NCT03339843|Drug|Abemaciclib|Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
108242|NCT03339817|Diagnostic Test|Polysomnography|During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.
108243|NCT03339804|Other|Chemotherapy|In chemoteraphy session, doxorubicin (60 mg/m2) and cyclophosphamide (600mg/m2) were administred in 45 min
108244|NCT03339791|Procedure|Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy. Technique: complete mobilization of the greater curvature and gastric fundus up to the angle of Hiss; stapling beginning at 3 to 4 cm away from the pylorus; bougie size 32 French; oversuture of the staple line; hiatoplasty in selected cases; routine drainage of the abdominal cavity
108245|NCT03339791|Procedure|Gastric Bypass|Laparoscopic Gastric Bypass. Technique: Pouch size 30 to 40 ml, biliopancreatic limb 70 to 100 cm, alimentary limb 100 to 120 cm, antecolic, routine closure of the mesenterial defects, routine drainage of the abdominal cavity
108246|NCT03339765|Behavioral|Strong Together serious game|The Strong Together serious game program is an interactive, immersive education program in which participants quickly learn the behaviors of self-advocacy and the potential consequences of self-advocating or not. Participants will receive weekly game sessions to play at home for three months.
108247|NCT03339752|Drug|Rosuvastatin|10 mg tablet
108248|NCT03339752|Drug|ACT-541468|25 mg hard capsule
108249|NCT03339739|Other|Isometric mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of soft clenching over three millimeters silicone bars bilaterally on molars
108250|NCT03339739|Other|Isotonic mandibular exercises|daily video guided three-minutes routine in 21 days (days of OC consumption) of isotonic dynamic contraction over calibrated cloth pegs on central incisors
108251|NCT03339739|Behavioral|Counseling group|subjects included in this group get an education brochure about the disorder and receive no further interventions
108252|NCT03339726|Drug|New Formulation Phenylephrine HCl|2 doses of one tablet 12 hours apart
108253|NCT03339726|Drug|Marketed Phenylephrine HCl|4 doses of one capsule 4 hours apart
108254|NCT03339726|Drug|Placebo|4 doses of placebo capsule and tablet taken 4 hours apart
108255|NCT03339713|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1*10^11 vp.
108256|NCT03339713|Biological|Fluarix|Fluarix will be administered as intramuscular injection.
108257|NCT03339713|Biological|Placebo|Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.
108258|NCT03339700|Drug|Gemcitabine|4800mg/m2, intravenous (IV), divided 4 days, 1200mg/m2/day, during days -5 to -2
108259|NCT03339700|Drug|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7 to -4.
108260|NCT03339700|Drug|Cyclophosphamide|80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
108261|NCT03339700|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
108262|NCT03339687|Behavioral|Experimental Mindset Induction|"This induction of a psychological state was extensively studied in cognitive science. Gollwitzer & Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list positive and negative, short- and long-term consequences of both deciding to act and not to act; indicating the probability of the occurrence of each of these consequences is required.~The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
108263|NCT03339674|Behavioral|Psychoeducational Group Intervention on Alcohol Drinking Related to Stress|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
108264|NCT03339674|Behavioral|Cognitive Training|Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
108265|NCT03339661|Drug|Group 1_No proph treatment|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
108266|NCT03339661|Drug|Group 2A_Proph treatment and γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. The occurrence of γδ T cells expansion during or at the end of secondary prophylaxis will define the group 2A.
108267|NCT03339661|Drug|Group 2B_Proph treatment and no γδ T cell expansion|After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, γδ T cell expansion will not be detected, so secondary prophylaxis will be initiated in continue during 3 months maximum. Patients who still not had γδ T cells expansion during or at the end of secondary prophylaxis will compose the group 2B.
108268|NCT03339648|Behavioral|Professional Development Enhancement|Professional development for SROs enhanced by content concerning trauma-informed care, cultural competency, restorative justice, and social-emotional learning.
108269|NCT03339635|Drug|Androgel (Testosterone gel)|Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
108270|NCT03339635|Drug|Placebo gel|Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
108271|NCT03339622|Combination Product|PPP001|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 9% THC / 2% CBD per pellet)
108272|NCT03339622|Combination Product|placebo|1 pellet smoked three times a day with titanium pipe (280 mg dried cannabis pellet - 0% THC / 0.6% CBD per pellet)
108273|NCT03339609|Diagnostic Test|Uroflow|Isolated uroflow measurement
108274|NCT03339609|Diagnostic Test|Uroflow/EMG|Uroflow measurement with superficial EMG testing of the pelvic floor
108275|NCT03339609|Diagnostic Test|US|Ultrasound of post void residual urine
108276|NCT03339596|Drug|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 4 times as intravenous infusions over 15 minutes.
108277|NCT03339596|Drug|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
108278|NCT03339583|Behavioral|Brief behavioral therapy|"program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording Relaxation and refreshment session for insomnia created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off."
108279|NCT03339583|Drug|Zopiclone|zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
108280|NCT03339557|Device|NexGen|Comparing two conventional designs and one novel design
108281|NCT03339557|Device|Persona|Comparing two conventional designs and one novel design
108282|NCT03339557|Device|PFC|Comparing two conventional designs and one novel design
108283|NCT03339544|Drug|Celebrex premedication|celebrex (celecoxib) 200mg is a non-steroidal anti-infalmmatory drug with selective COX-2 inhibition.
108284|NCT03339544|Drug|Placebo|placebo is given as a tablet before initiation of endodontic treatment
108285|NCT03339531|Radiation|2D radiotherapy|
108286|NCT03339518|Behavioral|BRIM3 educational intervention|Breast Cancer risk education and counseling
108287|NCT03339518|Behavioral|Wait List|Booklet at the end of study
108288|NCT03339505|Dietary Supplement|Salovum|Dietary supplement with high concentration of anti-secretory factor
108289|NCT03339505|Dietary Supplement|Placebo|Placebo for Salovum
108290|NCT03339492|Device|RCStim Model 1114|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
108291|NCT03339479|Diagnostic Test|dielectric property test|Test the dielectric property of resected lung nodules/mass through a touching probe after the lung tissue with nodules/mass has been resected and cut open, which usually takes only 1-5 minutes.
108292|NCT03339479|Diagnostic Test|frozen pathological examination|And after the dielectric property test, the lung tissue will be sent for frozen pathological examination.
108293|NCT03339479|Diagnostic Test|final pathological examination|All of the lung nodules/mass will be diagnosed by final pathological examination and recognized as the final diagnosis after surgery.
108294|NCT03339466|Device|Inspiratory muscle therapy|6 weeks of inspiratory muscle therapy
108295|NCT03339453|Drug|Nasal Glucagon|Administered nasally
108296|NCT03339453|Drug|Intramuscular Glucagon|Administered IM
108297|NCT03339440|Behavioral|Hearts & Parks|The Hearts & Parks intervention will be looking to evaluate how different types of physical activity and nutrition education and support (in addition to normal clinical care) through attendance and participation in the Duke Healthy Lifestyles/Bull City Fit clinic/community program, affect children's health. The investigators will be looking at changes in BMI, physical activity, nutrition and overall health.
108298|NCT03339427|Other|vitamin D|different doses of vitamin D supplementation
108299|NCT03339427|Other|control|control group
108300|NCT03339414|Other|collect blood|collect blood at different time point
108301|NCT03339401|Other|Standard of Care|SOC per study center guidelines
108302|NCT03339401|Drug|Brincidofovir|BCV
108303|NCT03339375|Device|esophageal Doppler|Goal directed fluid therapy using dynamic parameters from esophageal Doppler
108381|NCT03338751|Diagnostic Test|cognitive testing with HAD (PockeTalker) First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
108304|NCT03339362|Procedure|Active Procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Active: 4 X-ray guided intra-articular lumbar facet-joint injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml bupivacaine + 20mg methylprednisolone per joint"
108305|NCT03339362|Procedure|Sham procedure|"If they pass the diagnostic injection with a 50% or more in pain reduction, they are randomised to receive either the active procedure or sham procedure.~Sham: 4 X-ray guided peri-articular injections via a spinal needle at 2 bilateral lumbar levels using 0.5ml of 0.9% sodium chloride per joint."
108306|NCT03339349|Drug|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
108307|NCT03339336|Drug|BIIB074|Administered as specified in the treatment arm.
108308|NCT03339336|Drug|Placebo|Administered as specified in the treatment arm.
108309|NCT03339323|Other|Exercise|TKA patients do the exercise intervention
108310|NCT03339310|Device|Optimizer Smart System with 2-leads|The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
108311|NCT03339297|Drug|Defibrotide|6.25 mg/kg via 2-hour IV infusion every 6 hours
108312|NCT03339297|Drug|Standard of Care|Administered according to local institutional guidelines, physician preference, and patient need.
108313|NCT03339284|Drug|Dexamethasone sodium phosphate|Dexamethasone injection
108314|NCT03339284|Drug|Ropivacaine Hydrocloride|Ropivacaine injection
108315|NCT03339284|Drug|Sodium Chloride 9mg/mL|Sodium Chloride injection
108316|NCT03339271|Behavioral|Technology-Enhanced Support|The study nurse will meet with the caregiver daily until patient is discharged from the hospital. The caregiver will take home an iPad upon discharge, and will have an initial video chat with the study nurse within 24-48 hours of hospital discharge and weekly for 8 weeks after that.
108317|NCT03339271|Behavioral|Usual Care Support|The patient's doctor and nurses with input from the Palliative Care service will help the caregiver make a plan for discharge of the patient, and for taking care of the patient upon discharge. Someone from the study team will call the caregiver once a month for the duration of the study after the patient discharges from the hospital.
108318|NCT03339258|Drug|Doxazosin Mesylate, Extended Release|Doxazosin is FDA-approved for the treatment of hypertension and urinary outflow problems associated with benign prostatic hyperplasia. The immediate-release formulation is approved for use from 1mg up to 16mg. Based on drug company information and Micromedex, the SFVA pharmacy on-line reference resource for drug information, the only contraindication to use of doxazosin is hypersensitivity to doxazosin, its contents, or other quinazolines (e.g. prazosin, terazosin).
108319|NCT03339258|Drug|Placebo|Placebo, or inactive pill.
108320|NCT03339245|Other|Fructose Solution (75 Grams)|Fructose given in divided doses at breakfast and dinner.
108321|NCT03339245|Other|Glucose Solution (75 grams)|Glucose given in divided doses at breakfast and dinner.
108322|NCT03339232|Dietary Supplement|BCAA Supplement|Each teaspoon contains 1788 mg of BCAA and participants will take 7 teaspoons (12.5 grams of BCAA) per day divided into three separate servings. Each teaspoon contains L-leucine, isoleucine and valine in a 2:1:1 ratio.
108323|NCT03339232|Other|Physical Activity|Supervised low impact aerobic physical activity for one hour each week.
108324|NCT03339219|Drug|Cabozantinib|Cabozantinib tablets
108325|NCT03339206|Behavioral|Constituent message with FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm will also include an FDA logo, and information about the benefits of quitting smoking and the quitline. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
108326|NCT03339206|Behavioral|Constituent message without FDA and quitline|Messages about the chemical constituents of cigarette smoke will include text about chemicals in cigarette smoke and health effects of the chemicals, and an image of a person related to the health effect. This arm is identical to the arm above, except that it does not include FDA source or quit information. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
108327|NCT03339206|Behavioral|Littering message (Control)|Messages about littering cigarettes will include text designed to discourage people from littering their cigarette butts, and an image related to the message. Each condition has 5 messages that will be repeated 3 times in a counterbalanced order. Study investigators used text developed by investigators associated with our Center for Regulatory Research on Tobacco Communication. Design of these messages was developed by our team.
108328|NCT03339193|Device|Left atrial appendage closure|Percutaneous insertion of a Watchman FLX left atrial appendage closure device under general anesthesia with transesophageal echo guidance.
108329|NCT03339167|Dietary Supplement|Metabolic availability of lysine in millet|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from millet and 1 level from millet with lentils.
108330|NCT03339154|Other|Dietary Intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from chickpeas and 3 levels from chickpeas with rice.
108331|NCT03339141|Procedure|Intubation position|The investigators assess two different patient's intubation position : supine position and 25° head-up position looking at the intubation score (POGO score).
108332|NCT03339128|Drug|Eluxadoline|Oral tablets
108333|NCT03339128|Drug|Placebo|Oral tablets
108334|NCT03339115|Device|Cardiovalve Transfemoral Mitral Valve|The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
109672|NCT03329248|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
108335|NCT03339076|Device|"M3 MINI CATHETER"|"Participants in the study are using either a foley catheter or Clean Intermittent Catheter devices to facilitate bladder drainage. The study is an alternative method of facilitating bladder drainage with the M3 Mini Catheter."
108336|NCT03339050|Behavioral|Health for Hearts United|The intervention was framed around three conceptual components (awareness building, clinical learning, and efficacy development), and four types of programming (church-initiated, joint programming, standard programming (culturally tailored post cards and newsletters), and data collection health promotion (generic materials, clinical sessions with an Registered Dietitian). Key messages were identified for the intervention including eating better, moving around more, reducing stress, and taking charge of your health.
108337|NCT03339037|Device|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
108338|NCT03339037|Device|Normobaric air SHAM|60 sessions at 1 ATA 21% oxygen (air)
108339|NCT03339024|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
108340|NCT03339024|Other|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30 Day 30 - 12 months: No further oxytocin treatment, i.e. treatment-as-usual.
108341|NCT03339011|Behavioral|Motivational SMS text message|Motivational text messages delivered to the participants' mobile phones. The text messages contain motivational text and advice on physical activity.
108342|NCT03338998|Drug|BAF312|Supplied as an i.v. solution for days 1 through 7 and as a tablet for days 8 through 14
108343|NCT03338998|Drug|Placebo|Supplied as an i.v. solution for days 1 through 7 and as tablets for days 8 through 14
108344|NCT03338985|Genetic|Genetic analysis|Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
108345|NCT03338972|Biological|Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143|Given IV
108346|NCT03338972|Drug|Cyclophosphamide|Given IV
108347|NCT03338972|Drug|Fludarabine|Given IV
108348|NCT03338972|Other|Laboratory Biomarker Analysis|Correlative studies
108349|NCT03338972|Procedure|Leukapheresis|Undergo leukapheresis
108350|NCT03338959|Biological|Pembrolizumab|Given IV
108351|NCT03338959|Radiation|Radiation Therapy|Undergo radiation therapy
108352|NCT03338946|Device|CIED interrogation|CareLink Express interrogation
108353|NCT03338933|Behavioral|magnetic resonance imaging (MRI)|All subjects will undergo a baseline MRI and subjects in both alcohol groups (alcohol use disorder and combined alcohol and nicotine use disorder) will undergo a followup MRI 3 months after baseline.
108354|NCT03338920|Drug|sumatriptan nasal powder|nasal powder administered via nosepiece
108355|NCT03338920|Drug|Placebo|lactose monohydrate powder administered via nosepiece
108356|NCT03338907|Drug|Oxycarbon (5% CO2+ 95% O2)|Oxycarbon will be administered by mechanical ventilation
108357|NCT03338894|Behavioral|Yoga|1 Hour yoga class
108358|NCT03338881|Drug|[14C]-TAK-659|[14C]-TAK-659 solution.
108359|NCT03338881|Drug|TAK-659|TAK-659 tablets.
108360|NCT03338868|Other|Body composition|evaluated by Bodystat®1500 Bio-impedance Analyzer
108361|NCT03338868|Other|Physical activity level|assessed by the International Physical Activity Questionnaire-7
108362|NCT03338868|Other|Musculoskeletal pain intensity|evaluated with Visual Analog Scale
108363|NCT03338868|Other|Quality of life|assessed by the Nottingham Health Profile
108364|NCT03338868|Other|Psychological Well-Being|assessed by the Hospital Anxiety and Depression Scale
108365|NCT03338868|Diagnostic Test|Blood tests|Blood tests included serum glucose, triglyceride, high-density lipoprotein cholesterol (HDL-C), and uric acid levels. Blood samples were collected from the patients after one night of fasting.
108366|NCT03338855|Drug|Dapagliflozin|"The study consist of 5 weeks treatment period 1, 6-8 weeks wash-out period and 5 weeks treatment period 2.~The patient will be administered dapagliflozin 10 mg during Period 1 or Period 2."
108367|NCT03338842|Device|Distractor and Lower limb VR|In the first phase (A), subjects will receive the Distraction VR treatment during 5, 6, or 7 one-hour-long sessions occurring twice weekly. After the A phase, the remaining sessions (B phase) will consist of Lower-Limb VR treatment. This number includes a mean of 6 (range 5-7) phase A sessions and mean of 11 (range 10-12) phase B sessions.
108368|NCT03338829|Behavioral|Positive incentive|Compensation is paid for each glucose test completed
108369|NCT03338829|Behavioral|Loss aversion|Fixed compensation is offered to patients and they can earn a range of compensation at the completion of pregnancy depending on overall glucose testing adherence
108370|NCT03338816|Drug|Givosiran|by subcutaneous (SC) injection
108371|NCT03338816|Drug|Placebo|Sterile Normal Saline (0.9% NaCl)
108372|NCT03338803|Drug|Linagliptin|drug
108373|NCT03338790|Biological|Nivolumab|Specified dose on specified day
108374|NCT03338790|Drug|Docetaxel|Specified dose on specified day
108375|NCT03338790|Drug|Enzalutamide|Specified dose on specified day
108376|NCT03338790|Drug|Rucaparib|Specified dose on specified day
108377|NCT03338790|Drug|Prednisone|Specified dose on specified day
108378|NCT03338777|Biological|Suicide plus immunogene therapy|"Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.~Treated simultaneously with a subcutaneous vaccine produced with:~Formolized allogeneic tumor extracts and,~Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each)."
108379|NCT03338764|Drug|SM-1|SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam self-administered as needed to promote sleep
108380|NCT03338764|Drug|Placebo|Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials, self-administered as needed to promote sleep
108697|NCT03336333|Drug|Zanubrutinib|Zanubrutinib will be administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
108382|NCT03338751|Diagnostic Test|Cognitive testing without HAD First|tablet, loaded with REDCap will generate a random number that determines the order of test administration with the HAD first or second.
108383|NCT03338738|Diagnostic Test|Stool culture ans swab|"Patients with ESBL enterobacteria, antibiotic pressure are patients with ESBL positive result diagnosed by stool culture and a rectal swab.~The intervention correspond to addition of 4 stool samples (or 4 rectal swabs in the absence of stool emission) and a blood sample."
108384|NCT03338725|Other|Clinical pharmacy model|Patients who are being monitored by a clinical pharmacy model
108385|NCT03338699|Device|ShangRing|Topical anesthesia based, no-flip ShangRing circumcision.
108386|NCT03338699|Device|Mogen clamp|Mogen clamp circumcision
108387|NCT03338686|Procedure|Free Gingival Graft (FGG)|Free Gingival Graft (FGG) was performed on all study sites in this arm.
108388|NCT03338686|Procedure|Connective Tissue Graft followed by Laser Gingivoplasty|Connective Tissue Graft followed by Laser Gingivoplasty one month later on all study sites in this arm.
108389|NCT03338673|Device|tDCS|tDCS is a non-invasive procedure in which electrodes are attached to the scalp and send a small direct current to stimulate brain function
108390|NCT03338673|Other|BrainHQ|BrainHQ is a web-based, commercially available cognitive training program that includes exercises to enhance working memory
108391|NCT03338660|Biological|Infusion of Platelets|Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).
108392|NCT03338660|Biological|Infusion of Platelets|Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.
108393|NCT03338660|Biological|Placebo|Subjects will receive infusion placebo (saline).
108394|NCT03338647|Drug|DEB|Infusion of DEB or doxorubin/lipiodol through catheter in the hepatic artery
108395|NCT03338647|Radiation|SBRT|High precision radiation therapy to the liver tumor(s)
108396|NCT03338621|Drug|Pretomanid|200 mg tablets
108397|NCT03338621|Drug|Bedaquiline|100 mg tablets
108398|NCT03338621|Drug|Moxifloxacin|400 mg tablets
108399|NCT03338621|Drug|Pyrazinamide|500 mg tablets
108400|NCT03338621|Drug|HRZE|isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets
108401|NCT03338621|Drug|HR|isoniazid 75 mg plus rifampicin 150 mg combination tablets
108402|NCT03338608|Procedure|Anterior Cervical Decompression and Fusion|Patients will receive the anterior cervical decompression and fusion as part of their standard of care. They will be randomized to either receive the vertical or transverse platysma incision.
108403|NCT03338608|Procedure|Vertical Platysma Incision|A vertical platysma Incision will be used for the anterior cervical decompression and fusion surgical procedure
108404|NCT03338608|Procedure|Transverse Platysma Incision|A transverse platysma incision will be used for the anterior cervical decompression and fusion surgical procedure
108405|NCT03338569|Drug|Vitamin C|Continuous infusion of vitamin C
108406|NCT03338569|Drug|Placebo|Placebo designed to mimic intervention
108407|NCT03338556|Drug|PrEP-001|
108408|NCT03338556|Other|Placebo|
108409|NCT03338543|Device|PENS|percutaneous electrical nerve stimulation
108410|NCT03338543|Device|TENS|transcutaneous electrical nerve stimulation
108411|NCT03338530|Behavioral|Comprehensive School-Based Intervention|School staff administered the 5 components during the school year. Social Skills Groups were conducted 2-3x/wk. for a total of 60-90 min./wk.; each group contained 3-6 students with social impairments. The Individual Daily Note was administered across the school day to reinforce new skills and reduce problem symptoms. Students' performance on targets was linked to home rewards. Mind Reading computer instruction targeting emotion recognition skills was conducted 3x/wk. for a total of 60 min./wk. Therapeutic Activities were conducted 2x/wk. for a total of 40-60 min./wk.; these cooperative activities were designed to practice targeted skills. Parent Training was conducted 1x/month for 60-90 min./session in order to increase home-school communication and integrate the CSBI across settings.
108412|NCT03338517|Other|Helium Neon Laser|
108413|NCT03338504|Diagnostic Test|Invasive coronary angiography|Where patients are fit, coronary angiography will be performed via the femoral or radial artery with 6F arterial catheters. In patients with one or more stenoses in a major epicardial vessel, a coronary pressure guidewire (PressureWire™ Aeris™, St. Jude Medical, St. Paul, Minnesota) will be used to determine distal coronary pressure and the fractional flow reserve (FFR) calculated at maximal adenosine-induced (intravenous 140 μg/kg/min) hyperaemia. Optical coherence tomography (OCT) will be performed in all three coronary vessels using a Dragonfly® coronary imaging catheter (Abbott Diagnostics, Abbott Park, Illinois) with pullback at 20 mm/s to identify features consistent with vulnerable plaque or recent plaque rupture.(16) If there is evidence of inducible myocardial ischaemia due to coronary artery stenosis, revascularisation with percutaneous coronary intervention may be considered if in the patients best interests.
108414|NCT03338504|Radiation|CT coronary angiography|CT coronary angiography will be performed using a 128 multidetector row CT. Patients with a heart rate exceeding 65 beats/min will receive oral beta-blockade 1 hour before computed tomography. Additional intravenous beta blockers will be given depending on heart rate at the time of imaging. All patients will receive sublingual glyceryl trinitrate (300 μg) immediately prior to dual cardiac and respiratory-gated computed tomography imaging of the coronary arteries. The investigators will quantify total plaque burden using CT calcium scoring. A bolus of 80-100 mL of contrast will be injected intravenously at 5 mL/s. An assessment of the functional consequences of coronary artery stenosis will be made using the computed tomography fractional flow reserve (CT-FFR) technique, using the HeartFlow platform.
108442|NCT03338309|Other|Instantaneous wave-free ratio measurement|Instantaneous wave-free ratio measurement in order to evaluate functional significance of epicardial stenosis
108443|NCT03338296|Drug|lorcaserin hydrochloride XR|oral tablet
108444|NCT03338296|Drug|Placebo|oral tablet
108556|NCT03337399|Other|Early Integrated PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
108802|NCT03335540|Biological|Relatlimab|Specified dose on specified day
108415|NCT03338504|Diagnostic Test|Cardiac MRI|Cardiovascular magnetic resonance (CMR) will be performed using a 3T scanner. The MRI scan will consist of localisers, axial and coronal HASTE images, standard breath-held and ECG-gated cine sequences. Short-axis cine images will be obtained for the assessment of left ventricle function and volumes. Left ventricle volumes, mass and ejection fraction will be assessed using dedicated software and values indexed to body surface area. Breath-held, ECG-gated T2 mapping sequences of the myocardium will be performed in the short-axis as a marker of myocardial inflammation. T1-weighted imaging of the coronary arteries will be performed to look for evidence of recent intraplaque thrombus or haemorrhage. The late gadolinium enhancement and T2 mapping techniques will identify regions of new or old myocardial infarction as well as other patterns of injury. Where there are no contraindications, stress MRI will be performed using intravenous Regadenoson.
108416|NCT03338491|Behavioral|Induction of Implemental Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer & Keller (2016, p.3): The implemental mindset is evoked by asking participants to think of a personal project for which they have already made the decision to act but did not initiate any action yet. Subsequently, participants are asked to list the steps necessary for successful goal attainment and to plan out in detail when, where, and how they intend to act on each of these steps."
108417|NCT03338491|Behavioral|Induction of Deliberative Mindset|"This induction of a psychological state was extensively studied in basic cognitive science. Gollwitzer & Keller (2016, p.3): The deliberative mindset is evoked by asking participants to (a) name an unresolved, important personal problem that is causing rumination but for which they have not made a decision yet and (b) reflect on whether to take action or not. Further, to enhance the depth of reflection, participants are requested to list a number of positive and negative, short- and long-term consequences of both deciding to act and deciding not to act; indicating the probability of the occurrence of each of these consequences is required."
108418|NCT03338478|Diagnostic Test|Wii Balance Board|Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
108419|NCT03338465|Device|Duolith SD1, STORZ Medical, Switzerland with F-SW applicator|The procedure will be performed with the patient in lateral positioning of the decubitus. The treatment area will be prepared with a coupling ultrasound gel to minimize the loss of shockwave energy at the interface between the tip of the applicator and the skin. The inline ultrasonic guide will be used to concentrate the shockwaves on the pain area in the trochanteric region. No local anesthesia will be applied.
108420|NCT03338452|Behavioral|Low energy ketogenic diet|Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
108421|NCT03338439|Device|CSII|This retrospective, observational trial will evaluate 104 diabetic patients with prior treatment with MDI initiating CSII therapy compared to 109 diabetic patients continuing MDI.
108422|NCT03338426|Drug|Fimasartan 120mg|Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
108423|NCT03338426|Drug|Atorvastatin 40mg|Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
108424|NCT03338426|Drug|Placebo for Fimasartan 120mg|Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period
108425|NCT03338426|Drug|Placebo for Atorvastatin 40mg|Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period
108426|NCT03338413|Behavioral|Goal Management Training|9 GMT modules will be administered in 9X2 hour sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving.
108427|NCT03338413|Behavioral|Computerized Cognitive Training|9 modules will be administered in 9x1 hour session (ten groups). Computerized Cognitive Training using commercially available web-based platforms based on neuroplasticity, developed to target skills such as attention, memory, speed of processing and executive functioning. Homework assignment between sessions.
108428|NCT03338400|Drug|Dexamethasone|Patients will be randomized to Dexamethasone arm will receive 8mg (2ml) of Dexamethasone at the time of induction.
108429|NCT03338400|Drug|Normal saline|Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
108430|NCT03338387|Drug|Acipimox|Acipimox
108431|NCT03338387|Drug|Placebo|Placebo Other Names: Placebo (for Olbetam)
108432|NCT03338374|Device|Biventricular pacemaker|All subjects will receive a biventricular pacemaker at implantation. Programming will initially be to dual-chamber, dual-function rate-responsive pacing for 12 weeks; following reassessment, device will be reprogrammed to biventricular pacing for a further 12 weeks. Optional study extension: if incremental benefit is shown for biventricular pacing above dual chamber, the mechanism will be sought using echocardiographic evidence and the devices will be optimised according to this mechanism of action to see whether further benefit can be achieved.
108433|NCT03338361|Behavioral|active approach avoidance training and sham visual probe training|patients receive active AAT training and sham VPT training
108434|NCT03338361|Behavioral|sham approach avoidance training and active visual probe training|patients receive sham AAT training and active VPT training
108435|NCT03338361|Behavioral|active approach avoidance training and active visual probe training|patients receive active AAT training and active VPT training
108436|NCT03338361|Behavioral|sham approach avoidance training and sham visual probe training|patients receive sham AAT training and sham VPT training
108437|NCT03338348|Drug|Vosaroxin|Cycle 1-8: Dose Level 0: 70mg/m², Dose Level -1: 50mg/m², Dose Level -2: 40mg/m², IV over ten minutes, d 1+4 .
108438|NCT03338348|Drug|Azacitidine|"Cycle 1-8 Azacitidine: 75 mg/m²/d subcutaneously, d 1-7;~Maintenance with single agent azacitidine at 75 mg/m²/d on days 1-7 until relapse or progression."
108439|NCT03338335|Drug|prolonged DAPT|Dual antiplatelet therapy will be prescribed for more than 12 months
108440|NCT03338322|Device|Twisted file adaptive|Endodontic files that are used in preparation of root canals with adaptive motion
108441|NCT03338322|Device|Reciproc|Endodontic files that are used in root canal preparation with reciprocation motion
108803|NCT03335540|Biological|Cabiralizumab|Specified dose on specified day
108445|NCT03338283|Other|Electromassage|Electro-massage that will be performed by a specialist physiotherapist with more than 8 years of experience We use ENDOMED 482 (Enraf Nonius, Spain) for the elecro-massage. the current parameters are: frequency shift at 4000 Hz IFC, 100 Hz AMF in CV mode. We will gradually raise the current intensity until reaching a high level, but not so high as to cause pain or discomfort, nor evident muscle contraction, although a gentle vibration is allowed. The electro-massage was performed on the musculature of the shoulder and neck.
108446|NCT03338283|Other|Conservatory treatment|The control protocol will combine: (a) thermotherapy with infrared application; (b) active, self-assisted and isometric shoulder exercises, including Codman's pendulum exercises; (c) manual therapy, always in a pain-free range of movement; and (d) ultrasound in pulsatile mode over the acromium and scapulohumeral area.
108447|NCT03338270|Diagnostic Test|MRI|MRI sequence without intravenous contrast
108448|NCT03338257|Behavioral|Husky Reads Intervention|The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
108449|NCT03338244|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
108450|NCT03338244|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
108451|NCT03338218|Drug|Volulyte 6%|Solution for infusion
108452|NCT03338218|Drug|Ionolyte|Solution for infusion
108453|NCT03338205|Drug|Ketamine|1 mg/kg ketamine bolus IV
108454|NCT03338192|Other|QST|All participants will undergo quantitative sensory testing for assessment of endogenous pain modulation using painful heat, mechanical, and cold stimuli in a laboratory session lasting approximately 1 hour.
108455|NCT03338179|Behavioral|Judgement of learning evaluation|The hardware consists of two lists of 30 pairs of French words, each pair of words being composed of a word index and a target word (names of concrete objects). Among the 60 word pairs, 30 are strongly associated items (or easy items, the other 30 being weakly associated or difficult items.
108456|NCT03338166|Other|LDH serum level|Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome
108457|NCT03338127|Diagnostic Test|renal function test|2 ml blood sample to be investigated for renal function test
108458|NCT03338114|Drug|FLX-787-ODT (orally disintigrating tablet)|Oral Disintegrating Tablet
108459|NCT03338075|Radiation|fractionated stereotactic radiotherapy|The regular prescription doses were 52 Gy in 13 fractions or 52.5 Gy in 15 fractions.
108460|NCT03338062|Diagnostic Test|Hepatobiliary Iminodiacetic Acid (HIDA) scan|Hepatobiliary Iminodiacetic Acid (HIDA) scan will be performed for radiation treatment planning, midway through radiation treatment, and at 3, 6 and 12 months after completion of radiation treatment in addition to standard of care imaging.
108461|NCT03338062|Diagnostic Test|MRI with Eovist contrast|MRI with Eovist contrast will be performed for radiation treatment planning, midway through radiation treatment, and at 3, 6 and 12 months after completion of radiation treatment in addition to standard of care imaging.
108462|NCT03338049|Device|Veran System|Electromagnetic navigation bronchoscopy and electromagnetic navigation transthoracic needle aspiration
108463|NCT03338036|Device|Heart Rate Variability Biofeedback|HRV biofeedback constitutes initial training with the android device and application, and HRV training performed at home. This training will occur twice daily, and each session will take five minutes.
108464|NCT03338036|Device|Neurofeedback|LORETA Z-Score neurofeedback training will occur three times per week with a trained study investigator.
108465|NCT03338023|Drug|LY2963016|Administered SC
108466|NCT03338023|Drug|Lantus®|Administered SC
108467|NCT03338023|Drug|Insulin Lispro|Administered SC
108468|NCT03338010|Drug|LY2963016|Administered SC
108469|NCT03338010|Drug|Lantus®|Administered SC
108470|NCT03337997|Procedure|Irreversible Electroporation|Open Irreversible Electroporation by ultrasound guidance for tumors under 3 cm in diameter. Goal is to obtain an Amp rise of 12 or more
108471|NCT03337971|Dietary Supplement|PLACEBO|A food-grade proprietary product containing corn starch in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
108472|NCT03337971|Dietary Supplement|MBPM|A food-grade proprietary product containing per 100g; milk protein (46.4%), carbohydrate (40.6%), fat (0.7%), Vitamin D (2ug); calcium (1840mg) in powder form, flavoured and instantised to be dissolved in water. Supplied by Dairygold Ingredients, Mitchelstown, Co Cork, Ireland
108473|NCT03337958|Device|Ventilatory re-education|The first day of intervention consisted primarily in ventilatory re-education. During the realization of the technique he was videotaped with a Tablet so that later the patient could be seen and on the video to be able to give him the guidelines for the correction. On the second and third day of the intervention, ventilation re-education was performed and the inhalation technique was subsequently trained.
108474|NCT03337945|Drug|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
108475|NCT03337932|Drug|Doxycycline 100 milligram Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
108476|NCT03337932|Drug|Doxycycline 100 milligram Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
108477|NCT03337932|Drug|Controls without a history of lyme disease.|No intervention.
108478|NCT03337919|Drug|Nivolumab|Up to 8 cycles of nivolumab
108479|NCT03337906|Other|Observation|
108480|NCT03337893|Diagnostic Test|blood pressure|it will be done both right and left arms
108481|NCT03337880|Other|instrumental delivery|the birth was assisted with an extractor.
108482|NCT03337867|Device|Magstim Super Rapid2 System|Intermittent theta-burst-stimulation (iTBS) protocol
108483|NCT03337867|Device|Magstim Super Rapid2 System|Sham stimulation
108484|NCT03337841|Drug|Pembrolizumab|Each subject will receive administration of pembrolizumab 200mg IV once only before curative treatment such as hepatic resection or radiofrequency ablation, and will receive curative treatment after administration of pembrolizumab. After curative treatment, each subject will receive pembrolizumab 200mg IV every 3 weeks. Treatment will continue until tumor recurrence, occurrence of an unacceptable adverse event, or the 16th treatment with pembrolizumab.( The setting of 16 times administration is the period of adjuvant therapy of this trial is 12 month(=48weeks), administration of pembrolizumab is Q3W, so 16 times administration comes to 48 weeks.)
108485|NCT03337828|Other|Alcohol-free beer with regular composition|Subjects are provided with 2 alcohol-free beers with regular carbohydrates composition per day and healthy diet counselling during 10 weeks.
108486|NCT03337828|Other|Alcohol-free beer with modified composition|Subjects are provided with 2 alcohol-free beers with modified carbohydrates composition per day and healthy diet counselling during 10 weeks.
108487|NCT03337815|Drug|Treatment of MTX and TwHF placebo|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg,3 times a day, oral, for 24 weeks.
108488|NCT03337815|Drug|Treatment of TwHF and MTX placebo|Tripterygium wilfordii Hook F（TwHF)：20mg,3 times a day, oral, for 24 weeks.Methotrexate (MTX)placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
108489|NCT03337802|Behavioral|mediterranean diet|The Mediterranean diet (MD) is highly regarded as a healthy balanced diet. It is distinguished by a beneficial fatty acid profile that is rich in both monounsaturated and polyunsaturated fatty acids, high levels of polyphenols and other antioxidants, high intake of fiber and other low glycemic carbohydrates, and relatively greater vegetable than animal protein intake. Specifically, olive oil, assorted fruits, vegetables, cereals, legumes, and nuts; moderate consumption of fish, poultry, and red wine; and a lower intake of dairy products, red meat, processed meat and sweets characterize the traditional MD.
108490|NCT03337789|Dietary Supplement|Polygonatum sibiricum|Polygonatum sibiricum 800mg, 30-60 minutes before sleep, once a day for 4 weeks
108491|NCT03337789|Dietary Supplement|Placebo|Placebo 800mg, 30-60 minutes before sleep, once a day for 4 weeks
108492|NCT03337776|Other|WhatsApp message|WhatsApp message will be sent to invite subjects to participate in CRC screening
108493|NCT03337776|Other|Telephone call|Telephone call will be made to invite subjects to participate in CRC screening
108494|NCT03337750|Behavioral|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
108495|NCT03337737|Dietary Supplement|Extreme Endurance|Study will compare (in a crossover) placebo vs dietary supplement Extreme Endurance.
108496|NCT03337737|Other|Placebo|
108497|NCT03337724|Drug|Ipatasertib|Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1−21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
108498|NCT03337724|Drug|Paclitaxel|Paclitaxel, 80 mg/square meter (m^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
108499|NCT03337724|Drug|Placebo|Matching placebo, administered orally QD on Days 1−21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
108500|NCT03337698|Drug|Atezolizumab|Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Day 1 and 15 of each 28 day cycle.
108501|NCT03337698|Drug|Cobimetinib|Cobimetinib is administered orally on days 1-21 of a 28 day cycle.
108502|NCT03337698|Drug|RO6958688|"Cycle 1:~RO6958688 is administered by IV infusion on days 1, 8 , and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on days 1, 8 , and 15 of a 21 day cycle"
108503|NCT03337698|Drug|Docetaxel|Docetaxel is administered by IV on day 1 of each 21 day cycle. When combined with idasanutlin, docetaxel is administered by IV on Day 1 and Day 15 of each 28 day cycle.
108504|NCT03337698|Drug|CPI-444|CPI-444 is administered orally twice daily on Days 1- 21, out of a 21 day cycle.
108505|NCT03337698|Drug|Pemetrexed|Pemetrexed is administered by IV on Day 1 of a 21 day cycle.
108506|NCT03337698|Drug|Carboplatin|Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.
108507|NCT03337698|Drug|Gemcitabine|Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle
108508|NCT03337698|Drug|Linagliptin|Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle
108509|NCT03337698|Drug|Tocilizumab|Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.
108510|NCT03337698|Drug|Ipatasertib|Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
108511|NCT03337698|Drug|Idasanutlin|Idasanutlin will be administered orally once a day on Days 1-5 of each 28 day cycle.
108512|NCT03337672|Drug|Dexmedetomidine|Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
108513|NCT03337672|Drug|Midazolam|Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
108514|NCT03337659|Other|Family Integrated Care|FICare is a dynamic psycho-educational intervention. The goal of FICare is a change in culture and practice that permits, encourages and supports parents in their parenting role while their infant is receiving health care in a Level II NICU. Underpinned by adult learning and change theories, FICare empowers parents to build their knowledge, skill and confidence so that the family is well-prepared to care for their infant long before discharge.
108515|NCT03337646|Drug|Lisdexamfetamine Dimesylate|Medication to treat ADHD
108516|NCT03337633|Behavioral|Menu design|Participants were given 5 minutes to order a hypothetical meal from the assigned test menu by circling all items they wanted to order.
108517|NCT03337620|Device|Tx360|Tx360 used to deliver active and placebo drug interventions to SPG.
108555|NCT03337399|Other|Stepped PC|"Palliative Care is involvement of a team of clinicians that specialize in lessening (or palliating) many of these distressing physical and emotional symptoms and in helping patients and their family cope with a serious illness improves patients' and their loved ones' experience with their cancer"
108518|NCT03337607|Device|rESWT|"rESWT will be performed as follows:~Four rESWT sessions~One rESWT session per week~4 × 1000 radial extracorporeal shock waves (rESWs) per session (1000 rESWs each applied to the left and the right paravertebral muscles above L3 to S1 using the 36-mm applicator, plus 1000 rESWs each applied to the left and the right sacroiliac joint using the 15-mm convex applicator, in prone position of the patient.~rESWs applied at 15 Hz~Air pressure of the rESWT device gradually increased during the first 200 rESWs each until the maximum discomfort the patient can tolerate will be reached, followed by 800 rESWs at this air pressure / energy flux density.~No application of local anaesthetics"
108519|NCT03337607|Drug|Celecoxib|1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
108520|NCT03337607|Drug|Eperisone|3 x 50 mg per day for four weeks
108521|NCT03337594|Drug|Pre-operative MRI with Dotarem|Dotarem® (gadoterate meglumine - Guerbet)
108522|NCT03337594|Drug|Pre-operative MRI with MultiHance|MultiHance® (gadobenate dimeglumine - Bracco)
108523|NCT03337594|Procedure|Surgery|Cardiac surgery
108524|NCT03337581|Drug|Dexmedetomidine|see arms
108525|NCT03337568|Procedure|allogeneic hematopoietic cell transplantation|perform allogeneic hematopoietic cell transplantation (HCT) using conditioning regimen of busulfan, fludarabine, and antithymocyte globulin
108526|NCT03337555|Device|McGrath|McGrath videolaryngoscope
108527|NCT03337555|Device|Pentax|Pentax videolaryngoscope
108528|NCT03337555|Device|Macintosh|Macintosh direct laryngoscope
108529|NCT03337542|Biological|AR101|AR101
108530|NCT03337529|Other|Vitamin C|200 mg Vitamin C will be given on daily basis for 8 weeks
108531|NCT03337529|Other|Placebo|200 mg placebo will be given on daily basis for 8 weeks
108532|NCT03337516|Biological|Blood sampling|Blood sampling in order to assess cytarabine pharmacokinetics
108533|NCT03337516|Genetic|Genetic analysis|Genetic analysis in order to determine genetic polyporphism of Deoxycytidine Kinase and Cytidine Deaminase
108534|NCT03337503|Drug|THC and CDB in a 1 to 1 ratio|capsule containing cannabis oil
108535|NCT03337503|Drug|Experimental: THC and CBD in a 1 to 2 ratio|capsule containing cannabis oil
108536|NCT03337503|Drug|High CBD with trace THC oil|capsule containing cannabis oil
108537|NCT03337503|Other|placebo|carrier oil capsule
108538|NCT03337490|Drug|Ivermectin 0.5% Topical Application Lotion|Subjects on Test Product will receive a single dose, 117g, during the study to be applied at baseline.
108539|NCT03337490|Drug|Ivermectin 0.5% Topical Application Lotion [SKLICE]|Subjects on Reference Product will receive a single dose, 117g, during the study to be applied at baseline.
108540|NCT03337490|Drug|Placebo 0% Lotion|Subjects on Placebo will receive a single dose, 117g, during the study to be applied at baseline.
108541|NCT03337477|Drug|Placebo|Suspension administered orally for a treatment period of 24h. 2 sachets administered up to three times over 10h (at 0, 4 and 10h).
108542|NCT03337477|Drug|Sodium Zirconium Cyclosilicate(ZS)|Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. 10g administered up to three times over 10h (at 0, 4 and 10h).
108543|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
108544|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
108545|NCT03337477|Drug|Insulin|Insulin 0.1 units/kg administered as a bolus or for up to 30 minutes.
108546|NCT03337477|Drug|Glucose|Glucose 25g administered IV <15 minutes before the insulin.
108547|NCT03337464|Other|cycling exercise|5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
108548|NCT03337451|Drug|OPN-305|Patients will receive study drug every 4 weeks
108549|NCT03337438|Other|Personalized Feedback Intervention with Values|The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.
108550|NCT03337438|Other|Personalized Feedback Intervention Traditional|This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
108551|NCT03337425|Behavioral|Psychoeducational group therapy|The group-based psychoeducational program consists of 10 sessions, run over 10 consecutive weeks. Each session consist of a lecture, given by a recruited expert on the topic of the session (20 minutes) with a following discussion of the topic (45 minutes), facilitated by the course leader. All sessions are organized and led by the course leader, which also includes keeping structure in time, discussion and closing of the session. Psychoeducation comes in addition to standard treatment (ADHD treatment as usual).
108552|NCT03337425|Behavioral|Waiting list|Waiting list and standard treatment (ADHD treatment as usual)
108553|NCT03337425|Other|Standard treatment|Standard treatment consists of diagnostic assessment of ADHD and comorbidity, as well as treatment with medication. In addition, some patients receive cognitive behavioral therapy, although this is not systematically given to every patient. If needed, patients are also offered assistance with regard to economy, housing, education and work. As well as contact with family and network.
108554|NCT03337412|Other|Adapted physical activity|"Patients will be asked to complete questionnaires about their physical activity, diet and quality of life prior to hospital care.For an evaluation of the chronological evolution of their physical activity, they will be invited to complete the Physical Activity Questionnaire GPAQ 2.0 every 2 months, for the duration of the Research.At 6 months during a telephone contact and at 12 months, during a consultation, the food and quality of life questionnaires will also have to be informed. The evolution of weight, body mass index and metabolic biological factors will also be collected.~Employees will benefit from a life-health awareness program, accompanied by an APA educator, they are offered the opportunity to participate in physical activity workshops on a regular basis (12 workshops minimum over 6 months), adapted to their abilities and personalized.They will be invited to fill, from their home or on the website Fleury Michon, the same type of questionnaire"
108652|NCT03336684|Behavioral|Patient education|Rheumatoid arthritis patients will be provided with disease education literature
108804|NCT03335540|Biological|Ipilimumab|Specified dose on specified day
108557|NCT03337386|Device|inferior vena cava collapsibility|inferior vena cava diameters is obtained in the supine position with a convex probe .The probe is placed in the subxiphoid region or the right anterior midaxillary plane.The sagittal section of IVC is imaged. M-mode probe is used to identify the measurement of minimum and maximum venous dimensions over the respiratory cycle using the 3.5-5 MHz phased array probe. To standardize the measurements, measuring of the IVC diameter is performed at 2 cm caudal of the junction point of the right atrium and IVC. The difference between the maximum (D max) and minimum (D min)diameters of the target vein is normalized according to the standard formula to yield the collapsibility index (CI).
108558|NCT03337386|Device|subclavian vein collapsibility|Right SCV diameters is checked in the supine position using a high frequency linear array probe (6-13 MHz) and M-mode. To standardize the measurements, the probe is placed beneath the proximal part of the middle part of the clavicle perpendicular to long-axis of the SCV to obtain the best cross-sectional view of the vien. After the target vein is localized , the dynamic diameter change is recorded using M-mode to identify and measure the minimum and maximum venous diameters.To calculate SCV collapsibility index, the standard formula is used.
108559|NCT03337386|Other|central venous pressure|ultrasound guided 7.5-F central venous catheter is introduced via right internal jugular vein under local analgesia with 2% lidocaine for measuring the CVP.
108560|NCT03337373|Drug|cisatracurium|A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
108561|NCT03337360|Dietary Supplement|Impryl|Food supplement with betaine, cystine, zinc, niacin, folic acid (5MTHF-glucosamine), Vitamin B12 (cobalamin), Vitamin B6, Vitamin B2 (riboflavin)
108562|NCT03337360|Other|Placebo|Inactive ingredients, placebo
108563|NCT03337347|Device|CTC/DTC count|The presence of CTCs/DTCs in the peripheral blood and/or bone marrow may identify colorectal cancer patients with high risk of disease recurrence who may benefit from adjuvant therapy.
108564|NCT03337334|Device|tACS at tremor frequency|tACS applied between the stimulation electrodes at tremor frequency
108565|NCT03337308|Combination Product|Bempedoic Acid + Ezetimibe Fixed-Dose Combination|bempedoic acid + ezetimibe FDC 180 mg/10 mg tablet
108566|NCT03337308|Drug|Bempedoic Acid|bempedoic acid 180 mg tablet
108567|NCT03337308|Drug|Ezetimibe|ezetimibe 10 mg overencapsulated tablet
108568|NCT03337308|Drug|Placebos|placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
108569|NCT03337282|Procedure|Protocolized general anesthesia|Induction and maintenance of general anesthesia, post-operative analgesia with protocolized drugs and doses. Maintenance of MAP +/- 20% of baseline with vasopressors as needed.
108570|NCT03337269|Other|Educational video|Approximately 7 minute video on the HPV vaccine
108571|NCT03337269|Other|Educational handout|One page handout on the HPV vaccine
108572|NCT03337269|Other|Control|Control
108573|NCT03337256|Diagnostic Test|GI bleeding score|"Risk factor Score component value Age (years) 15-29 -2 30-44 -1.5 45-59 0 60-74 1.5~75 2.5 Haemoglobin(g/L)~10.0 0 <9.9 2 Systolic blood pressure (mmHg)~110 0 90-109 1.5 <90 2.5 Pulse (beats per min) <100 0~100 1.5 Creatinine (mmol/L) <200 0~200 3.5 Number of blood transfusion 0 0~1 1.5~2 2 Presenting symptom Melaena -1.5 Drug treatment Acid blcoking drug 1.5 anticoagulant 3 Endoscopy findings Clean-based ulcer -2 SRH or blood in stomach 4 Varices 5"
108574|NCT03337243|Procedure|HAM and HUMCWJ Injections|SURGENEX SurForce® (1cc) allograft placental based tissue matrix, will be injected using a 22 gauge, 2-inch needle. The injection site (medial, lateral, patellar) will be determined based on the side with the most joint space from the findings of the most recent x-rays. The Physician will insert the needle fully into the joint space and begin to expel the fluid. He will achieve a continuous injection flow as he withdraws the needle back out of joint space. Immediately following the SURGENEX SurForce® injection, an injection of Predictive Biotech CORECYTE(TM) (1 cc) allograft umbilical cord-derived Warton's Jelly tissue matrix will be administered. This will be done using the exact same protocol as the SURGENEX SurForce® injection.
108575|NCT03337230|Behavioral|Physical Activity|Fitbit Activity Monitor and IPAQ to give level of physical activity. Participants will be provided with education about physical activity recommendations and will be encouraged to set goals for improvement.
108576|NCT03337230|Behavioral|Diet|National Cancer Institute's ASA24 web-based dietary assessment tool to determine intake. Participants will be provided with education about healthy diets and will be encouraged to set goals for making enduring changes to dietary intake.
108577|NCT03337230|Behavioral|Social Support|Social support will be determined via self report scale measure and objective collection of social media communications. Each participant will be contacted through social media regularly with dietary and physical activity information and asked to support other participants via encouragement and sharing of information.
108578|NCT03337217|Procedure|Position during colonoscopy|Position during colonoscopy
108579|NCT03337204|Behavioral|Technology-assisted self-monitoring|Participants receive a Fitbit Zip, an iPad Mini tablet device, training on how to use the Fitbit and iPad, and are asked to complete brief surveys each night on their activity engagement that day (for two 7-day periods).
108580|NCT03337204|Behavioral|Workshop and Peer Mentoring|Participants receive a 3-hour Engaged4Life Workshop (psychoeducation + goal setting) and one-on-one peer mentoring via phone 2X/week for 3 weeks.
108581|NCT03337191|Drug|Levobupivacaine|% 0,125 levobupivacaine
108582|NCT03337191|Drug|Morphine Sulfate|10 mq/kg morphine sulfate
108583|NCT03337191|Device|Ultrasound|Ultrasound guided caudal block
108584|NCT03337178|Behavioral|Blinded Fitbit|Fitbit is worn for 3 months post-operatively with no activity feedback or step goals
108585|NCT03337178|Behavioral|Fitbit|Fitbit is worn for 3 months post-operatively with feedback and step goals
108586|NCT03337165|Biological|tolerogenic dendritic cells|dose-escalation
108587|NCT03337152|Drug|primaquine|Participants receive primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
108588|NCT03337152|Drug|chloroquine + primaquine|Participants will receive chloroquine for 3 days concomitant with primaquine for 14 days at 0.5 mg/Kg. Drug administration will be directly observed.
108694|NCT03336346|Drug|dolutegravir|HIV integrase strand transfer inhibitor used in combination ART
108589|NCT03337139|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session). Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
108590|NCT03337139|Behavioral|Standard Remote Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by participant self-report. Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
108591|NCT03337139|Behavioral|Digital Data Sharing Behavior Therapy for Weight Loss|Individual, monthly, brief phone calls with coach and weekly text messages. The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
108592|NCT03337126|Drug|Metronidazole Tablet|Comparator Drug
108593|NCT03337113|Other|Working Memory Training|The Working Memory Training condition: This condition will include 30 sessions across 4 weeks (10 remote sessions prior to initiation of the rTMS stimulation, and 20 lab sessions on rTMS stimulation days). Participants will complete three distinct WM tasks in each session: a visuospatial WM task, a backward digit span task, and a letter span task. In the training condition, the difficulty level of all three WM tasks will be automatically adjusted on a trial-by-trial basis. An identical protocol and software have demonstrated efficacy in increasing WM capacity, and this improvement in WM predicts reduction in addictive behavior.
108594|NCT03337113|Other|Sham Working Memory Training|In the Sham WMT condition, the difficulty level of the WM tasks will not be adjusted; instead it will remain at the initial easy level throughout each task (i.e., three items in each sequence). All other aspects of the condition are identical to the active WMT condition.
108595|NCT03337113|Device|repetitive Transcranial Magnetic Stimulation|"The rTMS Condition: rTMS will be delivered with a Magstim Rapid2 system using Magstim Air Film Coils. rTMS pulses will be delivered at 10 Hz (100% resting motor threshold, RMT) in 40, 5 second trains, with 15 second inter-train interval, for a total of 2000 pulses per session. Active or sham rTMS will be applied over the left DLPFC; corresponding with the standard F3 location on scalp (F3=left frontal lobe, location #3 for electrode placement using international 10-20 system for scalp measurements). Five consecutive daily sessions will occur on two consecutive weeks, for a total of 10 sessions. RMT, defined as the amount of energy required to induce movement in the contralateral abducer pollicis brevis in at least 50% of stimulations, will be assessed on first day of application."
108596|NCT03337113|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS will be identical to active treatment, with the exception that mu-metal plates attached to the sham coil block the magnetic field while providing a sensation of stimulation.
108597|NCT03337100|Behavioral|Co-Dispensing|"Implementation of a naloxone co-dispensing pharmacy program.~The intent of this program is to provide patients prescribed chronic opioid therapy naloxone under the terms of a standing order for potential opioid overdose reversal. Prior to implementing the program, a naloxone standing order will be implemented and pharmacy operational staff will provide training to pharmacy staff about the standing order and a naloxone co-dispensing protocol. Under a co-dispensing protocol, pharmacy staff members will identify opioid prescriptions meeting criteria for co-dispensing, prepare naloxone fills, offer patients naloxone, and provide counseling on its use."
108598|NCT03337087|Drug|Fluorouracil|Given IV
108599|NCT03337087|Other|Laboratory Biomarker Analysis|Correlative studies
108600|NCT03337087|Drug|Leucovorin Calcium|Given IV
108601|NCT03337087|Drug|Liposomal Irinotecan|Given IV
108602|NCT03337087|Drug|Rucaparib|Given PO
108603|NCT03337074|Other|Questionnaire, semen sample, fasting blood sample|Participants are asked to complete a questionnaire and provide a semen sample and fasting blood sample.
108604|NCT03337074|Other|Questionnaire|Participants are asked to complete a questionnaire.
108605|NCT03337074|Other|Questionnaire, fasting blood sample|Participants are asked to complete a questionnaire and provide a fasting blood sample.
108606|NCT03337061|Other|Mindfulness Meditation|Mindfulness Meditation delivered through a mobile application
108607|NCT03337048|Device|SpeediCath|SpeediCath is a standard intermittent catheter that is on the market.
108608|NCT03337035|Drug|intranasal oxytocin|4-24 IU per day, dosage gradually increases
108609|NCT03337035|Dietary Supplement|oral probiotics|200 million cfu per day
108610|NCT03337035|Dietary Supplement|oral placebo|2 pills per day
108611|NCT03337022|Drug|CC-90006|CC-90006
108612|NCT03337022|Other|Placebo|Placebo
108613|NCT03337009|Behavioral|Naloxone Navigator (NN)|Patients prescribed chronic opioid therapy will be identified and recruited to enroll in the study. Patients randomized to receive the web-based animated video (Naloxone Navigator) will be sent a link to the video after enrollment. The web-based, animated video provides education on what is an opioid overdose, how to prevent it, how to recognize an overdose, and how to respond with naloxone. This video also encourages patients to pick up naloxone from a pharmacy under a standing order.
108614|NCT03336996|Biological|stem cell transplantation|the motor nerve fiber damaged patient receive a treatment course stem cell transplantation after the hematoma removal.
108615|NCT03336996|Procedure|BOLD-fMRI drived DTI scanning|All patients should be receive cranial BOLD-fMRI drived DTI scanning scanning separately before the transplant and after the transplant 0, 1, 3, 6 and 12 months.
108616|NCT03336983|Drug|Zoledronic Acid|Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid
108617|NCT03336983|Drug|Enzalutamide|Patients from both arms will be treated with LHRH-A + Enzalutamide
108618|NCT03336970|Other|EDTA|
108619|NCT03336970|Other|NaOCl|
108620|NCT03336970|Other|CHX|
108621|NCT03336970|Other|Calcium hydroxide|
108622|NCT03336957|Procedure|periodontal treatment|non-surgical periodontal therapy (NPT) consisted of scaling, root planning, and oral hygiene instruction
108695|NCT03336346|Device|ENG implant|Reversible contraception implant
108696|NCT03336346|Drug|Efavirenz|non-nucleoside reverse transcriptase inhibitor used in combination ART
108623|NCT03336931|Diagnostic Test|Molecular profiling and drug testing|"Laboratory analysis including:~A. Tumour molecular profiling: targeted whole exon variant analysis, whole genome (DNA) and transcriptome (RNA) sequencing, methylation analysis, proteomics analysis, immunohistochemistry B. In vitro high-throughput drug sensitivity testing C. In vivo drug testing using patient-derived xenograft (PDX) models D. Liquid biopsies~Multi-disciplinary Tumour Board case discussion~Recommendation of personalised therapy"
108624|NCT03336918|Drug|Lithium|"Open-label lithium treatment for Bipolar Disorder Subjects~Healthy Controls only repeat testing - no intervention"
108625|NCT03336905|Other|Physical activity program and prevention after cancer|Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
108626|NCT03336892|Behavioral|Mental Health Care Coordination|Enhanced usual care with written mental health resources and system navigation information in addition to individualized mental health care coordination by a dedicated specially trained mental health care coordinator.
108627|NCT03336879|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
108628|NCT03336866|Drug|Placebo|Normal saline
108629|NCT03336866|Drug|IXT-m200|IXT-m200 is an anti-methamphetamine monoclonal antibody
108630|NCT03336853|Device|HybenX|"The material was introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement up to the working length.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length.~A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
108631|NCT03336853|Other|Placebo control|"The root canal was irrigated with sterile saline water with a syringe and a side-vented 30G needle activated for 20 seconds with a sterile paper point with and up and down movement up to the working length to ensure a flow of irrigant solution throughout the canal.~Finally, the canal was rinsed with sterile water using a syringe with a side-vented 30 G needle 1 mm shorter than the working length. A second sterile paper point was introduced in the root canal, up to the working length, for 10 seconds to detect the presence of blood and the millimeters of blood inside the root canal was measured again according the previous criteria."
108632|NCT03336840|Drug|Metformin tablets|0.5g (1 pill) of Metformin tablets administered three times a day orally before meal
108633|NCT03336840|Drug|ProMetS probiotics powder|4g (2 strips) of ProMetS probiotics powder administered orally every night
108634|NCT03336840|Drug|1. Metformin tablets; 2. ProMetS probiotics powder|"0.5g (1 pill) of Metformin tablets administered three times a day orally before meal;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
108635|NCT03336827|Behavioral|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
108636|NCT03336827|Behavioral|Cognitive-Behavioral Group Therapy and Hypnosis|The intervention consists in a pre-group interview and eight 2,5 h-session extended over 4 months. The intervention is based on cognitive-behavioral group therapy and hypnosis. To promote use of hypnosis at home, patients will receive audiorecordings of the hypnosis exercises. Starting immediately after the pre-group interview, the group will receive 3 app prompts a day promoting self-awareness and modulation of internal states, orientation of attention toward positive stimuli and inviting them to increase physical activity. Patients will be given a patient manual to promote an active approach to changes.
108637|NCT03336814|Drug|Terlipressin|Administration of terlipressine
108638|NCT03336814|Other|Placebo|Administration of placebo
108639|NCT03336801|Procedure|Back Surgery|All patients undergo basic back surgery.
108640|NCT03336801|Drug|Propofol|Anesthesia on propofol alone.
108641|NCT03336801|Drug|Sevoflurane|Anesthesia on sevoflurane alone.
108642|NCT03336788|Device|Transcranial Magnetic Stimulation (TMS - ) MagPro®|20 sessions navigated with Conventional Transcranial Magnetic Stimulation
108643|NCT03336788|Device|virtual reality for displaying interactive virtual environments|20 sessions navigated with virtual reality
108644|NCT03336775|Procedure|acupuncture|Acupuncture for 30 minutes per day for up to 20 sessions (over 4 weeks).
108645|NCT03336762|Diagnostic Test|Intra spinal pressure monitoring|Sub dural pressure monitoring using a FDA approved intracranial pressure monitor
108646|NCT03336762|Diagnostic Test|Intra spinal microdialysis monitoring|Sub arachnoid microdialysis monitoring using a FDA approved hepatic microdialysis catheter
108647|NCT03336749|Behavioral|Sensory group|The sensory re-learning consists of touch detection practice, i.e., touch discrimination to identify different materials, shapes, textures, weights and temperatures, proprioception and tactile object recognition in combination with task-specific training.
108648|NCT03336749|Other|Control group|Traditional task-specific training
108649|NCT03336736|Diagnostic Test|Exercise|"The study design will be a prospective cross-sectional observational project, with no intervention.~Data on a participant's physical activity levels, physical fitness and quality of life will be collected using physical testing and questionnaires."
108650|NCT03336723|Device|Dental Implant|Place a two piece zirconia dental implant on a healed ridge. At baseline, two month and crown placement take fluid samples with adsorbent paper in the per- implant crevicular fluid. At t2 and t3 repeat sample taken
108651|NCT03336697|Diagnostic Test|Nasal swab|a nasal swab will be performed by a trained physician by gently passing of a cotton swab in the nasal passage to get samples from middle meatus. This will be performed under guide of nasal anterior endoscopy to visualize the location of sampling. The cotton swab heads will be placed in sterile tubes and frozen at -80°C until DNA extraction.
108805|NCT03335540|Drug|IDO1 Inhibitor|Specified dose on specified day
108653|NCT03336671|Procedure|Endoscopic Sinus surgery|Endoscopic sinus surgery would be tailored to abnormal findings in the CT scan, as is the standard of care. Radiologists typically examine sinonasal disease of the sinuses, and they would also be requested to comment on the patency of the osteo-meatal unit, as this is a component of the Lund-McKay score. The Lund-McKay score is an objective radiologic grade of the severity of sinusitis. If there is sinus thickening, or narrowing of the OMU, endoscopic sinus surgery would be tailored to this using either balloon sinuplasty or traditional antrostomy. Patient undergoing endoscopic sinus surgery will likely have at least a maxillary antrostomy and anterior ethmoidectomy performed, with frontal sinusotomy, posterior ethmoidectomy, and sphenoidotomy performed depending on CT or endoscopy findings.
108654|NCT03336671|Procedure|Adenoidectomy|Adenoidectomy performed, routine, as a singular procedure not combined with any sinus surgery.
108655|NCT03336645|Drug|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
108656|NCT03336632|Drug|Chidamide|20 mg orally, twice weekly from D-7 to D+14
108657|NCT03336632|Drug|Cyclophosphamide|50 mg/Kg intravenously D+3, +4
108658|NCT03336632|Drug|cyclosporine A|3 mg/Kg intravenously then orally from D+5 to D+100 if no acute graft-versus-host disease
108659|NCT03336619|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
108660|NCT03336619|Drug|Placebo|Placebo administered orally twice daily for five days
108661|NCT03336606|Drug|MEDI0562|Surgical resection of tumor
108662|NCT03336593|Biological|Quadrivalent Influenza Vaccine|1 or 2 doses of Quadrivalent Influenza Vaccine depends on age
108663|NCT03336593|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
108664|NCT03336580|Drug|PRX004|"PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)"
108665|NCT03336567|Other|Telephonic interview|Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
108666|NCT03336541|Drug|Ketamine|Ketamine (0.5 mg/kg in 100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
108667|NCT03336541|Drug|Placebo|Placebo (100 ml normal saline) will be administered by intravenous infusion in 40 minutes after childbirth during cesarean delivery.
108668|NCT03336528|Drug|Degludec|Degludec is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dl and 180 mg/dl.
108669|NCT03336528|Drug|Glargine|Glargine is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus. Patients will be treated with bolus regimen given half of total daily dose (TDD) as basal once daily and half as aspart divided in three equal doses before meals. Patients with poor oral intake or with medical instruction to withhold oral intake (NPO) will receive the basal dose, but prandial dose will be held. Insulin dose will be adjusted daily to maintain a fasting and pre-dinner BG between 100 mg/dl and 180 mg/dl.
108670|NCT03336528|Drug|Aspart|Aspart insulin will be given in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, aspart insulin dose will be held.
108671|NCT03336528|Drug|Degludec post-discharge|Patients with an HbA1c between 7.5% and 10% will be discharged on preadmission oral antidiabetic agents plus degludec once daily. Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with degludec and aspart insulin before meals.
108672|NCT03336528|Drug|Glargine U100 post-discharge|Patients with an admission A1C ≥ 10% will be discharged on basal bolus regimen with glargine and aspart insulin before meals.
108673|NCT03336515|Device|Group C-Postural device activated|General recommendation not sleeping in supine position and the postural device activated (intervention group).
108674|NCT03336515|Device|Group B-Postural device no activated|General recommendation not sleeping in supine position and the postural device without any activation (placebo)
108675|NCT03336515|Behavioral|Group A-General Recommendation|General recommendation not sleeping in supine position
108676|NCT03336502|Drug|Posaconazole|Posaconazole 18 mg/mL IV solution; posaconazole 40 mg/mL oral suspension
108677|NCT03336476|Device|Videolaryngoscopy|Patients will be intubated with the video laryngoscope
108678|NCT03336476|Device|Direct laryngoscopy|Patients will be intubated with the direct laryngoscope
108679|NCT03336450|Drug|SHP615|SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
108680|NCT03336450|Drug|MHOS/SHP615|MHOS/SHP615
108681|NCT03336437|Drug|Estradiol vaginal ring|Estradiol 2mg vaginal ring
108682|NCT03336437|Other|Placebo vaginal ring|Silicone vaginal ring without any active estradiol
108683|NCT03336424|Diagnostic Test|Non-invasive investigations|Ultrasound, blood tests, urine analysis and culture, uroflowmetry
108684|NCT03336424|Diagnostic Test|Invasive investigations|Cystomanometry, pressure flow study, EMG
108685|NCT03336411|Behavioral|mHealth|Behavioral weight loss intervention using behavioral counseling focusing on physical activity and a one-size-fits-all, calorie-restricted, diet.
108686|NCT03336411|Behavioral|Personalized mHealth|Behavioral weight loss intervention with personalized dietary recommendations based on machine learning algorithm that integrates gut microbiota, dietary intake, physical activity and various blood parameters to predict postprandial glycemic response.
108687|NCT03336398|Drug|Ketamine Hydrochloride in saline|0.5 mg/kg IV of ketamine hydrochloride in saline will be administered with one of the MRS Scan
108688|NCT03336398|Drug|Saline|Saline will be administered with the other MRS scan
108689|NCT03336385|Dietary Supplement|Naxus|Non-digestible polysaccharides arabinoxylan (Naxus)
108690|NCT03336385|Dietary Supplement|Oatwell|Non-digestible polysaccharides oat beta-glucan (Oatwell)
108691|NCT03336385|Dietary Supplement|Placebo|Maltodextrin as placebo
108692|NCT03336372|Drug|Picato|Picato 0.05% or 0.015% topical gel applied nightly for 3 consecutive nights
108693|NCT03336359|Diagnostic Test|Tandem colonoscopy|Different image enhanced endoscopy systems
108698|NCT03336333|Drug|Bendamustine|Bendamustine will be administered intravenously at a dose of 90 mg/m2/day on the first 2 days of each cycle for 6 cycles. 1 cycle = 28 days.
108699|NCT03336333|Drug|Rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 on day 0 of cycle 1, and at a dose of 500 mg/m2 on day 1 of cycles 2 to 6. 1 cycle = 28 days.
108700|NCT03336333|Drug|Venetoclax|Venetoclax will be administered by mouth once daily.
108701|NCT03336320|Device|ICT Multidomain Intervention Training|Intervention composed of cognitive training (reasoning and memory training), nutritional counselling (advices to raise awareness about the importance of promoting a diversified and balanced diet), and physical exercises (program and monitoring of progression). The access of control group to the website will be limited to general information about eMIND study and links to the website of health authorities regarding to the healthy ageing topics.
108702|NCT03336307|Other|Rehabilitation program|"all patients received a rehabilitation program planned according to the European Physiotherapy guideline for Parkinson's disease and focus on:~endurance, strength, flexibility and balance with functional practice for all H/Y stage~endurance also for H/Y stage 1,~motor learning principles and cue functional for H/Y stage 2-3~external cues and self-instruction strategies and attention H/Y for stage 2-3 The rehabilitative program comprised 60-minute sessions a day (3d/wk)."
108703|NCT03336294|Radiation|SRM P31|All the volunteers involved in the CAMUS study will perform during the SRM P31 a quadricipital physical task at 70% 1-RM.
108704|NCT03336281|Drug|Ustekinumab|All participants will receive ustekinumab at study entry. Ustekinumab will not be provided by the sponsor. The treatment decision must have been taken by the investigator prior to, and independently of the participant's inclusion into the study following the standard clinical practice. Only data available from a participant's source medical records will be collected.
108705|NCT03336268|Behavioral|POINT|A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication assisted treatment (MAT) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MAT within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
108706|NCT03336255|Behavioral|South Asian Healthy Lifestyle Initiative (SAHELI)|Culturally tailored lifestyle intervention for South Asians.
108707|NCT03336242|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
108708|NCT03336229|Behavioral|Exercise intervention|Graduated walking programme, strengthening exercises and respiratory muscle training.
108709|NCT03336216|Biological|Cabiralizumab|specified dose on specified days
108710|NCT03336216|Drug|Nab-paclitaxel|specified does on specified days
108711|NCT03336216|Drug|Onivyde|specified dose on specified days
108712|NCT03336216|Biological|Nivolumab|specified dose on specified days
108713|NCT03336216|Drug|Fluorouracil|specified dose on specified days
108714|NCT03336216|Drug|Gemcitabine|specified dose on specified days
108715|NCT03336216|Drug|Oxaliplatin|specified dose on specified day
108716|NCT03336216|Drug|Leucovorin|Specified dose on specified days
108717|NCT03336216|Drug|Irinotecan Hydrochloride|Specified dose on specified days
108718|NCT03336203|Drug|Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet|treatment either with allopurinol or febuxostat
108719|NCT03336190|Behavioral|avatar-based training|Interaction with an avatar-based module to practice skills learned during the toolkit training
108720|NCT03336177|Other|Semi-structured face to face interviews.|Patients will be interviewed by open-ended questions face to face concerning their past experiences. The recorded interview will be transcribed and analyzed by psychodynamic and semio-pragmatic approach.
108721|NCT03336164|Behavioral|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the university restaurant
108722|NCT03336151|Behavioral|Front-of-pack labelling Nutri-Score|Introduction of the Nutri-Score front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
108723|NCT03336138|Other|AMA (Assistance for ambulatory patients)|telephone follow-up modality
108724|NCT03336125|Dietary Supplement|Vitamin D|Vitamin D (40µg/day) will be compared with placebo
108725|NCT03336125|Dietary Supplement|Placebo|120 mg olive oil
108726|NCT03336112|Behavioral|Internet-delivered cognitive behavioral therapy (I-CBT)|The intervention (I-CBT) will consist of 5 weeks of Internet-delivered cognitive behavioral therapy using three main parts. The first is psychoeducation that aims to educate the patients about chest pain and other causes than the cardiac ones. The other part concerns avoidance and exposure. This includes exposing the patients to physical activities that patients perceive as a threat to the heart. The third part contains awareness (mindfulness) training to teach the patients to have contact with the present moment despite chest pain and not trying to avoid it.
108727|NCT03336112|Other|Information program|Information program delivered by the Internet during 5 weeks.
108728|NCT03336099|Other|Spa Treatment|"Bath with immersion shower~Overall shower, penetrating shower~Multiple local application cataplasm~Single local application cataplasm~Inhalation or collective steam bath~Individual physiotherapy technique"
108729|NCT03336086|Combination Product|weight loss program|A low calorie diet+ Orlistat+ Soluble Fiber+ Physical activity
108730|NCT03336073|Drug|Carfilzomib|carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
108731|NCT03336073|Drug|Dexamethasone|dexamethasone oral at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16
108732|NCT03336073|Drug|cyclophosphamide|cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
108806|NCT03335540|Radiation|Radiation Therapy|Specified dose on specified day
108807|NCT03335527|Drug|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.1-0.2 ug/kg/h (0.025-0.05 ml/kg/h) from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
108733|NCT03336060|Diagnostic Test|Cortical Correlates of Jump Landing Task|The study participants perform counter-movement jumps (CMJ, flight time approximately 500 ms) followed by single leg landings. While under an anticipated condition, the individuals receive the visual information (presented on a screen) on which leg/ foot (left, right) they are required to land before self-initiated CMJs, the individuals will receive this information under the non-anticipated condition only after take-off (approximately 400 ms before ground contact).
108734|NCT03336047|Behavioral|personal activity intelligence|"Participants randomized to the PAI intervention will receive a Mio Slice fitness bracelet and asked to install the Mio Pai 2.0 app on their smart phone. This tracks their fitness score based on the PAI algorithm where the goal is to maintain 100 PAI points a week. PAI is earned incrementally based on time spent in three different heart rate zones, low, medium and high intensity. PAI is recorded every day and added to the weekly total and the PAI earned on the same day the previous week is deleted (on Tuesday, the PAI earned the previous Tuesday will disappear).~Participants will be encouraged to maintain 100 PAI during the 8 weeks intervention by telephone messages (sms)."
108735|NCT03336047|Behavioral|10,000 steps daily|Participants randomized to the 10,000 step intervention will receive a fit bit zip step counter and asked to obtain 10.000 steps per day. Participants will be encouraged to obtain 10.000 steps per day by telephone messages (sms).
108736|NCT03336021|Other|FAS program|Intervention households are farmers who will receive a forward contract through the FAS program; in addition, they may receive other support such as extension, seeds, etc.
108737|NCT03336008|Other|no intervention|No intervention but clinical assessement for all recruited subjects
108738|NCT03335982|Procedure|transendoscopic enteral tubing in mid-gut|A TET tube was inserted into mid-gut through the nasal orifice and fixed on the pylorus wall by one tiny titanium endoscopic clip under anesthesia.
108739|NCT03335969|Device|colon irrigation|Study is to compare bowel movement patterns before and after colon irrigation.
108740|NCT03335956|Drug|CORT125281, 40mg, fasted|CORT125281 is supplied as capsules for oral dosing
108741|NCT03335956|Drug|Prednisone 25mg, fasted|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
108742|NCT03335956|Drug|Placebo oral capsule, fasted|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
108743|NCT03335956|Drug|Pioglitazone 15mg Tablet|"Probe Substrate, Dose and Route of Administration:~15 Mg tablet, orally administered"
108744|NCT03335956|Drug|Placebo oral capsule, fed|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered"
108745|NCT03335956|Drug|Prednisone 25mg, fed|"Challenge Agent, Dose and Route of Administration:~Standard release 25 mg tablets, orally administered"
108746|NCT03335956|Drug|CORT125281, 120mg, fasted|CORT125281 is supplied as capsules for oral dosing
108747|NCT03335956|Drug|CORT125281, 360mg, fasted|CORT125281 is supplied as capsules for oral dosing
108748|NCT03335956|Drug|CORT125281, 720mg, fasted|CORT125281 is supplied as capsules for oral dosing
108749|NCT03335956|Drug|CORT125281, 360mg, fed|CORT125281 is supplied as capsules for oral dosing
108750|NCT03335956|Drug|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
108751|NCT03335956|Drug|CORT125281, 120mg|CORT125281 is supplied as capsules for oral dosing once daily
108752|NCT03335956|Drug|CORT125281, 180mg|CORT125281 is supplied as capsules for oral dosing twice daily
108753|NCT03335956|Drug|CORT125281, 240mg|CORT125281 is supplied as capsules for oral dosing twice daily
108754|NCT03335956|Drug|CORT125281, 360mg|CORT125281 is supplied as capsules for oral dosing once daily
108755|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal"
108756|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, twice daily"
108757|NCT03335956|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:~Placebo capsule, orally administered, once daily"
108758|NCT03335943|Drug|CDA-2 (Cell Differentiation Agent 2)|CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
108759|NCT03335930|Behavioral|a 12-week moderate-intensity exercise training|a 12-week, aerobic, moderate-intensity exercise training
108760|NCT03335917|Other|Hypoxia|Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
108761|NCT03335917|Other|Exercise|Graded cycling exercise to volitional fatigue
108762|NCT03335904|Other|Hyperoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at 300 mmHg while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
108763|NCT03335904|Other|Hypoxic Hypercapnic Ventilatory Response Test|End-tidal PO2 will be clamped at normoxic levels while end-tidal PCO2 will be increased in three minutes stages from baseline to +2, +4, and +6 mmHg.
108764|NCT03335904|Other|Repeated Hypoxic Apneas|Six hypoxic apnea cycles will be performed. One apneic cycle involves breathing 2-3 breaths of 100% Nitrogen and breath-holding for 20s followed by room air breathing.
108765|NCT03335904|Other|Hypoxic Sleep Study|Participants will be instrumented with a sleep monitoring system and will sleep in a normobaric hypoxic chamber with a fraction of inspired oxygen of 13.5%.
108766|NCT03335904|Drug|Losartan|Losartan, 50mg, BID
108767|NCT03335904|Drug|Placebo|Placebo, 50mg, BID
108768|NCT03335891|Procedure|Core Stabilization Exercises|Volunteers received an asthma education program and trained for diaphragmatic, pursed lip breathing exercises as well as participated in the core stabilization exercises program.
108769|NCT03335891|Procedure|Control|Volunteers received an asthma education program and trained for diaphragmatic andpursed lip breathing exercises
108770|NCT03335852|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection
108771|NCT03335839|Drug|tissue plasminogen activator|Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
108772|NCT03335839|Other|Saline|Placebo
108836|NCT03335345|Other|maintaining calorie intake|Maintaining enteral caloric intake at the same rate. No aspiration in the gastric tube.
108773|NCT03335826|Other|Combined Epi-GA/PCEA|An epidural catheter was placed before the induction of general anesthesia. General anesthesia was induced and maintained as in the control group, with the addition of epidural anesthesia which was maintained with the use of 0.5%-0.75% ropivacaine during surgery. Patient-controlled epidural analgesia with 0.12% ropivacaine and 0.5 ug/ml sufentanil was provided after surgery.
108774|NCT03335826|Other|GA/PCIA|General anesthesia was induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia was maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) were administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia with 0.5 mg/ml morphine was provided after surgery.
108775|NCT03335813|Device|Endoesophageal Brachytherapy|Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
108776|NCT03335800|Device|Apple Heart Study App|The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
108777|NCT03335787|Other|Intervention|Kinesio Tape apply to peroneal muscles in supine position starting from the peroneal muscle origin with using muscle activation technique by a certified KT1 and KT2 practitioner. Then ligament technique which will go through around ankle starting from medial and lateral metatarsophalangeal joints in order to improve ankle stability. Taping will be applied one week later and two weeks later prior to first application.
108778|NCT03335787|Other|Control|Any sham taping was not applied to the control group in order to prevent the sensory stimulant effect of taping. In order to achieve patients' blinding both groups participant will sign a same consent but control group will be called for taping a month later after study data collection completed.
108779|NCT03335774|Drug|Hydrocortisone Acetate Suppository, 25 mg|One (1) Hydrocortisone Acetate Suppository, 25 mg is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
108780|NCT03335774|Drug|Placebo (Vehicle) Suppository|One (1) Placebo (Vehicle) Suppository is inserted into the anal canal twice daily (morning and evening) for 2 weeks (14 days).
108781|NCT03335761|Device|InterStim Therapy|Device Programming
108782|NCT03335748|Other|Cognitive training Cogmed program|Cognitive training Cogmed program
108783|NCT03335735|Behavioral|Loss-framed text message|Participants in the intervention group will receive loss-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Loss aversion refers to people's tendency to prefer avoiding losses to acquiring equivalent gains: it's better to not lose $5 than to find $5, so the content of the messages will be related to loss of personal freedom, loss of money, and loss of future employment opportunities due to Driving Under the Influence (DUI) convictions.
108784|NCT03335735|Behavioral|Gain-Framed text message|Participants in the intervention group will receive gain-framed text messages related to drinking and driving on days during the week with a higher likelihood of alcohol consumption (Thursday-Saturday). Gain-framed messages have been shown to have a positive effect on preventative healthcare and include content framed in a manner that the participant gains something from taking preventative action. Message content will be related to saving lives, gaining control, and making loved ones happy.
108785|NCT03335722|Behavioral|Metronome-timed speech|Reading, narrative, and conversational speech tasks will be completed on each of the five intervention days. Metronome- timed speech will be practiced during these tasks, at near-normal (comfortable) speech rate for each participant. Each intervention session will be 40 minutes in duration.
108786|NCT03335722|Device|Active tDCS|1-mA tDCS with the anode (5 x 7 cm) placed over the left frontal cortex and the cathode (5 x 7 cm) placed symmetrically over the right frontal cortex. tDCS will be delivered using a direct current (DC) stimulator in 'study-mode' for 20 minutes. The current is ramped up to 1 mA over the first 15 seconds of stimulation and maintained at this level for remainder of the 20-minute stimulation session.
108787|NCT03335722|Device|Sham tDCS|Sham stimulation will be delivered using a DC-stimulator in 'study-mode' for 20 minutes. Participants will receive sham stimulation with the anode and cathode electrodes placed over the left and right frontal cortex as in the active arm. For sham stimulation, the current is ramped up over 15 seconds, maintained for 15 seconds at 1 mA and ramped down over 15 seconds at the start of stimulation and is then followed by brief (3ms) pulses every 55 seconds for the remainder of the 20-minute stimulation session.
108788|NCT03335709|Behavioral|ADL intervention|Overall, an adaptational approach is being applied. The intervention sessions include changes related to the person, the environment and/or the occupation.
108789|NCT03335683|Drug|Lenidase|drug per os twice day for 7 days, or for 10 days
108790|NCT03335670|Drug|[68Ga]Pentixafor|68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
108791|NCT03335657|Other|CBPT|The CBPT program focuses on a patient-oriented cognitive-behavioral self-management approach to improve physical function and reduce pain, through reductions in pain catastrophizing and fear of movement and increases in self-efficacy.
108792|NCT03335657|Other|Education Treatment|Participants receiving the education control arm are receiving a placebo intervention to control for the attention of the interventionist. They will receive standardized educational material addressing recovery from orthopaedic trauma.
108793|NCT03335631|Behavioral|Exercise|Moderate intensity mixed-modality exercise 4-5 days per week, with a target of 60 minutes per session.
108794|NCT03335618|Other|Activity Monitoring and Symptom Coaching|Triggered check-ins by study personnel to keep participants on track to meet fitness goals
108795|NCT03335618|Other|Passive Activity Monitoring|Passive step tracking without check-ins
108796|NCT03335579|Combination Product|inhalation or propofol ,epidural or general anesthesia, remifentanil or sufentanil|Different combination of opioids and anesthetics
108797|NCT03335566|Drug|Sonazoid™|Single Dose of Sonazoid™ 0.12 µL MB/kg as I.V. injection.
108798|NCT03335566|Drug|SonoVue®|Single Dose of SonoVue® 2.4 mL as I.V. injection.
108799|NCT03335553|Drug|BMS-986235|Specified dose on specified days
108800|NCT03335553|Other|Placebo|Specified dose on specified days
108801|NCT03335540|Biological|Nivolumab|Specified dose on specified day
108808|NCT03335527|Drug|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025-0.05 ml/kg/h from study recruitment in the ICU during mechanical ventilation, for no more than 72 hours.
108809|NCT03335514|Diagnostic Test|expression of GALNT4|Blood is obtained into ethylenediaminetetraacetic acid（EDTA） tubes from all subjects via antecubital venepuncture and the total RNA was extracted from blood.Realtime PCR was performed to measure the expression of GALNT4.
108810|NCT03335501|Device|Insulin pump|The participant's insulin pump will be used to infuse insulin
108811|NCT03335501|Device|Continuous glucose monitoring system|The Dexcom G4 Platinum will be used to measure glucose levels
108812|NCT03335501|Other|11-hour intervention with the single-hormone artificial pancreas|"Subjects will be admitted at IRCM at 9:30. An intravenous catheter will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing rapid-acting Aspart or faster acting Aspart will be placed in the insulin pump. Closed-loop strategy will start at 10:00 until 21:00. A glucose sensor reading will be entered manually into the computer every 10 minutes. The computer will generate a recommendation for the basal rates of insulin delivery. Pumps' parameters will then be changed manually to implement the computer generated recommendations.~At 12:00, a lunch meal will be served. An insulin bolus will be given 15 minutes before the meal. At 17:00, a dinner meal will be served. As recommended, an insulin bolus will be given at the time of the meal. Each subject will ingest the same meals during both visits.~Venous blood samples will be obtained for the measurement of plasma glucose and insulin concentrations. Blood samples will be taken every 20 minutes."
108813|NCT03335488|Drug|RAVICTI|RAVICTI, Oral Liquid Product 17.5 mL maximum total daily dose
108814|NCT03335488|Drug|NaPBA|"NaPBA in patients weighing < 20 Kg - 600 mg/Kg, maximum total daily dose~NaPBA in patients weighing > 20 Kg - 13 g/m2, maximum total daily dose"
108815|NCT03335475|Behavioral|Physical Activity Lifestyle Intervention|Coaches work with participants on three elements of behaviors change: (1) changing attitudes towards physical activity; (2) increase perceptions of other people's approval of physical activity for the participants; (3) increase perceptions of control over being physically active. These elements will be delivered using a non-judgmental stance accompanied by promoting appropriate goal-setting.
108816|NCT03335475|Behavioral|Physical Activity Monitoring|A physical activity monitor (Fitbit) will be provided to both groups.
108817|NCT03335462|Other|Paravertebral injections|Paravertebral injections will be performed in the thoraco-lumbar plexus area under CT guidance
108818|NCT03335462|Other|CT scan|CT scan will be performed as the needles are kept in their position after injecting the contrast
108819|NCT03335449|Other|Protective ventilation group|Application of a protective ventilation strategy in order to improve gas exchange and respiratory mechanics during Robotic surgery in deep Trendelenburg position.
108820|NCT03335436|Drug|Gabapentin|Participants will receive Gabapentin 600 mg by mouth one hour prior to scheduled cesarean delivery and 400 mg by mouth every 8 hours post delivery
108821|NCT03335436|Drug|Placebo|Participants will receive Placebo with similar appearance to gabapentin by mouth one hour prior to scheduled cesarean delivery and by mouth every 8 hours post delivery
108822|NCT03335423|Drug|Oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
108823|NCT03335423|Drug|Intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
108824|NCT03335423|Drug|Oral codeine and oral metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
108825|NCT03335423|Drug|Oral codeine and intravenous metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 1 week between the phases. Metformin was given both orally and through an intravenous route to be able to determine the absolute bioavailability of metformin. Metformin was given alone and together with codeine to investigate a potential interaction between the drugs. Lactate was measured as a proxy for metformin effect on the intestinal mucosa, both after oral and intravenous metformin
108826|NCT03335410|Other|Non- interventional|Non- interventional
108827|NCT03335397|Device|M-learning application|Mobile application with interactive contents available for android platform and Apple's operating system.
108828|NCT03335397|Other|Traditional learning process|Traditional content available in university library.
108829|NCT03335384|Diagnostic Test|Esophageal Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the esophagus through the nose
108830|NCT03335384|Diagnostic Test|Gastric Balloon|Small flexible catheter with deflated balloon at distal end to be inserted into the stomach through the nose
108831|NCT03335384|Diagnostic Test|Nasal Pressure Transducer|Pressure transducer inserted into nasal plug
108832|NCT03335371|Drug|TTP399|Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
108833|NCT03335371|Drug|TTP399|Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
108834|NCT03335371|Drug|Placebo Oral Tablet|Phase 2: Participants will receive Placebo oral tablets for 12 weeks
108835|NCT03335358|Behavioral|Dyadic (couples-based) positive psychology intervention|Self-administered behavioral intervention in which participants complete at least 2 activities alone and 2 together each week for 8 weeks. Positive psychology activities include expressing gratitude, practicing acts of kindness, fostering relationships, working toward a goal, focusing on the positive, spirituality, and savoring.
108837|NCT03335345|Other|maximum gastric vacuity|stopping enteral feeding at least 6 hours before extubation. Suction in the gastric tube (if its caliber permits) continuously for 6 hours before extubation
108838|NCT03335332|Behavioral|High intensity exercise|The exercise groups will receive identical exercise prescription for the first two months of the intervention, after which the HIE group will incorporate HIIT in their exercise regimen. The reason for this approach is to include a period of general conditioning and progressively increase intensity prior to submitting volunteers to HIE. This approach considers participant safety as arrhythmias may be uncovered during the first two months of MIE training. It will also improve participant compliance by increasing exercise self-efficacy and confidence prior to commencing HIIT.
108839|NCT03335332|Behavioral|Moderate intensity exercise|A training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with exercise training principles. Workouts will vary with respect to mode (walk, cycle) and duration (30 - 60 minutes). Each subject will be assigned an exercise physiologist and a heart rate monitor so that each session can be tracked and recorded. The first few exercise training sessions in both exercise groups (MIE and HIE) will supervised at our hospital based fitness centre until the subject is confident to complete the training independently.
108840|NCT03335319|Other|Periodized Exercise Training Regime|MCT 1st: 20 min on an ergometer; at Anaerobic Threshold (AT) 1 or, if the AT could not be adequately determined, 50-60% of the Heart Rate Reserve (HRR), Borg Rating of Perceived Exertion (RPE) equivalent 9-11. MCT 2nd: 20 minutes; 60-70%HRR, RPE 12-13. HIIT 1st: 4 interval training periods of 2 minutes (AT2 intensity or 80-90%HRR, RPE 15-17) and 4 active pauses of 2 minutes (below AT 1 or 40-50%HRR, RPE 6-9) between interval training periods. HIIT 2nd: same intervals as in 1st HIIT different intensities: high intensity interval above AT2 intensity or > 90%HRR, RPE 17-19 and active pauses at AT 1 or 50-60%HRR, RPE 9-11. Resistance training adaptation: 2 sets of 15-20 repetitions 50% 1RM; Hypertrophy: 2 sets 8-12 repetitions at 60% 1RM; Maximal Strength: 2 sets of 6-8 repetitions at 80% 1RM.
108841|NCT03335319|Other|Non Periodized Exercise Training Regime|To ensure that total training loads were similar in both groups despite differences in intensity, it will be used the training impulses (TRIMP) method from Edwards for the aerobic component and the volume load method for the RT component. All sessions will include 10 minutes of warm up and cool down standardized for both groups. By design, the non periodized group involves an identical total training volume and time commitment but differed regarding metabolic stress induced by the linear periodized group. All patients will be monitored with a HR monitor during the execution of the exercise session in order to achieve the HR training. Blood pressure will be assessed before and after completing each session. If necessary, the blood pressure will be measured during the ET session.
108842|NCT03335293|Drug|100 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
108843|NCT03335293|Other|normal saline|placebo comparator
108844|NCT03335293|Drug|200 mcg Epinephrine|This study will evaluate the optimal dose of epinephrine as an adjunct to spinal doses of 1.6 mL hyperbaric bupivacaine + 20 mcg preservative free fentanyl + 150 mcg preservative-free morphine.
108845|NCT03335280|Diagnostic Test|68Ga-citrate PET/MR|Study participants will undergo the 68Ga-citrate PET/MR imaging after all screening and baseline assessments have been completed. Patient shall begin imaging between 120 and 360 minutes after the injection of the radiopharmaceutical. Coverage for the scan will extend from the patient's vertex to the neck. The entire imaging study will take roughly 90 minutes.
108846|NCT03335267|Drug|CPX-351|Cytarabine:Daunorubicin Liposome Injection
108847|NCT03335254|Drug|TSX-011|TSX-011 are capsules with Testosterone Undecanoate (prodrug for androgen testosterone) as the primary ingredient.
108848|NCT03335241|Drug|Fludarabine and Pegylated liposomal doxorubicin|"Fludarabine 25mg/m2 iv on days d1-d3 of each 4-week cycle~Pegylated liposomal doxorubicin 30mg/m2 iv every 4 weeks"
108849|NCT03335241|Drug|Pegylated liposomal doxorubicin|Pegylated liposomal doxorubicin 50mg/m2 iv every 4 weeks
108850|NCT03335228|Device|Eclipse Easy Spin for PRP|Autologous platelet rich plasma is prepared from subject's blood with the Eclipse Easy Spin centrifuge and injected into affected areas.
108851|NCT03335215|Other|cognitive remediation|The innovative nature of this program is that it integrates both neuropsychological psychoeducation, the principles of reeducation of altered cognitive functions and the setting in addictological context benefiting from the interactions of the group situation. Thus, during the three months of REMED management, six modules corresponding to six altered cognitive domains that may have an impact on the maintenance of the therapeutic contract will be offered to patients. The REMED group will benefit from cognitive remediation of episodic memory disorders, executive and attentional functions, and the theory of the mind integrating psychoeducation, training and systematic situations related to an alcoholic context. The different procedures of neuropsychological management (facilitation, use of preserved capacities and compensation) will help to integrate the concepts and addictological strategies necessary to maintain the therapeutic contract taking into account cognitive impairments.
108852|NCT03335202|Diagnostic Test|analysis of microbiome|microbial profiling by next generation sequencing
108853|NCT03335189|Device|ASyMS-Can|Data reported by the participants will be sent to a secure, encrypted clinical central server hosting the risk-alerting algorithms. The web interfaces will provide a clinical portal for the nurses to screen and follow any alerts being triggered, as well as review patient-specific information. Based on these back-end computations, participants will receive automated self-care notifications on their mobile phones. If incoming symptom reports indicate severe adverse effects a designated clinic nurse will receive an 'amber alert', or 'red alert', that will require response within 30 minutes. Nurses will handle alerts during business hours (9 am to 5 pm). After-hour alerts will be sent to the oncologist or nursing supervisor on call as per usual care. Patients will be instructed that clinicians will not receive alerts during the evening hours or night and instructed to follow usual practice of contacting their family physician, or oncologist on call, or call 911, as required.
108854|NCT03335176|Behavioral|Endurance ad Resistance Training Exercise|Patients received a 6-week tele-supervised rehabilitation with 3 exercise sessions per week
108955|NCT03334422|Drug|Baricitinib|Administered orally
108956|NCT03334422|Drug|Placebo|Administered orally
108957|NCT03334409|Drug|Ascorbic Acid|Given IV
108958|NCT03334409|Drug|Pazopanib Hydrochloride|Given PO
108959|NCT03334396|Drug|Baricitinib|Administered orally.
108855|NCT03335163|Drug|Topiramate|"Topiramate - Participants will undergo a 6 week titrated regimen of oral topiramate to reach a maximum dose of 400mg per day:~Week 1 - topiramate PO 25mg daily Week 2 - topiramate PO 25mg twice daily Week 3 - topiramate PO 50mg twice daily Week 4 - topiramate PO 100mg twice daily Week 5 - topiramate PO 150mg twice daily Week 6 - topiramate PO 200mg twice daily"
108856|NCT03335150|Behavioral|CogSMART-PD|Cognitive Rehabilitation for persons with PD-MCI
108857|NCT03335150|Behavioral|Supportive Care|Support Group for persons with PD-MCI
108858|NCT03335137|Diagnostic Test|Drug Level Monitoring|Free (unbound) drug concentration 1 hour, 4 hours and 7.5 hours after primary load of piperacillin/tazobactam on day 1 and day 3 after admission
108859|NCT03335124|Drug|Vitamin C|Vitamin C: Vitamin C will be applied as per instructions described in arm/group descriptions.
108860|NCT03335124|Drug|Hydrocortisone|Hydrocortisone: Hydrocortisone will be applied as per instructions described in arm/group descriptions.
108861|NCT03335124|Drug|Thiamine|Intravenous thiamine will be applied as per instructions described in arm/group descriptions.
108862|NCT03335124|Drug|0.9% Sodium Chloride Injection|0.9 % Sodium Chloride will be applied as placebo as per instructions described in arm/group descriptions.
108863|NCT03335111|Other|Remote Ischemic Conditioning Equipment|BAIPC is admistrated by 5 cycles extremities ischemia (5-minute blood-pressure cuff inflation up to 50 mmHg higher than baseline, followed by 5-minute cuff deflation) for one week.
108864|NCT03335111|Procedure|Intravenous blood collection|Nurses will collect 5 ml intravenous blood with anticoagulant and 5ml total blood at 0d, 1d and 7-10d respectively. The blood samples will be stored for laboratory assay. The blood samples only use in this trial.
108865|NCT03335098|Drug|Bortezomib|Six 4-week cycles
108866|NCT03335085|Drug|Oxytocin|
108867|NCT03335085|Other|Placebo|
108868|NCT03335072|Drug|Azithromycin|Mass Drug Administration
108869|NCT03335059|Combination Product|Synergo® RITE + MMC|Subjects will receive a series of induction followed by a series of maintenance bladder instillations of Synergo® RITE + MMC
108870|NCT03335046|Behavioral|Home Visit|The intervention will consist of a series of home visitations to chronically absent students with co-morbid asthma. These visits will consist of a home environment evaluation, medication adherence and knowledge assessment, distribution of home environmental allergen reduction items such as mattress and pillow encasements, as well as review and reinforcement of any asthma action plans or care plans provided by patient's primary care physicians or medical home.
108871|NCT03335046|Behavioral|Standard Care|Standard care will refer to the procedures carried out by the school district to address students with chronic absenteeism. This includes parent-teacher and parent-school administrator meetings and communications and may also include home visits carried out by classroom teachers or student support center staff.
108872|NCT03335033|Combination Product|Contrast-enhanced ultrasound|Subjects will receive a low mechanical index (0.17-0.20) imaging during ultrasound contrast agent intravenous infusion. Real-time cine-loop including longitudinal and transverse images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the carotid artery will be acquired and digitally stored for offline analysis. Also use of a 3D ultrasound transducer to evaluate the feasibility of using US images with contrast to assess the residual diameter of the diseased vessel. Specifically, two 3D acquisitions of each lesion would be obtained after contrast has been injected.
108873|NCT03335033|Device|Shear Wave Elastography|Shear wave elastography will be performed with the General Electric Logiq E9 scanner acquiring images of each plaque in the longitudinal and transverse imaging planes. In each plane 10 measurements will be made and the in-phase/quadrature (IQ) data will be saved for further analysis. The plaque area in the imaging plane will be user-defined to extract the wave velocity values for a ROI analysis.
108874|NCT03335033|Device|Ultrasound Examination|A standard carotid US examination using Duplex imaging will performed using a linear array transducer to obtain longitudinal and transverse images. All ultrasound measurements will be made by a trained registered vascular technologist. Severity of stenosis of the plaque will be measured based on established protocol and guidelines.
108875|NCT03335020|Device|Shear Wave Elastography|The subject will be asked to lay on a hospital bed for ultrasound imaging of the arteries. The subject will have an automatic blood pressure cuff put on to measure blood pressure. The subject will also have a three-lead ECG taken during the experiment. The artery will be visualized using ultrasound imaging, and the depth of the arterial wall will be noted. The focal depth on the device will be set to measure shear wave propagation in the walls of the artery. Measurements will be made at multiple locations along the artery's length and at different phases of the cardiac cycle determined by ECG gating. Either or both the Verasonics or GE Logiq systems will be used for measurements. Measurements made with these systems use acoustic output within the FDA regulatory limits of diagnostic imaging.
108876|NCT03335020|Device|Pulse Wave Imaging|Researchers will use the Verasonics device to acquire data for measurement of wave velocity in the tissue of interest (arterial walls and surrounding tissue) due to the pressure pulse from ejection of blood by the heart into the systemic circulation. Using ECG gating we can regulate the timing of the individual acquisitions. In each acquisition, high frame rate ultrasound imaging is used to acquire data to measure the motion of the propagating waves. Multiple measurements on different heartbeats are made with varying delays to obtain measurements throughout the heart cycle assuming at that the behavior during consecutive heartbeats is similar. Multiple measurements will be made in a given artery and multiple locations in the arterial wall.
108877|NCT03335020|Drug|Contrast-Enhanced Ultrasound|Will be done using Lumason (Bracco Diagnostics, Inc) administered intravenously via slow hand infusion. Real-time contrast-enhanced carotid cine-loop (longitudinal and short axis) images obtained at least 3 seconds before and 5 minutes after the appearance of the contrast effect in the lumen of the determined artery will be acquired and digitally stored for off line analysis. Up to two vials will be used for a study.
108960|NCT03334396|Drug|Placebo|Administered orally.
108961|NCT03334383|Device|Sponge|Compressed cellulose sponge for use in laparoscopic surgery to retract the intestines from the surgical field.
108962|NCT03334357|Other|PAR|
108963|NCT03334357|Other|HIIT|
108964|NCT03334357|Other|WB-EMS|
108965|NCT03334344|Device|Ceevra Reveal|VR models generated using Ceevra Reveal are viewed by surgeons in connection with the case in addition to source CT/MR image.
108878|NCT03335020|Other|Strain Imaging|Measurements will be performed offline on the workstation using Echo PAC software (GE Healthcare Inc., Princeton, NJ). The media-adventitia interface of the arterial wall will be manually traced from a still frame image. The circumferential and radial strain curves will be automatically obtained. Measurements of the peak radial and circumferential strain, strain rate will be obtained. If arterial plaque is identified: A region of interest will be placed at the plaque in 3 different regions: 2 shoulder regions and the fibrous cap top, the measurement results of the peak longitudinal, radial and circumferential strain, strain rate will be acquired by the software.
108879|NCT03335020|Device|3-D Volume Ultrasound|When generating a 3D volume the ultrasound data can be collected in 4 common ways. Freehand, which involves tilting the probe and capturing a series of ultrasound images and recording the transducer orientation for each slice. Mechanically, where the internal linear probe tilt is handled by a motor inside the probe. Using an endoprobe, which generates the volume by inserting a probe and then removing the transducer in a controlled manner. The fourth technology is the matrix array transducer that uses beam steering to sample points throughout a pyramid shaped volume
108880|NCT03335007|Drug|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
108881|NCT03335007|Other|Placebo|Placebo tablet given one hour before starting the root canal treatment
108882|NCT03334994|Procedure|Intervention group:(Group B) connective tissue graft combined with immediate implant.|Patients will be treated with connective tissue graft combined with immediate implant.
108883|NCT03334981|Procedure|Concentrations in Meconium of Buprenorphine and Methadone|buprenorphine or methadone concentration measurement
108884|NCT03334955|Procedure|Laparoscopic ovarian drilling|A specially designed monopolar electrocautery probe was used to penetrate the ovarian capsule at 4 points, with the aid of a short burst of monopolar diathermy. The probe (which has a distal stainless steel needle measuring 10 mm in length and 2 mm in diameter) was applied to the surface of the ovary at a right angle to avoid slippage and to minimize surface damage. A monopolar coagulating current at a 40 W power setting was used. The needle was pushed through the ovarian capsule for about 4 mm depth into the ovarian tissue and electricity was activated for 4 seconds.
108885|NCT03334942|Behavioral|Child and Family Traumatic Stress Intervention|The Child and Family Traumatic Stress Intervention (CFTSI) is a 5-8 session intervention, initiated within 60 days of trauma exposure for youth reporting acute PTSS. CFTSI is designed for children age 7 and older, and requires the involvement of a parent who knows the child well enough to report changes in the child's behavior and symptoms. CFTSI targets modifiable risk and protective factors during the early post-trauma period to promote recovery and reduce PTSS via parent-child communication and cognitive and emotional processing. CFTSI uses skill modules (e.g., sleep disturbance, intrusive thoughts, anxiety) to teach effective strategies to decrease a child's PTSS. Coping and communication skills are taught and practiced in parent-child sessions and in the home.
108886|NCT03334929|Device|Virtual Reality headset|The participants in this group would wear Virtual Reality headset called Oculus Gear VR during their trigger point injections.
108887|NCT03334916|Drug|YMC026|YMC026 20mL TID
108888|NCT03334916|Drug|Placebo|Placebo 20mL TID
108889|NCT03334903|Drug|Gabapentin|600 mg gabapentin before and after surgery. 300 mg gabapentin for approx. 5 weeks after surgery.
108890|NCT03334890|Diagnostic Test|plasma mSEPT9 level|the plasma level of methylated SEPT9
108891|NCT03334877|Diagnostic Test|β -human chorionic gonadotropin|Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.
108892|NCT03334851|Drug|PF-06835375|Intravenous (IV) or subcutaneous (SC) administration. Subjects will receive one or two doses. Doses will be ascending and determined by emerging data.
108893|NCT03334851|Drug|Placebo|Matching placebo for PF-06835375 IV or SC. Subjects will receive one or two doses.
108894|NCT03334838|Drug|Nifurtimox (Lampit, BAYA2502)|Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
108895|NCT03334825|Other|Enhanced housing placement assistance|assistance in the rapid (fast-track) acquisition of permanent housing; and participation in a 12-month support services program designed to prevent PLWHA from relapsing into homelessness, with services focused on increasing clients' capacity to live independently and maintain housing stability
108896|NCT03334825|Other|Standard housing placement assistance|standard connections to services and housing programs offered by HASA, HOPWA, or Ryan White
108897|NCT03334812|Biological|LNA043|LNA043 Single dose
108898|NCT03334812|Biological|placebo to LNA043|placebo to LNA043 single dose
108899|NCT03334812|Biological|LNA043 40mg/4ml|LNA043 40mg/4ml Single Dose
108900|NCT03334812|Biological|placebo to LNA043 40mg/4ml|Matching placebo to 40 mg
108901|NCT03334799|Device|sacroiliac belt|standing and walking with the belt on and with the belt off
108902|NCT03334786|Drug|FLX-787-ODT|Oral Disintegrating Tablet
108903|NCT03334773|Behavioral|Nutrition education|
108904|NCT03334760|Other|Danish National Birth Cohort|DNBC is a nationwide cohort study of pregnant women and their offspring. The women were enrolled early during pregnancy between 1996 and 2002. They provided information on exposures during and after pregnancy by means of four computer-assisted telephone interviews in gestational weeks 12 and 30 and post-partum when the child was 6 and 18 months old.
108905|NCT03334747|Drug|KAE609|Exploration of different doses of KAE609 to establish safety profile.
108906|NCT03334747|Drug|Coartem|Control Arm
108907|NCT03334734|Drug|PBTZ169|Once a day for 14 days
108908|NCT03334734|Drug|Isoniazid|Once a day for 14 days
108909|NCT03334721|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
108910|NCT03334721|Drug|Placebo Oral Capsule|5 day trial of matched placebo
108966|NCT03334331|Other|Six-minute step test|Volunteers will be instructed to go up and down one step for six minutes
108967|NCT03334331|Other|Six-minute walk test|Volunteers will walk the longest distance possible by performing turns in a 30 meter corridor for six minutes
108968|NCT03334318|Other|Mean blood glucose|Mean of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108969|NCT03334318|Other|Blood glucose CV|Coefficient of variation of blood glucose values measures by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108911|NCT03334708|Diagnostic Test|Blood Draw|"If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria:~Patients and controls weighing 50kg or more~For draw amounts up to 50mL, there is no required hemoglobin threshold.~For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period.~Patients and controls weighing < 50kg~For patients whose hemoglobin is below normal limits but at least 7.0 gm/dL, no more than a total of 50 ml of blood or 5 ml/kg, whichever is less, may be collected per 56 day/eight week period, but no more than approximately 2 ml/kg of blood at any one time."
108912|NCT03334708|Diagnostic Test|Tumor Tissue Collection|Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
108913|NCT03334708|Diagnostic Test|Cyst Fluid|Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere
108914|NCT03334695|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1*10^11 vp in single-use vials.
108915|NCT03334695|Drug|Placebo|Placebo will be administered as sterile 0.9% saline for injection.
108916|NCT03334682|Drug|spironolactone|Dispensation of spironolactone at each visit according to the arm description described above.
108917|NCT03334682|Drug|Doxycycline|Dispensation of doxycycline then placebo, at each visit according to the arm description described above.
108918|NCT03334669|Behavioral|Parents Connect for Healthy Living (PConnect)|Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health;
108919|NCT03334669|Behavioral|Enhanced Nutrition Support|Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child is classified as overweight or obese;
108920|NCT03334669|Behavioral|Media Resources|Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families.
108921|NCT03334656|Biological|biological dressing|to test a biological dressing on the wound healing of the split-thickness skin graft donor site
108922|NCT03334656|Other|Paraffin gauze dressing|standard intervention : Paraffin gauze dressing on the wound healing
108923|NCT03334643|Dietary Supplement|Fiber mix|Participants will test white bread or fiber mix over a span of 2 weeks. During each testing block, each food will be tested twice over two consecutive days. There are 4 testing blocks in total (one for white bread and three for fiber mix).
108924|NCT03334630|Device|DiamondTemp Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
108925|NCT03334630|Device|TactiCath Quartz Ablation catheter|a pulmonary vein isolation procedure will be performed using radiofrequency ablation catheter
108926|NCT03334617|Drug|Durvalumab|Durvalumab given IV at 1500 mg Q4W ±2 days
108927|NCT03334617|Drug|AZD9150|AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
108928|NCT03334617|Drug|AZD6738|AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
108929|NCT03334617|Drug|Vistusertib|Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
108930|NCT03334617|Drug|Olaparib|Olaparib (AZD2281) given orally at 300 mg BD
108931|NCT03334617|Drug|Oleclumab|Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
108932|NCT03334604|Dietary Supplement|Multispecies probiotic|Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10^9 Colony Forming Units (CFU), twice daily, orally.
108933|NCT03334604|Other|Placebo|Placebo identical in taste, smell and color to the multispecies probiotic.
108934|NCT03334591|Drug|Apatinib|Apatinib 500mg with Docetaxel 60mg/m2
108935|NCT03334578|Drug|Gastrografin|Gastrografin group
108936|NCT03334565|Device|Low efficiency air filtration systems|
108937|NCT03334565|Device|High efficiency air filtration systems|
108938|NCT03334565|Device|Air filtration systems without filters (sham)|
108939|NCT03334539|Biological|HL036 ophthalmic solution|HL036 ophthalmic solution
108940|NCT03334539|Other|Placebo vehicle solution|Placebo vehicle solution
108941|NCT03334526|Other|physical training|workout on treadmill requiring the muscles of the lower limbs mostly in concentric (ascent) or eccentric (downhill)
108942|NCT03334526|Other|mental training|The task to imagine for the training group will be an abduction of the thumb
108943|NCT03334526|Other|electrical stimulation|electrical stimulation of the muscles
108944|NCT03334513|Drug|Bevacizumab|intravitreal injection of bevacizumab
108945|NCT03334513|Drug|Ranibizumab|intravitreal injection of ranibizumab
108946|NCT03334500|Device|[18F]FluorThanatrace|Fluorine-18 labeled FluorThanatrace [18F]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is < 10 μg.
108947|NCT03334500|Drug|Poly(ADP Ribose) Polymerase 1|Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
108948|NCT03334487|Drug|Dexamethasone|Oral
108949|NCT03334487|Drug|Rovalpituzumab tesirine|Intravenous
108950|NCT03334461|Combination Product|Exposure to oral antiseptics or enamel remineralisation agent|
108951|NCT03334448|Drug|LY900014-U200|Administered SC
108952|NCT03334448|Drug|LY900014-U100|Administered SC
108953|NCT03334435|Drug|Baricitinib|Administered orally
108954|NCT03334435|Drug|Placebo|Administered orally
108970|NCT03334318|Other|% time 70-180 mg/dL|Percent of time with blood glucose in the 70-180 mg/dL range as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108971|NCT03334318|Other|% time below 54 mg/dL|Percent of time with blood glucose below 54 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108972|NCT03334318|Other|% time above 180 mg/dL|Percent of time with blood glucose above 180 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108973|NCT03334318|Other|% time above 250 mg/dL|Percent of time with blood glucose above 250 mg/dL as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108974|NCT03334318|Other|MAGE (Mean amplitude of glucose excursions)|Mean amplitude of glucose excursions as measured by continuous glucose monitoring as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108975|NCT03334318|Other|LBGI (Low Blood Glucose Index)|Low blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108976|NCT03334318|Other|HBGI (High Blood Glucose Index)|High blood glucose index as measured by continuous glucose monitoring from week 80 to week 164 of the PERL trial.
108977|NCT03334318|Drug|Allopurinol|Oral allopurinol tablets administered in the PERL Clinical Trial
108978|NCT03334318|Drug|Placebo|Oral placebo tablets administered in the PERL Clinical Trial
108979|NCT03334305|Biological|TTRNA-DC vaccines with GM-CSF|After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.
108980|NCT03334305|Drug|Dose-intensified TMZ|After chemoradiation, subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. All subjects will have an additional five cycles of dose-intensified TMZ (for a total of 6 Cycles) with concurrent monthly DC vaccinations.
108981|NCT03334305|Biological|Autologous Hematopoietic Stem cells (HSCs)|Prior to chemoradiation, enrolled subjects will undergo a mobilized leukapheresis for collection of PBSCs and PBMCs for generation of DCs. One group will receive recommended dose of > 2 x 106 CD34+ HSCs/kg. Subjects enrolled in Group B will receive HSCs during TMZ Cycle 6 before receiving DC vaccine and T-cell infusion.
108982|NCT03334305|Biological|TTRNA-xALT|During TMZ Cycle 6 and with DC vaccine #8, an infusion of T-cells will be administered to all subjects.
108983|NCT03334305|Drug|Td vaccine|A full Td booster vaccine will be administered IM at Vaccine #1 to all subjects, and vaccine site pretreatment will be administered to all subjects prior to Vaccine#3, #6, and #8.
108984|NCT03334279|Other|Cigarette smokers|frequent cigarette smoking for not less than 5 years
108985|NCT03334279|Other|Simultaneous cigarette and cannabis smokers|frequent cigarette and cannabis smoking for not less than 5 years
108986|NCT03334266|Behavioral|Family Spirit Nurture (FSN)|The FSN home-visiting module consists of 36 60-minute lessons delivered by trained local FHCs, from 28 weeks gestation to 18 months postpartum. The lessons focus on three key content domains: 1) promotion of optimal breastfeeding, complementary and responsive feeding across early childhood; 2) promotion of healthy infant/toddler diet and physical activity, as well as reduced screen time and sedentary lifestyle; and 3) promotion of maternal psychosocial well-being, optimization of healthy food/beverage availability and identification/creation of safe play spaces in the home environment.
108987|NCT03334266|Other|Injury Prevention Education (IPE)|The control group will receive Injury Prevention Education (IPE). The IPE home-visiting module consists of 8 30-minute lessons delivered by trained local Family Health Liaisons (FHL), from 28 weeks gestation to 18 months postpartum. Injury prevention lessons focus on injury prevention topics relevant to the participating communities, including: motor vehicle safety for mothers and children; preventing scald burns; fire safety; child-proofing a home; preventing falls; preventing poisonings; and preventing animal bites.
108988|NCT03334266|Other|Optimized Standard Care (OSC)|OSC will be available to both in the FSN intervention and control groups. OSC consists of transportation assistance to prenatal and well-baby clinic visits as recommended by the Indian Health Service (IHS) and American Academy of Pediatrics (AAP) and rescue services through linkages to community agencies as needed.
108989|NCT03334253|Drug|Atropine|Daily 0.01% atropine eyedrops
108990|NCT03334253|Other|Placebo Eyedrops|Daily placebo eyedrops
108991|NCT03334240|Drug|CLS003|CLS003
108992|NCT03334240|Drug|Vehicle|Vehicle
108993|NCT03334227|Device|High-Flow nasal cannula (HFNC)|The patient will receive HFNC adjusted for SatO2 > 92% and with, at least, 30 liters of total flow.
108994|NCT03334214|Drug|IONIS DGAT2Rx|Single Dose of DGAT2Rx administered subcutaneously once weekly for 13 weeks
108995|NCT03334214|Drug|Placebo|Saline 0.9%
108996|NCT03334201|Other|Western Diet|high fat (40%), high sugar (25%) and low fiber (15g/day)
108997|NCT03334201|Other|Non-Western Diet|low fat (25%), low sugar (15%), high fiber (30g/day)
108998|NCT03334188|Behavioral|Patient engagement materials|The intervention is a brief, animated video designed to engage and activate patients around their HFrEF medication prescribing, as well as a HFrEF medication checklist.
108999|NCT03334188|Behavioral|No Intervention--Usual Care|Control for intervention--patient receives care as usual from provider to contrast against intervention arm.
109000|NCT03334175|Drug|Walnuts|1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
109024|NCT03333902|Procedure|QLB|QLB, quadratus lumborum block.
109025|NCT03333902|Procedure|Intravenous patient controlled analgesia (PCA)|Intravenous patient controlled analgesia (PCA) pump was used to supply additional analgesia and removed 48 h post-operationally.
109026|NCT03333889|Other|Vita Enamic hybrid crown|hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
109027|NCT03333889|Other|emax hybrid crown|high srength glass ceramic that can be milled in sections up to 1mm .
109075|NCT03333538|Biological|GamEvac-Lyo (component A)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component A
109001|NCT03334162|Behavioral|Sensorimotor training|"Supervised training sessions will last for about 20 to 30 minutes in total, including a child-specific warm-up and cool-down. The children will be asked to maintain balance in a previously acquired short-foot-position, knees slightly flexed (30°), without shoes. Training will consist of 5 playful balance exercises, chosen from a standardized pool of exercises according to the child's age, with increasing difficulty (5 degrees of difficulty - e.g. by reducing the base of support, or dual task exercises - per exercise depending on the age group) in order to allow for individual, optimal progression. Each of the 5 exercises will contain of 5 repetitions for 10sec. allowing for a 20sec. rest in between each set and a 1min rest between each exercise in order to avoid neural fatigue. Children will be given a training manual and diary to train at home after the study. Guardians will be instructed in order to be able to assist their children"
109002|NCT03334149|Other|Self-Monitoring of Blood Pressure|"BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system."
109003|NCT03334136|Drug|25-Hydroxyvitamin D|Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
109004|NCT03334136|Drug|Placebo oral capsule|Five capsules the first day and thereafter one capsule every week for 4 months.
109005|NCT03334123|Other|Functional training and cycling|"First 8 weeks: patients will perform 20 minutes of functional training before their dialysis procedure. The exercise program will be run by kinesiologists, who will also teach patients how to perform exercises on their own at home. During intradialysis cycling 3 times weekly participants will cycle on adapted ergometer. Participants will start with 10 - 15 minutes of cycling and then gradually increase time and intensity up to 45 minutes of duration.~Second phase of 8 weeks: participants will no longer perform functional training before dialysis but will be motivated, monitored and advised to perform functional exercise at home on non-dialysis days for 20-30 minutes and continue with cycling sessions during the dialysis procedures three times weekly."
109006|NCT03334123|Other|Cycling|"First 8 weeks: cycling on an adapted ergometer during dialysis; starting with 10 - 15 minutes of cycling and then gradually increasing time and intensity up to 45 minutes of duration.~Second 8 weeks: continue with cycling at the target duration and intensity during dialysis."
109007|NCT03334110|Procedure|A method of operation: LIMA-GSV-SCVBG|On the experimental group,We treat patients with the operation of LIMA-GSV composited Y graft and anastomose the GSV with selective coronary vein
109008|NCT03334110|Procedure|BIMA-SCVBG|On the other group, We treat patients with the operation of bilateral internal mammary artery composited LIMA-Right Mammary Artery（RIMA） y graft and anastomose the Right Mammary Artery(RIMA) with selective coronary vein.
109009|NCT03334097|Other|Prenatal education|"Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~rd: Puerperium.~rd :Breastfeeding~rd : Newborn care~rd :Positive parenting."
109010|NCT03334084|Drug|ARGX-113|intravenous or subcutaneous administration
109011|NCT03334071|Behavioral|Exercise|"High intensity interspersed with short periods of exercise at a moderate intensity (aerobic interval training). We will also include resistance training in each session.~The supervised in-hospital exercise training sessions will last <1 hour, exercise training intensities will be individually tailored to each CPET. Exercise training will involve repeated exercise bouts of 3 minutes at a moderate exercise intensity (80%AT) followed by 2 minutes of exercise at a high intensity (50%Δ) for a predetermined amount of time.~The home-based training programme will involve stair climbing (where possible) and brisk walking to achieve heart rates commensurate with those achieved during the in-hospital exercise training sessions."
109012|NCT03334058|Drug|ARGX-113|human IgG1-derived Fc fragment that binds to human neonatal Fc receptor (FcRn)
109013|NCT03334045|Radiation|PET/MR scans|Observations of glucose metabolism and dopamine binding potential
109014|NCT03334032|Other|Inpatient treatment for Anorexia nervosa|Nutritional rehabilitation in a clinic with specialized eating disorder service
109015|NCT03334019|Other|blood test|Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
109016|NCT03334006|Drug|Pentaglobin®|Standard of Care + Pentaglobin®
109017|NCT03333993|Other|Pilates Exercise|The Mat Pilates exercise will be performed twice a week and the duration of the sessions will be 60 minutes, consisting of 5 minutes of warm-up exercises, 50 minutes of strengthening exercises followed by 5 minutes of relaxation and stretching.
109018|NCT03333993|Other|Home exercises|Exercises for upper limbs according to the institutional routine.
109019|NCT03333954|Device|PRIMA|"The PRIMA Bionic Vision System is a device for treatment of patients who have lost their sight through outer retinal degenerative conditions of the eye such as atrophic dry age related macular degeneration.~The PRIMA System is designed to provide partial restoration of the patient's visual function through electrical stimulation of the retinal neurons by a sub-retinally implanted stimulator that replace part of the degenerate photoreceptors"
109020|NCT03333941|Device|ReCell® Autologous Cell Harvesting Device|RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.
109021|NCT03333928|Drug|HTD1801|HTD1801 tablets, 250mg
109022|NCT03333928|Drug|Placebo|tablets manufactured to mimic HTD1801 tablets
109023|NCT03333915|Drug|Pamiparib|Pamiparib is provided as oral capsules，Three dose levels will be evaluated as 20mg, 40mg, 60mg separately， twice a day in phase I and will be used with single dose based on RP2D in phase II.
109028|NCT03333876|Device|Nasal Dilator|Mute is a pair of nasal dilators that fit snugly in the nose of the snorer dilating the nostrils to help reduce or eliminate snoring. This is an over-the-counter (OTC) product and is cleared by FDA for use in the United States. The introduction video for Mute is located at http://mutesnoring.com/how-to-use/.
109029|NCT03333876|Device|Mandibular Advancement|"For purposes of this trial, we will be using an investigational myTAP V, which is not available for commercial use. The changes from the released product are: a vertical offset (+3mm) has been added to the design of the adjustment post and mechanism to improve overall comfort.~myTAPTM is a mandibular advancement device used for snoring relief. The product requires a prescription and is cleared by FDA for use in the United States."
109030|NCT03333876|Device|Positional Therapy|Sleep Positional Trainer (SPT) is a small device worn around the chest with an ergonomic band that continuously monitors the sleep position of the snorer. When the snorer is supine, it emits a gentle vibration to remind them to turn to the side to help reduce or eliminate their snoring.
109031|NCT03333863|Other|descriptive study which reviewed the data of patients hospitalized with positive bacterial cultures|A retrospective, descriptive study was conducted at shengjing hospital of China Medical University between 2015- 2017. Data regarding bacterial culture isolates, antimicrobial susceptibility spectrum, and the general data of patients with fever or suspicion of sepsis were collected.
109032|NCT03333850|Device|Visual feedback of physical activity|A monitor (tablet) will display the level of physical activity during hospitalisation. The monitor will be placed at the bedside (table).
109033|NCT03333850|Device|No feedback of physical activity|There will be no visual feedback of the physical activity (no monitor placed at the bedside (table)).
109034|NCT03333850|Device|Measurement of physical activity|A pair of accelerometers placed on the chest and on the thigh will measure the physical activity level during hospitalisation. The measurement is made continuously and stored on a secure web-server.
109035|NCT03333837|Behavioral|Dance Group|Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.
109036|NCT03333837|Behavioral|Non-Group Dance|The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.
109037|NCT03333837|Behavioral|Social Group|The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
109038|NCT03333837|Behavioral|No Contact|The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.
109039|NCT03333824|Drug|CYP1A2 (caffeine)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
109040|NCT03333824|Drug|CYP2C19 (omeprazole)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
109041|NCT03333824|Drug|CYP3A (midazolam)|In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
109042|NCT03333824|Drug|Kytril (granisetron)|Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775 capsules with a small amount of water.
109043|NCT03333824|Drug|Wee-1 kinase inhibitor AZD1775|Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
109044|NCT03333798|Behavioral|Cognitive-Behavioral Intervention|"A Cognitive-Behavioral intervention will be delivered by psychologists with LPCWs support. LPCWs who will be under the supervision and guidance of psychologists.~Volunteers will receive 11 weekly sessions of which six will be provided by psychologists and five by LPCWs.~The Cognitive-Behavioral component will be delivered through a set modules that will cover the following components:~The Cognitive-Behavioral model~Tackling traumatic events~Cognitive reprocessing~Relaxation techniques~Prevention of revictimization~Behavioral reactivation for the start of a new life The intervention will be given within the health system and volunteers will be seen if necessary by an interdisciplinary team including social workers, general physicians and psychiatrists."
109074|NCT03333551|Drug|F18 Florbetapir (amyvid) cardiac PET/CT imaging|Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
109045|NCT03333798|Behavioral|Standard psychosocial care|"The active control group will receive standard psychosocial care for intimate partner violence, provided by the participating health centers. Standard care is delivered by psychologists, social workers, general physicians and psychiatrists. Additionally, patients receive extramural support which includes telephone calls or domiciliary visits from a variety of health professionals (doctors, nurses, social workers and nursing assistants).~Psychology consultations typically occur every four weeks in each health center. Psychologists use a variety of approaches according to their personal preferences, including humanist, psychoanalytic, psychodynamic and cognitive-behavioral approaches. At the end of the intervention psychologists will be asked which approach or approaches they used."
109046|NCT03333785|Behavioral|eOncoNote|"Diagnosis phase: The patient's nurse navigator will initiate an eOncoNote to the patient's PCP, inviting them to send any questions related to the patient's diagnostic process. The nurse navigator will initiate case closure after the diagnostic process has been completed (case will be open up to 4 months).~Treatment phase: The patient's medical or radiation oncologist will initiate an eOncoNote to the patient's PCP inviting them to ask questions related to the patient's cancer treatment and/or request information related to the patient's co-morbidities. The oncologist will initiate case closure after the treatment has been completed.~Survivorship phase: The patient's registered nurse within the Wellness Beyond Cancer Program will send an eOncoNote invitation to the patient's PCP inviting them to ask any questions as the patient transitions back to their care. The nurse will initiate case closure after one year."
109047|NCT03333772|Behavioral|REAL-T Intervention|Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
109048|NCT03333759|Device|Alma - Harmony XL Laser|The Erbium YAG laser at a 2940nm wavelength is used for ablative laser resurfacing as well as treating acne scars.
109049|NCT03333746|Other|Laboratory Biomarker Analysis|Correlative studies
109050|NCT03333746|Drug|Lenalidomide|Given PO
109051|NCT03333746|Biological|Nivolumab|Given IV
109052|NCT03333746|Other|Pharmacological Study|Correlative studies
109053|NCT03333733|Behavioral|HENRY|"HENRY is an 8-week programme delivered in Children's Centres, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. It is currently delivered in ~ 35 local areas across England and Wales by trained health and community practitioners. Training includes:~Centre Level Training: to equip staff with knowledge and skills to promote and provide healthy nutrition within early years settings and support parents to provide healthy family lifestyles and nutrition for their families. The theoretical underpinning combines proven models of behaviour change including the Family Partnership Model, motivational interviewing and solution-focused support.~Practitioner Level Training: to deliver the 8-week HENRY programme, which aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition for their young children."
109054|NCT03333720|Dietary Supplement|Phenylalanine-free protein substitute tablets|Thirty eligible PKU patients (≥ 8 years), identified as current tablet users, will be recruited to this study. Patients will firstly observe a 7-day baseline period. During baseline, patients will continue with their existing diet and protein substitute prescription before receiving Phenylalanine-free protein subsitute tablets daily for 28 days in addition to appropriate nutritional management.
109055|NCT03333707|Behavioral|Pacifica App|The app contains several activities which are digital implementations of standard psychotherapy practices. Users may select which app elements they would like to use, and when. These app elements include relaxation and meditation activities, tools to examine your thoughts or self-talk, goal setting lists, and mood and health ratings. The app also has a peer support community where users can communicate with others who are having similar experiences. There is no minimum requirement for amount of time spent on any given activity, or in the app in total. The commercially available app has a feature to connect users to their existing healthcare providers, but this feature will not be available to study participants. Study participants may continue to see their existing providers.
109056|NCT03333694|Drug|Cutaneous Cream application|Cutaneous Cream application twice daily with experimental (CLL442)
109057|NCT03333694|Drug|Placebo Cutaneous Cream application|Cutaneous Cream application twice daily with placebo
109058|NCT03333681|Biological|Autologous mesenchymal stem cells|A single intravenous administration of autologous bone marrow derived mesenchymal stem cells(1000000 to 2000000 cells/Kg)
109059|NCT03333668|Drug|Lisdexamfetamine dimesylate|Lisdexamfetamine dimesylate (30mg for smaller, 50mg for larger boys) tablet
109060|NCT03333668|Drug|Guanfacine Extended Release Oral Tablet|Guanfacine Extended Release (0.05mg/kg) tablet
109061|NCT03333668|Drug|Placebo|Vitamin C (10mg) tablet
109062|NCT03333655|Procedure|Biopsy|Participants who received or are receiving CPI therapy for metastatic cancer or hematologic malignancies.
109063|NCT03333642|Procedure|Duodenal Ileal Interposition with Sleeve Gastrectomy|Laparoscopic or open Duodenal Ileal Interposition with Sleeve Gastrectomy
109064|NCT03333629|Behavioral|Enhanced early detection|standardized screening
109065|NCT03333616|Drug|Ipilimumab|is an immunotherapy medication that stimulates the immune system to fight cancer cells throughout the body.
109066|NCT03333616|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1. This results in the activation of T-cells and cell-mediated immune responses against tumor cells
109067|NCT03333603|Drug|esomeprazole|esomeprazole 40mg /tab oral Day1-Day14 then 40mg/2 tab oral Day15-Day56
109068|NCT03333590|Biological|rAAVrh74.MCK.GALGT2|Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)
109069|NCT03333577|Device|SoundArc|non-surgical attachment method for wearing a bone conduction hearing system
109070|NCT03333564|Dietary Supplement|VD3|50,000 IU VD3 / week for 8 weeks
109071|NCT03333564|Dietary Supplement|Omega3-FA|300 mg of omega3-FA once daily for 8 weeks
109072|NCT03333564|Dietary Supplement|VD3 and Omega-3FA|50,000 IU VD3 / week for 8 weeks and 300 mg of omega-3FA once daily for 8 weeks
109073|NCT03333564|Other|Control|No intervention was given
109077|NCT03333538|Biological|GamEvac-Lyo (component B)|Biological: GamEvac-Lyo (vaccine) vaccination, single administration, component B
109078|NCT03333538|Biological|GamEvac-Lyo|Biological: GamEvac-Lyo (vaccine) vaccination, therapeutic scheme: the sequential introduction of components A and b with an interval of 21 days
109079|NCT03333525|Other|Calculation of insulin dosages for different meals|Calculation of insulin dosages For CARB counting meals using insulin-carbohydrate ratio for dosing mealtime boluses. For fat protein counting meal ICR and additionally fat-protein unit were used for dosing of mealtime boluses.
109080|NCT03333512|Behavioral|Nap|Looking at the difference between continuous sleep opportunities and split-sleep opportunities.
109081|NCT03333499|Drug|YanXinShi placebo pills|participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
109082|NCT03333499|Drug|YanXinShi pills|participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
109083|NCT03333499|Drug|Trimetazidine pills|participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
109084|NCT03333499|Drug|YanXinShi and Trimetazidine pills|participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure
109085|NCT03333486|Drug|Cyclophosphamide|Given IV
109086|NCT03333486|Drug|Fludarabine Phosphate|Given IV
109087|NCT03333486|Other|Laboratory Biomarker Analysis|Correlative studies
109088|NCT03333486|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT
109089|NCT03333486|Radiation|Total-Body Irradiation|Undergo TBI
109090|NCT03333473|Behavioral|PPFP Clinical and Counseling Skills|Facilities will receive whole-site orientations on PPFP basics and skills Through training of trainers, followed by classroom and model-based and clinical-based practice, providers will receive training in PPDP counseling and service provision.
109091|NCT03333473|Behavioral|Facility-Level Leadership Management and Governance Training|The intervention will strengthen leadership management and governance practices required to help managers establish PPFP services at the facility level.
109092|NCT03333460|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique. The investigators will use a MagPro R30 with the Cool-B80 figure-of-eight coil (MagVenture, Falun, Denmark).
109093|NCT03333447|Other|MRI|
109094|NCT03333434|Device|Carbon Ankle Seven spring (A7 - Otto Bock, Germany)|
109095|NCT03333434|Device|Hinged AFO|
109096|NCT03333408|Drug|Postoperative Oral Antibiotics (Clindamycin or Augmentin)|Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
109097|NCT03333395|Drug|Nebulized heparin and salbutamol|HS Group medications (study group) (30 patients) which was prepared by adding Heparin 25000 IU in 5ml (5 ampoules of Heparin Sodium 5000 I.U/ML, Nile company for Pharmaceuticals and Chemical Industries-A.R.E.) to Salbutamol 5mg/2.5ml Nebulizer Solution (one Ventolin nebule containing a preservative-free solution of Salbutamol Sulphate BP 2.5mg, GlaxoSmithKline Inc.)
109098|NCT03333395|Drug|Nebulized salbutamol|S Group medications (control group) (30 patients) which was prepared by adding Salbutamol 5mg/2.5ml Nebulizer Solution + Na cl 0.9% 5ml.
109099|NCT03333382|Device|Plastic biliary stent|Plastic biliary stent which functions largely as a wick to siphon bile flow from the site of anastomotic leak.
109100|NCT03333382|Device|FCSEMS|FCSEMS has a relatively larger expansile diameter and membrane coating to provide an actual seal at site of anastomotic leak.
109101|NCT03333369|Drug|200 mg levodopa/50 mg benserazide|
109102|NCT03333369|Drug|Dextrose|
109103|NCT03333356|Radiation|pelvic radiotherapy|adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction /day (duration of RT is 38 days).
109104|NCT03333343|Drug|EGF816|Study Drug
109105|NCT03333343|Drug|trametinib|Study Drug
109106|NCT03333343|Drug|ribociclib|Study Drug
109107|NCT03333343|Drug|LXH254|Study Drug
109108|NCT03333343|Drug|INC280|Study Drug
109109|NCT03333343|Drug|gefitinib|Study Drug
109110|NCT03333330|Drug|Visipaque 320 and SonoVue|"Intervention is related to the administration of contrast agents:~Iodixanol, 320 mg of iodine per millilitre, Visipaque 320 (GE Healthcare, Milwaukee, WI, USA) for contrast-enahnced CTA, Sodium hexafluoride (SonoVue, Bracco Imaging, Milan, Italy) for CEUS"
109111|NCT03333317|Drug|Lumicitabine|Participants will receive oral administration of lumicitabine.
109112|NCT03333317|Drug|Placebo|Participants will receive oral administration of matching placebo.
109113|NCT03333304|Diagnostic Test|Procalcitonin measurement|Discontinuation of antimicrobials according to Procalcitonin Kinetics
109114|NCT03333291|Dietary Supplement|fecal suspension|helathy donor fecal suspension administered by duodenal scope
109115|NCT03333278|Drug|Vitamin C|Ascorbic acid 1.5g every 6 hours i.v. while in ICU, until shock resolution for a maximum of ten days
109116|NCT03333278|Drug|Thiamine|Thiamine 200mg every 12 hours i.v. while in ICU, until shock resolution for a maximum of ten days
109117|NCT03333278|Drug|Hydrocortisone,|Hydrocortisone 50mg every 6 hours i.v while in ICU, until shock resolution or for a maximum of 7 days, then tapered or stopped.
109118|NCT03333265|Drug|100mg Berberine hydrochloride|patients take the Berberine hydrochloride 100mg tablet by mouth, 2 times a day with 6 months
109119|NCT03333265|Drug|300mg Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 6 months
109120|NCT03333265|Drug|Placebo Oral Tablet|patients take mmic Berberine hydrochloride tablet by mouth, 2 times a day with 6 months
109121|NCT03333252|Behavioral|Intervention Condition|Caregivers will access caregiving related information. Care Recipients will access cognitive training program
109122|NCT03333252|Behavioral|Control Condition|Caregivers will access Nutrition and Health Promotion material. Care Recipients will access words and card games
109123|NCT03333239|Behavioral|psychodynamic psychotherapy|the intervention follows the published in german manual: Psychoanalytische Behandlung von Kindern und Jugendlichen mit Angststörungen und Depressionen: Behandlungsmanual (Baumeister-Duru, Hofmann, Timmermann & Wulf, 2013)
109670|NCT03329248|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
109124|NCT03333239|Behavioral|cognitive behavioral psychotherapy|the interventions follow the published in german manuals: Depression (Ihle, Groen, Walter, Esser, & Petermann, 2012) and Soziale Ängste und Leistungsängste (Büch, Döpfner, & Petermann, 2015)
109125|NCT03333239|Behavioral|psychodynamic family intervention|the intervention follows an adapted version of the manual: Chimp´s - Children of mentally ill parents (Wiegand-Gefe, Halverscheid, & Plass, 2011)
109126|NCT03333226|Procedure|Axillary Reverse Mapping (ARM)|ARM lymph node preservation versus removal
109127|NCT03333213|Other|Gua Sha|
109128|NCT03333200|Other|Palliative Care|Collecting information about the natural progression of these diseases
109129|NCT03333200|Biological|Hematopoetic Stem Cell Transplantation|Following patients who have received HSCT as part of their clinical care.
109130|NCT03333187|Procedure|Allogeneic stem cell transplantation|
109131|NCT03333187|Drug|Ruxolitinib continuous therapy|
109132|NCT03333174|Diagnostic Test|Cardiorespiratory monitoring|The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
109133|NCT03333161|Diagnostic Test|Cardiorespiratory monitoring|We will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations).
109134|NCT03333148|Drug|Nestle IMPACT Immunonutrition|Along with standard of care nutritional therapy patients (n=146) will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
109135|NCT03333148|Other|Arm B- Standard of Care|No intervention standard of care nutrition (n=146).
109136|NCT03333135|Device|Pulsed Electromagnetic Field|Therapy based on Biological Electromagnetic (BEM) microbial wave technology of the Pulsed Electromagnetic Field Therapy (PEMF). The device provides micro-magnetic emissions to the center of the palm (Laogong acupoint). While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will involve using the device on the Laogong acupoint for 16-min (8-min for left and 8-min for right hand).
109137|NCT03333135|Device|Pulsed Electromagnetic Field Sham|The device will function and be used exactly the same as the real PEMF device except when turned on and performing a treatment it will not produce an micro-magnetic emissions. The device will be used on the center of the palm (Laogong acupoint) of each hand. While participating in the study, the subjects will undertake 2 sessions of therapy every day (1 session in the morning and evening). Each session will involve using the device on the Laogong acupoint for 16-min (8-min for left and 8-min for right hand).
109138|NCT03333109|Biological|Erenumab|AMG334 is a fully human monoclonal antibody targeting the CGRP receptor under development for migraine prophylaxis in adults.
109139|NCT03333109|Other|Placebo|Placebo will match the active study drug and will be administered similarly.
109140|NCT03333096|Device|Ocusweep test battery|"Ocusweep test battery to measure vision, visual system and cognitive performance including attention~(Comparison of Ocusweep system to conventional neuropsychological test methods)~(With the help of Ocusweep tests, information is obtained about the functioning of the whole visual system - from the ability of the eye to see to the efficiency of the brain to process visual information and the accuracy of eye movements)"
109141|NCT03333096|Diagnostic Test|Neuropsychological test battery|Conventional neuropsychological test battery to measure executive functioning, attention, visuoconstructive abilities and processing speed
109142|NCT03333083|Drug|Raltegravir|Raltegravir (1200 mg once a day)
109143|NCT03333083|Drug|Lamivudine|Lamivudine (300 mg once a day)
109144|NCT03333070|Dietary Supplement|probiotic - Lactobacillus reuteri|The treated arm will receive 5 drops per day for 48 weeks
109145|NCT03333070|Other|placebo - with no active ingredient|The control arm will receive 5 drops per day for 48 weeks
109146|NCT03333057|Drug|NOV03|100% Perfluorohexyloctane
109147|NCT03333057|Drug|Placebo|Saline solution (0.9% sodium chloride solution)
109148|NCT03333044|Behavioral|Community Health Worker (CHW)-led health|Patients contacted a maximum of 10 times over 2 weeks to attend diabetes management sessions led by community health workers. Enrolled patients attend 5 Monthly group sessions led by a CHW held at the clinic
109149|NCT03333044|Behavioral|HIT-enabled|During one on one visit, CHWs will assess social needs of patients using mobile technology. CHWs will give referral sources to patients generated by mobile app, and they will track through mobile app.
109150|NCT03333044|Behavioral|Physician enabled care coordination|Forms on patient goal setting and referrals made are uploaded into EHR to physician
109151|NCT03333031|Drug|HS-196|HS-196 will be administered intravenously as a single dose
109152|NCT03333018|Drug|Aclidinium bromide|Administered as monotherapy, prescribed as recorded in the database.
109153|NCT03333018|Drug|Aclidinium bromide/formoterol|Administered in combination with formoterol fumarate (concomitant or as a fixed-dose combination), prescribed as recorded in the database.
109154|NCT03333018|Drug|Other COPD medication|"Other COPD medication including:~tiotropium; other long-acting anticholinergic (LAMAs; lycopyrronium bromide, umeclidinium); LABA (formoterol, salmeterol, indacaterol); LABA/ICS (formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone propionate, and vilanterol/fluticasone); LAMA/LABA (approved or under regulatory review or in development; glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol), prescribed as recorded in the database."
109155|NCT03333005|Drug|APX001 with Standard of Care anti-fungal agent|safety assessment
109156|NCT03332992|Behavioral|Viral changes|Telephone script language provided pre-questions regarding the fact that influenza viruses change each year
109157|NCT03332992|Behavioral|Protect others|Telephone script language provided pre-questions emphasizing the need to protect vulnerable others
109158|NCT03332992|Behavioral|General intentions|Question language asking about general interest in getting influenza vaccination
109159|NCT03332992|Behavioral|Behavioral intentions|Question language asking individual to make specific plans to be vaccinated
109160|NCT03332992|Behavioral|Accountability|Question language asking individual whether their care team can learn about their vaccination intentions
109161|NCT03332966|Diagnostic Test|Psychiatric questionnaires|"Participants will fill in questionnaires and be interviewed by clinic staff as part of routine intake assessments.~The questionnaires are: A-DES, APRI-B, ASSIST-Lite, A-TADS, AUDIT, BDI, BRS, ESPAD Gaming, FAD GF6+, GAD-7, IAT, ISI, Mini-SPIN, MSPSS, HSI (Nicotine), PSQI, ESPAD SoMe, SWEMWBS, YEAH"
109162|NCT03332953|Other|E-cigarettes with varying concentrations of nicotine & flavor|Subjects will be asked to vape various e-cigarettes containing e-liquids at three concentrations of nicotine and sweet flavor (9 stimuli per subject).
109163|NCT03332940|Drug|Tc 99M Sulfur Colloid|Sulfur colloid is a radiotracer that is indicated for imaging areas of functional reticuloendothelial cells in the liver, spleen, and bone marrow.
109164|NCT03332940|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
109165|NCT03332927|Other|Egg based breakfast foods|Two eggs/day, 6 days per week provided as breakfast foods such as burrito-type roll-up, egg sandwich and omelet.
109166|NCT03332927|Other|Non-egg based breakfast foods|Non-egg based control foods provided as breakfast foods 6 days per week such as waffles, ready-to-eat cereal, fruits and cheeses.
109167|NCT03332914|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
109168|NCT03332901|Other|this is an observational study, no intervention required|this is an observational study, no intervention required
109169|NCT03332888|Drug|Rituximab|Rituximab will be studied in patients with HFrEF, and verify the patients safety.
109170|NCT03332875|Behavioral|OurRelationship Online Program|OurRelationship.com is an online program designed to improve distressed romantic relationships.
109171|NCT03332862|Procedure|catheter ablation|catheter ablation for atrial fibrillation treatment
109172|NCT03332849|Biological|HM12470|HM12470 is a long-acting insulin analogue
109173|NCT03332836|Biological|HM12460A|HM12460A is a long-acting insulin
109174|NCT03332823|Behavioral|SME Ambassadors training & program|"Two train-the-ambassador workshops: to train the ambassadors on positive thinking and understanding of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~The trained SME ambassadors will provide voluntary services and promote mental well-being messages to vulnerable groups, such as ex-mental illness people, new arrivals, etc."
109175|NCT03332810|Behavioral|SME family based physical activity|"One train-the-trainer workshop: to train the service providers from 8-15 NGO service units on the concept of SME, ways of conducting mental well-being activities and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder).~Two SME family-based physical activities held by each NGO service unit: to organize enjoyable activities according to the needs of individual district as well as to promote positive psychology under the theme of SME. All these activities are organized by the NGO service providers in collaboration with District Healthy City Committee."
109176|NCT03332810|Behavioral|Gathering activity|- Gathering activities will be held for control groups. However, SME concept or techniques will not be introduced during the activity. Physical activity will not be used as the intervention method.
109177|NCT03332797|Drug|GDC-9545|GDC-9545 will be administered orally, once daily, on Days 1-28 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
109178|NCT03332797|Drug|Palbociclib|Palbociclib will be administered orally, once daily, at the label-recommended dose of 125 mg on Days 1-21 of each 28-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
109179|NCT03332797|Drug|LHRH Agonist|The LHRH agonist will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
109180|NCT03332784|Drug|TAK-925|TAK-925 Intravenous Infusion
109181|NCT03332784|Drug|Placebo|TAK-925 Placebo Intravenous Infusion
109182|NCT03332771|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
109183|NCT03332771|Drug|glimepiride|"Pharmaceutical form: capsule~Route of administration: oral"
109184|NCT03332771|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
109185|NCT03332771|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
109186|NCT03332771|Drug|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
109187|NCT03332758|Procedure|Pars plana vitrectomy|Standard of care treatment for retinal detachment, macular hole, or epiretinal membrane.
109188|NCT03332758|Procedure|External drainage|Standard of care treatment for retinal detachment.
109189|NCT03332732|Drug|VNRX-5133|β-lactamase inhibitor
109190|NCT03332732|Drug|VNRX-5022|Approved β-lactam antibiotic
109191|NCT03332732|Drug|Metronidazole|Approved antibiotic and antiprotozoal medication
109192|NCT03332732|Drug|Placebo|Placebo (matching VNRX-5133 + VNRX-5022)
109193|NCT03332719|Biological|Etanercept|
109194|NCT03332719|Drug|Methotrexate|
109195|NCT03332706|Other|observation|after the subjects are included into the groups,they are asked to do a questionaire.Then,we just observe the outcomes of pregnancy
109196|NCT03332693|Other|Exercise|Leg weight raising
109197|NCT03332693|Other|No exercise|Volunteers will not participate in exercise
109198|NCT03332680|Biological|EmbryoGlue® (laboratory culture medium)|Embryos placed in this medium prior to transfer
109199|NCT03332680|Biological|Standard control medium|Embryos placed in this medium prior to transfer
109200|NCT03332667|Radiation|131I-MIBG|Patients will receive 131I-MIBG on day 1. 131I-MIBG dose will be based on the dose level assigned at the time of patient registration
109201|NCT03332667|Drug|Ch14.18 Monoclonal Antibody|Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
109202|NCT03332654|Other|Determine prevalence of stress urinary incontinence|
109203|NCT03332641|Dietary Supplement|Citron peel extract|Citron peel extract for 12 weeks
109204|NCT03332641|Dietary Supplement|Placebo|Placebo for 12 weeks
109206|NCT03332615|Behavioral|Motivational Interviewing|Clinicians in the intervention arm will be taught Motivational Interviewing via a coaching model in which a didactic session is followed by feedback through review of clinicians' audio-recorded encounters.
109207|NCT03332615|Behavioral|Wait-list control|After consent, clinicians in the wait-list control arm will complete a survey to self-assess their motivational interviewing skills and burnout.
109208|NCT03332602|Dietary Supplement|free FeSO4|Testmeal with free FeSO4
109209|NCT03332602|Dietary Supplement|free FeSO4 and empty microspheres|Testmeal with free FeSO4 and empty micropsheres
109210|NCT03332602|Dietary Supplement|free FeSO4 and hylauronic acid|Testmeal with free FeSO4 and hyaluronic acid
109211|NCT03332602|Dietary Supplement|free FeSO4 and eudragit polymer|Testmeal with free FeSO4 and eudragit polymer
109212|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%|Testmeal with encapsulated FeSO4 with 3.2% Fe loading
109213|NCT03332602|Dietary Supplement|encapsulated FeSO4 20%|Testmeal with encapsulated FeSO4 with 20% Fe loading
109214|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%, encapsulated Vitamin A|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A
109215|NCT03332602|Dietary Supplement|encapsulated FeSO4 3.2%, encapsulated Vitamin A, free Folic Acid|Testmeal with encapsulated FeSO4 with 3.2% Fe loading, and encapsulated Vitamin A, with free folic acid.
109216|NCT03332602|Dietary Supplement|FeSO4 embedded in Hyaluronic acid|Testmeal with FeSO4 embedded in Hyaluronic acid
109217|NCT03332589|Drug|E6201|E6201 for Injection formulated in cyclodextrin for intravenous (IV) administration
109218|NCT03332576|Biological|DPX-Survivac|SubQ injection
109219|NCT03332576|Biological|DPX-Survivac(Aqueous)|SubQ injection
109220|NCT03332576|Drug|Cyclophosphamide|PO BID
109221|NCT03332563|Behavioral|Cognitive-behavioral intervention for chronic pain|WebMAP is a technology-based cognitive-behavioral intervention program that teaches relaxation skills, pain coping strategies and parent behavioral and communication techniques to youth with chronic pain and their parents.
109222|NCT03332550|Procedure|Laparoscopic lavage|Operation with laparoscopic lavage for perforated diverticulitis Hinchey 3
109223|NCT03332550|Procedure|Colon resection|Operation with colon resection for perforated diverticulitis Hinchey 4
109224|NCT03332537|Behavioral|Personalized IBS Pain SM|
109225|NCT03332524|Drug|SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg|2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
109226|NCT03332524|Drug|2 capsules Ibuprofen and 1 placebo|Ibuprofen and placebo
109227|NCT03332524|Drug|capsule Chlorpheniramine 4mg and 1 Placebo|Chlorpheniramine 4mg and one capsule Placebo 3/72days
109228|NCT03332511|Drug|Nilotinib|Nilotinib 300mg twice-daily
109229|NCT03332498|Drug|Pembrolizumab|200 milligrams of pembrolizumab will be given through an IV (intravenously) for about thirty minutes. Pembrolizumab is an anti-PD1 that functions by inhibiting checkpoint inhibition and reversing T cell suppression.
109230|NCT03332498|Drug|Ibrutinib|Ibrutinib oral capsules every day starting on cycle 1, day 1. Ibrutinib is primarily a BTK inhibitor which has been approved for the treatment of several hematologic malignancies.
109231|NCT03332485|Drug|ECP Colon Prep Kit|ECP Colon Prep Kit
109232|NCT03332485|Drug|MoviPrep®|MoviPrep®
109233|NCT03332472|Other|Telemedicine group|
109234|NCT03332472|Other|Conventional group|
109235|NCT03332459|Drug|Lumicitabine|Participants who received lumicitabine in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
109236|NCT03332459|Drug|Placebo|Participants who received placebo in a feeding Phase 2 study (64041575RSV2004) will be observed in this study.
109237|NCT03332446|Other|cold water immersion|10 min at 12-15°C
109238|NCT03332433|Device|High-flow nasal cannula oxygenation|Oxygen is supplied with a high-flow nasal cannula oxygenation device，the flow is up to 60L/min
109239|NCT03332381|Behavioral|Attention training technique|Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.
109240|NCT03332381|Behavioral|Mindful self-compassion|Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
109241|NCT03332368|Other|Traditional Chinese medicine|Chinese medicine has a long history of prevention and treatment of breast cancer, the effect is obvious. Chinese medicine its mechanism of action is from the whole, adjust the body yin and yang, blood, viscera function balance, emphasizing the combination of governance and external treatment of the combination of thinking, according to different clinical syndromes, using syndrome differentiation.
109242|NCT03332355|Drug|PAC-1 Compound|PAC-1 in combination with temozolomide (Component 2): after the MTD is established for single agent PAC-1 in Component 1, a modified-Fibonacci dose-escalation 3+3 design starts in Component 2, at a PAC-1 dose one level lower than the MTD of PAC-1 established in the single agent PAC-1 component (i.e., Component 1). PAC-1 will be taken in the morning on days 1-21 in each 28 day cycle. Temozolomide 150 mg/m2 dose is given for the 5 days starting at day 8 of cycle 1 in cohorts of 3-6 patients. The combination cohort that reaches MTD will expanded to at least 9 patients, similar to the PAC-1 alone cohort at MTD.
109243|NCT03332342|Other|Eye wash|Research subjects will perform a wash of their ocular surface with phosphate buffered saline
109244|NCT03332329|Drug|Entecavir|Entecavir is used for 96 weeks
109245|NCT03332329|Drug|Granulocyte Macrophage Colony Stimulating Factor|Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
109246|NCT03332329|Drug|Y peginterferon alfa-2b|Y peginterferon alfa-2b is used for 96 weeks
109247|NCT03332329|Drug|HBV vaccine|60ug HBV vaccine is used every four week for 24 weeks
109248|NCT03332316|Drug|Dexamethasone Sodium Phosphate|Dexamethasone injection
109249|NCT03332316|Drug|Ropivacaine Hydrochloride Inj 2 mg/ml|Ropivacaine injection
109250|NCT03332316|Drug|Sodium Chloride 9mg/mL|Sodium Chloride injection
109251|NCT03332303|Drug|Estrace® Cream|Brand Product
109252|NCT03332303|Drug|Estradiol Vaginal Cream|Generic formulation of the brand product
109253|NCT03332303|Drug|Vehicle Cream|Has no active ingredient
109254|NCT03332290|Behavioral|sport practice|the intervention was a training course lasting 10 days. It included 10 days of sports practice. For divers, diving was carried out using air at a maximum depth of 40-meters, with a maximum of one dives a day. For the multisport group (the non-divers), the course included kayaking, mountain climbing or hiking with a maximum of two activities a day.
109255|NCT03332277|Device|Active Bodysuits|The wear trial period will be 9-12 months for each subject depending on the active biofeedback training progress. The bodysuits should provide active biofeedback training to the users. By incorporating the IMU sensors, the body alignment in the sagittal or coronal planes can be detected to provide feedback to the users via a wireless platform. This training will be customized to each individual user and will achieve a uniform body alignment goal that benefits the user. The participants will be assessed using the Scoliosis Research Society questionnaire (SRS-22r), the Oswestry Disability Index (ODI) and health-related quality-of-life (HRQOL) measures.
109256|NCT03332264|Device|SeQuent Please OTW|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated balloon catheter
109257|NCT03332264|Device|Eluvia Vascular Stent System|Dilatation of occluded or highly stenosed vessel with paclitaxel-coated stent
109258|NCT03332264|Device|Nitinol stent|Dilatation of occluded or highly stenosed vessel with uncoated bare nitinol stent
109259|NCT03332251|Device|Posture Correction Girdle|Participants will be invited to undergo a fitting session of posture correction girdle. After the fitting, participants will join a 6-month wear trial of the posture correction girdle. Participants are required to wear the girdle for 8 hours a day and the compliance will be recorded by a logbook daily. Participants will be invited to undergo assessments before the wear trial, after the trial of 3 months, and after the trial of 6 months. The measure outcomes of the assessment include 1) ultrasound scanning image, 2) 3D body scan, 3) electromyography signal, 4) garment pressure, and 5) questionnaire.
109260|NCT03332238|Device|Autologous Stomal Vascular Fraction Material|Autologous Stomal Vascular Fraction Material Prepared from the Tissue Genesis® Icellator Cell Isolation System™
109261|NCT03332238|Device|Ringer's solution|Ringer's solution
109262|NCT03332225|Drug|Anakinra|Treatment with anakinra
109263|NCT03332225|Drug|Recombinant human interferon-gamma|Treatment with recombinant human interferon-gamma
109264|NCT03332225|Drug|Placebo|Treatment with Placebo
109265|NCT03332212|Drug|Empagliflozin|12 weeks
109266|NCT03332212|Drug|Placebo|12 Weeks
109267|NCT03332199|Other|Psycho-educational intervention|The total program, consisting of three intervention sessions, was given over a period of 3 weeks. The one face-to-face session of an-hour's duration was provided within a week of the chemotherapy cycle following recruitment. Two booster sessions of 20-30 minutes were then conducted by phone at one-week intervals after the first intervention session.
109268|NCT03332186|Drug|BMS-986231|Intravenous infusion administration
109269|NCT03332173|Drug|BGB-3111|BGB-3111 160 mg twice daily(BID) (in 80 mg white opaque capsules) administered orally
109270|NCT03332160|Device|Flexitouch head and neck lymphedema treatment system|Pneumatic compression device cleared for use by medical professionals and patients who are under medical supervision, for the treatment of many conditions such as: lymphedema; primary lymphedema; post mastectomy edema; edema following trauma and sports injuries; post immobilization edema; venous insufficiency; reducing wound healing time; treatment and assistance in healing stasis dermatitis, venous stasis ulcers, or arterial and diabetic leg ulcers. The Flexitouch system and garments for head and neck are intended for use by medical professionals and patients who are under medical supervision for the treatment of head and neck lymphedema.
109271|NCT03332160|Other|Standard home lymphedema care|May include daily self manual lymphatic drainage, exercise, skin care, compression garments (as appropriate).
109272|NCT03332147|Device|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
109273|NCT03332147|Device|reference group-Earlysense system|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
109274|NCT03332134|Behavioral|Intimate Partner Violence (IPV) Prevention Intervention|The IPV intervention consists of six sessions. Each session will cover one of 6 major modules to enhance transformation of motivation: 1) You, Me, and Us: Spending Meaningful Time Together, 2) I'm a Champion: I Can't Be Broken and I don't Accept Defeat! 3) Building Communication and conflict management strategies, and 4) Empowerment of the Couple: Planning Ahead, 5) Sexual communication and the sexual relationships, and 6) A Lens into Domestic Violence. The sessions will be audio-recorded and include a combination of didactics, interactive discussions, media use, and role play. The expected durations of session 1, 2-6, and the 3-month follow-up are 120 minutes, and 60-90 minutes, respectively.
109275|NCT03332121|Biological|B001|4 times intravenous injection totally,dosing at Day1,Day35,Day56,Day77
109276|NCT03332108|Other|EpxBreastfeeding|"We developed an algorithm using the Epharmix platform, an automated toll-free phone and text message-based system that can programmatically query patients via their personal phones and subsequently collect response data, allowing clinically-relevant responses to trigger alerts to designated healthcare providers. The intervention for breastfeeding, hereafter referred to as EpxBreastfeeding, was built using significant clinical and patient input to only ask the most clinically-relevant questions for breastfeeding in a multiple-choice manner, such as In the past [x] days, have you fed your baby 1) breast milk only, 2) breast milk and formula or 3) formula only?. These communications elicit patient-reports of breastfeeding at intervals of interest for the provider, which is, on average, every 2 days in the first three weeks postpartum and every 5 days subsequently. All data is filtered by clinician-designed algorithms to stratify patients into categories."
109277|NCT03332108|Other|Baby book survey|"We developed a baby book template that will be given to mothers allowing them to make note of dates related to their child's development during the first year. Examples include: When was baby's first appointment with his/her pediatrician? When did you add formula into baby's feeding? When did you start feeding baby only formula? When did you introduce solid food into baby's diet? When did baby first smile? When did you start reading to baby? What was the first book you read to baby? Whe"
109278|NCT03332095|Drug|Doravirine (DOR)|100 mg of DOR administered orally
109320|NCT03331809|Procedure|Conventional intubation|The attending anesthesiologist provided intubation with double-lumen tube endotracheal tube without two-handed jaw thrust.
109279|NCT03332095|Drug|Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF)|DOR/3TC/TDF administered orally as a fixed-dose combination (as a tablet, 100 mg/300 mg/300 mg, or as oral granules provided in three capsules that each contain 33.6 mg/100 mg/100 mg) once daily
109280|NCT03332095|Drug|Antiretroviral (ARV) medications|Participants in Cohort 1 will be taking a combination of dolutegravir (DTG) or raltegravir (RAL) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The ARV drugs will be prescribed by participants' own health care providers and will not be provided by the study.
109281|NCT03332082|Procedure|Tooth positioner|Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
109282|NCT03332069|Device|Modulated electro-hyperthermia|Modulated electro-hyperthermia device used is the EHY 2000 by Oncotherm GmbH
109283|NCT03332069|Radiation|External beam radiation|
109284|NCT03332069|Drug|Cisplatin|
109285|NCT03332069|Radiation|Brachytherapy|High Dose Rate
109286|NCT03332056|Drug|Belladonna and Opium|
109287|NCT03332056|Other|Placebo suppository|
109288|NCT03332043|Device|HIRREM|HIRREM (Brain State Technologies, Scottsdale, AZ) is a closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided algorithmic analysis to identify and translate selected brain frequencies into audible tones of varying pitch and timing, to support real-time self-optimization of brain activity.
109289|NCT03332043|Other|Ambient Nature Sounds|Digitally recordings of various ambient nature sounds such as a stream, waterfall, ocean waves, or rainfall, are provided via ear buds.
109290|NCT03332030|Diagnostic Test|Collection of Stem Cells|One time collection of a 20 ml blood sample
109291|NCT03332017|Drug|BGB-3111|BGB-3111 will be administered as two 80-mg capsules by mouth twice a day (160 mg twice a day)
109292|NCT03332017|Drug|obinutuzumab|Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks. 1 cycle = 28 days.
109293|NCT03332004|Drug|Indocyanine Green|0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
109294|NCT03331991|Biological|influenza vaccine|exposure to influenza vaccine
109295|NCT03331978|Behavioral|Rise - Treatment Education|Rise consists of a one-month intensive intervention (with three core 60-minute counseling sessions at weeks 1, 2, and 4) followed by two booster sessions (at weeks 12 and 20). If participants show nonadherence during booster sessions, they are offered up to four additional booster sessions (i.e., extra booster sessions if <85% of prescribed doses were taken in the past month). Thus, participants receive three core sessions in the first month, followed by 2-6 booster sessions over the next four months.
109296|NCT03331965|Drug|Metoclopramide 5 MG/ML Injectable Solution|A one-time dose of promotility agent (metoclopramide 10 mg in 10 mL saline IV) will be administered at the time of GJ placement.
109297|NCT03331965|Drug|Saline|A one-time dose of a placebo (10 mL saline IV) will be administered at the time of GJ placement.
109298|NCT03331952|Other|Prospective study|To identify and characterise patients with culture proven invasive pneumococcal disease or probable bacterial meningitis over the first three years after PCV13 introduction in Cambodia in January 2015.
109299|NCT03331952|Other|Prospective study|To identify and characterise patients hospitalised with clinical and/or radiologic pneumonia over the first three years after PCV13 introduction in Cambodia in January 2015
109300|NCT03331952|Other|Cross-sectional surveys|Three annual surveys, enrolling 450 children each year, will be done to identify and characterise pneumococcal nasopharyngeal colonisation in AHC out-patient department (OPD) attendees
109301|NCT03331939|Other|no stimulation|Vagal nerve stimulator will be set to no stimulation
109302|NCT03331939|Other|beta (25-30 Hz)|Vagal nerve stimulator will be set to beta (25-30 Hz)
109303|NCT03331939|Other|Theta (5 Hz)|Vagal nerve stimulator will be set to beta (5 Hz)
109304|NCT03331926|Drug|Xiapex|Follow-up of effect of treatment
109305|NCT03331913|Drug|Botulinum Toxin type A (intradermal / submucosal injection at pain area)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
109306|NCT03331913|Drug|Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)|Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
109307|NCT03331900|Drug|COR388|Administered as oral capsule
109308|NCT03331900|Drug|Placebo|Administered as oral capsule
109309|NCT03331887|Procedure|E-max CAD endocrown|endocrown used to restore endodontically treated teeth with E-max CAD endocrowns
109310|NCT03331887|Procedure|E-max CAd crowns retained with fiber reinforced composite post|fiber reinforced composite post need to restore endodontically treated tooth with E-max crown
109311|NCT03331874|Diagnostic Test|Reflectance Confocal Microscopy|In-vivo microscope
109312|NCT03331861|Drug|Metformin hydrochloride|Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
109313|NCT03331861|Drug|Placebo|Similar dosing regime as active comparator
109314|NCT03331848|Drug|Placebo oral capsule|BID
109315|NCT03331848|Drug|PXT002331 - 20mg|Oral
109316|NCT03331835|Biological|Brodalumab|"Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2-antibody that binds with high affinity to human interleukin 17 receptor A (IL-17RA).~Blocking IL-17RA inhibits IL-17 cytokine-induced responses and results in reduced or normalised inflammation of the skin in subjects with psoriasis."
109317|NCT03331835|Drug|Fumaric acid esters|Fumaric acid esters have been used to treat psoriasis since 1959. Systemic therapy with fumaric acid esters is based on an established dosing scheme with a gradual increase to improve tolerability, especially with regards to gastrointestinal side effects.
109318|NCT03331822|Other|Bright Light|high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day*Light Classic Light will be positioned at each nursing station in the ICU hallway.
109319|NCT03331809|Procedure|Two-handed jaw thrust|The assistant applied two-handed jaw thrust when intubating with double-lumen tube endotracheal tube.
109321|NCT03331796|Device|Active rTMS (Bilateral DLPFC)|TMS Stimulation Parameters for the active DLPFC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
109322|NCT03331796|Device|Active rTMS (Bilateral LPC)|TMS Stimulation Parameters for the active LPC rTMS intervention group will be: 10 Hz, 4-second train duration and 11-second inter-train interval. During each session, 2,000 pulses will be applied for each hemisphere (for a total of 4,000 pulses per session). Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
109323|NCT03331796|Device|Placebo rTMS (Inactive)|For the Placebo rTMS (Inactive) group, the participant will wear scalp electrodes through which a low voltage, low electric current (2-20mA at no more than 100V) is passed to mimic the sensation of receiving actual rTMS. Participants will receive 20 sessions (1 or 2 sessions per day, M-F).
109324|NCT03331783|Other|Standard hydrocolloid adhesive patch|This patch is made of a standard hydrocolloid adhesive
109325|NCT03331783|Other|LT-2|This patch is made of a new adhesive
109326|NCT03331783|Other|LT-21|This patch is made of a new adhesive
109327|NCT03331783|Other|33-20|This patch is made of a new adhesive
109328|NCT03331770|Drug|Latanoprost Ophthalmic Product|Multidose bottle, preserved with potassium sorbate, that can be stored at room temperature up to 30°C during all shelf life, the emulsion does not require shaking before use
109329|NCT03331757|Other|Glucose as reference food|Eleven subjects (male: 2, female: 9) consumed 50g glucose diluted in 300ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
109330|NCT03331757|Other|Fir honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of fir honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
109331|NCT03331757|Other|Heather honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of heather honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
109332|NCT03331757|Other|Citrus honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of citrus honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
109333|NCT03331757|Other|Pine honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of pine honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
109334|NCT03331757|Other|Thyme honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of thyme honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
109335|NCT03331757|Other|Chestnut honey|Eleven subjects (male: 2, female: 9) consumed 50g available carbohydrates of chestnut honey diluted in 300ml water, tested once, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
109336|NCT03331731|Drug|pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
109337|NCT03331718|Drug|PGA felt reinforcement|During pancreaticojejunostomy, 1) a 0.3 mm thick PGA felt (Neoveil®, Gunze, Japan) is pasted on the ventral side and the dorsal side of pancreatic parenchyma, through which suture between pancreatic parenchyma and jejunum is performed. 2) Before abdominal closure (after completion of all reconstruction, after washing in the abdominal cavity), a 0.15 mm thick PGA felt is further covered around the anastomotic site and fibrin glue is sprayed.
109338|NCT03331705|Device|Uro-C (Use of new cystoscope)|Diagnostic cystoscopic procedure of the urethra and bladder
109339|NCT03331692|Other|monitoring of the proper level of general anesthesia|The monitoring of the adequate level of general anesthesia was performed both clinically and instrumentally.
109340|NCT03331679|Behavioral|HIIT|2 Weeks of High Intensity Interval Training on a Cycle ergometer
109341|NCT03331666|Drug|Evolocumab|140 mg every 14 days A monoclonal antibody designed for the treatment of hyperlipidemia
109342|NCT03331653|Other|Dry Needling and Ischemic Compression at the Trigger Point|The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.
109343|NCT03331653|Other|Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point|The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
109344|NCT03331640|Drug|OFF|"OFF:~5-FU 2000 mg/m2 as 24 hour infusion + Na folinic acid 200 mg/m2 on D1, 8, 15, 22 Oxaliplatin 85 mg/m2 on D8, 22 3 weeks rest after D22; Cycle q42d"
109345|NCT03331640|Drug|FOLFIRI Protocol|Irinotecan 180 mg /m2 5-FU 400 mg/m2 (bolus) + 2400 mg/m2 as 46 hour infusion Na folinic acid 200 mg/m2 Cycle q2w
109346|NCT03331627|Drug|STR001-IT and STR001-ER|STR001-IT intrataympanic injection and STR001-ER tablet
109347|NCT03331614|Device|Flowaid FA-100 SCCD|The SCCD is a contained external non invasive electric muscle pump. The device attaches to the rear of the calf with 4 electrodes.
109348|NCT03331601|Drug|68GaNOTA-Anti-HER2 VHH1|Injection of the radiopharmaceutical and PET/CT 90 min post injection
109349|NCT03331588|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections
109350|NCT03331588|Procedure|Intercostal uniportal VATS|The surgical procedures followed principles of pulmonary resections
109351|NCT03331575|Radiation|Arm1 (Hypofractionated radiotherapy)|hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
109352|NCT03331562|Drug|Pembrolizumab|pembrolizumab solution for infusion
109353|NCT03331562|Drug|paricalcitol|Paricalcitol solution for injection
109354|NCT03331562|Drug|placebo|normal saline solution for injection
109387|NCT03331341|Drug|Vinblastine|Given IV
109388|NCT03331341|Drug|Doxorubicin|Given IV
109355|NCT03331536|Procedure|Roux en Y Gastric Bypass Pre-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
109356|NCT03331536|Procedure|Roux en Y Gastric Bypass Post-menopausal|The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
109357|NCT03331536|Procedure|Sleeve Gastrectomy Pre-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
109358|NCT03331536|Procedure|Sleeve Gastrectomy Post-menopausal|The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
109359|NCT03331523|Drug|Calcipotriene/Betamethasone Dipropionate|Topical suspension 0.005%/0.064% (Glenmark Pharmaceuticals Ltd)
109360|NCT03331523|Drug|Taclonex®|Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (LEO Pharma Inc.)
109361|NCT03331523|Drug|Placebo|Placebo of Calcipotriene/ betamethasone dipropionate topical suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd.)
109362|NCT03331510|Other|Strength testing before and after arthroscopic Latarjet|After patients, based on the ISI-Score, were assigned to treat their shoulder instability with an arthroscopic Latarjet procedure, they are eligible for this study. Strength of different involved muscles, as well as ROM will be measured before and at several time points after surgery.
109363|NCT03331497|Procedure|Tonsillotomy|About 2/3 of the palatine tonsil tissue is removed with coplator or bipolar knife.
109364|NCT03331484|Drug|Ticagrelor|Ticagrelor 90 mg twice daily
109365|NCT03331484|Drug|Rivaroxaban|Rivaroxaban 15 mg once daily (10mg for patients with moderate renal impairment, creatinine clearance: 30-50 mL/min by the Cockcoft Gault method)
109366|NCT03331471|Procedure|alveolar recruitment maneuver|applying alveolar recruitment maneuver using the anesthesia machine
109367|NCT03331471|Procedure|conventional ventilation|conventional ventilation using the anesthesia machine
109368|NCT03331458|Behavioral|exrecise intervention|Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
109369|NCT03331445|Drug|Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation|Inhaled Nitric Oxide 160ppm balance air
109370|NCT03331432|Dietary Supplement|Tauroursodeoxycholic acid|Taking tauroursodeoxycholic acid (1750 mg/day) capsules for 4 weeks.
109371|NCT03331432|Dietary Supplement|Placebo|Taking daily placebo capsules for 4 weeks.
109372|NCT03331419|Behavioral|Exercise test|30 sec of knee squats followed by a six minute walk test repeated on consecutive days.
109373|NCT03331406|Other|Physical Activity Program|12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.
109374|NCT03331393|Other|Non-interventional|Non-interventional
109375|NCT03331380|Device|MRI scan x 1 Healthy Volunteer|For objective 1 (protocol optimization), healthy volunteers undergo imaging using an investigational low SAR CMR scanner for up to two hours, some without- and some with- administration of intravenous gadolinium based contrast agents (GBCAs).
109376|NCT03331380|Device|MRI scan x 2 Healthy Volunteer|For objective 2 (comparative scanning of normals), healthy volunteers undergo two CMR examinations on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without- and some with- administration of intravenous GBCA.
109377|NCT03331380|Device|MRI scan x 2 - CAD patients|For objective 3 (comparative scanning of patients), subjects with known stable cardiovascular disease undergo two CMR examina-tions on two different MRI scanners (investigational low SAR CMR and conventional 1.5T CMR), some without- and some with- admin-istration of intravenous GBCA.
109378|NCT03331380|Device|MRI scan x 2- non CAD patients|For objective 4 (comparative scanning of patients), subjects with known or suspected disease, including neurological, musculoskeletal disease, abdominal or lung disease, will undergo two MR examinations on two different MRI scanners (investigational low SAR CMR and conventional MR).
109379|NCT03331367|Procedure|Blood draw|Patients in all four study arms will provide a blood sample to evaluate the immune response to prostate cancer treatment.
109380|NCT03331367|Procedure|Urine sample|Patients in all four study arms will provide a urine sample to evaluate the immune response to prostate cancer treatment.
109381|NCT03331354|Behavioral|Distant vocational learning|use of hybrid distance learning to facilitate successful employment outcomes
109382|NCT03331354|Other|Basic vocational services|self-help manual
109383|NCT03331341|Drug|Dacarbazine|Given IV
109384|NCT03331341|Drug|Doxorubicin Hydrochloride|Given IV
109385|NCT03331341|Other|Laboratory Biomarker Analysis|Correlative studies
109386|NCT03331341|Biological|Pembrolizumab|Given IV
109389|NCT03331328|Device|MonaLisa Touch|MonaLisa Touch is a fractional CO2 laser that has been specially designed with the DEKA pulse to stimulate vaginal tissue. It is delivered in a very precise manner and results in the synthesis of collagen and stratification of the vaginal epithelium with improvement of the vaginal pH and moisturization of the vaginal tissue due to increased blood flow and turgidity of the ground substance from the synthesis of the proteoglycans, hyaluronic acid and collagen.
109390|NCT03331315|Drug|Celecoxib|
109391|NCT03331315|Drug|Ketorolac|
109392|NCT03331302|Drug|Hyperpolarized Xenon-129 MRI (Experimental)|MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)
109393|NCT03331302|Drug|Radioactive Xenon-133 scintigraphy (Active Comparator)|Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)
109394|NCT03331289|Drug|Placebo|Placebo will be administered to 20 subjects after a 3 hour tracer equilibration period
109395|NCT03331289|Drug|Exenatide|Exenatide will be administered to 20 subjects after a 3 hour tracer equilibration period
109396|NCT03331289|Drug|Dapagliflozin|Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
109397|NCT03331289|Drug|Exenatide and Dapagliflozin|Exenatide and Dapagliflozin will be administered to 20 subjects after a 3 hour tracer equilibration period
109398|NCT03331276|Other|Formula B|Formula B to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
109399|NCT03331276|Other|Formula A|Formula A to be feed as the sole source of nutrition for 16 weeks to healthy term infants for 16 weeks.
109400|NCT03331263|Drug|Chlorhexidine Gluconate|2% CHG
109401|NCT03331250|Drug|Eribulin|It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die
109402|NCT03331237|Procedure|scalene block|scalene block using 5ml of ropivacaine
109403|NCT03331237|Procedure|ISO block|ISO block is a combined block of suprascapular nerve and brachial plexus cords using a single puncture
109404|NCT03331224|Device|OTSC|OTSC placement
109405|NCT03331224|Device|Endoscopic Standard therapy (combining two methods)|endoscopic standard therapy (two methods, e.g. clip and injection)
109406|NCT03331211|Drug|TKIs|Dasatinib combined with Chematherapy
109407|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel)|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
109408|NCT03331198|Biological|JCAR017 (lisocabtagene maraleucel) + ibrutinib|Participants eligible for this cohort should be receiving ibrutinib at the time of screening. For participants who previously discontinued ibrutinib, ibrutinib will be started at the time of enrollment. Ibrutinib treatment will continue for up to 90 days after JCAR017 infusion (or longer for participants who are receiving benefit from ibrutinib). Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive bridging chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
109409|NCT03331185|Biological|Freeze Dried Bone Allograft|Human derived bone particles used in oral and periodontal grafting procedures
109410|NCT03331185|Biological|L-PRF clot|L-PRF is a second-generation platelet rich plasma obtained from autologous blood and contains several different growth factors, platelets and leucocytes in a complex fibrin matrix to accelerate the healing of soft and hard tissues.
109411|NCT03331172|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
109412|NCT03331159|Device|NanoBone|Cage was filled with nanocrystalline hydroxyapatite embedded in a silica gel matrix
109413|NCT03331159|Device|Homologous Bone|Cage was filled with homologous bone
109414|NCT03331146|Drug|Saline|A placebo (saline infusion) will be administered after induction of general anesthesia.
109415|NCT03331146|Drug|Sodium Nitrite|Sodium nitrite infusion at a 267 mcg/kg/hr. will start after induction of general anesthesia via a dedicated IV line for 6 hrs.
109416|NCT03331133|Other|No intervention|
109417|NCT03331120|Device|ambulatory mirror image functional re-training through wearing 3D adjustable cervicothoracic Posture Corrective Orthotic(CTPCO)|Ambulatory a mirror image functional re-training This way of functional training will deliver via the use of adjustable cervicothoracic orthosis with the patient walking at approximately 2-3 miles per hour on a standard, motorized treadmill. The brace will reverse the abnormal posture according to the 3D posture analysis data. To facilitate tissue remodeling by reverse posture training, this called mirror image exercise.then the ambulatory exercises by using treadmill will be performed while the patient's mirror image posture will be held by the adjustable orthosis, ambulatory exercises for 20 minutes by using treadmill Based on Harrison et al and Hawes et al., approach, this program will be repeated 3 Times /week for 10 weeks.
109418|NCT03331094|Procedure|Surgery with graft|arthrodesis with autologous bone graft and using pedicular ilio-sacred EUROS ® screw
109419|NCT03331094|Procedure|surgery without graft|arthrodesis without bone graft using pedicular ilio-sacred EUROS ® screw
109420|NCT03331081|Other|Bladder Training|The patient will participate in a class in which the physiotherapist will provide the following information: on the anatomy and function of the MAP, using figures; on bladder function; guidelines on the positioning and voiding habits and the definition and main risk factors responsible for urinary incontinence. The bladder training will consist of a program of time micturition to increase bladder capacity and the interval between urinations. Urge suppression strategies will be targeted, and include distraction, relaxation, breathing, and MAP contraction (quick flicks).
109462|NCT03330821|Drug|Pevonedistat|Given IV
109463|NCT03330821|Other|Pharmacological Study|Correlative studies
109498|NCT03330535|Behavioral|Daily reminders|Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
109421|NCT03331081|Other|TMAP|There will be 36 monthly series of home training (totaling at the end of the 3 months of treatment 108 series) performed 3x / week, 3x / day. The training protocol consists of three daily TMAP series. One series consists of 8 maximum voluntary contractions, with maintenance of the contraction of 6 to 10 seconds (type I muscle fibers), with twice the rest time between contractions, followed by three to five rapid contractions (muscle fibers type II ). The protocol will total 24 contractions of MAP per day performed, which will be divided in the morning (8 contractions), late (8 contractions) and night (8 contractions).
109422|NCT03331081|Other|Bladder Training + TMAP|Will perform the exercises of the bladder training group and the TMAP in an associated way.
109423|NCT03331068|Behavioral|online questionnaire of MAX-PC|Scale measuring of the anxiety specific of prostate cancer, French version.
109424|NCT03331055|Device|PENS|percutaneous electrical nerve stimulation
109425|NCT03331055|Device|TENS|transcutaneous electrical nerve stimulation
109426|NCT03331042|Drug|SM-1|3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
109427|NCT03331042|Drug|D+Z|2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
109428|NCT03331042|Drug|D+L|2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
109429|NCT03331042|Drug|Placebo|Identical in appearance to SM-1, D+Z and D+L and has the same excipients, but no diphenhydramine, zolpidem, lorazepam or delayed-release coating materials.
109430|NCT03331029|Device|transesophageal investigation|Comparison of 3D ultrasound with transesophageal echocardiography
109431|NCT03331016|Behavioral|Heart to Heart Training|Training for foster and kinship caregivers on sexual health and how to effectively communicate with and monitor youth in their care, with the aim of reducing unintended pregnancies and sexually transmitted infections in this youth population.
109432|NCT03331003|Device|low level light therapy|iRestore low-level light therapy on androgenetic alopecia
109433|NCT03331003|Device|non-LLLT wavelength group|A LED light device is non-curative for the patients.
109434|NCT03330990|Drug|Entrectinib|600 mg oral capsule (fasted and fed)
109435|NCT03330990|Drug|Midazolam Hydrochloride|2 mg oral syrup (fasted)
109436|NCT03330977|Device|Pressure garments|"Patients will wear the pressure garments since 4 months after inclusion in order to have a comparison before and after use.~Usual practice would give to the patient the pressure garments at inclusion."
109437|NCT03330964|Other|electro-acupuncture|Electroacupuncture was administrated immediately after completion of oxaliplatin infusion,once a day for 3 days,30 minutes each time.
109438|NCT03330938|Behavioral|CBI and Resilience|A combination of CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring) + Resilience strengthening (Identifying resilient strengths and potentialities, plus Imagination and projection into the future).
109439|NCT03330938|Behavioral|Cognitive-behavioral Intervention|Only CBI techniques (Behavioural activation with positive reinforcement, Deep breathing and muscle relaxation, Cognitive restructuring).
109440|NCT03330925|Device|ElastiMed's SACS|A wearable medical device that improve circulation using smart materials
109441|NCT03330912|Device|Neutral seat height|Seat height set relative to participant's leg length with neutral set at the measured lower leg length
109442|NCT03330912|Device|Very low seat height|"Seat height set relative to participant's leg length, 2 below the measured lower leg length"
109443|NCT03330912|Device|Low seat height|"Seat height set relative to participant's leg length, 1 below the measured lower leg length"
109444|NCT03330912|Device|Very high seat height|"Seat height set relative to participant's leg length, 2 above the measured lower leg length"
109445|NCT03330912|Device|High seat height|"Seat height set relative to participant's leg length, 1 above the measured lower leg length"
109446|NCT03330899|Biological|H7N9 antigen + adjuvant IB160|H7N9 monovalent (fragmented and inactivated)
109447|NCT03330899|Biological|H7N9 antigen + adjuvant SE|H7N9 monovalent (fragmented and inactivated)
109448|NCT03330899|Biological|H7N9 antigen without adjuvant|H7N9 monovalent (fragmented and inactivated)
109449|NCT03330899|Biological|Placebo (PBS)|Placebo (Phosphate Buffered Saline -PBS)
109450|NCT03330886|Drug|Atezolizumab|Atezolizumab will be administered via IV at a 1200-mg dose over 60 minutes every 3 weeks (to be reduced to 30 minutes every 3 weeks if the first dose is tolerated).
109451|NCT03330873|Device|disposable balloon uterine stent|The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter
109452|NCT03330873|Device|Foley catheter|Foley catheter can partly separate the sides of uterus wall.
109453|NCT03330860|Other|Twelve clips regarding maternal and neonatal health topics|Twelve clips regarding maternal and neonatal health topics, designed with mixed 2D and 3D elements, each one about 45 seconds long (prepared based on the best available evidence and validated by clinical experts).
109454|NCT03330860|Other|Control Clip|Control clip with 2D elements about 45 seconds long, containing information on prenatal control and presented in conventional format (narration, static images and on screen text).
109455|NCT03330847|Drug|Olaparib Continuous (28-Day cycle) 300 mg BD.|Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
109456|NCT03330847|Drug|AZD6738 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).|Patients will be administered AZD6738 OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
109457|NCT03330847|Drug|Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).|Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
109458|NCT03330834|Biological|CAR-T cells to treat advanced lung cancer|"Drug: fludarabine. On days -4 through -2, fludarabine (25mg/m2) will be infused for 3 consecutive days; Drug: cyclophosphamide. On days -4 through -2, cyclophosphamide (250mg/m2) will be infused for 3 consecutive days.~Patients will receive the above chemotherapy for lymphocyte-depletion followed by PD-L1 CAR-T cells."
109459|NCT03330821|Drug|Cytarabine|Given IV
109460|NCT03330821|Drug|Idarubicin|Given IV
109461|NCT03330821|Other|Laboratory Biomarker Analysis|Correlative studies
109464|NCT03330808|Other|Epidural anesthesia|After anesthesia induction, epidural catheter is inserted into lumbar epidural in epidural with general anesthesia group. A 10 ml of 0.2% ropivacaine should be given in epidural space via a catheter when anastomosis of free flap is finished in epidural with general anesthesia group.
109465|NCT03330795|Biological|CD3/CD19 neg allogeneic BMT|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
109466|NCT03330782|Drug|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
109467|NCT03330782|Drug|Remifentanil|Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
109468|NCT03330769|Drug|New course of treatment|Prescription of new course of NSAIDs (monotherapy), steroid intra-articular injections (monotherapy), conventional DMARDs, biologic DMARDs, including switches or dose augmentations, indicated by the treating rheumatologist according to usual clinical practice.
109469|NCT03330756|Procedure|laparoscopic Roux-en-Y gastric bypass|laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
109470|NCT03330756|Procedure|laparoscopic Mini gastric bypass|laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
109471|NCT03330743|Behavioral|Parent Mentor with Standard Education|Parent mentors will provide coaching based on the current guidelines around diet and physical activity
109472|NCT03330743|Behavioral|Parent Mentor with Positive Deviance|Parent mentors will provide coaching based on findings from the positive deviance study
109473|NCT03330730|Other|IsereADOM service package|Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
109474|NCT03330717|Procedure|General anesthesia|Patients will undergo oncologic breast surgery on general anesthesia.
109475|NCT03330717|Procedure|Hypnosis sedation|Patients will undergo oncologic breast surgery on hypnosis sedation.
109476|NCT03330717|Procedure|General anesthesia with preoperative session of hypnosis|Patients will undergo surgery on general anesthesia but will have a preoperative session of hypnosis relaxation.
109477|NCT03330704|Drug|3% Sodium Chloride|3% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
109478|NCT03330704|Drug|23.4% Sodium Chloride|23.4% sodium chloride will be infused into patients for the treatment or prevention of raised intracranial pressure
109479|NCT03330704|Drug|8.4% Sodium Bicarbonate|8.4% sodium bicarbonate will be infused into patients for the treatment or prevention of raised intracranial pressure
109480|NCT03330691|Biological|Patient-derived CD19- and CD22 specific CAR|Patient-derived CD19-specific CAR also expressing an HER2t and CD22-specific CAR T-cells also expressing an EGFRt
109481|NCT03330678|Dietary Supplement|Probiotic (VSL#3)|Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
109482|NCT03330665|Behavioral|Meditation|Meditate 3 times a week using headspace app
109483|NCT03330639|Other|Capsaicin|Capsaicin is a homeopathic medication and there for this drug is not subject to the requirements of the FDA.
109484|NCT03330639|Other|Placebo|This group will receive the saline placebo solution.
109485|NCT03330626|Device|InBody group|As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.
109486|NCT03330626|Other|IO group|Fluid removal are guided by intake-output balance.
109487|NCT03330613|Diagnostic Test|PAEDS|pediatric emergency delirium scale
109488|NCT03330613|Procedure|TIVA|Total intravenous anesthesia with propofol
109489|NCT03330613|Procedure|Inhalational anesthesia|Inhalational (volatile) anesthesia with sevoflurane
109490|NCT03330600|Behavioral|aquatic physicotherapy|Aquatic physiotherapy will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. Kinesiotherapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment; joint mobilizations will be initiated on the shoulders and hips followed by stretching of the accessory muscles of the breath, spine erector, flexor and extensors of shoulder, elbow, hip, knee and ankle. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
109491|NCT03330600|Behavioral|immersion|The immersion will be performed in a bathtub with water heated to a temperature around 37º C and environment with adequate temperature and luminosity. The therapy will begin with smooth sliding movements in the aquatic environment, still in flexor restraint, allowing the child to adapt to the temperature of the new environment. The sessions will last 10 minutes and may be interrupted if the child shows signs of discomfort such as cyanosis, increased respiratory rate, bronchoaspiration or does not adapt to the environment, ie, remain crying for more than 5 minutes.
109492|NCT03330561|Drug|PRS-343|PRS-343
109493|NCT03330548|Behavioral|TeleMOVE!|Active comparator- telehealth treatment program for weight management and health promotion
109494|NCT03330548|Behavioral|Culinary Rx|Experimental Arm- An online instructional cooking and nutrition course to promote a whole-foods, plant-based lifestyle.
109495|NCT03330535|Behavioral|Reminders once a week|Participants in this group will receive active oral hygiene reminders through text messaging once a week.
109496|NCT03330535|Behavioral|Verbal oral hygiene instructions|Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.
109497|NCT03330535|Behavioral|Reminders three times a week|Participants in this group will receive active oral hygiene reminders through text messaging three times a week.
109499|NCT03330522|Other|Love, Sex, & Choices video series|Love, Sex, and Choices was written and scripted by the study team and underwent pilot testing in the target population. The series was divided into 15-to-20 minute episodes that were streamed weekly. The principles of reducing HIV risk were communicated through the characters and high risk situations. The lead characters model how women become more powerful, meaning more aware of themselves as worthy of respect, making choices intentionally, feeling free to pursue their intentions, and involving themselves in creating change. This process leads to higher power sex scripts in the characters, meaning pursuing intentional choices and health promoting behaviors. The lead characters model open communication about HIV testing with a resistant partner, and initiating condom use.
109500|NCT03330522|Other|Messages in text|"The comparison group received 12 weekly HIV health promotion written messages over the smartphone. The messages were based on prevailing CDC recommendations and the theoretical framework. An example is: Sexual health means respecting your own rights and feelings. Feeling pressured to have sex means limiting your choices and your freedom to love safely. …. If he doesn't like you being you, it may be time to walk. Other messages provided instructions on the correct condom use and the importance of HIV testing. The 12 messages were reviewed by ten African American and Latina undergraduate nursing students for ease of comprehension."
109501|NCT03330509|Other|SPARK intervention|An integrated model of care (SPARK care) in which the palliative care team co-rounds with the medical oncology team, supporting them in their delivery of basic palliative care, seamlessly stepping in and out to deliver specialist palliative care directly to patients when needed.
109502|NCT03330496|Other|Pain Measurement|Measurement of infant responses (behavioral and physiological) during a painful procedure.
109503|NCT03330470|Behavioral|exercise|participants will be subjected to 3 months supervised exercise intervention
109504|NCT03330470|Dietary Supplement|carnosine supplementation|participants will be instructed to take carnosine 2 times daily
109505|NCT03330470|Behavioral|stretching|participants will be subjected to 3 months supervised stretching program
109506|NCT03330470|Dietary Supplement|supplementation with placebo|participants will be instructed to take placebo 2 times daily
109507|NCT03330457|Biological|Andexanet alfa (bolus)|fXa inhibitor antidote
109508|NCT03330457|Drug|Betrixaban 80 mg PO QD|fXa inhibitor
109509|NCT03330457|Biological|Andexanet alfa (infusion IV)|fXa inhibitor antidote
109510|NCT03330444|Procedure|Endometrial biopsy and endometrial fluid collection|On the same day that the EB for ERA is indicated, in day 5 of a HRT cycle with 5 days of progesterone, according to the common clinical practice, a sample of EF will be aspirated immediately prior to EB for ERA. This EF sample will be used for the non-invasive diagnosis of the microbiome, also a small portion of the endometrial tissue obtained for the endometrial receptivity diagnosis by ERA will be used as a control for the study of the endometrial microbiome. Those patients with a receptive endometrium will continue their ART according to the standard clinical protocol. Those patients with non-receptive endometrium will follow the recommendation derived of the ERA test for the election of the day for a second EB sample, in which the collection of EF sample will be repeated. Finally, the receptivity and microbiome results in EF will be correlated with that on the endometrial tissue, and with the reproductive outcomes of these patients after the embryo transfer.
109511|NCT03330431|Behavioral|Progressive Muscle Relaxation (PMR)|"All groups undergo a PMR session, but they differ regarding the treatment before the PMR session. Two groups watch a video before undergoing PMR, the control group reads a text before undergoing PMR.~Progressive muscle relaxation (PMR) is a technique for learning to monitor and control the state of muscular tension. It was developed by American physician Edmund Jacobson in the early 1920s.~The technique involves learning to monitor tension in each specific muscle group in the body by deliberately inducing tension in each group. This tension is then released, with attention paid to the contrast between tension and relaxation."
109512|NCT03330418|Biological|Placebo|Starting with the forty-ninth dose,the trial went into the open phase. All participants were treated with the test drugs.
109513|NCT03330418|Biological|RC18 160 mg|In the Phase B,the researchers can adjust the dose of RC18 according to the subjects' willingness and recurrence, but the maximum dose of single dose should not exceed 320g.
109514|NCT03330405|Drug|Avelumab Phase 1b|Avelumab
109515|NCT03330405|Drug|Talazoparib Phase 1b|Talazoparib
109516|NCT03330405|Drug|Avelumab Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
109517|NCT03330405|Drug|Talazoparib Phase 2|The dose will be determined after the overall available data (including safety and preliminary anti tumor activity) emerging from the Phase 1b portion of the study have been evaluated.
109518|NCT03330392|Dietary Supplement|AGP|take two tablets per day (500 mg/day) for 8 weeks
109519|NCT03330392|Dietary Supplement|Placebo|take two tablets per day (500 mg/day) for 8 weeks
109520|NCT03330379|Device|Tracoe Smart CuffmanagerTM|In patients randomly assigned to the continuous adjustment strategy, in addition to standard care, the Tracoe Smart CuffmanagerTM will be connected to the tracheal cuff. Within the 2 days following the inclusion, all the intermittent Pcuff measurements will be collected as well as the incidence of Pcuff manual adjustments
109521|NCT03330366|Dietary Supplement|Allium hookeri extract|take two capsules per day (486 mg/day) for 8 weeks
109522|NCT03330366|Dietary Supplement|Placebo|take two capsules per day
109523|NCT03330353|Diagnostic Test|Pupillometry|Use of pupillometry to assess melanopsin-light pathway in patients with neurodegenerative diseases
109524|NCT03330340|Procedure|Percutaneous Vertebroplasty|The procedure takes place under sterile conditions. Local anesthesia is administered from skin to the periosteum of the targeted pedicle. Polymethylmethacrylate bone cement (Mendec Spine; Tecres SPA, Sommacampagna, Italy) is injected under continuous fluoroscopic imaging guidance using 1.0 ml syringes and 13 Gauge bone biopsy needles by bilateral procedures. The amount of injected cement in each treated vertebral body and any cement leakage is recorded.
109525|NCT03330327|Biological|HM12470|HM12470 is a long-acting insulin analogue
109526|NCT03330314|Biological|HM12460A|HM12460A is a long-acting insulin
109560|NCT03330093|Behavioral|Sleep Health in Preschoolers|In-person, family-based behavioral intervention
109561|NCT03330093|Behavioral|Health and Safety Intervention|In-person, family-based behavioral intervention
109671|NCT03329248|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
109527|NCT03330301|Other|D-tect|"This study is based on a unique Danish social experiment that took place during a well-defined period between 1937 and December 1985, when it was mandatory to fortify all margarine with vitamin D (1.25 μg/100 g). This well-defined vitamin D fortification period makes it possible to investigate the impact of fetal exposure to extra vitamin D from food fortification on the risk of developing diseases later on. This study is possible due not only to the well-defined adjacent time window but also to the complete registration of every citizen via a civil registration number. This number can be linked, on an individual level, to Danish birth, patient and medical registries; social and ethnic registries; and clinical and other large databases~Case-cohort study: vitamin D measurements from dried blood spots and the risk of diseases later on"
109528|NCT03330288|Drug|Theraflex, BAY 874017|The first three weeks which do have a different posology (3 capsules a day) according to the label should be entered as a distinct period to the treatment period with a recommended posology of 2 capsules a day
109529|NCT03330275|Device|Investigational Contact Lens|JJVC senofilcon A-based contact lens with new UV-blocker
109530|NCT03330275|Device|Commercial ACUVUE OASYS|senofilcon A
109531|NCT03330275|Device|Commercial ACUVUE OASYS and Spectacles|Senofilcon A and Spectacles
109532|NCT03330262|Device|BALCAP prosthesis|The noninvasive BALCAP prosthesis offers uses six degrees-of-freedom (6-DOF) sensing to detect postural imbalance and actuate low-amplitude vibrotactile cues directly to the head to provide the wearer with feedback concerning head tilt in the pitch and roll plane.
109533|NCT03330249|Drug|Split Cisplatin|25 mg/m2/day IV infusion at D1 to D4, at D22 to D25, at D43 to D46 during the radiotherapy.
109534|NCT03330249|Drug|Cisplatin|100 mg/m2/day IV infusion at D1, D22 and D43 during the radiotherapy.
109535|NCT03330249|Radiation|Radiotherapy|70 Gy in 35 fractions of 2 Gy in non-operated patients and 66 Gy in 33 fractions in post-operative.
109536|NCT03330236|Device|"Anesthetic depth management"|The propofol and remifentanil infusion rates will be adjusted to maintain the spectral edge frequency (SEF) value at 10-15 and the patient state index (PSI) value at 25-50 based on the SedLine EEG Brain Function Monitoring.
109537|NCT03330223|Device|Clopidogrel group;Ticagrelor group|A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.
109538|NCT03330210|Procedure|3D printing|Manufacturing and use of a model printed in 3D
109539|NCT03330197|Biological|Ad-RTS-hIL-12|2.0 x 10^11 viral particles (vp) per injection, one intratumoral injection of Ad-RTS-hIL-12
109540|NCT03330197|Drug|oral veledimex|2 dose levels (10mg/day, 20mg/day) 14 (or 15) oral daily doses of veledimex
109541|NCT03330184|Drug|Berberine Hydrochloride group|
109542|NCT03330184|Drug|Bifidobacterium group|
109543|NCT03330184|Drug|Berberine Hydrochloride and Bifidobacterium group|
109544|NCT03330184|Drug|placebo|
109545|NCT03330171|Biological|Measles vaccine|All participants will receive measles vaccine at 6 and 12 months of age, according to the South African immunization schedule. All study vaccines are currently licensed in South Africa and will be administered according to their approved dosages, formulations and indications.
109546|NCT03330171|Biological|Hepatitis-A vaccine|Half of the participants (n=135) will receive hepatitis-A vaccine at 18 months of age.
109547|NCT03330171|Biological|Varicella vaccine|Half of the participants (n=135) will receive varicella vaccine at 18 months of age.
109548|NCT03330158|Device|ASTS|Implantation of a motorized spinal distraction rod
109549|NCT03330145|Behavioral|Scales, questionnaires and inventory|Children will complete scales, questionnaires and inventory at 3 months post-loss and only 2 scales at 6 and 12 month post-loss
109550|NCT03330132|Biological|Standard inactivated influenza vaccine (NH formulation)|0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation.
109551|NCT03330132|Biological|MF 59 adjuvanted inactivated influenza vaccine (NH formulation)|0.5mL FLUAD(TM), Seqirus containing 45μg antigen; 15μg for each influenza strain included and MF59C.1 adjuvant (MF59®) with strains recommended by the WHO for the northern hemisphere formulation.
109552|NCT03330132|Biological|High-dose inactivated influenza vaccine (NH formulation)|0.5mL Fluzone® High-Dose, Sanofi Pasteur containing 180μg antigen; 60μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
109553|NCT03330132|Biological|Recombinant hemagglutinin inactivated influenza vaccine (NH formulation)|0.5mL Flublok®, Protein Sciences Corporation containing 180μg antigen, 45μg for each influenza strain included with strains recommended by the WHO for the northern hemisphere formulation.
109554|NCT03330119|Drug|Alternate Management|With the alternate management protocol, the pre-operative order set is the same, with the addition of a single preoperative dose of acetaminophen 1 g IV x1, gabapentin 600 mg PO x1, and ondansetron 8 mg IV x1. Post-operatively, patients receive the same ketorolac 30mg x 9 doses every 6 hours, as well as acetaminophen 975 mg every 6 hours, both given standing. These two are timed so the patient is receiving one of the two medications every 3 hours during their inpatient stay. After 9 doses of ketorolac, the patient receives 600mg of ibuprofen PO, also given standing, instead of the ketorolac. If the patient requires narcotics, they may receive them on an as needed basis. IV fluids are running at 80 cc/ hour. Patients are encouraged to ambulate, including the evening of the surgery, have their foley catheter removed 12 hours post-operatively, and can have a regular diet immediately.
109555|NCT03330119|Drug|Control|The regular Lankenau cesarean section order set includes routine vital signs, labs, IV fluids, and fetal heart monitoring. Post standard cesarean section orders include IV fluids running at 125 cc/ hour, along with routine post-partum care. In terms of pain control, most patients receive 9 doses of 30mg of IV ketorolac every 6 hours, along with hydromorphone, oxycodone/acetaminophen, or a hydromorphone PCA, per patient or attending request.
109556|NCT03330106|Drug|Pevonedistat|Pevonedistat intravenous infusion.
109557|NCT03330106|Drug|Docetaxel|Docetaxel intravenous infusion.
109558|NCT03330106|Drug|Carboplatin|Carboplatin intravenous infusion.
109559|NCT03330106|Drug|Paclitaxel|Paclitaxel intravenous infusion.
109562|NCT03330067|Device|Cold and dry CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of cold (19-21°C) and nonhumidified (0%) CO2.
109563|NCT03330067|Device|Warm and humidified CO2 pneumoperitoneum|In this arm, patients undergo pneumoperitoneum by the insufflation of warmed (95° F) and humidified (95% relative humidity) CO2, using a Lexion Insuflow device.
109564|NCT03330054|Device|fundoscope|Fundoscope for eye examination
109565|NCT03330041|Device|Fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material
109566|NCT03330028|Drug|Dexamethasone|10 mg by vein approximately 60 minutes before Paclitaxel.
109567|NCT03330028|Drug|Diphenhydramine|50 mg by vein approximately 60 minutes before Paclitaxel.
109568|NCT03330028|Drug|Famotidine|20 mg by vein approximately 60 minutes before Paclitaxel.
109569|NCT03330028|Drug|Mitomycin C|Mitomycin C 30 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
109570|NCT03330028|Drug|Cisplatin|Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.
109571|NCT03330028|Drug|Paclitaxel|"Starting dose of Paclitaxel is 20 mg/m2 in 3-7 liters of infusate administered using a rolling pump with hyperthermia for approximately 60 minutes through 3 to 4 small incisions in abdomen.~Dose-escalation scheme of Paclitaxel is in increments of 5 mg/m2."
109572|NCT03330002|Device|CE-marked MANTA vascular closure device (VCD)|Compile real word data on MANTA VCD.
109573|NCT03329989|Biological|Collagenase Clostridium Histolyticum|During 3 treatment visits 12 injections will be given per treatment area
109574|NCT03329976|Other|measurement of visual acuity|complete ophthalmologic examination of a macular SD-OCT, a fundus of eye, evaluation of the vision of contrasts (Pelli-Robson test) and quantification of metamorphopsies (M-Charts);
109575|NCT03329963|Behavioral|Healthy Lifestyle Intervention|Participants in the this group will receive group educational sessions that focus on diet, exercise, and social support once a month throughout the study. The sessions will provide an opportunity for participants to discuss issues related to living with obesity and aging.Participants will also attend regular scheduled clinic visits for assessment of outcomes.
109576|NCT03329963|Behavioral|Lifestyle Intervention|"The lifestyle modification will be achieved by group behavior therapy sessions designed to have older adults acquire positive weight-control skills/attitudes, and practice weight-maintenance skills.Participants will attend weekly group sessions (10-15 persons), which will last ~75-90 minutes. Visit frequency will be decreased to every 2 wks. from 6 to 12 mos. to prevent treatment fatigue. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~The exercise sessions are of ~90 min duration (~15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for one year. Aerobic exercises consist of treadmill, stationary cycling, and stair climbing."
109577|NCT03329950|Drug|CDX-1140|CDX-1140 will be administered every 4 weeks.
109578|NCT03329950|Drug|CDX-301|CDX-301 will be injected once a day for five days before Cycles 1 and 2.
109579|NCT03329937|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
109580|NCT03329924|Other|Activity level measurement by accelerometer|Eligible patients will wear an accelerometer to measure activity levels while in the ICU.
109581|NCT03329911|Drug|EU Avastin®|100 mg/4 mL
109582|NCT03329911|Drug|BAT1706|100 mg/4 mL
109583|NCT03329911|Drug|Paclitaxel|200 mg/m²
109584|NCT03329911|Drug|carboplatin|target area under the curve [AUC] 6 mg/mL•minute
109585|NCT03329898|Procedure|dried biological amnion graft|dried biological amnion graft. The amnion grafts were spread on the balloon end of disposable balloon uterine stent .
109586|NCT03329898|Device|disposable balloon uterine stent|the disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus.
109587|NCT03329898|Drug|estradiol valerate tablets|oral estradiol valerate tablets, which can promote endometrial growth after operation.
109588|NCT03329898|Drug|dydrogesterone Tablets|oral dydrogesterone Tablets
109589|NCT03329885|Drug|BMS-986251|Escalating oral dose
109590|NCT03329885|Other|Placebo|Escalating oral dose
109591|NCT03329872|Other|Data collection|data collection about symptoms without any specific clinical or biological intervention
109592|NCT03329859|Procedure|High resolution standardized laparoscopic cholecystectomy|High resolution standardized laparoscopic cholecystectomy
109593|NCT03329846|Drug|BMS-986205|specified dose on specified day
109594|NCT03329846|Biological|Nivolumab|Specified dose on specified day
109595|NCT03329846|Drug|Placebo|Specified dose on specified day
109596|NCT03329833|Behavioral|Motivational Interviewing|Motivational interviewing will consist of weekly phone calls for two months, bi-weekly phone calls for two months, and monthly phone calls for two months.
109597|NCT03329833|Behavioral|Web-based application|Web-based application participants will be asked to log activity at least on a daily basis.
109598|NCT03329807|Device|Transcranial Magnetic Stimulation|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the somatosensory cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 10Hz on the injured hemisphere by stroke; 1500 pulses with an intensity of 120% of MT 10 sessions of rTMS, one per day, always before conventional sensory therapy. rTMS it will be applied for about 20 minutes, five days per week.
109599|NCT03329807|Behavioral|conventional sensory therapy|Behavioral: conventional sensory therapy All patients will receive the same protocol of Sensory Therapy that will consist of the behavioral methods of Active Sensory Reeducation, Mirror Therapy and passive method that will consist in the administration of electric current by TENS (sensitive threshold). Participants will be instructed not to perform active muscular contraction during Interventions. The protocol it will be applied for about 60 minutes, five days per week.
109600|NCT03329781|Dietary Supplement|BCM-95|Consuming 1 capsule of BCM-95 per day.
109602|NCT03329755|Other|Dedicated and coordinated e-follow-up during the treatment period|"Completion of questionnaires using an electronic tool~Telephone follow-up between the nurse and the patient~Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)"
109603|NCT03329755|Other|Standard follow-up during the treatment period|- Completion of the Quality of Life Questionnaire Core 30 (QLQ-C30)
109604|NCT03329742|Other|Low protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
109605|NCT03329742|Other|Control protein diet|Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
109606|NCT03329729|Other|Rosuvastatin|Hyperlipidemic patients treated with rosuvastatin
109607|NCT03329716|Other|Brace weaning|For AIS patients who have been wearing Boston brace and attend clinic consultation where the decision for brace weaning is made, then weaning protocol of either arm will be prescribed
109608|NCT03329703|Behavioral|Project UPLIFT|A group, telephone-based intervention for depression that uses techniques from mindfulness-based therapy and cognitive therapy. The intervention consists of 8 sessions occurring at the same time and day every week.
109609|NCT03329690|Drug|DS-8201a|DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
109610|NCT03329690|Drug|Physician's Choice|"Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)"
109611|NCT03329677|Other|Transference-focused Psychotherapy (TFP)|Participants receive 18 months of bi-weekly TFP. Each sessions lasts 50 minutes. During sessions, a therapist employs assorted psychodynamic techniques tailored specially for symptoms and relational difficulties associated with BPD. A participant processes interpersonal experiences with her therapist in sessions alongside her therapist and gains therapeutic insight into her problematic ways of relating to her self and others.
109612|NCT03329664|Biological|Cytokine-induced killer cell|Immune-cell therapy with CIK cells
109613|NCT03329664|Other|Chemotherapy AND/OR Radiation Therapy|Routine treatments for colon cancer patients according to their stage
109614|NCT03329651|Drug|Metformin treatment|"Daily treatment with metformin tablets for 24 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-24: Metformin tablet 1000 mg x 2"
109615|NCT03329651|Drug|Placebo treatment|"Daily treatment with placebo tablets for 24 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-24: Placebo tablet 1000 mg x 2"
109616|NCT03329638|Drug|DE-127 Ophthalmic Solution low dose|Low dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
109617|NCT03329638|Drug|DE-127 Ophthalmic Solution medium dose|Medium dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
109618|NCT03329638|Drug|DE-127 Ophthalmic Solution high dose|High dose of DE-127 Ophthalmic Solution dosed once daily for 12 months
109619|NCT03329638|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution dosed once daily for 12 months
109620|NCT03329625|Behavioral|Pathways Triple P|Pathways Triple was developed by Matt Sanders and is a behavioral parent training intervention designed to treat child behavior problems and prevent child maltreatment.
109621|NCT03329625|Behavioral|Services as Usual|Families received family centered services and other parenting interventions as deemed appropriate by the child welfare case manager.
109622|NCT03329612|Procedure|Remote Ischemic Preconditioning|Serial inflations and deflations as detailed in the arm/group descriptions.
109623|NCT03329599|Drug|Polycap|Assigned to a polypill containing 2/3 antihypertensives, a moderate/high-intensity statin and Aspirin to be taken orally, once daily in the form of a hard capsule
109624|NCT03329586|Other|High-intensity training|6-month individualized home- and group-based training program with the goal to cycle the Mont Ventoux in France
109625|NCT03329573|Drug|Paroxetine IR tablets A|Paroxetine IR tablets A will be the investigational drug. These are film coated tablets with unit dose strength of 20 milligrams (mg) and will be administered via oral route. These tablets will be manufactured in GSKT.
109626|NCT03329573|Drug|Paroxetine IR tablets B|Paroxetine IR tablets B will be the reference drug. These are film coated tablets with unit dose strength of 20 mg and will be administered via oral route. These tablets will be manufactured in Mississauga.
109627|NCT03329560|Biological|Oral fecal microbiota transplantation|All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.
109628|NCT03329547|Drug|Cefixime test capsule|"SKF101804/cefixime test capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as a dark purple head and off white body locking type capsule with GSK' printed on cap and 400MG printed on body of capsule."
109629|NCT03329547|Drug|Cefixime reference capsule|"Cefixime reference capsule will be given with a single dose of 400 mg administered orally along with 240 mL of water. It will be available as red/orange hard gelatin size 0 capsule with Cefspan 400 mg printed on body of capsule."
109630|NCT03329534|Other|Gluten free diet|A month long gluten free diet
109631|NCT03329521|Other|Multicomponent Initiative|The initiative is grounded in a quality improvement framework and has four main components for the chronic kidney disease (CKD) programs, including: 1. Data (e.g., data collection and reports to CKD programs about their performance using best practices in audit and feedback); 2. Education (e.g., education toolkits for CKD program staff, renal patients and families, including living donor candidates); 3. Transplant Ambassadors (e.g., kidney transplant recipients and living kidney donors who discuss transplantation and living donation to patients and their families) and 4. Administration (e.g., provincial administrative support and resources provided to CKD programs to support local work).
109632|NCT03329508|Drug|P2B001|Fixed dose once daily combination capsule of pramipexole and rasagiline
109633|NCT03329508|Drug|Rasagiline|Rasagiline oral capsule
109634|NCT03329508|Drug|Pramipexole|Pramipexole low dose oral capsule
109636|NCT03329495|Procedure|SMA-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMA. The left boundary of resection is the left side of SMA, and artery sheath is not necessarily being opened.
109637|NCT03329495|Procedure|SMV-orientated right hemicoloectomy|Laparoscopic right hemicoloectomy for right colon cancer with a medial-to-lateral approach orientated by SMV. The left boundary of resection is the left side of SMV, and SMA is not exposed.
109638|NCT03329482|Other|PULSE ULTRASOUND|For group A, The PUS group received pulse mode of ultrasound (sonoplus 490s), with frequency of 1MHZ and intensity of 1.5w/cm according to Ebadi et al 10). Grey's formula was used to estimate the duration of ultrasound (US) for each patient 21). The average local exposure time was one minute and the effective radiating area of the transducer head was 5 cm2. For a patient with an area of low back pain of 40 cm2, the required total treatment time was: 1 min × (40 cm2/5 cm2) = 8 minutes. US was applied using slow circular movements, with the transducer head placed over the painful paravertebral low back region and Lofnac gel used as coupling medium.
109639|NCT03329482|Other|KNEADING MASSAGE|Kneading massage was done with the two hands maintaining a slow circular compression of soft tissues against underlying bone. Pressure was applied as the hands moved proximally, continuously maintaining a contact with the skin, according to Goat22). Lofnac gel was used as a coupling medium for the massage. This was done for an approximately ten and 12 minutes.
109640|NCT03329469|Device|Toshiba CT-FFR|Patients receiving CCTA to diagnose acute chest pain or unstable angina will receive CT-FFR to estimate rate of blood flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
109641|NCT03329456|Drug|Ropivacaine|Minimum effective volume
109642|NCT03329443|Drug|Spironolactone|each patient will receive 200 mg of spironolactone as per his/her angiography premedications
109643|NCT03329443|Drug|Placebo Oral Tablet|Each patient will receive a placebo tablet as per his/her angiography premedications
109644|NCT03329430|Other|Foot orthoses|Customized foot orthoses
109645|NCT03329417|Other|task-oriented training|Motor training targeted to goals that are relevant to the functional needs of the patient
109646|NCT03329404|Device|Mirasol Red Blood Cells (MIR RBCs)|Mirasol Red Blood Cells (MIR RBCs) derived from Mirasol-treated WB; WB will be Mirasol treated, centfifuged and leukoreduced and the derived RBCs will be stored before transfusion for up to 21 days and transfused according to the patient's transfusion schedule.
109647|NCT03329404|Device|Reference Red Blood Cells (REF RBCs)|Reference Red Blood Cells (REF RBCs) will be acquired from routine use inventory and transfused according to the patient's transfusion schedule.
109648|NCT03329391|Behavioral|Nurse-led psychosocial care|The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly discussions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
109649|NCT03329378|Drug|Docetaxel|Docetaxel 75mg/m2 IV, day 1
109650|NCT03329378|Drug|Carboplatin|Carboplatin AUC 6 IV, day 1
109651|NCT03329378|Drug|Trastuzumab|Trastuzumab 8mg/kg IV initial dose, followed by 6mg/kg IV , day 1
109652|NCT03329378|Drug|Pertuzumab|Pertuzumab 840 mg IV initial dose followed by 420 mg IV, day 1
109653|NCT03329378|Drug|Pegfilgrastim|Pegfilgrastim 6mg SC, day 2 Cycled as per arm
109654|NCT03329378|Drug|Trastuzumab|Trastuzumab 6mg/kg every 21 days to complete 1 year
109655|NCT03329378|Drug|Paclitaxel|Titrate the infusion rate on the initial Paclitaxel dose (40 ml/hr x 5 min, then 80 ml/hr x 5 min, then 120 ml/hr x 10 min, then 200 ml/hr). Subsequent Paclitaxel doses are given over 1 hour.
109656|NCT03329378|Drug|Doxorubicin|Doxorubicin 60 mg/m2 IV day 1
109657|NCT03329378|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 IV day 1
109658|NCT03329378|Drug|Paclitaxel|80 mg/m2 IV x 1 hour infusion on days 1, 8, and 15
109659|NCT03329339|Procedure|1 L PEG with ascorbic acid with prepackaged, low residue diet|Participants who were allocated to the 2 L PEG with ascorbic acid (PEGA) group took 250 ml of PEG with ascorbic acid at 15-min intervals, completing 1 L of the PEG with ascorbic acid protocol at 8:00 PM on the day prior to the procedure. The remaining 1 L of the PEG with ascorbic acid solution was administered in the same manner at 6:00 AM on the day of the procedure. Participants assigned to the 1 L PEG with ascorbic acid with PLD (PLD) group consumed a prepackaged, low residue diet (ZeroCol, Korea Medical Food Inc., Seoul, Korea) which consisted of a breakfast, lunch and dinner, the day prior to colonoscopy. The Participants took 1 L PEG with ascorbic acid solution at 6:00 AM on the day of the colonoscopy in the same way as described above. All of the subjects ingested 500 mL of water for every 1 L of 1 L PEG with ascorbic acid solution consumed. The Participants completed all of the administrations at least 2 hours before the colonoscopy.
109660|NCT03329326|Other|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
109661|NCT03329313|Drug|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
109662|NCT03329313|Drug|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
109663|NCT03329300|Behavioral|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
109664|NCT03329287|Behavioral|SCBT|SCBT, one hour per session.
109665|NCT03329287|Drug|SSRIs and/or SNRIs|SSRIs and/or SNRIs at a recommended dosage.
109666|NCT03329287|Behavioral|Psychological Placebo|Supportive and relaxation therapy, one our per session.
109667|NCT03329261|Drug|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
109668|NCT03329248|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
109669|NCT03329248|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
109673|NCT03329248|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
109674|NCT03329248|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
109675|NCT03329248|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
109676|NCT03329248|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
109677|NCT03329248|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
109678|NCT03329248|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
109679|NCT03329248|Drug|lovaza|Omega-3-acid ethyl esters
109680|NCT03329248|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
109681|NCT03329248|Procedure|SBRT|Stereotactic Body Radiation Therapy
109682|NCT03329235|Drug|PRP|platelet rich plasma
109683|NCT03329235|Drug|HA|hyaluronic acid
109684|NCT03329222|Other|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
109685|NCT03329222|Other|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
109686|NCT03329209|Drug|Vedolizumab|Vedolizumab intravenous infusion.
109687|NCT03329196|Drug|MT-6548|Oral tablet
109688|NCT03329196|Drug|Darbepoetin alfa|Subcutaneous
109689|NCT03329183|Drug|Irinotecan|High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
109690|NCT03329170|Behavioral|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is <12 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
109691|NCT03329157|Other|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
109692|NCT03329144|Behavioral|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
109693|NCT03329131|Device|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
109694|NCT03329118|Drug|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
109695|NCT03329105|Other|Sea Salt Mouth Rinse|Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.
109696|NCT03329105|Other|Standardized Oral Health Practices|Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
109697|NCT03329092|Drug|ATM-AVI|"(Creatinine clearance > 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
109698|NCT03329092|Drug|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
109699|NCT03329092|Drug|MER|"Where pathogen initially not suspected of being MER-resistant:~(Creatinine clearance > 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h~Where pathogen initially suspected of being MER-resistant (Creatinine clearance > 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h~(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h~(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
109700|NCT03329092|Drug|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight < 60 kg) followed by one of the following maintenance doses:~(Creatinine clearance > 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.~(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion~(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
109701|NCT03329079|Behavioral|Mobile Technology Plus|The intervention group MT+ will receive the premium-version mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
109702|NCT03329079|Behavioral|Mobile Technology|The comparison group MT will receive the basic-version mobile phone app only to self monitor eating, activity, and weight.
109703|NCT03329066|Behavioral|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
109704|NCT03329066|Behavioral|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
109705|NCT03329066|Behavioral|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
109706|NCT03329053|Behavioral|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.~The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
109707|NCT03329053|Behavioral|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
109708|NCT03329040|Other|No Intervention.|No intervention.
109709|NCT03329027|Device|Vibrating Capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
109710|NCT03329027|Device|Sham capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
109711|NCT03329014|Drug|Remimazolam|For induction and maintenance of sedation
109712|NCT03329014|Drug|Placebo|Control arm
109713|NCT03329001|Drug|Niraparib|Niraparib tablet formulation
109714|NCT03329001|Other|Niraparib|Niraparib capsule formulation
109715|NCT03328988|Procedure|QLB|bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
109716|NCT03328975|Drug|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
109717|NCT03328975|Other|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
109718|NCT03328962|Behavioral|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
109719|NCT03328949|Device|IVL Coronary Lithotripsy System|The coronary intravascular lithotripsy catheter is similar to other balloon devices that are routinely used during angioplasty procedures; however, it has electrodes inside the balloon which are designed to deliver energy to crack the calcified blockage using lithotripsy (acoustic energy).
109720|NCT03328936|Other|Laboratory Biomarker Analysis|Correlative studies
109721|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
109722|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
109723|NCT03328936|Other|Pharmacological Study|Correlative studies
109724|NCT03328923|Dietary Supplement|500mg brown seaweed powder|
109725|NCT03328923|Dietary Supplement|Placebo|
109726|NCT03328910|Device|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
109727|NCT03328897|Drug|Omalizumab|injection of 150mg or 300 mg
109728|NCT03328897|Drug|Placebo|Injection of placebo
109729|NCT03328884|Drug|Irinotecan Hydrochloride|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.~nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy."
109730|NCT03328871|Device|Fractional CO2 Laser|Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
109731|NCT03328871|Procedure|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
109732|NCT03328871|Procedure|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
109733|NCT03328858|Other|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
109734|NCT03328845|Drug|Toujeo SoloStar|
109735|NCT03328845|Drug|Tresiba|
109736|NCT03328845|Drug|Humalog Kwikpen|
109737|NCT03328845|Drug|NovoRapid|
109738|NCT03328845|Drug|Apidra|
109739|NCT03328832|Drug|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
109740|NCT03328832|Drug|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
109741|NCT03328832|Drug|rivaroxaban (10mg)|Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
109742|NCT03328819|Other|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM). TCM theory and practice are not based upon scientific knowledge, and acupuncture is a pseudoscience. There are a diverse range of acupuncture theories based on different philosophies, and techniques vary depending on the country. The method used in TCM is likely the most widespread in the US. It is most often used for pain relief, though it is also used for a wide range of other conditions.
109743|NCT03328793|Behavioral|Mood Assessment|Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
109744|NCT03328793|Behavioral|Emotion Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
109745|NCT03328793|Behavioral|Communication Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
109746|NCT03328793|Other|Mobility assessment|If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
109747|NCT03328793|Other|Music Intervention|The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
109748|NCT03328793|Other|Documentary watching|The patients will watch a documentary for 30 minutes in the presence of a volunteer
109749|NCT03328780|Device|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
109750|NCT03328767|Behavioral|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
109751|NCT03328754|Device|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
109752|NCT03328754|Device|Group 2 Forsus|Forsus placed bilaterally for class II correction
109753|NCT03328741|Behavioral|Online Osteoarthritis treatment|6 week online-program
109754|NCT03328741|Behavioral|Face-to-face osteoarthritis treatment|3 months face-to-face program
109755|NCT03328728|Device|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
109756|NCT03328728|Device|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
109757|NCT03328715|Device|intraoperative OCT|before and after surgery intraoperative OCT is performed
109758|NCT03328715|Device|stand-alone OCT|before and after surgery stand-alone OCT is performed
109759|NCT03328702|Device|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
109760|NCT03328689|Other|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
109761|NCT03328689|Other|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.~Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
109762|NCT03328676|Drug|Cannabis|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
109763|NCT03328676|Drug|Placebo oil|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
109764|NCT03328663|Other|CARE|Promote effective coping and reduce caregiving burden.
109765|NCT03328663|Other|Standard Transplant Care|Standard cared administered by the hospital.
109766|NCT03328650|Procedure|Measurement of Bone Material Strength Using Osteoprobe|Participants who have elected to participate in the optional, interventional arm of this study will undergo routine proximal humeral plate fixation for their proximal humerus fracture. Once the participant has been anesthetized prior to stabilizing the fracture with a ALPS proximal humerus plate, the participant's arm will be secured and the orthopaedic surgeon will indent the proximal humeral metaphysis, distal to the site of the fracture, at 10 to 15 locations ((~2 mm apart) using the OsteoProbe-RPI. The indent size is approximately ~300 μm in diameter and ~300 μm in depth. All Osteoprobe measurements (bone materal strength and bone indentation distance) taken will be relayed from the Osteoprobe to a laptop which is connected to the instrument during the surgical case.
109767|NCT03328650|Procedure|Measurement of Bone Indentation Distance Using Osteoprobe|Participants who have elected to participate in the optional, interventional arm of this study will undergo routine proximal humeral plate fixation for their proximal humerus fracture. Once the participant has been anesthetized prior to stabilizing the fracture with a ALPS proximal humerus plate, the participant's arm will be secured and the orthopaedic surgeon will indent the proximal humeral metaphysis, distal to the site of the fracture, at 10 to 15 locations ((~2 mm apart) using the OsteoProbe-RPI. The indent size is approximately ~300 μm in diameter and ~300 μm in depth. All Osteoprobe measurements (bone materal strength and bone indentation distance) taken will be relayed from the Osteoprobe to a laptop which is connected to the instrument during the surgical case.
109768|NCT03328637|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
109769|NCT03328624|Device|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
109770|NCT03328611|Device|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
109771|NCT03328598|Behavioral|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
109772|NCT03328598|Behavioral|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
109773|NCT03328598|Other|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
109774|NCT03328585|Behavioral|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
109775|NCT03328585|Behavioral|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
109776|NCT03328585|Other|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
109777|NCT03328572|Other|E-max Endocrown|Endocrown preparation
109778|NCT03328572|Other|Cerasmart Endocrown|Endocrown preparation
109779|NCT03328559|Diagnostic Test|ISET® - Isolation by Size of Tumor cells|early stage bronchial cancer patient will have a blood collection
109780|NCT03328559|Diagnostic Test|ISET® - Isolation by Size of Tumor cells|advanced stage bronchial cancer patient will have a blood collection
109781|NCT03328546|Other|Dietary intake|Dietary intake converted into dietary pattern scores.
109782|NCT03328533|Drug|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
109783|NCT03328533|Drug|Norepinephrine|Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
109784|NCT03328533|Drug|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
109785|NCT03328520|Behavioral|WILD 5 Wellness Intervention|"Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)"
109786|NCT03328507|Drug|BLI4900|BLI4900 Bowel Preparation
109787|NCT03328507|Drug|PEG Control|Polyethylene glycol-based bowel preparation
109788|NCT03328494|Drug|BOS172722|Oral capsules
109789|NCT03328494|Drug|Paclitaxel|IV infusion
109790|NCT03328481|Procedure|Loss-of-resistance Quadratus lumborum block|"ِA blunted 22-G, 11 mm, short-bevel facet needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected. The needle will be visualized by the ultrasound by another physician to ensure safety."
109791|NCT03328481|Procedure|Ultrasound-guided Quadratus lumborum block|A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
109792|NCT03328481|Procedure|General anesthesia|Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
109793|NCT03328468|Other|Breathing Exercise|Breathing exercise for stroke patients
109794|NCT03328455|Behavioral|Active training|Perceptual training is task-related.
109795|NCT03328455|Behavioral|Passive training|Training is not task-related.
109796|NCT03328442|Procedure|VISTA Technique|VISTA with PRF membrane includes Treatment of recession class I and II using autologous PRF membrane
109797|NCT03328442|Procedure|modified coronally advanced flap|modified coronally advanced flap with PRF membrane for Treatment of recession class I and II
109798|NCT03328429|Other|Excision|Bartholin gland will be excised
109799|NCT03328429|Other|Marsupialization|Bartholin gland will be marsupialised
109800|NCT03328416|Device|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
109801|NCT03328403|Device|Aspiration First|Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
109802|NCT03328403|Device|Stent retriever first|Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
109803|NCT03328390|Other|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
109804|NCT03328390|Other|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
109805|NCT03328377|Diagnostic Test|Metagenomic analysis of gut microbiota|All patients have rectal swaps/fecal samples subjected to metagenomic analysis
109806|NCT03328364|Drug|enzalutamide|oral
109807|NCT03328364|Drug|docetaxel|intravenous infusion
109808|NCT03328351|Other|manual therapy|"Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).~Cervical postero-anterior vertebral mobilization glides:~a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .~Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
109809|NCT03328351|Other|Superficial soft tissue massage|"1. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets~Strengthening Exercises:~for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
109810|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
109811|NCT03328312|Drug|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR >0.9
109812|NCT03328312|Drug|neostigmine+atropine|Number and time of bradycardic episodes (HR<60 bpm) as well as that of tachycardic episodes (HR>100 bpm) before tracheal extubation
109813|NCT03328312|Drug|neostigmine+atropine+sugammadex|4. Time of extubation
109814|NCT03328299|Drug|Dexmedetomidine|20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
109815|NCT03328299|Drug|bupivacaine|20 ml of 0.5 % bupivacaine
109816|NCT03328286|Behavioral|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
109817|NCT03328273|Drug|AZD6738|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
109818|NCT03328273|Drug|acalabrutinib|An experimental anti-cancer drug and Bruton's tyrosine kinase (BTK) inhibitor.
109819|NCT03328260|Device|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
109820|NCT03328247|Other|ASICA digital app|Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
109821|NCT03328234|Radiation|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
109822|NCT03328234|Drug|Paclitaxel|45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
109823|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
109824|NCT03328234|Drug|Paclitaxel|135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
109825|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
109826|NCT03328234|Other|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
109827|NCT03328208|Other|Comfort Talk® app|Test app
109828|NCT03328208|Other|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
109829|NCT03328195|Device|Neuro RX Gamma synchronous|Twenty minute treatment, six days per week for 12 weeks
109830|NCT03328195|Device|Sham|Twenty minutes, six days per week for 12 weeks with sham device
109831|NCT03328195|Device|Neuro RX Gamma asynchronous|Twenty minutes, six days per week for 12 weeks with sham device
109832|NCT03328182|Device|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
109833|NCT03328169|Behavioral|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
109834|NCT03328169|Behavioral|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
109835|NCT03328143|Drug|Lavender (Lavandula angustifolia)|Lavender (Lavandula angustifolia) is an essential oil.
109836|NCT03328130|Biological|AAV2/5-hPDE6B|Subretinal administration in one eye
109837|NCT03328117|Drug|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
109838|NCT03328117|Drug|Placebo oral capsule|Matching placebo oral capsule
109839|NCT03328104|Drug|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
109840|NCT03328104|Drug|Nelarabine|650 mg/m2 IV daily x Day 1-5
109841|NCT03328104|Drug|Cyclophosphamide|440 mg/m2 IV x Day 1-5
109842|NCT03328104|Drug|Etoposide|100 mg/m2 IV x Day 1-5
109843|NCT03328091|Other|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
109844|NCT03328091|Other|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
109845|NCT03328078|Drug|CA-4948|CA-4948 (formulated for oral administration for QD or BID dosing)
109846|NCT03328065|Other|Interviews|Semi-directed interviews, recorded and transcribed for analysis
109847|NCT03328065|Other|Questionnaires|economic and psycho-social questionnaires
109848|NCT03328052|Device|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
109849|NCT03328052|Other|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
109850|NCT03328039|Device|Garmin wearable device|Physiological data capture only
109851|NCT03328026|Biological|SV-BR-1-GM|SV-BR-1-GM inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2).
109852|NCT03328026|Biological|INCMGA00012|INCMGA00012 will be given 375 mg intravenously either ~2 or ~4 days after SV-BR-1-GM inoculation for up to 24 infusions. Cycles will be every 3 weeks.
109853|NCT03328026|Drug|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
109854|NCT03328026|Biological|Interferon Inoculation|Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after SV-BR-1-GM inoculation.
109855|NCT03328026|Drug|Epacadostat 600 mg BID|Epacadostat 600 mg twice daily given orally
109856|NCT03328000|Radiation|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
109857|NCT03327987|Biological|standard of care influenza vaccine|The standard of care annual 2017-2018 influenza vaccine will be used for this study.
109858|NCT03327974|Other|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.~Depasse is available for all on the App store and on Googleplay.~This application has several interests:~- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.~There is the possibility to generate a graph representing the evolution of these parameters.~Tips adapted to the actual mood are provided related to the dysfunctional parameters."
109859|NCT03327961|Device|scaffold|implantation of scaffold (eg Magmaris, Desolve, Others)
109860|NCT03327948|Device|Axonics Sacral Neuromodulation System (SNM) System|Axonics Sacral Neuromodulation System (SNM) System
109861|NCT03327935|Dietary Supplement|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) oral nutritional supplements and advice, 2) oral nutritional supplements and training exercise and 3) Standard hospital procedure. Primary outcome is loss of lean body mass
109862|NCT03327922|Device|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
109863|NCT03327909|Behavioral|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
109864|NCT03327896|Other|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
109865|NCT03327857|Biological|AbGn-168H|AbGn-168H (Neihulizumab) is a humanized monoclonal antibody
109866|NCT03327844|Drug|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
109867|NCT03327844|Drug|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
109868|NCT03327831|Drug|Aminolevulinic Acid|Topical application followed by activation by ambient sunlight
109869|NCT03327818|Procedure|hysterectomy|
109870|NCT03327818|Procedure|uterine conservative study|
109871|NCT03327805|Dietary Supplement|Choline|Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 14 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
109872|NCT03327805|Dietary Supplement|Placebo|Participants will consume 1000 mg (2x500 mg) of placebo for 14 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
109873|NCT03327792|Drug|Mavoglurant|200 mg Mavoglurant
109874|NCT03327792|Drug|Placebo|Placebo
109875|NCT03327766|Diagnostic Test|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D < 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
109876|NCT03327753|Behavioral|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
109877|NCT03327753|Behavioral|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
109878|NCT03327740|Drug|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
109879|NCT03327740|Drug|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
109880|NCT03327740|Drug|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
109881|NCT03327740|Drug|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
109882|NCT03327740|Drug|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
109883|NCT03327727|Drug|Investigational Agent: VL-2397|VL-2397
109884|NCT03327727|Drug|Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B|Voriconazole, Isavuconazole, or Liposomal amphotericin B
109885|NCT03327714|Behavioral|Mindfulness and compassion|
109886|NCT03327701|Drug|Benralizumab|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
109887|NCT03327688|Diagnostic Test|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
109888|NCT03327675|Other|68Ga-PSMA (HBED-CC) PET|68Ga-PSMA PET/MR
109889|NCT03327662|Other|Active CTC Assessment|CTC Counts used to guide treatment switch
109890|NCT03327649|Device|low level transcutaneous vagus nerve stimulation|Stimulation of the auricular branch of the vagus nerve
109891|NCT03327636|Device|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
109892|NCT03327610|Other|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
109893|NCT03327610|Other|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
109894|NCT03327610|Other|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
109895|NCT03327610|Other|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
109896|NCT03327610|Other|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
109897|NCT03327610|Other|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
109898|NCT03327597|Other|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
109899|NCT03327597|Other|Mental Health and Quality of Life questionnaire|Participants receive a Mental Health and Quality of Life questionnaire that will be answered electronically on the study website (www.blodskimun.is)
109900|NCT03327597|Other|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
109901|NCT03327597|Other|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
109902|NCT03327597|Other|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
109903|NCT03327597|Other|Clinical follow-up control|Control clinical visit
109904|NCT03327584|Procedure|Arthrocentesis|Athrocentesis
109905|NCT03327558|Drug|Apriso 0.375G ER CAP|ER capsule
109906|NCT03327558|Drug|APRISO 375 mg extended-release capsules|375 mg extended-release capsules
109907|NCT03327545|Device|Neural mobilization|Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.
109908|NCT03327545|Device|Soft tissue techniques and Stretching|Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes
109909|NCT03327545|Device|Control group|Did not receive any treatment.
109910|NCT03327532|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
109911|NCT03327532|Procedure|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
109912|NCT03327532|Biological|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
109913|NCT03327532|Other|Telephone interview|Telephone interview will be performed 3 months after discharge from hospital
109914|NCT03327519|Behavioral|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
109915|NCT03327519|Behavioral|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
109916|NCT03327506|Drug|Alprazolam 0.5 mg|alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
109917|NCT03327493|Diagnostic Test|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :~Biological assessment:~Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry~Lymphocytes Th1/Th2 pattern by flow cytometry~Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10~Clinical assessment:~Hemodynamic parameters~Cumulated doses of catecholamines~Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning)"
109918|NCT03327480|Other|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
109919|NCT03327467|Biological|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling or autologous)
109920|NCT03327454|Biological|Benepali|Administered as specified in the treatment arm.
109921|NCT03327441|Other|Almonds|Almonds will be provided as 15% energy
109922|NCT03327441|Other|Omelette|Omelettes will be provided as 15% energy
109923|NCT03327402|Drug|SHP465|SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
109924|NCT03327389|Drug|Dexmedetomidine|dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.
109925|NCT03327389|Drug|placebo|0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
109926|NCT03327376|Device|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
109927|NCT03327363|Device|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
109928|NCT03327350|Device|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
109929|NCT03327350|Drug|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
109930|NCT03327337|Procedure|Arthroscopic Assisted Balloon Tibioplasty|Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
109931|NCT03327324|Diagnostic Test|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
109932|NCT03327311|Device|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis & deep dermis).
110001|NCT03326765|Other|Questionnaires|"Epworth sleepiness scale~Pittsburgh sleep quality Index (PSQI)~EQ-5D Adults~Pediatric Daytime Sleepiness scale (PDSS)~Sleep disturbance Scale for Children (SDSC~EQ-5D Children~Sleaping diary"
109933|NCT03327298|Procedure|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
109934|NCT03327285|Biological|C-CAR011|CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
109935|NCT03327272|Drug|Methylprednisolone|Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
109936|NCT03327272|Drug|Saline|Administration of saline at surgical site prior to incision closure
109937|NCT03327259|Behavioral|Activity Planning|The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.
109938|NCT03327259|Behavioral|Therapist Guided Activity Practice|The therapist will work with the participant to plan and carry out a brief in-vivo version of their goal/target activity. The therapist will guide the participant through the activity for approximately 15 minutes.
109939|NCT03327246|Device|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
109940|NCT03327233|Device|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
109941|NCT03327220|Device|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
109942|NCT03327207|Other|Non Interventional|Non Interventional
109943|NCT03327194|Device|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.~The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.~ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.~The ADHEAR Audio Processor has the CE mark."
109944|NCT03327181|Dietary Supplement|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
109945|NCT03327168|Drug|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
109946|NCT03327168|Other|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
109947|NCT03327155|Drug|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
109948|NCT03327142|Diagnostic Test|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
109949|NCT03327129|Procedure|fMRI|An fMRI scan will be conducted to collect neuroimaging data. The scanning session will consist of a structural MRI, followed by resting state and task-based functional MRI protocol.
109950|NCT03327116|Drug|Methotrexate|oral, 15 mg per week, 24 weeks
109951|NCT03327103|Behavioral|CHAMPION|An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
109952|NCT03327090|Other|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
109953|NCT03327077|Other|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
109954|NCT03327064|Drug|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
109955|NCT03327064|Drug|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
109956|NCT03327051|Drug|Omeprazole|Proton pump inhibitor (PPI) that suppresses gastric acid secretion
109957|NCT03327051|Dietary Supplement|VSL #3|Probiotics
109958|NCT03327038|Behavioral|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
109959|NCT03327038|Other|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GAD-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
109960|NCT03327038|Behavioral|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
110002|NCT03326765|Procedure|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
110039|NCT03326505|Other|Supervised physical therapy|A combined physical therapy program of Balance, strengthening and endurance exercises
109961|NCT03327038|Other|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CACHE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GAD-7) symptoms.Quality of Life will be measured using the 10 item Short Inflammatory Bowel Disease Questionnaire (SIBDQ), which has a total score range of 10 to 70, with higher scores indicating better quality of life. Patient Satisfaction with Health Care in IBD will be measured using the 32 item CACHE Questionnaire, which scores from 0 -least satisfaction to 100-highest satisfaction.
109962|NCT03327038|Other|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms. Their depression symptoms will be reported on the 9-item Patient Health Questionnaire (PHQ-9), which has a total score ranging from 0 to 27, with scores of 5, 10, 15 and 20 representing cut points for mild, moderate, moderately severe, and severe depression. Their generalized anxiety symptoms will be reported on the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), which has a total score ranging from 0 to 21, with scores of 5, 10, and 15 representing cut points for mild, moderate, and severe anxiety. Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
109963|NCT03327025|Behavioral|Health education counseling|Health education counseling
109964|NCT03327012|Drug|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
109965|NCT03327012|Drug|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
109966|NCT03326999|Drug|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
109967|NCT03326999|Drug|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
109968|NCT03326999|Drug|Saline|Saline as placebo comparator
109969|NCT03326986|Drug|MK-7252|1 mg/mL or 20 mg/mL oral suspension in water volume to bring to a total of 240 mL
109970|NCT03326986|Drug|Placebo|Water volume of 240 mL
109971|NCT03326973|Behavioral|EuroQoL EQ-5D-3L|Overall QOL
109972|NCT03326973|Behavioral|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
109973|NCT03326973|Other|PRO-CTCAE|Additional potential immune-specific symptoms
109974|NCT03326973|Behavioral|Fatigue severity score questionnaire|Fatigue severity
109975|NCT03326973|Behavioral|The COST|Financial toxicity; satisfaction with ability to work
109976|NCT03326973|Behavioral|Physician information|Details on outside health providers
109977|NCT03326960|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane guided by Narcrotrend index monitoring.
109978|NCT03326960|Drug|Propofol|Anesthesia maintenance with propofol guided by Narcrotrend index monitoring.
109979|NCT03326960|Drug|Desflurane|Anesthesia maintenance with desflurane guided by Narcrotrend index monitoring.
109980|NCT03326947|Drug|docetaxel, cisplatin and 5-fluorouracil|"Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.~Other Names:~TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.~Radiation: radiotherapy"
109981|NCT03326934|Dietary Supplement|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
109982|NCT03326934|Dietary Supplement|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
109983|NCT03326921|Biological|CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR|Given IV
109984|NCT03326921|Drug|Fludarabine|Given IV
109985|NCT03326921|Other|Laboratory Biomarker Analysis|Correlative studies
109986|NCT03326908|Device|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
109987|NCT03326895|Device|Left-sided colon resection|Left-sided colon resection with powered stapler
109988|NCT03326882|Device|Endotracheal intubation|
109989|NCT03326869|Device|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
109990|NCT03326856|Biological|botulinum toxin, Type A|topical liniment
109991|NCT03326856|Biological|Vehicle|Vehicle Formulation
109992|NCT03326843|Drug|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
109993|NCT03326830|Device|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher&Paykel, New-Zealand).
109994|NCT03326830|Device|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
109995|NCT03326817|Other|Control Group|Patients receive standard care
109996|NCT03326817|Device|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
109997|NCT03326804|Device|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
109998|NCT03326791|Drug|Acetylsalicylic acid|Trombyl 160 mg once daily
109999|NCT03326791|Drug|Placebo Oral Tablet|Placebo one tablet daily
110000|NCT03326778|Procedure|AVR and CABG|Combined AVR with CABG
110003|NCT03326765|Procedure|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
110004|NCT03326765|Procedure|Actigraphy|type of sleep study based on bracelet around the wrist
110005|NCT03326752|Drug|DV281|- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
110006|NCT03326752|Device|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
110007|NCT03326752|Drug|DV281 (RP2D)|- Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
110008|NCT03326752|Drug|Approved Anti-PD-1 Inhibitor|FDA approved Anti-PD-1 Inhibitor
110009|NCT03326739|Procedure|Arterial Line Placement|arterial line placement
110010|NCT03326726|Drug|2% CHG|Chlorhexidine Gluconate
110011|NCT03326713|Behavioral|Telephone Counseling & Navigation (TCN)|A health coach will conduct a 15-30 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
110012|NCT03326713|Behavioral|Mailed Targeted Print (TP)|Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
110013|NCT03326713|Other|Usual Care (UC)|A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
110014|NCT03326700|Procedure|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
110015|NCT03326687|Behavioral|Treatment ABAB|Participants will perform the phases in the ABAB order.
110016|NCT03326687|Behavioral|Treatment BABA|Participants will perform the phases in the BABA order.
110017|NCT03326674|Drug|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine
110018|NCT03326674|Drug|Capecitabine|Capecitabine alone at approved dose
110019|NCT03326661|Procedure|Aspiration|Needle aspiration of pus from the peritonsilar abscess
110020|NCT03326661|Procedure|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
110021|NCT03326661|Drug|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
110022|NCT03326648|Other|Strength training|Heavy load strength training performed twice a week for 10 weeks.
110023|NCT03326648|Dietary Supplement|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
110024|NCT03326635|Other|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
110025|NCT03326622|Other|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
110026|NCT03326622|Other|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
110027|NCT03326609|Drug|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
110028|NCT03326596|Drug|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
110029|NCT03326583|Drug|Patiromer|Patiromer will be orally self-administered by participants.
110030|NCT03326570|Behavioral|Medical Data Collection|Medical information collected after bronchoscopy for up to 2 years.
110031|NCT03326557|Procedure|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
110032|NCT03326544|Other|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
110033|NCT03326544|Other|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
110034|NCT03326531|Other|Not applicable for this study|Not applicable for this study
110035|NCT03326518|Diagnostic Test|Lumentin® 44|Contrast agent
110036|NCT03326518|Diagnostic Test|Diluted Omnipaque®|Contrast agent
110037|NCT03326518|Diagnostic Test|Movprep®|Contrast agent
110038|NCT03326505|Biological|Umbilical cord derived Mesenchymal Stem Cells|Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
110133|NCT03325790|Other|Placebo|Placebo Comparator
110040|NCT03326492|Drug|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
110041|NCT03326479|Diagnostic Test|Caris Molecular Intelligence Profile|A comprehensive biomarker testing
110042|NCT03326453|Device|Mini dental implant|titanium mini dental implant which diameter less than 3 mm
110043|NCT03326440|Other|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
110044|NCT03326427|Behavioral|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
110045|NCT03326427|Other|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
110046|NCT03326414|Procedure|Constant PEEP - low tidal volume|The respirator is set according to study protocol
110047|NCT03326414|Procedure|Constant PEEP - high tidal volume|The respirator is set according to study protocol
110048|NCT03326414|Procedure|constant tidal volume - low PEEP|The respirator is set according to study protocol
110049|NCT03326414|Procedure|constant tidal volume - high PEEP|The respirator is set according to study protocol
110050|NCT03326388|Drug|Selumetinib|Selumetinib Intermittent Dosing
110051|NCT03326375|Radiation|SBRT|Maximum dose : 60Gray (Gy) Fraction : 2 to 5
110052|NCT03326362|Other|Resistance training|Comparison between high and low intensities trainings described in arms
110053|NCT03326349|Other|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
110054|NCT03326349|Other|Ictus.online|"An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant."
110055|NCT03326336|Combination Product|Gene therapy: GS030-DP AND Medical device: GS030-MD|GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
110056|NCT03326323|Procedure|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
110057|NCT03326310|Drug|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
110058|NCT03326310|Drug|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.~Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
110059|NCT03326297|Other|Osteopathy manual therapy|Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
110060|NCT03326297|Behavioral|Measures to support and education to the family|Pedagogical intervention in parents and health education
110061|NCT03326284|Other|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
110062|NCT03326284|Other|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
110063|NCT03326284|Other|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
110064|NCT03326284|Other|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
110065|NCT03326271|Procedure|Exeter stem|Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture
110066|NCT03326271|Procedure|Lubinus SP2 stem|Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
110067|NCT03326258|Drug|Glembatumumab Vedotin|Given IV
110068|NCT03326258|Biological|Ipilimumab|Given IV
110069|NCT03326258|Other|Laboratory Biomarker Analysis|Correlative studies
110070|NCT03326258|Biological|Nivolumab|Given IV
110071|NCT03326258|Other|Pharmacological Study|Correlative studies
110072|NCT03326245|Drug|Oral Methylphenidate followed by IV placebo|Oral MP (60 mg) will be given 30 minutes prior to bolus [11C] raclopride injection followed by iv placebo (PL) given 30 minutes post bolus injection of [11C]raclopride.
110073|NCT03326245|Drug|Oral placebo followed by IV Methylphenidate|Oral PL will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv MP (0.25 mg/kg) given 30 minutes post bolus injection of [11C]raclopride.
110074|NCT03326245|Other|Oral Placebo followed by IV Placebo|Oral PL will be given 30 minutes prior to bolus [11C]raclopride injection followed by iv PL given 30 minutes post bolus injection of [11C] raclopride.
110075|NCT03326232|Device|Continuous glucose monitoring|The blinded CGM group will be using the Medtronic iPro2 system (Enlite sensor + iPro2 transmitter). The real-time CGM group will be using the 530g system (inactivated 530g insulin pump (no insulin used, only used as display for CGM), Enlite sensor, MiniLink transmitter)
110076|NCT03326219|Procedure|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
110077|NCT03326206|Other|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
110078|NCT03326193|Drug|Niraparib|niraparib by mouth once daily continuously during 21 day cycle
110079|NCT03326193|Biological|Bevacizumab|bevacizumab intravenously D1 of every cycle for up to 15 months, including total duration of frontline use
110080|NCT03326180|Drug|Liposomal bupivacaine|266mg/20ml vial of EXPAREL
110081|NCT03326180|Drug|Bupivacaine hydrochloride|100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
110082|NCT03326167|Other|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
110083|NCT03326154|Other|No intervention, observational|Observation
110084|NCT03326141|Behavioral|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
110085|NCT03326141|Device|Physical activity monitors (e.g., Fitbit)|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
110086|NCT03326141|Behavioral|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
110087|NCT03326141|Behavioral|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
110088|NCT03326141|Other|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
110089|NCT03326128|Drug|Bupropion hydrochloride extended release|Antidepressant that is also effective in smoking cessation
110090|NCT03326115|Behavioral|Peer Visitation Program|The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
110091|NCT03326102|Drug|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
110092|NCT03326102|Drug|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
110093|NCT03326089|Procedure|Pulmonary rehabilitation|Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
110094|NCT03326076|Diagnostic Test|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
110095|NCT03326076|Other|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
110096|NCT03326076|Diagnostic Test|Peripheral blood gene expression profiling (AlloMap Kidney)|Patients will receive peripheral blood gene expression profiling testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
110097|NCT03326076|Diagnostic Test|Analytic platform (IBox)|Patients will receive IBox testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
110098|NCT03326063|Drug|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
110099|NCT03326063|Drug|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
110100|NCT03326050|Drug|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
110101|NCT03326050|Drug|Ciprofloxacin|cipro 750 tablet twice daily
110102|NCT03326050|Drug|Rifampicin|Rifampicin 150Mg Capsule twice daily
110103|NCT03326037|Genetic|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
110104|NCT03326011|Device|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
110105|NCT03325998|Device|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
110106|NCT03325985|Behavioral|Nurse-led telephonic case management|Telephonic meetings with a palliative care nurse. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
110107|NCT03325985|Behavioral|Facilitated,outpatient specialty palliative care|In-person palliative care visits with a palliative care provider. Palliative care is specialized medical care focused on providing a personalized layer of support dedicated to helping patients and their families cope with a serious illness.
110108|NCT03325972|Drug|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
110109|NCT03325972|Other|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
110110|NCT03325959|Device|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
110111|NCT03325959|Drug|Cymbalta / lyrica|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
110112|NCT03325959|Device|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
110113|NCT03325946|Behavioral|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
110114|NCT03325933|Other|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
110115|NCT03325933|Other|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
110116|NCT03325920|Device|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
110117|NCT03325907|Device|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
110118|NCT03325894|Drug|SHP465|SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
110119|NCT03325881|Drug|SHP465|SHP465 capsule 6.25 mg orally once daily for 4 weeks
110120|NCT03325881|Drug|Placebo|Placebo matching to SHP465 capsule orally once daily for 4 weeks
110121|NCT03325868|Drug|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
110122|NCT03325855|Other|None - Observational|None - Observational
110123|NCT03325842|Diagnostic Test|ASKp|30 items questionnaire
110124|NCT03325816|Drug|Nivolumab|Nivolumab is administered intravenously
110125|NCT03325816|Radiation|177Lu-DOTA0-Tyr3-Octreotate|"177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.~Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion"
110126|NCT03325803|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
110127|NCT03325803|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
110128|NCT03325803|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
110129|NCT03325803|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
110130|NCT03325803|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
110131|NCT03325790|Drug|200mg SPI-1005 BID|Active: low dose
110132|NCT03325790|Drug|400mg SPI-1005 BID|Active: high dose
110134|NCT03325777|Behavioral|Approach Bias Retraining|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
110135|NCT03325777|Behavioral|SHAM Training|SHAM Training
110136|NCT03325764|Other|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
110137|NCT03325751|Diagnostic Test|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
110138|NCT03325725|Device|NewBreez LD intra-laryngeal implant|NewBreez LD intra-laryngeal implantation
110139|NCT03325712|Drug|BI 705564|Film-coated tablet
110140|NCT03325712|Drug|Placebo|Film-coated tablet
110141|NCT03325699|Device|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
110142|NCT03325686|Dietary Supplement|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
110143|NCT03325686|Other|Placebo|placebo
110144|NCT03325673|Device|TrueTear|TrueTear Device should be used intranasally on contact lens (CL) wear days; it may also be used on non-CL wear days if participant chooses. The number of applications is determined by participant.
110145|NCT03325673|Device|TrueTear Sham Control|TrueTear sham device, which is not electrically active, should be used intranasally on contact lens (CL) wear days; it may also be used on non-CL wear days if participant chooses. The number of applications is determined by participant.
110146|NCT03325660|Other|whole body vibration|pelvic floor exercises
110147|NCT03325647|Drug|Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
110148|NCT03325647|Drug|Placebo injectable saline|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
110149|NCT03325634|Other|Laboratory Biomarker Analysis|Correlative studies
110150|NCT03325634|Other|Quality-of-Life Assessment|Ancillary studies
110151|NCT03325634|Other|Questionnaire Administration|Ancillary studies
110152|NCT03325634|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
110153|NCT03325621|Biological|PRS-080#022-DP|Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
110154|NCT03325621|Biological|PRS-080-Placebo#001|Placebo Comparator
110155|NCT03325608|Other|POISED Care|Using information collected, a propose plan of care and tailored interventions to the patients. Patients will understand natural history, and the prognosis of dementia; care protocols will be implemented.
110156|NCT03325608|Other|Usual Care|Usual care group will not receive the POISED structured assessment, attention to chronic disease management, or RCA related to the ED visit.
110157|NCT03325595|Drug|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
110158|NCT03325595|Drug|Placebo|Matching capsule placebo
110159|NCT03325569|Diagnostic Test|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
110160|NCT03325556|Drug|Placebo|Placebo, tablets, once daily by mouth
110161|NCT03325556|Drug|Pimavanserin 34 mg|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth
110162|NCT03325556|Drug|Pimavanserin 20 mg|Pimavanserin 20 mg total daily dose, tablets, once daily by mouth
110163|NCT03325543|Other|Verbal instruction and Vaginal palpation|The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.
110164|NCT03325530|Behavioral|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
110165|NCT03325504|Biological|Cultured Mesenchymal Stem Cells|Cultured Mesenchymal Stem Cells obtained from expanded bone marrow
110166|NCT03325504|Procedure|Autologous iliac crest graft|Autologous iliac crest grafting
110167|NCT03325491|Dietary Supplement|Acipimox|Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
110168|NCT03325491|Dietary Supplement|Placebo|Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
110169|NCT03325478|Other|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
110170|NCT03325465|Drug|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
110171|NCT03325465|Drug|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
110172|NCT03325452|Biological|venous lactate|value of venous lactate
110173|NCT03325439|Drug|Brivaracetam (BRV) iv|"Exploratory Cohort:~Subsequent to one or multiple therapeutic doses of midazolam ([MDZ], dose and dosing frequency of MDZ is at the discretion of the investigator), a low dose of Brivaracetam (BRV) intravenous (iv) solution for injection will be administered. At the discretion of the Investigator, 3 additional iv BRV doses, up to a total of 4 iv BRV doses (0.5mg/kg twice daily [bid]), can be administered during the 48-hour Evaluation Period.~Confirmatory Cohort:~During the Evaluation Period, subjects are expected to receive intravenous (iv) BRV bid. The dose and dosing frequency of BRV will be adjusted for the Confirmatory Cohorts based on the analysis of the data collected for the Exploratory Cohort."
110174|NCT03325439|Drug|Brivaracetam (BRV) oral|Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
110175|NCT03325426|Device|FitBit|Daily use of physical activity tracker coupled with weekly provider telemonitoring and feedback for 3 months
110176|NCT03325413|Behavioral|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
110177|NCT03325413|Behavioral|Preoperative information|Detailed preoperative information about delirium prevention and procedures
110178|NCT03325413|Behavioral|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
110179|NCT03325413|Dietary Supplement|Dietary supplements|Dietary supplements if necessary
110180|NCT03325413|Other|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
110181|NCT03325413|Procedure|Regional anesthesia|Regional anesthesia whenever possible
110182|NCT03325413|Other|Personal aids|Personal orientation aids until anesthesia induction
110183|NCT03325413|Device|Temperature management|Perioperative warming
110184|NCT03325413|Device|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
110185|NCT03325413|Procedure|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
110186|NCT03325400|Other|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).~Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
110187|NCT03325387|Drug|LY3305677|Administered SC
110188|NCT03325387|Drug|Placebo|Administered SC
110189|NCT03325374|Other|Questionnaires and examination|Patients with in the BLB patients study will have interview and questionnaire carried out.
110190|NCT03325361|Other|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
110191|NCT03325348|Drug|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
110192|NCT03325348|Drug|Labetalol|IV labetalol 20 mg & mint tablet will be given to patients every 15 min until one hour
110193|NCT03325335|Drug|Midazolam premedication|Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
110194|NCT03325335|Drug|Remifentanil infusion|Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
110195|NCT03325335|Drug|Propofol infusion|Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
110196|NCT03325322|Dietary Supplement|Fisetin|Flavonoid family
110197|NCT03325322|Drug|Placebo oral capsule|Placebo
110198|NCT03325309|Other|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
110199|NCT03325296|Drug|LEO 124249|Ointment containing LEO 124249
110200|NCT03325296|Other|Ointment vehicle|Ointment without active ingredients
110201|NCT03325283|Device|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
110202|NCT03325270|Dietary Supplement|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
110203|NCT03325270|Dietary Supplement|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
110204|NCT03325270|Dietary Supplement|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
110205|NCT03325257|Other|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
110206|NCT03325244|Other|EEG monitor|sleep patterns will be monitored using EEG monitor
110207|NCT03325244|Other|FitBit|activity levels will be monitored
110208|NCT03325231|Other|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
110209|NCT03325205|Other|Anodal tDCS|Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
110210|NCT03325205|Other|Sham tDCS|The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
110211|NCT03325192|Drug|Rapid pleurodesis protocol|"The pleural space will be evacuated completely through the newly placed IPC~20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space~The patient will be transferred to the recovery unit~Two hours after instillation the pleural space will be drained~After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
110212|NCT03325192|Other|Placebo|"The pleural space will be evacuated completely through the newly placed IPC~Only placebo (normal saline) will be instilled into the pleural space~The patient will be transferred to the recovery unit~Two hours after instillation the pleural space will be drained~After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged~Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
110213|NCT03325179|Other|Thread-embedding Therapy|
110214|NCT03325166|Drug|Ferumoxytol|Given IV
110215|NCT03325166|Other|Laboratory Biomarker Analysis|Correlative studies
110216|NCT03325166|Procedure|Magnetic Resonance Imaging|Undergo MRI
110217|NCT03325166|Biological|Pembrolizumab|Given IV
110218|NCT03325127|Drug|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
110219|NCT03325127|Drug|Zytiga|Abiraterone 1000 mg per day orally
110220|NCT03325127|Drug|Xtandi|Enzalutamide 160 mg per day orally
110221|NCT03325114|Drug|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
110222|NCT03325101|Procedure|Cryosurgery|Undergo cryosurgery
110223|NCT03325101|Biological|Pembrolizumab|Given IV
110224|NCT03325101|Procedure|Pheresis|Undergo apheresis
110225|NCT03325101|Biological|Therapeutic Autologous Dendritic Cells|Given IT
110226|NCT03325088|Procedure|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
110227|NCT03325088|Procedure|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
110228|NCT03325088|Procedure|Bronchial alveolar enema|For participants who had signed ancillary research consent
110229|NCT03325075|Biological|VAL-181388|Escalating dose levels
110230|NCT03325075|Other|Placebo|Saline
110231|NCT03325062|Behavioral|MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
110232|NCT03325062|Behavioral|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
110233|NCT03325049|Behavioral|The health-promoting conversations|The health-promoting conversations
110234|NCT03325049|Other|Usual Care|Usual Care
110235|NCT03325036|Diagnostic Test|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
110236|NCT03325023|Dietary Supplement|Dietary and life style modification and probiotic Sanprobi Super Formula|Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.
110237|NCT03325023|Other|Placebo|Placebo
110238|NCT03325010|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
110239|NCT03325010|Drug|Placebo oral capsule|non-active dosage form
110240|NCT03324997|Drug|Restylane Silk|Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
110241|NCT03324997|Drug|Saline|Saline as placebo
110242|NCT03324997|Device|Optical Coherence Tomography|An FDA-cleared non-invasive imaging device
110243|NCT03324984|Drug|1% chloroprocaine|In 2018, 1% Chloroprocaine was approved by the FDA for spinal anesthesia use.
110244|NCT03324984|Drug|0.75% bupivacaine|Bupivacaine is used on label
110245|NCT03324971|Other|Medications review|"Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.~This is in line with the best practice guidelines."
110246|NCT03324958|Device|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
110247|NCT03324958|Other|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
110248|NCT03324945|Behavioral|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
110249|NCT03324932|Drug|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
110250|NCT03324919|Behavioral|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
110251|NCT03324906|Device|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
110252|NCT03324893|Diagnostic Test|[F-18]-FCH PET/MRI|Subjects will undergo the [F-18]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
110253|NCT03324880|Biological|rhPTH(1-84)|rhPTH(1-84) 25, 50, 75, and 100 mcg QD SC injection will be administered
110254|NCT03324880|Biological|Placebo|Placebo QD SC injection will be administered
110255|NCT03324867|Drug|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
110256|NCT03324867|Drug|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
110257|NCT03324854|Procedure|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
110258|NCT03324854|Procedure|Drainage|Placement of active-close drainage in surgical site.
110259|NCT03324854|Drug|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
110260|NCT03324841|Diagnostic Test|Caris MI Profiling|Customized comprehensive biomarker testing
110261|NCT03324828|Drug|Hydroxyzine|Hydroxyzine solution
110262|NCT03324828|Other|Clowns intervention|Clowns intervention
110263|NCT03324815|Drug|Morphine|Pain Treatment
110264|NCT03324815|Drug|Methadone|Pain Treatment
110265|NCT03324802|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
110266|NCT03324802|Other|Quality-of-Life Assessment|Ancillary studies
110267|NCT03324802|Radiation|Radiation Therapy|hypofractionated radiation therapy
110268|NCT03324789|Other|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
110269|NCT03324789|Other|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
110270|NCT03324776|Drug|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
110271|NCT03324763|Other|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
110272|NCT03324737|Device|Interactive Smartphone App|"There are six main components to the APP.~Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.~Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.~Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.~Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.~Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals."
110273|NCT03324724|Behavioral|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
110274|NCT03324711|Diagnostic Test|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
110275|NCT03324685|Drug|BIIB074|BIIB074 is administered as specified in the treatment arm.
110276|NCT03324685|Drug|OC (ethinyl estradiol and levonorgestrel)|OC is administered as specified in the treatment arm.
110277|NCT03324672|Procedure|TRIGGER|only TRIGGER point will be included for the manual therapy
110278|NCT03324672|Procedure|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
110279|NCT03324659|Behavioral|Exercise and Meditation|The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
110280|NCT03324659|Behavioral|Control|The Control group will listen to a recorded audio book for 15 minutes, They will then sit quietly for 30 minutes. The intervention is completed five days per week for four weeks.
110281|NCT03324620|Other|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
110282|NCT03324607|Drug|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
110283|NCT03324607|Drug|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
110284|NCT03324594|Device|(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)|"WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.~WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.~The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available."
110285|NCT03324581|Drug|OPC-64005|Tablet
110286|NCT03324581|Drug|Atomoxetine|Capsule
110287|NCT03324581|Drug|Placebo|Tablet/Capsule
110288|NCT03324568|Behavioral|Parent Education Videos|Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.
110289|NCT03324568|Behavioral|Educational Handout|Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
110290|NCT03324555|Drug|ORIC-101|Oral suspension
110291|NCT03324542|Drug|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
110292|NCT03324529|Device|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (<10 breaths/min) with prolonged exhalation.
110293|NCT03324516|Procedure|Re-Suspension of the temporal muscle after a craniotomy.|The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
110294|NCT03324516|Procedure|Traditional re-suspension of the temporal muscle|The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
110295|NCT03324503|Drug|Glucocorticoid (prednisone or prednisolone)|≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
110296|NCT03324490|Procedure|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).~When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) & 5 μg dexmedetomidine will be injected."
110297|NCT03324490|Procedure|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle & a 20 G epidural catheter.~Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose & continued throughout the procedure."
110298|NCT03324490|Drug|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
110299|NCT03324490|Drug|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
110300|NCT03324490|Drug|Fentanyl|Neuro-axially injected
110301|NCT03324490|Drug|Dexmedetomidine|Neuro-axially injected
110302|NCT03324477|Drug|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
110303|NCT03324464|Behavioral|Central Executive Training: Working Memory|Computerized working memory training
110304|NCT03324464|Behavioral|Central Executive Training: Inhibitory Control|Computerized inhibitory control training
110305|NCT03324451|Behavioral|TTM Intervention for Insulin Initiation|The intervention contains three parts: (1) individual intervention; (2) insulin injection follow-up management; (3) motivational group activities. Different intervention strategies are applied to patients according to their stages of change.
110306|NCT03324451|Behavioral|Usual care|Regular patient education on insulin injection at the control arm hospital.
110307|NCT03324438|Behavioral|Home Telehealth T1D C2oYoT1-HR|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
110308|NCT03324438|Behavioral|Personalized Behavioral Health|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
110309|NCT03324438|Behavioral|Personalized Adherence Feedback|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
110310|NCT03324425|Drug|Simvastatin 40mg|Participants will receive simvastatin 40 mg by mouth daily at bedtime
110311|NCT03324412|Drug|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
110312|NCT03324412|Drug|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
110313|NCT03324399|Dietary Supplement|probiotic|a proprietary probiotic formulation
110314|NCT03324386|Behavioral|Experimental: Individual Orientation|This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
110315|NCT03324386|Behavioral|Experimental: VLE for Distance Learning|Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
110316|NCT03324386|Behavioral|Experimental: E-blended Lerarning|This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
110317|NCT03324386|Other|Conventional Therapy - Control Group|This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
110318|NCT03324373|Drug|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
110319|NCT03324373|Drug|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
110320|NCT03324373|Procedure|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.~After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
110321|NCT03324360|Drug|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
110322|NCT03324347|Procedure|Therapydog|Presence of a therapydog during a clinical examination in a dental clinic
110323|NCT03324334|Diagnostic Test|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
110324|NCT03324334|Diagnostic Test|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
110325|NCT03324321|Other|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
110326|NCT03324308|Diagnostic Test|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
110327|NCT03324295|Diagnostic Test|cortical cataract|Blood urea
110328|NCT03324282|Drug|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
110329|NCT03324282|Drug|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
110330|NCT03324269|Device|NOL|"After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value <10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 10 / decrement of 1 ng/ml of remifentanil Ce NOL gradient < 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 10 minutes after skin incision and sternotomy, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value <10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured."
110331|NCT03324256|Other|energy drink|16 oz cold commercially-available energy drink
110332|NCT03324256|Other|caffeinated drink|16oz cold commercially-available caffeinated drink
110333|NCT03324256|Other|Energy gum|2 pieces of commercially-available energy gum
110334|NCT03324256|Other|placebo gum|2 pieces of commercially-available placebo gum
110335|NCT03324256|Other|Control drink|16oz cold control drink
110336|NCT03324256|Other|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
110337|NCT03324243|Drug|Crenolanib|66.7 mg/m2 three times a day (TID)
110338|NCT03324243|Drug|Fludarabine|30 mg/m2/day, intravenous infusions over 30 mins.
110339|NCT03324243|Drug|Cytarabine|2000 mg/m2/day, intravenous infusions over 1-3 hours.
110340|NCT03324217|Other|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
110341|NCT03324204|Other|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
110342|NCT03324204|Other|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
110343|NCT03324191|Dietary Supplement|Placebo|Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
110344|NCT03324191|Dietary Supplement|Tea beverage|Tea beverage
110345|NCT03324191|Dietary Supplement|Tea extract (medium concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
110346|NCT03324191|Dietary Supplement|Tea extract (high concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
110347|NCT03324191|Dietary Supplement|High fat liquid meal challenge|"A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.~For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
110348|NCT03324178|Behavioral|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
110349|NCT03324178|Behavioral|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
110350|NCT03324165|Other|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
110351|NCT03324152|Other|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
110352|NCT03324152|Other|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
110353|NCT03324152|Other|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
110354|NCT03324139|Drug|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
110355|NCT03324139|Drug|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
110356|NCT03324113|Biological|SAR408701|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
110357|NCT03324113|Drug|dexamethasone|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
110358|NCT03324113|Drug|naphazoline|"Pharmaceutical form: solution for eye drop~Route of administration: eye drop"
110359|NCT03324113|Drug|diphenhydramine|"Pharmaceutical form: tablet~Route of administration: oral"
110360|NCT03324087|Diagnostic Test|HRQoL|use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
110361|NCT03324061|Drug|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
110362|NCT03324061|Drug|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
110363|NCT03324048|Other|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.~Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
110364|NCT03324035|Drug|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
110365|NCT03324035|Drug|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
110366|NCT03324035|Drug|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
110367|NCT03324009|Diagnostic Test|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
110368|NCT03323996|Other|Semi-Structured interviews|individual semi-structured interviews
110369|NCT03323983|Other|data collection|data collection
110370|NCT03323970|Other|semi-structured interviews|individual semi-structured interviews
110371|NCT03323957|Diagnostic Test|nutritional screening tool|screening of disease associated malnutrition in sick infants
110372|NCT03323944|Biological|huCART-meso cells|Intravenous administration of permanently modified CAR T cells that target mesothelin, given as single agent or in combination with a lymphodepleting dose of cyclophosphamide.
110373|NCT03323931|Behavioral|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
110462|NCT03323164|Drug|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
110374|NCT03323931|Behavioral|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
110375|NCT03323918|Other|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
110376|NCT03323918|Other|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
110377|NCT03323905|Device|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
110378|NCT03323892|Other|second masturbation|Husbands will be asked to produce a second sperm sample in the masturbatorium
110379|NCT03323879|Radiation|LDR/HDR|Focal LDR to dominant lesion with whole gland 19 Gy HDR
110380|NCT03323866|Drug|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
110381|NCT03323866|Drug|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
110382|NCT03323853|Other|CARS Report|Patients will be evaluated by emergency providers using the CARS report
110383|NCT03323840|Other|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
110384|NCT03323814|Device|Slow-wave optimization|employing sensory stimulation to enhance slow waves
110385|NCT03323801|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
110386|NCT03323775|Diagnostic Test|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
110387|NCT03323762|Device|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
110388|NCT03323749|Combination Product|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
110389|NCT03323749|Combination Product|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
110390|NCT03323749|Combination Product|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
110391|NCT03323723|Device|SUI Device|Pessary SUI device
110392|NCT03323710|Drug|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
110393|NCT03323710|Drug|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
110394|NCT03323697|Other|SZ-05|2.5g a day (3 capsules twice a day)
110395|NCT03323697|Drug|Escitalopram Pill|10 mg capsule plus 5 placebo capsules
110396|NCT03323684|Other|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
110397|NCT03323684|Other|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
110398|NCT03323684|Other|Control group (C)|No intervention will be done
110399|NCT03323684|Drug|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
110400|NCT03323684|Drug|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
110401|NCT03323684|Drug|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
110402|NCT03323671|Drug|preemptive mefenamic acid|preemptive analgesia before menstrual pain
110403|NCT03323671|Drug|mefenamic acid|mefenamic acid given only during menstruation
110404|NCT03323658|Drug|Bexarotene|Given topically
110405|NCT03323658|Other|Laboratory Biomarker Analysis|Correlative studies
110406|NCT03323658|Other|Questionnaire Administration|Ancillary studies
110460|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
110461|NCT03323164|Drug|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
110407|NCT03323632|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non‐damaged pathways of the central nervous system.
110408|NCT03323619|Procedure|anesthesia type|No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
110409|NCT03323606|Behavioral|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
110410|NCT03323606|Behavioral|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
110411|NCT03323593|Drug|Dexmedetomidine|blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
110412|NCT03323580|Other|SVV-based GDFT|Target SVV will be titrated with fluid bolus, and thus individual amount varied depending on the SVV value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as minimal cardiac indices, mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
110413|NCT03323580|Other|traditional fluid therapy|Fluid therapy will be done without goal-directed SVV . Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as minimal cardiac indices, mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
110414|NCT03323567|Drug|MD Muscle GUNA collagen|intramusclular injections of MD Muscle collagen
110415|NCT03323567|Drug|Lidocaine 2% Injectable Solution|intramuscular Lidocaine 2% injection
110416|NCT03323567|Drug|Saline Solution, Hypertonic|intramuscular Saline injection
110417|NCT03323554|Device|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
110418|NCT03323554|Device|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
110419|NCT03323541|Drug|Filgrastim Prefilled Syringe [Zarzio®]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils >1 giga/l)
110420|NCT03323528|Drug|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
110421|NCT03323528|Drug|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.~Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
110422|NCT03323502|Behavioral|ACP Specialist Program|New structured role with responsibility for ACP
110423|NCT03323489|Radiation|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
110424|NCT03323476|Other|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
110425|NCT03323476|Drug|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
110426|NCT03323463|Diagnostic Test|F-FMISO PET/CT Scan|Every participant will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment
110427|NCT03323463|Radiation|30 Gy over 3 weeks|Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the postoperative bed, all subclinical areas at risk for disease will receive the same dose at 30Gy.
110428|NCT03323463|Drug|Cisplatin|Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.
110429|NCT03323463|Drug|Carboplatin|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
110430|NCT03323463|Drug|5Fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
110431|NCT03323450|Behavioral|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~Baseline before the participant is introduced to the CogMed® training program~Within 2 weeks of completion of the CogMed® program~At 3 months of completion of the CogMed® program to establish maintenance of gains~At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
110432|NCT03323437|Drug|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
110433|NCT03323424|Radiation|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :~Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
110434|NCT03323424|Other|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :~Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
110435|NCT03323411|Behavioral|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
110436|NCT03323398|Biological|mRNA-2416|mRNA encoding human OX40L
110437|NCT03323398|Biological|Durvalumab|PD-L1 inhibitor
110438|NCT03323385|Drug|N1539|Once Daily
110439|NCT03323385|Drug|Placebo|Once Daily
110440|NCT03323372|Drug|3% potassium nitrate and 0.25% sodium fluoride|
110441|NCT03323372|Drug|5% potassium nitrate and 2% sodium fluoride|
110442|NCT03323359|Device|Hemopatch|Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the electronic Case Report Form. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
110443|NCT03323359|Procedure|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
110444|NCT03323346|Drug|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.~Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
110445|NCT03323333|Behavioral|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
110446|NCT03323307|Device|OCT imaging|imaging of retina using OCT device
110447|NCT03323281|Other|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
110448|NCT03323268|Device|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
110449|NCT03323255|Device|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
110450|NCT03323255|Device|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
110451|NCT03323242|Device|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
110452|NCT03323242|Device|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
110453|NCT03323229|Diagnostic Test|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
110454|NCT03323216|Diagnostic Test|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.~Test is performed prior the CRT implantation and 6 months after the CRT implantation."
110455|NCT03323216|Diagnostic Test|Study specific questionnaire|"Study specific questionnaire~The questionnaire is performed prior the CRT implantation and 6 months after the CRT implantation."
110456|NCT03323216|Procedure|Blood collection|"Blood collection during surgery:~coronary sinus~arterial~peripheral venous~Blood collection 6 months after surgery:~- peripheral venous"
110457|NCT03323203|Device|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
110458|NCT03323190|Behavioral|Inpatient COPD education|
110459|NCT03323177|Dietary Supplement|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
110463|NCT03323151|Drug|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ixazomib 3 mg) or escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities.
110464|NCT03323151|Drug|Ixazomib|Ixazomib by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
110465|NCT03323151|Drug|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
110466|NCT03323151|Drug|Ibrutinib|Ibrutinib by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
110467|NCT03323138|Procedure|Ex-PRESS and phacoemulsification|
110468|NCT03323125|Other|Self-Assessment Questionnaire|Self-assessment questionnaire with sun exposition, sun protection, vitiligo severity and vitiligo outbreaks, will be suggested to patient during medical consultation.
110469|NCT03323112|Biological|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
110470|NCT03323099|Behavioral|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
110471|NCT03323099|Behavioral|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
110472|NCT03323086|Behavioral|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
110473|NCT03323086|Other|Brochure|Brochures provided one time
110474|NCT03323073|Other|Resting state fMRI|One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
110475|NCT03323060|Device|Transanal endoscopic surgical procedure|Resection of tumors or lesions
110476|NCT03323047|Drug|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
110477|NCT03323047|Drug|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
110478|NCT03323047|Drug|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
110479|NCT03323047|Drug|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
110480|NCT03323034|Drug|Irinotecan Hydrochloride|Given IV
110481|NCT03323034|Drug|Pevonedistat|Given IV
110482|NCT03323034|Other|Pharmacological Study|Ancillary studies
110483|NCT03323034|Drug|Temozolomide|Given PO
110484|NCT03323021|Biological|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
110485|NCT03323021|Other|Standard of Care|Standard of Care
110486|NCT03323008|Other|Prototype|Usability testing and System Usability Scale
110487|NCT03322995|Drug|First-line Chemotherapy|The first-line therapy will be FOLFIRINOX or best available standard of care.
110488|NCT03322995|Drug|Second-line Chemotherapy|Second line therapies will be multi-agent and contain gemcitabine. Molecular profiling data from the initial EUS/FNA biopsy may be used at the discretion of the treating physician.
110489|NCT03322995|Radiation|Chemoradiation|50.4Gy in 28 fractions.
110490|NCT03322982|Behavioral|Low-fat diet|less than 20% calories from fat daily
110491|NCT03322969|Drug|Paclitaxel/DDP|receiving the modified chemotherapy
110492|NCT03322969|Drug|XELOX/SOX|receiving the original chemotherapy
110493|NCT03322956|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
110494|NCT03322930|Diagnostic Test|Rod sensitivity|diagnostic test for rod loss in central retina
110495|NCT03322917|Biological|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
110496|NCT03322904|Diagnostic Test|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system~Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula [IEC-PC¬] ‒ [CC-PC] / [CC-PC]."
110497|NCT03322891|Other|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
110498|NCT03322891|Other|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
110499|NCT03322878|Drug|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
110526|NCT03322670|Other|Patients with partial participation|- collection of clinical examination data
110527|NCT03322670|Other|Signs of CAP and a negative chest X-Ray|"collection of clinical examination data~telephone contact on day 28"
110528|NCT03322657|Drug|Neostigmine|Neostigmine injection
110529|NCT03322657|Drug|Glycopyrrolate|Glycopyrrolate injection
110530|NCT03322657|Drug|Sugammadex|Sugammadex injection
110500|NCT03322865|Drug|Obinutuzumab|"Induction:~Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15*~*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.~Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance~Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:~Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
110501|NCT03322852|Other|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
110502|NCT03322839|Behavioral|Multifaceted implementation strategies|The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.
110503|NCT03322839|Behavioral|Single implementation strategy|The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
110504|NCT03322826|Procedure|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
110505|NCT03322826|Procedure|lymphadenectomy|Routine lymph nodes dissection in lung cancer
110506|NCT03322813|Device|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma undergoing resection
110507|NCT03322800|Drug|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
110508|NCT03322800|Other|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
110509|NCT03322787|Device|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
110510|NCT03322774|Behavioral|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
110511|NCT03322774|Behavioral|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
110512|NCT03322774|Behavioral|Sleep Hygiene Education Control|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine. In Step 1, sleep hygiene control will be exclusively online. In Step 2, sleep hygiene control includes an in-person, face-to-face component.
110513|NCT03322761|Combination Product|Systematic exercise training|Combination of standard medical treatment and systematic early exercise training in persons with MS.
110514|NCT03322761|Behavioral|Educational program|Informations regarding health benefits of physical activity and exercise.
110515|NCT03322748|Other|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
110516|NCT03322748|Other|Usual physical therapy|Usual physical therapy
110517|NCT03322735|Drug|Fludarabine|25-30mg/m2/day IV for 3 days
110518|NCT03322735|Drug|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
110519|NCT03322735|Biological|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
110520|NCT03322709|Procedure|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
110521|NCT03322683|Procedure|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
110522|NCT03322683|Procedure|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
110523|NCT03322670|Other|Signs of CAP and a positive chest X-Ray|"collection of clinical examination data~biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)~self-reported questionnaires on duration of symptoms and restriction of activity~telephone contact on day 28 and day 90 if hospitalized before day 28"
110524|NCT03322670|Other|Patients directly hospitalized|"collection of clinical examination data~telephone contact on day 28 and retrieval of hospitalization report~telephone contact on day 90"
110525|NCT03322670|Diagnostic Test|Control patients|- bacteriological examinations (urine)
110531|NCT03322644|Behavioral|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
110532|NCT03322631|Drug|Tirzepatide|Administered SC.
110533|NCT03322631|Drug|Placebo|Administered SC.
110534|NCT03322618|Biological|blood samples|7 tubes of 6 ml (42 ml of blood )
110535|NCT03322592|Diagnostic Test|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
110536|NCT03322592|Diagnostic Test|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
110537|NCT03322579|Device|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
110538|NCT03322566|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
110539|NCT03322566|Drug|Epacadostat|Epacadostat administered orally twice daily.
110540|NCT03322566|Drug|Platinum-based chemotherapy|Investigator will select one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin.
110541|NCT03322566|Drug|Placebo|Matching placebo administered orally twice daily.
110542|NCT03322553|Device|GERD-X|Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
110543|NCT03322540|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
110544|NCT03322540|Drug|Epacadostat|Epacadostat administered orally twice daily.
110545|NCT03322540|Drug|Placebo|Matching placebo administered orally twice daily.
110546|NCT03322514|Dietary Supplement|Inulin-Propionate Esters|Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
110547|NCT03322514|Dietary Supplement|Inulin|Inulin
110548|NCT03322501|Behavioral|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
110549|NCT03322488|Procedure|Fistulodesis|"Fistulodesis comprises the following treatment steps:~Curettage and/or brushing of the fistula tract~Mini-excision of the inner (endoanal) fistula opening~Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)~Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)~Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.~Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)~Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)~Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
110550|NCT03322475|Device|PiQo4 laser system|The PiQo4 laser system
110551|NCT03322462|Drug|18F-AV-1451|Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451
110552|NCT03322449|Other|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
110553|NCT03322449|Other|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
110554|NCT03322436|Diagnostic Test|HeartLinc kit|Samples are collected and analyzed afterwards
110555|NCT03322423|Device|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
110556|NCT03322423|Device|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
110557|NCT03322423|Device|Spherical Contact Lens 2|BioTrue ONEDay Spherical
110558|NCT03322410|Biological|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for Twardowsky~High : D/P creatinine>0,8; D/D0 glucose<0,25~High average : 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38~Low average : 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48~Low  : D/P creatinine<0,5 ; D/D0 glucose>0,49."
110559|NCT03322397|Behavioral|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
110560|NCT03322397|Behavioral|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
110561|NCT03322397|Behavioral|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
110562|NCT03322384|Drug|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
110563|NCT03322384|Drug|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
110564|NCT03322384|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
110632|NCT03321799|Device|Sterile Antimicrobial Dressings|Control group, current hospital standard.
110935|NCT03319316|Drug|Durvalumab|Combination of durvalumab + tremelimumab treatment
110565|NCT03322371|Device|2-lead limited electroencephalography recording|The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
110566|NCT03322358|Other|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
110567|NCT03322358|Device|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
110568|NCT03322358|Other|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
110569|NCT03322319|Procedure|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.~Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
110570|NCT03322306|Genetic|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
110571|NCT03322293|Drug|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
110572|NCT03322293|Device|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
110573|NCT03322280|Procedure|TACE combined with iodine-125 seeds implantation|Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
110574|NCT03322280|Procedure|TACE|Only conventional TACE with lipiodol and chemotherapy drugs was performed.
110575|NCT03322267|Drug|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18 Gy/10 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
110576|NCT03322254|Other|respiratory pathogen panel|lab testing for respiratory pathogens
110577|NCT03322241|Other|overall wellness|Wellness lab testing
110578|NCT03322228|Other|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
110579|NCT03322215|Drug|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
110580|NCT03322215|Drug|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
110581|NCT03322215|Drug|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
110582|NCT03322202|Behavioral|Motivational Interviewing|Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
110583|NCT03322189|Genetic|pharmacogenomic|Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP
110584|NCT03322176|Other|Genetic testing|LYNCH genetic testing
110585|NCT03322163|Other|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
110586|NCT03322150|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
110587|NCT03322150|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
110588|NCT03322137|Drug|SNA-120|Pegcantratinib ointment
110589|NCT03322137|Drug|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
110590|NCT03322124|Drug|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
110591|NCT03322124|Other|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
110592|NCT03322111|Diagnostic Test|measurement of the cyclofusion|Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
110593|NCT03322098|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) within 3 minutes before spinal anesthesia
110594|NCT03322098|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) within 3 minutes before spinal anesthesia
110595|NCT03322085|Procedure|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
110596|NCT03322072|Device|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
110597|NCT03322059|Behavioral|Experimental|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
110693|NCT03321253|Device|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
110598|NCT03322059|Behavioral|Control|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
110599|NCT03322046|Behavioral|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
110600|NCT03322033|Device|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
110601|NCT03322020|Radiation|Cyberknife boost 18 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 18 Gy/3 fx
110602|NCT03322020|Radiation|Cyberknife boost 21 Gy|pelvis IMRT dose of 44 Gy/20 fx followed by Cyberknife boost 21 Gy/3 fx
110603|NCT03321994|Device|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
110604|NCT03321994|Device|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
110605|NCT03321981|Drug|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
110606|NCT03321981|Drug|Trastuzumab|humanised IgG1 monoclonal antibody
110607|NCT03321981|Drug|Vinorelbine|antineoplastic drug of vinca alkaloid family
110608|NCT03321981|Drug|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
110609|NCT03321968|Biological|Quadrivalent VLP Influenza Vaccine|30 µg/strain Quadrivalent VLP Influenza Vaccine
110610|NCT03321955|Drug|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5 and 6 months.
110611|NCT03321955|Diagnostic Test|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline and 6 months,
110612|NCT03321955|Diagnostic Test|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
110613|NCT03321942|Drug|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
110614|NCT03321942|Drug|Control group|Conventional treatment were used to treat patients with chronic renal failure.
110615|NCT03321929|Combination Product|LUM Imaging System|LUM015 will be administered 2 to 6 hours prior to surgery. All subjects will have intraoperative imaging using the LUM imaging device.
110616|NCT03321916|Device|577-nm PASCAL laser|The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
110617|NCT03321903|Device|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
110618|NCT03321903|Other|EPR Oximetry Measurement|An oximetry measurement visit consists of ~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
110619|NCT03321890|Drug|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
110620|NCT03321890|Drug|prednisone|oral, 20mg / day,after breakfast
110621|NCT03321890|Drug|Cyclophosphamide|oral, 50mg / day,after lunch
110622|NCT03321890|Drug|etoposide|oral, 50mg / day,after dinner
110623|NCT03321890|Drug|Methotrexate|oral, 10mg / times, once a week,after breakfast
110624|NCT03321877|Drug|Change to dose of patient's regular medication|Dose reduction of the drug each patient was already taking
110625|NCT03321864|Procedure|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
110626|NCT03321851|Device|V-sensor device user|Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
110627|NCT03321838|Behavioral|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
110628|NCT03321825|Device|Belotero® Volume Lidocaine|Mode of application: subdermal injection
110629|NCT03321812|Procedure|decalcification bone scaffold|Decalcification bone scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
110630|NCT03321812|Procedure|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
110631|NCT03321799|Device|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
110633|NCT03321786|Other|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
110634|NCT03321773|Drug|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
110635|NCT03321773|Drug|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
110636|NCT03321760|Radiation|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
110637|NCT03321747|Radiation|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
110638|NCT03321734|Drug|Caffeine|Infants will be started on oral caffeine base at 5 mg/kg/day. At 36 weeks + 0 days PMA drug dose will be increased to 5 mg/kg BID (total daily dose 10 mg/kg). Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. After discharge, all new doses will be calculated from the last weight recorded prior to discharge. The research pharmacy will prepare a bulk oral solution with active drug (caffeine base). While in the hospital, a daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare and dispense a sufficient quantity of caffeine base solution for outpatient treatment up to 42 weeks + 6 days.
110639|NCT03321734|Drug|Placebos|SyrSpend SF Unflavored will be used as the placebo for the control group infants. The volume of the placebo will match the volume of the study drug.
110640|NCT03321721|Other|Suture (nylon) for wound repair|suture of wound
110641|NCT03321682|Other|Functional Training|Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
110642|NCT03321682|Other|Strength Training|Exercises carried out using weights and involving the main muscle groups.
110643|NCT03321669|Procedure|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
110644|NCT03321656|Drug|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
110645|NCT03321656|Drug|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
110646|NCT03321643|Drug|Atezolizumab|Given IV
110647|NCT03321643|Drug|Gemcitabine|Given IV
110648|NCT03321643|Other|Laboratory Biomarker Analysis|Correlative studies
110649|NCT03321643|Drug|Oxaliplatin|Given IV
110650|NCT03321643|Biological|Rituximab|Given IV
110651|NCT03321630|Drug|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
110652|NCT03321630|Drug|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
110653|NCT03321617|Drug|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
110654|NCT03321565|Other|Behavioral counseling and optional meal replacement program|Medical assessment and medical supervision of weight loss Measurements of metabolism and body composition Individualized exercise programs Personal training Support group meetings Individual psychotherapy A variety of nutritional plans including meal replacement options Nutrition education Long-term weight maintenance and relapse prevention programs
110655|NCT03321552|Procedure|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
110656|NCT03321552|Device|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
110657|NCT03321539|Drug|CCRT+GP|Patients receive concurrent cisplatin 100mg/m2 every 21days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 on day 1) every 21 days for three cycles 4 weeks after radiotherapy.
110658|NCT03321539|Drug|CCRT+PF|Patients receive concurrent cisplatin 100mg/m2 every 21 days for three cycles during Intensity modulated-radiotherapy (IMRT) followed by adjuvant cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every 28 days for three cycles 4 weeks after radiotherapy.
110659|NCT03321526|Drug|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
110660|NCT03321526|Drug|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
110661|NCT03321526|Drug|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
110662|NCT03321526|Drug|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
110663|NCT03321526|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
110664|NCT03321526|Drug|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
110694|NCT03321240|Procedure|visual and quantitative SEEG signal analysis|signal SEEG analysis
110695|NCT03321240|Procedure|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
110696|NCT03321227|Other|Snack skipping|No snack provided
110697|NCT03321227|Other|Whole eggs|2 whole large eggs scrambled, provided as a snack
110698|NCT03321227|Other|Egg whites|2 egg whites scrambled, provided as a snack
110699|NCT03321227|Other|Egg yolks|2 egg yolks scrambled, provided as a snack
110700|NCT03321227|Other|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole eggs
110665|NCT03321513|Drug|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.~Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.~Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using sterile technique"
110666|NCT03321513|Drug|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.~Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.~Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.~The injection will be performed using a sterile technique."
110667|NCT03321500|Other|Versacryl soft liner|Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
110668|NCT03321500|Other|Silicone-based soft liner|gold standard for denture relining material
110669|NCT03321487|Device|Blood-Brain Barrier opening with MRgFUS|ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
110670|NCT03321474|Procedure|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.~The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
110671|NCT03321461|Drug|TMTP1|Fluorescent sites will be removed
110672|NCT03321461|Drug|ICG|Fluorescent sites will be removed
110673|NCT03321448|Drug|TMTP1-ICG|Detection of SLN
110674|NCT03321448|Drug|ICG|Detection of SLN
110675|NCT03321435|Other|placenta previa patient|women had placenta previa either major or minor degree
110676|NCT03321435|Other|normal women|those women had not placenta previa
110677|NCT03321422|Other|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
110678|NCT03321409|Diagnostic Test|The general population|After recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-CN will be compared with the PHQ-15.
110679|NCT03321409|Diagnostic Test|Patients with suspected CAD|In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-CN and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
110680|NCT03321396|Device|sodium alginate mixed with calcium lactate|"The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel."
110681|NCT03321370|Diagnostic Test|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
110682|NCT03321357|Diagnostic Test|five-repetition sit-to-stand test|"An armless chair with a hard seat was stabilised by placing it against a wall. Seated participants were asked to come forward on the chair seat until the feet were flat on the floor and to fold their upper limbs across the chest. Participants were then instructed to stand up all the way and sit down once without using the upper limbs. For those unable to complete the initial manoeuvre or who required assistance, the test was terminated. If successful on the initial sit to stand, participants were then asked to stand up all the way and sit down landing firmly, as fast as possible, five times without using the arms. Timing with a stopwatch was started on the command 'go' and stopped at the end of the completed fifth stand; the time taken was recorded as the participant's score.~(1) Jones et al."
110683|NCT03321344|Device|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
110684|NCT03321331|Combination Product|Lark (JITAI)|Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
110685|NCT03321331|Combination Product|MyFitnessPal (no JITAI)|MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
110686|NCT03321318|Drug|AK-R215|Investigational product is prescribed to all ofrandomized subjects
110687|NCT03321318|Drug|Bazedoxifene 20 mg|Investigational product is prescribed to all of randomized subjects
110688|NCT03321318|Drug|Cholecalciferol 800IU|Investigational product is prescribed to all of randomized subjects
110689|NCT03321292|Drug|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
110690|NCT03321292|Drug|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
110691|NCT03321279|Behavioral|Social Incentive|Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
110692|NCT03321266|Device|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
110701|NCT03321214|Other|Gluten Sensor Dose-Finding Intervention|"Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes. Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is < 20 ppm or a wheat icon for > 20 ppm (low or high gluten).~Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
110702|NCT03321201|Procedure|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
110703|NCT03321201|Procedure|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
110704|NCT03321188|Procedure|HIPEC|HIPEC with cisplatin
110705|NCT03321188|Drug|Carboplatin|Adjuvant IV chemotherapy
110706|NCT03321188|Drug|Paclitaxel|Adjuvant IV chemotherapy
110707|NCT03321175|Other|subcutaneous saline irrigation|200 cc saline irrigation
110708|NCT03321162|Diagnostic Test|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
110709|NCT03321149|Other|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
110710|NCT03321136|Drug|LSD|0.025 mg LSD per os, single dose
110711|NCT03321136|Drug|LSD|0.05 mg LSD per os, single dose
110712|NCT03321136|Drug|LSD|0.1 mg LSD per os, single dose
110713|NCT03321136|Drug|LSD|0.2 mg LSD per os, single dose
110714|NCT03321136|Drug|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
110715|NCT03321136|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
110716|NCT03321123|Drug|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
110717|NCT03321110|Other|Placebo|Placebo (dextrin)
110718|NCT03321110|Dietary Supplement|Coenzyme Q10|150 mg or 300 mg
110719|NCT03321097|Device|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
110720|NCT03321097|Device|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.~Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.~During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
110721|NCT03321084|Other|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
110722|NCT03321084|Other|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
110723|NCT03321071|Behavioral|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
110724|NCT03321071|Behavioral|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
110725|NCT03321058|Behavioral|Assessment|Assessment of patients' medication organisation and comprehension of generics
110764|NCT03320707|Drug|rHuPH20|Participants in Cohort 8 will receive single SC dose of rHuPH20 as a part of daratumumab formulation.
110726|NCT03321045|Drug|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
110727|NCT03321045|Diagnostic Test|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
110728|NCT03321032|Device|Polymer-free amphilimus-eluting stents|Cre8 coronary stent system (CID, Saluggia, Italy)
110729|NCT03321032|Device|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
110730|NCT03321019|Drug|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
110731|NCT03321019|Device|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
110732|NCT03321019|Other|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
110733|NCT03321019|Procedure|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
110734|NCT03321006|Device|Audio B-R 90 hearing aid device|Hearing aids will be the latest Audio B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies; Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
110735|NCT03321006|Drug|Duloxetine|We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
110736|NCT03320993|Other|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
110737|NCT03320980|Procedure|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
110738|NCT03320980|Procedure|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
110739|NCT03320967|Diagnostic Test|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
110740|NCT03320954|Behavioral|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
110741|NCT03320941|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally daily.
110742|NCT03320941|Drug|Placebo|Placebo will be supplied as tablets to be taken daily orally.
110743|NCT03320928|Other|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
110744|NCT03320915|Drug|Cholecalciferol|Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
110745|NCT03320902|Behavioral|Sudden death counselling|"The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.~The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.~The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.~Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings."
110746|NCT03320889|Other|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
110747|NCT03320876|Drug|filgotinib|one filgotinib oral tablet once daily.
110748|NCT03320863|Device|Enso device|An active Enso device that delivers neuromodulation therapy.
110749|NCT03320850|Drug|OnabotulinumtoxinA and Hydrogel admixture|BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
110750|NCT03320850|Drug|Placebo and Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation
110751|NCT03320837|Dietary Supplement|Infant formula|Breast milk substitute containing synbiotics
110752|NCT03320837|Other|Breast milk|Breast milk
110753|NCT03320811|Other|Data record|
110754|NCT03320798|Other|Data record|
110755|NCT03320772|Drug|TMVP1-ICG|Detection of SLN
110756|NCT03320772|Drug|ICG|Detection of SLN
110757|NCT03320759|Behavioral|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
110758|NCT03320746|Device|Activity tracker|Daily activity goal
110759|NCT03320733|Diagnostic Test|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
110760|NCT03320720|Other|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
110761|NCT03320720|Other|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
110762|NCT03320707|Drug|Daratumumab|Single SC dose of daratumumab will be administered in each of 8 dose cohorts.
110763|NCT03320707|Drug|Placebo|Placebo liquid will be administered as SC dose in each of first 7 dose cohorts.
110936|NCT03319316|Drug|Tremelimumab|Combination of durvalumab + tremelimumab treatment
110765|NCT03320694|Drug|Metformin|metformin 500mg twice daily & increased until 2500mg till normoglycemia was achieved and was continued till delivery
110766|NCT03320694|Drug|Insulin|The insulin group was given 3 S/C injections of regular insulin & one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
110767|NCT03320681|Device|Electrical Stimulation|Percutaneous electrical nerve stimulation
110768|NCT03320681|Other|Dry Needling Stimulation|Percutaneous nerve stimulation
110769|NCT03320668|Other|Otago Exercise Program (OEP)|"A nurse/physiotherapist supported by an instructor-trained professional will give Otago Exercise Program (OEP) education to 10-people groups in 5 sessions (1st, 2nd, 4th and 8th week and one reinforcement session after 6 months). Telephone calls to participants will be made during non-training months (following a predefined telephonic interview protocol) to follow up. The OEP reduces the number of falls and fall-related injuries, improving balance and strength, confidence in performing everyday activities without falling. Whilst it has been shown to be effective in 4 controlled trials in New Zealand, it has not been tested in a primary care setting in Spain for feasibility, impact, acceptability and cost-effectiveness."
110770|NCT03320655|Other|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
110771|NCT03320655|Other|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
110772|NCT03320642|Drug|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
110773|NCT03320642|Drug|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate, cyclosporine A/mycophenolate mofetil or tacrolimus plus post-treatment cyclophosphamide. Antithymocyte globulin may be included at the treating investigator's discretion with the tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil combinations.
110774|NCT03320629|Combination Product|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
110775|NCT03320629|Combination Product|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
110776|NCT03320616|Drug|EYP001a|Oral EYP001a capsules - 100 mg strength
110777|NCT03320603|Other|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
110778|NCT03320603|Other|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
110779|NCT03320590|Diagnostic Test|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
110780|NCT03320577|Behavioral|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
110781|NCT03320577|Behavioral|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
110782|NCT03320577|Behavioral|Control|Log dinner times
110783|NCT03320564|Diagnostic Test|F-18 FDG PET|Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
110784|NCT03320551|Behavioral|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
110785|NCT03320538|Other|Hou Gu Mi Xi|Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).
110786|NCT03320538|Other|Placebo|The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.
110787|NCT03320538|Drug|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
110788|NCT03320525|Dietary Supplement|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
110789|NCT03320512|Behavioral|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3.
110823|NCT03320304|Device|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
110824|NCT03320291|Device|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
110825|NCT03320265|Drug|PC-mAb|Monthly treatment for 3 months (4 administrations)
110826|NCT03320265|Drug|Placebo|Monthly treatment for 3 months (4 administrations)
110790|NCT03320512|Behavioral|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+.
110791|NCT03320512|Behavioral|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
110792|NCT03320499|Procedure|echo doppler at the bed|we practise the echo doppler at the patient 's bed
110793|NCT03320499|Procedure|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
110794|NCT03320486|Drug|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
110795|NCT03320486|Drug|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
110796|NCT03320473|Device|IC-8 IOL|The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
110797|NCT03320460|Drug|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
110798|NCT03320460|Device|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
110799|NCT03320460|Other|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
110800|NCT03320460|Other|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
110801|NCT03320447|Drug|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
110802|NCT03320447|Device|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
110803|NCT03320447|Drug|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
110804|NCT03320447|Device|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
110805|NCT03320434|Drug|PRT 0.5%|Six drops in each eye over a 17 day period.
110806|NCT03320434|Drug|PRT 1%|Six drops in each eye over a 17 day period.
110807|NCT03320434|Drug|Patanol|Six drops in each eye over a 17 day period.
110808|NCT03320434|Drug|Pred-forte|Four drops in each eye over a 3 day period.
110809|NCT03320434|Drug|PRT 0%|Six drops in each eye over a 17 day period.
110810|NCT03320421|Radiation|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.~Intensity modulated radiation treatment is used."
110811|NCT03320395|Device|Small bowel RFA treatment|"The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites."
110812|NCT03320382|Device|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
110813|NCT03320369|Other|elemental diet therapy|elemental formula
110814|NCT03320356|Other|the French version of the Oxford Shoulder Score|
110815|NCT03320343|Other|MRI|3D morphological MRI and diffusion tensor imaging
110816|NCT03320330|Other|Laboratory Biomarker Analysis|Correlative studies
110817|NCT03320330|Biological|Pepinemab|Given IV
110818|NCT03320330|Other|Pharmacological Study|Correlative studies
110819|NCT03320317|Other|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
110820|NCT03320317|Other|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
110821|NCT03320317|Other|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
110822|NCT03320317|Other|Learning session 4|Feedback report, Best practice symposium
110827|NCT03320252|Device|Endurant Chimney Graft Technique|Medtronic Endurant II and Endurant IIs Stent Graft Systems and balloon-expandable covered stent graft systems approved for use in the renal arteries. These devices will be utilized in a chimney graft configuration.
110828|NCT03320239|Behavioral|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
110829|NCT03320239|Behavioral|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
110830|NCT03320239|Behavioral|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
110831|NCT03320226|Dietary Supplement|Probiotic 10 (Nature's Bounty)|The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
110832|NCT03320200|Other|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
110833|NCT03320200|Other|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
110834|NCT03320187|Drug|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
110835|NCT03320187|Drug|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
110836|NCT03320174|Drug|Tafenoquine|Tafenoquine 200mg
110837|NCT03320174|Other|Placebo|Placebo
110838|NCT03320148|Behavioral|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination~Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.~Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).~Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
110839|NCT03320148|Other|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
110840|NCT03320135|Procedure|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
110841|NCT03320135|Procedure|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
110842|NCT03320122|Other|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
110843|NCT03320122|Other|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
110844|NCT03320122|Other|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
110845|NCT03320109|Other|Vitamin D|
110846|NCT03320096|Device|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3*4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
110847|NCT03320083|Behavioral|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
110848|NCT03320070|Drug|repository corticotropin injection|Acthar administered twice weekly SC
110849|NCT03320070|Drug|Placebo|Placebo administered twice weekly SC
110850|NCT03320057|Drug|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
110851|NCT03320031|Drug|Linagliptin|Take linagliptin 5mg a day.
110852|NCT03320031|Drug|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
110853|NCT03320018|Drug|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or infused into water for the patient to drink, as the patient's condition permits. This will be administered q 8 hours for 3 days.
110854|NCT03320018|Drug|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
110855|NCT03320018|Other|Placebo Hydrogen|Normal saline solution or water will be administered i.v. or p.o. respectively, in place of hydrogen solution.
110856|NCT03320018|Other|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
110857|NCT03320005|Other|Resistance training group|Resistive exercises for legs and arms
110858|NCT03319992|Device|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
110859|NCT03319953|Drug|TAK-041|TAK-041 suspension
110860|NCT03319953|Drug|Placebo|TAK-041 placebo-matching suspension
110861|NCT03319940|Drug|AMG 757|AMG 757 is a Half Life Extended (HLE) Bispecific T cell engager (BiTE®) targeting delta-like protein 3 (DLL3)
110862|NCT03319927|Behavioral|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
110863|NCT03319901|Drug|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."
110864|NCT03319901|Drug|Standard Chemotherapy|Standard treatment of chemotherapy is administered
110865|NCT03319888|Device|CPAP|continuous positive pressure in the airway
110866|NCT03319888|Other|conservative treatment|conservative treatment group with lifestyle modifications
110867|NCT03319875|Device|Epiduroscopic Laser Discectomy|Caudal epidural space after passing through sacral hiatus
110868|NCT03319862|Procedure|Inferior pédicule gynaecomastia|Inferior pédicule gynaecomastia
110869|NCT03319849|Combination Product|Renexus®|Surgery to receive one Renexus® device implant.
110870|NCT03319849|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure.
110871|NCT03319823|Drug|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure <160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment"
110872|NCT03319823|Drug|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure >120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure >120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is <120.
110873|NCT03319823|Drug|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~If sleep systolic blood pressure is > 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
110874|NCT03319810|Biological|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
110875|NCT03319797|Drug|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
110876|NCT03319784|Drug|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
110877|NCT03319784|Drug|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
110878|NCT03319771|Behavioral|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
110879|NCT03319771|Behavioral|Stretching-and-toning Exercise Training|12-weeks of supervised, stretching-and-toning exercise training
110880|NCT03319758|Other|Intact labial plate|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. Thirty patients are recruited. They are divided into two groups: intact labial plate and compromised labial plate.
110881|NCT03319758|Other|Compromised labial plate|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. Thirty patients are recruited. They are divided into two groups: intact labial plate and compromised labial plate.
110882|NCT03319745|Biological|Pembrolizumab|Given IV
110883|NCT03319732|Drug|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
110884|NCT03319719|Device|Belotero® Balance with integral lidocaine|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
110885|NCT03319719|Device|Belotero® Balance|Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
110886|NCT03319706|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
110887|NCT03319706|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
110888|NCT03319693|Genetic|Somatic Genetic|NGS analysis
110889|NCT03319680|Other|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
110890|NCT03319667|Drug|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous (IV)"
110891|NCT03319667|Drug|Bortezomib|"Pharmaceutical form: Lyophilized powder for injection~Route of administration: Intravenous/Subcutaneous"
110892|NCT03319667|Drug|Lenalidomide|"Pharmaceutical form: Capsules~Route of administration: Oral"
110893|NCT03319667|Drug|Dexamethasone|"Pharmaceutical form: Tablets, ampoules or vials for injection~Route of administration: Oral/Intravenous"
110894|NCT03319667|Drug|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets~Route of administration: Oral"
110895|NCT03319667|Drug|Ranitidine or equivalent|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
110896|NCT03319667|Drug|Diphenhydramine or equivalent|"Pharmaceutical form: Solution for injection~Route of administration: Intravenous"
110897|NCT03319654|Diagnostic Test|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
110898|NCT03319641|Diagnostic Test|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
110899|NCT03319628|Drug|XMT-1536|XMT-1536 will be administered once every 28 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
110900|NCT03319615|Behavioral|Dietary energy restriction|
110901|NCT03319602|Device|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
110902|NCT03319589|Dietary Supplement|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
110903|NCT03319576|Other|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
110904|NCT03319563|Drug|Local anesthetic-epinephrine|"Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.~Lidocaine 5 mg/Kg.~Epinephrine 5 mcg/ml of the total volume.~Add normal saline to a total volume of 100 ml/10 cm of the wound length."
110905|NCT03319563|Drug|Saline|normal saline 100 ml/10 cm of the wound length
110906|NCT03319550|Dietary Supplement|Casein|see experimental description
110907|NCT03319550|Dietary Supplement|Whey|see experimental description
110908|NCT03319550|Dietary Supplement|Leucine-enriched whey|see experimental description
110909|NCT03319537|Drug|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
110910|NCT03319537|Drug|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
110911|NCT03319511|Other|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
110912|NCT03319511|Other|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
110913|NCT03319498|Other|Peppermint Oil Vapor|"2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
110914|NCT03319498|Other|Mineral Oil Vapor|"2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
110915|NCT03319485|Device|ExAblate Pallidotomy|ExAblate Pallidotomy for Parkinson's Disease
110916|NCT03319485|Device|Sham ExAblate Pallidotomy|ExAblate MRgFUS Sham Procedure
110917|NCT03319459|Drug|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
110918|NCT03319459|Drug|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
110919|NCT03319459|Drug|Trastuzumab|HER2/neu receptor inhibitor
110920|NCT03319433|Device|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
110921|NCT03319420|Drug|LO2A eye drops|Sodium hyaluronate
110922|NCT03319420|Drug|Systane Ultra UD|Active Ingredients; Polyethylene Glycol Propylene Glycol
110923|NCT03319407|Device|EPAD monitoring system|EPAD system will be used as part of routine care
110924|NCT03319394|Behavioral|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
110925|NCT03319394|Behavioral|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
110926|NCT03319381|Behavioral|Following new SOPs|The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
110927|NCT03319368|Other|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
110928|NCT03319355|Behavioral|cognitive behavioral therapy|exercise therapy
110929|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to others
110930|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to self
110931|NCT03319342|Behavioral|Behavioral Intervention|Perform self-kindness meditation
110932|NCT03319342|Behavioral|Behavioral Intervention|Keep track of daily activities
110933|NCT03319342|Other|Questionnaire Administration|Ancillary studies
110934|NCT03319329|Device|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein & Coulter, 2014);(P. Singer & Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
110937|NCT03319290|Genetic|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
110938|NCT03319277|Other|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
110939|NCT03319277|Other|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
110940|NCT03319264|Other|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
110941|NCT03319264|Other|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
110942|NCT03319264|Radiation|DXA measurement|DXA measurement will be performed to assess patient's body composition
110943|NCT03319264|Other|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
110944|NCT03319264|Behavioral|Life habits Questionnaire|Life habits Questionnaire
110945|NCT03319238|Other|ketamine|The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
110946|NCT03319212|Device|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
110947|NCT03319199|Dietary Supplement|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
110948|NCT03319199|Other|Placebo - water|for a duration of 16 weeks
110949|NCT03319186|Procedure|EDIT Management|"EDIT management~Volumetric Pleural MRI for pre-aspiration pleural cavity volume~Large volume pleural aspiration with recording of intra-pleural pressure during aspiration~Volumetric Pleural MRI for post-aspiration pleural cavity volume~Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.~MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 < 14.5 cm H2O/L: allocated to 1st-line TP~EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
110950|NCT03319186|Procedure|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
110951|NCT03319173|Behavioral|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.~Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
110952|NCT03319160|Device|Defibrillation|Wearable Cardioverter Defibrillator
110953|NCT03319147|Dietary Supplement|Active|4g of essential amino acids
110954|NCT03319147|Dietary Supplement|Placebo|4g of maltdextrin
110955|NCT03319134|Device|active anodal HD-tDCS|1) active anodal HD-tDCS with memory task
110956|NCT03319134|Device|sham HD-tDCS|2) sham HD-tDCS with memory task
110957|NCT03319134|Device|active cathodal HD-tDCS|3) active cathodal HD-tDCS with memory task
110958|NCT03319121|Drug|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
110959|NCT03319121|Drug|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
110960|NCT03319108|Other|Exercise|Pulmonary Rehabilitation Program for 8 weeks
110961|NCT03319095|Device|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment, once per week during 8 weeks. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
110962|NCT03319082|Combination Product|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
110963|NCT03319069|Radiation|Hypofractionated radiotherapy|"Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~."
110964|NCT03319069|Radiation|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
110965|NCT03319056|Other|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
110966|NCT03319043|Drug|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
110967|NCT03319017|Procedure|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
110968|NCT03319004|Device|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
110969|NCT03318991|Procedure|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
110970|NCT03318978|Drug|[14C]-benzo[a]pyrene|Oral micro-dose range (25, 50, 100 and 250 ng)
111056|NCT03318315|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Adjuvanted 2017 Monovalent Inactivated Influenza A/H7N9 vaccine (2017 H7N9IIV)
110971|NCT03318952|Drug|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
110972|NCT03318952|Drug|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
110973|NCT03318939|Drug|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
110974|NCT03318913|Other|Placebo|5g of the sucralose administered as white plastic capsules
110975|NCT03318913|Other|Fish protein hydrolysates|5g of the FPH dissolving in 100 mL of water
110976|NCT03318900|Biological|Aldesleukin|Given IV
110977|NCT03318900|Drug|CD8-Positive T-Lymphocyte|Given IV
110978|NCT03318900|Drug|Cyclophosphamide|Given IV
110979|NCT03318900|Procedure|Leukapheresis|Undergo leukapheresis
110980|NCT03318900|Biological|Utomilumab|Given IV
110981|NCT03318887|Drug|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
110982|NCT03318874|Device|Blephasteam|Steam delivery goggles, once daily
110983|NCT03318874|Device|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
110984|NCT03318874|Drug|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
110985|NCT03318861|Genetic|Autologous genetically modified anti-BCMA CAR transduced T cells (KITE-585)|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells (KITE-585)
110986|NCT03318861|Drug|Cyclophosphamide|Administered intravenously
110987|NCT03318861|Drug|Fludarabine|Administered intravenously
110988|NCT03318848|Other|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
110989|NCT03318835|Drug|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
110990|NCT03318835|Drug|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
110991|NCT03318822|Device|Q-Collar|An externally-worn medical device that applies mild jugular compression
110992|NCT03318809|Drug|AMG 986|AMG 986
110993|NCT03318796|Device|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB & SB
110994|NCT03318783|Drug|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
110995|NCT03318783|Drug|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
110996|NCT03318770|Drug|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
110997|NCT03318757|Drug|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel TM) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
110998|NCT03318757|Drug|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
110999|NCT03318744|Drug|Aspirin|Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
111000|NCT03318744|Drug|Placebo Oral Tablet|Placebo resembling aspirin tablet will be be given to participants in control arm.
111001|NCT03318731|Other|Sugar Pill|Taken orally in capsule form
111002|NCT03318731|Dietary Supplement|Fenugreek Extract, Low Dose|Taken orally in capsule form
111003|NCT03318731|Dietary Supplement|Fenugreek Extract, High Dose|Taken orally in capsule form
111004|NCT03318718|Drug|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
111005|NCT03318718|Diagnostic Test|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
111006|NCT03318718|Diagnostic Test|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
111007|NCT03318705|Device|RS3000Adv|Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
111008|NCT03318692|Procedure|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
111009|NCT03318692|Procedure|CT|CT of operated area is performed within 7 days of surgery
111010|NCT03318679|Other|No intervention is planned.|None is planned
111011|NCT03318666|Behavioral|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:~a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)~adolescents will have access to the website specifically for adolescents: sova.pitt.edu~parents will have access to the website specifically for parents: wisesova.pitt.edu~These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team."
111057|NCT03318302|Other|Survey|Survey of the adult population in Israel
111083|NCT03318029|Dietary Supplement|Vitamin D supplementation|Vitamin D supplementation of 600 IU daily for 12 weeks
111084|NCT03318029|Dietary Supplement|Placebo|rice flour with no vitamin D
111012|NCT03318666|Other|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record. Also, each individual will receive a phone call from a research assistant who will communicate the information in the email and offer to inform the social worker or AHCP of questions the patient or parent may have.
111013|NCT03318640|Behavioral|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
111014|NCT03318627|Device|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
111015|NCT03318614|Dietary Supplement|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
111016|NCT03318614|Other|Control group|No probiotic intervention was given to the control group for three months.
111017|NCT03318601|Procedure|Blood taking|"Blood taking in 2 times :~J0 : 15 mL~J14 : 5 mL 20 mL in total volume"
111018|NCT03318588|Procedure|Vitrectomy|Pars plana vitrectomy
111019|NCT03318575|Device|autoRIC|Automated Remote Ischemic Conditioning
111020|NCT03318575|Device|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
111021|NCT03318562|Drug|eFT508|200 mg eFT508 dosed BID for 3 week cycles
111022|NCT03318549|Diagnostic Test|Visual Performance tests|The overall goal of this proposal is to improve our understanding of functional disability in glaucoma by using virtual reality tests to investigate objective performance during simulated daily life activities.
111023|NCT03318536|Drug|Granisetron Hydrochloride|Patients received Granisetron.
111024|NCT03318536|Drug|No Granisetron|Patients who did not receive Granisetron.
111025|NCT03318523|Drug|Placebo|Administered as specified in the treatment arm
111026|NCT03318523|Drug|BIIB054|Administered as specified in the treatment arm.
111027|NCT03318510|Device|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
111028|NCT03318497|Drug|3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT|Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
111029|NCT03318497|Procedure|Computed Tomography|Undergo PET/CT
111030|NCT03318497|Procedure|Positron Emission Tomography|Undergo PET/CT
111031|NCT03318497|Other|Laboratory Biomarker Analysis|Correlative studies
111032|NCT03318484|Drug|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
111033|NCT03318484|Combination Product|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
111034|NCT03318471|Drug|MgSo4|50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
111035|NCT03318471|Drug|0.9% NaCl|100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
111036|NCT03318458|Other|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
111037|NCT03318445|Drug|Rucaparib|All participants will take rucaparib by mouth
111038|NCT03318445|Drug|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
111039|NCT03318419|Drug|Cladribine|5mg/㎡ d1-5
111040|NCT03318419|Drug|G-CSF|300ug d0-14
111041|NCT03318419|Drug|Cytarabine|10mg/㎡ q12h SC d1-14
111042|NCT03318419|Drug|Pegaspargase|2500U/m2 im d1
111043|NCT03318406|Device|Bronchoscopic thermal vapor ablation|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
111044|NCT03318393|Drug|Bivalirudin|Continuous infusion
111045|NCT03318393|Drug|Unfractionated heparin|Continuous infusion
111046|NCT03318380|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
111047|NCT03318367|Other|Educational Intervention|Complete virtual reality education module
111048|NCT03318354|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
111049|NCT03318354|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
111050|NCT03318341|Device|Real Stimulation|The device applies wrist vibration at a subthreshold (imperceptible) level.
111051|NCT03318341|Device|Sham Stimulation|The device applies no vibration.
111052|NCT03318328|Other|survey|
111053|NCT03318315|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
111054|NCT03318315|Biological|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
111055|NCT03318315|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
111058|NCT03318289|Behavioral|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
111059|NCT03318276|Drug|SID142|SID142 is administrated to patients with PAD for 12 weeks
111060|NCT03318276|Drug|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
111061|NCT03318263|Diagnostic Test|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
111062|NCT03318250|Device|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
111063|NCT03318224|Other|none (observational study)|only assessments via questionnaires, no interventions
111064|NCT03318211|Drug|Magnesium Sulfate|Intravenous ampules of MgSo4 was given to only to control group after delivery
111065|NCT03318198|Other|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
111066|NCT03318198|Other|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
111067|NCT03318185|Procedure|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
111068|NCT03318185|Procedure|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
111069|NCT03318172|Device|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
111070|NCT03318159|Drug|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
111071|NCT03318146|Device|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
111072|NCT03318146|Drug|XALATAN®|one drop in the affected eye(s) once daily in the evening
111073|NCT03318133|Procedure|anesthesia|in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sacral plexus block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sacral plexus block with sedative anesthesia in elderly patients with hip fracture.
111074|NCT03318120|Behavioral|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
111075|NCT03318120|Behavioral|Standardized Exercise Training|Participants will perform required stretching, balancing, and strengthening exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
111076|NCT03318107|Device|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
111077|NCT03318094|Drug|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
111078|NCT03318094|Other|Saline|Intrabrachial saline will be given this day
111079|NCT03318081|Behavioral|cognitive function rehabilitation and bias modification|cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
111080|NCT03318068|Other|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
111081|NCT03318042|Other|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
111082|NCT03318042|Other|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
111085|NCT03318016|Drug|Cyclophosphamide|"ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV dose along with Mesna (in subjects receiving >1000mg/m2 Cy) and hydration for a maximum of 6 doses in the following dose escalation schema:~Cohort -1 (3-6 subjects, if needed): Cyclophosphamide 500 mg/m2~Cohort 1 (3-6 subjects): Cyclophosphamide 1000 mg/m2~Cohort 2 (3-6 subjects): Cyclophosphamide 2000 mg/m2~Cohort 3 (3-6 subjects): Cyclophosphamide 3000 mg/m2~Cohort 4 (3 subjects): Cyclophosphamide 4000 mg/m2"
111086|NCT03318003|Device|Auto-PAP|Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
111087|NCT03317990|Procedure|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a positive margin is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
111088|NCT03317977|Behavioral|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
111089|NCT03317977|Behavioral|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
111090|NCT03317964|Other|Saliva sample|Extract sample of saliva only once
111091|NCT03317951|Other|Novel integrated care concept (NICC)|Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
111092|NCT03317951|Other|Standard care|Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
111093|NCT03317938|Device|Fecobionics|Fecobionics is a new device for studying defecation
111094|NCT03317925|Procedure|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
111095|NCT03317912|Drug|Lidocaïne 2%|Continuous infusion during per and postoperative periods
111096|NCT03317912|Drug|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
111097|NCT03317899|Procedure|Hematopoietic Cell Transplantation|Undergo auto HSCT
111098|NCT03317899|Drug|Tbo-filgrastim|Given subcutaneously
111099|NCT03317886|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
111100|NCT03317873|Dietary Supplement|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
111101|NCT03317873|Dietary Supplement|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
111102|NCT03317860|Device|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
111103|NCT03317860|Device|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.~Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
111104|NCT03317847|Drug|Bromfenac 0.09 % Ophthalmic Solution|Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
111105|NCT03317847|Drug|Dexamethasone 0.1% ophthalmic suspension|Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.
111106|NCT03317834|Device|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
111107|NCT03317808|Diagnostic Test|Different exercise|Evaluating the difference between Heavy slow resistance and traditional exercise, based on the SPADI score.
111108|NCT03317795|Drug|Levonorgestrel IUS|LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
111109|NCT03317795|Drug|Tranexamic Acid|Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
111110|NCT03317782|Device|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index <20 indicates adequate analgesia.
111111|NCT03317769|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets social cognition for 2 hours per week.
111112|NCT03317769|Other|Commercially available computerized training|Training on computerized, casual video games for 2 hours per week.
111113|NCT03317769|Other|Optimized social skills training|Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
111114|NCT03317769|Other|Unstructured support group sessions|Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
111115|NCT03317756|Other|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
111116|NCT03317756|Other|Patient Control|Patients will receive an attention control
111117|NCT03317743|Drug|NOV140101 (IDX1197HCl)|The dose levels will be escalated following a 3+3 dose escalation scheme.
111118|NCT03317730|Drug|Xtampza ER|Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
111119|NCT03317717|Drug|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
111120|NCT03317717|Drug|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
111121|NCT03317704|Behavioral|Speed endurance training|Speed endurance training
111122|NCT03317691|Diagnostic Test|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
111123|NCT03317678|Dietary Supplement|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
111124|NCT03317678|Dietary Supplement|Non-fermented milk|A non-fermented milk drink.
111125|NCT03317665|Device|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
111126|NCT03317652|Other|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
111127|NCT03317652|Other|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
111128|NCT03317652|Drug|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
111129|NCT03317639|Behavioral|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
111130|NCT03317626|Diagnostic Test|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
111131|NCT03317613|Drug|Qutenza|Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
111132|NCT03317600|Device|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
111133|NCT03317600|Drug|Placebo|"Intervention is a placebo nerve block with isotonic saline"
111134|NCT03317587|Behavioral|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
111135|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
111136|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
111137|NCT03317548|Diagnostic Test|progesterone|according progesterone level to decide fresh or frozen embryo transfer
111138|NCT03317548|Diagnostic Test|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
111139|NCT03317535|Procedure|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
111140|NCT03317535|Procedure|Local anesthesia|Patients will be injected with Dexmeditomidine and remifentanil.
111141|NCT03317535|Procedure|Spontaneous breath|Patients will be kept spontaneous breath.
111142|NCT03317535|Procedure|Controlled ventilation|Patient will be kept with controlled ventilation.
111143|NCT03317509|Procedure|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
111144|NCT03317496|Drug|Avelumab 800 mg in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
111145|NCT03317496|Drug|Avelumab 800 mg in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
111146|NCT03317496|Drug|Avelumab 1200 mg in combination with pemetrexed/carboplatin|Avelumab Pemetrexed Carboplatin
111147|NCT03317496|Drug|Avelumab 1200 mg in combination with gemcitabine/cisplatin|Avelumab Gemcitabine Cisplatin
111261|NCT03316638|Drug|W0101 - Cohort A2|Administered every 3 or 4 weeks (Q3W or Q4W)
111148|NCT03317470|Other|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
111149|NCT03317470|Behavioral|Life Navigator|"The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.~The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
111150|NCT03317470|Other|Follow-up survey|-5 questions about the acceptability of the basic needs survey
111151|NCT03317470|Other|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
111152|NCT03317457|Biological|Durvalumab and Tremelimumab|immun checkpoint inhibitor
111153|NCT03317457|Drug|Doxorubicin|Anthracycline
111154|NCT03317444|Drug|TRC101|Oral suspension
111155|NCT03317444|Drug|Placebo|Oral suspension
111156|NCT03317431|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
111157|NCT03317418|Other|ATR-FTIR Spectrophotometry|Spectrometry imaging
111158|NCT03317405|Other|Placebo|Apply to the skin
111159|NCT03317405|Other|Questionnaire Administration|Ancillary studies
111160|NCT03317405|Drug|Z-Endoxifen Hydrochloride|Apply to the skin
111161|NCT03317392|Other|Laboratory Biomarker Analysis|Correlative studies
111162|NCT03317392|Drug|Olaparib|Given PO
111163|NCT03317392|Radiation|Radium Ra 223 Dichloride|Given IV
111164|NCT03317379|Behavioral|Peer mentorship|Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
111165|NCT03317379|Behavioral|Social support mentorship|Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
111166|NCT03317379|Behavioral|Recovery Record use with mentor|Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
111167|NCT03317366|Drug|ARQ 092|Open-label expanded access for ARQ 092 capsules
111168|NCT03317353|Device|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
111169|NCT03317353|Device|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
111170|NCT03317353|Other|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
111171|NCT03317340|Other|Background Sounds|Background music or sound of running water
111172|NCT03317327|Drug|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
111173|NCT03317327|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
111174|NCT03317314|Diagnostic Test|Lung Biopsy during LVAD Implantation|Lung Biopsy during LVAD Implantation
111175|NCT03317301|Drug|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
111176|NCT03317301|Drug|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
111177|NCT03317288|Device|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
111178|NCT03317275|Device|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
111179|NCT03317275|Procedure|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
111180|NCT03317275|Other|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
111181|NCT03317249|Diagnostic Test|ECG|12-lead electrocardiogram
111182|NCT03317249|Diagnostic Test|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
111183|NCT03317249|Diagnostic Test|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):~Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
111184|NCT03317249|Diagnostic Test|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
111185|NCT03317249|Other|Echocardiogram|optional (for non-IST participants only)
111186|NCT03317236|Drug|Quetiapine|A fixed 50 mg exteded release formulation.
111187|NCT03317223|Drug|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
111188|NCT03317210|Drug|iron sucrose (200 mg VENOFER®)|According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
111189|NCT03317210|Drug|recombinant human erythropoietin (10,000 U EPREX®)|According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
111190|NCT03317197|Drug|Control Group|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
111191|NCT03317197|Drug|Experimental Group 1|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
111192|NCT03317197|Drug|Experimental Group 2|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
111193|NCT03317197|Drug|Experimental Group 3|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
111194|NCT03317184|Procedure|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
111195|NCT03317184|Procedure|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
111196|NCT03317171|Dietary Supplement|Flavonoids, DHA, EPA|oral administration
111197|NCT03317171|Dietary Supplement|placebo compound|oral administration
111198|NCT03317158|Drug|Durvalumab|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
111199|NCT03317158|Radiation|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
111200|NCT03317158|Biological|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US."
111201|NCT03317145|Device|Neuromuscular electrostimulation (NMES) device|A mobile peroneal nerve stimulator
111202|NCT03317145|Device|Intermittent pneumatic compression (IPC) device|A foot pump or foot compression device
111203|NCT03317132|Behavioral|IPS|One year of IPS Support
111204|NCT03317119|Other|Laboratory Biomarker Analysis|Correlative studies
111205|NCT03317119|Drug|Trametinib|Given PO
111206|NCT03317119|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
111207|NCT03317093|Drug|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
111208|NCT03317093|Other|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
111209|NCT03317067|Drug|Dexmedetomidine|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
111210|NCT03317067|Other|Placebo|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
111211|NCT03317041|Other|Capacitive-resistive electric transfer (Tecar) therapy|The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
111212|NCT03317028|Drug|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
111213|NCT03317015|Drug|triamcinolone XRG5029|"Pharmaceutical form: spray solution~Route of administration: nasal"
111214|NCT03317015|Drug|fluticasone|"Pharmaceutical form: spray solution~Route of administration: nasal"
111215|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
111216|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
111217|NCT03317002|Drug|Placebo|Matching placebo (tablet)
111218|NCT03316976|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
111219|NCT03316963|Drug|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using five 1 mL syringes filled with 0.5 mL neostigmine each. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
111220|NCT03316950|Device|IntraGen RF|IntraGen is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
111221|NCT03316950|Device|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
111222|NCT03316937|Procedure|Types of scalers|Scaling
111223|NCT03316924|Procedure|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
111224|NCT03316911|Behavioral|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
111225|NCT03316898|Drug|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
111226|NCT03316898|Drug|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
111227|NCT03316898|Drug|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
111228|NCT03316898|Drug|Memantine|Memantine as prescribed by the physician as per standard of care.
111229|NCT03316885|Device|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
111230|NCT03316872|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
111231|NCT03316872|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
111232|NCT03316859|Drug|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
111233|NCT03316859|Other|Placebo pill|Placebo pill administered 1 hour pre-operatively
111234|NCT03316846|Behavioral|Internet-Delivered Cognitive Behavioral Therapy|
111235|NCT03316833|Device|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score <33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
111236|NCT03316820|Drug|K0706|Study treatment with water after an overnight fast
111237|NCT03316820|Drug|K0706|Study treatment with water after food
111238|NCT03316807|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
111239|NCT03316807|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
111240|NCT03316794|Drug|SC-005|intravenous
111241|NCT03316781|Drug|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
111242|NCT03316781|Drug|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
111243|NCT03316755|Behavioral|Exposure|Exposure to pamphlet
111244|NCT03316742|Combination Product|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
111245|NCT03316742|Combination Product|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
111246|NCT03316729|Drug|DS-9231|DS-9231 in saline solution for intravenous infusion
111247|NCT03316729|Drug|Placebo|Placebo is matching saline solution for intravenous infusion
111248|NCT03316716|Procedure|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
111249|NCT03316703|Procedure|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the conventional open approach (group A)."
111250|NCT03316703|Procedure|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.~The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
111251|NCT03316690|Drug|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:~Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
111252|NCT03316690|Drug|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:~Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
111253|NCT03316690|Behavioral|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
111254|NCT03316677|Procedure|Intraoperative testing of colorectal anastomoses|"Insert a Foley catheter through the anus into the rectum.~Insufflate the Foley balloon with 5 cc of air.~Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline~Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer~Remove the saline from the pelvic space.~Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer~Remove the methylene blue from rectum.~NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.~The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
111255|NCT03316677|Procedure|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
111256|NCT03316664|Behavioral|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
111257|NCT03316664|Behavioral|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
111258|NCT03316664|Other|COGPACK|Information already included in arm/group description.
111259|NCT03316651|Drug|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:~Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.~Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
111260|NCT03316638|Drug|W0101 - Cohort A1|Administered once every 2 weeks (Q2W)
111262|NCT03316638|Drug|W0101 - Expansion Phase|Administered according to recommended dose for expansion
111263|NCT03316625|Diagnostic Test|Bone densitometry measurement|Bone Densitometry and measurement of body composition
111264|NCT03316612|Dietary Supplement|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
111265|NCT03316612|Dietary Supplement|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
111266|NCT03316599|Drug|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
111267|NCT03316599|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
111268|NCT03316599|Drug|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
111269|NCT03316586|Drug|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
111270|NCT03316586|Drug|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
111271|NCT03316573|Drug|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
111272|NCT03316560|Biological|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR gene
111273|NCT03316547|Other|SENSE Program|Specific amounts of auditory, tactile, vestibular, kinesthetic, and visual exposure conducted daily through hospitalization. This includes specifically timed and set amounts of reading/talking/singing, cycled lighting, skin-to-skin (kangaroo) care or gentle human touch, rocking, and therapeutic exercises [passive range of motion (PROM), gentle stretching]. The intervention plan is intended to be implemented by parents when available, and by surrogates when the parents are unable to be present in the hospital. Specific amounts and timing of interventions will be tailored to the current medical status and age of each infant.
111274|NCT03316534|Drug|Aspirin|Aspirin (100 mg once a day)
111275|NCT03316521|Drug|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
111276|NCT03316495|Behavioral|PAMPHLET|EXPOSURE TO PAMPHLETS
111277|NCT03316482|Drug|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
111278|NCT03316469|Drug|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
111279|NCT03316469|Diagnostic Test|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
111280|NCT03316456|Diagnostic Test|Observational: Stool Sample Collection|"Observational: Stool Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
111281|NCT03316456|Diagnostic Test|Observational: Blood Sample Collection|"Observational: Blood Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
111282|NCT03316456|Diagnostic Test|Observational: Urine Sample Collection|"Observational: Urine Sample Collection~- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
111283|NCT03316443|Device|Glidescope|"The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter).~For endotracheal intubation with glidescope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.~Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation."
111284|NCT03316443|Device|Macintosh|The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first. The laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced.Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation.Maximal arterial blood pressure and heart rate changes will be recorded
111285|NCT03316430|Other|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
111286|NCT03316417|Other|Renal Tolerance to Immunotherapy|The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
111287|NCT03316391|Other|Dosage of urinary podocyturia|Dosage of urinary podocyturia at admission, delivery and post-partum visit
111288|NCT03316378|Drug|Ropivacaine injection|single dose, subcutaneous injection
111289|NCT03316365|Other|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
111290|NCT03316352|Procedure|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
111291|NCT03316352|Procedure|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
111292|NCT03316352|Device|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
111293|NCT03316352|Drug|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
111294|NCT03316339|Drug|Dexmedetomidine|Opioid-free anesthesia
111295|NCT03316339|Drug|Remifentanil|Opioid anesthesia
111296|NCT03316326|Drug|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
111297|NCT03316326|Drug|Oxaliplatin|85 mg/m2, D1
111298|NCT03316326|Drug|Irinotecan|150 mg/m2, D8
111299|NCT03316313|Diagnostic Test|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
111300|NCT03316300|Combination Product|Renexus®|Surgery to receive one Renexus® device implant.
111301|NCT03316300|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure.
111302|NCT03316287|Device|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
111303|NCT03316287|Device|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
111304|NCT03316287|Device|Sensor|Wearable biosensor for the collection of physiological data
111305|NCT03316274|Drug|Intra-lesional injection of nivolumab|All participants will receive 10mg in 1 mL injection into a single KS lesion in the skin, every 2 weeks for 4 doses.
111306|NCT03316248|Other|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
111307|NCT03316248|Other|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
111308|NCT03316222|Drug|GNS561|Escalating doses to be administered 3 times a week.
111309|NCT03316196|Behavioral|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
111310|NCT03316196|Behavioral|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
111311|NCT03316183|Other|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
111312|NCT03316170|Behavioral|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
111313|NCT03316170|Drug|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
111314|NCT03316157|Dietary Supplement|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
111315|NCT03316157|Behavioral|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
111316|NCT03316144|Biological|Toripalimab|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
111317|NCT03316131|Drug|Verinurad|Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
111318|NCT03316131|Drug|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
111319|NCT03316131|Drug|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
111320|NCT03316131|Other|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
111321|NCT03316118|Drug|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
111322|NCT03316118|Drug|saline|Group 2 will receive genicular nerve block using normal saline
111323|NCT03316105|Device|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
111324|NCT03316092|Diagnostic Test|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
111325|NCT03316079|Other|Chest physiotherapy techniques|Respiratory manual CPT
111994|NCT03310879|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
111326|NCT03316079|Device|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
111327|NCT03316066|Procedure|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
111328|NCT03316066|Procedure|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
111329|NCT03316053|Other|Tissue sample for genetic testing|Tissue sample to be obtained during routine endoscopy
111330|NCT03316040|Behavioral|JIC|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
111331|NCT03316014|Other|Adverse drug reaction|description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
111332|NCT03316001|Other|Review of multidetector row computed tomography scans|multidetector row computed tomography scans
111333|NCT03315988|Other|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
111334|NCT03315975|Biological|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
111335|NCT03315962|Behavioral|SPIRIT Intervention|The intervention will include implementing a teaching collaborative among group of DHOs and TB Supervisors, enabling text messaging between DHOs and front line providers, and establishing a report collaborative where DHOs will receive feedback on the performance of their district in administering IPT compared to other districts.
111336|NCT03315962|Combination Product|Single Pill Combination|Among the districts randomized to the DHO Intervention Arm, a sub-sample of individuals in the district who are eligible for IPT will receive a single pill combination (SPC) of INH/B6/TMP-SMX for IPT. The control group will receive non-coformulated INH, B6 and TMP-SMX for IPT.
111337|NCT03315949|Drug|Polyethylene Glycol (PEG)|Different method for bowel cleansing using same bowel cleanser. Same-day dose group : 4L PEG will be ingested on the day of colonoscopy Spli-dose group : 2L PEG will be ingested 1 day before colonoscopy, remaining 2L PEG will be ingested on the day of colonoscopy
111338|NCT03315936|Drug|BI 894416|Oral solution
111339|NCT03315936|Drug|Placebo|Oral solution
111340|NCT03315936|Drug|BI 894416 (treatment X and Z)|Tablet
111341|NCT03315936|Drug|BI 894416 (treatment Y)|Oral solution
111342|NCT03315923|Drug|Rituximab|Patients will receive 1 g of rituximab (two vials of Zytux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion as one treatment cycle. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
111343|NCT03315923|Drug|Glatiramer Acetate|Patients will receive 40 mg of glatiramer acetate three times per week through subcutaneous injection. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
111344|NCT03315910|Behavioral|Motivational Interviewing (MI)|two counseling sessions
111345|NCT03315910|Drug|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
111346|NCT03315910|Drug|Nicotine Lozenge|6 packs of NRT 2mg lozenge
111347|NCT03315910|Behavioral|Message Framing|health communication literature and quitting messages
111348|NCT03315910|Other|saliva sample|saliva samples from those reporting abstinence and analyze samples
111349|NCT03315897|Drug|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
111350|NCT03315897|Drug|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
111351|NCT03315884|Procedure|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
111352|NCT03315884|Procedure|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
111353|NCT03315871|Biological|PROSTVAC-V|Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.
111354|NCT03315871|Biological|PROSTVAC-F|Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.
111355|NCT03315871|Drug|MSB0011359C (M7824)|Fully human bi-functional fusion protein that combines lgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody administered visa IV infusion over 1 hour.
111356|NCT03315871|Biological|CV301|Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
111357|NCT03315845|Other|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.~Ultrasound of neuraxial anatomy to assess depth to epidural space."
111358|NCT03315832|Drug|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
111359|NCT03315832|Drug|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
111360|NCT03315819|Procedure|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.
111361|NCT03315819|Procedure|Immobilization interne rotation|Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
111362|NCT03315806|Other|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
111363|NCT03315806|Other|Placebo|140 mL of beetroot juice isent of nitrate
111364|NCT03315793|Drug|Duloxetine Hydrochloride|Administered orally
111365|NCT03315793|Drug|Placebo|Administered orally
111366|NCT03315780|Drug|Dulaglutide|Administered SC
111367|NCT03315780|Drug|Placebo|Administered SC
111368|NCT03315767|Diagnostic Test|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
111369|NCT03315767|Diagnostic Test|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
111370|NCT03315754|Drug|TOOKAD Soluble 4 mg/kg|Vascular targeted photodynamic therapy using TOOKAD Soluble
111371|NCT03315741|Drug|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
111372|NCT03315728|Other|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
111373|NCT03315702|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cm H2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
111374|NCT03315689|Drug|Vehicle|Vehicle Topical Solution
111375|NCT03315689|Drug|ATI-50002|ATI-50002 Topical Solution
111376|NCT03315676|Drug|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
111377|NCT03315676|Drug|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
111378|NCT03315663|Other|Sweetch App & DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
111379|NCT03315663|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
111380|NCT03315637|Procedure|Fetoscopic repair of spina bifida|Fetoscopic intrauterine repair of open spina bifida
111381|NCT03315624|Device|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
111382|NCT03315611|Drug|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
111383|NCT03315611|Other|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
111384|NCT03315598|Procedure|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
111385|NCT03315585|Device|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
111386|NCT03315572|Other|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
111387|NCT03315572|Other|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
111388|NCT03315572|Other|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
111389|NCT03315559|Drug|[14C]-GSK2269557 IV infusion|The [14C]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
111390|NCT03315559|Drug|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
111391|NCT03315559|Drug|[14C]-GSK2269557 oral solution|The [14C]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving [14C]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
111392|NCT03315546|Radiation|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
111995|NCT03310866|Device|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
111393|NCT03315533|Drug|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
111394|NCT03315533|Drug|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
111395|NCT03315533|Drug|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
111396|NCT03315520|Drug|Bendamustine|"BeEAC conditioning regimen:~bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
111397|NCT03315507|Drug|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
111398|NCT03315494|Drug|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
111399|NCT03315494|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
111400|NCT03315481|Procedure|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
111401|NCT03315481|Procedure|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
111402|NCT03315455|Drug|Emicizumab|Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
111403|NCT03315442|Other|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
111404|NCT03315429|Diagnostic Test|stress echocardiography|stress testing of patients with functional mitral regurgitation
111405|NCT03315416|Other|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
111406|NCT03315403|Diagnostic Test|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
111407|NCT03315390|Other|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
111408|NCT03315390|Other|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
111409|NCT03315377|Procedure|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
111410|NCT03315377|Procedure|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
111411|NCT03315364|Drug|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
111412|NCT03315364|Drug|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
111413|NCT03315351|Procedure|Brachytherapy|"Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.~The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan"
111414|NCT03315351|Other|PET-scan|"The patient will undergo 2 PET-scan during the clinical trial:~the first one is additional to the brachytherapy~the second one is realized 4 months after the brachytherapy"
111415|NCT03315338|Drug|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
111416|NCT03315338|Drug|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:~Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered."
111417|NCT03315338|Drug|Glucose|75 g in 300 mL solution, orally administered
111418|NCT03315338|Drug|Placebo oral suspension|"Reference Therapy, Dose and Route of Administration:~Placebo suspension, orally administered."
111419|NCT03315338|Drug|CORT118335, 75mg|CORT118335 is supplied as capsules for oral dosing
111420|NCT03315338|Drug|CORT118335, 225mg|CORT118335 is supplied as capsules for oral dosing
111421|NCT03315338|Drug|CORT118335, 675mg|CORT118335 is supplied as capsules for oral dosing
111422|NCT03315338|Drug|CORT118335, 600mg|CORT118335 is supplied as capsules for oral dosing
111423|NCT03315338|Drug|CORT118335, 630mg|CORT118335 is supplied as capsules for oral dosing
111424|NCT03315338|Drug|CORT118335, 375mg|CORT118335 is supplied as capsules for oral dosing
111425|NCT03315338|Drug|CORT118335, 100mg|CORT118335 is supplied as a suspension for oral dosing
111426|NCT03315338|Drug|CORT118335, 300mg|CORT118335 is supplied as a suspension for oral dosing
111427|NCT03315338|Drug|CORT118335, 900mg|CORT118335 is supplied as a suspension for oral dosing
111428|NCT03315338|Drug|CORT118335, 150mg|CORT118335 is supplied as a suspension for oral dosing
111429|NCT03315338|Drug|CORT118335, 1500mg|CORT118335 is supplied as a suspension for oral dosing
111430|NCT03315338|Drug|Placebo oral capsule|Placebo capsules, orally administered
111431|NCT03315338|Drug|CORT118335, dose to be determined|CORT118335 is supplied as suspension for oral dosing
111432|NCT03315325|Biological|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
111433|NCT03315312|Drug|Fluoride Varnishes|Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
111434|NCT03315312|Drug|Fissure Sealants|Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
111435|NCT03315299|Drug|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
111436|NCT03315286|Device|SHADE Ultraviolet Sensor|Patients will wear device for 6 months in addition to their own method of photo-protection.
111437|NCT03315286|Behavioral|Standard of care counseling|Patients will use their own method of photo-protection
111438|NCT03315273|Other|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
111439|NCT03315260|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
111440|NCT03315247|Behavioral|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
111441|NCT03315234|Genetic|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
111442|NCT03315221|Other|Test product|HMF with added lipids - Intervention group
111443|NCT03315221|Other|Control product|Commercially available HMF (without lipids) - control group
111444|NCT03315208|Behavioral|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
111445|NCT03315208|Other|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
111446|NCT03315195|Dietary Supplement|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
111447|NCT03315182|Biological|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
111448|NCT03315169|Other|External dressing|Application of external dressing whilst perianal abscess cavity heals.
111449|NCT03315169|Other|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
111450|NCT03315156|Diagnostic Test|Electrogustometery|Taste assessment using EGM
111451|NCT03315143|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
111452|NCT03315143|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
111453|NCT03315130|Drug|zilucoplan (RA101495)|Daily subcutaneous (SC) injection
111454|NCT03315130|Drug|Placebo|Daily subcutaneous (SC) injection
111455|NCT03315104|Biological|FLU-IGIV|Single dose, sterile liquid formulation for IV administration
111456|NCT03315104|Other|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration
111457|NCT03315091|Drug|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
111458|NCT03315091|Drug|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
111459|NCT03315078|Biological|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
111460|NCT03315078|Drug|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
111461|NCT03315078|Drug|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
111462|NCT03315065|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, < 1 hour
111463|NCT03315052|Drug|Budesonide|Oral steroid with high first-pass metabolism in liver
111464|NCT03315052|Drug|Tacrolimus（FK506）|Calcineurin immunosuppressant
111465|NCT03315052|Drug|Mycophenolate Mofetil|Immunosupressant
111466|NCT03315052|Drug|Prednisone|Immunosuppresant
111467|NCT03315039|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
111468|NCT03315026|Drug|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 (+/-2) after stem cell infusion.
111469|NCT03315026|Behavioral|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
111470|NCT03315013|Procedure|SLATE II|The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
111471|NCT03315000|Drug|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
111472|NCT03315000|Drug|Fluticasone Furoate|Same as fluticasone arm description
111473|NCT03315000|Drug|Placebos|Same as placebo arm description
111474|NCT03314987|Dietary Supplement|L-carnosine|a naturally occurring di-peptide
111475|NCT03314987|Other|placebo|an identically appearing supplement
111476|NCT03314974|Biological|HSCT with TBI Regimen|Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
111477|NCT03314974|Biological|HSCT with Non-TBI Regimen|Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus from day +5 until taper day +100 (day +60 for peds if no acute or chronic GVHD present) Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
111478|NCT03314935|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
111479|NCT03314935|Drug|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
111480|NCT03314935|Drug|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
111481|NCT03314935|Drug|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
111482|NCT03314935|Drug|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
111483|NCT03314935|Drug|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
111484|NCT03314935|Drug|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
111485|NCT03314922|Drug|Parsaclisib|Parsaclisib administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
111486|NCT03314909|Procedure|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
111487|NCT03314909|Procedure|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
111488|NCT03314909|Procedure|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
111489|NCT03314896|Procedure|Laparoscopic surgery|
111490|NCT03314883|Diagnostic Test|D-US ARF|Diaphragm ultrasound evaluation in acute hypoxic - hypercapnic respiratory failure (ARF) patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
111491|NCT03314870|Genetic|Genetic signature|To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
111492|NCT03314857|Device|SAPIEN XT THV|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
111493|NCT03314818|Device|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:~Determine plaque presence and plaque burden Presence of stenosis~Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.~Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
111494|NCT03314805|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
111495|NCT03314805|Drug|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
111496|NCT03314805|Procedure|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
111497|NCT03314792|Drug|Tapentadol|"Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
111498|NCT03314792|Drug|Oxycodone|"OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
111499|NCT03314766|Device|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
111500|NCT03314753|Other|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
111501|NCT03314740|Drug|Paclitaxel|Comparator active compound
111502|NCT03314740|Drug|Cediranib|Experimental compound
111503|NCT03314740|Drug|Olaparib|Experimental compound
111504|NCT03314727|Other|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
111505|NCT03314714|Procedure|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
111506|NCT03314701|Device|Biphasic Intermittent Positive Airway Pressure (BIPAP)|"Following endotracheal intubation BIPAP mode will be started with:~Inspiratory positive airway pressure [IPAP] at 20 cmH2O~Expiratory positive airway pressure [EPAP] at 5 cmH2O~PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]~Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
111507|NCT03314701|Device|Airway Pressure Release Ventilation (APRV)|"high airway pressure (Phigh) will be set at 20 cmH2O~low airway pressure ( Plow) will be set at 5 cmH2O~the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min~T high at 4.5-6 seconds~T low at 0.5 to 0.8 second"
111508|NCT03314688|Behavioral|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
111509|NCT03314688|Behavioral|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
111510|NCT03314675|Device|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
111511|NCT03314662|Biological|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
111512|NCT03314662|Biological|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
111607|NCT03313895|Behavioral|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
111608|NCT03313882|Other|no intervention is involved|
111513|NCT03314662|Biological|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
111514|NCT03314649|Other|Observational study|Lavage of the Peritoneal Cavity
111515|NCT03314636|Drug|Carfilzomib|See in arm description
111516|NCT03314636|Drug|Lenalidomide|See in arm description
111517|NCT03314636|Device|PET-CT|See in arm description
111518|NCT03314636|Drug|Dexamethasone|See in arm description
111519|NCT03314623|Behavioral|Weight bearing as tolerated|If fracture is deemed stable the subjects will be allowed to weight bear immediately after surgery.
111520|NCT03314610|Other|Gait speed|No intervention, only propose water and wait for need to void
111521|NCT03314597|Other|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
111522|NCT03314597|Other|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
111523|NCT03314584|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
111524|NCT03314584|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
111525|NCT03314571|Other|analgesia for labor|A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
111526|NCT03314558|Other|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
111527|NCT03314545|Procedure|laminate veneer with coronal post|laminate veneer with coronal post
111528|NCT03314545|Procedure|post,core and crown|post,core and crown
111529|NCT03314532|Procedure|TILA-TACE|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
111530|NCT03314519|Diagnostic Test|Lung ultrasonography by experienced anaesthesiologist|Use ultrasound image of lung at upper and lower lobe to detect lung collapse and compare grading of lung collapse by surgeon as gold standard
111531|NCT03314519|Diagnostic Test|Fiberoptic bronchoscopy for double lumen tube's position|Use fiberoptic bronchoscope via double lumen tube to detect optimum position of double lumen tube and record grading of lung collapse by surgeon as gold standard
111532|NCT03314506|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
111533|NCT03314493|Drug|Spironolactone 25Mg Tablet|Patients with coronary calcium score > 30 were treated with spironolactone for 12 months
111534|NCT03314480|Diagnostic Test|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
111535|NCT03314467|Diagnostic Test|polysomnography|"classical polysomnography~non invasive measurement of blood pressure~blood test: determination of HbA1c, glucose, C-peptide, hemoglobin, white blood cell count, trombocytes"
111536|NCT03314454|Drug|Beer|Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
111537|NCT03314454|Device|Videotaped drinking session|Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
111538|NCT03314441|Behavioral|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
111539|NCT03314428|Behavioral|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
111540|NCT03314415|Device|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
111541|NCT03314402|Drug|Jaktinib Dihydrochloride Monohydrate|Active Substance
111542|NCT03314402|Drug|placebo|Placebo
111543|NCT03314389|Device|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
111576|NCT03314142|Other|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
111708|NCT03313167|Other|Non-interventional|Non-interventional
111544|NCT03314376|Device|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
111545|NCT03314363|Diagnostic Test|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
111546|NCT03314363|Device|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
111547|NCT03314363|Device|IC|monitor patients during the whole study period with indirect calorimetry
111548|NCT03314363|Drug|NaCl predilution|Replace citrate predilution with NaCl
111549|NCT03314363|Diagnostic Test|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
111550|NCT03314363|Drug|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
111551|NCT03314363|Diagnostic Test|blood gas analysis under citrate predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
111552|NCT03314363|Dietary Supplement|pause and restart nutritional therapy|pause parenteral and enteral nutrition before indirect calorimetry is performed. and restart after first blood analysis for vitamine status
111553|NCT03314363|Diagnostic Test|evolution of vitamin and trace elements|blood analysis for vitamin and trace elements. Perform this blood analysis after restart of CRRT but before restart of nutritional therapy, 30 minutes after restart of nutritional therapy and 24h after restart of nutritional therapy.
111554|NCT03314337|Device|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
111555|NCT03314324|Drug|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
111556|NCT03314324|Drug|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
111557|NCT03314311|Behavioral|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
111558|NCT03314298|Drug|testosterone anastrozole|subcutaneous testosterone and anastrozole
111559|NCT03314285|Other|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
111560|NCT03314272|Device|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
111561|NCT03314259|Drug|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
111562|NCT03314259|Drug|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
111563|NCT03314246|Other|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
111564|NCT03314246|Other|Standard of care|Standard of care
111565|NCT03314233|Procedure|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
111566|NCT03314220|Behavioral|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
111567|NCT03314194|Other|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
111568|NCT03314181|Drug|Dexamethasone|Administered intravenously (IV) or as a tablet taken orally
111569|NCT03314181|Drug|Daratumumab|Administered by subcutaneous injection (preferred) or intravenously (IV)
111570|NCT03314181|Drug|Venetoclax|Tablet taken orally
111571|NCT03314181|Drug|Bortezomib|Administered by subcutaneous injection (preferred) or intravenously (IV)
111572|NCT03314168|Other|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
111573|NCT03314168|Other|Control group|The usual care will be recommended to avoid systematic physical exercise for 3 months and will receive general clinical recommendations such as nutritional intake and lifestyle issues in their respective hospital.
111574|NCT03314155|Diagnostic Test|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer ([18F]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
111575|NCT03314142|Other|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
111577|NCT03314142|Other|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
111578|NCT03314142|Other|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
111579|NCT03314142|Other|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
111580|NCT03314129|Behavioral|UltimEyes|A computer program developed to improve contrast sensitivity and visual acuity.
111581|NCT03314129|Behavioral|Contour Integration Training|A computerized program to improve contour integration (a form of perceptual organization).
111582|NCT03314129|Behavioral|UltimEyes + Contour Integration Training|The combination of UltimEyes and Contour Integration Training
111583|NCT03314129|Behavioral|MyBrainSolutions|A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.
111584|NCT03314116|Other|Guidance on auditory protection|by video or medic
111585|NCT03314103|Biological|One shot of the varicella-zoster virus vaccine|One shot of the live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
111586|NCT03314103|Biological|one shot of placebo|one shot of placebo with no live virus
111587|NCT03314090|Drug|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
111588|NCT03314064|Drug|Dolutegravir 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
111589|NCT03314025|Drug|Tamsulosin Hydrochloride 0.4 MG|Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
111590|NCT03314025|Drug|Placebo oral capsule|Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
111591|NCT03314025|Device|Foley catheter|Every patient with a post-operative urinary retention will have a foley catheter, as standard of care.
111592|NCT03314012|Device|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
111593|NCT03313999|Device|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
111594|NCT03313973|Procedure|with self stretching same muscle|with self stretching
111595|NCT03313973|Procedure|with self stretching of forearm muscles|without self stretching
111596|NCT03313960|Drug|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop | Premium (i.e., One Drop | Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
111597|NCT03313960|Other|"One Drop | Premium"|"Participants in this group will receive One Drop | Premium (i.e., One Drop | Experts in-app CDE coaching with the One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
111598|NCT03313947|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
111599|NCT03313947|Other|Questionnaire|"The following 6 questions will be asked during the preoperative visit:~While sleeping, does your child snore more than half the time?~While sleeping, does your child always snore?~Have you ever seen your child stop breathing during the night?~Does your child occasionally wet the bed?~Did your child stop growing at a normal rate at any time since birth?~Is your child overweight"
111600|NCT03313934|Combination Product|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
111601|NCT03313934|Combination Product|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
111602|NCT03313921|Diagnostic Test|Online Manifest Refraction|"The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.~The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000."
111603|NCT03313908|Procedure|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
111604|NCT03313895|Behavioral|ACT|ACT stands for combined aerobic exercise and cognitive training.
111605|NCT03313895|Behavioral|Cycling Only|Cycling on a recumbent stationary cycle
111606|NCT03313895|Behavioral|Cognitive Training Only|Engage in cognitive training on a computer
111609|NCT03313869|Dietary Supplement|XXS-2A + Omega-3 + Vitamin E + Selenium|Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
111610|NCT03313869|Dietary Supplement|control diet|habitual diet to be followed
111611|NCT03313856|Drug|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
111612|NCT03313856|Drug|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
111613|NCT03313830|Dietary Supplement|Whey Protein Hydrolysate (WPH)|Subjects will ingest WPH on one occasion.
111614|NCT03313830|Dietary Supplement|Intact Whey Protein (WHEY)|Subject will ingest WHEY on another occasion.
111615|NCT03313817|Device|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
111616|NCT03313804|Drug|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
111617|NCT03313804|Radiation|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
111618|NCT03313791|Dietary Supplement|Whey protein concentrate|see arm description
111619|NCT03313791|Dietary Supplement|Yoghurt|see arm description
111620|NCT03313791|Dietary Supplement|50%whey-50% casein (Standard)|see arm description
111621|NCT03313791|Dietary Supplement|50%whey-50% casein (Alternative)|see arm description
111622|NCT03313791|Dietary Supplement|Micellar Casein Isolate- WPH|see arm description
111623|NCT03313791|Dietary Supplement|Micellar Casein Isolate - Na-caseinate|see arm description
111624|NCT03313791|Dietary Supplement|Micellar Casein Isolate|see arm description
111625|NCT03313791|Dietary Supplement|UHT milk|see arm description
111626|NCT03313791|Dietary Supplement|Recombined milk|see arm description
111627|NCT03313791|Dietary Supplement|Recombined 50%whey milk|see arm description
111628|NCT03313791|Dietary Supplement|Ca-caseinate|see arm description
111629|NCT03313791|Dietary Supplement|Milk protein isolate|see arm description
111630|NCT03313778|Biological|mRNA-4157|Personalized cancer vaccine
111631|NCT03313778|Biological|Pembrolizumab|intravenous infusion
111632|NCT03313765|Behavioral|Motivational interviewing (MI)|Brief MI intervention
111633|NCT03313765|Other|Standard-of-care|Standard-of-care education and counseling
111634|NCT03313752|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
111635|NCT03313752|Other|Placebo|placebo
111636|NCT03313739|Other|An Educational Program|An educational program was designed for self-care during menopause using teach back method.
111637|NCT03313726|Drug|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
111638|NCT03313726|Drug|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
111639|NCT03313713|Dietary Supplement|Beta-glucans|Placebo consumption at breakfast (3 g per day)
111640|NCT03313713|Dietary Supplement|Placebo|Placebo consumption at breakfast (3 g per day)
111641|NCT03313700|Procedure|Robotic Assisted Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted distal gastrectomy will be performed in the experimental group.
111642|NCT03313700|Procedure|Laparoscopic Assisted Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted distal gastrectomy will be performed in the comparator group.
111643|NCT03313674|Device|Bright Light Therapy|Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
111644|NCT03313661|Drug|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
111645|NCT03313661|Drug|Gliclazide|gliclazide (60-120 mg)
111646|NCT03313648|Procedure|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
111647|NCT03313648|Procedure|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
111648|NCT03313635|Diagnostic Test|Men presenting with low-T|Evaluation of prealbumin levels.
111649|NCT03313622|Behavioral|Beads Task|Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
111650|NCT03313622|Behavioral|PROVOC Tasks|Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
111651|NCT03313609|Behavioral|Investigating Burnout in Intensive Care in Middle Incoming Turkey|single-group studies
111752|NCT03312842|Drug|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
111652|NCT03313596|Drug|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
111653|NCT03313596|Procedure|LT|Orthotopic LT and subsequent immunosuppression therapy
111654|NCT03313583|Procedure|Transfusion of blood products|
111655|NCT03313557|Drug|Wee-1 kinase inhibitor AZD1775|Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
111656|NCT03313544|Drug|Nivolumab|NIVOLUMAB
111657|NCT03313544|Device|MRI|Cardiac MRI 6 MONTHS
111658|NCT03313544|Biological|BLOOD SAMPLES|biological (BNP and troponin)
111659|NCT03313544|Device|trans-thoracic echocardiography|1, 3 and 6 months
111660|NCT03313531|Diagnostic Test|Thrombin Generation Assay|Inter lab variation and level of agreement will be determined
111661|NCT03313531|Drug|Treatment with recombinant coagulation factor|To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
111662|NCT03313518|Device|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
111663|NCT03313518|Device|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
111664|NCT03313505|Biological|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
111665|NCT03313505|Other|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
111666|NCT03313492|Behavioral|UV4.me2|"UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:~A mobile version of the site~Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)~Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback"
111667|NCT03313492|Behavioral|UV4.me|Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.
111668|NCT03313492|Behavioral|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention."
111669|NCT03313479|Drug|Dexmedetomidine|Dexmedetomidine will be given with GS
111670|NCT03313466|Behavioral|Internet cognitive behavioral therapy for insomnia (iCBTI)|An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
111671|NCT03313466|Behavioral|Class in sleeping well and improving insomnia|A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
111672|NCT03313453|Device|PuriCare (HEPA Air Cleaner)|The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
111673|NCT03313453|Device|Mock device of PuriCare|The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
111674|NCT03313440|Other|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
111675|NCT03313440|Other|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
111676|NCT03313427|Other|Physical Therapy Early Intervention|"At the UCIN:~Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.~Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.~At home:~Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age."
111677|NCT03313427|Other|Usual Care|NICU usual care
111678|NCT03313414|Drug|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
111679|NCT03313401|Drug|Aflibercept|Intravitreal aflibercept injection
111680|NCT03313401|Device|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
111681|NCT03313388|Dietary Supplement|Drink|Beverage to be consumed
111753|NCT03312816|Other|cookies enriched with POP|Cookies
111682|NCT03313375|Other|Continuous Exercise|Subjects will be asked to perform a 45 min exercise bout. 10 minutes will be a warmup (at a work rate associated with 50% heart rate max), 30 minutes at a wattage that elicits 75-80% heart rate max, and a 5 minute cool down period, returning them to approximately 50% heart rate max.
111683|NCT03313375|Other|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax.
111684|NCT03313362|Device|SPEAC System|Seizure Monitoring and Alerting System
111685|NCT03313362|Device|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
111686|NCT03313349|Behavioral|Psychotherapy: 1. cognitive therapy 2.family intervention|Psychotherapy delivered by trained psychologist for the student and the student´s parents
111687|NCT03313336|Drug|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
111688|NCT03313336|Drug|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
111689|NCT03313336|Drug|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
111690|NCT03313323|Biological|89Zirconium-labeled ipilimumab|Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
111691|NCT03313310|Behavioral|Employment Intervention|Participants will complete 4 workshop sessions in groups of 6-12. The workshop curriculum was based on the pre-existing iFOUR program, and tailored based on feedback from a Community Advisory Board (CAB), Focus Groups, and In Depth Interviews.
111692|NCT03313297|Drug|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
111693|NCT03313297|Drug|Placebo|Matching placebo
111694|NCT03313284|Procedure|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
111695|NCT03313284|Procedure|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
111696|NCT03313284|Procedure|Control|No intervention
111697|NCT03313258|Device|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
111698|NCT03313258|Device|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
111699|NCT03313245|Other|No Intervention/Observational Study|No Intervention/Observational Study
111700|NCT03313232|Other|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
111701|NCT03313232|Other|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
111702|NCT03313219|Drug|Gentuximab Injection|Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
111703|NCT03313206|Drug|Pembrolizumab|"Neo-adjuvant therapy :~Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.~Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).~Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
111704|NCT03313206|Procedure|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
111705|NCT03313206|Radiation|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
111706|NCT03313193|Other|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for ~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
111707|NCT03313180|Drug|Nintedanib|Administered twice daily
111785|NCT03312582|Procedure|Placebo|
111709|NCT03313154|Other|Neuropsychiatric screening|"Psychiatric diagnosis through:~clinical interview~the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);~HAM-D (Hamilton Scale for Depression);~PHQ-9 (Patient's Health Questionnaire-9 items);~MDQ (Mood Disorders Questionnaire);~YMRS (Young Mania Rating Scale);~ASRM (Altman Self Rating Mania scale);~BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).~Assessment of Quality of Life:~SF-12 (Short Form Health Survey-12 items).~Neuropsychological screening:~l) Addenbrooke's Cognitive Examination (ACE-R)."
111710|NCT03313141|Diagnostic Test|Ultrasound|Volitional and non volitional respiratory tasks
111711|NCT03313128|Other|Sanitation|Improved sanitation facility
111712|NCT03313115|Behavioral|Sleep/Wake Protocol|"During the day, a nurse will observe if the following elements were completed for each participant:~no caffeine after 3 pm~encourage activities to prevent napping (document % of day spent napping)~Lights on, blinds/door open~Reasonable effort for some noise in room~Eye glasses, hearing aids applied~Chair position/mobility at least 2x30 minutes~At night, a nurse will observe if the following elements were completed for each participant:~Appropriate pain control~Optimize room temperature~Warm bath before 2200~TV off by 2200~Prevent unnecessary alarms after 2200~Close curtains to room by 2200~Dim room lights by 2200~Family out of room by 2200~Door partially or fully closed after 2200~Number of RN interruptions after 2200~Offer eye mask/ear plugs~Medications administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other)~Dim hallway lights by 2200~Nurses station quiet"
111713|NCT03313102|Biological|blood samples|sample of 16 blood tubes
111714|NCT03313089|Behavioral|"Papas más nutritivas (PSAN)"|"Activities of the project Papas más nutritivas"
111715|NCT03313076|Drug|Omega-3 fatty acids (fish oil)|4 capsules comprising approximately 2 grams of EPA/DHA in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks
111716|NCT03313076|Drug|Vitamin D3 (cholecalciferol)|1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.
111717|NCT03313076|Drug|Vitamin D3 (cholecalciferol) placebo|1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.
111718|NCT03313076|Drug|Omega-3 fatty acid placebo|4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.
111719|NCT03313050|Biological|Multivalent|Pneumococcal conjugate vaccine
111720|NCT03313050|Biological|Tdap|Tetanus, diphtheria, acellular pertussis vaccine
111721|NCT03313050|Biological|polysaccharide|23-valent pneumococcal polysaccharide vaccine
111722|NCT03313037|Biological|Multivalent|Pneumococcal conjugate vaccine
111723|NCT03313037|Biological|Prevnar 13|Pneumococcal conjugate vaccine
111724|NCT03313037|Biological|PPSV23|Pneumococcal polysaccharide vaccine
111725|NCT03313037|Other|Saline|Placebo
111726|NCT03313011|Diagnostic Test|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
111727|NCT03312998|Radiation|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
111728|NCT03312985|Procedure|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
111729|NCT03312985|Procedure|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
111730|NCT03312972|Radiation|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 fraction, Up to 30 Gray (Gy) to target lesion
111731|NCT03312959|Drug|hyperbaric bupvacaine in Peribulbar block|hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
111732|NCT03312959|Drug|isobaric bupvacaine in Peribulbar block|isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
111733|NCT03312946|Device|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
111734|NCT03312920|Device|active anodal tDCS|active anodal tDCS with memory task
111735|NCT03312920|Device|sham tDCS|sham tDCS with memory task
111736|NCT03312920|Device|active cathodal tDCS|active cathodal tDCS with memory task
111737|NCT03312907|Drug|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
111738|NCT03312907|Drug|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
111739|NCT03312907|Drug|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
111740|NCT03312907|Drug|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
111741|NCT03312907|Drug|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day will administered by subjects in Arm A and B through Week 104.
111742|NCT03312907|Drug|Steriod Taper|Steriod taper will include prednisone doses equivalent to =< 5 mg/day in all Arms through Week 104.
111743|NCT03312894|Drug|TAK-653|TAK-653 tablets
111744|NCT03312894|Drug|Placebo|Placebo-matching tablets
111745|NCT03312881|Diagnostic Test|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
111746|NCT03312881|Diagnostic Test|neuroimaging|magnetic resonance imaging (MRI)
111747|NCT03312881|Other|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
111748|NCT03312868|Radiation|SBRT|Stereotactic Body Radiotherapy
111749|NCT03312855|Drug|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
111750|NCT03312855|Drug|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
111751|NCT03312855|Drug|Placebo|single dose, intravenous application of Placebo solution
111754|NCT03312803|Procedure|Mini autogenous skin graft|mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.
111755|NCT03312790|Device|Tasks|Augmented reality device Real condition
111756|NCT03312777|Drug|Omnitram|Omnitram tablets overencapsulated
111757|NCT03312777|Drug|Tramadol|Tramadol tablet overencapsulated
111758|NCT03312777|Drug|Placebo|Microcrystalline powder overencapsulated
111759|NCT03312764|Behavioral|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
111760|NCT03312764|Behavioral|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
111761|NCT03312751|Drug|Emapalumab|Emapalumab will be administered by intravenous infusion, twice weekly.
111762|NCT03312738|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) are administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
111763|NCT03312738|Drug|Exemestane|Exemestane 25 mg orally daily.
111764|NCT03312738|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) are administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
111765|NCT03312725|Device|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
111766|NCT03312712|Radiation|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.~Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.~After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.~18F-FDG will be administered intravenously at a dose of approximately 200 MBq.~Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
111767|NCT03312712|Other|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
111768|NCT03312712|Other|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
111769|NCT03312712|Diagnostic Test|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
111770|NCT03312699|Biological|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
111771|NCT03312699|Biological|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
111772|NCT03312699|Biological|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
111773|NCT03312699|Biological|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
111774|NCT03312699|Biological|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
111775|NCT03312699|Biological|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm [temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)] drink on alternate days, e.g., days 1, 3, 5 and 7.
111776|NCT03312686|Diagnostic Test|endoflip|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
111777|NCT03312673|Other|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
111778|NCT03312660|Dietary Supplement|Prebiotic group|Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
111779|NCT03312660|Dietary Supplement|Placebo group|Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
111780|NCT03312634|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day following a meal.
111781|NCT03312621|Behavioral|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
111782|NCT03312608|Diagnostic Test|Navigated transcranial magnetic stimulation|
111783|NCT03312595|Device|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
111784|NCT03312582|Drug|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
111786|NCT03312569|Procedure|Intracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. The right mesocolon is mobilized and the ileal mesentery is divided. The transverse colon and ileum are then divided with the stapler. Next, attention is turned to constructing the anastomosis. For this purpose, the terminal ileum and the transverse colon stump are brought together. A colotomy and ileostomy is created to form a common channel. The common enterotomy is then closed as per the surgeon's standard of care. The specimen is extracted through an off-midline incision (muscle splitting transverse incision, Pfannenstiel).
111787|NCT03312569|Procedure|Extracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. Intracorporeal devascularization may be performed at the surgeon's discretion. The gastrocolic ligament is taken down and the hepatic flexure is mobilized. After complete mobilization of the right colon, the midline incision is extended to serve as the extraction site. The specimen is delivered through the midline extraction incision and the anastomosis is conducted in a standard open technique. The two cut ends of the bowels are aligned for extracorporeal anastomosis.
111788|NCT03312556|Device|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
111789|NCT03312556|Drug|Placebo|Placebo pill or patch. Single dose
111790|NCT03312543|Device|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
111791|NCT03312543|Device|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
111792|NCT03312530|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
111793|NCT03312530|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified in the respective arm.
111794|NCT03312530|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
111795|NCT03312517|Drug|Suvorexant 10 mg|Subject will receive suvorexant 10mg
111796|NCT03312517|Drug|Suvorexant 20 mg|Subject will receive suvorexant 20mg
111797|NCT03312517|Drug|Placebo oral capsule|Subject will receive placebo.
111798|NCT03312504|Other|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
111799|NCT03312504|Other|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
111800|NCT03312478|Drug|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A~Route of administration: N/A"
111801|NCT03312465|Device|AS Domelock System|Hemi or Total Shoulder Arthroplasty
111802|NCT03312452|Device|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
111803|NCT03312452|Device|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
111804|NCT03312439|Behavioral|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
111805|NCT03312426|Drug|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
111806|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
111807|NCT03312413|Drug|Normal Saline|Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
111808|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
111809|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
111810|NCT03312400|Drug|Danazol|"Adult: 200 mg daily versus 400 mg daily.~Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months."
111811|NCT03312387|Other|Exercise|Aerobic exercise performed 3/d per week during intervention
111812|NCT03312387|Dietary Supplement|Essential Amino Acids|Mixture of 10g of essential amino acids ingested throughout intervention
111813|NCT03312387|Dietary Supplement|Placebo|10g of maltodextrin ingested throughout intervention
111814|NCT03312361|Drug|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
111815|NCT03312348|Device|Infrared imaging|Infrared image image acquisition of study participants
111996|NCT03310866|Device|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
111816|NCT03312335|Drug|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
111817|NCT03312322|Other|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
111818|NCT03312322|Other|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.~Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.~It is explained to the patient that he might or no experience the electrical stimulation sensation.~Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
111819|NCT03312322|Other|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
111820|NCT03312309|Procedure|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
111821|NCT03312283|Drug|lucentis|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
111822|NCT03312283|Drug|QL1205|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
111823|NCT03312270|Behavioral|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
111824|NCT03312257|Combination Product|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
111825|NCT03312244|Drug|Pyridostigmine Bromide|Pyridostigmine 180mg/day p.o.
111826|NCT03312244|Drug|Placebo|Placebo
111827|NCT03312231|Drug|AS03|Oil-in-water emulsion based adjuvant system
111828|NCT03312231|Biological|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
111829|NCT03312231|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for 2017 Monovalent Inactivated Influenza A/H7N9 virus vaccine (2017 H7N9 IIV)
111830|NCT03312218|Behavioral|Spaced educational intervention|A spaced educational intervention will be provided to participants
111831|NCT03312205|Biological|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
111832|NCT03312192|Device|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
111833|NCT03312192|Device|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
111834|NCT03312179|Device|PCI and DES stenting|Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
111835|NCT03312179|Drug|Incretins|Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
111836|NCT03312166|Device|Compression device|"interventions on patient are :~surgical excision of ear lobe keloid~application of compression device on sutured skin"
111837|NCT03312153|Drug|Neem|A natural irrigant solution act as anti-inflammatory and anti bacterial
111838|NCT03312153|Drug|2.5% sodium hypochlorite|anti bacterial root canal irrigant solution
111839|NCT03312140|Drug|Choline Chloride|
111840|NCT03312127|Device|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
111841|NCT03312114|Drug|Avelumab|Avelumab* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody)
111842|NCT03312101|Other|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
111843|NCT03312088|Device|Freedom Knee PCK Components|Total Knee Revision
111844|NCT03312075|Other|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
111845|NCT03312062|Other|Foam Rolling Exercise|Foam rolling exercise will be performed actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. There will be 2 sets and each set will be 1 minute. Single set contains 10 repetitions in 1 minute with 30 seconds resting period between sets.
111846|NCT03312036|Device|Coupled plasma filtration and adsorption (CPFA)|"Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation"
111847|NCT03312023|Drug|Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni]|1 pill once daily for 12 weeks for Group A
111848|NCT03312023|Drug|Sofosbuvir 400 MG [Sovaldi]|1 pill once daily for 12 weeks for Group C
111849|NCT03312023|Drug|Ledipasvir 90 MG|1 pill once daily for 12 weeks for Group D
111850|NCT03312010|Device|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
111851|NCT03312010|Device|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
111852|NCT03311997|Procedure|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
111853|NCT03311984|Diagnostic Test|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
111854|NCT03311971|Device|Virtual reality glasses|Patients will be treated with virtual glasses
111855|NCT03311971|Device|No VR glasses|Patients will not use VR glasses
111856|NCT03311958|Drug|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
111857|NCT03311945|Drug|Raltegravir|Raltegravir (1200 mg QD)
111858|NCT03311945|Drug|Lamivudine|Lamivudine (300 mg QD)
111859|NCT03311932|Drug|Infacort®|Immediate release multiparticulate formulation (granules) of hydrocortisone
111860|NCT03311932|Drug|Cortef®|Immediate release hydrocortisone tablets
111861|NCT03311906|Drug|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
111862|NCT03311906|Procedure|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
111863|NCT03311893|Procedure|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
111864|NCT03311880|Behavioral|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
111865|NCT03311867|Other|Ethibond Suture|Cerclage placement with ethibond
111866|NCT03311867|Other|Prolene Suture|Cerclage placement with prolene
111867|NCT03311854|Drug|NI-0501|NI-0501 will be administered at the initial dose of 6 mg/kg by intravenous infusion. NI-0501 treatment will be continued at the dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e. until study day 28.
111868|NCT03311841|Drug|Midazolam oral solution|Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
111869|NCT03311841|Drug|Dabigatran and pitavastatin oral solution|Dabigatran etexilate 375/10 μg and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
111870|NCT03311841|Drug|Atorvastatin and rosuvastatin oral solution|Atorvastatin 100/50 μg and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
111871|NCT03311841|Drug|Rifampin|Rifampin 600 mg single dose (two 300 mg capsules) administered orally
111872|NCT03311828|Biological|Daratumumab|Given IV
111873|NCT03311828|Drug|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
111874|NCT03311828|Procedure|Positron Emission Tomography|Undergo PET
111875|NCT03311828|Other|Pharmacological Study|Correlative studies
111876|NCT03311815|Diagnostic Test|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
111877|NCT03311789|Drug|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
111878|NCT03311763|Behavioral|EIM Fitness Practitioners|Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
111879|NCT03311763|Behavioral|Counseling and wearable device|Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
111880|NCT03311750|Drug|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
111881|NCT03311737|Combination Product|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
111882|NCT03311737|Combination Product|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
111883|NCT03311724|Drug|Tirzepatide|Administered SC
111884|NCT03311724|Drug|Placebo|Administered SC
111885|NCT03311711|Behavioral|SPIRIT-in person|The SPIRIT-in person intervention adapted for dementia will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
111886|NCT03311711|Behavioral|SPIRIT-remote|The SPIRIT-remote intervention adapted for dementia will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
111959|NCT03311191|Device|Measurement of skin oxygenation and oxygen consumption|Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
111887|NCT03311711|Behavioral|Usual care|At the time of the diagnosis of a dementing illness, an advanced practice nurse provides written information on advance directives to a patient and his/her family caregiver and reviews this information and encourages them to complete an advanced directive. This typically takes about 10 minutes. Patients and their family members may be referred to attorneys who can assist them in completing an advance directive. If completed, the presence of an advanced directive is documented in the electronic medical record and a copy of the advance directive is scanned to the electronic chart. Patients and families may be referred to a support group program organized by a social worker in which legal and financial issues are discussed in a group setting (by a lawyer).
111888|NCT03311698|Behavioral|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
111889|NCT03311685|Device|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
111890|NCT03311672|Drug|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
111891|NCT03311672|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
111892|NCT03311672|Radiation|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
111893|NCT03311659|Biological|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm in dTap group.
111894|NCT03311646|Other|Normal nicotine content cigarettes|Participants will smoke research cigarettes that have a normal nicotine content
111895|NCT03311646|Other|Lower nicotine content cigarettes|Participants will smoke research cigarettes that have a lower nicotine content
111896|NCT03311633|Procedure|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
111897|NCT03311620|Procedure|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
111898|NCT03311607|Drug|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
111899|NCT03311594|Drug|Low Alcohol|Low Alcohol Consumption
111900|NCT03311594|Drug|Moderate Alcohol|Moderate Alcohol Consumption
111901|NCT03311594|Drug|Placebo Alcohol|Placebo Alcohol Consumption
111902|NCT03311594|Other|Pain Induction|10% capsaicin solution placed on forearm and heat induction
111903|NCT03311594|Other|No Pain Induction|Water placed on forearm
111904|NCT03311581|Drug|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
111905|NCT03311581|Device|Sevoflurane|sevoflurane inhalation 2~4%
111906|NCT03311568|Device|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.~Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously~US registration repeated within each study participant consecutively on seven different regions of the body surface."
111907|NCT03311555|Drug|Apalutamide|240mg tablet daily for 36 weeks
111908|NCT03311555|Drug|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
111909|NCT03311555|Radiation|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
111910|NCT03311555|Drug|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
111911|NCT03311542|Biological|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
111912|NCT03311529|Behavioral|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
111913|NCT03311516|Other|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
111914|NCT03311516|Other|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
111915|NCT03311503|Biological|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
111916|NCT03311490|Device|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
111917|NCT03311477|Drug|ABBV-399|Intravenous infusion
111918|NCT03311464|Drug|adalimumab|Study drug will be administered subcutaneously.
111919|NCT03311451|Device|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
111991|NCT03310905|Procedure|Abdominal Wall Transplant|Transplant of abdominal wall alone or in combination with another solid organ transplant.
111920|NCT03311438|Other|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
111921|NCT03311425|Drug|Methylprednisolone|Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
111922|NCT03311425|Drug|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
111923|NCT03311412|Drug|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
111924|NCT03311412|Drug|Sym022|Sym022 is a recombinant, fully human antibody that binds LAG-3 and blocks the LAG-3/major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production.
111925|NCT03311412|Drug|Sym023|Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
111926|NCT03311399|Other|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
111927|NCT03311399|Other|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
111928|NCT03311386|Drug|Actilyse|thrombolytic therapy
111929|NCT03311373|Drug|Regimen A|2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure
111930|NCT03311373|Drug|Regimen B|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
111931|NCT03311373|Drug|Regimen C|2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure
111932|NCT03311373|Drug|Regimen D|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
111933|NCT03311360|Device|drug-coated balloon|Orchid and Dahlia DCB
111934|NCT03311360|Device|bare metal stent|any type of bare metal stent
111935|NCT03311347|Other|+Gz accelerations and positive pressure breathing|
111936|NCT03311334|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 days until cycle 2, and then every 14 days for combination with Nivolumab arm, and every 21 days for Pembrolizumab arm.
111937|NCT03311334|Drug|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 1 of the study.
111938|NCT03311334|Drug|Pembrolizumab|Pembrolizumab will be administered in the approved dose and schedule starting on Day 1 of the study.
111939|NCT03311321|Dietary Supplement|Vitamin K2 (menaquinone-7; 360-mcg/d)|four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
111940|NCT03311321|Dietary Supplement|Placebo-Control|four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
111941|NCT03311308|Drug|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years
111942|NCT03311308|Drug|Metformin|500 mg, by mouth, once a day for nine weeks.
111943|NCT03311295|Device|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
111944|NCT03311282|Device|infants bottles|"angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;~extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~flexors at the base to enhance elasticity and flexibility of the teat"
111945|NCT03311282|Device|Infants Bottles|"large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion~non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.~flexors at the base to enhance elasticity and flexibility of the teat"
111946|NCT03311282|Device|Infants Bottles|"teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.~flexors at the base to enhance elasticity and flexibility of the teat"
111947|NCT03311269|Device|ClariVein RES|ClariVein system
111948|NCT03311269|Drug|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
111949|NCT03311269|Drug|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
111950|NCT03311256|Diagnostic Test|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
111951|NCT03311243|Procedure|Non surgical periodontal therapy|
111952|NCT03311243|Drug|Chemical plaque control|
111953|NCT03311230|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
111954|NCT03311230|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
111955|NCT03311230|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
111956|NCT03311217|Behavioral|Healthy retail strategies|
111957|NCT03311204|Device|BlephEx|BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
111958|NCT03311204|Other|Lid Hygenix|Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
111992|NCT03310892|Behavioral|Generic message|Generic message
111993|NCT03310892|Behavioral|Tailored message|Tailored message
111960|NCT03311178|Drug|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
111961|NCT03311165|Other|no intervention|no intervention was given
111962|NCT03311152|Diagnostic Test|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
111963|NCT03311139|Drug|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
111964|NCT03311126|Drug|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of CLL and for indolent B cell NHLs progressing during or within 6 months of rituximab or a rituximab - containing regimen.
111965|NCT03311126|Drug|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 mAb.
111966|NCT03311113|Other|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
111967|NCT03311100|Other|immunohistochemistry assay|biomarkers expression
111968|NCT03311074|Biological|Strimvelis|Strimvelis is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. Strimvelis is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
111969|NCT03311061|Other|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
111970|NCT03311048|Other|Nasal swab|Nasal swab was collect to upper airways inflammation evaluation.
111971|NCT03311048|Other|Questionnaires|Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
111972|NCT03311035|Procedure|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
111973|NCT03311035|Procedure|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
111974|NCT03311022|Drug|Nefopam Hydrochloride 30mg Tablets|
111975|NCT03311022|Drug|Acupan® 30mg Tablets|
111976|NCT03311009|Drug|GLPG1972 cohort 1|GLPG1972 dose 1 provided as oral tablets q.d.
111977|NCT03311009|Drug|GLPG1972 cohort 2|GLPG1972 dose 2 provided as oral tablets q.d.
111978|NCT03311009|Drug|GLPG1972 cohort 3|GLPG1972 dose 3 provided as oral tablets q.d.
111979|NCT03311009|Drug|Placebo|Matching placebo provided as oral tablets q.d.
111980|NCT03310996|Other|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
111981|NCT03310983|Dietary Supplement|Docosahexaenoic acid|The main study, ADORE, includes providing DHA to participants during pregnancy. No intervention is included as part of this study.
111982|NCT03310970|Drug|Lidocaine patch 5%|Each subject will wear three Lidocaine patches for 12 hours.
111983|NCT03310970|Drug|Lidocaine Hydrochloride|Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.
111984|NCT03310970|Drug|Lidoderm 5 % Topical Patch|Each subject will wear three Lidoderm® patches for 12 hours.
111985|NCT03310957|Drug|SGN-LIV1A|IV infusion every 3 weeks
111986|NCT03310957|Drug|Pembrolizumab|IV infusion every 3 weeks
111987|NCT03310944|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
111988|NCT03310918|Other|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
111989|NCT03310918|Other|Standard Leukemia care|Standard care per the hospital guideline
111990|NCT03310905|Drug|Belatacept 5mg/kg IV monthly|Belatacept infusions following an isolated abdominal wall transplant.
111997|NCT03310853|Dietary Supplement|Probiotic|Dosing regimen of one capsule daily for a maximum of 18 weeks
111998|NCT03310853|Other|Placebo|Dosing regimen of one capsule daily for a maximum of 18 weeks
111999|NCT03310827|Behavioral|Personalized Nutrition|Diet plan based on nutrition-related gene test results
112000|NCT03310814|Other|Personalized nutrition|Receives individualized nutrition information
112001|NCT03310801|Procedure|ACP or Watchman|Left atrial appnedage occlusion using ACP or Watchman
112002|NCT03310775|Behavioral|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
112003|NCT03310762|Other|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
112004|NCT03310762|Other|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
112005|NCT03310749|Drug|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
112006|NCT03310749|Drug|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
112007|NCT03310749|Drug|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
112008|NCT03310736|Diagnostic Test|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
112009|NCT03310723|Device|Face Mask preoxygenation|Standard face mask preoxygenation.
112010|NCT03310723|Device|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
112011|NCT03310710|Device|Viabahn BX stent|Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
112012|NCT03310697|Other|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
112013|NCT03310697|Other|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
112014|NCT03310671|Procedure|Echocardiogram|"Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve~Pick up from:~Mean transvalvular pressure gradient~Aortic valve~Aortic valve opening area~Aortic valve opening area adjusted for body mass index~Bicuspid or tricuspid aorta~Thickness of the upper valve> 3 mm"
112015|NCT03310658|Device|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
112016|NCT03310645|Drug|BAY1817080|4 different doses over the course of study
112017|NCT03310645|Drug|Matching Placebo|Matching placebo for BAY
112018|NCT03310632|Drug|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
112019|NCT03310619|Biological|JCAR017|Gene modified autologous T cells
112020|NCT03310619|Drug|Durvalumab|Anti-PD-L1
112021|NCT03310619|Drug|CC-122|Pleiotropic Pathway Modifier
112022|NCT03310606|Other|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
112023|NCT03310593|Drug|Cannabidiol|Cannabidiol as active intervention.
112024|NCT03310593|Drug|Placebo|Placebo intervention.
112025|NCT03310580|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
112026|NCT03310580|Drug|AR-13324 Ophthalmic Solution 0.04%|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
112027|NCT03310580|Drug|AR-13324 Ophthalmic Solution Placebo|Administered to each eye, once daily (QD) in the evening (PM) for 28 days
112028|NCT03310567|Drug|Epacadostat + pembrolizumab|Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
112029|NCT03310554|Procedure|26cm suspended overlength biliary stents|The test group will be placed 26cm suspended overlength biliary stents in introhepatic bile duct in ERCP
112030|NCT03310554|Procedure|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
112031|NCT03310554|Procedure|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in introhepatic bile duct in ERCP
112032|NCT03310541|Drug|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
112033|NCT03310541|Drug|Enzalutamide|Enzalutamide 160 mg PO once daily
112034|NCT03310541|Drug|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
112035|NCT03310528|Behavioral|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
112036|NCT03310528|Procedure|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
112037|NCT03310515|Behavioral|Risk reduction counseling|Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
112038|NCT03310515|Other|Social harm interview|Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
112039|NCT03310515|Other|Computer-Assisted Self Interviewing technique|Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
112040|NCT03310489|Behavioral|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
112041|NCT03310489|Behavioral|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
112042|NCT03310476|Other|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
112043|NCT03310463|Drug|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
112044|NCT03310450|Other|140kms cycling|Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)
112045|NCT03310437|Procedure|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
112046|NCT03310424|Other|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
112047|NCT03310411|Drug|Lasmiditan|Administered orally
112048|NCT03310411|Drug|Sumatriptan|Administered orally
112049|NCT03310411|Drug|Placebo for Lasmiditan|Administered orally
112050|NCT03310411|Drug|Placebo for Sumatriptan|Administered orally
112051|NCT03310398|Behavioral|NeuroImaging|standard anatomical and functional imaging
112052|NCT03310398|Behavioral|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
112053|NCT03310385|Drug|GHX02|Herbal medicine originating from gualouhengryunhwan
112054|NCT03310385|Drug|Placebo|Placebo tablets
112055|NCT03310372|Radiation|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
112056|NCT03310372|Drug|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
112057|NCT03310359|Dietary Supplement|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
112058|NCT03310359|Other|Placebo|Matching placebo pill
112059|NCT03310333|Drug|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score <6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
112060|NCT03310333|Device|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
112061|NCT03310320|Drug|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
112062|NCT03310320|Drug|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
112063|NCT03310307|Drug|Vit D|50,000 IU
112064|NCT03310307|Other|Placebo|
112065|NCT03310294|Dietary Supplement|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
112066|NCT03310294|Dietary Supplement|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
112067|NCT03310281|Device|HOLD: Videogame|Videogame-like digital therapy
112068|NCT03310268|Other|0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total|Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
112069|NCT03310268|Other|1400 ppm fluoride as sodium monofluorophosphate (SMFP)|Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
112070|NCT03310268|Other|Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total|Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
112071|NCT03310255|Diagnostic Test|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
112072|NCT03310242|Behavioral|Sunlight Exposure|"Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks~Completing a Sun Diary after sunlight exposure"
112073|NCT03310242|Dietary Supplement|Vitamin D Supplementation|- Supplementation of vitamin D3 500 IU/day for 8 weeks
112074|NCT03310242|Other|Placebo|- Intake of placebo for 8 weeks
112075|NCT03310229|Radiation|plain chest x-ray|the participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients
112076|NCT03310216|Procedure|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
112077|NCT03310216|Procedure|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
112078|NCT03310203|Diagnostic Test|Iron|Labelled iron
112079|NCT03310151|Procedure|Imagined movements|Imagined wrist movements, 10-15 minutes, 4 times a day.
112080|NCT03310138|Device|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
112081|NCT03310138|Device|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
112082|NCT03310125|Drug|Colchicine|0.5mg tablet, twice daily for 10 days
112083|NCT03310125|Drug|Placebo|Placebo oral tablet, twice daily for 10 days
112084|NCT03310112|Behavioral|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
112085|NCT03310112|Behavioral|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
112086|NCT03310099|Behavioral|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
112087|NCT03310086|Device|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
112088|NCT03310086|Procedure|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
112089|NCT03310073|Biological|bOPV|Batch Number: 2042015
112090|NCT03310073|Biological|Pentabio|Batch number: 5050115 The vaccine shall be given intramuscularly.
112091|NCT03310073|Biological|IPV|The vaccine shall be given intramuscularly.
112092|NCT03310060|Drug|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
112093|NCT03310060|Drug|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
112094|NCT03310047|Drug|Infusion, Lidocaine, 0.5%, 5 mL|A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
112095|NCT03310047|Drug|Infusion, Lidocaine, 0.5%, 10 mL|A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
112096|NCT03310034|Dietary Supplement|NAD-precursors|Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.
112097|NCT03310034|Dietary Supplement|Control|Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
112098|NCT03310021|Biological|Andexanet alfa|fXa inhibitor antidote
112099|NCT03310021|Drug|Apixaban|factor Xa inhibitor
112100|NCT03310021|Drug|Rivaroxaban|factor Xa inhibitor
112101|NCT03310021|Drug|Edoxaban|factor Xa inhibitor
112102|NCT03310021|Drug|Placebo|Placebo
112103|NCT03310008|Biological|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
112104|NCT03309995|Device|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
112105|NCT03309995|Device|Placebo lozenges|Placebo lozenges
112106|NCT03309982|Dietary Supplement|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
112107|NCT03309982|Other|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
112108|NCT03309956|Device|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
112109|NCT03309956|Device|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
112110|NCT03309943|Drug|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
112111|NCT03309943|Drug|Placebo|Participants will take one dose of Placebo on two separate occasions.
112112|NCT03309930|Behavioral|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
112113|NCT03309917|Other|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min by infusion of noradrenaline.
112114|NCT03309917|Other|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min by infusion of noradrenaline.
112115|NCT03309917|Other|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min by infusion of noradrenaline.
112116|NCT03309904|Other|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
112117|NCT03309891|Drug|GX-H9|subcutaneous injection (weekly or twice-monthly)
112118|NCT03309891|Drug|Genotropin|subcutaneous injection (daily)
112119|NCT03309878|Biological|Mogamulizumab|Given IV
112120|NCT03309878|Biological|Pembrolizumab|Given IV
112121|NCT03309865|Dietary Supplement|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
112122|NCT03309865|Drug|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
112123|NCT03309839|Other|Blood collection|A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
112124|NCT03309826|Device|Positive Airway Pressure|Auto-PAP titration followed by fixed PAP treatment
112125|NCT03309826|Device|Nasal Dilator Strip|Nightly use of nasal dilator strip
112126|NCT03309813|Device|Transcranial ExAblate|ExAblate Thalamotomy for Chronic Trigeminal Neuropathic Pain
112127|NCT03309813|Device|Sham Transcranial ExAblate|Sham ExAblate Thalamotomy procedure
112128|NCT03309800|Drug|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
112129|NCT03309800|Drug|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
112130|NCT03309787|Behavioral|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
112131|NCT03309774|Diagnostic Test|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child~There will be:~Questionnaire KIDSCREEN 52~Visual Analogue Scale (EVA)~Neuropathic Pain 4 (DN4)~Pain of the child Gustave Roussy (DEGR)"
112132|NCT03309774|Diagnostic Test|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
112133|NCT03309774|Diagnostic Test|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
112134|NCT03309774|Other|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.~During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.~After every relaxation sessions children evaluate pain according to Eland Color Scale."
112135|NCT03309761|Other|Blood test|6ml blood sample taken
112136|NCT03309748|Procedure|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
112137|NCT03309748|Device|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
112138|NCT03309735|Drug|Micronized progesterone|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
112139|NCT03309735|Drug|Micronized progesterone|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
112140|NCT03309735|Drug|Dydrogesterone|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
112141|NCT03309722|Other|biomarker study|
112142|NCT03309709|Drug|subcutaneous progesterone|25mg daily for 7 days
112143|NCT03309696|Device|tDCS|transcranial direct current stimulation (tDCS)
112144|NCT03309696|Device|rTMS|repetitive transcranial magnetic stimulation (rTMS)
112145|NCT03309683|Device|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
112146|NCT03309670|Other|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
112147|NCT03309657|Drug|Ceftolozane/tazobactam|IV ceftolozane 2000mg /tazobactam 1000mg once only
112148|NCT03309644|Other|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
112149|NCT03309644|Other|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
112150|NCT03309631|Diagnostic Test|In vitro Diagnostic|
112151|NCT03309618|Drug|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
112152|NCT03309618|Drug|placebo|
112153|NCT03309605|Drug|ELX-02|ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug
112154|NCT03309605|Drug|Placebo|Placebo
112155|NCT03309592|Drug|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
112156|NCT03309592|Drug|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
112157|NCT03309579|Other|Liberal RBC Transfusion Strategy|RBC transfusion is triggered by a Hemoglobin value of ≤100g/L
112158|NCT03309579|Other|Restrictive RBC Transfusion Strategy|Optional RBC transfusion is triggered by a Hemoglobin value of ≤80g/L
112159|NCT03309566|Drug|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
112160|NCT03309553|Other|Current Primary Care Referral Process|Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
112161|NCT03309553|Other|Telemedicine Referral Process|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
112162|NCT03309540|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
112163|NCT03309527|Behavioral|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
112164|NCT03309527|Behavioral|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
112165|NCT03309514|Biological|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
112166|NCT03309501|Drug|Tong-Luo-Qu-Tong Plaster|for 14 days as two period of treatment, daily 1 time.
112167|NCT03309501|Drug|Qi-Zheng-Xiao-Tong Plaster|for 14 days as two period of treatment, daily 1 time
112168|NCT03309488|Diagnostic Test|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
112169|NCT03309475|Behavioral|SocialMIND|SocialMind is a mindfulness-based intervention including elements such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
112170|NCT03309475|Behavioral|Psychoeducational multicomponent intervention|The psychoeducational multicomponent intervention addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
112171|NCT03309475|Behavioral|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
112172|NCT03309475|Drug|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
112173|NCT03309462|Device|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
112174|NCT03309449|Device|Syringe and needle|Intramuscular administration of simulated naloxone
112175|NCT03309449|Device|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
112176|NCT03309449|Device|Nasal spray|Nasal spray administration of simulated naloxone
112177|NCT03309436|Drug|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
112178|NCT03309436|Procedure|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
112179|NCT03309423|Diagnostic Test|venous to arterial conversion (v-TAC)|Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
112180|NCT03309410|Diagnostic Test|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
112181|NCT03309358|Drug|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
112182|NCT03309358|Drug|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
112183|NCT03309345|Other|No intervention|No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
112184|NCT03309332|Device|AMPLATZER™ PFO Occluder|Implantation of the AMPLATZER™ PFO Occluder in the PFO
112185|NCT03309319|Drug|Rosiglitazone|rosiglitazone is added to the primary treatment
112226|NCT03309007|Drug|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
112227|NCT03309007|Drug|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
112186|NCT03309306|Other|Natural Environment/Stress Management|Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will capture baseline data for 4-7 days. After a 1-week break, participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also receive information on stress management
112187|NCT03309306|Behavioral|Natural Environment/Reduce Food Waste|"Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~Feedback on the amount of food waste their household created during the first week,~A goal to reduce the next week's food waste by 20% or more, and~Tips on how to reduce household food waste adapted from current consumer campaigns"
112188|NCT03309306|Other|Questionnaires|"Participants will complete the following questionnaires:~Food Environment Questionnaire Waste Toss Methods Questionnaire User Satisfaction Survey Post-Study System Usability Questionnaire (PSSUQ) Food Waste Tip Questionnaire (Intervention Group only)"
112189|NCT03309293|Biological|blood samples|blood samples
112190|NCT03309280|Other|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
112191|NCT03309267|Procedure|Intercostal block|Intercostal block +patient controlled analgesia
112192|NCT03309267|Procedure|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
112193|NCT03309254|Other|High Glycemic Index|High Glycemic Index Food
112194|NCT03309254|Other|Low Glycemic Index|Low Glycemic Index Food
112195|NCT03309241|Drug|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
112196|NCT03309241|Other|Placebo|Placebo Single Dose
112197|NCT03309228|Other|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
112198|NCT03309215|Other|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of >99 wt.% nickel one consist of >99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.~One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
112199|NCT03309202|Drug|PF-05221304|25 mg dose
112200|NCT03309176|Drug|Medroxyprogesterone Acetate 10 MG|Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
112201|NCT03309176|Other|Stair step protocol without Medroxyprogesterone Acetate|No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
112202|NCT03309163|Drug|Tramadol|Patient-controlled intravenous analgesia with Tramadol
112203|NCT03309163|Drug|Hydromorphone|Patient-controlled intravenous analgesia with Hydromorphone
112204|NCT03309163|Drug|Ropivacaine (Epidural analgesia)|Patient-controlled epidural analgesia with Ropivacaine.
112205|NCT03309150|Drug|M6620|Subject will either receive M6620 intravenously as a monotherapy on Day 1, 8 and 15 OR as a combination therapy on Day 2 and 9 of the study.
112206|NCT03309150|Drug|Carboplatin|Subject will receive carboplatin intravenous infusion as a combination therapy on Day 1 of the study.
112207|NCT03309150|Drug|Paclitaxel|Subject will receive paclitaxel intravenous infusion as a combination therapy on Day 1, 8 and 15 of the study.
112208|NCT03309137|Device|Chlorhexidine flush|"For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.~After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.~Discard the syringe and device in biohazard waste.~Blue Cap the IV as per routine practice."
112209|NCT03309124|Other|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
112210|NCT03309124|Other|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
112211|NCT03309124|Other|Mashed potatoes|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
112212|NCT03309124|Other|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
112213|NCT03309124|Other|Meal skipping|No food given
112214|NCT03309111|Biological|GBR 1342|GBR 1342 will be administered by intravenous (IV) infusion on Day 1 and Day 15 of each 28-day treatment cycle at escalating dose levels
112215|NCT03309098|Diagnostic Test|Ligmaster Arthrometer Assessment|Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
112216|NCT03309085|Procedure|Repeated CT scan|CT scan of chest on different PEEP levels, 4 in total
112217|NCT03309085|Device|CT scan|CT scan
112218|NCT03309072|Device|tDCS|active tDCS
112219|NCT03309072|Device|sham tDCS|sham tDCS
112220|NCT03309059|Device|water and soap|Use of soap and water in the area and subsequent diaper placement disposable.
112221|NCT03309059|Device|zinc oxide|Use of soap and water sanitation and application of zinc oxide.
112222|NCT03309059|Device|Non-Irritant Barrier Film|Use of soap and water hygiene and application of Non Irritant Barrier Film.
112223|NCT03309046|Other|REACH Individual Session|Individual telephone session with parent
112224|NCT03309046|Other|Education Webinar|Videos with information on caregiving
112225|NCT03309020|Procedure|Cataract|Cataract surgery and aqueous humor sampling.
112228|NCT03308994|Other|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
112229|NCT03308994|Other|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
112230|NCT03308981|Device|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
112231|NCT03308981|Other|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
112232|NCT03308968|Drug|Fremanezumab|Fremanezumab will be administered per dose and schedule specified in the arm.
112233|NCT03308968|Drug|Placebo|Placebo matching to fremanezumab will be administered per schedule specified in the arm.
112234|NCT03308955|Drug|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
112235|NCT03308955|Procedure|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
112236|NCT03308955|Procedure|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
112237|NCT03308942|Drug|Niraparib|PARP inhibitor, Capsule, 200mg dose, QD
112238|NCT03308942|Biological|PD-1 Inhibitor|Monoclonal antibody, IV administration
112239|NCT03308929|Device|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
112240|NCT03308916|Diagnostic Test|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
112241|NCT03308916|Diagnostic Test|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
112242|NCT03308916|Diagnostic Test|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
112243|NCT03308916|Diagnostic Test|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
112244|NCT03308916|Diagnostic Test|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
112245|NCT03308916|Diagnostic Test|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
112246|NCT03308916|Diagnostic Test|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
112247|NCT03308903|Diagnostic Test|DEXA scan|The participant will undergo a whole-body DEXA (DEXA; GE Medical Systems, Chalfont St Giles, UK) scan, lasting approximately 5 minutes. This scan will produce body composition data, including estimates of lean body mass (LBM), appendicular lean mass (aLM) and body fat percentage (BF%).
112248|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
112249|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
112250|NCT03308877|Behavioral|BMI|Four 45-minute, brief motivational sessions for substance use
112251|NCT03308877|Behavioral|Stadard Care (SC)|Standard procedures at pretrial program + assessement
112252|NCT03308864|Behavioral|Interpersonal Psychotherapy for Adolescents|Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
112253|NCT03308864|Behavioral|Treatment as usual|Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
112254|NCT03308851|Procedure|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
112255|NCT03308851|Procedure|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
112256|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
112257|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
112258|NCT03308825|Biological|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
112259|NCT03308812|Behavioral|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
112260|NCT03308812|Behavioral|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
112261|NCT03308799|Drug|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
112262|NCT03308799|Drug|Cal/BDP combination|calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
112263|NCT03308799|Drug|Cream vehicle|Vehicle Cream
112264|NCT03308786|Drug|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for five consecutive days every 8 weeks for 8 weeks
112265|NCT03308773|Other|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
112266|NCT03308760|Other|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
112267|NCT03308760|Other|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
112268|NCT03308760|Other|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
112269|NCT03308747|Dietary Supplement|Instantized Whey Protein Isolate|0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
112270|NCT03308734|Behavioral|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
112271|NCT03308721|Drug|NNC9204-1177 A 1.0 mg/mL|"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.~Dose gradually increased to 6000 μg."
112272|NCT03308721|Drug|PLACEBO|Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
112273|NCT03308708|Drug|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
112274|NCT03308682|Drug|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
112275|NCT03308669|Drug|Lasmiditan|Administered orally
112276|NCT03308669|Drug|Placebo|Administered orally
112277|NCT03308669|Drug|Topiramate|Administered orally
112278|NCT03308656|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
112279|NCT03308643|Drug|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
112280|NCT03308643|Other|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
112281|NCT03308630|Behavioral|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
112282|NCT03308604|Drug|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.~The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.~Irradiation will be performed after the second MRI.~The second injection will be followed by an MRI 4 hours later~The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.~Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/ kg (level 2). The starting dose level will be 30mg/kg."
112283|NCT03308604|Radiation|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
112284|NCT03308604|Radiation|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
112285|NCT03308604|Drug|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
112286|NCT03308591|Drug|NACT|Platin based chemotherapy
112287|NCT03308591|Procedure|RT+PLND|radical hysterectomy+pelvic lymphadenectomy
112288|NCT03308591|Drug|Adjuvant chemotherapy|Platin based chemotherapy
112289|NCT03308578|Drug|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
112290|NCT03308578|Drug|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
112291|NCT03308565|Biological|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
112293|NCT03308552|Drug|Paclitaxel|45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
112294|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
112295|NCT03308552|Drug|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
112296|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
112297|NCT03308539|Radiation|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
112298|NCT03308500|Behavioral|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
112299|NCT03308500|Behavioral|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
112300|NCT03308487|Dietary Supplement|vitamin D3 (1000 IU)|
112301|NCT03308487|Dietary Supplement|Vitamin D3 (2000 IU)|
112302|NCT03308474|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
112303|NCT03308461|Drug|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
112304|NCT03308448|Drug|Recombinant human erythropoietin|Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
112305|NCT03308435|Diagnostic Test|Geriatric assessment|the assessment includes functional tests (hand grip strength, SPPB (Short Physical Performance Battery)) and questionaires Euro-QoL 5D, LUTS, GDS, ADL, iADL, dietary recall).
112306|NCT03308435|Diagnostic Test|Psychiatric assessment|Psychiatric assessments includes HAMD-17 as well as Beck depression inventory, hospital anxiety and depression scale, SF36, PTSS-10
112307|NCT03308435|Diagnostic Test|Inflammatory assessment|analysis will include arginase, ADMA, SDMA, homoarginine, aminoacids + metabolites, tryptophan, kynurenine, kynurenine acid, cortisol, ACTH, Metanephrine, myeloperoxidase,
112308|NCT03308435|Diagnostic Test|Cardiological assessment|ECG, echocardiography
112309|NCT03308422|Behavioral|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
112310|NCT03308409|Other|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
112311|NCT03308396|Drug|Guadecitabine|Days 1-5 Dose 0: 60 mg/m^2 Dose -1: 45 mg/m^2
112312|NCT03308396|Drug|Durvalumab|Day 8 Durvalumab (1500 mg IV)
112313|NCT03308383|Other|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
112314|NCT03308370|Biological|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
112315|NCT03308357|Diagnostic Test|Drug assays to measure infliximab|See protocol
112316|NCT03308344|Behavioral|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and connection. It will be delivered in short, weekly sessions.
112317|NCT03308331|Other|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
112318|NCT03308318|Procedure|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
112319|NCT03308292|Other|Exercise|Aerobic exercise program
112320|NCT03308279|Diagnostic Test|Ultrasound|Ultrasound and Anthropometric meassures
112321|NCT03308266|Diagnostic Test|electromyography|
112322|NCT03308253|Device|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
112323|NCT03308253|Drug|Vancomycin|0.5 g Vancomycin per patient
112324|NCT03308253|Drug|Tobramycin|120 mg tobramycin per patient
112325|NCT03308253|Other|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
112326|NCT03308240|Behavioral|Magic Therapy|As described in the arm description
112327|NCT03308214|Drug|Imipenem|Imipenem 1.0 q 8h
112328|NCT03308201|Drug|Hemay022|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.~Part two: Hemay022 tablets will be taken in OTR dose group in combination with exemestane."
112329|NCT03308201|Drug|exemestane|Part one and Part two: Exemestane will be taken in 25mg once daily.
112330|NCT03308188|Behavioral|E-health program|The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
112331|NCT03308175|Device|flat fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females
112332|NCT03308175|Device|modified inclined fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
112333|NCT03308162|Behavioral|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
112334|NCT03308149|Drug|infiltration with triamcinolone and bupivacaine|facet joint infiltration
112335|NCT03308136|Procedure|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
112336|NCT03308136|Procedure|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.
112337|NCT03308136|Drug|1% Lidocaine|1% Lidocaine
112338|NCT03308123|Other|Observational study, not interventional|Not an intervention study
112339|NCT03308110|Drug|PF-06650833|Two formulations of PF-006650833
112340|NCT03308097|Behavioral|PrEP Mobile Messaging Intervention|See group description
112341|NCT03308097|Behavioral|Enhanced Standard of Care|See group description
112342|NCT03308084|Drug|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
112343|NCT03308084|Drug|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
112344|NCT03308071|Behavioral|Hypnosis|Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
112345|NCT03308058|Behavioral|Breastfeeding computer education|Breastfeeding computer education
112346|NCT03308045|Biological|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
112347|NCT03308032|Behavioral|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
112348|NCT03308032|Behavioral|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
112349|NCT03308019|Device|Photodynamic therapy|In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.
112350|NCT03308019|Procedure|Scaling and root planing (SRP)|In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
112351|NCT03308006|Biological|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
112352|NCT03307993|Drug|Idalopirdine|Idalopirdine 60-120 mg daily dose
112353|NCT03307980|Biological|SPK-9001|Observational long-term safety follow-up study of subjects previously treated in the C0371005 (formerly SPK-9001-101) protocol
112354|NCT03307967|Behavioral|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
112355|NCT03307954|Device|Ekso Therapy (Exoskeleton Suit)|
112356|NCT03307954|Other|Usual Physiotherapy|
112357|NCT03307941|Drug|Monalizumab|Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
112358|NCT03307941|Drug|Oxaliplatin|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
112359|NCT03307941|Drug|5-Fluorouracil|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
112360|NCT03307941|Radiation|Metabolic|Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
112420|NCT03307590|Drug|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
112421|NCT03307590|Drug|Bupivacaine|Caudal block by bupivavaine alone
112361|NCT03307941|Other|Metabolic|18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
112362|NCT03307941|Procedure|Surgery|Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
112363|NCT03307928|Diagnostic Test|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
112364|NCT03307928|Diagnostic Test|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
112365|NCT03307915|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5*10^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
112366|NCT03307915|Biological|MVA-Mosaic|Participants will receive MVA-Mosaic 10^8 pfu as IM injection at Weeks 24 and 36.
112367|NCT03307915|Biological|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.
112368|NCT03307915|Drug|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
112369|NCT03307902|Biological|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
112370|NCT03307902|Biological|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
112371|NCT03307902|Biological|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
112372|NCT03307876|Other|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
112373|NCT03307863|Drug|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
112374|NCT03307863|Drug|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
112375|NCT03307863|Drug|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
112376|NCT03307850|Other|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
112377|NCT03307837|Drug|CA-008|The active moiety of CA-008, capsaicin that has certain properties for treatment of post-operative pain.
112378|NCT03307837|Drug|CA-008 Placebo|Placebo product
112379|NCT03307824|Device|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
112380|NCT03307824|Procedure|Glue-Free Suture Technique|Suture Technique
112381|NCT03307811|Other|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
112382|NCT03307785|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
112383|NCT03307785|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
112384|NCT03307785|Drug|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.
112385|NCT03307785|Drug|Bevacizumab|Bevacizumab is a chemotherapy treatment that has been shown to be efficacious against a variety of different cancer types, including colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. Bevacizumab is in the angiogenesis inhibitor and monoclonal antibody families of medication. It works by slowing the growth of new blood vessels.
112386|NCT03307785|Drug|TSR-022|"TSR-022 is a monoclonal antibody against TIM-3 (also called HAVCR2), an immune checkpoint receptor. Immune checkpoint proteins are molecules that help to regulate the immune system so it does not mistakenly attack healthy cells. However, they can also keep immune cells from recognizing and killing cancer cells.~TIM-3 is found on the surface of certain T-cells, including tumor-infiltrating T-cells, that have left the bloodstream and migrated into the tumor environment. By binding to and blocking TIM-3, TRS-022 allows for T-cells to become activated so as to enhance T-cell-mediated attacks on tumors. These attacks reduce their growth."
112387|NCT03307785|Drug|Carboplatin Pemetrexed|Pemetrexed and platinum therapy in combination with pembrolizumab (anti-PD-1 antibody) has proven to be efficacious in a first line setting for nonsquamous NSCLC patients
112482|NCT03307044|Other|Questionnaire Administration|Ancillary studies
112388|NCT03307785|Drug|Carboplatin-Nab-Paclitaxel|Nab-paclitaxel is a formulation of paclitaxel that is indicated for locally advanced or metastatic NSCLC, as first-line treatment in combination with carboplatin in patients who are not candidates for curative surgery or radiation therapy. Nab-paclitaxel has shown increased ORR and time to progression in metastatic breast cancer compared with solvent-based paclitaxel and has shown antitumor activity and improved ORR compared with solvent-based paclitaxel as first-line therapy in patients with NSCLC.
112389|NCT03307772|Dietary Supplement|Probiotics|
112390|NCT03307772|Dietary Supplement|Prebiotics|
112391|NCT03307772|Dietary Supplement|Prebiotics and Probiotics|
112392|NCT03307772|Dietary Supplement|Placebo|
112393|NCT03307759|Drug|Pembrolizumab|Pembrolizumab
112394|NCT03307759|Radiation|Radiotherapy (SABR)|Radiotherapy
112395|NCT03307746|Drug|Varlilumab|"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
112396|NCT03307733|Behavioral|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
112397|NCT03307720|Drug|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
112398|NCT03307720|Drug|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
112399|NCT03307694|Diagnostic Test|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
112400|NCT03307694|Diagnostic Test|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
112401|NCT03307694|Diagnostic Test|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
112402|NCT03307681|Other|White bread|Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.
112403|NCT03307681|Other|Baked potato with skin|Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).
112404|NCT03307681|Other|Mashed potato served hot|Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.
112405|NCT03307681|Other|Fried French fries|Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.
112406|NCT03307681|Other|Meal skipping|No food given
112407|NCT03307668|Device|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
112408|NCT03307668|Device|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
112409|NCT03307655|Other|Control (fertile semen donors)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
112410|NCT03307655|Other|Patients (subfertile men)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
112411|NCT03307642|Other|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
112412|NCT03307629|Drug|NOX66|NOX66 delivered as rectal suppository.
112413|NCT03307629|Radiation|Irradiation Therapy|Radiation per selected tumour lesion.
112414|NCT03307616|Biological|Ipilimumab|Given IV
112415|NCT03307616|Biological|Nivolumab|Given IV
112416|NCT03307616|Radiation|Radiation Therapy|Undergo radiation therapy
112417|NCT03307603|Radiation|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
112418|NCT03307603|Drug|Phase Ib - nivolumab|240 mg intravenously
112419|NCT03307603|Drug|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
112422|NCT03307577|Drug|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
112423|NCT03307577|Other|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
112424|NCT03307564|Device|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
112425|NCT03307551|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
112426|NCT03307551|Drug|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
112427|NCT03307538|Radiation|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
112428|NCT03307512|Drug|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
112429|NCT03307512|Drug|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
112430|NCT03307499|Other|NeoPatch|NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
112431|NCT03307473|Behavioral|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
112432|NCT03307460|Drug|68Ga-NOTA-AE105|PET/MRI scan
112433|NCT03307447|Drug|Secukinumab|Secukinumab 300 mg subcutaneous injection
112434|NCT03307434|Other|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
112435|NCT03307434|Other|regular training|The regular training will be performed by control group according to the standard practice.
112436|NCT03307421|Other|debriefing without instructor|"The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.~The sequence of scenarios for each binomial will also be determined by randomization."
112437|NCT03307421|Other|debriefing with instructor|The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
112438|NCT03307408|Other|blood collection|Standard routine practice clinico-biological data will be collected
112439|NCT03307395|Procedure|Middel Meningeal Artery Embolization|Blood supply to the subdural hematoma via the middle meningeal artery is interrupted.
112440|NCT03307382|Device|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
112441|NCT03307356|Other|Uterine Transplant|Transplant of a uterus from a deceased donor
112442|NCT03307343|Behavioral|Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
112443|NCT03307278|Biological|House dust mite|As a stimulant to induce inflammasome activation
112444|NCT03307265|Device|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
112445|NCT03307265|Device|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
112446|NCT03307252|Drug|Digoxin|Tablet
112447|NCT03307252|Drug|Furosemide|Oral solution
112448|NCT03307252|Drug|Metformin|Oral solution
112449|NCT03307252|Drug|Rosuvastatin|Film-coated tablet
112450|NCT03307252|Drug|Verapamil|Film-coated tablet
112451|NCT03307252|Drug|Rifampin|Film-coated tablet
112452|NCT03307252|Drug|Cimetidine|Tablet
112453|NCT03307252|Drug|Probenecid|Tablet
112454|NCT03307239|Other|cold application|"We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.~For patients of the experimental group, they were received 15-minutes cold application."
112455|NCT03307239|Other|tap water packs application|"We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.~For patients of the sham group, they were received 15-minutes tap water application."
112483|NCT03307031|Other|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
112484|NCT03307031|Other|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
112456|NCT03307226|Behavioral|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
112457|NCT03307226|Behavioral|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
112458|NCT03307213|Device|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
112459|NCT03307213|Device|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
112460|NCT03307187|Behavioral|GLB Adapted for Individuals with Impaired Mobility|The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
112461|NCT03307174|Drug|Bupivacaine|
112462|NCT03307174|Drug|Fentanyl|
112463|NCT03307161|Other|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
112464|NCT03307148|Drug|ATRA|Administered orally on D1-15 of each 28 day cycle.
112465|NCT03307148|Drug|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
112466|NCT03307148|Drug|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
112467|NCT03307135|Device|single assessment with the MSPMI|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
112468|NCT03307135|Device|double assessment with the MSPMI with 7 days of interval|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
112469|NCT03307135|Device|double assessment with the MSPMI before and after treatment|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
112470|NCT03307122|Other|Routine Infant Formula 1|Routine infant formula with probiotic
112471|NCT03307122|Other|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
112472|NCT03307109|Other|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
112473|NCT03307096|Procedure|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
112474|NCT03307096|Procedure|FURS|Parents are treated by FURS
112475|NCT03307083|Other|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
112476|NCT03307070|Behavioral|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
112477|NCT03307070|Other|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
112478|NCT03307057|Behavioral|Social Communication Growth Charts (SCGC)|The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
112479|NCT03307057|Behavioral|Parent-Implemented (P-I) Condition|"The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.~Weekly home sessions with a family navigator include:~developing the visit agenda~intervention implementation including: guided/caregiver practice, feedback and problem solving~planning for parent implementation between sessions~Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat."
112480|NCT03307057|Behavioral|Clinician-Implemented (C-I) Condition|The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
112481|NCT03307044|Procedure|Laser Therapy|Undergo fractional CO2 laser therapy
112486|NCT03307018|Procedure|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
112487|NCT03307005|Drug|Zolpidem Tartrate|Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
112488|NCT03307005|Drug|Placebo oral capsule|Placebo capsule one per night taken for 7 nights
112489|NCT03306992|Behavioral|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).~For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face meetings (~30-40 minutes) or during the weekly phone calls. An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
112490|NCT03306979|Drug|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
112491|NCT03306979|Other|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.The initial placebo dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
112492|NCT03306966|Device|Endoscopic Linear Cutter Stapler and Reloads (Frankenman)|The Single Use Endoscopic Linear Cutter Stapler and Reloads from Frankenman received CE-mark in April 2013. It is used to staple and simultaneously divide tissue from the central line.
112493|NCT03306953|Procedure|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
112494|NCT03306940|Drug|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
112495|NCT03306927|Dietary Supplement|Whole yellow pea chili|Chili containing whole yellow peas
112496|NCT03306927|Dietary Supplement|Split yellow pea chili|Chili containing split yellow peas
112497|NCT03306927|Dietary Supplement|Rice chili|Chili containing long grain white rice
112498|NCT03306914|Other|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
112499|NCT03306914|Other|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
112500|NCT03306914|Drug|Albumin 5%|Infusion of Albumin 5% intra-operatively
112501|NCT03306914|Drug|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
112502|NCT03306901|Procedure|Esophagectomy|Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy
112503|NCT03306901|Drug|5-fluorouracil|3,200 ~ 4,000mg/m2 intravenously for 4 to 5 days.
112504|NCT03306901|Drug|Cisplatin|45~60mg intravenously over 1 hour on day 1
112505|NCT03306901|Radiation|Radiation therapy|45 Gy irradiation (5 days a week for 5 weeks)
112506|NCT03306888|Other|Physical Activity Coaching|Physical activity coaching over 4 months
112507|NCT03306875|Behavioral|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
112508|NCT03306862|Dietary Supplement|Whole yellow pea soup|Soup containing whole yellow peas
112509|NCT03306862|Dietary Supplement|Split yellow pea soup|Soup containing split yellow peas
112510|NCT03306862|Dietary Supplement|Potato soup|Soup containing potatoes
112511|NCT03306836|Drug|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
112512|NCT03306836|Drug|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
112513|NCT03306810|Other|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
112514|NCT03306797|Other|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:~wrist~ulnarization radialization~prono-supination~horizontal flexion-extension~vertical flexion-extension hand~grasping~pinching~extensors~interosseous shoulder-elbow~vertical flexion-extension~push forward"
112515|NCT03306797|Device|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.~With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.~With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
112516|NCT03306784|Other|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
112517|NCT03306771|Diagnostic Test|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
112518|NCT03306758|Drug|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
112519|NCT03306745|Dietary Supplement|Profertil female|"For micronutrient ingredients please see details above. PROfertil ® female is approved in Austria by the Austrian Ministry of Health and has a Free Sales Certificate."
112520|NCT03306745|Dietary Supplement|Folic acid 400 mg|Folic acid 400 mg
112657|NCT03305718|Other|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
112521|NCT03306732|Drug|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"After anesthesia induction~After separation from CPB~On the evening of the day of surgery (22:00)~On POD 1 twice a day at 8:00 and 22:00~On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
112522|NCT03306732|Drug|Normal saline (100ml)|"After anesthesia induction~After separation from CPB~On the evening of the day of surgery (22:00)~On POD 1 twice a day at 8:00 and 22:00~On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
112523|NCT03306719|Biological|Blood sampling|Serial blood sampling
112524|NCT03306706|Dietary Supplement|Whole pea muffins|2 muffins containing whole peas
112525|NCT03306706|Dietary Supplement|Split pea muffins|2 muffins containing split peas
112526|NCT03306706|Dietary Supplement|Wheat muffins|2 muffins containing wheat
112527|NCT03306693|Behavioral|Emotional skills|2-hour 3 group sessions
112528|NCT03306693|Behavioral|Relaxation and talking group|2-hour 3 group sessions
112529|NCT03306680|Radiation|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
112530|NCT03306667|Drug|FYU-981|Oral single dosing
112531|NCT03306654|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
112532|NCT03306628|Other|CO2 Laser Administration|The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
112533|NCT03306615|Drug|Hyaluronidase|1200 units (8 vials) of HYLENEX recombinant, will be diluted with 8 ml of 0.9% Sodium Chloride Injection, USP - Preservative-Free, Diluent in a 1:1 ratio (total volume = 16 mL) and dispensed in two 10 ml syringes (8ml in each syringe) for intramuscular injection.
112534|NCT03306615|Drug|Placebo|The placebo will consist of 16 ml of 0.9% Sodium Chloride Injection, USP - Preservative-Free, also dispensed in two 10 ml syringes for intramuscular injection. The label will include a statement that the product is limited to investigational use, and the original drug containers will be retained.
112535|NCT03306602|Device|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
112536|NCT03306602|Device|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
112537|NCT03306589|Biological|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
112538|NCT03306589|Biological|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
112539|NCT03306589|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
112540|NCT03306589|Drug|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
112541|NCT03306576|Device|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
112542|NCT03306576|Device|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
112543|NCT03306563|Diagnostic Test|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
112544|NCT03306550|Drug|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
112545|NCT03306550|Drug|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
112546|NCT03306537|Device|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
112547|NCT03306524|Device|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
112548|NCT03306524|Device|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
112549|NCT03306524|Device|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
112550|NCT03306524|Device|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
112551|NCT03306524|Device|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
112552|NCT03306524|Device|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
112553|NCT03306524|Device|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
112554|NCT03306524|Device|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
112555|NCT03306524|Device|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
112556|NCT03306524|Device|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
112557|NCT03306511|Other|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
112658|NCT03305718|Other|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
112558|NCT03306498|Drug|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
112559|NCT03306485|Other|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
112560|NCT03306472|Drug|Megestrol Acetate 40 MG|Progesterone Agonist
112561|NCT03306472|Drug|Megestrol Acetate 160 MG|Progesterone Agonist
112562|NCT03306472|Drug|Letrozole|Aromatase Inhibitor
112563|NCT03306459|Diagnostic Test|SF-36 (Short Form Health Survey)|"Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).~State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.~Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score."
112564|NCT03306446|Drug|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
112565|NCT03306433|Device|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
112566|NCT03306420|Drug|MS201408-0005A|Subjects will receive MS201408-0005A in 28-day cycles until confirmed disease progression or unacceptable toxicity.
112567|NCT03306420|Drug|MS201408-0005C|Subjects will receive MS201408-0005C in 28-day cycles until confirmed disease progression or unacceptable toxicity.
112568|NCT03306420|Drug|MS201408-0005B|Subjects will receive MS201408-0005B in 28-day cycles until confirmed disease progression or unacceptable toxicity.
112569|NCT03306407|Other|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
112570|NCT03306394|Drug|Trifluridine/Tipiracil hydrochloride (S95005)|
112571|NCT03306381|Other|Dietary intervention|Elimination of certain products.
112572|NCT03306368|Behavioral|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:~XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
112573|NCT03306355|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
112574|NCT03306355|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
112575|NCT03306342|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
112576|NCT03306329|Drug|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
112577|NCT03306329|Drug|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
112578|NCT03306329|Drug|Placebo|Placebo tablets administered once daily
112579|NCT03306316|Dietary Supplement|Prebiotic|Prebiotic experimental group
112580|NCT03306316|Dietary Supplement|Dextrose Control|Dextrose Control
112581|NCT03306290|Drug|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.~Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (~30 min), 1 tube (5 ml) of blood will be withdrawn~Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)~Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
112582|NCT03306277|Biological|Onasemnogene Abeparvovec-xioi|Non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
112583|NCT03306264|Drug|ASTX727|ASTX727 is a tablet for oral administration, containing the fixed-dose combination of 100 mg cedazuridine (a cytidine deaminase inhibitor) and 35 mg decitabine, given by mouth Dailyx5 in 28-day cycles (in Cycle 1 or Cycle 2, then in Cycle 3 and beyond).
112584|NCT03306264|Drug|Dacogen|Decitabine 20 mg/m^2 one-hour IV infusion Dailyx5 (in one 28-day cycle: either Cycle 1 or Cycle 2).
112585|NCT03306238|Procedure|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
112586|NCT03306238|Procedure|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
112587|NCT03306212|Drug|Botulinum toxin A|
112590|NCT03306199|Device|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
112591|NCT03306186|Device|HemoSpec|Blood sampling for analysis
112592|NCT03306173|Other|Commercially available cigarette|Commercially available cigarette with either ~0% or ~25% filter ventilation. Menthol flavor will be available in both types.
112593|NCT03306160|Other|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
112594|NCT03306147|Behavioral|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
112595|NCT03306134|Diagnostic Test|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.~Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire [4]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.~All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
112596|NCT03306121|Drug|TPF+CCRT|"Patients receive paclitaxel liposome (135mg/m2 on day 1) , cisplatin (25mg/m2 on day 1-3) and 5-fluorouracil (750mg/m2 civ 120h) every three weeks for three cycles of induction chemotherapy before radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
112597|NCT03306121|Drug|CCRT+ PF|"Patients receive cisplatin (80mg/m2 on day 1) and 5-fluorouracil (1000mg/m2 civ 96h) every four weeks for three cycles 4 weeks after radiotherapy.~Patients receive IMRT and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy (D1,D22,D43 of RT)"
112598|NCT03306108|Device|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
112599|NCT03306095|Other|Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
112600|NCT03306095|Other|Delayed refeeding group|Food Intake by patient after 4 hours i.e > 4 hours after the EVL procedure
112601|NCT03306082|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
112602|NCT03306069|Other|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
112603|NCT03306069|Other|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).~HIIT:~2 sessions per week~session 1: 2x4 min / session 2: 5x1 min, each at 85-95% HRmax~time-effort per week: ~30 min"
112604|NCT03306069|Other|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).~MIIT-HR:~2 sessions per week~session 1: 2x4 min / session 2: 5x1 min, each at 65-75% HRmax~time-effort per week: ~30 min"
112605|NCT03306069|Other|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).~MIIT-LT:~2 sessions per week~session 1: 2x4 min / session 2: 5x1 min, each at 105% LT~time-effort per week: ~30 min"
112606|NCT03306056|Other|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
112607|NCT03306056|Other|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~5 strength training exercises (chest, upper/lower back, abdominals, legs)~3 sets per exercise~time-effort per session: ~90 min~2 training sessions per week~duration of exercise intervention: 12 weeks"
112608|NCT03306056|Other|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~5 strength training exercises (chest, upper/lower back, abdominals, legs)~1 set per exercise~time-effort per session: ~20 min~2 training sessions per week~duration of exercise intervention: 12 weeks"
112609|NCT03306056|Other|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~time-effort per session: ~20 min~duration of exercise intervention: 12 weeks"
112610|NCT03306043|Drug|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
112611|NCT03306030|Drug|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
112612|NCT03306030|Drug|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
112613|NCT03306017|Other|Blood sampling|Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
112614|NCT03306004|Other|Questionare|
112615|NCT03305978|Device|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
112616|NCT03305978|Device|Low dose chest CT|standard diagnostic low dose chest CT
112617|NCT03305965|Behavioral|Patient navigation|Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
112618|NCT03305952|Behavioral|CBCT|
112619|NCT03305952|Other|TAU|
112620|NCT03305939|Behavioral|Life style Intervention|"The intervention will include 4 face-to-face group sessions in the first 6 months, followed by remote support strategies and intensification counseling sessions when needed. Ongoing support and contact shown to be important in supporting behavior change will consist of reminders, and motivational messages for small actionable behaviors, delivered using mobile text or voice messages. Program intensification will be offered to women who fail to meet their weight goals by the 6 month time point. All phases of the program focus on self- management across 3 themes~simple healthy eating and moderate physical activity messages;~behavioral skills such as problem solving/goal setting/self-monitoring; and~enhancing internal motivation, self-efficacy and self-management. The program is deliberately not prescriptive, and has a focus on sustainable behaviors and local context."
112621|NCT03305926|Other|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
112622|NCT03305926|Other|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
112623|NCT03305926|Other|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
112624|NCT03305926|Other|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
112625|NCT03305913|Drug|TAS 102|TAS-102 tablet
112626|NCT03305913|Drug|Regorafenib|Regorafenib tablet
112627|NCT03305900|Other|No Intervention|Cross-sectional study requiring a single serum sample
112628|NCT03305887|Device|STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue|This devices will be used in deep and intermediate layers of barbed suture group.
112629|NCT03305887|Device|CR8 VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
112630|NCT03305887|Device|STRATAFIX Spiral PGA-PCL sutures|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
112631|NCT03305887|Device|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
112632|NCT03305874|Other|Exposure to CBCIN risk score|The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
112633|NCT03305861|Procedure|ThuLEP|Thulium laser enucleation of prostate
112634|NCT03305861|Procedure|Green LEP|Greenlight laser enucleation of prostate
112635|NCT03305848|Drug|Nitrostat 0.4Mg Sublingual Tablet|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure > 100 mmHg.
112636|NCT03305822|Drug|LY900014|Administered SC
112637|NCT03305822|Drug|Insulin Lispro|Administered SC
112638|NCT03305809|Drug|LY3154207|Administered orally.
112639|NCT03305809|Drug|Placebo|Administered orally.
112640|NCT03305796|Radiation|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
112641|NCT03305783|Procedure|cholecystectomy|elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
112642|NCT03305770|Device|verofilcon A contact lenses|Daily disposable soft contact lenses
112643|NCT03305770|Device|delefilcon A contact lenses|Daily disposable soft contact lenses
112644|NCT03305757|Drug|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
112645|NCT03305757|Procedure|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
112646|NCT03305757|Procedure|Conventional|Conventional closure after mastectomy
112647|NCT03305731|Behavioral|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
112648|NCT03305718|Other|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
112649|NCT03305718|Other|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
112650|NCT03305718|Other|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
112651|NCT03305718|Other|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
112652|NCT03305718|Other|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
112653|NCT03305718|Other|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
112654|NCT03305718|Other|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
112655|NCT03305718|Other|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
112656|NCT03305718|Other|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
112659|NCT03305718|Other|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
112660|NCT03305705|Drug|Iron Carboxymaltose|Single intravenous infusion within 20 min
112661|NCT03305705|Drug|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
112662|NCT03305692|Diagnostic Test|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
112663|NCT03305679|Procedure|Direct provisional technique|The method of implantation will be accomplished directly.
112664|NCT03305679|Procedure|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
112665|NCT03305666|Drug|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
112666|NCT03305666|Drug|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
112667|NCT03305653|Device|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
112668|NCT03305640|Procedure|acetabular fracture surgery|acetabular fracture surgery
112669|NCT03305627|Other|Short PAP|Perioperative antibiotic prophylaxis for 24h
112670|NCT03305627|Other|Extended PAP|Perioperative antibiotic prophylaxis for >48h
112671|NCT03305614|Device|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
112672|NCT03305614|Behavioral|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
112673|NCT03305601|Other|application on smarthphone|application on smarthphone
112674|NCT03305588|Device|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
112675|NCT03305575|Drug|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
112676|NCT03305575|Drug|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.~During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
112677|NCT03305549|Other|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):~Blood urea nitrogen >112 mg/dL (40 mmol/L)~Serum potassium concentration >6 mmol/L~Serum potassium concentration >5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)~Arterial blood gas pH <7.15 in a context of pure metabolic acidosis (PaCO2 <35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate <12 mmol/L~Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min to maintain SpO2 >95% or requiring FiO2 >50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
112678|NCT03305549|Other|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
112679|NCT03305536|Dietary Supplement|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
112680|NCT03305523|Device|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
112681|NCT03305510|Diagnostic Test|vitamin D is below 20ng/ml|
112682|NCT03305497|Behavioral|Mobile Phone Application|110 persons will be equipped with a mobile phone application, trained in overdose prevention, and equipped with naloxone. The mobile phone app will allow persons witnessing an overdose to signal persons in the vicinity to respond with naloxone.
112683|NCT03305484|Other|No intervention|No intervention, observation only
112684|NCT03305471|Drug|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
112685|NCT03305471|Drug|Placebo|Placebo matching stock solution in bottle
112686|NCT03305471|Drug|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
112687|NCT03305471|Drug|DS-2330b Tablet|DS-2330b as tablet formulation
112688|NCT03305458|Behavioral|TFCBT|treatment as usual
112689|NCT03305458|Behavioral|eTFCBT|tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
112690|NCT03305445|Drug|Ipilimumab|Ipilimumab (1mg/kg)
112691|NCT03305445|Drug|Nivolumab|Nivolumab (3mg/kg)
112692|NCT03305432|Combination Product|sleeve + preoperative PPI|sleeve + preoperative PPI
112693|NCT03305432|Combination Product|sleeve + preoperative Placebo|sleeve + preoperative Placebo
112694|NCT03305419|Drug|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
112695|NCT03305419|Drug|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
112696|NCT03305406|Other|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
112697|NCT03305406|Other|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
112698|NCT03305393|Device|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
112699|NCT03305380|Other|No interventions|As this is a patient registry, there are no interventions.
112700|NCT03305367|Dietary Supplement|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGTT with no oil, low dose or high dose.
112701|NCT03305354|Behavioral|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
112702|NCT03305354|Behavioral|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
112703|NCT03305341|Drug|NDA Etoposide - study|Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule
112704|NCT03305341|Drug|NDA Etoposide - usual|Etoposide Injection plus Methotrexate Injection plus Topotecan Injection
112705|NCT03305328|Device|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
112706|NCT03305315|Other|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
112707|NCT03305315|Other|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
112708|NCT03305302|Procedure|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
112709|NCT03305289|Procedure|pulsed Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
112710|NCT03305289|Procedure|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
112711|NCT03305263|Drug|Hydroxychloroquine|One tablet a day from inclusion until end of pregnancy or gestational age 28
112712|NCT03305263|Drug|Hydroxychloroquine placebo|One tablet a day from inclusion until end of pregnancy or gestational age 28
112713|NCT03305250|Device|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
112714|NCT03305237|Other|Big Breakfast|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
112715|NCT03305237|Other|Big Dinner|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
112716|NCT03305224|Drug|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
112717|NCT03305211|Other|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
112718|NCT03305198|Biological|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
112719|NCT03305185|Combination Product|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
112720|NCT03305185|Device|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
112721|NCT03305172|Behavioral|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
112722|NCT03305159|Drug|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
112723|NCT03305159|Drug|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
112724|NCT03305146|Genetic|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.~For molecular biology technique, the samples will be processed within the UMR_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).~The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( <50ng) DNA."
112725|NCT03305133|Other|Immunohistochemistry|The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.
112726|NCT03305120|Other|pain VAS evaluation|each patient has to answer to a questionnaire about pain
112727|NCT03305107|Other|Exercise and Chocolate Milk|High intensity interval exercise Chocolate Milk
112728|NCT03305107|Other|Exercise and Water|High intensity interval exercise Water
112729|NCT03305107|Other|Sitting and Chocolate Milk|Sitting Chocolate Milk
112730|NCT03305107|Other|Sitting and Water|Sitting Water
112731|NCT03305094|Procedure|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
112732|NCT03305081|Device|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
112733|NCT03305068|Drug|Celecoxib|
112734|NCT03305055|Drug|ketamine|Information included in arm descriptions
112735|NCT03305055|Drug|Fentanyl|Information included in arm descriptions
112736|NCT03305029|Drug|SCNT-hES-RPE Cells|Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
112737|NCT03305016|Drug|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
112738|NCT03305003|Other|Spiral notebook|
112739|NCT03305003|Other|Mobile application|
112740|NCT03304990|Other|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
112741|NCT03304977|Other|questionnaire via smartphone|questionnaire via smartphone
112742|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
112743|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
112744|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
112745|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
112746|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
112747|NCT03304951|Device|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
112748|NCT03304938|Drug|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
112749|NCT03304938|Drug|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
112750|NCT03304925|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
112751|NCT03304912|Behavioral|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
112752|NCT03304899|Drug|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
112753|NCT03304873|Drug|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
112754|NCT03304873|Drug|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
112755|NCT03304860|Other|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
112756|NCT03304847|Other|ablation|radio-frequency applications on arrhythmogenic substrate
112757|NCT03304834|Device|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
112758|NCT03304821|Drug|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
112895|NCT03303690|Procedure|Ankle Spacer (AS)|All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
112896|NCT03303677|Drug|Saline Nasal|topical nasal saline rinses
112759|NCT03304821|Drug|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
112760|NCT03304808|Device|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
112761|NCT03304808|Behavioral|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.~Four exercise:~Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .~Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.~Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating~Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
112762|NCT03304782|Other|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
112763|NCT03304769|Device|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
112764|NCT03304756|Drug|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
112765|NCT03304743|Diagnostic Test|Dental panoramic radiograph|"If not performed within the previous 12 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.~OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
112766|NCT03304717|Drug|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.~Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
112767|NCT03304717|Other|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
112768|NCT03304652|Drug|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
112769|NCT03304652|Other|Natural Sleep|Natural Sleep without medication
112770|NCT03304639|Biological|Pembrolizumab|Given IV
112771|NCT03304639|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
112772|NCT03304626|Drug|Budesonide 3Mg Capsule|Budesonide capsule in place of prednisone (standard of care)
112773|NCT03304613|Behavioral|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
112774|NCT03304613|Behavioral|Promoting Resilience through Innovative Self-Management|Already noted.
112775|NCT03304600|Device|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
112776|NCT03304600|Device|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
112777|NCT03304587|Diagnostic Test|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
112778|NCT03304587|Diagnostic Test|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
112779|NCT03304587|Other|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
112780|NCT03304587|Other|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
112781|NCT03304587|Diagnostic Test|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
112782|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.
112897|NCT03303677|Drug|Budesonide Nasal|saline + budesonide nasal saline irrigation
112972|NCT03302988|Other|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
112783|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
112784|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
112785|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
112786|NCT03304587|Other|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
112787|NCT03304587|Other|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
112788|NCT03304587|Other|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
112789|NCT03304587|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
112790|NCT03304587|Other|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue & sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
112791|NCT03304574|Behavioral|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
112792|NCT03304561|Other|Traditional rehabilitation|traditional ACL rehabilitation program
112793|NCT03304561|Other|Cross-over training|Cross-over training addition to the traditional rehabilidation
112794|NCT03304548|Other|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
112795|NCT03304522|Drug|VX-150|1250 mg total dose administered as 250-mg capsules orally
112796|NCT03304522|Drug|Placebo|Matching Placebo
112797|NCT03304509|Other|Telematic follow-up|Telematic follow-up by using a platform with videoconference
112798|NCT03304496|Drug|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
112799|NCT03304496|Drug|Saline Solution|Previously described.
112800|NCT03304483|Other|246-km running|Spartathlon 2017
112801|NCT03304470|Drug|ATx201 2% Cream|Anhydrous Cream
112802|NCT03304470|Drug|ATx201 Cream Vehicle|Anhydrous Cream
112803|NCT03304457|Drug|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
112804|NCT03304457|Drug|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
112805|NCT03304444|Drug|Bupivacaine|bupivacaine hydrochloride used in TAP block
112806|NCT03304444|Drug|liposomal bupivacaine|liposomal bupivacaine used in TAP block
112807|NCT03304431|Drug|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
112808|NCT03304418|Drug|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg (1.49 mCi)/kg (+/- 10% total dose) for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
112809|NCT03304418|Radiation|Radiation|"All external beam radiations oligometastatic sites will commence 1 to 2 weeks after administration of Cycle 1 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.~Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:~Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)~Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)~Five fractions: 30 Gy total at 6Gy per fraction (SBRT)~Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
112931|NCT03303391|Other|Intradialytic Blood Pressure Slope Based Ultrafiltration|Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
112810|NCT03304405|Diagnostic Test|Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
112811|NCT03304392|Behavioral|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
112812|NCT03304392|Behavioral|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
112813|NCT03304379|Drug|Fasinumab|Solution for injection in pre-filled syringe
112814|NCT03304379|Other|Diclofenac|NSAID active comparator (capsule)
112815|NCT03304379|Other|Celecoxib|NSAID active comparator (capsule)
112816|NCT03304379|Drug|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
112817|NCT03304366|Diagnostic Test|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
112818|NCT03304353|Other|Self-managed protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day."
112819|NCT03304353|Other|Predetermined protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.~The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards."
112820|NCT03304340|Device|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
112821|NCT03304340|Device|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device & Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
112822|NCT03304340|Other|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
112823|NCT03304327|Behavioral|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
112824|NCT03304314|Diagnostic Test|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
112825|NCT03304301|Behavioral|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
112826|NCT03304288|Drug|Rituximab|Low-dose rituximab was used in combination with ATRA or as the monotherapy
112827|NCT03304288|Drug|All-trans retinoic acid|ATRA was used in combination with low-dose rituximab
112828|NCT03304275|Behavioral|Tdap|Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
112829|NCT03304262|Device|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
112830|NCT03304249|Behavioral|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
112831|NCT03304249|Other|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
113093|NCT03302078|Drug|BI 1015550|Fasted state
113094|NCT03302065|Drug|Tiotropium|
112832|NCT03304236|Device|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
112833|NCT03304223|Diagnostic Test|[18F]FB-IL2 PET scan|[18F]FB-IL2 PET scan procedure
112834|NCT03304210|Drug|PIPAC with Abraxane|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.
112835|NCT03304197|Dietary Supplement|Hypotonic|N/A: see arm description
112836|NCT03304197|Dietary Supplement|Isotonic|N/A: see arm description
112837|NCT03304197|Dietary Supplement|Placebo|N/A: see arm description
112838|NCT03304197|Other|Dehydrated|N/A: see arm description
112839|NCT03304184|Device|Photac-fil|Application of a tooth colored filling in a non-cavitated dental lesion.
112840|NCT03304184|Device|Biodentine|Application of a white colored filling in a non-cavitated dental lesion.
112841|NCT03304158|Behavioral|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
112842|NCT03304145|Other|The Carevive CPS|The Carevive Care Planning System (CPS) was developed to overcome challenges by providing an efficient, clinically integrated solution for both psychosocial and physical symptom distress screening and management through the delivery of personalized and evidence-based care plans at the point of care. The Carevive CPS simultaneously collects and aggregates discrete data for quality reporting and improvement.
112843|NCT03304132|Other|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
112844|NCT03304132|Other|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
112845|NCT03304106|Device|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
112846|NCT03304093|Drug|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
112847|NCT03304080|Drug|Anastrozole|1 mg orally daily, day 1 to day 28
112848|NCT03304080|Drug|Palbociclib|Dose I: 100 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to day 21, then 7 days off in a 28 day cycle
112849|NCT03304080|Drug|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
112850|NCT03304080|Drug|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
112851|NCT03304067|Behavioral|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view metrics from the devices, educational and clinical context content, and an asthma coach.
112852|NCT03304054|Drug|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
112853|NCT03304054|Drug|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
112854|NCT03304041|Dietary Supplement|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.~low-FODMAPs diet therapy for 3 weeks"
112855|NCT03304041|Dietary Supplement|Traditional dietary advice|"Traditional dietary advice(TDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period~traditional dietary advice for 3 weeks"
112856|NCT03304028|Device|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
112857|NCT03304028|Behavioral|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
112858|NCT03304028|Device|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
112859|NCT03304028|Other|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team…etc.
112860|NCT03304028|Behavioral|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
112861|NCT03304015|Behavioral|Behavioral Change Communications|HERrespect is developed by Business for Social Responsibility (BSR) and Change Associates. HERproject is one of BSR's numerous initiatives for improving women's lives through enhancement of access and knowledge (BSR, 2015). The factory-based component of HERrespect will be implemented by Change Associates. The intervention group will receive training (group session), research and consultancy services to the corporate and development sectors. HERrespect proposes to use the workplace as an incubator of dialogue among men and women to tackle underlying issues which allow violence against women and girls. Workplace offers a unique platform and environment to engage women who are gaining financial independence to reduce intimate partner violence and workplace violence.
112862|NCT03304002|Other|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
112863|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
112864|NCT03303989|Drug|MMF|Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
112865|NCT03303989|Drug|Placebo|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
112866|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
112867|NCT03303976|Biological|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
112868|NCT03303976|Biological|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
112869|NCT03303963|Diagnostic Test|Deeplex test, InSilixa chip assay, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:~Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)~Validating the InSilixa chip-based detection of resistance as a point of care test (Study 1 - phase 2)~Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
112870|NCT03303963|Diagnostic Test|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:~FDA microscopy~Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin"
112871|NCT03303950|Drug|Busulfan|Given IV
112872|NCT03303950|Drug|Cyclophosphamide|Given IV
112873|NCT03303950|Drug|Fludarabine|Given IV
112874|NCT03303950|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
112875|NCT03303950|Other|Laboratory Biomarker Analysis|Correlative studies
112876|NCT03303924|Drug|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
112877|NCT03303911|Drug|Cytisine|film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
112878|NCT03303898|Procedure|Blood sampling|sampling of 7 blood tubes
112879|NCT03303859|Diagnostic Test|Bacterial vaginosis|
112880|NCT03303846|Procedure|Magnetic Resonance Imaging|Undergo high risk breast cancer screening MRI
112881|NCT03303846|Procedure|Biospecimen Collection|Undergo blood and tissue sample collection
112882|NCT03303846|Other|Laboratory Biomarker Analysis|Correlative studies
112883|NCT03303833|Other|No intervention, observational study.|
112884|NCT03303807|Device|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
112885|NCT03303794|Drug|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
112886|NCT03303794|Drug|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
112887|NCT03303781|Other|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
112888|NCT03303768|Diagnostic Test|Ultrasound|Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
112889|NCT03303742|Other|deep chamfer|finish line marginal design of a full coverage crown preparation
112890|NCT03303742|Other|feather edge|finish line marginal design of a full coverage crown preparation
112891|NCT03303729|Dietary Supplement|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
112892|NCT03303729|Dietary Supplement|Cluster Dextrin|75 grams of Cluster Dextrin
112893|NCT03303729|Dietary Supplement|Placebo|75 grams of Glucose
112894|NCT03303703|Other|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
112898|NCT03303677|Drug|Topical Antibacterial (Product)|The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
112899|NCT03303664|Other|IMPROVE Protocol|Comprehensive pain management protocol
112900|NCT03303651|Procedure|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
112901|NCT03303651|Procedure|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
112902|NCT03303638|Behavioral|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
112903|NCT03303625|Biological|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1*10^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
112904|NCT03303625|Biological|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5*10^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
112905|NCT03303625|Drug|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
112906|NCT03303612|Device|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
112907|NCT03303612|Device|Transcutaneous cardiac monitor|The transcutaneous cardiac monitor is applied to the skin on the thorax. It may be necessary to shave the area. The monitor is water resistant and can be used in the shower. The monitor's location needs to be changed every 7 days. Instructions will be supplied to the patient.
112908|NCT03303586|Other|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
112909|NCT03303586|Other|Control|Participants will not wearing compression stockings for two weeks.
112910|NCT03303573|Drug|recombinant human erythropoietin|Subcutaneous rhEPO injection
112911|NCT03303547|Diagnostic Test|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
112912|NCT03303534|Dietary Supplement|ScandiShake|weight gain supplement low in protein
112913|NCT03303521|Drug|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
112914|NCT03303521|Drug|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
112915|NCT03303508|Diagnostic Test|anti-ds DNA|venous blood samples
112916|NCT03303495|Biological|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
112917|NCT03303495|Drug|CPT-11|180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
112918|NCT03303495|Drug|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
112919|NCT03303495|Drug|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
112920|NCT03303495|Drug|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
112921|NCT03303482|Behavioral|Enhancing Trauma Awareness (Diane Wagenhals, MEd—Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
112922|NCT03303469|Drug|FMISO|FMISO PET/CT imaging at baseline
112923|NCT03303469|Drug|FMISO|FMISO PET/CT post TACE
112924|NCT03303469|Drug|FMISO|FMISO PET/CT post SBRT
112925|NCT03303456|Other|Mobile health application - Ginger.io|the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
112926|NCT03303430|Diagnostic Test|MRI|Diffusion weighted imaging 24 hours after revascularisation
112927|NCT03303417|Diagnostic Test|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
112928|NCT03303417|Other|Kiwifruit|Kiwifruit
112929|NCT03303417|Other|calorie-matched sugar drink|calorie-matched sugar drink
112930|NCT03303404|Device|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
112932|NCT03303378|Drug|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.~The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
112933|NCT03303378|Drug|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
112934|NCT03303365|Radiation|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.~In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).~Dose prescription to the PTV for target lesions will be as follows:~20 Gy to the 70%-isodose (lesions < 2 cm max. diameter)~18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~6 x 5 Gy to the conformally surrounding isodose (lesions > 3 cm max. diameter)"
112935|NCT03303352|Procedure|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
112936|NCT03303339|Drug|Onvansertib|Onvansertib orally
112937|NCT03303339|Drug|Cytarabine|subcutaneously
112938|NCT03303339|Drug|Decitabine|intravenously
112939|NCT03303326|Behavioral|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
112940|NCT03303313|Drug|Cemdisiran|Subcutaneous (sc) injection of Cemdisiran
112941|NCT03303287|Behavioral|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
112942|NCT03303274|Procedure|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
112943|NCT03303248|Behavioral|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used with the standard of care visit with provider.
112944|NCT03303235|Drug|Methylergonovine|IV vs IM
112945|NCT03303222|Diagnostic Test|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
112946|NCT03303209|Other|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
112947|NCT03303196|Device|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
112948|NCT03303183|Device|Standard Impression technique|Silicone impression technique
112949|NCT03303183|Device|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
112950|NCT03303170|Device|Sebacia Microparticles|Topical microparticle suspension
112951|NCT03303170|Device|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
112952|NCT03303157|Other|no intervention|not relevant
112953|NCT03303144|Drug|Triferic|ferric pyrophosphate citrate
112954|NCT03303131|Other|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
112955|NCT03303118|Other|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
112956|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks or 12 weeks.
112957|NCT03303092|Drug|TEV-48125|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
112958|NCT03303092|Drug|Placebos|Placebo will be subcutaneously administered once monthly for 3 months.
112959|NCT03303079|Drug|TEV-48125|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
112960|NCT03303079|Drug|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
112961|NCT03303066|Drug|FG-4592|Oral
112962|NCT03303066|Drug|Placebo|Oral
112963|NCT03303053|Drug|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
112964|NCT03303053|Drug|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
112965|NCT03303053|Drug|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
112966|NCT03303040|Other|Electrical stimulation of hemidiaphragm|Electrical impulses
112967|NCT03303027|Device|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
112968|NCT03303027|Device|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
112969|NCT03303014|Device|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
112970|NCT03303001|Procedure|Subacromial high volume infiltration|This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL
112971|NCT03303001|Procedure|Subacromial conventional infiltration|This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
112973|NCT03302988|Other|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
112974|NCT03302975|Device|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
112975|NCT03302962|Behavioral|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
112976|NCT03302949|Dietary Supplement|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
112977|NCT03302936|Drug|Phenazopyridine|to be given preoperatively
112978|NCT03302923|Behavioral|Brisk walking|Prospective randomized clinical trial with 2 intervention groups and 1 control group.
112979|NCT03302910|Other|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
112980|NCT03302910|Other|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
112981|NCT03302910|Drug|Loop Diuretics|IV loop diuretics are commonly used in AHF management
112982|NCT03302910|Drug|Nitroglycerin|Nitroglycerin or nitrovasodilators are commonly used in AHF management
112983|NCT03302897|Biological|LEP-F1 + GLA-SE|Investigational vaccine
112984|NCT03302884|Other|biological sampling|Tumor and blood samples
112985|NCT03302871|Drug|Botulinum toxin type A|
112986|NCT03302871|Device|transcranial direct current stimulation|
112987|NCT03302871|Other|hybrid training model of CIMT and BIT|
112988|NCT03302871|Other|usual care|
112989|NCT03302858|Device|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
112990|NCT03302845|Drug|Omeprazole 40 MG|Omeprazole 40 mg capsule
112991|NCT03302845|Drug|Famotidine 40 mg|Famotidine 40 mg tablet
112992|NCT03302845|Drug|Telotristat ethyl 250 mg|Telotristat ethyl 250 mg tablet
112993|NCT03302832|Other|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
112994|NCT03302832|Other|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
112995|NCT03302819|Diagnostic Test|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
112996|NCT03302806|Other|Non interventional Study|
112997|NCT03302793|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
112998|NCT03302793|Device|tDCS|tDCS will be applied for 20 minutes.
112999|NCT03302793|Device|tDCS sham|
113000|NCT03302780|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
113001|NCT03302780|Device|tDCS|tDCS will be applied for 20 minutes.
113002|NCT03302780|Device|tDCS sham|
113003|NCT03302767|Other|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
113004|NCT03302754|Drug|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
113005|NCT03302741|Drug|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
113006|NCT03302741|Other|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
113007|NCT03302741|Device|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
113008|NCT03302741|Device|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
113095|NCT03302039|Drug|Single shot phenylephrine|A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
113009|NCT03302728|Drug|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
113010|NCT03302728|Drug|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
113011|NCT03302715|Genetic|Mucosal tissue sampling|Mucosal tissue sampling for DNA analysis
113012|NCT03302702|Other|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
113013|NCT03302689|Drug|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
113014|NCT03302689|Drug|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
113015|NCT03302676|Dietary Supplement|Chewing gum|
113016|NCT03302663|Diagnostic Test|MRI scan|Addition of advanced imaging sequences for fetal MRI
113017|NCT03302650|Drug|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
113018|NCT03302650|Drug|Normal saline|Patients will receive normal saline.
113019|NCT03302650|Drug|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
113020|NCT03302637|Other|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
113021|NCT03302611|Behavioral|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
113022|NCT03302598|Diagnostic Test|serum C-reactive protein|
113023|NCT03302585|Drug|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
113024|NCT03302585|Drug|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
113025|NCT03302572|Other|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
113026|NCT03302559|Other|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
113027|NCT03302559|Other|Facial cleanser|Facial cleanser in the morning and in the evening.
113028|NCT03302559|Other|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
113029|NCT03302559|Other|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
113030|NCT03302559|Device|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
113031|NCT03302546|Procedure|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
113032|NCT03302546|Procedure|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
113033|NCT03302533|Procedure|Total elbow arthroplasty|Implantation of a total elbow arthroplasty after distal humerus fracture
113034|NCT03302520|Device|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
113035|NCT03302520|Device|PEEK cage|PEEK cage
113036|NCT03302507|Procedure|BESS|Biportal endoscopic surgery
113037|NCT03302507|Procedure|ULBD|Unilateral laminotomy bilateral decompression
113038|NCT03302494|Device|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
113039|NCT03302494|Device|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
113040|NCT03302481|Other|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
113041|NCT03302455|Behavioral|eCBTI|The short-term eCBTI contains a one-week core course: daily listening to the 5-minute sleep course, recording the sleep diary, and selectively listening to audios of eCBTI tools. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
113042|NCT03302442|Other|Non interventional study|Not applicable - Non interventional Study
113043|NCT03302429|Other|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
113044|NCT03302429|Other|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
113045|NCT03302416|Drug|Hydrocortisone|
113046|NCT03302416|Radiation|[C-11]NOP-1A|
113047|NCT03302403|Genetic|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
113048|NCT03302403|Genetic|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
113049|NCT03302403|Genetic|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
113050|NCT03302403|Genetic|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
113051|NCT03302403|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
113052|NCT03302403|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
113053|NCT03302390|Procedure|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than <3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
113054|NCT03302377|Behavioral|physical activity counseling & Fitbit|Participants will receive individual counseling & guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
113055|NCT03302364|Drug|Risperidone|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
113056|NCT03302351|Drug|Dexmedetomidine|30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
113057|NCT03302351|Drug|ketamine|31 patients will receive intravenous ketamine 0.4 mg/kg.
113058|NCT03302351|Drug|Dexmetedomidine+Ketamine|33 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
113059|NCT03302338|Drug|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
113060|NCT03302338|Drug|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
113061|NCT03302325|Procedure|research blood draws|Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 3 times (including baseline and end of study).
113062|NCT03302299|Drug|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
113063|NCT03302299|Drug|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
113064|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
113065|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
113066|NCT03302273|Other|Corneal Epithelial Stem Cell Transplant|Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.
113067|NCT03302260|Behavioral|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
113068|NCT03302247|Biological|Nivolumab|Monoclonal antibody against non small cell lung cancer
113069|NCT03302247|Drug|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
113070|NCT03302234|Biological|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
113071|NCT03302234|Biological|ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
113072|NCT03302234|Other|placebo for ipilimumab|Normal saline solution administered as an IV infusion Q6W
113073|NCT03302221|Drug|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
113074|NCT03302221|Drug|0.25% ropivacaine epidural block|A 4-5 ml bolus of 0.25% ropivacaine was administered 1 h after the initiation of TEB.
113075|NCT03302221|Drug|0.5% ropivacaine local anaesthesia|local anaesthesia at the incision was induced by 0.5% ropivacaine by the surgeon just before the surgery.
113076|NCT03302208|Drug|Pregabalin|Pregabalin capsule 150 mg oral
113077|NCT03302208|Drug|Placebo|Placebo
113078|NCT03302195|Drug|Heparin|Based on patient body weight (UI/kg)
113079|NCT03302195|Procedure|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
113080|NCT03302182|Drug|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
113081|NCT03302182|Drug|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
113082|NCT03302169|Procedure|Radical prostatectomy with posterior rhabdosphincter reconstruction|To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.
113083|NCT03302169|Procedure|Radical prostatectomy without posterior rhabdosphincter reconstruction|Standard technique with a running suture to perform the urethrovesical anastomosis
113084|NCT03302156|Drug|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
113085|NCT03302143|Procedure|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
113086|NCT03302143|Procedure|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
113087|NCT03302130|Behavioral|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
113088|NCT03302130|Device|Arterial spin labeling MRI|Single PLD PCASL
113089|NCT03302130|Device|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
113090|NCT03302117|Other|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
113091|NCT03302091|Drug|BI 1467335|28 day treatment period
113092|NCT03302078|Drug|BI 1015550|Fed state
113096|NCT03302039|Drug|Fixed infusion phenylephrine.|Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
113097|NCT03302039|Drug|Variable infusion phenylephrine.|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
113098|NCT03302039|Drug|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
113099|NCT03302026|Behavioral|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
113100|NCT03302013|Procedure|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
113101|NCT03302013|Procedure|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
113102|NCT03302000|Other|Early Visual Stimulation|Early visual stimulation
113103|NCT03302000|Other|standard care|standard care
113104|NCT03301987|Other|Therapeutic exercise|30 minutes per day of therapeutic exercise
113105|NCT03301974|Procedure|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
113106|NCT03301974|Procedure|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
113107|NCT03301974|Procedure|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
113108|NCT03301948|Other|Overfeed|Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
113109|NCT03301948|Other|Energy Balance|Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
113110|NCT03301935|Procedure|Electrophysiology testing and exercise stress testing|Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
113111|NCT03301922|Behavioral|Work-focused Metacognitive therapy|Work-focused Metacognitive psychotherapy, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
113112|NCT03301922|Other|Waiting list|Waiting list
113113|NCT03301909|Device|PillCam™ Endoscopy System|Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
113114|NCT03301909|Drug|Bowel prep combination|Subject may be assigned to any bowel preparation combination.
113115|NCT03301896|Drug|LHC165|LHC165 intratumoral injection
113116|NCT03301896|Biological|PDR001|PDR001 infusion
113117|NCT03301883|Drug|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the arm description.
113118|NCT03301883|Drug|NSAIDs|Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
113119|NCT03301883|Drug|CSs|Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
113120|NCT03301883|Drug|MTX|Participants may receive MTX at a stable dose of less than or equal to (</=) 20 milligrams per square meter (mg/m^2).
113121|NCT03301870|Drug|ATx201 Gel 2%|2% active gel
113122|NCT03301870|Drug|ATx201 Gel 4%|4% active gel
113123|NCT03301870|Drug|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
113124|NCT03301870|Drug|Negative Control|Water for Injection, USP
113125|NCT03301870|Drug|ATx201 Placebo|matching placebo gel
113126|NCT03301857|Drug|Denosumab (Cohort A)|Cohort A: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
113127|NCT03301844|Combination Product|Blephapad Combo|"Blephapad Combo is used to cleanse, soften, sooth and decongest inflamed eyelids and cilia.~The combo also presents an applicator with a heatable tablet that is applied to the eyelid in order to clean and open occluded Meibomian glands, thereby allowing the production of lipids necessary for a healthy tear film. The heatable tablet is to be used prior to cleansing with Blephapad wipes."
113128|NCT03301844|Other|Standard treatment|Standard treatment, twice daily for one month, consisting in eyelid hygiene using wet, warm gauze.
113129|NCT03301831|Behavioral|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
113130|NCT03301818|Device|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
113131|NCT03301805|Drug|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~28 days a cycle."
113132|NCT03301792|Behavioral|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
113133|NCT03301779|Device|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
113134|NCT03301766|Drug|lidocaine 5% patch|transdermal patch
113162|NCT03301558|Drug|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
113135|NCT03301766|Drug|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
113136|NCT03301766|Drug|Non-medicated patch|non-medicated patch
113137|NCT03301740|Other|UF profiling during HD|"Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions."
113138|NCT03301740|Other|Conventional HD|Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
113139|NCT03301727|Other|Cognitive-Behavioural Therapy for Insomnia (CBT-I)|Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
113140|NCT03301714|Behavioral|Oral Health Education|Group based oral health education vs Individual motivational interviewing
113141|NCT03301701|Procedure|Radical prostatectomy|Radical prostatectomy
113142|NCT03301701|Radiation|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
113143|NCT03301688|Biological|Toripalimab|To compare the different drug batch number with different process
113144|NCT03301675|Other|Orange Juice (500 mL/d)|Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
113145|NCT03301662|Diagnostic Test|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
113146|NCT03301649|Drug|Ivermectin Lotion 0.5%|Ivermectin Lotion 0.5%
113147|NCT03301649|Drug|Placebo/Vehicle Lotion|Placebo
113148|NCT03301636|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
113149|NCT03301636|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks starting on day 1.
113150|NCT03301636|Drug|Indoximod|Indoximod will be administered orally every 12 hours starting at Day 1
113151|NCT03301623|Other|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
113152|NCT03301623|Other|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
113153|NCT03301610|Other|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
113154|NCT03301610|Other|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
113155|NCT03301597|Biological|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
113156|NCT03301597|Drug|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
113157|NCT03301584|Other|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.~Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.~Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.~Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.~Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
113158|NCT03301584|Other|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
113159|NCT03301571|Other|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
113160|NCT03301571|Other|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
113161|NCT03301571|Other|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
113163|NCT03301558|Drug|High dose sodium bicarbonate|3000 mg sodium bicarbonate
113164|NCT03301545|Procedure|Fast-Track to Bariatric Surgery|30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
113165|NCT03301532|Drug|Triheptanoin|Dietary supplementation with triheptanoin
113166|NCT03301506|Drug|Seladelpar 2 mg Capsule|Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.
113167|NCT03301506|Drug|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.
113168|NCT03301506|Drug|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.
113169|NCT03301493|Other|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
113170|NCT03301467|Drug|Avacopan|Orally administered
113171|NCT03301467|Drug|Avacopan Matching Placebo|avacopan matching placebo
113172|NCT03301454|Drug|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
113173|NCT03301441|Other|questionnaire ef-ID Migraine|"All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.~Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status."
113174|NCT03301428|Other|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
113175|NCT03301428|Other|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
113176|NCT03301415|Drug|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
113177|NCT03301402|Device|Air purifier|Air purifier with filter at automatic mode on all time
113178|NCT03301389|Other|Cardiac magnetic resonance imaging|The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
113179|NCT03301363|Device|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
113180|NCT03301350|Drug|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
113181|NCT03301350|Drug|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
113182|NCT03301350|Drug|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
113183|NCT03301350|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
113184|NCT03301350|Drug|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
113185|NCT03301350|Drug|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
113186|NCT03301337|Dietary Supplement|Meat protein absorption|Meat protein absorption when digested together with a full meal.
113187|NCT03301324|Device|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
113188|NCT03301311|Other|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
113189|NCT03301311|Other|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
113190|NCT03301298|Drug|SXC-2023|Oral capsule
113191|NCT03301298|Drug|Placebo oral capsule|Placebo given as oral capsule.
113192|NCT03301285|Drug|Zoledronic Acid|Treatment of osteoporosis
113193|NCT03301272|Drug|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
113194|NCT03301272|Other|Placebo|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
113374|NCT03300037|Device|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
113195|NCT03301259|Other|One-shape rotationary system|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
113196|NCT03301246|Device|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
113197|NCT03301233|Drug|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
113198|NCT03301220|Drug|Daratumumab SC: daratumumab + rHuPH20|Participants will receive daratumumab SC injection (daratumumab 1800 mg + rHuPH20 [2000 U/mL]) once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) until 39 cycles or up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study termination or study completion. Each cycle is 28 days in duration.
113199|NCT03301207|Drug|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
113200|NCT03301207|Drug|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
113201|NCT03301207|Drug|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
113202|NCT03301207|Drug|Midazolam|Midazolam 2 mg (1 milliliter [mL]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
113203|NCT03301194|Other|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
113204|NCT03301181|Drug|BGB-3111 (Arm A)|320 mg BGB-3111 single oral dose
113205|NCT03301181|Drug|Rifampin|600 mg rifampin once daily
113206|NCT03301181|Drug|BGB-3111 (Arm B)|Up to 80 mg BGB-3111 single oral dose
113207|NCT03301181|Drug|Itraconazole|200 mg itraconazole once daily
113208|NCT03301168|Biological|BPX-501 T cells|T cells transduced with CaspaCIDe® safety switch
113209|NCT03301168|Drug|AP1903|administered to inactivate BPX-501 cells in the event of GVHD
113210|NCT03301155|Drug|Anaferon for children|Per os. 1 tablet once daily (preferably at the same time of the day). For children of younger age (from 1 month through 3 years) the tablet should be dissolved in a small amount (1 tablespoon) of boiled water of room temperature.
113211|NCT03301155|Drug|Placebo|Per os. 1 tablet once daily (preferably at the same time of the day). For children of younger age (from 1 month through 3 years) the tablet should be dissolved in a small amount (1 tablespoon) of boiled water of room temperature.
113212|NCT03301142|Procedure|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
113213|NCT03301142|Procedure|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
113214|NCT03301129|Behavioral|Smoke|See arm/group descriptions.
113215|NCT03301116|Behavioral|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
113216|NCT03301116|Behavioral|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
113217|NCT03301103|Biological|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
113218|NCT03301103|Device|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
113219|NCT03301090|Other|Placebo|Placebo
113220|NCT03301090|Biological|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
113221|NCT03301090|Biological|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
113222|NCT03301077|Other|2-phase epidemiological study (screening, interviews)|first phase is the screening phase, second phase is the interview phase
113252|NCT03300778|Behavioral|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
113253|NCT03300778|Behavioral|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
113223|NCT03301064|Behavioral|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
113224|NCT03301064|Other|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
113225|NCT03301051|Biological|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
113226|NCT03301051|Biological|Placebo|Single dose of a Placebo
113227|NCT03301038|Drug|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
113228|NCT03301025|Drug|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
113229|NCT03301025|Drug|placebo|given a placebo identical capsule once one hour before anesthesia
113230|NCT03301012|Other|Recovery support as usual|same as arm
113231|NCT03301012|Other|Smartphone assisted relapse prevention|same as arm
113232|NCT03300999|Dietary Supplement|ginger tea|"1. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea~• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle."
113233|NCT03300973|Procedure|sling surgery|transoburator vaginal tape ,inside out procedure under spinal anathesia
113234|NCT03300960|Drug|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
113235|NCT03300960|Drug|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
113236|NCT03300947|Drug|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
113237|NCT03300947|Drug|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
113238|NCT03300947|Drug|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
113239|NCT03300934|Device|closed loop glucose control system|Cross over between Closed loop glucose system with DANA pump, Navigator II CGM and Cambridge AP algorithm FD2A, versus usual CSII pump treatment
113240|NCT03300921|Drug|Paricalcitol|"Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
113241|NCT03300908|Behavioral|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
113242|NCT03300908|Behavioral|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
113243|NCT03300895|Other|High-intensity interval training|21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
113244|NCT03300895|Other|Comparator: Moderate-intensity continuous exercise|30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
113245|NCT03300882|Other|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
113246|NCT03300843|Biological|Peptide loaded dendritic cell vaccine|On days 0, 14 (+/- 5 days), 28 (+/- 5 days), and 42 (+/- 5 days). The vaccine will be administered as both an intravenous (IV) infusion and a subcutaneous (SQ) injection. The total dose will be divided equally between IV and SQ containing 1.0E7 to 8.0E7 cells per cycle depending upon the manufacturing yield.
113247|NCT03300817|Other|Laboratory Biomarker Analysis|Correlative studies
113248|NCT03300817|Biological|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
113249|NCT03300804|Drug|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
113250|NCT03300804|Drug|Placebo|Placebo herb formulation
113251|NCT03300791|Other|Admitted|Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
113254|NCT03300765|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
113255|NCT03300765|Radiation|Intensity modulated radiation therapy|Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
113256|NCT03300752|Behavioral|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
113257|NCT03300752|Behavioral|Control Intervention|PCP will provide discussion of healthy lifestyles.
113258|NCT03300726|Diagnostic Test|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
113259|NCT03300726|Radiation|Functional MRI|Functional MRI during resting state and semantic memory task activation
113260|NCT03300713|Other|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
113261|NCT03300713|Other|usual follow-up|usual follow-up
113262|NCT03300687|Drug|FX-322|intratympanic injection
113263|NCT03300687|Drug|Placebo|intratympanic injection
113264|NCT03300674|Drug|Hydromorphone|Hydromorphone intravenous infusion
113265|NCT03300674|Drug|Lidocaine|Lidocaine intravenous infusion
113266|NCT03300661|Behavioral|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
113267|NCT03300648|Other|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
113268|NCT03300648|Other|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
113269|NCT03300635|Other|Mental distress and relaxation test|
113270|NCT03300635|Other|Glucose tolerance test|
113271|NCT03300635|Other|Exercise test|
113272|NCT03300609|Biological|Panitumumab|Given IV
113273|NCT03300609|Drug|Oxaliplatin|Given IV
113274|NCT03300609|Drug|Leucovorin Calcium|Given IV
113275|NCT03300609|Drug|Fluorouracil|Given IV
113276|NCT03300609|Drug|Capecitabine|Given PO
113277|NCT03300609|Other|Quality-of-Life Assessment|Ancillary studies
113278|NCT03300609|Other|Laboratory Biomarker Analysis|Correlative studies
113279|NCT03300596|Behavioral|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
113280|NCT03300596|Behavioral|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
113281|NCT03300583|Behavioral|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
113282|NCT03300583|Behavioral|Semi-structured interviews|1:1 semi-structured interviews led by the PI
113283|NCT03300570|Drug|Dolcanatide|Given PO
113284|NCT03300570|Other|Laboratory Biomarker Analysis|Correlative studies
113285|NCT03300570|Other|Placebo|Given PO
113286|NCT03300570|Other|Questionnaire Administration|Ancillary studies
113287|NCT03300557|Drug|Exemestane|Given PO
113288|NCT03300557|Other|Laboratory Biomarker Analysis|Correlative studies
113289|NCT03300557|Other|Pharmacokinetic Study|Correlative studies
113290|NCT03300557|Other|Questionnaire Administration|Ancillary studies
113291|NCT03300544|Drug|Capecitabine|Given PO
113292|NCT03300544|Drug|Fluorouracil|Given IV
113293|NCT03300544|Drug|Leucovorin|Given IV
113294|NCT03300544|Drug|Oxaliplatin|Given IV
113295|NCT03300544|Radiation|Radiation Therapy|Undergo chemoradiation
113296|NCT03300544|Biological|Talimogene Laherparepvec|Given intralesionally
113297|NCT03300531|Biological|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
113298|NCT03300531|Biological|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
113299|NCT03300531|Drug|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
113300|NCT03300518|Drug|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
113301|NCT03300518|Drug|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
113302|NCT03300518|Drug|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
113513|NCT03298880|Other|Modified VM VAD|modified VM using VAD
113303|NCT03300518|Drug|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
113304|NCT03300505|Drug|ARRx|Given intravenously (IV)
113305|NCT03300505|Drug|Enzalutamide|Given by mouth (PO)
113306|NCT03300492|Other|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days~+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at <1x105/kg."
113307|NCT03300479|Drug|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
113308|NCT03300479|Drug|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
113309|NCT03300466|Device|GP0045|Hyaluronic acid gel
113310|NCT03300466|Device|Comparator|Hyaluronic acid gel
113311|NCT03300453|Drug|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
113312|NCT03300440|Dietary Supplement|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
113313|NCT03300440|Dietary Supplement|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
113314|NCT03300427|Drug|sacubitril/valsatran|sacubitril/valsatran 100 or 200 mg BID
113315|NCT03300427|Drug|valsartan|Valsartan 80 or 160 mg BID
113316|NCT03300427|Drug|placebo to valsartan|placebo to valsartan 80 or 160 BID
113317|NCT03300427|Drug|placebo to sacubitril/valsartan|placebo to sacubitril/valsartan 100 or 200 mg BID
113318|NCT03300414|Other|One time blood draw|Same as part 1
113319|NCT03300401|Drug|Perflutren Lipid Microspheres|Receive intravenous injection just prior to ultrasound
113320|NCT03300401|Drug|Sulfur Hexafluoride Lipid Microspheres|Receive intravenous injection just prior to ultrasound
113321|NCT03300401|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo Contrast-Enhanced Ultrasound Imaging
113322|NCT03300401|Device|Positron Emission Tomography|Undergo PET/CT
113323|NCT03300401|Device|Computed Tomography|Undergo CT scan
113324|NCT03300401|Biological|Yttrium-90 (90Y)|Given IV
113325|NCT03300388|Dietary Supplement|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
113326|NCT03300388|Dietary Supplement|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
113327|NCT03300388|Other|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
113328|NCT03300375|Other|Home exercise program|Home-based, progressive exercise program using resistance bands
113329|NCT03300375|Other|Post Op instructions|Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
113330|NCT03300362|Drug|Seasonal influenza vaccine|Seasonal influenza vaccine
113331|NCT03300362|Drug|MVA-NP+M1|Trial vaccine
113332|NCT03300362|Drug|Sodium chloride|Saline placebo
113333|NCT03300349|Other|Fulfillment of a preventive programme|Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
113334|NCT03300349|Other|No fulfillment of a preventive programme|No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
113335|NCT03300336|Behavioral|STRIDE|Implementation of STRIDE inpatient hospital mobility program
113336|NCT03300323|Diagnostic Test|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
113337|NCT03300310|Other|nursing visit|nursing visit at patient home
113338|NCT03300310|Other|no nursing visit|the patient take his treatment without nursing visit
113339|NCT03300297|Other|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
113340|NCT03300297|Other|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
113341|NCT03300297|Other|Home Program|therapeutic exercise program and education
113342|NCT03300297|Other|Suboccipital Release|suboccipital soft tissue mobilization
113343|NCT03300284|Behavioral|Questionnaires|Quality of Life Questionnaires
113344|NCT03300271|Other|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
113345|NCT03300271|Other|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
113346|NCT03300271|Other|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
113370|NCT03300050|Biological|cH5/1N1 IIV|One 0.5 mL dose contains 15μg split hemagglutinin (HA)
113371|NCT03300050|Biological|cH8/1N1 IIV + adjuvant|One 0.5 mL dose contains 15μg split hemagglutinin (HA) with AS03 adjuvant
113372|NCT03300050|Biological|Normal saline|Administered as 0.25 mL nasal drops
113373|NCT03300050|Biological|Phosphate buffered saline|Administered as 0.5 mL injection
113347|NCT03300258|Device|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
113348|NCT03300258|Device|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
113349|NCT03300245|Radiation|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
113350|NCT03300232|Behavioral|Computer-based VC-CBT|Computer-based VC-CBT: Six, one-hour computerized therapy sessions delivered on an interactive computerized platform with two-session therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
113351|NCT03300219|Behavioral|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
113352|NCT03300206|Device|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
113353|NCT03300180|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
113354|NCT03300180|Other|Screening Only|The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
113355|NCT03300167|Device|The Liquid Biopsy System|The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
113356|NCT03300154|Behavioral|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
113357|NCT03300154|Behavioral|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
113358|NCT03300141|Other|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
113359|NCT03300141|Other|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
113360|NCT03300141|Other|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
113361|NCT03300128|Behavioral|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
113362|NCT03300128|Other|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
113363|NCT03300115|Drug|AC0010|After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
113364|NCT03300102|Other|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
113365|NCT03300089|Procedure|General anaesthesia|General anaesthesia
113366|NCT03300089|Procedure|Regional anaesthesia|Regional anaesthesia
113367|NCT03300063|Other|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
113368|NCT03300050|Biological|cH8/1N1 LAIV|One 0.5 mL dose contains cH8/1N1 LAIV titer of 10^7.5 +/- 0.5, egg infective dose 50%
113369|NCT03300050|Biological|cH5/1N1 IIV + adjuvant|One 0.5 mL dose contains 15μg split hemagglutinin (HA) with AS03 adjuvant
113375|NCT03300024|Device|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
113376|NCT03300024|Device|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
113377|NCT03300011|Device|stent|PTCA or PCI
113378|NCT03299998|Procedure|Maxillary and mandibular blocks|A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
113379|NCT03299998|Procedure|General anesthesia|Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
113380|NCT03299985|Other|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
113381|NCT03299985|Other|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
113382|NCT03299972|Dietary Supplement|Whey Protein|25 g whey protein supplementation twice daily (breakfast and lunch)
113383|NCT03299972|Dietary Supplement|Control|23.75 g maltodextrin twice daily (breakfast and lunch)
113384|NCT03299972|Other|Resistance Exercise|60 minutes of resistance exercise twice a week
113385|NCT03299959|Device|Agili-C implant|Agili-C implant
113386|NCT03299959|Procedure|SSOC|microfracture and/or debridement
113387|NCT03299946|Drug|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
113388|NCT03299946|Drug|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
113389|NCT03299920|Other|Standardized instructions|Specific instructions related to peripheral nerve block.
113390|NCT03299920|Other|Conventional instructions|Usual post-operative instructions.
113391|NCT03299907|Diagnostic Test|Spirometry|
113392|NCT03299894|Procedure|systematic calculation of qSOFA|calculation of qSOFA for each patient
113393|NCT03299881|Device|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
113394|NCT03299881|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
113395|NCT03299868|Device|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
113396|NCT03299855|Other|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
113397|NCT03299842|Drug|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
113398|NCT03299829|Drug|Trientine|Trientine is a chelating agent for removing the copper from the body
113399|NCT03299816|Behavioral|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
113400|NCT03299816|Behavioral|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
113401|NCT03299803|Behavioral|Men's Healing Pathways|Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
113402|NCT03299790|Other|high-intensity interval exercise training (HIIT)|This program includes 24 weeks of exercise training and is divided in different phases (phase 1: week 1-2, equal to the MIT group, phase 2: week 3-6, 6 bouts of high-intensity exercise, phase 3: week 7-12, 7 bouts of high-intensity exercise, phase 4: week 13-24, 8 bouts of high-intensity exercise). The exercise training program consists of 3 exercise sessions per week (for 6 months).
113403|NCT03299790|Other|moderate-intensity exercise training (MIT)|This program includes 24 weeks of exercise training and is not devided in phases. The exercise training program consists of 3 endurance exercise sessions per week (for 6 months). The total exercise volume equals the exercise volume of the HIIT group.
113404|NCT03299764|Device|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
113405|NCT03299764|Device|Standard non-invasive ventilation|Standard non-invasive ventilation
113406|NCT03299751|Biological|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.~The dosage of 11 biomarkers will be performed in a central laboratory."
113407|NCT03299738|Biological|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
113408|NCT03299725|Drug|colloidal bismuth sub-citrate|colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
113409|NCT03299712|Device|ArteFill|soft tissue filler
113410|NCT03299686|Drug|CJM112|Study treatment
113411|NCT03299686|Other|Placebo to CJM112|Placebo to match CJM112
113412|NCT03299660|Drug|Avelumab|Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
113413|NCT03299660|Drug|5 Fluorouracil|5FU continuous infusion 225mg/m2/day during radiotherapy
113414|NCT03299660|Drug|Capecitabine Pill|Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
113415|NCT03299660|Radiation|Radiotherapy|50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week
113416|NCT03299660|Procedure|Surgical Resection|Surgical resection of tumour mass post radiotherapy and chemotherapy
113417|NCT03299634|Other|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
113418|NCT03299621|Device|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
113419|NCT03299621|Drug|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
113420|NCT03299608|Diagnostic Test|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
113421|NCT03299595|Other|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
113422|NCT03299582|Device|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
113423|NCT03299582|Device|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
113424|NCT03299556|Other|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
113425|NCT03299543|Device|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
113426|NCT03299530|Other|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
113427|NCT03299517|Drug|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
113428|NCT03299517|Drug|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
113429|NCT03299504|Other|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
113430|NCT03299491|Other|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
113431|NCT03299491|Other|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
113432|NCT03299478|Other|Will look for immune infiltration|
113433|NCT03299465|Behavioral|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
113434|NCT03299452|Drug|Non Chemotherapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
113435|NCT03299452|Drug|Chemotherapy and target therapy|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
113436|NCT03299452|Drug|Chinese herb medicine|Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
113437|NCT03299439|Other|acupuncture|a stimulation of the body or auricular points
113438|NCT03299426|Biological|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
113439|NCT03299426|Biological|Meningococcal A Conjugate Vaccine (MCV-A)|Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
113440|NCT03299413|Biological|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
113441|NCT03299400|Device|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
113442|NCT03299387|Drug|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
113443|NCT03299387|Drug|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
113444|NCT03299374|Other|Pilates Intervention|Intervention based on Pilates principles
113445|NCT03299374|Other|Fall prevention intervention|Intervention based on principles to prevent falls
113446|NCT03299361|Other|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
113447|NCT03299348|Behavioral|AgingPLUS|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) how negative views on aging and negative age stereotypes undermine adults' health-promoting behaviors; (b) how adults can take control of their own aging; and (c) how personal goals can be achieved through more effective goal planning and action plans.
113448|NCT03299335|Other|Blood collection|assay of CPK and anti-cN-1A antibodies
113449|NCT03299322|Drug|Jia Wei Yang He granule|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
113450|NCT03299322|Drug|Jia Wei Yang He granule Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
113451|NCT03299309|Drug|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21, with injection of the PEP-CMV vaccine as follows: PEP-CMV Component A mixed with Montanide ISA-51 intradermally administered half in the RIGHT groin and half in the LEFT groin.
113452|NCT03299296|Drug|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
113453|NCT03299296|Drug|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:~Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
113454|NCT03299283|Diagnostic Test|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
113455|NCT03299270|Other|Questionnaires|Quality of Life and Functional recovery questionnaires
113456|NCT03299257|Drug|donepezil treatment|30-day donepezil treatment
113457|NCT03299244|Drug|Etelcalcetide|"Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.~Drug: Oral Placebo. Administered orally once a day."
113458|NCT03299244|Drug|Cinacalcet|"Cinacalcet was administered orally once a day. The starting dose was 25 mg daily, titrated up to 100 mg daily based on serum PTH and corrected calcium levels.~Drug: Intravenous Placebo Administered intravenously (IV) three times per week."
113459|NCT03299231|Device|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
113460|NCT03299231|Device|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
113461|NCT03299218|Dietary Supplement|SNF (Wawamum)|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
113462|NCT03299218|Behavioral|Social and behaviour change communication (SBCC)|SBCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
113463|NCT03299218|Other|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
113464|NCT03299205|Behavioral|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
113465|NCT03299192|Behavioral|Tai Chi|Yang Style Tai Chi
113466|NCT03299192|Behavioral|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
113467|NCT03299192|Other|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
113468|NCT03299179|Device|MRI scan|Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).
113469|NCT03299179|Device|Physiological monitoring|During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
113470|NCT03299179|Biological|Blood sample|Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.
113471|NCT03299179|Device|Blood pressure measurement|Measuring blood pressure before and after MRI-scan
113472|NCT03299179|Device|Body temperature|Measuring body temperature before and after MRI-scan
113514|NCT03298880|Other|Modified VM Manonmeter|Postural modified position VM using manometer
113881|NCT03296085|Procedure|Exam for quantity of edema|There is no intervention
113473|NCT03299179|Other|Questionnaires|Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)
113474|NCT03299179|Diagnostic Test|Pregnancy test|Test for pregnancy using a pregnancy dipstick test
113475|NCT03299166|Drug|BHV-4157|BHV-4157, 140mg capsule QD
113476|NCT03299166|Drug|Placebo|matching capsule QD
113477|NCT03299153|Other|barberry juice|
113478|NCT03299140|Behavioral|Family Focused Therapy|
113479|NCT03299127|Behavioral|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
113480|NCT03299114|Other|Whirlpool|
113481|NCT03299101|Other|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
113482|NCT03299088|Biological|Pembrolizumab|Given IV
113483|NCT03299088|Drug|Trametinib|Given PO
113484|NCT03299062|Diagnostic Test|Cytology and Immunohistochemistry|Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
113485|NCT03299049|Drug|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
113486|NCT03299049|Drug|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
113487|NCT03299049|Drug|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be freezed.
113488|NCT03299049|Drug|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be freezed. RPV LA should also be protected from light.
113489|NCT03299036|Device|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
113490|NCT03299023|Other|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
113491|NCT03298997|Procedure|Ligation and Hemorrhoidopexy|"Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to pudendal nerve block."
113492|NCT03298997|Procedure|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).~Prior to operation, the patients will be submitted to spinal anesthesia."
113493|NCT03298984|Drug|Alvocidib|IV bolus followed by IV infusion
113494|NCT03298984|Drug|Cytarabine|continuous infusion
113495|NCT03298984|Drug|Daunorubicin|IV bolus
113496|NCT03298971|Other|Questionnaires|Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
113497|NCT03298958|Drug|Rapamycin|Subject will be randomized to one of the 2 arms
113498|NCT03298958|Drug|Placebo Oral Tablet|Subject will be randomized to one of the 2 arms
113499|NCT03298945|Drug|Miralax-Gatorade Prep|2-L split-dose Miralax-Gatorade bowel prep for colonoscopy
113500|NCT03298945|Drug|Golytely|4-L split dose Golytely is the current standard prep at the VA
113501|NCT03298932|Procedure|Aortic valve surgery|Aortic valve surgery
113502|NCT03298919|Behavioral|Exercise Video Games|12 weeks laboratory based exercise videogames
113503|NCT03298919|Behavioral|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
113504|NCT03298919|Behavioral|Home exercise videogames|videogame console and active videogames
113505|NCT03298919|Behavioral|Home Standard Exercise|Personalized physical activity promotion materials
113506|NCT03298906|Drug|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
113507|NCT03298906|Drug|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
113508|NCT03298893|Drug|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
113509|NCT03298893|Drug|Cisplatin|40 mg/m2, once a week during radiotherapy
113510|NCT03298893|Radiation|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.~An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.~An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
113511|NCT03298880|Device|Supine VM VAD|Valsalva strain delivered using VAD
113512|NCT03298880|Device|Supine VAD manometer|supine Valsalva strain delivered using manometer
113515|NCT03298867|Biological|Teprotumumab|Approximately 38 participants will receive 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
113516|NCT03298867|Other|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
113517|NCT03298854|Device|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
113518|NCT03298841|Device|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:~Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
113519|NCT03298828|Biological|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
113520|NCT03298828|Biological|CD19 CAR T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
113521|NCT03298815|Biological|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
113522|NCT03298815|Other|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
113523|NCT03298802|Drug|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
113524|NCT03298802|Drug|Placebo Tablet|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
113525|NCT03298789|Other|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
113526|NCT03298789|Other|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
113527|NCT03298776|Device|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
113528|NCT03298776|Diagnostic Test|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
113529|NCT03298763|Genetic|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).~After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
113530|NCT03298763|Drug|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
113531|NCT03298750|Procedure|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.~One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.~A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.~The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.~These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.~Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).~Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
113532|NCT03298737|Behavioral|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
113533|NCT03298724|Behavioral|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
113534|NCT03298698|Drug|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
113535|NCT03298698|Drug|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
113536|NCT03298685|Other|semi structured interviews for all adolescents and their parent|Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
113537|NCT03298672|Drug|NDX-1017|Solution of NDX-1017 for subcutaneous injection
113538|NCT03298672|Drug|Placebo|Placebo solution for subcutaneous injection
113539|NCT03298659|Diagnostic Test|iFR|Treatment guided by instantaneous wave-free ratio
113540|NCT03298659|Diagnostic Test|CMR|Treatment guided by stress perfusion CMR
113541|NCT03298646|Drug|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
113542|NCT03298646|Drug|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
113543|NCT03298633|Other|ICSI|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
113654|NCT03297788|Radiation|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
113655|NCT03297762|Behavioral|gamification|incentives/rewards and contact between standard visits
113544|NCT03298633|Other|Conventional IVF|All patients will receive controlled ovarian hyperstimulation (COH) treatment, which is performed by standard routines at each study center. The COH treatment includes either gonadotrophin-releasing hormone agonist (GnRH-a) protocol or gonadotrophin-releasing hormone antagonist (GnRH-ant) protocol.Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
113545|NCT03298620|Other|Electric toothbrush|
113546|NCT03298620|Other|Control|Manual toothbrush
113547|NCT03298607|Dietary Supplement|Placebo|2 months treatment
113548|NCT03298607|Dietary Supplement|Serelys PMS|2 months treatment
113549|NCT03298594|Diagnostic Test|specific cervicograph|
113550|NCT03298581|Drug|Halobetasol Propionate|Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
113551|NCT03298568|Dietary Supplement|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
113552|NCT03298555|Behavioral|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
113553|NCT03298542|Drug|Golimumab|Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
113554|NCT03298542|Drug|Placebo|Matching placebo to golimumab.
113555|NCT03298529|Other|glucose solution|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
113556|NCT03298529|Other|Traditional egg pasta|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
113557|NCT03298529|Other|Pasta with eight egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
113558|NCT03298529|Other|Pasta with four eggs/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
113559|NCT03298529|Other|Hyperproteic pasta (with added gluten and albumin)|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
113560|NCT03298529|Other|Pasta with only four egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
113561|NCT03298516|Drug|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
113562|NCT03298516|Drug|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
113563|NCT03298503|Other|task-priority strategies|"posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).~supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray)."
113564|NCT03298477|Device|Nellix® System|Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
113565|NCT03298464|Biological|NGM313|Subcutaneous injection
113566|NCT03298464|Drug|Pioglitazone|White to off-white round tablet
113567|NCT03298451|Drug|Durvalumab|Durvalumab IV (intravenous infusion).
113568|NCT03298451|Drug|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
113569|NCT03298451|Drug|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
113570|NCT03298451|Drug|Sorafenib|Sorafenib, as per standard of care
113571|NCT03298451|Drug|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
113572|NCT03298451|Drug|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
113573|NCT03298425|Device|Treatment NMES|Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
113574|NCT03298425|Device|Placebo NMES|TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
113575|NCT03298412|Drug|Blinatumomab|"Blinatumomab will be supplied as 4 mL single-use sterile glass injection vials. Blinatumomab is administered as a continuous intravenous (IV) infusion.~Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval. The initial dose of blinatumomab will be 9 μg/day for the first 7 days of treatment. Blinatumomab dose will then be escalated (dose-step) to 28 μg/day starting on day 8 (week 2) followed by a dose-step to 112 μg/day starting on day 15 (week 3) and continuing until completion of therapy (day 57 of cycle 1)."
113576|NCT03298399|Biological|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
113577|NCT03298399|Biological|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
113656|NCT03297762|Device|Dexcom G5|Dexcom G5 continuous glucose monitor
113657|NCT03297749|Other|Observational study (no intervention)|No interventions
113955|NCT03295461|Procedure|SRP +10% E. officinalis gel application.|
113578|NCT03298399|Biological|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
113579|NCT03298386|Other|Systematic medication review with the STOPP/START tool|The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
113580|NCT03298373|Drug|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
113581|NCT03298373|Drug|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
113582|NCT03298360|Other|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
113583|NCT03298347|Drug|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
113584|NCT03298347|Drug|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
113585|NCT03298334|Biological|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
113586|NCT03298334|Other|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
113587|NCT03298321|Other|Effect of Vidaza treatment|The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
113588|NCT03298308|Device|Cranial Electric Stimulation|Micro amperage TCDS
113589|NCT03298295|Device|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
113590|NCT03298282|Other|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
113591|NCT03298282|Other|selective CTA|Coronary images by OCT and selective CTA and FFR values will be registered.
113592|NCT03298282|Other|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
113593|NCT03298269|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
113594|NCT03298269|Behavioral|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
113595|NCT03298256|Radiation|EOS X-rays|Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
113596|NCT03298243|Behavioral|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in FitBit activity monitors.
113597|NCT03298230|Behavioral|REmotely SuPervised Exercise Training|As described in the Arms section.
113598|NCT03298230|Behavioral|Supervised Exercise Training|As described in the Arms section.
113599|NCT03298217|Device|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
113600|NCT03298191|Drug|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
113601|NCT03298191|Drug|Ritodrine|Those women will be given Ritodrine for tocolysis
113602|NCT03298191|Drug|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
113603|NCT03298178|Procedure|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
113604|NCT03298178|Procedure|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
113605|NCT03298165|Device|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
113606|NCT03298152|Procedure|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
113607|NCT03298152|Procedure|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
113608|NCT03298139|Other|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
113609|NCT03298126|Procedure|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
113658|NCT03297736|Device|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
113956|NCT03295461|Procedure|SRP+ placebo gel application.|
113610|NCT03298113|Device|Cavilon Advanced Skin Protectant|Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
113611|NCT03298113|Device|IAD Hospital Standard Care|Devices such as local skin protectants will be used according to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
113612|NCT03298100|Other|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
113613|NCT03298087|Procedure|radical prostatectomy|surgical removal of the prostate
113614|NCT03298087|Radiation|stereotactic body radiotherapy|Highly targeted radiation
113615|NCT03298087|Drug|Leuprolide|Lowers serum testosterone
113616|NCT03298087|Drug|apalutamide|antiandrogen
113617|NCT03298087|Drug|abiraterone|Inhibits androgen synthesis
113618|NCT03298074|Drug|Apatinib|Apatinib, 500mg,po qd for continuous administration
113619|NCT03298074|Drug|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
113620|NCT03298061|Drug|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
113621|NCT03298061|Drug|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
113622|NCT03298048|Biological|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
113623|NCT03298048|Biological|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
113624|NCT03298048|Biological|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
113625|NCT03298035|Device|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
113626|NCT03298035|Device|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
113627|NCT03298022|Biological|AbGn-168H|monoclonal antibody
113628|NCT03298009|Drug|Canagliflozin 100mg|2-week intervention
113629|NCT03298009|Drug|Placebo oral capsule|2-week intervention
113630|NCT03298009|Radiation|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
113631|NCT03297996|Diagnostic Test|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
113632|NCT03297983|Drug|M7583|Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.
113633|NCT03297957|Drug|IC-GREEN|-Injection of ICG around the tumor per standard techniques will in the operating room and 0.5-2.5 mL of 500 micromolar ICG will be injected peri-tumorly into the subcutaneous tissue of the surrounding skin.
113634|NCT03297957|Device|Hands-free goggle system|-Manufactured at Washington University
113635|NCT03297944|Drug|Alprazolam|0.5 to 2mg administered at night or in the morning
113636|NCT03297944|Drug|Zolpidem|10mg administered at night or in the morning
113637|NCT03297944|Drug|Placebo|placebo administered at night and/or in the morning
113638|NCT03297931|Dietary Supplement|Corn Chips + Onion Dip|Non-pulse chip + non-pulse dip
113639|NCT03297931|Dietary Supplement|Yellow pea chip + hummus|Novel pulse chip + pulse spread
113640|NCT03297931|Dietary Supplement|Pinto bean chip + hummus|Commercial pulse chip + pulse spread
113641|NCT03297931|Dietary Supplement|Pinto bean chip + onion dip|Commercial pulse chip + non-pulse spread
113642|NCT03297931|Dietary Supplement|Yellow pea chip + onion dip|Novel pulse chip + non-pulse spread
113643|NCT03297931|Dietary Supplement|Corn chips + hummus|Non-pulse chip + pulse spread
113644|NCT03297918|Behavioral|Respiratory muscle training|The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
113645|NCT03297905|Behavioral|Complementary and Integrative Therapies|Intervention time period is 3 - 6 weeks.
113646|NCT03297905|Behavioral|Standard Rehabilitative Care|Intervention time period is 3 - 6 weeks.
113647|NCT03297879|Drug|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
113648|NCT03297840|Behavioral|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
113649|NCT03297827|Other|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic & hemorrhagic stroke.
113650|NCT03297814|Biological|Platelet lysate|Intramuscular injection of platelet lysate
113651|NCT03297814|Biological|Placebo|intramuscular injection of normal saline
113652|NCT03297801|Dietary Supplement|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
113653|NCT03297788|Radiation|SRS|"For SRS the dose prescription to the PTV will be as follows:~20 Gy to the 70%-isodose (lesions < 2 cm max. diameter)~18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)~6 x 5 Gy to the conformally surrounding isodose (lesions > 3 cm max. diameter)"
113659|NCT03297736|Device|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
113660|NCT03297723|Other|Therapeutic education Programm|"Intervention will include:~an identification of educational needs and expectations,~a bilateral agreement between patient and medical staff on the priority skills acquirement,~a structured educational activities tailored to the patient's need.~the making of an educational record."
113661|NCT03297710|Other|Quality-of-Life Assessment|Ancillary studies
113662|NCT03297710|Radiation|Radiation Therapy|Undergo radiation therapy
113663|NCT03297710|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
113664|NCT03297697|Procedure|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
113665|NCT03297697|Procedure|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
113666|NCT03297697|Procedure|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
113667|NCT03297684|Drug|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
113668|NCT03297671|Drug|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
113669|NCT03297671|Device|ELDONCARD|ELDONCARD point-of-care test.
113670|NCT03297671|Diagnostic Test|ELDONCARD Test|LHVs will perform ELDONCARD test.
113671|NCT03297658|Device|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
113672|NCT03297658|Device|sham|Micro electrodes will be placed but there will be no stimulation
113673|NCT03297645|Behavioral|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
113674|NCT03297645|Behavioral|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
113675|NCT03297645|Behavioral|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
113676|NCT03297645|Behavioral|Informational mail|Family will be mailed publicly available asthma information every 3 months.
113677|NCT03297632|Behavioral|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
113678|NCT03297619|Behavioral|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
113679|NCT03297619|Behavioral|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
113680|NCT03297606|Drug|Olaparib|300mg taken twice daily
113681|NCT03297606|Drug|Dasatinib|100mg administered orally once daily
113682|NCT03297606|Drug|Nivolumab plus Ipilimumab|"Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks."
113683|NCT03297606|Drug|Axitinib|5mg orally twice daily
113684|NCT03297606|Drug|Bosutinib|500mg orally once daily
113685|NCT03297606|Drug|Crizotinib|250mg orally twice daily
113686|NCT03297606|Drug|Palbociclib|125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
113687|NCT03297606|Drug|Sunitinib|50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
113688|NCT03297606|Drug|Temsirolimus|25mg infused over a 30-60 minute period once a week
113689|NCT03297606|Drug|Erlotinib|150mg orally, once daily
113690|NCT03297606|Drug|Trastuzumab plus Pertuzumab|"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
113691|NCT03297606|Drug|Vemurafenib plus Cobimetinib|"Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest"
113692|NCT03297606|Drug|Vismodegib|150mg taken orally, once daily
113693|NCT03297593|Drug|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
113694|NCT03297593|Drug|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
113695|NCT03297567|Behavioral|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
113733|NCT03297281|Other|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
113802|NCT03296683|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
113696|NCT03297554|Behavioral|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
113697|NCT03297541|Behavioral|m-health approach|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
113698|NCT03297528|Drug|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
113699|NCT03297515|Dietary Supplement|Madeos|Arm 1: Omega 3
113700|NCT03297515|Dietary Supplement|Placebo|Arm 2 : Placebo
113701|NCT03297502|Drug|pimecrolimus cream 1%|
113702|NCT03297502|Drug|Elidel (pimecrolimus) cream 1%|
113703|NCT03297502|Drug|placebo|
113704|NCT03297489|Procedure|Diagnostic Microscopy|Undergo observation via intravital microscopy
113705|NCT03297489|Drug|Fluorescein Sodium Injection|Given IV
113706|NCT03297489|Other|Laboratory Biomarker Analysis|Correlative studies
113707|NCT03297476|Diagnostic Test|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
113708|NCT03297463|Drug|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:~- Ipilimumab will be administered in a 3 + 3 dose escalation design.~The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).~If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.~The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.~In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.~Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
113709|NCT03297463|Drug|Interleukin-2 & Ipilimumab (P-II)|"Phase II:~- Interleukin-2 & Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
113710|NCT03297450|Device|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA
113711|NCT03297450|Behavioral|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
113712|NCT03297450|Device|Sham-tDCS|tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
113713|NCT03297437|Other|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
113714|NCT03297424|Drug|PLX2853|tablets
113715|NCT03297411|Procedure|Brief Temporoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
113716|NCT03297411|Procedure|Ultrabrief Temporoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
113717|NCT03297411|Procedure|Brief Frontoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
113718|NCT03297411|Procedure|Ultrabrief Frontoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
113719|NCT03297398|Drug|Group-1 (15mg, OPK-88004)|15mg, OPK-88004
113720|NCT03297398|Drug|Group-2 (25 mg,OPK-88004)|25 mg,OPK-88004
113721|NCT03297398|Other|Placebo|Placebo
113722|NCT03297385|Drug|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
113723|NCT03297372|Device|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
113724|NCT03297359|Biological|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
113725|NCT03297346|Other|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
113726|NCT03297333|Other|Resistance training|The resistance training group
113727|NCT03297333|Other|Aerobic interval training|The aerobic interval training group
113728|NCT03297320|Other|In-depth conversation about Goals of Care and ACP|In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
113729|NCT03297307|Behavioral|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
113730|NCT03297294|Drug|EMA401|capsules, oral
113731|NCT03297294|Drug|Placebo|Placebo to EMA401 capsules, oral
113732|NCT03297281|Other|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
113734|NCT03297268|Other|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
113735|NCT03297229|Behavioral|Peer mentoring|Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
113736|NCT03297229|Behavioral|Self-monitoring|"Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values."
113737|NCT03297216|Drug|17P|Synthetic progestin
113738|NCT03297216|Other|Placebo|Non-active placebo comparator
113739|NCT03297203|Behavioral|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
113740|NCT03297190|Behavioral|SMS|Receipt of SMS messages on nutrition and health topics
113741|NCT03297190|Behavioral|Interpersonal Counselling|Interpersonal counselling on health and nutrition topics
113742|NCT03297177|Procedure|Microcannula Harvest Adipose|Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
113743|NCT03297177|Device|Centricyte 1000|Closed System, Digestive Isolation & Concentration of AD-cSVF
113744|NCT03297177|Procedure|Sterile Normal Saline Infusion|Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
113745|NCT03297151|Dietary Supplement|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
113746|NCT03297151|Dietary Supplement|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
113747|NCT03297151|Dietary Supplement|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.~Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
113748|NCT03297138|Procedure|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
113749|NCT03297125|Device|NovoCure-TTF-200A|Adhesive bandages hold insulated ceramic discs (transducer arrays) that deliver electricity transformed into electromagnetic energy to the scalp. The battery operated-TTF device generates low intensity, intermediate frequency, alternating electrical fields to the brain. These electrical fields exert selective toxicity in proliferating cells thereby halting cell division and destroying the cancer cells.
113750|NCT03297112|Drug|Perflutren Lipid Microspheres|Given IV
113751|NCT03297112|Procedure|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
113752|NCT03297099|Procedure|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
113753|NCT03297099|Procedure|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
113754|NCT03297086|Procedure|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
113755|NCT03297073|Drug|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.~The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
113756|NCT03297073|Procedure|hepatic surgery|
113757|NCT03297060|Other|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
113758|NCT03297047|Device|combi cast|upper arm or forearm combi cast
113759|NCT03297021|Drug|Ondansetron 4 MG|dose as per arm selection
113760|NCT03297021|Drug|Ondansetron 8mg|dose as per arm selection
113761|NCT03297008|Other|No internvetion|No intervention, this is an observational study
113762|NCT03296995|Device|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
113763|NCT03296982|Other|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
113764|NCT03296982|Drug|edoxaban|
113765|NCT03296982|Drug|Enoxaparin|
113766|NCT03296982|Drug|Saline sham|
113799|NCT03296709|Device|PPC z|Installation of a preformed pediatric zircona crown
113800|NCT03296709|Device|PPC m|Installation of a preformed pediatric metal crown
113767|NCT03296969|Procedure|cesarean section|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
113768|NCT03296969|Procedure|Rectus muscle approximation|aprroximation of the lower parts of rectus abdomius muscles during cesarean section
113769|NCT03296956|Dietary Supplement|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
113770|NCT03296956|Other|Placebo|Matching placebo for appearance, taste
113771|NCT03296943|Combination Product|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
113772|NCT03296943|Combination Product|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
113773|NCT03296943|Behavioral|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
113774|NCT03296930|Drug|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
113775|NCT03296930|Drug|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
113776|NCT03296917|Drug|PrEP-001|A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
113777|NCT03296917|Drug|G-004|A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
113778|NCT03296904|Device|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
113779|NCT03296891|Other|PoCUS Guided Resuscitation of Shock|Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with undifferentiated shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
113780|NCT03296878|Other|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
113781|NCT03296878|Other|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
113782|NCT03296865|Device|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
113783|NCT03296852|Diagnostic Test|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
113784|NCT03296852|Drug|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
113785|NCT03296813|Drug|Torsemide|Loop diuretic
113786|NCT03296813|Drug|Furosemide|Loop diuretic
113787|NCT03296800|Drug|Bexagliflozin|Bexagliflozin 20 mg, tablet; qd
113788|NCT03296800|Drug|Probenecid|Probenecid tablets, 500 mg; bid
113789|NCT03296800|Drug|Rifampin|Rifampin, 600 mg (2 x 300 mg capsules); qd
113790|NCT03296800|Drug|Verapamil|Verapamil hydrochloride tablet, 120 mg; qd
113791|NCT03296787|Drug|TAK-954|TAK-954 intravenous infusion.
113792|NCT03296774|Behavioral|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
113793|NCT03296774|Behavioral|Usual Care|
113794|NCT03296748|Procedure|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
113795|NCT03296748|Procedure|anterior colporraphy|
113796|NCT03296735|Procedure|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
113797|NCT03296735|Procedure|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
113798|NCT03296722|Behavioral|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
113801|NCT03296696|Drug|AMG 596|Drug
113803|NCT03296670|Drug|Alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
113804|NCT03296670|Drug|Nitroglycerin|Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
113805|NCT03296657|Drug|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
113806|NCT03296644|Device|Class II correction using PowerScope2|
113807|NCT03296644|Device|Class II correction using Forsus|
113808|NCT03296631|Other|collection of diapers with fresh stools|collection of diapers with fresh stools
113809|NCT03296618|Drug|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
113810|NCT03296592|Diagnostic Test|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
113811|NCT03296579|Device|BiPAP|The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
113812|NCT03296579|Device|CPAP|The patient breathes against a constant pressure delivered by face mask.
113813|NCT03296579|Drug|Ipratropium|Nebulized q6h
113814|NCT03296579|Drug|Magnesium Sulfate|50mg/kg IV, 4 doses q6h
113815|NCT03296579|Drug|Aminophylline|6mg/kg IV (if no progress)
113816|NCT03296579|Drug|Standard steroid dose, hourly salbutamol, oxygen as needed|Standard common therapies for all three arms.
113817|NCT03296566|Behavioral|Patient Liaison|An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
113818|NCT03296553|Drug|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
113819|NCT03296553|Drug|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
113820|NCT03296540|Drug|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
113821|NCT03296540|Drug|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
113822|NCT03296527|Drug|Follitropin alfa|Fixed starting dose per day for first stimulation days. May be adjusted later based on individual response.
113823|NCT03296527|Drug|Follitropin delta|Fixed starting dose per day for first stimulation days.
113824|NCT03296514|Behavioral|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
113825|NCT03296501|Biological|Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients|3 injections of ADRC: 1 intraspinal and 2 intrathecal
113826|NCT03296488|Drug|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
113827|NCT03296488|Drug|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
113828|NCT03296475|Procedure|Abdominal Wall Closure Force (N).|This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
113829|NCT03296462|Other|Hip external rotation exercise|Standardised HER exercise training by physiotherapist (plus video recording of exercises)
113830|NCT03296462|Other|Pelvic floor muscle exercise|Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
113831|NCT03296449|Procedure|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
113832|NCT03296449|Procedure|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
113833|NCT03296436|Biological|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
113834|NCT03296423|Biological|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
113835|NCT03296423|Biological|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
113836|NCT03296410|Biological|EV71 and two measles attenuated live vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
113837|NCT03296410|Biological|EV71 and attenuated Japanese encephalitis vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
113838|NCT03296410|Biological|two measles attenuated live vaccine|infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
113839|NCT03296410|Biological|live attenuated Japanese encephalitis vaccine|infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
113840|NCT03296410|Biological|EV71 vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
113841|NCT03296397|Biological|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
113842|NCT03296397|Biological|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
113843|NCT03296384|Other|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
113844|NCT03296371|Procedure|Biospecimen Collection|Undergo saliva or buccal mucosa collection
113845|NCT03296371|Other|Laboratory Biomarker Analysis|Correlative studies
113846|NCT03296371|Other|Questionnaire Administration|Ancillary studies
113847|NCT03296358|Drug|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in ED.
113848|NCT03296358|Drug|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
113849|NCT03296345|Drug|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
113850|NCT03296319|Device|Echocardiography|Echocardiography guided fluid administration
113851|NCT03296306|Drug|Treatment duration of cisplatin based chemotherapy|"GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks~GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks~MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks~HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
113852|NCT03296293|Other|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
113853|NCT03296293|Other|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
113854|NCT03296293|Other|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
113855|NCT03296267|Procedure|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
113856|NCT03296254|Behavioral|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
113857|NCT03296254|Behavioral|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
113858|NCT03296241|Device|laser|
113859|NCT03296241|Device|sham control|
113860|NCT03296228|Radiation|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
113861|NCT03296228|Radiation|Flexibility Radiographs (awake traction)|awake traction
113862|NCT03296228|Radiation|Flexibility Radiographs (STUGA)|supine traction under GA
113863|NCT03296215|Other|Observational|To determine different patterns of admission and their Outcome
113864|NCT03296189|Drug|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
113865|NCT03296189|Drug|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
113866|NCT03296189|Drug|Placebos|10 mls normal saline
113867|NCT03296176|Biological|blood sample|blood sample for metabolome analyse
113868|NCT03296163|Drug|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
113869|NCT03296163|Drug|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
113870|NCT03296163|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 6 cycles
113871|NCT03296163|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
113872|NCT03296150|Behavioral|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
113873|NCT03296137|Biological|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
113874|NCT03296137|Drug|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
113875|NCT03296137|Drug|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
113876|NCT03296137|Drug|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
113877|NCT03296137|Drug|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
113878|NCT03296137|Drug|Fludara|5 doses (25 mg/m2) prior to TIL infusion
113879|NCT03296111|Other|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.~They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).~Patients will be asked to complete several questionnaires :~Questionnaire about the characteristics of ocular neuropathic pain (7 items)~DEQ-5 (Dry Eye Questionnaire)~ODI (Ocular Surface Disease Index)~BPI (Brief Pain Inventory)~HADS (Hospital Anxiety and Depression Scale)"
113880|NCT03296098|Drug|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
113882|NCT03296072|Drug|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres [mL] of tap water for 10 seconds before expectorating again.
113883|NCT03296072|Drug|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
113884|NCT03296072|Drug|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
113885|NCT03296059|Other|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
113886|NCT03296059|Other|conventional treatment|neonates is treated with conventional treatment.
113887|NCT03296046|Biological|Blood test|30 ml
113888|NCT03296033|Drug|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
113889|NCT03296033|Drug|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
113890|NCT03296020|Other|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
113891|NCT03296007|Behavioral|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
113892|NCT03295994|Procedure|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
113893|NCT03295994|Procedure|Non-Operative|Physical therapy (without surgery).
113894|NCT03295981|Drug|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
113895|NCT03295968|Other|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
113896|NCT03295955|Drug|Amoxicillin Clavulanate|"Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery"
113897|NCT03295942|Drug|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
113898|NCT03295916|Radiation|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
113899|NCT03295903|Dietary Supplement|Cannabidiol supplement|Subjects will be administered in a double-blinded, randomized and cross-over design
113900|NCT03295890|Procedure|Dry Needing|Dry Needling
113901|NCT03295877|Drug|RO7171009|Patients will receive RO7171009 via ITV injection.
113902|NCT03295864|Diagnostic Test|Multifrequency tympanometry at Inclusion|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
113903|NCT03295864|Diagnostic Test|Multifrequency tympanometry 6 month after surgery|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
113904|NCT03295851|Drug|Ferric carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
113905|NCT03295851|Drug|Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
113906|NCT03295838|Behavioral|Mentalization-based treatment|See Arm description
113907|NCT03295825|Diagnostic Test|Biomarker|Measument of heparin-binding protein in the serum of patients
113908|NCT03295812|Other|standard therapy|standard therapy,non-interventional study
113909|NCT03295799|Other|Patient Self-Management|Patient will manage their own warfarin therapy.
113910|NCT03295786|Drug|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
113911|NCT03295786|Device|Renishaw Drug Delivery System|Stereotactically implanted device
113912|NCT03295773|Diagnostic Test|3DRA|
113913|NCT03295760|Drug|Q10 Coenzyme|
113914|NCT03295747|Drug|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg.
113915|NCT03295734|Behavioral|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
113916|NCT03295734|Drug|Perindopril|4 mg qd titrated to 8 mg qd perindopril
113917|NCT03295734|Drug|Losartan|50 mg qd titrated to 100 qd losartan
113918|NCT03295734|Drug|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
113919|NCT03295721|Drug|HTX-011|HTX 011, 60 mg
113920|NCT03295721|Drug|Saline Placebo|Saline placebo
113921|NCT03295721|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg
113922|NCT03295721|Device|Luer-lock applicator|Applicator for instillation
113923|NCT03295721|Device|Vial access device|Device for withdrawal of drug product
113957|NCT03295448|Other|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
113958|NCT03295448|Other|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
113959|NCT03295448|Other|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
114020|NCT03294863|Device|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
113924|NCT03295708|Dietary Supplement|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
113925|NCT03295708|Dietary Supplement|soybean oil capsule|placebo capsule
113926|NCT03295695|Diagnostic Test|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
113927|NCT03295695|Biological|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-[18F]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.~Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
113928|NCT03295695|Diagnostic Test|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
113929|NCT03295682|Device|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
113930|NCT03295656|Drug|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
113931|NCT03295643|Device|Mobile smoking cessation program and CO breath sensor device|Mobile smoking cessation program delivered through an app with access to a breath sensor device and coaching support.
113932|NCT03295630|Device|Accelerometer|Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count.
113933|NCT03295617|Procedure|Thoracoscopy|Thoracoscopy surgery
113934|NCT03295604|Procedure|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
113935|NCT03295604|Procedure|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
113936|NCT03295591|Diagnostic Test|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
113937|NCT03295578|Other|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.~Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
113938|NCT03295578|Other|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
113939|NCT03295578|Device|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
113940|NCT03295565|Drug|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
113941|NCT03295565|Drug|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
113942|NCT03295565|Drug|Enzalutamide|Enzalutamide 160mg oral taken daily
113943|NCT03295552|Drug|Decitabine|decitabine 7mg/m2, d1-d5, q3w
113944|NCT03295552|Drug|Carboplatin|carboplatin AUC = 6, d6, q3w
113945|NCT03295539|Device|'Indigo' Mechanical thrombectomy system|"Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO"
113946|NCT03295526|Procedure|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
113947|NCT03295513|Other|Veneered zirconia|he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
113948|NCT03295513|Other|Monolithic zirconia|Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
113949|NCT03295500|Radiation|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
113950|NCT03295487|Procedure|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
113951|NCT03295474|Other|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.~Patients are taught to use the system during the first session of aerobic training.~During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).~At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).~The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.~The study takes off on the session during which the patients are autonomous in using the telehealthcare system.~If patients are not autonomous on the fifth session, the study also takes off."
113952|NCT03295461|Procedure|SRP+ 10% Emblica officinalis irrigation|
113953|NCT03295461|Procedure|SRP + 0.2% Chlorhexidine irrigation)|
113954|NCT03295461|Procedure|SRP + 0.9% Saline irrigation|
113960|NCT03295435|Other|Composition of functional tooth units|"Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups:~Group A: Natural units only Group B: Natural & Prosthetic units present Group C: No natural units present"
113961|NCT03295422|Procedure|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
113962|NCT03295422|Procedure|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
113963|NCT03295409|Behavioral|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
113964|NCT03295396|Drug|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
113965|NCT03295383|Drug|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
113966|NCT03295383|Drug|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:~patients younger than 75 years: 1.5 mg/kg/day, orally.~patients older than 75 years: 1 mg/kg/day, orally."
113967|NCT03295383|Drug|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
113968|NCT03295383|Drug|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
113969|NCT03295370|Procedure|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
113970|NCT03295344|Other|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces~US mode:~2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
113971|NCT03295344|Other|Tissue Doppler|Determine the threshold value for diaphragm mobility
113972|NCT03295318|Biological|Non-adjuvanted study formulation NmCV-5|Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
113973|NCT03295318|Biological|Adjuvanted study formulation NmCV-5|Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
113974|NCT03295318|Biological|Menactra|Menactra is available as ready to used solution containing polysacchride antigens A,C,Y&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
113975|NCT03295305|Behavioral|Action-Based Cognitive Remediation|
113976|NCT03295305|Behavioral|Unstructured support group|
113977|NCT03295292|Biological|Stem cells|Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
113978|NCT03295292|Other|Vehicle|50uL of commercially available fibrin sealant (Baxter, TISEEL)
113979|NCT03295266|Drug|MK-3866|Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
113980|NCT03295253|Procedure|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
113981|NCT03295240|Drug|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for dose level -1); day 1 and 2 ), rituximab (375 mg/m2; day 1), and ibrutinib one pill or four 140mg capsules (560 mg oral daily; day 1-28).
113982|NCT03295240|Drug|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle. Now also include a -2 dose level which has the reduced 3-day duration of Ventoclax 400 mg daily.
113983|NCT03295227|Drug|Pembrolizumab|"Part 1: 200 mg by vein on Day 1 of every 21 day cycle.~Part 2: Maximum tolerated dose from Part 1."
113984|NCT03295214|Drug|Acetaminophen|Acetaminophen given for pain relief
113985|NCT03295201|Other|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
113986|NCT03295201|Other|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
113987|NCT03295188|Dietary Supplement|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
113988|NCT03295188|Dietary Supplement|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
114019|NCT03294889|Radiation|Stereotactic body radition (SBRT)|"Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.~19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles~17 Gy in a single fraction to the urethra planning-risk volume (PRV)"
113989|NCT03295175|Diagnostic Test|Hematoxylin-eosin and smooth muscle actin markers|"The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present."
113990|NCT03295162|Drug|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
113991|NCT03295162|Combination Product|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
113992|NCT03295136|Behavioral|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
113993|NCT03295123|Other|phone interview with the mother|it's a telephone survey about children's health
113994|NCT03295110|Other|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
113995|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
113996|NCT03295097|Other|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
113997|NCT03295084|Drug|Irinotecan|Dose Escalation
113998|NCT03295084|Drug|Capecitabine|Dose Escalation
113999|NCT03295071|Other|Patient-reported outcomes (PROs)|Patient-reported outcomes (PROs)
114000|NCT03295058|Drug|Non ATG Conditioning regimen|50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4
114001|NCT03295058|Drug|GVHD Prophylaxis|Cyclosporine A (CsA 3 mg/kg) start day +5
114002|NCT03295058|Procedure|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
114003|NCT03295058|Drug|ATG conditioning regimen|the other 50% of the patients will receive Cyclophosphamide + ATG
114004|NCT03295032|Behavioral|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.~Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
114005|NCT03295019|Device|Test Oral Spray|HA formulation of FDA listed ingredients
114006|NCT03295019|Device|Placebo Oral Spray|Placebo formulation without the active ingredients
114007|NCT03295006|Device|TheraSphere|Patients who had received TheraSphere
114008|NCT03294993|Device|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
114009|NCT03294967|Dietary Supplement|Caffeine|As in group descriptions
114010|NCT03294967|Dietary Supplement|Vitamin E|As in group descriptions
114011|NCT03294954|Genetic|GINAKIT Cells|"Four dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.~Dose Level 1 = 3 x 10^6~Dose Level 2 = 1 x 10^7~Dose Level 3 = 3 x 10^7~Dose Level 4 = 1 x 10^8"
114012|NCT03294954|Drug|Cyclophosphamide|Cyclophosphamide (500 mg/m2/day) will be given for 2 days; given on day -4 and day -3 with GINAKIT cells given on day 0.
114013|NCT03294954|Drug|Fludarabine|Fludarabine (30 mg/m2/day) will be given for 3 days; given on day -4, day -3 and day -2 with GINAKIT cells given on day 0.
114014|NCT03294941|Combination Product|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
114015|NCT03294928|Other|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.~Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).~Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).~Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
114016|NCT03294915|Dietary Supplement|Resistant Starch|Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants
114017|NCT03294915|Dietary Supplement|Placebo|Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
114018|NCT03294902|Device|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 60 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 3 distinct subject groups: (1) Critical Limb Ischaemia group, (2) Peripheral artery disease with superficial femoral arterial (SFA) or popliteal artery disease and (3) PAD-free group. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
114021|NCT03294863|Other|Standard of Care|Without the embrace Scar Therapy Device
114022|NCT03294850|Procedure|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
114023|NCT03294850|Device|HepQuant SHUNT Dual Cholate Liver Diagnostic Kit|For the experimental group, the device will be used to monitor the effect of bariatric surgery on liver function. For the active comparator group, the device will be used for the assessment of baseline liver function.
114024|NCT03294824|Other|blood sample|peripheral blood samples are collected
114025|NCT03294811|Device|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
114026|NCT03294798|Biological|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
114027|NCT03294798|Biological|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
114028|NCT03294785|Procedure|Chuna manual therapy|Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.
114029|NCT03294785|Drug|Conventional medication|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
114030|NCT03294785|Procedure|Physical therapy|Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
114031|NCT03294772|Other|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
114032|NCT03294772|Other|liquid soap|DCCs received liquid soap and a program educational.
114033|NCT03294759|Other|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
114034|NCT03294759|Other|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
114035|NCT03294746|Other|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
114036|NCT03294746|Other|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
114037|NCT03294733|Procedure|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
114038|NCT03294720|Procedure|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
114039|NCT03294720|Device|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
114040|NCT03294707|Drug|AG10 oral tablet|Active single ascending dose
114041|NCT03294707|Drug|Placebo Oral Tablet|Placebo single dose
114042|NCT03294694|Drug|Ribociclib|Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
114043|NCT03294694|Drug|PDR001|Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
114044|NCT03294694|Drug|Fulvestrant|Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
114045|NCT03294681|Device|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
114046|NCT03294668|Behavioral|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
114047|NCT03294668|Other|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
114048|NCT03294655|Behavioral|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
114049|NCT03294642|Dietary Supplement|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
114050|NCT03294642|Dietary Supplement|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
114300|NCT03292718|Device|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
114051|NCT03294642|Dietary Supplement|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
114052|NCT03294629|Device|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
114053|NCT03294616|Device|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
114054|NCT03294603|Drug|CC-220|1mg [14C]-CC-220 will be administered as a single dose
114055|NCT03294603|Radiation|[14C]|Single dose of [14C]-CC-220 will contain approximately 1.4 μCi of radioactivity
114056|NCT03294590|Other|OHT Parent targeted text messages|For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.
114057|NCT03294590|Other|CWT Parent targeted text messages|For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
114058|NCT03294577|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
114059|NCT03294577|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
114060|NCT03294577|Other|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
114061|NCT03294577|Drug|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
114062|NCT03294564|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
114063|NCT03294564|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
114064|NCT03294551|Behavioral|HPV Vaccine Reminder Recall - Autodialer|Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
114065|NCT03294551|Behavioral|HPV Vaccine Reminder Recall - Texting|Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
114066|NCT03294538|Drug|Estrace® Cream|Brand Product
114067|NCT03294538|Drug|Generic Estradiol Cream|Generic formulation of the brand product
114068|NCT03294538|Drug|Vehicle Cream|Has no active ingredient
114069|NCT03294525|Drug|Lithium Carbonate Oral Tablet|lithium carbonate 500mg~2000mg/day
114070|NCT03294525|Drug|Escitalopram Pill|escitalopram 10~20mg/day
114071|NCT03294512|Behavioral|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
114072|NCT03294499|Other|Questionnaire|Patients will be asked to complete one off questionnaire.
114073|NCT03294486|Drug|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:~Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu~Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.~5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
114074|NCT03294473|Behavioral|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
114075|NCT03294473|Behavioral|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
114076|NCT03294473|Behavioral|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
114077|NCT03294460|Drug|Alcohol (Oral)|Oral Self-administration
114078|NCT03294460|Drug|Alcohol (IV)|IV Self-administration
114079|NCT03294460|Drug|Alcohol (Ethanol)|IV and Oral Self-administration
114138|NCT03294044|Behavioral|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
114080|NCT03294447|Behavioral|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
114081|NCT03294434|Other|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
114082|NCT03294421|Procedure|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
114083|NCT03294421|Procedure|standard closed tympanomastoidectomy|"Supine position and general anesthesia with orotracheal intubation~Antisepsis and placing of sterile fields~Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI~Retroauricular incision~Removal of the temporal muscle fascia~Elevation of the surgical flap of the tympanic meatus~Visualization and exploration of the cholesteatoma~Exploration of the ossicular chain~Mastoid debridement~Conservation of the upper posterior wall of the auditory conduct~Removal of the cholesteatoma~Tympanoplasty with the temporal fascia~Retroauricular suture with vycril 3.0 and mononylon 4.0"
114084|NCT03294408|Diagnostic Test|multimodal imaging|
114085|NCT03294395|Drug|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
114086|NCT03294395|Drug|Fosfomycin Oral Suspension|single dose 6g oral suspension
114087|NCT03294395|Drug|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
114088|NCT03294395|Drug|Ceftriaxone|single dose 500mg intramuscular injection
114089|NCT03294382|Drug|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
114090|NCT03294382|Drug|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
114091|NCT03294369|Other|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
114092|NCT03294356|Other|FT210771|An electronic cigarette
114093|NCT03294356|Other|FT210751|An electronic cigarette
114094|NCT03294356|Other|6T30134157764|An electronic cigarette
114095|NCT03294356|Other|G41A7C071|An electronic cigarette
114096|NCT03294356|Other|M011161212|An electronic cigarette
114097|NCT03294356|Other|FT21002|A combustible cigarette
114098|NCT03294343|Procedure|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
114099|NCT03294343|Procedure|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
114100|NCT03294343|Other|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
114101|NCT03294330|Drug|IC-Green KIT|fluorescence lymphangiography with the use of IC-Green
114102|NCT03294317|Device|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
114103|NCT03294304|Drug|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.
114104|NCT03294304|Drug|Cisplatin|Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
114105|NCT03294304|Drug|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
114106|NCT03294291|Procedure|Quadratus lumborum block|Postoperative pain procedure
114107|NCT03294291|Procedure|Caudal block|Postoperative pain procedure
114108|NCT03294278|Other|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
114109|NCT03294265|Behavioral|Peer support sessions|"Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.~Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise"
114110|NCT03294265|Behavioral|Reminders|"Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.~This intervention will be applied to both groups."
114111|NCT03294252|Drug|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before CIPPA.
114139|NCT03294044|Behavioral|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
114112|NCT03294252|Drug|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before CIPPA.
114113|NCT03294252|Drug|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
114114|NCT03294239|Procedure|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
114115|NCT03294239|Procedure|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
114116|NCT03294226|Device|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
114117|NCT03294226|Device|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
114118|NCT03294213|Device|aScope 4 Broncho|"Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use"
114119|NCT03294200|Device|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
114120|NCT03294187|Device|Wrist-worn wearables|See arm/group description.
114121|NCT03294174|Drug|Ropivacaine injection|Ropivacaine administered to provide nerve block
114122|NCT03294161|Drug|Immucillin DI4G|Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
114123|NCT03294161|Drug|Meglumine antimoniate|Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
114124|NCT03294148|Other|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
114125|NCT03294148|Behavioral|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
114126|NCT03294135|Biological|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
114127|NCT03294122|Radiation|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
114128|NCT03294122|Radiation|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
114129|NCT03294109|Drug|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
114130|NCT03294096|Dietary Supplement|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
114131|NCT03294096|Other|Routine care|Routine post-op care
114132|NCT03294083|Biological|Pexastimogene Devacirepvec (Pexa-Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
114133|NCT03294083|Biological|REGN2810|REGN2810 is a monoclonal antibody to Programmed Death-1 (PD-1)
114134|NCT03294070|Combination Product|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
114135|NCT03294057|Behavioral|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
114136|NCT03294057|Behavioral|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
114137|NCT03294057|Behavioral|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
114428|NCT03291821|Procedure|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
114140|NCT03294031|Other|Pilates|"Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing."
114141|NCT03294031|Other|Conventional Exercise|All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
114142|NCT03294018|Other|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
114143|NCT03294005|Diagnostic Test|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
114144|NCT03293992|Drug|0.01% RO7058584|Once daily morning administration for 7 days
114145|NCT03293992|Drug|0.1% RO7058584|Once daily morning administration for 7 days
114146|NCT03293992|Drug|1% RO7058584|Once daily morning administration for 7 days
114147|NCT03293992|Drug|Matching Placebo|Once daily morning administration for 7 days
114148|NCT03293992|Drug|Latanoprost 0.005%|Once daily morning or evening dosing
114149|NCT03293979|Diagnostic Test|Test A i Flu A&B implemented in emergency service|Test A i Flu A&B implemented in emergency service
114150|NCT03293940|Procedure|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
114151|NCT03293940|Procedure|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.~The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
114152|NCT03293927|Drug|Fentanyl|The patient will receive IV fentanyl
114153|NCT03293927|Drug|Dexmedetomidine|The patient will receive IV dexemedetomidine
114154|NCT03293914|Behavioral|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
114155|NCT03293901|Behavioral|Exercise|Treadmill exercise for 60 minutes with load carriage (weighted vest, 30% body weight) completed three times during the 6 day kinetic period.
114156|NCT03293875|Behavioral|Encuentro|a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV
114157|NCT03293862|Device|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
114158|NCT03293862|Procedure|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
114159|NCT03293862|Device|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
114160|NCT03293849|Other|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
114161|NCT03293836|Procedure|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
114162|NCT03293836|Procedure|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
114163|NCT03293823|Behavioral|VSOP training|a computerized cognitive training of attention and processing speed
114164|NCT03293823|Behavioral|MLA control|a computerized cognitive intervention of multiple mental leisure activities
114165|NCT03293810|Other|Observational study|Post-Authorization Safety Study
114166|NCT03293797|Behavioral|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
114167|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
114168|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.~Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
114169|NCT03293771|Other|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
114170|NCT03293771|Diagnostic Test|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
114171|NCT03293745|Behavioral|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
114172|NCT03293745|Behavioral|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
114173|NCT03293732|Biological|DCB07010|A protein based adjuvant originated from prokaryotic organism.
114174|NCT03293732|Biological|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
114175|NCT03293719|Device|BPK-S Integration UC|Primary Knee Endoprosthesis
114176|NCT03293706|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
114177|NCT03293706|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
114178|NCT03293706|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
114179|NCT03293706|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
114180|NCT03293706|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
114181|NCT03293693|Other|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
114182|NCT03293693|Other|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
114183|NCT03293693|Other|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
114184|NCT03293680|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
114185|NCT03293667|Other|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
114186|NCT03293654|Drug|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
114187|NCT03293654|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
114188|NCT03293654|Drug|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
114189|NCT03293641|Dietary Supplement|Zinc Sulfate Tablets|Zinc Sulfate Tablets 3 times every 7 days for 6 months.
114190|NCT03293641|Drug|Standard of Care|Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
114191|NCT03293628|Procedure|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
114192|NCT03293615|Other|exploration|Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.
114193|NCT03293602|Device|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
114194|NCT03293589|Procedure|open revascularization|surgical revascularization (i.e. Bypass surgery)
114195|NCT03293589|Procedure|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
114196|NCT03293576|Behavioral|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
114197|NCT03293563|Procedure|Radical nephrectomy versus partial nephrectomy (according surgeon judgement)|
114198|NCT03293537|Diagnostic Test|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
114199|NCT03293524|Genetic|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
114200|NCT03293524|Drug|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
114201|NCT03293511|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
114202|NCT03293511|Drug|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
114203|NCT03293498|Biological|NanoFlu|Vaccine
114204|NCT03293498|Biological|Fluzone HD - Day 0|Vaccine
114205|NCT03293498|Biological|Fluzone HD - Day 21|Vaccine
114206|NCT03293498|Other|Saline - Day 21|Placebo
114207|NCT03293485|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
114208|NCT03293472|Drug|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
114320|NCT03292562|Device|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1L flow, 30% FiO2).
114209|NCT03293472|Drug|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine~Device:~The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
114210|NCT03293459|Procedure|Balloon Retrograde Transvenous Obliteration (BRTO)|Catheterization of the gastrorenal shunt via the left renal vein will be accomplished using a catheter with a mounted occlusion balloon. Balloon occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours and deflated under fluoroscopy the next day. Followed by repeat CT abdomen to look for occlusion of shunts.
114211|NCT03293459|Dietary Supplement|Standard Medical Treatment (SMT)|These will include diet rich in BCAA (branch chain amino acids), laxatives and rifaximin
114212|NCT03293446|Diagnostic Test|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
114213|NCT03293433|Other|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
114214|NCT03293407|Drug|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
114215|NCT03293407|Device|Breelib nebulizer|Used for inhalation of Ventavis
114216|NCT03293394|Device|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
114217|NCT03293394|Device|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
114218|NCT03293381|Device|additional biopsies|additional biopsies
114219|NCT03293368|Biological|Platelet rich plasma|Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
114220|NCT03293368|Drug|Triamcinolone Acetonide|0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
114221|NCT03293355|Behavioral|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
114222|NCT03293342|Behavioral|D CBT|"Intervention:~a 3-5 session treatment of dental fear.~Psychoeducation about anxiety~Exploration of the individual anxiety~Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
114223|NCT03293342|Combination Product|Control|"Intervention:~Traditional treatment of dental fear common sense/ benzodiazepine"
114224|NCT03293329|Other|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
114225|NCT03293329|Other|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
114226|NCT03293329|Other|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
114227|NCT03293316|Device|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
114228|NCT03293303|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
114229|NCT03293290|Drug|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
114230|NCT03293277|Drug|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
114231|NCT03293277|Drug|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
114232|NCT03293277|Drug|Intranasal Placebo|Intranasal Placebo
114233|NCT03293277|Drug|Intravenous Placebo|Intravenous Placebo
114259|NCT03293056|Other|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
114321|NCT03292549|Procedure|Robotic partial surgery|Robotic partial surgery
114322|NCT03292536|Drug|Merestinib|"*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen*~Subjects will receive merestinib 40mg PO Qday (dose level 1) for 2 to 4 weeks followed by 80mg PO daily (dose level 2) for 4 to 10 weeks"
114462|NCT03291470|Biological|Placebo Control|2 mL normal saline injection
114234|NCT03293264|Behavioral|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
114235|NCT03293251|Procedure|Trabeculectomy with MMC|glaucoma surgeries
114236|NCT03293238|Procedure|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
114237|NCT03293238|Procedure|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
114238|NCT03293238|Procedure|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
114239|NCT03293238|Procedure|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
114240|NCT03293199|Procedure|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
114241|NCT03293199|Procedure|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
114242|NCT03293186|Combination Product|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
114243|NCT03293173|Combination Product|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
114244|NCT03293173|Combination Product|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
114245|NCT03293160|Other|Care management services|Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
114246|NCT03293147|Other|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
114247|NCT03293147|Other|Standard care|Standard care for hypertensive patients
114248|NCT03293121|Behavioral|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength & coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
114249|NCT03293121|Behavioral|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
114250|NCT03293108|Drug|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
114251|NCT03293108|Dietary Supplement|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
114252|NCT03293108|Dietary Supplement|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
114253|NCT03293095|Procedure|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
114254|NCT03293082|Device|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
114255|NCT03293082|Device|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
114256|NCT03293069|Drug|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
114257|NCT03293069|Drug|Placebo Oral Tablet|the placebo twice daily morning and evening.
114258|NCT03293056|Other|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
114260|NCT03293043|Device|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
114261|NCT03293030|Drug|Dupilumab|Dupilumab treatment
114262|NCT03293017|Drug|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
114263|NCT03293017|Drug|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
114264|NCT03293017|Drug|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
114265|NCT03293004|Dietary Supplement|Hydrolyzed collagen|Escalating dose of Hydrolyzed collagen
114266|NCT03293004|Dietary Supplement|Vitamin C|Escalating dose of Vitamin C
114267|NCT03293004|Dietary Supplement|Optimized Hydrolyzed Collagen and Vitamin C|combination of optimized doses of Hydrolyzed Collagen and Vitamin C
114268|NCT03293004|Dietary Supplement|Gummy Placebo|Gummy placebo
114269|NCT03292978|Dietary Supplement|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
114270|NCT03292978|Dietary Supplement|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
114271|NCT03292965|Drug|Neostigmine|Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
114272|NCT03292965|Drug|Sugammadex|Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
114273|NCT03292952|Drug|KP415 oral capsule|Daily dose
114274|NCT03292952|Drug|Placebo oral capsule|Daily dose
114275|NCT03292939|Diagnostic Test|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
114276|NCT03292926|Drug|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
114277|NCT03292926|Device|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
114278|NCT03292926|Drug|Dexamethasone|Dexamethasone will be used to prolong block duration
114279|NCT03292913|Behavioral|Positive Health Check|PHC is an online intervention that delivers tailored evidence-based prevention messages to HIV positive patients through a series of brief interactive videos designed to simulate a conversation with an HIV primary care provider.
114280|NCT03292913|Behavioral|Standard of Care|Standard of care for patients with HIV (this includes standard of care practices around ART initiation, adherence and retention)
114281|NCT03292874|Diagnostic Test|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
114282|NCT03292861|Drug|Thymoglobulin|Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
114283|NCT03292861|Drug|Mycophenolate Mofetil|3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
114284|NCT03292861|Drug|Tacrolimus|Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
114285|NCT03292861|Drug|Sirolimus|Maintenance doses of sirolimus at 12 months post-transplantation
114286|NCT03292861|Drug|Corticosteroids|125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
114287|NCT03292848|Drug|Brexpiprazole|Tablet
114288|NCT03292835|Device|LeiProtect®|Filmogenic dressing gel
114289|NCT03292822|Dietary Supplement|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
114290|NCT03292822|Drug|Paclitaxel|chemotherapeutic drug
114291|NCT03292809|Drug|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
114292|NCT03292809|Drug|Vehicle topical ocular, eye drops|Vehicle
114293|NCT03292796|Drug|Prostaglandins|
114294|NCT03292783|Drug|NOV1501 (ABL001)|VEGF/DLL4 targeting bispecific antibody
114295|NCT03292770|Device|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
114296|NCT03292757|Drug|Indocyanine Green|Fluorescent dye - indocyanine green
114297|NCT03292744|Drug|Alfacalcidol|alfacalcidol 0,5 mcg
114298|NCT03292731|Drug|Hydroxyprogesterone 250 Mg|Pregnant subjects randomized to this study arm will receive a weekly Intramuscular injection of 250mg hydroxyprogesterone caproate injection weekly from 16 0/7 to 36 6/7 weeks or delivery which ever is first.
114299|NCT03292731|Drug|hydroxyprogesterone 500mg|Pregnant subjects randomized to this study arm will receive a weekly Intramuscular injection of 500mg hydroxyprogesterone caproate injection weekly from 16 0/7 to 36 6/7 weeks or delivery which ever is first.
114301|NCT03292705|Behavioral|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
114302|NCT03292705|Behavioral|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
114303|NCT03292692|Behavioral|OurRelationship|Online intervention with coach support
114304|NCT03292679|Procedure|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.~Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
114305|NCT03292666|Drug|Oral Anticoagulant|Oral anticoagulants used to treat or prevent venous thromboembolism
114306|NCT03292653|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
114307|NCT03292653|Drug|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
114308|NCT03292653|Drug|Heavy Water|"Pharmaceutical form: Solution~Route of administration: Oral"
114309|NCT03292653|Drug|131-Iodine-Albumin|"Pharmaceutical form: Solution~Route of administration: Intravenous"
114310|NCT03292640|Drug|DFD-03 (0.1% tazarotene) Lotion|Subjects will apply a quarter (U.S coin) size amount of the study product all over the moistened face and rub it into the skin until foamy. Care should be taken to avoid the areas around the eyes, mouth, and nostrils. After a short time, the subject will rinse off the product by thoroughly rinsing with warm water. This procedure will be followed twice daily, in the morning and at bedtime, approximately 12 hours apart.
114311|NCT03292640|Drug|DFD-03 (0% tazarotene) Lotion (Placebo)|Subjects will apply a quarter (U.S coin) size amount of the study product all over the moistened face and rub it into the skin until foamy. Care should be taken to avoid the areas around the eyes, mouth, and nostrils. After a short time, the subject will rinse off the product by thoroughly rinsing with warm water. This procedure will be followed twice daily, in the morning and at bedtime, approximately 12 hours apart.
114312|NCT03292627|Device|Portable Noninvasive Hemodynamic Monitor|A non-invasive monitor for estimating patient's heart contractility and cardiac output by the change of thoracic electrical bioimpedance.
114313|NCT03292614|Diagnostic Test|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:~Autorefractor Keratometers:~Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)~Manual Refractometer:~Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),~Test device:~iTrace (TraceyTechnologies, Houston, Texas, USA),~Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
114314|NCT03292601|Device|Cinch Smart Strap|"The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient."
114315|NCT03292601|Other|Cinch Mobile App|The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
114316|NCT03292588|Biological|Mepolizumab|"Mepolizumab administered every 4 weeks by subcutaneous injection at a dose of:~100 mg for participants ≥12 years of age and~40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
114317|NCT03292588|Drug|Placebo|"Placebo administered every 4 weeks by subcutaneous injection at a dose of:~100 mg for participants ≥12 years of age and~40 mg for participants ages 6 to 11 years and weighing ≥40 kg.~Note: Participants 6 to 11 years of age and weighing ≥40 kg who were enrolled in the study under previous versions of the protocol and were initially assigned a 100 mg dose will have their dose reduced to 40 mg.~Participants 11 years of age will increase to the 100 mg dose if they become age 12 years during the study."
114318|NCT03292575|Drug|Anticoagulants|
114319|NCT03292562|Device|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria (described below) pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1L flow, 30% FiO2).
114427|NCT03291821|Diagnostic Test|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
114323|NCT03292523|Other|questionnaire|Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
114324|NCT03292510|Other|GO-OUT Group|Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention)
114325|NCT03292510|Other|Workshop Group|the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5 and 12 months from baseline
114326|NCT03292497|Procedure|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle >=25 degrees, or repaired if the posterior leaflet tethering angle <25 degrees.
114327|NCT03292497|Procedure|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
114328|NCT03292484|Biological|AR101|AR101
114329|NCT03292471|Device|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
114330|NCT03292458|Drug|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
114331|NCT03292445|Procedure|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
114332|NCT03292445|Drug|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover >10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
114333|NCT03292432|Behavioral|TERA Intervention|"A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with vsee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior)."
114334|NCT03292432|Behavioral|Standard of Care|Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
114335|NCT03292419|Procedure|Topography-guided LASIK|LASIK surgery
114336|NCT03292406|Drug|Placebo|Non active ingredients of CD11301
114337|NCT03292406|Drug|CD11301 0.03%|Topical Gel
114338|NCT03292406|Drug|CD11301 0.06%|Topical Gel
114339|NCT03292393|Behavioral|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
114340|NCT03292393|Behavioral|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
114341|NCT03292393|Device|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
114342|NCT03292393|Device|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
114343|NCT03292380|Other|No intervention was included|
114344|NCT03292367|Procedure|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
114345|NCT03292354|Other|Contrast media administration|All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
114346|NCT03292341|Other|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
114347|NCT03292341|Other|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
114348|NCT03292341|Other|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
114349|NCT03292341|Other|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
114350|NCT03292328|Other|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
114351|NCT03292328|Other|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
114352|NCT03292315|Drug|Exenatide 2 MG Injection [Bydureon]|Once weekly injection of 2mg of Exenatide
114353|NCT03292315|Other|No Intervention|No injection will be administered
114354|NCT03292302|Drug|Placebo|Placebo comparator
114355|NCT03292302|Drug|ELX-02|Synthetic aminoglycoside
114356|NCT03292289|Procedure|Pre- and post-operative consultation|Before and between the two interventions
114357|NCT03292289|Procedure|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
114358|NCT03292289|Procedure|Questionnaires|"QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~Stoma-QoL before and after the 2nd intervention~LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
114359|NCT03292276|Device|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).~Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
114360|NCT03292263|Drug|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
114361|NCT03292263|Drug|Nivolumab|iv infusion 100 mg on day -3, +17
114362|NCT03292263|Procedure|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
114363|NCT03292250|Drug|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
114364|NCT03292250|Drug|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
114365|NCT03292250|Drug|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
114366|NCT03292250|Drug|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
114367|NCT03292250|Drug|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
114368|NCT03292237|Dietary Supplement|Supplemental parenteral nutrition|Supplemental parenteral nutrition OLIMEL N12E (Baxter Healthcare Corporation)
114369|NCT03292224|Diagnostic Test|- Microscopic examination and culture of collected specimens|"Unstained wet mount with 10%-20% KOH.~Wet mounts stained with:~Lactophenol cotton blue.~India ink~Gram stain Culturing on Sabouraud´s dextrose agar ."
114370|NCT03292211|Behavioral|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
114371|NCT03292211|Behavioral|early standard intervention|Conventional early in-bed activities within three days after stroke
114372|NCT03292198|Other|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists."
114373|NCT03292198|Other|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
114374|NCT03292185|Drug|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
114375|NCT03292185|Drug|insulin degludec|17 U Insulin Degludec, single dose administration under the skin in the thigh.
114376|NCT03292185|Drug|liraglutide|0.6 mg Liraglutide, single dose administration under the skin in the thigh
114377|NCT03292172|Drug|Atezolizumab|Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
114378|NCT03292172|Drug|RO6870810|RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
114379|NCT03292159|Device|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
114380|NCT03292159|Device|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
114381|NCT03292146|Drug|Denosumab 60 MG [Prolia]|Denosumab 60mg injection at baseline and 6 months
114382|NCT03292146|Drug|Placebo Injection|Placebo Injection at baseline and 6 months
114383|NCT03292133|Drug|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
114384|NCT03292133|Drug|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
114385|NCT03292120|Other|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
114386|NCT03292081|Device|OFDI|PCI under OFDI guidance
114387|NCT03292081|Device|IVUS|PCI under IVUS guidance
114388|NCT03292068|Combination Product|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
114389|NCT03292068|Dietary Supplement|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
114390|NCT03292068|Other|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
114391|NCT03292042|Behavioral|Physical health promotion program|"The program has 24 sessions. Each session has two parts:~first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.~Second part: 1 hour of physical activity (walk)"
114392|NCT03292029|Diagnostic Test|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
114393|NCT03292016|Drug|APL-130277|APL-130277 sublingual thin film
114394|NCT03292016|Drug|APO-go|Subcutaneous APO-go
114395|NCT03292016|Drug|Apokyn|Subcutaneous APOKYN
114396|NCT03292003|Device|Journey II BCS Total Knee System|
114397|NCT03291990|Drug|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
114398|NCT03291977|Drug|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
114399|NCT03291977|Procedure|White-light surgery|The surgery will be performed under classical conditions
114400|NCT03291964|Diagnostic Test|Rapid Brain MRI|Children undergoing head CT for evaluation of acute head injury will also undergo rapid brain MRI with GRE sequence that is specific for blood. Their clinical care will not change at all based on the MRI.
114401|NCT03291951|Behavioral|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
114402|NCT03291938|Drug|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
114403|NCT03291938|Other|Pharmacodynamic Study|Correlative studies
114404|NCT03291938|Other|Pharmacokinetic Study|Correlative studies
114405|NCT03291925|Procedure|Selective invasive angiography based on CT/CCTA imaging.|
114406|NCT03291925|Procedure|Procedure/Surgery: Invasive angiography|
114407|NCT03291912|Procedure|Chuna Manual Therapy|"Unique manual therapy in traditional Korean medicine~Mandatory techniques for neck part and selective techniques for other part (if necessary)~Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
114408|NCT03291912|Procedure|Usual care|"Physical therapy based on traditional Korean medicine theory~Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity~Heat stimulation: either Hot pack or Infrared lamp~Patient education~Physical and pathological explanation of cervicogenic dizziness~Cause and risk factors of cervicogenic dizziness~Functions of muscles related to cervicogenic dizziness~Home exercising to self-manage cervicogenic dizziness"
114409|NCT03291899|Combination Product|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
114410|NCT03291886|Drug|Entinostat|Given PO
114411|NCT03291886|Drug|Entinostat(Placebo)|Given PO
114412|NCT03291886|Drug|Exemestane|Given PO
114413|NCT03291873|Procedure|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
114414|NCT03291860|Procedure|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
114415|NCT03291847|Device|fetal monitoring|Maternal fetal monitoring
114416|NCT03291847|Drug|Buprenorphine Naloxone|Treatment for opioid use disorder
114417|NCT03291847|Drug|Methadone|Treatment for opioid use disorder
114418|NCT03291821|Drug|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
114419|NCT03291821|Drug|GnRH antagonist|GnRH antagonist subcutaneously
114420|NCT03291821|Drug|GnRH analog|GnRH analog subcutaneously
114421|NCT03291821|Procedure|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
114422|NCT03291821|Diagnostic Test|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
114423|NCT03291821|Procedure|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
114424|NCT03291821|Procedure|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
114425|NCT03291821|Diagnostic Test|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
114426|NCT03291821|Procedure|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
114429|NCT03291821|Procedure|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
114430|NCT03291808|Behavioral|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
114431|NCT03291795|Other|Exercise Intervention|Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
114432|NCT03291782|Drug|D-0120|oral, single dose
114433|NCT03291743|Device|Capsule endoscopy|PillCam(TM) CROHN'S CAPSULE
114434|NCT03291730|Behavioral|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
114435|NCT03291730|Other|Art-therapy|May help reduce anxiety of receiving chemotherapy
114436|NCT03291717|Behavioral|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
114437|NCT03291704|Device|Thermal therapy device|Thermal therapy of blocked Meibomian glands
114438|NCT03291678|Procedure|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
114439|NCT03291678|Procedure|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
114440|NCT03291652|Diagnostic Test|DSA/3DRA|DSA/3DRA
114441|NCT03291613|Other|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
114442|NCT03291600|Behavioral|Virtual Psychiatric Care|Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
114443|NCT03291587|Other|Key Informant|Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation.
114444|NCT03291574|Procedure|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
114445|NCT03291574|Procedure|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
114446|NCT03291561|Procedure|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
114447|NCT03291561|Procedure|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
114448|NCT03291548|Dietary Supplement|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
114449|NCT03291548|Dietary Supplement|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
114450|NCT03291535|Other|Connected-device|This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.
114451|NCT03291535|Other|Usual care|This intervention will consist of usual clinical care as determined by the clinical pharmacist.
114452|NCT03291522|Procedure|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed first. If no sperm is found, the patient can choose to do a standard of care procedure (but not required).
114453|NCT03291509|Behavioral|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
114454|NCT03291509|Behavioral|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
114455|NCT03291509|Behavioral|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
114456|NCT03291509|Behavioral|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
114457|NCT03291496|Other|Blood Collection Preterm|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. Thereafter, one sample will be collected weekly until discharge. For preterm neonates that have suspected sepsis an additional sample will be collected within 24-48 hours of the initial sepsis evaluation.
114458|NCT03291496|Other|Blood Collection Term|A single 250 µl blood sample will be collected once the term neonate is >24 hours old.
114459|NCT03291483|Other|whole body vibration|whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
114460|NCT03291483|Other|plyometric training|Plyometric exercises refers to performance of stretch‐shortening cycle (SSC) movements that involve a high‐intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
114461|NCT03291470|Biological|TG-C|2 mL injection of allogeneic human chondrocytes expressing transforming growth factor-beta1
114463|NCT03291457|Drug|Tocilizumab|For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
114464|NCT03291457|Drug|Glucocorticoid Agent|Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
114465|NCT03291444|Biological|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
114466|NCT03291444|Biological|peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.
114467|NCT03291431|Device|Intermittent theta burst transcranial magnetic stimulation|Participants will be randomized to active or sham iTBS conditions, and receive 20 iTBS sessions over the course of 2 weeks
114468|NCT03291418|Drug|ATB-346 OR Placebo|Comparison of gastrointestinal effects
114469|NCT03291418|Drug|Naproxen sodium|Comparison of gastrointestinal effects
114470|NCT03291392|Genetic|Gene expression or biomarkers exploration|
114471|NCT03291379|Drug|BTG-002814 (vandetanib-eluting radiopaque beads)|BTG-002814 containing 100 mg vandetanib
114472|NCT03291366|Drug|UCMSCC|infusion of aUCMSC and conventional therapy
114473|NCT03291366|Drug|conventional treatment|conventional treatment
114474|NCT03291353|Drug|pembrolizumab|200 mg IV given every three weeks
114475|NCT03291327|Dietary Supplement|Probiotics|Lozenges for Home use
114476|NCT03291314|Drug|Axitinib|1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) [7].
114477|NCT03291314|Drug|Avelumab|2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
114478|NCT03291301|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
114479|NCT03291301|Other|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
114480|NCT03291288|Drug|Tolbutamide|Commercially available tolbutamide
114481|NCT03291288|Drug|Midazolam|Commercially available midazolam
114482|NCT03291288|Drug|Pexidartinib|Pexidartinib is formulated as opaque, white, 200-mg capsules
114483|NCT03291275|Other|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
114484|NCT03291262|Other|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
114485|NCT03291249|Drug|Foralumab|Anti CD3 mAb
114486|NCT03291249|Other|placebo|Placebo oral solution
114487|NCT03291249|Drug|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
114488|NCT03291236|Other|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
114489|NCT03291210|Other|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
114490|NCT03291210|Other|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
114491|NCT03291197|Drug|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
114492|NCT03291184|Device|peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.
114493|NCT03291171|Behavioral|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
114494|NCT03291158|Drug|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
114495|NCT03291145|Drug|Beta Blockers|With and without Beta Blockers
114496|NCT03291145|Drug|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
114497|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
114498|NCT03291106|Diagnostic Test|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
114499|NCT03291106|Diagnostic Test|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
114500|NCT03291106|Diagnostic Test|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
114501|NCT03291106|Diagnostic Test|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
114502|NCT03291093|Drug|18F-Flutemetamol PET/MRI|All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
114503|NCT03291080|Drug|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
114504|NCT03291080|Drug|Extracted capsules 13-CRA|Extracted capsules 13-CRA
114505|NCT03291067|Drug|MT-8554 Low dose|MT-8554 Low dose QD, oral, 12 weeks
114506|NCT03291067|Drug|MT-8554 Medium dose|MT-8554 Medium dose QD, oral, 12 weeks
114507|NCT03291067|Drug|MT-8554 High dose|MT-8554 High dose QD, oral, 12 weeks
114508|NCT03291067|Drug|Placebo|Placebo QD, oral, 12 weeks
114509|NCT03291054|Drug|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
114510|NCT03291054|Drug|Epacadostat|Epacadostat will be dosed at 100 mg PO twice a day (BID) daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
114511|NCT03291041|Drug|Tasimelteon|capsule
114512|NCT03291041|Drug|Placebo|capsule
114513|NCT03291028|Biological|Immune checkpoint inhibitor targeting PD1|RCC and UC patients treated with immune checkpoint blockade
114514|NCT03291015|Device|radiographic|using plain x ray to determind the treatment plan
114515|NCT03291015|Device|arthroscopy|using wrist arthroscopy to determind the treatment plan
114516|NCT03291002|Biological|CV8102|CV8102 alone
114517|NCT03291002|Biological|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
114518|NCT03290976|Other|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:~Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
114519|NCT03290976|Other|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:~Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure~Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
114520|NCT03290963|Drug|Lithium|Lithium will be dosed in units (LI level > or = 0.4 milliequivalents (mEq)/L)
114521|NCT03290963|Drug|Placebo|Placebo tablets, dosed in units
114522|NCT03290963|Drug|Ketamine|All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.
114523|NCT03290950|Drug|daratumumab|Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1; Daratumumab rate of infusion is per MSKCC guidelines.
114524|NCT03290950|Drug|carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
114525|NCT03290950|Drug|lenalidomide|Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
114526|NCT03290950|Drug|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, 16 and 22; Cycles 3-4: Dexamethasone 20mg/dose, days 1,2,8,9,15 and 16, Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
114527|NCT03290950|Drug|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 1, 2, 22; 40 mg/dose days 8 and 15, Cycles 2: Dexamethasone 40mg/dose, days 1, 8, 15; 20 mg/dose day 22, Cycles 3-4: Dexamethasone 40mg/dose, Days 1, 8 15, Cycles 5-8: Dexamethasone 20mg/dose, Days 1, 8, 15
114528|NCT03290937|Biological|Cetuximab|Given IV
114529|NCT03290937|Drug|Irinotecan|Given IV
114530|NCT03290937|Drug|Irinotecan Hydrochloride|Given IV
114531|NCT03290937|Other|Pharmacodynamic Study|Correlative studies
114532|NCT03290937|Biological|Utomilumab|Given IV
114533|NCT03290924|Behavioral|Low dose high frequency health worker training approach|"Two 4-day training sessions for skilled birth attendants~1-day peer practice coordinator training after first training session~Weekly, peer-led practice sessions using MamaNatalie® and NeoNatalie™ anatomic models~SMS reminder messages and quizzes~Routine telephone calls between master mentors and peer practice coordinators, and between project staff and master mentors~Health information officer training~Data collection and use training~Supply of simulators, newborn resuscitation equipment, and delivery sets"
114534|NCT03290924|Behavioral|Active Comparison|Training on data collection and reporting
114535|NCT03290898|Behavioral|High Intensity Interval Training|Training (HIIT)
114536|NCT03290885|Combination Product|Combined contact aspiration/Stent Retriever Technique|Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
114537|NCT03290885|Device|Stent retriever technique|"The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.~A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.~After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter."
114538|NCT03290872|Device|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
114539|NCT03290872|Device|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
114540|NCT03290859|Procedure|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
114541|NCT03290846|Drug|Secretin Human|Randomized, single-blinded secretin hydrochloride infusion.
114542|NCT03290846|Drug|Saline Solution|Randomized, single-blinded saline infusion.
114543|NCT03290846|Other|Cold exposure|All subjects will undergo a cold exposure PET scan.
114544|NCT03290833|Device|Robotic|Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
114545|NCT03290833|Other|Conventional therapy|An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
114546|NCT03290820|Radiation|Radiotherapy|Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
114547|NCT03290820|Drug|Concurrent chemotherapy|Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
114548|NCT03290820|Drug|Aspirin|Daily aspirin of 75mg, from the starting date of radiotherapy.
114549|NCT03290807|Device|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
114550|NCT03290794|Drug|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
114551|NCT03290781|Drug|SHP647|1 milliliter (mL) of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide an intended dose of drug (25 or 75 mg).
114552|NCT03290781|Other|Placebo|1 mL of sterile aqueous buffered solution.
114553|NCT03290768|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
114554|NCT03290768|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
114555|NCT03290768|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
114556|NCT03290755|Behavioral|semi-directed interviews|semi-directed interviews in order to collect socio-behavioral data
114557|NCT03290729|Procedure|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
114558|NCT03290716|Other|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
114559|NCT03290716|Other|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
114560|NCT03290703|Drug|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
114561|NCT03290703|Drug|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
114562|NCT03290677|Procedure|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
114563|NCT03290677|Procedure|Biopsy|Removing a small piece of the affected area to confirm cancer
114564|NCT03290664|Biological|CD3-/CD19-|CD3-/CD19- will be infused along with IL-2 on Day 0 following a preparative regimen of Fludarabine and Cyclophosphamide.
114565|NCT03290664|Biological|CD3-/CD56+|CD3-/CD56+ will be infused along with IL-2 on Day 0 following a preparative regimen of Fludarabine and Cyclophosphamide.
114566|NCT03290651|Dietary Supplement|Probiotic Natural Health Product - RepHresh Pro-B|Participants will take the probiotic or placebo daily for 90 days.
114567|NCT03290651|Dietary Supplement|Placebo|Participants will take the probiotic or placebo daily for 90 days.
114568|NCT03290638|Procedure|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
114569|NCT03290625|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
114570|NCT03290625|Drug|Ketamine Hydrochloride|Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
114571|NCT03290612|Dietary Supplement|Vitamin C|1.5g Ascorbic Acid
114572|NCT03290612|Other|Placebo|Inactive placebo to mimic 1.5g ascorbic acid.
114573|NCT03290599|Other|Mini Mental and Modified Mini Mental Test|Mini Mental Test was used for literate patients and Modified mini mental test was used for illiterated patients
114574|NCT03290586|Device|Flower Cube|single use, sterile disposable fixation construct
114575|NCT03290573|Device|short peripheral venous catheter|short peripheral venous catheter for infusion therapy in adult patients
114576|NCT03290560|Drug|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
114577|NCT03290560|Other|Placebo|Placebo Comparator: Phosphate buffered saline
114578|NCT03290547|Device|Cutera enLighten laser|Subjects will receive up to 10 laser treatments.
114579|NCT03290534|Device|CivaSheet|implanting CivaSheet for localized radiation dose delivery
114580|NCT03290521|Procedure|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
114581|NCT03290521|Procedure|No washing|no washing
114582|NCT03290508|Diagnostic Test|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
114583|NCT03290495|Drug|ketamine|ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia
114584|NCT03290495|Drug|saline|a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
114585|NCT03290482|Diagnostic Test|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
114586|NCT03290482|Device|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
114587|NCT03290482|Diagnostic Test|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
114588|NCT03290469|Other|clinical whole genome sequencing (cWGS)|Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
114589|NCT03290456|Drug|Prednisone 5mg/day extended of 12 additional months|Prednisone 5mg/day orally during 12 Month + 1 mg/week tapering until 0mg.
114590|NCT03290456|Drug|Placebo 5mg/day extended of 12 additionnal months.|1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 13
114591|NCT03290443|Drug|Enasidenib|100 mg enasidenib (CC-90007)
114592|NCT03290430|Behavioral|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
114593|NCT03290430|Behavioral|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
114594|NCT03290430|Behavioral|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
114595|NCT03290430|Behavioral|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
114596|NCT03290430|Behavioral|Texting support|Texts with smoking cessation support throughout the program
114597|NCT03290430|Drug|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
114598|NCT03290417|Dietary Supplement|Vitamin D|5000 IU/cap; One cap by mouth daily
114599|NCT03290417|Dietary Supplement|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
114600|NCT03290417|Dietary Supplement|Turmeric|250mg/cap; two capsules by mouth 4 times per day
114601|NCT03290391|Other|LINC-II|Strengths-based case management: 10 sessions over 12 months. Rapid ART initiation Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
114602|NCT03290378|Drug|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
114603|NCT03290378|Other|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
114604|NCT03290365|Drug|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
114605|NCT03290365|Drug|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
114606|NCT03290352|Other|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
114607|NCT03290339|Procedure|hysterectomy|laparoscopic hysterectomy and vaginal hysterectomy
114608|NCT03290326|Device|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
114609|NCT03290313|Drug|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
114610|NCT03290313|Drug|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
114611|NCT03290313|Other|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
114612|NCT03290300|Device|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
114613|NCT03290287|Drug|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
114614|NCT03290287|Drug|Other COPD medication|"Users of the following COPD medications:~Tiotropium~Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium~LABA: formoterol, salmeterol, indacaterol~LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.~LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
114615|NCT03290274|Device|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
114616|NCT03290274|Device|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
114617|NCT03290261|Other|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
114618|NCT03290248|Biological|B244 suspension|B244 suspension in 30ml/bottle
114619|NCT03290248|Biological|Vehicle|Vehicle, 30ml/bottle
114620|NCT03290235|Drug|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
114621|NCT03290222|Other|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
114622|NCT03290209|Procedure|Laparoscopic D1 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
114623|NCT03290209|Procedure|Laparoscopic D2 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
114624|NCT03290196|Drug|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
114625|NCT03290183|Device|Confocal laser endomicroscopy|Real-time microscopic imaging technique
114626|NCT03290170|Procedure|Measured Resection|Bony landmarks are used to set femoral component rotation.
114627|NCT03290170|Procedure|Gap Balancing|Relies on ligament releases prior to bone cuts.
114628|NCT03290157|Device|ColoprAPP|Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
114629|NCT03290131|Drug|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
114630|NCT03290131|Drug|Placebo|Placebo comparator
114631|NCT03290118|Other|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
114632|NCT03290118|Other|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
114633|NCT03290118|Other|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
114634|NCT03290118|Device|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
114635|NCT03290092|Drug|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
114636|NCT03290092|Drug|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
114637|NCT03290079|Drug|Pembrolizumab|Pembrolizumab Day 1 of each 3 week cycle.
114638|NCT03290066|Device|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
114639|NCT03290066|Other|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
114640|NCT03290053|Drug|SonoVue|SonoVue-infusion over 1 hour
114641|NCT03290053|Drug|Sodium chloride|Placebo
114642|NCT03290053|Procedure|Transcranial Ultrasound|Transcranial ultrasound aimed at the blockage
114643|NCT03290053|Procedure|Sham Transcranial Ultrasound|Placebo - machine is attached, but not active
114644|NCT03290027|Drug|DFD-03|DFD-03 Lotion
114645|NCT03290027|Other|Placebo Comparator|Vehicle (tazarotene 0%) Lotion
114646|NCT03290014|Diagnostic Test|polysomnography|Monitoring of brain activity and respiratory variables during sleep
114647|NCT03290014|Diagnostic Test|Actigraphy|monitoring daily physical activity for 7 days
114648|NCT03290014|Diagnostic Test|Osler test|Evaluation of subjects´ ability to remain awake
114649|NCT03289988|Other|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
114650|NCT03289975|Other|pulmonary ultrasound|Collect the aeration profile for each lung quadrant: profile A, profile B1, profile B2, profile C. Calculate the aeration score from O to 36 (LUS (Lung ultrasound) score).
114651|NCT03289962|Drug|RO7198457|RO7198457 will be administered by intravenous (IV) infusion, in 21-day cycles.
114652|NCT03289962|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion on Day 1 of every 21-day cycle.
114653|NCT03289949|Drug|Psilocybine|Oral dose of psilocybin.
114654|NCT03289949|Drug|Ketanserin|Oral dose of ketanserin.
114655|NCT03289936|Device|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
114656|NCT03289936|Device|sNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
114657|NCT03289923|Other|TMS+SST|Transcranial Magnetic Stimulation (TMS) with Self System Therapy (SST)
114658|NCT03289923|Other|Sham TMS + Sham Therapy|Sham Transcranial Magnetic Stimulation (TMS) + Sham Therapy
114659|NCT03289923|Device|TMS|Transcranial Magnetic Stimulation (TMS)
114660|NCT03289923|Behavioral|Cogntive Therapy|Self-Systems Therapy (SST)
114661|NCT03289910|Drug|Carboplatin|Given IV
114662|NCT03289910|Drug|Topotecan|Given IV
114663|NCT03289910|Drug|Topotecan Hydrochloride|Given IV
114664|NCT03289910|Drug|Veliparib|Given PO
114665|NCT03289897|Diagnostic Test|LiverMultiScan|LiverMultiScan is an imaging technique which is able to identify early liver disease.
114666|NCT03289884|Other|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
114667|NCT03289884|Other|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
114668|NCT03289884|Other|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
114669|NCT03289884|Other|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
114670|NCT03289884|Other|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
114671|NCT03289871|Device|Excilor|
114672|NCT03289871|Drug|Loceryl 5%|
114673|NCT03289858|Drug|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
114674|NCT03289858|Drug|Sodium Chloride|Saline Injection
114675|NCT03289845|Device|BHX implant (Bone anchored hearing system)|Bone anchored hearing system for hearing rehabilitation
114676|NCT03289832|Dietary Supplement|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
114677|NCT03289832|Dietary Supplement|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
114678|NCT03289819|Drug|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w. After the 25th patient has started trial treatment, all further included patients will receive 1 cycle of pembrolizumab i.v. 200 mg q3w monotherapy followed by 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w.
114679|NCT03289819|Drug|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
114680|NCT03289819|Drug|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
114681|NCT03289819|Drug|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
114682|NCT03289806|Procedure|Samples of fibroblasts from Tenon's capsule|
114683|NCT03289793|Other|Neurofeedback training|"Children in group A will receive BCI-based training implemented through original P300-based controlled games.~They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, the EEG system and an eye-tracking system, a 5-minutes relaxation phase, a short EEG recording at rest, a brief reminder of the instructions, 30 minutes of training by playing video games and finally a time for the child to wash her/his hair.~Moreover, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be answered."
114684|NCT03289793|Other|Active Sham control|"Children in group B will receive a training that is not based on brain activity, but in a blind fashion. They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.~Each session includes: installation of the child, setting up the EEG and eye-tracking systems, a 5-minutes relaxation phase, short EEG recording at rest, a brief reminder of the instructions, 30 minutes of video game based training and finally a time for the child to wash her/his hair.~Besides, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be performed."
114685|NCT03289793|Other|Baseline control group|The children included in this group will not receive any training. They only take part to the 4 neuropsychological sessions. Like others, they will attend 1 neuropsychological session every two months over six months.
114686|NCT03289767|Other|Curved-tube|"Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily."
114687|NCT03289754|Device|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
114688|NCT03289741|Drug|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
114689|NCT03289741|Drug|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
114690|NCT03289741|Behavioral|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire and Pain Score Diary.
114691|NCT03289728|Other|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.~Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with < moderate ischemia will receive medical treatment only (MT)."
114692|NCT03289728|Procedure|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
114693|NCT03289715|Device|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
114694|NCT03289702|Drug|CORETOX®|upper limb will be injected and evaluated in the study. Maximun injection dose is 360U.
114695|NCT03289702|Drug|BOTOX®|upper limb will be injected and evaluated in the study. Maximun injection dose is 360U.
114696|NCT03289689|Device|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
114697|NCT03289676|Combination Product|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
114698|NCT03289663|Drug|synergistic combination of insecticides|third generation insecticide -treated bednets
114699|NCT03289663|Drug|Pyrethroids|Conventional insecticide
114700|NCT03289650|Drug|Tacrolimus|immunosuppressive agent tacrolimus, given twice-daily
114701|NCT03289650|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|immunosuppressive agent extended-release tacrolimus, given once daily
114702|NCT03289637|Dietary Supplement|Vitamin D|Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level<50nmol/L at screening
114703|NCT03289624|Behavioral|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG & PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, & ending with a review of material, addressing questions, & previewing the next session. Sessions titles are: Communication & Health Education; Care Values; Care Preferences; Family, Friends, & Community Resources; Taking care of yourself—taking care of each other; & Take Action Now.~The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values & preferences are supported when decisions have to be in the future."
114704|NCT03289611|Biological|sFlt-1 / PlGF ratio|"Ambulatory management if sFlt-1 / PlGF ratio is below 38~usual management if sFlt-1/PlGF is between 38 and 85.~If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued"
114705|NCT03289598|Behavioral|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:~Education of the health care staff with three day's education focusing of aspects of food, meals and nutrition to old people.~The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
114706|NCT03289559|Drug|GnRH antagonist|
114707|NCT03289559|Drug|Aromatase Inhibitors|
114708|NCT03289559|Drug|Testosterone gel|
114709|NCT03289546|Behavioral|Mindfulness training|"The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'."
114710|NCT03289546|Behavioral|Aerobic training|Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
114711|NCT03289533|Drug|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
114712|NCT03289533|Drug|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
114713|NCT03289520|Drug|Clopidogrel|
114714|NCT03289520|Drug|Placebo|
114715|NCT03289507|Dietary Supplement|Treatment1|Longvida Capsule formulation A
114716|NCT03289507|Dietary Supplement|Treatment2|Longvida Capsule formulation B
114717|NCT03289507|Dietary Supplement|Treatment3|Curcuma longa extract of Rhizomes
114718|NCT03289494|Other|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
114719|NCT03289494|Other|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
114720|NCT03289481|Dietary Supplement|Active lozenge|nitric oxide generating lozenge
114721|NCT03289481|Drug|Placebo|placebo tablet
114920|NCT03287791|Drug|Generic Azelaic Acid Foam|Topical foam, generic formulation of the brand product.
114722|NCT03289468|Diagnostic Test|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
114723|NCT03289455|Biological|AUTO3 (CD19/22 CAR T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 5.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
114724|NCT03289442|Procedure|supine position|patients were positioned on their supine position to receive colonoscopy insertion
114725|NCT03289429|Drug|Atorvastatin|Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
114726|NCT03289429|Drug|Magnesium Sulfate|Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
114727|NCT03289429|Other|intravenous placebo|100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
114728|NCT03289429|Other|tablets placebo|Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
114729|NCT03289416|Combination Product|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
114730|NCT03289416|Combination Product|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
114731|NCT03289403|Drug|Immunomodulatory|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~Immunoglobulins will be used in cases not responding to treatment."
114732|NCT03289403|Drug|Thyroxine|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs"
114733|NCT03289390|Drug|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
114734|NCT03289377|Behavioral|RDAD Training|An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
114735|NCT03289364|Device|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
114736|NCT03289351|Drug|piperacillin-tazobactam|Single drug therapy
114737|NCT03289338|Drug|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
114738|NCT03289338|Drug|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
114739|NCT03289338|Drug|Placebos|Normal saline intravenous once a month for 3 months
114740|NCT03289325|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.~After surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation."
114741|NCT03289325|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.~After surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation."
114742|NCT03289299|Drug|Carfilzomib|36 mg/m2 IV given on days 1, 2, 8, 9, 15, and 16 of each cycle during induction and consolidation phases of the study.
114743|NCT03289299|Drug|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase."
114744|NCT03289299|Drug|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.
114745|NCT03289299|Drug|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
114746|NCT03289286|Other|Dedicated and coordinated e-follow-up.|"In pre- and post-surgery:~Completion of questionnaires using an electronic tool,~Telephone follow-up if necessary between the nurse and the patient."
114747|NCT03289273|Drug|Regorafenib (Stivarga, BAY73-4506)|As per the treating physicians discretion
114748|NCT03289260|Drug|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
114749|NCT03289260|Drug|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
114750|NCT03289260|Procedure|Fulguration|Surgical Excision and Fulguration of condyloma
114751|NCT03289247|Device|tissue adhesive (Leukosan®)|Tissue ahaesive
114752|NCT03289234|Drug|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes
114808|NCT03288753|Behavioral|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
114753|NCT03289221|Diagnostic Test|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.~Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
114754|NCT03289208|Drug|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes.
114755|NCT03289195|Procedure|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
114756|NCT03289182|Drug|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
114757|NCT03289169|Drug|MEDITOXIN®|20U of meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
114758|NCT03289156|Behavioral|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
114759|NCT03289156|Behavioral|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
114760|NCT03289143|Drug|Semorinemab|Participants will receive Semorinemab intravenously (IV).
114761|NCT03289143|Drug|Placebo|Matching placebo doses of Semorinemab given intravenously (IV).
114762|NCT03289143|Drug|[18F]GTP1|[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
114763|NCT03289117|Device|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
114764|NCT03289117|Device|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
114765|NCT03289104|Device|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
114766|NCT03289104|Device|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
114767|NCT03289091|Behavioral|water-based continuous aerobic training|Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
114768|NCT03289091|Behavioral|water-based interval aerobic training|Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
114769|NCT03289078|Other|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
114770|NCT03289052|Device|Restylane Volyme|Subcutis injection
114771|NCT03289039|Drug|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
114772|NCT03289039|Drug|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
114773|NCT03289026|Drug|Aripiprazole|Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
114774|NCT03289013|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
114775|NCT03289013|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
114776|NCT03289013|Other|LT-2|Newly developed adhesive
114777|NCT03289013|Other|LT-21|Newly developed adhesive
114778|NCT03289013|Other|LT-25|Newly developed adhesive
114779|NCT03289013|Other|33-20|Newly developed adhesive
114780|NCT03289000|Device|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
114781|NCT03288987|Drug|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
114782|NCT03288974|Drug|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
114783|NCT03288948|Other|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
114921|NCT03287791|Drug|Finacea® (Azelaic Acid) Foam|Topical foam, brand product.
114784|NCT03288935|Behavioral|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R&P service period (i.e., 60 days).
114785|NCT03288935|Behavioral|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation & resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
114786|NCT03288922|Procedure|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
114787|NCT03288922|Procedure|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
114788|NCT03288909|Other|MRI|
114789|NCT03288896|Behavioral|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
114790|NCT03288883|Device|Photothermal Non-ablative Erbium:YAG-laser|Laser treatment of the vagina for GSM
114791|NCT03288883|Device|Fractional Microablative CO2-laser|Laser treatment of the vagina for GSM
114792|NCT03288870|Drug|BCD-100|monoclonal antibody to PD-1 receptor
114793|NCT03288870|Drug|Docetaxel|Chemotherapy drug (taxane)
114794|NCT03288857|Device|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
114795|NCT03288844|Procedure|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
114796|NCT03288844|Other|Digital pictures|Digital pictures 2D to be taken at each visit
114797|NCT03288844|Other|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
114798|NCT03288831|Dietary Supplement|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
114799|NCT03288831|Dietary Supplement|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
114800|NCT03288818|Drug|Mechlorethamine Hydrochloride Gel|Given topically
114801|NCT03288818|Procedure|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
114802|NCT03288792|Device|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
114803|NCT03288779|Device|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
114804|NCT03288766|Procedure|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
114805|NCT03288753|Other|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
114806|NCT03288753|Behavioral|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
114807|NCT03288753|Behavioral|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
114809|NCT03288740|Drug|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
114922|NCT03287791|Drug|Vehicle Foam|Topical foam, placebo. Has no active ingredient.
114810|NCT03288740|Drug|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
114811|NCT03288740|Drug|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
114812|NCT03288740|Drug|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
114813|NCT03288727|Other|interviews with a psychologist|an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
114814|NCT03288714|Device|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
114815|NCT03288714|Device|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
114816|NCT03288701|Device|Seca medical Body Composition Analyser 515|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
114817|NCT03288688|Other|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
114818|NCT03288675|Device|aiTBS|In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
114819|NCT03288675|Behavioral|CCT|By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
114820|NCT03288675|Drug|SSRI|All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
114821|NCT03288662|Other|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
114822|NCT03288636|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
114823|NCT03288636|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
114824|NCT03288636|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
114825|NCT03288636|Drug|Placebo|Placebo
114826|NCT03288623|Dietary Supplement|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
114827|NCT03288623|Dietary Supplement|White/Milk chocolate (<35% cocoa)|white or milk chocolate (<35% cocoa) in tablet
114828|NCT03288610|Diagnostic Test|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
114829|NCT03288597|Radiation|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
114830|NCT03288597|Radiation|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
114831|NCT03288584|Drug|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
114832|NCT03288584|Drug|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
114833|NCT03288584|Drug|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
114834|NCT03288571|Biological|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
114835|NCT03288558|Other|A comprehensive perioperative mechanical ventilation strategy|"1) Intervention group.~Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
114836|NCT03288545|Drug|enfortumab vedotin|Intravenous (IV) infusion on days 1 and 8 every 21 days
114837|NCT03288545|Drug|pembrolizumab|IV infusion on day 1 every 21 days
114838|NCT03288545|Drug|cisplatin|IV infusion on day 1 every 21 days
114839|NCT03288545|Drug|carboplatin|IV infusion on day 1 every 21 days
114840|NCT03288545|Drug|gemcitabine|IV infusion on days 1 and 8 every 21 days
114841|NCT03288532|Drug|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
114842|NCT03288532|Drug|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
114843|NCT03288506|Behavioral|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
114844|NCT03288493|Biological|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired. Rimiducid (safety switch activator) may be administered as indicated."
114845|NCT03288493|Drug|Rimiducid|Rimiducid (safety switch activator) may be administered as indicated.
114846|NCT03288480|Drug|PT-112|This is a single arm study
114847|NCT03288467|Procedure|Root canal treatment with 5% NaOCl|
114848|NCT03288467|Procedure|Root canal treatment with 1% NaOCl|
114849|NCT03288454|Drug|Ciraparantag|Reversal of riva apixaban-induced anticoagulation via dose of ciraparantag or placebo
114850|NCT03288454|Drug|Placebo|Reversal of riva apixaban-induced anticoagulation via dose of ciraparantag or placebo
114851|NCT03288441|Drug|Hold|Hold antithrombotic therapy
114852|NCT03288441|Drug|Prophylactic dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type)
114853|NCT03288441|Drug|Change antithrombotic Drug|Change in type of antithrombotic therapy
114854|NCT03288441|Biological|Change platelet transfusion threshold|Increase or reduce platelet transfusion threshold
114855|NCT03288441|Drug|Full dose antithrombotics|Continue full dose antithrombotic therapy
114856|NCT03288441|Device|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
114857|NCT03288441|Drug|Intermediate dose antithrombotic|Reduction in antithrombotic medication dose to prophylactic dose (without changing type). Intermediate dose in between prophylactic and full dose
114858|NCT03288428|Drug|Nalbuphine|patient controlled analgesia with Nalbuphine
114859|NCT03288428|Drug|Morphine|patient controlled analgesia with Morphine
114860|NCT03288402|Other|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
114861|NCT03288389|Dietary Supplement|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
114862|NCT03288389|Dietary Supplement|Placebo|Placebo wafers
114863|NCT03288363|Device|tDCS|20 sessions of tDCS stimulation on dorsolateral prefrontal cortex with the apparatus DC-Stimulator Plus (Neuroconn)
114864|NCT03288350|Drug|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
114865|NCT03288324|Drug|Tofacitinib|Tofacitinib 5 mg twice daily
114866|NCT03288311|Other|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
114867|NCT03288311|Other|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
114868|NCT03288298|Drug|luteolin|flavonoid natural extract
114869|NCT03288298|Drug|nano-luteolin|nanoparticles of luteolin
114870|NCT03288272|Radiation|Whole Brain Radiotherapy|Radiotherapy of the whole brain
114871|NCT03288272|Other|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
114872|NCT03288259|Procedure|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
114873|NCT03288259|Drug|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
114874|NCT03288246|Diagnostic Test|point-of-care viral load test|A point-of-care viral load test returns viral load test results within 90 minutes.
114875|NCT03288233|Diagnostic Test|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
114876|NCT03288194|Behavioral|Problem-Solving Treatment|
114877|NCT03288194|Behavioral|Time Management|
114878|NCT03288181|Device|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
114879|NCT03288155|Dietary Supplement|Cocoa|Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
114880|NCT03288142|Other|Lark HTN Pro|The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
114881|NCT03288129|Drug|Perampanel|film-coated tablets
114882|NCT03288116|Diagnostic Test|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
114883|NCT03288103|Drug|Norditropin|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
114884|NCT03288090|Other|FSS: Fatigue Severity Scale|Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
114885|NCT03288090|Other|Neuropsychological evaluation battery|A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
114886|NCT03288090|Other|Other functional scores|Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
114887|NCT03288077|Other|Tryptophan|Beverage including tryptophan
114888|NCT03288064|Dietary Supplement|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
114889|NCT03288064|Dietary Supplement|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
114890|NCT03288064|Dietary Supplement|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
114891|NCT03288051|Other|Fluid management|Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
114892|NCT03288051|Drug|Norepinephrine|Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
114893|NCT03288051|Drug|Dobutamine|Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
114894|NCT03288038|Drug|Rosuvastatin|
114895|NCT03288038|Drug|Ezetimibe|
114896|NCT03288025|Behavioral|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
114897|NCT03287999|Diagnostic Test|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
114898|NCT03287999|Diagnostic Test|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
114899|NCT03287986|Other|MRI|Structural and functional sequences
114900|NCT03287973|Behavioral|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
114901|NCT03287973|Device|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
114902|NCT03287960|Drug|setmelanotide|Once daily subcutaneous injection
114903|NCT03287960|Drug|Placebo|During the double blind placebo withdrawal period, patients will receive RM-493 or placebo at variable times over an 8 week period
114904|NCT03287947|Drug|nintedanib|Oral nintendanib, taken twice daily
114905|NCT03287934|Device|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
114906|NCT03287934|Device|stereolithographic stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with stereolithographic technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
114907|NCT03287921|Drug|mono bronchodilatation|within indication according to current GOLD recommendation
114908|NCT03287921|Drug|dual bronchodilatation|within indication according to current GOLD recommendation
114909|NCT03287908|Drug|AMG 701|Patients will receive IV infusions of AMG 701
114910|NCT03287895|Behavioral|Decision Support|A two-part intervention to help patients make better decisions about CPR
114911|NCT03287882|Dietary Supplement|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
114912|NCT03287882|Behavioral|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
114913|NCT03287869|Drug|Brexpiprazole|Brexpiprazole tablet
114914|NCT03287856|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
114915|NCT03287843|Procedure|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
114916|NCT03287843|Procedure|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
114917|NCT03287830|Behavioral|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
114918|NCT03287817|Biological|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 900 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of anti-PD1 antibody (pembrolizumab).
114919|NCT03287804|Biological|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.~Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
114923|NCT03287791|Other|Cleanser|A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.
114924|NCT03287791|Other|Sunscreen|Sunscreen provided to participants, so they can apply it to their face when outdoors.
114925|NCT03287791|Other|Towel|A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.
114926|NCT03287791|Other|Moisturizing Lotion|Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
114927|NCT03287778|Dietary Supplement|Pyridoxine|Max dose of 400 mg QD PO
114928|NCT03287778|Dietary Supplement|Placebo|Matching placebos will be administered.
114929|NCT03287765|Drug|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
114930|NCT03287752|Device|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
114931|NCT03287752|Device|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
114932|NCT03287739|Behavioral|Assessment of behavioral biometric impairments|Assessment of behavioral biometric impairments
114933|NCT03287726|Dietary Supplement|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2x/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
114934|NCT03287726|Dietary Supplement|placebo|Placebo 2x/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
114935|NCT03287713|Drug|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
114936|NCT03287700|Other|No intervention|No intervention will be administered to any group in this observational study.
114937|NCT03287687|Drug|Carbon dioxide gas for insufflation|Carbon dioxide gas use for insufflation during endoscopy instead of air
114938|NCT03287687|Drug|Air|Air is the standard of practice and will be used in the control arm
114939|NCT03287674|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
114940|NCT03287674|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
114941|NCT03287674|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
114942|NCT03287674|Drug|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
114943|NCT03287674|Drug|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
114944|NCT03287674|Drug|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
114945|NCT03287661|Behavioral|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
114946|NCT03287648|Diagnostic Test|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
114947|NCT03287635|Drug|Corticotropin 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
114948|NCT03287622|Behavioral|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
114949|NCT03287622|Behavioral|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
114950|NCT03287609|Drug|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
114951|NCT03287609|Drug|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
114952|NCT03287596|Device|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
114953|NCT03287583|Behavioral|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
114954|NCT03287583|Other|Enhanced Control|Participants randomized to the enhanced control condition will receive a handout with gambling resources.
114955|NCT03287570|Device|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
114956|NCT03287570|Procedure|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
114957|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
114958|NCT03287544|Other|Combined rehabilitation|Linguistic training as well as communication training.
114959|NCT03287544|Other|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
114960|NCT03287531|Other|conventional therapy|Exercise therapeutic Ultrasound
114961|NCT03287531|Other|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
114962|NCT03287518|Dietary Supplement|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
114963|NCT03287518|Dietary Supplement|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
114964|NCT03287505|Drug|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
114965|NCT03287492|Other|Informational Intervention|Receive QPS
114966|NCT03287492|Other|Informational Intervention|Receive GIS
114967|NCT03287492|Other|Questionnaire Administration|Ancillary studies
114968|NCT03287479|Procedure|Gavi® Vitrification|A closed, semi-automated vitrification system
114969|NCT03287479|Procedure|Cryotop® Vitrification|An open, manual vitrification system
114970|NCT03287466|Drug|Oxygen|targeted oxygen therapy
114971|NCT03287453|Other|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
114972|NCT03287453|Other|Survey Administration|Ancillary studies
114973|NCT03287440|Behavioral|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
114974|NCT03287440|Behavioral|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
114975|NCT03287427|Drug|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
114976|NCT03287427|Drug|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
114977|NCT03287414|Drug|VAY736|VAY736 administered subcutaneously (s.c.) every 4 weeks
114978|NCT03287414|Drug|Placebo|Placebo administered s.c. every 4 weeks
114979|NCT03287401|Device|Electroencephalography|Patients electroencephalogram will be recorded
114980|NCT03287388|Procedure|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
114981|NCT03287388|Drug|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
114982|NCT03287388|Drug|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
114983|NCT03287375|Drug|PIPAC|
114984|NCT03287362|Behavioral|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
114985|NCT03287362|Behavioral|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
114986|NCT03287362|Behavioral|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
114987|NCT03287349|Other|Blood draw|Two 12.5 mL blood draws
114988|NCT03287349|Other|Photograph|Photograph of severe reaction, will be anonymized
114989|NCT03287349|Diagnostic Test|Autoimmune testing|Autoimmune testing in patients without prior testing
114990|NCT03287336|Drug|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
114991|NCT03287323|Other|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
114992|NCT03287310|Drug|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
114993|NCT03287310|Drug|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
114994|NCT03287310|Drug|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
114995|NCT03287297|Diagnostic Test|OGTT & HBA1c|oral glucose tolerance test & HBA1c: by measuring glycated hemoglobin
114996|NCT03287284|Device|Active Low Level Laser Therapy|Active application of Low Level Laser Therapy with a dose of 240 Joules
114997|NCT03287284|Behavioral|Resistance Training|Resistance Training
114998|NCT03287284|Device|Placebo Low Level Laser Therapy|Placebo application of Low Level Laser Therapy
114999|NCT03287271|Drug|VS-6063|"Phase 1:~First 3 patient cohort: VS-6063 200 mg PO twice daily~IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,~Phase 2:~VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
115000|NCT03287271|Drug|Paclitaxel|"Phase 1:~First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.~Phase 2:~Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
115071|NCT03286738|Drug|FOLFIRI, target agent|"Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab~Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
115001|NCT03287271|Drug|Carboplatin|"Phase 1:~First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.~Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
115002|NCT03287258|Other|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
115003|NCT03287258|Other|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
115004|NCT03287245|Drug|Idasanutlin|All participants will receive 150 milligrams (mg) idasanutlin orally, once daily for 5 days, every 28 days, until treatment discontinuation or end of study (up to 2 years). Intra-participant dose-escalation to 200 mg daily for 5 days may be permitted after Cycle 3 for those who demonstrate no hematocrit (Hct) control and/or for those with inadequately controlled leukocytosis and/or thrombocytosis in which the investigator judges that better control is important.
115005|NCT03287232|Drug|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
115006|NCT03287232|Drug|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
115007|NCT03287219|Drug|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
115008|NCT03287206|Biological|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
115009|NCT03287206|Biological|blood samples from parents|secondary controls for children's analyses
115010|NCT03287193|Biological|Blood sample|for patient and its parents
115011|NCT03287193|Genetic|high-throughput sequencing|exome or whole genome sequencing
115012|NCT03287180|Behavioral|Adolescent Community Reinforcement Approach (A-CRA)|The A-CRA is a modified version of the Community Reinforcement Approach for adolescents and transitional age youth. The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. In the current study, 12-weeks of A-CRA treatment will be provided to the intervention group.
115013|NCT03287180|Other|Combination of buprenorphine/naloxone 4/1|Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose of 4/1 mg will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
115014|NCT03287167|Drug|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
115015|NCT03287167|Drug|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
115016|NCT03287154|Device|Active tDCS stimulations|20 min, 2mA
115017|NCT03287154|Device|Sham tDCS|20 min, Sham
115018|NCT03287141|Diagnostic Test|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
115019|NCT03287141|Device|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
115020|NCT03287141|Device|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
115021|NCT03287128|Drug|Gemtuzumab Ozogamicin (GO)|patients included in a compassionate patient named program with GO
115022|NCT03287115|Other|Broccoli consumption|All subjects will eat broccoli on day 11
115023|NCT03287102|Procedure|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
115024|NCT03287089|Drug|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
115025|NCT03287089|Drug|Placebo Oral Tablet|Matching placebo
115026|NCT03287076|Drug|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
115027|NCT03287063|Other|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
115028|NCT03287050|Drug|Pembrolizumab|200 mg IV q 21 days
115029|NCT03287050|Radiation|SBRT|Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
115030|NCT03287037|Device|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
115031|NCT03287024|Device|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
115146|NCT03286088|Diagnostic Test|MitraClip|imaging as standard practice
115032|NCT03287011|Other|Shoplaq toothpaste|"ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health."
115033|NCT03287011|Other|Colgate toothpaste|fluoridated
115034|NCT03286972|Device|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
115035|NCT03286959|Procedure|PCR with calcium hydroxide|
115036|NCT03286959|Procedure|PCR with RMGIC|
115037|NCT03286959|Procedure|PCR with direct composite|
115038|NCT03286946|Procedure|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
115039|NCT03286946|Procedure|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
115040|NCT03286933|Behavioral|yoga|75 minute weekly group yoga classes for 8 weeks. Home program online.
115041|NCT03286920|Dietary Supplement|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
115042|NCT03286920|Dietary Supplement|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
115043|NCT03286907|Behavioral|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 & 8.
115044|NCT03286907|Behavioral|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, & 8.
115045|NCT03286907|Behavioral|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
115046|NCT03286881|Other|Brief psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
115047|NCT03286881|Other|Extensive psychotherapy|Usual psychological intervention in secondary care provided by a clinical psychologist.
115048|NCT03286881|Other|Combined intervention|Extensive psychotherapy and medication provided by a clinical psychologist and a psychiatrist.
115049|NCT03286881|Other|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
115050|NCT03286881|Other|Usual treatment|Medication provided by a general practitioner.
115051|NCT03286868|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
115052|NCT03286868|Device|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
115053|NCT03286855|Device|Vibrating Mesh Nebuliser|The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
115054|NCT03286855|Device|Standard Hospital Care|"The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser."
115055|NCT03286842|Drug|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
115056|NCT03286829|Drug|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
115057|NCT03286829|Drug|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
115058|NCT03286829|Drug|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
115059|NCT03286829|Drug|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
115060|NCT03286816|Drug|SodiumChloride|
115061|NCT03286816|Drug|Sodium Lactate|
115062|NCT03286803|Biological|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
115063|NCT03286790|Other|Data collection on pneumonia events|
115064|NCT03286777|Dietary Supplement|Placebo|Mannitol and silicon dioxide capsules
115065|NCT03286777|Dietary Supplement|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
115066|NCT03286777|Dietary Supplement|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
115067|NCT03286764|Other|Peppermint Oil|
115068|NCT03286764|Other|Distilled water|Distilled water spray as a placebo during Colonoscopy
115069|NCT03286751|Drug|LY900014|Administered SC
115070|NCT03286751|Drug|Insulin Lispro|Administered SC
115072|NCT03286725|Behavioral|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.~The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
115073|NCT03286712|Drug|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
115074|NCT03286699|Behavioral|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
115075|NCT03286699|Behavioral|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
115076|NCT03286686|Behavioral|point targets|In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.
115077|NCT03286686|Behavioral|tactile stimulation|In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.
115078|NCT03286686|Behavioral|visual images|Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
115079|NCT03286673|Dietary Supplement|calcium phosphate|
115080|NCT03286673|Dietary Supplement|Tricalcium Phosphate|
115081|NCT03286673|Dietary Supplement|Calcium carbonate|
115082|NCT03286673|Dietary Supplement|Placebo|
115083|NCT03286660|Diagnostic Test|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.~This test is combined with a questionnaire to collect quantitative and qualitative information:~dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise~Saturation at rest, and at the end of the exercise~the number of total a chair rise"
115084|NCT03286647|Procedure|Oral hygiene instruction|the participants will receive instructions to perform a satisfatory oral hygiene
115085|NCT03286634|Drug|Daunorubicin|Given IV
115086|NCT03286634|Drug|Prednisolone|Given PO or IV
115087|NCT03286634|Drug|Vincristine|Given IV
115088|NCT03286634|Drug|Epirubicin|Given IV
115089|NCT03286634|Drug|E-coli L-asparaginase|Given IM or IV
115090|NCT03286634|Drug|6-Mercaptopurine|Given PO
115091|NCT03286634|Drug|Methotrexate|Given IV, PO or IT
115092|NCT03286634|Drug|Hydrocortisone|Given IT
115093|NCT03286634|Drug|Cytarabine|Given IV, IT or SC
115094|NCT03286634|Drug|Cyclophosphamide|Given IV
115095|NCT03286621|Other|Administration of five eye-tracking paradigms|All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
115096|NCT03286608|Other|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
115097|NCT03286595|Other|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
115098|NCT03286582|Drug|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
115099|NCT03286582|Drug|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
115100|NCT03286569|Device|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
115101|NCT03286556|Drug|Autoantibody Reductive Therapy|TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
115102|NCT03286556|Drug|Treatment as Usual (TAU)|Antibiotics and steroids
115103|NCT03286543|Device|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
115104|NCT03286530|Drug|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.~After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
115105|NCT03286517|Biological|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)|A neurohormone
115106|NCT03286504|Behavioral|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-10 adolescents meeting once per month.
115107|NCT03286491|Diagnostic Test|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
115108|NCT03286478|Behavioral|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
115109|NCT03286478|Behavioral|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
115110|NCT03286478|Behavioral|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
115111|NCT03286465|Device|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
115112|NCT03286465|Device|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
115113|NCT03286452|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
115114|NCT03286439|Other|there will be offered a follow up visit|The investigators will offer the patients a follow up visit 3 and 12 months after discharge from the hospital.
115115|NCT03286426|Diagnostic Test|Vision/Eye screening|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
115116|NCT03286413|Procedure|microwave ablation|Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
115117|NCT03286400|Device|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
115118|NCT03286387|Other|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
115119|NCT03286374|Behavioral|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:~Four weeks with an institutional stay at Muritunet (BL)~Follow-up;~Eight weeks, telephone contact between therapist at Muritunet and the participant.~16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.~28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)~40 weeks, telephone contact between therapist at Muritunet and the participant.~52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
115120|NCT03286361|Device|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
115121|NCT03286335|Radiation|Proton Radiation|Radiation treatment
115122|NCT03286322|Other|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
115123|NCT03286322|Other|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
115124|NCT03286309|Device|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
115125|NCT03286296|Biological|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
115126|NCT03286283|Device|J-Plasma|Dermal resurfacing procedure with J-Plasma.
115127|NCT03286257|Behavioral|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
115128|NCT03286244|Drug|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).~Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
115129|NCT03286231|Diagnostic Test|CT imaging|Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
115130|NCT03286218|Drug|Lasmiditan|Administered orally
115131|NCT03286218|Drug|Alprazolam|Administered orally
115132|NCT03286218|Drug|Placebo|Administered orally
115133|NCT03286205|Drug|IV iron|IV iron infusion based on weekly or every 3 week dosage.
115134|NCT03286192|Behavioral|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
115135|NCT03286179|Other|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
115136|NCT03286153|Other|Ideal Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: [50kg + (2.3kg*every inch over 5 feet)].
115137|NCT03286153|Other|Actual Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
115138|NCT03286140|Procedure|Early endovenous ablation|
115139|NCT03286140|Procedure|Delayed endovenous intervention|
115140|NCT03286127|Other|specialized palliative care|specialized palliative care provided in different settings
115141|NCT03286114|Drug|Pembrolizumab|200mg IV every 21 days
115142|NCT03286101|Drug|0.5% Ivermectin lotion|The intervention is composed of a single application of the 0.5% ivermectin lotion.
115143|NCT03286101|Drug|Vehicle|The intervention is composed of a single application of the vehicle control.
115144|NCT03286088|Diagnostic Test|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
115145|NCT03286088|Diagnostic Test|Cardiac Magnetics Resonance|imaging as standard practice
115147|NCT03286075|Device|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.~The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
115148|NCT03286075|Device|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.~This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
115149|NCT03286075|Device|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.~Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
115150|NCT03286062|Combination Product|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
115151|NCT03286036|Other|biomarkers|This is an observational study, there is no intervention
115152|NCT03286023|Radiation|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
115153|NCT03286010|Behavioral|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
115154|NCT03285997|Biological|GC3110A|A single 0.5mL dose intramuscular injection
115155|NCT03285997|Biological|GCFLU Pre-filled syringe inj.|A single 0.25mL dose intramuscular injection
115156|NCT03285984|Other|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
115157|NCT03285984|Other|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
115158|NCT03285984|Other|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
115159|NCT03285984|Other|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
115160|NCT03285971|Other|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
115161|NCT03285958|Behavioral|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
115162|NCT03285945|Drug|PET3|Prednisolone 60 mg daily for 3 days
115163|NCT03285945|Drug|PET10|Prednisolone 60 mg daily for 10 days
115164|NCT03285932|Radiation|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.~Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.~Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
115165|NCT03285932|Radiation|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.~RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.~For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
115166|NCT03285919|Device|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
115167|NCT03285906|Drug|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
115168|NCT03285893|Other|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
115169|NCT03285880|Behavioral|Napping|Children nap during the nap opportunity
115170|NCT03285867|Procedure|TACE|transcatheter arterial chemoembolization
115171|NCT03285854|Diagnostic Test|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
115172|NCT03285841|Device|OCT-AFI|Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
115173|NCT03285828|Behavioral|motivationnal interviewing training|"The students received three four-hour sessions of basic motivationnal interviewing training :~Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.~Lectures and the distribution of memory aids.~Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.~Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training."
115174|NCT03285815|Device|Proton Therapy|
115175|NCT03285802|Drug|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
115176|NCT03285802|Drug|Everolimus|Everolimus 10mg daily q 28 days
115177|NCT03285789|Other|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.~All of these tests will be made during an unique visit of 1h30."
115178|NCT03285789|Other|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.~test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.~All of these tests will be made during an unique visit of 1h30."
115179|NCT03285763|Drug|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
115180|NCT03285737|Dietary Supplement|Whey|Supplement provided twice daily in 30g doses
115181|NCT03285737|Dietary Supplement|Collagen|Supplement provided twice daily in 30g doses
115182|NCT03285724|Device|Harpoon Artificial ePTFE Chords|The Harpoon Medical Transapical device is intended to be used to reduce the degree of degenerative mitral regurgitation by delivering and anchoring one or more ePTFE cords to the affected mitral valve leaflet(s) via a small left thoracotomy on the beating heart in patients with anterior, bi-leaflet or posterior prolapse.
115183|NCT03285711|Drug|Filgotinib|200 mg tablet administered orally once daily
115184|NCT03285711|Drug|Lanraplenib|30 mg tablet administered orally once daily
115185|NCT03285711|Drug|Filgotinib placebo|Tablet administered orally once daily
115186|NCT03285711|Drug|Lanreplenib placebo|Tablet administered orally once daily
115187|NCT03285698|Device|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
115188|NCT03285698|Device|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
115189|NCT03285685|Device|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
115190|NCT03285685|Device|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
115191|NCT03285685|Device|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
115192|NCT03285672|Drug|FP-101|Dose 1
115193|NCT03285672|Drug|Placebo Comparator|Dose 1
115194|NCT03285659|Other|Intervention: INDI Implementation|Implementation of a collaborative care model in the context of primary care to manage depression
115195|NCT03285646|Drug|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
115196|NCT03285646|Drug|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
115197|NCT03285633|Behavioral|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
115198|NCT03285620|Drug|AL-034|Participants will receive single oral dose of AL-034 under fed or fasted conditions in part 1 and part 2
115199|NCT03285620|Drug|Placebo|Participants will receive single oral dose of matching placebo (oral solution) under fed or fasted conditions in part 1 and part 2.
115200|NCT03285607|Biological|MCS110|-MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
115201|NCT03285607|Drug|Doxorubicin|-Standard of care
115202|NCT03285607|Drug|Cyclophosphamide|-Standard of care
115203|NCT03285607|Drug|Paclitaxel|-Standard of care
115204|NCT03285607|Procedure|Bone marrow aspirate|-Time of enrollment and at time of surgery
115205|NCT03285607|Procedure|Peripheral blood samples|-Time of enrollment and at time of surgery
115206|NCT03285607|Procedure|Tumor tissue|-Time of enrollment and at time of surgery
115207|NCT03285594|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
115359|NCT03284385|Drug|Adavosertib|Given PO
115208|NCT03285594|Drug|insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
115209|NCT03285594|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
115210|NCT03285581|Device|arm-1|Subject(s) will receive 2 RF treatments
115211|NCT03285568|Drug|Palbociclib|Observe patients receiving palbociclib for dose adjustment and lab monitoring
115212|NCT03285555|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
115213|NCT03285555|Device|VICRYL|Vicryl #1
115214|NCT03285542|Device|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
115215|NCT03285542|Device|Staples|staples for skin closure
115216|NCT03285529|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
115217|NCT03285529|Device|VICRYL|Vicryl #1
115218|NCT03285516|Behavioral|Safety Aid Reduction Treatment|START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
115219|NCT03285503|Drug|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
115220|NCT03285490|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical AK on the face or scalp.
115221|NCT03285490|Drug|Placebo|Vehicle Ointment wil be used in subjects with Clinically typical AK on the face or scalp.
115222|NCT03285477|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical AK on the face or scalp.
115223|NCT03285477|Drug|Placebo|Vehicle Ointment wil be used in subjects with Clinically typical AK on the face or scalp.
115224|NCT03285464|Other|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
115225|NCT03285451|Diagnostic Test|submental ultrasonography|Submental ultrasound, the noninvasive and convenient tool, has been widely applied to measure the tongue base thickness in patients with obstructive sleep apnea, so as to predict the severity and relationship with upper airway collapse.
115226|NCT03285438|Drug|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 24 months (12 to 48 months)
115227|NCT03285438|Drug|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 24 months (12 to 48 months)
115228|NCT03285425|Other|Natural history|Parent interview
115229|NCT03285412|Drug|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
115230|NCT03285412|Other|Endocrine therapy|Hormone therapy
115231|NCT03285386|Behavioral|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
115232|NCT03285386|Behavioral|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
115233|NCT03285373|Drug|NOAC|New Oral Anticoagulant
115234|NCT03285360|Combination Product|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
115235|NCT03285360|Combination Product|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
115236|NCT03285347|Device|Computer-based cognitive training|Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
115237|NCT03285334|Device|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
115238|NCT03285334|Device|iRace files|rotary mechanical preparation
115239|NCT03285321|Drug|Nivolumab|480mg
115240|NCT03285321|Drug|Nivolumab|3mg/kg
115241|NCT03285321|Drug|Ipilimumab|1mg/kg
115242|NCT03285308|Drug|Relamorelin|Relamorelin 10 μg injected twice daily for 12 weeks.
115243|NCT03285308|Drug|Placebo|Placebo injected twice daily for 2 weeks or 12 weeks.
115244|NCT03285295|Device|Alinity s HBsAg and Alinity s HBsAg Confirmatory Assay|For all donor specimens with investigational Alinity s HBsAg and Alinity s HBsAg Confirmatory results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
115245|NCT03285295|Device|Alinity s HTLV I/II Assay|For all donor specimens with investigational Alinity s HTLV I/II results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
115246|NCT03285295|Device|Alinity s Anti-HCV Assay|For all donor specimens with investigational Alinity s Anti-HCV results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
115247|NCT03285295|Device|Alinity s HIV Ag/Ab Combo Assay|For all donor specimens with investigational Alinity s HIV Ag/Ab Combo results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
115248|NCT03285295|Device|Alinity s Anti-HBc Assay|For all donor specimens with investigational Alinity s Anti-HBc results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
115249|NCT03285295|Device|Alinity s Chagas Assay|For all donor specimens with investigational Alinity s Chagas results that are discordant with final status after supplemental testing, an attempt will be made to obtain a follow-up whole blood specimen approximately 4 to 6 weeks after initial donation for further analysis.
115250|NCT03285282|Procedure|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
115251|NCT03285269|Diagnostic Test|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
115252|NCT03285269|Device|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
115253|NCT03285269|Procedure|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
115254|NCT03285256|Behavioral|Experimental memory training|The experimental memory training will be implemented as a computer program that uses state-of-the-art immersive technology to simulate prospective memory in everyday life in which one must remember to carry out tasks throughout the day, while engaging in current ongoing activity. Participants are asked to imagine they have a work-at-home job (ongoing activity), which is an independent program (CogMed QM) designed to train working memory, but that they also need to remember to carry out a number of tasks throughout the day. Using a touch screen, participants will need to touch objects in the simulated environment to appropriately interact with these stimuli according to their pre-assigned tasks.
115255|NCT03285256|Behavioral|Comparator memory training 1|The first comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
115256|NCT03285256|Behavioral|Comparator memory training 2|The second comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
115257|NCT03285243|Device|Monochromatic blue light|Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
115258|NCT03285217|Dietary Supplement|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
115259|NCT03285217|Dietary Supplement|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
115260|NCT03285191|Other|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
115261|NCT03285191|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
115262|NCT03285178|Drug|IW-1701|Oral Tablet
115263|NCT03285178|Drug|Placebo|Oral Tablet
115264|NCT03285165|Drug|0.2-0.7 mcg/kg/h dexmedetomedine infusion.|patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
115265|NCT03285165|Drug|10-70 mcg/kg/h propofol infusion.|Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
115266|NCT03285152|Other|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
115267|NCT03285152|Other|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
115268|NCT03285139|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
115269|NCT03285113|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
115270|NCT03285100|Diagnostic Test|Venipuncture|"Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.~At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
115271|NCT03285087|Drug|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of −2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
115272|NCT03285074|Other|No intervention|No intervention
115273|NCT03285061|Device|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
115274|NCT03285048|Behavioral|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
115606|NCT03282435|Other|standard lung cancer treament|standard non-small cell lung cancer treatment: surgery, chemotherapy
115275|NCT03285035|Device|Administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
115276|NCT03285022|Procedure|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
115277|NCT03285009|Other|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.~Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
115278|NCT03284996|Device|Doppler ultrasonography|Examination of the whole cases & controls by doppler ultrasound to measure renal resistive index.
115279|NCT03284983|Other|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
115280|NCT03284957|Drug|SAR439859|"Pharmaceutical form: capsule~Route of administration: oral"
115281|NCT03284957|Drug|palbociclib|"Pharmaceutical form: capsule~Route of administration: oral"
115282|NCT03284944|Device|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
115283|NCT03284944|Device|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
115284|NCT03284931|Drug|SAGE-217 high dose|high dose
115285|NCT03284931|Drug|Placebo|placebo
115286|NCT03284931|Drug|SAGE-217 low dose|low dose
115287|NCT03284918|Dietary Supplement|Plant stanol ester|
115288|NCT03284918|Dietary Supplement|Placebo|
115289|NCT03284905|Dietary Supplement|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
115290|NCT03284905|Dietary Supplement|Placebo supplement|Capsule containing maize starch
115291|NCT03284892|Behavioral|PED care|A once daily, 7-day PED Care intervention on reducing time to resume oral intake, rates of penetration and intervention at 10 days postextubation, and incidences of 30-day aspiration pneumonia in adult patients with prolonged intubation (≥48 hours)
115292|NCT03284892|Diagnostic Test|FEES test|Using FEES to see if participants have any aspiration or penetration and the level of it.
115293|NCT03284892|Other|usual care|usual care means the original care given by the ward the participants stay.
115294|NCT03284866|Other|Laboratory Biomarker Analysis|Correlative studies
115295|NCT03284866|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
115296|NCT03284866|Other|Saline|Given IM
115297|NCT03284853|Drug|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
115298|NCT03284853|Drug|GANFORT®|Topical sterile ophthalmic solution
115299|NCT03284840|Diagnostic Test|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
115300|NCT03284840|Diagnostic Test|Thyroid size|Thyroid size by ultrasound.
115301|NCT03284827|Drug|NOAC|edoxaban (60 mg once daily [OD]) for at least 6 months
115302|NCT03284827|Drug|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
115303|NCT03284814|Dietary Supplement|Single dose intervention with Standard product (SP)|hard capsules, 100 mg
115304|NCT03284814|Dietary Supplement|Single dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg
115305|NCT03284814|Dietary Supplement|Single dose intervention with Investigational product (IP)|syrup, 100 mg
115306|NCT03284814|Dietary Supplement|Multiple dose intervention with Standard product (SP)|hard capsules, 100 mg - 14 days
115307|NCT03284814|Dietary Supplement|Multiple dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg - 14 days
115308|NCT03284814|Dietary Supplement|Multiple dose intervention with Investigational product (IP)|syrup, 100 mg - 14 days
115309|NCT03284801|Other|management of acute disseminating encephalomyelitis|clinical audit on management of acute disseminating encephalomyelitis
115310|NCT03284788|Behavioral|ABT Weight Loss Intervention|This includes 15 sessions that are each 90 minutes in length. Intervention sessions will be weekly for the first 2 months, bi-weekly for the next 2 months, and monthly for the last 2 months.
115311|NCT03284775|Device|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
115312|NCT03284762|Drug|Rivaroxaban (Xarelto, Bay59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
115313|NCT03284749|Other|Copper impregnated wound dressing|Copper impregnated wound dressing
115314|NCT03284749|Other|Normal wound dressing|Normal wound dressing
115315|NCT03284749|Other|Copper impregnated maternity pads|Copper impregnated maternity pads
115316|NCT03284749|Other|Normal maternity pads|Normal maternity pads
115317|NCT03284736|Procedure|Resorbable membrane|
115318|NCT03284736|Procedure|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
115319|NCT03284723|Drug|PF-06804103|Dose Escalation Phase - Part 1
115320|NCT03284723|Drug|PF-06804103|Dose Expansion Phase - Part 2
115321|NCT03284710|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10^6 cell culture infectious dose (CCID)50 and < 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
115322|NCT03284710|Biological|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
115323|NCT03284710|Biological|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (~625 mcg aluminum content); delivered as a 0.5 mL IM injection
115324|NCT03284710|Biological|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
115325|NCT03284697|Procedure|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
115326|NCT03284697|Procedure|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
115327|NCT03284684|Other|Blood test|plasma concentration of circulating DNA of specific genes
115328|NCT03284671|Other|bifocal stimulation with tDCS|Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
115329|NCT03284645|Drug|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
115330|NCT03284645|Drug|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
115331|NCT03284645|Drug|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
115332|NCT03284619|Device|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
115333|NCT03284606|Device|TAPING|Taping in conjunction with common rehabilitation for hemiplegic patients
115334|NCT03284606|Procedure|Common rehabilitation|Common rehabilitation for hemiplegic patients
115335|NCT03284593|Drug|intensive chemotherapy|
115336|NCT03284593|Drug|Azacitidine|
115337|NCT03284580|Other|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
115338|NCT03284580|Other|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
115339|NCT03284580|Other|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
115340|NCT03284567|Behavioral|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.~Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors"
115341|NCT03284554|Dietary Supplement|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
115342|NCT03284554|Dietary Supplement|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
115343|NCT03284554|Dietary Supplement|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
115344|NCT03284541|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
115345|NCT03284541|Behavioral|Existing Public Health Practice|HIV testing, medication adherence, HIV risk reduction
115346|NCT03284528|Other|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
115347|NCT03284515|Biological|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
115348|NCT03284502|Drug|HM95573, cobimetinib|Drug: HM95573, cobimetinib Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
115349|NCT03284502|Drug|HM95573, cobimetinib|Drug: HM95573, cobimetinib based on the data for safety, tolerability, pharmacokinetics, and anti-tumor activity from the dosing schedules tested in Stage1, a potential RP2D and schedule will be selected for Stage 2.
115350|NCT03284489|Other|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
115351|NCT03284476|Other|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
115352|NCT03284463|Drug|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
115353|NCT03284463|Drug|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
115354|NCT03284450|Other|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
115355|NCT03284450|Other|SSRS|The SSRS (Howatson & Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
115356|NCT03284437|Behavioral|Early Cognitive Training|Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
115357|NCT03284424|Biological|Pembrolizumab|IV infusion
115358|NCT03284411|Device|Spinal Cord Stimulation|Programming
115360|NCT03284372|Behavioral|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
115361|NCT03284372|Behavioral|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=25) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
115362|NCT03284372|Behavioral|Text message + Incentive 2|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=25) to receive text message reminders plus Incentive 2 (at each of 10 check-in, successful participants will have a 2/5 chance of winning a small prize or a 2/25 chance of winning a bigger prize). The remainder of the Cohort (control) will receive text reminders.
115363|NCT03284359|Behavioral|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
115364|NCT03284346|Behavioral|Exercise Intervention|Undergo CARE
115365|NCT03284346|Behavioral|Exercise Intervention|Undergo standard stretching program
115366|NCT03284346|Other|Laboratory Biomarker Analysis|Correlative studies
115367|NCT03284346|Device|Monitoring Device|Receive Polar heart rate monitor
115368|NCT03284346|Other|Quality-of-Life Assessment|Ancillary studies
115369|NCT03284346|Other|Questionnaire Administration|Ancillary studies
115370|NCT03284333|Device|other|no arm
115371|NCT03284307|Drug|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
115372|NCT03284307|Drug|Ketamine|20 participants will be administered Ketamine.
115373|NCT03284307|Drug|Propofol|20 participants will be administered Propofol.
115374|NCT03284307|Drug|Sevoflurane|20 participants will be administered Sevoflurane.
115375|NCT03284294|Drug|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
115376|NCT03284294|Drug|Placebo|Oral placebo daily for 8 weeks
115377|NCT03284281|Device|Tragus stimulator|Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.
115378|NCT03284281|Device|Sham Tragus stimulator|No stimulation will be performed
115379|NCT03284268|Genetic|VCN-01|VCN-01 intravitreal injection
115380|NCT03284255|Device|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
115381|NCT03284255|Device|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
115382|NCT03284242|Procedure|Apheresis|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
115383|NCT03284229|Device|Excimer Laser Coronary Atherectomy|Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
115384|NCT03284216|Procedure|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion."
115385|NCT03284216|Procedure|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
115386|NCT03284216|Behavioral|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
115387|NCT03284203|Device|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
115388|NCT03284190|Procedure|Surgery|Surgery
115389|NCT03284177|Drug|Calcium (13C)Carbonate|C13-CAC breath test containing Calcium (13C) Carbonate was performed twice under fasting conditions.
115390|NCT03284177|Drug|Gastric acid inhibitors|Gastric acid inhibitor was orally administrated once daily for 4weeks after first C13-CAC breath test.
115391|NCT03284177|Other|Gastric pH monitoring|Gastric pH monitoring was performed once under fasting condition.
115392|NCT03284164|Drug|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
115393|NCT03284151|Radiation|Cyberknife|
115394|NCT03284138|Device|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
115395|NCT03284138|Device|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
115396|NCT03284125|Other|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
115468|NCT03283553|Other|Checklist, MyChart, OpenNotes|1) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
115469|NCT03283553|Other|Usual Care|Routine medical oncology care
115607|NCT03282435|Biological|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking
115397|NCT03284112|Behavioral|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (OSHH) or Seniors Can Have Optimal aging and Ongoing Longevity, to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
115398|NCT03284112|Behavioral|My Plate|"The program selected for the control arm, My Plate, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Plate as an entry point for the USDA's My Plate nutrition program. Students will learn about My Plate across the 3-day one-hour-a-day program."
115399|NCT03284099|Drug|ACEi, ARB|To take the ACEis or ARBs before bedtime instead of in the morning
115400|NCT03284086|Diagnostic Test|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
115401|NCT03284086|Diagnostic Test|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
115402|NCT03284073|Procedure|Uterus transplantation|Transplantation of the uterus from a live donor and IVF treatment
115403|NCT03284060|Behavioral|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.~16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:~pen and paper tasks focusing on specific emotion recognition component (20 min),~computerized tasks focusing on the same process (20 min),~a proposal of a home-based task (during 20 min)."
115404|NCT03284047|Drug|Botulinum toxin type A|Participants will be randomized to one of three botulinum toxin type A doses.
115405|NCT03284034|Device|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
115406|NCT03284034|Drug|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
115407|NCT03284021|Device|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
115408|NCT03284008|Other|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
115409|NCT03284008|Other|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
115410|NCT03283995|Other|Cardiac Volume Monitoring VolumeView|hemodynamic measure
115411|NCT03283995|Device|echocardiography|hemodynamic measure
115412|NCT03283982|Device|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
115413|NCT03283982|Device|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
115414|NCT03283969|Other|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
115415|NCT03283969|Other|Isocaloric powder|Isocaloric powder
115416|NCT03283956|Device|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
115417|NCT03283943|Radiation|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
115418|NCT03283943|Drug|Durvalumab|Durvalumab 1500 mg IV every 28 days
115419|NCT03283930|Behavioral|Active Attention Bias Modification Training|Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases
115420|NCT03283930|Behavioral|Placebo Attention Bias Modification Training|Placebo version of a computer-based attention bias modification training administered at weekly CBT session thought to not influence attentional biases
115421|NCT03283917|Biological|Daratumumab|Given IV
115422|NCT03283917|Drug|Dexamethasone|Given IV or PO
115423|NCT03283917|Drug|Ixazomib|Given PO
115424|NCT03283904|Other|Multicomponent physical activity intervention|School-based multicomponent intervention
115425|NCT03283891|Other|Educational intervention - humanistic nursing practice|"Four educational sessions:~Acquisition of core concepts of caring practice (I)~Acquisition of core concepts of caring practice (II)~Search for meaning: Influencing hope in persons through humanistic practice~Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
115426|NCT03283878|Drug|Cefazolin|"Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2."
115545|NCT03282981|Drug|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
115640|NCT03282136|Drug|Incretin Effect|The patients will receive incretins therapy.
115427|NCT03283865|Diagnostic Test|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
115428|NCT03283852|Genetic|blood sample|search for genetic mutations
115429|NCT03283839|Diagnostic Test|Posturography|Evaluation of postural control and of orientation function
115430|NCT03283826|Biological|ATA188|ATA188 is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ progressive multiple sclerosis.
115431|NCT03283826|Drug|Placebo|Placebo matching to ATA188
115432|NCT03283813|Dietary Supplement|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
115433|NCT03283813|Drug|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
115434|NCT03283813|Drug|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
115435|NCT03283800|Other|Copper impregnated compression stocking|Copper impregnated compression stocking
115436|NCT03283800|Other|Normal compression stocking|Normal compression stocking without copper
115437|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
115438|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
115439|NCT03283787|Device|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy
115440|NCT03283774|Other|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
115441|NCT03283761|Drug|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), every 14 days Stage II (N= 25), every 14 days
115442|NCT03283761|Drug|Oxaliplatin 85 mg/m^2|Stage I (N= 12), every 14 days Stage II (N= 25), every 14 days
115443|NCT03283761|Drug|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), every 14 days Stage II (N= 25), every 14 days
115444|NCT03283761|Drug|Leucovorin 400 mg/m^2|Stage I (N= 12), every 14 days Stage II (N= 25), every 14 days
115445|NCT03283748|Device|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
115446|NCT03283735|Behavioral|Elderly Enablement|The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
115447|NCT03283722|Device|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
115448|NCT03283709|Device|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
115449|NCT03283709|Device|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
115450|NCT03283696|Drug|Olaratumab|Administered IV
115451|NCT03283696|Drug|Doxorubicin|Administered IV
115452|NCT03283696|Drug|Ifosfamide|Administered IV
115453|NCT03283696|Drug|Mesna|Administered per standard of care
115454|NCT03283670|Drug|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
115455|NCT03283670|Drug|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
115456|NCT03283670|Drug|Placebo Gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
115457|NCT03283657|Behavioral|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
115458|NCT03283657|Behavioral|Usual care (UC)|Standard care with routine medical care.
115459|NCT03283631|Biological|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
115460|NCT03283618|Behavioral|Video Conferencing Group|
115461|NCT03283605|Radiation|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
115462|NCT03283605|Drug|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
115463|NCT03283605|Drug|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
115464|NCT03283592|Other|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
115465|NCT03283592|Other|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
115466|NCT03283566|Drug|Hydroxychloroquine|Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.
115467|NCT03283566|Drug|Placebo|Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
115470|NCT03283540|Procedure|TaTME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision
115471|NCT03283540|Procedure|TME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
115472|NCT03283514|Other|Complete denture|questionnaire
115473|NCT03283501|Procedure|PCI after TAVI|Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI
115474|NCT03283488|Drug|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
115475|NCT03283488|Drug|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
115476|NCT03283475|Procedure|thigh lift|liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
115477|NCT03283462|Dietary Supplement|AMAZ-02|AMAZ-02 containing softgels
115478|NCT03283462|Dietary Supplement|Placebo|Placebo containing softgels
115479|NCT03283449|Drug|18F-AV-1451|
115480|NCT03283449|Device|PET|PET scanner for brain imaging
115481|NCT03283436|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution|10 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 25 mg)
115482|NCT03283423|Device|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
115483|NCT03283410|Drug|Propofol|Propofol plasmatic concentration (Marsh)
115484|NCT03283397|Drug|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
115485|NCT03283397|Drug|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
115486|NCT03283384|Drug|Letrozole|Letrozole 2.5 mg daily.
115487|NCT03283384|Drug|Chemotherapy|Dose dense AC-T chemotherapy: consisting of 4 cycles of AC (doxorubicin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 2-weekly, plus G-CSF (6 mg once per cycle) 24-48 hr after chemotherapy, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m2 weekly).
115488|NCT03283384|Drug|Ribociclib plus letrozole|Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
115489|NCT03283371|Drug|Natalizumab|As specified in the treatment arm.
115490|NCT03283371|Other|Placebo|As specified in treatment arms.
115491|NCT03283358|Behavioral|Person-centered follow up|
115492|NCT03283345|Procedure|modified radical mastectomy|systemic responses to trauma are compared with evaluating inflammatory cytokine levels between premenopausal and postmenopausal patient groups with different estrogen levels who underwent modified radical mastectomy.
115493|NCT03283332|Other|No intervention|
115494|NCT03283319|Biological|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
115495|NCT03283319|Biological|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
115496|NCT03283319|Biological|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
115497|NCT03283319|Biological|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
115498|NCT03283319|Biological|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
115499|NCT03283293|Radiation|Target Volume Delineation after NACT|The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) were delineated in accordance with the head and neck magnetic resonance imaging (MRI) and endoscopy, which obtained two weeks after the last cycle of NACT. The first clinical target volume (CTV1) was defined as the GTVnx plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the high-risk sites of microscopic extension, the whole nasopharynx, and the location and extent of the primary tumor before NACT. The second clinical target volume (CTV2) was defined as the CTV1 plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the low-risk sites of microscopic extension, the level of the lymph node located before NACT, and the elective neck area. The prescribed dose to GTVnx, GTVnd, CTV1 and CTV2 were 68Gy/30f, 62-66Gy/30f, 60Gy/30f and 54Gy/30f, respectively.
115500|NCT03283280|Other|Ever X Posterior|Resin composite restoration can be made as a direct onlay
115501|NCT03283267|Drug|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
115502|NCT03283254|Behavioral|Practical Resources for Effective Postpartum Parenting|A preventive psychotherapy intervention for Postpartum Depression
115503|NCT03283254|Behavioral|Enhanced Treatment As Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community, clinical monitoring
115504|NCT03283241|Device|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
115505|NCT03283241|Device|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
115506|NCT03283228|Diagnostic Test|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
115507|NCT03283215|Diagnostic Test|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
115604|NCT03282448|Behavioral|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus & Miller, 2014).
115508|NCT03283202|Drug|Avadomide (CC-122)|Avadomide (CC-122) by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without avadomide (CC-122) administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
115509|NCT03283202|Drug|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
115510|NCT03283202|Drug|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
115511|NCT03283202|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
115512|NCT03283202|Drug|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
115513|NCT03283189|Other|Group discussions|The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
115514|NCT03283176|Diagnostic Test|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
115515|NCT03283163|Behavioral|Exercise Testing and Training|Each study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
115516|NCT03283150|Drug|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
115517|NCT03283150|Drug|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
115518|NCT03283150|Drug|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
115519|NCT03283137|Drug|TGR-1202|TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
115520|NCT03283137|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
115521|NCT03283124|Procedure|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
115522|NCT03283111|Biological|autologous stem cell transplantation|autologous stem cell transplantation
115523|NCT03283098|Device|Hemodialysis|AMG 416 will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
115524|NCT03283098|Device|Hemodialysis|The placebo will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
115525|NCT03283098|Procedure|Hemodialysis|AMG 416 will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
115526|NCT03283098|Procedure|Hemodialysis|The placebo will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
115527|NCT03283085|Drug|25 mg SHP647|SHP647 sterile aqueous buffered solution will be administered in dose of 25 mg subcutaneously.
115528|NCT03283085|Drug|75 mg SHP647|SHP647 sterile aqueous buffered solution will be administered in dose of 75 mg subcutaneously.
115529|NCT03283072|Device|Hypoxicator|Repeated bouts of hypoxia/normoxia
115530|NCT03283059|Drug|Octohydroaminoacridine Succinate|Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
115531|NCT03283059|Drug|Aricept|Aricept 5mg/day, P.O.
115532|NCT03283059|Drug|Placebos|Placebo Tablet: P.O. tid
115533|NCT03283046|Drug|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
115534|NCT03283046|Drug|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
115535|NCT03283046|Drug|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
115536|NCT03283046|Drug|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
115537|NCT03283033|Behavioral|New salad bar|New salad bar placed in school
115538|NCT03283033|Behavioral|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
115539|NCT03283020|Drug|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
115540|NCT03283020|Drug|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
115541|NCT03283007|Drug|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
115542|NCT03283007|Drug|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
115543|NCT03282994|Device|Dermal Cooling System|Cryotherapy
115544|NCT03282981|Drug|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
115605|NCT03282435|Biological|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking
115546|NCT03282968|Device|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
115547|NCT03282968|Other|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
115548|NCT03282955|Drug|Lipidem|Lipoplus i.v. lipid emulsion for parenteral nutrition
115549|NCT03282955|Drug|Lipofundin MCT 20%|Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition
115550|NCT03282942|Other|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.~The following exercises will compose the strength training protocol:~Squatting~Leg press~Knee Extension~Knee Flexion~Supine Challenge~High Pull~Elbow flexion~Extension of elbows~Development~Abdominal"
115551|NCT03282942|Other|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
115552|NCT03282929|Device|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
115553|NCT03282929|Device|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
115554|NCT03282929|Drug|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
115555|NCT03282929|Device|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
115556|NCT03282929|Device|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
115557|NCT03282916|Drug|Valacyclovir|Valacyclovir hydrochloride 500g caplet
115558|NCT03282916|Drug|Placebo|Placebo sugar pill 500mg caplet
115559|NCT03282890|Other|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
115560|NCT03282877|Behavioral|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
115561|NCT03282864|Device|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
115562|NCT03282851|Drug|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
115563|NCT03282851|Drug|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
115564|NCT03282851|Drug|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
115565|NCT03282838|Drug|DFN-15 (fasted)|DFN-15 administered to fasted subjects
115566|NCT03282838|Drug|DFN-15 (fed)|DFN-15 administered to fed subjects
115567|NCT03282838|Drug|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
115568|NCT03282825|Drug|Decitabine|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
115569|NCT03282825|Drug|Paclitaxel|"The subjects will be sequential administered with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.~Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
115570|NCT03282799|Drug|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
115571|NCT03282786|Other|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
115673|NCT03281902|Procedure|Biospecimen Collection|Undergo collection of blood
115572|NCT03282773|Device|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
115573|NCT03282773|Device|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
115574|NCT03282760|Biological|Human Neural Stem Cells|Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
115575|NCT03282747|Behavioral|no intervention|no intervention
115576|NCT03282734|Other|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
115577|NCT03282734|Other|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
115578|NCT03282721|Procedure|precise location of commissure|
115579|NCT03282708|Other|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).~Data collection with self-administered questionnaire"
115580|NCT03282682|Procedure|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
115581|NCT03282669|Drug|Intrathecal Morphine|Intrathecal Morphine administered in the operating room.
115582|NCT03282669|Drug|Intravenous hydromorphone|Intravenous hydromorphone administered via IV in the post operative area.
115583|NCT03282656|Biological|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
115584|NCT03282643|Drug|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
115585|NCT03282643|Drug|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
115586|NCT03282643|Drug|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
115587|NCT03282630|Procedure|Sphenopalatine ganglion acupuncture|"active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process~sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
115588|NCT03282617|Biological|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
115589|NCT03282591|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
115590|NCT03282591|Drug|Matching Placebo Tablets|Placebo Tablets
115591|NCT03282578|Device|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
115592|NCT03282578|Device|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
115593|NCT03282565|Other|Functional Resistance Training|A brace/cuff/exercise band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
115594|NCT03282565|Other|Control|A brace/cuff/exercise band will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
115595|NCT03282552|Device|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
115596|NCT03282539|Device|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
115597|NCT03282539|Device|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
115598|NCT03282526|Diagnostic Test|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
115599|NCT03282513|Drug|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
115600|NCT03282500|Behavioral|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
115601|NCT03282487|Drug|Modified release hydrocortisone|Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
115602|NCT03282474|Drug|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet [Sovaldi]
115603|NCT03282461|Drug|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
115608|NCT03282422|Device|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
115609|NCT03282422|Device|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
115610|NCT03282396|Drug|Ibrutinib|Given PO
115611|NCT03282370|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
115612|NCT03282370|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
115613|NCT03282357|Device|Radiesse injectable implant (dermal filler)|Subdermal injection.
115614|NCT03282357|Device|Restylane injectable implant (dermal filler)|Subdermal injection
115615|NCT03282344|Drug|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter
115616|NCT03282344|Drug|Nivolumab|360mg (flat dose) IV
115617|NCT03282331|Procedure|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
115618|NCT03282331|Procedure|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
115619|NCT03282331|Procedure|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
115620|NCT03282318|Drug|ASP6294|Subcutaneous (SC) injection
115621|NCT03282318|Drug|Placebo|SC injection
115622|NCT03282292|Procedure|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
115623|NCT03282279|Procedure|TVOR|Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
115624|NCT03282266|Procedure|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
115625|NCT03282266|Procedure|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
115626|NCT03282240|Biological|QIV-HD|0.7 mL-dose to be administered intramuscularly (IM) into the upper arm area
115627|NCT03282240|Biological|Licensed TIV-HD1|0.5 mL-dose to be administered IM into the upper arm area
115628|NCT03282240|Biological|Investigational TIV-HD2|0.5 mL-dose to be administered IM into the upper arm area
115629|NCT03282227|Drug|M207 Microneedle System|M207 Microneedle System 3.8 mg
115630|NCT03282214|Behavioral|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
115631|NCT03282201|Other|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
115632|NCT03282188|Biological|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
115633|NCT03282188|Drug|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
115634|NCT03282175|Other|Exercise|Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
115635|NCT03282175|Other|Training|Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
115636|NCT03282175|Other|Control group|The control group did not receive any treatment.
115637|NCT03282162|Drug|intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
115638|NCT03282162|Drug|intranasal placebo|An identical amount of intranasal administration of placebo will be assigned to each subject.
115639|NCT03282149|Biological|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
115641|NCT03282136|Device|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
115642|NCT03282123|Drug|MDMA|80 to 120 mg MDMA
115643|NCT03282123|Behavioral|Psychotherapy|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
115644|NCT03282110|Device|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
115645|NCT03282110|Other|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
115646|NCT03282110|Drug|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
115647|NCT03282097|Behavioral|DECAD decision aid|A mammography decision aid that will help caregivers of patients with Alzheimer's make decisions about stopping or continuing breast cancer screening.
115648|NCT03282097|Other|Home safety guide|The home safety guide provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
115649|NCT03282084|Diagnostic Test|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
115650|NCT03282084|Diagnostic Test|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
115651|NCT03282071|Behavioral|Joyful Parenting Intervention|"Two-session interactive talks for parents to promote praise & appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.~One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
115652|NCT03282058|Device|Silastic Stent|The silastic stent is a splint made of silicone.
115653|NCT03282045|Drug|Lysobact Complete Sprey|Inhaling spray
115654|NCT03282045|Drug|Tantum Verde® Spray|Inhaling spray
115655|NCT03282045|Drug|Pharyngal® Oromucosal Spray|Inhaling spray
115656|NCT03282045|Drug|Placebo|Inhaling spray
115657|NCT03282032|Other|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.~In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
115658|NCT03282019|Device|High-flow nasal cannula therapy|Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
115659|NCT03282019|Device|Home oxygen therapy (HOT)|All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
115660|NCT03282006|Drug|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
115661|NCT03281993|Other|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
115662|NCT03281980|Other|Psychosocial stimulation (PS)|"i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.~ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs~iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home."
115663|NCT03281980|Other|Government Intervention (UCT+HE)|fgbfgjhgykghilk
115664|NCT03281967|Device|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
115665|NCT03281954|Drug|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
115666|NCT03281954|Drug|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
115667|NCT03281941|Other|Inhaled capsaicin cough challenge|
115668|NCT03281928|Dietary Supplement|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
115669|NCT03281928|Dietary Supplement|Placebo|Sodium without Potassium Citrate
115670|NCT03281915|Procedure|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
115671|NCT03281915|Procedure|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
115672|NCT03281902|Procedure|Biopsy|Undergo tumor biopsy
115675|NCT03281889|Radiation|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
115676|NCT03281876|Biological|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
115677|NCT03281876|Biological|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
115678|NCT03281863|Diagnostic Test|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
115679|NCT03281837|Device|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
115680|NCT03281837|Other|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
115681|NCT03281824|Biological|ALT-P7 (HM2-MMAE)|Antibody-Drug Conjugate
115682|NCT03281811|Drug|Aminolevulinic Acid Hydrochloride|Given topically
115683|NCT03281811|Drug|Photodynamic Therapy|Undergo PDT
115684|NCT03281811|Other|Quality-of-Life Assessment|Ancillary studies
115685|NCT03281811|Radiation|Radiation Therapy|Undergo RT
115686|NCT03281798|Device|Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set|2.0 mm fetoscopy or flexible ureteroscope
115687|NCT03281785|Other|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
115688|NCT03281785|Other|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
115689|NCT03281785|Other|Pressure support mode (PS)|Pressure support mode (PS)
115690|NCT03281772|Other|Clinical Decision Software - provider portal|As noted in Arms
115691|NCT03281772|Other|Clinical Decision Software - patient portal|As noted in Arms
115692|NCT03281759|Device|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
115693|NCT03281759|Device|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
115694|NCT03281746|Procedure|Dental Procedure|Undergo dental examination
115695|NCT03281746|Other|Educational Intervention (prevention education)|Receive prevention education
115696|NCT03281746|Other|Interview|Ancillary studies
115697|NCT03281746|Other|Survey Administration|Ancillary studies
115698|NCT03281746|Other|Educational Intervention (one-on one education)|Receive one-on-one education
115699|NCT03281720|Procedure|TAD|the same intervention as listed in the arm description
115700|NCT03281707|Procedure|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
115701|NCT03281707|Other|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
115702|NCT03281694|Drug|Placebo|placebo skin patch and placebo oral solution
115703|NCT03281694|Drug|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
115704|NCT03281694|Drug|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
115705|NCT03281694|Drug|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
115706|NCT03281681|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
115707|NCT03281668|Behavioral|High intensity interval training (HIIT)|Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
115708|NCT03281655|Drug|Visnadine, prenylflavonoids and bovine colostrum|15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
115709|NCT03281642|Other|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
115710|NCT03281629|Device|Active TMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
115711|NCT03281629|Device|Sham TMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
115712|NCT03281616|Behavioral|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
115713|NCT03281603|Device|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
115714|NCT03281577|Drug|TAK-954|TAK-954 IV infusion.
115715|NCT03281577|Drug|Placebo|TAK-954 placebo-matching IV infusion.
115716|NCT03281564|Other|Quality of life after Essure® removal|Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
115717|NCT03281551|Drug|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
115718|NCT03281538|Drug|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
115719|NCT03281499|Other|da Vinci Surgical System Model IS4000|tailored radiotherapy regimen following transoral robotic surgery
115720|NCT03281486|Device|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
115721|NCT03281486|Device|Placebo|Placebo formulation without the active ingredients
115722|NCT03281473|Other|Strategy 1|PEEP titration according to transpulmonary-end-expiratory pressure
115723|NCT03281473|Other|Strategy 2|PEEP titration according to chest wall elastance measurement
115724|NCT03281460|Device|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
115725|NCT03281460|Procedure|laparoscopic myomectomy or hysterectomy without any morcellation bag|laparoscopic myomectomy or hysterectomy without any morcellation bag
115726|NCT03281447|Other|Nurse navigation|
115727|NCT03281447|Other|Current care coordination|
115728|NCT03281434|Dietary Supplement|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
115729|NCT03281434|Dietary Supplement|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
115730|NCT03281421|Other|Manual Therapy|The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
115731|NCT03281395|Procedure|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
115732|NCT03281395|Procedure|No rapid ventricular pacing|
115733|NCT03281382|Biological|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
115734|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
115735|NCT03281369|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
115736|NCT03281369|Drug|Oxaliplatin|Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
115737|NCT03281369|Biological|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
115738|NCT03281369|Drug|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1−21 of every 28-day cycle
115739|NCT03281369|Biological|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
115740|NCT03281369|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
115741|NCT03281369|Biological|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
115742|NCT03281369|Drug|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1−5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
115743|NCT03281369|Drug|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
115744|NCT03281369|Biological|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
115745|NCT03281369|Drug|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1−21 of every 28-day cycle.
115746|NCT03281356|Behavioral|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
115747|NCT03281343|Behavioral|Motivational Interviewing & Patient Navigator|The specific content, structure, and implementation approach for MI-NAV will be guided by IDIs conducted during Phase 1 and Phase 2. Our initial plan is to deliver MI-NAV in two waves. The first wave will be aimed at promoting uptake of PrEP at the prison, through the use of motivational interviewing. The second wave will be aimed at linking at-risk women to community-based PrEP care upon release from incarceration, by utilizing a patient navigator approach.
115748|NCT03281343|Behavioral|Standard of Care (SOC)|SOC will consist of a pamphlet regarding PrEP during incarceration, an offer of PrEP while incarcerated, and referral to community-based PrEP care upon release.
115749|NCT03281330|Behavioral|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
115750|NCT03281304|Drug|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
115751|NCT03281304|Drug|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
115752|NCT03281278|Other|standard treatment|standard medical treatment
115753|NCT03281265|Other|standard treatment|
115754|NCT03281239|Diagnostic Test|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :~laser doppler~blood tests~Holter ECG. No drug and no placebo were used in this arm."
115755|NCT03281226|Drug|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
115756|NCT03281226|Drug|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
115757|NCT03281213|Other|Thoracotomy|
115758|NCT03281200|Drug|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
115759|NCT03281200|Drug|L01 - Antineoplastic agents|L01 - Antineoplastic agents
115760|NCT03281200|Drug|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
115761|NCT03281200|Drug|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
115762|NCT03281200|Drug|L01XE31 - Nintedanib|L01XE31 - Nintedanib
115763|NCT03281187|Drug|Nasotestt 5 mg|The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
115764|NCT03281187|Drug|Androgel 50 mg|The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
115765|NCT03281187|Other|Nasotestt Placebo|The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
115766|NCT03281187|Other|Androgel Placebo|The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
115767|NCT03281161|Behavioral|Sun Safe Workplaces Program|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection policy promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
115768|NCT03281161|Behavioral|Attention Control|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection practice promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
115769|NCT03281148|Device|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
115770|NCT03281148|Device|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
115771|NCT03281135|Other|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
115772|NCT03281122|Drug|Placebo|Specified dose on specified days
115773|NCT03281122|Drug|BMS-986224|Specified dose on specified days
115774|NCT03281109|Diagnostic Test|diagnosis|diagnosis with ELISA
115775|NCT03281096|Drug|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
115776|NCT03281096|Drug|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
115777|NCT03281083|Drug|Levothyroxine Sodium|
115778|NCT03281057|Behavioral|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
115779|NCT03281044|Drug|Fecal microbiota capsules|Patients will receive FMP-402 capsules containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
115780|NCT03281044|Drug|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
115781|NCT03281031|Procedure|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
115782|NCT03281018|Behavioral|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
115783|NCT03280979|Drug|rescue regimen|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
115784|NCT03280979|Drug|high dose methotrxate|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
115785|NCT03280953|Diagnostic Test|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
115786|NCT03280927|Drug|Jublia®|Jublia® topical solution
115787|NCT03280914|Device|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
115788|NCT03280901|Other|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
115789|NCT03280875|Other|pedalling exercises|pedalling exercises on a bicycle ergometer
115790|NCT03280862|Device|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
115791|NCT03280849|Other|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
115828|NCT03280563|Drug|Entinostat|Entinostat will be given as 5 mg orally once a week on Days 1, 8 and 15 of each 21 day cycle.
115829|NCT03280563|Drug|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
115830|NCT03280563|Drug|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
115831|NCT03280563|Drug|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
115792|NCT03280836|Behavioral|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.~The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
115793|NCT03280810|Other|Movement group|Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
115794|NCT03280797|Procedure|Blood sample|2ml blood taken into TruCulture tube
115795|NCT03280771|Combination Product|Hope Soap|HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
115796|NCT03280771|Combination Product|Control group soap|A colourful, translucent bar or soap with the toy alongside it
115797|NCT03280758|Behavioral|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
115798|NCT03280745|Drug|Hypertonic saline|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
115799|NCT03280745|Drug|0.9% saline|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
115800|NCT03280732|Device|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
115801|NCT03280719|Device|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
115802|NCT03280719|Radiation|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
115803|NCT03280719|Device|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
115804|NCT03280719|Radiation|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
115805|NCT03280706|Dietary Supplement|Maltodextrin|Maltodextrin 50g in water 500ml
115806|NCT03280706|Dietary Supplement|Orange Juice|Orange juice 480ml + 20ml of water
115807|NCT03280706|Dietary Supplement|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
115808|NCT03280693|Diagnostic Test|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
115809|NCT03280680|Other|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
115810|NCT03280680|Other|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
115811|NCT03280680|Other|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
115812|NCT03280667|Drug|Pembrolizumab plus denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
115813|NCT03280654|Other|overactive bladder|Association between groups and over active bladder symptoms
115814|NCT03280641|Drug|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
115815|NCT03280641|Drug|Warfarin Sodium|Target INR:1.6-3.0
115816|NCT03280628|Procedure|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
115817|NCT03280628|Procedure|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
115818|NCT03280628|Procedure|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
115819|NCT03280615|Dietary Supplement|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
115820|NCT03280615|Dietary Supplement|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
115821|NCT03280602|Procedure|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
115822|NCT03280602|Procedure|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
115823|NCT03280589|Other|Sheetali/Sheekari Pranayama|Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex [6]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
115824|NCT03280589|Other|Sitting Quietly|Participant breaths in their natural way with out instruction
115825|NCT03280589|Other|Deep breathing|Participant is required to pay attention to each breath
115826|NCT03280563|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with entinostat in Stage 1, or exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
115827|NCT03280563|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
115832|NCT03280563|Drug|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
115833|NCT03280563|Drug|Abemaciclib|Abemaciclib will be given as 150mg twice daily during each 28-day cycle.
115834|NCT03280550|Drug|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection every 2 or 4 weeks.
115835|NCT03280550|Drug|Placebo|Matching placebo will be administered as a SC injection every 2 or 4 weeks.
115836|NCT03280537|Drug|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection every 2 to 4 weeks.
115837|NCT03280537|Drug|Placebo|Matching placebo will be administered as an SC injection every 2 or 4 weeks.
115838|NCT03280524|Other|reflexology|
115839|NCT03280524|Other|self-care guidelines with feet|
115840|NCT03280511|Drug|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 92 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
115841|NCT03280498|Procedure|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
115842|NCT03280485|Other|no intervention|no intervention validation of guidelines via database
115843|NCT03280472|Behavioral|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
115844|NCT03280472|Behavioral|Symptom tracking|Participants will track their symptoms
115845|NCT03280459|Procedure|robot-assisted cystectomy|Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
115846|NCT03280446|Device|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
115847|NCT03280433|Other|Aortic valve replacement|
115848|NCT03280420|Procedure|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
115849|NCT03280420|Procedure|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
115850|NCT03280407|Drug|Capecitabine|Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
115851|NCT03280407|Drug|FOLFOX regimen (oxaliplatin/leucovorin/5FU)|Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
115852|NCT03280407|Drug|CAPOX (oxaliplatin/capecitabine)|Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
115853|NCT03280394|Diagnostic Test|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
115854|NCT03280381|Other|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
115855|NCT03280381|Other|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
115856|NCT03280368|Other|Bloodtest|
115857|NCT03280368|Other|Questionnaires|
115858|NCT03280355|Behavioral|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
115859|NCT03280355|Behavioral|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres."
115860|NCT03280342|Drug|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
115861|NCT03280342|Drug|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
115862|NCT03280329|Other|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
115863|NCT03280329|Other|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
115864|NCT03280316|Procedure|surgery|patients with SVMs receive surgery
115865|NCT03280316|Procedure|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
115866|NCT03280316|Procedure|botulinum toxin A injection|BOTOX
115867|NCT03280316|Drug|M receptor antagonist|Tolterodine
115868|NCT03280303|Other|non-interventional|
115869|NCT03280290|Biological|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
115870|NCT03280277|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
115871|NCT03280277|Drug|Ferumoxytol|Given IV
115872|NCT03280264|Drug|KHK7580|oral administration
115873|NCT03280251|Drug|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
115874|NCT03280251|Drug|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
115875|NCT03280251|Other|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
115876|NCT03280251|Other|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
115877|NCT03280238|Diagnostic Test|Measurement of pupil dilation and analgesia nociception index|painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
115878|NCT03280225|Other|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
115879|NCT03280212|Drug|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
115880|NCT03280199|Other|simulation types|Different types of simulation interfaces and image acquisitions
115881|NCT03280186|Procedure|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
115882|NCT03280173|Drug|tafamidis|bioavailability study
115883|NCT03280160|Drug|Ibrutinib 140 MG Oral Capsule [Imbruvica]|"Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity.~After 12 cycles of ibrutinib, patients that do not achieve a complete response (CR) will be treated with the combination of ibrutinib and ofatumumab. Patients in CR after 12 cycles of ibrutinib will continue with ibrutinib alone.~Ofatumumab will be administered by IV infusion, 300mg on Day 1 and 1,000 mg on Day 8 of cycle 13, followed by 5 monthly infusions of 1,000 mg (Day 1 of subsequent 28-day cycles for cycles C14, C15, C16, C17, and C18).~A treatment cycle will be defined as lasting 28 days"
115884|NCT03280147|Drug|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
115885|NCT03280147|Drug|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
115886|NCT03280134|Procedure|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
115887|NCT03280121|Device|EsophyX ZR transoral device|TIF
115888|NCT03280108|Device|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision
115889|NCT03280108|Device|AcrySof Monofocal IOL|AcrySof Monofocal IOL Model SN60AT for single vision
115890|NCT03280095|Drug|co-codamol 15mg/500mg capsule|
115891|NCT03280095|Drug|co-codamol 30mg/500mg tablet|
115892|NCT03280082|Other|MUAC Program|All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
115893|NCT03280082|Other|Standard Program|All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
115894|NCT03280069|Device|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
115895|NCT03280056|Biological|NurOwn® (MSC-NTF cells)|Autologous transplantation of bone marrow derived mesenchymal stem cells propagated ex vivo and induced to secrete neurotrophic factors
115896|NCT03280056|Other|Placebo|Placebo
115897|NCT03280043|Procedure|Hematoma|Hematoma requiring return to operating room.
115898|NCT03280030|Drug|Midostaurin|Midostaurin 50 mg [two 25 mg capsules] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
115899|NCT03280030|Drug|Placebo|Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
115900|NCT03280017|Drug|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
115901|NCT03280017|Drug|Normal saline|normal saline infusion
115902|NCT03280004|Drug|Moxifloxacin Hydrochloride and Sodium Chloride Injection|Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
115903|NCT03279978|Drug|BI 730357|up to 28 days
115904|NCT03279978|Drug|Placebo|up to 28 days
115905|NCT03279978|Drug|Midazolam|Dose groups 4 & 5 only
115906|NCT03279965|Diagnostic Test|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
115907|NCT03279952|Drug|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
115908|NCT03279939|Device|OCT Angiography|OCT Angiography offers clinicians a non-invasive three-dimensional visualization of vasculature in the retina and choroid. The visualization of perfused vasculature in a three-dimensional layout, offers clinicians an aid in the identification of retinal and choroidal pathologies such as retinal ischemia, microaneurysms, retinal neovascularization and choroidal neovascular membranes.
115909|NCT03279939|Device|Color Fundus Photography|Non-contact white light photography.
115910|NCT03279939|Device|Fluorescein Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
115911|NCT03279939|Device|Indocyaine Green Angiography|An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
115912|NCT03279926|Behavioral|PLAY|Activity trackers + curriculum information
115913|NCT03279926|Behavioral|PLAY Parents|Enhanced parental engagement
115914|NCT03279926|Behavioral|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
115915|NCT03279913|Device|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
115916|NCT03279887|Diagnostic Test|Lung Ultrasound|
115917|NCT03279874|Other|Interviews|Semi-structured one-on-one interviews
115918|NCT03279861|Drug|Entresto|First line therapy in Entresto arm
115919|NCT03279861|Drug|Valsartan|"First line therapy in usual meds arm"
115920|NCT03279835|Other|Classic evaluation of neurocognitive functions|Symbol Digit Modalities Test (SDMT)
115921|NCT03279835|Other|New evaluation of neurocognitive functions|Cognitive Speed Computerized Test (CSCT)
115922|NCT03279822|Other|not any intervention|not any intervention
115923|NCT03279809|Drug|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
115924|NCT03279809|Drug|Placebo|Case with placebo medication for 6 months after stenting
115925|NCT03279796|Biological|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
115926|NCT03279796|Drug|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
115927|NCT03279783|Device|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
115928|NCT03279757|Drug|AHES 5 minutes|Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
115929|NCT03279757|Drug|AHES 15 minutes|Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
115930|NCT03279757|Drug|AHES 25 minutes|Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
115931|NCT03279757|Drug|LTC 5 minutes|Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
115932|NCT03279757|Drug|LTC 15 minutes|Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
115933|NCT03279757|Drug|LTC 25 minutes|Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
115934|NCT03279757|Device|fractional CO2 laser, 50 mJ, 5% density|Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
115935|NCT03279744|Drug|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm^2 and properly cover the entire lesion.
115936|NCT03279731|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
115937|NCT03279731|Drug|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
115938|NCT03279718|Procedure|Periodontal Treatment|Scaling and root planing
115939|NCT03279705|Device|Water jet channel|The separate water jet channel was used for infusing water.
115940|NCT03279705|Device|Accessory channel|The accessory channel was used for infusing and/or suctioning water
115941|NCT03279692|Drug|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
115942|NCT03279679|Procedure|costoclavicular infraclavicular block|Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
115943|NCT03279679|Procedure|paracoracoid infraclavicular block|Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
115944|NCT03279679|Device|Ultrasound|All the nerve blocks will be performed under realtime ultrasound guidance
115945|NCT03279679|Drug|Ropivacaine|0.5% ropivacaine will be used for the brachial plexus block in both groups.
115946|NCT03279666|Other|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
115947|NCT03279653|Procedure|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
115948|NCT03279640|Device|rTMS on ipsilesional M1|
115949|NCT03279640|Device|tDCS on contralesional M1|
115950|NCT03279627|Other|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
115951|NCT03279614|Drug|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
115952|NCT03279601|Drug|Capecitabine, Dacarbazine|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
115953|NCT03279601|Drug|Capecitabine, Temozolomide|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
115954|NCT03279588|Diagnostic Test|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
115955|NCT03279575|Behavioral|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
115956|NCT03279575|Behavioral|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
115957|NCT03279575|Behavioral|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
115958|NCT03279575|Behavioral|Control|Physicians in this arm will serve as a no-contact control group.
115959|NCT03279562|Drug|Nalmefene|Educational and behaviorally oriented drug counseling
115960|NCT03279549|Procedure|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
115961|NCT03279549|Procedure|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
115962|NCT03279549|Procedure|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
115963|NCT03279549|Procedure|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
115964|NCT03279536|Combination Product|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
115965|NCT03279536|Combination Product|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
115966|NCT03279523|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
115967|NCT03279510|Device|hearing aids|Subjects are fit with hearing aids.
115968|NCT03279497|Behavioral|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
115969|NCT03279497|Behavioral|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
115970|NCT03279484|Device|NAVIGO 4LV lead implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
115971|NCT03279471|Drug|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks. Dosing is capped at minimum effective dose.
115972|NCT03279471|Behavioral|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
115973|NCT03279471|Drug|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
115974|NCT03279458|Device|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
115975|NCT03279445|Genetic|Genetic testing|Two tubes of blood samples for genetic testing.
115976|NCT03279419|Diagnostic Test|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
115977|NCT03279406|Device|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
115978|NCT03279393|Drug|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
115979|NCT03279380|Other|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
115980|NCT03279380|Other|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
115981|NCT03279380|Other|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
115982|NCT03279367|Diagnostic Test|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
115983|NCT03279354|Behavioral|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
115984|NCT03279354|Behavioral|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics & Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
115985|NCT03279341|Drug|polyethylene glycol|osmotic laxative
115986|NCT03279341|Drug|Bisacodyl|stimulant laxative
115987|NCT03279341|Drug|Prucalopride|prokinetic
115988|NCT03279328|Drug|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
115989|NCT03279328|Other|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
115990|NCT03279328|Drug|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
115991|NCT03279315|Dietary Supplement|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
115992|NCT03279302|Drug|Glepaglutide|Solution for injection
115993|NCT03279289|Drug|Aflibercept|4 mg/kg administered intravenous infusion on day 1
115994|NCT03279289|Drug|Irinotecan|180 mg/m2 intravenous infusion
115995|NCT03279289|Drug|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
115996|NCT03279289|Drug|5Fluorouracil|400 mg/m2 intravenous bolus
115997|NCT03279289|Drug|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
116036|NCT03279055|Behavioral|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
116037|NCT03279042|Procedure|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
117065|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 180 days)|180 days
115998|NCT03279276|Procedure|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.~By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
115999|NCT03279263|Drug|MLR-1023|MLR-1023 Tablets
116000|NCT03279263|Other|Placebo|Matching Placebo Tablets
116001|NCT03279250|Drug|Abiraterone Acetate|Given PO
116002|NCT03279250|Drug|Apalutamide|Given PO
116003|NCT03279250|Biological|Gonadotropin-releasing Hormone Analog|Given IM
116004|NCT03279250|Drug|Prednisone|Given PO
116005|NCT03279250|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
116006|NCT03279237|Drug|Irinotecan|May help shrink tumor before surgery.
116007|NCT03279237|Drug|Oxaliplatin|May help shrink tumor before surgery.
116008|NCT03279237|Drug|Leucovorin|May help shrink tumor before surgery.
116009|NCT03279237|Drug|5-Fluorouracil|May help shrink tumor before surgery.
116010|NCT03279237|Drug|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
116011|NCT03279237|Radiation|Radiation Therapy|May help shrink tumor.
116012|NCT03279237|Drug|Carboplatin|Carboplatin may stop cancer cells from growing.
116013|NCT03279224|Biological|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
116014|NCT03279224|Biological|Autologous FMT|"1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.~3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.~3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
116015|NCT03279211|Other|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
116016|NCT03279211|Other|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
116017|NCT03279211|Other|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
116018|NCT03279198|Behavioral|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
116019|NCT03279198|Behavioral|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
116020|NCT03279198|Behavioral|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
116021|NCT03279198|Behavioral|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
116022|NCT03279172|Procedure|direct laryngoscope|procedure entubatıon
116023|NCT03279172|Procedure|videolaryngoscope|
116024|NCT03279159|Other|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
116025|NCT03279159|Other|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
116026|NCT03279146|Drug|Tenofovir exalidex (TXL)|Oral formulations
116027|NCT03279133|Drug|Ledipasvir 90mg/Sofosubvir 400mg|Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
116028|NCT03279120|Drug|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
116029|NCT03279120|Drug|Placebo|Used for 90 days (Continuous or Interrupted)
116030|NCT03279107|Other|Soluble corn fiber|soluble corn fiber
116031|NCT03279107|Other|maltodextrin|maltodextrin
116032|NCT03279094|Biological|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
116033|NCT03279081|Drug|Cx601|Cx601 eASCs intralesional injection.
116034|NCT03279081|Other|Placebo|Cx601 placebo-matching eASCs intralesional injection.
116035|NCT03279068|Other|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
116038|NCT03279042|Procedure|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using piezo-surgery cutting saws.
116039|NCT03279029|Biological|blood samples|blood samples
116040|NCT03279029|Biological|biopsy|biopsy of aortic valve
116041|NCT03279003|Device|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
116042|NCT03278990|Behavioral|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
116043|NCT03278990|Behavioral|Control writing exercise|In this sham comparator, participants will also write, however, the content of the writing exercise is different. Participants write for five minutes about what they did that day. Next, for five minutes, they write a letter to themselves next week.
116044|NCT03278977|Biological|Blood sample for specific analyzes|"Standard management of ALTE~Hospitalization in pediatric intensive care unit or pediatric emergencies~Etiologic research~Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
116045|NCT03278964|Procedure|Orbital decompression|
116046|NCT03278951|Behavioral|Video Conferencing Group|
116047|NCT03278951|Behavioral|In Person Group|
116048|NCT03278938|Drug|bupropion|FDA approved drug for treating depression
116049|NCT03278938|Drug|citalopram|FDA approved treatment for depression
116050|NCT03278925|Drug|Defined Green Tea Catechin Extract|Given PO
116051|NCT03278925|Other|Laboratory Biomarker Analysis|Correlative studies
116052|NCT03278925|Other|Pharmacological Study|Correlative studies
116053|NCT03278925|Other|Questionnaire Administration|Ancillary studies
116054|NCT03278886|Drug|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily for 8 weeks
116055|NCT03278886|Drug|Nalmefene|18 mg of nalmefene taken once daily for 8 weeks
116056|NCT03278873|Biological|either AAV - CNGB3 or AAV - CNGA3|Comparison of different dosages of either AAV - CNGB3 or AAV - CNGA3
116057|NCT03278860|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
116058|NCT03278860|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
116059|NCT03278860|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
116060|NCT03278860|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
116061|NCT03278847|Dietary Supplement|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:~Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)~This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle~This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
116062|NCT03278847|Dietary Supplement|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
116063|NCT03278847|Dietary Supplement|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:~Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)~This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.~This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
116064|NCT03278847|Dietary Supplement|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
116065|NCT03278834|Device|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
116066|NCT03278834|Device|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
116067|NCT03278821|Behavioral|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
116068|NCT03278821|Behavioral|Ekspert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
116069|NCT03278808|Drug|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
116070|NCT03278808|Drug|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
116071|NCT03278808|Drug|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
116072|NCT03278795|Procedure|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
116110|NCT03278496|Behavioral|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
116111|NCT03278496|Behavioral|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
116073|NCT03278795|Procedure|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
116074|NCT03278782|Biological|Pembrolizumab|Given IV
116075|NCT03278782|Drug|Romidepsin|Given IV
116076|NCT03278769|Procedure|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
116077|NCT03278756|Behavioral|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
116078|NCT03278756|Behavioral|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
116079|NCT03278743|Other|Cognitive performance and cognitive decline|Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
116080|NCT03278730|Drug|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
116081|NCT03278730|Drug|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
116082|NCT03278717|Drug|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
116083|NCT03278717|Drug|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
116084|NCT03278704|Other|RE only|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
116085|NCT03278704|Other|RE + HIIT|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
116086|NCT03278691|Drug|Saline|1 ml saline IV Q6H
116087|NCT03278691|Drug|Ketorolac|15 mg (15 mg/ml) IV Q6H
116088|NCT03278665|Drug|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
116089|NCT03278652|Other|Consumption of drugs for analgesic use|"Regular assessment of pain~Drug data will be collected (name, dosage, route of administration, time of delivery)"
116090|NCT03278639|Behavioral|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
116091|NCT03278639|Behavioral|Kinesiology|Training will be directed to ameliorate gait and balance
116092|NCT03278626|Drug|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
116093|NCT03278613|Device|ES-130|"The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device."
116094|NCT03278600|Genetic|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
116095|NCT03278587|Other|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
116096|NCT03278587|Other|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
116097|NCT03278587|Other|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
116098|NCT03278574|Procedure|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
116099|NCT03278574|Device|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
116100|NCT03278574|Device|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
116101|NCT03278561|Procedure|Sputum induction|Sputum induction according to the ERS protocol
116102|NCT03278561|Procedure|Blood sample|A blood sample of 100ml will be taken.
116103|NCT03278548|Drug|Volulyte 6%|Solution for infusion
116104|NCT03278548|Drug|Ionolyte|Solution for infusion
116105|NCT03278535|Diagnostic Test|CAREN-based gait analysis|subjects only walk at CAREN at different speed
116106|NCT03278522|Drug|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
116107|NCT03278509|Drug|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
116108|NCT03278509|Drug|Bisoprolol|Please see the section above.
116109|NCT03278496|Behavioral|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
116112|NCT03278483|Drug|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
116113|NCT03278483|Drug|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
116114|NCT03278470|Drug|HL237|Experimental
116115|NCT03278470|Drug|Placebo Oral Tablet|placebo with same properties except for active ingredient
116116|NCT03278457|Diagnostic Test|Positron Emission Tomography|Positron Emission Tomography
116117|NCT03278444|Other|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
116118|NCT03278444|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
116119|NCT03278444|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
116120|NCT03278431|Drug|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
116121|NCT03278431|Drug|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
116122|NCT03278431|Drug|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
116123|NCT03278431|Drug|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
116124|NCT03278418|Procedure|Tricuspid Valve Repair|It will be performed according to the surgeon preference
116125|NCT03278418|Procedure|Left-sided valve surgery|It will be performed according to the surgeon preference
116126|NCT03278405|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
116127|NCT03278392|Behavioral|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
116128|NCT03278392|Behavioral|Placebo Non-stress task|Subject engages in a friendly conversation about a neutral or happy topic (e.g. recent holiday, favorite past-times) for 15 minutes with a familiar research staff member.
116129|NCT03278379|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
116130|NCT03278366|Behavioral|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
116131|NCT03278353|Other|Exercise|"A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.~The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log."
116132|NCT03278353|Other|Manual Therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
116133|NCT03278340|Behavioral|Sun Safe Workplaces - Technology|After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
116134|NCT03278340|Behavioral|Sun Safe Workplaces -In Person|After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
116135|NCT03278327|Procedure|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
116136|NCT03278327|Device|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.~The device the most used in this case is the system COOK Medical Duett of Laboratories.~The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.~The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
116137|NCT03278314|Drug|tezacaftor/ivacaftor|orally administered TEZ/IVA combination therapy
116138|NCT03278301|Device|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
116202|NCT03277755|Drug|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
116139|NCT03278288|Device|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
116140|NCT03278275|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NORA-AE105
116141|NCT03278275|Device|PET/CT|Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
116142|NCT03278262|Drug|Aflibercept (Eylea, BAY86-5321)|Treatment-naïve eyes with neovascularization AMD (Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
116143|NCT03278249|Other|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
116144|NCT03278236|Behavioral|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
116145|NCT03278223|Device|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
116146|NCT03278223|Device|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
116147|NCT03278197|Other|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
116148|NCT03278197|Other|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
116149|NCT03278197|Other|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
116150|NCT03278197|Other|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
116151|NCT03278184|Device|tDCS sham motor cortex|the intervention 20 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
116152|NCT03278184|Device|active prefrontal cortex stimulation|the intervention 20 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
116153|NCT03278184|Device|active motor cortex stimulation|the intervention 20 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
116154|NCT03278171|Behavioral|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
116155|NCT03278158|Drug|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
116156|NCT03278158|Drug|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
116157|NCT03278158|Drug|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
116158|NCT03278158|Drug|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
116159|NCT03278158|Drug|XEN-D0501, 8 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 8 mg/tablet
116160|NCT03278145|Genetic|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
116161|NCT03278132|Biological|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
116162|NCT03278119|Diagnostic Test|PET Scan and nocturnal polysomnography|Amyloid PET scans will be used to assess amyloid burden in the brain, and nocturnal polysomnography will be used to assess sleep and cardiopulmonary variables
116163|NCT03278106|Other|Laboratory Biomarker Analysis|Correlative studies
116164|NCT03278106|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
116165|NCT03278080|Other|Road-tracking test|Driving with simulator program for SDLP measurement
116166|NCT03278080|Other|Car-following test|Driving with simulator program for DCV measurement
116167|NCT03278080|Other|Harsh-braking test|Driving with simulator program for BRT measurement
116168|NCT03278067|Other|Enhanced vaccine safety surveillance|Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
116169|NCT03278054|Other|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
116170|NCT03278054|Other|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
116171|NCT03278054|Other|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
116203|NCT03277755|Drug|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
116204|NCT03277755|Drug|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
116172|NCT03278041|Procedure|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :~Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.~1st step will be identify the facial artery and vein,~2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.~3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .~The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
116173|NCT03278041|Device|maxillary obturator|immediate surgical obturator
116174|NCT03278028|Drug|A-101 Topical Solution|A-101 Topical Solution
116175|NCT03278028|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
116176|NCT03278015|Drug|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
116177|NCT03278015|Drug|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
116178|NCT03278015|Drug|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
116179|NCT03277976|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
116180|NCT03277976|Device|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
116181|NCT03277963|Device|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
116182|NCT03277950|Other|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
116183|NCT03277950|Other|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
116184|NCT03277950|Other|Healthy|Healthy do not play game
116185|NCT03277937|Procedure|angiography in EUS-injection of coils + CYA|Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
116186|NCT03277924|Drug|Sunitinib 37.5 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
116187|NCT03277924|Drug|Nivolumab 10 MG/ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
116188|NCT03277898|Behavioral|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
116189|NCT03277898|Behavioral|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
116190|NCT03277885|Other|chronic pain|work related chronic pain
116191|NCT03277872|Device|Laryngoscopy with GlideScope (GVL) Blade|"st Laryngoscopy with GVL Blade~nd Laryngoscopy with MAC Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
116192|NCT03277872|Device|Laryngoscopy with MacIntosh (MAC) Blade|"st Laryngoscopy with MAC Blade~nd Laryngoscopy with GVL Blade~rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
116193|NCT03277859|Behavioral|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
116194|NCT03277846|Device|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
116195|NCT03277833|Dietary Supplement|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
116196|NCT03277833|Dietary Supplement|Placebo|Placebo, parallel design
116197|NCT03277820|Dietary Supplement|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
116198|NCT03277794|Behavioral|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
116199|NCT03277794|Behavioral|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
116200|NCT03277781|Other|Screening|Screening for AAA
116201|NCT03277768|Device|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
116238|NCT03277534|Other|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
116205|NCT03277742|Behavioral|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
116206|NCT03277742|Drug|Standard of care|DOTS plus standard DM2 care
116207|NCT03277729|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD20 CAR T cell IV
116208|NCT03277729|Drug|Cyclophosphamide|Given IV
116209|NCT03277729|Drug|Fludarabine|Given IV
116210|NCT03277729|Other|Laboratory Biomarker Analysis|Correlative studies
116211|NCT03277729|Procedure|Leukapheresis|Undergo leukapheresis
116212|NCT03277729|Drug|Fludarabine Phosphate|Given IV
116213|NCT03277716|Procedure|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
116214|NCT03277716|Procedure|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
116215|NCT03277716|Device|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
116216|NCT03277716|Drug|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
116217|NCT03277703|Biological|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.~Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
116218|NCT03277690|Drug|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.~During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
116219|NCT03277690|Drug|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.~During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
116220|NCT03277677|Drug|Normal saline|for resuscitation in sepsis patients
116221|NCT03277677|Drug|Ringer's Acetate|for resuscitation in sepsis patients
116222|NCT03277664|Behavioral|intervention group|"All the device-monitored adherence data from the previous week were downloaded from the background database and calculated by a qualified asthma nurse. Through free IMS (WeChat; Tencent, Shenzhen, CHN) available on mobile, the nurse offered feedback to the caregivers weekly according to the adherence rate and reminded them to keep taking the ICS. Caregivers were asked monthly Has our child inhaled the medicine according to the doctor's instructions? and How about the frequency? by telephone."
116223|NCT03277651|Diagnostic Test|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
116224|NCT03277638|Drug|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
116225|NCT03277638|Drug|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
116226|NCT03277638|Drug|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
116227|NCT03277638|Procedure|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
116228|NCT03277625|Procedure|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
116229|NCT03277599|Drug|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
116230|NCT03277599|Drug|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
116231|NCT03277599|Drug|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
116232|NCT03277586|Drug|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
116233|NCT03277586|Drug|Placebo|Identically formulated and packaged inactive substance
116234|NCT03277573|Drug|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
116235|NCT03277573|Drug|Placebo|Inactive ingredient
116236|NCT03277560|Other|No Intervention as it is an observational study|No Intervention as it is an observational study
116237|NCT03277534|Other|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
116274|NCT03277313|Biological|GAMMAGARD LIQUID|GAMMAGARD LIQUID IGI (Human), 10% Solution
116239|NCT03277521|Other|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
116240|NCT03277508|Device|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
116241|NCT03277508|Device|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
116242|NCT03277495|Behavioral|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
116243|NCT03277495|Other|Nicotine present in the SREC device and refills|Nicotine is present in the liquid in the SREC device and all refills. Two-thirds of the sample will receive nicotine in their SREC; one-third will not (placebo)
116244|NCT03277482|Drug|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
116245|NCT03277482|Drug|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
116246|NCT03277482|Radiation|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
116247|NCT03277469|Device|MRI|Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
116248|NCT03277469|Radiation|Brachytherapy|Radiation therapy that is delivered by inserting radioactive sources directly into a tumor
116249|NCT03277469|Device|MRI Tracker|The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
116250|NCT03277456|Biological|MVA-NP+M1|Intramuscular injection of novel vaccine
116251|NCT03277443|Procedure|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
116252|NCT03277443|Procedure|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
116253|NCT03277443|Device|2D cephalometric radiograph|2D cephalometric radiograph
116254|NCT03277443|Device|3D computerized tomography|3D computerized tomography
116255|NCT03277430|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
116256|NCT03277430|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
116257|NCT03277430|Drug|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
116258|NCT03277417|Other|Echocardiography|Imaging of fetal heart and amniotic fluid
116259|NCT03277404|Procedure|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
116260|NCT03277404|Procedure|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
116261|NCT03277391|Procedure|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
116262|NCT03277391|Device|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
116263|NCT03277378|Device|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
116264|NCT03277365|Other|Receive genetic risk information|Risk scores are provided by ResearchKit app.
116265|NCT03277352|Drug|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
116266|NCT03277352|Drug|Epacadostat|Epacadostat will be self-administered orally at the protocol-defined dose.
116267|NCT03277352|Drug|Pembrolizumab|Pembrolizumab will be administered IV at the protocol-defined dose.
116268|NCT03277339|Drug|Paroxetine|Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
116269|NCT03277339|Other|Thermal cure|Thermal cure is realized for 3 weeks
116270|NCT03277326|Procedure|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
116271|NCT03277326|Procedure|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
116272|NCT03277326|Procedure|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
116273|NCT03277313|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
116275|NCT03277300|Dietary Supplement|dietary supplement|good dietary supplement for critically ill patients
116276|NCT03277287|Radiation|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
116277|NCT03277274|Drug|TAK-954|TAK-954 intravenous infusion.
116278|NCT03277261|Biological|Ublituximab|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/oral placebo on specified days or teriflunomide/IV placebo (14 mg, OD starting on Week 1 Day 1)
116279|NCT03277261|Drug|Teriflunomide|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/oral placebo on specified days or teriflunomide/IV placebo (14 mg, OD starting on Week 1 Day 1)
116280|NCT03277248|Biological|Ublituximab|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/ oral placebo on specfied days or teriflunomide/ IV placebo (14mg, once daily starting on Week1 Day1)
116281|NCT03277248|Drug|Teriflunomide|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/ oral placebo on specfied days or teriflunomide/ IV placebo (14mg, once daily starting on Week1 Day1)
116282|NCT03277235|Behavioral|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
116283|NCT03277222|Biological|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the a nasal delivery device. Each escalated dose will be given for 1 week.
116284|NCT03277222|Biological|IN Lilly Diluent|Lilly Diluent twice daily taken after breakfast and again after dinner using the a nasal delivery device.
116285|NCT03277209|Drug|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
116286|NCT03277196|Drug|Ivacaftor|Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the morning dose of the Week 96 Visit.
116287|NCT03277183|Drug|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
116288|NCT03277183|Drug|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
116289|NCT03277170|Drug|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
116290|NCT03277157|Dietary Supplement|B. lactis B94|A probiotic dose of 15 billion per capsule.
116291|NCT03277157|Dietary Supplement|Placebo|Placebo capsule
116292|NCT03277144|Device|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
116293|NCT03277144|Other|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
116294|NCT03277131|Device|DURAFIBER Ag|DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
116295|NCT03277118|Device|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
116296|NCT03277105|Drug|Dara SC|Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
116297|NCT03277105|Drug|Dara IV|Participants will receive Dara IV 16 mg/kg once weekly at in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
116298|NCT03277092|Device|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
116299|NCT03277092|Procedure|Usual care|The blood drawing is performed traditionally
116300|NCT03277079|Drug|statin + ezetimibe|Combination of two drugs
116301|NCT03277079|Drug|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
116302|NCT03277066|Drug|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 will be evaluated against placebo topical patches.
116303|NCT03277066|Drug|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 will be evaluated against placebo topical patches.
116304|NCT03277066|Drug|Placebo patch|The study will evaluate active topical patches against topical placebo patches.
116305|NCT03277053|Device|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
116306|NCT03277053|Other|Control.|Patient receive an ipad with no application.
116307|NCT03277040|Other|CSA membership|Bi-weekly fresh food delivery
116308|NCT03277027|Other|interventional study|The participants wear a monitoring equipment (Actigraph) for a week. And parents do Child Health Questionnaire Parent Form 50 (CHQ-PF50), and Korean Parenting Stress Index-Short Form (K-PSI-SF)
116309|NCT03277001|Drug|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and < 50 ml/min) po.
116310|NCT03277001|Drug|Enoxaparin|Enoxaparin 40mg IH
116311|NCT03276988|Drug|Period 1 GX-30, Period 2 THYROGEN®|Part B - Sequence A. GX-30 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, THYROGEN® 0.9mg will be administered in Period 2.
116312|NCT03276988|Drug|Period 1 THYROGEN®, Period 2 GX-30|Part B - Sequence B. THYROGEN® 0.9mg will be administered at Day 1 and Day 2 in Period 1. After wash-out period of 2 to 3 weeks, GX-30 0.9mg will be administered in Period 2.
116313|NCT03276975|Drug|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
116314|NCT03276962|Biological|RTS,S/AS01E (Full dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
116315|NCT03276962|Biological|RTS,S/AS01E (1/5th dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
116316|NCT03276962|Biological|Rabies vaccine|Subjects will receive intramuscular injection of rabies vaccine (0.1 ml).
116317|NCT03276949|Device|Blood glucose measurement|Device used to measure blood glucose levels
116318|NCT03276936|Drug|FMX103 1.5%|FMX103 1.5% minocycline foam
116319|NCT03276910|Drug|EPREX|6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
116320|NCT03276910|Drug|sodium chloride AGUETTANT 0.9%|6 injections at 1ml in subcutaneous use
116321|NCT03276897|Other|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
116322|NCT03276884|Other|Experimental Infant Formula|amino acid-based infant formula powder
116323|NCT03276884|Other|Control Infant Formula|amino acid-based infant formula powder
116324|NCT03276871|Procedure|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
116325|NCT03276871|Device|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
116326|NCT03276858|Drug|CRN00808|Investigational drug
116327|NCT03276858|Drug|Placebo Oral Solution|Placebo
116328|NCT03276858|Drug|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
116329|NCT03276858|Drug|Placebo oral capsule|Placebo
116330|NCT03276845|Diagnostic Test|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
116331|NCT03276832|Drug|Imiquimod|Applied cutaneously
116332|NCT03276832|Other|Laboratory Biomarker Analysis|Correlative studies
116333|NCT03276832|Biological|Pembrolizumab|Given IV
116334|NCT03276819|Procedure|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
116335|NCT03276819|Behavioral|Psychological and Sociological evaluation|Cohort B ....
116336|NCT03276819|Behavioral|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
116337|NCT03276819|Behavioral|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
116338|NCT03276806|Behavioral|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
116339|NCT03276806|Behavioral|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
116340|NCT03276806|Other|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
116341|NCT03276806|Other|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
116342|NCT03276793|Other|MRI scan|Patients will undergo an MRI scan
116343|NCT03276793|Behavioral|Behavioral testing|Patients will complete a series of cognitive tasks
116344|NCT03276780|Behavioral|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
116345|NCT03276780|Drug|combination NRT|Both groups will receive combination NRT to help with smoking cessation
116346|NCT03276767|Other|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
116347|NCT03276741|Dietary Supplement|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
116348|NCT03276728|Drug|AMG 986 IV Dose Level A or matching Placebo|Single dose Healthy Volunteers
116349|NCT03276728|Drug|AMG 986 IV Dose Level B or matching Placebo|Single dose Healthy Volunteers
116350|NCT03276728|Drug|AMG 986 IV Dose Level C or matching placebo|Single dose Healthy Volunteers
116351|NCT03276728|Drug|AMG 986 IV Dose Level D or matching placebo|Single dose Healthy Volunteers
116352|NCT03276728|Drug|AMG 986 IV Dose Level E or matching Placebo|Single dose Healthy Volunteers
116353|NCT03276728|Drug|AMG 986 IV Dose Level F or matching Placebo|Multiple daily dose Healthy Volunteers
116354|NCT03276728|Drug|AMG 986 IV Dose Level G or matching Placebo|Multiple daily dose Healthy Volunteers
116355|NCT03276728|Drug|AMG 986 Oral Dose Level A or matching Placebo|Single dose Healthy Volunteer
116356|NCT03276728|Drug|AMG 986 Oral Dose Level B or matching Placebo|Single dose Healthy Volunteer
116357|NCT03276728|Drug|AMG 986 Oral Dose Level C or matching Placebo|Single dose Healthy Volunteer
116358|NCT03276728|Drug|AMG 986 Oral Dose Level D or matching Placebo|Single dose Healthy Volunteers
116359|NCT03276728|Drug|AMG 986 Oral Dose Level E or matching Placebo|Single dose Healthy Volunteers
116360|NCT03276728|Drug|AMG 986 Oral Dose Level F or matching Placebo|Single dose Healthy Volunteers
116361|NCT03276728|Drug|AMG 986 Oral Dose Level A or matching Placebo|Multiple daily dose Healthy Volunteers
116362|NCT03276728|Drug|AMG 986 Oral Dose Level B or matching Placebo|Multiple daily dose Healthy Volunteers
116363|NCT03276728|Drug|AMG 986 Oral Dose Level C or matching Placebo|Multiple daily dose Healthy Volunteers
116364|NCT03276728|Drug|AMG 986 Oral Dose Level D or matching Placebo|Multiple daily dose Healthy Volunteers
116365|NCT03276728|Drug|AMG 986 Oral Dose Level E or matching Placebo|Multiple daily dose Healthy Volunteers
116366|NCT03276728|Drug|AMG 986 Oral Dose Level F or matching Placebo|Multiple daily dose Healthy Volunteers
116367|NCT03276728|Drug|AMG 986 Oral Dose Regimen or matching placebo - R|Multiple daily dose - Patients with heart failure and reduced ejection fraction
116368|NCT03276728|Drug|AMG 986 Oral Dose Regimen or matching placebo - P|Multiple daily dose - Patients with heart failure and preserved ejection fraction
116369|NCT03276702|Procedure|Re-biopsy|For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
116370|NCT03276702|Other|Questionnaire|Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
116371|NCT03276689|Drug|Duloxetine|The patients will take duloxetine for 8 weeks.
116372|NCT03276689|Drug|Pregabaline|The patients will take pregabaline for 8 weeks.
116373|NCT03276689|Other|Placebo|The patients will take placebo for 8 weeks.
116374|NCT03276676|Drug|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor > 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
116375|NCT03276663|Other|Formula feeding regimen|The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
116376|NCT03276650|Other|data collection|biological, administrative, clinical, outcome date
116377|NCT03276637|Genetic|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's CLIA certified laboratory on 75 enrolled individuals
116378|NCT03276624|Procedure|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
116379|NCT03276611|Other|echocardiograghy|transthoracic echocardiograghy
116380|NCT03276598|Drug|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
116381|NCT03276598|Drug|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
116382|NCT03276598|Drug|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
116383|NCT03276598|Drug|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
116384|NCT03276598|Drug|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
116385|NCT03276572|Drug|225Ac−J591|225Ac−J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
116386|NCT03276559|Behavioral|EMPOWER|"EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment."
116387|NCT03276559|Other|Enhanced Usual Care|Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
116388|NCT03276546|Behavioral|shared decision-making tool (SHARE-D)|questionnaire
116389|NCT03276533|Drug|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
116390|NCT03276533|Drug|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
116391|NCT03276533|Drug|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
116392|NCT03276533|Drug|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
116393|NCT03276520|Diagnostic Test|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
116394|NCT03276520|Diagnostic Test|ethanol|alcohol urine screening with ethanol
116395|NCT03276507|Diagnostic Test|Pulmonary function studies|
116396|NCT03276507|Diagnostic Test|Echocardiogram|
116397|NCT03276507|Diagnostic Test|Electrocardiogram|
116398|NCT03276507|Diagnostic Test|Chest radiography|
116399|NCT03276507|Diagnostic Test|Blood test|
116400|NCT03276507|Behavioral|Quality of life questionnaire|
116401|NCT03276494|Device|Intraosseous|Intraosseous administration of hypertonic saline
116402|NCT03276494|Drug|Hypertonic saline|Intraosseous administration of hypertonic saline
116434|NCT03276169|Procedure|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
116403|NCT03276481|Diagnostic Test|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
116404|NCT03276481|Diagnostic Test|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
116405|NCT03276481|Diagnostic Test|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
116406|NCT03276481|Behavioral|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
116407|NCT03276468|Drug|Atezolizumab|1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
116408|NCT03276468|Drug|Obinutuzumab|1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
116409|NCT03276468|Drug|Venetoclax|800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
116410|NCT03276455|Genetic|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
116411|NCT03276442|Other|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
116412|NCT03276442|Other|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
116413|NCT03276403|Device|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
116414|NCT03276390|Behavioral|Hispanic Kidney Transplant Program (HKTP)|The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
116415|NCT03276364|Diagnostic Test|Ultrasound|Point-of-care ultrasound examination by pulmonary and critical care fellow
116416|NCT03276351|Device|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
116417|NCT03276351|Device|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
116418|NCT03276338|Behavioral|HOLA|To increase condom use and HIV testing
116419|NCT03276325|Drug|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
116420|NCT03276325|Drug|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
116421|NCT03276312|Device|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
116422|NCT03276299|Other|six minute walking test|six minute walking test
116423|NCT03276299|Other|six minute walking test|six minute walking test with encouragement
116424|NCT03276286|Device|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
116425|NCT03276273|Device|recording of Bispectral Index|recording of Bispectral Index
116426|NCT03276260|Device|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
116427|NCT03276247|Other|observation|observation
116428|NCT03276221|Behavioral|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
116429|NCT03276208|Other|Prenatal Massage|We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
116430|NCT03276208|Other|Mindfulness|The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
116431|NCT03276182|Device|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
116432|NCT03276169|Procedure|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
116433|NCT03276169|Procedure|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
116435|NCT03276156|Drug|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
116436|NCT03276143|Drug|BAY1213790|single dose intravenous infusion
116437|NCT03276143|Drug|Enoxaparin|daily subcutaneous injection
116438|NCT03276143|Drug|Apixaban|twice daily oral administration
116439|NCT03276104|Procedure|IOL repositioning|Intraocular lens repositioning by scleral suturing
116440|NCT03276104|Procedure|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
116441|NCT03276091|Behavioral|Colofit+ intervention|Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
116442|NCT03276078|Drug|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12μg administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
116443|NCT03276065|Device|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
116444|NCT03276065|Other|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
116445|NCT03276052|Drug|Aclidinium Bromide 200 μg|Aclidinium Bromide 200 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
116446|NCT03276052|Drug|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
116447|NCT03276052|Drug|Aclidinium Bromide 800 μg|Aclidinium Bromide 400 μg BID inhalation powder. Two oral inhalations via Genuair® dry powder inhaler (DPI)
116448|NCT03276039|Diagnostic Test|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
116449|NCT03276026|Drug|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
116450|NCT03276026|Drug|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
116451|NCT03276013|Drug|Pembrolizumab|pembrolizumab in combination with doxorubicin
116452|NCT03276000|Procedure|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
116453|NCT03275987|Behavioral|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
116454|NCT03275987|Behavioral|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
116455|NCT03275987|Behavioral|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
116456|NCT03275974|Biological|Carbon C 11 Glutamine|Given by IV
116457|NCT03275974|Biological|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given by IV
116458|NCT03275974|Procedure|Positron Emission Tomography|Undergo PET scan
116459|NCT03275974|Procedure|Biopsy|Undergo CT-guided core biopsy
116460|NCT03275974|Procedure|Blood Draw|Undergo venous blood draws
116461|NCT03275961|Behavioral|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
116462|NCT03275948|Other|whole grain|whole grain rye
116463|NCT03275948|Other|reference|white wheat bread
116464|NCT03275922|Drug|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
116465|NCT03275922|Drug|ZNS|Zolmitriptan Nasal Spray
116466|NCT03275909|Behavioral|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
116467|NCT03275896|Other|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
116468|NCT03275883|Procedure|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
116469|NCT03275870|Drug|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
116470|NCT03275857|Drug|Cisplatin|Weekly IV
116471|NCT03275844|Procedure|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
116472|NCT03275831|Device|PluroGel|Surfactant based gel
116473|NCT03275831|Device|Intrasite gel|Hydrogel
116474|NCT03275818|Drug|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
117066|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 270 days)|270 days
116475|NCT03275805|Device|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration (for the 6 week arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
116476|NCT03275805|Device|Standard of Care|12 weeks Pavlik Treatment Arm
116477|NCT03275792|Drug|D5-0.9%NS|Admission for intravascular volume expansion
116478|NCT03275792|Drug|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
116479|NCT03275779|Behavioral|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
116480|NCT03275779|Behavioral|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
116481|NCT03275766|Other|DLPFC facilitatory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
116482|NCT03275766|Other|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
116483|NCT03275766|Other|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
116484|NCT03275766|Other|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
116485|NCT03275753|Other|Visual Function Tests|All subjects will undergo a battery of visual function tests
116486|NCT03275740|Drug|PF-06755347|Single doses of PF-06755347 will be administered, at planned dose levels of 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 7.5 mg/kg, 15 mg/kg, and 30 mg/kg.
116487|NCT03275740|Drug|Placebo comparator|Placebo comparator
116488|NCT03275727|Behavioral|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
116489|NCT03275714|Device|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
116490|NCT03275701|Drug|Triumeq|Open Label, Switch to Triumeq (ABC/DTG/3TC)
116491|NCT03275688|Diagnostic Test|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
116492|NCT03275675|Drug|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
116493|NCT03275662|Behavioral|Dietary Fiber|
116494|NCT03275662|Behavioral|Fermented Foods|
116495|NCT03275649|Other|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
116496|NCT03275636|Biological|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
116497|NCT03275623|Drug|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
116498|NCT03275623|Other|Standard Prenatal Care|Continued surveillance of urinary cultures
116499|NCT03275610|Genetic|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
116500|NCT03275597|Drug|Durvalumab|Durvalumab is an FDA-approved immunotherapy for cancer. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
116501|NCT03275597|Drug|Tremelimumab|Tremelimumab is a monoclonal antibody against CTLA-4. It is an IgG 2 kappa isotype mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also known as CD152 (cluster of differentiation 152). This is an immunomodulatory therapy (IMT) that is being developed by AstraZeneca for use in the treatment of cancer.
116502|NCT03275597|Radiation|Stereotactic Body Radiotherapy|SBRT is a highly conformal approach to the delivery of radiation therapy, maximizing radiation dose to the tumor while minimizing dose to nearby normal tissues.
116503|NCT03275584|Drug|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
116504|NCT03275571|Behavioral|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
116505|NCT03275558|Drug|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.~Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
116506|NCT03275558|Drug|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
116507|NCT03275558|Drug|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
116508|NCT03275545|Other|No intervention|No intervention is being examined in this study
116509|NCT03275519|Other|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
116510|NCT03275519|Other|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
116511|NCT03275506|Drug|Pembrolizumab Injectable Product - Chemotherapy - Bev|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
116512|NCT03275506|Drug|Chemotherapy - Bev|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
116513|NCT03275493|Biological|Humanized CD19 CAR-T cells|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells
116514|NCT03275493|Biological|Humanized CD19 CAR-T cells with CRS suppression technology|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells with CRS suppression technology
116515|NCT03275467|Other|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
116516|NCT03275454|Drug|BIVV009 6.5 grams|Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
116517|NCT03275454|Drug|BIVV009 7.5 grams|Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
116518|NCT03275441|Diagnostic Test|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
116519|NCT03275428|Device|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
116520|NCT03275415|Drug|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
116521|NCT03275415|Drug|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
116522|NCT03275402|Biological|131I-omburtamab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
116523|NCT03275389|Biological|D-SUIV Formulation 1|1 Primary dose or 1 Booster dose will be administered intramuscularly (IM) in the deltoid region of non-dominant arm.
116524|NCT03275389|Biological|D-SUIV Formulation 2|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
116525|NCT03275389|Biological|D-SUIV Formulation 3|1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
116526|NCT03275389|Biological|D-SUIV Formulation 4|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
116527|NCT03275389|Biological|D-SUIV Formulation 5|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
116528|NCT03275389|Biological|D-SUIV Formulation 6|1 Booster dose will be administered IM in the deltoid region of non-dominant arm
116529|NCT03275389|Biological|D-SUIV Formulation 7|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
116530|NCT03275389|Biological|D-SUIV Formulation 8|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
116531|NCT03275389|Biological|D-SUIV Formulation 9|1 Booster dose will be administered IM in the deltoid region of non-dominant arm
116532|NCT03275389|Biological|Placebo|1 dose will be administered IM in the deltoid region of non-dominant arm
116533|NCT03275389|Biological|FLU-D-QIV|1 Primary dose and 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
116534|NCT03275376|Drug|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
116535|NCT03275376|Drug|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
116536|NCT03275363|Diagnostic Test|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).~NACC: Story recall, Benson's complex figure copy, colour trail test (black & white), verbal fluency, digit forward and backward span."
116537|NCT03275363|Diagnostic Test|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
116538|NCT03275363|Biological|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
116539|NCT03275363|Diagnostic Test|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
116540|NCT03275363|Diagnostic Test|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
116541|NCT03275350|Drug|Naltrexone Injectable Suspension|Six monthly injections of extended-release naltrexone
116542|NCT03275350|Other|Treatment as usual|Standard treatment for opioid use disorder provided at each HIV clinic
116543|NCT03275337|Device|Transcranial Direct Current Stimulation|tDCS is a non-invasive form of neuromodulation in which direct current is administered placed over a brain region of interest to induce physiological changes such as inhibition or excitation over that region.
116544|NCT03275324|Device|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
116545|NCT03275285|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
116546|NCT03275285|Drug|carfilzomib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
116547|NCT03275285|Drug|dexamethasone|"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
116548|NCT03275272|Diagnostic Test|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
116549|NCT03275259|Device|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
116550|NCT03275246|Device|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
116551|NCT03275220|Diagnostic Test|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
116552|NCT03275207|Drug|saline|an equal volume of saline
116553|NCT03275207|Drug|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous infusion, intraoperative
116591|NCT03274895|Drug|PHMB 0.02%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
117067|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 90 days)|90 days
116554|NCT03275194|Procedure|HIPEC|Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
116555|NCT03275181|Diagnostic Test|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
116556|NCT03275181|Diagnostic Test|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
116557|NCT03275181|Diagnostic Test|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
116558|NCT03275168|Behavioral|Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
116559|NCT03275168|Behavioral|Individual evidence-based STI/HIV prevention intervention|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
116560|NCT03275142|Device|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
116561|NCT03275129|Diagnostic Test|Ultrasound assessment of heart and lungs|Patients will receive an ultrasound assessment of their heart and lungs.
116562|NCT03275116|Drug|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
116563|NCT03275116|Drug|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
116564|NCT03275103|Drug|BFCR4350A|BFCR4350A will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
116565|NCT03275090|Drug|Smoflipid ®|
116566|NCT03275077|Device|Thromboelastography|A viscoelastic test of coagulation
116567|NCT03275064|Biological|LNA043|LNA043 intra-articular injection
116568|NCT03275064|Other|Placebo|Placebo intra-articular injection
116569|NCT03275051|Other|Safety and Efficacy assessments|Safety and efficacy assessment of OTL-300 in subjects with transfusion dependent beta-thalassemia will be performed.
116570|NCT03275038|Behavioral|Tai-Chi exercise|Behavioral: Tai-Chi exercise
116571|NCT03275038|Behavioral|Aerobic exercise|Behavioral: Aerobic exercise
116572|NCT03275025|Drug|YRA-1909 low dose|A low dose of YRA-1909; daily oral intake for 12 weeks
116573|NCT03275025|Drug|YRA-1909 mid dose|A mid dose of YRA-1909; daily oral intake for 12 weeks
116574|NCT03275025|Drug|YRA-1909 high dose|A high dose of YRA-1909; daily oral intake for 12 weeks
116575|NCT03275025|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
116576|NCT03275012|Drug|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and >15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.~Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
116577|NCT03275012|Drug|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
116578|NCT03274999|Device|TrueTear™ Application|Intranasal and extranasal application of TrueTear™ device for approximately 3 minutes at Day 0 and Day 14.
116579|NCT03274973|Drug|Zomacton|Injection
116580|NCT03274960|Combination Product|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
116581|NCT03274947|Device|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
116582|NCT03274947|Device|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
116583|NCT03274934|Behavioral|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
116584|NCT03274934|Behavioral|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
116585|NCT03274934|Behavioral|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
116586|NCT03274921|Diagnostic Test|Biological determination|Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
116587|NCT03274908|Other|regular medical treatment|regular medical treatment
116588|NCT03274895|Drug|PHMB 0.08%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
116589|NCT03274895|Drug|Propamidine 0.1%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
116590|NCT03274895|Drug|placebo|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
116592|NCT03274882|Drug|S95005|The treatment is given in open manner. It was administered until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), the patient was followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
116593|NCT03274869|Other|No intervention|No intervention
116594|NCT03274856|Drug|GLWL-01|Oral administration of 3 capsules, twice a day
116595|NCT03274856|Drug|Placebo|Oral administration of 3 capsules, twice a day
116596|NCT03274843|Other|Activity of everyday life|Kitchen workshop
116597|NCT03274830|Device|aneXys|150 patients with the aneXys cup
116598|NCT03274817|Drug|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
116599|NCT03274817|Drug|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
116600|NCT03274817|Drug|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
116601|NCT03274804|Biological|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
116602|NCT03274804|Drug|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
116603|NCT03274791|Diagnostic Test|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.~Slides for differential cell counts were stained with May-Grünwald Giemsa."
116604|NCT03274791|Diagnostic Test|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).~Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
116605|NCT03274791|Diagnostic Test|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).~Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
116606|NCT03274778|Drug|Ruxolitinib 20 MG|tablets
116607|NCT03274765|Diagnostic Test|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).~This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
116608|NCT03274752|Drug|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
116609|NCT03274752|Drug|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
116610|NCT03274713|Device|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
116611|NCT03274713|Device|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
116612|NCT03274700|Drug|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
116613|NCT03274700|Drug|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
116614|NCT03274687|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
116615|NCT03274687|Other|Laboratory Biomarker Analysis|Correlative studies
116616|NCT03274687|Other|Quality-of-Life Assessment|Ancillary studies
116617|NCT03274687|Radiation|Radiation Therapy|Undergo conventional radiation therapy
116618|NCT03274674|Other|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
116619|NCT03274661|Drug|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
116620|NCT03274648|Dietary Supplement|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
116621|NCT03274648|Dietary Supplement|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
116622|NCT03274648|Dietary Supplement|Habitual diet|Patients follow the habitual diet
116687|NCT03274206|Drug|Placebo|BLS-ILB-E710c-placebo
116623|NCT03274635|Behavioral|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
116624|NCT03274622|Behavioral|Impact Parent Training|
116625|NCT03274622|Behavioral|No Impact|
116626|NCT03274609|Combination Product|Augmented fluoroscopy|Augmented fluoroscopy based virtual navigation combined with use of radial EBUS probe and Rapid On Site Evaluation of Histology for diagnosis of peripheral pulmonary nodules.Controlled by cone beam CT.
116627|NCT03274596|Drug|Vitamin E|
116628|NCT03274596|Drug|Placebo|
116629|NCT03274583|Diagnostic Test|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
116630|NCT03274557|Procedure|RFM|
116631|NCT03274544|Other|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):~Huang Qi (Radix Astragali Membranaceus): 2 g~Dan Shen (Radix Salviae Miltiorrhizae): 1 g~Jiang Huang (Rhizoma Curcumae Longae): 1 g~Yin Xing (Semen Gingko Bilobae): 1 g~Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g~Bai He (Bulbus Lilii): 1g~Jin Yin Hua (Flos Lonicerae Japonicae): 1 g~Zi Su Ye (Folium Perillae Frutescentis): 1 g~Yin Yang Huo (Herba Epimedii): 1g"
116632|NCT03274531|Behavioral|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
116633|NCT03274518|Device|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.~High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
116634|NCT03274518|Device|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.~Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
116635|NCT03274505|Other|Questionnaires|"Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~Clinical evaluation~Routine neuropsychological evaluation (for stroke patients)~Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) > 10)"
116636|NCT03274492|Drug|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
116637|NCT03274492|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
116638|NCT03274492|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
116639|NCT03274492|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
116640|NCT03274492|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
116641|NCT03274492|Drug|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
116642|NCT03274492|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
116643|NCT03274492|Drug|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
116644|NCT03274479|Drug|PBF-1129|PBF-1129 once a day by oral administration
116645|NCT03274466|Device|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
116646|NCT03274466|Device|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
116647|NCT03274453|Drug|Ketamine|0.12 mg/kg/hr of ketamine post surgery
116648|NCT03274453|Drug|Saline|Saline will be administered at the same rate as the ketamine infusion.
116649|NCT03274440|Drug|Marijuana|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
116650|NCT03274440|Other|Placebo|Placebo control group, not receiving THC or CBD.
116651|NCT03274427|Device|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
116652|NCT03274427|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
116653|NCT03274427|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
116654|NCT03274414|Drug|Cisplatin|Cisplatin should be administered on day 1 (+/- 3 days) of the start of radiotherapy and then every 3 weeks (unless there is a delay for safety concerns such as neutropenia) for a total of 3 cycles. 100 mg/m^2 (dose reductions after the first cycle allowed for toxicity)
116655|NCT03274414|Radiation|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
116656|NCT03274414|Procedure|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
116710|NCT03273985|Other|Ischemic compression|Trigger point ischemic compression
116657|NCT03274414|Drug|cisplatin and etoposide|If the final surgical pathology report shows SNUC, at the discretion of the treating medical oncologist, the patient will receive an addition of etoposide chemotherapy to cisplatin chemotherapy. The dose of cisplatin will be decresed from 100 mg/m2 to 60 mg/m2. Cisplatin should be administered on days 1-2, 21-22 and 42-43 at a dose of 60 mg/m2 and Etoposide should be administered at days 1-3, 21-23, and 42-44 at a dose of 120 mg/m2.
116658|NCT03274401|Device|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
116659|NCT03274388|Procedure|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
116660|NCT03274388|Procedure|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
116661|NCT03274375|Drug|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
116662|NCT03274375|Drug|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):~at least 1 day before each IA session~the last injection will occur after the last session IA (minimum one day after)"
116663|NCT03274362|Behavioral|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
116664|NCT03274349|Procedure|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
116665|NCT03274349|Procedure|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
116666|NCT03274336|Behavioral|questionnaire|questionnaire post preanesthetic interview
116667|NCT03274336|Behavioral|face-to-face interview|Group A = face-to-face interview
116668|NCT03274336|Behavioral|brochure|after reading a brochure a face to face interview will take place
116669|NCT03274336|Behavioral|movie|after seeing a film about the procedure a face-to-face interview will take place
116670|NCT03274323|Device|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
116671|NCT03274323|Procedure|Trabeculectomy|Standard trabeculectomy
116672|NCT03274310|Behavioral|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
116673|NCT03274297|Drug|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
116674|NCT03274297|Drug|HMW PIB patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
116675|NCT03274284|Combination Product|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
116676|NCT03274271|Behavioral|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
116677|NCT03274271|Behavioral|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
116678|NCT03274271|Behavioral|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
116679|NCT03274271|Behavioral|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
116680|NCT03274258|Biological|Ipilimumab|Given IV
116681|NCT03274258|Biological|Nivolumab|Given IV
116682|NCT03274245|Behavioral|Intervention Package|"Community Level:~Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;~Transect Walk: village walk to identify and mark feces in community;~Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;~Wall painting: village map noting households that use latrines always.~Sub-Community level:~Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.~Household Level:~Household visits: to those with latrines to motivate use;~Latrine repairs: for households with non-functional latrines to make functional."
116683|NCT03274245|Other|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.~For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
116684|NCT03274232|Device|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
116685|NCT03274219|Biological|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
116686|NCT03274206|Biological|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
116688|NCT03274193|Behavioral|Yoga training program|The hatha yoga program will be led by an experienced yoga instructor. Each 60 minutes session will consist of 10 minutes of breathing exercises (pranayama), 40 minutes of yoga pose practice (asana), and 10 minutes of supine meditation/relaxation (savasana). Yoga props, such as blocks and belts, will be used in accordance to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably. The yoga poses are chosen for providing a restorative session and based on their purported relationship to restorative effects. Participants will be instructed to maintain their concentration and breath control at all times during the yoga session.
116689|NCT03274180|Other|Nursing consultation|travel preventive consultation was performed by nurse
116690|NCT03274167|Drug|Gabapentin 300mg|
116691|NCT03274167|Drug|Placebo oral capsule|
116692|NCT03274154|Dietary Supplement|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
116693|NCT03274141|Other|Non-Interventional|Non-Interventional
116694|NCT03274128|Radiation|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
116695|NCT03274128|Procedure|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
116696|NCT03274115|Device|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
116697|NCT03274102|Biological|Concomitant administration of EV71 vaccine with EPI vaccines|"The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
116698|NCT03274102|Biological|Single injection of EPI vaccine|"The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.~The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
116699|NCT03274102|Biological|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
116700|NCT03274089|Device|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:~Collects patient information using patient-specific identification~Prompts the user for answers to screening questions for acute conditions~Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index~Triages patients based on responses to screening questions, physiological parameters and blood test results~Provides recommendations to the patient on the care plan, self management and lifestyle choices"
116701|NCT03274076|Drug|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
116702|NCT03274076|Drug|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
116703|NCT03274063|Other|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
116704|NCT03274063|Other|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
116705|NCT03274037|Diagnostic Test|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.~The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece~The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
116706|NCT03274024|Device|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
116707|NCT03274024|Procedure|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
116708|NCT03274011|Drug|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
116709|NCT03273985|Other|Dry needling|Trigger point deep dry needling
116711|NCT03273972|Other|Written Informed Consent|To be completed prior to conducting any study related procedures
116712|NCT03273972|Other|Inclusion/Exclusion check|Eligibility check
116713|NCT03273972|Other|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
116714|NCT03273972|Other|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
116715|NCT03273972|Other|Pregnancy Test|If applicable for women of child bearing potential
116716|NCT03273972|Other|12 Lead ECG|participant resting supine
116717|NCT03273972|Other|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
116718|NCT03273972|Other|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
116719|NCT03273972|Other|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
116720|NCT03273972|Other|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
116721|NCT03273972|Other|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
116722|NCT03273972|Other|Concomitant medication check|Review of medication taken by the participant
116723|NCT03273972|Other|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
116724|NCT03273972|Other|Physical examination|Check overall health
116725|NCT03273972|Other|Medical history|Review of volunteers medial history
116726|NCT03273972|Other|AE/SAE review & reporting|Monitor safety from the point of consent
116727|NCT03273972|Drug|Dosing|To be performed at the end of the visit following completion all other study visits
116728|NCT03273959|Other|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
116729|NCT03273946|Drug|Fluticasone propionate|Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
116730|NCT03273933|Device|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
116731|NCT03273933|Device|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
116732|NCT03273920|Procedure|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
116733|NCT03273920|Procedure|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
116734|NCT03273907|Device|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
116735|NCT03273894|Diagnostic Test|Coagulation testing|"body temperature before the intervention~body temperature during the intervention including the way of measuring, each 15 minutes~body temperature at the end of surgery, signs of the patient's heat discomfort~body temperature during resting time in the postanesthesia care~standard coagulation tests + EXTEM, FIBTEM, NATEM - after anesthesia induction~blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM, NATEM.~if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
116736|NCT03273881|Drug|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.~Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.~Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.~Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.~Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
116737|NCT03273881|Drug|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
116738|NCT03273868|Other|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T5/T6 level followed by a single posterior to anterior thrust.
116739|NCT03273868|Other|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
116740|NCT03273855|Other|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
116741|NCT03273855|Other|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
116742|NCT03273842|Biological|PF-06881894|pre-filled syringe 6 mg
116744|NCT03273816|Behavioral|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
116745|NCT03273803|Diagnostic Test|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
116746|NCT03273790|Other|Non-interventional|Non-interventional
116747|NCT03273777|Procedure|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
116748|NCT03273751|Procedure|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
116749|NCT03273751|Procedure|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
116750|NCT03273738|Diagnostic Test|folate level measurement|the level of folate measured in plasma with homocysteine
116751|NCT03273738|Diagnostic Test|B12|B12 measurement in blood
116752|NCT03273725|Other|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
116753|NCT03273712|Radiation|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
116754|NCT03273712|Diagnostic Test|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
116755|NCT03273712|Drug|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
116756|NCT03273699|Device|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
116757|NCT03273686|Procedure|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
116758|NCT03273673|Other|Biofeedback Intervention|Visual and Tactile Biofeedback
116759|NCT03273660|Device|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.~0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).~A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
116760|NCT03273647|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
116761|NCT03273634|Drug|Lansoprazole Pill|once daily at night time
116762|NCT03273634|Drug|Placebo|Placebo
116763|NCT03273621|Procedure|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
116764|NCT03273595|Drug|Lapatinib|
116765|NCT03273595|Biological|Trastuzumab|
116766|NCT03273595|Drug|Paclitaxel|
116767|NCT03273595|Drug|Epirubicin|
116768|NCT03273595|Drug|Cyclophosphamide|
116769|NCT03273569|Procedure|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
116770|NCT03273556|Device|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%|"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
116771|NCT03273556|Device|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)|"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
116772|NCT03273543|Device|Restylane® Defyne|hyaluronic acid filler injection
116773|NCT03273530|Other|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
116774|NCT03273517|Procedure|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
116775|NCT03273504|Other|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
116776|NCT03273504|Other|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
116777|NCT03273491|Behavioral|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
116778|NCT03273491|Behavioral|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
116779|NCT03273478|Device|Endovascular treatment of bifurcation aneurysm with pCONUS2|"Patients suffering from a bifurcation aneurysm will be treated endovascularly with the pCONUS2 device.~The patients do not face any additional risks by participating in the study as the treatment does not differ from the standard of care in any way.~The patients will only be enrolled in the study if they give their written consent.~If they do not wish to participate in the observational study or if they wish to withdraw from it at a later date, they will not have any disadvantages."
116780|NCT03273465|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
116781|NCT03273452|Drug|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
116782|NCT03273439|Device|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
116783|NCT03273439|Device|Sham rTMS|Sham rTMS, without stimulation
116784|NCT03273426|Device|core needle biopsy|Ultrasound-guided core needle biopsy (14G x ≥5) for complete clinical response (cCR) or near-cCR predicted by MRI.
116785|NCT03273426|Device|vacuum-assisted biopsy|Ultrasound-guided vacuum-assisted biopsy (10G x ≥5) for complete clinical response (cCR) or near-cCR predicted by MRI.
116786|NCT03273413|Drug|Pravastatin|Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
116787|NCT03273413|Drug|Placebo|Inactive tablet
116788|NCT03273400|Other|Lumbar Mobilisations|Please see arm (intervention) description
116789|NCT03273387|Drug|Trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
116790|NCT03273387|Drug|Placebo oral capsule|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
116791|NCT03273374|Radiation|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
116792|NCT03273361|Behavioral|Compact Cycling Device|Participants pedaled a compact cycling device while simultaneously working at a desk.
116793|NCT03273348|Procedure|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
116794|NCT03273335|Device|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
116795|NCT03273322|Drug|Rivaroxaban 10 mg qd|10mg qd
116796|NCT03273322|Drug|Rivaroxaban 15 mg qd|15mg qd
116797|NCT03273322|Drug|DAPT|Aspirin 75 mg qd + Clopidogrel 75 mg qd
116798|NCT03273309|Other|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
116799|NCT03273309|Other|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
116800|NCT03273296|Drug|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
116801|NCT03273296|Drug|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
116802|NCT03273296|Drug|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
116803|NCT03273283|Behavioral|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
116804|NCT03273270|Radiation|transcranial magnetic stimulation|transcranial magnetic stimulation
116805|NCT03273257|Drug|Riociguat|"Riociguat will be initiated at 1 mg. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.~Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
116806|NCT03273257|Drug|Placebo|Placebo will be given analogue to riociguat with matching tablets.
116807|NCT03273257|Procedure|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
116808|NCT03273244|Device|NeuroSense monitoring and ANI monitoring|From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
116809|NCT03273231|Drug|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
116810|NCT03273231|Drug|Saline|0.9% saline solution
116811|NCT03273218|Device|Tiger catheter|
116812|NCT03273218|Device|Judkins catheter|
116813|NCT03273205|Device|Anodal tDCS|This group gets a real stimulation
116814|NCT03273205|Device|Sham tDCS|This group gets a sham stimulation
116815|NCT03273192|Drug|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
116816|NCT03273153|Drug|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
116817|NCT03273153|Drug|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
116818|NCT03273153|Drug|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
116819|NCT03273140|Device|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
116820|NCT03273127|Drug|Abediterol|A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
116821|NCT03273127|Drug|Placebo|Abediterol matching placebo without any pharmacological activity.
117068|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 180 days)|180 days
116822|NCT03273114|Behavioral|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
116823|NCT03273114|Other|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
116824|NCT03273101|Device|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
116825|NCT03273101|Other|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
116826|NCT03273088|Drug|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
116827|NCT03273075|Drug|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
116828|NCT03273075|Drug|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
116829|NCT03273075|Drug|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
116830|NCT03273075|Drug|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
116831|NCT03273062|Drug|Tolcapone 200 MG|Tolcapone 200 MG TID
116832|NCT03273062|Other|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
116833|NCT03273036|Drug|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
116834|NCT03273036|Drug|Placebos|no injected agent
116835|NCT03273023|Device|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
116836|NCT03273010|Procedure|Free gingival graft|Free gingival graft was harvested from palatal donor site
116837|NCT03273010|Procedure|Cyanoacrylate application|Periacyrl was applied on palatal wounds
116838|NCT03272984|Procedure|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
116839|NCT03272984|Procedure|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
116840|NCT03272971|Device|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
116841|NCT03272945|Procedure|Linked-color imaging|Linked-color imaging colonoscopy
116842|NCT03272932|Other|No intervention|No intervention
116843|NCT03272919|Other|Arm 1: Investigational INF|INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
116844|NCT03272919|Other|Arm 2: standardized muscle stretching and strength|subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
116845|NCT03272906|Device|Anodal transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
116846|NCT03272906|Device|Sham transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
116847|NCT03272906|Behavioral|Speech-language therapy|Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
116848|NCT03272893|Behavioral|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
116849|NCT03272880|Behavioral|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
116850|NCT03272867|Dietary Supplement|ProManna|
116851|NCT03272854|Other|No intervention performed, the study is observational|
116852|NCT03272828|Device|Nobel Biocare titanium dental implants|See above
116853|NCT03272815|Device|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
116854|NCT03272815|Device|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
116855|NCT03272802|Drug|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
116856|NCT03272802|Drug|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
116857|NCT03272789|Other|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
116858|NCT03272776|Device|Protector Laryngeal Mask airway|Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
116859|NCT03272763|Device|F&P Jupiter|Trial Full-Face mask which comes with three seal sizes and two headgear sizes.
116860|NCT03272750|Dietary Supplement|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
116861|NCT03272750|Dietary Supplement|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
116862|NCT03272750|Dietary Supplement|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
116863|NCT03272737|Procedure|1RM Test|The dynamic force of the lower limb muscles will be evaluated by the maximal repetition of knee extension and leg press exercise, according to the protocol presented in a previous study [37]. The elderly will perform a warm up consisting of 1 series with 10 unloaded repetitions. After the warm up, the mass to be lifted will be progressively increased until the maximum load that can be lifted is reached, with a maximum limit of 5 attempts and a 3 to 5 minutes interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10 (Radaelli, 2014).
116864|NCT03272737|Procedure|Speed gait test|To measure the gait speed of participants they will walk 4.6 metres and the time needed to cover this distance is measured. The mean of three attempts is recorded and divided by the distance. The participants included must achieve in the walking test an average of < 0.,9 m/s (Guralnik, 1994).
116865|NCT03272737|Device|Venous occlusion plethysmography protocol|A mercury-filled silastic tube, connected to a low-pressure transducer and a plethysmograph (D.E. Hokanson), will be placed around the largest circumference of the calf region. One cuff will be placed around the ankle and another around the thigh. The ankle cuff will be inflated to a supra-systolic pressure 30 seconds before starting the measurements. At 15-second intervals, the cuff around the thigh will be inflated above the venous pressure for a period of seven to eight seconds. Increased tension in the silastic tube reflects an increase in leg volume and vasodilation. The signal of the muscle blood flow wave will be recorded on a polygraph and analysed every minute, averaging three records per minute. The protocol will be performed during 5 minutes of rest, 3 minutes isometric exercise and 2 minutes of recovery (Bahia, 2006).
116866|NCT03272737|Device|Measurement of Arterial Stiffness - Pulse Wave Analysis and Velocity|"Arterial stiffness will be estimated from the carotid-femoral aortic pulse wave velocity [33]. Carotid-femoral aortic pulse waves will be recorded by tonometry (SphygmoCor, AtCor Medical, Australia). At the same time, an electrocardiogram will be obtained to calculate the wave transit time. Two distances will be measured: the recording point of the carotid artery and the sternal furcula (distance 1) and the sternal furcula and the recording point in the femoral artery (distance 2). The distance travelled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave velocity will be calculated as: carotid-femoral aortic pulse wave velocity = ¼ * distance travelled by the pulse wave (m) / transit time(s)."
116867|NCT03272737|Device|Isometric handgrip exercise protocol|In a supine position, the maximal voluntary handgrip force will be determined as the highest force in 3 consecutive attempts using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). For activation of the central command, mechanoreceptors and muscular metaboreceptors the individual will perform, after 5 minutes of rest (baseline records), 3 minutes of exercise at 30% MVC. This manoeuvre isolates the activation of muscle metaboreceptors, observing the selective activation of these. After the isometric handgrip exercise, 2 minutes of recovery will be performed. Throughout the protocol muscle blood flow, blood pressure and heart rate will be recorded.
116868|NCT03272737|Device|Vasodilatory capacity|The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
116869|NCT03272737|Device|Basal blood flow and vasodilatory capacity - Flow mediated dilation (FMD)|Images of the brachial artery will be recorded by a two-dimensional ultrasonography device with a spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
116870|NCT03272737|Diagnostic Test|Quality of Life EuroQol-5 Domain|This questionnaire is used to estimate the quality of life in participants before and after the study.
116871|NCT03272737|Other|Anthropometric Assessment|Anthropometric measurements will be made before and after the training program following the standardization of the International Society for Anthropometric Assessments. The body mass will be measured with an accuracy of 0.1 kg (Filizola). The stature will be obtained by means of the stadiometer with an accuracy of 0.5 cm. The BMI will be calculated as body mass divided by height squared. The circumference of the quadriceps will be measured with a tape measure (Seca) with a precision of 0.1 cm.
116872|NCT03272711|Drug|Vortioxetine 10 mg|
116873|NCT03272711|Behavioral|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
116874|NCT03272698|Drug|Ketamine|IV Ketamine 0.50 mg/kg
116875|NCT03272698|Procedure|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
116876|NCT03272685|Drug|Very Low Nicotine Content Cigarettes|0.4 mg/g nicotine; 9 mg tar
116877|NCT03272685|Drug|Normal Nicotine Content Cigarettes|15.8 mg/g nicotine; 9 mg tar
116878|NCT03272672|Other|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.~The brace will be maximally adjusted to unload the medial compartment."
116879|NCT03272659|Drug|Cysview|250 mL enema containing 1.6 mmol of hexaminolevulinate
116880|NCT03272646|Procedure|surgery|gastric resection or total gastrectomy
116881|NCT03272633|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
116882|NCT03272633|Biological|Irradiated Allogeneic Cells|Correlative studies
116883|NCT03272607|Other|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
116884|NCT03272594|Other|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
116885|NCT03272594|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
116886|NCT03272581|Other|Functional Training|Functional training has been defined as emphasizing multiple muscle and joint activities, combining upper and lower body movements, and utilizing more of the body in each movement. The primary goal of functional training is to transfer improvement achieve in one movement to enhancing the performance of another movement by affecting the entire neuromuscular system.
116887|NCT03272568|Drug|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
116888|NCT03272568|Drug|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
116889|NCT03272568|Device|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
116890|NCT03272555|Other|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
116891|NCT03272542|Dietary Supplement|Prebiotic: soluble corn fiber|prebiotic
116892|NCT03272542|Dietary Supplement|Placebo: maltodextrin|placebo
116893|NCT03272529|Other|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
116894|NCT03272529|Other|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
116895|NCT03272529|Other|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
116896|NCT03272516|Behavioral|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
116897|NCT03272516|Other|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
116898|NCT03272503|Drug|Pimozide 2mg/day (current) or 4 mg/day (study initiation)|Pimozide 2mg tablets will be taken once daily.
116899|NCT03272503|Drug|Placebo Oral Tablet|Identical matching placebo lactose tablets
116900|NCT03272490|Procedure|Medartis|Surgery using the medartis implant
116901|NCT03272490|Procedure|Synthes|Surgery using the Synthes implant
116902|NCT03272477|Drug|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
116903|NCT03272477|Drug|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
116904|NCT03272477|Drug|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
116905|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
116906|NCT03272477|Drug|Epirubicin|12 weeks (4cycles) of max. 90mg/sqm in adjuvant therapy phase
116907|NCT03272477|Drug|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
116908|NCT03272477|Drug|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
116909|NCT03272477|Drug|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
116910|NCT03272477|Drug|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
116911|NCT03272477|Drug|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
116912|NCT03272477|Drug|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
116913|NCT03272477|Drug|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
116914|NCT03272477|Drug|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
116915|NCT03272477|Drug|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
116916|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
116917|NCT03272477|Drug|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
116918|NCT03272477|Drug|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
116919|NCT03272477|Drug|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
116920|NCT03272477|Diagnostic Test|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
116921|NCT03272477|Procedure|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
116922|NCT03272464|Drug|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
116923|NCT03272464|Drug|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
116924|NCT03272464|Drug|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
116925|NCT03272451|Procedure|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
116926|NCT03272451|Procedure|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
116927|NCT03272438|Device|Accelerometer|Participants use an accelerometer to monitor their steps activity
116928|NCT03272438|Behavioral|Step goal|Participants are given a daily step goal to aim for
116929|NCT03272438|Behavioral|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
116930|NCT03272438|Behavioral|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
116931|NCT03272425|Drug|lesinurad/allopurinol 200/300 FDC tablets|Test Drug
116932|NCT03272425|Drug|lesinurad 200 mg|Comparator 1
116933|NCT03272425|Drug|allopurinol 300 mg|Comparator 2
116934|NCT03272412|Diagnostic Test|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
116935|NCT03272399|Other|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
116936|NCT03272386|Other|Observational study|Completing a questionnaire
116937|NCT03272373|Device|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
116938|NCT03272373|Device|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
116939|NCT03272347|Drug|Islatravir|Islatravir at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected dose may be administered.
116940|NCT03272347|Drug|Placebo to Islatravir|Placebo to islatravir is orally administered QD in capsule form for up to 52 weeks
116941|NCT03272347|Drug|Doravirine|Doravirine 100 mg is orally administered QD in tablet form for up to 144 weeks
116942|NCT03272347|Drug|Placebo to Doravirine|Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
116943|NCT03272347|Drug|Lamivudine|Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
116944|NCT03272347|Drug|Placebo to Lamivudine|Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
116945|NCT03272347|Drug|MK-1439A|MK-1439A consisting of 100 mg Doravirine + 300 mg Lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 144 weeks.
116946|NCT03272347|Drug|Placebo to MK-1439A|Placebo to MK-1439A is orally administered QD in tablet form for up to 52 weeks
116947|NCT03272334|Drug|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
116948|NCT03272321|Drug|Oxytocin|Syntocinon nasal spray
116949|NCT03272321|Drug|Placebo|Placebo nasal spray
116950|NCT03272295|Other|Reference cigarette|The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
116951|NCT03272295|Other|Cigarette with carob bean extract|Based on reference cigarette with added ingredient
116952|NCT03272295|Other|Cigarette with cocoa powder|Based on reference cigarette with added ingredient
116953|NCT03272295|Other|Cigarette with fenugreek extract|Based on reference cigarette with added ingredient
116954|NCT03272295|Other|Cigarette with fig juice|Based on reference cigarette with added ingredient
116955|NCT03272295|Other|Cigarette with glycerol|Based on reference cigarette with added ingredient
116956|NCT03272295|Other|Cigarette with guaiacol|Based on reference cigarette with added ingredient
116957|NCT03272295|Other|Cigarette with liquorice extract powder|Based on reference cigarette with added ingredient
116958|NCT03272295|Other|Cigarette plus I-menthol|Based on reference cigarette with added ingredient
116959|NCT03272295|Other|Cigarette with propylene glycol|Based on reference cigarette with added ingredient
116960|NCT03272295|Other|Cigarette with sorbitol|Based on reference cigarette with added ingredient
116961|NCT03272295|Other|Cigarette with multiple ingredients|Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
116962|NCT03272269|Drug|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
116963|NCT03272269|Other|Placebo|Solvent: alum hydroxide
116964|NCT03272256|Drug|IM156|Sequential 3+3 design.
116965|NCT03272243|Procedure|short segment posterior spine fixation|
116966|NCT03272243|Procedure|long segment posterior spine fixation|
116967|NCT03272230|Behavioral|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
116968|NCT03272230|Behavioral|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
116969|NCT03272230|Diagnostic Test|Neuropsychological assessment|MMS / MADRS / EBI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING / STROOP / STARKSTEIN / DAS
116970|NCT03272230|Behavioral|ICM_APATHY_TASKS|Apathy experimental task
116971|NCT03272230|Other|MRI|T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI
116972|NCT03272230|Biological|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
116973|NCT03272230|Diagnostic Test|Supplementary Neuropsychological Assessment - Parkinson's Disease|ACDD / QUIP / BIS-11 / ECMP / QUIP-RS
116974|NCT03272217|Drug|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
116975|NCT03272217|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
116976|NCT03272204|Behavioral|No pubic hair|Natural pubic hair to fully removed pubic hair
116977|NCT03272204|Behavioral|Pubic Hair|Removed pubic hair to natural pubic hair
116978|NCT03272191|Procedure|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
116979|NCT03272178|Device|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
116980|NCT03272178|Device|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
116981|NCT03272165|Drug|MEDI1341|Intravenous infusion over 60 minutes
116982|NCT03272165|Drug|Placebo|Intravenous infusion over 60 minutes
116983|NCT03272152|Genetic|Genome-wide DNA methylation|Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
116984|NCT03272139|Drug|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
116985|NCT03272139|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
116986|NCT03272126|Drug|Vitamin D|vitamin D given as bolus versus daily dosing
116987|NCT03272126|Drug|Placebo|identical looking as vitamin D
116988|NCT03272113|Behavioral|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
116989|NCT03272100|Procedure|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
116990|NCT03272087|Device|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
116991|NCT03272087|Device|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
116992|NCT03272074|Other|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
116993|NCT03272061|Other|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
117175|NCT03270644|Drug|Propranolol|Administered orally
116994|NCT03272048|Behavioral|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, & Rudd, 2011; Jin, Khazem, & Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, & Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
116995|NCT03272009|Drug|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
116996|NCT03272009|Drug|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
116997|NCT03272009|Drug|Entecavir|Tablets administered orally
116998|NCT03272009|Drug|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
116999|NCT03271996|Procedure|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
117000|NCT03271996|Procedure|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
117001|NCT03271983|Drug|Metronidazole gel 1|RLD gel
117002|NCT03271983|Drug|Metronidazole gel 2|generic gel
117003|NCT03271983|Drug|Metronidazole cream|generic cream
117004|NCT03271957|Procedure|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
117005|NCT03271944|Device|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
117006|NCT03271931|Behavioral|Active choice|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
117007|NCT03271931|Behavioral|Passive choice|EHR passive alert to cardiologists about prescribing a statin
117008|NCT03271918|Drug|Cabergoline|
117009|NCT03271905|Drug|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
117010|NCT03271905|Device|Mesh nebulization|Nebulization with Mesh device.
117011|NCT03271879|Drug|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
117012|NCT03271866|Drug|metformin|metformin 1500mg per day
117013|NCT03271853|Device|Sentinel BreastScan II|The SBS II will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBS II system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBS II captures this data digitally for subsequent analysis by Therma-Scan.
117014|NCT03271827|Device|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
117015|NCT03271814|Biological|LPS|0.6 by/kg LPS single dose iv
117016|NCT03271814|Other|Placebo|Sterile Water
117017|NCT03271801|Behavioral|child health education|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.
117018|NCT03271801|Behavioral|skills training|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
117019|NCT03271788|Other|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
117020|NCT03271775|Other|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
117021|NCT03271775|Other|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
117022|NCT03271762|Device|percutaneous mitral valve repair with MITRACLIP NT|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
117023|NCT03271762|Procedure|cardiac surgery|mitral valve repair or mitral valve remplacement
117024|NCT03271749|Other|PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections|The PROSM guidelines is described previously in study description
117025|NCT03271736|Behavioral|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
117026|NCT03271736|Device|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
117027|NCT03271723|Other|Observational study|No intervention
117028|NCT03271710|Device|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
117029|NCT03271697|Drug|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
117030|NCT03271697|Drug|Placebo|as a comparator comparing with AM group
117063|NCT03271463|Behavioral|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
117064|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 90 days)|90 days
117031|NCT03271684|Other|self-management|one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
117032|NCT03271684|Other|Control|Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
117033|NCT03271671|Other|NAVA during Non invasive ventilation|NIV during respiratory failure
117034|NCT03271671|Other|PSV during Non invasive ventilation|PSV during respiratory failure
117035|NCT03271658|Behavioral|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
117036|NCT03271658|Behavioral|Decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
117037|NCT03271645|Behavioral|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
117038|NCT03271645|Behavioral|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
117039|NCT03271645|Behavioral|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
117040|NCT03271645|Behavioral|Face-to-face counselling|Face-to-face counselling
117041|NCT03271632|Biological|CAR T cells|Infusion of multi-CAR T cells
117042|NCT03271619|Other|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
117043|NCT03271606|Combination Product|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
117044|NCT03271606|Combination Product|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
117045|NCT03271593|Other|No intervention|No intervention
117046|NCT03271580|Diagnostic Test|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
117047|NCT03271580|Procedure|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
117048|NCT03271580|Other|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
117049|NCT03271580|Other|Ankle Brachial Index|Blood pressure test
117050|NCT03271567|Diagnostic Test|Nanodisk-MS assay|Nanodisk-MS assay is a recently reported novel assay for quantitative detection of various MTB antigen peptides, using nanotechnology and mass spectrometry that showed remarkable sensitivity and specificity in diagnosing active pulmonary and extrapulmonary TB. This assay detected MTB-specific antigens, CFP-10 and ESAT-6, in patients' serum samples.
117051|NCT03271554|Drug|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
117052|NCT03271541|Drug|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
117053|NCT03271528|Drug|Lacosamide|Lacosamide titration will be done to a target dose of 300mg. Participants will take 100 mg of lacosamide once on day 1, twice per day from day 2 until day 6, on day 7 the lacrosamide dose will increase to 150 mg twice daily, and on day 8 the participant will take one dose of 150 mg.
117054|NCT03271528|Drug|Placebo oral capsule|Participants will take a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
117055|NCT03271515|Biological|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
117056|NCT03271502|Procedure|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
117057|NCT03271502|Procedure|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
117058|NCT03271489|Other|Elagolix Placebo|Tablets
117059|NCT03271489|Drug|E2/NETA|Capsules
117060|NCT03271489|Other|E2/NETA Placebo|Capsules
117061|NCT03271489|Drug|Elagolix|Tablets
117062|NCT03271476|Behavioral|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
117069|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 270 days)|270 days
117070|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
117071|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
117072|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
117073|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 90 days)|90 days
117074|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 180 days)|180 days
117075|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 270 days)|270 days
117076|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 90 days)|90 days
117077|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 180 days)|180 days
117078|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 270 days)|270 days
117079|NCT03271437|Behavioral|PC-based Flash|Progressive counting with Flash technique
117080|NCT03271437|Behavioral|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
117081|NCT03271424|Diagnostic Test|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
117082|NCT03271424|Diagnostic Test|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
117083|NCT03271424|Diagnostic Test|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
117084|NCT03271411|Behavioral|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
117085|NCT03271411|Behavioral|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
117086|NCT03271398|Behavioral|EMDR|Eye movement desensitization and reprocessing (intensive format)
117087|NCT03271398|Behavioral|PC|Progressive counting (intensive format)
117088|NCT03271385|Diagnostic Test|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
117089|NCT03271372|Drug|Avelumab|Given IV
117090|NCT03271372|Other|Laboratory Biomarker Analysis|Correlative studies
117091|NCT03271372|Other|Placebo|Given IV
117092|NCT03271359|Behavioral|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
117093|NCT03271359|Behavioral|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
117094|NCT03271346|Behavioral|intensive trauma-focused therapy|
117095|NCT03271333|Other|lung function tests|Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
117096|NCT03271320|Other|appearance scales|appearance scales : AVS; ASWAP; DAS 59
117097|NCT03271307|Behavioral|Optimized PITC|Providers will receive training on the importance of HIV testing and their role in testing as part of OPD care and morning HIV testing will be offered. Providers will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on PITC implementation.
117098|NCT03271307|Diagnostic Test|Facility HIVST|HIVST will be carried out in a group setting among patients in the waiting area of OPD clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting. Participants will use the HIVST kit in a group setting and will be given private settings (private room or booth) to interpret their results. Participants will disclose their results to their OPD provider if they choose. Routine linkage to confirmatory testing and ART initiation will be conducted.
117099|NCT03271307|Diagnostic Test|Index HIVST|HIVST demonstration and distribution will be provided to HIV-positive clients in participating facilities to distribute to their partners. Partners who have a reactive HIVST test result, or are unable or unwilling to use HIVST, will be asked to present at the health facility for routine HIV testing. Routine linkage to confirmatory testing and ART initiation will be conducted.
117100|NCT03271294|Device|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
117101|NCT03271281|Drug|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E[c(RGDyK)]2
117102|NCT03271281|Device|PET/CT|Following injection of 68Ga-NODAGA-E[c(RGDyK)]2 the patients will be subjected to whole body PET/CT
117103|NCT03271255|Drug|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
117104|NCT03271255|Drug|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
117105|NCT03271242|Other|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
117106|NCT03271242|Other|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
117107|NCT03271229|Biological|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
117108|NCT03271229|Biological|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
117109|NCT03271216|Device|No intervention|no intervention
117381|NCT03268941|Drug|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
117110|NCT03271203|Other|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
117111|NCT03271203|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
117112|NCT03271190|Behavioral|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.
117113|NCT03271190|Behavioral|ENGAGE DISCOVERY|Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
117114|NCT03271177|Device|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
117115|NCT03271177|Device|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
117116|NCT03271164|Device|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
117117|NCT03271164|Other|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
117118|NCT03271151|Drug|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
117119|NCT03271151|Other|Placebo|Placebo to compare outcomes against Duloxetine
117120|NCT03271138|Dietary Supplement|Bifidobacterium infantis NLS super strain (Natren LIFE START®2)|2 capsules, 3 times per day, for daily total of 12x10^9 CFU Bifidobacterium infantis NLS super strain
117121|NCT03271138|Other|Placebo|2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
117122|NCT03271125|Behavioral|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
117123|NCT03271125|Behavioral|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
117124|NCT03271112|Other|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
117125|NCT03271099|Other|Navigator|Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
117126|NCT03271086|Behavioral|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
117127|NCT03271086|Behavioral|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
117128|NCT03271086|Behavioral|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
117129|NCT03271073|Drug|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
117130|NCT03271060|Procedure|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
117131|NCT03271060|Procedure|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
117132|NCT03271047|Drug|binimetinib|Orally, twice daily.
117133|NCT03271047|Drug|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
117134|NCT03271047|Drug|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
117135|NCT03271034|Dietary Supplement|Mediterranean diet|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian weekly for ~4 months.
117136|NCT03271021|Drug|FMX101|FMX101, 4% minocycline foam
117137|NCT03271021|Drug|Vehicle Foam|Vehicle Foam
117138|NCT03271008|Device|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
117139|NCT03271008|Device|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
117140|NCT03271008|Device|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
117141|NCT03270995|Behavioral|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
117142|NCT03270995|Behavioral|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
117143|NCT03270982|Device|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
117144|NCT03270969|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
117145|NCT03270956|Biological|Neo-Kidney Augment™ (NKA)|Neo-Kidney Augment (NKA) Autologous selected renal cells (SRC).
117146|NCT03270943|Behavioral|MFY|Mindful Self-Compassion course for teens
117147|NCT03270943|Behavioral|TCY|Healthy Lifestyles course for teens
117148|NCT03270930|Procedure|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
117149|NCT03270917|Procedure|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
117150|NCT03270904|Device|Moleculight i:X™ fluorescence imaging|Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
117151|NCT03270891|Diagnostic Test|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression and/or anxiety. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
117152|NCT03270878|Drug|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
117153|NCT03270878|Drug|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
117154|NCT03270865|Device|PAF (Positioning And Fixation device)|"Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.~The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.~Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes."
117155|NCT03270852|Device|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.~The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
117156|NCT03270852|Other|No Enhanced reality|Identical rehabilitation without enhanced reality
117157|NCT03270839|Drug|Bonine 25Mg Chewable Tablet|Motion sickness drug
117158|NCT03270839|Drug|Kwells|Motion sickness drug
117159|NCT03270839|Drug|Placebo Oral Tablet|No active substance in the tablet
117160|NCT03270813|Behavioral|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
117161|NCT03270813|Behavioral|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
117162|NCT03270800|Biological|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
117163|NCT03270800|Biological|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
117164|NCT03270787|Drug|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
117165|NCT03270787|Drug|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
117166|NCT03270748|Drug|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
117167|NCT03270735|Drug|Snake venom thrombin (Treatment)|Snake venom thrombin
117168|NCT03270735|Drug|Placebo|No snake venom thrombin
117169|NCT03270722|Device|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
117170|NCT03270722|Procedure|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
117171|NCT03270709|Drug|Vitamin D3 450,000 IU orally|Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.
117172|NCT03270696|Drug|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
117173|NCT03270657|Device|IPG; RC+S|We will measure the effects of varying stimulation parameters on both the neural activity and changes in motor symptoms -- bradykinesia and tremor -- in subjects with Parkinson's disease (PD)
117174|NCT03270644|Drug|Lasmiditan|Administered orally
117176|NCT03270631|Other|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
117177|NCT03270631|Other|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
117178|NCT03270631|Other|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
117179|NCT03270631|Other|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
117180|NCT03270618|Device|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
117181|NCT03270605|Procedure|myomectomy|surgical removal of uterine fibroid at the time of cesarean section
117182|NCT03270592|Other|Service dog|Use of a individualized certified service dog
117183|NCT03270579|Drug|[18F]JNJ-64511070|An IV injection of 185 MBq [18F]JNJ-64511070 will be administered.
117184|NCT03270566|Device|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
117185|NCT03270553|Drug|plazomicin|single intravenous dose
117186|NCT03270553|Drug|metformin|single oral dose
117187|NCT03270527|Other|High SFA diet (Diet 1)|'Diet 1' will contain ~18% of its total energy as SFA .
117188|NCT03270527|Other|Low SFA diet (Diet 2)|'Diet 2' will contain ~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
117189|NCT03270514|Drug|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
117190|NCT03270514|Drug|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
117191|NCT03270501|Drug|Golimumab|"Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.~All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission."
117192|NCT03270488|Other|Laser|Laser (power of 3.0w).
117193|NCT03270488|Other|Placebo|Laser (power 0,0w)
117194|NCT03270475|Other|exercise training|subjects complete 4-5 weeks of training
117195|NCT03270462|Drug|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
117196|NCT03270449|Other|Multidisciplinary intervention|10 week multidisciplinary education and exercise
117197|NCT03270436|Behavioral|Traditional Diabetes Prevention Education|Faith based diabetes curriculum that teaches participants to connect faith and health.
117198|NCT03270436|Behavioral|Pacific Diabetes Prevention Education|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
117199|NCT03270423|Device|PathMate2|
117200|NCT03270423|Device|PathMateS|
117201|NCT03270410|Other|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.~At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
117202|NCT03270397|Behavioral|"Academic course The group- theory and practice"|"Active participation in the course The group- theory and practice."
117203|NCT03270384|Device|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
117204|NCT03270371|Device|Medium cut off dialysis|Hemodialysis
117205|NCT03270371|Device|Standard High Flux Dialyzer|Hemodialysis
117206|NCT03270358|Procedure|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.~Blood sampling in arterioveinous fistula right before a dialysis session"
117207|NCT03270358|Procedure|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
117208|NCT03270332|Drug|albuterol first then placebo|inhalation of 270μg albuterol (3 puffs) through a spacer at visit 2 and inhalation of placebo (3 puffs) through a spacer at visit 3
117209|NCT03270332|Drug|placebo first then albuterol|inhalation of placebo(3 puffs) through a spacer at visit 2 and inhalation of 270ug albuterol (3 puffs) through a spacer at visit 3
117210|NCT03270293|Device|Profhilo|
117211|NCT03270280|Drug|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
117212|NCT03270280|Drug|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
117213|NCT03270267|Other|Questionnaires|
117214|NCT03270254|Device|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
117250|NCT03269968|Device|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
117382|NCT03268928|Behavioral|Story Starters Intervention|Shared reading intervention
117215|NCT03270241|Device|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
117216|NCT03270228|Other|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
117217|NCT03270215|Procedure|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
117218|NCT03270202|Behavioral|PAI group|"physical activity defined as 100 weekly PAI during 1 year~smartphone application and a user-friendly activity wristband (Mio PAI Slice)"
117219|NCT03270202|Behavioral|Usual care|Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
117220|NCT03270189|Device|prism glasses|orthoptic treatment by wearing prisms when writing
117221|NCT03270176|Drug|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
117222|NCT03270176|Drug|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
117223|NCT03270163|Diagnostic Test|Transcutaneous electrical stimulation|"Patient will have the day of inclusion and then again after 20 minutes in finally, 72 hours (3 days) later :~Increasing electrical stimulation until muscle contraction~three simple electrical stimulations,~three doublets (ie 2 very close electrical stimulations) at frequency 10Hz~three doublets at the frequency of 100Hz~electrical stimulation leading to a maximum contraction of the muscle (called tetanus),"
117224|NCT03270150|Device|BTL-899|BTL-899
117225|NCT03270137|Device|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
117226|NCT03270137|Device|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
117227|NCT03270124|Behavioral|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of steps per day for which to aim.
117228|NCT03270124|Behavioral|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
117229|NCT03270124|Behavioral|Daily Activity Recording|A Fitbit will be worn by all participants to record daily activity.
117230|NCT03270111|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
117231|NCT03270111|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
117232|NCT03270111|Behavioral|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
117233|NCT03270111|Behavioral|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
117234|NCT03270098|Behavioral|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
117235|NCT03270098|Behavioral|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
117236|NCT03270085|Drug|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
117237|NCT03270085|Other|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
117238|NCT03270059|Drug|Ferumoxytol|Given IV
117239|NCT03270059|Drug|Gadolinium|Given IV
117240|NCT03270059|Procedure|Magnetic Resonance Imaging|Undergo MRI
117241|NCT03270046|Procedure|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
117242|NCT03270033|Drug|Dexamethasone|0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
117243|NCT03270033|Drug|Dexmedetomidine|0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
117244|NCT03270020|Drug|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
117245|NCT03270007|Drug|Vinorelbine|different from primary chemotherapy(containing anthracycline or paclitaxel)
117246|NCT03269994|Drug|Cefoxitin|Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
117247|NCT03269994|Drug|Piperacillin-tazobactam|Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
117248|NCT03269981|Radiation|Whole breast irradiation|Radiotherapy to the whole breast alone.
117249|NCT03269981|Radiation|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
117251|NCT03269968|Device|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
117252|NCT03269955|Drug|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
117253|NCT03269942|Procedure|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
117254|NCT03269942|Procedure|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
117255|NCT03269929|Other|Music therapy|Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia
117256|NCT03269929|Drug|Midazolam|Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
117257|NCT03269916|Other|Anti Mueller hormone|used to assess ovarian reserve parameters
117258|NCT03269916|Other|Estrogen|used to assess ovarian reserve parameters
117259|NCT03269916|Other|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
117260|NCT03269916|Other|Antral alveolar cell count|used to assess ovarian reserve parameters
117261|NCT03269903|Device|HILZO esophageal stent|A fully covered esophageal self-expandable metal stent for malignant dysphagia
117262|NCT03269890|Procedure|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
117263|NCT03269890|Procedure|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
117264|NCT03269864|Procedure|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
117265|NCT03269851|Radiation|computed tomography|ct will be done to detect radiological risk factors for neurological deficits after thoracolumbar fractures
117266|NCT03269838|Diagnostic Test|ECG|Primary Percutaneous coronary intervention
117267|NCT03269812|Procedure|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
117268|NCT03269799|Drug|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
117269|NCT03269799|Other|placebo|non surgical periodontal treatment+placebo for 2 months
117270|NCT03269786|Diagnostic Test|Liver function tests (ALT,AST,ALBUMIN,BILIRUBIN,INR,PC,CBC)|Liver function tests will be assessed after endoscopic varisceal treatment for 6 monthes
117271|NCT03269786|Device|biannual ultrasonography|portal vein diameter , portal vein velocity and flow direction, volume flow in portal vein , congetive index, spleen size.will be assessed after endoscopic varisceal treatment by using biannual ultrasonography for 6 monthes
117272|NCT03269773|Biological|FURESTEM-AD Inj.|"0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL"
117273|NCT03269773|Other|Placebo|0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
117274|NCT03269760|Drug|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
117275|NCT03269747|Drug|Prednisone|2 tablets of Prednisone 20 Mg in the morning
117276|NCT03269747|Drug|Placebo|2 Placebo tablets in the morning
117277|NCT03269721|Behavioral|Neuropsychological Assessment|Assessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
117278|NCT03269721|Procedure|Spirometry|Pre and post bronchodilator spirometry will be administered according to ATS guidelines.
117279|NCT03269721|Procedure|Arterial Blood Gas|Radial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
117280|NCT03269721|Procedure|Diffusion Capacity of the Lung for Carbon Monoxide|For measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
117281|NCT03269721|Diagnostic Test|6 Minute Walk Test|Distance walked in 6 minutes will be the primary outcome.
117282|NCT03269721|Procedure|Systemic Vascular Measures|Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
117283|NCT03269721|Biological|Blood Biomarkers|High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
117284|NCT03269721|Behavioral|Symptom Questionnaire Measures|M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
117285|NCT03269721|Procedure|Brain MRI|Primary neuroimaging outcomes of interest are white matter structural integrity
117286|NCT03269708|Behavioral|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
117287|NCT03269695|Drug|PF-06687234|SC QW
117288|NCT03269695|Drug|Placebo|SC QW
117289|NCT03269682|Device|3D PD T1 MRI sequence|After MRI has been performed (about 5 minutes of additional time compared to the usual sequences), a double reading of the MRI will be performed by two radiologists (1 experienced and 1 junior).
117290|NCT03269669|Drug|Bendamustine|Given IV
117291|NCT03269669|Drug|Cyclophosphamide|Given IV
117292|NCT03269669|Drug|Doxorubicin|Given IV
117293|NCT03269669|Drug|Doxorubicin Hydrochloride|Given IV
117294|NCT03269669|Drug|Lenalidomide|Given PO
117295|NCT03269669|Biological|Obinutuzumab|Given IV
117296|NCT03269669|Drug|Prednisone|Given PO
117297|NCT03269669|Drug|Umbralisib|Given PO
117298|NCT03269669|Drug|Vincristine|Given IV
117300|NCT03269643|Device|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
117301|NCT03269643|Device|Reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
117302|NCT03269630|Other|No intervention. Biospecimen collection only|Biospecimen collection
117303|NCT03269617|Dietary Supplement|Bacteriophage mixture|Four bacteriophage strains: LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae.
117304|NCT03269617|Other|Placebo Control|Placebo control capsule consisting of rice maltodextrin
117305|NCT03269604|Procedure|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
117306|NCT03269604|Procedure|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
117307|NCT03269604|Procedure|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
117308|NCT03269591|Device|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
117309|NCT03269591|Drug|diclofenac tablets|drugs
117310|NCT03269591|Diagnostic Test|Visual analogue scale|a graphic rating scale
117311|NCT03269591|Diagnostic Test|Progesterone blood level|blood test
117312|NCT03269591|Diagnostic Test|Menstrual symptom questionnaire|questionnaire
117313|NCT03269565|Biological|BCD-100|Anti-PD-1 monoclonal antibody
117314|NCT03269552|Drug|Carfilzomib|Given IV
117315|NCT03269552|Other|Laboratory Biomarker Analysis|Correlative studies
117316|NCT03269552|Biological|Rituximab|Given IV
117317|NCT03269539|Other|MRI Imaging|
117318|NCT03269526|Drug|EGFR BATs after standard of care chemo|Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.
117319|NCT03269513|Behavioral|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
117320|NCT03269500|Other|use of nutrition education tools|"Use of different nutrition education tools :~General advice: feeding seniors~Oral supplementation: instructions for use~Information about enriched food~Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled~How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream~Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
117321|NCT03269474|Procedure|Experimental Group|Subjects with EBS diagnosis
117322|NCT03269461|Device|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
117323|NCT03269448|Diagnostic Test|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
117324|NCT03269435|Procedure|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
117325|NCT03269435|Drug|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
117326|NCT03269422|Radiation|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
117327|NCT03269409|Other|Saline|5 cc's of saline will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
117328|NCT03269409|Device|The Celution System (Cytori Therapeutics)|The Celution System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
117329|NCT03269409|Biological|Adipose Derived Regenerative Cells (ADRC)|Adipose Derived Regenerative Cells (ADRC) will be harvested through autologous liposuction and processed outside the body autologous transplantation..
117330|NCT03269396|Procedure|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
117331|NCT03269383|Drug|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
117332|NCT03269383|Other|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
117333|NCT03269370|Behavioral|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
117334|NCT03269370|Behavioral|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
117335|NCT03269370|Behavioral|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)"
117336|NCT03269357|Other|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
117337|NCT03269344|Drug|Gabapentin|Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
117338|NCT03269344|Drug|Placebo Oral Capsule|Placebo
117339|NCT03269331|Behavioral|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
117340|NCT03269318|Drug|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
117341|NCT03269279|Drug|Mifepristone|Medication used in conjunction with misoprostol for abortion
117342|NCT03269279|Drug|Misoprostol|Medication used in conjunction with mifepristone for abortion
117343|NCT03269266|Diagnostic Test|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.~In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
117344|NCT03269240|Behavioral|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
117345|NCT03269240|Other|Onsite training|Participants are training at their health facilities
117346|NCT03269240|Other|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
117347|NCT03269227|Radiation|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.~Prescription doses:~Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.~Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
117348|NCT03269214|Drug|Topical Phenytoin 5%|Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
117349|NCT03269175|Other|Brain MRI|Brain MRI will be performed
117350|NCT03269175|Other|Blood sampling|Blood samples will be taken
117351|NCT03269162|Drug|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
117352|NCT03269162|Drug|Docetaxel|75mg/m2,ivgtt 30mins, d1
117353|NCT03269162|Drug|Pemetrexed|500mg/m2, ivgtt 30mins, d1
117354|NCT03269162|Drug|Cisplatin|75mg/m2, ivgtt >2h, d1
117355|NCT03269149|Other|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
117356|NCT03269149|Behavioral|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q&A will be encouraged.
117357|NCT03269136|Drug|PF-06863135|PF 06863135 will be administered intravenously. Increases in dose will continue until MTD is determined.
117358|NCT03269136|Drug|PF-06863135|PF-06863135 will be administered subcutaneously. Increases in dose will continue until MTD is determined.
117359|NCT03269123|Device|Pressop 1|A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
117360|NCT03269110|Diagnostic Test|SRS 2, CBCL, BRIEF-P|This study does not involve an intervention.
117361|NCT03269084|Other|No intervention. DIPP is an observational study.|
117362|NCT03269071|Drug|human fetal-derived Neural Stem Cells (hNSCs)|"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).~For dosage indications, see specific Treatment Cohorts (TC), from A to D.~The product will be administered intrathecally through lumbar puncture."
117363|NCT03269058|Drug|Dapagliflozin|Dapagliflozin 10 mg daily per os
117364|NCT03269058|Drug|Placebos|Placebo of Dapagliflozin per day per os
117365|NCT03269045|Drug|ORL-1B|Oral ORL-1B
117366|NCT03269032|Other|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, >11% Saturated Fatty Acids, <12% Monounsaturated Fatty Acids, and >8% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
117367|NCT03269032|Other|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, <7% Saturated Fatty Acids, >18% Monounsaturated Fatty Acids and <5% Polyunsaturated Fatty Acids.~Participants will receive 3 meals and 1 snack for each day during the study period."
117368|NCT03269019|Diagnostic Test|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
117369|NCT03269006|Device|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).~Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
117370|NCT03269006|Device|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
117371|NCT03269006|Device|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
117372|NCT03269006|Device|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
117373|NCT03268993|Dietary Supplement|Avmacol|Avmacol is a dietary supplement available over the counter
117374|NCT03268980|Other|Questionnaire Hospital Staff group|One-page questionnaire with 15 questions about tobacco habits
117375|NCT03268980|Other|Questionnaire students and patients group|One-page questionnaire with 17 questions about tobacco habits
117376|NCT03268967|Behavioral|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
117377|NCT03268954|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation
117378|NCT03268954|Drug|Pevonedistat|Pevonedistat intravenous infusion
117384|NCT03268915|Diagnostic Test|3 minutes sit-to-stand test|3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
117385|NCT03268902|Drug|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
117386|NCT03268902|Drug|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
117387|NCT03268902|Dietary Supplement|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
117388|NCT03268902|Drug|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
117389|NCT03268889|Drug|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
117390|NCT03268863|Device|Virtual Reality|Google Cardboard virtual reality headset
117391|NCT03268863|Other|Cold Pressor|A cold ice water bath for use in pain/discomfort simulation
117392|NCT03268850|Other|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
117393|NCT03268850|Behavioral|Wage Reimbursement A|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
117394|NCT03268850|Behavioral|Wage Reimbursement B|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to a certain amount (different from LW-A), based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.~Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
117395|NCT03268837|Device|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
117396|NCT03268837|Device|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
117397|NCT03268824|Device|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
117398|NCT03268824|Device|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
117399|NCT03268824|Other|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
117400|NCT03268811|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection will be administered once daily into 1 of the 4 quadrants of the abdomen or either thigh or arm.
117401|NCT03268811|Device|Syringe|Teduglutide will be administered using a syringe. Syringe is approved for use in Japan by pharmaceuticals and medical devices agency (PMDA).
117402|NCT03268811|Device|Needle|Teduglutide will be administered using needle. Needle is approved for use in Japan by PMDA.
117403|NCT03268811|Device|Vial Adapter for Device|Vial adapter for device is approved for use in Japan by PMDA.
117404|NCT03268798|Device|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
117405|NCT03268785|Diagnostic Test|Intraoperative identification method|After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
117406|NCT03268772|Drug|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
117407|NCT03268759|Other|fMRI|Observation of neural markers of reward processing
117408|NCT03268746|Device|AcrySof IQ PanOptix Multifocal IOL|AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject
117409|NCT03268733|Drug|Folic Acid|Tablet 5 mg
117410|NCT03268720|Other|FODMAP low diet|2 week FODMAP low diet
117411|NCT03268720|Other|gluten-free diet|2 week gluten-free diet
117412|NCT03268707|Device|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
117413|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
117435|NCT03268473|Other|Non-surgical periodontal therapy|Experimental: Non-surgical periodontal therapy (scaling and root planing) and supportive periodontal therapy
117436|NCT03268473|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 3 month visit
117414|NCT03268694|Behavioral|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.~N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
117415|NCT03268694|Behavioral|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
117416|NCT03268694|Behavioral|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
117417|NCT03268668|Other|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :~A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase > 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
117418|NCT03268655|Dietary Supplement|Ginger extract|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
117419|NCT03268655|Other|Placebo|2000 mg ginger extract daily for 6 weeks, plus 6 weeks washout
117420|NCT03268629|Behavioral|Mindfulness-Based Joyful Sleep|"The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
117421|NCT03268629|Behavioral|CBT-I|The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
117422|NCT03268616|Device|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .~healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.~COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
117423|NCT03268603|Drug|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
117424|NCT03268590|Drug|Oxygen|Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
117425|NCT03268577|Other|Internet-Based Intervention|Complete ASA24
117426|NCT03268577|Other|Internet-Based Intervention|Complete ACT24 reporting
117427|NCT03268577|Device|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
117428|NCT03268577|Other|Questionnaire Administration|Ancillary studies
117429|NCT03268564|Behavioral|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):~Viewing a promotion video and a demonstration video~Brief motivational interviewing through telephone~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders~Health promotion for re-testers:~Viewing a promotion video and a demonstration video~Visiting the HIVST-online webpage~Receiving a free self-testing kit and follow-up reminders"
117430|NCT03268525|Drug|Marcaine 0.5 % Injectable Solution|Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
117431|NCT03268525|Drug|Sodium Chloride 0.9%|Local infiltration by Sodium Chloride 0.9% prior to incision
117432|NCT03268512|Other|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
117433|NCT03268512|Other|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
117434|NCT03268499|Drug|Cisplatin|The procedure of TACE is the same irrespective of which regimen is used.
117439|NCT03268460|Diagnostic Test|serum electrolytes|Na+ , K+ , Cl- and calcium
117440|NCT03268460|Diagnostic Test|renal function test|blood urea and serum creatinine
117441|NCT03268460|Diagnostic Test|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
117442|NCT03268447|Dietary Supplement|Lactobacillus plantarum P8|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
117443|NCT03268447|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
117444|NCT03268434|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
117445|NCT03268434|Behavioral|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
117446|NCT03268421|Behavioral|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
117447|NCT03268421|Behavioral|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
117448|NCT03268421|Behavioral|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
117449|NCT03268408|Behavioral|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
117450|NCT03268395|Diagnostic Test|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
117451|NCT03268382|Drug|APR-246|Intravenous infusion
117452|NCT03268382|Drug|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
117453|NCT03268369|Radiation|MRI of the brain|to eliminate a structural intra-cerebral lesion
117454|NCT03268369|Radiation|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq [18F]F-A-85380
117455|NCT03268369|Radiation|PET scan [18F]FDG|exam performed after iv injection of 200 MBq [18F]FDG
117456|NCT03268343|Drug|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
117457|NCT03268304|Other|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
117458|NCT03268291|Other|Standard outpatient observation|Outpatient management according to Ministry of health standards
117459|NCT03268291|Behavioral|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
117460|NCT03268278|Drug|Buprenorphine|Buprenorphine plus local anesthetic
117461|NCT03268278|Drug|Sterile saline|Placebo 1,8 ml
117462|NCT03268278|Drug|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
117463|NCT03268239|Device|Additional MRI sequences|"Due to the participation in the study, the following sequences are added to the imaging protocol:~3D T1 GRE after injection (Gradient-Recalled Echo)~3D T1 TSE before injection (Turbo Spin Echo)~3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)~Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition."
117464|NCT03268226|Drug|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
117465|NCT03268213|Biological|Fecal Microbial Transplantation|"Fecal microbial transplant is offered as treatment option to eligible patients. Donors selected by the patients will be screened by questionnaire and by blood and stool tests for potential transmissible pathogens.~The stool filtrate will be administered in the ileum and/or cecum via colonoscopy"
117466|NCT03268200|Other|segmental reexamination|segmental reexamination during colonoscopy
117467|NCT03268187|Device|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
117468|NCT03268187|Behavioral|Self-Alert Training|Self-Alert Training
117469|NCT03268187|Behavioral|Relaxation Training|Relaxation Training
117470|NCT03268174|Other|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
117574|NCT03267498|Radiation|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
117471|NCT03268174|Other|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.~Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.~RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
117472|NCT03268161|Diagnostic Test|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
117473|NCT03268148|Device|LaserPen|low level laser is used before heel-lancing for newborn screening
117474|NCT03268135|Diagnostic Test|measurement of RNAs|
117475|NCT03268122|Other|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
117476|NCT03268122|Other|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.~A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
117477|NCT03268109|Other|assessment of cognitive impairment|Measure of Global Deficit Score
117478|NCT03268096|Device|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
117479|NCT03268083|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
117480|NCT03268083|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
117481|NCT03268083|Biological|EV71 vaccine ([1 μg total protein ] per dose)|Two vaccinations at 28 days apart
117482|NCT03268070|Device|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
117483|NCT03268070|Device|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
117484|NCT03268070|Device|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
117485|NCT03268070|Device|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
117486|NCT03268070|Device|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
117487|NCT03268057|Drug|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 20 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
117488|NCT03268044|Other|Hospital admission and surgery|Hospital admission and noncardiac surgery
117489|NCT03268031|Diagnostic Test|Visual field and OCT tests|Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
117490|NCT03268018|Device|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
117491|NCT03268005|Drug|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
117492|NCT03268005|Drug|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
117493|NCT03268005|Drug|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
117494|NCT03268005|Drug|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
117495|NCT03267992|Behavioral|COPD Co-Pilot AIR App|App. For COPD symptoms after Coil procedure
117496|NCT03267979|Other|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
117497|NCT03267979|Other|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
117498|NCT03267966|Diagnostic Test|Standardized method of pathological evaluation|PD specimen is evaluated according a standardized method of pathological evaluation, that includes: 1) multicolor inking; 2) axial slicing; 3) clearance definition of 1 mm
117499|NCT03267953|Behavioral|My Health CheckUp Online Stress Management Program|Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
117500|NCT03267953|Behavioral|Lay telephone coaching|The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
117501|NCT03267953|Behavioral|Motivational interviewing (telephone)|Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
117502|NCT03267940|Drug|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arms.
117503|NCT03267940|Drug|CIS|CIS will be administered as per the schedule specified in the respective arms.
117504|NCT03267940|Drug|GEM|GEM will be administered as per the schedule specified in the respective arms.
117505|NCT03267940|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arms.
117506|NCT03267927|Device|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
117507|NCT03267927|Device|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
117508|NCT03267927|Device|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
117509|NCT03267914|Other|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
117510|NCT03267914|Other|Brush|Patients will brush with the fluoride for 2 minutes each day.
117511|NCT03267901|Other|food|45 g of walnut / iso-caloric white bread
117512|NCT03267888|Biological|Pembrolizumab|Given 200 mg/kg IV.
117513|NCT03267888|Radiation|Radiation Therapy|Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
117514|NCT03267875|Procedure|Blood Test|draw out 2 blood tubes from a patient
117515|NCT03267862|Other|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
117516|NCT03267849|Other|drinking 2 bottles of tap water|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the intervention of drinking 2 bottles of water
117517|NCT03267836|Drug|Avelumab|-10mg/kg IV
117518|NCT03267836|Radiation|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
117519|NCT03267836|Procedure|Surgery|-Standard of care
117520|NCT03267823|Diagnostic Test|International Normal Ratio (INR)|Blood test for INR using laboratory and point of care methods
117521|NCT03267810|Device|TENS|TENS 7000
117522|NCT03267810|Other|Sham TENS|Inactive electrodes
117523|NCT03267797|Other|Peripheral Blood Monouclear Cell|Blood samples (20 mL) were taken from individual patients at the time of ovulation induction. Then PBMC were isolated and cultured (20-30 million cells) 48 hour at the presence of hCG (10IU/ml daily). Afterward,15-20 million PBMCs in 500 microlitres PBS were injected into the uterine cavity two days before embryo transfer (ET) using ET catheter.
117524|NCT03267797|Other|Phosphate Baffer Saline|Only 500 microlitres PBS will be injected into the uterine cavity, instead of PBMCs, two days before embryo transfer (ET) using ET catheter.
117525|NCT03267784|Biological|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
117526|NCT03267771|Drug|Progesterone Suppositories Vaginal|progesterone vaginal suppository
117527|NCT03267771|Drug|Dydrogesterone Oral Tablet|oral progesterone drug
117528|NCT03267771|Device|doppler ultrasound|pulsed doppler ultrasound
117529|NCT03267758|Dietary Supplement|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
117530|NCT03267758|Dietary Supplement|observation first|Observation for the first 6 weeks during which time the subjects will not consume Goodbelly. During weeks 6-12 of the study, following the observation period, the subjects will consume Goodbelly for 6 weeks.
117531|NCT03267745|Dietary Supplement|Amino Acid|23.7 g amino acid 3 times daily for 28 days
117532|NCT03267745|Device|Breg Brace single-leg immobilization|7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
117533|NCT03267745|Other|Placebo|Excipient-matched placebo 3 times daily for 28 days
117534|NCT03267732|Biological|Pegilodecakin|Pegilodecakin Alone
117535|NCT03267719|Device|laser therapy|Transvaginal erbium-laser treatment
117600|NCT03267303|Drug|TS-091 5mg|Orally taken once daily for 3 weeks
117601|NCT03267303|Drug|TS-091 10mg|Orally taken once daily for 3 weeks
117536|NCT03267706|Other|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
117537|NCT03267693|Diagnostic Test|Gastric and oropharyngeal PH|measurement of gastric and oropharyngeal PH and their relation to respiratory and gastrointestinal complication in mechanically ventilated patients
117538|NCT03267680|Drug|Cyclophosphamide|Given IV
117539|NCT03267680|Drug|Indomethacin|Given PO
117540|NCT03267680|Biological|IRX-2|Given via submucosal injection or SC
117541|NCT03267680|Other|Laboratory Biomarker Analysis|Correlative studies
117542|NCT03267680|Dietary Supplement|Multivitamin|Given zinc-containing multivitamin PO
117543|NCT03267680|Drug|Omeprazole|Given PO
117544|NCT03267680|Other|Placebo|Given via submucosal injections or SC
117545|NCT03267680|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
117546|NCT03267667|Diagnostic Test|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
117547|NCT03267654|Drug|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
117548|NCT03267654|Drug|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
117549|NCT03267654|Drug|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
117550|NCT03267628|Procedure|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
117551|NCT03267628|Procedure|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
117552|NCT03267628|Procedure|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
117553|NCT03267628|Procedure|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
117554|NCT03267602|Device|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,~older than 18 years, AHI> 15 and present obvious symptoms or~less than 18 years, AHI still> 5 after tonsillectomy and present obvious symptoms.~Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
117555|NCT03267589|Drug|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
117556|NCT03267576|Drug|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
117557|NCT03267576|Drug|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
117558|NCT03267576|Drug|Metformin|Participants will receive metformin at a stable dose of >= 1500 mg/day throughout the study including the washout period between each intervention.
117559|NCT03267563|Behavioral|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
117560|NCT03267563|Behavioral|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
117561|NCT03267563|Behavioral|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
117562|NCT03267550|Device|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
117563|NCT03267537|Behavioral|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
117564|NCT03267537|Behavioral|Conventional office-based CBT-I|Conventional office-based CBT-I
117565|NCT03267524|Behavioral|Exercise Intervention|Receive Walking for Recovery from Surgery prehabilitation intervention
117566|NCT03267524|Other|Quality-of-Life Assessment|Ancillary studies
117567|NCT03267524|Other|Survey Administration|Ancillary studies
117568|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
117569|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
117570|NCT03267511|Drug|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
117571|NCT03267511|Drug|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
117572|NCT03267498|Drug|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
117573|NCT03267498|Drug|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
117602|NCT03267303|Drug|Placebo|Orally taken once daily for 3 weeks
117575|NCT03267485|Device|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
117576|NCT03267459|Device|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
117577|NCT03267446|Device|3D Doppler Ultrasound|3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
117578|NCT03267433|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
117579|NCT03267433|Other|Laboratory Biomarker Analysis|Correlative studies
117580|NCT03267433|Biological|Rituximab|Given IV
117581|NCT03267420|Diagnostic Test|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
117582|NCT03267420|Diagnostic Test|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
117583|NCT03267420|Diagnostic Test|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
117584|NCT03267407|Other|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
117585|NCT03267381|Other|Blood draw (before surgery)|Blood will be drawn before surgery
117586|NCT03267381|Other|Blood draw (every 3 months)|Blood will be drawn every 3 months
117587|NCT03267381|Other|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
117588|NCT03267368|Behavioral|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
117589|NCT03267355|Device|Endoscopic Ultrasound|Indication of EUS
117590|NCT03267342|Behavioral|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
117591|NCT03267342|Behavioral|Peer support group|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
117592|NCT03267342|Behavioral|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as Automatic Teller Machine (ATM) cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
117593|NCT03267342|Behavioral|A matched savings account|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
117594|NCT03267329|Drug|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
117595|NCT03267329|Drug|Telmisartan|telmisartan 80mg
117596|NCT03267316|Biological|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
117597|NCT03267316|Drug|Cisplatin|Standard of care treatment
117598|NCT03267316|Drug|Gemcitabine|Standard of care treatment
117599|NCT03267316|Drug|Nab-paclitaxel|Standard of care treatment
117603|NCT03267290|Diagnostic Test|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
117604|NCT03267277|Drug|Sodium Thiosulfate|Sodium thiosulfate is a calcium chelator
117605|NCT03267264|Device|BD Nano™ vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or~subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period"
117606|NCT03267264|Device|NovoFine® vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or~subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period"
117607|NCT03267264|Device|NovoTwist®/NovoFine® Plus vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or~subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period"
117608|NCT03267264|Device|Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus|"Subjects will be randomized to~Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or~subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period"
117609|NCT03267251|Other|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
117610|NCT03267251|Other|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
117611|NCT03267238|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
117612|NCT03267212|Device|Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
117613|NCT03267212|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
117614|NCT03267212|Other|Functional Electrical Stimulation Row Training (FESRT)|FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
117615|NCT03267199|Drug|Thrombolytic|Thrombolytic therapy
117616|NCT03267199|Procedure|Primary PCI|Primary percutaneous coronary intervention
117617|NCT03267199|Diagnostic Test|Complete blood count|Blood sample for complete blood count
117618|NCT03267199|Diagnostic Test|Platelet function test|Blood sample for platelet function test
117619|NCT03267199|Diagnostic Test|ECG|Electrocardiogram
117620|NCT03267186|Drug|Ibrutinib|Given PO
117621|NCT03267186|Other|Laboratory Biomarker Analysis|Correlative studies
117622|NCT03267173|Drug|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
117623|NCT03267160|Diagnostic Test|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
117624|NCT03267147|Other|no intervention is given|no intervention is given
117625|NCT03267121|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
117626|NCT03267121|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|20mg bid p.o. every day for 14 days as a cycle
117627|NCT03267108|Drug|iNO|iNO30 mcg/kg IBW/hr, iNO45 mcg/kg IBW/hr, iNO75 mcg/kg IBW/hr
117628|NCT03267108|Drug|Placebo|Placebo
117629|NCT03267095|Behavioral|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
117630|NCT03267082|Other|Laparoscopic management of perforated appendicitis|"Insertion of Ports~Exposure of the Appendix~peritoneal toilet and aspiration of pus after abdominal exposure~Isolation of Mesoappendicular Artery~Clipping and Dividing of the Artery~Application of 3 x Endoloops~Division of the Appendix~Retrieval of the Appendix in an Endobag"
117631|NCT03267069|Other|survey|surveys will be administered at inclusion and follow-ups
117632|NCT03267056|Device|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter(trade name: Orchid) to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
117633|NCT03267043|Behavioral|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
117634|NCT03267043|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
117635|NCT03267030|Drug|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
117636|NCT03267017|Other|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
117637|NCT03267004|Device|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory~Meal A:~Turkey and Provolone Cheese Sandwich [whole wheat bread 52g(female & male), Turkey 70g(female) & 133g(male), Provolone cheese 23g(female & male), tomato 50g(female & male), lettuce 45g(female & male)]; Chicken and wild rice [chicken 98g(female & male), wild rice 71g(female) & 107g(male)]; chocolate chips cookies [44g(female) & 60.5g(male)]; potato chips [39g(female) & 52g(male)]."
117638|NCT03267004|Device|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory~Meal B:~Ham & Cheddar cheese wrap [Tortilla 45g(female & male), Ham deli 76g(female) & 103g(male), cheddar cheese 21g(female) & 32g(male), Spring Mix 36g(female & male), Fat Free ranch dressing 29g(female & male)]; Pasta with broccoli and Alfredo sauce [Pasta 91g(female) & 121g(male), Broccoli 66g(female & male), Alfredo sauce 38g(female) & 50g(male)]; Chocolate Ice-cream [107g(female), 138g(male)]; Red seedless grapes [365g (female), 471g(male)]."
117639|NCT03266991|Drug|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
117640|NCT03266991|Drug|Isoniazid|Treatment with daily isoniazid in 6 months
117641|NCT03266965|Drug|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
117642|NCT03266965|Dietary Supplement|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
117643|NCT03266939|Drug|Lorcaserin|10 mg acute administration of lorcasein
117644|NCT03266939|Drug|Placebo Oral Tablet|Placebo
117645|NCT03266926|Drug|Bupivacaine|0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
117646|NCT03266926|Drug|Premarin Vaginal cream|A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
117647|NCT03266913|Drug|Probiotic|Probiotics drop
117648|NCT03266900|Procedure|re-TURBT|2nd bladder biopsy within 4-6 weeks of initial biopsy
117649|NCT03266900|Drug|6 weeks BCG instillation|standard 6 weeks of BCG induction
117650|NCT03266861|Diagnostic Test|Exercise oximetry|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
117651|NCT03266848|Diagnostic Test|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
117652|NCT03266835|Device|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
117653|NCT03266822|Other|No intervention|Observational study
117654|NCT03266796|Behavioral|goal setting process|goal setting process during the first consultation
117655|NCT03266783|Drug|Apixaban|Refer to Apixaban group
117656|NCT03266783|Drug|Rivaroxaban|Refer to Rivaroxaban group
117657|NCT03266770|Device|RELIEF Stent|The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
117658|NCT03266744|Diagnostic Test|Computerised Tomography|
117659|NCT03266744|Diagnostic Test|Whole Body Magnetic Resonance Imaging|
117660|NCT03266744|Diagnostic Test|Bone scan|
117661|NCT03266731|Drug|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
117662|NCT03266718|Behavioral|Physical Activity Intervention|To develop and test a couple-based physical activity intervention among cancer survivors and their partners
117663|NCT03266705|Drug|tafamidis|bioequivalence study
117664|NCT03266692|Biological|ACTR087|Autologous T cell product
117665|NCT03266692|Biological|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
117666|NCT03266679|Other|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
117667|NCT03266666|Behavioral|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
117668|NCT03266666|Other|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
117669|NCT03266653|Drug|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
117670|NCT03266640|Drug|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
117671|NCT03266627|Drug|cytotoxic t-lymphocytes|adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
117672|NCT03266614|Behavioral|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
117673|NCT03266601|Drug|Recombinant Human Interferon α-2b Spray|Recombinant human interferon α-2b spray (trade name Jeferon, specifications: 1 million U/support, 10mL/support or 2 million U/support, 20mL/support, 2-8 ℃ dark storage and transportation), 1 million U/day, used for 3 days, observed to the 4th day (until the 96th hour).
117674|NCT03266601|Drug|Ribavirin|Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
117675|NCT03266588|Drug|Rimegepant|75 mg oral tablet
117676|NCT03266575|Behavioral|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
117677|NCT03266575|Behavioral|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
117678|NCT03266562|Diagnostic Test|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
117679|NCT03266562|Diagnostic Test|F-18 FDG|Evaluate uptake of F-18 FDG in breast tissue
117680|NCT03266549|Procedure|botulinum toxin augmented surgery|bilateral 7.0-mm medial rectus muscle recessions, with augmentation with 1.25units of botulinum toxin in 1 muscle for patients with deviations of 65 to 70 PD, and 2.5 units (either 1.25 units in both muscles or 2.5 units in 1 muscle) for patients with deviations greater than 70 PD
117681|NCT03266549|Procedure|conventional surgery|bilateral MR muscle recessions combined with unilateral or bilateral LR muscle resections (according to the standard correction tables )
117682|NCT03266536|Behavioral|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with < 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
117683|NCT03266523|Other|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
117684|NCT03266510|Other|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
117685|NCT03266510|Other|Sham training|Subjects will perform sham training for 6 weeks.
117686|NCT03266484|Dietary Supplement|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
117687|NCT03266484|Dietary Supplement|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
117688|NCT03266471|Diagnostic Test|Baseline blood sample|Blood sample for cytokine measurements and genetics.
117689|NCT03266471|Diagnostic Test|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
117690|NCT03266471|Other|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
117691|NCT03266471|Diagnostic Test|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 6 weeks but no more than 52 weeks.
117692|NCT03266471|Diagnostic Test|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 6 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
117693|NCT03266471|Diagnostic Test|Baseline stool sample|Stool sample for inflammatory markers or microbiome analysis.
117694|NCT03266471|Diagnostic Test|Post treatment stool sample|Stool sample for inflammatory markers or microbiome analysis.
117695|NCT03266458|Procedure|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
117696|NCT03266445|Drug|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication reduced perioperatively.
117697|NCT03266432|Other|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
117698|NCT03266419|Drug|Deep NMB using rocuronium|"Drug: rocuronium~Bolus dose: 0.7 mg/kg~Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
117699|NCT03266419|Drug|Moderate NMB using rocuronium|"Drug: rocuronium~Bolus dose: none~Continuous infusion: 0.2-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
117700|NCT03266406|Drug|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
117701|NCT03266393|Drug|Envarsus XR|Once daily sustained-release tacrolimus
117702|NCT03266393|Drug|Tacrolimus|Twice daily immediate-release tacrolimus
117703|NCT03266380|Diagnostic Test|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
117704|NCT03266367|Diagnostic Test|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
117705|NCT03266354|Procedure|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
117706|NCT03266341|Diagnostic Test|Cultures|Take different samples anddetection of anaerobes on enriched blood agar and other selective anaerobic cultures
117707|NCT03266328|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
117708|NCT03266315|Biological|FloraBaby|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
117709|NCT03266315|Other|Placebo|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
117710|NCT03266302|Device|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
117773|NCT03265743|Other|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
117774|NCT03265717|Biological|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
117711|NCT03266276|Other|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.~Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
117712|NCT03266263|Device|automatic computer-led feedback|automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume
117713|NCT03266263|Other|instructor-led feedback|feedback for CPR quality by instructors
117714|NCT03266250|Procedure|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
117715|NCT03266237|Drug|Vaxigrip®|To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
117716|NCT03266211|Other|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
117717|NCT03266211|Other|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
117718|NCT03266198|Other|No intervention|No intervention
117719|NCT03266185|Other|Shorter PICT|Shorter post-infusion cooling time
117720|NCT03266172|Drug|GSK2982772 Modified Release|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B, GSK2982772 MR minitablet in capsules with unit dose strength of 15, 30 or 60 mg will be administered by subjects for Days 1 to 3. In Part C, GSK2982772 MR tablet with unit dose strength of 240, 360 or 480 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
117721|NCT03266172|Drug|GSK2982772 Immediate Release|In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water. In part C, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water.
117722|NCT03266159|Drug|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
117723|NCT03266159|Drug|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.~Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
117724|NCT03266146|Drug|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
117725|NCT03266146|Drug|48 weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
117726|NCT03266133|Behavioral|Sleep Education for Pregnancy|Sleep education specific to pregnancy
117727|NCT03266120|Other|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
117728|NCT03266120|Other|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
117729|NCT03266107|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
117730|NCT03266094|Device|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
117731|NCT03266081|Drug|0.75% bupivacaine|topical anesthetic
117732|NCT03266068|Genetic|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
117733|NCT03266068|Procedure|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
117734|NCT03266068|Procedure|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
117735|NCT03266068|Diagnostic Test|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
117736|NCT03266055|Dietary Supplement|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
117775|NCT03265704|Other|AGA - Control group|Data processing from Patient Medical Files
117737|NCT03266055|Dietary Supplement|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
117738|NCT03266029|Device|Cordio App|
117739|NCT03266016|Other|Computerized Ventilator Protocol|Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.
117740|NCT03266016|Diagnostic Test|Esophageal Manometry|Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
117741|NCT03266016|Diagnostic Test|Respiratory Inductance Plethysmography (RIP)|RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
117742|NCT03266016|Diagnostic Test|Diaphragm Ultrasound|Daily measurement of diaphragm thickness and diaphragm contractile activity
117743|NCT03266016|Diagnostic Test|Maximal Inspiratory Pressure|Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
117744|NCT03266003|Other|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
117745|NCT03266003|Other|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
117746|NCT03265990|Procedure|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
117747|NCT03265990|Procedure|Conventional haemorrhoidectomy|"According to the Ferguson technique~Manual anal sphincter stretching up to 4 fingers~Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.~skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.~After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
117748|NCT03265977|Biological|H56:IC31|The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.
117749|NCT03265977|Other|Placebo|Normal saline
117750|NCT03265964|Drug|Uridine|Uridine is the active treatment in this clinical trial.
117751|NCT03265964|Drug|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
117752|NCT03265951|Drug|Ramelteon|8 mg once daily administered within 30 minutes of bedtime
117753|NCT03265951|Other|Usual Care|education brochure about sleep hygiene
117754|NCT03265938|Device|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
117755|NCT03265899|Drug|Oxytocin|40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
117756|NCT03265899|Drug|Placebo|Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
117757|NCT03265886|Drug|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
117758|NCT03265886|Drug|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
117759|NCT03265873|Other|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
117760|NCT03265860|Device|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
117761|NCT03265847|Behavioral|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
117762|NCT03265834|Other|< 10 days of antibiotics|Antibiotic duration
117763|NCT03265834|Other|28 days of antibiotics|Antibiotic duration
117764|NCT03265821|Procedure|Healing after treatment|
117765|NCT03265808|Drug|allogeneic human mesenchymal stem cells (allo-hMSCs)|Forty (40) subjects will be treated with a single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
117766|NCT03265808|Drug|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
117767|NCT03265795|Device|Poly Ether Ether Ketone PSI (patient specific implant).|reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
117768|NCT03265782|Drug|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
117769|NCT03265782|Drug|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
117770|NCT03265769|Other|radial access site|radial route
117771|NCT03265769|Other|femoral access site|femoral route
117772|NCT03265756|Device|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
117776|NCT03265704|Other|SGA - Control group|Data processing from Patient Medical Files
117777|NCT03265704|Other|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
117778|NCT03265704|Other|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
117779|NCT03265691|Other|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
117780|NCT03265691|Other|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
117781|NCT03265665|Behavioral|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive community-based walking intervention for African American (AA) women based on the Interaction Model of Client Health Behavior and Social Cognitive Theory. There are 2 phases to the intervention: Adoptive (16 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase and 1 during the maintenance phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, post-adoptive phase and post-maintenance phase.
117782|NCT03265665|Other|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.~Data will be collected at 3 time points: baseline, post-adoptive phase and post-maintenance phase."
117783|NCT03265652|Device|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
117784|NCT03265652|Device|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 2 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
117785|NCT03265639|Dietary Supplement|P-inulin|
117786|NCT03265626|Behavioral|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
117787|NCT03265626|Behavioral|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
117788|NCT03265626|Other|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
117789|NCT03265613|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
117790|NCT03265600|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
117791|NCT03265600|Behavioral|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
117792|NCT03265587|Other|No intervention|No intervention
117793|NCT03265574|Drug|Enalapril|Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
117794|NCT03265561|Device|Bone allograft|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
117795|NCT03265561|Device|Bone auto and allograft group|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
117796|NCT03265548|Device|Video Laryngoscope|The use of video laryngoscopy
117797|NCT03265535|Diagnostic Test|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
117978|NCT03264157|Drug|HyperRAB|A 20 IU/kg dose of Comparator HRIG will be given on Day 0 via IM injection.
117798|NCT03265522|Behavioral|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
117799|NCT03265522|Behavioral|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention)."
117800|NCT03265522|Behavioral|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
117801|NCT03265509|Dietary Supplement|glutamine supplementation|30 g/day glutamine supplementation for three months
117802|NCT03265509|Dietary Supplement|fantomalt supplementation|30 g/day fantomalt supplementation for three months
117803|NCT03265496|Procedure|Clinical exam|Clinical exam is performed before treatment start
117804|NCT03265496|Procedure|Liquid biopsy|Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
117805|NCT03265496|Procedure|Diagnostic exam|Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
117806|NCT03265496|Drug|1st line treatment|1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
117807|NCT03265496|Procedure|tumor evaluation|Tumor evaluation will be performed every 3 cycles of chemotherapy
117808|NCT03265496|Biological|Biopsy|Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
117809|NCT03265483|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
117810|NCT03265483|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
117811|NCT03265470|Drug|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
117812|NCT03265470|Drug|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
117813|NCT03265457|Other|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
117814|NCT03265444|Biological|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
117815|NCT03265431|Drug|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
117816|NCT03265418|Device|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
117817|NCT03265418|Other|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
117818|NCT03265418|Procedure|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
117819|NCT03265405|Drug|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
117820|NCT03265405|Drug|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
117821|NCT03265392|Other|Bread|Serving of wheat bread providing 50 g of carbohydrates
117822|NCT03265392|Other|Water|250 mL of water
117823|NCT03265392|Other|Lemon juice|250 mL of lemon juice
117824|NCT03265392|Other|Tea|250 mL of tea
117825|NCT03265392|Other|Peas|20 peas
117826|NCT03265379|Other|FACT-B and Brief Pain Inventory|Quality of Life Questionnaires
117827|NCT03265366|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
117828|NCT03265366|Device|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
117829|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|7 days of the prescribed diet
117830|NCT03265353|Other|Moderate Potassium/High Sodium Diet|7 days of the prescribed diet
117831|NCT03265353|Other|High Potassium/High Sodium Diet|7 days of the prescribed diet
117832|NCT03265340|Device|dTMS|
117833|NCT03265327|Dietary Supplement|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
117834|NCT03265327|Dietary Supplement|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
117835|NCT03265314|Behavioral|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
117836|NCT03265314|Behavioral|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
117979|NCT03264157|Biological|RabAvert|A 1.0 ml dose of active vaccine (2.5 IU/ml) will be given IM on 5 occasions: on Days 0, 3, 7, 14, and 28.
117837|NCT03265301|Procedure|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
117838|NCT03265301|Procedure|Office hysteroscopy|will be done in out patient clinic without anesthesia
117839|NCT03265301|Procedure|Conventional hysteroscopy|will be done in operative room under general anesthesia
117840|NCT03265288|Drug|LAU-7b|LAU-7b will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
117841|NCT03265288|Drug|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
117842|NCT03265275|Other|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
117843|NCT03265262|Diagnostic Test|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
117844|NCT03265249|Device|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
117845|NCT03265236|Diagnostic Test|Anti - modified citrullinate vimentin|patients with early and late RA
117846|NCT03265223|Drug|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
117847|NCT03265210|Behavioral|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
117848|NCT03265197|Drug|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
117849|NCT03265197|Other|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
117850|NCT03265184|Dietary Supplement|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
117851|NCT03265171|Biological|Plasminogen (Human)|
117852|NCT03265145|Drug|Stiolto Respimat|Duration - 12 months
117853|NCT03265145|Drug|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
117854|NCT03265145|Drug|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
117855|NCT03265145|Drug|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
117856|NCT03265132|Biological|anakinra|sub cutaneous injection
117857|NCT03265132|Drug|Placebo|sub cutaneous injection
117858|NCT03265119|Drug|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
117859|NCT03265119|Drug|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
117860|NCT03265106|Biological|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
117861|NCT03265093|Other|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
117862|NCT03265093|Drug|Corticosteroid|Corticosteroid injection
117863|NCT03265080|Biological|ADXS-NEO|Biopsy, blood draws, CT scans, trial product administration
117864|NCT03265067|Device|autoRIC|Application of the autoRIC device
117865|NCT03265054|Biological|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
117866|NCT03265041|Diagnostic Test|multi-slice CT coronary angiography and coronary angiography|multi-slice CT coronary angiography to evaluate graft number and patency validated by coronary angiography
117867|NCT03265028|Behavioral|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
117868|NCT03265015|Behavioral|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
117869|NCT03265015|Other|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas.
117870|NCT03265002|Dietary Supplement|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
117871|NCT03265002|Dietary Supplement|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
117872|NCT03265002|Dietary Supplement|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
117873|NCT03265002|Dietary Supplement|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
117874|NCT03264989|Drug|crizanlizumab|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion
117875|NCT03264976|Diagnostic Test|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
117876|NCT03264963|Other|Smart phone game play|Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
117877|NCT03264963|Other|Control|Recording of sleep environment 2 nights per week for 12 weeks
117878|NCT03264950|Diagnostic Test|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well"
117879|NCT03264937|Behavioral|Social-software management|Using Wechat application, a social platform, to manage warfarin therapy in patients with mechanical valve replacement.
117880|NCT03264924|Behavioral|IPAIR|Motivational interview training
117881|NCT03264911|Drug|Amoxicillin or Placebo|Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
117882|NCT03264898|Device|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
117883|NCT03264885|Other|Incentive Care|ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
117884|NCT03264872|Behavioral|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
117885|NCT03264872|Other|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
117886|NCT03264859|Diagnostic Test|NGAL levels early and post STEMI|NGAL levels early and post ST elevation MI (STEMI)
117887|NCT03264846|Diagnostic Test|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
117888|NCT03264833|Other|TempTraq|no intervention
117889|NCT03264820|Device|Laser Doppler|- Laser measurements at the level of each finger at 47 °C and at ambient temperature
117890|NCT03264820|Device|Laser speckle|- Laser measurements at the forearm
117891|NCT03264820|Behavioral|pain evaluation|Visual scale assesment pain
117892|NCT03264820|Other|Blood pressure and heart rate|Measurement of blood pressure and heart rate
117893|NCT03264807|Procedure|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
117894|NCT03264807|Procedure|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
117895|NCT03264794|Drug|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
117896|NCT03264794|Drug|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
117897|NCT03264794|Drug|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
117898|NCT03264781|Drug|Cyclofem|Intramuscularly injection 0.5 ml of Cyclofem or placebo
117899|NCT03264768|Device|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
117900|NCT03264768|Behavioral|physical activity tele coaching|3 month physical activity tele coaching intervention consisting of a project tailored smartphone application in combination with a step counter providing direct feedback.
117901|NCT03264768|Procedure|Lung volume reduction surgery (LVRS)|Patients not eligible for endoscopic lung volume reduction (or non responders of this intervention) can be referred for surgical lung volume reduction. With this procedure, the most emphysematous parts of the lungs will be surgically removed.
117902|NCT03264755|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
117903|NCT03264742|Other|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
117904|NCT03264729|Other|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
117942|NCT03264443|Behavioral|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
117943|NCT03264430|Drug|Ketamine|an antagonist of the NMDA receptor
117944|NCT03264430|Drug|bupivacaine|local anaesthetic
117945|NCT03264404|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
117905|NCT03264729|Other|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.~If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
117906|NCT03264729|Other|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
117907|NCT03264716|Device|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
117908|NCT03264677|Combination Product|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
117909|NCT03264677|Combination Product|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
117910|NCT03264677|Combination Product|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
117911|NCT03264664|Drug|E7386|oral capsules
117912|NCT03264651|Drug|enobosarm|Oral combination therapy of enobosarm and anastrozole
117913|NCT03264638|Drug|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
117914|NCT03264638|Drug|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
117915|NCT03264638|Drug|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
117916|NCT03264625|Drug|Cholecalciferol (2000iu qd)|Patients will receive oral Cholecalciferol (2000IU qd) apart from routine therapy for PD
117917|NCT03264625|Other|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
117918|NCT03264612|Behavioral|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.~The exercise included three stages: warming up, swimming and cooling down."
117919|NCT03264599|Device|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
117920|NCT03264586|Drug|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration~- EMLA cream was applied, 1 hour before the expected time of birth."
117921|NCT03264586|Drug|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.~In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.~The suture procedure was delayed 10 minutes after the injection of the aneathetic"
117922|NCT03264586|Procedure|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).~At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound~At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind~The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
117923|NCT03264573|Biological|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
117924|NCT03264573|Device|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
117925|NCT03264560|Behavioral|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
117926|NCT03264547|Drug|Pertuzumab|Every 3 weeks
117927|NCT03264547|Drug|Trastuzumab|Every 3 weeks
117928|NCT03264547|Drug|Docetaxel|Every 3 weeks
117929|NCT03264547|Drug|Paclitaxel|Every week
117930|NCT03264547|Drug|Eribulin|Administered for 2 weeks and is then stopped to be administered for 1 week
117931|NCT03264534|Procedure|limbal relaxing incisions|Manually performed surgical procedure
117932|NCT03264534|Procedure|astigmatic keratotomy|femtosecond laser guided surgical procedure
117933|NCT03264521|Other|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
117934|NCT03264508|Behavioral|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
117935|NCT03264508|Behavioral|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature >0.2°C.
117936|NCT03264495|Other|Weight the food served minus the left-overs|
117937|NCT03264482|Procedure|M-TURP|endoscopic resection of the prostatic adenoma
117938|NCT03264482|Procedure|THUVAP|vaporization of prostatic adenoma via THULIUM laser
117939|NCT03264456|Diagnostic Test|[18F] Fluciclovine PET/MRI|[18F] fluciclovine PET/MRI
117940|NCT03264456|Drug|[18F] fluciclovine|[18F] fluciclovine
117941|NCT03264443|Behavioral|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
117946|NCT03264404|Drug|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
117947|NCT03264378|Behavioral|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home—3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks—to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
117948|NCT03264365|Behavioral|Intervention|"Intervention (plus standard care)~Patients photographs during the ICU-stay,~Written information about life after ICU~First consultation face-to-face in hospital setting at three months after ICU~Visit ICU and photographs given~Consultations as needed"
117949|NCT03264352|Drug|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used.
117950|NCT03264352|Drug|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal,
117951|NCT03264352|Drug|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg (first 12.5 mg or then 25 mg daily) will be given subsequently if the blood pressure goal is still not reached.
117952|NCT03264352|Drug|Allisartan Isoproxil placebo|Allisartan Isoproxil placebo is identical to Allisartan Isoproxil 240mg.
117953|NCT03264352|Drug|Amlodipine placebo|Amlodipine 5mg placebo is identical to Amlodipine 5mg.
117954|NCT03264352|Drug|Hydrochlorothiazide placebo|Hydrochlorothiazide 25mg placebo is identical to Hydrochlorothiazide 25mg.
117955|NCT03264339|Behavioral|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
117956|NCT03264326|Other|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
117957|NCT03264326|Other|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
117958|NCT03264326|Other|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
117959|NCT03264313|Device|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
117960|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
117961|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
117962|NCT03264287|Procedure|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
117963|NCT03264287|Procedure|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
117964|NCT03264274|Drug|Aflibercept|Antiangiogenic
117965|NCT03264274|Procedure|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
117966|NCT03264261|Device|robotic training|robotic training, 3 times/week for 6 weeks
117967|NCT03264261|Device|treadmill training|treadmill training only, 3 times/week for 6 weeks
117968|NCT03264248|Device|E-Scale|Daily bodyweight system used under legs of bed
117969|NCT03264235|Device|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.~Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
117970|NCT03264235|Other|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
117971|NCT03264222|Other|Security screening procedure|Screening procedure with security device (model QPS 100)
117972|NCT03264209|Behavioral|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
117973|NCT03264196|Procedure|Open Reduction and Internal Fixation|Surgical treatment of fracture
117974|NCT03264183|Diagnostic Test|Transesophageal Echocardiography|TEE measures of right ventricular function
117975|NCT03264183|Diagnostic Test|Transthoracic Echocardiography|TTE measures of right ventricular function
117976|NCT03264170|Diagnostic Test|Prediction of pregnancy outcome|The intervention group will receive the individualised prediction of their pregnancy (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant.
117977|NCT03264157|Drug|HRIG|A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
117980|NCT03264144|Behavioral|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
117981|NCT03264131|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 4-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
117982|NCT03264131|Drug|CHEP|"Cyclophosphamide- 750 mg/m^2 IV over approximately 1 hour on D1 every 21 days for 4-6 cycles~Doxorubicin- 50 mg/m^2 IV over approximately 3-5 minutes on D1 every 21 days for 4-6 cycles.~Etoposide - 100 mg/m^2 IV over approximately 1 hour each day for 3 days every 21 days for 4-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 4-6 cycles."
117983|NCT03264118|Procedure|Scaling and root planing|Furcation treatment by scaling and root planing
117984|NCT03264118|Drug|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
117985|NCT03264105|Other|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
117986|NCT03264105|Other|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
117987|NCT03264092|Procedure|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the pancreatic lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
117988|NCT03264079|Drug|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
117989|NCT03264079|Drug|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
117990|NCT03264066|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1−21 of each 28-day cycle.
117991|NCT03264066|Drug|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for participants in cohort 7, the first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1; thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles"
117992|NCT03264053|Device|Socket shield|Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion
117993|NCT03264053|Procedure|Conventional immediate implantation|Conventional immediate implantation
117994|NCT03264027|Drug|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
117995|NCT03264027|Drug|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
117996|NCT03264027|Drug|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
117997|NCT03264001|Behavioral|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
117998|NCT03263988|Device|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
117999|NCT03263975|Other|Gatorade or Enterade|Commercially available oral rehydration therapies
118000|NCT03263962|Drug|Canrenone|Evaluation of canrenone therapy in patients with CHF
118001|NCT03263949|Other|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
118002|NCT03263936|Drug|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5
118003|NCT03263936|Drug|Vorinostat|Age <18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
118004|NCT03263936|Drug|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
118005|NCT03263936|Drug|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
118006|NCT03263936|Drug|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
118007|NCT03263923|Behavioral|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
118008|NCT03263923|Behavioral|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling~Training in reflective journaling and 4 weeks of online journaling"
118009|NCT03263910|Drug|NPO-11|20 ml NPO-11
118010|NCT03263910|Drug|Placebo|20 ml NPO-11(Placebo)
118011|NCT03263897|Device|insufflation|mobile interface driven insufflation of the ear canal
118012|NCT03263897|Device|placebo insufflation|mobile interface driven placebo insufflation of the ear canal
118013|NCT03263884|Device|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
118014|NCT03263884|Device|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
118015|NCT03263871|Dietary Supplement|PTM202|PTM202 given twice daily for 30 days.
118059|NCT03263559|Drug|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
118016|NCT03263871|Dietary Supplement|micro-nutrient sprinkles|Micro-nutrient sprinkles will be given twice daily for 30 days.
118017|NCT03263858|Device|Stent|Implantation of coronary stent in de novo coronary artery lesions
118018|NCT03263832|Diagnostic Test|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
118019|NCT03263819|Diagnostic Test|Oral glucose tolerance test|75 grams of glucose
118020|NCT03263806|Diagnostic Test|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
118021|NCT03263806|Diagnostic Test|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
118022|NCT03263793|Behavioral|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
118023|NCT03263780|Drug|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)
118024|NCT03263767|Drug|Fludarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
118025|NCT03263767|Drug|Clofarabine|30 mg/m² Intravenous 5 days from Day-6 to Day-2
118026|NCT03263767|Radiation|Full body irradiation|2 grays at Day-1
118027|NCT03263767|Drug|Cyclophosphamide|14 mg/kg intravenous 2 days at Day - 6 and day -5
118028|NCT03263767|Drug|Cyclophosphamide|50 mg/kg intravenous 2 days at day +3 and day +4
118029|NCT03263767|Other|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
118030|NCT03263767|Other|nuclear cells|CD3+ cells if needed after transplantation
118031|NCT03263754|Behavioral|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
118032|NCT03263754|Behavioral|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
118033|NCT03263741|Drug|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 135 mg/m2, iv, 3h, at D1. S-1: S-1: 40mg twice daily for patients with a body surface area (BSA) < 1.25 m2, 50mg twice daily for patients with a BSA of 1.25 m2 to < 1.5 m2, 60mg twice daily for patients with a BSA of ≥ 1.5 m2 for two weeks, and then suspend for one week.~Oxaliplatin: 85 mg/m2, iv, 2h, at D1."
118034|NCT03263728|Diagnostic Test|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
118035|NCT03263715|Drug|Tocilizumab Prefilled Syringe [Actemra]|Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
118036|NCT03263715|Drug|Placebos|Weekly administration of Placebo subcutaneous from Baseline to Week 16.
118037|NCT03263715|Drug|Glucocorticoids|Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
118038|NCT03263702|Device|Computational Mapping Algorithm|This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
118039|NCT03263689|Drug|Intrathecal morphine|ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
118040|NCT03263676|Device|Icon resuable underwear|Reusable incontinence underwear
118041|NCT03263676|Device|Disposable pad|Standard market disposable pad
118042|NCT03263663|Drug|targeted substance according to the avatar model|individualized second line treatment
118043|NCT03263650|Drug|Cabazitaxel|25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
118044|NCT03263650|Drug|Carboplatin|AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
118045|NCT03263650|Drug|Prednisone 5Mg|5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
118046|NCT03263650|Drug|Olaparib|Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
118047|NCT03263637|Drug|AZD4573|AZD4573 will be administered as a intravenous (IV) infusion.
118048|NCT03263624|Device|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
118049|NCT03263624|Drug|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
118050|NCT03263611|Drug|Placebo|single intradiscal injection
118051|NCT03263611|Drug|AMG0103|single intradiscal injection
118052|NCT03263585|Device|Spinal orthosis Spinomed|
118053|NCT03263585|Other|Equipment training|
118054|NCT03263572|Biological|Blinatumomab|Given IV
118055|NCT03263572|Drug|Cytarabine|Given intrathecally via spinal tap
118056|NCT03263572|Drug|Methotrexate|Given intrathecally via spinal tap
118057|NCT03263572|Drug|Ponatinib|Given PO
118058|NCT03263559|Procedure|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
118060|NCT03263559|Drug|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
118061|NCT03263559|Drug|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
118062|NCT03263559|Drug|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
118063|NCT03263559|Drug|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
118064|NCT03263559|Radiation|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
118065|NCT03263559|Drug|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
118066|NCT03263546|Behavioral|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.~Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
118067|NCT03263546|Behavioral|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.~Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
118068|NCT03263533|Drug|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
118069|NCT03263533|Drug|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
118070|NCT03263520|Drug|Nandrolone Decanoate|Drug administration
118071|NCT03263520|Drug|Dexamethasone|Drug administration
118072|NCT03263507|Drug|Placebo|Saline .9%
118073|NCT03263507|Drug|IONIS PKK-LRx|Ascending single and multiple doses of IONIS PKK-LRx administered subcutaneously
118074|NCT03263494|Device|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
118075|NCT03263481|Drug|Human Secretin for injection 16 mcg|Intravenous injection of human secretin for injection (16 mcg) will be administered over one minute. Pancreatic juice will be collected intraductally by continuous aspiration in 5-minute intervals for 30 minutes. Six samples will be collected at 5, 10, 15, 20, 25 and 30 minutes after secretin administration.
118076|NCT03263468|Procedure|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
118077|NCT03263468|Procedure|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting >48 hours to 45 days post primary PCI
118078|NCT03263455|Other|Kinesio taping group|"The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching."
118079|NCT03263455|Other|Sham Taping|"Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed"
118080|NCT03263442|Drug|Thiamine|200 mg IV three times daily for seven days
118081|NCT03263442|Drug|Normal saline|Normal saline IV three times daily for seven days
118082|NCT03263429|Drug|Glutaminase Inhibitor CB-839|Given by mouth
118083|NCT03263429|Biological|Panitumumab|Given by vein
118084|NCT03263429|Drug|Irinotecan Hydrochloride (phase I only)|Given by vein
118085|NCT03263429|Other|Laboratory Biomarker Analysis|Correlative studies
118086|NCT03263429|Other|Pharmacological Study|Correlative studies
118087|NCT03263429|Device|Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
118088|NCT03263416|Other|Dedicated and coordinated follow-up|"Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period~Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist~Completion of QLQ-C30 and GIRERD questionnaires"
118089|NCT03263416|Other|Standard follow-up|- Completion of QLQ-C30 and GIRERD questionnaires
118090|NCT03263403|Biological|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
118155|NCT03262831|Behavioral|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.
118091|NCT03263403|Biological|Quadri Meningo|Meningococcal polysaccharide vaccine Quadri Meningo vaccine manufactured by BiO-MeD Private Limited. Quadri Meningo [Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
118092|NCT03263390|Procedure|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
118093|NCT03263390|Drug|Anti Obesity Drugs|Response to FDA approved anti obesity medications
118094|NCT03263377|Dietary Supplement|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
118095|NCT03263351|Behavioral|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
118096|NCT03263351|Behavioral|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
118097|NCT03263338|Behavioral|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
118098|NCT03263325|Other|Discarded urine sample|Collection of discarded urine during surgery and following surgery
118099|NCT03263312|Behavioral|Exercise|Exercise training all patients enrolled.
118100|NCT03263299|Drug|cabergoline|Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
118101|NCT03263299|Drug|Aspirin|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
118102|NCT03263299|Drug|GnRH agonist|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
118103|NCT03263286|Device|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
118104|NCT03263273|Drug|1% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
118105|NCT03263273|Drug|3% Topical Minocycline Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the active intervention
118106|NCT03263273|Other|Topical Vehicle Gel|Treating Papulopustular Rosacea while monitoring for safety and efficacy of the vehicle intervention
118107|NCT03263260|Device|implant|coronary stent implantation
118108|NCT03263247|Behavioral|Memory Training|
118109|NCT03263247|Behavioral|Psychoeducation|
118110|NCT03263247|Behavioral|Alphabet search|
118111|NCT03263234|Other|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
118112|NCT03263221|Procedure|reduction and fixation|Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types
118113|NCT03263208|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
118114|NCT03263208|Drug|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
118115|NCT03263208|Biological|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
118116|NCT03263182|Behavioral|Introduction of the Safe Childbirth Checklist|"Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
118117|NCT03263169|Behavioral|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
118118|NCT03263156|Behavioral|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
118119|NCT03263143|Other|Palliative Care|Palliative Care Consultation within 24 to 48 hours after admission
118120|NCT03263130|Other|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
118156|NCT03262831|Behavioral|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
118157|NCT03262818|Device|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
118121|NCT03263117|Drug|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.~The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
118122|NCT03263117|Drug|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.~The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
118123|NCT03263117|Procedure|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
118124|NCT03263104|Dietary Supplement|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
118125|NCT03263104|Dietary Supplement|Maltodextrin|
118126|NCT03263091|Drug|FG-4592|Oral
118127|NCT03263091|Drug|Placebo|Oral
118128|NCT03263078|Drug|Propofol|Anesthesia was introduced by intravenous administration of 2ug/kg Fentanyl, 1mg‧kg-1 Lidocaine, 1-2mg‧kg-1 Propofol and 0.8-1.2mg‧kg-1 Rocuronium. After the endotracheal tube was inserted, anesthesia was maintained with TIVA using Target-controlled infusion(TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) based on the pharmacokinetics model proposed by Schnider et al. with a target effect-site concentration of 3.0~5.0mcg‧ml-1. We set up routine hemodynamic monitoring including electrocardiography, oximetry, NIBP, as well as PiCCO-Technology and cerebral oximetry.
118129|NCT03263078|Drug|Sevoflurane|Anesthesia was introduced by intravenous administration of 2ug/kg Fentanyl, 1mg‧kg-1 Lidocaine, 1-2mg‧kg-1 Propofol and 0.8-1.2mg‧kg-1 Rocuronium. After the endotracheal tube was inserted, anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2%). We set up routine hemodynamic monitoring including electrocardiography, oximetry, NIBP, as well as PiCCO-Technology and cerebral oximetry.
118130|NCT03263065|Dietary Supplement|Bran|220g rice pudding meal with raspberry jam with added bran flakes
118131|NCT03263065|Dietary Supplement|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
118132|NCT03263065|Dietary Supplement|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
118133|NCT03263052|Drug|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
118134|NCT03263039|Drug|Pembrolizumab|Pembrolizumab 200 mg Q3W
118135|NCT03263026|Drug|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
118136|NCT03263026|Other|R-CHOP + placebo|R-CHOP + placebo
118137|NCT03262974|Diagnostic Test|PCR|PCR
118138|NCT03262974|Diagnostic Test|HPLC-UV|HPLC-UV
118139|NCT03262961|Drug|Sildenafil 20 MG|
118140|NCT03262961|Drug|Placebo Oral Tablet|
118141|NCT03262948|Drug|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
118142|NCT03262948|Drug|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
118143|NCT03262948|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
118144|NCT03262935|Drug|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
118145|NCT03262935|Drug|Physician's choice|See drug label
118146|NCT03262909|Device|GelrinC|Patients will undergo GelrinC implantation.
118147|NCT03262909|Other|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
118148|NCT03262857|Drug|use of magnesium sulfate with lidocaine in inferior alveolar nerve block|
118149|NCT03262844|Behavioral|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
118150|NCT03262844|Procedure|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.~Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
118151|NCT03262831|Other|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
118152|NCT03262831|Procedure|Blood draw|"Baseline and end of treatment~To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
118153|NCT03262831|Behavioral|FACT-G questionnaire|"7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~Answers range from 0=not at all to 4=very much"
118154|NCT03262831|Procedure|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
118274|NCT03261934|Other|No intervention|No intervention
118158|NCT03262818|Device|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
118159|NCT03262805|Dietary Supplement|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
118160|NCT03262805|Other|Placebo|Microcrystalline cellulose
118161|NCT03262792|Dietary Supplement|Placebo|Microcrystalline cellulose
118162|NCT03262792|Dietary Supplement|ParActin|ParActin 150 mg
118163|NCT03262792|Dietary Supplement|ParActin|ParActin 300 mg
118164|NCT03262779|Biological|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
118165|NCT03262766|Other|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
118166|NCT03262766|Behavioral|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
118167|NCT03262766|Other|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
118168|NCT03262753|Procedure|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
118169|NCT03262753|Procedure|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
118170|NCT03262753|Procedure|Stent|Primary stent dilation treatment of coarctation of the aorta
118171|NCT03262740|Drug|BMS-986195|Oral administration of specified dose on specified days
118172|NCT03262740|Drug|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
118173|NCT03262727|Drug|BMS-986165|Oral administration of specified dose on specified days
118174|NCT03262727|Drug|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
118175|NCT03262714|Other|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
118176|NCT03262714|Other|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
118177|NCT03262714|Other|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
118178|NCT03262701|Drug|Hydrogen Peroxide Gel, 13 weeks|13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
118179|NCT03262701|Drug|Hydrogen Peroxide Gel, 26 weeks|26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
118180|NCT03262701|Other|Scaling and Root planing group|Subjects will receive the standard of care which is conventional non-surgical therapy for chronic periodontitis without custom tray application of 1.7% peroxide gel
118181|NCT03262688|Drug|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
118182|NCT03262688|Drug|Bupivacaine HCl infiltration|Infiltration of the surgical site
118183|NCT03262662|Drug|Varenicline|oral varenicline tablets
118184|NCT03262662|Behavioral|Brief smoking cessation counseling|~10-minute individual counseling at each of 6 clinic visits
118185|NCT03262636|Drug|Indocyanine Green|Indocyanine Green
118186|NCT03262623|Other|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
118187|NCT03262623|Other|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
118188|NCT03262610|Drug|Setmelanotide|daily subcutaneous injection
118189|NCT03262597|Other|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
118190|NCT03262597|Other|Pedialyte|Subjects will consume Pedialyte
118191|NCT03262597|Other|Gatorade|Subjects will consume Gatorade
118192|NCT03262597|Other|Water|Subjects will consume water as the control beverage
118193|NCT03262571|Diagnostic Test|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
118194|NCT03262558|Other|No intervention|Patients will undergo standard clinical routine practice in this indication
118195|NCT03262545|Drug|apatinib|Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
118196|NCT03262545|Drug|Placebos|Physical properties of placebos are consistent with apatinib
118197|NCT03262532|Other|Web-base simulator|Training manipulation of TEE using a Web-based simulator
118198|NCT03262532|Other|No web-base simulator|Training manipulation of TEE with out a web-base simulator
118199|NCT03262519|Diagnostic Test|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
118200|NCT03262506|Other|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
118201|NCT03262493|Device|Interventional Group|Use of the feeding tube attachment device (FTAD).
118202|NCT03262480|Other|stroke volume optimization|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.~If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension.Dobutamine 5 mic/kg/min will be started if cardiac index less than 2.5 l/m2."
118203|NCT03262467|Procedure|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
118204|NCT03262454|Drug|Atezolizumab|Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
118205|NCT03262441|Drug|Mycophenolate Mofetil 500Mg Tab|500 mg once daily for one week. If tolerating the drug, then initiate twice daily for 22 months
118206|NCT03262428|Other|Semi-structured interviews|Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.
118207|NCT03262415|Device|LabPatch Continuous Glucose Monitoring (CGM)|"The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.~The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm [0.618] x 15.7 mm [0.618]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.~A wire that connects the chip to a laptop that continuously captures glucose data."
118208|NCT03262402|Procedure|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
118209|NCT03262389|Drug|Fludeoxyglucose|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
118210|NCT03262389|Drug|Sodium Acetate C11|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
118211|NCT03262376|Dietary Supplement|Minerals + Vitamins|A mineral and vitamin tablet
118212|NCT03262376|Dietary Supplement|Botanical A|Botanical extract administered in capsule form
118213|NCT03262376|Dietary Supplement|Botanical B|Botanical extract administered in capsule form
118214|NCT03262376|Other|Placebo|Cellulose crystalline tablet
118215|NCT03262363|Combination Product|Curcumin/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.
118216|NCT03262363|Combination Product|Placebo/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
118217|NCT03262350|Behavioral|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
118218|NCT03262337|Other|none, this is an observational study|none, this is an observational study
118219|NCT03262324|Other|VAS-FA Turkish version|Self-reported outcome questionnaires
118220|NCT03262311|Other|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
118221|NCT03262298|Biological|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
118222|NCT03262285|Procedure|phacoemulsification|removal of cataract using ultrasound waves
118223|NCT03262285|Procedure|extracapsular cataract extraction|removal of cataract using surgical corneal incision
118224|NCT03262272|Device|VIE A Hemodialyzer|polysulfon membrane coated with vitamin E
118225|NCT03262272|Device|Rexsys 27H hemodialyzer|polyethersulfon membrane with large surface area : 2,7m²
118226|NCT03262272|Device|Leoceed 21HX hemodialyzer|polyslfon membrane with gamma sterilization
118227|NCT03262272|Device|Polypure 22S+ hemodialyzer|polysulfon membrane with steam sterilization
118228|NCT03262259|Behavioral|GSDG multi-component intervention|Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
118229|NCT03262246|Other|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
118230|NCT03262233|Combination Product|nicotine|
118231|NCT03262233|Other|placebo|
118232|NCT03262220|Radiation|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
118233|NCT03262207|Other|Extraction genomic DNA|
118234|NCT03262207|Other|Analysis of methylation profiles of numerous GSI and TE|
118235|NCT03262207|Other|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
118236|NCT03262207|Other|Method of protein detection by immunostaining and flow cytometry|
118237|NCT03262181|Other|Isometric Exercise|5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
118238|NCT03262181|Other|Sham Transcutaneous Electrical Nerve Stimulation|5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
118239|NCT03262168|Other|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
118240|NCT03262155|Biological|Blood test|
118241|NCT03262142|Drug|Piperacillin/tazobactam|Intravenous Piperacillin/tazobactam three times daily
118242|NCT03262142|Drug|Ciprofloxacin|Oral Ciprofloxacin twice daily
118243|NCT03262116|Drug|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
118244|NCT03262116|Drug|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
118245|NCT03262116|Drug|BC222 insulin lispro|Subjects will participate in one week of wearing the insulin only bionic pancreas using BC222 insulin lispro as the rapid acting insulin.
118246|NCT03262116|Device|Bionic Pancreas|The insulin-only bionic pancreas will be used in all three arms of the study
118247|NCT03262103|Biological|Intratumoral (IT) Poly ICLC 0.5 mg|0.5 mg IT once/week (week 1)
118248|NCT03262103|Biological|Intratumoral (IT) Poly ICLC 1.0 mg|1.0 mg IT once/week (week 1)
118249|NCT03262103|Biological|Intramuscular (IM) Poly ICLC|1 mg IM twice weekly (weeks 3-6)
118250|NCT03262103|Procedure|Radical Prostatectomy|as per standard care
118251|NCT03262090|Drug|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
118252|NCT03262090|Drug|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
118253|NCT03262090|Drug|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
118254|NCT03262090|Drug|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
118255|NCT03262090|Drug|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
118256|NCT03262077|Drug|Methylene Blue|Irradiation with low-level laser for 1, 3, and 5 min
118257|NCT03262077|Drug|Methylene Blue Oral Product|Irradiation with low-level laser for 1, 3, and 5 min
118258|NCT03262064|Combination Product|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.~Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.~Bronchiectasis severity index score parameters FACED Score"
118259|NCT03262051|Diagnostic Test|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
118260|NCT03262038|Drug|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
118261|NCT03262038|Drug|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
118262|NCT03262025|Procedure|Operated|Patients were either managed conservatively or underwent emergency laparotomy
118263|NCT03262012|Drug|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
118264|NCT03262012|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
118265|NCT03262012|Drug|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
118266|NCT03262012|Drug|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
118267|NCT03261999|Drug|Leuprolide Mesylate|Subcutaneous injection of 25mg Leuprolide Mesylate
118268|NCT03261986|Radiation|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
118269|NCT03261986|Procedure|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
118270|NCT03261973|Device|DV8|DV8 esophageal deviation tool
118271|NCT03261960|Drug|BLI4700|Oral bowel preparation
118272|NCT03261960|Drug|Magnesium bowel preparation|Oral bowel preparation
118273|NCT03261947|Drug|TAK-931|50 mg capsules
118275|NCT03261921|Drug|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
118276|NCT03261921|Drug|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
118277|NCT03261921|Drug|Bupivacaine|local anesthetic agent
118278|NCT03261908|Genetic|detection of genotype|detection of genotype by next generation sequencing
118279|NCT03261895|Behavioral|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinese medicine.
118280|NCT03261882|Other|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
118281|NCT03261869|Other|Cold application|
118282|NCT03261843|Biological|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
118283|NCT03261843|Procedure|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
118284|NCT03261830|Drug|Cefazolin|Primary intervention
118285|NCT03261830|Drug|Clindamycin|For use in Pre-operateive Antibiotics arm in cases of documented allergy to primary intervention.
118286|NCT03261830|Drug|Saline|Placebo Intervention
118287|NCT03261817|Behavioral|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).~The intensity of the activities will be individualized for each participant according to his/her physical condition"
118288|NCT03261817|Behavioral|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
118289|NCT03261804|Behavioral|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
118290|NCT03261791|Drug|Apatinib|Apatinib mesylate tablets 500 mg po qd.
118291|NCT03261778|Device|Acromion 2.0 Brace|Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
118292|NCT03261765|Other|Assessment of adhesions|Modified Nair scoring system
118293|NCT03261752|Diagnostic Test|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.
118294|NCT03261739|Biological|RYI-018|Anti-CB1 monoclonal antibody
118295|NCT03261739|Biological|Placebo|Placebo
118296|NCT03261726|Device|MedEl Test Electrode Placer|This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
118297|NCT03261713|Device|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
118298|NCT03261713|Device|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
118299|NCT03261700|Behavioral|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV and red flags, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
118300|NCT03261700|Other|Information and referral condition|Participants randomized to this arm will receive a brochure-based intervention, consisting of education, support and problem solving, safety planning as well as resources and referrals to address an array of health and social issues associated with IPV (including in VA and the community).
118301|NCT03261687|Other|water based exercise|
118302|NCT03261687|Other|land based exercise|
118303|NCT03261687|Behavioral|advice|general advice given to all subjects
118304|NCT03261674|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I)
118305|NCT03261674|Behavioral|ABT-I|Arousal-Based Therapy for Insomnia (ABT-I)
118306|NCT03261661|Behavioral|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
118346|NCT03261362|Dietary Supplement|Branched-chain amino acids reduced intake|
118573|NCT03259516|Drug|Melphalan|2 mg per os daily during the whole course of treatment
118574|NCT03259503|Drug|Busulfan|Given IV
118307|NCT03261661|Behavioral|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
118308|NCT03261661|Behavioral|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
118309|NCT03261661|Behavioral|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
118310|NCT03261648|Other|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
118311|NCT03261648|Other|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
118312|NCT03261635|Drug|Ranibizumab Injection|patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
118313|NCT03261635|Drug|Indomethacin|patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
118314|NCT03261622|Device|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
118315|NCT03261609|Other|preterm birth|The study compares young adult subjects born premature (< 29 weeks) versus term (-> 37 weeks)
118316|NCT03261596|Drug|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
118317|NCT03261583|Other|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
118318|NCT03261570|Drug|Pyridostigmine|60mg by mouth
118319|NCT03261570|Drug|Digoxin|0.5 (500mcg) by mouth
118320|NCT03261570|Drug|Placebo|Lactulose 50mg by mouth
118321|NCT03261557|Behavioral|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
118322|NCT03261557|Behavioral|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.~All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
118323|NCT03261544|Procedure|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
118324|NCT03261531|Device|Transcutaneous electrical nerve stimulation (TENS)|Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
118325|NCT03261518|Procedure|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
118326|NCT03261505|Device|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
118327|NCT03261492|Behavioral|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
118328|NCT03261492|Behavioral|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
118329|NCT03261479|Diagnostic Test|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
118330|NCT03261466|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
118331|NCT03261466|Drug|Placebos|
118332|NCT03261453|Device|Active Elipse Device|Intervention Device
118333|NCT03261453|Device|Elipse Sham Device|Control Device
118334|NCT03261427|Drug|Lyrica 150Mg Capsule|150 mg oral administered (BID)
118335|NCT03261427|Drug|YNP-1807 330Mg Tablet|330 mg oral administered (QD)
118336|NCT03261414|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
118337|NCT03261414|Procedure|usual care|Standard care before induction of anesthesia
118338|NCT03261401|Drug|M5717|Subjects will receive single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
118339|NCT03261401|Drug|M5717|Subjects will receive multiple ascending oral doses of M5717 after an overnight fast of at least 8 hours once daily for 3 days, followed by a 4-hour post-dose fast
118340|NCT03261401|Drug|Placebo|Subjects will receive placebo matched to M5717
118341|NCT03261401|Drug|M5717|Subjects will receive single ascending oral dose of M5717 from Part A or as applicable multiple ascending oral doses of M5717 from Part B after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
118342|NCT03261388|Behavioral|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
118343|NCT03261375|Device|Renal Denervation System|A renal denervation system with a 6 electrodes-on-net structure catheter
118344|NCT03261375|Drug|Antihypertensive Agents|Calcium channel blocker，Diuretic
118345|NCT03261375|Device|Sham Procedure|Catheterization without renal denervation
118347|NCT03261349|Drug|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
118348|NCT03261336|Drug|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
118349|NCT03261323|Procedure|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
118350|NCT03261323|Procedure|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
118351|NCT03261323|Other|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
118352|NCT03261310|Drug|Acetaminophen or Placebo|"Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively."
118353|NCT03261284|Drug|Dabigatran Etexilate 150 MG [Pradaxa]|Dabigatran Etexilate 150mg,bid
118354|NCT03261284|Drug|Warfarin Pill|Add warfarin dose according to INR values.
118355|NCT03261271|Behavioral|Weight Loss Program|Program involves one-on-one coaching, diet meal plan, and physical activity plan.
118356|NCT03261271|Behavioral|Standardized educational flyer|"The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants."
118357|NCT03261271|Behavioral|Weight Maintenance Program|Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
118358|NCT03261258|Other|Questionnaire|
118359|NCT03261219|Device|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
118360|NCT03261219|Device|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
118361|NCT03261206|Other|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
118362|NCT03261193|Drug|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
118363|NCT03261193|Drug|ITM + Bupivacaine QLB|QL plane block with local anesthesia
118364|NCT03261180|Other|Best Practice|Receive regular diet
118365|NCT03261180|Other|Laboratory Biomarker Analysis|Correlative studies
118366|NCT03261180|Dietary Supplement|Nutritional Intervention|Receive Nestle Impact AR
118367|NCT03261167|Drug|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
118368|NCT03261167|Drug|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
118369|NCT03261141|Combination Product|(PV-RQOL),(APA) ,Acoustic analysis|"severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.~Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).~the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
118370|NCT03261128|Other|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
118371|NCT03261115|Procedure|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
118372|NCT03261102|Biological|Adalimumab|
118373|NCT03261076|Behavioral|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
118374|NCT03261063|Device|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
118375|NCT03261050|Behavioral|Counter Attitudinal Therapy|8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.
118376|NCT03261050|Behavioral|Interpersonal Therapy|8 weekly 60 minute sessions of interpersonal-based treatment wherein women with an eating disorder complete verbal, written, and behavioral activities.
118377|NCT03261037|Other|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
118378|NCT03261037|Other|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
118379|NCT03261037|Other|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
118575|NCT03259503|Drug|Gemcitabine|Given IV
118380|NCT03261024|Device|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
118381|NCT03261024|Device|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
118382|NCT03261011|Biological|AK-104|Subjects will receive AK104 by intravenous administration.
118383|NCT03260998|Diagnostic Test|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
118384|NCT03260985|Other|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
118385|NCT03260972|Drug|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
118386|NCT03260972|Drug|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
118387|NCT03260959|Behavioral|Interview by hierarchical evocation's Method|Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
118388|NCT03260946|Other|Complementary medicine use|The prevalence of complementary medicine use
118389|NCT03260933|Other|No intervention given. This is a qualitative interview study|This is a qualitative interview study
118390|NCT03260920|Drug|Syntocinon|Intranasal Oxytocin
118391|NCT03260907|Procedure|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6~13.9mA).
118392|NCT03260907|Procedure|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
118393|NCT03260894|Drug|Pembrolizumab|Pembrolizumab 200 mg administered intravenously every 3 weeks.
118394|NCT03260894|Drug|Epacadostat|Epacadostat 100 mg administered orally twice daily.
118395|NCT03260894|Drug|Sunitinib|Sunitinib 50 mg administered orally once daily; 4 weeks on, 2 weeks off for 6-wk cycle.
118396|NCT03260894|Drug|Pazopanib|Pazopanib 800 mg administered orally once daily.
118397|NCT03260881|Drug|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
118398|NCT03260881|Drug|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
118399|NCT03260868|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
118400|NCT03260868|Drug|Glulisine|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
118401|NCT03260868|Drug|Aspart|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
118402|NCT03260868|Drug|Lispro|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
118403|NCT03260855|Other|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
118404|NCT03260855|Other|Human blood sample|The intervention is based on blood test.
118405|NCT03260842|Diagnostic Test|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
118406|NCT03260829|Drug|vitamin C|25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
118407|NCT03260816|Behavioral|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
118408|NCT03260816|Other|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
118409|NCT03260803|Drug|Oligopin|Oligopin ,150 mg ,once daily, 12 week
118410|NCT03260803|Drug|Placebo|Placebo,150 mg ,once daily, 12 week
118411|NCT03260790|Biological|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
118412|NCT03260790|Biological|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
118413|NCT03260777|Device|Trichoscopy|Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
118414|NCT03260764|Device|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
118415|NCT03260764|Device|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
118416|NCT03260764|Device|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
118417|NCT03260764|Device|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
118418|NCT03260751|Dietary Supplement|Zingiber officinale Roscoe extract 200 mg|2 cap/day, 800 mg/cap for 12 weeks
118419|NCT03260751|Dietary Supplement|Placebo|Placebo for 12 weeks
118420|NCT03260738|Device|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks. Among those 3 hours, patients receive 30 minutes of physical exercises dedicated to mobility of the spine supervised by robot Poppy.
118421|NCT03260738|Other|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 3 weeks.
118570|NCT03259516|Drug|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
118422|NCT03260725|Behavioral|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
118423|NCT03260725|Behavioral|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
118424|NCT03260712|Drug|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
118425|NCT03260712|Drug|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
118426|NCT03260712|Drug|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
118427|NCT03260699|Device|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
118428|NCT03260686|Other|experimental|video guide for upper limb exercise
118429|NCT03260673|Other|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
118430|NCT03260660|Device|Magnetic Resonance Elastography|The investigators plan to prospectively assess the agreement of liver stiffness measurements obtained using standard of care MR elastography techniques vs. MR elastography with varying amounts of imaging acceleration using compressed sensing in adult volunteers
118431|NCT03260647|Other|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
118432|NCT03260634|Drug|Voriconazole|
118433|NCT03260621|Diagnostic Test|stress CMR|additional stress CMR to the established clinical diagnostics
118434|NCT03260608|Behavioral|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
118435|NCT03260595|Drug|Crisaborole ointment 2%|Crisaborole ointment 2%
118436|NCT03260595|Drug|Vehicle|Vehicle
118437|NCT03260582|Other|LifePod®|The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
118438|NCT03260569|Drug|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
118439|NCT03260569|Drug|Placebo|Nitrogen plus oxygen
118440|NCT03260556|Drug|Pirfenidone|Increasing doses
118441|NCT03260556|Drug|Placebos|Increasing doses
118442|NCT03260543|Dietary Supplement|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
118443|NCT03260543|Dietary Supplement|Placebo|Placebo for 12 weeks.
118444|NCT03260530|Other|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
118445|NCT03260530|Other|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
118446|NCT03260517|Device|Medtronic Coronary Drug-Coated Balloon Catheter|Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
118447|NCT03260504|Biological|Aldesleukin|Given SC or IV
118448|NCT03260504|Biological|Pembrolizumab|Given IV
118449|NCT03260491|Drug|U3-1402|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
118450|NCT03260478|Procedure|Red Blood Cells Transfusion|Transfusion of packed red blood cells unit(s).
118451|NCT03260465|Device|seleXys PC|Total hip arthroplasty using the seleXys PC cup
118452|NCT03260465|Device|RM|Total hip arthroplasty using the RM cup
118453|NCT03260452|Procedure|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
118454|NCT03260439|Drug|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
118455|NCT03260439|Drug|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
118456|NCT03260426|Dietary Supplement|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
118457|NCT03260426|Dietary Supplement|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
118458|NCT03260426|Device|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
118459|NCT03260400|Device|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
118460|NCT03260387|Procedure|TPIAT|The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
118461|NCT03260374|Device|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
118462|NCT03260374|Device|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
118463|NCT03260374|Device|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
118464|NCT03260361|Other|Hypnosis, kinesitherapy, MEOPA|classical intervention
118465|NCT03260361|Other|Usual practice|Usual practice with treatments and physio
118466|NCT03260335|Behavioral|Anxiety management strategy|Anxiety management strategy as per standard care plan
118467|NCT03260322|Drug|ASP8374|intravenous
118468|NCT03260322|Drug|Pembrolizumab|intravenous
118469|NCT03260309|Procedure|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
118470|NCT03260309|Procedure|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
118471|NCT03260296|Other|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.~The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
118472|NCT03260283|Drug|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
118473|NCT03260283|Drug|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
118474|NCT03260283|Drug|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
118475|NCT03260270|Diagnostic Test|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
118476|NCT03260257|Other|Neurofeedback|Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
118477|NCT03260244|Procedure|cardiac mapping and radiofrequency ablation procedure|"It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.~Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart)."
118478|NCT03260231|Dietary Supplement|Milled seed mix|Dietary intervention with or without seed mix
118479|NCT03260205|Drug|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
118480|NCT03260205|Drug|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
118481|NCT03260205|Drug|SPD489|SPD489
118482|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
118483|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
118484|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
118485|NCT03260166|Drug|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
118486|NCT03260153|Drug|Deproteinised Calf Blood Serum Injection|
118487|NCT03260153|Drug|Placebo (Sodium Chloride)|
118488|NCT03260140|Behavioral|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
118489|NCT03260127|Behavioral|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
118490|NCT03260127|Behavioral|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
118491|NCT03260114|Other|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
118576|NCT03259503|Drug|Melphalan|Given IV
118492|NCT03260101|Other|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
118493|NCT03260088|Diagnostic Test|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
118494|NCT03260075|Other|cat|Cat living at the ward
118495|NCT03260062|Behavioral|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
118496|NCT03260062|Other|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
118497|NCT03260049|Procedure|pars plana vitrectomy|pars plana vitrectomy
118498|NCT03260023|Biological|TG4001|PhIb Dose escalation PhII established RP2D of the combination
118499|NCT03260023|Drug|Avelumab|Anti PD-L1
118500|NCT03260010|Drug|Fosfomycin|Infectofos 5 g
118501|NCT03259997|Dietary Supplement|Probiotic supplement|Probiotic supplement
118502|NCT03259997|Dietary Supplement|Placebo|Placebo
118503|NCT03259971|Dietary Supplement|Probiotic-Lactobacillus plantarum PS128|Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
118504|NCT03259971|Dietary Supplement|Placebo|placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
118505|NCT03259958|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
118506|NCT03259958|Drug|Aricept|Aricept Tablet
118507|NCT03259945|Other|Data collection|demographic and clinical data
118508|NCT03259945|Other|Review of ECGs|nature and frequency of proven conduction disorders
118509|NCT03259932|Other|no physical activity|no physical activity
118510|NCT03259932|Other|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
118511|NCT03259919|Drug|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
118512|NCT03259919|Drug|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
118513|NCT03259906|Other|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
118514|NCT03259906|Procedure|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
118515|NCT03259906|Procedure|posterior osteosynthesis|Osteosynthesis using a posterior plate
118516|NCT03259906|Procedure|Anterior osteosynthesis|Osteosynthesis using an anterior plate
118517|NCT03259893|Device|AliveCor mobile ECG cardiac monitor|AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
118518|NCT03259893|Behavioral|AF Program|The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
118519|NCT03259893|Other|Standard of care|Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
118520|NCT03259867|Drug|Opdivo Injectable Product or Keytruda Injectable Product|a PD-1 immune check inhibitor per Investigator decision
118521|NCT03259867|Combination Product|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
118522|NCT03259854|Device|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
118523|NCT03259854|Device|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
118524|NCT03259841|Other|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
118525|NCT03259828|Radiation|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
118526|NCT03259815|Procedure|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
118527|NCT03259815|Diagnostic Test|Pre and post-PCI coronary physiology measurements|Pre and post-PCI coronary physiology measurements will be performed but not disclosed to the operator
118528|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
118529|NCT03259789|Drug|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
118530|NCT03259776|Other|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
118531|NCT03259763|Device|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
118571|NCT03259516|Drug|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
118572|NCT03259516|Drug|Sildenafil|20 mg per os three times a day during the whole course of treatment
118532|NCT03259763|Device|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
118533|NCT03259750|Other|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
118534|NCT03259711|Drug|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
118535|NCT03259698|Drug|nPEP|"Toronto participants will receive tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat 10/200/150/150 mg (Genvoya) one tablet once daily as study drug to complete a 28 day course of PEP.~Ottawa participants will receive PEP medications outside of the trial in the form of tenofovir disoproxil fumarate/emtricitabine 300/200 mg (Truvada) once daily + raltegravir (Isentress) 400 mg twice daily to complete a 28 day course."
118536|NCT03259698|Behavioral|Text Messaging Support|Text messaging support service ('WelTel'): community-based research staff person provides standardized weekly 'check-in' messages during their 12-week course of nPEP follow-up.
118537|NCT03259698|Other|Nurse-Led nPEP|nPEP follow-up is provided by nurse-led care at a local sexual health clinic instead of a hospital-based ID physician.
118538|NCT03259685|Other|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
118539|NCT03259685|Other|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
118540|NCT03259685|Other|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
118541|NCT03259672|Drug|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
118542|NCT03259672|Drug|Desflurane|Desflurane was used as a maintenance anesthetic agent.
118543|NCT03259659|Other|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
118544|NCT03259646|Behavioral|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
118545|NCT03259633|Drug|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
118546|NCT03259620|Drug|CLS006|Furosemide Topical Gel
118547|NCT03259620|Drug|CLS006 Vehicle|Vehicle Topical Gel
118548|NCT03259607|Drug|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
118549|NCT03259607|Drug|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
118550|NCT03259607|Drug|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
118551|NCT03259607|Drug|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
118552|NCT03259594|Procedure|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
118553|NCT03259594|Drug|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
118554|NCT03259581|Combination Product|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
118555|NCT03259568|Device|Repetitive TMS|1-10 Hertz rTMS will be administered
118556|NCT03259555|Drug|Brexpiprazole|Starting dose of 2 mg/day; titrated to a max of 4 mg/day. Adjustments can be made to dosing
118557|NCT03259555|Drug|Placebo|Tablet taken daily
118558|NCT03259542|Drug|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
118559|NCT03259542|Drug|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
118560|NCT03259529|Drug|Bendamustine hydrochloride|70 mg/kg by intravenous (IV) infusion for up to 2 cycles
118561|NCT03259529|Drug|Gemcitabine 500 mg|500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
118562|NCT03259529|Drug|Gemcitabine 700 mg|700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
118563|NCT03259529|Drug|Gemcitabine 1000 mg|1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
118564|NCT03259529|Drug|Nivolumab|1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles
118565|NCT03259529|Drug|Rituximab|375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
118566|NCT03259516|Drug|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
118567|NCT03259516|Drug|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
118568|NCT03259516|Drug|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
118569|NCT03259516|Drug|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
118578|NCT03259503|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
118579|NCT03259503|Other|Pharmacokinetic Study|Correlative studies
118580|NCT03259503|Biological|Rituximab|Given IV
118581|NCT03259503|Drug|Vorinostat|Given PO
118582|NCT03259490|Drug|Empagliflozin/linagliptin/metformin HCl|Once daily
118583|NCT03259490|Drug|Empagliflozin|Once daily
118584|NCT03259490|Drug|Linagliptin|Once daily
118585|NCT03259490|Drug|Metformin HCl|Once daily
118586|NCT03259477|Procedure|precise segmental renal arterial clamping|Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.
118587|NCT03259477|Procedure|laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
118588|NCT03259464|Drug|BI 685509|3 sequential dose groups
118589|NCT03259464|Drug|Placebo|3 sequential dose groups
118590|NCT03259451|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
118591|NCT03259438|Behavioral|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
118592|NCT03259438|Behavioral|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
118593|NCT03259425|Drug|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then patient will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
118594|NCT03259425|Drug|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
118595|NCT03259412|Dietary Supplement|Fish Oil|Fish Oil Capsule
118596|NCT03259412|Dietary Supplement|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
118597|NCT03259399|Genetic|detection of genotype|detection of genotype by next generation sequencing
118598|NCT03259386|Device|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
118599|NCT03259373|Behavioral|Early Intervention|"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.~Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."
118600|NCT03259373|Behavioral|Delayed Intervention|Delayed intervention letters to patients' providers, where they may be identified, that explain this project, the nature of the problem, and identify a list of their patients who are flagged as at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation.
118601|NCT03259360|Behavioral|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
118602|NCT03259360|Behavioral|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
118603|NCT03259347|Behavioral|Group-based Therapy|Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.
118604|NCT03259334|Drug|SHP647|1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
118605|NCT03259334|Other|Placebo|1 mL of sterile aqueous buffered solution.
118606|NCT03259308|Drug|SHP647|1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
118607|NCT03259308|Drug|Placebo|1 mL of sterile aqueous buffered solution.
118608|NCT03259295|Device|Digiclamp (Skin tag removal initial)|Skin tag will be assessed for size, location, and overall appearance. After assessment that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site.
118609|NCT03259295|Device|Digiclamp (Skin tag removal follow-up)|Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
118610|NCT03259282|Biological|Analysis of gamma globulin|Electrophoresis of proteins
118611|NCT03259269|Other|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
118612|NCT03259256|Procedure|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
118613|NCT03259243|Drug|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
118616|NCT03259217|Drug|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
118617|NCT03259204|Device|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
118618|NCT03259191|Procedure|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
118619|NCT03259165|Drug|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)~SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times. (May be repeated) (Held if SBP decreases to < 120 mmHg)~Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If < 15, stop algorithm."
118620|NCT03259165|Drug|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~Patients receive 1 inch topical nitropaste~IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)~Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If < 15, stop algorithm."
118621|NCT03259152|Drug|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
118622|NCT03259139|Behavioral|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
118623|NCT03259126|Device|SCUT|Two different home made curtains were attached to the angiographic table
118624|NCT03259113|Device|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
118625|NCT03259100|Other|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
118626|NCT03259087|Drug|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
118627|NCT03259074|Biological|Secukinumab|Eligible subjects are randomized to one of three treatment arms in a 1:1:1 ratio
118628|NCT03259074|Biological|GP2017 (adalimumab biosimilar)|Eligible subjects are randomized to one of three treatment arms in a 1:1:1 ratio
118629|NCT03259061|Device|Flexible fiberoptic nasopharyngoscopy|"Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).~Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.~Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
118630|NCT03259048|Diagnostic Test|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
118631|NCT03259035|Drug|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
118632|NCT03259035|Drug|Capox|4 cycles of q3weekly CAPOX
118633|NCT03258996|Procedure|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, in the middel of the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.~With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.~Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.~All is stabilized by means of suspensory sutures of coronal traction on each point of contact.~Finally the vertical incision made is sutured."
118634|NCT03258996|Procedure|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.~A partial-total-partial thickness flap is elevated in the coronal-apical direction.~A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.~Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
118635|NCT03258983|Other|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
118636|NCT03258970|Other|Observational cohort study|taking vitamin supplements
118637|NCT03258957|Other|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
118638|NCT03258944|Other|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
118639|NCT03258931|Drug|Crenolanib|Crenolanib will be administered orally
118640|NCT03258931|Drug|Midostaurin|Midostaurin will be administered orally
118641|NCT03258931|Drug|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
118642|NCT03258931|Drug|Duanorubicin|90 mg/m2 IV
118643|NCT03258918|Behavioral|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
118644|NCT03258905|Behavioral|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
118645|NCT03258905|Behavioral|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
118646|NCT03258892|Other|Educational Intervention|Receive STG
118647|NCT03258892|Other|Quality-of-Life Assessment|Ancillary studies
118648|NCT03258892|Other|Survey Administration|Ancillary studies
118649|NCT03258879|Procedure|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
118650|NCT03258879|Procedure|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
118651|NCT03258866|Drug|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
118652|NCT03258866|Drug|Rituximab|given with a single dose of 375mg/m2
118653|NCT03258853|Device|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
118654|NCT03258853|Other|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
118655|NCT03258840|Dietary Supplement|EPA Supplement|EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
118656|NCT03258840|Dietary Supplement|EPA Placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
118657|NCT03258827|Procedure|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
118658|NCT03258827|Procedure|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
118659|NCT03258814|Behavioral|Active Supervised Training (AST)|The active supervised and standardized training consisted of 24 units of exercise within 20 weeks performed in certified training centers and was focused on back fitness, core strengthening and patient engagement to treat back pain and functional impairment.
118660|NCT03258814|Behavioral|Standard of Care (SOC) Physiotherapy|Standard of care physiotherapy as used in this study included active as well as passive training and massages according to the physiotherapist discretion.
118661|NCT03258788|Procedure|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.~Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.~Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
118662|NCT03258775|Other|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
118663|NCT03258762|Drug|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
118664|NCT03258762|Drug|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
118665|NCT03258749|Drug|Tiotropium|inhaled Tiotropium(18μg, qd)
118666|NCT03258749|Drug|Formoterol|inhaled formoterol(4.5μg, bid)
118667|NCT03258736|Procedure|inguinal hernia surgery|repair of inguinal hernia
118668|NCT03258723|Behavioral|Lifestyle Intervention|"The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.~The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series."
118669|NCT03258723|Drug|Metformin|At 6 months, intervention participants who have not been able to lose weight or bring their HbA1c below the high risk range of 6% (determined by point-of-care testing) will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
118670|NCT03258710|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
118671|NCT03258697|Drug|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
118672|NCT03258684|Drug|Hydrocortisone, Vitamin C, and Thiamine|Intervention
118673|NCT03258684|Other|Normal saline|Placebo
118674|NCT03258671|Drug|EGFR-TK Inhibitor|·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
118675|NCT03258671|Radiation|Intensity Modulated Radiation Therapy|"High dose group：DTGTV=70Gy；~first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；~late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。~Low dose group：DTGTV=50Gy;~first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；~late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"
118676|NCT03258658|Biological|Autologous Engineered Urethral Construct|urethral construct
118677|NCT03258645|Drug|Dabigatran|Oral anticoagulant (NOAC) thrombin inhibitor
118678|NCT03258632|Behavioral|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
118679|NCT03258619|Biological|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
118680|NCT03258619|Biological|Natriuresis|natriuresis levels
118681|NCT03258593|Drug|Durvalumab|Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that patient is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
118682|NCT03258593|Drug|Vicinium|Vicinium is administered in a 12 week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Maintenance Phase, Vincinium is administered every other week. The dose of Vincinium 30mg in 50 mL of saline.
118683|NCT03258567|Drug|Nivolumab|Nivolumab, 480 mg IV every 4 weeks for up to 2 years in subjects with responding disease with clinical benefit if they are tolerating treatment
118684|NCT03258554|Biological|Cetuximab|Given IV
118685|NCT03258554|Biological|Durvalumab|Given IV
118686|NCT03258554|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
118687|NCT03258554|Other|Laboratory Biomarker Analysis|Correlative studies
118688|NCT03258554|Other|Quality-of-Life Assessment|Ancillary studies
118689|NCT03258554|Other|Questionnaire Administration|Ancillary studies
118690|NCT03258541|Device|TraceIT®|This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.
118691|NCT03258541|Radiation|Volumetric Arc Therapy (VMAT)|VMAT - fractionation Schedule : 1.8 Gy per fraction, one fraction per day, 5 fractions per week for the elective PTV and 2 Gy per fraction, one fraction per day, 5 fractions per week for the PTV-boost using a simultaneous integrated boost technique.
118692|NCT03258541|Procedure|Surgery|Low anterior resection of the rectum: 8-10 weeks post-radiotherapy
118693|NCT03258528|Behavioral|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
118694|NCT03258515|Drug|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
118695|NCT03258515|Other|Placebo|AZD6094 matching placebo without any pharmacological activity.
118696|NCT03258515|Drug|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
118697|NCT03258502|Drug|RV521|RV521 drug in capsules
118698|NCT03258502|Drug|Placebo|Placebo in capsules
118699|NCT03258489|Device|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
118700|NCT03258489|Device|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
118701|NCT03258489|Device|TENS and IES Placebo|Same protocol without electrical output.
118702|NCT03258476|Drug|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
118703|NCT03258476|Behavioral|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
118704|NCT03258476|Drug|Placebo|Placebo oral capsule
118705|NCT03258463|Other|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
118768|NCT03257943|Drug|Ivermectin Lotion, 0.5%|Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
118769|NCT03257943|Drug|SKLICE (ivermectin) Lotion, 0.5%|SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
118770|NCT03257943|Drug|Vehicle of the Test product|Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
118771|NCT03257930|Drug|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
118706|NCT03258450|Behavioral|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
118707|NCT03258437|Dietary Supplement|DA-9401|
118708|NCT03258437|Dietary Supplement|Placebo|Placebo for 12 weeks.
118709|NCT03258424|Drug|PTI-428|PTI-428 or placebo will be given QD for 14 days.
118710|NCT03258424|Drug|Placebo|PTI-428 or placebo will be given QD for 14 days.
118711|NCT03258411|Device|Rapid Expansion of palatal suture|
118712|NCT03258398|Drug|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
118713|NCT03258398|Drug|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
118714|NCT03258385|Dietary Supplement|Vitamin B12 fortified UHT milk|Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12
118715|NCT03258385|Dietary Supplement|Plain UHT milk|Daily intake of 200 mL of plain UHT milk
118716|NCT03258372|Drug|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
118717|NCT03258359|Biological|PACTN|To treat patients with MDS who have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents or have declined hypomethylating therapy.
118718|NCT03258346|Other|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
118719|NCT03258346|Dietary Supplement|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
118720|NCT03258346|Dietary Supplement|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
118721|NCT03258333|Procedure|aortic valve replacement|Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
118722|NCT03258320|Drug|Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin|As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
118723|NCT03258307|Other|Preoperative level|Blood sample
118724|NCT03258294|Drug|Melatonin(Circadin®)|
118725|NCT03258294|Drug|Placebo Oral Tablet|
118726|NCT03258281|Drug|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
118727|NCT03258281|Drug|Placebo|Patients will receive placebo administered subcutaneously
118728|NCT03258268|Device|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.~Patients will receive standard of care with a board certified physician with EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
118729|NCT03258268|Other|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.~The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
118730|NCT03258255|Procedure|penil or pudendal nerve block in circumcision|regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
118731|NCT03258242|Drug|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
118732|NCT03258242|Drug|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
118733|NCT03258229|Dietary Supplement|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
118734|NCT03258229|Dietary Supplement|Placebo|Placebo for 8 weeks
118735|NCT03258216|Diagnostic Test|panendoscopy|panendoscopy
118736|NCT03258216|Diagnostic Test|tongue image|capture tongue images by Automatic Tongue Diagnosis System
118737|NCT03258203|Other|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
118738|NCT03258190|Drug|Lime Powder Regimen|LPR and placebo were randomly given to subjects for 6 months
118739|NCT03258177|Other|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
118740|NCT03258164|Biological|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
118741|NCT03258164|Biological|Standard Lipofilling|Non-ASC enriched fat grafts
118742|NCT03258151|Genetic|detection of genotype|detection of genotype by next generation sequencing
118743|NCT03258138|Behavioral|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
118744|NCT03258138|Behavioral|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
118745|NCT03258138|Behavioral|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
118746|NCT03258138|Behavioral|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
118747|NCT03258138|Behavioral|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
118748|NCT03258125|Genetic|real time PCR (rPCR)|A villus tissue (2.5 cm * 2.5 cm * 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
118749|NCT03258112|Procedure|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
118750|NCT03258099|Genetic|detection of genotype|detection of genotype by next generation sequencing
118751|NCT03258086|Diagnostic Test|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
118752|NCT03258073|Other|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
118753|NCT03258060|Procedure|Temporary pacing study|
118754|NCT03258060|Radiation|Body Surface Mapping|
118755|NCT03258047|Combination Product|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
118756|NCT03258034|Drug|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
118757|NCT03258021|Device|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
118758|NCT03258008|Drug|Utomilumab|Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.
118759|NCT03258008|Biological|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
118760|NCT03257995|Drug|Indacaterol maleate|150 μg via Concept1 device
118761|NCT03257995|Drug|Indacaterol acetate|150 μg via Concept1 device
118762|NCT03257995|Drug|Placebo|Capsule containing no active ingredients delivered via Concept1 device
118763|NCT03257982|Procedure|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
118764|NCT03257969|Behavioral|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
118765|NCT03257969|Behavioral|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
118766|NCT03257956|Device|Investigational Group|The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
118767|NCT03257956|Device|reference group|The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
118772|NCT03257917|Other|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
118773|NCT03257904|Procedure|intracranial pressure monitoring|measurement of intracranial pressure
118774|NCT03257891|Drug|Cabazitaxel|Cabazitaxel will be administered every 21 days
118775|NCT03257878|Other|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).~The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
118776|NCT03257865|Drug|Brexpiprazole|Starting dose of 2 mg/day; titrated to a max of 4 mg/day. Adjustments can be made to dosing
118777|NCT03257865|Drug|Placebo|Tablet taken daily
118778|NCT03257852|Drug|ASP5094|intravenously administration
118779|NCT03257852|Drug|Placebo|intravenously administration
118780|NCT03257852|Other|Methotrexate therapy|MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
118781|NCT03257839|Device|Routine Full-Field Digital Mammography|Routine screening mammography exam, CC + MLO views.
118782|NCT03257839|Device|Routine Digital Breast Tomosynthesis|Routine screening tomosynthesis exam, CC + MLO views.
118783|NCT03257839|Device|Automated Whole Breast Ultrasound|Bilateral breast ultrasound performed as an adjunct to mammography.
118784|NCT03257826|Device|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
118785|NCT03257813|Drug|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
118786|NCT03257813|Drug|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
118787|NCT03257800|Drug|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
118788|NCT03257800|Drug|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
118789|NCT03257787|Other|new adhesive strip|This is a strip made of a newly developed adhesive
118790|NCT03257774|Other|Adhesive strip A|Strip consisting of a newly developed adhesive
118791|NCT03257774|Other|Adhesive strip B|Strip consisting of a newly developed adhesive
118792|NCT03257774|Other|Adhesive strip C|Strip consisting of a newly developed adhesive
118793|NCT03257761|Biological|Durvalumab|Given IV
118794|NCT03257761|Drug|Guadecitabine|Given SC
118795|NCT03257748|Radiation|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
118796|NCT03257748|Radiation|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
118797|NCT03257735|Diagnostic Test|next-generation sequencing|"Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.~Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).~Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.~All the samples were tested by next-generation sequencing."
118798|NCT03257722|Drug|Pembrolizumab|Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
118799|NCT03257722|Drug|Idelalisib|Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
118800|NCT03257709|Procedure|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
118801|NCT03257709|Procedure|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
118802|NCT03257696|Diagnostic Test|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
118803|NCT03257683|Drug|Ranolazine|Study group will receive additional therapeutic dosing of drug.
118804|NCT03257670|Drug|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
118805|NCT03257670|Device|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
118833|NCT03257384|Other|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
118806|NCT03257657|Behavioral|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC Registered Dietitian (RD) at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
118807|NCT03257657|Behavioral|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
118808|NCT03257644|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream at the protocol-defined dose strength based on cohort assignment.
118809|NCT03257631|Drug|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
118810|NCT03257618|Drug|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
118811|NCT03257618|Other|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
118812|NCT03257592|Radiation|[11C]DPA-713 PET imaging|
118813|NCT03257579|Other|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
118814|NCT03257579|Behavioral|Education|Education Alone provided at St. Joseph's Hospital and Niagara Health System
118815|NCT03257553|Diagnostic Test|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
118816|NCT03257540|Device|Small Bone Intramedullary Nail|Patients undergoing a Lapidus Arthrodesis procedure for hallux valgus correction who are receiving a Phantom Small Bone Intramedullary nail will begin weight-bearing at 2 weeks and follow a pre-determined post-operative protocol.
118817|NCT03257527|Behavioral|ENHANCE group|The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.
118818|NCT03257527|Behavioral|MBSR group|"The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase."
118819|NCT03257514|Drug|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
118820|NCT03257514|Drug|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
118821|NCT03257501|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
118822|NCT03257488|Device|type IV portable monitoring (Somnocheck micro Weinmann)|Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
118823|NCT03257475|Radiation|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
118824|NCT03257462|Drug|SPR001|SPR001 Capsules
118825|NCT03257449|Dietary Supplement|Viscous Fibre|Meta-analysis of Randomized Controlled Trials
118826|NCT03257436|Device|CRT-D|Left Ventricular MultiSite Pacing
118827|NCT03257423|Drug|Ertapenem followed by levofloxacin and metronidazole|Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
118828|NCT03257423|Drug|Moxifloxacin|Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
118829|NCT03257423|Procedure|Appendectomy|Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
118830|NCT03257423|Other|Placebo|Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
118831|NCT03257397|Device|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
118832|NCT03257397|Device|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
118925|NCT03256708|Dietary Supplement|Placebo|Inactive ingredients
118834|NCT03257358|Drug|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
118835|NCT03257332|Procedure|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
118836|NCT03257319|Drug|inhaled titration of morphine chlorhydrate|Patient in arm A will receive 1 to 3 titration
118837|NCT03257319|Drug|IV placebo|Patient in arm A will receive 1 to 6 injection
118838|NCT03257319|Device|Inhaled placebo|Patient in arm B will receive 1 to 3 titration
118839|NCT03257319|Drug|IV titration of morphine chlorhydrate|Patient in arm BA will receive 1 to 6 injection
118840|NCT03257306|Procedure|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
118841|NCT03257306|Procedure|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
118842|NCT03257293|Behavioral|Modified Cystoscopy|The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
118843|NCT03257293|Behavioral|Routine Cystoscopy|Routine cystoscopy as done as part of routine clinical practice
118844|NCT03257280|Other|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
118845|NCT03257267|Drug|REGN2810|Intravenous (IV) administration every 3 weeks (Q3W)
118846|NCT03257267|Drug|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:~Antifolate: Pemetrexed~Topoisomerase 1 inhibitor: Topotecan or Irinotecan~Nucleoside analogue: Gemcitabine~Vinca alkaloid: Vinorelbine~The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
118847|NCT03257254|Drug|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
118848|NCT03257241|Drug|A arm (DA-90)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is > 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
118849|NCT03257241|Drug|B arm (DAC)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is > 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
118850|NCT03257241|Drug|A arm (CLAG-M)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
118851|NCT03257241|Drug|B arm (FLAG-IDA)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
118852|NCT03257228|Genetic|comparative semiquantitative immunohistochemistry|
118853|NCT03257215|Drug|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
118854|NCT03257215|Drug|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
118855|NCT03257215|Drug|Stoss placebo|A single 1.5 mL dose administered on Day 1
118856|NCT03257215|Drug|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
118857|NCT03257202|Drug|Clindamycin 1% Gel|topical clindamycin
118858|NCT03257202|Drug|Benzoyl peroxide 5% gel|topical benzoyl peroxide
118859|NCT03257202|Drug|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
118860|NCT03257189|Device|Physiological signal monitor|Wireless remote monitoring system intended for use by researchers and healthcare professionals for continuous collection of physiological data in home and healthcare settings.
118861|NCT03257189|Device|Heart rate and heart rate variability comparison device|FDA cleared reference device that monitors heart rate and heart rate variability in subjects
118862|NCT03257189|Device|Respiration rate comparison device|FDA cleared reference device that monitors respiration rate in subjects
118863|NCT03257189|Other|Activity classification|Visual annotation of subject posture and other activities used for reference
118864|NCT03257176|Behavioral|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
118865|NCT03257163|Drug|Capecitabine|Given PO
118866|NCT03257163|Other|Laboratory Biomarker Analysis|Correlative studies
118867|NCT03257163|Biological|Pembrolizumab|Given IV
118868|NCT03257163|Radiation|Radiation Therapy|Undergo radiation therapy
118869|NCT03257150|Procedure|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die.
118870|NCT03257150|Device|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the cancer tumor.
118871|NCT03257150|Drug|18F-Fluoroazomycin arabinoside|Positron Emission Tomography (PET) imaging agent for assessment of tumor hypoxia.
118872|NCT03257137|Other|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
118873|NCT03257124|Drug|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
118926|NCT03256695|Drug|Albuterol sulfate (ABS)|ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
118874|NCT03257111|Other|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
118875|NCT03257098|Biological|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
118876|NCT03257085|Other|Low-carbohydrate, high-fat|Participants following low-carbohydrate, high-fat diet for 8 weeks.
118877|NCT03257085|Other|High-carbohydrate, moderate-fat|Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
118878|NCT03257072|Biological|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
118879|NCT03257072|Biological|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
118880|NCT03257072|Biological|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
118881|NCT03257059|Other|Breakfast|Glutinous rice (75 grams of available carbohydrate)
118882|NCT03257059|Other|No Breakfast|No food to be served in the morning
118883|NCT03257046|Drug|ITI-214|Oral
118884|NCT03257046|Other|Placebo|Oral
118885|NCT03257033|Drug|Gemcitabine|Chemotherapy
118886|NCT03257033|Drug|nab-paclitaxel|Chemotherapy
118887|NCT03257033|Device|RenovoCath|Intra-arterial catheter
118888|NCT03257020|Diagnostic Test|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
118889|NCT03257007|Behavioral|Mindfulness|The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
118890|NCT03256994|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
118891|NCT03256994|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
118892|NCT03256981|Radiation|SBRT|SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.
118893|NCT03256981|Drug|TKI|Continued background TKI alone
118894|NCT03256968|Drug|Ataluren|ataluren
118895|NCT03256955|Device|Tof cuff|The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
118896|NCT03256955|Device|Tof Watch SX|The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
118897|NCT03256942|Device|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
118898|NCT03256929|Behavioral|Personalized Diet-driven microbiota|Based on the results of the individual microbiota profile, we will formulate a specific diet aiming to enrich the distinct microbiota with organisms correlated to better mental health. The dietitian will visit each participant twice a month.
118899|NCT03256929|Behavioral|General information on nutrition and health|General information on nutrition and health. The dietitian will visit each participant twice a month.
118900|NCT03256916|Drug|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
118901|NCT03256916|Drug|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
118902|NCT03256916|Radiation|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 46Gy/23 #/4.5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
118903|NCT03256903|Drug|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
118904|NCT03256903|Drug|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
118927|NCT03256682|Behavioral|Stress management counseling|stress management counseling based on CBT and relaxation
118928|NCT03256669|Procedure|umbilical incision|exploration through umbilical incision
118905|NCT03256890|Behavioral|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
118906|NCT03256890|Other|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
118907|NCT03256864|Drug|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.~In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
118908|NCT03256851|Behavioral|Telephone-Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week telephone call with an investigator."
118909|NCT03256851|Behavioral|In-Person Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.~Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.~Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.~This home exercise program will be paired with a 1x/week visit to the laboratory to work with a physical therapist or trained team member."
118910|NCT03256838|Drug|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
118911|NCT03256825|Diagnostic Test|Rapid diagnostics alone|Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.
118912|NCT03256825|Other|Real-time antimicrobial stewardship decision support|"A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:~Switch to active treatment if non-working empirical treatment~De-escalate broad spectrum empiric treatment when feasible~Promote early intravenous to per oral switch~Shorten treatment duration"
118913|NCT03256812|Device|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
118914|NCT03256812|Device|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
118915|NCT03256799|Drug|Ivacaftor/Ataluren|Both drugs were given in combination for 48 week study period
118916|NCT03256786|Behavioral|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
118917|NCT03256760|Biological|Endotoxin|Endotoxin
118918|NCT03256760|Biological|Placebo|Placebo
118919|NCT03256747|Device|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
118920|NCT03256747|Device|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
118921|NCT03256734|Other|Policy intervention|Incentive payment for physicians
118922|NCT03256721|Drug|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
118923|NCT03256721|Drug|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
118924|NCT03256708|Dietary Supplement|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
118930|NCT03256643|Behavioral|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
118931|NCT03256643|Behavioral|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
118932|NCT03256643|Behavioral|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
118933|NCT03256617|Other|Cognitive reassurance training|The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
118934|NCT03256604|Diagnostic Test|left-over sputum|Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
118935|NCT03256591|Other|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
118936|NCT03256578|Device|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
118937|NCT03256565|Diagnostic Test|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
118938|NCT03256552|Drug|Glycopyrronium MDI 28.8 micrograms|Glycopyrronium MDI 28.8 micrograms
118939|NCT03256552|Drug|Glycopyrronium MDI 14.4 micrograms|Glycopyrronium MDI 14.4 micrograms
118940|NCT03256552|Drug|Glycopyrronium MDI 7.2 micrograms|Glycopyrronium MDI 7.2 micrograms
118941|NCT03256552|Drug|Placebo MDI|Placebo Inhalation Aerosol
118942|NCT03256539|Behavioral|Sleep intervention|Behavioral sleep intervention program
118943|NCT03256539|Behavioral|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
118944|NCT03256526|Drug|Placebo|0 mg
118945|NCT03256526|Drug|PF-06835919 Low Dose|75 mg once daily
118946|NCT03256526|Drug|PF-06835919 High Dose|300 mg once daily
118947|NCT03256513|Other|model controlling|control blood pressure by statistical l model with anticipate lowest peri-procedure risk
118948|NCT03256513|Other|conventional controlling|control blood pressure by conventional strategy
118949|NCT03256500|Device|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
118950|NCT03256487|Drug|Buprenorphine|buprenorphine 0.3mg IV
118951|NCT03256487|Drug|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
118952|NCT03256474|Other|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
118953|NCT03256461|Behavioral|Lactate clearance 10% target group|Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
118954|NCT03256461|Behavioral|Lactate clearance 20% target group|Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
118955|NCT03256461|Behavioral|Standard EGDT group|Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
118956|NCT03256435|Behavioral|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)—delivered by trained interventionists—to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
118957|NCT03256422|Drug|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :~nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine~protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r~non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine~integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
118958|NCT03256409|Other|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
118986|NCT03256188|Behavioral|Active classroom|30 minutes of moderate-to-vigorous physical activity
118959|NCT03256409|Other|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
118960|NCT03256396|Procedure|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
118961|NCT03256383|Device|Lead testing|Fingerstick
118962|NCT03256370|Procedure|milk collection|"Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project~After completed informed consent, demographic data was collected and filled in case record form~Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis~Method of human milk oligosaccharide analysis :~Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method~High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
118963|NCT03256357|Behavioral|Constraint-induced movement therapy|In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
118964|NCT03256357|Behavioral|Action observation training|Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.
118965|NCT03256357|Behavioral|Placebo observation training|Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
118966|NCT03256344|Biological|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
118967|NCT03256344|Biological|Atezolizumab|A monoclonal antibody given by intravenous injection.
118968|NCT03256331|Drug|BEL-X-HG|"This study will be carried out in 2 parts:~A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment~A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment~Escalating dose levels of BEL-X-HG in 4 study cohorts will be as follows:~Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)~Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)~Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)~Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid)"
118969|NCT03256318|Other|No intervention|No intervention; surveys/questionnaires only
118970|NCT03256305|Device|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
118971|NCT03256305|Device|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
118972|NCT03256292|Drug|Testosterone replacement|Testosterone replacement therapy
118973|NCT03256292|Behavioral|lifestyle|lifestyle intervention consisting of diet and increased physical activity
118974|NCT03256279|Device|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
118975|NCT03256279|Device|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
118976|NCT03256253|Drug|Pregabalin|pregabalin up to 600 mg/day
118977|NCT03256240|Other|side-to-side functional end anastomosis|type of anastomosis
118978|NCT03256240|Other|Kono-S analstomosis|antimesenteric anastomosis
118979|NCT03256227|Behavioral|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
118980|NCT03256227|Behavioral|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
118981|NCT03256214|Procedure|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
118982|NCT03256214|Procedure|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
118983|NCT03256201|Behavioral|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake. For the last 5 days, all participants switch to Impact Advanced Recovery® (provided), as standard care at our facility.
118984|NCT03256201|Behavioral|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
118985|NCT03256201|Behavioral|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
118987|NCT03256175|Procedure|Percutaneous Coronary Intervention|PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
118988|NCT03256162|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
118989|NCT03256162|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
118990|NCT03256149|Drug|Dexamethasone|
118991|NCT03256149|Drug|Placebo|Normal saline (IV placebo)
118992|NCT03256136|Drug|Carboplatin|Chemotherapy
118993|NCT03256136|Drug|Nivolumab|will allow the body's immune system to work against tumor cells
118994|NCT03256136|Drug|pemetrexed|Chemo therapy
118995|NCT03256136|Drug|Ipilimumab|will allow the body's immune system to work against tumor cells
118996|NCT03256123|Dietary Supplement|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The biscuits for each subject will contain ~200 kcal with 10 g of red palm shortening/day (630 µg RE/day). This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 630 µg RE of vitamin A/day. This would fulfill ~70% of the RNI of vitamin A for children aged 7-11 years old.
118997|NCT03256123|Dietary Supplement|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
118998|NCT03256110|Behavioral|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
118999|NCT03256097|Device|XDP sound processing strategy|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
119000|NCT03256097|Device|Voice Guard sound processing strategy|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
119001|NCT03256097|Device|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
119002|NCT03256084|Procedure|Blood and tumor samples|Blood and tumor samples
119003|NCT03256071|Drug|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;~Modified BUCY:~Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
119004|NCT03256071|Drug|Modified BUCY|"Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.~Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
119005|NCT03256058|Procedure|Reinflation after early deflation|the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
119006|NCT03256058|Procedure|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
119007|NCT03256045|Drug|Carfilzomib|Given IV
119008|NCT03256045|Other|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
119009|NCT03256045|Drug|Dexamethasone|Given PO
119010|NCT03256045|Other|Laboratory Biomarker Analysis|Correlative studies
119011|NCT03256045|Drug|Panobinostat|Given PO
119012|NCT03256019|Procedure|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
119013|NCT03256006|Other|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
119014|NCT03255993|Drug|SPH3127 50mg|SPH3127 50mg
119015|NCT03255993|Drug|SPH3127 100mg|SPH3127 100mg
119016|NCT03255993|Drug|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
119017|NCT03255993|Drug|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
119018|NCT03255980|Device|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
119019|NCT03255980|Other|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
119020|NCT03255967|Behavioral|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to PWD-informal caregiver dyads through HHC
119021|NCT03255967|Behavioral|Standard of Care|Subjects receive care through usual home healthcare assignment process.
119022|NCT03255954|Other|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
119023|NCT03255941|Drug|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
119024|NCT03255941|Drug|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
119025|NCT03255928|Diagnostic Test|PAS assay, TGT|Evaluation of platelet function
119026|NCT03255915|Drug|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
119027|NCT03255915|Other|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
119028|NCT03255902|Behavioral|Parenting classes|Parenting Classes:The Incredible Years curriculum
119029|NCT03255889|Drug|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
119030|NCT03255889|Other|Placebo|Sunflower oil emulsion of equal calories.
119031|NCT03255876|Dietary Supplement|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
119032|NCT03255876|Dietary Supplement|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
119033|NCT03255863|Other|Questionnaire|Patient Self reported questionnaire filled in.
119034|NCT03255837|Device|Transcranial direct current stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
119035|NCT03255824|Drug|Dexmedetomidine and Midazolam|Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
119036|NCT03255824|Drug|Propofol, Midazolam, and Fentanyl|Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
119037|NCT03255811|Drug|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
119038|NCT03255798|Device|G2 and G3|Two iStent inject devices and one iStent supra device
119039|NCT03255785|Device|Cataract surgery plus one iStent and one iStent Supra implanted|Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
119040|NCT03255772|Diagnostic Test|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
119041|NCT03255759|Diagnostic Test|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
119042|NCT03255746|Behavioral|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
119043|NCT03255746|Behavioral|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
119044|NCT03255733|Device|Intense Therapeutic Ultrasound Treatment|
119045|NCT03255707|Device|eye patch|Occluding the better seeing eye for a given number of hours daily
119046|NCT03255707|Device|dichoptic treatment|dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
119047|NCT03255694|Drug|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
119048|NCT03255681|Procedure|PRP injections into nasojugal folds|"A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.~11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.~Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane"
119049|NCT03255655|Device|Intense Therapeutic Ultrasound Treatment - ITU|
119050|NCT03255642|Drug|Melatonin 2mg|4 weeks of 2mg prolonged release melatonin (Circadin)
119051|NCT03255642|Drug|ClonazePAM 0.5 MG|4 weeks of 0.5mg clonazepam (Rivotril)
119052|NCT03255629|Drug|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
119053|NCT03255629|Device|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
119054|NCT03255616|Other|mechanical stimulation|mechanical non-painful low- and high pressure stimuli to thoracolumbar segments of healthy subjects and low back pain patients
119055|NCT03255616|Other|vibrotactile stimulation|non-painful vibrotactile stimulation within a frequency range between 20-150Hz to thoracolumbar segments of healthy subjects and low back pain patients
119056|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
119057|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
119094|NCT03255330|Drug|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
119095|NCT03255330|Drug|Metamizol|Standardized treatment
119058|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
119059|NCT03255603|Other|Digestible Starch Supplementation|Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
119060|NCT03255590|Device|Real tDCS|Anodal Non-invasive brain stimulation to stimulate motor-associated areas in the brain
119061|NCT03255590|Device|Sham tDCS|Sham Non-invasive brain stimulation to stimulate motor-associated areas in the brain
119062|NCT03255590|Behavioral|Configuration task|Training the impaired hand on a configuration task
119063|NCT03255577|Procedure|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
119064|NCT03255564|Other|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.~Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
119065|NCT03255551|Drug|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
119066|NCT03255538|Other|DFM: Mean pressure|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment.
119067|NCT03255538|Other|DFM: Mean pressure - 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment decremented by 25%.
119068|NCT03255538|Other|DFM: Mean pressure + 25%|Deep friction massage as described by Dr. James Cyriax, performed with the mean pressure previously obtained in a baseline assessment incremented by 25%.
119069|NCT03255525|Other|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
119070|NCT03255525|Other|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
119071|NCT03255525|Other|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
119072|NCT03255512|Drug|Vericiguat (BAY1021189) + isosorbite mononitrate|"ISMN up-titration with 30 mg / 60 mg, about 7 days each, prior to start of vericiguat administration~Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be up-titrated to 5 mg and to 10 mg:~2.5 mg vericiguat for about 14 days followed by 5 mg vericiguat for about 14 days followed by 10 mg vericiguat for about 14 days~60 mg ISMN od on each day of vericiguat administration, taken 1 hour prior to vericiguat (in-house days) or together with vericiguat (out-patient days)"
119073|NCT03255512|Drug|Placebo + isosorbite mononitrate (ISMN)|"ISMN up-titration with 30 mg / 60 mg, about 7 days each, prior to start of placebo administration~Placebo for about 14 days, once daily~60 mg ISMN od on each day of placebo administration, taken 1 hour prior to placebo (in-house days) or together with placebo (out-patient days)"
119074|NCT03255499|Behavioral|Exercise|Exercise
119075|NCT03255499|Behavioral|Cognitive|Cognitive
119076|NCT03255499|Behavioral|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
119077|NCT03255486|Biological|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.~These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
119078|NCT03255473|Drug|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
119079|NCT03255473|Drug|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
119080|NCT03255447|Device|Immunoadsorption|Fresenius Globaffin
119081|NCT03255434|Drug|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
119082|NCT03255434|Drug|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
119083|NCT03255421|Other|Pressure measurement|Observational study No intervention, only fragmenting the emptying of the bladder
119084|NCT03255408|Drug|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
119085|NCT03255408|Drug|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
119086|NCT03255408|Drug|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
119087|NCT03255408|Drug|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
119088|NCT03255395|Device|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
119089|NCT03255382|Drug|Fumaderm|Fumaderm tablet administered orally
119090|NCT03255382|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
119091|NCT03255369|Other|Child exposed Zika virus proved|There will be applied Bayley Teste 3rd edition
119092|NCT03255356|Other|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
119093|NCT03255343|Device|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
119097|NCT03255317|Behavioral|Reinforcers|Memes/Gifs: Immediately after completing their daily ecological momentary assessment using the app, each participant is randomized to receive an inspirational or funny meme or gif that is displayed within the app. Life Insights: Immediately after completing both daily active tasks using the app, each participant is randomized to unlock a life insight. Life insights track data provided by the participant, are stored in a virtual library within the app, and are regularly updated with recent data points.
119098|NCT03255317|Behavioral|Notifications|Reminder Push Notifications: All participants receive a push notification reminder from the app at 6pm (the time at which data collection opens) to complete their daily data collection activities. Each day, each participant will be randomized to receive either a generic reminder or a reminder that contains more detailed information (e.g., about upcoming incentives). Inspirational Push Notifications: Each day, each participant will be randomized to receive a push notification at 4pm that contains inspirational song lyrics or celebrity quotes.
119099|NCT03255304|Behavioral|health mindest|groups be confronted with health aspects of food items
119100|NCT03255304|Behavioral|palatability mindset|groups be confronted with palatability aspects of food items
119101|NCT03255291|Behavioral|Risk Display App|-The Risk Display App provides participants with personalized risk results
119102|NCT03255291|Behavioral|Imagery Audio Recording - Sleep|-Imagine themselves improving sleep hygiene
119103|NCT03255291|Other|Survey|-Assesses a number of measures including comprehension, intentions, worry, perceived severity of risks, race, education, numeracy, imagery vividness, imagery practice, self-efficacy, affect, action plans, feelings about disease risk, and exercise and sleep behaviors
119104|NCT03255291|Behavioral|Imagery Audio Recording - Exercise|-Imagine themselves improving exercise
119105|NCT03255291|Other|Text message reminders|-Reminders to practice mental imagery
119106|NCT03255291|Other|Text Message Based Survey|-Assesses a number of measures including exercise, action plans, self-efficacy, affect, and behaviors
119107|NCT03255278|Biological|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
119108|NCT03255278|Biological|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
119109|NCT03255278|Biological|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
119110|NCT03255278|Biological|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
119111|NCT03255278|Biological|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
119112|NCT03255265|Other|no interventions|no interventions
119113|NCT03255252|Drug|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
119114|NCT03255252|Combination Product|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
119115|NCT03255239|Procedure|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
119116|NCT03255226|Drug|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
119117|NCT03255213|Other|Lingual Muscle Training|Lingual Muscle Training using the Iowa Oral Performance Instrument (OIPI) device
119118|NCT03255200|Device|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
119119|NCT03255187|Dietary Supplement|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA [24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)].
119120|NCT03255187|Dietary Supplement|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
119121|NCT03255174|Biological|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of biological components (human plasma‐derived fibrinogen and thrombin) embedded in a flexible composite patch component.
119122|NCT03255161|Behavioral|community health worker-audiologist communication education and support group|A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
119123|NCT03255148|Drug|Oxytocin|Syntocinon nasal spray
119124|NCT03255148|Drug|Placebo|Placebo nasal spray
119125|NCT03255135|Device|HIFU|High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
119126|NCT03255122|Behavioral|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, & Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
119127|NCT03255122|Behavioral|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
119128|NCT03255096|Drug|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
119129|NCT03255096|Drug|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
119130|NCT03255096|Drug|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
119131|NCT03255083|Drug|DS-1205c|DS-1205c 200 mg capsule
119132|NCT03255083|Drug|Osimertinib|Osimertinib 80 mg tablet
119133|NCT03255070|Drug|ARX788|An antibody drug conjugate
119134|NCT03255057|Device|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
119135|NCT03255057|Device|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
119136|NCT03255044|Drug|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
119137|NCT03255044|Drug|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
119138|NCT03255044|Other|guideline directed therapy|standard heart failure therapy
119139|NCT03255031|Dietary Supplement|Ketogenic Diet (KD)|Ketogenic Diet (KD) Meals and Shakes: Participants will be randomized to a meal plan of a ketogenic diet (KD) at the time they sign the consent (day 1 or 2 of admission). For each meal at breakfast, lunch and dinner, the diets will consist of a KD meal depending on treatment randomization. Compliance tests are done daily with a urine test measuring ketone levels. To ensure that the diet is double blind in both the outpatient and inpatient phases, solid snacks are always ketogenic and shakes are KD.
119140|NCT03255031|Dietary Supplement|Standard American (SA) Meals and Shakes|Standard American (SA) Meals and Shakes: Participants will be randomized to a meal plan of standard American (SA) diet at the time they sign the consent (day 1 or 2 of admission). For each meal at breakfast, lunch and dinner, the diet will consist of a SA meal (carbohydrate rich) depending on treatment randomization. Compliance tests are done daily with a urine test test measuring ketone levels. To ensure that the diet is double blind in both the outpatient and inpatient phases, solid snacks are always ketogenic and shakes are SA.
119141|NCT03255018|Biological|Pembrolizumab|Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
119142|NCT03255005|Device|Endomina|Endoscopic sleeve reduction
119143|NCT03255005|Behavioral|Diet|Multidisciplinary follow-up
119144|NCT03254992|Device|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
119145|NCT03254992|Device|ASD - Tangible task|Experimental group using Keyboard with more real activity.
119146|NCT03254992|Device|TD - Abstract task|Control group using Kinect with more virtual activity.
119147|NCT03254992|Device|TD - Tangible task|Control group using Keyboard with more real activity.
119148|NCT03254979|Behavioral|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:~A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.~With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).~A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
119149|NCT03254966|Drug|SHR0302|Oral tablets
119150|NCT03254966|Drug|Placebo|Oral tablets
119151|NCT03254953|Behavioral|self-monitoring of body weight|- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
119152|NCT03254953|Behavioral|self-monitoring of diet|"track their diet (food and drinks) daily using the MyFitnessPal mobile app~when they are asked to track diet will vary based on the arm"
119153|NCT03254953|Behavioral|weekly personalized feedback + lessons + action plans|- these are additional evidence-based intervention components
119154|NCT03254940|Behavioral|Charge|Text messaging-based study to determine effect of different components on weight loss.
119155|NCT03254927|Drug|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
119156|NCT03254914|Procedure|Home Blood Pressure|Measure Home Blood Pressure
119157|NCT03254901|Other|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
119158|NCT03254875|Behavioral|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
119159|NCT03254862|Procedure|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
119160|NCT03254862|Procedure|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
119161|NCT03254849|Drug|Empagliflozin|1 tablet
119162|NCT03254849|Drug|Hydrochlorothiazide 25 mg|1 tablet
119163|NCT03254836|Other|Standard of care|Elective radical surgery for adenocarcinoma.
119164|NCT03254810|Biological|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
119165|NCT03254810|Biological|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
119166|NCT03254810|Biological|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
119167|NCT03254797|Other|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
119168|NCT03254797|Other|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
119169|NCT03254784|Drug|BMS-986165 Capsule|Oral capsule
119170|NCT03254784|Drug|BMS-986165 Tablet|Oral tablet
119171|NCT03254771|Other|Decision aid|Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
119172|NCT03254758|Biological|Mesenchymal stem cell|Single dose of ADR-001, mesenchymal stem cells, is administered by intravenous 1 hour infusion.
119173|NCT03254745|Other|Pharmacist led pharmaceutical care|The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
119174|NCT03254732|Drug|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
119175|NCT03254732|Drug|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
119176|NCT03254719|Other|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
119177|NCT03254706|Other|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
119178|NCT03254706|Other|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
119179|NCT03254706|Other|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
119180|NCT03254706|Other|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
119181|NCT03254693|Combination Product|1-step self-etch approach (SE)|Application mode - Do not use etchan. According to the manufacturer's instructions.
119182|NCT03254693|Combination Product|selective enamel etching (SEE)|Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
119183|NCT03254693|Other|1-step self-etch for double time (SE2X)|Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
119184|NCT03254693|Other|1-step self-etch additional layer (SE1+)|Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
119185|NCT03254680|Dietary Supplement|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
119186|NCT03254667|Biological|Brodalumab|Brodalumab
119187|NCT03254667|Drug|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
119188|NCT03254654|Drug|Vinorelbine|Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
119189|NCT03254654|Drug|Apatinib|250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
119190|NCT03254641|Drug|human chorionic gonadotropin|5000 IE times one
119191|NCT03254628|Other|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
119192|NCT03254628|Other|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag & mask device.
119193|NCT03254628|Behavioral|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
119194|NCT03254628|Behavioral|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
119195|NCT03254628|Drug|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
119196|NCT03254628|Device|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
119197|NCT03254615|Behavioral|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
119198|NCT03254602|Device|Intense Therapeutic Ultrasound Treatment|
119199|NCT03254589|Drug|Methotrexate|See arm descriptions
119200|NCT03254589|Drug|Sulfasalazine|See arm description
119201|NCT03254589|Drug|Other DMARDs|See arm
119202|NCT03254576|Other|Functional MRI|
119203|NCT03254550|Other|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
119204|NCT03254537|Dietary Supplement|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
119205|NCT03254537|Dietary Supplement|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
119206|NCT03254524|Other|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
119207|NCT03254511|Drug|Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable|Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).
119208|NCT03254511|Radiation|Radiotherapy|Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.
119209|NCT03254511|Drug|Chemotherapeutic Combinations|Patients are going to receive weekly chemotherapy (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]).
119210|NCT03254498|Device|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
119211|NCT03254498|Device|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
119212|NCT03254485|Drug|IW-1973|Oral Tablet
119213|NCT03254485|Drug|Placebo Oral Tablet|Oral Tablet
119214|NCT03254472|Diagnostic Test|Measured concentrations of biomarkers|
119215|NCT03254459|Drug|Buprenorphine Sublingual Spray|0.5 mg Sublingual Spray
119216|NCT03254459|Drug|Morphine|4 mg Intravenous Injection
119217|NCT03254459|Drug|Oxycodone Hydrochloride|10 mg tablet
119218|NCT03254459|Drug|Zofran|4 mg oral disintegrating tablet (ODT) or IV injection given at the investigator's discretion for nausea
119219|NCT03254446|Drug|TRC150094|TRC150094 Tablet 45 mg
119220|NCT03254446|Drug|Placebo|Matching Placebo Tablet
119221|NCT03254433|Behavioral|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
119222|NCT03254433|Behavioral|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
119223|NCT03254420|Device|Calypso beacon implant|Calypso beacon implant before radiotherapy
119224|NCT03254420|Radiation|Radiotherapy IMRT|Radiotherapy IMRT
119225|NCT03254407|Other|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
119226|NCT03254394|Drug|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.~If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
119227|NCT03254394|Drug|Placebo|Dextrose 5% in water will be administered as active comparator.
119228|NCT03254394|Drug|FOLFOX regimen|"Each cycle (repeated every 14 days):~Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
119229|NCT03254381|Behavioral|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
119230|NCT03254381|Behavioral|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
119231|NCT03254368|Drug|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
119232|NCT03254368|Drug|Placebo|Placebo has the same excipients and appearance as ZGN-1061
119233|NCT03254355|Procedure|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
119234|NCT03254329|Other|Assessment of human milk nutrient composition|Observational study to measure nutrients in human milk during lactation and their relationship to maternal and infant nutritional status.
119235|NCT03254303|Other|Difficulty of catheterization in group 60 s|
119236|NCT03254303|Other|Difficulty of catheterization in group 90 s|
119237|NCT03254303|Other|Difficulty of catheterization in group 120 s|
119238|NCT03254290|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
119239|NCT03254290|Biological|Formocresol|Control group
119240|NCT03254277|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS
119241|NCT03254264|Behavioral|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
119242|NCT03254264|Behavioral|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
119316|NCT03253744|Drug|18F-DCFPyL|Subjects will receive 18F-DCFPyL at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 10 mCi.
119317|NCT03253744|Radiation|Tumor Irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy
119318|NCT03253744|Radiation|Prostate radiation + tumor boost irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate
119243|NCT03254251|Behavioral|Stair climbing|Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
119244|NCT03254238|Other|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
119245|NCT03254225|Behavioral|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
119246|NCT03254212|Device|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to > 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to < 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
119247|NCT03254199|Drug|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
119248|NCT03254199|Drug|Placebo ODT|Placebo ODT taken three times daily for 28 days
119249|NCT03254186|Drug|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
119250|NCT03254186|Drug|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
119251|NCT03254173|Drug|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
119252|NCT03254173|Drug|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
119253|NCT03254160|Drug|DNS-3379|DNS-3379
119254|NCT03254160|Drug|Placebo|Placebo
119255|NCT03254147|Drug|warfarin|warfarin
119256|NCT03254147|Drug|dabigatran|Non-vitamin K dependent oral anti-coagulants (NOACs)
119257|NCT03254147|Drug|Apixaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
119258|NCT03254147|Drug|Edoxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
119259|NCT03254147|Drug|Rivaroxaban|Non-vitamin K dependent oral anti-coagulants (NOACs)
119260|NCT03254134|Drug|Warfarin|patients treated with warfarin
119261|NCT03254134|Drug|Dabigatran|patients treated with Dabigatran
119262|NCT03254108|Drug|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
119263|NCT03254108|Drug|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
119264|NCT03254108|Drug|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
119265|NCT03254108|Drug|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
119266|NCT03254108|Drug|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
119267|NCT03254082|Other|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
119268|NCT03254082|Other|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
119269|NCT03254082|Other|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
119270|NCT03254082|Other|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
119271|NCT03254082|Other|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
119272|NCT03254069|Device|Stainless Steel Crowns|SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
119273|NCT03254056|Procedure|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
119274|NCT03254056|Procedure|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
119275|NCT03254043|Behavioral|Take-home Dosing Procedures|Within-subject evaluation across 2 phases with a final choice condition
119276|NCT03254030|Other|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
119319|NCT03253679|Drug|Adavosertib|Given PO
119277|NCT03254017|Procedure|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
119278|NCT03254017|Other|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
119279|NCT03254004|Drug|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
119280|NCT03253991|Device|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
119281|NCT03253978|Radiation|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
119282|NCT03253965|Other|Metronome Normal|Steps are timed with the beat of the metronome set to the subject's cadence
119283|NCT03253965|Other|Metronome Slow|Steps are timed with the beat of the metronome set to 85% of the subject's cadence
119284|NCT03253965|Other|Metronome Fast|Steps are timed with the beat of the metronome set to 115% of the subject's cadence
119285|NCT03253965|Other|Music Normal|Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
119286|NCT03253965|Other|Music Slow|Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
119287|NCT03253965|Other|Music Fast|Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
119288|NCT03253965|Other|No Auditory cueing|Steps are not timed with any auditory cue.
119289|NCT03253939|Procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
119290|NCT03253939|Procedure|Cytoreductive surgery alone|Exclusively Cytoreductive surgery approach
119291|NCT03253926|Drug|Lorcaserin|Lorcaserin 10mg BID
119292|NCT03253926|Drug|Placebo|Placebo capsule BID
119293|NCT03253926|Drug|Marijuana|Smoked marijuana cigarette
119294|NCT03253913|Drug|Sirolimus|Patients will be on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
119295|NCT03253913|Drug|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
119296|NCT03253900|Device|Stable rowing simulator|a standard stable/fixed rowing simulator
119297|NCT03253900|Device|Slides based rowing simulator|a slides based rowing simulator, i.e. horizontal plane unstable
119298|NCT03253900|Device|Tilt board based rowing simulator|a tilt board based rowing simulator; i.e. frontal plane unstable
119299|NCT03253887|Drug|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) received intraluminal ethanol at a volume sufficient to fill the catheter lumen, ranged from 0.1 to 0.3 ml, with the volume being previously established. ELT was maintained for two full hours in each catheter lumen, with the lumen remaining locked during this period. The same procedure was then carried out with the other lumen. Prior to and following ELT, flushing was performed using 5-10 ml of 0.9% saline solution.
119300|NCT03253874|Behavioral|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
119301|NCT03253861|Other|No intervention|No intervention
119302|NCT03253848|Other|Best Practice|Discussion between doctors and APL expert
119303|NCT03253848|Other|Laboratory Biomarker Analysis|Correlative studies
119304|NCT03253848|Procedure|Supportive Care|Receive simplified guidelines and support
119305|NCT03253835|Diagnostic Test|Single Group Assignment|
119306|NCT03253822|Other|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
119307|NCT03253809|Device|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
119308|NCT03253796|Biological|Golimumab QM: Period 1 (OL)|OL monthly injections of active golimumab 50 mg or 100 mg (two 50 mg injections) from Month 0 to Month 9 (Period 1, run-in)
119309|NCT03253796|Biological|Golimumab QM: Period 2 (DB)|"DB monthly injections of active golimumab 50 mg or 100 mg (two 50 mg injections) for 12 months, or until flare (Period 2, full treatment)"
119310|NCT03253796|Biological|Golimumab Q2M: Period 2 (DB)|"DB monthly injections of golimumab 50 mg or 100 mg (two 50 mg injections), alternating with placebo, for 12 months, or until flare (Period 2, reduced treatment)"
119311|NCT03253796|Other|Placebo QM: Period 2 (DB)|"DB monthly injections of placebo for golimumab for 12 months, or until flare (Period 2, treatment withdrawal)"
119312|NCT03253796|Biological|Golimumab QM: Period 2 (OL)|"OL golimumab 50 mg or 100 mg (two 50 mg injections) for 12 months (Period 2, full treatment re-started after flare)"
119313|NCT03253783|Behavioral|Pulse|
119314|NCT03253770|Device|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
119315|NCT03253757|Other|This study is non-interventional.|This study is non-interventional.
119320|NCT03253666|Other|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
119321|NCT03253653|Device|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
119322|NCT03253640|Other|Exposure|Healthcare associated infection (HAI)
119323|NCT03253627|Behavioral|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition—without mindfulness instruction—using similar modalities to MBSR training for a matched schedule.
119324|NCT03253627|Behavioral|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
119325|NCT03253614|Diagnostic Test|Audiometry|Extended high-frequency (EHF; 9-16 kHz) audiometry
119326|NCT03253614|Diagnostic Test|Urine biomarkers for renal tubular function|Kidney Injury Molecule-1
119327|NCT03253614|Diagnostic Test|Blood pressure|Blood pressure right arm, measured With standard Methods 3 times
119328|NCT03253601|Behavioral|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
119329|NCT03253588|Procedure|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
119330|NCT03253575|Diagnostic Test|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
119331|NCT03253562|Drug|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
119332|NCT03253562|Drug|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
119333|NCT03253549|Device|SMArTVIEW|Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
119334|NCT03253536|Other|observational|none (observational study)
119335|NCT03253523|Procedure|Occipital neurolysis|Surgical occipital nerve decompression
119336|NCT03253510|Other|Poly-amide|New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
119337|NCT03253510|Other|Poly-methyl methacrylate|Gold standard denture base material
119338|NCT03253497|Drug|Chlorobenzene Liquid|before induction will be used for oropharynx
119339|NCT03253484|Radiation|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
119340|NCT03253471|Drug|AL-611|AL-611 tablets
119341|NCT03253471|Drug|Placebo|Placebo to Match AL-611
119342|NCT03253458|Device|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, similar procedure as transperineal template guided mapping biopsies.
119343|NCT03253445|Behavioral|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
119344|NCT03253445|Other|Control|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
119345|NCT03253432|Other|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
119346|NCT03253419|Other|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
119347|NCT03253406|Behavioral|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
119348|NCT03253406|Behavioral|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
119349|NCT03253393|Device|Smart Touch Technology|hioxifilcon A contact lens in Smart Touch Technology Flat Pack (hydrogel) asmofilcon A contact lens in Smart Touch Technology Flat Pack (silicone hydrogel)
119350|NCT03253393|Device|Conventional lens packaging|hioxifilcon A contact lens in conventional lens packaging (hydrogel) asmofilcon A contact lens in conventional lens packaging (silicone hydrogel)
119351|NCT03253380|Other|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
119352|NCT03253367|Other|Blood is obtained, mostly during routine venipuncture|
119353|NCT03253354|Device|repetitive magnetic stimulation|Neurostimulation
119354|NCT03253341|Behavioral|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
119355|NCT03253341|Behavioral|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
119356|NCT03253328|Drug|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
119357|NCT03253328|Drug|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
119358|NCT03253289|Drug|Meclizine Oral Tablet|All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 21 days.
119359|NCT03253276|Drug|Obeticholic acid|Placebo-controlled
119360|NCT03253276|Drug|Placebos|
119361|NCT03253263|Drug|SHP607|Participants will receive intravenous infusion of SHP607 at doses of 250 mcg/kg/24 hours and 400 mcg/kg/24 hours from birth up to PMA 29 weeks + 6 days.
119362|NCT03253250|Drug|ETV；TDF；ADV|NAs
119363|NCT03253250|Drug|Peginterferon Alfa-2a|peginterferon
119364|NCT03253237|Device|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
119365|NCT03253224|Drug|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
119366|NCT03253224|Drug|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
119367|NCT03253198|Drug|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
119368|NCT03253198|Drug|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
119369|NCT03253185|Drug|SC-007|intravenous
119370|NCT03253172|Dietary Supplement|Potassium Chloride|Two potassium supplements with varying anions.
119371|NCT03253172|Dietary Supplement|Potassium Citrate|Potassium Citrate
119372|NCT03253172|Dietary Supplement|Placebo|Placebo
119373|NCT03253159|Behavioral|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
119374|NCT03253146|Diagnostic Test|VIM detection|VIM expression in serum and lymphocytes detection
119375|NCT03253133|Drug|Oxaliplatin|"Dose levels of Oxaliplatin:~4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1~Table 1: Dose levels~Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 * 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6~* Start level"
119376|NCT03253133|Drug|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
119377|NCT03253133|Drug|Oxycodone|Oxycodone
119378|NCT03253120|Other|Water|Patient/ Healthy volunteer will drink 5dl of Water
119379|NCT03253107|Drug|Chemotherapy|"Institutinal standard chemotherapy as first line~: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
119380|NCT03253094|Drug|Fluconazole|drug
119381|NCT03253094|Drug|SCY-078|drug
119382|NCT03253081|Behavioral|PARENT focused intervention|The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
119383|NCT03253081|Behavioral|CHILD focused intervention|The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
119384|NCT03253068|Drug|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
119385|NCT03253055|Radiation|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are ~8uSv and ~4uSv respectively.
119386|NCT03253055|Radiation|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
119426|NCT03252795|Procedure|uterus transplantation|transplantation of a uterus from a deceased donor
119387|NCT03253055|Other|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
119388|NCT03253055|Other|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
119389|NCT03253055|Other|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
119390|NCT03253055|Biological|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
119391|NCT03253055|Other|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
119392|NCT03253042|Other|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
119393|NCT03253042|Other|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
119394|NCT03253029|Dietary Supplement|Pure Encapsulations Branched Chain Amino Acid powder|
119395|NCT03253029|Dietary Supplement|control group (no BCAAs provided)|
119396|NCT03253016|Diagnostic Test|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
119397|NCT03253003|Device|Line extension of the Phonak Audéo B product family|The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
119398|NCT03252990|Diagnostic Test|PET-MRI|Additional 18F-choline PET-MRI examination
119399|NCT03252990|Procedure|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
119400|NCT03252977|Other|Tailored regimen of IV PCA according to pain sensitivity|In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
119401|NCT03252977|Other|Regimen of IV PCA without considering pain sensitivity|In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
119402|NCT03252964|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
119403|NCT03252964|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
119404|NCT03252964|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone, text messaging, and automated text messaging.
119405|NCT03252951|Behavioral|Eccentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
119406|NCT03252951|Behavioral|Concentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
119407|NCT03252951|Behavioral|Isometric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
119408|NCT03252951|Behavioral|Biofeedback|Standard of Care Biofeedback Training
119409|NCT03252938|Drug|IMP321|LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
119410|NCT03252938|Drug|Avelumab|Avelumab i.v.
119411|NCT03252925|Drug|N-Acetylcysteine|50mg/Kg.d, oral
119412|NCT03252925|Drug|Placebo Oral Tablet|50mg/Kg.d, oral
119413|NCT03252912|Biological|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
119414|NCT03252899|Other|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
119415|NCT03252899|Other|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
119416|NCT03252886|Procedure|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the Ambu-bagging during cardiopulmonary resuscitation
119417|NCT03252860|Other|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
119418|NCT03252847|Genetic|AAV-RPGR|Open label, non-randomised, dose-escalation intervention followed by randomised dose confirmation against a control arm
119419|NCT03252834|Diagnostic Test|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
119420|NCT03252821|Behavioral|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
119421|NCT03252821|Behavioral|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
119422|NCT03252808|Biological|TBI-1401(HF10)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
119423|NCT03252808|Drug|Gemcitabine|1000 mg/m^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
119424|NCT03252808|Drug|Nab-paclitaxel|125 mg/m^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
119425|NCT03252808|Drug|TS-1|TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
119428|NCT03252782|Device|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
119429|NCT03252769|Other|Self-sampling|
119430|NCT03252756|Other|Placebo|600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
119431|NCT03252756|Drug|Phytocannabinoid cannabidiol (CBD)|600mg CBD (PO) for 4 weeks, immediately followed by 1200mg CBD/ day (PO) for an additional 4 weeks (8 total weeks).
119432|NCT03252743|Behavioral|Exposure-based internet-delivered CBT|"The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises."
119433|NCT03252730|Other|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
119434|NCT03252717|Biological|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:~Three 6 ml EDTA samples for proteomic and genomic work package~One 6 ml dry sample for auto-antibodies analysis in the immunology work package~Two 4 ml EDTA samples for DNA extraction in the immunology work package~Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
119435|NCT03252704|Other|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
119436|NCT03252704|Other|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
119437|NCT03252678|Other|a book and videos about ACP|A book and three videos about advanced care planning are provided for self-education
119438|NCT03252678|Other|a book and videos about pain control|A book and three videos about pain control for cancer patients are provided for self-education
119439|NCT03252665|Drug|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
119440|NCT03252665|Drug|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
119441|NCT03252665|Drug|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
119442|NCT03252652|Radiation|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
119443|NCT03252639|Procedure|EVT for RAS & PBV acquisition protocol for target kidneys|
119444|NCT03252626|Drug|Alprostadil|"Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.~2ml Alprostadil injection added into 10ml 0.9% saline."
119445|NCT03252626|Drug|Normal saline|2ml normal saline injection added into 10ml 0.9% saline.
119446|NCT03252600|Drug|Cyclophosphamide|Given IV
119447|NCT03252600|Drug|Dexamethasone|Given IV
119448|NCT03252600|Biological|Elotuzumab|Given IV
119449|NCT03252600|Other|Laboratory Biomarker Analysis|Correlative studies
119450|NCT03252600|Drug|Lenalidomide|Given PO
119451|NCT03252600|Other|Pharmacological Study|Correlative studies
119452|NCT03252587|Drug|BMS-986165|administered orally
119453|NCT03252587|Other|Placebo|administered orally
119454|NCT03252574|Other|A|AIR+ Smart Mask Only
119455|NCT03252574|Other|B|AIR+ Smart Mask with micro-ventilator
119456|NCT03252561|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
119457|NCT03252561|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
119458|NCT03252535|Biological|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10^6 cells/kg body weight divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
119459|NCT03252535|Biological|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10^6 cells/kg body weight divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
119460|NCT03252535|Other|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
119461|NCT03252522|Combination Product|Broad Spectrum Micronutrients|60% of participants will take 3-4 capsules of broad spectrum micronutrients three times per day for eight weeks. Following the initial 8 weeks (of the RCT), all participants will have the option to participate in an open label extension, during which time the child would take the active micronutrient treatment for 8 weeks
119462|NCT03252522|Dietary Supplement|Placebo|40% of participants will take 3-4 capsules of inactive placebo three times per day for eight weeks.
119463|NCT03252509|Procedure|Percutaneous radiologic gastrostomy|Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
119464|NCT03252496|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
119465|NCT03252496|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
119466|NCT03252496|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
119467|NCT03252496|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
119468|NCT03252496|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
119469|NCT03252496|Drug|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
119470|NCT03252496|Drug|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
119471|NCT03252496|Drug|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
119472|NCT03252496|Drug|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
119473|NCT03252496|Drug|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
119474|NCT03252496|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
119475|NCT03252496|Drug|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
119476|NCT03252483|Other|Bundled HCV/HIV Screening|Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
119477|NCT03252483|Other|HIV Screening|Participants were randomized to an HIV-only screening group as a control comparator.
119478|NCT03252470|Procedure|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
119479|NCT03252457|Drug|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 3cycles
119480|NCT03252457|Drug|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle , If platelet count remained below 30 × 109/L or there were bleeding symptoms by day 10, an additional cycle of dexamethasone was given.
119481|NCT03252444|Other|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
119482|NCT03252444|Other|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
119483|NCT03252431|Drug|F-627|single dose pre-filled syringe
119484|NCT03252431|Drug|Neulasta|single dose pre-filled syringe
119485|NCT03252418|Drug|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
119486|NCT03252418|Device|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
119487|NCT03252405|Device|mask ventilation|before intravenous induction, mask application is made. then intravenous cannulation and induction
119488|NCT03252405|Device|intravenous cannulation|induction is applied by using intravenous cannulation
119489|NCT03252379|Procedure|hepaticojejunostomy|"Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall."
119490|NCT03252379|Procedure|modified hepaticojejunostomy with subcutaneous access loop|"In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place."
119491|NCT03252379|Procedure|modified hepaticojejunostomy with gastric access loop|"In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision."
119492|NCT03252366|Device|GELFOAM|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~A diamond bur will be used to make a rectangular osteotomy.~The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~Implant stability will be measured by osteal device~implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
119493|NCT03252366|Device|xenograft|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~A diamond bur will be used to make a rectangular osteotomy.~The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~Implant stability will be measured by osteal device~implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~The flap will then be closed using interrupted 4/0 resorbable sutures."
119494|NCT03252353|Drug|octreotide capsules|octreotide capsules 40mg/day, 60mg/day, 80 mg/day (individual dose titration)
119495|NCT03252353|Drug|Matching placebo|Matching placebo capsules
119496|NCT03252340|Drug|ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.~ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
119497|NCT03252327|Other|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
119498|NCT03252314|Device|Second-generation hydrogel coils|Hydrogel coils 90% by length
119499|NCT03252301|Device|PMD 200|finger sensor which estimate objectively the pain level
119500|NCT03252288|Behavioral|Reminders|Text of phone-call based reminders to mobile phones
119501|NCT03252288|Behavioral|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs >1 week but within 4 weeks of the scheduled visit
119502|NCT03252275|Other|Peer learning|Peer learning plus HBB and ECEB
119503|NCT03252262|Other|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
119504|NCT03252249|Other|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
119505|NCT03252249|Other|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
119506|NCT03252236|Behavioral|Tai Chi|Modified 12-form Yang style Tai Chi.
119507|NCT03252236|Behavioral|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
119508|NCT03252223|Drug|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
119509|NCT03252210|Procedure|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
119510|NCT03252197|Device|UGIJVC with needle guide device|Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
119511|NCT03252197|Device|UGIJVC without needle guide device|participants who are tested performance for ultrasound guided cannulation using conventional method.
119512|NCT03252184|Device|Low level laser therapy|The low level laser therapy will be performed with the CHATTANOOGA® equipment and the probe cluster (head) from the same manufacturer. For the interventions in groups 1, 2 and 3 (photobiostimulation) will be used, respectively, the energy doses of 2, 4 and 6J. A 670nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiostimulation) will be performed with the application of the device switched off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiostimulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser diode cluster probe will be placed in direct contact with the skin.
119513|NCT03252171|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
119514|NCT03252158|Behavioral|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.~Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2&3 and 5&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
119515|NCT03252145|Device|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
119516|NCT03252145|Other|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
119517|NCT03252132|Other|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
119518|NCT03252119|Device|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
119519|NCT03252106|Procedure|Contour augmentation with implant placement|Contour augmentation with implant placement
119520|NCT03252093|Drug|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
119521|NCT03252093|Drug|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
119522|NCT03252080|Behavioral|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
119523|NCT03252080|Behavioral|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
119524|NCT03252067|Drug|azithromycin eyedrop|Tear samples will be collected using the strips.
119525|NCT03252054|Diagnostic Test|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
119526|NCT03252041|Device|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
119527|NCT03252015|Drug|Probe Drug Cocktail|Administered orally
119528|NCT03252015|Drug|Lasmiditan|Administered orally
119529|NCT03252015|Drug|Placebo|Administered orally
119530|NCT03252002|Drug|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
119531|NCT03252002|Drug|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
119532|NCT03251976|Behavioral|video|informational video
119533|NCT03251976|Behavioral|usual care|usual physician counseling on end of life care
119534|NCT03251963|Drug|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
119535|NCT03251963|Drug|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
119536|NCT03251950|Behavioral|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
119537|NCT03251937|Device|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
119538|NCT03251924|Drug|BMS-986226|specified dose on specified days
119539|NCT03251924|Biological|Nivolumab|specified dose on specified days
119540|NCT03251924|Biological|Ipilimumab|specified dose on specified days
119541|NCT03251924|Biological|Tetanus Vaccine|specified dose on specified days
119542|NCT03251911|Drug|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
119543|NCT03251885|Other|swabs|Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
119544|NCT03251872|Drug|Olaparib|Olaparib tablets
119545|NCT03251859|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
119546|NCT03251859|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg daily
119547|NCT03251846|Device|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
119548|NCT03251820|Drug|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
119549|NCT03251807|Device|Twin-block|Functional treatment will be achieved using the Twinblock appliance
119550|NCT03251807|Other|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
119551|NCT03251794|Diagnostic Test|three dimensional ultrasound|evaluation of the suprarenal glands
119552|NCT03251794|Diagnostic Test|color Doppler|Doppler evaluation of the suprarenal artery
119553|NCT03251781|Other|Pulmonary Rehabilitation|Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
119554|NCT03251768|Drug|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
119555|NCT03251768|Drug|GCSF|GCSF 5 mcg/kg/day
119556|NCT03251755|Behavioral|Yoga|Exercise promotion using Chinese Yoga
119557|NCT03251742|Device|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
119558|NCT03251729|Procedure|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
119559|NCT03251729|Drug|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
119560|NCT03251716|Drug|berberine|berberine 300mg TID add-on for berberine adjunctive group
119561|NCT03251703|Procedure|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
120097|NCT03247660|Other|PFM training|See information included in arm/group descriptions.
119562|NCT03251690|Drug|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
119563|NCT03251690|Drug|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
119564|NCT03251677|Procedure|Surgical procedure, Hysterectomy|Surgical removal of the uterus
119565|NCT03251664|Dietary Supplement|Food groups consumed|
119566|NCT03251651|Drug|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
119567|NCT03251651|Drug|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
119568|NCT03251625|Drug|Probiotic Formula Capsule|
119569|NCT03251612|Drug|Based on sensitivity analysis|"5FU, infusional~Capecitabine~Oxaliplatin (FOLFOX)~Irinotecan (FOLFIRI)~FOLFOXIRI (triplet)~Bevacizumab~Panitumumab~Cetuximab~Regorafenib~Tas-102~Ramucirumab~Aflibercept~Pembrolizumab~Nivolumab~Vinorelbine and capecitabine~Sorafenib~Gemcitabine and capecitabine~Olaparib~Epirubicin"
119570|NCT03251599|Drug|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
119571|NCT03251599|Drug|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
119572|NCT03251586|Diagnostic Test|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
119573|NCT03251586|Diagnostic Test|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
119574|NCT03251573|Other|cognitive impairment|one are of patients were exposed to cognitive impairment
119575|NCT03251560|Drug|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
119576|NCT03251560|Drug|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
119577|NCT03251547|Drug|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
119578|NCT03251534|Procedure|Centromedullary nailing|
119579|NCT03251521|Other|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
119580|NCT03251508|Drug|Peanut OIT|Participants will be given increasing doses of the peanut oral immunotherapy (OIT) study drug every 2 weeks for 3 months up to the 300 mg maintenance dose and will maintain this dose for 3 months. Subjects will then switch to a food equivalent that contains 300 mg of peanut protein for an additional 6 months.
119581|NCT03251495|Drug|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
119582|NCT03251482|Drug|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.
119583|NCT03251482|Drug|JNJ-64179375 0.6 mg/kg|JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
119584|NCT03251482|Drug|JNJ-64179375 1.2 mg/kg|JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
119585|NCT03251482|Drug|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
119586|NCT03251482|Drug|JNJ-64179375 A mg/kg|JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
119587|NCT03251482|Drug|JNJ-64179375 B mg/kg|JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
119588|NCT03251482|Drug|JNJ-64179375 C mg/kg|JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
119589|NCT03251482|Drug|JNJ-64179375 D mg/kg|JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
119590|NCT03251482|Drug|Placebo JNJ-64179375|Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
119591|NCT03251482|Drug|Apixaban placebo|Matching apixaban placebo administered orally twice a day for 10 to 14 days.
119592|NCT03251482|Drug|Apixaban 2.5 mg|Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
119593|NCT03251469|Drug|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
119594|NCT03251469|Drug|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
119595|NCT03251456|Other|Tertiary care|"Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders~The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines~Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
119596|NCT03251456|Other|Usual Care|"Inform the parents that there are abnormalities after eye disease screening of their children~Inform the parents that they should take their children to the hospital for further consultation~Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
119597|NCT03251443|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
119598|NCT03251430|Procedure|gastrectomy|Distal gastrectomy, Total gastrectomy
119599|NCT03251417|Drug|Irinotecan|Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
119600|NCT03251417|Drug|Apatinib|Apatinib 500 mg oral take, daily
119601|NCT03251404|Other|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
119602|NCT03251391|Other|Cardiac Rehabilitation Program|"Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.~Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information."
119603|NCT03251391|Other|Conventional Therapy|Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
119604|NCT03251378|Drug|Fruquintinib (HMPL-013)|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.
119605|NCT03251365|Drug|HIPEC-gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
119606|NCT03251339|Drug|MSB11455|Participants received a single subcutaneous injection of MSB11455 6 milligram (mg) per (/) 0.6 milliliter (mL) on Day 1 in morning of treatment period 1 (28 Days) and 2 (28 Days). Period 1 and Period 2 are separated by a washout period of 35 Days.
119607|NCT03251339|Drug|US-Neulasta|Participants received a single subcutaneous injection of US-Neulasta 6 mg/0.6 mL on Day 1 in morning of treatment period 1 and 2. Period 1 and Period 2 are separated by a washout period of 35 Days.
119608|NCT03251326|Drug|Nabilone|Nabilone capsules (4 mg)
119609|NCT03251326|Drug|Cannabis|Cigarettes (0.0 and 5.6% THC)
119610|NCT03251326|Drug|Propranolol|Propranolol capsules (40mg)
119611|NCT03251326|Drug|Placebo|Placebo capsules
119612|NCT03251313|Combination Product|JS001 120mg+GP|In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
119613|NCT03251313|Combination Product|JS001 240mg+GP|In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
119614|NCT03251313|Combination Product|JS001 480mg+GP|In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
119615|NCT03251313|Combination Product|GP followed by JS001|In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
119616|NCT03251300|Drug|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
119617|NCT03251300|Drug|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
119618|NCT03251287|Drug|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
119619|NCT03251287|Drug|Placebo|Single dose of oral matching placebo
119620|NCT03251287|Diagnostic Test|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
119621|NCT03251287|Diagnostic Test|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
119622|NCT03251274|Other|machine bathing|machine bathing 20-min duration at evening
119623|NCT03251274|Other|traditional bathing|traditional bathing
119624|NCT03251261|Device|illumigene CMV assay, illumipro-10|CMV assay for detection of CMV
119625|NCT03251248|Drug|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
119626|NCT03251248|Drug|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
119627|NCT03251235|Behavioral|Cognitive Behaviour Therapy|
119628|NCT03251222|Drug|Dexmedetomidine|Intranasal aplication of dexmedetomidine
119629|NCT03251222|Other|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
119630|NCT03251209|Other|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
119631|NCT03251209|Other|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
119632|NCT03251209|Other|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
119633|NCT03251196|Other|No Intervention, and Observational Study|Observational Study
119634|NCT03251183|Diagnostic Test|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
119668|NCT03250910|Drug|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
119635|NCT03251183|Diagnostic Test|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
119636|NCT03251183|Diagnostic Test|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
119637|NCT03251183|Diagnostic Test|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
119638|NCT03251183|Diagnostic Test|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).~A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
119639|NCT03251170|Drug|Ketamine|Patients will receive :1 mg/Kg ketamine for induction of anesthesia
119640|NCT03251170|Drug|Fentanyl|Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
119641|NCT03251170|Drug|Midazolam|Patients will receive 0.05 mg/Kg midazolam
119642|NCT03251157|Other|Dietary intake of various nutrients, foods and biocompounds|Participants answered a self-administered FFQ, in which they reported the usual frequency of intake of a list of 250 food items
119643|NCT03251144|Drug|Switch to E/C/FTC/TAF daily|"If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.~b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
119644|NCT03251131|Other|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
119645|NCT03251105|Device|supraglottic airway intubation|
119646|NCT03251092|Drug|PTI-808|Active
119647|NCT03251092|Drug|Placebo|Placebo
119648|NCT03251092|Drug|PTI-428|Active
119649|NCT03251092|Drug|PTI-801|Active
119650|NCT03251066|Other|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
119651|NCT03251053|Device|Electronic cigarette use|Replacement of tobacco smoking with electronic cigarette vaping
119652|NCT03251053|Other|Control regular cigarette smokers|
119653|NCT03251040|Device|Autologous activated fibrin sealant|Application of fibrin sealant
119654|NCT03251027|Radiation|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
119655|NCT03251027|Other|Quality-of-Life|Ancillary studies
119656|NCT03251014|Other|YSS|Intervention providing steamed whole YSS (~265 g/day, 3 days/week) for eight weeks
119657|NCT03251014|Other|Salmon|Intervention providing steamed salmon fillet (~246 g/day, 3 days/week) for eight weeks
119658|NCT03251001|Procedure|Control|Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
119659|NCT03251001|Device|Acellular Dermal Matrix|Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
119660|NCT03250988|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
119661|NCT03250975|Drug|Budesonide and Azithromycin|Participant with acute laryngeal injury will be randomized at discharge to either a non-drug placebo control group or a medical therapy group consisting of azithromycin 250 mg and budesonide 0.5 mg for 14 days.
119662|NCT03250975|Other|Placebo control of budesonide and azithromycin|placebos of the medications will be given for 14 days in patients randomized to the control group
119663|NCT03250962|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
119664|NCT03250962|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
119665|NCT03250949|Procedure|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.~osteotomy site of the implant is wider by 0.2mm than the implant diameter"
119666|NCT03250923|Drug|silver citrate complex and acemannan|Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
119667|NCT03250910|Drug|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
119669|NCT03250871|Other|Support of patients during their surgery|"Support of patients is different. Patients in arm Placebo are supported by a nurse. Hypsnosis will be supervised by a nurse trained by the French Institute of Hypnosis."
119670|NCT03250858|Behavioral|Personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
119671|NCT03250858|Behavioral|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
119672|NCT03250832|Drug|TSR-033|TSR-033 is a humanized monoclonal antibody (IgG4)
119673|NCT03250832|Drug|Anti-PD-1|PD-1 is an IgG4 antibody
119674|NCT03250819|Other|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
119675|NCT03250793|Device|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
119676|NCT03250780|Procedure|indigo-carmine 0.2% using a spray catheter|
119677|NCT03250780|Procedure|0.03% using a foot pump|
119678|NCT03250767|Device|Integra Titan Modular Shoulder System 2.5|Primary Shoulder Joint Replacement
119679|NCT03250754|Device|Electroacupuncture|Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
119680|NCT03250741|Drug|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
119681|NCT03250741|Other|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
119682|NCT03250728|Biological|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium~On the EPCs we will study:~the endothelial permeability~the protein C system"
119683|NCT03250715|Other|Low Level Laser Therapy|For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
119684|NCT03250689|Drug|Danirixin|Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
119685|NCT03250689|Drug|Placebo|Placebo will be available as oval shaped, white film coated tablets.
119686|NCT03250689|Drug|Rescue medication|Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
119687|NCT03250689|Drug|Inhaled COPD maintenance medication|Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist [LAMA], long-acting beta-agonist [LABA]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
119688|NCT03250676|Drug|H3B-6545|Oral capsules by mouth once daily
119689|NCT03250663|Behavioral|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
119690|NCT03250663|Drug|EUCRISA|Participants are given EUCRISA (crisaborole) ointment 2%.
119691|NCT03250650|Device|TTNS|Transcutaneous tibial electric stimulation
119692|NCT03250650|Device|ES+TTNS|Transvaginal electric stimulation
119693|NCT03250637|Other|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
119694|NCT03250624|Drug|CD 5024 0.3% cream|Up to 4g daily, once a day, 7 days a week for 6 weeks
119695|NCT03250624|Drug|CD 5024 cream placebo|Up to 4g daily, once a day, 7 days a week for 6 weeks
119696|NCT03250611|Procedure|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
119697|NCT03250598|Drug|AG-348|50 mg single-dose
119698|NCT03250598|Drug|AG-348|5 mg single-dose
119699|NCT03250598|Drug|AG-348|200 mg single-dose
119700|NCT03250585|Diagnostic Test|Exhaled Breath Condensate (EBC)|Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
119701|NCT03250585|Diagnostic Test|Plasma Sample|Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
119702|NCT03250572|Diagnostic Test|serum ferritin|serum samples and ferritin ELISA test
119703|NCT03250559|Procedure|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
119704|NCT03250546|Procedure|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
119705|NCT03250546|Procedure|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
120098|NCT03247660|Other|HE|See information included in arm/group descriptions.
119706|NCT03250533|Device|Light emitting diodes (LED)|The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
119707|NCT03250533|Device|Fixed diphasic current|The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
119708|NCT03250520|Drug|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
119709|NCT03250507|Drug|Bupivacaine|0.25% bupivacaine for TAP block
119710|NCT03250507|Drug|Liposomal bupivacaine|Exparel for TAP block
119711|NCT03250507|Drug|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
119712|NCT03250494|Drug|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
119713|NCT03250494|Drug|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
119714|NCT03250494|Drug|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
119715|NCT03250481|Drug|Propofol|Sedation targeted to RASS -3-0 or RI 20-40
119716|NCT03250468|Behavioral|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
119717|NCT03250455|Diagnostic Test|CTA CTP|CT Angiography myocardial CT Perfusion
119718|NCT03250455|Diagnostic Test|CTA|CT Angiography
119719|NCT03250442|Device|PrevenaTM Device|The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
119720|NCT03250442|Other|Standard Dry Dressing|These are customary dry dressings.
119721|NCT03250429|Procedure|Sinus surgery|Standard Clinical Sinus Surgery
119722|NCT03250403|Drug|PRP injection|peri-neural injection of platelet rich plasma
119723|NCT03250403|Other|traditional medical treatment|traditional medical treatment
119724|NCT03250390|Device|Collection of volatile organic compounds during exhalation|"The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.~The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)"
119725|NCT03250377|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablet~Concentration: 25 mg and 50 mg~Route of administration: Oral use"
119726|NCT03250364|Device|Multilayer bandage|See arm/group descriptions
119727|NCT03250364|Device|Double compression bandage|See arm/group descriptions
119728|NCT03250364|Device|Cohesive bandage|See arm/group descriptions
119729|NCT03250364|Device|Adhesive compression bandage|See arm/group descriptions
119730|NCT03250364|Device|Kinesiotaping bandage|See arm/group descriptions
119731|NCT03250364|Other|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
119732|NCT03250364|Other|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
119733|NCT03250364|Behavioral|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
119734|NCT03250351|Other|Neurodynamic techniques|See arm/group descriptions
119735|NCT03250351|Other|Early physical therapy plus educational strategy|See arm/group descriptions
119736|NCT03250338|Drug|Crenolanib|Crenolanib will be administered orally
119737|NCT03250338|Drug|Cytarabine|"HAM regimen~FLAG-Ida"
119738|NCT03250338|Drug|Mitoxantrone|HAM regimen
119739|NCT03250338|Drug|Placebo Oral Tablet|Placebo will be administered orally
119740|NCT03250338|Drug|Fludarabine|FLAG-Ida regimen
119741|NCT03250338|Drug|Idarubicin|FLAG-Ida regimen
119742|NCT03250338|Drug|G-CSF|FLAG-Ida regimen
119743|NCT03250325|Biological|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
119744|NCT03250325|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
119745|NCT03250312|Other|The Osteopathic Manipulation|The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
119746|NCT03250299|Drug|Microtubule-Targeted Agent BAL101553|Given PO
119747|NCT03250299|Radiation|Radiation Therapy|Undergo radiation therapy
119748|NCT03250299|Other|Laboratory Biomarker Analysis|Correlative studies
119749|NCT03250299|Other|Pharmacological Study|Correlative studies
119750|NCT03250286|Device|EUS|"Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.~EUS examination is performed first, and if there is choledocholith, ERCP is performed."
119751|NCT03250286|Device|ERCP|"Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.~In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.~In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP."
119752|NCT03250273|Drug|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
119753|NCT03250273|Drug|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
119754|NCT03250273|Drug|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
119755|NCT03250273|Drug|Nivolumab|After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
119756|NCT03250260|Other|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
119757|NCT03250260|Other|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
119758|NCT03250247|Device|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.~Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.~The use of devices > 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.~Balloon angioplasty of inflow veins.~After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.~Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
119759|NCT03250234|Other|Adequate Carbohydrate|During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
119760|NCT03250234|Other|Low Carbohydrate|"During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.~For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion"
119761|NCT03250221|Device|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
119762|NCT03250221|Device|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
119763|NCT03250208|Dietary Supplement|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
119764|NCT03250208|Other|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
119765|NCT03250195|Diagnostic Test|PET/MRI|PET/MRI scan
119766|NCT03250182|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
119767|NCT03250169|Drug|Alemtuzumab|Licensed dose
119768|NCT03250156|Behavioral|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
119769|NCT03250156|Behavioral|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
119770|NCT03250143|Drug|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
119771|NCT03250130|Behavioral|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
119772|NCT03250117|Drug|Ropinirole oral product|oral immediate-release ropinirole
119773|NCT03250117|Drug|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
119805|NCT03249857|Behavioral|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
120099|NCT03247660|Behavioral|Educational strategy|See information included in arm/group descriptions.
119774|NCT03250104|Other|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
119775|NCT03250104|Other|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
119776|NCT03250091|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
119777|NCT03250091|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
119778|NCT03250091|Procedure|Biopsies for gastric microbiota|During upper endoscopy biopsies for gastric microbiota analysis will be obtained
119779|NCT03250091|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
119780|NCT03250078|Diagnostic Test|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
119781|NCT03250065|Device|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
119782|NCT03250052|Drug|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
119783|NCT03250052|Drug|(fimasartan and linagliptin) x 7days|Part A & Part B: Co-administration of fimasartan and linagliptin
119784|NCT03250039|Drug|PF-04965842|14C labeled PF-04965842
119785|NCT03250039|Drug|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
119786|NCT03250026|Behavioral|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
119787|NCT03250026|Behavioral|Care Manager|Regular contact Care Manager during around 12 weeks
119788|NCT03250013|Drug|ADHD medications|
119789|NCT03249987|Other|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
119790|NCT03249974|Device|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
119791|NCT03249961|Device|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
119792|NCT03249961|Device|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
119793|NCT03249961|Device|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
119794|NCT03249948|Procedure|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
119795|NCT03249948|Procedure|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
119796|NCT03249935|Drug|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
119797|NCT03249922|Device|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
119798|NCT03249909|Device|Exufiber Ag +|Gelling Fiber Dressing with Ag
119799|NCT03249909|Device|Exufiber|Gelling Fiber Dressing without Ag
119800|NCT03249909|Device|Aquacel Ag Extra|Gelling Fiber Dressing with Ag
119801|NCT03249896|Behavioral|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
119802|NCT03249883|Device|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.~In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
119803|NCT03249870|Drug|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:~First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15~Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
119804|NCT03249857|Behavioral|cognitive tasks + IQ + MINI|"Patients will perform different tasks:~cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).~Intelligence Quotient (IQ) test (PM38, Raven, 1960)~Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
120140|NCT03247361|Other|High-intensity IMT + Aerobic/resistance exercise|High-intensity IMT
119806|NCT03249844|Drug|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 6-week course of tapering Prednisolone given at a daily single oral dose in the morning:~week 1, oral Prednisolone 2 mg/kg/day (max 60 mg/day),~week 2, oral Prednisolone 1.5 mg/kg/day (max 50 mg/day),~week 3, oral Prednisolone 1 mg/kg/day (max 40 mg/day),~week 4, oral Prednisolone 0.75 mg/kg/day (max 30 mg/day),~followed by a further taper over 2 weeks."
119807|NCT03249831|Drug|Cyclophosphamide|Orally daily
119808|NCT03249831|Drug|Pentostatin|Intravenous
119809|NCT03249831|Drug|Rabbit anti-thymocyte globulin|Intravenous
119810|NCT03249831|Drug|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
119811|NCT03249831|Drug|Mycophenolate mofetil|IV or oral
119812|NCT03249831|Biological|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
119813|NCT03249818|Device|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
119814|NCT03249805|Device|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
119815|NCT03249805|Device|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
119816|NCT03249792|Drug|MK-2118 (IT)|IT injection
119817|NCT03249792|Drug|MK-2118 (SC)|SC injection
119818|NCT03249792|Biological|Pembrolizumab|IV infusion
119819|NCT03249779|Device|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
119820|NCT03249766|Other|Observational|Observational study
119821|NCT03249753|Drug|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
119822|NCT03249753|Drug|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
119823|NCT03249740|Drug|GB-102|Intravitreal injection of GB-102
119824|NCT03249740|Drug|Aflibercept|Intravitreal injection of Aflibercept.
119825|NCT03249727|Diagnostic Test|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (up to 4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
119826|NCT03249714|Drug|Ofatumumab subcutaneous injection|Patients randomized to the ofatumumab arm will receive subcutaneous injections of ofatumumab every 4 weeks
119827|NCT03249714|Drug|Placebo subcutaneous injection matching ofatumumab|Patients randomized to the placebo arm will receive subcutaneous injections of placebo every 4 weeks
119828|NCT03249701|Device|Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
119829|NCT03249701|Device|Electroacupuncture|The intervention will be administered by electrical acupoint machine, the brand is Great Wall.
119830|NCT03249701|Device|sham Transcutaneous Electrical Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
119831|NCT03249688|Other|Regular health advice|Routine healthy lifestyle counseling
119832|NCT03249688|Behavioral|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
119833|NCT03249688|Dietary Supplement|Medical food|Medical food product (Fortasyn Connect)
119834|NCT03249662|Procedure|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
119835|NCT03249662|Drug|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
119836|NCT03249649|Behavioral|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
119837|NCT03249636|Diagnostic Test|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
119869|NCT03249428|Device|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
119870|NCT03249402|Drug|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
119838|NCT03249623|Device|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
119839|NCT03249610|Behavioral|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
119840|NCT03249597|Diagnostic Test|Blood test: Glukos, SuPAR, Laktat and HBP|"Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP."
119841|NCT03249584|Device|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and benign bone tumors such as osteoid osteomas.
119842|NCT03249571|Dietary Supplement|Flavonoid supplement|2-weeks ingestion of flavonoid supplement
119843|NCT03249571|Dietary Supplement|Placebo|2-week ingestion of placebo supplement
119844|NCT03249558|Drug|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
119845|NCT03249558|Drug|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
119846|NCT03249558|Drug|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
119847|NCT03249532|Device|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
119848|NCT03249532|Device|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
119849|NCT03249532|Device|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
119850|NCT03249532|Device|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
119851|NCT03249519|Radiation|Radiation|50.4 Gy
119852|NCT03249519|Radiation|brachytherapy|35-40 Gy
119853|NCT03249519|Drug|Cisplatin|weekly 40 mg/m^2 (6cycles)
119854|NCT03249519|Other|Hyperthermia|10 times
119855|NCT03249506|Drug|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
119856|NCT03249506|Drug|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
119857|NCT03249506|Drug|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
119858|NCT03249506|Drug|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
119859|NCT03249506|Drug|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
119860|NCT03249506|Drug|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
119861|NCT03249506|Drug|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
119862|NCT03249506|Drug|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
119863|NCT03249493|Other|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.~HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results > 1000 cp/mL"
119864|NCT03249480|Biological|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
119865|NCT03249454|Device|Anodal tsDCS|During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
119866|NCT03249454|Device|Cathodal tsDCS|During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
119867|NCT03249454|Device|Sham tsDCS|During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
119868|NCT03249441|Behavioral|Compassion-focused therapy|"Session-by-session summary of CFT:~Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.~__________________________________________________________________________"
119871|NCT03249402|Drug|JNJ‑42847922|Participants will receive 40 mg of JNJ‑42847922 once daily on Days 14 to 21 in cycle 2.
119872|NCT03249389|Biological|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
119873|NCT03249376|Drug|Lumateperone|Lumateperone (ITI-007 60 mg)
119874|NCT03249376|Other|Placebo|Placebo
119875|NCT03249363|Procedure|Group A - Pulsed PVP-I Irrigation|
119876|NCT03249350|Behavioral|Standard Contingency Management (CM)|"CM utilizes behavior modification & cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
119877|NCT03249350|Behavioral|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
119878|NCT03249337|Drug|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
119879|NCT03249324|Behavioral|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
119880|NCT03249324|Other|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
119881|NCT03249311|Drug|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
119882|NCT03249311|Drug|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
119883|NCT03249311|Drug|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
119884|NCT03249298|Drug|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
119885|NCT03249298|Drug|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
119886|NCT03249285|Drug|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
119887|NCT03249285|Drug|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
119888|NCT03249272|Drug|Regadenoson|The coronary flow reserve measured by CMR that is induced by regadenoson versus adenosine will be compared.
119889|NCT03249272|Drug|Adenosine|The coronary flow reserve measured by CMR that is induced by regadenoson versus adenosine will be compared.
119890|NCT03249259|Drug|Choline alfoscerate|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
119891|NCT03249259|Drug|Placebo|Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
119892|NCT03249246|Other|No intervention|
119893|NCT03249233|Device|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
119894|NCT03249233|Device|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
119895|NCT03249220|Device|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
119896|NCT03249207|Drug|IL-1Ra|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
119897|NCT03249207|Drug|IL-1Ra Placebo|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
119956|NCT03248752|Behavioral|Fitbit use and reports|Participants will receive a Fitbit device to be used for the duration of the study. Participants will engage with the Fitbit and application and receive Weekly Progress Reports from Fitbit.
120141|NCT03247361|Other|Low-intensity IMT + Aerobic/resistance exercise|Low-intensity IMT
119898|NCT03249194|Drug|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
119899|NCT03249181|Drug|Dolutegravir|Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
119900|NCT03249181|Drug|Standard of Care (EFV + 2 NRTI backbone)|Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
119901|NCT03249168|Drug|Duloxetine 60mg|tablet
119902|NCT03249168|Drug|Placebo|Tablet
119903|NCT03249155|Behavioral|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example)
119904|NCT03249155|Behavioral|CUE - visual and auditory|patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
119905|NCT03249142|Drug|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
119906|NCT03249142|Drug|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)~ADJUVANT :~If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.~If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
119907|NCT03249116|Other|animal-assisted intervention|Interaction with a therapy dog
119908|NCT03249116|Other|active control|Interaction with a stuffed dog
119909|NCT03249103|Drug|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
119910|NCT03249103|Drug|Placebo oral capsule|Matching placebo capsules.
119911|NCT03249090|Other|Patient Self-Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do so online or via an automated telephone system. Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit and will be given to the oncologist and nurse caring for the patient."
119912|NCT03249090|Other|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
119913|NCT03249077|Behavioral|DPP enrolled|The online DPP program is 12 months in duration with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months. The DPP in-person program is 12 months and consist of weekly sessions for the first 6 months and monthly sessions for the remaining 6 months.
119914|NCT03249064|Diagnostic Test|CD 91 levels|
119915|NCT03249064|Diagnostic Test|Tregs|
119916|NCT03249051|Other|Indirect Calorimetry|Energy need is being determined using indirect Calorimetry
119917|NCT03249038|Other|Measurement of external blood loss|
119918|NCT03249038|Diagnostic Test|Serum Hemoglobin concentration|
119919|NCT03249025|Drug|Lidocaine|Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
119920|NCT03249025|Drug|Ketamine|initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
119921|NCT03249012|Other|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
119922|NCT03249012|Other|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
119923|NCT03248999|Diagnostic Test|rectal swab|stool samples by rectal swab
119924|NCT03248986|Other|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
119925|NCT03248973|Drug|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
119926|NCT03248960|Diagnostic Test|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
119927|NCT03248960|Diagnostic Test|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
120089|NCT03247712|Radiation|Radiation (3 days)|8Gy x 3 (Monday, Wednesday, Friday) GTV+3mm
119928|NCT03248960|Diagnostic Test|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
119929|NCT03248960|Diagnostic Test|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
119930|NCT03248947|Drug|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
119931|NCT03248947|Other|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
119932|NCT03248934|Other|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
119933|NCT03248934|Other|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
119934|NCT03248921|Procedure|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
119935|NCT03248908|Diagnostic Test|Pupillary dilation reflex|Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
119936|NCT03248908|Other|Standard of care|Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
119937|NCT03248895|Device|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
119938|NCT03248882|Drug|Placebo|Placebo
119939|NCT03248882|Drug|PF-05221304|PF-05221304, Experimental Drug
119940|NCT03248869|Other|Current Daily Survey|need description
119941|NCT03248869|Other|Mobile Health App|Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
119942|NCT03248856|Drug|Triamcinolone Acetonide|Intratympanic administration
119943|NCT03248843|Drug|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
119944|NCT03248830|Device|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
119945|NCT03248817|Drug|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
119946|NCT03248817|Drug|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
119947|NCT03248817|Drug|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
119948|NCT03248817|Drug|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
119949|NCT03248804|Behavioral|Soy group|
119950|NCT03248804|Behavioral|Non-soy group|
119951|NCT03248791|Drug|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
119952|NCT03248791|Drug|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
119953|NCT03248791|Drug|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
119954|NCT03248778|Behavioral|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
119955|NCT03248765|Other|post-surgical opioid use measured at 1 day and 1 week.|"Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).~2) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit )."
120090|NCT03247699|Other|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
119957|NCT03248752|Behavioral|Partner engagement|Participants will be connected with their partner in the Fitbit app and therefore have the ability to access their partner's progress. Participants' Weekly Progress Reports will be automatically forwarded to their partner. Participants will engage in a weekly discussion on the topic of their Weekly Progress Reports.
119958|NCT03248739|Device|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
119959|NCT03248739|Device|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
119960|NCT03248726|Drug|Polyethylene glycol and bisacodyl|Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
119961|NCT03248726|Drug|Split-dose polyethylene glycol|Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
119962|NCT03248713|Drug|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
119963|NCT03248713|Drug|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
119964|NCT03248700|Other|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
119965|NCT03248687|Other|Follow up|The intervention will be method of follow up.
119966|NCT03248674|Diagnostic Test|CT FFR|CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
119967|NCT03248661|Behavioral|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
119968|NCT03248648|Drug|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
119969|NCT03248648|Drug|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
119970|NCT03248609|Other|Milano grapes|Milano grapes to test post-prandial glycemic response
119971|NCT03248609|Other|Table grapes|Table grapes to test post-prandial glycemic response
119972|NCT03248609|Other|Grape juice|Grape juice to test post-prandial glycemic response
119973|NCT03248609|Other|Glucose beverage|Standardized glucose beverage to test post-prandial glycemic response
119974|NCT03248583|Other|Default option|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).~Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections."
119975|NCT03248583|Other|Psychoeducation|"Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
119976|NCT03248583|Other|Incentive|Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
119977|NCT03248570|Drug|Pembrolizumab|All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
119978|NCT03248570|Drug|Chemotherapy|At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
119979|NCT03248557|Diagnostic Test|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
119980|NCT03248544|Drug|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
119981|NCT03248544|Other|control|No intervention
119982|NCT03248531|Drug|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
119983|NCT03248531|Drug|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
119984|NCT03248531|Other|Placebo|Placebo will be provided matching Bimekizumab.
119985|NCT03248518|Behavioral|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
119986|NCT03248518|Behavioral|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
119987|NCT03248518|Behavioral|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
119988|NCT03248505|Device|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
120142|NCT03247361|Other|Sham IMT + Aerobic/resistance exercise|Aerobic and resistance exercise
119989|NCT03248505|Device|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
119990|NCT03248505|Other|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
119991|NCT03248505|Device|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
119992|NCT03248505|Device|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
119993|NCT03248505|Other|Placebo TENS|TENS device turned on, but with zero amplitude.
119994|NCT03248492|Drug|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
119995|NCT03248479|Drug|Hu5F9-G4|Hu5F9-G4 will be administered up to twice weekly.
119996|NCT03248479|Drug|Azacitidine|Azacitidine will be administered daily for 7 days in each 28-day cycle.
119997|NCT03248466|Biological|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
119998|NCT03248453|Other|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
119999|NCT03248440|Drug|SUN-131 1.5% TDS|SUN-131 1.5% TDS will be worn for 14 days
120000|NCT03248440|Drug|Placebo TDS|No active substance; Placebo TDS will be worn each day for 14 days
120001|NCT03248427|Drug|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
120002|NCT03248427|Drug|Letrozole 2.5mg|Daily continuous
120003|NCT03248427|Drug|Doxorubicin|60 mg/m2 as a continuous IV perfusion
120004|NCT03248427|Drug|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
120005|NCT03248427|Drug|Paclitaxel|80 mg/m2, in one hour IV infusion
120006|NCT03248414|Dietary Supplement|Lactobacillus sakei|1 pack contained 5 x 109 cfu
120007|NCT03248401|Drug|Cilostazol|Cilostazol 200 mg/day
120008|NCT03248401|Drug|Aspirin|Aspirin 100 mg/day
120009|NCT03248388|Device|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
120010|NCT03248388|Device|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
120011|NCT03248375|Radiation|Radiation Segmentectomy|The administration of radioactivity in a branch of an artery of the liver
120012|NCT03248362|Device|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
120013|NCT03248362|Device|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
120014|NCT03248349|Drug|Pharmacokinetics|"Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment~Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)~Whole blood is stored for DNA analysis~Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis"
120015|NCT03248336|Procedure|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
120016|NCT03248323|Radiation|dyna-pbv|
120017|NCT03248310|Behavioral|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
120018|NCT03248297|Drug|Azithromycin|Azithromycin tablet
120019|NCT03248297|Drug|Azithromycin and amoxicillin|azithromycin and amoxicillin
120020|NCT03248297|Drug|Placebo|Placebo tablet
120021|NCT03248284|Procedure|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
120022|NCT03248271|Drug|Insulin Lispro|Insulin
120023|NCT03248258|Other|Qualitative Interview and Focus group discussions|The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.
120024|NCT03248245|Other|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
120025|NCT03248245|Other|TAU|Ordinary practices related to interprofessional team collaboration
120026|NCT03248206|Behavioral|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
120091|NCT03247699|Other|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
120027|NCT03248193|Device|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.~Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.~Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.~Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
120028|NCT03248193|Device|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.~Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.~Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
120029|NCT03248167|Drug|Cannabidiol|600 mg daily
120030|NCT03248167|Drug|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be adminstred to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
120031|NCT03248154|Device|Procellera|burn dressing
120032|NCT03248141|Drug|Hemophilia B standard half-life|Benefix
120033|NCT03248141|Drug|Hemophilia B extended half-life|Alprolix
120034|NCT03248141|Drug|Hemophilia A standard half-life|Xyntha and other standard half-life agents
120035|NCT03248141|Drug|Hemophilia A extended half-life|Eloctate and Adynovate
120036|NCT03248128|Drug|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
120037|NCT03248128|Drug|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
120038|NCT03248115|Dietary Supplement|Green tea and green coffee extract tablets|"Tablets: participants were required to take 6 green tea and 3 green coffee extract tablets daily for a period of 8 weeks. No tablets were taken during the last 4 weeks of the study. Randomly chosen tablets were analysed to quantify their polyphenol content.~Urine collections: Several urine collections were required during the supplementation period in order have sufficient time points to estimate the plateau of the concentration of green tea and coffee polyphenols excreted in the urine to then be able to determine their bioavailability. There was a total of five 24-hour urine collections (at week 0 -before supplementation-, 2, 4, 8, and 12 -4 weeks after finishing the supplementation period).~Completion of study documents: Participants were provided with urine collection sheets, polyphenol questionnaires, checklists to record polyphenol tablet intake, and detailed instructions."
120039|NCT03248102|Diagnostic Test|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
120040|NCT03248089|Diagnostic Test|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
120041|NCT03248076|Drug|Fentanyl Citrate|1γ/Kg fentanyl
120042|NCT03248063|Drug|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 4 or 6 hours, without doing less than the minimum daily dose of 8 g/day and without exceeding the maximum daily dose of 12 g/day, administered as a 60-minutes infusion. This treatment will be administered for at least 7 days by intravenous route.~Dosing regimen will be adapted in patients with chronic renal failure (glomerular filtration rate below 30ml/min/1.73m²) and in patient with impaired hepatic function associated with renal impairment whatever the level of the estimation of the glomerular filtration rate, according to SPC."
120043|NCT03248063|Drug|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC. As currently recommended, investigators will be encouraged to use the intravenous route for the entire duration of treatment. However, in order to interfere as little as possible with usual practice in each center, the antimicrobial therapy will be let to the choice of the physician in charge of the patient after a minimum of 7 days of intravenous treatment.
120044|NCT03248050|Behavioral|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
120045|NCT03248037|Drug|Netarsudil|netarsudil opthalmic solution 0.02%
120046|NCT03248037|Drug|Placebo|Placebo eye drops
120047|NCT03248011|Other|Stretching|Lower extremity flexibility exercises will be performed
120048|NCT03248011|Other|Strengthening|Eccentric hamstring strengthening exercises will be performed
120049|NCT03248011|Other|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
120050|NCT03247998|Drug|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
120092|NCT03247686|Drug|RSLV-132|RNase Fc fusion protein
120051|NCT03247998|Drug|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
120052|NCT03247985|Device|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
120053|NCT03247985|Device|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open & laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid micro grips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
120054|NCT03247972|Drug|Evolocumab|Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
120055|NCT03247959|Behavioral|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
120056|NCT03247946|Behavioral|upright head position|Bottle feeding of infants with their head in upward and not supine head position
120057|NCT03247933|Device|Telemedicine: Maintenance Respiratory Rehabilitation|"Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).~A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.~They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.~The patient must send the exercises every day that are scheduled training exercises once have been completed."
120058|NCT03247920|Drug|Amoxicillin Clavulanate|Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
120059|NCT03247920|Drug|Antibiotics|Intravenous antibiotic therapy following local protocol
120060|NCT03247907|Device|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
120061|NCT03247907|Device|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
120062|NCT03247907|Device|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
120063|NCT03247907|Device|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
120064|NCT03247907|Device|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
120065|NCT03247907|Device|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
120066|NCT03247907|Device|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
120067|NCT03247907|Device|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
120068|NCT03247894|Other|Data search|Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
120069|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
120070|NCT03247881|Other|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
120071|NCT03247868|Combination Product|Botulinum Toxin+SPRInt|Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
120072|NCT03247855|Procedure|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
120073|NCT03247842|Procedure|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
120074|NCT03247829|Device|Hemodynamic management using CardioMEMS|Using the CardioMEMS HF system, clinicians will treat to target PA pressure ranges
120075|NCT03247803|Device|air-Q® SP|air-Q SP placement for airway maintenance,
120076|NCT03247803|Device|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
120077|NCT03247790|Drug|Lasmiditan|Administered orally
120078|NCT03247777|Other|Traditional strengthening|dead lifts, bench press, wrist curls, and lat pulldowns as examples
120079|NCT03247777|Other|Functional Strengthening|diagonal chops, one leg deadlifts, lateral plyometrics as examples
120080|NCT03247764|Drug|SSRIs or xylaria nigripes|Patients with comorbidity of epilepsy and depression will be used SSRIs or xylaria nigripes as antidepressants after discussing with them. They will still be followed up if they don't want to use any antidepressants.
120081|NCT03247751|Device|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
120082|NCT03247738|Drug|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
120083|NCT03247738|Other|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
120084|NCT03247725|Other|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
120085|NCT03247725|Other|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
120086|NCT03247712|Drug|Nivolumab|Nivolumab 240mg IV q2wks or 480mg IV q4wks
120087|NCT03247712|Procedure|Surgical Resection|Surgical Resection of Tumor
120088|NCT03247712|Radiation|Radiation (5 days)|8Gy x 5 (Mon-Fri) GTV+3mm
120100|NCT03247647|Behavioral|Enhanced Intervention|Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
120101|NCT03247647|Behavioral|Standard Intervention|Participants will write about the food they have eaten in the last 48 hours.
120102|NCT03247634|Behavioral|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
120103|NCT03247621|Behavioral|Whatsapp|
120104|NCT03247621|Behavioral|Article|
120105|NCT03247621|Behavioral|No Phone|
120106|NCT03247608|Behavioral|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
120107|NCT03247595|Dietary Supplement|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
120108|NCT03247595|Other|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
120109|NCT03247595|Other|Dulcolax Tablets|4 Dulcolox Tablets
120110|NCT03247582|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
120111|NCT03247569|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
120112|NCT03247556|Drug|Placebo|Placebo will be administered once daily
120113|NCT03247556|Drug|400mg SPN-812 ER|SPN-812 ER high dose A will be administered once daily and compared to Placebo
120114|NCT03247556|Drug|600mg SPN-812 ER|SPN-812 ER high dose B will be administered once daily and compared to Placebo
120115|NCT03247543|Drug|Placebo|Placebo qd
120116|NCT03247543|Drug|200mg SPN-812 ER|200mg SPN-812 ER qd
120117|NCT03247543|Drug|400mg SPN-812 ER|400mg SPN-812 ER qd
120118|NCT03247530|Drug|Placebo|Placebo oral capsule will be administered once daily
120119|NCT03247530|Drug|100mg SPN-812 ER|SPN-812 ER low dose A will be administered once daily and compared to placebo
120120|NCT03247530|Drug|200mg SPN-812 ER|SPN-812 ER low dose B will be administered once daily and compared to placebo
120121|NCT03247517|Drug|Placebo|Placebo will be administered once daily
120122|NCT03247517|Drug|200mg SPN-812 ER|SPN-812 low dose A will be administered once daily and compared to placebo
120123|NCT03247517|Drug|400mg SPN-812 ER|SPN-812 Low Dose B will be administered once daily and compared to placebo
120124|NCT03247491|Behavioral|Mindfulness|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
120125|NCT03247465|Other|Image Fusion|Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
120126|NCT03247452|Other|One-day Low fiber diet|One-day low fiber diet before colonoscopy
120127|NCT03247452|Other|Three-day low fiber diet|Three days low fiber diet before colonoscopy
120128|NCT03247452|Drug|Polyethylene Glycol plus ascorbic acid|2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
120129|NCT03247439|Device|Cartiva|Synthetic Cartilage Implant
120130|NCT03247426|Other|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
120131|NCT03247413|Drug|Dexamethasone 4 mg/ml|dexamethasone 4 milligram given post-ablation at each lesion site
120132|NCT03247413|Drug|Normal saline|Placebo, normal saline administered post-ablation at each lesion site
120133|NCT03247400|Drug|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
120134|NCT03247400|Drug|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
120135|NCT03247387|Device|MC10 BioStampRC|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
120136|NCT03247387|Device|APDM actigraphy device|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
120137|NCT03247387|Device|GENEActiv watch|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
120138|NCT03247374|Device|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes."
120139|NCT03247374|Other|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes."
120143|NCT03247348|Behavioral|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
120144|NCT03247322|Other|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
120145|NCT03247309|Biological|IMA201 Product|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
120146|NCT03247309|Diagnostic Test|IMA_Detect|IMA_Detect is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 therapy. IMA_Detect is intended for investigational use only.
120147|NCT03247309|Diagnostic Test|ACT-HLA|An assay used to determine whether a patient is positive for the allele HLA-A*02:01 or not, and thus is eligible for treatment with an ACTengine adoptive T-cell product.
120148|NCT03247296|Drug|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
120149|NCT03247283|Drug|BMS-986205|Carbon 14 tagged BMS-986205
120150|NCT03247270|Behavioral|Intervention I|Low intensive physical exercise
120151|NCT03247270|Behavioral|Intervention II|High intensive physical exercise
120152|NCT03247257|Procedure|General Anesthesia|Patients will be put under general anesthesia for cholecystectomy
120153|NCT03247257|Procedure|Epidural Anesthesia|Patients will receive Epidural Anesthesia for cholecystectomy
120154|NCT03247244|Drug|Cannabis|THC 10%, CBD <0.5%
120155|NCT03247244|Drug|Cannabis|THC 8.6%, CBD 8.6%
120156|NCT03247244|Drug|Cannabis|THC 0.6%, CBD 14%
120157|NCT03247231|Device|Endoscopic band ligation without resection|Endoscopic treatment of subepithelial tumors: autoamputation by endoscopic band ligation without resection.
120158|NCT03247231|Procedure|SINK|To obtain sample tissue biopsies after the endoscopic band ligation without resection, performing a single incisional with a needle-knife.
120159|NCT03247218|Drug|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
120160|NCT03247205|Behavioral|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
120161|NCT03247192|Dietary Supplement|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
120162|NCT03247192|Dietary Supplement|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
120163|NCT03247192|Dietary Supplement|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
120164|NCT03247179|Other|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
120165|NCT03247166|Device|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
120166|NCT03247153|Diagnostic Test|Echocardiography|Imaging of the heart using ultrasound
120167|NCT03247140|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
120168|NCT03247140|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
120169|NCT03247127|Radiation|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
120170|NCT03247114|Other|Water|Water, 300 ml at room temperature
120171|NCT03247114|Other|Glucose|Glucose, 50 grams in 300 ml water at room temperature
120172|NCT03247114|Other|Fructose|Fructose, 50 grams in 300 ml water at room temperature
120173|NCT03247114|Other|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
120174|NCT03247114|Other|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
120175|NCT03247101|Drug|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
120176|NCT03247101|Drug|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
120177|NCT03247101|Drug|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
120178|NCT03247088|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT IV
120179|NCT03247088|Drug|Busulfan|Given IV
120180|NCT03247088|Drug|Cyclophosphamide|Given IV
120181|NCT03247088|Biological|Filgrastim|Given SC
120182|NCT03247088|Drug|Fludarabine|Given IV
120183|NCT03247088|Drug|Mycophenolate Mofetil|Given PO
120184|NCT03247088|Drug|Sorafenib|Given PO
120185|NCT03247088|Drug|Tacrolimus|Given PO
120186|NCT03247075|Behavioral|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
120187|NCT03247075|Behavioral|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
120188|NCT03247062|Other|Quality improvement - sleep bundle|implementation of a sleep bundle
120189|NCT03247036|Drug|IV thrombolytic (t-PA) treatment vs not|Acute Stroke Protocol
120190|NCT03247023|Device|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
120191|NCT03247010|Other|Blood sampling|Blood samples are taken before each cycle of Radium 223
120192|NCT03246997|Other|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
120193|NCT03246997|Other|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
120194|NCT03246984|Device|VasQ|VasQ device implantation in patients with a new brachiocephalic or radiocephalic fistula creation.
120195|NCT03246971|Drug|Wafermine™ 50 mg|Administered as needed for 12 hours
120196|NCT03246971|Drug|Wafermine™ 75 mg|Administered as needed for 12 hours
120197|NCT03246971|Drug|Placebos|Administered as needed for 12 hours
120198|NCT03246971|Drug|Wafermine™ 25 mg|Administered as needed for 12 hours
120199|NCT03246958|Drug|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
120200|NCT03246958|Drug|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
120201|NCT03246945|Behavioral|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
120202|NCT03246932|Behavioral|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
120203|NCT03246932|Behavioral|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
120204|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
120205|NCT03246919|Drug|Oxytocin|Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
120206|NCT03246919|Drug|Placebo|Placebo will be administered after delivery of the placenta
120207|NCT03246906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
120208|NCT03246906|Drug|Cyclophosphamide|Given IV
120209|NCT03246906|Drug|Cyclosporine|Given PO
120210|NCT03246906|Drug|Mycophenolate Mofetil|Given PO
120211|NCT03246906|Drug|Sirolimus|Given PO
120212|NCT03246893|Device|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:~Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
120213|NCT03246893|Device|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:~Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
120214|NCT03246880|Drug|Tamsulosin 0.2mg|per oral for 12weeks after 2~4weeks run-in period
120215|NCT03246880|Drug|Tadalafil 5mg|per oral for 12weeks after 2~4weeks run-in period
120216|NCT03246867|Other|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
120217|NCT03246867|Other|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
120218|NCT03246867|Other|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
120219|NCT03246854|Drug|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
120220|NCT03246841|Other|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
120221|NCT03246828|Other|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
120222|NCT03246802|Radiation|HDR partial prostate brachytherapy|temporary radioactive implant
120251|NCT03246568|Procedure|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
120223|NCT03246789|Behavioral|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
120224|NCT03246789|Behavioral|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
120225|NCT03246776|Drug|Halometasone Triclosan|Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
120226|NCT03246763|Behavioral|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
120227|NCT03246750|Drug|B-MAD chemotherapy|B-MAD chemotherapy
120228|NCT03246737|Other|monitoring|
120229|NCT03246724|Drug|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 0.125 mg~Dose for BMI greater than or equal to 35: 0.25 mg"
120230|NCT03246724|Drug|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1.0 mg~Dose for BMI greater than or equal to 35: 2.0 mg"
120231|NCT03246724|Drug|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.~Dose for BMI less than 35: 1 capsule~Dose for BMI greater than or equal to 35: 2 capsule"
120232|NCT03246724|Drug|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.~Dose for BMI less than 35: volume to match volume of active intravenous medication~Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
120233|NCT03246711|Behavioral|Fasting|Totally or partially fasting the holy month of ramadan for muslims
120234|NCT03246698|Other|Isolytic Stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
120235|NCT03246698|Other|Static Stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
120236|NCT03246698|Other|Control group|They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
120237|NCT03246685|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
120238|NCT03246685|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
120239|NCT03246672|Behavioral|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
120240|NCT03246659|Drug|111In-CP04|Radiopharmaceutical preparation
120241|NCT03246659|Drug|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
120242|NCT03246646|Behavioral|Coaching|Telephone coaching along with web-based CRAFT course
120243|NCT03246633|Other|Perceptual Training|Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
120244|NCT03246620|Drug|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
120245|NCT03246620|Drug|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
120246|NCT03246620|Drug|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
120247|NCT03246607|Device|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
120248|NCT03246594|Device|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
120249|NCT03246594|Device|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
120250|NCT03246581|Drug|Tiotropium|inhalation
120252|NCT03246568|Procedure|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
120253|NCT03246555|Drug|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
120254|NCT03246555|Drug|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
120255|NCT03246542|Diagnostic Test|shistocytes percentage|
120256|NCT03246529|Drug|BL-8040 1.25mg/kg + G-CSF|Up to 2 SC injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
120257|NCT03246529|Drug|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
120258|NCT03246516|Other|Questionnaire|"Auto and hetero questionnaires:~STAI Y B, State-Trait Anxiety Inventoriage~Brief COPE~RHHI-24, Revised Health Hardiness Inventory~IPQ-R, Illness Perception Questionnaire"
120259|NCT03246490|Other|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
120260|NCT03246464|Device|Orthokeratology lenses|Rigid gas permeable contact lenses
120261|NCT03246464|Device|Single-vision spectacles|Regular single vision spectacles
120262|NCT03246451|Drug|Placebo Oral Tablet|2-4 tablets in 14 days
120263|NCT03246451|Drug|Metformin|1000-2000 mg in 14 days
120264|NCT03246451|Drug|Saline|9 mg/ml saline infusion during experimental days
120265|NCT03246451|Drug|Exendin (9-39)|Infusion of GLP-1 receptor antagonist used as a tool during experimental days
120266|NCT03246438|Behavioral|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
120267|NCT03246438|Behavioral|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
120268|NCT03246438|Behavioral|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
120269|NCT03246425|Other|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
120270|NCT03246425|Device|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
120271|NCT03246412|Diagnostic Test|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
120272|NCT03246399|Drug|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
120273|NCT03246386|Drug|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
120274|NCT03246386|Drug|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
120275|NCT03246360|Drug|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.~For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.~Pharmacological dosages will be performed on the third and sixth day in both arms"
120276|NCT03246347|Drug|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
120277|NCT03246321|Combination Product|repetitive ePIPAC-OX|Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area [BSA]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.
120278|NCT03246308|Radiation|Phototherapy|Taking blood sample.
120279|NCT03246295|Other|lifestyle intervention or insulin treatment|Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
120280|NCT03246282|Device|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
120281|NCT03246282|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
120282|NCT03246282|Device|Peripheral Catheterization|"20-gauge 1.0 catheter"
120283|NCT03246269|Diagnostic Test|MoCA|
120284|NCT03246256|Other|Group 1|
120285|NCT03246243|Device|nfant feeding solution|The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
120286|NCT03246243|Device|Waveguard (TM) EEG cap|EEG and EMG data will also be collected while the infant is being measured with the sensor during one of the first and one of the last sucking sessions. In addition, EEG and EMG data will be collected while the infant is at rest during one of the first and one of the last sucking sessions.EEG cap will be placed on subjects. Each electrode is located under each disc. EEG montage used for 32 channel recordings (Modified international 10/20 system).
120287|NCT03246243|Device|BabyMEG|Following a sucking session, simultaneous resting-state MEG/EEG data will be recorded from the infant during sleep with the BabyMEG. The resting-state MEG/EEG recording will last about 10 minutes, with preparation lasting about 30 minutes.
120288|NCT03246230|Biological|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
120289|NCT03246230|Biological|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
120290|NCT03246217|Behavioral|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
120291|NCT03246217|Behavioral|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
120292|NCT03246217|Behavioral|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
120293|NCT03246191|Other|blood sample collection|blood sample collection
120294|NCT03246178|Other|MSD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day −1 and was tapered off after 1 months if no aGVHD was observed."
120295|NCT03246178|Other|HFD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;~Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;~Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day −3 and was tapered off after 2 months if no aGVHD was observed."
120296|NCT03246165|Procedure|Cardiac surgery|Coronary bypass, heart valve replacement
120297|NCT03246152|Drug|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
120298|NCT03246139|Behavioral|Action observation, imagery & execution|The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
120299|NCT03246139|Behavioral|Action observation|The participants will be asked to observe videos and then practice what the participants observed.
120300|NCT03246139|Behavioral|Control treatment|The participants will receive UE training without watching videos or imagining movements/tasks.
120301|NCT03246126|Device|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
120302|NCT03246113|Drug|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
120303|NCT03246113|Drug|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
120304|NCT03246113|Radiation|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
120305|NCT03246100|Behavioral|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
120306|NCT03246087|Device|Acupunture|"acupuncture for plantar fasciosis~Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
120307|NCT03246087|Other|Standard of care|standard of care home exercise program
120308|NCT03246074|Drug|Fostamatinib and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg, 150 mg, or 200 mg)~Drug: Paclitaxel (60-80 mg/m2)"
120309|NCT03246061|Device|Intracept System|RF ablation
120310|NCT03246061|Other|Non-surgical conservative therapies|Conservative therapies
120311|NCT03246035|Behavioral|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline. Patients will then be referred to a Geriatrics Assessment Team, who will provide individualized recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
120517|NCT03244540|Drug|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
120312|NCT03246035|Other|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
120313|NCT03246022|Other|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
120314|NCT03246009|Drug|rHSA/GCSF|single injection-1.8mg
120315|NCT03246009|Drug|rHSA/GCSF|single injection-2.1mg
120316|NCT03246009|Drug|rHSA/GCSF|single injection-2.4mg
120317|NCT03246009|Drug|rHSA/GCSF|multiple injection-1.8mg
120318|NCT03246009|Drug|rHSA/GCSF|multiple injection-2.1mg
120319|NCT03246009|Drug|rHSA/GCSF|multiple injection-2.4mg
120320|NCT03245996|Device|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm in the first and second part of the study
120321|NCT03245996|Device|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm in the first and second part of the study
120322|NCT03245996|Device|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm in the first and second part of the study
120323|NCT03245996|Drug|Atenolol Pill|50 or 100 mg of atenolol is administered to subjects in the second part of the study
120324|NCT03245996|Drug|Nebivolol Pill|5 mg of nebivolol is administered to subjects in the second part of the study
120325|NCT03245996|Drug|Ivabradine Pill|5 or 7,5 mg of ivabradine is administered to subjects in the second part of the study
120326|NCT03245983|Behavioral|Questionnaire and interview|Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
120327|NCT03245970|Drug|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
120328|NCT03245970|Drug|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
120329|NCT03245970|Drug|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
120330|NCT03245957|Other|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
120331|NCT03245957|Other|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
120332|NCT03245944|Procedure|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
120333|NCT03245944|Procedure|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
120334|NCT03245931|Other|Qualitative Interview|Complete 6 open-ended qualitative questions on patients in the HOPE program to assess basic current understanding about Hepatitis C and topics of interest that patients in the HOPE program would like to learn more about.
120335|NCT03245918|Drug|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
120336|NCT03245918|Drug|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
120337|NCT03245905|Drug|Chidamide|Chidamide 30mg orally BIW (d1, 4, 8, 11, 15, 18). Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
120338|NCT03245892|Drug|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
120339|NCT03245892|Drug|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
120340|NCT03245892|Procedure|cytoreductive surgery|cytoreductive surgery
120341|NCT03245879|Behavioral|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for >48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
120375|NCT03245593|Other|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
120376|NCT03245580|Procedure|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
120342|NCT03245879|Behavioral|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
120343|NCT03245879|Behavioral|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
120344|NCT03245866|Other|Observational/ no intervention|
120345|NCT03245853|Drug|Riboflavin 5'-Phosphate|Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg [0.12%] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
120346|NCT03245840|Drug|Budesonide oral suspension|Budesonide oral suspension (BOS) 10 mL twice daily
120347|NCT03245827|Drug|Clomiphene|clomiphene capsule 25mg twice a week
120348|NCT03245827|Drug|Placebo|placebo capsule 25mg twice a week
120349|NCT03245814|Behavioral|Service Dog|A service dog trained to perform tasks that are specific to PTSD
120350|NCT03245788|Other|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
120351|NCT03245775|Behavioral|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
120352|NCT03245775|Behavioral|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
120353|NCT03245762|Drug|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
120354|NCT03245762|Drug|Placebo|4 IU/day of placebo administered via nasal spray device each morning
120355|NCT03245736|Drug|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
120356|NCT03245723|Procedure|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethsymography
120357|NCT03245723|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
120358|NCT03245723|Procedure|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
120359|NCT03245723|Procedure|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
120360|NCT03245710|Drug|Placebos|starch
120361|NCT03245710|Drug|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
120362|NCT03245684|Diagnostic Test|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
120363|NCT03245671|Drug|Kenalog Injectable Product|80 mg of Kenalog will be used.
120364|NCT03245671|Drug|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
120365|NCT03245671|Procedure|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
120366|NCT03245658|Drug|THC and CBD Mixture|Individually titrated doses on daily basis
120367|NCT03245645|Other|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
120368|NCT03245632|Other|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
120369|NCT03245619|Drug|GSK3335065|GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
120370|NCT03245619|Drug|Placebo|Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
120371|NCT03245606|Procedure|Liver biopsy|Measurement of liver fibrosis
120372|NCT03245606|Device|Abdominal MRI|Measurement of liver fibrosis
120373|NCT03245606|Device|Transient elastography|Measurement of liver fibrosis
120374|NCT03245593|Other|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
120377|NCT03245567|Other|PLM|Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
120378|NCT03245567|Other|Pre, post, delayed test|Participants will perform a pretest, a posttest and a delayed test at 6 months.
120379|NCT03245554|Drug|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
120380|NCT03245541|Drug|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 to PD-1 and CD80 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer. (MedImmune is a wholly owned subsidiary of AstraZeneca; AstraZeneca/MedImmune will be referred to as AstraZeneca throughout this document.) As durvalumab is an engineered mAb, it does not induce antibodydependent cellular cytotoxicity or complement-dependent cytotoxicity. The proposed mechanism of action for durvalumab is interference of the interaction of PD-L1 with PD-1 and CD80.
120381|NCT03245541|Radiation|Stereotactive Ablative Body Radiotherapy|6.6 Gy per fraction delivered every other day x 5 fractions
120382|NCT03245528|Drug|LJPC-501|angiotensin II
120383|NCT03245515|Drug|BMS-986195|specified dose on specified days
120384|NCT03245502|Biological|Blood transfusion|The transfusion of erythrocyte suspension
120385|NCT03245489|Drug|Pembrolizumab|200mg intravenous (IV) over 30 minutes
120386|NCT03245489|Drug|Clopidogrel|75mg/day oral
120387|NCT03245489|Drug|acetylsalicylic acid|81mg/day oral
120388|NCT03245476|Other|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
120389|NCT03245476|Other|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
120390|NCT03245463|Other|Educational handout|The educational handout will include information on self-management strategies.
120391|NCT03245463|Other|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
120392|NCT03245463|Drug|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
120393|NCT03245450|Drug|Eribulin mesilate|IV infusion
120394|NCT03245450|Drug|Irinotecan hydrochloride|IV infusion
120395|NCT03245437|Drug|Oxytocin nasal spray|nasal spray
120396|NCT03245437|Behavioral|Social Cognition Skills Training|Group based training in social cognition skills
120397|NCT03245437|Behavioral|Health Management|Group-based training in mental health management
120398|NCT03245437|Drug|Placebo nasal spray|placebo condition
120399|NCT03245424|Drug|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
120400|NCT03245411|Behavioral|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
120401|NCT03245398|Drug|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
120402|NCT03245385|Drug|Treatment with Halobetasol propionate 0.05% topical spray|Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
120403|NCT03245372|Procedure|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
120404|NCT03245372|Procedure|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
120405|NCT03245359|Device|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
120406|NCT03245359|Device|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
120407|NCT03245359|Drug|Short-term ON-Q|Bupivacaine 0.125%
120408|NCT03245359|Device|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
120409|NCT03245359|Device|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
120410|NCT03245359|Drug|Long-term ON-Q|Bupivacaine 0.125%
120411|NCT03245346|Drug|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
120412|NCT03245346|Drug|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
120413|NCT03245346|Drug|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
120414|NCT03245346|Drug|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
120415|NCT03245333|Drug|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
120416|NCT03245333|Drug|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
120417|NCT03245320|Device|Integra TITAN™ Total Shoulder Generation 1.0|Total Shoulder Arthroplasty or Hemiarthroplasty
120418|NCT03245307|Drug|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
121124|NCT03239873|Biological|M-M-R II®|Measles, Mumps, and Rubella virus vaccine live
120419|NCT03245307|Drug|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
120420|NCT03245307|Drug|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
120421|NCT03245294|Procedure|lumbar epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
120422|NCT03245281|Drug|Diuretic Suspension (DS)|Stop diuretic consumption in the 48h before the follow-up visit
120423|NCT03245281|Drug|Diuretic Increase (DI)|Double diuretics dosage in the 48h before the follow-up visit
120424|NCT03245281|Drug|Diuretic and Medication Suspension (DMS)|Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
120425|NCT03245268|Procedure|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
120426|NCT03245255|Drug|Sonazoid|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
120427|NCT03245242|Other|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
120428|NCT03245242|Other|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
120429|NCT03245229|Drug|ACT-132577|Capsule for oral administration
120430|NCT03245229|Drug|Rosuvastatin|Tablet for oral administration
120431|NCT03245216|Behavioral|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
120432|NCT03245216|Behavioral|rest|Seated rest before motor learning
120433|NCT03245216|Behavioral|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
120434|NCT03245203|Procedure|FOLFIRI+beacizumab|Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4~8 weeks.
120435|NCT03245203|Procedure|CRT|total dose of radiotherapy was 40~50Gy, a subdose of 1.8~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
120436|NCT03245190|Drug|Chiauranib|50mg, orally once daily
120437|NCT03245177|Biological|Pembrolizumab|Anti-PD-1 antibody
120438|NCT03245177|Radiation|Radiotherapy|60-66 Gy in 30-33 fractions, 2 Gy per fraction
120439|NCT03245164|Other|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
120440|NCT03245164|Other|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
120441|NCT03245151|Drug|Lenvatinib|oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
120442|NCT03245151|Drug|Everolimus|2 mg, 3 mg, or 5 mg tablets for oral suspension
120443|NCT03245138|Procedure|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
120444|NCT03245138|Procedure|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
120445|NCT03245125|Behavioral|High-intensity interval training|Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
120446|NCT03245112|Drug|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
120447|NCT03245099|Other|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
120448|NCT03245086|Device|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
120449|NCT03245086|Procedure|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
120450|NCT03245073|Other|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
120451|NCT03245073|Other|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
120452|NCT03245060|Behavioral|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
120453|NCT03245047|Dietary Supplement|Oral Nutritional Supplement with AN 777|Oral Nutritional Supplement with AN 777, 2 servings a day
120454|NCT03245047|Other|Oral Nutritional Supplement|Oral Nutritional Supplement, 2 servings a day
120455|NCT03245034|Behavioral|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
120456|NCT03245021|Drug|Opdivo|"All patients will receive:~Nivolumab 240mg IV q2-weekly for four cycles~Patients in complete remission (CR):~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles~Patients in CR:~Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)~Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:~Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
120457|NCT03245008|Drug|MT-5547|Solution for injection in pre-filled syringe
120458|NCT03245008|Drug|MT-5547-matching placebo|Solution for injection in pre-filled syringe
120459|NCT03244995|Procedure|Mind-Body Intervention Procedure|Undergo CBMB program
120460|NCT03244995|Other|Quality-of-Life Assessment|Ancillary studies
120461|NCT03244995|Other|Questionnaire Administration|Ancillary studies
120462|NCT03244982|Drug|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
120463|NCT03244982|Drug|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
120464|NCT03244956|Drug|Trametinib|2mg daily for a maximum of 6 weeks of treatment
120465|NCT03244956|Drug|Dabrafenib|150mg twice daily
120466|NCT03244956|Radiation|131I|5.5 GBq
120467|NCT03244956|Drug|rhTSH|0.9mg on two consecutive days after 35 days of treatment
120468|NCT03244943|Procedure|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
120469|NCT03244930|Drug|Plerixafor 0.12 mg/kg|Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
120470|NCT03244917|Behavioral|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
120471|NCT03244891|Other|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:~baseline~after fluid shift induced by passive head down position at 15 degrees~after fluid challenge with Ringer acetate 15ml*kg in head down position~A total of six steps will be considered for the analysis"
120472|NCT03244891|Other|Ventilation mode|"Each previous step will be done in two respiratory conditions:~spontaneous breathing~noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
120473|NCT03244878|Behavioral|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
120474|NCT03244865|Device|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and FHR data acquired for comparison with CTG data obtained through the traditional monitoring system. The comparison will be performed off-line.~Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
120475|NCT03244839|Procedure|bariatric surgery|bariatric surgery
120476|NCT03244826|Other|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
120477|NCT03244826|Other|Standard Care|The usual care provided by the transplant center at DFCI.
120478|NCT03244813|Other|Personalized activity program|Targeted physical activity
120479|NCT03244800|Drug|MEDI0382|MEDI0382 will be administered subcutaneously once daily for 49 days.
120480|NCT03244800|Drug|Placebo|Placebo will be administered subcutaneously once daily for 49 days.
120515|NCT03244540|Device|Stimuplex Ultra 360 needle|ultrasound-guided needle will be used for QLB and TAP and regional blocks
120516|NCT03244540|Drug|Ropivacaine|0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
120481|NCT03244787|Behavioral|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
120482|NCT03244774|Drug|Apatinib|"Apatinib 250mg p.o. qd in first cohort (3 subjects). 375mg p.o. qd in second cohort (3 subjects). 500mg p.o. qd in third cohort (3 subjects). 625mg p.o. qd in forth cohort (3 subjects); 750mg p.o. qd in fifth cohort (3 subjects).~Other Name:"
120483|NCT03244774|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
120484|NCT03244761|Procedure|The modified HFT|The HFT was modified by increasing the expiratory resistance.
120485|NCT03244748|Procedure|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
120486|NCT03244735|Other|Atkins diet|A nutritional regimen characterized by high fat low carbohydrate intake.
120487|NCT03244722|Dietary Supplement|Very-low calorie Diet (VLCD)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
120488|NCT03244722|Other|Standard of care (SOC)|Standard referral to nutrition services and consultation with registered dietitian to determine appropriate caloric needs for healthy weight management
120489|NCT03244709|Drug|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
120490|NCT03244696|Behavioral|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
120491|NCT03244696|Behavioral|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
120492|NCT03244683|Dietary Supplement|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
120493|NCT03244683|Other|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
120494|NCT03244683|Other|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
120495|NCT03244670|Other|Observation study only, no specific intervention|Observation study only, no specific intervention
120496|NCT03244657|Drug|conbercept ophthalmic injection （0.5mg）|"The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment"
120497|NCT03244657|Drug|conbercept ophthalmic injection （0.5mg）|"In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given."
120498|NCT03244644|Drug|RBX2660|RBX2660 is a microbiota suspension administered as an enema
120499|NCT03244644|Drug|Placebo|Placebo is normal saline solution administered as an enema
120500|NCT03244631|Procedure|Lumbar Plexus BLock|Peripheral nerve block
120501|NCT03244631|Procedure|Pericapsular injection|Injection around the area undergoing surgery
120502|NCT03244618|Device|CSSP Toothpaste|Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
120503|NCT03244618|Device|Fluoride Toothpaste|Toothpaste containing sodium monofluorphosphate
120504|NCT03244605|Other|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
120505|NCT03244605|Other|Rehabilitation Education|General health education
120506|NCT03244605|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
120507|NCT03244605|Drug|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
120508|NCT03244592|Drug|Minocycline|200 mg/day
120509|NCT03244592|Drug|Sugar pill|Matched placebo
120510|NCT03244579|Behavioral|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
120511|NCT03244566|Diagnostic Test|positron emission tomography|patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
120512|NCT03244553|Drug|Prucalopride|5 day treatment
120513|NCT03244540|Procedure|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
120514|NCT03244540|Procedure|QLB (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
121125|NCT03239860|Drug|GNbAC1 Monoclonal Antibody|Monthly IV
120518|NCT03244540|Procedure|subarachnoid anesthesia|subarachnoid anesthesia for each patients participating in the study with pencil point needle
120519|NCT03244540|Procedure|PCA (patient controlled analgesia)|All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
120520|NCT03244540|Drug|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
120521|NCT03244540|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
120522|NCT03244540|Drug|Bupivacaine|Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
120523|NCT03244527|Dietary Supplement|BCAA supplement|Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
120524|NCT03244527|Other|Aerobic exercise|The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
120525|NCT03244514|Other|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
120526|NCT03244501|Other|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
120527|NCT03244501|Other|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
120528|NCT03244488|Drug|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
120529|NCT03244488|Drug|Mecamylamine Pill|10 or 20mg of mecamylamine orally
120530|NCT03244475|Device|IASIS Micro Current Neurofeedback|The EEG interface device is the J&J Engineering I-330 C2, provided specifically for IASIS. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+, A-, B+, B-), with respect to the Common Neck Reference (isolated). During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scalp to record EEG signals. All four (A+, A-, B+, B-) electrodes are involved in applying weak electric current pulses back to the brain (the feedback process). The feedback signal consists two types of narrow pulse trains, both with 150 mV in amplitude: A Type 1 pulse is 25 ms in duration and contains carrier waves at ~50 KHz. The repetition rate of Type 1 pulse train is fixed at 3.6 Hz; A Type 2 pulse is 120 ns in duration and contains carrier waves at ~100 MHz.
120531|NCT03244475|Device|Nexalin|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a waveform that provides tES to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current. There is evidence that this waveform, at this frequency, results in improved clinical outcomes in terms of anxiety and pain. The specific mechanisms of action are not known, but available evidence suggests that this waveform alters the function of the hypothalamus and related structures. In particular, tES may lead to increases in levels of enkephalins and beta-endorphins in brain and CSF. Other data suggest that tES can alter endogenous levels of both substance P and serotonin. Regardless of which neuropeptide or neurotransmitter is ultimately found to be modulated by tES, it is hypothesized that repeated TES treatments over time serve to stimulate long-term neurochemical changes.
120532|NCT03244462|Drug|BAY1834845|Single oral dose (IR [immediate release] tablets)
120533|NCT03244462|Drug|BAY1834845|I.v. infusion of [13C6]-labeled BAY1834845
120534|NCT03244462|Drug|Methotrexate|Single dose of commercially available MTX
120535|NCT03244449|Other|No apply|
120536|NCT03244436|Procedure|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
120537|NCT03244423|Drug|Normal saline at induction|0.5 ml/kg
120538|NCT03244423|Drug|Normal saline infusion|1ml/kg/hr. during surgery for six hours
120539|NCT03244423|Drug|Intravenous tranexamic acid|50 mg/kg
120540|NCT03244423|Drug|infusion tranexamic acid|1mg/kg/hr infusionfor 6 hours
120541|NCT03244423|Drug|topical tranexamic acid|50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure
120542|NCT03244423|Drug|topical normal saline|2 ml/kg into the pericardial cavity before sternal closure
120543|NCT03244410|Diagnostic Test|complete blood picture|complete blood picture
120544|NCT03244397|Other|Physical therapy + educational strategy|See arm/group descriptions
120545|NCT03244397|Behavioral|Educational strategy|See arm/group descriptions
120546|NCT03244384|Other|Clinical Observation|Undergo observation
120547|NCT03244384|Other|Laboratory Biomarker Analysis|Correlative studies
120548|NCT03244384|Biological|Pembrolizumab|Given IV
120549|NCT03244384|Other|Pharmacological Study|Correlative studies
120550|NCT03244384|Other|Quality-of-Life Assessment|Ancillary studies
120551|NCT03244384|Other|Questionnaire Administration|Ancillary studies
120552|NCT03244371|Other|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
120553|NCT03244358|Drug|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
120554|NCT03244345|Behavioral|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
120555|NCT03244332|Other|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
120556|NCT03244332|Other|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
120557|NCT03244319|Drug|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight <60kg or concomitant use of certain P-glycoprotein inhibitors).
120558|NCT03244319|Drug|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
120559|NCT03244319|Drug|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
121126|NCT03239847|Other|EndoPhys Sheath and Radial Arterial Line|
121127|NCT03239847|Other|EndoPhys Sheath|
120560|NCT03244306|Biological|Patient-derived CD22-specific CAR T-cells also expressing an EGFRt|Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
120561|NCT03244293|Other|no intervention|
120562|NCT03244280|Drug|MOB015B|Topical formulation
120563|NCT03244267|Behavioral|Standard Education|Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
120564|NCT03244267|Behavioral|Medication Reminder App|Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
120565|NCT03244241|Drug|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
120566|NCT03244228|Drug|HTL0016878|Oral solution
120567|NCT03244228|Drug|Placebo - Concentrate|Matching placebo
120568|NCT03244215|Diagnostic Test|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
120569|NCT03244215|Diagnostic Test|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
120570|NCT03244215|Other|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
120571|NCT03244202|Other|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
120572|NCT03244202|Other|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
120573|NCT03244189|Behavioral|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
120574|NCT03244189|Behavioral|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
120575|NCT03244189|Behavioral|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
120576|NCT03244176|Drug|Avelumab|"All participants will receive the following treatment:~Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments~Then:~RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.~Then:~Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
120577|NCT03244163|Device|Spyglass DS cholangioscope|The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
120578|NCT03244163|Device|BML|Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
120579|NCT03244137|Other|Pulmonary rehabilitation|See group description.
120580|NCT03244124|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
120581|NCT03244124|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
120582|NCT03244124|Other|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
120609|NCT03243890|Dietary Supplement|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
120905|NCT03241472|Drug|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
120583|NCT03244124|Other|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
120584|NCT03244111|Behavioral|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
120585|NCT03244098|Behavioral|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
120586|NCT03244085|Drug|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
120587|NCT03244072|Drug|Moxifloxacin|Intracameral injection
120588|NCT03244072|Drug|Placebo|intracameral injection
120589|NCT03244059|Biological|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
120590|NCT03244059|Drug|Placebo|An identically appearing placebo infusion.
120591|NCT03244046|Behavioral|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
120592|NCT03244046|Behavioral|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
120593|NCT03244033|Other|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
120594|NCT03244033|Behavioral|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
120595|NCT03244020|Drug|Aspirin 325mg|Aspirin 325 mg by mouth once daily
120596|NCT03244020|Drug|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
120597|NCT03244007|Procedure|Vitrectomy|
120598|NCT03243994|Diagnostic Test|Absorption test with D-xylose and zink|Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
120599|NCT03243981|Device|Sciton SkinTyte (800-1800 nm) with Broadband Light Technology|This device has been used in the clinical setting to reduce cheek and submental laxity. SkinTyte delivers sequentially pulsed light (800-1200 nm, with a filter enabling focus on 590 nm) and broadband light (which can be turned on or off).
120600|NCT03243955|Device|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
120601|NCT03243955|Device|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
120602|NCT03243942|Drug|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
120603|NCT03243929|Behavioral|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
120604|NCT03243929|Behavioral|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
120605|NCT03243916|Radiation|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
120606|NCT03243903|Device|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
120607|NCT03243903|Device|needle-insulin pen|Using needle-insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
120608|NCT03243890|Dietary Supplement|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
120610|NCT03243877|Other|MammoAlert Screening Test|Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
120611|NCT03243864|Drug|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
120612|NCT03243851|Drug|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
120613|NCT03243851|Drug|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
120614|NCT03243838|Drug|Apatinib|docetaxel/carboplatin combined with apatinib as Neoadjuvant Treatment for Triple-Negative Breast Cancer
120615|NCT03243825|Radiation|combination group|chemotherapy (paclitaxel/cisplatinum) and brachytherapy
120616|NCT03243825|Drug|chemotherapy group|chemotherapy: (paclitaxel/cisplatinum)
120617|NCT03243812|Biological|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
120618|NCT03243812|Other|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
120619|NCT03243812|Other|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
120620|NCT03243812|Other|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
120621|NCT03243799|Behavioral|Group psychoeducation|Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
120622|NCT03243786|Behavioral|Lifestyle- Supportive Care|The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
120623|NCT03243773|Other|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
120624|NCT03243760|Drug|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
120625|NCT03243760|Drug|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
120626|NCT03243760|Drug|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
120627|NCT03243734|Device|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
120628|NCT03243721|Diagnostic Test|7T MRI|A high field MRI that will take approximately one hour.
120629|NCT03243721|Diagnostic Test|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
120630|NCT03243708|Behavioral|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
120631|NCT03243695|Other|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
120632|NCT03243695|Other|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
120633|NCT03243682|Procedure|Bidirectional Shock Wave Lithotripsy|the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
120634|NCT03243682|Procedure|Standard Shock Wave Lithotripsy|the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
120635|NCT03243669|Diagnostic Test|High-definition|High-definition colonoscopy
120636|NCT03243669|Diagnostic Test|Virtual chromoendoscopy|Virtual chromoendoscopy
120637|NCT03243669|Diagnostic Test|Standard|Standard colonoscopy
120638|NCT03243656|Drug|Eltrombopag|An oral thrombopoietin receptor agonist
120639|NCT03243643|Drug|HS-10241|HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
120640|NCT03243643|Drug|Apatinib|Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
120641|NCT03243630|Drug|IV nicotine|Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
120642|NCT03243630|Drug|Menthol flavor|American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
120643|NCT03243630|Drug|green apple|green apple will be added to the menthol flavor
120644|NCT03243630|Drug|green apple and menthol|menthol and green apple will be the active intervention
120645|NCT03243617|Other|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~Subjects may not wash their body with soap and water AFTER the applications"
120646|NCT03243617|Other|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:~LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.~Subjects may not wash their body with soap and water AFTER the applications"
120867|NCT03241758|Diagnostic Test|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
120647|NCT03243604|Drug|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
120648|NCT03243591|Other|Livionex gel|Brushing area of mucositis with gel
120649|NCT03243591|Other|Aquafresh gel|Aquafresh gel
120650|NCT03243578|Other|None as this is an observational study|
120651|NCT03243565|Biological|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
120652|NCT03243565|Biological|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
120653|NCT03243552|Drug|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
120654|NCT03243552|Behavioral|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
120655|NCT03243539|Procedure|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
120656|NCT03243526|Other|fluid therapy|fluid resuscitation guided by CVP or PPV
120657|NCT03243513|Other|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
120658|NCT03243500|Drug|Atracurium|5mg in 1 ml normal saline
120659|NCT03243500|Drug|Lidocaine 2%|
120660|NCT03243500|Drug|Bupivacaine 0.5%|
120661|NCT03243500|Drug|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
120662|NCT03243500|Procedure|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
120663|NCT03243487|Behavioral|structured adherence management program|Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy
120664|NCT03243487|Behavioral|Standard of care|Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
120665|NCT03243461|Drug|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
120666|NCT03243461|Drug|Temozolomide + Chloroquine|Chloroquine additionally to simultaneous radiochemotherapy with temozolomide
120667|NCT03243435|Procedure|Native 1,5 Tesla breast MRI|
120668|NCT03243422|Other|Successful aging education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh1. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
120669|NCT03243422|Other|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
120670|NCT03243396|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
120671|NCT03243383|Other|DiaTOHC Program|"Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review~Peri-discharge coordination of care~A1c-based adjustment of diabetes therapy~Post-discharge support"
120672|NCT03243357|Procedure|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
120673|NCT03243357|Procedure|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).~Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
120674|NCT03243344|Device|Surgiflo|using device during the endonasal surgery.
120675|NCT03243344|Device|Floseal|using device during the endonasal surgery.
120676|NCT03243344|Device|Algosteril|using device during the endonasal surgery.
120868|NCT03241745|Drug|Nivolumab|Nivolumab 480 mg IV once every 4 weeks
120677|NCT03243331|Drug|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
120678|NCT03243331|Drug|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
120679|NCT03243318|Diagnostic Test|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
120680|NCT03243305|Drug|AMPHORA|non-hormonal contraceptive vaginal gel
120681|NCT03243292|Other|Bronchial Thermoplasty|patients had radio frequency ablation of the smooth muscle for asthma
120682|NCT03243266|Diagnostic Test|CBC/Diff Reference Interval|Results will not be used to manage patients
120683|NCT03243253|Other|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
120684|NCT03243240|Diagnostic Test|mutlidetector computed tomography|"Multidetector computed tomography angiography with 16- MSCT scanner, medical system bright speed. Our protocol will include non-enhanced scanning then perform a triphasic angiography that includes arterial, portal and venous phases to detect acute gastrointestinal bleeding.~Images will be acquired with the following parameters slice thickness 5mm for the unenhanced phase and 1.25mm for the arterial phase and porto-venous phases"
120685|NCT03243227|Other|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
120686|NCT03243227|Other|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
120687|NCT03243214|Device|TMS|Real or Sham TMS will be given to the PD-MCI patient
120688|NCT03243214|Device|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
120689|NCT03243201|Drug|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
120690|NCT03243201|Other|Purified Water|Purified water will be given as placebo
120691|NCT03243188|Other|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
120692|NCT03243175|Drug|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
120693|NCT03243175|Device|left atrial appendage closure|left atrial appendage closure
120694|NCT03243162|Behavioral|CBPT-ACLR|The CBPT-ACLR program focuses on improving sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
120695|NCT03243162|Other|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
120696|NCT03243149|Device|fMRI - GE Medical System|"Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.~The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy."
120697|NCT03243136|Other|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
120698|NCT03243123|Device|Robotic passive mobilization|The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
120699|NCT03243110|Diagnostic Test|breathing test|Spirometry is a non-invasive means of measuring lung function: The participant is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the participant does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in participants. In methacholine challenge test, the participant breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.
120700|NCT03243097|Device|Phase I - Standard Microphone Cros Input|Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period
120948|NCT03241121|Behavioral|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
120701|NCT03243097|Device|Phase II - Automatic directional microphone Cros Input|Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.
120702|NCT03243097|Device|Phase III - No Cros Input|Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
120703|NCT03243084|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
120704|NCT03243084|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
120705|NCT03243071|Behavioral|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
120706|NCT03243071|Behavioral|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
120707|NCT03243058|Drug|Proleukin® (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin
120708|NCT03243058|Drug|Placebo - Concentrate|Randomized Placebo group will be administered subcutaneously
120709|NCT03243045|Procedure|Renal sympathetic denervation|Transcutaneous renal sympathetic denervation
120710|NCT03243032|Drug|Ibuprofen 600 mg|Ibuprofen 600mg given 30 minutes prior to beginning of surgery
120711|NCT03243032|Drug|Local anesthetic Group 1|0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
120712|NCT03243032|Drug|Placebo oral capsule|Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
120713|NCT03243032|Drug|Local anesthetic Control|2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
120714|NCT03243019|Drug|rapamycin|oral administration
120715|NCT03243019|Device|MRI|cervicofacial MRI
120716|NCT03243019|Biological|Rapamycin dosage|Biological dosage of Rapamycin level
120717|NCT03243006|Drug|Paracetamol|2 tablets of 500mg of paracetamol
120718|NCT03243006|Drug|Tramadol/Paracetamol combination|2 tablets of tramadol/paracetamol combination (32.5mg/325mg)
120719|NCT03243006|Drug|Placebo Oral Tablet|2 tablets of placebo
120720|NCT03242993|Drug|[18F]-AzaFol|[18F]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
120721|NCT03242993|Drug|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection"
120722|NCT03242980|Behavioral|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.~Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
120723|NCT03242967|Drug|Vadadustat|Oral tablet
120724|NCT03242967|Drug|Darbepoetin alfa|subcutaneous or intravenous
120725|NCT03242954|Other|Parental Permission Required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
120726|NCT03242954|Other|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
120727|NCT03242954|Other|Autonomous consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
120728|NCT03242941|Procedure|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the septal catheter, already in place in right atrium, will be positioned on the interatrial septum. If the patient will not be in sinus rhythm, he/she will be externally cardioverted in order to determine pacing thresholds and impedances on all septal catheter electrodes. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes. Subsequently, a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
120729|NCT03242928|Drug|AFQ056|Tablets
120730|NCT03242928|Drug|Placebo|Tablets
120731|NCT03242915|Drug|Pembrolizumab|200mg IV every 3 weeks
120732|NCT03242915|Drug|Carboplatin|AUC 5 IV every 3 weeks
120733|NCT03242915|Drug|Pemetrexed|500 mg/m^2 IV every 3 weeks
120734|NCT03242902|Device|Light therapy intensity 1|Exposure to white light (10.000 lux) in the morning
120735|NCT03242902|Device|Light therapy intensity 2|Exposure to white light (10-20 lux) in the morning
120736|NCT03242889|Drug|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
120737|NCT03242876|Other|Control|Control will be 109 g white bread to be consumed together with 200 mL water
120949|NCT03241121|Device|Eating patterns|Data collection on eating patterns via the smartphone app
120738|NCT03242876|Other|Test|Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
120739|NCT03242863|Other|Food proportionality|Proportions of high and low energy dense foods manipulated
120740|NCT03242850|Behavioral|Intervention Group|This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
120741|NCT03242837|Behavioral|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
120742|NCT03242837|Other|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
120743|NCT03242824|Drug|Fluorine F 18 Fluorodopa|Contrast used in PET
120744|NCT03242824|Radiation|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
120745|NCT03242824|Procedure|Positron Emission Tomography|imaging test
120746|NCT03242811|Diagnostic Test|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.~Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.~After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
120747|NCT03242785|Other|Self-monitoring/Self-titration|"The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:~Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.~Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)~Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment."
120748|NCT03242772|Drug|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward by 1 tablet = 3.1 mg or 0 mg every 2 weeks unless there are intolerable adverse effects or great improvement in ADHD symptoms to a target dose of 4 tablets = 12.4 mg or 0 mg of Adzenys- XR-ODT. The allowable dose range will range from 1.6/0 mg (1/2 tablet) to 18.6/0 mg (6 tablets). Doses may be reduced at any point during the trial (typically in 1 tablet increments) but only may be increased every two weeks in order to fully assess potential benefits and adverse events of the current dose.
120749|NCT03242772|Behavioral|P-ESDM|Weekly sessions of the behavioral intervention will be delivered by a certified P-ESDM therapist. All participants in the trial and their primary caregivers will receive coaching following a manualized intervention (includes individualized learning objectives, intervention coaching for behavior management, handouts).
120750|NCT03242772|Drug|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 24 weeks (starting 10 weeks prior to initiation of P-ESDM Intervention). Placebo appears identical to the active drug (Adzenys-XR-ODT) and flexible titration schedule will also be used.
120751|NCT03242759|Drug|nintedanib|Drug
120752|NCT03242759|Drug|pirfenidone|Drug
120753|NCT03242733|Other|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
120754|NCT03242720|Procedure|Cardiac Ablation for Atrial Fibrillation|Ablation of arrhythmia focus in the heart for atrial fibrillation
120755|NCT03242707|Biological|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.~The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
120756|NCT03242707|Drug|Hyaluronic Acid|Synvisc-One® is a high molecular weight sodium hyaluronate.
120757|NCT03242694|Diagnostic Test|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
120758|NCT03242694|Procedure|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
120759|NCT03242681|Procedure|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
120760|NCT03242668|Procedure|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
120761|NCT03242668|Procedure|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
120762|NCT03242668|Drug|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
120763|NCT03242655|Behavioral|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
120764|NCT03242642|Device|Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)|mitral valve replacement
120765|NCT03242642|Device|Surgical Mitral Valve Replacement (SMVR)|mitral valve replacement
120766|NCT03242629|Drug|oral chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
120767|NCT03242629|Drug|enema chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
120768|NCT03242616|Drug|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)~Pemetrexed (500 mg/m2, day 1)"
120769|NCT03242616|Drug|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
120770|NCT03242603|Biological|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
120771|NCT03242590|Drug|LPCN 1021|Oral testosterone undecanoate
120772|NCT03242564|Device|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
120773|NCT03242551|Drug|Chemotherapy|"AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days."
120774|NCT03242538|Behavioral|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
120775|NCT03242525|Diagnostic Test|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
120776|NCT03242512|Biological|TK006|Subcutaneous injection
120777|NCT03242499|Drug|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
120778|NCT03242499|Drug|Placebo|placebo for 48 weeks
120779|NCT03242486|Device|toric intraocular lens|
120780|NCT03242473|Other|Fluid Management|The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
120781|NCT03242460|Drug|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
120782|NCT03242460|Drug|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
120783|NCT03242460|Drug|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
120784|NCT03242447|Behavioral|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
120785|NCT03242447|Behavioral|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
120786|NCT03242434|Other|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose [5 grams (g)]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
120787|NCT03242434|Other|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
120788|NCT03242408|Drug|LPCN 1021|Oral testosterone undecanoate
120789|NCT03242382|Drug|Palbociclib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
120790|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
120791|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
120792|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
120793|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
120950|NCT03241108|Drug|NI-0101|Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
120951|NCT03241108|Other|Placebo|Placebo
120794|NCT03242356|Other|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :~oral intake of clear fluid during the labor~oral intake of solid meal during the labor~fasting duration for solid and liquids~instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, …)~discomfort related to thirst during labor~discomfort related to hunger during labor~We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
120795|NCT03242343|Device|VasQ|An external support device for AV fistula
120796|NCT03242330|Device|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
120797|NCT03242317|Drug|Mitomycin C|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
120798|NCT03242317|Device|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
120799|NCT03242304|Other|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
120800|NCT03242291|Other|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
120801|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
120802|NCT03242278|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
120803|NCT03242265|Diagnostic Test|IVDD for NK cell activity in whole blood|Two samples of one mL of blood (for baseline IFN-gamma activity and for NK cell activity) and blood samples collected for C-Reactive Protein and White Blood Cell Count, taken up to 8 weeks prior to biopsy and before treatment with antibiotics.
120804|NCT03242252|Drug|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
120805|NCT03242252|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
120806|NCT03242239|Biological|ALT02|
120807|NCT03242239|Biological|EU-licensed Herceptin|
120808|NCT03242239|Biological|US-licensed Herceptin|
120809|NCT03242226|Device|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
120810|NCT03242226|Device|single vision spectacles|Wear single vision spectacle only
120811|NCT03242213|Behavioral|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
120812|NCT03242200|Other|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
120813|NCT03242187|Procedure|Trans-anal total mesorectal excision(TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
120814|NCT03242187|Procedure|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
120815|NCT03242174|Other|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
120816|NCT03242161|Diagnostic Test|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
120817|NCT03242122|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
120818|NCT03242122|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
120819|NCT03242122|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
120820|NCT03242122|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
120821|NCT03242122|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
120822|NCT03242096|Combination Product|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
120823|NCT03242096|Combination Product|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
120824|NCT03242083|Other|quality of life questionnaire|quality of life questionnaire
120825|NCT03242070|Other|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
120826|NCT03242057|Other|NAVA|Infant will be extubated to NAVA, settings based per protocol
120827|NCT03242057|Other|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
120869|NCT03241732|Other|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
120870|NCT03241732|Dietary Supplement|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
121021|NCT03240718|Procedure|Laser treatment|CORE fractional CO2 laser treatment
121022|NCT03240705|Behavioral|Gratitude journaling|Gratitude journaling 3 times a week during surgical rotation
120828|NCT03242044|Procedure|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
120829|NCT03242031|Procedure|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
120830|NCT03242031|Procedure|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
120831|NCT03242018|Drug|Placebo|"Pharmaceutical form: Tablet~Route of administration: Oral"
120832|NCT03242018|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet~Route of administration: Oral"
120833|NCT03242005|Device|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
120834|NCT03242005|Device|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
120835|NCT03241992|Behavioral|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
120836|NCT03241953|Procedure|Periodontal surgery|A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
120837|NCT03241940|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
120838|NCT03241940|Drug|Cyclophosphamide|Given IV
120839|NCT03241940|Drug|Fludarabine Phosphate|Given IV
120840|NCT03241940|Other|Laboratory Biomarker Analysis|Correlative studies
120841|NCT03241940|Other|Questionnaire Administration|Ancillary studies
120842|NCT03241927|Biological|Pembrolizumab|Day 1 of each 3 week cycle
120843|NCT03241914|Drug|Megestrol Acetate|At a dosage of 160 mg/day
120844|NCT03241914|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
120845|NCT03241901|Drug|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
120846|NCT03241901|Drug|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
120847|NCT03241901|Other|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
120848|NCT03241888|Drug|Megestrol Acetate|At a dosage of 160 mg/day
120849|NCT03241888|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
120850|NCT03241875|Drug|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
120851|NCT03241875|Drug|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
120852|NCT03241875|Drug|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
120853|NCT03241862|Device|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
120854|NCT03241849|Procedure|Modified surgical technique for placenta accreta|suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
120855|NCT03241836|Diagnostic Test|trans-perineal ultrasonography|accuracy of trans perineal ultrasonography in identification of female pelvic floor dysfunction
120856|NCT03241823|Diagnostic Test|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
120857|NCT03241823|Diagnostic Test|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
120858|NCT03241823|Diagnostic Test|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
120859|NCT03241823|Diagnostic Test|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
120860|NCT03241810|Drug|Seribantumab|Seribantumab is a human monoclonal antibody that targets ErbB3, a cell surface receptor that is activated by the ligand heregulin. Heregulin-driven ErbB3 signaling has been implicated as a mechanism of tumor growth and resistance to targeted, cytotoxic and anti-endocrine therapies. When used in the combination setting, seribantumab is designed to block ErbB3 signaling in order to enhance the anti-tumor effect of a combination therapy partner.
120861|NCT03241810|Drug|Fulvestrant|Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
120862|NCT03241810|Drug|Placebo|Placebo
120863|NCT03241797|Procedure|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
120864|NCT03241784|Biological|Autologous T-regulatory lymphocytes|intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
120865|NCT03241784|Biological|Interleukin-2|Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
120866|NCT03241771|Behavioral|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
120871|NCT03241719|Drug|IL-2|Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
120872|NCT03241706|Drug|Fructose|IV fructose (1.3 mg/kg/min)
120873|NCT03241706|Drug|Saline|Saline given as a comparison to fructose.
120874|NCT03241706|Drug|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
120875|NCT03241706|Drug|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
120876|NCT03241706|Drug|Glucagon|IV glucagon (0.65 ng/kg/min).
120877|NCT03241706|Drug|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
120878|NCT03241693|Other|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.~In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
120879|NCT03241693|Other|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.~In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
120880|NCT03241680|Diagnostic Test|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.~Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
120881|NCT03241667|Device|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
120882|NCT03241654|Procedure|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
120883|NCT03241641|Drug|Tenofovir Alafenamide|25mg, Daily Oral
120884|NCT03241641|Drug|Tenofovir Disoproxil Fumarate|300mg, Daily Oral
120885|NCT03241628|Device|Dressing Glove|Viscose dressing glove
120886|NCT03241615|Other|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
120887|NCT03241602|Drug|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
120888|NCT03241602|Procedure|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
120889|NCT03241602|Combination Product|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
120890|NCT03241589|Other|VA Telederm mobile app introduction|VA employees begin use of OCC's VA Telederm mobile app.
120891|NCT03241589|Other|My Telederm mobile app introduction|VA employees begin use of OCC's My Telederm mobile app.
120892|NCT03241576|Behavioral|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
120893|NCT03241576|Behavioral|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
120894|NCT03241563|Drug|Sodium Deoxycholate|
120895|NCT03241563|Drug|Triamcinolone|Triamcinolone 40mg/ml
120896|NCT03241550|Drug|isavuconazonium sulfate - intravenous|IV infusion
120897|NCT03241550|Drug|isavuconazonium sulfate - oral|Oral
120898|NCT03241537|Radiation|Intensity modulated radiotherapy|
120899|NCT03241524|Other|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
120900|NCT03241511|Other|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
120901|NCT03241498|Other|Medicines optimisation|
120902|NCT03241485|Drug|Intrathecal morphine|5 micrograms/kilogram of intrathecal morphine administered in the spinal space, not to exceed 1mg
120903|NCT03241485|Drug|Placebo|Saline intrathecal given in the same manner as the intervention groups.
120906|NCT03241459|Device|Surmodics SurVeil DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter. Study is 1:1 randomized against comparator.
120907|NCT03241459|Device|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter. Study is 1:1 randomized against SurVeil DCB.
120908|NCT03241446|Drug|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
120909|NCT03241433|Other|High intensity interval training|exercise by use of stationary cycles
120910|NCT03241433|Other|Moderate intensity continuous training|exercise by use of stationary cycles
120911|NCT03241433|Other|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
120912|NCT03241420|Device|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
120913|NCT03241407|Other|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
120914|NCT03241407|Other|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
120915|NCT03241381|Diagnostic Test|vitamin D serum assay study and control groups|Serum- vitamin D assay
120916|NCT03241381|Diagnostic Test|Photometry|Serum- Hemoglobin assay
120917|NCT03241381|Other|Russels periodontal index|Clinical examination for periodontitis
120918|NCT03241368|Device|Capsule Endoscopy|At baseline subject will under the PillCam Crohn's Capsule Procedure
120919|NCT03241355|Dietary Supplement|prebiotic inulin-type fructan|
120920|NCT03241355|Dietary Supplement|Placebo maltodextrin|
120921|NCT03241342|Drug|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
120922|NCT03241342|Drug|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
120923|NCT03241316|Behavioral|Observational study of behaviour|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
120924|NCT03241303|Drug|Acarbose|Glucobay tablets on experimental day.
120925|NCT03241303|Drug|Placebo Oral Tablet|Placebo tablets on experimental day.
120926|NCT03241303|Drug|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
120927|NCT03241303|Drug|Placebo Saline|9 mg/ml placebo saline infusion on experimental day.
120928|NCT03241277|Procedure|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
120929|NCT03241264|Drug|ND-L02-s0201|Specified dose on specified day
120930|NCT03241251|Other|questionnaire|Questionnaire of psychosocial risk factors
120931|NCT03241238|Other|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
120932|NCT03241225|Behavioral|EM/PROTECT|EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
120933|NCT03241225|Behavioral|EM/MH|EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
120934|NCT03241212|Behavioral|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
120935|NCT03241199|Drug|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
120936|NCT03241186|Drug|Ipilimumab|1mg/kg
120937|NCT03241186|Drug|Nivolumab|3mg/kg
120938|NCT03241186|Drug|Nivolumab|480mg
120939|NCT03241173|Drug|INCAGN01949|In Phase 1 subjects will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment.
120940|NCT03241173|Drug|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
120941|NCT03241173|Drug|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
120942|NCT03241173|Drug|INCAGN01949|In Phase 1 subjects will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
120943|NCT03241160|Other|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
120944|NCT03241147|Drug|Lu AF35700|Single dose, 10 mg film coated tablet
120945|NCT03241134|Other|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
120946|NCT03241134|Other|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
120947|NCT03241121|Behavioral|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
120952|NCT03241095|Procedure|OMT (Osteopathic Manipulative Treatment)|The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.
120953|NCT03241095|Procedure|Sham intervention|The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
120954|NCT03241082|Device|ultrasound|validation of portable ultrasound to measure body composition
120955|NCT03241069|Other|Reference position|patient is put in a 30 degree supine position during 5 minutes
120956|NCT03241069|Other|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
120957|NCT03241069|Other|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
120958|NCT03241069|Drug|Nitroglycerin|0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
120959|NCT03241069|Other|leg rising|45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.
120960|NCT03241056|Behavioral|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
120961|NCT03241056|Other|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
120962|NCT03241043|Drug|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
120963|NCT03241043|Drug|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
120964|NCT03241030|Drug|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
120965|NCT03241030|Other|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
120966|NCT03241030|Drug|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
120967|NCT03241030|Drug|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
120968|NCT03241017|Drug|Durvalumab|Immunotherapy with Durvalumab after ASCT
120969|NCT03241004|Other|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
120970|NCT03240991|Other|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
120971|NCT03240978|Behavioral|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
120972|NCT03240965|Diagnostic Test|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
120973|NCT03240965|Other|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
120974|NCT03240965|Diagnostic Test|Taste-/smell-test|Taste-/smell-test
120975|NCT03240965|Diagnostic Test|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
120976|NCT03240939|Drug|Dutasteride 0.5 mg|single dose
120977|NCT03240939|Drug|Tadalafil 5 mg|single dose
120978|NCT03240939|Drug|YY-201|single dose
120979|NCT03240926|Device|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
120980|NCT03240913|Behavioral|Baseline and Follow-up Surveys|(completed online)
120981|NCT03240913|Other|Patient Reported Outcome Measure informed Decision Aid|(PROM-DA)
120982|NCT03240913|Other|Pamphlet|(usual care)
120983|NCT03240900|Device|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
120984|NCT03240900|Procedure|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
120985|NCT03240887|Behavioral|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
121084|NCT03240185|Behavioral|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
120986|NCT03240874|Behavioral|SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
120987|NCT03240874|Behavioral|SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
120988|NCT03240874|Behavioral|SweetMama Feasibility Testing - Pilot Randomized Trial|"Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage."
120989|NCT03240861|Other|18F-FHBG|Given IV
120990|NCT03240861|Biological|Aldesleukin|Given SC
120991|NCT03240861|Drug|Busulfan|Given IV
120992|NCT03240861|Biological|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
120993|NCT03240861|Procedure|Computed Tomography|Undergo PET/CT
120994|NCT03240861|Biological|Filgrastim|Given SC
120995|NCT03240861|Drug|Fludarabine|Given IV
120996|NCT03240861|Procedure|Leukapheresis|Undergo leukapheresis
120997|NCT03240861|Drug|Plerixafor|Given SC
120998|NCT03240861|Procedure|Positron Emission Tomography|Undergo PET/CT
120999|NCT03240848|Procedure|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
121000|NCT03240848|Procedure|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.
121001|NCT03240848|Procedure|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
121002|NCT03240835|Drug|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
121003|NCT03240835|Radiation|IMRT|intensity modulation radiation therapy
121004|NCT03240822|Procedure|Penile Transplant|Penile Allotransplantation
121005|NCT03240822|Biological|Monoclonal Antibody (Humanized Anti-CD52)|
121006|NCT03240822|Drug|Tacrolimus|
121007|NCT03240809|Biological|Brodalumab|140 mg SC dose
121008|NCT03240809|Biological|Brodalumab|70 mg SC dose
121009|NCT03240796|Procedure|minimal invasive surgery and secondary IOL implantation|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter and moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities. Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus.
121010|NCT03240796|Procedure|traditional cataract surgery and secondary IOL implantation|"traditional cataract surgery: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy (ACCC+ I/A + PCCC + Anti-vit).~Secondary IOL implantation: implant the IOL either into the capsule bag or fix at the ciliary sulcus."
121011|NCT03240783|Drug|Betamethasone OR Dexamethasone Injectable|Procedural agents. The steroid and local anaesthetic preparation will be standardized to replicate current radiology interventional practices that use either particulate or non-particulate steroids. Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml). Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).
121012|NCT03240783|Drug|Normal Saline Flush, 0.9% Injectable Solution|Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
121013|NCT03240783|Drug|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet: 15 day taper dosing is: days 1-5 8mg (4mg bd) , days 6-10 4 mg (2mg bd), and days 11-15 2 mg (1mg bd). The dexamethasone is over-encapsulated in a gelatine capsule that is identical to the placebo capsule in appearance.
121014|NCT03240783|Other|Sham Injection and/or oral placebo|The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
121015|NCT03240770|Device|VPro5 device|Use of the VPro5 device for 5 minutes a day
121016|NCT03240770|Other|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
121017|NCT03240757|Dietary Supplement|Breakfast|All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests [one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.
121018|NCT03240757|Other|exercise|aerobic exercise at 40% of VO2max, for 20 minutes
121019|NCT03240744|Biological|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
121020|NCT03240731|Biological|bone marrow transplant|haploidentical bone marrow transplant
121023|NCT03240692|Device|Accelerated theta-burst stimulation treatment|"All participants will receive intermittent theta-burst stimulation (iTBS) to the left dorsal lateral prefrontal cortex (L-DLPFC). The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of resting motor threshold (adjusted for cortical depth).~Stimulation will be delivered to L-DLPFC using the Magventure Magpro X100 and/or the NextStim TMS system."
121024|NCT03240679|Device|Extracellular Matrix|ECM are composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling have been investigated in preclinical as well as clinical pilot studies and found to facilitate constructive healing following EMR
121025|NCT03240666|Other|non applicable|non applicable
121026|NCT03240653|Other|Stratified response to Enzyme Therapy|Observational study involving reviewing retrospective and prospective data of participants medical history, pathology, imaging and health questionnaires.
121027|NCT03240640|Procedure|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
121028|NCT03240640|Procedure|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
121029|NCT03240627|Drug|LH-8|LH-8 cutaneous solution
121030|NCT03240627|Drug|Placebos|Placebo cutaneous solution
121031|NCT03240614|Device|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
121032|NCT03240614|Device|Bag-valve-mask|This intervention will be preoxygenation using a BVM apparatus for preoxygenation for 3 minutes. At the end of 3 minutes an ABG will be obtained.
121033|NCT03240614|Device|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
121034|NCT03240601|Device|Transcutaneous spinal cord stimulation|For tcSCS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
121035|NCT03240588|Device|Neurostimulation System|Spinal cord stimulation
121036|NCT03240575|Drug|Tiotropium|Fixed Dose Combination
121037|NCT03240575|Drug|Olodaterol|Fixed Dose Combination
121038|NCT03240575|Drug|Fluticasone propionate|Fixed Dose Combination
121039|NCT03240575|Drug|Salmeterol|Fixed Dose Combination
121040|NCT03240562|Procedure|serratus anterior plane block|before surgery :ultrasound-guided serratus anterior plane block
121041|NCT03240562|Drug|patient controlled analgesia|two groups have same intravenous patient controlled analgesia
121042|NCT03240549|Drug|bevacizumab|The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
121043|NCT03240536|Other|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.~The three guidelines included will be:~Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).~Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology~Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
121044|NCT03240523|Drug|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
121045|NCT03240497|Behavioral|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.~After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol [7]."
121046|NCT03240497|Behavioral|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
121047|NCT03240484|Diagnostic Test|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down.
121085|NCT03240159|Drug|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg~Active Comparator:~Down regulation of LH, during exposing in three different doses of Degarelix"
121086|NCT03240146|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device
121087|NCT03240133|Drug|BCX7353|oral liquid formulation
121088|NCT03240133|Drug|Placebo|oral liquid formulation to match BCX7353
121089|NCT03240120|Drug|Dabigatran etexilate|Pradaxa 150 mg hard capsules
121048|NCT03240484|Other|Gait Analysis|Certain patients may be asked to participate in a motion analysis procedure at the Human Movement Laboratory at the University of Ottawa. This procedure takes approximately 1.5 hours and you will only be asked to participate in the motion analysis procedure once. Participants will change into a custom-designed tight body suit, which has reflective markers on its surface for infrared video capture. Participants will then have pairs of surface electromyography (EMG) electrodes placed on certain areas of the skin on the legs and on the back. Wearing the EMG electrodes and marker suit, participants will perform 5 trials of walking on a level walkway, walking up and down a 3-step staircase, sitting from a standing position, and standing from a seated position.
121049|NCT03240471|Procedure|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
121050|NCT03240471|Procedure|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
121051|NCT03240458|Device|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
121052|NCT03240445|Drug|ODM-203 (Period 1)|ODM-203 400mg as tablets taken 30 minutes after food
121053|NCT03240445|Drug|ODM-203 (Period 2)|ODM-203 400mg as tablets taken 1 hour before a light breakfast
121054|NCT03240445|Drug|ODM-203 (Periods 3-6)|ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
121055|NCT03240432|Device|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
121056|NCT03240419|Dietary Supplement|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
121057|NCT03240419|Dietary Supplement|Placebo|capsule manufactured to mimic probiotic capsules.
121058|NCT03240406|Other|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
121059|NCT03240406|Other|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
121060|NCT03240393|Drug|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and < 6 cMET mutations
121061|NCT03240380|Behavioral|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.~Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
121062|NCT03240380|Behavioral|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.~When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
121063|NCT03240367|Other|Coutery|Stapler line bleeding control with coutery
121064|NCT03240354|Device|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
121065|NCT03240354|Device|Control|Cuff of endotracheal tube inflated with air
121066|NCT03240341|Behavioral|Patient Activation Measure Questionnaire|Measure the level of patient engagement in cancer care pathway
121067|NCT03240328|Biological|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
121068|NCT03240302|Device|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
121069|NCT03240302|Device|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
121070|NCT03240289|Behavioral|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
121071|NCT03240276|Other|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
121072|NCT03240276|Device|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
121073|NCT03240276|Other|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
121074|NCT03240263|Procedure|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device*. Resistance adjusted to the highest tolerable load.~*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
121075|NCT03240263|Procedure|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device*. Low training resistance adjusted to <10% maximal inspiratory pressure.~*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
121076|NCT03240250|Procedure|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
121077|NCT03240250|Procedure|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
121078|NCT03240237|Device|Optimizer SMART|Cardiac Contractility Modulation
121079|NCT03240224|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
121080|NCT03240224|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
121081|NCT03240211|Drug|Pembrolizumab|Pembrolizumab 200 mg IV
121082|NCT03240211|Drug|Pralatrexate|Pralatrexate 20-30 mg/m2 IV
121083|NCT03240211|Drug|Decitabine|Decitabine 10-20 mg/m2
121090|NCT03240120|Drug|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
121091|NCT03240107|Procedure|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.~The skin incision closed by continuous suture with 6-0 prolene."
121092|NCT03240107|Procedure|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.~. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
121093|NCT03240094|Other|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
121094|NCT03240081|Drug|50mcg estradiol cream|Use of study drug nightly
121095|NCT03240081|Drug|100mcg estradiol cream|Use of study drug nightly
121096|NCT03240068|Drug|Angiotensin 1-7|This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
121097|NCT03240068|Drug|Saline|Normal saline will be used as the placebo comparator.
121098|NCT03240055|Drug|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
121099|NCT03240055|Other|etomidate|receive etomidate only
121100|NCT03240042|Procedure|nasotracheal intubation|The participants either receive intubation via nasal route.
121101|NCT03240042|Procedure|orotracheal intubation|The participants either receive intubation via oral route.
121102|NCT03240029|Other|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
121103|NCT03240016|Drug|Pembrolizumab|200mg IV D1
121104|NCT03240016|Drug|abraxane|125mg/m^2 D1 and D8
121105|NCT03240003|Behavioral|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
121106|NCT03240003|Behavioral|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
121107|NCT03240003|Behavioral|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
121108|NCT03239990|Behavioral|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
121109|NCT03239977|Behavioral|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
121110|NCT03239977|Behavioral|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
121111|NCT03239964|Drug|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethasone (4 mg/mL) in wound tissue.
121112|NCT03239964|Other|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
121113|NCT03239951|Device|iTind|temporary implant
121114|NCT03239938|Behavioral|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
121115|NCT03239938|Behavioral|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
121116|NCT03239925|Radiation|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
121117|NCT03239925|Radiation|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
121118|NCT03239912|Device|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
121119|NCT03239912|Other|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
121120|NCT03239899|Drug|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at baseline.
121121|NCT03239886|Other|imatinib discontinuation|imatinib discontinuation
121122|NCT03239873|Biological|VARIVAX® PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
121123|NCT03239873|Biological|VARIVAX® 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
121128|NCT03239834|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
121129|NCT03239821|Device|VIPUN Balloon Catheter 0.1 deflated|deflation balloon
121130|NCT03239821|Drug|Codeine Phosphate|58.8 mg codeïne phosphate
121131|NCT03239821|Drug|Placebo|Sirupus Simplex
121132|NCT03239821|Device|VIPUN Balloon Catheter 0.1 inflated|VIPUN Balloon Catheter 0.1 inflated
121133|NCT03239808|Procedure|Incremental haemodialysis|It consists in reducing the frequency or number of sessions per week with which patients start the HD treatment. The experimental group will start with one session/week, then the number of weekly sessions will be increased to two and later to three as per criteria for progression
121134|NCT03239808|Procedure|Conventional haemodialysis|It is controlled through usual clinical practice, based on starting the HD treatment with three sessions per week (control group).
121135|NCT03239795|Other|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
121136|NCT03239782|Behavioral|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
121137|NCT03239769|Procedure|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
121138|NCT03239756|Biological|TK006|Subcutaneous injection
121139|NCT03239743|Device|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
121140|NCT03239743|Drug|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
121141|NCT03239717|Other|Whey protein powder|Subjects in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder (Abbott).
121142|NCT03239717|Other|BCAD2|Subjects in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
121143|NCT03239704|Behavioral|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
121144|NCT03239704|Other|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
121145|NCT03239704|Behavioral|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
121146|NCT03239691|Drug|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
121147|NCT03239691|Drug|Placebo|Matching placebo available as matching capsules for oral administration
121148|NCT03239678|Drug|100% Oxygen|Conventional preoxygenation with 100% oxygen
121149|NCT03239678|Drug|30% Oxygen|preoxygenation with 30% oxygen
121150|NCT03239678|Drug|21% Oxygen|preoxygenation with 21% oxygen
121151|NCT03239678|Drug|40% Oxygen|preoxygenation with 40% oxygen
121152|NCT03239678|Drug|60% Oxygen|preoxygenation with 60% oxygen
121153|NCT03239678|Drug|80% Oxygen|preoxygenation with 80% oxygen
121154|NCT03239665|Behavioral|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
121155|NCT03239665|Behavioral|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
121156|NCT03239652|Device|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
121157|NCT03239639|Behavioral|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
121158|NCT03239639|Other|Wait list control|No intervention
121159|NCT03239626|Radiation|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
121160|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
121161|NCT03239600|Drug|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
121162|NCT03239600|Drug|Placebo|Placebo solution will be administered by IV infusion.
121163|NCT03239600|Drug|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
121164|NCT03239587|Behavioral|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
121165|NCT03239587|Procedure|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.~Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
121166|NCT03239587|Behavioral|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
121243|NCT03239015|Drug|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
121167|NCT03239561|Drug|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
121168|NCT03239535|Biological|Mesenchymal stem cells|Intramuscular injection
121169|NCT03239535|Biological|Normal saline|Intramuscular injection
121170|NCT03239522|Drug|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of [14C]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
121171|NCT03239522|Drug|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of [14C]-GSK1278863 oral solution (total dose: 25 mg).
121172|NCT03239522|Drug|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
121173|NCT03239509|Procedure|bioprosthesis implantation between 2000-2015|Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
121174|NCT03239509|Procedure|mechanical prosthesis implantation between 2000-2015|Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
121175|NCT03239496|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
121176|NCT03239496|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
121177|NCT03239483|Drug|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
121178|NCT03239483|Drug|Placebo gel|Universal HEC placebo gel; administered rectally
121179|NCT03239470|Biological|Cohort 1: 1.0 x 10^8 PolyTregs|Each participant will receive a target cell dose of 1.0 x 10^8 polyclonal Tregs.
121180|NCT03239470|Biological|Cohort 2: 2.5x10^8 PolyTregs|Each participant will receive a target cell dose of 2.5x10^8 polyclonal Tregs.
121181|NCT03239457|Biological|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
121182|NCT03239444|Device|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
121183|NCT03239431|Other|asthmatic exacerbation|evaluate the risk factors, frequency and nature of asthma exacerbations
121184|NCT03239418|Device|Neuromuscular electrical stimulation|A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.
121185|NCT03239418|Device|Sham neuromuscular electrical stimulation|Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
121186|NCT03239405|Device|Suction callibrated system|One-step suction callibrated SG system
121187|NCT03239392|Drug|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
121188|NCT03239379|Drug|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
121189|NCT03239379|Drug|Placebo|Normal Saline
121190|NCT03239366|Other|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
121191|NCT03239366|Other|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
121192|NCT03239353|Drug|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
121193|NCT03239340|Drug|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
121194|NCT03239327|Drug|Misoprostol|
121195|NCT03239314|Drug|Saline Solution|Injected in the adductor canal
121196|NCT03239314|Drug|Dexamethasone|Injected in the adductor canal
121197|NCT03239301|Procedure|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
121198|NCT03239301|Procedure|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
121199|NCT03239288|Other|Control digestible carbohydrate|Single serving of control product
121200|NCT03239288|Other|Test resistant starch type 4|Single serving of test product
121201|NCT03239275|Procedure|Biocreative therapy|
121244|NCT03239015|Drug|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
121245|NCT03239015|Drug|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
121246|NCT03239015|Drug|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
121247|NCT03239015|Drug|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
121202|NCT03239262|Procedure|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.~GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
121203|NCT03239262|Procedure|No intervention|No intervention was performed in patients without ganglionated plexi.
121204|NCT03239249|Other|IKO-model|A systematic model for drop-out prevention.
121205|NCT03239249|Other|Treatment as usual|Schools randomized to control group (22) work as previously with school dropout
121206|NCT03239236|Procedure|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
121207|NCT03239236|Procedure|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
121208|NCT03239236|Procedure|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
121209|NCT03239236|Procedure|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
121210|NCT03239236|Procedure|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
121211|NCT03239236|Drug|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
121212|NCT03239236|Diagnostic Test|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
121213|NCT03239236|Diagnostic Test|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
121214|NCT03239236|Diagnostic Test|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
121215|NCT03239223|Drug|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
121216|NCT03239210|Drug|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
121217|NCT03239210|Drug|Placebo|placebo equivalent
121218|NCT03239184|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
121219|NCT03239184|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
121220|NCT03239171|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
121221|NCT03239171|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
121222|NCT03239158|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
121223|NCT03239158|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
121224|NCT03239145|Drug|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
121225|NCT03239145|Drug|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
121226|NCT03239132|Behavioral|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
121227|NCT03239132|Behavioral|Meditation educational materials|Meditation educational materials
121228|NCT03239119|Biological|rE-4 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
121229|NCT03239119|Biological|rE-4 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
121230|NCT03239119|Biological|Placebo 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
121231|NCT03239119|Biological|Placebo 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
121232|NCT03239106|Drug|Apremilast|Apremilast 30 mg BID daily
121233|NCT03239093|Other|No intervention|Observational study using official data from the Federal Office of Statistics
121234|NCT03239080|Drug|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
121235|NCT03239080|Other|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
121236|NCT03239054|Behavioral|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
121237|NCT03239054|Behavioral|Control group|Information will be given as part of standard care
121238|NCT03239041|Behavioral|Social navigation team|Social navigation team
121239|NCT03239028|Behavioral|Observational|
121240|NCT03239015|Drug|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
121241|NCT03239015|Drug|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
121242|NCT03239015|Drug|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
121248|NCT03239015|Drug|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
121249|NCT03239015|Drug|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
121250|NCT03239015|Drug|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
121251|NCT03238989|Other|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
121252|NCT03238976|Other|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
121253|NCT03238963|Drug|BI 1467335|Once daily
121254|NCT03238963|Drug|Placebo|Once daily
121255|NCT03238950|Other|Porcine model|participants to conduct training on porcine model
121256|NCT03238950|Other|Synthetic model|participants to conduct training on synthetic model
121257|NCT03238937|Device|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
121258|NCT03238924|Drug|Oxytocin|40 IU oxytocin nasal spray, self-administered
121259|NCT03238924|Drug|Placebos|Saline nasal spray, self-administered
121260|NCT03238911|Drug|Iron isomaltoside (Monofer)|administered IV
121261|NCT03238911|Drug|Ferric carboxymaltose|administered IV
121262|NCT03238898|Drug|Botulinum toxin type A|"botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
121263|NCT03238898|Other|Normal saline|"Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
121264|NCT03238885|Diagnostic Test|pelvic MR examination|All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
121265|NCT03238872|Behavioral|Cognitive Behavioural Therapy|
121266|NCT03238872|Other|Treatment as usual|
121267|NCT03238859|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
121268|NCT03238859|Device|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
121269|NCT03238846|Other|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
121270|NCT03238846|Other|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
121271|NCT03238833|Other|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
121272|NCT03238833|Other|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
121273|NCT03238820|Procedure|Robotic gastric gastrointestinal stromal tumors resection|Robotic gastric gastrointestinal stromal tumors resection
121274|NCT03238807|Drug|Human Chorionic Gonadotropin|500 IU of human Chorionic Gonadotropin
121275|NCT03238794|Procedure|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
121276|NCT03238794|Other|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
121277|NCT03238781|Drug|Placebo|Placebo Comparator
121278|NCT03238781|Drug|AMG 301|Investigational Product
121279|NCT03238781|Drug|AMG 301|Investigational Product
121280|NCT03238768|Other|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
121281|NCT03238768|Other|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
121282|NCT03238755|Other|Cardiac MRI/MRS|whole blood, plasma, and serum
121283|NCT03238742|Drug|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
121284|NCT03238742|Drug|normal saline|200ml normal saline every 12 hours for 5 days
121285|NCT03238729|Behavioral|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
121286|NCT03238729|Behavioral|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
121287|NCT03238716|Other|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
121329|NCT03238495|Drug|Taxotere, Carboplatin, Herceptin + Pertuzumab|TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
121288|NCT03238716|Other|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
121289|NCT03238716|Other|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at > 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
121290|NCT03238703|Drug|Anastrozole|Given PO
121291|NCT03238703|Drug|Exemestane|Given PO
121292|NCT03238703|Other|Laboratory Biomarker Analysis|Correlative studies
121293|NCT03238703|Drug|Letrozole|Given PO
121294|NCT03238703|Other|Quality-of-Life Assessment|Ancillary studies
121295|NCT03238703|Other|Questionnaire Administration|Ancillary studies
121296|NCT03238703|Drug|Tamoxifen Citrate|Given PO
121297|NCT03238703|Drug|Toremifene Citrate|Given PO
121298|NCT03238690|Device|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
121299|NCT03238677|Behavioral|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
121300|NCT03238677|Behavioral|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
121301|NCT03238677|Behavioral|Distributed Practice|2 sessions per week for 10 weeks
121302|NCT03238677|Behavioral|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
121303|NCT03238664|Procedure|Biopsy|Undergo biopsy of bladder tumor
121304|NCT03238664|Device|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
121305|NCT03238664|Other|Laboratory Biomarker Analysis|Correlative studies
121306|NCT03238664|Procedure|Radical Cystectomy|Undergo RARC
121307|NCT03238664|Device|Ultrasonography|Undergo CEUS
121308|NCT03238651|Drug|TAK-659|TAK-659 Tablets.
121309|NCT03238638|Drug|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
121310|NCT03238638|Drug|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
121311|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
121312|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
121313|NCT03238625|Drug|Lidocaine|Lidocaine injection
121314|NCT03238625|Drug|Sodium cloride 0.9%|Placebo
121315|NCT03238612|Drug|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
121316|NCT03238612|Drug|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
121317|NCT03238599|Behavioral|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
121318|NCT03238586|Behavioral|WELL Program|
121319|NCT03238560|Drug|Montelukast Chewable Tablet|Montelukast treatment was used at a dosage of 5mg/day once daily
121320|NCT03238547|Diagnostic Test|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
121321|NCT03238547|Diagnostic Test|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
121322|NCT03238534|Device|Neobianacid®|Oral administrations of Neobianacid® (30' after meals and on demand)
121323|NCT03238534|Drug|Omeprazole 20mg|Daily administration Omeprazole 20mg (per os, 30' before breakfast).
121324|NCT03238534|Other|Neobianacid® placebo|Oral administrations of Neobianacid® placebo (30' after meals and on demand)
121325|NCT03238534|Other|Omeprazole placebo|Daily administration Omeprazole placebo (per os, 30' before breakfast).
121326|NCT03238521|Procedure|Spinal osteosynthesis with classical pedicle finder|Posterior thoracic and lumbar osteosynthesis with classical pedicle finder
121327|NCT03238521|Procedure|Spinal osteosynthesis with pedicle finder with impedancemetry|Posterior thoracic and lumbar osteosynthesis with pedicle finder with impedancemetry
121328|NCT03238508|Procedure|Deferred stenting|Previously described
121330|NCT03238495|Drug|Metformin|TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
121331|NCT03238482|Drug|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
121332|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
121333|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
121334|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
121335|NCT03238469|Device|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
121336|NCT03238456|Behavioral|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
121337|NCT03238430|Drug|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
121338|NCT03238430|Drug|Morphine PCA|a postoperative Morphine PCA
121339|NCT03238430|Drug|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector after bolus of 20 ml
121340|NCT03238417|Other|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
121341|NCT03238404|Procedure|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
121342|NCT03238404|Procedure|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
121343|NCT03238391|Procedure|Ischemic preconditioning|It is mentioned before in arm/group descriptions
121344|NCT03238378|Radiation|Brachytherapy|Brachytherapy d 1-5(6)
121345|NCT03238378|Other|Hyperthermia|Hyperthermia d 2 + 5
121346|NCT03238365|Biological|Nivolumab|Given IV
121347|NCT03238365|Drug|Tadalafil|Given orally
121348|NCT03238365|Procedure|Therapeutic Conventional Surgery|Undergo surgery
121349|NCT03238352|Device|Potassium oxalate|Oral rinse containing 1.5 percent (%) KOX and 0 ppm fluoride
121350|NCT03238352|Drug|Sodium fluoride|Oral rinse containing 0.02% weight by weight (w/w) sodium fluoride (NaF)
121351|NCT03238352|Other|Placebo|Oral rinse containing 0% KOX and 0 ppm fluoride
121352|NCT03238326|Drug|Brexpiprazole|Once daily, oral tablets
121353|NCT03238313|Behavioral|Plan A|
121354|NCT03238313|Behavioral|Toxic Life Cycle of a Cigarette|Video
121355|NCT03238300|Drug|N-Acetylcysteine|N-Acetylcysteine pill.
121356|NCT03238300|Drug|Placebo Oral Capsule|Sugar pill to mimic.
121357|NCT03238287|Device|Mechanical chest compression|In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.
121358|NCT03238287|Other|Manuel chest compression|In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
121359|NCT03238274|Device|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
121360|NCT03238261|Radiation|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
121361|NCT03238248|Drug|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
121362|NCT03238248|Drug|Pevonedistat Infusion|20 mg/m2
121363|NCT03238248|Procedure|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
121364|NCT03238235|Drug|givinostat|suspension of givinostat (10 mg/mL)
121365|NCT03238235|Drug|placebo|suspension manufactured to mimic givinostat
121366|NCT03238222|Behavioral|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
121367|NCT03238209|Diagnostic Test|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
121368|NCT03238196|Drug|Erdafitinib|4mg - 8mg
121369|NCT03238196|Drug|Palbociclib|125 mg
121370|NCT03238196|Drug|Fulvestrant|500 mg
121371|NCT03238183|Drug|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
121372|NCT03238183|Device|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
121373|NCT03238170|Device|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
121374|NCT03238157|Drug|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
121375|NCT03238144|Other|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
121376|NCT03238131|Drug|Ivermectin|Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
121377|NCT03238131|Drug|Albendazole|Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
121378|NCT03238118|Other|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
121379|NCT03238118|Other|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.~Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
121380|NCT03238118|Other|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
121381|NCT03238105|Drug|Thioglycolic Acid|Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.
121382|NCT03238105|Device|Intense Pulsed Light|Monthly sessions for 3 months.
121383|NCT03238092|Drug|Testosterone|testosterone gel daily during the late luteal phase.
121384|NCT03238092|Drug|Estradiol|oral estradiol during the late luteal phase.
121385|NCT03238079|Biological|10% IGIV|300-900 mg/kg
121386|NCT03238066|Radiation|Brachytherapy|HDR/PDR brachytherapy
121387|NCT03238066|Other|Hyperthermia|Interstitial hyperthermia
121388|NCT03238053|Procedure|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
121389|NCT03238053|Device|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
121390|NCT03238053|Device|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
121391|NCT03238040|Other|None, observational study|Observational study, no interventions
121392|NCT03238027|Drug|SNDX-6352|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
121393|NCT03238027|Drug|Durvalumab|Durvalumab (MEDI4736) is a humanized IgG1 kappa mAb that blocks the interaction of PD-L1 with PD-1 CD80 (B7.1) molecules
121394|NCT03238014|Device|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
121470|NCT03237468|Other|Neck strengthening exercise to prevent concussion|Neck strengthening exercise to prevent concussion in student athletes.
121395|NCT03238001|Device|DCTclock|DCTclock is a quick and non-invasive test that measures cognitive function based on a computerized algorithmic analysis of the entire drawing process and output of a well-established cognitive assessment called The Clock Drawing Test (CDT).
121396|NCT03237988|Drug|CPI-444 Capsules|100mg Capsule
121397|NCT03237988|Drug|CPI-444 Tablets|100mg Tablets
121398|NCT03237975|Behavioral|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.~The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
121399|NCT03237975|Other|Routine health education|The control group will receive routine health education.
121400|NCT03237962|Device|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
121401|NCT03237962|Device|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
121402|NCT03237949|Behavioral|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
121403|NCT03237949|Behavioral|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
121404|NCT03237936|Drug|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
121405|NCT03237923|Device|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
121406|NCT03237910|Diagnostic Test|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
121407|NCT03237910|Procedure|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
121408|NCT03237910|Procedure|CPR|chest compressions and ventilations at a rate of 30:2
121409|NCT03237897|Behavioral|Preoperative education class|The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.
121410|NCT03237897|Behavioral|Pedometer|A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
121411|NCT03237871|Behavioral|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
121412|NCT03237858|Device|HeartLogic ON|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
121413|NCT03237858|Device|HeartLogic OFF|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
121414|NCT03237845|Drug|Rimegepant|active
121415|NCT03237845|Drug|Placebo|placebo
121416|NCT03237832|Drug|ARN-6039|Ascending doses per Cohort
121417|NCT03237832|Other|Placebo|Placebo to match ARN-6039
121418|NCT03237819|Drug|Sulfate, Magnesium|"Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.~For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)"
121419|NCT03237819|Drug|Placebo - Concentrate|For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
121420|NCT03237806|Drug|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
121421|NCT03237806|Drug|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
121422|NCT03237793|Procedure|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
121423|NCT03237793|Procedure|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment.
121424|NCT03237780|Drug|Atezolizumab|Given IV
121425|NCT03237780|Drug|Eribulin Mesylate|Given IV
121426|NCT03237780|Other|Laboratory Biomarker Analysis|Correlative studies
121427|NCT03237767|Other|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
121428|NCT03237767|Other|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
121429|NCT03237754|Device|tDCS device from neuroConn|weak electrical direct current stimulation
121430|NCT03237741|Drug|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
121431|NCT03237741|Drug|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
121432|NCT03237741|Drug|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
121433|NCT03237728|Drug|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
121434|NCT03237728|Drug|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
121435|NCT03237728|Drug|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
121436|NCT03237728|Drug|Placebos|Placebos,Q8h,Day1-Day7
121437|NCT03237715|Other|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
121438|NCT03237702|Dietary Supplement|Multi-Carotenoids|All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
121439|NCT03237689|Drug|Hydrocortisone|Low dose hydrocortisone (10mg)
121440|NCT03237689|Drug|Placebo Oral Tablet|capsules of starch 1500 powder
121441|NCT03237676|Other|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
121442|NCT03237676|Other|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.~Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
121443|NCT03237663|Biological|The oral O1 / O139 cholera vaccine (enteric capsules)|
121444|NCT03237637|Drug|oral propranolol|oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
121445|NCT03237637|Drug|oral atenolol|oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
121446|NCT03237624|Device|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
121447|NCT03237624|Device|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
121448|NCT03237624|Behavioral|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
121449|NCT03237611|Drug|Aprepitant 125 mg|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
121450|NCT03237611|Drug|Fosaprepitant 115 MG|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
121451|NCT03237611|Drug|Dexamethasone|Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
121452|NCT03237611|Drug|Ondansetron 16 MG|Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
121453|NCT03237585|Behavioral|Rural response system (RRS) intervention to reduce violence against women|The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
121454|NCT03237572|Drug|Pembrolizumab|Pembrolizumab (200 mg)
121455|NCT03237572|Device|High-intensity focused ultrasound (HIFU)|Ablation will target 50% of the tumor, up to 3 cubic centimeters
121456|NCT03237546|Procedure|Anesthetic regimen including SB|Group receiving general anesthesia with the serratus block
121457|NCT03237546|Procedure|Anesthetic regimen including SB or no block|Group receiving general anesthesia alone
121458|NCT03237533|Drug|Dexamethasone|Dexamethasone will be applied locally on the lesion
121459|NCT03237520|Other|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
121460|NCT03237520|Other|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
121461|NCT03237507|Drug|S-1|40-60mg/m^2 bid, days 1-14, oral，every 3 weeks.
121462|NCT03237507|Drug|oxaliplatin|100mg/m^2 days 1，intravenous infusion, every 3 weeks.
121463|NCT03237507|Device|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
121464|NCT03237507|Drug|Paclitaxel|intraperitoneal perfusion
121465|NCT03237481|Drug|HTX-011|HTX 011, 300 mg
121466|NCT03237481|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg
121467|NCT03237481|Drug|Saline placebo|Saline placebo
121468|NCT03237481|Device|Luer-lock applicator|Applicator for instillation
121469|NCT03237481|Device|Vial access device|Device for withdrawal of drug product
121471|NCT03237455|Diagnostic Test|Thoracic spine x-rays+whole spine MRI|PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints
121472|NCT03237455|Diagnostic Test|blood tests|blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.
121473|NCT03237455|Other|constitutional and demographic data collection|demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference
121474|NCT03237442|Biological|human umbilical cord mesenchymal stem cells|human UC-MSCs: 0.2ml(about 2*10^6 cells) subconjunctival injection
121475|NCT03237442|Biological|placebo|Saline injection
121476|NCT03237429|Diagnostic Test|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.~Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
121477|NCT03237416|Drug|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
121478|NCT03237416|Drug|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
121479|NCT03237416|Drug|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
121480|NCT03237403|Other|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
121481|NCT03237390|Drug|Gemcitabine Hydrochloride|Given IV
121482|NCT03237390|Other|Laboratory Biomarker Analysis|Correlative studies
121483|NCT03237390|Other|Pharmacological Study|Correlative studies
121484|NCT03237390|Drug|Ribociclib|Given PO
121485|NCT03237377|Drug|Durvalumab|1500mg via IV infusion every 4 weeks for up to 3 doses/cycles
121486|NCT03237377|Drug|Tremelimumab|75mg via IV infusion every 4 weeks
121487|NCT03237377|Radiation|Thoracic Radiation|5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction
121488|NCT03237364|Diagnostic Test|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
121489|NCT03237351|Device|Fluid therapy|Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
121490|NCT03237338|Procedure|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
121491|NCT03237338|Procedure|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
121492|NCT03237325|Drug|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
121493|NCT03237325|Drug|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
121494|NCT03237312|Procedure|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
121495|NCT03237312|Biological|Antimullerian hormone|"In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.~In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
121496|NCT03237299|Other|Collection of data|Collection of data on clinical, bacteriological and computed tomography data concerning the case, which will be needed by the adjudication committee and for defining the index date.
121497|NCT03237299|Other|No collection of data|The interviewer will note sociodemographic characteristics (age, weight, sex), symptoms and their evolution, and all drug intakes of the patient during the month before the index date.
121498|NCT03237286|Drug|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
121499|NCT03237286|Behavioral|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
121500|NCT03237273|Other|HEAD-US scoring system|HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
121501|NCT03237260|Drug|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
121526|NCT03237039|Other|fall-risk assessment|This evaluation will be performed after the radiographic scan, in the same day. The fall-risk assessment test will be performed by a biomedical engineer through OAK device (OAK, Khymeia, Italy). The OAK device integrates two force plates and sensory elastic straps applied to pelvis and limbs. This test, which takes approximately twenty minutes, accounts eight consecutive postural equilibrium exercises and provide the automatic detection of subject's postural parameters. At the end of the test, the fall-risk rating is automatically assigned.
121502|NCT03237234|Other|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
121503|NCT03237234|Device|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
121504|NCT03237221|Drug|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
121505|NCT03237208|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
121506|NCT03237208|Device|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
121507|NCT03237195|Other|additional soft tissue in neck dissections|Evaluation of submission of additional soft tissue in neck dissections for head and neck squamous cell carcinomas
121508|NCT03237182|Drug|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
121509|NCT03237182|Drug|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:~rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
121510|NCT03237156|Drug|TAK-906|TAK-906 capsules.
121511|NCT03237156|Drug|TAK-906 Placebo|Placebo capsules.
121512|NCT03237130|Procedure|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
121513|NCT03237117|Biological|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
121514|NCT03237104|Other|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
121515|NCT03237091|Other|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
121516|NCT03237091|Other|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
121517|NCT03237091|Other|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
121518|NCT03237091|Other|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
121519|NCT03237091|Other|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
121520|NCT03237078|Dietary Supplement|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
121521|NCT03237065|Drug|Iron Isomaltoside (Monofer)|administered IV
121522|NCT03237065|Drug|Ferric carboxymaltose|administered IV
121523|NCT03237052|Other|model|a model that has been established in advance.
121524|NCT03237052|Other|non-model|real-world psychiatrist decision
121525|NCT03237039|Radiation|X-ray examination|Radiological examination of frontal and lateral planes, simultaneously acquired with low dose X-ray system (EOS system, France) in one single exposition. The evaluation of the radiographic images will be performed by an orthopedic physician.Image processing will be performed by a biomedical engineer through sterEOS proprietary software and will provide the anatomical parameters needed to classify the sagittal profile.
121595|NCT03236415|Device|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
121527|NCT03237039|Other|gait cycle analysis|This assessment will be performed in the same session of fall-risk evaluation. The gait cycle analysis, which takes approximately forty minutes, will be executed by a biomedical engineer. Adhesive passive reflective markers will be placed on the skin according to a protocol suitable to characterize the alignment of lower limbs and trunk. The markers trajectories during walk will be recorded by an eight cameras optoelectronic system (BTS smart-D, Italy). A force platform (Kistler, Switzerland) placed in the middle of the pathway will detect the forces exchanged with the ground. The data analysis will provide the kinematic and kinetic descriptive parameters of gait cycle.
121528|NCT03237026|Other|No intervention required|No intervention required
121529|NCT03237013|Behavioral|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
121530|NCT03237013|Behavioral|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
121531|NCT03237000|Drug|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:~Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.~Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
121532|NCT03236987|Drug|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
121533|NCT03236987|Drug|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
121534|NCT03236987|Drug|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
121535|NCT03236987|Drug|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
121536|NCT03236974|Drug|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
121537|NCT03236974|Drug|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
121538|NCT03236961|Drug|Ertapenem|I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
121539|NCT03236961|Drug|Moxifloxacin|P.o. moxifloxacin 400 mg x1 for 7 days
121540|NCT03236948|Behavioral|Women for Women International Intervention|
121541|NCT03236935|Drug|L-NMMA|pan-nitric oxide synthase inhibitor
121542|NCT03236935|Drug|Pembrolizumab|PD-1 inhibitor
121543|NCT03236922|Procedure|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
121544|NCT03236922|Procedure|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
121545|NCT03236909|Device|MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System|Subjects will be implanted with the MED-EL SYNCHRONY/SYNCHRONY PIN Cochlear Implant System with +FLEX28 or +FLEXSOFT electrode arrays. Subjects will be fit with the SONNETEAS (ear-level) and/or RONDO (single-unit) external audio processors.
121546|NCT03236896|Behavioral|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
121547|NCT03236896|Behavioral|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
121548|NCT03236883|Drug|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
121549|NCT03236883|Other|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)*10^8/kg,once a month,repeated every 4weeks,three times in all.
121550|NCT03236857|Drug|chemotherapy|Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
121551|NCT03236857|Drug|venetoclax|Oral tablet for participants; Tablet for oral suspension (participants who cannot swallow a tablet)
121552|NCT03236844|Drug|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
121553|NCT03236831|Other|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:~Avoidance of potentially nephrotoxic medications.~Optimizing volume status (avoidance of volume overload or depletion)~Optimizing electrolytes and acid-base status~Minimizing IV contrast exposure when appropriate~Treating severe anemia~Optimization of hemodynamics (Mean arterial BP>65mmHg)"
121554|NCT03236818|Drug|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
121555|NCT03236805|Drug|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
121556|NCT03236805|Drug|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
121557|NCT03236792|Drug|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
121558|NCT03236792|Drug|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
121559|NCT03236792|Drug|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
121596|NCT03236415|Device|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
121560|NCT03236779|Other|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
121561|NCT03236766|Other|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches.
121562|NCT03236753|Procedure|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:~Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm~Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm~Both BL25: transverse insertion toward iliac crest, 4cm~Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm~Both BL26: oblique insertion toward iliolumbar ligament, 6cm~Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm~Both BL28: oblique insertion toward sacroiliac ligament, 6cm~Both GB30: perpendicular insertion, 6cm~Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
121563|NCT03236753|Procedure|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
121564|NCT03236740|Drug|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
121565|NCT03236740|Drug|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
121566|NCT03236727|Drug|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
121567|NCT03236701|Other|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
121568|NCT03236662|Drug|(-)-Epicatechin|
121569|NCT03236649|Drug|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
121570|NCT03236649|Drug|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
121571|NCT03236636|Drug|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
121572|NCT03236636|Drug|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
121573|NCT03236623|Other|Menthol Popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
121574|NCT03236610|Drug|tenofovir monotherapy|switching to tenofovir monotherapy
121575|NCT03236610|Drug|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
121576|NCT03236597|Other|Treadmill desk|A standing height desk with a treadmill attached.
121577|NCT03236584|Drug|lamivudine plus adefovir combination|continuing lamivudine plus adefovir
121578|NCT03236584|Drug|Tenofovir Disoproxil Fumarate|switching to tenofovir
121579|NCT03236571|Device|Rehabilitation program|The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
121580|NCT03236558|Procedure|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
121581|NCT03236545|Other|No to Low Endogenous Estrogen|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman & Timmer, 1999; Oberye, Mannaerts, Kleijn, & Timmer, 1999).
121582|NCT03236545|Other|Estradiol|Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, & Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane & Kohrt, 2012).
121583|NCT03236532|Dietary Supplement|Glutamine and exercise|
121584|NCT03236532|Dietary Supplement|Maltodextrin and exercise|
121585|NCT03236506|Drug|Zepatier Pill|Drugs will be given to participants to treat hepatitis C infection
121586|NCT03236506|Behavioral|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
121587|NCT03236506|Drug|Sofosbuvir Pill|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
121588|NCT03236493|Drug|PF-06700841|PF-06700841 will be administered as tablet
121589|NCT03236493|Drug|Placebo|Matching placebo will be administered as tablet
121590|NCT03236467|Behavioral|Progressive Exercise Training|Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
121591|NCT03236454|Device|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
121592|NCT03236441|Device|RIPC|Remote ischemic preconditioning
121593|NCT03236441|Device|Sham-RIPC|Control
121594|NCT03236428|Drug|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
121597|NCT03236389|Device|Q Collar|measuring changes in brain during MRI while wearing the Q collar
121598|NCT03236376|Other|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
121599|NCT03236376|Other|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
121600|NCT03236363|Behavioral|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
121601|NCT03236363|Behavioral|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
121602|NCT03236350|Device|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
121603|NCT03236350|Device|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
121604|NCT03236337|Behavioral|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
121605|NCT03236324|Device|ultrasound-guided nerve block|Transversalis fascia plane (TFP) block, ultrasound-guided
121606|NCT03236324|Drug|Saline|20 mL 0.9% saline administered on each side as bilateral TFP blocks
121607|NCT03236324|Drug|Bupivacaine-epinephrine|20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
121608|NCT03236311|Drug|SAR407899|Pharmaceutical form: Capsule Route of administration: Oral
121609|NCT03236311|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
121610|NCT03236311|Drug|Adenosine|Pharmaceutical form: Solution for injection Route of administration: Intravenous
121611|NCT03236311|Drug|Regadenoson|Pharmaceutical form: Solution for injection Route of administration: Intravenous
121612|NCT03236311|Drug|13N-ammonia|Pharmaceutical form: Solution for injection Route of administration: Intravenous
121613|NCT03236311|Drug|82Rubidium|Pharmaceutical form: Solution for injection Route of administration: Intravenous
121614|NCT03236298|Device|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
121615|NCT03236285|Behavioral|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
121616|NCT03236285|Behavioral|Continous exercise training in the fed state|Continous exercise training in the fed state
121617|NCT03236285|Behavioral|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
121618|NCT03236285|Behavioral|Continous exercise training in the fasting state|Continous exercise training in the fasting state
121619|NCT03236259|Dietary Supplement|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
121620|NCT03236259|Dietary Supplement|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
121621|NCT03236259|Dietary Supplement|Placebo|Maltodextrin. Daily ingestion of capsule
121622|NCT03236246|Drug|KRX-0502|Oral ferric citrate with meals
121623|NCT03236233|Drug|PC786 - Single doses|Safety and tolerability of single doses
121624|NCT03236233|Drug|Placebo - Single doses|Safety and tolerability of single doses
121625|NCT03236233|Drug|PC786 - Repeat doses|Safety and tolerability of repeat doses
121626|NCT03236233|Drug|Placebo - Repeat doses|Safety and tolerability of repeat doses
121627|NCT03236220|Drug|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
121628|NCT03236207|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
121629|NCT03236207|Other|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
121630|NCT03236181|Other|SFA|High saturated fatty acid/SFA oil source
121631|NCT03236181|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
121632|NCT03236181|Other|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
121633|NCT03236181|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
121634|NCT03236168|Drug|Ivermectin|A single weight based dose of ivermectin
121635|NCT03236168|Drug|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
121636|NCT03236168|Drug|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
121637|NCT03236155|Drug|opioid pain pills|patient will receive their pain pill prescription
121638|NCT03236142|Procedure|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
121639|NCT03236142|Procedure|Standard Duodenal Switch Operation|
121640|NCT03236129|Procedure|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
121641|NCT03236129|Procedure|Standard DLI|The patients in this arm benefit of a standard DLI.
121642|NCT03236116|Other|Almonds|Participants will consume almonds everyday for 6 months.
121643|NCT03236116|Other|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
121644|NCT03236103|Other|Clinical Recommendations|"The clinical recommendations will regard the following:~Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)~Optimizing volume status (avoidance of volume overload or depletion)~Optimizing electrolytes and acid-base status~Optimizing hemodynamics (Mean arterial BP>65mmHg)~Assessment of kidney function with serum creatinine and/or cystatin C~None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
121645|NCT03236090|Dietary Supplement|Vivomixx|Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
121646|NCT03236077|Behavioral|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
121647|NCT03236064|Drug|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
121648|NCT03236051|Procedure|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
121649|NCT03236051|Procedure|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
121650|NCT03236038|Diagnostic Test|Labeled triolein urea breath test|"The diagnosis of EPI will be made through the combination of two diagnostic tests.~The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.~The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."
121651|NCT03236025|Combination Product|Video+brief smoking cessation+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on pregnant women, fetuses, and newborns.
121652|NCT03236025|Combination Product|Text-message+brief smoking cessation+pamphlet|The text -message contains the same content with the videos
121653|NCT03236025|Other|brief smoking cessation+pamphlet|"The pamphlet showed the general information related to the smoking cessation, the brief smoking cessation only contains a sentence like You'd better quit smoking."
121654|NCT03236012|Drug|Botulinum Toxin Type A (Botox)|Maximum dose up to 400 units given one time
121655|NCT03235986|Drug|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)|Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
121656|NCT03235986|Drug|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)|Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
121657|NCT03235986|Other|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)|Nasal continuous positive airway pressure alone
121658|NCT03235986|Other|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)|nasal continuous positive airway pressure alone
121659|NCT03235973|Drug|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:~Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).~Cladribine during 5 days (day-6 to day-2) at one the following define dose level:~Dose 1: 10 mg/m²/d~Dose 2: 15 mg/m²/d~Dose 3: 20 mg/m²/d~Dose 4: 25 mg/m²/d~IV busulfan will be given on day-6 using fixed dose as following:~If age ≤ 60 years: starting dose of 130 mg/m²~If age > 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
121660|NCT03235960|Device|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
121661|NCT03235947|Drug|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
121662|NCT03235947|Drug|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
121663|NCT03235947|Drug|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
121664|NCT03235921|Drug|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
121665|NCT03235921|Other|placebo|no drug given to the control group
121666|NCT03235908|Other|Observation only|Observation only
121667|NCT03235895|Other|Educational material|Educational material given as a part of CME activity as through enhanced internet method
121668|NCT03235882|Diagnostic Test|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
121669|NCT03235869|Drug|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
121670|NCT03235869|Radiation|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
121671|NCT03235843|Device|AAIR pacing|Rate adaptive pacing using a MV sensor.
121672|NCT03235843|Device|DDI-pacing|Rate adaptive pacing OFF
121673|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
121674|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC)|See above in arm/group description
121675|NCT03235817|Other|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
121676|NCT03235817|Device|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
121786|NCT03234842|Drug|Chemotherapy|Concurrent weekly chemotherapy at standard doses
121677|NCT03235817|Device|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
121678|NCT03235804|Dietary Supplement|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a nutritional supplement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
121679|NCT03235778|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
121680|NCT03235778|Drug|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
121681|NCT03235765|Diagnostic Test|MACROGEN Pan Cancer Panel (Tier 2)|This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
121682|NCT03235752|Drug|TJ301 300mg|TJ301 300mg IV infusion
121683|NCT03235752|Drug|TJ301 600mg|TJ301 600mg IV infusion
121684|NCT03235752|Drug|Placebo|Placebo IV infusion
121685|NCT03235739|Drug|Naloxegol 25 MG|Oral Naloxegol 25 MG
121686|NCT03235739|Drug|Placebo|matching oral placebo
121687|NCT03235726|Drug|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
121688|NCT03235726|Drug|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
121689|NCT03235700|Other|Maximal hyperemia with adenosine followed by nicorandil|IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
121690|NCT03235700|Other|Maximal hyperemia with nicorandil followed by adenosine|IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
121691|NCT03235687|Diagnostic Test|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
121692|NCT03235674|Other|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
121693|NCT03235661|Device|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
121694|NCT03235661|Device|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
121695|NCT03235648|Procedure|cardiophrenic lymph nodes resection|surgical resection
121696|NCT03235622|Diagnostic Test|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
121697|NCT03235609|Drug|Fentanyl|fentanyl used with propofol for sedation
121698|NCT03235609|Drug|Ketamine|ketamine used with propofol for sedation
121699|NCT03235596|Device|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
121700|NCT03235583|Device|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
121701|NCT03235570|Drug|Pemigatinib|Pemigatinib at the protocol-defined dose administered once daily.
121702|NCT03235544|Drug|Parsaclisib|Parsaclisib at the protocol-defined dose.
121703|NCT03235531|Drug|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
121704|NCT03235531|Drug|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
121705|NCT03235505|Drug|Nicotine|Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI)
121706|NCT03235505|Drug|Varenicline Tartrate|Varenicline + Joytech eGo AIO electronic inhaler but without any nicotine content + MI
121707|NCT03235505|Behavioral|Motivational Interview|Placebo-varenicline + Joytech eGo AIO electronic inhaler but without any nicotine content +MI
121708|NCT03235492|Device|SmartAlbu|"Plan:~Consent an individual~Measure and record temperature, blood pressure, heart rate, height and weight~Obtain two samples of saliva for the SmartAlbu portable salivary sensor~Take a venous blood sample for HbA1c and~Glycated albumin~Obtain blood sample from a finger stick for point of care HbA1c device"
121709|NCT03235479|Drug|BHV-3000|75 mg tablet QD
121710|NCT03235479|Drug|Placebo Oral Tablet|equivalent of 75 mg tablet QD
121711|NCT03235466|Behavioral|Voice Therapy|See Arm 1 & 2
121712|NCT03235466|Behavioral|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 & 3
121713|NCT03235466|Behavioral|Heart Rate Variability Biofeedback|See Arm 2 & 3
121714|NCT03235453|Other|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
121715|NCT03235453|Other|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
121829|NCT03234517|Drug|Vaginal Probiotic|Vaginal Probiotic
121716|NCT03235440|Behavioral|Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
121717|NCT03235414|Device|MRI|Will receive a one time research MRI (MR elastography)
121718|NCT03235414|Diagnostic Test|Blood draw|Will receive a one time blood draw to confirm healthy liver status
121719|NCT03235401|Other|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
121720|NCT03235388|Other|Audit filters|Institutional implementation of audit filters
121721|NCT03235375|Drug|MEDI0382|MEDI0382 administered subcutaneously
121722|NCT03235362|Drug|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
121723|NCT03235362|Drug|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
121724|NCT03235362|Drug|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
121725|NCT03235349|Drug|Glecaprevir/Pibrentasvir|Coformulated tablet for oral administration
121726|NCT03235323|Device|External Counterpulsation|ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
121727|NCT03235284|Other|Exercises|A program of therapeutic exercises (GC) based on the PNF method for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes. The GC treatment program consists of the following protocols: a) protocol 1: 20 minutes diagonal exercise upper limb (flexion-abduction-external rotation and extension-abduction-internal rotation),10 minutes diagonal exercise scapula (anterior and posterior elevation) and 10 minutes of exercise for trunk extension; b) protocol 2: 20 minutes diagonal exercise lower limb (flexion-abduction-external rotation and flexion-abduction-internal rotation),10 minutes diagonal exercise pelvis (anterior and posterior depression), and 10 minutes gait cycle training
121728|NCT03235284|Other|Nintendo Wii|"Nintendo Wii program (GW) based on the use of the NW for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions).All treatment groups prior to perform the study interventions,stretches of upper and lower limbs for 10 minutes.~The GW treatment program consists of the following protocols: a) protocol 1 games (Boxing and Soccer); b) protocol 2 games (Golf and running). 20 minutes for each game"
121729|NCT03235284|Other|Exercises and Nintendo Wii|In GCW program will be performed 20 minutes GC protocol (1 or 2, used alternately between sessions a week) and 20 minutes GW protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols
121730|NCT03235271|Device|BrainPulse Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the skull motion caused by pulsatile cerebral blood flow from the cardiac cycle.~The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile cerebral blood flow. The system is powered by a rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
121731|NCT03235245|Drug|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
121732|NCT03235245|Drug|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
121733|NCT03235232|Drug|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
121734|NCT03235232|Drug|Combigan®|1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
121735|NCT03235219|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
121736|NCT03235219|Drug|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
121737|NCT03235206|Other|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
121738|NCT03235193|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
121739|NCT03235193|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
121740|NCT03235180|Drug|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
121741|NCT03235180|Device|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
121742|NCT03235180|Device|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
121743|NCT03235180|Device|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
121744|NCT03235167|Drug|CpG DNA|CpG DNA concentrate
121745|NCT03235167|Procedure|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization (TACE) therapy for liver cancer
121746|NCT03235167|Drug|Placebo - Concentrate|CpG DNA vehicle
121747|NCT03235154|Drug|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasivir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
121748|NCT03235141|Drug|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
121749|NCT03235141|Drug|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
121750|NCT03235128|Diagnostic Test|‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.|Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
121751|NCT03235115|Device|Methafilcon A IV|Contact Lens
121752|NCT03235115|Device|Ocufilcon B|Contact Lens
121753|NCT03235115|Device|Omafilcon A|Contact Lens
121754|NCT03235102|Other|No treatment given|Completion of a survey
121755|NCT03235076|Drug|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
121756|NCT03235063|Other|routinely care- no intervention|routinely care- no intervention
121757|NCT03235050|Drug|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
121758|NCT03235050|Drug|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
121759|NCT03235050|Drug|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
121760|NCT03235050|Drug|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
121761|NCT03235050|Drug|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
121762|NCT03235037|Drug|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
121763|NCT03235024|Biological|B244|B244 suspension
121764|NCT03235024|Biological|Vehicle|Vehicle suspension
121765|NCT03234998|Device|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
121766|NCT03234998|Device|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
121767|NCT03234985|Biological|Biological analyses|Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
121768|NCT03234972|Drug|Daratumumab|Daratumumab will be administered as an IV infusion at a dose of 16 mg/kg weekly for the first 3 cycles, q3w on Day 1 of Cycles 4-9, and then q4w thereafter.
121769|NCT03234972|Drug|Velcade|Velcade will be administered at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
121770|NCT03234972|Drug|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
121771|NCT03234959|Device|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
121772|NCT03234959|Other|Infant Massage|Infants will received IM by their parents
121773|NCT03234946|Behavioral|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
121774|NCT03234933|Device|Mobility Tracker|Tracking Patient's movements and calories
121775|NCT03234920|Dietary Supplement|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
121776|NCT03234920|Other|Placebo|The placebo will be 200 ml of fruit juice given twice daily
121777|NCT03234907|Drug|Vedolizumab IV|Vedolizumab IV infusion
121778|NCT03234907|Drug|Placebo|Vedolizumab placebo-matching
121779|NCT03234881|Behavioral|MOVE!|Participants randomized to the MOVE! arm will attend 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries.
121780|NCT03234881|Behavioral|MOVE!+gshCBT|Participants randomized to the MOVE!+gshCBT arm will attend the 16 weeks of 60-minute weekly MOVE! Treatment groups, along with up to 10 individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and partake in a walking program to gradually increase daily physical activity.
121781|NCT03234868|Device|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
121782|NCT03234868|Device|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
121783|NCT03234855|Device|LMD|Physician uses LMD to measure defect during procedure.
121784|NCT03234842|Radiation|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
121785|NCT03234842|Radiation|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
121787|NCT03234816|Drug|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
121788|NCT03234816|Drug|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
121789|NCT03234816|Drug|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
121790|NCT03234816|Drug|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
121791|NCT03234803|Other|poly-amide|new denture base material
121792|NCT03234803|Other|poly-methyl methacrylate|gold standard for denture base materials
121793|NCT03234790|Other|Filtered Air Exposure|Exposure to Filtered air
121794|NCT03234790|Other|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
121795|NCT03234777|Behavioral|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
121796|NCT03234777|Behavioral|Regular video|Developed by CDC
121797|NCT03234764|Other|Immunotherapy|
121798|NCT03234751|Drug|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
121799|NCT03234751|Drug|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
121800|NCT03234751|Drug|Placebo|48 hours of placebo.
121801|NCT03234738|Drug|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
121802|NCT03234738|Drug|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
121803|NCT03234712|Drug|ABBV-321|Intravenous infusion
121804|NCT03234699|Drug|Cenobamate|12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
121805|NCT03234699|Drug|midazolam|2 mg midazolam syrup (Days 7, 69, 105)
121806|NCT03234699|Drug|Warfarin Pill|5 mg (Days 7 and 105)
121807|NCT03234699|Drug|Omeprazole Pill|20 mg (Days 7 and 105)
121808|NCT03234699|Drug|Bupropion Pill|150 mg (Days 1 and 99)
121809|NCT03234686|Drug|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
121810|NCT03234686|Drug|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
121811|NCT03234673|Drug|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
121812|NCT03234673|Drug|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
121813|NCT03234673|Drug|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
121814|NCT03234660|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
121815|NCT03234660|Other|control|0.9% normal saline continuous infusion
121816|NCT03234647|Device|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
121817|NCT03234634|Procedure|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral~Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.~Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
121818|NCT03234621|Other|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
121819|NCT03234608|Behavioral|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
121820|NCT03234595|Drug|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
121821|NCT03234569|Procedure|sonoHSG|This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image. For the ultrasound images, General Electric will be supporting us by providing us the Voluson E10 and RIC5-9-D.
121822|NCT03234556|Procedure|Biopsy of Prostate|Undergo SR-Bx
121823|NCT03234556|Other|Laboratory Biomarker Analysis|Correlative studies
121824|NCT03234556|Diagnostic Test|Magnetic Resonance Imaging|Undergo MRI
121825|NCT03234556|Diagnostic Test|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
121826|NCT03234543|Procedure|Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
121827|NCT03234543|Procedure|No Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
121828|NCT03234517|Drug|Vaginal Clindamycin Cream|Vaginal Clindamycin Cream
121830|NCT03234491|Device|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
121831|NCT03234491|Drug|Afrezza low dose|Afrezza inhaled insulin low dose.
121832|NCT03234491|Drug|Afrezza high dose|Afrezza inhaled insulin high dose.
121833|NCT03234478|Other|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
121834|NCT03234465|Biological|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
121835|NCT03234465|Other|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
121836|NCT03234452|Dietary Supplement|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
121837|NCT03234452|Dietary Supplement|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
121838|NCT03234439|Behavioral|myStrength|myStrength is a digital self-care behavioral and wellness platform
121839|NCT03234426|Other|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
121840|NCT03234426|Other|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
121841|NCT03234413|Drug|Botulinum toxin type A|Botulinum toxin type A
121842|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
121843|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
121844|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
121845|NCT03234387|Other|No intervention - only assessments.|No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
121846|NCT03234374|Combination Product|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
121847|NCT03234374|Drug|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
121848|NCT03234361|Dietary Supplement|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
121849|NCT03234361|Dietary Supplement|Low Phosphate Phase|2 capsules of sodium chloride.
121850|NCT03234348|Device|Percutaneous coronary intervention|PCI + stent implantation
121851|NCT03234335|Other|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
121852|NCT03234322|Other|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
121853|NCT03234309|Drug|Ferumoxytol|Given IV
121854|NCT03234309|Procedure|Magnetic Resonance Imaging|Undergo MRI
121855|NCT03234296|Drug|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
121856|NCT03234296|Other|Placebo|Intravenous placebo followed by per oral placebo
121857|NCT03234283|Device|IRRIS InfraRed - Red Intubation System|IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
121858|NCT03234270|Device|Core temperature measurements|Core temperature measurements with coretemp pill
121859|NCT03234257|Device|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
121860|NCT03234244|Drug|Bazedoxifene 20 mg|To estimate the drug-drug interaction between Bazedoxifene and combination of Bazedoxifene and Cholecalciferol, Subject will take Bazedoxifene 20mg 1 tablet one time.
121861|NCT03234244|Drug|Cholecalciferol|To estimate the drug-drug interaction between Cholecalciferol and combination of Bazedoxifene and Cholecalciferol, Subject will take Cholecalciferol 2 tablets one time.
121862|NCT03234244|Drug|Bazedoxifene 20mg and Cholecalciferol|For estimate the Drug-Drug Interaction, Subject will take Bazedoxifene 1 tablet and Cholecalciferol 2 tablets at once.
121863|NCT03234231|Behavioral|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
121864|NCT03234231|Behavioral|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
121865|NCT03234205|Device|MRI scan|"MRI standard protocol with addition of:~a second clinical respiratory belt besides belt usually installed for clinical examination~a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination~12 sequences during free respiration are added lasting supplementary 15 minutes~Use of cardiac antennae usually used for cardiac MRI scans"
121939|NCT03233594|Other|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
121866|NCT03234192|Procedure|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
121867|NCT03234192|Procedure|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
121868|NCT03234192|Procedure|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
121869|NCT03234166|Other|Non interventional study|Only data will be taken of patient's file.
121870|NCT03234153|Drug|Durvalumab (Imfinzi)|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
121871|NCT03234153|Drug|Tremelimumab|Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
121872|NCT03234140|Genetic|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
121873|NCT03234140|Genetic|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
121874|NCT03234127|Genetic|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
121875|NCT03234114|Drug|Triple antithrombotic therapy|Including warfarin with targeted INR 2.0-2.5 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg per day (Bayer, Germany) and clopidogrel 75 mg per day (Sanofi, France)
121876|NCT03234114|Drug|Dual antithrombotc therapy|Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain) or clopidogrel 75 mg per day (Sanofi, France)
121877|NCT03234101|Behavioral|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:~1) Healthy body weight (Minimum: BMI <30kg/m2 or WC of <88 in females or <92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits & vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation >12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (>6 hours)"
121878|NCT03234088|Behavioral|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
121879|NCT03234075|Other|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation~with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation~delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway~Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)~Helping to carry out the pre-graft assessments of patients by a care coordinator"
121880|NCT03234062|Other|25% Cho diet|Subjects will consume meals containing 25% of the recommended intake of Choline (137.5 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
121881|NCT03234062|Other|50% Cho diet|Subjects will consume meals containing 50% of the recommended intake of Choline (275 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
121882|NCT03234062|Other|100% Cho diet|Subjects will consume meals containing 100% of the recommended intake of Choline (550 mg Choline/day) for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
121883|NCT03234049|Other|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
121884|NCT03234036|Drug|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
121885|NCT03234036|Drug|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
121886|NCT03234036|Drug|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
121887|NCT03234036|Drug|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
121888|NCT03234023|Behavioral|INTERVENTION GROUP|Offer recommendations of healthy living habits and control of pharmacy administration
121889|NCT03234010|Other|FT21092|An electronic cigarette
121890|NCT03234010|Other|FT21093|An electronic cigarette
121891|NCT03234010|Other|FT21096|An electronic cigarette
121892|NCT03234010|Other|FT21097|An electronic cigarette
121893|NCT03233997|Other|FT21018|An electronic cigarette
121894|NCT03233997|Other|FT21033|An electronic cigarette
121895|NCT03233997|Other|FT21034|An electronic cigarette
121896|NCT03233997|Other|FT21035|An electronic cigarette
121897|NCT03233984|Behavioral|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
121898|NCT03233971|Other|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
121940|NCT03233594|Other|Healthy Control Group|Participants will not receive any interventions.
121941|NCT03233581|Behavioral|Fitbit + Facebook + Coaching Group|Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
121899|NCT03233958|Behavioral|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation [Hunger, Weinhold, Bornhäuser, Link, & Schweitzer, 2015].
121900|NCT03233932|Drug|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
121901|NCT03233932|Drug|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
121902|NCT03233919|Device|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.~Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.~Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
121903|NCT03233906|Dietary Supplement|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
121904|NCT03233893|Other|light activated calcium silicate|"for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration."
121905|NCT03233880|Drug|Azithromycin 1gm|Azithromicin 1 gm oral single dose
121906|NCT03233880|Other|PLACEBO|placebo
121907|NCT03233854|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
121908|NCT03233854|Drug|Cyclophosphamide|Given IV
121909|NCT03233854|Drug|Fludarabine Phosphate|Given IV
121910|NCT03233854|Other|Laboratory Biomarker Analysis|Correlative studies
121911|NCT03233854|Other|Questionnaire Administration|Ancillary studies
121912|NCT03233828|Biological|Aldesleukin|500,000 IU in 0.1mL
121913|NCT03233828|Other|Saline|0.1 mL of sterile saline solution (0.9% m/v)
121914|NCT03233815|Drug|Propofol|Propofol anesthesia Dose: 4-6mg/kg/h
121915|NCT03233815|Drug|Sevoflurane|Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
121916|NCT03233802|Behavioral|Individualized Assess & Treatment (IATP)|See previous description
121917|NCT03233802|Behavioral|Packaged Cognitive-Behavioral (PCBT)|See previous description
121918|NCT03233802|Behavioral|Case Management (CaseM)|See previous description
121919|NCT03233789|Behavioral|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
121920|NCT03233776|Drug|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
121921|NCT03233763|Procedure|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
121922|NCT03233750|Behavioral|Stress Inoculation Training|see description in arm/group descriptions
121923|NCT03233750|Behavioral|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
121924|NCT03233737|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
121925|NCT03233737|Device|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
121926|NCT03233737|Device|One spray CTY-5339-P|Placebo. Metered spray bottle with ≈200 uL total spray volume. Contains no active ingredient (vehicle control).
121927|NCT03233724|Drug|Decitabine (DAC)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
121928|NCT03233724|Drug|Tetrahydrouridine (THU)|Administered orally on two consecutive days (preferably Tuesday and Wednesday) for two weeks out of three weeks x 9 weeks
121929|NCT03233724|Drug|Pembrolizumab|200 mg IV once a day every Wednesday, Thursday or Friday every 3 weeks.
121930|NCT03233711|Biological|Nivolumab|Given IV
121931|NCT03233711|Other|Patient Observation|Undergo observation
121932|NCT03233685|Behavioral|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
121933|NCT03233685|Behavioral|Normal Training|Normal training routine
121934|NCT03233672|Radiation|Hypo-fractionated postoperative IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
121935|NCT03233646|Device|Retinal Imaging|Non-invasive OCTA scan of retina
121936|NCT03233633|Drug|Medical Marijuana|oral capsule, high ratio CBD:THC
121937|NCT03233620|Other|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
121938|NCT03233607|Procedure|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation.
121942|NCT03233581|Behavioral|Fitbit only|Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
121943|NCT03233568|Diagnostic Test|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.~Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.~Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
121944|NCT03233555|Other|Informational Intervention|Receive brochure
121945|NCT03233555|Other|Internet-Based Intervention|Have access to EXCELS
121946|NCT03233555|Other|Quality-of-Life Assessment|Ancillary studies
121947|NCT03233555|Other|Questionnaire Administration|Ancillary studies
121948|NCT03233555|Behavioral|Telephone-Based Intervention|Receive quarterly calls
121949|NCT03233542|Behavioral|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
121950|NCT03233529|Drug|Crisaborole ointment 2% BID|Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)
121951|NCT03233529|Drug|Placebo ointment (vehicle)|Placebo ointment (vehicle) BID for 15 days (double blind)
121952|NCT03233503|Diagnostic Test|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
121953|NCT03233490|Other|web course|Web course Help Brain Heart was conducted Before CPR training.
121954|NCT03233490|Other|CPR training|No web course was conducted
121955|NCT03233451|Behavioral|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
121956|NCT03233438|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
121957|NCT03233438|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
121958|NCT03233425|Behavioral|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
121959|NCT03233412|Procedure|Control|Exertion of the cervix transformation zone
121960|NCT03233412|Drug|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
121961|NCT03233399|Device|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
121962|NCT03233399|Device|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
121963|NCT03233399|Device|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
121964|NCT03233386|Behavioral|Mantente REAL|substance abuse prevention curriculum for adolescents
121965|NCT03233373|Device|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
121966|NCT03233347|Drug|Brentuximab Vedotin|Given IV
121967|NCT03233347|Drug|Dacarbazine|Given IV
121968|NCT03233347|Drug|Doxorubicin Hydrochloride|Given IV
121969|NCT03233347|Other|Laboratory Biomarker Analysis|Correlative studies
121970|NCT03233347|Biological|Nivolumab|Given IV
121971|NCT03233347|Drug|Vinblastine|Given IV
121972|NCT03233334|Behavioral|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
121973|NCT03233321|Other|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
121974|NCT03233321|Other|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
121975|NCT03233308|Drug|Netarsudil Ophthalmic Solution 0.02%|1 drop daily (QD), in the morning (AM) Netarsudil Ophthalmic Solution 0.02% administered to one eye and Placebo comparator to the contralateral eye
121976|NCT03233308|Other|Placebo Comparator|1 drop daily (QD), in the morning (AM) of Placebo comparator administered to one eye and Netarsudil Ophthalmic Solution 0.02% to the contralateral eye
121977|NCT03233295|Drug|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
121978|NCT03233282|Other|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
122107|NCT03232346|Drug|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
121979|NCT03233282|Other|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
121980|NCT03233282|Other|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
121981|NCT03233282|Other|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
121982|NCT03233282|Other|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
121983|NCT03233282|Other|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
121984|NCT03233282|Other|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
121985|NCT03233282|Other|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
121986|NCT03233282|Other|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
121987|NCT03233282|Other|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
121988|NCT03233282|Other|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
121989|NCT03233269|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
121990|NCT03233256|Procedure|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
121991|NCT03233243|Drug|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
121992|NCT03233230|Drug|Evobrutinib|Evobrutinib low dose will be administered orally for 12 weeks.
121993|NCT03233230|Drug|Evobrutinib|Evobrutinib mid dose will be administered orally for 12 weeks.
121994|NCT03233230|Drug|Evobrutinib|Evobrutinib high dose will be administered orally for 12 weeks.
121995|NCT03233230|Drug|Placebo|Placebo matched to evobrutinib will be administered orally for 12 weeks.
121996|NCT03233230|Drug|Methotrexate|Subjects will receive stable background therapy of methotrexate 7.5 to 25 mg/week (oral or parenteral) for >= 16 weeks.
121997|NCT03233217|Biological|QIV-HD by IM|IM, injected into the upper arm (deltoid area)
121998|NCT03233217|Biological|QIV-SD by SC|SC, injected into the upper arm (posterior region)
121999|NCT03233217|Biological|QIV-HD by SC|SC, injection into the upper arm (posterior region)
122000|NCT03233204|Drug|Olaparib|Given PO
122001|NCT03233191|Procedure|Digital Mammography|Undergo DM
122002|NCT03233191|Procedure|Digital Tomosynthesis Mammography|Undergo TM
122003|NCT03233191|Other|Laboratory Biomarker Analysis|Correlative studies
122004|NCT03233178|Other|Non-interventional|
122005|NCT03233165|Procedure|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
122006|NCT03233165|Procedure|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
122007|NCT03233152|Drug|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).~Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
122108|NCT03232346|Drug|Buprenorphine|5-week buprenorphine taper
122008|NCT03233152|Drug|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
122009|NCT03233139|Drug|REGN2810|Patients will be administered REGN2810 as per protocol
122010|NCT03233139|Drug|Ipilimumab|To be administered per protocol
122011|NCT03233139|Drug|Platinum-doublet chemotherapy|To be administered per protocol
122012|NCT03233126|Drug|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
122013|NCT03233113|Behavioral|Exposure therapy|"Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, & Whiteside, 20011; Antony, Craske, & Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, & Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider."
122014|NCT03233100|Other|FMT|fecal microbiota transplantation
122015|NCT03233074|Other|Bone marrow analyses|This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
122016|NCT03233061|Diagnostic Test|cardiorespiratory fitness and daily physical activities evaluations|"The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.~Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine."
122017|NCT03233048|Device|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
122018|NCT03233035|Drug|Ketamine|25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
122019|NCT03233035|Drug|Placebo|0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
122020|NCT03233022|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
122021|NCT03233009|Other|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
122022|NCT03233009|Other|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
122023|NCT03233009|Other|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
122024|NCT03233009|Other|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
122025|NCT03233009|Other|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
122026|NCT03232996|Other|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
122027|NCT03232983|Drug|LY900014 (SC)|Administered SC
122028|NCT03232983|Drug|LY900014 (IV)|Administered IV
122029|NCT03232970|Other|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
122030|NCT03232957|Procedure|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
122031|NCT03232957|Procedure|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
122032|NCT03232957|Procedure|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
122033|NCT03232957|Drug|Morphine|intrathecal morphine
122034|NCT03232957|Drug|Bupivacaine|0.5 isobaric bupivacaine
122035|NCT03232944|Device|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
122036|NCT03232931|Device|Multisensory intervention|The intervention will be carried out in addition to standard care and will include 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking for the first 20 minutes of holding. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
122037|NCT03232931|Behavioral|Standard of care|Standard of care: parental skin-to-skin care and exposure to parent's voice
122038|NCT03232918|Drug|Half dose Oxytocin|Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
122039|NCT03232905|Drug|PF-06651600|PF-06651600 will be administered as tablet
122040|NCT03232905|Drug|Placebo|Matching placebo will be administered as tablet
122041|NCT03232892|Drug|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
122042|NCT03232879|Behavioral|Motor Imagery|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).
122109|NCT03232333|Device|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
122043|NCT03232879|Behavioral|Action Observation|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
122044|NCT03232866|Other|Pilates exercise|Pilates methods exercises
122045|NCT03232853|Other|Elearning|Elearning
122046|NCT03232827|Behavioral|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
122047|NCT03232827|Behavioral|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
122048|NCT03232827|Behavioral|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-very low sweetened waterpipe tobacco will be prepared.
122049|NCT03232827|Behavioral|Flavored-very low sweetened waterpipe|Pre-weighed flavored-very low sweetened waterpipe tobacco will be prepared.
122050|NCT03232814|Behavioral|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
122051|NCT03232801|Behavioral|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
122052|NCT03232801|Behavioral|general health education group|A general health and aging education group
122053|NCT03232788|Procedure|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
122054|NCT03232788|Device|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
122055|NCT03232788|Device|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
122056|NCT03232775|Other|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
122057|NCT03232775|Other|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
122058|NCT03232762|Dietary Supplement|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
122059|NCT03232762|Dietary Supplement|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
122060|NCT03232749|Procedure|intraarticular corticosteroid injections (IACSI)|ultrasound-guided IACSI will be administered
122061|NCT03232749|Drug|corticosteroid injections|Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
122062|NCT03232749|Device|Ultrasound|ultrasound-guided IACSI
122063|NCT03232736|Other|Pacemaker adjustments|LVAD subjects with CRT device will have leads turned both on and off in blinded manner
122064|NCT03232736|Device|CRT|CRT device
122065|NCT03232723|Diagnostic Test|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
122066|NCT03232710|Drug|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
122067|NCT03232710|Drug|abilify|Aripiprazol orodispersible tablets 10mg
122068|NCT03232697|Diagnostic Test|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
122069|NCT03232697|Diagnostic Test|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
122070|NCT03232684|Diagnostic Test|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
122071|NCT03232671|Diagnostic Test|MIF ELISA|Blood sample
122072|NCT03232645|Device|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
122073|NCT03232632|Drug|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
122074|NCT03232619|Biological|CD19 CART|Patients will get one course of CART treatment with the dose of 0.5-5*10~6/KgBW.
122075|NCT03232593|Drug|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
122076|NCT03232580|Drug|rhAnnexin V-128|Patients will receive a single administration of 99mTc-rhAnnexin V-128 at Day 0
122077|NCT03232567|Biological|NasoVAX|Single ascending dose study
122078|NCT03232554|Drug|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
122079|NCT03232554|Drug|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
122080|NCT03232554|Drug|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
122081|NCT03232541|Other|Standard care|A) Ordinary nausea treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
122110|NCT03232320|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
122111|NCT03232320|Drug|Placebo|Placebo (Normal saline)
122112|NCT03232307|Drug|Dexamethasone|Given PO
122113|NCT03232307|Drug|Ibrutinib|Given PO
122114|NCT03232307|Drug|Lenalidomide|Given PO
122082|NCT03232541|Device|Sham acupuncture|"B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model."
122083|NCT03232541|Device|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
122084|NCT03232528|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
122085|NCT03232528|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
122086|NCT03232515|Combination Product|To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA|Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
122087|NCT03232502|Diagnostic Test|Pharmacogenetic testing|Basic pharmacogenetic panel
122088|NCT03232476|Device|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
122089|NCT03232450|Drug|Aspirin|Subjects will receive 81 mg enteric coated aspirin
122090|NCT03232450|Device|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
122091|NCT03232450|Device|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
122092|NCT03232437|Device|Aina HbA1c Monitoring System|Monitoring test for quantitative determination of HbA1c
122093|NCT03232424|Device|NovoTTF-200A|"Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.~Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter."
122094|NCT03232424|Drug|Temozolomide|"Concomitant phase:~75 mg/m2 per day for 42 days concomitant with radiotherapy.~Begins 1 day prior to XRT start.~Maintenance phase:~Begins 4 weeks after concomitant phase completion (+/- 1 week).~Each cycle is 28 days (5 days of drug treatment followed by 23 days without).~Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.~Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
122095|NCT03232424|Radiation|3D conformal or intensity modulated radiation therapy (IMRT)|Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
122096|NCT03232411|Other|Questionnaires|Participants will be asked to complete a baseline questionnaire that asks questions about their demographic information, medical history, and smoking habits when they first enroll in the study. They will also be asked to complete a follow-up questionnaire 2 years later. The questionnaires will each take about 25 minutes to complete.
122097|NCT03232411|Other|Saliva Samples|Participants will be asked to provide a saliva sample using the saliva kit that will be mailed to them. Detailed instructions for collection will be included in the saliva collection packet.
122098|NCT03232411|Other|Tumor Tissue|Participants will be asked for permission to obtain a sample of their tumor tissue. Participants will receive a medical release form. Once they complete it and mail it back, investigators will request a small amount of tissue collected during the participant's prostate biopsy (or during their surgery, if they had surgery) from their health care provider.
122099|NCT03232398|Drug|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
122100|NCT03232398|Drug|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
122101|NCT03232385|Device|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
122102|NCT03232385|Procedure|Renal Biopsy or Ablation|Standard of Care
122103|NCT03232372|Device|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
122104|NCT03232372|Device|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
122105|NCT03232372|Device|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
122106|NCT03232359|Diagnostic Test|immature platelets fraction|IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
122115|NCT03232307|Biological|Rituximab|Given IV
122116|NCT03232281|Drug|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
122117|NCT03232281|Drug|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
122118|NCT03232268|Biological|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
122119|NCT03232255|Other|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
122120|NCT03232242|Diagnostic Test|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
122121|NCT03232216|Dietary Supplement|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
122122|NCT03232216|Dietary Supplement|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
122123|NCT03232203|Drug|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
122124|NCT03232190|Other|Web Application|Parents receive a web application that offers information and support until the age of 2.
122125|NCT03232177|Drug|Anagre Cap.|from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
122126|NCT03232164|Drug|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
122127|NCT03232151|Diagnostic Test|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
122128|NCT03232138|Dietary Supplement|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
122129|NCT03232138|Drug|Placebo|Inactive ingredients
122130|NCT03232125|Drug|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
122131|NCT03232125|Drug|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
122132|NCT03232112|Drug|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
122133|NCT03232112|Drug|BD PosiFlush (saline)|Subcutaneous injection once-weekly
122134|NCT03232099|Dietary Supplement|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
122135|NCT03232099|Other|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
122136|NCT03232086|Other|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
122137|NCT03232086|Other|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
122138|NCT03232073|Drug|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
122139|NCT03232047|Device|Combined executive function and memory training|Computerized combined executive function and memory training
122140|NCT03232034|Dietary Supplement|Calcium Citrate|1000 mg calcium as calcium citrate
122141|NCT03232034|Dietary Supplement|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
122142|NCT03232034|Dietary Supplement|Whey Protein Hydrolysate|50 g whey protein hydrolysate
122143|NCT03232021|Drug|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
122144|NCT03232021|Drug|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 75 mg administered 1 hour prior to the surgical operation
122145|NCT03232021|Drug|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule [Lyrica] 150 mg administered 1 hour prior to the surgical operation
122146|NCT03232008|Dietary Supplement|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
122147|NCT03232008|Dietary Supplement|Canderel+Lyle's Golden Syrup drink|Canderel: 1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water Lyle's Golden Syrup: 35 g (27g of glucose and fructose)
122148|NCT03231995|Biological|Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.|"Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.~Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)"
122149|NCT03231982|Drug|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
122150|NCT03231982|Drug|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
122151|NCT03231969|Drug|Bilastine 0.2%|1 drop in each eye at 3 separate times during a 25 day period.
122152|NCT03231969|Drug|Bilastine 0.4%|1 drop in each eye at 3 separate times during a 25 day period.
122153|NCT03231969|Drug|Bilastine 0.6%|1 drop in each eye at 3 separate times during a 25 day period.
122154|NCT03231969|Drug|Bilastine 0%|1 drop in each eye at 3 separate times during a 25 day period.
122155|NCT03231956|Device|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
122156|NCT03231943|Drug|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
122157|NCT03231943|Drug|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
122158|NCT03231930|Device|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
122159|NCT03231930|Device|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.~This test will be performed for participants who have a positive OraQuick HCV antibody result."
122160|NCT03231917|Procedure|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
122161|NCT03231917|Procedure|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
122162|NCT03231904|Diagnostic Test|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
122163|NCT03231878|Drug|MIN-102|MIN-102 treatment
122164|NCT03231878|Drug|Placebos|Placebo
122165|NCT03231865|Diagnostic Test|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
122166|NCT03231852|Other|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
122167|NCT03231839|Behavioral|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
122168|NCT03231839|Behavioral|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
122169|NCT03231839|Behavioral|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
122170|NCT03231813|Procedure|Sodium lauryl sulphate induced irritation|Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
122171|NCT03231813|Other|Emollient, moisturizing cream|Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
122172|NCT03231800|Drug|dasotraline|dasotraline 2mg capsule once daily
122173|NCT03231800|Drug|Placebo|Placebo capsule once daily
122174|NCT03231787|Diagnostic Test|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.~It will be used to measure platelet function after withdrawal of the antiplatelet agent.~If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
122175|NCT03231761|Other|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
122176|NCT03231761|Other|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
122177|NCT03231735|Device|Mid frequency ventilation|Mechanical ventilator used at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
122178|NCT03231735|Device|Standard frequency ventilation|Mechanical ventilator used at rates < 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
122179|NCT03231722|Drug|Panitumumab|6 mg/kg iv over 60 minutes, day 1
122180|NCT03231722|Drug|Irinotecan|150 mg/sqm iv over 60 minutes day 1
122181|NCT03231722|Drug|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
122182|NCT03231722|Drug|l-leucovorin|200 mg/sqm iv over 2 hours
122183|NCT03231722|Drug|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
122184|NCT03231709|Drug|Trelagliptin|Trelagliptin tablets
122185|NCT03231709|Drug|Alogliptin|Alogliptin tablets
122186|NCT03231683|Drug|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
122187|NCT03231683|Drug|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
122188|NCT03231683|Drug|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
122189|NCT03231683|Drug|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
122190|NCT03231670|Procedure|Blood sampling|5ml blood will be taken in addition to standard sampling
122191|NCT03231657|Diagnostic Test|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
122294|NCT03230695|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
122295|NCT03230695|Device|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
122296|NCT03230695|Device|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
122192|NCT03231631|Behavioral|Education plan and adherence to exercise|"Send text messages with motivational sense at any time of the day, every 3 or 4 days.~They will be given the option of performing directed exercise at the cardiac rehabilitation center.~It will be recorded in an Excel table every time that text is sent to the patient.~At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.~A monthly survey will be applied where the adherence to the exercise during the previous month is measured.~These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
122193|NCT03231618|Dietary Supplement|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
122194|NCT03231605|Biological|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
122195|NCT03231592|Other|CSA Group|Already included in the arm descriptions.
122196|NCT03231592|Other|Enhanced Usual Care Group|Already included in the arm descriptions.
122197|NCT03231579|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on/starting treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
122198|NCT03231566|Behavioral|Pain Neuroscience Education|See arm/group description
122199|NCT03231553|Other|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
122200|NCT03231540|Dietary Supplement|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
122201|NCT03231527|Procedure|coronary artery bypass grafting (CABG)|myocardial revascularization
122202|NCT03231514|Dietary Supplement|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
122203|NCT03231514|Other|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
122204|NCT03231514|Other|Exercise|All groups will participate in a standardized exercise intervention.
122205|NCT03231501|Drug|epitinib succinate|This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
122206|NCT03231488|Other|Mindfulness intervention|A 10 minute mindfulness of breath exercise
122207|NCT03231488|Other|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
122208|NCT03231475|Drug|SPH1188-11|qd.po
122209|NCT03231449|Other|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
122210|NCT03231436|Drug|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
122211|NCT03231436|Drug|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
122212|NCT03231423|Other|Drainage|Using drain after operation
122213|NCT03231397|Drug|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
122214|NCT03231397|Drug|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
122215|NCT03231397|Diagnostic Test|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
122216|NCT03231384|Device|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.~Doctormate, IPC-906"
122217|NCT03231371|Drug|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
122218|NCT03231358|Behavioral|Our Family Our Future|Our Family Our Future is a 'selective' behavioral prevention program, designed to address HIV/STI acquisition, sexual risk behavior, and depression among adolescents (ages 14-16) in communities with high HIV prevalence and from families where adolescents and parents already exhibit mild, potentially troublesome, depressive symptoms but do not reach the threshold for further screening for a significant clinical depressive disorder. This intervention involves parent-child dyads who receive the intervention in a community setting, in a facilitated group format. The intervention is comprised of 3-hour sessions, held weekly for 3 consecutive weeks with an individual family meeting in the third or fourth week depending on family desires.
122219|NCT03231345|Procedure|US guided IJ|IV catheter placement
122220|NCT03231345|Device|Ultrasound|Ultrasound-guided Internal Jugular vein
122221|NCT03231332|Other|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
122222|NCT03231319|Procedure|Fascia iliaca compartment block with IV-PCA|1. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
122297|NCT03230682|Drug|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
122298|NCT03230669|Other|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
122223|NCT03231319|Procedure|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.~Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
122224|NCT03231319|Procedure|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
122225|NCT03231306|Drug|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) are being treated on the pediatric MTD established by a phase I study (NCT02285439).
122226|NCT03231280|Device|SB-061|delivered via intra-articular injection
122227|NCT03231280|Other|Placebo|Placebo delivered via intra-articular injection
122228|NCT03231254|Device|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
122229|NCT03231228|Drug|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to <60 kg
122230|NCT03231228|Drug|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
122231|NCT03231215|Drug|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
122232|NCT03231202|Procedure|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.~Additional peripheral embolization is left to the discretion of the interventional radiologist."
122233|NCT03231176|Drug|Varlitinib|oral tablets, twice daily
122234|NCT03231176|Drug|Capecitabine|oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles
122235|NCT03231163|Other|No Music|Participants lie supine on a table while no music is played.
122236|NCT03231163|Other|Relaxing Classical Music|Participants lie supine on a table while classical music is played.
122237|NCT03231163|Other|Self-Selected Relaxing Music|Participants lie supine on a table while self-selected relaxing music is played.
122238|NCT03231150|Procedure|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
122239|NCT03231150|Procedure|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
122240|NCT03231150|Procedure|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
122241|NCT03231137|Combination Product|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
122242|NCT03231137|Drug|ATV gel|Atorvastatin gel
122243|NCT03231137|Biological|PRF|Platelet rich fibrin
122244|NCT03231137|Biological|PRGF|plasma rich in growth factor
122245|NCT03231124|Drug|LEO 32731|LEO 32731 is being developed by LEO Pharma.
122246|NCT03231124|Drug|Placebo|Placebo contains the same excipients in the same concentration, only lacking LEO 32731
122247|NCT03231111|Other|Preventive Multimedia Teaching Program|Preventive Multimedia Teaching Program
122248|NCT03231085|Drug|Ferrous fumarate or ferrostrane|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate or ferostrane per os or intravenous ferric carboxymaltose.
122249|NCT03231072|Device|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
122250|NCT03231046|Device|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
122251|NCT03231046|Procedure|Hepatic Biopsy or Ablation|Standard of Care
122252|NCT03231033|Drug|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
122253|NCT03231020|Other|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
122254|NCT03231007|Other|Questionnaire|A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
122255|NCT03230981|Device|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
122256|NCT03230968|Behavioral|Integral Action Program for Respiration|
122257|NCT03230955|Behavioral|Psychological and psycho-educational support by phone|The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)
122258|NCT03230955|Other|Brief counselling session|Brief counselling session
122259|NCT03230942|Other|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
122260|NCT03230942|Other|Pos-operative rehabilitation|Physical therapy treatment
122261|NCT03230929|Device|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
122262|NCT03230916|Drug|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
122263|NCT03230903|Other|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
122264|NCT03230903|Other|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
122265|NCT03230890|Device|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
122266|NCT03230864|Drug|Lu AF35700|10 mg/day, encapsulated tablets, orally
122267|NCT03230864|Drug|Risperidone|4-6 mg/day, encapsulated tablets, orally
122268|NCT03230864|Drug|Olanzapine|15-20 mg/day, encapsulated tablets, orally
122269|NCT03230851|Drug|aspirin 100mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/d
122270|NCT03230851|Drug|aspirin 100mg/2d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/2d
122271|NCT03230851|Drug|aspirin 100mg/3d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/3d
122272|NCT03230851|Drug|aspirin 50mg bid therapy|100mg aspirin for at least 5 days followed by aspirin 50mg bid
122273|NCT03230851|Drug|aspirin 75mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 75mg/d
122274|NCT03230851|Drug|aspirin 50mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 50mg/d
122275|NCT03230851|Drug|indobufen 100mg bid therapy|100mg aspirin for at least 5 days followed by indobufen 100mg bid
122276|NCT03230838|Drug|Ceftolozane|Ceftolozane 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days
122277|NCT03230838|Drug|Tazobactam|Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 7 to 14 days
122278|NCT03230838|Drug|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
122279|NCT03230825|Drug|Oral contraceptive|Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
122280|NCT03230825|Other|Expectant management|No intervention and a follow up visit a wewk later
122281|NCT03230812|Drug|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
122282|NCT03230799|Procedure|minimal invasive lens surgery|We decreased the size of the capsulorhexis opening to 1.0-1.5 mm in diameter. Then we moved the location of the capsulorhexis to the peripheral area of the lens instead of the central area. A 0.9 mm phacoemulsification probe was used to remove the lens contents and/or cortical opacities.
122283|NCT03230799|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
122284|NCT03230786|Drug|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
122285|NCT03230773|Device|Defibrillator model|Comparison of the performance of different public access defibrillators
122286|NCT03230760|Device|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
122287|NCT03230734|Drug|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
122288|NCT03230734|Drug|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
122289|NCT03230721|Procedure|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
122290|NCT03230721|Procedure|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
122291|NCT03230721|Procedure|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
122292|NCT03230708|Other|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
122293|NCT03230708|Drug|convention drugs|according to usage method of drugs
122300|NCT03230643|Device|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.~In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
122301|NCT03230630|Diagnostic Test|plasma melatonin levels|
122302|NCT03230617|Device|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
122303|NCT03230604|Device|Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite|Restorative cavities one, two and five with material Filtek Bulk Fill Composite
122304|NCT03230604|Device|Z 350 Xt Composite|Restorative cavities one, two and five with material Z 350 XT Composite
122305|NCT03230591|Other|Echocardiography|LV vortex flow in Echocardiography
122306|NCT03230578|Other|Pharmacists & women's perspectives on pharmacist prescribed hormonal contraception|The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
122307|NCT03230565|Drug|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
122308|NCT03230565|Drug|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
122309|NCT03230552|Other|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
122310|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
122311|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
122312|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
122313|NCT03230526|Drug|[18F]DPA-714 PET scan|"One PET scan using [18F]DPA-714 is done at M2 between two [123I]FP-CIT scan (DaTscan) done at M1 and M35.~Neuropsychological assessment is done at M0, M18 and M36"
122314|NCT03230513|Other|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
122315|NCT03230513|Other|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
122316|NCT03230500|Procedure|computer guided implant placement|implant will be placed immediately using computer aided surgical guide
122317|NCT03230487|Drug|BI 1015550|Part 1 - single rising dose. Part 2 multiple rising dose
122318|NCT03230487|Drug|Placebo|Part 1 - single rising dose. Part 2 multiple rising dose
122319|NCT03230474|Drug|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
122320|NCT03230474|Drug|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
122321|NCT03230461|Behavioral|Compression depth|
122322|NCT03230448|Other|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
122323|NCT03230435|Other|Treatment settings as usual.|Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
122324|NCT03230422|Device|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
122325|NCT03230422|Device|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
122326|NCT03230409|Behavioral|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents >12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
122327|NCT03230409|Behavioral|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
122354|NCT03230253|Behavioral|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
122328|NCT03230409|Biological|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
122329|NCT03230409|Behavioral|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
122330|NCT03230396|Dietary Supplement|Vitamingum Sport|Vitamin -supplemented chewing gum
122331|NCT03230396|Dietary Supplement|Vitamingum Immunity|Vitamin -supplemented chewing gum
122332|NCT03230396|Dietary Supplement|Placebo|Control chewing gum. No vitamin content.
122333|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
122334|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
122335|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
122336|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
122337|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
122338|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
122339|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
122340|NCT03230383|Drug|Placebo|Matching Placebo for PF-06865571 for each cohort.
122341|NCT03230370|Other|UFT|The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
122342|NCT03230370|Other|LFT|The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
122343|NCT03230357|Device|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
122344|NCT03230344|Procedure|open flap debridement|open flap debridement simultaneously with root canal treatment
122345|NCT03230344|Procedure|open flap debridement|open flap debridement and delayed root canal treatment
122346|NCT03230318|Drug|derazantinib|derazantinib will be orally administered at 300 mg once per day one hour prior to or two hours after a meal and is supplied as 100 mg capsules.
122347|NCT03230305|Other|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.~If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.~If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.~If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
122348|NCT03230292|Drug|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
122349|NCT03230279|Procedure|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
122350|NCT03230279|Procedure|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
122351|NCT03230266|Procedure|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
122352|NCT03230253|Behavioral|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
122353|NCT03230253|Behavioral|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
122355|NCT03230240|Drug|HIPEC|heated intraIP chemotherapy
122356|NCT03230227|Drug|Bupivacaine magnesium|bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
122357|NCT03230227|Drug|Bupivacaine only|bupivacaine 0.125% infusion in the presternum , for 48 hours
122358|NCT03230214|Diagnostic Test|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
122359|NCT03230201|Procedure|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
122360|NCT03230188|Other|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
122361|NCT03230188|Other|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
122362|NCT03230188|Other|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
122363|NCT03230175|Biological|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
122364|NCT03230162|Drug|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
122365|NCT03230162|Drug|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
122366|NCT03230149|Diagnostic Test|Measurements of the alpha-GAL enzyme activity|Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
122367|NCT03230136|Other|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
122368|NCT03230136|Other|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
122369|NCT03230123|Dietary Supplement|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
122370|NCT03230110|Diagnostic Test|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
122371|NCT03230097|Drug|BI 409306|twice daily
122372|NCT03230097|Drug|Placebo|twice daily
122373|NCT03230084|Device|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
122374|NCT03230071|Drug|TMBCZG|0.1g per pill which contains 14mg TMBCZG
122375|NCT03230071|Other|placebo|0.1g per pill which contains 0mg TMBCZG
122376|NCT03230058|Drug|Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops|instillation of drops
122377|NCT03230045|Device|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
122378|NCT03230045|Device|no treatment|electrodes are attached, but no stimulation is given
122379|NCT03230032|Device|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
122380|NCT03230019|Procedure|chest tube|VATS with chest tube placement
122381|NCT03230019|Procedure|two-lumen catheterization|VATS with two-lumen catheterization long the midclavicular line, second intercostal space
122382|NCT03230019|Device|two-lumen catheter|central venous catheter(two-lumen 7-Fr-20cm)
122383|NCT03230006|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion, over 16 sessions, following the published therapist guide with minor refinements for application in the proposed comorbid population.
122384|NCT03230006|Behavioral|Take Control|TC is a psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC, originally designed as a computerized treatment has been modified to be administered by the therapist to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
122385|NCT03229993|Diagnostic Test|OCT|OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
122386|NCT03229980|Drug|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
122387|NCT03229980|Drug|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
122388|NCT03229967|Diagnostic Test|16S rRNA stool microbiome sequencing.|This is an observational cohort that will undergo gut microbiome sequencing.
122389|NCT03229954|Drug|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.~If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
122390|NCT03229954|Drug|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
122391|NCT03229941|Procedure|Blood Transfusion|Blood Transfusion
122392|NCT03229928|Device|MOCHA|"MOCHA phone-based application~Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth~Wrist based sensor (applicable only to sensor wearing participants)."
122393|NCT03229915|Behavioral|cognitive processing therapy|Group therapy for PTSD patients
122394|NCT03229902|Behavioral|mantra meditation|see study description
122395|NCT03229889|Drug|Cialis 5Mg Tablet|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
122396|NCT03229889|Drug|Flomax 0.4Mg Capsule|Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
122397|NCT03229889|Combination Product|Cialis + Flomax|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
122398|NCT03229889|Drug|Placebo|This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
122399|NCT03229876|Biological|CD19-UCART|A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection.
122400|NCT03229863|Other|Sweet Potatos|Plum Organics, Just Sweet Potato
122401|NCT03229863|Other|Pears|Earth's Best, First Pears
122402|NCT03229850|Drug|Insulin lispro|Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
122403|NCT03229824|Device|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
122404|NCT03229811|Other|ESRD education + ACP|Targeted advance care planning education delivered in person by trained healthcare providers
122405|NCT03229798|Drug|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
122406|NCT03229798|Combination Product|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
122407|NCT03229785|Biological|Human Umbilical Cord Blood Plasma|Plasma collected from human umbilical cord blood
122408|NCT03229772|Device|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
122409|NCT03229759|Drug|Octenidine Dihydrocloride in aqueous solution|application of investigational product
122410|NCT03229759|Other|Vehicle Control|application of vehicle control
122411|NCT03229759|Other|Saline Control|application of placebo
122412|NCT03229746|Drug|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
122413|NCT03229746|Drug|vincristine|1mg intravenous weekly for 4 weeks
122414|NCT03229746|Drug|azathioprine|dose 100mg daily for at least 3 weeks
122415|NCT03229733|Device|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
122416|NCT03229733|Behavioral|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
122417|NCT03229720|Device|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
122418|NCT03229707|Device|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).~Images are then opened into Photoshop.~The INFO panel must be open.~Click on the small eyedropper in the Info panel window and click on ''Lab Color.~Place the mouse over the center of the tooth to be measured for L value.~Click on the HSB Color option, which stands for hue, saturation, and brightness."
122419|NCT03229707|Device|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
122420|NCT03229694|Drug|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
122421|NCT03229694|Drug|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
122422|NCT03229681|Behavioral|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
122423|NCT03229681|Behavioral|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
122424|NCT03229668|Drug|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
122425|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 75 mg administered 1 hour prior to the surgical operation
122426|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule [Lyrica] 150 mg administered 1 hour prior to the surgical operation
122427|NCT03229655|Procedure|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
122462|NCT03229408|Other|Placebo|Appears identical to experimental drug
122587|NCT03228446|Behavioral|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
122428|NCT03229642|Device|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
122429|NCT03229642|Device|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
122430|NCT03229629|Behavioral|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
122431|NCT03229629|Other|Food Voucher (Monetary)|Monthly voucher worth 200 birr(~$10) every month for the duration of 6 month
122432|NCT03229616|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
122433|NCT03229616|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
122434|NCT03229616|Drug|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days −3 to −2.
122435|NCT03229603|Other|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
122436|NCT03229590|Procedure|Surgical dislocation|Reduction of slipped epiphysis by surgical dislocation
122437|NCT03229577|Behavioral|Sudarshan Kriya Yoga|Yoga-based breathing program.
122438|NCT03229577|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness program.
122439|NCT03229577|Behavioral|Emotional Intelligence|Emotional Intelligence program.
122440|NCT03229564|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
122441|NCT03229564|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
122442|NCT03229551|Drug|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
122443|NCT03229551|Drug|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
122444|NCT03229538|Drug|Methylprednisolone|IV Steroid pre-operative and intra-operative
122445|NCT03229538|Drug|Isotonic saline|Isotonic saline pre-operative and intra-operative
122446|NCT03229525|Behavioral|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
122447|NCT03229525|Behavioral|Trauma Related Expressive Speaking|Participants will speak about the traumatic event over the course of six sessions.
122448|NCT03229525|Behavioral|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
122449|NCT03229512|Drug|Sildenafil|Topical 1% Sildenafil Cream
122450|NCT03229499|Drug|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:~adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
122451|NCT03229499|Drug|Placebo Oral Tablet|matching placebo tablet
122452|NCT03229486|Drug|Sugammadex Injection [Bridion]|Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
122453|NCT03229486|Drug|Neostigmine+Glycopyrronium|Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
122454|NCT03229460|Other|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
122455|NCT03229460|Device|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
122456|NCT03229460|Device|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
122457|NCT03229447|Behavioral|eLearning Modules|All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
122458|NCT03229447|Behavioral|Change Team Intervention|Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
122459|NCT03229434|Behavioral|Mountain hiking|Compare arm description
122460|NCT03229421|Other|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
122461|NCT03229408|Drug|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
122463|NCT03229382|Drug|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
122464|NCT03229369|Procedure|Isolated anatomic ACL reconstruction|Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
122465|NCT03229369|Procedure|Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction|Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnel will be performed with a 5mm drill, 1cm distal to the articular level, midway from the fibular head and Gerdy Tubercle, crossing the tibia toward its anteromedial cortex, 1cm distal to the ACL tunnel. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnel and then retrieved in the anteromedial aspect of the tibia, 1cm distal to the ACL tunnel entrance. ALL is fixed in full extension and neutral rotation, tying both graft extremities with 3 knots.
122466|NCT03229356|Other|Best Practices Advisory (BPA)|"BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.~Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
122467|NCT03229356|Other|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
122468|NCT03229343|Other|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
122469|NCT03229330|Procedure|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
122470|NCT03229330|Combination Product|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
122471|NCT03229317|Other|Plethysmography|Lung plethysmography
122472|NCT03229291|Drug|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
122473|NCT03229291|Drug|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
122474|NCT03229278|Drug|Enzyme Inhibitor Therapy|Given trigriluzole PO
122475|NCT03229278|Other|Laboratory Biomarker Analysis|Correlative studies
122476|NCT03229278|Biological|Nivolumab|Given IV
122477|NCT03229278|Biological|Pembrolizumab|Given IV
122478|NCT03229265|Drug|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
122479|NCT03229252|Drug|Placebo Inhalation Solution|Normal Saline Inhalation Solution
122480|NCT03229252|Drug|SPX-101|SPX-101 Inhalation Solution
122481|NCT03229239|Procedure|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
122482|NCT03229226|Other|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
122483|NCT03229200|Drug|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
122484|NCT03229174|Drug|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
122485|NCT03229174|Drug|Placebo|Placebo (sugar pill)
122486|NCT03229161|Behavioral|IWT-group|
122487|NCT03229148|Procedure|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
122488|NCT03229148|Procedure|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
122489|NCT03229135|Device|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
122490|NCT03229109|Device|Spectrophon dehydration body monitor|Participants (both males and females) were assigned to physical activity (running), biosensor was attached to subject's wrist
122491|NCT03229096|Drug|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.~Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).~Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
122585|NCT03228459|Other|Result and recommendation report|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
122592|NCT03228420|Device|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
122492|NCT03229083|Other|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
122493|NCT03229070|Other|Interval effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
122494|NCT03229070|Other|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
122495|NCT03229057|Drug|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
122496|NCT03229057|Drug|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
122497|NCT03229057|Drug|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
122498|NCT03229044|Genetic|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
122499|NCT03229031|Drug|ES135|ES135 will be administered via intrathecal
122500|NCT03229018|Diagnostic Test|Voxel size|200 μm and 300 μm Voxel Sizes
122501|NCT03229005|Procedure|implant insertion|during surgery soft tissues will be measured
122502|NCT03229005|Procedure|operculectomy|during second surgery soft tissues will be measured again
122503|NCT03229005|Procedure|prosthetic rehabilitation|after three months implants will be loaded with screw retained crown
122504|NCT03228992|Drug|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
122505|NCT03228992|Other|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
122506|NCT03228979|Other|Structured Semi-Interactive Stroke Prevention Package|the intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
122507|NCT03228966|Diagnostic Test|Echocardiogram|Screening echocardiogram
122508|NCT03228953|Other|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
122509|NCT03228940|Drug|RVX000222|oral, BID
122510|NCT03228927|Other|comparison of twin A to twin B|Comparison of Twin A to Twin B
122511|NCT03228914|Drug|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
122512|NCT03228914|Drug|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
122513|NCT03228901|Drug|Oxytocin|Administration of the hormone oxytocin
122514|NCT03228901|Drug|Placebos|
122515|NCT03228888|Other|Administration of rhytmic acoustic stimuli for gait training|The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
122516|NCT03228862|Drug|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
122517|NCT03228849|Procedure|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
122518|NCT03228849|Procedure|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
122519|NCT03228836|Drug|PD-1 Antibody|IBI308 200mg/3 weeks
122520|NCT03228823|Procedure|Radiofrequency ablation|RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
122588|NCT03228446|Behavioral|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
122521|NCT03228823|Drug|Amiodarone (Antiarrhythmic drug)|AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
122522|NCT03228810|Other|Blood draw|(2) 10 mL tubes will be collected
122523|NCT03228810|Procedure|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
122524|NCT03228797|Procedure|an ultrasound guided rectus sheath block|
122525|NCT03228797|Procedure|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
122526|NCT03228797|Procedure|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
122527|NCT03228784|Procedure|LASIK|
122528|NCT03228771|Drug|PRGF/ATV|Atorvastatin loaded in PRGF fibrin scaffold
122529|NCT03228771|Drug|ATV gel|Atorvastatin loaded in methyl cellulose gel
122530|NCT03228758|Procedure|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
122531|NCT03228745|Behavioral|Pre-operative MBSR|A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
122532|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
122533|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
122534|NCT03228732|Drug|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
122535|NCT03228732|Drug|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
122536|NCT03228732|Drug|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
122537|NCT03228719|Behavioral|Standardize PT after TKR with a Physical Activity Intervention|Standardized PT and a physical activity intervention. Participants will be provided a FitbitTM Zip within one week after enrolling in the study. Participants will self-track their steps/day using their FitbitTM Zip. Participants ≤ 3 weeks' post-operative TKR are expected to maintain and not increase steps/day. Beyond 3 weeks after surgery, step goals will be initiated and evaluated on a weekly basis. Progression of weekly steps/day goal will be a joint decision between the participant and physical therapist. As a guide, a 10-20% increase in steps/day until at least 6,000 steps/day is achieved. Each week the physical therapist will review the participant's steps/day goal and if at least 4 of the 7 previous days per week were at or above the prior week's steps/day goal, then next week's steps/day goal will increase. The physical therapist will discuss current steps/day with the participant using the Fitbit TM Zip and set a personalized steps/day goal each week during PT.
122538|NCT03228719|Other|Standardized PT after TKR|Participants in the control group will receive standardized PT provided by a licensed physical therapist at UDPT using the University of Delaware's Rehabilitation Guidelines for Unilateral Total Knee Replacement. Standardized PT also includes a printed home exercise program with an exercise log that is updated weekly by a physical therapist. PT appointment times range from 45-60 minutes with appointment occurring 1-3 times a week for 6-8 weeks.
122539|NCT03228706|Behavioral|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska & Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen & Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
122540|NCT03228693|Procedure|Biopsy and/or triamcinolone injection|Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
122541|NCT03228693|Procedure|Excisional Biopsy|Complete excision of an earlobe keloid will be taken.
122542|NCT03228680|Drug|Follitropin delta|Subcutaneous administration through pre-filled injection
122543|NCT03228680|Drug|Follitropin beta|Single daily subcutaneous injection in the abdomen.
122544|NCT03228667|Drug|ALT-803 + Pembrolizumab|Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.
122545|NCT03228667|Drug|ALT-803 + Nivolumab|Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.
122546|NCT03228667|Drug|ALT-803 + Atezolizumab|Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.
122547|NCT03228667|Drug|ALT-803 + Avelumab|Patients will receive 10 mg/kg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.
122586|NCT03228459|Diagnostic Test|Pulse wave velocity|Pulse wave velocity (PWV) will be used as an indicator of arterial stiffness. It will be measured non-invasively with the carotid to femoral PWV (cfPWV) according to standard protocols.
122548|NCT03228654|Procedure|Unipolar Electrocautery sealing of vessels|"Vaginal walls are incised by monoplar current (40 W)~A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~uterine vessels are individually secured.~Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
122549|NCT03228654|Procedure|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
122550|NCT03228641|Device|micro-excisional skin removal with coring needle|
122551|NCT03228628|Drug|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
122552|NCT03228628|Other|Placebo|inhale medical air (22% O2 - 78% N2)
122553|NCT03228615|Other|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
122554|NCT03228602|Other|Recording of GEP (Gustatory Evoked Potentials)|record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
122555|NCT03228589|Dietary Supplement|probiotic strain|8 weeks of treatment with probiotic strain
122556|NCT03228589|Dietary Supplement|Placebo|8 weeks of treatment
122557|NCT03228576|Combination Product|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
122558|NCT03228563|Other|Probioics|taking 1 probiotic capsule qd and H.S for three months
122559|NCT03228550|Dietary Supplement|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
122560|NCT03228550|Behavioral|Aerobic exercise|Static exercise cycle
122561|NCT03228550|Dietary Supplement|Placebo multinutrient|Placebo multinutrient supplement
122562|NCT03228537|Drug|Atezolizumab|Given IV
122563|NCT03228537|Drug|Cisplatin|Given IV
122564|NCT03228537|Procedure|Extrapleural Pneumonectomy|Undergo EPP
122565|NCT03228537|Drug|Pemetrexed Disodium|Given IV
122566|NCT03228537|Procedure|Pleurectomy|Undergo PD
122567|NCT03228537|Radiation|Radiation Therapy|Undergo RT
122568|NCT03228524|Drug|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
122569|NCT03228524|Behavioral|Therapeutic exercise|Standard physiotherapy
122570|NCT03228524|Drug|Placebo Oral Tablet|Placebo
122571|NCT03228511|Device|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
122572|NCT03228498|Drug|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
122573|NCT03228498|Drug|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
122574|NCT03228485|Device|MyBPH Care mobile app|The application that will give daily medication reminders and via which the questionnaires can be filled out.
122575|NCT03228472|Device|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.~TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
122576|NCT03228472|Device|sham stimulation|Placebo treatment
122577|NCT03228459|Diagnostic Test|Dried blood spot test|Dried capillary blood testing creatinine, uric acid and total cholesterol (reflotron® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
122578|NCT03228459|Diagnostic Test|Urine test|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
122579|NCT03228459|Diagnostic Test|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
122580|NCT03228459|Diagnostic Test|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
122581|NCT03228459|Diagnostic Test|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
122582|NCT03228459|Diagnostic Test|Determination of advanced glycation-end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnostics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
122583|NCT03228459|Diagnostic Test|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
122584|NCT03228459|Other|Biological sample collection|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. Moreover, a saliva sample will be collected.These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
122594|NCT03228407|Procedure|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
122595|NCT03228407|Diagnostic Test|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa.These will be obtained with a standard biopsy forceps inserted through the channel in gastroscope.
122596|NCT03228407|Diagnostic Test|Mucosal impedance (MI)|MI balloon measures epithelial impedance along a 10 cm length of esophagus. The gastroscope will be withdrawn and the MI balloon will be advanced into the esophagus through the mouth. The balloon will be inflated so that the sensors contact the esophageal mucosa. After MI measurements are obtained, the balloon will be deflated and withdrawn.
122597|NCT03228394|Drug|Ganaxolone|Ganaxolone IV
122598|NCT03228394|Drug|Placebo|Placebo IV
122599|NCT03228381|Device|BOSS Device|The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
122600|NCT03228368|Drug|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
122601|NCT03228355|Drug|Levcromakalim|To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
122602|NCT03228355|Drug|Saline|To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
122603|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
122604|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.~The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
122605|NCT03228329|Other|fluid boluses|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
122606|NCT03228316|Procedure|superior hypogastric plexus block|nerve plexus block
122607|NCT03228316|Radiation|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
122608|NCT03228303|Drug|Nilotinib 150 MG [Tasigna]|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
122609|NCT03228303|Drug|Imatinib 400mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
122610|NCT03228277|Drug|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
122611|NCT03228264|Device|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 96 minutes per day (80% of two hours) and the control group for 24 minutes per day (20% of two hours).
122612|NCT03228264|Device|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games: Flow Free (Big Duck Games LCC) and Bejeweled (PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 24 minutes and the control group for 96 minutes per day.
122613|NCT03228251|Other|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
122614|NCT03228238|Drug|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
122615|NCT03228238|Drug|Statin|Atorvastatin calcium 10mg
122616|NCT03228238|Drug|Standard medication for variant angina|Calcium Channel blocker or NG
122617|NCT03228225|Behavioral|Tele Cardiac Rehabilitation|Comprehensive intervention according to the secondary prevention goals
122618|NCT03228212|Device|CONTROL|ACUVUE OASYS
122619|NCT03228212|Device|TEST|senofilcon A with new UV blocker
122620|NCT03228199|Other|Intervention group|Will immediately receive a free pair of presbyopic glasses through the Clear Vision Workplace program. These glasses will correct the worker's vision at their usual working distance, and will not correct astigmatism.
122621|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
122622|NCT03228186|Drug|Pevonedistat|25mg/m2 days 1, 3, 5
122623|NCT03228186|Drug|Docetaxel|75mg/m2 day 1
122698|NCT03227679|Drug|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
122699|NCT03227666|Behavioral|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
122624|NCT03228160|Other|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m⁻⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
122625|NCT03228147|Dietary Supplement|Nutritional Supplementation|Given PO
122626|NCT03228147|Other|Questionnaire Administration|Ancillary studies
122627|NCT03228134|Drug|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
122628|NCT03228134|Drug|Yang He Ping Chuan Granule|Traditional Chinese Medicine
122629|NCT03228134|Other|Ke Chuan Liu Wei Granule placebo|Placebo
122630|NCT03228134|Other|Yang He Ping Chuan Granule placebo|Placebo
122631|NCT03228121|Procedure|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
122632|NCT03228121|Procedure|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
122633|NCT03228108|Drug|Ciprofloxacin|see study arms.
122634|NCT03228108|Drug|Trimethoprim/Sulfamethoxazole|see study arms.
122635|NCT03228108|Drug|Fosfomycin|see study arms.
122636|NCT03228108|Drug|Pivmecillinam/augmentin|see study arms.
122637|NCT03228095|Diagnostic Test|VOC detection in breath and in skin headspace|VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
122638|NCT03228095|Diagnostic Test|Breath sampling|Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
122639|NCT03228095|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
122640|NCT03228095|Procedure|Colonoscopy with biopsies|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
122641|NCT03228095|Procedure|Whole blood/ Plasma / serum sampling|Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
122642|NCT03228095|Diagnostic Test|Faecal sampling|Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
122643|NCT03228095|Procedure|Histological examination of surgical specimen|Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
122644|NCT03228095|Diagnostic Test|Headspace analysis for biological material|VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
122645|NCT03228082|Device|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
122646|NCT03228069|Procedure|Blood drawn after rabies booster vaccination|Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
122647|NCT03228056|Diagnostic Test|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
122648|NCT03228043|Drug|Apatinib|Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
122649|NCT03228043|Drug|CAPEOX|CAPEOX adjuvant chemotherapy for resectable colorectal
122650|NCT03228030|Dietary Supplement|Thiamine|Capsules
122651|NCT03228030|Dietary Supplement|Placebo|Identical capsules
122652|NCT03228017|Drug|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
122653|NCT03228004|Behavioral|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
122654|NCT03227991|Behavioral|Safety Planning Intervention|The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
122655|NCT03227991|Behavioral|Risk factors and Warning signs|Printed information sheet listing suicide risk factors and crisis hotlines
122656|NCT03227978|Combination Product|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
122657|NCT03227965|Biological|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
122658|NCT03227952|Device|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
122659|NCT03227939|Procedure|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
122700|NCT03227653|Drug|Efavirenz|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
122701|NCT03227653|Drug|Nevirapine|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
122660|NCT03227939|Procedure|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
122661|NCT03227926|Drug|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
122662|NCT03227913|Other|Two samples of saliva|"Without stimulation: the first will be used to measure the flow of naturally secreted saliva~With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation"
122663|NCT03227913|Other|Chewing behaviour|Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
122664|NCT03227913|Other|Study of the food bolus|"Analysis by a compression and viscosity test~Evaluation of the quantity of saliva incorporated by drying"
122665|NCT03227900|Drug|Lidocaine|Intragastric infusion of lidocain
122666|NCT03227900|Drug|Placebos|Intragastric infusion of water for injections
122667|NCT03227887|Other|Two samples of saliva|"Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva~With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
122668|NCT03227887|Other|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
122669|NCT03227887|Other|Study of the food bolus|"2 tests:~Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated~The bolus will be analysed visually"
122670|NCT03227887|Other|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
122671|NCT03227874|Dietary Supplement|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
122672|NCT03227874|Dietary Supplement|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
122673|NCT03227861|Drug|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
122674|NCT03227848|Device|Automated Heart Murmur Detection AI|Automated AI algorithm-based analysis of digital heart sound recordings to detect and classify heart murmurs. Heart sound recordings were fully blinded before undergoing one-time automated analysis. AI algorithm results for each recording include: AHA classification (Class I (pathologic heart murmur) versus class III (innocent heart murmur or no heart murmur), murmur timing, murmur grade, heart rate and S1/S2 identification.
122675|NCT03227835|Other|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR >29mL/min/1.73m2
122676|NCT03227822|Procedure|Short spot stenting|
122677|NCT03227822|Procedure|Long lesion stenting|
122678|NCT03227809|Behavioral|Handbook condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
122679|NCT03227809|Behavioral|Handbook plus condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
122680|NCT03227796|Drug|LEVI-04|LEVI-04 intravenous infusion
122681|NCT03227796|Drug|Placebo|Placebo intravenous infusion
122682|NCT03227783|Device|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
122683|NCT03227770|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
122684|NCT03227770|Device|hemodialysis|Low-flux hemodialysis treatment at a frequency of 2 times a week and online-hemodiafiltration treatment at a frequency of once a week, with each treatment session lasting 4 hours.
122685|NCT03227757|Device|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
122686|NCT03227744|Behavioral|Group therapy|Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.
122687|NCT03227744|Other|Surveys|MAX-PC, GAD and FACT-P
122688|NCT03227731|Drug|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
122689|NCT03227718|Behavioral|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
122690|NCT03227705|Drug|Prometrium|Intravaginal use, off label, of Prometrium
122691|NCT03227705|Device|Dr. Arabin, cerclage pessary perforated|A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
122692|NCT03227692|Device|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
122693|NCT03227692|Procedure|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
122694|NCT03227692|Device|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
122695|NCT03227679|Other|Nicotine Metabolite Ratio|This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
122696|NCT03227679|Drug|Varenicline|FDA-approved smoking cessation pharmacotherapy
122697|NCT03227679|Drug|Bupropion|FDA-approved smoking cessation pharmacotherapy
122702|NCT03227653|Drug|Lopinavir-Ritonavir Drug Combination|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
122703|NCT03227640|Procedure|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
122704|NCT03227640|Device|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
122705|NCT03227627|Device|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
122706|NCT03227627|Other|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
122707|NCT03227614|Behavioral|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
122708|NCT03227601|Device|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
122709|NCT03227588|Diagnostic Test|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
122710|NCT03227575|Behavioral|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
122711|NCT03227562|Drug|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
122712|NCT03227549|Procedure|Direct Superior Approach|Total hip arthroplasty using direct superior approach
122713|NCT03227549|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
122714|NCT03227549|Procedure|Posterior Approach|Total Hip Arthroplasty using posterior approach
122715|NCT03227497|Dietary Supplement|Whole Walnuts|Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
122716|NCT03227484|Drug|Empagliflozin 25mg|Once daily over 8 weeks
122717|NCT03227484|Drug|Placebo Oral Tablet|Once daily over 8 weeks
122718|NCT03227471|Drug|IVA|150-mg IVA film-coated tablet for oral administration
122719|NCT03227471|Drug|TEZ/IVA|100-mg TEZ / 150-mg IVA fixed dose combination (FDC) tablet for oral administration.
122720|NCT03227471|Drug|VX-445|VX-445 tablet for oral administration.
122721|NCT03227471|Drug|Matched Placebo|Matched placebo.
122722|NCT03227471|Drug|TEZ|50-mg tablet for oral administration.
122723|NCT03227471|Drug|VX-561|50-mg tablet for oral administration.
122724|NCT03227458|Other|DHEA|Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
122725|NCT03227458|Other|Placebo|Participants will take placebo daily for 36 weeks.
122726|NCT03227458|Behavioral|Exercise|bone-loading exercise on 3 days per week for 38 weeks
122727|NCT03227445|Device|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
122728|NCT03227445|Device|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
122729|NCT03227445|Device|HandiHaler DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
122730|NCT03227445|Other|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
122731|NCT03227432|Drug|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
122732|NCT03227432|Drug|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
122733|NCT03227432|Drug|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
122734|NCT03227432|Drug|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
122735|NCT03227419|Drug|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
122736|NCT03227419|Drug|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight <60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight >100 mg) 24 hours before the first subcutaneous injection."
122737|NCT03227406|Behavioral|Sleep deprivation|Subjects are kept awake all night.
122738|NCT03227406|Behavioral|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
122739|NCT03227393|Behavioral|Yoga training|Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
122740|NCT03227380|Other|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
122741|NCT03227367|Other|other : PRF|mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
122742|NCT03227354|Device|Vittamed 205|non-invasive Intracranial Pressure measurement
122743|NCT03227341|Other|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
122744|NCT03227328|Drug|concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy|"CDK4/6 inhibitor:~palbociclib~ribociclib~abemaciclib~Endocrine therapy:~non-steroidal or steroidal AI~fulvestrant"
122745|NCT03227328|Drug|chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)|"Standard Chemotherapy regimens will be classified as:~anthracycline + taxane,~taxane,~anthracycline,~capecitabine / fluoropyrimidines,~others.~Endocrine therapy:~non-steroidal or steroidal AI~fulvestrant"
122746|NCT03227302|Procedure|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
122747|NCT03227302|Procedure|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
122748|NCT03227302|Procedure|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
122749|NCT03227289|Other|Stayed in NRDS|The neonates with NRDS are stayed in NRDS.
122750|NCT03227289|Other|Converted to ARDS|The neonates with NRDS are converted to ARDS.
122751|NCT03227276|Dietary Supplement|Litramine|2 tablets to be taken 3 times a day after meals
122752|NCT03227276|Dietary Supplement|Placebo tablet|2 tablets to be taken 3 times a day after meals
122753|NCT03227263|Drug|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
122754|NCT03227263|Drug|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
122755|NCT03227224|Drug|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
122756|NCT03227224|Drug|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
122757|NCT03227198|Biological|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
122758|NCT03227198|Biological|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
122759|NCT03227185|Device|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
122760|NCT03227185|Device|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
122761|NCT03227172|Procedure|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
122762|NCT03227146|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
122763|NCT03227146|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
122764|NCT03227133|Other|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
122765|NCT03227133|Other|Psychiatric interview|
122766|NCT03227133|Other|Cardiovascular risk assessment|
122767|NCT03227120|Other|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.~Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
122768|NCT03227094|Diagnostic Test|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training & delivery of Jelly-Bean/75g glucose beverage
122769|NCT03227094|Diagnostic Test|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
122770|NCT03227094|Diagnostic Test|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
122771|NCT03227081|Behavioral|Sleep Deprivation|Sleep Deprivation
122772|NCT03227068|Other|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
122773|NCT03227068|Other|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
122774|NCT03227029|Biological|RSV ΔNS2/Δ1313/I1314L|10^6 plaque-forming units (PFU); administered as nose drops
122775|NCT03227029|Biological|RSV 276|10^5 PFU; administered as nose drops
122776|NCT03227029|Biological|Placebo|Administered as nose drops
122777|NCT03227016|Drug|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
122778|NCT03227016|Drug|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
122779|NCT03226990|Other|impression technique|impression technique with and without wax spacer
122780|NCT03226977|Device|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
122781|NCT03226977|Device|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
122782|NCT03226964|Device|high flow nasal oxygen|humidified high flow nasal oxygen
122783|NCT03226951|Device|Subthreshold 532nm laser|Subthershold 532nm laser
122784|NCT03226925|Diagnostic Test|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
122785|NCT03226925|Diagnostic Test|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
122786|NCT03226925|Diagnostic Test|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
122787|NCT03226899|Drug|Lesinurad|200 MG Oral Tablet
122788|NCT03226899|Drug|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
122789|NCT03226899|Drug|Placebo|matching placebo oral tablet
122790|NCT03226873|Behavioral|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
122791|NCT03226860|Device|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
122792|NCT03226860|Other|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
122793|NCT03226847|Procedure|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
122794|NCT03226834|Device|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
122795|NCT03226834|Other|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
122796|NCT03226821|Drug|Tesamorelin|Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
122797|NCT03226808|Device|Vivacit-E Liner|All subjects enrolled will receive the Vivacit-E liner.
122798|NCT03226795|Other|" Information-Motivation-Behavioral skills  intervention."|"information -> Reminders of medication: mobile application~Motivation -> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients~Behavioral skills -> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
122799|NCT03226782|Other|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
122800|NCT03226782|Other|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
122801|NCT03226769|Device|TrueTear|Intranasal application of TrueTear device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear per Patient Guide with assessments at Day 7, Day 14 and Day 30.
122802|NCT03226769|Device|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions with assessments at Day 7, Day 14 and Day 30.
122803|NCT03226756|Drug|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
122804|NCT03226743|Other|collaborative and stepped care model|"Including elements:~collaborative and stepped care of patients with mental disorders~treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities~initial training of participating health care providers~formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders~formalized ICD-diagnostics~guideline-oriented treatment recommendations~bibliotherapy or internet-based self-help for patient with mild to moderate disorders~online referral platform~case management for patients with severe disorders~systematic and regular monitoring~regular quality circles for participating health care providers"
122805|NCT03226730|Behavioral|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
122806|NCT03226730|Behavioral|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
122807|NCT03226717|Drug|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
122808|NCT03226691|Drug|Plerixafor|This is a single cohort phase 1 study to determine the safety of plerixafor mobilization and apheresis in SCD patients
122809|NCT03226678|Drug|APL-2|Complement (C3) Inhibitor
122810|NCT03226665|Diagnostic Test|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.~Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.~This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
122811|NCT03226626|Drug|Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD|Concomitant tumescent anesthesia antibiotic delivery (TAAD) & Intravenous antibiotic delivery (IVAD).
122812|NCT03226626|Device|SubQKath|The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
122813|NCT03226613|Procedure|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
122814|NCT03226613|Procedure|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
122815|NCT03226613|Procedure|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
122816|NCT03226600|Device|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
122817|NCT03226600|Device|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
122818|NCT03226587|Procedure|Blue light|Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
122819|NCT03226587|Procedure|control exposure|Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
122820|NCT03226574|Drug|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8,15, 25 or 35 mcg), epidural injection
122821|NCT03226561|Procedure|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
122822|NCT03226548|Other|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
122823|NCT03226535|Device|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
122824|NCT03226522|Drug|AXS-05|AXS-05
122825|NCT03226522|Drug|Bupropion|Bupropion
122826|NCT03226522|Drug|Placebo|Placebo
122827|NCT03226496|Behavioral|motivational interviewing|
122828|NCT03226483|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
122829|NCT03226470|Biological|T27|T27 suppository contain 500 µg of T27 and suppocire.
122830|NCT03226470|Biological|T512|T512 suppository contain 500 µg of T512 and suppocire.
122831|NCT03226457|Drug|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
122832|NCT03226457|Drug|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
122833|NCT03226457|Drug|Frusemide|Renal Physiology Test (RPT) days will be performed at week 1 and week 6 on each arm of this crossover trial. On these RPT days participants will undergo oral water loading (15mls/kg) and frequent urination at 30 minute intervals to gain a steady state diuresis. At a set time point, an intravenous bolus of furosemide at a dose of half the participant's usual loop diuretic dose will be administered.
122834|NCT03226444|Drug|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
122835|NCT03226444|Drug|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
122836|NCT03226444|Drug|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
122837|NCT03226431|Drug|Ascorbic Acid|ARINA-1 (inhaled ascorbic acid 88 mg/ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
122838|NCT03226418|Drug|Cytarabine|Given IV
122839|NCT03226418|Drug|Decitabine|Given IV
122840|NCT03226418|Drug|Idarubicin|Given IV
122841|NCT03226418|Other|Laboratory Biomarker Analysis|Correlative studies
122842|NCT03226418|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
122843|NCT03226418|Other|Quality-of-Life Assessment|Ancillary studies
122844|NCT03226418|Other|Questionnaire Administration|Ancillary studies
122845|NCT03226418|Drug|Azacitidine|Given by infusion
122846|NCT03226418|Drug|Venetoclax|oral tablet
122847|NCT03226418|Drug|glasdegib|oral tablet
122848|NCT03226405|Other|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
122849|NCT03226405|Other|Usual Care|the standard of care provided by the institution
122850|NCT03226392|Drug|QAW039|QAW039 once daily
122851|NCT03226392|Drug|Placebo|Placebo once daily
122852|NCT03226366|Other|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
122853|NCT03226353|Device|somofilcon A|contact lens
122854|NCT03226353|Device|omafilcon A|contact lens
122855|NCT03226340|Drug|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
122856|NCT03226340|Drug|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
122857|NCT03226327|Dietary Supplement|formula salt with very low sodium (Brand name: Manlikang)|hypertension patients will use the formula salt with very low (<20%) sodium （Manlikang) for six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the 24-hour urine sodium.
122858|NCT03226314|Procedure|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
122859|NCT03226301|Drug|Ibrutinib + Venetoclax 15 cycles|"Cycle 1 + 2: 420 mg ibrutinib, day 1-28 | Cycle 3: 420 mg ibrutinib, day 1-28 | 20 mg venetoclax, day 1-7 | 50 mg venetoclax, day 8-14 | 100 mg venetoclax, day 15-21 | 200 mg venetoclax, day 22-28 | Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28"
122860|NCT03226301|Drug|Ibrutinib until progression/relapse|420mg ibrutinib daily until progression/relapse
122861|NCT03226301|Drug|Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles|"Cycle 1: 420 mg ibrutinib | 20 mg venetoclax, day 1-7 | 50 mg venetoclax, day 8-14 | 100 mg venetoclax, day 15-21 | 200 mg venetoclax, day 22-28 | cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28"
122862|NCT03226275|Drug|Bisoprolol-Amlodipine FDC|Participants received a single oral dose of 5 milligram(mg)/5 mg bisoprolol-amlodipine FDC tablet (Concor AM®) either on Day 1 or Day 15 under fasting or fed conditions.
122863|NCT03226275|Drug|Bisoprolol|Participants received 5 mg bisoprolol tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
122864|NCT03226275|Drug|Amlodipine|Participants received 5 mg amlodipine tablet as a single oral dose either on Day 1 or Day 15 under fasting or fed conditions.
122865|NCT03226262|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.~The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
122866|NCT03226249|Procedure|Computed Tomography|Undergo FDG-PET/CT
122867|NCT03226249|Drug|Dacarbazine|Given IV
122868|NCT03226249|Drug|Doxorubicin Hydrochloride|Given IV
122869|NCT03226249|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
122870|NCT03226249|Other|Laboratory Biomarker Analysis|Correlative studies
122871|NCT03226249|Biological|Pembrolizumab|Given IV
122872|NCT03226249|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
122873|NCT03226249|Drug|Vinblastine Sulfate|Given IV
122874|NCT03226236|Radiation|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
122875|NCT03226236|Biological|Autologous DC vaccine|The first dose (7 to 14 x 10_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
122876|NCT03226236|Drug|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
122877|NCT03226223|Drug|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
122878|NCT03226210|Drug|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan & Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
122879|NCT03226197|Dietary Supplement|Ketone ester drink|Ketone ester drink
122880|NCT03226171|Drug|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
122881|NCT03226145|Procedure|MRI Motility|MRI sequence to assess colonic motility
122882|NCT03226145|Procedure|High Resolution Manometry|HRM of colon to assess motility
122883|NCT03226145|Drug|Bisacodyl|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
122884|NCT03226145|Drug|Hyoscine butylbromide|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
122885|NCT03226132|Behavioral|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
122886|NCT03226132|Behavioral|Repeated Contact|Repeated Contact
122887|NCT03226119|Diagnostic Test|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
122888|NCT03226106|Behavioral|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
122889|NCT03226106|Other|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
123048|NCT03224793|Drug|Placebo|Administered as specified in the treatment arm
122890|NCT03226093|Procedure|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
122891|NCT03226080|Drug|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
122892|NCT03226080|Drug|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
122893|NCT03226080|Drug|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
122894|NCT03226067|Drug|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
122895|NCT03226067|Drug|Placebo oral capsule|Matching capsules.
122896|NCT03226054|Behavioral|Lifestyle Modifications|Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
122897|NCT03226041|Device|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
122898|NCT03226028|Procedure|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
122899|NCT03226002|Device|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
122900|NCT03225989|Drug|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
122901|NCT03225976|Device|Light-Emitting Diode Device|"The therapy will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 180 J bilaterally on the quadriceps femoris muscle.~All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
122902|NCT03225976|Device|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second, third and fourth day of collection using a 25x40 cm2 LED blanket, with an equidistant distribution, with total energy per area of 0 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
122903|NCT03225963|Radiation|Chemoradiation with temozolomide|
122904|NCT03225950|Other|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
122905|NCT03225950|Diagnostic Test|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
122906|NCT03225950|Genetic|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
122907|NCT03225950|Diagnostic Test|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
122908|NCT03225937|Drug|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
122909|NCT03225937|Drug|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.~Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
122910|NCT03225924|Drug|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
122911|NCT03225924|Drug|Rituximab|cycles of 21 days - 375mg/m²
122912|NCT03225924|Drug|Cyclophosphamide|cycles of 21 days - 750 mg/m²
122913|NCT03225924|Drug|Doxorubicin|cycles of 21 days - 50mg/m²
122914|NCT03225924|Drug|Vincristine|cycles of 21 days - 1.4mg/m²
122915|NCT03225924|Drug|Prednisone|cycles of 21 days - 40mg/m²
122916|NCT03225911|Device|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
122917|NCT03225911|Device|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
122918|NCT03225911|Device|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
122919|NCT03225898|Other|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
122920|NCT03225898|Other|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
122921|NCT03225885|Other|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
122922|NCT03225885|Other|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
122991|NCT03225300|Radiation|Simultaneous integrated boost|Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
122992|NCT03225287|Drug|Zilucoplan (RA101495)|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
123049|NCT03224780|Diagnostic Test|maternal serum creatine kinase|Biochemical marker
122923|NCT03225859|Behavioral|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
122924|NCT03225846|Drug|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide (ASO)
122925|NCT03225846|Drug|Placebo|0.9% Sodium Chloride
122926|NCT03225833|Drug|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
122927|NCT03225833|Drug|Placebo|0.9% Sodium Chloride
122928|NCT03225794|Diagnostic Test|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
122929|NCT03225781|Device|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
122930|NCT03225768|Behavioral|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
122931|NCT03225755|Drug|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
122932|NCT03225742|Diagnostic Test|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
122933|NCT03225729|Device|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots <6 mm which are previously selected by the investigator team.
122934|NCT03225729|Device|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots <6 mm a small amount of nitrogen liquid.
122935|NCT03225716|Drug|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
122936|NCT03225716|Drug|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
122937|NCT03225703|Behavioral|Hopping|A unilateral, hopping based exercise programme lasting six months.
122938|NCT03225690|Drug|Morphine|Prevention of remifentanil induced hyperalgesia
122939|NCT03225690|Drug|Serum physiologic|For placebo, serum physiologic will use
122940|NCT03225677|Procedure|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
122941|NCT03225664|Biological|Pembrolizumab|Given IV
122942|NCT03225664|Other|Pharmacokinetic Study|Correlative studies
122943|NCT03225664|Drug|Trametinib|Given PO
122944|NCT03225651|Biological|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
122945|NCT03225651|Behavioral|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
122946|NCT03225638|Combination Product|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
122947|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
122948|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
122949|NCT03225625|Procedure|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
122950|NCT03225625|Procedure|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
122951|NCT03225625|Procedure|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
122952|NCT03225612|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
122953|NCT03225599|Other|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
122954|NCT03225560|Other|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
122955|NCT03225547|Drug|Pembrolizumab|Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.
122956|NCT03225547|Drug|Mifepristone|Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
123045|NCT03224806|Other|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
122957|NCT03225521|Behavioral|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
122958|NCT03225508|Diagnostic Test|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
122959|NCT03225508|Diagnostic Test|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
122960|NCT03225508|Diagnostic Test|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
122961|NCT03225495|Procedure|Standard implant|Arm - Standard Implant: implant placement in combination with guided bone regeneration;
122962|NCT03225495|Procedure|Ultra-narrow implant|Arm - Ultra-narrow implant: implant placement without guided bone regeneration
122963|NCT03225482|Behavioral|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
122964|NCT03225482|Behavioral|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
122965|NCT03225469|Behavioral|reinforced family member education|Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
122966|NCT03225456|Drug|Syntocinon|Intra-nasal oxytocin
122967|NCT03225456|Drug|Placebos|Intra-nasal placebo
122968|NCT03225430|Behavioral|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
122969|NCT03225430|Behavioral|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
122970|NCT03225417|Drug|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
122971|NCT03225417|Drug|Tacrolimus|Tacrolimus at dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
122972|NCT03225417|Drug|Sirolimus|Sirolimus oral solution. Standing 6 mg orally on day -5 and continued 4mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
122973|NCT03225417|Drug|Any prophylaxis for GVHD|Except antithymocyte globulin, cyclophosphamide or any T depletion protocol in vitro or in vivo.
122974|NCT03225404|Other|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
122975|NCT03225404|Other|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
122976|NCT03225391|Behavioral|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
122977|NCT03225391|Behavioral|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
122978|NCT03225378|Other|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
122979|NCT03225378|Other|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
122980|NCT03225365|Biological|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.~Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
122981|NCT03225352|Drug|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
122982|NCT03225352|Drug|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
122983|NCT03225352|Drug|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
122984|NCT03225352|Drug|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
122985|NCT03225339|Dietary Supplement|Low Energy Diet|Low Energy Diet
122986|NCT03225326|Drug|Computer controlled 4% articaine delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
122987|NCT03225326|Drug|Conventional 4% articaine delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
122988|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|ultra sound guided injection into the rectus sheath
122989|NCT03225313|Drug|Normal Saline Flush, 0.9% Injectable Solution_#5|injected into rectus sheath using ultrasound & locally surrounding the hernia
122990|NCT03225313|Drug|Bupivacaine Hydrochloride 0.5% Injection Solution_#4|locally surrounding the hernia
123046|NCT03224806|Other|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
123047|NCT03224793|Drug|BIIB059|Administered as specified in the treatment arm
122993|NCT03225274|Other|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.~On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.~On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
122994|NCT03225261|Dietary Supplement|Citrus extract|Citrus extract
122995|NCT03225261|Dietary Supplement|Placebo|Maltodextrin
122996|NCT03225248|Drug|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
122997|NCT03225248|Drug|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
122998|NCT03225235|Radiation|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
122999|NCT03225222|Diagnostic Test|biopsy|prostate biopsy
123000|NCT03225209|Other|OPTIFAST|OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
123001|NCT03225170|Behavioral|Self Affirmation|Participants will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them. The control group will rank the same list and be asked to will write about the 9th ranked item and why it might be important to someone else. The treatment and control condition are consistent with interventions used in other SA intervention studies.
123002|NCT03225105|Drug|M3541|Subjects will receive M3541 orally in combination with fractionated palliative RT for two consecutive calendar weeks (that is, Monday through Sunday, with Saturday and Sunday as M3541 / RT holidays).
123003|NCT03225105|Radiation|Palliative Radiotherapy (RT)|Subjects will receive RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Sunday, with Saturday and Sunday as M3541 / RT holidays).
123004|NCT03225092|Biological|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
123005|NCT03225066|Device|Poly-L-lactic acid - Sculptra|Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
123006|NCT03225053|Device|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
123007|NCT03225040|Drug|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
123008|NCT03225027|Behavioral|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
123009|NCT03225027|Behavioral|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
123010|NCT03225027|Behavioral|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
123011|NCT03225027|Behavioral|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
123012|NCT03225027|Other|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
123013|NCT03225027|Diagnostic Test|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
123014|NCT03225027|Diagnostic Test|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
123015|NCT03225027|Other|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
123016|NCT03225014|Device|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
123017|NCT03225014|Diagnostic Test|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
123018|NCT03225001|Device|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
123019|NCT03224988|Device|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
123020|NCT03224975|Other|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
123021|NCT03224962|Device|fluorescence camera|drug - diagnostic test
123022|NCT03224949|Other|Blood draw|Patients will have a one time blood draw
123023|NCT03224936|Device|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
123024|NCT03224923|Drug|Ticagrelor 60mg|twice daily
123025|NCT03224923|Drug|Clopidogrel 75mg|once daily
123026|NCT03224923|Drug|Aspirin 81 mg|once daily
123027|NCT03224910|Other|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
123028|NCT03224897|Device|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
123029|NCT03224897|Device|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
123030|NCT03224897|Device|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
123031|NCT03224884|Procedure|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
123032|NCT03224884|Procedure|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
123033|NCT03224871|Drug|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
123034|NCT03224871|Drug|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
123035|NCT03224871|Drug|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
123036|NCT03224871|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
123037|NCT03224858|Other|SUMMIT intervention|See description in experimental arm.
123038|NCT03224858|Other|Enhanced usual care|See description in active comparator arm.
123039|NCT03224845|Behavioral|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
123040|NCT03224832|Procedure|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.~The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.~All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.~Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .~Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
123041|NCT03224832|Procedure|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
123042|NCT03224819|Drug|AMG 673|Open label.
123043|NCT03224806|Other|Wholegrain bread|156.8g wholegrain bread
123044|NCT03224806|Other|White bread|122.6g white bread
123050|NCT03224780|Diagnostic Test|3D Doppler ultrasound|Doppler for placental vessels
123051|NCT03224767|Drug|Vemurafenib|Given PO
123052|NCT03224767|Drug|Cobimetinib|Given PO
123053|NCT03224767|Other|Laboratory Biomarker Analysis|Correlative studies
123054|NCT03224767|Other|Quality-of-Life Assessment|Ancillary studies
123055|NCT03224754|Behavioral|Determination of risk of malignancy of these thyroid lesions|This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.
123056|NCT03224741|Behavioral|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
123057|NCT03224741|Behavioral|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
123058|NCT03224741|Behavioral|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
123059|NCT03224728|Device|intraocular lens|
123060|NCT03224715|Other|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
123061|NCT03224702|Drug|M6495|Subjects will receive M6495 on Day 1
123062|NCT03224702|Drug|Placebo|Subjects will receive placebo matched to M6495 on Day 1
123063|NCT03224689|Device|PEEK-Optima Femoral Component|TKA Surgery
123064|NCT03224663|Other|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
123065|NCT03224663|Other|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
123066|NCT03224637|Procedure|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
123067|NCT03224637|Drug|Paracetamol (conventional)|
123068|NCT03224637|Drug|Ketorolac Tromethamine (conventional)|
123069|NCT03224624|Other|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
123070|NCT03224611|Device|light wand|"The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light."
123071|NCT03224598|Drug|A-101 Topical Solution 40%|A-101 Topical Solution 40%
123072|NCT03224585|Drug|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
123073|NCT03224585|Drug|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.~Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
123074|NCT03224572|Drug|high-dose vitamin C 30gm|High-dose vitamin C 30 gm in 500 ml normal saline, once per week, and total 4-week treatment.
123075|NCT03224572|Other|normal saline|500ml normal saline, once per week, and total 4-week treatment
123076|NCT03224559|Device|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
123077|NCT03224546|Behavioral|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
123078|NCT03224533|Diagnostic Test|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
123079|NCT03224520|Behavioral|Recommender CTHC|Enhanced Messaging
123080|NCT03224520|Behavioral|Standard CTHC|Standard Messaging
123081|NCT03224520|Other|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
123082|NCT03224520|Other|Standard Online Recruitment|Search Engine and Social Media Advertisements
123083|NCT03224507|Drug|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
123084|NCT03224507|Drug|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
123085|NCT03224494|Device|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
123123|NCT03224247|Procedure|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
123247|NCT03223272|Drug|Reserpine|Open label reserpine 0.1-0.25 mg pill orally
123086|NCT03224494|Other|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
123087|NCT03224494|Other|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
123088|NCT03224481|Other|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear. Also, information related to the debond visit and maintenance of optimal oral hygiene levels will be incorporated in the mobile application.
123089|NCT03224468|Drug|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
123090|NCT03224442|Procedure|PRF|soft tissue augmentation by prf
123091|NCT03224442|Procedure|Palatal Pedicle|soft tissue augmentation by palatal pedicle
123092|NCT03224429|Other|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
123093|NCT03224429|Other|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
123094|NCT03224416|Other|Alcohol Administration|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
123095|NCT03224416|Other|Placebo Alcohol Administration|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
123096|NCT03224416|Other|No Alcohol Administration|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
123097|NCT03224403|Drug|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
123098|NCT03224403|Drug|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
123099|NCT03224403|Drug|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
123100|NCT03224403|Drug|Placebo|2 placebo caplets
123101|NCT03224390|Other|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
123102|NCT03224377|Diagnostic Test|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
123103|NCT03224364|Procedure|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
123104|NCT03224364|Procedure|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
123105|NCT03224351|Drug|TEZ/IVA|100-mg TEZ/150-mg IVA fixed-dose combination (FDC) tablet for oral administration
123106|NCT03224351|Drug|VX-659|80-mg VX-659 tablet for oral administration
123107|NCT03224351|Drug|IVA|150-mg IVA tablet for oral administration
123108|NCT03224351|Drug|Matched Placebos|Placebo will be used as a comparator.
123109|NCT03224351|Drug|TEZ|50-mg tablet for oral administration.
123110|NCT03224351|Drug|VX-561|50-mg VX-561 tablet for oral administration.
123111|NCT03224338|Drug|Dolutegravir 50 mg|Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B*5701 allele screening assessment.
123112|NCT03224325|Drug|TAK-831 Tablet T2|Tak-831 tablets.
123113|NCT03224325|Drug|Placebo|TAK-831 placebo-matching suspension.
123114|NCT03224325|Drug|TAK-831 Suspension|TAK-831 Suspension.
123115|NCT03224312|Other|no intervention|no intervention
123116|NCT03224299|Drug|Octenidine Dihydrochloride [OCT] in Isopropyl Alcohol (1)|Application of investigational product #1
123117|NCT03224299|Drug|Octenidine Dihydrochloride [OCT] in Isopropyl Alcohol (2)|Application of investigational product #2
123118|NCT03224299|Other|ChloraPrep|Application of active control
123119|NCT03224286|Device|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
123120|NCT03224273|Other|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
123121|NCT03224260|Drug|BMS-986177|Oral Suspension
123122|NCT03224260|Other|Matched Placebo|Oral Suspension
123124|NCT03224247|Procedure|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
123125|NCT03224234|Device|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
123126|NCT03224234|Device|Insulclock without feedback|Not feedback on insulin administration.
123127|NCT03224221|Drug|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
123128|NCT03224221|Drug|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
123129|NCT03224208|Drug|Vemurafenib|Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
123130|NCT03224208|Drug|Cobimetinib|Cobimetinib will be given orally at 60 mg qd on Days 1−21 of each 28-day treatment cycle
123131|NCT03224182|Drug|Qapzola|One dose of 8 mg Qapzola on Day 1
123132|NCT03224182|Drug|Placebo|One dose of Placebo on Day 1
123133|NCT03224169|Behavioral|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
123134|NCT03224156|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
123135|NCT03224143|Behavioral|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
123136|NCT03224143|Behavioral|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
123137|NCT03224130|Other|Nurse Phone Call|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a one-time nurse phone call, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants), in improving pediatric patient transitions from hospital to home
123138|NCT03224130|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
123139|NCT03224117|Drug|DWJ211|inject the Drug into submental fat via subcutaneous
123140|NCT03224117|Drug|Normal saline|inject the Drug into submental fat via subcutaneous
123141|NCT03224104|Drug|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
123142|NCT03224104|Radiation|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
123143|NCT03224104|Drug|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
123144|NCT03224078|Other|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
123145|NCT03224065|Diagnostic Test|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
123146|NCT03224039|Drug|Sufentanil|Intranasal for one dose (experimental)
123147|NCT03224039|Drug|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
123148|NCT03224039|Drug|Morphine|intravenous push for one dose (active comparator)
123149|NCT03224013|Procedure|LASIK|LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
123150|NCT03224000|Procedure|Modified Barium Swallow (MBS)|Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
123151|NCT03224000|Behavioral|Swallowing Questionnaire|Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
123152|NCT03224000|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
123153|NCT03224000|Procedure|Video-Strobe Procedure|Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
123154|NCT03224000|Procedure|MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned with MRI guidance.
123155|NCT03224000|Procedure|Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned by standard-of-care.
123156|NCT03224000|Radiation|Intensity Modulated Radiotherapy (IMRT)|Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
123157|NCT03223987|Dietary Supplement|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.~Stool analysis at 2nd visit and last visit. Before-after study."
123158|NCT03223974|Device|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for >30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
123159|NCT03223974|Device|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
123160|NCT03223961|Drug|EPREX|60 000 U/week for at least 12 weeks
123161|NCT03223948|Device|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
123162|NCT03223935|Other|Corn nuts|Roasted corn nut snack
123163|NCT03223935|Other|Chickpeas|Roasted chickpea snack
123164|NCT03223935|Other|Yellow peas|Roasted yellow pea snack
123165|NCT03223935|Other|Pinto beans|Roasted pinto bean snack
123166|NCT03223935|Other|Soybeans|Roasted soybean snack
123167|NCT03223935|Other|Almonds|Roasted almond snack
123168|NCT03223922|Radiation|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
123169|NCT03223909|Drug|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
123170|NCT03223909|Drug|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
123171|NCT03223909|Drug|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
123172|NCT03223896|Drug|Naloxone hydrochloride 20mg/ml|Nasal spray
123173|NCT03223883|Drug|Curcumin|Oral supplement for 12 months
123174|NCT03223883|Other|Placebo|Oral placebo for 12 months
123175|NCT03223870|Diagnostic Test|Diagnostic|Diagnostic
123176|NCT03223857|Procedure|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
123177|NCT03223844|Drug|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
123178|NCT03223831|Other|Partially covered pyloro-duodenal stent|The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 & 12cm.
123179|NCT03223831|Other|Uncovered pyloro-duodenal stents|The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
123180|NCT03223818|Other|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.~All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
123181|NCT03223805|Other|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components~Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
123182|NCT03223792|Other|Control|Routine cow's milk-based infant formula
123183|NCT03223792|Other|Investigational|Partially-hydrolyzed cow's milk protein infant formula
123184|NCT03223779|Drug|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
123185|NCT03223779|Radiation|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
123186|NCT03223753|Other|Educational Intervention|Receive educational handouts about to physical activity
123187|NCT03223753|Other|Internet-Based Intervention|Access limited version of Sqord website
123188|NCT03223753|Other|Internet-Based Intervention|Access full version of interactive reward-based Sqord website
123189|NCT03223753|Other|Laboratory Biomarker Analysis|Correlative studies
123190|NCT03223753|Device|Monitoring Device|Wear Sqord activity monitor
123191|NCT03223753|Other|Quality-of-Life Assessment|Ancillary studies
123193|NCT03223740|Other|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:~First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.~2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
123194|NCT03223740|Other|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.~Chemotherapy 1:~All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.~Chemoradiotherapy:~At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.~Chemotherapy2:~2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
123195|NCT03223727|Diagnostic Test|Blood tests|Blood tests for several bone markers (see summary)
123196|NCT03223714|Drug|Conbercept Ophthalmic Injection|
123197|NCT03223714|Drug|sham injection|
123198|NCT03223701|Combination Product|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
123199|NCT03223688|Behavioral|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
123200|NCT03223688|Behavioral|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
123201|NCT03223688|Behavioral|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
123202|NCT03223675|Radiation|hippocampal-sparing WBRT|
123203|NCT03223662|Other|Chemoradiotherapy|Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
123204|NCT03223662|Procedure|Esophagectomy|Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
123205|NCT03223649|Other|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
123206|NCT03223649|Other|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
123207|NCT03223610|Drug|Venetoclax|Administered orally, days 2-14, at varying doses of 200-800mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
123208|NCT03223610|Drug|Ibrutinib|Administered orally, days 1-14, at a dose of 560mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
123209|NCT03223610|Drug|Prednisone|Administered orally, days 1-7, at a dose of 100mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
123210|NCT03223610|Drug|Obinutuzumab|Administered intraveneously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
123211|NCT03223610|Drug|Revlimid (lenalidomide)|Administered orally, days 1-15, at a dose of 15mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
123212|NCT03223597|Drug|Radium-223 dichloride|Registry of patients who receive Radium-223.
123213|NCT03223571|Other|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
123214|NCT03223558|Behavioral|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
123215|NCT03223545|Behavioral|MBCT-T|This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
123248|NCT03223259|Behavioral|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q&A.
123216|NCT03223545|Behavioral|Usual Care|"Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan."
123217|NCT03223532|Device|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
123218|NCT03223532|Device|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
123219|NCT03223519|Drug|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
123220|NCT03223519|Drug|Placebo|Powder for oral solution administered TID for 3 days
123221|NCT03223519|Drug|Ibuprofen|Powder for oral solution administered TID for 3 days
123222|NCT03223519|Drug|Magnesium|Powder for oral solution administered TID for 3 days
123223|NCT03223519|Drug|Vitamin C|Powder for oral solution administered TID for 3 days
123224|NCT03223506|Drug|Paracetamol|
123225|NCT03223493|Other|No treatment given|Completion of a questionnaire
123226|NCT03223480|Device|EUS-guided gastrojejunstomy|As listed in the arms description
123227|NCT03223467|Procedure|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
123228|NCT03223454|Biological|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
123229|NCT03223454|Biological|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
123230|NCT03223428|Drug|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
123231|NCT03223415|Other|Detection and isolation of C. difficile carriers|"Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.~Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward."
123232|NCT03223402|Other|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
123233|NCT03223389|Dietary Supplement|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
123234|NCT03223389|Dietary Supplement|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
123235|NCT03223389|Dietary Supplement|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
123236|NCT03223376|Combination Product|fruquintinib +paclitaxel|treatment arm(fruquintinib +paclitaxel)- subjects will receive Fruquintinib orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/m2 at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
123237|NCT03223376|Combination Product|fruquintinib placebo + paclitaxel|control arm(fruquintinib placebo + paclitaxel)- subjects will receive Fruquintinib placebo orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/m2 at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
123238|NCT03223363|Diagnostic Test|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
123239|NCT03223350|Drug|Capsaicin 0.1% Cream|Topical application
123240|NCT03223350|Drug|Placebos|placebo cream
123241|NCT03223337|Drug|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
123242|NCT03223324|Device|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
123243|NCT03223298|Drug|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
123244|NCT03223298|Drug|0.9% Sodium Chloride Injection|1cc syringe
123245|NCT03223285|Behavioral|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
123246|NCT03223285|Behavioral|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.~Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
123249|NCT03223246|Other|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
123250|NCT03223233|Other|procalcitonin level|serum procalcitonin level will be measured in both groups.
123251|NCT03223220|Drug|Ketamine|IV infusion
123252|NCT03223220|Other|Normal Saline|IV infusion
123253|NCT03223220|Drug|Midazolam injection|Injection
123254|NCT03223194|Genetic|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
123255|NCT03223168|Device|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
123256|NCT03223155|Drug|Nivolumab|"Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle."
123257|NCT03223155|Drug|Ipilimumab|"Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.~Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.~In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle."
123258|NCT03223155|Radiation|Stereotactic body radiation therapy|All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
123259|NCT03223142|Device|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
123260|NCT03223129|Other|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
123261|NCT03223129|Other|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
123262|NCT03223116|Procedure|Radiofrequency delivery|Radiofrequency to the gastroesophageal junction
123263|NCT03223103|Drug|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
123264|NCT03223103|Device|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
123265|NCT03223103|Biological|Peptides|synthetic long peptides (SLP) as vaccine substrate
123266|NCT03223090|Behavioral|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
123267|NCT03223090|Behavioral|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
123268|NCT03223064|Diagnostic Test|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
123269|NCT03223064|Diagnostic Test|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
123270|NCT03223051|Other|Motor assessment|An occupational therapist install the patient sitting in front of the test board and tell him the instructions
123271|NCT03223038|Other|No intervention|No intervention - exposure is mechanical ventilation in PICU
123272|NCT03223025|Drug|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
123273|NCT03223025|Drug|Nordilet®|0.03 mg/kg daily subcutaneous injections
123274|NCT03222999|Other|No intervention planned|No intervention planned
123275|NCT03222973|Drug|BIIB033 (opicinumab)|Administered as specified in the treatment arm
123276|NCT03222973|Drug|Placebo|Administered as specified in the treatment arm
123277|NCT03222960|Drug|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
123278|NCT03222960|Drug|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
123279|NCT03222947|Genetic|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
123280|NCT03222934|Device|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
123281|NCT03222921|Procedure|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
123282|NCT03222908|Behavioral|Intervention1: Contract Agreement|Smoking Cessation Contract
123283|NCT03222908|Behavioral|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
123284|NCT03222882|Procedure|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
123285|NCT03222869|Diagnostic Test|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
123286|NCT03222856|Drug|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
123287|NCT03222856|Drug|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
123288|NCT03222843|Drug|Hetrombopag Olamine|once daily
123289|NCT03222843|Drug|matching placebo|once daily
123290|NCT03222830|Procedure|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
123291|NCT03222817|Behavioral|HPV self-sampling|Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
123292|NCT03222804|Dietary Supplement|Bifidobacterium|Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
123293|NCT03222791|Other|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
123294|NCT03222791|Other|Mediterranean-style low-fat diet|The Israeli standard of care dietary guidelines for prediabetes.
123295|NCT03222765|Drug|Placebo, metformin, linagliptin, linagliptin + metformin|
123296|NCT03222752|Device|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
123297|NCT03222752|Device|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
123298|NCT03222739|Device|Ultrasound|An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
123299|NCT03222726|Other|exercise group|less than 6000 steps/day or 40,000 steps/week
123300|NCT03222713|Other|Program Self-regulation in health|The intervention program with children will be run by teachers and health professionals (Condition Group II) in 50-minute biweekly sessions which will take place in class in school year. During these sessions, the children will complete the following tasks: the reading of the chapters of Yellow Trials and Tribulations (one chapter per week) and the discussions and activities related to the topics of healthy eating and oral health.
123301|NCT03222700|Procedure|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
123302|NCT03222687|Drug|tacrolimus|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
123303|NCT03222687|Drug|prednisone|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
123304|NCT03222674|Biological|Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells|Infusion of Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
123305|NCT03222661|Diagnostic Test|Refraction|Refractive error measurement
123306|NCT03222648|Other|Structured Responsive Exercise Training|Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
123307|NCT03222635|Procedure|Endoscopic follow-up|Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
123308|NCT03222622|Drug|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
123309|NCT03222622|Drug|Placebo cream|Apply topically twice daily for 12 consecutive weeks
123310|NCT03222609|Drug|Ruxolitinib|Tablet; Oral
123311|NCT03222609|Drug|Navitoclax|Tablet; Oral
123312|NCT03222596|Behavioral|Exercise training|Exercise programme includes breathing and upper limbs exercises.
123313|NCT03222583|Drug|Placebo|Tablet; matching placebo
123314|NCT03222583|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
123315|NCT03222570|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
123316|NCT03222570|Drug|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
123317|NCT03222570|Other|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
123318|NCT03222557|Procedure|Electroacupuncture|Refer to arm description
123319|NCT03222557|Procedure|Sham Acupuncture|Refer to arm description
123320|NCT03222557|Device|Electroacupuncture|Refer to arm description
123321|NCT03222557|Device|Sham Acupuncture|Refer to arm description
123322|NCT03222544|Combination Product|methylene blue|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
123604|NCT03220399|Drug|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
123323|NCT03222544|Combination Product|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
123324|NCT03222531|Drug|sofosbuvir/velpatasvir|Drug: sofobuvir/velpatasvir
123325|NCT03222518|Drug|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
123326|NCT03222518|Drug|NSAID|21 pills of Ketaprofen 50mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
123327|NCT03222518|Drug|Placebo Oral Tablet|21 identical pills of Placebo are provided with a preconised dose of 1 pill 3 times per day over 7 days period
123328|NCT03222505|Device|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
123329|NCT03222505|Other|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
123330|NCT03222492|Biological|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
123331|NCT03222492|Biological|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
123332|NCT03222479|Behavioral|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
123333|NCT03222466|Other|Co-created PEM|A co-created PEM has been designed in collaboration with patients.
123334|NCT03222453|Biological|Hematopoetic stem cells|Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
123335|NCT03222440|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
123336|NCT03222427|Drug|LY3314814|Administered orally
123337|NCT03222427|Drug|[13C415N3] LY3314814|Administered as an IV infusion
123338|NCT03222414|Device|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
123339|NCT03222414|Device|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
123340|NCT03222414|Other|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
123341|NCT03222401|Drug|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
123342|NCT03222401|Drug|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
123343|NCT03222401|Drug|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
123344|NCT03222388|Other|Questionnaire - IIEF 5/15|International Index of Erectile Function
123345|NCT03222375|Device|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.~Some autowaves have the properties of quasi-particles!"
123346|NCT03222362|Other|Surgery|
123347|NCT03222349|Drug|Diazepam Buccal Soluble Film|Subjects will receive a single dose of DBSF . DBSF is provided in a range of doses from 5 to 12.5 mg . The appropriate dose of DBSF will be assigned on the basis of age and weight using an interactive web response system (IWRS) during check-in for the subject's first treatment period.
123348|NCT03222336|Behavioral|Family pedigree and data collection|"Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.~Collect and analyze medical history, genetic and biochemical assessment data"
123349|NCT03222323|Drug|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
123350|NCT03222323|Drug|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
123351|NCT03222323|Drug|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
123352|NCT03222323|Drug|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
123353|NCT03222323|Drug|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
123354|NCT03222310|Drug|Ipatasertib|Ipatasertib 100 mg tablet orally once daily.
123355|NCT03222310|Drug|Itraconazole|Itraconazole 100 mg capsules orally once daily.
123356|NCT03222297|Device|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
123357|NCT03222297|Device|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
123358|NCT03222284|Device|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
123359|NCT03222271|Device|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
123360|NCT03222258|Behavioral|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
123361|NCT03222258|Behavioral|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
123362|NCT03222232|Behavioral|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
123363|NCT03222219|Procedure|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
123364|NCT03222206|Drug|Salsalate|"Medicate salsalate 2g/day after run-in period~Check side effect after 1 month and Control dosage (2g/day or 3g/day)~Check side effect after 2 month"
123365|NCT03222206|Other|Placebo|"Medicate placebo 2g/day after run-in period~Check side effect after 1 month and Control dosage (2g/day or 3g/day)~Check side effect after 2 month"
123366|NCT03222193|Device|TRP|3 months of TRP tongue retraining
123367|NCT03222180|Behavioral|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
123368|NCT03222167|Drug|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
123369|NCT03222154|Device|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
123370|NCT03222154|Device|Placebo - Shock wave therapy|Simulation of shock wave therapy
123371|NCT03222141|Device|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
123372|NCT03222128|Device|TAVR|Implantation of the SAPIEN 3
123373|NCT03222102|Device|Phasix mesh|After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
123374|NCT03222089|Drug|Irinotecan|Irinotecan 165 mg/m² 1-hour IV day 1
123375|NCT03222089|Drug|Oxaliplatin|oxaliplatin 85 mg/m² 2-hours IV day 1
123376|NCT03222089|Drug|Levoleucovorin|Levoleucovorin 200 mg/m² 2-hours IV day 1
123377|NCT03222089|Drug|5-FU|5-FU 2800 mg/m² 46-hours flat continuous infusion IV
123378|NCT03222089|Drug|GM-CSF|GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
123379|NCT03222089|Drug|IL-2|Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
123380|NCT03222076|Biological|Ipilimumab|Given IV
123381|NCT03222076|Biological|Nivolumab|Given IV
123382|NCT03222063|Other|Play interventions|The following play were included in play interventions i.e building blocks, paint, puzzles, crayons, doctor set, ludo, snake and ladder. All hospitalized children in experimental group received play interventions at bed side. Taking into consideration the busy clinical setting, each participant received continuously 1 hour of hospital play interventions each day for continuous 5 days. Although the hospitalized children were free to choose according to their choice but still the younger children would be engaged in play such as doctor set, Drawing etc. to obtain more sensory experience and older children were offered play interventions such as puzzle, building blocks, ludo etc.with high cognitive demand.
123383|NCT03222050|Other|Distraction technique|
123384|NCT03222037|Device|senofilcon A|Acuvue Oasys 1-Day
123385|NCT03222037|Device|Control|Trial Frame with best spherocylindrical refraction (SCR)
123386|NCT03222024|Other|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
123387|NCT03222011|Procedure|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
123388|NCT03222011|Procedure|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
123389|NCT03221998|Drug|IV paracetamol|100 gram paracetamol infusion for moderate pain management
123390|NCT03221998|Drug|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
123391|NCT03221985|Other|questionnaires|questionnaire with application on smartphone
123392|NCT03221959|Device|Medical Device Vittamed 205|Intracranial pressure measurement
123393|NCT03221946|Drug|Diclofenac Sodium|tablet of 50mg,
123394|NCT03221946|Drug|Diclofenac sodium|Transdermal patch 100 mg
123395|NCT03221946|Drug|Diclofenac|intra muscular injection 100mg
123396|NCT03221933|Biological|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
123397|NCT03221933|Biological|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
123398|NCT03221920|Other|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
123399|NCT03221907|Drug|GLA5PR GLARS-NF1|Pregabalin tablet
123400|NCT03221907|Drug|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
123401|NCT03221907|Drug|Pregabalin|Pregabalin capsule
123402|NCT03221907|Drug|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
123403|NCT03221894|Dietary Supplement|GRAPE granules|GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
123404|NCT03221881|Drug|Pegylated Liposomal Doxorubicin and docetaxel|
123405|NCT03221868|Behavioral|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
123406|NCT03221868|Behavioral|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
123407|NCT03221855|Drug|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
123408|NCT03221855|Drug|Placebo|Capsules 10mg orally each 8 hours for 7 days.
123409|NCT03221842|Drug|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
123410|NCT03221842|Drug|Placebo|Excipients of C1-INH plus albumin
123411|NCT03221816|Drug|Tenavit®|The experimental group received one tablet of Tenavit® daily for a period of 4 months.
123412|NCT03221816|Drug|Placebo Oral Tablet|Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
123413|NCT03221803|Other|OT Vertical attachment|new extra coronal castable attachment
123414|NCT03221803|Other|OT cap attachment|standard extra coronal attachment
123415|NCT03221790|Other|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
123416|NCT03221777|Diagnostic Test|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.[87]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
123417|NCT03221764|Drug|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients [8]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
123418|NCT03221764|Device|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
123419|NCT03221751|Drug|prazosin hydrochloride|Prazosin is an oral capsule identical in appearance to prazosin capsules titrated in the same manner as prazosin.
123420|NCT03221751|Drug|placebo|Prazosin is an oral capsule identical in appearance to prazosin capsules titrated in the same manner as prazosin.
123421|NCT03221738|Behavioral|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
123422|NCT03221725|Procedure|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
123423|NCT03221712|Behavioral|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
123424|NCT03221699|Other|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
123425|NCT03221699|Other|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
123426|NCT03221686|Dietary Supplement|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
123427|NCT03221686|Dietary Supplement|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
123428|NCT03221660|Device|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
123429|NCT03221647|Other|Intestinal biopsies|Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
123430|NCT03221634|Biological|Pembrolizumab|IV infusion
123431|NCT03221634|Biological|Daratumumab|IV infusion
123432|NCT03221621|Procedure|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
123433|NCT03221621|Drug|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
123434|NCT03221608|Procedure|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
123435|NCT03221608|Procedure|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
123436|NCT03221595|Device|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
123437|NCT03221582|Drug|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
123438|NCT03221569|Drug|Intravenous ketamine|0.3mg/kg IVPB over 15 minutes
123439|NCT03221569|Drug|Ketorolac|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
123440|NCT03221569|Drug|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.~Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
123441|NCT03221569|Drug|Normal saline|1ml intravenous push as placebo for double-blinding purposes
123442|NCT03221556|Behavioral|Engagement-Focused Care Coordination|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
123771|NCT03219294|Drug|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
123443|NCT03221556|Behavioral|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
123444|NCT03221543|Device|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
123445|NCT03221530|Behavioral|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
123446|NCT03221530|Behavioral|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
123447|NCT03221517|Other|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
123448|NCT03221504|Other|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
123449|NCT03221504|Other|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
123450|NCT03221491|Device|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
123451|NCT03221478|Other|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
123452|NCT03221478|Other|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
123453|NCT03221478|Other|Kinesio Taping with tension|Kinesio Taping with tension
123454|NCT03221465|Behavioral|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
123455|NCT03221465|Behavioral|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
123456|NCT03221452|Behavioral|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
123457|NCT03221439|Behavioral|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):~The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.~Specific Functional training is designed to normalize maladaptive or provocative movement and posture.~Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)~Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
123458|NCT03221439|Other|Manual Therapy and Motor Control Exercise|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
123459|NCT03221426|Biological|Pembrolizumab|IV infusion
123460|NCT03221426|Drug|Placebo|Normal saline solution IV infusion
123461|NCT03221426|Drug|Cisplatin|IV infusion
123462|NCT03221426|Drug|Capecitabine|Oral tablets
123463|NCT03221426|Drug|5-fluorouracil|IV infusion
123464|NCT03221426|Drug|Docetaxel|IV infusion
123465|NCT03221426|Drug|Oxaliplatin|IV infusion
123466|NCT03221426|Drug|Leucovorin|IV infusion
123467|NCT03221413|Device|transcranial alternating current stimulation (tACS)|
123468|NCT03221400|Drug|PEN-866 Sodium|PEN-866 Sodium is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
123469|NCT03221387|Device|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
123470|NCT03221374|Behavioral|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
123471|NCT03221361|Device|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
123472|NCT03221361|Device|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
123473|NCT03221348|Biological|CHO-H01|Glyco-engineered anti-CD20 antibody
123474|NCT03221335|Device|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
123561|NCT03220685|Biological|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
123475|NCT03221322|Behavioral|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
123476|NCT03221309|Other|Evaluate model of care for HCV-infected adults with on-going opioid misuse|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
123477|NCT03221296|Behavioral|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
123478|NCT03221283|Behavioral|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
123479|NCT03221270|Device|tACS (alpha)|Neuroconn DC Stimulator
123480|NCT03221270|Device|Sham tACS (alpha)|Neuroconn DC Stimulator
123481|NCT03221257|Drug|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
123482|NCT03221257|Drug|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
123483|NCT03221257|Drug|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
123484|NCT03221244|Device|VR Treatment|Distractors
123485|NCT03221244|Device|VR Active Control|No distractors
123486|NCT03221231|Drug|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
123487|NCT03221231|Drug|Placebo Oral Tablet|twice daily, placebo
123488|NCT03221231|Other|Magnetic Resonance Imaging|
123489|NCT03221231|Other|Neurocognitive measures|
123490|NCT03221231|Other|Neuro-inflammatory measures|
123491|NCT03221218|Other|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
123492|NCT03221205|Device|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (measured at the nasal mask) via a resistance to assure the lack of distal pressure.
123493|NCT03221205|Device|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
123494|NCT03221192|Other|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, >3-7 (or >30-70) as moderate disease and >7-10 (or >70-100) as severe disease.
123495|NCT03221192|Other|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
123496|NCT03221192|Other|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
123497|NCT03221179|Biological|RO7049665|A single ascending dose (starting dose 1.5 micrograms [mcg])of RO7049665 will be administered SC.
123498|NCT03221179|Biological|Placebo|Matching placebo will be administered SC once.
123499|NCT03221166|Drug|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
123500|NCT03221166|Drug|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
123501|NCT03221153|Procedure|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
123502|NCT03221140|Drug|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
123503|NCT03221114|Behavioral|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
123504|NCT03221101|Device|Home ventilator|
123505|NCT03221088|Drug|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
123506|NCT03221088|Drug|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
123507|NCT03221075|Other|Registry|There is no intervention.
123508|NCT03221062|Device|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
123509|NCT03221049|Diagnostic Test|radiomics|
123510|NCT03221036|Drug|Vedolizumab IV|Vedolizumab IV infusion
123511|NCT03221036|Drug|Placebo|Matching-placebo IV infusion
123512|NCT03221023|Drug|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
123513|NCT03221023|Drug|Saline Solution|Individuals in the control arm will receive intrawound saline solution
123514|NCT03221010|Behavioral|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
123558|NCT03220711|Device|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
123559|NCT03220711|Drug|Fluorescein|Fluorescent dye used for imaging contrast only.
123515|NCT03221010|Behavioral|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
123516|NCT03220997|Dietary Supplement|Vitaflow Preload|Carbohydrate loading drink
123517|NCT03220984|Biological|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
123518|NCT03220971|Other|lipoprotein and apolipoproteins|To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
123519|NCT03220958|Drug|Metoclopramide|Metoclopramide 20mg
123520|NCT03220958|Drug|Diphenhydramine|Diphenhydramine 25mg
123521|NCT03220958|Drug|Normal saline|100ml normal saline
123522|NCT03220945|Other|Yoga|Receive yoga instruction
123523|NCT03220932|Procedure|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
123524|NCT03220932|Drug|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
123525|NCT03220919|Other|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
123526|NCT03220919|Other|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, >10.0 mmol/L.~Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, > 20 mmol/L."
123527|NCT03220906|Other|Blood pressure measurement|Blood pressure will be measured in both upper and lower extremities.
123528|NCT03220893|Diagnostic Test|Molecular Breast Imaging|Molecular breast imaging (MBI) is a new nuclear medicine technique that utilizes small semiconductor-based γ-cameras in a mammographic configuration to provide high-resolution functional images of the breast.
123529|NCT03220893|Diagnostic Test|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) creates a three dimensional picture of the breast using X-rays.
123530|NCT03220880|Drug|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
123531|NCT03220867|Drug|Risperidone: Xian Risperdal (test)|Participants will receive 1*1 mg tablet of Xian Risperdal under fasting or fed condition.
123532|NCT03220867|Drug|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
123533|NCT03220854|Radiation|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
123534|NCT03220854|Other|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
123535|NCT03220854|Other|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
123536|NCT03220841|Drug|Adalimumab Injection|Standard dose adalimumab induction and maintenance
123537|NCT03220841|Drug|Thiopurine|Dose optimized thiopurine
123538|NCT03220841|Procedure|Endoscopic balloon dilatation|Prior to randomization, suitable patients may undergo endoscopic balloon dilatation. Patients undergoing dilatation will be stratified to ensure equal numbers in each study arm.
123539|NCT03220828|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets)
123540|NCT03220815|Procedure|Drilling at low speed|
123541|NCT03220815|Procedure|Conventional drilling at high speed|
123542|NCT03220802|Dietary Supplement|OMNI-BiOTiC PPI|The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 12 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, Lactobacillus rhamnosus W71, in a concentration of 2 x 109 cfu/g).
123543|NCT03220789|Procedure|Drilling at low speed|
123544|NCT03220789|Procedure|Drilling at conventional or high speed|
123545|NCT03220776|Drug|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
123546|NCT03220776|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
123547|NCT03220776|Drug|Placebo Oral Tablet|5 day trial of matched placebo
123548|NCT03220763|Other|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
123549|NCT03220737|Biological|VAXCHORA (Cholera Vaccine, Live, Oral)|VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
123550|NCT03220737|Other|Placebo|Placebo control for this study is normal (0.9%) saline.
123551|NCT03220724|Biological|CH505TF|Administered by intramuscular (IM) injection in the thigh
123552|NCT03220724|Biological|CH505w53|Administered by IM injection in the thigh
123553|NCT03220724|Biological|CH505w78|Administered by IM injection in the thigh
123554|NCT03220724|Biological|CH505w100|Administered by IM injection in the thigh
123555|NCT03220724|Biological|DNA Mosaic-Tre|Administered by IM injection in the thigh
123556|NCT03220724|Biological|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
123557|NCT03220724|Biological|Placebo|Administered by IM injection in the thigh
123560|NCT03220698|Device|Tracheal ultrasonography|Tracheal ultrasonography
123562|NCT03220672|Behavioral|Tailored assessment and educational|Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
123563|NCT03220659|Device|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
123564|NCT03220659|Device|Standard settings|Normal bipolar LV pacing
123565|NCT03220646|Drug|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
123566|NCT03220646|Drug|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
123567|NCT03220633|Drug|ATB-346|
123568|NCT03220633|Drug|Placebo|
123569|NCT03220620|Other|GDT|individualized fluid therapy
123570|NCT03220607|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
123571|NCT03220594|Procedure|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
123572|NCT03220581|Behavioral|Referral for care|referral for addictions support
123573|NCT03220581|Behavioral|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
123574|NCT03220568|Other|Fatty acids present in adipose tissue samples|
123575|NCT03220555|Device|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
123576|NCT03220555|Drug|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
123577|NCT03220542|Drug|Probiotics|Saccharomyces boulardii
123578|NCT03220542|Dietary Supplement|Broccoli|Broccoli sprouts extract
123579|NCT03220542|Drug|Esomeprazole|Esomeprazole
123580|NCT03220542|Drug|Amoxicillin|Amoxicillin
123581|NCT03220542|Drug|Clarithromycin|Clarithromycin
123582|NCT03220529|Device|Brillouin Ocular Scanner|
123583|NCT03220516|Procedure|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
123584|NCT03220516|Procedure|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
123585|NCT03220516|Procedure|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
123586|NCT03220503|Procedure|endometrial injury|single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
123587|NCT03220490|Behavioral|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
123588|NCT03220490|Behavioral|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
123589|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
123590|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
123591|NCT03220477|Drug|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
123592|NCT03220477|Drug|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
123593|NCT03220477|Drug|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
123594|NCT03220464|Radiation|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
123595|NCT03220464|Radiation|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
123596|NCT03220464|Diagnostic Test|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
123597|NCT03220451|Procedure|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
123598|NCT03220438|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
123599|NCT03220425|Drug|Insulin detemir|
123600|NCT03220425|Drug|NPH insulin|
123601|NCT03220412|Behavioral|Movies with Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
123602|NCT03220399|Drug|NVP-1603-1 (P)|1capsule, single oral dosing
123603|NCT03220399|Drug|NVP-1603-2 (T)|1tablet, single oral dosing
123605|NCT03220386|Other|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
123606|NCT03220360|Procedure|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
123607|NCT03220360|Procedure|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
123608|NCT03220360|Procedure|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
123609|NCT03220347|Drug|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
123610|NCT03220334|Drug|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
123611|NCT03220334|Drug|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
123612|NCT03220321|Other|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
123613|NCT03220321|Other|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
123614|NCT03220308|Other|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
123615|NCT03220308|Other|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
123616|NCT03220295|Drug|Single Dose of VU319|Single dose of VU319
123617|NCT03220295|Drug|Single Dose Placebo|Single dose of placebo
123618|NCT03220295|Other|Fed State|drug is given 30 minutes after a high fat breakfast
123619|NCT03220295|Other|Fasted State|drug is given after an overnight fast
123620|NCT03220295|Drug|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
123621|NCT03220295|Drug|Placebo Dose Escalation|dose levels of the cohorts will be increased step wise
123622|NCT03220282|Other|Donor milk|For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
123623|NCT03220282|Other|Preterm infant formula|Preterm formula determined by clinical practice
123624|NCT03220269|Other|Out-of-hospital cardiac arrest (OHCA)|Data collection
123625|NCT03220269|Other|In-hospital cardiac arrest (IHCA)|Data collection
123626|NCT03220256|Drug|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
123627|NCT03220243|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
123628|NCT03220217|Drug|Satoreotide trizoxetan|Positron emission tomography (PET) imaging agent
123629|NCT03220204|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
123630|NCT03220204|Behavioral|MI-based educational control condition|The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
123631|NCT03220191|Drug|Palbociclib|palbociclib tablet formulation
123632|NCT03220191|Drug|Rabeprazole|rabeprazole as PPI
123633|NCT03220178|Drug|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
123634|NCT03220178|Drug|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
123635|NCT03220178|Drug|Anastrozole|1mg per day
123636|NCT03220178|Drug|Letrozole|2,5mg/day
123637|NCT03220178|Drug|Exemestane|25mg/day
123638|NCT03220165|Drug|MGL-3196|oral, 100 mg
123639|NCT03220152|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
123640|NCT03220139|Other|fat intake|Observational study on fat intake and mortality
123641|NCT03220126|Biological|LY3074828|Administered IV
123642|NCT03220126|Biological|LY900021|Administered SC
123643|NCT03220113|Combination Product|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
123772|NCT03219294|Drug|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
123773|NCT03219268|Biological|MGD013|Anti-PD-1, anti-LAG-3 bispecific DART protein
123644|NCT03220100|Other|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
123645|NCT03220087|Other|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
123646|NCT03220074|Drug|Oral Tablet|study drug given and monitored for efficacy and tolerability
123647|NCT03220061|Behavioral|music therapy|
123648|NCT03220048|Drug|PrEP-001|
123649|NCT03220048|Other|Placebo Comparator|
123650|NCT03220035|Other|Laboratory Biomarker Analysis|Correlative studies
123651|NCT03220035|Drug|Vemurafenib|Given PO
123652|NCT03220022|Drug|Cyclophosphamide|Given IV
123653|NCT03220022|Drug|Doxorubicin Hydrochloride|Given IV
123654|NCT03220022|Drug|Etoposide|Given IV
123655|NCT03220022|Biological|Filgrastim|Given SC
123656|NCT03220022|Drug|Ibrutinib|Given PO
123657|NCT03220022|Other|Laboratory Biomarker Analysis|Correlative studies
123658|NCT03220022|Biological|Pegfilgrastim|Given SC
123659|NCT03220022|Other|Pharmacological Study|Correlative studies
123660|NCT03220022|Drug|Prednisone|Given PO
123661|NCT03220022|Biological|Rituximab|Given IV
123662|NCT03220022|Drug|Vincristine Sulfate|Given IV
123663|NCT03220009|Procedure|Conventional Surgery|Undergo surgery
123664|NCT03220009|Biological|Ipilimumab|Given IV
123665|NCT03220009|Other|Laboratory Biomarker Analysis|Correlative studies
123666|NCT03220009|Biological|Nivolumab|Given IV
123667|NCT03220009|Other|Patient Observation|Undergo active surveillance
123668|NCT03220009|Radiation|Radiation Therapy|Undergo RT
123669|NCT03219996|Other|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
123670|NCT03219983|Drug|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
123671|NCT03219983|Drug|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
123672|NCT03219970|Drug|Osimertinib|80mg oral daily
123673|NCT03219957|Drug|AT-527|Ascending doses of AT-527 administered orally.
123674|NCT03219957|Other|Placebo Comparator|Matching placebo
123675|NCT03219944|Procedure|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
123676|NCT03219944|Procedure|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
123677|NCT03219931|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
123678|NCT03219931|Drug|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
123679|NCT03219918|Device|EndoRings II Distal Attachment|Colonoscopy cap
123680|NCT03219905|Device|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
123681|NCT03219905|Device|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
123682|NCT03219892|Device|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
123683|NCT03219892|Device|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
123684|NCT03219879|Behavioral|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
123685|NCT03219879|Other|Usual care|Usual care without any study-related intervention
123686|NCT03219866|Device|Nebulizers|Patients treated and discharged on nebulized bronchodilators
123687|NCT03219866|Device|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
123688|NCT03219866|Drug|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
123689|NCT03219866|Drug|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
123690|NCT03219866|Drug|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
123691|NCT03219866|Drug|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
123692|NCT03219866|Drug|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
123693|NCT03219853|Dietary Supplement|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched environment
123694|NCT03219853|Dietary Supplement|Conventional parsnips|Parsnips which have been grown in a conventional environment
123695|NCT03219840|Drug|CPC|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
123696|NCT03219840|Drug|Placebo|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
123697|NCT03219827|Other|Human biological samples|Blood samples collection
123698|NCT03219814|Other|The Body Project|The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
123699|NCT03219814|Other|Mediapsychoeducation|Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
123700|NCT03219801|Biological|mesenchymal stem cells|SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
123701|NCT03219788|Drug|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
123702|NCT03219788|Drug|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
123703|NCT03219788|Drug|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
123704|NCT03219775|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
123705|NCT03219762|Drug|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
123706|NCT03219749|Behavioral|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
123707|NCT03219736|Procedure|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
123708|NCT03219736|Device|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
123709|NCT03219736|Procedure|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
123710|NCT03219723|Drug|Vonoprazan|Vonoprazan tablets
123711|NCT03219723|Drug|Amoxicillin hydrate|Amoxicillin hydrate (potency)
123712|NCT03219723|Drug|Clarithromycin|Clarithromycin (potency)
123713|NCT03219723|Drug|Metronidazole|Metronidazole
123714|NCT03219710|Drug|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
123715|NCT03219710|Drug|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
123716|NCT03219710|Drug|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (>40 kg) - Day 1 -125mg , Day 2 & Day 3 - 80 mg PO
123717|NCT03219710|Drug|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
123718|NCT03219697|Behavioral|Parenting education program|If you are in the parenting education program group, you will be enrolled in our 10-week parenting education program, followed by three monthly 1-hr sessions. You and/or your partner will attend weekly parenting sessions which will take place at the office of your child's primary care provider for 10 weeks, followed by 3 booster sessions. Our Toronto Public Health Nurse, will arrange 2-4 home visits with you and your family during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions in your home, and making connections in your neighbourhood that you find helpful such as recreational or nutrition programs or other supports for your family.
123719|NCT03219684|Diagnostic Test|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
123720|NCT03219671|Drug|Nivolumab|nivolumab 240mg every 2 weeks
123721|NCT03219671|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
123722|NCT03219658|Behavioral|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
123723|NCT03219645|Drug|Ginkgo Diterpene Lactone Meglumine Injection|The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
123724|NCT03219645|Drug|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
123725|NCT03219632|Drug|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
123726|NCT03219619|Device|Cap-EGD|Undergoing cap-assisted endoscopy
123727|NCT03219619|Device|Duo|Undergoing side-viewing duodenoscope
123728|NCT03219606|Other|Organized education course of Modified Rodnan Skin Scoring|"Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).~Demonstration: Master instructor demonstrate the patient assessment without revealing his score.~Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
123729|NCT03219593|Drug|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
123730|NCT03219580|Drug|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
123731|NCT03219580|Drug|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
123732|NCT03219554|Drug|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
123733|NCT03219541|Behavioral|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
123734|NCT03219541|Behavioral|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
123735|NCT03219528|Drug|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
123736|NCT03219528|Other|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
123737|NCT03219515|Drug|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
123738|NCT03219515|Drug|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
123739|NCT03219502|Other|Best Practice|Receive standard of care
123740|NCT03219502|Other|Quality-of-Life Assessment|Ancillary studies
123741|NCT03219502|Other|Questionnaire Administration|Ancillary studies
123742|NCT03219502|Procedure|Repetitive Transcranial Magnetic Stimulation|Undergo rTMS
123743|NCT03219502|Procedure|Sham Intervention|Undergo sham rTMS
123744|NCT03219489|Other|Electronic medical record alert|"An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: Consider Progesterone 100-200 mg pv qhs > or =16 weeks, if previous spontaneous PTB or current short cervix, and no allergies to peanuts or progesterone.~This alert will appear on the Ministry of Health-mandated Perinatal Records."
123745|NCT03219476|Drug|Anastrozole|1 mg once daily.
123746|NCT03219476|Drug|Letrozole|2.5mg once daily.
123747|NCT03219476|Drug|Exemestane|25 mg once daily.
123748|NCT03219476|Drug|Tamoxifen|20 mg once daily.
123749|NCT03219463|Dietary Supplement|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
123750|NCT03219450|Drug|NeoVax|It stimulates the immune system to attack cancer cells.
123751|NCT03219450|Drug|Cyclophosphamide|It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
123752|NCT03219437|Drug|risankizumab|subcutaneous (SC) injection
123753|NCT03219437|Drug|methotrexate|capsule
123754|NCT03219411|Dietary Supplement|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
123755|NCT03219411|Other|placebo|Placebo administered orally as capsules three times a day over 12 weeks
123756|NCT03219398|Procedure|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
123757|NCT03219385|Device|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
123758|NCT03219372|Drug|Pravastatin Pill|statin
123759|NCT03219372|Drug|Placebo Oral Tablet|placebo
123760|NCT03219359|Procedure|Autologous stem cell transplant|Hematopoietic stem cell transplantation
123761|NCT03219359|Drug|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ >20x104/ml then leukapheresis daily to collection goal
123762|NCT03219359|Drug|Cyclophosphamide|Day -5 to -2: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
123763|NCT03219359|Drug|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
123764|NCT03219359|Drug|Methylprednisolone|Day -3 to -1: 1mg/kg prior to each ATG dose
123765|NCT03219359|Drug|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
123766|NCT03219346|Other|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
123767|NCT03219333|Drug|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
123768|NCT03219320|Drug|NYX-2925|NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
123769|NCT03219320|Drug|Placebo|Matching Placebo capsules.
123770|NCT03219307|Combination Product|NOVOCART 3D|Matrix associated autologous chondrocyte implant
123774|NCT03219268|Biological|MGD013 in combination with margetuximab|Anti-PD-1, anti-LAG-3 bispecific DART protein plus anti-HER2 monoclonal antibody
123775|NCT03219255|Drug|RELVAR 100 ELLIPTA|RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
123776|NCT03219242|Device|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
123777|NCT03219216|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet
123778|NCT03219203|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
123779|NCT03219190|Behavioral|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
123780|NCT03219177|Behavioral|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
123781|NCT03219177|Other|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
123782|NCT03219164|Drug|AZLI|75 mg/ml of aztreonam administered thrice daily via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
123783|NCT03219164|Drug|Placebo|Placebo administered thrice daily via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
123784|NCT03219151|Device|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
123785|NCT03219151|Other|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
123786|NCT03219138|Device|Acceleromyography|Use of an uncalibrated acceleromyography
123787|NCT03219125|Device|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
123788|NCT03219125|Device|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
123789|NCT03219112|Other|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
123790|NCT03219086|Procedure|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
123791|NCT03219086|Drug|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
123792|NCT03219086|Drug|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
123793|NCT03219073|Device|Active tDCS using tDCS device|Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
123794|NCT03219073|Device|SHAM tDCS using tDCS device|SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
123795|NCT03219060|Behavioral|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
123796|NCT03219060|Behavioral|Brief advice|Brief advice based on 5As
123797|NCT03219047|Other|Best Practice|Receive standard of care
123798|NCT03219047|Drug|Ibrutinib|Given at standard dose and schedule
123799|NCT03219047|Other|Patient Derived Xenograft|Xenograft developed
123800|NCT03219047|Other|Personalized Medicine|Receive treatment based on the results of the PDX models
123801|NCT03219034|Device|oral appliance - A|Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
123802|NCT03219034|Device|oral appliance - B|Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
123803|NCT03219008|Drug|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
123804|NCT03219008|Combination Product|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
123805|NCT03219008|Drug|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
123806|NCT03219008|Combination Product|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
123807|NCT03219008|Drug|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
123808|NCT03219008|Drug|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
123809|NCT03219008|Combination Product|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
123810|NCT03219008|Combination Product|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
123811|NCT03219008|Drug|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
123812|NCT03219008|Combination Product|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
123813|NCT03219008|Drug|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
123814|NCT03219008|Combination Product|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
123815|NCT03219008|Other|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
123816|NCT03218995|Drug|Eteplirsen|"Eteplirsen will be administered once a week by IV infusion for up to 96 weeks.~The starting dose is 2 mg/kg eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg over the course of the dose-titration period."
123817|NCT03218982|Behavioral|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
123818|NCT03218969|Drug|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
123819|NCT03218969|Drug|Placebo|matching placebo
123820|NCT03218956|Dietary Supplement|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.~The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
123821|NCT03218943|Device|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
123822|NCT03218943|Device|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
123823|NCT03218930|Behavioral|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
123824|NCT03218930|Behavioral|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
123825|NCT03218930|Behavioral|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
123826|NCT03218930|Behavioral|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
123827|NCT03218917|Drug|INS1007 10 mg oral tablet|Administered once per day for 24 weeks
123828|NCT03218917|Drug|INS1007 25 mg oral tablet|Administered once per day for 24 weeks
123829|NCT03218917|Drug|Placebo Oral Tablet|Administered once per day for 24 weeks
123830|NCT03218904|Dietary Supplement|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
123831|NCT03218904|Dietary Supplement|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3- single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
123832|NCT03218891|Behavioral|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~5 minutes warm up~30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~10 minutes of localized exercises;~5 minutes of relaxation."
123833|NCT03218865|Device|VIE high flux dialyzer|Asssesment of the therapeutic effect of the vitamin E coating
123834|NCT03218865|Device|Leoceed H high flux dialyzer|Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
123835|NCT03218852|Drug|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
123836|NCT03218852|Drug|prednisone alone|Prednisone is administered to participants in this group.
123837|NCT03218839|Device|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
123838|NCT03218826|Drug|Docetaxel|Given IV
123839|NCT03218826|Other|Laboratory Biomarker Analysis|Correlative studies
123840|NCT03218826|Other|Pharmacological Study|Correlative studies
123841|NCT03218826|Drug|PI3Kbeta Inhibitor AZD8186|Given PO
123842|NCT03218813|Behavioral|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.~After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
123843|NCT03218800|Combination Product|Ertapenem|"Dose: 1g per day if creatinine clearance > 30mL/min or 500 mg per day if creatinine clearance < 30mL/min.~Dilution: 50 ml saline solution. Duration 30 minutes."
123844|NCT03218787|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
123845|NCT03218787|Drug|DAPT|"3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for > 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care."
123846|NCT03218774|Behavioral|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
123847|NCT03218774|Behavioral|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
123848|NCT03218761|Diagnostic Test|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
123849|NCT03218761|Diagnostic Test|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
123850|NCT03218761|Diagnostic Test|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
123851|NCT03218748|Behavioral|Honest, Open, Proud (HOP)|"Three lessons, one for each two-hour session plus one booster session~Considering the pros and cons of disclosure:~Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure~Different ways to disclose:~Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure~Telling one's story:~Practice how to tell one's story, identifying peers who might be helpful with the coming out process~Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience"
123852|NCT03218735|Procedure|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
123853|NCT03218735|Procedure|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
123854|NCT03218722|Drug|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
123855|NCT03218722|Drug|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
123856|NCT03218709|Combination Product|High-dose multi-vitamins with minerals|The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
123857|NCT03218709|Combination Product|Low-dose multi-vitamins with minerals|The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
123858|NCT03218709|Combination Product|Hypouricemic tablets|The hypouricemic tablets contained skipjack,salvia and rosemary extract.
123859|NCT03218709|Combination Product|Placebo|The placebo tablets contained maltodextrin and tartrazine.
123860|NCT03218696|Device|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
123861|NCT03218696|Device|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
123862|NCT03218683|Drug|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit or progresses
123863|NCT03218683|Drug|AZD5991 + Venetoclax|Ascending oral doses of venetoclax until no longer tolerated or disease progression
123864|NCT03218657|Drug|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
123865|NCT03218657|Drug|Androgens|Androgens take orally 80mg qd
123866|NCT03218657|Drug|Cyclosporins|Cyclosporines take orally 3-5mg/kg*d qd
123867|NCT03218644|Other|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
123868|NCT03218644|Other|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
123869|NCT03218631|Drug|Oxandrin|"The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.~Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing."
123870|NCT03218605|Other|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
123871|NCT03218592|Drug|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
123872|NCT03218592|Drug|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
123873|NCT03218592|Drug|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
123874|NCT03218579|Dietary Supplement|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
123875|NCT03218579|Biological|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
123876|NCT03218566|Device|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
123877|NCT03218553|Drug|Dexamethasone|Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
123878|NCT03218553|Drug|Placebos|placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
123879|NCT03218540|Procedure|Fluid management protocol|SVV protocol: keep SVV 10-13% and give fluid when SVV > 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP < 8 mmHg
123880|NCT03218514|Drug|Dalteparin|
123881|NCT03218501|Drug|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
123882|NCT03218501|Drug|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
123883|NCT03218501|Drug|Placebo|Placebo is to be administered orally once daily for 2 weeks
123884|NCT03218488|Drug|Ustekinumab|Participants will not receive any intervention as a part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab within clinical practice (patients should either start therapy with ustekinumab within 2 months after the first assessment within the study or have started therapy with ustekinumab in the 12-week period before the first assessment within the study for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development of pediatric participants.
123885|NCT03218475|Other|MR Guided Focused Ultrasound|Two treatments of focused ultrasound under MRI guidance
123886|NCT03218462|Behavioral|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
123887|NCT03218436|Procedure|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
123888|NCT03218423|Device|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
123889|NCT03218410|Procedure|surgical pulmonary embolectomy|
123890|NCT03218410|Combination Product|catheter-directed thrombolysis|
123891|NCT03218397|Device|Accelerate PhenoTest™ BC Kit|Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
123892|NCT03218397|Device|Standard Culture and AST|Standard culture and antimicrobial susceptibility testing (AST)
123893|NCT03218384|Drug|Ferric Carboxymaltose|750 MG Iron Per 15 ML Injectable Solution
123894|NCT03218384|Drug|Placebo|normal saline
123895|NCT03218371|Procedure|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
123896|NCT03218345|Procedure|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
123897|NCT03218332|Diagnostic Test|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
123898|NCT03218319|Biological|Renin measurement|patients will have a blood sample for measuring renin activity
123899|NCT03218306|Device|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
123900|NCT03218306|Other|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
123901|NCT03218293|Device|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5‑min cuff inflation followed by 3‑min deflation to the bilateral upper arm after thrombolysis.
123902|NCT03218280|Drug|Vitamin C|
123903|NCT03218267|Other|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
123944|NCT03217877|Diagnostic Test|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9~15 months after the procedure according to the practice pattern of each participating center.
124020|NCT03217409|Drug|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
124021|NCT03217409|Drug|Rosuvastatin|Rosuvastatin 5Mg Tablet
123904|NCT03218267|Other|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
123905|NCT03218254|Drug|Methylphenidate|Titration of MTP for treatment of fatigue
123906|NCT03218254|Drug|Placebo|Placebo
123907|NCT03218241|Biological|PRT064445|Intravenous
123908|NCT03218241|Drug|Placebo|Intravenous to mimic PRT064445
123909|NCT03218228|Procedure|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
123910|NCT03218189|Other|Country characteristics|Observational study of country characteristics
123911|NCT03218176|Device|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123912|NCT03218176|Device|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123913|NCT03218176|Device|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123914|NCT03218176|Device|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123915|NCT03218176|Device|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123916|NCT03218176|Device|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123917|NCT03218176|Device|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123918|NCT03218176|Device|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
123919|NCT03218163|Drug|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
123920|NCT03218150|Procedure|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.~In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
123921|NCT03218137|Drug|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
123922|NCT03218124|Other|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
123923|NCT03218111|Other|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
123924|NCT03218111|Other|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
123925|NCT03218098|Procedure|Lobectomy via UVATS|lobectomy with small skin access 4 cm
123926|NCT03218085|Drug|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
123927|NCT03218085|Drug|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
123928|NCT03218072|Drug|HLX01|a potential rituximab biosimilar
123929|NCT03218059|Procedure|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
123930|NCT03218046|Behavioral|EMDR|Eye Movement Desensitisation and Reprocessing
123931|NCT03218033|Behavioral|Social Media|
123932|NCT03218020|Other|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
123933|NCT03218007|Biological|blood samples|to evaluate expression and functionnaly activity of A2AR
123934|NCT03217994|Drug|gel HP|gel of hygrogen peroxide for teeth bleaching
123935|NCT03217981|Other|Sepsis protocol|Adherence to the sepsis protocol
123936|NCT03217968|Device|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
123937|NCT03217955|Behavioral|CBT-SA|Info has been included in arm description
123938|NCT03217955|Behavioral|Standard Treatment|Info has been included in arm description
123939|NCT03217942|Drug|NGF|Intramuscular injection
123940|NCT03217929|Device|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
123941|NCT03217929|Device|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
123942|NCT03217916|Diagnostic Test|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.~All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.~Personnel who performed the assays of analyteswere blinded to the clinical information."
123943|NCT03217903|Diagnostic Test|Myelogram|Bone marrow aspiration after 3 cycles of Azacytidine treatment
123945|NCT03217877|Diagnostic Test|No Routine stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
123946|NCT03217851|Diagnostic Test|Blood Collection|blood smear and/or rapid diagnostic
123947|NCT03217851|Diagnostic Test|Dried Blood Spot|Dried Blood Spot on filter paper
123948|NCT03217838|Drug|AZD2811|"AZD2811 is a frozen sterile nanoparticle suspension for constitution for infusion. Each vial contains 10 mg/mL.~AZD2811 will be administered by IV infusion over 2 hours for doses up to and including 600 mg and by IV infusion over 4 hours for doses above 600 mg. AZD2811 will be given on Days 1 and 4 of each 28-day cycle."
123949|NCT03217838|Drug|Azacitidine|"Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg.~Patients should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Patients will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle."
123950|NCT03217825|Drug|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
123951|NCT03217825|Drug|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole- 5-methanol monopotassium salt.
123952|NCT03217812|Drug|Velcade|Participants will receive velcade 1.3 mg/m^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
123953|NCT03217812|Drug|Melphalan|Participants will receive melphalan 9 mg/m^2 (if serum creatine is >2 mg/dL at baseline, participants must be administrated 4.5 mg/m^2 of melphalan, instead of 9 mg/m^2), orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
123954|NCT03217812|Drug|Prednisone|Participants will receive prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
123955|NCT03217812|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
123956|NCT03217799|Device|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
123957|NCT03217773|Procedure|ESD|Refer to arm description
123958|NCT03217773|Procedure|TAMIS|Refer to arm description
123959|NCT03217760|Procedure|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
123960|NCT03217760|Other|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
123961|NCT03217760|Other|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
123962|NCT03217760|Other|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
123963|NCT03217760|Other|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate [HR], systolic blood pressure [SBP], and diastolic blood pressure [DBP]) are monitored during each of the 6 steps.
123964|NCT03217760|Other|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
123965|NCT03217760|Other|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
123966|NCT03217760|Other|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
123967|NCT03217760|Other|student preferences.|"When the treatment is complete the students are asked to report:~his/her level of satisfaction with the course of treatment,~whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session~whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
123968|NCT03217747|Biological|Anti-OX40 Antibody PF-04518600|Given IV
123969|NCT03217747|Drug|Avelumab|Given IV
123970|NCT03217747|Radiation|Radiation Therapy|Undergo radiation therapy
123971|NCT03217747|Biological|Utomilumab|Given IV
123972|NCT03217734|Biological|Adalimumab|Subcutaneous Injection
123973|NCT03217734|Drug|Methotrexate|Oral Tablet
123974|NCT03217734|Drug|Placebo|Oral Tablet
123975|NCT03217708|Device|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
123976|NCT03217695|Behavioral|Mindfulness-based Yoga Arm|
123977|NCT03217682|Other|Music Therapy|Music therapy sessions
123978|NCT03217682|Other|Massage Therapy|Massage therapy sessions
123979|NCT03217669|Drug|Epacadostat|Epacadostat tablet: 100mg or 300mg
123980|NCT03217669|Drug|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
123981|NCT03217656|Other|No intervention|
124019|NCT03217422|Other|Placebo|Placebo control with conversion to active VAY736
124055|NCT03217149|Drug|MV|MV is given to infant with ARDS
123982|NCT03217643|Drug|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
123983|NCT03217630|Other|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
123984|NCT03217617|Biological|TYF-IL-2Rg gene-modified autologous stem cells|Infusion of transduced autologous stem cells
123985|NCT03217604|Drug|Placebo|Treatment with placebo
123986|NCT03217604|Drug|PF-06852231|Treatment with PF-06852231
123987|NCT03217591|Drug|IW-1973|Oral Tablet
123988|NCT03217591|Drug|IW-1973|Oral Tablet
123989|NCT03217591|Drug|Placebo|Oral Tablet
123990|NCT03217578|Other|SMA Newborn Screening|
123991|NCT03217565|Drug|IV Tedizolid Phosphate|A single dose, or twice daily dose for 3 days, of tedizolid phosphate administered IV.
123992|NCT03217565|Drug|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension.
123993|NCT03217552|Diagnostic Test|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
123994|NCT03217539|Diagnostic Test|Imaging|
123995|NCT03217526|Other|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
123996|NCT03217500|Procedure|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
123997|NCT03217500|Procedure|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
123998|NCT03217500|Procedure|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
123999|NCT03217500|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
124000|NCT03217500|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
124001|NCT03217487|Procedure|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
124002|NCT03217487|Procedure|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
124003|NCT03217487|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
124004|NCT03217487|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
124005|NCT03217474|Procedure|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
124006|NCT03217474|Drug|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
124007|NCT03217474|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
124008|NCT03217461|Procedure|CorneaL epithelial autograft|After removal of the recipient's diseased dermoid, a size-match donor epithelial tissue will be obtained from the healthy area of the same eye (corneal epithelial autograft) using femtosecond laser technology, with the goal of closure of bare stromal area by sutured corneal epithelial tissue to ensure the integrity of ocular surface. This closure may also create a microenvironment that stimulates stromal cells' regenerative capacity and regulates their epithelial-mesenchymal transition process.
124009|NCT03217461|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
124010|NCT03217461|Procedure|Limbal autograft|Simple dermoid excision will be performed, followed by closure of the bare sclera by sutured femtosecond laser-assisted limbal autograft.
124011|NCT03217461|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
124012|NCT03217448|Drug|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
124013|NCT03217448|Drug|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
124014|NCT03217435|Procedure|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
124015|NCT03217435|Procedure|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
124016|NCT03217435|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
124017|NCT03217435|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
124018|NCT03217422|Biological|VAY736|VAY736
124022|NCT03217396|Procedure|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
124023|NCT03217383|Device|MATRx plus|The MATRx plus test is a 2- or 3-night home sleep test that uses temporary titration trays to move the lower jaw in response to respiratory events. The purpose of the test is to predict oral appliance therapy outcome, and to provide a protrusive position for individuals predicted to experience therapeutic success.
124024|NCT03217370|Other|education of guidelines|"Guidelines will be updated and education will be given to haematologists in several ways.~ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
124025|NCT03217357|Device|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
124026|NCT03217344|Procedure|conservative treatment|immobilization on sling of the injured arm
124027|NCT03217331|Drug|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
124028|NCT03217318|Device|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
124029|NCT03217305|Device|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
124030|NCT03217292|Procedure|Serratus Anterior Plane Block|
124031|NCT03217292|Drug|IV patient-controlled analgesia (PCA) tramadol|
124032|NCT03217266|Drug|MDM2 Inhibitor AMG-232|Given PO
124033|NCT03217266|Radiation|Radiation Therapy|Undergo radiation therapy
124034|NCT03217253|Other|Laboratory Biomarker Analysis|Correlative studies
124035|NCT03217253|Other|Pharmacological Study|Correlative studies
124036|NCT03217253|Drug|Tazemetostat|Given PO
124037|NCT03217240|Procedure|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
124038|NCT03217240|Other|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
124039|NCT03217240|Other|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
124040|NCT03217227|Other|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
124041|NCT03217227|Procedure|Cardiac Catherization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.~A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.~In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries."
124042|NCT03217227|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
124043|NCT03217214|Diagnostic Test|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
124044|NCT03217201|Device|Light Glasses (Experimental)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
124045|NCT03217201|Device|Light Glasses (Comparison)|The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device Is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similarly to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
124046|NCT03217188|Radiation|conventionally fractionated full dose re-irradiation|re-irradiation [70 Gy (RBE) in 2 Gy (RBE) fractions
124047|NCT03217188|Radiation|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break [+/- 2 weeks], repeated up to 4 cycles)."
124048|NCT03217175|Device|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
124049|NCT03217175|Device|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
124050|NCT03217175|Drug|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
124051|NCT03217175|Drug|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
124052|NCT03217162|Drug|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
124053|NCT03217162|Drug|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
124054|NCT03217149|Drug|heliox combined with MV|heliox combined with MV is given to infant with ARDS
124056|NCT03217136|Drug|Ceftolozane|Ceftolozane 20 mg/kg (maximum 1 g) administered IV every 8 hours for between 5 to 14 day
124057|NCT03217136|Drug|Tazobactam|Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days
124058|NCT03217136|Drug|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants =< 28 days old, start with a loading dose of 15 mg/kg; then if =< 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if > 2 kg are dosed 10 mg/kg every 8 hours.
124059|NCT03217136|Drug|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days
124060|NCT03217136|Drug|Placebo for Metronidazole|Placebo for Metronidazole administered IV every 8 hours for between 5 to 14 days.
124061|NCT03217123|Device|Deep Brain stimulation|Electrical stimulation at subcortical level
124062|NCT03217110|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
124063|NCT03217110|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
124064|NCT03217097|Drug|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
124065|NCT03217097|Drug|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
124066|NCT03217084|Drug|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
124067|NCT03217084|Drug|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
124068|NCT03217071|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
124069|NCT03217071|Radiation|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
124070|NCT03217058|Behavioral|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use, anxiety and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use, anxiety or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
124071|NCT03217045|Other|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
124072|NCT03217032|Biological|YUVA-GT-F801|Lentiviral factor VIII gene modified autologous hematopoeitic stem cells and mesenchymal stem cells
124073|NCT03217019|Procedure|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
124074|NCT03217019|Procedure|Direct|catheter insertion without guidewire assist(catheter over needle)
124075|NCT03217006|Procedure|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
124076|NCT03217006|Procedure|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
124077|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
124078|NCT03216993|Other|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
124079|NCT03216980|Dietary Supplement|PTSD/GAD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
124080|NCT03216980|Dietary Supplement|PTSD/GAD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
124081|NCT03216980|Dietary Supplement|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
124082|NCT03216980|Dietary Supplement|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
124083|NCT03216967|Drug|everolimus|Patients with viremia above 3 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
124084|NCT03216954|Drug|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
124085|NCT03216954|Drug|Placebos|Subjects will receive placebo capsules
124086|NCT03216954|Drug|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
124087|NCT03216941|Drug|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.~All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
124088|NCT03216928|Diagnostic Test|Blood test|
124089|NCT03216915|Drug|Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
124090|NCT03216902|Drug|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
124091|NCT03216902|Drug|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
124092|NCT03216902|Drug|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
124093|NCT03216902|Drug|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
124094|NCT03216902|Drug|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
124095|NCT03216902|Drug|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
124096|NCT03216889|Behavioral|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
124097|NCT03216889|Behavioral|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
124098|NCT03216876|Drug|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
124099|NCT03216863|Other|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
124100|NCT03216850|Device|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
124101|NCT03216837|Device|Cathodal transcranial direct current stimulation|The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
124102|NCT03216837|Device|Sham transcranial direct current stimulation|Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
124103|NCT03216824|Other|Dressing|A dressing is maintained on the CVAD exit site.
124104|NCT03216824|Other|No-Dressing|The CVAD exit site is not covered with a dressing.
124105|NCT03216811|Drug|nutraceutical|8-week administration of nutraceutical compound
124106|NCT03216798|Other|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
124107|NCT03216772|Device|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
124108|NCT03216759|Procedure|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
124109|NCT03216759|Drug|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
124110|NCT03216759|Procedure|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
124111|NCT03216746|Other|Oral health educational methods|An educational protocol including different methods of education will be evaluated through the knowledge score and periodontal indexes.
124112|NCT03216733|Device|COMBO|PCI with COMBO stent
124113|NCT03216733|Device|ORSIRO|PCI with ORSIRO stent
124114|NCT03216720|Procedure|CABG|"Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula~Grafting: pedicled left internal mammary artery, and no-touch~saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System~Target activated coagulation time of >400 seconds"
124115|NCT03216720|Procedure|Miniaturized extracorporeal circulation|"Centrifugal pump to reduce mechanical stress~Circuit coated with biosurface to increase haemocompatibilty.~Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution~Collapsible soft-shell reservoir for blood volume management~Cell-saving device~Venous air removing device and electric clamp system to air embolism"
124510|NCT03213665|Other|Laboratory Biomarker Analysis|Correlative studies
124511|NCT03213665|Drug|Tazemetostat|Given PO
124116|NCT03216720|Procedure|Conventional extracorporeal circulation|"Roller pump~Circuit uncoated~Hard-shell venous reservoir~Intermittend cold blood Harefield cardioplegia"
124117|NCT03216707|Device|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
124118|NCT03216707|Device|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
124119|NCT03216707|Device|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
124120|NCT03216707|Other|Capsaicin cream|Capsaicin cream
124121|NCT03216694|Diagnostic Test|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
124122|NCT03216681|Drug|Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
124123|NCT03216681|Drug|Tanakan 40mg|Administered orally three times a day, 1 tablet each time, for 45 days.
124124|NCT03216668|Drug|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
124125|NCT03216668|Drug|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
124126|NCT03216655|Other|phone call|Investigators give a regular follow-up to participants: phone call monthly
124127|NCT03216655|Other|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
124128|NCT03216642|Diagnostic Test|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
124129|NCT03216629|Behavioral|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
124130|NCT03216616|Behavioral|Cognitive Behavioural Therapy|
124131|NCT03216603|Behavioral|Health literacy intervention group|In the health literacy intervention group all patients will receive self-management help using a motivating interviewing (MI) technique delivered by two MI and COPD trained nurses once a week for eight weeks after hospitalization. Subsequently, the contact between the patients and the nurses will be by follow up motivational telephone calls once a month or more if needed for four months (i.a a total of six months intervention period).
124132|NCT03216590|Device|Compressive draping using adhesive incise drape|In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
124133|NCT03216577|Other|Phone interview measuring health-related quality of life variables|A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
124134|NCT03216564|Drug|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
124135|NCT03216551|Diagnostic Test|Intra-operative frozen section|Tumor histologic subtypes (whether it is lepidic predominant adenocarcinoma), N1 nodes metastasis (lymph nodes adjacent to the tumor will be sent to frozen section) and visceral pleural invasion will be determined by the intra-operative frozen section.
124136|NCT03216538|Drug|AS101 1% oral solution|0.4 ml daily p.o.
124137|NCT03216538|Drug|Placebo|0.4 ml daily p.o.
124138|NCT03216525|Drug|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
124139|NCT03216525|Drug|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
124140|NCT03216512|Other|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
124141|NCT03216499|Drug|HIF-2alpha Inhibitor PT2385|Given PO
124142|NCT03216499|Other|Pharmacological Study|Correlative studies
124143|NCT03216499|Other|Laboratory Biomarker Analysis|Correlative studies
124144|NCT03216499|Other|Pharmacogenomic Study|Correlative studies
124145|NCT03216486|Drug|BPS804|IV administration of BPS804 in 5% Dextrose solution
124146|NCT03216473|Drug|Neuronox|Clostridium Botulinum Toxin A 100 U
124147|NCT03216473|Drug|Botox|Clostridium Botulinum Toxin A 100 U
124148|NCT03216460|Device|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
124149|NCT03216447|Drug|Advagraf|Tacrolimus prolonged-release hard capsules (QD)
124150|NCT03216447|Drug|Prograf|Tacolimus capsules (q12h)
124151|NCT03216434|Diagnostic Test|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
124152|NCT03216421|Other|Quality of Life Questionnaires|Quality of Life questionnaires will be completed by each subject.
124153|NCT03216408|Drug|Neuronox|
124154|NCT03216408|Drug|Botox|
124155|NCT03216395|Device|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
124156|NCT03216395|Device|Hemo-clipping|Hemo-clipping <=20 clips
124157|NCT03216395|Device|thermo-coagulation|contact thermo-coagulation < = 8 pulses
124158|NCT03216395|Drug|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer <20 mls
124159|NCT03216382|Behavioral|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
124160|NCT03216382|Behavioral|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
124161|NCT03216369|Other|MRI|MRI perfusion imaging
124162|NCT03216356|Behavioral|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
124163|NCT03216356|Behavioral|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
124164|NCT03216356|Drug|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
124165|NCT03216356|Drug|Placebo|polyethylene glycol 3350 powder
124166|NCT03216356|Drug|Study Pill|250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
124167|NCT03216343|Drug|Chiauranib|CS2164
124168|NCT03216330|Other|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
124169|NCT03216317|Behavioral|Intervention Group|Isometric handgrip training consisting of four series
124170|NCT03216304|Drug|100 mg safinamide|"Safinamide will be administered as follows:~Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day~Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)~Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
124171|NCT03216304|Drug|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
124172|NCT03216304|Drug|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
124173|NCT03216291|Behavioral|biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
124174|NCT03216291|Device|Home Biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
124175|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
124176|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
124177|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
124178|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
124179|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
124180|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
124181|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
124182|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
124183|NCT03216265|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
124184|NCT03216265|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
124185|NCT03216265|Other|No treatment|No treatment.
124186|NCT03216252|Biological|samples|Blood samples, oral smear and urine
124187|NCT03216226|Drug|dasiglucagon|Glucagon Analog
124188|NCT03216226|Drug|GlucaGen|Native Glucagon
124189|NCT03216213|Other|Frame|Vignette is framed in a way that nudges participant to leave a legacy
124190|NCT03216213|Other|Norms|Vignette informs the participant that most people choose an option to try to nudge participant into choosing that option as well
124191|NCT03216200|Device|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
124192|NCT03216187|Drug|Pregabalin|pregabalin 150 mg capsules
124193|NCT03216187|Drug|Placebos|capsules identical to pregabalin but without active drug
124194|NCT03216174|Procedure|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
124195|NCT03216148|Diagnostic Test|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
124196|NCT03216122|Procedure|Conventional/Delayed Loading|
124197|NCT03216122|Procedure|Immediate Loading|
124198|NCT03216109|Behavioral|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
124199|NCT03216096|Drug|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
124200|NCT03216083|Drug|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
124201|NCT03216083|Other|Placebo|67mL IV normal saline
124202|NCT03216070|Drug|Dasatinib 50 MG|50mg of dasatinib orally daily
124203|NCT03216057|Dietary Supplement|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.
124204|NCT03216057|Dietary Supplement|Placebo|Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
124205|NCT03216031|Behavioral|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
124206|NCT03216018|Behavioral|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
124207|NCT03216005|Device|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
124208|NCT03215992|Device|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
124209|NCT03215979|Procedure|Platelet enriched plasma administration|It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
124210|NCT03215979|Procedure|Placebo Arm|5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
124211|NCT03215966|Combination Product|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
124212|NCT03215966|Drug|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
124213|NCT03215966|Drug|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
124214|NCT03215953|Device|cast shoe|ankle-high, custom-made, well-moulded cast shoe
124215|NCT03215953|Device|forefoot offloading shoe|Prefabricated shoe especially designed for relieving forefoot locations on the foot
124216|NCT03215940|Drug|Delta-9-Tetrahydrocannabinol|An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.
124217|NCT03215940|Drug|Cannabidiol|An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
124218|NCT03215940|Drug|Placebos|An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
124219|NCT03215927|Drug|Abatacept|Abatacept 125mg subcutaneous weekly
124220|NCT03215927|Other|Placebo|Placebo
124221|NCT03215914|Device|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
124222|NCT03215901|Behavioral|A Beautiful Future Video|Video delivering information on the longevity gains due to HIV treatment in the area.
124223|NCT03215901|Behavioral|Active Control Video|Video on another topic.
124224|NCT03215888|Procedure|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
124225|NCT03215875|Drug|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
124226|NCT03215875|Drug|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
124227|NCT03215862|Drug|Lactated Ringer|This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
124228|NCT03215862|Drug|Normal Saline 0.9% Infusion Solution Bag|This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
124229|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
124230|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
124231|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
124232|NCT03215836|Procedure|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
124233|NCT03215810|Procedure|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
124234|NCT03215810|Drug|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for 4 doses every 2 weeks prior to TIL. Nivolumab dose will be fixed at 480 mg every 4 weeks up to 12 months after TIL.
124235|NCT03215810|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
124512|NCT03213652|Drug|Ensartinib|Given PO
124513|NCT03213652|Other|Laboratory Biomarker Analysis|Correlative studies
124236|NCT03215810|Drug|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
124237|NCT03215810|Other|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
124238|NCT03215810|Drug|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
124239|NCT03215797|Drug|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
124240|NCT03215797|Drug|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
124241|NCT03215784|Dietary Supplement|Fish Oil|
124242|NCT03215784|Dietary Supplement|Probiotic|
124243|NCT03215784|Dietary Supplement|Placebo|
124244|NCT03215771|Device|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
124245|NCT03215758|Drug|QAW039|QAW039 once daily
124246|NCT03215758|Drug|Placebo|Placebo once daily
124247|NCT03215745|Behavioral|Delirium prevention program|Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
124248|NCT03215732|Diagnostic Test|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
124249|NCT03215719|Radiation|Standard Radiation Treatment|An interval scan at 4 weeks to assess for a good response defined as >40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (>40% nodal shrinkage).
124250|NCT03215719|Radiation|Dose-Deescalated Treatment|Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons
124251|NCT03215719|Drug|Cisplatinum|Standard of care chemotherapy
124252|NCT03215706|Biological|Ipilimumab|Specified dose on specified day
124253|NCT03215706|Biological|Nivolumab|Specified dose on specified day
124254|NCT03215706|Drug|Carboplatin|Specified dose on specified day
124255|NCT03215706|Drug|Paclitaxel|Specified dose on specified day
124256|NCT03215706|Drug|Pemetrexed|Specified dose on specified day
124257|NCT03215706|Drug|Cisplatin|Specified dose on specified day
124258|NCT03215693|Drug|X-396 capsule|225mg once daily
124259|NCT03215680|Other|Climate|Hot and temperate climate
124260|NCT03215667|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
124261|NCT03215654|Other|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
124262|NCT03215641|Device|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
124263|NCT03215628|Diagnostic Test|TCEUS|Intravenous sulphur hexafluoride microbubbles
124264|NCT03215615|Procedure|Periodontal surgery|Coronally advanced flap for root coverage
124265|NCT03215615|Procedure|Total Etch adhesive|Total-etch adhesive system (two step)
124266|NCT03215615|Procedure|Universal Adhesive|One-step self-etching adhesive system
124267|NCT03215615|Procedure|Nanofilled Composite|Partial nanofilled-resin composite restoration
124268|NCT03215615|Procedure|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
124269|NCT03215602|Other|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
124270|NCT03215602|Other|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
124271|NCT03215563|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
124272|NCT03215563|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
124273|NCT03215550|Procedure|CEA|Carotid Endarterectomy
124274|NCT03215550|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
124275|NCT03215550|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
124276|NCT03215537|Behavioral|comprehensive intervention|preoperative and postoperative exercise program
124277|NCT03215524|Biological|DCdP|Daratumumab, Cyclophosphamide, Dexamethasone, Pomalidomide
124278|NCT03215524|Biological|DCd+P|Daratumumab, Cyclophosphamide, Dexamethasone, + Pomalidomide added only at first confirmed biochemical progression
124279|NCT03215511|Drug|BAY2731954|BAY2731954 is administered as capsules or liquid formulation.
124514|NCT03213652|Other|Pharmacological Study|Correlative studies
124280|NCT03215498|Drug|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
124281|NCT03215498|Drug|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
124282|NCT03215485|Behavioral|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
124283|NCT03215485|Behavioral|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
124284|NCT03215485|Other|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
124285|NCT03215472|Other|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
124286|NCT03215472|Other|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
124287|NCT03215459|Device|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
124288|NCT03215446|Drug|maintenance of anaesthesia with propofol|
124289|NCT03215446|Drug|maintenance of anaesthesia with sevoflurane|
124290|NCT03215420|Diagnostic Test|MRI 3T|
124291|NCT03215407|Drug|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
124292|NCT03215407|Drug|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
124293|NCT03215394|Behavioral|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
124294|NCT03215394|Behavioral|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
124295|NCT03215394|Other|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
124296|NCT03215394|Behavioral|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
124297|NCT03215381|Drug|[11C]AZD1390|[11C]AZD1390
124298|NCT03215355|Drug|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.~Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
124299|NCT03215342|Behavioral|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
124300|NCT03215342|Behavioral|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
124301|NCT03215329|Procedure|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
124302|NCT03215303|Device|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
124303|NCT03215290|Procedure|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
124304|NCT03215277|Drug|Bimekizumab|One bimekizumab dose will be administered.
124305|NCT03215277|Drug|Certolizumab pegol|Two certolizumab pegol doses will be administered. One of these doses is a loading dose.
124306|NCT03215277|Other|Placebo|Placebo will be provided to maintain the blinding.
124307|NCT03215264|Drug|hydroxychloroquine|160mg daily
124308|NCT03215264|Drug|entinostat|2-5mg weekly
124309|NCT03215264|Drug|regorafenib|400-1200mg daily
124310|NCT03215251|Other|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
124311|NCT03215225|Procedure|Root canal orthograde treatment|
124312|NCT03215212|Other|eye mask|eye mask administered from 10 pm to 7 am
124313|NCT03215212|Other|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
124314|NCT03215212|Other|ear plug|ear plug administered from 10 pm to 7 am
124315|NCT03215199|Other|NAPT|Web-based depression and distress monitoring application
124316|NCT03215186|Other|observational study|
124317|NCT03215173|Behavioral|Fit After Baby|Mobile application
124318|NCT03215173|Behavioral|Text4Baby Control Group|Receive free text messages
124319|NCT03215160|Behavioral|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
124320|NCT03215147|Diagnostic Test|Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6~8 weeks later.
124321|NCT03215134|Other|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre & Rimes, submitted) and is now being evaluated in a primary mental-health service.
124322|NCT03215121|Procedure|One handed mask airway, switch to two hands|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds."
124323|NCT03215121|Procedure|Two handed mask airway + jaw thrust|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds."
124324|NCT03215121|Procedure|Two handed mask airway, switch to one hand|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds."
124325|NCT03215108|Device|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
124326|NCT03215095|Drug|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
124327|NCT03215095|Radiation|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
124328|NCT03215082|Other|Vestibular-Visual Intervention|vestibular-visual exercises
124329|NCT03215082|Behavioral|standard care|standard care
124330|NCT03215069|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
124331|NCT03215069|Drug|Placebo oral capsule|Placebo PO daily
124332|NCT03215056|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
124333|NCT03215056|Drug|Normal saline|Placebo
124334|NCT03215043|Dietary Supplement|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
124335|NCT03215043|Other|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
124336|NCT03215030|Drug|TAK-573|TAK-573 intravenous infusion.
124337|NCT03215030|Drug|Dexamethasone|Dexamethasone.
124338|NCT03215017|Device|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
124339|NCT03215017|Drug|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
124340|NCT03214965|Behavioral|Facebook group|A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
124341|NCT03214952|Drug|Vonoprazan|Vonoprazan tablets
124342|NCT03214939|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
124343|NCT03214926|Device|Moving Through Glass intervention|
124344|NCT03214913|Other|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
124345|NCT03214913|Other|Ruijin Strategy|"Ruijin Strategy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.~target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%~35%."
124346|NCT03214887|Biological|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
124347|NCT03214874|Drug|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
124348|NCT03214874|Drug|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
124349|NCT03214861|Other|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
124350|NCT03214848|Behavioral|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
124351|NCT03214835|Device|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
124352|NCT03214822|Dietary Supplement|H2MF|As described in the Experimental Arm description.
124353|NCT03214809|Diagnostic Test|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
124354|NCT03214796|Drug|Human albumin|Infusion of human albumin
124355|NCT03214783|Other|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
124356|NCT03214770|Drug|TheraCal|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
124357|NCT03214770|Drug|light-cured calcium hydroxide|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
124358|NCT03214757|Other|treatment of anemia.|drug treatment of anemia.
124359|NCT03214731|Drug|Artesunate|Artesunate was produced by pharmaceutical factory for research specifically
124360|NCT03214731|Other|placebo|placebo was produced by pharmaceutical factory for research specifically
124361|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
124362|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:~- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .~Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
124363|NCT03214692|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
124364|NCT03214679|Other|Accessible Care|Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
124365|NCT03214679|Other|Usual Care|Usual care entails referral to an on site HCV care coordinator (not provided by study)
124366|NCT03214666|Drug|GTB-3550 TriKE™ Phase I|"Bolus Test Dose: 20% of Daily Continuous Infusion Dose.~The 1st two patients will be assigned dose level 1. The study statistician will assign each new cohort of 2 patients to the most appropriate dose level based on updated toxicity probabilities.~Dose level 1 - 5 μg/kg/day~Dose level 2 - 10 μg/kg/day~Dose level 3 - 25 μg/kg/day~Dose level 4 - 50 μg/kg/day~Dose level 5 - 100 μg/kg/day~Dose level 6 - 200 μg/kg/day"
124367|NCT03214666|Drug|GTB-3550 TriKE™ Phase II|Patients will receive the maximum tolerated dose (MTD) established during Phase I with monitoring guidelines to stop the study early for excessive toxicity.
124368|NCT03214653|Drug|Propofol|Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
124369|NCT03214653|Drug|Sevoflurane|Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
124370|NCT03214640|Device|Rivanna Accuro US Device|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Rivanna Accuro U/S device. For subjects in group C-R or L-R, the needle insertion site will be the site identified by the Rivanna Accuro U/S device. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
124371|NCT03214640|Other|Palpation description:|When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified with Palpation method. For subjects in group C-P or L-P, the needle insertion site will be the site identified by the Palpation method. After placement of spinal for Cesarean or epidural for labor, the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.When the subject is ready for neuraxial procedure, the location for the epidural or spinal needle insertion will be identified by palpation using conventional landmarks (spinous process and iliac crest). Those in group P, the neuraxial block will be performed as in the usual method using the needle insertion site identified with palpation. After placement of neuraxial labor analgesia the usual standard dose of medication will be administered as in usual manner for patients regardless in this study or not.
124372|NCT03214640|Procedure|Neuraxial Analgesia|Labor analgesia will be provided utilizing the standard medications to provide labor analgesia
124373|NCT03214640|Procedure|Spinal Block|Spinal anesthetic medications will be utilized in providing surgical block for cesarean delivery as is standard of care
124374|NCT03214627|Device|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
124375|NCT03214627|Drug|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
124376|NCT03214627|Drug|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
124377|NCT03214614|Drug|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
124378|NCT03214614|Drug|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
124379|NCT03214614|Drug|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
124380|NCT03214614|Drug|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
124381|NCT03214601|Device|penetrating atherosclerotic ulcer, aorta branch cardiovascular implant|The Relay Branch System is intended to provide an option for patients with arch and proximal descending chronic thoracic aortic pathologies.
124382|NCT03214588|Drug|TAK-831|TAK-831 tablets
124383|NCT03214588|Drug|TAK-831 Placebo|TAK-831 placebo matching tablets
124384|NCT03214575|Device|Conventional method|
124385|NCT03214575|Procedure|GPS Method|
124386|NCT03214562|Drug|Cytarabine|Given IV
124387|NCT03214562|Biological|Filgrastim|Given SC
124388|NCT03214562|Drug|Fludarabine|Given IV
124389|NCT03214562|Drug|Fludarabine Phosphate|Given IV
124390|NCT03214562|Drug|Idarubicin|Given IV
124391|NCT03214562|Drug|Idarubicin Hydrochloride|Given IV
124392|NCT03214562|Biological|Pegfilgrastim|Given SC
124393|NCT03214562|Drug|Venetoclax|Given PO
124394|NCT03214549|Procedure|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
124395|NCT03214549|Procedure|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
124396|NCT03214536|Procedure|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
124397|NCT03214536|Drug|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
124398|NCT03214536|Procedure|Spine surgery|Surgery of lumbar spine
124399|NCT03214536|Procedure|anesthesia|general anesthesia
124400|NCT03214523|Behavioral|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
124401|NCT03214510|Drug|Bupivacaine|Given via thoracic epidural catheter or TAP block
124402|NCT03214510|Drug|Fentanyl|Given via thoracic epidural catheter
124403|NCT03214510|Drug|Hydromorphone Hydrochloride|Given via thoracic epidural catheter
124404|NCT03214510|Device|Implanted Medical Device|Undergo placement of thoracic epidural catheter
124405|NCT03214510|Device|Implanted Medical Device|Undergo placement of ultrasound-guided, four-quadrant transversus abdominus plane block
124406|NCT03214510|Drug|Liposomal Bupivacaine|Given via TAP block
124407|NCT03214510|Behavioral|Questionnaire|Ancillary studies
124408|NCT03214497|Device|Protector|All patients which are assigned to the Protector are studied with this laryngeal mask
124409|NCT03214497|Device|Supreme|All patients which are assigned to the Supreme are studied with this laryngeal mask
124410|NCT03214484|Other|By comparing the evolution of the visual acuity curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
124411|NCT03214484|Other|By comparing the evolution of the curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
124515|NCT03213639|Drug|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
124516|NCT03213639|Drug|Placebo Oral Tablet|once daily oral tablets
124412|NCT03214471|Behavioral|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
124413|NCT03214458|Device|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
124414|NCT03214445|Procedure|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
124415|NCT03214445|Procedure|Sealing margins with seal|Seal the margin of restoration with sealant without filler
124416|NCT03214406|Drug|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
124417|NCT03214406|Drug|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
124418|NCT03214393|Diagnostic Test|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
124419|NCT03214393|Diagnostic Test|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
124420|NCT03214380|Drug|LY900014|Administered SC
124421|NCT03214380|Drug|Insulin Lispro|Administered SC
124422|NCT03214380|Drug|Insulin Glargine|Administered SC
124423|NCT03214380|Drug|Insulin Degludec|Administered SC
124424|NCT03214367|Drug|LY900014|Administered SC
124425|NCT03214367|Drug|Insulin Lispro|Administered SC
124426|NCT03214367|Drug|Insulin Glargine|Administered SC
124427|NCT03214367|Drug|Insulin Degludec|Administered SC
124428|NCT03214354|Drug|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
124429|NCT03214354|Radiation|Total Body Irradiation|TBI 300 cGy on Day -2
124430|NCT03214354|Drug|Sirolimus|Sirolimus is used for GVHD prophylaxis
124431|NCT03214341|Radiation|MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses
124432|NCT03214328|Diagnostic Test|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
124433|NCT03214315|Procedure|Visceral adipose tissue specimen|specimen
124434|NCT03214302|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
124435|NCT03214289|Biological|Fecal Microbiota Transplantation|Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
124436|NCT03214276|Dietary Supplement|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
124437|NCT03214276|Dietary Supplement|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
124438|NCT03214250|Drug|APX005M|Administer intravenously once every 28-day Cycle
124439|NCT03214250|Drug|Nivolumab|Administer intravenously twice every 28-day cycle
124440|NCT03214250|Drug|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
124441|NCT03214250|Drug|Gemcitabine|Administer intravenously 3 times every 28-day cycle
124442|NCT03214237|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
124443|NCT03214224|Device|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
124444|NCT03214224|Device|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
124445|NCT03214198|Drug|Vonoprazan|Vonoprazan tablets
124446|NCT03214185|Procedure|IVF/ICSI|in vitro fertilization or intracytoplasmatic sperm injection
124447|NCT03214185|Genetic|PGS 2.0|Blastocysts are selected by PGS 2.0(NGS based) and only euploid embryos will be transferred.
124448|NCT03214185|Other|Conventional embryo morphology evaluation|Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
124449|NCT03214172|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
124450|NCT03214159|Drug|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
124451|NCT03214159|Drug|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
124452|NCT03214146|Biological|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10^6 cells/kg according to the protocol design.
124453|NCT03214133|Other|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
124454|NCT03214133|Other|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epictechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
124455|NCT03214107|Other|Exercise|Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
124456|NCT03214107|Other|Snack|Full snack or Distributed snack
124457|NCT03214094|Drug|Vonoprazan|Vonoprazan tablets
124458|NCT03214081|Drug|Vonoprazan|Vonoprazan tablets
124517|NCT03213626|Drug|Cabozantinib 40 MG|To be taken orally once daily
124518|NCT03213626|Drug|Erlotinib 100Mg Tab|To be taken orally once daily
124459|NCT03214055|Drug|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
124460|NCT03214042|Device|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
124461|NCT03214029|Diagnostic Test|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
124462|NCT03214016|Other|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
124463|NCT03214016|Other|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
124464|NCT03214003|Radiation|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
124465|NCT03214003|Radiation|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
124466|NCT03213990|Other|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
124467|NCT03213990|Other|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
124468|NCT03213977|Drug|R-DA-EPOCH|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
124469|NCT03213977|Drug|R-DA-EPOCH + auto-HSCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
124470|NCT03213977|Drug|R-CEOP90|R-CEOP90 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
124471|NCT03213977|Drug|R-CEOP90 + auto-HSCT|R-CEOP90 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
124472|NCT03213964|Biological|FATE-NK100|"FATE-NK100 Infusion (Day 0)~The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.~Dose Level 1: 1 x 10^7 cells/kg IP~Dose Level 2: >1x10^7 cells/kg to ≤3x10^7 cells/kg~Dose Level 3: Complete FATE-NK100 bag (≥3 x 10^7 to ≤ 10 x 10^7 cells/kg)"
124473|NCT03213964|Drug|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.~The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
124474|NCT03213951|Other|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
124475|NCT03213951|Diagnostic Test|PSMA-PET|PSMA-PET imaging done prior to surgery and compared to whole mount imaging.
124476|NCT03213938|Device|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
124477|NCT03213938|Device|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
124478|NCT03213925|Radiation|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.~Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).~Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
124479|NCT03213886|Drug|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD < 30 ng/mL) will be randomly allocated to an intervention group or control group.~For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.~For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.~Both groups:~Will follow the usual hip fracture rehabilitation pathway.~25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
124480|NCT03213873|Behavioral|HiBalance|Intervention of highly challenging balance training for 10 weeks.
124481|NCT03213873|Behavioral|Speech and communication therapy|Intervention conducted by speech and language therapist for 10 weeks.
124482|NCT03213860|Other|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The caregiver will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
124483|NCT03213847|Device|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
124545|NCT03213405|Biological|rBCG-N-hRSV 1/10|5x10^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
124546|NCT03213405|Biological|rBCG-N-hRSV full dose|5x10^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
124484|NCT03213834|Procedure|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
124485|NCT03213834|Procedure|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
124486|NCT03213834|Drug|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
124487|NCT03213834|Drug|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
124488|NCT03213821|Other|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
124489|NCT03213808|Other|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
124490|NCT03213782|Other|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
124491|NCT03213769|Drug|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
124492|NCT03213769|Drug|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
124493|NCT03213756|Device|Isometric exercises using Hand grip and elastic bands|"Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.~Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
124494|NCT03213743|Drug|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
124495|NCT03213730|Other|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
124496|NCT03213730|Other|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
124497|NCT03213717|Other|Heavy Casall HIT weight vest|A weight west with a weight of 10 % compared to the study subject
124498|NCT03213717|Behavioral|Standing|Study subjects will be standing for at least 50 minutes every hour
124499|NCT03213717|Dietary Supplement|Water load|Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
124500|NCT03213717|Behavioral|Sitting|Study subjects will be sitting for at least 50 minutes of every hour
124501|NCT03213717|Other|Light Casall HIT weight vest|A weight west with a weight of 1 % compared to the study subject
124502|NCT03213704|Drug|Larotrectinib|Given PO or via nasogastric- or gastric-tube
124503|NCT03213704|Drug|Larotrectinib Sulfate|Given PO or via nasogastric- or gastric-tube
124504|NCT03213691|Other|Laboratory Biomarker Analysis|Correlative studies
124505|NCT03213691|Drug|Selumetinib|Given PO
124506|NCT03213691|Drug|Selumetinib Sulfate|Given PO
124507|NCT03213678|Other|Laboratory Biomarker Analysis|Correlative studies
124508|NCT03213678|Other|Pharmacological Study|Correlative studies
124509|NCT03213678|Drug|Samotolisib|Given PO
124519|NCT03213613|Behavioral|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
124520|NCT03213613|Behavioral|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move an object to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
124521|NCT03213613|Behavioral|Low-dose Adaptive Attention Training|Participants in the low-dose training group will play a reduced number of sessions as the Adaptive Attention Training group. Specifically, they will train for two 30-minute sessions at the start and middle of a six-week period. To balance expectations of potential benefits, this group will receive identical recruitment and experimental instructions as the adaptive attention training group.
124522|NCT03213600|Device|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
124523|NCT03213587|Drug|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
124524|NCT03213574|Other|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
124525|NCT03213574|Other|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
124526|NCT03213561|Device|Stable and Independent Brain-computer Interfaces for Communication|"The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals."
124527|NCT03213548|Procedure|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
124528|NCT03213548|Procedure|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
124529|NCT03213522|Procedure|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
124530|NCT03213522|Procedure|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
124531|NCT03213509|Other|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
124532|NCT03213496|Behavioral|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
124533|NCT03213496|Other|Conventional care|Patient do not walk before surgery
124534|NCT03213483|Procedure|Coronally advanced flap and subepithelial connective tissue graft|The connective tissue graft is obtained by a single line incision from the palate.
124535|NCT03213483|Procedure|Coronally advanced flap and deepithelialized free gingival graft|The connective tissue graft is obtained by deepithelialization of a free gingival graft.
124536|NCT03213470|Other|magnetic resonance imaging|
124537|NCT03213457|Drug|Estradiol/Norethindrone Acetate|Capsules
124538|NCT03213457|Other|Placebo for Elagolix|Tablet
124539|NCT03213457|Drug|Elagolix|Tablet
124540|NCT03213457|Other|Placebo for E2/NETA|Capsules
124541|NCT03213444|Drug|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
124542|NCT03213444|Drug|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
124543|NCT03213418|Behavioral|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
124544|NCT03213405|Biological|rBCG-N-hRSV 1/100|5x10^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
124547|NCT03213405|Biological|Conventional BCG full dose|5x10^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
124548|NCT03213392|Drug|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
124549|NCT03213379|Device|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
124550|NCT03213366|Behavioral|E-PrEP- Peer-Led Intervention about PrEP|Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
124551|NCT03213366|Behavioral|BxNow - General Health Campaign|BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
124552|NCT03213353|Drug|Tablet paracetamol, guaifenesin and phenylephrine HCL|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
124553|NCT03213353|Drug|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
124554|NCT03213340|Other|Catechin Cohort 1|- 4 capsules taken with water 1 hour prior to meal
124555|NCT03213340|Other|Curcuminoid Cohort 2|- 2 capsules taken with water 1 hour prior to meal
124556|NCT03213340|Other|Flavonoid Cohort 3|- ~ 1 oz. serving consumed 30 minutes before meal
124557|NCT03213327|Device|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
124558|NCT03213314|Diagnostic Test|Multiparameter magnetic resonance imaging|LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
124559|NCT03213301|Drug|Lurbinectedin|3.2 mg/m2 i.v. every 3 weeks
124560|NCT03213288|Dietary Supplement|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
124561|NCT03213288|Dietary Supplement|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
124562|NCT03213288|Dietary Supplement|Placebo|No anthocyanins
124563|NCT03213275|Other|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
124564|NCT03213249|Other|Normal saline|Intraoperative pocket irrigation with normal saline
124565|NCT03213249|Drug|Cefazolin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
124566|NCT03213249|Procedure|Skin biopsy|Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
124567|NCT03213249|Procedure|Bilateral skin- or nipple-sparing mastectomies|Standard of care
124568|NCT03213249|Device|Tissue expander|Standard of care
124569|NCT03213249|Device|Breast implant|"Standard of care~Either breast implant or autologous flap"
124570|NCT03213249|Procedure|Autologous flap|"Standard of care~Either breast implant or autologous flap"
124571|NCT03213249|Other|Acellular dermal matrix sling|Standard of care
124572|NCT03213249|Drug|Gentamicin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
124573|NCT03213249|Drug|Bacitracin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
124574|NCT03213236|Diagnostic Test|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
124575|NCT03213210|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
124576|NCT03213197|Other|CPR video|Patient watches a short CPR video
124577|NCT03213171|Behavioral|Reception staff providing handout.|Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
124578|NCT03213171|Behavioral|Mobile Tablet (e.g. iPad)|Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
124579|NCT03213158|Drug|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle for 12 months.
124580|NCT03213145|Drug|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
124581|NCT03213145|Drug|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
124582|NCT03213145|Drug|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
124583|NCT03213132|Behavioral|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
124584|NCT03213132|Behavioral|Patient Education|Educational website containing information on insomnia
124611|NCT03212924|Behavioral|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
124585|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
124586|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
124587|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
124588|NCT03213106|Device|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
124589|NCT03213106|Device|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
124590|NCT03213093|Other|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
124591|NCT03213080|Device|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
124592|NCT03213054|Biological|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
124593|NCT03213054|Radiation|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
124594|NCT03213041|Drug|Carboplatin|Given IV
124595|NCT03213041|Other|Laboratory Biomarker Analysis|Correlative studies
124596|NCT03213041|Biological|Pembrolizumab|Given IV
124597|NCT03213028|Other|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
124598|NCT03213015|Diagnostic Test|Ankle dorsiflexion measurement|It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
124599|NCT03213002|Drug|Capecitabine|Capecitabine at 1500 mg/m2
124600|NCT03213002|Drug|Temozolomide|Temozolomide at 150 mg/m2 - 200 mg/m2
124601|NCT03212989|Drug|Vorinostat|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
124602|NCT03212989|Biological|HXTC|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
124603|NCT03212976|Procedure|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
124604|NCT03212963|Drug|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
124605|NCT03212950|Drug|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
124606|NCT03212950|Drug|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
124607|NCT03212937|Drug|Selinexor|Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity
124608|NCT03212937|Drug|ICE Chemotherapy|"IV Ifosfamide 5g/m^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle~IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle~IV Etoposide 100 mg/m^2 on Days 1-3 of each 21-day cycle"
124609|NCT03212924|Behavioral|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
124610|NCT03212924|Behavioral|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
124637|NCT03212716|Drug|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
124638|NCT03212716|Drug|Diltiazem|60 mgx3 per day during 10 days.
124639|NCT03212716|Drug|Placebos|Placebo of diltiazem
124612|NCT03212924|Behavioral|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
124613|NCT03212924|Behavioral|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
124614|NCT03212924|Behavioral|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
124615|NCT03212911|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
124616|NCT03212898|Other|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
124617|NCT03212885|Device|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
124618|NCT03212872|Diagnostic Test|Endoscopy|
124619|NCT03212859|Behavioral|Coach2Move|"Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:~Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.~Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.~The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.~In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions."
124620|NCT03212859|Behavioral|Usual Care|"Usual care physiotherapy among older adults:~Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.~Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)~Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.~Collaborate with other disciplines in a multidisciplinary context."
124621|NCT03212846|Other|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
124622|NCT03212833|Diagnostic Test|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
124623|NCT03212820|Procedure|Drilling at low speed|
124624|NCT03212820|Procedure|Drilling at conventional or high speed|
124625|NCT03212807|Drug|Durvalumab|Investigational Medicinal Product
124626|NCT03212807|Drug|Lenalidomide|Investigational Medicinal Product
124627|NCT03212794|Behavioral|Recovery coach|The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
124628|NCT03212781|Drug|Iron dextran|total dose infusion
124629|NCT03212781|Drug|Ferrous Fumarate|oral tablets
124630|NCT03212768|Procedure|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
124631|NCT03212755|Diagnostic Test|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
124632|NCT03212742|Drug|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
124633|NCT03212742|Drug|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
124634|NCT03212742|Radiation|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
124635|NCT03212729|Radiation|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
124636|NCT03212729|Procedure|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
124640|NCT03212703|Behavioral|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
124641|NCT03212703|Other|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
124642|NCT03212690|Drug|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
124643|NCT03212690|Procedure|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
124644|NCT03212677|Dietary Supplement|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
124645|NCT03212677|Dietary Supplement|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
124646|NCT03212677|Dietary Supplement|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
124647|NCT03212677|Other|Placebo|Cornstarch
124648|NCT03212664|Other|exercise|physical therapy exercises
124649|NCT03212651|Drug|Pembrolizumab|Pembrolizumab 200mg IV infusion
124650|NCT03212638|Drug|Baricitinib suspension|Administered orally
124651|NCT03212638|Drug|Baricitinib tablet|Administered orally
124652|NCT03212625|Drug|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
124653|NCT03212625|Drug|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
124654|NCT03212612|Diagnostic Test|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
124655|NCT03212599|Drug|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
124656|NCT03212586|Drug|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
124657|NCT03212586|Drug|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
124658|NCT03212573|Combination Product|ERAS protocol|ERAS protocol includes early oral intake and deambulation and multimodal analgesia
124659|NCT03212573|Combination Product|Standard care|Oral intake and deambulation 24h after surgery and only intravenous analgesia.
124660|NCT03212547|Behavioral|Verbal Intervention|"Promotion of verbal interventions:~Detecting whether the infant has social withdrawal.~The physician will verbally intervene.~Positive response (+) from the infant, the evaluator will point out this to the parents.~Negative response (-) from the infant, the evaluator will include the parents in the interaction.~If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.~If the infant does not establish positive contact (-)with the parents, repeat step 2.~If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.~At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
124661|NCT03212534|Other|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
124662|NCT03212521|Drug|Glecaprevir/Pibrentasvir|Glecaprevir/pibrentasvir 100 mg/40 mg co-formulated tablets taken orally as 3 tablets once a day.
124663|NCT03212508|Device|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
124664|NCT03212495|Drug|dexamedetomidine|intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
124665|NCT03212495|Drug|neostigmine|intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
124666|NCT03212469|Drug|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses~Safety run of the triple combination:~Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
124667|NCT03212469|Drug|Tremelimumab|"Preliminary steps : Safety Runs~Safety run of the triple combination:~Tremelimumab at 75mg/Q4W for up to 4 doses~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
124668|NCT03212469|Radiation|SBRT|"Preliminary steps : Safety Runs~Safety run of the dual combination:~SBRT at C1D15.~Safety run of the triple combination:~SBRT at C1D15.~Efficacy step~Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with~SBRT at C1D15, then~Durvalumab Q4W alone for up to 9 additional doses"
124669|NCT03212456|Drug|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
124670|NCT03212456|Drug|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
124671|NCT03212456|Procedure|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
124672|NCT03212456|Procedure|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
124673|NCT03212443|Procedure|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
124674|NCT03212443|Procedure|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
124675|NCT03212430|Drug|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
124676|NCT03212417|Other|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
124677|NCT03212404|Drug|CK-301 (cosibelimab)|CK-301 will be administered in periods of 28-day cycles.
124678|NCT03212391|Behavioral|Diet|52 weeks of Diet supervised by a dietician
124679|NCT03212391|Behavioral|Walking|26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
124680|NCT03212391|Behavioral|Nordic Walking|26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
124681|NCT03212378|Other|percutaneous coronary interventions|Percutaneous coronary intervention.
124682|NCT03212365|Drug|Fixed dose|Participants will receive 40 mg enoxaparin twice daily
124683|NCT03212365|Drug|Variable dose|Participants will receive 0.5mg/kg enoxaparin twice daily
124684|NCT03212352|Drug|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
124685|NCT03212352|Drug|Misoprostol|Regular treatment with Misoprostol 800 mcg.
124686|NCT03212339|Other|Therapeutic intervention|Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
124687|NCT03212326|Drug|Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]|Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
124688|NCT03212313|Drug|Tozadenant|Two 60 mg tablets for a total single study dose of 120 mg
124689|NCT03212300|Behavioral|Aerobic Exercise Training (AET)|20 sessions of AET over a 4 week period just prior to surgery
124690|NCT03212274|Drug|Olaparib|Given PO
124691|NCT03212261|Behavioral|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
124692|NCT03212248|Diagnostic Test|Thoracic Ultrasound (TUS)|
124693|NCT03212235|Radiation|Hypofractionated radiation therapy|Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
124694|NCT03212222|Other|Peek Acuity|Cell phone application for visual acuity screening
124695|NCT03212222|Other|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
124696|NCT03212209|Device|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
124697|NCT03212196|Procedure|Pancreaticogastrostomy with external drain|"Pancreatico-enteric anastomosis is provided according to the Bassi technique, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct."
124698|NCT03212196|Procedure|Pancreaticojejunostomy with transanastomotic drain|Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
124699|NCT03212183|Behavioral|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
124700|NCT03212183|Other|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
124701|NCT03212170|Drug|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
124702|NCT03212157|Other|Glucose infusion|Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
124703|NCT03212157|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
124704|NCT03212157|Diagnostic Test|FDG PET|FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
124705|NCT03212144|Other|High Intensity Interval Training|Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
124706|NCT03212144|Other|Peanut Consumption|Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
124707|NCT03212131|Drug|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
124708|NCT03212118|Behavioral|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
125447|NCT03206021|Drug|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
124709|NCT03212118|Behavioral|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
124710|NCT03212118|Behavioral|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
124711|NCT03212105|Behavioral|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
124712|NCT03212105|Other|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
124713|NCT03212092|Dietary Supplement|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
124714|NCT03212092|Dietary Supplement|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
124715|NCT03212079|Behavioral|Mycoach Smart Text|Personalized text messages to you cellphone to help you become more active
124716|NCT03212079|Behavioral|MyCoach on Amazon Alexa|This is an intelligent voice that you can communicate with via Amazon echo speaker
124717|NCT03212066|Behavioral|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
124718|NCT03212053|Biological|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
124719|NCT03212040|Diagnostic Test|needle biopsy|breast biopsy using different needle gauges
124720|NCT03212014|Other|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
124721|NCT03212014|Other|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
124722|NCT03212014|Other|Traditional rehabilitation|traditional exercise models in currently clinical use
124723|NCT03211988|Drug|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
124724|NCT03211975|Other|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
124725|NCT03211962|Other|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
124726|NCT03211949|Procedure|axillary block|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
124727|NCT03211949|Drug|Scandicaine|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
124728|NCT03211936|Procedure|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
124729|NCT03211936|Device|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
124730|NCT03211936|Device|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
124731|NCT03211936|Other|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
124732|NCT03211936|Other|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
124733|NCT03211923|Diagnostic Test|Transcranial magnetic stimulation (TMS)|Single pulse, monophasic transcranial magnetic stimulation
124734|NCT03211910|Device|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
124735|NCT03211910|Other|Standard Care of Treatment|Standard Care of Treatment
124736|NCT03211897|Drug|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
124737|NCT03211897|Drug|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
124738|NCT03211897|Drug|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
124739|NCT03211897|Drug|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
124771|NCT03211585|Device|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
124740|NCT03211884|Other|Problem-solving therapy|"PST consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet & greet session, participants will receive written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7 steps to solve at least one problem together before ending the training. Participants will keep a record of their problem-solving efforts between sessions and questions they have related to the application of PST. These records will be used as a basis for discussion during the intervention."
124741|NCT03211871|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
124742|NCT03211871|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
124743|NCT03211858|Drug|Insulin Lispro|SAR341402 100 units per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour postprandial plasma glucose (PPG < 10 millimolar/Liter [mmol/L] [<180 milligram/deciLiter {mg/dL}]) while avoiding hypoglycemia.
124744|NCT03211858|Drug|Novolog/Novorapid|NovoLog/NovoRapid 100 U/mL (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour postprandial plasma glucose (PPG < 10 mmol/L [<180 mg/dL]) while avoiding hypoglycemia.
124745|NCT03211858|Drug|Insulin glargine (HOE901)|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
124746|NCT03211845|Other|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
124747|NCT03211832|Other|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
124748|NCT03211819|Procedure|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.~After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
124749|NCT03211806|Behavioral|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
124750|NCT03211806|Device|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
124751|NCT03211793|Drug|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
124752|NCT03211793|Other|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
124753|NCT03211780|Device|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
124754|NCT03211767|Dietary Supplement|Aged garlic extract|Each capsule contains 600mg of aged garlic extract powder
124755|NCT03211767|Dietary Supplement|Placebo|Each capsule contains cellulose as a filler.
124756|NCT03211754|Dietary Supplement|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
124757|NCT03211741|Drug|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
124758|NCT03211728|Drug|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
124759|NCT03211728|Drug|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
124760|NCT03211715|Other|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
124761|NCT03211689|Other|Exercise Program|Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
124762|NCT03211676|Device|Theranova-500 dialyzer|hemodialysis with Theranova-500 dialyzer.
124763|NCT03211676|Device|Elisio-21H|hemodialysis with Elisio-21H dialyzer
124764|NCT03211663|Device|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
124765|NCT03211650|Drug|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
124766|NCT03211650|Drug|hyaluronic acid|Intra-articular injections of hyaluronic acid
124767|NCT03211650|Drug|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
124768|NCT03211637|Combination Product|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
124769|NCT03211611|Behavioral|Questionnaire given to the two groups|"Questionnaire given to the two groups :~Patients with BRCA ½ mutation GP"
124770|NCT03211598|Procedure|TACE with Surefire|Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
124772|NCT03211572|Drug|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
124773|NCT03211559|Other|Exercise|
125448|NCT03206008|Drug|Magnesium Sulfate|
124774|NCT03211546|Procedure|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
124775|NCT03211546|Procedure|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
124776|NCT03211507|Other|Computer-assisted telephone interview|Occupational history
124777|NCT03211507|Genetic|Genetic analysis|To include analysis of known susceptibility markers
124778|NCT03211494|Device|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
124779|NCT03211494|Other|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
124780|NCT03211468|Behavioral|Clinical intervention program to prevent eating disorders|See previous
124781|NCT03211455|Drug|Lidocaine|intravenous lidocaine versus placebo
124782|NCT03211455|Drug|isotonic saline|intravenous isotonic saline
124783|NCT03211442|Radiation|Radiotherapy|Breast cancer patients treated with radiotherapy
124784|NCT03211429|Behavioral|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
124785|NCT03211429|Other|Tai chi|Tai Chi training in the Yang style of 24 movement
124786|NCT03211429|Other|Postural control exercise|Individually adjusted progressive and specific postural control training,
124787|NCT03211416|Other|Laboratory Biomarker Analysis|Correlative studies
124788|NCT03211416|Biological|Pembrolizumab|Given IV
124789|NCT03211416|Drug|Sorafenib Tosylate|Given PO
124790|NCT03211403|Drug|SHR4640|SHR4640 or placebo once daily for a week
124791|NCT03211390|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
124792|NCT03211390|Diagnostic Test|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
124793|NCT03211364|Other|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
124794|NCT03211364|Other|Scapular mobilization|
124795|NCT03211351|Drug|Liposic|one eye of the participant recieved Lipoic
124796|NCT03211351|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
124797|NCT03211338|Biological|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
124798|NCT03211338|Biological|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
124799|NCT03211338|Biological|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
124800|NCT03211325|Procedure|Biopsy|
124801|NCT03211286|Drug|Tranexamic Acid|1 g of intravenous tranexamic acid in 100 mL of saline solution
124802|NCT03211286|Drug|Saline Solution|saline solution 100 mL intravenous
124803|NCT03211260|Device|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
124804|NCT03211247|Biological|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
124805|NCT03211247|Biological|Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
124806|NCT03211247|Biological|Placebo|Placebo patch, once daily
124807|NCT03211234|Drug|DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
124808|NCT03211234|Drug|DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
124809|NCT03211234|Drug|Lucentis|Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
124810|NCT03211221|Device|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies < or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
124811|NCT03211195|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
124812|NCT03211182|Behavioral|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
124813|NCT03211169|Procedure|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
124814|NCT03211169|Procedure|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
124815|NCT03211156|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
124816|NCT03211156|Other|Placebo|Placebo
124817|NCT03211143|Drug|CKD-381|Test drug: CKD-381
124818|NCT03211143|Drug|Nexium|Reference drug: Nexium
124819|NCT03211130|Behavioral|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
124820|NCT03211130|Behavioral|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
124821|NCT03211117|Drug|Docetaxel|Given IV
124822|NCT03211117|Drug|Doxorubicin Hydrochloride|Given IV
124823|NCT03211117|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
124824|NCT03211117|Other|Laboratory Biomarker Analysis|Correlative studies
124825|NCT03211117|Biological|Pembrolizumab|Given IV
124826|NCT03211117|Procedure|Therapeutic Conventional Surgery|Undergo surgery
124827|NCT03211104|Dietary Supplement|curcumin|
124828|NCT03211104|Dietary Supplement|Placebo|
124829|NCT03211078|Procedure|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
124830|NCT03211065|Drug|20% subcutaneous immunoglobulin|Subcutaneous Immunoglobulin
124831|NCT03211052|Drug|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
124832|NCT03211052|Procedure|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
124833|NCT03211039|Genetic|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
124834|NCT03211026|Other|No intervention|No intervention
124835|NCT03211013|Drug|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
124836|NCT03211013|Drug|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
124837|NCT03210987|Procedure|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
124838|NCT03210987|Procedure|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
124839|NCT03210961|Drug|PF-06826647 tablet|PF-06826647 tablet for oral administration
124840|NCT03210961|Drug|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
124841|NCT03210961|Other|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
124842|NCT03210961|Other|Placebo tablet|Matching placebo tablet
124843|NCT03210948|Device|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
124844|NCT03210948|Device|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
124845|NCT03210922|Device|Miami cervical collar|Collar group is put on the Miami cervical collar.
124846|NCT03210909|Drug|BMS-986231|BMS-986231
124847|NCT03210896|Dietary Supplement|Orange juice|Sub group I will drink Orange juice and have repeat measures.
124848|NCT03210870|Behavioral|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
124849|NCT03210857|Other|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.~As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
124850|NCT03210844|Procedure|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
124851|NCT03210818|Device|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
124852|NCT03210805|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
124853|NCT03210792|Device|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
124854|NCT03210779|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
124855|NCT03210779|Dietary Supplement|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
124856|NCT03210766|Drug|Nabilone|
124857|NCT03210766|Drug|THC/CBD|
124858|NCT03210740|Drug|AM001 Cream, 7.5%|Active Cream
124859|NCT03210740|Drug|Vehicle Cream|Placeo
124898|NCT03210376|Drug|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
124899|NCT03210376|Drug|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
124900|NCT03210376|Behavioral|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
124901|NCT03210363|Other|Human Biological samples|Blood sample
124860|NCT03210727|Behavioral|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
124861|NCT03210714|Drug|Erdafitinib|Given PO
124862|NCT03210714|Other|Laboratory Biomarker Analysis|Correlative studies
124863|NCT03210714|Other|Pharmacological Study|Correlative studies
124864|NCT03210701|Other|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
124865|NCT03210688|Drug|Prednisolone|Tablet prednisolone
124866|NCT03210688|Drug|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
124867|NCT03210675|Diagnostic Test|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
124868|NCT03210662|Radiation|External Beam Radiation Therapy|Undergo EBRT
124869|NCT03210662|Biological|Pembrolizumab|Given IV
124870|NCT03210649|Drug|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1~D14
124871|NCT03210649|Drug|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1~D14
124872|NCT03210636|Device|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
124873|NCT03210623|Device|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
124874|NCT03210623|Device|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
124875|NCT03210610|Diagnostic Test|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
124876|NCT03210597|Other|Exercise|The subjects performed training in aquatic environment
124877|NCT03210571|Device|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
124878|NCT03210558|Drug|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
124879|NCT03210558|Drug|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
124880|NCT03210545|Drug|Dexamethasone|A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid dexamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
124881|NCT03210532|Drug|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
124882|NCT03210532|Drug|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
124883|NCT03210532|Drug|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
124884|NCT03210519|Dietary Supplement|Eleutherococcus senticosus|taken orally once/day for 90 days
124885|NCT03210519|Other|Placebo|taken orally once/day for 90 days
124886|NCT03210506|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
124887|NCT03210493|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
124888|NCT03210480|Drug|Lithium sulphate prolonged-release 660 mg|Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
124889|NCT03210480|Drug|Lithium carbonate immediate-release 150 mg and 300 mg|Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
124890|NCT03210454|Other|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
124891|NCT03210454|Other|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
124892|NCT03210415|Other|Observational Study Model|There is no intervention for the study.
124893|NCT03210402|Device|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
124894|NCT03210402|Device|Elevated night pacing off|Device will be programmed to normal lower rates
124895|NCT03210389|Drug|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
124896|NCT03210376|Drug|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
124897|NCT03210376|Drug|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
124902|NCT03210350|Diagnostic Test|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
124903|NCT03210337|Drug|A-101 Topical Solution|A-101 Topical Solution
124904|NCT03210337|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
124905|NCT03210324|Drug|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
124906|NCT03210311|Device|compression|a compression stocking is worn, a garment compression class 2, flat knitted
124907|NCT03210298|Combination Product|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
124908|NCT03210285|Diagnostic Test|Whole exome sequencing|Whole exome sequencing
124909|NCT03210272|Drug|Placebo|Tablet
124910|NCT03210272|Drug|BI 1358894|Tablet
124911|NCT03210272|Drug|BI 1358894 (Test)|Fasting state
124912|NCT03210272|Drug|BI 1358894 (Reference)|Fed state
124913|NCT03210259|Drug|Humira®|Duration - 58 weeks
124914|NCT03210259|Drug|BI 695501|Duration - 58 weeks
124915|NCT03210246|Drug|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
124916|NCT03210246|Drug|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
124917|NCT03210246|Drug|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
124918|NCT03210246|Drug|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
124919|NCT03210233|Procedure|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
124920|NCT03210220|Procedure|Pecs II block|After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
124921|NCT03210207|Procedure|GASTROPLICATURE|All procedures were performed by a single surgeon. All patients underwent 2-row gastric plication. Dissection was started at the greater curvature of the stomach in contact to the gastric wall from prepyloric area to 2-cm proximal to the Hiss angle preserving the anatomy of Hiss angle. All vessels along the greater curvature were separated using LigaSure (Covidien, Mansfield, MA, USA). The greater curvature (from the perimeter) was invaginated using 2 rows of 00 prolene or 00 nylon sutures. Two layers of plication were performed with continuous sutures with 1 surgical sting in all patients to prevent any displacement of inverted folds such as eversion outside or intussusception into esophagus or pylorus. All sutures were extramucusal to avoid their absorption by gastric acid. Finally, a tube shaped stomach was achieved in which the greater curvature was inverted in to the stomach.
124922|NCT03210194|Behavioral|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
124923|NCT03210194|Behavioral|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
124924|NCT03210181|Other|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
124925|NCT03210181|Other|Placebo|Patients will receive an equivalent volume of normal saline
124926|NCT03210168|Other|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
124927|NCT03210155|Device|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
124928|NCT03210155|Device|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
124929|NCT03210142|Procedure|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
124930|NCT03210129|Behavioral|Motivational interviewing|"the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.~Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle."
124931|NCT03210103|Radiation|Radiation|Standard of Care: Radiation +/- Chemotherapy
124932|NCT03210103|Procedure|Transoral Surgery (TOS) + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection (plus radiation, if required)
124933|NCT03210077|Device|Monitoring|Monitoring
124934|NCT03210064|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
124935|NCT03210064|Drug|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
124936|NCT03210051|Device|Remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
124937|NCT03210051|Procedure|Endovascular treatment|Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
124938|NCT03210038|Drug|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
124939|NCT03210038|Drug|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
124940|NCT03210025|Drug|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
124941|NCT03210025|Drug|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
124942|NCT03210012|Diagnostic Test|Transthoracic echocardiography|Diagnostic test done prior and after the dive
124943|NCT03210012|Diagnostic Test|Blood samples|Diagnostic test done prior and after the dive
124944|NCT03209986|Procedure|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
124945|NCT03209986|Other|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
124946|NCT03209973|Drug|Tislelizumab (BGB-A317)|Tislelizumab (BGB-A317) 200 mg intravenously (IV) every-3-weeks (Q3W)
124947|NCT03209960|Diagnostic Test|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
124948|NCT03209960|Other|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
124949|NCT03209947|Diagnostic Test|Ulnar nerve Ultrasound|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
124950|NCT03209908|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
124951|NCT03209895|Dietary Supplement|Joint Health Product|Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
124952|NCT03209895|Dietary Supplement|Placebo|Palm oil Softgel capsule
124953|NCT03209895|Dietary Supplement|Glucosamine / Chondroitin|Glucosamine 1500 mg, Chondroitin 1200 mg per day
124954|NCT03209882|Device|TILS|Continuous-wave laser of a specific wavelength (1064 nm) that will be directed to the right forehead. The laser diode is supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
124955|NCT03209882|Device|sham|Same aperture of CG-5000 laser (HD Laser Center, Dallas, TX, USA), but the laser power will be turned to be 0 Watts.
124956|NCT03209869|Biological|Ex vivo Expanded and Activated Haploidentical Donor NK Cells|Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.
124957|NCT03209869|Biological|Hu14.18-IL2|The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
124958|NCT03209856|Drug|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
124959|NCT03209843|Procedure|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
124960|NCT03209830|Drug|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
124961|NCT03209830|Drug|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
124962|NCT03209817|Dietary Supplement|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
124963|NCT03209817|Dietary Supplement|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
124964|NCT03209804|Procedure|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
124965|NCT03209791|Other|Biopsies|Biopsy will be done on the Vastus Lateralis muscle in all groups
124966|NCT03209778|Other|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
124967|NCT03209765|Other|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
124968|NCT03209739|Other|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
124969|NCT03209713|Behavioral|HPV Vaccine Education|A one on one twenty-minute parental educational program providing facts about HPV, HPV-related cancers, and the HPV vaccine.
125449|NCT03206008|Drug|Normal saline|Placebo
124970|NCT03209713|Behavioral|Text Messaging Reminder|Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session. All participants randomized to the text message reminder arm will receive a welcome text message from the automated web-based text messaging service, Mosio, within 72 hours from registration. One week after receiving the welcome text message, they will receive the first weekly text messages reminding them of their child's eligibility for the first dose HPV vaccine. These weekly reminders will occur until uptake of the first dose of the vaccine is reported (through self-report outcome survey completion or submission of the HPV vaccination card/child's official immunization card) or for up to 12 weeks
124971|NCT03209700|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
124972|NCT03209687|Drug|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
124973|NCT03209674|Procedure|Cardiothoracic surgery|Cardiac or thoracic procedure
124974|NCT03209661|Drug|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
124975|NCT03209661|Drug|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
124976|NCT03209661|Drug|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
124977|NCT03209648|Drug|Debio 1450|Debio 1450, 40 mg capsule.
124978|NCT03209648|Drug|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
124979|NCT03209635|Dietary Supplement|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
124980|NCT03209635|Dietary Supplement|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
124981|NCT03209622|Procedure|Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge|when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
124982|NCT03209622|Drug|Nicotine patch|Arm A
124983|NCT03209622|Other|the external consultation|without patch
124984|NCT03209609|Device|VEST|External support for vein grafts, cobalt chrome braid
124985|NCT03209609|Procedure|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
124986|NCT03209596|Dietary Supplement|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
124987|NCT03209596|Dietary Supplement|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
124988|NCT03209583|Device|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
124989|NCT03209570|Other|Care planning using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
124990|NCT03209570|Other|Care planning without using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
124991|NCT03209557|Other|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
124992|NCT03209544|Behavioral|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, & Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
124993|NCT03209531|Behavioral|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
124994|NCT03209531|Behavioral|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
124995|NCT03209531|Device|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
124996|NCT03209518|Drug|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
124997|NCT03209505|Device|Acuvue Oasys|FDA approved contact lens, fit for daily wear
124998|NCT03209505|Device|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
124999|NCT03209492|Drug|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
125000|NCT03209479|Drug|Glatiramer acetate|Copaxone subcutaneous injection syringe
125001|NCT03209466|Drug|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
125002|NCT03209466|Drug|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
125041|NCT03209154|Device|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
125003|NCT03209453|Other|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
125004|NCT03209440|Behavioral|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
125005|NCT03209440|Behavioral|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
125006|NCT03209440|Behavioral|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
125007|NCT03209427|Drug|Morphine 100 μg|Intrathecal injection of morphine100 μg
125008|NCT03209427|Drug|Morphine 200 μg|Intrathecal injection of morphine 200 μg
125009|NCT03209401|Drug|Niraparib|an oral PARP inhibitor
125010|NCT03209401|Drug|Carboplatin|a platinum-based injection
125011|NCT03209362|Combination Product|SI-613|SI-613 will be repeated intra-articularly administered.
125012|NCT03209362|Combination Product|Placebo|Placebo will be repeated intra-articularly administered.
125013|NCT03209349|Procedure|Water Exchange Sigmoidoscopy|See arm description.
125014|NCT03209349|Procedure|Air Insufflation Sigmoidoscopy|See arm description.
125015|NCT03209336|Radiation|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
125016|NCT03209323|Device|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
125017|NCT03209323|Device|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
125018|NCT03209323|Device|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
125019|NCT03209323|Device|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
125020|NCT03209297|Other|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
125021|NCT03209284|Procedure|transcrestal sinus floor elevation|augmentation procedure with xenograft
125022|NCT03209271|Drug|Ringer's Acetate (warm)|Body temperature fluid
125023|NCT03209271|Drug|Ringer's Acetate (cold)|Room temperature fluid
125024|NCT03209258|Other|Care bundle of active management|"Intensive BP lowering to systolic target of <140mmHg;~Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;~Treatment of pyrexia to a target body temperature ≤37.5 ℃;~Reversal of anticoagulation to target INR <1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).~As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
125025|NCT03209258|Other|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
125026|NCT03209245|Biological|Purethal Mites|perennial allergren specific immunotherapy during 24 months
125027|NCT03209245|Other|placebo injection|perrenial injection wich were administered in same protocol as Purethal
125028|NCT03209245|Diagnostic Test|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
125029|NCT03209245|Diagnostic Test|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
125030|NCT03209232|Drug|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
125031|NCT03209219|Drug|Interferon Alfa-2A|3×10^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
125032|NCT03209219|Drug|Cyclosporine Pill|100mg， oral, bid
125033|NCT03209206|Drug|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
125034|NCT03209206|Drug|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
125035|NCT03209193|Drug|Sevoflurane|Sevoflurane use as main anesthetic drug during the surgery
125036|NCT03209193|Drug|Desflurane|Desflurane use as main anesthetic drug during the surgery
125037|NCT03209180|Drug|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
125038|NCT03209180|Drug|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
125039|NCT03209167|Behavioral|Questionnaire|Two study-specific questionnaires
125040|NCT03209154|Diagnostic Test|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
125042|NCT03209141|Diagnostic Test|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
125043|NCT03209128|Radiation|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
125044|NCT03209115|Drug|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
125045|NCT03209115|Drug|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
125046|NCT03209102|Other|Clinical assessment|"Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
125047|NCT03209102|Behavioral|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
125048|NCT03209102|Other|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
125049|NCT03209102|Biological|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
125050|NCT03209076|Procedure|Robotic|Robotic low anterior resection
125051|NCT03209076|Procedure|Laparoscopic|Laparoscopic low anterior resection
125052|NCT03209063|Diagnostic Test|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene mutation
125053|NCT03209050|Device|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
125054|NCT03209037|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
125055|NCT03209024|Other|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
125056|NCT03209024|Device|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
125057|NCT03209011|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
125058|NCT03208998|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
125059|NCT03208985|Drug|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
125060|NCT03208972|Drug|low dose hCG|
125061|NCT03208972|Drug|hp-FSH|
125062|NCT03208972|Drug|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.~<60 kg: Elonva 100 MCG > 60 kg: Elonva 150 MCG"
125063|NCT03208959|Drug|HTI-1090|IDO/TDO inhibitor
125064|NCT03208946|Other|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
125065|NCT03208946|Other|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
125066|NCT03208933|Drug|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
125067|NCT03208920|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
125068|NCT03208920|Other|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
125168|NCT03208075|Other|normal diet|Diet containing 1500mg of phosphorus
125169|NCT03208075|Other|low-phosphorus diet|Diet containing 500mg of phosphorus
125069|NCT03208907|Drug|CQ coadministered with PQ|115 subjects will be given 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
125070|NCT03208907|Drug|DHA-PQP coadministered with PQ|In this treatment group, others 115 subjects will take DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
125071|NCT03208907|Drug|CQ and PQ starting on Day 42|115 subjects will be given 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
125072|NCT03208907|Drug|DHA-PQP and PQ starting on Day 42|115 subjects will be given 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
125073|NCT03208894|Drug|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
125074|NCT03208881|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
125075|NCT03208868|Dietary Supplement|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
125076|NCT03208868|Dietary Supplement|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
125077|NCT03208855|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
125078|NCT03208842|Radiation|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity"
125079|NCT03208829|Other|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
125080|NCT03208829|Other|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
125081|NCT03208816|Behavioral|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
125082|NCT03208790|Drug|Thymoquinone 100mg|thymoquinone will be extracted from Nigella Sativa and packed in capsules of 100mg
125083|NCT03208790|Drug|thymoquinone 200mg|thymoquinone will be extracted from Nigella Sativa and packed in capsules of 200mg
125084|NCT03208790|Drug|Placebo oral capsule|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
125085|NCT03208777|Genetic|taking blood samples|taking blood samples and measure telomeric abnormalities
125086|NCT03208764|Drug|Nitric Oxide|Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
125087|NCT03208751|Behavioral|Exercise training|"Exercise intervention was divided into 3 phases:~Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).~Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
125088|NCT03208738|Behavioral|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
125089|NCT03208738|Behavioral|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
125090|NCT03208712|Drug|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
125091|NCT03208712|Drug|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
125092|NCT03208686|Behavioral|Intervention Group|A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology − a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
125093|NCT03208673|Device|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
125094|NCT03208660|Drug|Fycompa|Oral suspension
125095|NCT03208647|Other|AA or not|to study their risk factors
125096|NCT03208634|Device|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
125097|NCT03208608|Diagnostic Test|RBANS-H|The RBANS-H is a diagnostic cognitive test battery
125098|NCT03208595|Diagnostic Test|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
125099|NCT03208582|Drug|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
125100|NCT03208582|Dietary Supplement|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
125101|NCT03208556|Biological|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.~CAR T cell dose escalation: 1×10^5 /kg，1×10^6 /kg，3×10^6 /kg，and 6×10^6 CAR T cells/kg"
125170|NCT03208075|Other|high-phosphorus diet|Diet containing 2300mg of phosphorus
125102|NCT03208556|Drug|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
125103|NCT03208543|Device|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
125104|NCT03208530|Behavioral|Brief motivational interview intervention|A brief (<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
125105|NCT03208517|Other|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
125106|NCT03208504|Device|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
125107|NCT03208491|Other|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
125108|NCT03208491|Other|usual care|usual care of patient
125109|NCT03208478|Procedure|Adductor Canal perineural catheter placement|Patients will receive an Adductor Canal Block intervention for pain control following ACL reconstructive surgeries.
125110|NCT03208478|Procedure|Femoral Nerve perineural catheter placement|Patients will have a Femoral perineural catheter placed for pain control following ACL reconstructive surgery.
125111|NCT03208478|Device|Nimbus pump (Infutronix)|This is a FDA approved infusion device that is used in standard of care to store pain medication and to provide patients with continuous pain control medication at a set rate. This pump will be used for both the Adductor Canal and Femoral Nerve block participants.
125112|NCT03208465|Drug|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
125113|NCT03208465|Drug|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
125114|NCT03208452|Drug|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
125115|NCT03208452|Drug|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
125116|NCT03208439|Device|lower-limb cycling system|patients will receive 30-minute cycling exercise
125117|NCT03208426|Drug|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
125118|NCT03208426|Drug|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
125119|NCT03208426|Drug|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
125120|NCT03208426|Drug|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
125121|NCT03208426|Drug|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
125122|NCT03208426|Drug|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
125123|NCT03208426|Drug|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
125124|NCT03208426|Drug|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
125125|NCT03208413|Drug|Thalidomide|Thalidomide with a dosage of 25 mg at bedtime daily one week (days 1-7), then 50 mg at bedtime daily for one week (days 8-14), then 75 mg at bedtime daily for one week (days 15-21), then 100 mg at bedtime daily for 12 weeks (days 22-105), in the absence of unacceptable toxicity or severe deterioration.
125126|NCT03208400|Behavioral|virtual reality exposure|one-session exposure conveyed via virtual reality technology
125127|NCT03208387|Diagnostic Test|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
125128|NCT03208387|Diagnostic Test|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement). Neuroimaging data will be collected as soon as possible (can be the same day), for up to 6 weeks.
125129|NCT03208387|Behavioral|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
125130|NCT03208387|Behavioral|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
125131|NCT03208387|Behavioral|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
125132|NCT03208387|Behavioral|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
125133|NCT03208387|Behavioral|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
125134|NCT03208387|Diagnostic Test|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
125231|NCT03207607|Other|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
125135|NCT03208374|Behavioral|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the year prior to their most recent diagnosis they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
125136|NCT03208374|Behavioral|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
125137|NCT03208361|Drug|Penicillin V|
125138|NCT03208361|Drug|Amoxicillin|
125139|NCT03208348|Other|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
125140|NCT03208335|Drug|recombinant human endostatin|The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
125141|NCT03208322|Other|Non-Interventional|Non-Interventional
125142|NCT03208309|Drug|Diacerein|
125143|NCT03208309|Drug|Placebo|
125144|NCT03208296|Biological|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
125145|NCT03208283|Diagnostic Test|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
125146|NCT03208283|Diagnostic Test|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
125147|NCT03208270|Drug|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
125148|NCT03208270|Drug|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
125149|NCT03208257|Drug|Esmolol|Esmolol hydrochloride infusion
125150|NCT03208244|Drug|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
125151|NCT03208231|Biological|VRC01|40 mg/kg of VRC01 will be administered by subcutaneous injection.
125152|NCT03208231|Drug|Combination Antiretroviral Therapy (cART)|All infants will receive non-study provided cART. Each infant's cART regimen will be selected by his or her primary care provider and supplied through non-study sources (i.e., ARVs will not be provided through the study).
125153|NCT03208218|Drug|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
125154|NCT03208218|Drug|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
125155|NCT03208205|Procedure|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
125156|NCT03208192|Procedure|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
125157|NCT03208179|Drug|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
125158|NCT03208179|Drug|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
125159|NCT03208179|Drug|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
125160|NCT03208166|Device|Doctormate|Ischemic conditioning device
125161|NCT03208166|Other|Usual Care|Standard medical care
125162|NCT03208153|Procedure|Invasive|Coronary angiogram and revascularization if anatomically feasible
125163|NCT03208153|Procedure|Conservative|Conservative
125164|NCT03208127|Drug|Treatment with Direct Acting Antiviral tablet|HCV Treatment for 12 Weeks
125165|NCT03208114|Other|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
125166|NCT03208101|Biological|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
125167|NCT03208101|Biological|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
125171|NCT03208062|Other|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
125172|NCT03208049|Behavioral|Sleep Restriction Therapy|Sleep Restriction Therapy will regulate the time you spend in bed on the basis of information collected about your sleep from sleep diaries during the evaluation and during treatment. Sleep restriction therapy is designed to improve your sleep quality by matching the opportunity you give yourself for sleep to the amount of average sleep ability you exhibit on your sleep diaries. Once the quality of your sleep has improved then then sleep quantity is gradually increased by slowly increasing your sleep opportunity. Sleep restriction therapy will also attempt to strengthen your bed sleep connection by focusing on what activities you engage in when you are awake in the middle of the night.
125173|NCT03208049|Behavioral|Cognitive Therapy|Cognitive Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The treatment part of the study lasts six weeks. During the treatment, you will meet with the therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
125174|NCT03208036|Device|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
125175|NCT03208036|Device|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
125176|NCT03208023|Procedure|RESIPI Management Strategy|a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
125177|NCT03208023|Other|No intervention|No intervention
125178|NCT03208010|Behavioral|Diabetes Prevention Intervention|"Educational sessions with emphasis on physical activity, healthy diets, and strategies to promote behavioral change.~Specific goals set for weight loss and physical activities~Fitbits provided for monitoring physical activity goals~Weekly review of and feedback on effects of physical activity (Fitbits) & dietary changes (checklists)~14 bi-weekly support group sessions + 3 booster sessions every 6 months thereafter"
125179|NCT03208010|Other|Enhanced Usual Care|"Monitoring by existing personal physicians~Feedback on lab results~Referrals to physicians, if needed~Diabetes prevention educational materials"
125180|NCT03207997|Other|unenhanced MR sequences|2 additional unenhanced MR sequences
125181|NCT03207984|Procedure|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and MG
125182|NCT03207971|Procedure|Root coverage treatment with subepithelial connective tissue graft|Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
125183|NCT03207958|Drug|Belimumab|-Given over 1 hour
125184|NCT03207945|Drug|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
125185|NCT03207945|Other|Placebo|Placebo
125186|NCT03207932|Procedure|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
125187|NCT03207919|Behavioral|Lullaby Project|Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
125188|NCT03207906|Drug|VBP-926|Topical VBP-926 solution
125189|NCT03207893|Behavioral|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
125190|NCT03207893|Other|Routine Care|Subject's current t2d treatment
125191|NCT03207880|Device|Multi-level pregnancy test|Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
125192|NCT03207867|Drug|NIR178|NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.
125193|NCT03207867|Drug|PDR001|PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
125194|NCT03207854|Procedure|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
125195|NCT03207854|Other|Laboratory Biomarker Analysis|Correlative studies
125196|NCT03207854|Other|Questionnaire Administration|Ancillary studies
125197|NCT03207841|Other|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake.
125198|NCT03207828|Behavioral|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
125232|NCT03207607|Other|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
125233|NCT03207607|Other|Snack skipping|no snack
125199|NCT03207828|Other|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
125200|NCT03207815|Drug|Filgotinib|200 mg tablet(s) administered orally once daily
125201|NCT03207815|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
125202|NCT03207815|Drug|Prednisone|Tablet(s) administered orally once daily
125203|NCT03207802|Device|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
125204|NCT03207776|Other|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
125205|NCT03207776|Other|COPD Clinical Pathway|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
125206|NCT03207763|Device|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
125207|NCT03207763|Device|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
125208|NCT03207750|Biological|Rotarix|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
125209|NCT03207750|Biological|Pediarix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
125210|NCT03207750|Biological|Hiberix|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
125211|NCT03207750|Biological|Prevenar 13|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
125212|NCT03207737|Behavioral|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
125213|NCT03207737|Behavioral|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
125214|NCT03207724|Drug|Xilonix plus Onivyde and 5FU|Xilonix by IV
125215|NCT03207711|Behavioral|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
125216|NCT03207711|Behavioral|Mindfulness|Mindful eating app-use and instruction
125217|NCT03207698|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
125218|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
125219|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
125220|NCT03207685|Device|Additional Seizure Monitoring|Embrace could offer an additional layer of seizure monitoring
125221|NCT03207672|Drug|E7389-LF|intravenous infusion
125222|NCT03207659|Procedure|Basketing in RIRS|Treament of renal stones by fragmentation of stone under direct vision through a flexible ureteroscope and then actively extracting them using a basket
125223|NCT03207659|Procedure|Dusting in RIRS|Treament of renal stones by dusting the stone under direct vision through a scope and then leaving them to pass spontaneously
125224|NCT03207646|Other|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
125225|NCT03207633|Procedure|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
125226|NCT03207633|Procedure|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
125227|NCT03207633|Procedure|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
125228|NCT03207607|Other|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
125229|NCT03207607|Other|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
125230|NCT03207607|Other|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
125234|NCT03207594|Other|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
125235|NCT03207594|Other|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
125236|NCT03207594|Other|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
125237|NCT03207581|Behavioral|Professional Coaching|Professional, individualized coaching
125238|NCT03207568|Device|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
125239|NCT03207555|Drug|Ibrutinib|420 mg by mouth once daily.
125240|NCT03207542|Drug|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
125241|NCT03207529|Drug|Alpelisib|Given PO
125242|NCT03207529|Drug|Enzalutamide|Given PO
125243|NCT03207516|Dietary Supplement|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
125244|NCT03207516|Dietary Supplement|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
125245|NCT03207503|Procedure|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
125246|NCT03207490|Device|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
125247|NCT03207477|Diagnostic Test|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
125248|NCT03207464|Drug|[C-11]Methylreboxetine|8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a [C-11]MRB PET scan and a MRI scan.
125249|NCT03207451|Drug|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
125250|NCT03207451|Drug|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
125251|NCT03207451|Drug|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
125252|NCT03207451|Drug|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
125253|NCT03207438|Drug|Quetiapine 50 MG Extended Release Oral Tablet|OD
125254|NCT03207438|Drug|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
125255|NCT03207438|Drug|Placebos|Placebo
125256|NCT03207425|Drug|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
125257|NCT03207412|Biological|hAECs|human amniotic epithelial cells
125258|NCT03207412|Procedure|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
125259|NCT03207399|Drug|Epclusa|Patients will be treated with this drug for 12 weeks post lung transplant.
125260|NCT03207386|Behavioral|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
125261|NCT03207373|Diagnostic Test|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
125262|NCT03207360|Behavioral|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly videoconference-delivered sessions that will last between 45 and 60 minutes.
125263|NCT03207347|Drug|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
125264|NCT03207334|Drug|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase~Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant."
125265|NCT03207334|Drug|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.~Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
125266|NCT03207321|Dietary Supplement|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
125267|NCT03207308|Dietary Supplement|Vitamin A supplementation|200,000 IU of preformed vitamin A
125268|NCT03207295|Drug|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
125269|NCT03207295|Drug|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
125270|NCT03207269|Other|Dietary|Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
125271|NCT03207256|Drug|TGR-1202|Oral Daily TGR-1202
125272|NCT03207256|Drug|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
125273|NCT03207243|Drug|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
125274|NCT03207243|Drug|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
125275|NCT03207243|Drug|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
125276|NCT03207243|Drug|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
125277|NCT03207230|Device|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
125359|NCT03206671|Drug|Etoposide|see detailed protocol description
125360|NCT03206671|Drug|Ifosfamide|see detailed protocol description
125278|NCT03207230|Device|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
125279|NCT03207230|Device|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
125280|NCT03207217|Other|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
125281|NCT03207204|Procedure|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
125282|NCT03207204|Procedure|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
125283|NCT03207204|Procedure|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
125284|NCT03207204|Procedure|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
125285|NCT03207204|Procedure|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
125286|NCT03207204|Procedure|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
125287|NCT03207204|Procedure|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
125288|NCT03207204|Procedure|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
125289|NCT03207191|Drug|F16IL2|F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
125290|NCT03207191|Drug|BI 836858|BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
125291|NCT03207178|Biological|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5*10^6 cells/kg body weight,separately.
125292|NCT03207165|Drug|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min [stage 1] and will be titrated according to a blinded protocol from stages 2 to 5 [0.250, 0.375, 0.5 and >0.5 ug/kg/min]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be [increased/decreased/maintained] at stage [1-5]' so as to ensure that treating physicians remain blinded to the allocated drug.
125293|NCT03207165|Drug|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min [stage 1] and will be titrated according to a blinded protocol from stages 2 to 5 [5.0, 7.5, 10 and >10 ug/kg/min]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be [increased/decreased/maintained] at stage [1-5]' so as to ensure that treating physicians remain blinded to the allocated drug.
125294|NCT03207152|Biological|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
125295|NCT03207139|Drug|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.~The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
125296|NCT03207126|Diagnostic Test|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
125297|NCT03207113|Behavioral|Ned|Prostate cancer survivorship application.
125298|NCT03207100|Combination Product|Analgesia-first minimal sedation|Remifentanil is administered by intravenous infusion and maintaining dose 0.025 μg/kg/min for non-mechanically ventilated patients, maintaining dose 0.05 μg/kg/min for mechanically ventilated patients. If systolic BP is still ≥140 mmHg, then dexmedetomidine is applied using infusion pump with dose of 0.2 μg/kg/h, maintenance dose of dexmedetomidine can increased 0.1 μg/kg/h accordingly up to a maximum of 0.6 μg/kg/h. If BP is still not reduced, then the routine antihypertensive treatment of the IV antihypertensive treatment is applied. Mechanically ventilated patients are given rapid remifentanil (0.5 μg/kg) infusion as an analgesic prior to sputum aspiration to reduce procedure-related pain.
125361|NCT03206671|Drug|Methotrexate|see detailed protocol description
125299|NCT03207100|Combination Product|Antihypertensive treatment|Routine antihypertensive treatment is performed in accordance to the protocol of each respective research center. Antihypertensive drug, treatment protocol and dose are selected by the responsible clinician. Mechanically ventilated patients are given rapid physiological saline infusion as a controlled pretreatment.
125300|NCT03207087|Device|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
125301|NCT03207074|Diagnostic Test|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
125302|NCT03207061|Diagnostic Test|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
125303|NCT03207048|Device|Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
125304|NCT03207048|Device|Sham repetitive transcranial magnetic stimulation|Sham Transcranial Magnetic Stimulation
125305|NCT03207035|Procedure|Axillary brachial plexus block|Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
125306|NCT03207022|Procedure|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
125307|NCT03207009|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
125308|NCT03206996|Behavioral|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
125309|NCT03206996|Behavioral|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
125310|NCT03206996|Behavioral|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
125311|NCT03206983|Device|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
125312|NCT03206970|Drug|BGB-3111|BGB-3111 160 mg will be administered orally BID. Daily treatment with BGB-3111 may be continued for up to 3 years until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor.
125313|NCT03206957|Diagnostic Test|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
125314|NCT03206957|Diagnostic Test|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
125315|NCT03206957|Diagnostic Test|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.~Doppler ultrasound examination will assess renal arterial resistivity indexes"
125316|NCT03206957|Diagnostic Test|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
125317|NCT03206957|Diagnostic Test|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
125318|NCT03206944|Drug|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
125319|NCT03206944|Drug|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
125320|NCT03206931|Drug|Selitrectinib (BAY2731954)|Selitrectinib is administered as capsules or liquid formulation.
125321|NCT03206918|Drug|BGB-3111|BGB-3111 160 mg (two - 80 mg white opaque capsules) PO BID
125322|NCT03206905|Procedure|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
125323|NCT03206905|Behavioral|Diet and Exercise|nutritional/exercise counseling
125324|NCT03206892|Device|laparoscopic ovarian drilling|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
125325|NCT03206866|Diagnostic Test|serum regucalcin antibody|serum regucalcin antibody
125362|NCT03206671|Drug|Prednisolone|see detailed protocol description
125363|NCT03206671|Drug|Vincristine|see detailed protocol description
125326|NCT03206853|Procedure|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
125327|NCT03206840|Behavioral|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
125328|NCT03206827|Other|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
125329|NCT03206827|Other|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
125330|NCT03206827|Other|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
125331|NCT03206814|Other|Usual care|Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
125332|NCT03206814|Other|POST-strategy|Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
125333|NCT03206801|Procedure|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
125334|NCT03206788|Drug|Losartan|50 or 100 mg of losartan twice daily for 12 weeks, based on participant's weight.
125335|NCT03206788|Drug|placebo|matching placebo twice daily for 12 weeks
125336|NCT03206775|Behavioral|Cognitive Assessments (Phase 1)|"Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.~Assessments:~Visual Sweeps~Sustained Visual Attention~Associative Learning--Visual~Associative Learning--Auditory~Emotion Motion~Voice Choice"
125337|NCT03206775|Behavioral|Cognitive Battery A (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete self-report surveys.~Assessments:~On trails: Learning~Line Length Discrimination~Tap the Emotion~Sound Sweeps~BIS/BAS~TEPS~Feasibility survey"
125338|NCT03206775|Behavioral|Cognitive Battery B (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant will complete the complete self-report surveys.~Assessments:~Visual Time Order Judgment~Target Tracker~Emotional Face~Auditory Sound Discrimination~BIS/BAS~TEPS~Feasiblity assessment"
125339|NCT03206775|Behavioral|Cognitive Battery C (Phase 2)|"Participants will complete two visual assessments, one auditory assessment, and one social cognition assessment. Then the participant willcomplete self-report surveys.~Assessments:~Stroop 2AFC~Visual Task Switcher~Beep Seeker~Voice Choice~BIS/BAS~TEPS~Feasibility Survey"
125340|NCT03206762|Device|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm|Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
125341|NCT03206749|Drug|VX-150|Administered orally every 12 hours (q12h) for 2 days.
125342|NCT03206749|Drug|hydrocodone bitartrate/acetaminophen (HB/APAP)|Administered orally every 6 hours (q6h) for 2 days
125343|NCT03206749|Drug|Placebo|"Placebo matched to VX-150 orally q12h for 2 days.~Placebo matched to HB/APAP orally q6h for 2 days."
125344|NCT03206736|Other|Loop DS surgery|these patients will receive a loop DS bariatric procedure
125345|NCT03206723|Device|Bandage contact lens|"Bandage contact lenses (BCL) have the advantage of pain reduction, facilitating epithelial healing, and improved surface healing. They have been used in the ophthalmology community to treat post-operative eye pain due to the large corneal abrasion created during Excimer photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and radial keratotomy (RK) with good success.~Bandage contact lenses have also been used in studies in Europe through ophthalmology clinics to treat traumatic corneal abrasions with excellent results. A British study from 1987, found that large diameter contact lenses can be fitted satisfactorily without the use of special equipment such as keratometry. Studies in rabbits have also been performed showing improved rates of healing when using bandage contact lenses. BCLs have been used to treat epithelial defects from various causes for up to 7 months at a time."
125346|NCT03206723|Drug|Eyedrop|Fluoroquinolone eyedrops 4x/day
125347|NCT03206723|Drug|Hydrocodone|Hydrocone 1-2 tabs 4x/day if needed
125348|NCT03206710|Other|No current intervention|This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
125349|NCT03206697|Other|Mitochondrial DNA content and metabolic parameters|Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
125350|NCT03206684|Drug|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
125351|NCT03206684|Drug|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
125352|NCT03206671|Drug|Rituximab window|Rituximab window (375 mg/m²)
125353|NCT03206671|Drug|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
125354|NCT03206671|Drug|Cyclophosphamide|see detailed protocol description
125355|NCT03206671|Drug|Cytarabine|see detailed protocol description
125356|NCT03206671|Drug|Dexamethasone|see detailed protocol description
125357|NCT03206671|Drug|Doxorubicin hydrochloride|see detailed protocol description
125358|NCT03206671|Drug|Vindesine Sulfate|see detailed protocol description
125364|NCT03206658|Drug|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
125365|NCT03206658|Drug|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
125366|NCT03206645|Drug|PTC596|PTC596 will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
125367|NCT03206632|Drug|BI 690517|single dose
125368|NCT03206632|Drug|Placebo|single dose
125369|NCT03206619|Other|Social, Local and Mobile|Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
125370|NCT03206606|Device|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
125371|NCT03206580|Other|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
125372|NCT03206580|Other|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
125373|NCT03206567|Dietary Supplement|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
125374|NCT03206567|Other|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
125375|NCT03206554|Drug|Ropivacaine|Large volume local anaesthetic intraarticularly
125376|NCT03206554|Other|Saline|sham injection
125377|NCT03206528|Device|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
125378|NCT03206515|Device|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
125379|NCT03206515|Device|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
125380|NCT03206502|Device|Embrace + Alert App|Participants will wear an Embrace smartwatch to collect data, and will provide survey/diary information on the occurrence of seizures. The device sends data to the Alert app, which issues either true detections or false alarms when it detects a possible convulsive seizure. Participants are asked to either cancel (in real time) or mark (at a later time) all false alarms using the Alert app.
125381|NCT03206489|Device|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
125382|NCT03206489|Device|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
125383|NCT03206476|Behavioral|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
125384|NCT03206476|Behavioral|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
125385|NCT03206463|Drug|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
125386|NCT03206463|Drug|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
125387|NCT03206463|Drug|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
125388|NCT03206450|Procedure|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
125389|NCT03206450|Other|Laboratory Biomarker Analysis|Correlative studies
125390|NCT03206450|Other|Questionnaire Administration|Ancillary studies
125391|NCT03206437|Behavioral|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
125392|NCT03206437|Behavioral|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
125393|NCT03206411|Diagnostic Test|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
125394|NCT03206398|Device|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
125395|NCT03206385|Radiation|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
125396|NCT03206385|Radiation|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
125397|NCT03206372|Other|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
125398|NCT03206372|Other|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
125399|NCT03206346|Drug|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
125400|NCT03206346|Drug|Placebo oral capsule|Placebo, capsules daily for 5 days.
125401|NCT03206320|Drug|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
125402|NCT03206294|Other|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
125403|NCT03206281|Diagnostic Test|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
125404|NCT03206268|Device|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
125405|NCT03206255|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
125406|NCT03206255|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
125407|NCT03206242|Other|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
125408|NCT03206229|Drug|PEG-rhG-CSF|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
125409|NCT03206229|Drug|Neulasta (PEG-rhG-CSF)|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
125410|NCT03206216|Diagnostic Test|Diode Laser fiber type Selective Stimulator (DLss)|A laser device to assess pain sensitivity to stimulation
125411|NCT03206203|Drug|Atezolizumab|Given by vein
125412|NCT03206203|Drug|Carboplatin|Given by vein
125413|NCT03206203|Other|Laboratory Biomarker|Correlative study
125414|NCT03206203|Other|Quality-of-Life Assessment|Ancillary studies
125415|NCT03206190|Other|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
125416|NCT03206190|Behavioral|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
125417|NCT03206190|Diagnostic Test|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
125418|NCT03206190|Diagnostic Test|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
125419|NCT03206190|Diagnostic Test|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
125420|NCT03206190|Diagnostic Test|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
125421|NCT03206190|Diagnostic Test|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
125422|NCT03206177|Drug|Galunisertib|Galunisertib 150mg po BID day 4-17.)
125423|NCT03206177|Drug|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours
125424|NCT03206177|Drug|Carboplatin|IV day 1 Carboplatin AUC 6* over 1 hour (or 5* if no prior radiation therapy)
125425|NCT03206164|Other|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
125426|NCT03206151|Drug|CMAB009|for injection only
125427|NCT03206151|Drug|Irinotecan|for injection only
125428|NCT03206151|Drug|Folinic acid|for injection only
125429|NCT03206151|Drug|5-fluorouracil|for injection only
125430|NCT03206138|Biological|GX-188E, GX-I7|Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
125431|NCT03206138|Biological|GX-188E, Imiquimod|1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
125432|NCT03206112|Other|PAS25-cTBS150|PAS pairs TMS with peripheral nerve stimulation. PAS has the same risk as single-pulse TMS and is a safe procedure that has been used on thousands of participants worldwide. TBS is a special form of patterned TMS. TBS has more than minimal risk.
125433|NCT03206086|Drug|Eltrombopag|Daily dose - Non-Asian (greater than or equal to 12): 150 mg; Non-Asian (6-11): 75 mg; Non-Asian (4-5): 2.5 mg/kg; East Asian, South East Asian (greater than or equal to 12): 75 mg; East Asian, South East Asian (6-11): 37.5 mg; East Asian, South East Asian (4-5): 1.25 mg/kg
125434|NCT03206073|Drug|Durvalumab|1500 mg of durvalumab via IV infusion on Day 1 of each cycle until patients meet off treatment criteria
125435|NCT03206073|Drug|Tremelimumab|300 mg of tremelimumab via IV infusion on Day 1 of cycle 1
125436|NCT03206073|Biological|Pexa-Vec|3 x 10E8 pfu (DL 1) or 1 x 10E9 pfu (DL 2) via IV infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
125437|NCT03206060|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24
125438|NCT03206060|Drug|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period
125439|NCT03206060|Drug|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31, every 24 weeks during 3 years follow up period
125440|NCT03206060|Drug|Amino Acid solution|AA solution will be administered 60 minutes prior to each Lu-177- DOTATATE infusion.
125441|NCT03206047|Drug|Atezolizumab|Given IV
125442|NCT03206047|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC
125443|NCT03206047|Drug|Guadecitabine|Given SC
125450|NCT03205995|Biological|OMS721|Intravenous loading dose followed by daily subcutaneous injections
125451|NCT03205982|Device|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
125452|NCT03205982|Device|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
125453|NCT03205969|Device|Functional mobile game|Functional mobile game for chemotherapy side effect education
125454|NCT03205956|Drug|Levodopa|"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 65mg.~Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."
125455|NCT03205930|Biological|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
125456|NCT03205917|Biological|PGDM1400/Placebo (3mg/kg IV)|3/1 (6/2 if DLT)
125457|NCT03205917|Biological|PGDM1400/Placebo (10mg/kg IV)|3/1 (6/2 if DLT)
125458|NCT03205917|Biological|PGDM1400/Placebo (30mg/kg IV)|3/1 (6/2 if DLT)
125459|NCT03205917|Biological|PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)|3/1 (6/2 if DLT)
125460|NCT03205917|Biological|PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)|3/1 (6/2 if DLT);
125461|NCT03205917|Biological|PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)|3/1 (6/2 if DLT)
125462|NCT03205917|Biological|PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)|3 (max 9)
125463|NCT03205917|Biological|PGDM1400 + PGT121 (MTD IV)|3 (max 9)
125464|NCT03205904|Dietary Supplement|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
125465|NCT03205891|Drug|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
125466|NCT03205891|Drug|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
125467|NCT03205891|Device|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
125468|NCT03205878|Other|Telecoaching|"Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.~Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set."
125469|NCT03205878|Device|CPAP|Patients will receive CPAP according to standard care
125470|NCT03205852|Other|questionnaire|fulfillment of questionnaire
125471|NCT03205839|Behavioral|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
125472|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
125473|NCT03205800|Other|Mini-screw|Placement of a mini-screw
125474|NCT03205787|Dietary Supplement|Trifolium pratense|Red Clover extract standardized to isoflavone content.
125475|NCT03205774|Behavioral|6 hours fasting and free oral intake of water|Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
125476|NCT03205761|Drug|Olaparib|see information in arm description
125477|NCT03205735|Diagnostic Test|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
125478|NCT03205722|Other|Non-Interventional|Non-Interventional
125479|NCT03205709|Other|Computerized Cognitive Training|Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
125480|NCT03205709|Other|Crossword Puzzles|These are intended to mimic crossword puzzles in newspapers.
125481|NCT03205696|Drug|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
125482|NCT03205683|Other|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
125483|NCT03205683|Other|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
125484|NCT03205670|Procedure|Urethroplasty with a tissue-engineered construct|The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
125485|NCT03205657|Procedure|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
125486|NCT03205631|Other|Natural Frequency Patch|Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
125487|NCT03205618|Other|Non-Interventional|Non-Interventional
125488|NCT03205605|Drug|oxybutynin|patch
125489|NCT03205605|Drug|oxybutynin|gel
125490|NCT03205592|Diagnostic Test|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
125491|NCT03205579|Other|Video group|Using video for educate cancer pain patients
125492|NCT03205579|Other|conventional group|Face to face cancer pain education by trained nurse
125493|NCT03205566|Drug|Raltegravir 400Mg Tab|bd for 7 days
125494|NCT03205566|Drug|Lamivudine 150Mg Tablet|+ Raltegravir 400Mg tablet bd for 7 days
125495|NCT03205553|Other|Standard of Care Treatment Group|Non-treatment group will be placed in silo at time of birth and subsequently serially reduced in silo with umbilical tape until the bowel contents are at the level of fascial and deemed suitable for closure. A drain will be placed at the top of the silo as described below to aspirate peritoneal fluid for sampling. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons and will not receive peritoneal dialysis fluid.
125496|NCT03205553|Drug|Investigational Treatment Group|The Investigational treatment group will be treated with direct peritoneal resuscitation (DPR). These subjects will undergo DPR during the entirety of silo placement which is usually four to five days. The silo and drain placement will be placed as described below. No additional incisions will be made. These subjects will also be serially reduced with umbilical tape and closed as staged procedure which is the same as the non-treatment group.
125497|NCT03205540|Procedure|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
125498|NCT03205540|Procedure|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
125499|NCT03205527|Other|Overground slip perturbation training|Slips will be induced by a low-friction platform (65×30×0.6 cm, μ<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
125500|NCT03205514|Diagnostic Test|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
125501|NCT03205501|Drug|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
125502|NCT03205501|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
125503|NCT03205488|Drug|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
125504|NCT03205488|Drug|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
125505|NCT03205488|Drug|Placebo|2 capsules taken once daily
125506|NCT03205475|Behavioral|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
125507|NCT03205475|Behavioral|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
125508|NCT03205475|Behavioral|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
125509|NCT03205475|Behavioral|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
125510|NCT03205475|Behavioral|Video Feedback Only Phase 2|Receive video feedback and calls only
125511|NCT03205462|Drug|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
125512|NCT03205462|Drug|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
125513|NCT03205462|Drug|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
125514|NCT03205449|Behavioral|Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)|The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
125515|NCT03205449|Other|Parenting Effectiveness Service|Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. [12].
125516|NCT03205436|Other|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
125517|NCT03205423|Drug|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
125518|NCT03205410|Procedure|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
125519|NCT03205410|Procedure|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
125520|NCT03205397|Other|Experimental Group|Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child
125521|NCT03205397|Other|usual care|Usual care
125522|NCT03205384|Procedure|surgery|
125523|NCT03205371|Biological|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
125524|NCT03205371|Biological|MMR|Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
125525|NCT03205371|Biological|Varicella|Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
125526|NCT03205371|Biological|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
125527|NCT03205371|Biological|PCV13|Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
125528|NCT03205358|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
125529|NCT03205358|Biological|Meningococcal polysaccharide groups A, C, W 135 and Y conjugate vaccine|0.5 mL, Intramuscular
125530|NCT03205345|Drug|Emricasan (25 mg)|25 mg emricasan
125531|NCT03205345|Drug|Emricasan (5 mg)|5 mg emricasan
125532|NCT03205345|Drug|Placebo|Matching Placebo
125533|NCT03205332|Behavioral|Concreteness Training|
125534|NCT03205319|Device|e-learning|The e-learning for patients is a user friendly, audiovisual based, online-accessible program, designed especially for this study. The e-learning will contain information on dyspepsia and advice on lifestyle interventions
125535|NCT03205293|Behavioral|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
125536|NCT03205267|Drug|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to <G2.
125537|NCT03205254|Other|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
125538|NCT03205254|Other|Fast food diet|four days of participant-scaled isocaloric fast food meals
125539|NCT03205241|Dietary Supplement|n-3 PUFA|n-3 PUFA capsules containing EPA and DHA
125540|NCT03205241|Dietary Supplement|Placebo|Olive oil capsules
125541|NCT03205228|Drug|Omeprazole|A capsule of Omeprazole 20 mg & 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
125542|NCT03205228|Behavioral|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
125543|NCT03205228|Drug|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg & a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
125544|NCT03205215|Other|Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
125545|NCT03205215|Other|Waitlist Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
125546|NCT03205202|Dietary Supplement|Cocoa extract|
125547|NCT03205202|Dietary Supplement|Multivitamin|
125548|NCT03205202|Dietary Supplement|Cocoa extract placebo|
125549|NCT03205202|Dietary Supplement|Multivitamin placebo|
125550|NCT03205189|Other|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
125551|NCT03205176|Drug|AZD5153|AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.
125552|NCT03205176|Drug|Olaparib|Olaparib, 300 mg, will be taken BID as oral capsules.
125553|NCT03205163|Biological|Recombinant FVIII (rFVIII) (Low Dose)|Participants will receive a single IV low dose of rFVIII.
125554|NCT03205163|Biological|rFVIII (High Dose)|Participants will receive a single IV high dose of rFVIII.
125555|NCT03205163|Biological|BIVV001 (Low Dose)|Participants will receive single IV low dose of BIVV001.
125556|NCT03205163|Biological|BIVV001 (High Dose)|Participants will receive single IV high dose of BIVV001.
125557|NCT03205150|Drug|LIK066|LIK066 tablets will be taken orally once daily
125558|NCT03205150|Drug|Placebo|Placebo tablets will be taken orally once a day
125559|NCT03205137|Drug|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
125560|NCT03205137|Drug|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
125561|NCT03205137|Drug|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
125562|NCT03205137|Drug|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
125563|NCT03205124|Procedure|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
125564|NCT03205124|Procedure|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.~The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
125565|NCT03205098|Biological|Blood analysis|Blood test of biological markers of mesenteric ischemia
125566|NCT03205085|Radiation|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
125567|NCT03205085|Procedure|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
125568|NCT03205085|Other|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
125569|NCT03205072|Device|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
125570|NCT03205059|Behavioral|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
125571|NCT03205059|Behavioral|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
125572|NCT03205046|Drug|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
125573|NCT03205046|Drug|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
125574|NCT03205033|Drug|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
125575|NCT03205033|Drug|Placebo oral capsule|1 capsule/day 1 hour before go to bed
125576|NCT03205020|Diagnostic Test|serum amyloid a test|"Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.~Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.~The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University"
125577|NCT03205007|Behavioral|Health promotion nutrition program|Health promotion nutrition program
125578|NCT03204994|Drug|Indocyanine Green|Fluorescence guided lymphatic mapping using indocyanine green.
125579|NCT03204981|Device|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
125580|NCT03204981|Procedure|Ablation|standard ablation
125581|NCT03204968|Device|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
125582|NCT03204955|Drug|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.~Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
125583|NCT03204955|Drug|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
125584|NCT03204955|Drug|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
125585|NCT03204942|Device|PRF on DRG|RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
125586|NCT03204942|Device|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
125587|NCT03204942|Drug|Corticosteroid injection|Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
125588|NCT03204929|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
125589|NCT03204916|Other|Medical Chart Review|Data abstraction and central review
125590|NCT03204916|Other|Questionnaire Administration|Ancillary studies
125591|NCT03204903|Procedure|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
125592|NCT03204903|Procedure|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
125593|NCT03204890|Other|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
125594|NCT03204877|Drug|Melatonin|Oral capsules
125595|NCT03204877|Other|Placebo|Oral capsules
125596|NCT03204864|Device|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
125597|NCT03204864|Device|Conventional CS lead placement|Clinical Practice
125598|NCT03204851|Device|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
125599|NCT03204838|Genetic|IDH mutation test performed at diagnosis|Observation of the test result
125600|NCT03204825|Device|Active TENS|TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
125601|NCT03204825|Behavioral|Patient-Centred Education|Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking
125602|NCT03204825|Device|Placebo TENS|TENS device use with setting so that the stimulation delivered is ineffective
125603|NCT03204812|Biological|Durvalumab|Given IV
125604|NCT03204812|Biological|Tremelimumab|Given IV
125605|NCT03204799|Other|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
125606|NCT03204799|Drug|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
125607|NCT03204799|Drug|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
125608|NCT03204786|Drug|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
125609|NCT03204786|Drug|Placebo|Placebo Nasal Spray
125610|NCT03204773|Diagnostic Test|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
125611|NCT03204773|Diagnostic Test|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
125612|NCT03204773|Diagnostic Test|Brief Pain Inventory (BPI)|Testing for pain
125613|NCT03204773|Diagnostic Test|Becks Depression Inventory (BDI)|Screening for depression
125614|NCT03204773|Diagnostic Test|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
125615|NCT03204760|Drug|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
125616|NCT03204760|Drug|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
125617|NCT03204747|Other|Observational study : gait speed|No intervention, only propose water and wait for need to void
125618|NCT03204734|Drug|Capecitabine|Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
125619|NCT03204734|Drug|endocrine therapy|endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
125620|NCT03204721|Other|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
125621|NCT03204708|Device|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
125622|NCT03204708|Drug|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
125623|NCT03204695|Device|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
125624|NCT03204682|Device|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
125625|NCT03204669|Other|Trace elements replacement|
125626|NCT03204643|Behavioral|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
125627|NCT03204630|Dietary Supplement|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
125628|NCT03204630|Dietary Supplement|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
125629|NCT03204630|Other|Control|Standard infant formula
125630|NCT03204617|Biological|DNA.HTI 4 mg at weeks 0, 4 and 8 + MVA.HTI 2x10^8pfu at weeks 12 and 20 (DDDMM)|Vaccine DNA.HTI 4 mg at weeks 0, 4 and 8 + Vaccine MVA.HTI 2x10^8pfu at weeks 12 and 20 (DDDMM).
125631|NCT03204617|Biological|At least 24 weeks since DDDMM, ChAdOx1.HTI 5x10^10 Vp at weeks 0 and 12 + MVA.HTI 2x10^8pfu at week 24 (CCM)|At least 24 weeks since second MVA.HTI administration (week 20), administration of ChAdOx1.HTI 5x10^10 Vp at weeks 0 and 12 + MVA.HTI 2x10^8pfu at week 24.
125632|NCT03204617|Drug|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
125633|NCT03204604|Dietary Supplement|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
125634|NCT03204604|Dietary Supplement|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
125635|NCT03204604|Procedure|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of [11C]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using [11C]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post [11C]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
125667|NCT03204357|Other|Standard of Care Expectant management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
125773|NCT03203603|Other|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
125636|NCT03204604|Behavioral|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
125637|NCT03204604|Behavioral|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
125638|NCT03204604|Behavioral|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
125639|NCT03204604|Behavioral|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
125640|NCT03204591|Other|No intervention|No intervention
125641|NCT03204578|Drug|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
125642|NCT03204578|Drug|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
125643|NCT03204565|Procedure|coronally advanced flap|coronally advanced flap alone (CAF- control)
125644|NCT03204565|Device|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
125645|NCT03204552|Other|No intervention (observational study)|No intervention (observational study)
125646|NCT03204539|Drug|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
125647|NCT03204526|Device|deep brain stimulation|
125648|NCT03204513|Device|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
125649|NCT03204513|Device|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
125650|NCT03204500|Combination Product|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
125651|NCT03204500|Drug|Placebos|Administered orally under the same conditions
125652|NCT03204487|Drug|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp & Dohme, Wien)
125653|NCT03204474|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
125654|NCT03204474|Drug|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
125655|NCT03204461|Diagnostic Test|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
125656|NCT03204461|Other|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
125657|NCT03204448|Device|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
125658|NCT03204435|Procedure|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
125659|NCT03204435|Procedure|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
125660|NCT03204435|Procedure|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
125661|NCT03204435|Procedure|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
125662|NCT03204422|Other|No intervention|no any other intervention
125663|NCT03204396|Drug|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
125664|NCT03204396|Drug|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) once weekly for 12 weeks
125665|NCT03204370|Drug|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
125666|NCT03204357|Other|Fresh Autologous whole Blood|Subjects randomized this arm will receive fresh autologous whole blood
125741|NCT03203876|Biological|Ipilimumab|Specified dose on specified days
125668|NCT03204344|Dietary Supplement|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.~For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
125669|NCT03204344|Other|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.~For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
125670|NCT03204331|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
125671|NCT03204331|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
125672|NCT03204331|Drug|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor
125673|NCT03204331|Drug|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color and odor
125674|NCT03204318|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
125675|NCT03204318|Drug|Estradiol/norethindrone acetate|Capsule containing co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
125676|NCT03204318|Drug|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor
125677|NCT03204318|Drug|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color and odor
125678|NCT03204305|Drug|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
125679|NCT03204305|Drug|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
125680|NCT03204279|Drug|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
125681|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
125682|NCT03204279|Drug|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
125683|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
125684|NCT03204266|Drug|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 5 days preoperatively and 14 days postoperatively.
125685|NCT03204266|Dietary Supplement|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
125686|NCT03204253|Drug|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
125687|NCT03204253|Drug|rFSH alone|32 women who were stimulated with recombinant FSH alone
125688|NCT03204240|Other|Neuromuscular electrical stimulation|NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
125689|NCT03204227|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
125690|NCT03204227|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
125691|NCT03204201|Drug|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
125692|NCT03204188|Drug|Ibrutinib|Ibrutinib
125693|NCT03204188|Drug|Fludarabine|Fludarabine
125694|NCT03204188|Drug|Pembrolizumab|Pembrolizumab
125695|NCT03204175|Other|FIT Plus|"Group handwashing facilities~Daily group handwashing and toothbrushing activities~Sanitation operation and maintenance manuals for school officials~Toilet cleaning consumable~Toilet and handwashing station maintenance kits~Soap, toothbrushes, and toothpaste"
125696|NCT03204175|Other|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
125697|NCT03204162|Other|CPR Coaching|Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
125698|NCT03204149|Device|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.~Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.~After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
125905|NCT03202641|Procedure|PEEP ARDSnet|PEEP settings based on the low PEEP/high FiO2 table
125699|NCT03204149|Device|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.~Along with the sham device, the same generally accepted standard wound care procedures will be used."
125700|NCT03204123|Drug|Ga-HBED-iPSMA PET|Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
125701|NCT03204123|Diagnostic Test|PET/CT|PET/CT will be acquired using a GE 710 or 690 time-of-flight PET/CT scanner. Following a waiting period of 1-3 hours post 68Ga-HBED-iPSMA administration, patients will be scanned from top of the skull to mid-thigh. Images will be acquired with patients in a supine position with their arms raised above their head. If patients cannot raise their arms above the head, the arms will be comfortably positioned and secured by the side of the patient. The PET may be combined with a CT scan as a PET/CT or a MRI scan as PET/MR.
125702|NCT03204123|Diagnostic Test|MRI|Patients may undergo a diagnostic MRI of the prostate, other body parts or a whole-body MRI at the same imaging session as clinically indicated.
125703|NCT03204097|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
125704|NCT03204097|Drug|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
125705|NCT03204097|Drug|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
125706|NCT03204084|Device|Low-temperature Plasma Surgery System|In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
125707|NCT03204071|Drug|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
125708|NCT03204071|Drug|Aloevera|Oral prophylaxis followed by placement of aloevera gel
125709|NCT03204071|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
125710|NCT03204058|Drug|Placebos|Oral prophylaxis followed by placement of placebo gel
125711|NCT03204058|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
125712|NCT03204058|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
125713|NCT03204045|Drug|fentanyl|2 mL mixture of fentanyl with isotonic saline
125714|NCT03204045|Drug|Oxycodone|2 mL mixture of oxycodone with isotonic saline
125715|NCT03204045|Drug|control|isotonic saline 2 mL
125716|NCT03204032|Drug|Tegafur|Tegafur 40-60mg po bid(d1-d14);
125717|NCT03204032|Drug|Temozolomide|200mg po qd(d10-d14)
125718|NCT03204032|Drug|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
125719|NCT03204019|Drug|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
125720|NCT03204019|Drug|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
125721|NCT03204006|Drug|Dexmedetomidine|Dexmedetomidine preinduction
125722|NCT03204006|Drug|sterile saline|normal saline preinduction
125723|NCT03203980|Other|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
125724|NCT03203967|Procedure|Epidural morphine|2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
125725|NCT03203967|Procedure|Epidural placebo|5 ml normal saline is administered through the epidural catheter at the end of surgery.
125726|NCT03203967|Procedure|Single femoral nerve block|Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
125727|NCT03203967|Drug|Intravenous morphine analgesia|Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
125728|NCT03203954|Behavioral|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
125729|NCT03203954|Behavioral|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
125730|NCT03203954|Behavioral|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
125731|NCT03203941|Biological|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
125732|NCT03203928|Behavioral|Occupational Therapy Intervention for Women with ADHD|"The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).~Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments."
125733|NCT03203915|Dietary Supplement|Chardonnay grape pomace powder high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
125734|NCT03203915|Dietary Supplement|Chardonnay grape pomace powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
125735|NCT03203915|Dietary Supplement|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
125736|NCT03203902|Other|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
125737|NCT03203889|Behavioral|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
125738|NCT03203889|Behavioral|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
125739|NCT03203876|Biological|Lirilumab|Specified dose on specified days
125740|NCT03203876|Biological|Nivolumab|Specified dose on specified days
125742|NCT03203863|Diagnostic Test|anthropometric measures of fatness|The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
125743|NCT03203850|Drug|Deferasirox FCT|Taken orally once per day (QD)
125744|NCT03203850|Procedure|Phlebotomy|according to investigator's decision
125745|NCT03203837|Other|Plasma collection|We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
125746|NCT03203824|Dietary Supplement|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
125747|NCT03203824|Other|non dark chocolate|No dark chocolate will be given to this group during the procedures.
125748|NCT03203811|Drug|HTI-2088|3 dose levels
125749|NCT03203811|Drug|Placebo|placebo oral tablet
125750|NCT03203798|Procedure|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
125751|NCT03203798|Procedure|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
125752|NCT03203785|Dietary Supplement|Carbohydrate (maltodextrin)|maltodextrin flavored
125753|NCT03203785|Other|Placebo|non-caloric drink
125754|NCT03203772|Other|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
125755|NCT03203759|Other|Home hospitalization|See above
125756|NCT03203759|Other|Traditional inpatient hospitalization|See above
125757|NCT03203746|Drug|Lycopene + SRP|
125758|NCT03203746|Procedure|SRP only|
125759|NCT03203733|Device|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
125760|NCT03203733|Other|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
125761|NCT03203720|Behavioral|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
125762|NCT03203707|Behavioral|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
125763|NCT03203694|Behavioral|Walking|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
125764|NCT03203694|Behavioral|Unilateral leg heating|This intervention consists of 45-60 minutes of unilateral leg heating (40-42 degree C) 5 days per week for 8 weeks.
125765|NCT03203681|Drug|NATESTO® (4.5% nasal testosterone) Nasal Gel|To determine the effects of 125 uL/nostril, 11.0mg testosterone/dose of Natesto on serum testosterone, LH, FSH and Semen parameters.The study will identify men with confirmed hypogonadism (testosterone (T) <350 on 2 consecutive T samples collected greater than 1.5 hours apart between 6am and 10am with demonstrated symptoms of hypogonadism). Subjects will undergo a total of six study visits. At the first visit they will undergo screening procedures which will include signing of the consent form, physical exam, assessment for inclusion and exclusion criteria, SHIM and quality of life questionnaire, blood samples ( FSH, LH, Estradiol, and Testosterone) and a semen analysis. At visit 2, second semen analysis and blood analysis for Testosterone. After 12 weeks, a third visit for blood sample and semen analysis. The subjects will also be given SHIM and quality of life questionnaires, and repeated after 25 weeks.This is a prospective case study.
125766|NCT03203668|Radiation|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
125767|NCT03203655|Behavioral|CareMessage™|Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
125768|NCT03203655|Behavioral|Control Condition|Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
125769|NCT03203642|Drug|Tesevatinib|A once daily dose of tesevatinib 50 mg in a round tablet form of white to off-white color.
125770|NCT03203642|Drug|Placebo|A once daily dose of matching placebo.
125771|NCT03203629|Device|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
125772|NCT03203616|Drug|KADCYLA 160 MG Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
125774|NCT03203590|Drug|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
125775|NCT03203590|Drug|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
125776|NCT03203577|Procedure|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
125777|NCT03203564|Drug|Modufolin®|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
125778|NCT03203551|Other|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
125779|NCT03203538|Device|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
125780|NCT03203538|Device|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
125781|NCT03203538|Device|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
125782|NCT03203538|Device|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
125783|NCT03203538|Device|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
125784|NCT03203538|Device|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
125785|NCT03203525|Drug|Oxaliplatin|"Arm A: Dose Escalation Group Starting Dose of Oxaliplatin: 85 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.~Dose Expansion Group Starting Dose of Oxaliplatin: Maximum tolerated dose from Dose Escalation Group."
125786|NCT03203525|Drug|Leucovorin|"Dose Escalation Group Starting Dose of Leucovorin: 400 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.~Dose Expansion Group Starting Dose of Leucovorin: Maximum tolerated dose from Dose Escalation Group."
125787|NCT03203525|Drug|5-fluorouracil|"Dose Escalation Group Starting Dose of 5-fluorouracil: 400 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.~Dose Expansion Group Starting Dose of 5-fluorouracil: Maximum tolerated dose from Dose Escalation Group."
125788|NCT03203525|Drug|Bevacizumab|"Arm A: mFOLFOX6 + Bevacizumab + NovoTTF-100L System Dose Escalation Group Starting Dose of Bevacizumab: 5 mg/kg by vein on Days 1 and 15 of a 28 day cycle.~Arm B: DAT + NovoTTF-100L System Dose Escalation Group Starting Dose of Bevacizumab: 10 mg/kg by vein on Days 1 and 15 of a 28 day cycle.~mFOLFOX6 + Bevacizumab + NovoTTF-100L System Dose Expansion Group Starting Dose of Bevacizumab: Maximum tolerated dose from Dose Escalation Group.~DAT + NovoTTF-100L System Dose Escalation Group Starting Dose of Bevacizumab: 10 mg/kg by vein on Days 1 and 15 of a 28 day cycle.~DAT + NovoTTF-100L System Dose Expansion Group Starting Dose of Bevacizumab: Maximum tolerated dose from Dose Escalation Group."
125789|NCT03203525|Device|NovoTTF-100L|"NovoTTF-100L system applied to torso where the tumor is located for at least 18 hours a day.~NovoTTF-100L system delivers 100 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 1414mA RMS."
125790|NCT03203525|Drug|Liposomal Doxorubicin|"Dose Escalation Group Starting Dose of Liposomal Doxorubicin: 20 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.~Dose Expansion Group Starting Dose of Liposomal Doxorubicin: Maximum tolerated dose from Dose Escalation Group."
125791|NCT03203525|Drug|Temsirolimus|"Dose Escalation Group Starting Dose of Temsirolimus: 25 mg by vein on Days 1, 8, 15, and 22 of a 28 day cycle.~Dose Expansion Group Starting Dose of Temsirolimus: Maximum tolerated dose from Dose Escalation Group."
125792|NCT03203512|Dietary Supplement|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
125793|NCT03203512|Dietary Supplement|High-oleic safflower oil capsules|High-oleic safflower oil capsules for 12 weeks
125794|NCT03203499|Drug|ANS-6637 Oral Tablet|Ascending single doses administered orally.
125795|NCT03203499|Drug|Placebo Oral Tablet|Placebo administered orally.
125796|NCT03203486|Other|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
125797|NCT03203473|Drug|Ipilimumab|YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
125798|NCT03203473|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
125799|NCT03203460|Behavioral|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
125800|NCT03203447|Drug|suprachoroidal CLS-TA + IVT anti-VEGF agent|suprachoroidal injection of CLS-TA following either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
125801|NCT03203447|Drug|suprachoroidal sham + IVT anti-VEGF agent|suprachoroidal injection of CLS-TA following either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
125802|NCT03203434|Diagnostic Test|Urinary volatile organic compound analysis|
125838|NCT03203148|Diagnostic Test|Point-of-Care ACT|Comparison between two point-of-care devices for measurement of the activated clotting time
125803|NCT03203421|Biological|ChAdOx1 LS2|A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
125804|NCT03203421|Biological|MVA LS2|Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
125805|NCT03203408|Device|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
125806|NCT03203408|Device|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
125807|NCT03203395|Behavioral|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
125808|NCT03203369|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
125809|NCT03203356|Drug|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
125810|NCT03203343|Procedure|Operation - PIRS|Operation by its known design for PIRS group
125811|NCT03203343|Procedure|Operation - MARCY|Operation by its known design for MARCY group
125812|NCT03203330|Biological|TG-C|2 mL injection of allogeneic human chondrocytes expressing transforming growth factor-beta1
125813|NCT03203330|Biological|Placebo Control|2 mL normal saline injection
125814|NCT03203317|Drug|Insulin|2 h insulin clamp
125815|NCT03203317|Other|Exercise|Cycling exercise
125816|NCT03203304|Drug|Nivolumab|240mg every two weeks by IV infusion
125817|NCT03203304|Drug|Ipilimumab|1mg/kg every six weeks by IV infusion
125818|NCT03203291|Device|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
125819|NCT03203278|Behavioral|Web-based exercise programme|Aerobic, resistance and balance exercises
125820|NCT03203265|Other|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
125821|NCT03203265|Other|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
125822|NCT03203265|Other|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
125823|NCT03203252|Other|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
125824|NCT03203252|Other|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
125825|NCT03203252|Other|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
125826|NCT03203239|Device|Red Light (670 nm energy)|Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
125827|NCT03203239|Drug|Octafluoropropane|All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
125828|NCT03203226|Other|FELDENKRAIS METHOD (FM)|They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
125829|NCT03203213|Procedure|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
125830|NCT03203200|Behavioral|ZETRA cognitive behavioral structural|ZETRA cognitive behavioral structural
125831|NCT03203187|Other|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
125832|NCT03203187|Other|No intervention|No mango intake for two weeks.
125833|NCT03203174|Device|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
125834|NCT03203174|Device|Sham Microneedle|Flat roller with no needles on the roller
125835|NCT03203174|Drug|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
125836|NCT03203174|Other|Saline|Saline applied to the palm
125837|NCT03203161|Procedure|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
125839|NCT03203135|Behavioral|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
125840|NCT03203122|Other|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
125841|NCT03203122|Other|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
125842|NCT03203109|Behavioral|Postural Assessment Scale for Stroke (PASS)|Postural Assessment Scale for Stroke (PASS)
125843|NCT03203096|Dietary Supplement|Magnesium|Magnesium citrate / Magnesium oxide
125844|NCT03203096|Dietary Supplement|Placebo|
125845|NCT03203083|Other|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
125846|NCT03203070|Drug|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
125847|NCT03203070|Procedure|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
125848|NCT03203057|Other|coronary occlusion|percutaneous coronary intervention
125849|NCT03203044|Other|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
125850|NCT03203031|Procedure|General anesthesia|Standard general anesthesia
125851|NCT03203031|Procedure|Quadratus lumborum block|Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
125852|NCT03203018|Behavioral|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
125853|NCT03203005|Drug|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.~Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms [µg] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
125854|NCT03202992|Drug|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
125855|NCT03202979|Drug|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.~After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
125856|NCT03202979|Drug|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.~In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
125857|NCT03202979|Drug|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
125858|NCT03202966|Other|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
125859|NCT03202953|Procedure|ventilation strategy 1|"In Group I, after trendelenburg position, patients will be applied 1:1 ratio VCV.~Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
125860|NCT03202953|Procedure|ventilation strategy 2|"In group A, after trendelenburg position, patients will be applied autoflow VCV.~- Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
125861|NCT03202940|Drug|Alectinib|Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
125862|NCT03202940|Drug|Cobimetinib|Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
125863|NCT03202927|Drug|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
125864|NCT03202914|Behavioral|Usual protein and phosphorus diet|Diet intervention
125865|NCT03202914|Behavioral|Low protein and phosphorus diet|Diet intervention
125866|NCT03202914|Behavioral|Very low protein and phosphorus|Diet intervention
125867|NCT03202901|Dietary Supplement|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.~Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
125903|NCT03202654|Other|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
125904|NCT03202654|Other|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
125868|NCT03202901|Dietary Supplement|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.~Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:~V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).~V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
125869|NCT03202888|Behavioral|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
125870|NCT03202875|Drug|SAR341402|"Pharmaceutical form: solution~Route of administration: subcutaneous"
125871|NCT03202875|Drug|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
125872|NCT03202875|Drug|Insulin Aspart|"Pharmaceutical form: solution~Route of administration: subcutaneous"
125873|NCT03202862|Drug|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
125874|NCT03202849|Dietary Supplement|Vitamin D and A|A single dose of Vitamin A and Vitamin D will be given.
125875|NCT03202849|Dietary Supplement|Vitamin D and Placebo|A single dose of Vitamin D plus a placebo will be given.
125876|NCT03202836|Drug|progesterone|vaginal utrogestan
125877|NCT03202836|Drug|Tocolytics|tocolysis for 48 hours
125878|NCT03202836|Drug|Steroids|antenatal corticosteroids for 48 hours
125879|NCT03202823|Procedure|blood samples|3 tubes (5 ml volume) collected during surgery
125880|NCT03202823|Procedure|recover samples of atheromatous plaque|a carotid sample collected during surgery
125881|NCT03202797|Other|audiometric tests|tone and speech audiometry
125882|NCT03202797|Other|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
125883|NCT03202797|Other|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
125884|NCT03202784|Drug|BCX7353|BCX7353
125885|NCT03202771|Device|Home Biofeedback Therapy|Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
125886|NCT03202771|Other|Office Biofeedback Therapy|A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. Biofeedback Therapy (BT) will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
125887|NCT03202758|Drug|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:~STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)~STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
125888|NCT03202745|Other|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
125889|NCT03202745|Other|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
125890|NCT03202732|Other|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.~The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
125891|NCT03202719|Biological|Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|bOPV at 6, 10 and 14 weeks of age
125892|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|IPV at 14 weeks and 18 months of age
125893|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|IPV at 14 weeks, 18 weeks and 18 months of age
125894|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|IPV at 14 weeks and 9 months of age
125895|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|IPV at 6 weeks and 9 months of age
125896|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age|IPV at 6 and 14 weeks of age
125897|NCT03202706|Procedure|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
125898|NCT03202693|Drug|PA-824|
125899|NCT03202680|Other|USDA Style Diet|USDA style healthy diet, low in saturated fats.
125900|NCT03202680|Other|Lean Beef Diet|A lean beef containing healthy diet, low in saturated fats.
125901|NCT03202667|Drug|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
125902|NCT03202667|Drug|Placebo|Treatment with Placebo oral tablet once daily for 28 days
125906|NCT03202641|Procedure|PEEP LRM|A lung recruitment maneuver (LRM) followed by PEEP guided by transpulmonary pressure.
125907|NCT03202628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
125908|NCT03202628|Drug|Dexamethasone|Given PO
125909|NCT03202628|Drug|Ixazomib Citrate|Given PO
125910|NCT03202628|Other|Laboratory Biomarker Analysis|Correlative studies
125911|NCT03202628|Drug|Pomalidomide|Given PO
125912|NCT03202615|Dietary Supplement|L (lactoferrin)|Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets
125913|NCT03202615|Drug|F (ferrous sulphate)|Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
125914|NCT03202602|Other|Telemonitoring of CPAP treatment|Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
125915|NCT03202602|Other|Standard care|Office visits and monitoring of CPAP treatment at each visit.
125916|NCT03202589|Other|FOCUS Echocardiography|FOCUS Echocardiography
125917|NCT03202576|Device|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
125918|NCT03202563|Drug|Gemigliptin 50mg|For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
125919|NCT03202563|Drug|Dapagliflozin 10mg|For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
125920|NCT03202563|Procedure|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91"
125921|NCT03202563|Device|Continuous Glucose Monitoring System(CGMS)|For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
125922|NCT03202563|Drug|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
125923|NCT03202550|Drug|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
125924|NCT03202550|Drug|Placebo Comparator|Placebo oral pills
125925|NCT03202537|Drug|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
125926|NCT03202524|Biological|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
125927|NCT03202524|Biological|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
125928|NCT03202511|Drug|Probenecid Oral Tablet|Included in arm/group descriptions.
125929|NCT03202511|Drug|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
125930|NCT03202498|Device|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
125931|NCT03202498|Other|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
125932|NCT03202498|Device|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
125933|NCT03202498|Other|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 17 weeks, including the screening (up to 4 weeks), treatment (12 weeks) and 7-day follow up period.
125934|NCT03202485|Device|Toric Implantable Collamer Lens|uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
125935|NCT03202485|Device|ICL + Astigmatic keratotomy|uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
125936|NCT03202472|Device|Implanted Medical Device|Radiofrequency tag
125937|NCT03202472|Procedure|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
125938|NCT03202472|Other|Questionnaire Administration|Ancillary studies
125939|NCT03202472|Procedure|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
125940|NCT03202472|Procedure|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
125941|NCT03202459|Drug|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
125942|NCT03202459|Drug|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
125943|NCT03202459|Drug|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
125944|NCT03202446|Drug|1% Glycated Chitosan|
125945|NCT03202446|Device|Photothermal Laser|
125946|NCT03202446|Drug|Placebo|
125947|NCT03202446|Drug|Cyclophosphamide|
125948|NCT03202446|Drug|Standard of Care|
125949|NCT03202433|Device|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
125950|NCT03202420|Other|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
125951|NCT03202407|Drug|Calcium acetate and sevelamer hydrochloride|receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
125952|NCT03202394|Drug|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
125953|NCT03202394|Drug|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
125954|NCT03202381|Drug|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:~Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).~Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).~Treatment will be continued till clinically indicated or till disease progression."
125955|NCT03202368|Drug|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
125956|NCT03202355|Device|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
125957|NCT03202355|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
125958|NCT03202342|Other|Water|Water, 300 ml, at room temperature
125959|NCT03202342|Other|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
125960|NCT03202342|Other|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
125961|NCT03202342|Other|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
125962|NCT03202342|Other|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
125963|NCT03202329|Other|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
125964|NCT03202329|Other|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
125965|NCT03202316|Drug|Atezolizumab|Given IV
125966|NCT03202316|Drug|Cobimetinib|Given PO
125967|NCT03202316|Drug|Eribulin|Given IV
125968|NCT03202316|Other|Laboratory Biomarker Analysis|Correlative studies
125969|NCT03202316|Other|Pharmacological Study|Correlative studies
125970|NCT03202303|Drug|Cannabidivarin|Weight-based dosing of 10 mg/kg/day of CBDV
125971|NCT03202303|Drug|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
125972|NCT03202290|Behavioral|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
125973|NCT03202277|Behavioral|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
125974|NCT03202277|Behavioral|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
125975|NCT03202264|Other|TAPER|"The intervention is medication reduction. This arm is comprised of:~Medication reconciliation~Identification of patient priorities for care~Identification of medications that are potentially appropriate for discontinuation/dose reduction~Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce~Identification of medications for trial of discontinuation/dose reduction (shared decision making)~Pause of medication and clinical monitoring"
125976|NCT03202251|Other|It's is a cohort|It is a prospective, observational, cohort study
125977|NCT03202238|Other|Conventional|Conventional venepuncture without use of any venepuncture assistive device.
125978|NCT03202238|Device|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
125979|NCT03202238|Device|TenTaTorch|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
125980|NCT03202225|Device|constrained polyethylene|constrained polyethylene insert
125981|NCT03202212|Procedure|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
125982|NCT03202212|Procedure|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
125983|NCT03202199|Device|PET/MRI|2 PET/MRI examinations
125984|NCT03202186|Drug|Progesterone oral capsule|Oral capsule treatment
125985|NCT03202186|Drug|Placebo oral capsule|Oral capsule treatment
125986|NCT03202173|Diagnostic Test|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
125987|NCT03202147|Drug|Cromolyn|Active capsules for inhalation.
125988|NCT03202147|Other|Placebo|Non-active capsules for inhalation.
126142|NCT03201146|Drug|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
125989|NCT03202134|Other|opioid free anesthesia|general anesthesia blocking reflexes without using an opioid
125990|NCT03202121|Other|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
125991|NCT03202121|Other|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
125992|NCT03202121|Other|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
125993|NCT03202108|Dietary Supplement|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.~It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.~This product is to be consumed daily under the direction of a dietitian."
125994|NCT03202095|Drug|Creatine Monohydrate|5 grams daily of oral creatine monohydrate powder.
125995|NCT03202082|Behavioral|Neuropsychological testing|Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
125996|NCT03202069|Other|Even protein|Intake of even protein 5 day rotating menu
125997|NCT03202069|Other|Skewed protein|Intake of skewed protein 5 day rotating menu
125998|NCT03202056|Other|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
125999|NCT03202056|Other|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
126000|NCT03202043|Other|High dose vegetable juice|High dose (13 fl oz) vegetable juice
126001|NCT03202043|Other|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
126002|NCT03202043|Other|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
126003|NCT03202043|Other|Control bottled water|Control (12 fl oz) bottled water
126004|NCT03202030|Procedure|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
126005|NCT03202030|Procedure|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
126006|NCT03202017|Procedure|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
126007|NCT03202017|Procedure|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.~LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
126008|NCT03202004|Drug|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
126009|NCT03202004|Drug|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
126010|NCT03201991|Other|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
126011|NCT03201978|Drug|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
126012|NCT03201978|Drug|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
126013|NCT03201965|Drug|Cyclophosphamide|Participants will receive 300 mg/m^2 of cyclophosphamide as an oral or IV dose.
126014|NCT03201965|Drug|Bortezomib|Participants will receive 1.3 mg/m^2 of bortezomib as an subcutaneous (SC) injection.
126015|NCT03201965|Drug|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
126016|NCT03201965|Drug|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
126017|NCT03201952|Drug|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
126018|NCT03201952|Drug|Placebos|Ileostomy administration of 5cc saline placebo once
126019|NCT03201939|Drug|Lisinopril|ACE-inhibitor (lisinopril)(intervention arm
126020|NCT03201939|Other|Placebo Oral Tablet|Comparator placebo (control arm)
126021|NCT03201926|Dietary Supplement|mealworms|10g , 3 times a day , po, 2 months
126022|NCT03201926|Dietary Supplement|grain powder|grain powder, 10g ,3times one day,2months
126023|NCT03201913|Drug|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
126024|NCT03201900|Drug|E2007|Oral tablet
126025|NCT03201887|Behavioral|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
126026|NCT03201887|Behavioral|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
126027|NCT03201874|Behavioral|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
126028|NCT03201874|Behavioral|Education|Education about sickle cell disease to increase disease knowledge
126029|NCT03201861|Drug|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
126030|NCT03201861|Drug|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
126031|NCT03201848|Drug|Placebo|Placebo given to subject will be adjusted by body weight (<10kg, Placebo given to subject will be adjusted by body weight(<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
126032|NCT03201848|Drug|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
126033|NCT03201835|Drug|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
126034|NCT03201835|Drug|Sativex|spray X 4 actuations
126035|NCT03201835|Drug|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
126036|NCT03201835|Drug|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
126037|NCT03201835|Drug|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
126038|NCT03201822|Other|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
126039|NCT03201822|Other|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
126040|NCT03201822|Other|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
126041|NCT03201822|Other|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
126042|NCT03201809|Device|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
126043|NCT03201809|Drug|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
126044|NCT03201796|Drug|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
126045|NCT03201796|Drug|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
126046|NCT03201783|Other|immediate frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
126047|NCT03201783|Other|delayed frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
126048|NCT03201770|Drug|pyronaridine artesunate|Antimalarial treatment
126049|NCT03201757|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
126050|NCT03201744|Procedure|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
126051|NCT03201705|Device|Burst + Tonic|Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
126052|NCT03201692|Device|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
126053|NCT03201692|Device|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
126054|NCT03201679|Procedure|Repair of hip fracture|Patients undergoing hip fracture surgery
126055|NCT03201653|Procedure|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
126056|NCT03201640|Behavioral|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
126057|NCT03201640|Behavioral|virtual|Participants will be shown an immersive virtual reality preparation for surgery
126058|NCT03201627|Drug|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
126059|NCT03201614|Device|A-CP HA Kit|Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2
126060|NCT03201614|Device|ArthroVisc 40|Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2
126061|NCT03201614|Drug|Placebo|Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
126062|NCT03201601|Drug|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
126143|NCT03201146|Drug|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
127074|NCT03194373|Drug|Carboplatin|Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
126063|NCT03201601|Drug|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
126064|NCT03201588|Dietary Supplement|Formulaid|Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
126065|NCT03201575|Device|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
126066|NCT03201575|Device|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
126067|NCT03201562|Drug|PRX-100|Ophthalmic Solution
126068|NCT03201562|Drug|PRX-100 Component #1|Ophthalmic Solution
126069|NCT03201562|Drug|PRX-100 Vehicle|Ophthalmic Solution
126070|NCT03201549|Dietary Supplement|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
126071|NCT03201536|Device|conventional Suture|Sutures
126072|NCT03201536|Device|Zip3|wound closure device
126073|NCT03201523|Other|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
126074|NCT03201510|Other|Observational|HPTN 075 is an observational study in sub-Saharan MSM
126075|NCT03201484|Other|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
126076|NCT03201471|Drug|Chidamide + R-CHOP regimen|Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
126077|NCT03201458|Drug|Atezolizumab|Given IV
126078|NCT03201458|Drug|Cobimetinib|Given PO
126079|NCT03201458|Other|Laboratory Biomarker Analysis|Correlative studies
126080|NCT03201445|Drug|Filgotinib|200 mg tablet administered orally once daily
126081|NCT03201445|Drug|Placebo|Tablet administered orally once daily
126082|NCT03201445|Drug|Standard of Care|Standard of care therapy
126083|NCT03201432|Device|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
126084|NCT03201432|Device|Bare metal stent (BES)|Bare metal stent
126085|NCT03201419|Drug|FE 201836|Oral solution for daily intake
126086|NCT03201419|Drug|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
126087|NCT03201419|Drug|Placebo oral solution|Manufactured to mimic experimental drug
126088|NCT03201419|Drug|Placebo ODT|Manufactured to mimic active comparator drug
126089|NCT03201393|Drug|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B taken together twice a day for 12 weeks.
126090|NCT03201393|Drug|Placebo Capsules|One capsule contains placebo for component A and one capsule contains placebo for component B taken together twice a day for 12 weeks.
126091|NCT03201380|Other|TEP scanner with choline|
126092|NCT03201367|Drug|Rivaroxaban|Rivaroxaban 10 mg/12 hour
126093|NCT03201367|Other|symptomatic therapy for ascites, abdominal pain|
126094|NCT03201354|Procedure|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
126095|NCT03201354|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
126096|NCT03201354|Procedure|Cataract extraction|Cataract surgery and IOL implantation
126097|NCT03201341|Other|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
126098|NCT03201341|Other|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
126099|NCT03201341|Other|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
126100|NCT03201341|Other|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
126101|NCT03201341|Other|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
126102|NCT03201341|Other|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
126103|NCT03201341|Other|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
126104|NCT03201341|Other|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
126190|NCT03200782|Other|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
126105|NCT03201328|Other|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
126106|NCT03201328|Other|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
126107|NCT03201328|Other|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
126108|NCT03201302|Other|School physical education class|Children participated only in school physical education classes only.
126109|NCT03201302|Other|Taekwondo|Children participated only in taekwondo training only.
126110|NCT03201302|Other|Martial arts|Children participated only in martial arts training only.
126111|NCT03201302|Other|Climbing|Children participated only in climbing training only.
126112|NCT03201302|Other|Volleyball|Children participated only in volleyball training only.
126113|NCT03201302|Other|Artistic gymnastics|Children participated only in artistic gymnastics training only.
126114|NCT03201302|Other|Swimming|Children participated only in swimming training only.
126115|NCT03201302|Other|Dance|Children participated only in dance training only.
126116|NCT03201302|Other|Basketball|Children participated only in basketball training only.
126117|NCT03201302|Other|Wrestling|Children participated only in wrestling training only.
126118|NCT03201302|Other|Football (soccer)|Children participated only in football (soccer) training only.
126119|NCT03201302|Other|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
126120|NCT03201302|Other|Track and field|Children participated only in track and field training only.
126121|NCT03201302|Other|Tennis|Children participated only in tennis training only.
126122|NCT03201302|Other|Combination of activities 1|Children participated in two weight-bearing activities.
126123|NCT03201302|Other|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
126124|NCT03201276|Drug|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
126125|NCT03201263|Procedure|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
126126|NCT03201263|Procedure|Standard of care|Standard of care
126127|NCT03201250|Drug|Cabozantinib|"Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
126128|NCT03201237|Other|Action observation training|Each child observed a task video and then performed a task
126129|NCT03201224|Device|"After Group"|
126130|NCT03201211|Biological|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
126131|NCT03201211|Biological|Formulation 1 : NTHi-Mcat high dose adjuvanted vaccine GSK3277513A|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
126132|NCT03201211|Biological|Formulation 2 : NTHi-Mcat low dose adjuvanted vaccine GSK3339036A|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
126133|NCT03201211|Drug|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
126134|NCT03201198|Behavioral|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
126135|NCT03201198|Behavioral|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
126136|NCT03201185|Drug|Ramipril|Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
126137|NCT03201172|Device|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
126138|NCT03201159|Drug|VLX103|150mg tablets
126139|NCT03201146|Drug|Apatinib|Doses to be determined following the completion of Phase I of the study.
126140|NCT03201146|Drug|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
126141|NCT03201146|Drug|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
126144|NCT03201133|Diagnostic Test|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
126145|NCT03201120|Behavioral|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
126146|NCT03201120|Behavioral|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
126147|NCT03201107|Other|Pilates|"Training based on a basic level Pilates exercise program will be as follows:~A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
126148|NCT03201094|Device|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
126149|NCT03201094|Dietary Supplement|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
126150|NCT03201081|Other|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
126151|NCT03201068|Dietary Supplement|Probiotic supplement|Probiotic supplement capsule
126152|NCT03201068|Dietary Supplement|Placebo|Placebo capsule
126153|NCT03201055|Device|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
126154|NCT03201042|Diagnostic Test|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.~In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
126155|NCT03201042|Diagnostic Test|Serology based assay|"The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.~The Immunetics C6 Lyme ELISA assay.~A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines~A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.~Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
126156|NCT03201042|Diagnostic Test|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
126157|NCT03201016|Diagnostic Test|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
126158|NCT03201003|Biological|AR101|AR101 powder
126159|NCT03201003|Other|Placebo|Placebo powder
126160|NCT03200990|Device|iVAC2L pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L and the CFLVAD Impella CP on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
126191|NCT03200769|Device|CPAP active|CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg
126192|NCT03200769|Device|CPAP placebo|CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.
126161|NCT03200990|Device|Impella CP pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L and the CFLVAD Impella CP on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
126162|NCT03200977|Other|Non-Interventional|Non-Interventional
126163|NCT03200964|Other|anesthesia given as required for surgical procedure|
126164|NCT03200951|Drug|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
126165|NCT03200951|Drug|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
126166|NCT03200938|Device|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
126167|NCT03200938|Device|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
126168|NCT03200925|Other|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
126169|NCT03200912|Drug|Ingenol Mebutate (Picato®)|Brand product
126170|NCT03200912|Drug|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
126171|NCT03200912|Drug|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
126172|NCT03200899|Behavioral|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
126173|NCT03200899|Other|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
126174|NCT03200886|Device|Sinovial H-L|Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
126175|NCT03200886|Drug|Triamcinolone Acetonide|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
126176|NCT03200873|Device|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
126177|NCT03200860|Drug|Empagliflozin 10 MG|10 mg daily, oral, 30 days
126178|NCT03200860|Drug|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
126179|NCT03200847|Drug|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
126180|NCT03200834|Procedure|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
126181|NCT03200834|Procedure|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
126182|NCT03200821|Biological|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
126183|NCT03200821|Drug|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
126184|NCT03200808|Drug|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
126185|NCT03200795|Other|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula ([Heart rate reserve x training percentage] + resting heart rate)(Nuhu & Maharaj, 2017).~The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu & Maharaj, 2017)."
126186|NCT03200795|Other|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.~All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
126187|NCT03200782|Drug|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
126188|NCT03200782|Drug|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
126189|NCT03200782|Other|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
126262|NCT03200314|Other|Measurment of blood recirculation|Ultrasound based measurments of blood recirculating through the vvECMO circuit.
126193|NCT03200756|Behavioral|Sedentary Group|The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
126194|NCT03200756|Behavioral|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
126195|NCT03200730|Behavioral|Family Dignity Intervention group|A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
126196|NCT03200717|Drug|pazopanib|"Pazopanib is taken orally and will be administered daily as a fixed dose. Enrollment of 3rd-line patients will be restricted to ensure approximately 40 patients receive pazopanib as 2nd-line therapy.~Number of Cycles: until progression, unacceptable toxicity develops, death, pregnancy, start of new anti-cancer therapy, doctor/patient discontinuation, lost to follow-up, end of study, or study termination by sponsor."
126197|NCT03200704|Combination Product|IC2000 and SPY-PHI|This is a prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures as confirmed by Tc-99m and Gamma Probe.
126198|NCT03200691|Radiation|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
126199|NCT03200691|Drug|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
126200|NCT03200678|Other|isokinetic assessment|muscle torque assessement
126201|NCT03200665|Diagnostic Test|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
126202|NCT03200652|Dietary Supplement|Metabolic availability of lysine in wheat|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
126203|NCT03200639|Other|Combined training|The CT and CTc protocol (total length time ~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
126204|NCT03200639|Other|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time ~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (<60% of HRmax or Borg Scale at <5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
126205|NCT03200626|Procedure|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
126206|NCT03200613|Drug|Apixaban|2.5 mg orally twice daily
126207|NCT03200613|Drug|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
126208|NCT03200600|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
126209|NCT03200600|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
126210|NCT03200600|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
126211|NCT03200600|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
126212|NCT03200587|Drug|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
126213|NCT03200587|Drug|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
126214|NCT03200574|Diagnostic Test|4D Cardiac CT Scan|4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
126215|NCT03200574|Device|LivaNova Bioprothetic Aortic Valve Implant|Study includes patients that have received the commercially approved LivaNova bioprosthetic aortic heart valve Perceval, as standard of care.
126216|NCT03200561|Drug|Prednisolone|Prednisolone 2mg/Kg/day for 5 days
126217|NCT03200561|Biological|immunoglobulin|immunoglobulin 2g/Kg for 12 hours
126218|NCT03200548|Behavioral|Relaxing acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
126219|NCT03200548|Behavioral|Usual care|Negative control group. Participants are asked to carry on with their usual management practices and habits.
126291|NCT03200015|Drug|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
126373|NCT03199456|Device|Zip surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
126220|NCT03200548|Behavioral|Stimulating acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
126221|NCT03200548|Behavioral|Sham acupressure plus usual care|Positive control group. Chosen pressure points are not known to be effective.
126222|NCT03200535|Other|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
126223|NCT03200535|Other|Bulk outreach|A bulk letter or email will be sent
126224|NCT03200535|Other|Dietician call|Patients will receive a personalized call by a registered dietitian
126225|NCT03200522|Other|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
126226|NCT03200522|Other|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
126227|NCT03200509|Other|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
126228|NCT03200509|Other|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
126229|NCT03200496|Drug|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
126230|NCT03200496|Drug|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
126231|NCT03200496|Drug|TALION®|Reference drug : Talion®
126232|NCT03200483|Other|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
126233|NCT03200483|Other|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
126234|NCT03200483|Other|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
126235|NCT03200470|Other|No intervention: sample collection study|Sample collection and collection of laboratory values
126236|NCT03200457|Device|1,5 Tesla abdominal MRI|Measurement of the fat and iron
126237|NCT03200457|Device|3 Tesla abdominal MRI|Measurement of the fat and iron
126238|NCT03200444|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
126239|NCT03200444|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
126240|NCT03200444|Other|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
126241|NCT03200444|Other|P-4|Newly developed adhesive P-4
126242|NCT03200444|Other|P-15|Newly developed adhesive P-14
126243|NCT03200444|Other|P-16|Newly developed adhesive P-8
126244|NCT03200431|Other|New adhesive strip|This is a newly developed strip.
126245|NCT03200418|Other|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
126246|NCT03200418|Other|P-4|This patch is made of new adhesive
126247|NCT03200418|Other|P-15|This patch is made of new adhesive
126248|NCT03200418|Other|P-16|This patch is made of new adhesive
126249|NCT03200405|Device|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
126250|NCT03200405|Device|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
126251|NCT03200392|Device|laser root surface conditioning & laser DGG harvesting|laser root surface biomodification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
126252|NCT03200392|Device|laser root surface conditioning & blade DGG harvesting|laser root surface biomodification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
126253|NCT03200392|Procedure|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
126254|NCT03200379|Other|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
126255|NCT03200366|Behavioral|DVD|"A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed."
126256|NCT03200366|Behavioral|Patient Navigation|Participants talk by telephone with a Patient Navigator who is a population health nurse in the healthcare system. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
126257|NCT03200353|Device|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
126258|NCT03200340|Drug|EC-18|Oral administration of EC-18 twice daily
126259|NCT03200340|Drug|Placebo|Placebo to match EC-18 capsule administration
126260|NCT03200327|Procedure|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
126261|NCT03200327|Procedure|sacrospinofixation|Utero-vaginal suspension by bilateral anterior sacrospinofixation using the vaginal route
127075|NCT03194347|Diagnostic Test|molecular genetic analyses|molecular genetic analyses
126263|NCT03200301|Procedure|Intact Umbilical Cord Milking|Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
126264|NCT03200288|Device|HL-01: high and low molecular weight hyaluronic acid|2 ml intra-articular single injection
126265|NCT03200288|Device|Placebo|2 ml intra-articular single injection
126266|NCT03200275|Diagnostic Test|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
126267|NCT03200249|Radiation|Preoperative chemo-radiation with IG-IMRT dose escalation|
126268|NCT03200236|Behavioral|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
126269|NCT03200236|Behavioral|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
126270|NCT03200223|Behavioral|Personalized healthcare service|Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
126271|NCT03200210|Drug|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
126272|NCT03200210|Drug|Placebo|Pills manufactured to mimic Febuxostat tablets
126273|NCT03200197|Other|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
126274|NCT03200197|Other|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
126275|NCT03200184|Drug|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
126276|NCT03200158|Other|Endoscopy biopsy and blood|Medical operation
126277|NCT03200145|Other|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:~- Attention to the person based on:~Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.~Respect and acknowledge of the person.~Promotion of the autonomy.~Personalized treatment, with tailored attention and integrative cures~Protection of physical well-being, preventing damages and risks and promoting healthy habits.~Promotion of independence on daily activities.~Protection of privacy and personal matters~- Positive environment based on:~Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.~Social relationships, with proximity and collaboration with families.~Friendly organization, with empathetic professionals empowering users."
126278|NCT03200132|Diagnostic Test|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
126279|NCT03200119|Behavioral|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
126280|NCT03200106|Device|Alfapump|Alfapump implant
126281|NCT03200093|Drug|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
126282|NCT03200093|Drug|Placebo|Ora-Sweet 5mL taken by mouth once daily.
126283|NCT03200080|Drug|Tozadenant|2, 4, 6 or 8 Tozadenant 60 mg tablets
126284|NCT03200080|Drug|Placebo oral tablet|2, 4, 6 or 8 Tozadenant matching placebo tablets
126285|NCT03200080|Drug|d-amphetamine|2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
126286|NCT03200080|Drug|Placebo oral capsule|2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
126287|NCT03200067|Behavioral|Personalized health care service|Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
126288|NCT03200054|Other|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last ~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
126289|NCT03200041|Procedure|Blood sample|20 ml blood sample taken from vein in arm
126290|NCT03200028|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets executive function, memory and attention.
126292|NCT03200002|Drug|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
126293|NCT03200002|Drug|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count <1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count <1000/mm3.
126294|NCT03199989|Drug|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
126295|NCT03199989|Other|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
126296|NCT03199976|Drug|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
126297|NCT03199976|Drug|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
126298|NCT03199976|Drug|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
126299|NCT03199963|Drug|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
126300|NCT03199963|Drug|Placebo|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
126301|NCT03199950|Drug|Haloperidol|Haloperidol 2dd1mg (08.00am - 10.00pm)
126302|NCT03199950|Drug|Placebo Oral Tablet|Placebo oral 2dd (08.00am - 10.00pm)
126303|NCT03199937|Behavioral|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
126304|NCT03199937|Other|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
126305|NCT03199924|Drug|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
126306|NCT03199924|Drug|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
126307|NCT03199924|Drug|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
126308|NCT03199911|Drug|Topical Anti-Infective Product|Topical antibiotic ointment will be erythromycin. If the patient has an erythromycin allergy, bacitracin will be prescribed. If the patient cannot obtain either (i.e. lack of availability at the pharmacy), polysporin-bacitracin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
126309|NCT03199911|Drug|Topical Ointment|Artificial tear ointment
126310|NCT03199898|Diagnostic Test|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
126311|NCT03199885|Drug|Atezolizumab|Given IV
126312|NCT03199885|Drug|Paclitaxel|Given IV
126313|NCT03199885|Biological|Pertuzumab|Given IV
126314|NCT03199885|Other|Placebo|Given IV
126315|NCT03199885|Other|Quality-of-Life Assessment|Ancillary studies
126316|NCT03199885|Biological|Trastuzumab|Given IV
126317|NCT03199872|Biological|RV001V|Sc injection
126318|NCT03199846|Other|Non-Interventional|Non-Interventional
126319|NCT03199833|Device|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.~A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
126320|NCT03199833|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:~Upper limb passive motion~Arm Cycle ergometer with or without FES~Neuro Muscular Electrical Stimulation~Upper limb exercises using augmented or virtual reality environment~Occupational therapy exercises~Constraint induced movement therapy~Upper limb active movement (reaching, grasping, elevation, spatial orientation)~Repetitive task training~Mirror therapy~Writing training~Chemodenervation Therapy"
126321|NCT03199820|Device|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
126322|NCT03199820|Drug|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
126323|NCT03199807|Biological|NRT|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4-6 doses.
126324|NCT03199807|Radiation|Radiotherapy|Radiotherapy of the major mass by dose of 5Gy/F * 10F
126325|NCT03199794|Biological|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
126372|NCT03199469|Genetic|AT132|AT132 is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
126326|NCT03199781|Device|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
126327|NCT03199755|Drug|ACT|Current approved drug for treating malaria
126328|NCT03199755|Drug|DLA1|Experimental drug treatment, single dose.
126329|NCT03199755|Drug|DLA2|Experimental drug treatment, doubled the dose of DLA1.
126330|NCT03199742|Behavioral|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress & use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
126331|NCT03199742|Behavioral|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
126332|NCT03199729|Other|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
126333|NCT03199729|Other|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
126334|NCT03199729|Other|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
126335|NCT03199716|Other|Parent mentors|Parent mentors are to meet up with their assigned intervention group 4 times in 1 year and call the families monthly to document any diabetic complications
126336|NCT03199703|Device|Baylis transseptal system group|
126337|NCT03199703|Device|Standard conventional transseptal group|
126338|NCT03199690|Drug|Dolutegravir|Antiviral (integrase inhibitor)
126339|NCT03199690|Drug|Rifampicin|Antibiotic
126340|NCT03199677|Drug|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
126341|NCT03199664|Radiation|NB-UVB|NB-UVB given twice weekly for 6 months
126342|NCT03199664|Combination Product|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
126343|NCT03199651|Other|Best Practice|Receive usual care
126344|NCT03199651|Procedure|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
126345|NCT03199651|Procedure|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
126346|NCT03199651|Other|Laboratory Biomarker Analysis|Correlative studies
126347|NCT03199651|Other|Medical Chart Review|Undergo medical record abstraction
126348|NCT03199651|Other|Quality-of-Life Assessment|Ancillary studies
126349|NCT03199651|Other|Questionnaire Administration|Ancillary studies
126350|NCT03199651|Behavioral|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
126351|NCT03199638|Drug|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
126352|NCT03199638|Other|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
126353|NCT03199625|Behavioral|Cognitive therapy|
126354|NCT03199625|Behavioral|Behavior therapy|
126355|NCT03199625|Drug|SSRI antidepressants|
126356|NCT03199612|Drug|Sildenafil|To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
126357|NCT03199612|Drug|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
126358|NCT03199586|Drug|NP-G2-044|capsule
126359|NCT03199560|Drug|Tc 99m tilmanocept|lymphatic mapping agent
126360|NCT03199560|Drug|Tc 99m filtered sulfur colloid|lymphatic mapping agent
126361|NCT03199547|Drug|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
126362|NCT03199547|Drug|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
126363|NCT03199534|Drug|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
126364|NCT03199534|Drug|Botulinum toxin A 100u|Subject will receive injection of 100u Botulinum toxin A in either the office or while anesthetized.
126365|NCT03199534|Drug|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
126366|NCT03199521|Other|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
126367|NCT03199508|Diagnostic Test|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
126368|NCT03199508|Diagnostic Test|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
126369|NCT03199495|Other|electroacupuncture|acupuncture needle with TENS device
126370|NCT03199482|Drug|Dexamethasone Oral Tablet|single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo
126371|NCT03199482|Drug|Placebo|Placebo will be administrated 30 minutes before start of root canal treatment
126374|NCT03199456|Device|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
126375|NCT03199443|Diagnostic Test|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
126376|NCT03199430|Dietary Supplement|Epigallocatechin gallate|
126377|NCT03199430|Dietary Supplement|Placebo|1450mg Corn Flour
126378|NCT03199417|Drug|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
126379|NCT03199417|Other|Placebo|An identically packaged placebo cream
126380|NCT03199404|Device|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
126381|NCT03199391|Device|BioWick SureLock Implant|The BioWick™ SureLock™ implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick™ SureLock™ is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
126382|NCT03199378|Other|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
126383|NCT03199365|Behavioral|Behavioral Dietary Intervention|Undergo TSSC intervention sessions
126384|NCT03199365|Behavioral|Behavioral Intervention|Undergo TSSC intervention sessions
126385|NCT03199352|Other|RYGB hand-sewn|Patients will have the RYGB anastomosis hand-sewn
126386|NCT03199352|Other|RYGB linear-staple|Patients will have the RYGB anastomosis performed using a linear staple.
126387|NCT03199339|Drug|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
126388|NCT03199339|Drug|Placebo|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
126389|NCT03199326|Other|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
126390|NCT03199313|Drug|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
126391|NCT03199313|Drug|Placebo|Matching Sutezolid placebo
126392|NCT03199300|Drug|Anthracyclines|Chemotherapy regimen containing anthracyclines.
126393|NCT03199300|Drug|Trastuzumab|Systemic treatment including trastuzumab.
126394|NCT03199300|Drug|Cisplatin|Chemotherapy including cisplatin.
126395|NCT03199300|Drug|Bleomycin|Chemotherapy including bleomycin.
126396|NCT03199274|Procedure|Yttrium-90 Microsphere Radioembolization|Undergo standard of care Y-90 radioembolization
126397|NCT03199274|Drug|Perflutren Protein-Type A Microspheres|Given IV. Ultrasound contrast agent used in combination with radioembolization to potentially improve treatment of hepatocellular carcinoma
126398|NCT03199274|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
126399|NCT03199274|Procedure|SPECT imaging|single-photon emission computed tomography as part of standard of care
126400|NCT03199261|Drug|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
126401|NCT03199261|Drug|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
126402|NCT03199248|Procedure|Aspiration with percutaneous capsulotomy For digital mucous cysts|The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
126403|NCT03199235|Device|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
126404|NCT03199235|Other|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
126405|NCT03199222|Device|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
126406|NCT03199209|Other|Behavioral, Psychological or Informational Intervention|Receive information about healthy lifestyles
126407|NCT03199209|Other|Behavioral, Psychological or Informational Intervention|Receive information about healthy homes
126408|NCT03199209|Behavioral|Patient Visit|Attend study visit with research staff
126409|NCT03199209|Other|Questionnaire Administration|Ancillary studies
126410|NCT03199209|Other|Text Message|Receive information about healthy lifestyles
126411|NCT03199209|Other|Text Message|Receive texts about healthy homes
126412|NCT03199196|Device|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.~Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
126413|NCT03199196|Device|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.~Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
126414|NCT03199196|Behavioral|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
126415|NCT03199196|Behavioral|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
126416|NCT03199196|Behavioral|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
126417|NCT03199196|Behavioral|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
126418|NCT03199183|Radiation|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
126419|NCT03199183|Other|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
126420|NCT03199183|Genetic|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
126421|NCT03199170|Drug|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
126422|NCT03199170|Drug|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
126423|NCT03199170|Drug|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
126424|NCT03199157|Drug|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
126425|NCT03199144|Drug|Chemotherapy|3 cycles of Gemzar-Abraxane
126426|NCT03199144|Radiation|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
126427|NCT03199144|Procedure|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
126428|NCT03199131|Procedure|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
126429|NCT03199118|Procedure|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
126430|NCT03199118|Other|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
126431|NCT03199105|Other|Preoperative education with image illustrations and/or local tetracaine mucilage|The patients were given preoperative education with image illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
126432|NCT03199092|Behavioral|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
126433|NCT03199092|Behavioral|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
126434|NCT03199079|Device|Cervix Monitor|Cervix elasticity and length measurements by Cervix Monitor
126435|NCT03199053|Drug|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
126436|NCT03199053|Drug|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
126437|NCT03199053|Drug|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
126438|NCT03199040|Drug|Durvalumab|-Human monoclonal antibody
126439|NCT03199040|Biological|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
126440|NCT03199040|Device|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
126441|NCT03199040|Procedure|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
126442|NCT03199027|Other|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
126443|NCT03199014|Device|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
126444|NCT03199014|Device|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
126445|NCT03198975|Diagnostic Test|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
126446|NCT03198949|Drug|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.~(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
126447|NCT03198936|Dietary Supplement|Brain Pill|2 capsules to be taken twice a day with meals with a glassful of water
126448|NCT03198936|Dietary Supplement|Placebo|2 capsules to be taken twice a day with meals with glassful of water
126449|NCT03198923|Biological|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
126450|NCT03198884|Drug|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
126451|NCT03198871|Drug|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
126452|NCT03198871|Drug|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
126453|NCT03198858|Procedure|CartoUnivu™|Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™
126454|NCT03198858|Procedure|Ablation with Carto® 3 System|usual Pulmonary vein isolation Ablation with Carto® 3 System only
126455|NCT03198845|Other|video game|20-min per session for 3 times per week for a 4-week duration
126456|NCT03198845|Other|exercise|20-min per session for 3 times per week for a 4-week duration
126457|NCT03198832|Procedure|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
126458|NCT03198819|Drug|Local Rifampisin and İnrtravenous cefotaxime|
126459|NCT03198806|Other|Treadmill aerobic exercise in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 60 minutes of recovery at the supine position.
126460|NCT03198806|Other|Treadmill aerobic exercise and water intake in supine position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 60 minutes of recovery at the supine position.
126461|NCT03198806|Other|Treadmill aerobic exercise in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise followed by 10 minutes of recovery at the orthostatic position.
126462|NCT03198806|Other|Treadmill aerobic exercise and water intake in orthostatic position|The volunteers will be submitted to a cardiovascular rehabilitation session with 40 minutes of treadmill aerobic exercise and water intake followed by 10 minutes of recovery at the orthostatic position.
126463|NCT03198793|Drug|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily [QD]) over 8 weeks.
126464|NCT03198780|Other|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
126465|NCT03198767|Drug|LIK066|LIK066 50 mg tablets. Open-label, bulk, blister-pack.
126466|NCT03198767|Dietary Supplement|Carbohydrate 50%|50% carbohydrate in breakfast meal
126467|NCT03198767|Dietary Supplement|Carbohydrate 25%|25% carbohydrate in breakfast meal
126468|NCT03198767|Dietary Supplement|Carbohydrate 8%|8% carbohydrate in breakfast meal
126469|NCT03198767|Dietary Supplement|Carbohydrate 0%|0% carbohydrate in breakfast meal
126470|NCT03198767|Dietary Supplement|Psyllium|Powder 6 grams
126471|NCT03198767|Dietary Supplement|Calcium carbonate|Liquid 1 gram (4 mL equivalent sugar free)
126472|NCT03198754|Device|PEI Experimental Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
126473|NCT03198754|Device|Comparison Light|Ambient Light Fixture will turn on automatically and illuminate the hospital room from 7 to 10 AM each morning.
126474|NCT03198741|Drug|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
126475|NCT03198741|Drug|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
126476|NCT03198741|Drug|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
126477|NCT03198728|Drug|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
126478|NCT03198728|Drug|AndroGel|topical testosterone gel
126479|NCT03198715|Drug|DS1040b|DS-1040b in solution for intravenous infusion
126480|NCT03198715|Drug|Placebo|Saline solution for intravenous infusion
126481|NCT03198702|Drug|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
126482|NCT03198702|Other|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
126483|NCT03198689|Drug|Brentuximab Vedotin|Dose 0.6 mg/kg i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
126484|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
126485|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
126486|NCT03198676|Drug|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
126487|NCT03198676|Drug|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
126488|NCT03198663|Behavioral|POSSE|Popular-opinion leader
126489|NCT03198650|Drug|Acalabrutinib|Acalabrutinib
126490|NCT03198650|Drug|Obinutuzumab|Obinutuzumab
126491|NCT03198637|Drug|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
126492|NCT03198637|Drug|clinical assessment|
126493|NCT03198624|Drug|HTL0018318|Part A single dose Part B five doses
126494|NCT03198624|Drug|Placebo oral capsule|Part B only
126495|NCT03198611|Diagnostic Test|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
126496|NCT03198598|Behavioral|Iyengar Yoga|The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
126497|NCT03198598|Behavioral|Yoga app|The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
126498|NCT03198585|Drug|Empagliflozin 10 MG|Capsule, once a day for 90 days
126499|NCT03198585|Other|Placebo|Capsule, once a day for 90 days
126500|NCT03198572|Behavioral|Lifestyle intervention|Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.
126501|NCT03198572|Drug|Placebo|placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
126502|NCT03198572|Drug|Berberine|Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
126503|NCT03198559|Drug|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
126504|NCT03198559|Drug|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
126505|NCT03198546|Biological|GPC3 and/or TGFβ targeting CAR-T cells|Engineering GPC3 or or TGFβ targeting CAR combined with/or without IL7-CCL19 secreting vector into T cells isolated from patients with advanced HCC, and then transfusing them back the patients.
126506|NCT03198533|Device|Triathlon PA|Implantation of Knee Prosthesis
126507|NCT03198533|Device|Triathlon Pressfit|Implantation of Knee Prosthesis
126508|NCT03198520|Device|Solvay Dental 360™|polymer Removable Partial Denture (RPD)
126509|NCT03198507|Drug|RHB-105|"The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:~Rifabutin 150 mg~Amoxicillin 3000 mg~Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
126510|NCT03198507|Drug|Active Comparator|"The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~Amoxicillin 3000 mg~Omeprazole 120 mg~One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
126511|NCT03198494|Other|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
126512|NCT03198494|Other|Sham Background Noise|Background Noise used as a control
126513|NCT03198481|Behavioral|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
126514|NCT03198481|Behavioral|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
126515|NCT03198468|Device|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power
126516|NCT03198455|Dietary Supplement|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
126517|NCT03198455|Other|Placebo|Drinking water with food coloring and salt
126518|NCT03198442|Procedure|F-18 FDG breast PET scan|
126519|NCT03198429|Behavioral|Caring Dads|Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
126520|NCT03198429|Behavioral|Mothers in Mind|Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
126521|NCT03198416|Device|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
126522|NCT03198403|Drug|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
126564|NCT03198065|Procedure|Hand-made glove setting|The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
126565|NCT03198065|Procedure|Commercialized single-incision multiport setting|The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
126769|NCT03196817|Device|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
126523|NCT03198377|Device|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
126524|NCT03198377|Device|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
126525|NCT03198377|Device|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:~Fixed frequency at 100 Hz Pulse width 200 microseconds"
126526|NCT03198377|Device|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
126527|NCT03198364|Behavioral|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
126528|NCT03198364|Behavioral|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
126529|NCT03198351|Drug|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet~Route of administration: oral"
126530|NCT03198338|Drug|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
126531|NCT03198338|Drug|Normal Saline|0.9% Normal Saline
126532|NCT03198338|Device|Ultrasound|Ultrasound guided TAP block
126533|NCT03198325|Other|Stop of ART|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
126534|NCT03198312|Device|CathiportTM|fully implanted
126535|NCT03198312|Device|Implant Port|fully implanted
126536|NCT03198299|Device|MEI BIN insoles|wearing insoles for 12 weeks
126537|NCT03198286|Other|Informational Intervention|Receive treatment summary and survivor care plan
126538|NCT03198273|Other|Clinical pilates exercises|servical, lumbal, pelvic muscles
126539|NCT03198273|Other|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
126540|NCT03198260|Other|Fascial manipulation|Deep frictional massage
126541|NCT03198247|Other|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
126542|NCT03198247|Other|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
126543|NCT03198234|Biological|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
126544|NCT03198221|Drug|Golytely|bowel preparation
126545|NCT03198221|Drug|Clenpiq|bowel preparation
126546|NCT03198208|Drug|Fentanyl dose administration|
126547|NCT03198195|Procedure|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
126548|NCT03198182|Drug|Placebo|Specified dose on specified days
126549|NCT03198182|Drug|BMS-986036|Specified dose on specified days
126550|NCT03198169|Device|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
126551|NCT03198169|Device|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
126552|NCT03198156|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
126553|NCT03198156|Device|Sham stimulation|Sham stimulation
126554|NCT03198143|Drug|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
126555|NCT03198143|Drug|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
126556|NCT03198130|Drug|REGN2810|Intravenous (IV) use
126557|NCT03198117|Drug|Huaier Granule|a Chinese traditional medicine
126558|NCT03198117|Other|placebo|placebo
126559|NCT03198104|Device|MRI|
126560|NCT03198091|Drug|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
126561|NCT03198078|Drug|Brexpiprazole (OPC-34712)|Once-daily, tablets
126562|NCT03198078|Drug|Aripiprazole|Once-daily, tablets
126563|NCT03198078|Drug|Placebo|Once-daily, tablets
126566|NCT03198052|Biological|CAR-T cells targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, or CD80/86|CAR-T cells injection or transfusion: (1-10×10e6/kg CAR-T for each treatment; 3 or more cycles.
126567|NCT03198039|Behavioral|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
126568|NCT03198026|Drug|Ibrutinib|Given PO
126569|NCT03198026|Drug|Obinutuzumab|Given IV
126570|NCT03198013|Drug|Prednisolone|Specified dose on specified days
126571|NCT03198013|Drug|BMS-791826|Specified dose on specified days
126572|NCT03198013|Drug|Placebo|Specified dose on specified days
126573|NCT03198000|Drug|F# 13418-148 Eye Drops|ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
126574|NCT03198000|Drug|F#13418-158 Eye Drops|ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
126575|NCT03198000|Drug|F# PF-004390 Eye Drops|Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
126576|NCT03197987|Device|Endocuff|Endocuff-assisted colonoscopy
126577|NCT03197987|Device|cap|Cap-assisted colonoscopy
126578|NCT03197974|Behavioral|Mindfulness for Bipolar|Brief online self-management program with email coaching support
126579|NCT03197974|Behavioral|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
126580|NCT03197961|Combination Product|tenofovir/emtricitabine|At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
126581|NCT03197961|Drug|DMPA|After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
126582|NCT03197948|Other|Internet-Based Intervention|Complete questionnaire via a smartphone application
126583|NCT03197935|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered as per schedule described in respective arm.
126584|NCT03197935|Drug|Placebo|Placebo matched to atezolizumab will be administered as per schedule described in respective arm.
126585|NCT03197935|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per schedule described in the arms.
126586|NCT03197935|Drug|Doxorubicin|Doxorubicin will be administered as per schedule described in the arms.
126587|NCT03197935|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per schedule described in the arms.
126588|NCT03197935|Drug|Filgrastim|Filgrastim will be administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
126589|NCT03197935|Drug|Pegfilgrastim|Pegfilgrastim will be administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
126590|NCT03197922|Combination Product|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for 30 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement. If no continent bowel movement occurs, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely."
126591|NCT03197909|Other|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
126592|NCT03197896|Other|Educational Intervention|Review prostate cancer information
126593|NCT03197883|Other|Test Product|Restoring lipid balm
126594|NCT03197883|Other|Cleanser|Moisturizing facial cleanser
126595|NCT03197883|Other|Sunscreen|SPF (Sun Protection Factor) 50 sunscreen
126596|NCT03197870|Drug|AKB-9778|Subcutaneous AKB-9778 15mg
126597|NCT03197870|Drug|Placebo|Subcutaneous Placebo
126598|NCT03197857|Behavioral|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
126599|NCT03197857|Behavioral|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
126600|NCT03197857|Behavioral|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
126601|NCT03197857|Behavioral|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
126602|NCT03197818|Drug|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
126603|NCT03197818|Drug|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
126650|NCT03197571|Drug|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
126651|NCT03197571|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
126604|NCT03197805|Diagnostic Test|PAM 50 test|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
126605|NCT03197792|Other|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.~On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
126606|NCT03197779|Drug|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
126607|NCT03197779|Drug|Aspirin|Oral administration
126608|NCT03197779|Other|Placebo|Oral administration
126609|NCT03197766|Drug|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
126610|NCT03197766|Drug|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily
126611|NCT03197753|Device|Laryngeal mask airway|Laryngeal mask airway
126612|NCT03197753|Device|Nasotracheal intubation|Nasotracheal intubation
126613|NCT03197740|Drug|Donepezil patch|Treatment
126614|NCT03197740|Drug|aricept Tab|Comparator
126615|NCT03197727|Diagnostic Test|GC Saliva-Check BUFFER|Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
126616|NCT03197714|Drug|OPB-111077|"Two dose schemas will be employed:~Level 1: 200 mg daily~Level 2: 250 mg daily"
126617|NCT03197688|Other|Notapplicable|Not applicable as non-interventional study
126618|NCT03197675|Other|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
126619|NCT03197662|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
126620|NCT03197662|Drug|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
126621|NCT03197649|Procedure|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
126622|NCT03197636|Drug|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
126623|NCT03197623|Drug|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
126624|NCT03197623|Drug|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
126625|NCT03197610|Procedure|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
126626|NCT03197597|Other|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
126627|NCT03197584|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
126628|NCT03197584|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
126629|NCT03197584|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
126630|NCT03197584|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
126631|NCT03197584|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
126632|NCT03197584|Drug|Fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
126633|NCT03197584|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
126634|NCT03197584|Drug|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
126635|NCT03197584|Drug|omega-3 acid ethyl esters|omega-3 acid ethyl esters
126636|NCT03197584|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
126637|NCT03197584|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
126638|NCT03197584|Biological|ALT-803|Recombinant human super agonist IL-15 complex
126639|NCT03197584|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2 vaccine
126640|NCT03197584|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
126641|NCT03197584|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1 vaccine
126642|NCT03197584|Biological|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
126643|NCT03197584|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
126644|NCT03197584|Biological|haNK®|NK-92 [CD16.158V, ER IL-2]
126645|NCT03197571|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
126646|NCT03197571|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
126647|NCT03197571|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
126648|NCT03197571|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
126649|NCT03197571|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
126652|NCT03197571|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
126653|NCT03197571|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
126654|NCT03197571|Drug|Lovaza|Omega-3-acid ethyl esters
126655|NCT03197571|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
126656|NCT03197571|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]
126657|NCT03197571|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
126658|NCT03197571|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
126659|NCT03197571|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
126660|NCT03197571|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
126661|NCT03197571|Biological|GI-4000|RAS yeast vaccine
126662|NCT03197571|Biological|GI-6207|CEA yeast vaccine
126663|NCT03197571|Biological|GI-6301|Brachyury yeast vaccine
126664|NCT03197571|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
126665|NCT03197519|Behavioral|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
126666|NCT03197519|Behavioral|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
126667|NCT03197506|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
126668|NCT03197506|Other|Laboratory Biomarker Analysis|Correlative studies
126669|NCT03197506|Biological|Pembrolizumab|Given IV
126670|NCT03197506|Radiation|Radiation Therapy|Undergo radiation therapy
126671|NCT03197506|Drug|Temozolomide|Given PO
126672|NCT03197506|Procedure|Therapeutic Conventional Surgery|Undergo surgery
126673|NCT03197493|Drug|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
126674|NCT03197480|Drug|Aflibercept Injection [Eylea]|All subjects will receive 4 monthly intravitreal injections of aflibercept
126675|NCT03197467|Drug|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
126676|NCT03197454|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
126677|NCT03197454|Other|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
126678|NCT03197441|Other|Platelet-rich plasma|Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
126679|NCT03197428|Other|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
126680|NCT03197428|Other|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
126681|NCT03197415|Other|Platelet-rich plasma|intradiscal injection of plasma-rich platelet
126682|NCT03197402|Dietary Supplement|Leucine-enriched protein gel delivery system|Leucine enriched
126683|NCT03197402|Dietary Supplement|Milk protein gel delivery system|Non-leucine enriched
126684|NCT03197389|Drug|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
126685|NCT03197376|Biological|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
126686|NCT03197376|Biological|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
126687|NCT03197363|Other|Discovering novel risk factors.|The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, kidney, liver, gallbladder ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, the effect of standardized meal. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
126688|NCT03197350|Diagnostic Test|cMR|cardiac MRI done to complete the diagnosis
126689|NCT03197350|Biological|biomarker|Biomarker correlation with cMR parameters Prognostic information
126690|NCT03197337|Procedure|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
126691|NCT03197324|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
126692|NCT03197324|Drug|Digoxin|2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
126693|NCT03197311|Other|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
126694|NCT03197298|Drug|Clopidogrel|
126695|NCT03197298|Drug|Ticagrelor|
126726|NCT03197077|Drug|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
126727|NCT03197064|Drug|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
126696|NCT03197285|Other|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.~This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:~To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.~To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision~Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
126697|NCT03197285|Other|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
126698|NCT03197272|Procedure|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
126699|NCT03197246|Device|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
126700|NCT03197246|Device|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
126701|NCT03197233|Other|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
126702|NCT03197220|Other|fish|300 gr/week fish
126703|NCT03197220|Other|walnut|18 walnut per week
126704|NCT03197220|Other|fish-walnut|150 gr fish and 9 walnut per week
126705|NCT03197207|Procedure|"Dragon and Tiger warring in lifting and thrusting"|"Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later."
126706|NCT03197207|Procedure|"Dragon and Tiger warring in twisting-rotating"|When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
126707|NCT03197194|Drug|Alteplase|alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
126708|NCT03197194|Drug|acetylsalicylic acid|one tablet of aspirin 300 mg
126709|NCT03197194|Drug|Placebo Oral Tablet|One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
126710|NCT03197194|Drug|placebo IV|IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
126711|NCT03197181|Device|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
126712|NCT03197168|Behavioral|Intervention to reduce self-stigma among people with mental illness|"This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.~The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively."
126713|NCT03197168|Behavioral|Control|Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
126714|NCT03197155|Drug|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
126715|NCT03197129|Other|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. All ceiling fluorescent lighting is removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, and a lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
126716|NCT03197129|Other|traditional waiting room|The traditional waiting room: a waiting area outside the clinic with ten seats in one row faces the reception desk in an area of 15 square meters. The area is air-conditioned, moderately well-lit, without posters or paintings on the walls, and no reading material.
126717|NCT03197116|Other|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
126718|NCT03197116|Other|No other|No additional reminder will be offered
126719|NCT03197103|Drug|N-Acetylcysteine (NAC)|For more information read Experimental Arm description
126720|NCT03197090|Device|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
126721|NCT03197077|Procedure|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
126722|NCT03197077|Procedure|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
126723|NCT03197077|Procedure|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
126724|NCT03197077|Drug|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
126725|NCT03197077|Drug|Follitropin beta|Daily injection (three days) of follitropin beta
126728|NCT03197038|Behavioral|Partially supervised home-based walking exercise|Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
126729|NCT03197038|Behavioral|Control|Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
126730|NCT03197025|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) intravenous (IV) infused over 15 minutes approximately every 12 hours for a maximum of two doses.
126731|NCT03197025|Biological|E6 T Cell Receptor (TCR)|On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
126732|NCT03197012|Drug|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
126733|NCT03197012|Drug|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
126734|NCT03196999|Behavioral|Personalized Attention Bias Training|This self-help program will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user.
126735|NCT03196999|Behavioral|Neutral Attention Training Condition|This self-help program is a placebo control program that will be used on an iOS compatible phone. The placebo will contain only neutral words.
126736|NCT03196999|Behavioral|Non-Personalized Attention Bias Training|This self-help program administered on an app will aim to reduce neurobiological threat sensitivity with the ultimate goal of a low-cost and highly scalable self-help tool to alleviate symptoms of PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same for each user.
126737|NCT03196986|Drug|MIL60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
126738|NCT03196986|Drug|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to MIL60 at 7.5mg/kg
126739|NCT03196973|Drug|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
126740|NCT03196973|Drug|DF289|1 vial into the affected ear twice daily for 7 days
126741|NCT03196973|Drug|DF277|1 vial into the affected ear twice daily for 7 days
126742|NCT03196947|Drug|APO010|APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
126743|NCT03196934|Drug|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
126744|NCT03196921|Drug|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
126745|NCT03196908|Dietary Supplement|Energy Drink Brand 1|Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
126746|NCT03196908|Dietary Supplement|Energy Drink Brand 2|Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
126747|NCT03196908|Other|Placebo|Lime juice, water, and cherry flavoring
126748|NCT03196895|Behavioral|Weight reduction training|6 one-hour sessions of conventional weight reduction training
126749|NCT03196895|Behavioral|PPG training|Four 90-minute sessions of glycemic load and exercise training
126750|NCT03196895|Behavioral|discrete BG feedback|Blood glucose feedback from structured self-monitoring of blood glucose
126751|NCT03196895|Behavioral|continuous BG feedback|blood glucose feedback from continuous glucose monitoring
126752|NCT03196882|Drug|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
126753|NCT03196882|Drug|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
126754|NCT03196882|Drug|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
126755|NCT03196869|Device|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
126756|NCT03196869|Device|Routine intravenous drip|Routine intravenous drip-chemotherap
126757|NCT03196869|Drug|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
126758|NCT03196869|Drug|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
126759|NCT03196869|Drug|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
126760|NCT03196869|Drug|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
126761|NCT03196869|Radiation|intensity-modulated radiation therapy|control group is similar to Experimental group
126762|NCT03196856|Behavioral|Resistance and Plyometric Exercise|12 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
126763|NCT03196856|Dietary Supplement|Greek Yogurt (0% Plain)|200g 3x/day for 12 weeks.
126764|NCT03196856|Dietary Supplement|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 12 weeks.
126765|NCT03196843|Drug|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
126766|NCT03196843|Radiation|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
126767|NCT03196830|Biological|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
126768|NCT03196817|Drug|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
126772|NCT03196791|Drug|Sugammadex Sodium|"INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.~DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
126773|NCT03196778|Radiation|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
126774|NCT03196765|Drug|Sobetirome (NV1205)|Once a day oral dose of the study drug
126775|NCT03196752|Procedure|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
126776|NCT03196752|Other|simple palpation|conventional
126777|NCT03196739|Device|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
126778|NCT03196726|Behavioral|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
126779|NCT03196726|Behavioral|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
126780|NCT03196713|Behavioral|Early Intensive Behavioral Intervention|
126781|NCT03196700|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
126782|NCT03196674|Other|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
126783|NCT03196661|Biological|Influenza A (H7N9) virus vaccine|To prevent the infection of H7N9 virus.
126784|NCT03196648|Other|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
126785|NCT03196648|Other|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
126786|NCT03196648|Other|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
126787|NCT03196635|Device|Patient-Assisted (PA) Breast Compression|The technologist will properly position the breast and apply minimum compression. The subject will be instructed to apply compression as the technologist ensures the breast tissue is in appropriate position and tautness. The technologist will then guide the subject to achieve appropriate compression level, sufficient but not excessive, and the image will be acquired. This will be done for both standard views CC & MLO.
126788|NCT03196635|Device|Technologist-Controlled (TC) Breast Compression|TC compression will be conducted per standard of care practices at the site.
126789|NCT03196622|Device|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
126790|NCT03196609|Biological|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)~1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
126791|NCT03196596|Other|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
126792|NCT03196583|Device|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
126793|NCT03196570|Behavioral|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
126794|NCT03196570|Behavioral|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
126795|NCT03196557|Drug|Prenisolone|Specified dose on specified days
126796|NCT03196557|Drug|Placebo|Specified dose on dose on specified days
126920|NCT03195543|Diagnostic Test|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
126797|NCT03196544|Behavioral|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
126798|NCT03196544|Behavioral|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
126799|NCT03196531|Drug|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
126800|NCT03196531|Drug|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
126801|NCT03196518|Procedure|PET Imaging|PET/CT study immediately after injection
126802|NCT03196518|Other|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes
126803|NCT03196505|Drug|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
126804|NCT03196505|Drug|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
126805|NCT03196492|Other|No intervention|No intervention
126806|NCT03196479|Drug|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
126807|NCT03196479|Drug|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
126808|NCT03196466|Biological|Valproic acid|titration
126809|NCT03196466|Biological|carbamazepine|titration
126810|NCT03196466|Biological|phenobarbital|titration
126811|NCT03196466|Biological|phenytoin|titration
126812|NCT03196466|Biological|levetiracetam|titration
126813|NCT03196466|Biological|lamotrigine|titration
126814|NCT03196466|Biological|topiramate|titration
126815|NCT03196466|Biological|oxcarbazepine|titration
126816|NCT03196466|Biological|stiripentol|titration
126817|NCT03196466|Biological|clobazam|titration
126818|NCT03196453|Dietary Supplement|Probiotic|probiotic and/or placebo intervention in toddlers
126819|NCT03196427|Drug|Vedolizumab|Vedolizumab intravenous infusion.
126820|NCT03196414|Biological|CART-138/BCMA/19/more|Cyclophosphamide，Fludarabine，CART-138/BCMA /19/more cells Cyclophosphamide: 300 mg/m2 IV over 30 minutes on days -5 , -4,and -3; Fludarabine: 30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3 Biological: Anti-CD138/BCMA/CD19/more total CART cells 5x106- 100x106 CAR+ T cells per kg of recipient bodyweight
126821|NCT03196401|Drug|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
126822|NCT03196401|Radiation|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
126823|NCT03196388|Drug|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
126824|NCT03196375|Drug|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
126825|NCT03196375|Drug|Placebo ODT|Placebo ODT taken three times daily for 28 days
126826|NCT03196362|Drug|Pioglitazone + Metformin|One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
126827|NCT03196362|Drug|Placebo Oral Tablet|One tablet of placebo will be given twice daily
126828|NCT03196349|Drug|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
126829|NCT03196349|Drug|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
126830|NCT03196349|Drug|Rivaroxaban 10 MG|Will be randomized to receive open label rivaroxaban of 10mg daily
126831|NCT03196336|Other|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
126832|NCT03196310|Drug|Platelet Concentrate|Platelet Rich plasma
126833|NCT03196310|Drug|Corticosteroid injection|Kenalog
126834|NCT03196310|Other|Normal Saline|Placebo
126835|NCT03196297|Drug|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
126836|NCT03196297|Drug|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
126837|NCT03196284|Drug|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
126838|NCT03196284|Drug|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
127014|NCT03194802|Behavioral|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
127076|NCT03194334|Behavioral|Vegetarian diet|
126839|NCT03196271|Dietary Supplement|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
126840|NCT03196258|Behavioral|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
126841|NCT03196245|Other|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
126842|NCT03196232|Drug|Epacadostat|Given PO
126843|NCT03196232|Other|Laboratory Biomarker Analysis|Correlative studies
126844|NCT03196232|Biological|Pembrolizumab|Given IV
126845|NCT03196219|Drug|C16G2|C16G2
126846|NCT03196219|Other|Placebo|Varnish Placebo
126847|NCT03196206|Drug|BMS-986177|Oral Suspension
126848|NCT03196193|Procedure|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
126849|NCT03196193|Device|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
126850|NCT03196193|Device|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
126851|NCT03196180|Drug|Imiquimod|Given intravaginally
126852|NCT03196180|Drug|Topical Fluorouracil|Given intravaginally
126853|NCT03196167|Drug|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
126854|NCT03196167|Other|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
126855|NCT03196154|Diagnostic Test|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
126856|NCT03196154|Diagnostic Test|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
126857|NCT03196141|Diagnostic Test|StO2 and EndoPAT|"StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.~The EndoPAT probe will be place on a finger on the same arm.~Pulse oximeter probes will be connected to a finger on each hand."
126858|NCT03196128|Other|Digital communication|Communicating with patients via email and text message.
126859|NCT03196128|Other|Non digital|Communicating with patients via telephone and written appointment letters.
126860|NCT03196102|Behavioral|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
126861|NCT03196102|Behavioral|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
126862|NCT03196102|Behavioral|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
126863|NCT03196089|Procedure|Oxygen application|Supplemental oxygen via mask
126864|NCT03196076|Drug|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
126865|NCT03196063|Other|Eccentric|Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
126866|NCT03196063|Other|Modified Protocol|Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
126867|NCT03196050|Device|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:~1x per day: status update (how are you today?)~1x per week: 10 questions on general health status~1x per month: EORTC QLQ-C30 questionnaire"
126868|NCT03196037|Behavioral|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
127015|NCT03194802|Behavioral|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
127077|NCT03194334|Dietary Supplement|creatine|1g creatine/day
126869|NCT03196024|Behavioral|Family-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
126870|NCT03196024|Behavioral|Individual-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
126871|NCT03196011|Other|TKR with mechanical alignment method|TKR implanted using traditional mechanical alignment methods
126872|NCT03196011|Other|TKR with alternative alignment method|TKR implanted using alternative alignment methods
126873|NCT03195998|Diagnostic Test|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
126874|NCT03195985|Other|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
126875|NCT03195985|Other|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
126876|NCT03195972|Other|Drug diary filling|patient will fill every day a drug diary
126877|NCT03195959|Other|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
126878|NCT03195946|Drug|Lu AF35700|tablets for oral use, 10 mg/day
126879|NCT03195946|Drug|Midazolam|syrup for oral use, 4mg/day
126880|NCT03195946|Drug|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
126881|NCT03195933|Other|Cortisol|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
126882|NCT03195933|Other|Placebo|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
126883|NCT03195920|Device|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
126884|NCT03195907|Other|Pulmonary physiotherapy|
126885|NCT03195894|Device|TripleA|
126886|NCT03195881|Other|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
126887|NCT03195868|Device|Realief Therapy|Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
126888|NCT03195855|Other|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
126889|NCT03195842|Other|Recordable card|
126890|NCT03195829|Behavioral|Computerized Cognitive Stimulation|The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
126891|NCT03195829|Behavioral|Multimedia-based internet|The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
126892|NCT03195816|Behavioral|Computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
127052|NCT03194568|Device|Anterior Vertebral Tether|Vertebral body tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
126893|NCT03195803|Behavioral|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
126894|NCT03195790|Behavioral|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
126895|NCT03195777|Device|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, [FDG] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
126896|NCT03195764|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
126897|NCT03195751|Device|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
126898|NCT03195751|Device|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
126899|NCT03195738|Other|Cognitive Orientation to Occupational Performance (CO-OP)|"In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
126900|NCT03195725|Other|Review of notes|No intervention will occur
126901|NCT03195699|Drug|TTI-101|Patients in the first cohort are treated at dose level 1. Each cohort of a dose level will include at least 3 patients, who will be evaluated for at least one cycle (28-days). The next dose level will be determined after careful review of the tolerability and pharmacokinetics of the previous cohort. If the current dose is the lowest dose and the rule indicates dose de-escalation, we will treat the new patients at the lowest dose unless the number of DLTs reaches the elimination boundary, at which point we will terminate the trial for safety. If the current dose is the highest dose and the rule indicates dose escalation, we will treat the new patients at the highest dose.
126902|NCT03195686|Device|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
126903|NCT03195673|Drug|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 30 days later.
126904|NCT03195673|Procedure|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
126905|NCT03195660|Device|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
126906|NCT03195647|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.~Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
126907|NCT03195634|Drug|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day
126908|NCT03195621|Device|Stent implantation|Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
126909|NCT03195608|Device|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
126910|NCT03195608|Behavioral|Active Control|Participants will practice their driving on a driving simulator with feedback form a trained interventionist.
126911|NCT03195595|Device|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
126912|NCT03195595|Device|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
126913|NCT03195582|Drug|Corsodyl|following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
126914|NCT03195569|Drug|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
126915|NCT03195569|Drug|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
126916|NCT03195569|Drug|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
126917|NCT03195569|Drug|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
126918|NCT03195556|Device|Ultrasound|Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
126919|NCT03195543|Diagnostic Test|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
126921|NCT03195543|Diagnostic Test|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
126922|NCT03195543|Diagnostic Test|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
126923|NCT03195530|Drug|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
126924|NCT03195517|Other|Physical exercise|
126925|NCT03195504|Device|HFNC|High flow nasal oxygen (60 l) under GA
126926|NCT03195504|Device|CON (control)|Standard oxygen (10-15 l) under GA
126927|NCT03195491|Biological|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
126928|NCT03195478|Drug|Nivolumab|Specified dose of Nivolumab on specified days.
126929|NCT03195478|Drug|Ipilimumab|Specified Dose of Ipilimumab on specified days
126930|NCT03195465|Dietary Supplement|Dark Chocolate|Dark Chocolate bars with 70% cacao and 30% organic cane sugar where 4 squares of the dark chocolate will be administered twice daily between the hours of 6 a.m. and 6 p.m. daily for four weeks.
126931|NCT03195452|Drug|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
126932|NCT03195439|Device|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
126933|NCT03195426|Procedure|distal nerves blocks group|"ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.~SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.~SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
126934|NCT03195426|Procedure|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.~This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
126935|NCT03195413|Procedure|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
126936|NCT03195413|Drug|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
126937|NCT03195413|Device|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
126938|NCT03195400|Diagnostic Test|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
126939|NCT03195400|Diagnostic Test|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
126940|NCT03195400|Diagnostic Test|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
126941|NCT03195400|Diagnostic Test|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
126942|NCT03195387|Drug|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
126943|NCT03195374|Other|Prescription Opioid Misus Index|Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
126944|NCT03195361|Device|SRS - Self Retaining Support system|
126945|NCT03195348|Other|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
126946|NCT03195335|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
126947|NCT03195322|Procedure|Pre-pectoral Tissue Expander|All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
126948|NCT03195309|Drug|Ropivacaine|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
126949|NCT03195309|Drug|Fentanyl|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
126950|NCT03195296|Other|No intervention|No intervention related to the study is foreseen
126951|NCT03195283|Other|Meal service|The type of meal service in the hospital (usual care)
126952|NCT03195270|Drug|[18F]FDG|10 mCi of [18F]FDG via the antecubital vein in a bolus injection
126953|NCT03195270|Device|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
126954|NCT03195257|Other|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
126955|NCT03195257|Other|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
127053|NCT03194555|Drug|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B taken together twice daily for 12 weeks.
126956|NCT03195257|Other|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
126957|NCT03195244|Other|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
126958|NCT03195231|Drug|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
126959|NCT03195231|Drug|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
126960|NCT03195218|Device|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
126961|NCT03195205|Diagnostic Test|OraQuick HCV Rapid Antibody Test|HCV Screening
126962|NCT03195192|Other|biomarker study|This is a biomarker study
126963|NCT03195166|Diagnostic Test|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
126964|NCT03195153|Drug|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
126965|NCT03195153|Drug|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
126966|NCT03195153|Drug|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
126967|NCT03195140|Device|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
126968|NCT03195127|Other|multimodal physical therapy|Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
126969|NCT03195114|Diagnostic Test|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
126970|NCT03195101|Procedure|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
126971|NCT03195088|Drug|BI 473494|Solution for injection
126972|NCT03195088|Drug|Placebo|Solution for injection
126973|NCT03195075|Procedure|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
126974|NCT03195075|Procedure|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
126975|NCT03195062|Other|Test meal|Liquid test meal (fructose+glucose)
126976|NCT03195049|Diagnostic Test|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
126977|NCT03195036|Behavioral|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program.
126978|NCT03195023|Drug|Lisinopril|
126979|NCT03195023|Drug|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
126980|NCT03195010|Biological|Platelet Transfusion|Undergo lower dose platelet transfusion
126981|NCT03195010|Biological|Platelet Transfusion|Undergo higher dose platelet transfusion
126982|NCT03194997|Other|Dance|The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
126983|NCT03194997|Other|Pilates|The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 16 weeks, with 60 minutes the session.
126984|NCT03194984|Drug|Hydrogen peroxide 35%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
126985|NCT03194984|Drug|Hydrogen peroxide 38%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
126986|NCT03194971|Other|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
126987|NCT03194971|Other|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
127016|NCT03194789|Device|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
126988|NCT03194958|Behavioral|Specialized Quitline|Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
126989|NCT03194958|Behavioral|Basic Needs Navigator|Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
126990|NCT03194945|Drug|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
126991|NCT03194945|Drug|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
126992|NCT03194945|Drug|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
126993|NCT03194945|Drug|CSII alone|No OHA is given after short-term intensive CSII
126994|NCT03194932|Drug|Venetoclax|Venetoclax will be given as oral tablets, which are intended to be swallowed intact and may not to be crushed or otherwise altered for administration, or as an oral suspension for patients who cannot swallow tablets.
126995|NCT03194932|Drug|Cytarabine|Given intravenously (IV) or intrathecally (IT).
126996|NCT03194932|Drug|Idarubicin|Given IV.
126997|NCT03194932|Drug|Intrathecal Triple Therapy|Given IT.
126998|NCT03194919|Other|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen & Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
126999|NCT03194906|Drug|Memantine|Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
127000|NCT03194906|Other|Placebo|A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.
127001|NCT03194906|Other|Cognitive Assessment|Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
127002|NCT03194893|Drug|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
127003|NCT03194893|Drug|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
127004|NCT03194880|Device|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:~User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.~The laboratory component: For each test we will evaluate:~The percentage of assays completed~The percentage of assays incomplete (i.e. invalid result on two attempts)~Reasons for incomplete assays, e.g.~The sample could not be delivered to the strip or cartridge correctly~Invalid control~Results could not be interpreted~Others"
127005|NCT03194867|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
127006|NCT03194867|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
127007|NCT03194854|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
127008|NCT03194841|Other|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
127009|NCT03194828|Behavioral|Medication reminder|Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined
127010|NCT03194828|Behavioral|Medication monitoring only|Patients will use an electronic medication monitoring device to record their actual medication use
127011|NCT03194815|Drug|Intravenous immunoglobulin|This is a blood product containing antibodies from thousands of healthy donors.
127012|NCT03194815|Drug|Placebo|This is the control, or sham, treatment
127013|NCT03194815|Drug|Rituximab|Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
127078|NCT03194334|Dietary Supplement|Placebo|pills
127017|NCT03194789|Other|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
127018|NCT03194776|Drug|LLG783|LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
127019|NCT03194776|Drug|Placebo|Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
127020|NCT03194763|Diagnostic Test|coronary angiography|computed tomography acquisitions performed on a revolution CT
127021|NCT03194750|Other|Share ultrasound measurement of IVC collapsibility to Nephrology Attending|Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of < 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
127022|NCT03194750|Other|Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending|Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
127023|NCT03194737|Device|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
127024|NCT03194724|Other|Vitamin A supplementation|Bi annual vitamin A supplementation programme
127025|NCT03194711|Device|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
127026|NCT03194698|Device|IPL|Intense Pulsed Light with Meibomian Gland Expression
127027|NCT03194698|Procedure|MGX|Meibomian Gland Expression
127028|NCT03194685|Drug|FF-10101-01|FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached. In Phase 2a, subjects will be randomly assigned to 1 of 3 dose levels in a balanced fashion. The treatment will continue until, intolerable toxicity, or investigation/subject decision.
127029|NCT03194672|Behavioral|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.~The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
127030|NCT03194659|Dietary Supplement|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
127031|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode(3/1 regimen).
127032|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes episodes(6/2 regimen).
127033|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodesepisodes(3/2 regimen).
127034|NCT03194646|Other|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
127035|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
127036|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
127037|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
127038|NCT03194633|Drug|Nifedipine controlled-release tablets (Adalat, BAYA1040)|Nifedipine GITS 60 mg (once per day)
127039|NCT03194620|Other|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
127040|NCT03194620|Other|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
127041|NCT03194620|Other|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
127042|NCT03194620|Other|(−)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (−)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
127043|NCT03194620|Other|(−)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (−)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
127044|NCT03194620|Other|(−)-Epicatechin (EC)|Single oral intake of 120 µmol of (−)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
127045|NCT03194620|Other|(−)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (−)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
127046|NCT03194620|Other|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
127047|NCT03194607|Other|Functional walk tests|
127048|NCT03194607|Other|3D analysis of locomotion and posture|
127049|NCT03194607|Other|questionnaires|
127050|NCT03194594|Drug|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
127051|NCT03194581|Device|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
127054|NCT03194555|Drug|Placebo Capsules|One capsule contains placebo for component A and one capsule contains placebo for component B taken together twice daily for 12 weeks.
127055|NCT03194542|Drug|Luspatercept|Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
127056|NCT03194529|Biological|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
127057|NCT03194516|Other|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
127058|NCT03194503|Device|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.~Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
127059|NCT03194490|Other|combined intervention group|The combined intervention group received the cervical passive mobilization, stretching, and home program (Stretching and ROM exercise).Stretching, cervical passive mobilization, and range of motion: The manual therapy was conducted by a physical therapist who has licensed from the California Board of Physical Therapy. The cervical passive mobilization were selected by the physical therapist based on the participant's condition. Stretching techniques were performed in the combined intervention group for 30 seconds and repeated 3 times twice a week in the following order on the following muscles: anterior, middle and posterior scalene, upper fibers of trapezius, pectoralis minor and interspinous muscles .AROM Exercise were performed 10 repetitions 3-4 times daily. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral.
127060|NCT03194490|Other|The standard intervention|"The standard intervention group will receive cervical mobilization and home program (ROM exercises).~Cervical mobilization and range of motion: The manual therapy was conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs). The nature of PAIVMs techniques was selected by the physical therapist based on the participant's condition.~Active Cervical Range of Motion Exercises (ACROM) were performed 10 repetitions 3-4 times daily. Subjects were advised to maintain their usual activity within the limits of pain. The ACROM exercise consisted of the subject placing fingers over the manubrium bone and placing chin on the fingers. The subject was then instructed to rotate to one side as far as possible and return to neutral ."
127061|NCT03194477|Behavioral|Mobile-enhanced Engagement Intervention|Mobile phone based enhanced case management intervention for HIV positive & HIV negative young Black men who have sex with men.
127062|NCT03194464|Other|submaximal exercise (grip)|participants perform repeated gripping with visual feedback to task failure
127063|NCT03194451|Other|non-interventional study|teeth collection
127064|NCT03194438|Behavioral|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
127065|NCT03194425|Diagnostic Test|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
127066|NCT03194412|Dietary Supplement|Diet /nutritional|"• Duration:~the first stage - 3 months: 12 weeks~second stage - 3 months: 12 weeks~Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:~make a diet modification to include the products recommended in frailty~modifying eating habits~The diet modification is mainly focused on adequate supply:~vitamin D (according to Central Europe guidelines -2013 for seniors)~protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)"
127067|NCT03194412|Behavioral|Physical activity|"Duration:~the first stage - 3 months: 12 weeks~second stage - 3 months: 12 weeks~Frequency: twice a week~Duration of each session: 60 minutes~Worksheets for the elderly with frailty syndrome have been developed:~resistance exercises and strength training, which aim to improve muscle strength in the limbs~exercises aimed at improving motor coordination, flexibility and speed~stretching exercises."
127068|NCT03194412|Combination Product|Comprehensive therapy|"Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)~Duration:~the first stage - 3 months- 12 weeks~the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes"
127069|NCT03194412|Behavioral|Caregivers of elderly|"Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).~Duration:~the first stage - 3 months: 12 weeks~the second stage - 3 months: 12 weeks~Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes"
127070|NCT03194399|Behavioral|Personalized health care service|Physical activity coaching, other functional outcome observation
127071|NCT03194386|Other|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
127072|NCT03194386|Other|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
127073|NCT03194373|Drug|Palbociclib|"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
127079|NCT03194334|Dietary Supplement|Beta-alanine|0.8g beta-alanine per day
127080|NCT03194321|Drug|Tacrolimus Extended Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
127081|NCT03194308|Behavioral|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
127082|NCT03194295|Behavioral|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
127083|NCT03194295|Behavioral|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
127084|NCT03194282|Other|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
127085|NCT03194269|Device|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
127086|NCT03194256|Behavioral|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
127087|NCT03194230|Other|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
127088|NCT03194217|Drug|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
127089|NCT03194217|Drug|Placebo|Placebo
127090|NCT03194204|Diagnostic Test|matrix metalloproteinase -3(MMP-3) and Matrix metalloproteinase-9 (MMP-9)|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
127091|NCT03194191|Device|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
127092|NCT03194178|Other|Pierre Robin sequence patients|"4 questionnaires will be completed by the patient :~Kidscreen 52 (generic quality of life questionnaire)~Voice Handicap Index : VHI-9i (specific quality of life questionnaire)~Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)~MDI-C (composite depression scale for minors)"
127093|NCT03194165|Biological|Dolutegravir|Dosage
127094|NCT03194165|Biological|Raltegravir|Dosage
127095|NCT03194165|Biological|Rilpivirine|Dosage
127096|NCT03194165|Biological|Nevirapine|Dosage
127097|NCT03194165|Biological|Atazanavir|Dosage
127098|NCT03194165|Biological|Darunavir|Dosage
127099|NCT03194165|Biological|Ritonavir|Dosage
127100|NCT03194152|Dietary Supplement|Peanut|Dietary Supplement: Peanut
127101|NCT03194152|Dietary Supplement|Control|Dietary Supplement: High carbohydrate snacks
127102|NCT03194139|Drug|GC4711 30 mg IV|GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
127103|NCT03194139|Drug|GC4711 50 mg IV|GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.
127104|NCT03194139|Drug|GC4419 45 mg IV|GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
127105|NCT03194126|Procedure|Mifepristone + Misoprostol OR oxytocine + laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
127106|NCT03194126|Procedure|Mifepristone + Misoprostol OR oxytocine|standart support
127107|NCT03194113|Behavioral|Trauma-focused treatment|Weekly sessions
127108|NCT03194113|Behavioral|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
127109|NCT03194113|Behavioral|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
127110|NCT03194074|Drug|Propofol|In propofol/remifentanil group, propofol at a rate 75~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
127111|NCT03194074|Drug|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
127112|NCT03194061|Radiation|Hypofractionated Radiotherapy|20 fractions of 275cGy 5 days/week
127113|NCT03194061|Drug|Weekly cisplatin|Concomitant weekly cisplatin 35mg/m2 x 4 weeks
127114|NCT03194048|Other|Functional Chewing Training|"FuCT;~Family training~Providing optimal sitting posture for children to support oral sensorimotor functions~Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements~Massage of the upper and lower gums through the front teeth to molar area~Chewing training to stimulate lateral and rotational tongue movements~Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
127115|NCT03194048|Other|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;~Family training~passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
127116|NCT03194035|Biological|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
127117|NCT03194022|Other|Blood sample|measurement of electrolytes and blood count
127355|NCT03192280|Device|MS Band 2|"Wearable watch-like device with multiple sensors"
127118|NCT03194009|Drug|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
127119|NCT03194009|Behavioral|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
127120|NCT03193996|Device|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
127121|NCT03193983|Procedure|Flaps Coverage|Surgical group will undergo surgical coverage of the fingertip defect by V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
127122|NCT03193983|Procedure|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
127123|NCT03193970|Behavioral|Post‐Operative Recovery Registry|Multi‐institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
127124|NCT03193957|Drug|Etanercept|Etanercept PFS and Autoinjector
127125|NCT03193957|Device|Autoinjector|Autoinjector
127126|NCT03193944|Drug|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
127127|NCT03193944|Drug|Placebo vitamin D3|vitamin D as a placebo
127128|NCT03193931|Drug|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
127129|NCT03193931|Drug|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
127130|NCT03193918|Drug|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
127131|NCT03193918|Drug|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
127132|NCT03193918|Drug|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
127133|NCT03193905|Procedure|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
127134|NCT03193905|Procedure|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
127135|NCT03193866|Drug|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
127136|NCT03193853|Drug|Tak-228 & Tak-117|Patients will receive oral TAK-228 and TAK-117 tablets until disease progression.
127137|NCT03193853|Drug|Cisplatin & Nab Paclitaxel|following Tak-228 & Tak-117 standard nab paclitaxel plus cisplatin infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
127138|NCT03193840|Procedure|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
127139|NCT03193827|Device|In-line filtration|In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis
127140|NCT03193827|Device|Standard treatment|Patients are treated with standard intravenous solutions and vascular access management
127141|NCT03193814|Drug|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
127142|NCT03193801|Device|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
127143|NCT03193788|Drug|pemetrexed|Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
127144|NCT03193788|Drug|Folic Acid|folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
127145|NCT03193788|Drug|Vitamin B12 Injection|vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
127146|NCT03193788|Drug|Dexamethasone|Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
127147|NCT03193775|Biological|HBV vaccine|HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
127148|NCT03193762|Other|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
127149|NCT03193749|Drug|Amiodarone Hydrochloride|Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
127150|NCT03193749|Drug|Placebo Oral Tablet|Matching placebo for tablets of 200 mg of Amiodarone
127151|NCT03193736|Device|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.~The intervention is to be performed as stand-alone surgery."
127152|NCT03193723|Procedure|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):~Subdermic infiltration. Approximately 8 milliliters~Intradermic injection (making of the skin wheal). of approximately 6 milliliters.~Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose~Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.~Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
127153|NCT03193723|Procedure|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
127154|NCT03193710|Drug|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
127155|NCT03193710|Drug|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
127156|NCT03193710|Drug|Remifentanil|Remifentanil will be used for analgesia in both groups.
127157|NCT03193697|Device|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
127158|NCT03193697|Device|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
127159|NCT03193684|Drug|Dapagliflozin 10mg|subjects will receive daily dose of 10 mg dapagliflozin for 3 months
127160|NCT03193684|Drug|Control|Placebo
127161|NCT03193671|Diagnostic Test|Diagnosis|Improving diagnosis
127162|NCT03193658|Procedure|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
127163|NCT03193658|Drug|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
127164|NCT03193645|Drug|Degarelix|Injection
127165|NCT03193632|Diagnostic Test|US Muscle layer thickness (MLT) estimation|"Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane"
127166|NCT03193632|Diagnostic Test|REE estimation by indirect calorimetry|REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
127167|NCT03193619|Device|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
127168|NCT03193606|Other|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
127169|NCT03193593|Drug|Placebo|Placebo- Single injection of saline into Pectoralis Muscle
127170|NCT03193593|Drug|EB-001|Single injection of EB-001 into Pectoralis Muscle
127171|NCT03193580|Device|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
127172|NCT03193580|Device|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
127173|NCT03193580|Device|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
127174|NCT03193567|Biological|HEKT cell|3 cycles of HEKT cell treatment
127175|NCT03193502|Drug|rivaroxaban|rivaroxaban
127176|NCT03193489|Other|Follow-up|
127177|NCT03193489|Other|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
127178|NCT03193489|Other|Control Parkinson group|No treatment.
127179|NCT03193463|Drug|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
127180|NCT03193463|Drug|Topotecan (>8cc)|In predominantly enhancing mass with a volume of > 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
127181|NCT03193463|Device|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
127182|NCT03193463|Diagnostic Test|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
127183|NCT03193463|Drug|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
127184|NCT03193450|Behavioral|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
127185|NCT03193450|Behavioral|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
127186|NCT03193437|Drug|Open Label Selinexor|Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
127228|NCT03193190|Drug|Bevacizumab|Bevacizumab will be administered as per the schedule specified in the respective arm.
127229|NCT03193190|Drug|Emactuzumab|Emactuzumab will be administered as per the schedule specified in the respective arm.
127187|NCT03193424|Drug|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
127188|NCT03193411|Device|Visumax femtosecond laser|
127189|NCT03193411|Device|Moria M2 microkeratome (MK)|
127190|NCT03193398|Drug|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
127191|NCT03193398|Drug|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
127192|NCT03193385|Procedure|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
127193|NCT03193372|Drug|Azelaic Acid (Finacea Foam, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
127194|NCT03193359|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
127195|NCT03193346|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
127196|NCT03193346|Drug|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® [Sodium chloride 0.9 mg] IM injections in head/neck areas.
127197|NCT03193333|Drug|PRO-122|Posology: 1 drop every 12 hours for 90 days
127198|NCT03193333|Drug|Timolol eye drops|1 drop every 12 hours for 90 days
127199|NCT03193333|Drug|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
127200|NCT03193333|Drug|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
127201|NCT03193333|Other|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
127202|NCT03193333|Other|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
127203|NCT03193333|Drug|Krytantek|Posology: 1 drop every 12 hours for 90 days
127204|NCT03193320|Other|Fluid therapy protocol|Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
127205|NCT03193307|Drug|Microgynon|Run in period & Treatment Period
127206|NCT03193307|Drug|BI 409306|Day 18 & 29 (Treatment Period)
127207|NCT03193294|Diagnostic Test|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
127208|NCT03193281|Drug|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).~Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
127209|NCT03193281|Drug|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
127210|NCT03193268|Other|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
127211|NCT03193268|Other|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
127212|NCT03193255|Device|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
127213|NCT03193242|Other|Electronic Asthma Management System: eAMS|"Electronic Asthma Management System: eAMS Intervention~eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
127214|NCT03193229|Behavioral|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
127215|NCT03193229|Device|Fitbit|Fitbit
127216|NCT03193216|Drug|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
127217|NCT03193203|Drug|Etanercept|50 mg/mL PFS and AI
127218|NCT03193190|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
127219|NCT03193190|Drug|Gemcitabine|Gemcitabine will be administered as per the schedule specified in the respective arm.
127220|NCT03193190|Drug|Oxaliplatin|Oxaliplatin will be administered as per the schedule specified in the respective arm.
127221|NCT03193190|Drug|Leucovorin|Leucovorin will be administered as per the schedule specified in the respective arm.
127222|NCT03193190|Drug|Fluorouracil|Fluorouracil will be administered as per the schedule specified in the respective arm.
127223|NCT03193190|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
127224|NCT03193190|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
127225|NCT03193190|Drug|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
127226|NCT03193190|Drug|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
127227|NCT03193190|Drug|Selicrelumab|Selicrelumab will be administered as per the schedule specified in the respective arm.
127274|NCT03192839|Other|High dose PUFA|High dose PUFA
127230|NCT03193190|Drug|RO6874281|RO6874281 will be administered as per the schedule specified in the respective arm
127231|NCT03193177|Other|the 21-day fasting-like diet|a fasting-like diet with 400 KJ energy intake per day for 21 days
127232|NCT03193164|Device|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
127233|NCT03193164|Other|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
127234|NCT03193151|Procedure|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
127235|NCT03193138|Drug|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
127236|NCT03193125|Dietary Supplement|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
127237|NCT03193125|Dietary Supplement|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
127238|NCT03193112|Drug|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
127239|NCT03193099|Other|Brain imaging|Volume, DWS and DTI
127240|NCT03193099|Other|Neurological assessments|UHDRS
127241|NCT03193099|Behavioral|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
127242|NCT03193099|Behavioral|Behavioural assessments|Computerized game
127243|NCT03193086|Drug|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
127244|NCT03193073|Diagnostic Test|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
127245|NCT03193073|Diagnostic Test|serum fibroblast growth factor-23|serum levels of FGF-23
127246|NCT03193073|Diagnostic Test|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
127247|NCT03193047|Drug|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i (evolocumab) background therapy
127248|NCT03193047|Other|placebo|Daily matching placebo tablet in addition to monthly PCSK9i (evolocumab) background therapy
127249|NCT03193047|Drug|evolocumab|Monthly PCSK9i (evolocumab) background therapy
127250|NCT03193034|Device|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
127251|NCT03193021|Device|Cardiva Mid-Bore VVCS|The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
127252|NCT03193021|Other|Manual compression|Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
127253|NCT03192995|Drug|lorcaserin|lorcaserin 10 mg tablets taken orally twice daily
127254|NCT03192995|Drug|Placebo Oral Tablet|placebo tablets taken orally twice daily
127255|NCT03192982|Device|A-V impulse 6000 Series|foot pad and pump
127256|NCT03192982|Device|Standard treatment (compression)|Short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
127257|NCT03192969|Drug|Abatacept|Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
127258|NCT03192969|Other|Placebo|Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
127259|NCT03192969|Drug|Glucocorticoid Treatment|Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
127260|NCT03192956|Other|No active intervention|No active intervention is performed
127261|NCT03192943|Drug|BMS-986205|Specified dose on specified days
127262|NCT03192943|Biological|Nivolumab|Specified dose on specified day
127263|NCT03192930|Other|Hyperbaric exposure|Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
127264|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
127265|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
127266|NCT03192904|Device|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
127267|NCT03192904|Device|Stapling Device|Stapling Device, including linear stapler and curved stapler.
127268|NCT03192891|Diagnostic Test|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
127269|NCT03192878|Drug|Infliximab|infliximab biosimilar
127270|NCT03192865|Procedure|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
127271|NCT03192852|Other|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
127272|NCT03192852|Procedure|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
127273|NCT03192839|Other|Low dose PUFA|Low dose PUFA
127276|NCT03192826|Drug|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
127277|NCT03192826|Drug|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
127278|NCT03192826|Drug|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
127279|NCT03192813|Device|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
127280|NCT03192813|Device|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
127281|NCT03192774|Device|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
127282|NCT03192761|Procedure|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:~A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
127283|NCT03192761|Procedure|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:~A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
127284|NCT03192761|Procedure|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:~The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
127285|NCT03192735|Drug|ApatinibMesylateTablets|Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
127286|NCT03192722|Device|Colored near reading glasses|Participants are provided with colored near vision glasses.
127287|NCT03192709|Drug|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
127288|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
127289|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
127290|NCT03192696|Device|Atherectomy Catheter|Treatment of restenotic lesions within stents previously placed within the artery.
127291|NCT03192683|Device|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
127292|NCT03192683|Device|Regular sling|
127293|NCT03192670|Device|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
127294|NCT03192657|Drug|Basiliximab|The first administration should be within 8 weeks after disease onset.
127295|NCT03192657|Drug|Calcineurin Inhibitors|Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
127296|NCT03192657|Drug|Steroids|Dosage of steroid can be adjusted according to personal experience of the researcher.
127297|NCT03192644|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
127298|NCT03192644|Procedure|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
127299|NCT03192644|Drug|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
127300|NCT03192644|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
127301|NCT03192631|Other|Financial incentive|Incentive of $15 Canadian
127302|NCT03192618|Procedure|adjuvant transarterial chemoinfusion (TAI)|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
127303|NCT03192618|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
127304|NCT03192605|Other|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
127305|NCT03192605|Other|Placebo|Placebo - matched for calories and fiber
127306|NCT03192592|Other|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
127307|NCT03192579|Drug|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
127308|NCT03192579|Drug|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
127309|NCT03192566|Drug|Tylenol|Dosing of Tylenol for post operative pain control
127310|NCT03192553|Behavioral|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
127311|NCT03192553|Behavioral|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
127312|NCT03192553|Behavioral|One Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
127313|NCT03192553|Behavioral|CDC Procedure|Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
127314|NCT03192540|Other|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
127315|NCT03192527|Drug|KN015|experimental drug
127316|NCT03192527|Drug|Placebo|Comparator.
127317|NCT03192527|Drug|Triptorelin|The drug is used for down-regulation of endogenous FSH.
127318|NCT03192514|Other|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.~The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.~The electronic Deprescribing tool is designed to support clinical decisions"
127319|NCT03192488|Drug|Cetirizine|Cetirizine tablet 10 mg
127320|NCT03192488|Drug|Placebo oral capsule|Gelatin placebo
127321|NCT03192475|Behavioral|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
127322|NCT03192475|Behavioral|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
127323|NCT03192462|Biological|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
127324|NCT03192449|Drug|Albendazole.|Single dose 400mg orally
127325|NCT03192436|Device|Ultrasound|Low-intensity (Ispta < 720 mW/cm2, Isppa < 190 W/cm2) transcranial focused ultrasound
127326|NCT03192410|Behavioral|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
127327|NCT03192410|Behavioral|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
127328|NCT03192410|Biological|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
127329|NCT03192410|Biological|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
127330|NCT03192410|Genetic|DNA|SNPs (GWAS)
127331|NCT03192410|Biological|Mental well-being|Cognitive function; dispositional optimism; depression.
127332|NCT03192397|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
127333|NCT03192397|Drug|Cyclophosphamide|Given IV
127334|NCT03192397|Drug|Fludarabine Phosphate|Given IV
127335|NCT03192397|Other|Laboratory Biomarker Analysis|Correlative studies
127336|NCT03192397|Drug|Melphalan Hydrochloride|Given IV
127337|NCT03192397|Drug|Mycophenolate Mofetil|Given IV
127338|NCT03192397|Drug|Sirolimus|Given IV and PO
127339|NCT03192397|Radiation|Total-Body Irradiation|Undergo TBI
127340|NCT03192384|Behavioral|Educational programme|Educational programme for ward staff
127341|NCT03192371|Biological|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
127342|NCT03192358|Diagnostic Test|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
127343|NCT03192358|Other|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.~Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
127344|NCT03192345|Biological|SAR439459|"Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion"
127345|NCT03192345|Drug|Cemiplimab REGN2810|"Pharmaceutical form: solution~Route of administration: intravenous infusion"
127346|NCT03192332|Device|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
127347|NCT03192332|Drug|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
127348|NCT03192319|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection
127349|NCT03192306|Drug|Merlin|glycolic acid/ethanol solution
127350|NCT03192306|Drug|Ethanol|Ethanol solution
127351|NCT03192293|Drug|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
127352|NCT03192280|Drug|Leukotriene B4|Leukotriene B4 (LTB4)
127353|NCT03192280|Device|FLIR One|Thermal imaging attachment to iPhone
127354|NCT03192280|Device|SCIO|Handheld near-IR molecular spectroscopy device
127356|NCT03192280|Device|AGE reader|Portable bench top device for in-clinic near UV assessment
127357|NCT03192280|Device|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
127358|NCT03192280|Device|iPhone 7|Smart phone
127359|NCT03192254|Behavioral|self-monitoring|recording fruit and vegetable consumption
127360|NCT03192254|Behavioral|daily monetary incentives|daily payments for consuming fruits and vegetables
127361|NCT03192254|Behavioral|delayed lump sum monetary incentives|lump sum payments for consuming fruits and vegetables
127362|NCT03192241|Other|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
127363|NCT03192241|Other|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
127364|NCT03192228|Other|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
127365|NCT03192215|Drug|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
127366|NCT03192215|Drug|Aspirin|Aspirin 81 mg by mouth once daily.
127367|NCT03192202|Drug|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
127368|NCT03192189|Other|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
127369|NCT03192176|Drug|fezolinetant|The dose of ESN364 varies across 7 treatment groups, with groups receiving once a day or twice a day blinded study drug. Doses range from 30 mg to 180 mg total daily dosing for 12 weeks.
127370|NCT03192176|Drug|Placebo|Placebo administered BID for 12 weeks
127371|NCT03192176|Drug|Placebo|Placebo administered QD for 12 weeks
127372|NCT03192163|Other|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
127373|NCT03192150|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
127374|NCT03192150|Other|Vehicle|Placebo twice daily for 16 days
127375|NCT03192137|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
127376|NCT03192137|Other|Vehicle|Placebo twice daily for 16 days
127377|NCT03192124|Device|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.~Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
127378|NCT03192111|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
127379|NCT03192098|Device|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
127380|NCT03192085|Diagnostic Test|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
127381|NCT03192085|Diagnostic Test|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
127382|NCT03192059|Drug|Pembrolizumab|Efficacy of the combined treatment
127383|NCT03192059|Radiation|Radiation|Efficacy of the combined treatment
127384|NCT03192059|Drug|Vitamin D|Efficacy of the combined treatment
127385|NCT03192059|Drug|Aspirin|Efficacy of the combined treatment
127386|NCT03192059|Drug|Lansoprazole|Efficacy of the combined treatment
127387|NCT03192059|Drug|Cyclophosphamide|Efficacy of the combined treatment
127388|NCT03192059|Dietary Supplement|Curcumin|Efficacy of the combined treatment
127389|NCT03192046|Device|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
127390|NCT03192033|Other|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
127391|NCT03192033|Device|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
127392|NCT03192033|Device|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
127393|NCT03192033|Other|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
127394|NCT03192020|Procedure|Percutaneous needle fasciotomy|PNF is a treatment in which the cord causing the contracture is not excised, but only divided with a hypodermic needle. The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure.
127395|NCT03192020|Drug|Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord in the outpatient clinic and the cord can be ruptured by gently force after a day or two.
127396|NCT03192020|Procedure|Limited fasciectomy|In LF, the thickened part of the palmar fascia causing the contracture is excised through skin incision. LF is performed in general or regional anesthesia in operating room. LF has been the dominant technique of surgical treatment.
127397|NCT03192007|Device|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
127398|NCT03191994|Behavioral|Exercise|a structured, supervised eight week moderate intensity exercise intervention
127399|NCT03191981|Drug|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
127400|NCT03191981|Drug|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
127401|NCT03191981|Drug|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
127448|NCT03191578|Drug|Placebo|Administration of placebo
127449|NCT03191565|Other|Paper diary sheet|Writing skill-use and symptoms on a week matrix type sheet
127402|NCT03191968|Behavioral|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
127403|NCT03191968|Behavioral|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
127404|NCT03191942|Device|Modified ortho-k lenses|KETT MC lens
127405|NCT03191942|Device|Ortho-k lenses|KATT BeFree lens
127406|NCT03191929|Other|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.~Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
127407|NCT03191929|Other|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.~Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
127408|NCT03191916|Device|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
127409|NCT03191916|Device|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
127410|NCT03191903|Drug|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)
127411|NCT03191903|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
127412|NCT03191903|Drug|Triamcinolone Hexacetonide|20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide
127413|NCT03191877|Dietary Supplement|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
127414|NCT03191864|Drug|APT-1011|APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
127415|NCT03191864|Drug|Placebo|Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
127416|NCT03191851|Device|standard device|paracentesis using standard
127417|NCT03191851|Device|Melody Device|paracentesis using Melody Device
127418|NCT03191851|Device|Melody Device with Pump|paracentesis using Melody Device with Pump
127419|NCT03191838|Other|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
127420|NCT03191825|Other|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen & Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
127421|NCT03191825|Other|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
127422|NCT03191825|Other|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
127423|NCT03191812|Other|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
127424|NCT03191799|Drug|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
127425|NCT03191786|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered via IV infusion once every three weeks (QW3).
127426|NCT03191786|Drug|Vinorelbine|Vinorelbine will be administered per relevant local guidelines and Summary of Product Characteristics (SmPC) management.
127427|NCT03191786|Drug|Gemcitabine|Gemcitabine will be administered per relevant local guidelines and SmPC management.
127450|NCT03191565|Device|Monsenso DBT-app and IT monitoring program|Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
127428|NCT03191773|Combination Product|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.~Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
127429|NCT03191760|Behavioral|Behavioral Activation|Participants will be asked to attend 6 in-person therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
127430|NCT03191734|Device|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
127431|NCT03191721|Procedure|Surgical anti-infective therapy|Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
127432|NCT03191721|Procedure|Periodontal treatment|Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
127433|NCT03191721|Procedure|Oral Hygiene Instruction|Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
127434|NCT03191721|Drug|Triclosan toothpaste|Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
127435|NCT03191721|Drug|Fluoride toothpaste|Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
127436|NCT03191721|Procedure|Regular maintenance program|OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
127437|NCT03191708|Diagnostic Test|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
127438|NCT03191695|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
127439|NCT03191682|Drug|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
127440|NCT03191669|Other|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
127441|NCT03191656|Device|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
127442|NCT03191630|Behavioral|Fitbit (Control)|Study procedures include group sessions at the OSU Transplant Clinic with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Session 1 for the control group will be identical to the Intervention with the only exception being that participants in the control group will not be asked to increase their step goal. Throughout their participation, subjects will be asked questions only about their use of the Fitbit activity tracker. The research team will not be in contact with them for 6 months, after which time there will be a final group session.
127443|NCT03191630|Behavioral|SystemCHANGE and Fitbit (Intervention)|Study procedures include group sessions with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Study personnel will demonstrate proper Fitbit activity tracker use, and teach participants to sync to their smartphone and retrieve data from their Fitbit. Subjects will be called to encourage them to increase their step goal 5% each month. Fitbit activity tracker reports will be reviewed and participants will be asked to identify what people or things influence their physical activity. Subjects will be asked what they are learning about physical activity, their contentment level with current physical activity, and if they want to make changes. Participants will continue for months, after which time there will be a final group session.
127444|NCT03191617|Dietary Supplement|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
127445|NCT03191604|Other|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
127446|NCT03191591|Behavioral|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
127447|NCT03191578|Drug|RUTI®|Administration of RUTI®
127451|NCT03191552|Device|SPIO|"SPIO (stabilizing input pressure orthosis) 2 hours will receive conventional exercise therapy with the garment on during 2 hours. SPIO 6 hours group wore the SPIO 4 hours more in addition to 2 hours during therapy.~SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.~(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills"
127452|NCT03191552|Other|conventional exercises|range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills
127453|NCT03191539|Drug|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
127454|NCT03191526|Drug|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
127455|NCT03191526|Drug|Placebo (saline)|Intravenous injection every 12 weeks.
127456|NCT03191513|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
127457|NCT03191513|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
127458|NCT03191513|Dietary Supplement|Rapeseed oil|50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
127459|NCT03191500|Device|steerable catheter|peripheral vascular disease
127460|NCT03191487|Other|ChimioPal|"Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.~Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required."
127461|NCT03191487|Other|Usual pathways|In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
127462|NCT03191474|Behavioral|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.~Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
127463|NCT03191461|Diagnostic Test|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
127464|NCT03191448|Procedure|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
127465|NCT03191448|Device|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
127466|NCT03191448|Device|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
127467|NCT03191435|Device|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
127468|NCT03191435|Device|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
127469|NCT03191422|Behavioral|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
127470|NCT03191396|Drug|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
127471|NCT03191396|Drug|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
127472|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
127473|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
127474|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
127475|NCT03191383|Drug|Placebo (Formulation buffer S9b)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
127476|NCT03191370|Other|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
127477|NCT03191370|Drug|Local Anesthetics,Topical|Anesthetic spray
127478|NCT03191357|Other|n/a observational|Observational study
127479|NCT03191344|Behavioral|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
127480|NCT03191331|Behavioral|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
127481|NCT03191318|Other|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
127482|NCT03191318|Other|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
127483|NCT03191305|Drug|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
127484|NCT03191305|Drug|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
127485|NCT03191279|Procedure|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
127486|NCT03191266|Device|Active rTMS|Active rTMS will receive an intermittent rTMS stimulation protocol.
127487|NCT03191266|Device|Sham rTMS|Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.
127488|NCT03191253|Other|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
127489|NCT03191240|Drug|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
127490|NCT03191240|Drug|Normal saline|Placebo
127491|NCT03191214|Device|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery >30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
127492|NCT03191201|Drug|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
127493|NCT03191201|Drug|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
127494|NCT03191188|Drug|Levothyroxine Sodium|Thyroid hormone supplement
127495|NCT03191188|Drug|Placebo Oral Tablet|Placebo
127496|NCT03191175|Other|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
127497|NCT03191162|Drug|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
127498|NCT03191149|Drug|Osimertinib|Given PO
127499|NCT03191136|Drug|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
127500|NCT03191136|Drug|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
127501|NCT03191123|Procedure|hepatic resection|The aim of this intervention is to reach curative resection.
127502|NCT03191123|Procedure|TACE|The aim of this intervention is one of the palliative treatment.
127503|NCT03191110|Other|No intervention: observational study|
127504|NCT03191097|Drug|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
127505|NCT03191097|Drug|Placebo oral capsule|Placebo, capsules daily for 5 days.
127506|NCT03191084|Drug|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
127507|NCT03191084|Drug|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
127508|NCT03191084|Drug|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
127509|NCT03191071|Diagnostic Test|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.~The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
127510|NCT03191071|Diagnostic Test|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
127511|NCT03191071|Diagnostic Test|Blood sampling|A venous blood sample (17.5 mL) will be collected. Whole blood and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers and gene transcription patterns that could predict the necessity of antibiotic prescription or the severity of disease.
127512|NCT03191071|Diagnostic Test|Naso-pharyngeal swab and sputum culture|A pooled nasal swab will be performed and sputum will be collected. Samples will be stored at -80°C. Further analysis of the naso-pharyngeal swab and cultures of sputum will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
127513|NCT03191058|Device|Magnetic Seizure Therapy|"MST treatment will be administered using the MagPro MST with a Cool TwinCoil over the frontal cortex in the midline position using 100 Hz stimulation. The MST determination of seizure threshold will be done using 100% machine output applied at 100 Hz at progressively escalating train durations, commencing at 2 seconds and increasing by 2 seconds with each subsequent stimulation until an adequate seizure is produced. During subsequent sessions, one stimulation will be delivered using a train duration that is 4 seconds longer than the train duration at threshold (with a maximum train duration of 10 seconds).~This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes."
127514|NCT03191058|Device|Electroconvulsive Therapy|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. The ECT determination of seizure threshold and the adjustment of energy at subsequent sessions will be based on a standard published protocol. All participants will receive RUL-UB ECT at six times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
127515|NCT03191045|Diagnostic Test|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
127516|NCT03191032|Other|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
127517|NCT03191019|Behavioral|Mobile-phone app for smoking cessation|Android App for smoking cessation
127518|NCT03191006|Device|MEI BIN insoles|insoles
127519|NCT03190993|Other|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
127520|NCT03190993|Other|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
127521|NCT03190980|Other|5% glucose|Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
127522|NCT03190980|Other|30% glucose|Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
127523|NCT03190980|Other|Placebo|Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
127524|NCT03190967|Drug|T-DM1|T-DM1 3.6 mg/kg IV every 21 days
127525|NCT03190967|Drug|TMZ|Phase I: TMZ 30, 40 or 50 mg/m^2 daily; Phase II: TMZ at RP2D estimated in Phase I
127526|NCT03190954|Other|Placebo|Placebo (po) will be given 60 minutes prior to [11C]raclopride scan. MRI scan to follow end of PET scan.
127527|NCT03190954|Drug|Methylphenidate|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan. MRI scan to follow end of PET scan.
127528|NCT03190941|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
127529|NCT03190941|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
127530|NCT03190941|Biological|anti-KRAS G12V mTCR|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
127531|NCT03190941|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
127532|NCT03190915|Other|Laboratory Biomarker Analysis|Correlative studies
127533|NCT03190915|Other|Pharmacological Study|Correlative studies
127534|NCT03190915|Drug|Trametinib|Given PO
127535|NCT03190902|Behavioral|Attention Processing Training program (APT)|
127536|NCT03190902|Behavioral|nonspecific computer training (n-ST)|
127537|NCT03190889|Other|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
127538|NCT03190889|Other|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
127539|NCT03190876|Procedure|Variable drain usage|Influence of drain usage on seroma formation rate
127540|NCT03190863|Behavioral|Motor imagery combined with neurofeedback (MINF)|"7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen."
127541|NCT03190863|Behavioral|Motor imagery (MI)|"7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
127542|NCT03190863|Behavioral|Control (C)|"7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.~Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
127543|NCT03190850|Other|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
127544|NCT03190850|Other|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
127545|NCT03190824|Drug|OBP-301|A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
127546|NCT03190811|Biological|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.~DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
127547|NCT03190811|Biological|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
127548|NCT03190798|Drug|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.~Administered in 300mg tablets."
127549|NCT03190798|Drug|Placebo|Placebo for Canagliflozin
127550|NCT03190785|Other|Benzoic acid washout and exposure|see above
127551|NCT03190772|Other|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
127552|NCT03190772|Other|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
127553|NCT03190746|Diagnostic Test|TaqMan SNP analysis|TaqMan SNP analysis of the YWHAH gene
127554|NCT03190733|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
127555|NCT03190720|Device|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
127556|NCT03190707|Behavioral|Intervention|"Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.~Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.~Strengthen parenting skills through:~Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.~Teaching the woman/couple on the importance of breast-feeding and how to succeed."
127557|NCT03190694|Drug|Dapagliflozin 10mg|Tablet
127558|NCT03190681|Drug|Ritalin 10Mg Tablet|ingestion of an oral single-dose
127559|NCT03190668|Drug|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
127560|NCT03190668|Drug|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
127561|NCT03190668|Device|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
127562|NCT03190668|Device|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
127563|NCT03190655|Device|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
127564|NCT03190655|Device|Hydrogel|Hydrogel based wound dressing
127565|NCT03190642|Drug|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
127566|NCT03190629|Device|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
127567|NCT03190629|Device|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
127568|NCT03190616|Drug|apatinib|apatinib 500mg/qd, 28d/cycle
127569|NCT03190603|Drug|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
127570|NCT03190590|Device|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
127571|NCT03190590|Device|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability
127572|NCT03190590|Device|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
127573|NCT03190577|Genetic|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
127574|NCT03190551|Other|retroclavicular approach|Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
127575|NCT03190551|Other|costoclavicular approach|costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
127576|NCT03190538|Other|No intervention|There will be no specific intervention to these paediatric NASH patient
127577|NCT03190525|Other|Quality of life questionnaires|QLQ-C30
127578|NCT03190512|Other|Psychological measurements|Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
127579|NCT03190499|Other|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
127580|NCT03190486|Other|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
127581|NCT03190473|Device|DES|PCI with implantation of a DES
127582|NCT03190460|Other|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
127583|NCT03190460|Other|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
127584|NCT03190447|Device|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
127585|NCT03190447|Device|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
127586|NCT03190447|Device|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
127587|NCT03190447|Device|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
127588|NCT03190447|Device|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
127589|NCT03190434|Device|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
127590|NCT03190421|Diagnostic Test|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
127591|NCT03190421|Diagnostic Test|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
127592|NCT03190408|Other|Fluids|Fluids Administered in Shock
127593|NCT03190395|Procedure|CPVI Group|CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
127594|NCT03190395|Procedure|CPVI+LARA Group|CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
127595|NCT03190382|Other|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
127596|NCT03190369|Drug|Hylan G-F 20 (GZ/SAR402662)|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
127597|NCT03190369|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Intra articular"
127598|NCT03190356|Device|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
127599|NCT03190343|Procedure|cholangio-pancreatoscopy|
127600|NCT03190330|Drug|Ibrutinib 420 mg|Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
127601|NCT03190330|Drug|Ibrutinib 560 mg|Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
127602|NCT03190317|Other|HIV-infected Veterans who use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
127603|NCT03190317|Other|HIV-infected Veterans who do not use MHV|The investigators will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, the investigators will interview Veterans to understand why MHV is not used. Finally, the investigators will create an intervention based on the information learned that will encourage use of MHV and ask Veterans to test it out.
127604|NCT03190317|Other|Providers and staff of HIV-infected veteran|The investigators will interview providers and staff to understand why they think Veterans at their health system use or do not use the MHV portal for self management. The investigators will create and test an intervention based on information learned that will encourage use of MHV among Veterans and providers/staff.
127605|NCT03190304|Drug|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
127606|NCT03190304|Drug|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
127607|NCT03190278|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given following a lymphodepleting regimen
127608|NCT03190265|Drug|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
127609|NCT03190265|Drug|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
127610|NCT03190265|Drug|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
127611|NCT03190265|Drug|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
127612|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
127680|NCT03189706|Biological|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
127613|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
127614|NCT03190252|Other|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
127615|NCT03190252|Other|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
127616|NCT03190239|Drug|Apatinib|Apatinib 250mg qd
127617|NCT03190239|Drug|Pemetrexed|Pemetrexed 500mg/m2 qm
127618|NCT03190226|Procedure|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
127619|NCT03190226|Procedure|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
127620|NCT03190213|Drug|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
127621|NCT03190200|Device|MRI|No intervention - observational trial using MRI
127622|NCT03190187|Other|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
127623|NCT03190187|Other|Sham manipulation|Patients will receive simulated spinal manipulation without force application
127624|NCT03190174|Drug|Nab-Rapamycin|Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m2; at Dose Level 2, 3-6 six patients will receive 75 mg/m2; and at Dose Level 3, 3-6 patients will receive 100 mg/m2.
127625|NCT03190174|Biological|Nivolumab|A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
127626|NCT03190161|Behavioral|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level <6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
127627|NCT03190148|Other|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
127628|NCT03190148|Other|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
127629|NCT03190148|Other|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
127630|NCT03190135|Behavioral|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
127631|NCT03190135|Behavioral|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
127632|NCT03190122|Procedure|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. [NCT ID not yet assigned]
127633|NCT03190096|Procedure|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
127634|NCT03190083|Device|2-dimensional mammogram|This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
127635|NCT03190083|Device|digital breast tomosynthesis (DBT)|The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
127636|NCT03190070|Dietary Supplement|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
127637|NCT03190057|Device|BioFreedom stent|Percutaneous coronary intervention with BioFreedom stent
127638|NCT03190044|Dietary Supplement|PACR|Daily assumption of PACR for a 3-month period
127639|NCT03190044|Dietary Supplement|Placebo|Daily assumption of placebo
127640|NCT03190031|Other|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
127641|NCT03190031|Other|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
127642|NCT03190018|Device|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
127643|NCT03190005|Drug|clopidogrel|routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
127644|NCT03190005|Drug|Placebos|no medication, healthy subjects.
127645|NCT03189992|Drug|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
127646|NCT03189992|Drug|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
127647|NCT03189979|Behavioral|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
127677|NCT03189719|Drug|5-FU|800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration.
127678|NCT03189706|Drug|Irinotecan|50mg/m^2/day IV will be administered from day 1-5
127679|NCT03189706|Drug|temozolomide|(given concurrently with Irinotecan) 150mg/m^2/day orally
127648|NCT03189966|Procedure|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 1 ml/Kg of ropivacaine 0.3%was injected.
127649|NCT03189966|Procedure|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 1 ml/Kg of ropivacaine 0.3%was injected.
127650|NCT03189953|Radiation|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
127651|NCT03189940|Behavioral|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
127652|NCT03189940|Behavioral|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
127653|NCT03189927|Device|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
127654|NCT03189914|Drug|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
127655|NCT03189901|Drug|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
127656|NCT03189888|Device|apheresis|
127657|NCT03189875|Other|Standard of Care|Participants will be followed as per local routine clinical practice
127658|NCT03189862|Behavioral|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
127659|NCT03189836|Biological|ACTR707|autologous T cell product
127660|NCT03189836|Biological|rituximab|CD20-directed cytolytic antibody
127661|NCT03189823|Device|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
127662|NCT03189810|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
127663|NCT03189810|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
127664|NCT03189810|Behavioral|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
127665|NCT03189797|Other|tailored preventive program|In the study group they were given a preventive program as homecare program including tooth brushing 2/day with a fluoride toothpaste( 5000 ppm F) following the instructions in addition to fluoride mouth rinse. For the clinical approach motivational engagement was done by discussing with patients how to improve oral health behavior including amount of sugar, fibrous food and junk food. This in addition to pits and fissures sealant, F- varnish 2 times /year. and application of fluoride varnish every 6 months and dietary intake interventions.
127666|NCT03189784|Other|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
127667|NCT03189771|Procedure|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
127668|NCT03189758|Other|Observational Control Diet|Participants will follow their usual or normal diet for 30 days (days 1-30) while under study observation.
127669|NCT03189758|Other|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days (days 31-60). These meals should meet KDQOI guidelines for energy and protein (30-35 kcal/kg & 1.2 g/kg) as well as low phosphorus, potassium, and sodium. The meals are formulated to less than 600-800 mg sodium each (<2,000g/day) and will be ordered and delivered through momsmeals.com
127670|NCT03189745|Biological|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
127671|NCT03189732|Drug|Metformin Oral|
127672|NCT03189732|Drug|Metformin local in AT|
127673|NCT03189732|Other|Exercise|
127674|NCT03189719|Biological|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
127675|NCT03189719|Drug|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
127676|NCT03189719|Drug|Cisplatin|80 mg/m^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
127681|NCT03189706|Drug|GM-CSF|250mg/m2/day SC will be administered on days 6-10
127682|NCT03189693|Other|PVB|nerve stimulator-guided PVB will be performed at two levels
127683|NCT03189693|Other|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
127684|NCT03189693|Other|GA|All patients will receive general anesthesia.
127685|NCT03189693|Other|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
127686|NCT03189680|Other|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
127687|NCT03189667|Device|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:~All lesions to be predilated with high pressure balloons until waist is obliterated.~At least two minutes dilatation.~Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.~Multiple lesions:~To be treated with single balloon if possible.~To be treated with multiple inflation if cannot be covered with single balloon."
127688|NCT03189667|Device|Plain balloon angioplasty|"Plain balloon angioplasty~Vessel treatment with additional Plain balloon angioplasty:~Inflation to nominal pressure for at least 1 minute.~Balloon size: similar to predilation balloon."
127689|NCT03189667|Device|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.~Inflation to nominal pressure for at least 1 minute.~Balloon size: similar to the predilation balloon.~New drug coated balloon will be required for each lesion."
127690|NCT03189654|Device|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
127691|NCT03189641|Device|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
127692|NCT03189628|Biological|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
127693|NCT03189628|Drug|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
127694|NCT03189615|Drug|Lu AF35700|Single oral dose of 10 mg Lu AF35700
127695|NCT03189589|Drug|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
127696|NCT03189589|Drug|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
127697|NCT03189576|Diagnostic Test|blood draw|
127698|NCT03189563|Drug|DA-9805 45mg|DA-9805 15mg tid
127699|NCT03189563|Drug|DA-9805 90mg|DA-9805 30mg tid
127700|NCT03189563|Other|Placebo|Placebo, tid
127701|NCT03189550|Procedure|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
127702|NCT03189550|Procedure|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
127703|NCT03189550|Procedure|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
127704|NCT03189537|Drug|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)|Broad-spectrum antiviral agent
127705|NCT03189537|Drug|Placebo oral capsule|Placebo capsule to match Ingavirin capsule
127706|NCT03189524|Drug|BGB-3111|
127707|NCT03189511|Drug|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
127708|NCT03189498|Drug|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250 mg tablets) on Day 1.
127709|NCT03189485|Drug|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
127710|NCT03189472|Device|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
127711|NCT03189472|Device|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
127712|NCT03189459|Behavioral|Home Visit Program|RC: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation, patient medical history and comorbidities RN and SW: Home safety assessment SW: Psychosocial assessment of dyad, HADS, assessment of mobility and homebound status, needs assessment of dyad, caregiver medical history and comorbidities RC: patient and caregiver short MoCA, PD-Rx, health literacy assessment, satisfaction surveys; patient PDQ-39/PDQ-8
127713|NCT03189459|Behavioral|Caregiver Mentorship Program|"Both mentors and mentees will be completing this program:~Mentors will be asked to complete: 1) a Mentor Training - One 5-hour session at Rush University Medical Center; and 2) two 16-week periods of mentoring someone who is currently a caregiver for a patient with Parkinson's Disease~Caregivers mentees will be asked to complete a 16 week mentorship program with their assigned mentor"
127714|NCT03189446|Radiation|Vaginal Cuff Brachytherapy|Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy
127715|NCT03189446|Drug|Carboplatin|Carboplatin (AUC6) on day 1 for 3 cycles
127716|NCT03189446|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV over 1 hour on days 1,8 and 15 for 3 cycles
127717|NCT03189433|Drug|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
127718|NCT03189420|Procedure|Tumor resection|The tumors will be resected in routine therapeutic surgeries
127719|NCT03189407|Dietary Supplement|Moringa oleifera tea|
127720|NCT03189394|Behavioral|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
127721|NCT03189394|Behavioral|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
127722|NCT03189394|Behavioral|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
127723|NCT03189381|Radiation|Cohort A|Cohort A - WBRT dose = 25 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
127724|NCT03189381|Radiation|Cohort B|Cohort B - WBRT dose = 20 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
127725|NCT03189368|Device|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.~Programming features:~Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used)~Nearly simultaneous (Δt=5msec) second left ventricular pulse and~Threshold of ≤3.5V@0.5msec"
127726|NCT03189355|Procedure|Blood sampling|"D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~D4 zonulin"
127727|NCT03189355|Procedure|Bioelectrical impedance vector analysis|"D1~D4"
127728|NCT03189355|Procedure|Muscular echography|"D1~D4"
127729|NCT03189342|Behavioral|Single task training|The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times
127730|NCT03189342|Behavioral|dual task training|The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems
127731|NCT03189342|Behavioral|exercise-cognitive activity combined training|The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
127732|NCT03189329|Drug|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
127733|NCT03189329|Drug|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
127734|NCT03189316|Other|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
127735|NCT03189303|Device|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit or Corail femoral stem
127736|NCT03189290|Procedure|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
127737|NCT03189264|Procedure|percutaneous nephrolithotomy for kidney stones|Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
127738|NCT03189251|Other|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
127739|NCT03189238|Biological|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
127923|NCT03187834|Drug|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
127740|NCT03189225|Other|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
127741|NCT03189212|Behavioral|Usual Care Visit|Routine 6-month follow up appointment at the NYULMC transplant center
127742|NCT03189212|Behavioral|Telemedicine Visit|TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
127743|NCT03189199|Other|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
127744|NCT03189186|Drug|Pembrolizumab Injection [Keytruda]|Same as arm description
127745|NCT03189186|Procedure|Cryoablation|Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
127746|NCT03189186|Procedure|Nephrectomy|Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
127747|NCT03189173|Device|Oral appliance|"An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst/Somnomed) will be provided with a device (BluePro, BlueSom) for the duration of the study.~Patients will also be administered sham (room air) at 4 L/min via nasal cannula."
127748|NCT03189173|Drug|Oxygen|Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
127749|NCT03189173|Other|Oral appliance plus oxygen|Both treatments will be administered simultaneously.
127750|NCT03189173|Other|No treatment|Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
127751|NCT03189160|Biological|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
127752|NCT03189160|Biological|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
127753|NCT03189160|Other|Non-treatment control group|
127754|NCT03189147|Procedure|Biceps Tenodesis|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
127755|NCT03189147|Procedure|Debridement|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
127756|NCT03189134|Drug|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
127757|NCT03189134|Device|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
127758|NCT03189095|Behavioral|WOWii (Workout on Wheels Internet Intervention)|"Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.~Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.~Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.~Participants will complete surveys to report on their exercise self-efficacy and perceived barriers."
127759|NCT03189082|Procedure|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
127760|NCT03189069|Drug|Apixaban|Treatment for NVAF patients
127761|NCT03189069|Drug|Dabigatran|Treatment for NVAF patients
127762|NCT03189069|Drug|Rivaroxaban|Treatment for NVAF patients
127763|NCT03189069|Drug|Warfarin|Treatment for NVAF patients
127764|NCT03189056|Diagnostic Test|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
127765|NCT03189056|Biological|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
127766|NCT03189056|Procedure|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
127767|NCT03189043|Device|Antimicrobial Surface|Antimicrobial Surface
127768|NCT03189030|Biological|pLADD|via IV infusion
127769|NCT03189017|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
127770|NCT03189017|Drug|Placebos|The placebo is a white, round, uncoated tablet.
127771|NCT03189004|Behavioral|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"Identification and registration of pregnant women and services for them~Birth notification~Childhood vaccination services under EPI~Newly married couple identification~e-Referral.~e-monitoring"
127772|NCT03188991|Drug|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
127773|NCT03188978|Drug|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
127774|NCT03188978|Other|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
127775|NCT03188965|Drug|BAY1895344|Study drug will be administered as scheduled.
127776|NCT03188952|Diagnostic Test|International Caries Classification and Management System|Caries assessment and management system
127777|NCT03188939|Procedure|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
127778|NCT03188939|Procedure|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
127779|NCT03188939|Procedure|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
127780|NCT03188926|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
127781|NCT03188913|Diagnostic Test|Coagulation tests|The following plasma values will be measured: prothrombin time, activated partial thromboplastin time, thrombin time, functional fibrinogen, lactate, base excess, fibrin monomers, Factor XIII, Factor XII, Factor VIII, Fact von Willebrand, Plasmin, Plasminogen, Alpha-2-antiplasmin, antithrombin, protein C, Heparan sulfate, synecan 1. Surveys on the state of healing and moisture titration will be performed using Tewamether
127782|NCT03188900|Biological|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
127783|NCT03188887|Drug|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
127784|NCT03188887|Drug|Renin Angiotensin system (RAS) blockade|treatment with Renin angiotensin system (RAS) blockade
127785|NCT03188848|Drug|BPI-3016|Single-dose subcutaneous injection of BPI-3016
127786|NCT03188848|Drug|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
127787|NCT03188835|Dietary Supplement|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
127788|NCT03188835|Other|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
127789|NCT03188835|Radiation|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
127790|NCT03188835|Radiation|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
127791|NCT03188835|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
127792|NCT03188835|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
127793|NCT03188835|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
127794|NCT03188835|Device|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
127795|NCT03188835|Device|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
127796|NCT03188835|Device|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
127797|NCT03188835|Device|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
127798|NCT03188822|Device|Bioabsorbable steroid releasing sinus implant|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
127799|NCT03188822|Device|Bioabsorbable nasal dressing impregnated with steroid|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
127800|NCT03188809|Procedure|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
127801|NCT03188809|Procedure|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
127802|NCT03188796|Drug|Cholecalciferol|oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
127803|NCT03188796|Drug|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
127804|NCT03188783|Drug|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
127805|NCT03188783|Drug|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
127806|NCT03188757|Other|hyperglycaemic clamp|2h hyperglyceamic clamp
127807|NCT03188744|Other|Assessment of the pelvic floor function|Vaginal palpation and perineometry.
127808|NCT03188744|Other|Questionnaire application|Questionnaires: EORTC, WHOQoL-BREF, PFID-20; PSIQ-12 and PFIQ-7.
127809|NCT03188718|Device|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
127810|NCT03188705|Drug|Clopidogrel|Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
127811|NCT03188705|Drug|Aspirin|Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
127812|NCT03188692|Biological|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
127813|NCT03188679|Device|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
127814|NCT03188666|Drug|REGN2477|Pharmaceutical form: Powder for solution for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
127815|NCT03188666|Drug|Matching placebo|Pharmaceutical form: Powder for solution for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
127816|NCT03188653|Other|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
127817|NCT03188653|Other|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
127818|NCT03188653|Other|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
127819|NCT03188653|Other|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
127820|NCT03188653|Other|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
127821|NCT03188653|Other|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
127822|NCT03188653|Other|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free & Clear Liquid Cleanser
127823|NCT03188640|Procedure|Laparoscopic gastric-bypass surgery|Female participants with BMI >30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
127824|NCT03188627|Biological|Bronchial basal cells|Transplantation of autologous bronchial basal cells
127825|NCT03188614|Drug|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
127826|NCT03188575|Behavioral|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
127827|NCT03188575|Other|Waiting List|8 week waiting list period.
127828|NCT03188562|Other|PET/CT|Positron Emission Tomography (PET/CT)
127829|NCT03188562|Procedure|EBUS-TBNA, EUS-NA|Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
127830|NCT03188562|Procedure|TEMLA|Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
127831|NCT03188549|Other|AniosGel 85 NPC|Hand hygiene formula
127832|NCT03188549|Other|Softa-Man (Braun)|Hand hygiene formula
127833|NCT03188549|Other|Septol|alcohol-based hand rub
127834|NCT03188536|Other|No Intervention|No Intervention
127835|NCT03188523|Drug|MK-8504|After at least an 8-hour fast, a single oral dose of MK-8504 will be administered in capsule form.
127836|NCT03188510|Biological|LY3074828|Administered SC
127837|NCT03188497|Drug|Lobaplatin|Lobaplatin for Injection
127838|NCT03188497|Device|linear accelerator|Medical linear accelerator
127839|NCT03188471|Drug|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
127840|NCT03188471|Drug|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
127841|NCT03188458|Other|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 [approximately 4-8 weeks of age]).
127842|NCT03188445|Drug|Iron Isomaltoside 1000|Administered iv
127843|NCT03188445|Drug|ferrous fumarate with ascorbic acid|Oral administration
127844|NCT03188432|Drug|Carboplatin|Given IV and IP
127845|NCT03188432|Drug|Paclitaxel|Given IV
127846|NCT03188432|Other|Quality-of-Life Assessment|Ancillary studies
127847|NCT03188432|Other|Questionnaire Administration|Ancillary studies
127848|NCT03188432|Procedure|Surgical Procedure|Undergo CRS
127849|NCT03188393|Procedure|Biopsy of Breast|Undergo stereotactic biopsy
127850|NCT03188380|Diagnostic Test|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
127851|NCT03188380|Diagnostic Test|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
127852|NCT03188367|Diagnostic Test|Gluten or placebo capsules|Administration of gluten or placebo capsules
127853|NCT03188354|Diagnostic Test|18F-FDG|PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
127854|NCT03188354|Diagnostic Test|18F-fluciclovine|PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
127855|NCT03188354|Diagnostic Test|standard MRI|clinical routine MRI examination, both for primary staging and response to therapy assessment.
127856|NCT03188341|Other|vascular surgery procedure|"an elective open vascular surgery procedure~ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
127857|NCT03188328|Drug|AvidinOX|"AvidinOX vial containing 22.5 mg AvidinOX~+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume"
127858|NCT03188328|Drug|177Lu-ST2210|177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
127859|NCT03188328|Drug|177Lu-ST2210|Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
127860|NCT03188315|Genetic|HPV oncogenes|PCR and oncogenes detection
127861|NCT03188302|Other|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
127862|NCT03188289|Drug|Placebo gel|Placebo is the control group treated with a placebo gel.
127863|NCT03188289|Drug|Clorhexidine gel|Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
127864|NCT03188289|Drug|Clorhexidine-Chitosan gel|Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
127865|NCT03188289|Drug|Hyaluronic Acid gel|Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
127866|NCT03188276|Drug|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
127867|NCT03188276|Drug|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
127868|NCT03188263|Other|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
127869|NCT03188263|Other|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
127870|NCT03188250|Behavioral|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
127871|NCT03188237|Behavioral|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
127872|NCT03188224|Other|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
127873|NCT03188211|Other|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
127874|NCT03188211|Other|Control|Any educational program will be delivered to clinicians assigned to control arm
127875|NCT03188198|Drug|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
127876|NCT03188185|Drug|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
127877|NCT03188185|Drug|ALKS 5461 Placebo|Placebo tablet, administered sublingually
127878|NCT03188172|Drug|Cyclophosphamide|Chemotherapy
127879|NCT03188172|Drug|Bortezomib|Chemotherapy
127880|NCT03188172|Drug|Lenalidomide|Chemotherapy
127881|NCT03188172|Drug|Daratumumab|Chemotherapy
127882|NCT03188172|Drug|Dexamethasone|Chemotherapy
127883|NCT03188172|Drug|Melphalan|Chemotherapy
127884|NCT03188172|Drug|Filgrastim|Haematopoietic agent for the stem cell harvest
127885|NCT03188159|Drug|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
127886|NCT03188146|Drug|Ursodeoxycholic Acid|Standard care of PBC patients
127887|NCT03188133|Other|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
127888|NCT03188120|Drug|Spiriva Respimat|Drug
127889|NCT03188107|Other|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
127890|NCT03188094|Other|community health worker (CHW)-led health coaching for patients|Using a stepped-wedge design, investigators will implement the study in 25 NYC PCP sites enrolling 2,840 South Asian patients at- risk for T2DM.
127891|NCT03188081|Drug|Abatacept|Subcutaneous
127892|NCT03188068|Drug|Sirolimus|Oral administration
127893|NCT03188068|Drug|Prednisolone|Oral administered with sirolimus
127894|NCT03188068|Drug|Propranolol|Oral administered with sirolimus
127895|NCT03188055|Other|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.~The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option—incorporating rich narrative from clinical experience and translation of probabilistic information—while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
127896|NCT03188042|Device|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
127897|NCT03188042|Device|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
127898|NCT03188029|Diagnostic Test|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.~Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
127899|NCT03188016|Behavioral|Intensive Interaction with Music|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
127900|NCT03188016|Behavioral|Standard Intensive Interaction|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
127901|NCT03188003|Other|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
127902|NCT03188003|Other|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
127903|NCT03187990|Drug|[68Ga]PSMA-11|PET/MRI with [68Ga]PSMA will be compared to mpMRI for biopsy guidance.
127904|NCT03187977|Behavioral|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
127905|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert Ultra|Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
127906|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert VL|Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
127907|NCT03187951|Behavioral|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
127908|NCT03187951|Behavioral|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
127909|NCT03187951|Other|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
127910|NCT03187951|Behavioral|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
127911|NCT03187951|Behavioral|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
127912|NCT03187951|Behavioral|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
127913|NCT03187938|Diagnostic Test|Testing of Alkaline Phosphatase Levels|Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
127914|NCT03187925|Procedure|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
127915|NCT03187912|Drug|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
127916|NCT03187899|Drug|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
127917|NCT03187899|Drug|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
127918|NCT03187873|Behavioral|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
127919|NCT03187860|Procedure|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
127920|NCT03187860|Other|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
127921|NCT03187847|Device|Actigraph GT3X|"The primary outcomes are measured by the Actigraph GT3X (step counts) and FSMC (fatigue scale for motor and cognitive functions questionnaire) at three different points in time (Actigraph is worn for three weeks in total).~The secondary outcomes are emotional status, measured by the hospital anxiety and depression scale (HADS) and quality of life, measured by the Hamburg Quality of Life Questionnaire in MS (HAQUAMS)."
127922|NCT03187834|Drug|Azithromycin|Children in this arm will receive Azithromycin once a day.
127924|NCT03187834|Drug|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
127925|NCT03187834|Drug|Placebo|Children in this arm will receive Placebo once a day.
127926|NCT03187821|Procedure|Laser peripheral iridotomy|location of laser peripheral iridotomy
127927|NCT03187808|Other|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
127928|NCT03187808|Other|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
127929|NCT03187795|Drug|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
127930|NCT03187795|Drug|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
127931|NCT03187782|Diagnostic Test|ANSWatch|
127932|NCT03187769|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
127933|NCT03187769|Drug|Olanzapine|Daily oral dosing
127934|NCT03187756|Drug|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
127935|NCT03187743|Other|Blood samples|"Blood samples at 3 visits :~V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis only if previous treatment with low-dose prednisone~V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis~V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank"
127936|NCT03187730|Behavioral|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
127937|NCT03187730|Behavioral|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
127938|NCT03187730|Drug|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
127939|NCT03187704|Other|HEPA air filtration|Air filters were placed in participant homes
127940|NCT03187691|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
127941|NCT03187678|Drug|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
127942|NCT03187678|Drug|oral selexipag (Uptravi)|Uptravi is used as an auxiliary medicinal product, as part of the PAH standard treatment and administered according to the local prescribing information
127943|NCT03187665|Device|Radical 7|The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
127944|NCT03187665|Device|Radius 7|The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
127945|NCT03187652|Diagnostic Test|CT Perfusion Study|Brain and cardiac CT perfusion scan
127946|NCT03187652|Diagnostic Test|Echocardiogram|STI Echocardiography
127947|NCT03187652|Diagnostic Test|neuro-cogntive assessment|CBS neuro-cogntive assessment
127948|NCT03187639|Diagnostic Test|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or > 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
128059|NCT03186755|Drug|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
127949|NCT03187639|Diagnostic Test|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites… (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
127950|NCT03187626|Drug|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
127951|NCT03187626|Drug|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
127952|NCT03187600|Procedure|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
127953|NCT03187600|Procedure|Standard of Care Pharyngeal Flap|Included in study arm description
127954|NCT03187587|Device|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
127955|NCT03187587|Drug|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
127956|NCT03187574|Device|Elevate Ant™|Surgery with Elevate Ant™
127957|NCT03187574|Device|Perigee™|Surgery with Perigee™
127958|NCT03187561|Behavioral|Infant sleep-adapted coparenting intervention|The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
127959|NCT03187548|Drug|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
127960|NCT03187535|Device|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
127961|NCT03187535|Other|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
127962|NCT03187522|Device|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
127963|NCT03187509|Drug|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
127964|NCT03187509|Other|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
127965|NCT03187496|Drug|Midazolam|Each subject will receive midazolam on Days 1 and 12.
127966|NCT03187496|Drug|Caffeine|Each subject will receive caffeine on Days 1 and 12.
127967|NCT03187496|Drug|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
127968|NCT03187496|Drug|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
127969|NCT03187483|Procedure|orthodontic treatment|orthodontic treatment in maxillary crowding
127970|NCT03187470|Device|Different programming of a CRT defibrillator|Different programming of a CRT defibrillator using pacing modalities of a quadripolar left ventricular lead
127971|NCT03187457|Other|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
127972|NCT03187457|Other|Control: no treatment|Healthy women without Bacterial Vaginosis
127973|NCT03187444|Procedure|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
127974|NCT03187431|Biological|autologous bone marrow mesenchymal stem cells|intravenous infusion
127975|NCT03187418|Device|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power—2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time—0.5ms; micropulse off time—1.1ms; and duty cycle (proportion of each cycle during which the laser is on)—31.33 %.~The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).~The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
127976|NCT03187405|Drug|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
127977|NCT03187392|Drug|Lidocaine Injectable Product|3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
127978|NCT03187392|Drug|Lidocaine Topical Cream [LMX]|3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
127979|NCT03187379|Drug|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
127980|NCT03187379|Drug|Bupivacaine|60cc Bupivacaine
127981|NCT03187366|Other|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
128009|NCT03187119|Behavioral|Pictorial Asthma Action Plan|Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.
127982|NCT03187353|Drug|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
127983|NCT03187353|Drug|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
127984|NCT03187340|Behavioral|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
127985|NCT03187340|Behavioral|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
127986|NCT03187314|Drug|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
127987|NCT03187314|Drug|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
127988|NCT03187301|Drug|APL-130277|APL-130277 single dose
127989|NCT03187301|Drug|Placebo|Placebo single dose
127990|NCT03187301|Drug|Moxifloxacin|moxifloxacin 400mg single dose
127991|NCT03187288|Drug|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
127992|NCT03187275|Other|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
127993|NCT03187275|Other|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
127994|NCT03187262|Drug|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
127995|NCT03187249|Behavioral|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
127996|NCT03187249|Behavioral|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
127997|NCT03187249|Behavioral|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
127998|NCT03187223|Drug|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
127999|NCT03187223|Drug|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
128000|NCT03187210|Drug|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
128001|NCT03187210|Drug|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
128002|NCT03187197|Drug|Pradaxa®|Dabigatran etexilate
128003|NCT03187184|Device|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
128004|NCT03187171|Other|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
128005|NCT03187171|Device|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
128006|NCT03187158|Diagnostic Test|Forced Oscillation Technique|F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
128007|NCT03187132|Device|Digital Pain Reduction Kit|A two-component intervention consisting of (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain and to teach skills related to chronic pain; (2) TENS unit, used to reduce acute localized pain.
128008|NCT03187132|Device|Active Control|An active control TENS unit used to reduce acute localized pain.
128301|NCT03185000|Drug|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
128010|NCT03187119|Behavioral|Written Asthma Action Plan|Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
128011|NCT03187106|Drug|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
128012|NCT03187106|Drug|Placebo|Placebo representing standard of care
128013|NCT03187106|Drug|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
128014|NCT03187093|Drug|Vortioxetine|10-20 mg once daily for 8 weeks
128015|NCT03187093|Drug|Escitalopram|10-20 mg once daily for 8 weeks
128016|NCT03187080|Procedure|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
128017|NCT03187080|Other|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to our current standard of care, we will utilize the following perioperative strategies [Arsalani]:~Standardized written information given preoperatively.~Allow clear liquids for up to 2 hours prior to arrival at the surgery center.~Use paravertebral block to augment postoperative pain control.~Standardized multimodal analgesic regimen~Antiemetics~Easily accessible call-in or walk-in postop care/support~The proposed strategies differ from standard of care in the following ways:~PVB is less commonly used in elective surgery.~Patients do not eat or drink after midnight.~There is no standardized preoperative information packet.~Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
128018|NCT03187080|Procedure|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
128019|NCT03187080|Drug|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is *NOT* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
128020|NCT03187067|Device|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
128021|NCT03187054|Procedure|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
128022|NCT03187041|Other|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.~Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
128023|NCT03187028|Behavioral|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
128024|NCT03187028|Behavioral|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
128025|NCT03187015|Drug|Entinostat|HDAC (histone deacetylase inhibitor)
128026|NCT03187015|Drug|Midazolam|benzodiazepine central nervous system (CNS) depressant
128027|NCT03187002|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy—documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
128028|NCT03187002|Drug|Moderate IV Sedation|IV sedation with fentanyl and versed
128029|NCT03187002|Other|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
128030|NCT03187002|Other|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
128031|NCT03186989|Drug|IONIS MAPTRx|"Part 1: IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D.~Part 2: IONIS MAPTRx is administered intrathecally at quarterly intervals for 48."
128032|NCT03186989|Other|Placebo|A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks in Part 1. No placebo is given in Part 2.
128033|NCT03186976|Behavioral|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.~2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).~3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.~4) An OMRON BP monitor will be supplied to each patient. A target SBP of <140/80 mm/Hg will be targeted.~5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c<6.5%"
128034|NCT03186976|Other|Standard of Care|Recommendations based on current guidelines
128035|NCT03186963|Procedure|No immobilization|Conventional wrist dressing
128036|NCT03186963|Procedure|Volar splint|Volar plaster splint
128037|NCT03186950|Procedure|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
128038|NCT03186950|Procedure|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
128039|NCT03186937|Dietary Supplement|hominex-2|Hominex-2 is a methionine-free amino acid modified medical supplement
128040|NCT03186924|Behavioral|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
128041|NCT03186911|Behavioral|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
128042|NCT03186898|Radiation|Proton Therapy (Radiation Therapy)|Undergo proton therapy
128043|NCT03186898|Radiation|Photon Therapy (Radiation Therapy)|Undergo photon therapy
128044|NCT03186885|Behavioral|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
128045|NCT03186885|Behavioral|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
128046|NCT03186885|Behavioral|Control|Participants receive standard of care
128047|NCT03186872|Behavioral|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
128048|NCT03186859|Procedure|Roux-en-Y Gastric Bypass (RYGB) surgery|RYGB operation using surgeons' standard technique
128049|NCT03186859|Procedure|Sleeve Gastrectomy (SG) surgery|SG surgery using surgeons' standard technique
128050|NCT03186846|Device|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
128051|NCT03186846|Device|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
128052|NCT03186833|Other|no intervention|no intervention
128053|NCT03186820|Other|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
128054|NCT03186807|Diagnostic Test|ultrasonographic scan of fetal brain|"Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).~specific measurements as follow:~Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.~Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.~Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.~6. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
128055|NCT03186794|Other|Treadmill exercise training|The target training heart rate range is 70-80% of heart rate reserve, computed as: 0.7 and 0.85 (peak heart rate minus resting heart rate) + resting heart rate. Subjects will exercise for 30 minutes per session, completing on average 3 sessions per week, over approximately 12 weeks. During the training session, heart rate, treadmill speed, treadmill inclination, perceived fatigability index and RPE will be recorded. In the event that subjects cannot sustain 30 minutes of continuous treadmill walking at the target intensity, an interval approach will be used in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each of these sessions will last about 60 minutes but slightly longer if an interval approached is used.
128056|NCT03186781|Biological|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-FA/Sing) is an investigational ferritin vaccine.
128057|NCT03186781|Biological|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing)is an investigational plasmid DNA vaccine.
128058|NCT03186768|Behavioral|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
128060|NCT03186755|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
128061|NCT03186742|Drug|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
128062|NCT03186729|Drug|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
128063|NCT03186716|Dietary Supplement|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
128064|NCT03186716|Dietary Supplement|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
128065|NCT03186703|Behavioral|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
128066|NCT03186690|Other|Biodentine|
128067|NCT03186690|Other|Mineral Trioxide Aggregate|
128068|NCT03186677|Biological|ISU304/CB2679d|ISU304/CB2679d 75~150 IU/kg by intravenous or subcutaneous
128069|NCT03186677|Biological|BeneFix|BeneFIX 75 IU/kg, intravenous administration
128070|NCT03186664|Device|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
128071|NCT03186664|Drug|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.~Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
128072|NCT03186651|Device|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
128073|NCT03186638|Drug|Ibuprofen|Given PO
128074|NCT03186638|Other|Placebo|Given PO
128075|NCT03186638|Other|Questionnaire Administration|Ancillary studies
128076|NCT03186625|Drug|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.~Frequency:two times a day, one package per time. Duration:three months."
128077|NCT03186625|Drug|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
128078|NCT03186612|Behavioral|OT+VR intervention with videogames for the upper limb (dexterity)|Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
128079|NCT03186599|Behavioral|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
128080|NCT03186586|Drug|Ulipristal acetate|5mg/day/five days
128081|NCT03186586|Drug|Placebo|Placebo one pill a day for 5 days at the bleeding episode
128082|NCT03186573|Dietary Supplement|Grape juice|400ml diary of grape juice
128083|NCT03186573|Dietary Supplement|Maltodextrin|400ml diary of maltodextrin
128084|NCT03186560|Device|gekoTM|The geko™ W-2 devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W-2 device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
128085|NCT03186547|Drug|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
128086|NCT03186547|Procedure|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
128087|NCT03186534|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
128088|NCT03186534|Behavioral|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
128089|NCT03186508|Behavioral|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
128090|NCT03186508|Behavioral|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
128091|NCT03186495|Drug|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
128092|NCT03186482|Drug|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
128093|NCT03186482|Drug|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
128094|NCT03186482|Drug|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
128129|NCT03186287|Other|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
128130|NCT03186274|Behavioral|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
128302|NCT03185000|Other|Placebo|Administered Intravenously (IV)
128095|NCT03186469|Behavioral|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
128096|NCT03186469|Behavioral|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
128097|NCT03186456|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.
128098|NCT03186456|Drug|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
128099|NCT03186443|Drug|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
128100|NCT03186443|Drug|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
128101|NCT03186430|Behavioral|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.~Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.~Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
128102|NCT03186417|Biological|2 million hMSC/kg|2 million hMSCs/kg infusion
128103|NCT03186417|Biological|4 million hMSC/kg|4 million hMSC/kg infusion
128104|NCT03186417|Biological|6 million hMSC/kg|6 million hMSC/kg infusion
128105|NCT03186417|Biological|placebo|placebo infusion
128106|NCT03186404|Drug|Atorvastatin|Atorvastatin 40mg OD
128107|NCT03186404|Drug|Placebo oral tablet|Placebo
128108|NCT03186391|Other|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
128109|NCT03186378|Combination Product|VP-102 with applicator|Subjects will receive treatment to their molluscum contagiosum with VP-102.
128110|NCT03186365|Drug|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
128111|NCT03186352|Procedure|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:~application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
128112|NCT03186339|Procedure|TAVI|transfemoral transcatheter aortic valve implantation
128113|NCT03186339|Procedure|SAVR|isolated surgical valve replacement
128114|NCT03186339|Other|MM|management of aortic stenosis by medical treatment only
128115|NCT03186326|Drug|FOLFOX regimen|"A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
128116|NCT03186326|Drug|FOLFIRI Protocol|"A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
128117|NCT03186326|Drug|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
128118|NCT03186326|Drug|Panitumumab|Administered at 6 mg/Kg
128119|NCT03186326|Drug|Cetuximab|Administered at 500 mg/m²
128120|NCT03186326|Drug|Bevacizumab|Administered at 5 mg/Kg
128121|NCT03186326|Drug|Aflibercept|Administered at 4 mg/Kg
128122|NCT03186313|Drug|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
128123|NCT03186313|Drug|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.
128124|NCT03186313|Drug|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
128125|NCT03186313|Drug|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks
128126|NCT03186300|Device|PEPPER system|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
128127|NCT03186287|Other|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
128128|NCT03186287|Other|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
128131|NCT03186274|Behavioral|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
128132|NCT03186261|Drug|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
128133|NCT03186261|Drug|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
128134|NCT03186248|Procedure|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
128135|NCT03186235|Other|Flow cytometry|Isolation of T regulatory cells from blood
128136|NCT03186222|Diagnostic Test|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.~The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
128137|NCT03186209|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
128138|NCT03186209|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 40 inclusive.
128139|NCT03186196|Dietary Supplement|Diet containing Folate|
128140|NCT03186183|Behavioral|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
128141|NCT03186170|Other|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
128142|NCT03186157|Procedure|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
128143|NCT03186157|Procedure|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
128144|NCT03186144|Genetic|Blodd punction for genetic analysis|
128145|NCT03186131|Drug|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
128146|NCT03186131|Drug|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
128147|NCT03186118|Biological|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
128148|NCT03186105|Other|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
128149|NCT03186092|Other|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
128150|NCT03186079|Drug|Xiaojidaozhi Decoction oral capsules|Capsules with mixture of twelve Chinese herbal medicines granule inside
128151|NCT03186079|Drug|Placebo oral capsules|Capsules with flour granule inside
128152|NCT03186079|Drug|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
128153|NCT03186079|Behavioral|Toilet training|Toilet training has been considered a routine method in treatment of constipation
128154|NCT03186066|Device|Flamingo Device|Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
128155|NCT03186066|Procedure|Standard Therapy|Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
128156|NCT03186053|Drug|sodium creatine phosphate|sodium creatine phosphate .Loading dose followed by continuous infusion in operation
128157|NCT03186053|Drug|saline|.Loading dose followed by continuous infusion in operation
128158|NCT03186040|Drug|Lacosamide|Sodium channel blocker
128159|NCT03186027|Dietary Supplement|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: Reconnect"
128160|NCT03186027|Dietary Supplement|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.~Intervention: placebo"
128183|NCT03185832|Other|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
128161|NCT03186014|Device|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
128162|NCT03186001|Drug|Abobotulinum toxin A|The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
128163|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm1|Arm1: GI tumor beyond CRC, ESCC, BTC and GC&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
128164|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm2|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
128165|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm3|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.~OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
128166|NCT03185988|Drug|chemotherapy in combination with trastuzumab for arm4|Trastuzumab (Herceptin ®): same as above Combined with Irinotecan: 120 mg/m2 iv, day 1and day 8, every 3 weeks. OR Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks. OR Irinotecan: 120 mg/m2 iv, day 1and day 8 and Capecitabine(Xeloda®)1000 mg/m2 bid, d1-d14, every 3 weeks (by investigator's choice)
128167|NCT03185975|Behavioral|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
128168|NCT03185975|Behavioral|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
128169|NCT03185936|Procedure|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
128170|NCT03185923|Drug|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.~qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.~zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.~qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.~shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.~shenfu injection（Sanjiu Medical & Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
128171|NCT03185923|Drug|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.~placebo qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.~placebo zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.~placebo qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
128172|NCT03185910|Behavioral|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
128173|NCT03185910|Behavioral|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
128174|NCT03185897|Other|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
128175|NCT03185884|Other|Control|control carbohydrate blend
128176|NCT03185884|Other|Experimental|experimental carbohydrate blend
128177|NCT03185871|Drug|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
128178|NCT03185858|Behavioral|SINEMA intervention|"Provider-facing intervention includes the following components:~(1) Systematic cascade training for village doctors; (2) monthly follow-up visits with the support of the SINEMA APP; (3) village doctor group activities; (4) performance feedback and incentives.~Stroke survivor-facing intervention program includes the following components:~(1) Briefing session; (2) monthly follow-up visits and follow-up handout; (3) daily voice message for health education."
128179|NCT03185845|Drug|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
128180|NCT03185832|Device|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
128181|NCT03185832|Device|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
128182|NCT03185832|Device|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
128184|NCT03185819|Drug|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
128185|NCT03185819|Drug|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
128186|NCT03185819|Drug|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
128187|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
128188|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
128189|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
128190|NCT03185806|Device|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
128191|NCT03185793|Drug|Placebo|Placebo once daily for 5 weeks
128192|NCT03185793|Drug|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
128193|NCT03185793|Drug|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
128194|NCT03185780|Other|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.~Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.~Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
128195|NCT03185767|Other|blood sampling|blood sampling
128196|NCT03185754|Procedure|Sublobar resection|Sublobar resection
128197|NCT03185754|Procedure|lobectomy|lobectomy
128198|NCT03185741|Behavioral|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
128199|NCT03185741|Behavioral|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
128200|NCT03185728|Other|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
128201|NCT03185715|Behavioral|Oral and written counselling|Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
128202|NCT03185702|Genetic|Research genetic tests|DNA and tissue-based tests: karyotype, copy number variants, genome-wide association studies and induced pluripotent stem cells
128203|NCT03185689|Behavioral|Effectiveness of an intensified DSME in T2D adult patients|
128204|NCT03185676|Other|Bilberry|A bilberry based probiotic beverage
128205|NCT03185676|Other|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
128206|NCT03185663|Other|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
128207|NCT03185663|Other|a pillow between the legs|setting up a pillow between the legs before the care
128208|NCT03185650|Device|tPAD Device|A novel, transnasal aerosol generator
128209|NCT03185650|Device|PARI LC Star Nebulizer|Standard oral nebulizer
128210|NCT03185637|Procedure|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.~Common interventions for each of the conditions, which will be compared during analysis include the following:~Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
128211|NCT03185624|Drug|Rifaximin|Antibiotics
128212|NCT03185611|Drug|Rifaximin|Antibiotics
128213|NCT03185611|Drug|Azathioprine|immunomodulator
128214|NCT03185585|Other|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
128215|NCT03185585|Other|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
128216|NCT03185559|Device|Relievion Device- Treatment Stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
128217|NCT03185559|Device|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
128218|NCT03185546|Other|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 13 weeks.
128219|NCT03185546|Other|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for13 weeks
128220|NCT03185546|Other|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 13 weeks
128221|NCT03185546|Other|Low nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 13 weeks
128222|NCT03185546|Other|Tobacco Flavors|Participants can choose e-liquid flavors from a selection of tobacco flavors
128223|NCT03185546|Other|Tobacco and non-tobacco e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes tobacco and non-tobacco choices
128224|NCT03185533|Behavioral|Quality improvement (QI) interventions|"1. The ED admissions exhibited prolonged length of stay.~2. The Interventions for Reducing Medical Decision Time:~The ED director created QI education sessions and reported monthly QI outcomes.~The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.~The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.~3. The Interventions for Reducing Boarding Time~The ED patients could be admitted before 8 a.m. if the bed was vacant.~The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.~Monthly QI outcomes were reported in the hospital affairs meeting."
128419|NCT03184272|Procedure|start capnoperitoneum|measurement in supine position
128225|NCT03185507|Device|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
128226|NCT03185494|Biological|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
128227|NCT03185481|Drug|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
128228|NCT03185481|Drug|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
128229|NCT03185481|Drug|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
128230|NCT03185481|Drug|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
128231|NCT03185481|Drug|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
128232|NCT03185481|Drug|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
128233|NCT03185481|Drug|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
128234|NCT03185481|Drug|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
128235|NCT03185468|Genetic|4SCAR-PSMA|PSMA-specific 4th Generation CART
128236|NCT03185468|Genetic|4SCAR-FRa|FRa-specific 4th Generation CART
128237|NCT03185455|Other|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
128238|NCT03185442|Device|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
128239|NCT03185429|Biological|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7 TSA-DC on week 1,3,5,11,17,23,35,47.
128240|NCT03185429|Drug|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
128241|NCT03185416|Other|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
128242|NCT03185403|Other|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
128243|NCT03185403|Other|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
128244|NCT03185403|Drug|ropivacaine|
128245|NCT03185403|Drug|Sufentanil|
128246|NCT03185390|Procedure|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
128247|NCT03185364|Drug|Sildenafil Citrate|sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
128248|NCT03185364|Drug|Placebo Oral Tablet|placebos treatment for 12 weeks
128249|NCT03185351|Drug|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
128250|NCT03185351|Drug|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
128251|NCT03185351|Drug|Midazolam|0.03 mg/kg of midazolam by I.V. route
128252|NCT03185338|Behavioral|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
128253|NCT03185338|Behavioral|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
128254|NCT03185338|Behavioral|Active school recess|Teachers will design games and activities and will encourage children for being active
128255|NCT03185338|Behavioral|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
128256|NCT03185338|Behavioral|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
128257|NCT03185325|Other|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
128258|NCT03185325|Other|venous blood samples|venous blood samples are collected in healthy voulnteers
128259|NCT03185312|Diagnostic Test|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.~Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
128260|NCT03185299|Other|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
128261|NCT03185299|Other|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
128262|NCT03185286|Device|3d-printed personalized metal implant|3d-printed personalized metal implant will be used in subtalar arthrodesis.
128298|NCT03185013|Biological|VGX-3100|1 milliLiter (mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
128299|NCT03185013|Biological|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
128300|NCT03185013|Device|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
128263|NCT03185247|Behavioral|Transdiagnostic Group-Based Treatment|10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
128264|NCT03185234|Device|anodal tDCS|2 mA, 10 min, 5 sessions
128265|NCT03185234|Device|sham tDCS|sham stimulation, 10 min, 5 sessions
128266|NCT03185221|Device|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
128267|NCT03185221|Device|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
128268|NCT03185208|Drug|Lithium Carbonate|See lithium carbonate arm
128269|NCT03185208|Drug|Placebo oral capsule|See placebo arm
128270|NCT03185195|Drug|AQX-1125 Oral Tablet|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
128271|NCT03185195|Drug|[14C]-AQX-1125 IV|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
128272|NCT03185195|Drug|[14C]-AQX-1125 Oral Solution|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
128273|NCT03185182|Drug|Ioflupane I123|"185 MBq ioflupane I123 will be administered at one single occasion to the study subjects A one time dose of DaTSCAN is given via intravenous injection of 185 MBq Ioflupane (I123) .~The patient takes potassium iodine tablets prior to the DatSCAN injection to protect the thyroid gland. At the time of the DaTSCAN examination, the patient is injected intravenously at slow rate with 185MBq DaTSCAN solution."
128274|NCT03185169|Combination Product|Replens and coconut oil|
128275|NCT03185156|Drug|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
128276|NCT03185156|Drug|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
128277|NCT03185143|Drug|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B taken together to treat a single Qualified Migraine attack.
128278|NCT03185143|Drug|Sumatriptan 100 mg Capsules|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
128279|NCT03185143|Drug|Placebo capsules|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
128280|NCT03185130|Drug|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
128281|NCT03185130|Drug|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
128282|NCT03185130|Drug|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will recieve prochlorperazine 0.15 mg/kg up to 10mg IV slow push
128283|NCT03185130|Drug|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
128284|NCT03185104|Drug|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
128285|NCT03185104|Drug|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
128286|NCT03185091|Other|rapid ventricular pacing|
128287|NCT03185091|Procedure|Surgery|
128288|NCT03185078|Device|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
128289|NCT03185078|Other|Placebo ESWT|In the placebo application, rESWT device was switched on but without pressing the pedal during the same session period. The applicator was positioned to be the same as the other groups.
128290|NCT03185065|Drug|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
128291|NCT03185065|Drug|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
128292|NCT03185065|Drug|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
128293|NCT03185065|Drug|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
128294|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
128295|NCT03185039|Procedure|Blood and tumor samples|Blood and tumor samples
128296|NCT03185026|Behavioral|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :~Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix~Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.~and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)~5) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
128297|NCT03185026|Other|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
128303|NCT03184987|Drug|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
128304|NCT03184987|Drug|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
128305|NCT03184987|Drug|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
128306|NCT03184987|Other|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
128307|NCT03184961|Diagnostic Test|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
128308|NCT03184948|Device|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
128309|NCT03184935|Biological|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
128310|NCT03184935|Drug|Decitabine|Decitabine，20mg/m^2/d
128311|NCT03184922|Procedure|Adjustable versus fixed suspensory loop femoral side graft fixation|A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
128312|NCT03184909|Drug|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
128313|NCT03184909|Drug|Placebo|Placebo capsules of look alike inert substance for control
128314|NCT03184896|Procedure|Hip Fracture Surgery|Hip Fracture Surgery
128315|NCT03184883|Procedure|single conventional denture|mandibular conventional denture with soft liner
128316|NCT03184883|Procedure|single flexible denture|mandibular flexible compete denture
128317|NCT03184870|Drug|BMS-813160|specified dose on specified days
128318|NCT03184870|Biological|Nivolumab|specified dose on specified days
128319|NCT03184870|Drug|Nab-paclitaxel|chemotherapy regimen
128320|NCT03184870|Drug|Gemcitabine|chemotherapy regimen
128321|NCT03184870|Drug|5-fluorouracil (5-FU)|chemotherapy regimen
128322|NCT03184870|Drug|Leucovorin|chemotherapy regimen
128323|NCT03184870|Drug|Irinotecan|chemotherapy regimen
128324|NCT03184857|Procedure|open maxillary sinus lifting|biopsy of the region 6 months later
128325|NCT03184844|Drug|Thalidomide|thalidomide:50mg/d p.o at bedtime
128326|NCT03184831|Procedure|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
128327|NCT03184831|Procedure|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
128328|NCT03184818|Other|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
128329|NCT03184805|Drug|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
128330|NCT03184805|Drug|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
128331|NCT03184792|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
128332|NCT03184792|Other|Physical therapy|Physical therapy to improve arm and hand functions
128333|NCT03184779|Other|Ski and Snowboard Safety Video|The ski and snowboard safety video (~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
128334|NCT03184766|Drug|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
128335|NCT03184766|Drug|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
128336|NCT03184766|Drug|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
128337|NCT03184753|Biological|OC-IgT cells|Autologous human OC-IgT cells.
128420|NCT03184272|Procedure|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
128424|NCT03184272|Procedure|baseline alert 2|measurement in supine position
128338|NCT03184740|Device|Active Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
128339|NCT03184740|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
128340|NCT03184714|Device|NIPPV|BiPAP treatment for 3 years
128341|NCT03184701|Other|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
128342|NCT03184688|Procedure|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
128343|NCT03184688|Drug|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
128344|NCT03184675|Other|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
128345|NCT03184675|Other|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
128346|NCT03184662|Other|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.~First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
128347|NCT03184662|Other|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
128348|NCT03184649|Drug|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
128349|NCT03184649|Drug|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
128350|NCT03184649|Dietary Supplement|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
128351|NCT03184623|Other|muscle mass measurement|measurement of muscle mass by echocardiography
128352|NCT03184610|Device|OCT-scanning|All participants will be scanned with a OCT-device
128353|NCT03184597|Diagnostic Test|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
128354|NCT03184584|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily
128355|NCT03184571|Drug|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
128356|NCT03184558|Drug|Bemcentinib; pembrolizumab|Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor.
128357|NCT03184545|Device|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
128358|NCT03184545|Other|Physical therapy|Standard physical therapy exercises
128359|NCT03184532|Diagnostic Test|ultrasound|ultrasound examination of pyloric antrum
128360|NCT03184519|Diagnostic Test|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
128361|NCT03184506|Other|pre-warming|On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
128362|NCT03184506|Other|no warming|patients were covered only with two layers of cotton blanket
128363|NCT03184493|Drug|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
128364|NCT03184493|Drug|Celebrex|This group patients will receive celebrex.
128365|NCT03184493|Drug|Metformin|This group patients will receive metformin.
128366|NCT03184480|Drug|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
128367|NCT03184467|Drug|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
128368|NCT03184467|Drug|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
128369|NCT03184467|Drug|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
128421|NCT03184272|Procedure|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
128422|NCT03184272|Procedure|ATB loss of capnoperitoneum|measurement under ATB
128370|NCT03184454|Device|Medtronic PC+S Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
128371|NCT03184441|Device|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
128372|NCT03184428|Other|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
128373|NCT03184415|Drug|DWC20155|tablet
128374|NCT03184415|Drug|DWC20156|tablet
128375|NCT03184415|Drug|placebo of DWC20155|tablet
128376|NCT03184415|Drug|placebo of DWC20156|tablet
128377|NCT03184402|Drug|DWJ1252|tablet
128378|NCT03184402|Drug|Gasmotin|tablet
128379|NCT03184402|Drug|Placebo of Gasmotin|tablet
128380|NCT03184402|Drug|Placebo of DWJ1252|tablet
128381|NCT03184389|Behavioral|Prompt to use smartphone apps for stress management|Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
128382|NCT03184376|Dietary Supplement|Prebiotic oligofructose|Powder format
128383|NCT03184376|Dietary Supplement|Placebo maltodextrin|Powder format
128384|NCT03184363|Drug|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
128385|NCT03184350|Radiation|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
128386|NCT03184337|Behavioral|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
128387|NCT03184337|Behavioral|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
128388|NCT03184324|Drug|DWP14012|tablet
128389|NCT03184324|Drug|Esomeprazole|tablet
128390|NCT03184324|Drug|DWP14012 placebo|tablet
128391|NCT03184324|Drug|Esomeprazole placebo|tablet
128392|NCT03184311|Other|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
128393|NCT03184311|Other|Moderate-intensity contiuous training (MCT)|Supervised 12-week MCT 3 times per week on a bicycle ergometer.
128394|NCT03184298|Other|Social Norms Questionnaire|
128395|NCT03184298|Other|Standardized Interview|
128396|NCT03184298|Other|Group Discussion|
128397|NCT03184285|Procedure|baseline alert 1|measurement in supine position
128398|NCT03184285|Procedure|Anti-Trendelenburg-position (ATB)|measurement under ATB
128399|NCT03184285|Procedure|ATB in narcosis|measurement under ATB in narcosis
128400|NCT03184285|Procedure|baseline in narcosis 1|measurement in supine position in narcosis
128401|NCT03184285|Procedure|passive leg raising|measurement under passive leg raising
128402|NCT03184285|Procedure|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
128403|NCT03184285|Procedure|baseline in narcosis 2|measurement in supine position
128404|NCT03184285|Procedure|start capnoperitoneum|measurement in supine position
128405|NCT03184285|Procedure|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
128406|NCT03184285|Procedure|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
128407|NCT03184285|Procedure|ATB loss of capnoperitoneum|measurement under ATB
128408|NCT03184285|Procedure|baseline|measurement in supine position
128409|NCT03184285|Procedure|baseline alert 2|measurement in supine position
128410|NCT03184285|Procedure|torso position rising 30° at the beginning|measurement in the recovery unit
128411|NCT03184285|Procedure|torso position rising 30° at the end|measurement in the recovery unit
128412|NCT03184272|Procedure|baseline alert 1|measurement in supine position
128413|NCT03184272|Procedure|Anti-Trendelenburg-position (ATB)|measurement under ATB
128414|NCT03184272|Procedure|ATB in narcosis|measurement under ATB in narcosis
128415|NCT03184272|Procedure|baseline in narcosis 1|measurement in supine position in narcosis
128416|NCT03184272|Procedure|passive leg raising|measurement under passive leg raising
128417|NCT03184272|Procedure|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
128418|NCT03184272|Procedure|baseline in narcosis 2|measurement in supine position
128425|NCT03184272|Procedure|torso position rising 30° at the beginning|measurement in the recovery unit
128426|NCT03184272|Procedure|torso position rising 30° at the end|measurement in the recovery unit
128427|NCT03184259|Device|Robotic ankle system|Patients will wear the robotic ankle system and undergo 20-minute over-ground walking and 10-minute stair walking.
128428|NCT03184259|Device|Robotic knee system|Patients will wear the robotic knee system and undergo 20-minute over-ground walking and 10-minute stair walking.
128429|NCT03184246|Device|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
128430|NCT03184246|Device|Direct laryngoscopy|direct laryngoscopy will be used for intubation
128431|NCT03184233|Procedure|Rapid ventricular pacing|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture
128432|NCT03184233|Procedure|No rapid ventricular pacing|No rapid ventricular pacing is applied perioperatively.
128433|NCT03184220|Procedure|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.~Suboccipital induction~Posterior elongation of the cervical fascia in Supine position~Assisted cervical fascia~Myofascial induction of sternocleidomastoid"
128434|NCT03184220|Procedure|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
128435|NCT03184194|Drug|nivolumab-daratumumab|nivolumab-daratumumab will be given without low-dose cyclophosphamide until progression
128436|NCT03184194|Drug|nivolumab-daratumumab with low-dose cyclophosphamide|nivolumab-daratumumab with low-dose cyclophosphamide will be given until progression
128437|NCT03184181|Other|EPTE® group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
128438|NCT03184181|Other|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
128439|NCT03184168|Drug|[14C]lorlatinib|Extemporaneously compounded oral solution of [14C]lorlatinib (approximately 100 mg/100 µCi)
128440|NCT03184155|Drug|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
128441|NCT03184155|Drug|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
128442|NCT03184142|Behavioral|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
128443|NCT03184142|Behavioral|Video|Student watch a 15-minute intimidation video (see arm description).
128444|NCT03184142|Behavioral|Control group|No intervention. The students suture for 70 minutes
128445|NCT03184129|Device|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
128446|NCT03184129|Device|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
128447|NCT03184116|Behavioral|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning & Rehabilitation
128448|NCT03184103|Diagnostic Test|anti streptolysin o titre and serum complement test|diagnostic lab test
128449|NCT03184090|Drug|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
128450|NCT03184090|Drug|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
128451|NCT03184077|Procedure|Laceration Repair with Polyglactin 910|Polyglactin 910 suture for laceration repair
128452|NCT03184077|Procedure|Laceration Repair with poliglecaprone 25|poliglecaprone 25 suture for laceration repair
128453|NCT03184064|Dietary Supplement|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
128454|NCT03184064|Dietary Supplement|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
128455|NCT03184064|Dietary Supplement|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
128456|NCT03184064|Dietary Supplement|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
128457|NCT03184064|Dietary Supplement|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
128458|NCT03184038|Procedure|Cognitive Assessment|Undergo assessment of neurocognitive function of subjects with 1-4 metastases vs 5-10 metastases
128459|NCT03184038|Radiation|Stereotactic Radiosurgery|Undergo standard of care (SRS) Stereotactic Radiosurgery
128460|NCT03184038|Radiation|Stereotactic Body Radiation Therapy|Undergo standard of care (SBRT) Stereotactic Body Radiation Therapy
128531|NCT03183466|Procedure|arthroscopic debridement|
128461|NCT03184025|Other|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
128462|NCT03184012|Device|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
128463|NCT03184012|Device|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
128464|NCT03183999|Dietary Supplement|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
128465|NCT03183999|Dietary Supplement|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
128466|NCT03183986|Device|Phototherapy|Phototherapy for 24 hours.
128467|NCT03183973|Biological|PRF|patients who will receive PRF suspension
128468|NCT03183973|Biological|placebo group|patients who will receive Placebo
128469|NCT03183960|Behavioral|Mentor|Traditional rehabilitation.
128470|NCT03183947|Procedure|fMRI|collection of functional brain data for 1 hour per day
128471|NCT03183947|Behavioral|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 & 4; controls: Days 2 & 3)
128472|NCT03183947|Other|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
128473|NCT03183947|Other|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
128474|NCT03183947|Other|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3&4; controls: day 2&3) and after 4 weeks during a telephone interview
128475|NCT03183934|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.~This study is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
128476|NCT03183921|Other|No intervention|No Interventions
128477|NCT03183908|Biological|FLUAD|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
128478|NCT03183908|Biological|Fluzone High-Dose|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
128479|NCT03183895|Device|Mitral valve repair|The AccuCinch® Ventricular Repair System, implanted in the sub-valvular space of the left ventricle, is intended to reduce significant symptomatic mitral regurgitation and reverse left ventricular remodeling due to dilated cardiomyopathy of either ischemic or non-ischemic etiology via percutaneous interventional methods.
128480|NCT03183882|Behavioral|Personal Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months
128481|NCT03183882|Behavioral|Peer Normative Comparison Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
128482|NCT03183869|Drug|Fecal microbiota|fecal microbial transplantation
128483|NCT03183856|Device|Morning walk|a end-effector typed gait robot with a saddle
128484|NCT03183856|Other|no Morning walk|ambulation voluntary or with a help of walker
128485|NCT03183843|Drug|Dabigatran Etexilate|Dabigatran Etexilate 150 mg capsules for oral administration twice a day
128486|NCT03183843|Drug|Warfarin|Warfarin 2.5 mg tablets for oral administration once a day
128487|NCT03183830|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
128488|NCT03183830|Dietary Supplement|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
128489|NCT03183817|Behavioral|Person-centred care at distance|Person-centred care at distance through an eHealth platform
128490|NCT03183804|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
128491|NCT03183804|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
128492|NCT03183791|Behavioral|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.
128493|NCT03183791|Behavioral|Monitored Usual Care (MUC)|"The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app."
128494|NCT03183778|Drug|Patiromer|Patiromer is a drug used for the treatment of hyperkalemia, a condition that may lead to palpitations and arrhythmia.
128495|NCT03183778|Dietary Supplement|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
128496|NCT03183765|Drug|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.~Response to treatment will be evaluated by photographing the patients before treatment and 2 weeks after each session. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size or a decrease in the total number of warts), and no response (no change in size and number of warts)."
128637|NCT03182725|Drug|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
128497|NCT03183765|Procedure|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.~Response to treatment will be evaluated by photographing the patients before treatment and 2 weeks after each session. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size or a decrease in the total number of warts), and no response (no change in size and number of warts)."
128498|NCT03183752|Drug|Metformin|500 mg metformin three times daily
128499|NCT03183752|Drug|Placebo|500 mg placebo three times daily
128500|NCT03183739|Drug|ASP8062|ASP8062 will be administered orally.
128501|NCT03183739|Drug|Placebo|Placebo will be administered orally.
128502|NCT03183726|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.~This study is a follow-up study without intervention."
128503|NCT03183713|Behavioral|Cognitive Behavioral Therapy|Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
128504|NCT03183713|Behavioral|Sham Therapy|Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
128505|NCT03183700|Device|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
128506|NCT03183700|Other|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
128507|NCT03183674|Drug|Oxytocin|Single dose oxytocin 45 minutes before the test
128508|NCT03183674|Other|placebo|saline solution 0,9% spray nasal
128509|NCT03183661|Biological|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
128510|NCT03183648|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
128511|NCT03183635|Procedure|Balance training|Improvement of balance ability in stroke patients
128512|NCT03183622|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.~This tudy is a follow-up study without intervention.~Other Names:~Allogenic adipose-derived mesenchymal stem cells"
128513|NCT03183609|Other|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
128514|NCT03183609|Other|Rice Flour in Protein Shake|15 Grams Rice Flour BID
128515|NCT03183596|Drug|Bupivacaine|20-60cc of 0.25% Bupivacaine
128516|NCT03183596|Drug|Dexamethasone|2-4mg of Dexamethasone
128517|NCT03183583|Procedure|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
128518|NCT03183570|Drug|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) [18F]FP-R01-MG-F2 will be administered to patients with IPF
128519|NCT03183557|Drug|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
128520|NCT03183557|Drug|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
128521|NCT03183544|Combination Product|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
128522|NCT03183531|Diagnostic Test|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
128523|NCT03183518|Other|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
128524|NCT03183518|Other|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
128525|NCT03183505|Drug|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
128526|NCT03183505|Drug|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
128527|NCT03183492|Biological|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
128528|NCT03183479|Drug|Fibrinogen Concentrate Human|After start of surgery when all pedicle screws are placed, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
128529|NCT03183479|Drug|Normal saline|100mL normal saline will be administered to patients in control group as placebo
128530|NCT03183466|Procedure|arthroscopic repair|
128532|NCT03183453|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
128533|NCT03183440|Dietary Supplement|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery
128534|NCT03183440|Other|PLACEBO|women will daily take placebo (maltodextrin) from inclusion to delivery
128535|NCT03183427|Diagnostic Test|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
128536|NCT03183414|Other|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
128537|NCT03183388|Behavioral|BE-SMART|Subjects will participate in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the subject, and when appropriate, the subject's parent or guardian). Subjects will be asked to complete worksheets and practice the skills learned from these sessions and they will be asked questions about how they are feeling. There will interview assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication.
128538|NCT03183375|Drug|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
128539|NCT03183362|Device|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
128540|NCT03183362|Device|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
128541|NCT03183349|Procedure|deprotienized bovine bone (tutogen)|
128542|NCT03183349|Procedure|platelet rich fibrin|
128543|NCT03183336|Procedure|ridge split interpositional block graft|
128544|NCT03183336|Procedure|decortication Onlay block graft|
128545|NCT03183323|Behavioral|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
128546|NCT03183310|Drug|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
128547|NCT03183310|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
128548|NCT03183310|Drug|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
128549|NCT03183297|Drug|JMI-001|JMI-001, a combination product of naproxen and fexofenadine
128550|NCT03183297|Drug|Naproxen|Naproxen sodium 220mg
128551|NCT03183297|Drug|Fexofenadine|Fexofenadine 60mg
128552|NCT03183297|Drug|placebo|placebo comparator
128553|NCT03183271|Radiation|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
128554|NCT03183258|Other|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
128555|NCT03183245|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
128556|NCT03183245|Procedure|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
128557|NCT03183232|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
128558|NCT03183232|Biological|γδ T cell|γδ T cells will be used against Lung Cancer
128559|NCT03183232|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
128560|NCT03183219|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
128561|NCT03183219|Biological|γδ T cell|γδ T cells will be used against Liver Cancer
128562|NCT03183219|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
128563|NCT03183206|Procedure|Cryosurgery , IRE surgery ,surgery|surgery will be used in local tumor
128564|NCT03183206|Biological|γδ T cells|γδ T cells will be used against
128565|NCT03183206|Other|γδ T cells/ Surgery|Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
128566|NCT03183193|Other|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
128567|NCT03183193|Other|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
128568|NCT03183180|Diagnostic Test|Echocardiogram|Current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination
128569|NCT03183167|Other|No intervention|
128570|NCT03183154|Other|no intervention|no intervention
128571|NCT03183141|Drug|SER-109|SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
128572|NCT03183128|Drug|SER-109|"SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors~Other Names:~Eubacterial Spores, Purified Suspension, Encapsulated"
128573|NCT03183128|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
128574|NCT03183115|Procedure|Radiofrequency ablation|HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare).
128575|NCT03183115|Device|Endoscopy|The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
128576|NCT03183115|Drug|Lugol's Solution (1.5%)|Before the RFA intervention, the participants will received Lugol staining over the esophagus
128577|NCT03183102|Dietary Supplement|Flaxseed|2 months of dietary flaxseed supplementation
128578|NCT03183089|Drug|Rohto Dry-Aid®|
128579|NCT03183089|Drug|Systane® Ultra|
128580|NCT03183076|Other|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
128581|NCT03183076|Drug|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
128582|NCT03183063|Device|4DCT and SPECT/CT|Each patient will receive two 4DCT followed by SPECT/CT.
128583|NCT03183063|Device|4DCT with BiPAP and SPECT/CT|Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
128584|NCT03183063|Device|4DCT with CTA in suspected PE|Each patient will receive 4DCT before or after CTA for suspected PE
128585|NCT03183050|Behavioral|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
128586|NCT03183037|Procedure|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
128587|NCT03183037|Procedure|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
128588|NCT03183037|Other|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
128589|NCT03183037|Behavioral|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
128590|NCT03183024|Biological|benralizumab|open-label treatment
128591|NCT03183024|Biological|placebo|sterile water to mimic benralizumab
128592|NCT03183011|Other|MRI|Cardiac MRI
128593|NCT03182998|Other|Internet-Based Intervention|"Receive Knowing your Options decision aid"
128594|NCT03182998|Other|Internet-Based Intervention|"Receive Prostate Choice decision aid"
128595|NCT03182998|Other|Best Practice|Undergo usual care
128596|NCT03182998|Other|Quality-of-Life Assessment|Ancillary studies
128597|NCT03182998|Other|Questionnaire Administration|Ancillary studies
128598|NCT03182998|Other|Survey Administration|Ancillary studies
128599|NCT03182998|Other|Laboratory Biomarker Analysis|Correlative studies
128600|NCT03182985|Behavioral|Time Restricted Feeding|Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
128601|NCT03182972|Other|Medication reconciliation|Pre-post intervention
128602|NCT03182959|Drug|Avmacol®|Avmacol® tablets
128603|NCT03182946|Diagnostic Test|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
128604|NCT03182933|Drug|Peripheral Nerve Blockade|Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
128605|NCT03182933|Behavioral|10 meter walk test on post-operative day 1|Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
128606|NCT03182933|Other|In person and over the phone questionnaire|Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
128607|NCT03182933|Device|Force transduction of quadriceps strength|Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
128608|NCT03182920|Drug|Lasmiditan|Oral administration
128609|NCT03182920|Drug|Placebo|Oral administration
128610|NCT03182907|Biological|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
128611|NCT03182907|Drug|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
128612|NCT03182894|Drug|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
128613|NCT03182881|Other|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
128614|NCT03182881|Other|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
128615|NCT03182868|Device|PAS Goggles|Goggles to film eye motion
128616|NCT03182855|Drug|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
128617|NCT03182855|Drug|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
128618|NCT03182842|Device|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
128619|NCT03182842|Device|SMBG - Blinded Sensor|Insulin dosing based on SMBG
128620|NCT03182829|Diagnostic Test|DOAC Dipstick|Patients collect a sample of urine for analysis.
128621|NCT03182816|Biological|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
128622|NCT03182803|Biological|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
128623|NCT03182790|Behavioral|Instant Messaging IM|Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
128624|NCT03182790|Behavioral|Regular messages|Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
128625|NCT03182790|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
128626|NCT03182790|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
128627|NCT03182790|Behavioral|Brief advice|Very brief, minimal and general smoking cessation advice
128628|NCT03182790|Behavioral|COSH booklet|A general smoking cessation self-help booklet
128629|NCT03182790|Behavioral|Placebo Messages|Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
128630|NCT03182790|Behavioral|Warning Leaflet|The leaflet will include the information about the health risks of smoking.
128631|NCT03182777|Procedure|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
128632|NCT03182764|Other|No intervention|No intervention
128633|NCT03182751|Drug|Tranexamic Acid (TXA)|The cohort of patients treated with early administration of TXA in the Emergency Department will be compared to a control group who were not treated with TXA at any point.
128634|NCT03182751|Drug|Placebo|The cohort of patients treated with a placebo in the Emergency Department will be compared to the active comparator group that will receive early administration of Tranexamic Acid.
128635|NCT03182738|Behavioral|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
128636|NCT03182738|Behavioral|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
128638|NCT03182725|Drug|Placebo|A substance that has no therapeutic effect and will act as a control.
128639|NCT03182712|Dietary Supplement|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
128640|NCT03182712|Dietary Supplement|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
128641|NCT03182699|Diagnostic Test|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
128642|NCT03182699|Diagnostic Test|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
128643|NCT03182699|Diagnostic Test|Laboratory tests|drawing blood from dialysis machine
128644|NCT03182699|Diagnostic Test|Body composition monitoring|Measurement with BCM (Fresenius) machine
128645|NCT03182699|Diagnostic Test|lung ultrasound|ultrasound
128646|NCT03182686|Biological|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% HSA)
128647|NCT03182686|Other|Saline|0.9% sodium chloride
128648|NCT03182673|Drug|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg,0.5 mg and 2mg. Multiple tablets of SHR7390 will be administered orally to achieve targeted doses of SHR7390: 0.125 mg-4 mg. Tablets will be administered once daily or for 21 days and discontinued for 7 days with 240 ml water after 2 hours of the meal.
128649|NCT03182673|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
128650|NCT03182673|Drug|SHR3162|SHR3162 is provided as capsules containing SHR3162 at dosage strengths of 10mg,40mg and 100mg. The capsule of SHR3162 will be orally administered with 240ml water twice a day to achieve targeted doses of SHR3162 and the interval of SHR3162 capsules taken twice a day is about 12 hours.
128651|NCT03182647|Procedure|Surgically treatment of the ACL|Surgical initial ACL treatment
128652|NCT03182647|Other|Non surgical initial ACL treatment|Non surgical initial ACL treatment
128653|NCT03182634|Drug|Fulvestrant|
128654|NCT03182634|Drug|Neratinib|
128655|NCT03182634|Drug|AZD5363|
128656|NCT03182634|Drug|Olaparib|
128657|NCT03182634|Drug|AZD6738|
128658|NCT03182621|Behavioral|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
128659|NCT03182621|Behavioral|SPARK|traditional YMCA program
128660|NCT03182608|Diagnostic Test|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
128661|NCT03182595|Drug|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
128662|NCT03182582|Device|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
128663|NCT03182582|Procedure|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
128664|NCT03182569|Device|FLEXIBLE CATHETER|
128665|NCT03182569|Device|hourly rigid needle puncture|
128666|NCT03182556|Behavioral|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
128667|NCT03182556|Behavioral|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
128668|NCT03182543|Dietary Supplement|Mango pulp beverage|"The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
128669|NCT03182543|Dietary Supplement|Mango pulp and peel beverage|"The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
128670|NCT03182543|Dietary Supplement|Control beverage|"The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.~Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
128705|NCT03182257|Drug|ONO-7579|ONO-7579 Tablets
128706|NCT03182244|Drug|gilteritinib|oral
128707|NCT03182244|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
128708|NCT03182244|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|intravenous
128671|NCT03182530|Device|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
128672|NCT03182530|Device|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
128673|NCT03182530|Device|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
128674|NCT03182504|Drug|nacubactam|Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
128675|NCT03182504|Drug|meropenem|Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
128676|NCT03182491|Diagnostic Test|Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)|Analysis of biomarkers and basophil activation test
128677|NCT03182478|Behavioral|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
128678|NCT03182478|Behavioral|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
128679|NCT03182465|Diagnostic Test|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
128680|NCT03182452|Other|Alarm Advisor|Providing advice on alarm limits as part of routine medical care
128681|NCT03182439|Device|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
128682|NCT03182439|Device|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
128683|NCT03182439|Device|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
128684|NCT03182439|Device|Apple Watch|Apple Watch Heart Rate Monitoring Device
128685|NCT03182426|Drug|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
128686|NCT03182426|Drug|Alemtuzumab|T-cell depletion
128687|NCT03182426|Drug|Anakinra|Anti-inflammatory
128688|NCT03182426|Drug|Etanercept|Anti-inflammatory
128689|NCT03182426|Drug|Liraglutide|Beta-cell regeneration
128690|NCT03182413|Drug|Placebo|
128691|NCT03182413|Drug|Modafinil|
128692|NCT03182413|Drug|THN102|
128693|NCT03182400|Behavioral|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
128694|NCT03182400|Behavioral|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
128695|NCT03182374|Device|nSTRIDE APS|Intra-articular injection
128696|NCT03182374|Device|Synvisc-One|Intra-articular injection
128697|NCT03182361|Device|Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants|Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
128698|NCT03182348|Procedure|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
128699|NCT03182335|Other|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
128700|NCT03182322|Drug|intranasal insulin|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
128701|NCT03182322|Other|Placebo|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter placebo (formulation containing benzalkonium chloride, glycerol and water)
128702|NCT03182296|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
128703|NCT03182283|Behavioral|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
128704|NCT03182270|Diagnostic Test|nCLE|Procedure: EUS-FNA Device: nCLE
128709|NCT03182244|Drug|FLAG (Granulocyte colony-stimulating factor (G-CSF), Fludarabine, Cytarabine)|intravenous
128710|NCT03182231|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
128711|NCT03182218|Drug|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
128712|NCT03182205|Other|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
128713|NCT03182205|Other|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
128714|NCT03182192|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
128715|NCT03182179|Drug|Ondansetron 4 MG|Ondansetron is taken orally BD
128716|NCT03182179|Drug|Placebo|Placebo is taken orally BD
128717|NCT03182166|Drug|Golimumab (Optimization)|"Increase dose of golimumab.~For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.~For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks."
128718|NCT03182166|Diagnostic Test|Rectosigmoidoscopy|Rectosigmoidoscopy will be realized for calculated Mayo score
128719|NCT03182166|Biological|Blood samples|Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
128720|NCT03182153|Device|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
128721|NCT03182140|Drug|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
128722|NCT03182127|Radiation|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
128723|NCT03182127|Device|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
128724|NCT03182114|Other|supine position|the patient will be placed in regular supine position after spinal anesthesia
128725|NCT03182114|Other|left lateral tilted position|the patient will be placed in left lateral tilted position after spinal anesthesia
128726|NCT03182114|Drug|Bupivacaine|The patient will receive 10 mg Bupivacaine for spinal anesthesia
128727|NCT03182101|Behavioral|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
128728|NCT03182088|Drug|norepinephrine infusion (0.025 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)
128729|NCT03182088|Drug|norepinephrine infusion (0.050 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)
128730|NCT03182088|Drug|norepinephrine infusion (0.075 mcg/Kg/min)|The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).
128731|NCT03182088|Drug|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
128732|NCT03182075|Behavioral|Computerized Training|OCD participants will receive 14 sessions of training via computer within 3 weeks.
128733|NCT03182062|Procedure|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
128734|NCT03182062|Procedure|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
128735|NCT03182062|Procedure|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
128736|NCT03182049|Procedure|Airway assessment|Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
128737|NCT03182049|Procedure|Rheumatology assessment|Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
128738|NCT03182036|Device|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
128739|NCT03182010|Device|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
128843|NCT03181256|Procedure|Pulmonary Function Test|Undergo pulmonary function test
128844|NCT03181256|Procedure|Computed Tomography (CT)|Undergo chest CT
128740|NCT03182010|Device|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
128741|NCT03181997|Device|Native aortic valve|Native valve, with any transcatheter heart valve type
128742|NCT03181997|Procedure|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
128743|NCT03181984|Drug|Hemoporfin|Hemoporfin mediated photodynamic therapy
128744|NCT03181971|Behavioral|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
128745|NCT03181958|Device|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
128746|NCT03181958|Device|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
128747|NCT03181958|Device|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
128748|NCT03181945|Other|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
128749|NCT03181945|Other|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
128750|NCT03181932|Drug|Vancomycin inhalation powder|There will be 200 patients treated with Vancomycin inhalation powder or placebo (1:1 active to placebo). 150 subjects ≤21 years old, 50 subjects >21 years old.
128751|NCT03181932|Drug|Placebo inhalation powder|There will be 200 patients treated with Vancomycin inhalation powder or placebo (1:1 active to placebo). 150 subjects ≤21 years old, 50 subjects >21 years old.
128752|NCT03181919|Drug|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
128753|NCT03181906|Other|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
128754|NCT03181893|Drug|PF-06823859|A humanized immunoglobulin neutralizing antibody
128755|NCT03181893|Drug|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
128756|NCT03181880|Drug|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.~The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).~Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
128757|NCT03181880|Drug|Standard of Care|Brochodilators
128758|NCT03181867|Drug|18F-DCFPyL|Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
128759|NCT03181854|Behavioral|Telephone coaching|Telephone coaching about overcoming the crisis is provided once a week for 3 months and once in 2 weeks for another 3 months.
128760|NCT03181854|Behavioral|Consultation with PCT doctor|Consultation with PCT physician every 3 weeks.
128761|NCT03181841|Drug|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
128762|NCT03181841|Drug|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
128763|NCT03181828|Drug|Acetohydroxamic Acid Oral Tablet [Lithostat]|"AHA:~Acetohydroxamic acid has been an FDA approved medication for the treatment of struvite nephrolithiasis for over 25 years. According to the prescribing information, about 150 patients, including children, have been treated, most for periods of more than 1 year."
128764|NCT03181815|Drug|Cladribine|5mg/㎡ d1-5
128765|NCT03181815|Drug|G-CSF|300ug d0-9
128766|NCT03181815|Drug|Aclarubicin|10mg d3-6
128767|NCT03181815|Drug|Cytarabine|10mg/㎡ q12h SC d3-9
128768|NCT03181802|Drug|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
128769|NCT03181802|Drug|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
128770|NCT03181789|Biological|p24CE1/2 pDNA Vaccine|Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
128771|NCT03181789|Biological|p55^gag pDNA Vaccine|Administered bilaterally using the TDS-IM EP device
128772|NCT03181789|Biological|IL-12 pDNA Adjuvant|Administered bilaterally using the TDS-IM EP device
128773|NCT03181789|Biological|Placebo|Administered bilaterally using the TDS-IM EP device
128774|NCT03181789|Device|Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device|The TDS-IM EP device will be used to administer study product(s).
128775|NCT03181776|Other|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
128776|NCT03181776|Other|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
128777|NCT03181776|Other|supine position|The mother will be placed in standard supine position
128778|NCT03181763|Drug|Placebo|Placebo given day after startle assessment
128779|NCT03181763|Drug|MDMA|Participant will receive 100 mg MDMA one day after startle assessment
128780|NCT03181763|Behavioral|Acoustic startle|Startle assessment
128781|NCT03181750|Behavioral|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
128782|NCT03181737|Behavioral|Covivio/Relaxio|Informations already included in arm/group descriptions.
128845|NCT03181256|Other|Laboratory Biomarker|Correlative studies
129137|NCT03179228|Device|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
128783|NCT03181724|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
128784|NCT03181698|Diagnostic Test|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.~The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
128785|NCT03181685|Drug|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
128786|NCT03181685|Drug|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
128787|NCT03181685|Drug|recombinant FSH|Controlled ovarian stimulation (COS)
128788|NCT03181685|Drug|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
128789|NCT03181672|Procedure|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
128790|NCT03181672|Procedure|control group|Deltoid muscle injection with 1% lidocaine 10ml
128791|NCT03181659|Procedure|Manual Therapy, Therapeutic Education, Therapeutic Exercice|They will receive 8 sessions (2 sessions per week) of joint and neural manual therapy, and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation. The therapeutic exercise program is based on stabilization of the lumbopelvic region.
128792|NCT03181659|Procedure|Therapeutic Education, Therapeutic Exercice|They will receive a total of 8 sessions (2 sessions per week) of therapeutic exercise based on the stabilization of the lumbopelvic region and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation.
128793|NCT03181646|Drug|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
128794|NCT03181633|Drug|ACH-0144471|ACH-0144471 will be administered to all patients enrolled in the study.
128795|NCT03181620|Other|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
128796|NCT03181594|Device|ClariFix Device|Cryoablation in the nasal passageway using the ClariFix Device
128797|NCT03181581|Biological|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
128798|NCT03181581|Biological|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
128799|NCT03181568|Device|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
128800|NCT03181568|Procedure|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
128801|NCT03181555|Other|Exploratory|
128802|NCT03181542|Device|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
128803|NCT03181529|Drug|Psilocybin|Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
128804|NCT03181516|Biological|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
128805|NCT03181516|Other|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
128806|NCT03181503|Drug|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
128807|NCT03181503|Drug|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
128808|NCT03181490|Diagnostic Test|Circulating Tumor DNA Methylation Test|Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules
128809|NCT03181477|Device|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
128810|NCT03181464|Drug|Lidocaine 4%|lidocaine solution
128811|NCT03181464|Drug|Placebo|saline .9% injection
128812|NCT03181451|Drug|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
128813|NCT03181438|Procedure|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
128814|NCT03181438|Procedure|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
128846|NCT03181243|Procedure|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
128882|NCT03181009|Drug|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
128815|NCT03181412|Diagnostic Test|Questionnaire|"Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.~The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist."
128816|NCT03181399|Drug|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
128817|NCT03181386|Drug|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
128818|NCT03181386|Drug|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
128819|NCT03181386|Drug|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
128820|NCT03181373|Other|Cognitive rehabilitation program|Rehabilitation
128821|NCT03181360|Drug|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
128822|NCT03181360|Other|Control|Best standard treatment
128823|NCT03181347|Procedure|RYGB|Roux-en-Y Gastric Bypass
128824|NCT03181347|Procedure|SG|Sleeve Gastrectomy
128825|NCT03181347|Behavioral|Dietary and behavioral|Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
128826|NCT03181334|Behavioral|Branch I|FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
128827|NCT03181334|Behavioral|Branch II|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week."
128828|NCT03181334|Behavioral|Branch III|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks."
128829|NCT03181334|Behavioral|Branch IV|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive."
128830|NCT03181334|Behavioral|Branch V|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive."
128831|NCT03181321|Behavioral|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
128832|NCT03181308|Drug|Carotuximab (TRC105)|Anti Endoglin Antibody
128833|NCT03181308|Drug|OPDIVO|Programmed Death Receptor-1
128834|NCT03181295|Behavioral|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
128835|NCT03181282|Behavioral|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
128836|NCT03181269|Other|Intervention education|An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
128837|NCT03181269|Other|Placebo Education|An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
128838|NCT03181256|Procedure|Biospecimen Collection|Undergo collection of sputum
128839|NCT03181256|Procedure|Biospecimen collection|Undergo collection of nasal epithelium
128840|NCT03181256|Procedure|Biospecimen collection|Undergo collection of buccal epithelium
128841|NCT03181256|Procedure|Biospecimen collection|Undergo collection of blood
128842|NCT03181256|Procedure|Biospecimen collection|Undergo collection of urine
128847|NCT03181243|Procedure|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
128848|NCT03181230|Other|No intervention|No intervention
128849|NCT03181217|Other|water 0|300 ml tap water at 0 ºC
128850|NCT03181217|Other|water 22|300 ml tap water at 22 ºC
128851|NCT03181217|Other|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
128852|NCT03181217|Other|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
128853|NCT03181204|Procedure|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
128854|NCT03181204|Procedure|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
128855|NCT03181204|Procedure|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
128856|NCT03181191|Other|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
128857|NCT03181178|Dietary Supplement|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
128858|NCT03181178|Dietary Supplement|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
128859|NCT03181178|Behavioral|Nutrition education|This intervention provided nutrition education sessions
128860|NCT03181165|Behavioral|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
128861|NCT03181152|Diagnostic Test|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.~3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
128862|NCT03181139|Other|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
128863|NCT03181126|Drug|Navitoclax|tablet
128864|NCT03181126|Drug|Chemotherapy|peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)
128865|NCT03181126|Drug|Venetoclax|tablet
128866|NCT03181113|Drug|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
128867|NCT03181113|Drug|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
128868|NCT03181100|Drug|Atezolizumab|Given IV
128869|NCT03181100|Biological|Bevacizumab|Given IV
128870|NCT03181100|Drug|Cobimetinib|Given PO
128871|NCT03181100|Drug|Nab-paclitaxel|Given IV
128872|NCT03181100|Drug|Paclitaxel|Given IV
128873|NCT03181100|Drug|Vemurafenib|Given PO
128874|NCT03181087|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
128875|NCT03181074|Other|Non-Interventional|Non-Interventional
128876|NCT03181061|Other|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
128877|NCT03181048|Procedure|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
128878|NCT03181048|Procedure|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
128879|NCT03181035|Radiation|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
128880|NCT03181035|Drug|Pimonidazole|oral pimonidazole hypoxia labeling
128881|NCT03181022|Behavioral|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
128934|NCT03180749|Other|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
128883|NCT03181009|Drug|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
128884|NCT03180996|Device|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
128885|NCT03180983|Behavioral|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
128886|NCT03180970|Drug|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
128887|NCT03180970|Drug|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
128888|NCT03180970|Drug|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
128889|NCT03180970|Drug|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
128890|NCT03180970|Drug|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
128891|NCT03180957|Drug|Adalimumab|
128892|NCT03180957|Drug|Saline|
128893|NCT03180944|Drug|1.2% Lugol's solution|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
128894|NCT03180944|Drug|1.0% Lugol's solution|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
128895|NCT03180944|Drug|0.8% Lugol's solution|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
128896|NCT03180944|Drug|0.6% Lugol's solution|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
128897|NCT03180944|Drug|0.4% Lugol's solution|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
128898|NCT03180931|Device|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.~Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
128899|NCT03180918|Procedure|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
128900|NCT03180905|Device|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
128901|NCT03180905|Device|ImPACT Online|ImPACT Online will be administered at 2 time points.
128902|NCT03180892|Other|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
128903|NCT03180879|Drug|Test - RB ibuprofen acid orodispersible tablets|RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
128904|NCT03180879|Drug|Reference - RB Nurofen ibuprofen acid tablets|RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
128905|NCT03180879|Drug|Comparator - Dolormin ibuprofen lysine tablets|Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
128906|NCT03180866|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
128907|NCT03180840|Biological|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
128908|NCT03180827|Procedure|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
128909|NCT03180814|Other|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
128910|NCT03180801|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
128911|NCT03180801|Biological|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
128912|NCT03180801|Other|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
128913|NCT03180788|Procedure|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
128914|NCT03180788|Procedure|Traditional ESD|Endoscopic submucosa dissection
128915|NCT03180775|Other|Cellulose (control)|Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
128935|NCT03180736|Drug|Daratumumab|Daratumumab will be given at a dose of 16 mg/kg administered as an IV infusion (Dara IV) or 1800 mg subcutaneously (Dara SC) at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
128936|NCT03180736|Drug|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
128916|NCT03180775|Dietary Supplement|Glycine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128917|NCT03180775|Dietary Supplement|Alanine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128918|NCT03180775|Dietary Supplement|Leucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128919|NCT03180775|Dietary Supplement|Isoleucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128920|NCT03180775|Dietary Supplement|Valine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128921|NCT03180775|Dietary Supplement|Cysteine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128922|NCT03180775|Dietary Supplement|Arginine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128923|NCT03180775|Dietary Supplement|Methionine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128924|NCT03180775|Dietary Supplement|Glutamate|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128925|NCT03180775|Dietary Supplement|Glutamine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
128926|NCT03180762|Drug|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
128927|NCT03180762|Drug|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
128928|NCT03180762|Drug|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
128929|NCT03180762|Drug|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
128930|NCT03180762|Drug|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
128931|NCT03180762|Drug|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
128932|NCT03180762|Drug|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
128933|NCT03180762|Drug|Placebo|Matching placebo will be administered.
128937|NCT03180736|Drug|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
128938|NCT03180723|Drug|Rituximab|Intravenous injection
128939|NCT03180723|Drug|Cyclosporin|Oral tablets
128940|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
128941|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
128942|NCT03180710|Drug|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
128943|NCT03180710|Drug|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
128944|NCT03180697|Diagnostic Test|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
128945|NCT03180684|Biological|VGX-3100|One milliliter (1 mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24. A fifth dose and sixth dose of six mg VGX-3100 may be administered IM with EP per the judgment of the Investigator.
128946|NCT03180684|Drug|Imiquimod 5% cream|Participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
128947|NCT03180684|Device|CELLECTRA™ 2000|IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 2000 device.
128948|NCT03180671|Device|Deprogramer Sliding Guide|Use of the intraoral device.
128949|NCT03180671|Device|Deprogrammer Dawson B-Splint|Use of the intraoral device.
128950|NCT03180671|Device|Deprogrammer Kois|Use of the intraoral device.
128951|NCT03180658|Procedure|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
128952|NCT03180658|Procedure|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
128953|NCT03180645|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
128954|NCT03180645|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
128955|NCT03180645|Other|No treatment|No treatment
128956|NCT03180632|Drug|Lorazepam|Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
128957|NCT03180632|Other|Placebo|Patient receive one of two tablet of Placebo according to body weight
128958|NCT03180619|Drug|TAF|25 mg tablet administered orally once daily with food
128959|NCT03180606|Other|Multi-disciplinary and personalized primary care|Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
128960|NCT03180593|Drug|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
128961|NCT03180580|Behavioral|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
128962|NCT03180567|Diagnostic Test|Genetic Mutations|By next generation sequencing
128963|NCT03180554|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that participants wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
128964|NCT03180554|Other|Motivational nondirective resonance breathing (MNRB)|Motivational nondirective resonance breathing (MNRB) is a type of diaphragmatic breathing technique that trains the body to breathe at resonance frequency with a mental state of open-awareness.
128965|NCT03180541|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
128966|NCT03180528|Drug|Remetinostat|Applied topically under bandage occlusion
128967|NCT03180515|Device|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
128968|NCT03180502|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|Undergo IMRT
128969|NCT03180502|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
128970|NCT03180502|Drug|Temozolomide|Chemotherapy drug
128971|NCT03180489|Drug|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
128972|NCT03180489|Drug|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
129463|NCT03176537|Drug|Testosterone gel|Androgel (50mg testosterone), gel, daily
128973|NCT03180476|Drug|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
128974|NCT03180463|Drug|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2*10^7 cells,
128975|NCT03180463|Procedure|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
128976|NCT03180450|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
128977|NCT03180450|Drug|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
128978|NCT03180437|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
128979|NCT03180437|Biological|γδ T cell|γδ T cells will be used against Pancreatic Cancer
128980|NCT03180437|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Pancreatic Cancer
128981|NCT03180424|Drug|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
128982|NCT03180424|Behavioral|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
128983|NCT03180424|Drug|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
128984|NCT03180424|Behavioral|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
128985|NCT03180411|Behavioral|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.~Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
128986|NCT03180411|Behavioral|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
128987|NCT03180398|Device|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
128988|NCT03180385|Device|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
128989|NCT03180385|Device|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
128990|NCT03180372|Device|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
128991|NCT03180359|Biological|Recommended vaccine scheme according to French Vaccine Schedule 2015|"BCG~Measles mumps rubella (MMR)~Varicella (chicken pox)~Rotavirus~Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)~Yellow Fever~Diphteria tetanus poliomyelitis whopping cough (DTwP)~Haemophilus influenzae type b~Hepatitis B~Meningococcus conjugate~Pneumococcus~Human papillomavirus~Hepatitis A~Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
128992|NCT03180346|Device|PICO|Single Use Negative Pressure Dressing
128993|NCT03180346|Device|Aquacel|Occlusive surgical dressing infused with ionized silver
128994|NCT03180333|Drug|PNA|
128995|NCT03180333|Drug|PNA placebo|
128996|NCT03180320|Behavioral|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:~Baduanjin exercise;~evaluations of exercise capacity and clinical conditions;~consultations on exercise prescription and management of symptoms/signs during exercise;~education covering topics related to the CHF and exercise; and~a series of adherence strategies."
128997|NCT03180320|Drug|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
128998|NCT03180307|Drug|OTL38|0.025 mg/kg of OTL38 in 250ml D5W infused intravenously over 60 minutes
128999|NCT03180307|Device|near infrared imaging|Infrared imaging used to excite OTL38 for fluorecence
129000|NCT03180294|Drug|Bupropion Hydrochloride|Given PO
129001|NCT03180294|Other|Placebo|Given PO
129002|NCT03180281|Drug|DPP4|sitagliptin phosphate 100mg qd
129003|NCT03180281|Drug|Insulin|Insulin Glargine or detemir 0.2U/kg qd
129004|NCT03180281|Drug|SU|Glimepiride 1-2mg qd
129005|NCT03180268|Other|Clinical Observation|Undergo observation
129006|NCT03180268|Radiation|Radiation Therapy|Undergo radiation therapy
129007|NCT03180255|Combination Product|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
129008|NCT03180255|Other|Placebo|Ocular iontophoretic delivery of a placebo
129009|NCT03180242|Biological|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
129010|NCT03180242|Biological|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
129011|NCT03180242|Biological|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
129012|NCT03180229|Drug|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
129090|NCT03179579|Procedure|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
129091|NCT03179579|Procedure|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
129013|NCT03180216|Biological|Virus Specific T cells (VSTs)|"Pediatric and adult patients following any type of allogeneic transplant (HSCT) will receive VSTs as prophylaxis or treatment of reactivation or infection with CMV, adenovirus, EBV, HHV6, BK virus, JC virus, and/or HPIV3). The goal of this cell infusion will be to initiate an immune response against viral infections after HSCT.~VSTs will be generated using clinical grade overlapping peptides (Pepmixes) to directly stimulate PBMCs, growth promoting cytokines and the G-Rex culture device optimized for T cell expansion. Donor T-cells will be stimulated with overlapping peptide libraries encompassing pp65 and IE-1 (CMV), Hexon and Penton (Adenovirus), LMP2 and EBNA-1 (EBV), LgT and VP1 (BK virus), U54 and U90 (HHV6B), and Mat and NP (HPIV3)."
129014|NCT03180203|Device|INTELLiVENT-ASV|"After ICU admission:~The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.~After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if >10minutes PEEP:<9cmH2O,FiO2:<41%,VT/IBW<5ml/kg and RSB:<106l/l*min.~Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate >35b/min or increases >100% since start of SBT, FiO2 >50%, PeTCO2 increases >8mmHg.~Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
129015|NCT03180203|Device|Conventional modes|"After ICU admission:~The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.~After three hours: manual SBT is required if >10min PS<11cmH2O,PEEP<9cmH2O,FiO2<41%.~Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate >35b/min or increases >100% since the start of SBT, saturation <92% or the PeTCO2 increases >8mmHg.~Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.~If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
129016|NCT03180190|Drug|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by~Perimetry using Octopus perimeter and utilizing 24-2 test strategy,~Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
129017|NCT03180177|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The second HIPEC regimens are cisplatin 75 mg/m^2, 43°C, 90min.
129018|NCT03180177|Procedure|Interval debulking surgery|Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
129019|NCT03180177|Drug|neoadjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
129020|NCT03180177|Drug|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
129021|NCT03180164|Other|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
129022|NCT03180151|Procedure|piezotome assisted orthodontic tooth movement|"Surgical procedure~After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.~The incisions will be kept minimal.~The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.~A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.~As we will not use bone graft so we don't need use suturing after cortication.~We give patient antibiotic and analgesic cover."
129023|NCT03180138|Behavioral|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
129024|NCT03180138|Behavioral|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
129025|NCT03180125|Drug|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
129026|NCT03180125|Device|ultrasound|ultrasound guided injection
129027|NCT03180125|Drug|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
129028|NCT03180125|Drug|Corticosteroid and 1%lidocain|injection in the carpal tunnel
129029|NCT03180112|Genetic|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
129030|NCT03180099|Drug|Bupivacaine|Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
129031|NCT03180099|Drug|Bupivacaine|20 ml %0.1 Bupivacaine administered to Epidural Space
129032|NCT03180086|Other|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
129033|NCT03180073|Diagnostic Test|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
129034|NCT03180073|Diagnostic Test|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
129035|NCT03180073|Diagnostic Test|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
129464|NCT03176537|Drug|Placebos|Placebo, gel, daily
129036|NCT03180034|Biological|Cervarix|Vaccine indicated in females 9 through 25 years of age for the prevention of the following diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18: Cervical, vulvar, vaginal, and anal cancer cervical cancer; cervical intraepithelial neoplasia (CIN) Grade2 or worse and adenocarcinoma in situ; and cervical intraepithelial neoplasia (CIN) Grade 1 caused by Human Papillomavirus (HPV) types 16 and 18. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for use in females 9 through 25 years of age. Approved for three doses (0.5-mL each) by intramuscular injection at 0, 1, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose
129037|NCT03180034|Biological|Gardasil 9|Vaccine indicated in females 9 through 26 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58; and Genital warts (condyloma acuminata) caused by HPV types 6 and 11. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 months (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for three doses (0.5- mL each) intramuscular injection at 0, 2 months, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose intervention will be in 5000 girls ages 12-16 years.
129038|NCT03180021|Procedure|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.~At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
129039|NCT03180008|Behavioral|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
129040|NCT03180008|Behavioral|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
129041|NCT03179995|Drug|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
129042|NCT03179995|Other|Placebo|Normal saline will be administered in the same fashion as Octreotide
129043|NCT03179982|Behavioral|Safe South Africa|"Core components of the Safe South Africa intervention include the following:~Theory driven, best-evidence intervention approaches to adolescent HIV prevention~Linkages between HIV and IPV~Victim Empathy~Healthy Norms Regarding Masculinity~Bystander Intervention Skills"
129044|NCT03179969|Other|paravalvular leak|Observational study on patients with paravalvular leak
129045|NCT03179956|Drug|Ribociclib|Treatment with ribociclib [600mg] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
129046|NCT03179943|Drug|Atezolizumab|Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
129047|NCT03179943|Drug|Guadecitabine|Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
129048|NCT03179930|Drug|Entinostat|All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15
129049|NCT03179930|Drug|Pembrolizumab|pembrolizumab 200 mg IV on D1
129050|NCT03179917|Drug|Pembrolizumab|pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles
129051|NCT03179917|Radiation|Involved Site Radiation Therapy|30 Gy of ISRT
129052|NCT03179904|Drug|FASN Inhibitor TVB-2640|Given PO
129053|NCT03179904|Other|Laboratory Biomarker Analysis|Correlative studies
129054|NCT03179904|Drug|Paclitaxel|Given IV
129055|NCT03179904|Biological|Trastuzumab|Given IV
129056|NCT03179891|Drug|Pharmacokinetics and Safety of Diazepam Buccal Soluble Film|Comparative Pharmacokinetics and Safety of DBSF in subjects with epilepsy under conditions when they are not experiencing seizures (Interictal Period A) or when they are experiencing seizures (Ictal/peri-ictal Period B).
129057|NCT03179878|Drug|Placebo|Placebo
129058|NCT03179878|Drug|SYNB1020|Investigational Product
129059|NCT03179852|Behavioral|nutrition education|nutrition education
129060|NCT03179839|Behavioral|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.~MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
129061|NCT03179839|Behavioral|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
129136|NCT03179254|Drug|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
129497|NCT03176277|Drug|ONO-7475|ONO-7475 tablets
129062|NCT03179839|Drug|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
129063|NCT03179813|Procedure|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
129064|NCT03179813|Procedure|Control|During the third molar extraction the saline solution will be used in the control group
129065|NCT03179800|Device|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
129066|NCT03179800|Other|Sham Implantation|Sham Implantation
129067|NCT03179787|Drug|Aripiprazole oral product|oral administration of aripiprazole
129068|NCT03179774|Device|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
129069|NCT03179761|Biological|Quadrivalent Inactivated Influenza Vaccine|Given intramuscularly
129070|NCT03179761|Other|Laboratory Biomarker Analysis|Correlative studies
129071|NCT03179761|Biological|Trivalent Influenza Vaccine|Given intramuscularly
129072|NCT03179748|Drug|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
129073|NCT03179735|Drug|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
129074|NCT03179735|Drug|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
129075|NCT03179735|Drug|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.~First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
129076|NCT03179722|Behavioral|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
129077|NCT03179722|Behavioral|Additional data collection: questionnaires|"Pre-post study design.~At three timepoints, data is collected:~before the medication review (T-1week)~during the review (Tweek 3)~after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
129078|NCT03179709|Behavioral|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
129079|NCT03179696|Behavioral|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
129080|NCT03179683|Device|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
129081|NCT03179644|Other|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
129082|NCT03179631|Drug|Ataluren|10, 20 mg/kg
129083|NCT03179631|Drug|PLACEBO|10, 20 mg/kg
129084|NCT03179618|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
129085|NCT03179618|Drug|Lipid Regulating Drugs|Mainly including statins
129086|NCT03179618|Drug|Coronary Vasodilator|Mainly including nitrates
129087|NCT03179618|Drug|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
129088|NCT03179605|Drug|DFD06|Apply twice per day for 15 days
129089|NCT03179592|Drug|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
129092|NCT03179566|Behavioral|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
129093|NCT03179566|Behavioral|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
129094|NCT03179540|Procedure|Non-operative management|Patients who are eligible and provide informed consent to participate in the trial will undergo non-operative management (i.e., active surveillance for 24 months) according to the schedule outlined in the study protocol.
129095|NCT03179527|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
129096|NCT03179527|Drug|Lipid Regulating Drugs|Mainly including statins
129097|NCT03179527|Drug|Coronary Vasodilator|Mainly including nitrates
129098|NCT03179527|Drug|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
129099|NCT03179514|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
129100|NCT03179514|Drug|Lipid Regulating Drugs|Mainly including statins
129101|NCT03179514|Drug|Coronary Vasodilator|Mainly including nitrates
129102|NCT03179514|Drug|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
129103|NCT03179501|Drug|NP001|NP001
129104|NCT03179501|Drug|Placebo|Normal saline
129105|NCT03179488|Device|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
129106|NCT03179488|Device|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
129107|NCT03179475|Drug|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.~Oxycodone-Naloxone is available in the following oral dosages:~5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride~10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride~20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride~40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
129108|NCT03179462|Dietary Supplement|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
129109|NCT03179462|Dietary Supplement|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
129110|NCT03179462|Dietary Supplement|Tofu intake|Each participant will consume 2 ounces of tofu.
129111|NCT03179449|Diagnostic Test|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
129112|NCT03179449|Procedure|Surgery|Undergo surgical resection
129113|NCT03179449|Drug|Ferumoxytol|Given IV
129114|NCT03179449|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
129115|NCT03179436|Biological|MK-1308|MK-1308 is administered intravenously (IV) during the Dose Escalation Phase and Dose Confirmation Phase at either DL1 or DL2, and is administered IV during the Efficacy Expansion Phase at DL2.
129116|NCT03179436|Biological|Pembrolizumab|Pembrolizumab is administered IV at PDL1 on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase. Pembrolizumab is administered IV at PDL2 on Day 1 of each cycle for the Efficacy Expansion Phase (Arm G).
129117|NCT03179423|Drug|GNbAC1|Monthly IV repeated dose
129118|NCT03179423|Drug|Placebo|Monthly IV repeated dose
129119|NCT03179410|Drug|Avelumab|10 mg/kg intravenously every 2 weeks
129120|NCT03179397|Device|Model SC9|Experimental
129121|NCT03179397|Device|Model LI61SE|Active Comparator
129122|NCT03179384|Drug|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
129123|NCT03179358|Device|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
129124|NCT03179345|Drug|Gabapentin|
129125|NCT03179345|Drug|Pregabalin|
129126|NCT03179345|Other|Placebo|
129127|NCT03179332|Drug|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
129128|NCT03179332|Drug|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
129129|NCT03179332|Drug|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
129130|NCT03179319|Behavioral|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
129131|NCT03179293|Drug|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
129132|NCT03179293|Drug|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
129133|NCT03179280|Drug|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
129134|NCT03179267|Device|SNAP40|SNAP40 ambulatory monitoring device
129135|NCT03179254|Drug|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
129498|NCT03176264|Drug|PDR001|400 mg every 4 weeks
129138|NCT03179215|Diagnostic Test|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
129139|NCT03179202|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain."
129140|NCT03179176|Other|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
129141|NCT03179163|Drug|Captopril Pill|ACEi+SH
129142|NCT03179163|Drug|Enalapril Pill|ACEi
129143|NCT03179163|Drug|Hydrochlorothiazide|diuretic
129144|NCT03179150|Diagnostic Test|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
129145|NCT03179137|Other|Standard therapy|Patients with therapy prescribed independent of the study
129146|NCT03179111|Procedure|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
129147|NCT03179098|Other|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
129148|NCT03179098|Other|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
129149|NCT03179098|Other|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
129150|NCT03179085|Behavioral|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
129151|NCT03179059|Diagnostic Test|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
129152|NCT03179059|Diagnostic Test|Pregnancy test at follow up survey|We will provide a free pregnancy tests in for the future use, they are randomly selected from intervention #1 treatment group.
129153|NCT03179046|Diagnostic Test|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
129154|NCT03179020|Other|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
129155|NCT03179020|Other|Usual care|Management of the potential donor according usual care.
129156|NCT03179007|Biological|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
129157|NCT03178994|Drug|2% ketoconazole cream|2% ketoconazole cream applies twice daily
129158|NCT03178994|Drug|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
129159|NCT03178981|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
129160|NCT03178968|Other|Orange juice|3 immersion times in orange juice were investigated
129161|NCT03178955|Drug|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
129162|NCT03178942|Drug|Permethrin Cream, 5%|Permethrin Cream 5%
129163|NCT03178942|Drug|Elimite™ Cream (permethrin) 5%|Permethrin Cream 5%
129164|NCT03178929|Drug|S-Adenosyl Methionine|2000mg, po
129499|NCT03176264|Drug|bevacizumab|5 mg/kg every 2 weeks
129165|NCT03178903|Other|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
129166|NCT03178903|Other|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
129167|NCT03178903|Behavioral|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
129168|NCT03178890|Device|OHMG|Device will be implanted in all enrolled patients.
129169|NCT03178877|Other|No intervention|
129170|NCT03178864|Drug|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a GFR of <50 mL/min as per the Cockroft-Gault equation)
129171|NCT03178864|Drug|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
129172|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
129173|NCT03178851|Drug|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1−21 of each 28-day cycle, until loss of clinical benefit
129174|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
129175|NCT03178851|Biological|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
129176|NCT03178825|Device|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
129177|NCT03178812|Procedure|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
129178|NCT03178812|Diagnostic Test|Laboratory Blood test|Laboratory Blood Test
129179|NCT03178786|Behavioral|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
129180|NCT03178773|Behavioral|TExT-MED|messages designed to inspire motivation and behavior change
129181|NCT03178773|Behavioral|FANS|SMS delivered messages to family members to improve social support
129182|NCT03178760|Diagnostic Test|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;~Age~Gender~Weight~Length~Waist Circumference~Body mass index"
129183|NCT03178747|Diagnostic Test|Methylene blue|working solution methylene blue
129184|NCT03178747|Diagnostic Test|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
129185|NCT03178734|Device|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
129186|NCT03178721|Diagnostic Test|blood sample|study B regulatory in blood and its correlation with atherosclerosis
129187|NCT03178708|Drug|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
129188|NCT03178708|Other|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
129189|NCT03178695|Other|Autologous PRP injection into human ovarian tissue|Using FDA-approved equipment, blood plasma is received from participant, isolated/enriched into PRP, and infused into the ovaries under transvaginal ultrasound guidance.
129190|NCT03178682|Diagnostic Test|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
129191|NCT03178669|Drug|cobitolimod|Rectal administration
129192|NCT03178669|Drug|Placebo|Solution manufactured to mimic cobitolimod
129193|NCT03178656|Drug|Sorafenib|continuous application of the drugs
129194|NCT03178656|Procedure|surgery|curative resection
129195|NCT03178643|Drug|Proguanil Oral Tablet|Dosing of daily proguanil will be approximately 3mg/kg/day,
129196|NCT03178643|Drug|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
129197|NCT03178643|Drug|Dihydroartemisinin-Piperaquine (DP)|"3) The weight-based dosing of tablets of 40/320mg of DP is described below:~Weight (kg) No. of 40/320mg tabs DP daily for 3 days~≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½"
129198|NCT03178617|Other|Educational Intervention|Attend standard of care LIP
129199|NCT03178617|Other|Educational Intervention|Attend HIP
129200|NCT03178617|Other|Quality-of-Life Assessment|Ancillary studies
129201|NCT03178617|Other|Questionnaire Administration|Ancillary studies
129202|NCT03178604|Other|Classic massage|It involves applying the classic massage techniques: effleurage (gliding or sliding movement over the skin with a smooth continuous motion following the direction of the muscle fibers of the superficial muscles in a distal to proximal direction); petrissage (lifting, wringing, or squeezing of soft tissues in a kneading motion, or pressing or rolling of the tissues under or between the hands); tapotement (various parts of the hand striking the tissues at a fairly rapid rate). The general objective is to improve extensibility of muscle, tendon, fascia, joint capsule, and ligamentous structures.
129203|NCT03178604|Other|Sham massage|This group received a placebo intervention at the same time as the other group, maintaining only soft touch with the participant without exerting any mechanical pressure.
129204|NCT03178591|Drug|vildagliptin|
129205|NCT03178591|Drug|Dapagliflozin|
129206|NCT03178565|Other|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
129320|NCT03177564|Procedure|Protective ventilation 1|Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
129207|NCT03178565|Other|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
129208|NCT03178552|Drug|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
129209|NCT03178552|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D.
129210|NCT03178552|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV infusion on Day 1 Q21D.
129211|NCT03178552|Drug|Cisplatin|Participants will receive cisplatin 75 mg/m^2 IV on Day 1 Q21D.
129212|NCT03178552|Drug|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
129213|NCT03178552|Drug|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
129214|NCT03178552|Drug|Entrectinib|Participants will receive entrectinib 600 mg orally QD.
129215|NCT03178539|Drug|diclofenac|non steroidal anti-inflammatory drug
129216|NCT03178539|Drug|ketorolac|non steroidal anti-inflammatory drug
129217|NCT03178526|Drug|Lovastatin gel|Lovastatin gel1.2% topical gel was put into teh periodontal pocket using an insulin syringe
129218|NCT03178526|Drug|Placebo|placebo gel
129219|NCT03178513|Other|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~Medical assessment~Psychosocial assessment~Medication reconciliation~Follow-up of inpatient primary team's specific recommendations~Follow-up, as needed, with primary care team or inpatient team"
129220|NCT03178500|Drug|Clomiphene Citrate 50mg|stair-step clomiphene adminstration
129221|NCT03178487|Drug|Upadacitinib|Tablet
129222|NCT03178487|Drug|Upadacitinib Placebo|Tablet
129223|NCT03178474|Other|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
129224|NCT03178474|Other|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
129225|NCT03178474|Other|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
129226|NCT03178461|Other|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
129227|NCT03178435|Other|Measures to prevent AKI among critically ill patients|"Meticulous optimization of the fluid balance~Avoidance of nephrotoxic medications where possible~Optimisation of the hemodynamic status~Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia~Optimization of the underlying medical condition~Seek expert renal advise when necessary"
129228|NCT03178422|Drug|CQSS2|Nicotine Replacement Therapy
129229|NCT03178422|Drug|NicoDerm CQ Patch|Nicotine Replacement Therapy
129230|NCT03178409|Procedure|Hepatectomy|Removal of a part of the liver
129231|NCT03178396|Dietary Supplement|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
129232|NCT03178383|Behavioral|Project HEAL|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
129233|NCT03178383|Behavioral|Project HEAL 2.0|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
129234|NCT03178370|Device|Gastric Electrical Stimulation|Temporary and permanent gastric electrical stimulation
129235|NCT03178357|Other|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
129236|NCT03178357|Other|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
129237|NCT03178344|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
129238|NCT03178344|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
129239|NCT03178331|Other|Study questionnaires|filled by parents, school nurse and teacher
129240|NCT03178318|Procedure|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
129241|NCT03178305|Behavioral|Do CHANGE|"Besides the behavior change programme (Do Something Different)~All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)~patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).~Patients with hypertension will also be offered a bloodpressure monitor.~Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).~Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
129242|NCT03178292|Drug|Levofloxacin|Levofloxacin 500Mg daily for 5 days
129243|NCT03178292|Drug|Placebo|Placebo Oral Tablet daily for 5 days
129244|NCT03178279|Other|Physical Health Plan|Use of a Physical Health Plan by service users
129245|NCT03178266|Device|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
129246|NCT03178240|Behavioral|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
129247|NCT03178227|Behavioral|Photoaging Mirroring Intervention|"Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers."
129248|NCT03178214|Drug|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
129249|NCT03178201|Drug|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
129250|NCT03178188|Device|Pulsed-dye Laser|595 nm Pulsed-dye Laser; 7mm spot sizes, 6msec pulse durations, 8j/cm2 fluences, dynamic cooling device 30/20, 4 sessions with 4 weeks interval
129251|NCT03178188|Device|Sham|Cryogen spray with the setting of dynamic cooling device 30/20
129252|NCT03178175|Procedure|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
129253|NCT03178175|Procedure|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
129254|NCT03178149|Drug|ASP7317|subretinal injection
129255|NCT03178149|Other|Placebo|no treatment
129256|NCT03178149|Drug|tacrolimus|oral
129257|NCT03178149|Drug|mycophenolate mofetil (MMF)|oral
129258|NCT03178123|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
129259|NCT03178123|Biological|high-dose recombinant interferon a-2B|15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
129260|NCT03178110|Behavioral|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy two times per week, for eight weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased.
129261|NCT03178084|Drug|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
129262|NCT03178084|Drug|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
129263|NCT03178084|Drug|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
129264|NCT03178071|Drug|Lorlatinib|oral tablets, administered daily, continuously
129265|NCT03178058|Other|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.~Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
129266|NCT03178045|Other|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
129267|NCT03178045|Other|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
129268|NCT03178032|Biological|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
129269|NCT03178019|Other|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
129270|NCT03177993|Drug|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~allergy to ivermectin, diethylcarbamazine or albendazole;~pregnant;~breastfeeding within 7 days of delivery;~less than 2 years old; OR~less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~allergy to permethrin~crusted scabies"
129294|NCT03177811|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
129295|NCT03177811|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
129271|NCT03177993|Drug|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.~Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.~Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:~severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~allergy to ivermectin, diethylcarbamazine or albendazole;~pregnant;~breastfeeding within 7 days of delivery;~less than 2 years old; OR~less than 15 kg~In addition if less than 5 years old excluded from ivermectin.~Exclusion criteria for permethrin:~allergy to permethrin~crusted scabies"
129272|NCT03177993|Drug|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).~If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.~Exclusion criteria for diethylcarbamazine and albendazole:~severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);~allergy to diethylcarbamazine or albendazole;~pregnant;~breastfeeding within 7 days of delivery;~less than 2 years old; OR~less than 15 kg~Exclusion criteria for permethrin:~allergy to permethrin~crusted scabies"
129273|NCT03177980|Drug|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
129274|NCT03177980|Drug|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
129275|NCT03177967|Behavioral|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
129276|NCT03177967|Other|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
129277|NCT03177967|Other|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
129278|NCT03177954|Behavioral|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
129279|NCT03177941|Other|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
129280|NCT03177928|Device|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
129281|NCT03177915|Drug|Hylase|median nerve hydro-dissection using Hyalase + 10 cc saline injection
129282|NCT03177915|Drug|Saline|median nerve hydro-dissection using 10 cc saline injection
129283|NCT03177902|Drug|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
129284|NCT03177889|Combination Product|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid];~Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g~Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
129285|NCT03177876|Procedure|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
129286|NCT03177876|Procedure|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
129287|NCT03177863|Procedure|Expectancy|Clinical monitoring. See arm description
129288|NCT03177850|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
129289|NCT03177850|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
129290|NCT03177837|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
129291|NCT03177837|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
129292|NCT03177824|Drug|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
129293|NCT03177824|Drug|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
129563|NCT03175744|Device|Stellarex DCB|Intervention with the Stellarex DCB
129296|NCT03177798|Drug|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
129297|NCT03177798|Drug|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
129298|NCT03177785|Behavioral|EverydayMatters|
129299|NCT03177772|Behavioral|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
129300|NCT03177746|Drug|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.~Study drug should not be used more than 1 tablet every 24 hours during the treatment."
129301|NCT03177733|Procedure|Evaluation of a breast double block|"we made an association of the serratus block and the PIF block, which allows for a complete block of both the laterals branches of intercostal nerves (with the serratus block) and of anterior branches of intercostal nerves (with the PIF block). Therefore, this association of blocks may lead to a complete analgesia of the breast, while the serratus block alone only allows for an analgesia of the lateral part of the breast.~The objective is to analyze this technique through a collection form that evaluates the satisfaction and post-operative morphine consumption of women receiving this association before a general anesthesia for a unilateral mastectomy with homolateral total lymphadenectomy.~This is a purely observational study that assesses our current practice in this type of surgery."
129302|NCT03177720|Drug|Ciprofloxacin|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
129303|NCT03177720|Drug|Imipenem|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
129304|NCT03177707|Other|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.~The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
129305|NCT03177694|Device|Wireless bed sensor|Remote data collection
129306|NCT03177681|Other|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
129307|NCT03177681|Other|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
129308|NCT03177681|Behavioral|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
129309|NCT03177681|Device|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
129310|NCT03177681|Other|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
129311|NCT03177668|Drug|YS110|Intravenous administration
129312|NCT03177655|Other|Guided Imagery|Guided Imagery meditation
129313|NCT03177655|Other|Journaling|Keeping a journal
129314|NCT03177629|Drug|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.~Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
129315|NCT03177616|Other|Chiropractic Treatment|"The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:~posture correction/spinal stabilization exercises~soft tissue relaxation techniques~spinal manipulation (i.e. chiropractic adjustment)/mobilization~breathing and relaxing techniques~stretches, self-care~ergonomic modifications~bracing and supports"
129316|NCT03177603|Drug|GSK2586881|GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 0.8 mg/kg.
129317|NCT03177590|Other|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:~an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)~an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation~Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
129318|NCT03177577|Device|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
129319|NCT03177577|Device|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
129321|NCT03177564|Procedure|Protective ventilation 2|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
129322|NCT03177564|Procedure|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
129323|NCT03177538|Drug|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
129324|NCT03177538|Drug|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.~Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
129325|NCT03177525|Behavioral|Social SUCCESS|"Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism."
129326|NCT03177525|Behavioral|Wait List|Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
129327|NCT03177512|Behavioral|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
129328|NCT03177499|Procedure|Invasive PPG|Invasive PPG obtained by means of catheterization.
129329|NCT03177473|Device|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
129330|NCT03177460|Biological|Daratumumab|Given IV
129331|NCT03177460|Drug|FMS Inhibitor JNJ-40346527|Given PO
129332|NCT03177460|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
129333|NCT03177447|Behavioral|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
129334|NCT03177434|Drug|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
129335|NCT03177434|Drug|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
129336|NCT03177421|Other|Problematic bedtime media use counseling|Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.
129337|NCT03177421|Other|Sleep problem counseling|Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
129338|NCT03177395|Drug|PP100-01 (calmangafodipir)|PP100-01
129339|NCT03177395|Drug|Acetylcysteine|NAC
129340|NCT03177382|Radiation|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
129341|NCT03177382|Radiation|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
129342|NCT03177382|Procedure|TME|The TME operation will be given after the end of the neoadjuvant treatment.
129343|NCT03177382|Drug|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
129344|NCT03177356|Procedure|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
129345|NCT03177356|Procedure|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
129346|NCT03177317|Drug|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1~Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
129347|NCT03177304|Other|Web based IPT Training|
129348|NCT03177291|Drug|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
129349|NCT03177291|Drug|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
129350|NCT03177291|Drug|Paclitaxel|200 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
129351|NCT03177291|Drug|Pemetrexed|500 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
129352|NCT03177278|Drug|[14C]-plazomicin|single intravenous dose
129389|NCT03177018|Diagnostic Test|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
129353|NCT03177265|Behavioral|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
129354|NCT03177265|Behavioral|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
129355|NCT03177265|Behavioral|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
129356|NCT03177265|Behavioral|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
129357|NCT03177252|Drug|Lidocaine|-2% lidocaine will be given
129358|NCT03177252|Drug|Sodium chloride|-Normal saline will be given
129359|NCT03177252|Drug|Bupivacaine|-0.5% bupivacaine will be given
129360|NCT03177239|Drug|Nivolumab|"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing."
129361|NCT03177239|Drug|Ipilimumab|Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
129362|NCT03177226|Device|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
129363|NCT03177226|Device|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
129364|NCT03177187|Drug|AZD5069|10mg and 40mg plain, beige, film-coated tablets packaged in bottles
129365|NCT03177187|Drug|Enzalutamide 40 MG|Enzalutamide is presented in 40mg white to off white capsules. The capsules are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules. Each carton contains 4 wallets (112 soft capsules).
129366|NCT03177174|Drug|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
129367|NCT03177174|Drug|Docetaxel|Docetaxel
129368|NCT03177161|Other|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
129369|NCT03177148|Behavioral|Intervention by Clinicians|PCPs deliver 4 sessions of MI in person, and RDs deliver 6 sessions of MI via telephone. PCPs and RDs will receive 2 days of MI training.
129370|NCT03177148|Behavioral|Usual Care|PCPs provide care as normal
129371|NCT03177135|Device|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
129372|NCT03177122|Drug|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
129373|NCT03177109|Drug|5% fluoride varnish|Applied topically as a coating at single point in time
129374|NCT03177109|Drug|8% arginine containing paste|Applied topically as a coating at single point in time
129375|NCT03177109|Drug|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
129376|NCT03177096|Behavioral|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
129377|NCT03177096|Behavioral|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
129378|NCT03177096|Behavioral|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
129379|NCT03177083|Drug|peginterferon beta-1a|SC every 2 weeks
129380|NCT03177083|Drug|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
129381|NCT03177083|Drug|interferon beta-1b|Per SMPC
129382|NCT03177070|Drug|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
129383|NCT03177057|Behavioral|Compliance Monitoring|Record behavior
129384|NCT03177057|Other|Health Telemonitoring|Receive health monitoring text messages
129385|NCT03177057|Other|Questionnaire Administration|Ancillary studies
129386|NCT03177044|Behavioral|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
129387|NCT03177031|Device|Stay Safe Link (SSL)|CAPD system produced in Malaysia by Fresenius Medical Care
129388|NCT03177031|Device|Stay Safe (STS)|CAPD system produce in Germany by Fresenius Medical Care
129390|NCT03177005|Biological|CSL830|
129391|NCT03176992|Drug|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
129392|NCT03176979|Other|Contrast Agent|Given IV
129393|NCT03176979|Procedure|Digital Tomosynthesis Mammography|Undergo CESM with DBT
129394|NCT03176979|Procedure|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
129395|NCT03176966|Drug|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
129396|NCT03176966|Drug|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
129397|NCT03176966|Other|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
129398|NCT03176953|Drug|topiramate|active medication
129399|NCT03176953|Behavioral|prolonged exposure|psychotherapy
129400|NCT03176953|Drug|placebo|non-active medication
129401|NCT03176940|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
129402|NCT03176927|Diagnostic Test|magnetogastrogram|
129403|NCT03176914|Behavioral|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
129404|NCT03176914|Behavioral|conventional community interventions|community health programs as the sole source of health education
129405|NCT03176901|Behavioral|Mindfulness-Based Stress Reduction|This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
129406|NCT03176901|Behavioral|Health Enhancement Program|This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
129407|NCT03176888|Behavioral|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
129408|NCT03176888|Behavioral|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey & Greer (2012)
129409|NCT03176875|Other|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
129410|NCT03176875|Other|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
129411|NCT03176862|Diagnostic Test|cardiac magnetic resonance scan|An MRI scan of the heart
129412|NCT03176862|Diagnostic Test|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
129413|NCT03176862|Diagnostic Test|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
129414|NCT03176862|Diagnostic Test|12-lead ECG|Can be done immediately by the bedside.
129415|NCT03176862|Diagnostic Test|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
129416|NCT03176862|Biological|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
129417|NCT03176849|Dietary Supplement|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
129418|NCT03176849|Dietary Supplement|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.~Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
129419|NCT03176836|Diagnostic Test|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
129420|NCT03176836|Diagnostic Test|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
129421|NCT03176836|Diagnostic Test|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
129422|NCT03176823|Device|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
129423|NCT03176823|Other|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
129424|NCT03176810|Device|OCT|OCT is used to guide PCI.
129425|NCT03176810|Device|Angiography|Angiography is used to guide PCI.
129426|NCT03176797|Diagnostic Test|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
129427|NCT03176784|Drug|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
129428|NCT03176784|Drug|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
129429|NCT03176784|Other|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
129430|NCT03176784|Other|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
129433|NCT03176758|Drug|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
129434|NCT03176758|Drug|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
129435|NCT03176758|Device|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
129436|NCT03176745|Diagnostic Test|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
129437|NCT03176732|Device|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
129438|NCT03176719|Other|Venipuncture|"Full blood count and leukocyte differentiation.~Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)~Detection of anemia, thallasemia and sickle cell anemia (XN-20)~Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)~Circulating cytokines and inflammatory markers (ELIZA)~DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.~pan-Salmonella PCR~Gametocyte PCR"
129439|NCT03176706|Other|no intervention|this is a completely observational study, NO INTERVENTION
129440|NCT03176693|Drug|Phenoxybenzamine|Non-selective alpha blocker
129441|NCT03176693|Drug|Doxazosin|Selective alpha blocker
129442|NCT03176680|Procedure|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
129443|NCT03176667|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
129444|NCT03176667|Procedure|Intercostal block|The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
129445|NCT03176654|Procedure|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
129446|NCT03176654|Procedure|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
129447|NCT03176641|Other|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
129448|NCT03176641|Other|control|Meniscus repair surgery only
129449|NCT03176628|Dietary Supplement|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
129450|NCT03176628|Dietary Supplement|Placebo|Placebo capsule(s)
129451|NCT03176615|Dietary Supplement|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
129452|NCT03176589|Device|positive expiratory pressure (PEP)|Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
129453|NCT03176589|Other|Placebo comparator, Deep inspiration and expression in a placebo tube without resistance|Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
129454|NCT03176576|Behavioral|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
129455|NCT03176576|Other|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
129456|NCT03176576|Other|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
129457|NCT03176576|Other|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
129458|NCT03176563|Drug|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
129459|NCT03176563|Drug|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
129460|NCT03176563|Drug|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
129461|NCT03176563|Drug|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
129462|NCT03176550|Device|Transcutaneous electrical nerve stimulation|TENS is performed using a commercially available device (ProStim, Alimed Inc, Dedham, Massachusetts, USA). One pair of 2 x 3.5 inches rectangular electrodes (Vermed ChroniCare TENS Electrodes, Vermed, Buffalo, NY, USA) are placed to simultaneously stimulate both median and ulnar nerves at the wrist, while a second pair of round 2 inch diameter electrodes are used to stimulate the radial nerve on the forearm. Bursts of electrical stimulation at 10 Hz (100 microsecond pulse width duration) are delivered to all nerves simultaneously for 2 hours.
129465|NCT03176524|Drug|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
129466|NCT03176524|Drug|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
129467|NCT03176524|Drug|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
129468|NCT03176511|Behavioral|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
129469|NCT03176511|Behavioral|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
129470|NCT03176498|Biological|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
129471|NCT03176498|Drug|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
129472|NCT03176485|Other|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
129473|NCT03176472|Drug|ricolinostat|120 mg per dose in 12 mL liquid formulation
129474|NCT03176472|Drug|Placebo|12 mL liquid formulation placebo
129475|NCT03176459|Drug|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
129476|NCT03176459|Drug|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
129477|NCT03176446|Device|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
129478|NCT03176446|Device|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
129479|NCT03176446|Device|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
129480|NCT03176446|Drug|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
129481|NCT03176446|Drug|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
129482|NCT03176433|Device|Normothermic Machine Liver Perfusion|Liver Preservation Method
129483|NCT03176420|Procedure|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
129484|NCT03176407|Diagnostic Test|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
129485|NCT03176394|Device|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
129486|NCT03176394|Device|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
129487|NCT03176368|Other|Coconut Oil|Coconut Oil
129488|NCT03176355|Procedure|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
129489|NCT03176342|Other|patch test|Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
129490|NCT03176329|Other|Nursing 1 : INTELLIVENT-ASV|
129491|NCT03176329|Other|Nursing 2 : INTELLIVENT-ASV|
129492|NCT03176329|Other|Nursing 1 : Conventional mode|
129493|NCT03176329|Other|Nursing 2 : Conventional mode|
129494|NCT03176316|Drug|Naloxone|"Blinding/labeling/preparation of agents: No blinding is required in this study. The study drug will be prepared, unit dose labelled, and patient labelled according to institutional protocols.~Storage: Secured at room temperature in the central pharmacy then dispensed as a patient specific supply and stored at room temperature the automated dispensing cabinet. No more than a 24 hour supply will be dispensed at any given time.~Administration: 1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours"
129495|NCT03176303|Device|SpinalStim|PEMF osteogenesis stimulator
129496|NCT03176290|Diagnostic Test|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml−1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 − platelet count (×109 l−1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
129500|NCT03176264|Drug|mFOLFOX6|Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
129501|NCT03176251|Other|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
129502|NCT03176238|Drug|everolimus|10 mg tablet will be administered orally once daily on a continuous dosing schedule starting on Day 1
129503|NCT03176238|Drug|exemestane|25 mg tablet will be administered orally once daily on a continuous dosing schedule starting on Day 1
129504|NCT03176225|Procedure|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
129505|NCT03176225|Device|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
129506|NCT03176225|Device|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
129507|NCT03176212|Dietary Supplement|Milk fat globule membrane|
129508|NCT03176199|Drug|Oxycodone|Every 12 hours for control-released oxycodone (OxyContin®)
129509|NCT03176199|Drug|Oxycodone|Every 6 hours for immediate-released oxycodone (OxyNorm®)
129510|NCT03176186|Combination Product|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
129511|NCT03176173|Biological|Immunotherapy (standard of care)|Receive standard of care immunotherapy (nivolumab, pembrolizumab, atezolizumab)
129512|NCT03176173|Radiation|Image Guided Radiation Therapy|Undergo image guided radiation therapy
129513|NCT03176173|Other|Laboratory Biomarker Analysis|Correlative studies
129514|NCT03176160|Other|Palliative regimen consisting of LITT|Minimally invasive technique to necrotize intracranial lesions
129515|NCT03176147|Other|Iron deficiency anemia|The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
129516|NCT03176134|Drug|Tedizolid phosphate|Tedizolid phosphate IV solution or oral suspension
129517|NCT03176134|Drug|Comparator|Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
129518|NCT03176121|Drug|Oxycodone|Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
129519|NCT03176108|Behavioral|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
129520|NCT03176108|Behavioral|Body mediation|Body mediation (theatre)
129521|NCT03176095|Dietary Supplement|Probiotic|
129522|NCT03176095|Dietary Supplement|Placebo|
129523|NCT03176082|Other|Mailed Reminders with Fecal Immunochemical Testing kits|
129524|NCT03176082|Other|Reminder letter only|
129525|NCT03176069|Other|Evaluation and Comparison of women pelvic floor with and without sexual dysfunction|Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
129526|NCT03176069|Other|The physiotherapeutic treatment|"The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:~Kinesiotherapy~Manual therapy~Electrotherapy (electric electrostimulation, ultrasound)~Behavioral therapy"
129527|NCT03176056|Dietary Supplement|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
129528|NCT03176056|Dietary Supplement|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI > 24 and 30 kcal/day for underweight subjects with a BMI <18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
129529|NCT03176043|Procedure|IV Fluid Administration|Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
129530|NCT03176030|Dietary Supplement|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
129531|NCT03176017|Procedure|Holmium Laser ejaculatory sparing TUIP|Holmium (Hol): YAG laser at a power ranging from 35 to 60 W. The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
129532|NCT03176017|Procedure|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
129533|NCT03176004|Other|Attention Bias Modification|A computer game is used to facilitate attention away from threatening words.
129560|NCT03175770|Procedure|transoral radiofrequency Resection in Oropharyngeal Tumor Surgery|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
129686|NCT03174821|Device|Insulin pump|Blood glucose management device
129534|NCT03175991|Diagnostic Test|ultrasonography|"A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:~Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion."
129535|NCT03175978|Drug|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
129536|NCT03175965|Device|Somatosensory evoked potential|Somatosensory evoked potential on 24, 72 hours after cardiac arrest.
129537|NCT03175952|Diagnostic Test|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
129538|NCT03175939|Radiation|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
129539|NCT03175939|Drug|Cisplatin|cisplatin IV injection over 3 hours
129540|NCT03175939|Drug|5-FU|5-FU IV 24 hours continuous infusion
129541|NCT03175926|Device|placebo Diskus®|device will be given daily for one week, two puffs per day
129542|NCT03175926|Device|placebo Ellipta®|device will be given daily for one week, one puff per day
129543|NCT03175926|Device|Pulmicort® Turbuhaler®|device will be given daily for one week, two puffs per day
129544|NCT03175913|Device|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
129545|NCT03175913|Drug|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
129546|NCT03175900|Drug|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI）"
129547|NCT03175900|Drug|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.~Procedure: MRI scanning (fMRI and DTI)"
129548|NCT03175887|Device|TMS|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
129549|NCT03175874|Procedure|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
129550|NCT03175861|Other|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.~Then the patient will receive his treatment by conventional stereotactic radiotherapy"
129551|NCT03175848|Radiation|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
129552|NCT03175835|Drug|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1~Day5
129553|NCT03175835|Drug|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9~Day21
129554|NCT03175835|Drug|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22~Day26
129555|NCT03175822|Behavioral|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements [e.g., colour and line] and principles [e.g., proportion and balance] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
129556|NCT03175809|Other|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
129557|NCT03175809|Other|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
129558|NCT03175796|Behavioral|Infant Mental Health-Home Visiting|Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
129559|NCT03175783|Device|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
129561|NCT03175757|Dietary Supplement|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
129564|NCT03175744|Device|PTA Catheter|Intervention with an uncoated Standard PTA
129565|NCT03175731|Drug|Proton Pump Inhibitors|Pantoprazole(or other PPIs) 40-80mg intravenously everyday before endoscopic treatment. And pantorazole(or other PPIs)tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.
129566|NCT03175731|Drug|Placebo|Placebo 40-80mg intravenously everyday before endoscopic treatment.Placebo tablet 40mg by mouth everyday for 2 weeks after endoscopic treatment.
129567|NCT03175718|Other|VAC Wound Dressing|A total of 291 patients will be randomized to receive 2 weeks of Incisional Negative pressure wound dressing (Acetily®). The sterile dressing will be applied under a continuous pressure of 125mmHg. The dressing will be changed every 2-3 days. For a total duration of 2 weeks.
129568|NCT03175718|Other|Wound Dressing|A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days. For a total duration of 2 weeks.
129569|NCT03175705|Biological|HCC antigens-specific CD8+ T lymphocytes|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)"
129570|NCT03175705|Drug|IL-2|IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
129571|NCT03175705|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
129572|NCT03175692|Diagnostic Test|Whole Exome Sequencing|Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
129573|NCT03175679|Biological|iNKT cells|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of iNKT cells."
129574|NCT03175679|Drug|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
129575|NCT03175679|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
129576|NCT03175666|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
129577|NCT03175666|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
129578|NCT03175666|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
129579|NCT03175666|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
129580|NCT03175666|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
129581|NCT03175666|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
129582|NCT03175666|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
129583|NCT03175666|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
129584|NCT03175666|Drug|Lovaza|omega-3-acid ethyl esters)
129585|NCT03175666|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
129586|NCT03175666|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
129587|NCT03175666|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-CEA (carcinoembryonic antigen)
129588|NCT03175666|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
129589|NCT03175666|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1)
129590|NCT03175666|Biological|GI-4000|RAS yeast vaccine
129591|NCT03175666|Biological|GI-6207|CEA yeast vaccine
129592|NCT03175666|Biological|GI-6301|Brachyury yeast vaccine
129593|NCT03175666|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
129594|NCT03175653|Other|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
129595|NCT03175653|Other|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
129596|NCT03175640|Behavioral|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
129597|NCT03175627|Device|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
129598|NCT03175627|Device|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
129599|NCT03175614|Other|Intervention group|Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
129600|NCT03175614|Other|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
129601|NCT03175588|Other|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
129602|NCT03175575|Behavioral|Access to a community garden in deprived neighborhoods|
129603|NCT03175562|Other|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
129604|NCT03175562|Other|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
129605|NCT03175549|Drug|Apremilast|50 mg/bid, oral pill, 5 days following 9 day titration
129606|NCT03175549|Drug|Placebo|Oral pill, 14 days
129607|NCT03175536|Other|HDHP with PDL|Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of >$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
129687|NCT03174808|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
129688|NCT03174795|Drug|RO7079901|Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
129608|NCT03175523|Device|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
129609|NCT03175523|Device|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
129610|NCT03175497|Drug|Telatinib Mesylate|Telatinib mesylate tablets will be administrated twice a day orally
129611|NCT03175458|Procedure|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
129612|NCT03175458|Procedure|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
129613|NCT03175445|Other|CBCT scan by planmeca promax|software measurement tool of CBCT
129614|NCT03175432|Drug|Atezolizumab|Given IV
129615|NCT03175432|Biological|Bevacizumab|Given IV
129616|NCT03175432|Drug|Cobimetinib|Given PO
129617|NCT03175432|Procedure|Quality-of-Life Assessment|Ancillary studies
129618|NCT03175406|Diagnostic Test|Manipal cervical scoring system|
129619|NCT03175393|Device|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
129620|NCT03175380|Biological|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
129621|NCT03175367|Drug|Evinacumab|SC or IV administration
129622|NCT03175367|Drug|Matching placebo|SC or IV administration
129623|NCT03175367|Other|Background Lipid Modifying Therapy (LMT)|All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
129624|NCT03175354|Drug|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
129625|NCT03175354|Drug|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
129626|NCT03175341|Drug|Ascorbic Acid|1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
129627|NCT03175341|Drug|Placebos|100 ml normal saline 0.9%
129628|NCT03175328|Procedure|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
129629|NCT03175315|Behavioral|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
129630|NCT03175302|Behavioral|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
129631|NCT03175289|Other|Best Practice|Undergo therapy session conducted by a speech pathologist
129632|NCT03175289|Other|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
129633|NCT03175289|Other|Exercise Intervention|Perform prescribed home exercises
129634|NCT03175289|Other|Expiratory Muscle Strength Training|Participate in EMST
129635|NCT03175289|Other|Quality-of-Life Assessment|Ancillary studies
129636|NCT03175289|Other|Questionnaire Administration|Ancillary studies
129637|NCT03175250|Behavioral|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
129638|NCT03175250|Behavioral|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
129639|NCT03175250|Behavioral|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
129640|NCT03175237|Other|Mirror Therapy|
129641|NCT03175224|Drug|APL-101 Oral Capsules (formerly CBT-101)|Subjects will be assigned to a dose level of APL-101 in the order of study entry. Treatment includes 28-day cycles at five planned dose levels (100 mg, 200 mg, 300 mg, 400 mg, 550 mg). Each treatment cycle is administered by oral capsules consecutively every 12 hours.
129642|NCT03175211|Drug|BI 456906|single dose
129643|NCT03175211|Drug|Placebo|single dose
129644|NCT03175198|Drug|Prazaxa Capsules|capsules
129645|NCT03175172|Biological|CRS-207|Administered by IV infusion over approximately 1 hour.
129646|NCT03175172|Biological|Pembrolizumab|Administered by IV infusion over approximately 30 minutes.
129647|NCT03175159|Behavioral|Time & Intensity Matched Control|Ten counseling sessions
129648|NCT03175159|Behavioral|IMPACT|Ten counseling sessions
129649|NCT03175159|Behavioral|Standard of Care|Two counseling sessions
129650|NCT03175146|Radiation|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
129651|NCT03175133|Other|Strength exercise|Strengthening exercises performed with physical therapist.
129652|NCT03175120|Drug|Insulin degludec/liraglutide|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
129653|NCT03175120|Drug|Insulin degludec|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
129654|NCT03175107|Device|Exergaming|
129689|NCT03174795|Drug|Meropenem|Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
129690|NCT03174782|Drug|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
129655|NCT03175094|Behavioral|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
129656|NCT03175081|Drug|Ropivacaine|Patient undergo elective bariatric surgery will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
129657|NCT03175081|Drug|Normal saline|Patient undergo elective bariatric surgery will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
129658|NCT03175068|Behavioral|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
129659|NCT03175068|Behavioral|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
129660|NCT03175055|Device|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
129661|NCT03175042|Device|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
129662|NCT03175029|Drug|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
129663|NCT03175029|Drug|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
129664|NCT03175016|Procedure|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
129665|NCT03175016|Drug|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
129666|NCT03175016|Device|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
129667|NCT03175003|Other|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
129668|NCT03174977|Drug|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
129669|NCT03174964|Drug|IVIg|Patients will take a dose of 400mg/kg of IVIg 2 days before ET.
129670|NCT03174951|Drug|IVIg|Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
129671|NCT03174938|Diagnostic Test|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
129672|NCT03174938|Diagnostic Test|[18F]-RO6958948|PET imaging of Tau aggregates
129673|NCT03174938|Diagnostic Test|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
129674|NCT03174938|Diagnostic Test|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
129675|NCT03174925|Procedure|Shear Wave Elastography|Undergo elastography
129676|NCT03174912|Procedure|Intravesical BCG instillation|ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
129677|NCT03174899|Radiation|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys—and 6 total ROIs from bilateral kidneys will be averaged for each patient.
129678|NCT03174886|Drug|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
129679|NCT03174886|Drug|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
129680|NCT03174873|Procedure|laparoscopy|Laparoscopy will be done for unexplained infertile couples before starting IVF because not all pathologic lesions that discovered by laparoscope need IVF and so, protect patients from unneeded IVF program
129681|NCT03174860|Drug|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
129682|NCT03174860|Drug|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
129683|NCT03174847|Procedure|Adrenalectomy|Adrenalectomy for unilateral adrenal hyperplasia / adenoma
129684|NCT03174847|Drug|Mineralocorticoid Receptor Antagonists|Medical treatment with MRA / amiloride
129685|NCT03174834|Other|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
129691|NCT03174782|Drug|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
129692|NCT03174769|Other|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
129693|NCT03174769|Other|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
129694|NCT03174756|Drug|Hypochlorous Acid|Mouthwashes of antiplaque agents
129695|NCT03174756|Drug|Chlorhexidine|A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
129696|NCT03174756|Other|Placebo|Sterile water as placebo
129697|NCT03174743|Procedure|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
129698|NCT03174743|Procedure|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
129699|NCT03174743|Procedure|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
129700|NCT03174743|Procedure|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
129701|NCT03174730|Behavioral|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
129702|NCT03174730|Behavioral|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
129703|NCT03174717|Behavioral|Music performance|residents of LTC will learn and perform songs with musicians from the community
129704|NCT03174691|Diagnostic Test|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.~Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
129705|NCT03174678|Drug|Dexmedetomidine|1µg/kg dexmedetomidine oral
129706|NCT03174678|Other|apple juice|apple juice
129707|NCT03174665|Other|No intervention|
129708|NCT03174639|Procedure|Inverted and free ILM insertion|ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
129709|NCT03174626|Behavioral|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
129710|NCT03174626|Other|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
129711|NCT03174613|Drug|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
129712|NCT03174613|Drug|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
129713|NCT03174600|Other|Questionnaire|The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
129714|NCT03174587|Biological|allogenic bone marrow derived mesenchymal stem cells|Step -1 dose : 1.0x10^6cells/kg Step 1 dose : 2.0x10^6cells/kg Step 2 dose : 3.0x10^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
129715|NCT03174561|Dietary Supplement|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
129716|NCT03174561|Other|diet restriction|diet restriction for 28 days
129717|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
129718|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution~Route of administration: oral"
129719|NCT03174522|Drug|REX-001|REX-001 is administered through an intra-arterial catheter.
129720|NCT03174522|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
129721|NCT03174509|Procedure|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
129722|NCT03174509|Procedure|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
129723|NCT03174483|Drug|Hypertonic saline|nasal spray
129724|NCT03174483|Drug|Fluticasone Nasal|nasal spray
129725|NCT03174470|Device|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
129726|NCT03174457|Drug|Micafungin|Intravenous
129727|NCT03174444|Behavioral|Small Media|Bilingual brochures and access to bilingual website
129728|NCT03174431|Device|Continence Pessary|Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
129729|NCT03174431|Device|Poise Impressa (Disposable Intravaginal Device)|In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
129730|NCT03174418|Procedure|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
129754|NCT03174236|Other|Placebo|Suspension manufactured to match metronidazole
129755|NCT03174223|Drug|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
129731|NCT03174405|Drug|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
129732|NCT03174392|Other|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
129733|NCT03174392|Other|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
129734|NCT03174379|Procedure|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
129735|NCT03174379|Procedure|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
129736|NCT03174366|Drug|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
129737|NCT03174353|Drug|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
129738|NCT03174340|Behavioral|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
129739|NCT03174327|Diagnostic Test|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
129740|NCT03174314|Behavioral|standard object battery and training sequence|Used to examine human localization and identification performance. Object battery will include: trip hazards ('pucks' with various height/width combinations to represent children's toys, street debris, rocks, pets, etc.), furniture (chairs, desks, couches, benches), people, walls, and corridors. Objects will be recorded by placing them to the right or left on the path-of-travel. Raw sensor outputs for single obstacles and walls in isolation (trip-hazard pucks with 8 heights, chair, desk, person, wall) and the same set of single obstacles against a wall. This set of 23 raw sensor traces can be used in various combinations (e.g., encountering a curb and then a person, or a chair) to create a training sequence that will help experimentally naïve subjects to understand the correspondence between tactile stimulation and the real-world scenario it is intended to depict.
129741|NCT03174288|Other|Exercise|24 weeks of exercise treatment
129742|NCT03174288|Drug|Spironolactone|24 weeks of spironolactone
129743|NCT03174275|Drug|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
129744|NCT03174275|Drug|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
129745|NCT03174275|Drug|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
129746|NCT03174275|Drug|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
129747|NCT03174275|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
129748|NCT03174275|Radiation|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
129749|NCT03174262|Behavioral|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
129750|NCT03174249|Behavioral|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
129751|NCT03174236|Drug|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
129752|NCT03174236|Drug|Benzyl penicillin plus gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
129753|NCT03174236|Drug|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
129756|NCT03174210|Device|liquid oxygen device (LOD)|This oxygen Supplementation is used in special order
129757|NCT03174210|Device|portable oxygen concentrator (POC)|This oxygen Supplementation is used in special order
129758|NCT03174197|Drug|Atezolizumab|Given IV
129759|NCT03174197|Radiation|Radiation Therapy|Undergo RT
129760|NCT03174197|Drug|Temozolomide|Given PO
129761|NCT03174184|Drug|Rifampin|Oral administration of rifampin at a dosage of 20 mg/kg daily
129762|NCT03174184|Drug|MEROPENEM 2 grams TID|Intravenous administration at a dosage of 2 grams thrice daily
129763|NCT03174184|Drug|MEROPENEM 1 gram TID|Intravenous administration at a dosage of 1 gram thrice daily
129764|NCT03174184|Drug|MEROPENEM 3 grams QD|Intravenous administration at a dosage of 3 grams once daily
129765|NCT03174184|Drug|Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
129766|NCT03174184|Drug|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
129767|NCT03174171|Drug|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
129768|NCT03174158|Drug|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
129769|NCT03174158|Behavioral|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
129770|NCT03174158|Behavioral|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
129771|NCT03174145|Behavioral|Positive behaviour|Information about T4P1010 treatment
129772|NCT03174145|Drug|T4P1010 administration|Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
129773|NCT03174145|Genetic|Pharmacogenetic|Blood sample of 10 millilitres maximum
129774|NCT03174145|Other|Questionnaires and diary completion|Personnality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
129775|NCT03174132|Device|Restylane Perlane Lidocaine|Intradermal injection
129776|NCT03174132|Device|Restylane Perlane|Intradermal injection
129777|NCT03174119|Device|Light therapy - active|Active light will be used for one week, as compared to placebo light.
129778|NCT03174119|Device|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
129779|NCT03174106|Device|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
129780|NCT03174093|Behavioral|MATCh AFib application|The application comprehends five steps: (1) An educational video about how AF can cause stroke; (2) A calculator of risk scores (CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2); (3) A screen with pictograms to allow better understanding of the scores by patients and to demonstrate how much each anticoagulant can decrease stroke risk or increase bleeding risk; (4) A summary about types of medications available, and (5) An output formulary in which the physician can register patient's contact to continue receiving information about atrial fibrillation and anticoagulation through SMS. Physicians can save patient's history of INR tests and previous doses of anticoagulation prescribed and also use a calculator to adjust the dose.
129781|NCT03174080|Radiation|FDG (glucose labeled isotope of fluorine)|Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI
129782|NCT03174067|Drug|Buprenorphine|The participant receives buprenorphine
129783|NCT03174067|Drug|Clonidine|The participant receives clonidine
129784|NCT03174054|Procedure|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
129785|NCT03174041|Drug|Midazolam|Single dose midazolam
129786|NCT03174041|Drug|GDC-0853|Multiple doses GDC-0853 for 6 days
129787|NCT03174041|Drug|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
129788|NCT03174041|Drug|Rosuvastatin|Single dose rosuvastatin
129789|NCT03174041|Drug|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
129790|NCT03174041|Drug|Simvastatin|Single dose simvastatin
129791|NCT03174041|Drug|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
129792|NCT03174041|Drug|GDC-0853|Single dose GDC-0853
129793|NCT03174041|Drug|Itraconazole|Multiple doses itraconazole for 6 days
129794|NCT03174041|Drug|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
129795|NCT03174028|Device|laparoscopic pull-through|laparoscopic pull-through
129796|NCT03174015|Behavioral|Bauleni Secret|The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
129797|NCT03174002|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
129798|NCT03174002|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
129799|NCT03173989|Device|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
129800|NCT03173989|Behavioral|Orientation|Orientation for home.
129801|NCT03173976|Drug|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
129802|NCT03173963|Drug|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
129803|NCT03173963|Other|Placebo|1placebo tablet per day
129836|NCT03173677|Dietary Supplement|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
129804|NCT03173950|Drug|Nivolumab|Participants will receive nivolumab at standard dose of 240mg IV every 2 weeks for cycles 1 through 4, then doses of 480mg every 4 weeks for a total of 12 additional doses
129805|NCT03173937|Biological|CordIn|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn(TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn(TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn(TM) Noncultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
129806|NCT03173924|Drug|18F-NaF|IV x 1 followed by PET/CT IMAGING
129807|NCT03173924|Drug|18F-DCFPyL|IV x 1 (or x2) followed by PET/CT IMAGING
129808|NCT03173924|Drug|18F-FDG|IV x 1 followed by PET/CT IMAGING
129809|NCT03173911|Device|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
129810|NCT03173898|Procedure|PDL anesthesia versus local infiltration|Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.
129811|NCT03173885|Diagnostic Test|Preimplantation Genetic Screening|"laser assisted hatching~trophectoderm biopsy~next generation sequencing"
129812|NCT03173872|Procedure|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
129813|NCT03173859|Drug|Abiraterone|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
129814|NCT03173859|Drug|Apalutamide|apalutamide 240mg qD orally
129815|NCT03173833|Other|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
129816|NCT03173820|Genetic|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5*1/*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5*1/*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5*3/*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
129817|NCT03173820|Genetic|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
129818|NCT03173807|Behavioral|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
129819|NCT03173794|Other|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
129820|NCT03173781|Drug|droxidopa|medication
129821|NCT03173781|Drug|Placebo|medication
129822|NCT03173768|Procedure|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
129823|NCT03173742|Drug|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
129824|NCT03173742|Drug|T1,T3,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
129825|NCT03173742|Drug|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
129826|NCT03173742|Drug|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
129827|NCT03173742|Drug|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
129828|NCT03173742|Drug|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.~T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
129829|NCT03173729|Diagnostic Test|Biosensor Point of Care Device|This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
129830|NCT03173716|Drug|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
129831|NCT03173703|Device|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
129832|NCT03173703|Procedure|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
129833|NCT03173703|Device|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
129834|NCT03173690|Other|Medication reconciliation at the ICU|Medication reconciliation performed according to Integrated Medicines Management model
129835|NCT03173690|Other|Medication Reconciliation at the Ward|Medication reconciliation performed according to Integrated Medicines Management model
129837|NCT03173677|Dietary Supplement|Glucose intake|300 calories of glucose
129838|NCT03173677|Dietary Supplement|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
129839|NCT03173664|Device|KAMRA Inlay|Unilateral implantation of the KAMRA inlay in the corneal stroma.
129840|NCT03173651|Device|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
129841|NCT03173651|Device|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
129842|NCT03173651|Device|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
129843|NCT03173638|Procedure|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
129844|NCT03173625|Drug|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
129845|NCT03173625|Drug|Placebo|Sterile 0.9% w/v sodium chloride solution
129846|NCT03173612|Drug|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
129847|NCT03173599|Drug|PNA 40mg|The beginning dose is 40mg.
129848|NCT03173599|Drug|PNA 80mg|The single dose is 80mg.
129849|NCT03173599|Drug|PNA 160mg|The single dose is 160mg.
129850|NCT03173599|Drug|PNA 240mg|The single dose is 240mg.
129851|NCT03173599|Drug|PNA 360mg|The single dose is 360mg.
129852|NCT03173599|Drug|PNA 480mg|The single dose is 480mg.
129853|NCT03173599|Drug|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
129854|NCT03173586|Other|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
129855|NCT03173573|Drug|FDL176|CFTR modulator
129856|NCT03173573|Drug|Placebo|Placebo for FDL176
129857|NCT03173560|Drug|lenvatinib|lenvatinib capsules
129858|NCT03173560|Drug|everolimus|everolimus tablets
129859|NCT03173547|Drug|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
129860|NCT03173547|Drug|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
129861|NCT03173534|Device|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
129862|NCT03173534|Device|TAVR|Transcatheter Aortic Valve Replacement
129863|NCT03173521|Biological|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Three dose levels are available:~Starting dose is 6x1011 gc of vector per kg of body weight.~High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT~Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
129864|NCT03173508|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
129865|NCT03173508|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
129866|NCT03173495|Dietary Supplement|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
129867|NCT03173495|Dietary Supplement|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
129868|NCT03173495|Dietary Supplement|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
129869|NCT03173482|Other|questionnaire|asking about details of indication of cesarean section
129870|NCT03173469|Other|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
129871|NCT03173456|Drug|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
129872|NCT03173456|Drug|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
129873|NCT03173456|Drug|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
129874|NCT03173456|Drug|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
129875|NCT03173456|Drug|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
129876|NCT03173443|Device|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
129877|NCT03173443|Device|double lumen tube|fiberoptic intubation with double umen tube
129878|NCT03173430|Drug|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
129879|NCT03173417|Biological|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
129880|NCT03173417|Drug|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
129881|NCT03173404|Procedure|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
129882|NCT03173391|Drug|HMS5552|BID Oral administration
129883|NCT03173391|Drug|Placebo|BID Oral administration
129884|NCT03173378|Other|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
129885|NCT03173365|Drug|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
129886|NCT03173339|Procedure|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
129887|NCT03173339|Drug|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
129888|NCT03173339|Drug|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
129889|NCT03173339|Drug|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
129890|NCT03173339|Drug|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
129891|NCT03173326|Procedure|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
129892|NCT03173326|Procedure|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
129893|NCT03173313|Device|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
129894|NCT03173287|Procedure|Quantification of liver fibrosis|Procedure MRI and liver biopsy
129895|NCT03173274|Behavioral|Brief Motivational Intervention|Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
129896|NCT03173274|Behavioral|Contingency Management|Contingent Reinforcement for negative breath CO samples
129897|NCT03173274|Behavioral|Non-Contingent Reinforcement|Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value [CM control]
129898|NCT03173261|Diagnostic Test|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
129899|NCT03173248|Drug|AG-120 (ivosidenib) with Azacitidine|Continuous 28-day cycles of AG-120 (ivosidenib) 500 mg orally (PO) once daily (QD) in combination with azacitidine 75 mg/m2/day SC or IV for the first week of each cycle
129900|NCT03173248|Drug|Placebo with Azacitidine|Continuous 28-day cycles of Placebo orally (PO) once daily (QD) in combination with azacitidine 75 mg/m2/day SC or IV for the first week of each cycle
129901|NCT03173235|Diagnostic Test|Plasma level of vitamin D|messurement of plasma level of vitamin D
129902|NCT03173222|Procedure|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
129903|NCT03173209|Behavioral|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
129904|NCT03173196|Device|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
129905|NCT03173183|Drug|genuine regional Rhizoma Atractylodis (Maozhu granule)|"Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.~Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd."
129906|NCT03173170|Drug|TAK-954|TAK-954 Infusion
129907|NCT03173170|Drug|Itraconazole|Itraconazole Capsule
129908|NCT03173157|Other|Value Feedback Email|a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
129909|NCT03173144|Other|Primary exposure variable|"Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome~Low intake of red and processed meat (defined as below the lower tertile [33.3% of the total sample]) and high intake of dietary fibres (defined as those above the upper tertile [33.3% of the total sample]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
129910|NCT03173144|Other|Other (exploratory) exposure variables|"Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)~Pretreatment lifestyle-associated biomarkers~Combinations of lifestyle factors and lifestyle-associated biomarkers~Gene-environment interaction analyses~Pretreatment levels of inflammatory molecules"
129911|NCT03173131|Behavioral|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
129912|NCT03173118|Procedure|Endoscopic ultrasound elastography|Endoscopic ultrasound elastography performed on both groups of patients as per routine
129913|NCT03173105|Device|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
129914|NCT03173105|Device|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
129915|NCT03173105|Other|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
129916|NCT03173105|Other|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
129917|NCT03173092|Drug|Ixazomib|Ixazomib capsules.
129918|NCT03173092|Drug|Lenalidomide|Lenalidomide capsules.
129919|NCT03173092|Drug|Dexamethasone|Dexamethasone.
129920|NCT03173079|Other|pre- and postinterventional geriatric assessment in patients undergoing TAVI|geriatric assessment
129921|NCT03173066|Drug|Ferumoxytol|ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
129922|NCT03173053|Drug|Doxycycline|tablet
129923|NCT03173053|Drug|Trimethoprim|tablet
129924|NCT03173053|Drug|Sulfamethoxazole/trimethoprim|tablet
129925|NCT03173053|Drug|Clindamycin|tablet
129926|NCT03173053|Drug|Clarithromycin|tablet
129927|NCT03173053|Drug|Ciprofloxacin|tablet
129928|NCT03173053|Drug|Fusidic Acid|tablet or ointment
129929|NCT03173053|Drug|Rifampin|tablet
129930|NCT03173053|Drug|Chlorhexidine|Mouthwash or bodywash
129931|NCT03173053|Drug|Mupirocin|Nasal ointment
129932|NCT03173053|Drug|Betadine|Shampoo
129933|NCT03173040|Drug|NiuBangZi pill or NiuBangZi pill placebo|For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
129934|NCT03173027|Drug|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
129935|NCT03173014|Device|EEG|EEG monitoring
129936|NCT03173001|Diagnostic Test|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
129937|NCT03172988|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
129938|NCT03172988|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
129939|NCT03172988|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
129940|NCT03172988|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
129941|NCT03172975|Biological|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
129942|NCT03172975|Biological|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
129943|NCT03172975|Biological|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
129944|NCT03172975|Biological|Placebo|Physiological sterile saline solution
129945|NCT03172975|Drug|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
129946|NCT03172975|Other|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
129947|NCT03172962|Behavioral|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 8 weeks
129948|NCT03172962|Behavioral|Usual care (control)|Will receive the usual care at the hospital
129949|NCT03172936|Drug|MIW815|MIW 815 (ADU-S100) is a STING agonist
129950|NCT03172936|Biological|PDR001|PDR001 is an anti-PD-1 antibody
129951|NCT03172923|Device|sliding hip screw|fixation of the fracture with a sliding hip screw
129952|NCT03172923|Device|intramedullary nial|fixation of the fracture with an intramedullary nail
129953|NCT03172910|Drug|Ciraparantag|Reversal of rivaroxaban-induced anticoagulation via dose of ciraparantag or placebo
129954|NCT03172910|Drug|Placebo|Reversal of rivaroxaban-induced anticoagulation via dose of ciraparantag or placebo
129955|NCT03172897|Drug|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
129956|NCT03172897|Drug|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
129957|NCT03172884|Drug|Copanlisib BAY80-6946|12mg single dose, intravenous on Day 0
129958|NCT03172871|Drug|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
129959|NCT03172871|Drug|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
129960|NCT03172858|Device|Intracervical balloon catheter|cervical ripening balloon
129961|NCT03172858|Drug|Oxytocin|medication used to induce contractions
129962|NCT03172845|Procedure|percutaneous coronary intervention|percutaneous coronary intervention with drug-eluting stent implantation.
129963|NCT03172832|Procedure|PTBD|Percutaneous access and tube placement into the bile duct
129964|NCT03172832|Procedure|ERC|Endoscopic access and stent placement in the bile duct
129965|NCT03172819|Biological|OBP-301|"Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.~Additional administration of OBP-301 After the recommended dose of OBP-301 has been established, additional administration of OBP-301 is allowed. After completion of administration of OBP-301 on Day 1 - Day 29(+/- 4 days), if the target region has not disappeared, additional administration of OBP-301 is allowed after Day 43 or later.~The patients in Phase 1a, Pembrolizumab administration has continued, are included.~The recommended dose determined in the Phase 1a part will be administered 3 times biweekly (+/- 4 days); max 4 cycles."
129966|NCT03172819|Drug|Pembrolizumab|200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
129967|NCT03172806|Diagnostic Test|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
129968|NCT03172793|Drug|Telavancin Injection|Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
129969|NCT03172780|Drug|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
129970|NCT03172780|Drug|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
129971|NCT03172780|Drug|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
129972|NCT03172754|Drug|Nivolumab|PD-1 inhibitor
129973|NCT03172754|Drug|Axitinib|Tyrosine kinase inhibitor
129974|NCT03172741|Drug|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
129975|NCT03172741|Drug|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
129976|NCT03172728|Behavioral|psycho-education pamphlet|psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
129977|NCT03172715|Procedure|Locking plate|Osteosynthesis
129978|NCT03172715|Procedure|TKR|Total knee arthroplasty
129979|NCT03172702|Drug|Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
129980|NCT03172689|Device|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
129981|NCT03172676|Drug|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
129982|NCT03172676|Drug|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
129983|NCT03172676|Drug|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
129984|NCT03172663|Device|pure tone audiometry|for estimate the type and degree of hearing loss
129985|NCT03172650|Diagnostic Test|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
129986|NCT03172624|Drug|Nivolumab|nivolumab 3 mg/kg every 2 weeks
129987|NCT03172624|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
129988|NCT03172611|Other|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
129989|NCT03172598|Drug|MT-8554 low dose|Capsule
129990|NCT03172598|Drug|MT-8554 middle dose|Capsule
129991|NCT03172598|Drug|MT-8554 high dose|Capsule
129992|NCT03172598|Drug|Placebo|Capsule
129993|NCT03172585|Other|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
129994|NCT03172585|Other|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
129995|NCT03172572|Procedure|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
129996|NCT03172572|Procedure|Open pancreatoduodenectomy|Open resection
129997|NCT03172559|Radiation|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
129998|NCT03172546|Genetic|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
129999|NCT03172533|Drug|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
130000|NCT03172533|Drug|Placebo oral capsule|placebo
130001|NCT03172520|Device|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
130002|NCT03172520|Device|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
130003|NCT03172494|Drug|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
130004|NCT03172494|Drug|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
130005|NCT03172494|Drug|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.~For 26 weeks."
130006|NCT03172481|Drug|PRC-063 oral capsules|Daily dose
130007|NCT03172481|Drug|Placebo oral capsules|Daily dose
130008|NCT03172455|Drug|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)
130009|NCT03172442|Device|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
130010|NCT03172442|Device|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
130011|NCT03172442|Device|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
130012|NCT03172416|Drug|Oxaliplatin|"This is a prospective, single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.~The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3), 120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level."
130013|NCT03172403|Diagnostic Test|Height and weight|Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
130014|NCT03172403|Diagnostic Test|Blood samples|Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
130015|NCT03172403|Diagnostic Test|Skeletal muscle force|Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
130016|NCT03172403|Diagnostic Test|Skeletal muscle index|Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
130017|NCT03172403|Diagnostic Test|Muscle biopsy|Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
130018|NCT03172390|Device|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
130019|NCT03172377|Other|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
130020|NCT03172364|Other|Micellar cleanser|Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
130021|NCT03172364|Other|Micellar foaming cleanser|Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
130022|NCT03172351|Device|EDoF1|extended depth of focus IOL - EDoF1
130023|NCT03172351|Device|Monofocal|Monofocal IOL
130024|NCT03172351|Device|EDoF2|Comparison EDoF2 IOL
130025|NCT03172325|Drug|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
130026|NCT03172325|Drug|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
130027|NCT03172325|Drug|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
130028|NCT03172325|Drug|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
130029|NCT03172312|Procedure|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
130030|NCT03172299|Drug|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
130031|NCT03172299|Drug|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
130032|NCT03172286|Device|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
130033|NCT03172273|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
130034|NCT03172273|Procedure|paracentesis|paracentasis plus albumine invision
130035|NCT03172260|Device|E Balance Pro Therapy|Micro-current treatment
130036|NCT03172234|Other|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
130037|NCT03172234|Drug|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
130038|NCT03172234|Drug|Placebo Oral Tablet|in control group : the patients will receive Placebo Oral Tablet 90 minute prior to the surgery
130039|NCT03172221|Diagnostic Test|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
130040|NCT03172208|Biological|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
130041|NCT03172208|Biological|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
130042|NCT03172208|Biological|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
130043|NCT03172208|Biological|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
130044|NCT03172208|Other|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
130045|NCT03172208|Other|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
130046|NCT03172208|Other|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
130047|NCT03172195|Procedure|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
130048|NCT03172195|Biological|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
130049|NCT03172195|Biological|blood sample|Blood sample will be collected in more.
130050|NCT03172182|Behavioral|a 360-degree VR video tour|At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
130051|NCT03172169|Other|no Intervention|no Intervention
130052|NCT03172156|Genetic|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
130053|NCT03172143|Procedure|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
130054|NCT03172143|Procedure|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
130055|NCT03172130|Device|Straight CPAP|
130056|NCT03172130|Device|Sham CPAP|
130057|NCT03172117|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
130058|NCT03172117|Other|Normal saline 2mL|Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
130059|NCT03172091|Device|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
130060|NCT03172091|Device|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
130061|NCT03172078|Procedure|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP), and other upper gastrointestinal endoscopy.
130062|NCT03172065|Drug|Normal saline|intravenous flluid
130063|NCT03172065|Drug|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
130064|NCT03172052|Drug|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
130065|NCT03172052|Drug|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
130066|NCT03172052|Device|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
130067|NCT03172052|Device|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
130068|NCT03172026|Drug|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
130069|NCT03172026|Behavioral|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.~Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
130070|NCT03172026|Drug|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
130071|NCT03172013|Diagnostic Test|Platelet indices|MPV, PDW
130072|NCT03172000|Diagnostic Test|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
130073|NCT03171987|Drug|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
130074|NCT03171987|Drug|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
130075|NCT03171974|Drug|Dexamethasone|dexamethasone will be injected intracapsular under US
130076|NCT03171974|Device|US|dexamethasone will be injected intracapsular under US
130077|NCT03171961|Behavioral|online visit group|subjects has online visit with dietitian every 2 weeks+diet
130078|NCT03171961|Behavioral|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
130079|NCT03171961|Behavioral|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
130080|NCT03171948|Behavioral|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
130081|NCT03171948|Behavioral|Nut Free group|continue their diet without any nut consumption.
130082|NCT03171935|Device|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
130083|NCT03171935|Device|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 >92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 >96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
130084|NCT03171935|Device|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
130085|NCT03171922|Behavioral|Internet Diet|ID group have online dietary coach every 2 weeks
130086|NCT03171922|Behavioral|Clinic Diet|CD group have every 2 weeks visit at clinic
130087|NCT03171896|Other|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
130088|NCT03171896|Other|Sham|No clown will be present in the room during labor
130089|NCT03171870|Diagnostic Test|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
130090|NCT03171844|Other|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
130091|NCT03171831|Drug|Busulfan|Busulfan（4 mg/kg/day,4 days）
130092|NCT03171831|Drug|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
130093|NCT03171831|Drug|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
130094|NCT03171831|Drug|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
130095|NCT03171831|Drug|Tacrolimus|Tacrolimus（0.03mg/kg/day）
130096|NCT03171831|Drug|Methotrexate|Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
130097|NCT03171831|Drug|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
130098|NCT03171831|Drug|Basiliximab|Basiliximab（10mg on day 0 and +4）
130099|NCT03171818|Drug|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
130100|NCT03171818|Drug|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
130101|NCT03171805|Drug|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
130102|NCT03171792|Other|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
130103|NCT03171779|Other|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
130104|NCT03171766|Diagnostic Test|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
130105|NCT03171766|Diagnostic Test|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
130106|NCT03171766|Diagnostic Test|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
130107|NCT03171753|Diagnostic Test|questionnaire|questionnarie will be performed before the application of headphone and after their removal.
130108|NCT03171753|Diagnostic Test|laboratory test|laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
130109|NCT03171753|Diagnostic Test|cardiac monitoring|the cardiac monitoring will be performed through study period
130110|NCT03171753|Diagnostic Test|skin resistance|the skin resistance monitoring will be performed through study period
130111|NCT03171753|Device|Music listening|Listening prerecorded music through an individual headset for 30 min
130112|NCT03171753|Device|No sound|No sound through an individual headset for 30 min
130113|NCT03171740|Drug|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
130114|NCT03171740|Drug|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
130115|NCT03171740|Drug|Oral saline|Oral saline, 0.25ml/kg
130116|NCT03171740|Drug|Nasal saline|Nasal saline 0.01ml/kg
130117|NCT03171727|Drug|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
130118|NCT03171714|Device|Derma-Stent|The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
130119|NCT03171714|Device|Usual care, cotton gauze packing|Standard gauze packing used to pack a drained abscess.
130120|NCT03171662|Other|Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
130121|NCT03171649|Device|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:~anterior reaching (in a plane or in the space)~lateral elevation of the arm~hand to mouth movements with or without an object in the hand~moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
130122|NCT03171649|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:~Upper limb passive motion~Arm Cycle ergometer with or without FES~Neuro Muscular Electrical Stimulation~Upper limb exercises using augmented or virtual reality environment~Occupational therapy exercises~Constraint induced movement therapy~Upper limb active movement (reaching, grasping, elevation, spatial orientation)~Repetitive task training~Mirror therapy~Writing training~Chemodenervation Therapy"
130123|NCT03171623|Drug|globalagliatin hydrochloride|orally administration, single dose
130124|NCT03171623|Drug|placebo|orally administration, single dose
130125|NCT03171610|Drug|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
130265|NCT03170544|Drug|MK-1092, 32 nmol/kg|MK-1092, 32 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
130126|NCT03171610|Drug|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
130127|NCT03171597|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
130128|NCT03171597|Drug|Lipid Regulating Drugs|Mainly including statins
130129|NCT03171597|Drug|Coronary Vasodilator|Mainly including nitrates
130130|NCT03171597|Drug|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
130131|NCT03171597|Drug|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
130132|NCT03171597|Drug|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
130133|NCT03171584|Drug|Terbinafine|oral antifungal drugs
130134|NCT03171571|Other|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~survey like FFQ, SF36, dietary habits.~actimetry measurement~one year follow-up of weight, waist measurement~nutritional biomarkers"
130135|NCT03171558|Procedure|Gastric Pull Up|Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
130136|NCT03171558|Procedure|Free Flap Surgery|Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
130137|NCT03171545|Behavioral|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
130138|NCT03171545|Behavioral|Provider Education|Staff in clinics assigned to this group will receive team training and a checklist.
130139|NCT03171532|Procedure|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
130140|NCT03171519|Behavioral|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
130141|NCT03171519|Behavioral|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
130142|NCT03171506|Other|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that ~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
130143|NCT03171506|Other|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
130144|NCT03171493|Biological|MV-NIS|Attenuated measles virus encoding NIS (MV-NIS)
130145|NCT03171480|Drug|Monoket Pill|Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
130146|NCT03171467|Procedure|Salpingectomy|
130147|NCT03171454|Procedure|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
130148|NCT03171454|Procedure|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
130149|NCT03171441|Diagnostic Test|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
130150|NCT03171441|Diagnostic Test|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
130151|NCT03171428|Procedure|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
130152|NCT03171415|Drug|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
130153|NCT03171415|Drug|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-36 sites (0.1mL per site) into the abdominal subcutaneous fat.
130154|NCT03171402|Diagnostic Test|Astringency and bitterness perception|Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
130155|NCT03171389|Drug|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
130156|NCT03171376|Procedure|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
130157|NCT03171363|Behavioral|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
130158|NCT03171350|Diagnostic Test|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
130159|NCT03171337|Device|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
130160|NCT03171337|Device|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
130161|NCT03171337|Device|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
130162|NCT03171324|Drug|Iron Supplement|2 mg/kg/day elemental iron
130163|NCT03171311|Procedure|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
130267|NCT03170544|Drug|Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose
130164|NCT03171311|Procedure|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
130165|NCT03171298|Procedure|Laparoscopic Assisted Transanal Total Mesorectal Excision|"Abdominal approach with laparoscopic mobilization of the left colon~Laparoscopic isolation and transection of inferior mesenteric vessels .~Transabdominal dissection of the upper rectum and mesorectam.~Insertion of transanal platform and the creation of pneumorectum.~Occlusion of rectum 2 cm distal to the rectal lesion via purse string.~Transanal dissection of lower and mid mesorectam~The specimen will be extracted transanally"
130166|NCT03171285|Other|Less than 35 years old|Clinical and laboratory evaluations
130167|NCT03171285|Other|Greater than or equal to 35 years|Clinical and laboratory evaluations
130168|NCT03171272|Other|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.~Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
130169|NCT03171259|Other|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
130170|NCT03171246|Dietary Supplement|Solid food-based intervention|Individually tailored energy content according to age/activity
130171|NCT03171233|Other|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
130172|NCT03171233|Other|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
130173|NCT03171220|Biological|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
130174|NCT03171220|Biological|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
130175|NCT03171220|Drug|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
130176|NCT03171220|Drug|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
130177|NCT03171220|Biological|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
130178|NCT03171207|Device|Lite Run Gait Trainer|The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
130179|NCT03171207|Device|Current Harness System|There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
130180|NCT03171194|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
130181|NCT03171181|Other|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
130182|NCT03171168|Device|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
130183|NCT03171168|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
130184|NCT03171155|Device|XPro System|Implantation of the XPro System
130185|NCT03171142|Drug|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
130186|NCT03171142|Drug|Air|Air 21% via nasal cannula 2 litter per minutes
130187|NCT03171129|Device|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
130188|NCT03171129|Device|High flow Nasal Canula|Oxygen will be administered via nasal canula
130189|NCT03171116|Other|none intervention|it is not an interventional study; it is an observational study
130190|NCT03171090|Other|sphenopalatine block with local anesthetic|bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
130191|NCT03171090|Other|sphenopalatine block with saline|bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
130192|NCT03171077|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
130193|NCT03171077|Other|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
130266|NCT03170544|Drug|MK-1092, 64 nmol/kg|MK-1092, 64 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
130194|NCT03171077|Other|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
130195|NCT03171064|Behavioral|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
130196|NCT03171051|Device|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
130197|NCT03171051|Device|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
130198|NCT03171038|Other|Telemonitoring|
130199|NCT03171025|Drug|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
130200|NCT03171012|Other|Lower limbs CRT|cycle ergometer for lower limbs
130201|NCT03171012|Other|Upper limbs CRT|cycle ergometer for upper limbs
130202|NCT03171012|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
130203|NCT03171012|Other|respiration|respiration
130204|NCT03170999|Other|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
130205|NCT03170999|Other|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
130206|NCT03170999|Other|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
130207|NCT03170986|Behavioral|Multisectoral agriculture and Microfinance Intervention|
130208|NCT03170973|Other|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
130209|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
130210|NCT03170960|Drug|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
130211|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the Cohort Review Committee-determined recommended dose from the Dose Escalation Stage
130212|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at 60 mg qd
130213|NCT03170947|Device|Custom Insoles|"Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.~Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned."
130214|NCT03170947|Device|Standardized insoles|Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
130215|NCT03170934|Behavioral|Psychotherapy skills class|Rapid access, large-scale, psychotherapy classes that are open format and delivered in lecture style. One class - Managing Difficult Emotions (MDE) - is an 8-session, DBT-informed program. The other class - Mindfulness-Based Cognitive Behavioral Therapy (CBTm) - is a 4-session program.
130216|NCT03170921|Other|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
130217|NCT03170921|Other|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
130218|NCT03170921|Other|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
130219|NCT03170908|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
130220|NCT03170895|Drug|Sorafenib|Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
130221|NCT03170895|Drug|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
130222|NCT03170882|Drug|Ixazomib|Ixazomib capsules.
130223|NCT03170882|Drug|Pomalidomide|Pomalidomide capsules.
130224|NCT03170882|Drug|Dexamethasone|Dexamethasone tablets.
130261|NCT03170557|Other|Aspecific needle skin stimulation|Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
130262|NCT03170544|Drug|MK-1092, 4.0 nmol/kg|MK-1092, 4.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
130263|NCT03170544|Drug|MK-1092, 8.0 nmol/kg|MK-1092, 8.0 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
130264|NCT03170544|Drug|MK-1092, 16 nmol/kg|MK-1092, 16 nmol/kg, SC, as a single dose under the euglycemic clamp, in participants
130225|NCT03170869|Device|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
130226|NCT03170856|Other|Sub-maximal exercise|Subjects will participate in aerobic exercise 5 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 60 minutes 5times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
130227|NCT03170843|Device|use of plastic ring wound retractor|the experimental arm will use the plastic ring wound retractor for wound protection.
130228|NCT03170830|Diagnostic Test|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
130229|NCT03170817|Diagnostic Test|Cardiac Perfusion Rest/Stress Digital PET/CT|"Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.~These patients are given:~One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of ~20 minute duration.~A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart~One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of ~20 minute duration~Total patient time will take approximately up to 120 minutes."
130230|NCT03170817|Drug|N-13 ammonia|5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
130231|NCT03170817|Drug|Regadenoson|0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
130232|NCT03170791|Device|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
130233|NCT03170765|Biological|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
130234|NCT03170752|Behavioral|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
130235|NCT03170739|Drug|Dexmedetomidine|Dexmedetomidine given during surgery.
130236|NCT03170739|Drug|Dopamine|Dopamine given during surgery.
130237|NCT03170726|Drug|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
130238|NCT03170726|Drug|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
130239|NCT03170726|Other|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
130240|NCT03170713|Drug|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
130241|NCT03170713|Drug|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
130242|NCT03170713|Other|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
130243|NCT03170700|Behavioral|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
130244|NCT03170700|Behavioral|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
130245|NCT03170687|Device|short foot cast|metatarsal foot cast
130246|NCT03170687|Device|short leg cast|full short leg cast
130247|NCT03170674|Other|FT21039|an electronic cigarette product
130248|NCT03170674|Other|FT21092|an electronic cigarette product
130249|NCT03170674|Other|FT21018|an electronic cigarette product
130250|NCT03170661|Drug|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
130251|NCT03170648|Device|Acupuncture|Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
130252|NCT03170635|Behavioral|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
130253|NCT03170622|Diagnostic Test|Intervention group|This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
130254|NCT03170609|Biological|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
130255|NCT03170609|Biological|Placebo|Saline Control
130256|NCT03170596|Drug|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
130257|NCT03170596|Device|Microneedling|Microneedling is a method of percutaneous collagen induction
130258|NCT03170583|Device|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
130259|NCT03170570|Device|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
130260|NCT03170557|Other|Traditional chinese acupuncture|Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
130268|NCT03170544|Drug|Lispro 1.2 nmol/kg|Lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting ~12 hours after MK-1092 administration.
130269|NCT03170544|Drug|Placebo to glargine|Placebo to glargine, SC, as a single dose
130270|NCT03170544|Drug|Placebo to MK-1092|Placebo to MK-1092, SC, as a single dose
130271|NCT03170544|Other|Dextrose|20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
130272|NCT03170544|Biological|Insulin|Participants will receive insulin IV, as needed, prior to dosing and clamp initiation and after dosing.
130273|NCT03170531|Diagnostic Test|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
130274|NCT03170531|Diagnostic Test|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging. Volunteers may receive up to 3 scans to allow for comparisons of changes to the calibration files as we continue to test the coil and improve its performance.
130275|NCT03170518|Drug|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
130276|NCT03170518|Drug|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
130277|NCT03170518|Drug|Placebo|Matching placebo tablet will be administered orally once-daily.
130278|NCT03170505|Procedure|repairing fistula|A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
130279|NCT03170492|Other|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
130280|NCT03170492|Other|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
130281|NCT03170479|Dietary Supplement|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
130282|NCT03170479|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
130283|NCT03170466|Behavioral|Primary Palliative Care|The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
130284|NCT03170453|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
130285|NCT03170453|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
130286|NCT03170440|Other|Transcutaneous nerve stimulation location 1|Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
130287|NCT03170440|Other|Transcutaneous nerve stimulation location 2|Stimulation will be performed using electrodes placed in alternate location.
130288|NCT03170427|Device|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
130289|NCT03170427|Diagnostic Test|Sensory levels|Sensory levels are checked using ice test cold
130290|NCT03170427|Diagnostic Test|Motor block|motor block is measured by modified Bromage scale
130291|NCT03170427|Diagnostic Test|Sensory level|Sensory levels are checked using touch with alcohol puffs
130292|NCT03170401|Dietary Supplement|Protein supplementation|half the subjects will receive protein supplementation via enteral feedings and half will not receive the protein supplementation
130293|NCT03170388|Drug|IDP-126 Gel|Gel
130294|NCT03170388|Drug|IDP-126 Component A|Component A
130295|NCT03170388|Drug|IDP-126 Component B|Component B
130296|NCT03170388|Drug|IDP-126 Component C|Component C
130297|NCT03170388|Drug|IDP-126 Vehicle Gel|Vehicle Gel
130298|NCT03170375|Behavioral|Performance of WHEELS-I in promoting DASH/SRD adoption|Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.
130299|NCT03170375|Behavioral|Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors|Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
130300|NCT03170362|Other|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
130301|NCT03170349|Device|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
130423|NCT03169764|Biological|GI-4000|Ras yeast vaccine
130302|NCT03170336|Drug|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
130303|NCT03170336|Drug|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
130304|NCT03170323|Drug|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
130305|NCT03170323|Drug|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
130306|NCT03170310|Drug|Apatinib|Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
130307|NCT03170297|Other|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
130308|NCT03170284|Drug|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
130309|NCT03170271|Drug|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days) In the open label ANDHI IP sub study, all patients will receive benralizumab subcutaneously at Day 168 (Week 24), Day 196 (Week 28), Day 224 (Week 32), Day 280 (Week 40), Day 336 (Week 48), Day 392 (Week 56), Day 448 (Week 64), and Day 504 (Week 72).
130310|NCT03170271|Drug|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
130311|NCT03170258|Device|Neurofeedback (from fMRI and/or EEG)|During part of the task, a feedback display (e.g., thermometer stimulus) will be used to display the average brain activity for each participant. This signal will be acquired ~ every 1 second during the neurofeedback session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated display is the primary feedback mechanism provided to the participant.
130312|NCT03170245|Diagnostic Test|Interleukin-6|serum samples used for doing the test by ELISA
130313|NCT03170245|Diagnostic Test|HsC-RP|serum samples used for doing the test by ELISA
130314|NCT03170245|Diagnostic Test|Adiponectin level|serum samples used for doing the test by ELISA
130315|NCT03170245|Diagnostic Test|Carotid intima media thickness|Done by carotid doppler
130316|NCT03170232|Drug|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
130317|NCT03170232|Drug|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
130318|NCT03170232|Device|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
130319|NCT03170232|Drug|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
130320|NCT03170219|Combination Product|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
130321|NCT03170206|Drug|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
130322|NCT03170206|Drug|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
130323|NCT03170193|Drug|AMG 529|Ascending single doses of AMG 529 by subcutaneous (SC) or intravenous (IV) injection
130324|NCT03170193|Drug|Placebo|Single doses of matching placebo by SC or IV injection
130325|NCT03170180|Drug|Sunitinib|sunitinib 37.5mg daily
130326|NCT03170180|Drug|Gefitinib|Gefitinib 250mg daily
130327|NCT03170180|Drug|Imatinib|Imatinib 400mg daily
130328|NCT03170141|Biological|Antigen-specific IgT cells|Tumor antigen-specific IgT cells are infused intravenously or directly to the tumor location of the patients in a three-day split-dose regimen（day 0,10%; day1, 30%; day2, 60%）to complete a total targeted dose. Drug: cyclophosphamide 250 mg/m^2 d1-3; Drug: Fludarabine 25mg/m^2 d1-3
130329|NCT03170128|Procedure|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
130330|NCT03170128|Behavioral|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
130331|NCT03170115|Drug|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
130332|NCT03170115|Drug|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
130333|NCT03170102|Other|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
130334|NCT03170089|Behavioral|Oral Health Educational Program|Oral Hygiene methods learned
130335|NCT03170063|Procedure|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
130336|NCT03170050|Device|YYD701-2|HA Filler
130337|NCT03170050|Device|Restylane Perlane Lidocaine|HA Filler
130338|NCT03170037|Procedure|Standard V-E ventilation technique|For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
130339|NCT03170037|Procedure|Reversal V-E ventilation technique|While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
130340|NCT03170011|Behavioral|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
130341|NCT03169998|Device|EV1000 platform|a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
130342|NCT03169985|Drug|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
130343|NCT03169985|Drug|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
130344|NCT03169972|Biological|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
130345|NCT03169959|Drug|2.5 mg Saxagliptin tablet|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
130346|NCT03169959|Drug|5 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of sodium-glucose co-transporter 2 (SGLT-2), reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
130347|NCT03169959|Drug|Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
130348|NCT03169959|Drug|5 mg saxagliptin|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
130349|NCT03169959|Drug|10 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
130350|NCT03169959|Drug|Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.~Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.~Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
130351|NCT03169946|Procedure|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
130352|NCT03169946|Procedure|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
130353|NCT03169933|Radiation|Combined, intensified and modulated adjuvant radiotherapy|
130354|NCT03169920|Procedure|Modified-Minimally Invasive Surgical Technique + PRF|
130355|NCT03169920|Procedure|Modified-Minimally Invasive Surgical Technique|
130356|NCT03169907|Radiation|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:~Middle cerebral artery (MCA) peak systolic velocity (PSV):~Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):~Ductus venosus (DV) Doppler:~Cardiac functions:~Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):~Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:~Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
130357|NCT03169894|Drug|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
130358|NCT03169881|Drug|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
130359|NCT03169881|Drug|Placebo|normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
130360|NCT03169868|Diagnostic Test|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
130361|NCT03169855|Diagnostic Test|Slit lamp (LOCS III Score)|Diagnostic procedure only
130362|NCT03169842|Device|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
130363|NCT03169829|Dietary Supplement|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1~Animal only Protein~Refined only Grains~Limit Dairy~Low-k only"
130364|NCT03169829|Dietary Supplement|Low-k|"•¼ Animal, ¾ Plant Proteins~•½ Refined, ½ Whole Grain~Limit Dairy, provide Soymilk Dairy~Low-k only Fruit and Vegetables"
130424|NCT03169764|Biological|GI-6207|CEA yeast vaccine
130425|NCT03169764|Biological|GI-6301|Brachyury yeast vaccine
130365|NCT03169829|Dietary Supplement|Standard|"•¼ Animal, ¾ Plant Proteins~Refined, ½ Whole Grain~•Limit Dairy, provide Soymilk Dairy~Low-k, Fruit and Vegetables~High-k Fruit and Vegetables"
130366|NCT03169816|Drug|Lorcaserin|Lorcaserin 10mg, twice daily
130367|NCT03169816|Drug|Placebo|Matched placebo for lorcaserin condition dosed twice daily
130368|NCT03169803|Device|NeuroTronik CANS Therapy™ System|The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
130369|NCT03169790|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
130370|NCT03169790|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
130371|NCT03169790|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
130372|NCT03169790|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
130373|NCT03169790|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
130374|NCT03169790|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
130375|NCT03169790|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
130376|NCT03169790|Drug|Lovaza|Omega-3-acid ethyl esters
130377|NCT03169790|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
130378|NCT03169790|Drug|rituximab|Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
130379|NCT03169790|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
130380|NCT03169790|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
130381|NCT03169790|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
130382|NCT03169790|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
130383|NCT03169777|Biological|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
130384|NCT03169777|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
130385|NCT03169777|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
130386|NCT03169777|Biological|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
130387|NCT03169777|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
130388|NCT03169777|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
130389|NCT03169777|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
130390|NCT03169777|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
130391|NCT03169777|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
130392|NCT03169777|Biological|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
130393|NCT03169777|Drug|Lovaza|Omega-3-acid ethyl esters
130394|NCT03169777|Drug|oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
130395|NCT03169777|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
130396|NCT03169777|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
130397|NCT03169777|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
130398|NCT03169777|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
130399|NCT03169777|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
130400|NCT03169777|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
130401|NCT03169777|Biological|GI-4000|RAS yeast vaccine
130402|NCT03169777|Biological|GI-6207|CEA yeast vaccine
130403|NCT03169777|Biological|GI-6301|Brachyury yeast vaccine
130404|NCT03169777|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
130405|NCT03169764|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
130406|NCT03169764|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
130407|NCT03169764|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
130408|NCT03169764|Biological|Cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
130409|NCT03169764|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
130410|NCT03169764|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
130411|NCT03169764|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
130412|NCT03169764|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
130413|NCT03169764|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
130414|NCT03169764|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
130415|NCT03169764|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
130416|NCT03169764|Drug|Lovaza|Omega-3-acid ethyl esters
130417|NCT03169764|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
130418|NCT03169764|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex]
130419|NCT03169764|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen (CEA) vaccine
130420|NCT03169764|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 (HER2) vaccine
130421|NCT03169764|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
130422|NCT03169764|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1) vaccine
130426|NCT03169764|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
130427|NCT03169751|Device|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
130428|NCT03169738|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
130429|NCT03169738|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
130430|NCT03169738|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
130431|NCT03169738|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
130432|NCT03169738|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
130433|NCT03169738|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
130434|NCT03169738|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
130435|NCT03169738|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
130436|NCT03169738|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
130437|NCT03169738|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
130438|NCT03169738|Drug|Lovaza|Omega-3-acid ethyl esters
130439|NCT03169738|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
130440|NCT03169738|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
130441|NCT03169738|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL15N72D:IL-15RαSu/IgG1 Fc complex]
130442|NCT03169738|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
130443|NCT03169738|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
130444|NCT03169738|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
130445|NCT03169738|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
130446|NCT03169738|Biological|GI-4000|Ras yeast vaccine
130447|NCT03169738|Biological|GI-6207|CEA yeast vaccine
130448|NCT03169738|Biological|GI-6301|Brachyury yeast vaccine
130449|NCT03169738|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
130450|NCT03169725|Biological|Inactivated Poliomyelitis Vaccine (Sabin strain)|Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
130451|NCT03169725|Biological|Inactivated Poliomyelitis Vaccine (Salk strain)|Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
130452|NCT03169712|Behavioral|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
130453|NCT03169712|Behavioral|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
130454|NCT03169686|Behavioral|Cognitive and Behavioral Intervention|Participants who allocate to the intervention group will receive regular messages providing smoking cessation related information, such as advice, support, and distraction by professional team.
130455|NCT03169673|Diagnostic Test|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
130456|NCT03169660|Drug|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
130457|NCT03169647|Behavioral|Listening-based intervention|Participants will listen to pre-specified material on a CD
130458|NCT03169634|Procedure|short or long stemmed rTKR cemented|An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
130459|NCT03169634|Procedure|Cone with short stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
130460|NCT03169634|Procedure|Cone with long stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
130461|NCT03169621|Procedure|Endometrial Biopsy and endometrial fluid collection|"On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
130462|NCT03169595|Procedure|Surgery|Patients affected by epithelioid hemangioma treated with surgery
130463|NCT03169582|Drug|Avanafil|Drug administration (Avanafil)
130464|NCT03169582|Drug|Sildenafil|Drug administration (Sildenafil)
130465|NCT03169569|Procedure|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
130466|NCT03169569|Procedure|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
130467|NCT03169556|Device|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
130468|NCT03169556|Device|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
130469|NCT03169543|Behavioral|Sleep deprivation|36-hours total sleep deprivation
130470|NCT03169530|Other|Alcohol|~15 gm daily of beer, wine, or spirits for ~6 years
130471|NCT03169504|Other|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30*25 mm, 0.30*40 mm or 0.30*50 mm will be used 3 times weekly for 12 weeks.
130472|NCT03169504|Drug|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.~Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.~Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
130473|NCT03169504|Other|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
130474|NCT03169491|Device|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
130475|NCT03169478|Procedure|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
130476|NCT03169465|Procedure|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
130477|NCT03169465|Procedure|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
130478|NCT03169452|Device|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
130479|NCT03169439|Procedure|Irreversible electroporation|minimal invasive ablative technique for tumors
130480|NCT03169426|Drug|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
130481|NCT03169413|Genetic|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
130482|NCT03169400|Device|Theranova dialyzer|Hemoadialysis
130483|NCT03169387|Behavioral|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
130484|NCT03169387|Behavioral|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
130485|NCT03169374|Device|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
130486|NCT03169361|Drug|Ixazomib|Ixazomib capsules
130487|NCT03169348|Drug|sofosbuvir daclatasvir|oral tablets
130488|NCT03169348|Drug|Ledipasvir/sofosbuvir|oral tablets
130489|NCT03169335|Drug|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
130490|NCT03169335|Drug|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
130491|NCT03169335|Drug|Paclitaxel|175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
130492|NCT03169335|Drug|Carboplatin|AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
130493|NCT03169322|Procedure|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
130494|NCT03169309|Device|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
130495|NCT03169283|Other|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
130496|NCT03169283|Other|Cereal without B glucan|Cereal without B glucan
130563|NCT03168776|Device|Xience or Promus DES|Implant XIENCE family or Promus family only
130497|NCT03169270|Other|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
130498|NCT03169257|Behavioral|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
130499|NCT03169244|Drug|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
130500|NCT03169244|Drug|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
130501|NCT03169231|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
130502|NCT03169231|Other|Placebo|Intravenously delivered
130503|NCT03169218|Other|Mirror therapy|The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
130504|NCT03169218|Other|Placebo group|The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
130505|NCT03169205|Other|observation registry|observation registry
130506|NCT03169192|Drug|Zoledronic Acid|intravenous injections once every 3 months
130507|NCT03169179|Behavioral|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
130508|NCT03169166|Drug|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
130509|NCT03169153|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
130510|NCT03169153|Device|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
130511|NCT03169140|Device|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
130512|NCT03169140|Device|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
130513|NCT03169140|Behavioral|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
130514|NCT03169127|Drug|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
130515|NCT03169114|Drug|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
130516|NCT03169114|Procedure|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
130517|NCT03169101|Drug|Nicotine patch|"All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks."
130518|NCT03169101|Behavioral|Behavioral counseling|Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
130519|NCT03169088|Other|Coaching procedure|"In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~survey like FFQ, IPAQ, SF36, dietary habits.~actimetry measurement~one year follow-up of weight, waist measurement~nutritional biomarkers"
130520|NCT03169075|Behavioral|Supervised physical exercise programs|"A weekly supervised physical activity session of 60 min at the patient's home is planned for 3 months.~These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalized and adapted to each patient's profile.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
130521|NCT03169075|Behavioral|Adapted physical activity|"Program based on the recommendations for performing a physical activity. A booklet containing physical activity recommendations will be given to the patients after randomization.~The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.~Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT module AC/S, FACT-Gog, HADS, IPAQ"
130522|NCT03169062|Device|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
130564|NCT03168763|Behavioral|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
130523|NCT03169049|Device|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
130524|NCT03169049|Device|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
130525|NCT03169023|Behavioral|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
130526|NCT03169023|Behavioral|Enhanced Usual Care Packets|-From the American Cancer Society Website
130527|NCT03169023|Other|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
130528|NCT03169023|Other|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
130529|NCT03169023|Other|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
130530|NCT03169023|Other|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
130531|NCT03169023|Other|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
130532|NCT03169023|Behavioral|iOTA|-Washington University based intervention
130533|NCT03169010|Other|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
130534|NCT03169010|Genetic|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
130535|NCT03168997|Drug|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
130536|NCT03168984|Drug|UCB0942|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use"
130537|NCT03168984|Other|Placebo|"Pharmaceutical form: Film-coated tablet~Route of administration: Oral use"
130538|NCT03168971|Behavioral|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
130539|NCT03168958|Drug|Methadone|Methadone will be provided at induction of anesthesia
130540|NCT03168958|Drug|Saline|Saline will be administered at induction of anesthesia
130541|NCT03168945|Other|GeneXpert MTB/RIF|Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
130542|NCT03168945|Other|Smear microscopy|Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
130543|NCT03168919|Radiation|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
130544|NCT03168919|Drug|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
130545|NCT03168919|Device|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
130546|NCT03168906|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
130547|NCT03168906|Drug|Placebo|Saline bag
130548|NCT03168893|Device|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
130549|NCT03168893|Device|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
130550|NCT03168880|Drug|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
130551|NCT03168880|Drug|Paclitaxel only|
130552|NCT03168867|Behavioral|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
130553|NCT03168854|Biological|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
130554|NCT03168854|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
130555|NCT03168841|Drug|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
130556|NCT03168828|Drug|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
130557|NCT03168815|Device|High Flow Nasal Cannula or Low Flow Nasal Cannula|HFNC vs LFNC
130558|NCT03168802|Procedure|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
130559|NCT03168802|Procedure|Radiofrequency ablation|Radiofreuqency ablation therapy under C-arm navigation for facet joint syndrome.
130560|NCT03168789|Behavioral|Tension Tamer (TT)|Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
130561|NCT03168789|Behavioral|Lifestyle education program (SPCTL)|SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
130562|NCT03168776|Device|BuMA Supreme DES|Implant BuMA Supreme stent only
130565|NCT03168763|Behavioral|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
130566|NCT03168750|Device|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
130567|NCT03168737|Procedure|Computed Tomography|Undergo PET-CT scan
130568|NCT03168737|Radiation|Fluorine F 18-fluoroazomycin Arabinoside|Given IV
130569|NCT03168737|Procedure|Positron Emission Tomography|Undergo PET-CT scan
130570|NCT03168724|Behavioral|GMT intervention|
130571|NCT03168711|Drug|Inosine|Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
130572|NCT03168711|Drug|Placebo|Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
130573|NCT03168698|Drug|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
130574|NCT03168698|Drug|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
130575|NCT03168685|Device|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device [ActiGraph GT9X Link Actigraph Link] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
130576|NCT03168672|Device|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
130577|NCT03168659|Device|HeartLight|HeartLight Endoscopic Ablation System
130578|NCT03168659|Procedure|Ablation|Pulmonary vein isolation ablation
130579|NCT03168646|Procedure|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
130580|NCT03168646|Procedure|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
130581|NCT03168633|Behavioral|web-based DM2 information pages|"Each email will include information on one of the following topics:~The importance of physical activity~Correct nutrition~The importance of adhering to medication regimens.~Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).~The information will be provided by different approaches: medical research results, practical tips, patient testimonies.…"
130582|NCT03168620|Procedure|Restoration|
130583|NCT03168607|Drug|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
130584|NCT03168594|Drug|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
130585|NCT03168594|Drug|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
130586|NCT03168581|Drug|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
130587|NCT03168568|Drug|Valsartan/Sacubitril or placebo|tablet (double dummy)
130588|NCT03168568|Drug|Valsartan or placebo|tablet (double dummy)
130589|NCT03168555|Drug|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
130590|NCT03168542|Device|JJVC Fitting Guides|Subjects who are habitual soft spherical or toric contact lens wearers, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guide, with either the Multifocal Contact Lens or an Investigational Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes during a 1 day visit.
130591|NCT03168529|Drug|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
130592|NCT03168529|Drug|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
130593|NCT03168516|Device|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)|Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
130594|NCT03168503|Dietary Supplement|LGG+Promitor™|synbiotic
130595|NCT03168503|Dietary Supplement|Promitor™|Soluble Corn Fiber
130596|NCT03168503|Dietary Supplement|LGG-PB12+Promitor™|synbiotic
130597|NCT03168503|Dietary Supplement|Maltodextrin|Control
130598|NCT03168490|Dietary Supplement|Gluten Friendly bread|parallel study
130637|NCT03168191|Drug|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
130638|NCT03168191|Other|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
130639|NCT03168191|Other|Menthol Flavor|Menthol flavored e-cigarette for lab session
130599|NCT03168477|Other|dry needling|Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.
130600|NCT03168477|Other|spinal manipulation|HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).
130601|NCT03168477|Other|mobilization|Impairment-based mobilization targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
130602|NCT03168477|Other|exercise|Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
130603|NCT03168477|Other|modalities|Interferential electrotherapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 12 treatment sessions over 6 weeks.
130604|NCT03168464|Drug|Ipilimumab and Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
130605|NCT03168464|Drug|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
130606|NCT03168451|Behavioral|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
130607|NCT03168438|Genetic|NY-ESO-1ᶜ²⁵⁹T cells|NY-ESO-1ᶜ²⁵⁹T cells administered by infusion on Day 1
130608|NCT03168438|Drug|NY-ESO-1ᶜ²⁵⁹T in combination with pembrolizumab|NY-ESO-1ᶜ²⁵⁹T cells administered on Day 1, then pembrolizumab administered on Day 22 (3 weeks after initial infusion of NY-ESO-1ᶜ²⁵⁹T cells)
130609|NCT03168425|Other|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
130610|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
130611|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
130612|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
130613|NCT03168399|Dietary Supplement|PKU Explore|PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
130614|NCT03168386|Procedure|Intensive motor rehabilitation|Intensive motor rehabilitation during subacute stroke phase
130615|NCT03168373|Procedure|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
130616|NCT03168360|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
130617|NCT03168347|Behavioral|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
130618|NCT03168347|Behavioral|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
130619|NCT03168347|Behavioral|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
130620|NCT03168347|Behavioral|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
130621|NCT03168334|Drug|IDP-123 Lotion|lotion
130622|NCT03168334|Drug|IDP-123 Vehicle Lotion|Vehicle
130623|NCT03168321|Drug|IDP-123 Lotion|lotion
130624|NCT03168321|Drug|IDP-123 Vehicle Lotion|lotion
130625|NCT03168308|Drug|Sugammadex|Sugammadex 2 mg/kg
130626|NCT03168308|Drug|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
130627|NCT03168295|Drug|Dapagliflozin 10mg|SGLT2 inhibitor - Dapagliflozin
130628|NCT03168295|Drug|Placebo Oral Tablet|Placebo for Dapagliflozin
130629|NCT03168269|Diagnostic Test|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
130630|NCT03168256|Drug|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
130631|NCT03168256|Drug|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
130632|NCT03168256|Drug|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
130633|NCT03168256|Drug|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
130634|NCT03168243|Dietary Supplement|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
130635|NCT03168230|Procedure|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.~An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.~This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.~Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
130636|NCT03168204|Behavioral|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
130640|NCT03168178|Drug|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
130641|NCT03168178|Other|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
130642|NCT03168165|Other|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
130643|NCT03168152|Radiation|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
130644|NCT03168152|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
130645|NCT03168139|Drug|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
130646|NCT03168139|Drug|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
130647|NCT03168126|Device|Pro-AQT|Use of the device for advanced hemodynamic monitoring
130648|NCT03168100|Drug|Elotuzumab|administered via IV infusion
130649|NCT03168100|Drug|Lenalidomide|taken by mouth
130650|NCT03168100|Drug|Dexamethasone|taken by mouth
130651|NCT03168100|Drug|Bortezomib|administered as a subcutaneous injection
130652|NCT03168087|Other|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
130653|NCT03168074|Drug|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
130654|NCT03168061|Drug|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
130655|NCT03168048|Other|mobile application|Oncologic therapy support by means of a mobile application
130656|NCT03168035|Drug|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
130657|NCT03168022|Drug|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
130658|NCT03168022|Drug|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
130659|NCT03168009|Procedure|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
130660|NCT03167996|Behavioral|Use of HealthPals (Telemedicine supported by digital health platform)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.~The HealthPals app was developed by HealthPals, Inc."
130661|NCT03167970|Device|Pill cam|Patient is asked to swallow the esophageal capsule.
130662|NCT03167970|Other|EGD|Patient will undergo standard EGD
130663|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
130664|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
130665|NCT03167944|Device|Low thermal electrosurgery system|PEAK Plasmablade
130666|NCT03167944|Device|Conventional Electrocautery|Conventional Electrocautery
130667|NCT03167931|Other|MRI + transcranial Magnetic Stimulation|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
130668|NCT03167931|Other|transcranial electric stimulation + electroencephalogram|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
130669|NCT03167918|Drug|Calcium Dobesilate|gave each patient 0.5 g bid，
130670|NCT03167918|Drug|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
130671|NCT03167918|Drug|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
130672|NCT03167918|Drug|metformin|gave each patient 1000 mg, bid, PO
130673|NCT03167918|Drug|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
130674|NCT03167905|Device|Epidural delivery system|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
130675|NCT03167905|Drug|Entonox|Entonox will be given upon request in non-epidural group.
130676|NCT03167905|Drug|Meperidine|Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
130677|NCT03167905|Drug|Ultiva|Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
130678|NCT03167905|Drug|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
130679|NCT03167905|Drug|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
130680|NCT03167892|Device|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
130681|NCT03167879|Behavioral|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
130682|NCT03167866|Behavioral|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
130683|NCT03167866|Behavioral|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
130684|NCT03167853|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
130685|NCT03167840|Behavioral|Physical and Cognitive Training|Physical Exercise and Cognitive Training
130686|NCT03167840|Behavioral|Physical Training|Physical training alone
130687|NCT03167840|Behavioral|Cognitive training|Cognitive training alone
130688|NCT03167827|Other|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
130689|NCT03167827|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
130690|NCT03167827|Other|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
130691|NCT03167814|Dietary Supplement|Diet group|In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
130692|NCT03167788|Device|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
130693|NCT03167788|Other|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood & Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
130694|NCT03167775|Drug|Elemene Injection/Elemene Oral Emulusion|
130695|NCT03167762|Device|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
130696|NCT03167749|Diagnostic Test|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
130697|NCT03167736|Other|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.
130698|NCT03167736|Other|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
130699|NCT03167723|Device|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
130700|NCT03167710|Other|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
130701|NCT03167710|Other|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
130702|NCT03167697|Dietary Supplement|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
130703|NCT03167697|Other|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
130704|NCT03167684|Device|Oral appliance therapy|Fitted oral appliance
130705|NCT03167671|Device|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
130706|NCT03167671|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
130707|NCT03167658|Behavioral|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
130708|NCT03167645|Drug|Human albumin|Substitution according to pre-specified dosage
130709|NCT03167619|Drug|Olaparib Oral Product|olaparib 300mg twice daily
130710|NCT03167619|Drug|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
130711|NCT03167606|Behavioral|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
130712|NCT03167593|Dietary Supplement|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
130713|NCT03167593|Other|Control placebo|Maltodextrin
130714|NCT03167580|Procedure|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
130715|NCT03167580|Procedure|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
130716|NCT03167567|Behavioral|Presence of a medical clown during labor|Presence of a medical clown during labor
130717|NCT03167554|Other|Sham comparator|The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
130771|NCT03167177|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
130718|NCT03167554|Other|Experimental group 1|Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
130719|NCT03167554|Other|Experimental group 2|Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
130720|NCT03167541|Drug|Test|RB naproxen sodium tablets (2x220mg)
130721|NCT03167541|Drug|Reference|Aleve naproxen sodium tablets (2x220mg)
130722|NCT03167528|Behavioral|Relaxation|Relaxation
130723|NCT03167528|Behavioral|Hypnosis|Hypnosis
130724|NCT03167528|Behavioral|Holistic gymnastics|holistic gymnastics
130725|NCT03167528|Device|Transcutaneous electrical nerve stimulation (TENS)|TENS
130726|NCT03167528|Behavioral|Sophrology|Sophrology
130727|NCT03167515|Device|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
130728|NCT03167502|Other|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
130729|NCT03167502|Other|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
130730|NCT03167489|Behavioral|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
130731|NCT03167463|Procedure|flap|Repair choanal atresia with using flap during surgery
130732|NCT03167437|Drug|Vorinostat|It is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patient with cutaneous T-cell lymphoma (CTCL) who have progress, persistent or recurrent disease on or following two systemic therapies. We are using this drug off label for the purpose of this study
130733|NCT03167424|Device|Treatment of restenosis|Treatment of in-stent restenosis
130734|NCT03167411|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
130735|NCT03167411|Drug|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
130736|NCT03167398|Other|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
130737|NCT03167385|Drug|Apatinib Mesylate|oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
130738|NCT03167372|Other|Litebook® Advantage|Standard system light therapy device used in an investigation to assess the feasibility of conducting a randomized trial design. The lightbox produces different wavelengths of the light identical to the peak wavelengths of the sun - bright white, dim white and red light.
130739|NCT03167372|Other|Fitbit Flex2 TM|Standard system activity and sleep tracker
130740|NCT03167359|Radiation|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
130741|NCT03167333|Drug|platelet rich plasma|The amount of PPR was about 4-5 cc
130742|NCT03167333|Drug|Hyaluronic acid|HA was 2.5cc
130743|NCT03167307|Drug|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
130744|NCT03167307|Drug|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
130745|NCT03167294|Device|AquaBeam System|Aquablation
130746|NCT03167281|Combination Product|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
130747|NCT03167268|Drug|Lycopene|
130748|NCT03167268|Other|Placebo|
130749|NCT03167255|Drug|NS-065/NCNP-01|Received during weekly intravenous infusions
130750|NCT03167242|Drug|KAF156 and LUM-SDF|Exploration of different dose combinations of KAF156 and LUM-SDF. In Part B, up to three arms will be repeated in children 2 to 12 Years to confirm safety and efficacy from Part A.
130751|NCT03167242|Drug|Coartem|Control arm
130752|NCT03167216|Drug|Cromolyn Sodium|Mast cell stabilizer
130753|NCT03167216|Drug|Cetirizine Hydrochloride|Histamine receptor antagonist
130754|NCT03167203|Biological|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
130755|NCT03167190|Procedure|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
130756|NCT03167190|Procedure|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
130757|NCT03167177|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
130758|NCT03167177|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
130759|NCT03167177|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
130760|NCT03167177|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
130761|NCT03167177|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
130762|NCT03167177|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
130763|NCT03167177|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
130764|NCT03167177|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
130765|NCT03167177|Biological|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
130766|NCT03167177|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
130767|NCT03167177|Radiation|Stereotactic Body Radiation Therapy|radiation
130768|NCT03167177|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
130769|NCT03167177|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
130770|NCT03167177|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
130772|NCT03167177|Biological|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
130773|NCT03167177|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
130774|NCT03167177|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
130775|NCT03167164|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
130776|NCT03167164|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
130777|NCT03167164|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
130778|NCT03167164|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
130779|NCT03167164|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
130780|NCT03167164|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
130781|NCT03167164|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
130782|NCT03167164|Drug|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
130783|NCT03167164|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
130784|NCT03167164|Radiation|Stereotactic Body Radiation Therapy|radiation
130785|NCT03167164|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
130786|NCT03167164|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
130787|NCT03167164|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
130788|NCT03167164|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
130789|NCT03167164|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
130790|NCT03167151|Drug|Pembrolizumab|Solution for Infusion (Intravesical and Intravenous) 100mg/ 4mL vial
130791|NCT03167138|Biological|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
130792|NCT03167138|Device|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
130793|NCT03167125|Other|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
130794|NCT03167125|Other|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
130795|NCT03167112|Drug|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
130796|NCT03167112|Drug|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
130797|NCT03167112|Drug|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
130798|NCT03167112|Drug|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
130799|NCT03167099|Procedure|Full Weight Bearing|Participants will be randomized to one of two groups; full weight bearing, which is the intervention, or partial weight bearing, which is standard of care, after fixation of a distal femur fracture.
130800|NCT03167086|Behavioral|"From Catastrophizing to Recovery (FCR)"|"From Catastrophizing to Recovery (FCR): A single-session approximately 2-hr group intervention to treat PC.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the FCR sessions.~Content of intervention: FCR Participants have the 'FCR Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
130801|NCT03167086|Behavioral|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) [1& 2], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner [3].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk & Winter [4] for optional reading."
130802|NCT03167086|Behavioral|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
130803|NCT03167073|Other|BreastFeeding Friend (BFF)|A novel android app designed to improve breastfeeding rates among low-income women
130804|NCT03167073|Other|dummy app|A novel android app that looks identical to the intervention app (BFF) but contains limited content.
130805|NCT03167060|Device|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
130840|NCT03166787|Other|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
130806|NCT03167060|Device|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.~The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
130807|NCT03167047|Procedure|Caudal block|Caudal epidural
130808|NCT03167047|Procedure|Nerve Block|Peripheral nerve block
130809|NCT03167047|Drug|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
130810|NCT03167034|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
130811|NCT03167034|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
130812|NCT03167021|Other|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
130813|NCT03167008|Diagnostic Test|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
130814|NCT03167008|Diagnostic Test|blood sample|blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
130815|NCT03166995|Other|Low impact aerobic exercise|The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
130816|NCT03166995|Other|Postural exercises|The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
130817|NCT03166982|Procedure|transvaginal approach|
130818|NCT03166982|Procedure|laparoscopic approach|
130819|NCT03166969|Procedure|Holter 21 days|
130820|NCT03166956|Dietary Supplement|Glutamine and vitamin C enteral supplement|Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
130821|NCT03166943|Procedure|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:~by biplane Simpson's method.~by speckle tracking:"
130822|NCT03166943|Procedure|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:~Left atrial Volume~Mitral Inflow Patterns~Pulsed wave Doppler~Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.~Tissue Doppler Annular Early and Late Diastolic Velocities~Pulsed wave tissue doppler imaging~Primary measurements include the systolic , early diastolic, and late diastolic velocities."
130823|NCT03166930|Behavioral|Spasticity Take Control|Participants will attend two 2-hour classes, one week apart, consisting of education and a stretching program for spasticity management.
130824|NCT03166930|Behavioral|Stretching for People with MS: An Illustrated Manual|Participants will attend two 2-hour classes, one week apart, consisting of education and exercises for spasticity management from the manual.
130825|NCT03166917|Procedure|3D printing implant|3D printing implants in bone defect
130826|NCT03166917|Procedure|autogenous bone grafting|3D printing implants in bone defect
130827|NCT03166904|Drug|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
130828|NCT03166891|Drug|Chiauranib|Take 50mg orally once daily
130829|NCT03166878|Biological|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
130830|NCT03166865|Biological|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10~7 diluted on 5 mL of Platelet Rich Plasma
130831|NCT03166865|Other|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
130832|NCT03166852|Other|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
130833|NCT03166839|Other|Experiencing PPH|No intervention given
130834|NCT03166826|Other|Modified Apgar Scoring System|Modified APGAR scoring system
130835|NCT03166813|Procedure|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
130836|NCT03166813|Other|Control|Placement of blood pressure cuff without inflation for 30 minutes.
130837|NCT03166800|Drug|Mitoquinone|MitoQ will administered in either 20mg or 40mg capsules. The dose will administered for a 12-weeks treatment.
130838|NCT03166787|Other|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
130839|NCT03166787|Other|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
130946|NCT03165994|Radiation|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
130841|NCT03166787|Drug|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
130842|NCT03166787|Other|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
130843|NCT03166787|Drug|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
130844|NCT03166787|Drug|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
130845|NCT03166774|Other|Program of support of the sexual health|Patients included in the study have to answer to a questionnaire
130846|NCT03166761|Drug|Dexamethasone|Dexamethasone injection into the sacroiliac joint
130847|NCT03166761|Drug|Triamcinolone Acetonide|Triamcinolone injection into the sacroiliac joint
130848|NCT03166748|Combination Product|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.~Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
130849|NCT03166735|Drug|BI 1467335|once daily
130850|NCT03166735|Drug|Placebo|once daily
130851|NCT03166722|Other|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
130852|NCT03166722|Device|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
130853|NCT03166709|Behavioral|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; The Strong Link Between Addiction and Suicide; Suicide Myths and Facts; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs of Suicide; Suicide Risk Factors; Suicide Protective Factors; How You Can Prevent Addiction Related Suicide; Action Steps to Take if You or Someone You Know Becomes Suicidal
130854|NCT03166709|Behavioral|Intensive Outpatient Program standard session|Intensive Outpatient Program (IOP) substance abuse group session focused on depression, grief, or managing emotions. Site-specific session topic is what that IOP usually provides and was chosen by agency leads prior to start of study.
130855|NCT03166683|Other|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
130856|NCT03166683|Other|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
130857|NCT03166670|Diagnostic Test|stool examination|collection of stool specimen and microscopic examination for parasites
130858|NCT03166670|Diagnostic Test|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
130859|NCT03166657|Procedure|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
130860|NCT03166644|Device|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
130861|NCT03166631|Drug|BI 891065|Part A, B & C
130862|NCT03166631|Drug|BI 754091|Part B & C
130863|NCT03166618|Device|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
130864|NCT03166605|Drug|Simethicone|Giving simethicone before and after capsule ingestion.
130865|NCT03166592|Device|Magnetic resonance imaging with contrast|injection of gadolinium contrast then acquisition of images with magnetic resonance imaging then spectroscopy
130866|NCT03166579|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
130867|NCT03166566|Device|Laminar drainage implant surgery.|A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
130868|NCT03166553|Drug|Elemene|
130869|NCT03166540|Other|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
130947|NCT03165994|Drug|Paclitaxel|Paclitaxel IV infusion
130870|NCT03166540|Other|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
130871|NCT03166527|Drug|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
130872|NCT03166514|Dietary Supplement|Commercially Available Food Bar|
130873|NCT03166514|Dietary Supplement|Placebo|
130874|NCT03166501|Drug|Lanicemine|Three 60 min parenteral infusions over a 5 day period
130875|NCT03166501|Drug|Placebo|Three 60 min parenteral infusions over a 5 day period
130876|NCT03166488|Device|MRI|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
130877|NCT03166475|Procedure|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
130878|NCT03166462|Other|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
130879|NCT03166449|Dietary Supplement|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
130880|NCT03166449|Dietary Supplement|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
130881|NCT03166436|Procedure|Radiofrequency ablation|radiofrequency ablation
130882|NCT03166436|Procedure|Biliary stenting|biliary stenting
130883|NCT03166423|Drug|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
130884|NCT03166423|Device|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
130885|NCT03166410|Procedure|Cell injection|
130886|NCT03166397|Drug|Fludarabine|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
130887|NCT03166397|Drug|Cyclophosphamide|Cyclophosphamide 30mg/kg/day with Fludarabine (25 mg/m2/d) followed by 3 consecutive days of Fludarabine 25mg/m2/d.
130888|NCT03166397|Biological|TIL|TIL administration
130889|NCT03166397|Drug|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
130890|NCT03166384|Device|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
130891|NCT03166384|Procedure|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
130892|NCT03166371|Dietary Supplement|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
130893|NCT03166371|Other|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
130894|NCT03166358|Behavioral|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
130895|NCT03166345|Other|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
130896|NCT03166332|Behavioral|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and nuts
130897|NCT03166332|Behavioral|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
130898|NCT03166319|Device|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
130899|NCT03166306|Diagnostic Test|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
130900|NCT03166293|Behavioral|Intensive leg training with a physical therapist|Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
130901|NCT03166280|Drug|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
130902|NCT03166280|Drug|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
130903|NCT03166267|Device|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
130904|NCT03166254|Drug|Pembrolizumab|-Pembrolizumab will be given intravenously over the course of 30 minutes
130905|NCT03166254|Biological|NEO-PV-01 vaccine|-Generation of the vaccine is expected to take approximately 12 weeks
130906|NCT03166254|Procedure|Biopsy|-Surgical or core needle biopsy of an accessible site for DNA and RNA sequencing, immunological analysis, and generation of NEO-PV-01 vaccine
130907|NCT03166254|Drug|Poly ICLC|-NEO-PV-01 is combined with the adjuvant poly-ICLC prior to administration.
130908|NCT03166254|Procedure|Leukapheresis|-Peripheral blood mononuclear cells (PBMCs) for comprehensive immune system monitoring will be obtained from leukapheresis samples collected up to 7 days prior to initiation of NEO PV-01 vaccination and at 7 days (Week 20) following the first NEO-PV-01 booster vaccination.
130909|NCT03166254|Procedure|Peripheral blood samples|-Blood samples (80 mL) for immune monitoring will be obtained prior to study treatment and at Weeks 6, 14, 16, 24, 36, 48, 63, 75, 87, and 99.
130948|NCT03165994|Drug|Carboplatin|Carboplatin IV infusion
130910|NCT03166241|Diagnostic Test|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
130911|NCT03166241|Diagnostic Test|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
130912|NCT03166241|Diagnostic Test|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
130913|NCT03166241|Diagnostic Test|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
130914|NCT03166241|Diagnostic Test|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
130915|NCT03166241|Diagnostic Test|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
130916|NCT03166228|Drug|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
130917|NCT03166228|Drug|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
130918|NCT03166215|Drug|TAK-935|TAK-935 tablets.
130919|NCT03166215|Drug|Placebo|TAK-935 placebo-matching tablets.
130920|NCT03166189|Biological|bone marrow-derived MSC and HRT|"Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells~Three cycles of HRT following MSC transplantation;~Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;~Frozen/thawed embryo transfer 3-6 months after transplantation."
130921|NCT03166189|Other|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:~Three cycles of HRT preceding frozen/thawed embryo transfer;~Frozen/thawed embryo transfer."
130922|NCT03166176|Drug|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
130923|NCT03166163|Drug|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
130924|NCT03166163|Drug|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
130925|NCT03166150|Other|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
130926|NCT03166150|Other|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
130927|NCT03166137|Device|Carbon dioxide laser|Radiation by carbon dioxide laser
130928|NCT03166137|Device|Cryotherapy|Device using cooling effect
130929|NCT03166124|Drug|LY900014|Administered SC
130930|NCT03166124|Drug|Insulin Lispro|Administered SC
130931|NCT03166111|Drug|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
130932|NCT03166111|Drug|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
130933|NCT03166098|Diagnostic Test|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
130934|NCT03166085|Drug|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
130935|NCT03166085|Drug|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
130936|NCT03166072|Other|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
130937|NCT03166072|Other|No Intervention|Participants will continue to receive treatment as usual
130938|NCT03166059|Device|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
130939|NCT03166046|Device|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
130940|NCT03166046|Device|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
130941|NCT03166033|Other|the disease|Observation the patients and non-patients
130942|NCT03166020|Other|Rehabilitation|An occupational therapist will be required only for patient installation in front of the table.
130943|NCT03166007|Behavioral|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
130944|NCT03166007|Behavioral|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
130945|NCT03165994|Drug|APX005M|APX005M intravenous (IV) infusion
131128|NCT03164564|Drug|Placebo for oral CAB|Placebo tablets
130949|NCT03165994|Procedure|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 11-17
130950|NCT03165981|Biological|PCV13|ACIP Recommended vaccine
130951|NCT03165981|Biological|DTaP|ACIP Recommended vaccine
130952|NCT03165981|Biological|IIV|ACIP Recommended vaccine
130953|NCT03165968|Device|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
130954|NCT03165955|Drug|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
130955|NCT03165942|Other|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
130956|NCT03165942|Other|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
130957|NCT03165942|Drug|Ethanol|
130958|NCT03165929|Drug|Flurbiprofen|oral flurbiprofen spray
130959|NCT03165929|Drug|placebo|oral placebo spray
130960|NCT03165916|Device|Bard 5 Fr diameter feeding tube|A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
130961|NCT03165903|Behavioral|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
130962|NCT03165903|Behavioral|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
130963|NCT03165890|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
130964|NCT03165890|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
130965|NCT03165877|Other|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (<55%),consisting of salad, main course and dessert, respectively.
130966|NCT03165877|Other|Control|Subjects ate standard lunches and dinners (>60%),consisting of salad, main course and dessert, respectively.
130967|NCT03165864|Drug|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
130968|NCT03165864|Other|Placebo|Saline .9%
130969|NCT03165851|Other|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
130970|NCT03165838|Behavioral|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
130971|NCT03165838|Behavioral|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
130972|NCT03165825|Drug|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
130973|NCT03165825|Drug|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
130974|NCT03165812|Procedure|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
130975|NCT03165812|Procedure|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
130976|NCT03165799|Behavioral|Mindfulness Education|Mindfulness Education
130977|NCT03165786|Behavioral|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
130978|NCT03165773|Other|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
130979|NCT03165773|Other|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
130980|NCT03165760|Procedure|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
130981|NCT03165747|Drug|VSL#3|8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
130982|NCT03165747|Other|Placebo|Two placebo sachets taken orally daily in a single administration.
130983|NCT03165734|Drug|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsules contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
130984|NCT03165721|Drug|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by RECIST v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
130985|NCT03165695|Drug|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
130986|NCT03165695|Drug|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
130987|NCT03165669|Device|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
130988|NCT03165669|Other|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
130989|NCT03165643|Diagnostic Test|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
130990|NCT03165630|Behavioral|Transportation incentives|Free transportation only for the first 3 months post-discharge.
130991|NCT03165630|Behavioral|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
130992|NCT03165617|Biological|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
130993|NCT03165617|Biological|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
130994|NCT03165604|Other|standard information|The participates will be given a standard information regarding the water drink before physical activity
130995|NCT03165604|Other|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
130996|NCT03165591|Biological|V3-P|one tablet of V3-P given once daily for 2 months
130997|NCT03165578|Other|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
130998|NCT03165578|Other|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
130999|NCT03165565|Behavioral|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
131000|NCT03165565|Behavioral|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
131001|NCT03165552|Other|Acute kidney injury education|A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
131002|NCT03165539|Device|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
131003|NCT03165526|Device|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
131004|NCT03165513|Behavioral|mhGAP-IG|psychosocial interventions
131005|NCT03165500|Drug|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
131006|NCT03165500|Drug|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
131007|NCT03165500|Drug|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.~After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
131008|NCT03165500|Procedure|Third molar extraction|Anxious patients in need of third molar extraction
131009|NCT03165487|Other|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
131010|NCT03165487|Other|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
131011|NCT03165474|Other|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
131012|NCT03165474|Other|Didactic health information|Didactic health information and resources by email and/or text
131013|NCT03165448|Diagnostic Test|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
131014|NCT03165448|Diagnostic Test|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
131015|NCT03165448|Diagnostic Test|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
131016|NCT03165448|Diagnostic Test|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
131017|NCT03165435|Biological|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
131129|NCT03164564|Drug|Placebo for oral TDF/FTC|Placebo tablets
131018|NCT03165435|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
131019|NCT03165422|Other|Non-Interventional|Non-Interventional
131020|NCT03165409|Biological|Nivolumab|Melanoma intervention
131021|NCT03165409|Biological|Ipilimumab|Melanoma intervention
131022|NCT03165396|Drug|Propofol|Propofol is the most common clinical anesthetics.
131023|NCT03165396|Drug|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
131024|NCT03165383|Drug|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
131025|NCT03165383|Drug|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
131026|NCT03165357|Dietary Supplement|Sodium bicarbonate supplementation|
131027|NCT03165357|Dietary Supplement|Placebo treatment|
131028|NCT03165344|Other|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
131029|NCT03165344|Other|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
131030|NCT03165344|Other|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
131031|NCT03165331|Other|UNG Face IT|UNG Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
131032|NCT03165318|Device|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.~The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
131033|NCT03165318|Device|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.~The Sham device is identical to the PEMF device in physical appearance."
131034|NCT03165305|Other|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
131035|NCT03165292|Radiation|131I- mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
131036|NCT03165292|Drug|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
131037|NCT03165292|Drug|Thiotepa|Day 1-3 Thiotepa 300 mg/m²/day
131038|NCT03165292|Procedure|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
131039|NCT03165279|Procedure|Zenith Alpha Abdominal stentgraft|
131040|NCT03165266|Diagnostic Test|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :~II- transthoracic assessment of the Right ventricular systolic function by:~. Right Ventricle fractional area change.~. Tricuspid annular plane systolic excursion .~. Tissue Doppler derived tricuspid annular systolic velocity.~. Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.~IV Assessment of Right Ventricle chamber quantification:~Right ventricular basal, mid ,and longitudinal dimensions.~Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
131041|NCT03165253|Drug|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
131042|NCT03165253|Drug|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
131043|NCT03165253|Drug|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
131044|NCT03165253|Drug|Omeprazole|1 mg/kg/day
131045|NCT03165240|Drug|BI 690517|Film-coated tablet
131046|NCT03165240|Drug|Eplerenone|Film-coated tablet
131047|NCT03165240|Drug|Placebo|Film-coated tablet
131048|NCT03165227|Drug|BI 685509|Taken orally
131049|NCT03165227|Drug|Placebo|Taken orally
131050|NCT03165214|Device|coil|microcoils
131051|NCT03165214|Device|hystoacryl glue|hystoacryl mixed with lipidol
131052|NCT03165201|Device|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
131053|NCT03165175|Behavioral|prescription drug-abuse education smartphone application|As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
131054|NCT03165162|Behavioral|Food Order|randomly assigned orders of 7 bowls of granola, each with a different food label.
131055|NCT03165149|Drug|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
131056|NCT03165149|Drug|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
131057|NCT03165149|Drug|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
131058|NCT03165136|Drug|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
131059|NCT03165136|Drug|Placebo|placebo of hydroxychloroquine
131060|NCT03165123|Drug|Oral Azithromycin tablet|Oral azithromycin tablet will be given one hour before induction of anaesthesia.
131061|NCT03165123|Drug|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
131062|NCT03165110|Device|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
131063|NCT03165097|Drug|ACT-709478|Hard gelatine capsules for oral administration
131064|NCT03165097|Drug|Placebo|Placebo capsules matching ACT-709478 capsules
131065|NCT03165084|Behavioral|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.~Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
131066|NCT03165084|Other|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
131067|NCT03165084|Other|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
131068|NCT03165071|Drug|ACT-132577|Capsule
131069|NCT03165058|Diagnostic Test|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
131070|NCT03165045|Drug|Spiolto® Respimat®|6 weeks
131071|NCT03165006|Procedure|Mode of detection: Cancer detected at screening|Cancers detected as a result of screening mammograms.
131072|NCT03165006|Procedure|Mode of detection: Interval cancer|Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
131073|NCT03164993|Drug|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
131074|NCT03164993|Drug|Pegylated liposomal doxorubicin|Chemotherapy
131075|NCT03164993|Drug|Cyclophosphamide|Chemotherapy
131076|NCT03164993|Other|Placebo|Placebo
131077|NCT03164980|Other|no intervention - observational study|To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
131078|NCT03164967|Biological|Bivigam|
131079|NCT03164954|Diagnostic Test|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
131080|NCT03164941|Procedure|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
131081|NCT03164928|Drug|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
131082|NCT03164928|Other|Placebo|SC Q6M placebo
131083|NCT03164915|Biological|LIV-GAMMA SN Inj.|
131084|NCT03164902|Device|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose velpatasvir and sofosbuvir; fixed-dose ledipasvir and sofosbuvir; or fixed-dose glecaprevir and pibrentasvir; or fixed-dose sofosbuvir, velpatasvir, and voxilaprevir). The subject's prescribed HCV medication will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
131085|NCT03164889|Drug|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
131086|NCT03164889|Drug|Entecavir|Antiviral drug for hepatitis b virus (HBV)
131087|NCT03164876|Drug|AUT00206|4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
131088|NCT03164876|Drug|Placebo|4 capsules of placebo, twice daily, to take orally with food for 4 weeks
131089|NCT03164863|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
131090|NCT03164850|Device|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
131091|NCT03164837|Drug|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
131130|NCT03164564|Drug|CAB LA|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
131131|NCT03164564|Drug|Placebo for CAB LA|Administered as one 3 mL intramuscular injection in the gluteal muscle
131185|NCT03164148|Device|T-REX TRI00A|Case management consists of confirmation of hospital visit date, checking the adverse effect
131186|NCT03164135|Genetic|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
131187|NCT03164122|Drug|injection of microfat and plasma rich platelet PRP|intra-articular injections
131188|NCT03164122|Device|MRI|MRI 3T
131092|NCT03164824|Other|questionnaire|"Cross-cultural adaptation stage:~The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.~Psychometric properties testing stage:~The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.~At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.~At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).~At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
131093|NCT03164811|Procedure|goal directed fluid therapy|pulse pressure variation will be used to as a goal to guide fluid administration in this group
131094|NCT03164811|Other|Controlled|standard fluid treatment by an anesthesiologist
131095|NCT03164798|Procedure|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
131096|NCT03164785|Drug|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
131097|NCT03164772|Drug|Durvalumab|anti-PD-L1
131098|NCT03164772|Drug|Tremelimumab|anti-CTLA-4
131099|NCT03164772|Biological|BI 1361849|mRNA Vaccine
131100|NCT03164746|Other|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
131101|NCT03164746|Other|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
131102|NCT03164733|Other|incubation|standardized wear particles are co-incubated with isolated patient cells (monocytes)
131103|NCT03164707|Diagnostic Test|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
131104|NCT03164694|Drug|Apatinib|Apatinib was given 850 mg per day orally.
131105|NCT03164694|Drug|Pemetrexed|pemetrexed (500 mg/m2)
131106|NCT03164694|Drug|Carboplatin|carboplatin (AUC =5)
131107|NCT03164668|Other|menthol flavored e-cigarette|menthol flavored e-cigarette
131108|NCT03164668|Other|tobacco flavored e-cigarette|tobacco flavored e-cigarette
131109|NCT03164655|Drug|Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5-Fluorouracil|Oxaliplatin 100 mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5 mg/kg infusion in 30 minutes, Panitumumab 6 mg/kg, Irinotecan 180 mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400 mg/m² infusion in 2 hours, 5-Fluorouracil 2400 mg/m² infusion continuous in 46h
131110|NCT03164642|Behavioral|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
131111|NCT03164642|Behavioral|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
131112|NCT03164629|Device|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
131113|NCT03164616|Drug|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
131114|NCT03164616|Drug|Tremelimumab|IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
131115|NCT03164616|Drug|Abraxane + carboplatin|Standard of care chemotherapy (squamous and non-squamous patients)
131116|NCT03164616|Drug|Gemcitabine + cisplatin|Standard of care chemotherapy (squamous patients only)
131117|NCT03164616|Drug|Gemcitabine + carboplatin|Standard of care chemotherapy (squamous patients only)
131118|NCT03164616|Drug|Pemetrexed + carboplatin|Standard of care chemotherapy (non-squamous patients only)
131119|NCT03164616|Drug|Pemetrexed + cisplatin|Standard of care chemotherapy (non-squamous patients only)
131120|NCT03164603|Drug|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
131121|NCT03164590|Drug|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
131122|NCT03164590|Drug|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
131123|NCT03164590|Drug|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
131124|NCT03164577|Behavioral|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
131125|NCT03164577|Other|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
131126|NCT03164564|Drug|Oral CAB|CAB 30 mg tablet
131127|NCT03164564|Drug|Oral TDF/FTC|TDF/FTC 300 mg/200 mg fixed dose combination tablet
131132|NCT03164551|Device|GERI+ incubator|The embryo culture of consented subjects will be carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos will be reviewed firstly by GERI Assess software, using bright-field imaging. A GERI Assess score will be calculated for each embryo. The three embryos with the highest GERI Assess scores of a subject are then further assessed by Early Embryo Viability Assessment (EEVA). Finally the embryo(s) with the highest EEVA grade among the three are transferred and will be followed up until the achievement of implantation and confirmation of pregnancy.
131133|NCT03164551|Device|Conventional incubator|The embryo culture of consented subjects will be carried outin conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade will be transferred and will be followed up until the achievement of implantation and confirmation of pregnancy.
131134|NCT03164538|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
131135|NCT03164538|Behavioral|Diabetes Education|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
131136|NCT03164525|Diagnostic Test|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
131137|NCT03164512|Drug|Oral or vaporized cannabidiol|Acute drug exposure
131138|NCT03164512|Drug|Placebo|Placebo capsule/vapor
131139|NCT03164499|Behavioral|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
131140|NCT03164499|Behavioral|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.~Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
131141|NCT03164486|Drug|18F-αvβ6-BP|Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
131142|NCT03164473|Drug|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
131143|NCT03164473|Drug|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
131144|NCT03164473|Drug|Placebo-rituximab|4 infusions for 18 months
131145|NCT03164473|Drug|Placebo-azathioprine|oral tablets for 24 months
131146|NCT03164460|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT/IMPT
131147|NCT03164460|Radiation|Proton Radiation|Undergo IMRT/IMPT
131148|NCT03164460|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
131149|NCT03164447|Biological|UB-421|Monoclonal antibody by IV infusion
131150|NCT03164447|Drug|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
131151|NCT03164421|Drug|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
131152|NCT03164421|Drug|L-carnitine|L-carnitine in clomiphene resistant pcos women
131153|NCT03164408|Procedure|Orthopaedic Implant Removal|
131154|NCT03164395|Procedure|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
131155|NCT03164395|Procedure|External Cardioversion|External Cardioversion per institutional protocol
131156|NCT03164382|Drug|FOLFOX regimen|
131157|NCT03164382|Drug|Sorafenib 200Mg Tab|
131158|NCT03164356|Other|Socket Modification Regime|Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
131159|NCT03164343|Device|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
131160|NCT03164330|Behavioral|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
131180|NCT03164200|Other|Higher carbohydrate breakfast|Higher carbohydrate breakfast
131181|NCT03164187|Drug|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
131182|NCT03164161|Device|Cold pressor test|Described before.
131183|NCT03164161|Other|β-endorphins evaluation in saliva|Described before.
131184|NCT03164161|Other|β-endorphins evaluation in blood plasma|Described before.
131161|NCT03164330|Behavioral|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
131162|NCT03164330|Behavioral|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, & waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); & (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
131163|NCT03164330|Behavioral|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
131164|NCT03164330|Behavioral|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
131165|NCT03164330|Behavioral|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
131166|NCT03164317|Other|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
131167|NCT03164317|Other|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
131168|NCT03164304|Drug|Magnesium Sulfate|intravenous
131169|NCT03164291|Drug|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
131170|NCT03164278|Behavioral|Independent Transfer Training|Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
131171|NCT03164265|Biological|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
131172|NCT03164252|Radiation|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
131173|NCT03164252|Radiation|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
131174|NCT03164252|Radiation|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
131175|NCT03164239|Behavioral|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
131176|NCT03164226|Device|Digital plethysmography in the diagnosis of Acute Coronary Syndrome|To verify the contribution of digital plethysmography in the early diagnosis of acute coronary syndrome in emergency departments.
131177|NCT03164213|Device|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
131178|NCT03164213|Device|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.~During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
131179|NCT03164200|Other|High fat breakfast|High fat breakfast
131189|NCT03164109|Drug|GC4419 IV|50mg infused IV over 15 minutes
131191|NCT03164109|Drug|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
131192|NCT03164096|Drug|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
131193|NCT03164083|Biological|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
131194|NCT03164083|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
131195|NCT03164057|Drug|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
131196|NCT03164057|Drug|Decitabine|Administered intravenously (IV) over approximately one hour.
131197|NCT03164057|Drug|Cytarabine|Given IV or intrathecally (IT).
131198|NCT03164057|Drug|Daunorubicin|Given IV.
131199|NCT03164057|Drug|Etoposide|Given IV.
131200|NCT03164057|Combination Product|ITMHA|Given IT.
131201|NCT03164057|Drug|Idarubicin|Given IV.
131202|NCT03164057|Drug|Fludarabine|Given IV over approximately 30 minutes.
131203|NCT03164057|Drug|Mitoxantrone|Given IV.
131204|NCT03164057|Drug|Erwinia asparaginase|Given IV or intramuscularly (IM).
131205|NCT03164057|Drug|Sorafenib|Given PO.
131206|NCT03164057|Drug|G-CSF|Given IV.
131207|NCT03164057|Drug|Dexrazoxane|Given IV immediately before idarubicin administration.
131208|NCT03164057|Biological|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
131209|NCT03164031|Device|Close-fitting orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both pairs of shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
131210|NCT03164031|Device|Looser fitting shorts|Looser fitting shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
131211|NCT03164018|Drug|Fampridine|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
131212|NCT03163992|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
131213|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
131214|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
131215|NCT03163979|Biological|RapidArc|"RapidArc:~A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
131216|NCT03163979|Biological|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
131217|NCT03163966|Drug|CR6086|oral CR6086 capsules
131218|NCT03163966|Drug|Methotrexate|oral Methotrexate tablets
131219|NCT03163966|Drug|Placebo|oral CR6086 Placebo capsules
131220|NCT03163953|Behavioral|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
131221|NCT03163953|Behavioral|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
131222|NCT03163953|Other|Control|No intervention
131223|NCT03163940|Behavioral|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
131224|NCT03163927|Other|Simulation-based training|See arm description
131225|NCT03163914|Drug|Epinephrine|Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
131226|NCT03163914|Drug|Norepinephrine|Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
131227|NCT03163914|Drug|Phenylephrine|Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )
131228|NCT03163914|Drug|Saline|saline infusion will apply till the end of the surgery
131229|NCT03163901|Other|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
131230|NCT03163888|Procedure|Navigation TKR|Traditional over Conventional TKR
131330|NCT03163082|Behavioral|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
131231|NCT03163875|Other|Hospital Anxiety and Depression Scale|To assess the levels of depression and anxiety, quality of sleep and quality of life (QoL) in chronic urticaria patients, using an interdisciplinary approach combining interview/questionnaire-based psychiatric and dermatological evaluations
131232|NCT03163862|Procedure|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
131233|NCT03163862|Drug|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
131234|NCT03163862|Drug|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
131235|NCT03163849|Drug|Sofosbuvir , daclatasvir|Tablets
131236|NCT03163849|Drug|Placebos|oral tablets
131237|NCT03163836|Procedure|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
131238|NCT03163836|Procedure|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
131239|NCT03163823|Other|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
131240|NCT03163823|Other|Standard of Care|Standard of Care communication methods
131241|NCT03163810|Device|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
131242|NCT03163810|Device|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
131243|NCT03163797|Diagnostic Test|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
131244|NCT03163784|Biological|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
131245|NCT03163784|Biological|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
131246|NCT03163784|Drug|Antibiotic|Antibiotic pre-treatment
131247|NCT03163784|Drug|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
131248|NCT03163758|Device|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
131249|NCT03163758|Device|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
131250|NCT03163745|Procedure|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
131251|NCT03163732|Genetic|Blood and tumor samples|Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
131252|NCT03163719|Diagnostic Test|CK and Lactate dosages|"A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom."
131253|NCT03163706|Behavioral|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
131254|NCT03163693|Drug|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
131255|NCT03163693|Other|normal saline|receive equal volume of normal saline
131256|NCT03163680|Drug|Omeprazole 40 MG|Omperazole 40 mg twice daily
131257|NCT03163667|Drug|CB-839 plus everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
131258|NCT03163667|Drug|Placebo plus everolimus|Placebo is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
131259|NCT03163654|Procedure|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
131331|NCT03163082|Other|Interpretation Bias|"The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
131615|NCT03160885|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
131260|NCT03163654|Procedure|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
131261|NCT03163641|Device|Acuvue Oasys|Bandage Contact Lens
131262|NCT03163641|Device|Ocular Bandage Gel|0.75% crosslinked HA
131263|NCT03163628|Biological|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.~The calculation of positive and negative likelihood ratios will be performed.~The targeted performances are:~A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.~A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
131264|NCT03163615|Drug|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
131265|NCT03163615|Drug|Placebo oral capsule|4 capsules, po, from admission up to 84 days
131266|NCT03163602|Drug|Control group|Access flap and debridement
131267|NCT03163602|Device|Test group|Regenerative treatment
131268|NCT03163589|Drug|Erythropoietin|injection
131269|NCT03163589|Drug|normal saline|injection
131270|NCT03163576|Drug|Niacin|tablets
131271|NCT03163576|Drug|Phosphate Binder|tablets
131272|NCT03163563|Device|Easywarm|Warming blanket
131273|NCT03163563|Device|BairHugger|Patient warming mattress with continuous warm air.
131274|NCT03163550|Drug|ACHN-383|Oral dose
131275|NCT03163550|Drug|ACHN-789|Oral dose
131276|NCT03163550|Drug|Placebo|Oral dose
131277|NCT03163537|Device|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
131278|NCT03163524|Other|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
131279|NCT03163524|Other|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
131280|NCT03163511|Combination Product|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
131281|NCT03163498|Other|No intervantion. It´s a Cross-Sectional Study|No intervential
131282|NCT03163485|Device|Dialytrode|Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
131283|NCT03163485|Device|Standard treatment|Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
131284|NCT03163472|Procedure|Axillary brachial plexus block|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
131285|NCT03163472|Procedure|Axillary brachial plexus block|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
131286|NCT03163459|Drug|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
131287|NCT03163459|Device|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
131288|NCT03163446|Biological|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
131289|NCT03163446|Drug|Placebo|Placebo, given as a single 2 hour iv infusion
131290|NCT03163433|Behavioral|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
131291|NCT03163420|Drug|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
131292|NCT03163420|Other|Placebo|Fructose
131293|NCT03163407|Drug|Norepinephrine|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
131294|NCT03163407|Drug|Ephedrine|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
131295|NCT03163381|Drug|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
131296|NCT03163368|Radiation|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant stereotactic radiosurgery
131297|NCT03163368|Procedure|Neurosurgical resection|Surgical resection of newly diagnosed brain metastases
131298|NCT03163355|Other|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
131299|NCT03163342|Biological|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
131302|NCT03163316|Other|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.~The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.~Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
131303|NCT03163303|Behavioral|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
131304|NCT03163303|Behavioral|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
131305|NCT03163303|Drug|nicotine patch|14-day supply of nicotine patch
131306|NCT03163290|Other|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
131307|NCT03163290|Other|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
131308|NCT03163277|Drug|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
131309|NCT03163264|Behavioral|Peer Assisted Lifestyle|Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
131310|NCT03163264|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
131311|NCT03163251|Behavioral|READ-SG Sessions|In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
131312|NCT03163238|Drug|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
131313|NCT03163238|Drug|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
131314|NCT03163212|Dietary Supplement|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
131315|NCT03163199|Device|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
131316|NCT03163186|Procedure|Transarterial embolization|Transarterial hepatic embolization of liver cancer
131317|NCT03163173|Drug|GC4419|30 mg (~100 μCi) dose of [14C]GC4419
131318|NCT03163160|Procedure|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
131319|NCT03163160|Procedure|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks."
131320|NCT03163134|Device|Lumbar Drain|
131321|NCT03163121|Biological|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
131322|NCT03163121|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
131323|NCT03163121|Other|Normal Saline|0.9% sodium chloride
131324|NCT03163121|Biological|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
131325|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
131326|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
131327|NCT03163095|Device|Open Abdomen Management with ANPPT dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
131328|NCT03163095|Other|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
131329|NCT03163082|Other|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
131332|NCT03163082|Other|Evaluative Conditioning|The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
131333|NCT03163069|Combination Product|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
131334|NCT03163069|Combination Product|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
131335|NCT03163069|Combination Product|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
131336|NCT03163056|Behavioral|Cognitive-behavioral treatment (CBT)|The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
131337|NCT03163056|Behavioral|CBT+Behavioral Activation (BA)|This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
131338|NCT03163056|Behavioral|CBT+BA+ Contingency Management (CM)|This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
131339|NCT03163043|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
131340|NCT03163030|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
131341|NCT03163017|Device|2D Fluoroscopy|Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.
131342|NCT03163017|Device|3D Fluoroscopy|After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
131343|NCT03163004|Behavioral|Implementation of standing desks|Three standing desks will be introduced to the classroom
131344|NCT03162991|Other|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for ~30-55 minutes per exercise session.
131345|NCT03162978|Other|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
131346|NCT03162978|Other|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
131347|NCT03162965|Other|Oraquick HIV Self Test|This is an oral swab in home HIV test.
131348|NCT03162965|Other|Clinic Based HIV Counseling and Testing (HCT)|Receiving Counseling and Testing for HIV at the clinic.
131349|NCT03162926|Combination Product|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
131350|NCT03162913|Dietary Supplement|Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
131351|NCT03162913|Other|Placebo|12g red, strawberry-flavored powder, twice daily with water, for 90 days
131352|NCT03162900|Drug|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
131353|NCT03162900|Drug|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
131354|NCT03162900|Drug|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
131355|NCT03162900|Other|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
131356|NCT03162887|Other|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
131357|NCT03162887|Other|Counseling|Undergo a web-based decision counseling session
131358|NCT03162887|Other|Informational Intervention|"Receive a next steps document"
131359|NCT03162874|Drug|Placebo oral capsule|BID
131360|NCT03162874|Drug|PXT002331 - dose 1|Oral
131361|NCT03162874|Drug|PXT002331 - dose 2|Oral
131462|NCT03162081|Other|Comorbidity|Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
131656|NCT03160521|Drug|Risperidone ISM 75 mg|Monthly IM injection in the gluteal or deltoid muscle.
131362|NCT03162861|Drug|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
131363|NCT03162861|Drug|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
131364|NCT03162848|Behavioral|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
131365|NCT03162835|Other|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
131366|NCT03162822|Behavioral|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
131367|NCT03162822|Other|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
131368|NCT03162822|Other|Interpretation Bias Intervention|"The Interpretation Bias intervention has parents look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry."
131369|NCT03162822|Other|Evaluative Conditioning|The Evaluative Conditioning intervention presents parents with pictures of ambiguous child faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., sweet; cooperative).
131370|NCT03162796|Drug|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
131371|NCT03162796|Drug|Placebo|Participants will receive matching placebo as SC injection.
131372|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
131373|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
131374|NCT03162783|Drug|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
131375|NCT03162770|Behavioral|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
131376|NCT03162757|Procedure|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
131377|NCT03162744|Behavioral|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
131378|NCT03162731|Biological|Nivolumab|Given IV
131379|NCT03162731|Biological|Ipilimumab|Given IV
131380|NCT03162731|Radiation|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
131381|NCT03162731|Radiation|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
131382|NCT03162718|Behavioral|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
131383|NCT03162679|Behavioral|Skills training of Affect-Regulation - A culture-sensitive approach: STARK|Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
131384|NCT03162666|Device|ALTERA|degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. with up to grade 1 spondylolisthesis
131385|NCT03162653|Drug|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
131386|NCT03162653|Drug|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
131387|NCT03162627|Drug|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
131388|NCT03162627|Drug|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
131389|NCT03162614|Biological|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
131390|NCT03162614|Biological|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
131497|NCT03161691|Procedure|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
131780|NCT03159455|Drug|BI 1467335|Duration - 28 days
131391|NCT03162614|Procedure|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
131392|NCT03162601|Procedure|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
131393|NCT03162588|Drug|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
131394|NCT03162575|Behavioral|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal
131395|NCT03162562|Biological|Oregovomab|Monoclonal antibody against CA 125
131396|NCT03162562|Drug|Poly ICLC|Immune adjuvant
131397|NCT03162536|Drug|ARQ 531|ARQ 531 will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg.
131398|NCT03162536|Drug|ARQ 531|ARQ 531 will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal), or non-fasted conditions and is available in tablets in strengths of 5 mg or 20 mg.
131399|NCT03162523|Radiation|High-Dose Rate Brachytherapy|
131400|NCT03162510|Drug|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
131401|NCT03162510|Drug|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
131402|NCT03162510|Drug|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
131403|NCT03162510|Drug|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
131404|NCT03162497|Drug|Azithromycin|Azithromycin 15mg/g eyedrops
131405|NCT03162497|Drug|Doxycycline|Doxycycline 100 mg per os
131406|NCT03162484|Behavioral|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
131407|NCT03162471|Diagnostic Test|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
131408|NCT03162458|Drug|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
131409|NCT03162458|Drug|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
131410|NCT03162432|Drug|Vitamin D3|Oral Vitamin D3 therapy.
131411|NCT03162419|Drug|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
131412|NCT03162419|Biological|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
131413|NCT03162419|Biological|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
131414|NCT03162406|Dietary Supplement|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
131415|NCT03162406|Dietary Supplement|Placebo|Oral supplementation once per week for 6 months
131416|NCT03162393|Procedure|nerve transfer|
131417|NCT03162380|Other|Date collection|Date collection
131418|NCT03162367|Biological|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
131419|NCT03162367|Drug|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
131420|NCT03162354|Other|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:~Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
131421|NCT03162341|Procedure|ultrasonography|The tophus volume will be assess using ultrasonography.
131422|NCT03162341|Procedure|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
131423|NCT03162328|Device|PowerSleep Stim|Participants will wear the PowerSleep device with soft audio tones administered via the speakers during deep sleep throughout the night.
131424|NCT03162328|Device|PowerSleep Sham|Participants wear the same PowerSleep device as with the active treatment, however no audio tones will be administered via the speakers.
131425|NCT03162315|Procedure|Freeze all|
131426|NCT03162302|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
131498|NCT03161678|Drug|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
131781|NCT03159455|Drug|Placebo|Duration - 28 days
131427|NCT03162289|Other|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
131428|NCT03162289|Other|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
131429|NCT03162276|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
131430|NCT03162276|Behavioral|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
131431|NCT03162263|Device|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
131432|NCT03162250|Drug|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
131433|NCT03162250|Drug|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
131434|NCT03162250|Drug|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
131435|NCT03162237|Other|Porcine islets|"Porcine islets: 10000IEQ/Kg;~Tacrolimus: 0.087mg/kg, Bid;~mycophemo—latemofetil (MMF): 1g x 2/d;~NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
131436|NCT03162237|Other|Autologous Treg|Autologous Treg: 2x10^6/Kg
131437|NCT03162224|Drug|MEDI0457|MEDI0457 Administration by IM injection followed by electroporation (EP) using CELLECTRA®5P device.
131438|NCT03162224|Device|CELLECTRA®5P device (CELLECTRA 2000)|MEDI0457 Administration by IM injection followed by electroporation (EP) using CELLECTRA®5P device.
131439|NCT03162224|Drug|Durvalumab|Durvalumab will be administered intravenously at a dose of 1500mg every 4 weeks.
131440|NCT03162211|Other|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
131441|NCT03162198|Other|Cirrhosis with HCC|Cirrhosis with Hepatocellular Carcinoma
131442|NCT03162198|Other|Cirrhosis without HCC|Cirrhosis without Hepatocellular Carcinoma
131443|NCT03162185|Drug|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
131444|NCT03162185|Drug|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
131445|NCT03162159|Other|Collection of growth and bone maturation data|
131446|NCT03162146|Other|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
131447|NCT03162133|Other|Baduanjin exercise|
131448|NCT03162120|Drug|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
131449|NCT03162120|Drug|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
131450|NCT03162094|Drug|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
131451|NCT03162094|Drug|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
131452|NCT03162094|Drug|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
131453|NCT03162081|Diagnostic Test|Substance misuse screening|Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
131454|NCT03162081|Diagnostic Test|EQ-5D|Health related Quality of life
131455|NCT03162081|Diagnostic Test|Impulsivity screening|Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
131456|NCT03162081|Diagnostic Test|Cognitive screening|Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
131457|NCT03162081|Diagnostic Test|Functional tests|Timed up and go (TUG), Single leg balancing test (SLB)
131458|NCT03162081|Diagnostic Test|Cognistat|Assessment of cognitive domains
131459|NCT03162081|Diagnostic Test|Neuropsychological profiling|Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
131460|NCT03162081|Other|Clinical interview|Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
131461|NCT03162081|Other|Medication use|Detailed screen of used medications, interactions, side effects in electronic patient registry
131524|NCT03161522|Radiation|Radiation Therapy|Undergo RT
131463|NCT03162068|Other|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
131464|NCT03162055|Drug|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
131465|NCT03162055|Drug|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
131466|NCT03162042|Procedure|Tumor removal|Surgery
131467|NCT03162029|Other|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
131468|NCT03162016|Procedure|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
131469|NCT03161990|Procedure|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
131470|NCT03161990|Procedure|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
131471|NCT03161977|Other|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
131472|NCT03161964|Drug|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
131473|NCT03161964|Drug|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
131474|NCT03161938|Drug|Dexamethasone|intravenous
131475|NCT03161912|Drug|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion
131476|NCT03161886|Device|Pan-enteric Capsule Endoscopy (PCE)|Second generation of colon capsule endoscopy (Medtronic)
131477|NCT03161873|Device|Ava|Ava is a fertility monitoring bracelet that collects various physiological parameters
131478|NCT03161860|Behavioral|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
131479|NCT03161847|Other|Non-interventional study|Non-interventional study
131480|NCT03161834|Other|Observational|
131481|NCT03161821|Other|Observational|
131482|NCT03161782|Other|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
131483|NCT03161782|Other|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
131484|NCT03161782|Other|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
131485|NCT03161782|Other|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
131486|NCT03161769|Procedure|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
131487|NCT03161769|Device|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
131488|NCT03161756|Drug|Denosumab|Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
131489|NCT03161756|Drug|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
131490|NCT03161756|Drug|Ipilimumab|Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
131491|NCT03161743|Procedure|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
131492|NCT03161730|Other|McGrath videolaryngoscopy|Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
131493|NCT03161730|Other|Pentax videolaryngoscopy|Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
131494|NCT03161730|Other|Macintosh laryngoscopy|Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
131495|NCT03161717|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
131496|NCT03161717|Device|Loss of resistance (LOR)|Using loss of resistance technique only
131525|NCT03161509|Drug|Paracetamol|single dose of 1 gr paracetamol
131499|NCT03161678|Drug|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
131500|NCT03161665|Other|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
131501|NCT03161652|Drug|DME lactose pill|Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
131502|NCT03161652|Drug|DME levosulpiride|Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
131503|NCT03161652|Drug|DR lactose pill|Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
131504|NCT03161652|Drug|DR levosulpiride|Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
131505|NCT03161652|Drug|DR vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
131506|NCT03161652|Drug|DR vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
131507|NCT03161652|Drug|DME plus ranibizumab lactose pill|Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a lactose pill (placebo) orally TID for 24 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
131508|NCT03161652|Drug|DME plus ranibizumab levosulpiride|Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks for 12 weeks) will take a levosulpiride (75 mg/day) orally TID for 24 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
131509|NCT03161639|Other|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
131510|NCT03161626|Drug|Coagadex|Plasma-driven blood coagulation factor X concentration
131511|NCT03161613|Other|Non-Interventional|Non-Interventional
131512|NCT03161600|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at a surgical visit, enabling providers to deliver evidence-based and personalized treatment care plans to their breast cancer patients. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
131513|NCT03161574|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
131514|NCT03161561|Other|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
131515|NCT03161548|Drug|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:~Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
131516|NCT03161548|Procedure|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
131517|NCT03161548|Radiation|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:~Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
131518|NCT03161535|Other|exercise and dietary education|"A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.~Diet-teaching program (using dietary education booklet)."
131519|NCT03161535|Other|weekly telephone consultations concerning exercise and diet.|For each participant, we discussed exercise regimen-related issues and diet weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
131520|NCT03161522|Drug|Capecitabine|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
131521|NCT03161522|Drug|Chemotherapy|Receive induction chemotherapy
131522|NCT03161522|Procedure|Conventional Surgery|Undergo surgery
131523|NCT03161522|Drug|Fluorouracil|Patients will receive 5-fluorouracil (5-FU) and capecitabine as maintenance chemotherapy.
131526|NCT03161509|Drug|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
131527|NCT03161496|Genetic|detection of genotype|detection of genotype by next generation sequencing
131528|NCT03161483|Drug|CC-220|CC-220
131529|NCT03161483|Other|Placebo|Placebo QD PO
131530|NCT03161470|Other|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
131531|NCT03161470|Other|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
131532|NCT03161470|Other|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
131533|NCT03161457|Biological|JHL1101|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
131534|NCT03161457|Biological|MabThera|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
131535|NCT03161444|Other|Biological sample collection|A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
131536|NCT03161431|Drug|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
131537|NCT03161431|Biological|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
131538|NCT03161418|Drug|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
131539|NCT03161418|Drug|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
131540|NCT03161405|Drug|TAK-906 Maleate|TAK-906 capsule
131541|NCT03161405|Drug|Itraconazole|Itraconazole solution
131542|NCT03161392|Diagnostic Test|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
131543|NCT03161392|Diagnostic Test|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
131544|NCT03161379|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
131545|NCT03161379|Drug|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
131546|NCT03161379|Drug|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
131547|NCT03161379|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
131548|NCT03161366|Biological|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
131549|NCT03161353|Drug|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
131550|NCT03161353|Drug|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
131551|NCT03161353|Drug|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
131552|NCT03161353|Drug|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
131553|NCT03161353|Drug|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
131554|NCT03161353|Drug|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.~Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
131555|NCT03161340|Drug|Rapamycin|Patients will take Rapamycin 2 days before IVF until 15 days after IVF
131556|NCT03161327|Device|ABI using QuantaFlo™|"Perform Digital ABI:~Will be performed by the nurse/medical assistant with training to perform this test~The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~Usually each digit takes about 15 seconds to obtain a waveform~At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
131613|NCT03160898|Drug|Placebo|Oral
131557|NCT03161314|Procedure|Conservative physical therapy treatment with strengthening exercise program, and Conservative physical therapy treatment with stretching exercise program|(Sub-project 3) conservative physical therapy treatment with self-strengthening and with self-stretching home based exercises
131558|NCT03161288|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
131559|NCT03161288|Drug|Placebo|Matched placebo
131560|NCT03161262|Behavioral|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
131561|NCT03161249|Behavioral|Experimental group|The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
131562|NCT03161249|Other|Control group|Group that does not receive any treatment added to its usual treatment
131563|NCT03161236|Other|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
131564|NCT03161236|Other|non exercise program|continue usual lifestyle
131565|NCT03161223|Drug|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).~Starting dose: 1500 mg"
131566|NCT03161223|Drug|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).~Starting dose: 25 mg/m2"
131567|NCT03161223|Drug|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).~Starting dose: 12 mg/m2"
131568|NCT03161223|Drug|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).~Starting dose: 300 mg daily"
131569|NCT03161210|Other|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
131570|NCT03161210|Other|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
131571|NCT03161210|Other|Saline|Saline is a control group
131572|NCT03161197|Behavioral|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
131573|NCT03161184|Behavioral|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
131574|NCT03161184|Behavioral|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
131575|NCT03161171|Other|This is an observational study|This is an observational study
131576|NCT03161158|Device|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
131577|NCT03161158|Other|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
131578|NCT03161132|Drug|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
131579|NCT03161132|Drug|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
131580|NCT03161119|Device|Ultrasound guided embryotransfer with Cook K-Jets-551910-S|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
131614|NCT03160885|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
131581|NCT03161119|Device|Ultrasound guided embryotransfer with Cook k-soft-5000 (or K-J-SP-681710 and K-J-SPPE-681710)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.~The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
131582|NCT03161106|Dietary Supplement|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
131583|NCT03161106|Drug|Lactulose|Lactulose plus diet consumed by patient
131584|NCT03161106|Dietary Supplement|Diet|Protein Powder 15 to 20 gm/meal/day
131585|NCT03161093|Drug|Fasinumab|Solution for injection in pre-filled syringe
131586|NCT03161093|Drug|Naproxen|Pharmaceutical form: Capsule
131587|NCT03161093|Drug|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
131588|NCT03161093|Drug|Naproxen-matching placebo|Capsule
131589|NCT03161080|Device|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
131590|NCT03161080|Device|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
131591|NCT03161080|Device|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
131592|NCT03161067|Device|BiCNS|Surgical implantation
131593|NCT03161054|Drug|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).~Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).~Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
131594|NCT03161054|Drug|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).~Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
131595|NCT03161054|Drug|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
131596|NCT03161054|Drug|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).~Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
131597|NCT03161054|Drug|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
131598|NCT03161041|Procedure|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
131599|NCT03161041|Drug|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
131600|NCT03161028|Drug|Lipoic acid|1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
131601|NCT03161028|Drug|Placebo|The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
131602|NCT03161015|Drug|GBT440|Oral
131603|NCT03161002|Genetic|detection of genotype|detection of genotype by next generation sequencing
131604|NCT03160989|Other|physical exercises|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
131605|NCT03160976|Other|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
131606|NCT03160963|Other|Power Testing|Chair stand, vertical jump, computerized squat
131607|NCT03160950|Device|LuxaCrown|"Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.~Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). Approx. 0:40 minutes after the start of mixing, the filled impression will be placed in the patient's mouth and will stay there for approx. 1:45 - 2:20 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using PermaCem 2.0 luting cement (DMG, Germany)."
131608|NCT03160937|Other|Manual therapy|The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
131609|NCT03160924|Other|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
131610|NCT03160911|Device|Over-the-scope clip (OTSC)|The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline
131611|NCT03160911|Device|Conventional Endoscopic Haemostasis|This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
131612|NCT03160898|Drug|CK-2127107|Oral
131616|NCT03160872|Diagnostic Test|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
131617|NCT03160859|Other|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
131618|NCT03160859|Device|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
131619|NCT03160846|Drug|Inotrope|Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
131620|NCT03160833|Drug|HMPL-453|oral administrative
131621|NCT03160820|Biological|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
131622|NCT03160807|Drug|Levofloxacin|Levolet 500 mg OD for 5 days
131623|NCT03160807|Drug|Levofloxacin|Levolet 500 OD for 10 days
131624|NCT03160794|Diagnostic Test|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, [18F]DCFPyL
131625|NCT03160794|Radiation|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using [18F]DCFPyL PET/MRI
131626|NCT03160781|Biological|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
131627|NCT03160742|Device|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
131628|NCT03160729|Drug|Dexamethasone|pre-operative, single-shot injection
131629|NCT03160716|Device|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
131630|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
131631|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
131632|NCT03160703|Other|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
131633|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
131634|NCT03160690|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
131635|NCT03160677|Other|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 130 mm Hg
131636|NCT03160677|Other|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 185 mm Hg
131637|NCT03160664|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
131638|NCT03160664|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
131639|NCT03160664|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
131640|NCT03160651|Drug|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
131641|NCT03160638|Drug|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
131642|NCT03160625|Device|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
131643|NCT03160612|Behavioral|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
131644|NCT03160599|Other|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.
131645|NCT03160586|Diagnostic Test|Stuttering severity instrument-3|To measure of degree of stuttering in child
131646|NCT03160586|Diagnostic Test|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
131647|NCT03160573|Drug|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse
131648|NCT03160573|Drug|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse
131649|NCT03160573|Other|Placebo|Subjects in Placebo group will receive Placebo Rinse
131650|NCT03160560|Drug|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
131651|NCT03160560|Drug|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
131652|NCT03160560|Other|Placebo|Subjects in Placebo group will receive Placebo Rinse.
131653|NCT03160547|Other|Usual Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
131654|NCT03160547|Other|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
131655|NCT03160534|Other|preoperative exercise|Each intervention session contains a stretching part and aerobic training
131657|NCT03160521|Drug|Risperidone ISM 100 mg|Monthly IM injection in the gluteal or deltoid muscle.
131658|NCT03160521|Drug|Placebo of Risperidone ISM|Monthly IM injection in the gluteal or deltoid muscle.
131659|NCT03160508|Procedure|Fracture fixation with the TFNA|Fracture fixation with the TFNA
131660|NCT03160495|Other|All patients|All patients are scanned with PET/MR prior to surgery.
131661|NCT03160482|Diagnostic Test|Immunohistochemistry|Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
131662|NCT03160469|Device|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) & class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
131663|NCT03160456|Device|Transcutaneous electrical stimulation|The device needs to be started by pressing the 'on' button. Once the device is turned on the current intensity can be increased by pushing the '+' button and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the 'off' button.
131664|NCT03160456|Device|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
131665|NCT03160443|Behavioral|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :~Blood sampling~Calorimetry~Osteodensitometry~Psychiatric assessment~Endocrinologic assessment~Dietetic assessment~Neuropsychological assessment~Self-questionnaires~With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
131666|NCT03160430|Drug|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
131667|NCT03160430|Drug|Placebos|matching placebo capsule
131668|NCT03160404|Drug|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg/night
131669|NCT03160404|Behavioral|Exercise|The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
131670|NCT03160391|Behavioral|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
131671|NCT03160391|Behavioral|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
131672|NCT03160378|Behavioral|Organizational skills training|10 sessions of parent and child training in a group format.
131673|NCT03160378|Other|Treatment as usual|Treatment as usual in the outpatient clinic
131674|NCT03160365|Procedure|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
131675|NCT03160352|Other|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
131676|NCT03160339|Biological|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
131677|NCT03160339|Biological|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
131678|NCT03160313|Behavioral|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
131679|NCT03160313|Behavioral|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
131680|NCT03160300|Device|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
131681|NCT03160300|Device|Music|Relaxing music without a binaural beat component
131782|NCT03159442|Drug|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
131682|NCT03160287|Behavioral|Motivaltional interviews and infrequent motivational text messages|A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
131683|NCT03160274|Genetic|Genetic screening|Germline and/or tumor samples will be screened for mutations
131684|NCT03160261|Drug|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
131685|NCT03160248|Drug|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
131686|NCT03160248|Drug|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
131687|NCT03160235|Radiation|Magnetic resonance imaging|
131688|NCT03160235|Device|EEG|
131689|NCT03160235|Device|NIRS|
131690|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
131691|NCT03160196|Other|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
131692|NCT03160196|Other|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
131693|NCT03160170|Device|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator & Retractor (SISTER) device during surgery
131694|NCT03160144|Procedure|open lung approach|
131695|NCT03160131|Device|Neuro Vision Technology|"The Neuro Vision Technology method uses a special device in the form of light panels and neurological vision tests that give an overview of cognitive difficulties. This light panel is connected to a computer.~Static scanning is investigated using the special light panel with 24 light bulbs divided into two rows, the panel length corresponding to the 180 degrees that normal and well-functioning human eyes can see. Where it is considered relevant, the study participants are referred to the ophthalmologist, specialist optician, or a reading / visual clinic to ensure participants the optimal starting point for using his or her vision."
131696|NCT03160118|Drug|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
131697|NCT03160105|Drug|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
131698|NCT03160105|Other|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
131699|NCT03160092|Other|Intervention|"The intervention aims to:~Support the participant to explore their unusual experiences~Reduce the distress or anxiety participants feel in response to their unusual experiences, through:~Helping them to recognise how common these unusual experience~Supporting them to make sense of their unusual experiences~Supporting them to understand why they may be experiencing these symptoms~Challenging any unhelpful beliefs they hold about their symptoms~Help the participant to recognise the triggers to their unusual experiences~Support the participant to increase their activities and socialisation~The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
131700|NCT03160079|Drug|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)~Cycle length 42 days"
131701|NCT03160079|Drug|pembrolizumab|"Cycle 1 Pembroluzumab Day 15 and 36 IV infusion over 30 minutes (200mg)~Cycle 2-5 Pembroluzumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
131702|NCT03160066|Dietary Supplement|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
131703|NCT03160066|Dietary Supplement|Placebo|Placebo
131704|NCT03160053|Device|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
131705|NCT03160040|Drug|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
131706|NCT03160027|Device|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
131707|NCT03160014|Drug|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
131708|NCT03160001|Drug|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
131709|NCT03160001|Drug|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
131710|NCT03160001|Drug|Etanercept|Etanercept 50mg weekly
131711|NCT03159988|Drug|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
131712|NCT03159988|Behavioral|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
131713|NCT03159975|Drug|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
131714|NCT03159975|Drug|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
131715|NCT03159975|Drug|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
131783|NCT03159442|Drug|Placebo|Powder for inhalation administered via single dose DPI
131972|NCT03157934|Other|not applicable (observational study)|Observational study without study related intervention
131716|NCT03159962|Device|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
131717|NCT03159962|Device|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.~The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
131718|NCT03159949|Other|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
131719|NCT03159949|Other|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
131720|NCT03159936|Biological|Tofacitinib citrate|10 mg daily by mouth
131721|NCT03159923|Other|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
131722|NCT03159910|Behavioral|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
131723|NCT03159910|Behavioral|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
131724|NCT03159897|Drug|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
131725|NCT03159897|Drug|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
131726|NCT03159897|Drug|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
131727|NCT03159897|Drug|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
131728|NCT03159884|Drug|Conbercept|
131729|NCT03159871|Device|Stratafix suture|Stratafix barbed sutures during C-Sections.
131730|NCT03159871|Device|Vicryl suture|Standart Vicryl suture during C- Sections.
131731|NCT03159858|Device|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70‐year‐old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
131732|NCT03159845|Drug|Zinc Sulfate Oral Product|
131733|NCT03159845|Drug|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
131734|NCT03159845|Drug|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
131735|NCT03159845|Drug|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
131736|NCT03159832|Drug|SHR3824|All subjects were given SHR3824 20mg only one time.
131737|NCT03159819|Genetic|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
131738|NCT03159806|Device|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
131739|NCT03159793|Behavioral|Live Modelling Technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
131740|NCT03159793|Behavioral|Filmed Modelling technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
131741|NCT03159767|Device|ViMove Spinal Sensor|Sensors will be used to measure spinal movement
131742|NCT03159754|Procedure|Early Appendectomy|Removal of the appendix within 24 hours of admission
131743|NCT03159754|Procedure|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
131744|NCT03159754|Drug|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
131745|NCT03159741|Other|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
131746|NCT03159741|Other|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
131747|NCT03159741|Other|Placebo + GIP|Placebo and GIP are used as study tools.
131748|NCT03159741|Other|Placebo + Saline|Placebo
131749|NCT03159728|Behavioral|Educative intervention:|"In the induction of the new group members are present, including caregivers who start the program and those who coordinated.~In Module I: to strengthen the knowledge of the situation and the people involved in care.~In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.~In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
131853|NCT03158883|Drug|Avelumab|Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).
132181|NCT03155945|Drug|APD371|APD371 active treatment for 8 weeks.
131750|NCT03159715|Behavioral|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
131751|NCT03159715|Behavioral|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
131752|NCT03159715|Behavioral|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
131753|NCT03159702|Drug|Evomela|140 mg/m2/day IV on Day -6 for patients who are < 60 years of age. 100 mg/m2/day IV on Day -6 for patients who are ≥ 60 years 70 mg/m2/day IV on Day -6 For patients who are ≥60 years and/or HCT-CI score of >3
131754|NCT03159702|Drug|Fludarabine|"40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].) for patients who are < 60 years of age.~40 mg/ m2/day IV Days: -5, -4, -3, -2 for patients who are ≥ 60 years. 40 mg/m2/day IV Days -5, -4, -3, -2. For patients who are ≥60 years and/or HCT-CI score of >3"
131755|NCT03159702|Radiation|Total Body Irradiation|200 cGy Day: -1 for patients who are < 60 years of age. 200 cGy; Days: -2, -1 (total of 400cGy) for patients who are ≥ 60 years. 200 cGy; Days -1. For patients who are ≥60 years and/or HCT-CI score of >3.
131756|NCT03159689|Other|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
131757|NCT03159689|Other|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
131758|NCT03159676|Radiation|Proton beam|Proton beam
131759|NCT03159650|Device|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
131760|NCT03159637|Procedure|Laparoscopic Surgery|Insufflation of a gas (carbon dioxide) into the peritoneal cavity producing a pneumoperitoneum will be done. The positioning of the patients in Trendelenburg position will be done. intraoperative and postoperative outcomes will be assesed
131761|NCT03159624|Other|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
131762|NCT03159624|Other|Doyle silastic sheet|Doyle silastic sheet
131763|NCT03159611|Drug|Tenoten for children|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
131764|NCT03159611|Drug|Placebo|Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
131765|NCT03159598|Device|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
131766|NCT03159598|Device|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
131767|NCT03159598|Other|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
131768|NCT03159585|Drug|TAEST16001|After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
131769|NCT03159559|Drug|Lipo-PGE1|Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
131770|NCT03159546|Device|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
131771|NCT03159533|Behavioral|CHW Intervention|Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).
131772|NCT03159533|Behavioral|Wait List Control Group|4 education sessions beginning 6-12 months later.
131773|NCT03159520|Behavioral|Advice sheet|Advice on management of post orthodontic pain
131774|NCT03159507|Dietary Supplement|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
131775|NCT03159494|Other|High-Intensity Training|"8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.~As for the pilot study 6 times of training were completed"
131776|NCT03159481|Behavioral|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
131777|NCT03159468|Behavioral|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
131778|NCT03159468|Behavioral|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
131779|NCT03159468|Other|Alcohol consumption|Participants consume an alcoholic beverage in the lab.
131784|NCT03159429|Behavioral|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
131785|NCT03159429|Behavioral|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
131786|NCT03159416|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
131787|NCT03159403|Drug|Oritavancin|This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
131788|NCT03159390|Other|phenylacetate salt of ornithine|
131789|NCT03159377|Device|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
131790|NCT03159364|Biological|pathogen-specific CTLs|Patients will receive approximately 1x10^5~1x10^6 CTLs/kg as a single infusion via IV injection and may receive additional infusions.
131791|NCT03159351|Device|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110% motor threshold(MT), times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
131792|NCT03159351|Device|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
131793|NCT03159338|Biological|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
131794|NCT03159338|Biological|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
131795|NCT03159325|Behavioral|Healing Circles|See description in the arm description.
131796|NCT03159312|Behavioral|Physical activity based on a moderate exercise program|Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
131797|NCT03159299|Behavioral|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
131798|NCT03159286|Behavioral|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
131799|NCT03159286|Behavioral|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
131800|NCT03159286|Behavioral|Control|Participants view social networking site profiles with no alcohol content.
131801|NCT03159273|Dietary Supplement|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
131802|NCT03159260|Device|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
131803|NCT03159260|Other|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
131804|NCT03159247|Behavioral|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
131805|NCT03159234|Radiation|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
131806|NCT03159234|Radiation|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
132182|NCT03155932|Drug|APD334|APD334 active treatment for 24 weeks.
131807|NCT03159234|Radiation|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
131808|NCT03159221|Behavioral|BFST for Teens with Type 2 Diabetes|BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
131809|NCT03159195|Drug|Palbociclib|CDK 4/6 inhibitor for advanced/ metastatic breast cancer
131810|NCT03159182|Device|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
131811|NCT03159182|Device|Pressure garment|Custom made fabric pressure garment
131812|NCT03159169|Device|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
131813|NCT03159156|Behavioral|Applied Tension|Described above.
131814|NCT03159156|Behavioral|Respiration Control|Described above.
131815|NCT03159156|Behavioral|Applied Tension/Respiration Control|Described above.
131816|NCT03159143|Drug|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m^2.
131817|NCT03159143|Drug|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m^2
131818|NCT03159117|Drug|PF-06688992|(PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
131819|NCT03159104|Drug|Tenoten for children|Safety and Efficacy
131820|NCT03159104|Drug|Placebo|Safety and Efficacy
131821|NCT03159091|Drug|Rengalin|"Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).~Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before or 15-30 minutes after eating)"
131822|NCT03159091|Drug|Placebo|"Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).~Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before or 15-30 minutes after eating)"
131823|NCT03159078|Drug|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
131824|NCT03159065|Other|Bilberry|Fruit beverage with bilberry and fermented oatmeal
131825|NCT03159065|Other|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
131826|NCT03159065|Other|Mango|Fruit beverage with mango and fermented oatmeal
131827|NCT03159065|Other|Beetroot|Fruit beverage with beetroot and fermented oatmeal
131828|NCT03159065|Other|Rose hip|Fruit beverage with rose hip and fermented oatmeal
131829|NCT03159065|Other|Glucose drink|A reference glucose drink
131830|NCT03159052|Drug|SHR3824|Once daily, 52 weeks
131831|NCT03159052|Drug|Placebo|Once daily, 24 weeks
131832|NCT03159039|Other|Conventional Physiotherapy|
131833|NCT03159039|Other|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
131834|NCT03159013|Other|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
131835|NCT03159000|Drug|Saline|1ml of 1/3 saline
131836|NCT03159000|Combination Product|lidocaine/bupivacaine|1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
131837|NCT03158987|Other|Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity
131838|NCT03158974|Drug|VIR007|Cream
131839|NCT03158961|Procedure|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
131840|NCT03158948|Drug|MOTREM|Formulated LR12 peptide
131841|NCT03158948|Drug|Placebo|placebo
131842|NCT03158935|Drug|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
131843|NCT03158935|Drug|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
131844|NCT03158935|Procedure|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
131845|NCT03158935|Biological|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10^10 - 1.6x10^11 cells
131846|NCT03158935|Biological|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
131847|NCT03158922|Genetic|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
131848|NCT03158922|Other|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
131849|NCT03158922|Procedure|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
131850|NCT03158909|Device|Eyemask and earplugs|Eyemask and earplugs for use during the night, to improve sleep.
131851|NCT03158909|Other|Orientation about space and time|Information and orientation about space and time, given every night.
131852|NCT03158896|Biological|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)~Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
131854|NCT03158883|Radiation|Stereotactic ablative radiotherapy (SAR)|SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
131855|NCT03158870|Procedure|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
131856|NCT03158857|Drug|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
131857|NCT03158844|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
131858|NCT03158831|Drug|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
131859|NCT03158818|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
131860|NCT03158805|Drug|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
131861|NCT03158805|Other|Placebo|Placebo injection
131862|NCT03158792|Drug|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
131863|NCT03158792|Drug|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
131864|NCT03158779|Combination Product|SBRT and chemotherapy|Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
131865|NCT03158766|Other|Microdiscectomy|It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.
131866|NCT03158740|Behavioral|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
131867|NCT03158740|Behavioral|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
131868|NCT03158727|Drug|Cx611 or Placebo|Two intravenous infusions, one on day 1 and another one on day 3
131869|NCT03158714|Behavioral|Couples Connecting Mindfully|
131870|NCT03158714|Behavioral|ELEVATE|
131871|NCT03158688|Drug|Dexamethasone|Dexamethasone 40 mg will be taken orally or by IV infusion weekly. The IV administration of dexamethasone must be given on carfilzomib and/or daratumumab IV infusion days. Dexamethasone IV will be given on successive days at a split dose of 20 mg each treatment day on weeks with carfilzomib and/or daratumumab infusions. All subjects regardless of age will be required to receive 20 mg of dexamethasone on days 1 and 2 of cycle 1 (as a preinfusion medication for daratumumab infusion) followed by 20 mg of methylprednisolone or equivalent on the third day.
131872|NCT03158688|Drug|Daratumumab|Daratumumab will be administered as an IV infusion. On days 1 and 2 of cycle 1, daratumumab will be administered at a split-dose of 8 mg/kg in 500 mL normal saline. The dose of 16 mg/kg in 500 mL normal saline will be given once weekly as a single infusion for the remaining doses of the first 2 cycles (ie, days 8, 15, and 22 of cycle 1; and days 1, 8, 15, and 22 of cycle 2), then every 2 weeks for 4 cycles (cycles 3 to 6), and then every 4 weeks for the remaining cycles or until disease progression. The administration may be within ± 2 days for each scheduled dose.
131873|NCT03158688|Drug|Carfilzomib|"Carfilzomib will be administered as an intravenous (IV) infusion. On days when more than 1 investigational product is administered, the required order of administration is as follows: dexamethasone, pre-infusion medications for daratumumab, carfilzomib, daratumumab, and post infusion medications for daratumumab.~Carfilzomib will be dosed twice weekly over 30 ± 5 minutes, on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The administration may be within ± 2 days for each scheduled dose. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 56 mg/m2 beginning on cycle 1 day 8 and thereafter.~Each subject's first dose of carfilzomib will be calculated based upon baseline body surface area (BSA). Dose should be capped based on a BSA of 2.2 m2."
131874|NCT03158675|Procedure|fractional carbon dioxide(CO2) laser|-Fractional CO2 laser: Laser sessions will be performed at half month interval and it will be used with a wave length of 10,600nm.
131875|NCT03158675|Drug|Topical corticosteroid|Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
131876|NCT03158675|Radiation|Ultraviolet B narrow band|Ultraviolet B narrow band will be performed (wave length ranged from 300 to 320nm).The sessions will be performed twice weekly for 4 months.
131877|NCT03158662|Other|Survey|Survey Study
131878|NCT03158649|Other|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
131879|NCT03158623|Biological|Platelet Rich Plasma|
131880|NCT03158623|Biological|Cellerate|
131881|NCT03158610|Drug|Capecitabine|Oral fluorouracil
131882|NCT03158584|Drug|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
131883|NCT03158558|Behavioral|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson & Fredman, 2012)
131884|NCT03158545|Dietary Supplement|Olive oil Placebo|olive oil
131885|NCT03158545|Dietary Supplement|EPA-rich|EPA-rich omega-3 oil
131886|NCT03158545|Dietary Supplement|DHA-rich|DHA-rich omega-3 oil
131887|NCT03158532|Drug|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
131888|NCT03158532|Drug|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
131889|NCT03158532|Drug|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
131890|NCT03158532|Drug|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
131891|NCT03158519|Behavioral|iMETX intervention|"Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.~During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.~Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained."
131892|NCT03158506|Drug|HMS5552|[14C]-labelled HMS5552
131893|NCT03158480|Biological|DC-CIK immunotherapy|Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
131894|NCT03158467|Other|Surveys|Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
131895|NCT03158454|Procedure|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
131896|NCT03158454|Procedure|Non-Capsula Closure|No capsular closure procedure is performed.
131897|NCT03158441|Diagnostic Test|Breast MRI|comparison of DTI to dynamic MRI
131898|NCT03158428|Other|CSD170202AA|A moist snuff product
131899|NCT03158428|Other|CSD170202AB|A moist snuff product
131900|NCT03158415|Behavioral|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.~Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
131901|NCT03158402|Other|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
131902|NCT03158389|Drug|APG101|weekly i.v.
131903|NCT03158389|Drug|Alectinib|twice daily
131904|NCT03158389|Drug|Idasanutlin|on 5 days of a 28 days cycle
131905|NCT03158389|Drug|Atezolizumab|i.v. every 3 weeks
131906|NCT03158389|Drug|Vismodegib|daily orally
131907|NCT03158389|Drug|Temsirolimus|weekly i.v.
131908|NCT03158389|Drug|Palbociclib|orally on 21 days of a 28 days cycle
131909|NCT03158376|Drug|Gabapentin|
131910|NCT03158376|Drug|Placebo|
131911|NCT03158363|Other|LPS, 36 hour immobilization and fast|LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
131912|NCT03158350|Other|Instructed Brushing Method|Stationary Bristle Technique
131913|NCT03158337|Behavioral|Aerobic exercise|
131914|NCT03158324|Drug|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
131915|NCT03158311|Drug|QVM149|Indacaterol acetate / Glycopyrronium bromide / Mometasone furoate
131916|NCT03158311|Drug|Salmeterol/fluticasone plus tiotropium|free triple arm of Salmeterol/fluticasone plus tiotropium
131917|NCT03158298|Other|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
131918|NCT03158285|Drug|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
131919|NCT03158285|Drug|Placebo|Participants will receive matching placebo as SC injection.
131920|NCT03158272|Biological|Cabiralizumab|Specified dose on specified days
131921|NCT03158272|Biological|Nivolumab|Specified dose on specified days
131922|NCT03158259|Other|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
131923|NCT03158246|Drug|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
131924|NCT03158246|Drug|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
131925|NCT03158246|Dietary Supplement|calcium|600mg/d calcium for oral daily
131926|NCT03158246|Dietary Supplement|vitamin D|925IU/d vitamin D for oral daily
131927|NCT03158220|Biological|V503|V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
131928|NCT03158207|Device|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
131929|NCT03158207|Other|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
131930|NCT03158194|Behavioral|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
131931|NCT03158181|Other|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
131932|NCT03158168|Drug|Candida Antigen|Candida Albicans Antigen injection
131933|NCT03158168|Drug|Zinc Sulfate|Zinc Sulfate injection
131934|NCT03158142|Drug|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
131935|NCT03158129|Drug|Cisplatin|Given IV
131936|NCT03158129|Drug|Docetaxel|Given IV
131937|NCT03158129|Biological|Ipilimumab|Given IV
131938|NCT03158129|Biological|Nivolumab|Given IV
131939|NCT03158129|Drug|Pemetrexed|Given IV
131940|NCT03158116|Drug|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
131941|NCT03158103|Drug|MEK162|MEK162 at 30mg twice daily
131942|NCT03158103|Drug|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
131943|NCT03158090|Procedure|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
131944|NCT03158090|Drug|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
131945|NCT03158090|Radiation|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
131946|NCT03158064|Drug|Durvalumab|1500 mg by IV
131947|NCT03158064|Drug|Tremelimumab|75 mg by IV
131948|NCT03158051|Behavioral|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
131949|NCT03158051|Behavioral|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
131950|NCT03158038|Biological|Monovalent Influenza Vaccine|A single dose of monovalent influenza vaccine [10^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain] will be administered as intranasal spray on Day 1.
131951|NCT03158038|Other|Placebo|A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
131952|NCT03158025|Drug|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
131953|NCT03158025|Drug|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
131954|NCT03158025|Drug|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
131955|NCT03158025|Drug|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
131956|NCT03158025|Drug|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
131957|NCT03158025|Drug|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
131958|NCT03158012|Biological|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
131959|NCT03157999|Behavioral|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:~care coordination and system navigation (including facilitating timely primary care follow-up);~medication management;~assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);~evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;~patient and caregiver education; and goal setting and problem-solving therapy."
131960|NCT03157986|Other|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
131961|NCT03157986|Other|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
131962|NCT03157973|Other|Education intervention|eHealth tool and standardized nurse-led follow-up.
131963|NCT03157960|Other|Blueberry drink|Participant receive blueberry drink
131964|NCT03157960|Other|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
131965|NCT03157960|Other|Soft beverage|Participant receive a soft beverage drink
131966|NCT03157960|Other|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
131967|NCT03157960|Other|Fructose|Participant receive a drink containing fructose
131968|NCT03157960|Other|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
131969|NCT03157947|Behavioral|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
131970|NCT03157947|Behavioral|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
131971|NCT03157947|Behavioral|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
131973|NCT03157921|Radiation|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
131974|NCT03157921|Diagnostic Test|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
131975|NCT03157908|Device|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
131976|NCT03157895|Behavioral|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
131977|NCT03157869|Device|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
131978|NCT03157869|Other|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
131979|NCT03157856|Other|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
131980|NCT03157843|Drug|low-molecular-weight heparin|
131981|NCT03157804|Procedure|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
131982|NCT03157804|Biological|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
131983|NCT03157804|Other|Laboratory Biomarker Analysis|Correlative studies
131984|NCT03157804|Biological|Filgrastim|Given subcutaneously (SC)
131985|NCT03157804|Drug|Plerixafor|Given SC
131986|NCT03157804|Procedure|Bone Marrow Aspiration|
131987|NCT03157791|Drug|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
131988|NCT03157778|Other|Obese men|Biological measures before, just before, and after lunch, in obese men
131989|NCT03157778|Other|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
131990|NCT03157765|Procedure|endometrial biopsy|endometrial biopsy
131991|NCT03157752|Behavioral|Quality of life questionnaire|Quality of life questionnaire
131992|NCT03157739|Behavioral|MigraineManager: Individualized Self-Management Tool|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
131993|NCT03157726|Procedure|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
131994|NCT03157726|Procedure|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
131995|NCT03157713|Behavioral|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
131996|NCT03157713|Behavioral|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit Charge HR), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
131997|NCT03157713|Behavioral|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to <2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to <5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to <5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
131998|NCT03157700|Behavioral|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
131999|NCT03157674|Other|Non-Interventional|Non-Interventional
132000|NCT03157648|Other|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
132001|NCT03157635|Drug|RO7112689|RO7112689 will be administered as per schedule described in individual arm.
132002|NCT03157635|Drug|Placebo|Placebo will be administered as per schedule described in Part 1 placebo arm.
132003|NCT03157622|Behavioral|Exposure in vivo|10 sessions based on an individualized fear hierarchy
132004|NCT03157622|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
132005|NCT03157609|Device|Thermometry|Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
132006|NCT03157596|Other|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD & methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
132007|NCT03157583|Other|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
132008|NCT03157583|Other|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
132009|NCT03157583|Other|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
132010|NCT03157583|Other|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
132011|NCT03157583|Other|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
132012|NCT03157583|Other|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
132013|NCT03157583|Other|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
132014|NCT03157570|Behavioral|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
132015|NCT03157557|Behavioral|Lifestyle treatment|Lifestyle treatment
132016|NCT03157544|Behavioral|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain~The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
132017|NCT03157531|Device|B-Laser™ Atherectomy System|The B-Laser™ is indicated for use for atherectomy of infrainguinal stenoses
132018|NCT03157518|Dietary Supplement|Seeking Health Probiota Bifido|• This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
132019|NCT03157505|Drug|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
132020|NCT03157505|Other|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
132021|NCT03157492|Behavioral|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
132022|NCT03157492|Behavioral|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
132023|NCT03157479|Drug|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
132024|NCT03157479|Drug|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
132025|NCT03157479|Diagnostic Test|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
132026|NCT03157479|Diagnostic Test|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
132027|NCT03157440|Diagnostic Test|Ring oxymetry|a new type oxymetry wear on index finger like a ring
132028|NCT03157427|Device|CRYOBEAUTY MAINS|CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (<1g) and during a predetermined short duration (3 seconds)
132029|NCT03157414|Drug|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
132030|NCT03157414|Other|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
132031|NCT03157401|Drug|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
132032|NCT03157401|Drug|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
132033|NCT03157401|Drug|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
132034|NCT03157388|Drug|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.~7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
132035|NCT03157375|Device|Intraocular Lens Implantation|
132036|NCT03157362|Other|Near Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated.
132037|NCT03157362|Other|Near Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated, and converse with a confederate represented by an avatar.
132038|NCT03157362|Other|Far Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces a different room.
132039|NCT03157362|Other|Far Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces another room, and converse with a confederate represented by an avatar.
132040|NCT03157349|Other|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
132041|NCT03157349|Other|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
132042|NCT03157336|Other|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be < 10 ppm as per the recommendations of the World Health Organization.
132043|NCT03157323|Behavioral|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
132044|NCT03157310|Drug|Gefitinib|Daily oral administration of 250 mg Gefitinib
132045|NCT03157297|Device|MARVEL algorithm|Software download into implanted Micra device
132046|NCT03157284|Dietary Supplement|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
132047|NCT03157284|Dietary Supplement|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
132048|NCT03157271|Other|Intramuscular Dry Needling|Dry Needling is a procedure in which a solid filament needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple contraction knots, which are related to the production and maintenance of the pain cycle and interfere with movement patterns.
132049|NCT03157258|Behavioral|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
132050|NCT03157258|Behavioral|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
132051|NCT03157245|Diagnostic Test|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
132052|NCT03157232|Device|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
132053|NCT03157193|Drug|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
132054|NCT03157193|Drug|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
132055|NCT03157167|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
132056|NCT03157154|Other|Non interventional study|A query form to all concerned patients by each investigating centre will be send
132057|NCT03157141|Procedure|Ankle arthrodesis|Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
132058|NCT03157141|Procedure|Total ankle replacement|A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
132059|NCT03157128|Drug|LOXO-292|Oral LOXO-292
132060|NCT03157115|Device|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to heart contractility.~During a standard appointment for a patient suffering from a cardiac condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
132061|NCT03157102|Device|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher & Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 >92%.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
132062|NCT03157102|Device|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.~All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
132063|NCT03157089|Drug|Afatinib|Film-coated tablet
132064|NCT03157089|Drug|pembrolizumab|Solution for infusion
132065|NCT03157076|Device|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
132066|NCT03157063|Diagnostic Test|Data Collection Procedures|"Orientation (Consent, Screening Questionnaires) Clinic Measurements Body composition, via dual energy X-ray absorptiometry (DXA) Resting metabolic rate (RMR), via indirect calorimetry; Metabolic responses to a meal, via thermic effect of feeding (TEF) Subjective aspects of eating behavior using the Three Factor Eating Questionnaire (TFEQ) and Control of Eating Questionnaire (CEQ) Appetite, via visual analogue scales (VAS) pre- and post a prepared fixed meal and hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.~Home assessments - Data collected at home during a 14 day window Fitness Test (VO2submax and VO2max) and DXA functional magnetic resonance imaging (fMRI)"
132067|NCT03157050|Other|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
132068|NCT03157037|Biological|HMed-IdeS|One dose of 0.25 mg/kg BW HMed-IdeS on study day 1
132069|NCT03157024|Device|Ring Sham (RS)|
132070|NCT03157024|Device|Real Needle (RN)|
132071|NCT03157024|Device|Kim Sham (KS)|
132072|NCT03157011|Other|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
132073|NCT03156972|Procedure|Replacment of mitral valve|Mitral valve replacment by prothsis
132074|NCT03156959|Behavioral|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
132075|NCT03156959|Behavioral|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
132076|NCT03156946|Behavioral|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
132077|NCT03156946|Behavioral|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
132078|NCT03156933|Other|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
132079|NCT03156920|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
132080|NCT03156920|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
132081|NCT03156907|Drug|Buprenorphine/naloxone|HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
132082|NCT03156881|Other|Global Osteopathic Treatment|"The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change.~Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance."
132083|NCT03156855|Drug|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
132084|NCT03156855|Drug|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
132085|NCT03156842|Drug|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
132086|NCT03156842|Drug|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
132087|NCT03156842|Drug|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
132088|NCT03156829|Other|Splint|Custom made splint
132089|NCT03156829|Drug|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
132090|NCT03156829|Combination Product|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
132091|NCT03156816|Drug|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
132092|NCT03156816|Drug|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
132093|NCT03156803|Behavioral|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
132094|NCT03156790|Drug|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
132095|NCT03156764|Other|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
132096|NCT03156751|Diagnostic Test|Feasibility of introducing onsite test for syphilis in the package of antenatal care at rural primary health care in Burkina Faso|This study used a pre post intervention mixed methods quasi-experimental design with a group of health facilities offering ANC services. It was conducted in three phases, which consisted of a situational analysis using qualitative methods (Phase 1), selecting an appropriate test through evaluating 4 candidate tests and the participatory design and implementation of an intervention(Phase 2), and an evaluation combining review of record tools, interviews, time motion study and estimating incremental costs (Phase 3). The conceptual framework draws on multilevel assessment (MLA), policy triangle framework, MRC framework for designing complex interventions and the Normalization Process Model (NPM). The findings suggested that an intervention that introduces point of care test for syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV screening in pregnancy. Nonetheless, barriers identified by health workers need to be overcome.
132097|NCT03156738|Drug|MT-2990|Subjects will receive a single IV dose of MT-2990
132098|NCT03156738|Drug|Placebo|Subjects will receive a single IV dose of placebo
132099|NCT03156725|Drug|Ferrous Sulfate|
132100|NCT03156725|Dietary Supplement|Aspiron|
132101|NCT03156712|Dietary Supplement|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
132102|NCT03156686|Procedure|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
132103|NCT03156673|Biological|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
132104|NCT03156660|Behavioral|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.~Intervention Components:~Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).~Daily self-monitoring of steps and number of Small Changes~Daily weight self-monitoring on the BodyTraceTM e-scale~Fit Bit Alta activity trackers to self-monitor steps"
132105|NCT03156660|Behavioral|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.~Intervention Components:~Tailored calorie and fat goals based on their baseline weight.~Daily dietary intake and physical activity self-monitoring using a website or app.~Daily weight self-monitoring on the BodyTraceTM e-scale~Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention~Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions~Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day~Fit Bit Alta activity trackers to self-monitor steps"
132106|NCT03156660|Behavioral|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.~Intervention Components:~EatingWell Diet book.~Daily weight self-monitoring on the BodyTraceTM e-scale"
132107|NCT03156647|Diagnostic Test|Level of alpha-synuclein|Test of levels of total and ratio total:oligomeric in saliva
132108|NCT03156634|Other|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
132109|NCT03156634|Other|WebMD|WebMD is an internet based health information source.
132110|NCT03156621|Drug|Alirocumab|Alirocumab SC Q2W
132111|NCT03156621|Drug|Placebo|Matching placebo SC Q2W
132112|NCT03156608|Device|Novii ECG/EKG System|External fetal heart rate monitoring
132113|NCT03156608|Device|External fetal heart rate monitoring|External fetal heart rate monitoring
132114|NCT03156595|Behavioral|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
132115|NCT03156595|Behavioral|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
132116|NCT03156582|Other|Data collecting|
132117|NCT03156569|Diagnostic Test|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
132118|NCT03156556|Behavioral|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
132119|NCT03156543|Device|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.~It will be applied pre-op in all patients and post operatively in group B"
132120|NCT03156543|Other|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
132121|NCT03156530|Device|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
132122|NCT03156530|Other|Control|Not receive stimulation.
132123|NCT03156517|Device|Deep Brain Stimulation|
132124|NCT03156504|Drug|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
132125|NCT03156478|Behavioral|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
132126|NCT03156478|Behavioral|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
132127|NCT03156465|Device|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
132128|NCT03156452|Drug|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
132129|NCT03156452|Drug|Prednisolone|5mg tablets for oral administration
132130|NCT03156439|Drug|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
132131|NCT03156426|Other|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
132132|NCT03156413|Device|F&P nasal mask|Investigative Nasal Mask to be used for OSA therapy
132133|NCT03156400|Other|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
132134|NCT03156387|Procedure|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
132135|NCT03156387|Procedure|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
132136|NCT03156374|Device|Test use|Use of home ovulation test to predict ovulation
132137|NCT03156361|Drug|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
132138|NCT03156361|Drug|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
132139|NCT03156348|Other|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.~At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
132140|NCT03156335|Device|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
132141|NCT03156322|Drug|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
132142|NCT03156322|Drug|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
132143|NCT03156322|Drug|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
132144|NCT03156296|Drug|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
132145|NCT03156296|Drug|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
132146|NCT03156283|Behavioral|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
132183|NCT03155919|Dietary Supplement|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
132147|NCT03156283|Other|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
132148|NCT03156270|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
132149|NCT03156257|Biological|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
132150|NCT03156231|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
132151|NCT03156231|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
132152|NCT03156218|Drug|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
132153|NCT03156205|Behavioral|interactive music therapy|For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.
132154|NCT03156205|Behavioral|passive music listening|For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.
132155|NCT03156205|Behavioral|passive earphone-use|For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
132156|NCT03156192|Behavioral|Survey|Survey on the level of depression, quality of life, current and past music experiences, and perceived benefits of music in relation to psycho-social needs
132157|NCT03156179|Diagnostic Test|calcium isotope analysis|A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample [(42Ca/48Ca) / (44Ca/48Ca)] is the fractional calcium absorption.
132158|NCT03156166|Procedure|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
132159|NCT03156153|Drug|Bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
132160|NCT03156153|Drug|Placebo|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
132161|NCT03156140|Other|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
132162|NCT03156127|Drug|BR-UPS 5 mg tablet, Inisia 5 mg tablet|Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
132163|NCT03156114|Drug|BI 754111|Day 1 of 3 week cycle
132164|NCT03156114|Drug|BI 754091|Day 1 of 3 week cycle
132165|NCT03156101|Biological|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
132166|NCT03156088|Device|"Sacral Neuromodulator InterStim"|
132167|NCT03156075|Behavioral|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.~Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
132168|NCT03156062|Drug|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
132169|NCT03156049|Procedure|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
132170|NCT03156049|Procedure|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
132171|NCT03156036|Drug|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.~Chemotherapy during preoperative chemoradiotherapy:~Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).~dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
132172|NCT03156023|Drug|AMG 570|Investigational product solution in vial
132173|NCT03156023|Drug|Placebo|Placebo investigational product in vial
132174|NCT03156010|Device|Neuro Kinetics IPAS|Testing with PAS device
132175|NCT03156010|Device|Oculogica EyeBox|Testing with Oculogica EyeBox device
132176|NCT03156010|Device|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
132177|NCT03155997|Drug|Abemaciclib|Administered orally.
132178|NCT03155997|Drug|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
132179|NCT03155984|Drug|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
132180|NCT03155971|Device|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
132184|NCT03155919|Dietary Supplement|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
132185|NCT03155906|Other|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
132186|NCT03155893|Drug|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 [mg] ODV [1*25 mg tablet]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
132187|NCT03155893|Drug|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2 in Treatment E.
132188|NCT03155893|Drug|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) orally once daily on Days 3 to 7 in Treatment E.
132189|NCT03155893|Drug|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV [2*50 mg tablets] orally once daily on Days 8 to 14 in Treatment E.
132190|NCT03155893|Drug|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV [2*75 mg capsules]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
132191|NCT03155893|Drug|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 [3*400 mg tablets]) administered orally on Day 15 in Treatment A and B.
132192|NCT03155893|Drug|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
132193|NCT03155893|Drug|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
132194|NCT03155893|Drug|ODV 200 mg|Participants will receive ODV 200 mg (4*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
132195|NCT03155893|Drug|ODV 125 mg|Participants will receive ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
132196|NCT03155893|Drug|ODV 100 mg|Participants will receive ODV 100 mg (2*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
132197|NCT03155893|Drug|SMV 150 mg|Participants will receive SMV 150 mg (2*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
132198|NCT03155893|Drug|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3*400 mg tablets) administered on Day 15 in Treatment C.
132199|NCT03155867|Other|Meal replacement|The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
132200|NCT03155854|Procedure|Pretendinous cord excision|The cord/palmar fascia will be excised during surgery.
132201|NCT03155854|Procedure|Division/manipulation of the cord|The pretendinous cord will be divided and incised during surgery.
132202|NCT03155841|Behavioral|Life Skills Coaching|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.
132203|NCT03155841|Behavioral|Community Resources|The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
132204|NCT03155828|Device|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
132205|NCT03155789|Procedure|Lumbar Fusion|"Standard Transforaminal Lumbar Interbody Fusion (S TLIF)~Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)~AxiaLIF Fusion"
132206|NCT03155776|Diagnostic Test|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
132207|NCT03155763|Procedure|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
132208|NCT03155750|Other|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
132209|NCT03155750|Other|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
132210|NCT03155737|Other|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
132211|NCT03155737|Other|Knee health education|A course regarding knee health will be offered to the subjects in this group.
132212|NCT03155724|Device|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
132213|NCT03155711|Procedure|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
132214|NCT03155711|Procedure|Standard group|Supplemental oxygen through venturi mask
132215|NCT03155698|Combination Product|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
132258|NCT03155438|Diagnostic Test|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
132216|NCT03155698|Radiation|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
132217|NCT03155672|Behavioral|Art therapy|Art Therapy
132218|NCT03155646|Drug|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
132219|NCT03155646|Drug|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
132220|NCT03155646|Drug|Levobupivacaine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (NaCl 0.9%).
132221|NCT03155633|Other|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
132222|NCT03155633|Other|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
132223|NCT03155620|Procedure|Biopsy|Undergo biopsy
132224|NCT03155620|Procedure|Biospecimen Collection|Undergo collection of blood
132225|NCT03155620|Drug|Ensartinib|Given PO
132226|NCT03155620|Drug|Erdafitinib|Given PO
132227|NCT03155620|Other|Laboratory Biomarker Analysis|Undergo molecular analysis
132228|NCT03155620|Drug|Larotrectinib|Given PO or via nasogastric- or gastric-tube
132229|NCT03155620|Procedure|Mutation Carrier Screening|Undergo tumor tissue mutation screening
132230|NCT03155620|Drug|Olaparib|Given PO
132231|NCT03155620|Drug|Palbociclib|Given PO
132232|NCT03155620|Other|Pharmacological Study|Correlative studies
132233|NCT03155620|Drug|Samotolisib|Given PO
132234|NCT03155620|Drug|Selumetinib Sulfate|Given PO
132235|NCT03155620|Drug|Tazemetostat|Given PO
132236|NCT03155620|Drug|Ulixertinib|Receive PO
132237|NCT03155620|Drug|Vemurafenib|Given PO
132238|NCT03155607|Behavioral|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
132239|NCT03155594|Device|Freestyle Libre|Continuous glucose monitoring patch
132240|NCT03155581|Behavioral|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
132241|NCT03155581|Behavioral|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
132242|NCT03155568|Procedure|sciatic nerve block|sciatic nerve block at popliteal fossa
132243|NCT03155568|Procedure|ankle block|block of major nerves supplying the foot at the level of the ankle
132244|NCT03155568|Drug|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
132245|NCT03155555|Other|Measurement of aortic and carotid Doppler peak systolic velocity variation|Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
132246|NCT03155529|Procedure|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
132247|NCT03155516|Other|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.~Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
132248|NCT03155516|Other|Current practice procedure|Current practice clinical procedure for pain management
132249|NCT03155503|Drug|SUVN-911|Oral Tablet
132250|NCT03155503|Drug|Placebo|Oral Tablet
132251|NCT03155490|Behavioral|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
132252|NCT03155477|Dietary Supplement|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
132253|NCT03155477|Dietary Supplement|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
132254|NCT03155464|Procedure|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
132255|NCT03155464|Drug|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
132256|NCT03155451|Diagnostic Test|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
132257|NCT03155438|Diagnostic Test|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
132260|NCT03155399|Other|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
132261|NCT03155399|Other|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
132262|NCT03155386|Other|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~The intensity of lesion enhancement~The presence and type of artefacts on the recombined images.~The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
132263|NCT03155373|Diagnostic Test|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
132264|NCT03155373|Diagnostic Test|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
132265|NCT03155373|Diagnostic Test|Pulmonary function tests|Pre and post-operative pulmonary function tests
132266|NCT03155373|Diagnostic Test|Cardiac MRI|Pre and post-operative cardiac MRI
132267|NCT03155373|Other|Quality of life survey|Pre and post-operative quality of life survey (SF36)
132268|NCT03155373|Procedure|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
132269|NCT03155373|Procedure|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
132270|NCT03155360|Other|Non interventional study|Non interventional study
132271|NCT03155347|Drug|Tocilizumab|Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
132272|NCT03155347|Drug|MTX|Participants will receive MTX stable doses at 10 to 25 mg orally.
132273|NCT03155347|Drug|Placebo Matched to MTX|Placebo matched to MTX.
132274|NCT03155347|Drug|Placebo Matched to Tocilizumab|Placebo matched to tocilizumab.
132275|NCT03155334|Other|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):~individual reading of the text;~individual questionnaire for a quantitative and qualitative evaluation;~a brief semi-structured interview to each participant;~a text revision to address any problems identified from participant feedback."
132276|NCT03155321|Other|It's an observational study - no intervention is planned|No intervention is planned
132277|NCT03155308|Device|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
132278|NCT03155295|Other|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
132279|NCT03155295|Other|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
132280|NCT03155282|Procedure|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
132281|NCT03155269|Dietary Supplement|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
132282|NCT03155269|Dietary Supplement|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
132597|NCT03152474|Drug|Vitamin A 100,000 IU|Dosed Intramuscular once daily
132283|NCT03155256|Procedure|EUS-guided injection of coils with cyanoacrylate|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
132284|NCT03155256|Procedure|EUS-guided injection of coils|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
132285|NCT03155230|Other|no intervention|no intervention
132286|NCT03155204|Drug|tiotropium pMDI|inhalation
132287|NCT03155191|Biological|TBI-1501|"Phase-I portion:~Cyclophosphamide is administered for conditioning medication of TBI1501, that is CD19-CAR-T cells, (cohort -1: 3×10^5 cells/kg, cohort 1: 1×10^6 cells/kg, cohort 2: 3×10^6 cells/kg).~Phase-II portion:~Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
132288|NCT03155178|Drug|3M CHG/IPA Prep|Apply topically applied to intact skin.
132289|NCT03155178|Drug|ChloraPrep|Apply topically applied to intact skin.
132290|NCT03155165|Device|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
132291|NCT03155152|Other|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
132292|NCT03155152|Other|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
132293|NCT03155139|Diagnostic Test|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
132294|NCT03155139|Diagnostic Test|Confirmatory tests|Captopril challenge test, Saline infusion test
132295|NCT03155126|Other|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
132296|NCT03155113|Other|blood drawing|Before starting therapy a blood sample will be collected from any subject.
132297|NCT03155100|Drug|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
132298|NCT03155100|Drug|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
132299|NCT03155100|Drug|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
132300|NCT03155087|Drug|Metformin|
132301|NCT03155074|Behavioral|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
132302|NCT03155061|Drug|ONO-4578|ONO-4578 specified dose on specified days
132303|NCT03155061|Drug|ONO-4538|ONO-4538 specified dose on specified days
132304|NCT03155048|Drug|oral estrogen replacement therapy|oral estradiol group for endometrial preparation
132305|NCT03155048|Drug|Estradiol transdermal patch|transdermal estradiol group for endometrial preparation
132306|NCT03155035|Drug|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
132307|NCT03155035|Dietary Supplement|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
132308|NCT03155022|Device|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.~ICIC: Four cycles of [1 min balloon inflation followed by 1 min balloon deflation] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
132309|NCT03155022|Device|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
132310|NCT03155009|Drug|Alectinib|600 mg orally BID with food
132311|NCT03154996|Drug|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.~Dose: 146 micrometers (uM)"
132312|NCT03154996|Drug|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
132313|NCT03154996|Device|Synchromed II infusion pumps|Implanted subcutaneously to facilitate chronic infusion.
132314|NCT03154983|Drug|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
132598|NCT03152474|Other|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
132315|NCT03154970|Device|Craniocervical flexion training|The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
132316|NCT03154944|Device|Ostomy device 1|This device consists of a known adhesive and a new top film
132317|NCT03154944|Device|Ostomy device 2|This device consists of a new adhesive and a known top film
132318|NCT03154944|Device|Ostomy device 3|This device consists of a known adhesive and a new top film
132319|NCT03154931|Other|CBT-SG|To support the group.
132320|NCT03154931|Other|CFT-G|Teach compassionate skills.
132321|NCT03154918|Drug|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
132322|NCT03154892|Procedure|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
132323|NCT03154892|Procedure|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
132324|NCT03154879|Device|Amplitude integrated electroencephalography|Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
132325|NCT03154866|Dietary Supplement|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
132326|NCT03154866|Dietary Supplement|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
132327|NCT03154853|Other|Behavioral: short foot exercise|Behavioral: short foot exercise 30 repetitions per section (10 seconds for each contraction, 1 minute between sections), 3 times/ week, 3 weeks
132328|NCT03154840|Drug|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
132329|NCT03154827|Drug|BL-8040|Subjects will receive once daily SC injections of 1.25 mg/kg of BL-8040 on the first 3 days of each cycle.
132330|NCT03154827|Drug|Atezolizumab|Subjects will receive Atezolizumab 1200 mg by IV infusion on Day 2 of every cycle.
132331|NCT03154814|Drug|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
132332|NCT03154814|Drug|control|conventional CPB was applied without ulinastatin treatment
132333|NCT03154801|Other|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
132334|NCT03154775|Biological|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
132335|NCT03154762|Device|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
132336|NCT03154762|Device|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
132337|NCT03154749|Drug|TC (docetaxel/carboplatin) versus EC followed by T (epirubicin/cyclophosphamide followed by docetaxe)|TC (docetaxel/carboplatin) versus EC followed by T (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer
132338|NCT03154736|Other|Interview|Individual interview and group interview Socio-economic questionnaire
132339|NCT03154723|Drug|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
132340|NCT03154710|Device|SENTINEL|web-mediated follow up
132341|NCT03154697|Other|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
132342|NCT03154684|Other|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;~Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care~Inspection of the environment at the patient's home~Care and autonomy support~Social life support~Secondary prevention strategies:~Home exercise program (3x/weeks)~Protein enriched food preparation (20g whey protein/day)~Support to take vitamin D supplementation (2000 IU/day)~Recommendation and support to eat calcium rich foods~Motivation to be physically active"
132343|NCT03154684|Other|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
132344|NCT03154671|Other|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
132345|NCT03154658|Drug|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
132346|NCT03154645|Drug|Ibuprofen|non-steroidal anti-inflammatory drug
132347|NCT03154645|Drug|Acetazolamide|a diuretic
132348|NCT03154632|Device|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
132349|NCT03154632|Device|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
132350|NCT03154619|Drug|0.1% TR 987|TR 987 0.1%
132351|NCT03154619|Drug|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
132352|NCT03154606|Other|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
132353|NCT03154606|Other|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
132630|NCT03152227|Other|ACGG|50 high-producing chicks to households along with provision of technical input on production
132354|NCT03154606|Other|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
132355|NCT03154606|Other|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
132356|NCT03154606|Other|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
132357|NCT03154606|Other|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
132358|NCT03154606|Other|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
132359|NCT03154606|Other|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
132360|NCT03154606|Other|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
132361|NCT03154606|Other|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
132362|NCT03154606|Other|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
132363|NCT03154606|Other|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
132364|NCT03154593|Other|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
132365|NCT03154580|Drug|N-acetyl cysteine|Participants will receive 4 capsules at 11:15am on each experimental session day.
132366|NCT03154567|Drug|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
132367|NCT03154541|Drug|Synrinse|"Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse."
132368|NCT03154528|Diagnostic Test|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males & 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
132369|NCT03154515|Drug|Ingavirin|
132370|NCT03154515|Drug|Placebo|
132371|NCT03154502|Diagnostic Test|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
132372|NCT03154489|Other|acenocoumarol|medication review with follow-up in acenocoumarol treatment
132373|NCT03154489|Other|control|group
132374|NCT03154476|Drug|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
132375|NCT03154476|Drug|Placebo|Placebo capsules matching study drug
132376|NCT03154463|Procedure|TAP Blocks|TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
132377|NCT03154463|Procedure|continuous epidural infusion|Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant
132378|NCT03154450|Device|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
132379|NCT03154450|Device|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
132409|NCT03154177|Procedure|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention."
132862|NCT03150628|Drug|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
132380|NCT03154437|Biological|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
132381|NCT03154424|Procedure|External fixation in treatment the distal radius fracture|Compare two techniques
132382|NCT03154411|Drug|ABY-029|A minimum of 12 and a maximum of 18 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery. Two cohorts will be enrolled with a minimum of 6 and a maximum of 12 subjects in Cohort 1 and 6 patients in Cohort 2. Cohort 1 will include patients with an EGFR pathology score ≥ 1; Cohort 2 will include patients with an EGFR pathology score of < 1 (control).
132383|NCT03154385|Drug|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
132384|NCT03154372|Other|Expert supervised practice with validated metrics|
132385|NCT03154372|Other|self guided practice with validated metrics|
132386|NCT03154359|Drug|Atomoxetine Hydrochloride|Atomoxetine dose adjusted to achieve pre-defined concentration
132387|NCT03154333|Drug|diacerein 1% ointment|diacerein 1% ointment administered topically
132388|NCT03154333|Drug|A placebo ointment|vehicle ointment administered topically
132389|NCT03154320|Other|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
132390|NCT03154320|Other|Standard treatment|Standard treatment
132391|NCT03154307|Device|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
132392|NCT03154294|Drug|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
132393|NCT03154294|Drug|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
132394|NCT03154294|Drug|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
132395|NCT03154281|Drug|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
132396|NCT03154281|Drug|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
132397|NCT03154255|Behavioral|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
132398|NCT03154229|Other|Smartphone-based decision-support|WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
132399|NCT03154229|Other|Paper-based decision-support|WHO guidelines presented on paper
132400|NCT03154229|Other|Pre-Assessment of practices|Observation of baseline clinical practice.
132401|NCT03154216|Behavioral|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
132402|NCT03154216|Other|Drink|Beverage to be consumed after exercise
132403|NCT03154203|Other|No intervention in this study|No intervention in this study
132404|NCT03154190|Other|Best Practice|Receive usual care
132405|NCT03154190|Other|Laboratory Biomarker Analysis|Correlative studies
132406|NCT03154190|Procedure|Supportive Care|Undergo health care coach support
132407|NCT03154190|Other|Survey Administration|Ancillary studies
132408|NCT03154177|Behavioral|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
132410|NCT03154164|Device|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
132411|NCT03154151|Behavioral|Online Cognitive-Behavioral Therapy|Each participant will complete writing assignments focusing on how their experiences during the 9/11 attacks or the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
132412|NCT03154151|Behavioral|Online Supportive Therapy|Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
132413|NCT03154138|Device|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
132414|NCT03154138|Device|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.~The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
132415|NCT03154125|Drug|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
132416|NCT03154112|Device|Measurement of oxygen consumption and caloric expenditure|This study will involve an ~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
132417|NCT03154086|Drug|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
132418|NCT03154086|Drug|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
132419|NCT03154073|Behavioral|Moderate Intensity Exercise Training (MOD)|For the first 4 weeks, participant will be asked to complete 3 days of exercise/week at 50-65% heart rate maximum. Sessions will last between 30-40 minutes excluding the warm-up and cool down (5-10 minutes). After 4 weeks, the MOD group will be expected to match the exercise prescription. The exercise prescription for the MOD group for weeks 5-12 will be 4 days/week, 45 min/session completed at 60-65% heart rate maximum.
132420|NCT03154073|Behavioral|Vigorous Intensity Exercise Training (VIG)|The exercise lead in period will be the same as the moderate intensity exercise training program. After 6 weeks, the VIG group will be expected to match the exercise prescription. The exercise prescription for the VIG for weeks 7-12 will be 4 days/week, 45 min/session completed at 80-85% heart rate maximum.
132421|NCT03154060|Device|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
132422|NCT03154047|Drug|NEOD001|humanized monoclonal antibody
132423|NCT03154021|Combination Product|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
132424|NCT03154021|Combination Product|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
132425|NCT03154008|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
132426|NCT03153995|Procedure|soft tissue expansion|"Three surgeries will be carried out for each patient:~Soft tissue expansion (1st surgery); at baseline~Alveolar ridge augmentation (2nd surgery); after five weeks~Implant surgery (3rd surgery); after six months"
132427|NCT03153982|Drug|Ruxolitinib|15 mg or 20 mg (three or four 5 mg tablets) by mouth twice daily
132428|NCT03153969|Device|SHOFU Beautifil II LS|Placed under manufacturer's instructions
132429|NCT03153969|Device|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
132430|NCT03153956|Device|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
132431|NCT03153956|Device|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
132589|NCT03152539|Device|EEG|
132590|NCT03152539|Device|NIRS|
132432|NCT03153943|Device|HIP Mobile e-Monitoring support|3-month community-based extended-rehabilitation e-Monitoring and Coaching support program
132433|NCT03153943|Other|Workbook support|Printed material support
132434|NCT03153930|Behavioral|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
132435|NCT03153930|Behavioral|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
132436|NCT03153917|Other|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
132437|NCT03153904|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
132438|NCT03153904|Other|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
132439|NCT03153891|Other|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
132440|NCT03153891|Other|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
132441|NCT03153852|Drug|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
132442|NCT03153852|Drug|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
132443|NCT03153852|Drug|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
132444|NCT03153839|Behavioral|Aquatic physical activity in babies|"A programme based on four different types exercises realized in a swimming pool for twelve months.~Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again."
132445|NCT03153826|Other|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
132446|NCT03153813|Drug|capsaicin 8% patches (Qutenza)|
132447|NCT03153813|Other|Placebo patches|
132448|NCT03153800|Biological|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
132449|NCT03153787|Other|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
132450|NCT03153774|Diagnostic Test|Assessment of sarcopenia prevalence|Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
132451|NCT03153761|Other|CSD170201AA|A moist snuff product
132452|NCT03153761|Other|CSD170201AB|A moist snuff product
132453|NCT03153735|Device|CMDHA0101|Maximum injection dose : 22 ml
132454|NCT03153735|Device|PowerFill®|Maximum injection dose : 22 ml
132455|NCT03153722|Procedure|Pediatric discharge process interventions|"As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes."
132456|NCT03153696|Behavioral|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
132457|NCT03153683|Other|Registry|Collect standard of care clot and arterial blood during standard of care thrombectomy from Acute Ischemic Stroke Patients for lab analysis.
132458|NCT03153670|Other|functional magnetic resonance imaging|Performing functional magnetic resonance imaging with the deep brain stimulation activated.
132591|NCT03152526|Device|Interventions|CliniMACS® CD3 and CD19 Reagent System
132459|NCT03153657|Drug|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
132460|NCT03153657|Drug|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
132461|NCT03153644|Behavioral|Interview|1 hour semi-structured
132462|NCT03153644|Behavioral|Observation|Field Observation
132463|NCT03153618|Other|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
132464|NCT03153605|Other|Common toothpaste|different toothpaste
132465|NCT03153592|Procedure|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
132466|NCT03153592|Procedure|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
132467|NCT03153579|Drug|LSD|"Lysergic Acid Diethylamide~200ug per os, single dose"
132468|NCT03153579|Drug|Placebo|Capsules containing mannitol looking identical to LSD
132469|NCT03153566|Biological|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
132470|NCT03153566|Device|cryotherapy|10 sec 1 cycle into all genital warts
132471|NCT03153553|Other|Ischemic Preconditioning|Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
132472|NCT03153553|Other|Sham Intervention|Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
132473|NCT03153540|Device|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
132474|NCT03153540|Device|Sham iTBS|Sham intervention
132475|NCT03153527|Drug|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
132476|NCT03153527|Other|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
132477|NCT03153514|Biological|Obinutuzumab|"Obinutuzumab i.v.~[Day 0 = day of stem cell transplant]~Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)~Cycle 2: 1000 mg (d +1, +8, +15, +22)"
132478|NCT03153501|Diagnostic Test|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
132479|NCT03153488|Radiation|MRI|All participants will perform one MRI session before initiation of treatment. The imaging session will last about an hour including the structural and functional MRI portions. The subjects lie on a padded scanner couch in a dimly illuminated room, and wear foam earplugs to attenuate scanner sounds.
132480|NCT03153475|Device|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
132481|NCT03153462|Biological|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
132482|NCT03153449|Device|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
132483|NCT03153436|Biological|Myoinositol|
132484|NCT03153423|Procedure|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
132485|NCT03153410|Drug|Cyclophosphamide|"200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX for a total of 8 doses.~Other Names:~Cytoxan CY"
132486|NCT03153410|Drug|GVAX|"5E8 cells is to be administered one day after CY, pembrolizumab, and IMC-CS4/ LY3022855 for a total of eight doses.~Other Names:~Pancreatic cancer vaccine Panc 10.05 pcDNA1/GM-Neo, Panc 6.03 pcDNA1/GM-Neo"
132487|NCT03153410|Drug|Pembrolizumab|"200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine for a total of 18 doses.~Other Names:~MK-3475 KEYTRUDA"
132488|NCT03153410|Drug|IMC-CS4|75 mg for dose level 1 and 100 mg at dose level 2 will be administered (Day 1, Day 8 and Day 15) as a 30 minute(s) IV infusion one day prior to GVAX pancreas vaccine for a total 18 doses.
132489|NCT03153397|Other|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
132490|NCT03153397|Other|Osmolite|non-prebiotic fiber containing formula (Osmolite)
132491|NCT03153384|Procedure|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
132492|NCT03153358|Drug|Icotinib|icotinib 125 milligram three times a day
132493|NCT03153358|Radiation|SBRT|given radiation for the primary lesion
132592|NCT03152500|Device|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
132593|NCT03152500|Device|Acrysof SN60WF IOL|IOL in the bag
132494|NCT03153345|Device|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
132495|NCT03153345|Behavioral|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
132496|NCT03153332|Other|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
132497|NCT03153319|Drug|Adalimumab Injection [Humira]|Investigational Drug
132498|NCT03153319|Drug|Saline Solution for Injection|Placebo Comparator
132499|NCT03153306|Drug|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
132500|NCT03153293|Drug|rAAV2-ND4|a Single IVT Injection
132501|NCT03153280|Drug|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
132502|NCT03153280|Drug|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
132503|NCT03153280|Drug|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
132504|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
132505|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
132506|NCT03153267|Drug|Controls without a history of lyme disease.|No intervention.
132507|NCT03153254|Device|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
132508|NCT03153254|Device|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
132509|NCT03153241|Other|No intervention|No intervention
132510|NCT03153215|Other|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to fish oil and zinc supplementation.
132511|NCT03153215|Other|Placebo|Placebo tablets similar to Sildenafil will be given to control group in addition to fish oil and zinc supplementation.
132512|NCT03153202|Drug|Ibrutinib|once daily oral intake ibrutinib
132513|NCT03153202|Drug|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
132514|NCT03153176|Behavioral|Training|Training program 30 hours accumulated before, during and after intervention
132515|NCT03153176|Behavioral|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
132516|NCT03153176|Behavioral|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
132517|NCT03153163|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
132518|NCT03153150|Drug|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
132519|NCT03153150|Drug|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
132520|NCT03153150|Drug|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
132521|NCT03153150|Drug|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
132522|NCT03153150|Drug|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
132523|NCT03153150|Drug|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
132524|NCT03153150|Drug|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
132525|NCT03153137|Drug|Macitentan 10 mg|film-coated tablet; oral use
132526|NCT03153137|Drug|Placebo|film-coated tablet; oral use
132527|NCT03153124|Other|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
132528|NCT03153111|Drug|Macitentan|macitentan 10 mg; film-coated tablet; oral use
132529|NCT03153111|Drug|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
132530|NCT03153098|Behavioral|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
132531|NCT03153085|Biological|TBI-1401(HF10)|"1x10^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).~Following combination therapy, patients may continue to receive the 1x10^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration."
132532|NCT03153085|Drug|Ipilimumab|3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
132533|NCT03153072|Biological|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
132534|NCT03153059|Other|Stool frequency|This study is just observational study.
132599|NCT03152461|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
132535|NCT03153046|Dietary Supplement|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto‐oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
132536|NCT03153046|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
132537|NCT03153033|Behavioral|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
132538|NCT03153020|Other|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
132539|NCT03152994|Other|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
132540|NCT03152981|Drug|Desflurane|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
132541|NCT03152981|Drug|propofol|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
132542|NCT03152981|Drug|remifentanil|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
132543|NCT03152955|Drug|Ketamine|Ketamine will be applied in patient-controlled analgesia.
132544|NCT03152955|Other|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
132545|NCT03152955|Drug|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
132546|NCT03152955|Drug|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
132547|NCT03152942|Drug|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
132548|NCT03152942|Drug|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
132549|NCT03152929|Drug|Paravertebral Block|20-30 mL 0.5% Ropivacaine
132550|NCT03152929|Drug|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
132551|NCT03152916|Device|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
132552|NCT03152903|Biological|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.~VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
132553|NCT03152903|Other|Placebo|Single dose of Placebo is administered intradermally.
132554|NCT03152890|Drug|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
132555|NCT03152877|Drug|Bupivacaine Liposome Injectable Product|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
132556|NCT03152877|Drug|0.25% plain bupivacaine|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
132557|NCT03152864|Behavioral|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
132558|NCT03152851|Procedure|Pressure stimulus group|
132559|NCT03152838|Genetic|DNA methylation and Real-time Polymerase Chain Reaction Analysis|"Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.~DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes."
132594|NCT03152487|Other|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
132595|NCT03152487|Other|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
132560|NCT03152838|Diagnostic Test|Gilliam Autism Rating Scale Arabic version|"An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.~The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt."
132561|NCT03152825|Procedure|PCI|percutaneous coronary intervention attempt
132562|NCT03152812|Procedure|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
132563|NCT03152799|Procedure|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
132564|NCT03152799|Other|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
132565|NCT03152786|Other|Laboratory Biomarker Analysis|Correlative studies
132566|NCT03152786|Drug|Propranolol Hydrochloride|Given PO
132567|NCT03152786|Other|Questionnaire Administration|Ancillary studies
132568|NCT03152786|Other|Survey Administration|Ancillary studies
132569|NCT03152773|Procedure|MRI Right Heart guidewire catheterization|To conduct right heart guidewire catheterization using real-time MRI fluoroscopy in human research subjects already undergoing medically necessary right heart catheterization. We will use only passive MRI-compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
132570|NCT03152747|Device|ultrasound, b-scan|Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
132571|NCT03152734|Procedure|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
132572|NCT03152721|Device|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
132573|NCT03152721|Other|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
132574|NCT03152695|Device|High-intensity focused ultrasound|Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
132575|NCT03152682|Dietary Supplement|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
132576|NCT03152682|Other|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
132577|NCT03152643|Procedure|blastocyst-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single blastocyst-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
132578|NCT03152643|Procedure|cleavage-stage embryo transfer|All the participants will receive a long GnRH-agonist, ultra-long GnRH-agonist, short GnRH-agonist or GnRH antagonist protocol in combination with recombinant FSH. HCG will be administered for final oocyte maturation. Patients will have a single cleavage-stage embryos transferred. The outcomes of all the embryo transfers within 1 year after randomization will be followed up. Single embryo transfer (SET) is required for the first 3 embryo transfers within 1 year after randomization. For embryo transfers beyond the third within the 1 year, patients' treatment must follow their randomized allocation, and SET is no longer mandatory. Luteal phase support will be administered before embryo transfer. If pregnancy is confirmed, luteal phase support will be continued until 10 weeks of gestation. The follow up will be continued until 6 weeks after delivery.
132579|NCT03152591|Drug|LIK066|LIK066 tablets for oral administration
132580|NCT03152591|Drug|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
132581|NCT03152578|Other|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
132582|NCT03152578|Other|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
132583|NCT03152578|Other|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
132584|NCT03152565|Drug|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.~Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
132585|NCT03152552|Drug|LIK066|LIK066 was supplied in different doses as tablets taken orally.
132586|NCT03152552|Drug|Placebo|Placebo was supplied as tablets and capsules taken orally.
132587|NCT03152552|Drug|Empagliflozin|Empagliflozin was supplied as capsules taken orally.
132588|NCT03152539|Radiation|MRI|
132600|NCT03152448|Behavioral|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
132601|NCT03152435|Biological|EGFR CART|EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
132602|NCT03152422|Diagnostic Test|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
132603|NCT03152409|Drug|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
132604|NCT03152409|Drug|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
132605|NCT03152396|Other|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
132606|NCT03152383|Behavioral|Training trials|"A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level."
132607|NCT03152383|Behavioral|Progressive Ratio Session|The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
132608|NCT03152383|Behavioral|Re-test|10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
132609|NCT03152383|Behavioral|Pairing Protocol|15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
132610|NCT03152370|Drug|E7046|oral administration
132611|NCT03152370|Radiation|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
132612|NCT03152370|Radiation|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
132613|NCT03152370|Drug|capecitabine|chemotherapy
132614|NCT03152370|Drug|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
132615|NCT03152357|Device|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
132616|NCT03152344|Procedure|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value >12 seconds).
132617|NCT03152331|Behavioral|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
132618|NCT03152318|Drug|rQNestin|rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.
132619|NCT03152318|Drug|Cyclophosphamide|Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.
132620|NCT03152318|Procedure|Stereotactic biopsy|In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
132621|NCT03152305|Other|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
132622|NCT03152292|Other|Real-world, non-interventional|N/A - non-interventional
132623|NCT03152279|Diagnostic Test|Mucosal Impedance Catheter|During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
132624|NCT03152279|Diagnostic Test|Blood sample|At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
132625|NCT03152266|Other|No intervention. Observational study|Follow up of the function of the hip after reduction of the impacted fragment which associated with acetabular fractures
132626|NCT03152253|Behavioral|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
132627|NCT03152253|Behavioral|Peer Support|A group chat room for peer support
132628|NCT03152253|Other|Motivational Messages|Generic motivational messages not related to smoking cessation
132629|NCT03152240|Other|Non intervention|Non intervention
132991|NCT03149679|Drug|Cyclophosphamide|Chemotherapy
132631|NCT03152227|Behavioral|BCC|Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
132632|NCT03152214|Other|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at > 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.~Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
132633|NCT03152214|Other|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
132634|NCT03152201|Diagnostic Test|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
132635|NCT03152188|Drug|FMT|Fifteen FMT Openbiome capsules administered at the same time
132636|NCT03152188|Other|Placebo|Fifteen placebo capsules administered at the same time
132637|NCT03152175|Drug|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
132638|NCT03152175|Drug|Placebo|1mg / kg of matched placebo, oral capsule
132639|NCT03152162|Device|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
132640|NCT03152149|Drug|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
132641|NCT03152149|Drug|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
132642|NCT03152136|Device|Cala ONE device|The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.
132643|NCT03152123|Drug|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
132644|NCT03152123|Drug|Placebos|tablets over-capsuled
132645|NCT03152123|Drug|Phentermine|Phentermine 60 mg (capsule over-capsuled)
132646|NCT03152110|Other|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.~Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.~Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
132647|NCT03152097|Dietary Supplement|Commercially available Diindolylmethane|Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
132648|NCT03152097|Other|Placebo|A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
132649|NCT03152084|Drug|Dapagliflozin|The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
132650|NCT03152071|Procedure|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
132651|NCT03152071|Procedure|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
132652|NCT03152058|Drug|Certolizumab Pegol|"Certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.~The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
132653|NCT03152045|Behavioral|Communication Intervention|In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
132654|NCT03152032|Behavioral|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
132655|NCT03152019|Drug|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
132656|NCT03152019|Drug|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
132705|NCT03151642|Radiation|Radiation Therapy|Patients will have their radiation therapy coordinated and performed through the Radiation Oncology Department at the University of Pennsylvania. The development and delivery of the patient's radiation treatment plan will be at the discretion of the treating radiation oncologist, and details will be recorded in the patient's chart.
132657|NCT03152006|Other|ACT|Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
132658|NCT03151993|Drug|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
132659|NCT03151993|Drug|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
132660|NCT03151980|Procedure|Hamam treated skin and sun exposure|Hamam is a skin treatment (soaping and scrubbing).
132661|NCT03151980|Other|Untreated skin and sun exposure|Skin that will not receive Hamam.
132662|NCT03151967|Drug|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
132663|NCT03151967|Drug|Placebo|vaginal applicator with medium containing no drug
132664|NCT03151954|Procedure|functional endonasal sinus surgery|collect nasal polyps from patients
132665|NCT03151954|Procedure|nasal septal construction|collect inferior turbinates from patients as control arm
132666|NCT03151928|Diagnostic Test|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
132667|NCT03151889|Device|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
132668|NCT03151876|Drug|Chidamide|30 mg oral twice weekly for 2 weeks
132669|NCT03151876|Drug|Cladribine|6 mg/m2 intravenously daily for 5 days
132670|NCT03151876|Drug|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
132671|NCT03151876|Drug|Busulfan|3.2 mg/kg intravenously daily for 4 days
132672|NCT03151876|Procedure|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
132673|NCT03151863|Drug|Opioids|The usual opioid treatment used for nursing care
132674|NCT03151863|Drug|Dexmedetomidine|Dexmedetomidine is provided intranasally
132675|NCT03151863|Drug|Placebo|Normal saline is either given subcutaneously or intranasally
132676|NCT03151850|Other|ulcerative colitis|We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
132677|NCT03151850|Other|Control|We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
132678|NCT03151837|Dietary Supplement|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
132679|NCT03151837|Dietary Supplement|Placebo control|Starch
132680|NCT03151824|Other|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
132681|NCT03151811|Drug|Melflufen|Intravenous infusion
132682|NCT03151811|Drug|Pomalidomide|Oral capsules
132683|NCT03151811|Drug|Dexamethasone|Oral tablets
132684|NCT03151798|Behavioral|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
132685|NCT03151798|Behavioral|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
132686|NCT03151798|Other|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
132687|NCT03151785|Other|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
132688|NCT03151785|Other|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
132689|NCT03151785|Other|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
132690|NCT03151772|Drug|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
132691|NCT03151772|Drug|Metformin|Metformin 850 mg x 3 taken preoperatively
132692|NCT03151759|Radiation|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
132693|NCT03151746|Drug|Placebo|Placebo pill administered orally 1 hour before planned surgical procedure
132694|NCT03151746|Drug|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
132695|NCT03151733|Procedure|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
132696|NCT03151733|Procedure|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
132697|NCT03151720|Drug|loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
132698|NCT03151720|Drug|loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
132699|NCT03151707|Drug|Nicotinamide Riboside|Nicotinamide riboside 1000 mg/day
132700|NCT03151681|Drug|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
132701|NCT03151668|Drug|Dexmedetomidine|
132702|NCT03151655|Behavioral|MATTeRS Video|Narrative-based video intervention and accompanying workbook
132703|NCT03151655|Behavioral|Didactic Video|Education only video
132704|NCT03151642|Radiation|Chemotherapy|Patients will have their chemotherapy coordinated through the Medical Oncology department at the University of Pennsylvania, and will be followed by Medical Oncology at Penn during chemoradiation. As part of the standard of care for locally advanced esophageal cancer, neoadjuvant concurrent chemotherapy will likely consist of weekly carboplatin and paclitaxel, beginning within 1 day of starting radiation therapy and continuing until the completion of radiation treatment. Alternative chemotherapy regimens, dose adjustments or delays in administration will be determined at the discretion of the treating medical oncologist and recorded in the patient's chart.
132811|NCT03150849|Diagnostic Test|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
132992|NCT03149653|Drug|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
132706|NCT03151642|Procedure|Surgery|Patients will have their surgery coordinated and performed through Thoracic Surgery department at the University of Pennsylvania. Patients will undergo esophagectomy 4-8 weeks after the completion of neoadjuvant chemoradiation as part of the standard of care.
132707|NCT03151642|Device|MRI Imaging|A total of 40 paired MRI examinations from eligible participants will be collected in the Department of Radiology at the Hospital of the University of Pennsylvania. Participants will undergo two 1.5T MRI studies performed at two time points: (1) within 28 days prior to starting neoadjuvant chemoradiation, and (2) between radiation fraction 8-13 during treatment. The quantitative imaging studies for the trial (DWI) will be performed with and without respiratory gating using a navigator, with B values of 0, 100, 600 and 800 s/mm2.
132708|NCT03151642|Other|Blood Draws|The procedure of blood collection for each patient will be as follows: the total amount being drawn each time will be approximately 30 cc. Approximately 25 ml of blood will be collected into heparinized tubes, and immediately placed on ice in a prepared plastic bag and transported to the laboratory for processing within 1 hour. If necessary, we may need up to 2 hours in order to begin processing the blood; in the event that longer than this time period has transpired, the sample will be deemed inadequate for processing purposes. The first blood draw will be obtained prior to the first fraction of radiation treatment and will be coordinated to occur at the time of pre-treatment MRI. Thereafter, the second sample will be obtained during chemoradiation therapy, between fraction 8-13 and the blood draw will be coordinated with the on-treatment MRI scan.
132709|NCT03151629|Other|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
132710|NCT03151616|Other|anticholinergic risk scale|Risk summation scale for grading and studying anticholinergic medication exposure
132711|NCT03151603|Drug|Arctuvan|application of a herbal drug
132712|NCT03151603|Drug|Fosfomycin|application of an antibiotic drug
132713|NCT03151603|Drug|Placebo to Arctuvan|application of Placebo to Arctuvan
132714|NCT03151603|Drug|Placebo to Fosfomycin|application of Placebo to Fosfomycin
132715|NCT03151590|Behavioral|exercise training|
132716|NCT03151577|Procedure|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
132717|NCT03151564|Diagnostic Test|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
132718|NCT03151564|Diagnostic Test|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
132719|NCT03151551|Drug|Ixekizumab|Administered SC
132720|NCT03151551|Drug|Adalimumab|Administered SC
132721|NCT03151538|Behavioral|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
132722|NCT03151538|Other|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
132723|NCT03151525|Drug|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
132724|NCT03151525|Drug|Infliximab|IFX treatment for maintenance of remission
132725|NCT03151499|Drug|BI 409306|Reference and Test Treatment
132726|NCT03151499|Drug|Rifampicin|Test Treatment
132727|NCT03151486|Drug|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
132728|NCT03151486|Drug|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
132729|NCT03151486|Drug|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
132730|NCT03151486|Drug|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
132731|NCT03151486|Drug|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
132732|NCT03151486|Drug|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
132733|NCT03151486|Drug|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
132734|NCT03151486|Drug|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
132735|NCT03151486|Drug|Placebo|Participants will receive matching placebo in all cohorts.
132736|NCT03151460|Drug|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
132812|NCT03150836|Drug|Durvalumab|All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
132813|NCT03150836|Drug|Tremelimumab|Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
132737|NCT03151447|Radiation|stereotactic body radiation therapy|"In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks."
132738|NCT03151434|Procedure|US Guided Single Shot Paravertebral Block|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
132739|NCT03151434|Procedure|US Guided Paravertebral Catheter|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
132740|NCT03151434|Procedure|Thoracic Epidural|Epidural catheter will be placed in the thoracic region prior to surgery.
132741|NCT03151421|Behavioral|Home air quality monitoring and feedback|Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
132742|NCT03151408|Drug|Pracinostat|60 mg capsule
132743|NCT03151408|Drug|Placebos|capsule
132744|NCT03151408|Drug|Azacitidine|SC or IV injection
132745|NCT03151395|Other|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
132746|NCT03151382|Drug|Tandospirone Citrate|Tandospirone, 30-60 mg/d
132747|NCT03151382|Drug|Donepezil Hydrochloride|Donepezil, 10 mg/d
132748|NCT03151369|Drug|Morphine|patients with the visual analog scale over 3 will receive morphine
132749|NCT03151356|Device|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the [-2]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = [p2PSA /fPSA] x √tPSA
132750|NCT03151343|Drug|Empagliflozin|Empagliflozin tablet
132751|NCT03151343|Drug|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
132752|NCT03151330|Other|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
132753|NCT03151304|Drug|Pracinostat|45 mg capsule
132754|NCT03151304|Drug|Azacitidine|SC or IV injection
132755|NCT03151291|Dietary Supplement|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
132756|NCT03151291|Dietary Supplement|L-carnitine (LC)|daily intake of 4 g LC
132757|NCT03151291|Dietary Supplement|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
132758|NCT03151291|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
132759|NCT03151278|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
132760|NCT03151278|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
132761|NCT03151265|Device|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
132762|NCT03151252|Diagnostic Test|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
132763|NCT03151239|Dietary Supplement|NMN supplement|Intervention will last 8 weeks in the form of two capsules (250 mg total).
132764|NCT03151239|Other|Placebo|Intervention will last 8 weeks in the form of two capsules.
132765|NCT03151226|Device|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
132766|NCT03151213|Drug|Pregabalin 150mg|Pregabalin 150mg before RFA of liver cancer
132767|NCT03151213|Other|Placebo|Placebo before RFA of liver cancer
132768|NCT03151200|Device|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
132769|NCT03151200|Device|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
132770|NCT03151187|Other|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
132771|NCT03151174|Drug|Vitamin D 10000 UNT|10000 IU Vitamin D per day
132772|NCT03151174|Drug|Vitamin D 5000 UNT|5000 IU Vitamin D per day
132773|NCT03151161|Drug|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
132774|NCT03151161|Drug|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
132775|NCT03151148|Biological|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
132776|NCT03151148|Drug|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
132814|NCT03150836|Radiation|Radiation Therapy|In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
132993|NCT03149653|Drug|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
132777|NCT03151122|Behavioral|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.~After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
132778|NCT03151122|Procedure|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
132779|NCT03151109|Diagnostic Test|CT Scan|CT scan at minimum 1 year post op
132780|NCT03151096|Dietary Supplement|Riboflavin|one pill of Riboflavin will be taken orally with water
132781|NCT03151096|Dietary Supplement|Placebo|one pill of placebo will be taken orally with water
132782|NCT03151083|Behavioral|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
132783|NCT03151070|Other|QVLM Intervention package|"QVLM intervention package consists of 3 simultaneous interventions:~Social marketing to promote insitutional deliveries.~PRONTO training to public health personnel~Improve interaction with traditional birth attendants"
132784|NCT03151057|Drug|Idelalisib 100 MG|100mg BID beginning on day 90 (+/- 10days) and continuing until day 270 post transplant.
132785|NCT03151057|Drug|Placebo Oral Tablet|placebo
132786|NCT03151044|Drug|High-dose Epirubicin Combined with CVP ± Rituximab|Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
132787|NCT03151044|Drug|Standard-dose Epirubicin Combined with CVP ± Rituximab|Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
132788|NCT03151031|Procedure|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
132789|NCT03151018|Device|Resolute Onyx|
132790|NCT03151005|Drug|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
132791|NCT03151005|Drug|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
132792|NCT03150992|Dietary Supplement|Elemental 028 Extra Liquid|A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars & sweeteners.
132793|NCT03150979|Other|Provision of a cane|The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
132794|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
132795|NCT03150966|Drug|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
132796|NCT03150966|Drug|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
132797|NCT03150953|Device|MRI-safe bore covering|
132798|NCT03150940|Diagnostic Test|ECG|12 lead electrocardiogram used to demonstrate cardiac function
132799|NCT03150940|Diagnostic Test|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
132800|NCT03150927|Dietary Supplement|Probiotic Microbial Composite|125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
132801|NCT03150927|Dietary Supplement|Placebo|125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
132802|NCT03150914|Drug|Sirolimus|mTOR inhibitor or placebo
132803|NCT03150901|Diagnostic Test|no drug|laboratory tests
132804|NCT03150888|Drug|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
132805|NCT03150888|Other|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
132806|NCT03150875|Biological|IBI308|Anti-PD-1 therapy in Chinese non-squamous NSCLC patients will be investigated in this clinical trial.
132807|NCT03150875|Drug|Docetaxel|As 2nd line treatment to subjects with non-squamous NSCLC
132808|NCT03150862|Drug|BGB-290|BGB-290
132809|NCT03150862|Drug|TMZ|TMZ
132810|NCT03150862|Radiation|Radiation|Up to 60 Gy (total) over 6 - 7 weeks
132815|NCT03150823|Procedure|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
132816|NCT03150823|Procedure|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
132817|NCT03150823|Procedure|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
132818|NCT03150810|Drug|BGB-290|BGB-290
132819|NCT03150810|Drug|Temozolomide|TMZ
132820|NCT03150810|Drug|BGB-290|Dose/schedule selected based on dose escalation phase.
132821|NCT03150810|Drug|Temozolomide|Dose/schedule selected based on dose escalation phase.
132822|NCT03150797|Drug|Melatonin|Melatonin
132823|NCT03150797|Drug|Placebo oral capsule|Placebo
132824|NCT03150784|Other|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
132825|NCT03150771|Drug|Aripiprazole|Injection
132826|NCT03150758|Device|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
132827|NCT03150758|Device|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
132828|NCT03150758|Device|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
132829|NCT03150758|Device|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
132830|NCT03150745|Procedure|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
132831|NCT03150745|Procedure|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).~e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
132832|NCT03150745|Procedure|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
132833|NCT03150732|Drug|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
132834|NCT03150732|Drug|Local nalbuphine|Patients will receive local nalbuphine 10 mg
132835|NCT03150719|Drug|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
132836|NCT03150719|Drug|Ivacaftor|IVA 150 mg tablet.
132837|NCT03150719|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
132838|NCT03150719|Drug|Placebo|Placebo matched to IVA tablet.
132839|NCT03150706|Drug|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
132840|NCT03150693|Drug|Allopurinol|Given PO
132841|NCT03150693|Drug|Cytarabine|Given IT, IV, SC
132842|NCT03150693|Drug|Daunorubicin Hydrochloride|Given IV
132843|NCT03150693|Drug|Vincristine Sulfate|Given IV
132844|NCT03150693|Drug|Dexamethasone|Given PO or IV
132845|NCT03150693|Drug|Pegylated L-Asparaginase|Given IV
132846|NCT03150693|Drug|Methotrexate|Given IT, IV, PO
132847|NCT03150693|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
132848|NCT03150693|Drug|Cyclophosphamide|Given IV
132849|NCT03150693|Drug|Mercaptopurine|Given PO
132850|NCT03150693|Biological|Rituximab|Given IV
132851|NCT03150693|Drug|Doxorubicin|Given IV
132852|NCT03150693|Drug|Thioguanine|Given PO
132853|NCT03150693|Biological|Inotuzumab Ozogamicin|Given IV
132854|NCT03150693|Other|Laboratory Biomarker Analysis|Correlative studies
132855|NCT03150680|Genetic|SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins|Genotyping will be carried out by Next-Generation Sequencing (NGS)
132856|NCT03150667|Drug|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
132857|NCT03150667|Drug|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
132858|NCT03150654|Device|Laser pan-retinal photocoagulation|Green laser photocoagulator
132859|NCT03150641|Procedure|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
132860|NCT03150628|Drug|Perioperative chemotherapy|Perioperative chemotherapy
132861|NCT03150628|Procedure|Cytoreduction|Cytoreductive surgery
132863|NCT03150615|Other|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.~After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
132864|NCT03150615|Other|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.~After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
132865|NCT03150615|Device|nasojejunal tube insertion|
132866|NCT03150615|Other|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
132867|NCT03150602|Drug|Pralatrexate|This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
132868|NCT03150589|Drug|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
132869|NCT03150589|Drug|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
132870|NCT03150576|Drug|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
132871|NCT03150576|Drug|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
132872|NCT03150563|Other|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
132873|NCT03150550|Behavioral|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
132874|NCT03150550|Behavioral|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
132875|NCT03150537|Biological|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet H4 or IM injection
132876|NCT03150524|Diagnostic Test|TCD- cerebral blood flow velocities|Participants will undergo daily TCD for monitoring of cerebral blood flow.
132877|NCT03150524|Behavioral|Headache pain score|Participants will be evaluated by nurses for headache frequency and severity every shift.
132878|NCT03150524|Other|Neurological examination|Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
132879|NCT03150524|Diagnostic Test|Repeat Neuroimaging|All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
132880|NCT03150524|Drug|Nimodipine|Participants will be administered nimodipine every 4 hours.
132881|NCT03150524|Drug|Verapamil ER|Participants will be administered long acting verapamil every 12 hours.
132882|NCT03150511|Drug|Tesamorelin 2 Milligrams (MG)|Daily self-administered study drug
132883|NCT03150511|Drug|Placebo|Daily self-administered placebo
132884|NCT03150498|Drug|BTD-001|BTD-001 in fed vs fasted state
132885|NCT03150485|Device|JJVC Fitting Guides|Subjects who are habitual contact lens wearers with Presbyopic correction or Presbyopic symptoms, at least 40 years of age and no more than 70 years of age, will be fitted, according to the fitting guides, with either the Multifocal Contact Lens or an Toric Multifocal Contact Lens if refractive cylinder power of the eye is between -1.00 to -1.50. The Intervention is approximately 30-90 minutes of wear time during a 1-day visit.
132886|NCT03150472|Device|Graft Matrix|Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
132887|NCT03150459|Drug|Simvastatin 20 mg|Simvastatin 20 mg/day for 12 weeks (Group 1)
132888|NCT03150459|Drug|Simvastatin 40mg|Simvastatin 40 mg/day for 12 weeks (Group 2)
132889|NCT03150459|Drug|Rifaximin 400 mg|Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
132890|NCT03150459|Other|Placebo of Simvastatin|Placebo of Simvastatin for 12 weeks (Group 3)
132891|NCT03150459|Other|Placebo of Rifaximin|Placebo of Rifaximin for 12 weeks (Group 3)
132892|NCT03150446|Device|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
132893|NCT03150433|Behavioral|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
132894|NCT03150433|Other|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
132895|NCT03150420|Drug|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
132896|NCT03150420|Drug|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
132897|NCT03150394|Dietary Supplement|GASTRUS|Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
132898|NCT03150394|Other|PLACEBO|Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
132899|NCT03150381|Behavioral|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
132900|NCT03150381|Behavioral|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
132901|NCT03150381|Behavioral|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
132902|NCT03150368|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
132903|NCT03150355|Procedure|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
132904|NCT03150342|Diagnostic Test|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
132905|NCT03150329|Other|Laboratory Biomarker Analysis|Correlative studies
132906|NCT03150329|Biological|Pembrolizumab|Given IV
132907|NCT03150329|Drug|Vorinostat|Given PO
132908|NCT03150316|Drug|Treat Regimen|CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
132909|NCT03150290|Other|Indirect Calorimetry.|REE measurement
132910|NCT03150290|Device|18-FDG-PET|18-FDG-PET
132911|NCT03150277|Behavioral|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
132912|NCT03150277|Behavioral|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
132913|NCT03150264|Device|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
132914|NCT03150264|Device|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
132915|NCT03150251|Other|Cereal - oats|Consumption of one cereal in the beginning of each visit
132916|NCT03150251|Other|Cereal - cream of rice|Consumption of one cereal in the beginning of each visit
132917|NCT03150238|Other|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
132918|NCT03150225|Other|Concurrent training|"In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.~The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session."
132919|NCT03150225|Dietary Supplement|Eurycoma longifolia|Eurycoma longifolia will be administered by supplementation with the standard aqueous-soluble extract extract (Physta ™) in single 200mg capsules daily, and placebo by starch capsules. The supplementatio will last six months.
132920|NCT03150212|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
132921|NCT03150212|Dietary Supplement|Placebo|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
132922|NCT03150199|Behavioral|Positive Psychology + Motivational Interviewing|Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instruments and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 8 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered step-wise within sessions (rather than intertwined).
132923|NCT03150199|Behavioral|MI-based Health Education Intervention|Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments. Motivational interviewing topics (e.g., pros and cons of behavior change, importance and confidence of behavior change, identification of barriers and resources to change) will be presented related to each health behavior.
132924|NCT03150186|Other|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
132994|NCT03149653|Drug|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
132995|NCT03149653|Drug|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
132925|NCT03150186|Other|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
132926|NCT03150186|Other|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
132927|NCT03150173|Behavioral|Onsite treatment|Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
132928|NCT03150173|Behavioral|Enhanced referral|Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
132929|NCT03150173|Drug|Buprenorphine|all participants will receive buprenorphine
132930|NCT03150160|Drug|brinzolamide 1%/brimonidine 0.2% fixed combination|One drop applied topically to the affected eye(s) in the morning and evening
132931|NCT03150160|Drug|Placebo|One drop applied topically to the affected eye(s) in the morning and evening
132932|NCT03150160|Drug|travoprost 0.004% ophthalmic solution|One drop applied topically to the affected eye(s) in the evening
132933|NCT03150147|Other|Non-ischemic preservation|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
132934|NCT03150147|Other|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
132935|NCT03150134|Drug|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
132936|NCT03150134|Drug|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
132937|NCT03150121|Procedure|Uterine lavage|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
132938|NCT03150121|Procedure|Blood sample|5-10mL of blood will be drawn from participants.
132939|NCT03150121|Device|Uterine lavage catheter|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
132940|NCT03150108|Drug|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
132941|NCT03150108|Drug|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
132942|NCT03150108|Drug|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
132943|NCT03150095|Behavioral|Health coaching|Patients will work with a health coach by telephone
132944|NCT03150082|Drug|GR37547 tablet|"A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side."
132945|NCT03150082|Drug|Ciprofloxacin reference tablet|"A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side."
132946|NCT03150069|Other|Interview|In-person or telephone in-depth interview
132947|NCT03150056|Drug|GSK525762|GSK525762 will be available as 5 milligram (mg) and 25 mg white to slightly colored, round, biconvex with no markings, film-coated tablet and will be administered with 240 milliliter (mL) water. The 20 mg tablet formulation is in development and will be used when available.
132948|NCT03150056|Drug|Abiraterone|Abiraterone will be available as 250 mg white to off-white, oval tablets debossed with AA250 on one side. It will be administered with 240 mL water.
132949|NCT03150056|Drug|Enzalutamide|Enzalutamide will be available as 40 mg white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ. It will be administered with 240 mL water.
132950|NCT03150056|Drug|Prednisone|5 mg prednisone will be administered as a concomitant medication in combination with abiraterone
132951|NCT03150043|Device|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
132952|NCT03150030|Other|Combined hyper- and hypoglycaemic clamp|During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
132953|NCT03150030|Device|Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)|Implantation of a loop-recorder
132954|NCT03150030|Device|Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)|Monitoring with a continuous glucose monitor
132955|NCT03150017|Other|SPIRE|Online pain management programme.
132956|NCT03150004|Drug|CLAG-M regimen|"Patients will be started on CLAG-M regimen, which consists of the following:~Cladribine 5mg/m2 IV over two hours on days 1-5;~Cytarabine 2 gm/m2 IV over four hours on days 1-5, starting two hours after the Cladribine infusion is complete;~Mitoxantrone 10mg/m2 IV on days 1-3;~G-CSF at a dose of 300 μg on days 0-5."
132957|NCT03149991|Drug|Brexpiprazole|Administration of up to 3mg brexpiprazole
132958|NCT03149991|Drug|Ketamine|administration 6 times over two weeks of inhaled ketamine
132959|NCT03149991|Drug|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
132960|NCT03149965|Other|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
132961|NCT03149952|Other|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
132962|NCT03149939|Drug|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
132963|NCT03149926|Other|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
132964|NCT03149913|Device|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
132965|NCT03149913|Device|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
132966|NCT03149900|Drug|Secukinumab|See Arm Description
132967|NCT03149887|Drug|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
132968|NCT03149887|Drug|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
132969|NCT03149874|Drug|Hepatitis B Vaccines|either Hepatitis B recombinant DNA vaccine or Combined hepatitis A and B vaccine given to the patients
132970|NCT03149861|Procedure|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS >=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
132971|NCT03149861|Procedure|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
132972|NCT03149848|Drug|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
132973|NCT03149848|Drug|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
132974|NCT03149835|Other|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
132975|NCT03149822|Drug|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
132976|NCT03149822|Drug|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
132977|NCT03149809|Drug|solifenacin|Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
132978|NCT03149809|Behavioral|Pelvic floor muscle exercise-based behavioral therapy|Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
132979|NCT03149796|Other|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
132980|NCT03149783|Drug|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
132981|NCT03149783|Drug|sodium chloride|Placebo
132982|NCT03149770|Drug|Naloxone|naloxone vs placebo
132983|NCT03149770|Drug|Placebo|placebo vs naloxone
132984|NCT03149757|Behavioral|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring."
132985|NCT03149757|Behavioral|Information-only Control|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
132986|NCT03149744|Device|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
132987|NCT03149731|Device|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
132988|NCT03149718|Behavioral|Brief Intervention Medication Therapy Management|BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
132989|NCT03149718|Behavioral|Standard Medication Counseling (SMC)|Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
132990|NCT03149692|Other|Penile allograft transplantation|Proof of concept of surgical procedure
132996|NCT03149653|Drug|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
132997|NCT03149653|Drug|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
132998|NCT03149640|Drug|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
132999|NCT03149640|Drug|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
133000|NCT03149627|Other|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
133001|NCT03149614|Other|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
133002|NCT03149614|Other|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
133003|NCT03149588|Drug|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
133004|NCT03149588|Drug|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
133005|NCT03149575|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
133006|NCT03149575|Drug|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.~Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.~Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
133007|NCT03149575|Drug|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.~The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
133008|NCT03149575|Drug|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.~As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
133009|NCT03149562|Drug|plasma transfusions|These critical ill neonates with plasma transfusions
133010|NCT03149562|Drug|non-plasma transfusions|These critical ill neonates without plasma transfusions
133011|NCT03149549|Drug|CX-2009|CX-2009 Monotherapy
133012|NCT03149536|Diagnostic Test|Pharmacogenetic test|To develop a pharmacogenetic prediction test
133013|NCT03149510|Behavioral|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
133014|NCT03149497|Procedure|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
133015|NCT03149484|Device|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
133016|NCT03149484|Other|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
133017|NCT03149471|Diagnostic Test|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
133018|NCT03149458|Other|dance|dance program
133019|NCT03149458|Other|control|upper limb rehabilitation
133020|NCT03149445|Drug|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
133021|NCT03149445|Drug|Placebos|Study medication will be administered for 91 days.
133022|NCT03149432|Procedure|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
133023|NCT03149432|Drug|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
133024|NCT03149432|Procedure|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
133025|NCT03149432|Other|Local care|local care for directed healing of the stump.
133026|NCT03149419|Drug|Paroxetine|
133027|NCT03149419|Drug|Placebo oral capsule|
133028|NCT03149406|Other|Comparing the expression of miRNAs|by PCR, in symptomatic and asymptomatic carotid plaques.
133029|NCT03149393|Drug|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
133030|NCT03149393|Drug|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
133031|NCT03149380|Behavioral|Web-based education|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
133032|NCT03149367|Procedure|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
133033|NCT03149367|Procedure|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
133034|NCT03149354|Other|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
133035|NCT03149341|Other|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
133036|NCT03149328|Other|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
133037|NCT03149315|Drug|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
133038|NCT03149302|Other|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
133039|NCT03149302|Other|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
133040|NCT03149302|Other|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
133041|NCT03149302|Other|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
133042|NCT03149289|Drug|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
133043|NCT03149276|Other|Interpreter services|
133044|NCT03149263|Behavioral|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
133045|NCT03149250|Diagnostic Test|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
133046|NCT03149237|Behavioral|Couples-based services|Couples-based services, including treatment, counseling and peer mentoring in the community.
133047|NCT03149211|Drug|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
133048|NCT03149211|Drug|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
133049|NCT03149198|Other|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
133050|NCT03149198|Other|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.~The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
133051|NCT03149185|Behavioral|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
133052|NCT03149185|Behavioral|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
133053|NCT03149172|Device|Equimatrix®|Ridge preservation bone grafting after tooth extraction
133054|NCT03149172|Device|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
133055|NCT03149172|Device|Endobon®|Ridge preservation bone grafting after tooth extraction
133056|NCT03149159|Drug|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
133057|NCT03149159|Drug|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
133058|NCT03149159|Radiation|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
133059|NCT03149146|Other|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
133060|NCT03149146|Other|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
133061|NCT03149133|Other|Heavy hypertrophy training|Training with 75-80 % of 1-RM
133062|NCT03149133|Other|Light hypertrophy training|Training with 35-50 % of 1-RM
133063|NCT03149120|Biological|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
133064|NCT03149120|Drug|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
133065|NCT03149107|Drug|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
133066|NCT03149107|Drug|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
133067|NCT03149107|Behavioral|IPPI (Integrated Preventive Psychological Intervention)|IPPI (Integrated Preventive Psychological Intervention): 21 sessions, the first 20 sessions are scheduled weekly, the last session two weeks after session 20. Single blinded (statistician & rater)
133068|NCT03149107|Behavioral|PSM (Psychological stress management)|PSM (Psychological stress management): 11 sessions; the first 10 sessions will be offered biweekly, the last one 2 weeks after session 10. Single blinded (statistician & rater).
133069|NCT03149094|Behavioral|CBSM-SMI|The intervention group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
133070|NCT03149094|Behavioral|CBSM-SMI control|this group will receive the LifeSum app.
133071|NCT03149081|Drug|Boswellia|Boswellia is an extract from frankinscense
133072|NCT03149055|Drug|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
133073|NCT03149042|Diagnostic Test|CTAC Coronary|Diagnostic Test
133074|NCT03149029|Drug|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
133075|NCT03149029|Drug|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
133076|NCT03149029|Drug|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
133077|NCT03149016|Procedure|Corticotomy-assisted Retraction|Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
133078|NCT03149003|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
133079|NCT03149003|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
133080|NCT03148990|Biological|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
133081|NCT03148990|Biological|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
133082|NCT03148977|Procedure|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
133083|NCT03148964|Biological|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M18, M24 and every 6 months until the end of the study
133084|NCT03148938|Other|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:~walking test~coordination test~attention test~vision test"
133085|NCT03148925|Biological|SELA-070|Sub-cutaneous injection, multiple dose
133086|NCT03148925|Biological|Saline|Sub-cutaneous injection, multiple dose
133087|NCT03148912|Diagnostic Test|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
133088|NCT03148899|Drug|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
133089|NCT03148899|Drug|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
133090|NCT03148886|Other|PA intervention|"The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.~Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.~A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study."
133091|NCT03148873|Device|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
133092|NCT03148860|Drug|Methotrexate|subjects will receive once weekly 15 mg (3 capsules) MTX
133093|NCT03148860|Drug|Ustekinumab|subject will receive Ustekinumab open-label over a treatment period of 52 weeks
133094|NCT03148860|Other|Placebo|subjects will receive once weekly 3 capsules PLC to MTX
133095|NCT03148847|Other|Baseline care|
133096|NCT03148847|Other|Referential's dissemination|
133097|NCT03148834|Procedure|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
133098|NCT03148808|Combination Product|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
133099|NCT03148795|Drug|Talazoparib|1 mg daily
133100|NCT03148782|Behavioral|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
133101|NCT03148756|Drug|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
133102|NCT03148756|Drug|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.
133103|NCT03148743|Biological|Fecal microbiota|fecal microbiota transplantation
133104|NCT03148730|Device|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
133105|NCT03148717|Drug|Misoprostol|Cytotec
133106|NCT03148717|Other|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
133107|NCT03148704|Drug|palonosetron hydrochloride capsules|Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
133108|NCT03148691|Drug|A-101|Topical Solution
133109|NCT03148678|Behavioral|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
133110|NCT03148678|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
133111|NCT03148678|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
133112|NCT03148678|Behavioral|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
133113|NCT03148665|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
133114|NCT03148652|Other|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
133115|NCT03148639|Behavioral|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
133116|NCT03148639|Other|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
133117|NCT03148626|Other|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
133118|NCT03148626|Other|Control|Usual Education
133119|NCT03148600|Behavioral|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
133120|NCT03148600|Other|Standard arm|Standard medical and nursing care
133121|NCT03148587|Behavioral|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
133122|NCT03148587|Behavioral|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
133123|NCT03148574|Drug|Misoprostol|intrauterine tablets
133124|NCT03148574|Drug|Oxytocin|intravenous
133125|NCT03148561|Drug|misoprostol|It will receive misopristol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
133126|NCT03148548|Genetic|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;
133127|NCT03148535|Drug|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
133128|NCT03148535|Drug|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
133129|NCT03148522|Drug|Escitalopram|receive escitalopram
133130|NCT03148522|Drug|Duloxetine|receive duloxetine
133131|NCT03148522|Drug|Mirtazapine|receive mirtazapine
133132|NCT03148509|Drug|risperidone|DA receptor-mediated drugs
133133|NCT03148509|Drug|aripiprazole|DA receptor-mediated drugs
133134|NCT03148509|Drug|bupropion|DA receptor-mediated drugs
133135|NCT03148496|Device|Biologic Mesh|Biologic mesh placed during surgery
133136|NCT03148496|Procedure|Small Bytes|0.5 cm x 0.5 cm sutures used
133137|NCT03148496|Procedure|Large Bytes|1.0 x 1.0 sutures used
133138|NCT03148483|Other|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
133139|NCT03148483|Other|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
133140|NCT03148483|Dietary Supplement|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
133141|NCT03148483|Dietary Supplement|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
133142|NCT03148470|Device|Sham iTBS|Placebo stimulation
133143|NCT03148470|Device|Sham cTBS|Placebo stimulation
133144|NCT03148470|Device|intermittent theta burst stimulation (iTBS)|Excitatory rTMS
133145|NCT03148470|Device|continuous theta burst stimulation (cTBS)|inhibitory rTMS
133146|NCT03148457|Drug|Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)
133147|NCT03148457|Drug|Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
133148|NCT03148444|Drug|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
133149|NCT03148431|Drug|LY3002815|Administered IV
133150|NCT03148431|Drug|Placebo|Administered IV
133151|NCT03148418|Drug|Atezolizumab|Atezolizumab will be administered as monotherapy or combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study). Dosing regimen will be in accordance with the parent study and local prescribing information.
133152|NCT03148379|Device|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
133153|NCT03148379|Device|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
133154|NCT03148366|Drug|Levofloxacin based sequential therapy|D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
133155|NCT03148366|Drug|bismuth quadruple therapy for 10 days (BQ)|D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
133156|NCT03148353|Procedure|Subacromial injection|"Modified ultrasound guided corticosteroid subacromial injection~Standardized ultrasound guided corticosteroid subacromial injection"
133157|NCT03148340|Diagnostic Test|VIPS Monitoring|Bioimpedance asymmetry
133158|NCT03148327|Drug|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
133159|NCT03148327|Radiation|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
133160|NCT03148314|Drug|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
133161|NCT03148314|Drug|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
133162|NCT03148301|Other|Survey|Survey
133163|NCT03148288|Dietary Supplement|Vitamin D|VItamin D
133164|NCT03148288|Dietary Supplement|placebo|placebo
133165|NCT03148275|Other|Questionnaire Administration|Ancillary studies
133166|NCT03148275|Drug|Trametinib|Given PO
133167|NCT03148262|Device|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
133168|NCT03148262|Device|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
133169|NCT03148249|Other|interview|control group: interview, study group: explanation and exploration
133170|NCT03148236|Drug|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
133171|NCT03148236|Other|Placebo|50mL infused over 30 minutes
133172|NCT03148223|Device|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
133173|NCT03148210|Drug|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
133174|NCT03148210|Behavioral|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
133175|NCT03148210|Behavioral|Participant Education|Standardized education for asthma or COPD disease
133176|NCT03148184|Diagnostic Test|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
133177|NCT03148171|Other|WERK Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
133178|NCT03148158|Device|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
133179|NCT03148145|Behavioral|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
133180|NCT03148145|Behavioral|Message Delivery by Smartphone|Message Delivery by Smartphone
133181|NCT03148132|Drug|Bevacizumab Injection|0.5mg/0.02 mL
133182|NCT03148132|Drug|Ranibizumab Ophthalmic|0.25mg/0.025 mL
133512|NCT03145272|Drug|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
133183|NCT03148119|Drug|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a 5 amino acid linker [Gly-Gly-Gly-Ser-Lys] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
133184|NCT03148119|Device|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
133185|NCT03148106|Device|Somatosensory Electrical Stimulation|We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
133186|NCT03148080|Procedure|Cognitive Assessment|Complete CogState
133187|NCT03148080|Other|Questionnaire Administration|Complete Self-Report Questionnaire
133188|NCT03148067|Procedure|Intramedullary nailing for fracture fixation|
133189|NCT03148054|Device|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).~Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
133190|NCT03148041|Other|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.~2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.~The routine care for control group: different lecture and brochures will be used"
133191|NCT03148015|Other|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
133192|NCT03148002|Drug|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
133193|NCT03148002|Drug|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
133194|NCT03147989|Drug|MultiHance|gadolinium contrast agent
133195|NCT03147976|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
133196|NCT03147963|Drug|Docetaxel|Docetaxel will be given until progression or patient intolerance
133197|NCT03147950|Procedure|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
133198|NCT03147950|Procedure|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
133199|NCT03147937|Other|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
133200|NCT03147924|Other|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
133201|NCT03147885|Drug|Selinexor|Given PO
133202|NCT03147872|Other|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
133203|NCT03147859|Biological|Vedolizumab (brand name Entyvio)|IV infusion
133204|NCT03147846|Procedure|delayed cord clamping|delay of cord clamping for 60 seconds
133205|NCT03147846|Procedure|cord milking|active cord milking 5 times
133206|NCT03147833|Dietary Supplement|Sport beverages Protein|Beverage ingested before each night sleep during the intervention
133207|NCT03147833|Dietary Supplement|Sport beverages Carbohydrate|Beverage ingested before each night sleep during the intervention
133208|NCT03147807|Device|betaLACTA® rapid diagnostic test|Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
133209|NCT03147794|Device|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
133513|NCT03145259|Drug|Diclofenac Epolamine Patch|patch
133514|NCT03145259|Drug|diclofenac sodium solution|solution
133210|NCT03147781|Device|True AT with magnetic pellets|Magnetic pellets are affixed onto pre-selected auricular acupoints with tape.The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
133211|NCT03147781|Device|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment was initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
133212|NCT03147768|Device|Distal Pancreatectomy Sealing Using LTW|The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
133213|NCT03147755|Other|No intervention|No intervention
133214|NCT03147742|Drug|Ruxolitinib|Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
133215|NCT03147729|Radiation|Radiofrequency non ablation|Use of radiofrequency
133216|NCT03147716|Other|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
133217|NCT03147716|Other|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
133218|NCT03147716|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
133219|NCT03147716|Other|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
133220|NCT03147703|Behavioral|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
133221|NCT03147690|Drug|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The will be given twice during the intervention, for a total maximum dose per subject of 4.8mL.
133222|NCT03147677|Drug|Alfacalcidol|
133223|NCT03147677|Drug|Irbesartan|
133224|NCT03147638|Drug|Warfarin, NOAC|duration of treatment
133225|NCT03147625|Behavioral|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
133226|NCT03147612|Biological|Blinatumomab|Given via central catheter
133227|NCT03147612|Drug|Cyclophosphamide|Given IV
133228|NCT03147612|Drug|Cytarabine|Given intrathecally or IV
133229|NCT03147612|Biological|Filgrastim|Given SC
133230|NCT03147612|Drug|Methotrexate|Given intrathecally or IV
133231|NCT03147612|Biological|Pegfilgrastim|Given SC
133232|NCT03147612|Drug|Ponatinib|Given PO
133233|NCT03147612|Biological|Rituximab|Given IV
133234|NCT03147612|Drug|Vincristine|Given IV
133235|NCT03147599|Drug|Coloverin|Mebeverine hydrochloride 135 mg
133236|NCT03147599|Drug|Placebo|Placebo
133237|NCT03147586|Drug|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
133238|NCT03147586|Drug|placebo|placebo
133239|NCT03147573|Diagnostic Test|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
133240|NCT03147573|Diagnostic Test|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
133241|NCT03147573|Diagnostic Test|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
133242|NCT03147573|Diagnostic Test|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
133243|NCT03147560|Biological|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
133244|NCT03147560|Biological|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
133245|NCT03147560|Biological|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine at 2, 3 and 4 months of age, get 2 blood samples (1.5ml per sample) before the first dose and 28-35 days after the last dose. sIPV was given 0.5ml per dose and bOPV was given 0.1ml per dose.
133246|NCT03147547|Other|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
133515|NCT03145246|Procedure|regeneration treated teeth loss|number of regeneration treated teeth loss
133247|NCT03147547|Other|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
133248|NCT03147547|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
133249|NCT03147547|Other|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
133250|NCT03147534|Device|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
133251|NCT03147534|Device|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
133252|NCT03147534|Device|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
133253|NCT03147534|Device|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
133254|NCT03147521|Other|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
133255|NCT03147495|Other|no intervention|The proximal tibiofibular joint radiographs will be taken for the participants in both groups.
133256|NCT03147469|Procedure|Flexion|After changing the position of head and neck of subjects to flexion, the variables were measured.
133257|NCT03147469|Procedure|Extension|After changing the position of head and neck of subjects to extension, the variables were measured.
133258|NCT03147469|Procedure|Right rotation|After changing the position of head and neck of subjects to right flexion, the variables were measured.
133259|NCT03147456|Dietary Supplement|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
133260|NCT03147456|Dietary Supplement|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
133261|NCT03147443|Drug|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
133262|NCT03147443|Drug|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
133263|NCT03147443|Drug|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
133264|NCT03147430|Other|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
133265|NCT03147404|Drug|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
133266|NCT03147391|Device|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
133267|NCT03147378|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
133268|NCT03147365|Behavioral|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
133269|NCT03147365|Behavioral|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
133270|NCT03147352|Device|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
133271|NCT03147339|Other|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
133272|NCT03147326|Diagnostic Test|FDG-PET-CT|scanning method
133273|NCT03147326|Diagnostic Test|NaF-PET-CT|scanning method
133274|NCT03147326|Diagnostic Test|Whole-body MRI|scanning method
133275|NCT03147313|Device|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
133276|NCT03147313|Device|Sham|Extracorporeal shock wave treatment will be faked.
133277|NCT03147300|Behavioral|Current routine practice|Current routine practice for the primary care management of LBP
133472|NCT03145584|Drug|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
133278|NCT03147300|Behavioral|Multifaceted implementation of the BetterBack|"The multifaceted intervention is composed of the following:~Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians."
133279|NCT03147287|Drug|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
133280|NCT03147287|Drug|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
133281|NCT03147287|Drug|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
133282|NCT03147274|Behavioral|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
133283|NCT03147261|Other|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
133284|NCT03147248|Biological|Infliximab|
133285|NCT03147235|Behavioral|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
133286|NCT03147222|Behavioral|Fracture Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
133287|NCT03147209|Behavioral|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
133288|NCT03147196|Drug|Bicalutamide|Given PO
133289|NCT03147196|Other|Laboratory Biomarker Analysis|Correlative studies
133290|NCT03147196|Other|Questionnaire Administration|Ancillary studies
133291|NCT03147196|Drug|Raloxifene Hydrochloride|Given PO
133292|NCT03147183|Drug|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
133293|NCT03147170|Diagnostic Test|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
133294|NCT03147157|Other|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
133295|NCT03147144|Other|Ultrasonographic imaging|Ultrasound pelvic scan
133296|NCT03147131|Procedure|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
133297|NCT03147118|Diagnostic Test|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
133298|NCT03147105|Behavioral|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
133299|NCT03147092|Drug|Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Treatment of hypertensive subjects
133300|NCT03147092|Drug|Atenolol|Treatment of hypertensive subjects
133301|NCT03147092|Drug|Losartan potassium 50mg|Treatment of hypertensive subjects
133302|NCT03147092|Drug|Clonidine|Treatment of hypertensive subjects
133303|NCT03147079|Behavioral|Lifestyle intervention|
133304|NCT03147066|Drug|Dezocine|Dezocine (0.1 mg/kg）will be infused during surgery
133305|NCT03147066|Drug|Flurbiprofen Axetil|Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
133306|NCT03147053|Drug|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
133307|NCT03147053|Drug|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
133308|NCT03147040|Drug|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
133309|NCT03147040|Drug|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
133310|NCT03147027|Procedure|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
133311|NCT03147027|Other|medication|medication to prevent sustained VT and ICD therapies
133312|NCT03147014|Biological|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
133313|NCT03147001|Other|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
133314|NCT03147001|Other|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
133315|NCT03146988|Drug|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
133316|NCT03146975|Procedure|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
133317|NCT03146962|Drug|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B).
133318|NCT03146949|Device|Sorin Inspire Oxygenator|This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
133319|NCT03146949|Device|Medtronic Affinity Fusion|This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
133320|NCT03146923|Other|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides <15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition & Dietetic Institute (INDI) in 2010 and includes following main components:~Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~Restricting dairy intake (1-1.5 portions per day)~Avoiding foods high in phosphate~Avoiding foods with phosphate additives"
133321|NCT03146923|Other|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~Increased focus on avoiding additives~Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~Avoiding over-prescription of protein which carries an obligatory phosphorus load.~Focus on high protein foods with a low phosphorus to protein ratio"
133322|NCT03146897|Dietary Supplement|Supplementary Food|Supplementary food for treating MAM
133323|NCT03146871|Drug|Azacitidine|Given IV or SC
133324|NCT03146871|Drug|Decitabine|Given IV
133325|NCT03146871|Other|Laboratory Biomarker Analysis|Correlative studies
133326|NCT03146871|Other|Pharmacological Study|Correlative studies
133327|NCT03146871|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
133328|NCT03146858|Drug|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
133329|NCT03146845|Device|Allevyn Life Non-Bordered|Foam Dressing
133330|NCT03146845|Device|Standard Care|Foam Dressing
133331|NCT03146832|Behavioral|Exposure therapy (according to habituation approach)|Exposure instruction focuses on fear reduction during exposure sessions
133332|NCT03146832|Behavioral|Exposure therapy (according to inhibitory learning approach)|Exposure instruction focuses on expectation violation during exposure sessions
133333|NCT03146819|Device|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
133334|NCT03146819|Device|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
133335|NCT03146806|Drug|Intranasal ketamine|"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.~On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.~On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.~All doses of ketamine will be administered by an anesthesia research nurse."
133336|NCT03146793|Drug|Sodium Thiosulfate|25g intravenously 3 times per week
133337|NCT03146780|Procedure|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
133338|NCT03146780|Procedure|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
133339|NCT03146780|Procedure|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
133340|NCT03146780|Procedure|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
133341|NCT03146767|Device|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
133342|NCT03146754|Other|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines (2 phases)
133343|NCT03146741|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
133344|NCT03146728|Other|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
133345|NCT03146715|Other|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
133346|NCT03146702|Other|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
133347|NCT03146689|Drug|Topical NSAID|Applied four times daily
133348|NCT03146689|Drug|Topical Capsaicin|Applied four times daily
133349|NCT03146663|Drug|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
133350|NCT03146663|Drug|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
133351|NCT03146650|Biological|Ipilimumab|Given IV
133352|NCT03146650|Other|Laboratory Biomarker Analysis|Correlative studies
133353|NCT03146650|Biological|Nivolumab|Given IV
133354|NCT03146637|Biological|Activated CIK and bispecific antibody|CIK cells was activated by inhibitor and bispecific antibody of anti-CD3/MUC1/CEA/EpCAM/GPC3
133355|NCT03146637|Biological|Activated CIK|CIK cells was activated
133356|NCT03146624|Other|attachment retained obturator|obturator which retained by attachment
133357|NCT03146624|Other|clasp retained obturator|obturator which retained by clasp
133358|NCT03146611|Diagnostic Test|nCD64|neutrophil CD64
133359|NCT03146611|Diagnostic Test|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
133360|NCT03146598|Other|No intervention as it is a observational study|No intervention as it is a observational study
133361|NCT03146585|Device|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
134774|NCT03135431|Procedure|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
133362|NCT03146572|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
133363|NCT03146572|Other|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
133364|NCT03146559|Device|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
133365|NCT03146559|Device|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
133366|NCT03146533|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
133367|NCT03146533|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
133368|NCT03146533|Biological|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
133369|NCT03146520|Device|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
133370|NCT03146481|Drug|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
133371|NCT03146481|Other|Placebo|Placebo tablet given one hour before starting the root canal treatment
133372|NCT03146468|Drug|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
133373|NCT03146455|Other|no intervention|no intervention
133374|NCT03146442|Behavioral|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
133375|NCT03146429|Diagnostic Test|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
133376|NCT03146416|Drug|Evinacumab|SC or IV administration of Evinacumab
133377|NCT03146416|Drug|Placebo|Matching placebo
133378|NCT03146403|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
133379|NCT03146403|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
133380|NCT03146403|Other|0.9% normal saline|Placebo
133381|NCT03146390|Drug|Essential oils|all subjects will perform all interventions of all arms
133382|NCT03146390|Drug|Alcohol free essential oils|all subjects will perform all interventions of all arms
133383|NCT03146390|Other|Water|all subjects will perform all interventions of all arms
133384|NCT03146377|Drug|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
133385|NCT03146377|Drug|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
133386|NCT03146377|Drug|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
133387|NCT03146364|Device|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
133388|NCT03146351|Other|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
133389|NCT03146338|Other|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
133390|NCT03146325|Drug|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
133391|NCT03146325|Drug|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
133392|NCT03146312|Dietary Supplement|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
133393|NCT03146312|Dietary Supplement|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
133394|NCT03146299|Procedure|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more~LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
133395|NCT03146286|Dietary Supplement|Saturated fat|Palm stearin
133396|NCT03146286|Dietary Supplement|Placebo|Water
133397|NCT03146286|Dietary Supplement|Fish Oil|Fish Oil, Omega 3 PUFA
133398|NCT03146273|Dietary Supplement|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium~After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
133399|NCT03146260|Procedure|Conventional TESE|usual procedure for sperm extraction
133400|NCT03146260|Procedure|Microdissection TESE|Procedure of extraction is performed under the operating microscope
133401|NCT03146247|Drug|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
133402|NCT03146234|Genetic|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.~Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
133403|NCT03146221|Other|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
133404|NCT03146195|Other|Dynamic Magnetic resonance imaging|
133405|NCT03146182|Behavioral|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
133406|NCT03146182|Behavioral|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
133473|NCT03145584|Other|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
135435|NCT03130205|Radiation|18F-FDG-PET|18F Fluorodeoxyglucose Positron emission tomography
133407|NCT03146169|Behavioral|Training group|"The training workshop includes four two-hour sessions:~Session one - a knowledge, self-efficacy, and motivation enhancement session at baseline; Session two - an interpersonal communication and leadership skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing session at three months"
133408|NCT03146156|Behavioral|Lifestyle Intervention|The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
133409|NCT03146143|Procedure|ultrafiltration|ultrafiltration after cardiopulmonary bypass
133410|NCT03146130|Biological|Variation of behaviors of Parkinson's disease|Variation of hyper dopaminergic behaviors of Parkinson's disease
133411|NCT03146104|Drug|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
133412|NCT03146104|Drug|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
133413|NCT03146091|Other|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
133414|NCT03146091|Other|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
133415|NCT03146065|Biological|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
133416|NCT03146065|Drug|Placebo|Comparison of Placebo to different doses of PF-06730512
133417|NCT03146052|Drug|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
133418|NCT03146039|Radiation|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
133419|NCT03146026|Behavioral|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
133420|NCT03146013|Diagnostic Test|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
133421|NCT03146000|Drug|lidocaine-prilocaine cream|topical cream
133422|NCT03146000|Drug|meloxicam rectal suppository|suppository
133423|NCT03145987|Dietary Supplement|Vitis vinifera extract|
133424|NCT03145987|Other|Placebo|
133425|NCT03145974|Device|mechanical ventilation|ventilatory support
133426|NCT03145961|Drug|Pembrolizumab|200mg intravenous infusion
133427|NCT03145948|Drug|ABBV-553|It is administered orally.
133428|NCT03145948|Drug|Placebo|It is administered orally.
133429|NCT03145935|Diagnostic Test|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
133430|NCT03145935|Diagnostic Test|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
133431|NCT03145922|Other|Observational Study|Observational study utilizing bronchoscopy, and imaging
133432|NCT03145909|Drug|ABBV-176|Intravenous infusion
133433|NCT03145896|Dietary Supplement|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
133434|NCT03145883|Other|Home-Based Aerobic Exercise|
133435|NCT03145870|Other|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
133436|NCT03145857|Drug|[68]Ga-HA-DOTATATE|All participants will be injected with [68]Ga-HA-DOTATATE approximately 60 minutes before PET/CT or PET/MRI scan.
133437|NCT03145831|Drug|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
133438|NCT03145818|Other|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
133439|NCT03145792|Behavioral|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
133440|NCT03145792|Behavioral|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
133441|NCT03145766|Biological|VRVg 2|Modified formulation 1 of Purified Vero Rabies Vaccine Serum Free
133442|NCT03145766|Biological|VRVg 1|Initial formulation of Purified Vero Rabies Vaccine Serum Free
133443|NCT03145766|Biological|Imovax Rabies|Purified inactivated rabies vaccine prepared on human diploid cell cultures
133444|NCT03145766|Biological|VRVg 2|Modified formulation 2 of Purified Vero Rabies Vaccine Serum Free
133445|NCT03145766|Biological|VRVg 2|Modified formulation 3 of Purified Vero Rabies Vaccine Serum Free
133446|NCT03145753|Other|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
133447|NCT03145753|Other|HIV/HCV Education|Only education and support will be provided in this arm
133448|NCT03145740|Other|Intensive F.O.T.T.®|Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
133449|NCT03145740|Other|Unspecific Stimulation of face and mouth|The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
133450|NCT03145727|Device|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
133451|NCT03145727|Device|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
133452|NCT03145727|Device|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
133453|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
133454|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
133455|NCT03145688|Behavioral|Family Physical Activity Planning|"Families will receive the same guidelines as the standard education control group but will also be provided with family physical activity planning material. This material will include a skill training content workbook on how to plan for family physical activity. The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We will provide this material as prompts/suggestions. Families will be instructed to plan for when, where, how, and what physical activity will be performed & then track their physical activity. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions"
133456|NCT03145688|Behavioral|Family Physical Activity Habit Formation|Families will receive the same content as the education control condition and the physical activity planning condition but with additional material on creating physical activity support habits. A key component of the habit section will be based on planning for context-dependent repetition, with pointers on how to maintain repetition as habit forms. The importance of creating cues for parental support of child physical activity is then outlined. Cues will also be considered factors that a) can precede the support activity but b) not be present very often when the activity is not to be performed. We will suggest that cues that have repeated exposure during times when family physical activity is not present Parents will then be asked to brainstorm and create a plan of consistency and cues with the workbooks provided. These aspects will be re-introduced and discussed at week 6 and week 12 in booster sessions.
133457|NCT03145675|Drug|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5+0.25 mg/kg administered intravenously.
133458|NCT03145675|Drug|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg administered intravenously.
133459|NCT03145675|Drug|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg administered intravenously.
133460|NCT03145675|Drug|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg administered intravenously.
133461|NCT03145662|Device|high pressure balloon|high pressure balloon will be used to treat stenosis
133462|NCT03145662|Device|cutting balloon|cutting balloon will be used to treat stenosis
133463|NCT03145649|Other|Dietary therapy or insulin injection|
133464|NCT03145636|Device|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
133465|NCT03145636|Other|vBloc Achieve Weight Management Program|Remotely accessible web-based program to add additional support to subjects with vBloc therapy
133466|NCT03145636|Other|Control Weight Management (CWM) program|In person visits with Registered Dietician, or trained staff who will counsel subjects on energy balance, dietary intake, physical activity and eating behavior modification.
133467|NCT03145623|Drug|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
133468|NCT03145610|Other|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
133469|NCT03145610|Other|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
133470|NCT03145597|Device|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
133471|NCT03145597|Device|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
133474|NCT03145571|Procedure|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
133475|NCT03145558|Drug|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
133477|NCT03145545|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
133478|NCT03145532|Other|tDCS plus robotic training|Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
133479|NCT03145519|Device|Vasofix Certo Catheter|Placement of IV-catheter
133480|NCT03145519|Device|OptiVein Catheter|Placement of IV-catheter
133481|NCT03145506|Device|Multimodal Spectroscopy|optical measurement of excised tissue
133482|NCT03145493|Device|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
133483|NCT03145480|Drug|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
133484|NCT03145480|Drug|Ibrutinib|560mg po daily
133485|NCT03145480|Other|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
133486|NCT03145467|Drug|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
133487|NCT03145467|Drug|Zolmitriptan|Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
133488|NCT03145454|Device|electroencephalography helmet|electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.
133489|NCT03145454|Device|dermal electrode|dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.
133490|NCT03145454|Device|blood pressure sensors|blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.
133491|NCT03145454|Device|Pupillometry glasses|Pupillometry glasses will be performed during surgical gesture to determine the pain of child.
133492|NCT03145454|Device|Holter|Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
133493|NCT03145441|Device|CytoSorb®|CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
133494|NCT03145428|Diagnostic Test|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
133495|NCT03145415|Procedure|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
133496|NCT03145415|Procedure|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
133497|NCT03145402|Biological|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
133498|NCT03145402|Biological|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
133499|NCT03145389|Procedure|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
133500|NCT03145376|Diagnostic Test|geriatric assessment|"Clinical evaluation and geriatric assessment with:~CIRS: CIRS (Cumulative Illness Rating Scale)~ADL (Activities of Daily Living);~IADL (InstrumentalActivities of Daily Living);~Mini Nutritional Assessment;~Evaluation of quality of life (Short Form 36, SF-36).~Making a traditional 12-lead ECG.~A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;~transthoracic echocardiogram."
133501|NCT03145363|Behavioral|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
133502|NCT03145363|Behavioral|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
133503|NCT03145350|Other|High-fat, low-carbohydrate|Dietary intervention: 4 week
133504|NCT03145350|Other|Low-fat, high-carbohydrate|Dietary intervention: 4 week
133505|NCT03145337|Biological|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
133506|NCT03145337|Biological|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
133507|NCT03145324|Other|Collection of vaccine histories|
133508|NCT03145311|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|
133509|NCT03145298|Biological|Allogeneic Human Cardiosphere-Derived Stem Cells|Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue
133510|NCT03145298|Biological|Placebo|For use in Phase 1b - Double-blind randomized control portion of the study
133511|NCT03145285|Drug|Abiraterone Acetate|"Cohort 1:~Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.~Cohort 2:~Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
133516|NCT03145246|Procedure|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
133517|NCT03145233|Other|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
133518|NCT03145233|Other|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
133519|NCT03145220|Drug|EA-230|Active intervention
133520|NCT03145220|Other|Placebo (NaCl)|Placebo intervention
133521|NCT03145207|Drug|Lidocaine patch|lidocaine patch
133522|NCT03145194|Drug|Ticagrelor|2 x 90mg Ticagrelor tablets
133523|NCT03145194|Other|Placebo|2 x matching placebo tablets
133524|NCT03145181|Drug|JNJ-64007957 (IV)|Participants will receive IV infusion of JNJ-64007957.
133525|NCT03145181|Drug|JNJ-64007957 (SC)|Participants will receive SC injection of JNJ-64007957.
133526|NCT03145168|Other|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
133527|NCT03145168|Other|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
133528|NCT03145155|Behavioral|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
133529|NCT03145155|Behavioral|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
133530|NCT03145142|Procedure|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
133531|NCT03145142|Procedure|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
133532|NCT03145129|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
133533|NCT03145116|Device|CT ASPHINA 509|Intraocular lens
133534|NCT03145103|Device|CT ASPHINA 409|intraocular lens
133535|NCT03145077|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
133536|NCT03145077|Other|Questionnaire Administration|Ancillary studies
133537|NCT03145064|Drug|BGB-3111|BGB-3111 at a dose of 160 mg orally (PO) twice daily (BID)
133538|NCT03145051|Other|Saline solution|a nasal irrigation care
133539|NCT03145051|Other|Respimer Netiflow|a nasal irrigation care
133540|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
133541|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
133542|NCT03145038|Drug|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
133543|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
133544|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
133545|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
133546|NCT03145025|Device|Retisert|Intravitreal Implant
133547|NCT03145025|Drug|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
133548|NCT03145012|Drug|Ranitidine|Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
133549|NCT03144999|Biological|AAVCAGsCD59|AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
133550|NCT03144986|Device|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
133551|NCT03144973|Diagnostic Test|periosafe|mouth rinsing quick-test
133552|NCT03144960|Procedure|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
133553|NCT03144947|Biological|Trastuzumab IV|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles~Post-randomization phase:~Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
133586|NCT03144635|Drug|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
133950|NCT03141671|Drug|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
133554|NCT03144947|Biological|Trastuzumab SC|"Pre-randomization phase:~FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;~Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.~*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
133555|NCT03144947|Biological|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
133556|NCT03144947|Drug|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
133557|NCT03144934|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
133558|NCT03144934|Drug|Placebo|This is the placebo of GX-I7 described above.
133559|NCT03144921|Behavioral|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
133560|NCT03144908|Other|Standard Operating Procedures|Observational on Standard Operating Procedures
133561|NCT03144895|Procedure|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
133562|NCT03144882|Drug|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
133563|NCT03144882|Drug|Placebo|placebo
133564|NCT03144869|Behavioral|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
133565|NCT03144856|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
133566|NCT03144843|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
133567|NCT03144843|Drug|Placebos|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
133568|NCT03144830|Device|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
133569|NCT03144817|Other|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
133570|NCT03144804|Drug|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
133571|NCT03144778|Biological|Durvalumab|Given IV
133572|NCT03144778|Biological|Tremelimumab|Given IV
133573|NCT03144765|Procedure|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
133574|NCT03144739|Other|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
133575|NCT03144739|Other|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
133576|NCT03144726|Device|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
133577|NCT03144726|Other|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
133578|NCT03144713|Drug|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
133579|NCT03144713|Drug|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
133580|NCT03144713|Drug|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
133581|NCT03144687|Drug|Itacitinib|Itacitinib self-administered orally once daily at the protocol-defined dose.
133582|NCT03144687|Drug|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of < 20 mg daily established before entering the study.
133583|NCT03144674|Drug|Parsaclisib|Parsaclisib at the protocol-defined dose.
133584|NCT03144661|Drug|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
133585|NCT03144648|Other|lifestyle|Observational study
133587|NCT03144609|Procedure|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
133588|NCT03144609|Procedure|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
133589|NCT03144609|Procedure|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
133590|NCT03144596|Drug|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
133591|NCT03144596|Drug|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
133592|NCT03144583|Biological|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
133593|NCT03144570|Other|None, non-interventional study|Not applicable, non-interventional study
133594|NCT03144557|Other|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
133595|NCT03144544|Procedure|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
133596|NCT03144531|Behavioral|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
133597|NCT03144518|Other|Positive Affect Intervention|See Previous Description
133598|NCT03144518|Other|Neutral Control Intervention|See Previous Description
133599|NCT03144518|Biological|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
133600|NCT03144505|Behavioral|MCT combined with RT Group|
133601|NCT03144505|Behavioral|HIIT combined with RT Group|
133602|NCT03144492|Biological|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
133603|NCT03144479|Procedure|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
133604|NCT03144466|Combination Product|Pembrolizumab|antiPD1 monoclonal antibody
133605|NCT03144453|Drug|Sugammadex Injectable Product|Patients receive sugammadex at the end of the surgery
133606|NCT03144453|Drug|Neostigmine, Atropine|Patients receive neostigmine+atropine at the end of the surgery
133607|NCT03144414|Procedure|Laparoscopic hysterectomy|Laparoscopic hysterectomy
133608|NCT03144401|Drug|Misoprostol|mesotac
133609|NCT03144401|Other|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
133610|NCT03144388|Procedure|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
133611|NCT03144388|Procedure|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
133612|NCT03144375|Other|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
133613|NCT03144375|Procedure|Standard of Care sinus surgery|
133614|NCT03144362|Procedure|Bilateral Sliding Techniques|Bilateral Sliding Techniques
133615|NCT03144362|Procedure|Unilateral Sliding Techniques|Unilateral Sliding Techniques
133616|NCT03144336|Behavioral|Information provision|All study participants will receive weekly messages with HIV prevention information.
133617|NCT03144336|Behavioral|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
133618|NCT03144336|Behavioral|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
133619|NCT03144323|Behavioral|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
133620|NCT03144310|Other|lung ultrasound|lung ultrasound and blood gas
133621|NCT03144297|Other|Lumbar puncture|diagnostic lumbar puncture
133622|NCT03144297|Other|BOD POD (air-displacement plethysmography)|Assessment of body fat
133623|NCT03144284|Other|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
133624|NCT03144271|Drug|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
133625|NCT03144271|Drug|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
133626|NCT03144245|Biological|AMV564|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing
133627|NCT03144245|Combination Product|AMV564 in combination with pembrolizumab|AMV564 for administration via continuous intravenous daily infusion or subcutaneous dosing.in combination with pembrolizumab given IV every 21 days
133628|NCT03144232|Device|Active rTMS|rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose (49). Treatment will be delivered at 120% rMT. Each active TMS treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
133663|NCT03143894|Device|TDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
133629|NCT03144232|Device|Sham rTMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real TMS. This type of sham has been demonstrated to be indistinguishable from real TMS.
133630|NCT03144219|Diagnostic Test|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
133631|NCT03144219|Diagnostic Test|Non invasive intracranial compliance monitoring|A sensor of cardiac beat by beat cranial dilation will be used for monitoring intracranial compliance, in non-invasive fashion.
133632|NCT03144206|Drug|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
133633|NCT03144193|Other|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
133634|NCT03144180|Device|Q-cup|This technology is a different way of collecting umbilical cord blood.
133635|NCT03144167|Other|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
133636|NCT03144154|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
133637|NCT03144141|Other|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
133638|NCT03144128|Dietary Supplement|Vitamin D|5,000IU vitamin D given daily for 12 weeks
133639|NCT03144128|Dietary Supplement|Placebo|Placebo capsules given daily for 12 weeks
133640|NCT03144115|Drug|Oxytocin|
133641|NCT03144115|Drug|Placebos|
133642|NCT03144102|Behavioral|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
133643|NCT03144102|Device|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
133644|NCT03144102|Behavioral|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
133645|NCT03144102|Device|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
133646|NCT03144089|Device|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. When randomized to be placed first, the AOA will be inserted and evaluated first, followed by the Guedel oral airway.
133647|NCT03144089|Device|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. When randomized to be placed first, the Guedel oral airway will be inserted and evaluated first, followed by the Articulating Oral Airway (AOA).
133648|NCT03144076|Other|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
133649|NCT03144050|Device|SFDI Imaging|Imaging with SFDI device
133650|NCT03144024|Device|band implantation|
133651|NCT03144024|Device|rigid ring implantation|
133652|NCT03143998|Drug|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
133653|NCT03143985|Drug|TEW-7197|TEW-7197 is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). TEW-7197 inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
133654|NCT03143985|Drug|Pomalidomide|POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
133655|NCT03143972|Drug|Dexmedetomidine|Single drug administration
133656|NCT03143972|Drug|Remifentanil|Single drug administration
133657|NCT03143946|Dietary Supplement|Vitamin supplement;|Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
133658|NCT03143946|Other|Diet advice|
133659|NCT03143933|Drug|Propofol|I.V propofol
133660|NCT03143933|Drug|Fentanyl|
133661|NCT03143920|Combination Product|Hyperbaric Oxygen Therapy-|Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
133662|NCT03143907|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
133691|NCT03143621|Other|Water|Tap water heated to same temperature as coffee
133664|NCT03143881|Behavioral|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
133665|NCT03143868|Behavioral|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
133666|NCT03143855|Drug|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
133667|NCT03143855|Drug|Placebo|Placebo will be administered twice daily for for 5 days
133668|NCT03143842|Device|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
133669|NCT03143829|Other|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
133670|NCT03143816|Drug|Technosphere insulin|This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
133671|NCT03143803|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
133672|NCT03143803|Drug|Placebo|Similar looking inactive powder
133673|NCT03143790|Procedure|Extracorporeal Shockwave Terapy|Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
133674|NCT03143777|Device|Sara Combilizer|Combined tilt table and stretcher chair
133675|NCT03143764|Behavioral|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
133676|NCT03143751|Drug|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)~1-hour bolus (15 g if Na+ < 145 mmol/L; 7.5 g if 145 < Na+ < 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+< 150 mmol/L, reduced to 0.5 g/L if 150 < Na+ < 155 mmol/L, Discontinuation when 155 mmol/L<Na+"
133677|NCT03143738|Procedure|continuous anesthesia of adductor canal|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
133678|NCT03143738|Procedure|continuous anesthesia of femoral nerve|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
133679|NCT03143738|Procedure|Spinal anesthesia|Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
133680|NCT03143725|Drug|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
133681|NCT03143712|Drug|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
133682|NCT03143699|Other|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
133683|NCT03143686|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
133684|NCT03143673|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
133685|NCT03143660|Behavioral|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
133686|NCT03143660|Behavioral|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
133687|NCT03143647|Other|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
133688|NCT03143634|Behavioral|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
133689|NCT03143634|Behavioral|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
133690|NCT03143621|Dietary Supplement|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
133692|NCT03143608|Device|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
133693|NCT03143582|Other|Running|A 13-week running program where youth run for 30 minutes twice weekly.
133694|NCT03143569|Device|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
133695|NCT03143569|Device|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
133696|NCT03143556|Device|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
133697|NCT03143543|Drug|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
133698|NCT03143543|Drug|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
133699|NCT03143543|Other|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
133700|NCT03143543|Other|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
133701|NCT03143530|Procedure|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
133702|NCT03143530|Drug|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
133703|NCT03143530|Drug|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
133704|NCT03143517|Diagnostic Test|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
133705|NCT03143504|Diagnostic Test|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.~Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.~Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.~Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.~Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
133706|NCT03143491|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
133707|NCT03143478|Device|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.~A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.~During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
133708|NCT03143465|Drug|Calcitonin Gene-Related Peptide|
133709|NCT03143465|Drug|Sildenafil|
133710|NCT03143465|Drug|Placebo|
133711|NCT03143452|Drug|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
133712|NCT03143452|Drug|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
133713|NCT03143439|Behavioral|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
133714|NCT03143426|Procedure|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
133715|NCT03143413|Other|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).~Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
133716|NCT03143400|Drug|Lactobacillus salivarius BL 3123|Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
133717|NCT03143387|Other|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
133718|NCT03143387|Other|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
133719|NCT03143374|Device|[18F]T807 (also known as 18F-AV- 1451)|"experimental PET/CT scan of the brain. In this scan, imaging is done with specialized cameras that can pick up radiation signals given off by a radioactive tracer and determine where the signals come from.~The tracer used for this study is called [18]FT807 (also known as 18F-AV-1451). [18]FT807 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. [18]FT807 is an experimental tracer that has been studied in patients with known or suspected Alzheimer's disease, Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBS/CBD). In this study, patients will have one (1) [18F]T807 PET/CT scan performed at the University of Pennsylvania. The [18F]T807 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
133720|NCT03143361|Procedure|Aortic valve replacement|All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
133721|NCT03143348|Procedure|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
133722|NCT03143348|Procedure|Multiple blood draws|Blood draw at 6 peri-operative time points.
133723|NCT03143348|Procedure|Multiple blood draws|Blood draw at 7 peri-operative time points
133724|NCT03143335|Procedure|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
133725|NCT03143335|Procedure|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
133726|NCT03143322|Radiation|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
133727|NCT03143309|Behavioral|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
133728|NCT03143309|Other|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
133729|NCT03143283|Behavioral|Safety Study Lethal Means Counseling|Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
133730|NCT03143270|Drug|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
133731|NCT03143270|Drug|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
133732|NCT03143257|Device|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of BC of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.~The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
133733|NCT03143244|Drug|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
133734|NCT03143244|Drug|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
133735|NCT03143244|Drug|Control group (Normal Saline) (C)|Patients received normal saline in two sets
133736|NCT03143231|Other|Normal saline|The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
133737|NCT03143231|Other|Hypertonic saline|The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
133738|NCT03143218|Biological|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
133739|NCT03143218|Biological|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
133740|NCT03143218|Drug|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four rounds of SMC (SP+AQ) (August, September, October, November) One round of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
133741|NCT03143218|Drug|SMC placebo|Year 1, 2 and 3(2017/18/19) Four rounds of SMC placebo (August, September, October, November)
133742|NCT03143205|Behavioral|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
133743|NCT03143205|Behavioral|Writing tasks|Writing sessions to explore daily activities.
133744|NCT03143192|Combination Product|Micropulse Laser|Aflibercept injection with Micropulse laser.
133745|NCT03143192|Device|Sham Laser|Aflibercept injection with Sham Laser
133746|NCT03143166|Drug|Dabigatran Etexilate|Tablet, film coated
133747|NCT03143166|Drug|Rabeprazol sodium|Tablet
133748|NCT03143153|Biological|Nivolumab|Specified dose on specified days
133749|NCT03143153|Biological|Ipilimumab|Specified dose on specified days
133750|NCT03143153|Drug|Cisplatin|Specified dose on specified days
133751|NCT03143153|Drug|Fluorouracil|Specified dose on specified days
133752|NCT03143140|Other|PAFA|percutaneous ablation of tumor feeding artery
133753|NCT03143140|Other|tumor ablation|ablation of tumor area directly
133754|NCT03143114|Procedure|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
133755|NCT03143101|Biological|FluMist trivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
133756|NCT03143101|Biological|FluMist Quadrivalent (2015-2016)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
133757|NCT03143101|Biological|FluMist Quadrivalent (2017-2018)|0.2 mL (total dose in both nostrils) on Days 1 and 28. Each 0.2 mL dose will contain 10^7±0.5 FFU of each vaccine strain.
133758|NCT03143088|Behavioral|Medical clown|Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
133759|NCT03143075|Dietary Supplement|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
133760|NCT03143062|Diagnostic Test|NEWS|NEWS
133761|NCT03143049|Drug|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
133762|NCT03143049|Drug|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
133763|NCT03143036|Drug|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression~Patients will be assessed every 28 days (+/-10 days)."
133764|NCT03143023|Drug|arginine toothpaste|acid neutralizer toothpaste
133765|NCT03143023|Drug|fluoride toothpaste|bactericidal toothpaste
133766|NCT03143010|Drug|intrathecal Dexmedetomidine|injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
133767|NCT03143010|Drug|Dexmedetomidine 1.5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
133768|NCT03143010|Drug|Dexmedetomidine 3 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
133769|NCT03143010|Drug|Dexmedetomidine 5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
133770|NCT03142997|Diagnostic Test|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
133771|NCT03142984|Other|Cosmetic Products|"Phase 1:~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)~Phase 2:~Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Alternative Baby Wash & Shampoo (GTIN/UPC # 5011451106260)"
133772|NCT03142971|Procedure|focused shock wave therapy|
133773|NCT03142971|Procedure|ultrasound therapy|
133774|NCT03142958|Device|Integra Cadence Total Ankle System|Primary or revision on total ankle replacement
133775|NCT03142945|Other|Traditional Physical Therapy|Physical therapy-based interventions
133776|NCT03142945|Other|MDT based physical therapy|MDT based physical therapy
133777|NCT03142932|Device|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
133778|NCT03142932|Other|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
133779|NCT03142932|Behavioral|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
133780|NCT03142919|Biological|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
133781|NCT03142919|Biological|Placebo|Saline solution
133782|NCT03142906|Diagnostic Test|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
133783|NCT03142893|Drug|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
133784|NCT03142893|Drug|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
133785|NCT03142893|Drug|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
133786|NCT03142893|Drug|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
133787|NCT03142893|Drug|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
133788|NCT03142893|Drug|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
133789|NCT03142893|Drug|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
133790|NCT03142893|Drug|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
133791|NCT03142893|Drug|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
133792|NCT03142893|Drug|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
133793|NCT03142893|Drug|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
133794|NCT03142893|Drug|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
133837|NCT03142542|Drug|Placebo Oral Tablet|Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
133795|NCT03142880|Combination Product|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
133796|NCT03142867|Other|non-applicable|non-applicable
133797|NCT03142854|Drug|Polyethylene Glycol (PEG)|participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
133798|NCT03142854|Drug|Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
133799|NCT03142841|Other|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
133800|NCT03142828|Drug|Chlorhexidine|Healing abutment with Clorhexidine
133801|NCT03142828|Other|Placebo|Healing abutment without any antiseptic
133802|NCT03142802|Diagnostic Test|Low-dose computed tomography (LDCT)|"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:~Normal LDCT:~- Patient continues on the study (i.e. continued surveillance)~Suspicious LDCT:~- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study~Elevated serum tumour markers or other evidence of metastatic disease:~Patient goes off study"
133803|NCT03142789|Drug|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
133804|NCT03142789|Drug|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
133805|NCT03142789|Drug|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
133806|NCT03142789|Drug|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
133807|NCT03142776|Procedure|periodontal debridement|
133808|NCT03142776|Procedure|photodynamic therapy|
133809|NCT03142776|Drug|systemic clarithromycin|
133810|NCT03142763|Other|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
133811|NCT03142763|Dietary Supplement|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
133812|NCT03142750|Device|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
133813|NCT03142737|Other|Red kidney bean intake|Each participant will consume 1/2 cup of cooked red kidney bean
133814|NCT03142737|Other|Eggs intake|Each participant will consume 2 cooked large eggs.
133815|NCT03142737|Other|Peanut butter intake|Each participant will consume 2 tablespoons of peanut butter.
133816|NCT03142737|Other|Ground beef intake|Each participant will consume 2 ounces of 90% lean ground beef.
133817|NCT03142737|Other|Intact beef intake|Each participant will consume 2 ounces of intact beef.
133818|NCT03142724|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single [18F]MNI-968 injections and PET scans.
133819|NCT03142711|Other|No Medical Intervention|Validation of phone ePRO
133820|NCT03142698|Procedure|Quantification of hepatic steatosis|Quantification of hepatic steatosis (histology, and in MRI)
133821|NCT03142685|Device|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
133822|NCT03142672|Procedure|pulpotomy|vital endodontic procedure
133823|NCT03142672|Procedure|tooth filling|tooth filling
133824|NCT03142659|Other|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
133825|NCT03142646|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
133826|NCT03142620|Drug|Esomeprazole|40mg twice daily
133827|NCT03142620|Drug|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
133828|NCT03142620|Drug|Clarithromycin|500mg twice daily
133829|NCT03142620|Drug|Vitamin D3|5000IU
133830|NCT03142607|Drug|Metronidazole gel|1% Metronidazole gel
133831|NCT03142607|Drug|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
133832|NCT03142568|Drug|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
133833|NCT03142568|Other|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
133834|NCT03142555|Behavioral|Intensive Health Talk|Subjects in this group will receive treatments including a health education talk which focuses on smoking harms and provides information of active referral to other smoking cessation services.Intervention also includes quitting reminders, active referral information via social media. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
133835|NCT03142555|Behavioral|General Health Talk|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
133836|NCT03142542|Drug|ZYDENA TAB.75mg(Udenafil 75mg)|ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
133838|NCT03142529|Drug|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
133839|NCT03142516|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
133840|NCT03142516|Drug|Irinotecan|Irinotecan 150 mg/m2 will be administered as IV infusion over 90 min on day 1of first treatment cycle. If tolerance of this first dose is good, it will be scaled to a full dose of 180 mg/m2 starting from the second treatment cycle
133841|NCT03142516|Drug|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
133842|NCT03142516|Drug|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
133843|NCT03142503|Dietary Supplement|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
133844|NCT03142503|Dietary Supplement|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
133845|NCT03142503|Dietary Supplement|Placebo|Supplementation of 1g soybean oil, 3 times a day.
133846|NCT03142490|Other|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
133847|NCT03142490|Other|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
133848|NCT03142477|Other|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
133849|NCT03142477|Other|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
133850|NCT03142477|Other|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
133851|NCT03142464|Other|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
133852|NCT03142451|Drug|FMX-103|FMX-103 1.5% Topical Minocycline Foam
133853|NCT03142451|Other|Vehicle Foam|Vehicle Foam
133854|NCT03142438|Device|F&P Seal Improvement Project|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
133855|NCT03142399|Dietary Supplement|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
133856|NCT03142386|Other|Osteopathic manipulative treatment|
133857|NCT03142386|Other|Physiotherapy|
133858|NCT03142373|Other|CV4 technique|
133859|NCT03142373|Other|RR technique|
133860|NCT03142373|Other|Placebo treatment|
133861|NCT03142360|Drug|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
133862|NCT03142347|Procedure|Remote endarterectomy|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
133863|NCT03142347|Procedure|Remote endarterectomy + DCB balloon|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
133864|NCT03142334|Biological|Pembrolizumab|IV infusion
133865|NCT03142334|Drug|Placebo (saline solution)|IV infusion
133866|NCT03142321|Drug|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
133867|NCT03142295|Procedure|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
133868|NCT03142282|Drug|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
133869|NCT03142282|Radiation|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
133870|NCT03142269|Procedure|360°anterior capsule polishing|360°anterior capsule polishing was performed with double-ended capsule polisher
133871|NCT03142256|Behavioral|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
133872|NCT03142256|Drug|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
133873|NCT03142230|Other|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
133947|NCT03141671|Drug|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
133874|NCT03142230|Other|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
133875|NCT03142217|Other|Study of dysarthria in patients with Huntington's disease|Study of dysarthria in patients with Huntington's disease
133876|NCT03142204|Drug|[18F]F-AraG|Single dose IV injection of [18F]F-AraG for each imaging day.
133877|NCT03142191|Drug|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
133878|NCT03142191|Other|Placebo|Placebo
133879|NCT03142178|Drug|Experimental: 3VM1001 active 2g Cream 3 times daily|3VM1001 2g Cream with active ingredient administered 3 times daily
133880|NCT03142178|Drug|Experimental: 3VM1001 active 3g Cream 3 times daily|3VM1001 3g Cream with active ingredient administered 3 times daily
133881|NCT03142178|Drug|Experimental: 3VM1001 active 3g Cream 4 times daily|3VM1001 3g Cream with active ingredient administered 4 times daily
133882|NCT03142178|Drug|Placebo: 3VM1001 vehicle 2g Cream 3 times daily|3VM1001 placebo 2g vehicle Cream administered 3 times daily
133883|NCT03142178|Drug|Placebo: 3VM1001 vehicle 3g Cream 3 times daily|3VM1001 placebo 3g vehicle Cream administered 3 times daily
133884|NCT03142178|Drug|Placebo: 3VM1001 vehicle 3g Cream 4 times daily|3VM1001 placebo 3g vehicle Cream administered 4 times daily
133885|NCT03142165|Drug|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
133886|NCT03142165|Other|Placebo|Placebo
133887|NCT03142165|Drug|Diphenhydramine|50 mg intravenous administration
133888|NCT03142165|Drug|Famotidine|20 mg intravenous administration
133889|NCT03142152|Device|Carillon Mitral Contour System|The CARILLON implant (mXE2) is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
133890|NCT03142152|Other|Guideline Directed Heart Failure Medication|Heart failure medication per ACC/AHA guidelines
133891|NCT03142139|Biological|RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:~timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age~delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age."
133892|NCT03142139|Biological|RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:~timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age~delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age."
133893|NCT03142139|Biological|RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated|"• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated."
133894|NCT03142126|Device|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
133895|NCT03142100|Device|cochlear implants and hearing aids|speech perception tests and bimodal fitting
133896|NCT03142087|Other|exercises|exercise
133897|NCT03142074|Other|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue .
133898|NCT03142074|Radiation|ECG-gated CT|Image analysis of ECG-gated CT.
133899|NCT03142061|Procedure|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
133900|NCT03142048|Other|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
133901|NCT03142035|Drug|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
133902|NCT03142035|Drug|gonapeptyl|gonadotropic releasing hormone agonist
133903|NCT03142035|Procedure|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
133904|NCT03142022|Other|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
133905|NCT03142009|Other|Intergenerational culturally adapted curriculum|"Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week."
133906|NCT03141996|Other|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
133907|NCT03141996|Other|Standard of Care|Standard of care treatment
133948|NCT03141671|Drug|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
133949|NCT03141671|Radiation|Salvage radiation|Radiation
133908|NCT03141983|Drug|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). It is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra) but differs from human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. It is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
133909|NCT03141983|Drug|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
133910|NCT03141970|Drug|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
133911|NCT03141944|Other|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
133912|NCT03141931|Dietary Supplement|Lacritec|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
133913|NCT03141931|Dietary Supplement|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
133914|NCT03141918|Dietary Supplement|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
133915|NCT03141918|Other|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.~The Curcumin placebo will be given in 2 doses of 500mg per day."
133916|NCT03141905|Other|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
133917|NCT03141905|Other|Usual Care|Standard clinical care
133918|NCT03141892|Device|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
133919|NCT03141879|Other|HUR equipment resistance training intervention|Resistance training intervention
133920|NCT03141866|Other|Exercise Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
133921|NCT03141866|Other|Exercise Intervention 2: Machine-based resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
133922|NCT03141853|Other|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
133923|NCT03141853|Other|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
133924|NCT03141840|Device|ABL01|Experimental medical device
133925|NCT03141840|Device|Placebo|ABL01 lacking active component
133926|NCT03141827|Drug|Insulin|Insulin 40 IU, nasal spray, single dose
133927|NCT03141827|Drug|Placebo|Placebo, nasal spray, single dose
133928|NCT03141801|Device|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
133929|NCT03141801|Other|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
133930|NCT03141801|Other|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
133931|NCT03141788|Device|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
133932|NCT03141775|Other|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
133933|NCT03141736|Other|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
133934|NCT03141736|Other|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
133935|NCT03141736|Other|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
133936|NCT03141736|Other|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
133937|NCT03141723|Other|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
133938|NCT03141723|Other|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost [3 cents per bag] linear low-density bag measuring 10 × 8 × 24 in. and 1.2 mil thick) that will cover the infant's torso and lower extremities.
133939|NCT03141723|Other|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive
133940|NCT03141723|Other|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost [3 cents per bag]
133941|NCT03141710|Dietary Supplement|20 ml of prebiotic per day|12 volunteers will take 20ml of prebiotic per day for 12 weeks
133942|NCT03141697|Device|Carbon Dioxide|Insufflation of Carbon Dioxide
133943|NCT03141697|Device|Room air|Insufflation of room air
133944|NCT03141684|Drug|Atezolizumab|Given IV
133945|NCT03141684|Other|Laboratory Biomarker Analysis|Correlative studies
133946|NCT03141684|Other|Pharmacological Study|Correlative studies
133951|NCT03141671|Drug|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
133952|NCT03141671|Drug|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
133953|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
133954|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
133955|NCT03141658|Drug|Placebo|Multiple doses of placebo once daily for 6 days
133956|NCT03141658|Other|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
133957|NCT03141645|Other|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
133958|NCT03141645|Drug|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
133959|NCT03141632|Drug|Dulaglutide|Evaluation visit with assessment of fluid intake
133960|NCT03141632|Other|Placebo|Evaluation visit with assessment of fluid intake
133961|NCT03141593|Drug|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
133962|NCT03141593|Drug|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
133963|NCT03141593|Drug|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
133964|NCT03141593|Drug|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
133965|NCT03141580|Diagnostic Test|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
133966|NCT03141554|Drug|1% Betadine® PVP-I based mouth wash and gargle,|1% Betadine® PVP-I based mouth wash and gargle
133967|NCT03141554|Drug|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
133968|NCT03141554|Drug|Normal saline gargle|Normal saline gargle
133969|NCT03141541|Behavioral|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
133970|NCT03141528|Other|Self-learning|Training without supervision
133971|NCT03141528|Other|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
133972|NCT03141515|Device|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
133973|NCT03141502|Device|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
133974|NCT03141502|Procedure|Skin grafting|the standard technique of skin grafting after wound preparation.
133975|NCT03141489|Dietary Supplement|Tubefeeding|NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
133976|NCT03141476|Drug|Cefuroxime 1,5g|Patients with BMI of <30kg/m*m: 1,5 g Cefuroxime
133977|NCT03141476|Drug|Cefuroxime 3g|Patients with BMI of 30-50kg/m*m: 3g Cefuroxime
133978|NCT03141476|Drug|Cefuroxime 4,5g|Patients with BMI of >50kg/m*m: 4,5 g Cefuroxime
133979|NCT03141463|Biological|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
133980|NCT03141437|Other|Best Practice|Receive standard of care
133981|NCT03141437|Other|Educational Intervention|Receive educational materials
133982|NCT03141437|Other|Internet-Based Intervention|Use decision-making website
133983|NCT03141437|Other|Questionnaire Administration|Ancillary studies
133984|NCT03141424|Other|Tapering of ICS treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
133985|NCT03141398|Diagnostic Test|Continuous Glucose Monitoring (CGM)|Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
133986|NCT03141398|Diagnostic Test|Oral Glucose Tolerance Test (OGTT)|Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.
133987|NCT03141398|Diagnostic Test|T2* MRI of the Pancreas|MRI [Magnetic resonance imaging] of the pancreas which is safe and takes around 30 minutes.
133988|NCT03141385|Other|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
133989|NCT03141385|Other|Control|Four cycles of right upper limb pseudo ischemia and reperfusion, which will be induced by 5-minute blood pressure cuff inflation to a low pressure of 20 mmHg followed by 5-minute cuff deflated.
134037|NCT03141099|Other|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
133990|NCT03141372|Device|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
133991|NCT03141359|Radiation|SBRT|Primary tumor SBRT
133992|NCT03141359|Drug|Carboplatin|concurrent chemotherapy
133993|NCT03141359|Drug|Paclitaxel|concurrent chemotherapy
133994|NCT03141359|Drug|cis Platinum|concurrent chemotherapy
133995|NCT03141359|Drug|Etoposide|concurrent chemotherapy
133996|NCT03141359|Radiation|IMRT|mediastinal radiation
133997|NCT03141359|Drug|Durvalumab|adjuvant immunotherapy
133998|NCT03141346|Behavioral|Sugar reduction home visitation program|A home visitation program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months
133999|NCT03141346|Behavioral|Control home visitation program|Control home visitation program provided by a trained health educator over 24 months
134000|NCT03141346|Other|Home water delivery|Home delivery of bottled water administered over 24 months
134001|NCT03141333|Behavioral|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
134002|NCT03141320|Other|Interview/observation of social media comments|Interview with pregnant or postnatal women and observation of relevant social media comments
134003|NCT03141307|Behavioral|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
134004|NCT03141307|Behavioral|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
134005|NCT03141307|Behavioral|Control|Standard of care, paper-based brochure
134006|NCT03141294|Procedure|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
134007|NCT03141281|Behavioral|BrainHQ|BrainHQ
134008|NCT03141281|Behavioral|Rise of Nations|Rise of Nations
134009|NCT03141281|Behavioral|IADL Training|IADL Training
134010|NCT03141281|Behavioral|Active Control|Puzzle solving
134011|NCT03141268|Diagnostic Test|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
134012|NCT03141255|Device|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
134013|NCT03141255|Device|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
134014|NCT03141242|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
134015|NCT03141242|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
134016|NCT03141229|Behavioral|Mindfulness based stress reduction|
134017|NCT03141216|Device|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
134018|NCT03141216|Device|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
134019|NCT03141203|Drug|Romidepsin|10mg vial for Injection
134020|NCT03141203|Drug|Carfilzomib|60mg vial for injection
134021|NCT03141190|Behavioral|Mindfulness Based Stress Reduction - modified|already described
134022|NCT03141190|Behavioral|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
134023|NCT03141177|Biological|Nivolumab|Specified dose on specified day
134024|NCT03141177|Drug|Cabozantinib|Specified dose on specified days
134025|NCT03141177|Drug|Sunitinib|Specified dose on specified days.
134026|NCT03141177|Biological|Ipilimumab|Specified dose on specified days
134027|NCT03141164|Other|computerized training|Computerized training
134028|NCT03141151|Behavioral|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
134029|NCT03141151|Behavioral|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
134030|NCT03141138|Biological|TDENV-PIV|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
134031|NCT03141138|Biological|TDENV-LAV F17|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
134032|NCT03141125|Other|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
134033|NCT03141125|Other|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
134034|NCT03141112|Procedure|renal replacement therapy|
134035|NCT03141099|Other|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
134036|NCT03141099|Other|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
134038|NCT03141099|Other|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
134039|NCT03141086|Drug|LML134|LML134
134040|NCT03141086|Drug|Placebo|placebo
134041|NCT03141073|Drug|HMS5552|BID oral administration
134042|NCT03141073|Drug|Placebo|BID oral administration
134043|NCT03141060|Drug|Delamanid|Administered orally; dosing will be based on participants' age and weight.
134044|NCT03141060|Drug|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
134045|NCT03141047|Other|Lifespan Integration|A protocol based psychological treatment method
134046|NCT03141034|Drug|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
134047|NCT03141034|Drug|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
134048|NCT03141034|Genetic|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
134049|NCT03141034|Genetic|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
134050|NCT03141008|Other|Fibroscan changes with different diets|Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
134051|NCT03140995|Behavioral|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
134052|NCT03140982|Diagnostic Test|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
134053|NCT03140969|Drug|QR-110|RNA antisense oligonucleotide for intravitreal injection
134054|NCT03140956|Drug|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
134055|NCT03140943|Drug|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.~Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
134056|NCT03140930|Dietary Supplement|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
134057|NCT03140930|Dietary Supplement|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
134058|NCT03140930|Dietary Supplement|Placebo duodenal|Duodenal infusion of placebo (tap water)
134059|NCT03140930|Dietary Supplement|Placebo ileal|Ileal infusion of placebo (tap water)
134060|NCT03140917|Diagnostic Test|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
134061|NCT03140904|Other|Standard weekly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a weekly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
134062|NCT03140904|Other|Monthly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a monthly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
134063|NCT03140891|Device|NHFOV|NHFOV is used as the noninvasive mode after extubation
134064|NCT03140891|Device|NCPAP|NCPAP is used as the noninvasive mode after extubation
134065|NCT03140878|Dietary Supplement|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
134066|NCT03140878|Dietary Supplement|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
134067|NCT03140852|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
134068|NCT03140839|Behavioral|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
134069|NCT03140839|Behavioral|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
134070|NCT03140839|Other|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
134071|NCT03140826|Drug|meropenem|Antibiotics to treat infections.
134072|NCT03140813|Drug|AZD7325 (High-Dose)|15mg PO BID
134073|NCT03140813|Drug|AZD7325 (Low-Dose)|5mg PO BID
134074|NCT03140813|Drug|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
134075|NCT03140800|Device|intrauterine device|a method of contraception inserted in the uterus
134076|NCT03140787|Drug|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
134077|NCT03140787|Drug|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
134078|NCT03140774|Biological|Previously exposed to Ebola vaccine|Exposure of interest: participants must have had one or more previous Ebola vaccines, Ad26.ZEBOV , MVA-BN-Filo or r-VSV-ZEBOV to enter the study.
134079|NCT03140748|Other|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
134080|NCT03140735|Other|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
134081|NCT03140735|Other|Control group without heart disease|Control group without heart disease
134082|NCT03140722|Drug|vadadustat|vadadustat
134083|NCT03140722|Drug|epoetin alfa|epoetin alfa
134084|NCT03140709|Drug|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.~Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
134085|NCT03140696|Dietary Supplement|Egg Alone|A chicken egg will be offered for 2 days
134086|NCT03140696|Dietary Supplement|Egg and ready to use supplementary food (RUSF)|A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days
134087|NCT03140696|Dietary Supplement|Egg and breast milk|A chicken egg and breast milk will be offered for 2 days
134088|NCT03140683|Device|non-stress test|antepartum fetal monitoring
134089|NCT03140670|Drug|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
134090|NCT03140657|Drug|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 months
134091|NCT03140657|Drug|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 months
134092|NCT03140644|Other|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
134093|NCT03140631|Drug|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
134094|NCT03140618|Other|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.~The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
134095|NCT03140592|Procedure|Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.
134096|NCT03140579|Other|APRV|Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
134097|NCT03140566|Diagnostic Test|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index >50% in addition to relief of symptoms and signs of congestion before discharge.
134098|NCT03140566|Diagnostic Test|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
134099|NCT03140553|Drug|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
134100|NCT03140540|Other|TEE guided fluid therapy will be administered|Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta <20 ,200ml colloid bolus to be administered.
134101|NCT03140540|Other|Stroke volume variation guided intravenous fluid.|Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV >10, 200 ml of colloid bolus to be given
134102|NCT03140527|Drug|PTI-801|Active
134103|NCT03140527|Drug|Placebo|Placebo
134104|NCT03140527|Drug|PTI-808|Active
134105|NCT03140527|Drug|Placebo|Placebo
134106|NCT03140514|Drug|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
134107|NCT03140501|Device|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
134108|NCT03140488|Drug|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
134109|NCT03140449|Drug|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
134110|NCT03140449|Drug|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
134111|NCT03140449|Drug|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.~In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
134112|NCT03140436|Drug|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
134113|NCT03140436|Drug|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
134114|NCT03140423|Drug|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
134302|NCT03139019|Behavioral|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
134115|NCT03140423|Drug|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
134116|NCT03140410|Other|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.~Screening for the presence of crf gene, and mutations associated"
134117|NCT03140397|Dietary Supplement|Placebo|
134118|NCT03140397|Dietary Supplement|6-prenylnaringenin|
134119|NCT03140397|Dietary Supplement|8-prenylnaringenin|
134120|NCT03140384|Biological|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
134121|NCT03140371|Dietary Supplement|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.~The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
134122|NCT03140358|Drug|Atropine sulfate 0.01%|Atropine 0.01%
134123|NCT03140358|Drug|Placebo|placebo
134124|NCT03140332|Other|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
134125|NCT03140319|Biological|Fibroblast|Transplantation of 20 million cell by three injection
134126|NCT03140319|Biological|Placebo|Injection of Placebo
134127|NCT03140306|Diagnostic Test|Patients who have had split dose CT|Computed tomography
134128|NCT03140293|Drug|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
134129|NCT03140293|Drug|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
134130|NCT03140280|Drug|Freeze-Dried Black Raspberry Powder|25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
134131|NCT03140267|Diagnostic Test|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
134132|NCT03140254|Drug|Chlorhexidine gluconate|
134133|NCT03140254|Drug|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
134134|NCT03140254|Drug|Placebo|
134135|NCT03140241|Procedure|PDR measurement|"PDR measurement at two standardized times perioperatively:~: anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50~: administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth"
134136|NCT03140228|Device|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
134137|NCT03140228|Device|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
134138|NCT03140215|Device|laryngeal mask insertion (Baska)|
134139|NCT03140215|Device|laryngeal mask insertion (I-gel )|
134140|NCT03140202|Device|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
134141|NCT03140202|Device|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
134142|NCT03140176|Drug|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
134143|NCT03140163|Radiation|ULD-CT|Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
134144|NCT03140163|Radiation|CXR|Conventional chest radiograph
134145|NCT03140150|Device|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
134146|NCT03140150|Other|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
134147|NCT03140137|Drug|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
134148|NCT03140124|Behavioral|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
134303|NCT03139006|Device|Dual-layer spectral detector CT|A dual energy CT approach
134149|NCT03140124|Behavioral|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
134150|NCT03140111|Device|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
134151|NCT03140111|Device|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
134152|NCT03140098|Device|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
134153|NCT03140085|Biological|PYO Phage|Intravescial instillation
134154|NCT03140085|Drug|Antibiotics|Oral application
134155|NCT03140085|Other|Sterile bacteriology media|Sterile bacteriology media, with identical color as bacteriophage preparation
134156|NCT03140072|Drug|AZD9898|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
134157|NCT03140072|Drug|Matching Placebo|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
134158|NCT03140059|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
134159|NCT03140059|Procedure|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
134160|NCT03140046|Procedure|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
134161|NCT03140033|Drug|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
134162|NCT03140033|Drug|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
134163|NCT03140020|Procedure|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
134164|NCT03140020|Procedure|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
134165|NCT03140007|Device|single operator cholangioscopy|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
134166|NCT03140007|Device|ERCP guided brushing and biopsy|• If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
134167|NCT03139994|Other|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
134168|NCT03139981|Drug|ASN002|Daily dose of ASN002 for 28 days
134169|NCT03139981|Drug|Placebo Oral Tablet|Placebo for ASN002 for 28 days
134170|NCT03139968|Device|(sham) radiation absorbing drape (RADPAD®)|
134171|NCT03139955|Device|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
134172|NCT03139942|Device|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
134173|NCT03139929|Diagnostic Test|MSFP|MSFPhold and MSFParm
134174|NCT03139916|Drug|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
134175|NCT03139916|Drug|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
134176|NCT03139916|Radiation|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
134177|NCT03139890|Other|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
134178|NCT03139890|Other|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
134179|NCT03139890|Other|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
134180|NCT03139864|Procedure|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
134304|NCT03138993|Behavioral|Patient decision aid|Web-based patient decision aid plus a paper workbook.
134181|NCT03139851|Drug|Cyclophosphamide 50mg|One tablet per day. Cyclophosphamide will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
134182|NCT03139851|Drug|Pembrolizumab 100 MG in 4 ML Injection|IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
134183|NCT03139838|Behavioral|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
134184|NCT03139838|Behavioral|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
134185|NCT03139825|Other|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
134186|NCT03139812|Drug|Daily irrigation|Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
134187|NCT03139812|Device|30-day SiH CW|30-day continuous wear of silicone hydrogel contact lenses
134188|NCT03139799|Behavioral|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
134189|NCT03139799|Behavioral|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
134190|NCT03139786|Other|Study the natural history of bicuspid|Study the natural history of bicuspid
134191|NCT03139773|Dietary Supplement|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
134192|NCT03139773|Dietary Supplement|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
134193|NCT03139760|Behavioral|POWERSforID|Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
134194|NCT03139747|Drug|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
134195|NCT03139747|Drug|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
134196|NCT03139734|Device|Sacral Neuromodulation|S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
134197|NCT03139721|Device|Mosiac model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
134198|NCT03139708|Drug|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
134199|NCT03139708|Drug|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
134200|NCT03139708|Drug|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.~Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.~Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
134201|NCT03139695|Diagnostic Test|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
134202|NCT03139669|Device|Viba collection brush|HPV home collection kit using the viba collection brush to collect cervical cells for HPV DNA testing.
134203|NCT03139656|Behavioral|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
134305|NCT03138993|Behavioral|General sleep education|Web-based information about sleep plus a paper workbook
134410|NCT03138135|Behavioral|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
134204|NCT03139656|Behavioral|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
134205|NCT03139656|Behavioral|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
134206|NCT03139643|Other|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
134207|NCT03139643|Other|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
134208|NCT03139643|Other|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
134209|NCT03139617|Procedure|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
134210|NCT03139617|Procedure|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
134211|NCT03139604|Drug|Itacitinib|Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
134212|NCT03139604|Drug|Placebo|Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
134213|NCT03139604|Drug|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
134214|NCT03139604|Drug|Methylprednisolone|Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
134215|NCT03139591|Drug|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
134216|NCT03139578|Device|Test 8.5BC|senofilcon A contact lenses with 8.5 base curve
134217|NCT03139578|Device|Test 9.0BC|senofilcon A contact lenses with 9.0 base curve
134218|NCT03139578|Device|Control 8.5BC|narafilcon A contact lenses with 8.5 base curve
134219|NCT03139578|Device|Control 9.0BC|narafilcon A contact lenses with 9.0 base curve
134220|NCT03139565|Biological|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
134221|NCT03139565|Biological|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
134222|NCT03139552|Other|Apple Crisp|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
134307|NCT03138967|Drug|Rocuronium|Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
134223|NCT03139552|Other|Tea|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
134224|NCT03139552|Other|Oatmeal|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
134225|NCT03139539|Device|Ioban|
134226|NCT03139526|Other|observational study so no intervention|observational study, so no intervention
134227|NCT03139513|Drug|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
134228|NCT03139513|Drug|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
134229|NCT03139500|Drug|JNJ-61803534|Participants will receive JNJ-61803534 tablets orally.
134230|NCT03139500|Drug|Placebo|Participants will receive matching placebo.
134231|NCT03139500|Drug|Midazolam|Participants will receive single oral dose of midazolam.
134232|NCT03139487|Drug|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
134233|NCT03139487|Drug|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
134234|NCT03139474|Drug|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
134235|NCT03139474|Drug|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach > 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
134236|NCT03139461|Other|PT-REFER Capacity-building Toolkit|"Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)~Support from Change Agent~Technical Assistance Calls"
134237|NCT03139448|Device|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
134238|NCT03139448|Device|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
134239|NCT03139435|Procedure|Biopsy|Undergo skin biopsy
134240|NCT03139435|Other|Questionnaire Administration|Ancillary studies
134241|NCT03139435|Diagnostic Test|Ultrasound Tomography|Undergo peripheral nerve ultrasound
134242|NCT03139422|Drug|Tranexamic Acid 500 MG|oral tablets
134243|NCT03139422|Drug|Calcium Dobesilate|oral tablets
134244|NCT03139409|Procedure|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
134245|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
134246|NCT03139396|Procedure|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
134247|NCT03139383|Other|dextrose solution|The patients received 5%D/N/2 during surgery
134248|NCT03139383|Other|saline solution|The patients received NSS during surgery
134249|NCT03139370|Drug|KITE-718|A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
134250|NCT03139370|Drug|Cyclophosphamide|Administered intravenously
134251|NCT03139370|Drug|Fludarabine|Administered intravenously
134252|NCT03139370|Device|MAGE - A3/A6 Screening Test|A screening test for MAGE-A3/A6+ tumors
134253|NCT03139357|Other|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
134254|NCT03139344|Other|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of 1 Hz electrical stimulation.
134255|NCT03139344|Other|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of 3 Hz electrical stimulation.
134256|NCT03139331|Drug|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
134306|NCT03138980|Behavioral|BodiMojo Buddy for IBS|"Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature."
134257|NCT03139331|Drug|Irinotecan|"Patients will be given irinotecan at a dose of 25 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 25 to 37.5 mg/m2/dose or orally at a dose of 45 to 67.5 mg/m2/dose on days 1-5 of a 21-day cycle.~Note that some patients enrolled on an earlier protocol version received 50 mg/m2/dose IV on days 1-5 of the first 21-day cycle and then either 50 mg/m2/dose IV or 90 mg/m2/dose orally for subsequent 21-day cycles. This higher dose level is no longer being given to newly enrolled subjects."
134258|NCT03139331|Drug|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
134259|NCT03139318|Radiation|GRID radiotherapy|Patients will be treated with GRID radiotherapy
134260|NCT03139305|Drug|Glucagon|Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
134261|NCT03139305|Drug|Glucagon|High dose intravenous infusion for 72 hours at 25 ng/kg/min
134262|NCT03139305|Drug|Placebo|Intravenous infusion of saline for 72 hours
134263|NCT03139292|Device|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
134264|NCT03139292|Device|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
134265|NCT03139279|Drug|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
134266|NCT03139279|Other|Saline placebo|Intravenous saline/placebo
134267|NCT03139279|Drug|Propofol|Propofol titrated intravenous boluses
134268|NCT03139266|Behavioral|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
134269|NCT03139266|Behavioral|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
134270|NCT03139253|Drug|amoxicillin|amoxicillin 1000 mg bid. for 14 days
134271|NCT03139253|Drug|clarithromycin|clarithromycin 500 mg bid. for 14 days.
134272|NCT03139253|Drug|tinidazole|tinidazole 500 mg bid. for 14 days.
134273|NCT03139253|Drug|levofloxacin|levofloxacin 500 mg qd. for 14 days.
134274|NCT03139253|Drug|furazolidone|furazolidone 100 mg bid. for 14 days.
134275|NCT03139253|Drug|tetracycline|tetracycline 750 mg bid. for 14 days.
134276|NCT03139253|Drug|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
134277|NCT03139240|Drug|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
134278|NCT03139240|Other|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
134279|NCT03139227|Procedure|Bio specimen Collection|Patients undergo collection of blood and urine
134280|NCT03139227|Dietary Supplement|Dietary Intervention|Consume celery-banana bread
134281|NCT03139227|Other|Laboratory Biomarker Analysis|Correlative studies
134282|NCT03139214|Behavioral|Parenting Intervention|
134283|NCT03139201|Device|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
134284|NCT03139201|Device|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
134285|NCT03139175|Device|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
134286|NCT03139162|Other|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
134287|NCT03139149|Procedure|Adhesiolysis|"Method of video laparoscopic operation:~Open access in the left upper quadrant of the anterior abdominal wall,~Installation of trocars, depending on the prevalence of the adhesion process~Assessment of the peritoneal adhesion index~Detection of the asleep gut~Detection of obstacle area~Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity~If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
134288|NCT03139149|Radiation|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
134289|NCT03139149|Radiation|Computer tomography|Computer tomography of abdomen with iv contrast
134290|NCT03139149|Procedure|Ultrasound|Ultrasound of the abdomen (2 times)
134291|NCT03139149|Other|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
134292|NCT03139136|Drug|MBS2320|As described in the arm descriptions
134293|NCT03139136|Drug|Placebo|As described in the arm descriptions
134294|NCT03139123|Other|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
134295|NCT03139110|Behavioral|Presence of a mediator in the emergency departments|"The mediator tasks are :~Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times~Have a proactive attitude towards patients showing nervousness signs~Report patients expressing the will to leave the emergency departments before medical care~Manage conflicts between patients / accompanying persons and emergency staff and also between patients."
134296|NCT03139097|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
134297|NCT03139058|Other|Evaluation of the hepatic fibrosis|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
134298|NCT03139045|Biological|Venous puncture in elderly patients|Venous puncture in elderly patients
134299|NCT03139032|Drug|APD334|APD334 active treatment for 12 weeks.
134300|NCT03139019|Behavioral|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
134301|NCT03139019|Behavioral|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
134411|NCT03138135|Behavioral|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
134308|NCT03138967|Drug|Sugammadex|Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
134309|NCT03138967|Drug|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
134310|NCT03138967|Drug|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
134311|NCT03138928|Device|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
134312|NCT03138915|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
134313|NCT03138915|Procedure|CTA|Radiomic features were extracted from CTA images.
134314|NCT03138902|Dietary Supplement|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
134315|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.008 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. The maximum dose of NKTR-214 will be 0.012 mg/kg. This will include a fixed 3+3 dose escalation followed by intra-patient step-up dose escalation based on tolerability.
134316|NCT03138889|Drug|Pembrolizumab|Pembrolizumab (anti-PD-1) will be dosed as per label.
134317|NCT03138889|Drug|NKTR-214|NKTR-214: The dose will be 0.006 mg/kg intravenous (IV) infusion administered over 30 (± 5) minutes q3w. Following data review for safety and efficacy, additional patients may be dosed at a higher dose using the findings from the dose optimization cohorts.
134318|NCT03138876|Device|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
134319|NCT03138876|Drug|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
134320|NCT03138876|Procedure|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
134321|NCT03138863|Device|BALT GoldbBAL2 Detachable Balloon|Latex balloon, with radio‐opaque inclusion
134322|NCT03138863|Device|Catheter System|100 cm tapered micro‐catheter
134323|NCT03138850|Device|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
134324|NCT03138850|Device|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
134325|NCT03138850|Device|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
134326|NCT03138837|Diagnostic Test|Magnetic resonance imaging|Diffusion Weighted Magnetic resonance imaging
134327|NCT03138824|Procedure|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
134328|NCT03138824|Procedure|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
134329|NCT03138811|Drug|CSJ117|inhaled once daily dose
134330|NCT03138811|Drug|Placebo Comparator|inhaled once daily dose
134331|NCT03138798|Device|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
134332|NCT03138785|Drug|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
134333|NCT03138785|Radiation|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
134334|NCT03138772|Other|This is an observational study, no intervention used.|No intervention is being used in this study.
134335|NCT03138759|Drug|Pexidartinib|Orally, on Day 2
134336|NCT03138759|Drug|Probenecid|Orally, on Day 2
134337|NCT03138746|Procedure|HBO|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
134338|NCT03138746|Procedure|Hyperbaric air|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
134339|NCT03138733|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril 500 mg as 2 h infusion
134340|NCT03138733|Drug|Daptomycin|Daptomycin 6 mg/kg as 0.5 h infusion, with or without Aztreonam
134341|NCT03138720|Drug|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
134342|NCT03138707|Other|patients who die|
134343|NCT03138694|Other|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
134344|NCT03138681|Drug|Placebo|placebo is given intravenously twice a day for 14 days
134345|NCT03138681|Drug|ATP|ATP (100mg) is given intravenously twice a day for 14 days
134346|NCT03138681|Drug|Phosphocreatine|Phosphocreatine (1g) is given intravenously twice a day for 14 days
134371|NCT03138473|Diagnostic Test|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-[rSS/bSS]) ×100.
134347|NCT03138668|Drug|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
134348|NCT03138668|Drug|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
134349|NCT03138655|Drug|Vedolizumab|Vedolizumab IV infusion
134350|NCT03138642|Radiation|RT|All the patients receive extended resection to primary tumor and post-surgery RT. The patients are prescribed a EQD2 of 70-77Gy to GTV (residual tumor), 65-70Gy to CTV1(high-risk regions including tumor bed and gross macroscopic residual tumor), 50-55Gy to CTV2(low-risk regions) using Intensity-modulated radiotherapy (IMRT)
134351|NCT03138629|Drug|VAL-083|VAL-083 will be administered intravenously
134352|NCT03138616|Drug|vitamin D|take 1600 units of vitamin D daily for nine months
134353|NCT03138603|Drug|Metoprolol Tartrate|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg) prior to extubation, and subsequently an oral dose 25mg metoprolol tartrate in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
134354|NCT03138603|Drug|Placebo|Patients will receive up to 3 IV doses of study drug placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
134355|NCT03138590|Device|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
134356|NCT03138577|Diagnostic Test|Ultrasound Imaging|"M-mode tracings of right diaphragm motion will be made and recorded by a skilled anesthesiologist. Patients will be examined in the supine position and scanned from a low intercostal or subcostal approach using the liver as an acoustic window. Patients will be asked to perform a voluntary sniff (VS) test, for which they will be asked to forcefully inhale through the nose in a sniffing position. The above measurement will be performed immediately preceding the brachial plexus blockade, and then at 15 minute and 30 minutes after block."
134357|NCT03138577|Drug|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
134358|NCT03138577|Other|Bedside Negative Inspiratory Force Meter|A bedside negative inspiratory force (NIF) meter will be used to measure negative inspiratory force prior to the block and 30 minutes after the block.
134359|NCT03138564|Behavioral|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.~During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.~Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
134360|NCT03138564|Behavioral|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
134361|NCT03138551|Behavioral|Mealtime PREP (Promoting Routines of Exploration and Play)|
134362|NCT03138538|Drug|M8891|Subjects will receive M8891 orally once daily or twice daily at escalated dose levels for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
134363|NCT03138525|Other|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
134364|NCT03138525|Other|Blood sampling (controls)|Blood samples will be collected once at enrollment.
134365|NCT03138512|Biological|Nivolumab|Specified dose on specified days for 24 weeks
134366|NCT03138512|Biological|Ipilimumab|Specified dose on specified days for 24 weeks
134367|NCT03138512|Drug|Placebo|Specified dose on specified days for 24 weeks
134368|NCT03138499|Biological|Nivolumab|Specified dose on specified days
134369|NCT03138499|Biological|Brentuximab vedotin|Specified dose on specified days
134370|NCT03138473|Diagnostic Test|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.~The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, glomerular filtration rate (GFR) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of GFR below 60 ml/min/1.73 m2 (1 point for GFR between 59 and 50, 2 points for GFR between 49 and 40 and 3 points for GFR between 39 and 30 ml/min/1.73 m2). The GFR is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
134372|NCT03138460|Other|standard medications crossed over to cannabis|
134373|NCT03138447|Device|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
134374|NCT03138421|Drug|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
134375|NCT03138421|Drug|Placebo|Matching placebo
134376|NCT03138408|Drug|SC-004|Intravenous
134377|NCT03138408|Drug|ABBV-181|Intravenous
134378|NCT03138395|Diagnostic Test|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
134379|NCT03138382|Device|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve with vestibular nerve stimulator (GVS device) for for 45 minutes using binaural mastoid placement.
134380|NCT03138382|Device|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
134381|NCT03138356|Drug|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
134382|NCT03138356|Drug|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
134383|NCT03138356|Drug|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
134384|NCT03138356|Drug|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
134385|NCT03138356|Drug|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
134386|NCT03138356|Drug|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
134387|NCT03138356|Drug|500 mg Glucophage XR®|Used in treatments C, F and I.
134388|NCT03138330|Other|this study is observational, it is not an intervention|
134389|NCT03138317|Biological|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
134390|NCT03138317|Biological|Plasma|This group will receive a knee injection with 6 ml of plasma.
134391|NCT03138317|Biological|Placebo|This group will receive a knee injection with 6 ml saline solution.
134392|NCT03138304|Behavioral|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
134393|NCT03138304|Behavioral|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
134394|NCT03138291|Device|Somnodent|Each pregnant women will be treat with a Somnodent
134395|NCT03138278|Other|Telephone support on demand|Dedicated phone number for help and advice for caregivers
134396|NCT03138265|Behavioral|HIIT Device: ergometer|Supervised exercise training.
134397|NCT03138252|Drug|Oxytocin|
134398|NCT03138239|Radiation|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.~Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.~First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
134399|NCT03138226|Procedure|uterus transplantation|
134400|NCT03138213|Procedure|Total laparoscopic pancreaticoduodenectomy|Total laparoscopic pancreaticoduodenectomy
134401|NCT03138213|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
134402|NCT03138200|Biological|Blood transfusion|Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
134403|NCT03138187|Behavioral|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
134404|NCT03138187|Behavioral|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
134405|NCT03138174|Device|OneTouch Verio Flex Blood Glucose Monitoring System|Blood Glucose Monitoring System
134406|NCT03138161|Drug|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
134407|NCT03138161|Drug|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
134408|NCT03138161|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
134409|NCT03138148|Other|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
134412|NCT03138096|Biological|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
134413|NCT03138096|Other|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
134414|NCT03138083|Drug|OMO-1|OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
134415|NCT03138070|Drug|BYL719|BYL719 400 mg daily by mouth continue for 14 days
134416|NCT03138044|Procedure|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
134417|NCT03138031|Procedure|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
134418|NCT03138018|Diagnostic Test|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
134419|NCT03138018|Diagnostic Test|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
134420|NCT03138005|Other|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to ~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
134421|NCT03138005|Other|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
134422|NCT03137992|Drug|Placebo|Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
134423|NCT03137992|Drug|Test Product (tiotropium bromide inhalation powder)|"Double -Blind: Single dose of test product 18 mcg of test product (tiotropium bromide inhalation powder), a long acting muscarinic receptor antagonist, for double blind portion.~Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler."
134424|NCT03137992|Drug|Reference Product (Spiriva®)|Reference product (Spiriva®) 18 mcg.
134425|NCT03137979|Biological|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
134426|NCT03137979|Biological|Collagen scaffolds|Patients in this group were given collagen scaffolds.
134427|NCT03137979|Procedure|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
134428|NCT03137966|Drug|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
134429|NCT03137966|Drug|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
134430|NCT03137953|Procedure|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
134431|NCT03137953|Diagnostic Test|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
134432|NCT03137940|Device|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.
134433|NCT03137940|Device|sham tDCS|one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
134434|NCT03137927|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
134435|NCT03137927|Other|Placebo|Placebo
134436|NCT03137914|Biological|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
134437|NCT03137914|Procedure|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
134438|NCT03137901|Device|Capstesia|Picture of the arterial waveform taken with a smartphone
134439|NCT03137888|Radiation|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
134440|NCT03137888|Procedure|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
134441|NCT03137888|Drug|Temozolomide|Given PO
134442|NCT03137862|Other|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
134443|NCT03137862|Dietary Supplement|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
134444|NCT03137862|Dietary Supplement|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
134445|NCT03137849|Other|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
134446|NCT03137849|Other|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
134483|NCT03137537|Drug|Ivabradine|lower heart rate in heart failure patients.
134484|NCT03137537|Drug|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
134447|NCT03137849|Other|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
134448|NCT03137836|Behavioral|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.~Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
134449|NCT03137823|Diagnostic Test|throat culture|throat culture - from the tonsills and from the bucal surface
134450|NCT03137810|Procedure|placental cord drainage|"In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.~Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad."
134451|NCT03137810|Procedure|non placemtal cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
134452|NCT03137784|Drug|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
134453|NCT03137784|Drug|Placebo|In each treatment arm, patient will receive placebo
134454|NCT03137771|Radiation|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
134455|NCT03137771|Drug|Docetaxel|Given IV
134456|NCT03137771|Drug|Gemcitabine|Given IV
134457|NCT03137771|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
134458|NCT03137771|Drug|Pemetrexed Disodium|Given IV
134459|NCT03137771|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
134460|NCT03137771|Drug|Erlotinib Hydrochloride|Given PO
134461|NCT03137771|Drug|Pembrolizumab|Given IV
134462|NCT03137758|Drug|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
134463|NCT03137745|Other|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
134464|NCT03137732|Device|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
134465|NCT03137706|Procedure|Biospecimen Collection|Undergo fresh tumor tissue collection
134466|NCT03137706|Other|Laboratory Biomarker Analysis|Correlative studies
134467|NCT03137706|Other|Laboratory Procedure|Tissue stiffness and cell viability analysis
134468|NCT03137693|Other|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
134469|NCT03137693|Procedure|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
134470|NCT03137680|Behavioral|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
134471|NCT03137667|Other|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
134472|NCT03137654|Other|Affective Training|Intervention includes up to 12 training sessions (~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
134473|NCT03137654|Other|Neutral Training|Intervention includes up to 12 training sessions (~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
134474|NCT03137641|Other|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
134475|NCT03137628|Other|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance [sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h].~mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
134476|NCT03137615|Procedure|Pituitary surgery|Trans-sphenoidal resection of a pituitary gland lesion.
134477|NCT03137615|Drug|local anaesthetic injection|The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
134478|NCT03137602|Device|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
134479|NCT03137589|Other|Telemedical support|Participating sites will be advised by telemedicine support.
134480|NCT03137576|Procedure|Paravertebral Block (PVB)|PVB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%) in the paravertebral space (defined by the anterior aspect of the ribs, the vertebral body and the parietal pleura. The space is identified under ultrasonographic guidance by a dedicated Anesthesiologist.
134481|NCT03137576|Procedure|Erector Spinae Plane Block (ESPB)|ESPB consists in the injection of low concentration Ropivacaine (30 ml, 0.3%), in the anatomical plane between the Erector Spinae muscles and deeper surface of Rhomboid muscle. The space is identified under ecographic guidance, laterally to the spinous process of T5. The diffusion of the anesthetic solution along the space can be echographically appreciated.
134482|NCT03137563|Other|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
134485|NCT03137524|Device|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
134486|NCT03137511|Other|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
134487|NCT03137498|Drug|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
134488|NCT03137498|Drug|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
134489|NCT03137485|Procedure|Conventional open lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
134490|NCT03137485|Procedure|Percutaneous Endoscopic Translaminar lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
134491|NCT03137485|Device|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
134492|NCT03137472|Device|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
134493|NCT03137459|Combination Product|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
134494|NCT03137459|Other|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
134495|NCT03137446|Other|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
134496|NCT03137433|Dietary Supplement|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
134497|NCT03137420|Diagnostic Test|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
134498|NCT03137407|Biological|Botulinum Toxins, Type A|Intramuscular injection
134499|NCT03137407|Biological|Placebo|Intramuscular injection
134500|NCT03137394|Other|Observation|Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
134501|NCT03137381|Drug|CTP-543|tablets
134502|NCT03137381|Drug|Placebo|tablets
134503|NCT03137368|Drug|Exemestane Tablets|drug therapy
134504|NCT03137368|Other|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
134505|NCT03137368|Genetic|CYP2D6*10 gene test|CYP2D6*10 gene test
134506|NCT03137368|Drug|Tamoxifen|drug therapy
134507|NCT03137342|Behavioral|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
134508|NCT03137329|Behavioral|Exercise program|Physical therapy for aerobic and resistance training exercises
134509|NCT03137329|Dietary Supplement|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
134510|NCT03137329|Procedure|WLS|Weight loss surgery as planned
134511|NCT03137316|Diagnostic Test|intact parathyroid hormone level|obtain intact parathyroid hormone level from patients records.
134512|NCT03137303|Device|Spirometry|"Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.~At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group."
134513|NCT03137303|Drug|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
134514|NCT03137290|Drug|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
134515|NCT03137290|Drug|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
134551|NCT03137030|Drug|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
134552|NCT03137030|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
134553|NCT03137017|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
134516|NCT03137277|Procedure|screening colonoscopy|"Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.~Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps < 5 mm), or conventional polypectomy according to local standards."
134517|NCT03137264|Drug|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
134518|NCT03137251|Device|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
134519|NCT03137251|Device|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
134520|NCT03137251|Device|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
134521|NCT03137238|Other|Investigation of self-perception in Parkinson's disease|There is no therapeutic intervention.
134522|NCT03137225|Device|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
134523|NCT03137225|Device|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
134524|NCT03137212|Combination Product|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
134525|NCT03137212|Combination Product|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
134526|NCT03137199|Biological|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
134527|NCT03137186|Drug|Metformin|Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
134528|NCT03137173|Drug|Ceftobiprole medocaril|Ceftobiporole medocaril as 2 h infusion
134529|NCT03137173|Drug|Vancomycin plus Aztreonam|Vancomycin as 2 h infusion; Aztreonam as 0.5 h infusion
134530|NCT03137160|Biological|Ixekizumab|Injection
134531|NCT03137147|Behavioral|Intervention for Sleep and Pain in Youth|See arm description.
134532|NCT03137134|Drug|Crizotinib|Crizotinib in a coated microsphere formulation
134533|NCT03137134|Drug|Esomeprazole|Proton pump inhibitor, esomeprazole
134534|NCT03137121|Drug|Olanzapine|Olanzapine is used as an anti-emetic.
134535|NCT03137121|Other|Placebo|The placebo is a non-anti-emetic.
134536|NCT03137108|Device|Transcutaneous electrical spinal cord stimulation|Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
134537|NCT03137095|Other|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3, 4.5 & 5.
134538|NCT03137095|Other|Research Brain MRI|Optional sub-study participation includes undergoing research brain MRI to obtain structural and functional brain images at Assessment 4.5 and 6.
134539|NCT03137082|Drug|Guanfacine XR 3mgs/daily|Guanfacine 3mg tablet
134540|NCT03137082|Drug|Placebo (for guanfacine)|Sugar pill manufactured to mimic guanfacine tablets
134541|NCT03137069|Drug|GDC-0853|High dose of GDC-0853 orally, twice daily, from Day 1 to 56. Participants to have the option to enter an open-label extension (OLE) after completing the 8 week treatment period
134542|NCT03137069|Drug|Placebo|Matching placebo, orally, twice daily, from Day 1 to 56.
134543|NCT03137069|Drug|GDC-0853|Low dose of GDC-0853 orally, once daily from Day 1 to 56. Participants to have the option to enter an open-label extension (OLE) after completing the 8 week treatment period
134544|NCT03137069|Drug|GDC-0853|Middle dose of GDC-0853 orally, once daily from Day 1 to 56. Participants to have the option to enter an open-label extension (OLE) after completing the 8 week treatment period
134545|NCT03137069|Drug|Placebo|Matching placebo, orally, once daily, from Day 1 to 56
134546|NCT03137056|Device|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.~Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
134547|NCT03137056|Device|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.~Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
134548|NCT03137056|Device|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
134549|NCT03137043|Other|Questionnaire|Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.
134550|NCT03137043|Other|Software of Big Data|Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
134628|NCT03136406|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
134554|NCT03137017|Drug|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
134555|NCT03137004|Drug|Docetaxel|Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
134556|NCT03137004|Drug|S-1|S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
134557|NCT03136991|Drug|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
134558|NCT03136991|Drug|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
134559|NCT03136978|Diagnostic Test|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
134560|NCT03136965|Biological|PRP|Injection of autologous platelet rich plasma (PRP)
134561|NCT03136965|Procedure|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
134562|NCT03136965|Procedure|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
134563|NCT03136952|Device|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
134564|NCT03136939|Other|No intervention|No intervention
134565|NCT03136913|Device|Cytoplast® TXT-200|Non-resorbable membrane
134566|NCT03136913|Device|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
134567|NCT03136913|Procedure|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
134568|NCT03136913|Procedure|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
134569|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
134570|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
134571|NCT03136887|Device|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
134572|NCT03136874|Other|Interview and questionaires|"Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.~Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
134573|NCT03136861|Biological|AIN457|anti IL-17a monoclonal antibody
134574|NCT03136861|Drug|AIN457 Placebo|Placebo matching AIN457
134575|NCT03136848|Drug|Normothermic ex-vivo kidney perfusion Solution -Toronto|"The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney."
134576|NCT03136835|Drug|Maternal Hyperoxygenation|Oxygen via nasal prongs at 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
134577|NCT03136822|Other|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
134578|NCT03136822|Device|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
134579|NCT03136809|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
134580|NCT03136796|Drug|Meropenem|Patients will receive intravenous antibiotics eighter empirically or based on a culture.
134581|NCT03136783|Other|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
134582|NCT03136770|Dietary Supplement|CK-30|Compound K 600 mg
134583|NCT03136770|Dietary Supplement|Red ginseng extracts|Red ginseng extracts 2.94 g
134584|NCT03136757|Other|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:~to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier~to identify new intracellular signaling pathways that could lead to new therapeutic"
134585|NCT03136744|Behavioral|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
134586|NCT03136731|Diagnostic Test|Celiac disease antibody screening|Observational parameters
134587|NCT03136718|Other|Mobile-enabled RLOs (mRLOs)|A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
134588|NCT03136705|Drug|Nicotinamide|Nicotinamide tablet
134589|NCT03136705|Drug|Lanthanum Carbonate|Lanthanum Carbonate tablet
134590|NCT03136705|Drug|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
134591|NCT03136705|Drug|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
134592|NCT03136692|Behavioral|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
134593|NCT03136666|Drug|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
134594|NCT03136653|Biological|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops."
134595|NCT03136640|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
134596|NCT03136627|Drug|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
134597|NCT03136627|Drug|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
134598|NCT03136614|Device|Arteriograph|
134599|NCT03136601|Other|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
134600|NCT03136588|Device|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
134601|NCT03136575|Behavioral|Qigong|a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
134602|NCT03136575|Behavioral|Wait-list control|patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
134603|NCT03136562|Diagnostic Test|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
134604|NCT03136549|Other|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
134605|NCT03136549|Other|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
134606|NCT03136510|Drug|Apixaban 5 mg|"Bood collection for biological analyses at:~inclusion visit~follow-up visit at 1 month~end of research at 3 month"
134607|NCT03136497|Drug|ABT-199|Oral dose daily until disease progression
134608|NCT03136497|Drug|Ibrutinib|Oral dose daily until disease progression
134609|NCT03136497|Drug|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
134610|NCT03136484|Drug|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
134611|NCT03136484|Drug|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
134612|NCT03136484|Drug|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
134613|NCT03136484|Drug|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
134614|NCT03136458|Procedure|Ischemic preconditioning|Repeated remote ischemic preconditioning by arterial cuff insufflation.
134615|NCT03136458|Drug|Endovenous normal saline|endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
134616|NCT03136445|Drug|Tranexamic acid (TXA).|IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.
134617|NCT03136445|Drug|Placebo|IV (saline) or oral placebo tablets
134618|NCT03136419|Dietary Supplement|Lactobacillus casei DG|Lactobacillus casei DG probiotic supplementation for 8 weeks
134619|NCT03136419|Dietary Supplement|Placebo|Placebo supplementation for 8 weeks
134620|NCT03136406|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
134621|NCT03136406|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
134622|NCT03136406|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
134623|NCT03136406|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
134624|NCT03136406|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
134625|NCT03136406|Drug|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
134626|NCT03136406|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
134627|NCT03136406|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
134631|NCT03136406|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
134632|NCT03136393|Behavioral|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
134633|NCT03136393|Behavioral|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
134634|NCT03136380|Drug|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
134635|NCT03136380|Drug|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
134636|NCT03136367|Other|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
134637|NCT03136367|Other|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
134638|NCT03136354|Procedure|Endoscopic Submucosal Dissection|
134639|NCT03136354|Procedure|Laparoscopic assisted Gastrectomy|
134640|NCT03136341|Drug|Abobotulinum toxin A|Dosing will be determined at each study visit based upon muscles involved
134641|NCT03136341|Other|Placebo|Dosing will be determined at each study visit based upon muscles involved
134642|NCT03136328|Drug|68Ga-DOTATOC|The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
134643|NCT03136315|Other|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
134644|NCT03136302|Procedure|Deep Brain Stimulation|Deep Brain Stimulation
134645|NCT03136289|Behavioral|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
134646|NCT03136276|Other|IPS Empress CAD|standard etchable glass ceramics
134647|NCT03136276|Other|polished Celtra Duo|new glass ceramic material
134648|NCT03136263|Drug|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
134649|NCT03136263|Drug|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
134650|NCT03136250|Other|Group A (Control Group - Static Stretching + Standard Treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Conventional Static Stretching 15-30 seconds hold 3-5 repetitions (Page P, 2012) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles.
134651|NCT03136250|Other|Group B (Autogenic Inhibition - PIR + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Post Isometric Relaxation MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles. (Chaitow L, 2006)
134652|NCT03136250|Other|Group C (Reciprocal Inhibition - RI + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Reciprocal Inhibition MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid,Levator Scapulae and Upper Trapezius Muscles (Chaitow L, 2006)
134653|NCT03136237|Drug|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
134654|NCT03136237|Drug|Digoxin|Day 1 of Cohort 1
134655|NCT03136237|Drug|BCX7353 + digoxin|Day 19 of Cohort 1
134656|NCT03136237|Drug|Rosuvastatin|Day 1 of Cohort 2
134657|NCT03136237|Drug|rosuvastatin + BCX7353|Day 15 of Cohort 1
134658|NCT03136237|Drug|Cyclosporine + BCX7353|Day 14 of Cohort 3
134659|NCT03136224|Device|Thermocautery|
134660|NCT03136224|Device|Plastic Clamping|
134661|NCT03136224|Device|Surgical Circumcision|
134662|NCT03136211|Behavioral|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
134663|NCT03136198|Other|LUS-guided strategy-of-care|"For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.~Treatment protocol:~IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.~Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)~Reassessment every 2 hours"
134664|NCT03136198|Other|Usual Care|Patients will receive usual AHF care
134665|NCT03136198|Drug|Intravenous Loop Diuretic|IV loop diuretic
134666|NCT03136198|Drug|Vasodilator|IV, topical, or SL Vasodilator
134667|NCT03136198|Device|Non invasive Ventilation (NIV)|Face, mouth, or nasal mask applied to provide positive pressure ventilation
134668|NCT03136185|Drug|IMG-7289|Differentiation therapy
134669|NCT03136172|Device|NIRS (near Infra-red spectroscopy)|"NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)~Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)~Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
134670|NCT03136159|Device|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
134671|NCT03136146|Drug|Bortezomib|Given SC
134672|NCT03136146|Drug|Clofarabine|Given IV
134673|NCT03136146|Drug|Cyclophosphamide|Given IV
134674|NCT03136146|Drug|Dexamethasone|Given IV or PO
134675|NCT03136146|Drug|Etoposide|Given IV
134676|NCT03136146|Biological|Ofatumumab|Given IV
134677|NCT03136146|Biological|Pegfilgrastim|Given SC
134678|NCT03136146|Biological|Rituximab|Given IV
134679|NCT03136146|Drug|Vincristine Sulfate Liposome|Given IV
134680|NCT03136133|Dietary Supplement|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
134681|NCT03136120|Drug|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
134682|NCT03136120|Procedure|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
134683|NCT03136107|Other|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
134684|NCT03136107|Other|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
134685|NCT03136094|Behavioral|SBIRT+12|The standard SBIRT model is augmented by a 12 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
134686|NCT03136094|Behavioral|SBIRT+Usual Care|Patients receive usual SBIRT care
134687|NCT03136094|Behavioral|SBIRT+6|The standard SBIRT model is augmented by a 6 month period following identification of suicide risk during which participants received caring text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native young adults.
134688|NCT03136081|Diagnostic Test|Candidiasis infection occurence|Candidiasis infection occurence
134689|NCT03136068|Drug|Digoxin|Trans-abdominal injection
134690|NCT03136068|Drug|Placebo|Trans-abdominal injection
134691|NCT03136055|Drug|Pembrolizumab|200 mg every 3 weeks via IV infusion.
134692|NCT03136055|Drug|Irinotecan|"For patients in part B receiving pembrolizumab and chemotherapy with irinotecan. The starting dose for the safety lead-in is 125 mg/m2 irinotecan via IV infusion in a 2 weeks on, 1 week off format over 3 week cycles.~If the initial dose is not tolerated, the dose level will be decreased to 100 mg/m2."
134693|NCT03136055|Drug|Paclitaxel|For patients in part B receiving pembrolizumab and chemotherapy with paclitaxel. Patients will receive 80 mg/m2 of paclitaxel via IV infusion every week, with treatment breaks as needed.
134694|NCT03136042|Other|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
134695|NCT03136042|Other|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
134696|NCT03136042|Other|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
134697|NCT03136029|Dietary Supplement|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
134698|NCT03136029|Dietary Supplement|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
134699|NCT03136029|Other|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
134700|NCT03136016|Behavioral|educational activities|Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans
134701|NCT03136016|Behavioral|nudging|In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices
134702|NCT03136016|Behavioral|nudging + educational activities|Group 4 will receive both interventions
134703|NCT03136003|Drug|DDAVP|The participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
134704|NCT03136003|Behavioral|Exercise|The participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise until they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or exhaustion (whichever is first). Upon completion of planned exercise, work load is decreased to zero watts and participants will continue cycling at this cool-down rate for an additional 3-minutes, before getting off the ergometer.
134705|NCT03135990|Behavioral|Cognitive Behavioral Therapy with Virtual Reality Technology|Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
134706|NCT03135977|Drug|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
134707|NCT03135964|Device|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
134708|NCT03135951|Drug|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
134709|NCT03135938|Procedure|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
134710|NCT03135938|Procedure|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
134711|NCT03135925|Other|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
134712|NCT03135912|Drug|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
134713|NCT03135912|Drug|Placebo|Dosage method of SESC 01, without active ingredients.
134714|NCT03135912|Drug|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
134715|NCT03135899|Drug|BI 443651|Three doses, each 12 hours apart
134716|NCT03135899|Drug|Placebo|Three doses, each 12 hours apart
134717|NCT03135886|Other|Information Control|The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
134718|NCT03135886|Other|HIV and HCV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).
134719|NCT03135886|Other|HIV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
134720|NCT03135873|Dietary Supplement|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
134721|NCT03135873|Dietary Supplement|Placebo|Placebo is designed to have identical characteristics with verum.
134722|NCT03135860|Drug|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
134723|NCT03135847|Device|Tactor|The tactor is a small robot providing touch and vibration.
134724|NCT03135834|Biological|MenABCWY|N meningitidis group A, B, C, W, and Y vaccine
134725|NCT03135834|Biological|Saline|Placebo
134726|NCT03135834|Biological|rLP2086|Bivalent recombinant lipoprotein 2086 vaccine
134727|NCT03135834|Biological|MenACWY-CRM|meningococcal group A, C, W-135, and Y conjugate vaccine
134728|NCT03135821|Diagnostic Test|TCM|
134729|NCT03135795|Drug|Sufentanil|Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
134730|NCT03135795|Drug|dexmedetomidine|Patients received intravenous dexmedetomidine 1μg/Kg for induction.
134731|NCT03135795|Drug|propofol|Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
134732|NCT03135795|Drug|Rocuronium|Patients received intravenous rocuronium 0.6mg/Kg for induction.
134733|NCT03135795|Drug|sevoflurane|Patients received inhalation of sevoflurane (1-2%) for maintenance.
134734|NCT03135795|Drug|remifentanil|Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
134735|NCT03135795|Drug|Parecoxib|Parecoxib 40mg was given single intravenously before incision.
134736|NCT03135782|Other|Communication Skills Training|Undergo motivational interviewing training
134737|NCT03135782|Other|Medical Chart Review|Undergo medical chart review
134738|NCT03135782|Other|Questionnaire Administration|Ancillary studies
134739|NCT03135782|Other|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
134740|NCT03135769|Drug|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
134741|NCT03135743|Other|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
134742|NCT03135730|Genetic|ROHHAD|Suspected and Confirmed ROHHAD cases
134775|NCT03135431|Procedure|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
134807|NCT03135249|Drug|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
134915|NCT03134443|Drug|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
134743|NCT03135717|Dietary Supplement|Nutritional care|"Diagnosis of protein energy wasting : anthropometry, calculation of the nutrient intakes, evaluation of appetite, evaluation of gastrointestinal syndromes, hand grip test and bioimpedancemetry~Treatment of protein energy wasting : estimation of nutritional requirements, prescription of oral nutritional supplement or artificial nutrition, physical rehabilitation~Multidisciplinary approach (nephrologists, dieticians, physiotherapists, nurses)~Evaluation of the nutritional treatment (plasma albumin and prealbumin, weight evolution, muscle strength and body composition)"
134744|NCT03135704|Device|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
134745|NCT03135704|Other|Physiotherapy|Usual protocol for treatment of low back pain
134746|NCT03135665|Device|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.~Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.~SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
134747|NCT03135652|Radiation|adjuvant SBRT|adjuvant SBRT of liver lesions
134748|NCT03135652|Drug|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
134749|NCT03135639|Other|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
134750|NCT03135639|Other|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
134751|NCT03135626|Drug|Biodentine|
134752|NCT03135626|Drug|ProRoot (Aggregate)|
134753|NCT03135626|Drug|MTA Plus|
134754|NCT03135626|Drug|Ferric Sulfate 20 % Dental Gel|
134755|NCT03135613|Procedure|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
134756|NCT03135600|Procedure|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
134757|NCT03135587|Procedure|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
134758|NCT03135574|Diagnostic Test|MRI T2 sequence of the oculomotor tract|Patients with ophthalmoplegia will benefit from an MRI T2 sequence of the oculomotor tract (additional time of 4 minutes).
134759|NCT03135561|Behavioral|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
134760|NCT03135561|Behavioral|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
134761|NCT03135548|Drug|Spesolimab (low dose)|12 weeks treatment
134762|NCT03135548|Drug|Placebo|12 weeks treatment
134763|NCT03135548|Drug|Spesolimab (high dose)|12 weeks treatment
134764|NCT03135535|Device|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
134765|NCT03135522|Drug|Zinc Acetate 50 Mg Oral Capsule|"Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)~Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)~Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
134766|NCT03135522|Drug|Placebo oral capsule|"Day 0 (randomization) to day 3 Placebo (one capsule per day)~Day 4 to day 7 If well tolerated: placebo (two capsules per day)~Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
134767|NCT03135509|Drug|CC-220|CC-220 gelatin capsules
134768|NCT03135496|Other|Study of endothelial function biological markers|Study of endothelial function biological markers
134769|NCT03135457|Procedure|Autologous RBC transfusion|Autologous RBC transfusion 300ml 10 ml/min
134770|NCT03135457|Procedure|Saline transfusion|Saline transfusion 300ml 10ml/min
134771|NCT03135444|Behavioral|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
134772|NCT03135444|Behavioral|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
134773|NCT03135444|Behavioral|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
134776|NCT03135418|Device|Intervention|"Patients will use virtual reality d4evice to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 6 weeks each monday, wednesday and friday at same time for each patient.~In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
134777|NCT03135418|Device|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 6 weeks.
134778|NCT03135405|Behavioral|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
134779|NCT03135405|Behavioral|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
134780|NCT03135405|Behavioral|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
134781|NCT03135392|Procedure|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
134782|NCT03135392|Procedure|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
134783|NCT03135392|Procedure|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
134784|NCT03135379|Device|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
134785|NCT03135379|Device|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
134786|NCT03135366|Behavioral|Keheala|
134787|NCT03135366|Other|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
134788|NCT03135353|Device|3D saline infusion sonohysterography|instillation of saline in the uterine cavity using pediatric foley's catheter, then performing 3D ultrasound scan of the uterus and adenexae
134789|NCT03135353|Device|Office Hysteroscopy|an outpatient procedure done to assess the uterine cavity using the office hysteroscopy
134790|NCT03135340|Procedure|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
134791|NCT03135340|Procedure|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
134792|NCT03135340|Drug|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
134793|NCT03135340|Drug|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
134794|NCT03135327|Other|No intervention|No intervention
134795|NCT03135314|Dietary Supplement|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
134796|NCT03135314|Dietary Supplement|placebo|7 days of placebo intake
134797|NCT03135301|Drug|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
134798|NCT03135301|Drug|letrozole|letrozole 5 milligram tablets
134799|NCT03135288|Device|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
134800|NCT03135275|Procedure|Staged complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of ther other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
134801|NCT03135275|Procedure|Immediate complete PCI|During the index procedure, patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
134802|NCT03135275|Device|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
134803|NCT03135262|Drug|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams [mg], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
134804|NCT03135262|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
134805|NCT03135262|Drug|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
134806|NCT03135262|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m^2) on Day 1 of Cycles 1−6 during induction treatment and on Day 1 of every other month during consolidation treatment.
134913|NCT03134469|Dietary Supplement|Placebo supplement|Placebo supplement
134808|NCT03135236|Behavioral|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
134809|NCT03135223|Behavioral|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
134810|NCT03135210|Other|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
134811|NCT03135210|Device|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
134812|NCT03135184|Device|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
134813|NCT03135171|Drug|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
134814|NCT03135171|Drug|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
134815|NCT03135171|Drug|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
134816|NCT03135158|Other|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
134817|NCT03135145|Device|Lite Run Gait Trainer|"Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient."
134818|NCT03135145|Other|Usual Treatments|The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
134819|NCT03135132|Behavioral|Control group|Recommend to consume usual diet during 12-week study period
134820|NCT03135132|Behavioral|LCD group|Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
134821|NCT03135119|Behavioral|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
134822|NCT03135119|Behavioral|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
134823|NCT03135106|Drug|Erdafitinib|A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.
134824|NCT03135106|Drug|Fluconazole|A 400-mg fluconazole orally (4*100 mg capsules) will be administered from Day 1 to Day 11.
134825|NCT03135106|Drug|Itraconazole|A 200-mg itraconazole orally (2*100 mg capsules) will be administered from Day 1 to Day 11.
134826|NCT03135093|Other|No intervention|No Intervention
134827|NCT03135080|Other|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
134828|NCT03135080|Other|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
134829|NCT03135067|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
134830|NCT03135054|Drug|Quizartinib|Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor
134831|NCT03135054|Drug|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
134832|NCT03135041|Dietary Supplement|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
134833|NCT03135041|Dietary Supplement|Placebo|Effects of placebo supplement on weight loss during energy restriction
134834|NCT03135028|Drug|Entospletinib|400 mg tablet (s) orally twice daily
134835|NCT03135028|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
134836|NCT03135028|Drug|Cytarabine|"100 mg/m^2 intravenous (IV) administration twice daily on Days 1 to 7 of each 28-day induction cycle~3g/m^2 IV administration twice daily on days 1, 3 and 5 (<=60 years of age) or 1g/m^2 IV administration once daily on days 1-5 (>60 years of age) of each 28-day post-remission cycle (Hi-DAC)"
134837|NCT03135015|Other|Placebo capsules|16 x 250mg placebo capsules with 250ml water
134838|NCT03135015|Other|2g Axulin capsules|8 x Axulin capsules plus 8 x 250mg placebo capsules with 250ml water
134839|NCT03135015|Other|4g Axulin capsules|16 x Axulin capsules with 250ml water
134840|NCT03135015|Other|0g Axulin tablets|250ml water
134841|NCT03135015|Other|2g Axulin tablets|2 x 1g Axulin tablets with 250ml water
134842|NCT03135015|Other|4g Axulin tablets|4 x 1g Axulin tablets with 250ml water
134843|NCT03135002|Other|Other|
134844|NCT03134976|Drug|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
134845|NCT03134963|Other|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
134846|NCT03134963|Other|Blood pressure monitoring|Continuous blood pressure recording
134847|NCT03134963|Other|Heart rate monitoring|Continuous heart rate monitoring
134848|NCT03134963|Other|End tidal CO2 monitoring|Continuous ETCO2 monitoring
134849|NCT03134963|Other|Addenbrooke's cognitive examination|Performance of a memory test
134850|NCT03134950|Behavioral|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
134851|NCT03134937|Device|High-Flow Heated and Humidified Oxygen Therapy (HFHHNO)|Participants will undergo one session of high-flow heated and humidified oxygen therapy (HFHHNO) (up to 60-70 litre/min). They will undergo a gastric ultrasound scan after session of HFHHNO therapy.
134852|NCT03134924|Behavioral|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
134853|NCT03134924|Behavioral|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
134854|NCT03134911|Drug|DOAC or VKA|6 months - 2 years
134855|NCT03134911|Drug|VKA|6 months - 2 years
134856|NCT03134872|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
134857|NCT03134872|Drug|Carboplatin|Carboplatin
134858|NCT03134872|Drug|Pemetrexed|Pemetrexed
134859|NCT03134859|Behavioral|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
134860|NCT03134846|Drug|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
134861|NCT03134833|Behavioral|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.~Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
134862|NCT03134833|Behavioral|Peer Support|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
134863|NCT03134833|Behavioral|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
134864|NCT03134807|Other|Observation prospective|No intervention
134865|NCT03134794|Behavioral|Educational intervention applying the traffic light system (TLS)|The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
134866|NCT03134781|Behavioral|DoIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
134914|NCT03134456|Drug|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
134867|NCT03134781|Behavioral|DoIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
134868|NCT03134781|Behavioral|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
134869|NCT03134768|Other|This is not an interventional study|This is an observational study
134870|NCT03134755|Drug|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
134871|NCT03134742|Other|Control Group|No interventions this is the control group-no additional scans
134872|NCT03134742|Diagnostic Test|CT Scan|CT Scan of affected and contralateral limb
134873|NCT03134742|Diagnostic Test|DEXA Scans|DEXA Scan of affected and contralateral limb
134874|NCT03134742|Diagnostic Test|CT and DEXA Scans|CT Scan and DEXA Scan of affected and contralateral limb
134875|NCT03134729|Drug|Ropivacaine for Serratus Plane Block (SPB)|Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
134876|NCT03134703|Drug|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
134877|NCT03134703|Drug|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
134878|NCT03134690|Procedure|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
134879|NCT03134690|Procedure|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
134880|NCT03134677|Drug|Bupivacaine|2 ml of hyperbaric bupivacaine (0.5%) was given intrathecally to patients in a sitting position by midline attempt between the L3 and L4 intervertebral space.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
134881|NCT03134677|Drug|Sevoflurane|General anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
134882|NCT03134664|Procedure|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
134883|NCT03134664|Procedure|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
134884|NCT03134651|Device|Monitoring brain function|
134885|NCT03134651|Drug|propofol|
134886|NCT03134638|Drug|SY-1365 (Part 1)|"Two dosing schedules will be evaluated in dose escalation and a dose(s)/schedule(s) will be determined for Part 2:~Twice weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle.~Weekly: SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28 day) cycle."
134887|NCT03134638|Drug|Carboplatin|Carboplatin will be administered on Day 1 of each 3 week (21-day) cycle (Part 2 only)
134888|NCT03134638|Drug|Fulvestrant|Fulvestrant will be administered as an intramuscular (IM) dose of 500 mg every 2 weeks for the first 3 doses on Day 1 and Day 15 of the first 28-day cycle (Cycle 1), and on Day 1 of the second 28 day cycle (Cycle 2), and monthly thereafter starting on Day 1 of Cycle 3 (Part 2 only)
134889|NCT03134638|Drug|SY-1365 (Cohort 2)|In combination with carboplatin, SY-1365 will be administered by intravenous infusion over 1 or 2 hours for 2 weeks of each 3 week (21-day) cycle (Part 2 only)
134890|NCT03134638|Drug|SY-1365 (Cohort 5)|In combination with fulvestrant, SY-1365 will be administered by intravenous infusion over 1 or 2 hours once a week for 3 weeks of each 4 week (28-day) cycle (Part 2 only)
134891|NCT03134638|Drug|SY-1365 (Part 2 Single Agent)|SY-1365 will be administered by intravenous infusion over 1 or 2 hours twice a week for 3 weeks of each 4 week (28 day) cycle
134892|NCT03134612|Drug|Ondansetron 8 mg|
134893|NCT03134612|Drug|Lidocain 40 mg|
134894|NCT03134599|Device|etafilcon A|contact lens
134895|NCT03134599|Device|methafilcon A - Interozzo|contact lens
134896|NCT03134599|Device|methafilcon A - CVI (CooperVision)|contact lens
134897|NCT03134586|Other|Diagnostic imaging|
134898|NCT03134573|Drug|Interferon beta-1b (Betaferon, BAY86-5046)|Solution for injection
134899|NCT03134573|Device|Betaconnect auto-injector|Auto-injector for application of Betaferon solution which automatically covers injection related data
134900|NCT03134573|Device|myBETAapp|Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
134901|NCT03134560|Device|Vein Display Instrument|
134902|NCT03134547|Drug|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
134903|NCT03134547|Drug|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
134904|NCT03134534|Procedure|VATS lobectomy|a minimal invasive surgical types for NSCLC: VATS lobectomy
134905|NCT03134534|Procedure|RATS lobectomy|a minimal invasive surgical types for NSCLC: RATS lobectomy
134906|NCT03134508|Other|treated by antiTNFα|pregnant IBD women treated by antiTNFα
134907|NCT03134508|Other|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
134908|NCT03134495|Other|all children with at least one prescription of PPI|all children with at least one prescription of PPI
134909|NCT03134495|Other|all children with no prescription of PPI|all children with no prescription of PPI
134910|NCT03134482|Procedure|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
134911|NCT03134482|Procedure|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
134912|NCT03134469|Dietary Supplement|Probiotic supplement|Probiotic supplement
134916|NCT03134443|Drug|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
134917|NCT03134430|Other|Normal saline|Injection of Normal saline around peripheral nerve
134918|NCT03134430|Other|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
134919|NCT03134417|Dietary Supplement|Vitamin D and magnesium|Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
134920|NCT03134417|Dietary Supplement|Vitamin D|Daily vitamin D supplements are given to participants daily for 12 weeks.
134921|NCT03134417|Dietary Supplement|Placebo|Daily placebo are given to participants daily for 12 weeks.
134922|NCT03134404|Other|No Intervention|No Intervention is required for this study
134923|NCT03134391|Drug|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
134924|NCT03134378|Drug|Rabeprazole Sodium 20mg|Twice daily
134925|NCT03134378|Drug|Clarithromycin 500mg|Twice daily
134926|NCT03134378|Drug|Amoxicillin 500 Mg|Twice daily
134927|NCT03134365|Other|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
134928|NCT03134365|Other|Combined meal|Combined meal.
134929|NCT03134352|Drug|ZL-3101|A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
134930|NCT03134352|Drug|Placebo|A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
134931|NCT03134339|Drug|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
134932|NCT03134339|Drug|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
134933|NCT03134339|Drug|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
134934|NCT03134339|Drug|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
134935|NCT03134326|Device|R1-25 and R2-25 Pulse Oximeter Sensor|
134936|NCT03134313|Device|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
134937|NCT03134300|Diagnostic Test|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
134938|NCT03134287|Procedure|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
134939|NCT03134274|Device|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
134940|NCT03134261|Diagnostic Test|WB-MRI|scanning methods
134941|NCT03134261|Diagnostic Test|SPECT-CT|scanning methods
134942|NCT03134261|Diagnostic Test|Cholin-PET-CT|scanning methods
134943|NCT03134261|Diagnostic Test|PSMA-PET-CT|
134944|NCT03134248|Device|Dailies Aquacomfort Plus Toric|daily disposable contact lens
134945|NCT03134248|Device|1-Day Acuvue Moist for Astigmatism|daily disposable contact lens
134946|NCT03134248|Device|MyDay Toric|daily disposable contact lens
134947|NCT03134235|Other|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
134948|NCT03134222|Drug|Filgotinib|200 mg tablets administered orally once daily with or without food
134949|NCT03134222|Drug|Lanraplenib|30 mg tablets administered orally once daily with or without food
134950|NCT03134222|Drug|Filgotinib placebo|Tablets administered orally once daily with or without food
134951|NCT03134222|Drug|Lanraplenib placebo|Tablets administered orally once daily with or without food
134952|NCT03134209|Device|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
134953|NCT03134209|Other|Monocryl + Dermabond|conventional sutures and skin adhesive glue
134954|NCT03134209|Other|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
134955|NCT03134196|Drug|Masked Placebo|Oral Placebo
134956|NCT03134196|Drug|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
134957|NCT03134183|Drug|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D&E
134958|NCT03134183|Drug|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D&E
134959|NCT03134170|Other|Pharmacist review of therapy|Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
134960|NCT03134157|Drug|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
134961|NCT03134157|Drug|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
134962|NCT03134157|Drug|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
134963|NCT03134144|Behavioral|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
134964|NCT03134131|Drug|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
134965|NCT03134118|Drug|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
135139|NCT03132610|Drug|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
134966|NCT03134105|Other|Monthly Feedback on activity and patient-reported angina|Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
134967|NCT03134105|Other|End-of-Study Feedback|Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
134968|NCT03134092|Other|Probabilistic Risk Communication Tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids.
134969|NCT03134092|Other|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of an individuals' cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patients sharing their stories - put into a in a structured format of ~ 2-minute length and recorded.
134970|NCT03134079|Other|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
134971|NCT03134079|Other|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
134972|NCT03134079|Other|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
134973|NCT03134053|Device|extracorporeal shock-wave|to treat painful and retracting scars
134974|NCT03134053|Other|massage|to treat painful and retracting scars
134975|NCT03134040|Behavioral|Incentives (Rebate)|
134976|NCT03134040|Behavioral|Incentives (Donation)|
134977|NCT03134040|Behavioral|Feedback|
134978|NCT03134027|Procedure|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
134979|NCT03134014|Dietary Supplement|Breakfast|If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
134980|NCT03134001|Device|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
134981|NCT03133988|Biological|Margetuximab|anti-HER2 monoclonal antibody
134982|NCT03133975|Drug|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
134983|NCT03133975|Other|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
134984|NCT03133962|Other|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
134985|NCT03133949|Other|Establish the clinical, biological and radiological characteristics of patients|Establish the clinical, biological and radiological characteristics of patients
134986|NCT03133936|Biological|Fluarix|Fluarix (GSK). Quadrivalent (IIV-4) subvirion vaccine produced in embryonated hen's eggs and administered intramuscularly at a dose of not less than 15 ug of HA (as determined by SRID) per component.
134987|NCT03133923|Biological|≥3.0 lgCCID50/mlbut ＜3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but ＜3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
134988|NCT03133923|Biological|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
134989|NCT03133923|Biological|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
134990|NCT03133897|Drug|Dexamethasone|experimental group will receive 2 day treatment
134991|NCT03133897|Drug|Prednisone|control group will receive 4 day treatment
134992|NCT03133884|Other|acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
134993|NCT03133884|Other|superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
134994|NCT03133845|Procedure|Light sedation with propofol|Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.
134995|NCT03133845|Procedure|Induction with propofol|Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
135140|NCT03132597|Behavioral|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
134996|NCT03133845|Procedure|Maintenance anesthetic using a volatile anesthetic|Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
134997|NCT03133845|Procedure|Muscle relaxant during maintenance anesthesia|Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.
134998|NCT03133845|Procedure|Pain control with fentanyl|Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.
134999|NCT03133845|Procedure|Bispectral Index (BIS) monitoring for depth of anesthesia|All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.
135000|NCT03133845|Procedure|Spinal Anesthesia|Patients receiving spinal anesthesia will receive bupivacaine into the subarachnoid space.
135001|NCT03133845|Procedure|Midazolam administered during spinal anesthesia|Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.
135002|NCT03133845|Procedure|Cerebrospinal fluid collection|8 ml of cerebrospinal fluid may be collected prior to the administration of intrathecal administration of morphine for pain control.
135003|NCT03133845|Procedure|Administration of intrathecal morphine|Patient may receive intrathecal morphine for post-operative pain control.
135004|NCT03133832|Drug|Companion Tablet|Chinese-made drug for schistosomiasis treatment
135005|NCT03133819|Device|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
135006|NCT03133806|Device|Ultrasept LAA Closure System|The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
135007|NCT03133793|Drug|CoQ10|Participants will take 300mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
135008|NCT03133793|Drug|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
135009|NCT03133793|Other|Placebo pills|Participants will take matched placebo pills that are 300mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
135010|NCT03133793|Other|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
135011|NCT03133780|Drug|Ketamine|Patient will receive IV ketamine 0.5 mg/kg for 10 min
135012|NCT03133780|Drug|Midazolam|Patient will receive IV midazolam 0.05 mg/kg for 10 min
135013|NCT03133767|Drug|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
135014|NCT03133767|Drug|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
135015|NCT03133754|Procedure|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
135016|NCT03133754|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
135017|NCT03133741|Other|GIP-A|GIP-A (GIP receptor antagonist)
135018|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
135019|NCT03133741|Other|Placebo|Saline (9mg/mL)
135020|NCT03133741|Other|GIP-A + Exendin[9-39]|GIP receptor antagonist + GLP-1 receptor antagonist
135021|NCT03133728|Diagnostic Test|Alere Q Testing|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite (i.e. community, household, or facility level). Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 4 routine visits after ART initiation (3 months). Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation.
135022|NCT03133715|Procedure|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
135023|NCT03133715|Procedure|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
135024|NCT03133702|Other|Forensic cases|Forensic cases which were admitted to the Emergency Department
135025|NCT03133676|Drug|KA34|50 µg - 400 µg intra-articular injection (single or multiple doses)
135026|NCT03133676|Drug|Placebo|50 µg - 400 µg intra-articular injection (single or multiple doses)
135027|NCT03133663|Other|Electrocardiogram group|Experimental
135028|NCT03133663|Other|Pulse oximeter and auscultation group|Control
135029|NCT03133650|Drug|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
135030|NCT03133637|Drug|ceftriaxone|Eligible infants will receive ceftriaxone
135031|NCT03133611|Other|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
135032|NCT03133611|Other|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
135033|NCT03133585|Device|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
135034|NCT03133572|Device|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
135035|NCT03133572|Device|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.
135181|NCT03132259|Drug|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
135036|NCT03133559|Other|Observational|We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
135037|NCT03133546|Drug|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.~AstraZeneca will supply osimertinib as tablets for oral administration."
135038|NCT03133546|Drug|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
135039|NCT03133533|Procedure|laparoscopic repair|Surgical inguinal hernia repair using laparoscopic approach.
135040|NCT03133533|Procedure|robot-assisted repair|Surgical inguinal hernia repair using robot-assisted approach.
135041|NCT03133520|Device|High flow oxygen therapy|High-flow nasal oxygen [HFNO] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
135042|NCT03133507|Behavioral|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
135043|NCT03133507|Behavioral|Reassurance Condition|Children will be reassured by the experimenter .
135044|NCT03133507|Behavioral|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
135045|NCT03133494|Other|ABG analysis|ABG analysis was performed and compared between two groups
135046|NCT03133481|Procedure|Adductor Canal Nerve Block|Adductor Canal never technique
135047|NCT03133481|Drug|Femoral Nerve Block|Traditional technique
135048|NCT03133468|Drug|AJM347|Oral administration
135049|NCT03133468|Drug|Placebo|Oral administration
135050|NCT03133455|Other|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
135051|NCT03133442|Device|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
135052|NCT03133429|Device|MER|carotid artery stenting
135053|NCT03133416|Other|PRP preparation|
135054|NCT03133416|Device|Physiotherapy|
135055|NCT03133416|Other|PRP and physiotherapy|
135056|NCT03133377|Behavioral|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
135057|NCT03133364|Other|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
135058|NCT03133351|Device|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
135059|NCT03133338|Device|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
135060|NCT03133325|Device|GP0045|Hyaluronic acid gel
135061|NCT03133325|Device|Restylane Lyft Lidocaine|Hyaluronic acid gel
135062|NCT03133312|Drug|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
135063|NCT03133312|Drug|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
135064|NCT03133299|Drug|Glucocorticoids|Oral prednisolone for four months
135065|NCT03133299|Drug|Vitamin D|Oral vitamin D for two months
135066|NCT03133273|Other|Oncogramme®|Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
135067|NCT03133260|Diagnostic Test|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
135068|NCT03133260|Drug|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
135069|NCT03133260|Drug|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
135070|NCT03133247|Drug|SHR-1316|PD-L1
135071|NCT03133234|Drug|osimertinib|Oral dose of 80mg once daily
135072|NCT03133221|Drug|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
135073|NCT03133208|Procedure|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
135074|NCT03133195|Drug|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
135075|NCT03133195|Drug|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
135076|NCT03133195|Dietary Supplement|Calcium supplement|1000 mg/day of elemental calcium
135077|NCT03133195|Dietary Supplement|Vitamin D|20,000 IU/week of vitamin D2
135078|NCT03133182|Drug|Polypharmacy|Patients who are taking >=5 unique prescription drugs in the 3 months prior to surgery
135079|NCT03133169|Diagnostic Test|blood sample|blood sample for measuring liver and kidney function, CBC, ferritin level and erythrocyte glutamine level
135080|NCT03133169|Diagnostic Test|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
135081|NCT03133156|Other|Exercise Intervention|10-Week Aerobic Exercise Training
135108|NCT03132857|Other|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.
135082|NCT03133143|Behavioral|Cognifit|CogniFit is an Internet browser-based digital brain training program, to improve cognitive abilities based on a personalised brain training regimen. Participants are instructed to play all games assigned by cognifit from three categories (memory, spatial perception, and mental planning) during each training session. After playing the games in these three categories, they are free to choose which exercises they wish to play.
135083|NCT03133143|Behavioral|SIMS 4 (Maxis, Inc)|The Sims 4 is a life simulation PC game. It is purely an entertainment game without known cognitive or health-related outcomes. Does not iclude high-intensity action and competition. This specific game and non-competitive games like it in general do not improve attention, working memory, or other cognitive abilities despite being engaging and fun.
135084|NCT03133130|Drug|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
135085|NCT03133130|Drug|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
135086|NCT03133117|Radiation|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
135087|NCT03133104|Other|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
135088|NCT03133091|Drug|PIEB: Patient Intermittent Epidural Boluses|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
135089|NCT03133091|Drug|PCEA: Patient Controlled Epidural Analgesia|Each patient were randomized to PIEB (7 ml bolus every 30 minutes, with extra boluses (PCEA) of 6 ml every 20 minutes) or PCEA (5 ml in continuous perfussion + PCEA of 5 ml every 15 minutes).
135090|NCT03133078|Other|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
135091|NCT03133078|Other|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
135092|NCT03133065|Drug|treatment of HCV with oral direct acting antiviral therapy|A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
135093|NCT03133052|Behavioral|internet-based adaptive cognitive control training program|The cognitive training will be an internet-based adaptive cognitive control training program, specific training paradigms include Flanker, 1-back, 2-back. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
135094|NCT03133052|Behavioral|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
135095|NCT03133039|Procedure|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
135096|NCT03133026|Device|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
135097|NCT03133013|Device|SLEEPSCOPE|Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
135098|NCT03132987|Other|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
135099|NCT03132974|Drug|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
135100|NCT03132974|Other|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
135101|NCT03132974|Other|Placebo with manipulation procedure|Placebo granule with manipulation procedure
135102|NCT03132961|Other|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
135103|NCT03132948|Behavioral|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
135104|NCT03132935|Procedure|Telemedical support|Telemedical support by a physician in a telemedicine centre
135105|NCT03132922|Genetic|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
135106|NCT03132909|Other|Feelings Determination|Determine the feelings of doctors caring for their colleagues
135107|NCT03132870|Other|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
135436|NCT03130205|Procedure|Phlebotomy|3 EDTA tubes drawn from peripheral vein
135109|NCT03132844|Other|Analysis records of patients over 75 years of age|Demonstrate the percentage of patients over 75 years of age attending general medicine in the Somme, with an up-to-date vaccination schedule, in view of the HAS 2016 recommendations, for the following vaccines: DTp, influenza, pneumococcus, shingles.
135110|NCT03132831|Other|Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)|To determine the DMS of the orthopedic department of the Amiens University Hospital after Total Hip Prosthesis (PTH) and First-line Total Knee Prosthesis (PTG) with its confidence interval and to compare it according to the patient's day of operation
135111|NCT03132818|Other|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
135112|NCT03132805|Behavioral|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
135113|NCT03132805|Behavioral|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
135114|NCT03132792|Genetic|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells
135115|NCT03132779|Drug|Intralipid|Adose of intralipid given and rechecking NKcells activity
135116|NCT03132766|Behavioral|Case Management|Community Mental Health Workers (CMHW), who are trained surveillance system staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the SIQ to assess imminent risk, and referral to a local mental health center. Case managers will also facilitate connections to other care providers (traditional healers, church, Indian Health Service (IHS) social services/mental health, and private providers).
135117|NCT03132766|Behavioral|New Hope Curriculum|New Hope (NH) is psychoeducation to supplement and promote mental health services, while encouraging connections to traditional healers and caring adults. The intervention is designed to be implemented over 1 visit (2-4 hours) in a youth-preferred setting. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by WMAT-CAIH with Native actors, vignettes specific to this community, and Elders speaking in their tribal language (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life. Youth are encouraged to choose a support person from his/her family to take part in the intervention.
135118|NCT03132766|Behavioral|Elders' Resilience Curriculum|Elders' Resiliency (ER) intervention. Apache traditions confer behavioral repertoires and values taught through storytelling, observation, and parenting at the family and community level that have carried the Apache people through generations of adversity and historical trauma. ER is a brief (2-4 hours) distillation of these concepts intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength.
135119|NCT03132753|Behavioral|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with $1,000 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
135120|NCT03132727|Other|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.~Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
135121|NCT03132714|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
135122|NCT03132714|Drug|Amoxicillin 500mg|Administration of Amoxicillin 500mg tid for 7 days
135123|NCT03132714|Drug|Metronidazole 400mg|Administration of Metronidazole 400mg tid for 7 days.
135124|NCT03132714|Drug|Clarithromycin 500mg|Administration of Clarithromycin 500mg bid for 7 days
135125|NCT03132714|Procedure|Single application of PDT|Single application of photodynamic therapy (PDT) at day 0.
135126|NCT03132714|Procedure|Repeated application of PDT|Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
135127|NCT03132701|Drug|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
135128|NCT03132701|Drug|Saline|Same volume of saline is infused until 5 minutes before surgery ends
135129|NCT03132688|Drug|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
135130|NCT03132675|Biological|tavokinogene telseplasmid|Intratumoral tavokinogene telseplasmid (tavo, pIL-12) delivered by electroporation every 6 weeks
135131|NCT03132675|Biological|Pembrolizumab|Intravenous 3 weekly treatments
135132|NCT03132675|Device|ImmunoPulse|Device that electroporates the tavokinogene telseplasmid
135133|NCT03132662|Dietary Supplement|Omega-3|3 gr/day of Omega-3
135134|NCT03132662|Dietary Supplement|Very Low Calorie Diet|4 servings/day Optifast
135135|NCT03132636|Drug|REGN2810|Regimen as per protocol
135136|NCT03132623|Drug|andrographolide sulfonate|Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
135137|NCT03132623|Drug|andrographolide sulfonate simulation|Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
135138|NCT03132610|Drug|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
135141|NCT03132584|Drug|Cyclophosphamide|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~- Via IV Day 3"
135142|NCT03132584|Drug|Alemtuzumab|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days~Alemtuzumab will be administered as follows:~IV Day 1~IV Day 2~Target dose IV on Day 3 and 4"
135143|NCT03132571|Drug|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
135144|NCT03132571|Drug|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
135145|NCT03132571|Other|Placebo|Oral placebo taken once daily for the course of the study (16 week)
135146|NCT03132558|Drug|Radiopaque Media|
135147|NCT03132545|Diagnostic Test|SenseWear Armband (SWA) monitoring|Participants wore the SWA on their right arm
135148|NCT03132545|Diagnostic Test|total body dual-energy X-ray absorptiometry|DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
135149|NCT03132532|Device|Proton Beam Therapy|Proton Beam Therapy (radiation) at either 60 Gy, 66 Gy, or 72 Gy.
135150|NCT03132532|Drug|Carboplatin|IV infusion at standard dose, route, and schedule. Concurrent chemotherapy, Carboplatin, weekly during radiotherapy followed 3-6 weeks later by 2 cycles of consolidative chemotherapy
135151|NCT03132532|Drug|Paclitaxel|IV infusion at standard dose, route, and schedule. Concurrent chemotherapy, Paclitaxel, weekly during radiotherapy followed 3-6 weeks later by 2 cycles of consolidative chemotherapy
135152|NCT03132519|Drug|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
135153|NCT03132506|Other|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
135154|NCT03132493|Drug|Nivolumab 10 MG/ML|nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression
135155|NCT03132480|Other|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
135156|NCT03132467|Biological|Durvalumab|Given IV
135157|NCT03132467|Biological|Tremelimumab|Given IV
135158|NCT03132454|Drug|Decitabine|Given IV
135159|NCT03132454|Drug|Dexamethasone|Given IV or PO
135160|NCT03132454|Drug|Palbociclib|Given PO
135161|NCT03132454|Drug|Sorafenib|Given PO
135162|NCT03132441|Other|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
135163|NCT03132428|Drug|Nitric Oxide Gas, for inhalation: Observational Study|nitric oxide gas, for inhalation INOMAX provided either via mechanical ventilation or non invasive ventilation
135164|NCT03132415|Behavioral|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
135165|NCT03132415|Behavioral|AIDSVu|The investigators will use AIDSVu's available HIV/STI testing locator as the attention-control condition. The AIDSVu test locator provides a list of HIV testing sites in a city or zipcode.
135166|NCT03132402|Diagnostic Test|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
135167|NCT03132389|Other|No intervention|All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
135168|NCT03132376|Dietary Supplement|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
135169|NCT03132376|Dietary Supplement|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
135170|NCT03132376|Dietary Supplement|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
135171|NCT03132376|Dietary Supplement|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
135172|NCT03132376|Dietary Supplement|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
135173|NCT03132337|Other|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
135174|NCT03132324|Drug|INCB059872|INCB059872 tablets
135175|NCT03132311|Biological|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
135176|NCT03132298|Other|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
135177|NCT03132298|Other|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
135178|NCT03132285|Device|PrePex|Prepex is a non surgical male circumcision device
135179|NCT03132272|Device|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
135180|NCT03132259|Drug|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
135182|NCT03132246|Diagnostic Test|Blood draw|The only intervention patients experience is a non-standard of care blood draw. The blood is then tested in a basic science laboratory.
135183|NCT03132233|Dietary Supplement|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
135184|NCT03132233|Other|placebo powder|matched placebo powder to the IMP.
135185|NCT03132220|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is a 16 in-person hours intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
135186|NCT03132220|Behavioral|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 16 in-person hours that are broken into sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the sessions. The time involved will be similar to the MBCT intervention.
135187|NCT03132207|Other|Non interventionel study|Only one questionnaire will be done for women and professional
135188|NCT03132194|Drug|DPSG 7.5%|topical gel
135189|NCT03132194|Drug|Aczone|topical gel
135190|NCT03132194|Drug|Placebo|topical gel
135191|NCT03132181|Drug|Empagliflozin|Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
135192|NCT03132181|Other|Placebo|Patient will be treaded according to standard care but additionally take one tablet placebo per day
135193|NCT03132168|Behavioral|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
135194|NCT03132168|Procedure|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
135195|NCT03132168|Other|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
135196|NCT03132155|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
135197|NCT03132142|Drug|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
135198|NCT03132142|Drug|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
135199|NCT03132142|Drug|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
135200|NCT03132142|Drug|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
135201|NCT03132129|Diagnostic Test|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum.
135202|NCT03132129|Diagnostic Test|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
135203|NCT03132129|Diagnostic Test|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden.
135204|NCT03132129|Diagnostic Test|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
135205|NCT03132116|Drug|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
135206|NCT03132116|Drug|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
135207|NCT03132103|Dietary Supplement|Oral Vitamin D3|
135208|NCT03132103|Dietary Supplement|Placebo Oral Vitamin D3|
135209|NCT03132103|Radiation|Solar simulated radiation (SSR)|
135210|NCT03132103|Radiation|Placebo SSR|
135211|NCT03132090|Diagnostic Test|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
135212|NCT03132077|Procedure|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
135213|NCT03132064|Procedure|total knee arthroplasty|surgical repair for end stage of knee osteoarthritis.
135214|NCT03132051|Drug|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
135215|NCT03132038|Drug|Nivolumab|3mg/kg, every two weeks, during a maximum of one year
135216|NCT03132025|Drug|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
135217|NCT03132025|Drug|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
135218|NCT03132012|Behavioral|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
135219|NCT03132012|Behavioral|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
135220|NCT03131999|Drug|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
135221|NCT03131999|Drug|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
135222|NCT03131973|Drug|BMS-986195|Specified dose on specified days
135223|NCT03131973|Drug|Methotrexate|Specified dose on specified days
135224|NCT03131973|Drug|Leucovorin|Specified dose on specified days
135225|NCT03131973|Drug|Caffeine|Specified dose on specified days
135226|NCT03131973|Drug|Montelukast|Specified dose on specified days
135227|NCT03131973|Drug|Flurbiprofen|Specified dose on specified days
135228|NCT03131973|Drug|Omeprazole|Specified dose on specified days
135229|NCT03131973|Drug|Midazolam|Specified dose on specified days
135230|NCT03131973|Drug|Digoxin|Specified dose on specified days
135231|NCT03131973|Drug|Pravastatin|Specified dose on specified days
135232|NCT03131960|Device|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.
135233|NCT03131960|Other|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
135234|NCT03131947|Other|HIV positive patients|As above
135235|NCT03131934|Biological|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
135236|NCT03131934|Biological|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
135237|NCT03131934|Procedure|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
135238|NCT03131908|Drug|GSK2636771|"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.~Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."
135239|NCT03131908|Drug|Pembrolizumab|Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
135240|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
135241|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
135242|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
135243|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
135244|NCT03131882|Drug|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
135245|NCT03131882|Drug|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
135246|NCT03131869|Other|Thickened Beverages Nectar|Thickened beverages in nectar consistency
135247|NCT03131869|Other|Thickened Beverage Honey|Thickened beverages in honey consistency
135248|NCT03131856|Behavioral|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
135249|NCT03131843|Drug|Alcohol|Alcohol cleansing swab/wipe
135250|NCT03131843|Drug|No alcohol|No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
135251|NCT03131830|Other|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
135252|NCT03131817|Device|Activa PC+S Prefrontal|
135253|NCT03131804|Other|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
135254|NCT03131791|Device|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
135255|NCT03131791|Drug|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
135256|NCT03131778|Procedure|Liver resection|liver resections for colorectal liver metastases
135257|NCT03131765|Biological|YS-0N-001|Cancer vaccine
135258|NCT03131752|Behavioral|Elastic Resistance Intervention in Exacerbated Patients|The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
135259|NCT03131726|Drug|Simvastatin 40mg|see arm description
135260|NCT03131713|Drug|Acetaminophen|Acetaminophen 1000mg
135261|NCT03131700|Biological|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
135301|NCT03131427|Drug|Standard of care|Standard of care according to the updated national and/or international guidelines
135302|NCT03131414|Other|Diet|Dietary intake
135506|NCT03129542|Drug|Placebo capsule|Three doses taken every 8 hours.
135262|NCT03131700|Biological|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
135263|NCT03131687|Drug|tirzepatide|Administered SC
135264|NCT03131687|Drug|Dulaglutide|Administered SC
135265|NCT03131687|Drug|Placebo|Administered SC
135266|NCT03131674|Other|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
135267|NCT03131648|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
135268|NCT03131648|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
135269|NCT03131635|Behavioral|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
135270|NCT03131622|Behavioral|Digital Therapeutics|
135271|NCT03131609|Other|Container|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
135272|NCT03131609|Other|Silver Impregnated Wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
135273|NCT03131609|Other|Funnel|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
135274|NCT03131609|Other|Castile-soap wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
135275|NCT03131596|Procedure|IUB dilatation therapy|A Foley catheter (size 14fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-4.5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
135276|NCT03131583|Drug|Colchicine|Day-14~Day16 qd
135277|NCT03131583|Drug|Febuxostat|Day1 and Day8 qd
135278|NCT03131583|Drug|SHR4640|Day3~Day8 qd
135279|NCT03131570|Drug|Secukinumab|Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
135280|NCT03131570|Drug|Placebo followed by Secukinumab|Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
135281|NCT03131557|Device|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
135282|NCT03131557|Device|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
135283|NCT03131544|Device|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
135284|NCT03131531|Other|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
135285|NCT03131518|Behavioral|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
135286|NCT03131518|Behavioral|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
135287|NCT03131518|Behavioral|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
135288|NCT03131492|Diagnostic Test|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
135289|NCT03131479|Drug|LIK066|LIK066 50 mg tablets taken orally once daily before breakfast for 7 days.
135290|NCT03131466|Device|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
135291|NCT03131466|Drug|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
135292|NCT03131453|Drug|CNP520 50mg|Arm#1
135293|NCT03131453|Drug|CNP520 15mg|Arm#2
135294|NCT03131453|Other|Placebo to CNP520|Arm#3
135295|NCT03131440|Behavioral|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
135296|NCT03131440|Behavioral|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
135297|NCT03131440|Behavioral|App+|"Participants will receive deluxe version of smartphone app with additional features."
135298|NCT03131440|Behavioral|Online gym|Participants will receive access to online exercise videos.
135299|NCT03131440|Behavioral|App notifications|Participants will receive motivational app notifications
135300|NCT03131440|Behavioral|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
135303|NCT03131414|Other|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
135304|NCT03131401|Diagnostic Test|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
135305|NCT03131401|Diagnostic Test|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
135306|NCT03131401|Diagnostic Test|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
135307|NCT03131388|Diagnostic Test|Access AMH Assay|
135308|NCT03131375|Drug|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
135309|NCT03131375|Drug|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
135310|NCT03131375|Device|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
135311|NCT03131375|Device|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
135312|NCT03131349|Diagnostic Test|serum zinc and iron|history ,examination,investigations
135313|NCT03131336|Drug|PeproStat|solution for local application
135314|NCT03131336|Drug|Saline|solution for local application
135315|NCT03131323|Procedure|• Flexible fiberopticnasopharyngoscope|".~II- Equipments:~Flexible fiberopticnasopharyngoscope, 2.7 mm in diameter and fiberoptic light cable.~The camera: fitted with Three-CCD (Charged Couple Device) sensors.~A high resolution monitor.~A recording unit. III- Positioning:Infants and small children have to be held by a parent or an adult. Older children and adolescents usually tolerate office flexible nasopharyngoscopy once the procedure is explained. If office flexible nasopharyngoscopy failed because the child is not cooperative or if there is excessive secretions, general anesthesia may be required [8].~IV- Technique: Lubricant gel will be applied to the tip of the endoscope which will be now will be passed along the floor of the nose, between the inferior turbinate and the nasal septum, till it reaches the nasopharynx. Now the entire nose and the nasopharynx could be thoroughly examined and any abnormal findings could be detected and documented."
135316|NCT03131310|Other|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
135317|NCT03131297|Procedure|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
135318|NCT03131284|Behavioral|Intensive education|"For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity."
135319|NCT03131271|Other|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
135320|NCT03131258|Procedure|Donor Nephrectomy|48 Donor Nephrectomy Patients
135321|NCT03131219|Biological|ALXN1210|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
135322|NCT03131206|Drug|Alectinib|"Oral, BID~Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
135323|NCT03131193|Other|Physician|Study primary health centers will be staffed with an additional physician
135324|NCT03131193|Other|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
135325|NCT03131193|Behavioral|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
135326|NCT03131180|Other|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
135327|NCT03131167|Drug|SHP639 (n=60)|Drug SHP639 is a 9-amino acid, synthetic, C-type natriuretic peptide (CNP) analog.
135328|NCT03131167|Drug|Placebo Comparator (n=24)|Drug: Vehicle Ophthalmic placebo solution of the same composition as the test product.
135329|NCT03131154|Drug|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
135330|NCT03131154|Drug|Vehicle of ADX-102 Ophthalmic Solution|Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
135399|NCT03130491|Device|EMBLOK filter|Embolic Filter Protection System During TAVR
135331|NCT03131141|Drug|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
135332|NCT03131128|Behavioral|Mindfulness-based Intervention|"Keeping mindful when selecting food.~Be aware of hunger and satiety by the body clues.~Understanding how stress affect diet and life, and learn how to cope with stress in life.~Learning to identify overeating caused by mood, social stress and specific food."
135333|NCT03131128|Behavioral|Health Education Intervention|"Identifying improper diet patterns and attitudes~Understanding the impact of irrational cognition and attitudes on dietary behavior~Training coping skills for stresses in real life and preventing the recurrence of bulimia."
135334|NCT03131115|Procedure|Lateral Crural Strut Graft|surgical technique as described
135335|NCT03131115|Procedure|Bone Anchored Suspension|Surgical technique as described
135336|NCT03131076|Diagnostic Test|IPMN follow up|Follow up with MRI and laboratory blood tests
135337|NCT03131063|Other|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
135338|NCT03131050|Drug|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
135339|NCT03131050|Drug|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
135340|NCT03131050|Drug|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
135341|NCT03131037|Biological|AdV-tk (aglatimagene besadenovec) + valacyclovir|AdV-tk will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
135342|NCT03131024|Dietary Supplement|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
135343|NCT03131024|Other|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
135344|NCT03131011|Other|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
135345|NCT03130998|Behavioral|eKnowledge Broker|The intervention is the tailored support received by a knowledge broker via technology in Group B. The eKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the eKB, learn new evidence, and work with the eKB on how to best implement the evidence.
135346|NCT03130959|Biological|Nivolumab|Specified dose on specified day
135347|NCT03130959|Biological|Ipilimumab|Specified dose on specified day
135348|NCT03130946|Device|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
135349|NCT03130946|Device|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
135350|NCT03130933|Procedure|Lower third molar surgery|"All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.~Primary closure of the surgical area was done using 3-0 silk sutures."
135351|NCT03130933|Drug|Amoxicillin 500 Mg|The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
135352|NCT03130933|Other|Placebo|The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
135353|NCT03130920|Procedure|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.~Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
135354|NCT03130907|Device|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
135355|NCT03130894|Other|Plasma TMAO concentration|Plasma TMAO concentration
135356|NCT03130881|Drug|PLB1003|PLB1003 is a capsule and is administered orally.
135357|NCT03130868|Other|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
135358|NCT03130855|Drug|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
135359|NCT03130855|Drug|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
135360|NCT03130842|Drug|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
135361|NCT03130842|Drug|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
135362|NCT03130829|Dietary Supplement|Oligo Fucoidan|Oral, twice daily
135363|NCT03130829|Dietary Supplement|Placebo|Oral, twice daily
135400|NCT03130452|Drug|Lansoprazole 30mg|lansoprazole 30 mg tablet
135401|NCT03130452|Drug|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
135402|NCT03130452|Drug|Clarithromycin 500mg|Clarithromycin 500mg tablet
135403|NCT03130452|Drug|Metronidazole 500 mg|Metronidazole 500 mg tablet
135364|NCT03130816|Biological|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
135365|NCT03130803|Behavioral|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
135366|NCT03130790|Drug|Varlitinib|300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
135367|NCT03130790|Drug|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
135368|NCT03130790|Drug|Placebo|oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
135369|NCT03130790|Drug|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
135370|NCT03130777|Device|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to provide a simple and safe way to reduce the diameter of these large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
135371|NCT03130764|Drug|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
135372|NCT03130764|Drug|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
135373|NCT03130751|Behavioral|Pocket Coach for AYA with Cancer|The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model [Dr. Joan E. Haase et al] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
135374|NCT03130738|Drug|7-Day Miconazole Oil (Miconazole 2%)|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
135375|NCT03130738|Drug|14-Day Miconazole Oil (Miconazole 2%)|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
135376|NCT03130738|Drug|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
135377|NCT03130725|Procedure|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
135378|NCT03130725|Procedure|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
135379|NCT03130712|Drug|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
135380|NCT03130699|Behavioral|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
135381|NCT03130699|Behavioral|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
135382|NCT03130699|Behavioral|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
135383|NCT03130686|Device|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
135384|NCT03130660|Device|Ultrasonography|Ultrasound guidance for central line
135385|NCT03130647|Device|Focused ultrasound|Focused ultrasound
135386|NCT03130634|Drug|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
135387|NCT03130621|Diagnostic Test|Gene detection|Next-generation sequencing
135388|NCT03130608|Other|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
135389|NCT03130582|Drug|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
135390|NCT03130569|Behavioral|Web-based Module Group|
135391|NCT03130556|Drug|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
135392|NCT03130556|Other|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
135393|NCT03130556|Drug|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
135394|NCT03130543|Dietary Supplement|Rice cereal|Standard formula thickened with rice cereal
135395|NCT03130543|Dietary Supplement|Enfamil AR|Enfamil AR formula
135396|NCT03130517|Drug|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
135397|NCT03130504|Drug|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
135398|NCT03130491|Procedure|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
135404|NCT03130439|Drug|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
135405|NCT03130426|Drug|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
135406|NCT03130426|Drug|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
135407|NCT03130426|Drug|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
135408|NCT03130426|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
135409|NCT03130413|Device|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
135410|NCT03130413|Device|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
135411|NCT03130400|Procedure|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
135412|NCT03130387|Device|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
135413|NCT03130374|Biological|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
135414|NCT03130361|Device|Non-Invasive Ventilation|
135415|NCT03130348|Drug|Bortezomib|Given SC
135416|NCT03130348|Drug|Dexamethasone|Given PO
135417|NCT03130348|Drug|Ibrutinib|Given PO
135418|NCT03130348|Other|Laboratory Biomarker Analysis|Correlative studies
135419|NCT03130335|Procedure|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
135420|NCT03130335|Biological|BMA|Bone marrow will be aspirated from the iliac crest.
135421|NCT03130322|Other|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
135422|NCT03130322|Other|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).~Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
135423|NCT03130322|Other|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
135424|NCT03130322|Other|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
135425|NCT03130322|Other|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
135426|NCT03130283|Other|Home Hospitalization|Visit every 24 hours
135427|NCT03130283|Other|Conventional Hospitalization|No intervention
135428|NCT03130270|Drug|Apatinib mesylate tablet|"Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.~Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment."
135429|NCT03130257|Diagnostic Test|Blood Pressure Measurement|We are comparing 3 types of measuring blood pressure for making a new diagnosis of hypertension, clinic blood pressure, home blood pressure, and kiosk blood pressure measurements over a 3 week diagnostic time period
135430|NCT03130244|Device|Magnet Anastomosis System|The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
135431|NCT03130244|Drug|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
135432|NCT03130218|Other|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
135433|NCT03130205|Procedure|Core Needle Biopsy|Core Needle Biopsy is performed from liver metastasis.
135437|NCT03130205|Genetic|Molecular genetic analysis|Performed on biomaterial from peripheral vein and core needle biopsy
135438|NCT03130179|Drug|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
135439|NCT03130179|Drug|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
135440|NCT03130166|Procedure|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
135441|NCT03130166|Procedure|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
135442|NCT03130153|Drug|Aspirin Powder|Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
135443|NCT03130153|Drug|Normal saline|Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
135444|NCT03130140|Procedure|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
135445|NCT03130140|Other|Control|Conventional EUS-FNA
135446|NCT03130127|Drug|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
135447|NCT03130114|Drug|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
135448|NCT03130114|Other|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
135449|NCT03130101|Other|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
135450|NCT03130088|Other|no intervention planed|no intervention planed
135451|NCT03130062|Other|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
135452|NCT03130049|Procedure|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
135453|NCT03130036|Other|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
135454|NCT03130036|Other|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
135455|NCT03130023|Device|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
135456|NCT03130010|Drug|Nefopam or saline|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
135457|NCT03129997|Dietary Supplement|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
135458|NCT03129984|Device|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
135459|NCT03129971|Procedure|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
135460|NCT03129971|Procedure|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
135461|NCT03129945|Drug|Nifedipine|Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
135462|NCT03129945|Drug|Indomethacin|Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
135463|NCT03129932|Dietary Supplement|gluten phase|2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
135464|NCT03129932|Dietary Supplement|placebo phase|2 cakes without gluten will be consume during the 4 weeks of intervention
135465|NCT03129919|Device|Carriere SLX® (Passive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
135466|NCT03129919|Device|Empower® (Interactive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
135467|NCT03129906|Dietary Supplement|Gluten|
135468|NCT03129906|Dietary Supplement|Rice protein|
135469|NCT03129893|Device|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
135470|NCT03129880|Behavioral|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
135471|NCT03129880|Behavioral|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
135472|NCT03129867|Drug|Ticagrelor|Ticagrelor 60mg or 90 mg as routine use of each Center
135473|NCT03129854|Device|prostate cryotherapy|prostate cryotherapy added to experimental group within 6 months of ADT
135474|NCT03129841|Behavioral|Early dinner+Diet|Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
135475|NCT03129841|Behavioral|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
135507|NCT03129529|Device|Focused shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
135476|NCT03129828|Drug|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. for individuals < 65 years and 420 mg p.o. for individuals ≥ 65 years (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
135477|NCT03129789|Other|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
135478|NCT03129776|Drug|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
135479|NCT03129776|Drug|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
135480|NCT03129763|Behavioral|60mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.
135481|NCT03129763|Behavioral|70mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.
135482|NCT03129763|Behavioral|80mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.
135483|NCT03129763|Behavioral|90mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
135484|NCT03129763|Behavioral|100mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
135485|NCT03129750|Device|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
135486|NCT03129737|Procedure|Mitral valve surgery|Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
135487|NCT03129737|Procedure|Tricuspid valve annuloplasty|Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
135488|NCT03129711|Other|glazed Celtra Duo|zirconia reinforced lithium silicate
135489|NCT03129711|Other|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
135490|NCT03129698|Drug|Apatinib|Apatinib 250mg daily
135491|NCT03129685|Procedure|HALED|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
135492|NCT03129672|Procedure|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
135493|NCT03129659|Diagnostic Test|Coronary CT Angiography|Coronary CT angiography
135494|NCT03129646|Drug|Miltefosine|Miltefosine 10mg and 50mg capsules
135495|NCT03129646|Drug|Paromomycin|Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
135496|NCT03129646|Drug|Sodium stibogluconate|Sodium stibogluconate 33% 30 ml inj.
135497|NCT03129633|Other|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
135498|NCT03129594|Diagnostic Test|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
135499|NCT03129581|Behavioral|Dietary Counseling|Counseling to only eat during a restricted amount of time.
135500|NCT03129568|Biological|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
135501|NCT03129555|Drug|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135502|NCT03129555|Drug|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135503|NCT03129555|Drug|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135504|NCT03129555|Drug|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135505|NCT03129542|Drug|Midodrine Hydrochloride 10 milligrams|Three doses taken every 8 hours.
135508|NCT03129529|Device|Radial shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
135509|NCT03129516|Behavioral|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
135510|NCT03129490|Drug|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135511|NCT03129490|Drug|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135512|NCT03129490|Drug|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135513|NCT03129490|Drug|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
135514|NCT03129477|Procedure|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
135515|NCT03129464|Device|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
135516|NCT03129451|Diagnostic Test|Microbiome specimens in stool|Analyzing Microbiome specimens in stool
135517|NCT03129438|Diagnostic Test|continuous EEG (cEEG)|differential use of continuous versus routine EEG
135518|NCT03129438|Diagnostic Test|routine EEG (rEEG)|differential use of continuous versus routine EEG
135519|NCT03129425|Behavioral|ReNACE Psychoeducational Intervention|9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
135520|NCT03129425|Other|General Educational Program|5 sessions in groups of 15-20 people
135521|NCT03129412|Radiation|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
135522|NCT03129399|Device|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
135523|NCT03129399|Device|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
135524|NCT03129373|Device|Cryogenic treatment of warts|Treatment of common and plantar wart by cryotherapy treatment.
135525|NCT03129360|Drug|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
135526|NCT03129347|Drug|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
135527|NCT03129334|Behavioral|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
135528|NCT03129321|Drug|Econazole Nitrate Cream, 1%|
135529|NCT03129321|Drug|Placebo|
135530|NCT03129308|Diagnostic Test|Blood Sampling|4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
135531|NCT03129295|Drug|MPC-SHRC|Oral tablet four times a day for 3 days
135532|NCT03129295|Drug|Placebo Oral Tablet|Oral tablet four times a day for 3 days
135533|NCT03129282|Other|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
135534|NCT03129269|Procedure|MRI and PET scan|Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of [18F]AV-45 will be injected into each subject in an intravenous bolus.
135535|NCT03129256|Drug|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
135536|NCT03129243|Diagnostic Test|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
135537|NCT03129230|Procedure|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
135566|NCT03128957|Device|Licox cerebral oxygenation monitor|Measuring tissue cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
135567|NCT03128957|Other|Cerebral oxygenation|Measuring cerebral oxygenation with varying ventilation strategy
135538|NCT03129204|Behavioral|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
135539|NCT03129191|Device|Non-invasive bone conduction hearing aid A|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
135540|NCT03129191|Device|Non-invasive bone conduction hearing aid B|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
135541|NCT03129178|Dietary Supplement|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
135542|NCT03129165|Other|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.~Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.~Social: Social worker care."
135543|NCT03129139|Drug|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
135544|NCT03129126|Drug|Placebo|Placebo, normal saline
135545|NCT03129126|Drug|LP-10|Intravesical tacrolimus
135546|NCT03129113|Drug|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
135547|NCT03129113|Drug|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
135548|NCT03129100|Drug|Ixekizumab|Administered SC
135549|NCT03129100|Drug|Placebo|Administered SC
135550|NCT03129087|Behavioral|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
135551|NCT03129074|Drug|Varlitinib|everyday
135552|NCT03129074|Drug|Capecitabine|from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
135553|NCT03129061|Drug|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"Baseline: Blood sampling, tumor biopsy, [18F]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.~Anti PD-1 per standard of care~Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.~[18F]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
135554|NCT03129061|Drug|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"Baseline: Blood sampling, tumor biopsy, [18F]F-AraG PET/CT scan within two weeks prior to treatment.~Anti PD-1, single dose~Blood sampling, tumor biopsy and [18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
135555|NCT03129048|Behavioral|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.~The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.~The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.~The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
135556|NCT03129035|Procedure|Cesarean hystrectomy|Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
135557|NCT03129035|Procedure|Internal iliac artery ligation|The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
135558|NCT03129022|Procedure|epidural anaesthesia|Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
135559|NCT03129009|Drug|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
135560|NCT03129009|Drug|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
135561|NCT03128996|Drug|RIC regimen|Days -60 to -21: hydroxyurea (30mg/kg/day po) >6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if < 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if < 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
135562|NCT03128996|Drug|GVHD prophylaxis regimen|Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus & Start of mycophenolate mofetil (MMF) Days +30, +60, and +90: abatacept (IND) (10mg/kg/day IV)
135563|NCT03128983|Device|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
135564|NCT03128970|Other|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching stage into female uterus.
135565|NCT03128957|Device|IVOS cerebral oximeter|Measuring percutaneous cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
135748|NCT03127696|Behavioral|Lifestyle Modification Program|Lifestyle
135749|NCT03127696|Procedure|Sham|Sham
135568|NCT03128905|Drug|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine~Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.~Composition :~Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
135569|NCT03128905|Drug|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone~Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.~Composition :~Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
135570|NCT03128879|Drug|Ibrutinib|Given PO
135571|NCT03128879|Drug|Venetoclax|Given PO
135572|NCT03128866|Procedure|Hemipelvectomy|Undergo hemipelvectomy
135573|NCT03128866|Drug|Tranexamic Acid|Given IV
135574|NCT03128853|Device|Pulse CO-Oximeter and sensor|Noninvasive Pulse CO-Oximeter device and sensor are used to evaluate SpHb.
135575|NCT03128827|Device|RAM sensor|Acoustic Respiration Monitor
135576|NCT03128801|Procedure|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
135577|NCT03128801|Procedure|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
135578|NCT03128788|Procedure|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
135579|NCT03128775|Behavioral|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:~arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;~Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.~To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
135580|NCT03128775|Behavioral|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
135581|NCT03128775|Behavioral|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
135582|NCT03128762|Biological|ILC2 levels in blood|The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
135583|NCT03128749|Behavioral|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams & Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
135584|NCT03128749|Drug|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
135585|NCT03128736|Drug|Esomeprazole group|Esomeprazole 40mg qd
135586|NCT03128736|Drug|Dexlansoprazole group|Dexlansoprazole 60mg qd
135587|NCT03128723|Device|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
135588|NCT03128697|Behavioral|Satiating diet|
135589|NCT03128697|Behavioral|Control diet|
135590|NCT03128684|Other|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
135591|NCT03128684|Other|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
135592|NCT03128684|Other|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
135593|NCT03128684|Other|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
135594|NCT03128684|Other|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
135595|NCT03128684|Other|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
135596|NCT03128671|Behavioral|FAVoR Intervention|The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
135597|NCT03128658|Diagnostic Test|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
135598|NCT03128658|Diagnostic Test|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
135599|NCT03128645|Device|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
135600|NCT03128619|Procedure|Biopsy of Breast|Undergo biopsy
135601|NCT03128619|Drug|Copanlisib|Given IV
135602|NCT03128619|Other|Laboratory Biomarker Analysis|Correlative studies
135603|NCT03128619|Drug|Letrozole|Given PO
135604|NCT03128619|Drug|Palbociclib|Given PO
135605|NCT03128619|Other|Pharmacological Study|Correlative studies
135606|NCT03128606|Drug|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
135607|NCT03128606|Drug|Placebo single dose|Placebo, oral suspension, daily
135608|NCT03128606|Drug|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
135609|NCT03128606|Drug|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
135610|NCT03128606|Drug|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
135611|NCT03128606|Drug|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
135612|NCT03128606|Drug|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral tablet, multiple doses, daily for 14 days
135613|NCT03128606|Drug|GLPG3067/GLPG2222 Placebo multiple dose|GLPG3067 matching placebo oral suspension and GLPG2222 matching placebo oral tablet, multiple doses, daily for 14 days
135614|NCT03128606|Drug|GLPG3067/GLPG2222/GLPG2737 multiple dose|GLPG3067 oral tablet, GLPG2222 oral tablet and GLPG2737 oral capsule, multiple doses, daily for 14 days
135615|NCT03128606|Drug|GLPG3067/GLPG2222/GLPG2737 Placebo multiple dose|GLPG3067 matching placebo oral tablet, GLPG2222 matching placebo oral tablet and GLPG2737 matching placebo oral capsule, multiple doses, daily for 14 days
135616|NCT03128593|Drug|JR-141|IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
135617|NCT03128567|Device|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
135618|NCT03128554|Other|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
135619|NCT03128541|Diagnostic Test|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
135620|NCT03128528|Drug|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
135621|NCT03128528|Drug|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.~and provided by the sponsor."
135622|NCT03128515|Drug|Hydroxyurea|Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
135623|NCT03128489|Biological|Infanrix-IPV/Hib|Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
135624|NCT03128476|Dietary Supplement|Essence of Chicken|Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
135625|NCT03128476|Dietary Supplement|Placebo (Energy matched)|
135626|NCT03128463|Drug|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
135627|NCT03128450|Biological|human neural stem cell|human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
135628|NCT03128437|Behavioral|Aerobic Exercise|At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 [lower bound] or 0.80 [upper bound]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
135629|NCT03128424|Device|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
135630|NCT03128411|Drug|Bosutinib|All patinets will receive bosutinib at a starting dose of 400 mg QD.
135631|NCT03128398|Drug|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
135632|NCT03128385|Other|Intensive CIT Model Program|"Day Camp Model:~The treatment was delivered in group-based design, 6 hours a day for 6 days (36 hours in total)~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
135633|NCT03128385|Other|Distributed CIT Model Program|"Home-Based Model:~The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).~constraint of the unaffected hand to encourage the use of the affected hand~massed and repetitive practice of the affected hand during the period of constraint~use of behavioral techniques termed shaping to train the affected hand"
135634|NCT03128372|Device|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
135635|NCT03128359|Drug|Busulfan|Given IV
135636|NCT03128359|Drug|Cyclophosphamide|Given IV
135637|NCT03128359|Drug|Fludarabine Phosphate|Given IV
135638|NCT03128359|Procedure|Hematopoietic Cell Transplantation|Undergo PBSC HCT
135639|NCT03128359|Other|Laboratory Biomarker Analysis|Correlative studies
135640|NCT03128359|Drug|Melphalan Hydrochloride|Given IV
135641|NCT03128359|Drug|Mycophenolate Mofetil|Given IV or PO
135642|NCT03128359|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
135643|NCT03128359|Other|Quality-of-Life Assessment|Ancillary studies
135644|NCT03128359|Drug|Tacrolimus|Given IV
135645|NCT03128359|Radiation|Total-Body Irradiation|Undergo TBI
135646|NCT03128346|Procedure|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
135647|NCT03128346|Drug|Hydromorphone Hydrochloride|IV, Hydromorphone
135648|NCT03128346|Drug|Aspirin|Oral Aspirin
135649|NCT03128346|Drug|Acetaminophen|Oral acetaminophen
135650|NCT03128346|Drug|Fentanyl|IV, fentanyl
135651|NCT03128333|Other|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
135652|NCT03128333|Other|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
135653|NCT03128320|Drug|BAY1193397|Single dose of 1 mg BAY1193397 given in the fasted state
135654|NCT03128320|Drug|BAY1193397|Single dose of 5 mg BAY1193397 given in the fasted state
135655|NCT03128320|Drug|Placebo|Single dose of placebo given in the fasted state
135656|NCT03128307|Device|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
135657|NCT03128294|Other|Retrospective, cross-sectional descriptive analysis|This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
135658|NCT03128281|Behavioral|Questionnaires|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.~Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete."
135659|NCT03128281|Device|Conventional Insufflation System (CIS)|CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
135660|NCT03128281|Device|ConMed AirSeal Insufflation System (AIS) at Low Pressure|AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
135661|NCT03128281|Device|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
135662|NCT03128268|Device|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
135663|NCT03128255|Other|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
135664|NCT03128242|Drug|Oxytocin|intranasal administration of oxytocin (24IU)
135665|NCT03128242|Drug|placebo|intranasal administration of placebo (24IU)
135666|NCT03128216|Procedure|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
135667|NCT03128216|Procedure|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
135668|NCT03128216|Procedure|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
135669|NCT03128216|Drug|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
135670|NCT03128216|Drug|Bupivacaine|Local anesthetic used for Spinal Anesthesia
135671|NCT03128203|Drug|Oxytocin|Oxytocin, intranasally administrated
135672|NCT03128203|Drug|Placebos|Saline, intranasally administrated
135673|NCT03128190|Other|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
135674|NCT03128177|Dietary Supplement|Dietary sodium|High (6 g) versus low (1.5 g) sodium diet
135675|NCT03128164|Drug|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
135676|NCT03128151|Behavioral|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
135677|NCT03128138|Drug|SPH3127|"Drug: SPH3127 Tablet~Drug: Placebo Tablet"
135678|NCT03128125|Other|clinical examination in neurology|This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
135679|NCT03128125|Other|neuropsychological examination|This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
135680|NCT03128125|Other|anamnestic elements|Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
135681|NCT03128112|Other|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
135682|NCT03128099|Behavioral|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
135683|NCT03128086|Procedure|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
135684|NCT03128073|Device|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
135685|NCT03128060|Other|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
135686|NCT03128060|Other|Enhanced usual care|"Usual primary care consists of: 1) appointment-based access to primary care providers (PCPs) as requested by the patient; 2) case management services; and 3) provider support through palliative care consultation. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.~These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
135687|NCT03128047|Device|Optune NovoTTF-200A System|Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles.
135688|NCT03128034|Drug|Cyclosporine|Given PO or IV
135689|NCT03128034|Drug|Fludarabine Phosphate|Given IV
135690|NCT03128034|Other|Laboratory Biomarker Analysis|Correlative studies
135691|NCT03128034|Drug|Mycophenolate Mofetil|Given PO or IV
135692|NCT03128034|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
135693|NCT03128034|Other|Pharmacological Study|Correlative studies
135694|NCT03128034|Radiation|Pretargeted Radioimmunotherapy|Given 211^At-BC8-B10 IV
135695|NCT03128034|Drug|Sirolimus|Given PO
135696|NCT03128034|Radiation|Total-Body Irradiation|Undergo TBI
135697|NCT03128034|Device|Fludarabine|Given IV
135698|NCT03128021|Drug|Escitalopram Pill|Double-blinded, randomly assigned
135699|NCT03128021|Other|Placebo|Double-blinded, randomly assigned
135700|NCT03128021|Drug|Levomilnacipran Pill|Double-blinded, randomly assigned
135701|NCT03128008|Drug|Carboplatin|Single arm non randomized open label study. Subjects will recieve standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
135702|NCT03128008|Drug|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
135703|NCT03128008|Radiation|Daily hyperfractionated radiation therapy|All subjects will recieve 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
135704|NCT03127995|Radiation|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
135705|NCT03127995|Radiation|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
135706|NCT03127982|Behavioral|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
135707|NCT03127969|Other|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
135708|NCT03127969|Other|Joint protection and exercise|joint protection and exercise
135709|NCT03127956|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
135710|NCT03127943|Drug|Lidocaine|Efficacy for mandibular molar and canine anesthesia
135711|NCT03127930|Behavioral|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
135712|NCT03127917|Dietary Supplement|L-citrulline|L-citrulline capsules given at 6 g/day
135713|NCT03127917|Other|Placebo|Maltodextrin capsules given as placebo
135714|NCT03127904|Procedure|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
135750|NCT03127683|Other|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
135715|NCT03127904|Procedure|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.~As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
135716|NCT03127891|Behavioral|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
135717|NCT03127891|Other|control group|no intervention should be given to patients allocated to this group
135718|NCT03127878|Other|Exercise|
135719|NCT03127852|Device|Medly|
135720|NCT03127839|Procedure|Eccentric Strengthening|Use of eccentric strengthening exercises in treatment plan during visits and at home.
135721|NCT03127839|Procedure|Traditional Strengthening|Use of traditional strengthening exercises in treatment plan during visits and at home.
135722|NCT03127839|Behavioral|Pain education|Addition of pain neuroscience-focused education in addition to strengthening exercise program
135723|NCT03127826|Procedure|Risk Stratified Care|"Physical therapists providing care will all have attended live training in PIPT principles and be involved in monthly continuing education on these principles. The use of specific principles is guided by the patient's risk stratification (as determined by the STarT Back Tool).~Medium Risk:~- Reassurance will be provided to address specific concerns related to their LBP and implications on work~High Risk:~- Physical therapy will be psychologically augmented with the assessment of biopsychosocial risk factors and the adoption of cognitive behavioral principles that explore patient concerns and address unhelpful beliefs and behaviors, including tailored education (e.g., stress management and pain neuroscience), graded exercise, & graded exposure"
135724|NCT03127826|Procedure|Usual Care|Usual care at the general practitioner's discretion
135725|NCT03127813|Other|Application of continuous positive airway pressure (CPAP)|CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
135726|NCT03127800|Drug|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
135727|NCT03127787|Diagnostic Test|CMV Assay|Molecular diagnostic test to detect CMV
135728|NCT03127774|Drug|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2~Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
135729|NCT03127774|Drug|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours~Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
135730|NCT03127774|Procedure|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
135731|NCT03127761|Other|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
135732|NCT03127735|Drug|BAY1436032|"BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion."
135733|NCT03127722|Procedure|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline, 12 months and 60 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization.
135734|NCT03127722|Device|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
135735|NCT03127722|Procedure|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol.
135736|NCT03127709|Behavioral|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
135737|NCT03127709|Behavioral|Brief Test of Attention|Assesses auditory working memory
135738|NCT03127709|Behavioral|Symbol Span|Assesses visual working memory
135739|NCT03127709|Behavioral|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
135740|NCT03127709|Behavioral|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
135741|NCT03127709|Behavioral|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
135742|NCT03127709|Behavioral|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
135743|NCT03127709|Behavioral|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
135744|NCT03127709|Diagnostic Test|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
135745|NCT03127709|Diagnostic Test|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
135746|NCT03127709|Behavioral|Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)|This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.
135747|NCT03127696|Procedure|Fecal Microbiota Transplantation|FMT
135751|NCT03127683|Other|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
135752|NCT03127683|Other|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
135753|NCT03127683|Other|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
135754|NCT03127683|Device|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
135755|NCT03127670|Drug|Solanum melongena peel extract 0.05%|Administered topically twice daily for 12 weeks
135756|NCT03127657|Drug|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
135757|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
135758|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
135759|NCT03127644|Drug|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
135760|NCT03127631|Behavioral|Nutrition|Standardized advice on healthy diet practices.
135761|NCT03127631|Behavioral|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
135762|NCT03127631|Behavioral|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
135763|NCT03127631|Drug|Antiplatelet agent, such as Aspirin, or other low-dose antiplatelet agent|Prescription for a low-dose antiplatelet agent, such as aspirin 81-100mg daily or if intolerant of aspirin, other low-dose antiplatelet agent
135764|NCT03127631|Drug|Statin, such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
135765|NCT03127631|Drug|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >120mmHg, or other blood pressure lowering medication as applicable.
135766|NCT03127618|Drug|Lorlatinib|
135767|NCT03127605|Drug|Inotuzumab Ozogamicin|
135768|NCT03127592|Drug|Fixed Dose Combination|Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
135769|NCT03127592|Drug|Etodolac|Individual drug
135770|NCT03127592|Drug|Cyclobenzaprine|Individual drug
135771|NCT03127579|Behavioral|Longer meal duration|Participants have 50% more time to eat than usual
135772|NCT03127553|Dietary Supplement|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
135773|NCT03127553|Dietary Supplement|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
135774|NCT03127514|Drug|AMX0035|AMX0035
135775|NCT03127514|Other|Placebo|Matching Placebo Comparator
135776|NCT03127475|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
135777|NCT03127462|Behavioral|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
135778|NCT03127449|Drug|Alflutinib|patients take Alflutinib orally once per day at different dose
135779|NCT03127436|Drug|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
135780|NCT03127423|Procedure|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
135781|NCT03127423|Procedure|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
135782|NCT03127410|Other|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
135783|NCT03127397|Behavioral|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
135784|NCT03127384|Device|Restylane Lidocaine|Hyaluronic acid based filler
135785|NCT03127384|Other|No-treatment control|No-treatment control
135786|NCT03127371|Drug|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
135787|NCT03127371|Drug|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
135788|NCT03127358|Behavioral|Automated Directly Observed Therapy|Participants will be randomized to either a-DOT or TAU. Participants randomized to the a-DOT group will receive treatment for HCV with Elbasvir-Grazoprevir using a cellphone app to monitor adherence, w
135789|NCT03127358|Behavioral|Control, TAU|Participants in the control group (TAU), will receive treatment for HCV with Elbasvir-Grazoprevir as per standard of care.
135790|NCT03127345|Drug|Omegaven|Intravenous omega 3 fatty acid administration
135792|NCT03127332|Other|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
135793|NCT03127319|Drug|apatinib docetaxel zoledronic|apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
135794|NCT03127319|Drug|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
135795|NCT03127306|Diagnostic Test|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
135796|NCT03127293|Diagnostic Test|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
135797|NCT03127280|Other|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
135798|NCT03127267|Drug|Masitinib (6.0)|Masitinib (titration to 6.0 mg/kg/day)
135799|NCT03127267|Drug|Riluzole|Riluzole 50 mg tablet, treatment per os
135800|NCT03127267|Drug|Placebo|treatment per os
135801|NCT03127267|Drug|Masitinib (4.5)|Masitinib (titration to 4.5 mg/kg/day)
135802|NCT03127254|Behavioral|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
135803|NCT03127254|Behavioral|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
135804|NCT03127254|Behavioral|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
135805|NCT03127254|Behavioral|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
135806|NCT03127254|Behavioral|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
135807|NCT03127241|Device|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
135808|NCT03127241|Device|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.~Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
135809|NCT03127228|Other|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
135810|NCT03127228|Device|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
135811|NCT03127215|Drug|Olaparib|Olaparib 150 mg tablet
135812|NCT03127215|Drug|Physician's choice|treatment according to current guidelines
135813|NCT03127215|Drug|Trabectedin|Trabectedin 1.1mg/m² infusional solution
135814|NCT03127202|Device|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
135815|NCT03127189|Drug|Rilpivirine|Rilpivirine 25 mg immediate release oral solution.
135816|NCT03127189|Drug|Rilpivirine Long-acting Parenteral Formulation|RPV LA 600 mg extended-release suspension for IM injection.
135817|NCT03127176|Other|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at −80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
135818|NCT03127163|Device|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
135819|NCT03127137|Other|Control cohort group|Control cohort group will receive medications not predetermined by the set protocol.
135820|NCT03127137|Drug|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
135821|NCT03127137|Drug|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
135822|NCT03127124|Drug|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI)
135823|NCT03127124|Drug|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
135824|NCT03127124|Drug|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
135825|NCT03127124|Drug|Leucovorin Calcium Injection|Calcium N -[p -[[[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1).
135826|NCT03127124|Drug|Eloxatin Injectable Product|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum.
135827|NCT03127111|Genetic|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
135828|NCT03127111|Genetic|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
135829|NCT03127111|Genetic|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
135830|NCT03127111|Genetic|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
135831|NCT03127111|Genetic|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
135832|NCT03127098|Biological|ETBX-011|ETBX-011 immunization will be administered by subcutaneous (SC) injection.
135833|NCT03127098|Biological|ALT-803|ALT-803 will be administered by SC injection.
135834|NCT03127072|Device|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
135835|NCT03127072|Drug|chemotherapy ± target therapy|chemotherapy ± target therapy
135836|NCT03127059|Other|Breathing Exercises|"Key points in the intervention are~Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.~Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.~Inclusion of the breathing modification into walking and other physical activities.~Daily home exercise of BrEX."
135837|NCT03127059|Other|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
135838|NCT03127046|Drug|Aceclofenac|Oral single dose administration of aceclofenac 200mg
135839|NCT03127046|Drug|Esomeprazole|Oral single dose administration of aceclofenac 200mg
135840|NCT03127046|Drug|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
135841|NCT03127033|Other|Soft liner telescopes|"Soft liner telescopes: Overdenture will be adjusted by relieving acrylic opposite to the abutment about 2 mm using a metal stone. The relieved areas will be painted with an adhesive and the rest of the fitting surface of the denture will be painted with a separating medium.~The soft liner (Silicone based soft liner, mollosil, chairside soft relining-long term, DETAX, Germany) will then be applied in the relieved areas to act as a secondary coping The base and catalyst will be mixed according to the manufacturer's instructions on a glass slab. The mix will be placed on the relieved area, seated in the patient's mouth, the patient is asked to bite in centric relation and the excess liner is removed with a lancet."
135842|NCT03127020|Drug|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
135843|NCT03127007|Drug|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
135844|NCT03127007|Drug|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
135845|NCT03126994|Device|PhysioWave Cardiovascular Analyzer|Measurement of Pulse Wave Velocity, Pulse Rate, Body Weight and BMI
135846|NCT03126994|Device|AtCor XCEL PWA & PWV|Measurement of Pulse Wave Velocity and Pulse Rate
135847|NCT03126994|Device|Detecto SOLO|Measurement of Body Weight and BMI
135848|NCT03126981|Other|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
135849|NCT03126981|Other|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
135850|NCT03126968|Drug|Topical epinephrine|Prophylactic topical epinephrine
135851|NCT03126968|Drug|Placebos|Topical placebo (normal saline)
135852|NCT03126955|Diagnostic Test|Pre-Operative CISS-MRI Sequences|Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
135853|NCT03126955|Diagnostic Test|Pre-Operative Interictal Laryngoscopy|Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
135854|NCT03126955|Diagnostic Test|Pre-Operative Unilateral and Contralateral Botox|Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
135855|NCT03126942|Device|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
135856|NCT03126942|Device|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
135857|NCT03126929|Diagnostic Test|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
135858|NCT03126916|Biological|Aldesleukin|Given IV
135859|NCT03126916|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HSCT
135860|NCT03126916|Drug|Busulfan|Given IV
135861|NCT03126916|Drug|Carboplatin|Given IV
135862|NCT03126916|Drug|Cisplatin|Given IV
135863|NCT03126916|Drug|Crizotinib|Given PO
135864|NCT03126916|Drug|Cyclophosphamide|Given IV
135865|NCT03126916|Drug|Dexrazoxane Hydrochloride|Given IV
135866|NCT03126916|Biological|Dinutuximab|Given IV
135867|NCT03126916|Drug|Doxorubicin Hydrochloride|Given IV
135868|NCT03126916|Drug|Etoposide Phosphate|Given IV
135869|NCT03126916|Radiation|External Beam Radiation Therapy|Undergo EBRT
135876|NCT03126916|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
135877|NCT03126916|Drug|Thiotepa|Given IV
135878|NCT03126916|Drug|Topotecan Hydrochloride|Given IV
135879|NCT03126916|Drug|Vincristine Sulfate|Given IV
135880|NCT03126903|Device|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
135881|NCT03126877|Drug|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
135882|NCT03126877|Device|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
135883|NCT03126864|Procedure|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10^9 (expected range 5 x 10^8 - 5 x 10^10), for up to two days.
135884|NCT03126864|Drug|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
135885|NCT03126864|Drug|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
135886|NCT03126864|Biological|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is > 1.5 x 105/kg but ≤ 4.5 x 105/kg.
135887|NCT03126851|Other|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
135888|NCT03126825|Device|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
135889|NCT03126825|Device|CP910/CP920|The approved CP910 or CP920 Sound Processor.
135890|NCT03126812|Drug|Carboplatin|Carboplatin AUC=6
135891|NCT03126812|Drug|Paclitaxel|paclitaxel 80 mg/m2
135892|NCT03126812|Drug|Pembrolizumab|200 mg flat dose, starting cycle 2
135893|NCT03126799|Drug|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
135894|NCT03126799|Drug|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
135895|NCT03126786|Drug|IVT aflibercept|IVT aflibercept [2 mg (0.05 mL)]
135896|NCT03126786|Drug|Sham SC|sham SC
135897|NCT03126786|Drug|SC CLS-TA|SC CLS-TA [40 mg/mL]
135898|NCT03126773|Drug|BAY86-4891|Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.
135899|NCT03126760|Drug|Repository Corticotropin Injection|Administered subcutaneously once a day for 14 consecutive days
135900|NCT03126760|Drug|Placebo|Administered subcutaneously once a day for 14 consecutive days
135901|NCT03126747|Drug|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
135902|NCT03126734|Other|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
135903|NCT03126721|Drug|midazolam|a single oral dose of 2 mg midazolam
135904|NCT03126721|Drug|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
135905|NCT03126708|Drug|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
135906|NCT03126708|Drug|cisplatin plus paclitaxel|Chemotherapy
135907|NCT03126695|Drug|Ticagrelor granule|A P2Y12 receptor inhibitor provided as granule for suspension.
135908|NCT03126695|Drug|Ticagrelor pediatric tablets|A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
135909|NCT03126695|Drug|Ticagrelor pediatric tablets suspended in water|A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
135910|NCT03126695|Drug|Ticagrelor immediate release (IR) tablets (Commercial tablet)|A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
135911|NCT03126682|Drug|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
135912|NCT03126669|Device|Hyperbaric oxygen|Breathing 100% oxygen at 2ATA in the hyperbaric chamber
135913|NCT03126669|Device|Hyperbaric chamber, normal air|Hyperbaric chamber with normal air
135914|NCT03126656|Drug|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
135915|NCT03126643|Biological|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
135916|NCT03126630|Biological|Anetumab Ravtansine|Given IV
135917|NCT03126630|Other|Laboratory Biomarker Analysis|Correlative studies
135918|NCT03126630|Biological|Pembrolizumab|Given IV
135919|NCT03126630|Other|Pharmacological Study|Correlative studies
135920|NCT03126617|Biological|Elotuzumab|Elotuzumab (Emplicitii) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
135921|NCT03126604|Diagnostic Test|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
135922|NCT03126591|Drug|Olaratumab|Administered IV
135924|NCT03126578|Drug|LEO 32731|LEO 32731 is being developed by LEO Pharma.
135925|NCT03126578|Drug|Midazolam|Benzodiazepine
135926|NCT03126565|Other|Lifeline CareSage Flagging|Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
135927|NCT03126552|Biological|Necator americanus L3 larvae|50 Necator americanus L3 larvae
135928|NCT03126539|Drug|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
135929|NCT03126539|Radiation|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera UVB light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
135930|NCT03126539|Procedure|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
135931|NCT03126526|Behavioral|Food specific Inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
135932|NCT03126526|Behavioral|Implementation intentions|"It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future."
135933|NCT03126526|Behavioral|General inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
135934|NCT03126513|Procedure|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
135935|NCT03126487|Procedure|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
135936|NCT03126461|Radiation|SAbR|"For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose."
135937|NCT03126461|Drug|Ipilimumab|ipilimumab 3mg/kg IV q3wk x 4
135938|NCT03126461|Drug|Nivolumab|nivolumab 1 mg/kg IV q3wk x 4
135939|NCT03126448|Diagnostic Test|Highly Sensitive Assays|Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
135940|NCT03126435|Drug|EndoTAG-1|twice weekly
135941|NCT03126435|Drug|Gemcitabine|once weekly
135942|NCT03126422|Drug|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
135943|NCT03126409|Procedure|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
135944|NCT03126409|Procedure|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
135945|NCT03126396|Device|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
135946|NCT03126370|Drug|TDF with a boosted protease inhibitor|"Subjects who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment"
135947|NCT03126370|Drug|TAF with a boosted protease inhibitor|"Subjects will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment"
135948|NCT03126370|Drug|TAF with a boosted protease inhibitor and LDV/SOF|"After taking tenofovir alafenamide/emtricitabine for 12 weeks, subjects will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment"
135949|NCT03126357|Other|Product A|Usual Brand Cigarette
135950|NCT03126357|Other|Product B|FT21039 an electronic tobacco vapor product
135951|NCT03126357|Other|Product C|FT21092 an electronic tobacco vapor product
135952|NCT03126357|Other|Product D|FT21018 an electronic tobacco vapor product
135953|NCT03126357|Other|Product E|4mg nicotine gum
135954|NCT03126344|Device|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
135955|NCT03126344|Device|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
135956|NCT03126344|Device|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
135957|NCT03126331|Drug|Nivolumab|240mg every 2 weeks. At 12 weeks reassess. If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more
135958|NCT03126318|Drug|COR-001|Anti-inflammatory therapy
135959|NCT03126318|Drug|Placebo|Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
135960|NCT03126305|Other|OC-Go|OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
135961|NCT03126292|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
135962|NCT03126292|Other|Child Safety Handout|Handout regarding early child safety
135963|NCT03126279|Procedure|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
135964|NCT03126266|Radiation|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
135965|NCT03126253|Diagnostic Test|Anemia|"Hemoglobin level will be used as the parameter for diagnosing anemia. The HemoCue system was used to estimate the concentration of hemoglobin in capillary blood. WHO guidelines for the diagnosis of anemia that were adopted by the Demographic Health Surveys will be used in this study. Briefly, a hemoglobin concentration of less than 70 g/L will be consider to define severe anemia, 70-99 g/L for moderate anemia, and 100-109 g/L will be presumed to correspond to mild anemia. The above-mentioned classification of anemia as severe moderate and mild categories is based on blood hemoglobin cutoffs (will be adjusted for altitude and smoking) recommended by the Center for Disease Prevention of United States; this classification has also been adopted by the World Health Organization."
135966|NCT03126227|Biological|AR101|AR101 powder provided in capsules
135967|NCT03126227|Biological|Placebo|Placebo powder provided in capsules
135968|NCT03126214|Drug|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
135969|NCT03126188|Drug|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
135970|NCT03126188|Drug|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
135971|NCT03126188|Drug|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
135972|NCT03126175|Device|Below elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb.
135973|NCT03126175|Device|Above elbow immobilization|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
135974|NCT03126162|Procedure|InstilIing normal saline into bladder|Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
135975|NCT03126162|Procedure|Removal of foley catheter|Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
135976|NCT03126149|Drug|PF-06667272|Single ascending dose of PF-06667272
135977|NCT03126149|Other|Placebo|Single dose of placebo
135978|NCT03126136|Device|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
135979|NCT03126123|Procedure|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
135980|NCT03126110|Drug|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
135981|NCT03126110|Drug|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
135982|NCT03126110|Drug|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
135983|NCT03126097|Drug|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] and on Days 60 to 66 [JNJ-64155806 + COCP Coadministration Phase].
135984|NCT03126097|Drug|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
135985|NCT03126097|Drug|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
135986|NCT03126084|Drug|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
135987|NCT03126084|Drug|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
135988|NCT03126084|Drug|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
135989|NCT03126084|Drug|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
136298|NCT03123484|Drug|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
135990|NCT03126084|Procedure|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
135991|NCT03126084|Drug|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
135992|NCT03126071|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv 15min,d1,q3w.
135993|NCT03126071|Drug|Irinotecan|Irinotecan:250mg/m2,iv 90min,d1,q3w.
135994|NCT03126071|Drug|Oxaliplatin|Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
135995|NCT03126071|Drug|Bevacizumab|Bevacizumab:75mg/kg,iv 30min,d1,q3w.
135996|NCT03126058|Procedure|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
135997|NCT03126045|Device|Standard needle|"Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
135998|NCT03126045|Device|Atraumatic needle|"Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the Lucien Neuwirth Cancerology Institute. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.~When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
135999|NCT03126032|Other|GlycoCheck™-System|"Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.~Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay."
136000|NCT03126019|Drug|Parsaclisib|Parsaclisib at the protocol-defined starting dose for 8 weeks, followed by Parsaclisib at the protocol-defined dose QD
136001|NCT03126019|Drug|Parsaclisib|Parsaclisib at the protocol-defined starting dose for 8 weeks, followed by Parsaclisib at the protocol-defined dose once weekly
136002|NCT03126006|Procedure|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
136003|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
136004|NCT03125993|Behavioral|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week brisk walking.
136005|NCT03125980|Drug|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:~Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~Repeat every 3 weeks (Q3W)"
136006|NCT03125980|Drug|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:~Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1~Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14~Q3W"
136007|NCT03125967|Other|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
136008|NCT03125967|Other|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
136009|NCT03125954|Other|standardized exercise treatment for knee OA in Denmark (GLAiD)|objective measurement of physical activity before, during af after the GLAiD intervention
136010|NCT03125941|Drug|Dexamethasone|pre-operative intravenous administration
136011|NCT03125928|Drug|Atezolizumab|Monoclonal antibody
136012|NCT03125928|Drug|Paclitaxel|Chemotherapy
136013|NCT03125928|Drug|Trastuzumab|Monoclonal antibody
136014|NCT03125928|Drug|Pertuzumab|Monoclonal antibody
136015|NCT03125915|Behavioral|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
136016|NCT03125915|Behavioral|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
136017|NCT03125915|Behavioral|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
136018|NCT03125902|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
136019|NCT03125902|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
136020|NCT03125902|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
136021|NCT03125889|Device|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
136022|NCT03125876|Drug|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
136023|NCT03125863|Device|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
136024|NCT03125850|Other|randomized to day ward|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
136025|NCT03125850|Other|randomized to inpaitent|Participants will be randomized to day-ward group, and will accept routine treatment, care, centralized education of glaucoma knowledge
136026|NCT03125824|Device|Soliton Acoustic Wave Device|Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
136027|NCT03125811|Other|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
136028|NCT03125811|Drug|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
136029|NCT03125798|Device|LigaSure™|LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.
136030|NCT03125798|Device|Monopolar electrocautery|Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
136031|NCT03125772|Device|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
136032|NCT03125772|Device|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
136033|NCT03125746|Drug|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
136034|NCT03125746|Drug|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
136035|NCT03125733|Procedure|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:~Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.~Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.~Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.~Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
136036|NCT03125720|Other|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
136037|NCT03125707|Other|Registry study|not available
136038|NCT03125694|Drug|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
136039|NCT03125694|Drug|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
136040|NCT03125681|Procedure|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
136041|NCT03125681|Procedure|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
136042|NCT03125668|Behavioral|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
136043|NCT03125668|Behavioral|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).~During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
136044|NCT03125668|Behavioral|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
136045|NCT03125655|Diagnostic Test|Inflammatory markers|
136046|NCT03125642|Drug|Etoposide|"BEAM: 100 mg/m^2 IV over 2 hours BID on Days -5, -4, -3, -2 | CBV: 150 mg/m^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
136047|NCT03125642|Drug|BCNU|BEAM & CBV: 300 mg/m^2 IV over over 2 hours on Day -6
136048|NCT03125642|Drug|AraC|BEAM: 100 mg/m^2 IV over 1 hour BID on Days -5, -4, -3, -2
136049|NCT03125642|Drug|Melphalan|BEAM: 140 mg/m^2 IV over 20 minutes on Day -1
136050|NCT03125642|Procedure|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
136051|NCT03125642|Biological|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3
136052|NCT03125642|Drug|Cyclophosphamide|"CBV: 1.5 gm/M^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 | CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
136053|NCT03125642|Radiation|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
136054|NCT03125629|Drug|Ga-68-DOTA-TATE|Positron emission tomography / computed tomography (PET/CT) imaging radiolabel
136055|NCT03125629|Drug|F-18 FDG|Positron emission tomography / computed tomography (PET/CT) imaging radiolabel
136056|NCT03125629|Device|Positron Emission Tomography / Computed Tomography (PET/CT) Scan|Scan using a regular medical care Discovery 600 / 690 PET/CT scanner.
136057|NCT03125629|Device|Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Scan|Scan using a NOVEL GE PET/MRI scanner.
136058|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
136059|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
136060|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
136061|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
136062|NCT03125603|Other|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
136063|NCT03125590|Other|Testing the PEQ (Personalized Exercise Questionnaire)|Administer the questionnaire to 114 participants to classify their facilitators, barriers and preferences to exercise
136064|NCT03125577|Biological|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
136065|NCT03125577|Biological|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
136066|NCT03125577|Biological|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
136067|NCT03125577|Biological|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
136068|NCT03125577|Biological|4SCAR19 and 4SCAR70|4SCAR19 and 4SCAR70
136069|NCT03125577|Biological|4SCAR19 and 4SCAR30|4SCAR19 and 4SCAR30
136070|NCT03125564|Procedure|Fecal Microbiota Transplantation|Fecal microbiota transplantation
136071|NCT03125564|Procedure|Sham|Infusion of sham
136072|NCT03125564|Procedure|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
136073|NCT03125551|Dietary Supplement|Ginger|Ginger dosage at daily recommended allowance
136074|NCT03125551|Dietary Supplement|Garlic|Garlic dosage at daily recommended allowance
136075|NCT03125551|Dietary Supplement|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
136076|NCT03125551|Dietary Supplement|Ginseng|Ginseng dosage at daily recommended allowance
136077|NCT03125551|Other|Placebo|Daily dosage strategy
136078|NCT03125538|Other|Motor Imagery|"Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.~Exercise 1: 10m Walk~Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)~Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)~Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day."
136079|NCT03125538|Other|Control Task|"Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).~Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day."
136080|NCT03125525|Device|Cefaly device|Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
136081|NCT03125512|Device|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
136082|NCT03125512|Device|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
136083|NCT03125499|Other|Previous treated with TPX-100|No intervention, only observational
136084|NCT03125486|Drug|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
136085|NCT03125473|Biological|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
136086|NCT03125460|Device|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
136087|NCT03125447|Other|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
136088|NCT03125434|Other|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
136089|NCT03125421|Procedure|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
136090|NCT03125421|Procedure|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
136091|NCT03125408|Diagnostic Test|HCV Assay|Molecular diagnostic test to detect Hepatitus C
136092|NCT03125395|Drug|Lumacaftor|LUM/IVA will be administered q12h
136094|NCT03125382|Device|Carelink System|Patients start to perform device data transmission through Carelink system
136095|NCT03125382|Device|In office standard visit|Patients start or mantain in office standard visits
136096|NCT03125369|Procedure|Sleeve gastrectomy + duodeno-jejunal bypass|
136097|NCT03125369|Procedure|Roux-Y gastric bypass|
136098|NCT03125356|Other|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
136099|NCT03125343|Procedure|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.~They will be followed ever third month for the first two years as follows:~PET-CT is optional, but can be performed at inclusion~Pelvic MRI including diffusion weighted imaging according to appendix C.~Clinical examination~Endoscopy (flexible sigmoidoskopy) with photodocumentation~CEA~After two years the patients will be followed every six month with:~Pelvic MRI including diffusion weighted imaging according to appendix as at baseline~Clinical examination~Endoscopy with photodocumentation~CEA"
136100|NCT03125343|Procedure|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
136101|NCT03125343|Device|MRI|
136102|NCT03125330|Behavioral|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
136103|NCT03125317|Other|Music|a kind of music which the participant likes will be listened using speakers
136104|NCT03125317|Other|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
136105|NCT03125317|Other|control|No intervention
136106|NCT03125304|Other|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
136107|NCT03125291|Behavioral|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
136108|NCT03125278|Other|Medication knowledge|Participants will be asked questions over the phone about their medications
136109|NCT03125265|Other|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
136110|NCT03125252|Other|Bundle|"Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility~Factors of environment:~thirst~noise~pain and well-being~sleep~isolation"
136111|NCT03125252|Other|Standard Paramedical and Medical practices|"The current recommendations recommend the following scheme:~Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)~Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)~Use of reference antipsychotic pharmacological means"
136112|NCT03125239|Drug|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
136113|NCT03125239|Drug|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
136114|NCT03125226|Device|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
136115|NCT03125213|Drug|AL-3778|AL-3778 tablets
136116|NCT03125213|Drug|Peginterferon Alfa-2A|Peginterferon Alfa-2A for subcutaneous injection
136117|NCT03125213|Drug|Placebo Oral Tablet|Placebo to Match AL-3778 tablet
136118|NCT03125200|Drug|ADCT-502|Intravenous Infusion
136119|NCT03125187|Biological|Sodium heparin UQ Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
136120|NCT03125187|Biological|Sodium heparin FK Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
136121|NCT03125161|Drug|HAI|HAI
136122|NCT03125161|Drug|chemotherapy ± target therapy|chemotherapy ± target therapy
136123|NCT03125148|Device|Enteral stenting|Enteral stent for malignant duodenal obstruction
136124|NCT03125083|Biological|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
136125|NCT03125070|Other|Best Practice|Receive usual care
136126|NCT03125070|Other|Internet-Based Intervention|Receive INSPIRE and survivorship care plan
136127|NCT03125070|Other|Survey Administration|Correlative studies
136128|NCT03125057|Drug|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
136129|NCT03125031|Device|Rainbow adhesive adult/pediatric sensor|
136130|NCT03125031|Device|Rainbow adhesive adult/neonatal sensor|
136131|NCT03125018|Device|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
136132|NCT03125005|Device|Rainbow Universal Pulse Oximeter Sensor|
136133|NCT03124979|Device|LNCS DBI Sensor|Noninvasive Measurement of SpO2
136134|NCT03124966|Device|Pulse Oximeter sensor|
136135|NCT03124927|Device|DCI pulse oximeter sensor|
136136|NCT03124914|Other|Neuromuscular tests|Neuromuscular tests
136137|NCT03124901|Device|DCI pulse oximeter sensor|
136138|NCT03124875|Device|LimFlow Stent Graft System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
136139|NCT03124862|Device|ARM sensor|Acoustic Monitoring sensor that monitors respiratory rate
136140|NCT03124836|Device|Pulse Oximeter Sensor|
136141|NCT03124823|Device|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
136142|NCT03124797|Device|RD DCI Sensor|Noninvasive pulse oximeter sensor
136143|NCT03124784|Device|RD Disposable Sensors|Noninvasive pulse oximeter sensor
136144|NCT03124771|Device|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
136145|NCT03124758|Device|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
136146|NCT03124693|Device|Rainbow DCI pulse oximeter sensor|
136147|NCT03124680|Combination Product|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
136148|NCT03124680|Combination Product|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
136149|NCT03124667|Behavioral|Games|The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
136150|NCT03124667|Behavioral|Videos|The video training will emphasize health and educational information.
136151|NCT03124654|Behavioral|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
136152|NCT03124641|Device|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
136153|NCT03124641|Procedure|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
136154|NCT03124628|Other|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
136155|NCT03124628|Other|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
136156|NCT03124615|Drug|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
136157|NCT03124602|Device|Red Diamond Disposable Pulse Oximeter Sensor|Noninvasive Pulse Oximeter Sensor
136158|NCT03124589|Behavioral|Online Gambling Internet Intervention|CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
136159|NCT03124576|Device|Implantable loop recorder|Continuous rhythm monitoring Medtronic
136160|NCT03124563|Behavioral|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. Participants in the control group will be matched with the intervention group for how much contact they have with the researcher.
136161|NCT03124563|Behavioral|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily activity data. The first week of the study will provide a baseline measurement of activity. After this week, participants will be asked to increase their steps incrementally by 2,000 steps each week for the subsequent four weeks. To help achieve their step goals, they will receive maps of different routes near their home and/or work of varying distances and step counts. They will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire.
136162|NCT03124550|Behavioral|Exergame Experience|"Behavioral: Exergame Experience~Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 6-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time."
136163|NCT03124537|Behavioral|App Experimental condition|This group will be given the app to 1) count their steps, 2) add walks to their daily schedules, 3) create maps of their walking routes, and 4) text friends to invite them for a walk. Participants are asked to set a daily step goal and they can see how many steps they've taken each day since using the app. 2) There is an interface where participants can create maps based on walking routes. 3) They will also have the option to use a daily schedule to plan certain times in the day that they can walk. 4) The social feature gives participants the option to message friends, co-workers, or neighbors in one's contact list to invite them for a walk.
136164|NCT03124537|Behavioral|App Condition Control|This group will receive the app with the first component, the ability to count steps and set daily step goals. This group will also be able to track walks to see the time, distance, and steps of each walk, but not see these walks displayed as a map. This group will monitor their daily steps over a one-month period, and will be asked to use the app as much as possible.
136165|NCT03124524|Drug|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
136166|NCT03124524|Drug|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
136167|NCT03124511|Procedure|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
136168|NCT03124498|Biological|CIK Cell|Autologous cytokine-induced killer (CIK) cell
136296|NCT03123510|Dietary Supplement|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
136169|NCT03124485|Procedure|Endoscopic Sleeve Gastroplasty|An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
136170|NCT03124485|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
136171|NCT03124472|Procedure|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
136172|NCT03124472|Procedure|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~Closure of the anterior abdominal wall in layers"
136173|NCT03124459|Drug|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
136174|NCT03124459|Drug|Placebo|Recombinant fusion protein or buffer solution
136175|NCT03124446|Behavioral|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
136176|NCT03124446|Behavioral|Enhanced Usual Care Control|Participants in the enhanced usual care control group were spoken with by trained study staff, and as part of the enhanced usual care, were offered a referral to the study's psychiatrist and University counseling resources, if anxiety, depression, or suicidal ideation levels at baseline or follow-up reached clinical levels on the Beck Anxiety Inventory or the Revised Centers for Epidemiologic Studies Depression (CESD-R) scale. Participants in the control group were eligible to take the MB-College program during the following university term.
136177|NCT03124433|Drug|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
136178|NCT03124420|Drug|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
136179|NCT03124420|Drug|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
136180|NCT03124420|Drug|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
136181|NCT03124407|Drug|Capsaicin Topical Solution|OTC TFM compliant product with 0.25% capsaicin
136182|NCT03124407|Other|Drug product vehicle|This is the vehicle for the active treatment drug product
136183|NCT03124381|Device|Cleanser, Acne Mask|A facial cleanser will be used twice daily (morning and evening). The light therapy mask will be used for 10 minutes in the evening after washing/drying the face.
136184|NCT03124381|Device|Cleanser, Gel-Cream, Acne Mask|A facial cleanser will be used twice daily (morning and evening). In the evening after cleansing, the gel-cream will be applied full face and allowed to dry before the light therapy mask is used for 10 minutes.
136185|NCT03124368|Drug|ACH-0144471|Participants will receive study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period)
136186|NCT03124355|Drug|placebo sugar pill|placebo single oral dose
136187|NCT03124355|Drug|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
136188|NCT03124355|Drug|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
136189|NCT03124355|Device|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
136190|NCT03124355|Device|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
136191|NCT03124342|Other|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:~Nurse Practitioner In-Person Visit at the time of transfer from the ICU~Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources~Performance of formal medication reconciliation at the time of transfer from the ICU~Access to a dedicated 24-hour a day, 7-day a week contact line~ICU Recovery Clinic Visit Medical Examination.~ICU Recovery Clinic Medication Reconciliation and Counseling~ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist~ICU Recovery Clinic Case Management. A brief case management consultation~ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician~Directed Subspecialty Referrals"
136192|NCT03124329|Procedure|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
136297|NCT03123497|Other|completion of questionnaire|completion of questionnaire for patient and parent
136193|NCT03124329|Procedure|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
136194|NCT03124329|Biological|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
136195|NCT03124329|Device|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
136196|NCT03124316|Behavioral|Anticipated regret|Induce awareness of future regret about the unwanted behaviour
136197|NCT03124316|Behavioral|Material incentive|Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
136198|NCT03124316|Behavioral|Problem solving|Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
136199|NCT03124303|Procedure|High Density-Electroencephalogram|EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
136200|NCT03124303|Procedure|Magnetic Resonance Imaging|MRI scan of brain
136201|NCT03124290|Other|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
136202|NCT03124277|Dietary Supplement|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
136203|NCT03124277|Other|Control Group|Best local diet
136204|NCT03124238|Other|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
136205|NCT03124225|Drug|DMARD|
136206|NCT03124212|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
136207|NCT03124199|Drug|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
136208|NCT03124186|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
136209|NCT03124173|Other|Training session|The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
136210|NCT03124173|Other|First fMRI session|In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
136211|NCT03124173|Other|Second fMRI session|In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
136212|NCT03124173|Other|Third session of fMRI|In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
136213|NCT03124160|Drug|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini
136214|NCT03124160|Drug|ParaGard® CuT380A|ParaGard® CuT380A
136215|NCT03124147|Device|Neuroconn Eldith stimulator by Magstim|Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
136216|NCT03124134|Device|Gelesis200|Encapsulated hydrogel
136217|NCT03124134|Other|Water, only (placebo)|300 mL of water
136218|NCT03124121|Drug|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
136219|NCT03124108|Drug|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
136220|NCT03124108|Drug|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
136221|NCT03124108|Drug|Placebo|Two coated tablets daily for 12 weeks
136288|NCT03123536|Device|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
136289|NCT03123523|Diagnostic Test|Echocardiography at T0|
136290|NCT03123523|Diagnostic Test|Exercise test|
136222|NCT03124095|Behavioral|Combined exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
136223|NCT03124082|Drug|Remifentanil|continuous infusion intraop
136224|NCT03124082|Drug|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
136225|NCT03124082|Drug|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
136226|NCT03124082|Drug|Clonidine|clonidine 4 mcg/kg
136227|NCT03124069|Device|F&P Saturn|Participants will be placed on this arm for a total of 14 ± 5 days from Visit 2. Participants will be using the trial nasal mask during this treatment arm.
136228|NCT03124056|Device|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
136229|NCT03124043|Other|Livongo for Diabetes program|See description in arm/group description.
136230|NCT03124030|Procedure|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
136231|NCT03124017|Other|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
136232|NCT03124004|Procedure|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
136233|NCT03123991|Behavioral|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
136234|NCT03123991|Behavioral|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
136235|NCT03123978|Drug|Enzalutamide|Given PO
136236|NCT03123978|Drug|Niclosamide|Given PO
136237|NCT03123965|Drug|glecaprevir|Glecaprevir will be administered orally.
136238|NCT03123965|Drug|pibrentasvir|Pibrentasvir will be administered orally.
136239|NCT03123952|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
136240|NCT03123939|Biological|CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
136241|NCT03123913|Drug|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
136242|NCT03123913|Drug|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
136243|NCT03123900|Behavioral|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
136244|NCT03123900|Behavioral|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
136245|NCT03123900|Behavioral|Combined training|Subjects included in this group receive both types of intervention.
136246|NCT03123887|Other|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
136247|NCT03123874|Device|Sterile pump set-up|Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
136248|NCT03123874|Device|Mother's Own pump set-up|Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
136249|NCT03123861|Drug|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
136250|NCT03123861|Drug|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
136251|NCT03123848|Drug|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
136252|NCT03123835|Procedure|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
136253|NCT03123822|Device|Glasses|Glasses traditionally prescribed for refractive error
136291|NCT03123523|Biological|Biological assays|Creatinin, hematocrit and BNP assays
136292|NCT03123523|Device|MRI with contrast agent injection|With injection of gadolinium
136293|NCT03123523|Device|MRI without contrast agent injection|Without injection of gadolinium
136254|NCT03123809|Device|Gastric Electrical Stimulation (GES) System|Implantable GES System will be turned ON as an active intervention providing electrical stimulation to the muscle of stomach for 6 months in patients from the first arm, versus 3 months only of active stimulation in patients who are randomized to be in the second arm of the study. GES works by utilizing following parameters: Current 5 mA; Pulse Width 330µsec; Rate 14 Hz; Time ON 0.1 sec; Time OFF 5.0 sec.
136255|NCT03123783|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
136256|NCT03123783|Drug|Nivolumab|Nivolumab is an immune checkpoint (PD-1) blocking antibody
136257|NCT03123770|Drug|Pegylated liposomal doxorubicin|a new kind of doxorubicin
136258|NCT03123770|Drug|Cyclophosphamide|traditional chemotherapy drug
136259|NCT03123770|Drug|Epirubicin|traditional chemotherapy drug used in breast cancer
136260|NCT03123770|Drug|Docetaxel|traditional chemotherapy drug used in breast cancer
136261|NCT03123757|Other|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
136262|NCT03123757|Other|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
136263|NCT03123757|Other|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
136264|NCT03123744|Drug|Palbociclib 125mg|Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
136265|NCT03123731|Behavioral|Control Arm|Wearing Physical Activity Monitor
136266|NCT03123731|Behavioral|iSTEP|Physical Activity Intervention
136267|NCT03123731|Behavioral|iSTEP|Physical Activity and Diet Intervention
136268|NCT03123718|Drug|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
136269|NCT03123718|Drug|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged >70 years."
136270|NCT03123692|Drug|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
136271|NCT03123692|Drug|Placebo|14 days treatment with placebo
136272|NCT03123679|Radiation|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"Patient referred to radiotherapy treatment are evaluated with a baseline PFT [Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)].~RT simulation at the radiotherapy department and treatment planning.~Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.~Radiotherapy."
136273|NCT03123666|Drug|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
136274|NCT03123666|Other|Placebo|Placebo identical to GMCSF will be given
136275|NCT03123653|Drug|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
136276|NCT03123640|Other|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
136277|NCT03123627|Drug|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
136278|NCT03123627|Drug|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
136279|NCT03123614|Drug|Loteprednol Etabonate 0.5% Oph Gel|
136280|NCT03123614|Drug|Prednisolone Acetate 1% Oph Susp|
136281|NCT03123601|Device|Risk sign displays|"Set of sign displays designed to communicate fall, dehydration and pulmonary aspiration risks and reflect on tailored interventions to manage these events in nursing homes. Risk sign displays are:~Small, lightweight rubber coloured bracelets with phrases related with the different risks: prevent rather than fall, contain to protect, drink to hydrate and avoid choking.~Small and coloured signposts next to head of patients bed that are believed to offer some key advantages and increase technically the quality of immediate communication of information and data regarding procedures. It is expected to have greater subject compliance once they will have discrete messages with thoughtful design and colour."
136282|NCT03123588|Drug|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
136283|NCT03123588|Drug|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
136284|NCT03123588|Drug|Placebo|Anagrelide-placebo administered orally BID
136285|NCT03123588|Drug|Placebo|Ruxolitinib-placebo administered orally BID.
136286|NCT03123562|Combination Product|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
136287|NCT03123549|Device|Simplify Disc|Simplify Disc at two levels of the cervical spine
136294|NCT03123523|Diagnostic Test|Echocardiography at M24|
136295|NCT03123510|Dietary Supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
136299|NCT03123484|Drug|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
136300|NCT03123471|Drug|Apremilast|Apremilast 30 mg tablets BID from weeks 0 to 32.
136301|NCT03123471|Other|Placebo|Placebo tablets twice daily (BID) for 16 weeks; placebo participants were switched to apremilast 30 mg at week 16.
136302|NCT03123458|Biological|clonal fetal MSCs|
136303|NCT03123445|Drug|Endostar|Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total
136304|NCT03123445|Drug|Gemcitabine|Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
136305|NCT03123445|Drug|Cisplatin|Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
136306|NCT03123432|Dietary Supplement|immunomodulating nutrients enriched diet|
136307|NCT03123432|Dietary Supplement|standard diet|
136308|NCT03123419|Behavioral|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
136309|NCT03123406|Drug|Cinacalcet HCl|Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
136310|NCT03123393|Drug|TAK-659|TAK-659 Tablets
136311|NCT03123367|Device|Group 1: Nella VuSleeve|Sleeve
136312|NCT03123367|Device|Group 2: Nella NuSpec|Speculum
136313|NCT03123367|Device|Group 3: NellaSpec|Speculum
136314|NCT03123367|Device|Group 4: Nella Insert|Sleeve
136315|NCT03123354|Device|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
136316|NCT03123328|Device|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
136317|NCT03123315|Device|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
136318|NCT03123289|Drug|68-Gallium citrate PET/CT scan|After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
136319|NCT03123289|Drug|18F FDG PET/CT scan|Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
136320|NCT03123276|Drug|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
136321|NCT03123276|Drug|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
136322|NCT03123250|Device|Aquablation|To utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue using the AQUABEAM system, which is a personalized image-guided tissue removal system.
136323|NCT03123237|Diagnostic Test|DMSA scan|We explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.
136324|NCT03123224|Behavioral|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
136325|NCT03123224|Behavioral|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
136326|NCT03123211|Drug|Veliparib|Veliparib will be administered orally.
136327|NCT03123198|Behavioral|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
136328|NCT03123185|Drug|Placebo|Tablet and solution formulation
136329|NCT03123185|Drug|BI 705564|Tablet and solution formulation
136330|NCT03123185|Drug|BI 705564 (Test)|Fed state
136331|NCT03123185|Drug|BI 705564 (Reference)|Fasting state
136332|NCT03123172|Diagnostic Test|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
136333|NCT03123159|Diagnostic Test|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
136334|NCT03123146|Behavioral|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
136335|NCT03123120|Drug|Spesolimab|12 weeks treatment
136336|NCT03123120|Drug|Placebo|12 weeks treatment
136337|NCT03123107|Drug|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
136338|NCT03123094|Drug|BI 655130|single dose
136339|NCT03123094|Drug|Placebo|single dose
136376|NCT03122782|Drug|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
136377|NCT03122769|Radiation|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
136340|NCT03123081|Procedure|Umbilical Cord Milking|At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
136341|NCT03123068|Drug|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
136342|NCT03123068|Other|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
136343|NCT03123055|Drug|B-701|B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
136344|NCT03123055|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
136345|NCT03123042|Procedure|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
136346|NCT03123029|Drug|Venetoclax|Venetoclax will be administered orally.
136347|NCT03123016|Drug|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
136348|NCT03123016|Procedure|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
136349|NCT03123003|Device|SonicBone Ultrasound|Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
136350|NCT03123003|Device|Wrist X-ray|Bone age assessment by Wrist X-ray
136351|NCT03122990|Procedure|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
136352|NCT03122990|Procedure|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame."
136353|NCT03122977|Procedure|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
136354|NCT03122977|Procedure|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
136355|NCT03122964|Diagnostic Test|AssureMDx|combined panel of methylation and mutation markers for the detection of bladder cancer
136356|NCT03122951|Diagnostic Test|ovulation test use|Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
136357|NCT03122938|Dietary Supplement|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
136358|NCT03122938|Dietary Supplement|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
136359|NCT03122925|Device|MR|MR
136360|NCT03122912|Dietary Supplement|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
136361|NCT03122912|Dietary Supplement|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
136362|NCT03122899|Device|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
136363|NCT03122886|Dietary Supplement|Fat Emulsion|Given IV
136364|NCT03122886|Other|Placebo|Given IV
136365|NCT03122860|Drug|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
136366|NCT03122860|Drug|placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
136367|NCT03122847|Drug|Methylprednisolone|Intravenous methylprednisolone
136368|NCT03122821|Other|Transcranial direct stimulation|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS [2, 19-25]. It employs a battery-driven stimulator to deliver weak direct currents (0.5-2.0 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 6 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 6 weeks"
136369|NCT03122821|Other|Transcranial Magnetic stimulation|The Magnet will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 6 weeks
136370|NCT03122821|Other|Transcranial direct stimulation with mental imagery|The subject will be practicing mental imagery along with trans-cranial direct stimulation.A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.
136371|NCT03122821|Other|Transcranial magnetic stimulation with mental imagery|The subject will be practicing mental imagery along with trans-cranial magnetic stimulation.A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.
136372|NCT03122808|Diagnostic Test|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
136373|NCT03122808|Diagnostic Test|Partogram Analysis|Analysis of slope of partogram
136374|NCT03122795|Procedure|Microbiome transplant|A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
136375|NCT03122782|Drug|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
136378|NCT03122756|Drug|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
136379|NCT03122756|Other|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
136380|NCT03122743|Procedure|Biospecimen Collection|Undergo collection of serum samples
136381|NCT03122743|Other|Laboratory Biomarker Analysis|Correlative studies
136382|NCT03122743|Other|Questionnaire Administration|Ancillary studies
136383|NCT03122730|Combination Product|VentaProst|Part I - an equivalent dose of VentaProst compared to conventionally-administered aerosolized epoprostenol with subsequent dose titration to achieve a clinically significant hemodynamic response Part II - Dose titration to achieve a clinically significant hemodynamic response.
136384|NCT03122717|Drug|Gefitinib|gefitinib is a EGFR inhibitor
136385|NCT03122717|Drug|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
136386|NCT03122704|Procedure|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
136387|NCT03122691|Drug|cannabis|Cannabis will be self-administered by study participants
136388|NCT03122678|Drug|Thiamine|
136389|NCT03122678|Drug|Placebos|
136390|NCT03122665|Drug|Nefopam Low dose|Continuous intravenous infusion at 0.5 mg/ml for three hours.
136391|NCT03122665|Drug|Nefopam High dose|Continuous intravenous infusion at 1.0 mg/ml for three hours.
136392|NCT03122652|Drug|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
136393|NCT03122652|Drug|Placebo Oral Tablet|1 tablet once a day
136394|NCT03122639|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
136395|NCT03122639|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
136396|NCT03122626|Behavioral|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
136397|NCT03122613|Dietary Supplement|Curcumin|3g of Curcumin per day
136398|NCT03122613|Drug|Placebo|3g of Curcumin Placebo per day
136399|NCT03122587|Device|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
136400|NCT03122587|Device|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
136401|NCT03122587|Device|Active sham transcranial alternating current stimulation|Active sham (placebo)
136402|NCT03122574|Other|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
136403|NCT03122574|Other|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
136404|NCT03122561|Drug|Paracetamol 500 mg tablet at morning|Single dose oral paracetamol will be administered at 8.00 am
136405|NCT03122561|Drug|Paracetamol 500 mg tablet at midday|Single dose oral paracetamol will be administered at 2.00 pm
136406|NCT03122561|Drug|Paracetamol 500 mg tablet at night|Single dose oral paracetamol will be administered at 8.00 pm
136407|NCT03122548|Biological|CRS-207|Administered by IV infusion over 1 hour.
136408|NCT03122548|Biological|Pembrolizumab|Administered by IV infusion over 30 minutes.
136409|NCT03122535|Device|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
136410|NCT03122535|Device|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
136411|NCT03122522|Drug|ipilimumab|ipilimumab 3mg/kg
136412|NCT03122522|Drug|nivolumab|nivolumab 1mg/kg
136413|NCT03122509|Drug|durvalumab|1500 mg durvalumab via IV infusion
136414|NCT03122509|Drug|tremelimumab|75 mg tremelimumab via IV infusion
136415|NCT03122509|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
136416|NCT03122509|Procedure|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
136417|NCT03122496|Drug|durvalumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
136418|NCT03122496|Drug|tremelimumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
136419|NCT03122496|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT at 9Gy x 3 per standard of care given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
136420|NCT03122483|Diagnostic Test|blood biomarker|
136540|NCT03121677|Drug|Poly ICLC|-The personalized tumor vaccine will be co-administered with poly-ICLC.
136541|NCT03121677|Biological|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
136421|NCT03122470|Device|MRI guided biopsy|The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
136422|NCT03122470|Procedure|TRUS biopsy|The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
136423|NCT03122457|Drug|lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
136424|NCT03122444|Drug|Imipramine|Imipramine will be given daily for 21-30 days.
136425|NCT03122431|Drug|Thalidomide|Thalidomide 100mg/day
136426|NCT03122431|Drug|Hydroxychloroquine reduced|Hydroxychloroquine 400mg three times a week
136427|NCT03122431|Drug|Hydroxychloroquine high|Hydroxychloroquine 800mg/day for three months
136428|NCT03122418|Behavioral|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
136429|NCT03122405|Device|RAM sensors|Noninvasive acoustic monitoring device
136430|NCT03122392|Device|AMS 800|AMS 800 Artificial Urinary Sphincter
136431|NCT03122366|Diagnostic Test|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
136432|NCT03122353|Drug|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
136433|NCT03122353|Drug|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
136434|NCT03122353|Drug|Placebo|vehicle used as placebo
136435|NCT03122340|Drug|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
136436|NCT03122340|Other|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
136437|NCT03122327|Other|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
136438|NCT03122314|Drug|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
136439|NCT03122314|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
136440|NCT03122301|Drug|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
136441|NCT03122301|Drug|Saline|sham injection with saline
136442|NCT03122288|Behavioral|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
136443|NCT03122288|Other|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
136444|NCT03122275|Other|Customized text message invitation ( Step 1a)|Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
136445|NCT03122275|Other|Customized automatic phone call invitation (Step 1b)|Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
136446|NCT03122275|Other|Secretary phone call (Step 2)|Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
136447|NCT03122275|Other|Health professional face-to-face appointment (Step 3)|"Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.~During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening."
136448|NCT03122275|Other|Written Letter|"A written letter will be used to invite eligible women to cervical cancer screening.~This intervention will be used only for women randomized to active comparator arm."
136449|NCT03122262|Drug|Dolutegravir|DTG 50mg Oral Tablet once daily
136450|NCT03122262|Drug|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
136451|NCT03122262|Drug|Truvada|
136452|NCT03122262|Drug|Atripla|
136453|NCT03122249|Behavioral|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
136454|NCT03122236|Behavioral|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
136572|NCT03121456|Other|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
136455|NCT03122236|Behavioral|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
136456|NCT03122236|Device|Transcranial Direct Current Stimulation (tDCS) dosage A|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
136457|NCT03122236|Device|Transcranial Direct Current Stimulation (tDCS) dosage B|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
136458|NCT03122223|Biological|ALVAC-HIV (vCP2438)|expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10^6 cell culture infectious dose (CCID)50 and less than 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
136459|NCT03122223|Biological|Bivalent subtype C gp120/MF59|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
136460|NCT03122223|Biological|Bivalent subtype C gp120/AS01(B)|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
136461|NCT03122223|Biological|Placebo|Sodium Chloride for Injection, 0.9%, administered IM.
136462|NCT03122210|Device|Automated oxygen administration|In the control group, usual oxygen administration and titration is planned
136463|NCT03122197|Drug|Letrozole Oral Tablet|Daily treatment 1-5 days preop and resuming post op
136464|NCT03122184|Behavioral|Positive Psychology + Motivational Interviewing|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
136465|NCT03122184|Behavioral|Motivational Interviewing Health Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
136466|NCT03122171|Device|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bi-manual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
136467|NCT03122158|Drug|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
136468|NCT03122145|Drug|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
136469|NCT03122145|Device|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the base of tongue and hyolaryngeal complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
136470|NCT03122132|Drug|ombitasvir/paritaprevir/ritonavir 8 weeks|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
136471|NCT03122132|Drug|dasabuvir 8 weeks|Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
136472|NCT03122119|Drug|Platelet Rich Plasma Joint Injection|30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
136473|NCT03122106|Biological|Personalized neoantigen DNA vaccine|-Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
136474|NCT03122106|Device|TDS-IM Electrode Array System|-Ichor Medical Systems
136475|NCT03122106|Procedure|Peripheral blood draws|-Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
136476|NCT03122080|Device|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
136477|NCT03122080|Device|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
136478|NCT03122080|Other|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
136479|NCT03122067|Drug|oxytocin treatment|intranasal administration of oxytocin
136480|NCT03122067|Drug|placebo treatment|intranasal administration of placebo
136481|NCT03122054|Procedure|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
136482|NCT03122041|Drug|Sitagliptin|
136483|NCT03122041|Behavioral|Lifestyle intervention|
136484|NCT03122028|Device|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
136485|NCT03122015|Other|Therapeutic clown distraction|The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
136486|NCT03122002|Drug|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
136487|NCT03122002|Diagnostic Test|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
136488|NCT03122002|Other|Intravascular therapy|Intravascular therapy including thrombectomy
136489|NCT03122002|Other|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
136490|NCT03122002|Other|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
136491|NCT03121989|Drug|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
136492|NCT03121989|Other|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
136493|NCT03121989|Drug|NAC|Participants will be receiving NAC as part of their clinical treatment.
136494|NCT03121976|Device|Ultrasound|Femoral catheter inserted using ultrasound only
136495|NCT03121976|Device|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
136496|NCT03121963|Drug|Oxycodone|oxycodone tablet
136497|NCT03121963|Drug|Acetaminophen|acetaminophen tablet
136498|NCT03121963|Drug|Gabapentin|gabapentin tablet
136499|NCT03121963|Drug|Celecoxib|celecoxib tablet
136500|NCT03121963|Drug|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
136501|NCT03121950|Other|Dance|The primary intervention is a dance class
136502|NCT03121950|Other|music|the secondary intervention is listening to live music
136503|NCT03121937|Behavioral|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
136504|NCT03121924|Procedure|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.~The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
136505|NCT03121911|Other|Interval Training (IT)|"Each exercise session will consist of:~warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;~interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.~cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training."
136506|NCT03121911|Other|Inspiratory Muscle Training (IMT)|"The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.~All the others exercises will be identical between group 1 and 2."
136507|NCT03121898|Device|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
136508|NCT03121885|Behavioral|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
136509|NCT03121885|Other|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
136510|NCT03121872|Procedure|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
136511|NCT03121872|Procedure|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
136512|NCT03121859|Other|Neck stabilization exercise|Exercise
136513|NCT03121859|Other|TENS|Transcutaneous electrical nerve stimulation (TENS)
136514|NCT03121859|Other|IFC|Interferential current therapy(IFC)
136515|NCT03121846|Drug|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
136516|NCT03121833|Drug|Endostar|Recombinant Human Endostatin Injection
136517|NCT03121833|Drug|Placebo|500ml 0.9% sodium chloride
136518|NCT03121833|Drug|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
136519|NCT03121820|Drug|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
136520|NCT03121820|Drug|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
136521|NCT03121807|Other|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
136522|NCT03121807|Drug|Oxaliplatin|
136523|NCT03121807|Drug|5Fluorouracil|
136524|NCT03121807|Drug|Leucovorin|
136525|NCT03121794|Procedure|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
136526|NCT03121794|Device|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
136527|NCT03121781|Other|respiratory support- interface|change interface to RAM cannula
136528|NCT03121781|Other|respiratory support- interface|change interface to binasal prongs
136529|NCT03121742|Behavioral|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
136530|NCT03121742|Behavioral|Treatment as Usual|Standard care as part of inpatient hospitalization.
136531|NCT03121729|Procedure|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
136532|NCT03121716|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
136533|NCT03121716|Drug|Gemcitabine|gemcitabine
136534|NCT03121716|Drug|cis-platinum|cis-platinum
136535|NCT03121703|Other|lumbar stabilization exercise|lumbar stabilization exercise
136536|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
136537|NCT03121690|Drug|Prednisone|prednisone 40 mg/day for 7 days
136538|NCT03121690|Drug|placebo|5ml saline / day for 7 days
136539|NCT03121677|Biological|Personalized tumor vaccine|"Cycle 12 vaccine administration is optional~The peptides comprising the vaccine are reconstituted in up to 4 pools with 5 peptides per pool (A, B, C, and D) . At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection."
136542|NCT03121677|Procedure|Peripheral blood draws|-Time of biopsy, during the pre-treatment check (any time before cycle 1 day 1), Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
136543|NCT03121677|Procedure|Leukapheresis|"Prior to the initiation of treatment and up to five days prior to treatment on cycle 6 day 1, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.~Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
136544|NCT03121677|Biological|Rituximab|-Other anti-CD20 mAb treatment can be used
136545|NCT03121677|Procedure|Biopsy|-Biopsies on lymph node or extranodal site(s) are to be obtained at: screening (only after the patient is deemed eligible; during cycle 2 (after treatment on C2D15 and prior to treatment on C3D1); disease relapse or progression (if this occurs)
136546|NCT03121664|Drug|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
136547|NCT03121651|Device|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:~young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,~young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and~young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.~The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
136548|NCT03121638|Biological|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
136549|NCT03121638|Biological|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
136550|NCT03121638|Biological|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
136551|NCT03121638|Biological|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
136552|NCT03121638|Biological|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
136553|NCT03121625|Biological|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
136554|NCT03121612|Device|CPAP|CPAP therapy
136555|NCT03121599|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
136556|NCT03121586|Drug|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
136557|NCT03121573|Drug|Duloxetine|duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
136558|NCT03121560|Device|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
136559|NCT03121560|Device|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
136560|NCT03121547|Drug|Tapentadol 50 mg Oral Tablet|1 tablet administered
136561|NCT03121547|Drug|Tramadol Hydrochloride 100 mg Extended Release Oral Tablet|1 tablet administered
136562|NCT03121547|Drug|Placebo Oral Tablet|calcium tablet
136563|NCT03121534|Drug|Blinatumomab|"Induction phase consists of a single cycle of Blinatumomab therapy. Blinatumomab initiated at 9 mcg/day from day 1-7, followed by 28 mcg/day from day 8-14 (week 2). This is followed by 112 mcg/day from day 15-56. The induction cycle is 8 weeks in duration.~Patients who achieve an objective response after induction are eligible to receive one further cycle of Blinatumomab consolidation, delivered at 112 mcg/day by continuous vein infusion from day 1-28 (total of 4 weeks). Consolidation may be initiated 4-8 weeks after completion of the induction infusion of Blinatumomab."
136564|NCT03121534|Drug|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
136565|NCT03121521|Drug|Melatonin 10 mg|melatonin 10mg daily p.o.
136566|NCT03121521|Drug|Placebo|Placebo 10mg daily p.o.
136567|NCT03121508|Behavioral|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
136568|NCT03121495|Diagnostic Test|Second forward view (SFV) examination of the right colon|The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
136569|NCT03121482|Device|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
136570|NCT03121482|Device|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
136571|NCT03121469|Device|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
136844|NCT03119623|Drug|Enalapril|enalapril 5mg, titrated up to 10mg po BID
136573|NCT03121456|Other|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
136574|NCT03121443|Other|Perfusion index|supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
136575|NCT03121430|Device|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
136576|NCT03121430|Device|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
136577|NCT03121417|Biological|Nivolumab|240 mg given IV
136578|NCT03121404|Procedure|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
136579|NCT03121391|Procedure|Ventilator withdrawal algorithm|"Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor"
136580|NCT03121378|Other|Blood sample 1|Blood taken before prosthesis implantation
136581|NCT03121378|Other|Blood sample 2|Blood taken after prosthesis implantation
136582|NCT03121365|Behavioral|Digital/E-Book Arm|Promotion of early reader digital e-book reading
136583|NCT03121365|Behavioral|Standard/Board Book Arm|Promotion of early reader board book reading
136584|NCT03121352|Drug|Carboplatin|AUC 4.5 IV day 1 of 21-day cycle
136585|NCT03121352|Drug|Nab-paclitaxel|75mg/m2 IV days 1, 8 and 15 of 21-day cycle
136586|NCT03121352|Drug|Pembrolizumab|200 mg IV every 21 days
136587|NCT03121339|Biological|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (~140 mg tablet)
136588|NCT03121339|Biological|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (~275 mg tablet)
136589|NCT03121326|Diagnostic Test|blood and urine sampling|Ten mL blood and 15mL urine are collected.
136590|NCT03121313|Drug|tegafur-uracil|
136591|NCT03121300|Other|CT Scan|Quantitative lung SPECT-CT
136592|NCT03121300|Other|Lung CT|CT lung ventilation
136593|NCT03121300|Other|MRI|DCE MRI
136594|NCT03121300|Other|Walk Test|6 minute hall walk test
136595|NCT03121300|Other|SGRQ|St. George Respiratory Questionnaire
136596|NCT03121300|Other|Biological Sample Collection|Blood Draw
136597|NCT03121300|Other|Toxicity|Toxicity Evaluation
136598|NCT03121300|Other|Cardiac Assessment|Cardiac MRI Scan
136599|NCT03121287|Other|Imaging Biomarkers|Whole lung volumetric CT scans
136600|NCT03121287|Other|Pulmonary|Pulmonary Function Tests & 6 minute hall walk
136601|NCT03121287|Other|Imaging|Cardiac MRI
136602|NCT03121287|Other|Specimen Collection|Blood draw
136603|NCT03121274|Procedure|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
136604|NCT03121261|Drug|levobupivacaine|Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
136605|NCT03121261|Drug|clonidine|Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
136606|NCT03121248|Radiation|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
136607|NCT03121248|Radiation|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
136608|NCT03121248|Radiation|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
136609|NCT03121248|Radiation|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
136610|NCT03121248|Radiation|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
136611|NCT03121248|Radiation|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
136612|NCT03121248|Radiation|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
136613|NCT03121248|Radiation|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
136614|NCT03121235|Diagnostic Test|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
136615|NCT03121222|Drug|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
136616|NCT03121222|Drug|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
136617|NCT03121196|Other|Epices score|Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
136618|NCT03121183|Device|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
136619|NCT03121183|Behavioral|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
136659|NCT03120936|Behavioral|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
136660|NCT03120923|Drug|Lidocaine 3 cc|
136661|NCT03120923|Drug|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
136620|NCT03121170|Other|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25, Guilai(ST29) and Zigong(EX-CA1). All acupuncture points should be placed according to participants' feedback during treatment.
136621|NCT03121170|Other|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
136622|NCT03121157|Behavioral|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
136623|NCT03121131|Other|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
136624|NCT03121131|Other|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
136625|NCT03121131|Other|No clinical exam findings|No clinical exam findings are given to the radiologists
136626|NCT03121118|Other|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
136627|NCT03121092|Drug|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
136628|NCT03121079|Drug|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
136629|NCT03121066|Device|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
136630|NCT03121066|Device|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
136631|NCT03121053|Drug|sodium bicarbonate|
136632|NCT03121053|Drug|hypotone saline|
136633|NCT03121040|Dietary Supplement|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
136634|NCT03121014|Drug|Fludarabine|40 mg/m^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
136635|NCT03121014|Drug|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
136636|NCT03121014|Drug|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
136637|NCT03121014|Radiation|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
136638|NCT03121014|Procedure|Stem Cell Product Infusion|Day 0 according to BMT unit policy
136639|NCT03121014|Drug|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
136640|NCT03121014|Drug|Methotrexate|10 mg/m^2 on Day 1, 8 mg/m^2 on Days 3, 6 and 11
136641|NCT03121001|Drug|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
136642|NCT03121001|Drug|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
136643|NCT03121001|Drug|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
136644|NCT03121001|Radiation|Total body irradiation|3 Gy on day -1
136645|NCT03121001|Procedure|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
136646|NCT03121001|Drug|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
136647|NCT03121001|Drug|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
136648|NCT03120988|Biological|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
136649|NCT03120975|Other|Computerized decision support and audit & feedback|"suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system~mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment~suggestion of standard antimicrobial treatment duration according to indication"
136650|NCT03120975|Other|Audit & Feedback|* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
136651|NCT03120975|Other|Standard antibiotic stewardship|"Infectious diseases consultation on demand~Review of positive blood cultures~Availability of a antibiotic use guidelines (on paper and as PDF)"
136652|NCT03120962|Drug|Oxycodone|Oxycodone 20mg/day, for 4 weeks
136653|NCT03120962|Drug|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
136654|NCT03120962|Drug|Famciclovir|Famciclovir 500mg three-times daily for 7 days
136655|NCT03120949|Drug|Olokizumab 64 mg SC q4w|Treatment Arm 1, Experimental, Olokizumab 64 mg Subcutaneous q4w + Methotrexate (oral)
136656|NCT03120949|Drug|Olokizumab 64 mg SC q2w|Treatment Arm 2, Experimental, Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
136657|NCT03120949|Drug|Methotrexate|"Treatment Arm 1, Experimental, Olokizumab 64 mg Subcutaneous q4w + Methotrexate (oral);~Treatment Arm 2, Experimental, Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)"
136658|NCT03120936|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
136663|NCT03120897|Device|RAM sensor|Rainbow Acoustic Monitoring sensor for measurement of respiratory rate
136664|NCT03120884|Procedure|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
136665|NCT03120884|Procedure|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
136666|NCT03120858|Behavioral|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
136667|NCT03120845|Procedure|One visit RCT|Root canal treatment in one vist
136668|NCT03120845|Procedure|Post operative pain in two-visits RCT|Root canal treatment in Two visits
136669|NCT03120832|Biological|PAN-301-1|
136670|NCT03120819|Behavioral|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
136671|NCT03120819|Behavioral|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
136672|NCT03120806|Procedure|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
136673|NCT03120806|Procedure|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
136674|NCT03120793|Device|Esophageal balloon catheter|Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
136675|NCT03120780|Drug|Fentanyl 20 mcg|20 mcg fentanyl in 10 mL 0.125% bupivacaine
136676|NCT03120780|Drug|Fentanyl 100 mcg|100 mcg fentanyl in 10 mL 0.125% bupivacaine
136677|NCT03120767|Behavioral|Risk and Resilience|"The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills."
136678|NCT03120767|Behavioral|Coordinated Wellness Programming|"During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester."
136679|NCT03120754|Procedure|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
136680|NCT03120754|Procedure|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
136681|NCT03120728|Drug|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
136682|NCT03120715|Drug|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.
136683|NCT03120715|Drug|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
136684|NCT03120715|Drug|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
136685|NCT03120715|Drug|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
136686|NCT03120689|Other|Live Surgery using VITOM|The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
136687|NCT03120689|Other|Live Surgery without VITOM|The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
136688|NCT03120689|Other|Video viewing with VITOM|They will view the 10-minute standardized video filmed with the VITOM® camera.
136689|NCT03120689|Other|Video viewing with standard handheld high-definition camera|They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
136690|NCT03120676|Drug|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
136691|NCT03120663|Drug|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.~Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
136692|NCT03120650|Other|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
136693|NCT03120650|Other|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
136694|NCT03120637|Drug|Methylene Blue|
136695|NCT03120624|Procedure|Biopsy|Undergo image-guided biopsy
136696|NCT03120624|Procedure|Computed Tomography|Undergo SPECT/CT
136697|NCT03120624|Other|Laboratory Biomarker Analysis|Correlative studies
136698|NCT03120624|Other|Pharmacological Study|Correlative studies
136699|NCT03120624|Procedure|Planar Imaging|Undergo whole body planar imaging
136700|NCT03120624|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
136703|NCT03120611|Other|Virtual Reality Exercise|Game developed by the Kinect, adapted to the lying position of participants.
136704|NCT03120611|Other|Conventional exercise intradialysis|Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
136705|NCT03120598|Behavioral|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
136706|NCT03120598|Behavioral|ISF strategy|Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
136707|NCT03120585|Other|Fluid Management Intervention|Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR >4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
136708|NCT03120559|Device|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
136709|NCT03120559|Device|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
136710|NCT03120546|Device|rigid video stylet intubation|intubation using rigid video stylet
136711|NCT03120546|Device|video laryngoscope intubation|intubation using video laryngoscope
136712|NCT03120533|Drug|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
136713|NCT03120533|Drug|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
136714|NCT03120520|Drug|Plecanatide|
136715|NCT03120520|Drug|Matching placebo|
136716|NCT03120494|Drug|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
136717|NCT03120481|Other|no intervation|no intervention
136718|NCT03120468|Drug|Topiramate and N-Acetyl Cysteine|Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
136719|NCT03120468|Drug|Topiramate and Placebo|Topiramate up to 200 mg/day and Placebo for 12 weeks
136720|NCT03120455|Behavioral|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
136721|NCT03120455|Behavioral|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
136722|NCT03120455|Behavioral|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
136723|NCT03120442|Drug|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
136724|NCT03120442|Drug|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
136725|NCT03120442|Drug|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
136726|NCT03120429|Behavioral|Fish group|Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal
136727|NCT03120429|Behavioral|Control group|Control group will have hypo-energetic diet in which subjects have no seafood.
136728|NCT03120416|Behavioral|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
136729|NCT03120403|Procedure|intrathecal morphine|
136730|NCT03120390|Other|Best Practice|Undergo usual care
136731|NCT03120390|Behavioral|Exercise Intervention|Undergo AE
136732|NCT03120390|Behavioral|Exercise Intervention|Undergo RE
136733|NCT03120390|Other|Laboratory Biomarker Analysis|Correlative studies
136734|NCT03120390|Device|Monitoring Device|Receive Polar heart rate monitor
136735|NCT03120390|Other|Quality-of-Life Assessment|Ancillary studies
136736|NCT03120390|Other|Questionnaire Administration|Ancillary studies
136737|NCT03120377|Other|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
136738|NCT03120377|Other|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
136739|NCT03120364|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
136740|NCT03120364|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
136741|NCT03120351|Drug|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
136742|NCT03120351|Drug|Placebo patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
136743|NCT03120338|Diagnostic Test|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
136781|NCT03120026|Dietary Supplement|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
136843|NCT03119623|Drug|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
136744|NCT03120325|Device|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for two minutes on each side for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
136745|NCT03120312|Procedure|total hip replacement|primary hip replacement patients during past 5 years．
136746|NCT03120299|Drug|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
136747|NCT03120299|Drug|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
136748|NCT03120273|Drug|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
136749|NCT03120273|Drug|Lansoprazole Injection|30 mg q12h for 5 days.
136750|NCT03120260|Other|Diet|Intervention 'Diet+ short sleep versus normal sleep
136751|NCT03120247|Drug|OTM Dexmedetomidine 1µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
136752|NCT03120247|Drug|OTM Dexmedetomidine 0.75µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
136753|NCT03120247|Drug|OTM Dexmedetomidine 0.5µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
136754|NCT03120234|Drug|Dexmedetomidine|
136755|NCT03120234|Drug|Ketamine|
136756|NCT03120234|Drug|Fentanyl|
136757|NCT03120234|Drug|Placebos|o.9% normal saline will be used instead of ketamine
136758|NCT03120221|Diagnostic Test|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
136759|NCT03120208|Behavioral|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
136760|NCT03120208|Behavioral|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
136761|NCT03120208|Behavioral|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
136762|NCT03120208|Behavioral|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
136763|NCT03120208|Behavioral|EPDS, MINI, STAI-A and B, IES-R and QEVA (experience)|For the partners
136764|NCT03120195|Device|The EndoRotor®|The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
136765|NCT03120182|Drug|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
136766|NCT03120182|Drug|Placebo Oral Tablet|Patients will receive placebo medication 100mg daily for 12 days after randomization
136767|NCT03120169|Other|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
136768|NCT03120169|Other|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
136769|NCT03120156|Device|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
136770|NCT03120156|Device|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
136771|NCT03120156|Other|No insoles|control group with no insoles in the shoes
136772|NCT03120143|Other|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
136773|NCT03120143|Other|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
136774|NCT03120130|Biological|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
136775|NCT03120117|Procedure|Cough Test following Sling Surgery|Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
136776|NCT03120104|Other|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
136777|NCT03120104|Other|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just two weeks after the stoma closure
136778|NCT03120091|Device|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
136779|NCT03120065|Other|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
136780|NCT03120026|Dietary Supplement|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
136782|NCT03120013|Device|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
136783|NCT03120013|Device|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
136784|NCT03120000|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
136785|NCT03119987|Diagnostic Test|Red cell distribution widths|Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
136786|NCT03119974|Drug|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (> 2 months) complete response (platelets counts > 100 x 109/L) period on Tpo-RA treatment.
136787|NCT03119961|Device|SONOCLOUD®|BBB opening by ultrasound
136788|NCT03119948|Drug|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
136789|NCT03119948|Drug|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
136790|NCT03119948|Drug|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..~150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
136791|NCT03119935|Device|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
136792|NCT03119935|Device|Ambu bag|Participants ventilated the simulated patients by ambu bag
136793|NCT03119922|Other|No intervention|
136794|NCT03119909|Other|First session of fMRI: localization of the premotor areas of the medial frontal cortex|Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.
136795|NCT03119909|Other|Second fMRI session|The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.
136796|NCT03119909|Other|Third fMRI Session|This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.
136797|NCT03119909|Other|Training fMRI session|The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
136798|NCT03119909|Other|Pilot behavioral study|In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).
136799|NCT03119909|Other|fMRI Study|Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
136800|NCT03119896|Other|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
136801|NCT03119883|Other|Infusion of 13-Carbon labeled Glutamine|Intravenous infusion of 13-Carbon labeled glutamine followed by bone marrow aspiration
136802|NCT03119870|Other|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
136803|NCT03119870|Other|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
136804|NCT03119870|Other|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
136805|NCT03119857|Drug|Antiandrogen|
136806|NCT03119857|Drug|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary."
136807|NCT03119844|Other|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
136808|NCT03119844|Other|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
136809|NCT03119844|Other|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
136810|NCT03119831|Drug|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
136811|NCT03119831|Drug|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
136812|NCT03119831|Drug|C31G|Rinsing with 15ml for one minute twice daily for 14 days
136813|NCT03119818|Device|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
136814|NCT03119818|Other|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
136815|NCT03119792|Other|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
136816|NCT03119792|Other|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
136817|NCT03119779|Drug|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
136818|NCT03119779|Drug|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
136819|NCT03119766|Drug|Kolofort|Safety and Efficiency
136820|NCT03119766|Drug|Placebo|Safety and Efficiency
136821|NCT03119753|Device|Rapid Prototyping method of fabrication of complete denture|For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
136822|NCT03119753|Device|Conventional method of fabrication of complete denture|For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
136823|NCT03119727|Device|FreeO2|All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
136824|NCT03119714|Drug|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
136825|NCT03119714|Drug|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
136826|NCT03119701|Drug|Interferon Beta-1A|Lyophilisate for solution for injection.
136827|NCT03119701|Drug|Placebo|Lyophilisate for solution for injection as placebo.
136828|NCT03119688|Other|Test Product|Micellar cleanser (0.09 ml)
136829|NCT03119688|Other|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
136830|NCT03119688|Other|Reference Product|Sterile Water (0.09 ml)
136831|NCT03119688|Other|No Treatment|Unwashed area of the forearm
136832|NCT03119675|Device|GoCheck Kids (iOS)|Photorefraction method is used to screen amblyopia risk factors.
136833|NCT03119675|Device|GoCheck Kids (Windows)|Photorefraction method is used to screen amblyopia risk factors.
136834|NCT03119662|Drug|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
136835|NCT03119662|Drug|Placebos|100 mL saline, followed by a 10 mL saline flush.
136836|NCT03119649|Drug|GLPG2222 50 mg|Oral tablet(s) containing GLPG2222
136837|NCT03119649|Drug|GLPG2222 100 mg|Oral tablet(s) containing GLPG2222
136838|NCT03119649|Drug|Placebo|Matching oral tablet(s) containing placebo
136839|NCT03119649|Drug|GLPG2222 200 mg|Oral tablet(s) containing GLPG2222
136840|NCT03119649|Drug|GLPG2222 400 mg|Oral tablet(s) containing GLPG2222
136841|NCT03119636|Biological|NPC transplantation|The cells are stereotactically implanted in the striatum.
136842|NCT03119636|Drug|Levodopa|Levodopa is used depending on the patient's condition
136845|NCT03119610|Drug|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
136846|NCT03119610|Drug|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
136847|NCT03119597|Dietary Supplement|Wild Blueberry Powder-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
136848|NCT03119597|Dietary Supplement|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
136849|NCT03119584|Drug|linaclotide or placebo|
136850|NCT03119571|Procedure|Initial CCL admission|Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
136851|NCT03119571|Diagnostic Test|Initial ICU admission|Evaluate for additional testing and/or procedures
136852|NCT03119558|Drug|18F‑Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F‑Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
136853|NCT03119545|Behavioral|Beardslee family centered intervention|The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
136854|NCT03119532|Other|Receive metric feedback email|If the provider received an email about the participants performance metrics
136855|NCT03119519|Radiation|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
136856|NCT03119519|Drug|No Local Definitive Radiotherapy|Standard platinum-based doublet chemotherapy or EGFR-TKI (Gefitinib or Erlotinib) alone, according to gene test.
136857|NCT03119506|Behavioral|Recess|Recess timing and duration effects on lunch intake
136858|NCT03119493|Behavioral|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
136859|NCT03119480|Device|electronic alerts|electronic alerts for AKI
136860|NCT03119467|Drug|RP4010|Escalating doses starting at 25 mg
136861|NCT03119454|Drug|Diprospan|Intramuscular
136862|NCT03119441|Device|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
136863|NCT03119441|Device|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
136864|NCT03119428|Drug|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
136865|NCT03119428|Drug|Nivolumab|Human IgG4 anti-PD-1 monoclonal antibody
136866|NCT03119415|Behavioral|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
136867|NCT03119402|Behavioral|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
136868|NCT03119402|Device|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
136869|NCT03119389|Behavioral|Donning Non-Sterile Gloves without HH|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
136870|NCT03119376|Other|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
136871|NCT03119363|Device|Litebook Edge (Experimental)|"The Litebook Edge is a small (5 x 5 x 1) and lightweight (4.6 oz.) box designed to be placed on a table about 18 from the participant's head and within 45º visual field. The Litebook uses 60 premium light emitting diode (LED) lights which mimic the visible spectrum of sunlight for minimum glare and maximum eye comfort. For purposes of safety, the Litebook emits no ultraviolet (UV) light."
136872|NCT03119363|Device|Litebook Edge (Comparator)|"The Litebook Edge is a small (5 x 5 x 1) and lightweight (4.6 oz.) box designed to be placed on a table about 18 from the participant's head and within 45º visual field. The Litebook uses 60 premium light emitting diode (LED) lights which mimic the visible spectrum of sunlight for minimum glare and maximum eye comfort. For purposes of safety, the Litebook emits no ultraviolet (UV) light."
136873|NCT03119350|Other|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.~Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
136964|NCT03118518|Device|Cryoablation|Pulmonary vein isolation via ablation with cryoballon catheter
136965|NCT03118518|Drug|Antiarrhythmic drug|Antiarrhythmic drug initiation
137354|NCT03115879|Other|Hip manipulation simulation|Hip manipulation simulation
136874|NCT03119337|Other|Text-based follow-up|2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
136875|NCT03119324|Device|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
136876|NCT03119324|Device|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
136877|NCT03119324|Drug|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
136878|NCT03119311|Diagnostic Test|Video-oculography|Diagnostic Method for Exotropia Using Video-oculography
136879|NCT03119311|Diagnostic Test|APCT|alternative prism cover test
136880|NCT03119259|Behavioral|ABC Clinical Program|The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.
136881|NCT03119259|Behavioral|HABC 2.0|"HABC 2.0 is a mobile health information technology application whose primary user is the informal caregiver of a patient suffering from ADRD. It is integrated with the electronic medical record system (eMR-ABC) in operation in the ABC Clinical Program. HABC 2.0 performs the following functions:~supports informal caregivers in managing the behavioral and psychological symptoms of dementia (BPSD) by delivering on-demand, around the clock feedback and personalized self-management support without any intervention from the ABC team; and~elicits frequent, real-time, longitudinal assessments of patients and informal caregivers, enabling the ABC team to monitor BPSD data and informal caregiver health, intervening as needed in between scheduled visits."
136882|NCT03119246|Other|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
136883|NCT03119233|Device|PQ Bypass System|The PQ Bypass System is intended to improve blood flow in patients with symptomatic peripheral arterial disease due to >15 cm long occlusions and diffuse stenoses of femoro-popliteal arteries, including in-stent re-stenosis, with reference vessel diameters ranging from 5.0 - 6.7 mm
136884|NCT03119220|Device|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
136885|NCT03119207|Behavioral|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
136886|NCT03119194|Drug|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
136887|NCT03119168|Drug|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
136888|NCT03119168|Other|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
136889|NCT03119129|Behavioral|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
136890|NCT03119116|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
136891|NCT03119116|Drug|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
136892|NCT03119116|Drug|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
136893|NCT03119103|Device|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
136894|NCT03119077|Drug|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
136895|NCT03119077|Drug|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
136896|NCT03119077|Drug|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
136897|NCT03119064|Drug|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
136898|NCT03119064|Drug|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
136899|NCT03119051|Behavioral|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
136900|NCT03119051|Behavioral|Cognitive training plus physical exercise|"Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction."
136901|NCT03119038|Drug|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
136902|NCT03119038|Drug|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
136903|NCT03119038|Drug|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
136904|NCT03119038|Drug|Ketorolac|Intraoperative periarticular injection of 30 mg
136905|NCT03119038|Drug|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
136906|NCT03119025|Biological|Autologous DC-vaccines|"Patients will be vaccinated via intracutaneous injection of autologous DCs (5×106) combined with adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU).~Initiating course: one vaccination per week, during 1 month. Maintaining course: one vaccination per month, during 6 month. Patients will be monitored in a 2 months (after completing of initiating course), 7 months (after completing of maintaining course) and 13 months (in a 6 months post-vaccination follow-up)."
136907|NCT03119012|Drug|Clopidogrel|75mg/day
136908|NCT03119012|Drug|Ticagrelor|120mg/day
136909|NCT03119012|Drug|Aspirin|100mg/day
136910|NCT03118999|Dietary Supplement|OM3-FFA|Comparison of the effects of OM3-FFA versus OM3-MAG and OM3-EE in a crossover design
136911|NCT03118999|Dietary Supplement|OM3-MAG|Comparison of the effects of OM3-MAG versus OM3-FFA and OM3-EE in a crossover design
136912|NCT03118999|Dietary Supplement|OM3-EE|Comparison of the effects of OM3-EE versus OM3-FFA and OM3-MAG in a crossover design
136913|NCT03118986|Drug|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
136914|NCT03118986|Drug|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
136915|NCT03118973|Procedure|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
136916|NCT03118960|Device|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
136917|NCT03118960|Device|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
136918|NCT03118947|Drug|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
136919|NCT03118934|Device|Lotrafilcon B multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
136920|NCT03118934|Device|Nelfilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
136921|NCT03118934|Device|Delefilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
136922|NCT03118921|Device|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
136923|NCT03118908|Dietary Supplement|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
136924|NCT03118908|Dietary Supplement|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
136925|NCT03118908|Dietary Supplement|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
136926|NCT03118895|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
136927|NCT03118882|Behavioral|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
136928|NCT03118882|Behavioral|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
137053|NCT03117998|Biological|REMD-477|Administered as repeated SC doses in subjects with Type 1 Diabetes
136929|NCT03118882|Behavioral|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
136930|NCT03118856|Diagnostic Test|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
136931|NCT03118843|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
136932|NCT03118830|Drug|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
136933|NCT03118830|Drug|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
136934|NCT03118830|Drug|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
136935|NCT03118817|Drug|HM95573|"Dose: 450 mg BID~Regimen: twice daily (BID), continuous dosing~Duration: until progression disease or unacceptable toxicity develops"
136936|NCT03118804|Diagnostic Test|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
136937|NCT03118791|Dietary Supplement|anthocyanins|Acute intake of capsules
136938|NCT03118765|Drug|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
136939|NCT03118765|Drug|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
136940|NCT03118765|Drug|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
136941|NCT03118752|Behavioral|Collaborative Care|The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
136942|NCT03118739|Drug|RDEA3170 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
136943|NCT03118739|Drug|Placebo|Capsule administered orally, once daily for 24 weeks
136944|NCT03118713|Drug|metformin|oral
136945|NCT03118713|Drug|ipragliflozin|oral
136946|NCT03118713|Drug|glimepride|oral
136947|NCT03118700|Other|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
136948|NCT03118700|Other|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
136949|NCT03118687|Other|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
136950|NCT03118674|Drug|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
136951|NCT03118661|Other|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
136952|NCT03118661|Procedure|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
136953|NCT03118648|Diagnostic Test|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
136954|NCT03118635|Behavioral|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
136955|NCT03118622|Device|Pentax|Intubation using Pentax video laryngoscope in Pentax group
136956|NCT03118609|Other|Understanding Needs Survey|"2-hour Focus Group~Mailed or E-mailed Survey"
136957|NCT03118596|Device|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
136958|NCT03118596|Device|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
136959|NCT03118583|Dietary Supplement|300 mg/day of dietary supplement containing carrageenan|300 mg/day of dietary supplement containing carrageenan.
136960|NCT03118570|Drug|BPS804|Intravenous infusion
136961|NCT03118557|Other|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
136962|NCT03118544|Device|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
136963|NCT03118531|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
136966|NCT03118505|Device|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
136967|NCT03118505|Device|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
136968|NCT03118492|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
136969|NCT03118492|Drug|Cyclophosphamide|Given IV
136970|NCT03118492|Drug|Fludarabine|Given IV
136971|NCT03118492|Biological|Glycosylated Recombinant Human G-CSF AVI-014|Given IV
136972|NCT03118492|Other|Laboratory Biomarker Analysis|Correlative studies
136973|NCT03118492|Drug|Melphalan|Given IV
136974|NCT03118492|Drug|Mycophenolate Mofetil|Given PO
136975|NCT03118492|Drug|Tacrolimus|Given IV or PO
136976|NCT03118492|Radiation|Total-Body Irradiation|Undergo TBI
136977|NCT03118479|Drug|Anastrozole Pill|10 mg of Anastrozole to be taken daily for 3 months.
136978|NCT03118479|Drug|Testosterone|Androgel 7.5 g to be applied transdermally daily for 3 months.
136979|NCT03118479|Drug|Placebo Oral Tablet|One tablet to be taken daily for 3 months
136980|NCT03118466|Drug|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
136981|NCT03118466|Drug|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
136982|NCT03118466|Drug|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
136983|NCT03118466|Drug|Mitoxantrone|It interfere with cell reproduction
136984|NCT03118453|Behavioral|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
136985|NCT03118453|Behavioral|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
136986|NCT03118440|Procedure|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
136987|NCT03118440|Procedure|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
136988|NCT03118427|Procedure|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
136989|NCT03118427|Procedure|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
136990|NCT03118414|Other|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
136991|NCT03118414|Other|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.~They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
136992|NCT03118414|Other|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
136993|NCT03118401|Other|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
136994|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.~At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
136995|NCT03118388|Behavioral|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
136996|NCT03118388|Behavioral|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
136997|NCT03118375|Device|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
136998|NCT03118362|Drug|Plasmalyte|"Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
136999|NCT03118362|Drug|Ringer lactate|"Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.~Each patient will receive this solution up to 5 days."
137000|NCT03118349|Drug|MVT-1075|MVT-1075 is administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
137001|NCT03118349|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
137002|NCT03118336|Drug|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
137003|NCT03118323|Other|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
137004|NCT03118310|Behavioral|5:2 diet|Dietary intervention according to 5:2 diet during three months.
137005|NCT03118310|Behavioral|LCHF|Dietary intervention according to LCHF diet during three months.
137006|NCT03118310|Behavioral|Placebo diet|Placebo diet: normal dietary advice
137007|NCT03118297|Drug|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
137008|NCT03118297|Drug|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
137009|NCT03118284|Other|urine collection|
137010|NCT03118284|Other|Blood collection|
137011|NCT03118284|Behavioral|NRS|
137012|NCT03118271|Device|lumbar traction|
137013|NCT03118271|Procedure|spinal manipulation|
137014|NCT03118271|Procedure|surgery|
137015|NCT03118258|Behavioral|'Pap smear' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by direct patient referral for Pap smear testing in a partner health facility."
137016|NCT03118258|Behavioral|'Self-collected vaginal swab for HPV testing + pap smear triage' arm|"Women are invited to participate in a preventive consultation. Doctor of the World staff provides women with information in their mother tongue and uses visuals adressing cervical cancer, its causes and consequences and ways to prevent it.~This consultation is followed by patient referral for Pap smear testing in a partner health facility if the HPV-HR test is positive.~A women who tests negative for HPV-HR can still be referred for further Pap smear testing, or can be referred for a gynaecological consultation for any other reason."
137017|NCT03118245|Device|AuraGain|After anesthetic induction, AuraGain is inserted in children
137018|NCT03118245|Device|I-gel|After anesthetic induction, I-gel is inserted in children
137019|NCT03118232|Drug|Chlorhexidine gluconate (CHG)|2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.
137020|NCT03118232|Drug|Iodophor (10% povidone-iodine)|Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
137021|NCT03118219|Other|Positive adjustment coping intervention|see arm description
137022|NCT03118219|Other|Brainteaser|see arm description
137023|NCT03118206|Device|lumbar traction|
137024|NCT03118206|Procedure|spinal manipulation|
137025|NCT03118206|Procedure|surgery|
137026|NCT03118193|Other|olfactive tests|olfactive tests: odor identification, odor discrimination and olfactory threshold
137027|NCT03118193|Biological|blood test|one sample of 4mL
137028|NCT03118193|Biological|Collection of faeces|Collection of faeces by patient at home - optional
137029|NCT03118193|Device|Tissue Pulsatility imaging|Ultrasound exploration of brain pulsatility - optional
137030|NCT03118180|Biological|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
137031|NCT03118167|Dietary Supplement|Tea polyphenols|Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
137032|NCT03118167|Dietary Supplement|AOB-w|Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
137033|NCT03118167|Other|Placebo|Edible starches 0.35g, edible capsule
137034|NCT03118167|Other|Acrylamide (Potato Chips)|Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
137035|NCT03118154|Other|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
137036|NCT03118141|Procedure|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
137037|NCT03118141|Procedure|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
137038|NCT03118141|Procedure|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
137039|NCT03118128|Drug|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
137040|NCT03118115|Device|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
137041|NCT03118089|Dietary Supplement|Biscuit style oral nutritional supplement|
137042|NCT03118076|Drug|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
137043|NCT03118076|Drug|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
137044|NCT03118063|Diagnostic Test|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
137045|NCT03118050|Behavioral|Resistance exercise training|Supervised resistance exercise training, 3 times a week for 3 months
137046|NCT03118050|Behavioral|Bed rest|Bed rest for 5 days, followed by standard rehabilitation for 2 days
137047|NCT03118050|Behavioral|Intensive physical therapy|Intensive weight bearing PT, daily, during bed rest
137048|NCT03118037|Device|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
137049|NCT03118024|Drug|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
137050|NCT03118024|Drug|Catecholamines|catecholamine restrictive anesthesia protocol
137051|NCT03118011|Other|No smoking|No smoking
137052|NCT03118011|Other|Smoking|Ability to go out to smoke
137054|NCT03117998|Biological|Placebo Comparator|Administered as a repeated SC doses in subjects with Type 1 Diabetes
137055|NCT03117985|Other|no drug|Stopping antiretroviral therapy
137056|NCT03117972|Drug|FOLFOXIRI|12 cycles
137057|NCT03117972|Drug|FOLFOX|12 cycles
137058|NCT03117972|Drug|FOLFIRI|12 cycles
137059|NCT03117972|Drug|Bevacizumab|12 cycles
137060|NCT03117972|Drug|LV5FU2|Maintenance chemotherapy
137061|NCT03117972|Drug|Capecitabine|Maintenance chemotherapy
137062|NCT03117959|Device|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
137063|NCT03117959|Device|Stryker Triathlon Custom Fit Knee|
137064|NCT03117946|Other|Biological samples|blood and tumor tissue sample
137065|NCT03117933|Drug|Olaparib|Tablet, 100mg and 150mg
137066|NCT03117933|Drug|Cediranib|Tablet 15mg and 20mg
137067|NCT03117933|Drug|Paclitaxel|Intravenous (IV)
137068|NCT03117920|Drug|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
137069|NCT03117894|Drug|Ropivacaine 5 mg/ml, 35 ml|Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
137070|NCT03117894|Drug|Remifentanil 50 microg/ml|The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
137071|NCT03117894|Drug|Betamethason 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
137072|NCT03117894|Drug|Paracetamol 1,5 g|Administered preoperatively to prevent pain postoperatively.
137073|NCT03117894|Drug|Propofol|The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
137074|NCT03117894|Drug|Arcoxia, 120 mg|Administered preoperatively to prevent pain postoperatively.
137075|NCT03117894|Drug|Ondansetron 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
137076|NCT03117894|Drug|Morphine|Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
137077|NCT03117881|Behavioral|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
137078|NCT03117881|Behavioral|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
137079|NCT03117868|Other|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
137080|NCT03117855|Drug|Capecitabine|Given PO
137081|NCT03117855|Other|Laboratory Biomarker Analysis|Correlative studies
137082|NCT03117855|Radiation|Radioembolization|Undergo yttrium Y-90 radioembolization
137083|NCT03117842|Other|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
137084|NCT03117829|Behavioral|Diet and Exercise|Diet and Exercise Study to Improve Brain Blood Flow
137085|NCT03117816|Drug|AOP2014 / Pegylated-Proline-interferon alpha-2b|AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
137086|NCT03117816|Other|Surveillance|For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.
137087|NCT03117790|Drug|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
137088|NCT03117790|Drug|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
137089|NCT03117777|Behavioral|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
137090|NCT03117764|Device|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
137170|NCT03117296|Other|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
137171|NCT03117296|Other|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
137091|NCT03117764|Behavioral|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
137092|NCT03117764|Device|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.~The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.~Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
137093|NCT03117751|Drug|Prednisone|Given orally (PO).
137094|NCT03117751|Drug|Vincristine|Given intravenously (IV).
137095|NCT03117751|Drug|Daunorubicin|Given IV.
137096|NCT03117751|Drug|Pegaspargase|Given IV or intramuscularly (IM) .
137097|NCT03117751|Drug|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase. Given IV or intramuscularly (IM).
137098|NCT03117751|Drug|Rituximab|Given IV.
137099|NCT03117751|Drug|Cyclophosphamide|Given IV.
137100|NCT03117751|Drug|Cytarabine|Given IV.
137101|NCT03117751|Drug|Mercaptopurine|Given PO.
137102|NCT03117751|Drug|Dasatinib|Given PO.
137103|NCT03117751|Drug|Methotrexate|Given IV.
137104|NCT03117751|Drug|Blinatumomab|Given IV.
137105|NCT03117751|Drug|Ruxolitinib|Given PO.
137106|NCT03117751|Drug|Bortezomib|Given IV or subcutaneously (SQ).
137107|NCT03117751|Drug|Dexamethasone|Given PO.
137108|NCT03117751|Drug|Doxorubicin|Given IV.
137109|NCT03117751|Drug|Etoposide|Given IV.
137110|NCT03117751|Drug|Clofarabine|Given IV.
137111|NCT03117751|Drug|Vorinostat|Given PO.
137112|NCT03117751|Drug|Idarubicin|Given IV.
137113|NCT03117751|Drug|Nelarabine|Given IV.
137114|NCT03117738|Drug|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
137115|NCT03117738|Other|Placebo-Control|Saline with 30% auto-serum
137116|NCT03117725|Drug|Melatonin adminstration|The drug, melatonin will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
137117|NCT03117725|Drug|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
137118|NCT03117712|Diagnostic Test|Delirium Scores|"Confusion Assessment method for the ICU (CAM-ICU) and~The Intensive Care Delirium Screening Checklist (ICDSC)~Delirium Scores will be measured at the following timepoints:~Postoperative day (POD) 1~POD 2~POD 5"
137119|NCT03117712|Diagnostic Test|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:~Before induction of anaesthesia~Before going on cardiopulmonary bypass (CBP)~During CPB, 5 min after aortic cross clamping~After CPB~24 hours after CPB"
137120|NCT03117712|Diagnostic Test|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:~During cannulation of the ascending aorta~After aortic cross-clamp~After opening of the aortic cross-clamp~During decannulation"
137121|NCT03117699|Device|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~A standing pass from sitting on a chair~A straight line movement~A succession of left and right turns~An upward and downward travel of less than 1%.~Standard doorway~Standing on the toilet~A sitting pass from the toilet~One way to a bed~A sitting pass on the bed~A passenger seat sitting upright from the bed~A return to the starting point~A sitting pass on the starting chair"
137122|NCT03117686|Diagnostic Test|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
137123|NCT03117673|Other|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
137124|NCT03117660|Drug|Vitamin A|vitamin A daily X3-4 weeks
137125|NCT03117647|Procedure|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
137126|NCT03117634|Drug|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
137127|NCT03117634|Drug|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
137128|NCT03117608|Biological|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
137129|NCT03117608|Biological|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
137130|NCT03117595|Drug|Bupivacaine-fentanyl|Dosages as previously written
137131|NCT03117595|Drug|Bupivacaine-fentanyl morphine|Dosage as previously written
137132|NCT03117582|Other|Stool specimen|"The following stool specimen will be collected for this study:~4, 3mL stool specimen from patient~1, 25mL stool aliquot from donor"
137133|NCT03117569|Drug|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
137172|NCT03117296|Other|OT post procedure|PT and OT Daily until goals met or patient discharge.
137173|NCT03117296|Other|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
137134|NCT03117556|Procedure|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
137135|NCT03117530|Drug|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
137136|NCT03117517|Drug|Metformin|Metformin (1000 mg)
137137|NCT03117517|Drug|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
137138|NCT03117504|Other|questionnaire|a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
137139|NCT03117491|Procedure|GGNB injections|The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
137140|NCT03117491|Procedure|IANB injections|The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
137141|NCT03117491|Procedure|GGNB + IANB injections|The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
137142|NCT03117478|Other|Magneto-encephalography (MEG)|Magneto-encephalography
137143|NCT03117478|Other|Electro-encephalography (EEG)|Electro-encephalography
137144|NCT03117478|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
137145|NCT03117478|Other|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
137146|NCT03117478|Other|Meditation|Meditation
137147|NCT03117465|Other|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
137148|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
137149|NCT03117452|Behavioral|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
137150|NCT03117439|Other|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
137151|NCT03117426|Device|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
137152|NCT03117426|Device|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
137153|NCT03117413|Other|Positron emission tomography scan|"Binaural hearing assessments: speech recognition in noise and sound source localization~Voice perception assessment: voice/non-voice discrimination task, free categorization task~Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
137154|NCT03117387|Other|no intervention|This study contains no interventions
137155|NCT03117374|Behavioral|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
137156|NCT03117361|Drug|plitidepsin|
137157|NCT03117361|Drug|Bortezomib|
137158|NCT03117361|Drug|Dexamethasone|
137159|NCT03117348|Other|Enteral nutrition|Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
137160|NCT03117335|Drug|Placebos|"Drug 1:~Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
137161|NCT03117335|Drug|Sulijia|"Drug 1:~Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）~Drug 2:~Vinorelbine-Cisplatin:~Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
137162|NCT03117322|Biological|agave inulin|Duration: four weeks Dosage: powder 4 g/d
137163|NCT03117322|Biological|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
137164|NCT03117322|Other|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
137165|NCT03117322|Other|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
137166|NCT03117309|Drug|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
137167|NCT03117309|Drug|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
137168|NCT03117309|Drug|Nivolumab 3mg/kg|In combination with Ipilimumab
137169|NCT03117309|Drug|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
137218|NCT03116997|Drug|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
137174|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
137175|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
137176|NCT03117270|Drug|filgotinib|one filgotinib oral tablet q.d.
137177|NCT03117270|Drug|Placebo Oral Tablet|one placebo oral tablet q.d.
137178|NCT03117257|Drug|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
137179|NCT03117257|Drug|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
137180|NCT03117244|Other|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
137181|NCT03117244|Other|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
137182|NCT03117231|Device|Active Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
137183|NCT03117231|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
137184|NCT03117218|Diagnostic Test|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
137185|NCT03117205|Other|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
137186|NCT03117205|Other|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
137187|NCT03117192|Drug|Zinc Sulfate|Zinc supplementation in syrup form
137188|NCT03117192|Drug|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
137189|NCT03117179|Other|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
137190|NCT03117166|Drug|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
137191|NCT03117166|Drug|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
137192|NCT03117153|Other|DA-5502 liquid toothpaste|6 weeks study, brush three times daily, liquid toothpaste
137193|NCT03117153|Other|placebo|same flavor solution, brush three times daily
137194|NCT03117140|Drug|Ropivacaine 0.75%|Only ropivacaine 0.75% is administered for this arm of the interscalene block
137195|NCT03117140|Drug|Ropivacaine 0.75% + 300 mcg Buprenorphine|Ropivacaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
137196|NCT03117140|Drug|Ropivacaine 0.75% + 75 mcg clonidine|Ropivacaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
137197|NCT03117140|Drug|Ropivacaine 0.75% + 8 mg dexamethasone|Ropivacaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
137198|NCT03117127|Behavioral|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
137199|NCT03117127|Other|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
137200|NCT03117127|Other|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
137201|NCT03117114|Device|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
137202|NCT03117114|Other|Standard polypectomy|Absence of an EVD, standard polypectomy
137203|NCT03117101|Drug|Lucitanib|
137204|NCT03117088|Other|Checklist ISBAR3|"Checklist ISBAR 3~Use of an online based checklist for handovers with the following items:~Identification Situation Background Assessment Recommendation Read- back Risk~Established Checklist as communication tool"
137205|NCT03117088|Other|Checklist VICUR|"Checklist Vicur~Use of an online based alternative checklist for handovers with the following items:~Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?~alternative checklist missing communication tool"
137206|NCT03117075|Device|"using device for scoring pain scale, named ANAPA®"|wearable device for scoring pain scale
137207|NCT03117062|Other|occlusal reduction|relief of occlusion following endodontic treatment
137208|NCT03117049|Drug|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
137209|NCT03117049|Drug|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
137210|NCT03117049|Drug|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
137211|NCT03117049|Drug|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
137212|NCT03117049|Drug|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
137213|NCT03117036|Drug|Chemotherapy|Systemic chemotherapy with curative intent
137214|NCT03117023|Drug|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
137215|NCT03117010|Drug|Steroids|High dose dexamethasone 20 mg PO or IV
137216|NCT03117010|Drug|Etoposide|Etoposide 150mg/BSA
137217|NCT03116997|Drug|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
137219|NCT03116984|Procedure|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
137220|NCT03116984|Radiation|External- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
137221|NCT03116971|Drug|M3814|Participants received M3814 PiC or hot melt extrusion (HME) tablet orally once daily in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
137222|NCT03116971|Drug|Cisplatin|Cisplatin 75 milligram per square meter (mg/m^2) was administered over a 60-minute intravenous infusion on Day 1.
137223|NCT03116971|Drug|Etoposide|Etoposide 100 mg/m^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
137224|NCT03116958|Device|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
137225|NCT03116958|Device|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
137226|NCT03116945|Drug|68Gallium Citrate|Procedure: PET/CT Imaging
137227|NCT03116932|Behavioral|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
137228|NCT03116919|Other|Potato|Participants will be given an extra serving of potato a day
137229|NCT03116919|Other|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
137230|NCT03116906|Drug|BI 685509|to be given for a total of up to 15 days
137231|NCT03116906|Drug|Placebo|to be given for a total of up to 15 days
137232|NCT03116893|Drug|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
137233|NCT03116893|Drug|Itraconazole|Administration of itraconazole together with BI 685509
137234|NCT03116893|Drug|Rifampin|Administration of rifampicin together with BI 685509
137235|NCT03116893|Drug|BI 685509 Fasted Conditions|BI 685509, given alone
137236|NCT03116880|Procedure|Endovascular aortic repair|Endovascular aortic repair
137237|NCT03116867|Other|sonosalpingography|transvaginal ultrasound with saline infusion
137238|NCT03116841|Drug|Vonoprazan|Vonoprazan 20 mg
137239|NCT03116828|Drug|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
137240|NCT03116828|Drug|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
137241|NCT03116815|Other|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
137242|NCT03116802|Drug|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
137243|NCT03116789|Dietary Supplement|probiotics|Two capsules for daily
137244|NCT03116776|Procedure|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
137245|NCT03116776|Drug|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
137246|NCT03116763|Behavioral|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.
137247|NCT03116763|Other|Active Comparator: Control Group|The control group will receive standard care but without the iPeer2Peer program.
137248|NCT03116737|Drug|Benzocaine Otic Solution|
137249|NCT03116737|Drug|Placebo|
137250|NCT03116724|Procedure|central venous catheterization through Rt. IJV|"insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head~placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE~measurement of the depth of the catheter at insertion point"
137251|NCT03116711|Other|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
137252|NCT03116711|Other|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
137253|NCT03116711|Other|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
137254|NCT03116711|Other|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
137255|NCT03116698|Drug|Low dose DFD07 once daily|Low dose DFD07 once daily
137256|NCT03116698|Drug|High dose DFD07 once daily|High dose DFD07 once daily
137257|NCT03116698|Drug|High dose DFD07 twice daily|High dose DFD07 twice daily
137258|NCT03116698|Drug|Placebo twice daily|Placebo twice daily
137259|NCT03116685|Biological|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
137260|NCT03116685|Other|Placebo|Placebo
137261|NCT03116672|Drug|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
137307|NCT03116269|Drug|Cilostazol 100mg|
137262|NCT03116672|Drug|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
137263|NCT03116672|Drug|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
137264|NCT03116659|Drug|Doxycycline|Doxycycline 100 mg PO BID x 14 days
137265|NCT03116659|Drug|Imiquimod|up to 2 packs 3/ week x 28 days
137266|NCT03116646|Diagnostic Test|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
137267|NCT03116620|Other|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
137268|NCT03116607|Other|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
137269|NCT03116594|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
137270|NCT03116594|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
137271|NCT03116581|Other|Behavior|"Random-dots tasks: dots appear and move, most have a random trajectory but a given proportion of them move coherently to the same direction.~Vicarious reward Each trial begins with a cue, showing 'me' or 'him' and filled rectangle filled proportionally to the payoff. The cue and the square are depicted in yellow (oneself) or blue (other), depending on the beneficiary. The moving dots are then presented and the subjects respond. At the end of dots motion, the feedback is presented. If the response was correct, a pile of coins proportional to the payoff is shown. For incorrect responses and misses, a red-colored cross is displayed.~Audience effect Each trial begins with the display of two eyes (public) or a padlock (private). The moving dots are shown and the participant answers. Audience condition changes the information available on accuracy when submitting comments. In the observed condition, an arrow shows the response. In the observed condition, no feedback is displayed."
137272|NCT03116581|Other|fMRI (functional Magnetic Resonance Imagery)|"Both behavioral task (audience effect and vicarious reward) will be studied in fMRI (functional Magnetic Resonance Imagery). The same paradigms used in the behavioral experiment will be adapted for fMRI.~Audience Effect experiment: trials will last for 10 seconds maximum. With 80 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 320 trials and have a 54 minutes duration, in 3 runs of 17 minutes each.~Vicarious Reward experiment: trials will have a 10 seconds maximum duration. Using 40 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 200 trials and last for 54 minutes, in 6 runs of 9 minutes each."
137273|NCT03116581|Other|MEG (MagnetoEncephaloGraphy)|"Both behavioral task (audience effect and vicarious reward) will be studied in MEG (MagnetoEncephaloGraphy). The same paradigms used in the behavioral experiment will be used in MEG.~Audience Effect experiment: trials will last for 7 seconds maximum. With 100 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 400 trials and have a 47 minutes duration. Every 100 trials (about 12 minutes of tasks), a break will be proposed to the participants.~Vicarious Reward experiment: trials will have a 7.2 seconds maximum duration. Using 75 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 375 trials and last for 45 minutes. Every 125 trials (every 15 minutes), a break will be proposed to the participants."
137274|NCT03116555|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
137275|NCT03116555|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC
137276|NCT03116542|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
137277|NCT03116529|Combination Product|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.~Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as >10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy~Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.~Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
137278|NCT03116516|Drug|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
137279|NCT03116516|Drug|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
137280|NCT03116503|Other|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
137281|NCT03116490|Procedure|Anesthesia type|RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
137308|NCT03116269|Drug|Aspirin|
137309|NCT03116256|Dietary Supplement|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
137282|NCT03116464|Behavioral|Telemental Health Family Intervention|"Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs"
137283|NCT03116451|Behavioral|Foot Health Promoting Program|An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
137284|NCT03116438|Device|CADence|The CADence device collects acoustic (sound) data from locations on the chest for the purpose of identifying coronary artery turbulence, which may be indicative of coronary artery disease. The test will take approximately 15 minutes to complete. There are no follow-up procedures associated with the study.
137285|NCT03116425|Device|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
137286|NCT03116425|Device|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
137287|NCT03116425|Device|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
137288|NCT03116425|Procedure|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
137289|NCT03116425|Procedure|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.~To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).~Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.~Patients will have 4 sessions per day on 5 successive days per arm."
137290|NCT03116425|Procedure|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.~Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
137291|NCT03116412|Procedure|CT or PET scans|Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
137292|NCT03116399|Behavioral|PRISM 2.0 Condition|Access to the PRISM 2.0 program
137293|NCT03116399|Behavioral|Tablet Condition|Access to the tablet
137294|NCT03116386|Other|run-in period|observational time i.e. baseline situation
137295|NCT03116386|Device|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
137296|NCT03116386|Device|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
137297|NCT03116373|Other|mandible fixation|Intubation device will be fixed on mandible
137298|NCT03116373|Other|Maxilla fixation|Intubation device will be fixed on maxilla
137299|NCT03116360|Diagnostic Test|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
137300|NCT03116347|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
137301|NCT03116347|Biological|KIOVIG|100 mg/ml solution for infusion
137302|NCT03116347|Biological|Cuvitru|200 mg/ml solution for subcutaneous injection
137303|NCT03116321|Drug|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
137304|NCT03116308|Drug|Opicapone (OPC)|50 mg OPC capsules; oral route
137305|NCT03116295|Drug|Opicapone (OPC)|Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
137306|NCT03116282|Behavioral|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
137310|NCT03116256|Other|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
137311|NCT03116256|Other|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
137312|NCT03116230|Device|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
137313|NCT03116230|Device|Knee Sleeve|Commercially-available knee sleeve.
137314|NCT03116204|Other|Assessment of score SAS|Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
137315|NCT03116191|Drug|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
137316|NCT03116191|Drug|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
137317|NCT03116178|Other|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi<4 fluid rate is 50-60ml/hr and pvi>11 200ml colloid bolus transfusion till pvi value achieves normal range.~In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
137318|NCT03116178|Other|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
137319|NCT03116165|Behavioral|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
137320|NCT03116165|Behavioral|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
137321|NCT03116152|Biological|IBI308|IBI308 200mg Intravenous drip every three weeks；
137322|NCT03116152|Biological|paclitaxel/ irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
137323|NCT03116139|Diagnostic Test|V/Q imaging|Standard of care
137324|NCT03116139|Diagnostic Test|Computed tomography scan|Standard of care
137325|NCT03116126|Drug|Guanfacine|2mg oral daily tablet
137326|NCT03116126|Drug|Placebo|inactive oral daily tablet
137327|NCT03116113|Biological|AAV8-RPGR|Comparison of different dosages of AAV8-RPGR
137328|NCT03116087|Drug|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
137329|NCT03116087|Drug|Placebo|Placebo patch
137330|NCT03116074|Behavioral|Interactive Digital Health Tools|Discharge checklist, discharge video, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging, condition-specific educational videos
137331|NCT03116061|Other|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
137332|NCT03116048|Other|Chronic pain evaluation|Chronic pain assessment with study questionnaire
137333|NCT03116035|Other|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
137334|NCT03116035|Other|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
137335|NCT03116022|Drug|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
137336|NCT03116022|Drug|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
137337|NCT03116022|Drug|Vaginal Gel|Women using a base water gel lubricant during intercourse
137338|NCT03116009|Drug|Screening for diabetes with 1-hour GCT and HbA1|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
137339|NCT03115996|Drug|REGN3918|Intravenous (IV) or Subcutaneous (SC)
137340|NCT03115996|Drug|Placebo|Matching Placebo
137341|NCT03115983|Device|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
137342|NCT03115983|Device|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
137343|NCT03115983|Procedure|Decompression|Surgical decompression of a single level L1-S1.
137344|NCT03115983|Procedure|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
137345|NCT03115970|Procedure|capillary and venous lactate level measurement|capillary and venous lactate level measurement
137346|NCT03115957|Other|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
137347|NCT03115944|Device|Alma vShape Ultra|UltraSpeed ultrasound treatment, a series of four treatments
137348|NCT03115931|Other|no intervention|no intervention
137349|NCT03115918|Device|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
137350|NCT03115918|Other|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
137351|NCT03115892|Drug|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
137352|NCT03115892|Drug|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
137353|NCT03115879|Other|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
137355|NCT03115866|Behavioral|FRUVEDomics|FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
137356|NCT03115853|Drug|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
137357|NCT03115853|Drug|Placebo|Placebo tablet for Aliskerin
137358|NCT03115853|Drug|HCTZ|HCTZ 25mg every day for 18 weeks
137359|NCT03115853|Drug|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
137360|NCT03115827|Drug|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
137361|NCT03115827|Drug|Carbidopa|Carbidopa 200mg twice a day
137362|NCT03115801|Drug|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
137363|NCT03115801|Drug|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
137364|NCT03115801|Radiation|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
137365|NCT03115801|Drug|Pembrolizumab|Pembrolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
137366|NCT03115788|Other|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
137367|NCT03115788|Other|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
137368|NCT03115788|Device|iPad|
137369|NCT03115775|Dietary Supplement|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
137370|NCT03115775|Dietary Supplement|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
137371|NCT03115775|Dietary Supplement|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
137372|NCT03115775|Other|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
137373|NCT03115762|Biological|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
137374|NCT03115762|Biological|ASKB1202|
137375|NCT03115749|Other|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
137376|NCT03115749|Other|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
137377|NCT03115736|Drug|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
137378|NCT03115723|Procedure|Percutaneous coronary intervention|
137379|NCT03115723|Procedure|Coronary angiography|
137380|NCT03115710|Diagnostic Test|Rotating Scheimpflug camera (Pentacam HR)|One visit to Ophthalmology Department is required from participant. Parents or legal guardians must attend with their child. The interview and test during visit take approximately 15 minutes. Interview includes filling out a questionnaire about risk factors of the disease and double check on understanding the consent form. The child will sit in front of the instrument (Pentacam HR Scheimpflug imaging system). The rotational measuring procedure generates Scheimpflug images in three dimensions. The images taken during the examination are digitalized, and all image data are transferred to the computer. It calculates a 3D virtual model of the anterior eye segment, from which all additional information is derived.
137381|NCT03115697|Drug|Lactulose|Lactulose 20 mL
137382|NCT03115697|Drug|Rifaximin|Rifaximin 550 BD
137383|NCT03115697|Biological|Plasmapheresis|Plasmapheresis 8 hrly duration
137384|NCT03115671|Dietary Supplement|Vayarin|Vayarin capsule
137385|NCT03115658|Behavioral|Physical Activity|12 week print based intervention
137386|NCT03115645|Other|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
137387|NCT03115619|Drug|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
137388|NCT03115606|Device|C-Mac D Blade|Videolaryngoscope
137389|NCT03115606|Device|Fastrach LMA|Laryngeal mask airway
137390|NCT03115593|Procedure|Blind biopsy with a pipette|Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
137391|NCT03115593|Procedure|Targeted biopsy using hysteroscopy|During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
137392|NCT03115580|Device|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
137420|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about CRC screening
137393|NCT03115580|Device|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
137394|NCT03115567|Drug|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
137395|NCT03115554|Procedure|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
137396|NCT03115554|Procedure|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
137397|NCT03115528|Behavioral|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
137398|NCT03115515|Drug|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
137399|NCT03115489|Drug|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
137400|NCT03115489|Drug|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
137401|NCT03115476|Drug|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
137402|NCT03115476|Drug|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
137403|NCT03115476|Other|Vehicle gel|Vehicle to ingenol disoxate gel with no active ingredient
137404|NCT03115463|Other|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
137405|NCT03115450|Device|Ultrasound|Type of imaging technology to look at organs and structures inside the body
137406|NCT03115450|Device|Pupilometer|A device that measures pupil size and how it changes.
137407|NCT03115437|Other|Hard cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by hard cushioning.
137408|NCT03115437|Other|Soft cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by soft cushioning.
137409|NCT03115424|Drug|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
137410|NCT03115424|Drug|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
137411|NCT03115424|Procedure|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
137412|NCT03115411|Device|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
137413|NCT03115398|Behavioral|Pedometer-based Walking Program|Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
137414|NCT03115385|Dietary Supplement|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
137415|NCT03115385|Dietary Supplement|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
137416|NCT03115372|Other|Educational Intervention|Attend CRC education session
137417|NCT03115372|Other|Educational Intervention|Attend healthy nutrition session
137418|NCT03115372|Other|Informational Intervention|Receive CRC screening brochure
137419|NCT03115372|Other|Survey Administration|Ancillary studies
137421|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
137422|NCT03115359|Behavioral|Mindfulness Meditation|"The Mindfulness Meditation intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
137423|NCT03115359|Behavioral|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.~In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
137424|NCT03115346|Other|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
137425|NCT03115333|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
137426|NCT03115320|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
137427|NCT03115320|Other|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
137428|NCT03115307|Drug|Triptorelin|Triptoreline 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
137429|NCT03115294|Drug|Theophylline|iv injection
137430|NCT03115294|Procedure|Ventilator positive end expiratory pressure adjustment|Positive end-expiratory pressure variation
137431|NCT03115294|Device|Videorecording|Myocardial movement videorecording
137432|NCT03115281|Device|PCI|PCI
137433|NCT03115268|Behavioral|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
137434|NCT03115255|Drug|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
137435|NCT03115242|Other|Contrast injection Sonovue®|In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
137436|NCT03115229|Behavioral|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
137437|NCT03115216|Procedure|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
137438|NCT03115216|Procedure|CEIOL|Manual cataract extraction and intraocular lens placement
137439|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
137440|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
137441|NCT03115190|Diagnostic Test|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
137442|NCT03115177|Drug|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
137443|NCT03115177|Drug|Cefazolin|
137444|NCT03115164|Other|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
137445|NCT03115151|Drug|Bupivacaine|Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
137446|NCT03115151|Drug|Hydromorphone|Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
137447|NCT03115151|Drug|Fentanyl|Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
137448|NCT03115138|Other|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
137449|NCT03115125|Other|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
137450|NCT03115112|Drug|Bexagliflozin|20 mg, tablet
137452|NCT03115112|Drug|Placebo for sitagliptin|100 mg inactive tablet to match active comparator
137453|NCT03115112|Drug|Placebo for bexagliflozin|20 mg inactive tablet to match active comparator
137454|NCT03115099|Drug|LY3325656|Administered orally
137455|NCT03115099|Drug|Placebo|Administered orally
137456|NCT03115099|Drug|Liraglutide|Administered subcutaneously
137457|NCT03115099|Drug|Sitagliptin|Administered orally
137458|NCT03115073|Drug|Candiplus|Administration of Candiplus
137459|NCT03115073|Drug|Clotrimazole|Administration of Clotrimazole
137460|NCT03115060|Drug|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
137461|NCT03115047|Drug|Dexmedetomidine Injection|0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
137462|NCT03115047|Drug|Meperidine Injection|0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
137463|NCT03115034|Drug|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
137464|NCT03115034|Drug|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
137465|NCT03115034|Other|blank|Patients under CEA without taking melatonin or placebo
137466|NCT03115021|Device|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
137467|NCT03115021|Device|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
137468|NCT03115021|Device|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
137469|NCT03115021|Device|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
137470|NCT03115008|Behavioral|Video-based terminal feedback|Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
137471|NCT03114995|Drug|Tirofiban|
137472|NCT03114982|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
137473|NCT03114982|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
137474|NCT03114969|Device|Relvar ELLIPTA|ELLIPTA inhaler containing Relvar will be used by subjects as their maintenance treatment to control COPD.
137475|NCT03114969|Device|Symbicort TURBUHALER|TURBUHALER inhaler containing Symbicort will be used by subjects as their maintenance treatment to control COPD.
137476|NCT03114969|Device|Seretide DISKUS|DISKUS inhaler containing Seretide will be used by subjects as their maintenance treatment to control COPD.
137477|NCT03114969|Device|Spiriva HANDIHALER|HANDIHALER inhaler containing Spiriva will be used by subjects as their maintenance treatment to control COPD.
137478|NCT03114969|Device|BREEZHALER|BREEZHALER inhaler containing either Seebri or Ultibro will be used by subjects as their maintenance treatment to control COPD.
137479|NCT03114969|Device|Incruse ELLIPTA|ELLIPTA inhaler containing Incruse will be used by subjects as their maintenance treatment to control COPD.
137480|NCT03114969|Device|Anoro ELLIPTA|ELLIPTA inhaler containing Anoro will be used by subjects as their maintenance treatment to control COPD.
137481|NCT03114956|Procedure|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
137482|NCT03114956|Procedure|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
137483|NCT03114956|Procedure|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
137484|NCT03114956|Procedure|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
137485|NCT03114943|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
137486|NCT03114943|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
137487|NCT03114930|Other|"To study the absence of increased complications and events occurring in the mother-newborn"|"To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity."
137488|NCT03114917|Other|Cognitive AppRoaches to coMbatting Suicidality (CARMS)|The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
137489|NCT03114904|Other|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
137644|NCT03113630|Device|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
137645|NCT03113617|Procedure|Computed Tomography|Undergo PET/CT
137490|NCT03114891|Procedure|Theta-burst stimulation|A normal, FDA-approved clinical application of TMS involves long trains of repetitive TMS applied for approximately 40 minutes, 5 days/week, over 2-6 weeks, for a total of 10-30 TMS visits. The present study utilizes the same FDA-approved devices (Magventure Cool-Coil B65, MagVenture X100 Stimulator) to administer treatment. We will be modifying the FDA-approved protocol to stimulate in a well-replicated protocol, theta-burst stimulation (Huang et al., 2005), which will result in a greatly reduced number of total pulses delivered to the subject in any given TMS session.
137491|NCT03114878|Other|TRT / EMDR|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Eye Movement Desensitization and Reprocessing:~This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
137492|NCT03114878|Behavioral|TRT / CBT|"Tinnitus Retraining Therapy:~TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.~Cognitive Behavioral Therapy:~CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
137493|NCT03114865|Drug|Blinatumomab|Cycle 1 - Days 1-7: 9 ug/day IV daily
137494|NCT03114865|Drug|Blinatumomab|Cycle 1 - Days 8-28: 28 ug/day IV daily
137495|NCT03114865|Drug|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
137496|NCT03114865|Drug|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
137497|NCT03114852|Diagnostic Test|blood collection|They will have blood tested to renal genetic diseases
137498|NCT03114839|Dietary Supplement|Lactobacillus casei strain Shirota (LcS)|A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of LcS.
137499|NCT03114826|Genetic|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
137500|NCT03114813|Drug|Carvedilol|Non-selective beta-blocker as per routine clinical care
137501|NCT03114813|Other|MRI scan|One hour non-invasive MRI scan
137502|NCT03114813|Procedure|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
137503|NCT03114800|Device|E-Scale|The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
137504|NCT03114787|Other|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
137505|NCT03114774|Device|The bispectral index (BIS) monitoring|
137506|NCT03114774|Behavioral|Ramsay Sedation Scale (RSS) Score monitoring|
137507|NCT03114761|Radiation|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
137508|NCT03114748|Other|EEG|
137509|NCT03114748|Other|DBS switched OFF and ON|
137510|NCT03114722|Drug|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
137511|NCT03114722|Drug|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
137512|NCT03114709|Other|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness practices and physical activity.
137513|NCT03114709|Other|10 Keys to Health & Wellbeing|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
137514|NCT03114696|Dietary Supplement|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
137515|NCT03114696|Dietary Supplement|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
137516|NCT03114683|Drug|PD1|IBI308 200mg/3 weeks
137517|NCT03114670|Biological|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
137518|NCT03114657|Drug|Crenezumab|Crenezumab will be administered as IV infusion q4w for 100 weeks.
137519|NCT03114657|Drug|Placebo|Placebo will be administered as IV infusion q4w for 100 weeks.
137520|NCT03114644|Other|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
137521|NCT03114631|Biological|Dendritic cells pulsed with tumor lysate|
137522|NCT03114631|Biological|Dendritic cells pulsed with MUC-1/WT-1 peptides|
137524|NCT03114592|Other|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
137525|NCT03114579|Device|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
137526|NCT03114579|Device|NEXFIN HD|
137527|NCT03114566|Other|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
137528|NCT03114553|Genetic|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
137529|NCT03114540|Drug|GBT440|Oral
137530|NCT03114527|Drug|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
137531|NCT03114527|Drug|Everolimus|mTOR inhibitor
137532|NCT03114514|Biological|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
137533|NCT03114501|Behavioral|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
137534|NCT03114501|Behavioral|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
137535|NCT03114501|Behavioral|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
137536|NCT03114475|Radiation|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
137537|NCT03114475|Other|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
137538|NCT03114462|Radiation|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
137539|NCT03114462|Behavioral|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
137540|NCT03114449|Device|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
137541|NCT03114449|Device|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
137542|NCT03114436|Other|Observational Data Collection|All aspects of deceased donor care in the ICU.
137543|NCT03114423|Other|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
137544|NCT03114423|Other|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
137545|NCT03114410|Behavioral|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and peer educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of peer educators (who are young parents) will deliver the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth receive roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
137546|NCT03114397|Device|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
137547|NCT03114397|Device|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
137548|NCT03114384|Other|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
137549|NCT03114371|Drug|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
137550|NCT03114371|Drug|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
137551|NCT03114371|Drug|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
137552|NCT03114358|Other|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
137553|NCT03114345|Other|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
137646|NCT03113617|Drug|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
137554|NCT03114345|Other|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
137555|NCT03114332|Procedure|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
137556|NCT03114319|Drug|TNO155|TNO155 for oral administration
137557|NCT03114306|Procedure|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
137558|NCT03114306|Procedure|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
137559|NCT03114293|Behavioral|Smartphone App|The app includes an EBPI and physical activity feedback
137560|NCT03114280|Drug|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
137561|NCT03114280|Other|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
137562|NCT03114267|Other|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
137563|NCT03114254|Drug|Cabazitaxel|"Six cycles of chemotherapy comprising:~Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
137564|NCT03114241|Behavioral|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
137565|NCT03114228|Drug|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
137566|NCT03114215|Drug|MD1003|capsules 100mg 3 times per day
137567|NCT03114215|Drug|Placebo oral capsule|capsules 100mg lactose 3 times per day
137568|NCT03114202|Other|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
137569|NCT03114202|Other|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
137570|NCT03114189|Procedure|footbath|
137571|NCT03114189|Behavioral|care of sleep|
137572|NCT03114176|Dietary Supplement|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
137573|NCT03114163|Other|Non-Interventional|Non-Interventional
137574|NCT03114150|Behavioral|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
137575|NCT03114150|Behavioral|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
137576|NCT03114124|Device|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
137577|NCT03114124|Device|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
137578|NCT03114111|Drug|aminolevulinic acid (ALA)|
137579|NCT03114111|Drug|Placebo|
137580|NCT03114098|Other|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
137581|NCT03114085|Drug|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
137582|NCT03114085|Drug|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
137583|NCT03114072|Device|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
137584|NCT03114072|Device|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
137585|NCT03114059|Diagnostic Test|Glaucoma diagnostics|Heidelberg, Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological determination
137586|NCT03114046|Behavioral|Lower extremity Constraint-induced movement therapy(LE-CIMT)|"Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.~Both caregivers and participants will be individually interviewed before and after treatment."
137647|NCT03113617|Other|Laboratory Biomarker Analysis|Correlative studies
137587|NCT03114033|Other|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg
137588|NCT03114033|Other|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg.
137589|NCT03114020|Drug|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
137590|NCT03114020|Drug|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
137591|NCT03114007|Behavioral|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
137592|NCT03114007|Behavioral|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.~Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
137593|NCT03114007|Behavioral|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
137594|NCT03113994|Drug|Rosuvastatin Calcium|10mg Rosuvastatin, daily for 12 months
137595|NCT03113994|Drug|Placebo Oral Tablet|Placebo, daily for 12 months
137596|NCT03113994|Dietary Supplement|Coenzyme Q10|100mg CoQ10, daily for 12 months
137597|NCT03113994|Dietary Supplement|Calcium Carbonate|1250mg Calcium Carbonate, daily for 12 months
137598|NCT03113994|Dietary Supplement|Vitamin D|2000IU Vitamin D, daily for 12 months
137599|NCT03113981|Device|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
137600|NCT03113968|Procedure|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
137601|NCT03113968|Drug|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
137602|NCT03113955|Device|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
137603|NCT03113942|Drug|Pomalidomide 2 MG Oral Capsule [Pomalyst]|Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
137604|NCT03113929|Radiation|MRI|Research MRI
137605|NCT03113916|Behavioral|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
137606|NCT03113903|Behavioral|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
137607|NCT03113890|Genetic|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
137608|NCT03113890|Genetic|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
137609|NCT03113890|Other|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
137648|NCT03113617|Procedure|Positron Emission Tomography|Undergo PET/CT
137750|NCT03112811|Device|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
137610|NCT03113877|Other|Autonomic Dysfunction Testing|The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
137611|NCT03113864|Dietary Supplement|Placebo|Daily supplementation for 9 months
137612|NCT03113864|Dietary Supplement|Lutein|Daily Supplementation for 9 months
137613|NCT03113851|Radiation|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
137614|NCT03113851|Drug|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
137615|NCT03113825|Device|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
137616|NCT03113825|Drug|AVB-620|AVB-620 will be administered IV before the surgical procedure.
137617|NCT03113812|Drug|ABvac40|
137618|NCT03113812|Drug|Placebo|
137619|NCT03113799|Device|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
137620|NCT03113786|Biological|CLARIX™100|CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
137621|NCT03113786|Biological|CLARIX CORD 1K|CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues & Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
137622|NCT03113773|Drug|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10^6 - 3.0 X 10^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10^6 IU will be allowed per day.
137623|NCT03113773|Drug|Placebo Injection|Dextrose 5%
137624|NCT03113760|Drug|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
137625|NCT03113760|Other|0.9% sodium chloride|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
137626|NCT03113747|Biological|ALLO-ASCs|1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
137627|NCT03113734|Other|Construction and validation of a functional score|"All patients will be treated at the same way:~Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
137628|NCT03113708|Drug|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
137629|NCT03113695|Drug|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
137630|NCT03113695|Drug|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
137631|NCT03113695|Drug|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
137632|NCT03113682|Behavioral|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
137633|NCT03113669|Behavioral|CBT-GSH|
137634|NCT03113656|Other|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
137635|NCT03113656|Other|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
137636|NCT03113643|Drug|Azacitidine|Chemotherapy
137637|NCT03113643|Drug|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
137638|NCT03113643|Drug|Venetoclax|Venetoclax is a BH3-mimetic. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has sometimes shown to be linked with increased resistance to chemotherapy.
137639|NCT03113630|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
137640|NCT03113630|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
137641|NCT03113630|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
137642|NCT03113630|Device|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
137643|NCT03113630|Device|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
137649|NCT03113604|Other|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:~Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
137650|NCT03113591|Procedure|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
137651|NCT03113591|Procedure|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
137652|NCT03113578|Device|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
137653|NCT03113565|Behavioral|Count daily number of footsteps.|Using a connected electronic wristband to mainly quantify daily number of footsteps.
137654|NCT03113539|Other|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :~Modified low-dose, EKG-gated CT without contrast~Usual high-dose, EKG-gated CT with contrast~Comparing aortic diameters from the two protocols."
137655|NCT03113526|Procedure|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
137656|NCT03113513|Procedure|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
137657|NCT03113500|Drug|Brentuximab Vedotin|Given IV
137658|NCT03113500|Drug|Cyclophosphamide|Given IV
137659|NCT03113500|Drug|Doxorubicin|Given IV
137660|NCT03113500|Drug|Doxorubicin Hydrochloride|Given IV
137661|NCT03113500|Drug|Etoposide|Given IV
137662|NCT03113500|Drug|Etoposide Phosphate|Given IV
137663|NCT03113500|Other|Laboratory Biomarker Analysis|Correlative studies
137664|NCT03113500|Drug|Prednisone|Given PO
137665|NCT03113487|Other|Laboratory Biomarker Analysis|Correlative studies
137666|NCT03113487|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
137667|NCT03113487|Biological|Pembrolizumab|Given IV
137668|NCT03113474|Other|Food palatability|Food palatability is modulated
137669|NCT03113461|Device|CPAP|non-invasive positive airway pressure applied using an oronasal mask
137670|NCT03113448|Drug|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
137671|NCT03113448|Drug|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
137672|NCT03113435|Other|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
137673|NCT03113422|Drug|Induction Venetoclax|"1 cycle = 28 days.~Cycle 1-6: Obinutuzumab IV. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.~Cycle 1-6: Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab.~Cycle 2-6: Venetoclax 800 mg by mouth daily on Days 1-10 administered before obinutuzumab and/or bendamustine."
137674|NCT03113422|Drug|Maintenance Venetoclax|Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily for 24 cycles (1 cycle=1 month) and obinutuzumab 1000 mg IV every 2 months for 12 cycles. Patients with no evidence of disease will receive obinutuzumab 1000 mg IV every 2 months for 12 cycles.
137675|NCT03113409|Drug|Buprenorphine|Buprenorphine will be administered daily
137676|NCT03113409|Drug|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
137677|NCT03113409|Drug|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
137678|NCT03113396|Drug|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
137679|NCT03113396|Drug|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
137680|NCT03113383|Device|Thoracoabdominal Aortic Aneurysm Repair|Thoracoabdominal aortic aneurysm repair
137681|NCT03113370|Dietary Supplement|Fish Oil|Fish Oil capsules
137682|NCT03113370|Dietary Supplement|Placebo|Olive Oil
137683|NCT03113357|Other|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
137684|NCT03113357|Other|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
137685|NCT03113344|Drug|cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in children.
137686|NCT03113318|Procedure|Total mediastinal lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
137687|NCT03113318|Procedure|Only pulmonary metastasectomy|
137719|NCT03113071|Drug|Digoxin|Decitabine will be administered in combination with Digoxin
137688|NCT03113292|Other|Pilates|"The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.~."
137689|NCT03113292|Other|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
137690|NCT03113266|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
137691|NCT03113253|Drug|Tranexamic Acid|
137692|NCT03113253|Drug|Placebo|0.9% sodium chloride to mimic tranexamic acid
137693|NCT03113240|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
137694|NCT03113240|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
137695|NCT03113227|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
137696|NCT03113227|Diagnostic Test|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
137697|NCT03113214|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
137698|NCT03113214|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
137699|NCT03113214|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
137700|NCT03113214|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
137701|NCT03113214|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
137702|NCT03113214|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
137703|NCT03113201|Behavioral|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
137704|NCT03113201|Behavioral|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
137705|NCT03113188|Drug|CBP501|CBP501, CDDP plus Nivolumab
137706|NCT03113175|Behavioral|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
137707|NCT03113175|Behavioral|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
137708|NCT03113162|Biological|Autologous Hematopoietic Stem Cell|
137709|NCT03113162|Drug|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
137710|NCT03113136|Behavioral|Low wattage E cigarette device|The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
137711|NCT03113136|Behavioral|HIgh wattage E cigarette device|The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
137712|NCT03113136|Behavioral|Usual brand cigarette|The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
137713|NCT03113123|Drug|PrEP with Truvada®|"Associated with:~STD screening/treatment for syphilis, gonorrhoea and chlamydiae~HIV screening/therapy~Questionnaire~Addiction, social or psychological follow-up care if needed~Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites."
137714|NCT03113110|Drug|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
137715|NCT03113097|Other|Embryo transfer|Transfer of different qualities of embryos at blastocyst stage
137716|NCT03113084|Biological|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
137717|NCT03113084|Biological|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
137718|NCT03113071|Drug|Decitabine|Decitabine will be administered in combination with Digoxin
137720|NCT03113058|Combination Product|Adoptive transfer of γδT cells|Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
137721|NCT03113045|Other|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
137722|NCT03113032|Other|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
137723|NCT03113032|Other|Normal pre-surgical care|Routine pre-surgical care
137724|NCT03113019|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
137725|NCT03113006|Procedure|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
137726|NCT03112993|Drug|sugammadex|once at the end of the surgery
137727|NCT03112993|Drug|Neostigmine|once at the end of the surgery
137728|NCT03112980|Device|Transcatheter aortic valve implantation|(TAVI)
137729|NCT03112980|Procedure|Surgical aortic valve replacement|(SAVR)
137730|NCT03112967|Other|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
137731|NCT03112967|Other|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
137732|NCT03112954|Drug|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
137733|NCT03112954|Drug|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
137734|NCT03112941|Procedure|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
137735|NCT03112941|Other|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
137736|NCT03112928|Device|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.~A treatment session of MPE consists of:~Pain evaluation~Placement of the electrodes and fiducial marker~Practice of motor execution in Augmented Reality (AR)~Gaming using phantom movements~Practice of motor execution by matching random target postures of a virtual limb.~Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
137737|NCT03112928|Device|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
137738|NCT03112915|Procedure|quadratus lumborum block|QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
137739|NCT03112915|Procedure|Transversus abdominis plan block|TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
137740|NCT03112902|Device|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
137741|NCT03112889|Drug|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
137742|NCT03112876|Other|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
137743|NCT03112863|Drug|Bakuchiol|This group will receive bakuchiol
137744|NCT03112863|Drug|Retinol|This group will receive retinol
137745|NCT03112850|Device|Hearing aid|LOF hearing aid
137746|NCT03112850|Behavioral|Auditory Training|
137747|NCT03112837|Other|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
137748|NCT03112824|Drug|Ashwagandha Root Extract Capsule|Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.
137749|NCT03112824|Drug|Placebo Capsule|Participants will take one placebo capsule orally twice a day for 12 weeks.
137751|NCT03112811|Device|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
137752|NCT03112785|Device|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
137753|NCT03112772|Other|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
137754|NCT03112772|Other|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
137755|NCT03112759|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
137756|NCT03112746|Behavioral|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
137757|NCT03112733|Diagnostic Test|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
137758|NCT03112720|Device|Epidural Blood Patch|A device: 17 gauge Tuohy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloraprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
137759|NCT03112720|Drug|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
137760|NCT03112707|Drug|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
137761|NCT03112707|Drug|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
137762|NCT03112694|Other|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
137763|NCT03112681|Drug|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
137764|NCT03112681|Drug|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
137765|NCT03112681|Drug|Placebo Oral Tablet|Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
137766|NCT03112668|Behavioral|Cognitive Behavior Therapy|Undergo ACT
137767|NCT03112668|Other|Quality-of-Life Assessment|Ancillary studies
137768|NCT03112668|Other|Questionnaire Administration|Ancillary studies
137769|NCT03112668|Other|Survey Administration|Ancillary studies
137770|NCT03112655|Diagnostic Test|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin will be quantified in cerebrospinal fluid taken at the same time points.
137771|NCT03112642|Procedure|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered.
137772|NCT03112642|Device|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
137773|NCT03112616|Other|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
137774|NCT03112603|Drug|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
137775|NCT03112603|Drug|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
137776|NCT03112603|Drug|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
137777|NCT03112603|Drug|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
138104|NCT03110198|Drug|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
137778|NCT03112603|Drug|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
137779|NCT03112603|Drug|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
137780|NCT03112603|Drug|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
137781|NCT03112603|Drug|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
137782|NCT03112603|Drug|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
137783|NCT03112603|Drug|Ibrutinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
137784|NCT03112590|Biological|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
137785|NCT03112590|Drug|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m^2/week, for 12 weeks.
137786|NCT03112590|Drug|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
137787|NCT03112590|Other|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
137788|NCT03112590|Procedure|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
137789|NCT03112577|Drug|REGN3500|Intravenous (IV) use
137790|NCT03112577|Drug|Dupilumab|Subcutaneous (SC) use
137791|NCT03112577|Drug|Placebo|Matching placebo
137792|NCT03112577|Drug|Fluticasone propionate|Inhalation use
137793|NCT03112564|Other|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
137794|NCT03112564|Drug|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
137795|NCT03112551|Drug|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
137796|NCT03112538|Device|Insulin Pump|Medtronic Minimed Paradigm Veo Insulin Pump
137797|NCT03112538|Drug|Multiple daily injections of insulin|Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
137798|NCT03112525|Diagnostic Test|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
137799|NCT03112525|Genetic|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
137800|NCT03112512|Device|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
137801|NCT03112512|Device|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
137802|NCT03112499|Procedure|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
137803|NCT03112499|Procedure|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is accessed with the use of ultrasound, under fluoroscopic guidance. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
137864|NCT03112044|Drug|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
137804|NCT03112499|Procedure|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
137805|NCT03112486|Procedure|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
137806|NCT03112473|Behavioral|Task-orientated training|Bi/Uni/Placebo TENS and Task-orientated training on upper limb
137807|NCT03112473|Device|Transcutaneous electrical nerve stimulation (TENS)|
137808|NCT03112473|Device|Sham electrical nerve stimulation|
137809|NCT03112460|Device|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
137810|NCT03112447|Procedure|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
137811|NCT03112447|Procedure|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
137812|NCT03112434|Drug|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
137813|NCT03112408|Behavioral|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
137814|NCT03112408|Behavioral|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
137815|NCT03112408|Behavioral|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
137816|NCT03112408|Behavioral|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
137817|NCT03112395|Device|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
137818|NCT03112382|Drug|zinc supplement plus vitamin A and E|
137819|NCT03112382|Drug|vitamin A and E|
137820|NCT03112369|Behavioral|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
137821|NCT03112369|Behavioral|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
137822|NCT03112356|Drug|99mTc-Leukoscan® scintigraphy|Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
137823|NCT03112343|Device|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
137824|NCT03112343|Device|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
137825|NCT03112330|Device|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
137826|NCT03112330|Device|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
137827|NCT03112317|Other|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
137828|NCT03112304|Behavioral|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
137829|NCT03112304|Other|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
137830|NCT03112291|Procedure|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
137831|NCT03112278|Procedure|Ceramic ultrathin occlusal veneers|Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
137832|NCT03112278|Procedure|Composite resin ultrathin occlusal veneers|Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
137865|NCT03112044|Device|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
137833|NCT03112265|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
137834|NCT03112265|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
137835|NCT03112265|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
137836|NCT03112252|Other|no specifications. Depending on the patients|patients with allergic rhinitis
137837|NCT03112239|Device|Light-Emitting Diode Therapy (LEDT)|Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
137838|NCT03112226|Other|GnRHant + E2|GnRH antagonist with estradiol add-back
137839|NCT03112226|Other|GnRHant + Placebo|GnRH antagonist with placebo add-back
137840|NCT03112213|Drug|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
137841|NCT03112213|Drug|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
137842|NCT03112200|Procedure|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
137843|NCT03112200|Procedure|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
137844|NCT03112187|Drug|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
137845|NCT03112174|Drug|Ibrutinib|Administered orally once daily
137846|NCT03112174|Drug|Venetoclax|Administered orally once daily
137847|NCT03112174|Drug|Placebo Oral tablet to match Venetoclax|Administered orally once daily
137848|NCT03112161|Other|Eucaloric Feeding Period|
137849|NCT03112161|Other|Overfeeding Feeding Period|
137850|NCT03112161|Other|Underfeeding Feeding Period|
137851|NCT03112148|Drug|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).~For the the food effect assessment, the investigational product(s) are:~Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
137852|NCT03112135|Drug|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
137853|NCT03112135|Drug|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
137854|NCT03112135|Drug|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
137855|NCT03112122|Biological|autologous bone marrow concentrate|injection of autologous bone marrow concentrate
137856|NCT03112122|Biological|bone substitute i-FactorTM|subchondral injections of i-FactorTM
137857|NCT03112122|Procedure|core decompression|subchondral anterograde drilling
137858|NCT03112109|Other|'New care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
137859|NCT03112096|Drug|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
137860|NCT03112083|Dietary Supplement|Nutritional counseling A|Krill powder capsules
137861|NCT03112083|Dietary Supplement|Nutritional counselling B|Placebo capsules
137862|NCT03112070|Other|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
137863|NCT03112057|Diagnostic Test|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
138105|NCT03110198|Drug|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
137866|NCT03112031|Drug|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
137867|NCT03112031|Drug|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
137868|NCT03112031|Drug|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
137869|NCT03112018|Behavioral|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
137870|NCT03112018|Behavioral|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
137871|NCT03112018|Behavioral|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
137872|NCT03112018|Behavioral|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
137873|NCT03112018|Behavioral|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
137874|NCT03112005|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
137875|NCT03112005|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
137876|NCT03111992|Drug|PDR001|Anti-PD1 antibody
137877|NCT03111992|Drug|CJM112|Anti-IL-17A antibody
137878|NCT03111992|Drug|LCL161|Oral small molecule SMAC-mimetic
137879|NCT03111979|Dietary Supplement|beta-alanine|
137880|NCT03111979|Dietary Supplement|Placebo|
137881|NCT03111966|Other|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
137882|NCT03111953|Procedure|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately ~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
137883|NCT03111953|Procedure|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, ~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, ~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
137884|NCT03111940|Procedure|Optimisation of the result of intracoronary stenting according to specific algorithm|
137885|NCT03111927|Other|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula can begin as soon as the child is enrolled in the study (from 2 weeks up to 5 weeks of life) and will last up 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day will depend upon age, weight, and appetite. The product should be given daily ad libitum to the child from enrollment up to 12 months."
137886|NCT03111927|Other|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula can begin as soon as the child is enrolled in the study (from 2 weeks up to 5 weeks of life) and will last up 12 months of age (+/- 2 weeks).~The volume of feed required by the child per day will depend upon age, weight, and appetite. The product should be given daily ad libitum to the child from enrollment up to 12 months."
137887|NCT03111914|Diagnostic Test|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.~The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
137888|NCT03111901|Drug|Pembrolizumab|Pembrolizumab solution
137889|NCT03111901|Drug|Interleukin-2|Interleukin-2 solution
137890|NCT03111888|Device|Silicone Stent Airway Implant|The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient‐specific stent can be manufactured using rapid prototyping technology. The patient‐specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
137891|NCT03111875|Device|aggressive warming|Patients will be pre-warming 30 minutes before induction of anesthesia and aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C.
137892|NCT03111875|Device|routine thermal management|A forced-air cover will be positioned but will not initially be activated. The warmer will be activated when core temperature decrease to 35.5°C.
137893|NCT03111862|Diagnostic Test|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
137894|NCT03111849|Other|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
137895|NCT03111836|Behavioral|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
137896|NCT03111836|Behavioral|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
138030|NCT03110757|Biological|Hepatitis B Virus Vaccine (Recombinant)|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
137897|NCT03111836|Behavioral|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
137898|NCT03111823|Behavioral|Exercise Intervention|Undergo aerobic exercise sessions
137899|NCT03111823|Other|Quality-of-Life Assessment|Ancillary studies
137900|NCT03111823|Other|Questionnaire Administration|Ancillary studies
137901|NCT03111810|Drug|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
137902|NCT03111810|Drug|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
137903|NCT03111797|Drug|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
137904|NCT03111797|Other|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
137905|NCT03111784|Other|Fish consumption and lipid profiles|
137906|NCT03111771|Procedure|carcinological surgery|carcinological surgery for Group K +
137907|NCT03111771|Procedure|cervical surgery|cervical surgery for Group K-
137908|NCT03111758|Device|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
137909|NCT03111732|Biological|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
137910|NCT03111732|Drug|Oxaliplatin|130mg/m(2) IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
137911|NCT03111732|Drug|Capecitabine|750 mg/m(2) will be administered orally twice a day on Days 1-14 of cycles 1-6
137912|NCT03111706|Procedure|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
137913|NCT03111693|Other|Unenhanced Coro-CT|All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
137914|NCT03111680|Other|environmental intervention|a multi component environmental intervention
137915|NCT03111667|Behavioral|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
137916|NCT03111667|Other|Treatment as Usual|Referral to community resources
137917|NCT03111667|Behavioral|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
137918|NCT03111667|Behavioral|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
137919|NCT03111654|Diagnostic Test|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.~Analysis of selected therapeutic options for the prevention of AF ischemic events."
137920|NCT03111641|Diagnostic Test|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
137921|NCT03111628|Drug|Omalizumab|omalizumab 300 mg every 4 weeks by subcutaneous injection
137922|NCT03111615|Drug|Aromatase Inhibitors|"Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.~Venlafaxin 75 mg is to be administrated cases indicated"
137923|NCT03111602|Other|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
137924|NCT03111589|Biological|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
137925|NCT03111589|Diagnostic Test|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
137926|NCT03111563|Other|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
137927|NCT03111537|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
137928|NCT03111537|Other|E-Cigarette|Use of E-cigarette: multiple flavors offered.
137929|NCT03111537|Other|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
137930|NCT03111524|Other|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
137931|NCT03111524|Other|No intervention|No intervention is administered in this group as these are control groups
137932|NCT03111511|Drug|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
137933|NCT03111511|Drug|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
137934|NCT03111511|Drug|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
137935|NCT03111498|Other|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
137936|NCT03111498|Other|theory-based training programme|theory-based training programme for conducting VAD
137937|NCT03111485|Drug|Sinemet CR|Capsule 250 mg / 50 mg taken at bedtime
137938|NCT03111485|Drug|Placebo oral capsule|Capsule taken at bedtime
137939|NCT03111472|Other|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
137940|NCT03111459|Device|Medtronic Valiant Thoracoabdominal Stent Graft System|The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
137941|NCT03111446|Procedure|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
137942|NCT03111446|Procedure|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
137943|NCT03111433|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
137944|NCT03111433|Drug|Insulin|multiple dose insulin injection therapy
137945|NCT03111420|Drug|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
137946|NCT03111420|Device|Platelet function test|Blood is drawn for testing of platelet aggregation activity
137947|NCT03111407|Procedure|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
137948|NCT03111381|Drug|Toradol|IV toradol
137949|NCT03111368|Procedure|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
137950|NCT03111355|Dietary Supplement|Brazil nut|one nut a day for 2 months, no intervention for 2 months
137951|NCT03111342|Drug|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
137952|NCT03111342|Procedure|Dry-needling|A placement of thin needle into the cervix without substance injection
137953|NCT03111329|Other|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
137954|NCT03111316|Drug|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
137955|NCT03111316|Device|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
137956|NCT03111303|Device|mechanical ventilation|Connection to mechanical ventilator
137957|NCT03111290|Device|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
137958|NCT03111290|Device|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
137959|NCT03111277|Device|Experimental: ExAblate Transcranial treatment|Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
137960|NCT03111264|Behavioral|CHAMP|"The CHAMP only group intervention is based on Food Friends & Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
137961|NCT03111264|Behavioral|CHAMP+|The CHAMP+ component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The CHAMP+ intervention will span over the course of the CHAMP intervention.
137962|NCT03111251|Behavioral|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
137963|NCT03111251|Behavioral|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
138031|NCT03110757|Biological|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
138032|NCT03110744|Drug|Palbociclib|application on 21 consecutive days of a 28 days cycle
138033|NCT03110731|Behavioral|Physical training|Physical training (2x / week) was performed for 12 weeks
137964|NCT03111251|Behavioral|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
137965|NCT03111251|Behavioral|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
137966|NCT03111251|Behavioral|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
137967|NCT03111238|Drug|REX-001|REX-001 is administered through an intra-arterial catheter.
137968|NCT03111238|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
137969|NCT03111225|Diagnostic Test|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
137970|NCT03111212|Drug|Iloprost|Iloprost nebulized
137971|NCT03111212|Drug|control|sodium chloride 0,9% nebulized
137972|NCT03111199|Other|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
137973|NCT03111199|Other|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
137974|NCT03111199|Other|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
137975|NCT03111199|Other|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
137976|NCT03111186|Drug|Oxycodone Hcl 5Mg|oxycodone HCl 5 mg up to six times daily as needed for pain
137977|NCT03111186|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg up to six times daily as needed for pain
137978|NCT03111186|Drug|Acetaminophen 650 mg|Acetaminophen 650 mg up to four times daily as needed for pain
137979|NCT03111173|Device|Holter Device|MyECG E3.80 Holter Recorder
137980|NCT03111160|Procedure|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
137981|NCT03111160|Procedure|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
137982|NCT03111147|Device|0 degrees humeral component version|RTSA with humeral component positioned in 0 degrees of version
137983|NCT03111147|Device|30 degrees humeral component retroversion|RTSA with humeral component positioned in 30 degrees of retroversion
137984|NCT03111134|Procedure|modified component separation technique|a new abdomen closure technique based on component separation technique
137985|NCT03111121|Drug|Sugammadex|receive reversal with sugammadex 4mg/kg
137986|NCT03111121|Drug|neostigmine|receive reversal with neostigmine 0.04 mg/kg
137987|NCT03111121|Drug|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
137988|NCT03111108|Drug|EBR/GZR (50 mg/100 mg) FDC|One FDC tablet taken once daily by mouth for 8 or 12 weeks depending upon randomization.
137989|NCT03111095|Other|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
137990|NCT03111069|Procedure|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).~Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
138074|NCT03110432|Drug|Standard lipid lowering therapy|drug use according to the respective product labelling
137991|NCT03111069|Drug|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation."
137992|NCT03111069|Radiation|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
137993|NCT03111056|Behavioral|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
137994|NCT03111043|Diagnostic Test|Head to pelvis CT scan|Introduction of early head to pelvis CT scan within 6 hours of out of hospital arrest as an adjunct to standard of care (no randomization)
137995|NCT03111030|Behavioral|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:~An assessment of motivated the participant is to be physically active~A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.~B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.~Progress and barriers will be reassessed and discussed."
137996|NCT03111017|Other|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
137997|NCT03111004|Other|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
137998|NCT03110991|Behavioral|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
137999|NCT03110991|Behavioral|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
138000|NCT03110978|Biological|Nivolumab|Given IV
138001|NCT03110978|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
138002|NCT03110965|Behavioral|Yoga poses|Patients are asked to perform one or two yoga poses daily for 4-10 months
138003|NCT03110952|Biological|TDENV-PIV|Single-dose vial with pre-filled syringe, subcutaneous injection
138004|NCT03110952|Biological|TDENV-F17|Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
138005|NCT03110952|Other|Placebo|0.5 mL vial
138006|NCT03110939|Other|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
138007|NCT03110926|Drug|mFOLFOX6|Induction Chemotherapy
138008|NCT03110926|Combination Product|Chemoradiation|Chemoradiation
138009|NCT03110913|Other|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
138010|NCT03110900|Drug|Haloperidol + lorazepam|Haloperidol + lorazepam + placebo
138011|NCT03110900|Drug|Loxapine|loxapine + placebo
138012|NCT03110874|Drug|one-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
138013|NCT03110874|Drug|two-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
138014|NCT03110861|Device|Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement|Pulsta® Transcatheter Pulmonary Valve Replacement
138015|NCT03110848|Drug|Atorvastatin|Atorvastatin 20 mg daily
138016|NCT03110848|Drug|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
138017|NCT03110835|Radiation|Radioiodine|Administration of radioiodine
138018|NCT03110822|Drug|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered on days 1-28 of the treatment cycle.
138019|NCT03110822|Drug|Lenalidomide|Lenalidomide will be administered on Days 1-21 of the treatment cycle.
138020|NCT03110822|Drug|Methylprednisolone|Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
138021|NCT03110809|Dietary Supplement|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
138022|NCT03110809|Dietary Supplement|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
138023|NCT03110796|Device|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
138024|NCT03110796|Device|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
138025|NCT03110796|Device|Dressing without LU3103209|Dressing without LU3103209
138026|NCT03110783|Biological|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
138027|NCT03110770|Biological|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
138028|NCT03110770|Other|VRC-PBSPLA043-00-VP|A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
138029|NCT03110757|Biological|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
138034|NCT03110718|Device|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
138035|NCT03110705|Behavioral|sport|recreaational sport : diving or multisport
138036|NCT03110692|Behavioral|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
138037|NCT03110679|Biological|injection of autologous bone marrow concentrate|
138038|NCT03110679|Biological|injection of hyaluronic acid.|
138039|NCT03110666|Biological|Injection of autologous concentrated bone marrow aspirate|Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
138040|NCT03110653|Drug|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
138041|NCT03110653|Drug|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
138042|NCT03110640|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
138043|NCT03110640|Drug|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
138044|NCT03110640|Drug|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
138045|NCT03110627|Device|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
138046|NCT03110627|Device|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).~The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
138047|NCT03110601|Device|Control - Conventional SCS|Conventional SCS Parameters
138048|NCT03110601|Device|Test - Stimgenics SCS|Stimgenics SCS Parameters
138049|NCT03110588|Drug|PACE with Cabazitaxel (15 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
138050|NCT03110588|Drug|PACE with Cabazitaxel (20 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
138051|NCT03110575|Drug|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
138052|NCT03110562|Drug|Selinexor|oral 100 mg dose
138053|NCT03110562|Drug|Bortezomib|subcutaneous dose of 1.3 mg/m2
138054|NCT03110562|Drug|Dexamethasone|oral dose of 20mg
138055|NCT03110549|Drug|TMB-607|
138056|NCT03110549|Drug|Placebo|
138057|NCT03110536|Diagnostic Test|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.~The questionnaire also contains clinical cases that require triage coding."
138058|NCT03110536|Other|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
138059|NCT03110523|Drug|X0002|Before the first screening visit, there is a pre-Screening Telephone Call or email interview, the Screening Period of at least 14 days up to 3 weeks will consist of two visits for the assessment of eligibility including radiographic evaluation of the target knee joint space, all screening visits and double-blind treatment visit (week 2, 5, 10, 15, and 20 visits) are show in Study Flow Chart of Double-blind Period, and the open label period will be started from the Week 20 visit. All subjects treated with active drug or placebo complete the 20-week double-blind study will enter the Open-label study and will be treated with active drug, X0002 for 32 weeks.
138060|NCT03110523|Drug|Placebo|Before the first screening visit, there is a pre-Screening Telephone Call or email interview, the Screening Period of at least 14 days up to 3 weeks will consist of two visits for the assessment of eligibility including radiographic evaluation of the target knee joint space, all screening visits and double-blind treatment visit (week 2, 5, 10, 15, and 20 visits) are show in Study Flow Chart of Double-blind Period.
138061|NCT03110510|Drug|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
138062|NCT03110510|Drug|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
138063|NCT03110510|Drug|leucovorin calcium|Leucovorin 200 mg/m2
138064|NCT03110497|Radiation|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
138065|NCT03110484|Drug|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
138066|NCT03110484|Drug|Erlotinib|Erlotinib 100mg once daily
138067|NCT03110471|Behavioral|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
138068|NCT03110471|Behavioral|usual care|usual care
138069|NCT03110458|Drug|SENS-111 100mg|2 ODT (1 ODT SENS-111 and 1 ODT placebo)
138070|NCT03110458|Drug|SENS-111 200mg|2 ODT (2 ODT SENS-111)
138071|NCT03110458|Drug|Placebo Oral Tablet|2 ODT (2 ODT placebo)
138072|NCT03110445|Biological|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
138073|NCT03110432|Drug|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
138075|NCT03110419|Other|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
138076|NCT03110406|Other|whole-body vibration training|Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
138077|NCT03110393|Device|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
138078|NCT03110393|Device|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
138079|NCT03110380|Drug|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
138080|NCT03110380|Drug|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
138081|NCT03110380|Drug|DTG|50 mg tablet(s) administered orally once daily
138082|NCT03110380|Drug|DTG Placebo|Tablet(s) administered orally once daily
138083|NCT03110380|Drug|F/TAF Placebo|Tablet(s) administered orally once daily
138084|NCT03110380|Drug|B/F/TAF Placebo|Tablet(s) administered orally once daily
138085|NCT03110367|Behavioral|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
138086|NCT03110367|Behavioral|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
138087|NCT03110354|Drug|DS-3201b|DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
138088|NCT03110341|Drug|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
138089|NCT03110341|Drug|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
138090|NCT03110328|Drug|MK3475|anti-PD1 immunotherapy
138091|NCT03110315|Drug|Suvorexant|See detailed information in associated Arm Description.
138092|NCT03110315|Drug|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
138093|NCT03110302|Behavioral|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
138094|NCT03110289|Other|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
138095|NCT03110289|Other|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
138096|NCT03110276|Drug|EYP001a|10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
138097|NCT03110276|Drug|Placebo|Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
138098|NCT03110263|Other|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
138099|NCT03110263|Other|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
138100|NCT03110237|Other|Control Balance Training (BT) class|Circuit training class with 11 stations, including: step-ups, ball kicking, balance beam, sit to stand, walk and carry, tandem walking, walking over a mat, walking up a ramp, walking at different speeds, speed walk, dual task walking.
138101|NCT03110237|Other|Fallproof Balance Training (BT) class|There are four categories of exercises in this approach including: center of gravity control training (e.g. multi-directional weight shifts in standing, standing with altered base of support), multisensory training (e.g. standing on compliant surfaces, eyes open/closed), postural strategy training (e.g. resisted perturbation to facilitate ankle, hip or step strategy), and gait pattern variation training (e.g. walking with altered base of support , walking over and around obstacles). Each training category will be allocated 5 minutes with two exercises in each category. An additional 5 minutes will be allotted for games to challenge balance (balloon volleyball, pass the potato, circle soccer).There will be opportunity for group discussion and observational learning.
138102|NCT03110211|Procedure|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
138103|NCT03110211|Procedure|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
138106|NCT03110198|Drug|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
138107|NCT03110185|Device|EEG, fcDOT, fcMRI|Brain activity will be recorded using EEG, functional connectivity DOT and MRI will be used to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
138108|NCT03110172|Drug|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
138109|NCT03110159|Drug|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
138110|NCT03110159|Drug|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
138111|NCT03110146|Device|EnSite Precision|Ablation procedure
138112|NCT03110133|Drug|Full Spectrum Microbiota|Orally administered donor derived microbiota
138113|NCT03110133|Drug|Placebo|Placebo for CP101
138114|NCT03110120|Drug|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
138115|NCT03110120|Drug|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
138116|NCT03110120|Drug|0.5% levobupivacaine injectable solution with physiological saline|Serratus plane block realized with 20 ml of injectable solution of physiological saline
138117|NCT03110120|Drug|0.5% levobupivacaine injectable solution with physiological saline|local infiltration of the wound with 20 ml of injectable solution of physiological saline
138118|NCT03110107|Biological|Ipilimumab|Specified dose on specified days
138119|NCT03110107|Biological|BMS-986218|Specified dose on specified days
138120|NCT03110107|Biological|Nivolumab|Specified dose on specified days
138121|NCT03110094|Other|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes and use of surplus articular fluid (M0 and M3).
138122|NCT03110094|Other|Healthy volunteers|Collection of 2 tubes of blood. The values of the quantitative study of lymphocyte subpopulations will be compared to those obtained from healthy blood donors to define the standards used in this study.
138123|NCT03110081|Procedure|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
138124|NCT03110081|Procedure|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
138125|NCT03110068|Diagnostic Test|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
138126|NCT03110068|Diagnostic Test|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
138127|NCT03110055|Drug|Grazoprevir/Elbasvir|anti-viral treatment for HCV
138128|NCT03110055|Other|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
138129|NCT03110055|Procedure|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
138130|NCT03110029|Drug|Efinaconazole 10% Topical Application Solution [JUBLIA]|Topical efinaconazole 10% solution (Jublia)
138131|NCT03110029|Other|Application of Nail Polish|Application of Nail Polish
138132|NCT03110016|Device|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
138133|NCT03110003|Drug|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
138134|NCT03110003|Drug|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
138135|NCT03109990|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
138136|NCT03109990|Drug|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
138137|NCT03109977|Drug|Zr-DFO-pertuzumab PET/CT|Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
138138|NCT03109964|Device|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
138139|NCT03109964|Device|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
138140|NCT03109951|Drug|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
138141|NCT03109925|Device|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
143506|NCT03069248|Drug|Alpha Interferon|
138142|NCT03109912|Behavioral|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
138143|NCT03109912|Behavioral|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
138144|NCT03109912|Behavioral|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
138145|NCT03109912|Behavioral|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
138146|NCT03109899|Behavioral|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
138147|NCT03109886|Drug|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
138148|NCT03109873|Radiation|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
138149|NCT03109873|Drug|Metformin Hydrochloride|Given orally
138150|NCT03109873|Other|Placebo|Given orally
138151|NCT03109860|Behavioral|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
138152|NCT03109847|Drug|Metformin Hydrochloride|Given Orally
138153|NCT03109847|Other|Radioactive Iodine|Undergo radioactive iodine treatment
138154|NCT03109847|Other|Placebo|Given orally
138155|NCT03109834|Dietary Supplement|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).~During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
138156|NCT03109834|Other|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.~During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.~Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
138157|NCT03109834|Dietary Supplement|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)~Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).~Duration: 6 months (6.month / baseline II - 12.month)"
138158|NCT03109834|Other|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.~Placebo contains no micronutrients and omega-3 fatty acids.~Duration: 6 months (6.month / baseline II - 12.month)"
138159|NCT03109821|Other|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).~Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
138160|NCT03109808|Other|e-health strategy|"First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.~Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
138161|NCT03109808|Other|Traditional Oral Hygiene Education|traditional oral hygiene education
138162|NCT03109795|Drug|Clonidine Pill|sympathetic nerve activity blockade
138163|NCT03109795|Drug|Hydrochlorothiazide|Blood pressure-lowering control condition
138164|NCT03109769|Behavioral|Mobile phone application|
138165|NCT03109769|Behavioral|Verbal oral hygiene instructions|
138166|NCT03109756|Drug|OV101|Single-dose 5 mg OV101
138167|NCT03109743|Behavioral|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
138168|NCT03109743|Behavioral|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
138169|NCT03109730|Drug|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
138170|NCT03109730|Drug|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
138171|NCT03109730|Drug|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
138172|NCT03109730|Drug|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
138173|NCT03109730|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
138174|NCT03109717|Drug|Monoamine Oxidase Inhibitor (MAOI)|Monoamine Oxidase Inhibitor
138175|NCT03109704|Procedure|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
138176|NCT03109704|Procedure|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
138177|NCT03109704|Procedure|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
138178|NCT03109691|Drug|bupivacaine|group 1
138179|NCT03109691|Drug|Dexamethasone|group 2
138180|NCT03109691|Device|ultrasound|in all groups
138181|NCT03109678|Device|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
138182|NCT03109678|Device|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
138183|NCT03109678|Device|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
138184|NCT03109678|Device|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
138185|NCT03109665|Diagnostic Test|SD-OCT Angiography|SD-OCT Angiography
138186|NCT03109665|Diagnostic Test|SD-OCT|SD-OCT
138187|NCT03109652|Drug|Tranexamic Acid|"On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)"
138188|NCT03109639|Device|Conventional EUS FNA needle|Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
138189|NCT03109639|Device|Acquire FNB device|Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
138190|NCT03109626|Dietary Supplement|DHA|
138191|NCT03109613|Device|Positive end-expiratory pressure (PEEP)|level changes as per arm description
138192|NCT03109600|Biological|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
138193|NCT03109600|Biological|Vi polysaccharide vaccine|Vi polysaccharide vaccine
138194|NCT03109600|Biological|Influenzae vaccine|1 dose of Influenzae vaccine
138195|NCT03109600|Biological|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
138196|NCT03109587|Dietary Supplement|Vivomixx|900 billion of the following probiotic strains: L. acidophilus DSM24735; L. plantarum DSM24730; L. paracasei DSM24733; L. delbrueckii supsp. bulgaricus DSM24734, S. thermophilus DSM24731, B. longum DSM24736, B. breve DSM24732, and B. infantis DSM24737) maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
138222|NCT03109392|Drug|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
138197|NCT03109587|Dietary Supplement|Placebo|maltose (polysaccharide used as food additive, produced from starch), and silicon dioxide (food additive)
138198|NCT03109574|Device|BioFlo DuraMax Chronic Hemodialysis Catheter|
138199|NCT03109574|Device|Standard of Care Catheter|
138200|NCT03109561|Other|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
138201|NCT03109561|Genetic|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
138202|NCT03109561|Diagnostic Test|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
138203|NCT03109561|Other|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
138204|NCT03109548|Other|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
138205|NCT03109535|Behavioral|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
138206|NCT03109535|Behavioral|Fitbit only|Users receive a Fitbit Zip to wear daily.
138207|NCT03109522|Procedure|axillary reverse mapping (ARM)|"ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease."
138208|NCT03109522|Procedure|Standard axillary surgery (SLNB or ALND)|The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
138209|NCT03109509|Behavioral|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
138210|NCT03109509|Behavioral|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
138211|NCT03109496|Other|Collection of body fluids/swabs|Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
138212|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
138213|NCT03109457|Other|oral squamous cell carcinoma|Histological diagnosis of H&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
138214|NCT03109444|Diagnostic Test|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be >50%.
138215|NCT03109431|Behavioral|Level 1|"Youth will receive 1-5 text messages per day for 24 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.~Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
138216|NCT03109431|Behavioral|Level 2|"Youth will be enrolled in online, private discussion groups.~Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.~Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
138217|NCT03109431|Behavioral|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
138218|NCT03109418|Drug|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
138219|NCT03109418|Procedure|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
138220|NCT03109405|Device|Stimulation-assisted venous access|Stimulation-assisted venous access
138221|NCT03109405|Other|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
143720|NCT03067662|Other|Aerobic exercise|
138223|NCT03109392|Drug|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
138224|NCT03109392|Drug|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
138225|NCT03109379|Drug|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
138226|NCT03109366|Behavioral|Online patient-provider communication service|
138227|NCT03109353|Drug|ECP with 5-aminolevulinic acid|extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
138228|NCT03109340|Other|Supervised treadmill group (Group I)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
138229|NCT03109340|Device|ECE PEDO pedometer (Group II)|Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
138230|NCT03109327|Diagnostic Test|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
138231|NCT03109314|Drug|Donepezil|Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.
138232|NCT03109314|Behavioral|Single-letter training|Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).
138233|NCT03109314|Behavioral|Uncrowd training|Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
138234|NCT03109301|Drug|Selumetinib (AZD6244 hyd sulfate) 50mg/dose|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
138235|NCT03109301|Drug|Selumetinib (AZD6244 hyd sulfate) 25mg/m2|Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children < 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
138236|NCT03109288|Drug|Pioglitazone|15-45 mg po qd
138237|NCT03109288|Drug|Montelukast|10mg qd
138238|NCT03109288|Drug|Losartan|50-100mg/day (can be divided bid)
138239|NCT03109288|Drug|Hydroxychloroquine|200-400 mg qd/bid
138240|NCT03109275|Other|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
138241|NCT03109262|Diagnostic Test|Computed Tomography|Undergo PET/CT
138242|NCT03109262|Diagnostic Test|Positron Emission Tomography|Undergo PET/CT
138243|NCT03109262|Device|Yttrium Y 90 Glass Microspheres|Standard of care
138244|NCT03109249|Drug|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
138245|NCT03109249|Drug|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
138246|NCT03109236|Drug|Neupogen|5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
138247|NCT03109236|Procedure|CD133 Cells Transplantation|Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10^6 and up to 50-100 x 10^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
138248|NCT03109223|Other|sole source nutrition|Infant formula
138249|NCT03109210|Behavioral|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
138250|NCT03109210|Behavioral|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
138251|NCT03109197|Other|Biospecimin Collection|
138252|NCT03109184|Behavioral|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
138253|NCT03109171|Other|Laryngopharyngeal sensory test|The sensory measurements will include thresholds for laryngeal adductor reflex, cough reflex, gag reflex, and psychophysical sensory thresholds at the velopharynx and hypopharynx.
138254|NCT03109158|Drug|NC-6004|NC-6004 provided by NanoCarrier
138255|NCT03109158|Drug|Cetuximab|Commercially Available
138256|NCT03109158|Drug|5-FU|Commercially Available
138257|NCT03109145|Other|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
138258|NCT03109132|Device|Oridion Smart CapnoLine® H Plus with Wedge cannula|The subjects will assess the comfort level of the different cannulas
138259|NCT03109132|Device|Oridion Smart CapnoLine® Plus with Non-Wedge cannula|The subjects will assess the comfort level of the different cannulas
164407|NCT02915744|Drug|NKTR-102|
138260|NCT03109132|Device|Experimental sample line Model 3|The subjects will assess the comfort level of the different cannulas
138261|NCT03109132|Device|Experimental sample line Model 4|The subjects will assess the comfort level of the different cannulas
138262|NCT03109132|Device|Experimental sample line Model 5|The subjects will assess the comfort level of the different cannulas
138263|NCT03109132|Device|O2/CO2 cannula w/female luer (Westmed comfort plus #0504)|The subjects will assess the comfort level of the different cannulas
138264|NCT03109119|Drug|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
138265|NCT03109119|Drug|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
138266|NCT03109106|Device|PCT Arm|PCT-guided antibiotic therapy per study protocol
138267|NCT03109093|Drug|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.~In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.~Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
138268|NCT03109080|Drug|Olaparib|five levels of dose, per os administration, twice daily each day
138269|NCT03109080|Radiation|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
138270|NCT03109067|Other|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
138271|NCT03109054|Diagnostic Test|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
138272|NCT03109041|Device|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
138273|NCT03109028|Behavioral|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.~Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.~Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
138274|NCT03109028|Behavioral|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.~Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.~Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
138275|NCT03109028|Behavioral|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.~Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
138276|NCT03109028|Behavioral|Empowerment-Groupintervention|"Target group: Gender-sensitive group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for three months with continued supervision during the intervention.~Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.~Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
138277|NCT03109028|Behavioral|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.~Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
138278|NCT03109028|Other|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
138279|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
138280|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
138281|NCT03108989|Drug|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
138282|NCT03108989|Drug|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
138327|NCT03108612|Diagnostic Test|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
138283|NCT03108976|Other|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
138284|NCT03108976|Other|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
138285|NCT03108976|Other|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
138286|NCT03108963|Drug|L-carnitine and Metformin|L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
138287|NCT03108963|Drug|placebo|placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
138288|NCT03108950|Behavioral|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
138289|NCT03108937|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
138290|NCT03108937|Drug|saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
138291|NCT03108924|Drug|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
138292|NCT03108911|Other|Best Practice|Receive standard diet
138293|NCT03108911|Procedure|Biospecimen Collection|Provide stool sample
138294|NCT03108911|Other|Dietary Intervention|Receive GFD
138295|NCT03108911|Other|Laboratory Biomarker Analysis|Correlative studies
138296|NCT03108885|Other|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
138297|NCT03108872|Device|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
138298|NCT03108872|Drug|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
138299|NCT03108846|Drug|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
138300|NCT03108846|Drug|Placebo|Masked placebo
138301|NCT03108833|Drug|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
138302|NCT03108833|Drug|Alteplase|The drug is used for intravenous thrombolysis therapy
138303|NCT03108820|Behavioral|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
138304|NCT03108820|Other|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
138305|NCT03108807|Diagnostic Test|D-dimer test|D-dimer test
138306|NCT03108781|Drug|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
138307|NCT03108781|Drug|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
138308|NCT03108768|Device|Hearing Aid (Successor of Phonak Virto V)|The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
138309|NCT03108768|Device|Hearing Aid (Phonak Virto V)|Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
138310|NCT03108755|Drug|ASP7713|oral
138311|NCT03108755|Drug|Placebo|oral
138312|NCT03108742|Device|INSORB|dermal stapler for skin closure
138313|NCT03108742|Procedure|classic intradermal suture|intradermal suture for skin closure
138314|NCT03108729|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
138315|NCT03108716|Procedure|hamate hook removal|The patients were assigned to treat with hamate hook removal.
138316|NCT03108716|Procedure|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
138317|NCT03108716|Other|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
138318|NCT03108703|Radiation|SBRT|35-40 Gy delivered in 5 fractions
138319|NCT03108690|Drug|Continuous infusion of beta-lactam antibiotics .|Beta-lactam antibiotic will be administered as continous infusion.
138320|NCT03108690|Other|Therapeutic drug monitoring of beta-lactam antibiotics.|Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
138321|NCT03108677|Other|Blood samples|15 ml peripheral blood
138322|NCT03108664|Drug|SYL1001 ophthalmic solution|1 drop in the affected eye
138323|NCT03108664|Drug|Vehicle opthalmic solution|1 drop in the affected eye
138324|NCT03108651|Other|Case|Motivational message will be administrated.
138325|NCT03108638|Behavioral|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
138326|NCT03108625|Drug|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
138328|NCT03108599|Other|Enhanced Cab|The cab engineering intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep intervention.
138329|NCT03108599|Behavioral|Fit4Sleep|The behavioral sleep intervention includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The intervention arm will receive the behavioral sleep intervention in combination with the enhanced cab intervention.
138330|NCT03108586|Procedure|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
138331|NCT03108586|Procedure|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
138332|NCT03108560|Procedure|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
138333|NCT03108560|Procedure|lobectomy|patients receive lobectomy
138334|NCT03108547|Other|Determination of scalp hair steroids|
138335|NCT03108534|Drug|CHF1535 NEXThaler|Rescue treatment
138336|NCT03108534|Drug|CHF1535 pMDI|Rescue treatment
138337|NCT03108534|Drug|Placebo|Rescue treatment
138338|NCT03108521|Drug|Sitagliptin|Januvia
138339|NCT03108521|Drug|Liraglutide|
138340|NCT03108508|Dietary Supplement|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
138341|NCT03108508|Dietary Supplement|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
138342|NCT03108508|Dietary Supplement|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
138343|NCT03108495|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
138344|NCT03108495|Biological|LN-145 + pembrolizumab|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. The first dose of anti-PD-1 immunotherapy will be administered following tumor resection.
138345|NCT03108482|Drug|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
138346|NCT03108482|Drug|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
138347|NCT03108482|Drug|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
138348|NCT03108482|Drug|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
138349|NCT03108469|Drug|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
138350|NCT03108469|Other|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
138351|NCT03108456|Device|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
138352|NCT03108456|Device|Balloon|Vessel preparation with conventional and/or specialty balloons
138353|NCT03108443|Diagnostic Test|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
138354|NCT03108430|Other|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
138355|NCT03108417|Device|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
138356|NCT03108404|Other|Validation of a diagnostic test|Validation of a diagnostic test
138357|NCT03108391|Device|Ambu AuraGain|
138358|NCT03108391|Device|LMA Supreme|
138359|NCT03108378|Procedure|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
138360|NCT03108365|Device|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
138361|NCT03108365|Device|Cotton Gauze|Size: 1 x 1 cm
138362|NCT03108352|Drug|Conbercept ophthalmic injection|
138363|NCT03108352|Other|sham injection|
138364|NCT03108339|Other|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
138365|NCT03108326|Biological|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
138366|NCT03108313|Drug|aloe vera toothpaste|herbal toothpaste used to decrease salivary streptococcus bacterial count
138367|NCT03108313|Drug|fluoride toothpaste|chemical toothpaste used to decrease salivary streptococcus bacterial count
138368|NCT03108300|Drug|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
138369|NCT03108300|Drug|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
138370|NCT03108287|Drug|RAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
138371|NCT03108287|Drug|RBAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
138372|NCT03108274|Drug|Part 1, Period 1|Midazolam single oral dose
138373|NCT03108274|Drug|Part 1, Period 2|Multiple doses ACH-0144471 Single dose Midazolam
138374|NCT03108274|Drug|Part 2, Period 1|Fexofenadine single oral dose
138375|NCT03108274|Drug|Part 2, Period 2|Multiple doses ACH-0144471 Single dose Fexofenadine
138376|NCT03108274|Drug|Part 3, Period 1|Mycophenolate Mofetil single oral dose
138377|NCT03108274|Drug|Part 3, Period 2|Multiple doses ACH-0144471 Single dose Mycophenolate Mofetil
138378|NCT03108248|Drug|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
138379|NCT03108248|Device|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
138380|NCT03108235|Behavioral|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed Heart education toolkit, one education session and six weekly home visits.
138381|NCT03108235|Behavioral|HOM-HEMP with smartphone app|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP), comprising of a specifically developed Heart education toolkit, one education session and six weekly home visits with Smartphone app. Your smartphone will be used to monitor your health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference.
138382|NCT03108235|Behavioral|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
138383|NCT03108222|Other|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
138384|NCT03108209|Other|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
138385|NCT03108209|Other|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
138386|NCT03108196|Procedure|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
138387|NCT03108196|Procedure|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
138388|NCT03108183|Diagnostic Test|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
138389|NCT03108170|Other|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
138390|NCT03108170|Other|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
138391|NCT03108170|Other|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
138392|NCT03108157|Procedure|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
138393|NCT03108144|Behavioral|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
138394|NCT03108131|Drug|Atezolizumab|Given IV
138395|NCT03108131|Drug|Cobimetinib|Given PO
138396|NCT03108105|Device|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
138425|NCT03107845|Behavioral|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI & OQ-30), interpersonal functioning (IIP-32 & OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
138527|NCT03107013|Drug|[14C]-BTD-001|Carbon-14 labeled BTD-001
138528|NCT03107000|Procedure|Trabeculectomy|Incisional surgery for glaucoma
138397|NCT03108092|Other|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
138398|NCT03108092|Other|Control|Standard care in the department where the trial is conducted
138399|NCT03108079|Device|Cystosure Urinary Access System|"Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the fluid flow pattern during bladder drainage for~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the 3D bladder wall anatomy after emptying the bladder with~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)"
138400|NCT03108079|Device|Foley Catheter|"Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the fluid flow pattern during bladder drainage for~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)~Compare the 3D bladder wall anatomy after emptying the bladder with~The traditional Foley catheter (Catheter A)~The novel FDA approved Cystosure catheter (Catheter B)"
138401|NCT03108066|Drug|PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment of VHL disease-associated ccRCC.
138402|NCT03108053|Procedure|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
138403|NCT03108053|Device|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
138404|NCT03108027|Drug|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
138405|NCT03108027|Drug|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
138406|NCT03108027|Drug|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
138407|NCT03107988|Drug|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
138408|NCT03107988|Drug|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
138409|NCT03107988|Drug|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
138410|NCT03107975|Biological|human amniotic epithelial cells|intrathecal injection of human amniotic epithelial cells
138411|NCT03107962|Drug|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
138412|NCT03107949|Device|Lungpacer DPTS (Diaphragm Pacing Therapy System)|Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
138413|NCT03107936|Behavioral|smokeSCREEN game|smokeSCREEN is web-based videogame intervention focused on tobacco use prevention in teens. The game has 1.5-2 hours of unique game play and focuses on combustible cigarettes, e-cigarettes, and flavored tobacco products.smokeSCREEN. Guided by the social cognitive theory and the theory of planned behavior, smokeSCREEN addresses a range of challenges that teens often face involving peer pressure and the use of tobacco products. Participants are provided access to the smokeSCREEN game through a private, password-protected website link and instructed to complete the game.
138414|NCT03107923|Diagnostic Test|Dobutamine stress test|Test of myocardial reserve
138415|NCT03107910|Behavioral|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
138416|NCT03107910|Behavioral|Health Information Seeking|Seeking and evaluating online health information will be assessed.
138417|NCT03107897|Other|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
138418|NCT03107884|Drug|Metformin|A clinical oral dose of Metformin will be given to participant daily during bed rest
138419|NCT03107884|Drug|Placebo|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
138420|NCT03107871|Drug|Valganciclovir|Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
138421|NCT03107871|Drug|Simple Syrup|Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
138422|NCT03107858|Drug|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
138423|NCT03107858|Drug|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
138424|NCT03107845|Behavioral|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
138529|NCT03107000|Procedure|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
138426|NCT03107845|Behavioral|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
138427|NCT03107832|Procedure|thoracic epidural anesthesia procedure|general anesthesia procedure
138428|NCT03107819|Diagnostic Test|Plasma and urine metabolomics|Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
138429|NCT03107806|Device|OptiScanner®|"Glucose monitoring by OptiScanner® for 48 h~Glucose lowering intervention (insulin) guided by OptiScanner®"
138430|NCT03107793|Drug|Ustekinumab|Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
138431|NCT03107780|Other|Laboratory Biomarker Analysis|Correlative studies
138432|NCT03107780|Drug|MDM2 Inhibitor AMG-232|Given PO
138433|NCT03107780|Other|Pharmacological Study|Correlative studies
138434|NCT03107780|Radiation|Radiation Therapy|Undergo radiation therapy
138435|NCT03107767|Procedure|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
138436|NCT03107754|Drug|Lidocaine|Paracervical block will be injected at 4 points at the cervicovaginal junction to decrease pain
138437|NCT03107754|Drug|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 4 points at the cervicovaginal junction to decrease pain
138438|NCT03107741|Other|Generic Fitness|Subjects in this groups will receive three fitness lessons in a week while each session last for 1 hour throughout the 12 weeks experimental period
138439|NCT03107741|Other|Tai Chi|Subjects in this groups will receive three Tai Chi lessons in a week while each session last for 1 hour throughout the 12 weeks experimental period
138440|NCT03107728|Device|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
138441|NCT03107728|Device|Conventional orthotic brace|Participants will use the standard of care orthosis
138442|NCT03107715|Behavioral|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
138443|NCT03107715|Behavioral|Positive Messaging|iPad based behavioral intervention facilitated by researcher
138444|NCT03107702|Diagnostic Test|melatonin|the relationship between melatonin level and analgesia requirement.
138445|NCT03107689|Other|administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
138446|NCT03107676|Other|trunk extensors endurance training|endurance training
138447|NCT03107663|Drug|⁸⁹Zr-Df-IAB22M2C Infusion|A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
138448|NCT03107650|Procedure|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
138449|NCT03107611|Drug|Pimecrolimus Cream, 1%|
138450|NCT03107611|Drug|Placebo Cream|
138451|NCT03107598|Drug|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
138452|NCT03107585|Procedure|bilateral cervical plexus block|with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
138453|NCT03107559|Diagnostic Test|perfüsion index|Determination of the relationship between VAS values and PI in patients with normal delivery who undergo epidural analgesia
138454|NCT03107546|Device|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
138455|NCT03107546|Other|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
138456|NCT03107533|Other|Video recording of clinical visit|For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
138457|NCT03107520|Diagnostic Test|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
138458|NCT03107520|Drug|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
138459|NCT03107507|Drug|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
138460|NCT03107507|Drug|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
138491|NCT03107247|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
138492|NCT03107234|Other|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
164408|NCT02915744|Drug|Eribulin|
138461|NCT03107494|Device|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
138462|NCT03107481|Drug|Acetaminophen|Acetaminophen 1g IV
138463|NCT03107481|Drug|Hydromorphone|Hydromorphone 1mg IV
138464|NCT03107468|Other|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
138465|NCT03107468|Other|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
138466|NCT03107455|Device|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
138467|NCT03107442|Behavioral|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous [40-85% of the individual's heart rate reserve] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
138468|NCT03107429|Drug|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
138469|NCT03107429|Drug|Placebo|Placebo was a sugar based placebo placed in a capsule.
138470|NCT03107429|Other|Trendelenburg Position|Placed in Trendelenburg Position
138471|NCT03107416|Procedure|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
138472|NCT03107416|Drug|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
138473|NCT03107403|Behavioral|web form|The scale assessing the bereavement process is the one reported in Teissier 2010
138474|NCT03107390|Other|Evaluate the blood level of NTproBNP|Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
138475|NCT03107377|Drug|Amphora gel|5 g dose applied up to 1 hour prior to coitus
138476|NCT03107377|Drug|Placebo|5 g dose applied up to 1 hour prior to coitus
138477|NCT03107364|Other|Hospital stay|Collection of hospital lengths of stay and readmissions
138478|NCT03107351|Device|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
138479|NCT03107351|Device|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
138480|NCT03107338|Drug|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
138481|NCT03107338|Other|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
138482|NCT03107325|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
138483|NCT03107325|Drug|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
138484|NCT03107312|Procedure|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
138485|NCT03107299|Other|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
138486|NCT03107286|Drug|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
138487|NCT03107286|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
138488|NCT03107273|Other|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
138489|NCT03107260|Other|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
138490|NCT03107247|Drug|Tc-99M MDP|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MDP
138493|NCT03107221|Behavioral|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
138494|NCT03107208|Drug|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
138495|NCT03107208|Device|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
138496|NCT03107195|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
138497|NCT03107182|Drug|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
138498|NCT03107182|Drug|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
138499|NCT03107182|Drug|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
138500|NCT03107182|Drug|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
138501|NCT03107182|Drug|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
138502|NCT03107182|Drug|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
138503|NCT03107182|Drug|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
138504|NCT03107182|Drug|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
138505|NCT03107182|Drug|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
138506|NCT03107182|Drug|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
138507|NCT03107182|Procedure|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
138508|NCT03107182|Radiation|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
138509|NCT03107182|Radiation|Chemoradiotherapy|"Patients who have low risk disease with <50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).~Patients who have low risk disease and <30% reduction of tumor, patients who have high risk disease and <50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
138510|NCT03107169|Other|FMT|Patients in the FMT group received FMT-FURM
138511|NCT03107169|Drug|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
138512|NCT03107156|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
138513|NCT03107143|Device|Q2 System|
138514|NCT03107117|Behavioral|Computer Counseling|two computer counseling online programs for a teen and a parent
138515|NCT03107117|Behavioral|Standard Care|A referral for substance use counseling
138516|NCT03107104|Device|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
138517|NCT03107104|Device|TRC-50DX retinal camera|The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
138518|NCT03107091|Drug|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
138519|NCT03107078|Drug|Glucocorticoids|Intravenous Glucocorticoids (GCs)
138520|NCT03107065|Device|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
138521|NCT03107052|Drug|Fremanezumab|Fremanezumab
138522|NCT03107039|Behavioral|Exercise|A 12 week resistance exercise curriculum
138523|NCT03107039|Behavioral|Health Education|A 12 week health education curriculum
138524|NCT03107026|Drug|dasotraline 4mg|dasotraline 4mg tablet once daily
138525|NCT03107026|Drug|dasotraline 6mg|dasotraline 6mg tablet once daily
138526|NCT03107026|Drug|Placebo|Placebo tablet once daily
138530|NCT03106987|Drug|Active Comparator: Olaparib tablets|"Olaparib~300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
138531|NCT03106987|Drug|Placebo|"Placebo~300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
138532|NCT03106974|Device|orotracheal intubation Macintosh Laryngoscope|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
138533|NCT03106974|Device|orotracheal intubation Totaltrack VLM|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
138534|NCT03106961|Device|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
138535|NCT03106948|Drug|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
138536|NCT03106948|Drug|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
138537|NCT03106948|Drug|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
138538|NCT03106935|Drug|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1－2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
138539|NCT03106922|Drug|PMF104|"Powder for oral solution:~Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water"
138540|NCT03106922|Drug|Klean-prep|"Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water"
138541|NCT03106909|Radiation|pulmonary computed tomography (CT)|Pulmonary CT imaging
138542|NCT03106883|Behavioral|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
138543|NCT03106883|Behavioral|Sham training|3 sessions of sham attention training using non-affective stimuli
138544|NCT03106870|Drug|Insulin Mixtard|"Insulin dose:~0.7 IU/Kg (at the second trimester of pregnancy).~0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
138545|NCT03106870|Drug|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.~If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
138546|NCT03106857|Other|Group A|Group A Physical activity and low caloric diet for
138547|NCT03106844|Drug|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
138548|NCT03106831|Drug|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
138549|NCT03106831|Drug|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
138550|NCT03106818|Drug|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
138551|NCT03106818|Drug|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
138552|NCT03106818|Drug|conventional|only conventional post operative analgesics will be used
138553|NCT03106805|Procedure|early insertion|insertion at 4th postpartum week
138554|NCT03106805|Procedure|late insertion|insertion at 6th postpartum week
138555|NCT03106792|Dietary Supplement|Hairfinity #1|Main Hairfinity formulation
138556|NCT03106792|Dietary Supplement|Hairfinity #2|Variation to main formulation
138557|NCT03106792|Dietary Supplement|Hairfinity #3|Variation to main formulation
138558|NCT03106792|Dietary Supplement|Placebo|No active ingredients
138559|NCT03106779|Drug|ABL001|40 mg tablets will be taken orally twice a day (BID)
138560|NCT03106779|Drug|Bosutinib|500 mg tablets will be taken orally once daily (QD)
138561|NCT03106766|Drug|Acne cream 2X|Twice daily application of facial acne cream 2X after facial cleansing
138562|NCT03106766|Drug|Acne cream 1X|Twice daily application of facial acne cream 1X after facial cleansing
138563|NCT03106753|Drug|Bupivacaine|intrathecal bupivacaine 7.5 mg
138564|NCT03106753|Drug|Terbutaline|0.25 mg Terbutaline subcutaneously
138565|NCT03106740|Drug|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
138566|NCT03106740|Diagnostic Test|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of [11C]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
138567|NCT03106740|Other|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
138568|NCT03106727|Behavioral|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
138569|NCT03106714|Diagnostic Test|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
138570|NCT03106701|Procedure|Ablation|Epicardial Radiofrequency ablation
138571|NCT03106688|Diagnostic Test|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
138572|NCT03106688|Diagnostic Test|[11C]carfentanil PET scan|[11C]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
138573|NCT03106688|Diagnostic Test|[18F]FMPEP-d2 PET scan|[18F]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
138574|NCT03106688|Diagnostic Test|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand [18F]-FDG.
138575|NCT03106688|Diagnostic Test|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
138576|NCT03106688|Diagnostic Test|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
138577|NCT03106688|Diagnostic Test|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
138578|NCT03106688|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
138579|NCT03106675|Device|Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T|"Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.~Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area."
138580|NCT03106675|Device|Varian Truebeam Radiotherapy System|Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
138581|NCT03106662|Biological|mesenchymal stem cells|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
138582|NCT03106662|Drug|cyclophosphamide administration|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
138583|NCT03106649|Device|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
138584|NCT03106649|Device|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
138585|NCT03106636|Behavioral|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, postintervention, and 12 and 18 months postbaseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
138586|NCT03106636|Behavioral|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, postintervention, and 12 and 18 months postbaseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
138587|NCT03106623|Drug|ONO-8577|Oral administration of ONO-8577 once a daily for 4 weeks
138588|NCT03106623|Drug|solifenacin succinate + mirabegron|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
138589|NCT03106623|Drug|Placebo|Oral administration of Placebo once a daily for 4 weeks
138590|NCT03106610|Drug|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
138591|NCT03106610|Behavioral|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
138664|NCT03105921|Device|NanoKnife|The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
138592|NCT03106597|Drug|Manidipine 20mg|"After a 1~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
138593|NCT03106597|Drug|Amlodipine 10mg|"After a 1~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.~BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
138594|NCT03106584|Dietary Supplement|Aquamin-Plus|"Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg~Dosage:~4 Capsules is equal to effective dose"
138595|NCT03106584|Dietary Supplement|Glucosamine sulphate|"The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).~Dosage:~4 Capsules is equal to effective dose"
138596|NCT03106571|Drug|Pomaglumetad methionil|Tablets twice daily
138597|NCT03106571|Drug|Placebo|1-4 tablets twice daily
138598|NCT03106571|Drug|Methamphetamine|intravenous methamphetamine
138599|NCT03106558|Device|Total Knee Arthroplasty using Manual Instrumentation|
138600|NCT03106558|Device|Total Knee Arthroplasty using Robotic Arm|
138601|NCT03106545|Drug|Liposome bupivacaine|
138602|NCT03106532|Drug|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
138603|NCT03106532|Drug|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
138604|NCT03106532|Drug|Placebo ophthalmic solution|3 drops daily, 28 days
138605|NCT03106519|Drug|Liposome bupivacaine + bupivacaine|
138606|NCT03106506|Procedure|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
138607|NCT03106493|Other|None (observational)|None (observational)
138608|NCT03106467|Procedure|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
138609|NCT03106467|Procedure|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
138610|NCT03106454|Drug|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
138611|NCT03106454|Drug|Norethindrone|Norethindrone 1.05mg
138612|NCT03106441|Device|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
138613|NCT03106441|Device|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
138614|NCT03106428|Drug|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV
138615|NCT03106415|Drug|Binimetinib|Given PO
138616|NCT03106415|Other|Laboratory Biomarker Analysis|Correlative studies
138617|NCT03106415|Biological|Pembrolizumab|Given IV
138618|NCT03106402|Drug|topical bromfenac sodium hydrate|
138619|NCT03106389|Drug|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
138620|NCT03106389|Device|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
138621|NCT03106376|Other|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
138622|NCT03106376|Other|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
138623|NCT03106363|Drug|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
138624|NCT03106363|Drug|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
138625|NCT03106363|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
138626|NCT03106363|Drug|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
138766|NCT03105102|Drug|placebo for risankizumab IV|placebo for risankizumab administered by intravenous (IV) infusion
164409|NCT02915744|Drug|Ixabepilone|
138627|NCT03106350|Other|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
138628|NCT03106337|Device|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
138629|NCT03106324|Drug|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
138630|NCT03106311|Diagnostic Test|assessment of beta subunit of human chorionic gonadotropin|Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
138631|NCT03106298|Drug|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
138632|NCT03106285|Dietary Supplement|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10^8 CFU L retueri DSM17938
138633|NCT03106285|Dietary Supplement|Placebo|5 drops of placebo drops
138634|NCT03106259|Drug|FURESTEM-RA Inj.|Non-interventional observational study
138635|NCT03106233|Procedure|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
138636|NCT03106220|Behavioral|exercise|home exercise program
138637|NCT03106220|Other|placebo|encourage walking and physical therapy per standard care.
138638|NCT03106207|Procedure|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
138639|NCT03106194|Other|case management|
138640|NCT03106181|Device|iStent inject®|Insertion of iStent inject®
138641|NCT03106181|Procedure|Phacoemulsification and intraocular lens implant|Conventional phacoemulsification cataract surgery and intraocular lens implant
138642|NCT03106168|Procedure|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
138643|NCT03106155|Drug|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
138644|NCT03106142|Procedure|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
138645|NCT03106116|Device|Experimental: Enhanced External Counterpulsation|Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
138646|NCT03106116|Drug|Standard medical therapy|Guideline- driven standard medical treatment for 7 weeks
138647|NCT03106090|Other|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
138648|NCT03106077|Biological|Mirvetuximab Soravtansine|Given IV
138649|NCT03106064|Behavioral|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
138650|NCT03106064|Other|Usual Care|Usual hospital care
138651|NCT03106038|Drug|Nerindocianine for Injection|Procedure: routine minimally invasive pelvic surgery.
138652|NCT03106025|Device|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
138653|NCT03106012|Procedure|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
138654|NCT03106012|Procedure|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
138655|NCT03105986|Drug|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
138656|NCT03105986|Drug|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
138657|NCT03105973|Other|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
138658|NCT03105960|Drug|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
138659|NCT03105960|Drug|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
138660|NCT03105947|Other|Coconut oil|50g extravirgin coconut oil daily for four weeks
138661|NCT03105947|Other|Butter|50g butter daily for four weeks
138662|NCT03105947|Other|Olive oil|50g extra virgin olive oil daily for four weeks
138663|NCT03105934|Procedure|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
138665|NCT03105908|Behavioral|Internet delivered Acceptance and Commitment therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
138666|NCT03105908|Behavioral|Waiting list control condition|After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
138667|NCT03105895|Procedure|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
138668|NCT03105882|Device|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
138669|NCT03105869|Diagnostic Test|fluorocholine PET/CT|standard diagnostic PET/CT procedure
138670|NCT03105856|Biological|CERVARIX|- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
138671|NCT03105856|Biological|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp & Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
138672|NCT03105843|Drug|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
138673|NCT03105843|Diagnostic Test|Eucapneic Voluntary Hyperventilation (EVH) and Hypertonic Saline (HS) Challenge Tests|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
138674|NCT03105830|Drug|iv paracetamol|iv paracetamol
138675|NCT03105817|Device|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
138676|NCT03105804|Other|FT21039|An electronic cigarette
138677|NCT03105804|Other|FT21041|An electronic cigarette
138678|NCT03105804|Other|FT21044|An electronic cigarette
138679|NCT03105804|Other|FT21042|An electronic cigarette
138680|NCT03105791|Other|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
138681|NCT03105778|Diagnostic Test|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
138682|NCT03105765|Drug|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
138683|NCT03105765|Drug|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
138684|NCT03105752|Other|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
138685|NCT03105739|Other|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
138686|NCT03105713|Other|Patient Safety Checklist|The intervention is to be developed and implemented over three stages: 1) develop patient safety checklists for patients to use, 2) pilot testing of the checklists in 5 surgical clusters in two hospitals 3) a stepped wedge cluster randomized controlled trial of the patient safety checklists for patients to use.
138687|NCT03105700|Device|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
138688|NCT03105687|Behavioral|SMS reminders of medicines intake|The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
138689|NCT03105674|Drug|Multi-drug local anesthetics (Combination)|"Ropivacaine 0.5% - 30 ml~Ketorolac 30mg/ml - 1 ml~Kenalog 10 mg/ml - 5 ml~Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
138690|NCT03105674|Drug|Standard local anesthetics (Combination)|Marcaine and Lidocaine
138691|NCT03105661|Drug|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
138692|NCT03105661|Drug|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
138693|NCT03105661|Drug|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
138694|NCT03105648|Other|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
138727|NCT03105375|Drug|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
138767|NCT03105102|Drug|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
138695|NCT03105635|Other|Mixed method feasibility study|"Participating practices will receive the following:~Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.~Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals~Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.~Navigator: The services of a Navigator"
138696|NCT03105622|Behavioral|TV and music|Watching TV or listening to music while running on a treadmill
138697|NCT03105609|Device|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
138698|NCT03105596|Drug|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
138699|NCT03105583|Drug|Medication use during pregnancy|
138700|NCT03105583|Dietary Supplement|Supplement use during pregnancy|
138701|NCT03105583|Other|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
138702|NCT03105570|Procedure|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
138703|NCT03105557|Device|Urinary collecting device|Urinary collecting device
138704|NCT03105544|Other|simulation-based training|As described under group descriptions
138705|NCT03105518|Drug|Fentanyl|0.5, 1 mcg/kg
138706|NCT03105518|Drug|Acetaminophen|Single + Oxycodone
138707|NCT03105518|Drug|Oxycodone|With Acetaminophen
138708|NCT03105505|Drug|Permethrin 5%|Facial skin application once a night for 3 months.
138709|NCT03105505|Drug|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
138710|NCT03105505|Drug|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
138711|NCT03105479|Drug|Cadazolid|Granules for oral suspension to be administered twice daily
138712|NCT03105479|Drug|Vancomycin capsule|Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
138713|NCT03105479|Drug|Vancomycin solution|Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
138714|NCT03105466|Procedure|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
138715|NCT03105466|Device|Acellular Porcine Cornea|
138716|NCT03105466|Drug|Tacrolimus eye drops|
138717|NCT03105466|Drug|Tobradex eyedrops|
138718|NCT03105453|Other|3 Sampling points|When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
138719|NCT03105440|Other|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.~Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
138720|NCT03105440|Other|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.~Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
138721|NCT03105440|Other|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
138722|NCT03105440|Other|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
138723|NCT03105440|Other|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
138724|NCT03105440|Other|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
138725|NCT03105414|Device|Mechanical ventilation|Mechanical ventilation
138726|NCT03105401|Other|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
138764|NCT03105102|Drug|placebo for risankizumab SC|placebo for risankizumab administered by subcutaneous (SC) injection
138765|NCT03105102|Drug|risankizumab IV|risankizumab administered by intravenous (IV) infusion
138728|NCT03105375|Drug|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
138729|NCT03105375|Drug|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
138730|NCT03105362|Dietary Supplement|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
138731|NCT03105349|Drug|elbasvir/grazoprevir|16 weeks treatment
138732|NCT03105349|Drug|Sofosbuvir|16 weeks treatment
138733|NCT03105349|Drug|Ribavirin|16 weeks treatment
138734|NCT03105336|Biological|axicabtagene ciloleucel|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
138735|NCT03105336|Drug|Cyclophosphamide|Administered intravenously
138736|NCT03105336|Drug|Fludarabine|Administered intravenously
138737|NCT03105310|Drug|Pegylated interferon alfa|Pegylated interferon alfa
138738|NCT03105310|Drug|Ezetimibe|Ezetimibe
138739|NCT03105297|Device|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
138740|NCT03105297|Other|No strip|
138741|NCT03105284|Procedure|Liposuction|Fat harvest by liposuction (Colemans method)
138742|NCT03105245|Other|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
138743|NCT03105219|Drug|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
138744|NCT03105219|Other|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
138745|NCT03105206|Procedure|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
138746|NCT03105193|Drug|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
138747|NCT03105193|Drug|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
138748|NCT03105193|Drug|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
138749|NCT03105193|Drug|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
138750|NCT03105180|Other|A mixture of 2.7% sorbitol-0.54% mannitol solution|Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
138751|NCT03105167|Procedure|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
138752|NCT03105167|Procedure|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
138753|NCT03105154|Other|Prevena Dressing|Prevena dressing is applied on one groin
138754|NCT03105154|Other|Conventional Dressing|Conventional dressing is applied on the contralateral groin
138755|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to a given pressure followed by deflation, twice daily for 12 months.~Two different magnitude of limb ischemia pressure will be set: 200 mmHg and 40 mmHg above systolic pressure (60 patients for each).~Optimal inflating pressure will be determined based on the results."
138756|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of a given cycle of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The number of cycles of limb ischemia will be set as: 4, 5 and 6 (60 patients for each).~Optimal cycles for application will be determined based on the results."
138757|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of a given duration of bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.~The duration of each cycle for limb ischemia will be set as: 4, 5 and 6-min (60 patients for each).~Ischemia duration algorithm will be determined based on the results."
138758|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, once or twice daily for 12 months.~The method for application will be set as: once daily for 12 months and twice daily for 12 months (60 patients for each)."
138759|NCT03105128|Drug|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
138760|NCT03105128|Drug|risankizumab IV|Risankizumab administered by intravenous infusion
138761|NCT03105128|Drug|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
138762|NCT03105115|Drug|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
138763|NCT03105115|Drug|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
138768|NCT03105089|Procedure|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
138769|NCT03105076|Other|Decision aids|Shared decision making with decision aids
138770|NCT03105063|Diagnostic Test|ultrasound scan of the hip|validation of Ultrasound test as a tool for diagosing AIIS morphology
138771|NCT03105050|Other|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
138772|NCT03105024|Other|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
138773|NCT03105024|Other|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
138774|NCT03105011|Behavioral|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
138775|NCT03104998|Drug|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
138776|NCT03104985|Device|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
138777|NCT03104985|Other|Conventional therapy|"An elastic compression of lower extremities,~Pharmacotherapy,~Topical treatment"
138778|NCT03104972|Device|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
138779|NCT03104972|Device|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
138780|NCT03104972|Device|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
138781|NCT03104959|Dietary Supplement|N-acetyl cysteine|
138782|NCT03104959|Other|placebo|
138783|NCT03104946|Diagnostic Test|Mental Development Index;Auditory Brainstem Response;okineticnystagmus|mental development index(MDI）<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
138784|NCT03104920|Procedure|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
138785|NCT03104920|Procedure|Traditional treatment|A traditional perioperative management for HCC.
138786|NCT03104907|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
138787|NCT03104894|Procedure|Meibomian Glands Massage|Meibomian gland expression
138788|NCT03104894|Procedure|Sham Meibomian Glands Massage|Touching the eyelids gently
138789|NCT03104894|Device|Meibomian Massage device|Meibomian glands expression with applicator
138790|NCT03104881|Device|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
138791|NCT03104881|Device|2D end-effector type robot|2 dimension end-effector type upper extremity robot
138792|NCT03104868|Behavioral|TAKE IT Strategy|"The TAKE IT Strategy includes:~Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~SMS text-messaging to remind patients when to take all their medicine.~A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
138793|NCT03104855|Drug|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
138794|NCT03104842|Drug|Isatuximab|Antibody Intravenous
138795|NCT03104842|Drug|Carfilzomib|Intravenous
138796|NCT03104842|Drug|Lenalidomide|Capsel
138797|NCT03104842|Drug|Dexamethasone|Capsel
138798|NCT03104829|Behavioral|Motivational interviewing|
138799|NCT03104829|Drug|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
138800|NCT03104816|Drug|Acetaminophen IV Soln 10 MG/ML|
138801|NCT03104816|Drug|Acetaminophen|
138802|NCT03104816|Drug|Hydromorphone|
138803|NCT03104803|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
138804|NCT03104790|Biological|Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)|live attenuated influenza vaccine (LAIV)
138805|NCT03104777|Behavioral|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:~Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.~Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.~Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
138806|NCT03104764|Device|Scalpel|Labial frenulum removed by scalpel
138807|NCT03104764|Device|Er:YAG laser|Labial frenulum removed by Er:YAG laser
138808|NCT03104738|Other|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.~Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
138809|NCT03104725|Drug|N-Acetylcysteine|Oral
138810|NCT03104725|Procedure|Lumbar Puncture|Each patient undergoes a lumbar puncture (LP) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4- dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP is done after the patient has taken at least 5 doses of NAC (2 grams orally twice per day). The LP takes place about 2 hours after the last NAC dose.
138811|NCT03104725|Radiation|Fluoroscopy|If needed for lumbar puncture
138812|NCT03104712|Other|Glucose #1|50g available carbohydrate
138813|NCT03104712|Other|Glucose #2|50g available carbohydrate
138814|NCT03104712|Other|Glucose #3|50g available carbohydrate
138815|NCT03104712|Other|Spaghetti|50g available carbohydrate
138816|NCT03104712|Other|Rice|50g available carbohydrate
138817|NCT03104712|Other|Spaghetti + Tomato Sauce|50g available carbohydrate
138818|NCT03104712|Other|Rice + Tomato Sauce|50g available carbohydrate
138819|NCT03104712|Other|Spaghetti + Pesto|50g available carbohydrate
138820|NCT03104712|Other|Rice + Pesto|50g available carbohydrate
138821|NCT03104699|Drug|AGEN2034|anti-PD-1 antibody
138822|NCT03104686|Other|Short pasta (dry)|50g available carbohydrate of penne pasta
138823|NCT03104686|Other|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
138824|NCT03104686|Other|Bread|50g available carbohydrate of bread
138825|NCT03104686|Other|Glucose|50g available carbohydrate of glucose monohydrate
138826|NCT03104660|Device|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
138827|NCT03104647|Other|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
138828|NCT03104634|Drug|Aclidinium bromide/formoterol fumarate dihydrate|Cross-over design with washout interval. Randomized order of active and placebo arm
138829|NCT03104634|Drug|Placebo|Placebo and delivery device matched to active intervention
138830|NCT03104621|Drug|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
138831|NCT03104621|Drug|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
138832|NCT03104608|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
138833|NCT03104608|Other|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
138834|NCT03104595|Drug|EC-18|oral administration
138835|NCT03104582|Procedure|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
138836|NCT03104582|Procedure|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
138837|NCT03104569|Procedure|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
138838|NCT03104543|Behavioral|Education|30 minute education session; 15 minute booster session at 4 months
138839|NCT03104543|Behavioral|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
138840|NCT03104530|Other|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
138909|NCT03104036|Drug|Mesalazine 4G Enema|Standard mesalazine enema
138841|NCT03104517|Biological|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
138842|NCT03104517|Other|Placebo|Placebo control is the vehicle solution used for the study product.
138843|NCT03104504|Behavioral|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
138844|NCT03104504|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
138845|NCT03104504|Behavioral|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
138846|NCT03104504|Behavioral|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
138847|NCT03104491|Drug|Inotuzumab Ozogamicin|Participants will begin at 0.6mg/m2 and will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels is 0.1-0.6mg/m2
138848|NCT03104478|Procedure|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
138849|NCT03104465|Behavioral|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
138850|NCT03104439|Drug|Nivolumab|The antibodies in nivolumab work by causing programmed cell death of the cancer cells
138851|NCT03104439|Drug|Ipilimumab|The antibodies in ipilimumab work by not allowing cancer cell growth
138852|NCT03104439|Radiation|Radiation Therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
138853|NCT03104426|Drug|Darbepoetin Alfa|Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
138854|NCT03104413|Drug|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
138855|NCT03104413|Drug|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
138856|NCT03104413|Drug|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
138857|NCT03104400|Drug|Adalimumab|Adalimumab subcutaneous injection
138858|NCT03104400|Drug|ABT-494|Oral tablet
138859|NCT03104400|Drug|Placebo for ABT-494|Placebo oral tablet
138860|NCT03104400|Drug|Placebo for Adalimumab|Placebo subcutaneous injection
138861|NCT03104387|Other|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
138862|NCT03104387|Other|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
138863|NCT03104374|Drug|Placebo|Oral tablet
138864|NCT03104374|Drug|ABT-494|Oral tablet
138865|NCT03104361|Biological|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
138866|NCT03104348|Diagnostic Test|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
138867|NCT03104335|Drug|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
138868|NCT03104322|Other|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
138869|NCT03104322|Other|usual care|usual care
138870|NCT03104309|Device|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
138871|NCT03104296|Diagnostic Test|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.~The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
138872|NCT03104283|Drug|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
138873|NCT03104270|Drug|Elotuzumab|Elotuzumab IV at 10mg/kg Elotuzumab IV at 20mg/kg
138874|NCT03104270|Drug|Pomalidomide|Pomalidomide PO at 3mg
138875|NCT03104270|Drug|Carfilzomib|Carfilzomib 20mg/m2 IV Carfilzomib 56mg/m2 IV
138876|NCT03104270|Drug|Dexamethasone|Dexamethasone 28mg PO Dexamethasone 40mg PO or IV Dexamethasone 8mg IV
138877|NCT03104257|Other|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
138878|NCT03104231|Other|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
138879|NCT03104218|Other|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
138880|NCT03104218|Other|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
138907|NCT03104049|Device|Neuromuscular taping|"NMT applications:~rhomboid major muscle~muscles abdominals~spinal muscles~pectoralis major muscles~gastrocnemius muscle~upper trapezius muscle~anterior muscles of the neck"
138908|NCT03104036|Other|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
138881|NCT03104205|Behavioral|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and remote fitness device monitoring. We plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 8, 16 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2 (NCT03104192).
138882|NCT03104192|Behavioral|Develop & Refine MOWI w/o Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
138883|NCT03104192|Behavioral|Develop & Refine MOWI w Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Amulet and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A waves of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet/Fitbit to measure steps, activity type, duration and distance.
138884|NCT03104192|Behavioral|MOWI Weight Loss Maintenance|Participants who successfully completed the initial MOWI program will be offered the opportunity to participate in a 6-month weight management program. This program will consist of 8 group-based skills workshop sessions occurring approximately once monthly (every 3 weeks), which will be 90-120 minutes in length. The overall structure of the program will emphasize the following evidence-based weight management components: Goal setting/action planning, self-monitoring, receiving feedback regarding performance, reviewing relevant goals in the light of feedback, and e. psychological skills for increasing behavioral commitment (acceptance, willingness, thought monitoring, mindful decision making, and values clarification).
138885|NCT03104192|Dietary Supplement|Develop & Refine MOWI w Amulet/Protein|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Amulet/Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance. We will provide whey protein 3x/week after exercise sessions.
138886|NCT03104192|Behavioral|Develop & Refine MOWI w Fitbit|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance.
138887|NCT03104192|Dietary Supplement|Develop & Refine MOWI w Fitbit/Protein|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Fitbit to monitor activity. A dietician and physical therapist will lead the in-person sessions. A wave of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance. We will provide whey protein 3x/week after exercise sessions.
138888|NCT03104179|Device|Cytosorb Adsorber|Cytokine adsorption during CPB
138889|NCT03104166|Device|Medium Cut-Off (MCO) dialysis membrane|Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.
138890|NCT03104166|Device|High-Flux dialysis membrane|Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
138891|NCT03104153|Procedure|Early-drain removal|Drain removal at hospital discharge
138892|NCT03104140|Drug|Ketamine|After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
138893|NCT03104140|Drug|Thiopental|After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
138894|NCT03104127|Device|Alter G Bionic Leg|Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
138895|NCT03104127|Other|Normal therapy (physiotherapy)|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
138896|NCT03104114|Behavioral|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
138897|NCT03104114|Behavioral|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
138898|NCT03104101|Combination Product|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
138899|NCT03104101|Device|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
138900|NCT03104088|Diagnostic Test|CANTAB|CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)
138901|NCT03104088|Diagnostic Test|MOCA|Montreal cognitive assessment (MOCA) in German
138902|NCT03104075|Biological|Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23
138903|NCT03104075|Biological|Pneumococcal Vaccine Polyvalent|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
138904|NCT03104062|Diagnostic Test|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
138905|NCT03104062|Diagnostic Test|Platelet Aggregability|Obtained using Multiplate Analyzer
138906|NCT03104062|Diagnostic Test|Laboratory|it will be collected at patients arrival, Reative C-Protein, BNP, CK-mass, Troponine, interleukine-6, Creatinine.
138910|NCT03104023|Procedure|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
138911|NCT03104023|Combination Product|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
138912|NCT03104010|Drug|Somatropin Injection|Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.
138913|NCT03103997|Procedure|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
138914|NCT03103984|Other|Weight loss diet|Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
138915|NCT03103971|Biological|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
138916|NCT03103971|Drug|Cyclophosphamide|Given IV
138917|NCT03103971|Drug|Fludarabine|Given IV
138918|NCT03103971|Other|Laboratory Biomarker Analysis|Correlative studies
138919|NCT03103971|Procedure|Leukapheresis|Undergo leukapheresis
138920|NCT03103971|Other|Pharmacological Study|Correlative studies
138921|NCT03103958|Dietary Supplement|Probiotic|"Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.~Subjects will take two sachets per day after diluting them in 100 ml of water"
138922|NCT03103958|Dietary Supplement|Placebo|"The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.~Subjects will take two sachets per day after diluting them in 100 ml of water"
138923|NCT03103945|Device|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
138924|NCT03103932|Other|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
138925|NCT03103919|Device|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
138926|NCT03103919|Device|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
138927|NCT03103919|Drug|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
138928|NCT03103906|Other|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
138929|NCT03103906|Other|Cleanser (Reference Product)|Moisturizing facial cleanser
138930|NCT03103906|Other|Sunscreen (Reference Product)|SPF 50 sunscreen
138931|NCT03103893|Drug|Rapamycin|topical formulation
138932|NCT03103880|Device|mHealth Asthma Adherence System|This Intervention includes the use of the mobile application and connected sensors to track adherence and engage patients in their care.
138933|NCT03103880|Device|Remote Mobile Pulmonary Function Testing|This intervention includes remote patient monitoring of lung function using a connected spirometer used to capture pulmonary function testing (PFTs) monthly.
138934|NCT03103880|Device|Remote Mobile Peak Flow Capture|This intervention includes remote patient monitoring of lung function using a connected spirometer used to capture peak flow and FEV1 metrics weekly.
138935|NCT03103867|Device|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
138936|NCT03103867|Device|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
138937|NCT03103854|Behavioral|BURST physical activity|BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
138938|NCT03103854|Behavioral|Text Message Reminders|Patients were sent daily text message reminders to remind them to exercise.
138939|NCT03103854|Behavioral|Moderate Intensity Continuous Training|This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
138940|NCT03103841|Procedure|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
138941|NCT03103828|Behavioral|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
138982|NCT03103568|Drug|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
138983|NCT03103555|Drug|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
138984|NCT03103555|Drug|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
164410|NCT02915744|Drug|Vinorelbine|
138942|NCT03103828|Behavioral|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
138943|NCT03103828|Behavioral|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
138944|NCT03103815|Drug|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
138945|NCT03103802|Device|intra-oral digital scanner and extra-oral digital scanner|intra-oral and extra-oral digital scanners used to obtain digital models
138946|NCT03103789|Diagnostic Test|single catheter mucosal impedance testing|
138947|NCT03103789|Diagnostic Test|balloon assembly mucosal impedance testing|
138948|NCT03103776|Other|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
138949|NCT03103763|Drug|Warfarin|Patients on warfarin for atrial fibrillation
138950|NCT03103750|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
138951|NCT03103750|Drug|Raclopride|Used as a tracer for in vivo imaging.
138952|NCT03103750|Dietary Supplement|calcitriol|three 0.5 mcg capsules
138953|NCT03103750|Drug|Placebo oral capsule|three 0.5 mcg capsules
138954|NCT03103750|Procedure|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
138955|NCT03103750|Drug|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
138956|NCT03103737|Behavioral|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
138957|NCT03103724|Drug|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
138958|NCT03103711|Behavioral|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
138959|NCT03103698|Device|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
138960|NCT03103698|Other|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
138961|NCT03103685|Drug|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
138962|NCT03103672|Procedure|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
138963|NCT03103659|Other|personalised care plan|Quality of life assessement in elderly cancer patients
138964|NCT03103646|Drug|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg
138965|NCT03103646|Drug|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
138966|NCT03103646|Drug|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
138967|NCT03103633|Procedure|mean artery pressure|mean artery pressure declined with less than 20% of baseline
138968|NCT03103633|Procedure|bispectral index|BIS 45-60 before and after CPB; and BIS 40-45 during CPB
138969|NCT03103633|Procedure|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
138970|NCT03103633|Other|Controlled|receiving standard measures to achieve a heart rate (HR) in the range of 60-100 beats/min, central venous oxygen saturation (Svco2) higher than 70%, lactate level lower than 3 mmol/L, hematocrit value higher than 28%, and urinary output higher than 0.5 mL/kg/hr.
138971|NCT03103620|Device|COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System
138972|NCT03103607|Diagnostic Test|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
138973|NCT03103607|Diagnostic Test|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
138974|NCT03103594|Drug|DMSO|DMSO will be instilled intravesically.
138975|NCT03103594|Drug|Botox|Botox will be instilled intravesically with DMSO.
138976|NCT03103581|Drug|BLI4700|BLI4700 Bowel Preparation
138977|NCT03103568|Drug|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
138978|NCT03103568|Drug|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
138979|NCT03103568|Drug|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
138980|NCT03103568|Drug|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
138981|NCT03103568|Drug|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
138985|NCT03103542|Biological|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement~administered intravenously."
138986|NCT03103529|Other|Active Rehabilitation|
138987|NCT03103516|Procedure|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
138988|NCT03103516|Procedure|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
138989|NCT03103490|Drug|18F-FSPG|Patients will receive 8mCi of 18F-FSPG and undergo PET/MRI or PET/CT imaging to determine the ability of 18F-FSPG to localize to cardiac sarcoidosis or myocardial inflammation and the utility of PET/MR to detect these conditions.
138990|NCT03103477|Other|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
138991|NCT03103464|Other|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
138992|NCT03103464|Other|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
138993|NCT03103451|Drug|BCD-121|
138994|NCT03103451|Other|Placebo|
138995|NCT03103438|Biological|BCD-089|
138996|NCT03103412|Drug|TD-3504|TD-3504
138997|NCT03103412|Drug|15N2-tofacitinib|15N2-tofacitinib
138998|NCT03103412|Drug|Placebo|Placebo
138999|NCT03103399|Drug|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
139000|NCT03103399|Drug|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
139001|NCT03103399|Drug|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.~All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
139002|NCT03103399|Drug|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
139003|NCT03103386|Dietary Supplement|intake of food product with a patented fermented rye bran|During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
139004|NCT03103386|Dietary Supplement|intake of food product with common refined wheat|During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
139005|NCT03103373|Device|Conventional monitor|Patients underwent non-cardiac surgery will be monitoring by regular monitors
139006|NCT03103373|Device|Echocardiography|Patients will be monitoring by regular monitors plus echocardiography
139007|NCT03103360|Device|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
139008|NCT03103360|Procedure|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
139009|NCT03103334|Other|Zeneo® - Methotrexate|0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
139010|NCT03103334|Drug|Methotrexate Biodim®|1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
139011|NCT03103321|Other|Internet-Based Intervention|"Receive Knowing your Options decision aid"
139012|NCT03103321|Other|Internet-Based Intervention|"Receive Prostate Choice decision aid"
139013|NCT03103321|Other|Best Practice|Undergo usual care
139014|NCT03103321|Other|Quality-of-Life Assessment|Ancillary studies
139015|NCT03103321|Other|Questionnaire Administration|Ancillary studies
139016|NCT03103321|Other|Survey Administration|Ancillary studies
139017|NCT03103321|Other|Laboratory Biomarker Analysis|Correlative studies
139018|NCT03103308|Other|Walk Training and Transplant|Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
139019|NCT03103308|Other|Activity Monitoring and Transplant|Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
139020|NCT03103295|Biological|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
139021|NCT03103282|Device|PuraStat®|Synthetic haemostatic material
139022|NCT03103269|Behavioral|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
139023|NCT03103269|Other|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
139024|NCT03103256|Drug|YHP1701|PO, Once daily (QD), 8 weeks
139025|NCT03103256|Drug|YHR1703|PO, Once daily (QD), 8 weeks
139026|NCT03103256|Drug|YHR1704|PO, Once daily (QD), 8 weeks
139027|NCT03103243|Behavioral|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
139028|NCT03103230|Device|Cortical magnetic stimulation|Motor Evoked Potentials of lips and hand recorded after cortical magnetic stimulation
139071|NCT03102892|Procedure|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
139029|NCT03103217|Behavioral|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
139030|NCT03103204|Combination Product|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).~Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).~Oral hygiene instructions will be given for all participants."
139031|NCT03103191|Diagnostic Test|KL-6 levels|Measure of KL-6 in serum
139032|NCT03103178|Other|Quality of life questionnaire|Measurement of quality of life
139033|NCT03103152|Drug|High dose Aspirin & Vitamin D|Aspirin 1 x 300mg tablet daily & Vitamin D 4,000IU daily. (8 drops).
139034|NCT03103152|Drug|High dose Aspirin, Vitamin D placebo|Aspirin 1 x 300mg tablet daily & Vitamin D placebo (8 drops).
139035|NCT03103152|Drug|Low dose Aspirin , Vitamin D|Aspirin 1 x 100mg tablet daily & Vitamin D 4,000IU daily. (8 drops).
139036|NCT03103152|Drug|Low dose Aspirin, Vitamin D placebo|Aspirin 1 x 100mg tablet daily & Vitamin D placebo 8 drops daily.
139037|NCT03103152|Drug|Aspirin Placebo, Vitamin D|Aspirin 1 x 300mg placebo tablet daily & Vitamin D 4,000IU daily. (8 drops).
139038|NCT03103152|Drug|Aspirin placebo, Vitamin D placebo|Aspirin 1 x 100mg placebo tablet daily & Vitamin D 4,000IU daily. (8 drops).
139039|NCT03103139|Procedure|Transpapillary Stent|ERCP with placement of short stent
139040|NCT03103139|Procedure|Stent across bile leak|ERCP with long stent
139041|NCT03103126|Behavioral|Combined resistance exercise and walking|Combined resistance exercise and walking
139042|NCT03103100|Drug|1% Lidocaine|10 mL of 1% lidocaine
139043|NCT03103100|Drug|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
139044|NCT03103100|Drug|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
139045|NCT03103087|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
139046|NCT03103087|Drug|Estradiol/norethindrone acetate|Capsule containing a co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
139047|NCT03103087|Drug|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
139048|NCT03103087|Drug|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor
139049|NCT03103074|Drug|Botulinum B Toxin|Intradermal injections
139050|NCT03103074|Other|Placebo Saline|Intradermal injections
139051|NCT03103061|Drug|Lexiscan|Coronary vasodilator
139052|NCT03103048|Diagnostic Test|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
139053|NCT03103048|Diagnostic Test|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
139054|NCT03103048|Diagnostic Test|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
139055|NCT03103048|Diagnostic Test|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
139056|NCT03103035|Other|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
139057|NCT03103022|Drug|Acetaminophen|Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
139058|NCT03103022|Drug|ibuprofen|Oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
139059|NCT03103009|Drug|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
139060|NCT03102996|Drug|Nephrotrans|Sodium hydrogen carbonate, ATC-Code: A02AH
139061|NCT03102996|Other|Placebo|Identical capsules without active substance.
139062|NCT03102983|Other|MRI functional|vowels records and MRI session
139063|NCT03102957|Other|functional MRI|
139064|NCT03102944|Diagnostic Test|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
139065|NCT03102931|Other|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
139066|NCT03102931|Other|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
139067|NCT03102918|Drug|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
139068|NCT03102918|Drug|Placebo|Participants will receive placebo over a 6-week treatment period.
139069|NCT03102905|Other|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
139070|NCT03102892|Procedure|Scaling root planing|Treatment by scaling and root planing alone.
139072|NCT03102879|Procedure|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
139073|NCT03102879|Procedure|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
139074|NCT03102866|Other|Best Practice|Receive usual care
139075|NCT03102866|Behavioral|Exercise Intervention|Undergo aerobic and strength training exercise
139076|NCT03102866|Other|Quality-of-Life Assessment|Ancillary studies
139077|NCT03102866|Other|Questionnaire Administration|Ancillary studies
139078|NCT03102853|Other|Nordic diet|
139079|NCT03102853|Other|Control diet|
139080|NCT03102840|Diagnostic Test|Nasopharyngeal swab|Nasopharyngeal swab will be performed in all participants
139081|NCT03102840|Diagnostic Test|blood sampling|Blood sampling will be done by finger-prick in a sub-set of participants
139082|NCT03102827|Drug|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
139083|NCT03102827|Other|Placebo|Ambient air without high-flow therapy administered during first night
139084|NCT03102814|Behavioral|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
139085|NCT03102814|Behavioral|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
139086|NCT03102801|Drug|Humulin S|Humulin S used to induce hypoglycaemia
139087|NCT03102788|Behavioral|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.~The rheumatologist may also refer participants to occupational therapy if needed."
139088|NCT03102788|Behavioral|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
139089|NCT03102775|Other|Comprehensive follow-up program for low-income families|The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.
139090|NCT03102775|Other|local family projects|The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
139091|NCT03102762|Drug|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
139092|NCT03102762|Drug|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
139093|NCT03102749|Other|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
139094|NCT03102736|Drug|Placebos|Placebo saline
139095|NCT03102736|Drug|Ketamine|0.5 mg/kg ketamine
139096|NCT03102736|Drug|Nitroprusside|0.5 mcg/kg nitroprusside
139097|NCT03102723|Drug|Cangrelor|"Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.~Or~Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
139098|NCT03102710|Device|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
139099|NCT03102710|Other|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
139100|NCT03102710|Other|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
139101|NCT03102710|Other|Control cream|A neutral cream will be applied on the arm as a control.
139102|NCT03102697|Device|Air-filled Intragastric balloon|Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
139103|NCT03102684|Other|Secondhand exposure to e-cigarette aerosols (low)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
139104|NCT03102684|Other|Secondhand exposure to e-cigarette aerosols (high)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design."
139143|NCT03102372|Other|walking program|
139144|NCT03102372|Other|Very Low Calorie Diet|
139105|NCT03102671|Other|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
139106|NCT03102671|Other|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
139107|NCT03102658|Drug|Micafungin|Administration of study drug
139108|NCT03102645|Drug|Placebo Oral Tablet|Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
139109|NCT03102645|Drug|Imipramine Hydrochloride 25 MG|Two Imipramin DAK film coated tablets 25 mg each, single dose
139110|NCT03102632|Other|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
139111|NCT03102606|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
139112|NCT03102606|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
139113|NCT03102606|Other|Saline Placebo|Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
139114|NCT03102606|Other|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
139115|NCT03102593|Drug|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
139116|NCT03102593|Other|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
139117|NCT03102580|Other|OA Care Plan|Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
139118|NCT03102567|Drug|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
139119|NCT03102567|Drug|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
139120|NCT03102567|Drug|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
139121|NCT03102554|Genetic|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
139122|NCT03102541|Other|None intervention|
139123|NCT03102528|Other|No intervention|No intervention
139124|NCT03102515|Drug|USG-TAP block|
139125|NCT03102515|Drug|CIC|
139126|NCT03102502|Device|EECP|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
139127|NCT03102502|Drug|Medical therapy|Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
139128|NCT03102489|Drug|BP101|Nasal spray
139129|NCT03102489|Drug|Placebo|Nasal spray
139130|NCT03102476|Drug|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
139131|NCT03102463|Dietary Supplement|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
139132|NCT03102463|Dietary Supplement|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
139133|NCT03102463|Dietary Supplement|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
139134|NCT03102463|Other|Lipid Load|100mL oral lipid load
139135|NCT03102450|Drug|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.~Duration of treatment : 6 months (12 months optional)"
139136|NCT03102437|Device|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
139137|NCT03102424|Device|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
139138|NCT03102424|Device|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
139139|NCT03102398|Drug|TR-399 (5% Vardenafil HCl·3H2O, topical gel)|5% Vardenafil HCl·3H2O, topical gel, 2 drops (50ul, 2.5mg), q.d.
139140|NCT03102385|Behavioral|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
139141|NCT03102385|Behavioral|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
139142|NCT03102372|Dietary Supplement|Whey protein supplementation|
139145|NCT03102359|Drug|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
139146|NCT03102359|Device|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
139147|NCT03102346|Other|home-based cardiac rehabilitation|The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
139148|NCT03102333|Device|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
139149|NCT03102333|Device|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
139150|NCT03102320|Drug|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
139151|NCT03102320|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
139152|NCT03102320|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
139153|NCT03102307|Other|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
139154|NCT03102307|Procedure|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
139155|NCT03102294|Other|inspiratory muscle training|inspiratory muscle training with 50% of MIP
139156|NCT03102294|Other|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
139157|NCT03102255|Procedure|Sniffing position|All procedure is done under sniffing position.
139158|NCT03102255|Procedure|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
139159|NCT03102242|Drug|Atezolizumab|Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
139160|NCT03102229|Other|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
139161|NCT03102229|Other|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
139162|NCT03102216|Diagnostic Test|iSTAT|iSTAT troponin, INR, CG4+ and Chem8
139163|NCT03102216|Diagnostic Test|CBC|Complete Blood Count
139164|NCT03102216|Diagnostic Test|ECG|ElectroCardioGram
139165|NCT03102216|Diagnostic Test|Lodox|Low dose x-ray
139166|NCT03102190|Drug|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
139167|NCT03102177|Drug|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
139168|NCT03102164|Procedure|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
139169|NCT03102151|Other|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
139170|NCT03102125|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
139171|NCT03102112|Other|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
139172|NCT03102099|Procedure|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
139173|NCT03102099|Procedure|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
139174|NCT03102086|Procedure|Scaling|Scaling of dental calculus
139175|NCT03102073|Diagnostic Test|Radner test|"The A5 reading booklet is held by the subject~The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)~The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.~One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation~Stop criterion: reading time longer than 20 seconds or severe errors."
139176|NCT03102060|Other|Dietary Intervention|Undergo gluten free diet
139177|NCT03102060|Other|Laboratory Biomarker Analysis|Correlative studies
139178|NCT03102047|Drug|durvalumab|Within 3−7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
139179|NCT03102034|Biological|D46/NS2/N/ΔM2-2-HindIII|10^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
139180|NCT03102034|Biological|Placebo|Isotonic diluent; administered as nose drops
139181|NCT03102021|Drug|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
139182|NCT03102021|Drug|saline|saline 10 ml for 3 days
139211|NCT03101800|Drug|Azathioprine|Standard weight based azathioprine dosage
164411|NCT02915744|Drug|Gemcitabine|
139183|NCT03102008|Behavioral|Unified Protocol for Emotional Disorders in Adolescents (UP-A)|The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
139184|NCT03101995|Drug|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.~Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.~Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
139185|NCT03101982|Drug|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
139186|NCT03101969|Other|Call|not called, not reached, and spoken to
139187|NCT03101956|Procedure|Lumbar Spine Manipulation|• The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
139188|NCT03101956|Procedure|Lumbar Spine Manipulation Placebo|The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
139189|NCT03101943|Behavioral|Family Spirit Nurture (FSN)|The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
139190|NCT03101943|Other|Control Program|The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
139191|NCT03101943|Other|Water Delivery|Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
139192|NCT03101930|Drug|Liraglutide|subcutaneous liraglutide daily
139193|NCT03101930|Drug|Sitagliptin|oral sitagliptin daily
139194|NCT03101930|Other|hypocaloric diet|Reduced calorie intake to achieve weight loss.
139195|NCT03101930|Drug|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
139196|NCT03101930|Drug|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
139197|NCT03101917|Device|The Microtable® Stereotactic System|x
139198|NCT03101904|Dietary Supplement|Beetroot Juice|
139199|NCT03101904|Dietary Supplement|Placebo|
139200|NCT03101891|Procedure|Serial amnioinfusions with isotonic fluid|Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed isotonic fluid. Infusions may take up to 1 hour.
139201|NCT03101891|Device|Spinal needle|A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse isotonic fluid.
139202|NCT03101891|Drug|Isotonic fluid|Isotonic fluids, including normal saline or lactated ringers solution, will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.
139203|NCT03101878|Drug|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
139204|NCT03101878|Drug|Placebo|Saline .9%
139205|NCT03101865|Device|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
139206|NCT03101852|Dietary Supplement|Plumpy Nut|
139207|NCT03101852|Dietary Supplement|Plumpy Sup|
139208|NCT03101839|Drug|AZD4785|KRAS Antisense Oligonucleotide
139209|NCT03101826|Behavioral|Listening Project Protocol|The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
139210|NCT03101800|Drug|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
164412|NCT02915744|Drug|Paclitaxel|
139212|NCT03101787|Procedure|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.~The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.~Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.~Time from arrest to start of cannulation is < 60 minutes."
139213|NCT03101774|Device|Threshold inspiratory muscle training|Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
139214|NCT03101774|Device|Resistive inspiratory muscle training|Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
139215|NCT03101774|Other|Control group|Conventional therapy without any inspiratory muscle training program
139216|NCT03101748|Drug|Cyclophosphamide|Given IV
139217|NCT03101748|Drug|Doxorubicin Hydrochloride|Given IV
139218|NCT03101748|Other|Laboratory Biomarker Analysis|Correlative studies
139219|NCT03101748|Drug|Neratinib|Given PO
139220|NCT03101748|Drug|Paclitaxel|Given IV
139221|NCT03101748|Biological|Pertuzumab|Given IV
139222|NCT03101748|Biological|Trastuzumab|Given IV
139223|NCT03101735|Drug|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
139224|NCT03101722|Drug|BTHE and Huperzine A|huperzine A intervention
139225|NCT03101722|Other|BETH|basic treatment and health education
139226|NCT03101709|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
139227|NCT03101709|Drug|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
139228|NCT03101709|Biological|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
139229|NCT03101683|Radiation|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
139230|NCT03101670|Drug|filgotinib|one filgotinib oral tablet q.d.
139231|NCT03101670|Drug|Placebo Oral Tablet|one placebo oral tablet q.d.
139232|NCT03101644|Drug|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
139233|NCT03101631|Diagnostic Test|Comprehensive Geriatric Assessment (CGA)|"CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:~Nutritional Assessment: Mini Nutritional Assessment (MNA)~Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.~Cognitive Assessment: Mini-Mental State Examination (MMSE-30)~Psychological status: Geriatric Depression Scale (GDS)~Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)~Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)~Age~Haemoglobin~CrCl~Presence of geriatric syndromes"
139234|NCT03101618|Other|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
139235|NCT03101618|Other|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
139236|NCT03101605|Other|e-learning teaching module|As described
139237|NCT03101605|Other|Standard teaching method|As described
139238|NCT03101592|Other|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
139239|NCT03101592|Other|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
139240|NCT03101579|Drug|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
139241|NCT03101579|Drug|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
139242|NCT03101579|Drug|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
139243|NCT03101579|Drug|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
139244|NCT03101566|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV
139245|NCT03101566|Drug|Cisplatin|Cisplatin 25 mg/m2 IV
139246|NCT03101566|Drug|Ipilimumab|Ipilimumab 1 mg/kg IV
139247|NCT03101566|Drug|Nivolumab|Nivolumab 360 mg or 240 mg IV
139248|NCT03101553|Behavioral|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
139840|NCT03097120|Drug|placebo tablets|two placebo tablets daily
139249|NCT03101553|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
139250|NCT03101540|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
139251|NCT03101527|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
139252|NCT03101514|Drug|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
139253|NCT03101501|Drug|Mitomycin c|Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 30 seconds at the time of the surgical procedure.
139254|NCT03101501|Device|Raindrop Near Vision Inlay|Implanted to improve near vision in Presbyopic or Pseudophakic subjects.
139255|NCT03101488|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
139256|NCT03101475|Drug|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
139257|NCT03101475|Drug|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
139258|NCT03101475|Radiation|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
139259|NCT03101475|Other|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
139260|NCT03101462|Biological|Inactivated Influenza Vaccine|
139261|NCT03101462|Biological|Live Attenuated Influenza Vaccine|
139262|NCT03101449|Other|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
139263|NCT03101449|Other|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
139264|NCT03101436|Dietary Supplement|Extra Virgin Olive Oil and Red Wine|"Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)~Washout Period: 15 days~Phase II: Red Wine (270 ml per day) (1 month)"
139265|NCT03101423|Drug|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
139266|NCT03101423|Drug|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
139267|NCT03101410|Behavioral|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
139268|NCT03101410|Behavioral|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
139269|NCT03101384|Other|Diagnostic error|There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
139270|NCT03101371|Drug|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
139271|NCT03101371|Procedure|Standard of care catheter insertion|Catheter inserted right out of package.
139272|NCT03101358|Drug|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
139273|NCT03101345|Other|Peptamen® 1.5 vanilla|Administration orally
139274|NCT03101332|Behavioral|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.~Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.~Interventions are delivered by a psychologist in face-to-face sessions."
139275|NCT03101319|Drug|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
139276|NCT03101319|Drug|Placebo Oral Tablet|As mentioned in the description of the study arm
139277|NCT03101306|Other|MR scans|Additional imaging using MR scans.
139278|NCT03101293|Drug|TAK-831|TAK-831 film-coated tablet.
139279|NCT03101280|Drug|Atezolizumab|Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram [mg/kg]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
139280|NCT03101280|Drug|Rucaparib|The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
139281|NCT03101267|Drug|ASP4070|Intradermal vaccination at 2-week intervals
139282|NCT03101267|Drug|Placebo|Intradermal vaccination at 2-week intervals
139283|NCT03101254|Drug|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
139284|NCT03101254|Drug|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
139285|NCT03101254|Drug|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
139286|NCT03101241|Drug|CX-8998|T-type calcium channel blocker
139287|NCT03101241|Drug|Placebo|Placebo comparator
139358|NCT03100838|Drug|Nifedipine 60 MG Extended Release Oral Tablet|Reference Drug (Brand)
139288|NCT03101228|Behavioral|Reduced sitting|Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
139289|NCT03101215|Dietary Supplement|phosphorus|adding of phosphorus to high carbohydrate meal
139290|NCT03101202|Device|SSD tube|The SSD tube allows the suction of subglottic secretions that collect above the cuff of the endotracheal tube
139291|NCT03101189|Drug|ACT-541468|Capsule
139292|NCT03101189|Drug|placebo|Matching placebo capsule
139293|NCT03101176|Drug|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
139294|NCT03101163|Biological|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
139295|NCT03101163|Other|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
139296|NCT03101150|Drug|400 IU Vitamin D3|Antenatal multivitamin
139297|NCT03101150|Drug|4000 IU Vitamin D3|4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
139298|NCT03101137|Drug|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
139299|NCT03101137|Drug|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
139300|NCT03101137|Drug|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
139301|NCT03101124|Drug|Tranexamic Acid 25 mg/ml for wound surface moistening|Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
139302|NCT03101124|Drug|Tranexamic Acid 5 mg/ml as bolus in wound cavity|200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
139303|NCT03101124|Drug|Tranexamic Acid Injectable Solution|1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
139304|NCT03101111|Biological|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
139305|NCT03101111|Biological|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
139306|NCT03101098|Procedure|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
139307|NCT03101098|Procedure|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
139308|NCT03101085|Drug|S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules
139309|NCT03101085|Other|Placebo|Placebo capsules matched in size and color to S-equol capsules
139310|NCT03101072|Other|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
139311|NCT03101072|Other|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
139312|NCT03101072|Other|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
139313|NCT03101059|Procedure|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
139314|NCT03101046|Drug|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m2 every 3 weeks for 6 cycles (D1=D22).
139315|NCT03101046|Drug|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
139357|NCT03100851|Dietary Supplement|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10^8 CFU Lactobacillus casei strain Shirota every day after lunch.
139419|NCT03100292|Other|Sleeve gastrectomy or Roux-en-Y gastric bypass|
139316|NCT03101033|Device|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
139317|NCT03101033|Drug|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
139318|NCT03101033|Drug|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
139319|NCT03101033|Drug|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
139320|NCT03101020|Other|Active Visceral Manipulation|Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, duodenum-jejunum valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
139321|NCT03101020|Other|Standard care physiotherapy|The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
139322|NCT03101020|Other|Placebo Visceral Manipulation|The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
139323|NCT03101007|Device|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
139324|NCT03101007|Device|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
139325|NCT03100994|Drug|Bupivacaine|injecting anesthetics to different local
139326|NCT03100994|Device|Ultrasound|Ultrasound guided nerve block
139327|NCT03100981|Behavioral|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.~Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
139328|NCT03100981|Behavioral|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.~After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
139329|NCT03100968|Procedure|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
139330|NCT03100968|Device|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
139331|NCT03100955|Drug|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
139332|NCT03100955|Drug|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
139333|NCT03100942|Drug|Filgotinib|200 mg tablet administered orally once daily
139334|NCT03100942|Drug|Lanraplenib|30 mg tablet administered orally once daily
139335|NCT03100942|Drug|Tirabrutinib|40 mg tablet administered orally once daily
139336|NCT03100942|Drug|Filgotinib placebo|Tablet administered orally once daily
139337|NCT03100942|Drug|Lanraplenib placebo|Tablet administered orally once daily
139338|NCT03100942|Drug|Tirabrutinib placebo|Tablet administered orally once daily
139339|NCT03100929|Diagnostic Test|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
139340|NCT03100916|Drug|BI 690517|once daily
139341|NCT03100916|Drug|Placebo|once daily
139342|NCT03100916|Drug|BI 690517 (Reference)|Fasting
139343|NCT03100916|Drug|BI 690517|Non- fasting
139344|NCT03100903|Drug|BI 655130|single dose
139345|NCT03100890|Other|Preoperative training (hospital)|Preoperative hospital training
139346|NCT03100890|Other|Preoperative training (home)|Preoperative in-home training
139347|NCT03100877|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
139348|NCT03100877|Drug|Cyclophosphamide|Given IV
139349|NCT03100877|Biological|Filgrastim|Given SC or IV
139350|NCT03100877|Other|Laboratory Biomarker Analysis|Correlative studies
139351|NCT03100877|Drug|Lenalidomide|Given PO
139352|NCT03100877|Procedure|pheresis|Undergo apheresis
139353|NCT03100877|Drug|Melphalan|Given IV
139354|NCT03100877|Biological|Palifermin|Given IV
139355|NCT03100877|Radiation|Total Marrow Irradiation|Undergo TMI
139356|NCT03100864|Drug|Spesolimab|12 weeks treatment
164413|NCT02915744|Drug|Docetaxel|
139359|NCT03100838|Drug|Nifedipine 60 MG Extended Release Oral Tablet|Test Drug (Generic)
139360|NCT03100838|Drug|omeprazole/sodium bicarbonate|Proton Pump Inhibitor/Antacid for drug-drug interaction
139361|NCT03100838|Device|SmartPill (TM)|Gastric pH measurement using SmartPill (TM) Technology
139362|NCT03100825|Drug|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
139363|NCT03100812|Behavioral|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
139364|NCT03100812|Behavioral|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
139365|NCT03100799|Procedure|Arthroscopy|Arthroscopy of the target knee
139366|NCT03100799|Procedure|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
139367|NCT03100799|Diagnostic Test|MRI|MRI with and without a gadolinium-based contrast agent
139368|NCT03100786|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
139369|NCT03100786|Other|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
139370|NCT03100773|Other|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
139371|NCT03100773|Procedure|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
139372|NCT03100747|Procedure|Bilamellar 3 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3 mm from the eyelid margin
139373|NCT03100747|Procedure|Bilamellar 5 mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5 mm from the eyelid margin
139374|NCT03100747|Procedure|Trabut 3 mm|Trichiasis surgery using Trabut procedure with incision 3 mm from the eyelid margin
139375|NCT03100734|Biological|Benepali|As specified in the treatment arm
139376|NCT03100734|Biological|Enbrel|As specified in the treatment arm
139377|NCT03100721|Behavioral|PNE+Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
139378|NCT03100721|Procedure|Physiotherapy|Physiotherapy cover kinesitherapy and exercises techniques.
139379|NCT03100708|Procedure|PIPAC|"Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.~Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.~The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
139380|NCT03100695|Other|Concentrated autologous PRP-BMA|Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
139381|NCT03100669|Procedure|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
139382|NCT03100656|Other|A breakfast sandwich|A meat-based breakfast sandwich
139383|NCT03100643|Other|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
139384|NCT03100630|Drug|RO7239361|Specified dose on specified days
139385|NCT03100617|Behavioral|Psychosocial caregiver intervention|Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
139386|NCT03100604|Drug|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
139387|NCT03100604|Drug|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
139388|NCT03100591|Drug|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie [μCi]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
139389|NCT03100578|Device|WOPN TRANSMURAL DRAINAGE: PLASTIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a plastic double pigtail, 5-10 cm in length, diameters 7-8,5-10 Fr. Minimum one 10 Fr prosthesis.~Arm associated: PLASTIC STENT"
139455|NCT03100032|Procedure|Standard of Care|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
139456|NCT03100019|Dietary Supplement|Resveratrol|
139457|NCT03100019|Drug|Placebo|
139458|NCT03100006|Drug|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
139459|NCT03100006|Drug|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
139390|NCT03100578|Device|WOPN TRANSMURAL DRAINAGE: METALLIC STENT|"Endoscopic ultrasound-guided transmural drainage of walled-off pancreatic necrosis:~The pancreatic collection will be located with the linear echoendoscope, and we will proceed to choose an optimal area to perform the puncture guided by EUS; with the absence of intervening vessels.~This collection will be punctured with a 19 G needle or with an electrocautery device directly. Guidance will be advanced through the needle and the ostomy will proceed according to the routine of the experienced endoscopist.~Placement of a metal self-expanding fully covered luminal apposition stent: 10, 15 or 20 mm diameter.~Arm associated: SELF EXPANDABLE METALLIC STENT"
139391|NCT03100565|Drug|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
139392|NCT03100565|Other|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
139393|NCT03100552|Diagnostic Test|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
139394|NCT03100539|Other|Care giver treatment|"The caregiver -assisted massage (CG-M) intervention will consist of 3 treatment components:~An in-person training workshop~An instructional DVD recording to reinforce concepts taught during the in-person training session~A written treatment manual with illustrations and images to serve as a reference for participants.~Participants will be asked to engage in at least 3 care giver-assisted massage sessions (30 minutes each) every week at home for the 3-month intervention period. To standardize delivery and facilitate reproducibility of CG-M, the content and general structure of the caregiver-delivered massage routine is established and will be taught during the training workshop"
139395|NCT03100539|Other|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
139396|NCT03100526|Behavioral|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.~Goal:~Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients~Improve Veteran and staff satisfaction~Objectives:~Maintain the patient in the home setting as much as possible~Secure appropriate home environment to facilitate health and well-being~Utilize comprehensive team-based care~Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
139397|NCT03100513|Drug|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
139398|NCT03100513|Drug|Polyethylene Glycol|PEG as single dose of (3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
139399|NCT03100500|Drug|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
139400|NCT03100487|Device|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
139401|NCT03100461|Other|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
139402|NCT03100461|Other|Health Education|Standard of care approach that will provide basic information on CRC screening.
139403|NCT03100448|Device|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
139404|NCT03100435|Device|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
139405|NCT03100435|Other|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
139406|NCT03100422|Device|ARMin|arm therapy robot
139407|NCT03100422|Other|Occupational Therapy|bilateral arm training
139408|NCT03100409|Other|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).~Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.~No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.~Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.~Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
139409|NCT03100370|Device|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device.
139410|NCT03100370|Device|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device.
139411|NCT03100370|Device|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device.
139412|NCT03100357|Other|Thyroidectomy|Thyroid surgery for benign nodular goiter
139413|NCT03100344|Drug|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
139414|NCT03100344|Drug|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
139415|NCT03100331|Other|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
139416|NCT03100318|Drug|FYU-981|Oral daily dosing for 14 weeks
139417|NCT03100318|Drug|Benzbromarone|Oral daily dosing for 14 weeks
139418|NCT03100305|Other|Collection of blood and urine|Collection of blood and urine before nutritional support, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
164414|NCT02915744|Drug|Nab-paclitaxel|
139420|NCT03100279|Behavioral|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, & Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
139421|NCT03100279|Behavioral|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
139422|NCT03100266|Dietary Supplement|Probiotic|Lactobacillus rhamonosus GG
139423|NCT03100266|Other|Inactive capsules|Placebo
139424|NCT03100253|Drug|Tocilizumab|8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
139425|NCT03100253|Drug|Etanercept|a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab
139426|NCT03100253|Drug|Infliximab|infliximab if initial failure to the receptor fusion protein, etanercept.
139427|NCT03100253|Drug|Adalimumab|adalimumab if initial failure to the receptor fusion protein, etanercept.
139428|NCT03100253|Drug|Golimumab|golimumab if initial failure to the receptor fusion protein, etanercept.
139429|NCT03100253|Drug|Certolizumab Pegol|Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
139430|NCT03100240|Procedure|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
139431|NCT03100227|Other|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
139432|NCT03100227|Other|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
139433|NCT03100214|Other|Exercise|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
139434|NCT03100214|Other|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
139435|NCT03100201|Other|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
139436|NCT03100201|Other|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
139437|NCT03100188|Other|modified PD prescription|For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
139438|NCT03100175|Behavioral|physiotherapy|strength training for upper and lower limbs fitness and balance work out
139439|NCT03100162|Dietary Supplement|Probiotic|
139440|NCT03100162|Dietary Supplement|Placebo|
139441|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (<) 65 kg.
139442|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
139443|NCT03100149|Drug|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
139444|NCT03100136|Drug|[11C]PF-06809247|PET Tracer
139445|NCT03100123|Drug|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
139446|NCT03100123|Drug|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
139447|NCT03100110|Device|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
139448|NCT03100097|Device|Aspen Horizon 627 LSO|
139449|NCT03100084|Other|Blood sampling|Maternal blood sampling
139450|NCT03100071|Drug|Apixaban|Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
139451|NCT03100058|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
139452|NCT03100058|Drug|Placebo|Placebo
139453|NCT03100045|Drug|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
139454|NCT03100032|Biological|NVD-001|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
139460|NCT03099993|Other|Measurement of maximal forces of elbow pronosupination and flexion-extension|Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
139461|NCT03099980|Biological|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
139462|NCT03099967|Device|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
139463|NCT03099941|Other|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
139464|NCT03099915|Other|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
139465|NCT03099902|Diagnostic Test|Lung function|Spirometry test
139466|NCT03099902|Diagnostic Test|White blood cell DNA extraction|GSTP1 and TNFa polymorphisms with PCR
139467|NCT03099902|Diagnostic Test|Urinary testing|Urinary nicotine and cotinine detection
139468|NCT03099889|Behavioral|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
139469|NCT03099876|Procedure|treatment period|7 days treatment or 10 days treatment
139470|NCT03099863|Drug|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
139471|NCT03099863|Procedure|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
139472|NCT03099863|Drug|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
139473|NCT03099850|Other|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.
139474|NCT03099824|Drug|GC4711 Oral Capsule G-101|82 mg (1 capsule)
139475|NCT03099824|Drug|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
139476|NCT03099824|Drug|GC4711 Oral Capsule G-101|164 mg (2 capsules)
139477|NCT03099824|Drug|GC4711 Oral Capsule G-101|246 mg (3 capsules)
139478|NCT03099824|Drug|GC4711 Oral Capsule G-111|175 mg (1 capsule)
139479|NCT03099824|Drug|GC4711 Oral Capsule G-112|145 mg (1 capsule)
139480|NCT03099824|Drug|GC4711 Oral Capsule G-119|233 mg (1 capsule)
139481|NCT03099824|Drug|GC4711 Oral Capsule G-125|233 mg (1 capsule)
139482|NCT03099824|Drug|IV GC4711|GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
139483|NCT03099811|Behavioral|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
139484|NCT03099811|Behavioral|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
139485|NCT03099798|Other|Questionnaires|"All patients will complete a number of questionnaires at different time points.~SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ~1 week, 1 month, 3, 6 and 12 months after treatment"
139486|NCT03099798|Diagnostic Test|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
139487|NCT03099785|Drug|Rifamycin SV 600mg t.i.d.|Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
139488|NCT03099785|Drug|Rifamycin SV b.i.d. + Placebo|Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
139489|NCT03099785|Drug|Placebo t.i.d.|Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
139490|NCT03099772|Behavioral|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
139491|NCT03099759|Dietary Supplement|Vitamin D|Vitamin D2/D3
139492|NCT03099746|Behavioral|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
139493|NCT03099746|Behavioral|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
139494|NCT03099746|Behavioral|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
139495|NCT03099733|Other|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
139496|NCT03099720|Drug|Ropivacaine|local anesthetic will be given locally at the site of operation to decrease the level of pain after operation
139497|NCT03099720|Drug|Placebo|placebo fluid will be given at the site of operation locally
139498|NCT03099707|Behavioral|Treatment Ambassador|"This multi-component intervention, titled the Treatment Ambassador Program, will target people living with HIV who have not initiated ART within 3 months of testing positive. Our intervention will last for 8 sessions over 8-14 weeks, and will aim to address the three steams of influences on decision-making through a system of patient navigation and support with an assigned partner living with HIV who is trained in motivational interviewing. It will be aimed at addressing barriers to ART initiation identified through our prior qualitative research, as framed through the Theory of Triadic Influence, by addressing the three streams of influences on decision-making through a system of patient navigation and support."
139556|NCT03099304|Drug|Ruxolitinib cream|Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
139499|NCT03099694|Procedure|noninvasive high-frequency ventilation (nHFOV)|NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.
139500|NCT03099694|Procedure|nasal continuous positive airway pressure (nCPAP)|Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)
139501|NCT03099681|Other|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
139502|NCT03099668|Other|Visit to a multidisciplinary clinic|Visit to a multidisciplinary clinic
139503|NCT03099655|Device|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
139504|NCT03099642|Radiation|ultrasound-assisted lumbar puncture|The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
139505|NCT03099629|Behavioral|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
139506|NCT03099616|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
139507|NCT03099616|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
139508|NCT03099603|Drug|HTD1801|A small molecular compound for the treatment of primary sclerosing cholangitis
139509|NCT03099590|Dietary Supplement|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
139510|NCT03099590|Dietary Supplement|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
139511|NCT03099577|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
139512|NCT03099577|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
139513|NCT03099577|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
139514|NCT03099577|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
139515|NCT03099577|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
139516|NCT03099577|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
139517|NCT03099577|Radiation|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
139518|NCT03099564|Drug|Pembrolizumab|pembrolizumab 200mg IV every three weeks
139519|NCT03099564|Device|Y90 radioembolization|The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
139520|NCT03099551|Device|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
139521|NCT03099551|Device|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
139522|NCT03099538|Drug|Ixekizumab|Subcutaneous injection
139523|NCT03099525|Other|ILD|This is an observational study without any intervention.
139524|NCT03099512|Other|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
139525|NCT03099512|Other|Exercise|Exercises which improves muscle strength, ROM...
139526|NCT03099499|Drug|ONC201|ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
139527|NCT03099486|Drug|Regorafenib|The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
139528|NCT03099486|Drug|5-FU|5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
139529|NCT03099486|Drug|Leucovorin|D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
139555|NCT03099317|Other|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
168033|NCT02886793|Drug|fludeoxyglucose|
139530|NCT03099473|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
139531|NCT03099473|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
139532|NCT03099473|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
139533|NCT03099460|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
139534|NCT03099460|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
139535|NCT03099460|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
139536|NCT03099447|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
139537|NCT03099447|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
139538|NCT03099447|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
139539|NCT03099434|Behavioral|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
139540|NCT03099434|Behavioral|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
139541|NCT03099421|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
139542|NCT03099408|Drug|Metronidazole Oral|Oral metronidazole 400 mg BID for 7 days at first month.
139543|NCT03099408|Drug|"Metronidazole and Lactobacillus"|Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
139544|NCT03099382|Biological|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
139545|NCT03099382|Drug|Docetaxel|Subjects receive Docetaxel intravenous at the dose 75mg/m2 on Day 1 every 3 weeks
139546|NCT03099382|Drug|Irinotecan|Subjects receive Irinotecan intravenous at the dose 180mg/m2 on Day 1 every 2 weeks
139547|NCT03099369|Behavioral|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
139548|NCT03099369|Behavioral|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
139549|NCT03099369|Other|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
139550|NCT03099356|Drug|Cyclophosphamide|Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
139551|NCT03099356|Drug|Sirolimus|Sirolimus 4 mg, PO, days 1-28
139552|NCT03099343|Behavioral|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
139553|NCT03099330|Drug|TQ-B3139|TQ-B3139 p.o. qd
139554|NCT03099317|Other|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
139557|NCT03099304|Drug|Vehicle cream|Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
139558|NCT03099291|Biological|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
139559|NCT03099291|Biological|Placebo|Administered as nose drops
139560|NCT03099278|Drug|Ezetimibe|Ezetimibe 20 mg oral daily
139561|NCT03099265|Drug|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
139562|NCT03099265|Drug|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
139563|NCT03099252|Other|Parent-targeted BSweet2Babies video|The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
139564|NCT03099252|Other|HCP-targeted resources|"publically-available poster developed jointly by the study CoPIs and BFI Ontario~the publically-available webinar presented by the CoPIs"
139565|NCT03099239|Biological|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
139566|NCT03099226|Drug|Placebo|Placebo blue hard gelatine capsules
139567|NCT03099226|Drug|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
139568|NCT03099213|Drug|RAMIPRIL HOE498|Pharmaceutical form:Tablet Route of administration: Oral
139569|NCT03099200|Other|No Intervention|
139570|NCT03099187|Drug|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
139571|NCT03099187|Drug|Placebo|Matching placebo capsules three times in a day.
139572|NCT03099174|Drug|Xentuzumab|Once weekly administrated through one hour intravenous infusion
139573|NCT03099174|Drug|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (Starting dose Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
139574|NCT03099174|Drug|Letrozole|once a day
139575|NCT03099174|Drug|Anastrozole|once a day
139576|NCT03099174|Drug|Fulvestrant|once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
139577|NCT03099161|Drug|preladenant|Administered as an oral capsule BID on Days 1 through 21 of each 21-day cycle
139578|NCT03099161|Biological|pembrolizumab|Administered as IV infusion on Day 1 of each 21-day cycle
139579|NCT03099148|Drug|LY3337641 (R)|Administered orally
139580|NCT03099148|Drug|LY3337641 (T1)|Administered orally
139581|NCT03099148|Drug|LY3337641 (T2)|Administered orally
139582|NCT03099135|Drug|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
139583|NCT03099122|Biological|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder~Route of administration: intravenous"
139584|NCT03099122|Drug|Tacrolimus|"Pharmaceutical form: tablet~Route of administration: oral"
139585|NCT03099122|Drug|Methylprednisolone|"Pharmaceutical form: powder~Route of administration: intravenous"
139586|NCT03099122|Drug|Mycophenolate mofetil|"Pharmaceutical form: capsule~Route of administration: oral"
139587|NCT03099122|Drug|Mycophenolate Na|"Pharmaceutical form: capsule~Route of administration: oral"
139588|NCT03099122|Drug|prednisone|"Pharmaceutical form: tablet~Route of administration: oral"
139589|NCT03099109|Drug|LY3321367|Administered IV
139590|NCT03099109|Drug|LY3300054|Administered IV
139591|NCT03099096|Drug|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
139592|NCT03099070|Behavioral|Stress|Trier Social Stress Test
139593|NCT03099070|Other|Fasting|12-hour fasting prior to study visit
139594|NCT03099057|Other|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
139595|NCT03099044|Other|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
139596|NCT03099044|Other|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
139597|NCT03099044|Other|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
139598|NCT03099031|Drug|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
139599|NCT03099018|Diagnostic Test|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
139600|NCT03099005|Drug|Cannabis|vaporization of cannabis
139601|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
139602|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
139603|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
141783|NCT03082742|Drug|Hydrochlorothiazide|
139604|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
139605|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
139606|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
139607|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
139608|NCT03098979|Drug|Placebo|Orally once daily for 20 weeks
139609|NCT03098953|Drug|Loteprednol Etabonate|one drop per eye for each eye
139610|NCT03098940|Drug|Chewing Gum|During the study healthy subjects will receive single doses of the various strengths of dronabinol
139611|NCT03098927|Behavioral|Motor imagery training|Motor imagery training
139612|NCT03098914|Other|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
139613|NCT03098901|Diagnostic Test|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
139614|NCT03098888|Procedure|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
139615|NCT03098875|Drug|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
139616|NCT03098875|Drug|Propofol|General anesthesia using propofol as a hypnotic agent
139617|NCT03098875|Drug|Remifentanil|General anesthesia using remifentanil as an analgesic.
139618|NCT03098849|Other|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
139619|NCT03098836|Drug|ARN-509|240 mg orally daily
139620|NCT03098836|Drug|Abiraterone Acetate|1000 mg orally daily
139621|NCT03098836|Drug|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
139622|NCT03098823|Drug|RAYOS|FDA approved RAYOS for indication of fatigue in Lupus.
139623|NCT03098823|Drug|Prednisone|FDA approved corticosteroid frequently used for SLE.
139624|NCT03098810|Drug|Zinc sulphate|Oral syrup zinc sulphate
139625|NCT03098810|Other|Placebo|Oral syrup placebo
139626|NCT03098797|Drug|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
139627|NCT03098784|Other|Exposure to aircraft exhaust|The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. These people are subject to direct exposure to exhaust from aircraft engines.
139628|NCT03098784|Other|Non exposure to aircraft exhaust|The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. These people are not subject to direct exposure to exhaust from aircraft engines.
139629|NCT03098771|Procedure|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
139630|NCT03098771|Drug|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
139631|NCT03098745|Device|Omafilcon A|contact lens
139632|NCT03098745|Device|Somofilcon A|contact lens
139633|NCT03098745|Device|Omafilcon A - Proclear (PC)|contact lens
139634|NCT03098732|Device|Magnetically Enhanced Diffusion (MED)|Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
139635|NCT03098732|Device|MED Workstation Magnet Sham Control|Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
139636|NCT03098719|Behavioral|Active Mobility|see detailed discription
139637|NCT03098706|Procedure|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
139638|NCT03098706|Procedure|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
139639|NCT03098693|Behavioral|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
139640|NCT03098693|Behavioral|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
139641|NCT03098693|Behavioral|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
139642|NCT03098680|Drug|Albuterol Sulfate|see arm/group descriptions
139643|NCT03098680|Drug|Nicardipine Hydrochloride|see arm/group descriptions
139644|NCT03098680|Drug|Dobutamine Hydrochloride|see arm/group descriptions
139645|NCT03098680|Drug|Phenylephrine Hydrochloride|see arm/group descriptions
139646|NCT03098680|Drug|Verapamil Hydrochloride|see arm/group descriptions
139647|NCT03098680|Drug|Phentolamine Mesylate|see arm/group descriptions
139648|NCT03098680|Drug|Placebo|see arm/group descriptions
139649|NCT03098667|Device|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
141784|NCT03082742|Drug|Furosemide|
139650|NCT03098667|Device|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
139651|NCT03098654|Diagnostic Test|Blood glucose and blood pressure testing|Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
139652|NCT03098654|Behavioral|Diet and lifestyle counseling|All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
139653|NCT03098654|Drug|DM/HTN medications as needed|Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
139654|NCT03098641|Procedure|pelvic organ prolapse repair|Surgery to repair pelvic organ prolapse through the vagina using stitches with the addition of surgical mesh.
139655|NCT03098628|Biological|PCV Vaccine|PCV vaccination
139656|NCT03098615|Drug|Jublia (Efinaconazole 10% Topical Solution)|Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
139657|NCT03098589|Drug|Revlimid|Revlimid
139658|NCT03098576|Other|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
139659|NCT03098576|Other|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
139660|NCT03098563|Drug|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
139661|NCT03098550|Biological|Nivolumab|Specified dose on specified days
139662|NCT03098550|Biological|Daratumumab|Specified dose on specified days
139663|NCT03098537|Drug|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
139664|NCT03098537|Other|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
139665|NCT03098524|Procedure|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
139666|NCT03098524|Procedure|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
139667|NCT03098524|Procedure|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
139668|NCT03098511|Diagnostic Test|Neurological Diagnostic Evaluation|"Clinical Data:~Demographic data~Daily data (clinical exams, laboratory data)~Drug administration~Additional clinical or ancillary neurological determination test~Diagnostic Intervention:~CT-Perfusion~CT-Angiography reconstructions~Reference Standard:~- Clinical Neurological Exam~Blood Samples (Pharmacokinetics, Inflammatory & Nanovesicles Parameters):~At the time of patient enrolment~6 hours after patient enrolment~At the time of the clinical neurological exam~Secondary Outcome measures at 6 months:~extended Glasgow Outcome Scale (GOSe)~modified Rankin Scale (mRS)"
139669|NCT03098498|Procedure|Subgingival Debridement|Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
139670|NCT03098485|Drug|Levofloxacin|5 days of levofloxacin administration
139671|NCT03098485|Drug|Azithromycin|5 days of azithromycin administration
139672|NCT03098485|Drug|Cefpodoxime|5 days of cefpodoxime administration
139673|NCT03098459|Other|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
139674|NCT03098446|Behavioral|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
139675|NCT03098446|Behavioral|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
139676|NCT03098433|Drug|Liothyronine|Single dose
139677|NCT03098433|Drug|Levothyroxine|Active comparator
139678|NCT03098433|Drug|Placebos|Placebo
139679|NCT03098420|Drug|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
139680|NCT03098420|Drug|4mg Dexamethasone|1 mL (4mg) of dexamethasone
139681|NCT03098420|Drug|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
139682|NCT03098420|Drug|Morphine|
139683|NCT03098420|Drug|Bupivacaine Hydrochloride|
139684|NCT03098420|Drug|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
139685|NCT03098420|Drug|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
139686|NCT03098407|Drug|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
139687|NCT03098407|Drug|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
139688|NCT03098394|Device|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
139689|NCT03098394|Device|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
139690|NCT03098368|Drug|Rotigotine|
139691|NCT03098368|Drug|Placebo|Placebo of rotigotine patch
139692|NCT03098355|Biological|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
139693|NCT03098355|Drug|Interleukin-2|Interleukin-2 of 250,000iu/m^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
139694|NCT03098342|Procedure|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
139695|NCT03098342|Drug|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
139696|NCT03098329|Other|Ct/GC screening|Men aged 15-24 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
139697|NCT03098316|Diagnostic Test|Metabolomics analysis of patient samples|Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
139698|NCT03098290|Procedure|Catheter-based endovascular revascularization|(e.g. PTA-alone, Bare-Metal or Drug-Eluting-Stent, Covered Stent, Atherectomy, Mechanical Thrombectomy, Scoring Ballon, Cutting Ballon)
139699|NCT03098290|Procedure|Bypass-Surgery|Venous or alloplastic or comparable Bypass
139700|NCT03098290|Procedure|Endarterectomy|Endarterectomy, Patchplasty
139701|NCT03098277|Device|Accelerometer|Wear Microsoft Band 2
139702|NCT03098277|Other|Laboratory Biomarker Analysis|Correlative studies
139703|NCT03098277|Other|Physical Activity Measurement|Perform physical activities recorded by Microsoft Kinect 2
139704|NCT03098277|Behavioral|Telephone-Based Intervention|Complete PRO questionnaires
139705|NCT03098264|Procedure|Simultaneous surgery|Simultaneous surgery in complicated hepatolithiasis
139706|NCT03098264|Procedure|staged surgery|staged surgery in complicated hepatolithiasis
139707|NCT03098251|Procedure|3D typing|typing the patient with 3D typing system and give specific treatment
139708|NCT03098251|Procedure|routine typing|typing the patient with routine typing system and give specific treatment
139709|NCT03098238|Biological|Biological sample|Biological sampling of two citrate tubes (18 ml) during a normal blood
139710|NCT03098225|Radiation|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
139711|NCT03098225|Drug|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
139712|NCT03098212|Other|Aromatherapy|On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
139713|NCT03098199|Drug|300IU Gonal-F|<1.5 AMH group
139714|NCT03098199|Drug|150IU Menopur|<1.5 AMH group
139715|NCT03098199|Drug|225IU Gonal-F|1.6-2.5 AMH group
139716|NCT03098199|Drug|75IU Menopur|1.6-2.5 AMH group 2.6-6.9 AMH group >7.0 AMH group
139717|NCT03098199|Drug|150IU Gonal-F|2.6-6.9 AMH group
139718|NCT03098199|Drug|75IU Gonal-F|>7.0 AMH group
139719|NCT03098186|Behavioral|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
139720|NCT03098186|Behavioral|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
139721|NCT03098173|Procedure|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
139722|NCT03098173|Procedure|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
139723|NCT03098160|Drug|Evofosfamide|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
139724|NCT03098160|Drug|Ipilimumab|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
139725|NCT03098134|Behavioral|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
139726|NCT03098134|Other|Health Education|Video based health education covering common myths and false believes about dental surgeries
139727|NCT03098121|Drug|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir and elbasvir in a fixed-dose combination tablet once daily for 12 weeks.
139728|NCT03098108|Radiation|Concurrent chemo-proton therapy|Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
139729|NCT03098095|Behavioral|Physical Activity|Moderate physical activity
139730|NCT03098082|Device|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
139731|NCT03098056|Other|PROG2|"Nutritional Supplements to be administered:~Protein Shakes: one shake po twice daily~Phytosterol supplement: one capsule po twice daily~Cinnamon: one tablet twice daily~Fiber supplement; one shake twice daily~Antioxidant supplement: 2 capsules daily with dinner~Fish Oil supplement: 1 capsule twice daily with food~Probiotic supplement: 1 capsule twice daily with food"
139732|NCT03098030|Biological|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
139733|NCT03098030|Drug|Irinotecan|Irinotecan injection, IV infusion
139734|NCT03098030|Drug|Topotecan|Topotecan for injection
139735|NCT03098017|Other|Short pasta (dry)|50g available carbohydrate portion of penne (~71g uncooked) will be cooked according to package instructions and served with 500mL water
139736|NCT03098017|Other|Long pasta (dry)|50g available carbohydrate portion of spaghetti (~71g uncooked) will be cooked according to package instructions and served with 500mL water
139737|NCT03098017|Other|Couscous|50g available carbohydrate portion of couscous (~70g uncooked) will be cooked according to package instructions and served with 500mL water
139738|NCT03098017|Other|Glucose|50g available carbohydrate portion of glucose monohydrate (~55g) will be dissolved in 500mL water
139739|NCT03098004|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
139740|NCT03097991|Behavioral|Focused Coparenting Consultation|Six 90-minute sessions over 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
139741|NCT03097978|Device|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
139742|NCT03097978|Device|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
139743|NCT03097978|Other|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
139744|NCT03097978|Other|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
139745|NCT03097965|Dietary Supplement|PROGRAM|
139746|NCT03097965|Other|DIET|
139747|NCT03097939|Drug|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
139748|NCT03097939|Drug|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
139749|NCT03097926|Procedure|Long alimentary limb BPD-DS|BPD-DS with a long strict alimentary limb and a 100-cm common channel.
139750|NCT03097913|Device|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
139751|NCT03097900|Drug|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
139752|NCT03097900|Other|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
139753|NCT03097887|Procedure|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
139754|NCT03097887|Device|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
139755|NCT03097887|Device|V-Loc|Sewing device to perform the anti-reflux sutures.
139756|NCT03097874|Behavioral|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
139757|NCT03097874|Behavioral|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
139758|NCT03097861|Drug|Lubiprostone|24 mcg administered orally twice daily (BID)
139759|NCT03097861|Drug|Placebo|24 mcg administered orally twice daily (BID)
139760|NCT03097848|Procedure|RFA|for eligible cases, radiofrequency ablation will be given only.
139761|NCT03097848|Drug|Sorafenib|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
139762|NCT03097835|Drug|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
139763|NCT03097835|Drug|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
139764|NCT03097835|Other|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
139765|NCT03097809|Other|SEEG Recordings|To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
139766|NCT03097796|Drug|PUL-042|PUL-042 Inhalation Solution
139767|NCT03097783|Device|Restylane Perlane Lidocaine|Intradermal injection
139768|NCT03097770|Biological|anti-CD19/20-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
139769|NCT03097757|Diagnostic Test|Ultrasound|Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
168090|NCT02886299|Drug|Fenofibrate|
139770|NCT03097744|Device|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
139771|NCT03097705|Diagnostic Test|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
139772|NCT03097692|Procedure|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
139773|NCT03097692|Drug|Pharmacologic preconditionig|Pharmacologic preconditionig will be attained by sevoflurane anesthesia
139774|NCT03097679|Device|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
139775|NCT03097679|Device|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
139776|NCT03097666|Device|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
139777|NCT03097653|Other|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
139778|NCT03097653|Other|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
139779|NCT03097640|Other|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
139780|NCT03097627|Drug|ICG Intervention|The intervention to be administered is the drug indocyanine green.
139781|NCT03097627|Device|Near Infrared Camera|The intervention to detect the administered drug, indocyanine green.
139782|NCT03097614|Device|TrueTear|The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
139783|NCT03097601|Diagnostic Test|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
139784|NCT03097588|Drug|Netupitant|Given PO
139785|NCT03097588|Drug|Palonosetron Hydrochloride|Given PO
139786|NCT03097575|Drug|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
139787|NCT03097575|Device|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
139788|NCT03097562|Procedure|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
139789|NCT03097549|Device|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
139790|NCT03097549|Device|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
139791|NCT03097536|Other|Luna Bar|Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
139792|NCT03097523|Device|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
139793|NCT03097510|Behavioral|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
139794|NCT03097497|Other|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
139795|NCT03097497|Other|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
139796|NCT03097484|Drug|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
139797|NCT03097471|Device|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
139798|NCT03097458|Behavioral|Short-term Counselling for Families|Counselling for Families which can take up to 6 weeks, with regular meetings under the guidance of a trained psychotherapist.
139799|NCT03097445|Drug|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
139800|NCT03097432|Drug|ORALVAC COMPACT BÄUME|
139839|NCT03097120|Drug|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
168091|NCT02886299|Drug|Simvastatin|
139801|NCT03097419|Procedure|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.~The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.~The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.~Five (5) total iterations constitute the treatment.~The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
139802|NCT03097406|Procedure|Global Unite hemiarthroplasty|A hemiarthroplasty used for complex fractures of the proximal humerus.
139803|NCT03097406|Procedure|Global Advantage|A total shoulder prosthesis used for osteoarthritis
139804|NCT03097406|Procedure|Global FX|A hemiarthroplasty used for complex fractures of the proximal humerus.
139805|NCT03097406|Procedure|Global Unite total shoulder arthroplasty|A total shoulder prosthesis used for osteoarthritis
139806|NCT03097393|Diagnostic Test|measure Serum procalcitonin level|measuring procalcitonin level
139807|NCT03097380|Drug|AZD2115|AZD2115
139808|NCT03097380|Drug|SPIRIVA|Tiotropium
139809|NCT03097380|Radiation|[11C]AZ13754366|Radioligand
139810|NCT03097367|Diagnostic Test|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at <2 cm below SMSP, and Level -2: bladder neck at >2 cm below SMSP.
139811|NCT03097354|Other|no intervention/observational survey study design|no intervention/observational survey study design
139812|NCT03097341|Drug|xisomab 3G3- Dose 1|Participants will receive a single intravenous dose of 0.1 mg/kg xisomab 3G3.
139813|NCT03097341|Drug|xisomab 3G3-Dose 2|Participants will receive a single intravenous dose of 0.5 mg/kg xisomab 3G3.
139814|NCT03097341|Drug|xisomab 3G3-Dose 3|Participants will receive a single intravenous dose of 2.0 mg/kg xisomab 3G3.
139815|NCT03097341|Drug|xisomab 3G3- Dose 4|Participants will receive a single intravenous dose of 5.0 mg/kg xisomab 3G3.
139816|NCT03097341|Other|Placebo|Participants will receive a single intravenous dose of placebo.
139817|NCT03097328|Drug|TAK-228|TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
139818|NCT03097315|Combination Product|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 4 mg in 100 microliters, will be administered as a single injection at 2 timepoints
139819|NCT03097302|Procedure|Laser keratotomy|Penetrating femtosecond laser assisted keratotomy to treat preexisting corneal astigmatism during lens surgery.
139820|NCT03097289|Device|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
139821|NCT03097276|Procedure|blood simple|blood simple will be collected
139822|NCT03097276|Radiation|CT scan|CT scan
139823|NCT03097263|Other|Physical Rehabilitation program|
139824|NCT03097237|Other|Wholegrain rye|Cereal products based on wholegrain rye
139825|NCT03097237|Other|Refined wheat|Cereal products based on refined wheat
139826|NCT03097224|Behavioral|Prehabilitation|Four weeks of tele-supervised prehabilitation
139827|NCT03097211|Drug|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
139828|NCT03097211|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
139829|NCT03097211|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
139830|NCT03097211|Drug|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
139831|NCT03097198|Other|Plum-blossom Needle|"acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.~plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
139832|NCT03097198|Drug|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
139833|NCT03097159|Procedure|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
139834|NCT03097146|Other|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
139835|NCT03097133|Drug|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
139836|NCT03097133|Drug|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
139837|NCT03097133|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
139838|NCT03097120|Drug|0.625 mg of conjugated equine estrogen|one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
139841|NCT03097107|Drug|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
139842|NCT03097107|Drug|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
139843|NCT03097107|Drug|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
139844|NCT03097107|Drug|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
139845|NCT03097094|Diagnostic Test|Male dog|Male dog extract
139846|NCT03097094|Diagnostic Test|Female dog|Female dog extract
139847|NCT03097081|Other|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
139848|NCT03097081|Device|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
139849|NCT03097068|Drug|Lucentis|0.3mg Lucetnis
139850|NCT03097055|Procedure|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
139851|NCT03097055|Procedure|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
139852|NCT03097042|Procedure|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
139853|NCT03097042|Procedure|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
139854|NCT03097029|Drug|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
139855|NCT03097016|Drug|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
139856|NCT03097003|Drug|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
139857|NCT03096990|Drug|apremilast|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
139858|NCT03096977|Diagnostic Test|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
139859|NCT03096977|Device|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.~The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.~Verbal encouragement is given during four successive tentative: the last three are averaged.~Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
139860|NCT03096977|Device|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.~Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.~Repeat 3 times for each hand."
139861|NCT03096977|Device|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.~Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.~The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.~The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
139862|NCT03096977|Device|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.~The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.~To determine the discrimination threshold:~Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.~Perform the test 3 times."
139863|NCT03096964|Other|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
139864|NCT03096964|Other|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
139865|NCT03096951|Behavioral|Prehabilitation|Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
139866|NCT03096951|Other|Rehabilitation|Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
139867|NCT03096938|Diagnostic Test|methylation markers screening|Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis
139868|NCT03096925|Behavioral|Guided self-help|Web-based guided self-help intervention
139869|NCT03096912|Drug|Ribociclib|Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
139870|NCT03096899|Other|Observational|Best Supportive Care
139871|NCT03096886|Behavioral|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
168270|NCT02884921|Drug|Placebo|Placebo
139872|NCT03096873|Behavioral|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
139873|NCT03096860|Other|Active alcohol consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
139874|NCT03096860|Other|Placebo consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
139875|NCT03096847|Drug|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer will be treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
139876|NCT03096847|Drug|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer will be treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
139877|NCT03096847|Drug|goserelin|Premenopausal patients will additionally receive goserelin 3.6mg as monthly implant
139878|NCT03096834|Biological|AMG334 Pre-Filled Syringe (PFS)|subcutaneous injection of AMG 334
139879|NCT03096834|Biological|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of placebo
139880|NCT03096821|Drug|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
139881|NCT03096808|Radiation|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
139882|NCT03096795|Drug|MEDI3506|"Single doses of MEDI3506 for SAD and J-SD Cohorts~Multiple doses of MEDI3506 for MAD Cohorts"
139883|NCT03096795|Drug|placebo|"Single doses of placebo for SAD and J-SD Cohorts~Multiple doses of placebo for MAD Cohorts"
139884|NCT03096782|Biological|Anti-Thymocyte Globulin|Given IV
139885|NCT03096782|Drug|Busulfan|Given IV
139886|NCT03096782|Drug|Clofarabine|Given IV
139887|NCT03096782|Drug|Cyclophosphamide|Given IV
139888|NCT03096782|Biological|Filgrastim-sndz|Given SC
139889|NCT03096782|Drug|Fludarabine|Given IV
139890|NCT03096782|Drug|Melphalan|Given IV
139891|NCT03096782|Drug|Mycophenolate Mofetil|Given IV or PO
139892|NCT03096782|Biological|Rituximab|Given IV
139893|NCT03096782|Drug|Tacrolimus|Given IV
139894|NCT03096782|Radiation|Total-Body Irradiation|Undergo total body irradiation
139895|NCT03096782|Procedure|Umbilical Cord Blood Transplantation|Undergo cord blood transplant
139896|NCT03096769|Other|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
139897|NCT03096756|Drug|GC4702 dry powder|5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
139898|NCT03096756|Drug|GC4702 lipid suspension|112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
139899|NCT03096756|Other|GC4419 IV|infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.
139900|NCT03096756|Other|Placebo Dry Powder|Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
139901|NCT03096756|Other|Placebo lipid suspension|Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
139902|NCT03096756|Other|Fed Condition|with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.
139903|NCT03096756|Other|Fasting Condition|For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
139904|NCT03096756|Drug|GC4702 lipid suspension - Part 2|Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
139905|NCT03096743|Radiation|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
139906|NCT03096743|Radiation|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
139907|NCT03096743|Procedure|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
139908|NCT03096743|Other|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
141843|NCT03082209|Drug|Bevacizumab|IV infusion
139909|NCT03096743|Radiation|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
139910|NCT03096730|Drug|Normal saline|Normal saline is intravenously administrated before anesthesia induction
139911|NCT03096730|Drug|Remifentanil|Remifentanil is intravenously administrated
139912|NCT03096730|Drug|Sufentanil|Sufentanil is intravenously administrated
139913|NCT03096730|Drug|Dexmedetomidine|Dexmedetomidine is intravenously administrated before anesthesia induction
139914|NCT03096730|Drug|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
139915|NCT03096717|Diagnostic Test|colonoscopy and histology|colonic biopsies for detection of dysplasia
139916|NCT03096704|Diagnostic Test|vitamine d dosage|dosage of vitamine D in slow transit time constipation
139917|NCT03096691|Device|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
139918|NCT03096678|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
139919|NCT03096665|Diagnostic Test|blood test|Point of care blood analysis obtained from skin puncture
139920|NCT03096652|Procedure|Approach for cancer resection|
139921|NCT03096639|Device|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
139922|NCT03096613|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
139923|NCT03096587|Device|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
139924|NCT03096587|Device|ultrasonic activated irrigation|by Satelec,Acteon, France
139925|NCT03096574|Other|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 5-10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
139926|NCT03096561|Diagnostic Test|blood draw from three different vessels|Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
139927|NCT03096548|Behavioral|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
139928|NCT03096548|Behavioral|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
139929|NCT03096535|Procedure|Cooling|Individualized cooling protocol.
139930|NCT03096535|Procedure|Thermoneutral|Thermoneutral control day.
139931|NCT03096522|Drug|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
139932|NCT03096522|Procedure|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
139933|NCT03096509|Other|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
139934|NCT03096496|Other|QoL questionnaires|Quality of life questionnaires
139935|NCT03096483|Device|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
139936|NCT03096470|Procedure|anesthesia|no anesthesia
139937|NCT03096457|Drug|Paromomycin Sulfate|topical application 2 times a day during 20 days
139938|NCT03096457|Drug|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
139939|NCT03096457|Other|Placebo|topical application 2 times a day during 20 days
139940|NCT03096444|Drug|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
139941|NCT03096444|Drug|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
139942|NCT03096444|Drug|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
139943|NCT03096444|Combination Product|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
139944|NCT03096444|Drug|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
139945|NCT03096431|Behavioral|Physical Activity|"Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.~One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
139946|NCT03096431|Behavioral|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
139947|NCT03096418|Drug|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
139948|NCT03096405|Diagnostic Test|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
139949|NCT03096392|Drug|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
139950|NCT03096392|Drug|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
139951|NCT03096379|Diagnostic Test|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
139952|NCT03096366|Device|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
139953|NCT03096366|Other|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
139954|NCT03096353|Other|Placebo|saline
139955|NCT03096353|Drug|Naloxone|We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
139956|NCT03096340|Drug|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
139957|NCT03096327|Drug|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
139958|NCT03096327|Drug|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
139959|NCT03096314|Drug|Vitamin D3|540,000 IU vitamin D3
139960|NCT03096314|Drug|Placebo|A single, liquid enteral dose administered either orally or via naso/orogastric tube
139961|NCT03096301|Device|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
139962|NCT03096301|Device|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).~Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.~Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
139963|NCT03096301|Device|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
139964|NCT03096288|Drug|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
139965|NCT03096288|Other|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
139966|NCT03096275|Drug|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
139967|NCT03096275|Drug|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
139968|NCT03096275|Drug|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
139969|NCT03096275|Drug|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
139970|NCT03096275|Drug|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
139971|NCT03096262|Behavioral|Output-Focus Condition|Users are asked to tag more, and force feedback is exerted the more points the user has
139972|NCT03096262|Behavioral|Input-Focus Condition|Users are asked to tag more and force feedback is exerted based on the number of images the user has analyzed.
139973|NCT03096249|Drug|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
139974|NCT03096249|Other|Placebo|Placebo spray: single dose (3 puffs per nostril).
139975|NCT03096236|Device|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
139976|NCT03096223|Drug|KHK4083|IV administration
139977|NCT03096210|Procedure|Titanium-Prepared Platelet Rich Fibrin|Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
139978|NCT03096210|Procedure|Allograft|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
139979|NCT03096197|Device|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
139980|NCT03096197|Device|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
139981|NCT03096184|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
139982|NCT03096184|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
139983|NCT03096171|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
140015|NCT03095872|Device|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
140278|NCT03094247|Dietary Supplement|D-HO-RUTF|D-HO-RUTF: DHA, milk, linseed oil, palm oil, white sugar, high oleic peanuts
168334|NCT02884336|Other|No intervention|
139984|NCT03096158|Other|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:~The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
139985|NCT03096158|Other|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:~It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
139986|NCT03096158|Other|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:~Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
139987|NCT03096145|Behavioral|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
139988|NCT03096145|Behavioral|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
139989|NCT03096145|Behavioral|Health incentive|Smokers receive a $25 gift card if they call the quitline
139990|NCT03096132|Behavioral|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
139991|NCT03096132|Behavioral|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
139992|NCT03096119|Other|home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.
139993|NCT03096093|Biological|ACIT-1|Cell suspension
139994|NCT03096080|Drug|Tesevatinib|One dose of the study drug in liquid form
139995|NCT03096067|Other|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
139996|NCT03096067|Other|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
139997|NCT03096054|Drug|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
139998|NCT03096041|Device|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
139999|NCT03096041|Device|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
140000|NCT03096028|Other|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18&28 weeks of pregnancy is the primary exposure of interest
140001|NCT03096015|Behavioral|Intensive Comprehensive Aphasia Program|
140002|NCT03096002|Behavioral|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
140003|NCT03095989|Behavioral|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
140004|NCT03095976|Procedure|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
140005|NCT03095963|Other|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
140006|NCT03095963|Drug|levothyroxin|replacement therapy for hypothyroidism
140007|NCT03095950|Other|News items with spin|Interpretation of news items with spin
140008|NCT03095950|Other|News items without spin|Interpretation of news items without spin
140009|NCT03095924|Other|News items with spin|Interpretation of news items with spin
140010|NCT03095924|Other|News items without spin|Interpretation of news items without spin
140011|NCT03095911|Other|News items with spin|Interpretation of news items with spin
140012|NCT03095911|Other|News items without spin|Interpretation of news items without spin
140013|NCT03095898|Device|Electroacupuncture|Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
140014|NCT03095885|Other|Oxalate-rich Test Meal|
140016|NCT03095872|Drug|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
140017|NCT03095872|Drug|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
140018|NCT03095859|Other|Physical rehabilitation.|Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
140019|NCT03095846|Procedure|Cooling|Individualized cooling protocol
140020|NCT03095833|Other|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.~In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
140021|NCT03095833|Other|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
140022|NCT03095833|Other|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
140023|NCT03095833|Other|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
140024|NCT03095833|Other|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
140025|NCT03095833|Other|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
140026|NCT03095833|Other|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
140027|NCT03095833|Other|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
140028|NCT03095833|Other|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
140029|NCT03095833|Other|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
140030|NCT03095833|Other|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
140031|NCT03095820|Behavioral|Supportive therapy|
140032|NCT03095820|Behavioral|Multidomain intervention|
140033|NCT03095807|Drug|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
140034|NCT03095807|Drug|Placebo|Administered subcutaneously (s.c., under the skin)
140035|NCT03095794|Other|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
140036|NCT03095794|Other|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
140114|NCT03095339|Other|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
140115|NCT03095326|Dietary Supplement|Zinc|formula of ZnSO4, usually used to treat zinc deficiency.
140037|NCT03095794|Other|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
140038|NCT03095794|Other|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
140039|NCT03095781|Drug|XL888|Given PO
140040|NCT03095781|Biological|Pembrolizumab|Given IV
140041|NCT03095768|Other|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
140042|NCT03095755|Other|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
140043|NCT03095755|Other|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
140044|NCT03095742|Diagnostic Test|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
140045|NCT03095742|Diagnostic Test|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
140046|NCT03095729|Other|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
140047|NCT03095716|Other|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
140048|NCT03095703|Drug|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
140049|NCT03095690|Other|High resolution peripheral scanner (HRpQCT).|radius and tibia osteodensitometry measurement
140050|NCT03095677|Other|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
140051|NCT03095677|Other|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
140052|NCT03095664|Behavioral|Intervention group|A behavior change program with 4 monthly 90-min sessions about healthy eating and physical activity.
140053|NCT03095651|Biological|MK-5160 16 nmol/kg|MK-5160 16 nmol/kg, subcutaneous injection administered daily for 12 days
140054|NCT03095651|Biological|MK-5160 32 nmol/kg|MK-5160 32 nmol/kg, subcutaneous injection administered daily for 12 days
140055|NCT03095651|Biological|MK-5160 64 nmol/kg|MK-5160 64 nmol/kg, subcutaneous injection administered daily for 12 days
140056|NCT03095651|Biological|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous injection administered daily for 12 days
140057|NCT03095651|Biological|Placebo to Glargine|Placebo to glargine, subcutaneous injection administered daily for 12 days
140058|NCT03095651|Biological|Placebo to MK-5160|Placebo to MK-5160, subcutaneous injection administered daily for 12 days
140059|NCT03095651|Drug|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
140060|NCT03095651|Biological|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous injection administered daily for 12 days
140061|NCT03095638|Drug|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
140062|NCT03095638|Drug|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
140063|NCT03095638|Drug|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
140064|NCT03095638|Drug|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
140065|NCT03095612|Drug|Selinexor|Oral XPO1 inhibitor selinexor (KPT-330) in combination with Docetaxel
140066|NCT03095599|Biological|IVACFLU-S|"IVACFLU-S is seasonal inactivated, split virion, trivalent influenza vaccine (A/H3N2, A/H1N1, and B), produced in GCP facility by IVAC uses embryonated chicken eggs. This vaccine is purified by sucrose gradient ultracentrifugation (Alfa Wassermann, West Caldwell, NJ), and inactivated with formaldehyde. Each 0.5 mL dose of vaccine contains~NYMC X-179A (A/California/7/2009) (H1N1) - 15μg hemagglutinin (HA)~NYMC X-263B (A/HongKong/4801/2014) (H3N2) - 15μg HA~NYMC BX-35 (B/Brisbane/60/2008) (B) - 15μg HA"
140067|NCT03095599|Other|Placebo|Phosphate buffered saline with pH 7.2; 0.5 ml/per dose
140068|NCT03095586|Other|News items with spin|Interpretation of news items with spin
140069|NCT03095586|Other|News items without spin|Interpretation of news items without spin
140070|NCT03095573|Device|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
140071|NCT03095573|Device|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
140116|NCT03095326|Drug|Sucrose|Placebo of sucrose syrup
140117|NCT03095326|Biological|PCV Vaccine|Pneumococcal conjugate vaccine
140118|NCT03095326|Biological|PPV Vaccine|Pneumococcal polysaccharide vaccine
140072|NCT03095560|Device|NIRVANA|Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
140073|NCT03095547|Drug|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
140074|NCT03095547|Drug|Posaconazole|Pharmacokinetic assessment AUC 0-tau
140075|NCT03095547|Drug|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
140076|NCT03095547|Drug|F901318|Pharmacokinetic assessment AUC 0-tau
140077|NCT03095547|Drug|Tacrolimus|Pharmacokinetic assessment AUC 0-t
140078|NCT03095534|Behavioral|3-Step Workout for Life|a 10-week moderate exercise program
140079|NCT03095521|Drug|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
140080|NCT03095521|Drug|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
140081|NCT03095508|Drug|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
140082|NCT03095508|Drug|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
140083|NCT03095495|Device|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
140084|NCT03095495|Device|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
140085|NCT03095482|Device|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
140086|NCT03095482|Behavioral|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
140087|NCT03095469|Drug|Dexmedetomidine|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.
140088|NCT03095469|Drug|0.9%NaCl solution|when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
140089|NCT03095456|Drug|Revefenacin|Revefenacin administered via nebulization.
140090|NCT03095456|Combination Product|Spiriva Handihaler®|Spiriva Handihaler® contains Spiriva (also known as Tiotropium) and is administered via HandiHaler® device.
140091|NCT03095456|Drug|Placebo for Revefenacin|Placebo administered as double blind, double dummy via nebulization.
140092|NCT03095456|Drug|Placebo for Spiriva Handihaler®|Placebo administered as double blind, double dummy via Spiriva HandiHaler®.
140093|NCT03095443|Other|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
140094|NCT03095443|Other|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
140095|NCT03095443|Other|Attention Control|Participant receives an audio-book.
140096|NCT03095430|Device|Monitoring|Monitoring
140097|NCT03095417|Behavioral|Physical Exercise Intervention|In home exercise intervention.
140098|NCT03095417|Behavioral|Cognitive Training Intervention|Online cognitive training modules.
140099|NCT03095417|Behavioral|Stretching Control|In home stretching.
140100|NCT03095417|Behavioral|Cognitive Control|Online control puzzles and games.
140101|NCT03095404|Drug|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
140102|NCT03095404|Drug|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
140103|NCT03095391|Device|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
140104|NCT03095391|Device|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
140105|NCT03095378|Procedure|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
140106|NCT03095378|Procedure|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
140107|NCT03095378|Procedure|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
140108|NCT03095365|Other|Dry needling|Insertion of solid filament needles in the muscle
140109|NCT03095365|Other|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
140110|NCT03095365|Other|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
140111|NCT03095352|Biological|Pembrolizumab|200 mg Given IV
140112|NCT03095352|Drug|Carboplatin|Arm A: AUC 5 IV every 3 weeks Arm B: AUC 5 IV every 3 weeks
140113|NCT03095352|Biological|Trastuzumab|For HER2+ patients: IV every 3 weeks using standard approved dosing
140147|NCT03095144|Device|General anesthesia|Pyloromyotomy under general anesthesia
168734|NCT02881086|Drug|Daunorubicin (DNR)|
140119|NCT03095313|Other|18F-NaF|"At baseline a target dose of 125 MBq 18F-NaF will be administered intravenously to all subjects who will then undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. 125ml of iodine-based contrast agent (iohexol [Omnipaque™]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.~Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
140120|NCT03095300|Procedure|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
140121|NCT03095287|Biological|Alphanate|Daily intravenous infusion of Alphanate 100 IU/kg/day
140122|NCT03095274|Drug|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
140123|NCT03095274|Drug|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
140124|NCT03095261|Behavioral|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
140125|NCT03095261|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
140126|NCT03095261|Behavioral|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
140127|NCT03095261|Behavioral|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
140128|NCT03095248|Drug|Selumetinib|Continuous twice daily dosing; oral agent
140129|NCT03095235|Dietary Supplement|Dietary riboflavin|Dietary riboflavin is vitamin B2. It has been shown to be safe in children in the treatment of migraines at doses of 400 mg per day. There are no known documented side effects
140130|NCT03095222|Drug|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
140131|NCT03095222|Drug|Opioids|Standard of care for pain management.
140132|NCT03095209|Drug|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
140133|NCT03095209|Drug|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
140134|NCT03095209|Radiation|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
140135|NCT03095196|Device|Multipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
140136|NCT03095196|Device|Bipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
140137|NCT03095196|Drug|HF drugs|full medical therapy to treat HF symptoms and its progression.
140138|NCT03095183|Device|Grape flavored Puritan Junior tongue depressor|
140139|NCT03095183|Device|Traditional unflavored Puritan Regular Tongue Depressor|
140140|NCT03095170|Behavioral|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
140141|NCT03095170|Behavioral|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
140142|NCT03095170|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
140143|NCT03095170|Behavioral|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
140144|NCT03095170|Behavioral|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
140145|NCT03095157|Dietary Supplement|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
140146|NCT03095144|Device|Spinal anesthesia|Pyloromyotomy under spinal anesthesia
140148|NCT03095131|Device|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
140149|NCT03095118|Drug|Daratumumab|Open-label
140150|NCT03095105|Drug|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
140151|NCT03095092|Drug|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
140152|NCT03095079|Drug|recombinant human endostatin|"Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14"
140153|NCT03095066|Drug|AVP-786|oral capsules
140154|NCT03095066|Drug|Placebo|oral capsules
140155|NCT03095053|Procedure|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 5 of in vitro embryo culture. Biopsies will be performed using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.~Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, Illumina, California, USA)."
140156|NCT03095040|Drug|CM082 combined with everolimus|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
140157|NCT03095040|Drug|CM082|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
140158|NCT03095040|Drug|Everolimus|Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
140159|NCT03095027|Device|FID122819 contact lenses|Investigational spherical silicone hydrogel contact lenses for daily disposable wear
140160|NCT03095027|Device|Stenfilcon A contact lenses|Commercially available spherical silicone hydrogel contact lenses for daily disposable wear
140161|NCT03095014|Procedure|Cesarean Myomectomy|Myomectomy was done during Cesarean section
140162|NCT03095014|Procedure|Cesarean section|Cesarean delivery
140163|NCT03095001|Drug|Bevacizumab|Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
140164|NCT03095001|Drug|Carboplatin|carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
140165|NCT03095001|Drug|paclitaxel|paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
140166|NCT03094988|Behavioral|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
140167|NCT03094988|Other|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
140168|NCT03094962|Other|Motion capture|Capture kinematics of finger movements
140169|NCT03094962|Diagnostic Test|MR scan|Capture MR images of hand and fingers in three postures
140170|NCT03094962|Diagnostic Test|CT scan|Capture CT images of hand and fingers in three postures
140171|NCT03094949|Procedure|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
140172|NCT03094949|Procedure|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
140173|NCT03094936|Procedure|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
140174|NCT03094936|Device|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
140175|NCT03094923|Other|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.~The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
140394|NCT03093506|Other|Placebo Control|Saline
140176|NCT03094910|Diagnostic Test|Examination of vibration perception threshold in fingertips|Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
140177|NCT03094910|Diagnostic Test|Ewing's tests|A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
140178|NCT03094910|Diagnostic Test|Tilt table test|Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
140179|NCT03094910|Diagnostic Test|Thermography|An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
140180|NCT03094910|Diagnostic Test|123I-MIBG|123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
140181|NCT03094910|Diagnostic Test|Blood samples|"The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.~Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.~Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines."
140182|NCT03094897|Drug|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
140183|NCT03094897|Device|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
140184|NCT03094884|Radiation|Pulsed Low Dose Radiation|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
140185|NCT03094884|Drug|Carboplatin|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
140186|NCT03094884|Drug|Paclitaxel|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
140187|NCT03094871|Behavioral|FACE-PC|
140188|NCT03094858|Device|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
140189|NCT03094858|Device|Wristband|Wristband will monitor activity of all participants
140190|NCT03094858|Device|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
140191|NCT03094845|Biological|Placebo solution|15 injections over 7 weeks
140192|NCT03094845|Biological|hdmASIT+TM|15 injections over 7 weeks
140193|NCT03094832|Drug|ARQ 092|ARQ 092 should be taken either 1 hour before or 2 hours after a meal
140194|NCT03094819|Behavioral|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
140195|NCT03094819|Behavioral|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
140196|NCT03094806|Device|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
140197|NCT03094806|Device|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
140198|NCT03094793|Other|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.~Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
140199|NCT03094780|Behavioral|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
140200|NCT03094780|Other|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
140201|NCT03094767|Other|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
140202|NCT03094767|Other|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
140203|NCT03094754|Procedure|nevi excision|After general anesthesia, nevi excision in children is performed.
168735|NCT02881086|Drug|Methotrexate|
140204|NCT03094741|Other|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
140205|NCT03094728|Diagnostic Test|HLA cross matching|"HLA Typing and Mismatch~Cross matching (total and autocross):~Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result."
140206|NCT03094715|Device|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
140207|NCT03094715|Other|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
140208|NCT03094689|Other|Cold water immersion|
140209|NCT03094689|Other|Water immersion|
140210|NCT03094676|Other|Massage|Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
140211|NCT03094676|Other|Exercise|A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
140212|NCT03094663|Drug|Bupivacaine|0.5% with epinephrine 30cc
140213|NCT03094663|Drug|Methylprednisolone|40 mg/ml, 1 ml
140214|NCT03094663|Drug|Cefazolin|500 mg in 10 ml
140215|NCT03094663|Device|8 MHz. Chiba needle|22G/ 4 inches
140216|NCT03094663|Drug|15 cc of bupivacaine 0.25% with 2 mg of preservative free Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
140217|NCT03094663|Drug|25 cc 0.25% bupivacaine|25 cc 0.25% bupivacaine
140218|NCT03094663|Drug|20cc 0.25% bupivacaine|20cc 0.25% bupivacaine
140219|NCT03094663|Drug|2 mg IV dexamethasone.|2 mg IV dexamethasone.
140220|NCT03094663|Drug|bupivacaine 0.5% with epinephrine 30cc|bupivacaine 0.5% with epinephrine 30cc
140221|NCT03094650|Device|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
140222|NCT03094637|Drug|Azacitidine|Given IV
140223|NCT03094637|Biological|Pembrolizumab|Given IV
140224|NCT03094624|Other|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
140225|NCT03094624|Other|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
140226|NCT03094624|Other|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
140227|NCT03094624|Other|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
140228|NCT03094624|Other|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
140229|NCT03094611|Biological|Inotuzumab Ozogamicin|Given IV
140230|NCT03094598|Other|Leaflet|The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
140231|NCT03094598|Other|Brochure|The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
140232|NCT03094598|Other|Booklet|The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
140233|NCT03094585|Other|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
140234|NCT03094585|Other|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
140235|NCT03094572|Other|visual motor tasks|"This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game."
140276|NCT03094247|Drug|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
140277|NCT03094247|Dietary Supplement|HO-RUTF|HO-RUTF: Milk, linseed oil, palm oil, white sugar, high oleic peanuts
170327|NCT02869321|Procedure|Gastrostomy|
140236|NCT03094559|Device|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
140237|NCT03094546|Dietary Supplement|Polyamine|12 months of polyamine supplementation (6 capsules/day)
140238|NCT03094546|Dietary Supplement|Placebo|12 months of placebo intake (6 capsules/day)
140239|NCT03094533|Drug|TIVA|total intravenous anesthesia with propofol
140240|NCT03094533|Drug|VIMA|volatile induction and maintenance anesthesia with sevoflurane
140241|NCT03094520|Device|tDCS|Transcranial direct current stimulation (tDCS)
140242|NCT03094520|Device|sham-tDCS|sham stimulation
140243|NCT03094507|Drug|Tivicay|50 mg once daily
140244|NCT03094507|Drug|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
140245|NCT03094494|Other|none intervention|none intervention
140246|NCT03094481|Procedure|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
140247|NCT03094481|Procedure|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
140248|NCT03094481|Procedure|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
140249|NCT03094481|Drug|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
140250|NCT03094468|Drug|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
140251|NCT03094468|Drug|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
140252|NCT03094455|Other|Experimental group|Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
140253|NCT03094442|Drug|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
140254|NCT03094442|Drug|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
140255|NCT03094429|Drug|NaBen®|2000 mg/day or 1000 mg/day, twice daily
140256|NCT03094429|Other|Placebo|0 mg total, twice daily
140257|NCT03094416|Drug|levothyroxine sodium capsule|patients will be switched from their current levothyroxine sodium tablet to levothyroxine sodium capsule
140258|NCT03094403|Drug|Azelaic Acid 15% topical gel|Gel
140259|NCT03094403|Drug|Finacea® (azelaic acid) Gel, 15%|Gel
140260|NCT03094403|Drug|Placebo|Gel
140261|NCT03094377|Other|Multisensory therapy|Sensory stimulation, motor training and ADL training
140262|NCT03094377|Other|Conventional training|Motor training and ADL training
140263|NCT03094364|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
140264|NCT03094351|Procedure|esophagectomy|Robot assisted esophagectomy with extended two field lymphadenectomy.
140265|NCT03094351|Procedure|esophagectomy|Conventional thoracoscopic esophagectomy with extended two field lymphadenectomy.
140266|NCT03094338|Behavioral|stress, psychological|students respond to questionnaires
140267|NCT03094325|Device|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
140268|NCT03094325|Device|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
140269|NCT03094325|Device|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
140270|NCT03094325|Device|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
140271|NCT03094312|Procedure|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
140272|NCT03094286|Drug|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
140273|NCT03094273|Procedure|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
140274|NCT03094260|Device|High intensity bright light therapy|"Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
140275|NCT03094260|Device|Low intensity light therapy|"Treatment with light therapy in low intensity (<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.~Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
140279|NCT03094247|Dietary Supplement|C-RUTF|C-RUTF: Milk, linseed oil, palm oil, white sugar, standard peanuts
140280|NCT03094234|Device|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
140281|NCT03094234|Procedure|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
140282|NCT03094234|Drug|Propranolol|Appropriate dose of propranolol was administered to the patients.
140283|NCT03094221|Device|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
140284|NCT03094208|Other|dual task balance training|balance exercises with cognitive and motor dual tasks
140285|NCT03094208|Other|traditional balance training|balance exercises
140286|NCT03094195|Drug|EMA401|EMA401
140287|NCT03094195|Drug|Placebo|Placebo
140288|NCT03094182|Drug|Iron Isomaltoside 1000|Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
140289|NCT03094182|Drug|Normal saline|Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
140290|NCT03094169|Drug|AVID100 IV|AVID100 is administered once every 3 weeks
140291|NCT03094156|Drug|Placebo|1 capsule of placebo [to be taken orally, with 240 mL of potable water]
140292|NCT03094156|Drug|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg [to be taken orally, with 240 mL of potable water]
140293|NCT03094156|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg [to be taken orally, with 240 mL of potable water]
140294|NCT03094156|Drug|Comtan®|Entacapone 200 mg tablets [to be taken orally, with 240 mL of potable water]
140295|NCT03094143|Procedure|Aortic valve intervention|The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
140296|NCT03094130|Other|News items with spin|Interpretation of news items with spin
140297|NCT03094130|Other|News items without spin|Interpretation of news items without spin
140298|NCT03094117|Other|News items with spin|Interpretation of news items with spin
140299|NCT03094117|Other|News items without spin|Interpretation of news items without spin
140300|NCT03094104|Other|News items with spin|Interpretation of news items with spin
140301|NCT03094104|Other|News items without spin|Interpretation of news items without spin
140302|NCT03094091|Other|News items with spin|Interpretation of news items with spin
140303|NCT03094091|Other|News items without spin|Interpretation of news items without spin
140304|NCT03094078|Other|News item with spin|Interpretation of news item with spin
140305|NCT03094078|Other|News item without spin|Interpretation of news item without spin
140306|NCT03094065|Other|News items with spin|Interpretation of news items with spin
140307|NCT03094065|Other|News items without spin|Interpretation of news items without spin
140308|NCT03094052|Drug|Neratinib|
140309|NCT03094052|Drug|Trastuzumab|
140310|NCT03094052|Drug|Crofelemer|
140311|NCT03094052|Drug|Loperamide|
140312|NCT03094039|Procedure|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
140313|NCT03094039|Procedure|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
140314|NCT03094026|Behavioral|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
140315|NCT03094026|Behavioral|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
140316|NCT03094013|Other|Assessment|Assessment
140317|NCT03094000|Behavioral|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
140318|NCT03094000|Behavioral|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
140319|NCT03093987|Other|Critical care ultrasound|Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
140320|NCT03093974|Drug|Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%
140321|NCT03093974|Drug|Saline Solution|1 ml saline solution 0.45%
140322|NCT03093961|Device|IASD implant|Single arm for implant
140323|NCT03093948|Procedure|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
140324|NCT03093935|Device|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
140325|NCT03093922|Drug|Atezolizumab|1200 mg/m^2
140326|NCT03093922|Drug|Gemcitabine|1000 mg/m^2
140327|NCT03093922|Drug|Cisplatin|70 mg/m^2
140328|NCT03093909|Drug|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
140329|NCT03093896|Dietary Supplement|snack mix|commercial cereal mix with bits of beef jerky and coconut
140330|NCT03093896|Dietary Supplement|almonds, 1.5 oz|almonds, 1.5 oz/day
140331|NCT03093896|Dietary Supplement|almonds, 3 oz|almonds, 3.0 oz/day
140332|NCT03093883|Drug|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
140333|NCT03093883|Drug|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
140334|NCT03093870|Drug|Varlitinib|Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
140335|NCT03093870|Drug|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
140336|NCT03093870|Drug|Placebo (for Varlitinib)|oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
140337|NCT03093857|Diagnostic Test|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
140338|NCT03093844|Device|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
140339|NCT03093831|Drug|Ibrutinib|560mg administered orally once daily.
140340|NCT03093818|Other|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 50 genetic variants for the following 13 pharamacogenes: CYP1A2 (cytochrome P450), CYP2B6, CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
140341|NCT03093805|Dietary Supplement|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
140342|NCT03093792|Other|Control|
140343|NCT03093792|Other|American Heart Association plus exercise|
140344|NCT03093792|Other|Curves Complete - I plus exercise|
140345|NCT03093792|Other|Curves Complete - II plus exercise|
140346|NCT03093779|Other|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
140347|NCT03093753|Other|Control (study 1)|Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
140348|NCT03093753|Other|Test (study 1)|The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
140349|NCT03093753|Other|Control (study 2)|Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
140350|NCT03093753|Dietary Supplement|Test (study 2)|The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
140351|NCT03093753|Other|Control (study 3)|Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
140352|NCT03093753|Dietary Supplement|Test (study 3)|The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
140353|NCT03093753|Other|Control (study 4)|Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
140354|NCT03093753|Dietary Supplement|Test (study 4)|The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
140355|NCT03093753|Other|Control (study 5)|Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
140356|NCT03093753|Other|Test (study 5)|The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
140357|NCT03093753|Other|Control (study 6)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
140358|NCT03093753|Other|Test (study 6)|High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
140359|NCT03093753|Other|Control (study 7)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
140360|NCT03093753|Other|Test (study 7)|High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
140361|NCT03093740|Drug|Zepatier|Based on negative viral resistance testing of the donor treatment will be Zepatier
141844|NCT03082209|Drug|FOLFIRI|IV infusion
140362|NCT03093740|Drug|Zepatier plus Sofosbuvir|Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
140363|NCT03093714|Drug|FDL169|CFTR corrector
140364|NCT03093714|Drug|Placebo|Placebo for FDL169
140365|NCT03093701|Drug|TLC399 (ProDex)|2-vial system: TLC399-DSP and TLC399-Lipid
140366|NCT03093688|Biological|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8~1E10) and CD8+T cells(1E7~1E9) in one course of treatment.
140367|NCT03093675|Device|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
140368|NCT03093662|Device|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
140369|NCT03093662|Device|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
140370|NCT03093649|Other|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
140371|NCT03093649|Other|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
140372|NCT03093636|Device|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice App and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
140373|NCT03093636|Other|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
140374|NCT03093623|Behavioral|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
140375|NCT03093610|Procedure|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
140376|NCT03093610|Procedure|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
140377|NCT03093597|Other|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
140378|NCT03093597|Other|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
140379|NCT03093597|Other|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
140380|NCT03093597|Other|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
140381|NCT03093584|Device|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
140382|NCT03093584|Behavioral|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
140383|NCT03093571|Device|Auricular stimulation|Auricular stimulation with indwelling fixed needles
140384|NCT03093571|Behavioral|Relaxation|Progressive muscle relaxation
140385|NCT03093558|Behavioral|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
140386|NCT03093545|Biological|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
140387|NCT03093545|Biological|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
140388|NCT03093532|Other|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:~1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
140389|NCT03093532|Other|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
140390|NCT03093519|Drug|KHK6640|Intravenous administration
140391|NCT03093519|Drug|Placebo|Intravenous administration
140392|NCT03093506|Drug|Low-dose rhEpo|60IU/kg/week
140393|NCT03093506|Drug|Micro-dose rhEpo|20IU/kg/week
140395|NCT03093493|Diagnostic Test|Genotyping|Genotyping by next generation sequencing
140396|NCT03093480|Biological|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period, 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period, and prophylactic regimen in Follow-Up period as powder for injection administered intravenously.
140397|NCT03093467|Behavioral|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
140398|NCT03093467|Drug|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
140399|NCT03093467|Behavioral|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
140400|NCT03093454|Drug|Lavender Essential Oil|Lavender essential oil will be applied topically and by inhalation to the lavender group.
140401|NCT03093441|Other|Multimodal High-Intensity Interval Training Intervention|The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
140402|NCT03093428|Drug|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
140403|NCT03093428|Drug|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor
140404|NCT03093415|Drug|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
140405|NCT03093402|Drug|JBT-101|Participants will self-administer JBT-101 by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
140406|NCT03093402|Drug|Placebo|Participants will self-administer JBT-101 placebo by mouth (orally), at prescribed dose and frequency per protocol, Days 1-84. Administration of dose(s) should be at least 8 hours apart.
140407|NCT03093389|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
140408|NCT03093389|Drug|Placebo|Matching placebo capsules
140409|NCT03093376|Behavioral|Effortful Control Camp|"An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.~Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends."
140410|NCT03093376|Behavioral|Waitlist|Participants randomized to the control group will be given a set of written materials to complete at home with their caregivers after the post-wait list assessment. These materials will be adapted from the EC camp protocol and will include detailed instructions on how to perform the training tasks in a home setting. No additional neurophysiological, behavioral, or clinical data will be collected in subjects who complete the home EC training.
140411|NCT03093363|Other|Pharmacist's intervention|"Pharmacist's intervention with asthmatic patients:~Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)~Explanation of asthma and inflammation~Explanation of triggers and how to avoid it~Explanation of asthma treatments~Explanation of the inhalation technique with a physical demonstration~Emphasis on treatment adherence~Assessment of comorbidities and their treatment~Emphasis on influenza vaccination"
140412|NCT03093363|Other|Questionnaires for control group|- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
140413|NCT03093350|Biological|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.~Dose schedule:~Day 0: 2 x 10^7 cells/m2~Day 28: 2 x 10^7 cells/m2~If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
140414|NCT03093337|Other|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
140415|NCT03093324|Drug|ALKS 8700|Oral capsules, administered twice daily
140416|NCT03093324|Drug|Dimethyl Fumarate|Oral capsules, administered twice daily
140417|NCT03093311|Other|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
140418|NCT03093298|Other|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
140419|NCT03093272|Drug|Leuprolide Acetate|a GnRH agonist
140420|NCT03093272|Drug|Prednisone|Prednisone is a corticosteroid
170412|NCT02868814|Drug|Placebo|
140421|NCT03093272|Drug|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
140422|NCT03093272|Drug|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
140423|NCT03093259|Drug|ABX464|ABX464 is a new Anti-inflammatory drug
140424|NCT03093259|Drug|Placebo oral capsule|Placebo matching with ABX464
140425|NCT03093246|Dietary Supplement|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
140426|NCT03093246|Drug|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
140427|NCT03093246|Other|Placebo|Placebo pills over a period of 180 days
140428|NCT03093246|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
140429|NCT03093233|Other|no intervention|only descriptive data analysis
140430|NCT03093207|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
140431|NCT03093207|Other|Placebo|Placebo pills over a period of 180 days
140432|NCT03093207|Dietary Supplement|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
140433|NCT03093207|Drug|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
140434|NCT03093194|Other|vaginal preparation before CS with Septal soap and septol.|vaginal preparation before CS with Septal soap and septol.
140435|NCT03093194|Other|No vaginal preparation before CS with Septal soap and septol.|No vaginal preparation before CS with Septal soap and septol.
140436|NCT03093181|Other|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
140437|NCT03093181|Other|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
140438|NCT03093181|Other|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
140439|NCT03093181|Other|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
140440|NCT03093168|Biological|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
140441|NCT03093168|Drug|Fludarabine|dose: 25mg/m2/d
140442|NCT03093168|Drug|Cyclophosphamide|Dose: 40mg/kg
140443|NCT03093155|Drug|Ixabepilone|"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"
140444|NCT03093155|Drug|Bevacizumab|"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."
140445|NCT03093142|Device|tDCS & neurofeedback|tDCs and neurofeedback
140446|NCT03093142|Device|neurofeedback|Neurofeedback
140447|NCT03093142|Device|sham neurofeedback|sham neurofeedback
140448|NCT03093129|Drug|artesunate|"Artesunate (Trade name : Arinate®)~Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
140449|NCT03093129|Other|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
140450|NCT03093116|Drug|Oral repotrectinib (TPX-0005)|Oral repotrectinib (TPX-0005) capsules.
140451|NCT03093103|Drug|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
140452|NCT03093103|Drug|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
140453|NCT03093090|Dietary Supplement|Water|6 oz
140454|NCT03093090|Dietary Supplement|Parmalat™ Whole Milk|6 oz
140455|NCT03093090|Dietary Supplement|Similac Pro-Advance™|6 oz
140456|NCT03093090|Dietary Supplement|Ensure Plus™|6 oz
140457|NCT03093090|Drug|Furosemide 20 MG|Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
140458|NCT03093077|Device|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
140459|NCT03093064|Drug|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
140460|NCT03093064|Other|Placebo: normal saline|Normal saline, intravenous infusion
140461|NCT03093051|Device|Unpinning Termination therapy|Electrotherapy comprised of standard biphasic and monophasic pacing pulses
140462|NCT03093038|Device|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem & Delta-TT cup with a polyethylene insert
140463|NCT03093038|Device|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem & Delta Delta-TT cup with a Ceramic insert
140464|NCT03093038|Device|C2 stem & Delta-TT cup + ceramic|C2 femoral stem Delta Delta-TT cup with a Ceramic insert
140465|NCT03093025|Drug|TS-121 10 mg|Orally taken once daily
140466|NCT03093025|Drug|TS-121 50 mg|Orally taken once daily
140467|NCT03093025|Drug|Placebo|Orally taken once daily
140468|NCT03092999|Drug|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
140469|NCT03092986|Drug|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
140470|NCT03092986|Drug|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
140471|NCT03092986|Drug|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
140472|NCT03092986|Drug|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
140473|NCT03092986|Radiation|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
140474|NCT03092973|Diagnostic Test|Ultrasound|
140475|NCT03092960|Behavioral|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
140476|NCT03092960|Behavioral|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
140477|NCT03092947|Other|No intervention|
140478|NCT03092934|Drug|LY3295668|Oral capsules
140479|NCT03092921|Device|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
140480|NCT03092921|Device|F&P Mask|Investigative Mask to be used for OSA therapy
140481|NCT03092908|Dietary Supplement|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
140482|NCT03092908|Dietary Supplement|placebo (water)|Administer 5 ml placebo (water) three times a day.
140483|NCT03092895|Biological|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
140484|NCT03092895|Drug|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
140485|NCT03092895|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
140486|NCT03092895|Drug|GEMOX|Subjects receive GEMOX treatment every 2 weeks
140487|NCT03092882|Behavioral|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
140488|NCT03092869|Other|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
140489|NCT03092869|Other|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
140490|NCT03092856|Biological|Anti-OX40 Antibody PF-04518600|Given IV
140491|NCT03092856|Drug|Axitinib|Given PO
140492|NCT03092856|Other|Laboratory Biomarker Analysis|Correlative studies
140493|NCT03092856|Other|Placebo|Given IV
140494|NCT03092830|Genetic|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
140495|NCT03092817|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
140496|NCT03092817|Other|Placebo|"Treatment with matched placebo:~Standard saline for intravenous injection and placebo oral tablets containing cellulose"
140497|NCT03092804|Procedure|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
140498|NCT03092791|Biological|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
140499|NCT03092791|Biological|Reference IPV|Reference IPV intramuscular injection
140500|NCT03092791|Biological|sIPV Placebo|sIPV placebo-matching intramuscular injection
140501|NCT03092778|Procedure|Cryoablation|"A computed tomography (CT) scan will be completed to map out where to insert the cryoablation needle. Numbing medicine will be used to numb the skin and deeper tissues before inserting the needle.~The cryoablation needle will be inserted and directed toward the target area of the vagal nerve. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle in place, the study doctor(s) will freeze the zone over 3 minutes, a 2 minutes thaw will follow, then 2 more cycles of 3 minutes freeze and 2 minute thaw will complete the procedure. This portion of the procedure can last from 25 to 35 minutes. Once the targeted area has been properly treated, the cryoablation needle will be withdrawn."
140502|NCT03092765|Drug|E6011|Intravenous administration
140503|NCT03092765|Drug|Placebo|Intravenous administration
140504|NCT03092752|Drug|oral antidiabetic drugs|OADs usage conditions and dose selection in T2DM patients
140505|NCT03092739|Diagnostic Test|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
140506|NCT03092739|Diagnostic Test|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
140507|NCT03092726|Drug|ASP8062|ASP8062 30 mg was administered orally as a single daily dose, taken preferably in the morning with or without food.
140508|NCT03092726|Drug|Placebo|Placebo was administered orally as a single daily dose, taken preferably in the morning with or without food.
140887|NCT03089710|Other|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
140509|NCT03092713|Behavioral|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
140510|NCT03092713|Behavioral|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
140511|NCT03092674|Drug|Azacitidine|Given SC or IV
140512|NCT03092674|Drug|Cytarabine|Given IV
140513|NCT03092674|Drug|Decitabine|Given IV
140514|NCT03092674|Other|Laboratory Biomarker Analysis|Correlative studies
140515|NCT03092674|Drug|Midostaurin|Given PO
140516|NCT03092674|Biological|Nivolumab|Given IV
140517|NCT03092648|Biological|Bronchial basal cell|autologous bronchial basal cell transplantation
140518|NCT03092635|Drug|OPC|OPC is a derivative of grape seed extract
140519|NCT03092622|Other|Exercise|Exercise training intervention as described earlier.
140520|NCT03092609|Behavioral|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
140521|NCT03092609|Behavioral|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
140522|NCT03092596|Behavioral|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
140523|NCT03092596|Behavioral|Patient health navigator-administered screening tool|patient health navigator-administered screener
140524|NCT03092596|Behavioral|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
140525|NCT03092583|Other|Blood sample|35 mL, 7 tubes
140526|NCT03092570|Device|With stimulation|ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
140527|NCT03092570|Device|No stimulation|ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
140528|NCT03092557|Other|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
140529|NCT03092544|Drug|dimethyl fumarate|Active drug
140530|NCT03092531|Behavioral|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
140531|NCT03092518|Procedure|Surgery|Heated Intraperitonial Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitocycin C and sodium thiosulfate
140532|NCT03092518|Drug|Cisplatin|Cisplatin (90mg/m2) will be administered via circuit to the peritoneal cavity.
140533|NCT03092518|Drug|Mitomycin C|Mytomycin C 10mg/m2 will be administered via circuit to the peritoneal cavity
140534|NCT03092518|Drug|Sodium Thiosulfate|Sodium Thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
140535|NCT03092479|Behavioral|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
140536|NCT03092466|Procedure|femoral nerve catheter|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
140537|NCT03092466|Drug|femoral group|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
140538|NCT03092466|Drug|control group|infusion of saline solution (15ml) in femoral catheter
140539|NCT03092453|Biological|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
140540|NCT03092453|Drug|Cyclophosphamide 300mg/m^2|administered prior to subject's first DC dose
140541|NCT03092453|Drug|Pembrolizumab|administered 7-8 weeks after subject's last DC dose
140542|NCT03092440|Other|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
140543|NCT03092427|Dietary Supplement|VSL#3|Dietary Supplement
140544|NCT03092427|Other|Placebo|Placebo
140545|NCT03092414|Procedure|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
140546|NCT03092414|Procedure|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
140547|NCT03092388|Diagnostic Test|Multi Frequency Bioimpedance Analysis (mfBIA)|Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
140548|NCT03092388|Diagnostic Test|Polysomnography/Polygraphy (PSG/PG)|Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
140549|NCT03092388|Diagnostic Test|Capillary Blood Gas Analysis (CBGA)|CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
140550|NCT03092388|Diagnostic Test|Tilting Table with Hemodynamic Monitoring|A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
140551|NCT03092375|Drug|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
140552|NCT03092375|Drug|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
140553|NCT03092375|Drug|Sofosbuvir 400Mg Tab|Daily
140554|NCT03092349|Device|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
140555|NCT03092336|Other|Electrical Stimulation|electrical stimulation training
140556|NCT03092336|Other|Strength training|strength training group
140557|NCT03092323|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
140558|NCT03092310|Device|Artificial Pancreas Device|Artificial Pancreas Device
140559|NCT03092284|Biological|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC_ASC
140560|NCT03092284|Biological|Placebo|Saline
140561|NCT03092271|Behavioral|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
140562|NCT03092271|Behavioral|Zero Suicide Quality Improvement|ZSQI
140563|NCT03092258|Other|Questionnaire|Questionnaire to be completed by staff
140564|NCT03092245|Drug|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
140565|NCT03092245|Drug|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
140566|NCT03092232|Drug|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
140567|NCT03092232|Drug|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
140568|NCT03092232|Drug|PF-06865571|Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
140569|NCT03092232|Drug|Placebo|Matching Placebo for PF-06865571 for each cohort.
140570|NCT03092206|Drug|F/TAF|antiretroviral therapy
140571|NCT03092206|Drug|E/C/F/TAF|antiretroviral therapy
140572|NCT03092206|Drug|R/F/TAF|antiretroviral therapy
140573|NCT03092193|Drug|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
140574|NCT03092193|Drug|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
140575|NCT03092180|Drug|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
140576|NCT03092167|Other|Physical exercises|Physical exercises
140577|NCT03092154|Drug|Lipid-lowering agents (Artovastatin)|Artovastatin 20 mg /day, orally, 12 consecutive weeks.
140578|NCT03092141|Other|Physical training|
140579|NCT03092115|Device|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
140580|NCT03092102|Drug|HEC585|HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
140581|NCT03092089|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
140582|NCT03092089|Device|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
140583|NCT03092089|Procedure|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
140584|NCT03092076|Drug|Ticagrelor|180 mg loading dose
140585|NCT03092063|Behavioral|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
140586|NCT03092063|Behavioral|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
140587|NCT03092063|Behavioral|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
140588|NCT03092063|Behavioral|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
140589|NCT03092050|Behavioral|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
140590|NCT03092050|Behavioral|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
140591|NCT03092037|Procedure|Blood draw|The Investigators will collect serum and whole blood from participants.
140640|NCT03091725|Procedure|Roux-en-Y gastric bypass surgery|A bariatric surgery procedure which will help individuals achieve 16-18% weight loss
140641|NCT03091725|Behavioral|Very low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.
140642|NCT03091712|Device|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
141496|NCT03084913|Other|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
140592|NCT03092024|Other|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
140593|NCT03092011|Drug|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
140594|NCT03092011|Drug|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
140595|NCT03091998|Drug|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
140596|NCT03091998|Other|Placebo|Participants will receive an ~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
140597|NCT03091985|Device|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
140598|NCT03091985|Device|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
140599|NCT03091972|Procedure|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
140600|NCT03091972|Procedure|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
140601|NCT03091972|Procedure|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
140602|NCT03091946|Other|Overnight oats with additional dried fruits, nuts and seeds|Oatmeal
140603|NCT03091946|Other|Cooked cream of rice with additional dried fruits, nuts and seeds|Cooked cream of rice
140604|NCT03091933|Biological|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
140605|NCT03091920|Drug|IW-1973 Oral Tablet|40 mg QD doses of IW-1973
140606|NCT03091920|Drug|IW-1973 Oral Tablet|20 mg BID and 40 mg QD doses of IW-1973
140607|NCT03091920|Drug|Placebo Oral Tablet|Placebo Oral Tablet to Match Experimental Drug
140608|NCT03091894|Drug|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
140609|NCT03091894|Drug|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
140610|NCT03091881|Drug|Granisetron 0.1 MG/ML|Granisetron 0.1 MG/ML Will be given 10 min before spinal block
140611|NCT03091881|Drug|Placebos|Placebos will be given 10 min before spinal block
140612|NCT03091868|Drug|Placebo oral capsule|Matching placebo capsules. Oral administration.
140613|NCT03091868|Drug|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
140614|NCT03091868|Drug|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
140615|NCT03091868|Drug|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
140616|NCT03091868|Drug|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
140617|NCT03091855|Other|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
140618|NCT03091855|Diagnostic Test|Magnetic Resonance Imaging|MRI at baseline and at 24 months post-enrollment for 20 sub-study participants
140619|NCT03091842|Behavioral|Exercise Intervention|Undergo supervised CARE program
140620|NCT03091842|Behavioral|Exercise Intervention|Undergo supervised TARE program
140621|NCT03091842|Behavioral|Exercise Intervention|Undergo home-based stretching program
140622|NCT03091842|Other|Informational Intervention|Receive instructional DVD and booklet of the flexibility exercises
140623|NCT03091842|Other|Laboratory Biomarker Analysis|Correlative studies
140624|NCT03091842|Other|Quality-of-Life Assessment|Ancillary studies
140625|NCT03091842|Other|Questionnaire Administration|Ancillary studies
140626|NCT03091816|Device|Computed Tomography Perfusion Imaging|Undergo DPCT
140627|NCT03091816|Other|Laboratory Biomarker Analysis|Correlative studies
140628|NCT03091816|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
140629|NCT03091803|Device|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
140630|NCT03091803|Drug|Gadobenate Dimeglumine|Given IV
140631|NCT03091803|Drug|Gadoterate Meglumine|Given IV
140632|NCT03091803|Device|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
140633|NCT03091790|Device|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
140634|NCT03091790|Device|Biologic Mesh|Biologic mesh used during open ventral hernia repair
140635|NCT03091777|Drug|GDC-229|GDC-229 is a vaginal gel.
140636|NCT03091777|Drug|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
140637|NCT03091777|Drug|Placebo|Inactive arm of the study
140638|NCT03091751|Drug|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
140639|NCT03091738|Drug|Ramelteon Pill|Patients with compensated cirrhosis and insomnia will be provided ramelteon
140643|NCT03091699|Drug|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
140644|NCT03091699|Behavioral|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
140645|NCT03091686|Behavioral|HAPA SB Intervention Slideshow|In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.
140646|NCT03091686|Behavioral|HAPA MVPA Attention-Control Slideshow|In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
140647|NCT03091673|Drug|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
140648|NCT03091660|Biological|BCG Solution|Given intravesically
140649|NCT03091660|Biological|BCG Tokyo-172 Strain Solution|Given intravesically
140650|NCT03091660|Biological|BCG Tokyo-172 Strain Vaccine|Given ID
140651|NCT03091660|Other|Laboratory Biomarker Analysis|Correlative studies
140652|NCT03091647|Behavioral|acupressure intervention|Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
140653|NCT03091647|Behavioral|usual care|Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
140654|NCT03091634|Drug|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
140655|NCT03091634|Drug|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
140656|NCT03091595|Drug|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
140657|NCT03091595|Drug|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
140658|NCT03091582|Behavioral|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
140659|NCT03091582|Behavioral|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
140660|NCT03091582|Behavioral|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
140661|NCT03091569|Other|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
140662|NCT03091569|Other|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
140663|NCT03091543|Drug|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
140664|NCT03091543|Drug|Placebo|2 capsules of placebo
140665|NCT03091543|Drug|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
140666|NCT03091543|Drug|BIA 6-512 50 mg dose|2 capsules of 25 mg
140667|NCT03091543|Drug|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
140668|NCT03091543|Drug|BIA 6-512 200 mg dose|2 capsules of 100 mg
140669|NCT03091530|Other|Sleeper Stretch|The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.
140670|NCT03091530|Other|90/90 Hip Lift with Balloon Blow Exercise|The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
140671|NCT03091517|Behavioral|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:~Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.~The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
140923|NCT03089437|Behavioral|Prolonged Sitting|Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
140672|NCT03091504|Device|High flow nasal cannula|High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
140673|NCT03091504|Drug|Albuterol Sulfate|Albuterol is a short acting inhaled bronchodilator
140674|NCT03091491|Drug|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
140675|NCT03091491|Drug|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
140676|NCT03091478|Drug|Pembrolizumab|200mg every 3 weeks
140677|NCT03091439|Drug|Dalbavancin|Participants received Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and on Day 8.
140678|NCT03091439|Drug|Standard of Care|Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
140679|NCT03091426|Drug|Omiganan|Omiganan 1%
140680|NCT03091426|Drug|Omiganan|Omiganan 1.75%
140681|NCT03091426|Drug|Omiganan|Omiganan 2.5%
140682|NCT03091426|Drug|Placebo|Vehicle
140683|NCT03091413|Diagnostic Test|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.~We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.~We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.~We will performed the measure three times, and we will take into account the best one made by the patient."
140684|NCT03091400|Drug|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
140685|NCT03091400|Drug|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
140686|NCT03091387|Diagnostic Test|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
140687|NCT03091374|Drug|Somatotropin (Human)|
140688|NCT03091361|Other|imaging, no intervention|no intervention
140689|NCT03091348|Drug|Testosterone|Testosterone cypionate injection
140690|NCT03091335|Other|Music-listening|Patients listen to music on headphones
140691|NCT03091322|Device|Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8|Assessment of the AV Opt and LV VectorOpt features
140692|NCT03091309|Other|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
140693|NCT03091309|Behavioral|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
140694|NCT03091309|Behavioral|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
140695|NCT03091309|Behavioral|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
140696|NCT03091309|Other|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence [self-reported using the 5 item Medication Adherence Report Scale (MARS-5)] and IBD related disease activated [self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity].
140697|NCT03091309|Other|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence [self-reported using the Medication Adherence Report Scale (MARS-5)], patient trust in physician [self-reported using the Trust in Physician Scale (TIPS)], IBD related disease activated [self-reported using the PRO-2 or 6-Point Mayo Score], IBD-specific health related quality of life [self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)], patient satisfaction [self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire]and IBD specific knowledge [self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire].
140698|NCT03091257|Drug|Dabrafenib|Administered Orally BID
140699|NCT03091257|Drug|Trametinib|Administered Orally once daily
140700|NCT03091231|Diagnostic Test|mpUS multiparametric Ultrasound|compare the mpUS to other methods
140701|NCT03091192|Drug|Savolitinib|600 mg (400 mg if <50 kg) by mouth (PO) with a meal once daily (QD), continuously
140702|NCT03091192|Drug|Sunitinib|50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
140703|NCT03091179|Device|THRIVE|active nasal oxygen delivery system
140704|NCT03091179|Device|Endotracheal tube|a plastic tube for mechanical ventilation
140705|NCT03091166|Drug|Dexmedetomidine|
140706|NCT03091153|Other|Medication Review|In depth medication review with a focus on deprescribing
140707|NCT03091101|Device|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
140708|NCT03091088|Other|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
140709|NCT03091088|Other|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
140882|NCT03089723|Behavioral|Pulp-pulp pinch strength|submitted to pulp-pulp pinch strength strength at at baseline, 1 month, 3 months and 6 months
140710|NCT03091075|Drug|Oxandrolone Pill|Treatment group will receive 24 mg Oxandrolone per day if male and 12 mg Oxandrolone per day if female, with dosing starting at time of surgery and continuing 12 weeks postoperative
140711|NCT03091075|Drug|Placebo Oral Tablet|Placebo group will receive a placebo oral tablet, beginning at the time of surgery and continuing 12 weeks postoperative
140712|NCT03091062|Device|Vest® Airway Clearance System|High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
140713|NCT03091062|Device|Monarch™ System|Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
140714|NCT03091036|Other|Proactive healthcare intervention|There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
140715|NCT03091023|Procedure|Endometrial Biopsy and endometrial fluid collection|
140716|NCT03091010|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
140717|NCT03091010|Drug|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
140718|NCT03090997|Dietary Supplement|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
140719|NCT03090997|Dietary Supplement|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
140720|NCT03090997|Dietary Supplement|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
140721|NCT03090984|Device|PMMA (BKU)|At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.
140722|NCT03090984|Device|PS (Phylter)|At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation
140723|NCT03090984|Device|AN69ST (Evodial)|At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
140724|NCT03090971|Drug|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
140725|NCT03090971|Drug|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
140726|NCT03090958|Behavioral|AllyQuest|AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
140727|NCT03090945|Other|This is an obsevational cohort study|no intervention
140728|NCT03090932|Other|Blood draw|Research subjects will have two tubes of blood drawn, approximately 20mL.
140729|NCT03090919|Biological|Platelet transfusion|
140730|NCT03090919|Other|Saline|
140731|NCT03090906|Procedure|Soft tissue augmentation palate|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Palate (CG) The double incision was made approximately 2 to 3 mm apical to the gingival margins of premolars. The donor tissue was removed and cross-mattress sutures were used to approximate the wound on the palate.~In both groups the epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
140732|NCT03090906|Procedure|Soft tissue augmentation tuberosity|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Tuberosity (TG) The double incision was made from the distal of the terminal tooth. A second incision was made perpendicular to the linear incision at a distal point, which joined the two linear incisions. The graft was removed and a crossed horizontal suspension suture was used.~Epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
140733|NCT03090906|Device|Intraoral optical scan|Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.
140734|NCT03090893|Drug|ATryn continuous infusion|replenish serum thrombin levels
140735|NCT03090880|Drug|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
140736|NCT03090867|Other|Relatives or surrogates are encouraged to perform care|"The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.~All care are planned and perform under the supervision or/and in collaboration with a caregiver.~The relative or surrogate will give his opinion by completing the study questionnaires."
140737|NCT03090867|Other|Conventional ,care|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
140738|NCT03090854|Diagnostic Test|ADASCog|Neuropsychological test
140739|NCT03090841|Biological|Bio-specimen collected|
140740|NCT03090828|Behavioral|app-based therapeutic education|Patients will connect to a platform providing information on end-stage renal disease and to contact health care providers.
140741|NCT03090828|Behavioral|enhanced app-based therapeutic education|Patients in the enhanced app group will also have access to a social network. (forum, chat room)
140742|NCT03090815|Genetic|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
140883|NCT03089723|Drug|Lavage with physiologic saline solution|Joint lavage with physiologic saline solution. After emptying of the joint, 1mL saline solution will be injected.
140743|NCT03090802|Behavioral|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
140744|NCT03090776|Drug|Ketamine|low dose bolus and infusion ketamine, administered under general anesthesia
140745|NCT03090776|Other|Placebo saline|bolus and infusion saline, administered under general anesthesia
140746|NCT03090763|Genetic|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
140747|NCT03090750|Drug|Lavender Oil|Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
140748|NCT03090750|Drug|Bergamot Oil|Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
140749|NCT03090750|Other|Water|Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
140750|NCT03090737|Biological|Nivolumab|Specified Dose on Specified Days
140751|NCT03090724|Drug|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
140752|NCT03090711|Device|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
140753|NCT03090711|Device|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
140754|NCT03090711|Device|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
140755|NCT03090711|Device|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
140756|NCT03090698|Drug|Hylan G-F 20|intra-articular administration
140757|NCT03090698|Drug|Triamcinolone|Intra-articular administration
140758|NCT03090685|Procedure|True auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
140759|NCT03090685|Procedure|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
140760|NCT03090672|Drug|Normal Saline|Normal Saline IV delivery
140761|NCT03090672|Procedure|Tissue Stromal Vascular Fraction|tSVF
140762|NCT03090672|Biological|Platelet Rich Plasma|PRP
140763|NCT03090672|Procedure|Cellular Stromal Vascular Fraction|cSVF
140764|NCT03090659|Biological|LCAR-B38M CAR-T cell injection|
140765|NCT03090646|Other|Financial Incentive|Up to three gift cards to a major online retailer.
140766|NCT03090633|Device|Fetoscopy|Minimally invasive in-utero surgery
140767|NCT03090620|Drug|Physostigmine|Administration of physostigmine bolus followed by an infusion
140768|NCT03090620|Drug|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
140769|NCT03090607|Device|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
140770|NCT03090607|Drug|Saline|Endoscopic injection of saline
140771|NCT03090594|Procedure|Biopsy|Is to obtain pulmonary parenchyma samples using a flexible bronchoscope.
140772|NCT03090581|Procedure|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
140773|NCT03090581|Procedure|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
140774|NCT03090568|Drug|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
140775|NCT03090555|Procedure|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
141060|NCT03088371|Other|Pajunk Needle|For local anaesthesia application in psoas sciatic block
140776|NCT03090555|Procedure|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
140777|NCT03090542|Dietary Supplement|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
140778|NCT03090529|Other|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
140779|NCT03090516|Drug|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
140780|NCT03090516|Drug|Donepezil|Arm A：Aricept 5mg/day
140781|NCT03090516|Drug|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
140782|NCT03090503|Drug|Aripiprazole|Initial dose: 10 mg.
140783|NCT03090503|Drug|Risperidone|Initial dose: 2 mg.
140784|NCT03090490|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
140785|NCT03090490|Other|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
140786|NCT03090477|Behavioral|Pharmaceutical care and adherence aids|Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
140787|NCT03090464|Other|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
140788|NCT03090451|Behavioral|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
140789|NCT03090438|Procedure|Varicocele embolization|Ultrasound guided right internal jugular vein access with placement of a vascular sheath. Fluoroscopically guided selective catheterization of the left and right (if bilateral) spermatic veins to the level of the inguinal ligament. Occlusion of the spermatic vein(s) by embolization coils and a sclerosing agent (sodium tetradecyl sulphate 3%).
140790|NCT03090412|Drug|HPPH|Given IV
140791|NCT03090412|Other|Laboratory Biomarker Analysis|Correlative studies
140792|NCT03090412|Drug|Photodynamic Therapy|Undergo PDT
140793|NCT03090412|Other|Quality-of-Life Assessment|Ancillary studies
140794|NCT03090412|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
140795|NCT03090399|Device|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
140796|NCT03090386|Other|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
140797|NCT03090373|Device|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
140798|NCT03090360|Dietary Supplement|Infant formula (CF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
140799|NCT03090360|Dietary Supplement|Infant Formula (EF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
140800|NCT03090347|Other|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
140801|NCT03090334|Diagnostic Test|De-escalation|Antifungal therapy will be stopped according with BG results
140802|NCT03090321|Behavioral|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
140803|NCT03090321|Behavioral|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
140804|NCT03090321|Behavioral|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
140805|NCT03090321|Behavioral|Read AHA website|Daily reminder to read the newsfeed from the American Heart Association (AHA) website, this is a control arm
140806|NCT03090308|Other|Noninvasive positive pressure ventilation|All patients were ventilated using NIPPV (Engstrom Carestation), which was delivered to the patient through full-face mask and was started with pressure support of 8-12 cmH2O and PEEP of 3-5 cmH2O and gradually increased in 2 cmH2O steps. When patients tolerate FiO2 ≤ 0.5 with pressure support ≤ 8 cmH2O and PEEP ≤ 5 cmH2O for > 6 consecutive hours, withdrawal from NIPPV was attempted daily in 30 minutes spontaneous breathing trials.
140807|NCT03090295|Device|Palpation and Accuro|Identify placement for spinal
140808|NCT03090282|Procedure|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
140809|NCT03090269|Drug|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
140810|NCT03090256|Device|AcrySof® IQ PanOptix™ IOL|Multifocal intraocular lens (IOL) (near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
140811|NCT03090243|Device|Virtual colonoscopy|Inserting a Foley catheter through the anus, and gas inflating of the bowel.
141061|NCT03088371|Other|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
140812|NCT03090230|Device|Relay Pro Thoracic Stent-Graft System|RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
140813|NCT03090217|Behavioral|Pelvic Physiotherapy|1) daily pelvic floor muscle training (PFMT).
140814|NCT03090217|Behavioral|Standard care (SC)|1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
140815|NCT03090204|Procedure|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
140816|NCT03090191|Biological|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
140817|NCT03090191|Biological|Placebo|Normal saline solution (0.9% sodium chloride)
140818|NCT03090178|Other|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
140819|NCT03090165|Drug|ribociclib|400mg PO
140820|NCT03090165|Drug|ribociclib|600mg PO
140821|NCT03090165|Drug|Bicalutamide|150mg PO
140822|NCT03090152|Procedure|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
140823|NCT03090152|Procedure|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
140824|NCT03090152|Drug|Bupivacaine|EPCA: Bupivacaine 0.06%.
140825|NCT03090152|Drug|Placebo|EPCA: Saline.
140826|NCT03090139|Drug|Anti-TNF Therapy|Anti-TNF therapy.
140827|NCT03090126|Other|Therapeutic education|Questionnaires
140828|NCT03090113|Drug|Shuxuetong Injection|intravenous drip
140829|NCT03090113|Drug|Placebo Injection|intravenous drip
140830|NCT03090100|Drug|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
140831|NCT03090100|Drug|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
140832|NCT03090100|Drug|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
140833|NCT03090087|Biological|Hypoxia|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
140834|NCT03090087|Drug|Regadenoson|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
140835|NCT03090074|Behavioral|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
140836|NCT03090074|Behavioral|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
140837|NCT03090061|Diagnostic Test|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
140838|NCT03090061|Diagnostic Test|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
140839|NCT03090048|Drug|Vitamin A|Vitamin A 2-3 % concentration
140840|NCT03090048|Drug|Azithromycin|azithromycin monohydrate
140841|NCT03090035|Drug|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
140842|NCT03090035|Drug|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
140843|NCT03090022|Procedure|Strattice|Intra-abdominally Fixation
140844|NCT03090022|Procedure|Single running suture of abdominal fascia|Intra-abdominal suture
140845|NCT03090009|Drug|Flurbiprofen|100 mg twice a day for 14 days
140846|NCT03090009|Drug|Placebo Oral Tablet|placebo group
140847|NCT03089996|Procedure|Piezocision|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
140848|NCT03089996|Procedure|Corticotomy|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
140884|NCT03089723|Drug|Lavage with physiologic saline solution and Osteonil® Mini|Joint lavage with physiologic saline solution and Osteonil® Mini
140885|NCT03089723|Behavioral|Quick Dash|Answer Quick Dash questionnaire at baseline, 1 month, 3 months and 6 months
140886|NCT03089723|Behavioral|Sollerman Test|Perform Sollerman Test at baseline, 1 month, 3 months and 6 months
141062|NCT03088371|Drug|Lidocaine 1%|For psoas sciatic block.
140849|NCT03089996|Device|Control Side|The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
140850|NCT03089983|Drug|Naltrexone|A naltrexone implant lasting 90 days will be used to deliver naltrexone.
140851|NCT03089983|Drug|Methadone|Participants will receive daily or weekly doses of oral methadone.
140852|NCT03089983|Drug|Isoniazid|Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
140853|NCT03089983|Drug|Rifapentine|Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
140854|NCT03089970|Diagnostic Test|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
140855|NCT03089957|Drug|Ulinastatin|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
140856|NCT03089957|Other|Usual care|Usual care in ICU.
140857|NCT03089944|Drug|Glecaprevir/Pibrentasvir|Tablet
140858|NCT03089931|Procedure|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
140859|NCT03089918|Drug|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
140860|NCT03089905|Drug|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
140861|NCT03089905|Drug|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
140862|NCT03089905|Drug|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
140863|NCT03089879|Biological|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
140864|NCT03089866|Drug|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
140865|NCT03089853|Device|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
140866|NCT03089840|Device|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
140867|NCT03089814|Procedure|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
140868|NCT03089801|Other|Tablet-Enabled Video Telehealth|Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
140869|NCT03089788|Other|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
140870|NCT03089788|Other|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
140871|NCT03089775|Drug|BBI-2000|Experimental
140872|NCT03089775|Drug|Vehicle|Vehicle Comparator
140873|NCT03089775|Other|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
140874|NCT03089762|Biological|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
140875|NCT03089736|Behavioral|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
140876|NCT03089736|Behavioral|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
140877|NCT03089736|Other|Treatment as usual (TAU)|pharmacological treatment + advices
140878|NCT03089723|Behavioral|Visual Analog Scale (VAS)|Answer Visual Analog Scale (VAS) questionnaire at baseline, 1 month, 3 months and 6 months
140879|NCT03089723|Behavioral|Range of Motion (ROM)|submitted to ROM at at baseline, 1 month, 3 months and 6 months
140880|NCT03089723|Behavioral|Palmar grip strength|submitted to palmar grip strength at at baseline, 1 month, 3 months and 6 months
140881|NCT03089723|Behavioral|Lateral grip strength|submitted to lateral grip strength at at baseline, 1 month, 3 months and 6 months
140888|NCT03089697|Biological|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
140889|NCT03089697|Other|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
140890|NCT03089684|Other|No intervention|No intervention
140891|NCT03089671|Other|Vitamin B (riboflavin, vitamin B2)|Vitamin B is a natural health product approved as a colouring agent.
140892|NCT03089671|Other|5% Dextrose in Water (D5W)|5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
140893|NCT03089658|Drug|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
140894|NCT03089645|Biological|MEDI5083 monotherapy|Dose-escalation MEDI5083 monotherapy followed by monotherapy with Durvalumab
140895|NCT03089645|Biological|MEID5083 with Durvalumab or Tremelimumab|Sequential Medi5083 with concurrent Durvalumab or Tremelimumab, and intermittent Medi5083 with concurrent Durvalumab
140896|NCT03089645|Biological|Medi5083 with Durvalumab and Docetaxel|Medi5083 with concurrent Durvalumab and Docetaxel randomized against Durvalumab and Docetaxel
140897|NCT03089632|Other|Gluten-free diet|One-month gluten-free diet
140898|NCT03089619|Drug|Human-Spongiosa|after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
140899|NCT03089619|Device|collacone®|after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
140900|NCT03089606|Diagnostic Test|FDG PET/CT scan|FDG PET/CT scan with IV contrast prior to treatment and C11-AMT PET scan co-registered with CT scan without IV contrast
140901|NCT03089606|Diagnostic Test|C11-AMT PET scan|C11-AMT PET scan co-registered with CT scan without IV contrast after FDG PET/CT scan with IV contrast before pembrolizumab
140902|NCT03089606|Drug|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
140903|NCT03089606|Diagnostic Test|FDG PET/CT scan with IV contrast|At end of Pembrolizumab treatment
140904|NCT03089593|Other|Extract of ginger|The volunteers will receive two capsules containing 200mg of extract of ginger with 5% of gingerols (20 mg). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
140905|NCT03089593|Other|Placebo (Cellulose)|The volunteers will receive two capsules containing cellulose (placebo). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
140906|NCT03089580|Device|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
140907|NCT03089580|Procedure|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
140908|NCT03089567|Drug|Sodium Fluoride|5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
140909|NCT03089567|Drug|Silver diamine fluoride|38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
140910|NCT03089554|Drug|Therapeutic Intervention|Therapeutic Intervention
140911|NCT03089541|Behavioral|Survey Arm|Contingency Management for completion of surveys and evidence of tobacco use status
140912|NCT03089528|Device|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
140913|NCT03089528|Device|laringoscope|the trachea will be intubated with a laringoscope
140914|NCT03089515|Diagnostic Test|Cardio-Pulmonary Exercise Testing (CPET)|This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
140915|NCT03089502|Other|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
140916|NCT03089489|Diagnostic Test|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
140917|NCT03089476|Other|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
140918|NCT03089476|Other|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
140919|NCT03089463|Diagnostic Test|Observation|The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
140920|NCT03089450|Device|CGBio stent|Percutaneous Coronary Intervention
140921|NCT03089450|Device|Biomatrix flex|Percutaneous Coronary Intervention
140922|NCT03089437|Behavioral|Prolonged Standing|Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day
176610|NCT02820688|Drug|Prilocaine 1%|
140924|NCT03089424|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
140925|NCT03089424|Device|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
140926|NCT03089398|Procedure|Hybrid Coronary Revascularization|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
140927|NCT03089398|Device|Hybrid Coronary Revascularization|percutaneous revascularization of at least one non-LAD target
140928|NCT03089398|Device|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
140929|NCT03089385|Other|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
140930|NCT03089372|Device|ARIES-ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
140931|NCT03089346|Diagnostic Test|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
140932|NCT03089346|Diagnostic Test|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
140933|NCT03089333|Drug|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
140934|NCT03089333|Drug|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
140935|NCT03089320|Behavioral|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
140936|NCT03089320|Behavioral|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
140937|NCT03089320|Behavioral|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.~MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
140938|NCT03089307|Device|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
140939|NCT03089294|Device|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
140940|NCT03089281|Device|CRT-D|Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing.
140941|NCT03089268|Procedure|Colonoscopy|A colonoscopy will be performed to all individuals.
140942|NCT03089268|Procedure|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
140943|NCT03089268|Genetic|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
140944|NCT03089242|Other|observation of microRNA expression|no intervention
140945|NCT03089229|Drug|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
140946|NCT03089229|Drug|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
140947|NCT03089216|Procedure|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
140948|NCT03089216|Procedure|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
140949|NCT03089216|Procedure|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
140950|NCT03089216|Procedure|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
140951|NCT03089216|Drug|8% arginine and calcium carbonate|using during all the treatment.
140952|NCT03089203|Biological|CART T cells|1-3x10^7
140953|NCT03089203|Biological|CART T cells|1-3 x 10^8
140954|NCT03089203|Drug|Cyclophosphamide 1g/m^2|day -3 of cohort 3 subjects only
140955|NCT03089203|Biological|CART T cells|MTD given in Cohort 3 only
140956|NCT03089190|Dietary Supplement|DC7-2|Effects on appetite
140957|NCT03089190|Dietary Supplement|DC7-2 + potato protein isolate|Effects on appetite
140958|NCT03089190|Dietary Supplement|Potato protein isolate|Effects on appetite
140959|NCT03089190|Dietary Supplement|Placebo|Inactive whey protein, not expected to affect appetite.
140960|NCT03089177|Behavioral|Community Garden Intervention|"The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~A garden plot in a Denver Urban Garden~Seeds and plant starts~Introductory gardening workshop~Social events including garden-specific events and garden mentoring.~The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.~Duration of the intervention is 1 year."
140961|NCT03089164|Diagnostic Test|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
140962|NCT03089151|Behavioral|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:~A garden plot in a Denver Urban Garden~Seeds and plant starts~Introductory gardening workshop~Social events including garden-specific events and garden mentoring.~The non-gardening group will remain on the DUG wait lists and will not receive these resources.~Duration of the intervention is 1 year."
140963|NCT03089138|Drug|Regan Tangjiang|The treatment duration is 3 consecutive days.
140964|NCT03089125|Behavioral|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions~Patients will receive:~Psychoeducation~Relaxation training for reducing physiological stress~Behavioral techniques for managing acute breathlessness"
140965|NCT03089125|Other|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
140966|NCT03089112|Drug|HGP1607|
140967|NCT03089112|Drug|HGP1501|
140968|NCT03089112|Drug|HGP1607+HGP1501|
140969|NCT03089099|Other|Blood drawing|Blood drawing
140970|NCT03089086|Biological|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to <3 months apart in adolescents.
140971|NCT03089073|Drug|Desmopressin|60μg or 120μg once daily at bedtime
140972|NCT03089060|Device|Silicone Finger cap|Treatment with silicone finger cap
140973|NCT03089060|Device|Film Dressing|Treatment with conventional film dressing
140974|NCT03089047|Biological|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
140975|NCT03089047|Biological|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
140976|NCT03089021|Other|mulligan mobilization|mobilization with movement for spinous process or facet joint.
140977|NCT03089021|Other|maitland mobilization|posterioanterior of spinous process or facet joint.
140978|NCT03089008|Other|Eccentric exercises|
140979|NCT03089008|Other|Stretching exercises|
140980|NCT03088995|Diagnostic Test|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
140981|NCT03088982|Other|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.~The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
140982|NCT03088969|Other|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
140983|NCT03088956|Other|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
140984|NCT03088943|Other|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
140985|NCT03088943|Other|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
140986|NCT03088943|Other|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
141063|NCT03088371|Drug|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
176615|NCT02820688|Drug|Prilocaine 0.5%|
140987|NCT03088930|Drug|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
140988|NCT03088904|Biological|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL. Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
140989|NCT03088904|Biological|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
140990|NCT03088891|Other|Antioxidant-rich snacks|Bama Smoothies (Bama, Oslo, Norway), Freia Premium Dark Chocolate (Freia, Oslo, Norway), Walnuts (Eldorado, Norway), Dried fruits and berries (Cranberries, Gojiberries, apricots)(Bama, Oslo, Norway and Rema 1000, Norway)
140991|NCT03088891|Other|Control snacks|Milkshake (Tine, Oslo, Norway), YT restitusjonsdrikk (Tine, Oslo, Norway), Bixit (Sætre, Oslo, Norway), Ritz (Mondelez, Oslo, Norway), White chololate (Freia, Oslo, Norway)
140992|NCT03088878|Drug|Cirmtuzumab|Administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter
140993|NCT03088878|Drug|Ibrutinib|Self-administered orally once daily
140994|NCT03088878|Drug|Cirmtuzumab plus ibrutinib|"Cirmtuzumab: Administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter~Ibrutinib: Self-administered orally once daily"
140995|NCT03088865|Diagnostic Test|aspirating first blood volume into a regular blood collection tube|order of blood drawing
140996|NCT03088852|Drug|Magnesium Citrate 100 MG|initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
140997|NCT03088826|Drug|Morphine Sulfate|15mg PO morphine sulfate
140998|NCT03088826|Drug|Oxycodone|10mg Oxycodone
140999|NCT03088826|Drug|Acetaminophen|650 mg Acetaminophen
141000|NCT03088813|Drug|Irinotecan liposome injection|IV
141001|NCT03088813|Drug|Topotecan|IV
141002|NCT03088800|Drug|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
141003|NCT03088800|Drug|APAP|Oral APAP at 15mg/kg dose
141004|NCT03088787|Device|Nexfin measuremtents|There will be only observational recordings, no interevntion
141005|NCT03088774|Other|Information material|Online web-application developed together with patients with low back pain
141006|NCT03088761|Device|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
141007|NCT03088748|Device|Journey II posterior cruciate retaining total knee arthroplasty|
141008|NCT03088748|Device|Journey II posterior bi-cruciate retaining total knee arthroplasty|
141009|NCT03088735|Procedure|Blastocyst-stage embryo transfer strategy|Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.
141010|NCT03088735|Procedure|Cleavage-stage embryo transfer strategy|Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients
141011|NCT03088722|Other|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
141012|NCT03088709|Drug|Cyclophosphamide|IV medication given for prevention of graft versus host disease.
141013|NCT03088709|Drug|Tacrolimus|IV medication given for prevention of graft versus host disease.
141014|NCT03088709|Drug|Mycophenolate mofetil|IV medication given for prevention of graft versus host disease.
141015|NCT03088709|Other|Haploidentical Stem Cell Transplantation|A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
141016|NCT03088696|Other|stimulation|activation of the acupuncture point
141017|NCT03088696|Other|no stimulation|no activation of the acupuncture point
141018|NCT03088683|Device|Nathanson Retractor|Liver will be retracted with Nathanson retractor
141019|NCT03088683|Device|Reveel Retractor|Liver will be retracted with Reveel retractor
141020|NCT03088670|Drug|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
141021|NCT03088670|Drug|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
141022|NCT03088670|Drug|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).~Administration: orally"
141023|NCT03088644|Drug|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
141024|NCT03088644|Drug|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
141025|NCT03088631|Drug|Metformin|will receive metformin (1500 mg/day) starting with the commencement of oral contraceptive pills in the preceding cycle until the day of human chorionic gonadotropin triggering.
141026|NCT03088631|Other|Placebo|will receive corn-flour placebo tablets (three tablets daily).
141027|NCT03088618|Procedure|Nasal septoplasty|Type of surgery
141028|NCT03088605|Drug|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
141029|NCT03088605|Drug|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
141064|NCT03088371|Drug|Lidocaine 2 %|For psoas sciatic block in the post-operative period
141065|NCT03088371|Drug|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
141066|NCT03088358|Drug|TeaRx|
141067|NCT03088358|Drug|Enoxaparin|
141030|NCT03088592|Device|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
141031|NCT03088579|Device|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
141032|NCT03088566|Procedure|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
141033|NCT03088566|Procedure|Conventional foot screening|The foot screening is performed with clinical conventional methods.
141034|NCT03088553|Drug|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
141035|NCT03088540|Drug|Pemetrexed|Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
141036|NCT03088540|Drug|Paclitaxel|Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
141037|NCT03088540|Drug|Gemcitabine|Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
141038|NCT03088540|Drug|Cisplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
141039|NCT03088540|Drug|Carboplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
141040|NCT03088540|Drug|cemiplimab|Patients will be administered cemiplimab as per protocol.
141041|NCT03088527|Drug|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
141042|NCT03088514|Dietary Supplement|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
141043|NCT03088501|Behavioral|Interactive voice response system|IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
141044|NCT03088501|Behavioral|Mother and baby affairs workshop|Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
141045|NCT03088488|Diagnostic Test|fasting venous blood samples|
141046|NCT03088475|Behavioral|nurse-led smartphone-based self-management programme|The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource
141047|NCT03088475|Behavioral|exiting nurse-led diabetes service|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
141048|NCT03088462|Other|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
141049|NCT03088462|Behavioral|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
141050|NCT03088462|Behavioral|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
141051|NCT03088436|Device|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
141052|NCT03088423|Radiation|SBRT delivers high dose selective irradiation with millimeter precision to a small volume. The Cyberknife® is a robotic SBRT dedicated device that can deliver 100 to 200 photobeams to the target|Seven to ten days before the scheduled CT, 2-4 fiducial markers were implanted percutaneously 2 to 5 cm next to the lesion under sonographic guidance following administration of local anesthesia, thus allowing real-time tracking during treatment. The total dose delivered was 45 Gy on the 80% isodose, in three fractions over 10 days. Gross tumor volume (GTV) was defined as the tumor mass that could be discerned by diagnostic imaging. An isotropic margin of 5 mm was added to account for the microscopic extension (clinical target volume, CTV) and another 3 mm margin was added to compensate for uncertainties regarding the position (previsional target volume, PTV)
141053|NCT03088410|Drug|Zidovudine|neonatal 4 weeks prophylactic
141054|NCT03088410|Drug|Nevirapine|neonatal 4 weeks prophylactic
141055|NCT03088397|Behavioral|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
141056|NCT03088397|Behavioral|Website|Patient directed to website with information on various contraceptive methods.
141057|NCT03088397|Behavioral|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
141058|NCT03088384|Drug|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
141059|NCT03088371|Drug|Bupivacaine 0.25%|For psoas sciatic block.
141068|NCT03088345|Drug|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
141069|NCT03088345|Drug|Placebos|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
141070|NCT03088332|Procedure|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
141071|NCT03088306|Drug|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
141072|NCT03088306|Drug|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
141073|NCT03088306|Drug|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
141074|NCT03088306|Drug|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
141075|NCT03088306|Drug|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
141076|NCT03088306|Drug|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
141077|NCT03088306|Drug|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
141078|NCT03088306|Drug|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
141079|NCT03088293|Drug|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
141080|NCT03088293|Drug|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
141081|NCT03088280|Drug|Thymoglobulin|reduced dose (3mg/Kg)
141082|NCT03088267|Drug|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
141083|NCT03088267|Drug|Placebo extended-release oral suspension|6, 7 or 8 mL PO
141084|NCT03088254|Drug|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|Twinstar(80/10 mg) and Rosuvastatin 20 mg for 8 weeks
141085|NCT03088254|Drug|Group II (Telmisartan 80 mg, Amodipine 10 mg, Rosuvastatin placebo)|Twinstar(80/10 mg) and Rosuvastatin placebo for 8 weeks
141086|NCT03088254|Drug|Group III (Telmisartan 80 mg, Amlodipine placebo, Rosuvastatin 20 mg)|Twinstar placebo, Amlodipine 10 mg and Rosuvastatin 20 mg for 8 weeks
141087|NCT03088241|Other|switch|switch to second-line ART
141088|NCT03088228|Diagnostic Test|gingival crevicular fluid collection|
141089|NCT03088215|Device|shock-waves|Application of shock-waves (radial and focused)
141090|NCT03088202|Other|Educational program|E-learning lectures, group exercises, skills training
141091|NCT03088202|Other|Standardized care pathways|Pathways for systematic follow-up
141092|NCT03088202|Other|Early palliative care|Compulsory referral to palliative care at inclusion
141093|NCT03088176|Drug|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
141094|NCT03088176|Drug|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
141095|NCT03088176|Drug|Dabrafenib|150mg PO qday
141096|NCT03088176|Drug|Trametinib|2mg PO qday
141097|NCT03088163|Device|Diffusion weighted magnetic resonance imaging|The enrolled colorectal liver metastases patients will receive DWI-MRI screening to evaluate the liver metastases before the chemotherapy, after the first cycle of chemotherapy and in the regular efficacy evaluation time, respectively.
141098|NCT03088150|Procedure|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
141099|NCT03088150|Procedure|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
141100|NCT03088137|Drug|Follitropin alfa (Gonal-f)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
141101|NCT03088137|Drug|Follitropin alfa (Primapur)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
141102|NCT03088124|Drug|Apalutamide|Patients will take orally everyday 240 mg of Apalutamide.
141103|NCT03088111|Other|Collection of samples|To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
141104|NCT03088111|Biological|Obiltoxaximab|Obiltoxaximab standard of care
141105|NCT03088098|Device|LAAO|Left atrial appendage occlusion for stroke prevention
141106|NCT03088085|Procedure|Self-mobilization|Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
141107|NCT03088085|Procedure|Sleep Education|Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
141108|NCT03088072|Drug|Edoxaban|"Edoxaban 60mg once daily in patients with CrCl >50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.~If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow <5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.~If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference."
141109|NCT03088072|Device|WATCHMAN LAA Closure|Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device
141110|NCT03088072|Drug|Aspirin and Clopidogrel|"If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.~Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit."
141111|NCT03088072|Drug|Aspirin and Warfarin|If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
141112|NCT03088059|Drug|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
141113|NCT03088059|Drug|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
141114|NCT03088059|Drug|standard of care|Methotrexate, Paclitaxel, Docetaxel, Carboplatin, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
141115|NCT03088059|Drug|IPH2201|protocol v2.0 and 2.1 : Monalizumab 10mg/kg given intravenously over 60 minutes, once every 14 days, 1 cycle is 14 days protocol v4.0 : Monalizumab 750mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
141116|NCT03088059|Drug|Durvalumab|Durvalumab 1500mg given intravenously over 60 minutes, once every 28 days, 1 cycle is 28 days
141117|NCT03088059|Drug|Niraparib|Niraparib 300 mg given orally, once daily, 1 cycle is 28 days
141118|NCT03088059|Drug|BAY1163877|Rogaratinib 600 mg given orally, twice daily, 1 cycle is 28 days
141119|NCT03088046|Drug|Micronized Progesterone|"Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.~Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2)."
141120|NCT03088033|Device|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
141121|NCT03088033|Other|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
141122|NCT03088007|Other|Cognitive, adaptive, behavioral and academic assessment|Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
141123|NCT03087994|Behavioral|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
141124|NCT03087994|Behavioral|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance once during the study
141125|NCT03087968|Drug|GS-4997|Experimental drug
141126|NCT03087968|Drug|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
141127|NCT03087968|Device|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.~For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
141128|NCT03087968|Drug|Placebo|Placebo
141129|NCT03087955|Drug|SCYX 7158|
141130|NCT03087942|Drug|QAW039|450 mg
141131|NCT03087942|Drug|QAW39A|450 mg
141132|NCT03087942|Drug|QAW39A2107|450 mg
141133|NCT03087942|Drug|QAW39A2107|450 mg
141134|NCT03087929|Other|Follow up|
141177|NCT03087604|Drug|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
141178|NCT03087591|Other|Laboratory Biomarker Analysis|Correlative studies
141847|NCT03082183|Drug|Rifampicin|once daily
141135|NCT03087903|Dietary Supplement|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
141136|NCT03087890|Drug|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
141137|NCT03087890|Drug|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
141138|NCT03087877|Device|Acetaminophen Challenge (G6 CGM)|Evaluation of acetaminophen effect on CGM glucose sensing
141139|NCT03087864|Drug|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
141140|NCT03087864|Drug|Carboplatin|Chemotherapy
141141|NCT03087864|Drug|Paclitaxel|Chemotherapy
141142|NCT03087864|Radiation|Radiotherapy 23 x 1.8 Gy|Radiotherapy
141143|NCT03087851|Drug|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
141144|NCT03087825|Procedure|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
141145|NCT03087825|Procedure|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
141146|NCT03087799|Behavioral|Brief Behavioral Treatment for Sleep|The BBT arm will consist of 2 in-person treatment visits and 2 telephone check-in visits. Treatment will involve psychoeducation about sleep hygiene and stimulus control as well as sleep schedule modification and sleep restriction. The treatment manual is attached for clarification. This manual is used solely to guide clinical decision making and will not be provided to participants.
141147|NCT03087786|Drug|Nicotine Bitartrate Lozenge 4mg|Test Product
141148|NCT03087786|Drug|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
141149|NCT03087773|Drug|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
141150|NCT03087773|Drug|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
141151|NCT03087760|Drug|Pembrolizumab|Concurrent Pembrolizumab after proton reirradiation
141152|NCT03087747|Procedure|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
141153|NCT03087734|Device|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
141154|NCT03087734|Device|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
141155|NCT03087721|Behavioral|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
141156|NCT03087721|Behavioral|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
141157|NCT03087708|Drug|Naloxegol|Given PO
141158|NCT03087708|Other|Placebo|Given PO
141159|NCT03087708|Other|Laboratory Biomarker Analysis|Correlative studies
141160|NCT03087708|Other|Quality-of-Life Assessment|Ancillary studies
141161|NCT03087695|Diagnostic Test|Plasma EBV DNA|Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods.
141162|NCT03087682|Diagnostic Test|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
141163|NCT03087669|Device|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
141164|NCT03087669|Drug|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
141165|NCT03087656|Drug|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
141166|NCT03087656|Drug|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
141167|NCT03087643|Other|Passive mobilization - PM|
141168|NCT03087630|Behavioral|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
141169|NCT03087630|Behavioral|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
141170|NCT03087630|Behavioral|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
141171|NCT03087630|Behavioral|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
141172|NCT03087617|Device|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
141173|NCT03087617|Behavioral|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
141174|NCT03087617|Other|Usual Care|Usual Care for Lung Cancer Screening patients.
141175|NCT03087604|Procedure|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
141176|NCT03087604|Procedure|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
141179|NCT03087591|Biological|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|Given IV
141180|NCT03087578|Other|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
141181|NCT03087578|Drug|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
141182|NCT03087565|Procedure|subtotal hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.~Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics . The abdomen is closed in layers; the wound is covered with a sterile dressing."
141183|NCT03087565|Procedure|Total hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Revision of all pedicles to ensure hemostasis.~The abdomen is closed in layers; the wound is covered with a sterile dressing."
141184|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
141185|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
141186|NCT03087539|Biological|Abciximab|
141187|NCT03087539|Biological|Placebo|
141188|NCT03087526|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
141189|NCT03087513|Drug|Sugammadex Injection|1mls per 10kg basis-up to 100kg
141190|NCT03087513|Drug|Placebos|0.9% saline-1mls per 10kg basis-up to 100kg
141191|NCT03087474|Other|Non-Interventional|Non-Interventional
141192|NCT03087461|Behavioral|Exercise and self-management|The intervention will include aerobic exercise and self-management education using technology.
141193|NCT03087448|Drug|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.~Phase I dose escalation:~Ceritinib 300mg~Ceritinib 450mg~Ceritinib 450mg~The Phase II doses will be determined by Phase I dose escalation study"
141194|NCT03087448|Drug|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.~Phase I dose escalation:~Trametinib 1.5mg~Trametinib 1.5mg~Trametinib 2.0mg~The Phase II doses will be determined by Phase I dose escalation study"
141195|NCT03087435|Device|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
141196|NCT03087422|Behavioral|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
141197|NCT03087396|Device|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
141198|NCT03087370|Other|No intervention|No intervention
141199|NCT03087357|Other|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
141200|NCT03087344|Device|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
141201|NCT03087344|Device|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
141202|NCT03087344|Device|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
141203|NCT03087331|Other|medication reviews, assessment, recommendations, education.|
141204|NCT03087318|Behavioral|Physical activity|"Physical activity:~3 sessions / week at least~at least during 30 minutes each session~at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~during 3 months."
141205|NCT03087305|Diagnostic Test|Supraclavicular lymph node ultrasound|Patients will have supraclavicular lymph node assessed prior to EBUS-TBNA
141206|NCT03087292|Other|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
141207|NCT03087279|Behavioral|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
141208|NCT03087266|Procedure|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
141209|NCT03087266|Procedure|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
141210|NCT03087240|Procedure|Dental Prophylaxis|Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
141211|NCT03087227|Device|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
141212|NCT03087201|Drug|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined~Duration of treatment: 13 weeks"
141213|NCT03087201|Drug|placebo|analogous to experimental intervention
141214|NCT03087188|Other|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.~While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
141215|NCT03087175|Device|MGuard stent|MGuard micronet mesh-covered stent in treatment of STE and NSTE-ACS
141216|NCT03087175|Device|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of STE and NSTE-ACS For example, Resolute Onyx
141497|NCT03084913|Other|Prostate Cancer Foundation diet|followed for 8 weeks
141217|NCT03087162|Drug|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
141218|NCT03087149|Dietary Supplement|monitored vit D supplementation|The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born <30 GA, at 8 week of age for infants born <26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
141219|NCT03087149|Dietary Supplement|standard vit D supplementation|The vitamin D supplementation dose is 500IU from 7th day of age.
141220|NCT03087136|Diagnostic Test|anti-aquaporin-4 antibody|Serum anti-aquaporin-4 antibody
141221|NCT03087136|Diagnostic Test|anti-myelin oligodendrocyte glycoprotein|Serum anti-myelin oligodendrocyte glycoprotein
141222|NCT03087123|Behavioral|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
141223|NCT03087110|Biological|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (>1x10^7 cells/kg)
141224|NCT03087097|Biological|Fecal Microbiota Transplantation|Fecal microbiota delivered by rectal catheter enema in participants 12-60 months of age with stable SAM not responsive to at least 8 weeks of standard therapy.
141225|NCT03087084|Device|Cardiac Pacing and Impedance Measurement system|Subjects indicated for Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy Defibrillator device implant will be requested to perform some respiratory manoeuvres while impedance and electrogram signals are recorded by the system
141226|NCT03087071|Other|Laboratory Biomarker Analysis|Correlative studies
141227|NCT03087071|Biological|Panitumumab|Given IV
141228|NCT03087071|Drug|Trametinib|Given PO
141229|NCT03087058|Drug|Patiromer|4.2 g/day, 8.4 g/day and 16.8 g/day
141230|NCT03087058|Drug|Patiromer|2 g/day, 4 g/day and 8 g/day
141231|NCT03087058|Drug|Patiromer|1 g/day, 2 g/day and 4 g/day
141232|NCT03087032|Drug|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
141233|NCT03087032|Drug|insulin glargine|Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
141234|NCT03087019|Radiation|Radiation|Standard use of radiation is administered
141235|NCT03087019|Drug|Pembrolizumab|Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
141236|NCT03087006|Other|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
141237|NCT03087006|Other|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
141238|NCT03086993|Combination Product|Melphalan/HDS|Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
141239|NCT03086993|Drug|Cisplatin and Gemcitabine|continuous treatment with Cis/Gem until disease progression
141240|NCT03086980|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
141241|NCT03086980|Other|Treatment as Usual|Usual Care will be provided.
141242|NCT03086967|Device|Double-lumen balloon catheter|introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
141243|NCT03086954|Biological|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
141244|NCT03086941|Device|I-gel|To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
141245|NCT03086928|Other|lava ultimate|resin nano ceramic material
141246|NCT03086928|Other|E.max cad|Lithium disilicate glass ceramic
141247|NCT03086915|Drug|Neuromuscular Blocking Agent|Administration of neuromuscular blockers during anesthesia
141248|NCT03086902|Device|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
141249|NCT03086902|Device|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
141250|NCT03086889|Other|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
141251|NCT03086889|Other|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
141252|NCT03086876|Behavioral|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
180888|NCT02788331|Other|No intervention|
141253|NCT03086863|Device|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
141254|NCT03086863|Device|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
141255|NCT03086850|Behavioral|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:~<6000 steps/day: increase by 3000 steps/day~6000 - 10000 steps/day: reach 10000 steps/day~> 10000 steps/day: maintain or increase steps"
141256|NCT03086850|Other|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
141257|NCT03086837|Behavioral|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
141258|NCT03086824|Device|magnetic resonance-guided focused ultrasound|
141259|NCT03086811|Behavioral|Mother Infant Feeding Interaction very early training|"weekly training meetings on 4 topics:~What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~Who - feeding skills - knowledge and actual practices~From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~Prevention of obesity and emotional eating - practical advise and tips."
141260|NCT03086798|Procedure|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
141261|NCT03086798|Procedure|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
141262|NCT03086785|Drug|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
141263|NCT03086772|Behavioral|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
141264|NCT03086772|Behavioral|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
141265|NCT03086759|Procedure|platelet rich plasm|intra-articular infiltration with platelet rich plasm
141266|NCT03086759|Drug|Triamcinolone Hexacetonide|intra-articular infiltration withTriamcinolone Hexacetonide
141267|NCT03086759|Procedure|Isotonic Saline Solution|intra-articular infiltration with Isotonic Saline Solution
141268|NCT03086733|Drug|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
141269|NCT03086720|Procedure|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
141270|NCT03086720|Procedure|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
141271|NCT03086707|Other|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
141272|NCT03086681|Drug|Endostar|Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
141273|NCT03086681|Drug|DDP|DDP: 40mg /m2，per week, for 5 cycles
141274|NCT03086668|Procedure|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
141275|NCT03086668|Procedure|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
141276|NCT03086655|Behavioral|Tel-me-box with reminder features|Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.
141277|NCT03086655|Behavioral|Tel-me-box|Participants receive tel-me-box device with no reminder features added.
141278|NCT03086642|Drug|Talimogene laherparepvec|"T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).~On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL. The second injection up to 4.0 mL of 10^6, 10^7, or 10^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion."
141279|NCT03086629|Other|Patient Concerns Inventory|
141280|NCT03086629|Other|No Patient Concerns Inventory|
186083|NCT02750254|Drug|Cyclophosphamide|
141281|NCT03086616|Drug|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
141282|NCT03086564|Biological|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2*10^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
141283|NCT03086564|Procedure|TACE|TACE solely in the first day of a clinical course.
141284|NCT03086551|Device|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
141285|NCT03086551|Device|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
141286|NCT03086551|Behavioral|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
141287|NCT03086538|Drug|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
141288|NCT03086538|Drug|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
141289|NCT03086525|Other|Diagnosis/Prognosis|The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
141290|NCT03086512|Device|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
141291|NCT03086512|Device|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
141292|NCT03086486|Drug|Pretomanid|200mg tablets
141293|NCT03086486|Drug|Linezolid|Scored 600mg tablets
141294|NCT03086486|Drug|Bedaquiline|100mg tablets
141295|NCT03086486|Drug|Placebo Linezolid|Scored 600 mg tablets
141296|NCT03086473|Drug|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
141297|NCT03086473|Drug|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
141298|NCT03086460|Drug|CHF 1531|Dose Response: Test one of five different doses of CHF 1531
141299|NCT03086460|Drug|Formoterol Inhalation Solution|Active Control
141300|NCT03086460|Drug|Placebo|Matched Placebo
141301|NCT03086447|Device|Investigational Contact Lens|Senofilcon C Toric
141302|NCT03086447|Device|Marketed Contact Lens|Air Optix for Astigmatism
141303|NCT03086434|Other|Culturally Tailored Intervention|School-based substance use prevention
141304|NCT03086434|Other|Standard Substance Abuse Education|Class room program
141305|NCT03086421|Behavioral|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
141306|NCT03086408|Device|THRIVE|active nasal oxygen delivery system
141307|NCT03086408|Device|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
141308|NCT03086395|Drug|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
141309|NCT03086382|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
141310|NCT03086382|Drug|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
141311|NCT03086369|Drug|Olaratumab|Administered IV
141312|NCT03086369|Drug|Nab-paclitaxel|Administered IV
141313|NCT03086369|Drug|Gemcitabine|Administered IV
141314|NCT03086369|Drug|Placebo|Administered IV
141315|NCT03086356|Drug|Dabigatran etexilate|Days 1-4 and Day 8-11
141316|NCT03086356|Drug|Idarucizumab|Day 11
141317|NCT03086343|Drug|Upadacitinib matching placebo|Oral tablet
141318|NCT03086343|Drug|Abatacept matching placebo|IV infusion
141319|NCT03086343|Drug|Upadacitinib|Oral Tablet
141320|NCT03086343|Drug|Abatacept|IV infusion
141321|NCT03086330|Drug|Semaglutide|Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
141322|NCT03086330|Drug|Placebo|Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
141323|NCT03086317|Device|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
186785|NCT02744612|Drug|Ibrutinib|Given PO
141324|NCT03086317|Device|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
141325|NCT03086304|Device|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture points.
141326|NCT03086304|Device|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
141327|NCT03086291|Drug|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
141328|NCT03086278|Drug|AST-008|AST-008 is a toll-like receptor 9 agonist.
141329|NCT03086265|Device|THRIVE|active nasal oxygen delivery system
141330|NCT03086265|Device|Endotracheal tube|Plastic tube for supporting ventilation during surgery
141331|NCT03086252|Procedure|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
141332|NCT03086239|Drug|Rovalpituzumab tesirine|Intravenous
141333|NCT03086226|Drug|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
141334|NCT03086226|Drug|Itraconazole|This will be the active comparator
141335|NCT03086213|Drug|Propofol|anaesthetic
141336|NCT03086213|Drug|Sulfentanyl|anaesthetic
141337|NCT03086213|Drug|Dexmedetomidine|anaesthetic
141338|NCT03086213|Drug|Lidocaine|local anaesthetics
141339|NCT03086213|Drug|Ropivacaine|local anaesthetics
141340|NCT03086200|Behavioral|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.~Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
141341|NCT03086187|Device|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
141342|NCT03086174|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab|humanized anti-PD-1 monoclonal antibody Toripalimab is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
141343|NCT03086161|Behavioral|Interpersonal Psychotherapy|Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy
141344|NCT03086161|Behavioral|Treatment-as-usual|Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
141345|NCT03086148|Drug|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
141346|NCT03086148|Drug|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
141347|NCT03086135|Device|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
141348|NCT03086122|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
141349|NCT03086109|Other|Risk factors|Risk factors associated bone degenerative diseases
141350|NCT03086096|Device|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
141351|NCT03086083|Behavioral|EMDR standard protocol|Patient have only one standard EMDR session about a traumatic situation remembered by him.
141352|NCT03086083|Behavioral|protocol without brain stimulation|Patient have only one standard EMDR session about a traumatic situation remembered by him, however, without the bilateral brain stimulation.
141353|NCT03086070|Drug|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
141354|NCT03086070|Drug|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
141355|NCT03086057|Behavioral|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
141356|NCT03086057|Behavioral|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
141357|NCT03086044|Drug|Sofosbuvir/velpatasvir|4 weeks of treatment beginning on the day of transplant or as soon as the recipient is able to tolerate oral medications after transplantation.
141358|NCT03086044|Other|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
141493|NCT03084939|Drug|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
141359|NCT03086031|Behavioral|Program -based vocational rehabilitation intervention|"The VR intervention lasts for a total of 6-9 months with first six different modules (3-month) that are individually planned, and second a work placement program (approximately 3-6 months). Each of the different modules follows a comprehensive standard operating procedures (SOP's). The six modules will be grouped into (a) individual therapies which includes neuropsychological sessions (10-hours), balance between work and everyday life (20-hours), and job matching (10-hours), (b) grouped-based therapies which includes psycho education (18-hours), mindfulness (15-hours), and physiotherapy training (15-hours), (c) an manualized family intervention program (8 sessions of 90 minutes), and an individual caregiver coaching (12-hours), (d) a work placement program including work practice (3-6 month), supported employment by the rehabilitation team (30-hours), and the development of a post rehabilitation plan (4-hours)."
141360|NCT03086031|Behavioral|Conventional vocational rehabilitation (controls)|Treatment as usual delivered by the municipalities.
141361|NCT03086018|Device|Successor hearing aid to Juna|The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.
141362|NCT03086005|Drug|Metformin|
141363|NCT03085992|Drug|FOLFOXIRI plus Bevacizumab|"BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
141364|NCT03085992|Other|Chemoradiotherapy plus Bevacizumab|"FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;~EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;~BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
141365|NCT03085979|Procedure|Burch Colposuspension|Anti-incontinent surgery
141366|NCT03085979|Procedure|trans obturator tape|Anti-incontinent surgery
141367|NCT03085979|Procedure|tension free vaginal tape|Anti-incontinent surgery
141368|NCT03085966|Biological|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
141369|NCT03085953|Behavioral|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
141370|NCT03085953|Other|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
141371|NCT03085940|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
141372|NCT03085940|Drug|Placebo|Placebo
141373|NCT03085927|Behavioral|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
141374|NCT03085927|Behavioral|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
141375|NCT03085914|Drug|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose
141376|NCT03085914|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks
141377|NCT03085914|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 IV on Days 1 and 15
141378|NCT03085914|Drug|Leucovorin|Leucovorin 400 mg/m^2 IV on Days 1 and 15
141379|NCT03085914|Drug|5-Fluorouracil|5-Fluorouracil total dose of 2400 mg/m^2 on Days 1 and 15
141380|NCT03085914|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 IV on Days 1, 8, and 15
141381|NCT03085914|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 IV on Days 1, 8, and 15
141382|NCT03085914|Drug|Carboplatin|Carboplatin AUC 6 IV on Day 1 every 3 weeks
141383|NCT03085914|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 every 3 weeks
141384|NCT03085914|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 every 3 weeks
141385|NCT03085914|Drug|Cyclophosphamide|Cyclophosphamide 50 mg orally once daily
141386|NCT03085914|Drug|Carboplatin|Carboplatin AUC 5 IV on Day 1 every 3 weeks
141387|NCT03085914|Drug|Cisplatin|Cisplatin 75 mg/m^2 on Day 1 every 3 weeks
141388|NCT03085901|Device|Precizon toric intraocular lens|Phacoemulsification and implantation of Precizon toric intraocular lens
141389|NCT03085901|Device|Tecnis toric intraocular lens|Phacoemulsification and implantation of Tecnis toric intraocular lens
141390|NCT03085849|Drug|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
141391|NCT03085849|Drug|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
141392|NCT03085849|Drug|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity~Dose escalation scheme:~Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
141393|NCT03085836|Drug|TAK-438|TAK-438 tablets.
141394|NCT03085823|Device|Sirolimus Coated Balloon|
141395|NCT03085810|Drug|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
141396|NCT03085797|Drug|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
141397|NCT03085797|Drug|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
141398|NCT03085797|Drug|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations [50 g/actuation] in each nostril once daily).
141399|NCT03085784|Drug|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
141400|NCT03085771|Drug|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
141401|NCT03085771|Drug|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
141402|NCT03085758|Biological|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
141403|NCT03085758|Biological|Placebo|Single i.v. dose of placebo (control group)
141404|NCT03085745|Other|Transcranial Magnetic Stimulation (TMS)|TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
141405|NCT03085732|Drug|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
141406|NCT03085719|Drug|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
141407|NCT03085719|Radiation|Radiation|Radiation is used to shrink the cancer
141408|NCT03085706|Biological|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
141409|NCT03085680|Drug|Curcumin|Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
141410|NCT03085680|Drug|microcrystalline cellulose|Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
141411|NCT03085654|Drug|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
141412|NCT03085654|Drug|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
141413|NCT03085641|Device|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
141414|NCT03085628|Drug|Oxytocin|40IU
141415|NCT03085628|Drug|Placebo|40IU
141416|NCT03085615|Other|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
141417|NCT03085602|Behavioral|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
141418|NCT03085602|Behavioral|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
141419|NCT03085563|Drug|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
141420|NCT03085563|Drug|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
141421|NCT03085550|Procedure|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
141422|NCT03085550|Procedure|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
141423|NCT03085524|Diagnostic Test|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
141424|NCT03085524|Diagnostic Test|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
141425|NCT03085511|Behavioral|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
141494|NCT03084939|Drug|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
141558|NCT03084458|Behavioral|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
141426|NCT03085511|Behavioral|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
141427|NCT03085511|Behavioral|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
141428|NCT03085511|Behavioral|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
141429|NCT03085498|Other|No intervention|no intervention
141430|NCT03085485|Drug|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
141431|NCT03085485|Drug|Placebo|placebo pills
141432|NCT03085459|Behavioral|work Time|nurse got qualification certificate and the working time
141433|NCT03085446|Behavioral|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
141434|NCT03085446|Behavioral|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
141435|NCT03085433|Device|Microfluidic Sperm Sorting|Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
141436|NCT03085433|Procedure|in vitro fertilization|ivf/icsi
141437|NCT03085420|Diagnostic Test|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
141438|NCT03085407|Procedure|early cholecystectomy|cholecystectomy was done within 48 after admission
141439|NCT03085407|Procedure|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
141440|NCT03085394|Drug|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
141441|NCT03085394|Drug|Placebo|Preoperative intravenous administration of 10 ml saline
141442|NCT03085381|Biological|HPV vaccine|
141443|NCT03085381|Biological|Placebo|
141444|NCT03085368|Drug|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
141445|NCT03085355|Procedure|Exercises and PNE|Exercise for stretching and strength for neck muscles and pain neuroscience education
141446|NCT03085355|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
141447|NCT03085342|Diagnostic Test|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
141448|NCT03085329|Device|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
141449|NCT03085329|Device|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher & Paykel bubbler device, which is the standard of care at Nationwide Children's.
141450|NCT03085316|Device|Investigational device|Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
141451|NCT03085303|Device|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
141452|NCT03085290|Other|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
141453|NCT03085290|Other|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
141454|NCT03085277|Dietary Supplement|Bovine Colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
141455|NCT03085277|Dietary Supplement|Preterm Formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
141456|NCT03085264|Behavioral|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
141495|NCT03084926|Drug|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
141630|NCT03083821|Drug|Baraclude|Specified dose on specified day
141457|NCT03085251|Device|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure~Subjects will be asked to wash and dry their hands before the measurements.~The measurement procedure for each reagent system lot of a BGMS will be as follows:~Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.~Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.~Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.~The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
141458|NCT03085238|Device|M-Trap|Device(s) will be surgically implanted in the peritoneal cavity.
141459|NCT03085225|Drug|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).~Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
141460|NCT03085212|Behavioral|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
141461|NCT03085199|Procedure|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, LARS commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
141462|NCT03085186|Drug|Crizotinib|
141463|NCT03085173|Biological|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10^5, 3 x 10^5, 1 x 10^6, and 3 x 10^6 CAR T cells/kg.
141464|NCT03085160|Behavioral|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
141465|NCT03085160|Behavioral|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
141466|NCT03085147|Drug|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
141467|NCT03085134|Other|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
141468|NCT03085134|Other|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
141469|NCT03085121|Procedure|Distal femoral resection in total knee arthroplasty|EM and IM alignment systems are used to make the distal femoral cut in a random order.
141470|NCT03085108|Other|No Intervention|No Intervention
141471|NCT03085095|Drug|Relugolix|Relugolix 120 mg tablet administered orally once daily following an oral loading dose of 360 mg on Day 1
141472|NCT03085095|Drug|Leuprolide Acetate|Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in some Asian countries), every 3-months by subcutaneous or intramuscular injection
141473|NCT03085082|Diagnostic Test|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
141474|NCT03085069|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
141475|NCT03085056|Drug|Trametinib|trametinib orally 2mg daily during each 4 week cycle
141476|NCT03085056|Drug|Paclitaxel|paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks
141477|NCT03085043|Procedure|Bone Scan|Undergo bone scan
141478|NCT03085043|Procedure|Computed Tomography|Undergo CT of the abdomen and pelvis
141479|NCT03085043|Procedure|Magnetic Resonance Imaging|Undergo pelvic MRI
141480|NCT03085043|Procedure|Magnetic Resonance Whole Body Diffusion-Weighted Imaging|Undergo magnetic resonance whole body diffusion-weighted imaging
141481|NCT03085030|Drug|Antioxidant Formula|Antioxidant tablet will be taken by the patients
141482|NCT03085030|Drug|Placebo|The placebo will be taken by the patients
141483|NCT03085017|Device|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
141484|NCT03085017|Device|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
141485|NCT03085004|Drug|Ethanol|The cyst will be lavaged for 3 to 5 minutes using 98% ethanol as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
141486|NCT03085004|Drug|Normal saline|The cyst will be lavaged for 3 to 5 minutes using normal saline as the lavage agent prior to infusing the cyst with the paclitaxel + gemcitabine admixture.
141487|NCT03085004|Drug|Paclitaxel + Gemcitabine admixture|Following lavage, cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
141488|NCT03084978|Procedure|General Anesthesia|General anesthesia by standard endotracheal intubation.
141489|NCT03084978|Procedure|Conscious Sedation|Conscious sedation
141490|NCT03084952|Drug|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
141491|NCT03084952|Drug|Glucantime|Leishmaniasis standard drug in Brazil
141492|NCT03084939|Biological|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
141498|NCT03084900|Other|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
141499|NCT03084887|Behavioral|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
141500|NCT03084874|Behavioral|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
141501|NCT03084861|Drug|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
141502|NCT03084861|Drug|Conventional treatment|"Artificial tears: Lubristil ®~Therapeutic Contact lens: Air Optix Night&Day"
141503|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
141504|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
141505|NCT03084835|Behavioral|Usual Care|Brief cessation counseling
141506|NCT03084835|Behavioral|WEB+TXT|Access to Become an Ex website plus text messaging
141507|NCT03084835|Behavioral|WEB+TXT+TTS|Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
141508|NCT03084822|Behavioral|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
141509|NCT03084809|Drug|Cytokine-induced killer cells+ FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
141510|NCT03084809|Drug|FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
141511|NCT03084796|Drug|CHF 5259|Dose Response: Test one of four different doses of CHF 5259
141512|NCT03084796|Drug|Placebo|Placebo Control
141513|NCT03084796|Drug|Tiotropium Bromide 18 MCG Inhalation Capsule|Active Control
141514|NCT03084783|Drug|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
141515|NCT03084770|Diagnostic Test|Radiological imaging studies|Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67> 2%) a high quality imaging (CT scan or MRI) is required.
141516|NCT03084770|Other|Quality of Life Assessment|quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
141517|NCT03084757|Diagnostic Test|research of druggable molecular alterations on tumor biopsy|The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
141518|NCT03084744|Behavioral|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
141519|NCT03084744|Behavioral|Active monitoring|Active tele-monitoring by clinical psychologists.
141520|NCT03084731|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
141521|NCT03084718|Drug|CHF 781|Dose Response: Test one of three different doses of CHF 781
141522|NCT03084718|Drug|Placebos|Placebo Control
141523|NCT03084718|Drug|Beclomethasone Dipropionate|Active Control
141524|NCT03084705|Device|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
141525|NCT03084692|Behavioral|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
141526|NCT03084679|Other|Aerobic exercise in treadmill|30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
141848|NCT03082183|Drug|BI 425809|once daily
141527|NCT03084679|Other|Local strengthening exercises|15 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
141528|NCT03084679|Other|Stretching exercises|5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
141529|NCT03084666|Device|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
141530|NCT03084653|Other|Survey|Close-ended survey will be performed to the participants. The survey consisted of 18 questions (Appendix). The first six questions (#1-6) were related with respondent's demographical and educational data and experiences of surgical and laparoscopic practices. There were five questions to determine preferred technique for first entry (#7-11), three questions for complications (#12-14), and remaining four questions for safety maneuvers (#15-18).
141531|NCT03084640|Drug|CMP-001|CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
141532|NCT03084640|Drug|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
141533|NCT03084640|Drug|CMP-001|CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
141534|NCT03084627|Behavioral|Tailored dietary advice|The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
141535|NCT03084601|Drug|Calcium Hydroxide, Iodoform, paste|mixture of calcium hydroxide and iodoform
141536|NCT03084601|Drug|3-mixtatin|3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
141537|NCT03084588|Drug|methadone|Patients will be given methadone at induction of anesthesia
141538|NCT03084588|Procedure|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
141539|NCT03084575|Procedure|Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy|Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
141540|NCT03084575|Drug|hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)|L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
141541|NCT03084575|Device|Thermal RF lesioning is done using Bailys RF generator|
141542|NCT03084562|Other|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
141543|NCT03084549|Drug|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
141544|NCT03084549|Drug|Administration of placebo|Administration of placebo in the margins of the episiotomy
141545|NCT03084536|Drug|Bupivacaine|-Given after general anesthesia
141546|NCT03084536|Drug|Gabapentin|"As per routine care~Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years."
141547|NCT03084536|Drug|Celecoxib|"As per routine care~Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.~Naproxen will be substituted for celecoxib in patients with sulfa allergies."
141548|NCT03084536|Drug|Acetaminophen|-As per routine care
141549|NCT03084536|Drug|Midazolam|-As per routine care
141550|NCT03084536|Drug|Fentanyl|-As per routine care
141551|NCT03084523|Drug|Ferumoxytol Injectable Product|Patients will be administered a single dose of ferumoxytol as an MRI contrast
141552|NCT03084510|Device|Lotus™ Valve System|"The Lotus™ Valve System consisting of two main components:~a bioprosthetic bovine pericardial aortic valve, and~a delivery system Device sizes include 23 mm, 25 mm, and 27 mm diameter."
141553|NCT03084497|Procedure|Infant Massage|"The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.~Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.~When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation."
141554|NCT03084484|Dietary Supplement|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
141555|NCT03084484|Procedure|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
141556|NCT03084471|Biological|MEDI4736 (Durvalumab)|A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
141557|NCT03084471|Biological|MEDI4736 (Durvalumab) + Tremelimumab|"Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC.~Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation [CD]152) with CD80 and CD86 and increase release of cytokines (interleukin [IL]-2 and interferon [IFN]-γ) from human T cells, peripheral blood mononuclear cells and whole blood."
141559|NCT03084432|Diagnostic Test|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
141560|NCT03084419|Drug|Abatacept|"The IV dose varies according to weight:~<60kg=500mg~≥60 but≤100kg=750mg >100kg=1g~This equates to approximately 10mg/kg."
141561|NCT03084406|Other|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
141562|NCT03084380|Biological|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
141563|NCT03084380|Drug|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
141564|NCT03084380|Drug|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
141565|NCT03084367|Diagnostic Test|iFR pullback|iFR pullback assessment post angiographically successful PCI
141566|NCT03084354|Other|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
141567|NCT03084341|Procedure|Neuromuscular Electrical Elongation|Electrotherapy equipment will be used, choosing an interferential current through bipolar application,with a frequency of 4 kHz and a frequency modulation amplitude of 100 Hz.
141568|NCT03084341|Procedure|Proprioceptive Neuromuscular Facilitation|Hold-relax technique that involves lengthening the muscle to the point of limitation, at which point the individual performs an isometric contraction for up to 10 s, followed by a passive movement of the limb into the new end-range.
141569|NCT03084328|Dietary Supplement|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
141570|NCT03084315|Device|E-Cig Zero Nicotine|E-Cig Zero Nicotine
141571|NCT03084315|Device|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
141572|NCT03084289|Biological|ChAd63-METRAP|The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
141573|NCT03084289|Biological|MVA ME-TRAP|The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.
141574|NCT03084276|Other|High-fat meal|High-fat meal
141575|NCT03084276|Other|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
141576|NCT03084263|Procedure|Arthroscopic Assisted Open Reduction Internal Fixation|Surgical fixation of ankle fractures with use of arthroscopy.
141577|NCT03084263|Procedure|Open Reduction Internal Fixation|Surgical fixation of ankle fractures.
141578|NCT03084250|Drug|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
141579|NCT03084250|Drug|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
141580|NCT03084237|Biological|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
141581|NCT03084237|Biological|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
141582|NCT03084237|Drug|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
141583|NCT03084224|Genetic|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
141584|NCT03084211|Other|Light exercise discharge instructions|Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
141585|NCT03084198|Procedure|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
141586|NCT03084198|Procedure|Standard care for ALF|A standard of care for subjects with acute liver failure.
141587|NCT03084159|Behavioral|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
141588|NCT03084146|Other|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
141589|NCT03084133|Behavioral|Therapeutic Education Strategy|"In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002)."
141590|NCT03084120|Other|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
141591|NCT03084120|Other|Retrieval of umbilical cord blood.|-During childbirth
141592|NCT03084120|Other|Retrieval of placenta.|-During childbirth
141593|NCT03084120|Other|Collection of newborn's and mother's lock of hair.|-During childbirth
141594|NCT03084120|Other|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
141595|NCT03084120|Other|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
141596|NCT03084107|Other|Questionnaire|The elderly participated in the application of smart devices and requested to complete technology acceptance model (TAM) questionnaires for these devices.
141597|NCT03084094|Device|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
141598|NCT03084081|Device|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
141599|NCT03084081|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
141600|NCT03084081|Device|Thermocoagulator|Thermoablation
141601|NCT03084068|Other|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
141602|NCT03084068|Other|Placebo|Open rotator cuff surgery with standard suture repair
141603|NCT03084055|Behavioral|eMotion|eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
141604|NCT03084042|Device|fMRI|
141605|NCT03084029|Drug|Oxytocin|40 international units
141606|NCT03084029|Drug|Placebo|40 international units
141607|NCT03084003|Dietary Supplement|Almonds|
141608|NCT03084003|Dietary Supplement|Graham crackers|
141609|NCT03083990|Biological|IBI305(Bevacizumab)|3mg/kg, infusion in 90minutes
141610|NCT03083990|Drug|Avastin(Bevacizumab)|3mg/kg, infusion in 90minutes
141611|NCT03083977|Other|Safe and Sound Protocol|The intervention features music processed based on the resonating frequencies of the middle ear
141612|NCT03083964|Behavioral|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
141613|NCT03083964|Behavioral|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
141614|NCT03083951|Procedure|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
141615|NCT03083951|Procedure|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
141616|NCT03083938|Procedure|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
141617|NCT03083925|Device|TIPS|Transjugular Intrahepatic Portosystemic Shunt
141618|NCT03083912|Dietary Supplement|Fortimel Complete|The residents included receive 2 bottle por day.
141619|NCT03083899|Other|Out-patient clinic on demand|Free use of any resources in the out-patient clinic
141620|NCT03083899|Other|Scheduled out-patient clinic|Scheduled use of the out-patient clinic
141621|NCT03083886|Other|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
141622|NCT03083886|Other|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
141623|NCT03083886|Other|Usual PCP led care|Primary care provider will direct patients' care pathway.
141624|NCT03083873|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
141625|NCT03083860|Device|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
141626|NCT03083847|Drug|Chloroquine Phosphate|Chloroquine phosphate is FDA approved for suppressive treatment(prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a bloodstage schizonticide, highly active against replicating forms of bloodstage drug-sensitive parasites
141627|NCT03083847|Drug|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January 2014 )). Similar to chloroquine, pyrimethamine (in combination with sulfa drugs) was a drug of choice for malaria treatment and prophylaxis for decades because it was safe, well tolerated, affordable and highly effective; however, due to widespread resistance, pyrimethamine and pyrimethamine combinations have fallen out of favor for clinical use.
141628|NCT03083847|Biological|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
141629|NCT03083834|Diagnostic Test|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
141631|NCT03083808|Drug|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days~+~Physician's choice chemotherapy with one of the following every 21 days:~Docetaxel 75mg/m2 IV~Pemetrexed 500mg/m2 IV (non-squamous only)~Gemcitabine 1000mg/m2 IV on days 1 and 8"
141632|NCT03083795|Behavioral|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
141633|NCT03083782|Drug|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
141634|NCT03083782|Drug|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
141635|NCT03083782|Drug|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
141636|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
141637|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
141638|NCT03083743|Biological|Recombinant human Apo-2 ligand for Injection|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
141639|NCT03083743|Biological|Placebo|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
141640|NCT03083730|Other|Narrow band UVB treatment (NB-UVB)|NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
141641|NCT03083717|Diagnostic Test|Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)|2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
141642|NCT03083704|Biological|Andexanet alfa (Gen 1 Process 2)|factor Xa inhibitor antidote
141643|NCT03083704|Drug|Apixaban 5 MG|factor Xa inhibitor
141644|NCT03083704|Drug|Rivaroxaban 20 MG|factor Xa inhibitor
141645|NCT03083704|Drug|Enoxaparin sodium|low molecular weight heparin
141646|NCT03083704|Drug|Edoxaban 60 MG|factor Xa inhibitor
141647|NCT03083704|Biological|Andexanet alfa (Gen 2)|factor Xa inhibitor antidote
141648|NCT03083704|Biological|Andexanet alfa (Gen 1 Process 3)|factor Xa inhibitor antidote
141649|NCT03083704|Drug|Apixaban 10 MG|factor Xa inhibitor
141650|NCT03083704|Drug|Rivaroxaban 10 MG|factor Xa inhibitor
141651|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
141652|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
141653|NCT03083678|Drug|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
141654|NCT03083665|Drug|Placebo|"Pharmaceutical form: Film-coated tablets~Route of administration: Oral use"
141655|NCT03083665|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablets~Concentration: 25 mg tablets and 50 mg tablets~Route of administration: Oral use"
141656|NCT03083652|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
141657|NCT03083652|Other|Sham|Conventional physiotherapy with NMES device NOT activated
141658|NCT03083639|Drug|Esomeprazole Capsule|Esomeprazole Capsule
141659|NCT03083639|Drug|Esomeprazole Tablet|Esomeprazole Tablet
141660|NCT03083626|Other|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
141661|NCT03083613|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
141662|NCT03083613|Drug|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
141663|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
141664|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
141665|NCT03083600|Dietary Supplement|Placebo|Cellulose Placebo for 12-weeks
141666|NCT03083587|Behavioral|Normal lifestyle|Normal lifestyle
141667|NCT03083587|Behavioral|Exercise|Mild exercise 3 min every half hour
141668|NCT03083587|Procedure|muscle and fat biopsy|Biopsy under local anesthesia
141669|NCT03083587|Device|Continuous glucose monitoring|Glucose concentrations during the study period
141670|NCT03083587|Device|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
141671|NCT03083574|Device|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
141672|NCT03083561|Drug|LY3337641|Administered orally.
141673|NCT03083561|Drug|Placebo|Administered orally.
141674|NCT03083548|Diagnostic Test|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
141675|NCT03083548|Diagnostic Test|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests
141676|NCT03083548|Diagnostic Test|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
141677|NCT03083535|Procedure|Tooth Brushing|Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
141845|NCT03082196|Drug|Test varnish|Topical application of test varnish to the teeth 4 times per year.
141678|NCT03083535|Procedure|aloe vera Massaging|Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
141679|NCT03083535|Procedure|SRP with aloe vera massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
141680|NCT03083522|Drug|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
141681|NCT03083522|Drug|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
141682|NCT03083509|Other|Resistance exercise weight training session|A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
141683|NCT03083509|Other|High-Intensity stochastic cycling session|A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
141684|NCT03083509|Other|Simulated Team sport protocol|A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
141685|NCT03083496|Drug|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
141686|NCT03083496|Drug|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
141687|NCT03083483|Device|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
141688|NCT03083470|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
141689|NCT03083470|Other|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
141690|NCT03083457|Drug|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
141691|NCT03083457|Drug|General anesthetic|Total intravenous anesthesia with a standard protocol
141692|NCT03083457|Drug|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
141693|NCT03083457|Procedure|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
141694|NCT03083457|Procedure|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
141695|NCT03083444|Diagnostic Test|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
141696|NCT03083431|Drug|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg.d in 4 divided dosages)
141697|NCT03083431|Drug|Placebo|Oral solution containing the same excipients as propranolol solution
141698|NCT03083418|Device|control group|No EDP treatment
141699|NCT03083418|Device|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
141700|NCT03083405|Drug|Buspirone|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
141701|NCT03083392|Procedure|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
141702|NCT03083392|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
141744|NCT03083067|Drug|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
141745|NCT03083054|Biological|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
141746|NCT03083041|Biological|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
141747|NCT03083041|Drug|Apatinib|Apatinib tablet will be administered orally,once daily until progression
141703|NCT03083379|Device|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~The 10-breath cycle will be repeated three times with respiratory therapist coaching.~Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~Incentive Spirometry therapy and monitoring session will last about 15 minutes"
141704|NCT03083379|Device|EzPAP® POSITIVE AIRWAY PRESSURE|"A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~The 10-breath cycle will be repeated three times with respiratory therapist coaching.~Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~EzPAP® therapy and monitoring sessions will last about 15 minutes"
141705|NCT03083366|Device|PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)|Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
141706|NCT03083353|Drug|Isradipine|In the first CET session, participants will receive a dose of ISR and begin the session after waiting 75 minutes.
141707|NCT03083353|Behavioral|CET|Two 90-minute CET sessions will be conducted to expose participants to interoceptive and situational cues for tobacco use and craving.
141708|NCT03083353|Drug|Placebos|In the first CET session, participants will receive a dose of PBO and begin the session after waiting 75 minutes.
141709|NCT03083340|Behavioral|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
141710|NCT03083327|Dietary Supplement|Parenteral nutrition.|Nutrition support will be provides as per usual, but oral and enteral intake will be topped up with a standard parenteral nutrition solution. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L).
141711|NCT03083327|Other|Pragmatic standard care.|Nutrition support will be provided as per usual care.
141712|NCT03083314|Procedure|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
141713|NCT03083314|Procedure|COMPLETE AXILLARY DISSECTION (ALND)|
141714|NCT03083301|Other|Medical Files data extraction|Medical Files data extraction
141715|NCT03083288|Drug|[18F]FluorThanatrace|[18F]FluorThanatrace is a radiotracer for PET/CT
141716|NCT03083275|Other|Resistance Training|
141717|NCT03083262|Other|no intervention|None, there is no intervention
141718|NCT03083249|Other|Gardasil|None-data gathering only
141719|NCT03083236|Other|Standard PBI|Standard Parent Based Intervention (PBI)
141720|NCT03083236|Other|Enhanced|Enhanced Parent Based Intervention (EPBI)
141721|NCT03083223|Other|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
141722|NCT03083210|Drug|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
141723|NCT03083197|Drug|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
141724|NCT03083197|Drug|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
141725|NCT03083197|Drug|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
141726|NCT03083184|Drug|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
141727|NCT03083184|Drug|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
141728|NCT03083171|Drug|Endotoxin|At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
141729|NCT03083171|Drug|Placebo|At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
141730|NCT03083171|Drug|Adrecizumab|At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
141731|NCT03083158|Drug|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
141732|NCT03083145|Dietary Supplement|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
141733|NCT03083145|Dietary Supplement|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
141734|NCT03083145|Behavioral|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
141735|NCT03083132|Drug|modafinil 50mg|1 capsule oral daily
141736|NCT03083132|Drug|Placebo oral capsule|1 capsule oral daily
141737|NCT03083119|Drug|Xuesaitong soft capsule|Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
141738|NCT03083119|Drug|Placebo oral capsule|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
141739|NCT03083093|Diagnostic Test|The initial CTPA will be reviewed|The initial CTPA will be reviewed
141740|NCT03083080|Procedure|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
141741|NCT03083080|Drug|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
141742|NCT03083080|Drug|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
141743|NCT03083067|Drug|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
141748|NCT03083028|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
141749|NCT03083028|Procedure|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
141750|NCT03083015|Procedure|revascularization|a sterile sharp needle was used to irritate the apical tissue until bleeding occurred apically in the root canal space so as to create a biological scaffold for the regenerative process
141751|NCT03083015|Procedure|Apexification|a 3-5 mm thickness of MTA using a hand plugger and was verified radiographically.
141752|NCT03082989|Device|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
141753|NCT03082989|Other|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
141754|NCT03082963|Device|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium & then the left atrium.
141755|NCT03082950|Diagnostic Test|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
141756|NCT03082937|Drug|3 mg [14C]-A4250 capsule|Each subject will receive a single administration of 3 mg [14C]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 μCi), in the fasted state.
141757|NCT03082924|Device|Control group|Neither cycle training nor inspiratory muscle training.
141758|NCT03082924|Device|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
141759|NCT03082924|Device|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
141760|NCT03082924|Device|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
141761|NCT03082911|Other|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
141762|NCT03082911|Other|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
141763|NCT03082898|Device|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
141764|NCT03082885|Drug|Thymosin-α1|1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
141765|NCT03082872|Device|Cemented K-wire|Fracture of proximal phalanx was treated with Cemented K-wire.
141766|NCT03082872|Device|Transfixion Pinning|Fracture of proximal phalanx was treated with transfixion pinning.
141767|NCT03082859|Behavioral|Exercise|This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.
141768|NCT03082846|Radiation|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
141769|NCT03082846|Drug|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
141770|NCT03082833|Drug|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
141771|NCT03082820|Diagnostic Test|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
141772|NCT03082820|Diagnostic Test|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
141773|NCT03082820|Diagnostic Test|Nerve conduction studies (NCS)|NCS were performed with patients only.
141774|NCT03082807|Dietary Supplement|NCDsport|Negative Calorie Diet supplemented with exercise
141775|NCT03082807|Dietary Supplement|LCDsport|Low-Calorie diet with exercise
141776|NCT03082794|Dietary Supplement|NCD|Negative Calorie Diet
141777|NCT03082794|Dietary Supplement|LCD|Low Calorie Diet
141778|NCT03082781|Dietary Supplement|NCDsport|Negative Calorie Diet supplemented with exercise
141779|NCT03082781|Dietary Supplement|LCDsport|Low-Calorie diet with exercise
141780|NCT03082768|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two [18F]MNI-968 injections and PET scans.
141781|NCT03082755|Drug|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
141782|NCT03082755|Drug|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
141785|NCT03082729|Drug|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
141786|NCT03082716|Drug|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
141787|NCT03082716|Drug|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
141788|NCT03082703|Behavioral|Text Messaging|Subjects contacted 3 times weekly via text messaging for the study period.
141789|NCT03082690|Drug|DuoGel|1% IQP-0528 in gel formulation
141790|NCT03082677|Drug|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
141791|NCT03082664|Device|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
141792|NCT03082651|Other|Alternating run training load|Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
141793|NCT03082651|Other|Alternating footwear|Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
141794|NCT03082651|Other|Constant training|Runners will be assigned identical training sessions over a 7-day period.
141795|NCT03082651|Other|Constant footwear|Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
141796|NCT03082625|Drug|Transdermal Magnesium|Magnesium
141797|NCT03082625|Drug|Placebo|
141798|NCT03082612|Behavioral|Overcoming Psychological Distress through Hymns Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
141799|NCT03082612|Behavioral|Usual care|Usual care includes education to increase cancer knowledge, treatment coaches, and psychological services.
141800|NCT03082599|Device|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
141801|NCT03082586|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
141802|NCT03082586|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
141803|NCT03082586|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
141804|NCT03082586|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
141805|NCT03082586|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
141806|NCT03082586|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
141807|NCT03082573|Drug|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
141808|NCT03082560|Diagnostic Test|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
141809|NCT03082534|Drug|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.~Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
141810|NCT03082521|Behavioral|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
141811|NCT03082508|Device|Algisyl|Algisyl device (implants) administered during a surgical procedure
141812|NCT03082508|Drug|Standard Medical Therapy|as per protocol
141813|NCT03082495|Behavioral|Exercise|Supervised high-intensity aerobic interval training (HIT) during NACRT followed by unsupervised moderate-to-high intensity aerobic exercise after the completion of NACRT and before surgery
141814|NCT03082482|Behavioral|Self-help materials|Self-help smoking cessation materials
141846|NCT03082196|Drug|Standard varnish|Topical application of test varnish to the teeth 4 times per year
141815|NCT03082482|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke <10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
141816|NCT03082482|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
141817|NCT03082482|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
141818|NCT03082469|Device|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
141819|NCT03082456|Diagnostic Test|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 mCi Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
141820|NCT03082456|Diagnostic Test|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
141821|NCT03082456|Diagnostic Test|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
141822|NCT03082443|Other|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.~Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.~In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
141823|NCT03082430|Biological|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
141824|NCT03082417|Other|Implementation|"The PAINFREE Initiative is a Multifaceted intervention:~Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures~Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures~Inform the patients and their family about how to better manage the pain after a fracture"
141825|NCT03082404|Other|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
141826|NCT03082391|Device|Heavyweight Mesh|Patients will undergo ventral hernia repair with heavweight mesh.
141827|NCT03082391|Device|Mediumweight Mesh|Patients will undergo ventral hernia repair with mediumweight mesh.
141828|NCT03082352|Drug|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
141829|NCT03082352|Drug|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
141830|NCT03082339|Other|Cortisone|Observation of QTc-interval
141831|NCT03082313|Behavioral|Movement Intervention|At each visit, the caregiver will be reminded of the infant's movement rate and proportion of unilateral and bilateral movements from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time, with 1/3 single leg movements and 2/3 bilateral leg movements. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will use the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
141832|NCT03082300|Drug|naquotinib|Oral
141833|NCT03082287|Device|Fecal Calprotectin Level|Measurement of calprotectin in feces
141834|NCT03082274|Diagnostic Test|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
141835|NCT03082274|Diagnostic Test|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
141836|NCT03082261|Device|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
141837|NCT03082248|Other|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
141838|NCT03082248|Procedure|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
141839|NCT03082235|Drug|E6742|gelatin capsules
141840|NCT03082235|Drug|Placebo|gelatin capsules
141841|NCT03082209|Drug|ABBV-621|Intravenous (IV)
141842|NCT03082209|Drug|Venetoclax|tablet, oral
141849|NCT03082170|Device|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
141850|NCT03082170|Diagnostic Test|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
141851|NCT03082170|Behavioral|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
141852|NCT03082157|Behavioral|Mighty Men Intervention|African American men assigned to this condition will receive: tailored goals/ messages, self-monitoring, small group meetings and educational and community-based information and resources.
141853|NCT03082144|Drug|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
141854|NCT03082144|Drug|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
141855|NCT03082144|Radiation|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
141856|NCT03082131|Dietary Supplement|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
141857|NCT03082118|Device|Vesair Bladder Control System|Intravesical balloon
141858|NCT03082105|Other|Breathing in snow|Breathing in snow with different physical properties
141859|NCT03082092|Drug|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
141860|NCT03082092|Drug|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
141861|NCT03082079|Procedure|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
141862|NCT03082066|Other|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
141863|NCT03082053|Drug|varlitinib|IMP
141864|NCT03082053|Drug|capecitabine|Companion Medication
141865|NCT03082040|Behavioral|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
141866|NCT03082027|Diagnostic Test|ultrasonography|ultrasonography of median nerve
141867|NCT03082014|Drug|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
141868|NCT03082014|Drug|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
141869|NCT03082014|Drug|Atenolol|blood pressure lowering agent - beta-blocker
141870|NCT03082001|Drug|12% Sucrose|
141871|NCT03082001|Drug|24% Sucrose|
141872|NCT03081988|Other|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
141873|NCT03081975|Device|HD white light or NBI|Use of NBI or HD white light
141874|NCT03081962|Drug|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
141875|NCT03081962|Procedure|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
141876|NCT03081949|Drug|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
141877|NCT03081936|Dietary Supplement|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
141878|NCT03081936|Dietary Supplement|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
141879|NCT03081936|Dietary Supplement|Oral consumption of breast milk|Daily oral consumption of breast milk
141880|NCT03081923|Drug|Durvalumab|anti-PD-L1 mono therapy
141881|NCT03081923|Drug|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
141882|NCT03081910|Genetic|CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:~Dose level one: 1×10^7 cells/m2~Dose level two: 5×10^7 cells/m2~Dose level three: 1×10^8 cells/m2~The first six (6) patients treated on the study will be adults (>18 yrs of age). Six adolescents (age 12-18) will be treated before children (>3 yrs of age) are eligible.~Three dose levels will be evaluated. The T cells will be administered with Cytoxan and fludarabine."
141883|NCT03081910|Drug|Fludarabine|Patients will receive 3 daily doses of fludarabine (30 mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion. Infusions should be given following hospital/pharmacy recommendations (including dose adjustments as appropriate per institutional guidelines) however at a minimum the fludarabine should be infused over 30 minutes. Mesna, IV hydration and anti-emetics should also be provided following local institutional guidelines.
141884|NCT03081910|Drug|Cytoxan|Patients will receive 3 daily doses of cyclophosphamide (500 mg/m2/day) to induce lymphopenia, finishing at least 24 hours before T cell infusion. Infusions should be given following hospital/pharmacy recommendations (including dose adjustments as appropriate per institutional guidelines) however at a minimum the cyclophosphamide should be infused over 1 hour. Mesna, IV hydration and anti-emetics should also be provided following local institutional guidelines.
141914|NCT03081676|Drug|Placebo Oral Tablet|Placebo
141915|NCT03081676|Drug|Placebo infusion|Placebo (saline)
141916|NCT03081663|Procedure|Quads-Sparing Approach|Quadriceps-sparing mid-vastus approach for total knee arthroplasty
142024|NCT03080740|Drug|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
141885|NCT03081897|Drug|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
141886|NCT03081897|Drug|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
141887|NCT03081884|Drug|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.~Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
141888|NCT03081871|Other|Pharmacist-led cardiovascular risk service (CVRS)|CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
141889|NCT03081871|Other|Mobile access to study Personal Health Record|Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
141890|NCT03081871|Other|Web access to study Personal Health Record|Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
141891|NCT03081858|Drug|TSD-001|Administered via intravesical instillation.
141892|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
141893|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
141894|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
141895|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
141896|NCT03081832|Drug|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
141897|NCT03081832|Other|Control|Not treated.
141898|NCT03081819|Drug|SH003|Herbal medicine for cancer treatment
141899|NCT03081806|Drug|X0002|Before the first screening visit, there is a pre-Screening Telephone Call or email interview, the Screening Period of at least 14 days up to 3 weeks will consist of two visits for the assessment of eligibility including radiographic evaluation of the target knee joint space, all screening visits and double-blind treatment visit (week 2, 4, 8, 12 visits) are show in Study Flow Chart of Double-blind Period, and the open label period will be started from the Week 12 visit (see Table 2). All subjects treated with active drug or placebo complete the 12-week double-blind study will enter this Open-label study and will be treated with active drug, X0002.
141900|NCT03081780|Biological|FATE-NK100|"Preparative regimen:~Fludarabine 25 mg/m2 x 5 days start Day -6~Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4~Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
141901|NCT03081767|Diagnostic Test|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
141902|NCT03081754|Radiation|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
141903|NCT03081728|Device|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
141904|NCT03081728|Drug|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
141905|NCT03081715|Other|PD-1 Knockout T Cells|Programmed cell death 1(PD-1) gene will be knocked out by CRISPR Cas9
141906|NCT03081702|Drug|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
141907|NCT03081702|Drug|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
141908|NCT03081689|Drug|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
141909|NCT03081689|Drug|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
141910|NCT03081689|Drug|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
141911|NCT03081676|Drug|Glimepiride 1Mg Tablet|Glimepiride
141912|NCT03081676|Drug|Glucagon-like Peptide-1|GLP-1 infusion
141913|NCT03081676|Drug|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
189475|NCT02725697|Other|TCM treatment|
141917|NCT03081663|Procedure|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
141918|NCT03081650|Device|Airvo Humidifier|
141919|NCT03081611|Device|Ram cannula|Ventilatory support for preterm infants using Ram cannula
141920|NCT03081611|Device|Short nasal prongs|Ventilatory support for preterm infants using short nasal prongs
141921|NCT03081598|Drug|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
141922|NCT03081598|Other|Placebo|Placebo soft gelatine capsule
141923|NCT03081585|Behavioral|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
141924|NCT03081572|Diagnostic Test|Platelet aggregation|Platelet aggregation
141925|NCT03081559|Behavioral|Healthy Divas|Peer-based counseling to improve medication adherence and engagement in care
141926|NCT03081533|Other|Circle Dance Program (CircleCare)|Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
141927|NCT03081520|Behavioral|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
141928|NCT03081520|Behavioral|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
141929|NCT03081520|Behavioral|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
141930|NCT03081507|Behavioral|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
141931|NCT03081507|Behavioral|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
141932|NCT03081494|Drug|spartalizumab (PDR001)|100 mg lyophilisate in vial received 400 mg every 4 weeks
141933|NCT03081494|Drug|regorafenib|120 mg once daily first 21 days of each 28-day cycle (=4 weeks)
141934|NCT03081481|Drug|PRX302|Single prostate cancer lesion injected with PRX302
141935|NCT03081468|Device|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
141936|NCT03081468|Device|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
141937|NCT03081455|Diagnostic Test|Diagnostic Test|Genetic Diagnostic Testing
141938|NCT03081442|Drug|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
141939|NCT03081442|Device|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.~The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.~The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
141940|NCT03081416|Drug|Ketamine|Intranasal ketamine administration
141941|NCT03081416|Drug|Normal saline|
141942|NCT03081416|Drug|Metoclopramide|Standard therapy
141943|NCT03081416|Drug|Ketorolac|standard therapy
141944|NCT03081416|Drug|Dexamethasone|Standard therapy
141945|NCT03081416|Drug|Benadryl|Standard therapy
141946|NCT03081403|Device|Quantitative Sensory Testing|Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
141947|NCT03081390|Other|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
141948|NCT03081390|Other|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
141949|NCT03081390|Other|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
141950|NCT03081364|Other|Initiate ACLS protocol if lethal arrythmia develops|Cardiac Rhythm Management
141951|NCT03081351|Procedure|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
142025|NCT03080714|Device|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
141952|NCT03081351|Procedure|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
141953|NCT03081325|Procedure|low-dose lymphocyte immunotherapy|Peripheral venous blood (PBMCs) was drawn from the husbands of uRM and RIF patients and then the PBMCs were resuspended and administered intradermally to uRM and RIF patients 3 times at 3-week intervals. Once conceived, the uRM and RIF patients undergo 2 rounds of treatment at 8-week intervals.
141954|NCT03081286|Procedure|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
141955|NCT03081286|Procedure|Fat graft|The harvested lipoaspirate is injected at the site of pain.
141956|NCT03081286|Procedure|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
141957|NCT03081260|Other|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
141958|NCT03081260|Other|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
141959|NCT03081247|Drug|BGF 320/14.4/9.6 µg MDI|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
141960|NCT03081247|Drug|BFF 320/9.6 µg|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
141961|NCT03081234|Drug|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
141962|NCT03081234|Drug|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
141963|NCT03081234|Drug|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
141964|NCT03081221|Diagnostic Test|USG|
141965|NCT03081208|Drug|Nolasiban 900mg|Nolasiban dispersible tablets for single oral administration
141966|NCT03081208|Drug|Placebo|Placebo dispersible tablets for single oral administration
141967|NCT03081195|Behavioral|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
141968|NCT03081169|Drug|Enoxaparin Sodium 150 MG/ML Prefilled Syringe|The same drugs and dosages will be used in both groups, with only the timing being different
141969|NCT03081169|Drug|Heparin|The same drugs and dosages will be used in both groups, with only the timing being different
141970|NCT03081156|Drug|Glycopyrrolate / Formoterol|Exercise Tolerance
141971|NCT03081143|Drug|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
141972|NCT03081143|Drug|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
141973|NCT03081143|Drug|Paclitaxel|80 mg/m2 on day 1, 8, 15
141974|NCT03081130|Procedure|Intravenous laser irradiation treatment|control group
141975|NCT03081117|Drug|Insulin, intranasal|Regular insulin administered by specialized, non-commercial intranasal drug delivery device
141976|NCT03081117|Drug|Placebo, intranasal|Saline solution administered by specialized, non-commercial intranasal drug delivery device
141977|NCT03081104|Device|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
141978|NCT03081104|Device|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
141979|NCT03081104|Procedure|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
141980|NCT03081091|Device|Acupuncture|"The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:~Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm~The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms."
142021|NCT03080766|Drug|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
191505|NCT02711280|Drug|Propofol|
141981|NCT03081091|Device|Sham Acupuncture|"It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.~The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120."
141982|NCT03081078|Behavioral|Volunteer support|Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for two months. Participants will be free to respond or not.
141983|NCT03081078|Other|Mobile app|Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
141984|NCT03081065|Dietary Supplement|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
141985|NCT03081052|Drug|iNO|Subject will receive inhaled Nitric Oxide in this intervention
141986|NCT03081052|Drug|iEPO|Subject will receive inhaled Epoprostrenol in this intervention
141987|NCT03081039|Drug|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
141988|NCT03081039|Drug|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
141989|NCT03081039|Drug|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.~Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
141990|NCT03081026|Diagnostic Test|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
141991|NCT03081013|Behavioral|Social information|Social comparison information will be provided to the study participants weekly via SMS
141992|NCT03081013|Device|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
141993|NCT03080987|Drug|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
141994|NCT03080987|Drug|JNJ-64179375 1.0 mg/kg|JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
141995|NCT03080987|Drug|JNJ-64179375 2.5 mg/kg|JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
141996|NCT03080987|Other|Placebo|Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
141997|NCT03080987|Drug|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined).
141998|NCT03080974|Drug|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
141999|NCT03080974|Procedure|Irreversible Electroporation|Non-thermal ablation of tumor
142000|NCT03080961|Device|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
142001|NCT03080948|Behavioral|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
142002|NCT03080948|Other|Saliva samples|Germline DNA analysis
142003|NCT03080935|Drug|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
142004|NCT03080922|Biological|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
142005|NCT03080909|Dietary Supplement|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria; Lipid; Amino acid selected on their ability to stimulate release of GLP-1 and PYY
142006|NCT03080909|Dietary Supplement|Placebo|Maltodextrin, which is not expected to stimulate release of GLP-1 and PYY
142007|NCT03080896|Device|King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet|intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
142008|NCT03080896|Device|fiberoptic bronchoscope aScope III|Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
142009|NCT03080883|Drug|Apixaban|Given PO
142010|NCT03080870|Other|Art|Multicomponent art intervention
142011|NCT03080857|Other|Virtual Platform|The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart & Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.
142012|NCT03080844|Behavioral|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
142013|NCT03080844|Behavioral|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
142014|NCT03080831|Drug|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
142015|NCT03080831|Drug|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
142016|NCT03080818|Dietary Supplement|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
142017|NCT03080818|Other|Placebo|2 placebo capsules per day for 90 days
142018|NCT03080805|Drug|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/ m^2 BID)
142019|NCT03080805|Drug|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
142020|NCT03080792|Behavioral|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
142022|NCT03080753|Device|Sphinkeeper|Intersphincteric implants in the anal sphincter
142023|NCT03080740|Drug|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
142026|NCT03080714|Device|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
142027|NCT03080701|Behavioral|Auto Mailing Plus Money|Participant receives money as a thank you for completing CRC screening within 6 months.
142028|NCT03080701|Behavioral|Auto Mailing Plus Lottery|Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
142029|NCT03080688|Device|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.~Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
142030|NCT03080675|Dietary Supplement|Nutrional blend of ingredients including vitamins and fish oil|
142031|NCT03080675|Dietary Supplement|Control|
142032|NCT03080662|Device|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
142033|NCT03080662|Device|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
142034|NCT03080649|Device|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
142035|NCT03080649|Device|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
142036|NCT03080636|Other|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
142037|NCT03080636|Other|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
142038|NCT03080636|Other|Control session|30 minutes seated resting
142039|NCT03080597|Device|PrEP Smart app|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart.an application on their smart phones called PrEP Smart."
142040|NCT03080584|Other|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
142041|NCT03080571|Biological|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
142042|NCT03080571|Other|standard care|
142043|NCT03080558|Drug|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
142044|NCT03080545|Drug|Enstilar 0.005%-0.064% Topical Foam|Topical foam
142045|NCT03080532|Other|dietary habits|
142046|NCT03080519|Procedure|Endovascular Therapy|Balloon angioplasty and stenting for renal artery stenosis
142047|NCT03080506|Device|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
142048|NCT03080493|Drug|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
142049|NCT03080493|Drug|Placebo oral capsule|Packaged identical to gabapentin dosing
142050|NCT03080493|Drug|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
142051|NCT03080480|Drug|Pioglitazone|"Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.~pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily."
142052|NCT03080454|Device|sham Doublestim|PathMaker MyoRegulator device
142053|NCT03080454|Device|anodal Doublestim|PathMaker MyoRegulator device
142054|NCT03080441|Device|pressure stockings|pressure stockings worn during dialysis throughout treatment period
142055|NCT03080441|Drug|Midodrine|administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
142056|NCT03080441|Other|pressure stockings and midodrine|combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
142057|NCT03080428|Diagnostic Test|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
142058|NCT03080415|Drug|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day~SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients~DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
142059|NCT03080402|Device|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
142060|NCT03080389|Procedure|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.~The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
142061|NCT03080376|Other|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
142062|NCT03080376|Other|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
142168|NCT03079531|Drug|Secukinumab|We will be giving secukinumab to patients with papulopustular rosacea
142063|NCT03080376|Other|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
142064|NCT03080363|Drug|Bupivacaine|10 ml %0.5 bupivacaine
142065|NCT03080363|Drug|Lidocaine|10 ml %2 lidocaine
142066|NCT03080350|Drug|Fentanyl sublingual|Fentanyl sublingual
142067|NCT03080350|Drug|Fentanyl ev|Fentanyl ev
142068|NCT03080350|Drug|Placebo sublingual|Placebo sublingual
142069|NCT03080350|Drug|Placebo ev|Placebo - NaCL 0,9% ev
142070|NCT03080337|Other|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
142071|NCT03080324|Drug|Fentanyl sublingual|Fentanyl sublingual
142072|NCT03080324|Drug|Fentanyl ev|Fentanyl ev
142073|NCT03080324|Drug|Placebo sublingual|Placebo sublingual
142074|NCT03080324|Drug|Placebo ev|Placebo - NaCL 0,9% ev
142075|NCT03080311|Drug|APG-1252|"Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.~cycle"
142076|NCT03080298|Drug|BP101|
142077|NCT03080298|Drug|Placebo|
142078|NCT03080285|Device|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
142079|NCT03080285|Device|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
142080|NCT03080272|Other|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
142081|NCT03080259|Behavioral|Stimulant Diversion Prevention (SDP)|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
142082|NCT03080246|Behavioral|Strength Training Exercise|
142083|NCT03080220|Device|Astym|therapeutic massage instrument
142084|NCT03080220|Device|Stick|massage instrument
142085|NCT03080220|Device|Massage|massage instruments
142086|NCT03080207|Procedure|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks. Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise).
142087|NCT03080207|Procedure|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.~During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen.Also, all patients in this groups have received Complex Decongestive Physiotherapy (Manual lymph drainage (MLD), skin care, compression therapy and active therapeutic exercise)."
142088|NCT03080207|Procedure|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases. All patients in this group have received only Complex Decongestive Physiotherapy.
142089|NCT03080194|Drug|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
142090|NCT03080194|Drug|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
142091|NCT03080181|Drug|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
142092|NCT03080168|Device|Actigraph|This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
142093|NCT03080155|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
142094|NCT03080142|Drug|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
142095|NCT03080142|Drug|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
142096|NCT03080129|Dietary Supplement|Fresubin energy|dietary protein energy supplement
142097|NCT03080116|Drug|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
142098|NCT03080116|Drug|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
142099|NCT03080116|Other|Placebo|4 tablets, per OS
142100|NCT03080103|Procedure|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
142101|NCT03080103|Drug|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
142169|NCT03079518|Drug|Ferric Carboxymaltose|single shot infusion
142102|NCT03080090|Behavioral|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
142103|NCT03080090|Behavioral|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
142104|NCT03080077|Drug|Ricrolin+|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
142105|NCT03080077|Drug|Epi-Off|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
142106|NCT03080064|Behavioral|Health Coach Intervention|Please see arm description.
142107|NCT03080051|Drug|[18F]MNI-952|Subjects will undergo PET imaging using [18F]MNI-952, a PET radioligand for imaging tau.
142108|NCT03080051|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-952.
142109|NCT03080038|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
142110|NCT03080025|Behavioral|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.~The therapeutic tools are based on systemic approaches & techniques, which contains a resource- & solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).~Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):~a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
142111|NCT03080012|Other|Saliva sampling|Stimulated saliva samples are taken using cotton rolls.
142112|NCT03080012|Other|Plasma/serum sampling|Simultaneously with saliva sampling.
142113|NCT03079999|Drug|Aspirin|Twice daily aspirin
142114|NCT03079999|Drug|Placebo|Twice daily placebo
142115|NCT03079986|Other|Standard care irrespective of CL|Removal of surgical drains despite persistent CL, without dietary restrictions or dietary treatment for CL.
142116|NCT03079986|Other|Dietary treatment (MCT-diet)|Dietary treatment with MCT-diet until resolution of CL.
142117|NCT03079973|Drug|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
142118|NCT03079973|Drug|Vehicle of P-3073|Once daily for 24 weeks.
142119|NCT03079960|Device|Electrophysiological recording and measurement devices|Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
142120|NCT03079934|Device|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
142121|NCT03079921|Drug|Phentolamine|Physiologic receptor blockade (α1-receptor).
142122|NCT03079921|Drug|Propranolol|Physiologic receptor blockade (β2-receptor).
142123|NCT03079921|Drug|Placebo|100mL bag of Normal Saline Solution (NSS).
142124|NCT03079908|Other|da Vinci Skills Simulator®|Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
142125|NCT03079908|Other|LapSim®|Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
142126|NCT03079908|Other|Dry lab box laparoscopic training|No initial simulator training. Dry lab box laparoscopic Training only.
142127|NCT03079895|Behavioral|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
142128|NCT03079869|Drug|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
142129|NCT03079856|Behavioral|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a ~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
142130|NCT03079843|Other|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
142131|NCT03079843|Other|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
142132|NCT03079830|Drug|Piritramid|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
142133|NCT03079830|Drug|Saline|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
142134|NCT03079817|Other|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
142135|NCT03079817|Other|Proprioceptive Drills|Active balance and proprioception drills
142136|NCT03079804|Other|Experimental MWM|Mobilization with Movement
142137|NCT03079804|Other|Experimental Thrust|Mobilization grade 5 (Thrust)
142138|NCT03079804|Other|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
142139|NCT03079778|Procedure|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
142140|NCT03079778|Radiation|TACE plus RT|radiobiologically guided radiation
142141|NCT03079765|Behavioral|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
142142|NCT03079765|Behavioral|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
142143|NCT03079752|Behavioral|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment of suspected problems at 12 and 24 months of age
142144|NCT03079752|Behavioral|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
142145|NCT03079752|Behavioral|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
142146|NCT03079752|Behavioral|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
142147|NCT03079739|Diagnostic Test|fractional flow reserve|assessment with FFR in at least one coronary lesion
142148|NCT03079713|Device|Handheld vibrator triggered during intravitreal injection for wet ARMD|A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
142149|NCT03079713|Device|Normal eye esthesiometry with and without vibration|Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
142150|NCT03079713|Device|Handheld vibrator not triggered during intravitreal injection for wet ARMD|Control group undergoing standard intravitreal injection without triggering of the vibrator.
142151|NCT03079700|Biological|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
142152|NCT03079687|Drug|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
142153|NCT03079674|Other|observational only- no intervention|observational only- no intervention
142154|NCT03079648|Dietary Supplement|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 8 weeks.
142155|NCT03079648|Dietary Supplement|Placebo|Placebo for 8 weeks
142156|NCT03079635|Dietary Supplement|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
142157|NCT03079635|Dietary Supplement|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
142158|NCT03079622|Procedure|Electric Vacuum Aspiration|
142159|NCT03079622|Procedure|Manual Vacuum Aspiration|
142160|NCT03079609|Procedure|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
142161|NCT03079609|Procedure|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
142162|NCT03079596|Procedure|ERAS perioperative cares|Patient's preoperative counseling & education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction & Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.
142163|NCT03079596|Procedure|Conventional perioperative cares|No Patient's preoperative counseling & education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
142164|NCT03079583|Dietary Supplement|Intervention-group|Biofortified Rice is grown by foliar Zn application and is therefore biofortified
142165|NCT03079583|Dietary Supplement|Control-group|control Rice with normal zinc levels
142166|NCT03079557|Drug|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
142167|NCT03079544|Combination Product|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
194944|NCT02686281|Other|Placebo|
142170|NCT03079518|Other|blood withdrawal|for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
142171|NCT03079505|Drug|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
142172|NCT03079505|Drug|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
142173|NCT03079492|Device|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
142174|NCT03079479|Diagnostic Test|Muscle Strenght assesment|Muscle Strenght assesment of the hip muscles
142175|NCT03079479|Diagnostic Test|2D Kinematics Analysis|2D Kinematics Analysis of the gait
142176|NCT03079466|Other|CPAP|This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
142177|NCT03079453|Drug|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
142178|NCT03079440|Drug|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
142179|NCT03079427|Drug|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
142180|NCT03079427|Drug|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
142181|NCT03079414|Procedure|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
142182|NCT03079401|Biological|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
142183|NCT03079388|Dietary Supplement|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
142184|NCT03079388|Dietary Supplement|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
142185|NCT03079388|Drug|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
142186|NCT03079388|Drug|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
142187|NCT03079388|Other|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
142188|NCT03079388|Drug|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
142189|NCT03079388|Drug|Albendazole|Single dose albendazole 400mg given in the second trimester.
142190|NCT03079388|Combination Product|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
142191|NCT03079375|Other|basic intervention|medication review
142192|NCT03079375|Other|extended intervention|medication review, medication interview before discharge and follow-up
142193|NCT03079349|Other|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
142194|NCT03079349|Other|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
142195|NCT03079336|Behavioral|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
142196|NCT03079336|Behavioral|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
142197|NCT03079336|Behavioral|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.~The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
142198|NCT03079323|Radiation|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
142199|NCT03079310|Device|Spinal cord stimulation|Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
142200|NCT03079297|Drug|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
142201|NCT03079297|Other|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
142367|NCT03078205|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
197479|NCT02667275|Drug|A-101 Solution|
142202|NCT03079284|Other|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
142203|NCT03079271|Drug|Lacrisert, 5 Mg Ophthalmic Insert|
142204|NCT03079258|Other|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
142205|NCT03079245|Other|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
142206|NCT03079245|Other|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
142207|NCT03079245|Other|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
142208|NCT03079232|Device|OCTAV Patient|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
142209|NCT03079232|Device|OCTAV Control group|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
142210|NCT03079219|Drug|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
142211|NCT03079219|Drug|Experimental drug: Ondansetron|Day 1: 8mg BD, First dose 8mg, Second dose 8mg, 8 hours after first dose
142212|NCT03079219|Drug|Experimental drug: Dexamethasone|Day 1: 12mg QD
142213|NCT03079219|Drug|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
142214|NCT03079219|Drug|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
142215|NCT03079219|Drug|Standard: Ondansetron|Day 1: 8mg BD, First dose 8mg, second dose 8mg, 8 hours after first dose
142216|NCT03079219|Drug|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
142217|NCT03079206|Diagnostic Test|Food challenge|food challenge with hazelnut
142218|NCT03079206|Diagnostic Test|skin testing|Skin testing with hazelnut extract
142219|NCT03079206|Diagnostic Test|blood sampling|blood sampling to perform basophile activation tests
142220|NCT03079180|Other|Strength training at 80% 1RM|Detailed in Arms section's
142221|NCT03079180|Other|Strength training at 55% 1RM|Detailed in Arms section's
142222|NCT03079167|Drug|Epoetin Alfa|
142223|NCT03079167|Drug|Normal saline|
142224|NCT03079154|Other|Teacher-led MBCT course|9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy
142225|NCT03079154|Other|Self-guided MBCT course|9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
142226|NCT03079141|Drug|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.~When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
142227|NCT03079141|Other|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.~When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
142228|NCT03079128|Behavioral|Intervention|Weight Watchers Intervention
142229|NCT03079115|Drug|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
142230|NCT03079115|Drug|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
142231|NCT03079102|Drug|Nitric Oxide|An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
142232|NCT03079102|Drug|Nitrogen|Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
142259|NCT03078933|Device|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
201908|NCT02635724|Drug|Peramivir|
142233|NCT03079089|Drug|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
142234|NCT03079089|Drug|Transfusion graft|Graft of peripheral stem cells is preferred at DO
142235|NCT03079089|Drug|Prevention of GVHD|"Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
142236|NCT03079089|Drug|Care supports|According to the protocols of each center
142237|NCT03079089|Drug|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II."
142238|NCT03079076|Drug|Bupivacaine|20 ml %0,25 bupivacaine bilaterally
142239|NCT03079076|Drug|Saline|2 ml saline subcutaneously bilaterally
142240|NCT03079063|Biological|Eptacog alfa, biosimilar and reference medicinal product Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
142241|NCT03079063|Biological|Eptacog alfa biosimilar|Additional patients will receive eptacog alfa biosimilar, on demand, for treatment of every bleeding episode in a 12 months period, at dose 30 μg/kg for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
142242|NCT03079050|Drug|Dexlansoprazole 60 MG|This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
142243|NCT03079037|Device|Stimulation|Traditional deep brain stimulation
142244|NCT03079024|Device|Targeted Cognitive Training|"Auditory Training Module (20 hours): exercises designed to improve speed and accuracy of auditory processing while engaging working memory and cognitive control. Exercises adjust difficulty level to maintain an ~80% correct performance. Exercises contain stimuli spanning the acoustic organization of speech. In the initial stages, stimuli exaggerate the rapid temporal transitions by increasing amplitude and stretching in time. The exaggeration is gradually removed so that by the end, all stimuli have characteristics representative of real-world speech.~Social Cognition Module (10 hours): exercises designed to improve core deficits of social cognition in psychosis. Exercises apply principles of implicit learning to restore capacity to process and utilize socially-relevant information, and includes training to improve perception of affect (visual/vocal) and social cues (faces, gazes, social situations), theory of mind, self-referential style, emotion labeling and working memory."
142245|NCT03079024|Device|General Cognitive Exercises|The GCE will focus on executive dysfunction, as this domain is a significant, functionally important area of deficit in schizophrenia and has been the target of many previous studies. We will train this domain using a suite of engaging, adaptive web-based exercises that target executive function, intelligence, and spatial navigation developed by Posit Science. The exercises will be provide engaging, adaptive training as described in the Targeted Cognitive Training.
142246|NCT03079011|Drug|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
142247|NCT03079011|Drug|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
142248|NCT03079011|Drug|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
142249|NCT03078998|Device|Leap Motion Based Exercises|Game based exercise
142250|NCT03078985|Procedure|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
142251|NCT03078985|Device|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
142252|NCT03078959|Other|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
142253|NCT03078946|Drug|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
142254|NCT03078946|Drug|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
142255|NCT03078933|Device|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
142256|NCT03078933|Device|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
142257|NCT03078933|Device|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
142258|NCT03078933|Device|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
142362|NCT03078244|Other|N/A, observational study|
142260|NCT03078920|Device|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
142261|NCT03078907|Drug|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
142262|NCT03078907|Drug|Placebo|Matching film coated tablets
142263|NCT03078894|Diagnostic Test|Zika|Zika Diagnostic test
142264|NCT03078894|Diagnostic Test|Chikagunya|Chikagunya Diagnostic test
142265|NCT03078894|Diagnostic Test|Dengue|Dengue Diagnostic test
142266|NCT03078868|Device|Magnetic Resonance Scanner|MRI
142267|NCT03078855|Dietary Supplement|Vitamin D|vitamin D3 2,000 IU daily
142268|NCT03078855|Biological|Rituximab|Administered weekly x 4
142269|NCT03078855|Other|Placebo|methylcellulose
142270|NCT03078842|Dietary Supplement|Zinc tablets, 20 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
142271|NCT03078842|Dietary Supplement|Zinc tablets, 10 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
142272|NCT03078842|Dietary Supplement|Zinc tablets, 5 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
142273|NCT03078829|Drug|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
142274|NCT03078816|Device|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142275|NCT03078816|Device|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142276|NCT03078816|Device|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142277|NCT03078816|Device|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142278|NCT03078816|Device|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142279|NCT03078816|Device|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142280|NCT03078816|Device|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142281|NCT03078816|Device|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142282|NCT03078816|Device|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
142283|NCT03078803|Biological|Fecal Microbiota Transplant (FMT)|FMT delivered by colonoscopy and oral capsules
142284|NCT03078803|Biological|Placebo|Transfer of water only
142285|NCT03078790|Device|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
142286|NCT03078777|Drug|Fexofenadine|Fexofenadine will be administered to patients.
142287|NCT03078764|Other|Mobile health system|Patients will receive weekly automated IVR telephone calls for 12 weeks to assess their glycemic symptoms, medication adherence, dietary consumption, physical activity, sleep, and foot care. These 5-10 minute calls will follow a standardized Thai language IVR script developed specifically for this study.
142288|NCT03078764|Other|E-mail reports and technical support for mHealth system|Nurses will also receive a technical troubleshooting guide, and have similar access to live telephone technical support. Once their patients' calls begin, nurses will begin receiving weekly e-mail reports summarizing each patients' assessment results, any active self-management problems the patients reported, and suggested strategies for supporting the patient's self-management.
142289|NCT03078751|Drug|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).~Ribociclib will be supplied in the form of 200 mg tablets."
142290|NCT03078751|Drug|Adjuvant endocrine therapy|Letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy will include GnRH agonist administered every 28 days.
142291|NCT03078738|Drug|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
142292|NCT03078738|Other|Matching Placebo|Microcrystalline cellulose
142293|NCT03078725|Drug|Glyburide|oral hypoglycemic agent
142294|NCT03078725|Drug|Metformin|oral hypoglycemic agent
142295|NCT03078712|Other|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
142296|NCT03078712|Other|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
142363|NCT03078231|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
142297|NCT03078699|Radiation|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
142298|NCT03078686|Procedure|tSVF by lipoaspiration|Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
142299|NCT03078686|Procedure|PRP Concentration|Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
142300|NCT03078686|Procedure|Emulsification tSVF|Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
142301|NCT03078686|Procedure|cSVF isolation and concentration|Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
142302|NCT03078686|Procedure|cSVF in Normal Saline IV|cSVF + NS for IV Placement
142303|NCT03078673|Other|training intervention, motor skill training|cross country specific motor skill strength training
142304|NCT03078673|Other|training intervention, maximal strength training|general maximal strength training
142305|NCT03078673|Other|control group|regular training
142306|NCT03078660|Behavioral|Smartphone Application|The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
142307|NCT03078660|Behavioral|Traditional Nutritional Counseling|Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
142308|NCT03078647|Device|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
142309|NCT03078634|Other|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
142310|NCT03078634|Other|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
142311|NCT03078621|Biological|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
142312|NCT03078608|Behavioral|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
142313|NCT03078608|Behavioral|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
142314|NCT03078582|Drug|RA101495|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
142315|NCT03078569|Drug|Testosterone gel|treatment with testosterone gel
142316|NCT03078556|Drug|Dolutegravir|Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
142317|NCT03078556|Drug|Lamivudine|"Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.<br>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side."
142318|NCT03078556|Drug|Dolutegravir + Lamivudine FDC Formulation 1|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. &lt;br&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
142319|NCT03078556|Drug|Dolutegravir + Lamivudine FDC Formulation 2|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. &lt;br&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
142320|NCT03078543|Device|ANTHEM™ Total Knee System implant|"The ANTHEM™ Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ Total Knee System consists of the following components:~Cobalt-Chrome (Co-Cr) femoral components~Titanium primary tibial components~Posterior-stabilised cross-linked polyethylene tibial inserts~Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
142321|NCT03078530|Drug|Placebo|This is a pill with inactive ingredients
142322|NCT03078530|Drug|Visbiome|This is a probiotic mixture available to randomized study participants, starting with subject 29
142323|NCT03078530|Drug|VSL#3|This is a probiotic mixture available to the first 28 subjects randomized to the study
142324|NCT03078517|Device|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
142325|NCT03078517|Device|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
142326|NCT03078504|Device|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
142364|NCT03078231|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
142365|NCT03078218|Diagnostic Test|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
142366|NCT03078205|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
142327|NCT03078491|Other|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
142328|NCT03078478|Drug|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
142329|NCT03078478|Drug|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
142330|NCT03078465|Drug|Ticagrelor|Daily administration of ticagrelor 180mg for 12 months
142331|NCT03078465|Drug|Clopidogrel|Daily administration of clopidogrel 150mg for 12 months
142332|NCT03078452|Device|Power drill|Undergo bone marrow biopsy using power drill
142333|NCT03078452|Device|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
142334|NCT03078439|Other|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.~A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
142335|NCT03078426|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
142336|NCT03078426|Other|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
142337|NCT03078400|Drug|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
142338|NCT03078387|Diagnostic Test|imaging|imaging before and after treatment
142339|NCT03078374|Drug|Warfarin|Reduced dosage to obtain lower INR range
142340|NCT03078361|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
142341|NCT03078361|Behavioral|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
142342|NCT03078361|Behavioral|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
142343|NCT03078348|Other|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
142344|NCT03078348|Behavioral|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
142345|NCT03078348|Behavioral|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
142346|NCT03078335|Other|Glove based care|Described in Experimental Arm: Glove based care
142347|NCT03078335|Other|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
142348|NCT03078322|Drug|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
142349|NCT03078322|Drug|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
142350|NCT03078309|Drug|cannabis|single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
142351|NCT03078296|Other|survey respondents|all survey participants will be asked to complete a questionnaire
142352|NCT03078283|Other|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
142353|NCT03078270|Drug|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
142354|NCT03078270|Other|Placebo|single treatment visit for 5 injections of normal saline
142355|NCT03078257|Drug|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
142356|NCT03078257|Drug|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
142357|NCT03078257|Drug|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
142358|NCT03078257|Drug|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day."
142359|NCT03078257|Drug|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
142360|NCT03078257|Drug|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
142361|NCT03078257|Drug|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
142368|NCT03078192|Drug|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
142369|NCT03078192|Device|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
142370|NCT03078179|Dietary Supplement|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) for 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
142371|NCT03078179|Dietary Supplement|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics. They will drink the milk with probiotic for 3 months. Clinical and microbiological testing of saliva will be performed. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and demineralization in early Stage Decay and quantification of Streptococci of the mutans group.
142372|NCT03078153|Behavioral|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
142373|NCT03078153|Behavioral|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
142374|NCT03078140|Dietary Supplement|Triferdine|Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
142375|NCT03078140|Dietary Supplement|Triferdine/Ferli-6|"For the participants assigned to this group, urine iodine level will be checked first.~For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.~For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery."
142376|NCT03078127|Other|Baseline (Huff-Cough alone)|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
142377|NCT03078127|Device|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
142378|NCT03078127|Device|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
142379|NCT03078127|Device|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
142380|NCT03078114|Other|Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.
142381|NCT03078114|Other|Placebo Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
142382|NCT03078101|Drug|Empagliflozin 10 MG [Jardiance]|administered orally once daily
142383|NCT03078101|Drug|Placebo Oral Tablet|administered orally once daily
142384|NCT03078088|Drug|Tham|alkalinizer
142385|NCT03078088|Drug|Saline|Placebo
142386|NCT03078075|Drug|Active Medication Combination (AMC)|Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks ; Bupropion: 450 mg oral dose daily
142387|NCT03078075|Drug|Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
142388|NCT03078062|Drug|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
142389|NCT03078062|Drug|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
142390|NCT03078036|Genetic|Germline BRCA Test (blood)|If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
142391|NCT03078036|Genetic|FoundationOne Dx Genomic Profile (archival Tumour Specimen)|"Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:~Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.~Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile."
142392|NCT03078036|Other|Follow-up|"Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.~- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study."
142393|NCT03078023|Device|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
142394|NCT03078010|Drug|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
142395|NCT03078010|Drug|cefepime|(2 gm IV q 8 hrs)
142396|NCT03077997|Behavioral|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, & diabetes distress in people with type 2 diabetes mellitus.
142397|NCT03077984|Combination Product|Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
203254|NCT02626338|Drug|Fludarabine|
142398|NCT03077971|Behavioral|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
142399|NCT03077971|Behavioral|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
142400|NCT03077958|Procedure|Total Knee Replacement (2 different design)|Patients will randomely receive either Attune or PFC Sigma TKR
142401|NCT03077945|Behavioral|heart rate variability biofeedback and cognitive reappraisal|
142402|NCT03077945|Behavioral|control tasks|
142403|NCT03077932|Other|App Development and Open Pilot|"Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients interested in discontinuing opioid medication.~Phase 2 (open pilot) will involve conducting a 12-week open pilot trial (n=20) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate medication."
142404|NCT03077919|Drug|Ropivacaine|0.5% ropivacaine
142405|NCT03077919|Drug|Sham treatment|preservative-free normal saline
142406|NCT03077906|Other|Medical Files data extraction|Medical Files data extraction
142407|NCT03077893|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
142408|NCT03077893|Device|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
142409|NCT03077880|Procedure|intra-operatory measurement during implant placement|mucoperiosteal flap, soft tissue thickness measurement, implant insertion
142410|NCT03077867|Procedure|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
142411|NCT03077854|Radiation|Functional Lung Avoidance Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
142412|NCT03077854|Radiation|Standard Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)~Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)~Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
142413|NCT03077841|Radiation|External Radiation Therapy|Prescription dose is 35 Gy in 10 daily fractions delivered on consecutive treatment days. A treatment day is defined as a normal business day, typically Monday - Friday excluding institutional holidays. A 3 Gy in 3 fraction boost should be delivered if a close (less than 2 mm) margin is present and should not be delivered if margins are negative at a minimum of 2 mm or greater.
142414|NCT03077841|Behavioral|Questionnaires|Questionnaires completed at baseline, and at 6 months and 1, 2, 3, 4, and 5 years after receiving radiation. Questionnaires ask about how participant's breast currently looks and feels. It should take about 10 minutes to complete the questionnaires.
142415|NCT03077828|Drug|Carboplatin|Given IV
142416|NCT03077828|Drug|Etoposide|Given IV
142417|NCT03077828|Drug|Ifosfamide|Given IV
142418|NCT03077828|Other|Laboratory Biomarker Analysis|Correlative studies
142419|NCT03077828|Biological|Pembrolizumab|Given IV
142420|NCT03077815|Other|Systematically intermittent arm exercise|While holding a rubber ball for 5 minutes a day, together with strappy elastic compression arm veinElastic bandages defined for using this research provides of standard bandages, according to research personnel Guide, reached hand elbow near heart end 4 (2~6) cm at of arm local pressure strong 50 mm-Hg (+/-10 mm-Hg) (about equivalent to provides pressure strong 6.67 thousand PA (kPa), also about equivalent to 0.97 PSI (pound per square inch)), to reached 5 minutes arm movement Shi short reduced vein return, promotion pathway vein extended of effect
142421|NCT03077802|Other|Modified Seldinger technique, short axis|This is a technique for central venous catheterization. Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique is performed under short-axis ultrasound guidance.
142422|NCT03077802|Other|Seldinger technique, short aixs|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique is performed under short-axis ultrasound guidance.
142423|NCT03077802|Other|Modified Seldinger technique, long axis|This is a technique for central venous catheterization. Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique is performed under long-axis ultrasound guidance.
142424|NCT03077802|Other|Seldinger technique, long axis|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique is performed under long-axis ultrasound guidance.
142425|NCT03077789|Procedure|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
142426|NCT03077776|Procedure|Biopsy|Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
142427|NCT03077776|Procedure|Biopsy (optional)|[Optional] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
142428|NCT03077776|Procedure|Biopsy (metastatic)|Biopsy of metastatic site to be performed at the time of relapse
142429|NCT03077763|Drug|Sodium Nitrite|
142430|NCT03077750|Drug|VBP-245 Topical Gel|Topical application BID
142431|NCT03077750|Drug|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
142432|NCT03077737|Behavioral|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
142694|NCT03075501|Drug|Stimulant or sedative|CS+ for paired, CS0 for unpaired
142433|NCT03077737|Behavioral|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
142434|NCT03077724|Drug|Fish oil|Fish oil supplementation
142435|NCT03077724|Drug|Placebos|Olive Oil capsules
142436|NCT03077711|Drug|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
142437|NCT03077711|Drug|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
142438|NCT03077698|Drug|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
142439|NCT03077698|Drug|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
142440|NCT03077685|Drug|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection.
142441|NCT03077659|Drug|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
142442|NCT03077646|Behavioral|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
142443|NCT03077646|Behavioral|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
142444|NCT03077646|Behavioral|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.~After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
142445|NCT03077633|Procedure|Cervical Cerclage placement|Cervical Cerclage placement
142446|NCT03077633|Drug|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
142447|NCT03077620|Drug|Suvorexant|Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
142448|NCT03077620|Drug|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
142449|NCT03077607|Drug|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
142450|NCT03077607|Drug|Itraconazole|100 mg oral dose
142451|NCT03077607|Drug|Rifampin|600 mg oral dose
142452|NCT03077594|Device|Mucosal Impedance|Aim 1: Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Mucosal impedance will be measured 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
142453|NCT03077594|Other|Research Biopsies|Aim 1: Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation. Aim 2: Aim 2: Research biopsies will be taken 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
142454|NCT03077594|Device|Volumetric Laser Endomicroscopy|Aim 2: Volumetric laser endomicroscopy will be done and marked at 1 cm above gastroesophageal junction, 1 cm below previous squamous columnar junction, 1 cm above previous squamocolumnar junction.
142455|NCT03077581|Drug|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
142456|NCT03077581|Drug|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
142457|NCT03077581|Drug|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
142458|NCT03077568|Behavioral|My Stress Control|"The web-based program is designed to educate the users in how stress can affect their health, provide tools to handle stress and also educate the users in a problem-solving method to prevent and manage stress-related problems in the future.~The program is tailored for each user. The stress-management techniques included are: assertiveness training, change negative thinking, pleasant activity scheduling, relaxation, time-management, stimulus control and sleep restriction to improve sleep and physical activity.~Central techniques to support behaivor change in My Stress Controll are encourage intention formulation, specific goal-setting, feedback on performance and reevaluation of goals."
142459|NCT03077555|Drug|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
142460|NCT03077555|Drug|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
142461|NCT03077542|Procedure|haploidentical stem cell transplant|haploidentical stem cell transplant
142462|NCT03077542|Drug|sirolimus|conditioning regimen
142463|NCT03077542|Drug|campath|conditioning regimen
142464|NCT03077542|Drug|pentostatin|conditioning regimen
142465|NCT03077542|Drug|cyclophosphamide|conditioning regimen
142693|NCT03075501|Behavioral|Paired|Drug conditioning is assessed by pairing drug administration with a given context.
142466|NCT03077529|Dietary Supplement|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
142467|NCT03077529|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
142468|NCT03077516|Device|Mobi-C|Device for cervical intervertebral disc replacement at one or two contiguous levels
142469|NCT03077503|Drug|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
142470|NCT03077503|Drug|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
142471|NCT03077503|Drug|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
142472|NCT03077503|Device|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
142473|NCT03077490|Device|Transvaginal mesh Uphold TM Vaginal Support System|
142474|NCT03077490|Device|Transvaginal mesh Uphold TM Vaginal Support System.|
142475|NCT03077477|Drug|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
142476|NCT03077477|Drug|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:~Placebo Tablets, orally administered"
142477|NCT03077464|Behavioral|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
142478|NCT03077451|Other|Laboratory Biomarker Analysis|Correlative studies
142479|NCT03077451|Drug|Nelfinavir Mesylate|Given PO
142480|NCT03077438|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 mL, Intramuscular
142481|NCT03077438|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
142482|NCT03077425|Behavioral|Enhanced Usual Care (EUC)|Per Arm/Group Description, CHWs will provide a pamphlet and dental referral list to participants both groups.
142483|NCT03077425|Behavioral|Intervention|Per Arm/Group Description, CHWs will a) conduct 6 home visits with mothers/families over a 12 month period along with follow-up phone support, and b) patient navigation support for child to receive 2 dental visits: one by 12 months of age and one by 18 months of age.
142484|NCT03077412|Drug|Filgotinib|Tablet(s) administered orally once daily
142485|NCT03077412|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
142486|NCT03077399|Device|SCALA|All items of SCALA are applied
142487|NCT03077386|Behavioral|ENCOMPASS Intervention|Patients will be matched to a CHN who will conduct a needs assessment to determine the frequency of meetings. A CHN may perform any of the following: providing information to a patient's health care provider, translation, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health related goals, liaising with a patient's employer, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHN to be physically present at appointments or have direct contact with the patient's health care provider. Goal setting and support will be provided in person or over the telephone using motivational interviewing principles
142488|NCT03077373|Behavioral|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).~The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
142489|NCT03077360|Behavioral|Lifestyle|Lifestyle changes to lose weight or become more fit
142490|NCT03077347|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
142491|NCT03077334|Device|PET-CT|PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
142492|NCT03077321|Behavioral|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
142493|NCT03077321|Behavioral|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
142494|NCT03077308|Procedure|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual [every 10-14 months]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
142652|NCT03075891|Drug|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
142495|NCT03077295|Other|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
142496|NCT03077295|Other|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
142497|NCT03077282|Drug|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
142498|NCT03077256|Device|BioBurst Fluid, Burst Allograft|BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery
142499|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - deintensified|60 Gy at 2 Gy/fx
142500|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - standard|70 Gy at 2 Gy/fx
142501|NCT03077243|Drug|Cisplatin (or alternative) - deintensified|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses.
142502|NCT03077243|Drug|Cisplatin (or alternative) - standard|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 7 total doses.
142503|NCT03077243|Procedure|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
142504|NCT03077230|Behavioral|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
142505|NCT03077217|Drug|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
142506|NCT03077204|Biological|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
142507|NCT03077204|Device|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
142508|NCT03077191|Other|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
142509|NCT03077178|Procedure|Geriatric assessment|Geriatric assessment, questionnaire assessment
142510|NCT03077165|Drug|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
142511|NCT03077165|Drug|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
142512|NCT03077165|Drug|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
142513|NCT03077165|Drug|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
142514|NCT03077165|Drug|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
142515|NCT03077165|Drug|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
142516|NCT03077139|Device|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
142517|NCT03077126|Other|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
142518|NCT03077126|Device|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
142519|NCT03077126|Diagnostic Test|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
142520|NCT03077126|Procedure|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
142653|NCT03075891|Other|Oral placebo capsules|1 Capsule once-daily for 12 weeks
142654|NCT03075878|Drug|SYNT001|250mL IV infused over 1 hour
142521|NCT03077113|Diagnostic Test|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
142522|NCT03077113|Diagnostic Test|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
142523|NCT03077100|Other|Laboratory identification of positive cultures|Laboratory identification of positive cultures
142524|NCT03077087|Device|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
142525|NCT03077074|Other|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
142526|NCT03077061|Procedure|Open flap debridement|Open flap debridement using saline as irrigation
142527|NCT03077061|Device|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
142528|NCT03077048|Drug|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
142529|NCT03077035|Other|glass ionomer sealants|
142530|NCT03077035|Other|resin-based sealant|
142531|NCT03077009|Drug|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
142532|NCT03076996|Behavioral|Online support group|"Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.~The m/eHealth intervention components include:~Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis~Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis~Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
142533|NCT03076983|Device|Lung Monitoring with EIT device (PulmoVista 500)|"Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).~No medical interventions to routine patient care required."
142534|NCT03076970|Drug|lasmiditan 200 mg|drug including single placebo tablet
142535|NCT03076970|Drug|Sumatriptan|drug including single placebo tablet
142536|NCT03076970|Drug|matching placebo|single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
142537|NCT03076957|Drug|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
142538|NCT03076944|Drug|UltraEZ|Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
142539|NCT03076944|Drug|Enamelast|Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
142540|NCT03076931|Procedure|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
142541|NCT03076931|Procedure|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
142542|NCT03076931|Procedure|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
142543|NCT03076918|Device|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
142544|NCT03076918|Device|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
142545|NCT03076905|Drug|F901318|Evaluation of AUC0-t
142546|NCT03076892|Device|Aktilite® Galderma|preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes
142547|NCT03076892|Device|PHOS ISTOS PDT|preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
142548|NCT03076879|Behavioral|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.~Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.~Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.~Brochure; The brochure for cervical cancer and screening will be given after group training."
142549|NCT03076866|Other|observational follow-up:clinical, radiological et biological|
142550|NCT03076853|Other|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
142578|NCT03076541|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
142551|NCT03076840|Other|Kinesio tape|Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
142552|NCT03076827|Procedure|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
142553|NCT03076827|Procedure|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
142554|NCT03076801|Behavioral|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
142555|NCT03076788|Other|electrocardiogram and echocardiography|"We retrieved all electrocardiograms and echocardiography made during the clinical examination of each athlete and each sedentary control.~Standard 12 lead ECG~Trans-thoracic echocardiography examination of cardiac function, morphology and intracardiac flow."
142556|NCT03076775|Other|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if not eating (NPO) or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on the American Diabetes Association and the American College of Obstetricians and Gynecologists recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
142557|NCT03076762|Drug|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
142558|NCT03076749|Other|Creating models for the diagnosis of BL allergy|
142559|NCT03076736|Behavioral|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
142560|NCT03076736|Behavioral|Resource pack|Resource pack with information on living with aphasia and local community activities.
142561|NCT03076723|Other|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
142562|NCT03076723|Other|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
142563|NCT03076710|Drug|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
142564|NCT03076710|Drug|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
142565|NCT03076697|Diagnostic Test|Fundus photography|Fundus photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing disease along with the stage of disease. Several ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
142566|NCT03076684|Other|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
142567|NCT03076684|Drug|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
142568|NCT03076671|Behavioral|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
142569|NCT03076658|Radiation|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
142570|NCT03076645|Behavioral|Facilitator support and education|Group engaged with facilitator support and education
142571|NCT03076632|Device|Cervical plus transcranial stimulation|Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
142572|NCT03076632|Device|Cervical stimulation plus hand/wrist exercise|Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.
142573|NCT03076632|Device|Electromyographic (EMG)-triggered (closed-loop) stimulation|Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
142574|NCT03076619|Other|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
142575|NCT03076606|Diagnostic Test|ophthalmologist examination|ophthalmologist examination after geriatric consultation
142576|NCT03076593|Other|Exposure: Fall|Participants will be asked about prior falls
142577|NCT03076554|Drug|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
142649|NCT03075917|Other|Self Questionnaire|self questionnaire for allergic rhinitis control
203255|NCT02626338|Drug|G-CSF|
142579|NCT03076528|Other|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
142580|NCT03076528|Other|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
142581|NCT03076515|Device|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
142582|NCT03076515|Device|Sham Nerivio Migra|electrical stimulation- shame mode
142583|NCT03076489|Other|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
142584|NCT03076489|Other|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
142585|NCT03076489|Device|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
142586|NCT03076476|Device|Bioresorbable Vascular Scaffolds (BVS)|Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
142587|NCT03076476|Device|Drug-Eluting Stent (DES) - slow|"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS."
142588|NCT03076476|Device|Drug-Eluting Stent (DES) - standard(std)|Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
142589|NCT03076463|Dietary Supplement|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
142590|NCT03076450|Device|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
142591|NCT03076450|Diagnostic Test|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
142592|NCT03076437|Combination Product|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.~Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
142593|NCT03076424|Other|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
142594|NCT03076411|Drug|Pepsin|
142595|NCT03076385|Biological|VAL-506440|Escalating dose levels
142596|NCT03076385|Other|Placebo|
142597|NCT03076372|Drug|MM-310|MM-310
142598|NCT03076359|Behavioral|Traditional Healer Support Program|"Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients."
142599|NCT03076359|Drug|Standard of Care|First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
142600|NCT03076333|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
142601|NCT03076320|Combination Product|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
142602|NCT03076320|Combination Product|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
142603|NCT03076307|Behavioral|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
142604|NCT03076294|Device|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
142605|NCT03076294|Other|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
142606|NCT03076281|Drug|Metformin Hydrochloride|Given orally
142607|NCT03076281|Drug|Doxycycline|Given orally
142608|NCT03076281|Drug|Metformin +Doxycycline|Given orally
142650|NCT03075904|Drug|SYNT001|IV 250 mL over 1 hour
142651|NCT03075891|Drug|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
142609|NCT03076268|Behavioral|Treinta Millones de Palabras - Visitas al Hogar|TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism.
142610|NCT03076255|Procedure|Computed Tomography|Undergo CT simulation
142611|NCT03076255|Device|Medical Device|Given thermoplastic mask
142612|NCT03076255|Device|Medical Device|Given MID
142613|NCT03076255|Procedure|Cone-Beam Computed Tomography|Undergo CBCT imaging
142614|NCT03076242|Other|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
142615|NCT03076229|Behavioral|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
142616|NCT03076216|Device|OncoSil™|The implantation of OncoSil™ under EUS
142617|NCT03076203|Drug|Niraparib|Given orally
142618|NCT03076203|Radiation|Radium Ra 223 Dichloride|Given intravenously
142619|NCT03076190|Behavioral|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
142620|NCT03076177|Other|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
142621|NCT03076164|Drug|Trametinib|Trametinib 1.5mg once daily by mouth
142622|NCT03076164|Drug|Erlotinib|Erlotinib 75mg once daily by mouth
142623|NCT03076151|Drug|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
142624|NCT03076138|Device|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
142625|NCT03076125|Behavioral|SCORRE|3 components based on the Health Belief Model
142626|NCT03076125|Behavioral|Attention-Control Activity|sexual health education
142627|NCT03076112|Drug|Ipragliflozin|Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
142628|NCT03076112|Drug|Sitagliptin|Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
142629|NCT03076099|Drug|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
142630|NCT03076099|Other|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
142631|NCT03076086|Other|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
142632|NCT03076073|Other|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
142633|NCT03076060|Behavioral|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD."
142634|NCT03076060|Behavioral|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD."
142635|NCT03076047|Procedure|end-tidal CO2 (ETCO2) monitoring with Smart CapnoLine Plus O2|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2
142636|NCT03076034|Device|Reference Point Indentation|"The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of ~375 µm."
142637|NCT03076021|Drug|Isotretinoin|Drug interaction study
142638|NCT03076021|Drug|dextromethorphan|Drug interaction study
142639|NCT03076008|Other|Observational|No intervention
142640|NCT03075995|Other|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
142641|NCT03075956|Drug|5 mg E4 single-dose|A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
142642|NCT03075956|Drug|15 mg E4 single-dose|A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
142643|NCT03075956|Drug|45 mg E4 single-dose|A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
142644|NCT03075956|Drug|15 mg E4 multiple-dose|15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
142645|NCT03075943|Dietary Supplement|InSea2|Daily supplement: 2 capsules of InSea2
142646|NCT03075943|Dietary Supplement|Placebo|Daily supplement: 2 capsules of Placebo
142647|NCT03075930|Device|Extended Electrocardiogram|ECG with 3 additional leads and a 5 minute recording
142648|NCT03075930|Device|Body surface potential map|ECG with 184 leads and a 5 minute recording
203256|NCT02626338|Drug|Idarubicin|
142655|NCT03075865|Device|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
142656|NCT03075852|Device|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
142657|NCT03075839|Other|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
142658|NCT03075826|Drug|SGI-110|subcutaneously at a dose of 60 mg/m2
142659|NCT03075813|Other|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
142660|NCT03075800|Behavioral|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)|The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
142661|NCT03075787|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
142662|NCT03075761|Device|Fitbit|The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
142663|NCT03075761|Behavioral|30-minute education session|
142664|NCT03075748|Device|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
142665|NCT03075722|Device|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
142666|NCT03075709|Other|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
142667|NCT03075696|Drug|RO7082859|RO7082859 will be administered at a dose and as per the schedule specified in the respective arms.
142668|NCT03075696|Drug|Obinutuzumab|Obinutuzumab 1000 mg single dose IV infusion on Day -7 and per the schedule specified in the respective arms.
142669|NCT03075696|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion, if required, for the management of severe Cytokine Release Syndrome (CRS) occurring during or after any infusion of RO7082859, as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
142670|NCT03075683|Behavioral|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
142671|NCT03075683|Behavioral|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
142672|NCT03075670|Drug|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
142673|NCT03075670|Drug|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
142674|NCT03075657|Drug|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
142675|NCT03075657|Drug|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
142676|NCT03075657|Drug|Haloperidol|Haloperidol will be prescribed at a dose of 4 mg per day
142677|NCT03075657|Drug|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 4 mg per day
142678|NCT03075644|Drug|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
142679|NCT03075644|Drug|Norditropin|Daily subcutaneous injections (s.c., under the skin)
142680|NCT03075631|Other|Questionnaire|Questionnaires
142681|NCT03075618|Behavioral|Questionnaires|Questionnaires
142682|NCT03075579|Drug|Medication Other|medication of atomoxetine
142683|NCT03075579|Device|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
142684|NCT03075566|Biological|Healthy subjects|- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
142685|NCT03075566|Biological|Patients|- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
142686|NCT03075553|Other|Laboratory Biomarker Analysis|Correlative studies
142687|NCT03075553|Biological|Nivolumab|Given IV
142688|NCT03075540|Behavioral|Genetic Counseling and Testing YouTube Video|Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
142689|NCT03075527|Drug|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
142690|NCT03075527|Drug|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
142691|NCT03075514|Other|MKD|Modified ketogenic diet
142692|NCT03075514|Other|MCT|Medium chain triglyceride ketogenic diet
142695|NCT03075501|Drug|Placebo|CS- for paired, CS0 for unpaired
142696|NCT03075488|Device|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
142697|NCT03075488|Procedure|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
142698|NCT03075475|Behavioral|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
142699|NCT03075462|Drug|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
142700|NCT03075462|Drug|Apatinib|Apatinib at 250mg once daily, tablet oral
142701|NCT03075436|Behavioral|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
142702|NCT03075436|Behavioral|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
142703|NCT03075423|Drug|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd week
142704|NCT03075423|Drug|Sunitinib|Sunitinib is administered orally 50 mg tablets for 4 weeks on and 2 weeks off
142705|NCT03075410|Drug|GSK3036656|GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
142706|NCT03075410|Drug|Placebo|Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
142707|NCT03075397|Other|blood sample|A sample of HIV-1 infected patients's blood is collected
142708|NCT03075397|Other|sperm sample|A sample of HIV-1 infected patients's sperm is collected
142709|NCT03075384|Procedure|computer-assisted navigation system|The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
142710|NCT03075371|Other|Glucose|75 g of glucose dissolved in 300 ml of water
142711|NCT03075371|Other|Placebo|300 ml of tap water
142712|NCT03075358|Drug|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
142713|NCT03075358|Other|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
142714|NCT03075345|Behavioral|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
142715|NCT03075345|Behavioral|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
142716|NCT03075332|Other|combined training|Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
142717|NCT03075319|Procedure|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
142718|NCT03075319|Procedure|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups."
142719|NCT03075306|Behavioral|intervention|the 12-month CHAMPION intervention with 1) a health coach, a trained mental health program employee, who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents; and 2) support from health providers who will provide basic weight management messages and encouragement for behavior change.
142720|NCT03075293|Other|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
142721|NCT03075280|Procedure|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
142722|NCT03075267|Drug|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
142723|NCT03075267|Drug|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
142724|NCT03075267|Drug|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
142725|NCT03075254|Device|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
142726|NCT03075254|Device|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
142845|NCT03074448|Device|Aquanet|Aquanet bowel cleansing devices
142727|NCT03075254|Device|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
142728|NCT03075241|Drug|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
142729|NCT03075241|Drug|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
142730|NCT03075241|Drug|Placebo|Inactive or inert pill which will be used as a comparator
142731|NCT03075228|Device|IntelliCap|Sampling of the small intestine using a samling capsule.
142732|NCT03075215|Device|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
142733|NCT03075202|Device|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
142734|NCT03075189|Dietary Supplement|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.~The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.~Both groups have diet registration and testing at baseline, discharge and follow-up."
142735|NCT03075176|Device|Wavefront optimized LASIK|Wavefront optimized laser vision correction
142736|NCT03075176|Device|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
142737|NCT03075176|Device|Topography-guided LASIK|Topography-guided laser vision correction
142738|NCT03075176|Device|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
142739|NCT03075163|Procedure|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.~In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
142740|NCT03075163|Drug|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
142741|NCT03075137|Device|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
142742|NCT03075124|Device|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
142743|NCT03075111|Diagnostic Test|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
142744|NCT03075098|Device|Digital colposcope|Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
142745|NCT03075085|Behavioral|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
142746|NCT03075072|Radiation|Whole brain radiation|Treatment of the whole brain with radiation. When possible the hippocampus will be spared from radiation.
142747|NCT03075072|Radiation|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
142748|NCT03075059|Behavioral|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
142749|NCT03075046|Device|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
142750|NCT03075046|Other|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
142846|NCT03074448|Drug|Sodium Picosulfate|Sodium Picosulfate solution (Picoprep)
142847|NCT03074435|Device|Insecticidal paint|Houses will be painted with insecticidal paint
142751|NCT03075033|Device|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
142752|NCT03075033|Device|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
142753|NCT03075020|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
142754|NCT03075020|Other|AIR|Room air will be administered as placebo
142755|NCT03075007|Radiation|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
142756|NCT03075007|Procedure|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
142757|NCT03074994|Drug|Peri-articular TXA (15 mg/kg)|combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
142758|NCT03074994|Drug|Intraarticular TXA 2 g (40 mL)|inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
142759|NCT03074994|Procedure|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area|(Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
142760|NCT03074994|Procedure|TXA 40 mL inject into intraaricular knee capsule|after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
142761|NCT03074981|Device|Combined TopClosure & Vcare Alpha|"Combined TopClosure & Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.~Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.~The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
142762|NCT03074968|Drug|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
142763|NCT03074968|Drug|Normal saline|normal saline application
142764|NCT03074955|Device|leg wrapping with tension|"Apply elastic bandages with tension to both legs before injecting propofol.~After 3 minutes, remove elastic bandages."
142765|NCT03074955|Procedure|Trendelenburg position|"Apply Trendelenburg position positon of 10 degree after injectin propofol~After 3 minutes, change to supine position"
142766|NCT03074955|Device|leg wrapping without tension|"Apply elastic bandages without tension to both legs before injecting propofol.~After 3 minutes, remove elastic bandages"
142767|NCT03074955|Procedure|supine position|1.maintain supine position
142768|NCT03074942|Drug|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
142769|NCT03074929|Behavioral|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
142770|NCT03074916|Device|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
142771|NCT03074903|Device|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
142772|NCT03074890|Device|Application Protocol|Application lMassive Transfusion Protocol
142773|NCT03074877|Behavioral|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
142774|NCT03074864|Drug|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
142775|NCT03074851|Dietary Supplement|low sodium salt|To give free low sodium salt intervention for 2 months
142776|NCT03074851|Other|informational intervention|to give reporter informational intervention.
142777|NCT03074838|Procedure|Transarterial aortic valve implantation - TAVI|After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.
142778|NCT03074838|Procedure|Surgical aortic valve replacement - SAVR|The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
142779|NCT03074825|Drug|Chiauranib|Take 50mg orally once daily
142780|NCT03074812|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease [36]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
142848|NCT03074435|Device|Larvicide|Larval breeding sites will be treated with larvicide
142849|NCT03074435|Biological|Ivermectin|Doses of Ivermectin will be injected to peri-domestic animals
142850|NCT03074435|Behavioral|IEC|A reinforced information, education and communication strategy will be implemented.
142781|NCT03074799|Other|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.~Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).~Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
142782|NCT03074799|Other|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
142783|NCT03074786|Drug|Dapivirine|Silicone elastomer vaginal matrix ring
142784|NCT03074786|Drug|Truvada|Tablets to be taken orally daily
142785|NCT03074773|Drug|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
142786|NCT03074773|Device|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
142787|NCT03074773|Procedure|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
142788|NCT03074773|Drug|Bupivacaine|it is an amino amide local anesthetic drug
142789|NCT03074773|Other|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
142790|NCT03074760|Diagnostic Test|Adenovirus|Diagnostic test for the presence of the adenovirus in the population groups
142791|NCT03074760|Diagnostic Test|Rotavirus|Diagnostic test for the presence of the Rotavirus in the population groups
142792|NCT03074760|Diagnostic Test|H. pylori|Diagnostic test for the presence of H. pylori infection in the population groups
142793|NCT03074747|Diagnostic Test|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
142794|NCT03074734|Other|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck device, as well as the air quality which will be monitored using AirSpeck device.
142795|NCT03074721|Device|PCI Suite Software|PCI with PCI Suite Software
142796|NCT03074721|Other|conventional PCI|conventional PCI without PCI Software
142797|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
142798|NCT03074695|Procedure|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
142799|NCT03074695|Procedure|Standard Epidural (EPL)|Standard epidural placement
142800|NCT03074695|Drug|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
142801|NCT03074695|Drug|Standard Epidural (EPL)|Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
142802|NCT03074682|Device|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
142803|NCT03074682|Device|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
142804|NCT03074682|Device|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
142805|NCT03074669|Behavioral|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
142806|NCT03074656|Other|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
142807|NCT03074656|Other|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
142808|NCT03074643|Behavioral|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
142851|NCT03074422|Procedure|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
142852|NCT03074409|Drug|oxytocin|self-administration of oxytocin (nasal spray)
142853|NCT03074409|Drug|placebo|self-administration of placebo (nasal spray)
142809|NCT03074643|Behavioral|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
142810|NCT03074643|Dietary Supplement|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
142811|NCT03074643|Dietary Supplement|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
142812|NCT03074643|Dietary Supplement|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
142813|NCT03074630|Drug|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
142814|NCT03074630|Drug|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
142815|NCT03074617|Other|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
142816|NCT03074617|Other|sham field|no electromagnetic field
142817|NCT03074604|Procedure|aortic no-touch OPCABG|(Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
142818|NCT03074604|Procedure|OPCABG with partial clamp applying carbon dioxide|(Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
142819|NCT03074604|Procedure|OPCABG with partial clamp|"(Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp."
142820|NCT03074591|Drug|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
142821|NCT03074591|Drug|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
142822|NCT03074578|Behavioral|Watching Video-clip 1|Video -clip 1 contains violent images and text
142823|NCT03074578|Behavioral|Watching Video-clip 2|Video -clip 2 contains neutral images and text
142824|NCT03074565|Device|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
142825|NCT03074565|Device|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
142826|NCT03074552|Dietary Supplement|LactoLevure|The probiotic preparation will consist a combination of four probiotics: Lactobacillus acidophilus LA-5 1.75 × 109 CFU, Lactobacillus Plantarum 0.5 × 109 CFU, Bifidobacterium lactis BB-12 1.75 × 109 CFU και Saccharomyces boulardii 1.5 × 109 CFU per capsule (LactoLevure, UniPharma, Athens, Greece).
142827|NCT03074552|Other|Placebo|Placebo will consist of identical capsules of powdered glucose polymer
142828|NCT03074539|Drug|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
142829|NCT03074539|Procedure|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
142830|NCT03074539|Procedure|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
142831|NCT03074526|Other|Amniotic Fluid|Amniotic Fluid
142832|NCT03074526|Drug|Saline Placebo|Saline Placebo
142833|NCT03074513|Drug|Atezolizumab|Given IV
142834|NCT03074513|Biological|Bevacizumab|Given IV
142835|NCT03074513|Other|Laboratory Biomarker Analysis|Correlative studies
142836|NCT03074513|Other|Pharmacological Study|Correlative studies
142837|NCT03074500|Device|Kinesiotaping|Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
142838|NCT03074500|Other|Sham taping|Sham taping will be performed without using any technique
142839|NCT03074500|Other|Exercise|Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
142840|NCT03074487|Device|Near-infrared spectroscopy|
142841|NCT03074487|Device|Long loop reflex measurements|
142842|NCT03074474|Device|OviTex Permanent 1S|OviTex 1S is a reinforced bioscaffold consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
142843|NCT03074461|Procedure|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
142844|NCT03074461|Procedure|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
205186|NCT02612818|Device|Coelioscopy|
142854|NCT03074396|Device|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
142855|NCT03074396|Device|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
142856|NCT03074383|Behavioral|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
142857|NCT03074383|Behavioral|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
142858|NCT03074344|Device|XLHA+CoQ10|XLHA+CoQ10 for four times a day for 12 weeks.
142859|NCT03074344|Device|Hyaluronic acid (HA)|Hyaluronic acid (HA) for four times a day for 12 weeks.
142860|NCT03074331|Drug|SOF/VEL|400/100 mg FDC tablet(s) administered orally once daily
142861|NCT03074318|Drug|Avelumab|Given IV
142862|NCT03074318|Drug|Trabectedin|Given IV
142863|NCT03074305|Device|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms~DEB strategy~DES strategy"
142864|NCT03074292|Procedure|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
142865|NCT03074279|Other|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
142866|NCT03074266|Diagnostic Test|GEM Hemochron 100 ACT|Activated Clotting Time
142867|NCT03074253|Diagnostic Test|Echocardiography|Patients are undergoing echocardiography
142868|NCT03074253|Diagnostic Test|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
142869|NCT03074253|Diagnostic Test|computed tomography|Patients are undergoing computed tomography
142870|NCT03074253|Diagnostic Test|blood withdrawl|Peripheral blood samples are being collected from all patients
142871|NCT03074240|Procedure|TAPB Group|Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
142872|NCT03074240|Procedure|RSB Group|Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
142873|NCT03074240|Procedure|conversion to general anesthesia|For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
142874|NCT03074227|Other|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.~Faeces will be collected from a donor."
142875|NCT03074227|Other|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
142876|NCT03074214|Procedure|percutaneous coronary intervention|"All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery."
142877|NCT03074201|Procedure|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
142878|NCT03074201|Device|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
142879|NCT03074175|Radiation|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 <25%, lung V30 <18%, spinal cord <36 Gy.
142880|NCT03074162|Drug|Diclofenac Sodium|twice daily
142881|NCT03074162|Drug|Diclofenac & Capsaicin|twice daily
142882|NCT03074162|Drug|Diclofenac Sodium Topical Gel|twice daily
142883|NCT03074136|Device|Photodinamic therapy|Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.
142884|NCT03074136|Device|Diode laser|High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).
142885|NCT03074136|Drug|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
142928|NCT03073798|Drug|Placebo|500 mcg of placebo is used
142929|NCT03073785|Drug|Capecitabine|Given PO
142930|NCT03073785|Drug|Fluorouracil|Given IV
142931|NCT03073785|Other|Laboratory Biomarker Analysis|Correlative studies
142886|NCT03074123|Diagnostic Test|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
142887|NCT03074110|Device|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
142888|NCT03074097|Drug|Bupivacaine 0.25%|Each patient received bilateral single shot ultrasound guided rectus sheath block under complete aseptic condition in a dose of 30 ml of bupivacaine 0.25% in each side immediately after induction of general anaesthesia
142889|NCT03074071|Behavioral|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
142890|NCT03074058|Drug|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID
142891|NCT03074058|Drug|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
142892|NCT03074045|Drug|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
142893|NCT03074045|Drug|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
142894|NCT03074032|Drug|ONC1-0013B|ONC1-0013B per os daily
142895|NCT03074019|Dietary Supplement|Xylooligosaccacharide|XOS95 powder
142896|NCT03074019|Dietary Supplement|Maltodextrin|Maltodextrin powder
142897|NCT03074006|Drug|TEW-7197|50mg tablets (doses will be determined through dose-escalation part)
142898|NCT03073993|Procedure|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
142899|NCT03073980|Drug|IV Acetaminophen|IV Acetaminophen for pain control during procedure
142900|NCT03073980|Drug|PO Acetaminophen|PO Acetaminophen for pain control during procedure
142901|NCT03073980|Other|Placebo IV Acetaminophen|Placebo IV Acetaminophen
142902|NCT03073980|Other|Placebo PO Acetaminophen|Placebo PO Acetaminophen
142903|NCT03073967|Drug|Pritelivir|100 mg tablets
142904|NCT03073967|Drug|Foscarnet|Solution for iv infusion
142905|NCT03073967|Drug|Pritelivir|100 mg tablets
142906|NCT03073954|Other|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
142907|NCT03073954|Behavioral|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
142908|NCT03073941|Device|Persona total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
142909|NCT03073941|Device|Nexgen total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
142910|NCT03073928|Procedure|Interscalene Block|Regional Anesthesia procedure in the neck
142911|NCT03073928|Procedure|Paracoracoid SPB|Regional anesthesia procedure under the collar bone
142912|NCT03073928|Drug|Ropivacaine|Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
142913|NCT03073902|Diagnostic Test|Liquid biopsy|Liquid biopsy
142914|NCT03073889|Procedure|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
142915|NCT03073889|Procedure|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
142916|NCT03073889|Drug|Ropivacaine|
142917|NCT03073876|Drug|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
142918|NCT03073876|Drug|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
142919|NCT03073863|Drug|Atorvastatin|Analysis
142920|NCT03073850|Drug|Antiplatelet|ASA or clopidogrel
142921|NCT03073850|Drug|Low dose oral anticoagulant|Edoxaban of 30mg
142922|NCT03073850|Drug|Standard dose oral anticoagulant|Edoxaban of 60mg
142923|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16 virus
142924|NCT03073824|Device|vSculpt|Pelvic Floor Toning and Vaginal Rejuvenation Device
142925|NCT03073811|Dietary Supplement|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (Ensure Max) three times a day for two weeks before surgery and four weeks after surgery.
142926|NCT03073811|Other|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout and one oral nutrition supplement per day for two week before surgery.
142927|NCT03073798|Drug|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
142932|NCT03073785|Other|Pharmacological Study|Correlative studies
142933|NCT03073785|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
142934|NCT03073785|Drug|Zoledronic Acid|Given IV
142935|NCT03073772|Behavioral|Computer-based cognitive training|A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.
142936|NCT03073772|Behavioral|Physical fitness training|A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
142937|NCT03073759|Device|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
142938|NCT03073746|Other|Health Search|
142939|NCT03073746|Other|Standard Search|
142940|NCT03073733|Biological|human retinal progenitor cells|live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
142941|NCT03073733|Other|Mock injection|pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
142942|NCT03073707|Behavioral|Sample collection|Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
142943|NCT03073694|Drug|Mitomycin c|Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.
142944|NCT03073694|Drug|Melphalan|Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
142945|NCT03073681|Device|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
142946|NCT03073668|Procedure|Anterior pericardiotomy|The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.
142947|NCT03073668|Drug|Saline|During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
142948|NCT03073655|Other|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
142949|NCT03073655|Other|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
142950|NCT03073655|Other|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
142951|NCT03073642|Other|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
142952|NCT03073642|Other|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
142953|NCT03073629|Diagnostic Test|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
142954|NCT03073616|Device|Lung ultrasound|Lung ultrasound and chest RX
142955|NCT03073603|Drug|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
142956|NCT03073603|Drug|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
142957|NCT03073590|Combination Product|Intervention factory with hot lunch|A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
142958|NCT03073590|Combination Product|Intervention factory without lunch program|In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
142959|NCT03073590|Combination Product|Control factory with lunch program|One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
142960|NCT03073590|Behavioral|Control factory without lunch program|One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
142961|NCT03073577|Drug|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
142962|NCT03073564|Diagnostic Test|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
142963|NCT03073564|Diagnostic Test|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
209145|NCT02585011|Drug|Ropivacaine|
142964|NCT03073551|Other|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
142965|NCT03073525|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
142966|NCT03073525|Drug|Atezolizumab|Atezolizumab is provided in a single-use, 20-cc USP/Ph. Eur. Type 1 glass vial as a colorless to slightly-yellow, sterile, preservative-free clear liquid solution intended for IV administration. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. The atezolizumab drug product is formulated as 60 mg/mL atezolizumab in 20 mM histidine acetate, 120 mM sucrose, 0.04% polysorbate 20, pH 5.8 (Phase III formulation).
142967|NCT03073512|Other|Ultrasound examination|Participants will undergo ultrasound examination at 32 weeks gestation
142968|NCT03073499|Procedure|Oncological Home Hospitalization|
142969|NCT03073486|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
142970|NCT03073486|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
142971|NCT03073473|Diagnostic Test|NantHealth GPS Cancer Test|Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
142972|NCT03073460|Other|Ultrasound examination|This exam is performed at 40 weeks gestation
142973|NCT03073447|Other|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
142974|NCT03073421|Other|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
142975|NCT03073408|Drug|Propofol|Closed loop control for propofol administration guided by the BIS.
142976|NCT03073408|Drug|Propofol|Manual control group: Propofol administration adjusted manually.
142977|NCT03073395|Drug|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of [68Ga]P16-093
142978|NCT03073382|Other|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
142979|NCT03073369|Drug|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
142980|NCT03073369|Drug|Placebo|Oral Placebo - one capsule once daily for 6 weeks
142981|NCT03073356|Biological|Infusion of 3-OHB|Increase in 3-OHB levels
142982|NCT03073356|Biological|Infusion of placebo|NaCl
142983|NCT03073343|Dietary Supplement|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
142984|NCT03073330|Diagnostic Test|GDM screening with 75 g 2 hour GTT|Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.
142985|NCT03073330|Diagnostic Test|GDM screening with two step approach|1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
142986|NCT03073317|Diagnostic Test|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
142987|NCT03073304|Drug|Crystalloid based prime solution|Crystalloid based prime solution
142988|NCT03073304|Drug|Erythrocyte based prime solution|Erythrocyte based prime solution
142989|NCT03073291|Behavioral|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
142990|NCT03073278|Radiation|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
142991|NCT03073265|Device|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
142992|NCT03073252|Other|Normal Protein|Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
142993|NCT03073252|Other|HIgh Protein|Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
142994|NCT03073239|Genetic|ALS patients genetic characterization|Genetic findings in ALS patients
142995|NCT03073239|Other|ALS patients epidemiological caracterization|Epidemiological characterization in ALS patients
209146|NCT02585011|Drug|Epinephrine|
142996|NCT03073226|Device|Olympus Elite|New generation Olympus endoscope
142997|NCT03073226|Device|Olympus Spectrum|Current generation Olympus endoscope
142998|NCT03073213|Drug|Ixekizumab|Administered as SC injection
142999|NCT03073200|Drug|Etanercept|Administered SC
143000|NCT03073200|Drug|Ixekizumab|Administered SC
143001|NCT03073200|Drug|Placebo|Administered SC
143002|NCT03073135|Behavioral|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
143003|NCT03073135|Behavioral|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
143004|NCT03073122|Diagnostic Test|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
143005|NCT03073096|Procedure|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
143006|NCT03073083|Procedure|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
143007|NCT03073083|Procedure|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
143008|NCT03073083|Procedure|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
143009|NCT03073070|Drug|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
143010|NCT03073057|Drug|Budesonide/formoterol|2 inhalations as a single dose
143011|NCT03073057|Other|Charcoal|
143012|NCT03073057|Drug|Symbicort Turbuhaler|2 inhalations as a single dose
143013|NCT03073044|Diagnostic Test|BELASTUNGSFRAGEBOGEN PARKINSON KURZVERSION (BELA-P-K)|"we proposed the translation and validation of Bela-p-K, a questionnaire that evaluates the Quality of Life in parkinsonian patients.~we applied the method of translation and back-translation at dutch version of questionnaire. after, we evaluated 103 PD patients with Bela-p-K and PDQ39.~The internal consistency of questionnaire was analyzed calculating alpha-Chronbach. We also evaluated the construct validity correlating Bela-p-K and PDQ39"
143014|NCT03073031|Device|Tablet: Samsung Galaxy Tab A|
143015|NCT03073018|Drug|Fosinopril|oral administration, capsules
143016|NCT03073018|Drug|Pravastatin|oral administration, capsules
143017|NCT03073018|Drug|Fosinopril Placebo|oral administration, capsules
143018|NCT03073018|Drug|Pravastatin Placebo|oral administration, capsules
143019|NCT03073005|Other|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
143020|NCT03072992|Drug|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
143021|NCT03072992|Drug|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
143022|NCT03072992|Drug|Placebo|Placebo i.v. solution, once weekly for 12 weeks
143023|NCT03072979|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy
143024|NCT03072966|Device|Wearable device (Fitbit Charge HR® or Fitbit Alta ®)|Physical activities will be monitored by wearable device.
143025|NCT03072953|Drug|APD334|APD334 active treatment
143026|NCT03072940|Other|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
143027|NCT03072927|Device|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
143028|NCT03072914|Procedure|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
143029|NCT03072901|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
143030|NCT03072888|Device|TENS|Transcutaneous Electrical Nerve Stimulation will be apply
143031|NCT03072875|Device|CAMS-RAS|
143032|NCT03072862|Device|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
143033|NCT03072849|Procedure|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
143152|NCT03071965|Procedure|Surgery|Surgery to implant device for NT-501
143034|NCT03072849|Drug|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC <0.8.
143035|NCT03072836|Other|analysing microbiota|16SRNA gene sequencing of feces
143036|NCT03072823|Dietary Supplement|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
143037|NCT03072823|Dietary Supplement|placebo|olive oil ethyl esters
143038|NCT03072810|Behavioral|Positive mindfulness program|4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
143039|NCT03072784|Procedure|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
143040|NCT03072771|Drug|Blinatumomab|-Blinatumomab is a bispecific T cell engaging antibody
143041|NCT03072771|Procedure|Autologous stem cell transplant|-Standard of care
143042|NCT03072771|Drug|Carmustine|-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
143043|NCT03072771|Drug|Etoposide|-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
143044|NCT03072771|Drug|Cytarabine|-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
143045|NCT03072771|Drug|Melphalan|-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
143046|NCT03072771|Procedure|Peripheral blood draws|-Day +42, Day + 43, Day +56, and Day +100
143047|NCT03072758|Behavioral|Men's Club|"Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.~Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire."
143048|NCT03072745|Diagnostic Test|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
143049|NCT03072732|Device|u-Cor System|Monitoring System
143050|NCT03072732|Device|ZOE Fluid Status Monitor|Monitoring System
143051|NCT03072719|Drug|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
143052|NCT03072719|Drug|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
143053|NCT03072706|Device|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
143054|NCT03072706|Other|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
143055|NCT03072693|Procedure|Home-based remote heart failure management|For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
143056|NCT03072693|Procedure|Home-based physiological parameter recording only|For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
143057|NCT03072680|Behavioral|BPS PAST|"Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
143058|NCT03072680|Behavioral|BPS FUT|"Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
143059|NCT03072680|Behavioral|DAILY ACTIVITIES|"Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.~They will practice within a mobile app."
143060|NCT03072667|Drug|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
143061|NCT03072654|Procedure|Thyroidectomy|Remove the nodular goiter on the neck by thyroidectomy (standard procedure)
143062|NCT03072641|Dietary Supplement|ProBion Clinica|
143063|NCT03072628|Other|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
143064|NCT03072628|Other|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
143065|NCT03072628|Other|nicotine inhaler|use a nicotine inhaler for 30 minutes
143066|NCT03072628|Other|sham control|use an empty e-cigarette for 30 minutes
143067|NCT03072615|Diagnostic Test|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
143068|NCT03072602|Dietary Supplement|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
143069|NCT03072602|Other|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
143070|NCT03072589|Drug|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
143071|NCT03072576|Device|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
143072|NCT03072550|Device|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
143073|NCT03072524|Diagnostic Test|FAST PLUS test|FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
143074|NCT03072511|Behavioral|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
143075|NCT03072511|Drug|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
143076|NCT03072485|Drug|Sirolimus|Topical sirolimus applied to the skin
143077|NCT03072485|Drug|Metformin|Topical metformin applied to the skin
143078|NCT03072485|Drug|Diclofenac|Topical diclofenac applied to the skin
143079|NCT03072472|Device|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
143080|NCT03072446|Device|Gel-Beads embolic material|Patients will receive embolization of their uterine fibroids using Gel-Beads.
143081|NCT03072433|Behavioral|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
143082|NCT03072433|Behavioral|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
143083|NCT03072420|Other|Compression of the fingertip under MRI.|Compression of the fingertip by a static loading on the phalanx distal of the index of the subjects; Then also a shear stress in the transverse direction of the finger. The data provided by the MRI images will be geometric information such as the thickness of the skin and its possible variation as a function of the area of the finger, the total thickness of soft tissues in compression as a function of the variation in l The angle between the axis of the phalanx and the plane of contact; Mechanical type information relating to the displacements and reaction forces, to the internal deformations of the different areas of the finger.
143084|NCT03072407|Biological|PB-119 injection|
143085|NCT03072407|Biological|PB-119 injection placebo|
143086|NCT03072394|Drug|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
143087|NCT03072394|Drug|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
143088|NCT03072381|Biological|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
143089|NCT03072381|Drug|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
143090|NCT03072368|Other|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
143091|NCT03072355|Other|Elastic Band|Localized muscle resistance test for shoulder
143092|NCT03072355|Other|Isokinetic dynamometer|Localized muscle resistance test for shoulder
143093|NCT03072342|Procedure|Intensive Periodontal Treatment|
143094|NCT03072342|Procedure|Control Periodontal Treatment|
143095|NCT03072329|Procedure|Pudendal nerve block|
143096|NCT03072329|Drug|Bupivacaine|
143097|NCT03072316|Other|3D surface imaging|3D photography
143098|NCT03072316|Other|semi-structured interview|qualitative analysis using semi structured interview
143099|NCT03072316|Other|applanation tonometry|measurement of breast compressibility
143100|NCT03072303|Other|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
143101|NCT03072290|Drug|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
143102|NCT03072290|Drug|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
209147|NCT02585011|Drug|Saline|
143103|NCT03072277|Dietary Supplement|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
143104|NCT03072277|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
143105|NCT03072264|Behavioral|Body in Mind Training (BMT)|Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
143106|NCT03072264|Drug|Fluoxetine|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
143107|NCT03072264|Behavioral|Quality of Life Group|Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
143108|NCT03072238|Drug|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity
143109|NCT03072238|Drug|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water, plus prednisone/prednisolone, 5 mg twice daily (BID) until disease progression or intolerable toxicity
143110|NCT03072238|Drug|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity
143111|NCT03072225|Drug|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
143112|NCT03072225|Drug|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
143113|NCT03072212|Other|Observational study|No intervention
143114|NCT03072199|Drug|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
143115|NCT03072173|Drug|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
143116|NCT03072173|Drug|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
143117|NCT03072160|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
143118|NCT03072147|Drug|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
143119|NCT03072147|Drug|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
143120|NCT03072134|Biological|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
143121|NCT03072121|Drug|Shexiang Baoxin pill|Conventional western medicine & shexiang baoxin pill
143122|NCT03072121|Drug|SBP placebo|Conventional western medicine & placebo (for shexiang baoxin pill)
143123|NCT03072121|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
143124|NCT03072121|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
143125|NCT03072121|Drug|Atorvastatin Calcium|10 mg tablet, two tablets each night.
143126|NCT03072121|Drug|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
143127|NCT03072121|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
143128|NCT03072121|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
143129|NCT03072108|Dietary Supplement|Bonolive|2 caps per day of Bonolive
143130|NCT03072108|Dietary Supplement|Placebo|2 caps per day of Placebo
143131|NCT03072095|Behavioral|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
143132|NCT03072095|Behavioral|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
143133|NCT03072082|Drug|Danlou Tablet|Conventional western medicine & Danlou Tablet
143134|NCT03072082|Drug|DanLou Tablet placebo|Conventional western medicine & placebo (for Danlou Tablet)
143135|NCT03072082|Drug|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
143136|NCT03072082|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
143137|NCT03072082|Drug|Atorvastatin calcium|10 mg tablet, two tablets each night.
143138|NCT03072082|Drug|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
143139|NCT03072082|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
143140|NCT03072082|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
143141|NCT03072056|Drug|MIN-101|
143142|NCT03072043|Drug|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 50 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
143143|NCT03072043|Drug|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m^2.
143144|NCT03072030|Biological|GamEvac-Combi (vaccine)|vaccination
143145|NCT03072030|Biological|Placebo|vaccination
143146|NCT03072017|Behavioral|MBAT|Breathing-based intervention
143147|NCT03072004|Device|LLLT|The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
143148|NCT03072004|Device|Sham LLLT|"That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group"
143149|NCT03071991|Procedure|study group|local anesthetic drug will be used
143150|NCT03071991|Procedure|control group|no local anesthetic drug will be used
143151|NCT03071965|Biological|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
211295|NCT02570230|Other|NSS|NSS infusion
143153|NCT03071965|Procedure|Surgery|Sham surgery
143154|NCT03071939|Other|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.~The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
143155|NCT03071926|Drug|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
143156|NCT03071913|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
143157|NCT03071913|Other|Laboratory Biomarker Analysis|Correlative studies
143158|NCT03071900|Diagnostic Test|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
143159|NCT03071887|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
143160|NCT03071874|Drug|AZD2014|AZD2014 is a dual mTORC1/mTORC2 inhibitor
143161|NCT03071861|Drug|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
143162|NCT03071861|Drug|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
143163|NCT03071848|Other|No Intervention|This was an observational study.
143164|NCT03071822|Drug|cisplatin|PIGLETs
143165|NCT03071822|Drug|ifosfamide|PIGLETs
143166|NCT03071822|Drug|gemcitabine|PIGLETs
143167|NCT03071822|Drug|L-asparaginase|PIGLETs
143168|NCT03071822|Drug|etoposide|PIGLETs
143169|NCT03071822|Drug|dexamethasone|PIGLETs
143170|NCT03071796|Dietary Supplement|multivitamin supplement|supplement includes 97 natural extracts
143171|NCT03071796|Dietary Supplement|Placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
143172|NCT03071783|Device|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
143173|NCT03071770|Drug|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
143174|NCT03071757|Drug|ABBV-368|Intravenous infusion
143175|NCT03071757|Drug|ABBV-181|Intravenous infusion
143176|NCT03071744|Drug|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
143177|NCT03071731|Drug|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
143178|NCT03071731|Drug|Placebos|Administration of a nebulized placebo before the administration of a functional test
143179|NCT03071718|Other|Mediterranean diet|"Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:~7 portions of milk or yogurt plus whole grain cereals,~7 portions of nuts (30g)~At least 3 portion of absolute legumes~14 portions of vegetables~21 portions of fruit~4 portions of whole grain pasta~3 portions of whole grain pasta with vegetables or legumes~7 portions of whole grain bread~3 portions of fish~Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period."
143180|NCT03071718|Other|Control Diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
143181|NCT03071705|Drug|Metformin|500 mg PO BID
143182|NCT03071705|Drug|TKI|standard dose
143183|NCT03071692|Drug|K-877|0.2mg tablet
143184|NCT03071692|Drug|Placebo|K-877 matching placebo tablet
143185|NCT03071679|Drug|Omiganan|Omignan 1%, 2.5%
143186|NCT03071679|Drug|Imiquimod|Imiquimod 15mg
143187|NCT03071679|Drug|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
143188|NCT03071679|Drug|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
143189|NCT03071679|Drug|Placebo|Vehicle
143190|NCT03071666|Dietary Supplement|cobalamin|Vitamin supplment tablet containing 50µg cobalamin
143191|NCT03071666|Dietary Supplement|placebo|A tablet identical to the vitamin supplement but containing no vitamin B12
143192|NCT03071653|Procedure|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
143193|NCT03071653|Other|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:~A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)~A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)~A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)~The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
143194|NCT03071627|Other|New items with spin|Interpretation of news items with spin
143195|NCT03071627|Other|New items without spin|Interpretation of news items without spin
143196|NCT03071614|Other|News items with spin|Interpretation of news items with spin
143197|NCT03071614|Other|News items without spin|Interpretation of news items without spin
143329|NCT03070561|Biological|sublingual film with peanut extract|
143198|NCT03071601|Drug|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
143199|NCT03071601|Drug|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
143200|NCT03071588|Device|Mechanical rotary burs|A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.
143201|NCT03071588|Device|Carisolv gel|A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
143202|NCT03071575|Biological|Measles-rubella (MR) vaccine at 6 and 9 months|Arm A will receive MR vaccine dose at 6 and 9 months of age
143203|NCT03071575|Biological|Measles-rubella (MR) vaccine at 9 months|Arm A will receive MR vaccine dose at 9 months of age
143204|NCT03071562|Other|Yoga-mindfulness|"Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals & back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class."
143205|NCT03071549|Drug|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
143206|NCT03071549|Drug|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
143207|NCT03071536|Drug|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
143208|NCT03071523|Procedure|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
143209|NCT03071523|Procedure|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
143210|NCT03071510|Device|Atlas Genetics io® system|Specimen Collection
143211|NCT03071497|Diagnostic Test|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
143212|NCT03071484|Device|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
143213|NCT03071471|Device|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.~The MID-C System inherent benefits are:~Only two screws are used~Incision size is much smaller~Simpler operation with shorter operative time~Less complication thanks to the three points above.~Minimal spinal mobility loss"
143214|NCT03071432|Diagnostic Test|Paced breathing at 6, 10 and 15 breaths per minute|
143215|NCT03071419|Behavioral|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
143216|NCT03071406|Drug|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
143217|NCT03071406|Drug|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
143218|NCT03071406|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
143219|NCT03071393|Device|Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
143220|NCT03071393|Device|Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
143221|NCT03071380|Drug|Repatoxaban|1 tablet contains 10 mg rivaroxaban
143222|NCT03071380|Drug|Xarelto|1 tablet contains 10 mg rivaroxaban
143223|NCT03071367|Other|Clinical Simulation|
143224|NCT03071354|Dietary Supplement|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
143256|NCT03071146|Device|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
143225|NCT03071354|Dietary Supplement|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
143226|NCT03071341|Drug|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
143227|NCT03071328|Drug|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, soft tissue, or liver metastases in subjects with metastatic castrate resistant prostate cancer, metastatic urothelial carcinoma or metastatic renal cell carcinoma and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site will be obtained at the time of contrast injection and will be stained for CD155 expression.
143228|NCT03071315|Other|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
143229|NCT03071315|Other|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
143230|NCT03071302|Other|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
143231|NCT03071289|Radiation|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
143232|NCT03071289|Drug|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
143233|NCT03071289|Radiation|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
143234|NCT03071276|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
143235|NCT03071276|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
143236|NCT03071276|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
143237|NCT03071276|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
143238|NCT03071263|Drug|Patiromer|2 packets/day starting dose, administered orally
143239|NCT03071263|Drug|Placebo|2 packets/day starting dose, administered orally
143240|NCT03071263|Drug|Spironolactone|25 mg tablet/day starting dose, administered orally
143241|NCT03071250|Procedure|Total knee or Hip Arthroplasty|Patients who received either a total knee or hip arthroplasty will be identified
143242|NCT03071237|Procedure|Gastrectomy|Patients with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
143243|NCT03071224|Drug|[18F] MNI-946|Subjects will undergo PET imaging using [18F]MNI-946, a PET radioligand for imaging tau.
143244|NCT03071224|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-946.
143245|NCT03071211|Device|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
143246|NCT03071211|Device|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
143247|NCT03071198|Procedure|TME|"Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.~At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
143248|NCT03071198|Radiation|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
143249|NCT03071198|Drug|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
143250|NCT03071198|Drug|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
143251|NCT03071185|Procedure|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
143252|NCT03071172|Drug|Triptorelin for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
143253|NCT03071172|Drug|Recombinant Human Choriogonadotropin alfa Solution for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
143254|NCT03071172|Drug|Progesterone Soft Capsules|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
143255|NCT03071159|Device|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
143257|NCT03071120|Behavioral|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
143330|NCT03070548|Drug|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
143258|NCT03071107|Behavioral|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
143259|NCT03071094|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4
143260|NCT03071094|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
143261|NCT03071081|Drug|TOP1288|Oral TOP1288
143262|NCT03071081|Drug|Placebo to TOP1288|Oral placebo to TOP1288
143263|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
143264|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
143265|NCT03071055|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection
143266|NCT03071042|Drug|Apatinib|Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
143267|NCT03071042|Drug|Docetaxel|Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
143268|NCT03071029|Behavioral|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
143269|NCT03071003|Drug|SENS-401|Oral Administration
143270|NCT03071003|Drug|Placebo|Oral Administration
143271|NCT03070990|Drug|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
143272|NCT03070977|Other|Interprofessional clinical training unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical training unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the training unit there are more students than in the other standard psychiatric wards and several professions are included.~A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.~The training unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
143273|NCT03070964|Drug|plitidepsin|
143274|NCT03070951|Drug|Placebo + Placebo Add-back|Placebo tablets and Placebo Add-back for oral administration once daily
143275|NCT03070951|Drug|OBE2109 + Placebo Add-back|OBE2109 tablets and Placebo Add-back for oral administration once daily
143276|NCT03070951|Drug|OBE2109 + Add-back|OBE2109 tablets and Add-back for oral administration once daily
143277|NCT03070938|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
143278|NCT03070925|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
143279|NCT03070899|Drug|Placebo + Placebo Add-back|Placebo tablets and Placebo Add-back for oral administration once daily
143280|NCT03070899|Drug|OBE2109 + Placebo Add-back|OBE2109 tablets and Placebo Add-back for oral administration once daily
143281|NCT03070899|Drug|OBE2109 + Add-back|OBE2109 tablets and Add-back for oral administration once daily
143282|NCT03070886|Drug|Bicalutamide|Given orally
143283|NCT03070886|Drug|Docetaxel|Given IV
143284|NCT03070886|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
143285|NCT03070886|Drug|Flutamide|
143286|NCT03070886|Drug|Goserelin Acetate|
143287|NCT03070886|Other|Laboratory Biomarker Analysis|Correlative studies
143288|NCT03070886|Drug|Leuprolide Acetate|
143289|NCT03070886|Drug|Nilutamide|
143290|NCT03070873|Device|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
143291|NCT03070873|Device|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
143292|NCT03070873|Procedure|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
143293|NCT03070860|Radiation|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.~PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
143294|NCT03070847|Drug|Tranexamic Acid|Dose: 5mg/kg
143295|NCT03070847|Drug|Tranexamic Acid|Dose: 10mg/kg
143296|NCT03070847|Drug|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
143297|NCT03070834|Device|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
143298|NCT03070821|Other|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
143299|NCT03070821|Device|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
143300|NCT03070795|Procedure|early feeding|start oral sips four hours after cesarean section
143301|NCT03070795|Procedure|delayed feeding|start oral feeding on post operation day 1 (>12hours) after surgery
143302|NCT03070782|Drug|ISIS 681257|Randomly assigned to one of the dosing cohorts.
143303|NCT03070782|Drug|Placebo|Randomly assigned to one of the dosing cohorts. Dose of placebo in each cohort will match volume of active in that cohort.
143304|NCT03070769|Procedure|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
143305|NCT03070756|Device|Minimal-Intervention - Specification of device settings|- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration <=15 min, softPAP Level is selected based on patient comfort
143306|NCT03070743|Procedure|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
143307|NCT03070730|Drug|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
143308|NCT03070730|Drug|Atenolol|Atenolol: 50 mg Q.D.
143309|NCT03070730|Drug|Placebos|Placebo: t.i.d
143310|NCT03070717|Procedure|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
143311|NCT03070704|Drug|insulin degludec/liraglutide|Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician
143312|NCT03070691|Drug|LDE225B|Cream, 2x daily
143313|NCT03070691|Drug|Vehicle|cream, 2x daily
143314|NCT03070678|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
143315|NCT03070678|Drug|Mefenamic acid|"Pharmaceutical form: capsule~Route of administration: oral"
143316|NCT03070665|Drug|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
143317|NCT03070652|Behavioral|NBO, Newborn behavioral observation|
143318|NCT03070652|Behavioral|Practice as usual|
143319|NCT03070639|Behavioral|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
143320|NCT03070639|Behavioral|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
143321|NCT03070626|Dietary Supplement|PreOp®|No preoperative drink.
143322|NCT03070613|Drug|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
143323|NCT03070600|Drug|Universal PrEP Counseling|Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
143324|NCT03070600|Drug|Targeted PrEP Counseling|"Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~Risk Score >5 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners).~participant declines partner self-tests regardless of partner HIV status, and/or~their partner declines self-testing or tests positive."
143325|NCT03070587|Behavioral|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
143326|NCT03070574|Drug|mesalamine 2400 MG (5-ASA)|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
143327|NCT03070574|Drug|mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
143328|NCT03070574|Other|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
211586|NCT02568033|Drug|Docetaxel|
143331|NCT03070535|Other|HIGH and LOW meal ingestion|The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
143332|NCT03070522|Drug|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
143333|NCT03070522|Drug|Placebos|Placebo
143334|NCT03070509|Drug|Lisdexamfetamine|lisdexamfetamine 50 mg single dose
143335|NCT03070496|Biological|Blood sampling|Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
143336|NCT03070496|Procedure|ECG|ECG will be performed at 6 months after myocardial infarction
143337|NCT03070496|Device|MRI|MRI will be performed at 1, 12 and 36 months after myocardial infarction to analyse ventricular remodeling and reperfusion.
143338|NCT03070496|Other|Quality of life questionnaire|Patients will pass a quality of life questionnaire at 12, 24 and 36 months after myocardial infarction
143339|NCT03070483|Drug|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
143340|NCT03070470|Drug|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
143341|NCT03070470|Drug|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
143342|NCT03070470|Drug|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
143343|NCT03070470|Drug|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
143344|NCT03070470|Drug|Placebo|Placebo (administered orally)
143345|NCT03070470|Drug|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.~In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
143346|NCT03070457|Other|Early discharge|Patients randomised to early discharge or not
143347|NCT03070457|Other|Conventional protocol|Discharge as usually done 48-72 hours after surgery
143348|NCT03070444|Device|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
143349|NCT03070444|Device|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
143350|NCT03070444|Device|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
143351|NCT03070444|Procedure|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
143352|NCT03070444|Other|Questionnaire|A questionnaire is completed at the follow-up visits.
143353|NCT03070431|Radiation|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
143354|NCT03070418|Procedure|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
143355|NCT03070405|Drug|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
143356|NCT03070405|Drug|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
143357|NCT03070392|Biological|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
143358|NCT03070392|Drug|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
143359|NCT03070392|Biological|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
143360|NCT03070392|Biological|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion over 30 minutes every 3 weeks until confirmed disease progression or unacceptable toxicity
143361|NCT03070379|Procedure|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
143362|NCT03070366|Drug|Chemotherapy|"cisplatin~5FU~carboplatin~cetuximab"
143363|NCT03070366|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy
143364|NCT03070353|Drug|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
143365|NCT03070340|Diagnostic Test|Breast Magnetic Resonance Imaging (MRI)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
143366|NCT03070340|Diagnostic Test|Contrast Enhanced Mammography (CEDM)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
143440|NCT03069794|Diagnostic Test|Use of stable force platform|Use of stable force platform to appreciate the posture before and after spinal surgery
211587|NCT02568033|Drug|Paclitaxel|
143367|NCT03070327|Biological|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10^6, 3x10^6, and 1x10^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
143368|NCT03070327|Drug|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
143369|NCT03070327|Drug|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
143370|NCT03070314|Drug|Echinaforce junior|Echinacea Purpurea Extract Pill, sweetened and with orange flavour
143371|NCT03070301|Drug|LEE011|LEE011 200 mg daily
143372|NCT03070301|Drug|everolimus|everolimus 5 mg daily or 2.5mg daily
143373|NCT03070288|Other|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
143374|NCT03070275|Biological|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
143375|NCT03070275|Procedure|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
143376|NCT03070262|Drug|CA|caffeic acid, 300mg, tid, po
143377|NCT03070262|Drug|placebo group|placebo tablet, 3 tablets, tid, po
143378|NCT03070249|Behavioral|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
143379|NCT03070236|Other|Survey|Select questions will be ask in the survey
143380|NCT03070223|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
143381|NCT03070223|Drug|Placebos|One tablet taken once daily, orally with or without food
143382|NCT03070210|Procedure|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
143383|NCT03070210|Procedure|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
143384|NCT03070197|Other|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
143385|NCT03070197|Other|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
143386|NCT03070184|Other|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
143387|NCT03070184|Dietary Supplement|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
143388|NCT03070184|Other|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
143389|NCT03070184|Drug|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
143390|NCT03070171|Drug|dabigatran etexilate|single dose
143391|NCT03070158|Behavioral|Attachment Promotion|"Attachment Promotion consists of:~Education session about newborn and mother care.~Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)~Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.~Daily Phone follows up."
143392|NCT03070145|Other|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
143393|NCT03070132|Drug|BIIB074|Administered as specified in the treatment arm
143394|NCT03070132|Drug|Placebo|Matched placebo
143395|NCT03070119|Drug|BIIB067|Participants will receive a loading dose regimen followed by maintenance dosing.
143396|NCT03070106|Dietary Supplement|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
143397|NCT03070093|Drug|gilteritinib|oral
143398|NCT03070080|Procedure|restrictive fluid strategy|restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour
143399|NCT03070080|Procedure|conservative fluid strategy|conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
143400|NCT03070067|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
143401|NCT03070054|Drug|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
143402|NCT03070041|Other|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
143403|NCT03070028|Procedure|crystallised phenol|crystallised phenol will be applied to sinus cavity
143404|NCT03070028|Procedure|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
143441|NCT03069781|Drug|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
143442|NCT03069781|Drug|Polycose|400 mg/day for 10-days of Polycose (Abbott Laboratories, St. Laurent, QC, Canada)
143443|NCT03069768|Device|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
143502|NCT03069274|Behavioral|Intervention|General nutritional recommendations, change drinking habits
143503|NCT03069274|Behavioral|General nutritional recommendations|Only general nutritional recommendations were given
143405|NCT03070015|Behavioral|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI > 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables & no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch & 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (~50% kcal from carbohydrate,~25% from protein,~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
143406|NCT03070015|Behavioral|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts & sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day & men ate 1500 kcal/day. Subjects with BMI >40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
143407|NCT03070002|Biological|Denosumab|Given SC
143408|NCT03070002|Other|Laboratory Biomarker Analysis|Correlative studies
143409|NCT03069989|Drug|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
143410|NCT03069989|Drug|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
143411|NCT03069989|Drug|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
143412|NCT03069976|Drug|Metronidazole|Flagyl x 14 days.
143413|NCT03069963|Drug|Z0063|"Pharmaceutical form: chewable tablets~Route of administration: oral"
143414|NCT03069963|Drug|Gaviscon|"Pharmaceutical form: chewable tablets~Route of administration: oral"
143415|NCT03069950|Drug|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
143416|NCT03069950|Drug|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
143417|NCT03069950|Drug|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
143418|NCT03069950|Drug|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
143419|NCT03069950|Drug|DEXAMETHASONE|flat dose of 25 mg on Day 1
143420|NCT03069950|Drug|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
143421|NCT03069937|Drug|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
143422|NCT03069937|Drug|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
143423|NCT03069924|Behavioral|Gain-framed messaging|counseling plus gain-framed messaging
143424|NCT03069924|Drug|Nicotine replacement therapy|counseling plus NRT
143425|NCT03069924|Combination Product|Gain-framed messaging plus NRT|counseling plus gain-framed messaging and NRT
143426|NCT03069924|Behavioral|Counseling alone|Counseling only
143427|NCT03069911|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
143428|NCT03069911|Biological|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
143429|NCT03069898|Behavioral|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
143430|NCT03069885|Device|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
143431|NCT03069885|Other|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
143432|NCT03069872|Diagnostic Test|Transvaginal ultrasound|Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
143433|NCT03069859|Drug|TXA (1g)|1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
143434|NCT03069859|Drug|Placebo (0.9% saline)|0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
143435|NCT03069846|Device|Spectra-Scope|"The Spectra-Scope consists of the light collection module and the spectral analysis module.~The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.~Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.~All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF."
143436|NCT03069833|Diagnostic Test|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
143437|NCT03069820|Drug|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
143438|NCT03069807|Other|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
143439|NCT03069807|Other|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
143504|NCT03069261|Device|Indocyanine green angiography|
143505|NCT03069248|Drug|Rituximab|
143444|NCT03069768|Drug|Chantix|For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
143445|NCT03069755|Other|No intervention|No intervention
143446|NCT03069742|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
143447|NCT03069742|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
143448|NCT03069729|Other|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
143449|NCT03069716|Device|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
143450|NCT03069716|Device|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
143451|NCT03069703|Biological|PCV13|one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)
143452|NCT03069703|Biological|PPV23|one dose of PPV23 at M5
143453|NCT03069703|Drug|Rituximab|375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
143454|NCT03069690|Behavioral|HABITpreg|Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.
143455|NCT03069690|Behavioral|HABITpost|Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.
143456|NCT03069677|Other|music|patients in this group will receive research-selected music after the golden moment has been completed between the patient, provider, and nursing staff
143457|NCT03069677|Drug|Midazolam|patients in this group will receive IV midazolam (1mg to 2mg max) after the golden moment has been completed
143458|NCT03069664|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
143459|NCT03069664|Device|Covered Self-expandable Metal Stent|Pancreatic duct stent
143460|NCT03069651|Other|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
143461|NCT03069638|Drug|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
143462|NCT03069638|Drug|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
143463|NCT03069625|Behavioral|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
143464|NCT03069625|Behavioral|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
143465|NCT03069612|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
143466|NCT03069599|Procedure|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
143467|NCT03069586|Procedure|Pulmonary recruitment|At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
143468|NCT03069586|Procedure|No pulmonary recruitment|At the end of surgery no intervention was completed
143469|NCT03069560|Device|SMS|SMS contact from the caregiver with patient after discharge in intervention group
143470|NCT03069547|Other|Quadriceps Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc."
143501|NCT03069287|Behavioral|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
143471|NCT03069547|Other|Hip Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc."
143472|NCT03069534|Drug|RhIL-2|RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
143473|NCT03069521|Device|EndoArt™ Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
143474|NCT03069508|Drug|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
143475|NCT03069482|Device|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
143476|NCT03069482|Drug|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
143477|NCT03069482|Drug|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
143478|NCT03069482|Behavioral|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
143479|NCT03069482|Device|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
143480|NCT03069469|Drug|DCC-3014|CSF1R inhibitor
143481|NCT03069456|Device|BIS|
143482|NCT03069456|Device|ADMS|
143483|NCT03069443|Other|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
143484|NCT03069430|Behavioral|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
143485|NCT03069417|Behavioral|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
143486|NCT03069391|Behavioral|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
143487|NCT03069391|Device|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
143488|NCT03069391|Device|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
143489|NCT03069378|Drug|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
143490|NCT03069378|Drug|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
143491|NCT03069365|Drug|Glecaprevir/pibrentasvir|Film-coated tablet
143492|NCT03069352|Drug|Placebo|tablet
143493|NCT03069352|Drug|Venetoclax|tablet
143494|NCT03069352|Drug|Cytarabine|Subcutaneous
143495|NCT03069339|Drug|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
143496|NCT03069339|Procedure|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
143497|NCT03069326|Drug|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
143498|NCT03069326|Drug|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
143499|NCT03069313|Dietary Supplement|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
143500|NCT03069300|Drug|N-acetyl cysteine (NAC)|
143507|NCT03069235|Behavioral|Family member / peer support|supplemental individualized counselling
143508|NCT03069235|Behavioral|Enhanced intervention with counselor support|"hands on EBF demonstrations"
143509|NCT03069235|Behavioral|standard of care|one on one and in-group counselling
143510|NCT03069222|Other|Standard Rehabilitative Treatment|The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
143511|NCT03069209|Biological|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
143512|NCT03069183|Drug|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
143513|NCT03069183|Drug|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
143514|NCT03069170|Biological|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
143515|NCT03069157|Procedure|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
143516|NCT03069144|Drug|HAT1 topical solution|HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
143517|NCT03069144|Drug|Calcipotriol|Calcipotriol ointment (0.005%) will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
143518|NCT03069131|Drug|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
143519|NCT03069131|Other|Placebo|twice daily administration of 1 rifaximin placebo tablet
143520|NCT03069118|Behavioral|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
143521|NCT03069118|Behavioral|Control - Resource List|Tailored list of resources.
143522|NCT03069105|Other|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
143523|NCT03069092|Behavioral|aerobic exercise|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
143524|NCT03069092|Behavioral|resistance exercise|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
143525|NCT03069092|Behavioral|Combined resistance and aerobic exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
143526|NCT03069079|Procedure|Oral hygiene advice, non surgical periodontal treatment|For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
143527|NCT03069066|Device|Bioresorbable vascular scaffold. Absorb GT1 (Abbott)|
143528|NCT03069040|Procedure|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
143529|NCT03069040|Procedure|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
211890|NCT02565888|Drug|Cobicistat|
143530|NCT03069027|Procedure|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
143531|NCT03069027|Drug|saline adrenaline|
143532|NCT03069027|Drug|Xylocaine, adrenaline|
143533|NCT03069014|Drug|400mg LM11A-31-BHS|1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning & evening) for 26 weeks
143534|NCT03069014|Drug|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning & evening) for 26 weeks
143535|NCT03069014|Drug|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning & evening) for 26 weeks
143536|NCT03069001|Drug|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
143537|NCT03069001|Drug|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
143538|NCT03068988|Biological|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
143539|NCT03068988|Procedure|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
143540|NCT03068975|Drug|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
143541|NCT03068975|Drug|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
143542|NCT03068962|Other|beetroot Juice|Beetroot Juice
143543|NCT03068962|Other|Buxton water|natural mineral water
143544|NCT03068962|Other|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
143545|NCT03068949|Biological|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
143546|NCT03068949|Biological|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
143547|NCT03068949|Biological|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
143548|NCT03068936|Radiation|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
143549|NCT03068936|Drug|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
143550|NCT03068910|Drug|Micronized progesterone|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
143551|NCT03068910|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
143552|NCT03068910|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
143553|NCT03068897|Drug|Metaxalone|Metaxalone 400-800mg
143554|NCT03068897|Drug|Tizanidine|Tizanidine 2-4mg
143555|NCT03068897|Drug|Baclofen|Baclofen 10-20mg
143556|NCT03068897|Drug|Ibuprofen 600 mg|Ibuprofen
143557|NCT03068897|Behavioral|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
143558|NCT03068884|Device|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
143559|NCT03068884|Dietary Supplement|L-Tyrosine|Administration of 2 grams tyrosine
143560|NCT03068884|Device|Transcranial direct current stimulation (sham)|Sham tDCS
143561|NCT03068884|Dietary Supplement|Cellulose (placebo)|Administration of 2 grams cellulose
143562|NCT03068871|Other|ACT|Psycho-educational group
143563|NCT03068871|Other|CET|Psycho-educational group
143564|NCT03068858|Diagnostic Test|real-time feedback of SYNTAX score category|
143565|NCT03068845|Device|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
143566|NCT03068845|Device|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
143567|NCT03068832|Biological|Personalized peptide vaccine|-It may take 3-4 months for sequencing, neoantigen prediction, and peptide manufacturing
143568|NCT03068832|Drug|Poly ICLC|-Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.
143569|NCT03068832|Procedure|Peripheral blood draw|"After trial enrollment and up to 7 days after the 1st vaccine dose~2 weeks after last dose~Time of progression or discontinuation"
143570|NCT03068819|Drug|CIML NK Cell Infusion|-Day 0
143571|NCT03068819|Procedure|CD3+ T Cell Product Infusion|-Day -1
143572|NCT03068819|Procedure|Peripheral blood draw|-Screening, Day -3 (+/-2), Day 0, Day +7, Day +14, Day +28, Day +50, Day +100, 6 months, 9 months, 12 months, 18 months, 2 years, and at any clinically indicated bone marrow biopsy/aspirate collection
143648|NCT03068234|Drug|Steroids|Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
143649|NCT03068221|Other|anaerobic exercise|assessing anaerobic exercise status
144283|NCT03063424|Diagnostic Test|Exercise challenge on a cycle ergometer|
143573|NCT03068806|Diagnostic Test|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|The investigators will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
143574|NCT03068793|Diagnostic Test|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia, major depressive disorder, gambling disorder, or post traumatic stress disorder and healthy controls.
143575|NCT03068780|Drug|Oleogel-S10|10% birch bark extract in 90% sunflower oil
143576|NCT03068780|Drug|Placebo|Sunflower oil gel
143577|NCT03068767|Dietary Supplement|Vitamin D|
143578|NCT03068754|Drug|Acthar|Repository corticotropin for subcutaneous injection
143579|NCT03068754|Drug|Placebo|Matching placebo for subcutaneous injection
143580|NCT03068741|Drug|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
143581|NCT03068741|Drug|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
143582|NCT03068741|Drug|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
143583|NCT03068741|Drug|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is <90mmHg and continued until systolic blood pressure is >=100mmHg.
143584|NCT03068728|Device|Arista|
143585|NCT03068728|Device|Nexfoam|
143586|NCT03068728|Device|Nasopore|
143587|NCT03068715|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator."
143588|NCT03068715|Device|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
143589|NCT03068715|Device|Open label TBS-DLPFC|"All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or NextStim TMS device."
143590|NCT03068702|Device|Optical Coherence Tomography Angiography|
143591|NCT03068689|Procedure|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level.
143592|NCT03068689|Other|Placebo|Placebo
143593|NCT03068676|Behavioral|Space from Depression|internet-delivered CBT
143594|NCT03068676|Behavioral|Space from Anxiety|internet-delivered CBT
143595|NCT03068663|Other|Sampling|Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
143596|NCT03068650|Biological|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
143597|NCT03068637|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
143598|NCT03068624|Biological|Aldesleukin|Given SC
143599|NCT03068624|Biological|Autologous CD8+ SLC45A2-specific T Lymphocytes|Given via hepatic arterial infusion
143600|NCT03068624|Drug|Cyclophosphamide|Given IV
143601|NCT03068624|Biological|Ipilimumab|Given IV
143602|NCT03068611|Behavioral|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
143603|NCT03068611|Behavioral|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
143604|NCT03068598|Device|PulseOn watch/Suunto Spartan Ultra watch|The Watch (PulseOn or Suunto Spartan Ultra) and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
143605|NCT03068585|Drug|Neovasculgen (Cambiogeneplasmid)|treatment
143606|NCT03068533|Other|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
143607|NCT03068533|Other|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
143608|NCT03068520|Diagnostic Test|PET MR|PET MR with 18 Fluorodopa ([18F]-DOPA) will be performed on patient at set intervals
143718|NCT03067688|Drug|Temisartan+Rosuvastatin|PO, Once daily(QD), 8weeks
143609|NCT03068507|Behavioral|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
143610|NCT03068481|Drug|KDT-3594|Oral administration
143611|NCT03068481|Drug|Placebo|Oral administration
143612|NCT03068468|Drug|BIIB092|BIIB092 intravenous infusion on specified days
143613|NCT03068468|Drug|Placebo|Placebo intravenous infusion on specified days
143614|NCT03068455|Biological|nivolumab|Specified Dose on Specified Days
143615|NCT03068455|Biological|ipilimumab|Specified Dose on Specified Days
143616|NCT03068442|Drug|Imaging with flutemetamol F 18 PET/CT|All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
143617|NCT03068429|Drug|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
143618|NCT03068416|Biological|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
143619|NCT03068403|Procedure|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
143620|NCT03068390|Behavioral|RICHH Intervention|Whole health cardiovascular disease (CVD) self-care risk reduction intervention
143621|NCT03068390|Behavioral|Usual care|Referral to primary care provider
143622|NCT03068377|Dietary Supplement|Experimental|Soft gel capsules containing a mixture of tomato extract, lutein, zeaxanthin as well as other phytonutrients and vitamins
143623|NCT03068377|Dietary Supplement|Placebo|soft gel capsules without test material
143624|NCT03068351|Drug|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram [mg/kg] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
143625|NCT03068351|Biological|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
143626|NCT03068338|Device|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
143627|NCT03068338|Device|Intermittent pneumatic compression|Conventional device used by hospitals
143628|NCT03068325|Other|TF-EAT|
143629|NCT03068312|Drug|Ivacaftor|Ivacaftor, 150 mg every 12 hours (q12h)
143630|NCT03068312|Drug|Placebo|Placebo matched to Ivacaftor
143631|NCT03068299|Other|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
143632|NCT03068299|Other|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
143633|NCT03068286|Behavioral|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
143634|NCT03068286|Behavioral|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored.Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
143635|NCT03068286|Behavioral|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
143636|NCT03068273|Device|Real-time CGM data|
143637|NCT03068260|Drug|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
143638|NCT03068260|Drug|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
143639|NCT03068260|Drug|Acetaminophen|1 g orally administered postoperatively
143640|NCT03068260|Drug|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
143641|NCT03068260|Device|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
143642|NCT03068260|Drug|Morphine|intravenously administered morphine via PCA-pump
143643|NCT03068260|Device|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
143644|NCT03068247|Drug|Duloxetine|10 week treatment
143645|NCT03068247|Drug|Placebo|10 week treatment
143646|NCT03068234|Drug|Pirfenidone|A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
143647|NCT03068234|Drug|Placebo oral capsule|Placebo for pirfenidone capsule
143650|NCT03068208|Procedure|Methylene blue-mediated photodynamic therapy|The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
143651|NCT03068195|Procedure|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
143652|NCT03068195|Procedure|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
143653|NCT03068182|Device|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
143654|NCT03068182|Device|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
143655|NCT03068182|Other|Exercise|
143656|NCT03068156|Radiation|308-nm excimer laser|monochromator UVB laser (308nm)
143657|NCT03068130|Drug|Bardoxolone methyl|Capsules of Bardoxolone methyl
143658|NCT03068117|Other|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).~Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
143659|NCT03068104|Other|No intervention|
143660|NCT03068091|Device|Chest CT|Inspiration and expiration chest CT
143661|NCT03068091|Diagnostic Test|Pulmonary Function Testing|Measure lung function
143662|NCT03068078|Dietary Supplement|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
143663|NCT03068065|Drug|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
143664|NCT03068065|Drug|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
143665|NCT03068065|Drug|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
143666|NCT03068052|Behavioral|No incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
143667|NCT03068052|Behavioral|Incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
143668|NCT03068039|Other|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
143669|NCT03068039|Other|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
143670|NCT03068026|Device|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
143671|NCT03068026|Other|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
143672|NCT03068013|Behavioral|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
143673|NCT03068013|Behavioral|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, psychoeducation and crisis intervention, which is the usual care intervention provided in our centres.
143674|NCT03068000|Behavioral|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
143675|NCT03068000|Behavioral|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
143676|NCT03067987|Device|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.~Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).~Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)~."
143719|NCT03067675|Device|Topcon DRI OCT Triton (plus)|OCT Machine used for diagnostic purposes
143677|NCT03067974|Drug|Ketamine Hcl 100Mg/Ml Inj|10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation
143678|NCT03067961|Other|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
143679|NCT03067948|Behavioral|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
143680|NCT03067935|Drug|glembatumumab vedotin|
143681|NCT03067922|Other|Non interventional study|Not applicable. No intervention will be done. it is an observational study assessing pain after mastectomy and the quality of life as assessed from validated questionnaires given to the patients at regular intervals
143682|NCT03067909|Other|CIED surgery|
143683|NCT03067896|Drug|Bupivacaine|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
143684|NCT03067896|Drug|Dexmedetomidine|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
143685|NCT03067896|Drug|Magnesium Sulfate|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
143686|NCT03067883|Drug|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.~These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.~Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).~Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
143687|NCT03067870|Biological|Stem Cell Transplantation|"Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.~Transplantation of autologous bone marrow derived stem cells in joints."
143688|NCT03067857|Biological|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
143689|NCT03067844|Drug|Alirocumab|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
143690|NCT03067831|Biological|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
143691|NCT03067818|Procedure|Unaffected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to unaffected hemisphere site prior to practice
143692|NCT03067818|Procedure|Affected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to affected hemisphere site prior to practice
143693|NCT03067818|Procedure|Control Transcranial Magnetic Stimulation|Non-invasive brain stimulation to control site prior to practice
143694|NCT03067805|Behavioral|Sexual Infidelity Condition|
143695|NCT03067805|Behavioral|Emotional Infidelity Condition|
143696|NCT03067805|Behavioral|Neutral Condition|
143697|NCT03067805|Behavioral|Player in Jealousy Condition|
143698|NCT03067805|Behavioral|Player in Non-Jealousy Condition|
143699|NCT03067792|Drug|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
143700|NCT03067792|Drug|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
143701|NCT03067779|Other|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
143702|NCT03067766|Procedure|Art Therapy|Participate in a comic art creation workshop
143703|NCT03067766|Other|Interview|Undergo qualitative interviews
143704|NCT03067766|Procedure|Quality-of-Life Assessment|Ancillary studies
143705|NCT03067766|Other|Questionnaire Administration|Ancillary studies
143706|NCT03067753|Drug|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
143707|NCT03067753|Drug|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
143708|NCT03067753|Drug|Prednisolone|
143709|NCT03067740|Drug|Bupivacaine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
143710|NCT03067740|Drug|Dexmedetomidine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
143711|NCT03067727|Drug|Dinoprostone|The DVI contains 10 mg Dinoprostone
143712|NCT03067727|Drug|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
143713|NCT03067714|Other|Infant formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
143714|NCT03067714|Other|Standard infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
143715|NCT03067701|Drug|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
143716|NCT03067688|Drug|Temisartan+Amlodipine+Rosuvastatin (Combination drug)|PO, Once daily(QD), 8weeks
143717|NCT03067688|Drug|Temisartan+Amlodipine|PO, Once daily(QD), 8weeks
143721|NCT03067649|Behavioral|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
143722|NCT03067649|Behavioral|Information only control|Participants are provided with a pamphlet containing referral information
143723|NCT03067636|Behavioral|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
143724|NCT03067636|Behavioral|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
143725|NCT03067636|Behavioral|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
143726|NCT03067623|Drug|PRP|PRP intrauterine infusion
143727|NCT03067623|Device|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
143728|NCT03067610|Radiation|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
143729|NCT03067610|Drug|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
143730|NCT03067597|Drug|Dinoprostone|The DVI contains 10 mg dinoprostone
143731|NCT03067571|Biological|Daratumumab|Given IV
143732|NCT03067558|Diagnostic Test|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.~The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
143733|NCT03067558|Diagnostic Test|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
143734|NCT03067545|Other|Step rate increase|increase the step rate during running by 10% steps per minute
143735|NCT03067532|Procedure|existed simulation system user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
143736|NCT03067532|Procedure|home made simulator user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery instrument.
143737|NCT03067519|Other|Fast track surgery|early feeding and mobilization after surgery
143738|NCT03067519|Other|Conventional management|Management per the primary surgeon
143739|NCT03067506|Other|No intervention|No intervention
143740|NCT03067493|Biological|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
143741|NCT03067480|Device|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
143742|NCT03067467|Drug|Hyperpolarized 13C-Pyruvate|Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
143743|NCT03067467|Drug|Gadolinium|Brain MRI performed with and without gadolinium-based contrast.
143744|NCT03067454|Procedure|Early mobilisation|"Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented."
143745|NCT03067454|Procedure|Operation|Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
143746|NCT03067441|Drug|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
143747|NCT03067428|Dietary Supplement|Glucose|Participants will adhere to a fructose restricted diet for a period of six weeks (<7.5 grams/meal and/or <10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.
143748|NCT03067428|Dietary Supplement|Fructose|Participants will adhere to a fructose restricted diet for a period of six weeks (<7.5 grams/meal and/or <10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.
143749|NCT03067415|Drug|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
143750|NCT03067415|Drug|D565(Latanoprost 50㎍/㎖)|D565 once daily
143751|NCT03067402|Other|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
143752|NCT03067402|Diagnostic Test|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
143753|NCT03067389|Diagnostic Test|Diagnostic test|Genetic diagnostic test
143754|NCT03067376|Drug|[14C]-CORT125134|
143755|NCT03067363|Drug|MOR107|MOR107 solution for injection
146052|NCT03049878|Drug|Paracetamol Codeine|preoperative administration
143756|NCT03067363|Drug|Placebo|Solution for injection manufactured to match MOR107 solution for injection
143757|NCT03067363|Other|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
143758|NCT03067337|Device|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
143759|NCT03067337|Device|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
143760|NCT03067311|Behavioral|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
143761|NCT03067311|Behavioral|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
143762|NCT03067285|Drug|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
143763|NCT03067285|Drug|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
143764|NCT03067272|Device|FemBloc® Permanent Contraceptive System|The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
143765|NCT03067259|Other|Exposure Group|Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
143766|NCT03067246|Device|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
143767|NCT03067246|Device|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
143768|NCT03067233|Other|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
143769|NCT03067220|Other|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
143770|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
143771|NCT03067207|Behavioral|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
143772|NCT03067194|Drug|Celecoxib 100 MG|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
143773|NCT03067194|Drug|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
143774|NCT03067181|Other|Best Practice|Undergo observation
143775|NCT03067181|Drug|Bleomycin|Given IV
143776|NCT03067181|Biological|Bleomycin Sulfate|Given IV
143777|NCT03067181|Drug|Carboplatin|Given IV
143778|NCT03067181|Drug|Cisplatin|Given IV
143779|NCT03067181|Drug|Etoposide|Given IV
143780|NCT03067181|Drug|Etoposide Phosphate|Given IV
143781|NCT03067181|Other|Laboratory Biomarker Analysis|Correlative studies
143782|NCT03067181|Other|Pharmacogenomic Study|Correlative studies
143783|NCT03067181|Other|Quality-of-Life Assessment|Ancillary studies
143784|NCT03067181|Other|Questionnaire Administration|Ancillary studies
143785|NCT03067168|Drug|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
143786|NCT03067168|Drug|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
143787|NCT03067155|Genetic|CMV-specific T cells|
143788|NCT03067155|Drug|Standard anti-viral therapy|Continue with the anti-viral treatment as per standard of care.
143789|NCT03067142|Other|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
143790|NCT03067129|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet (100 mg/40 mg)
143791|NCT03067129|Drug|Glecaprevir/Pibrentasvir|Oral pediatric formulation
143792|NCT03067116|Diagnostic Test|Posturography Evaluation|Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
143793|NCT03067116|Diagnostic Test|Anthropometrics|measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
143794|NCT03067116|Diagnostic Test|Vitals|measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
143795|NCT03067116|Other|Health and daily activity questionnaires|one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
143796|NCT03067103|Drug|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
143797|NCT03067103|Drug|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
146053|NCT03049878|Drug|Placebo Oral Tablet|preoperative administration
143798|NCT03067103|Drug|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
143799|NCT03067090|Device|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.~The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
143800|NCT03067077|Procedure|SMILE|SMILE surgery
143801|NCT03067077|Procedure|LASIK|LASIK surgery
143802|NCT03067064|Other|no intervention|Clinical examination
143803|NCT03067051|Drug|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
143804|NCT03067051|Device|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
143805|NCT03067038|Device|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy with single port device
143806|NCT03067038|Device|Three port laparoscopic cholecystectomy|Laparoscopic cholecystectomy with three port
143807|NCT03067025|Device|Actigraphy|Actiwatch Spectrum Plus will be worn on the non-dominant wrist 24 hours/day for seven days. Actigraphy is a valid and reliable objective measure of sleep patterns, including sleep quality, duration, and timing when compared to polysomnography (PSG).
143808|NCT03067012|Other|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
143809|NCT03066999|Procedure|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
143810|NCT03066999|Device|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
143811|NCT03066986|Drug|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
143812|NCT03066986|Biological|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely <20mcg. Therefore minimum effective maintenance dose not yet defined."
143813|NCT03066973|Behavioral|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
143814|NCT03066960|Procedure|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
143815|NCT03066960|Procedure|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
143816|NCT03066947|Biological|SV-BR-1-GM|See above
143817|NCT03066947|Drug|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
143818|NCT03066947|Biological|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
143819|NCT03066934|Other|noninvasive ventilation respiratory support|
143820|NCT03066921|Dietary Supplement|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
143821|NCT03066921|Dietary Supplement|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
143822|NCT03066908|Device|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
143823|NCT03066895|Device|BabyGentleStick|Experimental device.
143824|NCT03066895|Device|Standard Lancing Device|HMC standard of care.
143825|NCT03066882|Dietary Supplement|NCD|negative calorie diet
143826|NCT03066882|Dietary Supplement|LCD|low calorie diet
143827|NCT03066869|Drug|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
143828|NCT03066856|Other|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:~reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.~reducing high glycemic index food and high insulinemic foods.~reducing sources of saturated fat (red and processed meat, milk and dairy products).~eating mostly food of plant origin, with a wide variety of seasonal products."
143829|NCT03066843|Drug|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
143830|NCT03066843|Device|Blue light therapy|Subjects will be exposed to blue light
143831|NCT03066830|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
143832|NCT03066830|Drug|placebo|"Pharmaceutical form: tablet~Route of administration: oral"
143833|NCT03066830|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
143834|NCT03066830|Drug|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
143835|NCT03066817|Drug|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
143836|NCT03066817|Drug|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
143837|NCT03066804|Drug|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
143838|NCT03066804|Drug|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
143839|NCT03066804|Drug|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
143840|NCT03066804|Drug|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
143841|NCT03066804|Drug|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
143842|NCT03066804|Drug|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
143843|NCT03066791|Dietary Supplement|Turmeric tablets|
143844|NCT03066791|Dietary Supplement|Curcumin and Bioperine tablets|
143845|NCT03066791|Dietary Supplement|Placebo tablets|
143846|NCT03066778|Biological|Pembrolizumab|IV infusion on Day 1 of each cycle prior to chemotherapy
143847|NCT03066778|Drug|Normal saline solution|IV infusion on Day 1 of each cycle prior to chemotherapy
143848|NCT03066778|Drug|Carboplatin|IV infusion on Day 1 of each cycle
143849|NCT03066778|Drug|Cisplatin|IV infusion on Day 1 of each cycle
143850|NCT03066778|Drug|Etoposide|IV infusion on Days 1, 2 and 3 of each cycle
143851|NCT03066765|Device|Linguaflex Tongue Retractor|Tongue implant
143852|NCT03066739|Drug|Remifentanil|0.1 micrograms/kg/mL
143853|NCT03066739|Drug|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
143854|NCT03066739|Drug|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
143855|NCT03066713|Other|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
143856|NCT03066713|Other|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
143857|NCT03066713|Other|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
143858|NCT03066713|Other|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
143859|NCT03066700|Device|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
143860|NCT03066687|Drug|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet [G-024] and one 5-mg tablet [G-025]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
143861|NCT03066674|Other|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
143862|NCT03066674|Other|Control group|TENS,Exercises,Postural education ,Home exercises program.
143863|NCT03066661|Drug|Entrectinib|Open-label expanded access, capsules
143864|NCT03066648|Drug|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
143865|NCT03066648|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
143866|NCT03066648|Drug|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
143867|NCT03066635|Drug|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
143868|NCT03066635|Drug|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
143869|NCT03066622|Drug|Standard of Care as per attending physician|Patients are randomized to standard of care medication (as determined by attending physician)
143870|NCT03066622|Drug|5mg rapidly dissolving olanzapine|5mg rapidly dissolving olanzapine
143871|NCT03066609|Drug|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
143872|NCT03066609|Drug|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
143873|NCT03066609|Drug|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
143874|NCT03066596|Behavioral|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
143875|NCT03066583|Biological|trephination with placebo|trephination under US guidance and placebo injection
143876|NCT03066583|Biological|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
143877|NCT03066570|Behavioral|Graded Exposure|Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
143878|NCT03066557|Procedure|TACE and Apatinib|TACE and Apatinib 250mg po qd
143879|NCT03066557|Procedure|TACE|TACE
143880|NCT03066544|Drug|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
143881|NCT03066544|Drug|Naratriptan Pill|one pill will be administered twice each day for 5 days
143882|NCT03066544|Drug|Dexamethasone|one tablet will be administered twice each day for 3 days
143883|NCT03066544|Drug|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
143884|NCT03066531|Behavioral|ACT-based intervention|
143885|NCT03066531|Behavioral|CBT-based intervention|
143886|NCT03066518|Drug|Melatonin 5 mg|
143887|NCT03066518|Other|Placebo|
143888|NCT03066505|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
143889|NCT03066505|Device|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
144393|NCT03062644|Drug|MR308|four times daily; Mode of Administration:oral
143890|NCT03066492|Other|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
143891|NCT03066492|Other|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
143892|NCT03066479|Device|Fitbit|Wearable activity & sleep tracker.
143893|NCT03066479|Other|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
143894|NCT03066479|Diagnostic Test|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
143895|NCT03066466|Drug|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
143896|NCT03066466|Drug|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
143897|NCT03066466|Drug|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
143898|NCT03066453|Drug|Tobi Inhalant Product|inhaled tobramycin 300 mg twice per day
143899|NCT03066453|Drug|Nebcin|10 to 12 mg/kg/day in 1 injection for adults and 10 to 12 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
143900|NCT03066440|Drug|Normal saline|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
143901|NCT03066440|Drug|Lactated Ringers|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
143902|NCT03066427|Drug|Sunitinib|Sunitinib 50 mg/d
143903|NCT03066414|Procedure|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
143904|NCT03066401|Procedure|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
143905|NCT03066388|Other|Pulse pressure variations|Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
143906|NCT03066375|Device|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
143907|NCT03066362|Other|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
143908|NCT03066349|Other|Questionnaires|FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
143909|NCT03066336|Device|Erchonia LunulaLaser|Active Low Level Laser Light Therapy
143910|NCT03066323|Other|Rice with tea extract|Rice with tea extract
143911|NCT03066323|Other|Rice without tea extract|Rice without tea extract
143912|NCT03066310|Diagnostic Test|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
143913|NCT03066297|Procedure|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
143914|NCT03066271|Other|Exercise +|Usual care
143915|NCT03066271|Other|Control +|Usual care
143916|NCT03066258|Genetic|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
143917|NCT03066245|Biological|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
143918|NCT03066219|Drug|BRM421|A topical solution of BRIM421 ophthalmic drops
143919|NCT03066219|Drug|Placebo|vehicle ophthalmic drops
143920|NCT03066206|Drug|Poziotinib|Given PO
143921|NCT03066193|Drug|Dronabinol|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks.
143922|NCT03066193|Dietary Supplement|Palmotoyletahnolamide|Participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
143923|NCT03066180|Device|Viveve SUI treatment|Non-ablative radiofrequency treatment with surface cooling
143924|NCT03066167|Other|Validation of different dysphagia scores|
143925|NCT03066154|Drug|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
143926|NCT03066154|Drug|androgen deprivation therapy|ADT according to the standard of care
143927|NCT03066154|Radiation|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
143928|NCT03066128|Diagnostic Test|Point-of-care viral load testing|Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
143929|NCT03066128|Other|Lab-based viral load testing|Viral load testing will be lab based and follow standard of care procedures
143930|NCT03066115|Drug|L-NMMA|See arm description.
143931|NCT03066115|Drug|Ketorolac|See arm description.
143932|NCT03066115|Drug|Ascorbic Acid|See arm description.
143933|NCT03066115|Procedure|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
143996|NCT03065582|Other|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
143997|NCT03065582|Other|Topical Product B|topical application of product A without topical antioxidants
143934|NCT03066115|Procedure|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
143935|NCT03066102|Other|muscle fatigue|"Modified push-up plus exercise:~the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
143936|NCT03066089|Drug|Fenfuro|
143937|NCT03066076|Drug|Antithyroid Drug|Antithyroid drug
143938|NCT03066076|Procedure|Total thyroidectomy|Operation
143939|NCT03066050|Other|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
143940|NCT03066050|Other|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
143941|NCT03066050|Other|CABG|Participants underwent coronary artery bypass grafting
143942|NCT03066037|Procedure|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
143943|NCT03066011|Drug|Isavuconazonium sulfate|Oral and Intravenous
143944|NCT03066011|Drug|Voriconazole|Oral and Intravenous
143945|NCT03066011|Drug|Posaconazole|Oral and intravenous
143946|NCT03065998|Drug|Opipramol|PO
143947|NCT03065998|Drug|Baclofen|PO
143948|NCT03065985|Device|3 radiofrequency ablation procedures (Habib™ EUS-RFA)|"Patients in the treatment group will receive standard chemotherapy plus 3 radiofrequency ablation procedures, each one month apart.~Investigators will use the Habib™ EUS-RFA, product number 6700, which is a 1 Fr wire (0.33 mm, 0.013) with a working length of 200 cm, which can be inserted through the biopsy channel of an echoendoscope and is compatible with a 19G or 22G echoendoscopic needle. RF power is applied to the electrode at the end of the wire to coagulate tissue in the pancreas at 10 Watts for 2 minutes for each application. It has a CE mark and FDA 510(k) approval."
143949|NCT03065985|Drug|Standard chemotherapy|Standard chemotherapy
143950|NCT03065985|Other|Best Medical Care|Best Medical Care
143951|NCT03065972|Procedure|Surgical fistula creation from patient's anatomy|Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.
143952|NCT03065972|Device|Surgical Graft implant|Patient will be randomized via computer system, to receive the fistula or graft. If graft, surgeon implants hemodialysis access using an FDA approved graft.
143953|NCT03065959|Drug|reldesemtiv|oral
143954|NCT03065959|Drug|Placebo|oral
143955|NCT03065946|Other|Early wakening|By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
143956|NCT03065933|Drug|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
143957|NCT03065907|Other|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
143958|NCT03065894|Other|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.~Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
143959|NCT03065894|Other|Current Care in Family Medicine|Patient education, medication management
143960|NCT03065881|Device|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV [1] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
143961|NCT03065868|Drug|H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)|H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
143962|NCT03065855|Procedure|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
143963|NCT03065855|Procedure|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
143998|NCT03065582|Other|Topical Product C|Topical application of antioxidants only
143999|NCT03065582|Other|Control|No product applied
144000|NCT03065569|Drug|Bupivacaine|16 mL of 0.125% bupivacaine
144001|NCT03065556|Drug|188-0551 Solution|Topical solution containing active drug
144002|NCT03065556|Drug|Vehicle Solution|Topical solution containing no active drug
144394|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
143964|NCT03065842|Behavioral|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (3-weeks), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.~The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
143965|NCT03065842|Behavioral|Usual Standards|Usual standards according to the school curriculum in Kenya.
143966|NCT03065829|Behavioral|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
143967|NCT03065829|Behavioral|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
143968|NCT03065816|Drug|Z0063|Pharmaceutical form: chewable tablets Route of administration: oral
143969|NCT03065816|Drug|Gaviscon|Pharmaceutical form: chewable tablets Route of administration: oral
143970|NCT03065803|Procedure|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).~Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
143971|NCT03065803|Procedure|Guided bone regeneration technique for post-extraction dental socket preservation|After full‑thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension‑free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
143972|NCT03065790|Diagnostic Test|2-Deoxy-2-[18F]fluoro-D-glucose (FDG)|2-Deoxy-2-[18F]fluoro-D-glucose (FDG)
143973|NCT03065777|Device|ONE ENDO|single file rotary system
143974|NCT03065777|Device|F6 SKYTaper|single file rotary system
143975|NCT03065777|Device|ProTaper Universal|multi-file rotary system
143976|NCT03065764|Drug|89Zr-Pembrolizumab|"eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab."
143977|NCT03065751|Device|Plasmaexchange|TPE against fresh frozen plasma
143978|NCT03065738|Other|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
143979|NCT03065725|Procedure|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
143980|NCT03065712|Drug|F-18 Fluoroestradiol|F-18 Fluoroestradiol will be administered for PET/CT scan.
143981|NCT03065712|Procedure|Computed Tomography|Undergo PET/CT
143982|NCT03065712|Procedure|Positron Emission Tomography|Undergo PET/CT
143983|NCT03065712|Other|Laboratory Biomarker Analysis|Correlative studies
143984|NCT03065699|Device|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
143985|NCT03065686|Genetic|identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
143986|NCT03065673|Procedure|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
143987|NCT03065673|Procedure|Placebo gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the placebo gel~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
143988|NCT03065660|Drug|Mifepristone, Oral, 200 Mg|The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
143989|NCT03065660|Drug|Placebo Oral Tablet|The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
143990|NCT03065647|Device|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
143991|NCT03065634|Behavioral|Return to work and living healthy after head and neck cancer|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
143992|NCT03065634|Behavioral|socio-legal counseling|"Non-manualized socio-legal counseling~two socio-legal counseling sessions delivered by a social worker"
143993|NCT03065621|Drug|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
143994|NCT03065595|Dietary Supplement|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
143995|NCT03065595|Other|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
144003|NCT03065530|Drug|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
144004|NCT03065530|Drug|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
144005|NCT03065530|Drug|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
144006|NCT03065530|Drug|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
144007|NCT03065517|Device|VillageWhere App|VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
144008|NCT03065517|Device|Attention-Control Placebo App|Mobile phone app for use on both Android and iOS platforms.
144009|NCT03065504|Dietary Supplement|Turmeric|
144010|NCT03065504|Dietary Supplement|Turmeric-containing combination tablet|
144011|NCT03065504|Dietary Supplement|Placebo tablets|
144012|NCT03065491|Dietary Supplement|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
144013|NCT03065491|Other|Placebo|Oral administration: 1 tablet per day
144014|NCT03065478|Dietary Supplement|OnLife|Daily dosing of dietary supplement OnLife
144015|NCT03065465|Device|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
144016|NCT03065465|Other|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
144017|NCT03065439|Diagnostic Test|Static balance testing|Postural sway will be measured using a force plate (Metitur Good Balance System®).
144018|NCT03065400|Drug|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
144019|NCT03065387|Drug|Everolimus|Given PO
144020|NCT03065387|Drug|Neratinib|Given PO
144021|NCT03065387|Drug|Palbociclib|Given PO
144022|NCT03065387|Drug|Trametinib|Given PO
144023|NCT03065374|Biological|IMM-529|IMM-529
144024|NCT03065374|Other|Placebo|Matching placebo
144025|NCT03065348|Dietary Supplement|oral whey protein|This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
144026|NCT03065348|Dietary Supplement|Immunonutrition|This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
144027|NCT03065348|Dietary Supplement|Carbohydrate Drink|"Resource® preload™ contains the following elements:~Per portion à 50gr 47.5 gr carbohydrate, < 10mg sodium, 190kcal"
144028|NCT03065348|Other|Preoperative hydration|If urine specific gravity is >1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
144029|NCT03065348|Other|continous spinal anesthesia|Surgery will be performed under continuous spinal anesthesia without general anesthesia
144030|NCT03065335|Drug|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
144031|NCT03065335|Other|Placebo|0.5 mg/kg IV saline
144032|NCT03065322|Other|To assess risk of OSA|The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
144033|NCT03065309|Drug|Remifentanil|bolus dose
144034|NCT03065296|Behavioral|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
144035|NCT03065296|Other|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
144036|NCT03065283|Procedure|Diaphragm lift|The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
144037|NCT03065283|Procedure|Relaxation of the diaphragm pillars|Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
144038|NCT03065270|Other|Use unstable shoes Masai Barefoot Technology (MBT)|Use of unstable shoes during 9 weeks, at least four hours per day.
144039|NCT03065270|Other|Use conventional sport shoes|Use of conventional sport shoes during 9 weeks, at least four hours per day.
144040|NCT03065257|Procedure|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
144041|NCT03065244|Drug|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
144042|NCT03065244|Drug|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
144200|NCT03064009|Other|Infection|This is an observational trial
144043|NCT03065231|Device|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
144044|NCT03065231|Device|Lumbar Drain|
144045|NCT03065218|Radiation|99mTc sestamibi|The patient will receive an injection into the vein of a radioisotope 99mTc sestamibi dose 25mCi and will be imaged in 1 day.
144046|NCT03065205|Device|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
144047|NCT03065192|Drug|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
144048|NCT03065179|Drug|Nivolumab/Ipilimumab|IV immunotherapy
144049|NCT03065179|Radiation|SBRT|SBRT will be delivered in conjunction with immunotherapy
144050|NCT03065166|Other|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
144051|NCT03065166|Other|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
144052|NCT03065140|Other|Training or detraining|A period of detraining or a supervised exercise program.
144053|NCT03065127|Behavioral|Cognitive Training|Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
144054|NCT03065127|Behavioral|Cognitive Behavioural Therapy|CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
144055|NCT03065127|Behavioral|Proprioceptive Training|Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
144056|NCT03065114|Other|PGS|chromosome abnormality test from PGS and relationship between embryo development
144057|NCT03065101|Device|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
144058|NCT03065101|Other|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
144059|NCT03065101|Device|Sliding Hip Screw|Sliding Hip Screw
144060|NCT03065088|Behavioral|aLIFE|The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.
144061|NCT03065088|Behavioral|eLIFE|The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.
144062|NCT03065088|Behavioral|control|The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
144063|NCT03065075|Drug|Phenazopyridine|Phenazopyridine 200 mg on morning of postoperative day 1
144064|NCT03065062|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
144065|NCT03065062|Drug|Gedatolisib|Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
144066|NCT03065049|Behavioral|Peer-Facilitated Counseling|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
144067|NCT03065049|Behavioral|Fitbit activity tracker|Participants will be given a Fitbit activity tracker to monitor physical activity.
144068|NCT03065036|Drug|prestudy topical glaucoma medications|Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
144069|NCT03065023|Drug|MK-4621|IT/IL injection Fixed concentration of 0.2 mg/mL Starting dose: 0.2 mg
144070|NCT03065010|Drug|BCD-115|Inhibitor of CDK8/19
217472|NCT02525809|Device|Sunfit®|
144071|NCT03064997|Dietary Supplement|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
144072|NCT03064997|Dietary Supplement|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
144073|NCT03064984|Other|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
144074|NCT03064984|Other|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
144075|NCT03064971|Behavioral|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
144076|NCT03064971|Behavioral|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
144077|NCT03064971|Behavioral|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
144078|NCT03064958|Other|Herbs and spices|Mix of commonly used herbs and spices
144079|NCT03064958|Other|High fat meal|Meal containing 1000kcal and 45g fat
144080|NCT03064945|Device|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
144081|NCT03064932|Other|Controlled feeding diet|Average American diet with different levels of spices
144082|NCT03064919|Behavioral|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
144083|NCT03064906|Device|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
144084|NCT03064893|Device|Alloderm|Reconstruction material
144085|NCT03064893|Device|Dermacell|Reconstruction material
144086|NCT03064880|Other|SV maximization|Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change < 10% and maintained for 20 minutes
144087|NCT03064867|Drug|Venetoclax|Beginning with 400mg daily on days 1-10 of cycle 1-3
144088|NCT03064867|Drug|RICE|rituximab, ifosfamide, carboplatin, etoposide on day 1-3 every 21 days
144089|NCT03064854|Drug|PDR001|Powder for solution for infusion
144090|NCT03064854|Drug|Cisplatin|Intravenous infusion
144091|NCT03064854|Drug|Gemcitabine|Intravenous infusion
144092|NCT03064854|Drug|Pemetrexed|Intravenous infusion
144093|NCT03064854|Drug|Carboplatin|Intravenous infusion
144094|NCT03064854|Drug|Paclitaxel|Intravenous infusion
144095|NCT03064854|Drug|Canakinumab|Subcutaneous injection
144096|NCT03064841|Drug|No Treatment|No treatment
144097|NCT03064828|Radiation|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
144098|NCT03064828|Radiation|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
144099|NCT03064815|Device|Videocapsule endoscopy|"Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.~Capsule endoscopy helps doctors see inside your small intestine — an area that isn't easily reached with more-traditional endoscopy procedures."
144100|NCT03064815|Procedure|colonoscopy|Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
144101|NCT03064815|Diagnostic Test|PROMETHEUS® IBD sgi Diagnostic™|This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
144102|NCT03064815|Diagnostic Test|Fecal calprotectin|A stool test to measure inflammation in the gut.
144103|NCT03064802|Device|BioBurst Fluid, Burst Allograft|BioBurst Fluid or Burst Allograft used to augment spinal fusion
144104|NCT03064776|Device|m-RESIST Patients|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
144105|NCT03064776|Device|m-RESIST Caregivers|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
144106|NCT03064763|Drug|Talimogene laherparepvec|T-VEC will be administered by intralesional injection only into injectable cutaneous, subcutaneous, and nodal tumors, with or without image ultrasound guidance. On day 1 (week 0) the first dose of talimogene laherparepvec will be up to 4.0 mL of 106 PFU/mL. The second injection up to 4.0 mL of 108 or 107 PFU/mL, should be administered 3 weeks (+ 5) days after the initial injection (no sooner than day 22 but should not be delayed more than 5 days after the 21-day time point). The dose of 108 PFU/mL will be diluted 1:10 to obtain a concentration of 107 PFU/mL immediately prior to injection. Subsequent injections up to 4.0 mL of 108 or 107 PFU/mL should be given every 2 wks (± 3) days. The maximum volume of talimogene laherparepvec to be administered at each treatment visit is 4.0 mL
144107|NCT03064750|Behavioral|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
144108|NCT03064750|Other|Waiting list|patients wait as usual until surgery without special treatment.
144109|NCT03064737|Other|Skin biopsy for genetic analyze|"It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.~This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.~The skin biopsy will be performed according to the Clinical Department use."
144110|NCT03064724|Behavioral|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
144111|NCT03064711|Diagnostic Test|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
144112|NCT03064698|Other|Post-partum Doppler ultrasound|Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.
144113|NCT03064672|Device|transcervical Balloon Catheters|induction of labor by transcervical Balloon Catheters insertion
144114|NCT03064646|Other|Organ Preservation|Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
144115|NCT03064633|Drug|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
144116|NCT03064633|Drug|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
144117|NCT03064633|Drug|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
144118|NCT03064620|Biological|PCV|PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
144119|NCT03064607|Other|Fluid collection|Fluids tested for biomarker S100beta
144120|NCT03064594|Procedure|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
144121|NCT03064581|Behavioral|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
144122|NCT03064568|Drug|Misoprostol 100Mcg Tab|
144123|NCT03064568|Drug|Placebo|
144124|NCT03064542|Drug|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
144125|NCT03064529|Device|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
144126|NCT03064516|Procedure|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
144127|NCT03064516|Procedure|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
144128|NCT03064503|Biological|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
144129|NCT03064503|Device|MRI|MRI will be performed to measure interstitial fibrosis
144130|NCT03064503|Biological|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
144131|NCT03064490|Drug|Pembrolizumab|Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
144132|NCT03064477|Behavioral|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
144133|NCT03064477|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
144134|NCT03064464|Other|None Intervention|It is observational study, no interventios to any of the three study arms
144281|NCT03063437|Biological|Encapsulated placebo|30 capsules
144135|NCT03064451|Procedure|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
144136|NCT03064438|Drug|ACCU-D1|ACCU-D1
144137|NCT03064438|Drug|Placebo Comparator|Placebo Comparator
144138|NCT03064425|Biological|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
144139|NCT03064412|Biological|Urine sample collection|A urine sample will be collected in each of the 3 trimesters of pregnancy, and also at 6 weeks post partum.
144140|NCT03064412|Biological|Saliva collection|A saliva sample will be collected at one time point during the study - likely at the initial baseline visit.
144141|NCT03064399|Procedure|without lateral ligament repairment|microfracture without repairment of the lateral ligament
144142|NCT03064399|Procedure|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
144143|NCT03064386|Procedure|Plate fixation|internal fixation with the plate
144144|NCT03064386|Procedure|Screw fixation|internal fixation with the screw
144145|NCT03064360|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
144146|NCT03064360|Device|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
144147|NCT03064360|Behavioral|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
144148|NCT03064347|Dietary Supplement|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144149|NCT03064347|Dietary Supplement|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144150|NCT03064347|Dietary Supplement|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144151|NCT03064347|Dietary Supplement|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144152|NCT03064347|Dietary Supplement|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144153|NCT03064347|Dietary Supplement|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144154|NCT03064347|Dietary Supplement|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144155|NCT03064347|Dietary Supplement|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
144156|NCT03064334|Procedure|Total Knee Arthroplasty|surgical knee joints Arthroplasty
144157|NCT03064321|Behavioral|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
144158|NCT03064321|Other|Information Control|Information on websites that are general health promoting
144159|NCT03064308|Other|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
144160|NCT03064295|Device|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
144161|NCT03064295|Drug|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
144162|NCT03064295|Drug|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
144163|NCT03064282|Other|Placebo|observation of skin changes if any
144164|NCT03064282|Drug|papaverine|observation of symptoms
144165|NCT03064269|Biological|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
144282|NCT03063424|Diagnostic Test|Eucapnic voluntary hyperventilation|
144166|NCT03064256|Behavioral|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
144167|NCT03064256|Behavioral|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
144168|NCT03064243|Drug|apatinib|apatinib 500mg po. qd.
144169|NCT03064230|Other|QoL questionnaire SF-12 and and a screening questionnaire|patient were asked to fill questionnaires
144170|NCT03064217|Procedure|CLP and 12 weeks waiting|Restorative treatments will be initiated 12 weeks after clinical crown lengthenings (CLPs).
144171|NCT03064217|Procedure|Digital impression taken at surgery|The final impression will be made at surgery.
144172|NCT03064191|Combination Product|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
144173|NCT03064191|Other|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
144174|NCT03064165|Drug|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
144175|NCT03064165|Procedure|Sham block|Injection as for obturator nerve block, but with placebo
144176|NCT03064165|Procedure|Obturator nerve block|Postoperative obturator nerve block
144177|NCT03064165|Drug|Sodium Chloride 9mg/mL|Placebo
144178|NCT03064152|Device|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
144179|NCT03064139|Behavioral|MCG|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
144180|NCT03064139|Behavioral|SCG|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
144181|NCT03064126|Device|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
144182|NCT03064126|Drug|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
144183|NCT03064126|Procedure|Standard Balloon Angiplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
144184|NCT03064113|Drug|Placebo|
144185|NCT03064113|Drug|TD-4208 700 μg|
144186|NCT03064113|Drug|TD-4208 350 μg|
144187|NCT03064113|Drug|Ipratropium 500 μg|
144188|NCT03064100|Other|Observational Study|Exclusion from the study
144189|NCT03064087|Device|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
144190|NCT03064087|Device|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH & Co. KG, Wiesbaden, Germany).
144191|NCT03064087|Device|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
144192|NCT03064087|Device|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
144193|NCT03064087|Diagnostic Test|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH & Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
144194|NCT03064074|Drug|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
144195|NCT03064061|Device|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
144196|NCT03064048|Dietary Supplement|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
144197|NCT03064048|Dietary Supplement|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
144198|NCT03064035|Drug|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
144199|NCT03064022|Other|Growth|Some preterm infants grow at higher rates than others
144201|NCT03063996|Procedure|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
144202|NCT03063996|Procedure|Peripheral IJ access procedure|standard of care guided IV access into IJ
144203|NCT03063983|Drug|Cyclophosphamide|Continuous oral cyclophosphamide
144204|NCT03063983|Drug|Methotrexate|Continuous oral methotrexate
144205|NCT03063970|Device|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
144206|NCT03063970|Other|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
144207|NCT03063944|Drug|STAT Inhibitor OPB-111077|Given PO
144208|NCT03063944|Drug|Decitabine|Given IV
144209|NCT03063944|Drug|Venetoclax|Given PO
144210|NCT03063931|Drug|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
144211|NCT03063931|Drug|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
144212|NCT03063918|Other|Informational Intervention|Receive a workbook
144213|NCT03063918|Other|Quality-of-Life Assessment|Ancillary studies
144214|NCT03063918|Other|Questionnaire Administration|Ancillary studies
144215|NCT03063918|Other|Survey Administration|Ancillary studies
144216|NCT03063918|Behavioral|Telephone-Based Intervention|Receive personalized dietary intervention
144217|NCT03063905|Drug|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
144218|NCT03063892|Drug|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
144219|NCT03063892|Drug|Saline solution|Saline solution is used as the placebo comparator
144220|NCT03063879|Drug|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness < 12 KPa) or 24 weeks if cirrhotic
144221|NCT03063866|Drug|Propofol|Propofol 1 mg/kg i.v
144222|NCT03063866|Drug|Midazolam|Midazolam 3 mg i.v
144223|NCT03063866|Drug|Fentanyl|fentanyl 0.5 ug/kg
144224|NCT03063853|Other|Removal of surgical clips at day 4 post operative vs day 8 post operative|Removal of surgical clips at day 4 post operative vs day 8 post operative
144225|NCT03063853|Procedure|Elective cesarean delivery|non emergent elective cesarean delivery
144226|NCT03063840|Device|Microwave ablation|Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
144227|NCT03063827|Drug|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
144228|NCT03063827|Diagnostic Test|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
144229|NCT03063814|Behavioral|APP|See arm description
144230|NCT03063814|Behavioral|PHY|see arm description
144231|NCT03063801|Other|Data extraction in medical files|Data extraction from medical files, countraverified by the bloodbank database for accuracy.
144232|NCT03063788|Drug|3BNC117-Copper-64|3 mg/kg 3BNC117 combined with radio-isotope Copper-64
144233|NCT03063775|Device|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
144234|NCT03063775|Other|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
144235|NCT03063775|Other|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
144236|NCT03063775|Device|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
144237|NCT03063762|Drug|Atezolizumab|"Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule"
144238|NCT03063762|Drug|Bevacizumab|"Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle."
144239|NCT03063762|Drug|RO6874281|"Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part"
144240|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
144241|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
144242|NCT03063736|Drug|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
144243|NCT03063736|Biological|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
217473|NCT02525809|Device|Quartz®|
144244|NCT03063723|Drug|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
144245|NCT03063723|Drug|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
144246|NCT03063710|Drug|olaparib|Initial dose is 300mg twice daily. Study treatment can be dose reduced to 250 mg bd as a first step and to 200 mg bd as a second step. There is no maximum duration for taking study treatment. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria.
144247|NCT03063684|Device|Fractional / Pixel CO2 Laser|"The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.~For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application."
144248|NCT03063671|Drug|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
144249|NCT03063658|Drug|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
144250|NCT03063658|Drug|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
144251|NCT03063645|Drug|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
144252|NCT03063645|Drug|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
144253|NCT03063645|Drug|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
144254|NCT03063632|Biological|Interferon Gamma-1b|Given SC
144255|NCT03063632|Other|Laboratory Biomarker Analysis|Ancillary studies
144256|NCT03063632|Biological|Pembrolizumab|Given IV
144257|NCT03063619|Drug|Afimoxifene|Applied topically
144258|NCT03063619|Other|Laboratory Biomarker Analysis|Correlative studies
144259|NCT03063619|Other|Placebo|Applied topically
144260|NCT03063619|Other|Questionnaire Administration|Ancillary studies
144261|NCT03063606|Behavioral|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
144262|NCT03063606|Drug|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
144263|NCT03063580|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets~Route of administration: oral"
144264|NCT03063580|Drug|Rifampicin|"Pharmaceutical form: capsules~Route of administration: oral"
144265|NCT03063567|Device|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
144266|NCT03063554|Procedure|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
144267|NCT03063554|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
144268|NCT03063541|Drug|Acetylsalicylic acid|100 mg daily as one tablet
144269|NCT03063541|Other|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
144270|NCT03063528|Behavioral|Healthy Eating and Physical Activity|"Participants will be assigned to a group of 8-10 other pregnant women to work towards the same healthy eating or physical activity behavior challenge each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as drink 8 full glasses of water 3 times this week. Participants will track their healthy eating and physical activity behaviors in a mobile app. The HEPA condition will have access to podcasts and informational tips for having a healthy pregnancy through the study website. The HEPA condition will be able to log their weight on a daily basis and track their overall weight gain on a chart through the study website."
144271|NCT03063528|Behavioral|Stress Reduction and Management|"Participants will be put into a group of 8-10 other pregnant women to work towards the same stress reduction and management goal each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as take a 15 minute technology break each day this week. Participants will track their stress reduction and management behaviors in a mobile app. In addition, the SRAM condition will have access to meditation podcasts and informational tips for having a healthy pregnancy through the study website. Lastly, the SRAM condition will be able to rate their stress level on a daily basis and track their stress on a graph."
144272|NCT03063515|Drug|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
144273|NCT03063489|Drug|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
144274|NCT03063476|Drug|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
144275|NCT03063476|Drug|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
144276|NCT03063463|Procedure|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
144277|NCT03063463|Procedure|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
144278|NCT03063450|Drug|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
144279|NCT03063450|Other|Placebo|Matched placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
144280|NCT03063437|Biological|Encapsulated fecal microbiota preparation|30 capsules
144284|NCT03063411|Other|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
144285|NCT03063411|Other|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
144286|NCT03063398|Diagnostic Test|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
144287|NCT03063385|Behavioral|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
144288|NCT03063385|Behavioral|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
144289|NCT03063372|Dietary Supplement|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
144290|NCT03063372|Other|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
144291|NCT03063359|Drug|Intranasal fentanyl + Oral Placebo|Administration of intranasal fentanyl (1.5µg/kg) and Oral placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
144292|NCT03063359|Drug|Oral Morphine + Intranasal Placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo (NaCl 0.9%) in children with acute pain in traumatic context on arrival in emergency pediatric department.
144293|NCT03063346|Dietary Supplement|Protein hydrolysate high dose|
144294|NCT03063346|Dietary Supplement|Protein hydrolysate low dose|
144295|NCT03063346|Dietary Supplement|Placebo|
144296|NCT03063333|Other|Coping-oriented hypnosis|Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
144297|NCT03063333|Other|Neutral hypnosis|Hypnosis using neutral suggestions plus current treatment
144298|NCT03063320|Other|Spice blend|Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
144299|NCT03063307|Procedure|Atraumatic Restorative Treatment|
144300|NCT03063307|Other|Silver Diamine Fluoride|
144301|NCT03063294|Other|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
144302|NCT03063294|Other|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
144303|NCT03063281|Other|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
144304|NCT03063268|Behavioral|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
144305|NCT03063268|Behavioral|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
144306|NCT03063268|Behavioral|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
144307|NCT03063255|Drug|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
144308|NCT03063255|Drug|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
144309|NCT03063242|Drug|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
144310|NCT03063242|Biological|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
144311|NCT03063229|Device|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
144312|NCT03063229|Other|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
144313|NCT03063229|Procedure|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
144314|NCT03063229|Device|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
144315|NCT03063229|Procedure|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
144316|NCT03063229|Other|Food Diary|Participants will keep a 7 day weighed food diary.
144317|NCT03063229|Device|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
144318|NCT03063229|Other|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
144319|NCT03063229|Procedure|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
144320|NCT03063229|Procedure|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
144321|NCT03063229|Drug|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
144322|NCT03063229|Drug|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
144323|NCT03063203|Drug|Decitabine|"After 2 cycles, patients with progressive disease or relapse (a clear progression with at least >20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference~Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant~Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference~Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles~Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses~Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
144324|NCT03063203|Procedure|Bone marrow biopsy/aspirate|"Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse~Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only~Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician"
144325|NCT03063203|Procedure|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
144326|NCT03063203|Procedure|Skin biopsy|"Optional but if refuse skin biopsy then participant can provided buccal swab~There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine~If WBC at time of enrollment is >30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter"
144327|NCT03063203|Procedure|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
144328|NCT03063190|Drug|Vitamin D|patients will receive vitamin D supplementation according to guidelines
144329|NCT03063190|Drug|Placebo Oral Tablet|patients will receive placebo oral tablets
144330|NCT03063177|Procedure|Spinal manipulative therapy|A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
144331|NCT03063164|Device|Intralase IFS150|Intralase flap creation
144332|NCT03063164|Device|Visumax|Visumax flap creation
144333|NCT03063151|Diagnostic Test|Surface Electromyography (EMG)|
144334|NCT03063112|Device|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
144335|NCT03063112|Drug|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
144336|NCT03063112|Device|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
144337|NCT03063112|Drug|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
144338|NCT03063099|Other|ReNu™ Injection|Injection into the hip for the treatment of Osteoarthritis.
144339|NCT03063086|Drug|QVM149 150/50/80 μg o.d.|A
144340|NCT03063086|Drug|QVM149 150/50/160 μg o.d.|B
144341|NCT03063086|Drug|salmeterol/fluticasone FDC 50/500 μg b.i.d.|C
144342|NCT03063073|Drug|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection [Precedex]
144343|NCT03063073|Drug|Bupivacaine|
144344|NCT03063060|Other|vitamin D levels and Calcium levels examination|observational
144345|NCT03063047|Other|PD21871AA|A 100s size menthol cigarette.
144346|NCT03063047|Other|PD21872AA|A 100s size menthol cigarette.
144347|NCT03063034|Other|PD21864AA|A king size menthol cigarette.
144348|NCT03063034|Other|PD21864AB|A king size menthol cigarette.
144349|NCT03063021|Drug|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
144350|NCT03063008|Device|PEEK|"Procedure/Surgery:~TLIF fusion with common PEEK cages."
144351|NCT03063008|Device|TiPEEK|"Procedure/Surgery:~TLIF fusion with titanium coated PEEK cages."
144352|NCT03062995|Other|Infant Formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
144353|NCT03062995|Other|Standard Infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
144354|NCT03062982|Drug|Fluzoparib|2 doses separated by 7 days.
144395|NCT03062644|Drug|MR308|given four times daily to maintain the blind; Mode of Administration:oral
144355|NCT03062969|Procedure|Cleavage stage biopsy group|"intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF~Time lapse embryo culture~Cleavage stage biopsy~aCGH analysis~Fresh euploid embryo transfer"
144356|NCT03062969|Procedure|Trophectoderm biopsy group|"ICSI-IVF~Time lapse embryo culture~Day 3 zona pellucida opening~Trophectoderm biopsy~aCGH analysis~Frozen-thawed euploid embryo transfer"
144357|NCT03062956|Drug|MYK-491 or placebo|Oral suspension
144358|NCT03062943|Drug|Nintedanib|
144359|NCT03062930|Behavioral|Track 1|Training of non-paretic arm followed by sham condition
144360|NCT03062930|Behavioral|Track 2|Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
144361|NCT03062917|Diagnostic Test|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
144362|NCT03062904|Drug|Inhaled Bronchodilators +/- Inhaled Methacholine|"Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer~Inhaled Methacholine based on international recommendations"
144363|NCT03062891|Procedure|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
144364|NCT03062878|Other|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
144365|NCT03062878|Other|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
144366|NCT03062878|Other|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
144367|NCT03062878|Other|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
144368|NCT03062865|Other|No intervention|
144369|NCT03062852|Device|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
144370|NCT03062839|Drug|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
144371|NCT03062813|Drug|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
144372|NCT03062813|Drug|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
144373|NCT03062800|Drug|Thalidomide|100-200mg/d,oral ,qn
144374|NCT03062800|Drug|pemetrexed|(500mg/m^2) on day 1 of 21-days cycle,ivgtt
144375|NCT03062800|Drug|cisplatin|(75mg/m^2) on day 1 of 21-days cycle, ivgtt
144376|NCT03062800|Drug|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
144377|NCT03062787|Device|Cingal® (Hyaluronic Acid plus Triamcinolone Hexacetonide)|Intra-articular injection
144378|NCT03062787|Device|Monovisc® (Sodium hyaluronate)|Intra-articular injection
144379|NCT03062774|Biological|PB-119 injection|
144380|NCT03062761|Other|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
144381|NCT03062761|Other|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
144382|NCT03062735|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
144383|NCT03062735|Other|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
144384|NCT03062722|Procedure|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
144385|NCT03062709|Behavioral|Breathe Easy Coalition written materials|written materials about secondhand and thirdhand environmental smoke exposure in children
144386|NCT03062709|Behavioral|Maine Tobacco Helpline|referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.
144387|NCT03062709|Diagnostic Test|Urine cotinine testing|the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
144388|NCT03062696|Behavioral|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
144389|NCT03062683|Other|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
144390|NCT03062670|Other|Retreat|Full day off-site training session
144391|NCT03062657|Device|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
144392|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
217592|NCT02525016|Drug|Lidocaine|
144396|NCT03062631|Drug|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
144397|NCT03062618|Drug|PRCL-02|Oral tablet(s) administered with water
144398|NCT03062618|Drug|Placebo Oral Tablet|Administered with water
144399|NCT03062605|Drug|Iodine (Betadine)|
144400|NCT03062605|Biological|NaOCL|
144401|NCT03062592|Dietary Supplement|Pine nut oil|Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
144402|NCT03062579|Drug|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
144403|NCT03062566|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
144404|NCT03062553|Behavioral|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
144405|NCT03062553|Behavioral|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.~MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
144406|NCT03062553|Device|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
144407|NCT03062540|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
144408|NCT03062540|Drug|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
144409|NCT03062527|Other|Dietary Intervention: Low vs. moderate glycemic index|
144410|NCT03062514|Device|PINS Vagus Nerve Stimualtor|PINS Vagus Nerve Stimualtor
144411|NCT03062501|Drug|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
144412|NCT03062488|Drug|IV acetaminophen|multi-modal analgesia with IV acetaminophen
144413|NCT03062488|Drug|Fentanyl|single modal analgesia
144414|NCT03062488|Drug|PO acetaminophen|multi-modal analgesia with PO acetaminophen
144415|NCT03062475|Behavioral|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.~With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
144416|NCT03062462|Drug|Clopidogrel|double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 5-7 days
144417|NCT03062462|Drug|ticagrelor|half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 5-7 days
144418|NCT03062449|Drug|L-Serine|Gummy containing L serine dose
144419|NCT03062449|Other|Placebo Gummy|Gummy with no dosing of L Serine
144420|NCT03062436|Other|Stopping the standard drug therpy|Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
144421|NCT03062436|Diagnostic Test|Quantitative bcrabl recording every month for first 6 months|Monthly recording of quantitative bcrabl by RQPCR on patients peripheral blood derived RNA. RQPCR will have minimum sensitivity of log4.5
144422|NCT03062423|Drug|Sofodelevier|1 tablet contains 400 mg sofosbuvir
144423|NCT03062423|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
144424|NCT03062423|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
144425|NCT03062410|Other|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
144426|NCT03062397|Drug|JPI-289 Low-dose|JPI-289 Low dose will be intravenously administered during 24 hours
144427|NCT03062397|Drug|JPI-289 High-dose|JPI-289 High dose will be intravenously administered during 24 hours
144428|NCT03062397|Drug|Placebo|Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
144429|NCT03062384|Dietary Supplement|AT-001|
144430|NCT03062384|Dietary Supplement|Placebo|
144431|NCT03062371|Behavioral|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
144432|NCT03062358|Biological|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
144433|NCT03062358|Drug|placebo|Normal saline solution administered as an IV infusion Q3W
144600|NCT03061032|Drug|Sofosbuvir/Ledipasvir 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
144434|NCT03062358|Other|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
144435|NCT03062345|Other|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
144436|NCT03062345|Other|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
144437|NCT03062332|Genetic|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
144438|NCT03062319|Drug|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
144439|NCT03062319|Drug|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
144440|NCT03062293|Device|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
144441|NCT03062280|Drug|Hydrocortisone|Modified release hydrocortisone
144442|NCT03062267|Other|Mobile Interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
144443|NCT03062254|Drug|radium-223 dichloride|6 doses of Radium-223
144444|NCT03062241|Procedure|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
144445|NCT03062215|Behavioral|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
144446|NCT03062202|Behavioral|SilverCloud|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
144447|NCT03062176|Drug|Anakinra|Anakinra (Kineret)
144448|NCT03062163|Other|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
144449|NCT03062163|Other|Placebo|Transdermal patch loaded with normal saline
144450|NCT03062150|Drug|Placebo|Placebo
144451|NCT03062150|Drug|Fludrocortisone|Fludrocortisone
144452|NCT03062150|Drug|D-Cycloserine|D-Cycloserine
144453|NCT03062137|Diagnostic Test|blood gas sampling|
144454|NCT03062124|Procedure|SpyGlass pancreatoscopy|During the SpyGlass pancreatoscopy procedure visually guided biopsies and flushing liquid are collected from the pancreatic duct
144455|NCT03062111|Procedure|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
144456|NCT03062111|Procedure|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
144457|NCT03062098|Device|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
144458|NCT03062085|Other|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
144459|NCT03062072|Drug|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
144460|NCT03062059|Drug|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
144461|NCT03062046|Device|RF ablation|RF ablation
144462|NCT03062020|Device|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
144463|NCT03062007|Drug|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
144464|NCT03061981|Drug|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
144465|NCT03061981|Drug|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
144466|NCT03061981|Drug|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
144467|NCT03061968|Behavioral|acupressure|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
144468|NCT03061955|Biological|influenza vaccination|administration of influenza vaccination
144469|NCT03061942|Other|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
145615|NCT03053479|Procedure|Transvaginal mesh procedure|see arm/group descriptions
144470|NCT03061942|Other|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
144471|NCT03061916|Dietary Supplement|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
144472|NCT03061916|Dietary Supplement|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
144473|NCT03061916|Drug|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
144474|NCT03061903|Device|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.~Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
144475|NCT03061903|Device|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.~AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
144476|NCT03061877|Other|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
144477|NCT03061864|Behavioral|Periviable Birth Plan|
144478|NCT03061851|Behavioral|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
144479|NCT03061851|Other|Maltose app|"Weekly diabetes-related science articles.~Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~Personalize the development of diet, exercise program.~different insulin and oral hypoglycemic drug medication time to remind.~hypoglycemic drug side effects query."
144480|NCT03061838|Drug|MabThera®|1000 mg intravenously
144481|NCT03061838|Drug|Ritumax®|1000 mg intravenously
144482|NCT03061825|Device|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
144483|NCT03061812|Drug|Rovalpituzumab tesirine|Administered on Day 1 via intravenous infusion in a 42-day cycle for 2 cycles.
144484|NCT03061812|Drug|Topotecan|Administered on Day 1-5 via intravenous infusion in a 21-day cycle.
144485|NCT03061799|Dietary Supplement|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
144486|NCT03061799|Dietary Supplement|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
144487|NCT03061773|Other|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
144488|NCT03061773|Behavioral|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
144489|NCT03061760|Procedure|Radical prostatectomy|Radical prostatectomy due to prostate cancer.
144490|NCT03061760|Diagnostic Test|Initial evaluation|Questioners, Ultrasound, Uroflowmetry
144491|NCT03061760|Diagnostic Test|Evaluation after 1,3,6,9,12 months|Questioners, Ultrasound, Uroflowmetry
144492|NCT03061747|Device|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
144493|NCT03061734|Drug|ALLOD-2|ALLOD-2: Component A (regular dose) plus Component B
144494|NCT03061734|Drug|ALLOD-2H|ALLOD-2H: Component A (high dose) plus Component B
144495|NCT03061734|Drug|Component A (regular dose)|Component A (regular dose) of ALLOD-2
144496|NCT03061734|Drug|Component B|Component B of ALLOD-2
144497|NCT03061734|Drug|Placebo|Placebo for Component A plus Placebo for Component B
144498|NCT03061721|Drug|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
144499|NCT03061721|Drug|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
144500|NCT03061721|Drug|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
144501|NCT03061721|Drug|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
144502|NCT03061708|Drug|AZD2014|mTOR inhibitor
144503|NCT03061682|Device|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
144504|NCT03061656|Drug|Cyclophosphamide|1st HDCT
144505|NCT03061656|Drug|Carboplatin|1st HDCT
144506|NCT03061656|Drug|Etoposide|1st HDCT
144507|NCT03061656|Radiation|131I-MIBG|2nd HDCT
144508|NCT03061656|Drug|Thiotepa|2nd HDCT
144509|NCT03061656|Drug|Melphalan|2nd HDCT
144510|NCT03061643|Drug|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
144511|NCT03061643|Other|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
144512|NCT03061630|Drug|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
144513|NCT03061630|Drug|Cisplatin|D1: CISPLATIN 60G/M2
144514|NCT03061617|Other|VCV mode|set fixed 6ml/kg tide volume
144515|NCT03061617|Other|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
144516|NCT03061604|Device|Hemospray|Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
144517|NCT03061604|Drug|Octreotide|"Octreotide will be administered to all patients at time of admission and will be continued for 24 hours~• Dosage: 50 mcg bolus at admission then 25 mcg/hour"
144518|NCT03061604|Biological|Blood transfusion|Blood transfusion will be administered to all patients if needed
144519|NCT03061604|Drug|Ceftriaxone|Ceftriaxone will be administered to all patients on daily basis
144520|NCT03061591|Dietary Supplement|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
144521|NCT03061591|Other|Placebo|Placebo capsules
144522|NCT03061578|Diagnostic Test|Tear Film Imager|Ocular surface imaging assessment by the Tear Film Imager (TFI)
144523|NCT03061578|Diagnostic Test|Low Humidity Environmental Exposure Chamber (LH-EEC)|Subjects will enter the LH-EEC (<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
144524|NCT03061565|Drug|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
144525|NCT03061565|Drug|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
144526|NCT03061552|Diagnostic Test|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
144527|NCT03061539|Drug|Nivolumab & Ipilimumab|"Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses.~6 week gap after last combination dose.~480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent."
144528|NCT03061526|Other|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
144529|NCT03061513|Drug|Ubiquinol|Ubiquinol caplets 600mg/day
144530|NCT03061513|Dietary Supplement|Placebo|placebo
144531|NCT03061487|Procedure|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
144532|NCT03061474|Drug|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
144533|NCT03061474|Drug|Placebo Comparator|Oral Tablet
144534|NCT03061461|Device|rESWT|"All patients will receive standard care as follows:~Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~The clean wounds will be assessed using the TIME concept.~Treatment with rESWT.~Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith & Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT."
144535|NCT03061461|Device|Sham rESWT|"All patients will receive standard care as follows:~Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~The clean wounds will be assessed using the TIME concept.~Treatment with sham rESWT.~Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT."
144536|NCT03061448|Behavioral|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
144537|NCT03061435|Procedure|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
144538|NCT03061435|Procedure|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
144539|NCT03061422|Other|Xylitol|caries prevention chewing gum
144540|NCT03061422|Other|xylitol with bicarbonate|caries prevention chewing gum
144541|NCT03061422|Other|paraffin|chewing gum
144542|NCT03061409|Dietary Supplement|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
144543|NCT03061409|Dietary Supplement|Placebo|served as placebo
144544|NCT03061396|Other|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
144545|NCT03061396|Other|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
144546|NCT03061383|Other|8% Arginine based toothpaste|toothpaste
144547|NCT03061383|Other|8% strontium acetate based toothpaste|toothpaste
144548|NCT03061383|Other|placebo|toothpaste
144549|NCT03061370|Procedure|Esophagectomy or Gastrectomy|Surgical resection
144550|NCT03061357|Behavioral|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
146197|NCT03048877|Drug|Placebo Oral Tablet|Placebo Oral Tablet
144551|NCT03061344|Biological|DVIU treated with liquid buccal mucosal graft|DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
144552|NCT03061331|Drug|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
144553|NCT03061331|Drug|Placebo|No Active Drug
144554|NCT03061292|Procedure|Pectoral Nerve Block|
144555|NCT03061292|Procedure|Without Pectoral Nerve Block|
144556|NCT03061279|Device|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
144557|NCT03061279|Device|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
144558|NCT03061266|Behavioral|E-health Education|E-health education on shared care program will be established by different type's professionals including diabetes physicians, pharmacists, dietitians and diabetes health teacher.
144559|NCT03061266|Other|Routine care|Routine care on shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
144560|NCT03061253|Other|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
144561|NCT03061253|Other|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
144562|NCT03061253|Other|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
144563|NCT03061240|Device|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
144564|NCT03061227|Drug|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
144565|NCT03061227|Drug|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
144566|NCT03061214|Drug|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
144567|NCT03061214|Drug|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
144568|NCT03061214|Drug|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
144569|NCT03061214|Drug|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
144570|NCT03061214|Drug|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
144571|NCT03061214|Drug|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
144572|NCT03061201|Biological|SB-525|Single dose of investigational product SB-525
144573|NCT03061188|Other|Laboratory Biomarker Analysis|Correlative studies
144574|NCT03061188|Biological|Nivolumab|Given IV
144575|NCT03061188|Other|Pharmacological Study|Correlative studies
144576|NCT03061188|Drug|Veliparib|Given PO
144577|NCT03061175|Other|Internet-Based Intervention|Receive web-based CPM-DA
144578|NCT03061175|Other|Survey Administration|Ancillary studies
144579|NCT03061162|Radiation|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
144580|NCT03061149|Other|Low-level laser therapy|
144581|NCT03061149|Other|Ultrasound treatment|
144582|NCT03061136|Drug|Clonazepam|
144583|NCT03061136|Drug|Placebo|
144584|NCT03061123|Other|Questionnaire|
144585|NCT03061110|Biological|Stromal Vascular Fraction|Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
144586|NCT03061110|Other|Usual Care|Usual care will include over-the-counter and prescription methods to treat xerostomia.
144587|NCT03061097|Biological|Autologous fecal microbiota transplant|Fecal Microbiota Transplant (FMT) FMT is the process by which processed donor microbiota material is transplanted into recipients, by either upper or lower gastrointestinal delivery. The aim is to reconstitute the normal intestinal microbial flora in recipients. FMT can be administered by either enema or capsule depending on eligibility criteria. In this study, the fecal microbiota preparation will be made from the participant's own stool (autologous FMT).
144588|NCT03061097|Other|Placebo|Placebo FMT material delivered via enema.
144589|NCT03061071|Device|NightBalance Sleep Position Trainer (SPT)|Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
144590|NCT03061071|Device|Automated Adjusting Positive Airway Pressure (APAP)|Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
144591|NCT03061058|Drug|Docetaxel|intraperitoneal and/or intravenous
144592|NCT03061058|Drug|Oxaliplatin|intravenous
144593|NCT03061058|Drug|Cisplatin|intraperitoneal
144594|NCT03061058|Drug|Irinotecan|intraperitoneal and/or intravenous
144595|NCT03061058|Drug|Pemetrexed|intraperitoneal and/or intravenous
144596|NCT03061058|Drug|S1|oral
144597|NCT03061045|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
144598|NCT03061032|Drug|Sofosbuvir/Ledipasvir 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
144599|NCT03061032|Drug|Sofosbuvir/Ledipasvir plus Ribavirin 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.
217707|NCT02524106|Drug|Placebo|placebo
144601|NCT03061032|Drug|Sofosbuvir/Ledipasvir plus Ribavirin 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
144602|NCT03061019|Procedure|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
144603|NCT03061019|Procedure|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
144604|NCT03061006|Drug|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL > 15 to 30 mL/min); Assessment of kidney function every 6 months.
144605|NCT03061006|Drug|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
144606|NCT03060993|Drug|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
144607|NCT03060993|Drug|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
144608|NCT03060980|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
144609|NCT03060980|Drug|Empagliflozin (oral)|10 mg/day and 25 mg/day
144610|NCT03060980|Drug|Glimepiride (oral)|1-6 mg/day
144611|NCT03060967|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
144612|NCT03060954|Device|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
144613|NCT03060954|Device|FINE VISION®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
144614|NCT03060941|Behavioral|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
144615|NCT03060941|Behavioral|Facility access|Participants will receive at 6 month membership to a local fitness facility.
144616|NCT03060941|Behavioral|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
144617|NCT03060941|Behavioral|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
144618|NCT03060941|Behavioral|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
144619|NCT03060928|Procedure|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
144620|NCT03060928|Procedure|Micro-perforations|Biological stimulation with micro-perforations
144621|NCT03060928|Procedure|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
144622|NCT03060915|Device|Polysomnography|Patient's undergo a polysomnography
144623|NCT03060915|Device|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
144624|NCT03060902|Behavioral|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
144625|NCT03060889|Drug|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
144626|NCT03060863|Behavioral|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
144627|NCT03060863|Behavioral|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
144628|NCT03060863|Behavioral|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
144629|NCT03060863|Behavioral|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
144630|NCT03060850|Drug|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
144631|NCT03060837|Diagnostic Test|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
144632|NCT03060837|Other|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
144633|NCT03060837|Other|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
144634|NCT03060837|Other|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
144635|NCT03060837|Procedure|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
144636|NCT03060837|Procedure|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
144637|NCT03060824|Other|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
144638|NCT03060798|Drug|Desflurane|general anesthesia using desflurane.
144639|NCT03060798|Device|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vessel occlusion test
144640|NCT03060785|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|
144641|NCT03060772|Drug|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
146287|NCT03048136|Drug|Nivolumab|Specified dose on specified days
144642|NCT03060759|Device|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
144643|NCT03060746|Other|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
144644|NCT03060733|Other|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
144645|NCT03060707|Drug|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
144646|NCT03060694|Other|diabetes|"a history of diabetes and using anti-diabetic medicines.~fasting serum glucose level greater than 7.1mmol/L, or glycosylated hemoglobin percentage greater than 6.5%."
144647|NCT03060681|Drug|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
144648|NCT03060668|Other|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
144649|NCT03060668|Other|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
144650|NCT03060655|Biological|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
144651|NCT03060655|Biological|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
144652|NCT03060642|Device|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
144653|NCT03060642|Device|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
144654|NCT03060629|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
144655|NCT03060629|Biological|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) mixed with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
144656|NCT03060629|Biological|Placebo|Participants will receive matching placebo.
144657|NCT03060603|Drug|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
144658|NCT03060577|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
144659|NCT03060577|Drug|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
144660|NCT03060564|Procedure|tendon graft|JRF Orthopedics Tendon Graft
144661|NCT03060564|Other|No intervention|No intervention
144662|NCT03060551|Procedure|SVF injection|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
144663|NCT03060538|Drug|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
144664|NCT03060538|Other|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
144665|NCT03060525|Behavioral|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
144666|NCT03060512|Drug|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
144667|NCT03060512|Drug|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.~Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
144668|NCT03060486|Device|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.~Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
144669|NCT03060473|Drug|Azithromycin|Azithromycin 1 gm PO once
144670|NCT03060473|Drug|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
144671|NCT03060473|Drug|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
144672|NCT03060473|Drug|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days
144673|NCT03060460|Diagnostic Test|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
144674|NCT03060447|Drug|Vesatolimod|8 mg dose administered as four 2 mg tablets orally every 14 days
144675|NCT03060447|Drug|Vesatolimod Placebo|Tablet administered orally once every 14 days
144676|NCT03060447|Drug|ART|ART regimens administered in accordance with their Prescribing Information
144677|NCT03060434|Drug|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
144678|NCT03060434|Drug|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
144679|NCT03060421|Device|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
144680|NCT03060395|Dietary Supplement|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
144681|NCT03060395|Dietary Supplement|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
144682|NCT03060395|Dietary Supplement|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
144683|NCT03060395|Dietary Supplement|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
144684|NCT03060395|Dietary Supplement|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
144685|NCT03060395|Dietary Supplement|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
144686|NCT03060395|Dietary Supplement|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
144687|NCT03060395|Dietary Supplement|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
144688|NCT03060382|Device|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
144689|NCT03060382|Biological|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
144690|NCT03060369|Device|CareGuide™ device|CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
144691|NCT03060356|Biological|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
144692|NCT03060343|Biological|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10^5 cells/kg, Dose Level Two: 1.0×10^6 cells/kg, Dose Level Three: 1.0×10^7 cells/kg.~At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
144693|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy|This group will undergo modified laparoscopic ventral mesh rectopexy alone
144694|NCT03060330|Procedure|Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
144695|NCT03060317|Behavioral|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
144696|NCT03060304|Drug|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
144697|NCT03060304|Drug|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
144698|NCT03060291|Behavioral|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
144699|NCT03060291|Behavioral|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
144700|NCT03060278|Behavioral|Self-help materials|Self-help smoking cessation materials.
144701|NCT03060278|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke < 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
144702|NCT03060278|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
144703|NCT03060278|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
144704|NCT03060265|Drug|Paracetamol|Administrating Paracetamol IV pre-cesarean section
144705|NCT03060265|Drug|PLACEBO|Administrating SALINE IV pre-cesarean section
144706|NCT03060239|Other|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
144707|NCT03060226|Diagnostic Test|blood sample|Search of blood predictive marker (s)
144708|NCT03060213|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
144741|NCT03059979|Other|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
144742|NCT03059966|Procedure|Microsurgery technique for root coverage|Microsurgery technique for root coverage adapted for macrosurgery
144743|NCT03059966|Biological|Microsurgery technique for root coverage associated to EMD|Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
144709|NCT03060200|Other|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
144710|NCT03060200|Other|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
144711|NCT03060187|Other|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
144712|NCT03060174|Other|monitoring and non-medical prophylaxis of delirium|
144713|NCT03060161|Behavioral|Health in the right measure|Nutritional monitoring and individual guidance on regular physical exercise.
144714|NCT03060148|Device|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
144715|NCT03060135|Behavioral|Check Your Drinking|A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking
144716|NCT03060135|Behavioral|Hello Sunday Morning|Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
144717|NCT03060122|Device|NIN|The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
144718|NCT03060122|Device|Sham CES|The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
144719|NCT03060122|Device|CES|Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
144720|NCT03060109|Other|Blood draw within 12 hours of injury|
144721|NCT03060096|Other|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
144722|NCT03060096|Other|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
144723|NCT03060096|Other|Enhanced Usual Care Control|"Participants with moderate to severe anxiety/depression that are randomized to Enhanced Usual Care Control (EUC) will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
144724|NCT03060083|Other|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
144725|NCT03060083|Other|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
144726|NCT03060070|Drug|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
144727|NCT03060070|Drug|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
144728|NCT03060070|Drug|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
144729|NCT03060057|Device|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
144730|NCT03060044|Drug|Salmeterol/fluticasone Easyhaler|
144731|NCT03060044|Drug|Salmeterol/fluticasone Easyhaler with charcoal|
144732|NCT03060044|Drug|Seretide Diskus|
144733|NCT03060044|Drug|Seretide Diskus with charcoal|
144734|NCT03060031|Drug|Oxytocin|Oxytocin intranasal administration, 40 IU, 5 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
144735|NCT03060031|Drug|Placebo|Placebo intranasal administration, 5 puffs per nostril delivered approximately 45 minutes prior to pain tasks
144736|NCT03060018|Device|Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor|The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
144737|NCT03060005|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
144738|NCT03060005|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
144739|NCT03059992|Drug|Ibrexafungerp|Experimental Study Drug
144740|NCT03059979|Drug|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
145616|NCT03053479|Procedure|Amreich-Richter procedure|see arm/group descriptions
144744|NCT03059940|Behavioral|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
144745|NCT03059940|Procedure|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
144746|NCT03059940|Other|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
144747|NCT03059940|Behavioral|Cessation Counseling|Brief cessation counseling given by LDCT provider.
144748|NCT03059940|Behavioral|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
144749|NCT03059940|Behavioral|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
144750|NCT03059940|Drug|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
144751|NCT03059940|Drug|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
144752|NCT03059940|Behavioral|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
144753|NCT03059940|Other|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
144754|NCT03059927|Procedure|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith & Nephew, Cruciate Retaining design
144755|NCT03059927|Procedure|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Anterior Stabilized design
144756|NCT03059927|Procedure|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Posterior Stabilized design
144757|NCT03059914|Device|InterOss|Anorganic bovine bone mineral - Xenograft
144758|NCT03059914|Device|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
144759|NCT03059901|Other|Caminamos App|Mobile phone that encourages Latina women to walk together through social support.
144760|NCT03059888|Drug|Abatacept Injection|Subcutaneous administration of abatacept
144761|NCT03059875|Behavioral|Medical consultation for a Standardized Geriatric Evaluation|
144762|NCT03059862|Dietary Supplement|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
144763|NCT03059862|Dietary Supplement|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
144764|NCT03059849|Drug|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
144765|NCT03059836|Dietary Supplement|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
144766|NCT03059836|Dietary Supplement|Placebo|Organic Sunflower Oil 5000mg per day
144767|NCT03059823|Drug|INCMGA00012|Anti-PD-1 monoclonal antibody
144768|NCT03059797|Drug|Anlotinib|Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
144769|NCT03059797|Drug|Placebo|Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
144770|NCT03059784|Other|APP-based multifaceted management|Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
144771|NCT03059771|Behavioral|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
144772|NCT03059771|Behavioral|Control|The control group will only engage in a goal-setting session.
144773|NCT03059758|Other|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
144774|NCT03059745|Procedure|Cholecystectomy|Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
144775|NCT03059732|Other|Treatment|Observe the treatments of gastric cancer in each group
144776|NCT03059719|Biological|Exenatide injection(Byetta)|
144777|NCT03059719|Biological|PB-119 injection|
144778|NCT03059706|Device|RegenoGel-OSP™|intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery
144779|NCT03059706|Other|saline|intra-articular injection of saline after arthroscopic surgery
144780|NCT03059693|Drug|HAT1 topical cream|
144781|NCT03059693|Drug|Vehicle cream|
144782|NCT03059680|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
144783|NCT03059667|Drug|Atezolizumab|Atezolizumab at 1200 mg IV every 3 weeks
144784|NCT03059667|Drug|Topotecan|oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
144785|NCT03059667|Drug|Carboplatin|In accordance with the summary of product characteristics.
144786|NCT03059667|Drug|Etoposide|In accordance with the summary of product characteristics.
144787|NCT03059654|Procedure|tracheostomy|
144788|NCT03059628|Other|Personalized Normative Feedback|"This PNF technique use information designed to correct normative misperceptions to reduce heavy drinking. Much of the alcohol consumption among college students stems from the fairly widespread perception that one's peers expect regular and sometimes extreme drinking participation (subjective drinking norms). The PNF approach is designed to counter this perception by giving students accurate figures on how much their peers actually drink (actual drinking norms). It also aims to improve students' understanding of alcohol use in general and the firmly established negative outcomes associated with short - and long-term patterns of excessive drinking."
144789|NCT03059628|Other|Brief Therapeutic Intervention|BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
144790|NCT03059628|Other|Evaluation questionnaire|The patient have to fill the same evaluation questionnaire at J0, M6 and M12
144791|NCT03059615|Drug|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
144792|NCT03059615|Drug|Doxorubicin|Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
144793|NCT03059602|Other|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
144794|NCT03059576|Other|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.~Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.~Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.~Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
144795|NCT03059563|Drug|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
144796|NCT03059563|Other|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
144797|NCT03059537|Drug|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
144798|NCT03059511|Drug|Nalbuphine|Opioid Pain Medicine
144799|NCT03059498|Procedure|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
144800|NCT03059498|Procedure|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
144801|NCT03059498|Drug|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
144802|NCT03059485|Biological|DC/AML Fusion Vaccine|The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
144803|NCT03059485|Other|Observation|Traditional care provided by the hospital.
144804|NCT03059472|Behavioral|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
144805|NCT03059472|Behavioral|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
144806|NCT03059446|Drug|Cenicriviroc|Cenicriviroc 150 mg tablet once daily in the morning with food.
144807|NCT03059433|Other|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
144808|NCT03059407|Behavioral|Dog therapy only|Canine assisted therapy only during echocardiogram
144809|NCT03059407|Behavioral|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
144810|NCT03059407|Behavioral|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
144811|NCT03059394|Device|Non intervention study|Test - Retest of measurements
144812|NCT03059381|Drug|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
144813|NCT03059368|Device|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
144814|NCT03059355|Biological|UCMSCs|Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
144815|NCT03059355|Biological|BMMSCs|Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
144816|NCT03059355|Other|Placebo|a single administration of placebo delivered via peripheral intravenous infusion.
144817|NCT03059342|Procedure|single event multilevel surgery|
144850|NCT03059108|Procedure|Early Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.
144851|NCT03059108|Procedure|Conventional Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
144818|NCT03059329|Drug|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
144819|NCT03059316|Combination Product|Massimo device|Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).
144820|NCT03059316|Drug|Nitroglycerin drug|Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins
144821|NCT03059316|Drug|Labetalol|Labetalol is an antagonist of adrenergic receptors (a1, b1, b2) which is used as an hypotensive inducer. This drug targets the beta receptors 5 to 10 times more specific than alpha receptors so that minor tachycardia happens
144822|NCT03059303|Drug|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.~Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
144823|NCT03059303|Drug|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.~Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
144824|NCT03059303|Drug|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
144825|NCT03059303|Drug|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
144826|NCT03059303|Drug|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.~Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
144827|NCT03059303|Drug|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
144828|NCT03059303|Drug|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
144829|NCT03059290|Device|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
144830|NCT03059277|Drug|Intravitreal Aflibercept|Intravitreal Aflibercept 2mg
144831|NCT03059264|Other|Natural history|Longitudinal disease progression
144832|NCT03059251|Biological|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
144833|NCT03059238|Drug|Celecoxib 200mg oral capsule|
144834|NCT03059238|Drug|parecoxib sodium|
144835|NCT03059238|Drug|controlled-release oxycodone|
144836|NCT03059225|Device|repetitive transcranial magnetic stimulation (rTMS)|undergo 10-min of contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or 10-min ipsilesional 5-Hz rTMS for 10 daily sessions
144837|NCT03059225|Device|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
144838|NCT03059225|Behavioral|Computer-integrated Speech Training|Computer-integrated Speech Training program for 20 mins
144839|NCT03059212|Device|rTMS|Device: rTMS 5Hz rTMS over M1 or inferior frontal lobe
144840|NCT03059212|Device|Sham stimulation|Device: rTMS Sham stimulation over M1 or inferior frontal lobe
144841|NCT03059199|Behavioral|Single-Arm Feasibility Study|Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
144842|NCT03059186|Behavioral|Gratitude diary|"The intervention involves keeping a record of three things that the individual feels grateful for during that day.~This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week."
144843|NCT03059173|Dietary Supplement|Inofolic (r)|Dietary supplement Inofolic containing myo-inositol (4 g) and folic acid (0.2 mg) in a same bags Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
144844|NCT03059173|Drug|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
144845|NCT03059173|Dietary Supplement|placebo|Placebo Dietary supplement containing placebo substance and folic acid (0.2 mg)in a same bags
144846|NCT03059160|Drug|Tridecanoic Acid|3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout
144847|NCT03059147|Drug|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
144848|NCT03059147|Drug|Nivolumab|Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
144849|NCT03059134|Drug|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
145415|NCT03055000|Biological|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
144852|NCT03059095|Behavioral|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
144853|NCT03059082|Behavioral|Recovery Navigator on an as needed basis up to 6 months|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit."
144854|NCT03059082|Behavioral|Recovery Navigator prior to hospital discharge|This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
144855|NCT03059082|Other|No interaction with Recovery Navigator|This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
144856|NCT03059069|Drug|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
144857|NCT03059069|Drug|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
144858|NCT03059056|Drug|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
144859|NCT03059043|Device|viscoelastic-free implantation system|Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
144860|NCT03059043|Device|standard viscoelastic-assisted Implantation system|This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
144861|NCT03059030|Device|TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.|The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
144862|NCT03059017|Drug|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
144863|NCT03059017|Drug|Niosomes|Niosomes
144864|NCT03059004|Behavioral|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
144865|NCT03059004|Behavioral|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
144866|NCT03059004|Behavioral|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
144867|NCT03059004|Behavioral|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 14 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
144868|NCT03058991|Behavioral|Distress Tolerance Intervention|See arm/group description.
144869|NCT03058991|Behavioral|Working Memory Intervention|See arm/group description.
144870|NCT03058991|Behavioral|Control Informational Intervention|See arm/group description.
144871|NCT03058978|Device|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
144872|NCT03058965|Drug|[18F]MNI-958|Subjects will undergo PET imaging using [18F]MNI-958, a PET radioligand for imaging tau.
144873|NCT03058965|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-958.
144874|NCT03058965|Drug|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
144875|NCT03058952|Behavioral|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
144876|NCT03058952|Behavioral|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
144877|NCT03058939|Drug|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
144878|NCT03058939|Drug|Perjeta|Only administered to patients with HER2-positive disease.
144879|NCT03058939|Drug|Herceptin SC|Only administered to patients with HER2-positive disease.
144880|NCT03058939|Drug|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
144881|NCT03058939|Drug|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
144882|NCT03058939|Drug|LHRH agonist|Administered to all premenopausal patients.
144883|NCT03058939|Drug|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
144884|NCT03058939|Drug|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
144885|NCT03058926|Other|Data Management and Monitoring|"Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.~MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study."
145160|NCT03056846|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
144886|NCT03058900|Drug|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
144887|NCT03058900|Other|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
144888|NCT03058900|Drug|Methotrexate (MTX)|Weekly methotrexate in maximum tolerable dosis
144889|NCT03058887|Other|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
144890|NCT03058887|Other|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
144891|NCT03058874|Device|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
144892|NCT03058874|Other|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
144893|NCT03058861|Behavioral|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
144894|NCT03058848|Dietary Supplement|PKU Start|"PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.~The recommended amount of the product for each participant will be determined and prescribed by a dietitian."
144895|NCT03058835|Drug|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
144896|NCT03058822|Drug|BMS-931699|BMS-931699 single subcutaneous dose on Day 1
144897|NCT03058809|Device|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
144898|NCT03058796|Device|Contralaterally Controlled Functional Electrical Stimulation (CCFES)|The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.
144899|NCT03058796|Device|Hand Therapy Video Games|The use of video games with NMES to encourage therapeutic hand movement at home
144900|NCT03058783|Drug|IDP-124 Lotion|Lotion
144901|NCT03058783|Drug|IDP-124 Vehicle Lotion|Lotion
144902|NCT03058770|Other|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
144903|NCT03058770|Other|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
144904|NCT03058757|Drug|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation|"Intravesical mitomycin-C 40mg/20ml instillation~one day before surgery~four hours before surgery"
144905|NCT03058744|Drug|IDP-118 Lotion|Lotion
144906|NCT03058744|Drug|HP Monad Lotion|Lotion
144907|NCT03058744|Drug|Ultravate Cream|Cream
144908|NCT03058744|Drug|Tazorac Cream|Cream
144909|NCT03058731|Device|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
144910|NCT03058731|Device|Control|Paraesophageal hernia repair with other biologic mesh
144911|NCT03058718|Other|Procalcitonin|The application of antimicrobial agents is determined by PCT results.
144912|NCT03058718|Other|Clinical Experience|The application of antimicrobial agents is determined by clinical experience of doctors.
144913|NCT03058705|Drug|Hexaminolevulinate HCL|Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
144914|NCT03058705|Device|Near Infrared Fluorescence (NIRF)|NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
144915|NCT03058692|Biological|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
144916|NCT03058692|Other|Placebo|Placebo is saline injection
144917|NCT03058692|Biological|Quadrivalent Recombinant Seasonal Influenza Vaccine|Quadrivalent Inactivated Influenza Vaccine (IIV4) for intramuscular injection is indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine.
144918|NCT03058679|Other|Diet|food for the diet will be provided to the participants for 6 weeks
144919|NCT03058666|Drug|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
144920|NCT03058666|Device|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
145500|NCT03054376|Other|Immobilization|Full length cast of one leg R/L randomized
144921|NCT03058653|Procedure|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
144922|NCT03058653|Device|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
144923|NCT03058640|Other|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.~• Participants must attend at LEAST 20/24 classes"
144924|NCT03058627|Procedure|PCI|FFR guided PCI
144925|NCT03058614|Drug|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
144926|NCT03058614|Diagnostic Test|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
144927|NCT03058614|Diagnostic Test|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
144928|NCT03058588|Genetic|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
144929|NCT03058575|Dietary Supplement|Dietary MACs|"All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:~Day 1: 1 scoop of product (morning, in the clinic)~Day 2: 1 scoop of product (morning)~Day 3: 2 scoops of product (morning and evening)~Day 4: 2 scoops of product (morning and evening)~Days 5-60: 3 scoops of product (morning, afternoon, evening)~Other Names:~Dietary fiber supplement"
144930|NCT03058575|Other|Control|No Intervention for 8 weeks
144931|NCT03058562|Drug|ABX-1431|ABX-1431, capsules, 40 mg in the fasting state
144932|NCT03058562|Drug|Placebo Comparator|Matching Placebo
144933|NCT03058562|Drug|ABX-1431|ABX-1431, capsules, 20 mg with a high fat meal
144934|NCT03058549|Behavioral|Family Expectations|Relationship education and referral services for expectant couples.
144935|NCT03058536|Device|Arabin Pessary|The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
144936|NCT03058536|Drug|Vaginal Progesterone|Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
144937|NCT03058536|Other|Arabin Pessary and Progesterone|Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
144938|NCT03058510|Procedure|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
144939|NCT03058497|Device|Temperature-Controlled Laminar Airflow Device (Airsonett®)|
144940|NCT03058484|Behavioral|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
144941|NCT03058471|Drug|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
144942|NCT03058471|Drug|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
144943|NCT03058471|Drug|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
144944|NCT03058458|Drug|PIN201104|IV or SC administration
144945|NCT03058458|Drug|Placebo|IV or SC administration
144946|NCT03058445|Device|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
144947|NCT03058445|Device|CVC|Injection of 5 ml of saline
144948|NCT03058432|Radiation|Radiotherapy alone|
144949|NCT03058432|Radiation|Concurrent chemoradiotherapy|
144950|NCT03058419|Drug|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1*100 mg + 1*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
144951|NCT03058419|Drug|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6*100 mg capsules) orally on Day 8.
144952|NCT03058419|Drug|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion [2 (milligram per milliliter (mg/mL)] as a drug cocktail on Day 1, 7 and 11.
144953|NCT03058419|Drug|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
144954|NCT03058419|Drug|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
144955|NCT03058419|Drug|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
144956|NCT03058419|Drug|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
144957|NCT03058419|Drug|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
144958|NCT03058406|Drug|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
144959|NCT03058393|Other|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
145280|NCT03056027|Diagnostic Test|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
218565|NCT02518178|Device|NFC Necklace|
144960|NCT03058380|Other|Stated-Preferences Evaluation Instrument|A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
144961|NCT03058367|Dietary Supplement|IQP-AE-103 (330mg)|High dose capsules
144962|NCT03058367|Dietary Supplement|IQP-AE-103 (165mg)|Low dose capsules
144963|NCT03058367|Dietary Supplement|Placebo|Placebo identical to verum capsules
144964|NCT03058354|Drug|Propofol|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
144965|NCT03058354|Procedure|general anaesthesia|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
144966|NCT03058341|Drug|propofol|Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
144967|NCT03058341|Drug|Sevoflurane|
144968|NCT03058328|Other|Cognitive testing, testing of heart rate variability and blood samples|
144969|NCT03058302|Behavioral|CETA (Common Elements Treatment Approach)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
144970|NCT03058289|Drug|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.~The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.~The drug is stored frozen and must be dosed at room temperature.~Escalation of the drug dose and number of injected tumors is possible in subsequent treatment sessions.~The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area"
144971|NCT03058289|Biological|anti-PD-1 antibody|The anti-PD-1 antibody will be added concomitantly with INT230-6 as noted in cohort DEC
144972|NCT03058289|Biological|anti-CTLA-4 antibody|The anti-CTLA-4 antibody will be added concomitantly with INT230-6 as noted in cohort FEC subject to approval by the study steering committee
144973|NCT03058276|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
144974|NCT03058276|Other|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
144975|NCT03058276|Other|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
144976|NCT03058263|Drug|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
144977|NCT03058250|Other|Transesophageal echocardiography|
144978|NCT03058237|Drug|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
144979|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
144980|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
144981|NCT03058237|Drug|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
144982|NCT03058224|Drug|IGN-ES001|Only active product will be compared with placebo as described in Arms and Interventions.
144983|NCT03058224|Drug|Parol 500 mg Tablets (acetaminophen)|Analgesic Rescue Medication
144984|NCT03058211|Diagnostic Test|Echocardiography|Standard protocols
144985|NCT03058211|Diagnostic Test|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
144986|NCT03058198|Diagnostic Test|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
144987|NCT03058172|Other|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
144988|NCT03058172|Other|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
144989|NCT03058159|Other|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
145281|NCT03056014|Drug|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
144990|NCT03058146|Behavioral|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
144991|NCT03058146|Behavioral|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
144992|NCT03058133|Other|fMRI study|Functional brain activations of face-voice processing during a gender task
144993|NCT03058120|Other|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
144994|NCT03058107|Dietary Supplement|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
144995|NCT03058107|Dietary Supplement|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
144996|NCT03058094|Drug|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
144997|NCT03058094|Drug|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
144998|NCT03058094|Drug|AC0010|300mg, orally, BID
144999|NCT03058081|Device|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher&Paykel)
145000|NCT03058068|Biological|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
145001|NCT03058068|Biological|Placebo|1 peripheral intravenous infusion
145002|NCT03058055|Behavioral|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
145003|NCT03058055|Behavioral|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
145004|NCT03058055|Behavioral|Reading|Book club that includes weekly one hour meetings and daily reading assignments
145005|NCT03058042|Other|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
145006|NCT03058042|Other|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
145007|NCT03058029|Device|Gelesis200|Subject would take Gelesis200 capsules 2 times per day.
145008|NCT03058029|Device|Placebo|Subject would take placebo capsules 2 times per day.
145009|NCT03058016|Other|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
145010|NCT03058003|Diagnostic Test|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
145011|NCT03058003|Other|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
145012|NCT03057990|Drug|Pyrimethamine|Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
145013|NCT03057977|Drug|Empagliflozin|once daily
145014|NCT03057977|Drug|Placebo|once daily
145015|NCT03057964|Device|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
145016|NCT03057964|Device|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
145017|NCT03057951|Drug|Empagliflozin|once daily
145018|NCT03057951|Drug|Placebo|once daily
145019|NCT03057938|Drug|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
145020|NCT03057925|Device|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
145021|NCT03057912|Biological|TALEN|TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
145022|NCT03057912|Biological|CRISPR/Cas9|CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
145023|NCT03057899|Drug|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
145024|NCT03057899|Drug|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
145282|NCT03056014|Dietary Supplement|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
145025|NCT03057886|Device|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
145026|NCT03057873|Dietary Supplement|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
145027|NCT03057873|Dietary Supplement|Placebo|Dry powder to be mixed with 10 ounces of cold water
145028|NCT03057860|Other|No study intervention|
145029|NCT03057847|Drug|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
145030|NCT03057834|Behavioral|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
145031|NCT03057821|Other|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
145032|NCT03057808|Behavioral|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
145033|NCT03057808|Behavioral|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
145034|NCT03057795|Biological|Brentuximab|Given IV
145035|NCT03057795|Drug|Brentuximab Vedotin|Given IV
145036|NCT03057795|Other|Laboratory Biomarker Analysis|Correlative studies
145037|NCT03057795|Biological|Nivolumab|Given IV
145038|NCT03057782|Device|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
145039|NCT03057782|Device|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
145040|NCT03057782|Device|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
145041|NCT03057782|Device|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
145042|NCT03057782|Device|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
145043|NCT03057769|Drug|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
145044|NCT03057769|Drug|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
145045|NCT03057769|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
145046|NCT03057756|Combination Product|Km+ Mfx+ Pto + H + Cfz +E+Z|Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
145047|NCT03057743|Device|Positron emission tomography (PET/CT) imaging|
145048|NCT03057743|Device|radiotracer [18F]ISO-1|
145049|NCT03057730|Biological|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
145050|NCT03057717|Other|2D ultrasound assessment|2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
145051|NCT03057704|Drug|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
145052|NCT03057704|Drug|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
145053|NCT03057691|Other|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
145054|NCT03057678|Other|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
145055|NCT03057665|Device|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
145056|NCT03057652|Device|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
145283|NCT03056014|Dietary Supplement|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
145057|NCT03057652|Device|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
145058|NCT03057652|Device|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.~REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
145059|NCT03057639|Other|Quality-of-Life Assessment|Ancillary studies
145060|NCT03057639|Other|Questionnaire Administration|Ancillary studies
145061|NCT03057626|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
145062|NCT03057626|Other|Laboratory Biomarker Analysis|Correlative studies
145063|NCT03057626|Other|Quality-of-Life Assessment|Ancillary studies
145064|NCT03057613|Drug|Pembrolizumab|200mg every 3 weeks for 16 weeks given by IV infusion
145065|NCT03057613|Radiation|IMRT 60-66Gy|60-66Gy for 6 weeks
145066|NCT03057600|Drug|Pac-CB|CB-839 administered as oral tablets twice daily (BID) in combination with standard weekly paclitaxel in 28-day cycles
145067|NCT03057587|Device|NIRS Monitoring|NIRS data will be collected throughout the surgery
145068|NCT03057574|Drug|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
145069|NCT03057561|Drug|Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)|Gadolinium based contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
145070|NCT03057561|Drug|Cardiac MRI with contrast agent, Gadovist|Brand of Gd-DO3A-butrol; contrast agent used in cardiac MRI scanning using 3.0 Tesla MRI
145071|NCT03057548|Procedure|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins~OR~FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.~Ablation of the Pulmonary Veins alone"
145072|NCT03057548|Procedure|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW~OR~RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW~Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
145073|NCT03057535|Drug|Sodium Bicarbonate|
145074|NCT03057535|Drug|Sodium Chloride|
145075|NCT03057522|Behavioral|Change in running cadence|The intervention will involve a home exercise program designed to increase the running cadence in recreational runners.
145076|NCT03057509|Drug|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotracer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
145077|NCT03057509|Device|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
145078|NCT03057509|Other|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
145079|NCT03057509|Drug|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
145080|NCT03057496|Device|Collision warning device|The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery, all contained within a shoulder bag. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
145081|NCT03057483|Biological|Seasonal Influenza vaccine|Seasonal Influenza vaccine
145082|NCT03057470|Drug|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
145083|NCT03057470|Drug|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
145084|NCT03057470|Drug|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
145085|NCT03057470|Other|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
145086|NCT03057457|Device|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
145087|NCT03057444|Dietary Supplement|SymbioIntest|The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
145088|NCT03057431|Drug|Placebo oral capsule|Once daily for 3 years
145089|NCT03057431|Drug|12.5 mg hydrochlorothiazide|Once daily for 3 years
145090|NCT03057431|Drug|25.0 mg hydrochlorothiazide|Once daily for 3 years
145091|NCT03057431|Drug|50.0 mg hydrochlorothiazide|Once daily for 3 years
218637|NCT02517684|Drug|Azathioprine|
145092|NCT03057418|Drug|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
145093|NCT03057392|Other|immersion|participants will sit in a 34-35C while receive dialysis
145094|NCT03057392|Other|sham session|dialysis while sitting in the dialysis chair
145095|NCT03057379|Other|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
145096|NCT03057366|Drug|Pevonedistat|Pevonedistat intravenous infusion.
145097|NCT03057366|Drug|[14C]-Pevonedistat|[14C]-Pevonedistat intravenous infusion.
145098|NCT03057366|Drug|Docetaxel|Docetaxel intravenous infusion.
145099|NCT03057366|Drug|Carboplatin|Carboplatin intravenous infusion.
145100|NCT03057366|Drug|Paclitaxel|Paclitaxel intravenous infusion.
145101|NCT03057353|Device|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
145102|NCT03057340|Biological|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
145103|NCT03057327|Behavioral|Improve awareness of checking moles|"Intervention:~Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
145104|NCT03057327|Other|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
145105|NCT03057314|Drug|Amorphous Calcium Carbonate|"Subjects will be administered with:~ACC tablets, containing 200 mg elemental calcium~1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
145106|NCT03057301|Device|iCare home tonometer|All subjects will be taught to use the home care tonometer.
145107|NCT03057288|Device|fiducial markers placement|The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
145108|NCT03057275|Device|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
145109|NCT03057262|Device|Repositioning splint|Application of repositioning splint in the study group.
145110|NCT03057249|Other|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
145111|NCT03057236|Behavioral|Cognitive Behavior Coping Skills|The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
145112|NCT03057223|Device|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
145113|NCT03057210|Other|Stress Protocol|Participants will be submitted to an exercise protocol consisting of a jumping program and a maximum short cycle test (ALMEIDAetal). The jumping program consists of 10 sets of 10 jumps with one minute interval between sets. The participants will then perform the Wingate Anaerobic Test protocol, which will be performed on a Biotec 2100 cycle ergometer (Cefise, Nova Odessa, Brazil). A 5-minute warm-up will be carried out where the participant will pedal at a speed of 60 to 90 rpm with a fixed load of 1.0 kg and perform sprints in the 2nd and 4th minute and the test itself, which consists of a maximum of pedals In 30 seconds with a stipulated load of 0.075 kP · kg-1 of the participant's body mass.
145114|NCT03057210|Other|Massage Protocol|"the present protocol will have a total of 12 minutes duration, being six minutes in the anterior region of the thigh (three minutes for each limb) and six minutes in the posterior region of the trunk.~Surface and deep sliding techniques will be used, the latter being presented in two intensities, moderate or intense, gradually increased. The massage will be performed towards the muscle fibers, from distal to proximal and following the lymphatic flow. In addition to the standardization of the intensity of the massage performed by the physiotherapist, in order to avoid causing discomfort and possible variations in the application of the technique, participants should report their level of comfort from a scale that considers the technique light, moderate or Intense, corresponding respectively to surface slip, Deep Slip 1 and Deep Slip 2."
145115|NCT03057197|Procedure|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
145116|NCT03057184|Behavioral|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
145117|NCT03057145|Drug|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
145118|NCT03057145|Drug|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
145119|NCT03057132|Device|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
145120|NCT03057119|Behavioral|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
145121|NCT03057119|Behavioral|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
145122|NCT03057119|Behavioral|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
145284|NCT03056001|Drug|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
145123|NCT03057119|Behavioral|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
145124|NCT03057119|Behavioral|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
145125|NCT03057106|Drug|Durvalumab|MEDI4736
145126|NCT03057106|Drug|Tremelimumab|Tremelimumab
145127|NCT03057106|Drug|Platinum-Based Drug|Pemetrexed, cisplatin, carboplatin or gemcitibine
145128|NCT03057093|Other|Non interventional study|retrospective noninterventional study
145129|NCT03057080|Procedure|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
145130|NCT03057067|Procedure|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
145131|NCT03057054|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
145132|NCT03057054|Biological|Lactobacillus plantarum strain 299|Given PO or via NG or G tube
145133|NCT03057054|Biological|Lactobacillus plantarum strain 299v|Given PO or via NG or G tube
145134|NCT03057054|Other|Placebo|Given PO or via NG or G tube
145135|NCT03057041|Drug|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
145136|NCT03057041|Drug|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
145137|NCT03057028|Drug|Anakinra|
145138|NCT03057015|Drug|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
145139|NCT03057015|Drug|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
145140|NCT03057015|Drug|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
145141|NCT03057015|Drug|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
145142|NCT03057015|Drug|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
145143|NCT03057002|Drug|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized [1-13C]pyruvate flux during magnetic resonance spectroscopic imaging.
145144|NCT03056989|Drug|SPX-101|Inhalation solution twice daily for 7 days.
145145|NCT03056976|Device|Single-implant mandibular overdenture|Complete mandibular denture retained by a single midline implant
145146|NCT03056976|Device|Two-implant mandibular overdenture|Complete mandibular denture retained by two implants in the canine region
145147|NCT03056976|Device|Fixed mandibular denture|A fixed mandibular denture retained by four implants
145148|NCT03056963|Behavioral|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
145149|NCT03056963|Behavioral|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
145150|NCT03056950|Device|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
145151|NCT03056937|Other|Bariatric surgery|evaluations pre and post bariatric surgery.
145152|NCT03056937|Other|Control|without intervention, it will be performed only evaluations
145153|NCT03056924|Biological|Pneumococcal Pneumonia vaccine|Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
145154|NCT03056924|Biological|Influenza vaccine|Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
145155|NCT03056924|Biological|Hepatitis B vaccine|Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
145156|NCT03056911|Drug|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
145157|NCT03056885|Other|Conventional One-Lung Ventilation|Vt 10 ml/kg
145158|NCT03056885|Other|Protective One-lung ventilation|Vt 5 ml/kg
145159|NCT03056859|Device|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
145329|NCT03055676|Other|Late drain removal|Removing drain(s) on postoperative day 5 or later
145161|NCT03056846|Dietary Supplement|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
145162|NCT03056846|Dietary Supplement|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
145163|NCT03056846|Dietary Supplement|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
145164|NCT03056833|Drug|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
145165|NCT03056833|Drug|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
145166|NCT03056833|Drug|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
145167|NCT03056820|Other|25° head-up position|Participant will be positioned at 25° angle for procedure.
145168|NCT03056820|Other|55° head-up position|Participant will be positioned at 55° angle for procedure.
145169|NCT03056807|Other|25° head-up position|Angle person is positioned for procedure.
145170|NCT03056807|Other|55° head-up position|Angle person is positioned for procedure.
145171|NCT03056794|Other|No intervention|This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
145172|NCT03056781|Behavioral|social interaction|Participants will engage in a social interaction with another person
145173|NCT03056781|Behavioral|food consumption|Participants will be offered food stuffs to eat/drink
145174|NCT03056768|Behavioral|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
145175|NCT03056768|Behavioral|Active control|Health promotion activities provided by local health bureau.
145176|NCT03056755|Drug|alpelisib|300 mg; oral; once daily
145177|NCT03056755|Drug|fulvestrant|500 mg; intramuscular injection on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter
145178|NCT03056755|Drug|letrozole|2.5 mg; oral; once daily
145179|NCT03056755|Drug|Goserelin|Every 28 days (only for men in cohort B and premenopausal women). Administered as injectable subcutaneous implant (3.6 mg)
145180|NCT03056755|Drug|Leuprolide|Every 28 days (only for men in cohort B and premenopausal women). Administered as injectable intramuscular depot (7.5 mg)
145181|NCT03056742|Biological|Stempeucel(R)|Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
145182|NCT03056729|Drug|BIIB076|Administered as single intravenous (IV) infusion
145183|NCT03056729|Drug|Placebo|Administered as single IV infusion
145184|NCT03056716|Procedure|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
145185|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
145186|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
145187|NCT03056690|Drug|ASP0819|oral
145188|NCT03056690|Drug|Placebo|oral
145189|NCT03056677|Dietary Supplement|Control|200mls water will be given prior to a mixed carbohydrate meal
145190|NCT03056677|Dietary Supplement|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
145191|NCT03056677|Dietary Supplement|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
145192|NCT03056664|Procedure|Routine drainage surgery|
145193|NCT03056664|Biological|MSC injection 01|Local MSC injection in peri-anal with a dose of 3×10E6/kg
145194|NCT03056664|Biological|MSC injection 02|Local MSC injection in peri-anal with a dose of 6×10E6/kg
145195|NCT03056664|Other|placebo|NS injection instead of MSC
145196|NCT03056651|Other|treatment in day-care heart failure unit|
145197|NCT03056638|Drug|Degarelix|Degarelix monthly for 6 months
145198|NCT03056638|Radiation|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
145199|NCT03056625|Other|Vitamin A fortified rice|Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
145200|NCT03056625|Other|Normal rice|Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
145201|NCT03056612|Other|Observation protocol|The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
145202|NCT03056599|Drug|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
145203|NCT03056599|Device|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO™ device in soft tissue sarcoma patients undergoing surgery.
145204|NCT03056586|Device|vaginal pessary|A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
145205|NCT03056573|Device|Transaortic TAVR Implant|Transaortic TAVR implant
145206|NCT03056573|Device|Subclavian /Axillary TAVR implant|Subclavian /Axillary TAVR implant
145207|NCT03056560|Behavioral|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
145208|NCT03056547|Other|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
145209|NCT03056534|Device|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
145210|NCT03056521|Other|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
145211|NCT03056508|Behavioral|Exercise plus nutrition|On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
145212|NCT03056508|Behavioral|Exercise|Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at ~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
145213|NCT03056495|Drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
145214|NCT03056482|Drug|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
145215|NCT03056482|Drug|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
145216|NCT03056482|Drug|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
145217|NCT03056469|Other|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
145218|NCT03056456|Drug|LY900014|Administered subcutaneously (SC)
145219|NCT03056456|Drug|Insulin Lispro|Administered SC
145220|NCT03056443|Device|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
145221|NCT03056430|Behavioral|Training|
145222|NCT03056417|Behavioral|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
145223|NCT03056404|Other|additional blood sample|
145224|NCT03056404|Other|respiratory functional exploration|
145225|NCT03056391|Drug|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
145226|NCT03056378|Biological|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
145227|NCT03056365|Procedure|Advanced Nurse (AN)|Protocoled AN-based management of detox
145228|NCT03056365|Procedure|General Practitioner (GP)|'As usual' medical management of detox
145229|NCT03056352|Drug|Metoclopramide|Intravenous medication drip
145230|NCT03056352|Drug|Diphenhydramine|Intravenous medication drip
145231|NCT03056339|Drug|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
145232|NCT03056339|Drug|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
145233|NCT03056339|Drug|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
145234|NCT03056339|Biological|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.~Starting dose: 10E5"
145235|NCT03056339|Drug|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
145236|NCT03056326|Drug|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
145237|NCT03056326|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
145238|NCT03056326|Drug|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
145239|NCT03056326|Drug|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
145240|NCT03056313|Behavioral|Proactive support of labor|In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
145241|NCT03056313|Behavioral|support of labor as usual|In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
145242|NCT03056300|Device|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler|Powered Vascular Stapler used on vessels
145243|NCT03056287|Behavioral|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
145244|NCT03056287|Other|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
145245|NCT03056274|Drug|Metformin|Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes
145246|NCT03056274|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
145247|NCT03056261|Procedure|Combined general and epidural|Combined general and epidural anaesthesia
145248|NCT03056261|Procedure|General anaesthesia|General anaesthesia
145413|NCT03055013|Other|Quality-of-Life Assessment|Ancillary studies
222476|NCT02489968|Drug|Placebo|
145249|NCT03056248|Drug|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
145250|NCT03056248|Drug|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
145251|NCT03056235|Device|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
145252|NCT03056235|Device|Saline|Saline control
145253|NCT03056222|Device|Ablation catheter|Ablation of paroxysmal atrial fibrillation
145254|NCT03056209|Drug|KL1333 25 mg|oral administration, single dose, 25 mg 1 tab
145255|NCT03056209|Drug|KL1333 50 mg|oral administration, single dose, 25 mg 2 tabs
145256|NCT03056209|Drug|KL1333 100 mg|oral administration, single dose, 100 mg 1 tab
145257|NCT03056209|Drug|KL1333 200 mg|oral administration, single dose, 100 mg 2 tabs
145258|NCT03056209|Drug|KL1333 400 mg|oral administration, single dose, 100 mg 4 tabs
145259|NCT03056209|Drug|KL1333 600 mg|oral administration, single dose, 100 mg 6 tabs
145260|NCT03056209|Drug|KL1333 800 mg|oral administration, single dose, 100 mg 8 tabs
145261|NCT03056209|Drug|Placebo|oral administration, placebo
145262|NCT03056196|Diagnostic Test|point of care ultrasound|want to assess the ability of d-dimer test and point of care ultrasound to role out lower leg DVT
145263|NCT03056183|Behavioral|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
145264|NCT03056170|Device|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
145265|NCT03056157|Behavioral|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
145266|NCT03056157|Behavioral|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on problems occurring in the present (with no focus on trauma or re-visiting past experiences).
145267|NCT03056144|Device|whole body vibration therapy|"The whole body vibration therapy regime is as follows:~Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3~st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min~nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min~th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min~th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min >5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min~The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
145268|NCT03056131|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
145269|NCT03056118|Drug|6-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
145270|NCT03056118|Drug|12-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
145271|NCT03056118|Device|Zotarolimus eluting stent|Zotarolimus eluting stent is applied to coronary stenotic lesion
145272|NCT03056118|Device|Biolimus eluting stent|Biolimus eluting stent is applied to coronary stenotic lesion
145273|NCT03056105|Other|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence—refraining from eye contact as well as verbal and written communication—except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
145274|NCT03056092|Drug|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
145275|NCT03056079|Drug|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
145276|NCT03056066|Device|Plethysmograph|A full Body Plethysmography examination
145277|NCT03056053|Drug|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
145278|NCT03056040|Biological|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to <60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to <100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
145279|NCT03056040|Biological|Eculizumab|All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
145285|NCT03056001|Drug|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1
145286|NCT03055988|Drug|Tiotropium|Fixed Dose Combination
145287|NCT03055988|Drug|Olodaterol|Fixed Dose Combination
145288|NCT03055988|Drug|Fluticasone propionate|Fixed Dose Combination
145289|NCT03055988|Drug|Salmeterol|Fixed Dose Combination
145290|NCT03055975|Diagnostic Test|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
145291|NCT03055962|Drug|E2609|tablet
145292|NCT03055962|Drug|Placebo|tablet
145293|NCT03055949|Behavioral|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
145294|NCT03055936|Drug|Levodopa|Levodopa 50 mg or 100 mg or 150 mg
145295|NCT03055936|Drug|Carbidopa|Carbidopa 12,5 mg or 25 mg or 65 mg
145296|NCT03055936|Drug|ODM-104|ODM-104 50 mg or 100 mg
145297|NCT03055923|Device|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
145298|NCT03055910|Diagnostic Test|Fractional Flow Reserve Measurement|Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses
145299|NCT03055897|Device|iLux 2020 System|Application of heat to the meibomian glands to determine potential impact on eyes and surrounding tissue.
145300|NCT03055884|Device|tDCS|active tDCS versus sham tDCS
145301|NCT03055884|Behavioral|Verbal paired-associate learning task|with or without repeated retrieval practice
145302|NCT03055871|Behavioral|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
145303|NCT03055871|Behavioral|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
145304|NCT03055858|Device|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
145305|NCT03055845|Drug|STA363|STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
145306|NCT03055845|Drug|Placebo|Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
145307|NCT03055832|Device|iLux 2020 System|Medical device that applies localized heat and pressure therapy to the eyelid in order to express melted meibum from obstructed glands
145308|NCT03055832|Device|LipiFlow Pulsation System|Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
145309|NCT03055819|Device|Brow Lift|Minimally Invasive Brow Lift
145310|NCT03055806|Drug|IX-01 400 mg|IX-01 400 mg caplet
145311|NCT03055806|Drug|Placebo|Placebo caplet(s)
145312|NCT03055806|Drug|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
145313|NCT03055806|Drug|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
145314|NCT03055793|Other|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
145315|NCT03055780|Device|CT-FFR. CTA. FFR|Study is to compare results of CT FFR against CTA and interventional FFR
145316|NCT03055767|Drug|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
145317|NCT03055767|Other|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
145318|NCT03055754|Procedure|Argon randomized arm|Endoscopic argon plasma coagulation
145319|NCT03055754|Procedure|Control arm|No Endoscopic procedure
145320|NCT03055741|Drug|Donepezil|5mg or 10mg, once a day, 24 weeks
145321|NCT03055741|Drug|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
145322|NCT03055741|Drug|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
145323|NCT03055728|Diagnostic Test|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
145324|NCT03055728|Diagnostic Test|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
145325|NCT03055702|Other|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
145326|NCT03055689|Behavioral|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
145327|NCT03055689|Behavioral|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
145328|NCT03055676|Other|Early drain removal|Removing drain(s) on postoperative day 3
145330|NCT03055663|Other|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
145331|NCT03055663|Procedure|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
145332|NCT03055663|Drug|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
145333|NCT03055650|Device|iLux 2020 System|Heating and compression to express clogged meibomian glands
145334|NCT03055637|Procedure|Furlow double opposing z-plasty|* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
145335|NCT03055637|Procedure|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
145336|NCT03055624|Device|Embosphere microparticles for prostate artery embolization|Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
145337|NCT03055611|Drug|ELOCTA|Extended half-life factor VIII product
145338|NCT03055611|Drug|ALPROLIX|Extended half-life factor IX product
145339|NCT03055598|Drug|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
145340|NCT03055585|Biological|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
145341|NCT03055585|Other|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
145342|NCT03055572|Other|Olfactory Training with Essential Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
145343|NCT03055572|Other|Olfactory Training with Pure Fragrance Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
145344|NCT03055559|Dietary Supplement|Globifer Forte|
145345|NCT03055546|Drug|Oxytocin|intranasal administration of oxytocin
145346|NCT03055546|Drug|Placebo|intranasal administration of placebo
145347|NCT03055533|Behavioral|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
145348|NCT03055520|Other|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
145349|NCT03055520|Other|placebo|nonspecific recreation including befriending and free simple activities.
145350|NCT03055507|Drug|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
145351|NCT03055507|Drug|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
145352|NCT03055507|Drug|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
145353|NCT03055494|Biological|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 followed by monthly dosing up to Week 48
145354|NCT03055494|Biological|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
145355|NCT03055481|Other|High irradiance level of phototherapy|High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
145356|NCT03055481|Other|Low irradiance level of phototherapy|Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
145357|NCT03055468|Behavioral|Peer support|Peer support and antidepressant medications
145358|NCT03055455|Diagnostic Test|MR imaging|Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
145359|NCT03055442|Other|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
145360|NCT03055442|Other|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
145361|NCT03055429|Other|Full Scale Unit|Pre-test, usability, post-test
145362|NCT03055416|Other|Mobile Men App Prototype|Testing of app functionality
145363|NCT03055403|Drug|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
145364|NCT03055403|Drug|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
145365|NCT03055390|Drug|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
145366|NCT03055390|Drug|placebo|2ml of saline intravenous
145367|NCT03055377|Drug|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
145368|NCT03055377|Drug|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
145414|NCT03055013|Other|Questionnaire Administration|Ancillary studies
145369|NCT03055351|Behavioral|Stop&Go Intervention|Stop&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
145370|NCT03055338|Drug|MK-8189|Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
145371|NCT03055338|Drug|Risperidone|Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
145372|NCT03055338|Drug|Placebo matching MK-8189|Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.
145373|NCT03055338|Drug|Placebo matching risperidone|Oral placebo capsule(s) matching the risperidone capsule, administered QD.
145374|NCT03055325|Other|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
145375|NCT03055312|Drug|TPC|"Conventional chemotherapy(choose a):~TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.~GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 & days 8)every 3 weeks.~GC:(Gemcitabine 1000mg/m2 on days 1 & days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 & days 8) every 3 weeks"
145376|NCT03055312|Drug|Bicalutamide 150 mg|Bicalutamide 150mg/day,every 28 days
145377|NCT03055299|Other|COMEX intervention|Comprehensive Exercise
145378|NCT03055286|Drug|CWP232291|"For cohort 1-3, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.~For cohort 4, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 7 following 250 mg/m2 CWP232291 infusion."
145379|NCT03055273|Behavioral|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
145380|NCT03055260|Device|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
145381|NCT03055260|Device|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
145382|NCT03055247|Drug|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
145383|NCT03055247|Drug|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
145384|NCT03055247|Drug|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are < 10 /μL) to the day of the last LP.
145385|NCT03055234|Drug|Oral Treprostinil|Extended-release oral tablet for TID administration
145386|NCT03055234|Drug|Placebo|Matching placebo for TID administration
145387|NCT03055221|Drug|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
145388|NCT03055208|Radiation|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
145389|NCT03055195|Drug|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
145390|NCT03055195|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
145391|NCT03055182|Other|Physical rehabilitation program|Patients participate during 4 weeks to a physical rehabilitation program.
145392|NCT03055169|Genetic|genetic analysis|
145393|NCT03055169|Biological|blood and stools samples|
145394|NCT03055156|Device|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
145395|NCT03055156|Device|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
145396|NCT03055143|Drug|SPARC-08-038|2 mg/ml intravenous infusion
145397|NCT03055143|Drug|Ref-08-038|2 mg/ml intravenous infusion
145398|NCT03055130|Other|Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist|
145399|NCT03055117|Behavioral|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
145400|NCT03055117|Behavioral|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
145401|NCT03055117|Behavioral|Home exercise|Supervised home exercise
145402|NCT03055104|Other|management of severe malnutrition|multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
145403|NCT03055091|Other|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
145404|NCT03055091|Other|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
145405|NCT03055078|Biological|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
145406|NCT03055052|Other|Standard formula for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
145407|NCT03055052|Other|Formula with higher protein and new fat blend for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
145408|NCT03055026|Drug|Rivaroxaban|Tablets
145409|NCT03055026|Drug|Placebo|Tablets
145410|NCT03055013|Procedure|Conventional Surgery|Undergo nephrectomy
145411|NCT03055013|Biological|Nivolumab|Given IV
145412|NCT03055013|Other|Patient Observation|Undergo observation
222477|NCT02489955|Drug|Amikacin|
145416|NCT03055000|Biological|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
145417|NCT03055000|Other|Placebo|WFI (0.5mL) on Day 0 and Day 21
145418|NCT03054987|Procedure|EUS-BD|EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
145419|NCT03054987|Procedure|ERCP|During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
145420|NCT03054974|Other|Modern rehabilitation treatment|PT 1 hour per day and OT 30min per day
145421|NCT03054974|Other|Modern rehabilitation &TCM|Traditional Chinese Medicine, including massage and medicated bath
145422|NCT03054974|Other|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment with Baimai Ruangao and massage
145423|NCT03054974|Other|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
145424|NCT03054961|Device|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
145425|NCT03054948|Drug|SMOFLipid|SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
145426|NCT03054948|Drug|Standard therapy|In most cases standard therapy will be IntraLipid.
145427|NCT03054935|Other|Indirect Calorimetry|Measurement of resting energy expenditure
145428|NCT03054922|Drug|Normal Saline|IV infusion of 0.9% NaCl throughout surgery.
145429|NCT03054922|Drug|Lactated Ringer|IV infusion of lactated ringer throughout surgery.
145430|NCT03054922|Drug|Normosol-R Inj|IV infusion of Normosol throughout surgery.
145431|NCT03054909|Biological|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
145432|NCT03054909|Biological|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
145433|NCT03054896|Drug|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
145434|NCT03054896|Other|DA-EPOCH-R|Intensive chemotherapy regiment
145435|NCT03054870|Drug|Xe-133|Xe-133 ventilation scintigraphy
145436|NCT03054870|Drug|Technegas|Technegas ventilation scintigraphy
145437|NCT03054857|Drug|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
145438|NCT03054857|Drug|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
145439|NCT03054844|Drug|Lidocaine|Lidocaine will be administered before administration of midazolam.
145440|NCT03054844|Drug|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
145441|NCT03054844|Drug|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
145442|NCT03054831|Drug|liquid oxycodone|"The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).~In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.~The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU)."
145443|NCT03054805|Drug|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
145444|NCT03054805|Drug|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight < 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
145445|NCT03054792|Drug|18F-FAZA (F18-Fluoroazomycin Arabinoside)|Intravenous administration of a hypoxia marker, 18F- Fluoroazomycin arabinoside (FAZA), before a PET-MR imaging in order to identify areas of lower oxygen content on samples of a tumour.
145446|NCT03054792|Diagnostic Test|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
145447|NCT03054792|Diagnostic Test|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
145448|NCT03054792|Diagnostic Test|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
145449|NCT03054779|Other|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
145450|NCT03054779|Other|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
145451|NCT03054779|Other|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
145452|NCT03054766|Procedure|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
145453|NCT03054766|Drug|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
145501|NCT03054376|Other|Training with non immobilized leg|Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
145454|NCT03054753|Behavioral|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
145455|NCT03054740|Drug|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
145456|NCT03054740|Drug|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
145457|NCT03054727|Other|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score > or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
145458|NCT03054727|Other|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score < 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires."
145459|NCT03054714|Device|catheter replacement|catheter removal and delayed replacement, versus exchange over a guidewire
145460|NCT03054701|Other|Hip specific resistance exercise|Hip specific resistance exercise
145461|NCT03054701|Other|Knee specific resistance exercise|Knee specific resistance exercise
145462|NCT03054688|Device|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
145463|NCT03054675|Diagnostic Test|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
145464|NCT03054662|Other|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
145465|NCT03054662|Diagnostic Test|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
145466|NCT03054662|Drug|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
145467|NCT03054662|Other|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
145468|NCT03054623|Procedure|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
145469|NCT03054610|Drug|Betamethason Sodium Phosphate|
145470|NCT03054610|Drug|Ropivacaine|
145471|NCT03054610|Drug|Botulinum Toxins, Type A|
145472|NCT03054597|Device|Circular light motion|Exercise with circular light motion
145473|NCT03054597|Device|Diagonal light motion|Exercise with diagonal light motion
145474|NCT03054597|Device|Peripheral light motion|Exercise with peripheral light motion
145475|NCT03054597|Procedure|Exercise|
145476|NCT03054584|Other|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
145477|NCT03054558|Other|Pelvic ultrasound both two dimensional and three dimentional|
145478|NCT03054545|Drug|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
145479|NCT03054532|Drug|Durvalumab|Durvalumab intravenous 1500 mg
145480|NCT03054532|Drug|Lenali|Lenalidomide oral 20 mg/day
145481|NCT03054519|Drug|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
145482|NCT03054519|Drug|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
145483|NCT03054506|Device|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
145484|NCT03054506|Device|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
145485|NCT03054506|Device|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
145486|NCT03054493|Behavioral|no intervention|no intervention
145487|NCT03054480|Device|Fractional Micro-Needle Radiofrequency|
145488|NCT03054480|Drug|Botulinum toxin type A|
145489|NCT03054467|Drug|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
145490|NCT03054467|Drug|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
145491|NCT03054454|Procedure|Podiatry|Podiatry treatments and care from the multidisciplinary team.
145492|NCT03054441|Other|Actigraph|Actigraphs worn on wrists
145493|NCT03054428|Drug|Dupilumab|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
145494|NCT03054428|Drug|Placebo|Subcutaneous injection among the different quadrants of the abdomen (avoiding navel and waist areas), upper thighs, and upper arms.
145495|NCT03054415|Procedure|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
145496|NCT03054402|Drug|BAY1834845|Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group
145497|NCT03054402|Drug|Placebo|Single dose of placebo
145498|NCT03054389|Other|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
145499|NCT03054389|Other|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
222478|NCT02489955|Drug|Tobramycin|
145502|NCT03054376|Other|Exercise training with both legs|Exercise training will be conducted regularly on a cycle ergometer during a four week period
145503|NCT03054363|Drug|Tucatinib in Combination with Palbociclib and Letrozole|"Starting dose of combination therapy :~Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily~Dose modifications, if necessary:~If Palbociclib toxicity increased:~Tucatinib 300 mg PO BID Palbociclib 100 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily~If Tucatinib toxicity increased:~Tucatinib 250 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily~If Palbociclib and Tucatinib toxicity increased:~Tucatinib 250 mg PO BID Palbociclib 100 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily~Additional dose levels per protocol if PKs indicate a significant change to the metabolism of Tucatinib regardless of clinical toxicity."
145504|NCT03054350|Drug|Vadadustat|Daily oral dose
145505|NCT03054350|Drug|Placebo|Daily oral dose
145506|NCT03054337|Drug|Vadadustat|
145507|NCT03054337|Drug|Placebo|
145508|NCT03054324|Diagnostic Test|Fractional Flow Reserve|Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing.
145509|NCT03054311|Behavioral|Lifestyle Matters|
145510|NCT03054298|Biological|huCART-meso cells|Intravenous or intrapleural lentiviral transduced huCART-meso cells in 6 cohorts with and without cyclophosphamide in a 3+3 dose escalation design.
145511|NCT03054285|Drug|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
145512|NCT03054272|Behavioral|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
145513|NCT03054259|Drug|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
145514|NCT03054259|Drug|Methylprednisolone|100mg infusion on days 1 and 15
145515|NCT03054259|Drug|Normal Saline|250ml infusion on days 1 and 15
145516|NCT03054246|Other|Evaluation of chewing side preference|"The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle."
145517|NCT03054233|Procedure|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
145518|NCT03054220|Drug|Dextromethorphan 5 MG|
145519|NCT03054220|Drug|Tramadol 10 mg|
145520|NCT03054220|Drug|Duloxetine 60mg|
145521|NCT03054220|Drug|Paroxetine 20 mg|
145522|NCT03054207|Drug|Clopidogrel 300Mg Tablet|
145523|NCT03054207|Drug|Prasugrel 60Mg|
145524|NCT03054194|Drug|E2730|capsules
145525|NCT03054194|Drug|Placebo|capsules
145526|NCT03054181|Biological|HyQvia|
145527|NCT03054168|Drug|Sustanon 250|The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
145528|NCT03054168|Drug|Zoladex|The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
145529|NCT03054168|Other|Placebo|
145530|NCT03054155|Device|Alexandrite Laser|Alexandrite 755nm hair removal laser
145531|NCT03054142|Other|no intervention|
145532|NCT03054129|Other|Rehabilitation and balance training|"Stretching will be applied as hold-relax technique in PNF for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.~Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
145533|NCT03054129|Other|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
145534|NCT03054116|Diagnostic Test|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
145535|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
145536|NCT03054103|Drug|Midazolam + Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
145537|NCT03054103|Drug|Midazolam + Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
145538|NCT03054090|Other|Quality Improvement Support|Practices will receive a blended strategy of quality improvement facilitation to help participating practices incorporate PCOR clinical and organizational findings while building their overall practice capabilities. Primary care practices will be provided tools and training to improve the rates of screening and treatment of risk factors for heart attacks and strokes, as well as other chronic illnesses and the delivery of preventive services.
145539|NCT03054077|Other|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
145540|NCT03054064|Device|Indego Exoskeleton|Six study sessions including five Indego training sessions over two weeks.
145541|NCT03054051|Behavioral|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
145542|NCT03054038|Drug|Afatinib|Given by mouth
145543|NCT03054038|Biological|Necitumumab|Given IV
145544|NCT03054038|Other|Laboratory Biomarker Analysis|Correlative studies
145545|NCT03054025|Device|Smart Phone Monitoring Device|Use activity tracker application
145546|NCT03053999|Other|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
145582|NCT03053765|Other|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
222479|NCT02489955|Drug|Colomycin|
145547|NCT03053999|Other|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
145548|NCT03053986|Dietary Supplement|Apple polyphenols|1 tablet per day at evening before sleeping
145549|NCT03053986|Other|Placebo|1 tablet per day at evening before sleeping
145550|NCT03053973|Device|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
145551|NCT03053973|Other|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
145552|NCT03053960|Device|Computed Tomography|Undergo helical CT scan
145553|NCT03053960|Device|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
145554|NCT03053960|Device|Cone-Beam Computed Tomography|Undergo CBCT scan
145555|NCT03053960|Device|Magnetic Resonance Imaging|Undergo MRI scan
145556|NCT03053960|Procedure|Therapeutic Conventional Surgery|Undergo resection of tumor
145557|NCT03053960|Procedure|Histopathologic Examination|Correlative studies
145558|NCT03053947|Drug|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
145559|NCT03053934|Behavioral|Online video-based counselling|Videoconferencing facilitates communication between individuals (i.e., the counsellor and the client) in different geographical locations enabling them to interact simultaneously with each other on a computer monitor in real time. In other words, both the client and the therapist communicate live using both visual and audio aids simulating in-person therapy albeit from two separate geographical locations.
145560|NCT03053934|Behavioral|Traditional in-person counselling|"Traditional in-person counselling is often referred to as face-to-face and can be loosely defined as any mental health intervention, whereby the clinician is in the same room with a client. The terms in-person and same room are used less frequently, but it has been argued that these terms are more descriptive (since in videoconferencing, clients are also seen face-to-face on screen). Therefore, the current study uses the term in-person to describe traditional, face-to-face counselling."
145561|NCT03053921|Procedure|recession coverage|recession coverage done using Zuchellis technique
145562|NCT03053921|Procedure|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
145563|NCT03053908|Procedure|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
145564|NCT03053908|Procedure|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
145565|NCT03053895|Procedure|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
145566|NCT03053895|Procedure|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
145567|NCT03053882|Other|mouthwash|mouthwash containing herbal peppermint or green tea
145568|NCT03053869|Drug|Benzodiazepine - limited use strategy|"No routine use of any intraoperative benzodiazepines.~Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
145569|NCT03053869|Drug|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.~Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
145570|NCT03053856|Drug|Pembrolizumab|Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
145571|NCT03053856|Procedure|Curative resection|Neoadjuvant concurrent chemoradiotherapy followed by curative resection
145572|NCT03053856|Procedure|Neoadjuvant concurrent chemoradiotherapy|RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
145573|NCT03053856|Drug|Cisplatin|25mg/m2 once weekly
145574|NCT03053856|Drug|Paclitaxel|50mg/m2 once weekly
145575|NCT03053843|Dietary Supplement|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
145576|NCT03053830|Drug|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
145577|NCT03053817|Other|Exercise group|Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
145578|NCT03053804|Radiation|MR/PET|MR/PET with contrast media and FDG-18
145579|NCT03053791|Procedure|Deep brain stimulation in mesencephalic locomotor region|Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
145580|NCT03053791|Device|Implantation of a Deep brain stimulation system|Implantation of a Medtrinic Activa SC Impulse Generator for chronic Stimulation of the selected target.
145581|NCT03053778|Other|Early follow-up|Early follow-up until 4 weeks after discharge
223762|NCT02481089|Other|validation group|
145583|NCT03053752|Procedure|Transcutaneous Electric Nerve Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
145584|NCT03053739|Drug|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
145585|NCT03053739|Drug|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
145586|NCT03053726|Procedure|Variable Frequency Stimulation|vary the frequency of the stimulation parameter
145587|NCT03053713|Behavioral|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
145588|NCT03053713|Behavioral|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
145589|NCT03053700|Drug|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
145590|NCT03053700|Device|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
145591|NCT03053687|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
145592|NCT03053687|Dietary Supplement|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
145593|NCT03053674|Other|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
145594|NCT03053674|Other|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
145595|NCT03053648|Other|Self-acupressure|The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
145596|NCT03053648|Other|Sleep hygiene education|A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
145597|NCT03053635|Drug|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
145598|NCT03053622|Biological|Mirikizumab Test|Administered SC
145599|NCT03053622|Biological|Mirikizumab Test|Administered IV
145600|NCT03053622|Biological|Mirikizumab Reference|Administered SC
145601|NCT03053596|Device|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
145602|NCT03053583|Device|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
145603|NCT03053570|Device|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
145604|NCT03053570|Device|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
145605|NCT03053557|Behavioral|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
145606|NCT03053544|Drug|Metformin|Participants will self‐administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
145607|NCT03053531|Device|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
145608|NCT03053518|Device|iPro2 CGM with Enlite sensors|A professional, blinded, continuous glucose monitoring device will be inserted on the abdominal region to measure interstitial glucose every 5 min for 4 times / day.
145609|NCT03053518|Behavioral|LifeStyle|Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
145610|NCT03053505|Biological|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.~Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
145611|NCT03053505|Drug|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
145612|NCT03053492|Device|Duck Duck Punch Play|The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
145613|NCT03053492|Behavioral|Commercially Available Game Play|The behavioral intervention will include playing a hands-free video game available off-the-shelf.
145614|NCT03053479|Procedure|Laparoscopic sacrocolpopexy|see arm/group descriptions
146288|NCT03048136|Drug|Ipilimumab|Specified dose on specified days
145617|NCT03053466|Drug|APL-501|"Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). In the Dose Escalation Segment, each treatment cycle is comprised of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle. In the Cohort Extension, the treatment cycle will consist of 2 doses of study drug administered on Days 1 and 15 of a 28-day cycle and 1 dose of study drug administered on Day 1 of a 21-day cycle.~In Dose and Disease Expansion, the treatment cycle will consist of 2 doses of study drug (non-weight based dosing of 400 mg) administered on Days 1 and 15 of a 28-day cycle."
145618|NCT03053453|Procedure|Spinal Surgery|TKA under standard of care spinal surgery.
145619|NCT03053453|Device|Verasense Knee System device|Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
145620|NCT03053440|Drug|BGB-3111|160mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
145621|NCT03053440|Drug|Ibrutinib|420mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
145622|NCT03053427|Drug|Placebo|Oral administration
145623|NCT03053427|Drug|Gabapentin enacarbil|Oral administration
145624|NCT03053414|Dietary Supplement|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
145625|NCT03053401|Procedure|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
145626|NCT03053401|Procedure|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
145627|NCT03053401|Device|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
145628|NCT03053401|Device|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
145629|NCT03053401|Drug|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
145630|NCT03053401|Drug|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
145631|NCT03053388|Drug|Nitric Oxide|Nitric Oxide given via inhalation in cycles
145632|NCT03053388|Other|Supportive treatment|Supportive treatment (including oxygen)
145633|NCT03053375|Device|MDCure|Battery powered portable pulsed electromagnetic therapy device
145634|NCT03053362|Drug|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
145635|NCT03053362|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
145636|NCT03053336|Behavioral|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
145637|NCT03053323|Behavioral|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
145638|NCT03053297|Other|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.~These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
145639|NCT03053284|Drug|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
145640|NCT03053284|Drug|Saline Solution|Saline Solution injection will be given once per study visit
145641|NCT03053271|Drug|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
145642|NCT03053271|Drug|Placebo|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
145643|NCT03053258|Device|Collection of exhaled breath sample|Collect exhaled breath sample from patients with suspected VAP
145644|NCT03053245|Behavioral|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
145645|NCT03053245|Behavioral|Attention Control|Patients in this group will receive regular wellness calls from the research team.
145646|NCT03053232|Device|Purse string suture device|Using purse string suture device to close gastrointestinal perforation under endoscopy.
145647|NCT03053232|Device|Endoclips|Using endoclips to close gastrointestinal perforation under endoscopy.
145648|NCT03053219|Drug|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
145649|NCT03053206|Drug|ADE Protocol|"ADE chemotherapy~Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
145650|NCT03053193|Diagnostic Test|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the DiscoverPrint testing array.
145651|NCT03053167|Drug|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
145652|NCT03053167|Drug|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
145653|NCT03053154|Other|Sagittal pelvic tilt assessment|Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
145654|NCT03053141|Device|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
145655|NCT03053128|Device|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
145656|NCT03053128|Other|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
145657|NCT03053115|Drug|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
145658|NCT03053115|Drug|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
145659|NCT03053115|Drug|Placebos|Controls will take placebo two hours after dinner
145660|NCT03053102|Drug|ACH-0144471|ACH-0144471 will be administered to all patients enrolled in the study.
145661|NCT03053089|Drug|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
145662|NCT03053076|Other|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
145663|NCT03053076|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
145664|NCT03053063|Drug|SEL|Tablets administered orally once daily
145665|NCT03053063|Drug|Placebo|Tablets administered orally once daily
145666|NCT03053050|Drug|SEL|Tablets administered orally once daily
145667|NCT03053050|Drug|Placebo|Tablets administered orally once daily
145668|NCT03053037|Procedure|final apical size instrumentation|root canal instrumentation to two different final preparation sizes
145669|NCT03053011|Other|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
145670|NCT03052998|Drug|Ivermectin|Effect of Ivermectin on frequency of seizures
145671|NCT03052985|Procedure|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
145672|NCT03052972|Drug|18F-AV-1451|Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18FAV- 1451.
145673|NCT03052959|Behavioral|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
145674|NCT03052959|Other|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
145675|NCT03052946|Procedure|Bulking agent|Filling bulking agent in the anal canal
145676|NCT03052946|Procedure|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
145677|NCT03052933|Drug|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level1), or 60 mg/dose (level II) of copanlisib. Maximal tolerated dose will be determined by standard 3+3 dose escalation design For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.~Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
145678|NCT03052933|Drug|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,200 mg/m2 on Days 1 and 15 of each 28-day treatment cycle until maximum 6 cycles.
145679|NCT03052920|Device|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
145680|NCT03052907|Behavioral|BSPAN|"Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.~Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach & Health Promotion and Delivery & Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach & Health Promotion component (Medium Capacity).~Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
145681|NCT03052894|Device|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.~This will be compared to measurements using a current monitoring device in the same patient."
225445|NCT02469155|Drug|Placebo|
145682|NCT03052894|Device|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.~This will be used as the clinical monitoring device and as a comparator."
145683|NCT03052881|Device|Robot assisted surgery|The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of <10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
145684|NCT03052868|Other|Cognitive Assessment|Cognitive testing session
145685|NCT03052855|Other|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
145686|NCT03052842|Drug|C16G2 Strip|Antimicrobial Peptide
145687|NCT03052842|Other|Placebo Strip|Placebo
145688|NCT03052829|Behavioral|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
145689|NCT03052829|Behavioral|Usual care|Subjects will undergo their usual care without intervention
145690|NCT03052816|Drug|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
145691|NCT03052816|Drug|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
145692|NCT03052803|Device|Fractional flow reserve measure|Comparison of different devices measuring fractional flow reserve
145693|NCT03052790|Procedure|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
145694|NCT03052790|Device|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
145695|NCT03052777|Behavioral|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
145696|NCT03052764|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
145697|NCT03052764|Drug|Placebo (saline)|Placebo (saline) injection into the bladder.
145698|NCT03052751|Drug|UCB7665|"UCB7665 will be administered in 2 different dosages (dose 1 and dose 2) in dosage regimen 1 and 2.~UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)"
145699|NCT03052751|Other|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
145700|NCT03052725|Drug|reslizumab|Reslizumab was provided in a pre-filled syringe.
145701|NCT03052712|Behavioral|social cognition|battery of tests of social cognition
145702|NCT03052699|Procedure|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
145703|NCT03052686|Other|Childbirth with uterine rupture|No intervention. Follow-up of women with rupture uterine at the childbirth.
145704|NCT03052673|Drug|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
145705|NCT03052673|Drug|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
145706|NCT03052660|Drug|Midazolam|Oral administration preoperatively
145707|NCT03052660|Drug|Placebo oral capsule|Oral administration preoperatively
145708|NCT03052647|Device|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
145709|NCT03052647|Device|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
145710|NCT03052634|Drug|RC48-ADC|
145711|NCT03052634|Drug|Lapatinib plus capecitabine|
145712|NCT03052621|Procedure|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
145713|NCT03052608|Drug|Lorlatinib|ALK-positive NSCL treatment
145714|NCT03052608|Drug|Crizotinib|ALK-positive NSCL treatment
145715|NCT03052595|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
145716|NCT03052595|Diagnostic Test|Testing of autonomous nervous system function|Autonomous nervous system function will be assessed using a battery of tests (orthostasis, Valsalva manoeuvre, heart rate variability recording, blood hormone levels, ect.)
145717|NCT03052595|Diagnostic Test|Stroop test|Stroop test will be used to test cognitive function
145718|NCT03052582|Other|Milk type|
145719|NCT03052569|Drug|RXDX-105|Oral Capsules
145751|NCT03052257|Behavioral|Educational - glaucoma|Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
145753|NCT03052257|Behavioral|Educational - general|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
227942|NCT02451865|Drug|Docetaxel|Given IV
145720|NCT03052556|Procedure|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).~This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).~Patients with an initial abnormal pap smear or a positive HPV test will be monitored:~In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period~In case of an abnormal smear:~ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
145721|NCT03052543|Device|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
145722|NCT03052530|Device|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
145723|NCT03052517|Drug|QAW039 Dose 1|QAW039 Dose 1 once daily
145724|NCT03052517|Drug|QAW039 Dose 2|QAW039 Dose 2 once daily
145725|NCT03052517|Drug|Placebo|Placebo once daily
145726|NCT03052504|Other|Registration of complications|Prospective registration
145727|NCT03052491|Dietary Supplement|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
145728|NCT03052478|Drug|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
145729|NCT03052465|Other|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
145730|NCT03052452|Other|My Nutritional Health App|The My Nutritional Health app built in LifeData will be used as the data collection platform for this study. We will use the data collected in the app testing to develop population-level FAST scores.
145731|NCT03052439|Other|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
145732|NCT03052426|Device|Ergotron WorkFit - TL|A sit to stand work station.
145733|NCT03052413|Dietary Supplement|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
145734|NCT03052413|Dietary Supplement|placebo|Eligible subjects will receive Placebo to take daily for 180 days
145735|NCT03052400|Drug|Mifepristone 600 mg daily|Glucocorticoid receptor antagonist
145736|NCT03052400|Drug|Placebo|Matching placebo
145737|NCT03052387|Other|assigned intervention|"* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.~chin block graft~Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.~The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.~Low vestibular incision exposing the symphysis area to the inferior border of the mandible.~Using fissure bur to harvest the graft for the defect.~Closure using vicryl 3-O sutures."
145738|NCT03052374|Behavioral|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
145739|NCT03052361|Drug|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
145740|NCT03052361|Drug|Placebos|similar looking and tasting liquid placebo
145741|NCT03052348|Other|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
145742|NCT03052348|Other|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
145743|NCT03052335|Device|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
145744|NCT03052335|Procedure|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
145745|NCT03052322|Drug|MSB11022|Participants received MSB11022 (modified buffer and stabilizer) subcutaneously at dose of 40 milligram (mg) every other week from Day 1 up to Week 48.
145746|NCT03052322|Drug|EU-Humira|Participants received EU-Humira subcutaneously at dose of 40 mg every other week from Day 1 up to Week 48.
145747|NCT03052309|Device|Passeo-18 Lux DCB|The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)
145748|NCT03052296|Device|Passeo-18 Lux DCB|The endovascular procedure is conducted as per the local standard practice and device instruction for use
145749|NCT03052283|Other|Questionnaire|non-interventional
145750|NCT03052270|Drug|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
145752|NCT03052257|Behavioral|Dose monitoring and reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
146013|NCT03050151|Device|Prefilled syringe|Delivery of Dupilumab by prefilled syringe
145754|NCT03052257|Behavioral|Dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
145755|NCT03052244|Device|tDCS+VI|2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
145756|NCT03052244|Device|tDCS Sham+VI Sham|2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
145757|NCT03052231|Device|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
145758|NCT03052218|Device|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
145759|NCT03052205|Drug|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
145760|NCT03052179|Dietary Supplement|Poly-biotic|Before-after treatment
145761|NCT03052166|Device|QT Ultrasound scan|QT Ultrasound scan
145762|NCT03052153|Other|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
145763|NCT03052140|Device|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
145764|NCT03052140|Device|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
145765|NCT03052127|Drug|Light-activated AU-011|Study treatment
145766|NCT03052114|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
145767|NCT03052075|Other|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
145768|NCT03052062|Dietary Supplement|Lipidrive|LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
145769|NCT03052049|Device|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
145770|NCT03052036|Procedure|Coronary Angiography|Coronary angiography to determine location of blocked or narrowed arteries.
145771|NCT03052036|Procedure|Coronary revascularisation|PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
145772|NCT03052036|Other|Optimal Medical Therapy|Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
145773|NCT03052023|Procedure|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
145774|NCT03052023|Procedure|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
145775|NCT03052023|Procedure|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
145776|NCT03052010|Other|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
145777|NCT03052010|Drug|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
145778|NCT03052010|Drug|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
145817|NCT03051672|Drug|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
145818|NCT03051672|Radiation|Palliative radiotherapy|Treatment to shrink a cancer, slow down its growth, or control symptoms
145819|NCT03051659|Drug|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
145893|NCT03051022|Drug|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
145779|NCT03051997|Behavioral|Caregiver Contingency Management + Usual Drug Court Treatment|In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
145780|NCT03051997|Behavioral|Usual Drug Court Treatment|Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
145781|NCT03051984|Device|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
145782|NCT03051971|Device|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
145783|NCT03051971|Device|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
145784|NCT03051958|Behavioral|Internet mindfulness&exposure treatment|"See description under Arm."
145785|NCT03051958|Other|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
145786|NCT03051945|Drug|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
145787|NCT03051945|Other|Normal saline|Placebo
145788|NCT03051932|Drug|Ofiramev® (IV Acetaminophen)|Post -op pain medication
145789|NCT03051932|Drug|Placebo IV administration|Post -op pain
145790|NCT03051919|Other|observation|
145791|NCT03051906|Biological|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
145792|NCT03051906|Biological|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
145793|NCT03051906|Radiation|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
145794|NCT03051893|Drug|Chronocort|Modified formulation of hydrocortisone
145795|NCT03051880|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
145796|NCT03051880|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
145797|NCT03051854|Behavioral|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
145798|NCT03051841|Drug|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
145799|NCT03051828|Procedure|fencing|No intervention: practice fencing
145800|NCT03051802|Device|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
145801|NCT03051789|Device|Menstrual Cup|Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect ~30 ml of menstrual blood when inserted into the vaginal canal
145802|NCT03051789|Other|Cash transfer|A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank. Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.
145803|NCT03051789|Other|Cups and Cash|Combination of both interventions, using the same interventions and implementation methods.
145804|NCT03051776|Other|Kinesio Taping|
145805|NCT03051776|Other|Compression Garment|
145806|NCT03051750|Other|Complex Physical Therapy plus Pressotherapy|
145807|NCT03051750|Other|Kinesio Taping|
145808|NCT03051724|Other|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
145809|NCT03051711|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish Orange
145810|NCT03051698|Drug|C1-inhibitor|100 Unit/kg IV, one gift prior to broncho provocation.
145811|NCT03051698|Other|Saline|0.9% NaCl
145812|NCT03051698|Drug|Antibiotics|vancomycin, ciprofloxacin, metronidazole
145813|NCT03051685|Drug|DFN-15 Dose 1|
145814|NCT03051685|Drug|DFN-15 Dose 2|
145815|NCT03051685|Drug|DFN-15 Dose 3|
145816|NCT03051685|Drug|Active Comparator|
228740|NCT02446444|Drug|LHRHA|
145820|NCT03051659|Drug|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
145821|NCT03051646|Drug|Acetylsalicylic acid at 1st visit, then Placebo at 2nd visit|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise; Placebo oral capsule is administered one hour prior to exercise
145822|NCT03051646|Drug|Placebo at 1st visit, then Acetylsalicylic acid at 2nd visit|Placebo oral capsule is administered one hour prior to exercise; 650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
145823|NCT03051633|Behavioral|Be Under Your Own Influence|School based anti-drug use communications campaign
145824|NCT03051620|Drug|Discontinue alendronate|136 patients with osteoporosis stopping treatment with alendronate.
145825|NCT03051607|Drug|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
145826|NCT03051594|Device|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
145827|NCT03051594|Other|caries detector dye|dye used to detect the residual caries.
145828|NCT03051594|Diagnostic Test|visual tactile assessment|method usually used to detect the residual caries.
145829|NCT03051581|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
145830|NCT03051568|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
145831|NCT03051555|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
145832|NCT03051542|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
145833|NCT03051529|Other|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
145834|NCT03051516|Other|Laboratory Biomarker Analysis|Correlative studies
145835|NCT03051516|Other|Placebo|Given IM
145836|NCT03051516|Other|Questionnaire Administration|Ancillary studies
145837|NCT03051516|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
145838|NCT03051503|Drug|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
145839|NCT03051503|Device|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
145840|NCT03051490|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
145841|NCT03051490|Drug|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
145842|NCT03051477|Drug|Helixor® M|3-hour IV infusion on Monday, Wednesday, and Friday of each week.
145843|NCT03051464|Procedure|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
145844|NCT03051464|Radiation|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
145845|NCT03051464|Radiation|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
145846|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
145847|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.~All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
145890|NCT03051074|Behavioral|Comparison|Watching a relaxing film for up to 90 minutes
145891|NCT03051048|Procedure|Reperfusion|
145892|NCT03051035|Drug|KO-947|Intravenous administration
145848|NCT03051451|Drug|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
145849|NCT03051438|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
145850|NCT03051438|Procedure|Three-port VATS|The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
145851|NCT03051425|Dietary Supplement|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
145852|NCT03051425|Dietary Supplement|Placebo|120 mL of low-fat milk
145853|NCT03051412|Other|No Intervention|No intervention
145854|NCT03051399|Dietary Supplement|Placebo|The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.
145855|NCT03051399|Dietary Supplement|EpiCor|The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
145856|NCT03051386|Biological|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
145857|NCT03051373|Drug|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
145858|NCT03051373|Drug|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
145859|NCT03051360|Drug|PCSK9 Inhibitor [EPC]|Patients will receive PCSK9 inhibitor by a biweekly injection
145860|NCT03051360|Drug|Placebos|Patients will receive Placebo by a biweekly injection
145861|NCT03051347|Other|Itch Questionnaire and Interview|
145862|NCT03051347|Other|Stigma Questionnaire and Interview|
145863|NCT03051347|Other|Cognitive Interview and PROMIS Itch Questionnaire|
145864|NCT03051334|Other|diagnosed as bicuspid aortic valve|
145865|NCT03051321|Device|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
145866|NCT03051308|Combination Product|NPT and UW Solution|Tissue preservation solutions for transplantation
145867|NCT03051295|Other|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
145868|NCT03051282|Drug|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
145869|NCT03051269|Drug|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
145870|NCT03051269|Device|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
145871|NCT03051256|Drug|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
145872|NCT03051256|Drug|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
145873|NCT03051243|Drug|Linagliptin and Basal Insulin|Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
145874|NCT03051243|Drug|Basal Insulin and Bolus Insulin|Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
145875|NCT03051217|Other|Placebo|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use Q2W"
145876|NCT03051217|Drug|Certolizumab Pegol|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
145877|NCT03051191|Diagnostic Test|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
145878|NCT03051178|Device|Responsive deep brain stimulation|Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
145879|NCT03051165|Device|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
145880|NCT03051152|Procedure|D1 gastrectomy|Gastrectomy with limited lymph node dissection
145881|NCT03051152|Procedure|D2 gastrectomy|Gastrectomy with extended lymph node dissection
145882|NCT03051139|Behavioral|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
145883|NCT03051126|Other|Tissue Samples|Fresh residual tissue samples will be obtained during parathyroid and/or pancreas tumor intervention (for pancreas tumor intervention in MEN1 patients with hyperparathyroidism and pancreatic lesions).
145884|NCT03051100|Drug|Bempedoic acid 180mg|bempedoic acid 180 mg
145885|NCT03051100|Drug|Ezetimibe 10mg|ezetimibe 10 mg
145886|NCT03051100|Drug|Atorvastatin 20mg|atorvastatin 20 mg
145887|NCT03051100|Other|Placebo|placebo
145888|NCT03051087|Drug|Ganirelix acetate|
145889|NCT03051074|Behavioral|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
229058|NCT02444039|Device|SL-3G|Slit Lamp
145894|NCT03051022|Drug|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
145895|NCT03051009|Drug|Desmopressin ODT 25 μg|
145896|NCT03051009|Drug|Desmopressin ODT 50 μg|
145897|NCT03050996|Procedure|robotic radical prostatectomy|Urodynamic evaluation during robotic radical prostatectomy
145898|NCT03050983|Device|IPI|Enable the IPI algorithm and IPI alarm algorithm
145899|NCT03050957|Dietary Supplement|menthol|Alimentary bolus supplemented with menthol
145900|NCT03050944|Other|Lifestyle behaviour and dietary habits assessment|Lifestyle behaviour and dietary habits assessment
145901|NCT03050931|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
145902|NCT03050918|Behavioral|Follow-up Phone Call|Patients will receive a first call attempt within 72 hours discharge.
145903|NCT03050905|Drug|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
145904|NCT03050905|Drug|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).~Study Regimen: dasabuvir (250 mg twice daily)"
145905|NCT03050879|Drug|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
145906|NCT03050866|Drug|Cabazitaxel|25mg/m2 q3w
145907|NCT03050866|Other|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
145908|NCT03050866|Other|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
145909|NCT03050866|Other|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
145910|NCT03050866|Other|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
145911|NCT03050853|Behavioral|E-cigarette|The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
145912|NCT03050840|Behavioral|Way to Health|An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
145913|NCT03050827|Drug|3% oxybutynin|Topical Gelnique 3%TM (3% oxybutynin) applied daily for 20 weeks in type 2 diabetic subjects with established peripheral neuropathy. Subjects will be randomized into placebo or active drug arms and instructed in how to apply 84 mg Gelnique 3%TM or hydrogel placebo to cover a 2 by 2 region of skin adjacent to the initial biopsy site. Treatment will continue daily for 20 weeks, with monthly phone calls to monitor compliance.
145914|NCT03050827|Drug|Placebo|Non-active placebo for 3% oxybutynin
145915|NCT03050814|Drug|Avelumab|10 mg/kg IV over 30-60 min on Day 1
145916|NCT03050814|Biological|Ad-CEA vaccine|Subcutaneous injection in the thigh prior to Avelumab on Day 1 of cycles 1, 2 3, 5, 7, 9; every 6 cycles thereafter.
145917|NCT03050814|Drug|Bevacizumab|5mg/kg IV over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
145918|NCT03050814|Drug|5-FU|400mg/m2 (only Arm A) IV bolus on day 1. Part of the standard of care therapy.
145919|NCT03050814|Drug|Leucovorin|400mg/m2 IV over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
145920|NCT03050814|Drug|Oxaliplatin|85mg/m2 (Arm A) or 68mg/m2 (Arm B) IV over 2 hours on day 1 (Arm A) or Day 2 (Arm B). Part of the standard of care therapy.
145921|NCT03050814|Drug|Capecitabine|625 mg/m2 twice a day by mouth. Part of the standard of care therapy.
145922|NCT03050814|Drug|5-FU|2400 mg/m2 (Arm A and B) IV over 46 hours (+/-2 hours) to start on Day 1 (ARM A) or Day 2 (Arm B). Part of the stanard of care therapy.
145923|NCT03050801|Device|rTMS|Altering the connectivity of trans-synaptic pathways
145924|NCT03050788|Device|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
145925|NCT03050775|Device|Heated Ventilator Circuit|active heat and humidification during anesthesia by warming inspire gases without a heat-moisture exchanger
145926|NCT03050775|Device|Standard Ventilator Circuit|no active heat and humidification during anesthesia
145927|NCT03050762|Other|Data Collection|Participant information collected from either source document or direct participant response.
145928|NCT03050762|Behavioral|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
145929|NCT03050749|Device|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
145930|NCT03050736|Drug|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
145931|NCT03050723|Device|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
145932|NCT03050710|Device|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
145933|NCT03050684|Procedure|vaginal lavage group|vaginal washing will be applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
145934|NCT03050684|Procedure|Control Group|vaginal washing will be not applied with steril %0.9 NaCl serum (20cc) before intravaginal PGE2 insertion.
145935|NCT03050671|Device|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
145936|NCT03050671|Device|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
145937|NCT03050632|Behavioral|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
145938|NCT03050632|Behavioral|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
145939|NCT03050619|Drug|Empagliflozin|
145940|NCT03050619|Drug|Other SGLT2 inhibitors|
145941|NCT03050619|Drug|Other non-insulin GLDs|metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists
145942|NCT03050606|Other|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
145943|NCT03050606|Other|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
145944|NCT03050593|Diagnostic Test|MRI scan, Echo scan|
145945|NCT03050580|Behavioral|self-esteem enhancement group|Subjects in the treatment group will join a six-session treatment for recognizing their strengths and resources through group activities and sharing. Each session is 1.5-2 hours long, and all sessions are designed for 4-8 abused women. The activities are designed and led with an aim to improve their self-esteem, general health, as well as to reduce the level of depression. This service is provided by registered social workers.
145946|NCT03050580|Behavioral|Standard care for abused women|The shelter standard care and services will be provided to the abused women in one randomized shelter. Besides, standard care in shelters includes residential accommodations, emotional support, legal, housing and financial advice and referrals will be given to survivors who reported being abused.
145947|NCT03050567|Diagnostic Test|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
145948|NCT03050554|Drug|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
145949|NCT03050554|Radiation|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
145950|NCT03050541|Drug|MDMA|This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.
145951|NCT03050541|Drug|Placebo|
145952|NCT03050528|Behavioral|Supervised Exercise|Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
145953|NCT03050528|Behavioral|Acceptance and Commitment Therapy|Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
145954|NCT03050515|Biological|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
145955|NCT03050502|Device|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
145956|NCT03050502|Other|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
145957|NCT03050489|Procedure|On-Pump CABG.|Standard On-Pump CABG.
145958|NCT03050489|Procedure|Off-Pump CABG.|Standard Off-Pump CABG.
145959|NCT03050489|Procedure|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
145960|NCT03050476|Drug|bRESCAP|intravenous application before, during, and for 24 hours after heart surgery
145961|NCT03050476|Drug|placebo|intravenous application before, during, and for 24 hours after heart surgery
145962|NCT03050463|Procedure|Biospecimen Collection|Undergo blood and saliva sample collection
145963|NCT03050463|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
145964|NCT03050463|Other|Questionnaire Administration|Ancillary studies
145965|NCT03050450|Drug|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
145966|NCT03050450|Drug|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
145967|NCT03050450|Drug|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
145968|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
145969|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
145970|NCT03050437|Drug|Cisplatin|cisplatin is added to Pem/cis arm
145971|NCT03050437|Drug|Pemetrexed|Pem is applied to both arms
145972|NCT03050424|Drug|Ferric Carboxymaltose|Ferric Carboxymaltose injectable Product
145973|NCT03050424|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9%
145974|NCT03050411|Drug|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
145975|NCT03050411|Drug|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
145976|NCT03050398|Drug|Ribociclib|ribociclib + letrozole
145977|NCT03050398|Drug|letrozole|ribociclib + letrozole
145978|NCT03050385|Device|transcranial direct current stimulation|
145979|NCT03050372|Device|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
145980|NCT03050372|Device|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
145981|NCT03050359|Drug|TAK-438|TAK-438 tablets
145982|NCT03050359|Drug|Lansoprazole|Lansoprazole capsules
145983|NCT03050359|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets.
145984|NCT03050359|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
145985|NCT03050359|Drug|Bismuth-Containing Quadruple Therapy|Amoxicillin, clarithromycin and bismuth potassium citrate/bismuth tripotassium dicitrate.
145986|NCT03050320|Other|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
145987|NCT03050320|Other|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
145988|NCT03050307|Drug|TAK-438|TAK-438 tablets
145989|NCT03050307|Drug|Lansoprazole|Lansoprazole capsules
145990|NCT03050307|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
145991|NCT03050307|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
145992|NCT03050307|Drug|Bismuth-Containing Quadruple Therapy|Bismuth-Containing Quadruple Therapy
145993|NCT03050294|Behavioral|Phone calls|Phone calls twice daily
145994|NCT03050294|Drug|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
145995|NCT03050281|Other|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
145996|NCT03050281|Other|Lectures|Standard Anatomy lectures were offered.
145997|NCT03050255|Other|Medical air|
145998|NCT03050255|Other|Oxygen (2Liter/min)|
145999|NCT03050255|Other|Oxygen (4Liter/min)|
146000|NCT03050242|Drug|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
146001|NCT03050229|Drug|Empagliflozin|Empagliflozin 10mg/day once daily before or after breakfast
146002|NCT03050229|Drug|Placebo|Placebo once daily before or after breakfast
146003|NCT03050216|Biological|ALT-803|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4~ALT-803 Stimulated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.~ALT-803 to Facilitate NK Cell Survival and Expansion:~ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
146004|NCT03050203|Other|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
146005|NCT03050203|Other|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
146006|NCT03050190|Genetic|Therapeutic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
146007|NCT03050177|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
146008|NCT03050177|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
146009|NCT03050164|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
146010|NCT03050164|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
146011|NCT03050151|Drug|Dupilumab|Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
146012|NCT03050151|Device|Auto-injector Device|Delivery of Dupilumab by auto-injector device
146014|NCT03050125|Device|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
146015|NCT03050125|Device|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
146016|NCT03050125|Device|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
146017|NCT03050112|Other|MacNew questionnaire|Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
146018|NCT03050099|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
146019|NCT03050086|Drug|BPX-04 1% minocycline topical gel|once daily administration of topical minocycline gel to face
146020|NCT03050086|Drug|BPX-04 2% minocycline topical gel|once daily administration of topical minocycline gel to face
146021|NCT03050086|Drug|BPX-04 vehicle topical gel|once daily administration of topical minocycline gel to face
146022|NCT03050060|Drug|Atezolizumab|Given IV
146023|NCT03050060|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
146024|NCT03050060|Other|Laboratory Biomarker Analysis|Correlative studies
146025|NCT03050060|Drug|Nelfinavir Mesylate|Given PO
146026|NCT03050060|Biological|Nivolumab|Given IV
146027|NCT03050060|Biological|Pembrolizumab|Given IV
146028|NCT03050060|Drug|Nelfinavir|Given PO
146029|NCT03050047|Biological|BCD-100|Anti-PD1 monoclonal antibody
146030|NCT03050034|Device|WIN @ Hospital system|WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
146031|NCT03050034|Other|Traditional monitoring|Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
146032|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
146033|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
146034|NCT03049995|Procedure|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
146035|NCT03049995|Procedure|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
146036|NCT03049995|Procedure|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
146037|NCT03049995|Procedure|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
146038|NCT03049995|Procedure|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
146039|NCT03049995|Procedure|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
146040|NCT03049995|Procedure|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
146041|NCT03049982|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
146042|NCT03049969|Device|tDCS stimulation|up to 4.0 mA, dorsolateral prefrontal cortex (montage dependent on specific area of deficit) while completing cognitive training tasks
146043|NCT03049956|Diagnostic Test|Ocular vestibular evoced myogenic potentials|The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
146044|NCT03049943|Device|low level laser|
146045|NCT03049930|Drug|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
146046|NCT03049930|Drug|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
146047|NCT03049917|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
146048|NCT03049904|Behavioral|Vr2L 2Spirit|"Three weeks exploring the Vr2L 2Spirit island.~Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use & condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.~Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.~Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels."
146049|NCT03049891|Other|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
146050|NCT03049891|Other|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
146051|NCT03049891|Other|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
146054|NCT03049852|Drug|CBT-001|One drop in the study administered three times daily (TID)
146055|NCT03049852|Drug|Vehicle|One drop in the study administered three times daily (TID)
146056|NCT03049839|Behavioral|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
146057|NCT03049839|Behavioral|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
146058|NCT03049839|Behavioral|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
146059|NCT03049826|Other|Nutritional status|Body composition and nutrient status
146060|NCT03049813|Behavioral|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
146061|NCT03049813|Other|Supported Employment (Services as Usual)|Standard supported employment services.
146062|NCT03049800|Device|Magnetic Resonance Imaging|Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner and a Prisma 3T scanner.
146063|NCT03049787|Other|Home Exercise Protocol|Home exercise therapy protocol given to patient to be completed at home.
146064|NCT03049787|Other|Physical Therapy Protocol|Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
146065|NCT03049761|Device|Water Flosser|Power interdental cleaner
146066|NCT03049761|Device|String Floss|Mechanical interdental cleaner
146067|NCT03049761|Device|Manual Toothbrush|ADA standard soft bristle toothbrush
146068|NCT03049748|Device|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
146069|NCT03049748|Other|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
146070|NCT03049735|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
146071|NCT03049735|Drug|Estradiol/norethindrone acetate|Capsule containing a co-formulated tablet of estradiol 1.0 mg and norethindrone acetate 0.5 mg administered orally once daily
146072|NCT03049735|Drug|Placebo for E2/NETA|Placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor
146073|NCT03049735|Drug|Placebo for relugolix|Placebo tablet administered orally once daily and manufactured to match the relugolix tablet in size, shape, color, and odor
146074|NCT03049722|Device|Pacemaker|
146075|NCT03049696|Behavioral|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
146076|NCT03049683|Other|Vestibular evoked myogenic potentials (VEMPs)|The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
146077|NCT03049670|Device|latent available chlorine (LAC)|local application on the necrotic infected tissue
146078|NCT03049657|Device|Angiolite|Percutaneous coronary intervention
146079|NCT03049657|Device|Xience|Percutaneous coronary intervention
146080|NCT03049644|Procedure|Mechanical Diagnosis and Therapy|Identification of directional preference.
146081|NCT03049644|Procedure|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
146082|NCT03049631|Dietary Supplement|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
146083|NCT03049631|Dietary Supplement|Raspberry|Red raspberries (1 cup equivalent)
146084|NCT03049618|Other|Laboratory Biomarker Analysis|Correlative studies
146085|NCT03049618|Biological|Pembrolizumab|Given IV
146086|NCT03049618|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
146087|NCT03049605|Device|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
146088|NCT03049605|Device|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
146089|NCT03049605|Drug|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
146090|NCT03049592|Other|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
146091|NCT03049579|Dietary Supplement|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
146092|NCT03049579|Dietary Supplement|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
146093|NCT03049566|Other|preoperative questionnaires|no intervention, cross-sectional survey in a single group
146094|NCT03049553|Device|Cobas HPV-DNA test|"Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other"
146253|NCT03048409|Other|Enteral Formula|Enteral feeding with a peptide-based formula.
146095|NCT03049553|Device|Liquid-based cytology|Liquid-based cytology (LBC) is the standard screening test in the Danish cervical screening program.
146096|NCT03049540|Drug|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
146097|NCT03049540|Drug|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
146098|NCT03049527|Behavioral|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
146099|NCT03049501|Behavioral|Caregiving condition|The intervention will consist of multimedia features accessible via the study-provided tablet. The components include: skill-building sessions and modules; a resource guide; an annotated reading list; information and tips; expert educational seminars (video); and structured support group sessions (6 sessions). All the sessions (home-based, one-on-one, and support group sessions) will last about 60-90 minutes.
146100|NCT03049501|Behavioral|Nutrition condition|The intervention will provide resource and information tips on topics related to Nutrition for a total of 8 sessions. The first and last session will be home-based and all the other sessions will be conducted via web-conferencing using the tablet provided.
146101|NCT03049488|Drug|VRC-RSVRGP084-00VP|VRC-RSVRGP084-00-VP is a sterile, aqueous, buffered solution filled into single dose vials
146102|NCT03049462|Drug|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50mg tablets.
146103|NCT03049462|Other|Placebo|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
146104|NCT03049449|Biological|Anti-CD30-CAR T cells|Dose-escalation trial starting dose: 0.15x106 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x106 CAR+ T cells/kg)infuse on day 0
146105|NCT03049449|Drug|Cyclophosphamide|300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3
146106|NCT03049449|Drug|Fludarabine|30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
146107|NCT03049436|Other|Program of adapted physical activity|
146108|NCT03049423|Device|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
146109|NCT03049423|Diagnostic Test|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
146110|NCT03049410|Procedure|Intracorporeal Robot Assisted Radical Cystectomy|Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration
146111|NCT03049410|Procedure|Open Radical Cystectomy|Removal of bladder and adjacent organs
146112|NCT03049397|Other|Communication Intervention|Complete Enhancing Connections program
146113|NCT03049397|Other|Questionnaire Administration|Ancillary studies
146114|NCT03049384|Other|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
146115|NCT03049384|Other|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
146116|NCT03049371|Other|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
146117|NCT03049358|Other|Physiologic Testing|Undergo UPSIT smell test
146118|NCT03049358|Other|Quality-of-Life Assessment|Ancillary studies
146119|NCT03049358|Procedure|Sham Intervention|Undergo sham training
146120|NCT03049358|Procedure|Therapeutic Procedure|Undergo olfactory training
146121|NCT03049358|Other|rose essential oil|patient smells rose oil in vial
146122|NCT03049358|Other|lemon essential oil|patient smells lemon oil in vial
146123|NCT03049358|Other|clove essential oil|patient smells clove oil in vial
146124|NCT03049358|Other|eucalyptus essential oil|patient smells eucalyptus oil in vial
146125|NCT03049358|Other|canola oil placebo|patient smells canola oil in vial
146126|NCT03049345|Procedure|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
146127|NCT03049345|Drug|Radioactive Tracers|see above
146128|NCT03049345|Drug|Methylene Blue 20 MG/ML|see above
146129|NCT03049332|Behavioral|self- and family-management intervention sessions|The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
146130|NCT03049319|Device|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
236956|NCT02387125|Drug|Metronomic CPA|
146131|NCT03049319|Device|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
146132|NCT03049319|Device|Psoriashield|The psoriashield will be applied to patient's back.
146133|NCT03049319|Device|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
146134|NCT03049319|Device|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
146135|NCT03049319|Device|Xtrac laser|The Xtrac laser will be applied to patient's back.
146136|NCT03049306|Drug|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
146137|NCT03049306|Drug|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
146138|NCT03049306|Device|CPAP|Patients will sleep in the lab wearing CPAP
146139|NCT03049293|Drug|Midazolam|The impact of Midazolam levels in follicular fluid.
146140|NCT03049280|Device|Transoral robotic surgery|Transoral robotic surgery for T1 & T2 oropharyngeal cancers
146141|NCT03049267|Drug|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
146142|NCT03049267|Drug|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
146143|NCT03049241|Other|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
146144|NCT03049228|Diagnostic Test|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.~The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
146145|NCT03049228|Diagnostic Test|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
146146|NCT03049228|Diagnostic Test|Blood analysis|To determine blood glucose metabolism and renal function.
146147|NCT03049228|Diagnostic Test|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
146148|NCT03049228|Diagnostic Test|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
146149|NCT03049215|Device|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
146150|NCT03049215|Device|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
146151|NCT03049189|Drug|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
146152|NCT03049189|Drug|Everolimus|Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
146153|NCT03049189|Other|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
146154|NCT03049176|Drug|PrEP (Truvada)|oral, daily Truvada for HIV-negative participants
146155|NCT03049176|Drug|Antiretrovirals|oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant
146156|NCT03049176|Procedure|Semen washing|collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination
146157|NCT03049176|Procedure|Artificial vaginal insemination|collection of semen from an HIV-negative man, followed by intravaginal insemination
146158|NCT03049163|Drug|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
146159|NCT03049137|Procedure|Computer Guided Stent Augmentation|Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
146160|NCT03049137|Procedure|Free Hand Augmentation|Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
146161|NCT03049137|Drug|Platelet-rich fibrin (PRF)|
146162|NCT03049137|Device|implant|
146254|NCT03048396|Procedure|Uterus transplantation|
146163|NCT03049124|Behavioral|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than < 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than < 60% of heart rate reserve) component.
146164|NCT03049111|Biological|Der f|Inhalation of Der f in mild asthmatics who are sensitive to Der f.
146165|NCT03049098|Behavioral|Simulation|A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
146166|NCT03049085|Drug|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
146167|NCT03049085|Drug|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
146168|NCT03049072|Radiation|Protons and Carbon Ions|
146169|NCT03049059|Device|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
146170|NCT03049059|Drug|4% hydroquinone cream|
146171|NCT03049046|Drug|CC100|synthetic caffeic acid phenethylester
146172|NCT03049046|Drug|Placebos|Diluent
146173|NCT03049033|Other|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
146174|NCT03049033|Other|Occupational Therapy|Occupational Therapy uses traditional motor training.
146175|NCT03049033|Other|Music Supported Therapy|Music Supported Therapy uses musical instruments to train fine motor movements.
146176|NCT03049020|Procedure|laparoscopic sacrocolpopexy|standard laparoscopic sacrocolpopexy for prolapse treatment
146177|NCT03049007|Diagnostic Test|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
146178|NCT03048994|Dietary Supplement|Glutamine|"Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.~IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.~An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
146179|NCT03048994|Dietary Supplement|Placebo|"Nutritional support will be continued as per managing ICU team discretion.~Management of severe sepsis will be continued as per managing ICU team discretion.~Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.~To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
146180|NCT03048981|Drug|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
146181|NCT03048968|Procedure|Gait, sit-to-stand movement, stair climbing and treadmill gait|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test. Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
146182|NCT03048968|Procedure|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
146183|NCT03048968|Device|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement, stair climbing and treadmill gait with GEMS and without GEMS in elderly adults.~Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
146184|NCT03048968|Device|treadmill|Cortical activation is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
146185|NCT03048955|Device|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
146186|NCT03048955|Procedure|Direct decompression Surgery|A surgical procedure - the control
146187|NCT03048942|Drug|Cabazitaxel|3 weekly cyctotoxic chemotherapy
146188|NCT03048942|Drug|Paclitaxel|Weekly cyctotoxic chemotherapy
146189|NCT03048929|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
146190|NCT03048929|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
146191|NCT03048916|Other|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
146192|NCT03048916|Other|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
146193|NCT03048903|Drug|Rheum Palmatum Root|Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
146194|NCT03048903|Drug|Starch Corn|Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
146195|NCT03048890|Behavioral|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
146196|NCT03048877|Drug|Apatinib Oral Tablet|Apatinib Mesylate Tablets
237068|NCT02386306|Drug|GC021109|
146198|NCT03048851|Device|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
146199|NCT03048851|Device|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
146200|NCT03048851|Device|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
146201|NCT03048851|Device|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
146202|NCT03048851|Procedure|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
146203|NCT03048838|Behavioral|Risk reduction behavioral intervention|
146204|NCT03048838|Behavioral|Wellness Promotion Intervention|
146205|NCT03048825|Drug|Colchicine|Colchicine 0.5 mg twice daily
146206|NCT03048825|Drug|Spironolactone|Spironolactone 25 mg once daily
146207|NCT03048825|Device|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
146208|NCT03048825|Drug|Colchicine-Placebo|Matching Colchicine-placebo twice daily
146209|NCT03048825|Drug|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
146210|NCT03048812|Device|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
146211|NCT03048812|Device|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
146212|NCT03048799|Device|Radiofrequency|The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
146213|NCT03048786|Behavioral|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
146214|NCT03048786|Behavioral|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
146215|NCT03048773|Device|shockwave therapy|Intervention with shockwave therapy
146216|NCT03048773|Other|PT|Physical therapy 3 times per week for 3 weeks
146217|NCT03048773|Other|placebo|sham shockwave therapy
146218|NCT03048760|Other|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans & 1 after approx. 2 weeks of radiotherapy treatment.
146219|NCT03048747|Drug|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
146220|NCT03048721|Procedure|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
146255|NCT03048383|Drug|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
146256|NCT03048383|Drug|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
237069|NCT02386306|Other|Placebo|
146221|NCT03048721|Procedure|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
146222|NCT03048708|Procedure|Bariatric surgery|patients who had received treatment with bariatric surgery for medical reasons
146223|NCT03048695|Behavioral|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
146224|NCT03048682|Device|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
146225|NCT03048682|Device|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
146226|NCT03048669|Other|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
146227|NCT03048656|Other|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
146228|NCT03048643|Behavioral|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
146229|NCT03048630|Behavioral|Education|Owner-to-Worker training about reducing chemical exposures in nail salons
146230|NCT03048604|Device|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
146231|NCT03048591|Device|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
146232|NCT03048578|Drug|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
146233|NCT03048578|Drug|Placebo|Subcutaneous Saline Solution
146234|NCT03048565|Behavioral|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
146235|NCT03048552|Behavioral|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
146236|NCT03048539|Procedure|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
146237|NCT03048526|Device|NovaTears®|Topical eye drops for lubrication of the ocular surface
146238|NCT03048526|Device|Hydrabak®|Eye drops
146239|NCT03048513|Other|Patient who presented with melioidosis in head and neck|Investigators assess the patients who had the pus culture positive with Burkholderia pseudomallei.
146240|NCT03048500|Other|Laboratory Biomarker Analysis|Correlative studies
146241|NCT03048500|Drug|Metformin Hydrochloride|Given PO
146242|NCT03048500|Biological|Nivolumab|Given IV
146243|NCT03048474|Drug|nivolumab and ipilimumab|
146244|NCT03048461|Device|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
146245|NCT03048461|Drug|Placebo|intradermal injections to an area of alopecia
146246|NCT03048448|Drug|Fevipiprant|Single 450mg dose
146247|NCT03048435|Other|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
146248|NCT03048435|Other|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
146249|NCT03048422|Drug|Dolutegravir|One 50 mg DTG tablet will be administered orally once daily
146250|NCT03048422|Drug|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) will be administered orally once daily
146251|NCT03048422|Drug|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) will be administered orally once daily
146252|NCT03048422|Drug|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) will be administered orally once daily
146257|NCT03048383|Drug|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
146258|NCT03048370|Procedure|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
146259|NCT03048370|Procedure|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
146260|NCT03048370|Procedure|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
146261|NCT03048370|Procedure|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
146262|NCT03048370|Procedure|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
146263|NCT03048370|Procedure|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
146264|NCT03048357|Device|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
146265|NCT03048357|Other|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
146266|NCT03048344|Drug|ORH-2014|ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
146267|NCT03048344|Drug|ORH-2014|ORH-2014 capsule at recommended dose orally.
146268|NCT03048331|Device|Functional Electrical Stimulation|"Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:~300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause."
146269|NCT03048318|Procedure|Arterial Flushing|
146270|NCT03048318|Procedure|Portal Flushing|
146271|NCT03048292|Other|Acute Endovascular Stroke Treatment|
146272|NCT03048279|Behavioral|Questionnaires|"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."
146273|NCT03048253|Biological|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
146274|NCT03048240|Device|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.~The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
146275|NCT03048240|Drug|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
146276|NCT03048227|Device|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
146277|NCT03048214|Procedure|Infraclavicular nerve block|Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
146278|NCT03048214|Procedure|General anaesthesia|Usual practice for upper limb surgeries.
146279|NCT03048201|Device|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
146280|NCT03048201|Device|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
146281|NCT03048201|Device|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
146282|NCT03048188|Other|wound dressing|Manuka honey wound dressing
146283|NCT03048175|Procedure|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
146284|NCT03048162|Drug|sodium chloride|500 ml of 0.9% isotonic sodium chloride
146285|NCT03048162|Drug|Hydroxyethylstarch|500 ml of 6% Hydroxyethylstarch
146286|NCT03048162|Drug|Ringer-Lactate Infusion Solution Bag|500 ml of Ringer-Lactate Infusion Solution Bag
146289|NCT03048123|Procedure|Hepatic arterial infusion|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
146290|NCT03048123|Procedure|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
146291|NCT03048123|Drug|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
146292|NCT03048123|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
146293|NCT03048110|Drug|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5, In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8.
146294|NCT03048110|Drug|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1, 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7.
146295|NCT03048110|Drug|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10.
146296|NCT03048097|Drug|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
146297|NCT03048097|Drug|Rubidium|used in PET scans
146298|NCT03048097|Diagnostic Test|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
146299|NCT03048084|Drug|Levetiracetam|Antiepileptic drug levetiracetam
146300|NCT03048084|Drug|Valproic Acid|Antiepileptic drug valproic acid
146301|NCT03048071|Other|Data collection within medical files|Data collection within medical files
146302|NCT03048058|Drug|brimonidine topical gel 0.33% & survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
146303|NCT03048058|Drug|brimonidine topical gel 0.33% & SOC|All subjects will receive standard-of-care brimonidine topical gel 0.33%
146304|NCT03048045|Procedure|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD >/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
146305|NCT03048032|Procedure|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
146306|NCT03048032|Procedure|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
146307|NCT03048019|Drug|Tirofiban|Patients will receive Tirofiban during the PCI procedure
146308|NCT03048019|Drug|Cangrelor|Patients will receive Cangrelor during the PCI procedure
146309|NCT03048006|Procedure|MRI with Dotarem|
146310|NCT03047993|Drug|Azacitidine|Given IV or SC
146311|NCT03047993|Drug|Glutaminase Inhibitor CB-839|Given PO
146312|NCT03047980|Drug|Sirolimus|Low dose oral sirolimus
146313|NCT03047967|Diagnostic Test|lung function tests|baby-body plethysmography
146314|NCT03047967|Diagnostic Test|Nasal brushing|Epithelial sample collecting for in vitro study
146315|NCT03047954|Drug|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
146316|NCT03047954|Drug|Placebo - Cap|Matching Placebo capsule administered
146386|NCT03047304|Diagnostic Test|Trans abdominal sonography|Trans abdominal sonography in order to measure fetal PR interval.
147264|NCT03040726|Other|Questionnaire Administration|Ancillary studies
146317|NCT03047941|Diagnostic Test|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
146318|NCT03047928|Drug|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
146319|NCT03047928|Biological|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
146320|NCT03047915|Other|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
146321|NCT03047902|Other|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.~In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
146322|NCT03047902|Other|Group 2- Parents will not be present for the Questionnaire|
146323|NCT03047889|Drug|standard therapy|standard therapy for advanced/metastatic breast cancer
146324|NCT03047876|Procedure|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
146325|NCT03047863|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.~EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
146326|NCT03047863|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
146327|NCT03047850|Diagnostic Test|Comparison of Delta Down and Delta Pulse Pressure|Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
146328|NCT03047837|Drug|Aspirin (ASA) + Metformin (MET)|Arm D (experimental arm) Treatment: active ASA + active MET Dose: 100 mg, 1 tablet daily + 850 mg,1 tablet twice a day (BID) Duration: 12 months
146329|NCT03047837|Drug|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
146330|NCT03047837|Drug|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
146331|NCT03047837|Drug|Placebos|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
146332|NCT03047824|Device|Intravascular continuous monitoring|Bedside usual insulin therapy guided by continuous glucose monitoring
146333|NCT03047824|Other|Standard of care|Bedside usual insulin therapy guided by intemittent glucose monitoring
146334|NCT03047811|Other|TCR - T cell therapy|Low dose group: 1 x 10 ^8 /kg T cell total reinfusion. High dose groups: 10 x 10 ^ 8 / kgT cell total reinfusion.
146335|NCT03047798|Drug|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
146336|NCT03047772|Drug|Atorvastatin|Routine dose of Atorvastatin therapy
146337|NCT03047772|Drug|Intensive Atorvastatin|Intensive dose of Atorvastatin therapy
146338|NCT03047772|Drug|Low dose BMMSC|Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
146339|NCT03047772|Drug|Middle dose BMMSC|Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
146340|NCT03047772|Drug|High dose BMMSC|High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
146341|NCT03047772|Drug|Transplantation|Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
146342|NCT03047759|Device|water flosser|Powered
146343|NCT03047759|Device|air floss|Powered
146344|NCT03047746|Device|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
146345|NCT03047733|Device|The XTRAC Excimer Laser System|Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.
146346|NCT03047733|Drug|Topical tacrolimus 0.1% ointment|Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
146347|NCT03047720|Other|One|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
146383|NCT03047330|Drug|Leuprolide Acetate|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
146384|NCT03047330|Other|Fragmented sleep|Fragmented sleep will be experimentally induced.
146385|NCT03047317|Biological|MABp1|Single dose of intravenous MABp1
147342|NCT03040128|Drug|Minocycline|high-dose, intravenous minocycline
146348|NCT03047720|Other|Two|"In the initial phase, participant baseline is established. In the Therapeutic Phase, each participant will complete the study phases (S1 and S2) in the order determined by their assigned treatment arm. During the scheduled awakening protocol using Lully Sleep Guardian, a scheduled awakening will be performed each night with the Lully pod.~During the initial and therapeutic phases of this study, participants are asked to enter responses daily into a Lully Study app. The app will send a prompt each morning. The questions the participant is prompted to answer serve to document occurrence of bedwetting and the degree of wetness.~In addition, the family will complete the KIDSCREEN 27 and the Vancouver questionnaire at defined intervals throughout the study."
146349|NCT03047707|Diagnostic Test|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
146350|NCT03047694|Other|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
146351|NCT03047694|Other|usual care|speech therapy
146352|NCT03047681|Diagnostic Test|venous blood withdrawl|patients will be asked for a venous blood sample
146353|NCT03047668|Dietary Supplement|diet with/without supplementation|diet with/without supplementation with PUFAs
146354|NCT03047655|Behavioral|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
146355|NCT03047655|Dietary Supplement|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
146356|NCT03047642|Device|CRP|Prospective case series of febrile children and adults. The results of the fever triage assay tests will not be provided to the treatment teams nor used to inform patient care.
146357|NCT03047629|Drug|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
146358|NCT03047629|Other|Placebo|Daily dosing with a placebo
146359|NCT03047616|Other|Blood and Urine Collection|
146360|NCT03047603|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
146361|NCT03047590|Behavioral|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
146362|NCT03047590|Behavioral|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
146363|NCT03047590|Behavioral|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
146364|NCT03047577|Behavioral|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
146365|NCT03047564|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
146366|NCT03047564|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
146367|NCT03047551|Procedure|Transabdominal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
146368|NCT03047551|Procedure|Transvaginal sonography|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
146369|NCT03047538|Drug|Atorvastatin, Amlodipine, Perindopril|To compare free and fixed combination of atorvastatin, perindopril, amlodipine
146370|NCT03047525|Biological|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
146371|NCT03047512|Behavioral|Experimental: Internet-based program|"Adolescents who obtain a score between 2 and 4 on the PHQ-3 will be invited to use the information module, the psychoeducational material and the symptom monitoring with personalized automatic feedback.~Adolescents who obtain a score between 5 and 6 on the PHQ-3 will be invited to use, in addition to the above, group forum activities (peer support moderated by mental health professionals) and the possibility of a chat (individualized support by mental health professionals).~Adolescents who obtain a score greater than 6 on the PHQ-3 or that have suicidal thoughts will be invited to see the mental health counselor of the institution and the possibility of their reference to face-to-face professional attention will be considered."
146372|NCT03047499|Drug|Botulinum toxin type A|Botulinum toxin type-A injection
146373|NCT03047473|Biological|avelumab|add on of avelumab 10mg/kg IV to standard therapy
146374|NCT03047460|Other|multimodal evoked potentials|
146375|NCT03047447|Behavioral|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
146376|NCT03047421|Diagnostic Test|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
146377|NCT03047408|Procedure|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
146378|NCT03047395|Biological|risankizumab|Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
146379|NCT03047382|Other|AKI Care Bundle|Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.
146380|NCT03047356|Behavioral|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
146381|NCT03047356|Other|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
146382|NCT03047343|Other|Retrospective data extraction in medical files|Retrospective data extraction in medical files
147343|NCT03040128|Other|normal saline infusion|
146387|NCT03047291|Drug|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
146388|NCT03047291|Device|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
146389|NCT03047278|Procedure|Serial Blood Samples|Serial blood samples were collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
146390|NCT03047278|Procedure|Serial Urine Samples|Serial urine samples were collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
146391|NCT03047278|Drug|Gabapentin 300 mg|All patients were treated with oral single dose of gabapentin 300 mg.
146392|NCT03047278|Drug|Cetirizine Hydrochloride 10 mg|Patients of control group were treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
146393|NCT03047265|Drug|Paclitaxel|Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
146394|NCT03047265|Drug|Cisplatin|Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
146395|NCT03047252|Device|Home-based rehabilitation with a digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises"
146396|NCT03047252|Other|Conventional Home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application"
146397|NCT03047239|Device|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
146398|NCT03047226|Other|next-generation sequencing|Use next-generation sequencing to test germline mutation and microsatellite instability.
146399|NCT03047213|Other|Laboratory Biomarker Analysis|Correlative studies
146400|NCT03047213|Drug|Sapanisertib|Given PO
146401|NCT03047200|Biological|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
146402|NCT03047187|Diagnostic Test|ACLR|"quadriceps and hamstring isometric muscles test~single hop for distance~IKDC, KOOS, Tampa and ACL-RSI Questionnaires"
146403|NCT03047174|Other|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
146404|NCT03047174|Other|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.~Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
146405|NCT03047161|Device|fetal MCG|assess fetal heart rate and rhythm
146406|NCT03047148|Other|Data mining from records|The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
146407|NCT03047135|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
146408|NCT03047109|Drug|Phenylephrine|50 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
146409|NCT03047109|Drug|Ephedrine|50 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
146410|NCT03047096|Drug|hyaluronic acid|intra-Articular injection
146411|NCT03047096|Drug|hyaluronic acid and corticosteroids|intra-Articular injection
146412|NCT03047083|Other|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
146413|NCT03047083|Other|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
146414|NCT03047070|Drug|Lidocaine|IV Lidocaine infusion
146415|NCT03047070|Drug|Normal saline|IV normal saline infusion
146416|NCT03047057|Drug|Lidocaine|IV Lidocaine infusion
146417|NCT03047057|Drug|IV normal saline|IV normal saline infusion
146448|NCT03046771|Behavioral|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
147344|NCT03040115|Other|Non-Interventional Study|
149339|NCT03025009|Drug|Basal Insulin Peglispro|Administered SC.
146418|NCT03047044|Other|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: ~ 8 hr: 2 - 4 ml, 8-24 hr: 1 - 3 ml, 24 hours ~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 0.5 ml).
146419|NCT03047044|Other|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
146420|NCT03047018|Behavioral|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
146421|NCT03047005|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
146422|NCT03047005|Other|Placebo|Placebo
146423|NCT03046992|Drug|YH25448|"Dose Escalation: YH25448 20mg~320mg, PO~Dose Expansion: YH25448 40mg~240mg, PO~Dose Extension: Recommended Dose 240mg of YH25448"
146424|NCT03046979|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
146425|NCT03046966|Procedure|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:~Using state of the art technology, a Storz C-MAC video laryngoscope~Identifying anatomical landmarks~Practice on the manikin until intubation occurs within 15 seconds"
146426|NCT03046966|Other|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
146427|NCT03046953|Drug|Avelumab|anti-PDL1 antibody
146428|NCT03046940|Other|Patient-centered style of communication|Different doctor-patient communication
146429|NCT03046940|Other|Doctor-centered style of communication|Different doctor-patient communication
146430|NCT03046927|Drug|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
146431|NCT03046927|Other|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
146432|NCT03046914|Genetic|HLA-B*5801 test|Check whether a participant has HLA-B*5801 allele or not, before administration of allopurinol
146433|NCT03046901|Drug|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
146434|NCT03046888|Procedure|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
146435|NCT03046875|Other|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
146436|NCT03046875|Other|Sham stimulation|Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
146437|NCT03046862|Drug|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
146438|NCT03046862|Drug|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
146439|NCT03046862|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1& D8 every 3 weeks
146440|NCT03046862|Drug|Cisplatin|Cisplatin 25 mg/m2 iv on D1& D8 every 3 weeks
146441|NCT03046849|Other|next-generation sequencing|Use next-generation sequencing to test germline mutation.
146442|NCT03046836|Drug|Oxytocin|40 IU oxytocin nasal spray
146443|NCT03046836|Drug|Placebo|Saline
146444|NCT03046810|Device|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
146445|NCT03046797|Device|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
146446|NCT03046797|Device|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
146447|NCT03046784|Other|haemodynamic evaluation|continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
146554|NCT03045926|Drug|Diosmectite (Smecta®)|
149340|NCT03025009|Drug|Insulin Glargine|Administered SC.
146449|NCT03046758|Drug|A combination of fosfomycin, metronidazole and GM-CSF i.p.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
146450|NCT03046732|Other|"Implementing Explore Transplant Education"|"The Explore Transplant Ontario (ETO) education program"
146451|NCT03046719|Drug|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
146452|NCT03046719|Drug|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
146453|NCT03046706|Behavioral|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
146454|NCT03046706|Behavioral|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
146455|NCT03046693|Drug|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
146456|NCT03046693|Drug|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
146457|NCT03046680|Other|Health Coaching|
146458|NCT03046680|Other|Multiprofessional Team|
146459|NCT03046667|Dietary Supplement|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
146460|NCT03046667|Dietary Supplement|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
146461|NCT03046654|Diagnostic Test|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os`.
146462|NCT03046654|Diagnostic Test|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
146463|NCT03046654|Diagnostic Test|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
146464|NCT03046641|Other|Continuous training|Study group I (42 participants) received the continuous training.
146465|NCT03046641|Other|The interval training|Study group II (40 participants) received the interval training.
146466|NCT03046628|Device|TcPO2|
146467|NCT03046628|Device|Green laser (at 532nm) and a fast camera|
146468|NCT03046615|Device|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
146469|NCT03046615|Device|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
146470|NCT03046589|Drug|DP13|dose escalation
146471|NCT03046589|Drug|placebo|control to dose-escalation
146472|NCT03046576|Diagnostic Test|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
146473|NCT03046563|Other|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
146474|NCT03046563|Other|Pressing the Sham points|Pressing the sham points for eight minutes
146475|NCT03046550|Drug|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies (XC41, XC42, XC44, and XC84) which bind to non-overlapping epitopes on BoNT/C/D. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
146476|NCT03046550|Drug|Placebo|placebo
146477|NCT03046537|Diagnostic Test|Breath test|Collecting breath test from participants
146478|NCT03046524|Other|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
146479|NCT03046511|Drug|Cefazolin|A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
146480|NCT03046498|Behavioral|Evidence-Based Program|DSMP and DPP
146481|NCT03046485|Behavioral|Self management program 'Living with Vision Loss'|group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
146482|NCT03046472|Other|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.~All participants will get 10-15 minutes of exercise for performing every day."
146483|NCT03046459|Biological|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
146484|NCT03046446|Drug|FX006 32 mg|Single intra-articular injection
146485|NCT03046420|Other|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
146486|NCT03046407|Biological|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
146487|NCT03046394|Device|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
146488|NCT03046394|Device|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
146489|NCT03046394|Device|A-DER|Triton by Otto Bock, advertised for activity category 3-4
146490|NCT03046381|Drug|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
146491|NCT03046368|Behavioral|Targeted cover letter|The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
146492|NCT03046355|Procedure|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
147345|NCT03040102|Other|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
146493|NCT03046355|Procedure|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
146494|NCT03046342|Diagnostic Test|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.~Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
146495|NCT03046329|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
146496|NCT03046316|Other|local consolidative treatment|local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
146497|NCT03046303|Procedure|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
146498|NCT03046290|Procedure|circumcision|
146499|NCT03046290|Drug|Lidocaine|
146500|NCT03046290|Drug|Ropivacaine|
146501|NCT03046277|Other|No intervention|No intervention
146502|NCT03046251|Drug|Natalizumab|
146503|NCT03046238|Drug|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
146504|NCT03046238|Drug|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
146505|NCT03046225|Device|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
146506|NCT03046225|Device|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
146507|NCT03046225|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
146508|NCT03046212|Device|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
146509|NCT03046212|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
146510|NCT03046199|Other|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
146511|NCT03046199|Other|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
146512|NCT03046186|Diagnostic Test|Mixed meal test with double tracer technique|
146513|NCT03046173|Other|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
146514|NCT03046173|Other|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
146515|NCT03046160|Other|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
146516|NCT03046160|Other|neck and scapular exercises.|A program of 12 neck and scapular exercises.
146517|NCT03046160|Other|corrective tape|elastic tape used to correct the anterior tilt of the scapula
146518|NCT03046147|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
146519|NCT03046134|Biological|PCV13|Conjugated pneumococcal vaccine
146520|NCT03046121|Behavioral|Family-centered Function-focused Care (Fam-FFC)|"An educational empowerment model for family CGs that includes a care pathway, provided within a social-ecological in-patient framework promoting specialized care to patients with ADRD. The intervention creates an enabling milieu for the person with ADRD through environmental and policy assessment/modification, staff education, unit-based champions, and individualized goal setting that focuses on functional recovery during hospitalization and the immediate post-acute period."
146521|NCT03046108|Device|blind injection of Morton neuroma|Introduction of a needle based in anatomical landmark
146522|NCT03046108|Drug|blind injection of Mepivacaine|blind injection of 1 cc of Mepivacaine Normon 2% ®
146523|NCT03046108|Drug|blind injection of Triamcinolone|blind injection of 40 mg of triamcinolone (trigon depot ®)
146524|NCT03046108|Device|ultrasound guided injection|Introduction of a needle based guided by ultrasound
146525|NCT03046108|Drug|guided injection of mepivacaine|ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
146526|NCT03046108|Drug|guided injection of Triamcinolone|ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
146527|NCT03046095|Other|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
146528|NCT03046095|Procedure|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
146529|NCT03046082|Drug|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
237124|NCT02385851|Drug|Pegfilgrastim|
146530|NCT03046069|Other|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
146531|NCT03046069|Other|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
146532|NCT03046069|Other|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
146533|NCT03046069|Other|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
146534|NCT03046069|Other|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
146535|NCT03046056|Drug|Filgotinib|Tablet(s) administered orally once daily
146536|NCT03046056|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
146537|NCT03046043|Procedure|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
146538|NCT03046043|Procedure|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
146539|NCT03046030|Other|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
146540|NCT03046030|Other|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles [20, 35, 104-106]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling [20, 35, 104]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
146541|NCT03046030|Other|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
146542|NCT03046030|Other|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
146543|NCT03046017|Device|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
146544|NCT03046017|Other|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
146545|NCT03046017|Other|Control cream|A neutral cream will be applied as a control.
146546|NCT03046004|Other|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
146547|NCT03046004|Other|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
146548|NCT03045991|Behavioral|aerobic exercise training|The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
146549|NCT03045991|Behavioral|control training|The control training program will receive 30 minutes non-aerobic exercise training, including stretching muscle skills, joint mobility exercises; in addition to one 30-minute session of unstructured mental activities, such as reading books or reading educational films.
146550|NCT03045991|Behavioral|cognitive training|The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
146551|NCT03045965|Procedure|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
146552|NCT03045952|Procedure|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
146553|NCT03045939|Device|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
146555|NCT03045913|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
146556|NCT03045900|Other|Shaded bulk-fill resin composite|Dental bulk-fill resin composite with shades A1, A2, A3
146557|NCT03045887|Drug|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
146558|NCT03045887|Drug|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
146559|NCT03045887|Drug|Placebo|Lactose as powder for inhalation
146560|NCT03045861|Drug|GSK2838232|GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
146561|NCT03045861|Drug|Cobicistat|Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
146562|NCT03045848|Device|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
146563|NCT03045835|Device|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
146564|NCT03045835|Device|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
146565|NCT03045822|Drug|Bioimpedance analysis|
146566|NCT03045809|Diagnostic Test|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
146567|NCT03045796|Device|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
146568|NCT03045783|Drug|Cefotiam|Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
146569|NCT03045770|Drug|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
146570|NCT03045770|Drug|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
146571|NCT03045770|Drug|Irinotecan|Irinotecan was used as first line treatment with AGC.
146572|NCT03045770|Drug|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
146573|NCT03045770|Drug|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
146574|NCT03045744|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
146575|NCT03045718|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
146576|NCT03045705|Behavioral|Routine pain management|Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman`s wishes to receive analgesia by the medical team.
146577|NCT03045705|Behavioral|No inquiry regarding analgesia|women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
146578|NCT03045692|Diagnostic Test|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
146579|NCT03045692|Diagnostic Test|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
146580|NCT03045679|Other|RYGB|laparoscopic RYGB
146581|NCT03045679|Other|OAGB/MGB|laparoscopic OAGB/MGB
146582|NCT03045666|Other|Exercise program|patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
146583|NCT03045653|Drug|Tamoxifen Oral Product|Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
146584|NCT03045640|Other|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
146585|NCT03045627|Drug|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
146586|NCT03045627|Drug|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
146587|NCT03045627|Drug|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
146588|NCT03045627|Drug|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
146589|NCT03045614|Other|No intervention|No intervention
146590|NCT03045601|Diagnostic Test|CT-FFR|Invasive FFR and CCTA With CT-FFR
146591|NCT03045601|Diagnostic Test|Stress echocardiography|Stress echocardiography and invasive FFR
146592|NCT03045588|Other|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
147346|NCT03040102|Other|Standard of Care|Standard of Care practice is used
238636|NCT02374567|Drug|Opipramol|
146593|NCT03045562|Drug|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
146594|NCT03045562|Drug|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
146595|NCT03045549|Device|Digital biofeedback system|"The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
146596|NCT03045549|Other|Conventional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
146597|NCT03045536|Device|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
146598|NCT03045523|Drug|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
146599|NCT03045523|Drug|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
146600|NCT03045523|Drug|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
146601|NCT03045510|Drug|decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
146602|NCT03045497|Drug|Perflutren Lipid Microspheres|Given IV
146603|NCT03045497|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
146604|NCT03045497|Device|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
146605|NCT03045484|Drug|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
146606|NCT03045484|Other|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
146607|NCT03045471|Drug|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
146608|NCT03045471|Drug|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
146609|NCT03045458|Device|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
146610|NCT03045458|Device|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
146611|NCT03045445|Diagnostic Test|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
146612|NCT03045445|Diagnostic Test|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
146613|NCT03045432|Other|video-teaching|By watching a video specially designed by a rehabilitation team, the participants may learn how to position their affected arm properly (30 minutes per time, twice a day for five days in a week), how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly (15 minutes per time, twice a day for five days in a week), and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy.
146614|NCT03045432|Other|oral-teaching|The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.
146615|NCT03045432|Other|regular rehabilitation program|Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
146616|NCT03045419|Procedure|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
146617|NCT03045406|Drug|Apixaban|Tablets
146618|NCT03045406|Drug|Dalteparin|Injections
146619|NCT03045393|Drug|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
146620|NCT03045380|Other|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
146621|NCT03045380|Other|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
146622|NCT03045367|Procedure|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
146623|NCT03045354|Other|Mashed potatoes|Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
146624|NCT03045354|Other|Traditional breakfast|Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
146625|NCT03045354|Other|Breakfast skipping|No breakfast
146626|NCT03045354|Other|French fries|Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
146627|NCT03045354|Other|Beans|Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
146628|NCT03045341|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
146629|NCT03045341|Behavioral|Behavioral Weight Loss (BWL) counseling|BWL counseling
146630|NCT03045341|Other|Placebo|Placebo
146631|NCT03045328|Drug|Ibrutinib|Given PO
146632|NCT03045328|Other|Laboratory Biomarker Analysis|Correlative studies
146633|NCT03045328|Other|Pharmacological Study|Correlative studies
146634|NCT03045328|Drug|Venetoclax|Given PO
146635|NCT03045315|Other|IVF Procedure|
146636|NCT03045302|Drug|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
146637|NCT03045289|Behavioral|Plant-Based Diet|Women will be provided with 3 meals daily, delivered to their home, for 8 weeks, along with a multivitamin, and will attend weekly office visits.
146638|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
146639|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
146640|NCT03045263|Behavioral|Pivotal Response Treatment|Behavioral intervention for autism
146641|NCT03045250|Device|Corneal confocal microscopy|Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
146642|NCT03045250|Procedure|Skin biopsy|Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
146643|NCT03045250|Procedure|Nerve conduction study|Nerve conduction studies will be use to assess for neuropathy.
146644|NCT03045250|Other|Blood draw|Subjects will undergo a one time blood draw for biomarkers.
146645|NCT03045237|Other|physical exercises classes|3 physical exercises classes, one of them in the pool.
146646|NCT03045224|Device|PTA, balloon angioplasty, stent|
146647|NCT03045211|Device|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table with an oscillating tabletop system. The tabletop system moves automatically and slowly (velocity of approximately 3 mm/s) from side-to-side in the horizontal plane (in a linear movement pattern) and facilitates stepping by the user to stay centered in front of the working table surface.
146648|NCT03045198|Drug|Azithromycin|
146649|NCT03045185|Procedure|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.~Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
146650|NCT03045172|Biological|Platelet Rich Plasma|PRP
146651|NCT03045172|Drug|Placebo|Saline
146652|NCT03045159|Behavioral|Strong Families Strong Forces|Parenting program
146653|NCT03045159|Behavioral|Strong Parents|self-care program
146654|NCT03045146|Other|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
146655|NCT03045133|Drug|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
146656|NCT03045133|Drug|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
146685|NCT03044873|Drug|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
146686|NCT03044860|Procedure|Double-balloon enteroscopy (DBE) with biopsy retrieval|With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every ~30 cm of the small intestine and specific locations in the large intestine
146657|NCT03045107|Procedure|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
146658|NCT03045107|Procedure|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
146659|NCT03045081|Behavioral|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
146660|NCT03045068|Biological|Platelet Transfusion|"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.~Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts~Subsequent platelet transfusion continued till completion via central venous access to the patient"
146661|NCT03045068|Biological|FFP and Cryoprecipitate|"1 unit of cryoprecipitate administered during MUF and or after MUF as needed~FFP transfusion 10ml/kg during MUF and or after MUF as needed"
146662|NCT03045068|Biological|PRBC and cell saver Transfusion|1. Transfuse for target Hematocrit > 40 in neonates with SV physiology; Transfuse for Hematocrit> 33 for 2-Ventricle physiology
146663|NCT03045068|Biological|Factor Concentrate (Bebulin)|1. Based on clinical bleeding and achievement of hemostasis
146664|NCT03045055|Device|Remote ischemic conditioning.|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 4 times.
146665|NCT03045055|Procedure|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
146666|NCT03045055|Device|Sham remote ischemic conditioning|Sham RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on unilateral arms and inflated to 60 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 4 times.
146667|NCT03045042|Drug|Enzyme Replacement Agent|Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
146668|NCT03045029|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
146669|NCT03045016|Drug|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
146670|NCT03045003|Behavioral|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
146671|NCT03044977|Drug|90Y-DOTA-3-Tyr-Octreotide|Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.
146672|NCT03044977|Drug|131I-MIBG|Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.
146673|NCT03044964|Drug|Ranolazine|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
146674|NCT03044964|Drug|Placebo|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
146675|NCT03044951|Procedure|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
146676|NCT03044951|Procedure|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
146677|NCT03044938|Drug|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
146678|NCT03044938|Drug|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
146679|NCT03044925|Procedure|Remote magnetic navigation|Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
146680|NCT03044925|Procedure|Cryoablation|Pulmonary vein isolation and other areas ablation used by cryoballoon
146681|NCT03044912|Drug|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
146682|NCT03044899|Procedure|All surgeries in adult patients|All surgeries in adult patients
146683|NCT03044886|Dietary Supplement|vitamin D|Subjects took vitamin D or placebo
146684|NCT03044873|Drug|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
146687|NCT03044847|Other|COPD group|The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
146688|NCT03044834|Other|PPB|Global current care
146689|NCT03044821|Procedure|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
146690|NCT03044808|Drug|Lidocaine|
146691|NCT03044808|Drug|Saline|
146692|NCT03044795|Drug|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
146693|NCT03044782|Other|53-Item Survey|
146694|NCT03044769|Procedure|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
146695|NCT03044756|Drug|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
146696|NCT03044743|Drug|Fludarabine|To modify immune micro-environment
146697|NCT03044743|Drug|Cyclophosphamide|To modify immune micro-environment
146698|NCT03044743|Drug|Interleukin-2|To sustain the survival of infused T cells
146699|NCT03044730|Drug|Capecitabine|Given PO
146700|NCT03044730|Other|Laboratory Biomarker Analysis|Correlative studies
146701|NCT03044730|Biological|Pembrolizumab|Given IV
146702|NCT03044717|Other|Nutrition survey|Survey will be done prior to the initiation of the education
146703|NCT03044717|Other|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
146704|NCT03044717|Other|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
146705|NCT03044691|Behavioral|ResearchACTS software|screen patients for tobacco and nicotine product use (using the anticipate and ask components of the 6As) by having youth complete a tobacco and nicotine use screening tool using the ResearchACTS software.
146706|NCT03044678|Behavioral|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
146707|NCT03044678|Behavioral|Self-Study|Books for youth about anxiety management
146708|NCT03044665|Drug|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
146709|NCT03044665|Drug|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
146710|NCT03044652|Device|WO2085 Moisturising Cream|2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
146711|NCT03044652|Drug|Estriol Cream 0.1%|0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
146712|NCT03044639|Drug|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
146713|NCT03044626|Drug|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
146714|NCT03044626|Drug|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
146715|NCT03044613|Drug|Nivolumab|240mg or 1 mg/kg administered IV
146716|NCT03044613|Drug|Relatlimab|80mg administered IV
146717|NCT03044613|Drug|Carboplatin|standard care dose
146718|NCT03044613|Drug|Paclitaxel|standard care dose
146719|NCT03044613|Radiation|Radiation|standard care dose
146720|NCT03044600|Other|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
146721|NCT03044600|Other|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
146722|NCT03044587|Drug|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
146723|NCT03044587|Drug|Arm Cisplatin + Gemcitabine (Arm B)|Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
146724|NCT03044574|Device|SCD|IPC with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
146725|NCT03044574|Device|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
146726|NCT03044574|Drug|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
146727|NCT03044561|Drug|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
146728|NCT03044561|Drug|matching placebo|orally, 4 times per day for 21 days
146768|NCT03044171|Device|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
146769|NCT03044171|Drug|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
146729|NCT03044548|Other|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.~Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.~Receivers: nurses working at HC level with children with malnutrition.~Reference guidelines:~• Current National IMAM guidelines~Attitude and philosophy:~• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
146730|NCT03044522|Other|Opioid Education|
146731|NCT03044509|Diagnostic Test|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
146732|NCT03044509|Diagnostic Test|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
146733|NCT03044496|Drug|Supraclavicular nerve block|Supraclavicular nerve block using ultrasound and 10ml ropivacaine 0.5% with 20ml mepivacaine 1%
146734|NCT03044483|Other|Measurement of sublingual microcirculatory parameters|Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
146735|NCT03044470|Other|cryotherapy|Role of cryotherapy in reduction of post operative pain
146736|NCT03044457|Procedure|TKA|"femoral and tibial positioning using the reversed gap technique"
146737|NCT03044444|Dietary Supplement|citrus extract|Participants will receive either a low or high dose citrus extract
146738|NCT03044444|Other|placebo|participants will receive 500mg of maltodextrin
146739|NCT03044431|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
146740|NCT03044418|Other|application of ET laser tube in propofol anesthesia|The special endotracheal laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
146741|NCT03044405|Diagnostic Test|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
146742|NCT03044405|Diagnostic Test|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
146743|NCT03044392|Other|Next Bolus Interval|Next Bolus Interval 15, 30, or 45 minutes
146744|NCT03044379|Drug|Dapivirine gel (0.05%)|MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
146745|NCT03044379|Other|Universal HEC placebo gel|
146746|NCT03044366|Other|general anesthesia management of preterm infants|general anesthesia management of preterm infants
146747|NCT03044353|Drug|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
146748|NCT03044353|Biological|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
146749|NCT03044340|Other|impedance measurement and pain evaluation|Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
146750|NCT03044327|Procedure|LPS challenge|LPS inhalation and bronchial instillation
146751|NCT03044314|Drug|Illoprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
146752|NCT03044301|Combination Product|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
146753|NCT03044301|Combination Product|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
146754|NCT03044301|Combination Product|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
146755|NCT03044288|Other|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
146756|NCT03044288|Other|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
146757|NCT03044275|Other|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
146758|NCT03044275|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
146759|NCT03044262|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device
146760|NCT03044262|Other|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
146761|NCT03044249|Drug|MP-101|Capsules
146762|NCT03044249|Drug|Placebo|Capsules
146763|NCT03044236|Procedure|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
146764|NCT03044210|Other|Metabolic evaluation|"diet assessment~biological evaluation~clinical evaluation~metabolic evaluation (calorimetry)"
146765|NCT03044197|Device|MRI/ultrasound transperineal prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
146766|NCT03044197|Device|transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
146767|NCT03044184|Drug|Tranexamic Acid|Transamine is an antifibrinolytic medication given systemically via the intravenous route
146770|NCT03044171|Drug|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
146771|NCT03044158|Device|GeneXpert I|Onsite molecular testing with GeneXpert I as a replacement for microscopy
146772|NCT03044158|Behavioral|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
146773|NCT03044158|Other|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
146774|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
146775|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
146776|NCT03044145|Behavioral|Treatment as usual|Standard mental health treatment at FHMC
146777|NCT03044132|Other|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
146778|NCT03044119|Biological|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
146779|NCT03044119|Biological|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
146780|NCT03044106|Device|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
146781|NCT03044093|Drug|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
146782|NCT03044093|Drug|Placebo|The group that will only get Misoprostol
146783|NCT03044093|Drug|Misoprostol|Both groups will get think drug
146784|NCT03044080|Drug|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
146785|NCT03044080|Drug|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
146786|NCT03044067|Other|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
146787|NCT03044067|Other|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
146788|NCT03044054|Device|ECHOPULSE|HIFU Under ultrasound guidance
146789|NCT03044041|Drug|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
146790|NCT03044028|Device|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
146791|NCT03044015|Behavioral|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
146792|NCT03044015|Behavioral|as usual|
146793|NCT03044002|Device|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
146794|NCT03044002|Device|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
146795|NCT03043989|Drug|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
146796|NCT03043989|Drug|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
146797|NCT03043989|Drug|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
146798|NCT03043976|Device|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
146799|NCT03043963|Behavioral|Sleep Extension|Lengthen the duration of sleep time.
146800|NCT03043963|Behavioral|Sleep Timing|Regularize the timing of the sleep period.
146801|NCT03043950|Drug|Panitumumab + FOLFIRI or FOLFOX|Patients will be scheduled to receive first line therapy with the combination of Panitumumab (6 mg / kg i.v, given once every two weeks) and FOLFIRI or FOLFOX, according to current SmPC Germany.
146802|NCT03043937|Other|registry|
146803|NCT03043924|Drug|Cyproterone Acetate + estradiol|"PCOS will receive:~50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
146804|NCT03043924|Drug|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
147347|NCT03040089|Device|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
146805|NCT03043898|Other|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
146806|NCT03043898|Other|Lung sound recording|Lung sounds are recorded using a sensor array.
146807|NCT03043885|Device|FDBA|Graft material used to graft extraction socket
146808|NCT03043885|Device|PRF|Autologous blood product used to graft extraction socket
146809|NCT03043885|Procedure|Blood Clot|Surgical treatment of extraction socket without addition of graft material
146810|NCT03043872|Drug|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
146811|NCT03043872|Drug|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
146812|NCT03043872|Drug|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
146813|NCT03043872|Drug|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
146814|NCT03043872|Drug|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
146815|NCT03043859|Behavioral|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
146816|NCT03043846|Other|Follow-up every 3 months during 1 year (data collection in eCRF)|
146817|NCT03043846|Other|Follow-up every month to follow the pre-defined strategy|
146818|NCT03043833|Behavioral|The Wellbeing Course|"The Wellbeing Course (Titov et al., 2011) includes five online lessons:~Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~Lesson 2 presents different strategies to generate realistic cognitions.~Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material."
146819|NCT03043820|Drug|Raloxifene|Oral selective estrogen receptor modulator (SERM).
146820|NCT03043820|Drug|Placebo|Tablets identical in form and color to intervention.
146821|NCT03043807|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
146822|NCT03043807|Drug|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles. Dose may decreased in the following intervals: 65 mg/M2, 55 mg/M2, 35 mg/M2.
146823|NCT03043807|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
146824|NCT03043807|Radiation|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
146825|NCT03043807|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg / day may be given at the investigator's discretion.
146826|NCT03043794|Radiation|Stereotactic Body Radiation SBRT|Stereotactic Body Radiation to the breast to 21 Gy
146827|NCT03043781|Other|Continuous epidural infusion|Continuous infusion, 5 ml/h
146828|NCT03043781|Other|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
146829|NCT03043742|Drug|Bone Marrow Derived Autologous CD133+ Selected Cell Product|Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
146830|NCT03043729|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2, as 2h infusion on Day 1 (Arm A + Arm B)
146831|NCT03043729|Drug|5-FU|5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w (Arm A + Arm B)
146832|NCT03043729|Drug|Leucovorin|Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
146833|NCT03043729|Biological|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
146834|NCT03043716|Other|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
146835|NCT03043703|Device|AirSense 10 AutoSet for Her|Positive airway pressure
146836|NCT03043690|Dietary Supplement|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
146837|NCT03043690|Other|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
146838|NCT03043677|Biological|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.~Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
146839|NCT03043664|Drug|Somatuline Depot|Somatuline depot (Lanreotide depot) 90mg SQ every 3 weeks
146840|NCT03043664|Drug|Keytruda|Keytruda (pembrolizumab) 200mg IV every 3 weeks
146841|NCT03043651|Drug|Oral Treprostinil|Sustained-release oral tablets for TID administration
146842|NCT03043638|Procedure|CAF+ADM+PRP|CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
146843|NCT03043638|Procedure|CAF+ADM|CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
146879|NCT03043469|Other|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
146880|NCT03043469|Other|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
147348|NCT03040089|Drug|Neoquine Cream 2%|2% hydroquinone cream
146844|NCT03043625|Other|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
146845|NCT03043625|Other|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
146846|NCT03043612|Device|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
146847|NCT03043612|Device|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
146848|NCT03043599|Radiation|Thoracic Radiation Therapy|All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).
146849|NCT03043599|Drug|Ipilimumab|Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.
146850|NCT03043599|Drug|Nivolumab|Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.
146851|NCT03043573|Behavioral|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
146852|NCT03043573|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
146853|NCT03043560|Drug|Ezogabine|daily for 5 weeks
146854|NCT03043560|Drug|Placebos|placebo pill daily for 5 weeks
146855|NCT03043547|Drug|nal-IRI|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion)
146856|NCT03043547|Drug|5-FU|5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion)
146857|NCT03043547|Drug|leucovorin|leucovorin (400 mg/m2 as 0.5 hour infusion)
146858|NCT03043534|Other|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:~WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
146859|NCT03043534|Other|Brush|All subjects randomized to brush will use the brush with each shave
146860|NCT03043521|Drug|Dexlansoprazole 60 MG|
146861|NCT03043521|Drug|CJ-12420 50mg|
146862|NCT03043521|Drug|CJ-12420 100mg|
146863|NCT03043521|Drug|CJ-12420 200mg|
146864|NCT03043508|Other|Chart Review|Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
146865|NCT03043508|Behavioral|Questionnaire|Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
146866|NCT03043495|Procedure|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
146867|NCT03043495|Drug|Dexamethasone|Various doses of Dexamethasone (2, 4 & 8 mg) to be used as an Adjuvant to Local anesthetic drugs
146868|NCT03043482|Drug|Single VS-105/placebo to healthy|In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
146869|NCT03043482|Drug|Multiple VS-105/placebo to healthy|In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
146870|NCT03043482|Drug|Multiple VS-105/placebo to HD subjects|In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
146871|NCT03043469|Other|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
146872|NCT03043469|Other|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
146873|NCT03043469|Other|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
146874|NCT03043469|Other|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
146875|NCT03043469|Other|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
146876|NCT03043469|Other|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
146877|NCT03043469|Other|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
146878|NCT03043469|Other|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
147372|NCT03039920|Other|Conventional cigarette|
146881|NCT03043469|Diagnostic Test|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
146882|NCT03043469|Other|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
146883|NCT03043469|Other|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
146884|NCT03043469|Other|Breath-hold test|Holding the breath a few times for as long as possible.
146885|NCT03043469|Other|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
146886|NCT03043469|Other|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
146887|NCT03043456|Device|Thermoplastic complete denture|A device used to substitute the teeth for edentulous patients made of thermoplastic resin
146888|NCT03043456|Device|Conventional acrylic resin complete denture|A device used to substitute the teeth for edentulous patients made of acrylic resin
146889|NCT03043443|Drug|Melatonin|Natural health product for sleep problems treatment
146890|NCT03043443|Drug|Placebo|Lactose containing pills
146891|NCT03043430|Drug|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
146892|NCT03043430|Drug|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
146893|NCT03043417|Behavioral|CHC's given the intervention|CHC's NOT given the intervention
146894|NCT03043404|Device|Transcatheter aortic valve replacement|TAVR with Lotus Valve Flex System
146895|NCT03043391|Biological|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
146896|NCT03043378|Behavioral|Questionnaires|Participants complete three questionnaires at consultation visit.
146897|NCT03043365|Drug|control fish oil|4 capsules, 3 times a day after meals
146898|NCT03043365|Drug|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
146899|NCT03043352|Dietary Supplement|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
146900|NCT03043352|Dietary Supplement|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
146901|NCT03043339|Other|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
146902|NCT03043339|Other|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
146903|NCT03043339|Other|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
146904|NCT03043339|Other|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
146905|NCT03043326|Drug|Tenofovir Disoproxil Fumarate and Emtricitabine|This is an observational study. Pre-exposure Prophylaxis with TDF/3TC will be distributed to all participants elegible to receive PrEP.
146906|NCT03043313|Drug|Trastuzumab|Given intravenously (into the vein; IV)
146907|NCT03043313|Drug|Tucatinib|Given orally
146908|NCT03043300|Other|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.~This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
146909|NCT03043300|Other|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.~This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
146910|NCT03043300|Other|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
146911|NCT03043300|Other|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.~This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
147373|NCT03039907|Procedure|Total Knee Arthroplasty|Total knee arthroplasty
238637|NCT02374567|Drug|Trimipramine|
146912|NCT03043300|Other|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
146913|NCT03043300|Other|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.~This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
146914|NCT03043300|Other|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.~The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
146915|NCT03043287|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
146916|NCT03043274|Drug|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
146917|NCT03043261|Behavioral|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
146918|NCT03043248|Drug|TRK-700|repeated oral administration
146919|NCT03043248|Drug|Digoxin|single oral administration with/without TRK-700
146920|NCT03043248|Drug|Midazolam|single oral administration with/without TRK-700
146921|NCT03043222|Device|UroLift as artifical device for prostatic urethral lift.|UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
146922|NCT03043222|Device|Embospheres Microspheres as embolic agents for prostate artery embolization|Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
146923|NCT03043209|Genetic|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
146924|NCT03043196|Drug|SRP plus Rosuvastatin gel|SRP followed by Rosuvastatin placement into intrabony defect
146925|NCT03043196|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
146926|NCT03043183|Procedure|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
146927|NCT03043170|Device|Ultrasound Cardiac Output Monitor|a device for assessing haemodynamics continuously and non-invasively using Doppler wave ultrasound
146928|NCT03043157|Drug|rocuronium|intravenous rocuronium infusion
146929|NCT03043144|Other|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
146930|NCT03043144|Other|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
146931|NCT03043144|Other|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
146932|NCT03043144|Other|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
146933|NCT03043144|Other|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
146934|NCT03043144|Other|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
146935|NCT03043131|Drug|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
146936|NCT03043131|Drug|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
146937|NCT03043118|Other|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
146938|NCT03043105|Drug|Thalidomide, cyclophosphamide and prednisone|"Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;~Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;~Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
146939|NCT03043079|Diagnostic Test|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
146940|NCT03043066|Procedure|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
146941|NCT03043066|Drug|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
146942|NCT03043053|Drug|oxytocin nasal spray|oxytocin intranasal spray
146943|NCT03043053|Drug|Placebo|Placebo nasal spray
146944|NCT03043040|Behavioral|Telephone follow up|Already described in previous page
146945|NCT03043040|Behavioral|Treatment as usual|Already described in previous page
146946|NCT03043027|Drug|liposomal bupivicaine|local anesthetic
146947|NCT03043027|Drug|Bupivacaine|local anesthetic
146948|NCT03043027|Drug|Saline Solution|saline injection
146984|NCT03042741|Biological|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
146985|NCT03042741|Biological|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
146986|NCT03042728|Behavioral|Dog Interaction|A therapy dog will visit the patients.
146987|NCT03042728|Behavioral|Human Interaction|A human will visit the patients.
149341|NCT03025009|Drug|Placebo|Administered SC.
146949|NCT03043014|Drug|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
146950|NCT03043001|Drug|Memantine|All the subjects will receive add-on memantine for 12 week
146951|NCT03042988|Other|Heating pad|Heat stress applied on the trunk for up to 8 hours
146952|NCT03042988|Other|Sham control|heating pad turned off applied on the trunk for up to 8 hours
146953|NCT03042975|Other|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
146954|NCT03042975|Procedure|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
146955|NCT03042962|Other|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
146956|NCT03042962|Procedure|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
146957|NCT03042949|Device|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
146958|NCT03042949|Device|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
146959|NCT03042936|Behavioral|Insulin Superheroes Club Curriculum|This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
146960|NCT03042923|Drug|lactulose:mannitol (L:M) oral challenge|
146961|NCT03042910|Drug|Talazoparib|Talazoparib 1 mg orally once daily.
146962|NCT03042897|Dietary Supplement|Dietary Intervention|Undergo DASH diet
146963|NCT03042897|Behavioral|Exercise Intervention|Undergo in aerobic exercise
146964|NCT03042897|Other|Laboratory Biomarker Analysis|Correlative studies
146965|NCT03042897|Other|Quality-of-Life Assessment|Ancillary studies
146966|NCT03042884|Behavioral|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.~Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.~Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.~At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
146967|NCT03042884|Device|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.~Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
146968|NCT03042871|Drug|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
146969|NCT03042858|Other|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
146970|NCT03042858|Other|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
146971|NCT03042845|Device|Tiger cardiac catheter|Tiger cardiac catheter
146972|NCT03042845|Device|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
146973|NCT03042832|Behavioral|LOCI|Leadership development with coaching and organizational change support
146974|NCT03042832|Behavioral|WEBINAR|Webinar leadership training
146975|NCT03042819|Drug|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
146976|NCT03042819|Drug|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
146977|NCT03042806|Behavioral|questionnaire|all the COPD patients will be ask to complete the questionnaire
146978|NCT03042793|Biological|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
146979|NCT03042780|Drug|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
146980|NCT03042780|Drug|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
146981|NCT03042767|Biological|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
146982|NCT03042767|Other|Placebo|Matched Placebo
146983|NCT03042754|Diagnostic Test|XpertMTB/RIF|
146988|NCT03042715|Behavioral|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
146989|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
146990|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
146991|NCT03042689|Drug|Regorafenib|Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
146992|NCT03042663|Procedure|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
146993|NCT03042650|Behavioral|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
146994|NCT03042650|Behavioral|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
146995|NCT03042637|Drug|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
146996|NCT03042624|Dietary Supplement|Fermented rice|7 g of powder obtained from Lactobacillus paracasei CBA L74
146997|NCT03042624|Dietary Supplement|Maltodextrins|7 g of maltodextrins powder
146998|NCT03042611|Drug|Apatinib|Daily oral dose of Apatinib plus Best Supportive Care defined as palliative non-cancer therapy at the Investigator's discretion
146999|NCT03042611|Other|Placebo|Daily oral dose of Placebo with Best Supportive Care defined as palliative non-cancer therapy at the Investigator's discretion
147000|NCT03042598|Device|Biphasic Cuirass Ventilation|The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
147001|NCT03042585|Radiation|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
147002|NCT03042572|Drug|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5*10^6 MSC per site; total 150*10^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
147003|NCT03042572|Other|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
147004|NCT03042559|Device|Protonics Knee brace|The Protonics system has been introduced to physical therapists as a potential treatment for PFPS. The system includes a brace set to resist knee flexion and a set of specific exercises to perform daily. Through resistance to knee flexion, the system is advertised to decrease retropatellar contact pressure due to changes in pelvis inclination and available hip rotation. Specifically, resistance to knee flexion is purported to increase hamstring activity and inhibit the activity of the tensor fasciae latae and psoas muscles. The manufacturer asserts that prolonged use of the system results in greater hamstring activation, which leads to permanent structural changes through reciprocal inhibition at the hip and pelvis. The warm-up consisted of the subject wearing the ProtonicsTM knee brace set at a moderate resistance level and flexing the knees while sitting, standing, and reclining in the supine and prone positions.
147005|NCT03042559|Device|Sports Cords|Subjects assigned to the sport cord group were asked to do the same warm-ups and exercises using the sport cord in the supine, standing, sitting, and prone positions. prone. The only difference is that subjects were asked to only walk backwards instead of forwards in order to avoid activation of the hip flexor muscle. The appropriate level of resistance for each subject was calculated by multiplying their weight in pounds by 0.3. Subjects were then given either light, medium, or heavy resistance cords according to the following classification scheme: light (pink color) with resistance 3 (R3), 0-30 lbs.; medium (orange color) with resistance 5 (R5) 0-50 lbs.; heavy (yellow color) with resistance 7 (R7) 0-70 lbs. All subjects completed three study visits, and a total of four measurements were taken at baseline, immediately following the first session, at two weeks, and at 4 weeks.
147006|NCT03042546|Drug|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
147007|NCT03042546|Drug|PMMA|PMMA with abx will be used in the defect
147008|NCT03042546|Other|No treatment|The defect will not be treated
147009|NCT03042533|Device|Conventional Compression|Method of Nail fitting
147010|NCT03042533|Device|Standard Backslapping|Method of Nail fitting
147011|NCT03042533|Device|Dynamic Locking with Backslapping|Method of Nail fitting
147012|NCT03042520|Other|Observation only|
147013|NCT03042507|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
147014|NCT03042494|Dietary Supplement|Control|Isocaloric food without the test prebiotic.
147015|NCT03042494|Dietary Supplement|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
147016|NCT03042468|Drug|177Lu-PSMA-617|177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
149342|NCT03024996|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
147017|NCT03042468|Drug|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging
147018|NCT03042455|Device|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.~The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
147019|NCT03042455|Device|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
147020|NCT03042455|Other|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
147021|NCT03042442|Diagnostic Test|Point-of care biomarkers|Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC
147022|NCT03042442|Other|Clinical, venous blood samples, pancreatic tissue|Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.
147023|NCT03042442|Other|Follow-up|Participants will be assessed (by telephone) over a period of 2 years
147024|NCT03042429|Drug|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
147025|NCT03042429|Drug|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
147026|NCT03042416|Drug|18F-DOPA|18F-DOPA intravenous injection single dose
147027|NCT03042403|Other|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
147028|NCT03042377|Other|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
147029|NCT03042377|Drug|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
147030|NCT03042377|Drug|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid & antibiotic paste and the cavity was filled with temporary restorative material.
147031|NCT03042377|Drug|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
147032|NCT03042364|Other|Pipelle de Cornier|RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
147033|NCT03042351|Device|Magic Kegel app|Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
147034|NCT03042338|Behavioral|CET: Central Executive Training|CET: Central Executive Training
147035|NCT03042338|Behavioral|CET: Comparison Executive Training|CET: Comparison Executive Training
147036|NCT03042325|Drug|Alogliptin|Alogliptin tablets
147037|NCT03042312|Drug|Lu177-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
147038|NCT03042299|Drug|TAK-536|TAK-536 granules.
147039|NCT03042299|Drug|TAK-536|TAK-536 tablet.
147040|NCT03042273|Dietary Supplement|High Strength Cranberry|Softgel capsule
147041|NCT03042273|Dietary Supplement|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
147042|NCT03042260|Drug|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
147043|NCT03042260|Drug|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
147044|NCT03042234|Other|Group I|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
147604|NCT03038152|Device|Medical Device|Receive Magseed via ultrasound guided injection
147045|NCT03042234|Other|Group II|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
147046|NCT03042234|Other|Group III|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
147047|NCT03042208|Other|Self guided handout|Written handout with basic weight management strategies
147048|NCT03042208|Behavioral|Weight Watchers|Access to Weight Watchers in-person meetings and online tools
147049|NCT03042195|Other|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
147050|NCT03042182|Biological|Oral therapeutic vaccine V3-X to treat cholangiocarcinoma|One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
147051|NCT03042169|Drug|Preoperative Chemotherapy|Standard chemotherapy regiments according to risk of recurrence
147052|NCT03042169|Procedure|Surgery|the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
147053|NCT03042169|Drug|Postoperative chemotherapy|Chemotherapy should be restarted between D1 and D30 post-randomization
147054|NCT03042156|Radiation|Palliative Radiation Therapy|
147055|NCT03042143|Biological|Human umbilical cord derived CD362 enriched MSCs|Infusion of Human umbilical cord derived CD362 enriched MSCs
147056|NCT03042143|Biological|Placebo (Plasma-Lyte 148)|Infusion of placebo
147057|NCT03042130|Other|Standard of care|standard of care
147058|NCT03042130|Drug|Iron Carboxymaltose|Two IV doses
147059|NCT03042117|Other|periodontal probing|A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
147060|NCT03042104|Device|Edwards SAPIEN 3 THV|Patients in experimental arm will receive SAPIEN 3 THV.
147061|NCT03042091|Drug|Polyethylene Glycol|Given orally
147062|NCT03042091|Drug|Neomycin|Given orally
147063|NCT03042091|Drug|Metronidazole Hydrochloride|Given orally
147064|NCT03042091|Procedure|Therapeutic Conventional Surgery|Undergo colorectal resection
147065|NCT03042078|Device|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
147066|NCT03042078|Device|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
147067|NCT03042065|Device|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
147068|NCT03042065|Device|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
147069|NCT03042052|Drug|detrusor infection of Botulinum toxin|detrusor injection
147070|NCT03042039|Other|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
147071|NCT03042013|Drug|ASP8273|Oral
147072|NCT03042000|Other|non-NCRT|without the preoperative concurrent chemoradiothearpy (no neoadjuvant chemoradiation)
147073|NCT03042000|Other|NCRT|the preoperative concurrent chemoradiothearpy (neoadjuvant chemoradiation)
147074|NCT03042000|Drug|capecitabine with oxaliplatin|combined chemotherapy with capecitabine with oxaliplatin
147075|NCT03042000|Drug|capecitabine|single-agent chemotherapy with capecitabine
147076|NCT03042000|Procedure|TEM|transanal endoscopic microsurgery (TEM) excision of the lesion
147077|NCT03042000|Procedure|radical resection|radical resection of rectal cancer
147078|NCT03041987|Other|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
147079|NCT03041974|Procedure|Red Blood Cell transfusion|
147080|NCT03041974|Procedure|Microparticles quantification|Flow cytometric quantification of microparticles in transfused blood
147081|NCT03041961|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
147082|NCT03041961|Dietary Supplement|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
147083|NCT03041961|Dietary Supplement|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
147084|NCT03041948|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
147085|NCT03041948|Procedure|Caudal-epidural nerve block|See arm description
147086|NCT03041948|Drug|Acetaminophen|See arm description
147087|NCT03041948|Drug|Sevoflurane|See arm description
147088|NCT03041948|Drug|Remifentanil|See arm description
147089|NCT03041948|Drug|Propofol|See arm description
147090|NCT03041948|Drug|Morphine|See arm description
147091|NCT03041948|Drug|Ondansetron|See arm description
147092|NCT03041948|Drug|Dexamethasone|See arm description
147093|NCT03041948|Drug|Ketorolac|See arm description
147094|NCT03041935|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
147095|NCT03041935|Procedure|Caudal-epidural nerve block|See arm description
147096|NCT03041935|Drug|Acetaminophen|See arm description
147097|NCT03041935|Drug|Sevoflurane|See arm description
147098|NCT03041935|Drug|Remifentanil|See arm description
147099|NCT03041935|Drug|Propofol|See arm description
147100|NCT03041935|Drug|Morphine|See arm description
147101|NCT03041935|Drug|Ondansetron|See arm description
147102|NCT03041935|Drug|Dexamethasone|See arm description
147103|NCT03041935|Drug|Ketorolac|See arm description
147104|NCT03041935|Drug|Ropivacaine|See arm description
147105|NCT03041909|Drug|GBT440|Oral drug
147106|NCT03041896|Device|coflex® Interlaminar Technology|Interlaminer Technology
147107|NCT03041883|Procedure|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
147108|NCT03041883|Procedure|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
147109|NCT03041870|Device|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of [11C]DASB bolus.
147110|NCT03041857|Radiation|Observational use of fluoroscopy|
147111|NCT03041844|Device|Low Frequency, Low Intensity Ultrasound|Therapeutic ultrasound (20 kHz, <100 mW/cm2 spatial peak-temporal peak)
147112|NCT03041844|Device|Sham Applicator|Sham ultrasound applicator
147113|NCT03041818|Behavioral|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
147114|NCT03041805|Procedure|EVLT|Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
147115|NCT03041805|Procedure|RFA|Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
147116|NCT03041805|Procedure|USFS|Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
147117|NCT03041805|Procedure|HL/stripping|High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
147118|NCT03041805|Procedure|Miniphlebectomy|Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
147119|NCT03041805|Procedure|Sclerotherapy|Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
147120|NCT03041805|Device|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
147121|NCT03041805|Drug|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
147122|NCT03041792|Drug|Liraglutide|Liraglutide
147123|NCT03041792|Other|Placebo|Placebo
147124|NCT03041779|Drug|Diclofenac Sodium 50Mg Suppository|
147125|NCT03041779|Drug|Paracetamol 500Mg Suppository|
147126|NCT03041766|Biological|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
147127|NCT03041766|Drug|GLA-SE solution|Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
147128|NCT03041740|Drug|Perfluorooctyl Bromide|Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
147129|NCT03041727|Other|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
147130|NCT03041727|Other|Standard exercises protocol|Stretching and strengthening exercises
147131|NCT03041701|Drug|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
147132|NCT03041701|Drug|Ganitumab|Once every 2 weeks beginning on day 0.
147133|NCT03041688|Drug|Decitabine|Given IV
147134|NCT03041688|Drug|MDM2 Inhibitor AMG-232|Given PO
147135|NCT03041675|Device|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
147136|NCT03041675|Device|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
147137|NCT03041662|Diagnostic Test|MR/MRCP|MR/MRCP
147138|NCT03041649|Other|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
147139|NCT03041649|Other|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
147140|NCT03041636|Drug|Ruxolitinib|Given PO
147141|NCT03041636|Drug|Ruxolitinib Phosphate|Given PO
147142|NCT03041610|Behavioral|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
147143|NCT03041597|Procedure|placement of implants|surgical procedure and placement of implants
147144|NCT03041597|Procedure|immediate loading|cone-anchored implant supported removable dental prostheses placement
147145|NCT03041597|Procedure|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
147146|NCT03041597|Device|Ankylos implant|
147147|NCT03041584|Procedure|Guided placement|implant placement with use of guide
147148|NCT03041584|Procedure|Non-guided placement|conventional implant placement
147149|NCT03041584|Device|Astra Tech TX implant|
147150|NCT03041571|Behavioral|Patient Provider Orientation Scale|Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
147179|NCT03041389|Behavioral|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
238638|NCT02374567|Drug|Amitriptyline|
147151|NCT03041571|Behavioral|Interview performed by MHP student|"The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system."
147152|NCT03041558|Behavioral|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
147153|NCT03041558|Behavioral|SafeCare (SC)|SafeCare intervention as usual
147154|NCT03041545|Device|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
147155|NCT03041532|Procedure|Proximal retroflexion|The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
147156|NCT03041532|Procedure|Frontal view|The investigator explore twice right colon with frontal viewing
147157|NCT03041519|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
147158|NCT03041519|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
147159|NCT03041506|Drug|Lidocaine|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
147160|NCT03041506|Procedure|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.~Lidocaine 2%: 15 -20 ml."
147161|NCT03041506|Drug|Midazolam|IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
147162|NCT03041506|Drug|Ketamine|IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
147163|NCT03041493|Behavioral|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
147164|NCT03041493|Behavioral|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
147165|NCT03041493|Behavioral|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
147166|NCT03041480|Diagnostic Test|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
147167|NCT03041467|Device|IN.PACT AV Access DCB|IN.PACT™ AV Access Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
147168|NCT03041467|Device|Standard Balloon Angioplasty Catheter|Standard PTA Balloon
147169|NCT03041454|Other|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
147170|NCT03041441|Device|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
147171|NCT03041441|Procedure|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
147172|NCT03041441|Procedure|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
147173|NCT03041428|Device|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
147174|NCT03041415|Behavioral|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
147175|NCT03041415|Behavioral|ALED + Our Voice PA Program|"12-week class focused on teaching self-regulatory skills to increase regular PA~Neighborhood assessment, consensus-building, & advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
147176|NCT03041402|Other|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
147177|NCT03041402|Other|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
147178|NCT03041402|Other|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
147213|NCT03041103|Other|Food Product 1|50 grams of fortified nutritious product from legumes
238639|NCT02374567|Drug|Nortriptyline|
147180|NCT03041389|Behavioral|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
147181|NCT03041376|Behavioral|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
147182|NCT03041363|Drug|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
147183|NCT03041350|Other|Smartphone video-assisted ALS(advanced life support)|As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated
147184|NCT03041337|Diagnostic Test|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.~The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
147185|NCT03041324|Biological|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
147186|NCT03041311|Drug|Trilaciclib|Trilaciclib IV
147187|NCT03041311|Drug|Placebo|Placebo IV
147188|NCT03041311|Drug|Carboplatin|Carboplatin IV
147189|NCT03041311|Drug|Etoposide|Etoposide IV
147190|NCT03041311|Drug|Atezolizumab|Atezolizumab IV
147191|NCT03041298|Procedure|MR mammography with Dotarem|
147192|NCT03041285|Drug|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository) daily from Day 0(1 day before radiotherapy) until 7 days after radiotherapy. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 0 until 7 days after radiotherapy.~All patients will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 fractions.~Radiotherapy session will involve irradiation of 1-2 lesions.~."
147193|NCT03041285|Radiation|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive one course of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 20 Gray in 5 daily fractions on consecutive days. Radiotherapy session (week 1) will involve irradiation to 1-2 lesions.
147194|NCT03041259|Drug|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
147195|NCT03041259|Drug|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
147196|NCT03041246|Procedure|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
147197|NCT03041233|Other|Observation / Data Collection|"The following data will be reviewed / collected:~BASELINE VISIT: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.~ABLATION PROCEDURE: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).~6 and 12 MONTH FOLLOW-UP (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
147198|NCT03041220|Procedure|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
147199|NCT03041207|Behavioral|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
147200|NCT03041194|Other|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
147201|NCT03041181|Drug|Docetaxel|Docetaxel 75 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
147202|NCT03041181|Drug|Nivolumab|Nivolumab 360 mg IV Day 1 of each cycle (21 days = 1 cycle)
147203|NCT03041181|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV Day 1 and Day 8 of each cycle (21 days = 1 cycle)
147204|NCT03041181|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV Day 1 of each cycle (21 days = 1 cycle)
147205|NCT03041168|Device|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
147206|NCT03041155|Behavioral|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
147207|NCT03041142|Behavioral|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
147208|NCT03041142|Other|Routine|The participants continued to maintain their routine
147209|NCT03041129|Diagnostic Test|oral glucose tolerance test|6 hours OGTT
147210|NCT03041129|Diagnostic Test|MRI of liver|MRI of the liver and use of DIXON method
147211|NCT03041116|Drug|fosmetpantotenate (RE-024)|Daily dosing
147212|NCT03041116|Drug|Placebo|Daily dosing
147262|NCT03040726|Drug|Palonosetron Hydrochloride|Given PO
147214|NCT03041090|Device|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
147215|NCT03041077|Dietary Supplement|Instaflex Advanced|Joint function
147216|NCT03041077|Dietary Supplement|Placebo|Placebo
147217|NCT03041064|Other|50/100|SPF
147218|NCT03041064|Other|100/50|SPF
147219|NCT03041051|Biological|PCV13|
147220|NCT03041051|Biological|PPV23|
147221|NCT03041038|Drug|Secukinumab|Anti IL-17A antibody
147222|NCT03041038|Drug|Placebo|
147223|NCT03041025|Drug|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
147224|NCT03041025|Drug|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
147225|NCT03041012|Drug|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
147226|NCT03041012|Drug|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
147227|NCT03041012|Drug|Antiretrovirals|Combination antiretroviral therapy
147228|NCT03040999|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
147229|NCT03040999|Drug|Placebo|Normal saline or dextrose solution administered as an IV infusion Q3W
147230|NCT03040999|Drug|Cisplatin|100 mg/m^2 administered as an IV infusion Q3W
147231|NCT03040999|Radiation|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
147232|NCT03040999|Radiation|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
147233|NCT03040986|Other|Laboratory Biomarker Analysis|Correlative studies
147234|NCT03040986|Drug|Selumetinib Sulfate|Given PO
147235|NCT03040973|Drug|capmatinib|tablet for oral use 400 mg BID
147236|NCT03040947|Other|Cardiovascular Magnetic Resonance|
147237|NCT03040934|Device|Firehawk sirolimus target eluting coronary stent system|98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system
147238|NCT03040934|Device|XIENCE Everolimus-Eluting Coronary Stent System|98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
147239|NCT03040921|Procedure|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
147240|NCT03040895|Other|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
147241|NCT03040895|Other|Treatment as usual|Treatment as usual through the data collection period (6 months)
147242|NCT03040882|Other|cotton sock|Application of a cotton sock in the immediate postoperative period before applied the Walker
147243|NCT03040882|Other|Elastic Compression Wraps|Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
147244|NCT03040856|Dietary Supplement|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
147245|NCT03040856|Dietary Supplement|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
147246|NCT03040856|Other|Placebo|Placebo capsules containing olive oil
147247|NCT03040830|Drug|Progesterone 100 IM/day|Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
147248|NCT03040817|Procedure|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:~A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.~B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.~D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.~E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
147249|NCT03040817|Drug|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
147250|NCT03040804|Radiation|Low dose Radiotherapy|Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
147251|NCT03040791|Drug|Nivolumab|Nivolumab
147252|NCT03040778|Drug|Pentoxifylline|Pentoxifylline is a commonly used medication for muscle pain associated with peripheral artery disease. It is a methylated xanthine derivative that improves peripheral blood flow, flexibility of red blood cell membranes, microcirculation, and tissue oxygenation and reduces viscosity of blood.
147253|NCT03040778|Drug|Placebo|Placebo tablets
147254|NCT03040778|Drug|Tocopherol|Tocopherol (vitamin E) impairs tissue fibrosis and is a potent oxygen radical scavenger that may reduce damage caused by free radicals impacting necrosis.
147255|NCT03040765|Drug|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 20 patients with b-thalassemia major
147256|NCT03040765|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 20 patients with b-thalassemia major
147257|NCT03040752|Drug|Nifedipine 20 Mg|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
147258|NCT03040752|Drug|Ritodrine Oral Tablet|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
147259|NCT03040739|Other|use of O'ARM imaging system|use of O'ARM imaging system
147260|NCT03040726|Drug|Netupitant|Given PO
147261|NCT03040726|Drug|Palonosetron|Given PO
147263|NCT03040726|Other|Placebo|Given PO
147265|NCT03040713|Drug|18F-AV-1451|Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
147266|NCT03040713|Drug|18F-AV-45|Subjects with no qualifying amyloid scan within three years will receive single IV administration of 370 MBq (10 mCi) of 18F-AV-45 prior to enrollment as a screening assessment
147267|NCT03040700|Other|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
147268|NCT03040700|Other|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX—Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
147269|NCT03040687|Biological|Anti CS6 BSIgG product (Lot PD1601105CS)|
147270|NCT03040687|Biological|Anti B7A BSIgG product (Lot PD1601132ET)|
147271|NCT03040687|Biological|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
147272|NCT03040687|Biological|B7A- CS6-expressing ETEC challenge strain|
147273|NCT03040674|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
147274|NCT03040661|Procedure|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
147275|NCT03040648|Device|DSA|DSA was used for detection of intravascular injection
147276|NCT03040648|Device|RTF|RTF was used for detection of intravascular injection
147277|NCT03040635|Drug|Risdiplam|Single oral doses of Risdiplam will be administered on Day 1.
147278|NCT03040635|Drug|Placebo|Single oral doses of Risdiplam matching placebo will be administered on Day 1.
147279|NCT03040622|Device|WATCHMAN Left Atrial Appendage Closure|WATCHMAN Left Atrial Appendage Closure
147280|NCT03040609|Behavioral|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
147281|NCT03040609|Behavioral|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
147282|NCT03040609|Behavioral|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
147283|NCT03040596|Drug|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
147284|NCT03040596|Behavioral|Standard voice therapy|Standard voice therapy sessions
147285|NCT03040583|Other|No intervention|Patients data will be collected during their disease follow-up
147286|NCT03040570|Procedure|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
147287|NCT03040570|Procedure|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining >94%.
147288|NCT03040557|Device|Flexible footwear|- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
147289|NCT03040557|Device|Orthopedic insole|- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
147290|NCT03040544|Procedure|LTB-Curriculum|The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 MIS experts as a benchmark. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of MIS basic skills comparable to the expert level.
147291|NCT03040544|Procedure|Laparoscopic cholecystectomy|Performing Laparoscopic cholecystectomy by surgical residents without previous experience in MIS
147292|NCT03040531|Dietary Supplement|Genistein aglycone|27mg bid in tablets
147293|NCT03040531|Drug|Alendronate Oral Tablet|70 mg/week in tablets
147294|NCT03040531|Dietary Supplement|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
147295|NCT03040518|Behavioral|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
147296|NCT03040518|Behavioral|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
147297|NCT03040505|Other|questionnary|Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
147298|NCT03040479|Drug|lasmiditan 200 mg|single dose
147299|NCT03040466|Device|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
147300|NCT03040466|Device|reusable digital ureteroscope|We will use reusable digital ureteroscopes for the treatment of kidney and ureter stones.
149343|NCT03024996|Other|Placebo|Placebo matching to atezolizumab q3w
147301|NCT03040466|Device|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
147302|NCT03040453|Device|Microwave ablation|
147303|NCT03040453|Device|Irreversible electroporation|
147304|NCT03040440|Device|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated
147305|NCT03040440|Device|TaperGaurd endotracheal tube|TaperGaurd endotracheal tube was intubated
147306|NCT03040427|Drug|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
147307|NCT03040414|Device|MedtronicMinimed 670G 3.0 hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID).
147308|NCT03040414|Device|Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and Guardian Sensor (3).
147309|NCT03040401|Drug|Cohort 1, Ceplene® and Proleukin®|"Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
147310|NCT03040401|Drug|Cohort 2, Ceplene® and Proleukin®|"Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
147311|NCT03040401|Drug|Cohort 3, Ceplene® and Proleukin®|"Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.~IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
147312|NCT03040375|Behavioral|Peer counselling|
147313|NCT03040362|Drug|[14C]-lasmiditan|[14C]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
147314|NCT03040349|Behavioral|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
147315|NCT03040349|Behavioral|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
147316|NCT03040349|Behavioral|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
147317|NCT03040336|Behavioral|Prehabilitation|The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
147318|NCT03040323|Drug|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
147319|NCT03040323|Drug|Placebos|Placebos injected prior to ultrasound-guided biopsy
147320|NCT03040310|Other|Back Rx program|The Back Rx program can be viewed via a smartphone app.
147321|NCT03040297|Device|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
147322|NCT03040297|Device|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
147323|NCT03040297|Device|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
147324|NCT03040284|Device|Echodia® hand-held equipment (ELIOS)|
147325|NCT03040271|Other|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
147326|NCT03040258|Other|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
147327|NCT03040245|Behavioral|Whiplash book|
147328|NCT03040232|Other|biomechanical assessment|biomechanical and strength assessment of both groups
147329|NCT03040219|Drug|Folic Acid|Tablets
147330|NCT03040193|Drug|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
147331|NCT03040193|Drug|Saline Nebulization|Normal Saline Delivered via Nebulization
147332|NCT03040180|Drug|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
147333|NCT03040180|Device|EndoVE|Electroporation using an endoscopic electroporation device
147334|NCT03040167|Procedure|PEC 1 block|Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
147335|NCT03040167|Drug|Bupivacaine with epinephrine|Treatment group
147336|NCT03040167|Drug|Normal saline|Placebo group
147337|NCT03040154|Other|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
147338|NCT03040154|Other|Usual Care Video that is publicly available|
147339|NCT03040141|Drug|Low dose of VIS410|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
147340|NCT03040141|Drug|High dose of VIS410|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
147341|NCT03040141|Drug|Placebo|Single intravenous infusion of placebo in addition to oseltamivir
147349|NCT03040076|Behavioral|Cognitive Bias Treatment|Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
147350|NCT03040076|Behavioral|Relaxation Condition|Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
147351|NCT03040063|Procedure|Combined endovascular approach (EVAR)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Heparin 70-80 IU/kg i.a.~implantation of peripheral stent graft VIABAHN~implantation of peripheral stent SUPERA into stent graft~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards~control angiography in 12 hrs or earlier according to clinical status and symptoms~repeated angiography in 24 hrs"
147352|NCT03040063|Procedure|Standard optimal therapy (OPT)|"puncture of SFA in orthograde position if possible~DSA through 4F dilator, proof of occlusion~wire test~Unfractionated heparin 70-80 IU/kg i.a.~insertion of strait flush catheter for local thrombolysis~administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)~control angiography in 12 hrs or according to clinical status and symptoms~repeated angiography in24 hrs~Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
147353|NCT03040050|Other|rPCR results|Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
147354|NCT03040050|Other|Control group|Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
147355|NCT03040024|Drug|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
147356|NCT03040024|Drug|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
147357|NCT03040024|Device|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
147358|NCT03040011|Drug|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
147359|NCT03040011|Drug|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
147360|NCT03040011|Procedure|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
147361|NCT03040011|Procedure|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
147362|NCT03040011|Drug|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
147363|NCT03039985|Device|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
147364|NCT03039985|Device|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
147365|NCT03039972|Diagnostic Test|No intervention|No intervention
147366|NCT03039959|Diagnostic Test|No intervention|No intervention
147367|NCT03039946|Device|Closed-Loop GDFT|Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
147368|NCT03039946|Other|Restrictive Fluid Therapy|Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
147369|NCT03039933|Behavioral|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
147370|NCT03039933|Other|Treatment As Usual|Treatment As Usual
147371|NCT03039920|Device|Electronic cigarette|
147374|NCT03039894|Other|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
147375|NCT03039881|Device|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
147376|NCT03039855|Device|TIARA valve and transapical delivery system|Transcatheter mitral valve replacement
147377|NCT03039842|Drug|Dextromethorphan|
147378|NCT03039842|Drug|Memantine|
147379|NCT03039842|Drug|dextromethorphan+memantine|
147380|NCT03039842|Drug|placebo+valproate|
147381|NCT03039829|Dietary Supplement|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
147382|NCT03039829|Dietary Supplement|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
147383|NCT03039829|Dietary Supplement|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
147384|NCT03039816|Device|Nasaleze|Nasaleze cellulose powder
147385|NCT03039816|Device|Placebo|Lactose powder in the same plastic container as Nasaleze and with the same taste
147386|NCT03039803|Procedure|uterine closure during cesarean section|
147387|NCT03039790|Biological|NoV Vaccine|No NoV vaccine injection administered.
147388|NCT03039764|Device|Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
147389|NCT03039751|Drug|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
147390|NCT03039751|Drug|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
147391|NCT03039738|Device|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) & Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
147392|NCT03039738|Device|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
147393|NCT03039725|Other|Observational|Retrospective chart review on vaccine compliance
147394|NCT03039699|Drug|Ergoferon|
147395|NCT03039699|Drug|Placebo|
147396|NCT03039686|Drug|RO7239361|Take RO7239361 subcutaneously on specified days over a 48 week blinded period
147397|NCT03039686|Drug|Placebo for RO7239361|Take placebo subcutaneously on specified days over a 48 week blinded period
147398|NCT03039673|Drug|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS."
147399|NCT03039673|Drug|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available."
147400|NCT03039673|Drug|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
147401|NCT03039660|Behavioral|RefreshMD|Online Sleep Improvement Course
147402|NCT03039660|Behavioral|Bond Between Us|Online Educational Course
147403|NCT03039621|Drug|Ergoferon|
147404|NCT03039621|Drug|Placebo|
147405|NCT03039608|Drug|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）|local steroid injection and oral steroid
147406|NCT03039608|Drug|oral steroid administration（prednisone）|oral steroid
147407|NCT03039595|Other|Ploidy and tumour:stromal ratio measurements|Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)
147408|NCT03039582|Diagnostic Test|Bidigital palpation|palpation of the anovaginal distance with two fingers
147409|NCT03039582|Diagnostic Test|Perineal ultrasound|ultrasound measurement of the anovaginal distance
147410|NCT03039569|Behavioral|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
147411|NCT03039556|Behavioral|Normal Daily Steps|Complete normal daily ambulation for one week
147412|NCT03039556|Behavioral|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
147413|NCT03039556|Behavioral|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
147414|NCT03039543|Drug|Rocuronium|Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
147415|NCT03039543|Drug|Sugammadex|Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
147416|NCT03039530|Behavioral|Group Cognitive Behavioral Therapy|9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.
147417|NCT03039530|Behavioral|Postnatal Care As Usual|Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
150395|NCT03017287|Device|GlucoMe App|Assessment of the the GlucoMe App
147418|NCT03039517|Device|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
147419|NCT03039517|Device|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
147420|NCT03039504|Dietary Supplement|Potensa, a succinate-based dietary supplement|Potensa - a dietary supplement: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
147421|NCT03039504|Dietary Supplement|Placebo|Placebo: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
147422|NCT03039491|Biological|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
147423|NCT03039491|Biological|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
147424|NCT03039478|Dietary Supplement|Xylitol 7g|Xylitol 7g in 300mL tap water
147425|NCT03039478|Dietary Supplement|Erythritol 10g|Erythritol 10g in 300mL tap water
147426|NCT03039478|Dietary Supplement|Xylitol 17g|Xylitol 17g in 300mL tap water
147427|NCT03039478|Dietary Supplement|Xylitol 35g|Xylitol 35g in 300mL tap water
147428|NCT03039478|Dietary Supplement|Erythritol 25g|Erythritol 25g in 300mL tap water
147429|NCT03039478|Dietary Supplement|Erythritol 50g|Erythritol 50g in 300mL tap water
147430|NCT03039465|Device|Modified Trans-Esophageal Prosthesis|This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
147431|NCT03039452|Behavioral|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
147432|NCT03039439|Procedure|Biospecimen Collection|Previously collected tumor tissue and blood samples
147433|NCT03039439|Other|Laboratory Biomarker Analysis|Correlative studies
147434|NCT03039426|Drug|Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
147435|NCT03039426|Drug|Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
147436|NCT03039413|Drug|Copper Cu 64 TP3805|Given IV
147437|NCT03039413|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
147438|NCT03039413|Procedure|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
147439|NCT03039400|Behavioral|Physiotherapist-guided home exercise with web-based support|
147440|NCT03039400|Behavioral|Physiotherapist-guided home exercise with standard support|
147441|NCT03039387|Device|anodal transcranial direct current stimulation|
147442|NCT03039387|Device|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
147443|NCT03039374|Other|Magnetic resonance imaging|The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
147444|NCT03039361|Behavioral|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
147445|NCT03039348|Other|semi-structured interview using a questionnaire|semi-structured interview using a questionnaire
147446|NCT03039322|Diagnostic Test|Serum Golgi Protein 73|Serum test
147447|NCT03039309|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
147448|NCT03039296|Procedure|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
147449|NCT03039283|Device|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
147450|NCT03039270|Other|With sonic activation (SMART Device®)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
147451|NCT03039270|Other|Control (Without sonic activation)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
147452|NCT03039257|Dietary Supplement|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
147681|NCT03037593|Drug|4000 IU vitamin D3|vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
147453|NCT03039244|Other|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
147454|NCT03039244|Other|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
147455|NCT03039244|Device|Diode Laser|
147456|NCT03039231|Device|Freespira Breathing System|Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
147457|NCT03039218|Device|Dornier Aries 2|Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
147458|NCT03039218|Device|Placebo / Sham|Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
147459|NCT03039205|Drug|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
147460|NCT03039205|Drug|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
147461|NCT03039192|Drug|Esketamine|Intranasal esketamine solution 84 milligram (mg)
147462|NCT03039192|Other|Placebo|Intranasal Placebo solution
147463|NCT03039179|Device|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
147464|NCT03039166|Device|MRI 7T|
147465|NCT03039166|Device|MRI 3 T|
147466|NCT03039166|Biological|blood sample|
147467|NCT03039140|Other|Educational Intervention|Attend weekly educational sessions
147468|NCT03039140|Behavioral|Exercise Intervention|Participate in CR program
147469|NCT03039140|Other|Quality-of-Life Assessment|Ancillary studies
147470|NCT03039140|Other|Questionnaire Administration|Ancillary studies
147471|NCT03039127|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
147472|NCT03039114|Drug|Parsaclisib|Parsaclisib at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
147473|NCT03039114|Drug|Hexal|Bendamustine 90 mg/m^2 administered intravenously at protocol-defined timepoints.
147474|NCT03039114|Drug|Gazyvaro|Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
147475|NCT03039101|Procedure|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
147476|NCT03039101|Procedure|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
147477|NCT03039101|Procedure|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
147478|NCT03039101|Procedure|Peripheral blood|Peripheral blood draw
147479|NCT03039101|Drug|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
147480|NCT03039101|Drug|Placebo Oral Tablet|one pill orally, daily, for 1 week
147481|NCT03039088|Other|Follow-up after 12 weeks after TNF alpha blockers initiation|
147482|NCT03039075|Drug|Metformin SR Tablet|Metformin SR Tablet made in Conquer pharmaceutical co., LTD
147483|NCT03039049|Drug|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
147484|NCT03039036|Procedure|Amniotomy|Artificially rupturing membranes
147485|NCT03039036|Device|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
147486|NCT03039036|Drug|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
147487|NCT03039023|Dietary Supplement|Choline Bitartrate|500mg choline bitartrate tablets
147488|NCT03039023|Other|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
147489|NCT03039023|Other|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
147490|NCT03038984|Behavioral|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
147491|NCT03038984|Behavioral|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
147492|NCT03038971|Biological|Dose Level 1|Short and Tall Ragweed Mix
147493|NCT03038971|Biological|Dose Level 2|Short and Tall Ragweed Mix
147494|NCT03038971|Biological|Placebo|Saline with 0.4% Phenol
147495|NCT03038958|Drug|Isobaric 2-chloroprocaine|intrathecal injection of 50 mg isobaric 2-Chloroprocaine
147496|NCT03038958|Drug|Hyperbaric prilocaine|intrathecal injection of 50 mg hyperbaric prilocaine 2%
147497|NCT03038945|Other|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
147498|NCT03038945|Other|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
147499|NCT03038919|Drug|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
147500|NCT03038919|Other|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
147501|NCT03038893|Diagnostic Test|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
147502|NCT03038893|Diagnostic Test|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
147503|NCT03038880|Drug|Faricimab|Faricimab will be administered via IVT injections as specified during the treatment period.
147504|NCT03038880|Drug|Ranibizumab|Ranibizumab will be administered via IVT injections as specified during the treatment period.
147505|NCT03038867|Drug|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
147506|NCT03038867|Other|Placebo|Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
147507|NCT03038854|Other|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
147508|NCT03038854|Other|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
147509|NCT03038854|Other|Cows' milk|Homogenized store-bought full fat cow's milk.
147510|NCT03038841|Device|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
147511|NCT03038828|Biological|Leukocyte Interleukin, Injection|Immunotherapy
147512|NCT03038815|Device|VACOped|restriction of ankle joint motion
147513|NCT03038815|Device|Ortho Tri|restriction of ankle joint motion
147514|NCT03038802|Biological|Therapeutic hepatitis B vaccine|HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
147515|NCT03038802|Biological|Commercial Hepatitis B vaccine|Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
147516|NCT03038776|Biological|Recombinant influenza hemagglutinin|Avian H7N9 influenza vaccine
147517|NCT03038763|Other|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
147518|NCT03038763|Diagnostic Test|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
147519|NCT03038750|Other|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
147520|NCT03038750|Other|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
147521|NCT03038750|Other|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
147522|NCT03038750|Other|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
147523|NCT03038750|Other|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
147524|NCT03038750|Other|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
147525|NCT03038750|Other|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
147526|NCT03038750|Other|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
147527|NCT03038750|Other|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
147528|NCT03038750|Other|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
147529|NCT03038750|Other|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
147530|NCT03038750|Other|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
147531|NCT03038750|Other|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
147532|NCT03038750|Other|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
147533|NCT03038750|Other|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
147534|NCT03038750|Other|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
147535|NCT03038750|Other|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
147536|NCT03038750|Other|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
147537|NCT03038750|Other|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
147538|NCT03038750|Other|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
147539|NCT03038737|Other|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).~The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
147540|NCT03038737|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
147541|NCT03038724|Diagnostic Test|Rapid HIV test|
147542|NCT03038711|Drug|BMS-986166|Specified dose on specified days
147543|NCT03038711|Other|Placebo matching BMS-986166|Specified dose on specified days
147544|NCT03038685|Behavioral|Strokecoach.be - digital coaching program for stroke patients|The stroke coach gives patients two education sessions during hospitalization (risk factor management, review of medications and clinical evolution). During these sessions, study participation will be proposed. Eligibility will partially depend on their historical use of the internet and e-mail. The aim is to have the digital platform personalized for his/her individual needs, risk factors and remaining neurologic signs/symptoms. Tips and tricks to deal with lifestyle modification will be delivered on regular basis. Meanwhile, patients will be asked to complete on a pre-specified frequency their data regarding their cardiovascular risk profile. Additionally, participants will be contacted at 0.5-1-2 and 6 months by phone calls or videoconsultancy. To standardize, an adapted, digital version of the standardized WSO Post-Stroke Checklist shall be used as a decision-support flowchart. A report of the consultation will be derived after the videoconsultancy.
147545|NCT03038672|Biological|Nivolumab|Given IV
147546|NCT03038672|Drug|Varlilumab|Given IV
147547|NCT03038659|Device|Penile Duplex|Measuring intima media thickness
147548|NCT03038646|Drug|MIN-101|
147549|NCT03038633|Other|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
147550|NCT03038620|Drug|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
147551|NCT03038620|Drug|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
147552|NCT03038607|Drug|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
147553|NCT03038594|Drug|Somatropin|
147554|NCT03038594|Drug|0.09% Saline Solution|
147555|NCT03038568|Diagnostic Test|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
147556|NCT03038542|Behavioral|Gain-framed text messages|
147557|NCT03038542|Behavioral|Standard care text messages|
147558|NCT03038529|Procedure|Classic postrolateral extraarticular percutaneous approach for O3 injection|Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
147559|NCT03038529|Procedure|Postrolateral transforaminal approach (Yess approach ) for O3 injection|Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
147560|NCT03038516|Drug|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
147561|NCT03038516|Device|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
147562|NCT03038503|Drug|Methylene Blue|after defined refractory shock (need NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
147563|NCT03038503|Drug|Terlipressin|after defined refractory shock (need NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
147564|NCT03038490|Dietary Supplement|ABOUND|an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
147565|NCT03038477|Drug|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
147566|NCT03038464|Diagnostic Test|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
147567|NCT03038451|Drug|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
147568|NCT03038438|Device|Abre venous self-expanding stent system|venous stent
147569|NCT03038425|Drug|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
147570|NCT03038425|Drug|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
147571|NCT03038399|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
147572|NCT03038399|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
147573|NCT03038399|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
147574|NCT03038399|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
147605|NCT03038139|Other|Cervical exercises|Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
147682|NCT03037580|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
147575|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
147576|NCT03038373|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
147577|NCT03038347|Behavioral|Training|Six modules containing PDF-files with text-based information, video files, case studies with associated questions and practical exercises. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules and associated exercises once a week. After six weeks the training is completed.
147578|NCT03038347|Behavioral|Education only|Six modules containing only PDF-files with text-based information. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules once a week. After six weeks the education is completed.
147579|NCT03038334|Dietary Supplement|Magnesium sulfate|Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
147580|NCT03038321|Drug|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
147581|NCT03038321|Drug|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
147582|NCT03038321|Drug|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
147583|NCT03038308|Drug|Ropinirole|
147584|NCT03038295|Drug|Propranolol|Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
147585|NCT03038295|Drug|placebo|Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
147586|NCT03038282|Dietary Supplement|Chromium Chloride|Transdermal chromium chloride 50 to 600 mcg/day.
147587|NCT03038282|Other|Individual Exercise|Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
147588|NCT03038269|Behavioral|Upper Extremity Robotics, tDCS|Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
147589|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
147590|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.~XELOX:~Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks~Surgery Procedure:~Total Mesorectal Excision"
147591|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
147592|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10^11 Sf2WC cells administered orally on Days 0, 28, and 56
147593|NCT03038243|Other|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
147594|NCT03038230|Drug|MCLA-117 bispecific antibody|MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
147595|NCT03038217|Drug|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
147596|NCT03038217|Procedure|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
147597|NCT03038217|Procedure|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
147598|NCT03038217|Other|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
147599|NCT03038204|Procedure|The papillary muscle approximation|"Surgery is performed through median sternotomy, aortic and bicaval cannulation, normothermic perfusion, and antegrade cardioplegia with the use of cardioplegic solution.~After coronary anastomosis, the mitral valve is exposed by a transseptal incision.~The papillary muscles are approximated through the mitral valve at the level of papillary muscles heads. Nonabsorbable, braided sutures of 2-0 (Ethibond, Ethicon, Inc.) with PTFE felt pledgets are used for this purpose.~Annuloplasty mitral rings of different sizes are anchored using multiple deep U-shaped stitches of Ethibond 2-0 (Ethicon, Inc., USA). After MV repair, the LV is forcefully filled with saline water to test the valve competence. After satisfactory hydraulic test walls of the heart chambers are sutured."
147600|NCT03038191|Device|Neuroelectrics Enobio 8(R)|Monitoring
147601|NCT03038178|Drug|LAI plus multi-drug regimen|Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
147602|NCT03038152|Procedure|Axillary Lymph Node Dissection|Undergo targeted axillary lymph node dissection
147603|NCT03038152|Procedure|Localization|Undergo axillary lymph node localization
147731|NCT03037203|Other|Placebo|
147606|NCT03038139|Other|Lumosacral exercises|Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
147607|NCT03038126|Other|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
147608|NCT03038126|Other|Usual care|Standard clinical care
147609|NCT03038113|Drug|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.
147610|NCT03038113|Drug|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
147611|NCT03038113|Drug|Immune Modulator|Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.
147612|NCT03038100|Drug|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m^2) IV infusion on Day 1 of each 21-day cycle
147613|NCT03038100|Drug|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) on Day 1 of each 21-day cycle for a total of 6 cycles
147614|NCT03038100|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
147615|NCT03038100|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
147616|NCT03038100|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
147617|NCT03038087|Device|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:~A molded plastic headpiece containing the antenna array, and~A processing control unit.~The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
147618|NCT03038061|Other|Patients undergoing Laparoscopic Surgery|Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
147619|NCT03038048|Procedure|Varying needle size with intravitreal ranibizumab or aflibercept|Varying gauge of needle, 33 gauge vs 30 gauge
147620|NCT03038035|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
147621|NCT03038035|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
147622|NCT03038022|Drug|MGL-3196|Oral
147623|NCT03038022|Drug|Placebo|Oral
147624|NCT03038009|Drug|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
147625|NCT03037996|Other|patients' response|patients' satisfaction to anesthesia services
147626|NCT03037983|Device|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
147627|NCT03037983|Device|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
147628|NCT03037970|Drug|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
147629|NCT03037970|Other|Placebo|Collagen Wound Dressing wetted with buffer.
147630|NCT03037957|Device|ARIES Group A Strep Assay|
147631|NCT03037944|Drug|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
147632|NCT03037944|Device|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
147633|NCT03037931|Drug|Ferric carboxymaltose|Intravenous Iron
147634|NCT03037931|Drug|Placebos|Normal Saline Solution
147635|NCT03037918|Dietary Supplement|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
147636|NCT03037905|Device|SignatureSuite OR Integration System by STERIS Corporation|SignatureSuite OR Integration System by STERIS Corporation is a device that controls audio and visual components of the operating room environment in order to provide a more relaxing and calming operating room environment for patients prior to surgery and on emergence from anesthesia after surgery.
147637|NCT03037892|Drug|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
147638|NCT03037892|Drug|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
147639|NCT03037892|Drug|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
147640|NCT03037879|Other|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
147680|NCT03037606|Drug|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
238640|NCT02374567|Drug|Doxepin|
147641|NCT03037879|Other|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
147642|NCT03037879|Other|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
147643|NCT03037879|Other|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
147644|NCT03037866|Behavioral|LifeSkills Training for College|The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
147645|NCT03037853|Other|Healthy volunteers|MRI scanner
147646|NCT03037840|Device|Low intensity amplitude-modulated RF EMFs|Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
147647|NCT03037827|Procedure|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
147648|NCT03037827|Device|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
147649|NCT03037814|Device|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
147650|NCT03037814|Device|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
147651|NCT03037814|Device|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
147652|NCT03037814|Device|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
147653|NCT03037801|Device|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
147654|NCT03037788|Drug|WO3979|Application of cream to each axilla
147655|NCT03037788|Drug|WO3970|Application of cream to each axilla
147656|NCT03037788|Drug|WO3992|Application of cream to each axilla
147657|NCT03037788|Drug|Placebo (WO3988)|Application of cream to each axilla
147658|NCT03037775|Other|Baseline|measurement of baseline hemodynamic parameters
147659|NCT03037775|Device|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
147660|NCT03037775|Device|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
147661|NCT03037775|Device|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
147662|NCT03037762|Procedure|Flexible Endoscopic Evaluation of Swallowing|
147663|NCT03037749|Drug|Alcohol beverage|Alcohol beverage
147664|NCT03037749|Drug|Placebo beverage|Placebo beverage
147665|NCT03037736|Drug|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
147666|NCT03037736|Drug|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
147667|NCT03037736|Drug|Normal saline|Normal saline will be used as the placebo.
147668|NCT03037723|Other|CT simulation|
147669|NCT03037710|Device|HealthPatch|A multi-sensor device to collect continuous vital signs
147670|NCT03037697|Other|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
147671|NCT03037697|Other|Traditional Treatment|"Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
147672|NCT03037684|Diagnostic Test|neurophysiology|electrophysiologic measurements of peripheral nerves
147673|NCT03037671|Device|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
147674|NCT03037658|Other|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).~Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
147675|NCT03037645|Drug|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
147676|NCT03037632|Behavioral|Family Heart Talk Booklet|
147677|NCT03037619|Behavioral|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
147678|NCT03037619|Behavioral|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
147679|NCT03037606|Drug|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
150752|NCT03014804|Other|Laboratory Biomarker Analysis|Correlative studies
147683|NCT03037580|Drug|Placebo|Placebo (sugar pill) for TID oral administration
147684|NCT03037567|Behavioral|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
147685|NCT03037554|Device|Sleepwear with Lateralized Thermal Characteristics|Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
147686|NCT03037554|Device|Sham-Lateralized Sleepwear|Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
147687|NCT03037541|Drug|Carac Cream|Carac Cream will be used once daily for seven consecutive days
147688|NCT03037541|Drug|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
147689|NCT03037528|Behavioral|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
147690|NCT03037528|Behavioral|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
147691|NCT03037528|Behavioral|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
147692|NCT03037528|Behavioral|dietary tracking|Participants will be asked to track their diet consistently.
147693|NCT03037515|Drug|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
147694|NCT03037502|Behavioral|Intervention|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 120 African American and 120 Latino men; to compare changes in HbA1c, diabetes risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 6-months
147695|NCT03037489|Drug|MIV-711|MIV-711 administered orally once daily
147696|NCT03037476|Behavioral|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
147697|NCT03037476|Behavioral|In-person PFI|A 1.5 hour in-person brief personalized feedback intervention utilizing a motivational interviewing approach to discuss the student's PSM misuse, alcohol and other drug use, and review personalized graphic feedback.
147698|NCT03037450|Procedure|Miniinvasive corneal neurotization|Neurotization of a neurotrophic cornea
147699|NCT03037437|Drug|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
147700|NCT03037437|Drug|Hydroxychloroquine (HCQ)|400mg by mouth daily
147701|NCT03037424|Drug|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
147702|NCT03037424|Drug|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
147703|NCT03037411|Device|Peripheral stenting|stent implantation during the index procedure
147704|NCT03037398|Device|Vercise Deep Brain Stimulation System|
147705|NCT03037385|Drug|pralsetinib (BLU-667)|pralsetinib (BLU-667) is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
147706|NCT03037372|Drug|ART, Atorvastatin|ART, Atorvastatin
147707|NCT03037372|Drug|ART, Rosuvastatin|ART, Rosuvastatin
147708|NCT03037372|Drug|ART, No statin|ART, No statin
147709|NCT03037372|Drug|Healthy-HIV-negative|Age-matched, Healthy HIV-negative
147710|NCT03037359|Biological|Bivigam|Human immune globulin
147711|NCT03037359|Biological|Other|Human immune globulin
147712|NCT03037346|Other|Questionnaire Administration|Complete questionnaires about MPOAD
147713|NCT03037346|Other|Questionnaire Administration|Ancillary studies
147714|NCT03037346|Other|Video|Watch educational video
147715|NCT03037333|Procedure|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
147716|NCT03037333|Procedure|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
147717|NCT03037320|Procedure|comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth|
147718|NCT03037307|Other|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
147719|NCT03037307|Other|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
147720|NCT03037307|Other|Negative Control|No adhesive
147721|NCT03037294|Dietary Supplement|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
147722|NCT03037294|Drug|Preoperative intra-articular corticosteroid injection|Intra-articular injection of corticosteroid (combination of betamethasone and bupivacaine) 2 weeks before surgery.
147723|NCT03037281|Diagnostic Test|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
147724|NCT03037268|Device|Lytro Plenoptic Camera and 28D lens|"visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~screened and consented for study~subjected to bilateral plenoptic ophthalmoscopy~mydriatic, single-field fundus images obtained~images reviewed for quality and diagnostic utility by a masked grader"
147725|NCT03037255|Other|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
147726|NCT03037242|Procedure|Transtibial pullout technique|Evaluating radographs
147727|NCT03037229|Device|Smartphone ECG|
147728|NCT03037229|Device|Standard 12-lead ECG|
147729|NCT03037216|Other|Exercise Intervention|10 Week aerobic exercise training
147730|NCT03037203|Drug|JZP-110|75 mg, 150 mg, 300 mg
147732|NCT03037190|Other|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
147733|NCT03037164|Device|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
147734|NCT03037164|Device|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
147735|NCT03037151|Drug|Grazaoprevir/Elbasavir|treatment naive
147736|NCT03037151|Drug|Grazaoprevir/Elbasavir/RBV|treatment experienced
147737|NCT03037138|Other|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
147738|NCT03037125|Procedure|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
147739|NCT03037125|Procedure|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
147740|NCT03037112|Behavioral|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
147741|NCT03037112|Behavioral|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
147742|NCT03037099|Behavioral|Enhanced GI Concept Education|
147743|NCT03037073|Drug|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
147744|NCT03037073|Drug|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
147745|NCT03037060|Other|[11C]-(+)-PHNO PET scan|PET scan
147746|NCT03037060|Other|Alcohol Self-Administration|Session for assessing motivation for consuming alcohol.
147747|NCT03037060|Other|Craving Task|Cue exposure paradigm
147748|NCT03037060|Other|MRI scan|MRI scan scan to analyze the PET data will be administered.
147749|NCT03037060|Other|Neuropsychological Assessment|Cognitive questionnaires administered over course of study.
147750|NCT03037047|Drug|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
147751|NCT03037047|Drug|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
147752|NCT03037034|Device|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
147753|NCT03037008|Device|Perineal Sonography|In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
147754|NCT03036995|Drug|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
147755|NCT03036995|Other|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
147756|NCT03036943|Radiation|Fluciclovine|Fluciclovine (18F) PET/CT scan completed >= 48 hours prior to surgical resection for breast cancer
147757|NCT03036930|Other|Laboratory Biomarker Analysis|Correlative studies
147758|NCT03036930|Other|Questionnaire Administration|Ancillary studies
147759|NCT03036930|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
147760|NCT03036904|Drug|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
147761|NCT03036904|Drug|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
147762|NCT03036904|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
147763|NCT03036904|Drug|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
147764|NCT03036904|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
147799|NCT03036644|Device|e-cigarette (PG+VG with nicotine; high temperature)|
147765|NCT03036904|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
147766|NCT03036904|Drug|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
147767|NCT03036891|Drug|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
147768|NCT03036891|Drug|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
147769|NCT03036878|Other|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
147770|NCT03036865|Drug|BOS161721|Single dose administered IV or SC
147771|NCT03036865|Drug|Placebo|Single dose administered IV or SC
147772|NCT03036852|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
147773|NCT03036839|Drug|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
147774|NCT03036826|Drug|Piperacillin/tazobactam|antiinfective therapy with Piperacillin/Tazobactam within routine care
147775|NCT03036826|Drug|Meropenem|antiinfective therapy with Meropenem within routine care
147776|NCT03036813|Drug|voxelotor|
147777|NCT03036813|Other|Placebo|
147778|NCT03036800|Drug|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
147779|NCT03036800|Other|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
147780|NCT03036787|Behavioral|family based intervention|behavioural advises to family for normal motor development
147781|NCT03036774|Procedure|Ultrasonic measurement of antral area|"Antral area is measured by ultrasound using a curvilinear abdominal probe of 2-5 MHz and a Logiq E (General Electrics) type echograph or equivalent.~Ultrasound is done before the induction of general anesthesia. Three consecutive measurements of the anteroposterior (AP) and cranio-caudal (CC) diameters are performed.~Antral area (CSA expressed in mm²) is show by the following formula: CSA = AP × CC × π / 4.~Antral area will correspond to the average of the three measures."
147782|NCT03036761|Procedure|Auriculotherapy|3 sessions of auriculotherapy at one month intervals.
147783|NCT03036748|Dietary Supplement|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 5 consecutive days.
147784|NCT03036748|Drug|Tbl amiloride|Drug: Amiloride Amiloride tablet 10-20 mg two times daily (morning and afternoon) for one day
147785|NCT03036735|Device|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
147786|NCT03036722|Other|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
147787|NCT03036722|Other|Placebo control porridge|control porridge matched for energy and fat content.
147788|NCT03036709|Drug|VRC-HIVMAB01060-00-AB (VRC01)|"VRC01 will be administered at a dose of 40 mg/kg intravenously every 3 weeks for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.~The first dose of VRC01 will be administered on the same day that antiretroviral therapy (ART) is interrupted. In the simian model, VRC01 administered intravenously achieved peak serum levels within one hour of infusion and was slowly metabolized with an average half-life of 7.61 days.The second infusion of VRC01 will occur at the midpoint of this highest risk period."
147789|NCT03036709|Other|Sodium Chloride for Injection USP, 0.9%|Normal saline (Sodium Chloride for Injection USP, 0.9%) will be administered intravenously every three weeks to participants assigned to the placebo arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.
147790|NCT03036696|Other|Pregnant Mothers Interview|"Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.~Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
147791|NCT03036696|Other|Breastfeeding Mothers Interview|"Breastfeeding mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.~Data collection for breastfeeding mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.~The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
147792|NCT03036683|Device|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
147793|NCT03036683|Device|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
147794|NCT03036657|Device|MAC acupuncture needles|"Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture~Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
147795|NCT03036657|Device|Electrostimulator 6c.Pro, Pantheon Research, Venice, CA|"Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture~Used for Interventions:~Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min"
147796|NCT03036644|Device|e-cigarette (PG+VG without nicotine; low temperature)|
147797|NCT03036644|Device|e-cigarette (PG+VG with nicotine; low temperature)|
147798|NCT03036644|Device|e-cigarette (PG+VG without nicotine; high temperature)|
147800|NCT03036644|Other|tobacco cigarette|
147801|NCT03036618|Dietary Supplement|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
147802|NCT03036618|Dietary Supplement|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
147803|NCT03036605|Drug|Bupivacaine|%0.5 bupivacaine
147804|NCT03036605|Drug|Dexamethasone|8 mg Dexamethasone
147805|NCT03036592|Behavioral|Early OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
147806|NCT03036592|Behavioral|Late OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
147807|NCT03036579|Device|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
147808|NCT03036566|Device|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
147809|NCT03036553|Other|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
147810|NCT03036540|Device|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
147811|NCT03036527|Procedure|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
147812|NCT03036527|Procedure|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
147813|NCT03036527|Procedure|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
147814|NCT03036514|Device|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
147815|NCT03036514|Drug|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
147816|NCT03036501|Drug|[^14C]-Risdiplam|[^14C]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries [μCi]) of [14C]-labeled Risdiplam.
147817|NCT03036488|Biological|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
147818|NCT03036488|Drug|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
147819|NCT03036488|Drug|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
147820|NCT03036488|Drug|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
147821|NCT03036488|Drug|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
147822|NCT03036488|Drug|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
147823|NCT03036488|Drug|Placebo|normal saline solution or dextrose: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
147824|NCT03036488|Biological|Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim|For prevention of neutropenia, filgrastim 5 μg/kg/day via subcutaneous (SC) injection administered per standard of care after chemotherapy OR pegfilgastrim 100 µg/kg (individualized) or 6 mg (general approach) via SC injection administered per standard of care.
147825|NCT03036475|Device|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
147826|NCT03036462|Drug|Iron|i.v. iron administration
147827|NCT03036462|Drug|Saline|i.v. NaCl administration
147828|NCT03036449|Behavioral|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply~- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.~Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..~Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.~Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
147829|NCT03036436|Behavioral|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
147830|NCT03036423|Behavioral|Online video education|
147831|NCT03036423|Behavioral|Computerized mental exercises|
147832|NCT03036410|Device|standard telephone setting|without streaming function
147833|NCT03036410|Device|DECT|cordless telephone (streaming to both hearing devices)
147834|NCT03036410|Device|EasyCall|accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
147835|NCT03036410|Device|DuoPhone|streaming function, which provides the speech signal to both ears
147836|NCT03036397|Drug|SRX246|180mg qam/ 120mg qhs for 5-7 days
147837|NCT03036397|Drug|Placebo|twice daily for 5-7 days
147838|NCT03036384|Drug|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of 60mg of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 5µg of sufentanyl
147839|NCT03036384|Drug|HB Prilocaine 2%|The dose of 60mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 5µg of sufentanyl
147840|NCT03036384|Drug|Sufentanil|5µg sufentanyl
147841|NCT03036384|Drug|Morphine|100 µgMorphine
147842|NCT03036371|Behavioral|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
147843|NCT03036358|Other|teledermatology consult|Information from the dermatologic assessment will be entered into the patients chart.
147844|NCT03036358|Other|Routine Care|The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
147845|NCT03036345|Device|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
147846|NCT03036332|Behavioral|Aerobic interval training|Carried out 3 times per week for 16 weeks
147847|NCT03036319|Device|Active tDCS|Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
147848|NCT03036319|Device|Sham tDCS|Participants will receive sham tDCS for up to 260 sessions
147849|NCT03036319|Behavioral|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 260 sessions
147850|NCT03036319|Device|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
147851|NCT03036319|Device|Sham tACS|Participants will receive sham transcranial alternating current stimulation for up to 260 sessions
147852|NCT03036319|Device|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA per electrode for up to 40 minutes for up to 260 sessions
147853|NCT03036319|Device|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 260 sessions
147854|NCT03036306|Drug|SCX-001|Nefopam cream formulation
147855|NCT03036306|Other|Placebo|Cream formulation without Nefopam
147856|NCT03036293|Drug|Tenoten|Safety and Efficiency
147857|NCT03036293|Drug|Placebo|Safety and Efficiency
147858|NCT03036280|Drug|Elenbecestat (E2609)|tablet
147859|NCT03036280|Drug|Placebo|tablet
147860|NCT03036280|Drug|Elenbecestat (E2609)|tablet
147861|NCT03036267|Behavioral|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
147862|NCT03036267|Other|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
147863|NCT03036254|Device|HBOT intervention|HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure above the ambient atmosphere.
147864|NCT03036254|Device|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
147865|NCT03036241|Device|Conventional angioplasty|Angioplasty with conventional balloon
147866|NCT03036241|Device|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
147867|NCT03036228|Drug|Karonudib|Dose escalation of administration with oral solution of Karonudib.
147868|NCT03036215|Behavioral|PACT Experimental Arm|The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
147869|NCT03036202|Drug|Epinephrine|This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
147870|NCT03036189|Behavioral|baa nnilah|7 meetings in the community led by a trained community facilitator
147871|NCT03036176|Behavioral|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
147872|NCT03036176|Other|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
147873|NCT03036163|Drug|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
147874|NCT03036163|Drug|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
147875|NCT03036163|Drug|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
147876|NCT03036163|Drug|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
147877|NCT03036163|Drug|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
147878|NCT03036163|Drug|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
147879|NCT03036163|Drug|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
147880|NCT03036150|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
147881|NCT03036150|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
147882|NCT03036137|Device|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
147883|NCT03036137|Device|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
238641|NCT02374567|Drug|Maprotiline|
147884|NCT03036124|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
147885|NCT03036124|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
147886|NCT03036111|Drug|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
147887|NCT03036111|Procedure|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
147888|NCT03036098|Biological|nivolumab|Specified Dose on Specified Days
147889|NCT03036098|Biological|ipilimumab|Specified Dose on Specified Days
147890|NCT03036098|Drug|gemcitabine|Specified Dose on Specified Days
147891|NCT03036098|Drug|cisplatin|Specified Dose on Specified Days
147892|NCT03036098|Drug|carboplatin|Specified Dose on Specified Days
147893|NCT03036085|Drug|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
147894|NCT03036085|Drug|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
147895|NCT03036085|Drug|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
147896|NCT03036085|Drug|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
147897|NCT03036072|Other|Strict normothermia|
147898|NCT03036072|Device|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
147899|NCT03036059|Drug|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
147900|NCT03036046|Drug|F901318 with fluconazole low dose|adverse events
147901|NCT03036046|Drug|F901318 with fluconazole high dose|adverse events
147902|NCT03036046|Drug|F901318 with posaconazole|adverse events
147903|NCT03036033|Device|SaeboGlove|All participants are given a Saebo glove to use during their stroke recovery.
147904|NCT03036020|Radiation|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
147905|NCT03036007|Other|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
147906|NCT03036007|Other|Exercises with Internet support|Neck-specific exercise with Internet support
147907|NCT03035994|Other|Real-Time Biofeedback|A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
147908|NCT03035981|Other|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
147909|NCT03035981|Other|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
147910|NCT03035981|Other|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
147911|NCT03035981|Other|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
147912|NCT03035981|Other|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
147913|NCT03035981|Other|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
147914|NCT03035981|Other|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
147915|NCT03035968|Other|Vojta therapy|
147916|NCT03035968|Other|conventional physiotherapy|
147917|NCT03035955|Drug|Azelaic acid|15% gel twice daily for four weeks to one side of face
147918|NCT03035942|Drug|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
147919|NCT03035942|Drug|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
147920|NCT03035942|Drug|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
147921|NCT03035929|Drug|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
147922|NCT03035916|Other|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
147923|NCT03035916|Other|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
147924|NCT03035916|Other|control|The Control group receives standard IV-inhaled general anesthesia.
147925|NCT03035903|Device|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
148005|NCT03035396|Device|Diassess Influenza A and B Test|
150753|NCT03014804|Biological|Nivolumab|Given IV
147926|NCT03035903|Device|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
147927|NCT03035890|Radiation|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
147928|NCT03035890|Drug|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:~Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)~Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)~Atezolizumab 1200 mg once every 3 weeks (21 day cycle)~These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
147929|NCT03035877|Behavioral|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
147930|NCT03035877|Behavioral|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
147931|NCT03035864|Drug|rhNGF|Eye Drop 20 μg/mL
147932|NCT03035864|Other|Vehicle|Vehicle Eye Drop
147933|NCT03035851|Behavioral|Aerobic exercise|
147934|NCT03035851|Behavioral|Stretch and Strength|
147935|NCT03035838|Drug|Fosaprepitant|Within 24 hours from injury, IVAMEND (the intravenous formulation of the NK-1 antagonist fosaprepitant) will be administered at a dose of 300 mg, intravenously over 1 hour.
147936|NCT03035825|Dietary Supplement|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
147937|NCT03035825|Other|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
147938|NCT03035812|Drug|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
147939|NCT03035799|Other|Paleolithic diet|Paleolithic diet
147940|NCT03035799|Other|General Healthful Diet|General Healthful Diet
147941|NCT03035773|Behavioral|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
147942|NCT03035773|Behavioral|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
147943|NCT03035773|Behavioral|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
147944|NCT03035760|Drug|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
147945|NCT03035747|Procedure|conventional surgery|high ligation and stripping of incompetent saphenous veins
147946|NCT03035747|Procedure|endovenous laser ablation|endovenous laser ablation of incompetent saphenous veins
147947|NCT03035747|Procedure|sclerotherapy|ultrasound guided or catheter or or any other methods sclerotherapy of incompetent saphenous or varicose veins
147948|NCT03035747|Procedure|endovenous radiofrequency ablation|endovenous radiofrequency ablation of incompetent saphenous veins
147949|NCT03035747|Procedure|phlebectomy|hooks phlebectomy of varicose veins
147950|NCT03035734|Drug|BMS-986141 Form A Tablet|tablet
147951|NCT03035734|Drug|BMS-986141 Form B tablet (low dose)|tablet
147952|NCT03035734|Drug|BMS-986141 Form B tablet (high dose)|tablet
147953|NCT03035721|Dietary Supplement|Low protein formula|Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
147954|NCT03035721|Dietary Supplement|Standard protein formula|Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
147955|NCT03035708|Drug|Varenicline|1 mg BID
147956|NCT03035708|Drug|Placebo oral capsule|1 mg BID
147957|NCT03035695|Device|Axiostat®|
147958|NCT03035695|Device|Cotton Gauze|
147959|NCT03035682|Other|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
147960|NCT03035682|Other|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
147961|NCT03035669|Behavioral|Mindfulness group|8 week program
147962|NCT03035669|Behavioral|Reading group|8 week program
147963|NCT03035656|Drug|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
147964|NCT03035656|Other|Saline|Administration of saline via epidural injection intra-operatively
147965|NCT03035643|Device|Ascyrus Medical Dissection Stent placement|The study is a prospective, non-randomized, non-blinded, single-arm, single center study evaluating the feasibility and safety of this new design of stent. The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
147966|NCT03035630|Drug|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
147967|NCT03035630|Drug|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
147968|NCT03035617|Drug|Bupivacaine|Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
147969|NCT03035617|Other|Saline|In control arm mesh will be soaked in normal saline solution as is routinely done.
147970|NCT03035604|Other|Comprehensive Geriatric Assessment|Undergo nutritional geriatric assessment
147971|NCT03035591|Drug|ODM-207|
147972|NCT03035578|Drug|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
147973|NCT03035578|Drug|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
147974|NCT03035565|Behavioral|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
147975|NCT03035565|Behavioral|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
147976|NCT03035552|Behavioral|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
147977|NCT03035539|Other|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
147978|NCT03035539|Other|Standard treatment|Standard treatment
147979|NCT03035513|Other|Continuous spikes and waves during slow sleep (CSWS)|
147980|NCT03035500|Other|Educational Intervention|Receive health education
147981|NCT03035500|Other|Laboratory Biomarker Analysis|Correlative studies
147982|NCT03035500|Other|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
147983|NCT03035500|Other|Quality-of-Life Assessment|Ancillary studies
147984|NCT03035500|Other|Questionnaire Administration|Ancillary studies
147985|NCT03035487|Device|Ultrasound guided prostate exam using SOC ultrasound system|
147986|NCT03035487|Device|mpMRI guided prostate examination using PI-RADS v2|mpMRI guided prostate examination using standard of care MRI system
147987|NCT03035487|Device|High-resolution micro-ultrasound guided prostate biopsy|
147988|NCT03035474|Other|Digital Engagement|Patient engagement to improve self-management/medication adherence
147989|NCT03035474|Other|Direct Engagement|Health system engagement to improve local QI programs
147990|NCT03035448|Behavioral|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.~Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
147991|NCT03035448|Other|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
147992|NCT03035435|Other|fast-track rehabilitation|
147993|NCT03035435|Other|standard care rehabilitation|
147994|NCT03035422|Drug|Sequential Packaging (SET)|"Sequential chemotherapy:~Thiotepa 5 mg / kg / day for 1 day (D-13)~Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)~Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)~Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)~Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)~Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
147995|NCT03035422|Drug|Transfusion graft|Graft of peripheral stem cells is preferred at D0
147996|NCT03035422|Drug|Prevention of GVHD|"Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5~Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)~Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
147997|NCT03035422|Drug|Care supports|According to the protocols of each center
147998|NCT03035422|Drug|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II"
147999|NCT03035409|Drug|Anamorelin Hydrochloride|Given PO
148000|NCT03035409|Behavioral|Exercise Intervention|Undergo physical activity
148001|NCT03035409|Other|Laboratory Biomarker Analysis|Correlative studies
148002|NCT03035409|Other|Nutritional Assessment|Undergo nutritional counseling
148003|NCT03035409|Other|Quality-of-Life Assessment|Ancillary studies
148004|NCT03035409|Other|Questionnaire Administration|Ancillary studies
148006|NCT03035383|Procedure|Purse string technique|Thyroidectomy closure is performed using purse string suturing technique.
148007|NCT03035383|Procedure|Conventional technique|Thyroidectomy closure is performed using conventional suturing technique.
148008|NCT03035370|Biological|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
148009|NCT03035370|Biological|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
148010|NCT03035370|Biological|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
148011|NCT03035370|Biological|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
148012|NCT03035357|Drug|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
148013|NCT03035344|Other|Metabolome study|Metabolome study in ALL patients compared to healthy controls
148014|NCT03035331|Procedure|Cryosurgery|Undergo cryosurgery
148015|NCT03035331|Biological|Dendritic Cell Therapy|Given IT
148016|NCT03035331|Biological|Pembrolizumab|Given IV
148017|NCT03035331|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given by injection
148018|NCT03035331|Other|Quality-of-Life Assessment|Ancillary studies
148019|NCT03035305|Dietary Supplement|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):~For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks~For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
148020|NCT03035305|Drug|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):~For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg~For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg~D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
148021|NCT03035279|Drug|SC-006|Intravenous
148022|NCT03035279|Drug|ABBV-181|Intravenous
148023|NCT03035266|Device|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
148024|NCT03035266|Other|Standard rehabilitation|Standard of care for post-operative condition
148025|NCT03035253|Drug|OMP-305B83|
148026|NCT03035253|Drug|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
148027|NCT03035253|Drug|FOLFOX|Treatment will consist of OMP-305B83 and the FOLFOX chemotherapy regimen.
148028|NCT03035240|Behavioral|Financial Education|Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
148029|NCT03035227|Procedure|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
148030|NCT03035227|Drug|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
148031|NCT03035214|Drug|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
148032|NCT03035188|Drug|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
148033|NCT03035175|Other|Video Laryngoscopy|Residents intubate using video laryngoscopy.
148034|NCT03035175|Other|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
148035|NCT03035162|Device|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
148036|NCT03035149|Other|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
148037|NCT03035123|Behavioral|Therapeutic education|Interventional arm
148038|NCT03035110|Behavioral|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
148039|NCT03035097|Other|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
148040|NCT03035084|Drug|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
148041|NCT03035084|Drug|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
148042|NCT03035084|Drug|Placebo oral capsule|Placebo oral capsule
148043|NCT03035071|Procedure|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
238657|NCT02374567|Drug|Duloxetine|
148044|NCT03035071|Procedure|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
148045|NCT03035058|Drug|Vedolizumab|Vedolizumab intravenous infusion
148046|NCT03035058|Drug|Placebo|Placebo
148047|NCT03035045|Drug|Paracetamol|
148048|NCT03035045|Drug|Placebo Oral Tablet|
148049|NCT03035032|Drug|Leuprolide|Subcutaneous Injection
148050|NCT03035019|Behavioral|Lantern|This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
148051|NCT03035006|Drug|Lipotecan|Lipotecan based concurrent chemoradiotherapy
148052|NCT03034993|Behavioral|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
148053|NCT03034980|Other|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
148054|NCT03034967|Drug|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
148055|NCT03034967|Drug|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
148056|NCT03034967|Drug|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
148057|NCT03034967|Drug|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
148058|NCT03034954|Device|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
148059|NCT03034954|Device|Sham HD-tDCS|Participants will receive sham HD-tDCS
148060|NCT03034941|Drug|Metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
148061|NCT03034941|Drug|Liraglutide + metformin|In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
148062|NCT03034915|Drug|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
148063|NCT03034915|Drug|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
148064|NCT03034915|Drug|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
148065|NCT03034915|Drug|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
148066|NCT03034915|Drug|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
148067|NCT03034863|Behavioral|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
148068|NCT03034863|Behavioral|Treatment-as-Usual|The comparison condition will be an assessment-only enhanced treatment-as-usual (TAU).
148069|NCT03034850|Procedure|CRS/HIPEC|The generic surgical approach involved peritonectomy procedures and visceral resections called CRS as described by Sugarbaker (1995). Peritoneal disease burden was assessed using the perito- neal cancer index (PCI), which scores 13 intra-abdominal sites on a scale of 0 (no disease) to 3 (lesion size > 5 cm), thus giving a range of possible scores from 0 to 39. The same team performed the surgical procedure of all included patients. Before connection to the patient, the circuit was filled with dextrose 5% (2 L/m2 body surface area) and warmed to 37°C.
148070|NCT03034837|Drug|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
148071|NCT03034837|Drug|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
148072|NCT03034824|Procedure|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
148073|NCT03034824|Procedure|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
148074|NCT03034824|Procedure|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
148075|NCT03034811|Device|Persona Partial Knee system|Fixed bearing partial knee
148076|NCT03034785|Device|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
148077|NCT03034772|Drug|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
148078|NCT03034772|Other|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
148079|NCT03034759|Other|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
148080|NCT03034746|Other|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
148081|NCT03034746|Other|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
148082|NCT03034733|Drug|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
148083|NCT03034733|Drug|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
148084|NCT03034720|Behavioral|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
148085|NCT03034707|Dietary Supplement|biotin|
148086|NCT03034694|Other|teledermatology consult|teledermatology consult
148087|NCT03034694|Other|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
148088|NCT03034681|Other|Physiotherapy technique: TENS|
148089|NCT03034681|Other|Physiotherapy technique: Vojta Therapy|
148090|NCT03034668|Dietary Supplement|CS16-003 Full dose|350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
148091|NCT03034668|Dietary Supplement|CS16-003 Half dose|175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg
148092|NCT03034668|Dietary Supplement|Placebo|Maltodextrin: 350 mg
148093|NCT03034655|Device|CDP|Vestibular rehabilitation using CDP
148094|NCT03034655|Device|Mobile posturography|Vestibular rehabilitation using mobile posturography
148095|NCT03034655|Other|10 sessions|Vestibular rehabilitation, ten sessions
148096|NCT03034655|Other|5 sessions|Vestibular rehabilitation, five sessions
148097|NCT03034642|Procedure|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
148098|NCT03034629|Behavioral|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
148099|NCT03034616|Device|OLIVA device|"OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.~This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs"
148100|NCT03034603|Dietary Supplement|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
148101|NCT03034603|Dietary Supplement|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
148102|NCT03034590|Other|questionnaire|
148103|NCT03034577|Drug|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
148104|NCT03034577|Drug|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
148105|NCT03034564|Drug|Northera|
148106|NCT03034564|Drug|Placebo Oral Tablet|
148107|NCT03034551|Behavioral|Financial Incentive, Mobile Phone App, and Cellular Scale|Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
148108|NCT03034538|Drug|Zonegran|100mg
148109|NCT03034538|Drug|Zonegran|200mg
148110|NCT03034499|Procedure|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
148111|NCT03034499|Procedure|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
148112|NCT03034486|Drug|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
148338|NCT03032757|Dietary Supplement|Essential amino acids|240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
148113|NCT03034473|Other|Translational Research and multimodal treatment|"Blood/biopsy samples (tumor & mucosa) are taken pretherapeutically. Blood samples (serum & plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma & serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):~Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.~TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen [(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75]."
148114|NCT03034460|Drug|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
148115|NCT03034460|Drug|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
148116|NCT03034460|Drug|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
148117|NCT03034460|Drug|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
148118|NCT03034447|Other|Questionnaire|Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
148119|NCT03034447|Other|Lung Function Test|Children are going to blow in a machine that measures how the lung is working
148120|NCT03034447|Other|Home Sleep Study|Children are going to sleep at home with a device that tells if they stop breathing during sleep
148121|NCT03034434|Device|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
148122|NCT03034421|Behavioral|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
148123|NCT03034408|Drug|Nalmefene|
148124|NCT03034408|Drug|Baclofen|
148125|NCT03034408|Drug|Placebo Oral Capsule|
148126|NCT03034395|Procedure|Wide Local Excision|Surgery
148127|NCT03034382|Drug|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
148128|NCT03034382|Drug|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
148129|NCT03034382|Drug|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
148130|NCT03034382|Drug|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
148131|NCT03034369|Other|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
148132|NCT03034369|Other|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
148133|NCT03034369|Other|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
148134|NCT03034369|Other|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
148135|NCT03034369|Other|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
148136|NCT03034369|Other|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
148137|NCT03034369|Other|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
148138|NCT03034369|Other|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
148139|NCT03034369|Other|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
148140|NCT03034369|Other|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
148141|NCT03034369|Other|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
148142|NCT03034369|Other|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
148143|NCT03034369|Other|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
148144|NCT03034356|Drug|Levetiracetam|Anticonvulsant drug
148145|NCT03034356|Drug|Placebo|Placebo
148146|NCT03034343|Behavioral|Mindfulness|
148147|NCT03034330|Other|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
148148|NCT03034330|Other|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
148149|NCT03034317|Device|NeuRx DPS|Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
148150|NCT03034304|Biological|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
148339|NCT03032744|Other|Asthma Assessment & Management|Asthma Assessment & Management based on NAEPP-EPR3 guidelines
148151|NCT03034304|Drug|Ifosfamide|2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
148152|NCT03034291|Dietary Supplement|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
148153|NCT03034291|Dietary Supplement|White chocolate|
148154|NCT03034278|Other|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
148155|NCT03034252|Procedure|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
148156|NCT03034239|Dietary Supplement|Protein supplementation|+ insect protein
148157|NCT03034239|Other|Resistance training|Resistance exercise
148158|NCT03034226|Other|Glucose clamp technique|Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
148159|NCT03034213|Device|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
148160|NCT03034213|Device|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
148161|NCT03034200|Drug|ONC201|625mg ONC201 will be given weekly for up to one year or until progression.
148162|NCT03034161|Device|Thermal imaging|Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
148163|NCT03034148|Diagnostic Test|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
148164|NCT03034135|Drug|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
148165|NCT03034135|Drug|Temozolomide (TMZ)|TMZ is given per standard of care
148166|NCT03034109|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
148167|NCT03034096|Drug|Propofol|Maintenance of general anesthesia with propofol infusion
148168|NCT03034096|Drug|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
148169|NCT03034083|Behavioral|Elevate|Study participants receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
148170|NCT03034070|Diagnostic Test|Diagnostic performance 3D T1|"Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study."
148171|NCT03034057|Drug|Sayana Press|Sayana Press in the Uniject injection system
148172|NCT03034018|Drug|suvorexant|10-20 mg taken at bedtime for four weeks
148173|NCT03034018|Drug|placebo|placebo taken at bedtime for four weeks
148174|NCT03034005|Drug|Budesonide|1600 ug inhaled daily for 6 weeks
148175|NCT03033992|Device|Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)|The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
148176|NCT03033966|Device|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
148177|NCT03033953|Dietary Supplement|Native whey|
148178|NCT03033953|Dietary Supplement|Milk|
148179|NCT03033953|Other|Strength training|
148180|NCT03033940|Radiation|Observational use of fluoroscopy|
148181|NCT03033927|Diagnostic Test|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
148182|NCT03033914|Drug|doxorubicin|Doxorubicin: 25 mg/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
148183|NCT03033914|Drug|Bleomycin|Bleomycin: 10 units/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
148184|NCT03033914|Drug|vinblastine|Vinblastine: 6 mg/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
148185|NCT03033914|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
148186|NCT03033914|Drug|Nivolumab|nivolumab 240mg q14 days
148187|NCT03033901|Device|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
148188|NCT03033901|Device|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
148189|NCT03033901|Other|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
148190|NCT03033888|Behavioral|Health-Literacy Focused Education Session|
148191|NCT03033875|Behavioral|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days. The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish. The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
148340|NCT03032744|Other|Asthma Education|Asthma education on medications
148192|NCT03033875|Behavioral|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
148193|NCT03033862|Device|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
148194|NCT03033862|Device|Drug Eluting Stent|Drug Eluting Stent
148195|NCT03033849|Device|Blood glucose monitoring system for self-testing Contour® Next One|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
148196|NCT03033849|Device|Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect|
148197|NCT03033849|Device|Blood glucose monitoring system for self-testing FreeStyle Freedom Lite|
148198|NCT03033849|Device|Blood glucose monitoring system for self-testing OneTouch® Verio|
148199|NCT03033849|Device|Blood glucose monitoring system for self-testing GlucoMen® areo|
148200|NCT03033836|Drug|ARV treatment|Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
148201|NCT03033823|Drug|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
148202|NCT03033823|Drug|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
148203|NCT03033810|Device|Fractional flow reserve and instantaneous wave-free ratio|"To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~The development of software for the automatic detection of the lowest point of microvascular resistance."
148204|NCT03033797|Device|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
148205|NCT03033797|Device|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
148206|NCT03033784|Drug|8 International Units (IU) of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
148207|NCT03033784|Drug|24IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
148208|NCT03033784|Drug|48IU of Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
148209|NCT03033784|Drug|Placebo|Participants will receive an intranasal placebo to match the oxytocin doses.
148210|NCT03033771|Device|Implantation with the Multilayer Flow Modulator (MFM)|Endovascular implantation with the MFM
148211|NCT03033758|Other|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
148212|NCT03033745|Drug|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
148213|NCT03033732|Drug|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
148214|NCT03033732|Drug|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
148215|NCT03033719|Procedure|Laparotomy|Open surgery
148216|NCT03033719|Procedure|Laparoscopy|Minimally invasive surgery
148217|NCT03033706|Procedure|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
148218|NCT03033706|Procedure|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
148219|NCT03033706|Procedure|Brain tumor excision|Brain tumor excision under general anesthesia
148220|NCT03033693|Other|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
148221|NCT03033693|Other|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
148222|NCT03033680|Drug|[F-18]PBR06|PET radiopharmaceutical
148223|NCT03033667|Dietary Supplement|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
148224|NCT03033667|Dietary Supplement|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
148225|NCT03033667|Dietary Supplement|Group C|Over night fasting with no supplementation
148226|NCT03033654|Other|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
148341|NCT03032744|Other|Controller medication at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
148227|NCT03033641|Device|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
148228|NCT03033628|Device|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
148229|NCT03033628|Device|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
148230|NCT03033615|Device|PixelShine|Machine learning algorithm
148231|NCT03033615|Device|Conventional processing|Iterative reconstruction software
148232|NCT03033602|Behavioral|written exposure therapy|five sessions of writing about traumatic experience.
148233|NCT03033602|Behavioral|CPT, cognitive only|12 sessions of cognitive therapy related to traumatic experience.
148234|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
148235|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
148236|NCT03033576|Biological|Ipilimumab|Given IV
148237|NCT03033576|Biological|Nivolumab|Given IV
148238|NCT03033563|Procedure|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
148239|NCT03033550|Behavioral|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
148240|NCT03033537|Drug|Verapamil|Local treatment of erectile dysfunction
148241|NCT03033524|Drug|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
148242|NCT03033511|Drug|Placebo for dexamethasone|Placebo for administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
148243|NCT03033511|Drug|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
148244|NCT03033511|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
148245|NCT03033511|Drug|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
148246|NCT03033498|Drug|ABBV-951|ABBV-951 administered by subcutaneous infusion.
148247|NCT03033485|Radiation|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
148248|NCT03033472|Drug|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
148249|NCT03033472|Drug|Oral Placebo|Oral Placebo 30 minutes before treatment
148250|NCT03033459|Behavioral|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
148251|NCT03033459|Behavioral|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
148252|NCT03033446|Radiation|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
148253|NCT03033446|Drug|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
148254|NCT03033433|Drug|DCB-DM101|determination of optimal dose for Stage 2
148255|NCT03033420|Device|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
148256|NCT03033407|Other|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
148257|NCT03033394|Drug|Beta-lactam antibiotic|Routine clinical dosing
148258|NCT03033381|Device|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
148306|NCT03033004|Device|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
148259|NCT03033381|Device|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
148260|NCT03033368|Drug|Rilpivirine|Rilpivirine 25 mg tablet
148261|NCT03033355|Drug|Intradetrusor injection of Botulinum Toxin-A|Using cystoscopy, Botulinum Toxin-A is injected into the bladder.
148262|NCT03033342|Drug|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
148263|NCT03033342|Drug|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
148264|NCT03033342|Drug|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
148265|NCT03033342|Drug|Oral single doses of placebo|Single doses of placebo to match MRX-4
148266|NCT03033342|Drug|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
148267|NCT03033342|Drug|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
148268|NCT03033329|Drug|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
148269|NCT03033329|Drug|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
148270|NCT03033329|Drug|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
148271|NCT03033329|Drug|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
148272|NCT03033329|Drug|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
148273|NCT03033316|Drug|Dexamethasone|
148274|NCT03033303|Biological|Hu3F8|Day 1: hu3F8 infused iv over ~30 to 90 minutes. Day 3: hu3F8 infused iv over ~30 to 90 minutes. Day 5: hu3F8 infused iv over ~30 to 90 minutes.
148275|NCT03033303|Drug|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
148276|NCT03033303|Drug|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
148277|NCT03033290|Drug|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
148278|NCT03033290|Drug|placebo|placebo control
148279|NCT03033277|Biological|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
148280|NCT03033277|Biological|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
148281|NCT03033264|Drug|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
148282|NCT03033264|Device|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
148283|NCT03033251|Device|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
148284|NCT03033251|Device|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
148285|NCT03033251|Device|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
148286|NCT03033225|Drug|Verteporfin PDT|the study drug will be given through an IV infusion. approximately one hour later The physician will direct the endoscope that has an ultrasound to your pancreas, and the treatment laser will be guided to the sites on your pancreas where the tumors are located. This will be done using a ultrasound to find the tumor and place a needle from inside the stomach or small intestine into the tumor. This is a standard procedure for obtaining tissue from a tumor. In this study, a special fiberoptic probe will be placed through the needle to allow light to be delivered to the tumor
148287|NCT03033212|Other|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
148288|NCT03033212|Other|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
148289|NCT03033199|Drug|Probiotic Agent|probiotic capsules containing three viable and freezedried strains—Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
148290|NCT03033199|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
148291|NCT03033160|Drug|Estradiol Ring|
148292|NCT03033147|Drug|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment
148293|NCT03033147|Drug|Oral placebo|placebo 30 minutes before root canal treatment
148294|NCT03033134|Device|BSJ003W|BSJ003W implant
148295|NCT03033121|Drug|Growth Hormone|
148296|NCT03033108|Drug|Emixustat|Once daily, tablet for oral administration
148297|NCT03033095|Drug|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
148298|NCT03033082|Other|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)~B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.~C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.~D- The Eysenck Personality Questionnaire (EPQ):~The Arabic version of the EPQ was used."
148299|NCT03033069|Drug|Brexpiprazole (OPC-34712)|
148300|NCT03033069|Drug|Sertraline|
148301|NCT03033069|Other|Placebo|
148302|NCT03033056|Behavioral|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
148303|NCT03033043|Device|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
148304|NCT03033030|Diagnostic Test|Ultrasound|Ultrasound examination
148305|NCT03033017|Other|Blood Testing|
148307|NCT03033004|Device|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
148308|NCT03033004|Device|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
148309|NCT03032978|Other|Calcium hydroxide|Pulp capping material
148310|NCT03032978|Other|Calcium silicate|Pulp capping material
148311|NCT03032965|Drug|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.~Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
148312|NCT03032965|Drug|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
148313|NCT03032952|Other|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
148314|NCT03032939|Procedure|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
148315|NCT03032926|Behavioral|Open Trial|Behavioral Intervention
148316|NCT03032913|Procedure|Blood samples|Blood samples for both group
148317|NCT03032913|Procedure|Portal vein blood sample|Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
148318|NCT03032887|Behavioral|voice prompts|voice prompts on disinfectant dispenser
148319|NCT03032887|Behavioral|agitation|Education, reminders and optimising materials
148320|NCT03032874|Procedure|Colonoscopy|They all had screening colonoscopy
148321|NCT03032861|Other|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
148322|NCT03032848|Drug|Conjugated Estrogen|use of 1 gram per day
148323|NCT03032848|Drug|Promestriene|use of 1 gram per day
148324|NCT03032848|Drug|Estriol|use of 1 gram per day
148325|NCT03032848|Drug|Vaginal Moisturizer - Cream|use of 1 gram per day
148326|NCT03032809|Other|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
148327|NCT03032796|Behavioral|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
148328|NCT03032796|Behavioral|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
148329|NCT03032796|Behavioral|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
148330|NCT03032796|Behavioral|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
148331|NCT03032783|Radiation|Total-Body Irradiation|Undergo Total Body Irradiation
148332|NCT03032783|Procedure|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
148333|NCT03032783|Drug|Cyclophosphamide|Given IV
148334|NCT03032783|Drug|Tacrolimus|Given IV
148335|NCT03032783|Drug|Mycophenolate Mofetil|Given IV
148336|NCT03032783|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
148337|NCT03032770|Device|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
148342|NCT03032731|Behavioral|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
148343|NCT03032731|Other|Control|Standard, publicly available NHS resources for healthy lifestyles.
148344|NCT03032718|Behavioral|Whole-body vibration training|Whole-body vibration exercise
148345|NCT03032705|Device|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
148346|NCT03032705|Device|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
148347|NCT03032692|Device|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
148348|NCT03032692|Other|Exercise with biofeedback|
148349|NCT03032692|Other|exercise without biofeedback|
148350|NCT03032679|Other|Non interventional study|No intervention
148351|NCT03032666|Drug|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
148352|NCT03032653|Other|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.~6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
148353|NCT03032653|Other|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
148354|NCT03032640|Other|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
148355|NCT03032640|Other|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
148356|NCT03032640|Other|Stool sampling|Subjects will provide a stool sample.
148357|NCT03032640|Other|Sodium Saccharin|Subjects in group 1 and group 3 will be provided with sodium saccharin.
148358|NCT03032640|Other|Placebo|Subjects in group 2 will be provided with placebo.
148359|NCT03032640|Other|Lactisole|Subjects in group 3 and group 4 will be provided with lactisole.
148360|NCT03032627|Procedure|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
148361|NCT03032614|Drug|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
148362|NCT03032614|Drug|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
148363|NCT03032614|Drug|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
148364|NCT03032601|Dietary Supplement|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
148365|NCT03032588|Biological|sIPV|Participants will receive single dose (0.5 milliliter [mL]) of sIPV as a suspension for intramuscular injection on Day 1.
148366|NCT03032588|Biological|cIPV|Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
148367|NCT03032575|Behavioral|SEARCH010/RV254|
148368|NCT03032562|Diagnostic Test|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
148369|NCT03032549|Dietary Supplement|RTD|Ready to Drink Supplement
148370|NCT03032549|Dietary Supplement|Placebo|Placebo
148371|NCT03032536|Drug|AL-3778|AL-3778 tablets or capsules
148372|NCT03032536|Drug|Entecavir|Entecavir once daily for 14 days
148373|NCT03032536|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
148374|NCT03032523|Diagnostic Test|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
148375|NCT03032510|Drug|Eravacycline|
148376|NCT03032510|Drug|Ertapenem|
148377|NCT03032510|Drug|Placebo|
148378|NCT03032510|Drug|Levofloxacin|
148379|NCT03032497|Device|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
148380|NCT03032484|Drug|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
148381|NCT03032484|Drug|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
148421|NCT03032211|Device|Alfapump|Implant Alfapump® System
150754|NCT03014804|Other|Quality-of-Life Assessment|Ancillary studies
148382|NCT03032471|Other|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
148383|NCT03032458|Drug|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
148384|NCT03032458|Drug|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
148385|NCT03032458|Drug|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
148386|NCT03032445|Other|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
148387|NCT03032445|Other|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
148388|NCT03032432|Device|Dynamic Elastic Garment (DEG) brace|Improve function of the shoulder
148389|NCT03032432|Drug|Corticosteroid injection|Injection to improve rotator cuff tendinosis pain and functional score
148390|NCT03032419|Biological|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
148391|NCT03032419|Biological|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
148392|NCT03032406|Drug|Hydroxychloroquine|Hydroxychloroquine
148393|NCT03032406|Drug|Everolimus|Everolimus
148394|NCT03032393|Other|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
148395|NCT03032393|Other|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
148396|NCT03032380|Drug|S-649266|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
148397|NCT03032380|Drug|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
148398|NCT03032380|Drug|Linezolid|600 mg of Linezolid will be administered intravenously over 30 minutes to 2 hours, every 12 hours.
148399|NCT03032367|Drug|bedaquiline|
148400|NCT03032354|Drug|Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Combination therapy of probiotics during 6 months
148401|NCT03032354|Other|Placebo, (Placebo group)|Placebo during 6 months
148402|NCT03032328|Dietary Supplement|vitamin D supplement|Patients will be given a dose of vitamin D for at least 2 months
148403|NCT03032315|Drug|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
148404|NCT03032315|Drug|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
148405|NCT03032315|Drug|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
148406|NCT03032302|Dietary Supplement|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
148407|NCT03032302|Dietary Supplement|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
148408|NCT03032289|Behavioral|Active Transport|Active transport, most commonly walking or cycling, is the use of physical activity to commute.
148409|NCT03032276|Other|Safe motherhood and newborn health promotion package|The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
148410|NCT03032263|Device|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
148411|NCT03032263|Device|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
148412|NCT03032250|Other|Communication Intervention|Attend interventionist sessions
148413|NCT03032250|Other|Watch video|Watch video on a DVD
148414|NCT03032250|Other|Module completion of the Prepare to Care kit|Complete modules of the Prepare to Care kit
148415|NCT03032250|Other|Quality-of-Life Assessment|Ancillary studies
148416|NCT03032250|Other|Survey Administration|Ancillary studies
148417|NCT03032250|Other|Salivary cortisol collection|Obtained at three times a day (at awakening, 30 minutes post awakening and bedtime) for two consecutive days for eligible caregivers in both groups. Samples collected by placing a cotton ball under the tongue for approximately 1-2 minutes which is subsequently stored in a plastic tube and refrigerated.
148418|NCT03032237|Other|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Intervention group will receive protein-rich meals and protein-rich foods and drinks."
148419|NCT03032237|Other|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.~To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.~Control group will receive standard (not protein-rich) meals and standard foods and drinks."
148420|NCT03032224|Procedure|Resection of the esophagus and the gastroesophageal junction|
148422|NCT03032198|Device|Imagio OA/US|Diagnostic opto-acoustic gray-scale ultrasound
148423|NCT03032185|Device|Transcutaneous Elevtrical Nerve Stimulation|
148424|NCT03032172|Drug|Risdiplam|Risdiplam will be administered orally once daily.
148425|NCT03032159|Behavioral|Text2Breathe Study Group|
148426|NCT03032146|Procedure|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
148427|NCT03032133|Procedure|Regional pain control|Regional pain catheter
148428|NCT03032133|Procedure|Local pain control|Local intraarticular pain catheter
148429|NCT03032120|Dietary Supplement|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
148430|NCT03032120|Dietary Supplement|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
148431|NCT03032107|Drug|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
148432|NCT03032107|Drug|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
148433|NCT03032094|Procedure|connective tissue graft|palatal connective tissue graft to attain root coverage
148434|NCT03032081|Other|High intensity exercise|High intensity exercise, defined as an exercise intensity of > 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
148435|NCT03032081|Other|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
148436|NCT03032068|Other|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
148437|NCT03032042|Drug|Azithromycin|
148438|NCT03032042|Drug|Albendazole|
148439|NCT03032042|Drug|Delayed treatment|Albendazole+Azithromycin
148440|NCT03032029|Device|Adaptive Servo-Ventilation|Bi-Level positive airway pressure with a targeted minute ventilation
148441|NCT03032003|Other|Cysticlean|2 BID for 15 days
148442|NCT03032003|Other|Placebo|2 BID for 15 days
148443|NCT03031990|Behavioral|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
148444|NCT03031990|Behavioral|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
148445|NCT03031990|Behavioral|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
148446|NCT03031977|Other|visceral mobilization|
148447|NCT03031964|Device|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
148448|NCT03031951|Behavioral|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 4 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum.Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
148449|NCT03031938|Drug|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
148450|NCT03031925|Other|ANXA2|serum and urinary concentration
148451|NCT03031912|Biological|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
148452|NCT03031912|Other|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
148453|NCT03031899|Procedure|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
148454|NCT03031899|Diagnostic Test|Rose Bengal|the lesions stained positive were subjected to biopsy
148455|NCT03031899|Diagnostic Test|toluidine blue|the lesions stained positive were subjected to biopsy
148456|NCT03031886|Other|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
148457|NCT03031886|Other|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
148458|NCT03031873|Device|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
148620|NCT03030599|Drug|JZP-258|
148459|NCT03031860|Other|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
148460|NCT03031847|Device|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
148461|NCT03031847|Device|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
148462|NCT03031834|Drug|Quinapril|
148463|NCT03031821|Drug|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
148464|NCT03031821|Drug|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months~1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
148465|NCT03031808|Drug|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
148466|NCT03031808|Drug|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
148467|NCT03031808|Other|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
148468|NCT03031795|Drug|Ketorolac|Oral Tablet
148469|NCT03031795|Drug|Placebo|Oral Tablet
148470|NCT03031782|Drug|AIN457|Secukinumab (AIN457) is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
148471|NCT03031782|Other|Matched placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
148472|NCT03031756|Device|glycine powder air-polishing (Air-Flows)Perio Powder|
148473|NCT03031756|Device|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
148474|NCT03031730|Drug|Carfilzomib|Given IV
148475|NCT03031730|Drug|Dexamethasone|Given PO or IV
148476|NCT03031730|Other|Laboratory Biomarker Analysis|Correlative studies
148477|NCT03031730|Drug|Lenalidomide|Given PO
148478|NCT03031730|Drug|MDM2 Inhibitor AMG-232|Given PO
148479|NCT03031730|Other|Pharmacological Study|Correlative studies
148480|NCT03031717|Procedure|Transjugular intrahepatic portosystemic shunt|
148481|NCT03031704|Procedure|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
148482|NCT03031691|Drug|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
148483|NCT03031691|Drug|trifluridine/tipiracil|
148484|NCT03031678|Device|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
148485|NCT03031652|Device|Phacoemulsification|The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant
148486|NCT03031639|Procedure|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
148487|NCT03031626|Biological|Medical Air vs Oxygen|Medical Air/Oxygen will be given
148488|NCT03031613|Procedure|PEEP group|Application of 5cmH20 positive end expiratory pressure
148489|NCT03031613|Procedure|ZEEP group|No application of positive end expiratory pressure
148490|NCT03031600|Diagnostic Test|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
148491|NCT03031600|Diagnostic Test|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
148492|NCT03031587|Other|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
148493|NCT03031587|Device|MRI|cardiac MRI
148494|NCT03031574|Drug|SUVN-D4010|Tablets
148495|NCT03031561|Device|Ultrasound|Undergo standard ultrasound
148496|NCT03031561|Device|MicoPure ultrasound|Undergo MicoPure ultrasound
148497|NCT03031561|Procedure|Biopsy of Breast|Undergo breast biopsy or surgical resection
148498|NCT03031548|Device|Point-of-care ultrasound exam|No intervention
148499|NCT03031548|Radiation|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
148500|NCT03031535|Drug|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
148501|NCT03031535|Drug|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
148502|NCT03031535|Diagnostic Test|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
148503|NCT03031535|Diagnostic Test|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
148504|NCT03031522|Radiation|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
148505|NCT03031509|Biological|Human Amniotic Epithelial Cells|Human Amniotic Epithelial Cells transplant after debridement
148506|NCT03031509|Procedure|debridement|debridement
148507|NCT03031496|Drug|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
148621|NCT03030599|Other|Placebo|
149018|NCT03027661|Drug|Bupivacaine|Inject 10 mL of 0.5% bupivacaine into cervical stroma
148508|NCT03031496|Drug|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
148509|NCT03031483|Drug|clarithromycin and lenalidomide|"Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total."
148510|NCT03031470|Drug|Reparixin|Reparixin 168 hrs continuous infusion
148511|NCT03031470|Other|Standard care procedures|Standard procedures for administration of Immunosuppressive and support post transplant therapies
148512|NCT03031457|Diagnostic Test|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
148513|NCT03031444|Drug|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
148514|NCT03031444|Drug|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
148515|NCT03031431|Device|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
148516|NCT03031418|Diagnostic Test|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
148517|NCT03031405|Drug|Oxytocin nasal spray|
148518|NCT03031405|Drug|Placebos|Placebo nasal spray
148519|NCT03031392|Diagnostic Test|Sensitivity test|Routine clinical and radiographic examination
148520|NCT03031379|Other|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
148521|NCT03031366|Other|3d roadmap guidance|TIPS was established using 3d roadmap
148522|NCT03031366|Other|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
148523|NCT03031353|Drug|Misoprostol|Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
148524|NCT03031353|Drug|Placebos|placebos tablet will be given before elective Cesarean sections
148525|NCT03031340|Drug|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
148526|NCT03031340|Other|placebo|placebo
148527|NCT03031327|Device|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
148528|NCT03031327|Device|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
148529|NCT03031327|Device|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
148530|NCT03031314|Device|barbed suture|
148531|NCT03031314|Device|standard suture|
148532|NCT03031301|Device|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
148533|NCT03031301|Device|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
148534|NCT03031288|Device|A|standard bottle
148535|NCT03031288|Device|B|vented base bottle
148536|NCT03031275|Radiation|High-resolution computed tomography|HRCT of the thorax
148537|NCT03031275|Radiation|Magnetic resonance imaging|MRI of the brain
148538|NCT03031275|Behavioral|Cognitive testing|Neuropsychological testing
148539|NCT03031262|Drug|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
148540|NCT03031262|Drug|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
148541|NCT03031249|Drug|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
148542|NCT03031249|Drug|all-trans retinoic acid|ATRA at a dose of 30mg/㎡/d on day 1-14.
148543|NCT03031249|Drug|Arsenic Trioxide|ATO at a dose of 10mg/d on day 1-14
148544|NCT03031236|Behavioral|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
148545|NCT03031223|Radiation|low-level laser therapy|low-level laser therapy
148546|NCT03031210|Drug|Amoxicillin|(90 mg/kg/day) twice daily
148547|NCT03031197|Combination Product|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
148548|NCT03031184|Drug|Mirtazapine|
148549|NCT03031184|Other|Placebo|
148654|NCT03030274|Device|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
238658|NCT02374567|Drug|Agomelatine|
148550|NCT03031171|Behavioral|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
148551|NCT03031171|Behavioral|Non-Navigated|Randomly matched sample of non-navigated clinic patients
148552|NCT03031158|Behavioral|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
148553|NCT03031158|Behavioral|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
148554|NCT03031145|Biological|Felis Domesticus|Nasal Administration of Felis Domesticus
148555|NCT03031132|Behavioral|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
148556|NCT03031132|Behavioral|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
148557|NCT03031132|Behavioral|Breakfast Skipping|Participants will skip breakfast each morning.
148558|NCT03031119|Drug|Placebo|Tablets administered once or twice daily, with food, in Part A.
148559|NCT03031119|Drug|PF-06835919|Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
148560|NCT03031119|Drug|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
148561|NCT03031093|Radiation|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
148562|NCT03031093|Device|High Flow Nasal Cannula|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.
148563|NCT03031080|Device|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
148564|NCT03031067|Device|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
148565|NCT03031054|Procedure|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
148566|NCT03031054|Procedure|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
148567|NCT03031041|Procedure|Ultrasound-guided short-axis hydrodissection with 5cc normal saline|Ultrasound-guided short-axis hydrodissection with 5cc normal saline between carpal tunnel and median nerve
148568|NCT03031041|Procedure|Ultrasound-guided long-axis hydrodissection with 3cc normal saline|Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
148569|NCT03031028|Other|ketogenic diet|Ketogenic Diet is a high fat, low carbohydrate diet.
148570|NCT03031015|Device|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
148571|NCT03031015|Device|Plating|Fractures were reduced and then fixed with Plate.
148572|NCT03031002|Behavioral|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
148573|NCT03030989|Drug|Chlorhexidine Gluconate 2% Wipe|
148574|NCT03030989|Drug|Placebo Wipe|
148575|NCT03030976|Drug|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
148576|NCT03030976|Drug|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
148577|NCT03030963|Other|Equal ratio ventilation(ERV)|Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation
148578|NCT03030963|Other|"I:E Ratio 1:2"|Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
148579|NCT03030950|Drug|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
148580|NCT03030950|Drug|Normal saline|to give normal saline to the other group as a placebo
148581|NCT03030937|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
148582|NCT03030937|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC.
148583|NCT03030924|Device|Solace|Noninvasive physiologic monitor
148584|NCT03030911|Drug|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
148585|NCT03030911|Drug|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
148586|NCT03030911|Drug|Fentanyl|The drug will be administered in both groups
148587|NCT03030911|Device|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
148588|NCT03030898|Diagnostic Test|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
238659|NCT02374567|Drug|Pyritinol|
148589|NCT03030885|Drug|131I-MIP-1095|"First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.~2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
148590|NCT03030872|Device|Investigational software|The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
148591|NCT03030859|Other|Usual Care|Undergo usual care only
148592|NCT03030859|Other|Usual Care plus LEF-SCP|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, as well as review LEF self-care educational manual and videos
148593|NCT03030859|Other|Usual Care plus LEF-SCP plus Follow-up|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, and review LEF self-care educational manual and videos, as well as meet with the study lymphedema therapist
148594|NCT03030846|Other|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
148595|NCT03030846|Other|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
148596|NCT03030833|Device|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
148597|NCT03030820|Procedure|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
148598|NCT03030807|Diagnostic Test|Right heart cathetarization (in case of suspected PH)|
148599|NCT03030794|Device|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
148600|NCT03030794|Device|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
148601|NCT03030768|Drug|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
148602|NCT03030768|Behavioral|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
148603|NCT03030755|Other|Optical coherence tomography|
148604|NCT03030742|Other|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:~Satisfaction with pain control 2-4 weeks postpartum~Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)~Patient characteristics associated with high opioid use~Methods of storage and disposal of unused opioids"
148605|NCT03030716|Dietary Supplement|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
148606|NCT03030703|Dietary Supplement|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
148607|NCT03030690|Other|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
148608|NCT03030690|Other|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
148609|NCT03030690|Other|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
148610|NCT03030677|Procedure|Pectoralis type 2 block and catheter insertion without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
148611|NCT03030677|Procedure|Pectoralis type 2 block and catheter insertion with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
148612|NCT03030677|Drug|Lidocaine|
148613|NCT03030664|Dietary Supplement|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10^8 CFU) of the study product in connection with feeding
148614|NCT03030664|Drug|Placebo|Same formulation as study product, without probiotics.
148615|NCT03030651|Behavioral|Breastfeeding Education and Support|Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
148616|NCT03030638|Drug|Olodaterol|Drug
148617|NCT03030638|Drug|Indacaterol|Drug
148618|NCT03030625|Radiation|IGRT/VMAT focal therapy boost to DIL|Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
148619|NCT03030612|Drug|ARGX-110 with AZA|
148622|NCT03030573|Procedure|Reconstruction of the bile duct with the round ligament|In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
148623|NCT03030560|Drug|Lidocaine|patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
148624|NCT03030560|Drug|0.9% Sodium-chloride|patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
148625|NCT03030547|Device|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
148626|NCT03030534|Combination Product|Educational package and software package|Using Information and communication technology to deliver health promoting activities
148627|NCT03030534|Other|Health promotion tips|Give general information on health promotion
148628|NCT03030521|Diagnostic Test|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
148629|NCT03030508|Other|No intervention|
148630|NCT03030495|Device|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
148631|NCT03030495|Device|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
148632|NCT03030482|Procedure|touch massage|Patients will have a touch massage session during 30 minutes the intervention will take place remotely (1 h) of all events that can generate anxiety
148633|NCT03030469|Other|Change in electronic health record default for new opioid analgesic prescriptions|
148634|NCT03030456|Device|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
148635|NCT03030430|Biological|BAT1706 injection|1mg/kg, IV on day 1
148636|NCT03030430|Biological|EU-sourced Avastin|1mg/kg, IV on day 1
148637|NCT03030430|Biological|US-sourced Avastin|1mg/kg, IV on day 1
148638|NCT03030417|Drug|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand DNA breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1- DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
148639|NCT03030391|Other|PET|
148640|NCT03030391|Other|MRI|
148641|NCT03030378|Other|Laboratory Biomarker Analysis|Correlative studies
148642|NCT03030378|Biological|Pembrolizumab|Given IV
148643|NCT03030378|Biological|Recombinant Interleukin-12|Given SC
148644|NCT03030365|Device|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
148645|NCT03030352|Behavioral|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
148646|NCT03030339|Other|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
148647|NCT03030339|Other|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
148648|NCT03030339|Other|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
148649|NCT03030326|Behavioral|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
148650|NCT03030313|Device|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
148651|NCT03030300|Drug|Novolin 30R;Pioglitazone;Metformin|"Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;~Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;~Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
148652|NCT03030287|Drug|OMP-305B83|intravenous (in the vein) infusion
148653|NCT03030287|Drug|Paclitaxel|administered intravenously
238660|NCT02374567|Drug|Piracetam|
148655|NCT03030261|Drug|Elotuzumab|"During induction therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1, 8, 15, and 22 for Cycles 1-2 and Days 1 and 15 for Cycles 3-4. Elotuzumab will be administered intravenously at a dose of 10 mg/kg.~During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg."
148656|NCT03030261|Drug|Pomalidomide|During induction therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 4 mg. During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
148657|NCT03030261|Drug|Dexamethasone|During induction, dexamethasone will be taken by mouth on Days 1, 8, and 15 of each of four 28-day cycles at a starting dose of 40 mg. During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
148658|NCT03030261|Procedure|Autologous stem cell transplant|-Standard of care
148659|NCT03030261|Drug|Melphalan|-Standard of care
148660|NCT03030248|Drug|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
148661|NCT03030248|Drug|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
148662|NCT03030235|Drug|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10Mg Oral Tablet
148663|NCT03030235|Drug|Dapagliflozin matching placebo|Dapagliflozin matching placebo
148664|NCT03030222|Drug|Empagliflozin 10Mg Tab|Empagliflozin 10Mg Tab
148665|NCT03030222|Drug|Placebo Oral Tablet|Empagliflozin matching placebo
148666|NCT03030209|Procedure|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
148667|NCT03030196|Drug|Denosumab|NaCl 0.9% injection is used as placebo
148668|NCT03030183|Drug|Zilucoplan (RA101495)|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
148669|NCT03030170|Device|ENDO GIA X-tra Thick reload with Tri Staple Technology|Suture of the pancreas by normal stapling
148670|NCT03030170|Device|ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology|Suture of the pancreas by reinforced stapling
148671|NCT03030157|Drug|pirarubicin(THP)|
148672|NCT03030144|Other|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
148673|NCT03030131|Drug|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
148674|NCT03030118|Drug|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
148675|NCT03030118|Drug|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
148676|NCT03030105|Drug|BPN14770|investigational drug
148677|NCT03030105|Drug|BPN14770 placebo|placebo
148678|NCT03030105|Drug|Donepezil|comparator
148679|NCT03030105|Drug|Donepezil placebo|placebo
148680|NCT03030105|Drug|Scopolamine 0.6 MG/ML|cognition impairment
148681|NCT03030105|Drug|Scopolamine placebo|placebo
148682|NCT03030092|Other|Maximal Strength Training|leg pres and abduction exercises
148683|NCT03030079|Device|Experimental Electrical Stimulation Regimen|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
148684|NCT03030066|Drug|DS-1001b|Generic not assigned
148685|NCT03030053|Dietary Supplement|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
148686|NCT03030053|Dietary Supplement|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
148687|NCT03030040|Behavioral|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
148688|NCT03030027|Behavioral|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
148689|NCT03030027|Other|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
148690|NCT03030014|Behavioral|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
148764|NCT03029572|Procedure|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
148905|NCT03028493|Behavioral|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
238661|NCT02374567|Drug|Donepezil|
148691|NCT03030014|Other|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
148692|NCT03030001|Biological|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
148693|NCT03029988|Drug|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
148694|NCT03029988|Procedure|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
148695|NCT03029975|Behavioral|Resistance Training Exercise|Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
148696|NCT03029975|Behavioral|Beef Protein Consumption|Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
148697|NCT03029962|Behavioral|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
148698|NCT03029949|Behavioral|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
148699|NCT03029949|Behavioral|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
148700|NCT03029949|Other|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
148701|NCT03029923|Behavioral|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
148702|NCT03029923|Behavioral|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
148703|NCT03029910|Other|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
148704|NCT03029910|Other|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
148705|NCT03029897|Other|My eReport France|"patients are educated to the use of My eReport France application"
148706|NCT03029884|Device|Medtronic Activa PC+S|In Aim 2 we will perform closed loop DBS versus sham (randomized) to evaluate efficacy of stimulation for analgesia. In Aim 3, closed-loop DBS will be compared to open-loop DBS in a patient blinded, randomized fashion.
148707|NCT03029871|Biological|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
148708|NCT03029858|Other|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
148709|NCT03029845|Drug|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
148710|NCT03029845|Drug|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
148711|NCT03029845|Drug|Placebo|Participants will take placebo twice a day for 2 weeks
148712|NCT03029832|Drug|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
148713|NCT03029832|Drug|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
148714|NCT03029819|Behavioral|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
148715|NCT03029819|Behavioral|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
148716|NCT03029819|Behavioral|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al. Clinical practice guideline for treating tobacco use and dependence, 2008).
149014|NCT03027700|Device|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
238662|NCT02374567|Drug|Rivastigmine|
148717|NCT03029819|Drug|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke >10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
148718|NCT03029806|Other|Aldosterone response to AngII LS|Change in aldosterone from baseline to after Ang II infusion on a LS diet
148719|NCT03029806|Other|Renal blood flow response to salt|Change in renal blood flow: High salt to low salt diet
148720|NCT03029806|Other|Vascular Stiffness|Change in vascular stiffness, baseline compared to AngII
148721|NCT03029793|Other|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
148722|NCT03029793|Other|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
148723|NCT03029780|Biological|Opdivo|Specified dose on specified days
148724|NCT03029780|Biological|Yervoy|Specified dose on specified days
148725|NCT03029767|Other|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
148726|NCT03029767|Other|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.~Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
148727|NCT03029767|Other|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
148728|NCT03029754|Procedure|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
148729|NCT03029741|Drug|AZD0284|Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
148730|NCT03029741|Drug|[14C]AZD0284|Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg [14C]AZD0284 solution
148731|NCT03029715|Drug|Propofol|Total intravenous anaesthesia.
148732|NCT03029715|Drug|Remifentanil|Narcotics
148733|NCT03029715|Drug|Dexmedetomidine|Total intravenous anaesthesia
148734|NCT03029715|Drug|Desflurane|Inhalation anaesthesia.
148735|NCT03029702|Drug|Insulin|Insulin will be used for GDM treatment
148736|NCT03029702|Drug|Glyburide|Glyburide will be used for GDM treatment
148737|NCT03029702|Drug|Metformin|Metformin will be used for GDM treatment
148738|NCT03029689|Drug|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
148739|NCT03029689|Drug|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
148740|NCT03029689|Drug|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
148741|NCT03029676|Drug|benzodiazepines|sedative
148742|NCT03029676|Drug|opioid|analgetic, sedative
148743|NCT03029676|Procedure|spinal anesthesia|
148744|NCT03029663|Procedure|Transurethral resection of the bladder tumour|
148745|NCT03029650|Drug|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
148746|NCT03029650|Drug|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
148747|NCT03029637|Device|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
148748|NCT03029637|Device|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
148749|NCT03029624|Device|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
148750|NCT03029611|Drug|Carboplatin|Given IV
148751|NCT03029611|Procedure|Gynecological Surgical Procedure|Undergo cytoreductive surgery
148752|NCT03029611|Other|Laboratory Biomarker Analysis|Correlative studies
148753|NCT03029611|Drug|Paclitaxel|Given IV
148754|NCT03029611|Biological|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
148755|NCT03029598|Drug|Carboplatin|Given IV
148756|NCT03029598|Other|Laboratory Biomarker Analysis|Correlative studies
148757|NCT03029598|Biological|Pembrolizumab|Given IV
148758|NCT03029585|Drug|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
148759|NCT03029585|Drug|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
148760|NCT03029585|Drug|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
148761|NCT03029585|Drug|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
148762|NCT03029585|Drug|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
148763|NCT03029572|Drug|Diet supplementation|Micronutriment supplementation therapy
150755|NCT03014804|Other|Questionnaire Administration|Ancillary studies
148765|NCT03029559|Other|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).~Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
148766|NCT03029559|Other|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
148767|NCT03029559|Other|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
148768|NCT03029533|Drug|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
148769|NCT03029533|Drug|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
148770|NCT03029520|Other|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
148771|NCT03029520|Other|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
148772|NCT03029507|Behavioral|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
148773|NCT03029507|Behavioral|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
148774|NCT03029494|Device|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
148775|NCT03029494|Drug|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
148776|NCT03029494|Device|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
148777|NCT03029494|Dietary Supplement|Vitamin C|1000 mg
148778|NCT03029481|Drug|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
148779|NCT03029468|Behavioral|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
148780|NCT03029468|Behavioral|eEducation|Pain and sickle cell disease education delivered through a mobile electronic device
148781|NCT03029455|Drug|VX-659|
148782|NCT03029455|Drug|Tezacaftor|
148783|NCT03029455|Drug|Ivacaftor|
148784|NCT03029455|Drug|VX-659 Matching Placebo|
148785|NCT03029455|Drug|Triple Combination (TC) Matching Placebos|
148786|NCT03029442|Drug|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
148787|NCT03029442|Other|Placebo (normal saline)|Identical Denosumab volume of normal saline
148788|NCT03029429|Drug|Theophylline|oral theophylline
148789|NCT03029429|Drug|Placebos|oral placebo
148790|NCT03029416|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
148791|NCT03029403|Drug|Pembrolizumab|Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
148792|NCT03029403|Biological|DPX-Survivac|Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
148793|NCT03029403|Drug|Cyclophosphamide|Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
148794|NCT03029390|Dietary Supplement|Berberine|"Berberine capsules, 500 mg, three per day before each meal during 14 weeks.~The patients will have a running period during two weeks:~First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg"
148795|NCT03029390|Drug|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.~The patients will have a running period:~First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).~From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
148796|NCT03029377|Other|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
148871|NCT03028805|Other|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
150759|NCT03014791|Other|Cardiac output and lung function|Core Measurement
148797|NCT03029364|Behavioral|Study Protocol|"Participants will complete three study protocols 7 - 28 days apart which includes:~3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention."
148798|NCT03029351|Drug|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
148799|NCT03029351|Drug|Placebos|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
148800|NCT03029338|Biological|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
148801|NCT03029312|Device|Galileo M|Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
148802|NCT03029299|Device|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
148803|NCT03029286|Behavioral|Usual Care Arm|Health information provided by the American Cancer Society Website
148804|NCT03029286|Behavioral|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
148805|NCT03029273|Drug|Cyclophosphamide and Fludarabine|Seven days prior to infusion of TCR-T cell, subjects receive cytoreductive chemotherapy with cyclophosphamide (250-500mg/m2/day) plus fludarabine (25mg/m2/day) for 3 days.
148806|NCT03029273|Biological|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (500,000 IU/day) will be administered for 14 days concomitantly to each subject.
148807|NCT03029260|Other|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.~The intervention will be delivered in one session only."
148808|NCT03029260|Other|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.~The intervention will be delivered in one session only."
148809|NCT03029247|Drug|Daprodustat|Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg to be administered once daily.
148810|NCT03029247|Drug|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
148811|NCT03029234|Drug|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles.
148812|NCT03029234|Drug|Carfilzomib|Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle.
148813|NCT03029221|Other|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
148814|NCT03029221|Other|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
148815|NCT03029221|Other|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
148816|NCT03029208|Drug|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
148817|NCT03029208|Drug|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 20, 30, 40, 60, 80, 100 and 150 mcg.
148818|NCT03029208|Drug|Iron therapy|Iron therapy will be administered if ferritin is <=100 ng/mL and/or TSAT is <=20%.
148819|NCT03029195|Device|Nasoalveolar molding therapy|Presurgical infant orthopedics
148820|NCT03029182|Other|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
148821|NCT03029182|Behavioral|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
148822|NCT03029169|Drug|Propafenone i.v.|Treatment
148823|NCT03029169|Drug|Amiodarone i.v.|Treatment
148824|NCT03029156|Device|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.~The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
148825|NCT03029156|Device|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
148826|NCT03029143|Drug|Vedolizumab IV|Vedolizumab intravenous infusion
148827|NCT03029130|Device|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
148828|NCT03029117|Procedure|correction of rheumatic valve lesions|
148829|NCT03029104|Combination Product|CXLO Corneal Strengthening Solution and UVA Illumination Device|CXLO Corneal Strengthening Solution
148830|NCT03029091|Drug|Losartan Potassium|Participants will receive Losartan potassium for 4 months.
148831|NCT03029078|Drug|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
148832|NCT03029052|Behavioral|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
148833|NCT03029039|Other|Blood samples|Blood samples will be collected at inclusion.
148834|NCT03029026|Other|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
148835|NCT03029026|Procedure|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.~Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
148836|NCT03029026|Procedure|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
148837|NCT03029026|Radiation|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
148838|NCT03029026|Procedure|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
148839|NCT03029026|Procedure|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
148840|NCT03029026|Other|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
148841|NCT03029013|Drug|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
148842|NCT03029000|Drug|Tbo-filgrastim|solution for subcutaneous injection
148843|NCT03028987|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
148844|NCT03028987|Biological|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
148845|NCT03028974|Biological|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
148846|NCT03028974|Biological|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
148847|NCT03028961|Other|Stanford Letter|Receive and complete the Stanford Letter
148848|NCT03028961|Other|Interview|Undergo semi-structured, research staff-led interview
148849|NCT03028961|Other|Questionnaire Administration|Ancillary studies
148850|NCT03028961|Other|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
148851|NCT03028948|Other|Internet-Based Intervention|Access ITW
148852|NCT03028948|Other|Questionnaire Administration|Ancillary studies
148853|NCT03028948|Other|Survey Administration|Ancillary studies
148854|NCT03028935|Behavioral|Exercise Intervention|Undergo instructor-led exercise program
148855|NCT03028935|Behavioral|Nutritional Intervention|Undergo instructor-led nutritional education program
148856|NCT03028922|Device|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
148857|NCT03028909|Drug|Oseltamivir|Standard of care for influenza caused by Type A strains
148858|NCT03028909|Drug|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
148859|NCT03028909|Drug|Placebo|Salt-water solution containing no active ingredients.
148860|NCT03028896|Procedure|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
148861|NCT03028883|Other|Dose adjustments|Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
148862|NCT03028870|Drug|V120083|Capsules
148863|NCT03028870|Drug|Naproxen|Capsules
148864|NCT03028870|Drug|Placebo|Capsules to match V120083 and/or naproxen
148865|NCT03028857|Drug|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner.
148866|NCT03028857|Dietary Supplement|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner.
148867|NCT03028844|Other|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
148868|NCT03028831|Dietary Supplement|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
148869|NCT03028831|Dietary Supplement|Resistant starch|70g high-amylose maize starch
148870|NCT03028805|Other|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
148904|NCT03028493|Behavioral|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
238663|NCT02374567|Drug|Galantamine|
148872|NCT03028792|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
148873|NCT03028792|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
148874|NCT03028779|Procedure|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
148875|NCT03028766|Drug|AZD1775|AZD1775 is a potent, selective small molecule inhibitor of WEE1
148876|NCT03028766|Drug|Cisplatin|Chemotherapy drug
148877|NCT03028766|Radiation|Radiotherapy|Intensity Modulated Radiotherapy
148878|NCT03028753|Device|Bladder scan post void residual|After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
148879|NCT03028753|Procedure|Straight catheter post void residual|After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
148880|NCT03028753|Procedure|Back fill voiding trial|Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
148881|NCT03028740|Drug|Cenicriviroc|1 tablet QD
148882|NCT03028740|Drug|Placebo|1 tablet QD
148883|NCT03028727|Procedure|Ultrasonic Scaling and root planing|Procedure of scaling and root planing at day 0 and at 1 week
148884|NCT03028727|Procedure|980 nm diode laser irradiation|Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
148885|NCT03028714|Behavioral|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
148886|NCT03028701|Drug|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
148887|NCT03028688|Device|High flow nasal cannula oxygen|Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
148888|NCT03028675|Drug|Gd-DTPA-ST|The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm (patients only). The
148889|NCT03028675|Drug|Control|No Contrast Agent
148890|NCT03028662|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
148891|NCT03028649|Dietary Supplement|β-hydroxy-β-methylbutyrate and a placebo supplementation|
148892|NCT03028623|Procedure|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
148893|NCT03028623|Procedure|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
148894|NCT03028610|Device|radiofrequency generator|
148895|NCT03028597|Behavioral|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
148896|NCT03028597|Behavioral|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
148897|NCT03028584|Behavioral|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
148898|NCT03028571|Drug|Trimethaphan|Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
148899|NCT03028571|Other|Saline|IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
148900|NCT03028545|Behavioral|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
148901|NCT03028532|Drug|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
148902|NCT03028519|Drug|Vitamin D3|
148903|NCT03028506|Other|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
238664|NCT02374567|Drug|Memantine|
148906|NCT03028480|Drug|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
148907|NCT03028467|Drug|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
148908|NCT03028467|Drug|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
148909|NCT03028467|Drug|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
148910|NCT03028467|Drug|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
148911|NCT03028467|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
148912|NCT03028467|Drug|Folic acid|Folic acid tablet 5 mg per week is given orally.
148913|NCT03028454|Dietary Supplement|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
148914|NCT03028454|Dietary Supplement|Placebo|Capsules containing rice flour powder.
148915|NCT03028441|Other|Placebo|Placebo
148916|NCT03028441|Biological|VRC-CHKVLP059-00-VP|Measles-vectored Chikungunya vaccine
148917|NCT03028428|Biological|Placenta Derived Mesenchymal Stem Cell|1ml 1*10^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
148918|NCT03028428|Drug|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
148919|NCT03028415|Device|AMPLEX®|A bone graft substitute
148920|NCT03028415|Procedure|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
148921|NCT03028402|Procedure|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
148922|NCT03028389|Procedure|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
148923|NCT03028376|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
148924|NCT03028363|Drug|Olumacostat Glasaretil Gel, 5.0%|Gel containing Olumacostat Glasaretil
148925|NCT03028363|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
148926|NCT03028350|Drug|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
148927|NCT03028350|Drug|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
148928|NCT03028337|Radiation|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.~Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
148929|NCT03028337|Behavioral|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.~Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
148930|NCT03028324|Device|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
148931|NCT03028311|Procedure|Angiography|Undergo angiography
148932|NCT03028311|Procedure|Computed Tomography|Undergo SPECT-CT
148933|NCT03028311|Procedure|Planar Imaging|Undergo planar imaging
148934|NCT03028311|Radiation|Radioembolization|Undergo radioembolization
148935|NCT03028311|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT-CT
148936|NCT03028311|Radiation|Technetium Tc-99m Albumin Aggregated|Given via arterial catheter
148937|NCT03028311|Other|Yttrium Y 90 Resin Microspheres|Given via arterial catheter
148938|NCT03028298|Drug|Low dose sildenafil citrate|
148939|NCT03028298|Drug|High dose sildenafil citrate|
148940|NCT03028285|Drug|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
148941|NCT03028272|Other|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
148942|NCT03028272|Other|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
148943|NCT03028259|Other|lab results|Comparison of lab results
148944|NCT03028246|Device|ExAblate 4000 System|Focused ultrasound
148945|NCT03028233|Behavioral|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
148946|NCT03028233|Behavioral|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
148947|NCT03028220|Device|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
148948|NCT03028220|Device|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
148949|NCT03028207|Procedure|Medical tests|During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
149015|NCT03027687|Device|tDCS|tDCS is an electrical brain stimulation method
148950|NCT03028207|Other|Questionnaire|During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
148951|NCT03028194|Procedure|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
148952|NCT03028194|Procedure|Placebo|No procedure after delivery of the placenta
148953|NCT03028168|Other|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
148954|NCT03028168|Other|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
148955|NCT03028168|Other|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
148956|NCT03028155|Drug|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
148957|NCT03028155|Drug|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
148958|NCT03028142|Drug|1.5 mg RPL554 plus tiotropium|
148959|NCT03028142|Drug|6 mg RPL554 plus tiotropium|
148960|NCT03028142|Drug|Placebo plus tiotropium|
148961|NCT03028129|Drug|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly. The administration will be supervised.
148962|NCT03028129|Drug|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
148963|NCT03028116|Biological|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
148964|NCT03028116|Biological|Placebo|water for injection
148965|NCT03028103|Drug|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
148966|NCT03028103|Drug|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
148967|NCT03028103|Drug|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
148968|NCT03028103|Drug|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
148969|NCT03028090|Device|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
148970|NCT03028077|Dietary Supplement|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
148971|NCT03028077|Dietary Supplement|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
148972|NCT03028077|Dietary Supplement|Placebo|Placebo 1 g/day
148973|NCT03028064|Other|blood taking|in this cohort study, we will take blood to examine the platelet function
148974|NCT03028038|Drug|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
148975|NCT03028038|Drug|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.~High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
148976|NCT03028025|Device|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
148977|NCT03028025|Device|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
148978|NCT03028012|Drug|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
148979|NCT03028012|Drug|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
148980|NCT03028012|Drug|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
149016|NCT03027674|Drug|10% nifedipine cream|Topical treatment for Raynaud
149017|NCT03027674|Drug|5% sildenafil cream|Topical treatment for Raynaud
148981|NCT03027999|Other|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of~a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.~A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP > 2.7"
148982|NCT03027986|Behavioral|postural rehabilitation program|This program is based on sensory-motor control
148983|NCT03027973|Drug|UPA|Experimental drug
148984|NCT03027973|Drug|TEA|Active comparator
148985|NCT03027973|Drug|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
148986|NCT03027973|Drug|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
148987|NCT03027960|Drug|Empagliflozin|10mg empagliflozin for a 2-week period
148988|NCT03027960|Drug|Placebo Oral Capsule|10 mg placebo for a 2-week period
148989|NCT03027947|Device|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
148990|NCT03027934|Drug|Ticagrelor|Ticagrelor, 90mg twice daily
148991|NCT03027934|Drug|Prasugrel|Prasurgrel, 10mg once daily
148992|NCT03027921|Other|elastography|
148993|NCT03027908|Other|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
148994|NCT03027908|Other|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
148995|NCT03027895|Device|Lumen-apposing metal stent (LAMS)|Endoscopic Ultrasound-guided Drainage of WON with LAMS
148996|NCT03027895|Device|Double pigtail plastic stent (DPPS)|Endoscopic Ultrasound-guided Drainage of WON with DPPS
148997|NCT03027882|Other|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
148998|NCT03027869|Device|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
148999|NCT03027856|Device|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
149000|NCT03027843|Drug|Growth Hormone|in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
149001|NCT03027830|Device|iFR pressure-wire|The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
149002|NCT03027830|Device|Conventional|Other diagnostic devices (including FFR and angiography)
149003|NCT03027817|Procedure|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
149004|NCT03027804|Procedure|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
149005|NCT03027791|Behavioral|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
149006|NCT03027791|Behavioral|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
149007|NCT03027778|Other|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
149008|NCT03027752|Procedure|Operation carotid endarterectomy with plastic of xenopericardial patch|Under local anesthesia Sol.Novocaini 0.25%, wires or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Common carotid artery cut then performed a longitudinal arteriotomy on the front of the anterior surface of the internal carotid artery. Under the visual control performs a sequence of endarterectomy of the internal carotid artery. Plastic arteriotomy performed patche of ksenoperikardial (Kemperiplas-Neo) treated with epoxy compounds.
149009|NCT03027752|Procedure|New method of operation сarotid endarterectomy with autoarterial remodeling of bifurcation CCA|Under local anesthesia Sol.Novocaini 0.25%, or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Carotid glomus separated and moves downward and backward bifurcation of the common carotid artery. External carotid artery is cut off at an angle of 45º from the mouth with a portion of the common carotid artery, then performed a longitudinal arteriotomy on the front of the medial surface of the internal carotid and posterior-lateral surface of the external carotid artery. Under the visual control performs a sequence of endarterectomy of the internal and external carotid arteries. The final recovery of the arteries is performed by crosslinking of their walls with each other in a side by side type between the internal and external carotid arteries 6/0 Polypropylene thread with two needles.
149010|NCT03027739|Biological|CART-19|CART-19 cells treated
149011|NCT03027726|Behavioral|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
149012|NCT03027726|Other|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
149013|NCT03027713|Procedure|weaning protocol|The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
149019|NCT03027661|Drug|0.9% Sodium Chloride|Inject 10 mL of 0.9% NaCl into cervical stroma
149020|NCT03027648|Procedure|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
149021|NCT03027635|Device|PleurX, peritoneal tunnelated catheter|A permanent catheter
149022|NCT03027635|Device|Large Volume Paracentesis|Short time drainage
149023|NCT03027635|Drug|Ciprofloxacin 500Mg Tablet|SBP prophylaxis
149024|NCT03027622|Behavioral|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
149025|NCT03027609|Drug|AR-105|monoclonal antibody
149026|NCT03027609|Drug|placebo|matching placebo
149027|NCT03027596|Procedure|Remote ischemic conditioning|
149028|NCT03027583|Dietary Supplement|Probiotic|6 weeks daily oral intake of a probiotic strain.
149029|NCT03027583|Dietary Supplement|Placebo|6 weeks daily oral intake of placebo.
149030|NCT03027570|Behavioral|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
149031|NCT03027570|Behavioral|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
149032|NCT03027570|Other|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
149033|NCT03027557|Drug|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
149034|NCT03027557|Drug|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
149035|NCT03027557|Other|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
149036|NCT03027557|Other|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
149037|NCT03027544|Radiation|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.~TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles."
149038|NCT03027531|Behavioral|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
149039|NCT03027518|Other|WILD 5 Wellness|Participants will be asked to voluntarily engage in integrated, prescriptive, and trackable wellness interventions combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition.
149040|NCT03027505|Drug|Ready to Use Therapeutic Food (RUTF)|"MUAC used as the primary admission and exit criteria for children with MUAC <125mm and no medical complication.~Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:~MUAC <115 mm: 175 kcal /kg/day~115 <MUAC <120mm: 125kcal/kg/day~120 <MUAC <125mm: 75kcal/kg/day"
149041|NCT03027492|Other|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
149042|NCT03027479|Other|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
149043|NCT03027466|Behavioral|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition).Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
149044|NCT03027414|Drug|Transcranial Magnetic Stimulatin Sham|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
149045|NCT03027414|Device|Transcranial Magnetic Stimulation|TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
149046|NCT03027388|Drug|LB-100|LB-100 will be infused over 2 hours via syringe pump in the OR or 1-12 hours before to surgery. The dose established from a Phase I study will be 2.33 mg/m(2).
149047|NCT03027375|Drug|Qishen Granules|The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).
149048|NCT03027375|Drug|Placebo|The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
149049|NCT03027362|Other|Cognitive behavioral therapy (CBT) and medication|Sixteen sessions over 14 weeks.
149050|NCT03027362|Other|Psychoeducation and medication|
149051|NCT03027349|Other|No intervention are provided|
149052|NCT03027336|Dietary Supplement|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
150760|NCT03014791|Other|Heart rate variability|Core Measurement
149053|NCT03027336|Dietary Supplement|Placebo|patients will take one tablet daily for 12 weeks.
149054|NCT03027323|Device|AxoTrack System|The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
149055|NCT03027284|Drug|Merestinib|Administered orally
149056|NCT03027284|Drug|Cisplatin|Administered IV
149057|NCT03027284|Drug|Gemcitabine|Administered IV
149058|NCT03027258|Other|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
149059|NCT03027245|Drug|Eribulin|
149060|NCT03027232|Other|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
149061|NCT03027219|Drug|Alprostadil|Vasodilator for anastomosis-site of free flap
149062|NCT03027206|Other|Vibration technique|Comparison of different technique
149063|NCT03027206|Other|Acceleration of expiratory flow|Comparison of different technique
149064|NCT03027193|Biological|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens
149065|NCT03027193|Biological|MVA HAV|The MVA HAV vaccine consists of the replication deficient modified vaccinia virus Ankara (MVA) containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens.
149066|NCT03027180|Device|Noninvasive positive airway pressure with different levels|
149067|NCT03027167|Drug|Aspirin|
149068|NCT03027167|Device|(Post- discharge) Mechanical Compression Device|
149069|NCT03027154|Biological|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
149070|NCT03027154|Biological|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
149071|NCT03027141|Behavioral|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
149072|NCT03027128|Biological|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
149073|NCT03027115|Drug|Tamsulosin|Tamsulosin treatment for 7 days pre-operatively
149074|NCT03027102|Biological|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
149075|NCT03027076|Procedure|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
149076|NCT03027076|Procedure|Collect midstream urine samples|Collect midstream urine samples
149077|NCT03027063|Behavioral|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
149078|NCT03027063|Behavioral|Usual Care|Participants will receive the ACC/AHA exercise guidelines
149079|NCT03027050|Procedure|T-PRF|Applied for treatment of periodontal bone loss.
149080|NCT03027050|Procedure|Open Flap Debridement alone|
149081|NCT03027024|Device|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
149082|NCT03027011|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
149083|NCT03027011|Procedure|Control|Control group without remote ischemic preconditioning
149084|NCT03026998|Procedure|MRI|MRI will be performed each year during 10 years.
149085|NCT03026985|Other|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
149086|NCT03026972|Biological|Placebo|The placebo drug contains 20mg mannitol and 10 millimole(mM) phosphate buffer(PB).population I～population IV are coxal muscle injection of placebo.
149087|NCT03026972|Biological|Low dose adjuvant|Population I and polulation IV are coxal muscle injection of low dose adjuvant.
149088|NCT03026972|Biological|High dose adjuvant|Population II ,Population III and Population IV are coxal muscle injection of high dose adjuvant.
149089|NCT03026972|Biological|Low dose vaccine|Population I and population IV are coxal muscle injection of low dose vaccine.
149090|NCT03026972|Biological|High dose vaccine|Population II,population III and population IV are coxal muscle injection of high dose vaccine .
149091|NCT03026959|Behavioral|Mindfulness|The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, & Bédard, (2015).
149092|NCT03026946|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
149093|NCT03026946|Drug|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
149094|NCT03026933|Drug|KI1107 4 Capsules, QD|KI1107 4 Capsules
149095|NCT03026933|Drug|Rosuvastatin Calcium 20 MG, QD|Rosuvastatin Calcium 20mg, QD
149096|NCT03026920|Procedure|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
149097|NCT03026907|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
149098|NCT03026907|Drug|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
149099|NCT03026894|Radiation|Panoramic Radiograph|Measurement of bone resorption
149100|NCT03026894|Device|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
149101|NCT03026881|Drug|Fluzoparib|Fluzoparib either at 20,30,40mg twice daily,capsule oral.
149102|NCT03026881|Drug|Apatinib|Oral
149103|NCT03026881|Drug|Paclitaxel|Intravenous injection
149104|NCT03026868|Procedure|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
149105|NCT03026855|Biological|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
149106|NCT03026842|Drug|Decitabine|20 mg/m2/day for 5 days
149107|NCT03026842|Drug|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
149108|NCT03026842|Drug|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
149109|NCT03026842|Drug|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
149110|NCT03026829|Device|CART sound therapy|"The study consists of two parts:~Phase 1: laboratory evaluation of CART sound acceptability~Phase 2: take home evaluation of CART sound therapy including baseline without CART"
149111|NCT03026816|Device|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
149112|NCT03026803|Drug|Oxaliplatin|Given IV
149113|NCT03026803|Drug|Capecitabine|Given PO
149114|NCT03026790|Other|Medication management|Individualized management of medications for pain
149115|NCT03026790|Other|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
149116|NCT03026790|Drug|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
149117|NCT03026777|Drug|intravenous crystalloid fluid, 500 mL|
149118|NCT03026764|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
149119|NCT03026764|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
149120|NCT03026751|Procedure|Bone Marrow Aspirate|Bone marrow aspirate
149121|NCT03026738|Procedure|Laparoscopic anterior mesh rectopexy|fixation of the rectum anteriorly using laparosopy and polypropylene mesh
149122|NCT03026738|Procedure|Laparoscopic posterior mesh rectopexy|fixation of the rectum posteriorly using laparosopy and polypropylene mesh
149123|NCT03026738|Device|polypropylene mesh|A strip of polypropylene mesh will be introduced and sutured.
149124|NCT03026725|Other|Tri-calcium Phosphate|A paste contains Tri Calcium Phosphate & Fluoride
149125|NCT03026725|Other|Placebo|paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
149126|NCT03026712|Device|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
149127|NCT03026712|Device|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks."
149128|NCT03026699|Behavioral|eSNAP|Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.
149129|NCT03026699|Behavioral|Questionnaires|Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
149130|NCT03026673|Other|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
149131|NCT03026660|Dietary Supplement|Moringa Oleifera|
149132|NCT03026660|Dietary Supplement|Cabbage Placebo|
149133|NCT03026647|Procedure|Suture|To examine different types of suture material used for hysterotomy closure in cesarean section and determine if one is preferred above other types due to a complications profile.
149134|NCT03026634|Behavioral|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
149135|NCT03026621|Dietary Supplement|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
149136|NCT03026621|Other|Herbal tea|This is an herbal tea that will look like the control
150761|NCT03014791|Other|Blood sample & spot urine sample|Core Measurement
149137|NCT03026608|Behavioral|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
149138|NCT03026595|Other|no intervention|no intervention
149139|NCT03026582|Device|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
149140|NCT03026569|Other|Orange juice (500 mL/d)|The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.
149141|NCT03026556|Drug|Dabigatran vs. Rivaroxaban|observed for 6 years
149142|NCT03026556|Drug|Dabigatran vs. Apixaban|Observed for 6 years
149143|NCT03026543|Procedure|Pulmonary Recruitment Maneuver|
149144|NCT03026543|Procedure|Laparoscopic cholecystectomy|
149145|NCT03026543|Device|Ventilator|
149146|NCT03026530|Procedure|Pulmonary recruitment maneuver|The participants in the experimental arm receives 1 minute of ventilator-piloted pulmonary recruitment with positive inspiratory pressure set to 40 cm H2O, at the end of laparoscopic bariatric surgery.
149147|NCT03026530|Procedure|Laparoscopic bariatric surgery|
149148|NCT03026530|Device|Ventilator|
149149|NCT03026517|Drug|Dabrafenib|
149150|NCT03026517|Drug|Trametinib|
149151|NCT03026517|Drug|Phenformin|
149152|NCT03026504|Drug|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
149153|NCT03026491|Other|Chewing evaluation|Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
149154|NCT03026478|Drug|Betamethasone Dipropionate|
149155|NCT03026478|Drug|Clobetasol Propionate|
149156|NCT03026465|Device|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
149157|NCT03026465|Device|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
149158|NCT03026452|Procedure|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
149159|NCT03026426|Behavioral|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.~Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
149160|NCT03026413|Procedure|pulmonary vein antrum modification|
149161|NCT03026400|Procedure|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
149162|NCT03026400|Procedure|Subumbilical incision|Considered here as the ''control'' intervention.
149163|NCT03026387|Behavioral|Neuropsychological battery tests|"The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test.~The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention and verbal fluidity"
149164|NCT03026374|Behavioral|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
149165|NCT03026361|Genetic|global proteomic profiling|Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
149166|NCT03026348|Biological|RSV F Vaccine with Aluminum Phosphate Adjuvant|
149167|NCT03026348|Biological|RSV F Vaccine|
149168|NCT03026348|Biological|Matrix-M1 Adjuvant|
149169|NCT03026348|Other|Phosphate Buffer|
149170|NCT03026335|Behavioral|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
149171|NCT03026335|Behavioral|Control|Business as usual with students in non-itervened schools
149172|NCT03026322|Other|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
149173|NCT03026322|Other|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
149174|NCT03026309|Other|no intervantion|no intervention is being performed, only observational evaluations.
149294|NCT03025347|Other|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
149175|NCT03026296|Behavioral|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
149176|NCT03026283|Device|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
149177|NCT03026270|Other|Paraffin|The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
149178|NCT03026257|Device|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
149179|NCT03026257|Device|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
149180|NCT03026257|Device|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
149181|NCT03026257|Device|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
149182|NCT03026257|Device|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
149183|NCT03026257|Device|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
149184|NCT03026257|Device|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
149185|NCT03026257|Device|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
149186|NCT03026244|Dietary Supplement|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
149187|NCT03026244|Dietary Supplement|Placebo product|3 periods of 3 weeks placebo product
149188|NCT03026231|Biological|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
149189|NCT03026231|Drug|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
149190|NCT03026218|Other|GlucoseMama application with blood sugar monitoring and carb monitoring.|We will use the Glucosemama application to review glucose and carb logs on a weekly basis. This will be reviewed with the patient in order to adjust dietary and medicals.
149191|NCT03026218|Other|Group prenatal care for GDM.|group prenatal care is a group based intervention where individuals with GDM will meet together to learn about pregnancy and diabetes.
149192|NCT03026205|Drug|ARMS-I|
149193|NCT03026192|Device|near infrared spectroscopy|Near infrared spectroscopy will be placed on infants both with and without hsPDA
149194|NCT03026179|Behavioral|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
149195|NCT03026166|Drug|ipilimumab|Intravenous
149196|NCT03026166|Drug|nivolumab|Intravenous
149197|NCT03026166|Drug|rovalpituzumab tesirine|Intravenous
149198|NCT03026153|Behavioral|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
149199|NCT03026153|Behavioral|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
149200|NCT03026140|Drug|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
149201|NCT03026140|Drug|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
149202|NCT03026140|Drug|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
149203|NCT03026127|Behavioral|Cognitive Reappraisal Intervention for Suicide Prevention|Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
149204|NCT03026127|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
149205|NCT03026114|Other|No intervention is planned in our study.|No intervention is planned in our study.
149206|NCT03026101|Other|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches to replicate migraine pain
149207|NCT03026088|Drug|Bisoprolol|Subjects will receive Bisoprolol at a dose of 1.25 milligram (mg) up to Weeks 3, and then it will be up-titrated to 2.5 mg up to Week 6 , 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18, and 10 mg up to Week 26.
149208|NCT03026075|Device|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
149209|NCT03026062|Biological|Durvalumab|Given IV
149210|NCT03026062|Biological|Tremelimumab|Given IV
149211|NCT03026049|Device|deep venous stenting|Deep venous stent
149212|NCT03026036|Radiation|PET Scan with Raclopride|A subsample (21 per group) will complete the PET imaging.
238665|NCT02374567|Drug|Nicergoline|
149213|NCT03026023|Drug|Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin|HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
149214|NCT03026010|Procedure|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
149215|NCT03025997|Dietary Supplement|Active yoghurt|Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
149216|NCT03025997|Dietary Supplement|Placebo yoghurt|Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
149217|NCT03025984|Behavioral|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
149218|NCT03025971|Device|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
149219|NCT03025958|Drug|Nimotuzumab|
149220|NCT03025958|Radiation|Radiation|
149221|NCT03025945|Drug|Nepafenac 0.3%|
149222|NCT03025945|Drug|Saline Solution|
149223|NCT03025932|Procedure|repair of giant hiatal hernia with mesh and anterior fundoplication|
149224|NCT03025906|Drug|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
149225|NCT03025906|Drug|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
149226|NCT03025893|Drug|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
149227|NCT03025893|Drug|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
149228|NCT03025880|Drug|Pembrolizumab|Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
149229|NCT03025880|Drug|Gemcitabine|Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.
149230|NCT03025867|Drug|Niraparib|
149231|NCT03025854|Other|laboratory biomarker analysis|
149232|NCT03025841|Drug|Ceftaroline|
149233|NCT03025828|Drug|ACTHar|for 6 months
149234|NCT03025815|Other|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
149235|NCT03025815|Other|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
149236|NCT03025789|Drug|Fexinidazole|Tablets of 600 mg Patients with a weight between 20 and 34kg: 1200mg for 4 days, then 600mg for 6 days Patients with a weight of 35kg and above: 1800mg for 4 days, then 1200mg for 6 days
149237|NCT03025776|Behavioral|Reaching|sitting reaching under various task conditions (size, speed, location)
149238|NCT03025776|Behavioral|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many & which hand to use, kinematic data collected
149239|NCT03025763|Other|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
149240|NCT03025763|Other|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
149241|NCT03025763|Procedure|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
149242|NCT03025763|Procedure|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
149243|NCT03025763|Procedure|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
149244|NCT03025763|Procedure|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
149245|NCT03025763|Procedure|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
149246|NCT03025750|Biological|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
149247|NCT03025750|Biological|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
149295|NCT03025334|Device|transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
238666|NCT02374567|Drug|Acamprosate|
149248|NCT03025724|Drug|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
149249|NCT03025724|Device|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
149250|NCT03025724|Other|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
149251|NCT03025698|Drug|Eltrombopag|Tablet for oral use, once daily
149252|NCT03025698|Drug|hATG|Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
149253|NCT03025698|Drug|CsA|Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
149254|NCT03025685|Procedure|TRUST technique|A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily
149255|NCT03025685|Procedure|Anchoring Technique|A standard endovascular technique of coronary wire support improvement
149256|NCT03025685|Procedure|Coronary stenting|A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
149257|NCT03025659|Other|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
149258|NCT03025646|Other|Mental Health care services & home based training|"From day 0 of the study period we will initiate setting up the intervention in two schools, which will include two components:~Implementing mental health care services at schools targeting the mothers diagnosed as having depression who have consented to participate in the study (intervention mother).~Psychologists will provide counseling session over 4-6 months period. Every month a psychiatrist will visit each school for reviewing the records of the mothers and mothers will be referred to the National Institute of Mental Health (NIMH) if necessary~Organizing training sessions of the intervention mothers for supporting enhanced child care at home.~Organizing training of the intervention mothers by special educator through a parental training module in the schools. Special educator will conduct refresher training at home every month."
149259|NCT03025633|Other|PEARL|PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
149260|NCT03025620|Dietary Supplement|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
149261|NCT03025620|Dietary Supplement|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
149262|NCT03025607|Device|JOOL Health Mobile Phone Application|JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
149263|NCT03025594|Drug|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
149264|NCT03025594|Drug|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
149265|NCT03025581|Other|Nipple stimulation|For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
149266|NCT03025568|Other|PEEK|PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
149267|NCT03025568|Other|Bre.flex|In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
149268|NCT03025555|Other|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.~It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
149269|NCT03025555|Other|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
149270|NCT03025542|Drug|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
149271|NCT03025542|Other|Placebo|Subjects will receive injections of Placebo.
149272|NCT03025529|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation or TMS is a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. This magnetic field can pass through the head safely and painlessly. TMS can be used to change activity in the brain.
149273|NCT03025529|Device|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation or sham TMS is like active TMS, a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. TMS can be used to change activity in the brain but in this intervention, the coil will be angled 90 degrees from the scalp, resting on one wing of the coil, and therefore will not be delivering active TMS.
149274|NCT03025516|Device|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
149275|NCT03025516|Device|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
149276|NCT03025503|Other|nipple stimulation|
149277|NCT03025490|Device|Capnographic monitoring|Capnographic monitoring is used during the sedation.
149278|NCT03025477|Drug|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
149279|NCT03025477|Drug|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
149280|NCT03025477|Drug|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"carboplatin (IV) - paclitaxel (IV) (3 cycles)~Interval surgery~Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
149281|NCT03025477|Drug|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"Cisplatin (IV) - Epirubicin (IV) (3 cycles)~Interval surgery :~if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)~if CC>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
149282|NCT03025464|Device|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
149283|NCT03025451|Behavioral|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
149284|NCT03025425|Device|Trilogy 100 ® (Philips Respironics)|Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
149285|NCT03025412|Procedure|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
149286|NCT03025412|Behavioral|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
149287|NCT03025399|Drug|Tangwang prescription|A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
149288|NCT03025399|Drug|Placebo|Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
149289|NCT03025386|Other|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
149290|NCT03025386|Other|Electroencephalography|Mesure of the mismatch negativity wave
149291|NCT03025373|Other|Visuo-acoustic stimulation|Controlled visual and acoustic stimulation in a virtual reality setting
149292|NCT03025360|Drug|Larotrectinib (Vitrakvi, BAY2757556)|Larotrectinib will be administered orally as capsule or liquid solution as specified by the treating physician.
149293|NCT03025347|Other|Control|Participants complete a resting control condition instead of a run.
149296|NCT03025321|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
149297|NCT03025308|Drug|Filgotinib|Tablet(s) administered orally once daily
149298|NCT03025308|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
149299|NCT03025295|Drug|Dexmedetomidine|
149300|NCT03025295|Drug|Saline|
149301|NCT03025282|Drug|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
149302|NCT03025282|Drug|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
149303|NCT03025282|Drug|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
149304|NCT03025282|Drug|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
149305|NCT03025282|Drug|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
149306|NCT03025282|Drug|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
149307|NCT03025269|Drug|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
149308|NCT03025256|Biological|Nivolumab|Given IV or IT
149309|NCT03025243|Device|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
149310|NCT03025230|Other|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
149311|NCT03025230|Other|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
149312|NCT03025217|Behavioral|Total Lifestyle Coaching (TLC)|
149313|NCT03025204|Biological|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
149314|NCT03025204|Procedure|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
149315|NCT03025191|Behavioral|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
149316|NCT03025191|Behavioral|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
149317|NCT03025191|Behavioral|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
149318|NCT03025191|Behavioral|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
149319|NCT03025178|Procedure|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
149320|NCT03025165|Other|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
149321|NCT03025165|Other|Home-Based ART Delivery|Provision of ART care to an individual at their home
149322|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
149323|NCT03025152|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
149324|NCT03025152|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
149325|NCT03025139|Other|Educational Intervention|Attend survivorship education
149326|NCT03025139|Other|Laboratory Biomarker Analysis|Correlative studies
149327|NCT03025139|Procedure|Meditation Therapy|Attend mindfulness meditation
149328|NCT03025139|Other|Questionnaire Administration|Ancillary studies
149329|NCT03025126|Other|Multimedial Rehabilitation|
149330|NCT03025126|Other|Usual care program|Usual care at home program according to healthcare professional's advice
149331|NCT03025113|Drug|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
149332|NCT03025113|Drug|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
149333|NCT03025087|Drug|Hydroxychloroquine|Participants will be getting hydroxychloroquine
149334|NCT03025061|Other|Assessment of E-nose measurements|Breath sampling through E-nose pneumopipe
149335|NCT03025048|Behavioral|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
149336|NCT03025035|Drug|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
149337|NCT03025022|Drug|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
149338|NCT03025009|Drug|LY3192767|Administered SC.
149344|NCT03024983|Other|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
149345|NCT03024983|Other|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
149346|NCT03024983|Other|Bread|Bread (122 g) eaten with 500 mL of water
149347|NCT03024983|Other|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
149348|NCT03024983|Other|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
149349|NCT03024983|Other|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
149350|NCT03024957|Drug|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
149351|NCT03024957|Drug|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
149352|NCT03024957|Drug|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
149353|NCT03024944|Drug|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
149354|NCT03024931|Other|observational study|No intervention
149355|NCT03024905|Behavioral|Village meeting and travel vouchers|"The interventions are:~Village meetings by community health workers to educate women and their families about safe birthing.~Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery."
149356|NCT03024905|Device|Birth kit with misoprostol|Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).
149357|NCT03024892|Procedure|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
149358|NCT03024892|Procedure|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
149359|NCT03024892|Procedure|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
149360|NCT03024892|Procedure|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
149361|NCT03024879|Drug|Erythromycin|
149362|NCT03024879|Drug|Saline|
149363|NCT03024853|Behavioral|BPS PAST|
149364|NCT03024853|Behavioral|BPS PRESENT|
149365|NCT03024853|Behavioral|BPS FUTURE|
149366|NCT03024853|Behavioral|CONTROL|
149367|NCT03024840|Drug|Sevoflurane|Sevoflurane: 1%~2%
149368|NCT03024840|Drug|Propofol|Propofol: 9-15 mg/kg/h
149369|NCT03024827|Drug|CanniMed® 1:20|A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
149370|NCT03024814|Drug|Acetaminophen|"The first group will receive acetaminophen as the following~Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
149371|NCT03024814|Drug|Dextrose 5|"The second group will receive placebo (D5W) as the following~Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
149372|NCT03024801|Drug|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
149373|NCT03024801|Drug|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
149374|NCT03024788|Device|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
149375|NCT03024775|Dietary Supplement|Wheat flour|Wheat flour will be administered three times per day for 15 days.
149376|NCT03024775|Dietary Supplement|Placebo|Placebo (xylose) will be administered three times per day for 15 days.
149377|NCT03024762|Procedure|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
149378|NCT03024736|Other|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in~the treatment of opioid-maintained pregnant women"
149379|NCT03024723|Device|nasal mask CPAP|CPAP and ventilation administered via nasal mask
149380|NCT03024710|Behavioral|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
149381|NCT03024697|Procedure|Pectoral Plane Block|
149382|NCT03024697|Procedure|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
149383|NCT03024684|Drug|Atorvastatin|Atorvastatin 10mg daily
149384|NCT03024684|Drug|Placebo Oral Tablet|Placebo one tablet daily
149385|NCT03024671|Other|Patch test application|test patch with cosmetic product will be applied to the back
149386|NCT03024658|Other|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
149387|NCT03024645|Behavioral|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
149388|NCT03024645|Other|Treatment as usually (TAU)|performed in primary care settings
149389|NCT03024632|Procedure|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
149390|NCT03024619|Other|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
149391|NCT03024606|Behavioral|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
149392|NCT03024593|Behavioral|Health- and illness-related internet use|
149393|NCT03024580|Drug|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
149394|NCT03024580|Drug|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
149395|NCT03024580|Drug|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
149396|NCT03024580|Drug|Exemestane 25 MG|Exemestane 25 mg PO daily
149397|NCT03024580|Drug|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
149398|NCT03024580|Drug|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
149399|NCT03024567|Dietary Supplement|Salt|10 capsules daily for 14 days
149400|NCT03024567|Dietary Supplement|Placebo|10 capsules daily for 14 days
149401|NCT03024554|Device|Implantation of the Bifurcated Multilayer Flow Modulator|
149402|NCT03024528|Behavioral|CPOT assessment|Polish version of Critical care pain observation tool validation.
149403|NCT03024515|Drug|opioids titration|Standard Practice Arm
149404|NCT03024515|Drug|predefined titration steps|comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
149405|NCT03024502|Drug|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
149406|NCT03024502|Drug|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
149407|NCT03024502|Drug|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
149408|NCT03024489|Drug|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
149409|NCT03024489|Drug|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
149410|NCT03024489|Drug|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
149411|NCT03024489|Drug|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
149412|NCT03024489|Drug|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
149413|NCT03024489|Radiation|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33-35 fractions.
149414|NCT03024476|Behavioral|Behavioral intensification|"Suggested algorithm for behavioral intensification:~If frequency of BP measurement ≤5 in a week, send a texting message~If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~Target range of home-systolic blood pressure: 110 - 135~If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management"
149415|NCT03024476|Drug|Pharmacological intensification based on olmesartan|"Study drug will be provided from the roll-in period.~Step I:~Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~Use olmesartan 40 mg if mean systolic blood pressure >150 during the immediate past 2 days~Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~Use of beta-blockers is permitted if clinically indicated.~At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule."
149416|NCT03024476|Device|Bluetooth-equipped sphygmomanometer|"Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)"
149417|NCT03024463|Procedure|IM-SLNB and IMLN dissection|Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection
149418|NCT03024450|Drug|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
149419|NCT03024437|Drug|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
149420|NCT03024437|Drug|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
149421|NCT03024437|Drug|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
149422|NCT03024424|Behavioral|Early disclosure|
149423|NCT03024424|Behavioral|Late disclosure|
149424|NCT03024411|Other|iPod (Music/video games)|Experimental patients will be given an iPod to enjoy music/video games during induction of labor.
149425|NCT03024385|Behavioral|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
149426|NCT03024372|Device|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
238667|NCT02374567|Drug|Lithium|
149427|NCT03024372|Device|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
149428|NCT03024359|Dietary Supplement|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
149429|NCT03024320|Behavioral|M2M|An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic & 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic & 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).
149430|NCT03024320|Behavioral|Attention Control|Telecoaching on health-based topics, not including physical activity.
149431|NCT03024307|Other|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
149432|NCT03024294|Other|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
149433|NCT03024268|Device|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
149434|NCT03024255|Drug|BBI-4000 Concentration 1|Lowest test dose
149435|NCT03024255|Drug|BBI-4000 Concentration 2|Test dose between high and low concentrations
149436|NCT03024255|Drug|BBI-4000 Concentration 3|Highest test dose
149437|NCT03024255|Drug|Vehicle (Placebo)|Vehicle without drug
149438|NCT03024242|Device|Tight vaginoscope|
149439|NCT03024229|Device|LifePort® perfusion machine|Renal perfusion on LifePort® machine
149440|NCT03024216|Drug|Atezolizumab1200 mg IV|Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
149441|NCT03024216|Drug|Sipuleucel-T|Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
149442|NCT03024203|Behavioral|Cognitive Remediation - Executive Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
149443|NCT03024203|Behavioral|Cognitive Remediation - Perceptual Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.
149444|NCT03024190|Other|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
149445|NCT03024190|Other|stretching exercise|15- min stretching exercise for upper extremity twice daily
149446|NCT03024190|Other|OT rehabilitation program|regular rehabilitation program for 3 weeks
149447|NCT03024177|Drug|Vapendavir|Vapendavir Tablets, 264 mg
149448|NCT03024177|Drug|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
149449|NCT03024164|Other|Treatment following current guidelines|Treatment following current guidelines
149450|NCT03024151|Drug|Comthyroid|T4/T3 combination replacement
149451|NCT03024151|Drug|Synthroid|T4 mono replacement
149452|NCT03024138|Radiation|Repeat CT scan|
149453|NCT03024125|Other|High protein|To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
149454|NCT03024125|Other|Normal protein|To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
149455|NCT03024125|Other|Training|The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
149456|NCT03024112|Device|Heated humified high-flow nasal cannula Oxygen|
149457|NCT03024112|Other|Standard oxygen therapy|
149458|NCT03024099|Other|Hippotherapy once a week|Hippotherapy once a week
149459|NCT03024099|Other|Hippotherapy twice a week|Hippotherapy twice a week
149460|NCT03024086|Drug|DWJ1252|DWJ1252 and Placebo of Gasmotin
149461|NCT03024086|Drug|Gasmotin|Gasmotin and Placebo of DWJ1252
149462|NCT03024073|Procedure|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
149463|NCT03024060|Drug|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
149464|NCT03024060|Drug|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
149465|NCT03024060|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
149466|NCT03024060|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
149467|NCT03024047|Device|Pacemaker|
149468|NCT03024034|Drug|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
150277|NCT03018158|Device|denture wear.|MR Imaging was collected with or without denture wear.
149469|NCT03024021|Device|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia [36.5 C]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
149470|NCT03024008|Biological|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.~A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.~internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
149471|NCT03023995|Procedure|CAF with Platelet rich fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
149472|NCT03023995|Procedure|CAF with connective tissue graft|In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
149473|NCT03023982|Drug|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
149474|NCT03023982|Device|Ultrasound|All blocks will be done under ultrasound
149475|NCT03023982|Procedure|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
149476|NCT03023982|Drug|Opioids|standard pain control with opioids
149477|NCT03023982|Drug|NSAID|standard pain control with NSAIDs
149478|NCT03023969|Drug|ozone oxygen mixture|receive 10 ml of ozone oxygen mixture under variable dosing
149479|NCT03023956|Procedure|Locking plates were used for proximal humeral fractures.|
149480|NCT03023943|Other|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
149481|NCT03023930|Other|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
149482|NCT03023930|Other|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
149483|NCT03023917|Procedure|umbilical cord milking|Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
149484|NCT03023917|Procedure|umbilical cord clamping immediately|umbilical cord was cut immediately after birth
149485|NCT03023904|Biological|Nivolumab|Given IV
149486|NCT03023904|Other|Laboratory Biomarker Analysis|Correlative studies
149487|NCT03023891|Drug|Prednisone|Prednisone 60 mg tablet once
149488|NCT03023878|Drug|Blinatumomab|Blinatumomab monotherapy
149489|NCT03023878|Drug|Investigator's Choice Chemotherapy|Investigator's Choice Chemotherapy
149490|NCT03023865|Procedure|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
149491|NCT03023852|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
149492|NCT03023852|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg (1*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
149493|NCT03023826|Drug|LY3202626 (R-Fasting)|Administered orally
149494|NCT03023826|Drug|LY3202626 (T1-Fasting)|Administered orally
149495|NCT03023826|Drug|LY3202626 (T1-Fed)|Administered orally
149496|NCT03023813|Other|Intervention|Written material provided.
149497|NCT03023800|Procedure|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
149498|NCT03023800|Procedure|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
149499|NCT03023787|Drug|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
149500|NCT03023787|Drug|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
149501|NCT03023774|Drug|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
149502|NCT03023761|Device|low level laser|low level laser irradiation
149503|NCT03023761|Device|laser sham|laser without irradiation
149504|NCT03023748|Drug|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
149505|NCT03023735|Other|None. This is an observational study|
150278|NCT03018145|Device|Wagon|
150279|NCT03018145|Device|Standard stretcher car|
149506|NCT03023722|Drug|anetumab ravtansine|Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
149507|NCT03023709|Biological|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
149508|NCT03023709|Biological|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
149509|NCT03023696|Procedure|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
149510|NCT03023696|Procedure|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
149511|NCT03023683|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
149512|NCT03023670|Procedure|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
149513|NCT03023670|Procedure|cardiopulmonary bypass|Low rate (4\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
149514|NCT03023657|Other|Detection of arousal|Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
149515|NCT03023644|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
149516|NCT03023631|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
149517|NCT03023618|Device|FloTrac|Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
149518|NCT03023605|Behavioral|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:~Clinical Update Sessions for staff ED (20 physicians)~training sessions for residents that rotate in ED (60 physicians )~Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value~Development of posters, with brief information~Dissemination by e-mail of scientific information~Direct reminder during the working day"
149519|NCT03023592|Drug|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
149520|NCT03023579|Other|The star excursion balance test|
149521|NCT03023566|Drug|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
149522|NCT03023553|Biological|Fluzone®|Influenza Virus Vaccine Suspension for Intramuscular Injection
149523|NCT03023553|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
149524|NCT03023540|Drug|PXT3003|Liquid oral solution, 5 mL (Dose 1 or Dose 2) bid OR 10 mL (Dose 1) bid for 9 consecutive months
149525|NCT03023527|Drug|Nivolumab|
149526|NCT03023527|Drug|Pomalidomide|
149527|NCT03023527|Drug|Dexamethasone|
149528|NCT03023527|Drug|Elotuzumab|
149529|NCT03023514|Dietary Supplement|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
149530|NCT03023514|Drug|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
149531|NCT03023501|Drug|Gabapentin|
149532|NCT03023501|Drug|Placebo Oral Capsule|
149533|NCT03023488|Procedure|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
149534|NCT03023488|Device|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
149535|NCT03023488|Device|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
149536|NCT03023475|Device|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
149537|NCT03023475|Device|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
149538|NCT03023462|Drug|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
149539|NCT03023462|Drug|Ketobemidone Hydrochloride|In case of insufficient analgesia, judged by the patient.
149540|NCT03023462|Drug|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
149541|NCT03023462|Drug|Ropivacaine|Local anesthetic for the block
149542|NCT03023449|Drug|Nitric Oxide|Inhaled Nitric Oxide gas
149543|NCT03023436|Procedure|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.~A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.~Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
149625|NCT03022838|Drug|Caffeine|From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
149664|NCT03022500|Drug|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
149544|NCT03023436|Procedure|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
149545|NCT03023436|Drug|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
149546|NCT03023436|Drug|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
149547|NCT03023423|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
149548|NCT03023423|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
149549|NCT03023410|Procedure|VERASENSE|Sensor-Assisted Revision TKA
149550|NCT03023397|Biological|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
149551|NCT03023358|Drug|chidamide|30mg po twice a week
149552|NCT03023358|Drug|cyclophosphamide|750mg/m2 iv on day 1
149553|NCT03023358|Drug|liposomal doxorubicin|30mg/m2 iv on day 1
149554|NCT03023358|Drug|vincristine|1.4mg/m2 iv on day 1
149555|NCT03023358|Drug|prednisone|100mg/d po on day 1-5
149556|NCT03023345|Device|Microwave trans rectal focal treatment|Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
149557|NCT03023332|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
149558|NCT03023332|Behavioral|Biofeedback training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior."
149559|NCT03023332|Behavioral|Bipolar Education|An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
149560|NCT03023319|Drug|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
149561|NCT03023319|Drug|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
149562|NCT03023306|Other|Antiemetics perioperatively|Preemptive group ondansetron 4 mg will be administered 1h before surgery Intraoperative group Ondansetron 4 mg will be administered intraoperatively
149563|NCT03023293|Other|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
149564|NCT03023280|Procedure|Radiofrequency ablation|
149565|NCT03023267|Behavioral|Music therapy and Kangaroo care|Mother holding baby in skin to skin position while singing
149566|NCT03023267|Behavioral|Kangaroo Care alone|Mother holding baby in skin to skin position without singing
149567|NCT03023254|Other|Hydrotherapy|3-week Avène hydrotherapy
149568|NCT03023241|Procedure|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
149569|NCT03023228|Behavioral|diabetes self-management education|1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
149570|NCT03023215|Procedure|Meditation|Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
149571|NCT03023215|Procedure|Electroencephalogram|Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
149572|NCT03023215|Behavioral|Questionnaires|Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.
149573|NCT03023215|Procedure|Heart Rate|Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
149574|NCT03023202|Other|PMMTB (Precision Medicine Molecular Tumor Board)|PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
149575|NCT03023189|Drug|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid for 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.~Total dose : 4 g of TA"
149576|NCT03023189|Drug|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline for 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
149577|NCT03023176|Biological|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
149578|NCT03023176|Biological|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
149579|NCT03023163|Other|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
149580|NCT03023150|Other|Ischemic Preconditioning|
149581|NCT03023150|Other|Sham|
149662|NCT03022526|Drug|Bupivacaine / fentaNYL|
149663|NCT03022513|Other|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
149582|NCT03023137|Behavioral|Walking & dietary modification|"Daily walking at a moderate pace (4 km/h) > 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding >12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.~At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
149583|NCT03023124|Drug|Trabectedin|Treatment with trabectedin repeated every 21 days for 6 cycles
149584|NCT03023124|Drug|Adriamycin|Treatment with Adriamycin at day 1 every 21 days for 6 cycles
149585|NCT03023124|Drug|Dacarbazine|Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
149586|NCT03023111|Drug|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
149587|NCT03023111|Drug|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
149588|NCT03023111|Drug|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
149589|NCT03023098|Device|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
149590|NCT03023098|Device|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
149591|NCT03023085|Drug|BLI4700|BLI4700 bowel preparation
149592|NCT03023072|Other|Incontinence Detection System|
149593|NCT03023059|Drug|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
149594|NCT03023046|Drug|Cyclophosphamide|Given IV
149595|NCT03023046|Drug|Dasatinib|Given PO
149596|NCT03023046|Drug|Doxorubicin|Given IV
149597|NCT03023046|Drug|Etoposide|Given IV
149598|NCT03023046|Drug|Imatinib Mesylate|Given PO
149599|NCT03023046|Other|Laboratory Biomarker Analysis|Correlative studies
149600|NCT03023046|Drug|Prednisone|Given PO
149601|NCT03023046|Biological|Rituximab|Given IV
149602|NCT03023046|Drug|Vincristine Sulfate|Given IV
149603|NCT03023033|Behavioral|mHealth messaging|SMS appointment reminders and health messaging via mobile phones
149604|NCT03023033|Behavioral|Transport Payments|A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
149605|NCT03023020|Drug|Aspirin|Dosing per current guidelines and local practice
149606|NCT03023020|Drug|P2Y12 inhibitor|Dosing per current guidelines and local practice
149607|NCT03023007|Procedure|Loco-regional anaesthesia|Loco-regional anaesthesia
149608|NCT03022994|Other|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
149609|NCT03022981|Drug|SOF/VEL|FDC tablet or oral granules administered once daily
149610|NCT03022968|Drug|[18F]T807 PET|Imaging with [18F]T807 PET
149611|NCT03022955|Dietary Supplement|Dark chocolate bar|Dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
149612|NCT03022955|Dietary Supplement|Dark chocolate mousse|Dark chocolate mousse (150g, ~500kcal, ~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
149613|NCT03022955|Dietary Supplement|White chocolate bar|White chocolate bar (0% cocoa solids (~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
149614|NCT03022955|Dietary Supplement|White chocolate mousse|White chocolate mousse (150g, ~500kcal, ~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
149615|NCT03022942|Other|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
149616|NCT03022942|Other|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
149617|NCT03022929|Behavioral|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
149618|NCT03022916|Drug|Jublia|Application of Jublia to the nails of both big toes
149619|NCT03022916|Other|Nail polish|Application of nail polish to one big toe nail
149620|NCT03022903|Procedure|Aminolevulinic Acid (ALA)|Photosensitizing
149621|NCT03022890|Behavioral|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
149622|NCT03022890|Behavioral|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
149623|NCT03022877|Drug|Levosimendan|In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
149624|NCT03022851|Device|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
149626|NCT03022825|Drug|ALT-803|BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.
149627|NCT03022825|Drug|BCG|BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.
149628|NCT03022812|Other|Neck-specific exercise|Neck-specific exercise
149629|NCT03022799|Drug|KM-819|
149630|NCT03022799|Drug|Placebo|
149631|NCT03022786|Other|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
149632|NCT03022786|Other|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.~There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
149633|NCT03022786|Other|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
149634|NCT03022773|Other|Carotenoid measurements|"Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.~Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.~Carotenoid measurements in the blood are obtained through routine venipuncture."
149635|NCT03022760|Behavioral|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
149636|NCT03022747|Drug|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
149637|NCT03022747|Drug|Standard treatment|Oral 6-mercaptopurine and methotrexate
149638|NCT03022734|Drug|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
149639|NCT03022734|Radiation|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
149640|NCT03022721|Other|No interventions are planned for this study.|No interventions are planned for this study, it is purely observational.
149641|NCT03022708|Device|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
149642|NCT03022695|Device|High Intensity Focused Ultrasound|
149643|NCT03022669|Behavioral|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
149644|NCT03022669|Behavioral|Mobile Application|
149645|NCT03022669|Other|Website|American Heart Association patient education website
149646|NCT03022656|Device|Active Brace system|
149647|NCT03022643|Behavioral|Interpersonal Social Rhythms Psychotherapy|The treatment involves 8-weeks of individual psychotherapy. Weekly sessions will be 60-minute long and will take place at the Pain Research Center. The treatment focuses on 1) the link between life events, pain severity, sleep disturbances, fatigue, and mood, 2) social and behavioral rhythms and sleep-wake disturbances, 3) identification and management of rhythm dysregulation and the triggers for it, 4) allowing and facilitating the mourning of the loss healthy self, 5) identification and appropriate management of symptoms.
149648|NCT03022643|Other|Bright Light Device|All patients will be provided with a bright light device (Re-Timer) and will be instructed to use it in the first 2-hours of the day (for a minimum of 30 minutes) throughout the 8-week treatment period.
149649|NCT03022630|Other|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
149650|NCT03022630|Other|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
149651|NCT03022617|Drug|Apremilast|
149652|NCT03022604|Dietary Supplement|C4/Generation 4|12 grams of C4/Generation 4
149653|NCT03022604|Dietary Supplement|C450X|12 grams of C450X
149654|NCT03022604|Dietary Supplement|Placebo|12 grams of flavored dextrose
149655|NCT03022591|Other|Management|management of twin pregnancies with a short cervix diagnosed between 16 0/7 WGA to 27 6/7 WGA.
149656|NCT03022578|Procedure|Laser Interstitial Thermal Therapy|Undergo LITT
149657|NCT03022578|Drug|Lomustine|Given PO
149658|NCT03022565|Drug|Vorinostat|Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
149659|NCT03022539|Radiation|Repeat CT scan|
149660|NCT03022526|Procedure|CSE|
149661|NCT03022526|Procedure|Epidural|
149665|NCT03022474|Behavioral|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
149666|NCT03022461|Other|Long term follow-up|
149667|NCT03022448|Other|No Intervention|This is a NIS. No intervention.
149668|NCT03022435|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
149669|NCT03022435|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
149670|NCT03022435|Biological|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
149671|NCT03022422|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
149672|NCT03022422|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
149673|NCT03022409|Drug|AZD6738|"AZD6738 is an oral agent and will be dosed at 160 mg. AZD6738 tablets should be taken at the same time each day, approximately 12 hours apart (maximum ± 2 hour window) with one glass of water.~AZD6738 is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ataxia telangiectasia and Rad3-related protein (ATR), with good selectivity against other phosphatidylinositol 3-kinase-related kinase (PIKK) family members."
149674|NCT03022409|Drug|Olaparib|"Olaparib is available as a green film-coated tablet containing 100 mg or 150 mg of Olaparib. Patients will be administered Olaparib orally twice daily at 300 mg bid. The Olaprib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water.~Olaparib (AZD2281, KU-0059436) is a potent Polyadenosine 5'diphosphoribose [poly (ADP ribose)] polymerisation (PARP) inhibitor (PARP-1, -2 and -3) that is being developed as an oral therapy, both as a monotherapy (including maintenance) and for combination with chemotherapy and other anti-cancer agents."
149675|NCT03022396|Biological|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
149676|NCT03022396|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
149677|NCT03022383|Device|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
149678|NCT03022370|Behavioral|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
149679|NCT03022357|Other|Patient assessment|Clinical examination, Examination, Questionnaires
149680|NCT03022357|Radiation|DATScan|In small subgroup
149681|NCT03022357|Radiation|Orbital X-Ray|If foreign body in eye needs exclusion
149682|NCT03022357|Other|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
149683|NCT03022344|Radiation|Cardiac CT|
149684|NCT03022318|Drug|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
149685|NCT03022305|Behavioral|Group one - standard therapy|Group two - standard physical therapy treatment for shoulder and hip maladjustment.
149686|NCT03022305|Behavioral|Group two - neuromuscular therapy|Use of physical therapy treatment for shoulder and hip maladjustment.
149687|NCT03022292|Drug|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
149688|NCT03022292|Device|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
149689|NCT03022279|Procedure|TAP Blocks|ultrasound guided transversus abdominis plane block utilizing 0.2% ropivacaine
149690|NCT03022279|Procedure|local wound infiltration|local anesthesia provided at the surgical site utilizing 0.2% ropivacaine
149691|NCT03022279|Drug|0.2% ropivacaine|2.5 mg/kg or 1 mL/kg of 0.2% ropivacaine
149692|NCT03022279|Device|ultrasound|ultrasound guidance
149693|NCT03022266|Behavioral|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
149694|NCT03022253|Biological|Liberal platelet transfusion|"Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:~PDA closes or~A maximum of 120 hours after the point of randomisation"
149695|NCT03022253|Biological|Restrictive platelet transfusion|"The investigators will transfuse platelets only if:~(i) Platelet count is < 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count < 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count < 1, 00,000 per microliter and requires a neurosurgical procedure"
149696|NCT03022253|Drug|Paracetamol|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Paracetamol:~Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
149873|NCT03020836|Behavioral|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
149697|NCT03022253|Drug|Ibuprofen|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:~Ibuprofen:~Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral"
149698|NCT03022240|Drug|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
149699|NCT03022240|Drug|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
149700|NCT03022240|Drug|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
149701|NCT03022240|Drug|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
149702|NCT03022227|Other|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
149703|NCT03022214|Dietary Supplement|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
149704|NCT03022214|Dietary Supplement|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~EnduraCell broccoli sprout powder: 3 capsules~Bulk Powders Green tea extract: 1 capsule~Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
149705|NCT03022201|Drug|DA-9701|Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
149706|NCT03022201|Drug|Domperidone|Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
149707|NCT03022201|Drug|Placebo domperidone|
149708|NCT03022201|Drug|Placebo DA-9701|
149709|NCT03022175|Drug|SPR741|"SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days."
149710|NCT03022175|Drug|Placebo|0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
149711|NCT03022149|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
149712|NCT03022149|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
149713|NCT03022136|Other|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
149714|NCT03022123|Drug|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
149715|NCT03022110|Device|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
149716|NCT03022097|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
149717|NCT03022097|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
149718|NCT03022097|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
149719|NCT03022097|Drug|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
149720|NCT03022084|Device|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
149721|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
149722|NCT03022071|Other|Cognitive psychotherapy|In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
149723|NCT03022058|Device|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
149724|NCT03022045|Drug|risankizumab|risankizumab administered by subcutaneous injection
149725|NCT03022032|Device|Fitbit Zip|Fitbit Zip
149726|NCT03022032|Other|HOPE App|HOPE App
149727|NCT03022032|Other|Standard of Care|Standard of Care
149728|NCT03022032|Device|Fitbit Charge 2|Fitbit Charge 2
149729|NCT03022019|Device|ReNovaCell|
149730|NCT03022006|Drug|elbasvir, grazoprevir|
149731|NCT03021993|Drug|Nivolumab|Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
149732|NCT03021980|Behavioral|SuperFIT|Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
149733|NCT03021954|Biological|Platelet Rich Plasma|Platelet rich plasma is produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
149734|NCT03021941|Drug|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
149735|NCT03021928|Other|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 60 hours, 132 hours, 228 hours, or 324 hours (+/- 12 hours each).
149736|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
149737|NCT03021902|Drug|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
149738|NCT03021902|Device|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.~Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
149739|NCT03021889|Behavioral|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
149740|NCT03021889|Behavioral|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
149741|NCT03021876|Drug|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
149742|NCT03021876|Other|usual intake|baseliner
149743|NCT03021863|Behavioral|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
149744|NCT03021863|Behavioral|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
149745|NCT03021863|Behavioral|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
149746|NCT03021863|Behavioral|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
149747|NCT03021863|Behavioral|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
149748|NCT03021863|Behavioral|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
149749|NCT03021863|Behavioral|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
149750|NCT03021863|Behavioral|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
149751|NCT03021863|Behavioral|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
149752|NCT03021850|Procedure|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
149753|NCT03021837|Other|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
149754|NCT03021811|Device|KLOX LumiHeal BioPhotonic System|Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
149755|NCT03021798|Other|No Drug and no aspecific intervention|No intervention
149756|NCT03021785|Biological|TK001|TK001 will be administered intravitreal injection.
149757|NCT03021772|Drug|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
149758|NCT03021772|Drug|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
149759|NCT03021759|Behavioral|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
149760|NCT03021759|Behavioral|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
149761|NCT03021746|Behavioral|Diabetes Self Management Support (DSMS)|
149762|NCT03021733|Procedure|Operative management|Rotator cuff surgery
149763|NCT03021720|Procedure|Arterial access|Location of arterial puncture
149764|NCT03021694|Dietary Supplement|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
149765|NCT03021681|Other|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
149766|NCT03021668|Device|Prevena Peel & Place Dressing|Prevena Peel & Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
149767|NCT03021668|Other|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
149768|NCT03021655|Behavioral|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
150007|NCT03019991|Drug|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
149769|NCT03021655|Behavioral|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
149770|NCT03021655|Behavioral|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
149771|NCT03021642|Drug|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 1 (Day 1)
149772|NCT03021642|Drug|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 2 (Day 22)
149773|NCT03021642|Drug|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of reference treatment of film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 1 (Day 1)
149774|NCT03021642|Drug|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test treatment of film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 2 (Day 22)
149775|NCT03021629|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay|
149776|NCT03021616|Other|energy drink|32oz of commercially available energy drink
149777|NCT03021616|Other|Moxifloxacin 400mg|400mg moxifloxacin active control drink
149778|NCT03021616|Other|Placebo|Placebo drink
149779|NCT03021603|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:~Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.~Purpose: help participants to develop positive thoughts.~The programme consists of four sessions:~Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
149780|NCT03021590|Drug|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all~,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
149781|NCT03021590|Drug|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
149782|NCT03021577|Device|Orbital Atherectomy System (OAS)|The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
149783|NCT03021577|Device|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
149784|NCT03021577|Procedure|Magnetic Resonance Imaging (MRI)|In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
149785|NCT03021564|Other|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
149786|NCT03021538|Device|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
149787|NCT03021538|Device|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
149788|NCT03021525|Procedure|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in <15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
149789|NCT03021525|Procedure|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate <100 bpm, mean arterial pressure >65 mmHg, SpO2>94%, and core temperature >36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
149790|NCT03021512|Procedure|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
149791|NCT03021512|Procedure|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
149792|NCT03021499|Drug|Voclosporin|calcineurin inhibitor
149793|NCT03021499|Drug|Placebo Oral Capsule|matching placebo capsule
149794|NCT03021486|Drug|Chlorpromazine|Given IV
149795|NCT03021486|Drug|Haloperidol|Given IV
149796|NCT03021486|Other|Quality-of-Life Assessment|Ancillary studies
149797|NCT03021486|Other|Questionnaire Administration|Ancillary studies
149798|NCT03021473|Device|The Masimo Radical-7|The Masimo Radical-7 is a noninvasive monitor that measures arterial oxygen saturation (SpO2), pulse rate (PR), and perfusion index (PI), along with optional measurements of hemoglobin (SpHb), carboxyhemoglobin (SpCO®), total oxygen content (SpOC), methemoglobin (SpMet), Pleth Variability Index (PVI®), Oxygen Reserve Index (ORI™), Acoustic Respiration Rate (RRa®), and Pleth Respiration Rate (RRp).
149799|NCT03021473|Device|Masimo Root|The Masimo Root is a patient monitoring and connectivity platform that has been cleared by the Food and Drug Administration (FDA) for noninvasive patient monitoring.
150051|NCT03019705|Other|Observation|
149800|NCT03021473|Other|Blood draw|0.5 mL blood samples will collected and analyzed in the operating room using point of care standard epoc® blood gas analysis system, for a total volume of 2.5 mL of blood.
149801|NCT03021460|Drug|Ibrutinib|Given PO
149802|NCT03021460|Other|Laboratory Biomarker Analysis|Correlative studies
149803|NCT03021460|Biological|Pembrolizumab|Given IV
149804|NCT03021434|Other|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
149805|NCT03021434|Other|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
149806|NCT03021434|Other|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
149807|NCT03021421|Procedure|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
149808|NCT03021421|Procedure|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
149809|NCT03021408|Other|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
149810|NCT03021408|Other|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
149811|NCT03021408|Other|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
149812|NCT03021395|Drug|Decitabine|Decitabine at a dose of 20mg/㎡/d on day 1-5.
149813|NCT03021382|Other|data collection, non-intervention|
149814|NCT03021369|Device|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
149815|NCT03021356|Device|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
149816|NCT03021343|Drug|Colchicine|colchicine given as per trial protocol
149817|NCT03021330|Drug|Daunomycin and Cytarabine (DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
149818|NCT03021330|Drug|Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.~Daunomycin at a dose of 60mg/㎡/d on day 1-3."
149819|NCT03021317|Drug|ACTHar|The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
149820|NCT03021304|Drug|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
149821|NCT03021291|Device|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
149822|NCT03021278|Other|Saline injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
149823|NCT03021278|Other|Sham injection|In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
149824|NCT03021265|Drug|T80/A5/H12.5 FDC|Drug
149825|NCT03021252|Device|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), twice a day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
149826|NCT03021252|Device|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, twice a day, during 8 weeks.
149827|NCT03021239|Procedure|Echo Guided Testing|
149828|NCT03021239|Procedure|Hemodynamic-Echo Ramp Testing -|
149829|NCT03021226|Behavioral|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
149830|NCT03021226|Behavioral|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
149831|NCT03021226|Behavioral|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
149832|NCT03021200|Device|Green indocianine|Laser fluorescence using green indocianine guiding the surgical procedure.
149833|NCT03021187|Drug|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
150136|NCT03019081|Other|placebo|placebo
240088|NCT02364206|Drug|LY2228820|
149834|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
149835|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
149836|NCT03021187|Drug|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
149837|NCT03021174|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
149838|NCT03021174|Behavioral|Nutrition Education Control|12 weeks of implementing eating tips
149839|NCT03021161|Drug|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
149840|NCT03021161|Other|Placebo Oral Capsule|Capsule containing no probiotic
149841|NCT03021148|Other|Questionnaire|Administration of questionnaire.
149842|NCT03021135|Procedure|Conventional Endoscopic Mucosal Resection|Conventional Endoscopic Mucosal Resection
149843|NCT03021135|Procedure|Underwater Endoscopic Mucosal Resection|Underwater Endoscopic Mucosal Resection
149844|NCT03021122|Device|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
149845|NCT03021122|Device|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
149846|NCT03021109|Device|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
149847|NCT03021096|Other|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
149848|NCT03021083|Device|IONSYS Patch|Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
149849|NCT03021070|Other|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
149850|NCT03021057|Drug|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
149851|NCT03021044|Other|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
149852|NCT03021044|Other|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
149853|NCT03021031|Other|Observational|Observational study
149854|NCT03021018|Drug|Brivaracetam|"Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
149855|NCT03021018|Drug|Lorazepam|"Pharmaceutical Form: Solution for injection~Route of Administration: intravenous"
149856|NCT03021005|Behavioral|HIV Self-testing|
149857|NCT03020992|Drug|Certolizumab Pegol|"pharmaceutical form: solution for infusion in prefilled syringe~concentration: 200 mg/mL~route of administration: subcutaneous"
149858|NCT03020979|Drug|Apatinib|Patients will take 500mg apatinib daily orally.
149859|NCT03020966|Drug|Acetaminophen|Oral acetaminophen, intravenous placebo
149860|NCT03020966|Drug|Acetaminophen|Intravenous acetaminophen, oral placebo
149861|NCT03020953|Other|Exercise + Estrogen|12 weeks resistance training and estrogen patches
149862|NCT03020953|Other|Exercise + Placebo|12 weeks resistance training and placebo patches
149863|NCT03020940|Drug|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.~Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.~Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.~Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
149864|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
149865|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
149866|NCT03020914|Device|Audiovisual Distraction|watching a movie using video glasses and headphones
149867|NCT03020901|Drug|Teicoplanin for Injection|Use Teicoplanin for Injection
149868|NCT03020888|Device|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
149869|NCT03020875|Drug|Ofirmev|Intravenously administered acetaminophen.
149870|NCT03020875|Drug|Per Os Acetaminophen|Orally administered acetaminophen.
149871|NCT03020862|Dietary Supplement|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
149872|NCT03020836|Behavioral|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
240089|NCT02364206|Drug|Temozolomide|
149874|NCT03020823|Drug|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
149875|NCT03020810|Drug|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
149876|NCT03020797|Drug|Perampanel|
149877|NCT03020797|Drug|Placebo Oral Tablet|
149878|NCT03020784|Drug|Placebo|Placebo
149879|NCT03020784|Drug|PF-06818883|Treatment
149880|NCT03020771|Biological|KIRIM-KONGO-VAX|Crimean-Congo Hemorrhagic Fever Vaccine
149881|NCT03020771|Other|Placebo|
149882|NCT03020758|Dietary Supplement|Dried Fruit|Mixture of equal parts 4 dried fruits (figs, raisins, dates, plums) totaling 3/4 cup daily.
149883|NCT03020758|Other|High Carbohydrate Snack|Calorie-matched carbohydrate-rich snack.
149884|NCT03020745|Drug|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
149885|NCT03020745|Drug|Placebo|Placebo is available as a Clear colorless solution.
149886|NCT03020732|Procedure|test groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
149887|NCT03020732|Procedure|control groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
149888|NCT03020719|Drug|Oral Glutathione|Oral Glutathione oral powder
149889|NCT03020719|Drug|Placebo|Placebo oral powder
149890|NCT03020706|Drug|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
149891|NCT03020693|Procedure|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
149892|NCT03020693|Procedure|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
149893|NCT03020680|Dietary Supplement|Coenzyme Q10|To examine whether 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
149894|NCT03020654|Other|Virtual environment with fast moving objects|A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
149895|NCT03020654|Other|Virtual environment with no movement|A beach/park environment with static objects, the individual will complete head and eye exercises.
149896|NCT03020641|Procedure|Low pressure pneumoperitoneum|Low pressure pneumoperitoneum
149897|NCT03020641|Procedure|standard pneumoperitoneum pressure|standard pneumoperitoneum pressure
149898|NCT03020628|Biological|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
149899|NCT03020628|Biological|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
149900|NCT03020615|Drug|Hydroxyurea|Given orally once daily.
149901|NCT03020602|Other|Laboratory Biomarker Analysis|Correlative studies
149902|NCT03020602|Other|Pharmacological Study|Correlative studies
149903|NCT03020602|Drug|Ubidecarenone Injectable Nanosuspension|Given IV
149904|NCT03020589|Drug|Tacrolimus|See description in arm/group sections
149905|NCT03020576|Device|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
149906|NCT03020576|Other|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
149907|NCT03020563|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine
149908|NCT03020563|Drug|Bupivacaine|Bupivacaine
149909|NCT03020537|Biological|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
149910|NCT03020524|Biological|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
149911|NCT03020511|Other|Ancient wheat flours|Ancient wheat flours will be administered in open label for 30 days
149912|NCT03020498|Biological|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
149913|NCT03020498|Biological|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
149914|NCT03020485|Other|Isomaltulose|Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
149915|NCT03020485|Other|Sucrose|Sucrose is normal table sugar
149916|NCT03020472|Biological|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
149917|NCT03020459|Procedure|peeling-reposition|"After dying with Brilliant Blue G (BBG, Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then the ILM was peeled from inferior to superior area continuously. The ILM roll  was unfolded with assistance of perfluoro-n-octane (PFO). Finally, the position of the fixed ILM flap is adjusted under PFO bubble using flute needle or forceps.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.Patients are introduced to maintain facedown position for two weeks postoperatively."
149954|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL.
240090|NCT02364206|Radiation|radiotherapy|
149918|NCT03020459|Procedure|peeling|After dying with Brilliant Blue G (Brilliant Blue; Gender, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then, the strand of ILM was peeled off radially from the foveal center to vascular arcade. In result, a round -shaped with 2.5-3.5 disc diameter ILM -peeled area was created.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas. Patients are encourage to maintain facedown position for two weeks postoperatively.
149919|NCT03020459|Drug|Brilliant Blue G|We intravitreal injected 0.1ml of Brilliant Blue G (Brilliant Blue; Gender, Germany) to dye ILM before ILM peeling.
149920|NCT03020459|Other|postoperative posture|Patients of both two groups need to keep prone position for two weeks after the operation.
149921|NCT03020459|Device|Constellation 23-gauge vitrectomy system|All surgical procedures are operated on the Constellation 23-gauge vitrectomy system (Alcon Laboratories Inc, Fort Worth, TX).
149922|NCT03020446|Device|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
149923|NCT03020433|Device|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
149924|NCT03020433|Device|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
149925|NCT03020433|Device|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
149926|NCT03020433|Device|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
149927|NCT03020420|Other|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
149928|NCT03020407|Procedure|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
149929|NCT03020407|Drug|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
149930|NCT03020407|Drug|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
149931|NCT03020368|Biological|Leeches|
149932|NCT03020368|Drug|Diclofenac|
149933|NCT03020355|Procedure|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord—the cord will unclamped and the blood will drained until the flow ceased.
149934|NCT03020355|Procedure|not Placental Blood Drainage|In the control group, the clamped cord will not released.
149935|NCT03020329|Drug|Paclitaxel liposome|"Patients receive paclitaxel liposome(135mg/m2 on day 1),cisplatin (75mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (3750mg/m2 CIV 120h ) every three weeks for three cycl es before the radiotherapy.~Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.~Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:60Gy/30F,2.0Gy/daily."
149936|NCT03020329|Drug|Cisplatin|Cisplatin (75mg/m2 Separate injection on day 1 to 3) with Paclitaxel liposome and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2) every three weeks for three cycles during radiotherapy.
149937|NCT03020329|Drug|5-fu|Fluorouracil (3750mg/m2 CIV 120h)with Paclitaxel liposomeand cisplatin every three weeks for three cycles before the radiotherapy.
149938|NCT03020329|Radiation|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:60Gy(Gray)/30F(Fraction),2.0Gy/daily,5 days/week.
149939|NCT03020316|Behavioral|Peer Mentor|A volunteer with a similar disease as the subject
149940|NCT03020316|Behavioral|Transcendental Meditation|A meditation technique
149941|NCT03020303|Drug|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
149942|NCT03020303|Drug|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
149943|NCT03020290|Device|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
149944|NCT03020277|Other|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
149945|NCT03020264|Device|glycemic sensor FREESTYLE Libre Pro|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
149946|NCT03020251|Other|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
149947|NCT03020251|Other|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
149948|NCT03020238|Procedure|BiClamp group|electric energy
149949|NCT03020238|Procedure|water jet group|water jet energy
149950|NCT03020225|Dietary Supplement|White cheese|animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
149951|NCT03020225|Dietary Supplement|Green peas|Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
149952|NCT03020225|Dietary Supplement|Mankai|Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
149953|NCT03020212|Drug|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
150392|NCT03017313|Drug|LHRH analogues|3-or 6-month formulations
240192|NCT02363335|Drug|Placebo|
149955|NCT03020199|Radiation|nbUVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application will be performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face is recommended
149956|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
149957|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
149958|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
149959|NCT03020199|Drug|Calcipotriol|Its a topical treatment for Psoriasis. the concentration it is used is 50mcg/g
149960|NCT03020199|Drug|Betamethasone|this is topical cream which is used in 0.5mg/g concentration
149961|NCT03020186|Other|Physical activity|
149962|NCT03020186|Other|Physical activity+ MED diet|
149963|NCT03020186|Other|Physical activity+green MED diet|****Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 8 and 14 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
149964|NCT03020173|Other|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
149965|NCT03020160|Drug|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms.
149966|NCT03020134|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
149967|NCT03020134|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
149968|NCT03020134|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
149969|NCT03020134|Drug|Placebo|Placebo
149970|NCT03020121|Procedure|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
149971|NCT03020108|Other|Blood sample|2 cc blood samples will be drawn from antecubital vein
149972|NCT03020095|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
149973|NCT03020095|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
149974|NCT03020095|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
149975|NCT03020095|Drug|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)administered orally
149976|NCT03020082|Drug|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
149977|NCT03020082|Drug|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
149978|NCT03020082|Drug|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
149979|NCT03020082|Drug|RBV|RBV administered orally 500mg (5 tablets)( body weight ＜75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
149980|NCT03020069|Device|CGMS Device|
149981|NCT03020069|Other|No Device|
149982|NCT03020056|Drug|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
149983|NCT03020056|Procedure|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
149984|NCT03020030|Drug|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
149985|NCT03020030|Drug|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
149986|NCT03020030|Drug|Cyclophosphamide|Standard of Care
149987|NCT03020030|Drug|CYTARABINE|Standard of Care
149988|NCT03020030|Drug|DASATINIB|Standard of Care
149989|NCT03020030|Drug|DEXAMETHASONE|Standard of Care
149990|NCT03020030|Drug|Dexrazoxane|Standard of Care
149991|NCT03020030|Drug|Doxorubicin|Standard of Care
149992|NCT03020030|Drug|ETOPOSIDE|Standard of Care
149993|NCT03020030|Drug|HYDROCORTISONE|Standard of Care
149994|NCT03020030|Drug|LEUCOVORIN CALCIUM|Standard of Care
149995|NCT03020030|Drug|MERCAPTOPURINE|Standard of Care
149996|NCT03020030|Drug|METHOTREXATE|Standard of Care
149997|NCT03020030|Drug|NELARABINE|Standard of Care
149998|NCT03020030|Drug|Vincristine|Standard of Care
149999|NCT03020017|Other|Laboratory Biomarker Analysis|Correlative studies
150000|NCT03020017|Other|Pharmacological Study|Correlative studies
150001|NCT03020017|Drug|Targeted Molecular Therapy|Given NU-0129 IV
150002|NCT03020004|Drug|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
150003|NCT03020004|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
150004|NCT03020004|Drug|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
150005|NCT03020004|Drug|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)
150006|NCT03019991|Drug|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
150008|NCT03019991|Drug|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
150009|NCT03019978|Other|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
150010|NCT03019965|Drug|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
150011|NCT03019965|Drug|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
150012|NCT03019965|Drug|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
150013|NCT03019965|Drug|Extended Imipenem|Imipenem administered in 6 hours infusion.
150014|NCT03019965|Drug|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
150015|NCT03019965|Drug|Extended Meropenem|Meropenem administered in 8 hours infusion.
150016|NCT03019952|Behavioral|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
150017|NCT03019939|Drug|Isavuconazole|Given PO or IV
150018|NCT03019926|Biological|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
150019|NCT03019913|Other|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
150020|NCT03019900|Procedure|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
150021|NCT03019887|Drug|risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
150022|NCT03019874|Dietary Supplement|Cranberry Extract|3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)
150023|NCT03019861|Behavioral|Ayurvedic nutritional counseling|
150024|NCT03019861|Behavioral|Conventional nutritional counseling|
150025|NCT03019848|Dietary Supplement|Curcumin|
150026|NCT03019848|Other|Placebo|
150027|NCT03019835|Drug|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
150028|NCT03019835|Other|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
150029|NCT03019822|Drug|LSD|100ug per os, single dose
150030|NCT03019822|Drug|MDMA|125mg per os, single dose
150031|NCT03019822|Drug|Amphetamine|40.3mg per os, single dose
150032|NCT03019822|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs
150033|NCT03019809|Biological|G-CSF for Conditioning before HSCT.|Mobilization of hematopoietic stem (HSC) into circulation
150034|NCT03019809|Biological|Plerixafor for Conditioning before HSCT.|Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
150035|NCT03019796|Behavioral|EXERCISE TRAINING|EXERCISE TRAINING AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).
150036|NCT03019796|Behavioral|NO EXERCISE TRAINING|REMAINING INACTIVE AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).
150037|NCT03019783|Drug|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
150038|NCT03019783|Other|Placebo|The control group will stay on their baseline regimen
150039|NCT03019770|Behavioral|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
150040|NCT03019757|Radiation|DaTscan|A functional imaging of the dopamine transporter using the radioligand [123I]FP-CIT
150041|NCT03019757|Radiation|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
150042|NCT03019757|Radiation|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
150043|NCT03019757|Genetic|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
150044|NCT03019757|Procedure|Polysomnogram|Overnight sleep study
150045|NCT03019757|Behavioral|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
150046|NCT03019744|Device|MeCFES-assisted task-oriented upper limb rehabilitation|
150047|NCT03019744|Other|Usual Care task-oriented upper limb rehabilitation|
150048|NCT03019731|Behavioral|Therapist-directed Behavioral Therapy|The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).
150049|NCT03019731|Behavioral|Home-based DVD Therapy|In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
150050|NCT03019718|Other|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
150052|NCT03019666|Biological|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"Cyclophosphamide 40 mg/kg x 1 day on Day -5~Fludarabine 25 mg/m^2 x 3 days (Day -5, Day -4, day-3)"
150053|NCT03019653|Drug|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
150054|NCT03019653|Drug|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
150055|NCT03019640|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
150056|NCT03019640|Drug|Carmustine|Given IV
150057|NCT03019640|Biological|Cord Blood-derived Expanded Allogeneic Natural Killer Cells|Given IV
150058|NCT03019640|Drug|Cytarabine|Given IV
150059|NCT03019640|Drug|Etoposide|Given IV
150060|NCT03019640|Biological|Filgrastim|Given SC
150061|NCT03019640|Drug|Lenalidomide|Given PO
150062|NCT03019640|Drug|Melphalan|Given IV
150063|NCT03019640|Biological|Rituximab|Given IV
150064|NCT03019627|Drug|NGF|Eye Drop 20 μg/mL
150065|NCT03019627|Other|Vehicle|Vehicle Eye Drop
150066|NCT03019614|Drug|Hydrocortisone|Generic hydrocortisone
150067|NCT03019614|Drug|Chronocort|Modified formulation of hydrocortisone
150068|NCT03019601|Behavioral|Group Education|Structured group education on family planning facilitated by Peer Champions
150069|NCT03019588|Biological|Pembrolizumab|IV infusion
150070|NCT03019588|Drug|Paclitaxel|IV infusion
150071|NCT03019575|Drug|Corifollitropin alfa|Corifollitropin alfa 100 μg (body weight ≤60 kg) or 150 μg (body weight >60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1/Week 0 through Week 64).
150072|NCT03019575|Drug|hCG|hCG 500-5000 IU by SC injection; first dose will be administered on the last day of Week 12 (Day 85), and treatment will continue, twice a week, from Week 13 through Week 64.
150073|NCT03019562|Drug|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
150074|NCT03019562|Drug|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
150075|NCT03019549|Drug|Lanabecestat|Administered orally
150076|NCT03019549|Drug|Rosuvastatin|Administered orally
150077|NCT03019536|Drug|LY3303560 - IV|Administered IV
150078|NCT03019536|Drug|Placebo - IV|Administered IV
150079|NCT03019536|Drug|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
150080|NCT03019536|Drug|Flortaucipir F18|Administered IV during the PET scan performed during the study.
150081|NCT03019523|Dietary Supplement|Caffeine Blend|Taken orally in capsule form
150082|NCT03019523|Other|Sugar Pill|Taken orally in capsule form
150083|NCT03019510|Behavioral|No exercise|No exercise will be done on the day of the study night to be tested
150084|NCT03019510|Behavioral|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
150085|NCT03019510|Behavioral|Evening exercise|Evening exercise will be done on the day of the study night to be tested
150086|NCT03019497|Behavioral|Specific Modules|Educational session about a specific related problem
150087|NCT03019497|Behavioral|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
150088|NCT03019484|Behavioral|Breastfeeding support|Self-efficacy
150089|NCT03019471|Genetic|Isolation of tumor DNA|
150090|NCT03019458|Dietary Supplement|MINGO|6 20oz sachets will be taken daily by intervention group
150091|NCT03019432|Behavioral|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
150092|NCT03019419|Drug|Perampanel|4mg/d or 8mg/d
150093|NCT03019419|Drug|placebo|placebo
150094|NCT03019406|Drug|avalglucosidase alfa GZ402666|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
150095|NCT03019406|Drug|alglucosidase alfa GZ419829|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
150096|NCT03019393|Other|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
150097|NCT03019380|Device|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
150098|NCT03019367|Procedure|Umbilical cord milking UCM|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.
150099|NCT03019367|Procedure|Delayed cord clamping DCC|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
150100|NCT03019354|Device|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
150101|NCT03019354|Device|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
150102|NCT03019328|Other|Peanut in diet|
150103|NCT03019302|Device|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
150104|NCT03019289|Drug|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 67.5 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
150164|NCT03018834|Drug|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
150105|NCT03019276|Drug|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
150106|NCT03019263|Dietary Supplement|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
150107|NCT03019263|Other|Control|Nutritional counseling
150108|NCT03019250|Dietary Supplement|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
150109|NCT03019250|Dietary Supplement|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours.
150110|NCT03019237|Drug|anti-IgE|intranasal anti-IgE
150111|NCT03019237|Other|intranasal allergen|intranasal allergen
150112|NCT03019237|Other|intranasal saline|intranasal placebo
150113|NCT03019224|Procedure|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
150114|NCT03019224|Procedure|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.~The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
150115|NCT03019224|Procedure|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
150116|NCT03019224|Procedure|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
150117|NCT03019224|Procedure|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
150118|NCT03019224|Drug|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
150119|NCT03019224|Procedure|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
150120|NCT03019211|Other|Exercise|
150121|NCT03019198|Drug|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
150122|NCT03019198|Drug|Placebo - Concentrate|
150123|NCT03019185|Drug|Placebo Oral Capsule|Capsule containing an inert placebo
150124|NCT03019185|Drug|Bardoxolone Methyl|Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
150125|NCT03019172|Combination Product|Lactobacillus reuteri|Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5*10^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc
150126|NCT03019172|Dietary Supplement|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
150127|NCT03019159|Device|Teleconsulting|
150128|NCT03019146|Other|HIIT|
150129|NCT03019146|Other|HOLD|
150130|NCT03019146|Other|HUG|
150131|NCT03019133|Device|Sound reduction|Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.
150132|NCT03019133|Device|Sound masking|Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
150133|NCT03019120|Drug|Vitamin D|"Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.~Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.~Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).~Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
150134|NCT03019094|Device|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
150135|NCT03019081|Drug|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
150137|NCT03019055|Biological|CAR-20/19-T|"CAR-20/19-T cells will be administered either fresh or thawed after cryopreservation by IV injection.~Phase 1~Dose Level -1: 1 x 10^5 CAR-20/19-T cells/kg~Dose Level 0: 2.5 x10^5 CAR-20/19-T cells/kg (starting dose level)~Dose Level 1: 7.5 x10^5 CAR-20/19-T cells/kg~Dose Level 2: 2.5 x10^6 CAR-20/19-T cells/kg (goal cell dose)~Phase 1b~Expansion Dose Level: 2.5 x 10^6 cells/kg (single infusion)"
150138|NCT03019042|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
150139|NCT03019042|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
150140|NCT03019029|Other|18-F Florbetapir PET/MR scan|18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
150141|NCT03019016|Procedure|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
150142|NCT03019003|Drug|Azacitidine|Demethylating agent
150143|NCT03019003|Drug|Durvalumab|anti-PD-L1
150144|NCT03019003|Drug|Tremelimumab|anti-CTLA-4
150145|NCT03018990|Other|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
150146|NCT03018977|Other|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
150147|NCT03018977|Other|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
150148|NCT03018964|Procedure|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
150149|NCT03018964|Procedure|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
150150|NCT03018951|Other|Tool Development meeting|Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.
150151|NCT03018951|Other|Pilot Test 1 assessment session|Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.
150152|NCT03018951|Other|Pilot Test 2 assessment session|Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
150153|NCT03018938|Drug|Insulin Analog Mid Mixture|Administered SC
150154|NCT03018938|Drug|Basal Insulin Analog|Administered SC
150155|NCT03018925|Drug|Golimumab|
150156|NCT03018912|Other|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~How many days a week are you satisfied with your sleep?~How many days a week is sleepiness a problem?"
150157|NCT03018899|Procedure|paravertebral block|Ultrasound guided two-segment paravertebral block
150158|NCT03018899|Procedure|epidural anesthesia|thoracic epidural anesthesia
150159|NCT03018886|Other|GHRH plus arginine test|One ug/kg GHRH [GHRH(1-29), GEREF Serono, Italy] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
150160|NCT03018873|Other|remote ischemic preconditioning （RIPC）|once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
150161|NCT03018860|Procedure|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
150162|NCT03018860|Procedure|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
150163|NCT03018847|Device|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
150165|NCT03018834|Drug|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
150166|NCT03018821|Drug|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
150167|NCT03018821|Drug|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
150168|NCT03018821|Drug|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
150169|NCT03018821|Drug|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
150170|NCT03018821|Drug|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
150171|NCT03018821|Drug|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
150172|NCT03018821|Drug|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
150173|NCT03018821|Drug|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
150174|NCT03018821|Drug|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
150175|NCT03018821|Drug|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
150176|NCT03018821|Drug|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
150177|NCT03018821|Drug|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
150178|NCT03018821|Drug|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
150179|NCT03018808|Other|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
150180|NCT03018808|Other|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass.
150181|NCT03018808|Other|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
150182|NCT03018808|Procedure|Blood test|Blood samples will be collected at indicated time points
150183|NCT03018808|Other|anthropometric measures|Anthropologic measures will be performed.
150184|NCT03018808|Other|Oximetry|Digital pulse oximeter on the index finger after five minutes rest and before receiving bronchodilator for spirometry will be used to measure the pulse arterial oximetry. The average of three measurements at 10 second intervals will be recorded. The heart rate will be provided by the pulse oximeter.
150185|NCT03018795|Procedure|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
150186|NCT03018782|Other|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
150187|NCT03018769|Drug|Chinese Herb|
150188|NCT03018756|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
150189|NCT03018756|Drug|Placebo|0.9% saline solution will be inhaled via nebulizer
150190|NCT03018743|Drug|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
150191|NCT03018730|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
150192|NCT03018717|Other|Telemonitoring Constant|telemedicine of Constant
150193|NCT03018717|Other|Standard clinical care|The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
150194|NCT03018704|Drug|Topiramate|anticonvulsant medication
150195|NCT03018704|Drug|placebo|inactive medication
150196|NCT03018691|Drug|OPA-15406|
150197|NCT03018691|Drug|Placebos|
150198|NCT03018665|Drug|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
150199|NCT03018665|Drug|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
150200|NCT03018665|Drug|Metformin|oral，0.85g，twice a day in three months
150201|NCT03018652|Drug|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
150202|NCT03018652|Drug|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
150203|NCT03018639|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
150204|NCT03018626|Drug|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
150205|NCT03018626|Drug|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
150206|NCT03018626|Drug|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
150833|NCT03014297|Drug|everolimus|everolimus
150207|NCT03018626|Drug|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
150208|NCT03018626|Drug|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
150209|NCT03018626|Drug|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
150210|NCT03018626|Drug|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
150211|NCT03018626|Drug|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
150212|NCT03018626|Drug|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
150213|NCT03018626|Drug|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
150214|NCT03018613|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
150215|NCT03018613|Other|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
150216|NCT03018600|Behavioral|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
150217|NCT03018587|Device|TruSculpt|Subject(s) will receive 1 Trusculpt (Radio Frequency) Device Treatment
150218|NCT03018561|Other|Exercise and Cognitive testing|Maximal cardiopulmonary test Rest cognitive testing
150219|NCT03018548|Other|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
150220|NCT03018535|Drug|Rituximab|Rituximab,1 g IV, day 1 and day 15
150221|NCT03018535|Drug|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
150222|NCT03018535|Drug|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
150223|NCT03018522|Other|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the 7th day after surgery, and the 3rd month after surgery
150224|NCT03018509|Drug|JTE-451|Active drug tablets containing JTE-451
150225|NCT03018509|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
150226|NCT03018496|Dietary Supplement|Beta-Hydroxy-Beta-Methylbutyrate|
150227|NCT03018496|Other|Placebo|
150228|NCT03018483|Device|Variable PSV|"Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.~In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician."
150229|NCT03018483|Device|Conventional PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.
150230|NCT03018483|Device|Automated PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.
150231|NCT03018483|Device|NAVA|NAVA level is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the Edi level was increased by step of 0,2 cm/h2o/ mcvolt, PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.
150232|NCT03018470|Other|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
150233|NCT03018457|Device|ISQ|Measured by Osstell.
150234|NCT03018444|Drug|Atorvastatin|Atorvastatin tablet
150235|NCT03018444|Other|Placebo|Placebo tablet
150236|NCT03018431|Other|CT Scan|patients undergoing chest CT scan at admission and repeated lung ultrasonography
150237|NCT03018418|Radiation|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
150238|NCT03018418|Drug|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
150239|NCT03018405|Biological|NKR-2 cells|"In cohorts 1-6, the schedule of administration will be 3 NKR-2 doses administered with a 2-week interval. In absence of progressive disease at the first tumor assessment following NKR-2 administration (on Visit D29 for hematological tumors or on Visit D57 for solid tumors), and according to product availability, the patient will receive a new cycle of 3 administrations maximum with a 2-week interval, at a dose of 1x109 NKR-2 cells per injection, or at the same dose of cycle 1 if it was below 1x109 NKR-2 cells.~Patients in cohorts 8-9 (solid arm) and 10-11 (hematological arm) of first segment will receive 3 treatment doses at 1x109 NKR-2 (cohorts 8 and 10) or 3x109 NKR-2 (cohorts 9 and 11) per injection, with a 1-week interval between each dose. A second cycle of three NKR-2 injections at the same dose as in 1st cycle will be administered 2 weeks after the third NKR-2 injection, and with a 2-week interval between each dose."
150240|NCT03018392|Device|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
150241|NCT03018366|Drug|17beta Estradiol|Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks +/- 1week. PAT index and sphygmoCor vascular measures and serum immune markers will be measured after 6 and 12 weeks +/- 1week on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
150242|NCT03018366|Drug|Transdermal placebo patch|Participants will use a dose of placebo patches for 12 weeks +/- 1 week. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
150243|NCT03018366|Drug|Progesterone|After 12 weeks +/- 1week of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks +/- 3 days. Progesterone 200mg is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.
150834|NCT03014297|Drug|fosbretabulin|fosbretabulin
150244|NCT03018366|Drug|Placebo Pill|After 12 weeks +/- 1week of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks +/- 3 days.
150245|NCT03018353|Drug|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
150246|NCT03018340|Drug|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
150247|NCT03018340|Other|Placebo|Placebo, taken as two tablets, once daily by mouth All patients continued to receive selective serotonin reuptake inhibitor/serotonin norepinephrine reuptake inhibitor (SSRI/SNRI) antidepressants at a stable dose for the duration of the study.
150248|NCT03018314|Other|Blood sample|Serum analysis
150249|NCT03018301|Drug|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
150250|NCT03018301|Other|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
150251|NCT03018288|Drug|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30 minute IV infusion (prior to RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if patients are doing well they may continue pembolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
150252|NCT03018288|Biological|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of HSPPC-96 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of TMZ. HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Patients who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if patients are doing well they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
150253|NCT03018288|Drug|Temozolomide|TMZ will be administered on day 1 of radiation therapy (before RT treatment) and continue throughout RT at the dose of 75 mg/m2. Post RT: The starting TMZ dose will be 150 mg/m2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
150254|NCT03018288|Other|Placebo|One week post RT, patients will receive weekly x 4 a dose of HSPPC-96 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of TMZ. HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Patients who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if patients are doing well they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
150255|NCT03018275|Biological|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
150256|NCT03018249|Drug|Entinostat|Given PO
150257|NCT03018249|Procedure|Hysterectomy|Undergo hysterectomy
150258|NCT03018249|Other|Laboratory Biomarker Analysis|Correlative studies
150259|NCT03018249|Drug|Medroxyprogesterone Acetate|Given IM
150260|NCT03018236|Drug|Alcohol N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
150261|NCT03018236|Drug|Alcohol Placebo|Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
150262|NCT03018236|Drug|Cocaine N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
150263|NCT03018236|Drug|Cocaine Placebo|Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
150264|NCT03018223|Drug|Fludarabine|Myeloablative conditioning: 40 mg/m^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
150265|NCT03018223|Drug|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
150266|NCT03018223|Drug|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
150267|NCT03018223|Radiation|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
150268|NCT03018223|Procedure|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
150269|NCT03018223|Drug|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
150270|NCT03018223|Drug|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
150271|NCT03018223|Drug|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is > 1,000/mm^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
150272|NCT03018210|Procedure|Surgical repair of the rotator cuff|
150273|NCT03018197|Other|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
150274|NCT03018184|Other|MRI and Muscle Dynamometer|
150275|NCT03018171|Drug|Clonidine|Intrathecal clonidine addiction
150276|NCT03018171|Drug|Sufentanil|Intrathecal
150280|NCT03018132|Other|mental health screening, education and referral program|"I. Psychosocial assessments:~Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.~Exercise, smoking & substance use, sleep and nutrition.~II. If women are above cutoff values the SCID will be conducted.~III. Education and referral information via Maternal Mental Health NOW:~All receive a brochure entitled, Speak Up When You Are Down~If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID~Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.~IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
150281|NCT03018119|Other|Survey|
150282|NCT03018106|Drug|Ospemifene|Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.
150283|NCT03018106|Drug|Vaginal conjugated estrogens|Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
150284|NCT03018093|Biological|C-CAR-011|CD19-targeted chimeric antigen receptor T cells
150285|NCT03018080|Drug|Pembrolizumab|IV (in the vein) on day 1 of a 21 day cycle
150286|NCT03018080|Drug|Paclitaxel|IV (in the vein) on days 1 and 8 of a 21 day cycle
150287|NCT03018067|Drug|RDX227675|
150288|NCT03018067|Drug|Placebo|
150289|NCT03018054|Drug|E6007|once daily administration
150290|NCT03018054|Drug|Placebo|once daily administration
150291|NCT03018041|Drug|Omacor|"As described in Arms."
150292|NCT03018041|Drug|Placebo Oral Capsule|"As described in Arms."
150293|NCT03018028|Drug|Semaglutide|Oral administration once daily
150294|NCT03018028|Drug|Placebo|Oral administration once daily
150295|NCT03018028|Drug|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
150296|NCT03018015|Drug|Ibuprofen 400 mg oral powder|
150297|NCT03018015|Drug|Ibuprofen 400 mg film-coated tablet|
150298|NCT03018015|Drug|Ibuprofen 400 mg soft capsule|
150299|NCT03018002|Other|iSTAR|"Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.~CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results."
150300|NCT03017989|Device|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
150301|NCT03017963|Drug|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
150302|NCT03017950|Drug|CKD-330|
150303|NCT03017950|Drug|D086|
150304|NCT03017950|Drug|CKD-330 + D086|
150305|NCT03017937|Device|Q-collar|capture ultrasound images at each pressure point
150306|NCT03017924|Device|Q collar|q-collar concussion prevention device
150307|NCT03017911|Procedure|Piccline|
150308|NCT03017898|Procedure|Laser Coagulation|Laser coagulation of anal fistula
150309|NCT03017872|Drug|NRTIs|"In SOC arm, choice of NRTIs determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.~In D2N arm, NRTIs are predetermined."
150310|NCT03017872|Drug|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
150311|NCT03017872|Drug|Darunavir|800mg tablet by mouth once daily for 96 weeks.
150312|NCT03017872|Drug|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
150313|NCT03017859|Device|High flow nasal cannula|We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep.
150314|NCT03017846|Drug|Cantharidin|Application of topical cantharidin
150315|NCT03017833|Other|Laboratory Biomarker Analysis|Correlative studies
150316|NCT03017833|Drug|Metformin|Given PO
150317|NCT03017833|Other|Pharmacological Study|Ancillary studies
150318|NCT03017833|Drug|Sapanisertib|Given PO
150319|NCT03017820|Biological|Biological Therapy|Given VSV-hIFNbeta-NIS IV
150320|NCT03017820|Procedure|Computed Tomography|Undergo SPECT/CT
150321|NCT03017820|Other|Laboratory Biomarker Analysis|Correlative studies
150322|NCT03017820|Other|Pharmacological Study|Correlative studies
150323|NCT03017820|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
150324|NCT03017807|Biological|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
150393|NCT03017300|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
242866|NCT02343536|Drug|Rituximab|
150325|NCT03017768|Dietary Supplement|Acute tryptophan depletion|an amino-acid mixture will be administered without tryptophan (active comparator). After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of depleted tryptophan levels on esophageal sensitivity
150326|NCT03017768|Dietary Supplement|Placebo|an amino-acid mixture with tryptophan (placebo mixture) will be administered. After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation
150327|NCT03017768|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
150328|NCT03017755|Other|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
150329|NCT03017729|Biological|Botulinum toxin type A|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
150330|NCT03017716|Other|Gluten free diet|The investigators will evaluate the effect of a gluten free diet (GFD) in IBP patients, randomly assigned to receive standard therapy for IBP or standard therapy for IBP plus GFD, for a period of at least one year.
150331|NCT03017703|Drug|Eplerenone|
150332|NCT03017664|Other|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
150333|NCT03017664|Other|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
150334|NCT03017651|Dietary Supplement|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
150335|NCT03017651|Dietary Supplement|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
150336|NCT03017638|Other|Questionaire|Patients undergoing primary laparoscopic colectomy patients under general anesthesia with an additional Quadratus lumborum block (QLB ) will be asked to fill out a questionnaires detailing: numeric verbal analogue scores (VAS) and quality of recovery score(QoR) preoperatively, 24 hours, 48 hour and four weeks after surgery. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption in order to assess the analgesic efficacy of QLB for primary laparoscopic colectomy. QLB will be performed as per standard routine regimens, in the operating room after induction of general anesthesia and prior to surgery.
150337|NCT03017625|Other|Blood is drawn|Blood analyses
150338|NCT03017612|Device|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
150339|NCT03017599|Device|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.~EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
150340|NCT03017586|Device|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
150341|NCT03017573|Procedure|Tumor biopsies / Tumor surgery|"Tumoral tissues samples must be collected at different times points :~at the time of surgery~before first cycle of adjuvant treatment (if possible)~at progression (if possible)~OR~before neoadjuvant therapy~at the time of surgery~before first cycle of adjuvant treatment (if possible)~at progression (if possible)"
150342|NCT03017573|Procedure|Blood withdrawal|"Blood samples must be collected at different times points :~at the time of surgery~after surgery~before first cycle of adjuvant treatment~before second cycle of adjuvant treatment~at progression~OR~before neoadjuvant therapy~during neoadjuvant therapy (post cycle 1)~at the time of surgery~before first cycle of adjuvant treatment~before second cycle of adjuvant treatment~at progression"
150343|NCT03017560|Behavioral|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
150344|NCT03017547|Drug|IC14|Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
150345|NCT03017547|Other|Placebo|sterile normal saline for infusion
150346|NCT03017534|Procedure|Spinal Manual Therapy|Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
150347|NCT03017521|Drug|TAS-117|TAS-117 16mg, daily
150348|NCT03017508|Drug|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
150349|NCT03017508|Drug|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
150350|NCT03017495|Drug|Midazolam|2 mg/mL oral solution
150351|NCT03017495|Drug|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
150352|NCT03017482|Device|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:~Questionnaires about the utility and impact of the device~Use of the device in children younger than the current FDA approval range"
150394|NCT03017300|Device|PFLEX®|A device used to offer resisive to inspiratory muscle
242867|NCT02343536|Drug|cyclophosphamide|
150353|NCT03017469|Other|ARISE|"Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) [Shepell], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness~Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing~Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation~Five online, instructor-guided mindfulness sessions (Zoom)"
150354|NCT03017456|Behavioral|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
150355|NCT03017443|Behavioral|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
150356|NCT03017443|Behavioral|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (~50% kcal from carbohydrate, ~25% from protein, ~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
150357|NCT03017443|Behavioral|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included < 30% fat (< 7% saturated fat), < 150 mg/d of cholesterol, and < 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu [7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
150358|NCT03017443|Behavioral|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
150359|NCT03017430|Drug|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
150360|NCT03017430|Drug|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
150361|NCT03017430|Drug|Doxylamin|
150362|NCT03017430|Drug|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
150363|NCT03017417|Other|Exercise Intervention|Various exercise tests
150364|NCT03017417|Other|standard of care|standard treatment
150365|NCT03017404|Drug|Doxorubicin Hydrochloride Liposome Injection|
150366|NCT03017404|Drug|Cyclophosphamide|
150367|NCT03017404|Drug|docetaxel|
150368|NCT03017391|Drug|metoclopramide|metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
150369|NCT03017391|Drug|granisetron|granisetron patch 3.1mg/24 hours, use until toxicity
150370|NCT03017391|Drug|Dexamethasone|dexamethasone 8 mg, last step in both algorithms
150371|NCT03017391|Drug|Granisetron 2Mg Tablet|granisetron 2 mg loading dose
150372|NCT03017378|Biological|TB/FLU-01L|TB / FLU-01L (intranasal application)
150373|NCT03017378|Biological|TB/FLU-01L|TB/FLU-01L (sublingual application)
150374|NCT03017365|Other|Stable Resistance Training|traditional machine-based resistance training
150375|NCT03017365|Other|Unstable Resistance Training|free weight resistance training using unstable devices
150376|NCT03017365|Other|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
150377|NCT03017352|Drug|Exenatide|
150378|NCT03017352|Drug|Placebos|
150379|NCT03017339|Other|Functional Exercise|
150380|NCT03017339|Radiation|Low Level Laser Therapy|
150381|NCT03017339|Radiation|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
150382|NCT03017326|Drug|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
150383|NCT03017326|Drug|Doxorubicin|Arms C, D and E used in combination
150384|NCT03017326|Drug|Carboplatin|Arms C and D used in combination
150385|NCT03017326|Drug|5Fluorouracil|Arm C used alone
150386|NCT03017326|Drug|Vincristine|Arms C and D used in combination
150387|NCT03017326|Drug|Etoposide|Arm D used in combination
150388|NCT03017326|Drug|Irinotecan|Arm D used in combination
150389|NCT03017326|Drug|Gemcitabine|Arm F used in combination
150390|NCT03017326|Drug|Oxaliplatin|Arm F used in combination
150391|NCT03017326|Drug|Sorafenib|Arm used in combination
242868|NCT02343536|Drug|Vincristine|
150396|NCT03017274|Other|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
150397|NCT03017261|Device|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
150398|NCT03017248|Drug|Ketamine|ketamine
150399|NCT03017248|Drug|Placebos|0.9% normal saline
150400|NCT03017248|Drug|Morphine|Morphine
150401|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as two 160 mL ready-to-drink bottles, per subject, without further reconstitution, before administration.
150402|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two sachets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
150403|NCT03017222|Drug|Ondansetron|Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
150404|NCT03017222|Drug|Ramosetron|Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
150405|NCT03017209|Dietary Supplement|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
150406|NCT03017209|Dietary Supplement|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
150407|NCT03017209|Other|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
150408|NCT03017196|Other|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
150409|NCT03017183|Procedure|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
150410|NCT03017183|Procedure|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
150411|NCT03017170|Drug|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
150412|NCT03017170|Drug|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
150413|NCT03017157|Other|Echo-cardiogram|Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function
150414|NCT03017157|Other|Blood test|Blood test to determine thyroid function
150415|NCT03017131|Biological|Aldesleukin|Given SC
150416|NCT03017131|Drug|Cyclophosphamide|Given IV
150417|NCT03017131|Drug|Decitabine|Given IV
150418|NCT03017131|Biological|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
150419|NCT03017131|Other|Laboratory Biomarker Analysis|Correlative studies
150420|NCT03017118|Dietary Supplement|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
150421|NCT03017118|Other|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
150422|NCT03017105|Other|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
150423|NCT03017105|Other|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
150424|NCT03017092|Behavioral|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
150425|NCT03017079|Dietary Supplement|semi-solid agent|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 mins
150426|NCT03017079|Other|standard enteral feeding|Intermittent enteral feeding is applied less than 60 mins
150427|NCT03017066|Device|Ultrasound|Ultrasound assessment of gastric volume is performed three times; before ingestion of infant formula or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
150428|NCT03017066|Other|General anesthesia|Scheduled operation under general anesthesia
150429|NCT03017053|Radiation|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
150430|NCT03017053|Procedure|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
150431|NCT03017040|Device|CT scan|A CT scan of the wrist
150432|NCT03017040|Device|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
150483|NCT03016702|Other|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
151559|NCT03009058|Drug|Cyclophosphamide|Standard of Care chemotherapy
150433|NCT03017027|Behavioral|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
150434|NCT03017027|Behavioral|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
150435|NCT03017001|Dietary Supplement|CHO (carbohydrate)|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia
150436|NCT03017001|Drug|intravenous w-3 PUFA|Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
150437|NCT03017001|Other|CHO (carbohydrate) plus intravenous w3-PUFA|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
150438|NCT03016988|Drug|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
150439|NCT03016988|Drug|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
150440|NCT03016988|Drug|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
150441|NCT03016975|Device|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
150442|NCT03016962|Device|cap-assisted colonoscopy|cap-assisted colonoscopy
150443|NCT03016962|Device|Standard colonoscopy|Standard colonoscopy
150444|NCT03016949|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
150445|NCT03016949|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
150446|NCT03016923|Device|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
150447|NCT03016897|Other|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
150448|NCT03016884|Biological|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
150449|NCT03016871|Drug|Carboplatin|Given IV
150450|NCT03016871|Drug|Etoposide|Given IV
150451|NCT03016871|Drug|Ifosfamide|Given IV
150452|NCT03016871|Other|Laboratory Biomarker Analysis|Correlative studies
150453|NCT03016871|Biological|Nivolumab|Given IV
150454|NCT03016858|Procedure|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
150455|NCT03016832|Drug|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
150456|NCT03016832|Drug|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
150457|NCT03016832|Drug|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
150458|NCT03016832|Drug|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
150459|NCT03016819|Drug|AL 3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
150460|NCT03016819|Drug|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
150461|NCT03016806|Radiation|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
150462|NCT03016806|Radiation|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
150463|NCT03016806|Drug|Cyclophosphamide|50 mg/kg or 60 mg/kg
150464|NCT03016806|Drug|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
150465|NCT03016806|Procedure|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
150466|NCT03016806|Drug|Busulfan|0.8 mg/kg x 16 doses
150467|NCT03016806|Drug|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
150468|NCT03016806|Drug|Melphalan|140 mg/m2
150469|NCT03016793|Drug|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
150470|NCT03016793|Drug|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
150471|NCT03016793|Drug|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
150472|NCT03016780|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
150473|NCT03016780|Other|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
150474|NCT03016767|Procedure|Manual oral stimulation protocol|
150475|NCT03016754|Device|Wearable Cardioverter Defibrillator|LifeVest Wearable Cardioverter Defibrillator
150476|NCT03016741|Biological|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
150477|NCT03016741|Drug|Prednisone|Given by mouth
150478|NCT03016741|Drug|Abiraterone Acetate|Given by mouth
150479|NCT03016741|Drug|Enzalutamide|Given by mouth
150480|NCT03016728|Behavioral|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
150481|NCT03016715|Drug|Sirolimus 2%|
150482|NCT03016715|Drug|Vehicle|
150484|NCT03016702|Other|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
150485|NCT03016676|Other|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
150486|NCT03016676|Other|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
150487|NCT03016663|Procedure|Technique of Breast Lipofilling|"Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
150488|NCT03016650|Drug|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
150489|NCT03016650|Drug|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
150490|NCT03016637|Device|SharkCore (TM) FNB Exchange System|
150491|NCT03016624|Device|OCT guided PCI|oct guided
150492|NCT03016624|Device|Angiography guided PCI|angio guided
150493|NCT03016611|Drug|Chewing Ticagrelor LD|180 mg Chewing Ticagrelor
150494|NCT03016611|Drug|Chewing Prasugrel LD|60 mg Chewing Prasugrel
150495|NCT03016598|Drug|Intranasal oxytocin|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
150496|NCT03016598|Drug|Intranasal placebo|Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
150497|NCT03016585|Other|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
150498|NCT03016572|Behavioral|Standard of Care|Follow-Up Calls, Questionnaires
150499|NCT03016572|Behavioral|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
150500|NCT03016572|Behavioral|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
150501|NCT03016559|Other|releasing muscle|At baseline, hip and knee angles were measured. The quadratus lumborum muscle was released. After that, the hip and knee angles were re-measured.
150502|NCT03016546|Behavioral|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
150503|NCT03016546|Behavioral|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
150504|NCT03016533|Drug|Dolutegravir film-coated tablets|Dolutegravir film-coated tablets will be provided as 10 mg, 25 mg and 50 mg tablets. It will be administered at the dose of approximately 1 mg/kilogram (kg) with maximum dose of 50 mg to subjects as per their age and weight band.
150545|NCT03016247|Behavioral|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
150505|NCT03016533|Drug|Dolutegravir film-coated dispersible tablets|Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to subjects as per their age and weight band.
150506|NCT03016520|Drug|DWJ1392|
150507|NCT03016520|Drug|DWC20164|
150508|NCT03016494|Drug|Co-administration of DWC20155 and DWC20156|
150509|NCT03016494|Drug|DWJ1386 Tab.|
150510|NCT03016481|Behavioral|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
150511|NCT03016481|Behavioral|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
150512|NCT03016468|Drug|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
150513|NCT03016468|Drug|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
150514|NCT03016455|Other|Presence of DSA w/ cAMR|
150515|NCT03016455|Other|Presence of DSA w/o cAMR|
150516|NCT03016455|Other|No DSA No cAMR|
150517|NCT03016442|Device|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
150518|NCT03016442|Drug|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
150519|NCT03016403|Behavioral|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
150520|NCT03016403|Behavioral|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
150521|NCT03016377|Biological|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10^5), dose level 1 (5 x 10^5), and dose level 2 ( 1x 10^6)
150522|NCT03016377|Drug|Rimiducid|Subjects who develop grade 4 CRS or grade 2/3 CRS that is unresponsive to standard of care interventions will be given Rimiducid at .4 mg/kg.
150523|NCT03016377|Drug|Cyclophosphamide|900 mg/m^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
150524|NCT03016377|Drug|Fludarabine|25 mg/m^2/day IV over 30 minutes administered for 3 consecutive days.
150525|NCT03016364|Device|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
150526|NCT03016351|Other|Aerobic Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
150527|NCT03016351|Other|Resistance Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
150528|NCT03016338|Drug|Niraparib|200 or 300 mg daily PO, for 28 day cycle
150529|NCT03016325|Drug|HNO Donor|Infusion
150530|NCT03016325|Drug|Placebo|Infusion
150531|NCT03016312|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
150532|NCT03016312|Drug|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
150533|NCT03016299|Procedure|microfracture techniques|Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
150534|NCT03016286|Other|vibration|Whole body vibration at 25Hz frequency
150535|NCT03016273|Procedure|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
150536|NCT03016260|Biological|Infliximab|Anti-TNF alpha originator
150537|NCT03016260|Biological|Adalimumab|Anti-TNF alpha originator
150538|NCT03016260|Biological|Etanercept|Anti-TNF alpha originator
150539|NCT03016260|Biological|Golimumab|Anti-TNF alpha originator
150540|NCT03016260|Biological|Certolizumab Pegol|Anti-TNF alpha originator
150541|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
150542|NCT03016260|Biological|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
150543|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
150544|NCT03016247|Behavioral|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
150756|NCT03014791|Other|Brief lifestyle/medical history questionnaire|Core Measurement
150546|NCT03016234|Drug|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
150547|NCT03016234|Drug|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
150548|NCT03016221|Other|Axanova hot gel|Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
150549|NCT03016221|Other|Axanova activ gel|Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
150550|NCT03016221|Other|Perskindol Dolo Gel|Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
150551|NCT03016221|Other|Perskindol Classic Gel|Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
150552|NCT03016221|Other|Perskindol Cool Kühl-Gel|Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
150553|NCT03016221|Other|Dolor-X Hot Gel|Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
150554|NCT03016221|Other|Dolor-X Classic Gel|Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
150555|NCT03016221|Other|Dolor-X Cool Gel|Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
150556|NCT03016208|Drug|Misoprostol vaginal insert|
150557|NCT03016182|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
150558|NCT03016182|Procedure|Control|Control group witnout remote ischemic preconditioning
150559|NCT03016169|Device|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
150560|NCT03016156|Other|CRADLE|"A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.~The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts."
150561|NCT03016156|Other|Red reflex testing|Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
150562|NCT03016143|Biological|Allantoic Split Inactivated Seasonal flu Vaccine|Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
150563|NCT03016143|Biological|VAXIGRIP|Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
150564|NCT03016130|Other|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
150565|NCT03016117|Procedure|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
150566|NCT03016104|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
150567|NCT03016104|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
150568|NCT03016104|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
150569|NCT03016091|Drug|Pembrolizumab|anti PD-L1
150570|NCT03016078|Device|Mepilex Border Post-Op Ag|To investigate if there was any skin damage under the dressing from operation day to last visit.
150571|NCT03016065|Dietary Supplement|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
150572|NCT03016065|Dietary Supplement|Control|Baked goods (2 snacks) without added fiber
150573|NCT03016052|Behavioral|ABMT|Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
242869|NCT02343536|Drug|Prednisone|
150574|NCT03016039|Dietary Supplement|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
150575|NCT03016026|Procedure|ERAS|Undergo an ERAS program
150576|NCT03016013|Biological|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.Study investigator evaluate the patients of curative effect.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
150577|NCT03016013|Biological|RC18 160 mg plus MTX|
150578|NCT03016000|Drug|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
150579|NCT03016000|Other|Observation|Just observation
150580|NCT03015987|Other|diode laser activated irrigation|diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
150581|NCT03015974|Drug|Corticosteroid|
150582|NCT03015974|Drug|Cyclophosphamide|
150583|NCT03015974|Drug|Mycophenolate mofetil|
150584|NCT03015974|Drug|Dipyridamole|
150585|NCT03015974|Drug|ACE Inhibitor or Angiotensin receptor antagonist|
150586|NCT03015961|Drug|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
150587|NCT03015961|Drug|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl"
150588|NCT03015948|Drug|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
150589|NCT03015948|Drug|Placebo|a single dose of placebo (n=2) for each dose cohort .
150590|NCT03015935|Procedure|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
150591|NCT03015935|Procedure|Veress entry|First trocar entry will be performed with Veress
150592|NCT03015922|Drug|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
150593|NCT03015922|Biological|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
150594|NCT03015909|Drug|Somatropin|
150595|NCT03015896|Other|Laboratory Biomarker Analysis|Correlative studies
150596|NCT03015896|Drug|Lenalidomide|Given PO
150597|NCT03015896|Biological|Nivolumab|Given IV
150598|NCT03015883|Radiation|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
150599|NCT03015870|Behavioral|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
150600|NCT03015870|Behavioral|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
150601|NCT03015857|Drug|phenylephrine|- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
150602|NCT03015857|Drug|Norepinephrine|- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
150603|NCT03015857|Drug|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
150604|NCT03015857|Drug|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
150605|NCT03015857|Drug|Placebo (normal saline)|
150606|NCT03015844|Drug|131-I-meta-iodobenzylguanidine|
150607|NCT03015831|Drug|Colchicine|Colchicine will be given to open heart surgery patients
150608|NCT03015831|Drug|Placebo Oral Tablet|Placebo Oral Tablet will be given to open heart surgery patients according to randomization
150609|NCT03015818|Other|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
150610|NCT03015805|Behavioral|Contingency Management|"Contingency Management (CM) utilizes behavior modification & cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
150611|NCT03015805|Behavioral|Probation as Usual|Standard services that a young person would receive while under probation supervision in the state of Oregon.
150612|NCT03015792|Drug|Dexamethasone|Given PO
150613|NCT03015792|Drug|Ibrutinib|Given PO
150614|NCT03015792|Other|Laboratory Biomarker Analysis|Correlative studies
150615|NCT03015792|Drug|Lenalidomide|Given PO
150616|NCT03015792|Other|Pharmacological Study|Correlative studies
150617|NCT03015792|Other|Quality-of-Life Assessment|Ancillary studies
150618|NCT03015779|Other|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
150647|NCT03015610|Drug|matched placebo|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
150757|NCT03014791|Other|Anthropometric measures|Core Measurement
150758|NCT03014791|Other|Blood pressure and arterial stiffness|Core Measurement
150619|NCT03015766|Other|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
150620|NCT03015766|Other|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
150621|NCT03015753|Behavioral|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
150622|NCT03015753|Other|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
150623|NCT03015740|Other|Laboratory Biomarker Analysis|Correlative studies
150624|NCT03015740|Biological|Nivolumab|Given IV
150625|NCT03015740|Other|Quality-of-Life Assessment|Ancillary studies
150626|NCT03015740|Other|Questionnaire Administration|Ancillary studies
150627|NCT03015740|Drug|Sitravatinib|Given PO
150628|NCT03015727|Drug|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
150629|NCT03015727|Drug|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
150630|NCT03015727|Radiation|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
150631|NCT03015727|Drug|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
150632|NCT03015714|Other|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
150633|NCT03015714|Other|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
150634|NCT03015701|Drug|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
150635|NCT03015701|Other|Placebo|placebo matching mifepristone
150636|NCT03015688|Radiation|x-ray images|
150637|NCT03015675|Drug|ascorbic acid|20g/day, D1-3, every 2 weeks
150638|NCT03015675|Drug|mFOLFOX6|"mFOLFOX6~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
150639|NCT03015662|Other|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
150640|NCT03015662|Other|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
150641|NCT03015649|Device|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
150642|NCT03015636|Behavioral|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
150643|NCT03015636|Other|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
150644|NCT03015623|Biological|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
150645|NCT03015623|Device|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
150646|NCT03015610|Drug|commercially available lansoprazole|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks
150750|NCT03014817|Procedure|Electrocautery|Dissection with electrocautery
150648|NCT03015597|Behavioral|Contingency Management|Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of <10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
150649|NCT03015571|Device|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
150650|NCT03015571|Device|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
150651|NCT03015571|Device|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
150652|NCT03015571|Device|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
150653|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
150654|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
150655|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
150656|NCT03015545|Device|paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
150657|NCT03015545|Device|paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
150658|NCT03015545|Device|non-paretic leg-control|standing on the vibration platform, with no vibration signals delivered.
150659|NCT03015545|Device|non-paretic leg-WBV|standing on the vibration platform, with WBV at 30Hz, 1.5mm.
150660|NCT03015532|Drug|HTX-011|
150661|NCT03015532|Drug|Saline Placebo|
150662|NCT03015532|Drug|Bupivicaine HCl|Bupivacaine HCl without epinephrine
150663|NCT03015532|Drug|Ropivacaine|
150664|NCT03015519|Drug|Albiglutide|30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
150665|NCT03015519|Drug|Placebo|Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
150666|NCT03015506|Other|Bread|
150667|NCT03015493|Other|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
150668|NCT03015493|Other|Traction|Traction techniques for the cervical spine
150669|NCT03015480|Behavioral|Remote counseling|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
150670|NCT03015467|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1
150671|NCT03015467|Other|normal saline|normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
150672|NCT03015454|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
150673|NCT03015454|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
150674|NCT03015441|Other|Milk product fermented by lactic bacteria or not fermented|2 pots of 125g consumed daily during 28 days
150675|NCT03015428|Other|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
150676|NCT03015415|Procedure|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
150677|NCT03015415|Procedure|Non-surgical intervention|Rehabilitation with splinting protocols
150678|NCT03015402|Drug|Sodium Nitrite|40 mg PO (by mouth) TID (three times each day) for 10 weeks
150679|NCT03015402|Drug|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 10 weeks
150680|NCT03015389|Procedure|Diagnostic Test|WATS3D brush biopsy
150681|NCT03015350|Drug|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
150682|NCT03015350|Drug|Desflurane|Measurement of blood desflurane level during one lung ventilation
150683|NCT03015337|Behavioral|New physical education instructions|
150684|NCT03015324|Drug|Hydroxychloroquine|Hydroxychloroquine
150685|NCT03015311|Drug|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
150686|NCT03015311|Drug|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
150687|NCT03015298|Device|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
150688|NCT03015298|Device|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
150689|NCT03015285|Behavioral|Cognitive Behavioural Therapy|A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
150690|NCT03015272|Behavioral|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
150691|NCT03015272|Behavioral|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
150692|NCT03015259|Drug|Budesonide/Formoterol fumarate dihydrate|Experimental: Treatment 1
150693|NCT03015259|Drug|Symbicort|Active Comparator: Treatment 2
150694|NCT03015259|Drug|Placebo|Placebo Comparator: Treatment 3
150695|NCT03015246|Drug|Buprenorphine-Naloxone|To blind the varying maintenance doses, on each protocol day the participant will always take a total of 4 tablets at the same time, with a mixture of active and placebo tablets. Total daily doses will differ, depending on the periods/weeks within each study phase.
150696|NCT03015246|Drug|Morphine|During each participant's first experimental week, one morphine dose will be administered orally at 9:00 pm the evening prior to each of the 3 inpatient experimental sessions.
150697|NCT03015246|Drug|Yohimbine|Yohimbine (or matching placebo)will be administered at 12:00pm on each of the experimental sessions.
150698|NCT03015246|Drug|Hydrocortisone|Hydrocortisone or matching placebo will be administered 45 min after Yohimbine.
150699|NCT03015246|Drug|Matching Placebo for Yohimbine|Yohimbine (or matching placebo) will be administered at 12:00pm on each of the experimental sessions.
150700|NCT03015246|Drug|Matching Placebo for Hydrocortisone|Hydrocortisone or matching placebo will be administered 45 min after Yohimbine.
150701|NCT03015220|Drug|Semaglutide|Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
150702|NCT03015220|Drug|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
150703|NCT03015207|Drug|NNC0194-0499|
150704|NCT03015207|Drug|Placebo|
150705|NCT03015194|Device|Edwards SAPIEN 3 transcatheter heart valve|Used to relieve aortic stenosis in patients with symptomatic heart disease
150706|NCT03015194|Device|ASHI INTECC Astato XS 20|"The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step."
150707|NCT03015181|Biological|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
150708|NCT03015168|Radiation|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
150709|NCT03015155|Procedure|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
150710|NCT03015142|Device|New image-guidance software|Patients in this group had spine surgery with new image-guidance software application
150711|NCT03015129|Drug|Durvalumab|
150712|NCT03015129|Drug|Tremelimumab|
150713|NCT03015116|Other|Stretching|Daily foot and ankle stretching protocol
150714|NCT03015116|Other|Cryotherapy|Daily cryotherapy in conjunction with stretching
150715|NCT03015116|Device|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
150716|NCT03015116|Device|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
150717|NCT03015103|Device|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
150718|NCT03015090|Drug|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
150719|NCT03015077|Dietary Supplement|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
150720|NCT03015077|Dietary Supplement|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
150721|NCT03015077|Radiation|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
150722|NCT03015064|Other|Myocardial Infarction|Observational study of myocardial Infarction patients
150723|NCT03015051|Drug|Oxygen|
150724|NCT03015025|Genetic|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
150751|NCT03014804|Biological|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
150725|NCT03015012|Genetic|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
150726|NCT03015012|Other|Standard Nutrition Intervention (SNI)|Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
150727|NCT03014999|Device|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
150728|NCT03014999|Device|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
150729|NCT03014999|Device|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
150730|NCT03014973|Biological|intra-prostatic concentration of sexual steroids|
150731|NCT03014973|Procedure|Trans-rectal biopsy|
150732|NCT03014960|Other|Online Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
150733|NCT03014947|Drug|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
150734|NCT03014947|Drug|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
150735|NCT03014947|Drug|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
150736|NCT03014921|Other|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
150737|NCT03014921|Other|saline solution injection|Injection of a 250mL saline solution
150738|NCT03014908|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
150739|NCT03014895|Drug|Placebo|Intravenous infusion
150740|NCT03014895|Drug|E3112|Intravenous infusion
150741|NCT03014882|Drug|L-Carnitine and N-acetyl cysteine|
150742|NCT03014869|Device|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
150743|NCT03014856|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
150744|NCT03014843|Drug|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
150745|NCT03014843|Drug|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
150746|NCT03014843|Other|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
150747|NCT03014830|Drug|Alirocumab|150 mg SQ every 2 weeks
150748|NCT03014830|Drug|Placebos|Placebo injections SQ every 2 weeks
150749|NCT03014817|Procedure|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
243571|NCT02338531|Drug|PF-03084014|
150762|NCT03014791|Other|24 hour ambulatory blood pressure monitor|Detailed Measurement (Optional for participants).
150763|NCT03014791|Other|24 hour urine collection|Detailed Measurement (Optional for participants).
150764|NCT03014791|Other|Echocardiograph: Left ventricular mass|Detailed Measurement (Optional for participants).
150765|NCT03014791|Other|Large artery structure: Carotid intima-media thickness|Detailed Measurement (Optional for participants).
150766|NCT03014791|Other|Small artery structure: Minimum forearm vascular resistance|Detailed Measurement (Optional for participants).
150767|NCT03014791|Other|Large artery endothelial function|Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
150768|NCT03014791|Other|Small artery endothelial function: Forearm blood flow|Detailed Measurement (Optional for participants).
150769|NCT03014791|Other|Dundee step test|Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
150770|NCT03014791|Other|Detailed haemodynamic response to submaximal exercise|Detailed Measurement (Optional for participants).
150771|NCT03014791|Other|Cardiopulmonary fitness: Maximum oxygen consumption|Detailed Measurement (Optional for participants).
150772|NCT03014791|Other|Haemodynamic response to mental stress|Detailed Measurement (Optional for participants).
150773|NCT03014778|Drug|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
150774|NCT03014778|Drug|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
150775|NCT03014765|Other|EDOP|no intervention
150776|NCT03014752|Other|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
150777|NCT03014752|Other|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
150778|NCT03014739|Other|Supersonic ShearWave Elastography|ShearWave Elastography (SWE) is part of routine ultrasound examination
150779|NCT03014726|Device|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
150780|NCT03014713|Drug|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
150781|NCT03014713|Drug|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
150782|NCT03014713|Drug|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
150783|NCT03014700|Biological|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
150784|NCT03014700|Biological|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
150785|NCT03014687|Drug|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
150786|NCT03014687|Drug|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
150787|NCT03014674|Biological|Lyophilized mepolizumab|Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.
150788|NCT03014674|Biological|Liquid mepolizumab|Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.
150789|NCT03014674|Device|Prefilled autoinjector|Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.
150790|NCT03014674|Device|Prefilled Safety Syringe|Single use, disposable safety syringe with a retracting needle guard and locking system.
150791|NCT03014661|Other|Quality of life under or after therapy with Pollinex quattro|To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
150792|NCT03014648|Drug|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
150793|NCT03014635|Biological|Botulinum Toxins, Type A|Intramuscular injection
150794|NCT03014635|Biological|Placebos|Intramuscular injection
150795|NCT03014622|Biological|Botulinum Toxins, Type A|Intramuscular injection
150796|NCT03014622|Biological|Placebos|Intramuscular injection
150797|NCT03014596|Other|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
150798|NCT03014583|Device|Precision Spectra™ system|Neurostimulation procedures
150869|NCT03013998|Drug|Entospletinib (BAML-16-001-S4)|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg.
151560|NCT03009045|Drug|Tedizolid|200mg oral tedizolid one pill per day
150799|NCT03014570|Behavioral|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
150800|NCT03014570|Behavioral|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
150801|NCT03014557|Device|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
150802|NCT03014544|Device|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
150803|NCT03014544|Device|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
150804|NCT03014531|Other|almond|
150805|NCT03014531|Other|high-carbohydrate control food|
150806|NCT03014518|Other|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
150807|NCT03014518|Other|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
150808|NCT03014505|Biological|FMT|Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
150809|NCT03014505|Other|traditional treatments|traditional treatments for Decompensated Cirrhosis in part 2
150810|NCT03014492|Device|Q Collar|Collar designed to mitigate slosh in the brain
150811|NCT03014479|Drug|Trelagliptin|Trelagliptin 100 mg or 50 mg
150812|NCT03014479|Drug|Daily DPP-4 inhibitor|Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
150813|NCT03014466|Behavioral|Use of Video Projector|Bed mounted video projector that is used to play videos of the patient's choosing prior to induction of anesthesia
150814|NCT03014466|Behavioral|Use of Video Tablet|7 inch video tablet that is used for displaying videos of the patient's choosing prior to induction of anesthesia
150815|NCT03014440|Drug|Cannabidiol|
150816|NCT03014427|Other|Biological Database|Biological Database
150817|NCT03014414|Behavioral|Fun First|Learn key enjoyable maintenance skills before losing weight
150818|NCT03014414|Behavioral|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
150819|NCT03014401|Procedure|Arthroscopic debridement with stem cell transplantation|Autologous fat pad harvest and transplantation of cells after standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
150820|NCT03014401|Procedure|Arthroscopic debridement only|standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
150821|NCT03014388|Other|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
150822|NCT03014388|Other|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
150823|NCT03014375|Drug|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
150824|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|"Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: ~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC."
150825|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
150826|NCT03014349|Other|Analysis of medical records|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
150827|NCT03014336|Device|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
150828|NCT03014323|Drug|Galantamine|Galantamine 4 mg twice a day for 4 weeks
150829|NCT03014323|Drug|Placebo|Placebo 1 capsule twice a day for 4 weeks
150830|NCT03014310|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
150831|NCT03014310|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
150832|NCT03014310|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
150835|NCT03014271|Behavioral|Sources of Strength (SOS) Prevention Program|Sources of Strength is an evidence based program for youth suicide that trains student key leaders to strengthen social connectedness and healthy norms school-wide and is listed on the National Registry of Evidence Based Programs and Practices (NREPP).
150836|NCT03014258|Biological|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
150837|NCT03014232|Procedure|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
150838|NCT03014232|Procedure|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
150839|NCT03014219|Drug|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
150840|NCT03014193|Device|Semiquantitative Multi-Level Pregnancy Test|
150841|NCT03014180|Device|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
150842|NCT03014167|Drug|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
150843|NCT03014154|Other|Training|
150844|NCT03014141|Other|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
150845|NCT03014141|Other|Maltodextrin|11 g of Maltodextrin
150846|NCT03014128|Other|Clinical examination and data processing of questionnaires|xy
150847|NCT03014115|Dietary Supplement|combination ARA + DHA|combination ARA + DHA supplemented infant formula
150848|NCT03014115|Dietary Supplement|DHA|DHA supplemented infant formula
150849|NCT03014102|Drug|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
150850|NCT03014089|Biological|mRNA-1325|Escalating dose levels
150851|NCT03014089|Other|Placebo|
150852|NCT03014076|Drug|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
150853|NCT03014076|Drug|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
150854|NCT03014050|Device|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
150855|NCT03014037|Procedure|Unilateral Bone Marrow Procurement|A total of 61cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass, investigators will obtain 2.3cc of BMA with a 60cc syringes.
150856|NCT03014037|Procedure|Bilateral Bone Marrow Procurement|30.5cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10.17cc per pass) using 60cc syringes. The collection from each PSIS will be combined to yield a total of 61cc.
150857|NCT03014024|Other|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
150858|NCT03014024|Other|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
150859|NCT03014011|Other|Hypoglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
150860|NCT03014011|Other|Euglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
150861|NCT03013998|Biological|Samalizumab (BAML-16-001-S1)|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
150862|NCT03013998|Biological|BI 836858 (BAML-16-001-S2)|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to a maximum dose of 320 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
150863|NCT03013998|Other|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
150864|NCT03013998|Drug|Daunorubicin (BAML-16-001-S1)|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
150865|NCT03013998|Drug|Cytarabine (BAML-16-001-S1)|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
150866|NCT03013998|Drug|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
150867|NCT03013998|Drug|AG-221 (BAML-16-001-S3)|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
150868|NCT03013998|Drug|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
150870|NCT03013998|Drug|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with entospletinib for patients with disease progression.
150871|NCT03013998|Drug|Entospletinib (BAML-16-001-S5)|400 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be de-escalated to 200 mg twice daily or 200 mg once daily based on occurrence of dose-limiting toxicity.
150872|NCT03013998|Drug|Decitabine (BAML-16-001-S5)|20 mg/m2, IV, on days 1 through 5 or 10 of each 28-day cycle and continuing for up to 11 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib if subsequent induction cycles are necessary and continues for up to 2 total induction cycles including decitabine, with administration on days 1 through 10 of each 28-day cycle. During subsequent consolidation, decitabine is administered on days 1 through 5 of each 28-day cycle and continuing for up to 11 cycles. Duration may be reduced by up to 2 days based on occurrence of dose-limiting toxicity, and patients may switch to entospletinib monotherapy maintenance at any time if they develop toxicity or are unwilling to continue decitabine during consolidation therapy.
150873|NCT03013998|Drug|Entospletinib (BAML-16-001-S6)|400 mg, oral, twice daily for 5 years until time of intolerance or disease progression.
150874|NCT03013998|Drug|Azacitidine (BAML-16-001-S6)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with entospletinib for patients not attaining complete remission or complete remission with incomplete blood count recovery.
150875|NCT03013998|Drug|Daunorubicin (BAML-16-001-S6)|60 mg/m2, IV, on days 1-3 or 1-2 of each 28-day cycle for the first and second induction cycle, respectively
150876|NCT03013998|Drug|Cytarabine (BAML-16-001-S6)|100 mg/m2, IV, on days 1 through 7 or 1 through 5 of each 28-day cycle for the first and second induction cycle, respectively; 1000 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle for the consolidation cycles
150877|NCT03013998|Drug|Pevonedistat (BAML-16-001-S9)|20 mg/m2, IV, on days 1, 3, and 5 of each 28-day cycle and continuing for 24 cycles in the absence of toxicity or disease progression
150878|NCT03013998|Drug|Azacitidine (BAML-16-001-S9)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
150879|NCT03013998|Drug|AG-120 (BAML-16-001-S16)|500 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 250 mg based on occurrence of dose-limiting toxicity.
150880|NCT03013998|Drug|Azacitidine (BAML-16-001-S16)|75 mg/m2, IV or SC, on days 1 through 7 or days 1 through 5 and then 8 through 9 (based on institutional guidelines) of each 28-day cycle and continuing for 12 cycles in the absence of toxicity or disease progression
150881|NCT03013998|Drug|Gilteritinib (BAML-16-001-S8)|"120 mg, oral, daily, with treatment continuing based on bone marrow results at 28 and 56 days. Patients with partial response at 28 days continue treatment for an additional 28 days. Patients with complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) at 28 or 56 days continue treatment for 5 years until time of intolerance or disease progression. Patients with less than partial response at 28 days or partial response at 28 days followed by less than CR or CRi at 56 days proceed to combination treatment with decitabine or non-study alternative.~The combination dose is 80 mg, oral, daily, for 5 years until time of intolerance or disease progression (patients who do not achieve CR or CRi after 3 cycles will discontinue study treatment). The combination dose may be escalated to 120 mg daily or de-escalated to 80 mg daily given after decitabine rather than in combination with decitabine based on absence or occurrence of dose-limiting toxicity."
150882|NCT03013998|Drug|Decitabine (BAML-16-001-S8)|20 mg/m2, IV, on days 1 through 10 of each 28-day cycle and continuing for up to 3 cycles. Treatment starts after 1-2 cycles of monotherapy with gilteritinib if patients do not attain complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) with monotherapy. Patients who do not achieve CR/CRi after 3 cycles of combination therapy will discontinue study treatment. If CR or CRi is obtained with combination therapy after 3 cycles, decitabine will be administered on days 1-5 of each subsequent 28-day cycle until progression, intolerance, or patient desire to discontinue therapy.
150883|NCT03013985|Drug|Glargine U300|Glargine U300 is a new generation long-acting insulin.
150884|NCT03013985|Drug|Glargine U100|Glargine U100 is a long-acting insulin.
150885|NCT03013985|Drug|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
150886|NCT03013959|Drug|Pranoprofen|it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
150887|NCT03013946|Behavioral|Concomitant coaching|"The corner stones of the pro-active coaching are as follows:~Patient education:~Information on nature and severity of treatment emergent AEs~information about remedies for TEAEs~propagation and explanation of tests and treatment decisions~Patient instruction on self-care and preventive measures~Preemptive AE treatment strategies~Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach"
150888|NCT03013933|Drug|Brentuximab Vedotin|Given IV
150889|NCT03013933|Drug|Cyclosporine|Given PO
150890|NCT03013933|Other|Laboratory Biomarker Analysis|Correlative studies
150891|NCT03013933|Other|Pharmacological Study|Correlative studies
150892|NCT03013933|Drug|Verapamil|Given PO
150893|NCT03013907|Behavioral|UPLIFT|Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
150894|NCT03013907|Behavioral|Usual care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
150895|NCT03013881|Biological|UB-921|150 mg/vial
150896|NCT03013881|Biological|Herceptin|440 mg/vial
150940|NCT03013491|Drug|vemurafenib|
150897|NCT03013855|Device|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
150898|NCT03013855|Device|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
150899|NCT03013842|Device|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
150900|NCT03013829|Behavioral|KPD Educational Video|LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
150901|NCT03013816|Behavioral|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
150902|NCT03013816|Behavioral|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
150903|NCT03013816|Behavioral|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
150904|NCT03013803|Dietary Supplement|Nutricomp Drink Plus Fibre|
150905|NCT03013790|Drug|Melatonin|Patients will receive Melatonin at 2 different doses or a placebo
150906|NCT03013777|Behavioral|8-week CBT Program|
150907|NCT03013764|Behavioral|normal protein diet|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
150908|NCT03013764|Behavioral|high protein intake|subjects will undergo 10 days of low physical activity while consuming a high protein diet
150909|NCT03013751|Drug|Udenafil|Active drug
150910|NCT03013738|Behavioral|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
150911|NCT03013738|Other|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
150912|NCT03013725|Other|No intervention|No intervention
150913|NCT03013712|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
150914|NCT03013699|Behavioral|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
150915|NCT03013699|Behavioral|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
150916|NCT03013686|Procedure|Interval appendectomy|Laparoscopic appendectomy
150917|NCT03013686|Procedure|Follow-up with MRI|Abdominal MRI
150918|NCT03013673|Other|No intervention|No intervention
150919|NCT03013660|Other|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
150920|NCT03013647|Drug|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:~mild curettage of the AK lesions~application of a chemical sunscreen SPF 30~application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)~exposition to daylight, for 120 minutes~cleaning of the face"
150921|NCT03013634|Drug|Dexmedetomidine|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
150922|NCT03013634|Drug|Normal saline|Equal volume normal saline substitute for dexmedetomidine
150923|NCT03013608|Procedure|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
150924|NCT03013595|Behavioral|TRAM feedback|
150925|NCT03013582|Biological|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
150926|NCT03013582|Procedure|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
150927|NCT03013556|Drug|Group A, TDF|TDF for 96 weeks
150928|NCT03013556|Drug|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
150929|NCT03013556|Drug|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
150930|NCT03013543|Drug|Setmelanotide|RM-493 once daily subcutaneous injection
150931|NCT03013530|Procedure|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
150932|NCT03013517|Drug|Viaskin Peanut 250µg|
150933|NCT03013504|Drug|HD201|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
150934|NCT03013504|Drug|Herceptin|Loading dose of 8mg/kg in Cycle 1 and 6mg/kg in subsequent cycles.
150935|NCT03013504|Drug|Docetaxel|75mg/m2 via i.v. infusion during cycles 1 to 4.
150936|NCT03013504|Drug|Epirubicin|75 mg/m2 via i.v. infusion during cycles 5-8.
150937|NCT03013504|Drug|Cyclophosphamide|500 mg/m2 via i.v. infusion during cycles 5-8.
150938|NCT03013491|Drug|CX-072|
150939|NCT03013491|Drug|ipilimumab|
150941|NCT03013478|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
150942|NCT03013478|Behavioral|CBT4CBT program|
150943|NCT03013465|Other|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
150944|NCT03013465|Other|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
150945|NCT03013452|Device|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
150946|NCT03013452|Behavioral|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
150947|NCT03013439|Drug|Iron Isomaltoside|The trial is a dose escalating trial.
150948|NCT03013426|Drug|NVX-508|Administration of NVX-508 emulsion intravenously
150949|NCT03013413|Procedure|Shear Wave Elastography|Undergo ultrasound-based elastography imaging using the Aixplorer system
150950|NCT03013413|Procedure|Ultrasound Elasticity Imaging|Undergo ultrasound-based elastography imaging using the Aixplorer system
150951|NCT03013413|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo standard of care ultrasound-guided prostate biopsy
150952|NCT03013400|Drug|Ebselen|Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
150953|NCT03013400|Drug|Placebo oral capsule|Placebo is identical in appearance to the ebselen capsules
150954|NCT03013387|Radiation|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
150955|NCT03013387|Procedure|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
150956|NCT03013387|Drug|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
150957|NCT03013361|Drug|Bupivacaine|Post operative pain control
150958|NCT03013361|Drug|Ropivacaine|Post operative pain control
150959|NCT03013361|Other|Normal Saline|Acts as comparator
150960|NCT03013348|Device|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography [EEG] recordings) that are pathognomonic for PNES activity.
150961|NCT03013335|Drug|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).~Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
150962|NCT03013322|Drug|Physostigmine|
150963|NCT03013322|Drug|Isotonic Saline|
150964|NCT03013309|Behavioral|Family Check-Up 4 Health|A parent-training intervention to improve child health and manage obesity
150965|NCT03013309|Other|Treatment as usual|Treatment as usual
150966|NCT03013296|Other|GIP-A|GIP-A
150967|NCT03013296|Other|Placebo|Placebo
150968|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
150969|NCT03013296|Other|GIP-A + Exendin[9-39]|GIP-A + Exendin[9-39]
150970|NCT03013283|Other|self questionnaire|"Interface side effects and degree of satisfaction of the patients~Technician evaluation and device measures."
150971|NCT03013270|Other|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
150972|NCT03013270|Other|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).~(Aerobic (30min) + Resistance (30min) = 60 min)"
150973|NCT03013270|Other|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
150974|NCT03013270|Other|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics or treadmill (at the same intensity) for 30 min (Aerobic training = 60 min)
150975|NCT03013257|Device|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
150976|NCT03013244|Behavioral|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
150977|NCT03013231|Behavioral|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
150978|NCT03013218|Drug|ALX148|ALX148
150979|NCT03013218|Drug|Pembrolizumab|Keytruda
150980|NCT03013218|Drug|Trastuzumab|Herceptin
150981|NCT03013218|Drug|Rituximab|Rituxan
150982|NCT03013205|Procedure|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
150983|NCT03013205|Procedure|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
150984|NCT03013205|Procedure|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
150985|NCT03013205|Procedure|Physiotherapy|
151561|NCT03009032|Dietary Supplement|PMT25341|
150986|NCT03013192|Other|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
150987|NCT03013166|Other|Corticosteroid medication|Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
150988|NCT03013153|Procedure|Low ligation with apical lymph node dissection|Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
150989|NCT03013153|Procedure|High ligation|High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
150990|NCT03013140|Drug|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV<5%"
150991|NCT03013140|Procedure|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
150992|NCT03013127|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
150993|NCT03013114|Drug|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
150994|NCT03013101|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
150995|NCT03013088|Device|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
150996|NCT03013075|Procedure|Spinal anesthesia with Bupivacaine heavy and Morphine|Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
150997|NCT03013075|Drug|Bupivacaine heavy and Morphine|
150998|NCT03013075|Drug|General Anesthetics|
150999|NCT03013049|Procedure|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
151000|NCT03013049|Procedure|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
151001|NCT03013036|Device|Ultrasonography|
151002|NCT03013036|Drug|Sevoflurane|
151003|NCT03013036|Drug|intravenous midazolam|
151004|NCT03013036|Drug|Propofol|
151005|NCT03013036|Drug|fentanyl and rocuronium|
151006|NCT03013023|Behavioral|BS|NNS, FT, positional support, and oral sucrose feeding
151007|NCT03013023|Behavioral|Routine care|Routine NICU care
151008|NCT03013023|Behavioral|PITP|Parents will learn to regulate infant responses while implementing caregiving activities.
151009|NCT03013023|Behavioral|BS+PITP|Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
151010|NCT03013010|Drug|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
151011|NCT03013010|Radiation|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
151012|NCT03013010|Procedure|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
151013|NCT03013010|Drug|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
151014|NCT03012997|Other|Fraction of inspired oxygen 40%|
151015|NCT03012997|Other|Fraction of inspired oxygen 100%|
151083|NCT03012516|Behavioral|Ordinary PAP-treatment at the health care center|
151157|NCT03012048|Device|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
151016|NCT03012984|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
151017|NCT03012984|Drug|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml) diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
151018|NCT03012971|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
151019|NCT03012971|Drug|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
151020|NCT03012958|Other|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
151021|NCT03012945|Drug|Combined Epi-GA/PCEA|An epidural catheter was placed before the induction of general anesthesia. General anesthesia was induced and maintained as in the control group, with the addition of epidural anesthesia which was maintained with the use of 0.5%-0.75% ropivacaine during surgery. Patient-controlled epidural analgesia with 0.12% ropivacaine and 0.5 ug/ml sufentanil was provided after surgery.
151022|NCT03012945|Drug|GA/PCIA|General anesthesia was induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia was maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) were administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia with 0.5 mg/ml morphine was provided after surgery.
151023|NCT03012932|Behavioral|HPV self-sampling|All participants will receive HPV self-sampling intervention. HPV self-sampling is a cervical cancer screening that can be done in private, using a device that is similar to a tampon. This intervention tests for high-risk HPV, the primary cause of cervical cancer. Each participant will complete the intervention one time only.
151024|NCT03012919|Other|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
151025|NCT03012906|Other|the prevalence of ischemic events|
151026|NCT03012893|Device|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
151027|NCT03012893|Device|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
151028|NCT03012893|Procedure|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
151029|NCT03012880|Biological|Daratumumab|Given IV
151030|NCT03012880|Drug|Dexamethasone|Given PO
151031|NCT03012880|Drug|Ixazomib Citrate|Given PO
151032|NCT03012880|Other|Laboratory Biomarker Analysis|Correlative studies
151033|NCT03012880|Drug|Lenalidomide|Given PO
151034|NCT03012880|Other|Questionnaire Administration|Ancillary studies
151035|NCT03012867|Other|Diben, Fresenius Kabi|Patients receive Diben continously for 7 days
151036|NCT03012867|Other|Fresubin original fibre, Fresenius Kabi|Patients receive Fresubin original fibre continously for 7 days
151037|NCT03012854|Procedure|short-myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
151081|NCT03012529|Drug|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
151082|NCT03012516|Behavioral|PAP-treatment by physiotherapist|
247371|NCT02309177|Drug|Carboplatin|
151038|NCT03012854|Procedure|long-myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
151039|NCT03012854|Procedure|full-thickness myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
151040|NCT03012854|Procedure|circular myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.~Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
151041|NCT03012841|Device|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
151042|NCT03012828|Drug|Moxidectin|Moxidectin is a broad spectrum macrocyclic lactone endectocide
151043|NCT03012828|Other|Placebo|
151044|NCT03012815|Drug|Gabapentin|Gabapentin administered as a taper
151045|NCT03012815|Drug|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
151046|NCT03012815|Drug|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
151047|NCT03012802|Procedure|Colorectal Surgery|Postoperative Audit
151048|NCT03012789|Procedure|Surgery|Surgical excision
151049|NCT03012776|Device|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
151050|NCT03012776|Procedure|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
151051|NCT03012763|Drug|Paracetamol|Oral administration of 250 mg paracetamol
151052|NCT03012763|Drug|Sulfasalazine|Oral administration of 50 mg sulfasalazine
151053|NCT03012763|Drug|Fexofenadine|Oral administration of 120 mg fexofenadine
151054|NCT03012763|Drug|Valsartan|Oral administration of 40 mg valsartan
151055|NCT03012763|Device|non-caloric water|Oral administration of 240 ml non-caloric water
151056|NCT03012763|Device|caloric drink|Oral administration of 240 ml caloric drink
151057|NCT03012763|Device|grapefruit juice|Oral administration of 240 ml grapefruit juice
151058|NCT03012750|Drug|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
151059|NCT03012737|Device|Trilogy 100 ® (Philips Respironics)|Trilogy 100 ® (Philips Respironics) on MPV mode.
151060|NCT03012724|Device|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
151061|NCT03012724|Device|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
151062|NCT03012711|Other|Neuromuscular exercise training|
151063|NCT03012698|Device|Ocular Repetitive Magnetic Stimulation (RMS) treatment|"First stage: Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated.~Second stage: will be treated on both eyes, applying treatment to both eyes sequentially during the same visit."
151064|NCT03012672|Drug|Cladribine|Given IV
151065|NCT03012672|Drug|Cytarabine|Given IV
151066|NCT03012672|Biological|Granulocyte Colony-Stimulating Factor|Given SC
151067|NCT03012672|Drug|Mitoxantrone Hydrochloride|Given IV
151068|NCT03012672|Other|Quality-of-Life Assessment|Ancillary studies
151069|NCT03012672|Other|Questionnaire Administration|Ancillary studies
151070|NCT03012659|Behavioral|Contraceptive Counseling Training|"Intervention sites will receive:~In person training: All staff at an intervention health center will participate in a one-day counseling training.~On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.~Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
151071|NCT03012646|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
151072|NCT03012633|Device|Lysis timer|Lysis Timer compared with standard laboratory test to diagnose hyperfibrinolysis during liver transplantation.
151073|NCT03012620|Drug|Pembrolizumab|Treatment
151074|NCT03012607|Drug|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
151075|NCT03012594|Drug|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
151076|NCT03012581|Drug|Nivolumab|Treatment
151077|NCT03012568|Device|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
151078|NCT03012542|Dietary Supplement|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
151079|NCT03012542|Dietary Supplement|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
151080|NCT03012529|Drug|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
247522|NCT02308007|Drug|Metronidazole|
151084|NCT03012503|Drug|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
151085|NCT03012503|Drug|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
151086|NCT03012490|Other|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
151087|NCT03012490|Other|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
151088|NCT03012490|Other|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
151089|NCT03012477|Drug|Cisplatin|Cisplatin will be given on the first day of every cycle. Each cycle is 21 days long.
151090|NCT03012477|Drug|AZD1775|The first dose of AZD1775 will be administered in clinic on the first day of the second cycle. Subsequent doses will be taken approximately 12 hours apart for a total of five doses. Each cycle is 21 days long.
151091|NCT03012464|Other|Pathologic and functional assessment|Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
151092|NCT03012451|Behavioral|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
151093|NCT03012438|Device|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
151094|NCT03012425|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
151095|NCT03012425|Device|Acupuncture|
151096|NCT03012425|Behavioral|questionnaires|
151097|NCT03012425|Other|Diurnal Cortisol|saliva test
151098|NCT03012412|Behavioral|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
151099|NCT03012399|Behavioral|Hypnosedation|Undergo hypnosedation
151100|NCT03012399|Other|Questionnaire Administration|Ancillary studies
151101|NCT03012399|Behavioral|Verbal Support|Speak with min-body specialist
151102|NCT03012386|Drug|Sildenafil Citrate|phosphodiesterase 5 inhibitor
151103|NCT03012373|Procedure|Ear acupressure alone|The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
151104|NCT03012373|Procedure|Electroacupuncture plus ear acupressure|Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
151105|NCT03012360|Drug|ceftriaxone|2 g iv every 24h
151106|NCT03012360|Drug|ciprofloxacin|400 mg iv every 8h
151107|NCT03012360|Drug|imipenem|1 g iv every 8h
151108|NCT03012360|Drug|linezolid|600 mg iv every 12h
151109|NCT03012360|Drug|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
151110|NCT03012347|Drug|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
151111|NCT03012347|Drug|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
151112|NCT03012334|Drug|Lasmiditan|Dose is based on treatment sequence in 5-way crossover
151113|NCT03012334|Drug|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
151114|NCT03012334|Other|Placebo|Placebo comparator based on treatment sequence in 5-way crossover
151115|NCT03012321|Drug|Olaparib|
151116|NCT03012321|Drug|Abiraterone Acetate|
151117|NCT03012321|Drug|Prednisone|
151118|NCT03012282|Device|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
151119|NCT03012269|Behavioral|Working memory training|
151120|NCT03012256|Other|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
151212|NCT03011736|Procedure|Parathyroidectomy|Undergo parathyroidectomy
151121|NCT03012243|Procedure|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
151122|NCT03012243|Procedure|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
151123|NCT03012230|Other|Laboratory Biomarker Analysis|Correlative studies
151124|NCT03012230|Biological|Pembrolizumab|Given IV
151125|NCT03012230|Drug|Ruxolitinib Phosphate|Given PO
151126|NCT03012217|Other|Observational Study|
151127|NCT03012204|Device|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
151128|NCT03012204|Device|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
151129|NCT03012204|Device|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .~rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.~The four groups are the combinations of real or sham ①/②/③."
151130|NCT03012204|Device|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
151131|NCT03012191|Drug|Gentamicin Sulfate|Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
151132|NCT03012178|Procedure|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
151133|NCT03012165|Drug|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
151134|NCT03012165|Drug|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
151135|NCT03012165|Drug|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
151136|NCT03012152|Procedure|Standard conservative breast surgery|
151137|NCT03012152|Procedure|Oncoplastic breast surgery|
151138|NCT03012126|Behavioral|Healthy Weight Clinic|
151139|NCT03012126|Behavioral|Healthy Weight and Your Child|
151140|NCT03012113|Drug|Mirabegron|
151141|NCT03012113|Other|Short term mild cooling|
151142|NCT03012113|Drug|Placebo Oral Capsule|
151143|NCT03012100|Drug|Cyclophosphamide|Given PO
151144|NCT03012100|Other|Laboratory Biomarker Analysis|Correlative studies
151145|NCT03012100|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
151146|NCT03012100|Other|Placebo|Given ID
151147|NCT03012100|Biological|Sargramostim|Given ID
151148|NCT03012087|Behavioral|MyHealthyChoices|My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
151149|NCT03012087|Other|Health Risk Assessment|The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
151150|NCT03012074|Behavioral|Type 2 Diabetes Self-Management|Patients with Type 2 Diabetes
151151|NCT03012061|Drug|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
151152|NCT03012061|Drug|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
151153|NCT03012061|Drug|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
151154|NCT03012061|Drug|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
151155|NCT03012048|Device|Silver-impregnated ceramic tablet|"A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.~This intervention was removed from the study in July 2017 (approximately at 1 year of follow-up)."
151156|NCT03012048|Device|Silver-impregnated ceramic water filter|"Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.~This intervention was replaced with ceramic filters without silver in Dec 2017 (approximately at 1.5 years of follow-up)."
151158|NCT03012035|Other|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
151159|NCT03012035|Other|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
151160|NCT03012009|Device|full ablative CO2 laser|ablation to the level of de dermal papilla
151161|NCT03012009|Device|fractional ablative CO2 laser|180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
151162|NCT03012009|Drug|MAL|
151163|NCT03012009|Device|LED lamp|peak wavelength 630 nm, 37J/cm2
151164|NCT03012009|Drug|lidocaine hydrochloride 2% with epinephrine|
151165|NCT03011996|Drug|CLR 500mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
151166|NCT03011996|Drug|CJ-12420 100mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
151167|NCT03011996|Drug|CJ-12420 50mg|Cohort 2: bid for 7 days
151168|NCT03011996|Drug|AMX 1g|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
151169|NCT03011996|Drug|Pantoprazole 40mg|Cohort 2: bid for 7 days
151170|NCT03011983|Device|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
151171|NCT03011983|Device|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
151172|NCT03011983|Behavioral|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
151173|NCT03011970|Drug|Oxytocin|
151174|NCT03011970|Drug|Placebo|
151175|NCT03011944|Other|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
151176|NCT03011931|Drug|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
151177|NCT03011918|Other|Data Collection prior to first fall for all fallers|Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected
151178|NCT03011918|Other|Hgb value|Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected
151179|NCT03011918|Other|Vitamin D|Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..
151180|NCT03011918|Other|C-Reactive Protein|Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
151181|NCT03011905|Drug|Dexamethasone|4 ml DexaGalen 4 mg/ml
151182|NCT03011905|Drug|NaCl (Control)|4 ml NaCl 9 mg/ml
151183|NCT03011905|Drug|Paracetamol|Premedication and as needed after operation
151184|NCT03011905|Drug|EtoriCoxib|Premedication and first 2 postoperative days.
151185|NCT03011905|Drug|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
151186|NCT03011905|Drug|Ropivacaine|In brachial plexus block
151187|NCT03011892|Drug|Ruxolitinib cream|Ruxolitinib 1.5% cream
151188|NCT03011892|Drug|Ruxolitinib cream|Ruxolitinib 0.5% cream
151189|NCT03011892|Drug|Ruxolitinib cream|Ruxolitinib 0.15% cream.
151190|NCT03011892|Drug|Triamcinolone 0.1% cream|Triamcinolone 0.1% cream BID
151191|NCT03011892|Drug|Vehicle cream|
151192|NCT03011879|Other|clinical pathway|
151193|NCT03011866|Drug|Wound topically irrigated with 500mg TXA|
151194|NCT03011866|Drug|1mg/kg/hr TXA intravenous infusion till the last suture|
151195|NCT03011840|Other|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
151196|NCT03011827|Other|Fibrinogen and/or platelets administration|Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
151197|NCT03011814|Biological|Durvalumab|Given IV
151198|NCT03011814|Other|Laboratory Biomarker Analysis|Correlative studies
151199|NCT03011814|Drug|Lenalidomide|Given PO
151200|NCT03011801|Behavioral|Interpersonal Therapy|reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
151201|NCT03011801|Behavioral|Enhanced usual care|Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
151202|NCT03011788|Drug|Golytely Oral Solution|Bowel purge prior to,colonoscopy
151203|NCT03011775|Drug|Pioglitazone 15 mg Tablet|1 tablet per day in the morning for 6 months
151204|NCT03011775|Drug|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
151205|NCT03011775|Drug|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
151206|NCT03011775|Drug|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
151207|NCT03011775|Drug|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
151208|NCT03011775|Drug|ramipril 5 MG|1 tablet per a day
151209|NCT03011762|Device|Computer controlled mandibular positioner|Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
151210|NCT03011749|Other|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
151211|NCT03011736|Other|Laboratory Biomarker Analysis|Correlative studies
151213|NCT03011723|Behavioral|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.~The music therapy consists of one or more of the following activities:~Singing~Listening to live music~Listening to recorded music~Dancing~Conversations about memories/reminiscence~Exercising to music~Breathing exercises and relaxing exercises~The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
151214|NCT03011710|Device|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
151215|NCT03011710|Device|Marlboro Gold (Conventional cigarette)|Conventional cigarette
151216|NCT03011710|Device|Cigarette tip|Placebo device
151217|NCT03011684|Drug|Tamoxifen|For ER Positive Randomization
151218|NCT03011684|Drug|Letrozole|For ER Positive Randomization
151219|NCT03011671|Drug|Acetazolamide|ACZ will be given at an initial dose of 250 mg twice a day (BID) and then escalated to 500 mg BID after 1 week. ACZ will be given on days 1-21 of each cycle.
151220|NCT03011671|Drug|Temozolomide|For cycle 1 of the maintenance phase, TMZ will administered at 150 mg/m2 on days 1- 5 followed by 23 days with no drug. For cycles 2- 6, TMZ can be increased to 200 mg/m2 at the discretion of the treating investigator.
151221|NCT03011658|Procedure|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
151222|NCT03011645|Drug|Ziprasidone|Given by mouth, single dose of 60 mg.
151223|NCT03011645|Drug|Lorcaserin|Given by mouth, single dose of 20 mg.
151224|NCT03011645|Drug|Placebo Oral Tablet|Given by mouth, single dose.
151225|NCT03011632|Drug|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
151226|NCT03011632|Drug|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
151227|NCT03011619|Behavioral|Usual Standard of Care|medication management, group therapy, and individual therapy.
151228|NCT03011619|Behavioral|Cognitive Behavioral Therapy Condition (CBT)|CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
151229|NCT03011606|Procedure|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
151230|NCT03011593|Other|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
151231|NCT03011580|Dietary Supplement|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
151232|NCT03011580|Dietary Supplement|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
151233|NCT03011567|Drug|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
151234|NCT03011567|Drug|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
151235|NCT03011554|Device|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
151236|NCT03011541|Procedure|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
151237|NCT03011541|Procedure|Arm 2|"Procedure/Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IVIT (Intravitreal)~Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)"
151238|NCT03011541|Procedure|Arm 3|"Procedure/Surgery: RB (Retrobulbar)~Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: ST (Subtenon)~Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IV (Intravenous)~Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)~Procedure/Surgery: IO (Intraocular)~Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells."
151239|NCT03011528|Drug|VDC-IE x2|"Week 1, 5, 9 and week 13:~Vincristine, IV, D1, 1.5mg/m²~Doxorubicine, IV, D1-D2, 37.5mg/m²~Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, 7, 11 and week 15:~Ifosfamide, IV, D15 to D19, 1.8g/m²/d~Etoposide, IV, D15 to D19, 100mg/m²/d"
151240|NCT03011528|Drug|VDC-IE|"Week 1 and week 5:~Vincristine, IV, D1, 1.5mg/m²~Doxorubicine, IV, D1-D2, 37.5mg/m²~Cyclophosphamide, IV, D1, 1.2g/m²~Week 3, and week 7:~Ifosfamide, IV, D15 to D19, 1.8g/m²/d~Etoposide, IV, D15 to D19, 100mg/m²/d"
151241|NCT03011528|Drug|TEMIRI|"Week 9, 12, 15 and week 18:~Temozolomide, PO, D1 to D5, 150mg/m²/d~Irinotecan, IV, D1 to D5, 50mg/m²/d"
151242|NCT03011528|Drug|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:~Busulfan, IV, D-5 to D-2, dosa according to the weight~Melphalan, IV, D-1, 140 mg/m²~Peripheral Blood Stem Cell infusion:~- PBSC infusion, D0, at least 3.10^6 CD34/kg"
151243|NCT03011528|Drug|Maintenance|"1st year : VCC~Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)~Cyclophosphamide, PO, 25mg/m² continuously~Celecoxib, PO, according to the weight, twice a day, continuously, (except during radiation therapy)~< 20kg: 100 mg bid~20-50kg: 200 mg bid~> 50kg: 400 mg bid"
151244|NCT03011528|Procedure|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
151562|NCT03009032|Dietary Supplement|Placebo|Lactose
151563|NCT03009019|Drug|DFN-15 Active|
151245|NCT03011528|Radiation|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
151246|NCT03011502|Other|Biological samples collection of blood and feces|
151247|NCT03011489|Device|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
151248|NCT03011476|Drug|Donepezil|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
151249|NCT03011476|Drug|Placebos|"Start with 5 mg/day for 4 weeks~Increased to 10 mg/day for 8 weeks"
151250|NCT03011463|Drug|intravenous infusion of 2 mg trospium chloride|intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
151251|NCT03011463|Drug|oral administration of 30 mg trospium chloride|oral administration of 30 mg trospium chloride with 240 ml tap water
151252|NCT03011463|Drug|oral administration of 300 mg ranitidine|oral administration of 300 mg ranitidine with 240 ml tap water
151253|NCT03011463|Drug|oral administration of 500 mg clarithromycin|oral administration of 500 mg clarithromycin with 240 ml tap water
151254|NCT03011450|Drug|K-877|
151255|NCT03011450|Drug|Fenofibrate|
151256|NCT03011450|Drug|Placebo (for K-877)|
151257|NCT03011437|Other|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
151258|NCT03011424|Device|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
151259|NCT03011398|Procedure|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
151260|NCT03011385|Behavioral|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.~The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
151261|NCT03011385|Behavioral|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.~The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
151262|NCT03011385|Behavioral|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
151263|NCT03011385|Behavioral|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
151264|NCT03011372|Drug|Pemigatinib|"Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.~Participants will receive either the intermittent dose (as written) or continuous dosing."
151265|NCT03011359|Other|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.3 ml by pressing bolus button (The interval: ~ 6 hr: 1.5 - 3.5 ml, 6-24 hr: 1 - 3 ml, 24 hr ~ : 0.5 - 2.5 ml). Conversely, if the bolus button is not used for 90 minutes, the administered amount of drug per hour is setted to be reduced by 0.1 ml, and the maximum (or minimum) allowable flow rate is 3.5 ml (or 0.5 ml).
151266|NCT03011359|Other|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
151267|NCT03011346|Device|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
151268|NCT03011346|Device|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
151269|NCT03011333|Drug|HTX-011|
151270|NCT03011333|Drug|Bupivacaine HCl without epinephrine|
151271|NCT03011333|Drug|Saline Placebo|
151272|NCT03011320|Drug|EC1456|intravenous (IV) bolus dose
151273|NCT03011320|Drug|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
151274|NCT03011307|Drug|Oxytocin|spinal injection of oxytocin
151275|NCT03011307|Drug|Placebos|spinal injection of placebo
151276|NCT03011294|Device|Continuous positive airway pressure (CPAP)|
151277|NCT03011294|Device|Nasal strip|
151278|NCT03011281|Drug|Tofacitinib|
151279|NCT03011268|Other|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
151280|NCT03011268|Other|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
151281|NCT03011255|Biological|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
151282|NCT03011229|Device|Pro Core Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
151400|NCT03010228|Biological|VLA15 without Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
151283|NCT03011229|Device|medtronic Sharkcore Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
151284|NCT03011216|Behavioral|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
151285|NCT03011216|Behavioral|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
151286|NCT03011203|Other|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
151287|NCT03011190|Behavioral|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
151288|NCT03011177|Drug|Teneligliptin|teneligliptin 20mg qd
151289|NCT03011177|Drug|Linagliptin|linagliptin 5mg qd
151290|NCT03011164|Procedure|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
151291|NCT03011138|Procedure|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
151292|NCT03011125|Drug|dexlansoprazole injection|
151293|NCT03011125|Other|placebo|
151294|NCT03011112|Procedure|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
151295|NCT03011099|Device|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
151296|NCT03011099|Other|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
151297|NCT03011060|Procedure|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
151298|NCT03011060|Drug|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
151299|NCT03011047|Procedure|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
151300|NCT03011047|Procedure|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
151301|NCT03011034|Drug|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
151302|NCT03011034|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
151303|NCT03011021|Drug|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
151304|NCT03011021|Biological|UCB-Treg|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml normal saline
151305|NCT03011021|Drug|Insulin|Receive insulin following clinician's instruction.
151306|NCT03011008|Drug|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
151307|NCT03011008|Drug|Insulin|Receive insulin following clinician's instruction.
151308|NCT03010995|Drug|Prazosin|Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
151309|NCT03010982|Drug|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
151310|NCT03010969|Procedure|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
151311|NCT03010943|Device|Virtual reality headset|Feasibility and tolerance
151312|NCT03010930|Other|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
151313|NCT03010930|Other|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
151314|NCT03010917|Drug|Fish Oil with ethanol and placebo ethanol infusions|Fish Oil with ethanol and placebo ethanol infusions
151315|NCT03010917|Drug|Placebo with ethanol and placebo ethanol infusions|Placebo with ethanol and placebo ethanol infusions
151316|NCT03010904|Other|Dietary intervention|
151317|NCT03010891|Behavioral|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC > 45 minutes
151318|NCT03010891|Behavioral|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC < 20 minutes
151319|NCT03010878|Other|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.~Yoga was delivered in sitting, standing, and floor postures"
151320|NCT03010878|Other|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
151564|NCT03009019|Other|DFN-15 Placebo|
151321|NCT03010865|Drug|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
151322|NCT03010865|Drug|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
151323|NCT03010852|Behavioral|Focused incentive spirometer education and monitoring|
151324|NCT03010839|Procedure|Modified Remote Ischemic Preconditioning|mRIPC will be induced at 24 h, 12 h and 1 h before surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
151325|NCT03010839|Procedure|Control|Control group witnout remote ischemic preconditioning
151326|NCT03010813|Procedure|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
151327|NCT03010800|Device|With Yoni.Fit|Abbreviated Pad Test with Yoni.Fit first, then without Yoni.Fit.
151328|NCT03010800|Device|Without Yoni.Fit|Abbreviated Pad Test without Yoni.Fit, then with Yoni.Fit.
151329|NCT03010787|Drug|V565|single ascending dose of V565
151330|NCT03010787|Drug|V565|Multiple dose
151331|NCT03010787|Drug|Placebo|Single and multiple dose
151332|NCT03010787|Drug|V565|Open-label single dose
151333|NCT03010787|Drug|V565|Open-label single ascending dose
151334|NCT03010774|Behavioral|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
151335|NCT03010774|Behavioral|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
151336|NCT03010761|Drug|escitalopram|antidepressant use for the betel-quid abstinence
151337|NCT03010761|Drug|Moclobemide|antidepressant use for the betel-quid abstinence
151338|NCT03010761|Drug|Placebo - Cap|Placebo - Cap
151339|NCT03010748|Device|Scheimpflug tomography system (Pentacam) measurement|The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
151340|NCT03010735|Dietary Supplement|Bifidobacterium animalis A6|Daily take 4.0E+10 CFU of Bifidobacterium animalis A6, 6 months
151341|NCT03010735|Dietary Supplement|Placebo|
151342|NCT03010722|Drug|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
151343|NCT03010696|Other|No interventions, questionnaire, collect specimen|
151344|NCT03010683|Drug|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
151345|NCT03010683|Drug|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
151346|NCT03010670|Drug|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
151347|NCT03010670|Other|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
151348|NCT03010657|Other|Experimental intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
151349|NCT03010644|Other|n/a - observational study|n/a - observational study
151350|NCT03010631|Drug|Lubiprostone Capsule|48 mcg of capsule administered once orally under fasted condition
151351|NCT03010631|Drug|Lubiprostone Sprinkle Formulation|48 mcg of sprinkle formulation administered once orally under fasted condition
151352|NCT03010631|Drug|Lubiprostone Sprinkle Formulation|48 mcg of sprinkle formulation administered once orally under fasted condition
151353|NCT03010631|Drug|Lubiprostone Sprinkle Formulation|48 mcg of sprinkle formulation administered once orally under fed condition
151354|NCT03010618|Other|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
151355|NCT03010605|Device|Measuring Every Day Device|
151356|NCT03010605|Other|Physical Therapy|
151357|NCT03010579|Drug|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
151358|NCT03010579|Drug|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
151359|NCT03010553|Procedure|Detection and resection of sentinel lymph node|
151360|NCT03010540|Drug|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
151361|NCT03010540|Drug|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
151362|NCT03010527|Drug|Bimekizumab|"Subjects with a PASI90 response at Week 12 in PS0010 entering PS0011 will receive the same treatment dose.~Subjects who do not achieve PASI90 response at Week 12 in PS0010 will be assigned to a higher treatment dose.~Subjects that were initially randomized to bimekizumab dosage regimen 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3."
151363|NCT03010527|Other|Placebo|"Subjects with a PASI90 response at Week 12 in PS0010 entering PS0011 will receive placebo.~Subjects who do not achieve PASI90 response at Week 12 in PS0010 will be assigned to bimekizumab dosage regimen 1."
151364|NCT03010501|Other|Food Energy Density|Food Energy density manipulated
151365|NCT03010488|Behavioral|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
151366|NCT03010488|Behavioral|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
151367|NCT03010488|Device|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
151368|NCT03010475|Drug|Furosemide|Oral administration A total of three single doses.
151369|NCT03010475|Drug|Rosuvastatin|Oral administration. A total of three single doses.
151370|NCT03010475|Drug|SNAC|Oral administration. A total of five single doses.
151371|NCT03010475|Drug|Semaglutide|Oral administration. Once daily.
151372|NCT03010462|Device|Nexstim NBS guided active rTMS|Nexstim NBS guided active rTMS + standardized task-oriented therapy
151373|NCT03010462|Device|Nexstim NBS guided sham rTMS|Nexstim NBS guided sham rTMS + standardized task-oriented therapy
151374|NCT03010449|Device|Intra-bronchial valve and blood|Intra-bronchial valve implantation in combination with autologous blood instillation
151375|NCT03010436|Drug|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
151376|NCT03010423|Drug|Nicorandil|Subjects will be administered nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks
151377|NCT03010384|Other|Rehabilitation program|
151378|NCT03010371|Behavioral|Positive Psychotherapy|Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).
151379|NCT03010371|Behavioral|Positive Online Psychotherapy|The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.
151380|NCT03010371|Behavioral|Online Support Group|The Online Support Group (OSG) consists of a virtual patient community. Individuals assigned to this condition have web access to a private online forum in which they interact asynchronously (supervised and dependent by the Catalan Health Department). The forums have eight pre-defined topics that coincide with those of the previous experimental conditions. The forum is moderated and energized by the webmaster with the aim of increasing participation, solving basic technical problems and ensuring minimum rules of operation and respect. Participants can interact at any time of the day and their participations are registered and analyzed at the end of the group.
151381|NCT03010358|Drug|Entospletinib|Given PO
151382|NCT03010358|Other|Laboratory Biomarker Analysis|Correlative studies
151383|NCT03010358|Biological|Obinutuzumab|Given IV
151384|NCT03010358|Other|Pharmacological Study|Correlative studies
151385|NCT03010345|Device|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
151386|NCT03010345|Other|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
151387|NCT03010332|Biological|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
151388|NCT03010319|Device|PriMatrix Dermal Repair Scaffold|Application of PriMatrix to ulcer
151389|NCT03010319|Device|Secondary Dressings|Dressings to ensure moist wound environment
151390|NCT03010319|Device|Offloading device|Offloading device to decrease pressure to wound area
151391|NCT03010306|Other|CASITA|
151392|NCT03010280|Dietary Supplement|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
151393|NCT03010280|Dietary Supplement|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
151394|NCT03010267|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
151395|NCT03010267|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
151396|NCT03010267|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
151397|NCT03010241|Drug|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
151398|NCT03010241|Drug|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
151399|NCT03010228|Biological|VLA15 with Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
151507|NCT03009448|Other|Interview|Each subject will be interviewed using a semi constructed interview.
151401|NCT03010215|Other|Distal Metatarsal Minimally invasive Osteotomy (DMMO)|"Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.~In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer."
151402|NCT03010202|Drug|Dexamethasone|Comparing the effect of Rituximab infusion With or without Dexamethasone
151403|NCT03010202|Drug|Rituximab|Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
151404|NCT03010189|Device|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
151405|NCT03010189|Device|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
151406|NCT03010189|Device|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
151407|NCT03010176|Drug|MK-1454|IT injection
151408|NCT03010176|Biological|Pembrolizumab|IV infusion
151409|NCT03010163|Other|Health Fair|Testing includes weight, height, waist and blood pressure testing
151410|NCT03010163|Other|Pedometer|The Fitbit One/Alta/Inspire wireless tracking pedometers measures steps taken, calories burned, distance traveled and sleep pattern. The Fitbit Alta/Inspire also sends reminders to move, which are notifications that remind the wearer to walk at least 250 steps each hour. If the wearer has not walked 250 steps within the hour, the device will vibrate and send an on-screen reminder 10 minutes before the hour. The reminders to move will be turned off during baseline and will be turned on at randomization for all participants.
151411|NCT03010163|Other|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
151412|NCT03010163|Other|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
151413|NCT03010150|Procedure|Biospecimen Collection|Provide blood samples
151414|NCT03010150|Other|Questionnaire Administration|Ancillary studies
151415|NCT03010137|Procedure|Incisional Negative Pressure Wound Therapy|
151416|NCT03010137|Procedure|Standard Closure with Skin Glue|
151417|NCT03010137|Device|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
151418|NCT03010137|Device|Dermabond|Final wound closure with skin glue.
151419|NCT03010124|Procedure|Blood sample|
151420|NCT03010111|Other|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
151421|NCT03010098|Device|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
151422|NCT03010098|Device|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
151423|NCT03010085|Procedure|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
151424|NCT03010085|Procedure|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
151425|NCT03010072|Drug|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
151426|NCT03010072|Drug|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
151427|NCT03010059|Drug|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
151428|NCT03010059|Drug|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
151429|NCT03010046|Drug|ANX005|Single ascending dose intravenous infusion
151430|NCT03010046|Drug|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
151431|NCT03010046|Drug|Placebos|0.9% saline intravenous infusion
151432|NCT03010033|Other|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).~pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
151433|NCT03010020|Behavioral|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
151434|NCT03010020|Behavioral|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
151435|NCT03009994|Procedure|Repair of uterine incision|
151436|NCT03009994|Procedure|Exteriorization of the uterus|
151437|NCT03009994|Procedure|Non exteriorization of the uterus|
151438|NCT03009981|Drug|Apalutamide|Take apalutamide 240 mg (four 60 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
151508|NCT03009435|Other|prophylactic manual rotation|
151509|NCT03009422|Drug|Local application pentostam|
151510|NCT03009422|Drug|intra-lisional pentostam|
151511|NCT03009422|Device|fractional CO2 laser|
151601|NCT03008733|Other|Electro myography surface nerves|Electro myography surface nerves
151602|NCT03008720|Device|Transcranial direct current stimulation (tDCS)|
151439|NCT03009981|Drug|LHRH Analogue|"Patients will receive a LHRH analogue therapy of either Degarelix OR Leuprolide with bicalutamide.~Degarelix:~Patients will receive subcutaneous injections every 28 days (+/- 3 days). Patients will receive a loading dose of 240 mg (two 120 mg injections) on C1D1, followed by maintenance dose of 80 mg on Day 1 of subsequent cycles.~Leuprolide:~Patients treated with leuprolide will receive a 7.5 mg IM injection on C1D1. Patients in arm A ONLY will take this in combination with bicalutamide 50 mg orally once daily starting on C1D1 and continuing for 28 days through completion of cycle 1. Starting on C2D1, patients will continue on one of the following two treatments at investigator discretion:~Leuprolide 7.5 mg IM injection on Day 1 of subsequent cycles without concurrent bicalutamide.~OR:~Leuprolide 22.5 mg IM injection at the following visits without concurrent bicalutamide: C2D1, C5D1, C8D1, and C11D1."
151440|NCT03009981|Drug|Abiraterone Acetate|Take abiraterone acetate 1000 mg (four 250 mg tablets) orally once daily, starting on C1D1 and continuing throughout 52-week treatment period.
151441|NCT03009981|Drug|Prednisone|Take two prednisone 5 mg tablets daily, starting on C1D1 and continuing throughout the 52-week treatment period. Following completion of treatment period, patients will taper off prednisone per institutional guidelines. Suggested tapering plan: prednisone 5 mg daily for 7 days, then 2.5 mg daily for 7 days before discontinuing.
151442|NCT03009968|Other|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
151443|NCT03009929|Other|Observational study|No intervention, observational only
151444|NCT03009916|Drug|"cholestagel® (Colesevelam)"|3750mg
151445|NCT03009916|Drug|Placebos|3750mg
151446|NCT03009890|Procedure|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
151447|NCT03009890|Procedure|Cast treatment|Hospitals may use their preferred protocol
151448|NCT03009877|Device|Optiflow F&P 850™ System|"Optiflow™ (Fisher & Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.~This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
151449|NCT03009877|Device|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
151450|NCT03009877|Drug|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
151451|NCT03009877|Drug|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
151452|NCT03009877|Drug|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
151453|NCT03009877|Drug|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
151454|NCT03009877|Device|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
151455|NCT03009864|Drug|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
151456|NCT03009864|Drug|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
151457|NCT03009851|Behavioral|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
151458|NCT03009838|Drug|Letrozole|oral tablets 2.5 mg
151459|NCT03009838|Procedure|ovarian drilling|laparoscopic electrocauterization
151460|NCT03009812|Procedure|Longitudinal uterine incision|
151461|NCT03009812|Procedure|Transverse uterine incision|
151462|NCT03009799|Drug|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
151463|NCT03009799|Drug|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
151464|NCT03009786|Other|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
151465|NCT03009773|Other|rehabilitation multitasking walking.|rehabilitation multitasking walking.
151466|NCT03009773|Other|Traditional walking rehabilitation|Traditional walking rehabilitation
151467|NCT03009760|Drug|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
151468|NCT03009760|Drug|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
151469|NCT03009760|Drug|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
151470|NCT03009760|Drug|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
151471|NCT03009734|Drug|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
151472|NCT03009721|Drug|Other: Not applicable-observational study|
151473|NCT03009708|Other|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
151474|NCT03009695|Device|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
151556|NCT03009058|Biological|cetuximab|Standard of Care immunotherapy
151557|NCT03009058|Biological|Anti-PD1|Standard of Care immunotherapy
151558|NCT03009058|Biological|Ipilimumab|Standard of Care immunotherapy
151475|NCT03009695|Device|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
151476|NCT03009695|Device|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
151477|NCT03009682|Drug|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.~Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
151478|NCT03009656|Other|No study specific interventions|
151479|NCT03009643|Drug|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
151480|NCT03009643|Device|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
151481|NCT03009643|Device|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
151482|NCT03009630|Procedure|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
151483|NCT03009630|Device|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
151484|NCT03009617|Behavioral|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
151485|NCT03009604|Drug|Simethicone|Simethicone 40mg oral tablets
151486|NCT03009604|Drug|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram & disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
151487|NCT03009591|Other|Experimental group|"Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.~Transverse sliding of the flexor muscles of the wrist and fingers.~Transverse sliding for the biceps brachii muscle.~Longitudinal surface sliding over the superficial fascia in the posterior arm region.~Transverse sliding over the brachial triceps tendon.~Transverse sliding for the pectoralis major muscle.~Transverse sliding for the posterior axillary region pectoralis major muscle.~Induction of the posterior axillary fold.~Induction (crossed hands over the brachial region and forearm).~Maneuver of transverse planes for the cervicothoracic region.~Upper limb telescopic maneuver."
151488|NCT03009578|Drug|Iron Sucrose Injection|iron Intramuscular injections
151489|NCT03009578|Drug|Ferrous Bisglycinate|oral iron tablets
151490|NCT03009565|Other|coronary artery disease|
151491|NCT03009552|Procedure|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
151492|NCT03009539|Behavioral|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
151493|NCT03009526|Drug|Sulfadoxine-pyrimethamine|
151494|NCT03009526|Drug|dihydroartemisinin-piperaquine|
151495|NCT03009513|Drug|Teneligliptin+Glimepiride|
151496|NCT03009500|Drug|Bupivacaine|
151497|NCT03009500|Drug|Depo-Medrol Injectable Product|
151498|NCT03009500|Other|Saline (Sodium Chloride) solution|
151499|NCT03009500|Drug|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
151500|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
151501|NCT03009487|Drug|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
151502|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
151503|NCT03009474|Drug|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
151504|NCT03009474|Drug|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
151505|NCT03009461|Procedure|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
151506|NCT03009461|Drug|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
249619|NCT02292719|Drug|Sofosbuvir|Tablet
151512|NCT03009409|Drug|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely."
151513|NCT03009409|Other|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
151514|NCT03009396|Drug|RHB-104; a fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine|For patients who are not in remission after 26 weeks in the RHB-104-01 study
151515|NCT03009383|Device|A bedside portable endoscopy|
151516|NCT03009344|Drug|tazemetostat|tazemetostat tablets
151517|NCT03009331|Procedure|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
151518|NCT03009331|Procedure|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
151519|NCT03009318|Other|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS and MET PET scan before surgery. The lesion will be considered as a glioma when either MRS or MET PET results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
151520|NCT03009305|Other|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
151521|NCT03009305|Device|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
151522|NCT03009305|Device|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
151523|NCT03009292|Drug|lenvatinib|once daily continuous dosing
151524|NCT03009266|Drug|Sonazoid|Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
151525|NCT03009253|Other|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
151526|NCT03009240|Drug|Decitabine|Given IV
151527|NCT03009240|Other|Laboratory Biomarker Analysis|Correlative studies
151528|NCT03009240|Drug|Pevonedistat|Given IV
151529|NCT03009240|Other|Pharmacological Study|Correlative studies
151530|NCT03009227|Procedure|Colonic resection with D2 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection
151531|NCT03009227|Procedure|Colonic resection with D3 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
151532|NCT03009214|Drug|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
151533|NCT03009201|Drug|Doxorubicin|Given IV
151534|NCT03009201|Drug|Ribociclib|Given PO
151535|NCT03009175|Device|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
151536|NCT03009162|Drug|Lasmiditan|200 mg, single oral tablet
151537|NCT03009149|Other|Aerobic exercise|Aerobic exercise will perform 3 days per week
151538|NCT03009136|Drug|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
151539|NCT03009136|Drug|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
151540|NCT03009123|Other|Erectile dysfunction|Patients with ED are considered belonging to the exposure group.
151541|NCT03009110|Device|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
151542|NCT03009110|Device|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
151543|NCT03009097|Biological|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
151544|NCT03009097|Drug|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
151545|NCT03009084|Behavioral|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
151546|NCT03009071|Procedure|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
151547|NCT03009071|Device|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
151548|NCT03009058|Biological|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
151549|NCT03009058|Drug|Gemcitabine|Standard of Care chemotherapy
151550|NCT03009058|Drug|Nabpaclitaxel|Standard of Care chemotherapy
151551|NCT03009058|Drug|Capecitabine|Standard of Care chemotherapy
151552|NCT03009058|Drug|Folinic Acid|Standard of Care chemotherapy
151553|NCT03009058|Drug|Fluorouracil|Standard of Care chemotherapy
151554|NCT03009058|Drug|Irinotecan|Standard of Care chemotherapy
151555|NCT03009058|Drug|Oxaliplatin|Standard of Care chemotherapy
151565|NCT03009006|Drug|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
151566|NCT03009006|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
151567|NCT03008993|Behavioral|HQIS implementation|
151568|NCT03008980|Other|Diagnostic Test|
151569|NCT03008967|Other|Arthroplasty and postoperative rehabilitation.|Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.
151570|NCT03008954|Device|GSP3|Each capsule of GSP3 (previously Attiva) contains 700 mg of a mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
151571|NCT03008954|Dietary Supplement|Avicel (modified Cellulose)|Each capsule of Avicel contains approximately 350 mg of microcrystalline cellulose
151572|NCT03008941|Biological|FMT|Capsules with fecal microbiota from healthy donors
151573|NCT03008941|Other|Placebo|Placebo capsules
151574|NCT03008928|Behavioral|Alcooquizz|
151575|NCT03008915|Drug|Aspirin|81mg aspirin taken once per day in the morning
151576|NCT03008915|Drug|Placebo|placebo taken once per day in the morning
151577|NCT03008902|Procedure|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
151578|NCT03008889|Drug|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
151579|NCT03008889|Drug|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.~In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.~If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
151580|NCT03008876|Drug|Acetaminophen|infants receive acetaminophen for treatment of their PDA
151581|NCT03008876|Drug|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
151582|NCT03008863|Other|Education|
151583|NCT03008850|Drug|MgSo4|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
151584|NCT03008850|Drug|Placebo|"Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
151585|NCT03008837|Device|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
151586|NCT03008837|Other|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
151587|NCT03008811|Procedure|Pulmonary vein isolation with cryoballoon catheter.|Device: Arctic Front Advance™ cardiac cryoablation catheter system.
151588|NCT03008811|Procedure|Pulmonary vein isolation with radiofrequency ablation.|Device: TactiCath™ Quartz irrigated ablation catheter (St. Jude Medical) with aid of 3-D mapping system (EnSite Precision, St. Jude Medical).
151589|NCT03008798|Drug|Herbal Medicine C-117|C117 formula including 2 herbals and 2 insects
151590|NCT03008798|Drug|The Placebo of Herbal Medicine C-117|
151591|NCT03008785|Other|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
151592|NCT03008785|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
151593|NCT03008785|Other|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
151594|NCT03008759|Other|Dentifrice 100% Nano-F|Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
151595|NCT03008759|Other|Dentifrice 50% Nano-F|Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
151596|NCT03008759|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
151597|NCT03008746|Other|water used for oral wash|
151598|NCT03008746|Other|sputum|
151599|NCT03008746|Other|oral wash|
151600|NCT03008733|Other|Ultrasound UHF peripheral nerves|Ultrasound UHF peripheral nerves
249707|NCT02292082|Drug|Dexamethasone|
151603|NCT03008720|Device|Functional electrical stimulation (FES)|
151604|NCT03008720|Device|Sham stimulation|
151605|NCT03008707|Procedure|Laparoscopic Peritoneal Lavage|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites
151606|NCT03008694|Device|PET/CT|pet/ct is used as radiotherapy simulation
151607|NCT03008681|Device|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
151608|NCT03008668|Other|acupuncture|a stimulation of the body or auricular points
151609|NCT03008655|Procedure|intradermal tranexamic acid|intradermal tranexamic acid injection
151610|NCT03008655|Device|Nd-YAG|six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
151611|NCT03008642|Other|CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
151612|NCT03008629|Device|Podofix nail brace|Podofix nail brace
151613|NCT03008629|Device|Combiped nail brace|Combiped nail brace
151614|NCT03008629|Device|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
151615|NCT03008616|Biological|AMAG-423 (digoxin immune fab)|AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
151616|NCT03008616|Other|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
151617|NCT03008603|Device|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
151618|NCT03008590|Drug|Naltrexone|One 4.5 mg capsule each evening
151619|NCT03008590|Drug|Placebo|One capsule each evening
151620|NCT03008577|Other|Change in ambient operating room temperature|
151621|NCT03008564|Other|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:~Age~Gender~Weight~Height~BMI~Distance of ASIS to base of patella~Distance of Point A to base of patella~Distance of Point B to base of patella~Distance of apex of femoral triangle to base of patella"
151622|NCT03008551|Drug|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
151623|NCT03008551|Drug|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
151624|NCT03008538|Other|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
151625|NCT03008538|Other|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
151626|NCT03008525|Biological|subcutaneous and visceral adipose tissue biopsies|
151627|NCT03008525|Biological|blood samples analysis|
151628|NCT03008512|Drug|Genexol-PM|
151629|NCT03008499|Biological|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
151630|NCT03008486|Device|Real soft splint (6 cm)|
151631|NCT03008486|Device|Placebo soft splint (1 cm)|
151632|NCT03008473|Device|video laryngoscope and chest CT iminge|
151633|NCT03008473|Device|Conventional intubation of uniblocker|
151634|NCT03008460|Drug|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
151635|NCT03008460|Drug|Klean-Prep®|Oral solution taken the evening before the colonoscopy
151636|NCT03008447|Drug|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
151637|NCT03008447|Drug|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
151638|NCT03008447|Drug|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
151639|NCT03008447|Drug|PBO|Single dose of placebo administered within 5 minutes before bedtime.
151640|NCT03008434|Other|Assigned Interventions|Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
151641|NCT03008421|Dietary Supplement|Astarte® (HSO Health Care GmbH, Vienna, Austria)|oral intake of Astarte® (HSO Health Care GmbH, Vienna, Austria) as described
151642|NCT03008421|Other|Placebo|Identical-looking oral potato-maltodextrin-based placebo
151643|NCT03008408|Drug|Ribociclib|"Phase I Safety Lead-In: Ribociclib 250 mg by mouth daily for 28 days.~Phase II: Ribociclib 250 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle."
151644|NCT03008408|Drug|Everolimus|"Phase I Safety Lead-In: Everolimus 2.5 mg by mouth daily for 28 days.~Phase II: Everolimus 2.5 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle."
151645|NCT03008408|Drug|Letrozole|"Phase I Safety Lead-In: Letrozole 2.5 mg by mouth daily for 28 days.~Phase II: Letrozole 2.5 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle."
151646|NCT03008395|Behavioral|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
151647|NCT03008395|Other|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
151648|NCT03008382|Drug|Metoprolol Tartrate Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
151649|NCT03008382|Drug|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
151650|NCT03008369|Other|Laboratory Biomarker Analysis|Correlative studies
151651|NCT03008369|Drug|Lenvatinib|Given PO
151652|NCT03008369|Other|Quality-of-Life Assessment|Ancillary studies
151653|NCT03008356|Dietary Supplement|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
151654|NCT03008356|Behavioral|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
151655|NCT03008356|Dietary Supplement|Placebo capsules|
151656|NCT03008343|Device|Irreversible Electroporation|One kind of electric ablation machine from Angiodynamic company (USA)
151657|NCT03008343|Biological|Natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
151658|NCT03008330|Biological|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
151659|NCT03008317|Device|PEEK|a metallic denture base
151660|NCT03008304|Drug|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
151661|NCT03008291|Procedure|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
151662|NCT03008291|Procedure|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
151663|NCT03008291|Procedure|Dual Chamber Pacemaker Implantation|
151664|NCT03008278|Drug|Olaparib|Give PO
151665|NCT03008278|Biological|Ramucirumab|Given IV
151666|NCT03008265|Other|Postoperative fascial dehiscence|
151667|NCT03008252|Other|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
151668|NCT03008252|Other|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
151669|NCT03008239|Device|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
151670|NCT03008239|Device|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
151671|NCT03008226|Device|Implementation of 9 mm intrabronchial valves|
151672|NCT03008213|Drug|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
151673|NCT03008200|Device|ultrasound examination|intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
151674|NCT03008187|Drug|SEL24/MEN1703|SEL24/MEN1703 will be given as oral capsules once daily for 14 consecutive days over a 21-day treatment cycle.
151675|NCT03008174|Other|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
151676|NCT03008161|Drug|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
151677|NCT03008161|Drug|Placebo|Placebo
151678|NCT03008148|Radiation|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
151679|NCT03008148|Drug|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
151680|NCT03008148|Drug|Siroquine|"Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).~Maintenance Phase: JP001(2 tablets once a day) for 48 weeks until disease progression confirmed."
151681|NCT03008135|Other|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
151682|NCT03008135|Other|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
151683|NCT03008122|Other|Placebo|Placebo
151684|NCT03008122|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
151685|NCT03008109|Drug|EGFR-TK Inhibitor|
151686|NCT03008096|Procedure|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
151687|NCT03008083|Drug|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
151688|NCT03008083|Drug|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
151689|NCT03008070|Drug|IVA337|1200mg
151690|NCT03008070|Drug|IVA337|800mg
151691|NCT03008070|Drug|Placebo|Placebo to match
151692|NCT03008057|Dietary Supplement|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
151693|NCT03008057|Dietary Supplement|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
151694|NCT03008044|Device|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
151695|NCT03008031|Procedure|CESM with a reduced dose of contrast agent|
151720|NCT03007927|Drug|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
151721|NCT03007927|Drug|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
151759|NCT03007589|Other|sun protection fabrics|fabrics
151696|NCT03008018|Drug|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
151697|NCT03008005|Drug|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
151698|NCT03008005|Drug|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
151699|NCT03008005|Drug|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
151700|NCT03007992|Drug|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
151701|NCT03007979|Drug|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
151702|NCT03007979|Drug|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
151703|NCT03007979|Drug|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
151704|NCT03007979|Procedure|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
151705|NCT03007979|Drug|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
151706|NCT03007979|Procedure|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~Baseline~C1D15~C2D1~Every 2-3 months thereafter (to coincide with imaging studies)~Time of progression"
151707|NCT03007979|Procedure|Circulating tumor cell blood draw|-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression
151708|NCT03007979|Procedure|Tumor biopsy (optional)|-Baseline and progression
151709|NCT03007966|Procedure|Ilioinguinal / Iliohypogastric Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
151710|NCT03007966|Procedure|Quadratus Lumborum Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
151711|NCT03007966|Drug|Bupivacaine 0.25%|Administered as part of the local anesthetic mixture
151712|NCT03007966|Drug|Epinephrine 1:200k|Administered as part of the local anesthetic mixture
151713|NCT03007966|Drug|Clonidine 1.66mcg/cc|Administered as part of the local anesthetic mixture
151714|NCT03007953|Behavioral|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
151715|NCT03007940|Other|Coach Site Visit|The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
151716|NCT03007940|Other|Walk-through|Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
151717|NCT03007940|Other|Learning Sessions|The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
151718|NCT03007940|Other|Coaching|A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
151719|NCT03007940|Other|Business as Usual|Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
151722|NCT03007901|Behavioral|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (~30 min) relating to climate change, energy use, and carbon footprint.
151723|NCT03007888|Drug|IR CD-LD|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
151724|NCT03007888|Drug|ER CD-LD|Extended Release capsules containing carbidopa-levodopa flexible dosing
151725|NCT03007875|Biological|high-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
151726|NCT03007836|Biological|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
151727|NCT03007823|Biological|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
151728|NCT03007810|Drug|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
151729|NCT03007810|Drug|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
151730|NCT03007797|Behavioral|vaccination rate for influenza|
151731|NCT03007784|Device|transcranial direct current stimulation (tDCS) / Comparison of current intensities|
151732|NCT03007771|Device|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
151733|NCT03007758|Procedure|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
151734|NCT03007758|Procedure|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
151735|NCT03007745|Device|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
151736|NCT03007732|Drug|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
151737|NCT03007732|Drug|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion at time of fiducial marker placement (1-2 weeks prior to Cycle 1, Day 1) and 21 days after the 1st injection of SD-101.
151738|NCT03007732|Drug|Leuprolide acetate|22.5 mg will be given intramuscularly (IM). First injection 3 months prior to Cycle 1 Day 1. Intermittent androgen deprivation therapy will be given every 3 months starting Cycle 1, Day 1 for 3 additional doses.
151739|NCT03007732|Drug|Abiraterone Acetate|1000 mg oral dosage will be given daily for 3 months prior to Cycle 1, Day 1 and daily for 9 months starting Cycle 1, Day 1.
151740|NCT03007732|Drug|Prednisone|5 mg oral dosage will be given daily for 3 months prior to Cycle 1 Day 1 and daily for 9 months starting Cycle 1, Day 1.
151741|NCT03007732|Radiation|Stereotactic Body Radiation Therapy|7 Gy x 5 fractions (35 Gy total) 1-2 weeks after fiducial marker placement and simulation over 10-14 days.
151742|NCT03007719|Drug|Fluorine F 18 Ara-G|Given IV
151743|NCT03007719|Procedure|Positron Emission Tomography|Undergo PET/MR imaging
151744|NCT03007719|Procedure|Magnetic Resonance Imaging|Undergo PET/MR imaging
151745|NCT03007706|Procedure|Women undergo cesarean section delivery|
151746|NCT03007693|Drug|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
151747|NCT03007693|Drug|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
151748|NCT03007680|Other|Core muscle activation|
151749|NCT03007654|Device|Mediclore|apply medical device fully around intrauterine surgery area
151750|NCT03007654|Device|Adept|apply medical device fully around intrauterine surgery area
151751|NCT03007641|Behavioral|Didactic session|This session will include an overview of the approach to and management of older MBC patients through a case-based presentation.
151752|NCT03007641|Behavioral|Comprehensive Geriatric Assessment|The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.
151753|NCT03007628|Device|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
151754|NCT03007628|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
151755|NCT03007628|Other|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
151756|NCT03007615|Other|Intimate Lubricant Gel|
151757|NCT03007602|Other|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.~Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
151758|NCT03007589|Drug|otc sunscreens|Sunscreens of various SPF levels and ingredients
151760|NCT03007589|Other|Optical Filters|Optical filters and surfaces used in solar simulators
151761|NCT03007576|Biological|RegStem|RegStem, 1.5 ml, one injection
151762|NCT03007563|Device|bilirubin concentration estimation from smartphone pictures|pictures taken of the skin covering the breast bone
151763|NCT03007563|Procedure|bilirubin concentration measured in standard blood samples|
151764|NCT03007563|Device|bilirubin concentration measured by transcutaneous device|
151765|NCT03007550|Procedure|Laparoscopic total gastrectomy|LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
151766|NCT03007550|Procedure|Open total gastrectomy|OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
151767|NCT03007537|Drug|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
151768|NCT03007537|Drug|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
151769|NCT03007537|Procedure|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
151770|NCT03007524|Drug|High dose Rosuvastatin|20mg/d qN, at least 6 months
151771|NCT03007524|Drug|Low dose Rosuvastatin|10mg/d qN, at least 6 months
151772|NCT03007511|Device|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
151773|NCT03007485|Other|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
151774|NCT03007472|Device|CI532|Cochlear implant
151775|NCT03007472|Device|Nucleus 7|Sound processor
151776|NCT03007459|Other|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
151777|NCT03007459|Other|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
151778|NCT03007446|Drug|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
151779|NCT03007446|Drug|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
151780|NCT03007446|Drug|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
151781|NCT03007433|Other|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
151782|NCT03007420|Drug|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
151783|NCT03007420|Drug|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
151784|NCT03007407|Drug|durvalumab|Following three doses of hypofractionated palliative radiation (Days −2, −1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
151785|NCT03007407|Drug|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days −2, −1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
151786|NCT03007394|Drug|Lorcaserin|Lorcaserin Capsule
151787|NCT03007394|Drug|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
151788|NCT03007381|Drug|Ketorolac Tromethamine|Intravenous analgesic
151789|NCT03007381|Drug|Normal Saline|Sham comparator
151790|NCT03007368|Other|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
151791|NCT03007368|Other|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
151792|NCT03007368|Other|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
151793|NCT03007368|Other|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
151794|NCT03007368|Other|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
151795|NCT03007368|Other|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
151796|NCT03007368|Other|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
151797|NCT03007368|Other|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
151798|NCT03007355|Other|peripheral perfusion index measurement|
151799|NCT03007342|Drug|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|
151800|NCT03007342|Drug|Placebo|
151801|NCT03007329|Drug|Exenatide|Exenatide will be combined with Dapagliflozin
251771|NCT02277106|Drug|SAGE-547|
151802|NCT03007329|Drug|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
151803|NCT03007329|Drug|Dapagliflozin|Dapagliflozin, in both arms
151804|NCT03007316|Procedure|VIP graft|
151805|NCT03007303|Drug|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
151806|NCT03007303|Other|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
151807|NCT03007290|Other|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
151808|NCT03007277|Other|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
151809|NCT03007264|Device|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
151810|NCT03007251|Other|"Eurythmy Therapy Movement R"|
151811|NCT03007251|Other|"Eurythmy Therapy Movement L"|
151812|NCT03007251|Other|"Eurythmy Therapy Movement B"|
151813|NCT03007251|Other|Normal movements during walking or standing|
151814|NCT03007238|Biological|Aldesleukin|Given SC
151815|NCT03007238|Procedure|Extracorporeal Photopheresis|Undergo ECP
151816|NCT03007238|Other|Laboratory Biomarker Analysis|Correlative studies
151817|NCT03007238|Other|Quality-of-Life Assessment|Ancillary studies
151818|NCT03007225|Drug|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.~Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
151819|NCT03007225|Drug|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
151820|NCT03007212|Procedure|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
151821|NCT03007173|Procedure|umbilicus preserving surgery|excision of umbilical complex
151822|NCT03007160|Drug|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
151823|NCT03007147|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
151824|NCT03007147|Drug|Cyclophosphamide|Given IV
151825|NCT03007147|Drug|Cytarabine|Given IV, SC, or IT
151826|NCT03007147|Drug|Daunorubicin Hydrochloride|Given IV
151827|NCT03007147|Drug|Dexamethasone|Given PO or IV
151828|NCT03007147|Drug|Dexrazoxane Hydrochloride|Given IV
151829|NCT03007147|Drug|Doxorubicin|Given IV
151830|NCT03007147|Drug|Etoposide|Given IV
151831|NCT03007147|Biological|Filgrastim|Given IV
151832|NCT03007147|Drug|Ifosfamide|Given IV
151833|NCT03007147|Drug|Imatinib Mesylate|Given PO
151834|NCT03007147|Other|Laboratory Biomarker Analysis|Correlative studies
151835|NCT03007147|Drug|Leucovorin Calcium|Given PO or IV
151836|NCT03007147|Drug|Mercaptopurine|Given PO
151837|NCT03007147|Drug|Mercaptopurine|Given PO
151838|NCT03007147|Drug|Methotrexate|Given IT
151839|NCT03007147|Drug|Methylprednisolone|Given IV
151840|NCT03007147|Drug|Pegaspargase|Given IV
151841|NCT03007147|Drug|Prednisolone|Given PO
151842|NCT03007147|Other|Questionnaire Administration|Ancillary studies
151843|NCT03007147|Drug|Therapeutic Hydrocortisone|Given IT
151844|NCT03007147|Drug|Thioguanine|Given PO
151845|NCT03007147|Drug|Vincristine Sulfate|Given IV
151846|NCT03007134|Other|Retrospective Chart Review|No intervention.
151847|NCT03007121|Drug|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
151848|NCT03007121|Drug|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
151849|NCT03007121|Drug|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
151850|NCT03007108|Other|blood withdrawal|
152118|NCT03005184|Drug|Sacubitril-Valsartan 200 mg bid|oral medication
151851|NCT03007095|Behavioral|Evaluation of the children's social cognitive development|standardized neuropsychological tests
151852|NCT03007082|Device|Revive SE intracranial thrombectomy device|"Intra-arterial mechanical thrombectomy with Revive SE；~According to patient condition, the investigator could determine intravenous thrombolysis or not at his/her discretion"
151853|NCT03007069|Other|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
151854|NCT03007069|Other|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
151855|NCT03007056|Other|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
151856|NCT03007043|Other|blood sample|
151857|NCT03007030|Drug|Brentuximab Vedotin|Given IV
151858|NCT03007030|Other|Laboratory Biomarker Analysis|Correlative studies
151859|NCT03007017|Procedure|Deceased donor nephrectomy, prior to cross clamp of donor aorta|"The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study."
151860|NCT03007017|Procedure|Deceased donor nephrectomy, standard of care|The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
151861|NCT03007004|Drug|Botulinum toxin type B (2500 units / vial)|
151862|NCT03007004|Drug|Physiological saline|
151863|NCT03006991|Other|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
151864|NCT03006978|Device|TearCare|
151865|NCT03006978|Device|Warm Compress|
151866|NCT03006965|Drug|Octocog Alfa|Pharmacokinetic Characterization of the Hemophilia A Population in Spain using an standalone web-based software
151867|NCT03006952|Drug|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
151868|NCT03006952|Drug|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
151869|NCT03006939|Procedure|Cytoreductive surgery|Cytoreductive surgery in terms of tumor debulking is performed in order to promote survival
151870|NCT03006926|Drug|lenvatinib|4 mg capsules
151871|NCT03006926|Drug|pembrolizumab (200 mg)|30-minute intravenous infusion
151872|NCT03006913|Behavioral|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
151873|NCT03006913|Behavioral|By phone|Patients in the phone arm will receive a scheduled call at their home.
151874|NCT03006913|Behavioral|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
151875|NCT03006900|Other|Pilates|Pilates
151876|NCT03006900|Other|Massage|Massage
151877|NCT03006887|Drug|lenvatinib|lenvatinib capsules
151878|NCT03006887|Drug|pembrolizumab|pembrolizumab intravenous infusion
151879|NCT03006874|Drug|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
151880|NCT03006874|Drug|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
151881|NCT03006874|Drug|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
151882|NCT03006861|Dietary Supplement|3.5 mL/d topical creatine|
151883|NCT03006861|Dietary Supplement|3.5 mL/d topical placebo|
151884|NCT03006861|Dietary Supplement|21 g/d Oral creatine|
151885|NCT03006861|Dietary Supplement|21 g/d oral placebo|
151886|NCT03006848|Drug|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
151887|NCT03006848|Other|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
151888|NCT03006835|Drug|Clopidogrel|
151889|NCT03006822|Other|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
151890|NCT03006822|Other|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
151891|NCT03006822|Other|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
151892|NCT03006809|Biological|Fecal Microbiota Transplantation (FMT), OpenBiome|Delivered by colonoscopy, enema or orally (as capsules)
151893|NCT03006809|Other|pretreatment antibiotics|5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
151894|NCT03006783|Procedure|Cross-face nerve graft|connecting the healthy facial nerve to the affected facial nerve
151895|NCT03006770|Biological|PLX-PAD|Local intramuscular (IM) injections of PLX-PAD in the index leg.
151896|NCT03006770|Biological|Placebo|Local intramuscular (IM) injections of Placebo in the index leg.
151897|NCT03006757|Other|titanium dioxide denture base|
151898|NCT03006744|Behavioral|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
151899|NCT03006744|Behavioral|Reading enjoyment training|Training on how to make reading enjoyable for children.
151900|NCT03006731|Behavioral|High Intensity Interval Training|Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.
151901|NCT03006731|Behavioral|Moderate Intensity Continuous Exercise|MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
151902|NCT03006718|Other|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
151903|NCT03006705|Drug|Nivolumab|
151904|NCT03006705|Drug|Tegafur-gimeracil-oteracil potassium|
151905|NCT03006705|Drug|Oxaliplatin|
151906|NCT03006705|Drug|Capecitabine|
151907|NCT03006705|Drug|Placebo|
151908|NCT03006692|Other|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
151909|NCT03006679|Drug|Meropenem-Vaborbactam|meropenem 2 g and vaborbactam 2 g
151910|NCT03006679|Drug|Piperacillin/Tazobactam|piperacillin 4 g and tazobactam 0.5 g
151911|NCT03006666|Behavioral|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.~In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .~The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).~Individuals who do not pass will receive intensive remediation and be required to repeat the examination.~Community Health Worker Coaching Intervention."
151912|NCT03006666|Behavioral|Data Only|The teams randomly allocated will not have access to Community Health Workers.
151913|NCT03006653|Behavioral|Assessment only|Mobile ecological assessment only.
151914|NCT03006640|Drug|Subcutaneous nitroglycrin|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
151915|NCT03006640|Drug|Subcutaneous saline|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
151916|NCT03006627|Drug|postoperative morphine|Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
151917|NCT03006614|Drug|NVB|
151918|NCT03006614|Drug|EPI|
151919|NCT03006614|Drug|DDP|
151920|NCT03006614|Drug|CAP|
151921|NCT03006614|Drug|GEM|
151922|NCT03006614|Drug|H|
151923|NCT03006614|Drug|CTX|
151924|NCT03006614|Drug|T|
151925|NCT03006601|Other|Office-based accommodative/vergence therapy|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
151926|NCT03006588|Procedure|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
151927|NCT03006575|Radiation|split-course radiotherapy|split-course chest radiation at 40-51 Gy/10-17f and 15-24 Gy/5-8f
151928|NCT03006575|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
151929|NCT03006562|Drug|Subcutaneous Heparin|5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
151930|NCT03006549|Behavioral|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
151931|NCT03006536|Device|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
152009|NCT03005925|Device|Smartphone|Smartphone application coupled with a hand dynamometer
152010|NCT03005925|Other|physical follow up|regular visits with the specialist
151932|NCT03006523|Procedure|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
151933|NCT03006510|Other|Hypoglycemia prediction alert|"In real time, for a patient with a glucose <90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.~If the Risk score is >35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.~If a patient is determined to be at risk for hypoglycemia, the following will occur:~Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
151934|NCT03006497|Other|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
151935|NCT03006484|Other|No intervention|No intervention will be needed.
151936|NCT03006471|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
151937|NCT03006471|Drug|Placebo - Cap|one per day before breakfast during 12 weeks.
151938|NCT03006445|Drug|FYU-981|
151939|NCT03006432|Drug|Oxaliplatin|
151940|NCT03006432|Drug|5Fluorouracil bolus|
151941|NCT03006432|Drug|5Fluorouracil continu|
151942|NCT03006432|Drug|Docetaxel|
151943|NCT03006432|Drug|Folinic Acid|
151944|NCT03006419|Drug|Basiliximab|Standard induction therapy
151945|NCT03006419|Drug|Thymoglobulin|Induction therapy
151946|NCT03006406|Drug|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
151947|NCT03006393|Drug|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
151948|NCT03006393|Other|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
151949|NCT03006380|Drug|oxytocin|Ecbolic used to reduce blood loss
151950|NCT03006367|Drug|NFC-1 100 mg|
151951|NCT03006367|Drug|NFC-1 200 mg|
151952|NCT03006367|Drug|NFC-1 400 mg|
151953|NCT03006367|Drug|NFC-1 800 mg|
151954|NCT03006354|Device|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
151955|NCT03006354|Device|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
151956|NCT03006341|Drug|Dabigatran etexilate|observed upto 12 months
151957|NCT03006341|Drug|Warfarin|Observed upto 12 months
151958|NCT03006328|Behavioral|GEM|GEM tool +Health Coaching
151959|NCT03006328|Behavioral|Enhanced Usual Care|Patients in the EUC arm will receive non-tailored weight management handouts. Patients will follow-up with their primary care teams as needed.
151960|NCT03006315|Device|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
151961|NCT03006315|Behavioral|Mobile Health quality of life assessements|
151962|NCT03006302|Drug|Epacadostat|50, 100, or 300 mg taken by mouth twice a day, every day of each cycle
151963|NCT03006302|Drug|Pembrolizumab|200 mg IV on Day 1 of each cycle
151964|NCT03006302|Biological|CRS-207|1x10^9 CFU given IV on Day 2 of Cycles 3-6 (Arm A) or Day 2 of Cycles 1-6 (Arm B)
151965|NCT03006302|Drug|CY|200 mg/m^2 given IV on Day 1 of Cycles 1-2 (Arm A only)
151966|NCT03006302|Biological|GVAX|5x10^8 cells given as 6 intradermal injections on Day 2 of Cycles 1-2 (Arm A only)
151967|NCT03006276|Drug|DFN-15 Active|
151968|NCT03006276|Other|DFN-15 Placebo|
151969|NCT03006263|Procedure|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
151970|NCT03006263|Procedure|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
151971|NCT03006250|Drug|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
151972|NCT03006250|Drug|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
151973|NCT03006237|Drug|IS-001|10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
151974|NCT03006237|Device|da Vinci® Si/Xi Surgical System|robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging
151975|NCT03006224|Other|One Lung Ventilation|
151976|NCT03006211|Other|Nitrogen protoxide|
151977|NCT03006211|Other|Oxygen|
152011|NCT03005912|Device|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
152012|NCT03005912|Device|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
151978|NCT03006185|Device|Ablative Fractional Carbon Dioxide (CO2) Laser|Ablative Fractional Carbon Dioxide (CO2) Laser treatment is randomly allocated to one of two tests areas in each study participant. Laser treatment consists of targeted ablation of actinic keratoses and field laser treatment of the entire test area. After laser treatment, application of methyl aminolevulinate (MAL), a topical photosensitising agent, is performed. The test area thereafter undergoes 2 hours of daylight photodynamic therapy.
151979|NCT03006185|Device|Microdermabrasion|Microdermabrasion (processing of the skin with a sandpaper-like material) is randomly allocated to one of two tests areas in each study participant. Microdermabrasion treatment consists of targeted treatment of actinic keratoses and field treatment of the entire test area. Afterwards, application of methyl aminolevulinate (MAL), a topical photosensitising agent, is performed. The test area then undergoes 2 hours of daylight photodynamic therapy.
151980|NCT03006172|Drug|GDC-0077|Participants will receive oral GDC-0077 once daily on Days 1-28 of each cycle.
151981|NCT03006172|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle.
151982|NCT03006172|Drug|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1−28 of each cycle.
151983|NCT03006172|Drug|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1−21 of each cycle.
151984|NCT03006172|Drug|Metformin|Participants will receive oral metformin once daily, starting on Cycle 1, Day 1, as tolerated.
151985|NCT03006159|Drug|SHR0534|
151986|NCT03006159|Drug|Placebo|
151987|NCT03006146|Drug|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
151988|NCT03006120|Procedure|Retroperitoneal hematoma due to cardiac catheterization|
151989|NCT03006107|Procedure|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .~The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
151990|NCT03006107|Procedure|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
151991|NCT03006081|Drug|Intravitreal Aflibercept injection|Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
151992|NCT03006068|Drug|Upadacitinib (ABT-494)|Upadacitinib (ABT-494) will be administered orally.
151993|NCT03006068|Drug|Placebo|Placebo will be administered orally.
151994|NCT03006055|Device|Circulating tumor cells|
151995|NCT03006042|Drug|Bupivacaine|
151996|NCT03006029|Drug|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
151997|NCT03006016|Drug|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
151998|NCT03006016|Other|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
151999|NCT03006003|Drug|Raloxifene|Raloxifene tratment more than 4 weeks
152000|NCT03006003|Drug|Alendronate|Alendronic acid 70mg with Colecalciferol 70mcg
152001|NCT03005990|Other|Exercise training group|The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
152002|NCT03005977|Procedure|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
152003|NCT03005964|Drug|AM001 Cream, 7.5%|Active Cream
152004|NCT03005964|Drug|Vehicle Cream|Placebo
152005|NCT03005951|Other|A= Yes Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
152006|NCT03005951|Other|B=No Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
152007|NCT03005938|Procedure|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.~SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
152008|NCT03005938|Procedure|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
251772|NCT02277106|Drug|Placebo|
152013|NCT03005912|Device|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
152014|NCT03005912|Device|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
152015|NCT03005899|Drug|SyB P-1501|"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"
152016|NCT03005899|Drug|SyB P-1501 placebo|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
152017|NCT03005886|Procedure|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).~All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
152018|NCT03005886|Procedure|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
152019|NCT03005886|Procedure|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
152020|NCT03005873|Drug|TLC599 LD group|Single dose via intra-articular injection
152021|NCT03005873|Drug|Normal Saline|Single dose via intra-articular injection
152022|NCT03005873|Drug|TLC599 HD group|Single dose via intra-articular injection
152023|NCT03005860|Drug|2,6-Diisopropylphenol|In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
152024|NCT03005860|Drug|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
152025|NCT03005860|Drug|Fentanyl Citrate|Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
152026|NCT03005860|Drug|Atracurium Besylate|Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
152027|NCT03005847|Dietary Supplement|fermented papaya preparation|dietary supplementation with fermented papaya preparation
152028|NCT03005834|Other|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
152029|NCT03005821|Other|Chinese pediatric massage therapy + usual care|
152030|NCT03005821|Other|Sham massage therapy + usual care|
152031|NCT03005808|Drug|Ropivacaine|Surgery for appendicitis
152032|NCT03005795|Device|Headphones|Music can be heard through headphones
152033|NCT03005795|Other|No Headphones|No Headphones will be used.
152034|NCT03005782|Drug|REGN3767|
152035|NCT03005782|Drug|cemiplimab|
152036|NCT03005756|Device|Needle guiding robot|This intervention is to evaluate the safety and efficacy of a needle guiding robot for assisting targeting in CT-guided radiofrequency ablation of hepatocelluar carcinomas.
152037|NCT03005743|Radiation|Magnetic Resonance Image based Brachytherapy|MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines [Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A]
152038|NCT03005743|Radiation|Conventional Radiograph based Brachytherapy|The standard conventional radiography based prescription will be according to Manchester system Point A and bladder & rectum ICRU point dose constraints
152039|NCT03005730|Other|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
152040|NCT03005730|Other|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
152041|NCT03005717|Drug|LIPO-202|
152042|NCT03005717|Drug|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
152043|NCT03005704|Drug|Antiplatelet treatment|Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
152044|NCT03005691|Radiation|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.~The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
152078|NCT03005470|Other|UCT|Participants in the control group will receive usual clinical treatment (UCT) on pre-scheduled visits, but will not receive any technological tool to stimulate blood pressure control or lifestyle modification.
152079|NCT03005457|Behavioral|Hemiparesis Therapy with VR|An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
152045|NCT03005691|Other|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
152046|NCT03005691|Procedure|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
152047|NCT03005678|Drug|Denosumab|active treatment group
152048|NCT03005678|Drug|Alendronate|comparator
152049|NCT03005665|Drug|Acetazolamide|
152050|NCT03005665|Drug|Normal Saline|
152051|NCT03005652|Behavioral|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
152052|NCT03005652|Behavioral|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
152053|NCT03005639|Drug|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
152054|NCT03005626|Other|Therapeutic education|
152055|NCT03005626|Other|Standard follow-up|
152056|NCT03005613|Procedure|ischial spine fascia fixation|The participants will receive ischial spine fascia fixation.
152057|NCT03005613|Procedure|sacrospinous ligament fixation|The participants will receive sacrospinous ligament fixation.
152058|NCT03005574|Behavioral|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
152059|NCT03005574|Behavioral|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
152060|NCT03005561|Behavioral|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
152061|NCT03005548|Device|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
152062|NCT03005548|Drug|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).~Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
152063|NCT03005535|Other|Vitaminized corn oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
152064|NCT03005535|Other|Olive oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
152065|NCT03005522|Drug|oral dexamethasone|Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
152066|NCT03005522|Drug|Placebo Oral Capsule|dosed with placebo
152067|NCT03005509|Other|TQIM checklist|"The intervention phase will include an intense training period covering:~Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
152068|NCT03005496|Drug|Zinc|included in intervention arm
152069|NCT03005496|Drug|Nifedipine|included in intervention and control arm
152070|NCT03005496|Drug|Beta Carotene|included in intervention arm
152071|NCT03005496|Drug|Vitamin D3|included in intervention arm
152072|NCT03005496|Drug|Dexamethasone|included in intervention and control arm
152073|NCT03005483|Drug|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
152074|NCT03005483|Other|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
152075|NCT03005470|Device|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
152076|NCT03005470|Device|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
152077|NCT03005470|Device|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
152080|NCT03005444|Drug|Rivaroxaban|10mg/day, for 2 years
152119|NCT03005184|Drug|Icatibant|intravenous medication
152081|NCT03005431|Behavioral|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
152082|NCT03005418|Biological|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) is a Humacyte Human Acellular Vessel (HAV), which is a tissue-engineered vascular prosthesis for arterial bypass or reconstruction in patients with peripheral arterial disease or peripheral arterial trauma. It is a sterile, non-pyrogenic acellular tubular vessel composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
152083|NCT03005405|Procedure|Ionomer Restoration (control)|Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements
152084|NCT03005405|Procedure|Ionomer Sealant (test)|Sealing of moderate caries lesions without any caries removal or cavity opening.
152085|NCT03005405|Procedure|Oral hygiene orientation and professional fluoride application|Oral hygiene orientation and professional fluoride application
152086|NCT03005392|Other|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.~The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
152087|NCT03005379|Drug|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
152088|NCT03005379|Drug|Placebo|Oral capsule-delivered placebo
152089|NCT03005366|Drug|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
152090|NCT03005366|Drug|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
152091|NCT03005353|Drug|Cumin seed extract|patients will receive the drug in suppository form
152092|NCT03005353|Drug|clotrimazole|patients will receive the drug in suppository form
152093|NCT03005340|Drug|Treatment B|Bazedoxifene 20 mg
152094|NCT03005340|Drug|Treatment C|Cholecalciferol granule 10 mg
152095|NCT03005340|Drug|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
152096|NCT03005327|Drug|X4P-001|Mavorixafor will be provided as either 25 mg or 100 mg capsules.
152097|NCT03005314|Procedure|chemotherapy|chemotherapy before surgery
152098|NCT03005314|Procedure|Surgery|chemotherapy after surgery
152099|NCT03005301|Device|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25~40mm in length and 0.30~0,38mm in diameter.Waveform: continuous-wave with frequency of 120~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
152100|NCT03005301|Device|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.~The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120~250 times per minute and current intensity within patients' tolerance.~Treatment time: each treatment time is 30 minutes."
152101|NCT03005288|Drug|bimagrumab|monthly intravenous infusion
152102|NCT03005288|Other|placebo|monthly intravenous infusion
152103|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).~Follicle and endometrium can be evaluated: on the day of final injection or one day later.~hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.~OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.~Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
152104|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.~From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.~As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred"
152105|NCT03005262|Drug|MLN8237|
152106|NCT03005249|Procedure|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
152107|NCT03005249|Other|the control group|The patients will be assigned to the control group for cerebral palsy.
152108|NCT03005236|Drug|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
152109|NCT03005236|Drug|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
152110|NCT03005223|Drug|Co-administration of DWC20155/DWC20156|
152111|NCT03005223|Drug|DWC20163|
152112|NCT03005210|Drug|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
152113|NCT03005210|Drug|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
152114|NCT03005210|Drug|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
152115|NCT03005197|Device|Laser Doppler Flowmetry|
152116|NCT03005184|Drug|Valsartan 80 mg bid|oral medication during run-in and washout period
152117|NCT03005184|Drug|Enalapril 10 mg bid|oral medication
152120|NCT03005184|Drug|Placebo|intravenous medication
152121|NCT03005171|Drug|Bupivacaine|Thoracic epidural bupivacaine infusion
152122|NCT03005171|Drug|Lidocaine|Intravenous lidocaine infusion
152123|NCT03005158|Other|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
152124|NCT03005158|Other|Randomization Phase|Standard care or HighSTEACS pathway.
152125|NCT03005158|Other|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are <5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
152126|NCT03005145|Other|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
152127|NCT03005145|Other|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
152128|NCT03005132|Other|Normal brain tissue|The investigators will extract total protein, DNA and RNA from the samples.
152129|NCT03005119|Drug|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
152130|NCT03005119|Drug|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
152131|NCT03005106|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
152132|NCT03005106|Procedure|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
152133|NCT03005093|Other|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
152134|NCT03005093|Other|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
152135|NCT03005067|Drug|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
152136|NCT03005067|Other|Placebo|Reference product containing vehicle without carbomer 980 gel
152137|NCT03005054|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
152138|NCT03005054|Procedure|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
152139|NCT03005041|Other|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
152140|NCT03005041|Other|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
152141|NCT03005015|Drug|Lenvatinib|
152142|NCT03005015|Drug|Doxorubicin|
152143|NCT03005002|Biological|Durvalumab|Given IV
152144|NCT03005002|Other|Laboratory Biomarker Analysis|Correlative studies
152145|NCT03005002|Biological|Tremelimumab|Given IV
152146|NCT03004989|Behavioral|Programme|The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
152147|NCT03004976|Biological|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10^7 TNCC/kg.
152148|NCT03004976|Other|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 [pink]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
152149|NCT03004963|Device|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
152150|NCT03004963|Device|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
152151|NCT03004937|Other|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
152152|NCT03004924|Drug|SHP640|Instill 1 drop of SHP640 (povidone-iodine [PVPI] 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
152153|NCT03004924|Drug|PVP-I 0.6%|Instill 1 drop of PVP-I 0.6% ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
156344|NCT02973997|Biological|Pembrolizumab|Given IV
152154|NCT03004924|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
152155|NCT03004911|Device|ProFibro (Mobile application)|ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
152156|NCT03004911|Device|Paper booklet|A 64-page booklet with content similar to the mobile application
152157|NCT03004898|Behavioral|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
152158|NCT03004885|Device|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
152159|NCT03004846|Drug|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.~GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
152160|NCT03004846|Drug|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
152161|NCT03004833|Drug|Nivolumab|Infusion of Nivolumab
152162|NCT03004833|Drug|Adriamycin|Infusion of Adriamycin
152163|NCT03004833|Drug|Vinblastine|Infusion of Vinblastine
152164|NCT03004833|Drug|Dacarbazine|Infusion of Dacarbazine
152165|NCT03004820|Device|Remote Ischemic Conditioning|RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
152166|NCT03004807|Dietary Supplement|Centrum Silver Mens' Formula|Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
152167|NCT03004807|Other|Control|A matching tablet to the dietary supplement, but without any active ingredients
152168|NCT03004794|Other|medical records review|
152169|NCT03004781|Behavioral|Parenting program|
152170|NCT03004768|Drug|BMS-986165|Oral solution dose of 24 mg [14C] BMS-986165 containing approximately 100 micro Ci of TRA
152171|NCT03004755|Other|Tissue Harvest|
152172|NCT03004742|Dietary Supplement|Flavonoid|Flavonoid rich supplement
152173|NCT03004742|Dietary Supplement|Placebo|Placebo
152174|NCT03004729|Other|CoMiSS questionnaire|
152175|NCT03004716|Other|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.~During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
152176|NCT03004703|Drug|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
152177|NCT03004703|Drug|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
152178|NCT03004690|Device|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
152179|NCT03004690|Device|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
152180|NCT03004677|Behavioral|Continuous skin-to-skin contact|Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
152181|NCT03004677|Other|Standard Care|Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
152182|NCT03004664|Behavioral|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
152183|NCT03004664|Behavioral|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
152184|NCT03004651|Other|Power Doppler ultrasound|Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
152185|NCT03004651|Other|Clinical evaluation|swollen joint count (SJC) as componant of SDAI
152186|NCT03004638|Drug|MEDI6012 40 mg|Participants received 3 doses of 40 milligram (mg) MEDI6012 IV on Days 1, 8, and 15.
152187|NCT03004638|Drug|Placebo|Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
152188|NCT03004638|Drug|MEDI6012 120 mg|Participants received 3 doses of 120 mg MEDI6012 IV on Days 1, 8, and 15.
152189|NCT03004638|Drug|MEDI6012 300 mg|Participants received 3 doses of 300 mg MEDI6012 IV on Days 1, 8, and 15.
152190|NCT03004638|Drug|Placebo IV Push|Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
152191|NCT03004638|Drug|MEDI6012 IV Push|Participants received 3 doses of MEDI6012 by IV push as 300 mg loading dose on Day 1, and maintenance doses of 150 mg and 100 mg on Day 3 and Day 10, respectively.
152192|NCT03004625|Drug|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
152193|NCT03004625|Drug|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
152194|NCT03004625|Drug|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
152195|NCT03004612|Combination Product|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
152911|NCT02999373|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
152196|NCT03004612|Drug|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
152197|NCT03004599|Device|SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System|Transcatheter Aortic Valve Implantation via Transfemoral Approach
152198|NCT03004586|Device|25-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
152199|NCT03004586|Device|22-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
152200|NCT03004586|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
152201|NCT03004573|Other|Neuropsychological detailed tests with focus on social cognition|MATTIS, MOCA, BREF, Light points test, PDQ39
152202|NCT03004560|Procedure|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
152203|NCT03004560|Procedure|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
152204|NCT03004547|Other|Measuring sodium content|Sodium MRI measurement of sodium content in the tissues of all participants
152205|NCT03004534|Drug|darolutamide|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
152206|NCT03004521|Drug|Quetiapine|Quetipatine prescribed in addition to the patient's existing antidepressant treatment.
152207|NCT03004521|Drug|Lithium|Lithium prescribed in addition to the patient's existing antidepressant treatment.
152208|NCT03004508|Dietary Supplement|Gingko Biloba Extract|120mg/day, twice a day, 6 month
152209|NCT03004508|Dietary Supplement|Placebo|120mg/day, twice a day, 6 month
152210|NCT03004495|Drug|CHF5259 and CHF6001|b.i.d. for 14 days
152211|NCT03004495|Drug|CHF5259 + placebo|b.i.d. for 14 days
152212|NCT03004495|Drug|CHF6001 + placebo|b.i.d. for 14 days
152213|NCT03004495|Other|Placebo|b.i.d. for 14 days
152214|NCT03004469|Drug|P-3074|
152215|NCT03004469|Drug|Finasteride|
152216|NCT03004469|Drug|P-3074 Vehicle|
152217|NCT03004469|Drug|Finasteride Placebo|
152218|NCT03004456|Other|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
152219|NCT03004443|Drug|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
152220|NCT03004443|Drug|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
152221|NCT03004430|Behavioral|Mantra Meditation|Silent mantra meditation with spiritual mantra
152222|NCT03004430|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation
152223|NCT03004417|Drug|CHF 6001 Dose1|CHF 6001 plus placebo
152224|NCT03004417|Drug|CHF 6001 Dose2|CHF 6001 only (high dose)
152225|NCT03004417|Other|Placebo|Placebo only
152226|NCT03004404|Drug|Placebo|
152227|NCT03004404|Drug|BI 730357|
152228|NCT03004378|Behavioral|Activity Tracking Device|Fitbit Alta
152229|NCT03004365|Drug|27.2 mg C16G2 Varnish|Antimicrobial Peptide
152230|NCT03004365|Drug|13.6 mg C16G2 Varnish|Antimicrobial Peptide
152231|NCT03004365|Drug|54.4 mg C16G2 Varnish|Antimicrobial Peptide
152232|NCT03004365|Drug|Placebo Varnish|Placebo
152233|NCT03004352|Other|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
152234|NCT03004352|Other|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
152235|NCT03004339|Drug|SOR007 Ointment 2.0%|
152236|NCT03004339|Drug|SOR007 Ointment 1.0%|
152237|NCT03004339|Drug|SOR007 Ointment 0.3%|
152238|NCT03004339|Drug|SOR007 Ointment 0.15%|
152239|NCT03004339|Drug|SOR007 Ointment Placebo|
152240|NCT03004339|Drug|Taclonex® Ointment|
152241|NCT03004313|Procedure|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
152242|NCT03004313|Procedure|MRI scan|
152243|NCT03004313|Procedure|Quantitative Sensory Testing (QST)|
152244|NCT03004300|Procedure|Rapid maxillary expansion|Device
152245|NCT03004300|Procedure|Adenotonsillectomy|Surgery
152246|NCT03004287|Drug|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
152247|NCT03004287|Drug|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
152248|NCT03004287|Drug|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
152249|NCT03004287|Drug|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
152250|NCT03004287|Drug|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
152251|NCT03004287|Drug|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
152252|NCT03004287|Drug|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
152253|NCT03004287|Drug|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
152254|NCT03004287|Drug|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
152255|NCT03004287|Procedure|ASCT|day 0 of Transplant(s)
152256|NCT03004287|Drug|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
152257|NCT03004287|Drug|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
152258|NCT03004274|Other|Running sutures|
152259|NCT03004274|Other|Interrupted sutures|
152361|NCT03003637|Drug|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
152260|NCT03004261|Biological|donor derived cytomegalovirus specific T lymphocytes|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
152261|NCT03004261|Drug|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
152262|NCT03004261|Drug|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
152263|NCT03004248|Biological|Botulinum Toxins, Type A|Intramuscular Injection
152264|NCT03004235|Device|Observational data collection|Observational data collection
152265|NCT03004222|Drug|Bupivacaine|20 ml of 0.5% Bupivacaine
152266|NCT03004222|Drug|Placebos|
152267|NCT03004209|Drug|Erythropoietin|three times per a week 100IU / k
152268|NCT03004196|Drug|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
152269|NCT03004196|Drug|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
152270|NCT03004196|Other|Control Group|No Probiotic toothpaste & Chlorhexidine Mouthwash
152271|NCT03004183|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
152272|NCT03004183|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
152273|NCT03004183|Radiation|SBRT|Low-dose SBRT
152274|NCT03004183|Drug|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
152275|NCT03004170|Behavioral|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
152276|NCT03004170|Behavioral|Telephone-Administered Coping Effectiveness Training|
152277|NCT03004157|Procedure|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
152278|NCT03004144|Other|FLOAT|
152279|NCT03004131|Drug|Azelastine hydrochloride + fluticasone propionate nasal spray|
152280|NCT03004131|Drug|Placebos|
152281|NCT03004131|Drug|fluticasone propionate nasal spray + loratadine|
152282|NCT03004118|Dietary Supplement|Nutridrink|Liquid meal of 200ml
152283|NCT03004118|Device|High resolution manometry probe|Catheter inserted via the nose into the stomach to measure intragastric pressure.
152284|NCT03004118|Device|perfusion catheter|Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
152285|NCT03004118|Drug|Placebo Oral Tablet|4 week oral intake (daily)
152286|NCT03004118|Drug|Ursochol oral tablet|4 week oral intake (daily) (dose of 10.5mg/kg/day)
152287|NCT03004118|Device|Duodenal fluid aspiration catheter|Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
152288|NCT03004118|Procedure|Duodenogastroscopy|Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
152289|NCT03004118|Procedure|Blood sample|Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
152290|NCT03004105|Drug|Selumetinib|"Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in."
152291|NCT03004105|Drug|Durvalumab|Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
152292|NCT03004105|Behavioral|Phone Calls|About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
152293|NCT03004092|Procedure|blood sample|Twice weekly blood sample, and at every outpatient visit
152294|NCT03004066|Drug|Daptomycin|standard care
152295|NCT03004053|Device|Reflectance Confocal Microscopy (RCM) endoscope device|
152296|NCT03004040|Biological|Flu Vaccine|
152297|NCT03004027|Other|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
152298|NCT03004014|Other|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
152299|NCT03004001|Drug|Alirocumab|150 mg biweekly
152300|NCT03004001|Drug|Alirocumab placebo|placebo
152301|NCT03004001|Drug|Atorvastatin|20 mg/day
152302|NCT03003988|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
152303|NCT03003988|Dietary Supplement|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
152304|NCT03003988|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
152305|NCT03003975|Device|PVI by single cryoballoon application guided by Achieve Mapping Catheter|Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff < or = -40 degrees C)
152306|NCT03003975|Device|PVI by 2 routine cryoballoon applications|Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
152307|NCT03003962|Drug|Durvalumab (MEDI4736)|Anti-PD-L1 monoclonal Antibody monotherapy
152308|NCT03003962|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
152309|NCT03003962|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
152310|NCT03003962|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
152311|NCT03003962|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
152312|NCT03003962|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
152313|NCT03003949|Drug|Estradiol|Transdermal Estradiol worn every day for 16 weeks (patch changed every 7 days).
152314|NCT03003949|Drug|Placebos|Placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
152315|NCT03003949|Drug|Progesterone|Micronized progesterone (200 mg) will be administered every day for 12 days during weeks 17-18 (8 weeks after randomization to estradiol/placebo) and again at weeks 25-26 (which is the end of the 16 week intervention).
152316|NCT03003949|Drug|Placebo Oral Tablet|Placebo pills will be administered every day during weeks 17 and 18 and again for weeks 25-26.
152317|NCT03003936|Behavioral|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
152318|NCT03003923|Behavioral|Taste exposure|Exposure to the same vegetable
152319|NCT03003923|Behavioral|Nutritional education|Eat Well and Strive for Five nutritional education
152320|NCT03003910|Behavioral|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
152321|NCT03003910|Behavioral|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
152322|NCT03003897|Other|Soluble Fiber|Participants receiving soluble fiber.
152323|NCT03003897|Other|Placebo|Participants receiving placebo.
152324|NCT03003884|Drug|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
152325|NCT03003884|Drug|Propofol|Initial dose plus supplemental doses as necessary.
152326|NCT03003871|Device|Powered toothbrush|Oral-B® AdvancePowerTM 400 series
152327|NCT03003871|Device|Manual toothbrush|Oral-B® Pro-Health All-In-One
152328|NCT03003871|Other|Toothpaste|Colgate Maximum Cavity Protection®
152329|NCT03003871|Other|0.2% chlorhexidine gluconate mouth rinse|CorsodylPTMP
152330|NCT03003858|Device|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
152331|NCT03003845|Other|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
152332|NCT03003845|Other|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
152333|NCT03003832|Other|Change in electronic health record default for new opioid analgesic prescriptions|
152334|NCT03003819|Device|Control Collagen Wound Dressing|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
152335|NCT03003819|Device|Test Collagen Matrix|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
152336|NCT03003806|Device|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
152337|NCT03003806|Other|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
152338|NCT03003793|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Hyperinsulinemic euglycemic clamp to detect insulin sensitivity
152339|NCT03003780|Behavioral|Mindful Steps|Integrated website, activity tracker, and mind-body training
152340|NCT03003754|Behavioral|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
152341|NCT03003754|Behavioral|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
152342|NCT03003741|Drug|Bupivacaine|One 4 cc intraorbital injection at the end of procedure
152343|NCT03003741|Drug|EXPAREL|One 4 cc intraorbital injection at the end of procedure
152344|NCT03003728|Drug|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
152345|NCT03003728|Drug|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
152346|NCT03003728|Procedure|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
152347|NCT03003728|Biological|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
152348|NCT03003728|Drug|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
152349|NCT03003715|Procedure|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi [11 C] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
152350|NCT03003715|Procedure|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
152351|NCT03003715|Procedure|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
152352|NCT03003715|Other|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
152353|NCT03003702|Device|Nonin|
152354|NCT03003689|Procedure|Scaling and Root Planing|Standard of care scaling and root planing using hand instruments and ultrasonic scaler
152355|NCT03003689|Device|Er:YAG Laser|Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
152356|NCT03003676|Biological|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
152357|NCT03003676|Drug|Cyclophosphamide|Pre-treatment
152358|NCT03003676|Drug|Pembrolizumab|PD1 blockade
152359|NCT03003663|Device|SensableCare System|The SensableCare System is evaluated for reducing bed falls.
152360|NCT03003650|Device|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
152362|NCT03003637|Drug|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
152363|NCT03003624|Device|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
152364|NCT03003624|Device|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
152365|NCT03003624|Device|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
152366|NCT03003611|Procedure|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
152367|NCT03003611|Procedure|general anesthesia|Patient will be anesthetized with a classical general anesthesia
152368|NCT03003598|Other|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
152369|NCT03003598|Other|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
152370|NCT03003585|Other|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
152371|NCT03003585|Other|Fiberoptic bronchoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
152372|NCT03003572|Other|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
152373|NCT03003559|Device|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
152374|NCT03003546|Other|Laboratory Biomarker Analysis|Correlative studies
152375|NCT03003546|Drug|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Given IV
152376|NCT03003546|Other|Pharmacological Study|Correlative studies
152377|NCT03003533|Genetic|SPK-8011|A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
152378|NCT03003520|Drug|Durvalumab|"Durvalumab was supplied in single use vials as a liquid solution containing 500 mg (nominal) of durvalumab at a concentration of 50 mg/mL to be infused by intravenous (IV) injection.~Day 1 of each treatment cycle (Induction Period and Consolidation Period) started with the administration of IV durvalumab followed by a 2-hour observation period post infusion."
152379|NCT03003520|Drug|Rituximab|Subsequent to durvalumab infusion, rituximab was administered by IV. Rituximab administration could be split over 2 consecutive days according to local clinical practice. Rapid infusion of rituximab was not allowed in this clinical study.
152380|NCT03003520|Drug|Doxorubicin|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
152381|NCT03003520|Drug|Vincristine|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
152382|NCT03003520|Drug|Cyclophosphamide|A component of the CHOP therapy administered by IV. CHOP therapy was administered following rituximab.
152383|NCT03003520|Drug|Prednisone|"Prednisone was administered as an IV infusion or by mouth (PO) on Day 1, followed by PO administration on Days 2-5 of each cycle.~Prednisone could be given prior to other drugs of the CHOP therapy. It was administered after lenalidomide dosing in the R2-CHOP treatment arm."
152384|NCT03003520|Drug|Lenalidomide|Lenalidomide was administered orally in capsule form on Days 1-14 of the DUR+R2-CHOP treatment arm only.
152385|NCT03003507|Dietary Supplement|Enteral Formula With Fructose|Low-carbohydrate Enteral Formula With Fructose
152386|NCT03003507|Dietary Supplement|Enteral Formula Without Fructose|Low-carbohydrate Enteral Formula Without Fructose
152387|NCT03003494|Drug|Spiolto® Respimat®|observations taken in a period of approximately 6 weeks
152388|NCT03003468|Drug|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
152389|NCT03003468|Drug|MK-3475|200mg IV
152390|NCT03003468|Drug|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
152391|NCT03003455|Procedure|Nasotracheal intubation over a bougie|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
152392|NCT03003455|Procedure|Conventional Nasotracheal Intubation|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
152393|NCT03003442|Dietary Supplement|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
152394|NCT03003442|Dietary Supplement|Placebo|Placebo
152395|NCT03003429|Other|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
153041|NCT02998450|Drug|IMR-687|1 of 6 possible single doses administered orally following overnight fast
152396|NCT03003416|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
152397|NCT03003403|Behavioral|Intervention Program|Balance is testing a pragmatic approach to promote weight maintenance among overweight patients and patients with obesity within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
152398|NCT03003390|Drug|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given <24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
152399|NCT03003377|Device|laryngeal mask supreme|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
152400|NCT03003377|Device|laryngeal mask proseal|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
152401|NCT03003364|Drug|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
152402|NCT03003364|Drug|Placebo|Placebo in a blinded syringe
152403|NCT03003338|Drug|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
152404|NCT03003338|Drug|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
152405|NCT03003325|Drug|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
152406|NCT03003325|Procedure|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
152407|NCT03003325|Drug|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
152408|NCT03003299|Device|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
152409|NCT03003286|Behavioral|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
152410|NCT03003286|Behavioral|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
152411|NCT03003273|Other|stoppage of antibiotics|antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
152412|NCT03003273|Other|amoxycillin/clavulanic acid|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
152413|NCT03003273|Other|levofloxacin|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
152414|NCT03003260|Other|CBD chewing gum|
152415|NCT03003260|Other|Placebo|
152416|NCT03003247|Drug|IDP-120 Gel|IDP-120 Gel is a combination product
152417|NCT03003247|Drug|IDP 120 Component A Gel|Monad of Component A
152418|NCT03003247|Drug|IDP 120 Component B Gel|Monad of Component B
152419|NCT03003247|Drug|IDP 120 Vehicle Gel|Vehicle
152420|NCT03003234|Procedure|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
152421|NCT03003234|Device|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
152422|NCT03003234|Dietary Supplement|Nutri drink|Liquid meal of 200 ml.
152423|NCT03003221|Behavioral|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
152424|NCT03003221|Behavioral|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
152425|NCT03003208|Other|Pulmonary rehabilitation|An exercise and education program
152426|NCT03003195|Drug|Montanide ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
152427|NCT03003169|Other|Medical questionnaire|"quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)~Hospital Anxiety and Depression scale~satisfaction care questionnaire (IN-PATSAT32)"
152428|NCT03003156|Procedure|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
152429|NCT03003156|Procedure|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
152430|NCT03003143|Drug|Vigabatrin 500 MG|
152431|NCT03003130|Device|Restylane Defyne|Intradermal injection
152432|NCT03003130|Device|Restylane|Intradermal injection
152433|NCT03003117|Behavioral|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula and baby food vouchers from 6 to 24 m (component 3).~One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
152434|NCT03003117|Behavioral|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
152435|NCT03003104|Drug|DMT210 Topical Gel 5%|
152436|NCT03003104|Other|Vehicle Control|
152437|NCT03003091|Other|Needs-based patient education|
152438|NCT03003091|Other|Traditional patient education|
152439|NCT03003078|Device|OncoSil™|The implantation of OncoSil™
152440|NCT03003065|Drug|Temoporfin|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
152441|NCT03003052|Procedure|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
152442|NCT03003039|Biological|GB241|
152443|NCT03003039|Biological|Rituximab|
152444|NCT03003026|Other|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
152445|NCT03003026|Other|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
152446|NCT03003013|Procedure|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
152447|NCT03003000|Drug|ibuprofen|
152448|NCT03003000|Drug|caffeine|
152449|NCT03003000|Drug|placebo|
152450|NCT03002987|Behavioral|Active Pregnancy policy|Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
152451|NCT03002974|Drug|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
152452|NCT03002974|Drug|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
152453|NCT03002974|Drug|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
152454|NCT03002974|Drug|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
152455|NCT03002961|Drug|RBP-6000|single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments
152456|NCT03002961|Drug|Suboxone|RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
152457|NCT03002948|Other|Orgasm|"clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.~Female Sexual Function Index orgasm domain score"
152458|NCT03002935|Drug|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
152459|NCT03002922|Drug|BAY987517|Sunscreen formula Y65-158
152460|NCT03002909|Device|epidural catheter|
152461|NCT03002909|Device|preperitoneal catheter|
152462|NCT03002896|Behavioral|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
152463|NCT03002896|Other|Treatment as Usual|
152566|NCT03002064|Drug|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
152464|NCT03002883|Behavioral|Usual Care|"Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource"
152465|NCT03002883|Behavioral|Brief Motivational Interviewing|Peer educator conducts brief motivational interviewing about smoking cessation and participant goals
152466|NCT03002883|Behavioral|Direct referral to quitline|Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
152467|NCT03002870|Other|Questionnaires|Patients will receive questionnaires yearly to follow their QOL
152468|NCT03002857|Device|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
152469|NCT03002857|Device|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
152470|NCT03002857|Device|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
152471|NCT03002844|Drug|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
152472|NCT03002844|Drug|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
152473|NCT03002844|Drug|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
152474|NCT03002831|Biological|Cytokine-induced Killer Cells|
152475|NCT03002831|Drug|Tegafur-Gimeracil-Oteracil Potassium|
152476|NCT03002805|Drug|CBT-1®|"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:~Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 37.5 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
152477|NCT03002792|Procedure|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
152478|NCT03002779|Drug|JNJ-53718678|Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
152479|NCT03002766|Procedure|Breast conservative surgery|
152480|NCT03002753|Behavioral|detached mindfulness|Please see detailed study description.
152481|NCT03002753|Behavioral|cognitive restructuring|Please see detailed study description.
152482|NCT03002714|Other|Exercise|
152483|NCT03002701|Behavioral|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
152484|NCT03002688|Other|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
152485|NCT03002675|Drug|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
152486|NCT03002662|Other|colonoscopy|
152487|NCT03002649|Drug|Tofacitinib|Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
152488|NCT03002636|Procedure|anesthesia|Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
152489|NCT03002623|Drug|CUDC-907|60 mg (2 capsules of 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
152490|NCT03002610|Other|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
152491|NCT03002610|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
152492|NCT03002610|Other|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
152493|NCT03002597|Device|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
152494|NCT03002584|Other|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).~Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
152495|NCT03002571|Drug|IDP-124 Lotion|Lotion
152496|NCT03002571|Drug|IDP-124 Vehicle Lotion|Lotion
152497|NCT03002545|Dietary Supplement|Magnesium citrate|
152498|NCT03002545|Dietary Supplement|Placebo|
152499|NCT03002532|Radiation|whole brain radiotherapy|
152500|NCT03002519|Biological|PLX-R18|Intramuscular (IM) administration of PLX-R18
152501|NCT03002506|Drug|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
152502|NCT03002493|Drug|Eribulin mesylate|"Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.~Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate."
152503|NCT03002493|Drug|Eribulin mesylate|
152504|NCT03002493|Drug|Rifampicin|Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
152530|NCT03002298|Behavioral|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
156345|NCT02973958|Drug|Bupivacaine|See active comparator description
152505|NCT03002480|Other|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
152506|NCT03002467|Other|PESI score|
152507|NCT03002454|Drug|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
152508|NCT03002441|Device|Same-Day Dilapan-S|Dilapan-S cervical dilators placed the same day as the D&E procedure
152509|NCT03002441|Device|Overnight Dilapan-S|Dilapan-S cervical dilators placed the day prior to D&E procedure
152510|NCT03002428|Drug|Teriparatide (PF708)|Subcutaneous injection
152511|NCT03002428|Drug|Teriparatide (Forteo)|Subcutaneous injection
152512|NCT03002415|Other|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention."
152513|NCT03002415|Other|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
152514|NCT03002402|Behavioral|Internet-based CBT-I|Internet-based cognitive-behavioral treatment for insomnia
152515|NCT03002389|Drug|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
152516|NCT03002389|Drug|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
152517|NCT03002376|Drug|REGN2810|REGN2810 treatment
152518|NCT03002363|Behavioral|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
152519|NCT03002363|Behavioral|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
152520|NCT03002337|Behavioral|Aromatherapy massage|All of the participants in the aromatherapy group underwent aromatherapy massage for 70 minutes every two weeks between 16 to 36 weeks GA (ten sessions total). The aromatic massage oils were composed of 2 c.c. lavender (Lavandula angustifolia) blended with 98 c.c. almond oil. This concentration of the mixed essential oil was kept at room temperature for massage use.
152521|NCT03002337|Behavioral|Yoga exercise|Prenatal yoga was offered in six 70-minute yoga sessions per week for 20 weeks, with 10-12 women in each session. Each participant should attend two sessions of yoga every two days, held in a quiet room near the prenatal clinic. Yoga specifically designed for women during the second and third trimesters, was guided by a midwife who was certified as a yoga instructor. Yoga included physical postures/ stretch, deep breathing, guided imagery, and deep relaxation. Before each posture/stretch, the instructor guided participants to relax each body part and calm their mind.
152522|NCT03002324|Behavioral|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
152523|NCT03002324|Behavioral|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
152524|NCT03002324|Behavioral|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
152525|NCT03002324|Behavioral|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
152526|NCT03002324|Behavioral|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
152527|NCT03002311|Other|Epharmix|An electronic intervention platform uses SMS text messaging or pre-recorded phone messages for various adherence tracking and data collection applications, in order to supplement clinical care. Specific messages include proactively asking patients or a designated patient advocate if the patient has experienced a medical event recently; requesting specific care-related information, such as glucose values, current mood, or medication adherence; and providing health care education, i.e. what to do if they are experiencing physical symptoms. Patients receiving the messages are also provided with key contact information for their designated health care provider to promote patient engagement, as well as prompt and appropriate medical intervention.
152528|NCT03002311|Other|Standard of care|Current standard of care as designated by clinical provider or clinic's standard operating practice.
152529|NCT03002311|Other|Placebo|Depending on the specific disease/condition studied, in addition to standard of care, participants in the control arm may receive text or phone calls requesting clinical data (e.g. mood, weight, blood glucose level, or disease specific events) that a patient can provide on their own. Depending on the disease condition, these answers may trigger a prompt for the patient to call in to the provider, although no alert will be sent to the provider prompting a call to the patient. Patients are able to contact their provider at any time as per standard of care, but are not proactively prompted by the Epharmix system to contact their provider based on responses/values provided for data collection.
152531|NCT03002298|Behavioral|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
152532|NCT03002298|Behavioral|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
152533|NCT03002298|Behavioral|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
152534|NCT03002285|Behavioral|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
152535|NCT03002285|Behavioral|Control group|Group with typical development that performed the Fitts law in a computer task
152536|NCT03002272|Device|TAVR|subjects that underwent TAVR more than 3 years ago
152537|NCT03002272|Device|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
152538|NCT03002259|Drug|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
152539|NCT03002246|Other|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
152540|NCT03002233|Drug|TRK-820|
152541|NCT03002220|Drug|radium-223|Radium-223 at a dose of 55 kBq
152542|NCT03002207|Device|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
152543|NCT03002207|Procedure|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
152544|NCT03002194|Device|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
152545|NCT03002194|Other|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
152546|NCT03002181|Other|Education|70 minute education session.
152547|NCT03002168|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
152548|NCT03002168|Dietary Supplement|Placebo|Placebo tablets identical in appearance to the active comparator
152549|NCT03002168|Radiation|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
152550|NCT03002168|Radiation|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
152551|NCT03002155|Other|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
152552|NCT03002142|Device|Hearing aids|Phonak Audéo B-R (Target V 5.0)
152553|NCT03002142|Device|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
152554|NCT03002129|Other|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
152555|NCT03002116|Other|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
152556|NCT03002103|Drug|EndoTAG-1|
152557|NCT03002103|Drug|Paclitaxel|
152558|NCT03002103|Drug|Gemcitabine Hydrochloride|
152559|NCT03002090|Dietary Supplement|Iron trained|"Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.~Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
152560|NCT03002090|Dietary Supplement|Iron Untrained|1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
152561|NCT03002090|Dietary Supplement|BZKL Trained|"BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.~Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
152562|NCT03002090|Dietary Supplement|BZKL Untrained|1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
152563|NCT03002090|Dietary Supplement|Placebo Trained|1. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
152564|NCT03002090|Dietary Supplement|Placebo Untrained|No intervention
152565|NCT03002077|Drug|Rapastinel|Rapastinel pre-filled syringes for IV injections.
152680|NCT03001219|Drug|RO7123520|Participants will receive intravenous infusion of RO7123520.
152567|NCT03002064|Drug|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
152568|NCT03002064|Drug|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
152569|NCT03002051|Device|EUS-guided drainage|"Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.~EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.~After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).~After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.~After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
152570|NCT03002038|Drug|Azathioprine|Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
152571|NCT03002038|Drug|Rituximab|Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
152572|NCT03002025|Drug|JNJ-64304500|Participants will receive JNJ-64304500 as SC injection.
152573|NCT03002025|Drug|Placebo|Participants will receive matching placebo to JNJ-64304500 as SC injection.
152574|NCT03002012|Drug|Sertraline|sertraline 400mg/day
152575|NCT03002012|Drug|Placebo Oral Tablet|matched placebo tablet
152576|NCT03002012|Drug|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
152577|NCT03001999|Behavioral|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:~Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
152578|NCT03001986|Biological|inactivated EV71 vaccine (KMB-17 cells)|Receiving 2 doses of the EV71 inactivated vaccine at an interval of 1 month.
152579|NCT03001973|Other|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
152580|NCT03001960|Drug|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
152581|NCT03001960|Drug|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
152582|NCT03001947|Other|No intervention|Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
152583|NCT03001934|Other|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
152584|NCT03001921|Other|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
152585|NCT03001908|Other|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
152586|NCT03001908|Other|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
152587|NCT03001895|Drug|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
152588|NCT03001882|Biological|Nivolumab|Specified dose on specified days
152589|NCT03001882|Biological|Ipilimumab|Specified dose on specified days
152590|NCT03001869|Drug|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
152591|NCT03001856|Procedure|Oblique Intradermal Suture|
152592|NCT03001856|Procedure|Intradermal Suture|
152593|NCT03001843|Drug|Ketamine|Anesthesia of only Ketamine
152594|NCT03001843|Drug|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
152595|NCT03001843|Behavioral|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
152596|NCT03001830|Biological|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
152597|NCT03001817|Drug|K-877|
152598|NCT03001817|Drug|Fenofibrate|
152599|NCT03001817|Drug|Placebo (for K-877)|
152600|NCT03001817|Drug|Placebo (for Fenofibrate)|
152601|NCT03001791|Procedure|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
152602|NCT03001791|Procedure|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
152603|NCT03001791|Procedure|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
152604|NCT03001778|Other|Usability Testing|"Usability testing of ready made workouts in a group format."
152605|NCT03001765|Other|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
152606|NCT03001752|Device|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
152607|NCT03001752|Device|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
152608|NCT03001752|Device|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
152609|NCT03001739|Drug|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
152610|NCT03001726|Procedure|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
152611|NCT03001726|Drug|oxaliplatin|oxaliplatin 100 mg/m2
152612|NCT03001726|Drug|S1|S1 40mg/m2
152613|NCT03001726|Drug|Docetaxel|docetaxel 40 mg/m2
152614|NCT03001713|Behavioral|CV WIZARD|"This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations."
152615|NCT03001700|Device|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
152616|NCT03001687|Dietary Supplement|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
152617|NCT03001687|Other|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
152618|NCT03001674|Device|Conductance catheterization|CD Leycom Conductance Catheter
152619|NCT03001661|Device|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
152620|NCT03001661|Drug|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
152621|NCT03001648|Procedure|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
152622|NCT03001635|Drug|Oxytocin|26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
152623|NCT03001635|Drug|Placebos|26 patients will receive 0.9% normal saline infusion for 6h as placebo
152624|NCT03001622|Biological|IFX-1|chimeric, monoclonal antibody
152625|NCT03001609|Drug|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi[14C]
152626|NCT03001596|Procedure|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
152627|NCT03001596|Procedure|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
152628|NCT03001596|Procedure|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
152629|NCT03001583|Behavioral|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
152630|NCT03001583|Behavioral|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
152631|NCT03001570|Drug|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
152632|NCT03001557|Drug|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
152633|NCT03001557|Drug|Lemborexant 5 mg|Lemborexant 5 mg tablets
152634|NCT03001557|Drug|Lemborexant 10 mg|Lemborexant 10 mg tablets
152635|NCT03001557|Drug|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
152636|NCT03001557|Drug|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
152637|NCT03001544|Biological|TS23|comparison of different doses
152638|NCT03001531|Device|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
152639|NCT03001531|Device|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
152640|NCT03001479|Dietary Supplement|Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid|HMF with additional hydrolyzed protein
152641|NCT03001466|Drug|urea-loaded nanoparticles eye drops|one drop five times a day for 8 weeks
152642|NCT03001466|Drug|Balance Salt Solution eye drops|one drop five times a day for 8 weeks
152643|NCT03001453|Drug|Liposomal Bupivacaine|266mg liposomal bupivacaine
152644|NCT03001453|Drug|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
152645|NCT03001453|Drug|Saline|Normal saline
152756|NCT03000595|Drug|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
152646|NCT03001440|Other|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
152647|NCT03001427|Behavioral|Structured center-based lifestyle intervention|
152648|NCT03001427|Behavioral|Standard education and physician advice|
152649|NCT03001414|Biological|Placebo followed by Autologous EPCs transfected with human eNOS|4 doses of placebo in first 6 months followed by 4 doses of autologous EPCs transfected with eNOS in second 6 months
152650|NCT03001414|Biological|Autologous EPCs transfected with human eNOS followed by Placebo|4 doses of autologous EPCs transfected with eNOS in first 6 months followed by 4 doses of placebo in second 6 months
152651|NCT03001414|Biological|Autologous EPCs transfected with human eNOS|4 doses of autologous EPCs transfected with eNOS in first 6 months which is repeated in second 6 months
152652|NCT03001401|Other|iDesign|One group will under go standard LASIK using iDesign platform (J&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
152653|NCT03001401|Other|SMILE|The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
152654|NCT03001388|Procedure|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
152655|NCT03001375|Procedure|Laparoscopic high anterior resection splenic flexure mobilization|
152656|NCT03001375|Procedure|Laparoscopic high anterior resection without splenic flexure mobilization|
152657|NCT03001362|Radiation|Radical external beam radiotherapy|pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy.
152658|NCT03001349|Procedure|Computed Tomography|Undergo PET/CT
152659|NCT03001349|Drug|Gallium Ga 68-Edotreotide|Given IV
152660|NCT03001349|Procedure|Positron Emission Tomography|Undergo PET/CT
152661|NCT03001336|Other|no intervention|This is a cross-sectional study
152662|NCT03001323|Drug|Degludec|"Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
152663|NCT03001323|Drug|Standard long-acting|"Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
152664|NCT03001310|Biological|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
152665|NCT03001297|Biological|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
152666|NCT03001297|Biological|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
152667|NCT03001297|Biological|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
152668|NCT03001297|Biological|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
152669|NCT03001297|Biological|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
152670|NCT03001284|Other|NO intervention|
152671|NCT03001271|Drug|Angiotensin 1-7|
152672|NCT03001271|Other|Placebo|
152673|NCT03001258|Other|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
152674|NCT03001245|Behavioral|Interpersonal Counseling|Interpersonal Counseling 1+6 sessions
152675|NCT03001245|Behavioral|Standard treatment|Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
152676|NCT03001232|Behavioral|Movement-oriented Dementia Care|The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
152677|NCT03001219|Drug|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
152678|NCT03001219|Drug|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
152679|NCT03001219|Drug|Placebo|Participants will receive intravenous infusion of placebo.
152681|NCT03001206|Device|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.~The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.~The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
152682|NCT03001193|Drug|DF 01|
152683|NCT03001193|Drug|Oxytocin|
152684|NCT03001193|Drug|Placebo|
152685|NCT03001154|Behavioral|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
152686|NCT03001154|Behavioral|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
152687|NCT03001154|Other|Waiting-list|Weekly assessments of public speaking
152688|NCT03001141|Other|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
152689|NCT03001128|Drug|Antiretroviral treatment pause|Antiretroviral treatment pause
152690|NCT03001102|Device|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
152691|NCT03001102|Device|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
152692|NCT03001102|Device|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
152693|NCT03001089|Drug|Oral Fludrocortisone (enteral)|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
152694|NCT03001089|Drug|Placebo Oral Tablet|oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
152695|NCT03001076|Drug|Bempedoic acid|bempedoic acid 180 mg tablet
152696|NCT03001076|Drug|Ezetimibe|ezetimibe 10 mg tablet
152697|NCT03001076|Other|Placebo|matching placebo tablet
152698|NCT03001063|Other|Supported Self-Management|This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
152699|NCT03001063|Other|Enhanced treatment as usual|Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
152700|NCT03001050|Device|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
152701|NCT03001024|Behavioral|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
152702|NCT03001024|Behavioral|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
152703|NCT03001011|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
152704|NCT03001011|Drug|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet~Route of administration: oral"
152705|NCT03000998|Behavioral|Web App Intervention Group|All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
152706|NCT03000998|Behavioral|Usual Customary Care Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
152707|NCT03000985|Behavioral|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
152708|NCT03000972|Procedure|Cement augmentation|
152709|NCT03000972|Procedure|PFN-A Nail|
152710|NCT03000946|Drug|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
152711|NCT03000946|Drug|Octreotide|Solution for Subcutaneous use 100μg, every 8 hours Subcutaneous injection for 6,5 days
152712|NCT03000920|Other|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
152713|NCT03000920|Other|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
152714|NCT03000907|Other|Intervention|Diet and physical exercises
152715|NCT03000894|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
152716|NCT03000881|Other|standard adhesive|This is a standard adhesive (hydrocolloid)
152717|NCT03000881|Other|New adhesive strip|This is a newly developed adhesive strip
152718|NCT03000868|Procedure|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
152719|NCT03000868|Procedure|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
152757|NCT03000595|Drug|Placebo|The vehicle cream
152758|NCT03000582|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
152720|NCT03000855|Procedure|EUS-guided choledocho-duodenostomy|"The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation."
152721|NCT03000855|Procedure|Endoscopic retrograde cholangiopancreatography with covered metallic stent|After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
152722|NCT03000842|Device|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
152723|NCT03000842|Device|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
152724|NCT03000829|Other|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
152725|NCT03000829|Other|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
152726|NCT03000816|Radiation|SBRT|Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
152727|NCT03000803|Behavioral|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
152728|NCT03000803|Behavioral|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
152729|NCT03000790|Device|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.~The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
152730|NCT03000777|Dietary Supplement|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
152731|NCT03000777|Other|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
152732|NCT03000764|Other|skin biopsies|"Biopsies (12 G) will be performed :~in non-irradiated breast skin~in irradiated breast skin"
152733|NCT03000764|Other|blood samples|"blood samples are collected:~10 ml in EDTA tube~2,5 ml in PAXgene Blood RNA tube~4 ml in EDTA tube"
152734|NCT03000751|Other|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
152735|NCT03000751|Other|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
152736|NCT03000751|Other|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
152737|NCT03000725|Behavioral|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.~Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
152738|NCT03000725|Behavioral|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
152739|NCT03000712|Biological|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml drug: saline solution
152740|NCT03000699|Behavioral|Cognitive Bias Modification|Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
152741|NCT03000686|Biological|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
152742|NCT03000686|Other|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
152743|NCT03000673|Drug|Enoxaparin|Specified dose of Enoxaparin on specified days
152744|NCT03000673|Drug|unfractionated heparin (UFH)|Specified dose of UFH on specified days
152745|NCT03000673|Drug|BMS-986177|Specified dose of BMS-986177 on specified day
152746|NCT03000660|Drug|Venetoclax|Venetoclax at one of four escalating doses
152747|NCT03000660|Drug|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
152748|NCT03000647|Procedure|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
152749|NCT03000647|Procedure|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
152750|NCT03000634|Drug|Elotuzumab|Administered through a small tube that goes directly into the vein
152751|NCT03000634|Drug|Bortezomib|Administered as a subcutaneous injection under the skin
152752|NCT03000634|Drug|Lenalidomide|Capsule taken by mouth
152753|NCT03000634|Drug|Dexamethasone|Taken by mouth
152754|NCT03000608|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
152755|NCT03000608|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
152759|NCT03000582|Dietary Supplement|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
152760|NCT03000582|Dietary Supplement|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
152761|NCT03000582|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
152762|NCT03000569|Drug|SAGE-217|
152763|NCT03000556|Drug|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
152764|NCT03000543|Biological|Vaccine|Pentavalent vaccine. It is a combination of five different antigens (Hepatitis B (HBV)/ Haemophilus influenzae type b (HiB) / Tetanus-Diphtheria-whole cell Pertussis (TDwP)).
152765|NCT03000530|Drug|SAGE-217|
152766|NCT03000530|Drug|Placebo|
152767|NCT03000504|Device|Ballooned intercostal drain|Patients will have a Rocket Medical 16F ballooned intercostal drain inserted as per usual clinical guidelines. No other change to treatment will be made, and the drain is inserted in exactly the same way as a standard drain, using the Seldinger technique.
152768|NCT03000491|Other|No intervention|
152769|NCT03000478|Behavioral|Prolonged Exposure|
152770|NCT03000478|Behavioral|Virtual Reality Exposure Therapy|
152771|NCT03000465|Procedure|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
152772|NCT03000452|Drug|DARATUMUMAB|DARATUMUMAB
152773|NCT03000452|Drug|DURVALUMAB|DURVALUMAB
152774|NCT03000439|Drug|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
152775|NCT03000439|Drug|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
152776|NCT03000426|Procedure|Free gingival graft|Free gingival graft removal from palate for socket preservation
152777|NCT03000426|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
152778|NCT03000413|Drug|Ketamine|Active treatment
152779|NCT03000413|Drug|Fentanyl|
152780|NCT03000400|Behavioral|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
152781|NCT03000400|Behavioral|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
152782|NCT03000387|Drug|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
152783|NCT03000387|Drug|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
152784|NCT03000374|Drug|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
152785|NCT03000374|Drug|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
152786|NCT03000374|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
152787|NCT03000374|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
152788|NCT03000361|Procedure|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
152789|NCT03000348|Drug|Cysteamine|Oral Cysteamine Capsule
152790|NCT03000348|Drug|Placebo Oral Capsule|Placebo Oral Capsule
152791|NCT03000322|Device|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
152792|NCT03000309|Drug|Apremilast|
152793|NCT03000296|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
152794|NCT03000283|Drug|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.~The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
152795|NCT03000270|Device|Impella unloading prior to PPCI|Impella unloading prior to PPCI
152796|NCT03000257|Drug|Venetoclax|Tablet taken orally
152797|NCT03000257|Drug|Rovalpituzumab Tesirine|Intravenous infusion
152798|NCT03000257|Drug|ABBV-181|Intravenous infusion
152799|NCT03000218|Drug|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
152800|NCT03000218|Drug|Metformin|Day 29 to 56: Metformin 500mg bid
152801|NCT03000218|Drug|Placebo|Day 1 to 56: Placebo bid
152802|NCT03000205|Device|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain at Week0
152803|NCT03000205|Device|Normal saline and Lidocaine.|Normal Saline injection for chronic shoulder pain at Week0 (Arms:Placebo Comparator: Placebo)
152804|NCT03000179|Drug|Avelumab|Avelumab through a vein once every 2 weeks
152805|NCT03000166|Behavioral|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
152806|NCT03000153|Other|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
152807|NCT03000140|Behavioral|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
152839|NCT02999893|Drug|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
152808|NCT03000140|Behavioral|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
152809|NCT03000127|Drug|AndroGel 1 % Topical Gel|testosterone gel
152810|NCT03000127|Drug|Placebos|Placebo gel
152811|NCT03000114|Procedure|Percutaneous Needle Aponeurotomy|
152812|NCT03000114|Drug|XIAFLEX|
152813|NCT03000101|Other|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
152814|NCT03000101|Other|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
152815|NCT03000088|Device|intubate with 60° angled stylet|
152816|NCT03000088|Device|intubate with 60° angled stylet|
152817|NCT03000075|Drug|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
152818|NCT03000075|Drug|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
152819|NCT03000062|Behavioral|Intervention group|Please see the preceding section
152820|NCT03000049|Other|bedside blood culture|
152821|NCT03000036|Drug|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
152822|NCT03000036|Device|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
152823|NCT03000036|Drug|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
152824|NCT03000010|Device|Incisional Wound Vac|
152825|NCT03000010|Other|Standard Bandage|
152826|NCT02999997|Behavioral|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
152827|NCT02999984|Genetic|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells|Infusion of OTL-101 after reduced intensity conditioning
152828|NCT02999971|Other|circuit class therapy in water|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
152829|NCT02999971|Other|circuit class therapy on land|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
152830|NCT02999958|Biological|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
152831|NCT02999945|Dietary Supplement|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
152832|NCT02999945|Dietary Supplement|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
152833|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
152834|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
152835|NCT02999932|Other|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
152836|NCT02999919|Procedure|spinal anesthesia|12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
152837|NCT02999906|Drug|Oral Treprostinil|Sustained release oral tablets for three times daily administration
152838|NCT02999906|Drug|Placebo|Placebo (sugar pill) for three times daily oral administration
251773|NCT02277093|Drug|Pacritinib|
152840|NCT02999880|Procedure|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
152841|NCT02999867|Dietary Supplement|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
152842|NCT02999867|Dietary Supplement|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
152843|NCT02999854|Biological|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
152844|NCT02999854|Drug|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
152845|NCT02999854|Procedure|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
152846|NCT02999854|Procedure|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a total body irradiation (TBI) or non-TBI conditioning regimen
152847|NCT02999841|Drug|Acarbose|1-2 week: 50mg tid; 3-24 week: 100mg tid.
152848|NCT02999841|Drug|Vildagliptin|1-24 week: 50mg bid
152849|NCT02999828|Biological|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
152850|NCT02999815|Procedure|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
152851|NCT02999815|Procedure|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
152852|NCT02999802|Behavioral|Exercise|Progressive resistance exercise training
152853|NCT02999789|Device|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
152854|NCT02999789|Device|SmartInhaler|The SmartInhaler is a medication monitoring system manufactored by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
152855|NCT02999776|Device|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
152856|NCT02999776|Drug|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
152857|NCT02999776|Drug|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
152858|NCT02999763|Device|SlimShape|SlimShape radiofrequency treatment to the abdomen
152859|NCT02999750|Other|individual therapy|Patient will be treated with individual therapy.
152860|NCT02999737|Biological|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
152861|NCT02999737|Biological|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
152862|NCT02999724|Drug|Gabapentin|Gabapentin 300-600 mg 1 hour preop
152863|NCT02999724|Other|placebo|placebo capsule(s) 1 hour preop
152864|NCT02999711|Drug|REGN3500|REGN3500 dose
152865|NCT02999711|Drug|Placebo|Matching placebo
152866|NCT02999698|Other|Observational|Observational
152867|NCT02999685|Behavioral|Home-base Pulmonary Rehab with Health Coaching|
152868|NCT02999672|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
152869|NCT02999659|Device|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
152870|NCT02999646|Other|MVX-ONCO-1|Autologous cells: 1 vial containing 4x106 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x105 MVX-1 cells
152871|NCT02999633|Drug|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
152872|NCT02999633|Drug|dexamethasone|Pharmaceutical form:pills Route of administration: oral
152873|NCT02999633|Drug|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
152874|NCT02999633|Drug|acetaminophen|Pharmaceutical form:pills Route of administration: oral
152875|NCT02999633|Drug|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
152876|NCT02999633|Drug|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
152877|NCT02999620|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
152878|NCT02999620|Dietary Supplement|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
152879|NCT02999607|Other|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
152880|NCT02999594|Drug|Tramadol Hydrochloride|50mg intramuscularly
152881|NCT02999594|Drug|Distilled Water|2ml intramuscularly
152882|NCT02999581|Dietary Supplement|C4 Extreme, C4 Extreme (without Advantra Z)|
152883|NCT02999568|Other|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
152884|NCT02999555|Procedure|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
152885|NCT02999542|Other|Music|Children will be randomised to receive either music via headphones or silence via headphones
152886|NCT02999542|Other|No music|Children will be randomised to receive either music via headphones or silence via headphones
152887|NCT02999529|Other|Educational Video|Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
152888|NCT02999516|Other|Motor imaginary|Participants imagine doing a motor task watching a video recording
152889|NCT02999516|Other|Non Motor imaginary|Participants watch a television documentary
152890|NCT02999516|Other|tDCS|transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
152891|NCT02999516|Other|tDCS sham|tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
152892|NCT02999516|Other|Neurofeedback|EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
152893|NCT02999516|Other|Neurofeedback sham|EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
152894|NCT02999503|Behavioral|Nutritional education|Nutritional education trough a personal online nutritional consultant
152895|NCT02999490|Radiation|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
152896|NCT02999477|Drug|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
152897|NCT02999477|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
152898|NCT02999477|Procedure|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
152899|NCT02999464|Other|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
152900|NCT02999464|Other|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
152901|NCT02999451|Device|snare-assisted POEM|POEM was performed by using snare in place of common knives
152902|NCT02999451|Device|knife-assisted POEM|POEM was performed by using common knives
152903|NCT02999438|Device|Actigraph to check activity levels at home|
152904|NCT02999425|Other|Education|Educational intervention
152905|NCT02999412|Procedure|Comprehensive medication review|"A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.~The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature [4]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.~Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
152906|NCT02999412|Procedure|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:~In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.~A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.~A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
152907|NCT02999412|Procedure|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
152908|NCT02999399|Other|Brussel Sprouts|Subjects are given ~150 g of Brussels sprouts once daily for 7 consecutive days.
152909|NCT02999399|Drug|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene [D10]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
152910|NCT02999373|Other|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
252739|NCT02269813|Other|MammaPrint|
152912|NCT02999360|Behavioral|Language therapy|There will be three blocks of treatment, ideally three times a week 100 minutes per day. Treatment will target impairment-directed speech language therapy (SLT) approaches or compensatory-directed SLT in each of the three treatment blocks. Half of the participants will receive the impairment-directed SLT. Half of the participants, will receive treatment that will target compensatory-directed speech language therapy approaches that are focused on functional communication skills in the conversational context. Methods of treatment will include PACE (Promoting Aphasics Communicative Effectiveness (Davis, 2005), conversational coaching (Hopper et al., 2002), and supported conversation (Kagan et al., 2001). The clinician will model and encourage all (verbal and non verbal) modalities of communication.
152913|NCT02999360|Behavioral|Background Music|30 minutes background music only
152914|NCT02999360|Behavioral|Aerobic Exercise|There will be three blocks of treatment and the AE will take place for all participants during one or two treatment blocks (randomly assigned), threetimes a week (sessions are three times a week prior to speech therapy but may be one or two times a week if a session is missed or may be up to four or five times a week if one or two sessions are missed and rescheduled due to weather or other circumstances).
152915|NCT02999334|Behavioral|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
152916|NCT02999321|Other|aspartame|will be given 5mg aspartame or 15 mg aspartame
152917|NCT02999321|Other|water|control group
152918|NCT02999308|Other|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
152919|NCT02999295|Biological|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
152920|NCT02999295|Biological|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
152921|NCT02999282|Device|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
152922|NCT02999282|Device|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
152923|NCT02999269|Device|MECTA Spectrum 5000Q Amplitude|Current
152924|NCT02999256|Dietary Supplement|Montmorency Tart Cherry Juice|
152925|NCT02999256|Other|Placebo|
152926|NCT02999243|Behavioral|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
152927|NCT02999243|Behavioral|Harm reduction education|Both arms will receive harm reduction education
152928|NCT02999230|Other|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
152929|NCT02999230|Other|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
152930|NCT02999230|Other|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
152931|NCT02999230|Other|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
152932|NCT02999217|Drug|Iron isomaltoside|"Intravenous injection 1 g given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
152933|NCT02999217|Drug|Saline|"Intravenous injection given postoperatively in the recovery ward.~Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.~Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.~Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
152934|NCT02999204|Drug|Vitamin D3|Two different doses of Vitamin D3
152935|NCT02999191|Drug|BI 1467335 (Treatment A)|
152936|NCT02999191|Drug|BI 1467335 (Treatment B)|
152937|NCT02999191|Drug|BI 1467335 (Treatment C)|
152938|NCT02999178|Drug|Nintedanib|
152939|NCT02999178|Drug|Placebo|
152940|NCT02999165|Other|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
152941|NCT02999165|Other|Nasogastric feeding|The control intervention is feeding via nasogastric tube
152942|NCT02999152|Other|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.~Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
152943|NCT02999126|Drug|Propofol|Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
152944|NCT02999126|Drug|Remifentanil Hydrochloride|Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
152945|NCT02999100|Drug|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
152946|NCT02999100|Drug|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
153038|NCT02998489|Other|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
252740|NCT02269813|Other|BluePrint|
152947|NCT02999100|Drug|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
152948|NCT02999100|Device|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
152949|NCT02999087|Drug|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
152950|NCT02999087|Drug|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
152951|NCT02999087|Drug|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
152952|NCT02999087|Radiation|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
152953|NCT02999074|Other|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
152954|NCT02999074|Other|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
152955|NCT02999074|Other|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
152956|NCT02999048|Drug|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
152957|NCT02999022|Drug|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
152958|NCT02999022|Drug|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
152959|NCT02999009|Device|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
152960|NCT02998996|Biological|15 µg HA/strain and 1% Endocine™|intranasal administration
152961|NCT02998996|Biological|15 µg HA/strain and 2% Endocine™|intranasal administration
152962|NCT02998996|Biological|15 µg HA/strain|intranasal administration
152963|NCT02998996|Biological|intramuscular comparator|intramuscular administration
152964|NCT02998996|Biological|intranasal comparator|intranasal administration
152965|NCT02998996|Biological|Placebo, Saline|intranasal administration
152966|NCT02998983|Drug|Racotumomab|
152967|NCT02998970|Drug|Empagliflozin|single oral tablet once daily.
152968|NCT02998970|Drug|Placebo|single oral tablet once daily.
152969|NCT02998957|Device|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
152970|NCT02998957|Device|Sham AcuTENS|Portable TENS electrostimulation device with no electrical output
152971|NCT02998931|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
152972|NCT02998931|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
152973|NCT02998918|Dietary Supplement|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
152974|NCT02998918|Dietary Supplement|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
152975|NCT02998905|Drug|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
152976|NCT02998905|Drug|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
152977|NCT02998892|Behavioral|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
152978|NCT02998892|Behavioral|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
152979|NCT02998879|Drug|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
152980|NCT02998866|Procedure|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI [means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
153039|NCT02998476|Drug|Parsaclisib|Parsaclisib once daily for 8 weeks followed by once weekly
153040|NCT02998463|Device|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
152981|NCT02998853|Other|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
152982|NCT02998840|Biological|B244|odorless suspension
152983|NCT02998840|Biological|Vehicle|odorless suspension
152984|NCT02998827|Drug|Thalidomide|
152985|NCT02998827|Drug|infliximab, azathioprine|other treatment include infliximab, azathioprine
152986|NCT02998827|Other|enteral nutrition|
152987|NCT02998814|Other|acid-etch|acid-etch
152988|NCT02998814|Other|self-etch adhesive|Self etch (7th generation ) bonding agent
152989|NCT02998814|Other|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
152990|NCT02998814|Other|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
152991|NCT02998801|Other|IPAD|Patients undergoing surgery will watch the video using an PAD
152992|NCT02998801|Other|VR Goggles|Patients undergoing surgery will watch the video using goggles
152993|NCT02998775|Drug|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
152994|NCT02998736|Drug|Cialis|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.~Influenza vaccine 0.5mL day of surgery"
152995|NCT02998736|Biological|Influenza vaccine|One 0.5mL intramuscular injection the day of surgery
152996|NCT02998723|Other|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
152997|NCT02998723|Other|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
152998|NCT02998697|Drug|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
152999|NCT02998697|Drug|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
153000|NCT02998684|Device|Active Transcranial Direct Current Stimulation|
153001|NCT02998684|Device|Sham Transcranial Direct Current Stimulation|
153002|NCT02998684|Behavioral|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
153003|NCT02998671|Biological|CJM112|
153004|NCT02998671|Other|Placebo|
153005|NCT02998658|Device|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
153006|NCT02998658|Device|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
153007|NCT02998645|Drug|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily. Dosing is done according to age and ethnicity (East Asian)
153008|NCT02998645|Drug|Cyclosporine|Supplied in oral soft gel capsules or oral solution and dosage is based on body weight and administered every 12 hours. Dosing is titrated individually according to therapeutic trough level for 6 months.
153009|NCT02998632|Procedure|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
153010|NCT02998632|Procedure|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
153011|NCT02998619|Radiation|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
153012|NCT02998606|Drug|Naloxegol|MOVANTIK™ 25 mg, daily
153013|NCT02998606|Drug|Placebo Oral Capsule|Placebo 25 mg, daily
153014|NCT02998593|Drug|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
153015|NCT02998593|Drug|Placebo|Oral use of placebo capsules by patients for 3 months.
153016|NCT02998580|Device|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
153017|NCT02998580|Device|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
153018|NCT02998567|Drug|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
153019|NCT02998567|Drug|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
153020|NCT02998554|Drug|SHP640|Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
153021|NCT02998554|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
153022|NCT02998541|Drug|SHP640|Participants will receive one drop of SHP640 (0.1 % dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
153023|NCT02998541|Drug|PVP-I 0.6%|Participants will receive one drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
153024|NCT02998541|Other|Placebo|Participants will receive one drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
153025|NCT02998528|Biological|Nivolumab|
153026|NCT02998528|Drug|Cisplatin|
153027|NCT02998528|Drug|Vinorelbine|
153028|NCT02998528|Drug|Gemcitabine|
153029|NCT02998528|Drug|Docetaxel|
153030|NCT02998528|Drug|Pemetrexed|
153031|NCT02998528|Drug|Carboplatin|
153032|NCT02998528|Drug|Paclitaxel|
153033|NCT02998528|Biological|Ipilimumab|This arm is closed and no longer enrolling patients.
153034|NCT02998515|Device|Companion (Liquid oxygen device)|
153035|NCT02998515|Device|Activox (concentrator)|
153036|NCT02998502|Device|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
153037|NCT02998489|Other|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
156346|NCT02973958|Drug|Sevoflurane|See active comparator description
153042|NCT02998450|Drug|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
153043|NCT02998437|Drug|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
153044|NCT02998437|Drug|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
153045|NCT02998437|Drug|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
153046|NCT02998424|Drug|Propofol|Continuous infusion
153047|NCT02998424|Device|Pupillary diameter measurement|Instantaneous measure
153048|NCT02998411|Other|Titration|
153049|NCT02998398|Other|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
153050|NCT02998385|Drug|Cisplatin|intravenous, concomitant to irradiation
153051|NCT02998385|Radiation|radiotherapy|
153052|NCT02998372|Procedure|patellar stabilization|surgery to either alter soft tissues around the patella or reorient the patellar tendon to restore patellar stability
153053|NCT02998359|Device|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
153054|NCT02998359|Device|Total hip arthroplasty|A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
153055|NCT02998333|Procedure|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
153056|NCT02998320|Drug|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
153057|NCT02998307|Procedure|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
153058|NCT02998294|Device|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
153059|NCT02998294|Device|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
153060|NCT02998281|Device|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
153061|NCT02998268|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
153062|NCT02998268|Drug|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
153063|NCT02998268|Drug|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
153064|NCT02998255|Drug|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
153065|NCT02998255|Drug|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
153066|NCT02998242|Drug|Apatinib|
153067|NCT02998242|Radiation|SBRT to symptomatic bony metastatic bony site(s)|
153068|NCT02998229|Device|Artisse™|Intrasaccular Device
153069|NCT02998216|Procedure|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
153070|NCT02998203|Dietary Supplement|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
153071|NCT02998190|Drug|Single Ascending Doses of EB8018|
153072|NCT02998190|Drug|Single Ascending Doses of placebo|
153073|NCT02998190|Drug|Multiple Ascending Doses of EB8018|
153074|NCT02998190|Drug|Multiple Ascending Doses of placebo|
153075|NCT02998164|Behavioral|augmentative and alternative communication technology|
153076|NCT02998164|Behavioral|Usual Care|No change to the therapy care received
153077|NCT02998151|Drug|Acamprosate|two 666 pills
153078|NCT02998151|Drug|Lovastatin|two 20mg pills
153079|NCT02998151|Drug|Minocycline|two 135mg pills
153080|NCT02998151|Drug|Placebo|
153081|NCT02998125|Procedure|Total knee arthroplasty|prospective assessments for the functional outcome before and after the total knee arthroplasty
153082|NCT02998112|Drug|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
153083|NCT02998112|Drug|Saline|
153084|NCT02998099|Drug|Rivipansel|A single dose of IV rivipansel over 20 minutes.
153085|NCT02998086|Behavioral|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
153086|NCT02998073|Behavioral|Stop, Now and Plan|SNAP program was developed to target justice-involved youth (6 years and older) who have problems with aggression, CD, and/or gang affiliation. SNAP focuses on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP treatment is delivered over a 13-week period.
153087|NCT02998060|Procedure|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
156347|NCT02973958|Drug|Acetaminophen|See active comparator description
153088|NCT02998060|Device|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
153089|NCT02998060|Device|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
153090|NCT02998047|Drug|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of multiple myeloma.
153091|NCT02998034|Device|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
153092|NCT02998034|Device|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
153093|NCT02998021|Device|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
153094|NCT02998021|Device|Standard Dumbbell|"Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks.~The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.~To obtain as much data as possible on resistance training with vibration within study timeline, a modification was recently approved by the IRB to cease enrolling subjects into standard dumbbell training."
153095|NCT02998008|Behavioral|high intensity interval training|
153096|NCT02997995|Drug|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
153097|NCT02997995|Drug|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
153098|NCT02997995|Procedure|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
153099|NCT02997982|Drug|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
153100|NCT02997969|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
153101|NCT02997969|Biological|Protein/MF59 vaccine|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
153102|NCT02997969|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
153103|NCT02997956|Drug|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
153104|NCT02997956|Procedure|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
153105|NCT02997943|Behavioral|Step 1 Treatment: APP|Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
153106|NCT02997943|Behavioral|Step 1 Treatment: APP + Coaching|Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
153107|NCT02997943|Behavioral|Step 2 Treatment Strategy: Modest Step-up|In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
153108|NCT02997943|Behavioral|Step 2 Treatment Strategy: Vigorous Step-up|In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
153109|NCT02997930|Behavioral|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
153110|NCT02997930|Behavioral|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
153111|NCT02997930|Behavioral|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
153112|NCT02997930|Behavioral|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
153113|NCT02997930|Behavioral|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
153114|NCT02997930|Behavioral|General Depression Scale (GDS)|A measure of the of presence of depression.
153115|NCT02997917|Behavioral|Education|
153116|NCT02997917|Behavioral|Sham|
153117|NCT02997904|Device|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
153118|NCT02997891|Diagnostic Test|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
153119|NCT02997891|Diagnostic Test|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
153120|NCT02997878|Biological|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human ubmical cord
153121|NCT02997865|Behavioral|Stepped care for depression|Cognitive behavior therapy (CBT), plus referral to the participant's own physician to discuss antidepressant medications if indicated.
153122|NCT02997852|Behavioral|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
153123|NCT02997839|Behavioral|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.~Group two will be woken every 2 hours, which is the standard NCCU protocol."
153124|NCT02997826|Other|Infantil formula|
153125|NCT02997800|Drug|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP >20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
153126|NCT02997800|Drug|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
153127|NCT02997800|Drug|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
153128|NCT02997800|Other|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
153129|NCT02997800|Other|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
153130|NCT02997774|Other|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
153131|NCT02997774|Other|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
153132|NCT02997761|Biological|Blinatumomab|Given IV
153133|NCT02997761|Drug|Ibrutinib|Given PO
153134|NCT02997748|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
153135|NCT02997735|Behavioral|Quitline Delivered Treatment|The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
153136|NCT02997722|Drug|Ketamine|Patients randomly allocated to the treatment group will receive a ketamine infusion over the course of 45 minutes. The dose will be 0.5 mg/kg. Patients will be monitored for 30 minutes after the completion of the infusion.
153137|NCT02997722|Drug|Normal Saline|Patients randomly allocated to the control group will receive an infusion of 100 mL of normal saline over the course of 30 minutes. Patients will be monitored for 30 minutes after the completion of the infusion.
153138|NCT02997709|Device|MRI-US fusion guided biopsy|MRI-US fusion guided biopsy (MUFgBx) of prostate for research at baseline and 2-2.5 years post-treatment for those who have been treated with radiotherapy to the prostate (as opposed to those treated post-prostatectomy).
153139|NCT02997709|Device|Multiparametric MRI|Multiparametric MRI at Baseline and various time points post-treatment per study protocol.
153140|NCT02997696|Drug|ONO-4474|
153141|NCT02997696|Drug|Placebo matching ONO-4474|
153142|NCT02997683|Device|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
153143|NCT02997683|Other|exercises at home on the floor|exercises at home on the floor
153144|NCT02997670|Other|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
153145|NCT02997657|Behavioral|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
153146|NCT02997657|Behavioral|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
153147|NCT02997657|Drug|Transdermal Patch, Nicotine|
153148|NCT02997644|Behavioral|Video Education|"The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.~The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer."
153149|NCT02997644|Behavioral|Usual Care Group|Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
153150|NCT02997631|Device|MEDi Robot|Distraction therapy using an interactive humanoid robot
153151|NCT02997618|Behavioral|Community based exercise programme|20 week community (home or gym based) exercise programme
153152|NCT02997618|Other|Control|Usual care consisting of advice.
153153|NCT02997605|Drug|GlucoCorticoid|"After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone."
153154|NCT02997592|Device|SpinCare dressing|The burn wound is dressed using the SpinCare wound dressing
153155|NCT02997579|Procedure|patellar resurfacing|patellar component insert with cement
153156|NCT02997566|Other|Autonomic evaluation|
153157|NCT02997553|Drug|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
153158|NCT02997553|Drug|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.~Lymphoscintigraphy is performed to identify the sentinel node"
153159|NCT02997553|Device|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
153160|NCT02997527|Device|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
153161|NCT02997514|Behavioral|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
153162|NCT02997514|Behavioral|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
153163|NCT02997501|Procedure|T790M+ Testing|The patient will need to have T790M+ testing
153164|NCT02997501|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
153165|NCT02997501|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
153166|NCT02997501|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
153167|NCT02997501|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
153168|NCT02997501|Procedure|Plasma AZD9291 testing|The patient will need to have plasma AZD9291 testing before treatment
153169|NCT02997488|Device|Pentax Airwayscope|intubation using Pentax Airwayscope
153170|NCT02997488|Device|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
153171|NCT02997436|Device|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.~Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.~Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
153172|NCT02997410|Device|Ozone|
153173|NCT02997410|Device|Placebo (for Ozone)|
153174|NCT02997410|Device|Dental treatment with occlusal splint|
153175|NCT02997397|Procedure|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
153176|NCT02997397|Procedure|tourniquet(-)|
153177|NCT02997384|Other|Information|information of women about their risk of breast cancer and the screening methods recommended for them
153178|NCT02997371|Drug|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
153179|NCT02997371|Drug|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
153180|NCT02997358|Drug|Doxorubicin|
153181|NCT02997358|Drug|Trabectedin|
153182|NCT02997345|Other|There is no intervention associated with this study.|There is no intervention associated with this study.
153183|NCT02997332|Drug|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
153184|NCT02997332|Drug|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
153185|NCT02997332|Drug|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
153186|NCT02997332|Drug|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
153187|NCT02997306|Procedure|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
153227|NCT02996942|Biological|Factor VIII replacement|Patients receive their usual treatment
153188|NCT02997306|Procedure|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
153189|NCT02997293|Other|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
153190|NCT02997280|Drug|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight > 40 kg, 0.08 mg/kg bid for children with body weight < 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
153191|NCT02997267|Procedure|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
153192|NCT02997241|Biological|OncoCare|Personalized monitoring
153193|NCT02997241|Drug|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
153194|NCT02997228|Drug|Atezolizumab|Given IV
153195|NCT02997228|Biological|Bevacizumab|Given IV
153196|NCT02997228|Drug|Fluorouracil|Given IV
153197|NCT02997228|Drug|Leucovorin Calcium|Given IV
153198|NCT02997228|Drug|Oxaliplatin|Given IV
153199|NCT02997228|Other|Quality-of-Life Assessment|Ancillary studies
153200|NCT02997228|Other|Questionnaire Administration|Ancillary studies
153201|NCT02997215|Drug|Lidocaine|lidocaine infusion during surgery
153202|NCT02997215|Drug|Saline Placebo|saline infusion at same rate as intervention group during surgery
153203|NCT02997202|Drug|gilteritinib|oral
153204|NCT02997202|Drug|Placebo|oral
153205|NCT02997189|Drug|OTO-104|12 mg dexamethasone administered intratympanically
153206|NCT02997176|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
153207|NCT02997163|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
153208|NCT02997150|Drug|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.~The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.~At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
153209|NCT02997137|Dietary Supplement|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
153210|NCT02997137|Other|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
153211|NCT02997124|Procedure|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
153212|NCT02997124|Procedure|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
153213|NCT02997111|Device|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
153214|NCT02997085|Device|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
153215|NCT02997085|Device|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
153216|NCT02997059|Drug|Fluconazole|200 mg/ day
153217|NCT02997059|Other|Placebo|
153218|NCT02997033|Other|No intervention|No intervention
153219|NCT02997020|Other|EDSPD|The equipment & conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
153220|NCT02997007|Device|active tDCS|Participants will receive active tDCS over the angular gyrus on five consecutive days
153221|NCT02997007|Device|sham tDCS|Participants will receive sham tDCS over the angular gyrus on five consecutive days
153222|NCT02996968|Procedure|Self-removal|Self-discontinuation of a transurethral catheter
153223|NCT02996955|Behavioral|social support|behaviour change intervention
153224|NCT02996955|Behavioral|treatment of illness perceptions|educational interview
153225|NCT02996955|Device|Activ8|wearing a move monitor
153226|NCT02996955|Other|activity advice|walking or cycling 5 days a week during at least half an hour
252741|NCT02269813|Other|TargetPrint|
153228|NCT02996929|Device|LC System|Subjects will undergo CIED lead extraction with the LC system
153229|NCT02996916|Drug|Olmesartan|10-40mg daily
153230|NCT02996916|Drug|Amlodipine|2.5-10mg daily
153231|NCT02996890|Biological|MV-ZIKA|MV-Zika vaccine
153232|NCT02996890|Other|Placebo|physiological saline
153233|NCT02996864|Other|Healthy Detours App|"The app features:~Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.~User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.~Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
153234|NCT02996864|Other|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
153235|NCT02996838|Drug|TQ-B3234|TQ-B3234 p.o. qd
153236|NCT02996825|Drug|Gemcitabine Hydrochloride|Given IV
153237|NCT02996825|Other|Laboratory Biomarker Analysis|Correlative studies
153238|NCT02996825|Biological|Mirvetuximab Soravtansine|Given IV
153239|NCT02996825|Other|Pharmacological Study|Correlative studies
153240|NCT02996812|Drug|Exendin (9-39)|
153241|NCT02996799|Other|Umbilical cord milking|Milking of the umbilical cord at delivery
153242|NCT02996786|Dietary Supplement|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
153243|NCT02996786|Other|Placebo|Consisting of corn starch and carboxymethyl cellulose
153244|NCT02996773|Drug|Bendamustine|"After transplant, on day +4, Cyclophosphamide and Bendamustine will be given intravenously~Dose level 1: 20 mg/m2 Dose Level 2: 60 mg/m2 Dose Level 3: 100 mg/m2"
153245|NCT02996773|Drug|Cyclophosphamide|"After transplant, on day +4, Cyclophosphamide and Bendamustine will be given intravenously~Dose level 1: 40 mg/kg Dose Level 2: 20 mg/kg Dose Level 3: 0 mg/kg"
153246|NCT02996760|Drug|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
153247|NCT02996747|Procedure|curettage (intralesional surgery)|comparison of two different tumors treated by curettage
153248|NCT02996734|Procedure|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
153249|NCT02996721|Biological|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
153250|NCT02996695|Drug|Artesunate|Artesunate is a succinic ester of artemether.
153251|NCT02996695|Drug|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
153252|NCT02996695|Biological|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
153253|NCT02996695|Other|Placebo|Placebo
153254|NCT02996682|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
153255|NCT02996682|Drug|RBV|Capsules administered orally in a divided daily dose
153256|NCT02996656|Drug|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
153257|NCT02996656|Drug|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
153258|NCT02996643|Device|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
153259|NCT02996630|Procedure|Sonography|Fetal Ultrasound exploration
153260|NCT02996630|Device|Magnetic Resonance Imaging|Fetal MRI for brain study
153261|NCT02996630|Other|Bailey Test|Neurodevelopment paediatric assessment test performed at 2 years of age.
153262|NCT02996630|Procedure|Surgical intervention|Congenital Heart Disease repair
153263|NCT02996630|Procedure|Brain monitoring|EEG and continuous brain oximetry before surgery.
153264|NCT02996630|Procedure|cord blood sample|Cord blood samples will be taken after birth in both groups.
153265|NCT02996617|Drug|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
153266|NCT02996617|Drug|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
153267|NCT02996604|Other|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
153268|NCT02996591|Procedure|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
153269|NCT02996591|Procedure|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
153270|NCT02996591|Drug|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
153271|NCT02996591|Procedure|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
153272|NCT02996591|Procedure|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
153273|NCT02996578|Dietary Supplement|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
253400|NCT02265237|Drug|ribavirin|tablets
153274|NCT02996578|Dietary Supplement|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
153275|NCT02996578|Dietary Supplement|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
153276|NCT02996578|Dietary Supplement|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
153277|NCT02996565|Other|Best Practice Clinic-Based Care|"Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:~Improved recognition of uncontrolled BP at primary care encounters,~Therapeutic action to address uncontrolled BP at primary care encounters,~Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks."
153278|NCT02996565|Other|Telehealth Care|"All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:~Referral to care by MTM pharmacist or Nurse Practitioner and receiving a home blood pressure telemonitoring device~Systematic home BP telemonitoring with data transmitted into patient medical record~Systematic home-based care by pharmacist or nurse practitioner via telephone and/or secure email"
153279|NCT02996552|Procedure|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
153280|NCT02996552|Procedure|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
153281|NCT02996539|Other|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
153282|NCT02996513|Other|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
153283|NCT02996500|Drug|PF-06650833|Investigational
153284|NCT02996500|Drug|Placebo|Placebo
153285|NCT02996500|Drug|Tofacitinib|Investigational
153286|NCT02996487|Drug|Vancomycin|
153287|NCT02996487|Other|Placebo|
153288|NCT02996474|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
153289|NCT02996474|Drug|Decitabine|Will be administered at a dose of 20 mg/m2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
153290|NCT02996461|Biological|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
153291|NCT02996448|Drug|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
153292|NCT02996435|Behavioral|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
153293|NCT02996435|Other|No Intervention|Participants will receive physician- or nurse-guided standard of care.
153294|NCT02996422|Behavioral|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
153295|NCT02996422|Behavioral|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
153296|NCT02996409|Drug|HVIGI|High Volume Image-Guided Injection with a saline/lidocain solution
153297|NCT02996409|Drug|LVIGI|Placebo control with injection of a saline/lidocain solution (low volume)
153298|NCT02996409|Other|Progressive exercise program|A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
153299|NCT02996396|Device|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
153300|NCT02996383|Device|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
153301|NCT02996383|Device|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
153302|NCT02996370|Other|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
153303|NCT02996370|Other|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
153304|NCT02996370|Other|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
153305|NCT02996370|Other|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
153306|NCT02996370|Other|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
153307|NCT02996344|Other|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
156348|NCT02973958|Drug|Ibuprofen|See active comparator description
153308|NCT02996344|Other|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
153309|NCT02996331|Other|2 hour repositioning|Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
153310|NCT02996331|Other|3 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
153311|NCT02996331|Other|4 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
153312|NCT02996318|Device|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
153313|NCT02996318|Device|Sirolimus coated balloon|Sirolimus coated balloon
153314|NCT02996305|Drug|OV101 Regimen 1|
153315|NCT02996305|Drug|OV101 regimen 2|
153316|NCT02996305|Other|Placebo|
153317|NCT02996292|Device|Traditional brackets|Treating of crowding using traditional brackets
153318|NCT02996292|Device|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
153319|NCT02996292|Device|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
153320|NCT02996266|Device|Targeted Temperature Management|Prophylactic normothermia
153321|NCT02996266|Other|Standard Care|No intervention to control temperature unless fever occurs
153322|NCT02996253|Procedure|FHL transfer|endoscopic transfer og flexor hallucis longus
153323|NCT02996240|Dietary Supplement|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
153324|NCT02996227|Procedure|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
153325|NCT02996227|Procedure|Epidural analgesia|Epidural catheters will be inserted preoperatively.
153326|NCT02996227|Drug|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
153327|NCT02996227|Drug|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
153328|NCT02996214|Drug|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m2, given on day 1 of a 21-day cycle, for 6 cycles.
153329|NCT02996214|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, given on days 1 and 8 of a 21-day cycle, for 6 cycles.
153330|NCT02996214|Drug|Cisplatin|Cisplatin 75 mg/m2, given on day 1 of a 21-day cycle, for 6 cycles.
153331|NCT02996201|Other|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
153332|NCT02996188|Procedure|routine therapeutic paracentesis|
153333|NCT02996175|Behavioral|Behavioral Sleep Treatment|"Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems~Information on healthy sleep hygiene, preventative techniques, and use of visual supports~Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking~Information on procedures for delayed sleep onset and problematic sleep associations~Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
153334|NCT02996175|Behavioral|Standard of care sleep treatment enhanced with psychoeducation|"Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome~Introduction to understanding and interpreting results from clinical evaluations~Introduction to educational planning, expectations, and transition planning~Introduction to lifespan development and advocacy and support services available~Feedback on current concerns and methods for obtaining services to manage concerns"
153335|NCT02996162|Device|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
153336|NCT02996162|Device|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
153337|NCT02996149|Procedure|Endoscopic lung volume reduction coil treatment|
153338|NCT02996136|Device|Flu Symptoms|Flu Symptoms
153339|NCT02996123|Other|cad/cam maxillary dentures|patients wearing cad/cam designed and milled dentures
153340|NCT02996110|Biological|Nivolumab|
153341|NCT02996110|Biological|Ipilimumab|
153342|NCT02996110|Biological|Relatlimab|
153343|NCT02996110|Drug|BMS-986205|
153344|NCT02996110|Drug|BMS-813160|
153377|NCT02995837|Other|Sleep Study|Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
153604|NCT02994056|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
153345|NCT02996097|Device|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
153346|NCT02996097|Drug|Intralesional Triamcinolone Acetonide|
153347|NCT02996071|Procedure|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
153348|NCT02996058|Drug|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
153349|NCT02996058|Drug|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
153350|NCT02996045|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.~This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored >4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
153351|NCT02996032|Other|Vascular and Pulmonary Ultrasound|
153352|NCT02996019|Drug|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
153353|NCT02996019|Device|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
153354|NCT02996019|Device|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
153355|NCT02996006|Procedure|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
153356|NCT02995993|Drug|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
153357|NCT02995980|Device|Dual-Energy Contrast-Enhanced (DECE) mammography|Contrast mammography
153358|NCT02995980|Device|digital mammography|routine digital mammography
153359|NCT02995967|Procedure|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
153360|NCT02995967|Drug|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
153361|NCT02995954|Drug|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
153362|NCT02995928|Procedure|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
153363|NCT02995928|Procedure|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
153364|NCT02995915|Drug|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
153365|NCT02995915|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
153366|NCT02995915|Behavioral|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
153367|NCT02995915|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
153368|NCT02995915|Behavioral|Mobile Monitoring|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings and breathalyzer. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for providing the video recordings, regardless of abstinence.
153369|NCT02995902|Device|FLT-PET|
153370|NCT02995902|Device|MRI|
153371|NCT02995889|Device|FLT-PET|
153372|NCT02995876|Procedure|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
153373|NCT02995876|Procedure|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
153374|NCT02995863|Device|Rigid Rocker Sole Footwear|
153375|NCT02995863|Device|Therapeutic Footwear|
153376|NCT02995850|Drug|CRS+HIPEC|"Ib~Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.~II~① CRS If PCI <12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.~If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI <12, CRS will be done.~② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.~③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.~④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks."
153378|NCT02995837|Other|Neurocognitive Testing|Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
153641|NCT02993731|Drug|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
153379|NCT02995837|Other|CBF During Wakefulness|Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
153380|NCT02995837|Other|CBF During Sleep|This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
153381|NCT02995824|Other|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) [lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)] [Group 1] versus other ART regimens including boosted PI or NNRTIs [Group 2] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
153382|NCT02995811|Other|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
153383|NCT02995798|Other|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
153384|NCT02995785|Other|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
153385|NCT02995785|Other|traditional training|traditional training:Give TMS online lecture(15-min).
153386|NCT02995772|Drug|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
153387|NCT02995772|Drug|Tamoxifen|Comparison of efficacy with chemotherapy
153388|NCT02995772|Procedure|SOB|Comparison of efficacy with chemotherapy
153389|NCT02995772|Drug|FAC|Comparison of efficacy with hormonal therapy
153390|NCT02995772|Drug|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
153391|NCT02995772|Drug|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
153392|NCT02995759|Other|Seizure Action Plan|The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
153393|NCT02995746|Drug|Dexamethasone|"On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant~Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant~Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan~Anticipated duration of the study: 6 months"
153394|NCT02995733|Drug|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
153395|NCT02995720|Drug|Fimasartan/Amlodipine combination drug, Rosuvastatin|
153396|NCT02995707|Drug|Thalidomide|thalidomide:50mg/d p.o at bedtime
153397|NCT02995694|Drug|Estradiol|Estradiol Vaginal Cream
153398|NCT02995694|Drug|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
153399|NCT02995694|Drug|Reference|Estrace Vaginal Cream
153400|NCT02995681|Other|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
153401|NCT02995681|Other|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
153402|NCT02995668|Other|Strength-Function|Preoperative functional and strength capabilities training.
153403|NCT02995668|Other|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
153404|NCT02995655|Drug|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
153405|NCT02995655|Drug|Azacitidine|Azacitidine at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle.
153406|NCT02995655|Procedure|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
153407|NCT02995655|Procedure|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
153408|NCT02995642|Drug|18F-FPPRGD2|One single intravenous injection.
153409|NCT02995642|Device|Positron emission tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
153410|NCT02995642|Procedure|Computed tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
153411|NCT02995642|Device|Magnetic Resonance Imaging|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
153412|NCT02995629|Procedure|laser indirect ophthalmoscopy pan retinal photocoagulation|"Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation~Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves~Target treatment of 250 spots~Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first~After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength"
153678|NCT02993471|Drug|Drug Cocktail|Administered orally
153413|NCT02995616|Device|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for a minimum of 20 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
153414|NCT02995616|Device|100% guidance force|Patients will walk in the Lokomat with 100% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
153415|NCT02995616|Device|60% guidance force|Patients will walk in the Lokomat with 60% GF for a minimum of 20 minutes (same amount of body weight support and walking speed as in the first session)
153416|NCT02995603|Device|Nano-X patient rotation|Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.
153417|NCT02995590|Drug|Hyperpolarized Helium|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
153418|NCT02995577|Other|Feeding tolerant|
153419|NCT02995577|Other|Feeding intolerant|
153420|NCT02995577|Other|Necrotizing enterocolitis|
153421|NCT02995564|Behavioral|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
153422|NCT02995551|Procedure|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
153423|NCT02995551|Behavioral|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
153424|NCT02995512|Drug|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
153425|NCT02995486|Other|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
153426|NCT02995473|Drug|NP000888|270 µg/g topical (BID) for 24 weeks
153427|NCT02995473|Drug|Vehicle|Topical (BID) for 24 weeks
153428|NCT02995460|Behavioral|interval training|4x4 high intensity interval training
153429|NCT02995447|Other|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
153430|NCT02995434|Device|Virtual Reality Headset|"The following VR experiences will be used:~Virtual Meditative Walk:http://painstudieslab.com/projects/virtual-meditative-walk/ Qualia: Zen Eagle:http://www.mobiointeractive.com/big-picture/index.html Obduction: http://obduction.com/ Carpe Lucem: http://store.steampowered.com/app/433700/Carpe_Lucem__Seize_The_Light_VR/"
153431|NCT02995434|Other|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). These will be functionally similar to the VR experiences. These will include:~Virtual Meditative Walk:http://painstudieslab.com/projects/virtual-meditative-walk/ Qualia: Zen Eagle:http://www.mobiointeractive.com/big-picture/index.html Obduction: http://obduction.com/ The Witness: http://store.steampowered.com/app/210970/"
153432|NCT02995408|Behavioral|Relaxation Response Resiliency Program for Parents of Children with ASD|
153433|NCT02995395|Device|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.~o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
153434|NCT02995382|Procedure|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
153435|NCT02995369|Device|Dryshield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
153436|NCT02995369|Other|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
153437|NCT02995356|Other|Collecting cervical liquid and sera samples|
153438|NCT02995343|Procedure|Hypogastric and/or uterine artery ligation|
153439|NCT02995330|Procedure|Bone marrow transplantation|Infused with non-T-cell depleted bone marrow from a related female donor on Day 0
153440|NCT02995330|Drug|Cytoxan|Cytoxan 50mg/kg IV on Days +3 and +4
153441|NCT02995330|Drug|testosterone cypionate|testosterone cypionate 400 mg IM will be administered on Day +60, +90, and +120 (every 30 days x 3 doses)
153442|NCT02995317|Other|Number of falls based on an one year follow-up|
153443|NCT02995304|Drug|Morphine premedication|30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
153444|NCT02995304|Drug|Midazolam premedication|All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
153445|NCT02995304|Drug|Saline premedication (placebo)|30 children in midazolam only group will receive saline after midazolam
153446|NCT02995291|Drug|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
153447|NCT02995291|Drug|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
153448|NCT02995278|Other|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
153449|NCT02995265|Other|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
153492|NCT02994992|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153450|NCT02995265|Other|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
153451|NCT02995252|Other|Blood draws|
153452|NCT02995252|Drug|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
153453|NCT02995252|Other|Knowledge Index Questionnaire|
153454|NCT02995252|Other|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
153455|NCT02995252|Procedure|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
153456|NCT02995239|Drug|CJ-12420 formulation 2|CJ-12420 formulation 2
153457|NCT02995239|Drug|CJ-12420 formulation 1|CJ-12420 formulation 1
153458|NCT02995226|Other|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
153459|NCT02995226|Other|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
153460|NCT02995213|Behavioral|Accelerometer based feedback about paretic arm use|
153461|NCT02995200|Behavioral|Accelerometer Based Feedback|
153462|NCT02995187|Drug|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
153463|NCT02995174|Device|Dichoptic video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
153464|NCT02995174|Device|Video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
153465|NCT02995161|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-106)
153466|NCT02995161|Drug|SPF control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153467|NCT02995148|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-104)
153468|NCT02995148|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153469|NCT02995135|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z43-094)"
153470|NCT02995135|Drug|SFP Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153471|NCT02995122|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z43-090)"
153472|NCT02995122|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153473|NCT02995109|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z11-004)"
153474|NCT02995109|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153475|NCT02995096|Procedure|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
153476|NCT02995096|Drug|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
153477|NCT02995083|Drug|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
153478|NCT02995083|Drug|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
153479|NCT02995083|Drug|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
153480|NCT02995070|Procedure|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
153481|NCT02995070|Device|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
153482|NCT02995070|Device|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
153483|NCT02995057|Device|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
153484|NCT02995044|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-180)
153485|NCT02995044|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153486|NCT02995031|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-177)
153487|NCT02995031|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153488|NCT02995018|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-174)
153489|NCT02995018|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
153490|NCT02995005|Drug|Tenofovir Disoproxil Fumarate|300 mg daily
153491|NCT02994992|Drug|BAY 987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-100)
153679|NCT02993471|Drug|Ixekizumab|Administered SC
153493|NCT02994979|Other|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
153494|NCT02994979|Other|Sham comparator|Usual care plus sham visits by CNA
153495|NCT02994966|Device|Surrosense|
153496|NCT02994966|Other|Standard care|
153497|NCT02994953|Drug|Avelumab|Subjects will receive avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
153498|NCT02994953|Drug|M9241|Subjects will receive Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.
153499|NCT02994953|Drug|Avelumab (Once weekly)|Subjects will receive avelumab once weekly in combination with M9241 every 4 weeks at M9241 maximum tolerated dose (MTD) for first 12 weeks followed by avelumab once every 2 weeks plus M9241 once every 4 weeks at M9241 MTD until a criterion for treatment discontinuation has been met.
153500|NCT02994953|Drug|M9241 (MTD)|Subjects will receive M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
153501|NCT02994953|Drug|Avelumab (Expansion cohort)|Subjects in the expansion cohorts will receive Induction Therapy (Avelumab once weekly + M9241 once every 4 weeks) through Cycle 3 (for 12 weeks) then starting at Cycle 4, Continuation Therapy (Avelumab once every 2 weeks + M9241 once every 4 weeks).
153502|NCT02994940|Drug|Acetaminophen|
153503|NCT02994927|Drug|CCX168|Orally administered
153504|NCT02994927|Drug|Prednisone|Orally administered
153505|NCT02994927|Drug|Cyclophosphamide|Orally or intravenously administered
153506|NCT02994927|Biological|Rituximab|Intravenously administered
153507|NCT02994927|Drug|Azathioprine|Orally administered
153508|NCT02994914|Other|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
153509|NCT02994888|Drug|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
153510|NCT02994875|Dietary Supplement|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
153511|NCT02994875|Other|Placebo|Sugar pill
153512|NCT02994862|Other|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
153513|NCT02994862|Other|Conventional Bonding|Normal Bonding Protocol
153514|NCT02994836|Biological|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
153515|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
153516|NCT02994836|Biological|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
153517|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
153518|NCT02994810|Other|Breastfeeding guidance|Breastfeeding guidance
153519|NCT02994784|Drug|Propylene Glycol-Free Melphalan Hydrochloride|Intravenous Propylene Glycol-Free Melphalan Hydrochloride
153520|NCT02994771|Drug|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
153521|NCT02994771|Drug|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
153522|NCT02994758|Other|Personalised treatment|Treatment based on NGS or DSRT
153523|NCT02994745|Drug|Fimasartan, Atorvastatin|
153524|NCT02994732|Drug|[14C]-BVD-523|[14C]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
153525|NCT02994719|Drug|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
153526|NCT02994719|Device|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
153527|NCT02994706|Procedure|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
153528|NCT02994706|Other|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
153529|NCT02994693|Device|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
153530|NCT02994680|Device|Three-burner LPG stove|The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
153531|NCT02994680|Other|Delivery of LPG tanks|One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
153532|NCT02994680|Other|Vouchers for LPG tanks|One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
153533|NCT02994667|Device|Permanent Pacemaker Placement|
153957|NCT02991599|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
153534|NCT02994654|Device|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.~The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
153535|NCT02994641|Procedure|COMA Score Assessment|
153536|NCT02994628|Other|Water|Water only without carbohydrate
153537|NCT02994628|Other|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
153538|NCT02994628|Other|Cavendish banana|Ingest Cavendish banana (common banana)
153539|NCT02994628|Other|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
153540|NCT02994602|Drug|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
153541|NCT02994589|Other|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
153542|NCT02994589|Device|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
153543|NCT02994589|Other|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
153544|NCT02994576|Drug|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
153545|NCT02994563|Device|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
153546|NCT02994550|Drug|FSH/LH|
153547|NCT02994537|Other|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
153548|NCT02994524|Procedure|Rerouting technique for transsphincteric perianal fistula|
153549|NCT02994498|Drug|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
153550|NCT02994485|Drug|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
153551|NCT02994472|Radiation|Gastric emptying scintigraphy using 99mTc-DTPA|
153552|NCT02994446|Device|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
153553|NCT02994433|Drug|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
153554|NCT02994433|Drug|Placebo gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
153555|NCT02994433|Device|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
153556|NCT02994407|Drug|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.~Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
153557|NCT02994394|Drug|OPC-41061|
153558|NCT02994381|Drug|RPC1063|
153559|NCT02994368|Other|Observation|
153560|NCT02994355|Other|Systems Analysis and Improvement Approach|"Understanding the cascade from FP clinic enrollment to HIV testing~Use process mapping to identify modifiable bottlenecks~Define and implement workflow adaptations to eliminate modifiable bottlenecks~Monitor change in performance~Repeat the analysis and improvement cycle (steps 1-4)"
153561|NCT02994342|Device|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
153562|NCT02994329|Device|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
153563|NCT02994316|Other|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
153564|NCT02994290|Drug|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
153565|NCT02994290|Behavioral|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.~Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.~All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
153601|NCT02994082|Behavioral|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
253401|NCT02265224|Drug|Acetylcysteine|
153566|NCT02994277|Device|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
153567|NCT02994264|Radiation|adjuvant concurrent chemoradiation|
153568|NCT02994251|Drug|gemcitabine|1000 mg/m^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
153569|NCT02994251|Drug|Cisplatin|25 mg/m^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
153570|NCT02994251|Drug|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
153571|NCT02994238|Device|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
153572|NCT02994225|Drug|Indocyanine Green|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.~Near Infra-red images acquisition is performed during surgery"
153573|NCT02994212|Dietary Supplement|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
153574|NCT02994199|Other|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
153575|NCT02994186|Procedure|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
153576|NCT02994186|Other|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
153577|NCT02994173|Drug|Oxycodone|Current clinical practice, used as a control in this study
153578|NCT02994173|Drug|S-Ketamine 0.25|dosage
153579|NCT02994173|Drug|S-Ketamine 0.5|dosage
153580|NCT02994173|Drug|S-Ketamine 0.75|dosage
153581|NCT02994160|Other|FastLIFE electrode|Implant temporary FastLIFE electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
153582|NCT02994147|Drug|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
153583|NCT02994147|Drug|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
153584|NCT02994134|Behavioral|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
153585|NCT02994134|Behavioral|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
153586|NCT02994108|Behavioral|txt2protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
153587|NCT02994108|Behavioral|Sexual Health Knowledge Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
153588|NCT02994095|Behavioral|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
153589|NCT02994082|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
153590|NCT02994082|Behavioral|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
153591|NCT02994082|Behavioral|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
153592|NCT02994082|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
153593|NCT02994082|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
153594|NCT02994082|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
153595|NCT02994082|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
153596|NCT02994082|Drug|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
153597|NCT02994082|Drug|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
153598|NCT02994082|Drug|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
153599|NCT02994082|Drug|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
153600|NCT02994082|Behavioral|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
153602|NCT02994069|Drug|Cisplatin|Cisplatin
153603|NCT02994069|Radiation|XRT|Radiation Therapy
153605|NCT02994056|Drug|RBV|Tablets administered orally at 600 mg, if well tolerated then up to a maximum total daily dose of 1000 to 1200 mg (based on weight) divided twice daily.
153606|NCT02994043|Behavioral|Mindfulness Plus Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.
153607|NCT02994043|Behavioral|Relapse Prevention Therapy|An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.
153608|NCT02994017|Other|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
153609|NCT02994004|Other|no intervention|
153610|NCT02993991|Drug|Mocetinostat|Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
153611|NCT02993991|Biological|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
153612|NCT02993965|Other|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
153613|NCT02993952|Device|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
153614|NCT02993952|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
153615|NCT02993939|Procedure|Interscalene block|Ultrasound guided single shot block above the clavicle
153616|NCT02993939|Procedure|Infraclavicular-suprascapular block|Combined block of nerves far away from phrenic nerve
153617|NCT02993926|Drug|Enantone|Enantone suspension for injection
153618|NCT02993926|Drug|GnRH agonist|A non-Enantone GnRH agonist
153619|NCT02993913|Drug|Simmiparib|Simmiparib Tablets, oral administration
153620|NCT02993900|Device|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
153621|NCT02993887|Behavioral|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
153622|NCT02993887|Behavioral|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
153623|NCT02993874|Dietary Supplement|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
153624|NCT02993874|Dietary Supplement|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
153625|NCT02993861|Other|Anti-epileptics|
153626|NCT02993848|Other|No intervention|
153627|NCT02993835|Other|Labeled iron salt Fe54|Fe salt enriched with Fe 54 isotopes
153628|NCT02993835|Other|Labeled iron salt Fe57|Fe salt enriched with Fe 57 isotopes
153629|NCT02993835|Other|Labeled iron salt Fe58|Fe salt enriched with Fe 58 isotopes
153630|NCT02993822|Drug|Orvepitant Maleate|Tablet, once daily, oral
153631|NCT02993822|Drug|Placebo|Tablet, once daily, oral
153632|NCT02993809|Biological|BM-ECs and PRPE|
153633|NCT02993809|Biological|BM-ECs|
153634|NCT02993783|Drug|Vedolizumab|Vedolizumab IV infusion
153635|NCT02993770|Procedure|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
153636|NCT02993770|Procedure|External DCR|External DCR
153637|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, Month 6 and 12, respectively
153638|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Month 1, 7 and 13, respectively
153639|NCT02993757|Biological|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, intramuscular at Day 0 and Month 6, respectively
153640|NCT02993757|Biological|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, intramuscular at Day 0 and Month 6, respectively
153642|NCT02993731|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
153643|NCT02993731|Drug|Gemcitabine|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
153644|NCT02993718|Drug|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
153645|NCT02993718|Drug|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
153646|NCT02993705|Drug|Trabectedin|
153647|NCT02993692|Device|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
153648|NCT02993679|Procedure|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
153649|NCT02993666|Device|Bair Hugger|forced air warming with Bair Hugger air warmer
153650|NCT02993653|Radiation|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
153651|NCT02993640|Drug|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
153652|NCT02993627|Dietary Supplement|Spirulina|2 g(4* 500 mg tablets) daily intake of Spirulina Platensis
153653|NCT02993627|Other|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
153654|NCT02993601|Device|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
153655|NCT02993601|Device|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
153656|NCT02993601|Other|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
153657|NCT02993601|Other|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
153658|NCT02993601|Device|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
153659|NCT02993601|Device|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
153660|NCT02993601|Device|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
153661|NCT02993588|Drug|Melatonin|Melatonin 6 mg tablet once daily
153662|NCT02993588|Other|Placebo|one tablet once daily
153663|NCT02993575|Drug|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
153664|NCT02993562|Drug|Levothyroxine|Normal treatment with levothyroxine.
153665|NCT02993536|Other|Biospecimen Collection|
153666|NCT02993523|Drug|Azacitidine|Solution for subcutaneous or intravenous administration
153667|NCT02993523|Drug|Venetoclax|Tablet
153668|NCT02993523|Drug|Placebo|Tablet
153669|NCT02993510|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
153670|NCT02993510|Device|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
153671|NCT02993510|Device|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
153672|NCT02993497|Device|Infrared camera|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
153673|NCT02993497|Device|RVM(Respiratory Volume Monitor)|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
153674|NCT02993484|Drug|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
153675|NCT02993484|Biological|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
153676|NCT02993484|Other|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
153677|NCT02993484|Other|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
153680|NCT02993458|Other|DASH diet|DASH style diet rich in fruits, vegetables, and low‐fat dairy foods and low in saturated fat and total fat
153681|NCT02993458|Other|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
153682|NCT02993458|Other|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
153683|NCT02993458|Other|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
153684|NCT02993445|Other|Alternate Nostril Breathing|
153685|NCT02993445|Device|Foot Reflexology|
153686|NCT02993432|Device|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
153687|NCT02993432|Drug|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
153688|NCT02993419|Drug|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
153689|NCT02993419|Other|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
153690|NCT02993406|Drug|Bempedoic acid 180 mg tablet|Patients take bempedoic acid 180 mg tablet orally once daily
153691|NCT02993406|Drug|Matching placebo tablet|Patients take matching placebo tablet orally once daily
153692|NCT02993393|Other|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
153693|NCT02993393|Other|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
153694|NCT02993380|Dietary Supplement|Stir-fried olive oil group|Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
153695|NCT02993380|Dietary Supplement|Natural olive oil group|Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
153696|NCT02993367|Drug|Butylphthalide Soft Capsules|DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
153697|NCT02993367|Drug|Placebo Butylphthalide Soft Capsules|
153698|NCT02993354|Device|The EUM300 (electrical uterine myography)|External monitor intended for the evaluation of electrical signals originating in the uterus, thus providing a tool for measuring uterine activity as well as fetal heart rate.
153699|NCT02993341|Drug|Tranexamic Acid|
153700|NCT02993341|Other|Saline Wash|
153701|NCT02993328|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
153702|NCT02993328|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
153703|NCT02993315|Biological|nDC vaccination|
153704|NCT02993315|Biological|placebo injection|
153705|NCT02993302|Drug|1α-D3|patients were given PTU and 1α-D3
153706|NCT02993302|Drug|Placebos|patients were given PTU and placebos
153707|NCT02993289|Other|Different well-known treatments|
153708|NCT02993276|Device|Neurocap®|NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
153709|NCT02993263|Device|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
153710|NCT02993250|Drug|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
153711|NCT02993250|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
153712|NCT02993250|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
153713|NCT02993237|Drug|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
153714|NCT02993237|Drug|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
153715|NCT02993224|Drug|deferasirox dispersable tablet (DT)|"DT will be provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The required number of DT should be stirred into water, apple juice or orange juice until fully dissolved once a day before 12 PM on empty stomach. The starting dose on Baseline Day 1 would be as following:~Deferasirox DT of 20 mg/kg/day in transfusion-dependent thalassemia (TDT)~Deferasirox DT of 10 mg/kg/day in non- transfusion-dependent thalassemia (NTDT),"
153716|NCT02993224|Drug|deferasirox film coated tablet (FCT)|"FCT will be provided as 90 mg, 180 mg, 360 mg dispersible tablets for oral use. FCT should be taken once a day before 12 PM with or after light meal. If there is difficulty in swallowing, pill may be crushed and sprinkled over soft food. The starting dose on Baseline The equivalent FCT starting dose on Week 25 is:~Deferasirox FCT of 14 mg/kg/day in transfusion-dependent thalassemia (TDT)~Deferasirox FCT of 7 mg/kg/day in non- transfusion-dependent thalassemia (NTDT)."
153717|NCT02993211|Device|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
153718|NCT02993211|Device|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
153719|NCT02993198|Drug|Carvedilol|
156349|NCT02973958|Drug|Ketorolac|See experimental arm description
153720|NCT02993185|Behavioral|Your Move|"Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
153721|NCT02993185|Behavioral|Eat Smart|"Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months after the program ends."
153722|NCT02993159|Drug|Afimoxifene|Applied to the breast
153723|NCT02993159|Other|Laboratory Biomarker Analysis|Correlative studies
153724|NCT02993159|Other|Placebo|Given PO
153725|NCT02993159|Other|Placebo|Applied to the breast
153726|NCT02993159|Drug|Tamoxifen Citrate|Given PO
153727|NCT02993146|Other|Laboratory Biomarker Analysis|Correlative studies
153728|NCT02993146|Other|Pharmacological Study|Correlative studies
153729|NCT02993146|Other|Quality-of-Life Assessment|Ancillary studies
153730|NCT02993146|Drug|Ropidoxuridine|Given PO
153731|NCT02993146|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
153732|NCT02993133|Drug|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
153733|NCT02993107|Biological|AR101|AR101 powder provided in capsules & sachets
153734|NCT02993094|Drug|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
153735|NCT02993094|Drug|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
153736|NCT02993068|Other|Educational Intervention|Watch genetic testing online educational video
153737|NCT02993068|Other|Genetic Counseling|Receive post-telephone genetic counseling
153738|NCT02993068|Other|Genetic Counseling|Receive pre-telephone genetic counseling
153739|NCT02993068|Other|Laboratory Biomarker Analysis|Correlative studies
153740|NCT02993068|Other|Questionnaire Administration|Ancillary studies
153741|NCT02993055|Drug|Ulimorelin|
153742|NCT02993055|Other|Placebo|
153743|NCT02993042|Device|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
153744|NCT02993029|Drug|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
153745|NCT02993029|Drug|Celecoxib|Celecoxib capsule 200mg qd by mouth.
153746|NCT02993016|Procedure|patient-specific instruments|
153747|NCT02993016|Device|The Signature™ Vanguard|
153748|NCT02993016|Procedure|conventional instruments|
153749|NCT02993016|Device|Vanguard PS(posterior stabilized)|
153750|NCT02993003|Device|Nasopharyngeal probe|nasopharyngeal probe insertion
153751|NCT02992990|Procedure|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
153752|NCT02992977|Biological|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
153753|NCT02992964|Drug|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
153754|NCT02992951|Device|DACC-Coated Post Operative Dressing|Leukomed Sorbact is a non-active coated wound dressing, containing Dialkylcarbomoylchloride. This is a bacteria-binding compound that adheres bacteria via hydrophobic interaction and removes them from the wound bed at dressing change.
153755|NCT02992938|Drug|Acetazolamide|
153756|NCT02992938|Drug|Placebo Oral Tablet|
153757|NCT02992925|Biological|DPT-IPV-Hib-High（Combined Vaccine）|
153758|NCT02992925|Biological|DPT-IPV-Hib-Low（Combined Vaccine）|
153759|NCT02992925|Biological|Hib vaccine|
153760|NCT02992925|Biological|DPT-IPV|
153761|NCT02992912|Drug|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
153762|NCT02992912|Procedure|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
153763|NCT02992899|Other|gammaCore/electroCore|Vasal nerve stimulation (VNS) will be self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) will be adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery will be 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan will be conducted; following an additional 8 minutes, a second VNS delivery will be administered, after which another scan will be obtained.
153958|NCT02991586|Behavioral|Dialectical Behaviour Therapy|Group of families
253548|NCT02264093|Drug|Propranolol|
153764|NCT02992899|Other|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) will be self-administered using the electroCore non-invasive VNS device. The device will be programmed such that no actual power is delivered. The duration of delivery will be 2 minutes, one minute into which the HR-PET scan will be conducted; following an additional 8 minutes, a second sham VNS delivery will be administered, after which another scan will be obtained.
153765|NCT02992886|Radiation|Preoperative radiation|Radiation treatment before surgery
153766|NCT02992886|Drug|Raltitrexed|concurrent chemotherapy
153767|NCT02992886|Procedure|Pelvic surgery|
153768|NCT02992873|Device|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
153769|NCT02992873|Device|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
153770|NCT02992860|Drug|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by > 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
153771|NCT02992860|Procedure|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
153772|NCT02992860|Other|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
153773|NCT02992860|Other|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
153774|NCT02992860|Procedure|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
153775|NCT02992860|Genetic|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
153776|NCT02992860|Procedure|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
153777|NCT02992860|Procedure|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
153778|NCT02992860|Procedure|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
153779|NCT02992847|Other|Unenhanced MRI|
153780|NCT02992834|Biological|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
153781|NCT02992834|Biological|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
153782|NCT02992821|Procedure|Bed-side pocket size ultrasound imaging|
153783|NCT02992821|Procedure|High frame rate tracking doppler|
153784|NCT02992808|Drug|recombinant gonadotropins|
153785|NCT02992808|Drug|HP-HMG|
153786|NCT02992795|Device|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
153787|NCT02992782|Behavioral|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
153788|NCT02992782|Behavioral|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
153789|NCT02992782|Behavioral|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
153790|NCT02992756|Drug|Growth Factors|"one dose~1 mL of PRP obtained by PRGF Endoret"
153791|NCT02992743|Genetic|Autologous genetically modified T Cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 1.
153792|NCT02992730|Behavioral|No Intervention|No Intervention
153793|NCT02992704|Drug|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
153794|NCT02992691|Drug|20% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
153795|NCT02992691|Drug|35% w/w sodium bicarbonate|Dentifrice containing 35% w/w sodium bicarbonate.
153796|NCT02992691|Drug|50% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
153797|NCT02992691|Drug|67% w/w sodium bicarbonate|Dentifrice containing 67% w/w sodium bicarbonate.
153798|NCT02992691|Drug|0% w/w sodium bicarbonate|Dentifrice containing 0% sodium bicarbonate and 1450 parts per million (ppm) fluoride.
153799|NCT02992678|Drug|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
153800|NCT02992678|Drug|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
153801|NCT02992665|Drug|Ca Ionophore A23187|Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
153802|NCT02992665|Other|Placebo|Placebo is used to control Ca ionophore group
153803|NCT02992652|Drug|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
153804|NCT02992639|Behavioral|Control group|The participants who included in control group did not receive any treatment.
153805|NCT02992639|Behavioral|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
153806|NCT02992626|Other|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
153807|NCT02992626|Other|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
153808|NCT02992613|Procedure|total knee arthroplasty with ultra-congruent (UC) insert|
153809|NCT02992613|Procedure|total knee arthroplasty with posterior-stabilized (PS) insert|
153810|NCT02992587|Other|CAF, Comprehensive assessment of frailty|CAF, Comprehensive assessment of frailty. A scoring system of the patients physical status. By smaller physical test of balance, strength and walking speed.
153811|NCT02992574|Radiation|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
153812|NCT02992561|Behavioral|FORNET (adapted version)|
153813|NCT02992548|Drug|Pravastatin|
153814|NCT02992535|Device|Intense Pulse Light Energy delivery (IPL)|
153815|NCT02992522|Drug|Lenalidomide|Given PO
153816|NCT02992522|Biological|Obinutuzumab|Given IV
153817|NCT02992522|Drug|Venetoclax|Given PO
153818|NCT02992509|Device|EMED detruset(TM) intravesical electrical stimulation|"There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered."
153819|NCT02992496|Drug|Ketamine|1mg/kg, 6 applications over 2 weeks
153820|NCT02992496|Drug|Midazolam Hydrochloride|0.03mg/kg, 6 applications over 2 weeks
153821|NCT02992483|Drug|MIK665|MIK665
153822|NCT02992470|Dietary Supplement|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
153823|NCT02992470|Dietary Supplement|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
153824|NCT02992457|Drug|Sofosbuvir|Sofosbuvir 400 mg daily.
153825|NCT02992457|Drug|Ribavirin|Ribavirin 1000-1200 mg daily
153826|NCT02992457|Drug|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
153827|NCT02992457|Drug|Simeprevir|Olysio once daily.
153828|NCT02992457|Drug|Daclatasvir|Dakla once daily for three months.
153829|NCT02992457|Drug|Ritaprevir, paritaprevir, ombetasvir|Querevo for three months
153830|NCT02992457|Drug|Sofosbuvir and Ledipasvir|Once daily for three months
153831|NCT02992457|Drug|Salvage therapy|three months in repeated treatment failure
153832|NCT02992444|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
153833|NCT02992444|Other|Experimental adhesive strip|This is a strip of a newly developed adhesive.
153834|NCT02992431|Behavioral|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
153835|NCT02992431|Other|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
153836|NCT02992418|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Month 1, 7 and 13, respectively
153837|NCT02992418|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Month 1, 7 and 13, respectively
153838|NCT02992418|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Month 1
153839|NCT02992418|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0
153840|NCT02992405|Behavioral|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
153841|NCT02992405|Behavioral|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
153842|NCT02992392|Drug|Liposic|one eye of the participant recieved Lipoic
153843|NCT02992392|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
153844|NCT02992379|Device|pivot splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
153845|NCT02992379|Device|stabilizing splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
153846|NCT02992366|Procedure|implant placement|implant placement
153847|NCT02992353|Procedure|Three-port pulmonary resection surgery|Three-port pulmonary resection surgery
153848|NCT02992353|Procedure|Single-port or two-port surgery|Single-port or two-port pulmonary resection surgery
153849|NCT02992340|Drug|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
153959|NCT02991573|Device|Prime & Bond Universal|Prime & Bond Universal
153960|NCT02991573|Device|Ceram X|
153850|NCT02992340|Drug|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
153851|NCT02992340|Drug|Gemcitabine|On D1 and D8, every 3 weeks. Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
153852|NCT02992314|Device|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
153853|NCT02992314|Device|Placebo|Placebo formulation with out the active ingredients
153854|NCT02992301|Drug|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
153855|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
153856|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
153857|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
153858|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
153859|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
153860|NCT02992288|Drug|Placebo|Orally once daily for 20 weeks
153861|NCT02992275|Other|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
153862|NCT02992275|Other|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
153863|NCT02992262|Device|Point of care ocular ultrasound|
153864|NCT02992236|Drug|VAS203|Infusion of NO-Synthase inhibitor VAS203
153865|NCT02992236|Drug|Saline|Infusion of saline
153866|NCT02992210|Genetic|4SCAR-GD2|
153867|NCT02992197|Biological|Rotarix, dose 1|Rotarix, dose 1
153868|NCT02992197|Biological|Rotarix, dose 2|Rotarix, dose 2
153869|NCT02992197|Drug|Placebo (for Rotarix dose 2)|Sterile water to provide volume equivalent as a second dose of Rotarix
153870|NCT02992184|Device|HCV RNA detection with Genedrive assay|
153871|NCT02992184|Device|HCV RNA detection with RealTime HCV|
153872|NCT02992171|Behavioral|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
153873|NCT02992158|Behavioral|behavioral activation|
153874|NCT02992158|Behavioral|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
153875|NCT02992132|Drug|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
153876|NCT02992132|Drug|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
153877|NCT02992132|Other|Placebo|Placebo, taken as two tablets, once daily by mouth
153878|NCT02992119|Biological|RTS,S/AS01B Fractional dose|RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.
153879|NCT02992119|Biological|Double RTS,S/AS01E Fractional dose|A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
153880|NCT02992119|Biological|RTS,S/AS01E Standard dose|RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.
153881|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Standard dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2
153882|NCT02992119|Biological|RTS,S/AS01E Fractional dose|RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
153883|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Fractional dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.
153884|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
153885|NCT02992106|Other|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:~Children aged 0-6 years old:~Questionnaire on socio-demographic characteristics~Dutch Eating Behaviour Questionnaire~Food Frequency Questionnaire~Ages and Stages Questionnaire~Strengths and Difficulties Questionnaire~Questionnaire on developmental milestones~Questionnaire on behaviour~Children older than 6 years:~Questionnaire on socio-demographic characteristics~Dutch Eating Behaviour Questionnaire~Food Frequency Questionnaire~Pediatric Quality of Life Questionnaire~Children's Behaviour Questionnaire in Dutch~Questionnaire on developmental milestones~Developmental Coordination Disorder Questionnaire~Strengths and Difficulties Questionnaire"
153886|NCT02992106|Other|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
153887|NCT02992106|Other|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
153888|NCT02992106|Other|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
153889|NCT02992106|Other|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
153890|NCT02992106|Other|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
153891|NCT02992106|Other|Faces Pain Scale|After performing the measurements with the EndoPAT device, Harpender kalliper and ultrasound, the children will be asked to fill out a Faces Pain Scale, validated for children aged 4-16 years old and obtained for use from the International Association for the Study of Pain
153892|NCT02992093|Other|all the indicators|BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
153893|NCT02992080|Biological|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
153894|NCT02992054|Other|stimulating activities|
153961|NCT02991573|Device|Prime & Bond XP|Control
153962|NCT02991573|Procedure|technique 1|
153895|NCT02992041|Drug|VVZ-149 Injections|A novel analgesic drug candidate, VVZ-149 Injections shows dual antagonistic activity with moderate potency on glycine transporter type 2 (GlyT2, IC50=0.86 uM) and serotonin receptor 2A (5HT2A, IC50=1.3 uM), which are therapeutic targets for pain. GlyT2 inhibitors have been studied by many pharmaceutical companies as a well-known and promising analgesic candidate because of their role in inhibitory (glycine) modulation and regional specificity.
153896|NCT02992041|Drug|Placebo|Same formulation and appearance with VVZ-149 Injections
153897|NCT02992028|Drug|Intravenous Nutrition (Vitamins) injection|
153898|NCT02992028|Drug|Intravenous Saline injection|
153899|NCT02992015|Drug|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
153900|NCT02992002|Other|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
153901|NCT02991989|Behavioral|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.~Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
153902|NCT02991989|Dietary Supplement|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
153903|NCT02991976|Procedure|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
153904|NCT02991963|Other|Interview|A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
153905|NCT02991963|Other|Blood collection (Dried Blood Spot)|Dried Blood Spot
153906|NCT02991963|Other|Blood Collection (Venous Blood collection)|Venous Blood collection
153907|NCT02991963|Other|Blood Smear|Slide blood smear
153908|NCT02991950|Drug|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
153909|NCT02991937|Drug|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
153910|NCT02991937|Procedure|Surgical Treatment|Appendectomy
153911|NCT02991911|Biological|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
153912|NCT02991911|Biological|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
153913|NCT02991911|Biological|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
153914|NCT02991898|Biological|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose~Sirolimus 8mg-12mg oral loading dose followed by signle dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.~Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.~DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion."
153915|NCT02991885|Biological|HAL-MPE1|Weekly subcutaneous administrations of HAL-MPE1
153916|NCT02991885|Drug|HAL-MPE1 placebo|Weekly subcutaneous administrations of HAL-MPE1 placebo
153917|NCT02991872|Procedure|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
153918|NCT02991859|Drug|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
153919|NCT02991859|Drug|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
153920|NCT02991859|Drug|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
153921|NCT02991859|Drug|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
153922|NCT02991833|Other|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
153963|NCT02991573|Procedure|technique 2|
153923|NCT02991833|Other|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
153924|NCT02991820|Device|Miller|Direct laryngoscopy and endotracheal intubation attempted by each provider using direct laryngoscopy (DL) with a Miller laryngoscope
153925|NCT02991820|Device|Macintosh|Direct laryngoscopy and endotracheal intubation attempted by each provider using DL with a Macintosh laryngoscope
153926|NCT02991820|Device|C-MAC|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the C-MAC video laryngoscope
153927|NCT02991820|Device|GlideScope|Indirect laryngoscopy and endotracheal intubation attempted by each provider using the GlideScope video laryngoscope
153928|NCT02991807|Drug|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
153929|NCT02991807|Drug|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
153930|NCT02991794|Device|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
153931|NCT02991781|Other|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
153932|NCT02991781|Drug|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
153933|NCT02991781|Other|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
153934|NCT02991781|Other|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
153935|NCT02991768|Drug|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
153936|NCT02991768|Drug|Placebos|Placebo is matched to the study drug.
153937|NCT02991742|Other|contrast media|Compare 2 contrast media
153938|NCT02991729|Other|iPad-based decision aid|This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
153939|NCT02991729|Other|Genetic counseling appointment|All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
153940|NCT02991716|Other|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
153941|NCT02991703|Device|pOpmètre®|the pOpmètre® uses saturation sensors,
153942|NCT02991703|Device|Sphygmocor|the Sphygmocor uses applanation tonometry
153943|NCT02991690|Other|Hypothermia|To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification [510(k), K030421]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
153944|NCT02991677|Behavioral|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
153945|NCT02991677|Other|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
153946|NCT02991677|Behavioral|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
153947|NCT02991664|Other|Equia Forte|Glass ionomer restorative system
153948|NCT02991664|Other|G-aenial Posterior|Micro hybrid composite resin
153949|NCT02991651|Drug|IRX4204|RXR agonist
153950|NCT02991651|Drug|erlotinib|inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
153951|NCT02991638|Drug|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
153952|NCT02991625|Drug|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
153953|NCT02991625|Other|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
153954|NCT02991625|Other|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
153955|NCT02991612|Drug|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
153956|NCT02991599|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
253549|NCT02264093|Drug|Talsaclidine|
153964|NCT02991560|Other|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
153965|NCT02991560|Other|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
153966|NCT02991560|Device|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
153967|NCT02991560|Device|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
153968|NCT02991547|Other|Observational|
153969|NCT02991534|Behavioral|CV Toolkit Components|"Patient completes a CV self screener.~Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.~Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
153970|NCT02991521|Procedure|Fast exam|Positional change before Fast exam
153971|NCT02991508|Drug|Placebo|
153972|NCT02991508|Drug|Adrecizumab|
153973|NCT02991495|Biological|Stamaril, Sanofi Pasteur|"Full dose~Fractional dose: one fifth (1/5)"
153974|NCT02991495|Biological|Yellow fever vaccine, Bio-Manguinhos|"Full dose~Fractional dose: one fifth (1/5)"
153975|NCT02991495|Biological|Yellow fever vaccine, Institut Pasteur|"Full dose~Fractional dose: one fifth (1/5)"
153976|NCT02991495|Biological|Yellow fever vaccine, Chumakov Institute|"Full dose~Fractional dose: one fifth (1/5)"
153977|NCT02991495|Biological|Yellow fever vaccine, Chumakov Institute|"Full dose~Fractional dose: one fifth (1/5)"
153978|NCT02991495|Biological|Yellow fever vaccine, Chumakov Institute|"Full dose~Fractional dose: one fifth (1/5)"
153979|NCT02991482|Drug|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
153980|NCT02991482|Drug|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
153981|NCT02991482|Drug|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
153982|NCT02991469|Drug|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
153983|NCT02991456|Drug|Rolapitant|single 180 mg dose by mouth
153984|NCT02991456|Drug|Ondansetron|8 mg by mouth daily
153985|NCT02991443|Behavioral|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
153986|NCT02991430|Device|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
153987|NCT02991430|Device|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
153988|NCT02991417|Biological|CDVAX|
153989|NCT02991404|Procedure|Multimodal Peripheral Nerve Block Injection|After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
153990|NCT02991404|Procedure|Single Shot Adductor Canal Block|A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.
153991|NCT02991404|Drug|Initial Bolus|20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine
153992|NCT02991404|Drug|Continuous infusion|Continuous infusion of 0.125% bupivacaine
153993|NCT02991391|Other|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
153994|NCT02991378|Behavioral|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
153995|NCT02991365|Other|nasal insulin|
153996|NCT02991365|Other|placebo spray|
153997|NCT02991352|Device|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
153998|NCT02991339|Drug|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
153999|NCT02991326|Other|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow (using latex gloves for intra oral techniques):~Compression of the fourth ventricle;~inhibitory intra-oral pressure technique (IPT) of the temporal muscle;~inhibition of the inferior head of the lateral pterygoid muscle;~intra-oral inhibition of the masseter muscle;~Balanced ligamentous tension (BLT) of the accessory ligaments - sphenopalatine;~BLT of the accessory ligaments - pterygomandibular raphe;~sphenopalatine ganglion technique;~Craniosacral rebalancing;"
154134|NCT02990338|Drug|pomalidomide|Pharmaceutical form:capsule Route of administration: oral
154000|NCT02991326|Other|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
154001|NCT02991313|Device|Endocardial Ablation Procedure|
154002|NCT02991300|Device|BioPoly RS Partial Resurfacing Patella Implant|
154003|NCT02991287|Procedure|Inguinal hernia repair|
154004|NCT02991287|Procedure|Abdominal hysterectomy|
154005|NCT02991287|Procedure|Vaginal hysterectomy|
154006|NCT02991287|Procedure|Thoracotomy|
154007|NCT02991274|Procedure|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
154008|NCT02991261|Drug|SPARC001 type I|Treatment type I
154009|NCT02991261|Drug|SPARC001 type II|Treatment type II
154010|NCT02991261|Drug|Reference001 type I|Hydrocodone-acetaminophen
154011|NCT02991261|Drug|Reference001 type II|Hydrocodone Acetaminophen
154012|NCT02991248|Device|robotic training|robotic training by applying pelvis force perturbation
154013|NCT02991248|Device|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
154014|NCT02991248|Device|treadmill|conventional treadmill training only
154015|NCT02991235|Dietary Supplement|PRJ212|6 capsules of study product will be taken daily and orally.
154016|NCT02991235|Dietary Supplement|Placebo|6 capsules of study product will be taken daily and orally.
154017|NCT02991222|Drug|SPARC001 type I|Treatment type I
154018|NCT02991222|Drug|SPARC001 type II|Treatment type II
154019|NCT02991222|Drug|Reference001 type I|Hydrocodone-Acetaminophen
154020|NCT02991222|Drug|Reference001 type II|Hydrocodone-Acetaminophen
154021|NCT02991209|Drug|Testosterone|
154022|NCT02991209|Drug|Placebos|
154023|NCT02991196|Drug|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered [90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
154024|NCT02991183|Behavioral|ACT|A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
154025|NCT02991170|Procedure|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
154026|NCT02991170|Procedure|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
154027|NCT02991157|Drug|Nimodipine|
154028|NCT02991144|Genetic|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
154029|NCT02991144|Drug|Oral prednisone|Initiated before dosing with DTX301, sustained for 4 weeks, followed by tapering
154030|NCT02991131|Drug|Tedizolid (Sivextro, BAY1192631)|Antibiotic
154031|NCT02991131|Drug|Linezolid|Antibiotic
154032|NCT02991118|Drug|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
154033|NCT02991118|Drug|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
154034|NCT02991092|Procedure|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
154035|NCT02991079|Other|Intervention group|"Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.~Counseling on physical activity and Mediterranean diet."
154036|NCT02991079|Other|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
154037|NCT02991053|Drug|ketamine|
154038|NCT02991040|Device|Revanesse Ultra+ (with lidocaine)|Bilateral nasolabial fold trial to compare the safety and efficacy profiles of Revanesse® Ultra + (with lidocaine) to Revanesse® Ultra (comparator)
154039|NCT02991040|Device|Revanesse Ultra|Comparator without lidocaine
154040|NCT02991027|Device|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
154041|NCT02991027|Device|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
154042|NCT02991014|Behavioral|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
154043|NCT02991014|Behavioral|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
154044|NCT02991014|Behavioral|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
154045|NCT02991001|Procedure|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
154046|NCT02991001|Procedure|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
154047|NCT02991001|Device|Ultrasound|
154048|NCT02991001|Drug|Normal Saline|
154049|NCT02990975|Drug|ketamine|
154050|NCT02990962|Drug|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
154051|NCT02990962|Drug|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
154052|NCT02990949|Other|Timing of trigger|
154053|NCT02990936|Other|Tumor delineation|Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
154054|NCT02990923|Device|High-Flow Needleless Valve|
154055|NCT02990923|Device|DualCap Disinfection Devices|
154056|NCT02990910|Drug|personalized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
154057|NCT02990910|Device|conventional opioid analgesia|(b) all received 25μg/kg morphine
154058|NCT02990897|Behavioral|clinical decision support message|The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
154059|NCT02990884|Drug|ketamine|
154060|NCT02990871|Other|early neurological rehabilitation|start of neurological rehabilitation between 3rd and 15th day after ABI
154061|NCT02990871|Other|no-early neurological rehabilitation|start of neurological rehabilitation between 20th and 90th day after ABI
154062|NCT02990858|Drug|PRO 140 SC injections|
154063|NCT02990845|Drug|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
154064|NCT02990832|Device|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.~The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.~Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.~Maximum treatment course will be 28 days (end of study) or until wound closure."
154065|NCT02990819|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory SOPs and using aseptic technique.
154066|NCT02990806|Biological|NI-071|20 ml vial containing 100 mg for a final reconstitution volume of 10 mg/mL
154067|NCT02990806|Biological|Infliximab|20 ml vial containing 100 mg for a final reconstitution volume of 10 mg/mL
154068|NCT02990793|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
154069|NCT02990793|Device|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
154070|NCT02990780|Radiation|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
154071|NCT02990780|Radiation|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
154072|NCT02990754|Behavioral|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
154073|NCT02990728|Drug|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
154074|NCT02990728|Device|Mirena®|
154075|NCT02990715|Device|C-Scan System|"To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy~To evaluate the safety of the C-Scan Capsule System procedure"
154076|NCT02990702|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
154077|NCT02990702|Other|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
154078|NCT02990702|Drug|Bupivacaine|
154079|NCT02990702|Device|Ultrasound|
154080|NCT02990689|Device|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
154081|NCT02990689|Device|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
154082|NCT02990689|Device|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
154083|NCT02990676|Behavioral|Computerised cognitive training|Computerised cognitive training regime
154084|NCT02990663|Other|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
154085|NCT02990663|Other|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
154086|NCT02990650|Behavioral|Balance Task Training with therapist guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The therapist will provide guarding support"
154135|NCT02990338|Drug|dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
154087|NCT02990650|Behavioral|Balance task training with robotic guarding support|"Nine balance tasks:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
154088|NCT02990650|Behavioral|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:~long forward step~forward reach~push forward~push backward~step over hurdle~step up on foam surface~step up on solid surface~sit-to-stand~step onto slippery surface The guarding support will be provided by a robot"
154089|NCT02990637|Dietary Supplement|OLECOL|Olive leaf extract
154090|NCT02990637|Dietary Supplement|Placebo|Maltodextrin
154091|NCT02990624|Radiation|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
154092|NCT02990611|Other|Non_Interventional|Non-Interventional
154093|NCT02990611|Other|Non-Interventional|Non-Interventional
154094|NCT02990611|Other|Non-Interventional|Non-Interventional
154095|NCT02990585|Other|Back school|
154096|NCT02990546|Drug|midodrine|Midodrine will be given to treatment arm as enteral medication
154097|NCT02990546|Other|Standard of Care|Patients in the control arm will receive standard of care for septic shock
154098|NCT02990533|Drug|Testosterone|
154099|NCT02990533|Dietary Supplement|Protein Supplement|
154100|NCT02990533|Other|Placebo Injection|
154101|NCT02990533|Other|Placebo supplement|
154102|NCT02990507|Other|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
154103|NCT02990507|Other|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
154104|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
154105|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
154106|NCT02990494|Behavioral|STANDARD|Standard Internet-delivered behavioral weight loss
154107|NCT02990494|Behavioral|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
154108|NCT02990494|Behavioral|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
154109|NCT02990481|Biological|TRK-950|Intravenously over 60 minutes, on day 1, 8 and 15 of each cycle
154110|NCT02990481|Biological|TRK-950|"Low dose: intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle~High dose: intravenously over 60 minutes, on day 1 and 15 of each cycle"
154111|NCT02990481|Biological|TRK-950|Low dose: Intravenously over 60 minutes, on day 1, 8, 15 and 22 of each cycle
154112|NCT02990481|Biological|TRK-950|Complying with the schedule of either low or high dose of Arm 2 as appropriate for the chosen schedule.
154113|NCT02990468|Drug|BMX-001|Subcutaneous injection.
154114|NCT02990468|Radiation|Radiation Therapy|Patients will receive standard dose intensity modulated radiation therapy (IMRT).
154115|NCT02990468|Drug|Cisplatin|Cisplatin will be administered per institution's standard of care practice.
154116|NCT02990455|Drug|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
154117|NCT02990442|Device|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
154118|NCT02990429|Procedure|Forced Air warmer|"record room temperature~record core temperature (tympanic membrane)~General anesthesia~using forced air warmer (bair hugger)~Intravenous fluid at room temperature~room temperature and core temperature q15 minutes~anesthesia finish, stop bair hugger~record core temperature before recovery room"
154119|NCT02990429|Procedure|Intravenous Fluid Warmer|"record room temperature~record core temperature (tympanic membrane)~General anesthesia~using ranger warmer~Intravenous fluid at room temperature~room temperature and core temperature q15 minutes~anesthesia finish, stop ranger warmer~record core temperature before recovery room"
154120|NCT02990416|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
154121|NCT02990416|Biological|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
154122|NCT02990416|Radiation|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
154123|NCT02990403|Drug|Aspirin|
154124|NCT02990403|Drug|Heparin|
154125|NCT02990403|Drug|Prednisone|
154126|NCT02990403|Drug|Immunoglobulin|
154127|NCT02990403|Drug|Dydrogesterone|
154128|NCT02990377|Behavioral|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
154129|NCT02990364|Drug|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
154130|NCT02990364|Drug|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
154131|NCT02990364|Drug|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
154132|NCT02990351|Procedure|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
154133|NCT02990338|Drug|isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
156820|NCT02970396|Behavioral|self-management|
154136|NCT02990325|Drug|ABX464 150mg|ABX464 given orally at 150 mg per day from Day 0 to Day 28 (Cohort 1/ HIV infected subjects)
154137|NCT02990325|Drug|ABX464 50mg|ABX464 given orally at 50 mg per day from Day 0 to Day 84 (Cohort 3 / HIV infected subjects) or from Day 0 to Day 28 (Cohort 2 / non HIV infected subjects)
154138|NCT02990312|Drug|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
154139|NCT02990299|Behavioral|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
154140|NCT02990286|Drug|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
154141|NCT02990286|Drug|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
154142|NCT02990286|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
154143|NCT02990273|Biological|Blood transfusion|
154144|NCT02990260|Dietary Supplement|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
154145|NCT02990260|Dietary Supplement|Lynside Wall Basic|yeast cell walls
154146|NCT02990260|Dietary Supplement|Placebo|Maize starch and magnesium stearate
154147|NCT02990247|Device|anharmonic morphological analysis of the respiratory signals (AMARS)|
154148|NCT02990234|Procedure|Capsular Repair|
154149|NCT02990234|Procedure|No Capsular Repair|
154150|NCT02990221|Drug|Ingenol mebutate|150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
154151|NCT02990221|Procedure|cryotherapy|application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
154152|NCT02990208|Behavioral|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens & Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
154153|NCT02990208|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger & Pauli, 2011)
154154|NCT02990195|Other|Chyme reinfusion|
154155|NCT02990169|Device|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
154156|NCT02990169|Device|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
154157|NCT02990156|Device|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
154158|NCT02990156|Device|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
154159|NCT02990143|Procedure|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
154160|NCT02990130|Other|Observational|
154161|NCT02990117|Other|No Intervention|No Intervention
154162|NCT02990091|Drug|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
154163|NCT02990091|Dietary Supplement|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
154190|NCT02989883|Other|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
154288|NCT02989116|Behavioral|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
154289|NCT02989116|Genetic|Saliva collection|Collection of a saliva sample for genotyping
154164|NCT02990078|Drug|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
154165|NCT02990078|Device|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
154166|NCT02990078|Other|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
154167|NCT02990065|Dietary Supplement|PROTEIN SUPPLEMENTATION|
154168|NCT02990052|Procedure|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
154169|NCT02990052|Procedure|Conservative treatment|Closed reduction & casting of distal radius fracture
154170|NCT02990039|Behavioral|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
154171|NCT02990026|Behavioral|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
154172|NCT02990013|Device|Avenova|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
154173|NCT02990013|Drug|Povidone-iodine 5% solution|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
154174|NCT02990013|Drug|4% chlorhexidine|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
154175|NCT02990013|Drug|Isopropyl alcohol|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
154176|NCT02990000|Behavioral|Scientific Match|Consecutive consenting patients at each site will be randomly assigned to condition. The project coordinator, unaware of therapist baseline performance, will generate the randomization sequences using an online random generator. Therapists will be crossed—that is, some of their cases will be matched, while others will be non-matched. Within condition, patients will be assigned sequentially to the site-specific therapists until therapists reach their study quota. In the low probability event that there is no therapist meeting minimal match criteria for a patient in the match condition, that patient will be removed from the study protocol (though will, of course, still receive treatment) and replaced with the next patient where a match does exist (this will also be carefully tracked).
154177|NCT02989987|Behavioral|Narrative Exposure Therapy|
154178|NCT02989987|Behavioral|Social Support|A local counselors provides social support on demand.
154179|NCT02989974|Behavioral|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.~Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
154180|NCT02989961|Other|Resticutis|Autologous, Activated-Platelets type of Preparation
154181|NCT02989961|Other|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
154182|NCT02989948|Device|Physician-modified aortic endograft|Physician-modified fenestrated endografting for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
154183|NCT02989935|Procedure|Ventilation|Measurements of ventilation with subjects seated, and breathing across a pneumotachygraph and pressure transducer to measure inspiratory airflow, during both resting and CO2 stimulated breathing.
154184|NCT02989935|Procedure|Parasternal EMG|Recordings of electrical activity (EMG) from the parasternal intercostal muscle in the second intercostal space on the upper anterior chest wall adjacent to the sternum.
154185|NCT02989935|Procedure|Phrenic magnetic stimulation|Bilateral maximal magnetic stimulation (Magstim) of the phrenic nerves.
154186|NCT02989922|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
154187|NCT02989909|Device|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
154188|NCT02989909|Device|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
154189|NCT02989896|Device|perfusion index|
154287|NCT02989116|Behavioral|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
154191|NCT02989870|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy."
154192|NCT02989870|Drug|Sorafenib|Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
154193|NCT02989870|Drug|Bavituximab|Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
154194|NCT02989857|Drug|AG-120|
154195|NCT02989857|Drug|AG-120 matched placebo|
154196|NCT02989844|Drug|N-803|N-803 at 6 mcg/kg SQ Day 1 of a 4 week (28 day) cycle with ± 1 week window Continue N-803 every 4 weeks for 10 doses or until relapse, unacceptable toxicity, or patient refusal, whichever comes earlier.
154197|NCT02989831|Device|Vibrating insoles 'on'|Duration: 30-60 seconds
154198|NCT02989818|Other|Endoscopic Submucosal Dissection|This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
154199|NCT02989805|Behavioral|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
154200|NCT02989792|Genetic|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
154201|NCT02989792|Other|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
154202|NCT02989779|Drug|NK1 Antagonist|
154203|NCT02989779|Drug|Placebo Oral Capsule|
154204|NCT02989766|Behavioral|Education on Breast Feeding|Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
154205|NCT02989753|Dietary Supplement|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
154206|NCT02989753|Dietary Supplement|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
154207|NCT02989753|Dietary Supplement|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
154208|NCT02989740|Procedure|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
154209|NCT02989727|Drug|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
154210|NCT02989727|Drug|Placebos|Placebo tablets
154211|NCT02989714|Drug|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
154212|NCT02989714|Drug|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
154213|NCT02989701|Drug|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
154214|NCT02989688|Dietary Supplement|Nepro HP (Abbott Nutrition)|oral nutritional supplement drink with modified carbohydrate composition
154215|NCT02989688|Dietary Supplement|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
154216|NCT02989688|Dietary Supplement|Fortisip compact 125 ml (Nutricia)|Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
154217|NCT02989675|Drug|10% dextrose|Bolus of 10% dextrose 5mls/kg
154218|NCT02989662|Drug|Mifepristone|Participants receive 6 doses.
154219|NCT02989662|Drug|Placebo - Cap|Participants receive 6 doses
154220|NCT02989649|Drug|Alogliptin|Alogliptin tablets
154221|NCT02989649|Drug|Alogliptin FDC With Pioglitazone|Alogliptin FDC with pioglitazone tablets
154222|NCT02989649|Drug|Alogliptin FDC With Metformin|Alogliptin FDC with metformin tablets
154223|NCT02989636|Other|Laboratory Biomarker Analysis|Correlative studies
154224|NCT02989636|Biological|Nivolumab|Given IV
154225|NCT02989636|Radiation|Stereotactic Radiosurgery|Undergo SRS
154226|NCT02989623|Radiation|Copper Cu 64 TP3805|Given Intravenously
154227|NCT02989623|Procedure|Positron Emission Tomography and Computed Tomography Scan|Undergo copper Cu 64 TP3805 PET/CT scan
154228|NCT02989610|Device|Omnidirectional stimulation|Symptom relief and side effect thresholds will be evaluated using omnidirectional stimulation with the DBS lead.
154229|NCT02989610|Device|Directional stimulation|Symptom relief and side effect thresholds will be evaluated using directional contacts of the DBS lead.
154230|NCT02989597|Drug|Methadone Hydrochloride|IV administration of methadone intra-operatively for a single dose
154231|NCT02989597|Other|Standard pain regimen|Control
154232|NCT02989584|Drug|Atezolizumab|
154233|NCT02989584|Drug|Gemcitabine|
154234|NCT02989584|Drug|Cisplatin|
154235|NCT02989571|Drug|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
154236|NCT02989571|Drug|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
154237|NCT02989558|Drug|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
154290|NCT02989116|Procedure|Brain Magnetic Resonance Imaging|Structural and functional MRI
154238|NCT02989558|Drug|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
154239|NCT02989545|Device|Anal Tape|
154240|NCT02989519|Drug|dydrogesterone|
154241|NCT02989519|Drug|Micronized progesterone|
154242|NCT02989493|Drug|Doxazosin|Doxazosin
154243|NCT02989493|Other|Placebo|Placebo
154244|NCT02989480|Radiation|PET CT|PET CT scans
154245|NCT02989480|Other|Cardiac MRI|Cardiac MRI
154246|NCT02989467|Drug|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
154247|NCT02989467|Drug|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
154248|NCT02989454|Other|Assessment of exercise capacity and cardiac energetics|Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
154249|NCT02989428|Procedure|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
154250|NCT02989415|Other|Mechanical Ventilation|Mechanical ventilation during robotic surgery
154251|NCT02989402|Drug|Rivastigmine|15 cm2 patch sizes loaded with 27 mg of rivastigmine
154252|NCT02989389|Drug|LY3323795|Administered orally
154253|NCT02989389|Drug|Itraconazole|Administered orally
154254|NCT02989389|Drug|Placebo|Administered orally
154255|NCT02989376|Procedure|After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.|When the ratio of the end diastolic velocity in the common carotid arteries is greater than 1.4 or the diastolic flow in the internal carotid artery is not detected by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment. If vessel occlusion is not detected by carotid duplex ultrasound, additional vascular imaging including MR angiography or CT angiography is considered.
154256|NCT02989363|Procedure|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
154257|NCT02989363|Procedure|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
154258|NCT02989363|Procedure|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
154259|NCT02989363|Procedure|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
154260|NCT02989350|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
154261|NCT02989350|Dietary Supplement|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
154262|NCT02989324|Drug|MisoprostoL|Vaginal MisoprostoL
154263|NCT02989324|Device|Foley Catheter|Misoprostol Plus Foley Catheter
154264|NCT02989311|Dietary Supplement|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
154265|NCT02989311|Dietary Supplement|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
154266|NCT02989298|Other|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
154267|NCT02989272|Drug|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
154268|NCT02989272|Other|saline group|saline group (30 patients) who will receive pretreatment by saline solution
154269|NCT02989259|Drug|Apatinib|apatinib 500mg p.o. qd
154270|NCT02989246|Other|Ventilator protocol|Open loop ventilator management by a computer based protocol
154271|NCT02989246|Device|Esophageal Catheter|Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
154272|NCT02989233|Other|Non-surgical periodontal treatment|Scaling and oral hygiene instructions with brochure, model or video
154273|NCT02989220|Other|Positive Reappraisal Coping Intervention|
154274|NCT02989207|Procedure|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
154275|NCT02989207|Device|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
154276|NCT02989207|Drug|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
154277|NCT02989194|Drug|VIS410 low dose|Single intravenous fixed low dose of VIS410
154278|NCT02989194|Drug|VIS410 high dose|Single intravenous fixed high dose of VIS410
154279|NCT02989194|Drug|Placebo|Single intravenous infusion of placebo
154280|NCT02989181|Device|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
154281|NCT02989168|Drug|GBT440|
154282|NCT02989142|Behavioral|INTER-ACT|"Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind & Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.~Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.~By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders."
154283|NCT02989129|Behavioral|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
154284|NCT02989129|Drug|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
154285|NCT02989116|Behavioral|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
154286|NCT02989116|Behavioral|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
154291|NCT02989116|Behavioral|Cognitive testing|Battery of cognitive and academic tasks on executive functions
154292|NCT02989090|Other|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
154293|NCT02989090|Other|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
154294|NCT02989064|Genetic|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|Infusion of autologous genetically modified MAGE A10ᶜ⁷⁹⁶T on Day 1
154295|NCT02989051|Other|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
154296|NCT02989051|Other|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of >85% of normal fluid recommendations (for a healthy child).
154297|NCT02989038|Other|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
154298|NCT02989038|Other|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
154299|NCT02989038|Other|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
154300|NCT02989025|Drug|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
154301|NCT02989012|Drug|GanMaoKangNing Granules|3 times a day, 2 bags each time.
154302|NCT02989012|Drug|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
154303|NCT02989012|Drug|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
154304|NCT02989012|Drug|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
154305|NCT02988999|Dietary Supplement|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
154306|NCT02988999|Dietary Supplement|erythritol|non-calorie sweetener
154307|NCT02988986|Drug|TAK-228|MTORC1/2 inhibitor
154308|NCT02988986|Drug|Tamoxifen|Non-steroidal anti-estrogen
154309|NCT02988973|Drug|roxadustat|Oral administration
154310|NCT02988973|Drug|DA|Subcutaneous administration
154311|NCT02988960|Drug|ABBV-927|Intravenous
154312|NCT02988960|Drug|ABBV-927|Intratumoral
154313|NCT02988960|Drug|ABBV-181|Intravenous
154314|NCT02988947|Other|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
154315|NCT02988921|Device|MRI and CT|
154316|NCT02988921|Radiation|Ratiotherapy|
154317|NCT02988921|Drug|Paclitaxel, platinum-based drug|
154318|NCT02988908|Drug|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
154319|NCT02988908|Drug|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.~Participants also received 2 weeks of memory training at weeks 13-14"
154320|NCT02988895|Radiation|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
154321|NCT02988882|Drug|Dexamethasone|
154322|NCT02988882|Other|Placebo Vehicle|
154323|NCT02988869|Drug|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
154324|NCT02988869|Drug|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
154325|NCT02988869|Drug|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
154326|NCT02988869|Drug|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
154327|NCT02988856|Device|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
154328|NCT02988843|Drug|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
154329|NCT02988843|Drug|Bevacizumab|15 mg/kg every 21 days
154330|NCT02988830|Device|Subcutaneous Electric Lumbar Stimulation|
154331|NCT02988817|Biological|Enapotamab vedotin (HuMax-AXL-ADC)|All arms of the trial (both in escalation and expansion phase) will be administered enapotamab vedotin (HuMax-AXL-ADC)
154332|NCT02988804|Device|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
154333|NCT02988804|Device|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
154334|NCT02988791|Dietary Supplement|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
154335|NCT02988791|Dietary Supplement|Placebo|Placebo
154336|NCT02988778|Drug|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
154337|NCT02988778|Drug|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
154338|NCT02988765|Procedure|Groin ultrasound +/- fine needle aspiration|"Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).~The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound"
154339|NCT02988752|Device|Electronic Mobile Device|Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
154340|NCT02988752|Device|Optical Coherence Tomography|Measure C/D Ratio With OCT, Considered Gold Standard Equipment
154341|NCT02988739|Biological|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
154342|NCT02988739|Device|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
154343|NCT02988726|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
154344|NCT02988713|Device|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
154345|NCT02988700|Drug|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
154346|NCT02988700|Drug|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2‑3mm deeper."
154347|NCT02988661|Behavioral|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
154348|NCT02988648|Radiation|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
154349|NCT02988635|Other|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
154350|NCT02988622|Device|Fraxel Laser|One half of the scar is treated with Fraxel Laser
154351|NCT02988622|Device|CO2 Laser|One half of the scar is treated with CO2 Laser.
154352|NCT02988609|Device|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
154353|NCT02988596|Other|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
154354|NCT02988596|Other|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich/Berlin Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
154355|NCT02988583|Device|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
154356|NCT02988583|Device|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
154357|NCT02988570|Behavioral|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
154358|NCT02988557|Procedure|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
154359|NCT02988557|Device|treadmill|walking on a treadmill with a sloped surface
154360|NCT02988544|Procedure|Artificial shrinkage|Artificial shrinkage of blastocyst
154361|NCT02988531|Other|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
154362|NCT02988518|Behavioral|COGMED program|"Patient should connect on his computer at home, 5 times a week, for 5 weeks. Every day, the patient has to do 8 exercises for a total duration of 30 to 45 minutes.~In total, the patient will have to complete 25 sessions. The difficulty level of the proposed items adjust automatically to the patient's maximum capacity to compel him to provide a cognitive effort. A progression index assesses the progress made by the patient.~Every week, the investigator will call the patient for 10 minutes in order to gather the patient's feelings, his difficulties, provide some advice and encourage him.~The investigator will have to analyze the results of curves available for each event, as well as the patient's progress index."
154363|NCT02988505|Other|Standard care|
154364|NCT02988492|Device|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole--‐brain CTP in predicting 24 hour DWI--‐MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
154365|NCT02988479|Other|Out of pocket payments in patients|
154366|NCT02988466|Biological|Haplo HCT <55 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Melphalan (Mel)~Total body irradiation (TBI)~Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
154367|NCT02988466|Biological|Haplo HCT ≥55 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Melphalan (Mel): Dose reduction by 30%~Total body irradiation (TBI)~Non-T-cell depleted donor bone marrow stem cell infusion"
154368|NCT02988466|Drug|GVHD Prophylaxis|"Cyclophosphamide (Cy)~Tacrolimus (Tac)~Mycophenolate mofetil (MMF)"
154369|NCT02988466|Biological|Haplo HCT ≥55 and < 65 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Melphalan (Mel)~Total body irradiation (TBI)~non-T-cell depleted donor bone marrow stem cells"
154370|NCT02988466|Biological|Haplo HCT ≥65 and ≤75 years old|"Fludarabine (Flu)~Cyclophosphamide (Cy)~Total body irradiation (TBI)"
154371|NCT02988453|Other|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 2 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 6 months.
154372|NCT02988440|Drug|PDR001|PDR001 will be administered intravenously
154373|NCT02988440|Drug|Sorafenib|Sorafenib is formulated as a tablet.
154374|NCT02988401|Drug|Insulin|All patients will receive either insulin or placebo using the Vianase III N2B device during the first 24 weeks of the study.
154375|NCT02988401|Drug|Placebo (Sterile diluent)|All patients will receive either insulin or placebo using Vianase III N2B device during the first 24 weeks of the study.
154376|NCT02988388|Procedure|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
154377|NCT02988375|Behavioral|dCBTI|
154378|NCT02988375|Behavioral|Sleep Education|
154379|NCT02988362|Drug|HL068 16/10mg|Candesartan 16mg and Amlodipine 10mg
154380|NCT02988362|Drug|Candesartan 16mg and Amlodipine 10mg|
154381|NCT02988349|Other|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
154382|NCT02988323|Other|Cervicovestibular Physio (CV PT)|See description in CVPT arm
154383|NCT02988323|Other|Low-Level Aerobic Exercise (LLAE)|See description in LLAE arm
154384|NCT02988323|Other|Combination (LLAE and CV PT)|See description in LLAE and CVPT arm
154385|NCT02988310|Other|No intervention|
154386|NCT02988297|Drug|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
154387|NCT02988297|Drug|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
154388|NCT02988284|Other|No intervention|
154389|NCT02988271|Other|Interview|Participate in interview
154390|NCT02988271|Procedure|Meditation Therapy|Complete meditation therapy
154391|NCT02988271|Procedure|Quality-of-Life Assessment|Complete questionnaires
154392|NCT02988271|Procedure|Supportive Care|Receive supportive care
154393|NCT02988258|Genetic|CMV-TCR transduced donor-derived T cells|Dose escalation
154394|NCT02988245|Drug|Geneticure Panel for HTN therapy|Using either Genetics (Geneticure for HTN multi-gene panel) or JNC-8 guidelines for prescribing for patients with hypertension
154395|NCT02988245|Drug|JNC-8|Using JNC-8 guidelines to guide therapy
154396|NCT02988232|Drug|Sogyeonghwalhyeol-tang|herbal extract
154397|NCT02988232|Drug|Placebo|extract powder with same appearance, odor and color as SGHH
154398|NCT02988219|Drug|Bupivacaine-fentanyl|Local anesthetic
154399|NCT02988219|Device|Holter ECG monitor|3-chanel, CM5 leads
154400|NCT02988219|Procedure|Open kidney cancer surgery|Lateral position
154401|NCT02988219|Procedure|General anesthesia|
154402|NCT02988219|Procedure|Epidural Anaesthesia|
154403|NCT02988206|Behavioral|Personalized Objects|personalized objects are based on the observation or the reports from family
154404|NCT02988206|Behavioral|non-personalized Objects|non-personalized objects are based on the suggestion in CRS-R,which are comb and cup
154405|NCT02988193|Device|optima4BP Medication Management|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
154406|NCT02988180|Other|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
154407|NCT02988180|Other|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
154408|NCT02988154|Other|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
154409|NCT02988154|Other|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
154410|NCT02988128|Device|Treatment for intracranial aneurysms|Embolization of aneurysms
154411|NCT02988115|Drug|bempedoic acid|bempedoic acid 180 mg tablet
154412|NCT02988115|Other|placebo|Matching placebo tablet
154413|NCT02988102|Other|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
154459|NCT02987907|Drug|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
154460|NCT02987907|Drug|Normal Saline|use normal saline 2ml I.A. during TACE
154461|NCT02987894|Device|ACURATE neo™ Aortic Bioprosthesis|TAVI, transcatheter aortic valve replacement. Transfemoral access.
154414|NCT02988089|Drug|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.~If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
154415|NCT02988089|Drug|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
154416|NCT02988089|Drug|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
154417|NCT02988089|Drug|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
154418|NCT02988089|Drug|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
154419|NCT02988089|Drug|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
154420|NCT02988076|Device|PEER Interactive Report|A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
154421|NCT02988063|Drug|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
154422|NCT02988050|Drug|Remifentanil|Remifentanil used for conscious sedation.
154423|NCT02988050|Drug|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
154424|NCT02988050|Drug|Propofol|Used for conscious sedation.
154425|NCT02988050|Drug|Bupivacaine|Local anaesthetics
154426|NCT02988050|Drug|Lidocaine|Local anaesthetic
154427|NCT02988050|Drug|Epinephrine|With local anaesthetic for skin infiltration.
154428|NCT02988037|Behavioral|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
154429|NCT02988024|Drug|LY03005|LY03005
154430|NCT02988024|Drug|Pristiq|
154431|NCT02988011|Procedure|Gastric by-pass surgery|Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
154432|NCT02988011|Dietary Supplement|Low-caloric diet|Energy restricted diet with a total energy intake of 800-1200kcal/day
154433|NCT02987998|Drug|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
154434|NCT02987998|Drug|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
154435|NCT02987998|Drug|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
154436|NCT02987998|Drug|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
154437|NCT02987985|Drug|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
154438|NCT02987985|Drug|Acetaminophen|acetaminophen 15 mg/kg
154439|NCT02987985|Drug|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
154440|NCT02987985|Drug|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
154441|NCT02987985|Drug|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
154442|NCT02987985|Drug|Sevoflurane|Sevoflurane (dose titrated to effect)
154443|NCT02987985|Drug|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
154444|NCT02987972|Biological|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
154445|NCT02987972|Biological|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
154446|NCT02987972|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
154447|NCT02987959|Drug|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
154448|NCT02987946|Device|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
154449|NCT02987946|Drug|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
154450|NCT02987920|Drug|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
154451|NCT02987920|Drug|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
154452|NCT02987920|Drug|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
154453|NCT02987920|Drug|Oxycodone|Multimodal analgesic regimen to Group A and Group B
154454|NCT02987920|Drug|Celecoxib|Multimodal analgesic regimen to Group A and Group B
154455|NCT02987920|Drug|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
154456|NCT02987920|Drug|Ketorolac|Multimodal analgesic regimen to Group A and Group B
154457|NCT02987920|Drug|Gabapentin|Multimodal analgesic regimen to Group A and Group B
154458|NCT02987920|Drug|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
158516|NCT02958150|Procedure|Standard Clinical Practice|
154462|NCT02987881|Behavioral|Home-based aerobic exercise and nutritional counseling|Moderate walking and running with nutritional counseling at study visits.
154463|NCT02987868|Drug|Amino acid supplement first day|An orally administered supplement of the proprietary amino acid derivative
154464|NCT02987868|Drug|Placebo first day|A non-active orally administered supplement of the proprietary amino acid derivative
154465|NCT02987868|Drug|Amino acid supplement second day|An orally administered supplement of the proprietary amino acid derivative
154466|NCT02987868|Drug|Placebo second day|A non-active orally administered supplement of the proprietary amino acid derivative
154467|NCT02987855|Procedure|Lipoaspiration|Closed syringe harvesting subdermal fat
154468|NCT02987855|Procedure|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
154469|NCT02987855|Procedure|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
154470|NCT02987842|Device|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
154471|NCT02987829|Drug|TRC253|TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.
154472|NCT02987816|Device|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
154473|NCT02987816|Device|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
154474|NCT02987803|Other|Data|The tool displays star ratings of hospitals on how labor-friendly they are. The star ratings (1 through 5) are based on hospital-level cesarean delivery rates. The data comes from The Leapfrog Group and is supplemented by publicly available state data. The data displayed will be customized to the users geographic location.
154475|NCT02987790|Other|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are <35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak> 100mg / L), with a limit of seven days, if there is clinical improvement.
154476|NCT02987764|Other|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
154477|NCT02987751|Drug|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
154478|NCT02987751|Drug|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
154479|NCT02987738|Drug|Dapagliflozin|two administrations in the evening and 12 hours later
154480|NCT02987738|Drug|Placebo Oral Tablet|two administrations in the evening and 12 hours later
154481|NCT02987725|Behavioral|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
154482|NCT02987725|Behavioral|Attention Control|A 30-minute historical story read by a research clinician.
154483|NCT02987712|Other|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
154484|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
154485|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
154486|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
154487|NCT02987686|Drug|Topical Infliximab|Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
154488|NCT02987673|Procedure|MGB/OAGB|
154489|NCT02987673|Procedure|LSG|
154490|NCT02987660|Procedure|Topography Guided LASIK|Corneal surgery for refractive error correction
154491|NCT02987660|Procedure|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
154492|NCT02987660|Device|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
154493|NCT02987660|Device|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
154494|NCT02987647|Other|Hidrafemme|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
154495|NCT02987647|Other|Vagidrat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
154496|NCT02987647|Other|Lubrinat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
154497|NCT02987647|Other|Antrofi|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
154498|NCT02987634|Other|PeriActive|mouthwash
154499|NCT02987621|Device|tDCS|Less than 10V of Transcranial Direct Current Stimulation
253550|NCT02264080|Drug|WAL2014|
154500|NCT02987621|Device|Sham tDCS|Sham 0V of Transcranial Direct Current Stimulation
154501|NCT02987608|Device|Power Up|Smartphone phone app
154502|NCT02987595|Other|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
154503|NCT02987595|Other|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
154504|NCT02987582|Behavioral|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
154505|NCT02987569|Behavioral|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
154506|NCT02987569|Behavioral|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
154507|NCT02987569|Device|iPad|
154508|NCT02987556|Device|Continuous Glucose Monitoring|Collection of glucose data
154509|NCT02987556|Device|External Insulin Pump|insulin delivery
154510|NCT02987556|Other|telemdecine|Remote follow up by care health providers team
154511|NCT02987556|Device|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo or Kaleido insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
154512|NCT02987543|Drug|olaparib|300 mg (2x 150 mg tablets) twice daily
154513|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg capsules) once daily
154514|NCT02987543|Drug|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
154515|NCT02987543|Drug|abiraterone acetate|1,000 mg (2 x 500 mg tablets) once daily
154516|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg tablets) once daily
154517|NCT02987530|Drug|Dolutegravir|Oral use, 50mg/day
154518|NCT02987530|Drug|Darunavir-cobicistat|Oral use, 800-150mg/day
154519|NCT02987530|Drug|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
154520|NCT02987517|Other|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
154521|NCT02987517|Other|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
154522|NCT02987517|Other|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
154523|NCT02987504|Drug|Samalizumab|Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
154524|NCT02987491|Behavioral|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
154525|NCT02987465|Drug|Darbepoetin Alfa|Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
154526|NCT02987465|Drug|Acetylcholine|Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
154527|NCT02987465|Drug|Noradrenaline|Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
154528|NCT02987465|Drug|BQ 123|BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
154529|NCT02987452|Other|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
154530|NCT02987452|Other|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
154531|NCT02987452|Other|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
154532|NCT02987439|Other|Pulmonary rehabilitation|The intervention is pulmonary rehabilitation
154533|NCT02987426|Behavioral|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:~Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
154534|NCT02987413|Biological|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10^8 cells) will be performed, escalated from 30 days apart
154535|NCT02987400|Drug|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
154536|NCT02987400|Drug|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
154537|NCT02987387|Device|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
154538|NCT02987374|Biological|2011-2012 Fluzone IIV3 (IM)|2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
154539|NCT02987361|Device|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
154540|NCT02987348|Drug|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
154541|NCT02987348|Drug|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
154542|NCT02987348|Drug|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
154543|NCT02987335|Drug|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
154544|NCT02987322|Dietary Supplement|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
154545|NCT02987296|Dietary Supplement|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
154546|NCT02987296|Dietary Supplement|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
154547|NCT02987270|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
154548|NCT02987257|Drug|cyclosporin A|In addition to supportive care as described in the respective arm, cyclosporine 1.7 mg/kg IV for 2 weeks will be started upon enrolment in the study. A single subcutaneous injection of placebo will mask the cyclosporine arm.
154549|NCT02987257|Drug|Etanercept 50 MG Solution for Injection|In addition to supportive care as described, 50 mg sc will be given once upon enrolment in the study. An IV placebo will mask the cyclosporine arm.
154550|NCT02987257|Drug|Placebos|Intravenous and subcutaneous saline to match cyclosporine and etanercept in an identical delivery container/syringe
154551|NCT02987244|Drug|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.~Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
154552|NCT02987244|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
154553|NCT02987244|Drug|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
154554|NCT02987244|Drug|Vindesine|vindesine (4mg)was administered intravenously on d1;
154555|NCT02987244|Drug|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
154556|NCT02987244|Drug|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
154557|NCT02987231|Procedure|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
154558|NCT02987231|Device|ES|Local electric stimulation for 120 seconds, once a day for a week
154559|NCT02987231|Device|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
154560|NCT02987218|Drug|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
154561|NCT02987218|Drug|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
154562|NCT02987205|Device|Revanesse Ultra|NLF correction
154563|NCT02987205|Device|Restylane|NLF Correction
154564|NCT02987192|Device|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
154565|NCT02987192|Device|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
154566|NCT02987179|Other|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
154567|NCT02987166|Radiation|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions~30 Gy in 5 fractions of 6 Gy each for prostate gland"
154568|NCT02987166|Drug|Pembrolizumab|200 mg
154569|NCT02987153|Radiation|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
154570|NCT02987140|Behavioral|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
154571|NCT02987114|Drug|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
154572|NCT02987101|Procedure|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
154573|NCT02987101|Other|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
154574|NCT02987101|Drug|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
154575|NCT02987088|Drug|Sodium Nitrite|
154576|NCT02987075|Other|Compacting embryo transferring|transfer of 2 utilizable compacting embryos
154577|NCT02987075|Other|Non- compacting embryo transferring|transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
154578|NCT02987036|Device|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
154579|NCT02987036|Device|Jet nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
154580|NCT02987023|Procedure|uterus transplantation|Uterus transplantation from live donor
154581|NCT02987010|Drug|IDH305|Isocitrate Dehydrogenase 1 inhibitor
154582|NCT02986984|Other|There is no intervention|There are no interventions
154583|NCT02986971|Device|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
154584|NCT02986958|Other|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
154585|NCT02986958|Other|Usual care|routine primary care
154586|NCT02986945|Behavioral|Resiliency App|
154587|NCT02986932|Device|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
154662|NCT02986347|Procedure|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
158867|NCT02955706|Drug|Acetyl-L-Carnitine|TID
154588|NCT02986919|Drug|CPI-0610|"Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
154589|NCT02986906|Drug|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
154590|NCT02986906|Drug|2cc 0.9% normal saline+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 0.9% normal saline+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
154591|NCT02986906|Device|Ultrasound|The ultrasound was used for injection guidance
154592|NCT02986893|Behavioral|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
154593|NCT02986893|Behavioral|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
154594|NCT02986880|Drug|Botulinum toxin A|
154595|NCT02986880|Procedure|Placebo|Injection of sodium chloride (NaCl) 9/1000
154596|NCT02986867|Radiation|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
154597|NCT02986854|Biological|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
154598|NCT02986828|Drug|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
154599|NCT02986828|Drug|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
154600|NCT02986828|Device|Ultrasound|
154601|NCT02986815|Other|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the [11C]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
154602|NCT02986776|Behavioral|Inpatient Care|21 days of inpatient substance misuse treatment
154603|NCT02986776|Behavioral|Outpatient Care|21 days of outpatient substance misuse treatment
154604|NCT02986763|Biological|Questionnaire, blood, urine, hair and dust samplings|
154605|NCT02986750|Device|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
154606|NCT02986750|Device|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
154607|NCT02986750|Device|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
154608|NCT02986737|Device|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
154609|NCT02986711|Behavioral|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
154610|NCT02986711|Behavioral|Control|Only survey questions about smoking status
154611|NCT02986698|Biological|in utero hematopoietic stem cell transplantation|This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
154612|NCT02986685|Drug|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
154613|NCT02986685|Drug|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
154614|NCT02986672|Dietary Supplement|Calanus oil|Omega-3 oil in form of calanus oil
154615|NCT02986672|Other|Medical Paraffin|2ml per day
154616|NCT02986659|Drug|Metformin|
154617|NCT02986659|Drug|Placebo|
154618|NCT02986633|Other|Echocardiography|
154619|NCT02986620|Genetic|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
154620|NCT02986607|Drug|parathyroid hormon 1-84|Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
154621|NCT02986594|Drug|Aspirin|
154622|NCT02986594|Drug|Heparin|
154623|NCT02986568|Drug|Cisplatin|If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles)
154624|NCT02986568|Drug|Cisplatin|Before surgery, neoadjuvant chemotherapy with cisplatin (40mg/m2 on day 1 of each 7 day cycle for 5 cycles) is performed.
154625|NCT02986568|Procedure|Peritoneal mesometrial resection|Perform Fusion Peritoneal mesometrial resection (PMMR).
154626|NCT02986568|Procedure|Radical hysterectomy|Type C radical hysterectomy.
154627|NCT02986568|Radiation|Concurrent chemoradiation therapy (CCRT)|Radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle
154628|NCT02986568|Procedure|Laterally extended endopelvic resection, Total mesometrial resection|"After neoadjuvant chemotherapy, if pelvic wall invasion is absent, perform Fusion Total mesometrial resection (TMMR).~If pelvic wall invasion is present, perform Fusion Laterally extended endopelvic resection (LEER) with preserving bladder, rectum and anus."
154629|NCT02986568|Procedure|Total mesometrial resection|"If tumor size < 5cm, perform Fusion Total mesometrial resection (TMMR)~If tumor sized ≥ 5cm, perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above."
154663|NCT02986347|Procedure|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
154664|NCT02986334|Drug|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
154630|NCT02986568|Drug|5-fluorouracil, Cisplatin|"After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with 5-fluorouracil and cisplatin. (5-fluorouracil 1000mg/m2 on day 1-5 and Cisplatin 60mg/m2 on day 1 of each 21 day cycle)~If not, no adjuvant therapy."
154631|NCT02986568|Drug|5-fluorouracil, Cisplatin|"After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with 5-fluorouracil and cisplatin. (5-fluorouracil 1000mg/m2 on day 1-5 and Cisplatin 60mg/m2 on day 1 of each 21 day cycle)~If not, no adjuvant therapy."
154632|NCT02986568|Drug|Doxorubicin, Cisplatin|"After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with doxorubicin and cisplatin. (Doxorubin 60mg/m2 and Cisplatin 50mg/m2 on day 1 of each 21 day cycle)~If not, no adjuvant therapy."
154633|NCT02986568|Procedure|Staging operation|Perform surgical staging include hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph node dissection and para-aortic lymph node dissection.
154634|NCT02986568|Radiation|Radiotherapy or Concurrent chemoradiation therapy (CCRT)|Undergo adjuvant therapy after surgical staging. Radiotherapy only or CCRT (radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle)
154635|NCT02986568|Radiation|Concurrent chemoradiation therapy (CCRT)|If risk factor is reported in pathologic report, undergo adjuvant CCRT. (radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle)
154636|NCT02986555|Device|Existing Biofeedback|Using relaxing assisted biofeedback approach
154637|NCT02986555|Device|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
154638|NCT02986542|Procedure|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
154639|NCT02986529|Drug|GV-971|
154640|NCT02986529|Drug|Placebos|
154641|NCT02986516|Other|Randomized Cohort|Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
154642|NCT02986516|Radiation|Prospective cohort|Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
154643|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
154644|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
154645|NCT02986490|Biological|Blood sample|Blood sample
154646|NCT02986477|Other|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
154647|NCT02986464|Device|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
154648|NCT02986464|Other|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant`s age, weight and condition by the anesthetist and the pain clinic nurse.
154649|NCT02986451|Drug|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
154650|NCT02986451|Drug|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
154651|NCT02986451|Drug|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
154652|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.~Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
154653|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).~This condition will only last two weeks."
154654|NCT02986425|Other|STRIP intervention|"The STRIP intervention consists of 9 steps:~structured history taking of medication~recording medication and diagnoses in STRIPA~structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria~communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation~shared decision-making with the patient with possible adaptation of the recommendation~optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)~generation of general practioner (GP) report~delivery of the report to the patient and to the GP (optional additional direct communication)~follow-up"
154655|NCT02986425|Other|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
154656|NCT02986412|Other|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
154657|NCT02986399|Other|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
154658|NCT02986386|Procedure|Dental occlusion restoration|Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
154659|NCT02986386|Procedure|Orthodontic treatment of malocclusion|Orthodontic therapy to treat malocclusion
154660|NCT02986373|Biological|risankizumab|Risankizumab administered by subcutaneous injection.
154661|NCT02986360|Behavioral|Vidscrip educational video|Vidscrip educational video provide to women
154665|NCT02986334|Drug|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
154666|NCT02986334|Drug|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
154667|NCT02986321|Drug|CHF6001|Dose response: Test one of 4 different doses of CHF6001
154668|NCT02986321|Drug|Budesonide|active control
154669|NCT02986321|Drug|Placebo|placebo control
154670|NCT02986308|Other|No intervention|
154671|NCT02986295|Device|BioMimeTM Stent, Ultimaster® Stent|
154672|NCT02986282|Device|ABI measurement using both doppler and oscillometric method|
154673|NCT02986269|Procedure|general anesthesia across LMA|general anesthesia across LMA
154674|NCT02986269|Procedure|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
154675|NCT02986269|Procedure|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
154676|NCT02986256|Behavioral|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
154677|NCT02986256|Behavioral|Visit at home|Home visit by the referring nurse every 15 days
154678|NCT02986243|Other|Exercise|6 months worth of exercise regimen
154679|NCT02986243|Dietary Supplement|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
154680|NCT02986230|Other|Cancer prevention wizard (CPW)|The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
154681|NCT02986217|Other|regular structured assessment of surgical performance|
154682|NCT02986204|Procedure|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT~questions about your medical/contraception history~Review medical record~physical examination~urine sample for pregnancy test~Visit 2a - Radiology~Have an ultrasound of your arm~The radiologist will mark your arm at the location of the implant.~Visit 2b~ultrasound of your arm to locate the implant. This is done by feeling the area.~Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.~Have the removal procedure video recorded.~Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:~Provide a urine sample for pregnancy test~Have the implant removal site examined"
154683|NCT02986204|Procedure|continuation of ING implant|"the researcher(s) will ask you to:~To answer questions about your medical and contraception history~Review your medical record~Have a physical examination by the researcher~Provide a urine sample for pregnancy test~Have an ultrasound of your arm"
154684|NCT02986191|Procedure|Mucograft|This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
154685|NCT02986191|Procedure|Connective Tissue Graft|This will be used in the traditional manner to correct gingival recession
154686|NCT02986178|Biological|PVSRIPO|A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)
154687|NCT02986165|Dietary Supplement|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
154688|NCT02986165|Dietary Supplement|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
154689|NCT02986165|Dietary Supplement|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
154690|NCT02986152|Behavioral|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
154691|NCT02986139|Drug|Commercial Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the commercial formulation.
154692|NCT02986139|Drug|New Formulation Etanercept|Etanercept was supplied in a single-use SureClick autoinjector as a sterile, preservative-free solution for SC injection containing 0.98 mL of 50 mg/mL etanercept in the new formulation.
154693|NCT02986126|Behavioral|Resiliency Class|See Arm Description
154694|NCT02986126|Other|Resource for Services (RS)|See Resource for Services (RS) Description
154695|NCT02986113|Behavioral|MAPS tailored multimedia patient activation program|
154696|NCT02986113|Behavioral|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
154697|NCT02986113|Behavioral|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
154698|NCT02986113|Behavioral|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
154730|NCT02985866|Other|Sensor Augmented Therapy|Use of personal pump with study CGM & glucometer at home for 3 months
158868|NCT02955706|Drug|Placebo of Acetyl-L-Carnitine|TID
154699|NCT02986100|Drug|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and [14C]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of [14C]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of [14C]-rucaparib
154700|NCT02986100|Drug|Rucaparib|200 & 300 mg tablet
154701|NCT02986087|Device|Fetal Tracheal Occlusion|Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of <25%, LHR <1, o/e LHR<30% (moderate), singleton pregnancy, no known other anomalies, gestational age < 29 weeks 6 days, no maternal disease, maternal age > 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center as a requirement to enter the TOTAL trial.
154702|NCT02986074|Device|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
154703|NCT02986074|Device|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
154704|NCT02986061|Device|Urinary catheter|
154705|NCT02986048|Other|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
154706|NCT02986035|Other|ECA cream|
154707|NCT02986022|Behavioral|Resilience|Self-efficacy, optimism, altruism, goal setting
154708|NCT02986022|Behavioral|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
154709|NCT02986009|Behavioral|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
154710|NCT02986009|Behavioral|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
154711|NCT02985996|Drug|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
154712|NCT02985996|Drug|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
154713|NCT02985983|Drug|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 66.
154714|NCT02985983|Drug|Placebo|Administered Placebo by subcutaneous (SC) injection until week 16. Administered KHK4827 by SC injection from week 17 until week 66.
154715|NCT02985970|Other|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
154716|NCT02985957|Biological|Nivolumab|Specified dose on specified days
154717|NCT02985957|Biological|Ipilimumab|Specified dose on specified days
154718|NCT02985957|Drug|Cabazitaxel|Specified dose on specified days
154719|NCT02985957|Drug|Prednisone|Specified dose on specified days
154720|NCT02985944|Procedure|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
154721|NCT02985931|Other|Diagnostic imaging scans of SPECT and MRI|
154722|NCT02985918|Device|High-intensity NPPV|The patients will receive noninvasive positive pressure ventilation using S/T mode. The inspiratory positive airway pressure will be initially set at 10 cmH2O, and will be continuously adjusted by increments/decrements of 1-2 cmH2O, according to subjects' tolerance (up to 30 cmH2O), to obtain a VT of 15 mL/kg of predicted body weight, and to achieve normocapnia as possible as it can.
154723|NCT02985918|Device|Conventional-intensity NPPV|The patients will receive noninvasive positive pressure ventilation using S/T mode. The inspiratory positive airway pressure will be initially set at 10 cmH2O, and will be continuously adjusted by increments/decrements of 1-2 cmH2O, according to subjects' tolerance (up to 20 cmH2O), to obtain a VT of 10 mL/kg of predicted body weight.
154724|NCT02985905|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
154725|NCT02985892|Other|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
154726|NCT02985892|Other|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.~Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
154727|NCT02985879|Drug|placebo|Placebo solution for IV infusion
154728|NCT02985879|Drug|ABBV-8E12|ABBV-8E12 solution for IV infusion
154729|NCT02985866|Device|Artificial Pancreas|Use of CTR at home for 3 months
154822|NCT02985216|Drug|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
154731|NCT02985840|Drug|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
154732|NCT02985840|Drug|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
154733|NCT02985827|Drug|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
154734|NCT02985827|Drug|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
154735|NCT02985801|Drug|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
154736|NCT02985801|Drug|Placebo Oral Capsule|Placebo Oral Capsule
154737|NCT02985775|Biological|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
154738|NCT02985762|Drug|EXPAREL|
154739|NCT02985749|Drug|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
154740|NCT02985736|Drug|Topicort Topical Spray|
154741|NCT02985723|Device|AT LISA tri toric 939MP|
154742|NCT02985710|Device|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
154743|NCT02985710|Procedure|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
154744|NCT02985710|Procedure|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
154745|NCT02985697|Drug|Dexmedetomidine|The intervention being tested is intranasal dexmedetomidine
154746|NCT02985697|Drug|Midazolam Hydrochloride|Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
154747|NCT02985697|Drug|Nitrous Oxide|Nitrous oxide to be administered in conjunction with other interventions, per study design.
154748|NCT02985684|Device|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
154749|NCT02985671|Drug|orphenadrine, acetaminophen, caffeine and diclofenac sodium|orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
154750|NCT02985671|Drug|Diclofenac Sodium 50 MG|Voltaren (diclofenac sodium 50mg) tablet
154751|NCT02985671|Drug|Placebo (for experimental drug)|tablet without active substances, manufactured to mimic experimental product tablet
154752|NCT02985671|Drug|Placebo (for Voltaren)|tablet without active substances, manufactured to mimic Voltaren 50mg tablet
154753|NCT02985658|Drug|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.~At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.~The patient will receive therapy as long as there is therapeutic benefit"
154754|NCT02985658|Drug|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
154755|NCT02985658|Drug|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
154756|NCT02985645|Procedure|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
154757|NCT02985645|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
154758|NCT02985632|Drug|BMS-986141|
154759|NCT02985619|Drug|Bevacizumab|
154760|NCT02985619|Drug|Triamcinolone Acetonide|
154761|NCT02985606|Other|Caffeine powder -60|
154762|NCT02985606|Other|Caffeine powder -30|
154763|NCT02985606|Other|Caffeine powder 0|
154764|NCT02985606|Other|Placebo powder -60|
154765|NCT02985606|Other|Placebo powder -30|
154766|NCT02985606|Other|Placebo powder 0|
154767|NCT02985593|Drug|KHK4083|
154768|NCT02985593|Drug|Placebo|
154769|NCT02985580|Dietary Supplement|Blueberry|
154770|NCT02985580|Dietary Supplement|Placebo|
154771|NCT02985567|Other|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
154772|NCT02985554|Drug|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
154773|NCT02985541|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg Levonorgestrel per day
154774|NCT02985528|Other|further diagnostic|further diagnostic procedures - mainly CHEST CT -
154775|NCT02985515|Combination Product|Smell training|"Eligible participants will be provided with a NeilMed Sinus Rinse Regular Bottle Kit and a one-month supply of USP Grade Sodium Chloride & Sodium Bicarbonate Mixture commercially prepared packets. Participants will need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation. The contents of two capsules (0.5mg budesonide each) will be dissolved into NeilMed Sinus Rinse Regular Bottle along with the saline rinse. Both nasal cavities will be irrigated once daily for 30 days.~Participants who do not have objective improvement in their olfaction after the trial of budesonide irrigation will have a baseline resting-state fMRI (rs-fMRI) and undergo 12 weeks of smell training. Smell training involves the participants smelling 4 vials of essential odors twice a day for 12 weeks. Following smell training, participants will have their smell ability re-evaluated and a second rs-fMRI performed."
154776|NCT02985502|Other|pancreatogenic diabetes|pancreatogenic diabetes
154777|NCT02985489|Dietary Supplement|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
253551|NCT02264080|Drug|Placebo|
154778|NCT02985476|Other|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
154779|NCT02985450|Biological|Engerix-B|Hepatitis B Vaccine
154780|NCT02985437|Drug|Surfactants|
154781|NCT02985437|Drug|Saline Solution|
154782|NCT02985424|Other|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
154783|NCT02985411|Behavioral|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
154784|NCT02985411|Other|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
154785|NCT02985398|Biological|ALD403 (Eptinezumab)|
154786|NCT02985385|Other|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
154787|NCT02985372|Drug|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
154788|NCT02985372|Drug|Cytarabine|
154789|NCT02985359|Dietary Supplement|Nutributter|Daily 20g Nutributter provided to children 6 to 24 month of age
154790|NCT02985359|Behavioral|Social Behavioral Change Communication (SBCC)|Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
154791|NCT02985346|Biological|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
154792|NCT02985333|Drug|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
154793|NCT02985333|Drug|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
154794|NCT02985333|Drug|Dexamethasone|Dexamethasone 20mg iv d1-4
154795|NCT02985320|Biological|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
154796|NCT02985320|Biological|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
154797|NCT02985320|Biological|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
154798|NCT02985320|Biological|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
154799|NCT02985320|Biological|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
154800|NCT02985320|Biological|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
154801|NCT02985320|Biological|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
154802|NCT02985307|Behavioral|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
154803|NCT02985307|Behavioral|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
154804|NCT02985294|Other|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and `threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
154805|NCT02985281|Drug|Sofosbuvir Oral Product|direct acting antiviral drug for HCV infection
154806|NCT02985281|Drug|Ribavirin|antiviral drug for HCV infection
154807|NCT02985268|Device|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
154808|NCT02985268|Drug|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
154809|NCT02985268|Device|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
154810|NCT02985255|Drug|Docetaxel|Neoadjuvant Arm
154811|NCT02985255|Drug|Cisplatin|Neoadjuvant Arm
154812|NCT02985255|Drug|5FU|Neoadjuvant Arm
154813|NCT02985255|Radiation|Radiotherapy|Neoadjuvant Arm
154814|NCT02985255|Procedure|Glossectomy|Neoadjuvant Arm
154815|NCT02985242|Drug|Empagliflozin|Empagliflozin film-coated tablet
154816|NCT02985242|Drug|Glimepiride|Glimepiride tablet
154817|NCT02985242|Drug|Empagliflozin placebo|Placebo tablet manufactured to mimic Empagliflozin 25 mg film-coated tablet
154818|NCT02985242|Drug|Glimepiride placebo|Placebo tablet manufactured to mimic Glimepiride 2 mg tablet
154819|NCT02985229|Drug|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
154820|NCT02985229|Drug|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
154821|NCT02985216|Drug|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO~YHD1119 600mg, PO"
154823|NCT02985203|Drug|Vinorelbine Oral|Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
154824|NCT02985190|Drug|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
154825|NCT02985177|Drug|Fentanyl intranasal + Oral Hydromorphone|Analgesics
154826|NCT02985177|Drug|Fentanyl intranasal + Oral ibuprofen|Analgesics
154827|NCT02985164|Radiation|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
154828|NCT02985164|Radiation|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
154829|NCT02985151|Device|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
154830|NCT02985138|Procedure|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
154831|NCT02985138|Procedure|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
154832|NCT02985138|Device|Pedicle screw and cage|Pedicle screw and cage
154833|NCT02985125|Drug|LEE011|Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
154834|NCT02985125|Drug|Everolimus|Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
154835|NCT02985112|Device|FFR and IVUS-NIRS|
154836|NCT02985099|Drug|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
154837|NCT02985099|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
154838|NCT02985086|Drug|Cefoxitin|
154839|NCT02985086|Drug|oxytocin/misoprostol|
154840|NCT02985073|Device|Veritas®|Biologic mesh
154841|NCT02985073|Device|TIGR®|Non biologic mesh
154842|NCT02985060|Device|Arctic Sun|"Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.~Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed~Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours~Recovery phase:Rewarming velocity: 0.05~0.1℃ (within 30 hours)"
154843|NCT02985060|Other|Standard treatment|"All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.~In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.~Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.~Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
154844|NCT02985060|Drug|Saline|
154845|NCT02985047|Other|Brief Admission|Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
154846|NCT02985034|Procedure|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
154847|NCT02985021|Drug|Carboplatin|Chemotherapy
154848|NCT02985021|Drug|Docetaxel|Chemotherapy
154849|NCT02984995|Drug|Quizartinib|A novel second-generation FLT3 inhibitor
154850|NCT02984982|Drug|Alirocumab SAR236553|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
154851|NCT02984982|Drug|Atorvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
154852|NCT02984982|Drug|Rosuvastatin|"Pharmaceutical form: tablet~Route of administration: oral"
154853|NCT02984982|Drug|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
154854|NCT02984982|Drug|Bezafibrate|"Pharmaceutical form: tablet~Route of administration: oral"
154855|NCT02984982|Drug|Ezetimibe|"Pharmaceutical form: tablet~Route of administration: oral"
154856|NCT02984982|Drug|Antiplatelets|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
154857|NCT02984982|Drug|Anticoagulants|"Pharmaceutical form: tablet or capsule~Route of administration: oral"
154858|NCT02984956|Device|pleth variability index|
154859|NCT02984943|Device|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
154860|NCT02984930|Drug|Administration of study drug (esomeprazole, mosapride)|Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
154861|NCT02984930|Drug|Administration of study drug (esomeprazole, placebo tablet)|Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
154862|NCT02984930|Procedure|upper endoscopy, scintigraphy|After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
154863|NCT02984917|Procedure|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
154864|NCT02984917|Procedure|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
154865|NCT02984904|Other|survey|survey
154866|NCT02984891|Procedure|Optical Coherence Tomography (OCT)|Procedure will be performed using the OCT Dragonfly catheter is a hydrophilic-coated catheter that uses infrared light with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, and maximum tissue penetration with OCT is approximately 1.5 mm-3 mm.
154973|NCT02984150|Dietary Supplement|dodecanoic acid|
154974|NCT02984150|Dietary Supplement|saline|
155215|NCT02982369|Other|Spinal Manipulation|High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region
154867|NCT02984891|Procedure|Intravascular Ultrasound (IVUS)|Procedure will be performed using the IVUS Kodama catheter is a hydrophilic-coated catheter that used high-fidelity ultrasound transmission to capture high-definition images of coronary artery anatomy. It uses ultrasound waves with a frequency of 40 or 60 MHz, as opposed to 20 MHz in conventional IVUS, to improve resolution while optimizing tissue penetration. It provides axial resolution of < 40 microns and tissue penetration of 10 mm.
154868|NCT02984878|Device|Revanesse Ultra|Nasolabial Fold correction
154869|NCT02984865|Drug|Sulfentanyl|
154870|NCT02984865|Drug|Nalbuphine|
154871|NCT02984865|Drug|flubiprofen axetil|
154872|NCT02984865|Procedure|rectus sheath block|Transversus abdominis plane (TAP) block combined with rectus sheath (RS) block will be applied in Group ESRD
154873|NCT02984852|Drug|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
154874|NCT02984852|Drug|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
154875|NCT02984852|Drug|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
154876|NCT02984852|Drug|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
154877|NCT02984839|Device|Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology|Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
154878|NCT02984826|Other|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
154879|NCT02984826|Other|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
154880|NCT02984813|Drug|GlaucoHealth|Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
154881|NCT02984813|Drug|GlaucoSelect|Containing curcumin, bilberry extract, and grape seed extract
154882|NCT02984813|Drug|Placebo|No active ingredients
154883|NCT02984800|Other|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
154884|NCT02984800|Other|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
154885|NCT02984800|Other|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
154886|NCT02984787|Procedure|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
154887|NCT02984787|Procedure|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
154888|NCT02984774|Procedure|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
154889|NCT02984774|Procedure|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
154890|NCT02984774|Procedure|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
154891|NCT02984774|Procedure|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
154892|NCT02984761|Radiation|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
154893|NCT02984761|Procedure|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
154894|NCT02984748|Device|Cochlear implant|
154895|NCT02984735|Other|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
154896|NCT02984722|Drug|Metformin|
154975|NCT02984137|Other|testing, evaluation, sampling|neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological & neurocognitive status by using a predefined neuropsychological assessment battery.
155212|NCT02982382|Other|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
154897|NCT02984709|Behavioral|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period) Small gift ($5 gift card code sent every 2 weeks for 8 weeks)
154898|NCT02984709|Behavioral|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit
154899|NCT02984696|Drug|1 mg of transdermal estradiol daily and 10mg of oral MPA|
154900|NCT02984683|Drug|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
154901|NCT02984670|Behavioral|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
154902|NCT02984670|Behavioral|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
154903|NCT02984670|Behavioral|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
154904|NCT02984657|Procedure|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.|RTP, reverse Trendelenburg positioning
154905|NCT02984657|Procedure|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.|RTP, reverse Trendelenburg positioning
154906|NCT02984644|Drug|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
154907|NCT02984644|Drug|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
154908|NCT02984631|Procedure|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
154909|NCT02984618|Procedure|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
154910|NCT02984618|Procedure|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
154911|NCT02984605|Dietary Supplement|nutritional meal replacement|1 times a day with bags of nutritional meal replacement + individualized exercise prescription
154912|NCT02984592|Behavioral|physical exercise|regular exercise programs in the previous 6 months.
154913|NCT02984579|Device|YD REBA MTB-MDR|Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.
154914|NCT02984579|Device|Hain Genotype MTBDRplus V1|Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance
154915|NCT02984579|Device|Hain Genotype MTBDRplus V2|Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
154916|NCT02984566|Device|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
154917|NCT02984540|Other|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
154918|NCT02984540|Other|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
154919|NCT02984527|Device|wet wipes|intimate hygiene with disposable wet wipes
154920|NCT02984527|Device|water and soap|Intimate hygiene with water and soap
154921|NCT02984514|Radiation|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
154922|NCT02984501|Radiation|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
154923|NCT02984501|Drug|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
154924|NCT02984488|Procedure|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
154925|NCT02984488|Procedure|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
154926|NCT02984475|Drug|Metformin|
155014|NCT02983825|Device|Continuous positive airway pressure (CPAP); level changes|as per arm description
155015|NCT02983799|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily
159548|NCT02951117|Drug|Dexamethasone|Tablet or intravenous infusion
154927|NCT02984462|Procedure|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
154928|NCT02984449|Behavioral|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
154929|NCT02984449|Behavioral|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
154930|NCT02984436|Procedure|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
154931|NCT02984436|Behavioral|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0‒10.
154932|NCT02984410|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|IMRT (Simultaneous Integrated Boost (SIB) and accelerated regimen) with selective neck node dissection
154933|NCT02984410|Procedure|Trans Oral Surgery (TOS)|TOS (Trans Oral Laser Microsurgery (TLM), Trans Oral Robotic Surgery (TORS), conventional) with selective neck node dissection
154934|NCT02984397|Drug|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
154935|NCT02984397|Drug|Placebo|
154936|NCT02984397|Other|Standard of Care|
154937|NCT02984384|Drug|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
154938|NCT02984384|Drug|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
154939|NCT02984371|Procedure|Coronary artery bypass grafting|
154940|NCT02984371|Procedure|Epicardial ganglionated plexi ablation|
154941|NCT02984371|Procedure|implantable loop recorder|
154942|NCT02984358|Other|Animal protein based diet|
154943|NCT02984358|Other|Low-nucleotide mycoprotein based diet|
154944|NCT02984358|Other|High-nucleotide mycoprotein based diet|
154945|NCT02984345|Other|Mycoprotein beverage|Mycoprotein protein beverage
154946|NCT02984345|Other|Milk protein beverage|Milk protein beverage
154947|NCT02984332|Other|Lower limb immobilisation (leg brace)|
154948|NCT02984319|Dietary Supplement|Cherry versus placebo concentrate|Acute cherry concentrate
154949|NCT02984306|Dietary Supplement|Cherry powder|
154950|NCT02984306|Dietary Supplement|Placebo|
154951|NCT02984293|Drug|Atorvastatin|Atorvastatin 80 mg once daily for 28 days.
154952|NCT02984293|Drug|Placebo|Placebo once daily for 28 days.
154953|NCT02984267|Device|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
154954|NCT02984267|Other|Palpation|Using palpation only to evaluate the spine prior to epidural placement
154955|NCT02984254|Device|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
154956|NCT02984254|Device|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
154957|NCT02984254|Device|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
154958|NCT02984254|Device|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
154959|NCT02984254|Device|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
154960|NCT02984254|Device|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
154961|NCT02984254|Device|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
154962|NCT02984241|Behavioral|eHealth Coping Skills Training|Access to a specialized coping skills training website
154963|NCT02984241|Behavioral|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
154964|NCT02984241|Behavioral|Coach Support|Access to a professional coach by phone
154965|NCT02984228|Biological|PRP|
154966|NCT02984228|Drug|Hyaluronic Acid|
154967|NCT02984228|Device|Ultrasound|
154968|NCT02984202|Device|auditory midbrain implant (AMI)|
154969|NCT02984189|Other|Inspiratory muscle training|The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
154970|NCT02984176|Drug|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
154971|NCT02984176|Drug|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
154972|NCT02984163|Behavioral|Exercise|Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
154976|NCT02984124|Behavioral|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:~Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated~Description of CPR and dying process provided~Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)~Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
154977|NCT02984124|Behavioral|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
154978|NCT02984111|Drug|normal saline|
154979|NCT02984111|Drug|erythropoietin|
154980|NCT02984098|Drug|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
154981|NCT02984085|Drug|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.~By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
154982|NCT02984072|Drug|Menthol|Topical menthol in aqueous cream
154983|NCT02984072|Drug|Aqueous Cream|placebo
154984|NCT02984059|Genetic|Genomic DNA|blood draw
154985|NCT02984059|Genetic|RNA analysis|Mucosal Biopsy via colonoscopy
154986|NCT02984059|Genetic|Microbiome|Stool microbiome
154987|NCT02984059|Other|Calprotectin|stool or blood analysis for calprotectin
154988|NCT02984059|Other|Pain questionnaires|PSDS PCS-C/P PBI APPT
154989|NCT02984059|Other|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
154990|NCT02984046|Drug|Protein CC16|
154991|NCT02984033|Radiation|Head and Neck patients|Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
154992|NCT02984007|Behavioral|Motivational Interviewing|"Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.~The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes."
154993|NCT02984007|Other|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
154994|NCT02983994|Device|TURBUHALER®|
154995|NCT02983994|Device|SPIROMAX®|
154996|NCT02983981|Drug|Topicort Topical Spray|open label Topicort spray
154997|NCT02983968|Other|Description of the cirrhosis management|
154998|NCT02983955|Device|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
154999|NCT02983942|Dietary Supplement|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
155000|NCT02983942|Dietary Supplement|Routine diet|Routine diet is given without blood ketone requirement
155001|NCT02983929|Procedure|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
155002|NCT02983916|Procedure|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
155003|NCT02983903|Procedure|transbronchial biopsy|
155004|NCT02983890|Drug|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
155005|NCT02983890|Drug|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.~Both arms receives both treatments, randomly assigned"
155006|NCT02983877|Behavioral|iTAB-CV Stage 2|In the second stage, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1.
155007|NCT02983877|Behavioral|iTAB-CV Stage 1|Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.
155008|NCT02983864|Behavioral|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
155009|NCT02983864|Behavioral|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
155010|NCT02983864|Behavioral|Relaxation|A one session intervention focused on increasing relaxation skills
155011|NCT02983864|Behavioral|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
155012|NCT02983851|Procedure|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
155013|NCT02983851|Procedure|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
155016|NCT02983786|Drug|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
155017|NCT02983773|Drug|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
155018|NCT02983773|Drug|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
155019|NCT02983773|Drug|Placebo|1 smoked placebo marijuana cigarette
155020|NCT02983760|Device|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
155021|NCT02983760|Device|CTPA-based strategy|Strategy based on pulmonary angiography
155022|NCT02983760|Device|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
155023|NCT02983747|Other|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
155024|NCT02983747|Drug|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
155025|NCT02983734|Drug|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
155026|NCT02983734|Drug|Placebos|Sugar pill
155027|NCT02983721|Procedure|transradial|transradial route for coronary angiography and PCI
155028|NCT02983721|Procedure|Transfemoral|transfemoral route for coronary angiography and PCI
155029|NCT02983708|Biological|Peripheral blood mononuclear cells (mPBMC)|
155030|NCT02983708|Drug|G-CSF|
155031|NCT02983708|Drug|Placebo|
155032|NCT02983695|Drug|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
155033|NCT02983682|Drug|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
155034|NCT02983669|Dietary Supplement|Thyme|Thyme capsule 350 mg twice daily
155035|NCT02983669|Other|Placebo|Placebo capsule 350 mg twice daily
155036|NCT02983656|Biological|live attenuated varicella vaccine|
155037|NCT02983630|Other|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
155038|NCT02983617|Drug|Tirabrutinib|80 mg (1 x 80 mg or 4 x 20 mg or 2 x 40 mg) tablets administered orally once daily
155039|NCT02983617|Drug|Entospletinib|400 mg (2 x 200 mg) tablets administered orally once daily
155040|NCT02983617|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
155041|NCT02983604|Drug|GS-5829|Tablet(s) administered orally once daily
155042|NCT02983604|Drug|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
155043|NCT02983604|Drug|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling~Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
155044|NCT02983591|Drug|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
155045|NCT02983591|Drug|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
155046|NCT02983591|Drug|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
155047|NCT02983578|Drug|AZD9150|AZD9150 3 mg/kg administered by vein on Days 1, 8, 15, and 22 of every 28 day cycle.
155048|NCT02983578|Drug|MEDI4736|MEDI4736 fixed dose of 1500 mg (20 mg/kg Q4W) administered monthly.
155049|NCT02983565|Device|Intelligent oxygen therapy system (iO2Ts)|
155050|NCT02983552|Other|iPad®|Binocular therapy using a Dig Rush application on an iPad®
155051|NCT02983552|Other|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
155052|NCT02983526|Device|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
155053|NCT02983513|Behavioral|Early Intervention|
155054|NCT02983487|Procedure|Nasopharyngeal sampling|Nasopharyngeal sample by aspiration or swabbing
155055|NCT02983487|Procedure|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
155056|NCT02983474|Procedure|cholecystectomy|"Laparoscopic surgery~Reverse Trendelenburg position~Skin incision and trocar insertion~CO2 gas insufflation~Intra-abdominal inspection and gallbladder exposure~Gallbladder traction~Calot triangle exposure~Cystic artery and cystic duct isolation~Gallbladder bed dissection~Bleeding control~Gallbladder extraction~Trocar removal and wound closure~Open surgery~Supine position~Skin incision~Intra-abdominal inspection and gallbladder exposure~5. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
155057|NCT02983461|Drug|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
155058|NCT02983461|Drug|Placebo|Placebo oral tablet, 3 times a day for 10 weeks
155059|NCT02983448|Device|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
155060|NCT02983435|Other|G1 - Thrust manipulation|Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
155133|NCT02982889|Drug|LIQ865B bupivacaine formulation|single subcutaneous injection in medial calf
155134|NCT02982889|Drug|Diluent for LIQ865|Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
155135|NCT02982889|Drug|0.5% bupivacaine hydrochoride|single subcutaneous injection
253552|NCT02264067|Drug|Talsaclidine|
155061|NCT02983435|Other|G2 - Muscle Energy|Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
155062|NCT02983422|Drug|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
155063|NCT02983422|Drug|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
155064|NCT02983422|Drug|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
155065|NCT02983409|Radiation|Pstone|A adult patients who were diagnosed as urinary stone by the urinary CT
155066|NCT02983396|Device|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
155067|NCT02983383|Procedure|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
155068|NCT02983383|Procedure|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
155069|NCT02983370|Procedure|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
155070|NCT02983357|Radiation|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
155071|NCT02983357|Other|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
155072|NCT02983357|Other|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
155073|NCT02983344|Drug|Ropivacaine|Fascia iliaca compartment block using ropivacaine
155074|NCT02983344|Drug|Fentanyl|Intravenous fentanyl
155075|NCT02983344|Device|Ultrasound|Ultrasound-guided fascia iliaca compartment block
155076|NCT02983331|Procedure|complications during procedure|patients may have anesthesia related complications during procedure
155077|NCT02983305|Device|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
155078|NCT02983292|Device|PyroTITAN™ HRA|Humeral Resurfacing
155079|NCT02983279|Dietary Supplement|Dietary Intervention|Undergo caloric restriction diet
155080|NCT02983279|Other|Counseling|Undergo counselor-led dietary counseling
155081|NCT02983279|Procedure|Therapeutic|Undergo standard of care surgery
155082|NCT02983266|Device|InTENsity MicroCombo|An electrotherapy device.
155083|NCT02983253|Other|blood sample|none, only laboratory tests on blood serum
155084|NCT02983240|Device|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
155085|NCT02983227|Drug|GDC 0853|GDC-0853 tablet will be administered orally BID for 52 weeks.
155086|NCT02983214|Drug|Clopidogrel|
155087|NCT02983214|Drug|Cilostazol|
155088|NCT02983201|Other|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
155089|NCT02983201|Other|thumbtack needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
155090|NCT02983188|Drug|Berberine|Berberine tablets, 0.3g every time, two times daily
155091|NCT02983188|Drug|Placebos|Placebo tablets, 0.3g every time, two times daily
155213|NCT02982382|Other|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
155092|NCT02983188|Drug|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs will be generally allowed, including benzodiazepines and non-benzodiazepines insomnia and anti-anticholinergics for extrapyramidal symptoms, but anti-hyperlipidemic, antihypertensive and antidiabetic drugs will be not allowed. For those who have been under anti-hyperlipidemic, antihypertensive and antidiabetic treatment, they will be required to discontinue these treatments when they enter the trial.
155093|NCT02983175|Other|ultrasound assessment of gastric content|"Achievement of gastric ultrasound (specific procedure) :~Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.~Standardised achievement of the antral ultrasound by the following method:~First, a qualitative assessment of antral contents in 3 grades according to the Perlas method [24].~Second, performing a quantitative analysis of antral contents calculating the CSA.~Then, volume of gastric contents calculation as from the CSA."
155094|NCT02983149|Device|Double lumen tube|Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
155095|NCT02983149|Device|Fuji blocker|Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
155096|NCT02983149|Device|EZ blocker|Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
155097|NCT02983136|Behavioral|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:~Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and~The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
155098|NCT02983123|Procedure|1-hour hs-cTnT|
155099|NCT02983110|Procedure|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
155100|NCT02983110|Procedure|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
155101|NCT02983110|Procedure|Female Genital Tract Sampling|Cohorts B only will have cervical cells, cervical tissue, and vaginal tissue collected
155102|NCT02983097|Drug|Rituximab|Rituximab 375 mg/m²
155103|NCT02983097|Drug|Cisplatin|Cisplatinum 100 mg / m²
155104|NCT02983097|Drug|Carboplatin|Carboplatinum AUC5
155105|NCT02983097|Drug|Dexamethasone|Dexamethasone 40 mg
155106|NCT02983097|Drug|Cytarabine|Cytarabine 2000 mg/m², administered twice
155107|NCT02983097|Drug|Lenalidomide|5-20 mg administered either d1-d7, or d-6-d7
155108|NCT02983097|Drug|PegFilgrastim|PegFilgrastim 6 mg
155109|NCT02983097|Procedure|peripheral stem cell collection|collection of peripheral stem cells for autologous stem cell transplantation
155110|NCT02983084|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
155111|NCT02983071|Drug|G1T38|
155112|NCT02983071|Drug|Fulvestrant|
155113|NCT02983058|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner
155114|NCT02983058|Device|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
155115|NCT02983045|Drug|Combination of NKTR-214 + nivolumab|Patients with select tumor types will receive NKTR-214 doses administered either q3w or q2w, in combination with 240 mg nivolumab q2w or in combination with 360 mg of nivolumab q3w.
155116|NCT02983045|Drug|Combination of NKTR-214 + nivolumab|Select patient cohorts with select tumor types will be dosed with NKTR-214 + nivolumab at the RP2D + other anti-cancer therapies per institution standard.
155117|NCT02983045|Drug|Combination of NKTR-214 + nivolumab + ipilimumab|Combination of NKTR-214 at 0.006 mg/kg q3w in combination with nivolumab and ipilimumab in up to three different dosing schedules to identify dose and schedules that will proceed into Part 4.
155118|NCT02983045|Drug|Combination of NKTR-214 + nivolumab + ipilimumab|Combination of NKTR-214 + nivolumab + ipilimumab will be administered at the RP2D dose/schedule in patient cohorts with select tumor types.
155119|NCT02983032|Behavioral|BBTI|3 group sessions over 4 weeks
155120|NCT02983019|Drug|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
155121|NCT02983006|Biological|DS-8273a|"Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)~Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
155122|NCT02983006|Biological|Nivolumab|5 mg/kg IV Q 3 weeks
155123|NCT02982980|Procedure|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
155124|NCT02982980|Procedure|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
155125|NCT02982967|Other|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
155126|NCT02982954|Drug|Nivolumab|Specified dose on specified day
155127|NCT02982954|Drug|Ipilimumab|Specified Dose on Specified Day
155128|NCT02982941|Drug|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
155129|NCT02982915|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
155130|NCT02982915|Biological|Fluzone High Dose Vaccine|Intramuscular injection
155131|NCT02982902|Biological|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10^3 - 10^5 virus - specific, antigen selected T cells per kg of recipient weight.
155132|NCT02982889|Drug|LIQ865A bupivacaine formulation|single subcutaneous injection in medial calf
155136|NCT02982876|Procedure|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
155137|NCT02982876|Procedure|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
155138|NCT02982876|Device|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
155139|NCT02982850|Drug|Dabigatran|
155140|NCT02982850|Drug|Acetylsalicylic acid|
155141|NCT02982850|Drug|Warfarin|
155142|NCT02982837|Drug|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
155143|NCT02982837|Drug|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
155144|NCT02982824|Dietary Supplement|Magnesium|Oral magnesium
155145|NCT02982824|Drug|Placebo - Concentrate|Placebo will be given
155146|NCT02982811|Device|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
155147|NCT02982798|Drug|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
155148|NCT02982798|Drug|JLP-1310|administration of JLP-1310
155149|NCT02982785|Behavioral|Standard post-operative rehabilitation|
155150|NCT02982772|Other|Combination Therapy|"Brief behavioral intervention~The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
155151|NCT02982772|Other|Standard Care Intervention|"Brief Behavioral Intervention~The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.~Standard Flavored Gums for 10 weeks"
155152|NCT02982759|Behavioral|Multi-Level Intervention|The multi-level interventions will include activities at the individual level, family level, school level, and community level.
155153|NCT02982759|Behavioral|Genetic Newsletters|The comparison will receive generic newsletters
155154|NCT02982746|Other|gPCC (Gothenburg Person Centred Care)|
155155|NCT02982733|Other|ABS|Ankaferd Blood Stopper
155156|NCT02982733|Device|TR Band|Transradial band
155157|NCT02982733|Other|CS|Sterile Gauze
155158|NCT02982720|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously.
155159|NCT02982720|Drug|Sylatron|Sylatron will be administered subcutaneously.
155160|NCT02982707|Drug|BMS-986177|Single oral dose
155161|NCT02982694|Drug|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
155162|NCT02982694|Drug|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
155163|NCT02982681|Drug|Platelet rich fibrin|In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
155164|NCT02982681|Drug|Bioactive Glass|The control site were packed with the bioactive glass graft alone
155165|NCT02982668|Other|Initial enteral feeding|
155166|NCT02982668|Drug|erythromycin|gastrointestinal (GI) motility improving
155167|NCT02982655|Procedure|Individualized BP lowering|
155168|NCT02982642|Drug|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
155169|NCT02982642|Drug|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
155170|NCT02982629|Behavioral|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
155171|NCT02982616|Dietary Supplement|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
155172|NCT02982616|Behavioral|Positive emotion|Positive emotion induced by facial expressions and classic music.
155173|NCT02982616|Dietary Supplement|saline|saline
155174|NCT02982616|Behavioral|neutral emotion|Neutral emotion induced by facial expressions and classic music.
155175|NCT02982603|Drug|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761
155176|NCT02982603|Drug|Ginkgo Biloba Extract 761|Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761
155177|NCT02982603|Drug|Placebos|Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
155178|NCT02982590|Drug|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
155179|NCT02982590|Drug|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
155180|NCT02982577|Drug|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
155181|NCT02982577|Other|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
155182|NCT02982564|Behavioral|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
155214|NCT02982382|Other|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
155183|NCT02982564|Behavioral|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
155184|NCT02982551|Drug|Insulin|Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
155185|NCT02982551|Other|Taste Task|Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
155186|NCT02982551|Other|Magnetic Resonance Imaging|Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
155187|NCT02982551|Drug|Dextrose|During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
155188|NCT02982538|Behavioral|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
155189|NCT02982538|Behavioral|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
155190|NCT02982525|Dietary Supplement|No Mussels|Habitual diet only
155191|NCT02982525|Dietary Supplement|One mussel portion|1 x 75g mussel portions provided per week
155192|NCT02982525|Dietary Supplement|Two mussel portions|2 x 75g mussel portions provided per week
155193|NCT02982525|Dietary Supplement|Three mussel portions|3 x 75g mussel portions provided per week
155194|NCT02982512|Drug|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
155195|NCT02982499|Device|magnetic resonance image (MRI)|
155196|NCT02982486|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
155197|NCT02982486|Drug|Nivolumab|Ninolumab 240 mg IV every 2 weeks
155198|NCT02982460|Other|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
155199|NCT02982460|Other|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
155200|NCT02982447|Device|blue laser imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
155201|NCT02982447|Device|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
155202|NCT02982434|Drug|Pharmaceutical composition containing botulinum toxin|
155203|NCT02982434|Drug|0.9% normal saline|
155204|NCT02982434|Procedure|Coronary artery bypass grafting|
155205|NCT02982421|Behavioral|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
155206|NCT02982421|Behavioral|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
155207|NCT02982408|Dietary Supplement|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.~The participant will receive food corresponding to ~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
155208|NCT02982408|Behavioral|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.~The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
155209|NCT02982408|Behavioral|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).~The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
155210|NCT02982395|Drug|Nanoxel®M|Intravesical
155211|NCT02982395|Drug|Mitomycin-C|Intravesical
155216|NCT02982369|Other|Pain Education|Subjects will receive pain education based in biopsychosocial approach
155217|NCT02982369|Other|Sham|A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
155218|NCT02982356|Procedure|Fetal Selective Reduction Technology|Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16~24 weeks, 24~27+6 weeks,>28weeks
155219|NCT02982356|Drug|Potassium Chloride|
155220|NCT02982343|Behavioral|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
155221|NCT02982343|Behavioral|Falls management only|Participants will undergo a session of falls management and education.
155222|NCT02982330|Behavioral|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing <10% carbohydrate, ~75% fat, and 15% protein. Matched for calories to the active comparator arm.
155223|NCT02982330|Behavioral|Guidelines Breakfast|A low fat breakfast containing ~55% carbohydrate, <30% fat, and 15% protein. Matched for calories to the experimental arm.
155224|NCT02982317|Procedure|Manual palpation identification lumbar spine|
155225|NCT02982317|Procedure|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
155226|NCT02982317|Procedure|Lumbar level identification gold standard ultrasound|
155227|NCT02982304|Device|Deep Brain Stimulation|Deep Brain Stimulation Electrode
155228|NCT02982291|Procedure|Williams flexion protocol|The Williams flexion protocol group will participate in 15 treatment sessions.
155229|NCT02982291|Procedure|Focused spinal stenosis rehabilitation|The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
155230|NCT02982278|Behavioral|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
155231|NCT02982252|Behavioral|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
155232|NCT02982239|Behavioral|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
155233|NCT02982239|Device|Fitness tracker|All 40 chosen students will receive a fitness tracker. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
155234|NCT02982239|Device|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
155235|NCT02982239|Device|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
155236|NCT02982239|Other|Information Session|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q&A period.~Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
155237|NCT02982239|Behavioral|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
155238|NCT02982226|Device|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
155239|NCT02982226|Device|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
155240|NCT02982213|Other|Companion Present|A companion will be present during the epidural catheter placement.
155241|NCT02982187|Device|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
155242|NCT02982187|Device|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
155243|NCT02982187|Device|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
155244|NCT02982187|Device|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
155245|NCT02982187|Other|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
155246|NCT02982187|Other|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
155247|NCT02982187|Other|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
155248|NCT02982187|Other|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
155249|NCT02982174|Device|3D OCT-1 Maestro|Image acquisition of the posterior surface of the eye
155250|NCT02982174|Device|DRI OCT Triton|Image acquisition of the posterior surface of the eye
155251|NCT02982161|Drug|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
155252|NCT02982161|Drug|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
155253|NCT02982161|Drug|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
155254|NCT02982148|Device|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
155255|NCT02982148|Device|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
155256|NCT02982135|Other|bypass surgery and indrect bypass surgery|bypass surgery ： patients recieved STA-MCA bypass indrect bypass surgery：patients recieved EDAS or mutiple bur holes
155257|NCT02982122|Other|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
155258|NCT02982096|Device|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
155259|NCT02982096|Other|Standard of Care|Acellular burn wound management
155260|NCT02982083|Drug|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
155261|NCT02982083|Drug|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
155262|NCT02982070|Behavioral|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
155263|NCT02982057|Device|the ABSORB:bioresorbable vascular scaffold|
155264|NCT02982057|Drug|O.M.T|
155265|NCT02982044|Other|Suprasystolic (300 mmHg) cuff compressions|10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
155266|NCT02982044|Other|Handgrip exercise|10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
155267|NCT02982044|Other|Passive heat stress|10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
155268|NCT02982031|Procedure|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
155269|NCT02982031|Procedure|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
155270|NCT02982018|Device|senofilcon A with new UV blocker|Investigational Contact Lens
155271|NCT02982018|Device|senofilcon A|J&J Marketed Contact Lens
155272|NCT02982005|Drug|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
155273|NCT02982005|Drug|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
155274|NCT02981979|Drug|Leflunomide 10mg Tab|20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
155275|NCT02981979|Drug|Prednisone Acetate|basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
155276|NCT02981979|Drug|Placebos|used in control group during the induced remission therapy for 24 weeks.
155277|NCT02981966|Drug|Dapagliflozin|dapagliflozin, 10mg tablet
155278|NCT02981966|Drug|Placebo|Placebo for dapagliflozin
155279|NCT02981953|Device|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
155280|NCT02981940|Drug|Abemaciclib|Abemaciclib capsule
155281|NCT02981940|Procedure|Surgery|Surgery
155282|NCT02981927|Other|Physical inactivity|
155283|NCT02981914|Drug|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
155284|NCT02981901|Other|Patient with ovarian epithelial cancer|
155285|NCT02981888|Radiation|X-Ray|X-ray of the abdomen will be performed to assess colonic transit
155893|NCT02977104|Other|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
155286|NCT02981875|Other|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
155287|NCT02981875|Other|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
155288|NCT02981862|Other|CaptHPV method|"20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly."
155289|NCT02981836|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
155290|NCT02981836|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
155291|NCT02981823|Procedure|hip replacement|The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
155292|NCT02981810|Device|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
155293|NCT02981810|Procedure|tonsillectomy|
155294|NCT02981797|Other|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
155295|NCT02981784|Drug|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
155296|NCT02981784|Procedure|allogeneic stem cell transplantation|
155297|NCT02981771|Behavioral|Balance activity program|Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
155298|NCT02981771|Behavioral|Strength activity program|Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
155299|NCT02981745|Drug|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
155300|NCT02981732|Other|Liuwei Dihuang Pill|
155301|NCT02981719|Procedure|irreversible electroporation|irreversible electroporation with chemotherapy in pancreatic cancer
155302|NCT02981719|Drug|chemotherapy：Gemcitabine|Intravenous infusion for 30 minutes
155303|NCT02981706|Procedure|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
155304|NCT02981706|Procedure|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
155305|NCT02981693|Procedure|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
155306|NCT02981680|Procedure|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
155307|NCT02981680|Procedure|sham-RIPC|
155308|NCT02981667|Other|Exercise intensity|Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
155309|NCT02981654|Device|Alma Lasers Pixel carbon dioxide laser system|The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
155310|NCT02981641|Radiation|Intraoperative radiotherapy (IORT)|Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1
155311|NCT02981641|Drug|Sequential chemotherapy|Sequential chemotherapy
155312|NCT02981641|Radiation|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
155313|NCT02981641|Drug|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
155314|NCT02981628|Biological|Inotuzumab Ozogamicin|Given IV
155315|NCT02981628|Other|Laboratory Biomarker Analysis|Correlative studies
155316|NCT02981628|Other|Pharmacological Study|Correlative studies
253553|NCT02264067|Drug|Placebo|
155317|NCT02981615|Drug|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
155318|NCT02981615|Drug|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
155319|NCT02981602|Drug|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
155320|NCT02981602|Drug|Placebo|Placebo
155321|NCT02981589|Device|Invasive mechanical ventilation|Invasive ventilation was performed to all eligible patients. When patients met predefined criteria, spontaneous breathing trial was performed. Given spontaneous breathing trial passed, patients were extubated; on the contrary, patients would continue to receive invasive ventilation. If patients had respiratory failure after extubation, reintubation and invasive ventilation were necessary.
155322|NCT02981576|Biological|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
155323|NCT02981563|Other|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
155324|NCT02981537|Device|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
155325|NCT02981537|Device|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
155326|NCT02981524|Drug|CY|CY is administered intravenously at 200 mg/m2
155327|NCT02981524|Biological|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
155328|NCT02981524|Drug|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
155329|NCT02981511|Device|optiflow|Optiflow device used for preoxygenation
155330|NCT02981498|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
155331|NCT02981498|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
155332|NCT02981485|Device|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
155333|NCT02981472|Drug|Apixaban|0.4mg/m solution, 0.5mg and 5 mg tablet
155334|NCT02981472|Drug|Vitamin K Antagonist (VKA)|1, 2.5, and 5 mg
155335|NCT02981472|Drug|Low Molecular Weight Heparin (LMWH)|100mg/mL
155336|NCT02981459|Drug|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
155337|NCT02981446|Drug|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
155338|NCT02981446|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
155339|NCT02981420|Behavioral|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
155340|NCT02981407|Biological|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
155341|NCT02981394|Procedure|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
155342|NCT02981381|Device|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
155343|NCT02981381|Device|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
155344|NCT02981381|Device|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
155345|NCT02981368|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
155346|NCT02981368|Diagnostic Test|PET/CT imaging|PET/CT imaging will be acquired 1-2 hours post-PyL injection
155347|NCT02981355|Procedure|Microfracture treatment|Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
155348|NCT02981355|Device|BST-CarGel|BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
155349|NCT02981342|Drug|Abemaciclib|Administered orally
155350|NCT02981342|Drug|LY3023414|Administered orally
155351|NCT02981342|Drug|Gemcitabine|Administered IV
155352|NCT02981342|Drug|Capecitabine|Administered orally
155471|NCT02980484|Procedure|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
155353|NCT02981329|Drug|Metformin|Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.
155354|NCT02981329|Behavioral|Questionnaires|Questionnaires will be completed to assess the impact quality of life
155355|NCT02981316|Biological|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
155356|NCT02981303|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
155357|NCT02981303|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
155358|NCT02981290|Drug|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
155359|NCT02981290|Drug|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
155360|NCT02981290|Drug|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
155361|NCT02981290|Drug|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
155362|NCT02981277|Drug|Transcricoid injection|Lignocaine delivery using Transcricoid Injection
155363|NCT02981277|Drug|Spray as you go|Lignocaine delivery using Spray as you go method
155364|NCT02981264|Drug|Transcricoid Injection|
155365|NCT02981264|Drug|Spray as you go|
155366|NCT02981251|Behavioral|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
155367|NCT02981238|Dietary Supplement|Phytostandard® Eschscholtzia / Valerian|
155368|NCT02981225|Dietary Supplement|Phytostandard® Rhodiola-Saffron|
155369|NCT02981212|Drug|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
155370|NCT02981212|Drug|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
155371|NCT02981212|Drug|Corticosteroid|combination with Mycophenolate Mofetil
155372|NCT02981212|Drug|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
155373|NCT02981199|Procedure|stem cell transplantation|conditioning with chemotherapy [VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)], then stem cell transfusion
155374|NCT02981186|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
155375|NCT02981186|Device|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
155376|NCT02981173|Drug|0.143 mg/kg Psilocybin|0.143 mg/kg psilocybin capsule ingested on each of three test days (5 days apart +/- 1-2 days)
155377|NCT02981173|Drug|0.0143 mg/kg Psilocybin|0.0143 mg/kg psilocybin capsule ingested on each of three test days (5 days apart +/- 1-2 days)
155378|NCT02981173|Drug|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
155379|NCT02981160|Other|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
155380|NCT02981147|Drug|Phytus (Cisti, Thyme and Ivy Leaves)|Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
155381|NCT02981134|Procedure|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
155382|NCT02981121|Behavioral|Exercise and Diet remedies|
155383|NCT02981121|Drug|Metformin|
155384|NCT02981108|Drug|HS-10296|
155385|NCT02981095|Procedure|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
155386|NCT02981095|Drug|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
155387|NCT02981095|Drug|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
155388|NCT02981082|Drug|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
155389|NCT02981082|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
155390|NCT02981069|Drug|Dapagliflozin|10mg
155391|NCT02981069|Drug|Exenatide|Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
155392|NCT02981069|Drug|Placebo|Placebo for Dapagliflozin
155393|NCT02981056|Other|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
155394|NCT02981056|Other|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
155472|NCT02980471|Device|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
155395|NCT02981056|Other|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
155396|NCT02981030|Drug|Mifepristone|Women seeking medical abortion will be offered the option to take mifepristone at home
155397|NCT02981030|Drug|Misoprostol|Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
155398|NCT02981017|Device|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
155399|NCT02980991|Drug|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
155400|NCT02980991|Drug|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
155401|NCT02980978|Behavioral|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
155402|NCT02980965|Drug|letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
155403|NCT02980965|Drug|fluorouracil, epirubicin, cyclophosphamide, docetaxel|Patients received fluorouracil 500mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 500mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 100mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
155404|NCT02980952|Other|High-fat overfeeding|
155405|NCT02980952|Other|Forearm immobilization|
155406|NCT02980939|Other|iv fluid infusion|Intravenous isotonic saline infusion
155407|NCT02980926|Drug|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
155408|NCT02980926|Drug|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
155409|NCT02980913|Device|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
155410|NCT02980913|Device|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
155411|NCT02980900|Dietary Supplement|Post exercise protein-polyphenol supplement|Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
155412|NCT02980900|Dietary Supplement|Post exercise placebo supplement|Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
155413|NCT02980900|Dietary Supplement|Pre bed protein-polyphenol supplement|Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
155414|NCT02980900|Dietary Supplement|Pre bed placebo supplement|Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
155415|NCT02980887|Other|No Intervention|There is no intervention in this observational study
155416|NCT02980874|Drug|suprachoroidal CLS-TA + IVT aflibercept|suprachoroidal injection of CLS-TA following a 2 mg intravitreal injection of aflibercept
155417|NCT02980874|Drug|suprachoroidal sham + IVT aflibercept|suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
155418|NCT02980861|Procedure|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
155419|NCT02980861|Procedure|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
155420|NCT02980848|Other|Screening digital mammography|Screening with digital mammography alone
155421|NCT02980848|Other|Screening digital breast tomosynthesis|Screening with digital mammography plus digital breast tomosynthesis
155422|NCT02980848|Other|Screening breast magnetic resonance imaging|Screening with digital mammography plus breast magnetic resonance imaging
155423|NCT02980848|Other|Diagnostic mammography|Pre-operative diagnostic work-up with mammography alone
155424|NCT02980848|Other|Pre-operative breast magnetic resonance imaging|Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
155425|NCT02980835|Drug|Normal Saline|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
155426|NCT02980835|Drug|Ropivacaine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
155473|NCT02980458|Drug|Deferiprone 500Mg Tablet|
155474|NCT02980458|Drug|Deferiprone 500 MG Oral Tablet [Ferriprox]|
155475|NCT02980445|Behavioral|Outdoor activity 1|40-minute outdoor activity
254074|NCT02260388|Drug|Pregabalin|
155427|NCT02980835|Drug|Epinephrine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
155428|NCT02980835|Drug|Dexamethasone|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
155429|NCT02980809|Drug|Apatinib|
155430|NCT02980809|Drug|Topotecan|
155431|NCT02980796|Behavioral|Exercise|Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
155432|NCT02980796|Behavioral|Practice|Each experimental day participants will complete a session of skilled motor practice.
155433|NCT02980783|Device|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ (hyaluronic acid) with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 1; volume of injection will not exceed 2 mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1 mL per side.
155434|NCT02980757|Drug|Gliclazide 120 mg MR Tablets Formula A|
155435|NCT02980757|Drug|Gliclazide 120 mg MR Tablets|
155436|NCT02980757|Drug|Gliclazide 120 mg MR Tablets Formula B|
155437|NCT02980744|Behavioral|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
155438|NCT02980731|Drug|Venetoclax|Tablet
155439|NCT02980718|Behavioral|intensive olfactory training|
155440|NCT02980718|Behavioral|ordinary olfactory training|
155441|NCT02980705|Drug|SUNPG1622 I dose|Injection
155442|NCT02980705|Drug|Placebo dose|Injection
155443|NCT02980692|Drug|SUNPG1623 I|injection
155444|NCT02980692|Drug|SUNPG1623 II|injection
155445|NCT02980692|Drug|SUNPG1623 III|injection
155446|NCT02980692|Drug|SUNPG1623 IV|injection
155447|NCT02980692|Drug|PLACEBO|injection
155448|NCT02980679|Drug|CTC|After injection of CTC, a whole body and thyroid scan will be performed.
155449|NCT02980679|Drug|G-PERT|After injection of G-PERT, a whole body and thyroid scan will be performed.
155450|NCT02980666|Drug|Teduglutide|0.05 mg/kg/day SC injection once daily for 24 weeks.
155451|NCT02980653|Drug|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
155452|NCT02980627|Behavioral|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
155453|NCT02980614|Device|4D flow imaging|To compare the quantification of pulmonary valve leakage by standard 2D flow MRI and 4D flow MRI by measuring the regurgitation fraction (ratio of retrograde blood flow to anterograde flow) in the pulmonary artery
155454|NCT02980601|Device|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
155455|NCT02980601|Procedure|STSG|0.012mm STSG
155456|NCT02980588|Device|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
155457|NCT02980575|Other|Music|
155458|NCT02980575|Other|Exercise|
155459|NCT02980562|Drug|Polyethylene Glycols|(Split dose 2L PEG-Asc)
155460|NCT02980562|Drug|Bisacodyl|(1L PEG-Asc plus bisacodyl)
155461|NCT02980549|Other|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
155462|NCT02980523|Drug|PRO-157|PRO-157 (Pazufloxacin 0.06%) Laboratories Sophia S.A. de C.V., ophthalmic solution
155463|NCT02980523|Drug|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
155464|NCT02980523|Drug|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
155465|NCT02980523|Drug|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
155466|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil|
155467|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan|
155468|NCT02980497|Other|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
155469|NCT02980497|Other|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
155470|NCT02980484|Procedure|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
254075|NCT02260388|Drug|Mexiletine|
155476|NCT02980445|Behavioral|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
155477|NCT02980432|Other|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
155478|NCT02980419|Behavioral|presentation of visual and vestibular stimuli|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
155479|NCT02980406|Dietary Supplement|FODMAP|Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
155480|NCT02980406|Dietary Supplement|Glucose (control)|Glucose is not a FODMAP.
155481|NCT02980393|Behavioral|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
155482|NCT02980380|Other|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient. For patient who can still open their eyes but cannot use any other means of communication will control an EEG based BCI for communication."
155483|NCT02980367|Other|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
155484|NCT02980367|Procedure|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
155485|NCT02980341|Drug|U3-1402|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
155486|NCT02980328|Device|Low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
155487|NCT02980328|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
155488|NCT02980315|Other|CAR-T cells|the patients treat with CAR-T cells
155489|NCT02980302|Procedure|Cutaneous biopsy|Under local anesthesia
155490|NCT02980276|Drug|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
155491|NCT02980276|Other|Placebo|Women randomised to the placebo group will receive 1 placebo tablet once daily, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
155492|NCT02980263|Drug|Canakinumab|
155493|NCT02980250|Drug|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
155494|NCT02980250|Drug|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
155495|NCT02980250|Drug|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
155496|NCT02980250|Drug|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
155497|NCT02980237|Other|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
155498|NCT02980237|Other|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
155499|NCT02980224|Drug|OmegaD|OmegaD Softgels
155500|NCT02980224|Drug|Placebo|Placebo Softgels
155562|NCT02979782|Procedure|PCI|stenting procedure
155563|NCT02979769|Drug|Palovarotene dose level 1|Palovarotene will be taken orally once daily at approximately the same time each day.
155501|NCT02980211|Device|Ridge Reconstruction|Tooth extraction will be attempted in minimally traumatic, flapless, fashion. Following tooth extraction, the existence of the suspected dehiscence defect will be confirmed; absence of a defect will result in subject exclusion from the study and the case will be considered an intent-to-treat. Horizontal and vertical dimensions of the defect will be measured using a UNC-15 probe. After creating a soft tissue 'pouch' using tunneling instruments, a non-absorbable dense-PTFE (dPTFE) [Cytoplast TXT-200, Osteogenics Biomedical] barrier membrane, trimmed to the size and shape that would allow for complete extension over the existing defect, will be tucked between the mucosa and the alveolar bone. The socket will then be grafted using a particulate bone allograft [EnCore, Osteogenics Biomedical] and the socket access will be sealed with an extension of the dPTFE membrane to ensure complete coverage of the bone graft and the crestal bone.
155502|NCT02980198|Biological|IFN-Kinoid|IM administration
155503|NCT02980198|Other|Placebo|IM administration
155504|NCT02980198|Other|ISA 51|adjuvant
155505|NCT02980185|Procedure|Laparoscopic primary cytoreduction|Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
155506|NCT02980172|Other|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
155507|NCT02980159|Other|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
155508|NCT02980146|Other|Non interventional study|
155509|NCT02980133|Drug|Fp MDPI|
155510|NCT02980133|Drug|FS MDPI|
155511|NCT02980133|Drug|Placebo|
155512|NCT02980120|Other|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig & Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
155513|NCT02980120|Other|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner & Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
155514|NCT02980120|Other|EDI-2|The Eating Disorder Inventory 2 (Paul & Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
155515|NCT02980120|Other|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig & Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
155516|NCT02980120|Other|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke & Krischer, 2011).
155517|NCT02980120|Other|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann & Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
155518|NCT02980120|Device|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
155519|NCT02980107|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
155520|NCT02980107|Other|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
155521|NCT02980094|Dietary Supplement|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
155522|NCT02980094|Dietary Supplement|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
155523|NCT02980094|Dietary Supplement|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
155524|NCT02980094|Dietary Supplement|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
155525|NCT02980081|Other|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
155526|NCT02980068|Drug|15N Nitrate|1,000 mg/11.8 mmol, oral, on day one, hour zero
155527|NCT02980068|Drug|14N Nitrate|1,000 mg/11.18 mmol, oral, on day hour, hour zero
155528|NCT02980055|Procedure|collagen matrix|Surgical procedure for root coverage using collagen matrix
155529|NCT02980055|Procedure|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
155530|NCT02980042|Drug|Ocrelizumab|A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells
155531|NCT02980042|Drug|Rituximab|A chimeric monoclonal antibody against CD20.
155532|NCT02980029|Drug|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
155533|NCT02980029|Other|Placebo|Placebo
155534|NCT02980016|Drug|rifapentine + isoniazid|Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
155535|NCT02980016|Drug|Isoniazid|Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
155536|NCT02980003|Drug|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
155537|NCT02980003|Drug|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
155538|NCT02980003|Drug|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
155539|NCT02979990|Other|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
155540|NCT02979990|Other|Control Video|The control group will have access to a video about the IVF process
155541|NCT02979977|Drug|cetuximab|30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Doses will be administered on the same day of each week (+/- 1 day).
155542|NCT02979977|Drug|afatinib|Patients will take a single oral dose of afatinib each day at a dose of 40 mg. Afatinib dose will not be escalated beyond the 40 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
155543|NCT02979964|Behavioral|Audit and Feedback|
155544|NCT02979938|Other|Semen analysis and semen PCR for Zika virus|Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.
155545|NCT02979925|Device|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
155546|NCT02979925|Device|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
155547|NCT02979912|Biological|Platelet Lysate|Eye drops of Platelet Lysate
155548|NCT02979899|Biological|TRC105|TRC105 antibody
155549|NCT02979899|Drug|Votrient|pazopanib
155550|NCT02979886|Drug|GnRH-a|the hormone reaction to the down regulation of the patients
155551|NCT02979886|Drug|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
155552|NCT02979873|Drug|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and proteomics assay (research labs).
155553|NCT02979860|Behavioral|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
155554|NCT02979860|Behavioral|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
155555|NCT02979860|Behavioral|Sleep timing|Sleep timing: bed time kept consistent
155556|NCT02979847|Procedure|hybrid catheter ablation|trans-xyphoid epicardial puncture is performed and 20-pole catheter via SL-1 sheath is inserted. Voltage mapping or activation mapping or CFAE mapping is performed as rhythm status. Epicardial and Endocardial side ablation were performed.
155557|NCT02979847|Procedure|conventional endocardial ablation|trans-femoral puncture is performed. Voltage mapping or activation mapping or CFAE mapping is performed as rhythm status. Endocardial side ablation were performed and Epicardial side is not assessed.
155558|NCT02979821|Drug|Poziotinib|A cycle of study treatment is defined as 28 days.
155559|NCT02979808|Device|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
155560|NCT02979795|Procedure|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)
155561|NCT02979782|Procedure|Endo-CABG|minimal invasive cardiac intervention
155564|NCT02979769|Drug|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
155565|NCT02979756|Procedure|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
155566|NCT02979743|Behavioral|Occupational therapy|
155567|NCT02979743|Other|Occupational therapy puls acupuncture and massage methods|
155568|NCT02979730|Other|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
155569|NCT02979730|Other|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
155570|NCT02979717|Dietary Supplement|High protein, high fiber dietary supplement|
155571|NCT02979717|Other|Low protein, low fiber comparator|
155572|NCT02979704|Drug|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
155573|NCT02979704|Drug|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
155574|NCT02979691|Radiation|SIB-IMRT|
155575|NCT02979691|Drug|S-1|
155576|NCT02979678|Other|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
155577|NCT02979665|Drug|Ranibizumab Ophthalmic|"Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME)."
155578|NCT02979639|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
155579|NCT02979626|Procedure|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
155580|NCT02979613|Drug|TAF|25 mg tablet administered orally once daily
155581|NCT02979613|Drug|TDF|300 mg tablet administered orally once daily
155582|NCT02979613|Drug|TAF Placebo|Tablet administered orally once daily
155583|NCT02979613|Drug|TDF Placebo|Tablet administered orally once daily
155584|NCT02979587|Device|Harmony TPV System|"The Harmony™ TPV (Model NTPV0022) is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame.~The Harmony TPV 25 and mTPV 25 (Model HTPV254952 and HTPV254252, respectively) is comprised of a 25mm porcine pericardium valve, sewn to a polyester covered asymmetrical hourglass nitinol frame with larger diameter inflow and outflow as well as shorter length compared to TPV 22 (Harmony TPV 25 and mTPV 25 are not applicable for Continued Clinical Experience).~The Harmony Delivery System (DS) for the TPV 22, TPV 25, and mTPV 25 (NTPVDS0022 and HTPVDS0025) are all 25 Fr delivery systems using a coil loading catheter."
155585|NCT02979574|Procedure|Electro-Acupuncture (EA)|Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
155586|NCT02979574|Procedure|Battle Field Acupuncture (BFA)|Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
155587|NCT02979574|Device|Wait List Control (WLC)|After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
155588|NCT02979561|Drug|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
155589|NCT02979561|Drug|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
155590|NCT02979548|Drug|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
155591|NCT02979548|Drug|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
155592|NCT02979548|Drug|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
155593|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, Months 6 and 12
155594|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Months 1, 7 and 13
155595|NCT02979535|Biological|Human Papillomavirus Bivalent [Types16 and 18] Vaccine, Recombinant|0.5 mL, intramuscular at Day 0 and Month 6
155596|NCT02979535|Biological|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant|0.5 mL, intramuscular at Day 0 and Month 6
155597|NCT02979522|Drug|Brentuximab vedotin|Brentuximab vedotin infusion
155598|NCT02979522|Drug|Doxorubicin|Doxorubicin infusion
155599|NCT02979522|Drug|Vinblastine|Vinblastine infusion
155600|NCT02979522|Drug|Dacarbazine|Dacarbazine infusion
155601|NCT02979509|Other|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
155645|NCT02979119|Drug|Coagulation proteins|Documentation of factor VIII and factor IX products from the first exposure day onwards
155602|NCT02979496|Dietary Supplement|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
155603|NCT02979496|Dietary Supplement|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
155604|NCT02979496|Dietary Supplement|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
155605|NCT02979496|Dietary Supplement|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
155606|NCT02979483|Procedure|Integrative supportive care|"At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)~At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:~Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial~- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.~Patients will be treated by: FOLFOX7lightened"
155607|NCT02979457|Behavioral|Awareness of degree of worry|degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
155608|NCT02979444|Behavioral|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
155609|NCT02979431|Biological|ALX-0171 3.0 mg/kg|
155610|NCT02979431|Biological|ALX-0171 6.0 mg/kg|
155611|NCT02979431|Biological|ALX-0171 9.0 mg/kg|
155612|NCT02979431|Other|Placebo|
155613|NCT02979405|Drug|Phenylephrine|prophylactic infusion of phenylephrine 40 mcg/min
155614|NCT02979392|Drug|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
155615|NCT02979379|Other|Pain|
155616|NCT02979366|Drug|S64315|S64315 will be administered via i.v. infusion over 30 minutes once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
155617|NCT02979353|Behavioral|Shed-Meds: A Patient-Centered Deprescribing Intervention|The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
155618|NCT02979340|Procedure|MRI|non-invasive assessment of hepatic fibrosis and steatosis
155619|NCT02979327|Drug|Adderall capsule|Amphetamine
155620|NCT02979327|Drug|Placebo capsule|Placebo capsule
155621|NCT02979314|Device|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
155622|NCT02979301|Drug|Tamoxifen|5 mg or 10 mg tamoxifen per day for 30 days.
155623|NCT02979288|Drug|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
155624|NCT02979288|Other|NO Intervention|NO Intervention
155625|NCT02979275|Procedure|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
155626|NCT02979262|Behavioral|Fathers for Change|
155627|NCT02979262|Behavioral|Parent Education|
155628|NCT02979249|Drug|Oral Iron|for one year
155629|NCT02979236|Device|STENTYS Xposition S|
155630|NCT02979223|Drug|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.~There is a difference in the order of intake between two group"
155631|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
155632|NCT02979210|Other|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
155633|NCT02979197|Drug|OE 10 mg amlodipine besylate tablet|
155634|NCT02979197|Drug|OE 200 mg celecoxib capsule|
155635|NCT02979197|Drug|Matched placebo for OE amlodipine besylate tablet|
155636|NCT02979197|Drug|Matched placebo for OE celecoxib capsule|
155637|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
155638|NCT02979171|Device|Laryngeal Mask Airway Classic|
155639|NCT02979158|Procedure|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
155640|NCT02979158|Procedure|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
155641|NCT02979145|Other|No intervention involved|
155642|NCT02979132|Drug|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
155643|NCT02979132|Drug|Ferinject(R)|Single-dose Ferinject(R) administration
155644|NCT02979132|Dietary Supplement|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
159549|NCT02951104|Device|Noninvasive cardiac output monitor (NICOM)|
155646|NCT02979106|Other|Test meal|Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
155647|NCT02979093|Drug|Oxytocin|All women in both groups will receive 2 fMRIs according to our research protocol. Fifty minutes before the first fMRI, the women will administer nasal spray which will randomly contain either oxytocin or placebo. A month later the woman will return for the 2nd fMRI and administer nasal spray containing the substance they did not receive at the first scan. The randomization is double blinded with only the pharmacy knowing which nasal spray to provide at which fMRI visit.
155648|NCT02979093|Drug|Placebos|All women in both groups will receive 2 fMRIs according to our research protocol. Fifty minutes before the first fMRI, the women will administer nasal spray which will randomly contain either oxytocin or placebo. A month later the woman will return for the 2nd fMRI and administer nasal spray containing the substance they did not receive at the first scan. The randomization is double blinded with only the pharmacy knowing which nasal spray to provide at which fMRI visit.
155649|NCT02979080|Other|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
155650|NCT02979067|Procedure|Nasal oxygen flow|Nasal oxygen flow during apnoea
155651|NCT02979054|Device|T4020|
155652|NCT02979054|Device|Placebo|
155653|NCT02979041|Behavioral|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.~The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
155654|NCT02979041|Other|Standard Care|physiotherapy and medical care as provided currently
155655|NCT02979028|Device|TEAS|Transcutaneous electrical acupoint stimulation
155656|NCT02979015|Drug|alirocumab SAR236553 (REGN727)|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
155657|NCT02979015|Drug|placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
155658|NCT02978989|Procedure|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
155659|NCT02978989|Procedure|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
155660|NCT02978976|Drug|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
155661|NCT02978976|Drug|saline|saline placebo injection in the same regimen.
155662|NCT02978963|Behavioral|Cognitive behavioral therapy|CBT focused on reducing intolerance of uncertainty
155663|NCT02978950|Other|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
155664|NCT02978950|Other|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
155665|NCT02978924|Device|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
155666|NCT02978911|Procedure|preoperative cerebral MRI and operative findings|
155667|NCT02978885|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT CT
155668|NCT02978885|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
155669|NCT02978859|Drug|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
155670|NCT02978846|Other|Clinical Observation|Undergo side effects evaluation using cards
155671|NCT02978833|Biological|PRP|
155672|NCT02978833|Biological|Whole Blood|
155673|NCT02978833|Device|Ultrasound|
155674|NCT02978820|Other|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
155675|NCT02978820|Other|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
155676|NCT02978807|Procedure|Point of care and venous screening|
155677|NCT02978781|Drug|SAGE-217|
155678|NCT02978781|Drug|Placebo|
155679|NCT02978768|Other|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
155680|NCT02978768|Device|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
155681|NCT02978768|Device|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
155682|NCT02978755|Drug|GM102|GM102 escalating doses (phase1)
155683|NCT02978755|Drug|Paclitaxel + carboplatin|GM102 escalating doses combined with paclitaxel and carboplatin
155684|NCT02978755|Drug|GM102|GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
155685|NCT02978742|Behavioral|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
161199|NCT02938845|Procedure|total abdominal hysterectomy(TAH)|
155686|NCT02978742|Behavioral|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
155687|NCT02978729|Other|Two-way videoconference remote genetic counseling|
155688|NCT02978729|Other|Telephone remote genetic counseling|
155689|NCT02978716|Drug|Trilaciclib|G1T28
155690|NCT02978716|Drug|Gemcitabine|Gemcitabine
155691|NCT02978716|Drug|Carboplatin|Carboplatin
155692|NCT02978703|Drug|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
155693|NCT02978690|Drug|BI655130|
155694|NCT02978677|Radiation|Radiotherapy 68 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton
155695|NCT02978677|Radiation|Radiotherapy 72 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton
155696|NCT02978677|Radiation|Radiotherapy 60 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton
155697|NCT02978664|Procedure|Air insufflation|Air insufflation during colonoscopy including insertion phase
155698|NCT02978664|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
155699|NCT02978664|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
155700|NCT02978651|Drug|Pitolisant (BF2.649)|
155701|NCT02978651|Drug|Placebo Oral Tablet|
155702|NCT02978638|Device|Finetech Vocare Bladder System|Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
155703|NCT02978625|Other|Laboratory Biomarker Analysis|Correlative studies
155704|NCT02978625|Biological|Nivolumab|Given IV
155705|NCT02978625|Biological|Talimogene Laherparepvec|Given IT
155706|NCT02978612|Drug|Capecitabine|Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
155707|NCT02978599|Drug|AVL-3288|daily for 5 days
155708|NCT02978599|Drug|Placebo|daily for 5 days
155709|NCT02978586|Device|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline [Ga-68]PSMA PET/MR. If participants test positive for [Ga-68]PSMA tumor uptake, they will under up to 2 additional scans
155710|NCT02978573|Device|Cartiva|Cartiva Synthetic Cartilage Implant
155711|NCT02978560|Device|fluorescence-mediated photoplethysmography|Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
155712|NCT02978547|Drug|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
155713|NCT02978534|Drug|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
155714|NCT02978521|Other|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
155715|NCT02978508|Drug|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
155716|NCT02978508|Drug|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
155717|NCT02978495|Drug|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
155718|NCT02978495|Drug|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
155719|NCT02978495|Drug|Paclitaxel|80mg/m2 weekly for 12 weeks
155720|NCT02978495|Drug|Cyclophosphamide|600mg/m2 4 cycles each 21 days
155721|NCT02978482|Drug|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until confirmed disease progression or unacceptable toxicity
155722|NCT02978482|Drug|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
155723|NCT02978469|Other|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.~the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.~In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
155772|NCT02978053|Behavioral|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
161299|NCT02938039|Device|I-Gel LMA|I-Gel Laryngeal Mask Airways
155724|NCT02978456|Device|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus ~10% of distal reference vessel diameter).
155725|NCT02978456|Device|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro stent size and length is selected by intravascular ultrasound measurements.
155726|NCT02978443|Drug|Nivolumab|
155727|NCT02978443|Drug|Ipilimumab|
155728|NCT02978430|Device|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
155729|NCT02978430|Other|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
155730|NCT02978417|Drug|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
155731|NCT02978417|Drug|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
155732|NCT02978404|Drug|Nivolumab|Nivolumab is administered to patients to a maximum of 2 year.
155733|NCT02978404|Radiation|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
155734|NCT02978391|Procedure|endoscopic adhesive powder|
155735|NCT02978391|Drug|epinephrine|
155736|NCT02978391|Device|Endoscopic Wound Dressing (Next Biomedical)|
155737|NCT02978378|Other|biomarker levels|The level of the biomarker hyaluronic acid will be measured
155738|NCT02978365|Other|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
155739|NCT02978365|Device|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
155740|NCT02978352|Other|learning|
155741|NCT02978339|Drug|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
155742|NCT02978326|Drug|SAGE-217|
155743|NCT02978326|Drug|Placebo|
155744|NCT02978313|Drug|Cetuximab|anti-EGFR monoclonal antibody
155745|NCT02978313|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
155746|NCT02978313|Drug|FOLFIRI|Irinotecan+LV5FU2
155747|NCT02978300|Device|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
155748|NCT02978300|Device|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
155749|NCT02978287|Drug|BAVU Solution|Tissue preservation solution for transplantation
155750|NCT02978274|Drug|MMF engraftment|MMF withdrawal by engraftment post haplo-SCT
155751|NCT02978274|Drug|MMF 2 month|MMF withdrawal by 2 month post haplo-SCT
155752|NCT02978261|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
155753|NCT02978235|Drug|TAS4464|Intravenous (IV) Infusion
155754|NCT02978222|Biological|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
155755|NCT02978222|Drug|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
155756|NCT02978209|Device|7.5 %|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 0 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
155757|NCT02978196|Procedure|Injection of 99m-Tc-NM-01|Patient is injected with micro-dose of 99m-Tc-NM-01
155758|NCT02978183|Biological|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
155759|NCT02978183|Drug|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
155760|NCT02978170|Procedure|Cone-Beam Computed Tomography|Undergo CBCT
155761|NCT02978157|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
155762|NCT02978157|Drug|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
155763|NCT02978144|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
155764|NCT02978144|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
155765|NCT02978131|Other|Histopathological study|
155766|NCT02978131|Other|Molecular study (Polymerase chain reaction)|
155767|NCT02978118|Device|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
155768|NCT02978105|Other|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
155769|NCT02978105|Other|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
155770|NCT02978079|Device|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
155771|NCT02978066|Other|Spinal anaesthesia|
155853|NCT02977325|Other|water cure|
254648|NCT02256722|Drug|KUC 7483 CL|
155773|NCT02978053|Behavioral|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
155774|NCT02978040|Drug|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
155775|NCT02978040|Drug|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old) .
155776|NCT02978040|Drug|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
155777|NCT02978027|Behavioral|Brief Advice|
155778|NCT02978027|Behavioral|NIAAA Clinician's Guide|
155779|NCT02978027|Behavioral|Motivational Interviewing (MI)|
155780|NCT02978014|Device|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
155781|NCT02978001|Other|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
155782|NCT02977988|Behavioral|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
155783|NCT02977988|Behavioral|Brain and Recovery (B&R)|B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
155784|NCT02977975|Other|Raw sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
155785|NCT02977975|Other|Pasteurized sauerkraut|Sauerkraut without live bacteria.
155786|NCT02977962|Behavioral|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
155787|NCT02977962|Other|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
155788|NCT02977949|Drug|Raloxifene|
155789|NCT02977936|Dietary Supplement|Cartimotil Fort|1 to 4 capsules per day during 90 days
155790|NCT02977923|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
155791|NCT02977923|Other|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant`s age, weight and condition by the anesthetist and pain clinic nurse.
155792|NCT02977910|Procedure|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
155793|NCT02977897|Drug|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
155794|NCT02977884|Behavioral|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
155795|NCT02977871|Procedure|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
155796|NCT02977858|Other|Educational practice for HCPs,Dissemination only|Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
155797|NCT02977858|Other|Educational practice for HCPs,Spaced Education|Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
155854|NCT02977312|Drug|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
155798|NCT02977845|Behavioral|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
155799|NCT02977832|Dietary Supplement|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
155800|NCT02977832|Drug|Alfuzosin|10Mg Oral Tablet, Extended Release
155801|NCT02977819|Other|Meditation practice|18 months
155802|NCT02977819|Other|Learning English as a foreign language|18 months
155803|NCT02977793|Device|Tomey EM-4000 Specular Microscope|
155804|NCT02977793|Device|Konan CellChek XL Specular Microscope|
155805|NCT02977780|Drug|Temozolomide|Temzolomide capsules
155806|NCT02977780|Drug|Neratinib|Neratinib tablets
155807|NCT02977780|Drug|CC-115|CC-115 capsule
155808|NCT02977780|Drug|Abemaciclib|Abemaciclib capsules
155809|NCT02977767|Procedure|Conversational hypnosis|Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
155810|NCT02977754|Other|This is an observational study|Imaging
155811|NCT02977741|Drug|Olanzapine|
155812|NCT02977728|Other|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
155813|NCT02977715|Biological|IMVAMUNE|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE liquid formulation or lyophilized formulation) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
155814|NCT02977689|Drug|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
155815|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|"Chest MRI during the MRI cerebral~2 tubes of blood taken during the medical visit"
155816|NCT02977650|Procedure|Endoscopic ultrasonography-guided fine needle aspiration|
155817|NCT02977637|Procedure|Feraheme MRI/MRA|
155818|NCT02977624|Behavioral|The Cognitive Orientation to daily Occupational Performance|
155819|NCT02977611|Drug|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
155820|NCT02977585|Device|10 cmH2O peep|positive end expiratory pressure
155821|NCT02977572|Device|Non-Invasive Ventilation|In arm description
155822|NCT02977572|Device|Continuous Positive AirwayPressure CPAP|In arm description
155823|NCT02977559|Device|Laryngeal Tube Suction Disposable|Device for ventilation
155824|NCT02977559|Device|Laryngeal Mask Airway AuraGain|Ventilation device
155825|NCT02977546|Device|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
155826|NCT02977546|Device|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
155827|NCT02977533|Drug|GZ402668|"Pharmaceutical form: solution~Route of administration: subcutaneous"
155828|NCT02977533|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
155829|NCT02977533|Drug|Acyclovir|"Pharmaceutical form: tablet~Route of administration: oral"
155830|NCT02977520|Procedure|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
155831|NCT02977507|Other|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
155832|NCT02977507|Drug|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
155833|NCT02977507|Other|SkinMedica Facial Cleanser|SkinMedica facial cleanser applied to the face as directed.
155834|NCT02977507|Other|SkinMedica Rejuvenative Moisturizer|SkinMedica rejuvenative moisturizer applied to the face as directed.
155835|NCT02977507|Other|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen|SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.
155836|NCT02977494|Drug|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
155837|NCT02977494|Drug|Bortezomib|
155838|NCT02977494|Drug|Dexamethasone|
155839|NCT02977468|Drug|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of one to two cycles.
155840|NCT02977468|Radiation|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
155841|NCT02977442|Behavioral|exercise|
155842|NCT02977429|Other|standardized fluid therapy|The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.
155843|NCT02977429|Other|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
155844|NCT02977416|Other|anti-TNFα|
155845|NCT02977403|Behavioral|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
155846|NCT02977403|Behavioral|Booster Attention Retraining|All subjects can opt to undergo attention bias training after the randomized phase of the study is complete
155847|NCT02977390|Other|Passive leg raise|By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
155848|NCT02977377|Other|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
155849|NCT02977377|Other|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
155850|NCT02977364|Drug|HS-10241|
155851|NCT02977351|Procedure|Non-surgical periodontal treatment|
155852|NCT02977338|Other|Retrospective review|
155855|NCT02977299|Drug|Aripiprazole|Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
155856|NCT02977299|Device|Repetitive transcranial magnetic stimulation (rTMS)|Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
155857|NCT02977299|Drug|Venlafaxine XR|Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
155858|NCT02977286|Drug|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
155859|NCT02977286|Drug|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
155860|NCT02977286|Drug|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
155861|NCT02977286|Drug|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=6 days after scheduled opioid initiation.
155862|NCT02977286|Drug|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
155863|NCT02977286|Drug|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
155864|NCT02977286|Drug|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation.
155865|NCT02977286|Drug|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
155866|NCT02977273|Other|Thin/100% Portion|Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)
155867|NCT02977273|Other|Thin/150% Portion|Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)
155868|NCT02977273|Other|Thick/100% Portion|Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)
155869|NCT02977273|Other|Thick/150% Portion|Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
155870|NCT02977260|Other|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
155871|NCT02977260|Other|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
155872|NCT02977260|Other|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
155873|NCT02977260|Other|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
155874|NCT02977247|Other|Non-Interventional|Only standard care procedures will be performed for clinical intervention and diagnostic purposes.
155875|NCT02977247|Device|Automated Whole Breast Ultrasound|Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
155876|NCT02977234|Drug|Isoamyl 2-Cyanoacrylate|
155877|NCT02977221|Procedure|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
155878|NCT02977208|Procedure|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
155879|NCT02977208|Procedure|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
155880|NCT02977208|Procedure|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms
155881|NCT02977208|Drug|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
155882|NCT02977195|Drug|NP137|Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
155883|NCT02977182|Other|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
155884|NCT02977169|Radiation|PORT|3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline
155885|NCT02977169|Drug|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
155886|NCT02977156|Biological|Pexa-Vec|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
155887|NCT02977156|Drug|Ipilimumab|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
155888|NCT02977143|Procedure|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
155889|NCT02977130|Behavioral|Map group|diabetes shared care plus conversation map intervention
155890|NCT02977130|Behavioral|Control group|diabetes shared care
155891|NCT02977117|Other|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
155892|NCT02977117|Other|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
254649|NCT02256722|Drug|Bisoprolol|
155894|NCT02977091|Other|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
155895|NCT02977078|Behavioral|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
155896|NCT02977078|Device|Inhaler casing|Monitors inhaler use
155897|NCT02977078|Device|Mobile application|Mobile application software linked to inhaler casing
155898|NCT02977065|Drug|Atorvastatin 20mg|PO daily for 4weeks
155899|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
155900|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
155901|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
155902|NCT02977065|Drug|Rosuvastatin 10 mg|PO daily for 4weeks
155903|NCT02977065|Drug|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
155904|NCT02977052|Drug|Ipilimumab|
155905|NCT02977052|Drug|Nivolumab|
155906|NCT02977052|Procedure|Surgery|Surgery will be done at 6 weeks
155907|NCT02977052|Procedure|Blood for PBMCs|Blood will be taken for translational research on PBMCs
155908|NCT02977052|Procedure|Biopsies|Biopsies will be taken during screening and at relapse.
155909|NCT02977039|Other|NDPR diet|nutrient rich plant based diert
155910|NCT02977039|Other|USDA healthy eating diet|DASH diet
155911|NCT02977026|Behavioral|CYD|
155912|NCT02977026|Behavioral|AHC|
155913|NCT02977013|Diagnostic Test|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
155914|NCT02977000|Drug|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
155915|NCT02976987|Drug|Cidofovir|
155916|NCT02976974|Other|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
155917|NCT02976974|Other|Therapeutic exercise|"Shoulder extension: Elastic bands.~Shoulder flexion: Elastic bands~Shoulder external rotation: Elastic bands.~Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.~Thoracic column movements: Flexion-extension"
155918|NCT02976961|Other|Supportive care|Information, guidance, supportive care, and psychological intervention
155919|NCT02976948|Other|No intervention|
155920|NCT02976935|Other|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
155921|NCT02976922|Dietary Supplement|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
155922|NCT02976909|Drug|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
155923|NCT02976896|Drug|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
155924|NCT02976883|Other|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of [18F]HX4 and PET/CT scan
155925|NCT02976870|Radiation|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
155926|NCT02976857|Biological|C-CAR-011|lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
155927|NCT02976844|Procedure|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
155928|NCT02976831|Drug|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
155929|NCT02976831|Drug|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
155930|NCT02976805|Drug|4L PegLyte + 15 mg bisacodyl|Randomized
155931|NCT02976805|Drug|6L PegLyte + 15 mg bisacodyl|Randomized
155932|NCT02976792|Procedure|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
155933|NCT02976779|Drug|OWC MGC cream|Topical cream containing 3% CBD and 3% THC for Psoriasis treatment
155934|NCT02976779|Drug|OWC Control Cream|Topical Cream without active ingredients
155935|NCT02976766|Drug|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
155936|NCT02976766|Drug|Placebo|Participants will receive placebo three times a day for 10 days.
155937|NCT02976753|Drug|efmoroctocog alfa|extended half-life factor VIII product
155938|NCT02976753|Drug|Factor VIII|conventional factor VIII product
155939|NCT02976740|Radiation|SBRT|Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
155940|NCT02976740|Drug|Immunological Agent|Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
155941|NCT02976740|Drug|Immunological Factors|Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
155942|NCT02976727|Drug|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
155943|NCT02976727|Drug|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
156209|NCT02974907|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
155944|NCT02976727|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
155945|NCT02976727|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
155946|NCT02976727|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
155947|NCT02976727|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
155948|NCT02976727|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
155949|NCT02976714|Other|spontaneous sputum|"CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).~The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate."
155950|NCT02976701|Drug|DLBS1033|
155951|NCT02976701|Drug|Placebo|
155952|NCT02976701|Drug|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
155953|NCT02976688|Other|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
155954|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
155955|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
155956|NCT02976662|Procedure|Artificial shrinkage|Artificially eliminated blastocoelic fluid before vitrification procedures.
155957|NCT02976636|Behavioral|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
155958|NCT02976636|Behavioral|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
155959|NCT02976623|Other|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
155960|NCT02976610|Device|Hemolysis Point-of-Care test|Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
155961|NCT02976597|Drug|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAP block. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
155962|NCT02976597|Drug|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAP block divided into 5mg on each side.
155963|NCT02976597|Drug|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAP block divided into 7.5mg on each side.
155964|NCT02976571|Drug|Bupivacaine|Sub cutaneous and/or Intraperitoneal Marcaine application
155965|NCT02976558|Behavioral|Clown theatrical Performance|
155966|NCT02976558|Procedure|Acupuncture|Acupuncture according to Traditional Chinese Medicine
155967|NCT02976558|Behavioral|Music Therapy TaKeTiNa|
155968|NCT02976545|Device|fMRI|fMRI examination
155969|NCT02976545|Behavioral|psychiatric evaluation|psychiatric evaluation
155970|NCT02976532|Other|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
155971|NCT02976519|Drug|BI 443651|twice daily
155972|NCT02976519|Drug|Placebo|twice daily
155973|NCT02976506|Behavioral|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
156027|NCT02976025|Other|Collaborative Care|Standard collaborative care implementation training and support.
156028|NCT02976012|Drug|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
155974|NCT02976506|Behavioral|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
155975|NCT02976493|Other|No Intervention|No Intervention
155976|NCT02976480|Procedure|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
155977|NCT02976480|Procedure|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
155978|NCT02976467|Drug|Fulacimstat (BAY1142524)|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
155979|NCT02976467|Drug|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
155980|NCT02976454|Behavioral|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
155981|NCT02976454|Behavioral|Family-based behavioral obesity treatment|Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
155982|NCT02976441|Radiation|Radiation therapy|
155983|NCT02976441|Drug|Temozolomide|
155984|NCT02976441|Procedure|Stem cell collection|
155985|NCT02976441|Procedure|Stem cell infusion|
155986|NCT02976428|Procedure|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
155987|NCT02976428|Procedure|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
155988|NCT02976415|Other|In-Bed Cycling|20 minutes of in-bed cycling, either active, passive or a combination of active and passive.
155989|NCT02976402|Radiation|SBRT|"Postoperative RT consisting in:~31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week~32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
155990|NCT02976389|Other|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
155991|NCT02976389|Other|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
155992|NCT02976389|Other|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
155993|NCT02976376|Other|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
155994|NCT02976363|Radiation|Radiotherapy breast cancer|
155995|NCT02976363|Other|Evaluation Maximal Respiratory Pressures|
155996|NCT02976337|Drug|Naloxone|active drug infusion
155997|NCT02976337|Drug|Normal Saline|placebo comparator
155998|NCT02976324|Device|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
155999|NCT02976311|Procedure|cesarean section(C/S) via the modified Misgav-Ladach technique|the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
156000|NCT02976311|Procedure|cesarean section via the Pfannenstiel-Kerr technique|the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
156001|NCT02976298|Other|transcranial magnetic stimulation|comparison of different conditions of transcranial magnetic stimulation
156029|NCT02976012|Procedure|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
156030|NCT02975999|Drug|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
156210|NCT02974894|Dietary Supplement|Probiotic (Lactobacillus Plantarum)|
156002|NCT02976285|Procedure|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
156003|NCT02976272|Other|bortezomib|
156004|NCT02976259|Drug|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
156005|NCT02976246|Dietary Supplement|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
156006|NCT02976246|Other|Placebo|One tablet of placebo given once daily.
156007|NCT02976220|Other|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
156008|NCT02976194|Drug|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
156009|NCT02976181|Device|IPG|Patient might require IPG device to be implanted under standard of care
156010|NCT02976168|Other|12° head down tilt|supine head down tilt
156011|NCT02976155|Other|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
156012|NCT02976142|Procedure|neoadjuvant chemoimmunotherapy|
156013|NCT02976129|Drug|V565|Daily dosing of V565 three times a day orally for 6 weeks
156014|NCT02976129|Drug|Placebo|Daily dosing of placebo three times a day orally for 6 weeks
156015|NCT02976116|Drug|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
156016|NCT02976116|Drug|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
156017|NCT02976103|Device|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
156018|NCT02976103|Other|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
156019|NCT02976077|Behavioral|RC2S+|new cognitive remediation program
156020|NCT02976077|Behavioral|active comparator|cognitive remediation program
156021|NCT02976064|Behavioral|PreHabilitation|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.~Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.~Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.~Work plan execution & 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)~6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
156022|NCT02976064|Behavioral|Rehabilitation in chronic stable patients in primary care|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.~Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.~Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.~Work plan execution & 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk & patients with mild disease."
156023|NCT02976064|Behavioral|Rehabilitation in mild chronic patients and citizens at risk|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.~Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.~Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.~Work plan execution & 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.~6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
156024|NCT02976051|Radiation|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
156025|NCT02976038|Drug|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
156026|NCT02976025|Other|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support.
156031|NCT02975999|Drug|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
156032|NCT02975986|Other|123I-BMIPP|Uptake of radioactive isotope by the kidney
156033|NCT02975986|Other|99mTc-MAG3|Uptake of radioactive isotope by the kidney
156034|NCT02975973|Device|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
156035|NCT02975960|Biological|injection of autologous stromal vascular fraction|"Acquiring autologous stromal vascular fraction (SVF) from liposuction~purifying SVF from lipoaspirates and making syringe filled with SVF~SVF injection - Inject SVF on fingers subcutaneously."
156036|NCT02975947|Device|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher & Paykel's HUMIGARD system (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
156037|NCT02975947|Device|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
156038|NCT02975934|Drug|Rucaparib|Rucaparib will be administered daily.
156039|NCT02975934|Drug|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
156040|NCT02975921|Drug|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
156041|NCT02975895|Device|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
156042|NCT02975895|Device|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
156043|NCT02975882|Drug|Irinotecan Hydrochloride|Given PO
156044|NCT02975882|Other|Laboratory Biomarker Analysis|Correlative studies
156045|NCT02975882|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
156046|NCT02975882|Other|Pharmacological Study|Correlative studies
156047|NCT02975882|Drug|Temozolomide|Given PO
156048|NCT02975869|Other|Standard Leukemia Care|
156049|NCT02975869|Other|Palliative Care|
156050|NCT02975856|Dietary Supplement|Table Red Wine|
156051|NCT02975856|Dietary Supplement|Young Port Red Wine|
156052|NCT02975843|Drug|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
156053|NCT02975830|Radiation|Three dimensional CT based images|Right bronchial angle, left bronchial angle
156054|NCT02975817|Other|Hibler's|Passive body heat retention using multiple-layer tight wrapping of patient
156055|NCT02975817|Other|Warm Air|Active, convective warming of patient using warm air blanket
156056|NCT02975804|Device|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
156057|NCT02975791|Other|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
156058|NCT02975791|Procedure|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
156059|NCT02975778|Device|Pain Monitor™|Pain measured by Pain Monitor™
156060|NCT02975765|Procedure|Piezosurgery|The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
156061|NCT02975752|Genetic|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
156062|NCT02975739|Device|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
156063|NCT02975726|Device|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
156064|NCT02975726|Procedure|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
156065|NCT02975726|Biological|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
156066|NCT02975726|Procedure|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
156067|NCT02975700|Drug|PLX3397|
156068|NCT02975687|Biological|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
156069|NCT02975674|Device|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
156070|NCT02975674|Device|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
156071|NCT02975648|Behavioral|educational model + follow up|"educational programme (with booklets and orientation)~telephone follow up (that will be started in preoperative for six months)."
156072|NCT02975648|Behavioral|usual care|"orientations about the surgery and the rehabilitation by health professionals~one scheduled appointment for evaluation by health professionals at six months after the Percutaneous Coronary Intervention"
156073|NCT02975635|Other|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
156074|NCT02975622|Procedure|Central venous catheterization|Ultrasound guided central venous catheterization
254650|NCT02256722|Drug|Propranolol|
156075|NCT02975609|Radiation|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
156076|NCT02975609|Radiation|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
156077|NCT02975596|Other|Awareness|Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
156078|NCT02975596|Other|Education|Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
156079|NCT02975596|Other|Empowerment|"Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines."
156080|NCT02975596|Other|Accessibility|Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
156081|NCT02975583|Drug|Vorapaxar|2.08 mg oral tablet daily
156082|NCT02975583|Drug|Placebos|Placebo oral tablet daily
156083|NCT02975570|Drug|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
156084|NCT02975570|Drug|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
156085|NCT02975570|Drug|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
156086|NCT02975570|Drug|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
156087|NCT02975570|Drug|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
156088|NCT02975557|Drug|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
156089|NCT02975557|Drug|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
156090|NCT02975557|Drug|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
156091|NCT02975544|Behavioral|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
156092|NCT02975531|Other|Simulator's construction|Model to build the mold for the simulator
156093|NCT02975531|Other|Model Features|Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.
156094|NCT02975531|Other|Parameterization technique|Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.
156095|NCT02975531|Other|Simulator training|Training of pompage technique using the simulator.
156096|NCT02975531|Other|Training Evaluation|Evaluation of volunteers from GE group before and after training with the simulator.
156097|NCT02975518|Biological|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
156098|NCT02975505|Other|Strict blood pressure control|Systolic Blood Pressure Target < 120 mm Hg (measured at home)
156099|NCT02975492|Drug|Cholecalciferol sequential dose|sequential dose administration of the treatment
156100|NCT02975492|Drug|Cholecalciferol daily dose|daily dose administration of the treatment
156101|NCT02975479|Drug|ALK Diluent|
156102|NCT02975479|Drug|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
156103|NCT02975466|Device|Insertion of AirQ Blocker and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
156104|NCT02975466|Device|Insertion of AuraGain and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
156105|NCT02975466|Device|Insertion of I-Gel and intubation through the device|Insertion of the SGA device and evaluation of easiness of endotracheal intubation
156106|NCT02975453|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
156107|NCT02975440|Drug|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
156108|NCT02975440|Drug|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
156109|NCT02975440|Drug|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
156110|NCT02975427|Other|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
156111|NCT02975414|Procedure|rTARUP technique|obot-assisted rTARUP technique
156112|NCT02975401|Procedure|rTAPP technique|robot-assisted rTAPP technique
156207|NCT02974920|Drug|Aspirin|Aspirin 100 mg once daily for 180 days
156113|NCT02975388|Drug|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
156114|NCT02975375|Procedure|Preoperative geriatric consult or assessment|A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.
156115|NCT02975375|Procedure|No Preoperative geriatric consult or assessment|No assessment or consult billed in the 4 months before surgery
156116|NCT02975362|Other|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
156117|NCT02975362|Other|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
156118|NCT02975349|Drug|M2951|M2951 low dose will be administered for 48 weeks
156119|NCT02975349|Drug|M2951|M2951 mid dose will be administered for 48 weeks
156120|NCT02975349|Drug|M2951|M2951 high dose will be administered for 48 weeks
156121|NCT02975349|Drug|Placebo|Placebo will be administered for 24 weeks
156122|NCT02975349|Drug|Tecfidera|Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (47 weeks)
156123|NCT02975349|Drug|M2951|Following Placebo for 24 weeks, M2951 low dose will be administered for 24 weeks
156124|NCT02975336|Drug|Placebo|Placebo matched to M2951 will be administered for 52 weeks in double-blind treatment period.
156125|NCT02975336|Drug|M2951|M2951 low dose will be administered for 52 weeks in double-blind treatment period.
156126|NCT02975336|Drug|M2951|M2951 mid dose will be administered for 52 weeks in double-blind treatment period.
156127|NCT02975336|Drug|M2951|M2951 high dose will be administered for 52 weeks.
156128|NCT02975336|Drug|M2951|M2951 will be administered for 104 weeks in open-lable extension period at a dose of 50 milligrams twice a day.
156129|NCT02975323|Drug|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
156130|NCT02975310|Procedure|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
156131|NCT02975310|Procedure|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
156132|NCT02975310|Other|General Anesthesia|ESS will be performed under general anesthesia in the operating room
156133|NCT02975310|Other|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
156134|NCT02975297|Drug|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
156135|NCT02975297|Drug|NRT|Nicotine Patch (21mg) / 24 hours.
156136|NCT02975297|Behavioral|Counseling|Brief individual behavioral smoking cessation counseling.
156137|NCT02975297|Drug|Placebo|Normal saline.
156138|NCT02975271|Drug|Serlopitant|
156139|NCT02975271|Drug|Placebo|Matching placebo
156140|NCT02975258|Procedure|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
156141|NCT02975258|Other|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
156142|NCT02975258|Procedure|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
156143|NCT02975258|Procedure|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
156144|NCT02975258|Radiation|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
156145|NCT02975258|Procedure|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
156146|NCT02975258|Procedure|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin & into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
156211|NCT02974894|Dietary Supplement|Placebo|
161300|NCT02938026|Procedure|Bariatric surgery|
156147|NCT02975258|Procedure|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
156148|NCT02975245|Procedure|Semen collection and analysis|Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
156149|NCT02975232|Behavioral|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
156150|NCT02975232|Behavioral|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
156151|NCT02975219|Drug|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
156152|NCT02975206|Drug|Serlopitant High Dose|serlopitant tablets - high dose
156153|NCT02975206|Drug|Placebo Oral Tablet|placebo tablet
156154|NCT02975206|Drug|Serlopitant Low Dose|serlopitant tablets - low dose
156155|NCT02975193|Behavioral|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
156156|NCT02975193|Behavioral|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
156157|NCT02975193|Behavioral|Montreal Cognitive Assessment|Standard clinical questionnaire
156158|NCT02975180|Device|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
156159|NCT02975180|Behavioral|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
156160|NCT02975167|Other|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
156161|NCT02975167|Other|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
156162|NCT02975167|Procedure|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
156163|NCT02975167|Behavioral|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
156164|NCT02975167|Behavioral|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
156165|NCT02975167|Procedure|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
156166|NCT02975154|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
156167|NCT02975141|Drug|Afatinib 30Mg Tab|Study Drug
156168|NCT02975141|Drug|Afatinib 40Mg Tab|Study Drug
156169|NCT02975141|Drug|Gemzar|Chemotherapy Backbone
156170|NCT02975141|Drug|Abraxane|Chemotherapy Backbone
156171|NCT02975128|Device|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
156172|NCT02975115|Other|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
156173|NCT02975102|Device|CBL-101 Eye Drops|CBL-101 Eye Drops 3 to 6 times per day for 3 months.
156174|NCT02975102|Device|Vismed® Multi|Vismed® Multi 3 to 6 times per day for 3 months.
156175|NCT02975089|Dietary Supplement|"multi-nutrient supplement"|"1.3g/d multivitamins & minerals powder~Leaflet content (same as control)"
156176|NCT02975089|Dietary Supplement|"multi-nutrient & soy protein supplement"|"1.3g/d multivitamins & minerals powder~16g/d isolated soy protein powder~Leaflet content (same as control)"
156208|NCT02974907|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
161301|NCT02938026|Behavioral|Telephone Intensive Lifestyle Counselling|
156177|NCT02975089|Dietary Supplement|Nutrition education on balanced diet & food supplement|"Nutrition education with a designed plate~10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~25g/d milk powder (skimmed and calcium added)~Leaflet content (same as control)"
156178|NCT02975076|Drug|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
156179|NCT02975076|Drug|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
156180|NCT02975076|Drug|Aspirin|
156181|NCT02975076|Drug|Clopidogrel|
156182|NCT02975076|Drug|placebo of clopidogrel|
156183|NCT02975063|Behavioral|A&T IYCF intervention|(1) Interpersonal communication through frontline workers/volunteers to increase mothers' knowledge and practice of optimal infant and young child feeding (IYCF) behaviors. Interpersonal communication will involve multiple contacts with mothers and an array of IYCF messages; (2) Community mobilization activities to raise awareness of the benefits of optimal IYCF practices among opinion leaders and family members, and increase their support to mother for IYCF; (3) Training of facility and community-based health workers on IYCF to improve their ability to support mothers and provide timely information on IYCF; and (4) Mass media communication on IYCF.
156184|NCT02975050|Other|Location|
156185|NCT02975037|Drug|Sildenafil|sildenafil 25 mg PO
156186|NCT02975037|Drug|Erythromycin|erythromycin 250 mg PO
156187|NCT02975037|Drug|Itraconazole|itraconazole 100 mg PO
156188|NCT02975024|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
156189|NCT02975024|Device|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
156190|NCT02975024|Device|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
156191|NCT02975011|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
156192|NCT02975011|Procedure|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
156193|NCT02975011|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
156194|NCT02975011|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
156195|NCT02975011|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
156196|NCT02975011|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
156197|NCT02975011|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
156198|NCT02975011|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
156199|NCT02974998|Behavioral|Young Women's Health CoOp (YWHC)|Participants will receive HTC and engage in a two-session gender-focused intervention. The intervention will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encourages positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
156200|NCT02974998|Behavioral|Standard HTC|Participants will receive the standard HTC available in South Africa for this population.
156201|NCT02974985|Device|injection of Restylane Lyft and Restylane L|Intervention--Injections of volumizing products to the midface, nasolabial fold, and marionette folds in female patients in two different age groups
156202|NCT02974959|Device|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
156203|NCT02974959|Device|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
156204|NCT02974946|Device|RenalGuard|
156205|NCT02974933|Drug|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
156206|NCT02974920|Drug|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
156212|NCT02974881|Device|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
156213|NCT02974868|Drug|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
156214|NCT02974868|Drug|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
156215|NCT02974868|Drug|Placebo|Placebo
156216|NCT02974855|Biological|PF-06741086|PF-06741086 subcutaneous (SC) injection
156217|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
156218|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
156219|NCT02974855|Biological|PF-06741086|PF-06741086 intravenous (IV) infusion
156220|NCT02974842|Device|MAKO 7|Hysteroscopic cell sampling
156221|NCT02974829|Other|follow-up|
156222|NCT02974816|Device|Glooko's mobile application|Standard of care and Remote monitoring
156223|NCT02974803|Drug|Dabrafenib|
156224|NCT02974803|Drug|Trametinib|
156225|NCT02974790|Procedure|Echocardiography|Two-dimensional imaging echocardiography
156226|NCT02974777|Drug|DAPT reduction|Reduction of standard dose DAPT due to low platelet reactivity
156227|NCT02974777|Drug|DAPT on-target|Standard DAPT within the therapeutic window of platelet reactivity
156228|NCT02974777|Drug|DAPT intensification|Intensification of standard dose DAPT due to high platelet reactivity
156229|NCT02974764|Other|No intervention/exposures|
156230|NCT02974751|Procedure|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
156231|NCT02974738|Drug|PT2977|PT2977 is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
156232|NCT02974725|Drug|LXH254|LXH254 will be supplied as tablet for oral use.
156233|NCT02974725|Drug|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
156234|NCT02974725|Drug|Trametinib|Trametinib will be supplied as film-coated tablet for oral use
156235|NCT02974725|Drug|LXH254|Trametinib will be supplied as film-coated tablet for oral use
156236|NCT02974725|Drug|Ribociclib|Ribociclib will be supplied in tablets and hard gelatin capsules.
156237|NCT02974712|Drug|Fentanyl|
156238|NCT02974712|Drug|Saline|
156239|NCT02974699|Dietary Supplement|Potato Starch (Bob's Red Mill)|Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
156240|NCT02974699|Dietary Supplement|Pregelatinized Starch (Resource ThickenUp)|Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
156241|NCT02974686|Drug|Everolimus|
156242|NCT02974686|Drug|Mycophenolic Acid|
156243|NCT02974673|Procedure|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
156244|NCT02974660|Drug|Protamine sulfate|
156245|NCT02974660|Drug|0.9% NaCl|
156246|NCT02974647|Drug|Ruxolitinib|
156247|NCT02974634|Other|OSMT group to UC group|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
156248|NCT02974621|Biological|Bevacizumab|Given IV
156249|NCT02974621|Drug|Cediranib|Given PO
156250|NCT02974621|Drug|Cediranib Maleate|Given PO
156251|NCT02974621|Drug|Olaparib|Given PO
156252|NCT02974582|Behavioral|Exposure to smoking advertising with coupon|Direct mail marketing of smoking advertising with discount coupon
156253|NCT02974582|Behavioral|Exposure to smoking advertising without coupons|Direct mail marketing of smoking advertising without discount coupon
156254|NCT02974582|Behavioral|Exposure to non health related images|Control group
156255|NCT02974569|Device|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
156256|NCT02974556|Procedure|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
156257|NCT02974556|Procedure|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
156258|NCT02974556|Drug|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
156259|NCT02974543|Device|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
156294|NCT02974348|Drug|Dihydroartemisinin piperaquine|Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs
156295|NCT02974348|Drug|Paracetamol|Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation
254651|NCT02256722|Drug|Acipimox|
156260|NCT02974543|Device|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.~The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
156261|NCT02974530|Other|Neurological evaluation|
156262|NCT02974530|Other|Laryngological evaluation|
156263|NCT02974530|Other|MRI evaluation|
156264|NCT02974530|Other|Breathing investigation|
156265|NCT02974530|Other|MRI and articulatory investigation|
156266|NCT02974530|Other|Postural investigation|
156267|NCT02974530|Other|Voice and soundscape investigation|
156268|NCT02974517|Device|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
156269|NCT02974504|Drug|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
156270|NCT02974504|Drug|Linagliptin|linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
156271|NCT02974491|Other|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
156272|NCT02974478|Dietary Supplement|Orange juice with meals|orange juice (20% of energy requirement/day)
156273|NCT02974478|Dietary Supplement|Orange juice between meals|orange juice (20% of energy requirement/day)
156274|NCT02974478|Dietary Supplement|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
156275|NCT02974465|Procedure|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
156276|NCT02974465|Procedure|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
156277|NCT02974465|Procedure|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
156278|NCT02974439|Drug|LANDI-Amlodipine Besylate Tablet 5mg|LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
156279|NCT02974439|Drug|Norvasc Tablets 5mg|Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
156280|NCT02974426|Radiation|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
156281|NCT02974426|Radiation|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
156282|NCT02974426|Drug|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
156283|NCT02974413|Behavioral|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
156284|NCT02974400|Behavioral|Internet-based, CBT-oriented, guided self-help|The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
156285|NCT02974387|Drug|Fluorometholone(FML)|
156286|NCT02974387|Drug|Loteprednol (Lotemax)|
156287|NCT02974374|Drug|PF-06835919|Single or repeated, escalating dose
156288|NCT02974374|Other|Placebo|Single or repeated, escalating dose
156289|NCT02974361|Drug|Ibuprofen|
156290|NCT02974361|Drug|Ibuprofen Lysine|
156291|NCT02974361|Drug|Ibuprofen-LDH|
156292|NCT02974348|Drug|Arthemeter-lumefantrine|Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
156293|NCT02974348|Drug|Artesunate mefloquine|Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs
156296|NCT02974348|Drug|Amoxicillin|Amoxicillin is an antibiotic with no reported activity on plasmodium
156297|NCT02974348|Drug|Quinine|quinine sulphate is an antimalaria drug administered as a second line or rescue drug
156298|NCT02974335|Behavioral|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
156299|NCT02974322|Drug|GED-0301|GED-0301
156300|NCT02974322|Drug|Placebo|Placebo
156301|NCT02974309|Behavioral|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
156302|NCT02974309|Behavioral|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
156303|NCT02974296|Device|transcranial magnetic stimulation|non invasive brain stimulation approach
156304|NCT02974283|Other|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .~Other Names:"
156305|NCT02974270|Drug|Leuprolide|
156306|NCT02974257|Drug|Thiamine|Thiamine 500mg IV twice daily for 2 days
156307|NCT02974257|Other|placebo|100mL normal saline IV every 12 hours for 2 days
156308|NCT02974244|Drug|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
156309|NCT02974244|Drug|basal insulin|basal insulin treatment in the customary clinical care in USA
156310|NCT02974231|Radiation|Intensity-modulated radiation therapy|
156311|NCT02974205|Procedure|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
156312|NCT02974205|Device|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
156313|NCT02974205|Device|össur brace|Rehabilitation after acute isolated PCL rupture
156314|NCT02974192|Other|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
156315|NCT02974179|Biological|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
156316|NCT02974166|Other|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
156317|NCT02974166|Other|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
156318|NCT02974166|Drug|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
156319|NCT02974166|Drug|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
156320|NCT02974153|Biological|ALD403 (Eptinezumab)|
156321|NCT02974153|Biological|Placebo|
156322|NCT02974140|Device|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
156323|NCT02974140|Procedure|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
156324|NCT02974127|Radiation|Radiotherapy|Multisession radiosurgery
156325|NCT02974114|Drug|Paracetamol and caffeine|Test product containing 500 mg paracetamol and 65 mg caffeine
156326|NCT02974114|Drug|Paracetamol|Test product containing 500 mg paracetamol
156327|NCT02974114|Other|Placebo|Placebo to match paracetamol 665mg sustained release tablets
156328|NCT02974101|Other|registration of AdaptiveStim|
156329|NCT02974088|Device|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
156330|NCT02974088|Device|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
156331|NCT02974075|Procedure|Salvage lymph node dissection|Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
156332|NCT02974062|Other|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
156333|NCT02974049|Drug|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole"
156334|NCT02974049|Drug|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
156335|NCT02974049|Drug|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
156336|NCT02974036|Other|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
156337|NCT02974023|Device|Pain Gear|PainGear [ActiPatch®] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
156338|NCT02974010|Drug|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
156339|NCT02974010|Drug|Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
156340|NCT02974010|Drug|Ketamine Intravenous Infusion|Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
156341|NCT02974010|Drug|Saline Solution Intravenous Infusion|Radomized administration of Ketamine or Placebo in a 3 to 1 ratio
156342|NCT02973997|Other|Laboratory Biomarker Analysis|Correlative studies
156343|NCT02973997|Drug|Lenvatinib|Given PO
156350|NCT02973945|Device|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
156351|NCT02973945|Device|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.~The aerobic capacity training plan will be conducted three times a week over 24 sessions."
156352|NCT02973932|Behavioral|Cognitive-bahavioral psychotherapy|
156353|NCT02973919|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, & Renssen, 1999; de Jongh, Holmshaw, Carswell, & van Wijk, 2011; Lapsekili & Yelboga, 2014; Muris, Merckelbach, van Haaften, & Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
156354|NCT02973919|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger & Pauli, 2011).
156355|NCT02973906|Other|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
156356|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
156357|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
156358|NCT02973893|Biological|Placebo|Placebo
156359|NCT02973893|Biological|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
156360|NCT02973893|Biological|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
156361|NCT02973880|Drug|NETILDEX™ ophthalmic gel|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) ophthalmic gel immediately after the surgery then 1 drop twice daily (b.i.d.) from Day 1 until Day 14 after surgery + 1 drop of XANTERGEL™ ophthalmic gel twice daily (b.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
156362|NCT02973880|Drug|NETILDEX™ eye drops solution|"1 drop of NETILDEX™ (Netilmicin Sulfate 3mg/ml / Dexamethasone Disodium Phosphate 1mg/ml) eye drops solution immediately after the surgery then 1 drop four times a day (q.i.d.) from Day 1 until Day 14 after surgery.~Bromfenac 0.9 mg/ml 1 drop twice daily (b.i.d.) for 3 days before cataract surgery."
156363|NCT02973841|Device|Sono-ease device|insertion of US guided IJV using sono-ease device
156364|NCT02973828|Procedure|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
156365|NCT02973815|Behavioral|NU-HOME Intervention|The NU-HOME family intervention consists of group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
156366|NCT02973802|Biological|ATX-GD-59|Disease specific immune modulating treatment for Graves Disease
156367|NCT02973789|Device|NovoTTF-100L|Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.
156368|NCT02973789|Drug|Immune checkpoint inhibitors or docetaxel|Patients receive standard of care with Immune checkpoint inhibitors or docetaxel
156369|NCT02973776|Drug|LEO 90100 aerosol foam|
156370|NCT02973776|Drug|Dermoval®/Dermovate®|
156371|NCT02973776|Drug|Diprosone|
156372|NCT02973776|Drug|Elocon|
156373|NCT02973776|Drug|Locoid|
156374|NCT02973776|Other|LEO 90100 foam vehicle|
156375|NCT02973763|Drug|Alflutinib|
156376|NCT02973750|Procedure|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
156377|NCT02973750|Procedure|Tissue Collection|Tissue collection during debulking surgery.
156378|NCT02973750|Procedure|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
156379|NCT02973737|Drug|pyrotinib|400 mg once daily
156380|NCT02973737|Drug|placebo|400 mg once daily
156381|NCT02973737|Drug|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
156382|NCT02973724|Drug|Remifentanil|The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
163642|NCT02920957|Device|comfilcon A|contact lens
156383|NCT02973724|Drug|Propofol anesthesia|Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
156384|NCT02973711|Drug|Nilotinib|Nilotinib 300 mg BID
156385|NCT02973711|Drug|Ruxolitinib|Ruxolitinib, 10, 15 or 20mg BID
156386|NCT02973698|Other|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
156387|NCT02973698|Other|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
156388|NCT02973698|Other|Control|No intervention will do
156389|NCT02973685|Procedure|Hepatic arterial infusion chemotherapy|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
156390|NCT02973685|Procedure|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
156391|NCT02973685|Drug|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
156392|NCT02973685|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
156393|NCT02973672|Drug|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
156394|NCT02973659|Drug|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
156395|NCT02973659|Drug|Placebos|
156396|NCT02973646|Drug|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
156397|NCT02973646|Drug|Peginterferon Alfa-2B|
156398|NCT02973633|Device|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
156399|NCT02973633|Drug|Gadolinium DOTA Meglumine|Late Gadolinium enhancement
156400|NCT02973620|Drug|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
156401|NCT02973607|Procedure|Nephrectomy|This is observational in design.
156402|NCT02973594|Drug|Ivabradine|
156403|NCT02973594|Drug|Placebo|
156404|NCT02973581|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
156405|NCT02973581|Drug|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
156406|NCT02973581|Drug|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
156407|NCT02973581|Drug|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
156408|NCT02973568|Other|Observational Study|
156409|NCT02973555|Other|PRP injection|autologous intrauterine infusion of PRP
156410|NCT02973542|Drug|Ethosuximide|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
156411|NCT02973542|Other|Placebo|The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.
156412|NCT02973529|Device|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
156413|NCT02973529|Device|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
156414|NCT02973516|Drug|P03277|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
156415|NCT02973516|Drug|P03277 half dose|P03277 will be administered at 0.05 mmol/kg BW (corresponding to 0.1 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
156416|NCT02973503|Drug|Elbasvir/Grazoprevir Fixed Dose Combination|Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
156417|NCT02973490|Device|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
156418|NCT02973477|Drug|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
156419|NCT02973477|Drug|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
156420|NCT02973464|Drug|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
156421|NCT02973464|Drug|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
156422|NCT02973451|Drug|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
156423|NCT02973451|Drug|local Bupivacaine|Bupivacaine Trocar Site Infiltration
156464|NCT02973113|Biological|EBVST Cells|EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
163643|NCT02920957|Device|senofilcon C|contact lens
156424|NCT02973438|Device|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
156425|NCT02973438|Device|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
156426|NCT02973425|Behavioral|Take a Break as an augmentation to NRT-sampling in Motivation Phase|NRT sampling experience & Suite of mHealth motivational tools and mini-games.
156427|NCT02973425|Behavioral|NRT and mHealth assessment tool without feedback|NRT and mHealth assessment tool without feedback
156428|NCT02973399|Drug|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
156429|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
156430|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
156431|NCT02973373|Device|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
156432|NCT02973373|Other|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
156433|NCT02973360|Drug|Docosahexaenoic Acid|Oral Capsule
156434|NCT02973360|Drug|Placebo|Oral Capsule
156435|NCT02973347|Other|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
156436|NCT02973347|Other|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
156437|NCT02973334|Other|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
156438|NCT02973334|Other|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
156439|NCT02973334|Other|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
156440|NCT02973321|Drug|SAR425899|"Pharmaceutical form: solution~Route of administration: subcutaneous"
156441|NCT02973321|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
156442|NCT02973321|Drug|Liraglutide|"Pharmaceutical form: solution~Route of administration: subcutaneous"
156443|NCT02973321|Drug|Metformin|"Pharmaceutical form: tablets~Route of administration: oral"
156444|NCT02973308|Other|Observer|Observer A and observer B
156445|NCT02973295|Drug|Silymarin|Capsules contains 100 mg of silymarin
156446|NCT02973295|Other|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
156447|NCT02973282|Other|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
156448|NCT02973269|Biological|daxibotulinumtoxin type A|Intramuscular injection
156449|NCT02973269|Biological|Placebo|Intramuscular injection
156450|NCT02973243|Device|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
156451|NCT02973230|Other|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
156452|NCT02973217|Device|Immunostimulating Interstitial Laser Thermotherapy|
156453|NCT02973204|Drug|Sorafenib|
156454|NCT02973204|Procedure|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
156455|NCT02973204|Drug|Everolimus|
156456|NCT02973204|Drug|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
156457|NCT02973191|Drug|JCAR015|
156458|NCT02973178|Device|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
156459|NCT02973152|Procedure|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
156460|NCT02973152|Procedure|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
156461|NCT02973139|Other|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
156462|NCT02973139|Other|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
156463|NCT02973126|Procedure|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
156465|NCT02973113|Biological|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
156466|NCT02973100|Drug|Dulaglutide|Administered SC
156467|NCT02973100|Drug|Placebo|Administered SC
156468|NCT02973087|Biological|von Willebrand factor (Recombinant)|Packaged in boxes with 2 glass vials, one containing the lyophilized rVWF, and the second vial containing the diluent.
156469|NCT02973087|Biological|Antihemophilic Factor (Recombinant)|Packaged in boxes with 2 glass vials, one containing the lyophilized rFVIII, and the second vial containing the diluent
156470|NCT02973074|Dietary Supplement|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
156471|NCT02973061|Other|Questionnaires|All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
156472|NCT02973048|Drug|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
156473|NCT02973048|Drug|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
156474|NCT02973035|Drug|Amlodipine|
156475|NCT02973035|Drug|Valsartan|
156476|NCT02973022|Other|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
156477|NCT02972996|Other|Blueberry|22 g freeze-dried whole blueberry powder
156478|NCT02972996|Other|Placebo|22 g placebo blueberry powder
156479|NCT02972983|Drug|Daptomycin|Adjuvant therapy for up to five days
156480|NCT02972983|Other|Placebo|Placebo
156481|NCT02972970|Device|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
156482|NCT02972957|Biological|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
156483|NCT02972957|Drug|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
156484|NCT02972944|Procedure|Laparoscopic cholecystectomy|
156485|NCT02972944|Procedure|Non-operative treatment|
156486|NCT02972918|Drug|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
156487|NCT02972905|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
156488|NCT02972905|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
156489|NCT02972879|Procedure|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
156490|NCT02972879|Procedure|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:~LASER 904nm~P: 1.5W/cm²~30mV/cm²~Area 2 cm²~1 Joule por ponto ( in the A1 pulley)"
156491|NCT02972879|Procedure|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
156492|NCT02972879|Procedure|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
156493|NCT02972866|Drug|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
156494|NCT02972853|Behavioral|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
156495|NCT02972840|Drug|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib in combination with BR
156496|NCT02972840|Drug|Placebo in combination with bendamustine and rituximab|Placebo in combination with BR
156497|NCT02972827|Device|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
156498|NCT02972827|Other|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
156499|NCT02972814|Device|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
156500|NCT02972814|Device|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
156501|NCT02972814|Device|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
156502|NCT02972801|Procedure|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
156503|NCT02972788|Drug|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
156504|NCT02972788|Other|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
156505|NCT02972775|Other|no interventions. observational study|
156506|NCT02972762|Drug|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
156507|NCT02972749|Behavioral|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
156508|NCT02972736|Radiation|Radiation dose expressed as DAP|
156509|NCT02972723|Drug|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
156821|NCT02970383|Behavioral|Initial prescription for 10 narcotic tabs|Reduced number of pills in initial prescription post-operatively
156510|NCT02972710|Other|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
156511|NCT02972710|Other|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
156512|NCT02972697|Radiation|11C-acetate ligand|
156513|NCT02972697|Radiation|FDG ligand|
156514|NCT02972684|Device|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
156515|NCT02972671|Device|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
156516|NCT02972671|Device|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
156517|NCT02972658|Drug|Lanabecestat|Administered orally
156518|NCT02972645|Drug|LY3305677|Administered SC
156519|NCT02972645|Drug|Placebo|Administered SC
156520|NCT02972632|Drug|Vortioxetine|Vortioxetine tablet
156521|NCT02972619|Other|Structured Multicomponent Intervention (MCI)|Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
156522|NCT02972593|Biological|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb >7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
156523|NCT02972580|Genetic|Genetic characterization|Confirmatory genetic testing for mutation in DMD gene (Carrier Status) for subjects in respective Cohorts
156524|NCT02972567|Dietary Supplement|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
156525|NCT02972567|Dietary Supplement|Control|Maltodextrin
156526|NCT02972554|Drug|Propanolol hydrochloride|One-time dose of 40mg of propranolol
156527|NCT02972554|Other|Placebo|Outside casing matching that of active drug
156528|NCT02972541|Device|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
156529|NCT02972541|Device|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
156530|NCT02972528|Biological|Platelet Lysate|Direct injection of allogenic Platelet Lysate
156531|NCT02972528|Biological|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
156532|NCT02972515|Behavioral|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
156533|NCT02972515|Device|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
156534|NCT02972502|Drug|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
156535|NCT02972502|Drug|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
156536|NCT02972502|Other|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
156537|NCT02972502|Drug|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
156538|NCT02972489|Device|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
156539|NCT02972489|Device|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
156540|NCT02972476|Drug|Budesonide & formoterol fumarate and Aclidinium bromide|
156541|NCT02972476|Drug|Fluticasone 500 & salmeterol and Aclidinium bromide|
156542|NCT02972476|Drug|Fluticasone 250 & salmeterol and Aclidinium bromide|
156543|NCT02972476|Drug|Aclidinium bromide & formoterol fumarate|
156544|NCT02972463|Dietary Supplement|Immunoglobulin Y|
156545|NCT02972463|Other|Placebo|
156546|NCT02972450|Biological|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection."
156547|NCT02972450|Biological|GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab|"The vaccine is a solution of HIV MVA vectors (see section 1.3.2) in S08 buffer (10mM Tris/hydrochloride (Tris/HCl), Saccharose 5% (w/v), 10mM Sodium Glutamate (Na Glu), 50mM Sodium Chloride (NaCl), water PPI, pH 8.0).~0.5ml of ANRS MVA HIV-B (1 x 108 pfu/ml) or placebo for MVA (S8 buffer) will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection. Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline."
156548|NCT02972450|Drug|Vedolizumab 300 MG [Entyvio]|Vedolizumab is administered as an intravenous infusion over 30 mins in the dominant arm. After infusion, the line should be flushed with 30mls of normal saline.
156549|NCT02972450|Other|Placebo|"Placebo for MVA it is a solution composed of S08 buffer (as for the MVA vaccine) that will be administered intramuscularly in the deltoid muscle of the non-dominant upper arm. Participants will be observed for one hour after the injection.~Placebo for GTU-MultiHIV B-clade vaccine: Sodium Chloride (NaCl) for infusion, 0.9%.~Placebo for Vedolizumab: Sodium Chloride (NaCl) for infusion, 0.9% in 250 ml infusion bags."
156550|NCT02972437|Other|sample taking|throat culture and oral cavity sample
156551|NCT02972424|Drug|Teriparatide Prefilled Syringe|TPTD 20 mcg
156552|NCT02972424|Drug|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
156553|NCT02972411|Behavioral|Voluntary ventilatory response|Training of the subjects for voluntary increase in the respiratory minute ventilation
156554|NCT02972411|Drug|Acetazolamide|Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
156555|NCT02972398|Drug|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
156556|NCT02972398|Drug|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
156557|NCT02972385|Procedure|Mouthwash sample|A one time mouthwash sample will be performed.
156558|NCT02972385|Procedure|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
156559|NCT02972372|Procedure|CRT|"Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity"
156560|NCT02972372|Procedure|surgery|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
156561|NCT02972359|Drug|Neridronic acid|Neridronic acid administered as intravenous infusion.
156562|NCT02972346|Drug|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
156563|NCT02972333|Drug|AZD9291 80mg oral each day|All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
156564|NCT02972333|Radiation|Radiation therapy|Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
156565|NCT02972320|Drug|temozolomide|temozolomide maintain therapeutic
156566|NCT02972307|Other|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
156567|NCT02972294|Drug|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
156568|NCT02972294|Drug|Tranexamic Acid|Tranexamic acid will be use.
156569|NCT02972294|Drug|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
156570|NCT02972294|Drug|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
156571|NCT02972281|Biological|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
156572|NCT02972268|Drug|Tamsulosin 0.2mg + Solifenacin 5mg|Tamsulosin 0.2mg + Solifenacin 5mg for 12wks
156573|NCT02972268|Drug|Tamsulosin 0.2mg + Placebo(Solifenacin)|Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks
156574|NCT02972255|Drug|RO7079901|RO7079901 will be administered as per schedule described in individual arm.
156575|NCT02972255|Drug|Meropenem|Meropenem will be administered as per schedule described in individual arm.
156576|NCT02972255|Other|RO7049389 Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
156577|NCT02972255|Other|Meropenem Placebo|Placebo matching to meropenem will be administered as per schedule described in individual arm.
156578|NCT02972242|Radiation|Field of View|Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
156579|NCT02972229|Radiation|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
156580|NCT02972229|Radiation|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
156581|NCT02972216|Drug|Nolbaxol|
156582|NCT02972216|Drug|Taxotere|
156583|NCT02972216|Drug|cisplatin|
156614|NCT02971943|Procedure|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
156615|NCT02971930|Biological|BAY94-9027|Intravenous infusion of BAY94-9027
156584|NCT02972203|Behavioral|Mindfulness Training for Primary Care|• MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
156585|NCT02972203|Behavioral|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
156586|NCT02972190|Procedure|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
156587|NCT02972190|Procedure|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
156588|NCT02972190|Device|Pedicle screw and interbody cage|Pedicle screw and interbody cage
156589|NCT02972177|Procedure|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
156590|NCT02972177|Procedure|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
156591|NCT02972164|Behavioral|Weight loss program for school children|"The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.~The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being."
156592|NCT02972151|Drug|Comprehensive treatment of TCM|Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
156593|NCT02972151|Other|Expectant treatment|Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
156594|NCT02972125|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
156595|NCT02972125|Drug|Lacosamide (LCM) dry syrup|Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
156596|NCT02972112|Behavioral|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
156597|NCT02972112|Other|Sham|standard birth preparation sessions.
156598|NCT02972099|Device|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
156599|NCT02972099|Device|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
156600|NCT02972086|Behavioral|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
156601|NCT02972073|Other|Exercise intervention|Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
156602|NCT02972060|Drug|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
156603|NCT02972060|Drug|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.~This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
156604|NCT02972047|Behavioral|Diaphragmatic Breathing|Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.
156605|NCT02972047|Behavioral|Sham Comparator|Sham therapy (listening to music/watching TV for 30 minutes after each meal
156606|NCT02972034|Drug|MK-8353|PO capsule
156607|NCT02972034|Biological|Pembrolizumab|IV infusion
156608|NCT02972021|Device|High-flow nasal cannula|
156609|NCT02971995|Device|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
156610|NCT02971995|Device|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
156611|NCT02971982|Drug|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
156612|NCT02971982|Drug|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
156613|NCT02971956|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
156616|NCT02971917|Radiation|Chest x-ray image acquisition|Obtain a digital X-ray chest image of the patient
156822|NCT02970383|Behavioral|Inital prescription for 30 narcotic tabs|
156617|NCT02971917|Radiation|Creation of TRUVIEW ART applied image|"Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.~Outcome: 2 versions of chest image~Original Chest X-ray (w/o TRUVIEW ART)~TRUVIEW ART applied image"
156618|NCT02971917|Radiation|Comparison of TRUVIEW ART image with original image|Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
156619|NCT02971904|Other|human milk collection|
156620|NCT02971891|Drug|CLS006 (Furosemide) Topical Gel|
156621|NCT02971891|Drug|Vehicle Topical Gel|
156622|NCT02971878|Biological|Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)|Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
156623|NCT02971865|Behavioral|CBT/CMT|Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
156624|NCT02971865|Other|Control group traditional primary care|No change in care usually given
156625|NCT02971839|Drug|CTP-656, 20 mg (QD)|
156626|NCT02971839|Drug|CTP-656, 100 mg (QD)|
156627|NCT02971839|Drug|CTP-656, 150 mg (QD)|
156628|NCT02971839|Drug|Placebo (QD)|
156629|NCT02971839|Drug|Kalydeco, 150 mg Tablet (BID; open-label)|
156630|NCT02971826|Device|REVIVETM SE thrombectomy|Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
156631|NCT02971813|Behavioral|Facebook|"Volunteers will be recruited during inpatient stay, or via phone call or in person after discharge and prior to beginning cardiac rehabilitation.~Participants will be given a baseline BREQ-3 survey and a PNSE scale.~Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.~The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.~Educational posts will cover topics that will cover healthcare information.~Provider support will be posted much like the educational posts.~The data collection for this study will take place prior to beginning cardiac rehabilitation, at which time the participants will receive the BREQ-3 and PNSE surveys either in person or via email link.~Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
156632|NCT02971800|Drug|sodium fluorescein injection 10%|
156633|NCT02971787|Dietary Supplement|Probiotics|Day 1-21: 2 capsules per day
156634|NCT02971787|Dietary Supplement|Salt|Day 8-21: 10 tablets à 600 mg per day
156635|NCT02971761|Drug|Enobosarm|Given PO
156636|NCT02971761|Other|Laboratory Biomarker Analysis|Correlative studies
156637|NCT02971761|Biological|Pembrolizumab|Given IV
156638|NCT02971748|Biological|Pembrolizumab|Given IV
156639|NCT02971735|Other|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
156640|NCT02971722|Drug|JY09|2mg/1ml/bottle
156641|NCT02971722|Drug|Placebo|1ml/bottle
156642|NCT02971709|Behavioral|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
156643|NCT02971696|Drug|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
156644|NCT02971696|Drug|Best Supportive care|Liver Support, pain management
156645|NCT02971683|Drug|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
156646|NCT02971683|Drug|Placebo|Placebo of Abatacept subcutaneous
156647|NCT02971670|Biological|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
156648|NCT02971644|Device|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
156649|NCT02971631|Other|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
156650|NCT02971631|Other|Placebo|Infusion of 1% human albumin in normal saline
156651|NCT02971605|Drug|Psilocybin|25 mg/70 kg Psilocybin
156652|NCT02971592|Device|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
156653|NCT02971592|Other|Mock Device|reception of device that does not apply the electromagnetic field
156654|NCT02971579|Procedure|ERCP|Endoscopic procedure used to manage biliary and pancreatic diseases
156655|NCT02971553|Device|Upright Resuscitator with PEEP|
156656|NCT02971553|Device|Upright Resuscitator|
156657|NCT02971540|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
156823|NCT02970370|Other|no intervention|
254652|NCT02256722|Drug|Salmeterol|
156658|NCT02971540|Drug|Tramadol|in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
156659|NCT02971540|Drug|Bupivacaine|patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
156660|NCT02971540|Drug|Ropivacaine|patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
156661|NCT02971540|Other|control group|patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
156662|NCT02971527|Device|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
156663|NCT02971527|Device|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
156664|NCT02971514|Behavioral|Flossing before Brushing|
156665|NCT02971514|Behavioral|Brushing before Flossing|
156666|NCT02971501|Biological|Bevacizumab|Given IV
156667|NCT02971501|Other|Laboratory Biomarker Analysis|Correlative studies
156668|NCT02971501|Drug|Osimertinib|Given PO
156669|NCT02971488|Other|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.~Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
156670|NCT02971475|Procedure|extracorporeal shock wave lithotripsy|People in this group would be treated with ESWL only.
156671|NCT02971475|Procedure|endoscopic drainage of the main pancreatic duct|People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
156672|NCT02971475|Drug|Analgesics|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
156673|NCT02971462|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
156674|NCT02971449|Device|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
156675|NCT02971449|Other|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
156676|NCT02971436|Device|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
156677|NCT02971436|Device|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
156678|NCT02971436|Device|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
156679|NCT02971436|Device|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
156680|NCT02971436|Device|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
156681|NCT02971436|Device|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
156682|NCT02971423|Drug|ETX2514|
156683|NCT02971423|Drug|Placebo|matching placebo infusion
156684|NCT02971423|Drug|Sulbactam|
156685|NCT02971423|Drug|Imipenem/Cilastatin|
156686|NCT02971410|Other|Laboratory Biomarker Analysis|Correlative studies
156687|NCT02971410|Other|Quality-of-Life Assessment|Ancillary studies
156688|NCT02971410|Drug|Simvastatin|Given PO
156689|NCT02971397|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
156690|NCT02971397|Drug|Cytarabine|Given IV
156691|NCT02971397|Drug|Daunorubicin Hydrochloride|Given IV
156692|NCT02971397|Other|Laboratory Biomarker Analysis|Correlative studies
156693|NCT02971384|Drug|Echinaforce|
156694|NCT02971371|Device|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
156695|NCT02971358|Procedure|Radical prostatectomy|Standard radical prostatectomy with extended lymph node dissection is performed.
156696|NCT02971345|Procedure|Stent and Iodine-125 seed strand implantation|The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
156697|NCT02971345|Device|Stent|Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
156698|NCT02971345|Device|Iodine-125 seed|The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
156699|NCT02971345|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
156700|NCT02971345|Drug|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
156701|NCT02971345|Other|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
156731|NCT02971098|Procedure|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
156909|NCT02969759|Other|Skin Biopsy|
156945|NCT02969525|Drug|Bimekizumab|Bimekizumab in different dosage regimens.
254656|NCT02256709|Drug|Placebo tablet|
156702|NCT02971332|Procedure|Stapled Transanal Rectal Resection|"The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.~The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure."
156703|NCT02971319|Device|Tc-99M-Tetrofosmin SPECT|
156704|NCT02971319|Device|F-18 FDG PET|
156705|NCT02971306|Drug|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
156706|NCT02971306|Drug|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
156707|NCT02971306|Drug|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
156708|NCT02971293|Drug|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
156709|NCT02971293|Drug|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
156710|NCT02971293|Drug|Placebo|The subject will receive Placebo single dose DPI.
156711|NCT02971267|Other|Observational|None, observational only
156712|NCT02971254|Drug|Sevoflurane|
156713|NCT02971254|Drug|Desflurane|
156714|NCT02971241|Behavioral|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
156715|NCT02971228|Drug|Insulin Lispro|Used to lower blood glucose. Commercially available by prescription and is indicated for patients with T1DM, but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
156716|NCT02971228|Drug|ZP4207 (dasiglucagon)|A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
156717|NCT02971228|Drug|Glucagon|A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
156718|NCT02971228|Device|iPhone-based bionic pancreas|An experimental device.
156719|NCT02971228|Device|iLet-based bionic pancreas|An experimental device.
156720|NCT02971215|Device|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)~+ Physical Therapy protocol."
156721|NCT02971215|Device|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
156722|NCT02971202|Drug|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)~glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)~somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
156723|NCT02971202|Drug|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
156724|NCT02971189|Device|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
156725|NCT02971176|Radiation|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
156726|NCT02971176|Radiation|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
156727|NCT02971163|Behavioral|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
156728|NCT02971150|Behavioral|Brief Behavioral Treatment for Insomnia|
156729|NCT02971137|Behavioral|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
156730|NCT02971137|Behavioral|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
156732|NCT02971085|Procedure|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
156733|NCT02971072|Procedure|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
156734|NCT02971072|Other|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
156735|NCT02971059|Dietary Supplement|Phenylalanine intake|Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
156736|NCT02971046|Other|varying protein intakes|Four randomly assigned levels of protein intake in a repeated measured design.
156737|NCT02971033|Drug|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
156738|NCT02971033|Drug|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
156739|NCT02971033|Drug|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
156740|NCT02971020|Other|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
156741|NCT02971007|Drug|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
156742|NCT02971007|Drug|Fluconazole|
156743|NCT02970981|Biological|Nivolumab|
156744|NCT02970981|Biological|Ipilimumab|
156745|NCT02970968|Drug|VLY-686 (Tradipitant)|oral capsule
156746|NCT02970968|Other|Placebo|placebo oral
156747|NCT02970955|Procedure|Inoperable thoracic nodes metastases|The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
156748|NCT02970942|Drug|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
156749|NCT02970942|Drug|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
156750|NCT02970929|Drug|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
156751|NCT02970916|Drug|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1~FOLFIRI regimen immediately after aflibercept:~Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.~* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
156752|NCT02970903|Device|VitalPAD|VitalPAD prototype device
156753|NCT02970903|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
156754|NCT02970890|Device|Portable Pain Away™|Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
156755|NCT02970877|Biological|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
156756|NCT02970877|Biological|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
156757|NCT02970864|Device|Polynerve|Polymer biomaterial nerve conduit
156758|NCT02970838|Other|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.~Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
156759|NCT02970825|Other|Exercise|Moderate to high intensity physical training
156760|NCT02970825|Other|Relaxation|Low intensity physical activity and mindfulness
156761|NCT02970812|Device|EMS|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
156762|NCT02970812|Device|TENS|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
156763|NCT02970786|Drug|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c[RGDyK])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
156764|NCT02970773|Drug|Rivaroxaban Oral Tablet|oral application of Xarelto
156765|NCT02970747|Drug|Carfilzomib|In accordance with SmPC.
156766|NCT02970734|Behavioral|Breathe|Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
156767|NCT02970734|Behavioral|Resource Webpage|Static webpage listing anxiety resources.
156768|NCT02970721|Drug|Antipsychotic|Antipsychotic monotherapy
156769|NCT02970721|Drug|Antidepressant|Antidepressant monotherapy
156770|NCT02970721|Drug|Antipsychotic and Antidepressant|Polytherapy
156771|NCT02970708|Device|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
156772|NCT02970708|Device|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
156773|NCT02970695|Device|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
156818|NCT02970409|Device|saline|catheter lock using saline
156819|NCT02970409|Device|Heparin|catheter lock using Heparin
156774|NCT02970695|Device|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
156775|NCT02970682|Drug|SFX-01|Stabilised Sulforaphane
156776|NCT02970682|Drug|Fulvestrant|Fulvestrant
156777|NCT02970682|Drug|Tamoxifen|Tamoxifen
156778|NCT02970682|Drug|Aromatase Inhibitors|
156779|NCT02970669|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
156780|NCT02970669|Drug|enalapril|Enalapril tablet taken orally.
156781|NCT02970669|Drug|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
156782|NCT02970669|Drug|matching placebo enalapril|matching placebo enalapril tablet taken orally
156783|NCT02970656|Behavioral|Teens.Connect|Teens.Connect combines two internet psycho-educational programs, TEENCOPE™, an internet version of coping skills training using a graphic novel format combined with social media, and an internet diabetes problem-solving educational program (Managing Diabetes)
156784|NCT02970643|Drug|Olanzapine|Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
156785|NCT02970643|Drug|Palonosetron|Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
156786|NCT02970630|Drug|Tacrolimus|once a day
156787|NCT02970630|Drug|Everolimus|twice daily
156788|NCT02970617|Other|Memory Intervention|Ring bell after final radiation treatment
156789|NCT02970617|Other|Questionnaire Administration|Ancillary studies
156790|NCT02970617|Radiation|Radiation therapy|Radiation therapy with or without chemotherapy
156791|NCT02970604|Drug|Aspirin|Non enteric coated aspirin
156792|NCT02970591|Other|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
156793|NCT02970591|Other|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 25 energy % proteins and 65 energy % fat.
156794|NCT02970591|Other|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
156795|NCT02970578|Procedure|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
156796|NCT02970565|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
156797|NCT02970565|Behavioral|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
156798|NCT02970552|Drug|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
156799|NCT02970552|Drug|Placebo|Indistinguishable placebo vaginal suppository
156800|NCT02970539|Drug|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
156801|NCT02970539|Drug|Ramucirumab|Ramucirumab will be administered by iv infusion.
156802|NCT02970526|Drug|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
156803|NCT02970513|Other|Psychiatric evaluation|The purpose of this study is to determine whether the presence of pathogenic Escherichia coli in colon is associated with psychiatric disorders.
156804|NCT02970500|Drug|Methylphenidate HCl 10Mg SR|Methylphenidate HCl 10Mg SR (Phase 1) and Methylphenidate HCl 20Mg SR (Phase 2)
156805|NCT02970500|Drug|Placebo Group|Placebo
156806|NCT02970487|Device|Intraocular implant of the Precisight|Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
156807|NCT02970474|Device|Conventional Bolus|Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
156808|NCT02970474|Device|3D Printed Bolus|The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
156809|NCT02970461|Other|Gamified Group|See Gamified Group in Arms description.
156810|NCT02970461|Other|Control Group|See Control Group in Arms description.
156811|NCT02970448|Procedure|LITT|MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.
156812|NCT02970448|Radiation|Radiation therapy|One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.
156813|NCT02970448|Drug|Temozolomide|Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
156814|NCT02970435|Behavioral|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
156815|NCT02970435|Behavioral|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
156816|NCT02970435|Behavioral|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
156817|NCT02970422|Other|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
156944|NCT02969525|Other|Placebo|
156824|NCT02970357|Other|DIAPASON Questionnaire|"50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :~what is diabetes~Monitoring~Hypoglycemia and Hyperglycemia~Nutrition~Insuline"
156825|NCT02970357|Behavioral|WHO-5|5 item questionnaire of the World Health Organization about quality of life
156826|NCT02970344|Behavioral|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
156827|NCT02970331|Drug|pefcalcitol ointment, 0.005%|pefcalcitol ointment, 0.005%
156828|NCT02970318|Drug|Acalabrutinib (ACP-196)|Acalabrutinib monotherapy
156829|NCT02970318|Drug|Rituximab|Rituximab in combination with idelalisib or bendamustine
156830|NCT02970318|Drug|Idelalisib|Idelalisib in combination with rituximab
156831|NCT02970318|Drug|Bendamustine|Bendamustine in combination with rituximab
156832|NCT02970305|Drug|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
156833|NCT02970305|Drug|Placebo|Placebo, taken as two tablets, once daily by mouth
156834|NCT02970292|Drug|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
156835|NCT02970292|Drug|Placebo|Placebo, taken as two tablets, once daily by mouth
156836|NCT02970279|Behavioral|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
156837|NCT02970253|Procedure|Capsular resection|Capsular resection
156838|NCT02970253|Procedure|Capsular retention|Capsular retention
156839|NCT02970240|Procedure|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
156840|NCT02970227|Other|Observation|None, observation only
156841|NCT02970214|Other|no intervention, only observational|no intervention, only observational
156842|NCT02970201|Other|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
156843|NCT02970188|Behavioral|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
156844|NCT02970175|Drug|Terlipressin administration|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
156845|NCT02970175|Procedure|bronchoscopy under local anesthesia|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
156846|NCT02970175|Procedure|Biopsy sampling|Patients undergoing a bronchoscopy under local anesthesia for biopsy sampling of endobronchial lesions. Bronchoscopy will be done with terlipressin administration
156847|NCT02970162|Drug|Amifampridine Phosphate|
156848|NCT02970162|Drug|Placebo Oral Tablet|
156849|NCT02970149|Other|NA (observational)|
156850|NCT02970136|Device|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
156851|NCT02970136|Device|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
156852|NCT02970136|Device|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
156853|NCT02970136|Other|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
156854|NCT02970136|Other|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
156855|NCT02970123|Behavioral|Sit Less, Interact, Move More (SLIMM)|
156856|NCT02970097|Drug|20ml bolus of 0.5% ropivicaine|local anesthetic
156857|NCT02970097|Drug|10 ml of 0.5% ropivicaine|local anesthetic
156858|NCT02970097|Drug|Midazolam|1-2 mg of medication given intravenously before nerve block
156859|NCT02970097|Drug|Fentanyl|50-100 mcg of medication given intravenously before nerve block
156860|NCT02970084|Other|Nutraceutical product based on vitamin K2 (PLAK2)|
156861|NCT02970058|Other|Platelet-rich Plasma|The active group will receive Platelet-rich Plasma following spinal injection
156862|NCT02970058|Other|Control|The control group will receive saline as a placebo
156863|NCT02970045|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
156864|NCT02970045|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
156865|NCT02970045|Other|Medical Chart Review|Review of medical chart
156866|NCT02970045|Other|Quality-of-Life Assessment|Ancillary studies
156867|NCT02970045|Other|Questionnaire Administration|Ancillary studies
156868|NCT02970032|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
156869|NCT02970032|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
156870|NCT02970019|Drug|K0706|Once a day administration after fast
156871|NCT02970019|Drug|Placebo|Once a day administration after fast
156872|NCT02970006|Device|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
156873|NCT02969993|Other|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
156874|NCT02969980|Drug|Cyclophosphamide|Cyclophosphamide 25 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
156875|NCT02969967|Device|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
156876|NCT02969954|Other|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
156877|NCT02969941|Other|transcranial magnetic stimulation|The stimulations were performed by MagStim Rapid2.
156878|NCT02969928|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
156879|NCT02969928|Drug|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
156880|NCT02969928|Drug|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
156881|NCT02969928|Drug|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
156882|NCT02969915|Behavioral|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
156883|NCT02969915|Behavioral|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
156884|NCT02969902|Device|Buzzy® device|
156885|NCT02969902|Device|Hand-held computer|
156886|NCT02969889|Device|Airtraq|video laryngoscope with a channel
156887|NCT02969889|Device|ILMA|
156888|NCT02969876|Drug|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
156889|NCT02969863|Device|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
156890|NCT02969863|Device|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
156891|NCT02969863|Other|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
156892|NCT02969863|Other|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
156893|NCT02969850|Dietary Supplement|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
156894|NCT02969850|Other|Placebo|Subjects in this group will receive a placebo.
156895|NCT02969850|Dietary Supplement|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
156896|NCT02969837|Drug|Elotuzumab|Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3 and Beyond on days 1 and 15
156897|NCT02969837|Drug|Carfilzomib|Carfilzomib will be given on Day 1 and 8 of Cycle 1, Days 1, 8, and 15 of Cycles 2-8, and Days 1 and 15 of Cycles 9 and beyond
156898|NCT02969837|Drug|Lenalidomide|Lenalidomide will be given on days 1-21 for all cycles.
156899|NCT02969837|Drug|Dexamethasone|"Dexamethasone will be given as follows:~Cycle 1 and 2: Days 1, 2, 8, 9, 15, 16, and 22 Cycles 3 and Beyond: Days 1, 8, 15, and 22"
156900|NCT02969824|Behavioral|Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (15min-20min) and intensity (60%-75% max HR) will increase over the intervention period.
156901|NCT02969798|Drug|Dapagliflozin|10mg/day
156902|NCT02969798|Drug|Saxagliptin|5mg/day
156903|NCT02969798|Drug|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
156904|NCT02969798|Drug|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
156905|NCT02969785|Other|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
156906|NCT02969785|Other|G2: back strengthening exercises|Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
156907|NCT02969772|Other|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
156908|NCT02969772|Other|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
156910|NCT02969746|Drug|Activated Charcoal|"Patients will take oral activated charcoal after randomization in the intervention arm.~A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)"
156911|NCT02969733|Drug|Xylocaine|Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
156912|NCT02969733|Drug|Ketamine|Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
156913|NCT02969733|Drug|isotonic saline serum intravenous administration|
156914|NCT02969720|Dietary Supplement|Phytosterols|Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
156915|NCT02969720|Dietary Supplement|Titanium Dioxide|Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
156916|NCT02969707|Device|repetitive Transcranial Magnetic Stimulation|The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
156917|NCT02969707|Device|Sham repetitive Transcranial Magnetic Stimulation|This will be identical to active rTMS except the stimulation will be blocked. Both active and sham repetitive Transcranial Magnetic Stimulation will receive simulation from a specially designed coil which is capable of delivering either active rTMS or sham rTMS in a manner, which is randomized by the system itself and therefore blinded to the treater.
156918|NCT02969694|Other|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.~The entire consultation takes place in the usual practice of consultations for this addiction."
156919|NCT02969681|Drug|ascorbic acid|1.5g/kg/day, D1-3, every 2 weeks
156920|NCT02969681|Drug|Chemotherapy|"mFOLFOX6~Oxaliplatin 85 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks~with or without bevacizumab 5mg/kg, every 2 weeks"
156921|NCT02969655|Drug|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
156922|NCT02969655|Drug|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
156923|NCT02969655|Drug|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
156924|NCT02969655|Drug|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
156925|NCT02969655|Drug|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
156926|NCT02969655|Drug|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
156927|NCT02969642|Device|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
156928|NCT02969629|Drug|Apomorphine|
156929|NCT02969629|Drug|Normal Saline|
156930|NCT02969616|Biological|Trinity Elite|cell based allograft
156931|NCT02969603|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
156932|NCT02969603|Other|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
156933|NCT02969590|Drug|Leuprolide acetate|Following this spontaneous cycle, participants received a single intramuscular injection of leuprolide acetate (11.25mg, LupronVR; Abbvie, Chicago, IL), a dose documented to suppress ovarian function for at least 3 months. Ovarian suppression is confirmed with serum E2 less than or equal to 35 pg/ml 21-28 day post-injection.
156934|NCT02969590|Drug|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
156935|NCT02969590|Drug|Progestin|Synthetic progestin to assess effects on cervical mucus.
156936|NCT02969577|Behavioral|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
156937|NCT02969577|Behavioral|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
156938|NCT02969577|Other|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
156939|NCT02969564|Other|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
156940|NCT02969564|Other|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
156941|NCT02969551|Device|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
156942|NCT02969538|Other|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
156943|NCT02969538|Other|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
156946|NCT02969512|Other|HIPPER|"Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes. A trainer (an occupational therapist or physiotherapist) will be able to remotely monitor the participant's progression on the HIPPER modules and will phone participants to check in if there is no online activity for 2 weeks. Participants will also be given the phone number and email of the trainer to contact if experiencing difficulty using the modules or with any other aspects of the study.~The total amount one could exercise using this program is 30 hours. However, it is up the participant how much they actually exercise."
156947|NCT02969512|Other|In-Person Education|2 x 2-hour in-person educational small group sessions
156948|NCT02969473|Drug|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
156949|NCT02969473|Drug|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.~Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
156950|NCT02969460|Behavioral|Neurotrack Virtual Cognitive Health Program|
156951|NCT02969447|Drug|Administration of 10 units of intra venous oxytocin after fetal expulsion|
156952|NCT02969434|Other|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
156953|NCT02969421|Other|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
156954|NCT02969421|Other|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
156955|NCT02969408|Drug|Albuterol Sulfate|Albuterol sulfate will be administered as per the dose and schedule specified in the arm.
156956|NCT02969382|Drug|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
156957|NCT02969382|Drug|Placebo - Cap|One Placebo capsule daily for 4 weeks
156958|NCT02969369|Drug|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
156959|NCT02969369|Drug|Placebo capsule|Placebo once daily
156960|NCT02969356|Biological|Botulinum toxin type A|Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs).
156961|NCT02969356|Other|GSC|The GSC is a motivational tool. The physiotherapist will teach each subject the stretching postures and exercises to perform on a daily basis throughout the study. These will be tailored to the individual subject's needs and will form the GSC therapy.
156962|NCT02969343|Behavioral|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
156963|NCT02969330|Device|Stimulator|
156964|NCT02969330|Dietary Supplement|Glucose|300ml tap water with 75g glucose
156965|NCT02969317|Drug|Tiotropium|Fixed dose combination
156966|NCT02969317|Drug|Olodaterol|Fixed dose combination
156967|NCT02969304|Drug|dimethyl fumarate|"Off-Label Use: All participants <18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate~On-Label Use: All participants >18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
156968|NCT02969291|Behavioral|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
156969|NCT02969278|Procedure|18FDG-PET/TC|Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
156970|NCT02969278|Procedure|Sentinel node biopsy|Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
156971|NCT02969265|Drug|Amlodipine|Amlodipine Capsules
156972|NCT02969265|Drug|TCV-116CCB|TCV-116CCB Tablets
156973|NCT02969265|Drug|Amlodipine Placebo|Amlodipine placebo-matching capsules
156974|NCT02969265|Drug|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
156975|NCT02969252|Drug|Rifamycin SV-MMX® 600|
156976|NCT02969239|Drug|Norepinephrine|bolus administered norepinephrine 5mcg intravenously, if SBP <90mmHg or 20% decrease from baseline
156977|NCT02969239|Drug|Phenylephrine|bolus administered phenylephrine 100mcg intravenously, if SBP <90mmHg or 20% decrease from baseline
156978|NCT02969226|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
157031|NCT02968888|Dietary Supplement|Native whey|
255094|NCT02253901|Drug|BILR 355 BS|
156979|NCT02969226|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
156980|NCT02969226|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS >0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O
156981|NCT02969226|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
156982|NCT02969200|Drug|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
156983|NCT02969187|Drug|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
156984|NCT02969187|Drug|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
156985|NCT02969187|Drug|Saline|
156986|NCT02969174|Other|zimin Lu,Guo Sa|chengzhong Liu
156987|NCT02969148|Procedure|Laparoscopic bursectomy and D2 lymphadenectomy|The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
156988|NCT02969148|Procedure|Laparoscopic D2 lymphadenectomy|D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
156989|NCT02969135|Behavioral|Progressive early passive and active movement|Post-surgical physical therapy including active exercise
156990|NCT02969135|Behavioral|Limited early passive movement|Post-surgical physical therapy including passive mobilisation
156991|NCT02969122|Procedure|standard gastrectomy with D2 lymphadenectomy|standard distal or total gastrectomy and accorded D2 lymphadenectomy
156992|NCT02969122|Procedure|hyperthermic intraperitoneal chemotherapy|Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
156993|NCT02969122|Procedure|Extensive intraperitoneal lavage|Lavage of peritoneal cavity with 1000ml saline for 10 times
156994|NCT02969122|Other|Preoperative chemotherapy|Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
156995|NCT02969122|Other|Postoperative chemotherapy|SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
156996|NCT02969096|Procedure|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
156997|NCT02969083|Procedure|RNU|Radical surgical removal by open or laparoscopic access
156998|NCT02969083|Drug|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
156999|NCT02969083|Drug|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
157000|NCT02969070|Dietary Supplement|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
157001|NCT02969070|Dietary Supplement|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
157002|NCT02969057|Other|Breakfast with rice bran oil gel|25 grams of rice bran oil gel
157003|NCT02969057|Other|Breakfast with rice bran oil|25 grams of rice bran oil
157004|NCT02969057|Other|Breakfast with palm oil gel|25 grams of palm oil gel
157005|NCT02969057|Other|Breakfast with palm oil|25 grams of palm oil
157006|NCT02969044|Drug|Placebo|
157007|NCT02969044|Drug|PF-06651600|200mg pill every day (QD) for 8 weeks
157008|NCT02969031|Behavioral|Enhanced SCOPE training|Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
157009|NCT02969031|Behavioral|Standard Communication training|Standard Communication training
157010|NCT02969018|Drug|PF-06700841|
157011|NCT02969018|Other|Placebo|
157012|NCT02969005|Radiation|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
157013|NCT02968992|Drug|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
157014|NCT02968992|Other|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
157015|NCT02968966|Other|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
157016|NCT02968953|Drug|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
157017|NCT02968940|Biological|Avelumab|Avelumab 10 mg/kg intravenously (IV) every 2 weeks
157018|NCT02968940|Radiation|Hypofractionated radiation therapy (HFRT)|Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
157019|NCT02968927|Drug|Everolimus 0.5 MG|
157020|NCT02968927|Drug|Auranofin 6 MG|
157021|NCT02968927|Drug|Vitamin D3|
157022|NCT02968927|Drug|CC-11050|
157023|NCT02968927|Drug|2HRbZE/4HRb|
157024|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
157025|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
157026|NCT02968901|Drug|macitentan|used in open label
157027|NCT02968901|Drug|tadalafil|used in open label
157028|NCT02968888|Other|Strength training|
157029|NCT02968888|Dietary Supplement|Milk 1%|
157030|NCT02968888|Dietary Supplement|Whey protein concentrate 80|
157032|NCT02968875|Device|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
157033|NCT02968875|Other|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
157034|NCT02968862|Other|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
157035|NCT02968849|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose > 10^6 cell culture infectious dose 50% (CCIDv50) and < 1 × 10^8 CCIDv50 (nominal dose of 10^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
157036|NCT02968849|Biological|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
157037|NCT02968849|Biological|Placebo|Sodium Chloride for injection, 0.9% delivered IM
157038|NCT02968836|Dietary Supplement|Blend of amino acids|The product will be poured in bottles containing the enteral nutrition that the patient receives as standard of care.
157039|NCT02968836|Dietary Supplement|Maltodextrin only|The product will be poured in bottles containing the enteral nutrition that the patient receives as standard of care.
157040|NCT02968823|Other|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 2
157041|NCT02968823|Other|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 2
157042|NCT02968810|Other|Laboratory Biomarker Analysis|Correlative studies
157043|NCT02968810|Other|Placebo|Given PO
157044|NCT02968810|Other|Questionnaire Administration|Ancillary studies
157045|NCT02968810|Drug|Simvastatin|Given PO
157046|NCT02968797|Device|SafeSed|Monitor respiratory parameters
157047|NCT02968784|Device|ExAblate MRgFUS|ExAblate treatment of prostate cancer less than or equal to Grade 7
157048|NCT02968771|Other|Non intervention|
157049|NCT02968758|Device|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
157050|NCT02968745|Other|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
157051|NCT02968732|Procedure|Radical Cystectomy|
157052|NCT02968719|Drug|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
157053|NCT02968719|Drug|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
157054|NCT02968719|Drug|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
157055|NCT02968719|Drug|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
157056|NCT02968719|Drug|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
157057|NCT02968706|Device|High Flow Nasal Cannula|Heated humidified high flow oxygen of 50 L/min at FiO2 of 40%
157058|NCT02968706|Device|Conventional Nasal Cannula|Supplemental oxygen of 2-5 L/min
157059|NCT02968706|Other|Patient satisfaction questionnaire|Questionnaire
157060|NCT02968693|Device|antibiotic-loaded calcium sulfate|To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.
157061|NCT02968693|Device|antibiotic-loaded polymethyl methacrylate|One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.
157062|NCT02968693|Drug|Vancomycin|Vancomycin powder was added into the combination therapy group and PMMA groups
157063|NCT02968680|Procedure|Sentinel Lymph Node Biopsy|Undergo SLNB
157064|NCT02968680|Device|Ultrasonography|Undergo sonazoid-enhanced ultrasonography
157065|NCT02968680|Drug|Sonazoid|Patients receive sonazoid intradermally (ID) and undergo ultrasound imaging.
157066|NCT02968667|Behavioral|Empowerment|6 weeks of empowerment program and supported face to face discussion
157094|NCT02968498|Dietary Supplement|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
157483|NCT02965482|Device|Wright Nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
157484|NCT02965482|Device|Aerogen Solo Nebulizer|Aerogen Ltd., Galway, Ireland
157067|NCT02968654|Procedure|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
157068|NCT02968654|Procedure|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
157069|NCT02968641|Drug|Lonafarnib|antiviral farnesyltransferase inhibitor
157070|NCT02968641|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
157071|NCT02968628|Other|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
157072|NCT02968628|Other|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
157073|NCT02968628|Other|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
157074|NCT02968628|Other|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
157075|NCT02968615|Behavioral|Dietary Intervention|Participants were instructed to increase both their dietary fiber intake to 35 g/day and protein intake to 0.8 g per kilogram/day of their ideal body weight. Patients in both conditions will receive intensive dietary instruction for 6 weeks, followed by a 6 weeks maintenance phase. Participants received dietary instructions via individual and group sessions led by registered dietitians.
157076|NCT02968602|Drug|Minocycline|Minocycline capsules taken twice daily for two weeks.
157077|NCT02968602|Other|Placebo|Placebo capsules taken twice daily for two weeks.
157078|NCT02968589|Behavioral|Training|
157079|NCT02968576|Drug|TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]|
157080|NCT02968576|Device|Proteus Sensor System|
157081|NCT02968563|Drug|Tirabrutinib|Tablets administered orally once daily
157082|NCT02968563|Drug|Idelalisib|Tablets administered orally once daily
157083|NCT02968563|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
157084|NCT02968537|Behavioral|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
157085|NCT02968537|Behavioral|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
157086|NCT02968537|Behavioral|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
157087|NCT02968537|Behavioral|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
157088|NCT02968537|Behavioral|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
157089|NCT02968537|Behavioral|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
157090|NCT02968511|Biological|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
157091|NCT02968498|Dietary Supplement|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
157092|NCT02968498|Dietary Supplement|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
157093|NCT02968498|Dietary Supplement|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
157095|NCT02968498|Dietary Supplement|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
157096|NCT02968498|Dietary Supplement|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
157097|NCT02968485|Drug|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
157098|NCT02968472|Genetic|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
157099|NCT02968459|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
157100|NCT02968459|Other|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
157101|NCT02968446|Dietary Supplement|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
157102|NCT02968446|Dietary Supplement|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
157103|NCT02968446|Drug|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
157104|NCT02968433|Drug|Infusions of young plasma|Participants will receive four twice- weekly infusions of 1 unit young plasma (male, ages between 18-25)
157105|NCT02968420|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
157106|NCT02968407|Other|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
157107|NCT02968394|Drug|omalizumab|
157108|NCT02968381|Behavioral|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
157109|NCT02968381|Behavioral|Control Condition|Telephone coaching using standard cognitive behavioral methods
157110|NCT02968368|Drug|Ferric maltol|
157111|NCT02968368|Other|Placebo|
157112|NCT02968355|Other|Observational study|Observational study
157113|NCT02968342|Device|Vaginal progesterone 8%|vaginal self application
157114|NCT02968316|Other|BIA measurement|observation only
157115|NCT02968303|Drug|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
157116|NCT02968290|Procedure|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
157117|NCT02968290|Device|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
157118|NCT02968290|Device|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
157119|NCT02968277|Device|LifeWalker Upright|LifeWalker (LW) upright walker
157120|NCT02968277|Device|Predicate Device|Individual's personal walker
157121|NCT02968277|Device|Standard Rollator|A control rollator device
157122|NCT02968251|Behavioral|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
157123|NCT02968238|Behavioral|Cognitive-behavioral therapy|10 weekly sessions of cognitive-behavioral therapy
157124|NCT02968238|Behavioral|Yoga|10 weeks of biweekly yoga sessions (N = 20)
157125|NCT02968225|Behavioral|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
157126|NCT02968212|Drug|Clofazimine|All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.
157127|NCT02968212|Other|sugar pill|All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.
157128|NCT02968199|Behavioral|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
157129|NCT02968186|Behavioral|Implementation program|Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
157485|NCT02965469|Behavioral|Breathe2Relax|The app teaches diaphragmatic breathing and has audiovisual coaching
157130|NCT02968173|Drug|Palivizumab|Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of RSV.
157131|NCT02968160|Drug|Telmisartan 40mg + Rosuvastatin 20mg|
157132|NCT02968160|Drug|Telmisartan 80mg + Rosuvastatin 20mg|
157133|NCT02968160|Drug|Telmisartan 40mg, 80 mg|
157134|NCT02968160|Drug|Rosuvastatin 20mg|
157135|NCT02968147|Device|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
157136|NCT02968147|Device|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
157137|NCT02968134|Drug|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
157138|NCT02968121|Drug|Brexpiprazole, OPDC-34712|
157139|NCT02968108|Drug|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects <40 kg or 130 mg for subjects >= 40 kg in Group 1 and 9 mg/kg for subjects < 40 kg or 390 mg for subjects >= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at Week 8.
157140|NCT02968095|Behavioral|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
157141|NCT02968095|Behavioral|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
157142|NCT02968082|Drug|Scopolamine|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
157143|NCT02968082|Drug|Placebo|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
157144|NCT02968069|Device|NBI|Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
157145|NCT02968056|Procedure|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
157146|NCT02968043|Other|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
157147|NCT02968043|Other|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
157148|NCT02968030|Other|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.~n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
157149|NCT02968004|Drug|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
157150|NCT02968004|Drug|Somatropin|Once daily subcutaneous injection of Genotropin
157151|NCT02967991|Device|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
157152|NCT02967965|Other|Imagery|MRI at year 3
157153|NCT02967952|Device|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
157154|NCT02967939|Drug|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
157155|NCT02967939|Drug|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
157156|NCT02967926|Procedure|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
157157|NCT02967913|Procedure|Bladder flap|bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
157158|NCT02967887|Drug|cisplatin and 5-fluorouracil|Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
157159|NCT02967874|Procedure|Intra-articular auto-SVFs injection|Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation
157160|NCT02967874|Drug|Hyaluronic Acid|Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
157161|NCT02967861|Behavioral|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
157162|NCT02967861|Procedure|Scaling and root planing|It is a mechanical debridement of dental plaque.
157230|NCT02967315|Procedure|Fluid administration|Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.
157231|NCT02967315|Procedure|Blood Draw|One to two teaspoons of blood will be drawn for basic metabolic panel.
157486|NCT02965456|Drug|IDP 121 Lotion|Lotion
157163|NCT02967848|Other|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
157164|NCT02967848|Other|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
157165|NCT02967848|Other|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
157166|NCT02967835|Behavioral|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
157167|NCT02967822|Genetic|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
157168|NCT02967822|Genetic|Biological samples for healthy relatives|Blood samples.
157169|NCT02967809|Device|echography|cardiac and pulmonary echography
157170|NCT02967796|Dietary Supplement|Proteochoc|
157171|NCT02967783|Device|ID adaptor|ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
157172|NCT02967783|Device|ID Jet Injector (Tropis, Pharmajet)|ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
157173|NCT02967783|Device|Needle and syringe|Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
157174|NCT02967770|Other|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
157175|NCT02967770|Drug|Standard of Care Second Line Therapy|
157176|NCT02967757|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
157177|NCT02967744|Drug|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
157178|NCT02967731|Drug|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
157179|NCT02967705|Behavioral|Pain management group|Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
157180|NCT02967692|Biological|Spartalizumab (PDR001)|Spartalizumab (PDR001) will be supplied in vial in liquid or lyophilized pharmaceutical form. Spartalizumab (PDR001) will be administered via intravenous infusion over 30 minutes (up to 2 hours) once every 4 or 8 weeks.
157181|NCT02967692|Other|Placebo|Placebo will be a Dextrose 5% in water (D5W) infusion supplied by the site.
157182|NCT02967692|Drug|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-28 of a 28-day cycle.
157183|NCT02967692|Drug|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-28 of a 28-day cycle.
157184|NCT02967679|Drug|MD1003|
157185|NCT02967666|Radiation|FDG ligand|
157186|NCT02967666|Radiation|DOTANOC ligand|
157187|NCT02967653|Drug|Atorvastatin|Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
157188|NCT02967640|Drug|Ketalar|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of an approximately 1 mg/ml ketalar solution (1 ml of ketalar 10 mg/ml + 9 ml of NaCl 9%) injected 2 times with 1-12 weeks between each injection
157189|NCT02967640|Drug|NaCl 9%|2,5 ml - if well tolerated immediately followed by another 2,5 ml - of a 9% NaCl solution injected 2 times with 1-12 weeks between each injection
157190|NCT02967627|Device|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
157191|NCT02967627|Device|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
157192|NCT02967614|Drug|[A]|One eye drop(about 40ul) / Day1 ~ Day8 / BID
157193|NCT02967614|Drug|[B]|One eye drop(about 40ul) / Day1 ~ Day92 / BID
157194|NCT02967614|Drug|[A]+[B](1)|One eye drop(about 40ul) / Day9 ~ Day100 / BID
157195|NCT02967614|Drug|[A]+[B](2)|One eye drop(about 40ul) / Day93 ~ Day100 / BID
157196|NCT02967601|Behavioral|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
157232|NCT02967315|Procedure|Pregnancy test|A urine pregnancy test will be performed in female subjects.
157233|NCT02967315|Procedure|Electrocardiogram|12 lead ECG
157234|NCT02967302|Drug|Morphine Sulfate|active intervention
157235|NCT02967302|Drug|Triamcinolone|active control
157236|NCT02967302|Drug|placebo|placebo control
157237|NCT02967289|Drug|Irinotecan|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
157487|NCT02965456|Drug|IDP-121 Vehicle Lotion|Lotion
157197|NCT02967588|Behavioral|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.~Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').~Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
157198|NCT02967575|Device|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~Implantation through a standard anterior cervical approach~Midline identification~Routine discectomy with endplate preparation and decompression~Implant sizing and trial implantation~Keel preparation~Implant preparation and loading of the appropriate Triadyme-C implant~Triadyme-C insertion, positioned as close to the midline as possible"
157199|NCT02967562|Other|Inflation Breaths|
157200|NCT02967562|Other|Sustained Inflation|
157201|NCT02967549|Device|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
157202|NCT02967549|Device|PAV|PAV delivered by the Stephanie ventilator (Stephan)
157203|NCT02967523|Device|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
157204|NCT02967510|Drug|Estriol|
157205|NCT02967510|Drug|Placebo|
157206|NCT02967497|Drug|YQ1|Oral administered powder
157207|NCT02967484|Device|acupuncture|"Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
157208|NCT02967458|Drug|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
157209|NCT02967445|Device|Arabin Pessary|Arabin silicon pessary
157210|NCT02967445|Device|Cervical cerclage|
157211|NCT02967432|Drug|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
157212|NCT02967432|Drug|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
157213|NCT02967419|Other|No Intervention|
157214|NCT02967406|Behavioral|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
157215|NCT02967393|Drug|ccIIV4|
157216|NCT02967393|Drug|IIV4|
157217|NCT02967380|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
157218|NCT02967380|Drug|Gadobenate Dimeglumine|Given IV
157219|NCT02967380|Drug|Gadobutrol|Given IV
157220|NCT02967380|Radiation|Gadopentetate Dimeglumine|Given IV
157221|NCT02967367|Device|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
157222|NCT02967367|Device|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
157223|NCT02967367|Device|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
157224|NCT02967354|Radiation|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer [11C]5-hydroxy-tryptophan
157225|NCT02967341|Other|Ciprofloxacin administration|Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
157226|NCT02967328|Other|RP% Measurement by FCM as a Diagnostic Test for ITP|
157227|NCT02967315|Procedure|Cardiac Magnetic Resonance Imaging (CMRI)|"There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.~The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast."
157228|NCT02967315|Procedure|Central venous line placement|An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.
157229|NCT02967315|Procedure|Chest X-ray|A chest X-ray will be performed for safety reasons to rule out pneumothorax (< 1% risk) after central line placement.
157441|NCT02965781|Other|Placebo|Topical solution
157238|NCT02967289|Drug|Folfox Protocol|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
157239|NCT02967276|Drug|Metformin XR|500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
157240|NCT02967276|Drug|Dexamethasone|4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
157241|NCT02967250|Drug|ursodeoxycholic acid|Subjects will be provided ~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over ~2 weeks to a stable dose for 4 weeks.
157242|NCT02967237|Drug|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
157243|NCT02967224|Drug|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157244|NCT02967224|Drug|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157245|NCT02967224|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157246|NCT02967224|Drug|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157247|NCT02967224|Drug|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157248|NCT02967211|Drug|insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157249|NCT02967211|Drug|insulin glargine (U100)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157250|NCT02967211|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157251|NCT02967211|Drug|insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157252|NCT02967211|Drug|insulin degludec|"Pharmaceutical form: solution~Route of administration: subcutaneous"
157253|NCT02967198|Device|CT/US fusion|Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
157254|NCT02967198|Device|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
157255|NCT02967185|Behavioral|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
157256|NCT02967172|Drug|Ropivacaine|
157257|NCT02967172|Drug|Epinephrine|
157258|NCT02967172|Drug|Morphine|
157259|NCT02967172|Drug|0.9% sodium chloride solution|
157260|NCT02967159|Drug|Abediterol|Treatment A: Abediterol 2.5 μg via DPI
157261|NCT02967159|Drug|AZD7594|Treatment B: AZD7594 440 μg via DPI
157262|NCT02967159|Drug|AZD7594/abediterol|Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
157263|NCT02967159|Drug|AZD7594 and abediterol|Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
157264|NCT02967146|Device|adhesive barrier|After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
157265|NCT02967133|Drug|Nivolumab|"Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.~Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated."
157266|NCT02967133|Drug|nab-paclitaxel|Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
157267|NCT02967120|Other|no intervention|
157268|NCT02967107|Procedure|Cold snare polypectomy|Use of a polypectomy snare closed over a polyp without electrocautery
157269|NCT02967107|Procedure|Endoscopic mucosal resection|Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
157270|NCT02967094|Drug|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
157271|NCT02967094|Drug|Administration of water before upper endoscopy|
157272|NCT02967081|Procedure|Collection of dentinal fluid using a cellulose membrane|After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
157273|NCT02967042|Device|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
157274|NCT02967029|Drug|Esmolol Hydrochloride|the influence of brevibloc as a hypotensive agent on rSO2
157275|NCT02967029|Drug|Remifentanil Hydrochloride|the influence of remifentanyl as a hypotensive agent on rSO2
157276|NCT02967016|Behavioral|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
157277|NCT02966990|Device|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
157278|NCT02966977|Other|Conventional microbiological identification by culture plate|Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
157279|NCT02966977|Other|Direct mass spectrometry identification from urine sample|The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
157280|NCT02966964|Drug|DWPUR001|
157281|NCT02966964|Drug|Placebo|
157282|NCT02966951|Biological|Adipose tissue derived mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection.
157675|NCT02964000|Device|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
157283|NCT02966925|Device|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
157284|NCT02966912|Dietary Supplement|400 mg of Magnesium Oxide twice daily for 24 weeks|
157285|NCT02966912|Other|Open label (none)|
157286|NCT02966899|Dietary Supplement|Omega-3 fatty acids|
157287|NCT02966886|Procedure|Eccentric Reaming|"Pre-operative CT imaging and surgical planning software based on pre-operative CT scans will be used in each case to determine the degree of eccentric (high side) anterior reaming to within < 10 degrees of neutral glenoid version."
157288|NCT02966886|Procedure|Augmented Glenoid Component Implantation|Patients will undergo standard glenoid preparation and implantation of a posteriorly augmented glenoid component. The degree of posterior augment will be based on pre-operative CT scan assessment and templating software with the goal of correcting glenoid retroversion to within 10 degrees of neutral version.
157289|NCT02966886|Procedure|Posterior Glenoid Bone Grafting|Patient will undergo a total shoulder arthroplasty as per standard technique. Glenoid version will be restored to within 10 degrees of neutral with a posterior glenoid bone graft. The bone graft will be harvested from the humeral head and fixed to the posterior glenoid with mini-fragment screws.
157290|NCT02966873|Drug|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
157291|NCT02966873|Behavioral|Cognitive Behavioral Therapy|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
157292|NCT02966873|Drug|Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
157293|NCT02966860|Drug|Oral solution OC/APAP|
157294|NCT02966847|Procedure|CBCT acquisition|Acquisitions are performed with the DynaCT function of a C-arm Artis Zeego System® device
157295|NCT02966847|Procedure|Anesthesia and surgery|The anesthesia and surgery will take place according clinical routine practice
157296|NCT02966834|Drug|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
157297|NCT02966834|Drug|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
157298|NCT02966821|Drug|Surufatinib|Patients receive oral Surufatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
157299|NCT02966808|Behavioral|cognitive and behavioural questionnaires|
157300|NCT02966795|Drug|Glecaprevir/Pibrentasvir|Fixed-dose combination tablets taken orally once a day.
157301|NCT02966782|Drug|venetoclax|Tablet
157302|NCT02966782|Drug|azacitidine|Powder for injection, subcutaneously or intravenous
157303|NCT02966769|Other|Overall survival|Compare overall survival between both groups.
157304|NCT02966756|Drug|Venetoclax|tablet
157305|NCT02966743|Drug|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
157306|NCT02966743|Drug|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
157307|NCT02966730|Drug|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
157308|NCT02966717|Drug|Rituximab|Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
157309|NCT02966717|Drug|conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
157310|NCT02966717|Drug|Mesenchymal stem cells|Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
157311|NCT02966704|Dietary Supplement|intrinsically labeled milk protein|
157312|NCT02966691|Other|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
157313|NCT02966678|Procedure|Color Vision Test|Farnsworth Panel D15/Hue test plus Ishihara charts
157314|NCT02966665|Other|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
157315|NCT02966665|Drug|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
157316|NCT02966665|Drug|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
157317|NCT02966665|Drug|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
157318|NCT02966665|Other|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
164548|NCT02914613|Drug|SF0166 Topical Ophthalmic Solution|
157319|NCT02966665|Drug|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
157320|NCT02966665|Drug|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
157321|NCT02966652|Drug|DITEST|Lipid formulation of native oral testosterone.
157322|NCT02966652|Drug|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
157323|NCT02966613|Device|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
157324|NCT02966600|Other|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
157325|NCT02966600|Other|Physical Activity|The control group followed its usual weekly physical activity routine
157326|NCT02966587|Biological|Durvalumab|Given IV
157327|NCT02966587|Other|Laboratory Biomarker Analysis|Correlative studies
157328|NCT02966574|Device|whole body MRI|The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
157329|NCT02966561|Behavioral|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):~Instruction on how, where and when to perform the behaviour~Prompt goal setting for physical activity~Prompt self-monitoring of behaviour~Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
157330|NCT02966561|Behavioral|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:~Revision of knowledge on exercise recommendations~Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)~Revision of self-regulation of endurance exercise intensity~Revision of strengthening activities consistent with the exercise recommendations.~Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
157331|NCT02966561|Other|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training [45 min] and 3 units/week of strength training [45 min] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups [2-4 units/week with 45 min]. PR is implemented by an interdisciplinary rehabilitation team.
157332|NCT02966548|Drug|Relatlimab|Specified dose on specified days
157333|NCT02966548|Drug|Nivolumab|Specified dose on specified days
157334|NCT02966535|Device|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
157335|NCT02966535|Device|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
157336|NCT02966522|Drug|Thalidomide|
157337|NCT02966522|Drug|Dexamethasone|
157338|NCT02966509|Behavioral|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
157339|NCT02966496|Biological|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
157340|NCT02966496|Biological|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
157341|NCT02966483|Procedure|TaTME|Transanal Total Mesorectal Excision
157342|NCT02966483|Procedure|LpTME|Conventional Laparoscopic Total Mesorectal Excision
157343|NCT02966470|Device|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
157344|NCT02966457|Drug|Colistimethate Sodium|Selective oral intestinal decolonization
157345|NCT02966444|Other|MUFA-rich HF Meal|
157346|NCT02966444|Other|PUFA-rich HF Meal|
157347|NCT02966444|Other|SFA-rich HF Meal|
157348|NCT02966431|Behavioral|Counseling|
157349|NCT02966431|Behavioral|No Counseling|
157350|NCT02966418|Procedure|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
157351|NCT02966418|Procedure|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
157442|NCT02965768|Drug|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
164552|NCT02914587|Other|Manual Implantation|
157352|NCT02966392|Device|Tracoe cuff pressure controller|Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
157353|NCT02966379|Device|cochlear implantation|"Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:~Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,~mastoidectomy + posterieur tympanostomy ,~insertion through round window,~stop at the first resistance point"
157354|NCT02966366|Device|Cochlear implant|
157355|NCT02966353|Drug|ruxolitinib|Ruxolitinib will be supplied to the investigator by sponsor in 5 mg tablets. Ruxolitinib should be taken orally, approximately 12 hours apart (morning and night) without regard to food unless instructed to temporarily hold taking drug by investigator.
157356|NCT02966340|Drug|Prazosin|2mg Prazosin
157357|NCT02966340|Drug|Placebo|Placebo
157358|NCT02966327|Device|Bilateral leg compression stockings|Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.
157359|NCT02966327|Behavioral|Individualized exercise|Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques
157360|NCT02966327|Behavioral|Lymphedema risk reduction|Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
157361|NCT02966314|Drug|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
157362|NCT02966314|Drug|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
157363|NCT02966301|Drug|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
157364|NCT02966288|Drug|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
157365|NCT02966288|Drug|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
157366|NCT02966275|Device|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
157367|NCT02966275|Device|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
157368|NCT02966262|Device|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
157369|NCT02966249|Drug|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
157370|NCT02966249|Drug|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
157371|NCT02966249|Drug|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
157372|NCT02966249|Drug|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
157373|NCT02966249|Drug|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
157374|NCT02966249|Drug|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
157375|NCT02966236|Drug|Tranexamic Acid|
157376|NCT02966236|Drug|Placebos|
157377|NCT02966223|Radiation|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
157378|NCT02966197|Procedure|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
157379|NCT02966197|Device|Prophylactic internal iliac artery balloon|
157380|NCT02966197|Radiation|Radiology operation|
157381|NCT02966184|Drug|preservative free albuterol|Preservative free albuterol for nebulization
157382|NCT02966171|Drug|HMPL-453|oral administration
157383|NCT02966158|Other|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
157384|NCT02966145|Other|Observational Study|
157385|NCT02966132|Behavioral|iMD|Interactive video education delivered on a tablet computer
157386|NCT02966132|Behavioral|NPA|
157387|NCT02966119|Drug|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
157388|NCT02966106|Device|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
157389|NCT02966106|Other|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
157480|NCT02965495|Drug|YYD302 2ml|YYD302 2ml
157481|NCT02965495|Drug|YYD302 3ml|YYD302 3ml
157482|NCT02965495|Drug|Placebo 3ml|phosphate buffered saline 3ml
157390|NCT02966093|Drug|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
157391|NCT02966093|Drug|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
157392|NCT02966080|Drug|HEP-IV|
157393|NCT02966067|Device|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution [1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)] at a rate of 1 mL/min.
157394|NCT02966067|Device|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution [1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)] at a rate of 1 mL/min.
157395|NCT02966054|Behavioral|Digital Health Physical Activity Intervention Group|Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
157396|NCT02966041|Drug|Ondansetron|Ondansetron/Zofran is an antiemetic drug used to prevent and treat nausea and vomiting.
157397|NCT02966041|Drug|Saline|Normal saline is salt water and is acting as a placebo in this study. A placebo is an inactive substance that looks identical to the test drug, but it contains no therapeutic ingredient.
157398|NCT02966028|Drug|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
157399|NCT02966028|Drug|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
157400|NCT02966015|Device|Coloplast test catheter|This is a newly developed catheter
157401|NCT02966002|Drug|Aspirin|
157402|NCT02965989|Procedure|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
157403|NCT02965976|Biological|Botulinum Toxin Type A|Given IM
157404|NCT02965976|Procedure|Esophagectomy|Undergo esophagectomy
157405|NCT02965976|Other|Quality-of-Life Assessment|Ancillary studies
157406|NCT02965963|Drug|Dopamine|
157407|NCT02965963|Drug|Metoclopramide|
157408|NCT02965963|Drug|Placebos|
157409|NCT02965963|Other|Rest|
157410|NCT02965963|Other|Exercise - 60%|60% of VO2max
157411|NCT02965963|Other|Exercise - 85%|85% of VO2max
157412|NCT02965950|Drug|Cyclophosphamide|I.v. infusion
157413|NCT02965937|Other|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
157414|NCT02965937|Other|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
157415|NCT02965924|Drug|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
157416|NCT02965911|Drug|Fenofibrate|Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
157417|NCT02965911|Drug|UDCA|Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
157418|NCT02965898|Dietary Supplement|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
157419|NCT02965898|Dietary Supplement|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
157420|NCT02965885|Drug|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor and then at one dose schedule in advanced breast and lung cancer.
157421|NCT02965872|Other|No intervention|
157422|NCT02965859|Drug|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
157423|NCT02965859|Drug|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
157424|NCT02965859|Drug|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
157425|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
157426|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
157427|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
157428|NCT02965859|Drug|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
157429|NCT02965859|Drug|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
157430|NCT02965846|Drug|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
157431|NCT02965846|Drug|Vehicle|1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
157432|NCT02965833|Device|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix|For cleaning, disinfection and overnight storage of contact lenses
157433|NCT02965833|Device|Habitual Multi-Purpose Contact Lens Solution|
157434|NCT02965833|Device|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
157435|NCT02965820|Device|Opti-Free® PureMoist® contact lens solution|
157436|NCT02965820|Device|Habitual Multi-Purpose Contact Lens Solution|
157437|NCT02965820|Device|Habitual Contact Lenses|Subject's habitual contact lens brand worn in a daily wear modality for 30 days.
157438|NCT02965807|Device|Bronchial Thermoplasty|patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
157439|NCT02965794|Other|Care pathways for colorectal cancer|development of a care pathway for this patient group
157440|NCT02965781|Drug|SADBE|Topical solution
157443|NCT02965755|Other|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
157444|NCT02965742|Device|Stratos|A machine made by DMS group.
157445|NCT02965742|Device|"Hologic QDR 4500A"|A machine made by Hologic inc.
157446|NCT02965742|Device|"Hologic HORIZON A"|A machine made by Hologic inc.
157447|NCT02965729|Behavioral|Family-based weight management|"The Our Lifestyles, Our Lives family-based weight management intervention consisted of 10 weekly 90-minute group sessions focused on physical activity, nutrition, and behavioral modification. Parents and siblings were encouraged to join the participant in these sessions. Sessions were interactive and included cooking demonstrations, light to moderate intensity physical activity that engaged all family members, and behavioral counseling sessions in both mixed (parent and child) and parent-only format."
157448|NCT02965729|Behavioral|Pedometer|In addition to participating in the family-based weight management intervention, participants were given a pedometer (Omron HJ-324U, Omron Healthcare, Lake Forest, IL) and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10.
157449|NCT02965729|Behavioral|Individualized step goals|In addition to participating in the family-based weight management intervention, participants were given a step goal to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
157450|NCT02965716|Biological|Pembrolizumab|Given IV
157451|NCT02965716|Biological|Talimogene Laherparepvec|Given IL
157452|NCT02965703|Drug|Aspirin|Given PO
157453|NCT02965703|Other|Laboratory Biomarker Analysis|Correlative studies
157454|NCT02965703|Other|Placebo|Given PO
157455|NCT02965703|Other|Questionnaire Administration|Ancillary studies
157456|NCT02965690|Procedure|NexGen CR|Total Knee Replacement
157457|NCT02965690|Procedure|GMK Sphere|Total Knee Replacement
157458|NCT02965677|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
157459|NCT02965677|Device|Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
157460|NCT02965664|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
157461|NCT02965664|Drug|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
157462|NCT02965651|Behavioral|ECA System|"The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login."
157463|NCT02965638|Other|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
157464|NCT02965638|Other|Administration of placebo gas|The placebo arm (Placebo Group) will receive air via nasal cannula up to 24 hours daily
157465|NCT02965612|Device|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
157466|NCT02965612|Procedure|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
157467|NCT02965599|Drug|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
157468|NCT02965599|Drug|Placebo|Placebo is a white, opaque, gelatin capsule.
157469|NCT02965586|Drug|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
157470|NCT02965573|Biological|ARGX-113|
157471|NCT02965573|Drug|Placebo|
157472|NCT02965560|Diagnostic Test|plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.|
157473|NCT02965547|Device|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
157474|NCT02965547|Procedure|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
157475|NCT02965547|Procedure|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
157476|NCT02965534|Device|Spectacle/Glasses|
157477|NCT02965521|Behavioral|Website and text messages|Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
157478|NCT02965508|Other|Home-based Primary Care|Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
157479|NCT02965508|Other|Usual Care|Office based care
164711|NCT02913313|Biological|Nivolumab|
157488|NCT02965443|Drug|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
157489|NCT02965443|Drug|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
157490|NCT02965430|Device|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
157491|NCT02965417|Drug|Sym004|Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
157492|NCT02965404|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
157493|NCT02965404|Biological|control live attenuated varicella vaccine|The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
157494|NCT02965404|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
157495|NCT02965378|Drug|Docetaxel|Given IV
157496|NCT02965378|Drug|FGFR Inhibitor AZD4547|Given PO
157497|NCT02965378|Other|Laboratory Biomarker Analysis|Correlative studies
157498|NCT02965352|Device|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
157499|NCT02965352|Device|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
157500|NCT02965352|Device|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
157501|NCT02965326|Procedure|Nasal swab; rectal biopsy.|Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
157502|NCT02965313|Procedure|SSLS Procedure|Synthetic suture repair
157503|NCT02965313|Procedure|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
157504|NCT02965287|Other|Serum metabolomics profiling|The serum samples will be used to get a metabolomic profile
157505|NCT02965274|Drug|Torrent's Fluoxetine Tablets|
157506|NCT02965274|Drug|Warner Chilcott LLC's Sarafem Tablet|
157507|NCT02965261|Drug|Torrent's Fluoxetine Tablets|
157508|NCT02965261|Drug|Warner Chilcott LLC Sarafem Tablets|
157509|NCT02965248|Drug|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).~mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.~sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.~Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
157510|NCT02965248|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
157511|NCT02965248|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
157512|NCT02965222|Device|the time-lapse videography|The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
157513|NCT02965209|Procedure|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
157514|NCT02965196|Drug|IV Dexamethasone Therapy|
157515|NCT02965196|Other|IV Normal Saline (NaCl 0.9%)|
157516|NCT02965183|Other|Temperature measurements|
157517|NCT02965157|Biological|CART20|
157518|NCT02965144|Other|no treatment|no treatment
157519|NCT02965131|Procedure|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
157520|NCT02965118|Drug|PAC-14028 cream 1.0%|topical application
157521|NCT02965118|Drug|PAC-14028 cream Vehicle|topical application
157522|NCT02965105|Device|Coloplast Test Catheter|This is a newly developed intermittent catheter
157523|NCT02965105|Device|Speedicath|This is a marketed Catheter which is used as comparator
157524|NCT02965092|Genetic|Second generation CAR-T cells|
157525|NCT02965079|Device|ECCO2R|The ECCO2R system was developed from the principle of ECMO systems by underscoring the importance of carbon dioxide elimination rather than direct improvement of oxygenation in some patients. The circuit of the ECCO2R system can be set up in venovenous (VV) or arteriovenous (AV). For VV setup, a low flow pump is used to maintain a low extracorporeal flow rate using only 20-30 % of cardiac output. The ECCO2R system does not provide complete pulmonary function as it can achieve only limited oxygenation but provides predominantly carbon dioxide removal. As neither VV nor AV circuit allows full cardiopulmonary bypass, the system provides respiratory function but no cardiac support
157526|NCT02965066|Device|Coloplast Test Catheter|Newly developed intermittent catheter
157527|NCT02965066|Device|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
157528|NCT02965053|Drug|EOS789|
157529|NCT02965053|Drug|Placebo|
157530|NCT02965053|Drug|Renvela|
157531|NCT02965040|Drug|Roxadustat|Oral
157532|NCT02965027|Drug|Prazosin|
157533|NCT02965027|Drug|Placebos|
157534|NCT02965014|Behavioral|Face-to-Face Young Women's CoOp (YWC)|Participants will receive HIV counseling and testing (HCT) and engage in a two-session face-to-face YWC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
157535|NCT02965014|Behavioral|mHealth Young Women's CoOp (YWC)|Participants will receive HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face YWC delivery format. Participants will also receive a tablet to complete the two-session intervention.
157536|NCT02965014|Behavioral|HIV Counseling and Testing|Participants will receive standard HIV counseling and testing (HCT).
157537|NCT02965001|Drug|68Ga-NOTA-AE105|The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.
157538|NCT02964988|Drug|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
157539|NCT02964988|Device|PET/CT|Whole body PET/CT
157540|NCT02964975|Procedure|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
157541|NCT02964975|Drug|Optimal medical therapy|Medical threatment according to guidelines
157542|NCT02964962|Device|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
157543|NCT02964949|Drug|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
157544|NCT02964936|Drug|roxadustat|Oral administration
157545|NCT02964910|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
157546|NCT02964897|Behavioral|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
157547|NCT02964897|Behavioral|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
157548|NCT02964884|Drug|Lovastatin|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks and 40mg of Lovastatin per day starting at week 3 through week 11.
157549|NCT02964884|Behavioral|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week of intensive, one-on-one tutoring intervention (either reading or sham; Visit 2)
157550|NCT02964884|Drug|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
157551|NCT02964884|Behavioral|"Other Academic sham tutoring"|No reading (sham) tutoring. Children will receive intensive tutoring on a subject other than reading.
157552|NCT02964871|Device|Sofia Fluorescent Immunoassay Analyzer Influenza A+B|The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.
157553|NCT02964871|Other|Usual care|Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
157554|NCT02964858|Radiation|Standard Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
157555|NCT02964858|Radiation|Experimental Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
157556|NCT02964845|Behavioral|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
157557|NCT02964845|Other|Enhanced Treatment as Usual|Linkage to Primary care.
157558|NCT02964832|Device|Grasp method|
157559|NCT02964832|Device|Armband-in-hand method|
157560|NCT02964832|Device|Armband-on-arm method|
157561|NCT02964819|Other|exercise|
157562|NCT02964819|Device|Interferential current therapy|
157563|NCT02964819|Device|Therapeutic Ultrasound|
157564|NCT02964806|Dietary Supplement|Ordinary Diet|
157565|NCT02964806|Dietary Supplement|Modified Atkin's Diet|
157566|NCT02964806|Dietary Supplement|Ketogenic Diet|
157567|NCT02964793|Other|intervention group|"The intervention will include~clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements~the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document~the use of the EFW values mentioned on US report, to plot EFW on the customised chart~and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
157568|NCT02964780|Procedure|Gastric bypass surgery|
157569|NCT02964780|Behavioral|Conservative weight loss program|
157570|NCT02964754|Device|CT scan for internal fixation|In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
157571|NCT02964754|Procedure|conventional internal fixation|In the control group, patients will undergo conventional internal fixation.
157572|NCT02964741|Device|Active Comparator|non-invasive brain stimulation (active protocol)
157573|NCT02964741|Device|Sham Comparator|non-invasive brain stimulation (sham protocol)
157574|NCT02964728|Drug|Botulinum Neurotoxin Type A|topical injection
157575|NCT02964728|Other|Normal saline|topical injection
157576|NCT02964715|Drug|Empagliflozin|25 mg daily for 6 months
157577|NCT02964702|Device|Thrombectomy Device T-01|
157578|NCT02964689|Drug|Binimetinib|Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.
157579|NCT02964689|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration
157580|NCT02964689|Drug|Cisplatin|Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
157581|NCT02964676|Procedure|ab interno trabeculectomy with Trabectome|123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
157582|NCT02964676|Procedure|trabeculectomy|123 PACG will be recruited to receive trabeculectomy to reduce IOP
157583|NCT02964663|Device|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
157584|NCT02964650|Device|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
157585|NCT02964637|Other|Observational Study|
157586|NCT02964624|Other|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
157587|NCT02964611|Behavioral|Observational Study|This is an observational study.
157588|NCT02964598|Behavioral|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
157589|NCT02964598|Behavioral|Sleep coaching|A new personalized program, duration 4-6 weeks
157590|NCT02964598|Device|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
157591|NCT02964598|Other|Control|Minimal information on sleep timing and advancing the sleep rhythm
157592|NCT02964598|Other|Psychoeducation|An extensive information platform in the internet created for this purpose
157593|NCT02964585|Drug|Canagliflozin|100 mg
157594|NCT02964585|Drug|Placebo|1 tablet daily for 16 weeks
157595|NCT02964572|Drug|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
157596|NCT02964572|Drug|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
157597|NCT02964559|Biological|Pembrolizumab|Given IV
157598|NCT02964546|Other|Blood sample|2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
157599|NCT02964533|Other|thunder-fire moxibustion therapy|burn moxa stick and heat shenque acupoint
157600|NCT02964533|Other|common moxa-stick moxibustion|burn moxa stick and heat shenque acupoint
157601|NCT02964520|Behavioral|Neurofeedback training|uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
157602|NCT02964520|Behavioral|Sham comparator: Sham neurofeedback training|in UNEVEN neurofeedback sessions (1,3,5,7,9): up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz) in EVEN neurofeedback sessions (2,4,6,8,10): down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)
157603|NCT02964507|Drug|GSK525762|For Phase I, GSK525762 will be available as 5 mg and 25 mg oral tablets. Subjects will be initially dosed at 60 mg daily (Dose Level 1). Further subjects will be dosed based on the dose limiting toxicity rate, at a higher 'Dose Level 2' (or still higher, based on PK data), same 'Dose Level 1', or lower 'Dose Level 1'.
157604|NCT02964507|Drug|Placebo|Placebo will match GSK525762 tablets, and will be provided in Phase II only. Dosing will be done until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
157605|NCT02964507|Drug|Fulvestrant|Fulvestrant will be supplied as a solution for injection in a prefilled syringe, at a strength of 250 milligrams (mg) per 5 milliliters (mL), for slow intramuscular (IM) injection into the buttocks. Two 5 mL injections (total 500 mg of fulvestrant) will be administered, one in each buttock, on Day 1, Day 15, Day 29, and once monthly thereafter.
157676|NCT02963987|Other|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size (100% Baseline portions and increased 50% for 150% portions)
157677|NCT02963974|Device|Cochlear implant|Implantation
157606|NCT02964468|Radiation|3DCRT treatment (sequential boost)|"Radiotherapy:~3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.~3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.~Chemotherapy:~According to routine clinical practice of the participating centers."
157607|NCT02964468|Radiation|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:~IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.~Chemotherapy:~According to routine clinical practice of the participating centers."
157608|NCT02964455|Drug|Docetaxel|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks during chest radiation
157609|NCT02964455|Drug|Nedaplatin|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks of during chest radiation
157610|NCT02964455|Radiation|chest radiation|continuous chest radiation at 64 Gy/32f
157611|NCT02964442|Other|Capsinoids|12 mg of Gel capsules
157612|NCT02964442|Other|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
157613|NCT02964429|Device|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
157614|NCT02964416|Drug|Injection Tramadol|
157615|NCT02964416|Other|placebo|0.9% Normal saline in 10 ml syringe
157616|NCT02964403|Drug|Cox-2|
157617|NCT02964403|Drug|Indomethacin|
157618|NCT02964390|Procedure|Balloon Pulmonary Angioplasty|
157619|NCT02964377|Drug|(+)- Epicatechin|
157620|NCT02964351|Biological|High PSA levels|
157621|NCT02964338|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
157622|NCT02964338|Drug|Placebo|Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
157623|NCT02964325|Device|Mirasol platelets (MIR PLTs)|The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
157624|NCT02964325|Device|Reference platelets (REF PLTs)|The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
157625|NCT02964312|Device|Nasal Implant|Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
157626|NCT02964299|Device|Mandibular advancement bite block|Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
157627|NCT02964286|Device|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
157628|NCT02964273|Drug|Tolvaptan|"Tolvaptan 7.5, 15, and 30 mg spray-dried, immediate release tablets with matching placebo. Subjects will be randomized to receive either active tolvaptan or matching placebo for 12 months in Phase A, followed by open-label tolvaptan for 24 months in Phase B. Study medication will be administered orally as a split-dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. Phase A and Phase B starting doses will be based on weight. After 1 week, subjects will be asked to up-titrate once from their starting dose. Subjects may down-titrate at any time during the trial; however, subjects will be asked to stay on the highest tolerable dose (by weight group) if possible. The titration schedules for Phase A and Phase B are similar.~Frequency: Twice daily."
157629|NCT02964273|Drug|Matching Placebo|"Placebo matching Tolvaptan 7.5, 15, and 30 mg spray-dried, immediate release tablets. Subjects will be randomized to receive either active tolvaptan or matching placebo for 12 months in Phase A, followed by open-label tolvaptan for 24 months in Phase B. Study medication will be administered orally as a split-dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. Phase A and Phase B starting doses will be based on weight. After 1 week, subjects will be asked to up-titrate once from their starting dose. Subjects may down-titrate at any time during the trial; however, subjects will be asked to stay on the highest tolerable dose (by weight group) if possible. The titration schedules for Phase A and Phase B are similar.~Frequency: Twice daily."
157630|NCT02964260|Drug|Chemotherapy drug|Doxorubicin/Platinum agents
157631|NCT02964260|Drug|Embolic agents|Lipiodol/Gelatin sponge/PVA/Blank microspheres
157632|NCT02964260|Procedure|Simultaneously|1-3 days
157633|NCT02964260|Procedure|Sequentially|1 month
157634|NCT02964260|Device|Ablation|Radiofrequency ablation/Microwave ablation
157635|NCT02964247|Drug|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
157636|NCT02964247|Drug|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
157637|NCT02964234|Behavioral|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
157638|NCT02964234|Behavioral|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
157739|NCT02963506|Drug|Bimekizumab|Bimekizumab in different dosages.
157740|NCT02963493|Drug|Melflufen|
157741|NCT02963493|Drug|Dexamethasone|
157639|NCT02964221|Other|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online. .
157640|NCT02964208|Device|AMPLATZER™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
157641|NCT02964195|Drug|Rifaximin|ALFA WASSERMANN S.p.A.
157642|NCT02964182|Drug|Cigarette|Smoke usual brand of cigarettes
157643|NCT02964182|Other|Electronic Cigarette|Smoke ECIG-Hi
157644|NCT02964182|Other|Electronic Cigarette|Smoke ECIG-Lo
157645|NCT02964182|Other|Questionnaire Administration|Ancillary studies
157646|NCT02964182|Other|Survey Administration|Ancillary studies
157647|NCT02964182|Drug|Very Low Nicotine Content Cigarette|Smoke very low nicotine content cigarette
157648|NCT02964169|Behavioral|Family Planning Support|
157649|NCT02964156|Other|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
157650|NCT02964156|Other|No intervention|No intervention
157651|NCT02964143|Device|Cellular Matrix / A-CP HA|Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
157652|NCT02964143|Device|Ostenil® Plus|Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
157653|NCT02964143|Device|RegenKit-BCT-1|Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
157654|NCT02964130|Other|No name|
157655|NCT02964104|Drug|insulin 287|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
157656|NCT02964104|Drug|placebo|Administered once daily subcutaneously for 35 days
157657|NCT02964104|Drug|insulin degludec|Administered once daily subcutaneously for 35 days
157658|NCT02964104|Drug|placebo|Administered once weekly subcutaneously for 35 days
157659|NCT02964091|Drug|sofosbuvir/ledipasvir|
157660|NCT02964078|Drug|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
157661|NCT02964078|Drug|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
157662|NCT02964065|Biological|Live-Attenuated influenza Vaccine(LAIV)|
157663|NCT02964065|Biological|Placebo|
157664|NCT02964052|Other|Brain CT imaging|Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
157665|NCT02964039|Behavioral|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
157666|NCT02964039|Behavioral|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
157667|NCT02964039|Behavioral|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
157668|NCT02964026|Device|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
157669|NCT02964013|Biological|MK-7684|Administered as an intravenous (IV) infusion on Day 1 of 21-day infusion Cycles 1-35
157670|NCT02964013|Biological|pembrolizumab|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
157671|NCT02964013|Drug|pemetrexed|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-4
157672|NCT02964013|Drug|carboplatin|Administered as an IV infusion on Day 1 of 21-day infusion Cycles 1-35
157673|NCT02964000|Device|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
157674|NCT02964000|Device|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
157678|NCT02963961|Behavioral|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
157679|NCT02963948|Behavioral|Meetings with implementation leader(s)|The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
157680|NCT02963948|Behavioral|the SAAS survey|Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
157681|NCT02963948|Behavioral|Patient surveys|Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
157682|NCT02963935|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
157683|NCT02963935|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
157684|NCT02963935|Behavioral|CMS Intensive Behavior Therapy|Intensive Behaviour Therapy for obesity
157685|NCT02963922|Drug|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
157686|NCT02963922|Drug|Placebo|Injected subcutaneously (s.c., under the skin) once daily
157687|NCT02963909|Biological|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
157688|NCT02963909|Other|Placebo|0.9% Sodium Chloride 5 mcg
157689|NCT02963909|Biological|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
157690|NCT02963909|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
157691|NCT02963896|Drug|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
157692|NCT02963883|Other|SVO2 group / control group|
157693|NCT02963870|Other|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
157694|NCT02963844|Other|Inspiratory Muscle Training|
157695|NCT02963844|Other|Inspiratory Muscle Training Sham|
157696|NCT02963831|Biological|ONCOS-102|ONCOS-102 will be administered intraperitoneally infusion at weekly intervals for 6 weeks.
157697|NCT02963831|Drug|Durvalumab|Durvalumab will be administered by IV infusion once every four weeks for a total of 12 four-week cycles.
157698|NCT02963818|Other|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
157699|NCT02963818|Other|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
157700|NCT02963818|Other|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
157701|NCT02963805|Behavioral|High intensity physical activity (HIPA)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
157702|NCT02963805|Behavioral|Fundamental movement skill (FMS)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
157742|NCT02963480|Procedure|Cardiac Surgery|
157743|NCT02963467|Procedure|cigarette|smoking 4 conventional cigarettes
157744|NCT02963467|Procedure|"dummy cigarette"|"smoking a dummy cigarette"
157772|NCT02963233|Procedure|Closed reduction and percutaneous pinning and immobilization|
157773|NCT02963233|Procedure|Non-operative reduction and immobilization|
157894|NCT02962310|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
255095|NCT02253901|Drug|Ritonavir|
157703|NCT02963805|Behavioral|Physical activity signposting (PASS)|A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
157704|NCT02963792|Other|Preventing Professionals burnout|
157705|NCT02963779|Drug|LY2775240|Administered orally
157706|NCT02963779|Drug|Placebo|Administered orally
157707|NCT02963779|Drug|Apremilast|Administered orally
157708|NCT02963766|Drug|Dulaglutide|Administered SC
157709|NCT02963766|Drug|Placebo|Administered SC
157710|NCT02963740|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
157711|NCT02963740|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
157712|NCT02963740|Behavioral|Group Phone Calls|Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
157713|NCT02963740|Behavioral|Diet|Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
157714|NCT02963727|Biological|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
157715|NCT02963714|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
157716|NCT02963714|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
157717|NCT02963701|Drug|Ibuprofen|Fixed dose combination
157718|NCT02963701|Drug|Pseudoephedrine-HCl|Fixed dose combination
157719|NCT02963688|Genetic|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
157720|NCT02963662|Procedure|laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
157721|NCT02963662|Procedure|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
157722|NCT02963649|Device|DCB|Drug Coated Balloon
157723|NCT02963649|Device|PTA|Percutaneous Transluminal Angioplasty
157724|NCT02963636|Other|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
157725|NCT02963610|Drug|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
157726|NCT02963610|Drug|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
157727|NCT02963597|Device|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
157728|NCT02963597|Other|Standard Medical Therapy|Standard medical therapy according to current guidelines.
157729|NCT02963584|Other|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
157730|NCT02963571|Procedure|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
157731|NCT02963558|Device|cycle ergometry|The cycler will provide 3 different possible modes of cycling—passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
157732|NCT02963545|Other|Usual care patients in neurology department|patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
157733|NCT02963545|Biological|blood and urines sampling|Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
157734|NCT02963545|Procedure|Psychiatric evaluation|depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
157735|NCT02963532|Other|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
157736|NCT02963519|Device|VistaCare®|
157737|NCT02963519|Device|Dressings|
157738|NCT02963506|Other|Placebo|
157745|NCT02963454|Device|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.~During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
157746|NCT02963454|Drug|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
157747|NCT02963454|Drug|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
157748|NCT02963428|Behavioral|Enhanced Care|"In addition to standard of care, the study participants will also receive:~i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
157749|NCT02963415|Behavioral|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
157750|NCT02963402|Drug|Tocilizumab|
157751|NCT02963402|Drug|Adalimumab|
157752|NCT02963389|Drug|Tripegfilgrastim|
157753|NCT02963376|Drug|0.05 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).
157754|NCT02963376|Drug|0.05 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).
157755|NCT02963376|Drug|0.10 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
157756|NCT02963376|Drug|0.10 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
157757|NCT02963376|Drug|0.17 mL/kg DDFPe|Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
157758|NCT02963376|Drug|0.17 mL/kg Placebo|Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
157759|NCT02963363|Other|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.~5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
157760|NCT02963350|Drug|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
157761|NCT02963337|Drug|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
157762|NCT02963337|Drug|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
157763|NCT02963324|Drug|Ivermectin|
157764|NCT02963311|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
157765|NCT02963311|Drug|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
157766|NCT02963298|Procedure|Continuous renal replacement therapy|
157767|NCT02963285|Other|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 3 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
157768|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
157769|NCT02963272|Other|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
157770|NCT02963259|Device|SJM Infinity|IPG replacement procedure
157771|NCT02963246|Behavioral|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.~In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
157774|NCT02963220|Behavioral|CBT-AR|20-40 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
157775|NCT02963207|Other|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
157776|NCT02963207|Other|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
157777|NCT02963194|Drug|Oxytocin|
157778|NCT02963194|Drug|Placebo|
157779|NCT02963181|Drug|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
157780|NCT02963181|Drug|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation"
157781|NCT02963168|Drug|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
157782|NCT02963155|Other|Blood samples|
157783|NCT02963129|Drug|Mupirocin|Mupirocin ointment in the nose for 5 days
157784|NCT02963129|Other|Placebo|Placebo ointment in the nose for 5 days
157785|NCT02963116|Drug|AZD5718 IR tablet|
157786|NCT02963116|Drug|AZD5718 oral suspension|
157787|NCT02963116|Drug|Rosuvastatin tablet|
157788|NCT02963103|Drug|Tacrolimus|Oral
157789|NCT02963090|Drug|Topotecan|"Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities."
157790|NCT02963090|Drug|Pembrolizumab|200 mg IV every 21-days until progression of disease or unacceptable toxicities.
157791|NCT02963077|Drug|A4250|
157792|NCT02963077|Drug|CRC (A3384)|
157793|NCT02963077|Drug|Questran|
157794|NCT02963077|Drug|Placebo|
157795|NCT02963064|Biological|Humanized anti-CD117 Monoclonal Antibody|Procedure: one time intravenous infusion of anti-CD117 antibody
157796|NCT02963064|Procedure|Blood Forming Stem Cell Transplant (CD34+CD90+)|Procedure: one time intravenous infusion of donor blood forming stem cells
157797|NCT02963051|Drug|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
157798|NCT02963051|Drug|Disulfiram|"80 mg three times a day~Source of disulfiram: Cantex Pharmaceuticals"
157799|NCT02963051|Drug|Copper gluconate|"1.5 mg three times a day~Source of copper gluconate: Cantex Pharmaceuticals"
157800|NCT02963038|Biological|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
157801|NCT02963025|Procedure|PEEP level|
157802|NCT02963025|Procedure|Use of recruitment maneuvers|
157803|NCT02963012|Other|ultrasound examination|
157804|NCT02962999|Drug|Ketamine|After induction, patients will be received 1 mg/kg ketamine bolus, then administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
157805|NCT02962999|Drug|Saline|After induction, patients will be received saline bolus, then will be administered saline infusion intraoperatively.
157806|NCT02962986|Drug|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
157807|NCT02962986|Drug|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
157808|NCT02962973|Device|CARMAT TAH|
157809|NCT02962973|Procedure|Surgical intervention|
157810|NCT02962960|Drug|Anifrolumab|subcutaneous administration every 2 weeks from week 0 to week 50
157811|NCT02962960|Drug|Placebo|subcutaneous administration every two weeks from week 0 to week 50
157812|NCT02962947|Drug|Propranolol|80 mgR propranolol once daily
157813|NCT02962947|Drug|Placebo|placebo once daily
157814|NCT02962934|Other|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
157815|NCT02962934|Other|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.~Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
157816|NCT02962921|Drug|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
157817|NCT02962908|Biological|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
157818|NCT02962908|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
157819|NCT02962908|Biological|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
157820|NCT02962908|Biological|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
157821|NCT02962895|Biological|VAY736|VAY736
157822|NCT02962895|Other|Placebo|Placebo control
157823|NCT02962882|Device|Mepilex Border|Multi-layer Foam Dressings
157824|NCT02962869|Drug|BAY987517|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
157825|NCT02962869|Other|Untreated skin|One site is patched without treatment as control
157826|NCT02962856|Drug|BAY987517|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
157827|NCT02962856|Other|Untreated Skin|This site is patched without treatment as irradiated control
157861|NCT02962570|Device|Oxygen Flow Stopped|Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
157895|NCT02962310|Drug|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
159019|NCT02954653|Drug|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
157828|NCT02962843|Behavioral|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 & 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills & Problem Solving.
157829|NCT02962830|Drug|Sufentanil|intra-amniotic injection of 50 micrograms of Sufentanil
157830|NCT02962817|Other|Educational intervention|
157831|NCT02962817|Other|Video explaining the clinical practice guidelines on low back pain|
157832|NCT02962804|Drug|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
157833|NCT02962804|Radiation|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
157834|NCT02962791|Procedure|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
157835|NCT02962791|Device|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
157836|NCT02962791|Device|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
157837|NCT02962791|Device|Echocardiography|Standard Echocardiography will de bone for patient
157838|NCT02962752|Dietary Supplement|Blackadder Juice|
157839|NCT02962752|Other|Placebo|
157840|NCT02962739|Drug|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
157841|NCT02962713|Procedure|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
157842|NCT02962713|Procedure|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
157843|NCT02962700|Device|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
157844|NCT02962687|Behavioral|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
157845|NCT02962687|Behavioral|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
157846|NCT02962674|Device|ProstaCare System|
157847|NCT02962661|Biological|Intravenous Infusion of Human Mesenchymal Stem Cells (hMSCs)|Intravenous Infusion of Mesenchymal Stromal Cells (MSCs) Group: 4 weekly doses of MSCs administered intravenously at a dose of 2 x 10^6 cells/Kg.
157848|NCT02962661|Other|Routine Heart Failure Medical Therapy|Participants treated with routine heart failure medical therapy, Ace-inhibitors/Non-Selective beta blockers and when necessary diuretics/Aldosterone Inhibitors per institutionally defined standard of care.
157849|NCT02962661|Biological|Transendocardial Injections of Mesenchymal Stromal Cells|Transendocardial Injections of Mesenchymal Stromal Cells (MSCs) Group: 15 injections of 0.2 ml MSCs at a total dose of 15 x 10^7 cells during one operative procedure using the MyoStarTM injection catheter (Biosense Webster, Inc.).
157850|NCT02962648|Drug|Iron Isomaltoside|
157851|NCT02962635|Device|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
157852|NCT02962622|Other|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
157853|NCT02962609|Other|Semielevated Side-lying Position-ESL|The infants in the experimental group (n = 38) were held in the ESL position. In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of a pillow prepared by the researcher from the beds that were previously used in the unit and infantswere held in the side-lying position as in the breast-feeding position where their right ear faced the ceiling and the other ear faced the arms of the researcher. Their knees and hip were leaned against the researcher's arms and their head and neck were held at the same level by the researcher; whereas, their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
157854|NCT02962609|Other|Semielevated Supine Position|The ESU position was applied to the infants in the control group (n=42). In this position, their head and trunk were elevated to an angle of 45-60◦ with the help of the same pillow that was prepared by the researcher from the beds previously used in the unit and was used in the experimental group and they was laid in the supine position in the arms of the researcher. Their head and neck were held at the same level by the researcher, whereas their chin was held in the flexion posture mildly facing the floor. The researcher supported their head, neck, and shoulder with her left hand and controlled the bottlewith her right hand.
157855|NCT02962596|Other|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
157856|NCT02962583|Other|Weight loss|
157857|NCT02962583|Drug|Probiotic Formula|
157858|NCT02962583|Drug|Placebos|
157859|NCT02962570|Device|On Demand Oxygen Delivery|Supplemental oxygen flow is controlled such that it is on only during inhalation.
157860|NCT02962570|Device|Traditional, Always-On, Oxygen Delivery|Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.
157893|NCT02962323|Drug|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
157862|NCT02962557|Device|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
157863|NCT02962544|Procedure|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
157864|NCT02962544|Procedure|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
157865|NCT02962544|Device|Visumax device|
157866|NCT02962544|Device|FS 200 device|
157867|NCT02962531|Drug|IX-01 caplets 1600 mg (4 x 400 mg), fasted|oral dose under fasted conditions
157868|NCT02962531|Drug|IX-01 caplets 1600 mg (4 x 400 mg), fed|oral dose under fed conditions
157869|NCT02962531|Drug|IX-01 aqueous dispersion 1600 mg (20 mL), fasted|oral dose under fasted conditions
157870|NCT02962518|Device|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
157871|NCT02962518|Procedure|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
157872|NCT02962518|Drug|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
157873|NCT02962492|Drug|Exenatide/Exenatide extended release|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
157874|NCT02962492|Drug|Dapagliflozin|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
157875|NCT02962492|Drug|Placebo|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
157876|NCT02962466|Other|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
157877|NCT02962453|Device|Morning walk|gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays
157878|NCT02962453|Device|Ground Walker|gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
157879|NCT02962440|Drug|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing [3H]-somapacitan
157880|NCT02962427|Drug|Sphenopalatine ganglion Block|
157881|NCT02962427|Procedure|Epidural blood patch|
157882|NCT02962414|Drug|everolimus|everolimus, 2mg dispersible tablets
157883|NCT02962401|Drug|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1"
157884|NCT02962401|Drug|Idelalisib|"6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
157885|NCT02962388|Drug|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
157886|NCT02962388|Drug|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
157887|NCT02962388|Drug|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
157888|NCT02962375|Dietary Supplement|Active|100% orange juice with orange pomace fiber
157889|NCT02962375|Dietary Supplement|Control|100% orange juice
157890|NCT02962336|Drug|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
157891|NCT02962336|Drug|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
157892|NCT02962323|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
157896|NCT02962297|Drug|Vitamin E softgel|All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
157897|NCT02962297|Drug|Placebo|"All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).~Height and weight, waist-to-hip ratio Review of diet and exercise"
157898|NCT02962284|Drug|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
157899|NCT02962271|Device|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
157900|NCT02962258|Drug|Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|oral, crossover
157901|NCT02962258|Drug|Tribenzor of Daichi Sankyo Inc. USA|oral, crossover
157902|NCT02962245|Drug|berberine|
157903|NCT02962245|Drug|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
157904|NCT02962232|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
157905|NCT02962232|Device|PTA catheter|control group
157906|NCT02962219|Behavioral|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
157907|NCT02962219|Behavioral|Home Exercise Programme (HEP)|Written advice on exercise at home
157908|NCT02962206|Device|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
157909|NCT02962206|Procedure|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
157910|NCT02962180|Device|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
157911|NCT02962167|Biological|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
157912|NCT02962167|Biological|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
157913|NCT02962154|Radiation|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
157914|NCT02962154|Other|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:~Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
157915|NCT02962154|Other|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:~Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
157916|NCT02962154|Other|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:~Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
157917|NCT02962154|Other|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:~Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
157918|NCT02962154|Other|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:~EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
157919|NCT02962154|Other|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
157920|NCT02962141|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
157921|NCT02962141|Device|Balloon Dilatation Catheter|Control group
157922|NCT02962128|Dietary Supplement|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high [10% energy] LA-containing diet for 12 weeks.
157923|NCT02962128|Dietary Supplement|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low [2.5% energy] LA-containing diet for 12 weeks.
157924|NCT02962115|Behavioral|Decision Aid Invitation|electronic invitation to complete web-based decision aid
157925|NCT02962102|Drug|Calcifediol|Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4
157926|NCT02962102|Drug|Calcitriol|Calcitriol 4mcg PO/NGT/OGT daily x 5
157927|NCT02962102|Drug|Placebos|Placebo (medium chain triglyceride oil) daily x 5
157928|NCT02962089|Dietary Supplement|Branched chain amino acids (BCAA)|
157929|NCT02962089|Dietary Supplement|Placebo|
157930|NCT02962076|Radiation|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|this tracer detects the distribution of sympathetic nerve fibers in the left ventricle
157931|NCT02962063|Biological|durvalumab|Durvalumab can be given irrespective of CBC, at the discretion of the treating physician.
157932|NCT02962063|Drug|carboplatin AUC 2/paclitaxel|
157933|NCT02962063|Radiation|External beam radiation|
157934|NCT02962063|Procedure|esophagogastrectomy|
159020|NCT02954653|Drug|Daunorubicin|60-90 mg/m2 daily for 3 days
157935|NCT02962050|Procedure|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
157936|NCT02962050|Procedure|High Resolution Manometry|High resolution manometry will be performed to measure pressures across the various anatomical zones of swallowing.
157937|NCT02962050|Other|DIGEST|DIGEST will be used to analyze the safety and efficiency of swallowing bolus trials.
157938|NCT02962050|Other|Penetration Aspiration Scale|The Penetration Aspiration Scale will be used to analyze the safety of the swallowing bolus trials.
157939|NCT02962050|Other|Normalized Residue Ratio Scale|The Normalized Residue Ratio Scale will be used to analyze the efficiency of the swallowing bolus trials.
157940|NCT02962050|Device|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
157941|NCT02962050|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
157942|NCT02962050|Drug|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
157943|NCT02962050|Device|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
157944|NCT02962050|Other|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
157945|NCT02962050|Other|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
157946|NCT02962037|Other|Melatonin and light therapy|
157947|NCT02962024|Drug|Morphine Sulfate|
157948|NCT02962024|Drug|Bupivacaine Hydrochloride|
157949|NCT02962011|Device|Knotless barbed suture|uterine incision closure
157950|NCT02962011|Device|polyglactin 910|uterine incision closure
157951|NCT02961998|Drug|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
157952|NCT02961998|Drug|Sorafenib|Each group will receive sorafenib as basic treatment.
157953|NCT02961972|Dietary Supplement|monohydrate and micronized creatine|oral supplementation with creatine
157954|NCT02961972|Other|placebo|oral supplementation with maltodextrin (control group)
157955|NCT02961959|Procedure|Surgery|Arthrodesis of SI-joints, Physiotherapy
157956|NCT02961959|Other|Non-surgery|Physiotherapy
157957|NCT02961946|Drug|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
157958|NCT02961933|Other|Apneic oxygenation|Nasal cannula apneic oxygenation
157959|NCT02961933|Other|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
157960|NCT02961920|Device|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
157961|NCT02961920|Device|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
157962|NCT02961907|Procedure|PEPCI|"Both parents will receive:~consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required~endocrinologist consultation then dietitian follow-up if required~actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
157963|NCT02961894|Device|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
157964|NCT02961881|Drug|blinatumomab|Drug used as a treatment for relapsed/refractory B-cell precursor ALL
157965|NCT02961868|Other|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
157966|NCT02961868|Genetic|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
157967|NCT02961868|Other|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
157968|NCT02961868|Other|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
157969|NCT02961855|Drug|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
157970|NCT02961855|Drug|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
157971|NCT02961842|Drug|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
157972|NCT02961842|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
159021|NCT02954653|Drug|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
157973|NCT02961842|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
157974|NCT02961842|Drug|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
157975|NCT02961842|Drug|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
157976|NCT02961842|Drug|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
157977|NCT02961842|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
157978|NCT02961842|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
157979|NCT02961842|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
157980|NCT02961829|Drug|Maraviroc|antiretroviral intensification
157981|NCT02961829|Drug|Dolutegravir|antiretroviral intensification
157982|NCT02961829|Biological|Dendritic Cell Vaccine|Therapeutic vaccination
157983|NCT02961829|Drug|Auranofin|purging
157984|NCT02961829|Drug|Sirtuin Histone deacetylase inhibitor|latency disruption
157985|NCT02961816|Drug|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
157986|NCT02961816|Drug|Panobinostat|20 mg by mouth daily from Day -9 to -2.
157987|NCT02961816|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
157988|NCT02961816|Drug|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
157989|NCT02961816|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
157990|NCT02961816|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
157991|NCT02961816|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
157992|NCT02961816|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
157993|NCT02961816|Drug|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
157994|NCT02961816|Other|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
157995|NCT02961816|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
157996|NCT02961816|Biological|Stem Cell Infusion|Stem cells administered by vein on Day 0.
157997|NCT02961816|Drug|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
157998|NCT02961803|Drug|MD1003 100 mg capsule|
157999|NCT02961803|Drug|Placebo|
158000|NCT02961790|Drug|Oxybutynin Chloride|Given PO
158001|NCT02961790|Other|Placebo|Given PO
158002|NCT02961790|Other|Quality-of-Life Assessment|Ancillary studies
158003|NCT02961790|Other|Questionnaire Administration|Ancillary studies
158004|NCT02961777|Other|implementation of care pathway|implementation of a care pathway
158005|NCT02961764|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
158006|NCT02961764|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
158007|NCT02961751|Drug|Ciprofloxacin|Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
158008|NCT02961738|Behavioral|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
158009|NCT02961725|Biological|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml
158010|NCT02961712|Biological|NK cells|single intravenous injection of NK cells (0.9~1*10^9)
158011|NCT02961712|Biological|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
158012|NCT02961699|Device|Transpose ® RT System|adipose-derived stem cell therapy
158013|NCT02961699|Other|debridement/dressing of wound|standard of care debridement and wound dressing
158014|NCT02961686|Radiation|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
158015|NCT02961673|Biological|HU-014 Inj|Clostridium botulinum type A
158016|NCT02961673|Biological|Botox Inj|Clostridium botulinum type A
158017|NCT02961660|Drug|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
158018|NCT02961647|Procedure|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
158019|NCT02961634|Device|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
158020|NCT02961634|Drug|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
158021|NCT02961621|Behavioral|Stress Reduction Training for 9-1-1 Telecommunicators|
158022|NCT02961608|Drug|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
158023|NCT02961595|Biological|Oral Polio Vaccine (OPV)|Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).
158053|NCT02961335|Procedure|Bronchoscopy|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
158024|NCT02961582|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted.~Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
158025|NCT02961582|Other|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
158026|NCT02961569|Procedure|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
158027|NCT02961556|Drug|AJG555|Participants will receive 1 to 6 sachets daily per participants' age and conditions.
158028|NCT02961543|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
158029|NCT02961543|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
158030|NCT02961530|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
158031|NCT02961530|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
158032|NCT02961517|Other|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
158033|NCT02961504|Biological|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
158034|NCT02961504|Biological|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
158035|NCT02961491|Drug|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
158036|NCT02961478|Drug|IOHEXOL|Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
158037|NCT02961465|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
158038|NCT02961452|Other|Cross reaction detection|
158039|NCT02961439|Behavioral|Epworth Richmond's Echocardiography Focused Year|a year long echo teaching program
158040|NCT02961426|Drug|sofosbuvir|combination sofosbuvir ravidasvir treatment for non cirrhotic and compensated cirrhotic patients
158041|NCT02961400|Other|PUSH text messages|The intervention is designed to remind participants of treatment components.
158042|NCT02961400|Other|PULL text messages|The intervention is designed to remind participants to recall treatment components.
158043|NCT02961400|Behavioral|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
158044|NCT02961400|Behavioral|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
158045|NCT02961387|Device|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
158046|NCT02961387|Device|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
158047|NCT02961374|Drug|Erlotinib|Given PO
158048|NCT02961374|Drug|Erlotinib Hydrochloride|Given PO
158049|NCT02961361|Drug|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
158050|NCT02961361|Drug|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
158051|NCT02961348|Other|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
158052|NCT02961348|Other|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
255096|NCT02253901|Drug|TRUVADA|
158054|NCT02961335|Procedure|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
158055|NCT02961335|Procedure|Biopsy sampling|Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
158056|NCT02961322|Other|lobo-isthmectomy assisted robot|
158057|NCT02961309|Drug|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
158058|NCT02961296|Other|No intervention|No intervention will be needed.
158059|NCT02961283|Drug|ASN003 ascending doses|
158060|NCT02961283|Drug|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
158061|NCT02961270|Drug|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
158062|NCT02961257|Drug|cabazitaxel|"Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or~Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.~Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.~Standard cabazitaxel premedication will be used"
158063|NCT02961257|Drug|Prednisone|Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
158064|NCT02961257|Drug|Granulocyte colony-stimulating factor (G-CSF)|Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every administration of cabazitaxel
158065|NCT02961244|Other|Prewarming and perioperative warming with Forced Air Warming device and its blankets.|
158066|NCT02961244|Device|Forced Air Warming blanket|
158067|NCT02961231|Biological|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
158068|NCT02961231|Biological|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
158069|NCT02961231|Biological|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
158070|NCT02961231|Biological|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
158071|NCT02961218|Drug|Ilaris, Canakinumab|Monthly doses of 300 mg canakinumab subcutaneously (s.c)
158072|NCT02961218|Drug|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
158073|NCT02961205|Dietary Supplement|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
158074|NCT02961192|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
158075|NCT02961192|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
158076|NCT02961192|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
158077|NCT02961179|Behavioral|Increased dairy product|
158078|NCT02961179|Behavioral|Dietary counselling|
158079|NCT02961166|Drug|IgM enriched Immunoglobulins|Treatment for 3 days
158080|NCT02961153|Other|death|
158081|NCT02961140|Other|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
158082|NCT02961140|Other|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
158083|NCT02961127|Other|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
158084|NCT02961114|Procedure|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
158085|NCT02961114|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
158086|NCT02961114|Biological|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
158087|NCT02961101|Drug|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
158088|NCT02961101|Drug|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
158089|NCT02961101|Drug|Chemotherapy|Chemotherapy be given depends on the cancer type and treatment regimen before enrollment.
158090|NCT02961088|Other|Pasta as part of a low GI/GL diet|
158091|NCT02961075|Other|local surface anesthesia|Airway anesthesia for Bronchoscopy
158092|NCT02961075|Device|Laryngeal tube|
158093|NCT02961062|Drug|SAF312|
158094|NCT02961062|Drug|Placebo|
158095|NCT02961049|Procedure|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
158096|NCT02961049|Procedure|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
158097|NCT02961049|Procedure|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
158098|NCT02961049|Procedure|Wash and dry|Wash and dry with absorbent paper.
158099|NCT02961049|Device|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
158100|NCT02961049|Device|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
158101|NCT02961049|Procedure|Photoactivated|Photoactivated for 20 seconds
158102|NCT02961036|Other|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
158103|NCT02961036|Other|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
158104|NCT02961036|Other|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
158105|NCT02961036|Other|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
158106|NCT02961036|Other|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
158107|NCT02961036|Other|Group A Reminder|One survey reminder at 14 days
158108|NCT02961036|Other|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
158109|NCT02961023|Other|Exercise therapy|"3-week residential phase and 12-week outpatient phase.~Residential phase~Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.~A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.~1.5 to 2 hours of exercise will be performed daily, with rest intervals.~At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase~Ongoing exercise prescription will be based on tolerability, progress and HR~Outpatient phase~A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs~Participants will be provided with a cycle ergometer, weights and a HR monitor~Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
158110|NCT02961010|Behavioral|Keeping Safe|A whole school Preventative Education programme
158111|NCT02960997|Drug|Sirolimus, 2%|
158112|NCT02960997|Drug|Vehicle|
158113|NCT02960984|Other|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
158114|NCT02960971|Procedure|Thoracic surgery for lung cancer|Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
158115|NCT02960945|Drug|CTP-543, 16 mg (2 x 8 mg tablet)|
158116|NCT02960945|Drug|Jakafi 15Mg Tablet|
158117|NCT02960932|Device|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
158118|NCT02960919|Drug|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
158119|NCT02960919|Drug|parenteral ampicillin/ penicillin|
158120|NCT02960919|Drug|gentamicin|
158121|NCT02960906|Drug|Nivolumab|"For Arms 1A and 4A:~Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.~For Arms 1B, 2B, 3B and 4B:~Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol."
158122|NCT02960906|Drug|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:~Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
158123|NCT02960906|Drug|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
158124|NCT02960906|Drug|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
158125|NCT02960893|Drug|BHV-4157|Loose filled capsule
158126|NCT02960893|Drug|Placebo Comparator|BHV-4157 placebo-matching loose filled capsule
158127|NCT02960880|Drug|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
158128|NCT02960880|Drug|Phenprocoumon (branded and generics)|Individually adjusted dose
158129|NCT02960854|Biological|Nivolumab|Specified dose on specified days
158130|NCT02960841|Other|Intracavitary Manual Lymphatic Drainage|
158131|NCT02960841|Other|Conventional treatment|
158132|NCT02960828|Procedure|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
158133|NCT02960828|Drug|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
158134|NCT02960828|Device|Subthreshold Laser|
158135|NCT02960815|Biological|Intanza|
158136|NCT02960815|Biological|Mutagrip|
158137|NCT02960815|Drug|Aldara|
158138|NCT02960802|Procedure|kidney transplantation|
158139|NCT02960789|Other|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
158140|NCT02960789|Other|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
158141|NCT02960789|Device|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
158142|NCT02960789|Other|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
158143|NCT02960789|Device|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
158144|NCT02960776|Behavioral|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
158145|NCT02960763|Drug|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
158146|NCT02960763|Drug|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
158147|NCT02960763|Drug|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
158148|NCT02960763|Drug|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
158149|NCT02960763|Drug|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
158150|NCT02960750|Behavioral|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
158151|NCT02960750|Behavioral|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
158152|NCT02960737|Device|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
158153|NCT02960724|Other|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
158154|NCT02960711|Drug|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
158155|NCT02960711|Drug|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
158156|NCT02960698|Other|IRM and comportemental tasks|
158157|NCT02960685|Procedure|Echocardiography|
158158|NCT02960659|Drug|Liraglutide|Randomized controlled trial of metformin + liraglutide vs. metformin alone over 3 months in youth with type 2 diabetes.
158159|NCT02960659|Drug|Metformin|Paired study of metformin over 3 months in youth with type 2 diabetes compared to controls (youth with prediabetes or type 2 diabetes not treated with metformin).
158160|NCT02960646|Drug|Cyclophosphamide|Given IV
158161|NCT02960646|Biological|Filgrastim|Given SC
158162|NCT02960646|Drug|Fludarabine Phosphate|Given IV
158163|NCT02960646|Other|Laboratory Biomarker Analysis|Correlative studies
158164|NCT02960646|Drug|Melphalan|Given IV
158165|NCT02960646|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA depleted peripheral blood stem cell transplantation
158166|NCT02960646|Biological|Rituximab|Given IV
158167|NCT02960646|Drug|Tacrolimus|Given IV or PO
158168|NCT02960646|Radiation|Total-Body Irradiation|Undergo TBI
158169|NCT02960633|Device|Corail with collar.|
158170|NCT02960633|Device|Corail without collar.|
158171|NCT02960620|Device|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
158172|NCT02960607|Drug|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
158173|NCT02960594|Biological|INO-1400|
158174|NCT02960594|Biological|INO-9012|
158175|NCT02960594|Biological|INO-1401|
158176|NCT02960581|Biological|PGT121 3mg/kg IV|3mg/kg administered by IV Infusion
158177|NCT02960581|Biological|PGT121 10mg/kg IV|10mg/kg administered by IV infusion
158178|NCT02960581|Biological|PGT121 30mg/kg IV|30mg/kg administered by IV infusion
158179|NCT02960581|Biological|PGT121 3mg/kg SC|"3mg/kg administered by SC injection~Placebo: None"
158180|NCT02960581|Biological|Placebo (0.9% Sodium Chloride Injection USP (Saline))|
158181|NCT02960568|Drug|Primaquine|30 mg oral primaquine one time
158182|NCT02960555|Biological|Isatuximab|Given IV
158183|NCT02960555|Other|Laboratory Biomarker Analysis|Correlative studies
158184|NCT02960542|Behavioral|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
158185|NCT02960529|Procedure|extra-peritoneal high ligation of hernia|
158186|NCT02960529|Procedure|intraabdominal high ligation of hernia|
158187|NCT02960516|Device|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
158188|NCT02960503|Drug|Azithromycin|Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
158189|NCT02960503|Other|Placebo|Study participants will be randomized to the control arm (placebo three times a week for 6 months).
158190|NCT02960490|Drug|E6011|subcutaneous administration
158191|NCT02960490|Drug|Placebo|subcutaneous administration
158192|NCT02960477|Other|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
158193|NCT02960477|Other|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
158194|NCT02960464|Device|Transcranial direct current stimulation|
158195|NCT02960464|Device|Sham Transcranial direct current stimulation|
158196|NCT02960451|Other|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
158197|NCT02960451|Other|Usual care|Medication and psychotherapy as available form community providers
158198|NCT02960438|Drug|E6011|subcutaneous administration
158199|NCT02960438|Drug|Placebo|subcutaneous administration
158200|NCT02960425|Dietary Supplement|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
158201|NCT02960425|Dietary Supplement|Placebo|Topical placebo
158202|NCT02960412|Drug|furosemide|10mg lasix given intraoperatively
158203|NCT02960412|Drug|Normal Saline|Normal saline given intraoperatively as placebo
158204|NCT02960399|Biological|Zostavax®|Zostavax® immunization
158205|NCT02960386|Other|Machine Learning Algorithm|The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
158206|NCT02960373|Other|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
158207|NCT02960373|Other|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
158208|NCT02960373|Other|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
158209|NCT02960373|Other|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
158210|NCT02960347|Device|High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor|Non-invasive focal neuromodulation
158211|NCT02960334|Device|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
158212|NCT02960308|Radiation|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
158213|NCT02960295|Device|1-Self-monitoring of blood glucose|"Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Intervention: At every office visit and at every telephone (virtual) visit the patient's physician will review glucose results and make adjustments in diet, activity, or medication to bring glucose into desired range."
158214|NCT02960295|Device|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Consultation with the nutritionist will be obtained for women gaining in excess of or less than that indicated for her pre-pregnancy BMI, per Institute of Medicine (IOM) standards.
158215|NCT02960295|Device|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment. Patients with elevated blood pressure will be requested to come to Obstetrics Triage immediately for further assessment.
158216|NCT02960295|Device|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.Those reporting a fetal heart rate outside of the normal range will be requested to come to ObstetricTriage for further assessment.
158217|NCT02960295|Procedure|5-Visits with caregivers|Telephone visits will alternate with in-office visits.Those failing to keep appointments will be contacted and reappointed at a mutually convenient time.
158218|NCT02960282|Procedure|Biospecimen Collection|Undergo collection of fecal specimens
158219|NCT02960282|Other|Laboratory Biomarker Analysis|Correlative studies
158220|NCT02960269|Other|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
158221|NCT02960256|Device|ekocardiogram test|ekocardiogram test
158222|NCT02960243|Device|Deep Brain Stimulation|"DBS System Medtronic~DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral~These settings will be used to evaluate effects of voice tremor as well"
158223|NCT02960230|Biological|K27M peptide|K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently
158224|NCT02960217|Drug|UX007|liquid for oral (PO) administration
158225|NCT02960217|Drug|Placebo|liquid safflower oil for PO administration
158226|NCT02960204|Drug|Emricasan|
158227|NCT02960204|Drug|Placebo|
158228|NCT02960191|Device|Magnetic resonance imaging (MRI)|
158229|NCT02960178|Behavioral|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
158230|NCT02960178|Behavioral|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
158231|NCT02960165|Behavioral|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
158232|NCT02960165|Behavioral|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
158233|NCT02960152|Other|diagnostic|full-mouth periodontal examination
158234|NCT02960139|Device|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
158235|NCT02960126|Drug|Aspirin|
158236|NCT02960126|Drug|Clopidogrel|
158237|NCT02960113|Drug|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
158279|NCT02959879|Drug|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
255158|NCT02253459|Drug|Capecitabine|
158238|NCT02960113|Device|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
158239|NCT02960100|Other|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
158240|NCT02960100|Other|Media Intervention|Receive targeted HPV vaccine narrative-style video
158241|NCT02960100|Other|Survey Administration|Ancillary studies
158242|NCT02960087|Radiation|Low dose rate brachytherapy|I-125 to a total dose of 144 Gy
158243|NCT02960087|Radiation|High dose rate brachytherapy|19 Gy in 1 fraction plus intraprostatic boost to GTV
158244|NCT02960074|Biological|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
158245|NCT02960061|Drug|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
158246|NCT02960061|Procedure|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
158247|NCT02960061|Drug|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
158248|NCT02960061|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
158249|NCT02960048|Device|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
158250|NCT02960048|Device|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .~Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.~Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .~Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
158251|NCT02960035|Drug|etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
158252|NCT02960035|Drug|etanercept (half dose)|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
158253|NCT02960035|Drug|placebo|
158254|NCT02960022|Drug|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
158255|NCT02960022|Drug|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 will receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
158256|NCT02960022|Drug|prednisone|Subjects enrolling from study 9785-CL-0011 will receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
158257|NCT02960009|Device|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients
158258|NCT02959996|Drug|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
158259|NCT02959996|Drug|Placebo|placebo injection in the Pfannenstiel incision
158260|NCT02959983|Drug|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
158261|NCT02959983|Drug|Placebo|Placebo matching eluxadoline oral tablets BID with food.
158262|NCT02959970|Drug|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
158263|NCT02959957|Drug|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
158264|NCT02959957|Drug|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
158265|NCT02959944|Drug|ibrutinib|Ibrutinib capsules administered orally daily
158266|NCT02959944|Drug|Placebo|Placebo capsules administered orally daily
158267|NCT02959944|Drug|Prednisone|Prednisone administered daily
158268|NCT02959931|Other|High Potassium Meal|Breakfast meal that provides ~2400 mg of dietary potassium. Meals are isocaloric.
158269|NCT02959931|Other|Low Potassium Meal|Breakfast meal that provides ~540 mg of potassium. Meals are isocaloric.
158270|NCT02959918|Drug|SEL-212|SEL-212
158271|NCT02959918|Drug|SEL-037|SEL-037, biologic
158272|NCT02959918|Drug|SVP-rapamycin (SEL-110)|
158273|NCT02959905|Biological|TSA-CTL|On day 0,TSA-CTL will be infused intravenously on the Patient Care Unit over 20-30 minutes.
158274|NCT02959905|Drug|Cyclophosphamide|Cyclophosphamide 500 mg/m2/day IV in 250 ml for one day.
158275|NCT02959905|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 2 days.
158276|NCT02959892|Drug|Amphetamine|Amphetamine tablets
158277|NCT02959892|Drug|TAK -041|TAK-041 oral suspension
158278|NCT02959879|Drug|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
159550|NCT02951091|Other|biomarker screening|immunohistochemistry and in situ hybridization
158280|NCT02959879|Procedure|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
158281|NCT02959879|Drug|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
158282|NCT02959879|Drug|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
158283|NCT02959866|Other|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
158284|NCT02959853|Drug|Anastrazole|
158285|NCT02959853|Behavioral|weight loss|
158286|NCT02959840|Device|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
158287|NCT02959840|Drug|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
158288|NCT02959840|Drug|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
158289|NCT02959827|Drug|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
158290|NCT02959814|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
158291|NCT02959801|Procedure|Percutaneous mechanical thrombectomy|Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
158292|NCT02959788|Other|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
158293|NCT02959775|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
158294|NCT02959775|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
158295|NCT02959762|Dietary Supplement|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
158296|NCT02959762|Dietary Supplement|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
158297|NCT02959762|Dietary Supplement|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
158298|NCT02959749|Drug|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
158299|NCT02959749|Drug|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
158300|NCT02959736|Behavioral|MATADOC and CRS-R|Behavioural assessments for Disorders of Consciousness
158301|NCT02959710|Drug|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
158302|NCT02959710|Drug|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
158303|NCT02959710|Drug|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz [237 mL of Ensure® Original] at Hour 0 on Day 1)
158304|NCT02959697|Drug|Subcut. + Subconj. Xylocaine|Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
158305|NCT02959697|Drug|Subcut. + Sham Subconj. Injection|Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
158306|NCT02959697|Procedure|Blepharoptosis Repair|Patients will undergo blepharoptosis repair using an anterior approach.
158307|NCT02959671|Device|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
158308|NCT02959658|Drug|Dimethyl Fumarate|
158309|NCT02959658|Drug|Placebo Oral Capsule|Manufactured to mimic Dimethyl Fumarate capsules
158310|NCT02959632|Behavioral|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
158311|NCT02959619|Drug|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
158312|NCT02959606|Drug|Sarpogrelate SR 300mg|
158313|NCT02959606|Drug|Clopidogrel|
158314|NCT02959593|Device|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
158315|NCT02959580|Drug|Hydrocortisone Butyrate|topical use
158316|NCT02959580|Procedure|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
158317|NCT02959567|Device|Aqueduct 100 dilation|
158318|NCT02959554|Drug|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
158319|NCT02959554|Drug|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
158320|NCT02959554|Drug|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
158321|NCT02959541|Drug|Leucovorin|
158322|NCT02959528|Other|Working memory training|n-back training program
158323|NCT02959528|Other|perceptual training|visual-perceptual training program
158324|NCT02959515|Procedure|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
158325|NCT02959515|Procedure|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.~Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
158399|NCT02958956|Drug|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
158326|NCT02959502|Other|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
158327|NCT02959502|Other|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
158328|NCT02959489|Behavioral|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
158329|NCT02959489|Behavioral|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
158330|NCT02959476|Drug|Ropivacaine|Anesthetic
158331|NCT02959476|Drug|Placebos|Inactive comparator
158332|NCT02959463|Other|Laboratory Biomarker Analysis|Correlative studies
158333|NCT02959463|Radiation|Palliative Radiation Therapy|Undergo palliative radiation therapy
158334|NCT02959463|Biological|Pembrolizumab|Given IV
158335|NCT02959463|Radiation|Radiation Therapy|Undergo hemithoracic radiation therapy
158336|NCT02959450|Dietary Supplement|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
158337|NCT02959437|Drug|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 through 6.
158338|NCT02959437|Drug|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
158339|NCT02959437|Drug|Epacadostat|Epacadostat tablets will be administered orally twice daily.
158340|NCT02959437|Drug|INCB057643|INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
158341|NCT02959437|Drug|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks of each 21-day cycle starting on Cycle 2 Day 1.
158342|NCT02959437|Drug|Epacadostat|Epacadostat tablets will be administered orally twice daily starting at Cycle 2 Day 1.
158343|NCT02959437|Drug|INCB059872|INCB059872 will be orally self- administered once daily OR every other day beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.
158344|NCT02959424|Other|Spanish Northwestern Esophageal Quality of Life questionnaire|
158345|NCT02959411|Drug|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
158346|NCT02959411|Drug|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
158347|NCT02959398|Device|Standard mammography|Standard mammography
158348|NCT02959398|Device|Standard mammography and tomosynthesis|Standard mammography and tomosynthesis
158349|NCT02959385|Radiation|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
158350|NCT02959385|Procedure|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
158351|NCT02959372|Other|lung ultrasound|
158352|NCT02959372|Other|placebo|lung ultrasound. The attending physician will not know the result
158353|NCT02959359|Drug|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
158354|NCT02959359|Drug|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
158355|NCT02959346|Procedure|Sham Acupuncture|"Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
158400|NCT02958943|Behavioral|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
158517|NCT02958137|Procedure|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
158356|NCT02959346|Procedure|Acupuncture|"Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
158357|NCT02959333|Biological|hAEC|hAEC: human amniotic epithelial cells
158358|NCT02959320|Procedure|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
158359|NCT02959307|Device|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
158360|NCT02959307|Device|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
158361|NCT02959294|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
158362|NCT02959294|Device|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
158363|NCT02959294|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
158364|NCT02959281|Other|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
158365|NCT02959268|Device|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
158366|NCT02959255|Drug|Esomeprazole|dosage difference
158367|NCT02959229|Drug|Lactoferrin|
158368|NCT02959229|Drug|Placebo (for Lactoferrin)|placebo in form of distilled water
158369|NCT02959216|Other|Aerobic Exercise|Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
158370|NCT02959216|Other|Stretching Exercise|Participants will be given a prescription to complete a standardized stretching protocol.
158371|NCT02959190|Drug|Galcanezumab|Administered SC
158372|NCT02959177|Drug|Galcanezumab|Administered SC
158373|NCT02959177|Drug|Placebo|Administered SC
158374|NCT02959164|Drug|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~*Starting Dose Level"
158375|NCT02959164|Drug|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.~Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;~*Starting Dose Level"
158376|NCT02959151|Drug|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
158377|NCT02959138|Drug|Lanraplenib.|20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
158378|NCT02959125|Other|NutFish Based Food Supplementation|Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish
158379|NCT02959125|Dietary Supplement|Multiple micronutrients|Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg
158380|NCT02959125|Behavioral|Health Education in Pregnancy Class|Health education on pregnancy, complication, and breastfeeding by research team members
158381|NCT02959125|Other|Government Food Supplementation|Cookies contain 500 Calories and 5 gram protein make from flour and egg
158382|NCT02959125|Dietary Supplement|Fe Supplementation|Ferrous Fumarate 60mg and folic acid 0.400 mg
158383|NCT02959112|Drug|Epinephrine|
158384|NCT02959112|Other|Sterile water|
158385|NCT02959112|Drug|Indomethacin Rectal Suppository|
158386|NCT02959073|Other|Symptom Recording|Subjects muss record their allergic symptoms after contact with their cats
158387|NCT02959060|Drug|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
158388|NCT02959060|Drug|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
158389|NCT02959047|Drug|Alirocumab|150mg SQ every 2 weeks
158390|NCT02959047|Drug|Matching placebo|SQ every 2 weeks
158391|NCT02959021|Behavioral|weight loss intervention - self directed|
158392|NCT02959021|Behavioral|weight loss intervention - peer coach|
158393|NCT02959008|Device|measure TOI and BP|Both groups measure TOI and BP.
158394|NCT02958995|Other|No Intervention|
158395|NCT02958982|Drug|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
158396|NCT02958982|Drug|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
158397|NCT02958969|Drug|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
158398|NCT02958969|Drug|Placebo Oral Tablet|placebo
158439|NCT02958631|Drug|Losartan|
158701|NCT02956785|Drug|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
158401|NCT02958930|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
158402|NCT02958917|Drug|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 40 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
158403|NCT02958917|Other|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 40 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
158404|NCT02958904|Other|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
158405|NCT02958891|Other|Data collection|Collection epidemiological dental measures
158406|NCT02958878|Drug|Tamsulosin|
158407|NCT02958878|Drug|Placebo Oral Capsule|
158408|NCT02958865|Drug|PF-06651600 or Placebo|Delivered orally for 8 weeks.
158409|NCT02958865|Drug|PF-06700841 or Placebo|Delivered orally for 8 weeks.
158410|NCT02958865|Drug|PF-06700841|Delivered orally for 24 weeks.
158411|NCT02958865|Drug|PF-06651600|Delivered orally for 24 weeks.
158412|NCT02958852|Drug|Letrozole|
158413|NCT02958852|Drug|Letrozole and atorvastatin|
158414|NCT02958852|Drug|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
158415|NCT02958839|Procedure|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
158416|NCT02958826|Other|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
158417|NCT02958813|Behavioral|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
158418|NCT02958813|Behavioral|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
158419|NCT02958800|Other|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.~Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.~Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
158420|NCT02958787|Radiation|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
158421|NCT02958774|Radiation|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
158422|NCT02958761|Biological|intraarticular injections of platelet lysate|
158423|NCT02958761|Drug|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
158424|NCT02958748|Other|taking blood sample|
158425|NCT02958735|Other|Exercise Challenge|Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
158426|NCT02958722|Procedure|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
158427|NCT02958722|Drug|physiological solution|
158428|NCT02958722|Drug|carbon dioxide|
158429|NCT02958709|Drug|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
158430|NCT02958709|Drug|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
158431|NCT02958709|Drug|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
158432|NCT02958696|Drug|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
158433|NCT02958683|Other|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
158434|NCT02958670|Other|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
158435|NCT02958657|Other|Exercise Training|Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
158436|NCT02958644|Dietary Supplement|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
158437|NCT02958644|Dietary Supplement|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
158438|NCT02958631|Drug|Fimasartan|
158440|NCT02958618|Procedure|"30 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
158441|NCT02958618|Procedure|"60 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
158442|NCT02958618|Procedure|"180 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
158443|NCT02958605|Device|Smartphone apps|If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.
158444|NCT02958605|Device|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
158445|NCT02958592|Other|two-dimensional shear-wave elastography (SWE)|performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
158446|NCT02958579|Other|No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.|
158447|NCT02958566|Drug|Acetaminophen|
158448|NCT02958566|Drug|Gabapentin|
158449|NCT02958566|Drug|Orphenadrine|
158450|NCT02958566|Drug|Lidocaine|
158451|NCT02958566|Drug|Marcaine|
158452|NCT02958566|Drug|Ketamine|
158453|NCT02958566|Drug|Methadone|
158454|NCT02958566|Drug|Tramadol|
158455|NCT02958566|Drug|Ketorolac|
158456|NCT02958566|Drug|Morphine Sulfate|
158457|NCT02958566|Drug|Fentanyl|
158458|NCT02958566|Drug|Dilaudid|
158459|NCT02958566|Drug|Hydrocodone-Acetaminophen Tab 5-325 MG|
158460|NCT02958566|Drug|Morphine Sulfate|PCA
158461|NCT02958566|Drug|Fentanyl|PCA
158462|NCT02958566|Drug|Dilaudid|PCA
158463|NCT02958566|Drug|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
158464|NCT02958553|Device|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
158465|NCT02958553|Device|Subject's own passive prosthesis|Devices will vary. Data gathered will form a baseline.
158466|NCT02958540|Biological|SynGEM|Prime / boost vaccination in each group
158467|NCT02958540|Other|placebo|prime /boost vaccination
158468|NCT02958527|Drug|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
158469|NCT02958514|Device|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of *500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
158470|NCT02958514|Drug|Tobramycin and Dexamethasone Ophthalmic Ointment|
158471|NCT02958501|Drug|Colecalciferol|Drug
158472|NCT02958488|Device|High Flow Nasal Cannula|
158473|NCT02958475|Behavioral|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
158474|NCT02958475|Behavioral|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
158475|NCT02958475|Behavioral|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
158476|NCT02958462|Other|follow up|
158477|NCT02958449|Device|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
158478|NCT02958436|Drug|REGN3500|
158479|NCT02958436|Drug|Placebo|
158480|NCT02958423|Device|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
158481|NCT02958423|Device|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
158482|NCT02958423|Device|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
158483|NCT02958423|Device|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
158484|NCT02958410|Biological|Anti-CD30-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
158485|NCT02958397|Biological|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
158486|NCT02958384|Biological|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
158487|NCT02958371|Procedure|fMRI|
158488|NCT02958371|Behavioral|fruit-flavored drink ingestion|
158489|NCT02958358|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
158490|NCT02958345|Biological|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
158491|NCT02958345|Other|Placebo|Injection of 0.65 mL of sterile normal saline
158492|NCT02958332|Other|video game program|Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
158493|NCT02958306|Biological|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
158494|NCT02958280|Behavioral|Fit&Sober App|Fit&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
158495|NCT02958280|Behavioral|Brief Advice|Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
158496|NCT02958267|Biological|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
158497|NCT02958267|Biological|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
158498|NCT02958267|Device|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution [10 mg/mL], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
158499|NCT02958241|Other|MRI|Supine and weight bearing MRI
158500|NCT02958228|Behavioral|Positive Mental Imagery Training (PMIT)|
158501|NCT02958228|Behavioral|Cognitive Control Training (CCT)|
158502|NCT02958228|Other|Treatment as Usual|
158503|NCT02958215|Drug|Phenylephrine|it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
158504|NCT02958215|Other|Placebo|5 ml normal saline will be given before spinal anesthesia
158505|NCT02958202|Drug|BMN 044 IV 6 mg/kg|
158506|NCT02958202|Drug|BMN 044 IV 9 mg/kg|
158507|NCT02958202|Drug|BMN 044 SC 6 mg/kg|
158508|NCT02958189|Behavioral|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
158509|NCT02958189|Behavioral|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
158510|NCT02958176|Behavioral|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
158511|NCT02958176|Behavioral|Autogenic Training|Autogenic training recording provided on a CD
158512|NCT02958163|Procedure|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
158513|NCT02958163|Drug|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
158514|NCT02958163|Radiation|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:~48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)~For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.~For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
158515|NCT02958150|Drug|Dexmedetomidine|
158518|NCT02958111|Drug|Capecitabine|Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
158519|NCT02958085|Drug|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
158520|NCT02958085|Drug|Placebo|Dosed either once daily or once weekly
158521|NCT02958072|Other|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
158522|NCT02958059|Biological|Pacetin® (cefoxitin)|1~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
158523|NCT02958059|Biological|Placebo|10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
158524|NCT02958046|Drug|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
158525|NCT02958033|Radiation|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
158526|NCT02958007|Behavioral|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
158527|NCT02958007|Behavioral|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
158528|NCT02957994|Drug|Tenofovir alafenamide fumarate|Patients on TDF will be switched to TAF
158529|NCT02957981|Behavioral|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
158530|NCT02957981|Behavioral|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
158531|NCT02957968|Drug|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
158532|NCT02957968|Drug|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
158533|NCT02957968|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
158534|NCT02957968|Drug|Carboplatin|carboplatin AUC 1.5 once weekly for 12 weeks.
158535|NCT02957968|Drug|Decitabine|Given IV
158536|NCT02957968|Drug|Pembrolizumab|Given IV
158537|NCT02957955|Behavioral|High-Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
158538|NCT02957942|Device|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
158539|NCT02957929|Drug|APX001 single IV dose|
158540|NCT02957929|Drug|APX001 single oral dose 1|
158541|NCT02957929|Drug|APX001 single oral dose 2|
158542|NCT02957929|Drug|APX001 single oral dose 3|
158543|NCT02957929|Drug|APX001 single oral dose fasted|
158544|NCT02957929|Drug|APX001 single oral dose fed|
158545|NCT02957929|Drug|APX001 multiple oral doses 1|
158546|NCT02957929|Drug|APX001 multiple oral doses 2|
158547|NCT02957929|Drug|APX001 multiple oral doses 3|
158548|NCT02957929|Drug|Cytochrome P450 substrates|
158549|NCT02957929|Drug|Matching placebo control|
158550|NCT02957903|Drug|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
158551|NCT02957903|Drug|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
158552|NCT02957890|Biological|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
158553|NCT02957890|Biological|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
158554|NCT02957890|Biological|Placebo|Round 2 (May): 0.5mL normal saline
158555|NCT02957877|Drug|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
158556|NCT02957877|Drug|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
158557|NCT02957864|Drug|tenofovir alafenamide|
158558|NCT02957864|Drug|abacavir|
158559|NCT02957851|Drug|Medical Air|
158560|NCT02957851|Drug|EMONO|
158561|NCT02957838|Dietary Supplement|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
158562|NCT02957838|Dietary Supplement|mock|Low fat banana milkshake without C18:0 supplement.
158563|NCT02957825|Device|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
158564|NCT02957812|Device|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
158565|NCT02957799|Behavioral|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
158566|NCT02957799|Behavioral|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
158567|NCT02957786|Drug|Cytisine|Cytisine tablets
158568|NCT02957786|Behavioral|Behavioural support|Withdrawal-orientated cessation support
158569|NCT02957786|Drug|Varenicline|Varenicline tablets
158570|NCT02957773|Behavioral|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
158571|NCT02957773|Behavioral|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
158572|NCT02957773|Behavioral|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
158573|NCT02957773|Behavioral|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
158574|NCT02957760|Drug|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
158575|NCT02957747|Behavioral|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
158576|NCT02957734|Procedure|Rehabilitation of severely worn dentitions|Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
158577|NCT02957721|Other|Usual Care|Patients will not be given the intervention but receive usual care for T2D.
158578|NCT02957708|Other|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.~SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
158579|NCT02957708|Other|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
158580|NCT02957695|Device|Placebo-Neurofeedback|The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
158581|NCT02957695|Device|Active-Neurofeedback|"The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH."
158582|NCT02957682|Drug|Praluent (Alirocumab)|
158583|NCT02957682|Drug|Placebo|
158584|NCT02957669|Behavioral|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
158585|NCT02957669|Behavioral|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
158586|NCT02957656|Biological|H7N9 pLAIV|10^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
158587|NCT02957656|Biological|H7N9 pIIV|Administered by intramuscular injection in the deltoid.
158588|NCT02957656|Biological|AS03 adjuvant|Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
158589|NCT02957643|Drug|Iron|
158590|NCT02957630|Drug|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
158785|NCT02956265|Device|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
255500|NCT02251171|Drug|Tipranavir|
158591|NCT02957630|Drug|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7‑day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
158592|NCT02957630|Drug|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4‑day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
158593|NCT02957617|Drug|BIIB074|Participants will receive an initial dose regimen of 350mg orally twice daily (BID), which may be reduced to 200mg based on tolerability for up to 12 months.
158594|NCT02957604|Drug|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
158595|NCT02957591|Dietary Supplement|Vivomixx®|Food supplementation with Vivomixx®. Vivomixx® (Mendes SA, Lugano, Switzerland) is a probiotic mixture of 8 strains: Streptococcus thermophiles DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. Bulgaricus DSM 24734).
158596|NCT02957591|Other|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
158597|NCT02957578|Device|Solo TTD|Placement of tympanostomy tube with Solo TTD
158598|NCT02957565|Behavioral|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
158599|NCT02957565|Other|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
158600|NCT02957565|Behavioral|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.~After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
158601|NCT02957552|Biological|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
158602|NCT02957539|Behavioral|Financial rewards|Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.
158603|NCT02957539|Behavioral|Non-Financial rewards|Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
158604|NCT02957526|Behavioral|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
158605|NCT02957526|Behavioral|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
158606|NCT02957513|Behavioral|Text Messaging (TM)|As specified in the arm description above
158607|NCT02957513|Behavioral|Health Coaching (HC)|As specified in the arm description above
158608|NCT02957513|Behavioral|Enhanced Usual Care (EC)|As specified in the arm description above
158609|NCT02957500|Device|Mediclore® (adhesion barrier)|
158610|NCT02957487|Device|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
158611|NCT02957474|Drug|GED-0301|
158612|NCT02957474|Drug|Omeprazole|
158613|NCT02957461|Device|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
158614|NCT02957448|Drug|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
158615|NCT02957448|Drug|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
158616|NCT02957435|Drug|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
158617|NCT02957422|Dietary Supplement|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
158618|NCT02957422|Dietary Supplement|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
158786|NCT02956252|Procedure|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
158787|NCT02956252|Procedure|General anesthesia|General anesthesia was used in patients who underwent LC
158619|NCT02957409|Drug|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
158620|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
158621|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
158622|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
158623|NCT02957383|Other|Wavelength|wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
158624|NCT02957383|Other|Intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
158625|NCT02957331|Drug|Propranolol|
158626|NCT02957318|Dietary Supplement|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
158627|NCT02957318|Dietary Supplement|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
158628|NCT02957318|Dietary Supplement|Placebo|Low-fiber control
158629|NCT02957305|Drug|Misoprostol 400 µg|Evaluate the required cervix dilation in the moment of the intrauterne suction
158630|NCT02957305|Drug|Misoprostol 200 µg|Evaluate the required cervix dilation in the moment of the intrauterne suction
158631|NCT02957292|Drug|Levonorgestrel (13,5 mg) intrauterine device|
158632|NCT02957292|Device|Cooper (380mm2) intrauterine device|
158633|NCT02957279|Drug|Antibiotics|In the sepsis group, antibiotics were used when needed.
158634|NCT02957266|Radiation|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
158635|NCT02957266|Radiation|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
158636|NCT02957266|Drug|Cisplatin|Weekly Cisplatin
158637|NCT02957266|Drug|Gemcitabine|Weekly Gemcitabine
158638|NCT02957266|Genetic|PIK3CA|PIK3CA mutations rate
158639|NCT02957266|Genetic|KRAS|KRAS mutations rate
158640|NCT02957266|Genetic|BRAF|BRAF mutations rate
158641|NCT02957266|Genetic|RRM1|RRM1 mutations rate
158642|NCT02957253|Other|risk factors|monitoring risk factors due to deterioration of the liver disease
158643|NCT02957253|Other|self-care|information and motivation to adherence to self-care instructions and medical treatment
158644|NCT02957253|Other|nutrition|nutritional assessment and activities to prevent malnutrition
158645|NCT02957253|Other|lifestyle|motivation of lifestyle changes essential for disease progress and
158646|NCT02957253|Other|psychosocial needs|psychosocial care.
158647|NCT02957253|Other|Nurse-led clinic|compensated disease once yearly, decompensated disease twice a month to every third month
158648|NCT02957240|Behavioral|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.~Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
158649|NCT02957240|Behavioral|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.~Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
158650|NCT02957227|Device|No intervention is part of this study but patients use an EEG device during observational data collection.|
158651|NCT02957214|Behavioral|Pain education|
158652|NCT02957201|Other|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
158653|NCT02957188|Other|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
158654|NCT02957175|Other|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
158655|NCT02957162|Drug|Atorvastatin|
158656|NCT02957162|Other|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
158657|NCT02957149|Other|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
158658|NCT02957149|Device|Angel Concentrated Platelet Rich Plasma System|
158729|NCT02956616|Drug|ketorolac|Ketorolac, sold under the brand name Toradol among others, is a nonsteroidal anti-inflammatory drug in the family of heterocyclic acetic acid derivatives, used as an analgesic. It is considered a first-generation NSAID. Ketorolac acts by inhibiting the bodily synthesis of prostaglandins.
255501|NCT02251171|Drug|Ritonavir|
158659|NCT02957136|Device|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
158660|NCT02957123|Drug|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
158661|NCT02957110|Behavioral|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
158662|NCT02957097|Drug|Gabapentin|Medication used for management of neuropathic pain conditions
158663|NCT02957097|Drug|Placebo|Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
158664|NCT02957058|Procedure|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
158665|NCT02957045|Procedure|Cough pressure measurement|
158666|NCT02957045|Device|Pcough|
158667|NCT02957032|Drug|F16IL2|"All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.~Treatment will be repeated every 28 days for up to three cycles."
158668|NCT02957032|Drug|cytarabine|Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
158669|NCT02957019|Drug|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
158670|NCT02957019|Drug|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
158671|NCT02957019|Drug|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
158672|NCT02957006|Device|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
158673|NCT02956993|Drug|vonapanitase|
158674|NCT02956993|Drug|Placebo|
158675|NCT02956980|Biological|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
158676|NCT02956967|Other|Overall satisfaction questionnaires of home use of Nivestim|
158677|NCT02956954|Drug|Enzyme replacement therapy (Agalsidase alpha (Replagal®))|Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
158678|NCT02956954|Procedure|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be assessed every 6 months during 2 years
158679|NCT02956941|Behavioral|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
158680|NCT02956915|Procedure|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
158681|NCT02956902|Other|Clinician supported smartphone application intervention|
158682|NCT02956889|Drug|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
158683|NCT02956889|Radiation|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
158684|NCT02956876|Drug|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
158685|NCT02956876|Other|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
158686|NCT02956876|Other|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
158687|NCT02956863|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
158688|NCT02956863|Procedure|Exercises|Exercise for stretching and strength for neck muscles
158689|NCT02956850|Other|Placebo|Placebo matching to RO7020531 will be administered as per schedule specified in the respective arm.
158690|NCT02956850|Drug|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
158691|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
158692|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
158693|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
158694|NCT02956837|Drug|Placebo (Formulation buffer S9b)|A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
158695|NCT02956824|Other|Standard care|Current care
158696|NCT02956811|Drug|Dapagliflozin|SGLT2 inhibitor
158697|NCT02956811|Drug|Placebo|Matching Placebo
158698|NCT02956798|Radiation|Stereotactic ablative body radiation (SABR)|SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
158699|NCT02956785|Drug|10 mg Dinoprostone; CTS, UK|
158700|NCT02956785|Drug|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
158702|NCT02956772|Drug|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
158703|NCT02956772|Drug|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
158704|NCT02956759|Procedure|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
158705|NCT02956746|Biological|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
158706|NCT02956746|Biological|Imovax|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
158707|NCT02956746|Biological|RabAvert|Subjects will receive SYN023 or HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
158708|NCT02956746|Biological|HyperRAB ST (human rabies immune globulin)|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
158709|NCT02956733|Procedure|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
158710|NCT02956733|Procedure|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
158711|NCT02956720|Device|UltraShape Power|non-invasive body contouring procedure
158712|NCT02956707|Other|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
158713|NCT02956694|Behavioral|Training of clinicians + tools|The clinicians will have access to a distance training program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. Each DB will be designed in two versions, one adapted to clinicians (C-DB), and a simplified version adapted to patients/caregivers (P-DB). They will receive the five C-DBs by email, at a rate of 1 per week for 5 weeks. Furthermore, they will also be invited to use the 5 P-DBs with their patients. To this end, they will receive a stack of printed copies of the P-DBs for use in home care consultations, and we will also leave some copies in a wall file in each consultation room of the clinic.
158714|NCT02956694|Other|Usual care|Healthcare providers from the clinics allocated to the control group will practice as usual and have access to the same training program after the end of the study data collection (delayed intervention).
158715|NCT02956681|Behavioral|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
158716|NCT02956681|Behavioral|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
158717|NCT02956668|Other|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
158718|NCT02956668|Other|Blindsight Training alone|The patient undergo visual rehabilitation
158719|NCT02956655|Other|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
158720|NCT02956655|Drug|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)~Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland~The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
158721|NCT02956655|Other|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
158722|NCT02956655|Behavioral|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
158723|NCT02956655|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
158724|NCT02956642|Device|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
158725|NCT02956642|Device|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
158726|NCT02956629|Drug|Uprifosbuvir|Participants take 3 tablets each containing 150 mg uprifosbuvir q.d. by mouth.
158727|NCT02956629|Drug|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
158728|NCT02956629|Drug|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on uprifosbuvir + RZR alone.
158865|NCT02955719|Other|Psychiatric Consultation|
255502|NCT02251171|Drug|Rifabutin|
158730|NCT02956616|Other|Chewing Gum|Xylitol chewing gum will be provided to patients immediately after the procedure and will be provided 3 times per day for a duration of 30 minutes at each time, based on a metanalysis and systematic review. Patient's will be encouraged on its use for return of bowel function.
158731|NCT02956616|Procedure|Enhanced Recovery Protocol|enhanced recovery protocol (detailed previously) will include several evidence-based recommendations including early ambulation, early diet initiation, early removal of urinary catheter, early removal of postoperative dressing and standing ketorolac for 24 hours postoperatively.
158732|NCT02956603|Other|Fine wire EMG electrodes|Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
158733|NCT02956590|Drug|Pitavastatin|Statin
158734|NCT02956590|Drug|Placebo|Placebo
158735|NCT02956564|Procedure|intrauterine intervention|choose different surgeries according to different causes
158736|NCT02956551|Biological|DC vaccine|subcutaneous administration
158737|NCT02956538|Drug|Thalidomide|
158738|NCT02956538|Drug|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
158739|NCT02956525|Drug|Dexibuprofen|Dexibuprofen 200 mg
158740|NCT02956512|Drug|Dexibuprofen|Dexibuprofen 300mg
158741|NCT02956499|Drug|APX001 single dose 1|
158742|NCT02956499|Drug|APX001 single dose 2|
158743|NCT02956499|Drug|APX001 single dose 3|
158744|NCT02956499|Drug|APX001 single dose 4|
158745|NCT02956499|Drug|APX001 single dose 5|
158746|NCT02956499|Drug|APX001 single dose 6|
158747|NCT02956499|Drug|APX001 multiple dose 1|
158748|NCT02956499|Drug|APX001 multiple dose 2|
158749|NCT02956499|Drug|APX001 multiple dose 3|
158750|NCT02956499|Drug|APX001 multiple dose 4|
158751|NCT02956499|Drug|Matching Placebo|
158752|NCT02956486|Drug|Elenbecestat (E2609)|tablet
158753|NCT02956486|Drug|Placebo|tablet
158754|NCT02956473|Device|Supine MRI|
158755|NCT02956473|Other|Neoadjuvant Therapy|
158756|NCT02956473|Device|Ultrasound|
158757|NCT02956473|Device|Mammography|
158758|NCT02956473|Procedure|Standard of Care|
158759|NCT02956460|Device|fanfilcon A|contact lens
158760|NCT02956460|Device|senofilcon A|contact lens
158761|NCT02956447|Drug|Kisspeptin 112-121|0.313 µg/kg IV
158762|NCT02956447|Drug|Gonadotropin Releasing Hormone (GnRH)|0.075 ug/kg IV
158763|NCT02956434|Behavioral|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
158764|NCT02956421|Biological|RABIPUR®|Biological rabies vaccine
158765|NCT02956421|Biological|PIKA rabies vaccine|Biological rabies vaccine
158766|NCT02956408|Dietary Supplement|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
158767|NCT02956395|Other|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.~The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
158768|NCT02956382|Drug|Ibrutinib|Ibrutinib is dispensed as a capsule.
158769|NCT02956382|Drug|Venetoclax|Venetoclax is dispensed as a tablet.
158770|NCT02956369|Dietary Supplement|Control|Control granulates (maize starch and long-chain fatty acids) with powder
158771|NCT02956369|Dietary Supplement|SATIOSTAT|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
158772|NCT02956356|Dietary Supplement|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
158773|NCT02956356|Dietary Supplement|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
158774|NCT02956356|Dietary Supplement|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
158775|NCT02956356|Dietary Supplement|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
158776|NCT02956343|Device|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
158777|NCT02956317|Drug|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
158778|NCT02956317|Drug|Placebo|Normal Saline
158779|NCT02956304|Other|PMv stimulation (iTBS)|PMv stimulation (iTBS)
158780|NCT02956304|Other|PMv inhibition (cTBS)|PMv inhibition (cTBS)
158781|NCT02956304|Other|Control (SHAM)|Control (SHAM)
158782|NCT02956291|Device|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
158783|NCT02956278|Drug|Allopurinol|
158784|NCT02956278|Other|Placebo|lactose placebo pill
158866|NCT02955719|Other|Lifestyle Intervention Resources|
158788|NCT02956239|Procedure|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
158789|NCT02956239|Procedure|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
158790|NCT02956239|Procedure|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
158791|NCT02956226|Drug|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
158792|NCT02956226|Drug|Placebo|Olive oil and flavors solution.
158793|NCT02956226|Drug|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
158794|NCT02956213|Other|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
158795|NCT02956213|Other|Sham Control/Active Comparator|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place. Then at cross over, there will be an active HEPA portable air filter used
158796|NCT02956200|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
158797|NCT02956187|Behavioral|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
158798|NCT02956187|Dietary Supplement|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
158799|NCT02956174|Device|Co-Cr single crown|
158800|NCT02956174|Other|Periodontal parameters|
158801|NCT02956161|Device|Stimulation of up-phase of sleep slow oscillation|
158802|NCT02956161|Device|Random stimulation of up phase of sleep slow oscillation|
158803|NCT02956161|Device|No stimulation|
158804|NCT02956148|Radiation|Radioligand [18F]MNI-659|The effective radiation dose for the injection of [18F]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
158805|NCT02956122|Biological|GLASSIA|GLASSIA [Alpha1-Proteinase Inhibitor (Human)]
158806|NCT02956122|Drug|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
158807|NCT02956122|Biological|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
158808|NCT02956109|Drug|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
158809|NCT02956109|Drug|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
158810|NCT02956109|Drug|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
158811|NCT02956096|Device|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
158812|NCT02956096|Device|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
158813|NCT02956083|Other|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
158814|NCT02956083|Other|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
158815|NCT02956083|Other|saline|Saline - no brand name
158816|NCT02956070|Drug|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
158817|NCT02956070|Drug|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch [50%], lactose monohydrate [35%], dibasic calcium phosphate [14%], and magnesium stearate [1%]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
158818|NCT02956057|Drug|Polyethylene Glycols|
158819|NCT02956057|Drug|Natrium picosulfate / Magnesium citrate|
158820|NCT02956057|Drug|Polyethylene glycol / Ascorbic acid|
158821|NCT02956044|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
158822|NCT02956044|Drug|Metformin|1000 mg metformin
158823|NCT02956044|Drug|Glimepiride|4 mg glimepiride
158824|NCT02956044|Drug|Sitagliptin|100 mg sitagliptin
158825|NCT02956031|Other|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
158826|NCT02956031|Other|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
158827|NCT02956031|Procedure|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
158828|NCT02956005|Drug|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
158829|NCT02955992|Behavioral|Improving communication during the end-of-life process|
158830|NCT02955979|Other|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.~After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.~Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
158831|NCT02955966|Device|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
158832|NCT02955966|Biological|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
158833|NCT02955953|Drug|LY2963016|Administered SC
158834|NCT02955940|Drug|Ruxolitinib|5 mg BID
158835|NCT02955940|Drug|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
158836|NCT02955940|Drug|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
158837|NCT02955927|Drug|0.01% atropine eye drops|
158838|NCT02955927|Device|ortho-k|
158839|NCT02955901|Other|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
158840|NCT02955901|Other|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
158841|NCT02955888|Drug|PBI4050|Investigational Medicinal Product
158842|NCT02955888|Drug|Placebo|Comparator
158843|NCT02955875|Behavioral|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
158844|NCT02955862|Other|Vietnam Cryptococcal Retention in Care Study (CRICS)|"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.~Other Names:~• Fluconazole"
158845|NCT02955849|Device|SLT laser|Patients will be offered initial SLT laser by doctors
158846|NCT02955823|Drug|Rituximab-Dexamethasone-Lenalidomide|"st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22~nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22~if <PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th~if <PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
158847|NCT02955810|Drug|Daratumumab|
158848|NCT02955810|Drug|Cyclophosphamide|
158849|NCT02955810|Drug|Bortezomib|
158850|NCT02955810|Drug|Dexamethasone|
158851|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
158852|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine|0.5 mL, Intramuscular
158853|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
158854|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine|0.5 mL, Intramuscular
158855|NCT02955784|Device|Sinasprite Mobile App|Mobile App
158856|NCT02955771|Combination Product|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
158857|NCT02955771|Combination Product|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
158858|NCT02955771|Device|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
158859|NCT02955758|Biological|Pembrolizumab|Given IV, 200mg fixed dose, every 3 weeks
158860|NCT02955745|Other|Iodine-129|The present study is an observational study and does not therefore include an investigational product in the proper sense because the used tracer (semi-stable iodine isotope) has no physiological effect on the participants. 129I will be used as tracer to measure appearance in plasma, urine and stools after the oral administered of the 129I-tracer.
158861|NCT02955732|Device|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
158862|NCT02955719|Drug|Sertraline|
158863|NCT02955719|Drug|Venlafaxine|
158864|NCT02955719|Other|CBT/Psychological Therapy|
158869|NCT02955693|Drug|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
158870|NCT02955680|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
158871|NCT02955680|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
158872|NCT02955667|Procedure|invivo microscopy group|patients receive invivo micro-colposcopy examination
158873|NCT02955667|Procedure|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
158874|NCT02955654|Behavioral|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
158875|NCT02955654|Drug|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
158876|NCT02955654|Behavioral|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
158877|NCT02955641|Drug|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
158878|NCT02955641|Drug|Nepafenac 0.1%|four drops a day for four days after LPI treatment
158879|NCT02955641|Drug|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
158880|NCT02955628|Drug|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
158881|NCT02955615|Drug|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.~SLE background therapy includes ..."
158882|NCT02955615|Drug|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.~SLE background therapy includes ..."
158883|NCT02955602|Drug|MBX-8025 2 mg Capsule|"Initial 8-week treatment:~• MBX-8025 2 mg~Extension:~The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
158884|NCT02955602|Drug|MBX-8025 5 mg Capsule|"Initial 8-week treatment:~• MBX-8025 5 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
158885|NCT02955602|Drug|MBX-8025 10 mg Capsule|"Initial 8-week treatment:~• MBX-8025 10 mg~Extension:~Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
158886|NCT02955589|Drug|HBI-8000|Oral, twice weekly
158887|NCT02955576|Device|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.~Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
158888|NCT02955576|Device|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.~The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
158889|NCT02955576|Other|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.~Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
158890|NCT02955563|Other|CSDM Web-Based Tool Intervention|The web and tablet-based tool is designed to help family members become familiar with ICU environment, routines, and clinicians, prepare for family meetings, and learn how to make values-based decisions for their loved one. The tool contains short videos, interactive exercises, and links to other resources. Family members work through the tool shortly after admission to the ICU, before each family meeting, and any other time they wish to during the ICU admission.
158891|NCT02955550|Drug|rhIL-2|Human recombinant Interleukin-2
158892|NCT02955550|Biological|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
158893|NCT02955537|Other|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
158894|NCT02955524|Drug|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
158895|NCT02955524|Drug|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
158896|NCT02955511|Device|Blade MAC size 3|Patient will be intubated using the DL- Blade MAC size 3
158897|NCT02955511|Device|Blade MAC size 3.5|Patient will be intubated using the DL- Blade MAC size 3.5
158898|NCT02955511|Device|Inscope Blade size 3.5|Patient will be intubated using the Inscope Blade size 3.5
158899|NCT02955498|Drug|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
158900|NCT02955498|Drug|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
158901|NCT02955485|Other|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
158902|NCT02955472|Drug|GLA5PR GLARS-NF3 tablet 150mg|A new formulation(3rd.) of Pregabalin CR tablet
158903|NCT02955472|Drug|GLA5PR GLARS-NF1 tablet 150mg|A new formulation(1st.) of Pregabalin CR tablet
158904|NCT02955459|Drug|VNRX-5133|
158905|NCT02955459|Drug|Placebo|
158906|NCT02955446|Drug|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
158907|NCT02955433|Other|Rideshare-based transportation|
158908|NCT02955420|Drug|BC 007|
158909|NCT02955420|Drug|NaCl 0.9 %|
158910|NCT02955407|Other|no intervention|observational case-control study
158911|NCT02955394|Drug|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
158912|NCT02955394|Drug|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
158913|NCT02955381|Device|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
158914|NCT02955381|Device|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
158915|NCT02955368|Drug|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
158916|NCT02955368|Drug|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
158917|NCT02955368|Drug|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
158918|NCT02955355|Biological|HYQVIA|Participants will receive subcutaneous (SC) HYQVIA/HyQvia which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
158919|NCT02955342|Other|no intervention|no intervention
158920|NCT02955329|Drug|Nicotine only|In the Nicotine only arm, participants will vape tobacco leaves with nicotine out of the PAX device.
158921|NCT02955329|Drug|THC only|In the THC only arm, participants will vape marijuana leaves with nicotine out of the PAX device.
158922|NCT02955329|Drug|Nicotine and THC|In the nicotine/THC arm, participants will vape marijuana leaves with THC combined with tobacco leaves with nicotine out of the PAX device.
158923|NCT02955329|Device|PAX Loose Leaf Vaporizer|In all three arms, the participant will be using the same PAX electronic cigarette device. The only difference is whether the participant will be vaping nicotine only, THC only, or nicotine and THC.
158924|NCT02955303|Other|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
158925|NCT02955290|Other|Laboratory Biomarker Analysis|Correlative studies
158926|NCT02955290|Biological|Nivolumab|Given IV
158927|NCT02955290|Biological|Pembrolizumab|Given IV
158928|NCT02955290|Biological|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
158929|NCT02955277|Other|TECH: Tablet Enhancement of Cognition and Health|TECH protocol - cognitive training using touchscreen tablet gaming applications
158930|NCT02955264|Dietary Supplement|D-Galactose|
158931|NCT02955251|Drug|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
158932|NCT02955251|Drug|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
158933|NCT02955238|Behavioral|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).~Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
158934|NCT02955225|Device|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
158935|NCT02955225|Device|Passive shoe insole|A deactivated insole measures shoe pressure only.
158936|NCT02955212|Drug|Upadacitinib|Oral formulation once daily
158937|NCT02955212|Drug|Placebo|Oral formulation once daily
158938|NCT02955199|Behavioral|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
158939|NCT02955199|Behavioral|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
158940|NCT02955186|Drug|Saracatinib|Saracatinib 125 mg once per day for 8 days
158941|NCT02955186|Drug|Placebos|Placebo once per day for 8 days
158942|NCT02955173|Procedure|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
158943|NCT02955160|Biological|Multivalent|Pneumococcal conjugate vaccine
158944|NCT02955160|Biological|Tdap|Tetanus, diphtheria, and pertussis vaccine
158945|NCT02955147|Drug|Ustekinumab|Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
158946|NCT02955147|Drug|Prednisone|Prednisone is an anti-inflammatory medication
158947|NCT02955134|Drug|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
158948|NCT02955134|Drug|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
158949|NCT02955134|Drug|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
158950|NCT02955134|Drug|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
158951|NCT02955121|Genetic|CYP2C19 genotyping|
158952|NCT02955108|Procedure|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
158953|NCT02955108|Procedure|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
158954|NCT02955095|Device|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
158955|NCT02955082|Drug|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
158956|NCT02955069|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 antibody directed against Programmed Death-1 (PD-1) receptor that blocks the binding of PD-L1 and PD-L2. PDR001 dose is 400 mg infusion every 4 weeks.
158957|NCT02955056|Drug|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
158958|NCT02955043|Behavioral|Behavioral techniques|"Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.~Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.~The intervention will be adapted to individual needs based on assessments of sleep and activity patterns."
158959|NCT02955030|Biological|NSV0001|sublingual
158960|NCT02955030|Biological|"Influenza HA vaccine Biken HA"|subcutaneous
158961|NCT02955030|Biological|Placebo|sublingual
158962|NCT02955017|Behavioral|traditional follow_up|"Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.~Two days of a complete medical check at 9 and 15 months"
158963|NCT02955017|Behavioral|"distance follow-up new technologies"|"Multidisciplinary support with long distance monitoring Mobile apps.~Two days of a complete medical check at 9 and 15 months"
158964|NCT02955004|Procedure|Electrical cardioversion|Transthoracic direct current electrical cardioversion
158965|NCT02954991|Drug|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
158966|NCT02954991|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
158967|NCT02954991|Drug|Mocetinostat|Mocetinostat is an HDAC inhibitor.
158968|NCT02954991|Drug|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
158969|NCT02954978|Drug|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
158970|NCT02954978|Drug|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
158971|NCT02954978|Drug|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
158972|NCT02954965|Behavioral|Reward|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
158973|NCT02954965|Behavioral|Approach|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
158974|NCT02954952|Device|PSI Rev 1.X|PSI Rev 1.X is an older version of the PSI measurement.
158975|NCT02954952|Device|PSI Rev 2.X|PSI Rev 2.X is a newer version of the PSI measurement.
158976|NCT02954939|Drug|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
158977|NCT02954939|Drug|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
158978|NCT02954926|Drug|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
158979|NCT02954913|Procedure|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
158980|NCT02954900|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
158981|NCT02954900|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
158982|NCT02954887|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
158983|NCT02954874|Other|Laboratory Biomarker Analysis|Correlative studies
158984|NCT02954874|Other|Patient Observation|Undergo standard monitoring
158985|NCT02954874|Biological|Pembrolizumab|Given IV
158986|NCT02954874|Other|Quality-of-Life Assessment|Ancillary studies
158987|NCT02954874|Other|Questionnaire Administration|Ancillary studies
158988|NCT02954874|Radiation|Radiation Therapy|Undergo radiation therapy
158989|NCT02954861|Other|No intervention|No intervention
158990|NCT02954848|Drug|Placebo|TAK-438 placebo-matching tablets
158991|NCT02954848|Drug|TAK-438 10 mg|TAK-438 tablets
158992|NCT02954835|Device|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
158993|NCT02954835|Device|Traditional Dressing|Sterile gauze dressing secured by tape.
158994|NCT02954822|Drug|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.~Glimepiride : Glimepiride 4mg QD~Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
158995|NCT02954822|Drug|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
158996|NCT02954809|Device|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
158997|NCT02954809|Device|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
158998|NCT02954796|Drug|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
158999|NCT02954783|Behavioral|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual wattmax, a personalized exercise program will be prescribed.~After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of wattmax for 1 min followed by recovery for 3 min at 30% of wattmax. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
159000|NCT02954783|Behavioral|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
159001|NCT02954757|Procedure|HIFU treatment|High intensity focused ultrasound
159002|NCT02954744|Procedure|HIFU treatment|High intensity focused ultrasound
159003|NCT02954731|Behavioral|UP-CBT|"Psychotherapy in groups based on the Unified Protocol a third generation CBT-type psychotherapy"
159004|NCT02954731|Behavioral|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
159005|NCT02954718|Other|activity training|
159006|NCT02954705|Other|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
159007|NCT02954692|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
159008|NCT02954692|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
159009|NCT02954692|Drug|sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
159010|NCT02954692|Drug|meglitinides|"Pharmaceutical form: tablet~Route of administration: oral"
159011|NCT02954692|Drug|thiazolidinediones|"Pharmaceutical form: tablet~Route of administration: oral"
159012|NCT02954692|Drug|alpha-glucosidase inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
159013|NCT02954692|Drug|GLP1 Receptor Agonist|"Pharmaceutical form: pen for injection~Route of administration: subcutaneous"
159014|NCT02954692|Drug|Dipeptidyl peptidase-IV (DPP-IV) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
159015|NCT02954692|Drug|Sodium-glucose transport-2 (SGLT-2) inhibitors|"Pharmaceutical form: tablet~Route of administration: oral"
159016|NCT02954679|Other|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
159017|NCT02954666|Device|radio-frequency ablation (nMARQ™ or Smart Touch™ catheter)|"Patients will undergo a tailored radio-frequency ablation of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.~The ablation procedure is considered complete when one of the following conditions is fulfilled:~P-P interval < 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval < 600 ms after 5 minute of waiting time; 5 radiofrequency applications > 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
159018|NCT02954653|Biological|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
159022|NCT02954653|Drug|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
159023|NCT02954640|Biological|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
159024|NCT02954627|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
159025|NCT02954614|Behavioral|Active play in after school programs (ASP)|"A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP~A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period"
159026|NCT02954601|Drug|ORMD-0801 (qd)|Dose 1 = ORMD-0801 (qd)
159027|NCT02954601|Drug|ORMD-0801 (bid)|Dose 2 = ORMD-0801 (bid)
159028|NCT02954601|Drug|ORMD-0801 (tid)|Dose 3 = ORMD-0801 (tid)
159029|NCT02954601|Other|Placebo|fish oil placebo
159030|NCT02954588|Dietary Supplement|Pyridoxamine|
159031|NCT02954588|Dietary Supplement|Placebo|
159032|NCT02954575|Drug|Wilate|
159033|NCT02954562|Other|fMRI|Participants will undergo two to three fMRI scans
159034|NCT02954549|Dietary Supplement|Vitamin D3|As in Arms
159035|NCT02954536|Drug|pembrolizumab|
159036|NCT02954536|Drug|trastuzumab|
159037|NCT02954536|Drug|capecitabine|
159038|NCT02954536|Drug|cisplatin|
159039|NCT02954536|Drug|Oxaliplatin|Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
159040|NCT02954536|Drug|5-Fluorouracil|Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
159041|NCT02954523|Drug|Dasatinib|oral every day
159042|NCT02954523|Drug|Osimertinib|oral every day
159043|NCT02954510|Drug|ferumoxytol|ferumoxytol will assess patency of coronary arteries
159044|NCT02954497|Device|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
159045|NCT02954497|Procedure|Surgical Placement of Jarvik 2015 VAD|Surgical Implant of the Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
159046|NCT02954484|Drug|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
159047|NCT02954484|Drug|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
159048|NCT02954484|Drug|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
159049|NCT02954484|Drug|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
159050|NCT02954484|Drug|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
159051|NCT02954484|Drug|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
159052|NCT02954458|Drug|TED|0.05 mg/kg SC injection once daily.
159053|NCT02954458|Other|SOC|Standard safety assessments and adjustments in nutritional support.
159054|NCT02954458|Device|Syringe|Teduglutide will be administered using syringe.
159055|NCT02954458|Device|Needle|Teduglutide will be administered using needle.
159056|NCT02954445|Biological|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
159057|NCT02954432|Device|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
159058|NCT02954432|Device|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
159059|NCT02954419|Other|No intervention|No intervention
159060|NCT02954406|Drug|TAK-659|TAK-659 immediate release tablet
159061|NCT02954406|Drug|Bendamustine|Bendamustine intravenous infusion
159062|NCT02954406|Drug|Rituximab|Rituximab intravenous infusion
159063|NCT02954406|Drug|Gemcitabine|Gemcitabine intravenous infusion
159064|NCT02954406|Drug|Lenalidomide|Lenalidomide capsule
159065|NCT02954406|Drug|Ibrutinib|Ibrutinib capsule
159159|NCT02953756|Radiation|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
164712|NCT02913300|Drug|Lignocaine 1% concentration solution|
159066|NCT02954393|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
159067|NCT02954393|Drug|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
159068|NCT02954393|Drug|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
159069|NCT02954393|Drug|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
159070|NCT02954393|Drug|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
159071|NCT02954393|Drug|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
159072|NCT02954393|Drug|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
159073|NCT02954380|Device|Zio|long term continuous monitoring
159074|NCT02954367|Dietary Supplement|PROTEIN|Immediately (<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
159075|NCT02954367|Dietary Supplement|CARBOHYDRATE|Immediately (<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
159076|NCT02954354|Drug|Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
159077|NCT02954354|Drug|Placebo to Baloxavir Marboxil|2 to4 X 20-mg tablets taken orally
159078|NCT02954354|Drug|Oseltamivir|75 mg capsules taken orally
159079|NCT02954354|Drug|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75 mg capsules
159080|NCT02954341|Device|CardioMEMS HF System|
159081|NCT02954328|Device|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
159082|NCT02954315|Other|Almonds|
159083|NCT02954302|Procedure|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
159084|NCT02954302|Procedure|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
159085|NCT02954289|Behavioral|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.~Session 2: Calcium and Vitamin D -Keys to Bone Health~Session 3: Fruits and Veggies -Your New Best Friends~Session 4: Let's Talk About Fat~Session 5: Shopping Therapy~Session 6: Celebrity Chefs Share Their Secrets"
159086|NCT02954276|Drug|Omexa Sublingual Sumatriptan tablet|75 mg
159087|NCT02954276|Drug|Imitrex Oral Product|100 mg
159088|NCT02954263|Drug|TD-1439|
159089|NCT02954263|Drug|Placebo|
159090|NCT02954250|Behavioral|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
159091|NCT02954237|Device|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
159092|NCT02954224|Other|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
159160|NCT02953743|Drug|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
159161|NCT02953730|Drug|PEG-rhG-CSF|
159162|NCT02953717|Radiation|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
159163|NCT02953717|Radiation|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
159211|NCT02953379|Drug|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
159093|NCT02954211|Device|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.~For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
159094|NCT02954211|Behavioral|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
159095|NCT02954198|Drug|Tacrolimus|goal trough level 5-12ng/mL
159096|NCT02954198|Drug|Prednisone|goal dose 5mg QD
159097|NCT02954198|Drug|Mycophenolate mofetil|goal dose 1g BID
159098|NCT02954198|Drug|Everolimus|goal trough level 3-8ng/mL
159099|NCT02954185|Device|WellClub|
159100|NCT02954185|Behavioral|Standard Therapy|
159101|NCT02954172|Drug|Bevacizumab in combination with Paclitaxel/Carboplatin|Drug Bevacizumab 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
159102|NCT02954172|Drug|Avastin in combination with Paclitaxel/Carboplatin|Drug Avastin 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
159103|NCT02954159|Drug|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
159104|NCT02954159|Drug|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
159105|NCT02954159|Other|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
159106|NCT02954146|Behavioral|Connectd mobile application|Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
159107|NCT02954133|Device|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
159108|NCT02954133|Device|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
159109|NCT02954133|Device|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
159110|NCT02954133|Device|Invisalign (3.5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 3.5 days.
159111|NCT02954120|Other|no intervention provided|
159112|NCT02954107|Other|MRI|
159113|NCT02954107|Other|24h-EEG + video|
159114|NCT02954107|Other|Neuropsychological tests|
159115|NCT02954081|Drug|Phase I: Fumaric acid esters. Phase II: Apremilast|Apremilast
159116|NCT02954068|Drug|IV Oxytocin + IM placebo|
159117|NCT02954068|Drug|IM Oxytocin + IV placebo|
159118|NCT02954055|Drug|Paclitaxel|Arm A
159119|NCT02954055|Drug|Cyclophosphamide|Arm B
159120|NCT02954055|Drug|Capecitabine|Arm B
159121|NCT02954055|Drug|Vinorelbine|Arm B
159122|NCT02954042|Device|Pelvital probe|Pelvital probe
159123|NCT02954042|Device|Placebo Probe|Placebo Probe
159124|NCT02954029|Device|ezClot (hemostasis pad)|ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.
159125|NCT02954029|Device|BloodSTOP ix pad|BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.
159126|NCT02954029|Device|Rotary compression device|Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
159127|NCT02954016|Device|ePass|Subject is implanted with the device for up to 3 years.
159128|NCT02954003|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
159129|NCT02953990|Behavioral|MOMS Program|
159130|NCT02953977|Behavioral|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
159164|NCT02953691|Drug|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
159165|NCT02953691|Drug|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
159166|NCT02953678|Drug|Ruxolitinib|
164713|NCT02913300|Drug|Lignocaine 2% concentration solution|
159131|NCT02953964|Other|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
159132|NCT02953964|Other|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
159133|NCT02953964|Other|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
159134|NCT02953951|Other|blood transfusion|blood transfusion different sources
159135|NCT02953938|Biological|Ranibizumab|"Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment"
159136|NCT02953938|Radiation|Grid&Direct short pulse laser photocoagulation|Grid&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
159137|NCT02953912|Procedure|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
159138|NCT02953912|Procedure|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
159139|NCT02953899|Behavioral|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
159140|NCT02953899|Behavioral|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
159141|NCT02953886|Device|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
159142|NCT02953873|Drug|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
159143|NCT02953873|Drug|Mycophenolate mofetil|≥500mg twice a day
159144|NCT02953873|Drug|Prednisone|goal dose 5mg daily
159145|NCT02953873|Drug|Mycophenolate Sodium|≥360mg twice a day
159146|NCT02953860|Drug|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
159147|NCT02953847|Drug|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
159148|NCT02953847|Drug|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
159149|NCT02953847|Drug|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
159150|NCT02953834|Drug|kisspeptin 112-121|Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
159151|NCT02953834|Other|Insulin Resistance Test|Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
159152|NCT02953834|Other|Placebo|Receive intravenous fluids for up to 16 hours that do not contain any study drug
159153|NCT02953821|Drug|Acthar Gel|1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)
159154|NCT02953821|Drug|Placebo Gel|1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
159155|NCT02953808|Drug|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
159156|NCT02953808|Drug|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
159157|NCT02953782|Drug|Hu5F9-G4|Hu5F9-G4 will be administered weekly.
159158|NCT02953782|Drug|Cetuximab|Cetuximab will be administered weekly.
159551|NCT02951078|Procedure|Thulium Laser en Bloc Resection of bladder tumor|
159167|NCT02953678|Drug|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
159168|NCT02953665|Drug|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
159169|NCT02953665|Drug|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
159170|NCT02953652|Drug|HBI-8000|Orally twice weekly
159171|NCT02953639|Drug|Basmisanil|Participants will receive either 80 milligrams (mg) or 240 mg of basmisanil twice daily orally for 24 weeks.
159172|NCT02953639|Drug|Placebo|Participants will receive placebo-matched to basmisanil orally twice daily for 24 weeks.
159173|NCT02953626|Behavioral|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
159174|NCT02953613|Device|NIRS/IVUS|Cardiac catheterization using infraredx
159175|NCT02953600|Dietary Supplement|Standard Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
159176|NCT02953600|Other|Zero Spirulina Platensis|the zero pill-taken group is a comparison for two other groups.
159177|NCT02953600|Dietary Supplement|Double Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
159178|NCT02953587|Procedure|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
159179|NCT02953587|Drug|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
159180|NCT02953587|Drug|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
159181|NCT02953574|Procedure|daily sleep enhancement nursing protocol|
159182|NCT02953561|Drug|Avelumab|Given IV
159183|NCT02953561|Drug|Azacitidine|Given SC or IV
159184|NCT02953561|Other|Laboratory Biomarker Analysis|Correlative studies
159185|NCT02953548|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
159186|NCT02953535|Drug|Magicbuvir|1 tablet contains 400 mg sofosbuvir
159187|NCT02953535|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
159188|NCT02953535|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
159189|NCT02953522|Other|191 mcg/day of Folate|Diet containing 191 mcg / day of Folate
159190|NCT02953522|Other|90 mcg / day of Folate|Diet containing 90 mcg / day of Folate
159191|NCT02953509|Drug|Hu5F9-G4|Hu5F9-G4 infusions will be administered weekly.
159192|NCT02953509|Drug|Rituximab|Rituximab infusions will be administered weekly for one cycle (28 days) and then every 4 weeks up to 6 cycles.
159193|NCT02953496|Drug|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
159194|NCT02953483|Other|Red blood cells|Packed red blood cells to final hematocrit of 14%
159195|NCT02953470|Behavioral|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
159196|NCT02953470|Behavioral|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
159197|NCT02953457|Biological|Durvalumab|Given IV
159198|NCT02953457|Other|Laboratory Biomarker Analysis|Correlative studies
159199|NCT02953457|Drug|Olaparib|Given PO
159200|NCT02953457|Biological|Tremelimumab|Given IV
159201|NCT02953444|Other|Thirty-Second Mindfulness Practice|
159202|NCT02953444|Other|Three-Minute Mindfulness Practice|
159203|NCT02953431|Device|CPAP|CPAP will be administered with a CPAP machine
159204|NCT02953418|Device|Radiofrequency ablation|RFA
159205|NCT02953405|Drug|Clopidogrel|
159206|NCT02953392|Device|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
159207|NCT02953392|Device|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
159208|NCT02953392|Device|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
159209|NCT02953392|Device|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
159210|NCT02953379|Drug|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
256749|NCT02241980|Other|Physician survey|
159212|NCT02953366|Drug|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
159213|NCT02953366|Drug|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
159214|NCT02953353|Device|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
159215|NCT02953353|Other|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
159216|NCT02953353|Other|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
159217|NCT02953340|Drug|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
159218|NCT02953340|Drug|Pegfilgrastim|Subcutaneous injection administered on Day 2 of each cycle.
159219|NCT02953340|Drug|Docetaxel|75mg/m^2 IV infusion administered on Day 1 of each cycle
159220|NCT02953340|Drug|Cyclophosphamide|600mg/m^2 IV infusion administered on Day 1 of each cycle
159221|NCT02953327|Biological|Bacille Calmette-Guerin|
159222|NCT02953327|Biological|BCG solvent|
159223|NCT02953314|Drug|VX-661|
159224|NCT02953314|Drug|Ivacaftor|
159225|NCT02953301|Drug|resminostat|
159226|NCT02953301|Drug|Placebo|
159227|NCT02953275|Drug|vedolizumab|standard of care
159228|NCT02953275|Drug|Pentoxifylline|added to vedolizumab
159229|NCT02953275|Drug|placebo|added to vedolizumab
159230|NCT02953262|Behavioral|Supported Adopted Intervention 1|Participants in this encouragement condition will receive a training guide with (a) insights from other Veterans on how to use My HealtheVet for diabetes self-management, (b) step-by-step guidance for how to sign up for My HealtheVet and, (c) detailed guidance on how to learn to use key features.
159231|NCT02953262|Behavioral|Supported Adopted Intervention 2|Participants will be offered optional attendance at a group training session. These sessions will be offered at least every other week at a computer lab at the VA hospital.
159232|NCT02953262|Behavioral|Supported Adopted Intervention 3|Participants will also be offered a one-on-one My HealtheVet training.
159233|NCT02953262|Behavioral|Attention Control Intervention 4|Participants will receive a mailed brochure with basic My HealtheVet content.
159234|NCT02953236|Procedure|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
159235|NCT02953236|Procedure|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
159236|NCT02953223|Other|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
159237|NCT02953210|Drug|dexter ketamine|multimodal anesthesia without opioids ketamine as induction drug
159238|NCT02953210|Drug|Lidocaine Hydrochloride|continuous infusion intravenous
159239|NCT02953210|Drug|Fentanyl Hydrochloride|intravenous
159240|NCT02953210|Drug|Clonidine Hydrochloride|clonidine intravenous pre induction
159241|NCT02953210|Drug|Midazolam Hydrochloride|premedication
159242|NCT02953210|Drug|Isoflurane Volatile Liquid|maintenance of general anesthesia
159243|NCT02953210|Drug|Rocuronium Injectable Solution|induction of general anesthesia
159244|NCT02953210|Drug|Propofol 1 % Injectable Suspension|induction of general anesthesia
159245|NCT02953210|Drug|Dexamethasone-21-Sulfobenzoate, Sodium Salt|at the end of the procedure 4mg IV
159246|NCT02953210|Drug|Ranitidine Hydrochloride|at the end of the procedure
159247|NCT02953210|Drug|Ondansetron Hydrochloride|at the end of the procedure
159248|NCT02953210|Drug|Ketorolac Injectable Solution|at the of the procedure
159249|NCT02953210|Drug|Bupivacaine Hydrochloride|at the end of the procedure for infiltration of trocar wounds
159250|NCT02953197|Radiation|FDG-PET guided radiation dose escalation|Selective dose escalation
159251|NCT02953184|Drug|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
159252|NCT02953184|Drug|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
159253|NCT02953184|Drug|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
159254|NCT02953184|Drug|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
159255|NCT02953184|Drug|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
159256|NCT02953184|Drug|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
159257|NCT02953184|Procedure|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
159258|NCT02953184|Procedure|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
159259|NCT02953184|Procedure|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
159471|NCT02951533|Drug|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
159260|NCT02953171|Other|Raw, lacto-fermented sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
159261|NCT02953171|Dietary Supplement|Mutaflor|The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
159262|NCT02953171|Other|Pasteurized sauerkraut|Sauerkraut without live bacteria.
159263|NCT02953171|Other|Placebo capsule|Capsules without probiotics
159264|NCT02953158|Other|Haas Avocado|Hypocaloric weight loss diet
159265|NCT02953158|Behavioral|Dietary Counseling|Dietary Counseling
159266|NCT02953145|Drug|Tisseel|Tisseel will be applied to open areas lateral to the cleft palate repair
159267|NCT02953132|Drug|MT-4129|
159268|NCT02953132|Drug|Placebo|
159269|NCT02953119|Other|Prehabilitation|
159270|NCT02953106|Drug|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
159271|NCT02953106|Drug|Placebos|Placebo nasal spray
159272|NCT02953093|Drug|Acarbose|see arm description
159273|NCT02953093|Other|Placebo|See arm description
159274|NCT02953080|Behavioral|Call for life using M health SMS|
159275|NCT02953067|Procedure|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
159276|NCT02953067|Procedure|Primary arthrodesis|Primary arthrodesis versus ORIF
159277|NCT02953067|Procedure|Conservative treatment|Conservative treatment versus open reduction and internal fixation
159278|NCT02953054|Drug|DMTS|DMTS applied before surgery and worn for 72 hours
159279|NCT02953054|Drug|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
159280|NCT02953041|Drug|Glycopyrronium|long-acting muscarinic antagonist
159281|NCT02953041|Drug|Indacaterol|ultra long-acting beta agonist
159282|NCT02953028|Device|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
159283|NCT02953028|Device|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
159284|NCT02953015|Behavioral|Manipulative articulatory (ART) and myofascial techniques|Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.
159285|NCT02953015|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
159286|NCT02953015|Drug|OnabotulinumtoxinA (Prophylaxis therapy)|Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
159287|NCT02953002|Device|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
159288|NCT02952989|Drug|SGN-2FF|SGN-2FF oral daily dosing.
159289|NCT02952989|Drug|pembrolizumab|200 mg every 3 weeks by IV infusion
159290|NCT02952976|Device|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
159291|NCT02952976|Device|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
159292|NCT02952963|Drug|Chenodeoxycholic Acid|
159293|NCT02952963|Drug|Colesevelam|
159294|NCT02952950|Other|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
159295|NCT02952937|Drug|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
159296|NCT02952937|Drug|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
159297|NCT02952924|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
159298|NCT02952924|Other|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
159299|NCT02952924|Drug|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
159552|NCT02951078|Procedure|Electrical transurethral resection of bladder tumor|
164847|NCT02912312|Other|Quality-of-Life Assessment|Ancillary studies
159300|NCT02952911|Device|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
159301|NCT02952898|Drug|GDC 695|GDC 695 is a topical gel.
159302|NCT02952898|Drug|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
159303|NCT02952898|Drug|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
159304|NCT02952885|Drug|Pegvisomant|Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their injections from 10 mg twice a week to 10 mg daily if used as combination therapy or 10 to 20 mg daily if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
159305|NCT02952872|Behavioral|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
159306|NCT02952859|Other|Irreversible electroporation|
159307|NCT02952846|Other|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
159308|NCT02952833|Drug|Saline|Sodium chloride solution.
159309|NCT02952833|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
159310|NCT02952820|Drug|lemborexant|
159311|NCT02952820|Drug|Placebo|
159312|NCT02952807|Drug|Misoprostol|vaginal Misoprostol Plus Foley Catheter
159313|NCT02952807|Device|Foley Catheter|
159314|NCT02952794|Procedure|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
159315|NCT02952781|Device|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
159316|NCT02952768|Behavioral|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
159317|NCT02952755|Drug|Co-administration of DWC20155/DWC20156|
159318|NCT02952755|Drug|DWC20162|
159319|NCT02952742|Drug|Black Cohosh|Vital Nutrients Black Cohosh Extract
159320|NCT02952742|Other|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
159321|NCT02952729|Drug|XMT-1522|one intravenous dose administered in-clinic every 21 days
159322|NCT02952716|Biological|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
159323|NCT02952716|Other|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
159324|NCT02952703|Behavioral|brief pre-delivery smoking cessation counseling|
159325|NCT02952703|Behavioral|additional pre-delivery smoking cessation counseling|
159326|NCT02952703|Behavioral|post- delivery smoking cessation counseling|
159327|NCT02952703|Behavioral|incentives|
159328|NCT02952690|Device|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
159329|NCT02952690|Device|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
159330|NCT02952677|Behavioral|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
159331|NCT02952677|Behavioral|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
159332|NCT02952677|Other|Control|Participants received usual care
159333|NCT02952664|Behavioral|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
159334|NCT02952651|Procedure|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
159335|NCT02952625|Other|Imaging|Single arm Imaging (PET/MR) study
159336|NCT02952599|Drug|Edoxaban|Prescribed according to approved label
159337|NCT02952586|Drug|Avelumab|Avelumab + SOC Chemoradiation
159338|NCT02952586|Other|Chemoradiation|Cisplatin + Radiation Therapy
159339|NCT02952573|Drug|JNJ-42756493|Once daily dosing
159340|NCT02952573|Drug|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
159341|NCT02952560|Other|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
159342|NCT02952547|Drug|Co-administration of DWC20155 and DWC20156|
159343|NCT02952547|Drug|DWJ1366 Tab.|
159344|NCT02952534|Drug|Rucaparib|Rucaparib will be administered daily
159345|NCT02952521|Procedure|Blood Draw|CA125 and ctDNA
159346|NCT02952521|Procedure|Tumor Tissue Biopsy|Only collected at time of surgery if patient undergoes surgical debulking
159347|NCT02952508|Drug|CLR 131 single dose|Radiopharmaceutical
159348|NCT02952508|Drug|CLR 131 multiple dose|Radiopharmaceutical
159425|NCT02951845|Drug|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 1.
159349|NCT02952495|Behavioral|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
159350|NCT02952482|Procedure|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
159351|NCT02952469|Drug|(68Ga)PSMA-HBED-CC|Experimental radiotracer for imaging prostate cancer
159352|NCT02952456|Other|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
159353|NCT02952443|Behavioral|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
159354|NCT02952443|Behavioral|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
159355|NCT02952430|Procedure|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
159356|NCT02952417|Other|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
159357|NCT02952404|Procedure|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
159358|NCT02952391|Other|[18F] FEOBV PET scan|Cholinergic PET scan with the tracer [18F]Fluoroethoxybenzovesamicol
159359|NCT02952378|Drug|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
159360|NCT02952365|Drug|Tissue sealant|Application of tissue sealant on eyes undergoing LASIK enhancement
159361|NCT02952352|Behavioral|Diabetes Prevention Program|Culturally adapted diabetes prevention program
159362|NCT02952339|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
159363|NCT02952339|Biological|Placebo|Administered as nose drops
159364|NCT02952326|Procedure|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
159365|NCT02952326|Procedure|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
159366|NCT02952313|Device|Nasal Implant|
159367|NCT02952300|Procedure|neolix|single rotation file
159368|NCT02952300|Procedure|wave one|single reciprocation file
159369|NCT02952287|Device|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
159370|NCT02952274|Device|mandibular overdenture retained with single midline implant using locator attachment|
159371|NCT02952274|Device|mandibular overdenture retained with single midline implant using ball attachment|
159372|NCT02952261|Device|template-guided localization|Based on CT data, digital model of the navigational template was created using CAD software and imported to 3D printer. The navigational template serves as a guider to the localizer in lung nodule localization.
159373|NCT02952261|Other|CT-guided localization|Percutaneous lung nodule localization was conducted under the real-time guidance of CT scan. This is the conventional method of transthoracic lung nodule localization.
159374|NCT02952248|Drug|BI 754091|
159375|NCT02952235|Other|SPF50+|Sun protection
159376|NCT02952235|Other|SPF100+|Sun protection
159377|NCT02952222|Drug|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
159378|NCT02952222|Drug|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
159379|NCT02952222|Drug|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
159380|NCT02952209|Device|Xenograft|
159381|NCT02952196|Drug|drug administration|administering drug to patient with amphetamine addiction
159470|NCT02951533|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
257278|NCT02237937|Drug|Venlafaxine|
159382|NCT02952183|Device|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.~Both PAMS I and IOM will be used for monitoring."
159383|NCT02952170|Other|MRI|MRI to assess hepatic steatosis
159384|NCT02952157|Drug|Lidocaine jelly application|
159385|NCT02952157|Drug|Normal saline application|
159386|NCT02952144|Device|Lixelle® treatment|The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
159387|NCT02952131|Procedure|Lipoaspiration|Closed Syringe Harvesting Autologous Subdermal Fat
159388|NCT02952131|Procedure|AD-cSVF|Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
159389|NCT02952131|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
159390|NCT02952118|Device|Forrest Snoring device|
159391|NCT02952092|Drug|roxadustat|Oral
159392|NCT02952092|Drug|Darbepoetin alfa|Intravenous
159393|NCT02952079|Device|Blephex|Lid margin exfoliation
159394|NCT02952079|Device|MiboFlo|Lid warming treatment
159395|NCT02952066|Procedure|Bronchial biopsy|Bronchial tissue taken during biopsy
159396|NCT02952053|Device|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
159397|NCT02952053|Device|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle. 10 fast in and fast out needle insertions."
159398|NCT02952040|Drug|ASP1517|Oral dose
159399|NCT02952040|Drug|Lanthanum carbonate hydrate|Oral dose
159400|NCT02952027|Behavioral|Use-recording, patient-reminder alarm for incentive spirometry|
159401|NCT02952014|Dietary Supplement|C4 Extreme|Pre-Workout Dietary Supplement
159402|NCT02952014|Dietary Supplement|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
159403|NCT02952014|Dietary Supplement|Placebo|Pre-Workout Dietary Supplement
159404|NCT02952001|Drug|4mg CLS-TA Suprachoriodal Injection|This drug was administered in the Parent study, CLS1001-301.
159405|NCT02951988|Drug|Rapastinel|Rapastinel pre-filled syringes for IV injections.
159406|NCT02951988|Drug|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
159407|NCT02951975|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
159408|NCT02951962|Drug|Twynsta 80/5mg|Hypertension
159409|NCT02951962|Drug|Crestor 20mg|Hyperlipidemia
159410|NCT02951936|Device|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.~If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
159411|NCT02951936|Device|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
159412|NCT02951923|Dietary Supplement|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
159413|NCT02951923|Dietary Supplement|Soy|
159414|NCT02951910|Device|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
159415|NCT02951897|Procedure|lobectomy|
159416|NCT02951897|Procedure|segmentecomy|
159417|NCT02951897|Drug|chemotherapy（pemetrexed+CISPLATIN）|
159418|NCT02951897|Procedure|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
159419|NCT02951897|Other|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E&M-) CTCs.
159420|NCT02951884|Procedure|Aspiration|A needle is placed into the knee joint and all of the blood that is in the joint is removed.
159421|NCT02951884|Drug|Bupivacaine|An injection of 20cc bupivacaine 0.5% with 1:200,00 epinephrine
159422|NCT02951858|Behavioral|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
159423|NCT02951858|Behavioral|Control Group|The participants only receive the materials about the harm of substance use.
159424|NCT02951845|Drug|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
159683|NCT02950103|Drug|Phosphoethanolamine|Phosphoethanolamine PO daily
159426|NCT02951845|Drug|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 2.
159427|NCT02951819|Drug|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.~Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.~Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
159428|NCT02951819|Drug|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m^2 ) on Days 1, 8, 15, and 22 for every 28 days.
159429|NCT02951819|Drug|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
159430|NCT02951819|Drug|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
159431|NCT02951806|Drug|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
159432|NCT02951806|Drug|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
159433|NCT02951793|Other|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C>4 versus AUDIT-C of 4 or below.
159434|NCT02951793|Other|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
159435|NCT02951793|Other|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
159436|NCT02951780|Drug|LY3185643|Administered SC
159437|NCT02951780|Drug|rGlucagon|Administered SC
159438|NCT02951767|Drug|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
159439|NCT02951754|Drug|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
159440|NCT02951741|Other|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
159441|NCT02951728|Drug|Rituximab|
159442|NCT02951728|Drug|Cyclophosphamide|
159443|NCT02951728|Drug|Doxorubicin|
159444|NCT02951728|Drug|Vincristine|
159445|NCT02951728|Drug|Prednisone|
159446|NCT02951728|Drug|Decitabine|
159447|NCT02951715|Drug|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
159448|NCT02951702|Drug|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
159449|NCT02951689|Dietary Supplement|Probiotic|
159450|NCT02951689|Dietary Supplement|Placebo|
159451|NCT02951676|Procedure|Extraction|Extraction of impacted third molar teeth
159452|NCT02951663|Dietary Supplement|Protein|
159453|NCT02951650|Device|Cyberonics VNS|Vagus nerve stimulation
159454|NCT02951637|Drug|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
159455|NCT02951637|Drug|Gefitinib|Gefitinib (250mg daily)
159456|NCT02951624|Behavioral|Control|Control intervention
159457|NCT02951624|Behavioral|Breaker|Short breaks of physical activity
159458|NCT02951624|Behavioral|Prolonger|longer breaks of physical activity
159459|NCT02951624|Behavioral|Intermediate|Intermediate breaks of physical activity
159460|NCT02951611|Procedure|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
159461|NCT02951611|Procedure|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
159462|NCT02951598|Drug|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
159463|NCT02951585|Device|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
159464|NCT02951585|Device|PLACEBO|Intra-articular injection of physiological serum (saline solution)
159465|NCT02951572|Device|NIV|
159466|NCT02951559|Device|Nasal Brushing|"Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril."
159467|NCT02951546|Dietary Supplement|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol <300 mg/day, dietary fiber 25 g/day.
159468|NCT02951546|Dietary Supplement|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
159469|NCT02951546|Other|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
164848|NCT02912312|Other|Questionnaire Administration|Ancillary studies
159472|NCT02951520|Procedure|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
159473|NCT02951507|Other|O T unilateral attachment|O T unilateral attachment system
159474|NCT02951507|Other|New design of extracoronal attachment system|O T unilateral attachment
159475|NCT02951494|Other|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
159476|NCT02951481|Behavioral|Systematic evaluation by an ID expert.|"Specific bundle of measures:~Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).~To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."
159477|NCT02951468|Procedure|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed [14]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
159478|NCT02951455|Behavioral|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
159479|NCT02951455|Behavioral|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
159480|NCT02951455|Behavioral|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
159481|NCT02951455|Behavioral|PF|Whether the intervention is delivered by a peer facilitator.
159482|NCT02951455|Behavioral|LC|Whether the intervention is delivered by a licensed clinician.
159483|NCT02951442|Biological|Biological sample|
159484|NCT02951442|Procedure|Non invasive Arterial investigations|
159485|NCT02951442|Procedure|Abdominal tomodensitometry|
159486|NCT02951429|Drug|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
159487|NCT02951429|Drug|Placebo|Placebo matched with sildenafil.
159488|NCT02951429|Drug|Sildenafil|Sildenafil will be given as 20 mg, TID.
159489|NCT02951416|Other|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
159490|NCT02951403|Procedure|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
159491|NCT02951403|Other|Conservative treatment|Physiotherapy protocol is introduced to patients.
159492|NCT02951390|Other|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
159493|NCT02951377|Other|Exercise (MDT approach)|Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
159494|NCT02951377|Drug|Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)|An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
159495|NCT02951364|Drug|LDV/SOF|90/400 mg tablet administered orally once daily
159496|NCT02951351|Drug|Proparacaine|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
159497|NCT02951351|Procedure|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
159498|NCT02951338|Behavioral|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
159542|NCT02951143|Drug|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 501) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 500) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
159543|NCT02951143|Drug|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
159544|NCT02951130|Drug|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
159499|NCT02951338|Other|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.~Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
159500|NCT02951325|Other|Adjuvant RT|"Radiation therapy:~All patients will be offered conformal technique with IMRT +/- image guidance. The adjuvant RT will start within 8 weeks from the date of surgery if chemotherapy not planned or 4 weeks from the date of last adjuvant chemo cycle.~Dose:~•50.4 Gray (Gy) in 28 fractions (1.8Gy/#) for the nodal PTV. For R1 and/or R2 resection increased to 54-56 Gy in 28 fractions based on the constraints achieved during planning.~Patient assessments:~Clinical:~Toxicity:~Weekly RT with toxicity scoring.~RTOG toxicity criteria at baseline, 6-8 weeks post RT and f/b 3 monthly x 2 years and 6 monthly x 5 years.~QOL will be assessed at baseline f/b 3-6 monthly.~Disease evaluation:~i. first f/u all patients will be at 6-8 week to assess toxicity. ii. Clinical evaluation of the disease will be done at each f/u visit. iii. CT scan (abdomen and pelvis) 6 monthly from visit 2 onwards up to 2 years f/b 12 monthly or as clinically indicated."
159501|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
159502|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
159503|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
159504|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
159505|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
159506|NCT02951312|Drug|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
159507|NCT02951312|Drug|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
159508|NCT02951299|Drug|Pentoxifylline 400Mg Tablet|Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
159509|NCT02951286|Device|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
159510|NCT02951286|Device|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
159511|NCT02951273|Other|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.~Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
159512|NCT02951260|Drug|Metformin|17 days treatment with metformin
159513|NCT02951260|Other|Placebo|17 days treatment with placebo
159514|NCT02951247|Device|Hearing Aid|Successor of Phonak Virto V90-10 NW O
159515|NCT02951234|Other|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
159516|NCT02951234|Other|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
159517|NCT02951221|Drug|BIIB074 Treatment A|Lower dose RCF fasted
159518|NCT02951221|Drug|BIIB074 Treatment B|Lower dose DCF fasted
159519|NCT02951221|Drug|BIIB074 Treatment C|Higher dose DCF fasted
159520|NCT02951221|Drug|BIIB074 Treatment D|Higher dose DCF fed
159521|NCT02951208|Device|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
159522|NCT02951208|Behavioral|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
159523|NCT02951208|Device|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
159524|NCT02951208|Behavioral|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
159525|NCT02951195|Drug|VX-152|
159526|NCT02951195|Drug|Tezacaftor|
159527|NCT02951195|Drug|Ivacaftor|
159528|NCT02951195|Drug|Triple Placebo|
159529|NCT02951195|Drug|Placebo for VX-152|
159530|NCT02951182|Drug|Tezacaftor|
159531|NCT02951182|Drug|Ivacaftor|
159532|NCT02951182|Drug|VX-440|
159533|NCT02951182|Drug|Matched Placebos|
159534|NCT02951169|Other|No intervention|No intervention. Treatment are accordance with clinical practice.
159535|NCT02951156|Biological|Avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
159536|NCT02951156|Biological|Utomilumab|Investigational, fully human IgG2 CD 137/4-1BB agonist
159537|NCT02951156|Biological|Rituximab|CD20-directed cytolytic antibody
159538|NCT02951156|Other|Azacitidine|Antimetabolite antineoplastic agent and demethylation agent.
159539|NCT02951156|Drug|Bendamustine|Alkylating drug
159540|NCT02951156|Drug|Gemcitabine|Nucleoside analogue
159541|NCT02951156|Drug|Oxaliplatin|Platinum-based drug
159545|NCT02951130|Drug|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
159546|NCT02951117|Drug|Venetoclax|Tablet
159547|NCT02951117|Drug|ABBV-838|Intravenous infusion
159553|NCT02951065|Other|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
159554|NCT02951065|Other|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
159555|NCT02951052|Drug|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
159556|NCT02951052|Drug|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
159557|NCT02951052|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
159558|NCT02951052|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
159559|NCT02951052|Drug|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:~INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)~NNRTI (either the initial or second cART regimen)~Boosted PI (or atazanavir [ATV] unboosted) (either the initial or second PI-based cART regimen)"
159560|NCT02951039|Drug|Edoxaban|Prescribed according to approved label
159561|NCT02951026|Other|Not applicable (no therapy is administered as part of this study)|"No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study."
159562|NCT02951013|Other|restrictive transfusion|Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
159563|NCT02951013|Other|liberal transfusion|
159564|NCT02951000|Procedure|platysma suture|
159565|NCT02951000|Procedure|no platysma suture|
159566|NCT02950987|Device|Whole Body MRI|
159567|NCT02950974|Drug|Sterofundin|Fluid loading
159568|NCT02950974|Drug|NSS|Fluid loading
159569|NCT02950961|Behavioral|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators will be offering in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators will be training appropriate MH providers in CALM and studying the ways in which the intervention needs to be tailored to women Veterans. The investigators will also examine the relative importance of patient preference with regard to engagement and retention in care.
159570|NCT02950948|Drug|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
159571|NCT02950948|Drug|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
159572|NCT02950935|Drug|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
159573|NCT02950935|Drug|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
159574|NCT02950922|Drug|RVT-501 0.2% ointment|
159575|NCT02950922|Drug|RVT-501 0.5% ointment|
159576|NCT02950922|Other|Vehicle ointment|Placebo comparator
159577|NCT02950909|Procedure|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
159578|NCT02950909|Procedure|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
159579|NCT02950909|Procedure|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
159580|NCT02950909|Procedure|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
159581|NCT02950896|Other|observational fetal heart rate monitoring|Patients will have fetal heart rate monitoring
159582|NCT02950883|Drug|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).~Other Names:~Hyper-Sal™, inhaled saline"
159684|NCT02950090|Behavioral|MobilWise|see arm description for MobilWise above
159685|NCT02950090|Behavioral|Fitbit Only|see arm description for Fitbit above
159583|NCT02950883|Drug|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.~Other Names: Normal saline"
159584|NCT02950870|Drug|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
159585|NCT02950870|Drug|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
159586|NCT02950870|Drug|Ribavirin|Patients will be treated with ribavirin if necessary.
159587|NCT02950857|Drug|EPEG|(Pegylated erythropoeitin)
159588|NCT02950844|Other|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.~In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
159589|NCT02950831|Other|Accelerometry|Record of activity levels using a wrist worn accelerometer
159590|NCT02950818|Behavioral|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of five two and a half hour group sessions and telephone counseling offered by a trained facilitator employed by the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators, to help them reach their goals.
159591|NCT02950805|Drug|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
159592|NCT02950805|Drug|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
159593|NCT02950792|Device|ViewRay MRI|ViewRay Magnetic Resonance Imaging
159594|NCT02950792|Radiation|Stereotactic Body Radiation Therapy Boost|In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors < 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors < 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) < 20 Gy with V20 < 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
159595|NCT02950779|Other|Handgrip Strength Measurement|
159596|NCT02950766|Drug|NeoVax|combination of Neoantigen peptides and poly-ICLC
159597|NCT02950766|Drug|Ipilimumab|local administration of ipilimumab
159598|NCT02950753|Drug|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
159599|NCT02950753|Drug|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
159600|NCT02950727|Device|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
159601|NCT02950727|Device|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
159602|NCT02950714|Other|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
159603|NCT02950714|Other|LIN_WAIT|Usual care for three months prior to access to the LIN
159604|NCT02950701|Device|Observational data collection.|
159605|NCT02950688|Biological|Seasonal LAIV|10^7.0 fluorescent focus units (FFU); administered by intranasal spray
159606|NCT02950688|Biological|Placebo|Administered by intranasal spray
159607|NCT02950688|Biological|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10^6 TCID50; administered intranasally
159608|NCT02950662|Other|Overdenture|Active comparator will be metal housing and peek housing
159609|NCT02950649|Device|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
159610|NCT02950649|Device|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
159611|NCT02950636|Other|Yoga|Restorative Yoga
159612|NCT02950623|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
159613|NCT02950623|Other|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
159614|NCT02950610|Device|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
159615|NCT02950597|Device|Observational Study to Evaluate Utility of Non-invasive Hemodynamic Monitoring|
159731|NCT02949817|Other|Conventional OT group|2. Conventional OT group will recieve the conventional occupational therapy and one more conventional occupational therapy additionally. The additional occupational therapy training will be performed 30 minutes daily 5 times per week, for 4 weeks.
159616|NCT02950584|Other|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
159617|NCT02950584|Other|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
159618|NCT02950571|Behavioral|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
159619|NCT02950571|Behavioral|Standard Care|High level of support from an interdisciplinary team.
159620|NCT02950558|Drug|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
159621|NCT02950558|Procedure|Nerve block|insertion of catheter to deliver continuous 5 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
159622|NCT02950545|Device|Placebo Lenses|AcuVue Oasys Bandage Lenses with no prescription
159623|NCT02950545|Device|Spherical Lenses|1-DAY ACUVUE® MOIST contact lenses
159624|NCT02950545|Device|Toric Lenses|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
159625|NCT02950532|Other|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
159626|NCT02950519|Other|monitoring of cuff pressures|Cuff pressure will be checked per standard and additionally a minimum of every 8 hours.
159627|NCT02950506|Device|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
159628|NCT02950506|Other|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
159629|NCT02950493|Other|perflutren lipid microsphere|Definity is tool for diagnosis used in echocardiography. Compare activated Definity with compressed Definity.
159630|NCT02950480|Drug|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
159631|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
159632|NCT02950467|Drug|Psilocybin|One individual oral psilocybin treatment session
159633|NCT02950467|Behavioral|Modified brief Supportive Expressive Group Therapy|Ten sessions of twice-weekly manualized group therapy
159634|NCT02950454|Other|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
159635|NCT02950454|Other|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
159636|NCT02950441|Dietary Supplement|Nicotinamide Riboside|
159637|NCT02950441|Other|Placebo|
159638|NCT02950428|Device|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
159639|NCT02950415|Behavioral|virtual|Parent is present via an internet pad (iPad)
159640|NCT02950415|Behavioral|coaching|Parent learns what to say verbally to soothe child
159641|NCT02950415|Behavioral|physical|Parent is present in the operating room
159642|NCT02950415|Behavioral|no coaching|Parent does not learn what to say verbally to soothe child
159643|NCT02950402|Other|Two Dried Plums per day|Subjects will consume Two Dried Plums per day
159644|NCT02950402|Other|Six Dried Plums per day|Subjects will consume Six Dried Plums per day
159645|NCT02950389|Device|PMMA filter|
159646|NCT02950389|Device|HFR17 filter|
159647|NCT02950389|Device|F7 filter|
159648|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
159649|NCT02950376|Other|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
159732|NCT02949804|Behavioral|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
159733|NCT02949791|Procedure|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
164849|NCT02912312|Radiation|Radiation Therapy|Undergo standard RNI
159650|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
159651|NCT02950337|Radiation|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
159652|NCT02950337|Radiation|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
159653|NCT02950337|Radiation|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
159654|NCT02950324|Behavioral|Prehabilitation|Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
159655|NCT02950324|Behavioral|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
159656|NCT02950311|Drug|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
159657|NCT02950311|Other|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
159658|NCT02950285|Other|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
159659|NCT02950259|Drug|Cyclophosphamide|One dose of cyclophosphamide 300 mg/m2 IV infusion
159660|NCT02950259|Drug|Indomethacin|Indomethacin 25 mg three times a day for 21 days
159661|NCT02950259|Drug|Omeprazole|One tablet of omeprazole daily for 21 days
159662|NCT02950259|Dietary Supplement|Multivitamin|Daily multivitamin containing 15-30 mg of zinc for 21 days.
159663|NCT02950246|Procedure|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
159664|NCT02950246|Drug|2% alcoholic chlorhexidine|
159665|NCT02950246|Drug|povidon iodine|
159666|NCT02950233|Drug|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
159667|NCT02950233|Drug|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
159668|NCT02950233|Drug|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID [first week]; 1 capsule BID [following three weeks]).
159669|NCT02950233|Drug|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
159670|NCT02950220|Drug|Ibrutinib|Given PO
159671|NCT02950220|Other|Laboratory Biomarker Analysis|Correlative studies
159672|NCT02950220|Biological|Pembrolizumab|Given IV
159673|NCT02950207|Genetic|miRNA|miRNA extraction
159674|NCT02950194|Procedure|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
159675|NCT02950181|Device|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
159676|NCT02950168|Procedure|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
159677|NCT02950155|Drug|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
159678|NCT02950155|Drug|Sodium Chloride solution|A single infusion of Placebo/Sham.
159679|NCT02950142|Other|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
159680|NCT02950142|Other|CPOE without order sets for lab testing|CPOE only
159681|NCT02950129|Other|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
159682|NCT02950116|Device|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~Patient's breathing pattern is stable for a minimum of 5 breaths~Start of washout by inhaling 100% oxygen (initiated by lab technician)~Continuous stable breathing pattern until end of washout test~End target = 1/40th of start N2 concentration~To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~Three N2-MBW-tests are performed consecutively. Time between each test is [duration of the previous test*1.5] (e.g. test duration = 6 min., time to next test = 6*1.5 = 9 min.)"
257279|NCT02237937|Drug|Amitriptyline|
159686|NCT02950077|Behavioral|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
159687|NCT02950064|Drug|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose~Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
159688|NCT02950051|Drug|Fludarabine|Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
159689|NCT02950051|Drug|Cyclophosphamide|Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
159690|NCT02950051|Biological|Rituximab|Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
159691|NCT02950051|Drug|Bendamustine|Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
159692|NCT02950051|Drug|Venetoclax|"Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)~cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d~cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d~cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d"
159693|NCT02950051|Biological|Obinutuzumab|"Obinutuzumab i.v.~cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d~cycles 2-6: 1000 mg, d1, q28d"
159694|NCT02950051|Drug|Ibrutinib|"Ibrutinib p.o.~cycles 1-12: 420 mg, d1-28, q28d~cycles 13-36: 420 mg, d1-28, q28d"
159695|NCT02950038|Drug|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
159696|NCT02950038|Drug|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
159697|NCT02950025|Device|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
159698|NCT02950025|Device|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
159699|NCT02950025|Other|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"30 questions~28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much~1 question asking about overall health with answers ranging from 1=very poor to 7 excellent~1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
159700|NCT02950012|Dietary Supplement|OPTI-BIOME™ Bacillus subtilis MB40|
159701|NCT02950012|Other|Placebo|
159702|NCT02949999|Drug|Voclosporin|
159703|NCT02949986|Behavioral|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
159704|NCT02949973|Drug|voclosporin|
159705|NCT02949960|Drug|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
159706|NCT02949960|Drug|Vehicle Control|Topical Vehicle Gel applied twice daily
159707|NCT02949947|Drug|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
159708|NCT02949947|Dietary Supplement|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
159709|NCT02949947|Behavioral|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
159710|NCT02949934|Drug|Tolcapone|
159711|NCT02949934|Drug|Placebo|
159712|NCT02949921|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
159713|NCT02949908|Drug|Rebif|Participants diagnosed with RRMS who had discontinued their oral or injectable first-line multiple sclerosis (MS) medication, and have been receiving subcutaneous Interferon beta-1a (IFNβ-1b) (Rebif) were observed during the study. Participants received Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
159714|NCT02949895|Drug|BMS-986012|
159715|NCT02949895|Drug|Cisplatin|
159716|NCT02949895|Drug|Etoposide|
159717|NCT02949882|Dietary Supplement|Yakult|Containing at least 6,5*10^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
159718|NCT02949882|Dietary Supplement|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
159719|NCT02949869|Other|Spinal Sonography|As described previously
159720|NCT02949856|Device|Mallinckrodt, COVIDIEN|
159721|NCT02949856|Device|Endotracheal tube, Unomedica|
159722|NCT02949843|Drug|Chemotherapy|Receive other treatment
159723|NCT02949843|Biological|Immunotherapy|Receive other treatment
159724|NCT02949843|Other|Laboratory Biomarker Analysis|Correlative studies
159725|NCT02949843|Biological|Nivolumab|Given IV
159726|NCT02949843|Biological|Pembrolizumab|Given IV
159727|NCT02949843|Drug|Targeted Molecular Therapy|Receive drug targeting secondary mutation
159728|NCT02949843|Drug|Tyrosine Kinase Inhibitor|Given PO
159729|NCT02949830|Drug|givosiran (ALN-AS1)|givosiran by subcutaneous (SC) injection
159730|NCT02949817|Device|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|1.The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with pediatric brain injury patients. 20 of All 40 children will receive the conventional occupational therapy and additional video-game based rehabilitation therapy, 30 minutes daily 5 times per week, for 4 weeks.
257280|NCT02237937|Drug|Escitalopram|
159734|NCT02949791|Other|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
159735|NCT02949791|Other|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
159736|NCT02949778|Procedure|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
159737|NCT02949778|Drug|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
159738|NCT02949778|Drug|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
159739|NCT02949765|Drug|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
159740|NCT02949765|Dietary Supplement|Iron-rich diet|
159741|NCT02949752|Drug|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
159742|NCT02949739|Behavioral|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
159743|NCT02949726|Drug|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
159744|NCT02949726|Device|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
159745|NCT02949713|Behavioral|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
159746|NCT02949700|Drug|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
159747|NCT02949687|Procedure|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
159748|NCT02949674|Drug|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
159749|NCT02949674|Drug|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
159750|NCT02949661|Procedure|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
159751|NCT02949661|Procedure|Local wound infiltration|Patients will receive local wound infiltration
159752|NCT02949648|Device|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
159753|NCT02949622|Behavioral|Multimodal intervention program|"The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
159754|NCT02949622|Other|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
159755|NCT02949609|Other|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
159756|NCT02949609|Other|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
159757|NCT02949596|Behavioral|Quality of life and quality of sexual life questionnaires|
159758|NCT02949583|Drug|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
159759|NCT02949583|Drug|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
159760|NCT02949570|Drug|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
159761|NCT02949557|Procedure|Decortication + bone grafts|
159762|NCT02949544|Other|water immersion|warm water immersion
159763|NCT02949531|Drug|oxygen|
159764|NCT02949518|Other|ERAS for Spine Pathway|The study team emphasizes that all components of the ERAS pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERAS pathway will receive these standard of care components.
159765|NCT02949505|Behavioral|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
159766|NCT02949492|Drug|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
159767|NCT02949479|Behavioral|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
159768|NCT02949466|Drug|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
159769|NCT02949466|Device|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
159770|NCT02949453|Behavioral|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:~first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour~second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
159771|NCT02949440|Procedure|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
159772|NCT02949440|Procedure|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
159773|NCT02949414|Procedure|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
159774|NCT02949401|Behavioral|Use of Virtual Reality App|The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
159775|NCT02949388|Drug|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
159776|NCT02949388|Drug|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
159777|NCT02949388|Drug|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
159778|NCT02949375|Drug|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
159779|NCT02949375|Drug|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
159780|NCT02949375|Drug|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
159781|NCT02949362|Drug|Teduglutide|0.05mg/kg
159782|NCT02949362|Other|SOC|Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
159783|NCT02949349|Drug|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
159784|NCT02949349|Drug|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
159785|NCT02949349|Drug|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
159786|NCT02949336|Radiation|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
159787|NCT02949323|Other|urinary stone|patients of group one have urinary stones
159788|NCT02949310|Drug|Nefopam|
159789|NCT02949310|Drug|Normal Saline|
159790|NCT02949297|Device|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
159791|NCT02949284|Drug|Abiraterone Acetate|Given PO
159792|NCT02949284|Drug|Androgen Receptor Antagonist ARN-509|Given PO
159793|NCT02949284|Biological|Gonadotropin-releasing Hormone Analog|Given SC
159794|NCT02949284|Drug|Prednisone|Given PO
159795|NCT02949284|Other|Quality-of-Life Assessment|Ancillary studies
159796|NCT02949284|Other|Questionnaire Administration|Ancillary studies
159797|NCT02949284|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
159798|NCT02949271|Other|Programmed Intermittent Epidural Bolus|
159799|NCT02949271|Other|Continuous Epidural Infusion|
159800|NCT02949271|Drug|Ropivacaine|
159801|NCT02949271|Drug|Fentanyl|
159802|NCT02949258|Drug|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
159803|NCT02949258|Drug|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
159804|NCT02949258|Drug|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
159805|NCT02949258|Drug|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
159806|NCT02949245|Procedure|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity~Routinely performed surgical correction of spinal deformity"
159807|NCT02949232|Drug|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
159808|NCT02949232|Drug|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
159809|NCT02949219|Other|Laboratory Biomarker Analysis|Correlative studies
159810|NCT02949219|Biological|Pembrolizumab|Given IV
159811|NCT02949206|Drug|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
159812|NCT02949206|Drug|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
159813|NCT02949206|Drug|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
159814|NCT02949193|Drug|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
159815|NCT02949193|Drug|Sitagliptin|sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
159816|NCT02949180|Device|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
160688|NCT02942459|Other|Music Listening|25 weekly Hours of Being Together with an unknown Care Staff Member
159817|NCT02949167|Behavioral|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
159818|NCT02949141|Device|Lung Ultrasound|All patients will receive lung ultrasound, chest x-ray and computed tomography
159819|NCT02949141|Device|Chest X-ray|All patients will receive chest x-ray as per usual care for evaluation for pneumonia
159820|NCT02949141|Device|Chest Computed Tomography (CT)|All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
159821|NCT02949128|Biological|ALXN1210|"Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.~≥ 40 to <60 kg: 2400 mg loading, then 3000 mg every 8 weeks~≥ 60 to <100 kg: 2700 mg loading, then 3300 mg every 8 weeks~≥100 kg: 3000 mg loading, then 3600 mg every 8 weeks"
159822|NCT02949115|Dietary Supplement|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
159823|NCT02949115|Dietary Supplement|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
159824|NCT02949115|Dietary Supplement|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
159825|NCT02949115|Dietary Supplement|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
159826|NCT02949102|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
159827|NCT02949102|Dietary Supplement|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
159828|NCT02949089|Drug|ACH04|The subjects will receive the study medication in each group
159829|NCT02949076|Behavioral|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
159830|NCT02949063|Behavioral|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
159831|NCT02949050|Biological|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
159832|NCT02949050|Biological|SCIT|Treatment group consists of patients who completed > 1 year of SCIT while control group patients did not undergo SCIT
159833|NCT02949037|Other|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
159834|NCT02949024|Drug|IVT Aflibercept|IVT aflibercept [2 mg (50 µL)]
159835|NCT02949024|Drug|SC CLS-TA|[4 mg (100 µL)]
159836|NCT02949011|Drug|Baloxavir Marboxil|Tablets taken orally
159837|NCT02949011|Drug|Placebo to Baloxavir Marboxil|Matching tablets taken orally
159838|NCT02949011|Drug|Oseltamivir|Capsules taken orally
159839|NCT02949011|Drug|Placebo to Oseltamivir|Matching placebo capsules taken orally
159840|NCT02948998|Drug|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
159841|NCT02948985|Other|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
159842|NCT02948972|Procedure|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
159843|NCT02948972|Procedure|In vitro fertilization without surgery|IVF without endometriosis surgery
159844|NCT02948959|Drug|Dupilumab|Pharmaceutical form:Solution Route of administration: subcutaneous
159845|NCT02948959|Other|Placebo|Pharmaceutical form:Solution Route of administration: subcutaneous
159846|NCT02948959|Drug|Asthma Controller Therapies (incl. prednisone/prednisolone)|Pharmaceutical form:Aerosol, capsules, tablets, oral solution Route of administration: inhaled, oral
159847|NCT02948959|Drug|Asthma Reliever Therapies|Pharmaceutical form:Nebulized, aerosol Route of administration: inhaled
159848|NCT02948946|Procedure|NETest|5 mL of blood will be drawn from participants for testing.
159849|NCT02948920|Drug|Ephedrine|9 mg of ephedrine (3 ml)
159850|NCT02948920|Drug|NSS|3 ml of normal saline
159851|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
159852|NCT02948894|Device|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
159853|NCT02948881|Drug|ibandronate|
159881|NCT02948634|Device|Active Phoenix Laser Treatment|The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
159854|NCT02948842|Drug|Clostridium Histolyticum Collagenase|0.08ml of XIAFLEX® (0.58 mg of XIAFLEX® mixed with 0.39 mL of sterile diluent) in a single location within the stricture, chased by an additional 0.25 mL of reconstituted XIAFLEX® to allow for clearance of the original 0.08 mL of reconstituted XIAFLEX® from the transurethral syringe into the urethral stricture. This is based on 0.25 mL residual fluid that remains within the lumen of the injeTAK syringe. Thus, by adding the additional 0.25 mL of XIAFLEX® as a chase, we are expecting the original total of 0.08 mL of XIAFLEX® to be injected into the area of scarring.
159855|NCT02948842|Other|Saline|0.08ml of injectable normal saline
159856|NCT02948829|Biological|Tetravalent Dengue Vaccine Candidate|TDV subcutaneous injection
159857|NCT02948816|Behavioral|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
159858|NCT02948816|Behavioral|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
159859|NCT02948816|Behavioral|Colouring|Participants will spend 30 minutes colouring quietly.
159860|NCT02948803|Behavioral|smartphone based intervention with Active Coach app|
159861|NCT02948790|Device|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
159862|NCT02948790|Device|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
159863|NCT02948777|Drug|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
159864|NCT02948764|Device|Vacuum-Assisted Biopsy|The vacuum-assisted (7-10G), minimal invasive biopsy (VAB), either guided by ultrasound, or by mammography (stereotaxy) during the second trial visit (V2) will be performed once. In analogy to the German S3 guideline on primary breast cancer management we recommend to take at least 12 biopsies with 10G needles or less in case of larger needle sizes.
159865|NCT02948738|Behavioral|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
159866|NCT02948738|Behavioral|Standard Asthma Education|Basic review of asthma action plan and inhaler use
159867|NCT02948725|Other|Cross-education + standard rehabilitation|
159868|NCT02948712|Behavioral|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
159869|NCT02948712|Behavioral|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
159870|NCT02948699|Dietary Supplement|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
159871|NCT02948686|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
159872|NCT02948686|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
159873|NCT02948686|Other|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
159874|NCT02948686|Other|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
159875|NCT02948673|Dietary Supplement|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
159876|NCT02948673|Other|Placebo|4 oral placebo tablets for 4 weeks
159877|NCT02948660|Other|zolpidem tartrate|
159878|NCT02948660|Other|melatonin|
159879|NCT02948647|Other|Standard of care plus sugar-reduction education|This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
159880|NCT02948634|Device|Sham Phoenix Laser Treatment|Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
159926|NCT02948192|Other|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
257281|NCT02237937|Drug|Amitriptylinoxide|
159882|NCT02948621|Procedure|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
159883|NCT02948595|Other|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
159884|NCT02948595|Other|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
159885|NCT02948582|Drug|Glycopyrrolate Inhalation Solution12.5μg|Glycopyrrolate Inhalation Solution12.5μg via eFlow, once daily
159886|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 50μg|Glycopyrrolate Inhalation Solution 50μg via eFlow, once daily
159887|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 100μg|Glycopyrrolate Inhalation Solution 100μg via eFlow, once daily
159888|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 200μg|Glycopyrrolate Inhalation Solution 200μg via eFlow, once daily
159889|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 400μg|Glycopyrrolate Inhalation Solution 400μg via eFlow, once daily
159890|NCT02948582|Drug|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
159891|NCT02948569|Drug|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
159892|NCT02948543|Biological|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
159893|NCT02948543|Drug|Mitomycin C (MMC)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
159894|NCT02948517|Other|Time restricted feeding|Time restricted feeding
159895|NCT02948504|Procedure|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
159896|NCT02948491|Other|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
159897|NCT02948478|Other|Exposed|Precarious patients
159898|NCT02948478|Other|Non exposed|Non precarious patients
159899|NCT02948452|Other|fMRI|fMRI: reward task, anxiety provocation
159900|NCT02948439|Other|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
159901|NCT02948426|Biological|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the MTD.
159902|NCT02948400|Behavioral|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
159903|NCT02948361|Other|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
159904|NCT02948348|Drug|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
159905|NCT02948322|Device|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
159906|NCT02948322|Drug|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
159907|NCT02948322|Procedure|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
159908|NCT02948309|Drug|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
159909|NCT02948309|Drug|Placebo|1ml subcutaneous injection 3 times/week
159910|NCT02948296|Device|medial prefrontal cortex|neuroimaging and craving will be assessed after medial prefrontal cortex stimulation
159911|NCT02948296|Device|dorsolateral prefrontal cortex|neuroimaging and craving will be assessed after dorsolateral prefrontal cortex stimulation
159912|NCT02948296|Device|sham stimulation|neuroimaging and craving will be assessed after sham stimulation
159913|NCT02948283|Other|Laboratory Biomarker Analysis|Correlative studies
159914|NCT02948283|Drug|Metformin Hydrochloride|Given PO
159915|NCT02948283|Other|Pharmacological Study|Correlative studies
159916|NCT02948283|Drug|Ritonavir|Given PO
159917|NCT02948283|Other|Quality-of-Life|Ancillary studies
159918|NCT02948283|Other|Questionnaire|Ancillary studies
159919|NCT02948257|Device|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
159920|NCT02948244|Dietary Supplement|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
159921|NCT02948244|Dietary Supplement|Placebo|Placebo
159922|NCT02948231|Device|Mistral implantation|Mistral Implant is implanted in the Mitral valve
159923|NCT02948218|Device|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
159924|NCT02948205|Procedure|3D group|infertility patient get TU-LESS by 3D Laparoscopy
159925|NCT02948205|Procedure|normal group|infertility patient get normal laparoscopic surgery
165754|NCT02905240|Device|nSTRIDE APS|single intra-articular injection
159927|NCT02948179|Procedure|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
159928|NCT02948166|Procedure|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
159929|NCT02948166|Procedure|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
159930|NCT02948153|Other|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
159931|NCT02948140|Procedure|MRI|
159932|NCT02948140|Procedure|Abdominal scanner|
159933|NCT02948127|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
159934|NCT02948127|Biological|Placebo|Administered as nose drops
159935|NCT02948114|Other|Control: Cow milk-based infant formula|
159936|NCT02948114|Other|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
159937|NCT02948114|Other|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
159938|NCT02948114|Other|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
159939|NCT02948101|Biological|Anti-CSF1 Monoclonal Antibody PD-0360324|Given IV
159940|NCT02948101|Drug|Cyclophosphamide|Given PO
159941|NCT02948101|Other|Laboratory Biomarker Analysis|Correlative studies
159942|NCT02948075|Drug|Quisinostat|
159943|NCT02948075|Drug|Paclitaxel|
159944|NCT02948075|Drug|Carboplatin|
159945|NCT02948036|Other|Mobile-device, plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (42 total sessions).
159946|NCT02948023|Biological|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
159947|NCT02948010|Device|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher & Paykel Healthcare CPAP Device
159948|NCT02948010|Device|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
159949|NCT02948010|Device|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
159950|NCT02948010|Device|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
159951|NCT02948010|Device|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
159952|NCT02948010|Device|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
159953|NCT02948010|Device|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
159954|NCT02948010|Device|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
159955|NCT02948010|Device|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
159956|NCT02947997|Device|OFDI capsule|Imaging of esophagus using OFDI capsule and system
159957|NCT02947984|Radiation|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
159958|NCT02947984|Radiation|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
159959|NCT02947971|Device|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
159960|NCT02947958|Other|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
159961|NCT02947958|Other|Hospital (control)|The patient will keep his usual care at the tertiary care.
159962|NCT02947945|Drug|Reslizumab|All subjects will receive Reslizumab
159963|NCT02947932|Drug|Resveratrol|pre-ERCP intervention
159964|NCT02947932|Drug|Indomethacin|post-ERCP intervention in high risk patients
159965|NCT02947919|Behavioral|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
159966|NCT02947906|Other|No intervention|No intervention
159967|NCT02947893|Drug|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
159968|NCT02947893|Drug|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
160689|NCT02942446|Device|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
159969|NCT02947880|Drug|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
159970|NCT02947880|Drug|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
159971|NCT02947867|Drug|aganirsen|aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
159972|NCT02947854|Drug|Fimaporfin (Photosensitizer)|
159973|NCT02947854|Biological|Hiltonol (Poly-ICLC)|
159974|NCT02947854|Biological|HPV E7 (Human Papilloma Virus E7) peptides|
159975|NCT02947854|Biological|KLH (Keyhole Limpet Hemocyanin)|
159976|NCT02947841|Other|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
159977|NCT02947841|Other|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
159978|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
159979|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
159980|NCT02947802|Other|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
159981|NCT02947802|Other|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
159982|NCT02947789|Procedure|Emergency surgery|Patients undergoing emergency surgery
159983|NCT02947776|Behavioral|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
159984|NCT02947776|Behavioral|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
159985|NCT02947763|Drug|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
159986|NCT02947750|Drug|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
159987|NCT02947750|Other|6R-BH4 placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
159988|NCT02947750|Dietary Supplement|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
159989|NCT02947750|Other|Exercise training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
159990|NCT02947750|Other|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
159991|NCT02947750|Dietary Supplement|Histidine and beta-alanine supplementation|Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
159992|NCT02947750|Other|Histidine and beta-alanine placebo|Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
159993|NCT02947737|Other|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
159994|NCT02947737|Other|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
159995|NCT02947724|Drug|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
159996|NCT02947711|Drug|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
159997|NCT02947711|Drug|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
159998|NCT02947685|Drug|palbociclib|o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
160032|NCT02947464|Device|Standard clinical practice + Rapid Maxillary Expansion|Mid-palatal suture osteogenic distraction delivered through a self-activated acrylic intraoral device custom-fit into the children´s palate and maxillary posterior teeth providing a transverse expansion of the dentofacial skeleton.
160752|NCT02942017|Drug|Placebo|Intravenous infusion of matching placebo for SAGE-547.
159999|NCT02947685|Drug|trastuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
160000|NCT02947685|Drug|pertuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
160001|NCT02947685|Drug|letrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
160002|NCT02947685|Drug|Anastrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
160003|NCT02947685|Drug|Exemestane|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
160004|NCT02947685|Drug|Fulvestrant|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
160005|NCT02947672|Drug|Intravenous Dexamethasone|
160006|NCT02947672|Drug|Intraperitoneal Dexamesathone|
160007|NCT02947646|Device|BabyGentleStick™ ON|
160008|NCT02947646|Device|BabyGentleStick™ OFF|
160009|NCT02947633|Drug|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
160010|NCT02947633|Drug|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.~Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
160011|NCT02947620|Drug|Metformin/Atorvastatin 1500mg/40mg, QD|
160012|NCT02947620|Drug|Metformin 1500mg, QD|
160013|NCT02947620|Drug|Atorvastatin 40mg, QD|
160014|NCT02947607|Procedure|Colon biopsies|
160015|NCT02947581|Drug|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
160016|NCT02947581|Drug|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
160017|NCT02947568|Other|non-interventional study|
160018|NCT02947555|Other|Non interventional|
160019|NCT02947542|Device|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
160020|NCT02947542|Device|Standard catheter|Coronary angiography will be performed using a standard catheter.
160021|NCT02947529|Drug|Tranexamic Acid|
160022|NCT02947529|Other|Placebo|
160023|NCT02947516|Procedure|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
160024|NCT02947516|Procedure|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
160025|NCT02947503|Drug|Metformin HCL 850 CF|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
160026|NCT02947490|Other|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
160027|NCT02947490|Other|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
160028|NCT02947490|Other|Standard BP management|GP to measure BP and manage BP control
160029|NCT02947490|Other|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
160030|NCT02947477|Behavioral|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
160031|NCT02947464|Procedure|Standard clinical practice|Control weight will be started in obese children to decrease upper airway resistance and airway collapsibility. Close follow-up in order to detect comorbidities.
257282|NCT02237937|Drug|Nortriptyline|
160033|NCT02947451|Other|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.~Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
160034|NCT02947451|Other|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
160035|NCT02947438|Drug|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
160036|NCT02947438|Drug|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
160037|NCT02947412|Other|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
160038|NCT02947399|Radiation|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
160039|NCT02947386|Other|Laboratory Biomarker Analysis|Correlative studies
160040|NCT02947386|Biological|Nimotuzumab|Given IV
160041|NCT02947386|Biological|Nivolumab|Given IV
160042|NCT02947373|Drug|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
160043|NCT02947360|Other|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
160044|NCT02947347|Drug|ibrutinib|ibrutinib 560mg administered orally
160045|NCT02947347|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
160046|NCT02947347|Drug|rituximab|rituximab 375mg/m^2 IV
160047|NCT02947347|Drug|ibrutinib|ibrutinib 560mg administered orally
160048|NCT02947347|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
160049|NCT02947347|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
160050|NCT02947334|Biological|Bococizumab|Bococizumab PFS
160051|NCT02947334|Drug|Placebo|Placebo
160052|NCT02947321|Procedure|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. RFA probes will be placed and connected to the RFA generator and the generator is activated. The RFA is performed.
160053|NCT02947321|Procedure|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
160054|NCT02947282|Other|Educational Workshop|They will attend a 2 hour class on pelvic floor health
160055|NCT02947269|Drug|Prucalopride|Prucalopride 2mg capsule
160056|NCT02947269|Drug|Placebo Oral Capsule|Placebo capsule
160057|NCT02947256|Procedure|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
160058|NCT02947256|Procedure|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
160059|NCT02947243|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
160060|NCT02947243|Drug|Morphine|As per unit's protocol
160061|NCT02947230|Other|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
160062|NCT02947217|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
160063|NCT02947217|Other|Sterile Saline|0.5 mL of sterile Saline administered im
160064|NCT02947204|Other|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
160065|NCT02947204|Other|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
160180|NCT02946320|Device|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
160066|NCT02947191|Biological|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
160067|NCT02947178|Procedure|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
160068|NCT02947178|Behavioral|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
160069|NCT02947178|Behavioral|Pill Count|Patient reported as needed (prn) pain medication usage
160070|NCT02947178|Drug|Bupivacaine|
160071|NCT02947178|Drug|Liposomal Bupivacaine|
160072|NCT02947165|Drug|NIS793|Anti-TGF beta antibody tested on a Q3W regimen or alternative Q2W regimen.
160073|NCT02947165|Drug|PDR001|Anti-PD-1 antibody tested on a Q3W regimen or alternative Q4W regimen.
160074|NCT02947152|Drug|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
160075|NCT02947139|Drug|Co-administration of DWC20155/DWC20156|
160076|NCT02947139|Drug|DWC20161|
160077|NCT02947126|Drug|Hypertonic Saline|Inhaled 7% Hypertonic saline
160078|NCT02947126|Drug|Isotonic Saline|Inhaled 0.9% Isotonic saline
160079|NCT02947126|Drug|Indium-DTPA|Inhaled Indium 111 DTPA
160080|NCT02947126|Drug|Technetium Sulfur Colloid|Inhaled Technetium99m sulfur colloid
160081|NCT02947113|Drug|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
160082|NCT02947113|Radiation|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
160083|NCT02947113|Drug|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
160084|NCT02947113|Drug|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
160085|NCT02947100|Drug|SCD-Omegatex™|"Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose."
160086|NCT02947087|Drug|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
160087|NCT02947087|Drug|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
160088|NCT02947074|Behavioral|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
160089|NCT02947061|Drug|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
160090|NCT02947061|Drug|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
160091|NCT02947048|Drug|L1-79|
160092|NCT02947048|Drug|Placebo|
160093|NCT02947035|Procedure|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
160094|NCT02947035|Procedure|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
160095|NCT02947022|Drug|Calcium DTPA|"On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
160096|NCT02947022|Drug|Zinc DTPA|"On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.~The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
160097|NCT02947009|Behavioral|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
160098|NCT02946996|Drug|Metformin|
160099|NCT02946996|Other|OPC|OPC is a derivative of grape seed extract
160100|NCT02946983|Other|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
160101|NCT02946983|Other|Control|Intragastric administration of distilled water
160102|NCT02946970|Other|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
160103|NCT02946970|Other|Control|Intragastric administration of distilled water
160104|NCT02946957|Behavioral|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
160105|NCT02946957|Behavioral|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
160317|NCT02945215|Drug|IBI301|IBI301 375mg/㎡
160106|NCT02946944|Drug|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \ g + 10 mg apixaban 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
160107|NCT02946944|Drug|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
160108|NCT02946931|Drug|Prizbind|Idarucizumab
160109|NCT02946918|Drug|Levothyroxine|Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps
160110|NCT02946892|Drug|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
160111|NCT02946892|Drug|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
160112|NCT02946879|Biological|AAV OPTIRPE65|comparison of different doses of AAV RPE65
160113|NCT02946853|Procedure|Atrioventricular junctional (AVJ) ablation|RF energy delivery to AV node to create complete AV block
160114|NCT02946853|Device|Cardiac resynchronization therapy - defibrillator|Insertion of device capable of providing biventricular pacing and cardiac defibrillation
160115|NCT02946840|Device|FNA with 25 G Beacon needle|
160116|NCT02946827|Dietary Supplement|Balanced low FODMAPs /gluten free diet|
160117|NCT02946827|Dietary Supplement|Balanced gluten free diet|
160118|NCT02946814|Drug|essential oils|
160119|NCT02946814|Drug|essential oils without mouthwash|
160120|NCT02946814|Drug|sterile water|
160121|NCT02946801|Drug|Essential oils|
160122|NCT02946801|Drug|Essential oils without alcohol|
160123|NCT02946801|Drug|Sterile water|
160124|NCT02946788|Drug|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
160125|NCT02946762|Other|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
160126|NCT02946736|Behavioral|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
160127|NCT02946736|Behavioral|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
160128|NCT02946723|Procedure|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
160129|NCT02946723|Procedure|X-ray|Lead implantation surgery for SNM using X-ray technique
160130|NCT02946710|Biological|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
160131|NCT02946697|Behavioral|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
160132|NCT02946684|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
160133|NCT02946684|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
160134|NCT02946671|Biological|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
160135|NCT02946671|Biological|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
160136|NCT02946658|Procedure|lipoaspiration|Closed syringe harvesting subdermal fat
160137|NCT02946658|Procedure|ADcSVF|Isolation of AD-cSVF
160138|NCT02946658|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
160139|NCT02946645|Device|Neuromuscular Bite (orthotic/sub-lingual)|Bite is a device which simulates a set of properly positioned teeth
160140|NCT02946645|Procedure|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises~Place knuckle of index finger between top and bottom teeth.~Remove it, keeping the teeth separated one-knuckle apart.~Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
160141|NCT02946645|Other|Placebo|No interventions.
160142|NCT02946632|Drug|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
160143|NCT02946632|Drug|Stepwise add-on therapy|metformin -> glimepirde -> sitagliptin
160144|NCT02946619|Behavioral|Self-Regulation Condition|
160145|NCT02946619|Behavioral|Enhanced self-Regulation Condition|
160146|NCT02946606|Drug|GX-H9|Human growth hormone
160147|NCT02946606|Drug|Genotropin|Human growth hormone
160318|NCT02945215|Drug|Rituximab|Rituximab 375mg/㎡
165755|NCT02905240|Device|Saline|single intra-articular injection
160148|NCT02946593|Behavioral|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 & 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
160149|NCT02946593|Behavioral|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
160150|NCT02946580|Drug|MOVANTIK™ (naloxegol)|
160151|NCT02946580|Drug|Sugar Pill|
160152|NCT02946567|Other|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
160153|NCT02946567|Other|Generic Game|Participants will play a generic game without any particular information about hearing health care.
160154|NCT02946554|Biological|HepaStem|
160155|NCT02946541|Drug|evogliptin 5mg|evogliptin 5mg, QD
160156|NCT02946541|Drug|Placebo|Placebo, QD
160157|NCT02946528|Device|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
160158|NCT02946528|Device|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
160159|NCT02946515|Behavioral|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
160160|NCT02946515|Behavioral|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
160161|NCT02946502|Procedure|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
160162|NCT02946489|Drug|CI-581a|CI-581a will be administered in wk2 and potentially in wk 3 or 4.
160163|NCT02946476|Other|prognostic impact of non cardiac comorbidities|
160164|NCT02946463|Biological|Ravulizumab|All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to <60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to <100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
160165|NCT02946463|Biological|Eculizumab|All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
160166|NCT02946450|Drug|Other: Not applicable-observational study|
160167|NCT02946437|Drug|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
160168|NCT02946437|Drug|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
160169|NCT02946437|Drug|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
160170|NCT02946437|Device|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
160171|NCT02946424|Drug|Placebo Oral Capsule|12 month course of daily placebo
160172|NCT02946424|Drug|Simvastatin|12 month course of daily simvastatin
160173|NCT02946411|Procedure|Cardiac surgery|Glucose level will be measured after cardiac surgery.
160174|NCT02946385|Biological|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.
160175|NCT02946385|Biological|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
160176|NCT02946372|Procedure|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
160177|NCT02946359|Drug|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
160178|NCT02946346|Other|vaginal sampling|
160179|NCT02946320|Device|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
160366|NCT02944825|Drug|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
160181|NCT02946320|Device|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
160182|NCT02946307|Device|Restore DEB（dimeter>2.00 mm）|
160183|NCT02946307|Device|Resolute DES|
160184|NCT02946307|Device|Restore DEB（dimeter:2.00 mm）|
160185|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
160186|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
160187|NCT02946281|Behavioral|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
160188|NCT02946268|Drug|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
160189|NCT02946255|Behavioral|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions."
160190|NCT02946255|Behavioral|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
160191|NCT02946255|Behavioral|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
160192|NCT02946242|Device|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
160193|NCT02946229|Device|Ultrasound scan|Collection of ultrasound data sets that include routine ultrasound data (eg, extravascular lung fluid, cardiac velocity time integral and inferior vena cava) on the commercial GE Vivid S70 Ultrasound System which are used to test feasibility of next generation ultrasound algorithms being developed to process these data types.
160194|NCT02946216|Genetic|ctDNA analysis|
160195|NCT02946203|Other|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
160196|NCT02946203|Other|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
160197|NCT02946190|Biological|Pertagen® aP + Td-pur®|see arm/group descriptions
160198|NCT02946190|Biological|Boostrix® dTpa|see arm/group descriptions
160199|NCT02946177|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
160200|NCT02946177|Other|Sterile Saline|0.5 mL of sterile Saline administered im
160201|NCT02946164|Behavioral|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
160202|NCT02946151|Device|UNEEG implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link, providing continuous data on brain activity.
160203|NCT02946138|Radiation|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
160204|NCT02946125|Drug|MDD-administered EYN-1601|Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery
160205|NCT02946125|Drug|Phenylephrine 2.5% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop
160206|NCT02946125|Drug|Phenylephrine 10% Eyedrop|Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
160207|NCT02946099|Procedure|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
160208|NCT02946099|Procedure|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
160209|NCT02946086|Behavioral|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
160210|NCT02946086|Behavioral|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
160211|NCT02946073|Drug|buprenorphine|
160212|NCT02946073|Other|Placebo|
160213|NCT02946060|Other|Audiobooks|iPods with audiobooks
160214|NCT02946060|Other|Tempo-pace synchronized playlists|Playlists with or without RAS
160215|NCT02946060|Other|Usual Care|iPods containing either a silent track or white noise
160367|NCT02944825|Drug|No Intervention|No intervention
160216|NCT02946047|Drug|Ixazomib|Patients Will be given oral Ixazomib on days 1, 8 and 15 of a 28 day cycle. Additional cycles, dosing days may be added and dose increased based on patient tolerability.
160217|NCT02946034|Drug|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
160218|NCT02946034|Drug|Mavyret|12 weeks treatment with AbbVie Mavyret
160219|NCT02946021|Device|Head and neck garments for pneumatic compression device|Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds; and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
160220|NCT02946021|Drug|NIRFLI with ICG|Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
160221|NCT02946008|Radiation|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
160222|NCT02946008|Procedure|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
160223|NCT02945995|Procedure|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
160224|NCT02945982|Drug|Entecavir+Carvedilol+ Placebo|The subjects will be taking 1Carvedilol tablet per day at first week and 2 Carvedilol tablets per day from second week. At the same time,the subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 96 weeks.
160225|NCT02945982|Drug|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking 1Carvedilol tablet per day at first week and 2 Carvedilol tablets per day from second week. At the same time,the subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
160226|NCT02945982|Drug|Entecavir+Carvedilol+ Fuzheng Huayu +TCM analysis|The subjects will be taking 1Carvedilol tablet per day at first week and 2 Carvedilol tablets per day from second week. At the same time,the subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.During this time,the subjects will be taking herbal medicine under TCM analysis.
160227|NCT02945969|Behavioral|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
160228|NCT02945956|Drug|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 96 weeks.
160229|NCT02945956|Drug|Entecavir + Fuzheng Huayu|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
160230|NCT02945943|Other|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
160231|NCT02945943|Other|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
160232|NCT02945904|Procedure|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
160233|NCT02945891|Device|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
160234|NCT02945865|Other|Pain assessment|Pain assessment with assessment tools
160235|NCT02945852|Drug|apatinib|apatinib 500mg/d until progressive Disease
160236|NCT02945839|Drug|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
160237|NCT02945839|Behavioral|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
160238|NCT02945839|Behavioral|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
160239|NCT02945826|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
160240|NCT02945826|Device|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
160241|NCT02945813|Drug|Metformin|850mg PO BID; 48 weeks
160242|NCT02945813|Radiation|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
160243|NCT02945800|Drug|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m^2 intravenously (IV)
160244|NCT02945800|Drug|Gemcitabine|Gemcitabine: 1000 mg/m^2 intravenously (IV)
160245|NCT02945787|Behavioral|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
160246|NCT02945787|Behavioral|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet. Outcomes will be assessed through 24 months.
160247|NCT02945774|Radiation|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
160248|NCT02945761|Procedure|High concentration of sugar solution|
160249|NCT02945761|Procedure|conventional surgical dressing change|
160250|NCT02945735|Behavioral|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
166463|NCT02899338|Drug|BI695501Autoinjector|
160251|NCT02945722|Drug|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
160252|NCT02945722|Other|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
160253|NCT02945709|Behavioral|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
160254|NCT02945709|Behavioral|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
160255|NCT02945709|Behavioral|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
160256|NCT02945696|Procedure|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
160257|NCT02945696|Drug|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
160258|NCT02945683|Dietary Supplement|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
160259|NCT02945683|Dietary Supplement|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
160260|NCT02945670|Behavioral|Focus Group|We had recruited 64 women and completed 7 focus group sessions
160261|NCT02945657|Drug|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
160262|NCT02945644|Drug|Trazodone|take at bedtime for 14 days
160263|NCT02945644|Drug|Placebo|take at bedtime for 14 days
160264|NCT02945631|Radiation|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
160265|NCT02945631|Radiation|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
160266|NCT02945618|Device|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.~Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
160267|NCT02945618|Other|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
160268|NCT02945605|Other|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:~Eye-Head coordination, gaze stability and convergence exercises~Sitting balance~Standing static balance (i.e. feet-in-place)~Dynamic balance (feet moving, but not walking)~Ambulation (gait exercises)~Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
160269|NCT02945605|Other|Standard of Care|Standard care as directed by a physician.
160270|NCT02945592|Behavioral|Cueing|
160271|NCT02945579|Radiation|External Beam Radiation Therapy|Undergo EBRT
160272|NCT02945579|Other|Laboratory Biomarker Analysis|Correlative studies
160273|NCT02945579|Other|Quality-of-Life Assessment|Ancillary studies
160274|NCT02945579|Other|Questionnaire Administration|Ancillary studies
160275|NCT02945579|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
160276|NCT02945566|Procedure|Standard TME surgery|Total mesorectal excision
160277|NCT02945566|Drug|Long course concurrent chemoradiation|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
160278|NCT02945566|Radiation|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
160279|NCT02945553|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
160280|NCT02945553|Device|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
160281|NCT02945527|Drug|Acetazolamide|As described above
160282|NCT02945527|Drug|Dexamethasone|As described above
160283|NCT02945514|Other|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
160753|NCT02942017|Drug|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547
160284|NCT02945501|Device|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
160285|NCT02945501|Device|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
160286|NCT02945488|Other|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
160287|NCT02945488|Other|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
160288|NCT02945488|Other|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
160289|NCT02945462|Biological|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
160290|NCT02945449|Biological|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
160291|NCT02945436|Behavioral|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
160292|NCT02945436|Behavioral|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
160293|NCT02945410|Other|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
160294|NCT02945410|Other|Protein|Participants will consume 1.7 g protein/kg BW/day.
160295|NCT02945410|Other|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
160296|NCT02945410|Dietary Supplement|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
160297|NCT02945410|Other|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
160298|NCT02945397|Behavioral|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
160299|NCT02945397|Behavioral|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
160300|NCT02945384|Behavioral|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
160301|NCT02945371|Behavioral|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
160302|NCT02945371|Behavioral|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
160303|NCT02945358|Procedure|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
160304|NCT02945332|Behavioral|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
160305|NCT02945332|Behavioral|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
160306|NCT02945332|Device|Fitbit Flex|
160307|NCT02945306|Procedure|Adenotonsillectomy|
160308|NCT02945306|Drug|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
160309|NCT02945293|Other|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
160310|NCT02945280|Drug|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
160311|NCT02945267|Drug|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
160312|NCT02945267|Drug|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
160313|NCT02945254|Device|NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)|
160314|NCT02945241|Drug|Vancomycin|Intravenous
160315|NCT02945241|Other|Cystatin C dosing algorithm|Expressed in milliliters per minute
160316|NCT02945241|Other|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
160319|NCT02945202|Device|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
160320|NCT02945202|Device|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
160321|NCT02945202|Device|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
160322|NCT02945176|Device|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
160323|NCT02945163|Drug|Tenofovir|Tenofovir Disoproxil Fumarate
160324|NCT02945163|Drug|Lamivudine|Lamivudine
160325|NCT02945163|Drug|Efavirenz|Efavirenz
160326|NCT02945150|Drug|grazoprevir plus elbasvir (fixed dose combination)|HCV treatment for 12 to 16 weeks. Treatment length based upon presence of baseline resistance associated variant in the HCV virus
160327|NCT02945124|Other|K tape|Applying K tape to children to the lower limb muscles during motor activities.
160328|NCT02945111|Behavioral|Real-time view|
160329|NCT02945111|Behavioral|No visual support|
160330|NCT02945098|Other|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
160331|NCT02945098|Other|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
160332|NCT02945085|Other|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
160333|NCT02945085|Other|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
160334|NCT02945072|Procedure|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
160335|NCT02945072|Procedure|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
160336|NCT02945059|Procedure|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
160337|NCT02945046|Drug|Fremanezumab - A|Subcutaneous injection
160338|NCT02945046|Drug|Fremanezumab - B|Intravenous infusion followed by subcutaneous injection
160339|NCT02945046|Drug|Placebo|Matching placebo
160340|NCT02945033|Drug|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
160341|NCT02945033|Drug|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
160342|NCT02945033|Procedure|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
160343|NCT02945033|Biological|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
160344|NCT02945033|Biological|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
160345|NCT02945020|Drug|Dabigatran etexilate mesylate|Participants will receive dabigatran etexilate mesylate 75 mg, orally.
160346|NCT02945020|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg, orally.
160347|NCT02945020|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg, orally.
160348|NCT02945007|Drug|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
160349|NCT02944994|Other|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
160350|NCT02944994|Other|Routine Care|This arm will reflect typical care received in routine mental health care
160351|NCT02944981|Drug|Gabapentin|Single oral dose
160352|NCT02944981|Drug|Placebo|Single oral dose
160353|NCT02944968|Device|THERMOCOOL SMARTTOUCH® SF-5D catheter|
160354|NCT02944955|Drug|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).~Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
160355|NCT02944942|Procedure|General anesthesia|Patients undergoing general anesthesia
160356|NCT02944929|Other|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
160357|NCT02944916|Device|IryPump R Set|
160358|NCT02944903|Other|Audit|Questionnair
160359|NCT02944890|Device|Drug Eluting Balloon Catheters(RESTORE DEB）|
160360|NCT02944890|Device|Drug Eluting Balloon Catheters(SeQuent® Please）|
160361|NCT02944877|Behavioral|Harnessing Online Peer Education (HOPE) Social Media Intervention|
160362|NCT02944864|Drug|TQ-B3395|TQ-B3395 p.o. qd
160363|NCT02944838|Behavioral|Senior Change Makers Advocacy Program|see description
160364|NCT02944838|Behavioral|Senior Change Makers Physical Activity Program|see description
160365|NCT02944825|Drug|Ciprofloxacin|first line prophylactic oral antibiotic
160973|NCT02940444|Drug|Heparin|
160368|NCT02944812|Drug|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
160369|NCT02944799|Drug|Placebo|Discontinuation of alendronate treatment
160370|NCT02944799|Drug|Alendronate|
160371|NCT02944799|Drug|Calcium|Daily dietary supplement of 800mg calcium
160372|NCT02944799|Drug|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
160373|NCT02944786|Behavioral|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
160374|NCT02944773|Procedure|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
160375|NCT02944760|Other|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
160376|NCT02944747|Behavioral|Education & paper based calendar|The participants will be counseled on importance of remembering LMP. In addition, they will be provided a free calendar to record their LMP dates.
160377|NCT02944747|Behavioral|Education & SMS system|The participants will be counseled on importance of remembering LMP. They will be asked to send the LMP date via SMS. Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
160378|NCT02944747|Behavioral|Education & smart-phone application|The participants will be counseled on importance of remembering LMP. Participants will be asked to record the LMP on a calendar app. This will be transferred to central server via internet Participants will be reminded via SMS if they have not sent their dates (max -3 reminders)
160379|NCT02944734|Drug|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
160380|NCT02944734|Drug|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
160381|NCT02944734|Drug|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
160382|NCT02944734|Drug|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
160383|NCT02944721|Genetic|Genetical analyses|
160384|NCT02944721|Other|Chronic pain identification questionnaires|
160385|NCT02944721|Other|Neurophysiological and psychophysical evaluations|
160386|NCT02944721|Other|Quality of life questionnaires|
160387|NCT02944708|Drug|Conventional chemotherapy|
160388|NCT02944708|Drug|Maintenance chemotherapy 1|
160389|NCT02944708|Drug|Maintenance chemotherapy 2|
160390|NCT02944695|Other|audit|Practice adherence to guidelines
160391|NCT02944682|Other|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 18 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
160392|NCT02944669|Device|ReWalk Personal Device|
160393|NCT02944656|Drug|Gabapentin|Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
160394|NCT02944656|Drug|Placebo|Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
160395|NCT02944643|Other|Mindfulness and Support Groups|
160396|NCT02944630|Behavioral|Psychotherapy|Individual psychotherapy
160397|NCT02944617|Other|Laboratory Biomarker Analysis|Correlative studies
160398|NCT02944617|Dietary Supplement|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
160399|NCT02944617|Drug|VEGF‐TKI|Must be received as standard of care chemotherapy
160400|NCT02944604|Drug|PEG-rhG-CSF|
160401|NCT02944591|Device|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
160402|NCT02944578|Drug|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.~Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules at bedtime every day (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
160403|NCT02944578|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules at bedtime every day (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.~Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
160404|NCT02944565|Biological|Daratumumab|Given IV
160494|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks & 9 months
257283|NCT02237937|Drug|Trimipramine|
160405|NCT02944552|Drug|bicyclol tablet 25mg|Patients in the low dose group administrated bicyclol tablet 25mg, one bicyclol blank analog tablet and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
160406|NCT02944552|Drug|bicyclol tablet 50mg|Patients in the high dose group administrated bicyclol tablet 50mg and two polyene phosphatidylcholine blank analog capsules orally, three times daily for 4-8 weeks.
160407|NCT02944552|Drug|polyene phosphatidylcholine capsule 456mg|Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
160408|NCT02944526|Drug|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
160409|NCT02944526|Drug|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
160410|NCT02944513|Device|Quell|
160411|NCT02944500|Drug|liraglutide|
160412|NCT02944500|Other|Placebo|
160413|NCT02944487|Drug|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
160414|NCT02944487|Drug|Placebo|Matching placebo capsules
160415|NCT02944474|Drug|Lucerastat|Capsule for oral administration containing lucerastat
160416|NCT02944474|Drug|Placebo|Placebo capsules matching lucerastat capsules
160417|NCT02944461|Drug|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
160418|NCT02944448|Drug|CR845 tablet 1 mg|CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
160419|NCT02944448|Drug|CR845 tablet 2.5 mg|CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
160420|NCT02944448|Drug|CR845 tablet 5 mg|CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
160421|NCT02944448|Drug|Placebo tablet|Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
160422|NCT02944435|Drug|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
160423|NCT02944435|Drug|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
160424|NCT02944409|Device|total knee prothesis VEGA System|total knee replacement
160425|NCT02944396|Drug|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
160426|NCT02944396|Drug|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
160427|NCT02944396|Drug|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
160428|NCT02944396|Drug|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
160429|NCT02944396|Drug|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
160430|NCT02944383|Drug|Gemcabene|
160431|NCT02944383|Drug|Placebo Oral Tablet|
160432|NCT02944370|Behavioral|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
160433|NCT02944357|Drug|Cisplatin|Given IV
160434|NCT02944357|Drug|Gemcitabine Hydrochloride|Given IV
160435|NCT02944357|Procedure|Radical Cystectomy|Undergo cystectomy
160436|NCT02944357|Biological|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
160437|NCT02944344|Behavioral|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
160438|NCT02944331|Procedure|Endovenous steam ablation|
160439|NCT02944318|Behavioral|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
160440|NCT02944305|Procedure|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
160441|NCT02944292|Procedure|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
160442|NCT02944292|Drug|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.~All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
160443|NCT02944266|Other|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
160444|NCT02944253|Other|Low energy diet 70g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 70 gram carbohydrates
160445|NCT02944253|Other|Low energy diet 100g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 100 gram carbohydrates
160446|NCT02944253|Other|Low energy diet 130g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 130 gram carbohydrates
160447|NCT02944227|Drug|Lucentis|Lucentis fixed-treatment arm
160448|NCT02944214|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
160449|NCT02944214|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
160450|NCT02944201|Drug|Carvedilol|Carvedilol will give twice daily until prostatectomy
160495|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6&14 weeks & 9 months
258799|NCT02226406|Other|C: Walk in place|
160451|NCT02944188|Procedure|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
160452|NCT02944188|Procedure|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
160453|NCT02944175|Drug|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
160454|NCT02944175|Drug|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
160455|NCT02944162|Biological|anti-CD33 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
160456|NCT02944149|Procedure|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
160457|NCT02944136|Behavioral|enhanced usual care|usual care from health providers
160458|NCT02944136|Behavioral|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
160459|NCT02944123|Drug|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
160460|NCT02944123|Drug|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
160461|NCT02944123|Drug|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
160462|NCT02944110|Drug|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
160463|NCT02944110|Drug|Placebo|Oral dose of placebo tablets
160464|NCT02944097|Dietary Supplement|Vineatrol 30 native powder|
160465|NCT02944097|Dietary Supplement|Vineatrol 30 micelles|
160466|NCT02944084|Dietary Supplement|Rice bran extract|
160467|NCT02944084|Dietary Supplement|Porridge in water|
160468|NCT02944084|Dietary Supplement|Porridge in milk|
160469|NCT02944071|Device|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
160470|NCT02944058|Procedure|Multiloc nail|Intervention is surgery with Multiloc nail
160471|NCT02944058|Procedure|Philos plate|Intervention is surgery with Philos plate
160472|NCT02944045|Drug|Methylprednisolone|"Methylprednisolone intra veinous~Day 1 to 5 : 30mg twice per day~Day 6 to 10 : 30mg per day~Day 11 to 21 : 20mg per day"
160473|NCT02944045|Drug|Placebo|saline serum
160474|NCT02944032|Other|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
160475|NCT02944032|Other|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
160476|NCT02944019|Drug|Edoxaban|Prescribed according to approved label
160477|NCT02944006|Procedure|multi-parametric MRI|multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.
160478|NCT02943993|Drug|Edoxaban|Prescribed according to approved label
160479|NCT02943980|Device|CMAC Videolaryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
160480|NCT02943980|Device|Macintosh Laryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
160481|NCT02943967|Procedure|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
160482|NCT02943967|Procedure|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
160483|NCT02943954|Procedure|Angiography guided PCI|
160484|NCT02943954|Device|Fractional Flow Reserve (FFR)|
160485|NCT02943941|Other|Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
160486|NCT02943928|Device|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
160487|NCT02943928|Device|traditional method by experience|Operator inserted the double lumen tube by experience
160488|NCT02943915|Device|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
160489|NCT02943915|Device|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
160490|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks & 9 months
160491|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks & 9 months
160492|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6&14 weeks & 9 months
160493|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks & 9 months
160496|NCT02943889|Biological|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
160497|NCT02943876|Other|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
160498|NCT02943863|Device|HFNC followed by conventional nasal cannula|
160499|NCT02943863|Device|Conventional nasal cannula followed by HFNC|
160500|NCT02943850|Biological|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
160501|NCT02943850|Device|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
160502|NCT02943837|Procedure|Device: 22G FNA needle|
160503|NCT02943837|Procedure|Device: 20G FNB needle|
160504|NCT02943824|Other|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
160505|NCT02943824|Other|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
160506|NCT02943811|Device|UTERINE MANIPULATOR|Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
160507|NCT02943798|Drug|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
160508|NCT02943798|Drug|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
160509|NCT02943785|Drug|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
160510|NCT02943785|Drug|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
160511|NCT02943772|Other|Local hypothermia|Cooled brick
160512|NCT02943772|Other|Control|Control brick
160513|NCT02943759|Drug|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
160514|NCT02943759|Drug|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
160515|NCT02943746|Dietary Supplement|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
160516|NCT02943746|Dietary Supplement|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
160517|NCT02943733|Drug|TAS-102|Anti-metabolite agent, taken orally.
160518|NCT02943733|Drug|Temozolomide|Oral chemotherapy drug.
160519|NCT02943733|Drug|Filgrastim|Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
160520|NCT02943733|Drug|Pegfilgrastim|Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
160521|NCT02943720|Drug|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
160522|NCT02943720|Drug|placebo|placebo
160523|NCT02943707|Procedure|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
160524|NCT02943707|Drug|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
160525|NCT02943694|Device|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
160526|NCT02943681|Biological|Measles vaccine|
160527|NCT02943668|Drug|Deferasirox|Given PO
160528|NCT02943668|Other|Laboratory Biomarker Analysis|Correlative studies
160529|NCT02943655|Drug|combined contraceptive pills (microcept)|oral combined contraceptive once daily
160530|NCT02943655|Drug|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
160531|NCT02943655|Drug|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
160532|NCT02943642|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
160533|NCT02943642|Drug|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
160534|NCT02943629|Device|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
160535|NCT02943629|Device|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
160536|NCT02943629|Device|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
160642|NCT02942771|Other|Cohort 4 Placebo|Placebo twice daily on Days 1 through 5
160643|NCT02942758|Drug|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
160537|NCT02943616|Device|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.~Scaffold diameters: 2.5, 3.0, and 3.5 mm~Scaffold lengths: 8, 12, 18, 23 and 28 mm~Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
160538|NCT02943603|Drug|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
160539|NCT02943590|Drug|Placebo|A pill taken once a day
160540|NCT02943590|Drug|Atorvastatin|A pill taken once a day
160541|NCT02943577|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
160542|NCT02943577|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
160543|NCT02943564|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
160544|NCT02943564|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
160545|NCT02943551|Other|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
160546|NCT02943551|Other|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.~The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
160547|NCT02943551|Other|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.~For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
160548|NCT02943551|Other|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.~The first report will have two parts:~The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.~The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
160549|NCT02943551|Other|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
160550|NCT02943538|Device|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
160551|NCT02943538|Device|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
160552|NCT02943538|Other|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
160553|NCT02943525|Procedure|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
160554|NCT02943512|Other|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
160555|NCT02943499|Behavioral|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
160556|NCT02943499|Behavioral|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
160557|NCT02943499|Device|Smartphone|
160558|NCT02943486|Other|dac-MSCs|Cell-free therapy
160559|NCT02943486|Other|MSCs|Cell-based therapy
160560|NCT02943486|Drug|Fitostimoline|Triticum vulgare
160561|NCT02943473|Drug|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
160562|NCT02943460|Drug|Cilofexor|Tablet(s) administered orally once daily
160563|NCT02943460|Drug|Placebo to match Cilofexor|Tablet(s) administered orally once daily
160564|NCT02943447|Drug|Cilofexor|Tablet(s) administered orally once daily
160565|NCT02943447|Drug|Placebo to match Cilofexor|Tablet(s) administered orally once daily
160566|NCT02943434|Other|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
160567|NCT02943421|Procedure|Transverse B-Lynch suture|
160568|NCT02943408|Behavioral|person-centered mental health intervention|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
160569|NCT02943408|Behavioral|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
160570|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
160571|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
160572|NCT02943382|Other|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
160573|NCT02943369|Drug|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
160574|NCT02943369|Drug|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
160575|NCT02943356|Drug|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
160576|NCT02943343|Other|No intervention|
160577|NCT02943330|Other|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
160578|NCT02943317|Drug|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
160579|NCT02943317|Drug|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
160580|NCT02943304|Other|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
160581|NCT02943291|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
160582|NCT02943291|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
160583|NCT02943278|Behavioral|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
160584|NCT02943278|Behavioral|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
160585|NCT02943265|Other|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
160586|NCT02943252|Drug|Apatinib|apatinib 500 mg in tablet once daily
160587|NCT02943252|Drug|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
160588|NCT02943239|Drug|REGN1033|REGN1033
160589|NCT02943239|Drug|REGN2477|REGN2477
160590|NCT02943239|Other|Placebo|Placebo
160591|NCT02943226|Device|Becton Dickinson Nexiva Diffusics System|Becton Dickinson Nexiva Diffusics System will be used to inject IV contrast and will be compared to a single hole catheter to see if it improves image quality in the main vessels in the abdomen and pelvis because of its novel design.
160592|NCT02943226|Device|Standard intravenous catheter|Standard catheter with one hole at the tip will be compared to a novel 3 hole catheter to see which catheter provides the best image quality.
160593|NCT02943213|Drug|Chlorpromazine Hydrochloride|Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
160594|NCT02943187|Behavioral|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
160595|NCT02943187|Dietary Supplement|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
160596|NCT02943174|Behavioral|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
160597|NCT02943174|Other|Treatment as Usual (TAU)|Standard personalized treatment of cancer
160598|NCT02943161|Dietary Supplement|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
160599|NCT02943148|Other|Davey score for striae gravidarum|
160600|NCT02943135|Drug|lidocaine in-situ gel|
160601|NCT02943135|Drug|placebo in-situ gel|
160602|NCT02943122|Device|Ambulatory blood pressure monitor|
160603|NCT02943109|Other|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
160604|NCT02943109|Other|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
160605|NCT02943109|Other|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
160606|NCT02943109|Other|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
160607|NCT02943096|Dietary Supplement|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
160608|NCT02943096|Other|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
160644|NCT02942758|Drug|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
160645|NCT02942758|Drug|ATRA|ATRA *45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; *this regimen will be chosen for the first dose to be evaluated.
160646|NCT02942758|Drug|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
160609|NCT02943083|Behavioral|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
160610|NCT02943070|Device|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
160611|NCT02943057|Drug|2% guttae ganciclovir|2% guttae ganciclovir 5 times a day for 6 weeks
160612|NCT02943044|Device|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
160613|NCT02943031|Other|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
160614|NCT02943018|Other|anovaginal distance variation|Kappa calculation
160615|NCT02943005|Procedure|Rotator cuff repair|
160616|NCT02942992|Behavioral|Resistance exercise|resistance exercise
160617|NCT02942966|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
160618|NCT02942953|Device|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
160619|NCT02942940|Device|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
160620|NCT02942940|Other|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
160621|NCT02942927|Other|Medication reduction|Systematic approach to reduction in polypharmacy.
160622|NCT02942914|Drug|LY3209590|Administered SC
160623|NCT02942914|Drug|Placebo|Administered SC
160624|NCT02942914|Drug|Insulin Glargine|Administered SC
160625|NCT02942901|Procedure|PET-CT|
160626|NCT02942888|Dietary Supplement|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
160627|NCT02942888|Dietary Supplement|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
160628|NCT02942875|Other|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.~The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
160629|NCT02942875|Other|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
160630|NCT02942862|Drug|Orcein staining|Prognostic value of venous emboli detected by orcein staining
160631|NCT02942849|Drug|r-hFSH|As per standard clinical practice
160632|NCT02942836|Device|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
160633|NCT02942823|Other|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
160634|NCT02942810|Drug|WCK 5222|IV infusion over a period of 60 minutes
160635|NCT02942771|Drug|Cohort 1 - TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
160636|NCT02942771|Drug|Cohort 2- TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
160637|NCT02942771|Drug|Cohort 3 - TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
160638|NCT02942771|Other|Cohort 1 Placebo|Placebo twice daily on Days 1 through 5
160639|NCT02942771|Other|Cohort 2 Placebo|Placebo twice daily on Days 1 through 5
160640|NCT02942771|Other|Cohort 3 Placebo|Placebo twice daily on Days 1 through 5
160641|NCT02942771|Drug|Cohort 4 - TT301/MW189|0.25 mg/kg IV twice daily on Days 1 through 5
160647|NCT02942745|Behavioral|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
160648|NCT02942745|Behavioral|Betel Nut Cessation Booklet|Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
160649|NCT02942732|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
160650|NCT02942706|Drug|Cetuximab|anti-EGFR monoclonal antibody
160651|NCT02942706|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
160652|NCT02942706|Drug|FOLFIRI|Irinotecan+LV5FU2
160653|NCT02942693|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
160654|NCT02942693|Radiation|Particle Therapy|Same total dose and fractionation will be used in both arms.
160655|NCT02942680|Drug|acetylsalicylic acid started for 24 hours before surgery|
160656|NCT02942680|Drug|acetylsalicylic acid stayed for 5 days before surgery|
160657|NCT02942654|Drug|LY900014|Administered subcutaneously (SC)
160658|NCT02942654|Drug|Insulin Lispro|Administered SC
160659|NCT02942641|Procedure|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received indwelling urethral catheter as the intervention."
160660|NCT02942641|Procedure|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.~Patients in this group received CIC as the intervention."
160661|NCT02942641|Device|Foley|
160662|NCT02942628|Other|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
160663|NCT02942615|Other|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
160664|NCT02942602|Drug|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
160665|NCT02942602|Drug|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
160666|NCT02942602|Drug|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
160667|NCT02942602|Drug|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
160668|NCT02942602|Behavioral|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
160669|NCT02942589|Other|Meal portion size|
160670|NCT02942576|Drug|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
160671|NCT02942576|Drug|VKA-Based Regimen|Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, United Kingdom (UK), Taiwan and Korea.
160672|NCT02942576|Drug|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
160673|NCT02942576|Drug|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in France.
160674|NCT02942576|Drug|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Spain.
160675|NCT02942563|Drug|FOLFOXIRI|"Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME."
160676|NCT02942550|Drug|Methylnaltrexone bromide (Relistor®).|
160677|NCT02942550|Drug|Sodium Chloride 9mg/mL|
160678|NCT02942537|Device|Microwave treatment|Percutaneous or vaginal application of microwave antenna with microwave treatment of fibroma
160679|NCT02942537|Procedure|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
160680|NCT02942524|Other|Communication Intervention|Complete TEPID
160681|NCT02942524|Other|Questionnaire Administration|Ancillary studies
160682|NCT02942524|Other|Survey Administration|Ancillary studies
160683|NCT02942498|Drug|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
160684|NCT02942498|Drug|Placebo|Placebo
160685|NCT02942485|Drug|Metronidazole|P/r suppositories
160686|NCT02942485|Drug|Tinidazole|P/o tablets
160687|NCT02942459|Other|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music Therapist
160690|NCT02942433|Behavioral|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
160691|NCT02942433|Behavioral|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
160692|NCT02942433|Behavioral|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
160693|NCT02942420|Drug|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
160694|NCT02942407|Drug|apixaban|oral anticoagulant
160695|NCT02942407|Drug|warfarin|oral anticoagulant
160696|NCT02942394|Device|sinus-Obliquus Stent System|
160697|NCT02942381|Drug|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
160698|NCT02942381|Drug|Placebo|
160699|NCT02942368|Device|tDCS|Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
160700|NCT02942355|Drug|anastrozole|Anastrozole by mouth daily
160701|NCT02942355|Drug|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
160702|NCT02942342|Procedure|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
160703|NCT02942329|Drug|apatinib|Apatinib was administered 250mg or 375mg orally daily. For gastric cancer patients, the dose would be 250mg or 375mg daily. For hepatocellular carcinoma patients, the dose would be 250mg daily.
160704|NCT02942329|Drug|SHR-1210|SHR-1210 was administered 200mg (3mg/kg for underweight patients) iv every 2 weeks.
160705|NCT02942316|Device|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively~after induction, before opioid administration~after opioid administration, steady state~surgical incision~end of procedure"
160706|NCT02942303|Drug|Dysport|
160707|NCT02942303|Procedure|lateral orbicularis injection|
160708|NCT02942303|Procedure|Lateral orbicularis + corrugator injection|
160709|NCT02942290|Drug|Azacitidine|Powder for injection; taken subcutaneously or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 & Days 1-2 of Week 2 of 28 day cycle.
160710|NCT02942290|Drug|Venetoclax|Tablet
160711|NCT02942277|Biological|Pfs25M-EPA|The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
160712|NCT02942277|Biological|Pfs230D1M-EPA|The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
160713|NCT02942277|Other|AS01|AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL.
160714|NCT02942277|Biological|Engerix-B|ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
160715|NCT02942277|Biological|Menactra|Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
160716|NCT02942277|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
160717|NCT02942277|Drug|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
160718|NCT02942264|Drug|Zotiraciclib (TG02)|"Phase I: Two treatment arms and several dose levels are planned; In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered;~--A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: ( winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study."
160719|NCT02942264|Drug|TMZ|"Phase I: In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with Zotiraciclib (TG02) will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + Zotiraciclib (TG02) versus dd/mn TMZ alone using a Bayesian clinical trial design."
160720|NCT02942251|Other|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
160721|NCT02942251|Other|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
160722|NCT02942251|Other|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
160723|NCT02942251|Other|Laboratory abnormality|This group will be suggested to more safety antidepressants.
160724|NCT02942251|Other|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
160725|NCT02942251|Other|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
160726|NCT02942238|Procedure|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.~Intervention: Procedure: Complete mesocolic excision (CME)"
160727|NCT02942238|Procedure|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.~Intervention: Procedure: D3 radical operation"
160728|NCT02942212|Behavioral|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
160729|NCT02942212|Behavioral|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
160730|NCT02942212|Other|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
160731|NCT02942212|Drug|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke >10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
160732|NCT02942212|Behavioral|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
160733|NCT02942212|Behavioral|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
160734|NCT02942212|Behavioral|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
160735|NCT02942199|Other|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
160736|NCT02942173|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
160737|NCT02942160|Biological|Collagenase Clostridium Histolyticum|
160738|NCT02942147|Device|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
160739|NCT02942147|Procedure|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
160740|NCT02942121|Other|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
160741|NCT02942108|Procedure|piezo surgery|
160742|NCT02942108|Procedure|conventional surgery|
160743|NCT02942095|Drug|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
160744|NCT02942095|Drug|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
160745|NCT02942082|Other|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
160746|NCT02942082|Other|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
160747|NCT02942069|Behavioral|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
160748|NCT02942056|Drug|Cinnamon|Cinnamon tablets to treat type 2 DM
160749|NCT02942056|Drug|placebo|placebo
160750|NCT02942043|Drug|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.~Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
160751|NCT02942030|Other|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
160754|NCT02942004|Drug|Placebo|Intravenous infusion of matching placebo for either SAGE-547 60 μg/kg/h or 90 μg/kg/h.
160755|NCT02942004|Drug|SAGE-547 60 μg/kg/h|Intravenous infusion of SAGE-547.
160756|NCT02942004|Drug|SAGE-547 90 μg/kg/h|Intravenous infusion of SAGE-547.
160757|NCT02941991|Biological|hESC-RPE|sub-retinal injection
160758|NCT02941978|Behavioral|Motivational interview|Patients assigned to the intervention group receive additional medical consultation aiming to boost optimal uptake of the anticoagulation regimen prescribed. Initially (i.e., at hospital discharge), this includes a physician-patient interactive session and provision of an educational leaflet. The leaflet is designed in a culturally and linguistically conceivable template in Greek language. It uses simple terms together with both written and pictorial materials. Patients in the intervention group will also undergo short telephonic sessions at 1 week, 2 months, 6 months and 12 months following hospital discharge
160759|NCT02941978|Behavioral|Control|Patients assigned to the control group receive usual treatment, corresponding to standard practice and management of hospitalized patients with AF. For both patient-groups, the choice of OAC agent and any other background therapy is left to the discretion of the treating physician.
160760|NCT02941965|Procedure|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
160761|NCT02941965|Procedure|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
160762|NCT02941952|Device|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
160763|NCT02941939|Other|Hyperbaric chamber|
160764|NCT02941939|Other|Ambient pressure|
160765|NCT02941926|Drug|Ribociclib|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
160766|NCT02941926|Drug|Letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
160767|NCT02941926|Drug|Goserelin|Only for men and premenopausal women: administered as an injectable subcutaneous implant once every 28 days
160768|NCT02941926|Drug|Leuprolide|Only for men and premenopausal women: administered as an injectable intramuscular depot once every 28 days
160769|NCT02941913|Drug|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
160770|NCT02941900|Genetic|MC1R genotyping|
160771|NCT02941900|Behavioral|MC1R Testing Website|The website includes three educational modules about genetic testing with corresponding knowledge questions.
160772|NCT02941900|Behavioral|Baseline Survey|
160773|NCT02941887|Behavioral|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
160774|NCT02941874|Other|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
160775|NCT02941861|Other|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
160776|NCT02941861|Other|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
160777|NCT02941848|Drug|HGP0816|
160778|NCT02941848|Drug|HGP1404|
160779|NCT02941848|Drug|HCP1306|
160780|NCT02941835|Radiation|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
160781|NCT02941822|Drug|Ambroxol|Details outlines in the intervention description.
160782|NCT02941796|Drug|HCP1105|
160783|NCT02941796|Drug|HCP0918|
160784|NCT02941796|Drug|HCP0816|
160785|NCT02941783|Drug|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
160786|NCT02941770|Behavioral|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
160787|NCT02941770|Other|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
160788|NCT02941757|Behavioral|Mediterranean diet Intervention|"Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.~Peer-education and support~Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.~Email or text message encouragement and reminders during the intervention."
160789|NCT02941744|Drug|nivolumab|low fixed dose ipilimumab in combination with nivolumab
160790|NCT02941744|Drug|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
160791|NCT02941731|Drug|HIP1403|Oseltamivir 6mg/mL
160792|NCT02941731|Drug|HGP0919|Oseltamivir phosphate 6mg/mL
160793|NCT02941718|Behavioral|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
160794|NCT02941718|Behavioral|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
161070|NCT02939794|Drug|Placebo|Saline (normal saline, sodium chloride)
160795|NCT02941705|Biological|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
160796|NCT02941705|Biological|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
160797|NCT02941692|Drug|Oxytocin|
160798|NCT02941692|Drug|Placebo|Placebo for Oxytocin
160799|NCT02941679|Drug|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
160800|NCT02941679|Drug|HGP1011|Boehringer Ingelheim
160801|NCT02941679|Drug|HCP0910|GlaxoSmithKline
160802|NCT02941653|Device|Potassium nitrate 2% gel|"Teeth will be cleaned using rubber cups associated to pumice and water;~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
160803|NCT02941653|Device|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water~Relative isolation with roller cotton will be done;~Prior to each bleaching session, the patients will receive the potassium OXALATE 5%~Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.~A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
160804|NCT02941640|Procedure|E group|The securing the base of appendix by endoloop.
160805|NCT02941640|Procedure|S group|The securing the base of appendix by Stapler.
160806|NCT02941640|Procedure|H group|The securing the base of appendix by Hem-o-lok clip.
160807|NCT02941640|Procedure|DS group|The securing the base of appendix by DS clip.
160808|NCT02941640|Device|Endoloop|
160809|NCT02941640|Device|Stapler|
160810|NCT02941640|Device|Hem-o-lok clip|
160811|NCT02941640|Device|DS clip|
160812|NCT02941627|Device|Neuro Cochlear Implant System|
160813|NCT02941614|Behavioral|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire (PHQ), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm. The PHQ starts with a 2-item screen, and branches to the full screening instrument as needed.
160814|NCT02941601|Drug|Necitumumab|Administered IV
160815|NCT02941601|Drug|Gemcitabine|Administered IV
160816|NCT02941601|Drug|Carboplatin|Administered IV
160817|NCT02941588|Procedure|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
160818|NCT02941575|Other|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
160819|NCT02941575|Other|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
160820|NCT02941562|Radiation|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
160821|NCT02941562|Drug|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
160822|NCT02941562|Radiation|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
160823|NCT02941562|Drug|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
160824|NCT02941562|Procedure|Radical rectal cancer resection|Radical rectal cancer resection
160825|NCT02941562|Drug|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.~Repeat every 2 weeks"
160826|NCT02941549|Other|Placebo capsules|
160827|NCT02941549|Drug|DS102|
160828|NCT02941536|Diagnostic Test|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
160829|NCT02941523|Drug|NOX66|NOX66 administration
160830|NCT02941523|Drug|Carboplatin|Carboplatin administration
160831|NCT02941510|Drug|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
160832|NCT02941510|Other|Placebo|Subject(s) will participate in all study activities but will receive placebo.
160833|NCT02941497|Behavioral|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
160834|NCT02941484|Procedure|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
160835|NCT02941484|Procedure|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
160836|NCT02941471|Device|Interferential Stimulation|Transabdominal interferential electrcial stimulation
160837|NCT02941471|Device|TENS stimulation|Transabdominal standard electrical stimulation
160838|NCT02941445|Drug|sitagliptin and metformin|
160839|NCT02941445|Drug|Metformin|
160840|NCT02941432|Other|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
160841|NCT02941419|Biological|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
160842|NCT02941393|Device|Intrauterine pressure catheter|
160843|NCT02941393|Device|External tocodynamometry|
160844|NCT02941367|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
160845|NCT02941367|Drug|Sulfonylurea|"Pharmaceutical form: tablet~Route of administration: oral"
160846|NCT02941367|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
160847|NCT02941367|Drug|basal insulin|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
160848|NCT02941354|Drug|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
160849|NCT02941341|Drug|r-hFSH|As per standard practice
160850|NCT02941328|Drug|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
160851|NCT02941328|Drug|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
160852|NCT02941315|Drug|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
160853|NCT02941315|Drug|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
160854|NCT02941315|Drug|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
160855|NCT02941315|Drug|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
160856|NCT02941302|Procedure|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
160857|NCT02941289|Procedure|visual search performance of everyday objects in realistic scenes|
160858|NCT02941276|Device|Active Electrostimulator device|Patients who will receive a fully functioning device
160859|NCT02941276|Device|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
160860|NCT02941250|Device|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
160861|NCT02941237|Device|Pulse oximeter|"Time taken to measure oxygen saturation.~Completion of usability questionnaire"
160862|NCT02941224|Device|SELUTION DCB (sirolimus coated balloon)|
160863|NCT02941211|Device|Aqueduct -100|
160864|NCT02941198|Device|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
160865|NCT02941198|Device|Cu T380 A|Cu T380 A will be inserted into the uterus
160866|NCT02941185|Drug|Devit-3 Oral Drop|
160867|NCT02941172|Other|Cold exposure|Controlled cold exposure is performed before and during PET scan
160868|NCT02941172|Other|[18F]FMPEP-d2|PET radiotracer used in imaging
160869|NCT02941172|Other|[18F]FDG|PET radiotracer used in imaging
160870|NCT02941159|Biological|SF2000SD|This is an intergrase inhibitor
160871|NCT02941159|Biological|Placebo|
160872|NCT02941146|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
160873|NCT02941133|Other|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
160874|NCT02941133|Other|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
160875|NCT02941107|Drug|Rotarix (RV1)|Oral
160876|NCT02941107|Drug|Placebo|Oral
160877|NCT02941094|Device|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
160878|NCT02941094|Device|Ultrasound|Xario, Toshiba Tokyo Japan
160879|NCT02941081|Dietary Supplement|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
160880|NCT02941081|Dietary Supplement|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
160881|NCT02941081|Other|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
160882|NCT02941068|Drug|fluconazole and caspofungin|
160883|NCT02941055|Other|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
160884|NCT02941055|Other|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
160885|NCT02941042|Drug|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
160886|NCT02941042|Drug|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
160887|NCT02941029|Other|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
160888|NCT02941016|Drug|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
160889|NCT02941003|Device|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
259932|NCT02218099|Drug|Placebo|Oral
160890|NCT02941003|Other|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
160891|NCT02941003|Device|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
160892|NCT02940990|Radiation|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
160893|NCT02940990|Drug|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
160894|NCT02940977|Other|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
160895|NCT02940964|Behavioral|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
160896|NCT02940964|Behavioral|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
160897|NCT02940951|Other|QPSS|Home care providers use an electronic tablet-based system (QPSS) that includes standardized instruments for assessing patient and family caregiver quality of life and satisfaction with care in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
160898|NCT02940951|Other|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
160899|NCT02940938|Other|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
160900|NCT02940925|Other|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
160901|NCT02940925|Other|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
160902|NCT02940912|Drug|Apomorphine|
160903|NCT02940912|Drug|Placebo|
160904|NCT02940899|Other|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
160905|NCT02940886|Drug|Iron isomaltoside|
160906|NCT02940886|Drug|Iron sucrose|
160907|NCT02940873|Behavioral|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
160908|NCT02940873|Behavioral|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
160909|NCT02940860|Drug|Iron isomaltoside|
160910|NCT02940860|Drug|Iron Sucrose|
160911|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
160912|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
160913|NCT02940821|Other|Toothbrushing|Mechanical plaque removal
160914|NCT02940821|Other|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
160915|NCT02940821|Other|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
160916|NCT02940821|Other|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
160917|NCT02940821|Other|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
160918|NCT02940808|Dietary Supplement|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
160919|NCT02940808|Other|Placebo|Oral consumption of capsule containing a placebo substance.
160920|NCT02940795|Other|Coke|Patients were given a 20 ounce bottle of Coke Cola.
160921|NCT02940795|Other|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
160922|NCT02940782|Procedure|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
160923|NCT02940782|Procedure|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
160924|NCT02940782|Device|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
160925|NCT02940769|Device|light glasses|light glasses
160926|NCT02940769|Device|sham glasses (placebo)|sham light glasses
160927|NCT02940756|Drug|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
160928|NCT02940756|Drug|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
160929|NCT02940756|Drug|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
160930|NCT02940743|Behavioral|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
161162|NCT02939092|Drug|Pomegranates peel extract|Pomegranate is antimicrobial
160931|NCT02940743|Behavioral|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
160932|NCT02940743|Behavioral|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
160933|NCT02940730|Drug|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
160934|NCT02940730|Drug|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
160935|NCT02940717|Other|Vita suprinity|New glass ceramic material
160936|NCT02940717|Other|Emax CAD|standard etchable glass ceramic used for laminate venneers
160937|NCT02940704|Procedure|Reciproc|"Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.~There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.~Reciproc file selection: R40 (40/0.06) is to be used."
160938|NCT02940704|Procedure|One Shape|"Coronal preflaring will be performed using Gates Glidden drill.~Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.~For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
160939|NCT02940691|Drug|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
160940|NCT02940678|Other|No intervention|
160941|NCT02940665|Other|ERAS|Patients in the ERAS group received the ERAS protocol
160942|NCT02940652|Radiation|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
160943|NCT02940639|Other|Non-interventional|
160944|NCT02940626|Drug|ASN100|monoclonal antibody combination of ASN-1 and ASN-2
160945|NCT02940626|Drug|Placebo|Placebo
160946|NCT02940613|Behavioral|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
160947|NCT02940600|Device|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
160948|NCT02940600|Procedure|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
160949|NCT02940587|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
160950|NCT02940574|Drug|Syntocinon (Oxytocin)|Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
160951|NCT02940574|Other|Placebo (Physiological water (solution of sodium chloride (NaCl) in water))|Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
160952|NCT02940561|Drug|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
160953|NCT02940561|Drug|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
160954|NCT02940548|Drug|Nifedipine GITS|Nifedipine GITS 30~60mg/day for 8 weeks
160955|NCT02940548|Drug|Amlodipine besylate|Amlodipine besylate 5~10mg/day for 8 weeks
160956|NCT02940535|Drug|Diphereline (Triptorelin embonate)|
160957|NCT02940535|Drug|Decapeptyl (Triptorelin)|
160958|NCT02940535|Drug|human menopausal gonadotropin|
160959|NCT02940535|Drug|human chorionic gonadotropin|
160960|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
160961|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
160962|NCT02940509|Drug|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:~Ketamine (0.5mg/kg)~Magnesium sulfate (2g)"
160963|NCT02940509|Drug|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
160964|NCT02940496|Drug|Elbasvir/Grazoprevir|Given PO
160965|NCT02940496|Other|Laboratory Biomarker Analysis|Correlative studies
160966|NCT02940496|Biological|Pembrolizumab|Given IV
160967|NCT02940496|Drug|Ribavirin|Given PO
160968|NCT02940483|Drug|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
160969|NCT02940470|Other|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
160970|NCT02940470|Other|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
160971|NCT02940457|Device|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
160972|NCT02940457|Device|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
160974|NCT02940431|Other|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
160975|NCT02940431|Other|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
160976|NCT02940418|Biological|Adipose mesenchymal cells with bone marrow mononuclear cells|Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
160977|NCT02940405|Drug|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
160978|NCT02940405|Drug|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
160979|NCT02940392|Device|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.~The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
160980|NCT02940379|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
160981|NCT02940379|Drug|midazolam|"Pharmaceutical form: HCl syrup~Route of administration: oral"
160982|NCT02940379|Drug|metoprolol|"Pharmaceutical form: tablet~Route of administration: oral"
160983|NCT02940366|Drug|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
160984|NCT02940366|Drug|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
160985|NCT02940353|Device|TREFOIL concept|
160986|NCT02940314|Drug|HIP1503|
160987|NCT02940314|Drug|HGP1103|
160988|NCT02940301|Drug|Ibrutinib|Given PO
160989|NCT02940301|Other|Laboratory Biomarker Analysis|Correlative studies
160990|NCT02940301|Biological|Nivolumab|Given IV
160991|NCT02940288|Other|Auricular Acupuncture|Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
160992|NCT02940288|Other|Sham Acupuncture|Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
160993|NCT02940262|Radiation|Gallium Ga 68-labeled PSMA-11|Given IV
160994|NCT02940262|Other|Laboratory Biomarker Analysis|Correlative studies
160995|NCT02940262|Procedure|Positron Emission Tomography|Undergo PET imaging
160996|NCT02940249|Dietary Supplement|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
160997|NCT02940249|Dietary Supplement|Placebo|
160998|NCT02940236|Other|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
160999|NCT02940223|Drug|Ethyl Icosapentate|Given by mouth 2 gm orally daily plus physical activity
161000|NCT02940223|Behavioral|Exercise Intervention|Complete resistance exercises and undergo walking program
161001|NCT02940223|Behavioral|Exercise Intervention|Meet with exercise specialist and complete stretching exercises
161002|NCT02940223|Other|Laboratory Biomarker Analysis|Correlative studies
161003|NCT02940223|Other|Placebo|Given PO
161004|NCT02940223|Behavioral|Quality-of-Life Assessment|Ancillary studies
161005|NCT02940223|Other|Questionnaire Administration|Ancillary studies
161006|NCT02940210|Device|Mediclore® (adhesion barrier)|
161007|NCT02940197|Behavioral|MediterrAsian diet|no other description
161008|NCT02940184|Drug|Tablet Sitagliptin 100mg (evening before and morning of experiments)|On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
161009|NCT02940184|Other|Intestinal Fructose administration|On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
161010|NCT02940171|Procedure|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
161011|NCT02940171|Procedure|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
161012|NCT02940158|Other|1/4 cup- Small red lentil|
161013|NCT02940158|Other|1/4 cup- Small green lentil|
161014|NCT02940158|Other|1/4 cup- corn|
161015|NCT02940158|Other|1/4 cup- macaroni|
161016|NCT02940158|Other|1/4 cup- white potato|
161017|NCT02940158|Other|1/4 cup- white rice|
161018|NCT02940158|Other|1/2 cup- small red lentil|
161019|NCT02940158|Other|1/2 cup- small green lentil|
161020|NCT02940158|Other|1/2 cup- corn|
161021|NCT02940158|Other|1/2 cup- macaroni|
161022|NCT02940158|Other|1/2 cup- white potato|
161023|NCT02940158|Other|1/2 cup- white rice|
161024|NCT02940145|Other|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
161025|NCT02940132|Drug|SC10914|SC10914 will be administered orally.
161198|NCT02938845|Procedure|total laparoscopic hysterectomy(TLH)|
161026|NCT02940119|Device|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
161027|NCT02940106|Device|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
161028|NCT02940106|Device|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
161029|NCT02940093|Other|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
161030|NCT02940080|Other|Dietary|
161031|NCT02940067|Other|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
161032|NCT02940054|Other|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
161033|NCT02940041|Procedure|Pre-surgical diagnosis of uterine malignant tumors|All patientes who fit inclusion criteria will undergo a gynecologic sonography, pelvic MRI, determination of LDH, as in regular practice. No additional interventions will be done to any patient.
161034|NCT02940028|Behavioral|Expressive writing|Brief expressive writing intervention
161035|NCT02940028|Behavioral|Control writing|Brief fact-based writing exercise.
161036|NCT02940002|Drug|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
161037|NCT02940002|Drug|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
161038|NCT02940002|Drug|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
161039|NCT02939989|Drug|Sofosbuvir|Tablet
161040|NCT02939989|Drug|ABT-493/ABT-530|Tablet
161041|NCT02939989|Drug|Ribavirin|Tablet
161042|NCT02939976|Device|Single Vessel Disease|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
161043|NCT02939976|Procedure|Multi-vessel Disease, Culprit Vessel Only|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
161044|NCT02939976|Procedure|Multi-vessel Disease, Complete Revascularization|Complete revascularization of all diseased arteries
161045|NCT02939976|Device|Medtronic Resolute family of stents|Revascularization with Medtronic Resolute family of stents in infarct related artery
161046|NCT02939976|Device|Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology|Complete revascularization of all diseased arteries
161047|NCT02939976|Device|Terumo Glidesheath Slender|Possible use of Terumo Glidesheath Slender
161048|NCT02939976|Device|Terumo TR Band Radial Compression Device|Possible use of Terumo TR Band Radial Compression Device
161049|NCT02939963|Procedure|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
161050|NCT02939963|Procedure|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
161051|NCT02939950|Device|samfilcon A soft contact lenses|soft contact lenses
161052|NCT02939950|Device|PureVision contact lenses|contact lenses
161053|NCT02939937|Drug|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
161054|NCT02939937|Drug|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
161055|NCT02939924|Device|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
161056|NCT02939911|Device|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
161057|NCT02939898|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
161058|NCT02939898|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
161059|NCT02939872|Drug|aspirin and clopidogrel|at the discretion of investigator
161060|NCT02939872|Drug|Clopidogrel only|at the discretion of investigator
161061|NCT02939859|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
161062|NCT02939859|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
161063|NCT02939859|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
161064|NCT02939846|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
161065|NCT02939833|Procedure|Scalp Nerve Blocks With Ropivacaine|
161066|NCT02939833|Procedure|Scalp Nerve Blocks With Saline|
161067|NCT02939820|Drug|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
161068|NCT02939807|Drug|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.~ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
161069|NCT02939794|Drug|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
161071|NCT02939781|Device|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
161072|NCT02939768|Other|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit ~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed ~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
161073|NCT02939768|Other|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
161074|NCT02939768|Other|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
161075|NCT02939755|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
161076|NCT02939755|Behavioral|Enhanced Usual Care|usual care from health providers
161077|NCT02939742|Drug|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
161078|NCT02939742|Drug|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
161079|NCT02939729|Other|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
161080|NCT02939729|Device|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
161081|NCT02939729|Other|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
161082|NCT02939716|Other|Rhubarb|300gm rhubarb
161083|NCT02939716|Other|Bread|2 slices bread
161084|NCT02939716|Other|Lettuce|300g lettuce
161085|NCT02939703|Other|Diet|Participants will consume either a Control Western Diet or a Microbiome Enhancer Diet.
161086|NCT02939690|Device|UVC|UVC insertion depth calculated by [(3× birth weight (Kg) + 9)/2+1)]
161087|NCT02939690|Device|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
161088|NCT02939690|Device|Ultrasound|
161089|NCT02939677|Other|Targeted exercise|"12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)"
161090|NCT02939664|Device|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
161091|NCT02939664|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
161092|NCT02939651|Drug|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
161093|NCT02939638|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
161094|NCT02939638|Other|Control Diet|Participants will be asked to continue their usual diets for the 16-week study period.
161095|NCT02939625|Device|muscle training|
161096|NCT02939625|Device|Continue Positive Airway Pressure|
161097|NCT02939625|Device|bilevel positive airway pressure|
161098|NCT02939612|Behavioral|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
161099|NCT02939599|Drug|QCC374|0.015mg and 0.06mg
161100|NCT02939586|Procedure|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
161101|NCT02939586|Procedure|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
161102|NCT02939573|Drug|Colchicine|Randomized to colchicine 0.6 mg x 2/day
161103|NCT02939573|Drug|Dapsone|Randomized to dapsone 150 mg/day
161104|NCT02939573|Drug|Azathioprine|Randomized to azathioprine 2 mg/kg/day
161105|NCT02939560|Device|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
161106|NCT02939547|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
161107|NCT02939521|Procedure|Surgery|
161108|NCT02939508|Other|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
161109|NCT02939508|Other|Non-colon originated: Neostigmin, Colonoscopy decompression|
161110|NCT02939495|Drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
161111|NCT02939482|Drug|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
161112|NCT02939469|Other|Physiologic maneuvers|"Subjects will perform~Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
161113|NCT02939456|Other|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
161114|NCT02939443|Radiation|supine- and prone-position Computed Tomography|
161115|NCT02939430|Drug|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
161116|NCT02939430|Drug|Intravenous neostigmine and atropine|
161117|NCT02939417|Other|Grape seed extract|Grape seed extract - collagen cross-linking agent
161118|NCT02939391|Drug|KW-6356|Oral administration
161119|NCT02939391|Drug|KW-6356|Oral administration
161120|NCT02939391|Drug|Placebo|Oral administration
161121|NCT02939378|Dietary Supplement|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
161122|NCT02939378|Dietary Supplement|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
161123|NCT02939365|Drug|Belatacept|The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
161124|NCT02939352|Device|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
161125|NCT02939352|Device|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
161126|NCT02939339|Device|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
161127|NCT02939339|Device|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
161128|NCT02939326|Drug|EB-001 injection|
161129|NCT02939326|Drug|Placebo injection|
161130|NCT02939313|Device|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
161131|NCT02939313|Device|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
161132|NCT02939313|Device|sham|sham stimulation
161133|NCT02939300|Drug|Nivolumab|
161134|NCT02939300|Drug|Ipilimumab|
161135|NCT02939287|Drug|Aprepitant|Add aprepitant to anti-emetic regimen
161136|NCT02939287|Drug|Olanzapine|add olanzapine to anti-emetic regimen
161137|NCT02939287|Drug|Aprepitant plus Olanzapine|add aprepitant and olanzapine to anti-emetic regimen
161138|NCT02939274|Drug|Verteporfin|
161139|NCT02939274|Device|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
161140|NCT02939261|Behavioral|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
161141|NCT02939261|Behavioral|Control|monthly emails with general health information
161142|NCT02939248|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
161143|NCT02939248|Drug|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
161144|NCT02939235|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
161145|NCT02939235|Drug|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
161146|NCT02939222|Device|Implant placement|Routine implant placement in the ideal three dimensional implant position
161147|NCT02939209|Drug|Hydromorphone Hcl 2Mg Tab|Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
161148|NCT02939209|Drug|Placebo|Patients may be randomized to placebo.
161149|NCT02939196|Procedure|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
161150|NCT02939196|Procedure|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
161151|NCT02939183|Drug|Immediate Release (IR) Formulation|Immediate Release (IR) Formulation
161152|NCT02939183|Drug|Gastro-Retentive (GR) Formulation|Gastro-Retentive (GR) Formulation
161153|NCT02939183|Drug|Dexamethasone|Dexamethasone
161154|NCT02939183|Drug|Pomalidomide|Pomalidomide
161155|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses with Molded Mark|
161156|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses|
161157|NCT02939157|Other|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
161158|NCT02939144|Dietary Supplement|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
161159|NCT02939131|Behavioral|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
161160|NCT02939131|Behavioral|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
161161|NCT02939105|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
161163|NCT02939092|Drug|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
161164|NCT02939079|Drug|Fingolimod|Produced by Osveh ® Pharm Company in Iran
161165|NCT02939079|Dietary Supplement|Fish Oil|produced by Zahravi ® Pharm Company in Iran
161166|NCT02939079|Drug|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
161167|NCT02939053|Device|SOZO|The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.
161168|NCT02939040|Behavioral|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
161169|NCT02939027|Device|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
161170|NCT02939027|Device|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
161171|NCT02939014|Drug|Brentuximab Vedotin|Brentuximab vedotin IV infusion
161172|NCT02939001|Device|iris recognition scanner|
161173|NCT02938988|Procedure|Antimicrobial photodynamic therapy|Described in arm/group
161174|NCT02938988|Procedure|Scaling and root planning|Described in arm/group
161175|NCT02938988|Device|red laser|658nm; 0.1W; 2229J/cm², 10s per point
161176|NCT02938988|Drug|methylene blue dye|
161177|NCT02938975|Other|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.~This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
161178|NCT02938975|Other|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
161179|NCT02938975|Other|Placebo lotion|A liposome lotion with no DEET
161180|NCT02938975|Other|Army combat uniform|Army combat uniform with no permethrin
161181|NCT02938962|Drug|Tranexamic Acid|
161182|NCT02938949|Drug|alirocumab|
161183|NCT02938949|Drug|placebo|
161184|NCT02938936|Other|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
161185|NCT02938923|Drug|Testosterone|Topical testosterone gel 1%
161186|NCT02938923|Drug|Placebo gel|Inactive skin gel
161187|NCT02938923|Behavioral|Supervised exercise training|Multicomponent exercise program focused primarily on progressive resistance exercise training
161188|NCT02938923|Behavioral|Home exercise program|Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.
161189|NCT02938923|Behavioral|Health Education Modules|30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
161190|NCT02938910|Other|non interventional study|Non invasive imaging study without interventional procedures
161191|NCT02938897|Behavioral|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
161192|NCT02938897|Behavioral|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
161193|NCT02938897|Behavioral|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
161194|NCT02938884|Device|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
161195|NCT02938871|Dietary Supplement|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
161196|NCT02938871|Dietary Supplement|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
161197|NCT02938845|Behavioral|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
161200|NCT02938832|Behavioral|Advice on what food to choose and eat|Dietary advice
161201|NCT02938819|Other|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
161202|NCT02938819|Other|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
161203|NCT02938806|Other|No intervention|No intervention
161204|NCT02938793|Drug|Durvalumab|intravenous administration
161205|NCT02938793|Drug|Tremelimumab|intravenous administration
161206|NCT02938780|Other|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
161207|NCT02938780|Other|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
161208|NCT02938754|Behavioral|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
161209|NCT02938754|Behavioral|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
161210|NCT02938741|Drug|Anti－human Thymoglobulin|r-ATG 2.5MG/KG*4days were used in the conditioning
161211|NCT02938741|Drug|Placebo|r-ATG 2.5MG/KG*4days were not used in the conditioning
161212|NCT02938728|Other|Biopsies|
161213|NCT02938715|Other|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
161214|NCT02938689|Other|Exercise|
161215|NCT02938663|Behavioral|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
161216|NCT02938650|Drug|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
161217|NCT02938624|Drug|Pembrolizumab 200 mg IV single dose|Pembrolizumab 200 mg IV single dose, 21 days later surgery
161218|NCT02938624|Drug|Pembrolizumab 200 mg IV twice interval 21 days|Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
161219|NCT02938624|Drug|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
161220|NCT02938624|Drug|Pembrolizumab 100 mg I.V single dose|Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
161221|NCT02938624|Procedure|Surgical resection of tumor|Surgical resection of tumor by any of the acceptable procedures
161222|NCT02938598|Behavioral|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
161223|NCT02938585|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
161224|NCT02938585|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
161225|NCT02938572|Drug|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
161226|NCT02938572|Drug|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
161227|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
161228|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
161257|NCT02938364|Other|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
161258|NCT02938364|Other|Placebo|Non pressure bands put on the wrists of the participant
161302|NCT02938013|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
161229|NCT02938546|Radiation|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
161230|NCT02938533|Behavioral|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
161231|NCT02938520|Drug|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
161232|NCT02938520|Drug|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
161233|NCT02938520|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
161234|NCT02938520|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
161235|NCT02938520|Drug|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
161236|NCT02938520|Drug|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
161237|NCT02938507|Drug|Formulation 1 solabegron|
161238|NCT02938507|Drug|Formulation 2 solabegron|
161239|NCT02938494|Drug|IDP-123 Lotion|Lotion
161240|NCT02938494|Drug|Tazorac Cream|Cream
161241|NCT02938494|Drug|Vehicle Lotion|Lotion
161242|NCT02938494|Drug|Vehicle Cream|Cream
161243|NCT02938468|Drug|Dexamethasone|
161244|NCT02938468|Procedure|Any surgical intervention aim at treating chronic subdural hematoma|
161245|NCT02938442|Biological|P10s-PADRE with MONTANIDE™ ISA 51 VG|Vaccination with standard chemotherapy
161246|NCT02938442|Drug|Standard Chemotherapy|Standard chemotherapy only
161247|NCT02938429|Other|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
161248|NCT02938416|Device|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
161249|NCT02938416|Device|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
161250|NCT02938403|Behavioral|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
161251|NCT02938403|Behavioral|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
161252|NCT02938390|Procedure|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
161253|NCT02938377|Behavioral|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
161254|NCT02938377|Behavioral|CBT4CBT|9 computerized modules delivered at the participant's pace
161255|NCT02938377|Drug|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
161256|NCT02938364|Other|Earplugs|Plastic earplugs on both ears
161259|NCT02938351|Behavioral|Collaborative care|Therapist will use iPad (Vidyo) once a week during dialysis for approximately one hour. The therapist will teach the patient cognitive-behavioral strategies to manage their mood and pain. The PI is a clinical psychologist and will provide supervision to the therapist providing the intervention. The sessions for depression will include (1) intake, (2) review of the rational for using CBT to treat depression and/or pain, (3) identifying thought patterns, (4) changing thought patterns, (5) relaxation techniques, (6) rest-activity pacing, and (7) coping strategies. Homework to practice these techniques will be provided after each session.
161260|NCT02938338|Procedure|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
161261|NCT02938312|Behavioral|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
161262|NCT02938312|Behavioral|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
161263|NCT02938299|Drug|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
161264|NCT02938299|Procedure|Surgery|Surgical resection of melanoma tumor lesions
161265|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
161266|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
161267|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
161268|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
161269|NCT02938286|Device|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
161270|NCT02938286|Drug|AHES|Topical application at test region I-IV under occlusion for 15 minutes
161271|NCT02938273|Drug|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
161272|NCT02938273|Radiation|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
161273|NCT02938273|Drug|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
161274|NCT02938260|Drug|Metoprolol vs Diltiazem|
161275|NCT02938247|Dietary Supplement|High caloric, high protein ONS|
161276|NCT02938234|Dietary Supplement|High caloric, high protein ONS|
161277|NCT02938221|Device|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
161278|NCT02938208|Device|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
161279|NCT02938195|Radiation|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
161280|NCT02938195|Procedure|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
161281|NCT02938182|Drug|clopidogrel|clopidogrel troche 75 mg daily for three months
161282|NCT02938169|Behavioral|exercise|"stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.~bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.~walking exercise: treadmill gait with tolerable gait speed~flexibility exercise: stretching exercise(control)"
161283|NCT02938143|Procedure|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
161284|NCT02938143|Procedure|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
161285|NCT02938130|Other|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
161286|NCT02938117|Other|cycling exercises|
161287|NCT02938104|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.~Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
161288|NCT02938104|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
161289|NCT02938104|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
161290|NCT02938091|Other|High-fat diet|Typical Western diet
161291|NCT02938091|Other|Low-fat diet|Traditional Caribbean Hispanic diet
161292|NCT02938078|Device|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
161293|NCT02938065|Procedure|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
161294|NCT02938065|Other|2% milk|16 participants will drink 10 ounces of 2% milk
161295|NCT02938065|Other|apple juice|16 participants will drink 10 ounces of apple juice
161296|NCT02938065|Other|ensure clear|16 participants will drink 10 ounces of ensure clear
161297|NCT02938052|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
161298|NCT02938039|Device|Ambu LMA|Ambu Laryngeal Mask Airways
161303|NCT02938013|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
161304|NCT02938000|Device|Theraband with exercise video|Theraband exercise band for resistance training
161305|NCT02938000|Other|usual care with advice to exercise|advice to exercise
161306|NCT02937974|Drug|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
161307|NCT02937974|Drug|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
161308|NCT02937961|Biological|Early SLED|withing 6 to 12 hours
161309|NCT02937961|Biological|Late SLED|when absolute indications will meet
161310|NCT02937948|Other|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
161311|NCT02937948|Radiation|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
161312|NCT02937935|Biological|Protocol Guided Renal Replacement Therapy|In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
161313|NCT02937935|Biological|On Demand Renal Replacement Therapy|Patients to be randomized to the intervention as per standard of care
161314|NCT02937922|Other|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 50-60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
161315|NCT02937922|Other|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 60 to 90 seconds between sets and exercises. The weight will be adjusted to 60 to 70% of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
161316|NCT02937922|Other|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
161317|NCT02937909|Other|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
161318|NCT02937896|Drug|Desmopressin|40 micrograms Nasal Desmopressin.
161319|NCT02937896|Drug|Ketorolac|30mg intravenous Ketorolac.
161320|NCT02937896|Drug|Normal Saline|1cc intravenous Normal Saline.
161321|NCT02937896|Drug|Normal Saline|4 puffs nasal Normal Saline.
161322|NCT02937883|Other|Empowerment intervention|Empowerment intervention for persons with young onset dementia
161323|NCT02937870|Device|Test Product 1|Test adhesive 1 with a thin nozzle
161324|NCT02937870|Device|Test Product 2|Test adhesive 2 with a thin nozzle
161325|NCT02937870|Device|Reference Product|Adhesive Cream
161326|NCT02937870|Other|Negative Control|No adhesive
161327|NCT02937857|Drug|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
161328|NCT02937857|Drug|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
161329|NCT02937844|Biological|Anti-PD-L1 CSR T cells|Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
161330|NCT02937844|Drug|Cyclophosphamide|250 mg/m^2, d1-3
161331|NCT02937844|Drug|Fludarabine|25mg/m^2, d1-3
161332|NCT02937831|Biological|RIXUBIS|
161333|NCT02937818|Drug|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
161334|NCT02937818|Drug|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
161335|NCT02937818|Drug|AZD6738 and olaparib|AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
161336|NCT02937805|Device|Moisturizing vaginal and vulvar sea buckthorn oil cream|
161337|NCT02937805|Device|Moisturizing vaginal and vulvar cream|
161338|NCT02937792|Drug|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
161339|NCT02937779|Drug|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
161340|NCT02937779|Device|Rapid tests HBe Ag|For all HBs Ag positive women
161341|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
161342|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
161386|NCT02937467|Device|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
161387|NCT02937454|Drug|ferric carboxymaltose|FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
161388|NCT02937454|Other|Normal saline 0.9%|Normal saline will be administered as a bolus injection.
161343|NCT02937740|Drug|NATESTO Testosterone Nasal Gel|"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.~For three times daily (after Visit 4 [Day 90] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
161344|NCT02937727|Device|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
161345|NCT02937714|Other|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents & school based interventions for various psychiatric problems
161346|NCT02937701|Biological|ABP 710|Administered by intravenous infusion
161347|NCT02937701|Biological|Infliximab|Administered by intravenous infusion
161348|NCT02937688|Device|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
161349|NCT02937675|Drug|Tomivosertib (eFT-508)|eFT508
161350|NCT02937662|Drug|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
161351|NCT02937662|Drug|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
161352|NCT02937662|Drug|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
161353|NCT02937662|Drug|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
161354|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient and surgeon are blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
161355|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using 36-Fr bougie|After gastric mobilization, the 36-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient and surgeon are blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
161356|NCT02937636|Other|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride & 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
161357|NCT02937636|Other|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
161358|NCT02937623|Device|Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)|Experimental dissolvable polymer strip containing Novamin (15% weight by weight[w/w] calcium sodium phosphosilicate).
161359|NCT02937610|Procedure|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
161360|NCT02937597|Behavioral|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
161361|NCT02937597|Behavioral|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
161362|NCT02937597|Behavioral|HSE|National HSE e-learning programme only
161363|NCT02937584|Drug|GP MDI (PT001) 14.4 μg|Glycopyrronium
161364|NCT02937584|Drug|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
161365|NCT02937571|Drug|Carfilzomib|
161366|NCT02937571|Drug|Lenalidomide|
161367|NCT02937571|Drug|Dexamethasone|
161368|NCT02937558|Drug|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
161369|NCT02937558|Other|Placebo|Isotonic saline
161370|NCT02937545|Other|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
161371|NCT02937545|Other|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
161372|NCT02937532|Behavioral|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
161373|NCT02937532|Behavioral|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
161374|NCT02937519|Device|Chrono-chemotherapy pump:Melodie|
161375|NCT02937519|Device|Routine intravenous drip|
161376|NCT02937519|Drug|induction Chrono-chemotherapy|
161377|NCT02937519|Drug|induction Routine-chemotherapy|
161378|NCT02937519|Drug|cisplatin chrono-chemotherapy|
161379|NCT02937519|Drug|cisplatin routine-chemotherapy|
161380|NCT02937519|Radiation|intensity-modulated radiation therapy|
161381|NCT02937506|Drug|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
161382|NCT02937506|Drug|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
161383|NCT02937493|Behavioral|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
161384|NCT02937480|Other|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
161385|NCT02937480|Other|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
161509|NCT02936635|Drug|tirasemtiv|Oral
161389|NCT02937441|Other|Ultrasonic Measurement|"How we measure;~First measurement shall be taken in 4 hours.~Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,~Third measurement shall be taken after fluid treatment.~Fourth measurement shall be taken at patients polyclinic control."
161390|NCT02937428|Behavioral|Look away from the needle|Participant looks away from the needle during vaccination
161391|NCT02937428|Behavioral|Look at the needle|Participant looks at the needle during vaccination
161392|NCT02937415|Procedure|Breath carbon monoxide|Breath carbon monoxide measurement.
161393|NCT02937415|Procedure|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
161394|NCT02937415|Procedure|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
161395|NCT02937402|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
161396|NCT02937402|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
161397|NCT02937389|Procedure|Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
161398|NCT02937376|Drug|N-acetyl cystein|A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
161399|NCT02937376|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
161400|NCT02937363|Dietary Supplement|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
161401|NCT02937363|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
161402|NCT02937350|Drug|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
161403|NCT02937337|Device|Laryngeal mask insertion with videostylet guided technique|
161404|NCT02937337|Device|Laryngeal mask insertion with standard blind technique|
161405|NCT02937324|Device|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
161406|NCT02937324|Other|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
161407|NCT02937311|Other|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
161408|NCT02937311|Other|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
161409|NCT02937311|Other|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
161410|NCT02937298|Dietary Supplement|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
161411|NCT02937298|Dietary Supplement|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
161412|NCT02937298|Dietary Supplement|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
161413|NCT02937298|Dietary Supplement|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
161414|NCT02937285|Drug|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
161415|NCT02937285|Drug|Mitoxantrone|10 mg / m² monthly infusion for 6 months
161416|NCT02937272|Drug|LY3200882|Administered orally
161417|NCT02937272|Drug|LY3300054|Administered intravenously
161418|NCT02937272|Drug|Gemcitabine|Administered intravenously
161419|NCT02937272|Drug|nab-Paclitaxel|Administered intravenously
161420|NCT02937272|Drug|Cisplatin|Administered intravenously
161421|NCT02937272|Radiation|Intensity Modulated Radiotherapy|
161422|NCT02937259|Other|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
161423|NCT02937246|Device|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
161424|NCT02937246|Device|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
161425|NCT02937233|Biological|Zika Virus Purified Inactivated Vaccine|
161426|NCT02937233|Other|Placebo|
161427|NCT02937220|Procedure|monolithic zirconia crown|New crown material used as final restoration for dental implants
161428|NCT02937220|Procedure|metal ceramic crown|Conventional crown material used as final restoration for dental implants
161429|NCT02937207|Drug|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
161430|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
161431|NCT02937207|Drug|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
161432|NCT02937207|Drug|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
161433|NCT02937207|Drug|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
161434|NCT02937207|Drug|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
161435|NCT02937207|Drug|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
161436|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
161437|NCT02937207|Drug|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
161438|NCT02937207|Drug|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
161439|NCT02937207|Drug|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
161440|NCT02937207|Drug|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
161441|NCT02937194|Behavioral|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
161442|NCT02937194|Behavioral|Pamphlets distribution|Oral health pamphlets distribution
161443|NCT02937181|Drug|Ceftaroline|IV Ceftaroline will be given for 72 hours
161444|NCT02937168|Drug|Reslizumab|Reslizumab will be administered as per the dose and schedule specified in the arm.
161445|NCT02937168|Drug|Fludeoxyglucose F 18 (FDG)|FDG will be administered by IV infusion prior to each PET/CT scan.
161446|NCT02937168|Drug|Placebo|Placebo matching to reslizumab will be administered as per the schedule specified in the arm.
161447|NCT02937142|Behavioral|cognitive behavior group therapy|1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
161448|NCT02937142|Other|Treatment as usual|Education on ADHD, and ADHD medication if indicated
161449|NCT02937116|Drug|IBI308|
161450|NCT02937116|Drug|IBI308\Cisplatinum\Pemetrexed|
161451|NCT02937116|Drug|IBI308\cisplatin\gemcitabine|
161452|NCT02937116|Drug|IBI308\oxaliplatin\capecitabine|
161453|NCT02937116|Drug|IBI308\etoposide\cisplatin|
161454|NCT02937116|Drug|IBI308\irinotecan\5-FU|
161455|NCT02937103|Biological|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
161456|NCT02937090|Other|Blood Draw|Blood sample will be drawn from participants at study entry.
161457|NCT02937090|Other|Stool collection|Stool will be collected from participants at study entry.
161458|NCT02937077|Device|Medtronic Reveal LINQ|
161459|NCT02937051|Other|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
161460|NCT02937025|Device|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
161461|NCT02937012|Drug|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
161462|NCT02937012|Drug|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
161463|NCT02937012|Drug|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
161464|NCT02936999|Drug|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
161465|NCT02936973|Device|Real catgut implantation at acupoints|"Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
161466|NCT02936973|Device|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.~lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
161467|NCT02936947|Device|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
161468|NCT02936947|Other|Free breathing|Free breathing
161469|NCT02936947|Other|Active Breathing Control|Active Breathing Control
161470|NCT02936934|Drug|Morphine|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
161471|NCT02936934|Drug|Oxycodone|"Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
163171|NCT02924246|Biological|cholera vaccination|Oral cholera vaccination on day 0 and day 14
161472|NCT02936908|Other|Ventilatory support|Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
161473|NCT02936895|Drug|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
161474|NCT02936895|Drug|Placebo|Placebo for 2 days
161475|NCT02936882|Procedure|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
161476|NCT02936869|Behavioral|Performance-based monetary incentives|
161477|NCT02936856|Device|Hepatic Arteriography|
161478|NCT02936843|Drug|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
161479|NCT02936843|Drug|PLACEBO|Placebo for Salsalate; 2 Tabets, 3 times daily by mouth (total of 3 grams daily)
161480|NCT02936830|Drug|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
161481|NCT02936830|Drug|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
161482|NCT02936830|Drug|Glycerol|Glycerol with water in a 1: 1 ratio
161483|NCT02936817|Device|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
161484|NCT02936817|Radiation|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
161485|NCT02936804|Device|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
161486|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
161487|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
161488|NCT02936752|Drug|Entinostat|Given PO
161489|NCT02936752|Biological|Pembrolizumab|Given IV
161490|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
161491|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
161492|NCT02936726|Behavioral|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
161493|NCT02936726|Behavioral|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
161494|NCT02936713|Other|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
161495|NCT02936700|Behavioral|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
161496|NCT02936700|Behavioral|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at~decreasing the tendency to try to escape unpleasant mental experiences~increasing psychological flexibility~developing acceptance of psychological events and engagement in valued actions"
161497|NCT02936687|Drug|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure ~8-15 mmHg that is within the range observed during exercise.
161498|NCT02936687|Drug|ET-1 Inhibition|ET-1 inhibition: Ambrisentan is an antagonist of the ETA receptor. Subjects will receive 10 mg of Ambrisentan in a pill form 90-150 minutes prior to the OGTT. This class of drugs have been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Ambrisentan will be taken orally. Systemic delivery of endothelin antagonist have been shown at chronic dosing to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
161499|NCT02936687|Drug|NOS Inhibition Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
161500|NCT02936687|Device|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
161501|NCT02936687|Device|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
161502|NCT02936687|Other|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
161503|NCT02936687|Drug|ET-1 Inhibition Placebo|Placebo pill similar in size and shape to Ambrisentan will be used as placebo control.
161504|NCT02936674|Device|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
161505|NCT02936674|Device|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
161506|NCT02936661|Drug|Tranexamic Acid|
161507|NCT02936661|Drug|Placebo|
161508|NCT02936648|Other|quality improvement intervention|The intervention activities included: assessment, planning, stakeholder engagement, education, ongoing process monitoring, program adaptation, problem identification and problem solving, data audit/feedback, program marketing, network development, among others.
161510|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
161511|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
161512|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
161513|NCT02936609|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
161514|NCT02936596|Drug|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
161515|NCT02936596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid
161516|NCT02936583|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
161517|NCT02936570|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-067)"
161518|NCT02936557|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z09-054)"
161519|NCT02936544|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code:Z09-054)
161520|NCT02936518|Procedure|Lingual frenotomy and/or maxillary labial frenectomy|
161521|NCT02936505|Drug|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):~Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; >12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily."
161522|NCT02936505|Drug|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
161523|NCT02936505|Drug|Rabbit Anti thymocyte globulin|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
161524|NCT02936505|Drug|Corticosteroids|"Corticosteroids:~Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.~From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg > 6 months."
161525|NCT02936505|Drug|Tacrolimus|"Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, >12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
161526|NCT02936492|Drug|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
161527|NCT02936492|Drug|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
161528|NCT02936492|Drug|BAY1003803 0.01% ointment|Topical administration for 22 h per day
161529|NCT02936492|Drug|BAY1003803 0.1% ointment|Topical administration for 22 h per day
161530|NCT02936492|Drug|Lipophilic cream vehicle|Topical administration for 22 h per day
161531|NCT02936492|Drug|Ointment vehicle|Topical administration for 22 h per day
161532|NCT02936492|Drug|Clobetasol propionate|Topical administration for 22 h per day
161533|NCT02936479|Drug|C1-INH (Berinert)|
161534|NCT02936466|Behavioral|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :~At least one connection per week during 4 weeks~Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.~After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
161535|NCT02936453|Procedure|Device implantation|"Implantation of Specify 5-6-5 lead or Go-2 lead in epidural space~Implantation of Activa RC neurostimulator"
161536|NCT02936427|Drug|Dexamethasone|perineural infiltration of dexamethasone
161537|NCT02936414|Drug|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
161538|NCT02936414|Drug|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
161539|NCT02936401|Behavioral|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
161540|NCT02936388|Procedure|SIRT|catheter-based application of radioactive microspheres into the hepatic artery
161541|NCT02936388|Procedure|DSM-TACE|catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
161542|NCT02936375|Drug|Iguratimod|25mg twice a day, orally administrated
161543|NCT02936375|Drug|Cyclophosphamide|1g/m², every 4 weeks, intravenous
161544|NCT02936375|Drug|Azathioprine|2mg/kg·d, once a day, orally administrated
161545|NCT02936375|Drug|Steroids|Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
161546|NCT02936362|Other|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
161674|NCT02935517|Biological|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
161547|NCT02936362|Other|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
161548|NCT02936349|Other|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
161549|NCT02936336|Other|exercise|circuit exercise, aerobic dance and Tai Chi exercise
161550|NCT02936323|Drug|PEN-221|Administration of PEN-221 once every three weeks
161551|NCT02936310|Behavioral|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
161552|NCT02936297|Dietary Supplement|High dose Gluten|
161553|NCT02936297|Dietary Supplement|Low dose Gluten|
161554|NCT02936297|Dietary Supplement|Lactose free placebo|
161555|NCT02936284|Behavioral|Music Enhancement|
161556|NCT02936284|Behavioral|Play Date|
161557|NCT02936271|Other|Vasculera|"Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment."
161558|NCT02936271|Other|Placebo|
161559|NCT02936258|Procedure|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
161560|NCT02936258|Procedure|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
161561|NCT02936258|Procedure|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
161562|NCT02936245|Other|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
161563|NCT02936206|Drug|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
161564|NCT02936206|Drug|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
161565|NCT02936193|Procedure|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
161566|NCT02936193|Procedure|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
161567|NCT02936180|Biological|HD-TIV|
161568|NCT02936180|Biological|SD-QIV|
161569|NCT02936167|Biological|Ringer Lactate|
161570|NCT02936167|Biological|Plasmalyte|
161571|NCT02936154|Drug|PF-06650833|
161572|NCT02936154|Drug|placebo|
161573|NCT02936141|Behavioral|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
161574|NCT02936128|Other|TruSkin|
161575|NCT02936128|Other|Wound Cover|
161576|NCT02936115|Other|TruSkin®|
161577|NCT02936115|Other|Wound Cover|
161578|NCT02936102|Drug|FAZ053|Anti-PD-L1 Antibody
161579|NCT02936102|Drug|PDR001|Anti-PD-1 Antibody
161580|NCT02936089|Drug|Ara-C|Ara-C was administered at 1-2 g/m2 q12 h ×6 cycles
161581|NCT02936089|Other|autologous HSCT|
161582|NCT02936089|Other|allogeneic HSCT|
161583|NCT02936076|Other|Exercise intervention|
161584|NCT02936076|Other|Delayed exercise intervention|
161585|NCT02936063|Procedure|Surgical staples|Closure of surgical wound at skin level with surgical staples
161586|NCT02936063|Procedure|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
161587|NCT02936050|Procedure|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
161588|NCT02936037|Drug|MD1003 100mg capsule|
161589|NCT02936037|Drug|PLACEBO|an inactive substance
161590|NCT02936024|Procedure|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
161591|NCT02936024|Procedure|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
161592|NCT02936011|Device|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
161593|NCT02935998|Drug|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
163172|NCT02924246|Other|raw milk|raw milk
161594|NCT02935985|Other|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.~Participants will be assessed (clinically or by telephone) over a period of 180 days."
161595|NCT02935972|Drug|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
161596|NCT02935972|Drug|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
161597|NCT02935972|Drug|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
161598|NCT02935959|Drug|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
161599|NCT02935959|Drug|nebulized Dexmedetomidine|
161600|NCT02935959|Drug|nebulized midazolam|
161601|NCT02935946|Other|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
161602|NCT02935933|Drug|bupivicaine|Paravertebral block
161603|NCT02935933|Drug|morphine|
161604|NCT02935933|Drug|Dexmedetomidine|
161605|NCT02935920|Behavioral|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
161606|NCT02935907|Drug|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
161607|NCT02935894|Drug|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
161608|NCT02935894|Other|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
161609|NCT02935894|Drug|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
161610|NCT02935881|Device|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
161611|NCT02935881|Procedure|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
161612|NCT02935855|Drug|Dabigatran|
161613|NCT02935855|Drug|Apixaban|
161614|NCT02935855|Drug|Rivaroxaban|
161615|NCT02935855|Drug|Edoxaban|
161616|NCT02935855|Drug|Warfarin|
161617|NCT02935855|Drug|Acenocumarole|
161618|NCT02935842|Other|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
161619|NCT02935842|Other|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
161620|NCT02935829|Other|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
161621|NCT02935829|Other|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
161622|NCT02935829|Other|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
161623|NCT02935829|Other|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
161624|NCT02935829|Other|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
161625|NCT02935829|Other|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
161626|NCT02935816|Radiation|Whole body MRI|We have developed and assessed the feasibility of performing whole--‐body multi--‐parametric MRI for staging metastatic disease. We hypothesize that a whole body multi--‐parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole--‐body multi--‐parametric MRI within this population of men
163173|NCT02924246|Other|pasteurized milk|pasteurized milk
161627|NCT02935803|Procedure|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
161628|NCT02935790|Drug|ACY-241|tablet
161629|NCT02935790|Drug|nivolumab|infusion
161630|NCT02935790|Drug|ipilimumab|infusion
161631|NCT02935777|Dietary Supplement|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
161632|NCT02935777|Dietary Supplement|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
161633|NCT02935764|Drug|Irinotecan|180 mg/m2 iv gtt, d1
161634|NCT02935764|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
161635|NCT02935764|Drug|Leucovorin|400mg/m2 iv gtt,d1
161636|NCT02935751|Other|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
161637|NCT02935738|Drug|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
161638|NCT02935725|Drug|Low dose AUT00206 800mg|
161639|NCT02935725|Drug|High dose AUT00206 2000 mg|
161640|NCT02935725|Drug|Placebo|
161641|NCT02935725|Drug|Ketamine|
161642|NCT02935725|Other|Saline|
161643|NCT02935712|Drug|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.~Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
161644|NCT02935712|Drug|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
161645|NCT02935712|Drug|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
161646|NCT02935699|Drug|Test Drug (JDP-205)|Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
161647|NCT02935699|Drug|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of ~2 minutes
161648|NCT02935686|Biological|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5*10^10 viral particles (vp), administered intramuscularly.
161649|NCT02935686|Biological|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
161650|NCT02935686|Biological|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
161651|NCT02935686|Other|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
161652|NCT02935673|Drug|lumicitabine|Oral administration of lumicitabine as tablet.
161653|NCT02935673|Drug|Placebo|Oral administration of matching placebo.
161654|NCT02935660|Device|enLighten Laser|Laser tattoo removal treatment
161655|NCT02935647|Drug|Diprivan|
161656|NCT02935634|Biological|Nivolumab|
161657|NCT02935634|Biological|Ipilimumab|
161658|NCT02935634|Biological|Relatlimab|
161659|NCT02935634|Biological|BMS-986205|
161660|NCT02935634|Drug|Rucaparib|
161661|NCT02935621|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
161662|NCT02935621|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
161663|NCT02935608|Drug|BIIB074|Administered as specified in the treatment arm
161664|NCT02935608|Drug|Placebo|Matched placebo
161665|NCT02935595|Drug|Ketamine|Ketamine Hydrochloride Injection
161666|NCT02935582|Drug|Enstilar® aerosol foam|Treatment according to local labelling
161667|NCT02935582|Drug|Other topical|Treatment according to local practise
161668|NCT02935569|Device|Compression HeadBand|"commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
161669|NCT02935556|Other|no intervention|database and epigenetic study
161670|NCT02935543|Biological|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10^7 CART19 cells, Day 2, 30% fraction: 3x10^7-1.5x10^8 CART19 cells, Day 3, 60% fraction: 6x10^7-3x10^8 CART19 cells
161671|NCT02935530|Drug|s-LMWH|2125KU, subcutaneous injection of 5-10 days
161672|NCT02935530|Drug|LMWH|4250KU, subcutaneous injection of 5-10 days
161673|NCT02935530|Drug|Argatroban|20mg, injection for 5-10 days
161748|NCT02934893|Other|Medication Management Clinic|referral to medication management clinic from primary care
161675|NCT02935504|Behavioral|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:~Toolkit Care coordination Psychiatric consultation Implementation support~Engage clinic leaders and staff~Identify leadership group and prepare for change~Assess readiness to implement PRISM~Identify steps to achieve goals~Implement PRISM components into the clinic~Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
161676|NCT02935504|Behavioral|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
161677|NCT02935491|Device|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.~Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
161678|NCT02935478|Device|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
161679|NCT02935465|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
161680|NCT02935465|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
161681|NCT02935452|Behavioral|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
161682|NCT02935439|Other|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
161683|NCT02935426|Device|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
161684|NCT02935426|Device|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
161685|NCT02935413|Device|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
161686|NCT02935413|Behavioral|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
161687|NCT02935400|Drug|Hemin|Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
161688|NCT02935387|Other|Taper|Taper
161689|NCT02935374|Drug|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
161690|NCT02935374|Drug|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
161691|NCT02935374|Drug|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
161692|NCT02935361|Drug|Atezolizumab|Given IV
161693|NCT02935361|Drug|Guadecitabine|Given SC
161694|NCT02935348|Radiation|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
161695|NCT02935335|Drug|Menotrophin|
161696|NCT02935322|Drug|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
161697|NCT02935322|Drug|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
161698|NCT02935322|Drug|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
161699|NCT02935322|Other|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.~In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
163174|NCT02924246|Other|UHT milk|UHT milk
161700|NCT02935309|Drug|Lenvatinib|Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
161701|NCT02935309|Drug|Capecitabine|Pre-surgery Capecitabine, 850 mg/m^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
161702|NCT02935309|Radiation|External Radiation Therapy (XRT)|Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
161703|NCT02935296|Behavioral|Integrated Intervention|systems navigation, psychosocial counseling
161704|NCT02935283|Procedure|MRI|MRI, fMRI, 1H MRS, DTI
161705|NCT02935283|Behavioral|Behavioral|Battery of executive function tasks
161706|NCT02935257|Biological|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
161707|NCT02935231|Drug|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
161708|NCT02935231|Behavioral|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
161709|NCT02935231|Other|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
161710|NCT02935218|Behavioral|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
161711|NCT02935205|Drug|Enzalutamide|Given PO
161712|NCT02935205|Drug|Indomethacin|Given PO
161713|NCT02935192|Biological|Vaccine|Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
161714|NCT02935192|Other|Placebo|Phosphate buffered saline, 0.5 mL by IM injection
161715|NCT02935179|Dietary Supplement|White sweet potato diet|The diet were supplied 516 kcal daily
161716|NCT02935166|Other|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
161717|NCT02935153|Biological|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
161718|NCT02935127|Procedure|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
161719|NCT02935127|Procedure|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
161720|NCT02935114|Drug|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)~37% Carbamide Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
161721|NCT02935114|Drug|35% hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)~35% Hydrogen Peroxide application (2 sessions of 45 minutes)~Tooth sensitivity (Verbal and visual scale) and color evaluation"
161722|NCT02935101|Drug|Prednisolone|formulated for oral administration. encapsulated.
161723|NCT02935101|Drug|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
161724|NCT02935088|Device|Fractional Flow Reserve|Measurement of physiologic parameters
161725|NCT02935075|Drug|Tenofovir disoproxil fumarate|Oral daily
161726|NCT02935075|Drug|Lamivudine|Oral daily
161727|NCT02935075|Drug|Efavirenz|Oral daily
161728|NCT02935062|Behavioral|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
161729|NCT02935062|Behavioral|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
161730|NCT02935062|Behavioral|Placebo Therapy|No intervention to improve speech.
161731|NCT02935049|Procedure|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
161732|NCT02935036|Drug|ADPS topical product|topical product
161733|NCT02935036|Drug|Placebo Control|topical product
161734|NCT02935023|Radiation|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
161735|NCT02935010|Drug|Esomeprazole|proton pump inhibitor
161736|NCT02935010|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
161737|NCT02935010|Drug|Amoxicillin|antibiotic for H. pylori eradication
161738|NCT02935010|Drug|Clarithromycin|antibiotic for H. pylori eradication
161739|NCT02935010|Drug|Metronidazole|antibiotic for H. pylori eradication
161740|NCT02935010|Drug|Levofloxacin|antibiotic for H. pylori eradication
161741|NCT02934997|Other|Observational study|
161742|NCT02934958|Behavioral|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
161743|NCT02934958|Behavioral|Standard of Care|Patients will be tracked to compare how effective are usual care methods
161744|NCT02934945|Drug|budesonide 160μg/formoterol 4.5μg|SMART regimen
161745|NCT02934932|Drug|Brexpiprazole|Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
161746|NCT02934919|Drug|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
161747|NCT02934906|Procedure|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
161749|NCT02934893|Other|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
161750|NCT02934880|Other|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
161751|NCT02934880|Other|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
161752|NCT02934867|Other|Protocol phone advice|Protocol phone advice
161753|NCT02934867|Other|Usual phone advice|Usual phone advice
161754|NCT02934841|Drug|Conbercept|
161755|NCT02934841|Drug|sham|
161756|NCT02934828|Drug|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
161757|NCT02934828|Drug|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
161758|NCT02934815|Other|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
161759|NCT02934802|Device|Total Knee prothesis e motion PS Pro|
161760|NCT02934789|Procedure|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
161761|NCT02934789|Drug|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
161762|NCT02934776|Device|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
161763|NCT02934763|Drug|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
161764|NCT02934763|Drug|Saline|Saline as placebo
161765|NCT02934750|Behavioral|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:~Breathe in through your nose (as if you are smelling something) for about 2 seconds.~Pucker your lips like you're getting ready to blow out candles on a birthday cake.~Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.~Repeat."
161766|NCT02934737|Other|Progression of diabetes|
161767|NCT02934724|Procedure|Self sample from vagina|Self sample using The Rover's Evalyn Brush
161768|NCT02934724|Procedure|Self sample from the oral cavity|Self sample using COPAN FloqSwab
161769|NCT02934724|Other|Questionnaire|Questionnaire about vaccination status and sexual behaviour
161770|NCT02934698|Drug|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
161771|NCT02934685|Radiation|hypofraction|70 Gy in 28 fractions over 5.6 weeks
161772|NCT02934685|Radiation|convention|80Gy in 40 fractions over 8 weeks
161773|NCT02934672|Other|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
161774|NCT02934646|Device|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
161775|NCT02934633|Behavioral|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
161776|NCT02934633|Behavioral|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
161777|NCT02934620|Device|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
161778|NCT02934620|Device|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
161779|NCT02934620|Behavioral|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
161780|NCT02934607|Drug|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
161781|NCT02934607|Drug|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
161864|NCT02934009|Device|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
161782|NCT02934594|Other|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
161783|NCT02934568|Drug|LEE011|Single agent LEE011 or in combination with other treatments
161784|NCT02934555|Drug|Ubiquinol|300 mg Ubiquinol (3 mL liquid Ubiquinol).
161785|NCT02934555|Dietary Supplement|Ensure|50 mL Ensure
161786|NCT02934542|Device|AutoLap system|
161787|NCT02934529|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
161788|NCT02934529|Drug|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
161789|NCT02934529|Drug|5-FU|5-FU 400 mg/m² bolus day 1, q d15
161790|NCT02934529|Drug|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
161791|NCT02934529|Drug|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
161792|NCT02934529|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
161793|NCT02934529|Drug|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
161794|NCT02934529|Drug|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
161795|NCT02934529|Drug|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
161796|NCT02934529|Drug|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
161797|NCT02934516|Procedure|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 4-5 Allies forceps applied 1.5 to 2 cm apart from the other along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.~Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
161798|NCT02934503|Biological|Pembrolizumab|200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
161799|NCT02934503|Drug|Cisplatin|75 mg/m2
161800|NCT02934503|Drug|Carboplatin|AUC 6
161801|NCT02934503|Drug|Etoposide|IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
161802|NCT02934503|Radiation|Radiation therapy|Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
161803|NCT02934490|Device|Mesh|Meshes were made by Gynemech TM PS, (Johnson & Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
161804|NCT02934477|Other|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
161805|NCT02934464|Drug|RAMUCIRUMAB|
161806|NCT02934464|Drug|Paclitaxel|
161807|NCT02934464|Drug|FOLFOX 4|
161808|NCT02934464|Drug|mFOLFOX 6|
161809|NCT02934464|Drug|XELOX|
161810|NCT02934438|Dietary Supplement|Neo40|
161811|NCT02934438|Dietary Supplement|Placebo|
161812|NCT02934425|Other|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
161813|NCT02934425|Other|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
161814|NCT02934412|Drug|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
161815|NCT02934412|Drug|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
161816|NCT02934399|Other|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.~A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
161817|NCT02934386|Device|WinMedical WinPack device|
161818|NCT02934373|Device|A New Sound Processor|
161819|NCT02934360|Device|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
161820|NCT02934347|Procedure|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
161821|NCT02934334|Other|Observational|
161822|NCT02934321|Dietary Supplement|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
161823|NCT02934321|Dietary Supplement|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
161824|NCT02934308|Device|Skin Conductance Monitor|
161825|NCT02934295|Biological|Determination of Anti-Rubella Antibody, E1|
161826|NCT02934282|Drug|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
161827|NCT02934269|Drug|Placebo|
161828|NCT02934269|Drug|CC-90006|
161829|NCT02934256|Drug|Icotinib|Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
161830|NCT02934243|Device|laryngeal mask insertion|airway management with laryngeal mask
161861|NCT02934048|Other|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
161862|NCT02934035|Drug|Antidepressant|
161863|NCT02934022|Drug|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
161831|NCT02934230|Behavioral|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)~Aerobics: Walking for 20 minutes at moderate intensity.~Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
161832|NCT02934217|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
161833|NCT02934217|Drug|Placebo|One single intravenous bolus injection of Placebo
161834|NCT02934217|Procedure|Echocardiography|3 years after AMI
161835|NCT02934204|Drug|methotrexate|
161836|NCT02934204|Drug|temozolomide|
161837|NCT02934191|Drug|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
161838|NCT02934191|Other|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
161839|NCT02934191|Drug|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
161840|NCT02934191|Drug|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
161841|NCT02934178|Biological|WRSS1|
161842|NCT02934165|Behavioral|Family Safety 123|Theoretically-based injury prevention videos for families
161843|NCT02934165|Behavioral|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
161844|NCT02934152|Drug|H pylori eradication|H pylori eradication
161845|NCT02934152|Other|H pylori eradication timing|Early or late eradication
161846|NCT02934139|Drug|Cavosonstat|CFTR modulator that stabilizes CFTR
161847|NCT02934139|Other|Placebo|Matched placebo
161848|NCT02934126|Other|breast cancer patients|semi structured face to face interviews
161849|NCT02934113|Behavioral|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
161850|NCT02934113|Behavioral|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
161851|NCT02934100|Device|Shock Master 300|"Extracorporeal Shock Wave Therapy~In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:~Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
161852|NCT02934100|Device|Skanlab 25 BODYWAVE|"Electric field diathermy therapy - Capacitive energy transfer system (CETS)~Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:~Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
161853|NCT02934100|Device|EVO US13 CosmoGamma|"Ultrasound therapy~Doses applied as following:~Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:~Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
161854|NCT02934100|Device|Sham LASER CTL1106MX|"Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.~Each patient will also receive kinesiotherapy treatment that will consist of:~eight-minute massage of posterior lower leg muscles~plantar aponeurosis stretching"
161855|NCT02934087|Procedure|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
161856|NCT02934074|Other|No intervention|
161857|NCT02934061|Device|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
161858|NCT02934061|Drug|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
161859|NCT02934048|Other|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
161860|NCT02934048|Other|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
162002|NCT02932930|Drug|0.2% Ropivacaine|0,2ml/kg of 0,2% ropivacaine
260027|NCT02217631|Drug|Placebo|
161865|NCT02933996|Device|TEAS+GA group|The acupoints including Zusanli and Shenshu, were identified before electrical stimulation with surface electrodes. Selection of these acupoints was based on a consensus between the acupuncturists of the study.
161866|NCT02933996|Device|Sham TEAS+GA group|No electrical stimulation sensation is performed in the Sham TEAS group. In the Sham TEAS group, pseudo-stimulation is provided by deliberately connecting the electrodes to the incorrect output socket of the electroacupuncture device, and thus there is no flow of electric current. Patients could see the output light flashing but no current was transmitted throughout the procedure. Patients would be told that the stimulation frequency selected was not perceivable by human beings.
161867|NCT02933983|Other|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
161868|NCT02933970|Other|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
161869|NCT02933944|Biological|TG02-treatment|
161870|NCT02933944|Drug|Pembrolizumab|
161871|NCT02933918|Other|Probiotics|Safety of nasal irrigation with probiotics in healthy volunteers
161872|NCT02933905|Drug|Intravitreal Ranibizumab injection|
161873|NCT02933892|Procedure|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
161874|NCT02933879|Drug|NVXT topical|topical treatment
161875|NCT02933879|Drug|Placebo (Vehicle) Topical|Placebo (Vehicle) Topical
161876|NCT02933866|Drug|DSXS topical|topical treatment
161877|NCT02933866|Drug|Vehicle topical|topical treatment
161878|NCT02933853|Drug|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
161879|NCT02933853|Drug|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
161880|NCT02933840|Device|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
161881|NCT02933827|Drug|ELIXCYTE|Adipose-derived stem cells (ADSCs)
161882|NCT02933814|Drug|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
161883|NCT02933801|Drug|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
161884|NCT02933801|Other|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
161885|NCT02933788|Drug|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
161886|NCT02933788|Drug|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
161887|NCT02933775|Genetic|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
161888|NCT02933775|Drug|Fludarabine|30 mg/m^2/day×4 days
161889|NCT02933775|Drug|Cyclophosphamide|500 mg/m^2/day×2 days
161890|NCT02933762|Drug|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
161891|NCT02933762|Drug|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
161892|NCT02933749|Device|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
161893|NCT02933749|Device|BIS|Bispectral index
161894|NCT02933736|Drug|Ribociclib|
161895|NCT02933723|Procedure|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
161896|NCT02933697|Drug|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
161897|NCT02933697|Drug|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
161898|NCT02933684|Drug|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
161899|NCT02933684|Behavioral|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
161900|NCT02933684|Drug|Placebo|Administered in pill form.
161901|NCT02933671|Procedure|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
161902|NCT02933671|Procedure|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
161903|NCT02933671|Drug|Ropivacaine|Local anesthetic (numbing drug)
161904|NCT02933671|Drug|Saline|Salt water placebo
161905|NCT02933658|Drug|Telmisartan|
161906|NCT02933658|Drug|Amlodipine|
161907|NCT02933658|Drug|Rosuvastatin|
161908|NCT02933645|Drug|Actrapid|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
162003|NCT02932930|Drug|0.9% normal saline|0,2ml/kg of 0.9% normal saline
162162|NCT02931747|Dietary Supplement|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
161909|NCT02933645|Drug|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
161910|NCT02933645|Radiation|[18F]-FDG PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq [18F]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
161911|NCT02933645|Drug|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
161912|NCT02933632|Other|Physical Therapy-SAP|"Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~Day 4 and other days) Patients repeated the gait training until the discharge date."
161913|NCT02933632|Other|Physical Therapy-ARP|"Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~Day 2) Patients repeated three times the day 1-3°approach;~Day 3) Patients repeated three times the day 1-3°approach."
161914|NCT02933606|Drug|BNC210|
161915|NCT02933606|Drug|Placebo|
161916|NCT02933593|Drug|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
161917|NCT02933593|Drug|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
161918|NCT02933593|Drug|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
161919|NCT02933580|Drug|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
161920|NCT02933580|Other|Placebo|Participants will receive matching placebo tablets on Day 1.
161921|NCT02933567|Other|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
161922|NCT02933554|Device|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
161923|NCT02933528|Drug|DSXS Topical product|once daily for 28 days
161924|NCT02933515|Other|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
161925|NCT02933502|Drug|DSXS topical product|treatment daily for 28 days
161926|NCT02933489|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
161927|NCT02933489|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
161928|NCT02933489|Other|Quality-of-Life Assessment|Ancillary studies
161929|NCT02933489|Other|Questionnaire Administration|Ancillary studies
161930|NCT02933476|Device|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
161931|NCT02933463|Other|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
161932|NCT02933463|Other|Clinpro sealant|
161933|NCT02933450|Drug|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
161934|NCT02933437|Drug|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
161935|NCT02933424|Dietary Supplement|Protein Powder|
161936|NCT02933411|Other|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
162083|NCT02932358|Other|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
162084|NCT02932358|Other|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
162291|NCT02930733|Drug|Saline|2 ml saline subcutaneously bilaterally
161937|NCT02933411|Other|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.~Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
161938|NCT02933411|Other|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participant evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
161939|NCT02933411|Other|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
161940|NCT02933398|Procedure|Robotic Assisted Nephrectomy|Robotic (Davinci)
161941|NCT02933398|Procedure|Laparoscopic Assisted Nephrectomy|Regular Laparoscopic Technique.
161942|NCT02933385|Behavioral|Health Risks assessement|Home made questionnaire questioning about the participant's lifestyle habits, risk factors and other.
161943|NCT02933385|Behavioral|Web-based health discussions|Create interactions between the employees.
161944|NCT02933385|Behavioral|SOScuisine website|Site that is personalized to the employee. It provides menus, grocery shopping list and other.
161945|NCT02933385|Behavioral|Health screening|Screen for diabetes, cholesterol, blood pressure and body weight.
161946|NCT02933385|Behavioral|Closing events|these aim to motivate the employees to continue into the program.
161947|NCT02933385|Behavioral|Coaching|The first year participant will be coached by a nurse, second year by a nutritionist, and third year by a kinesiologist.
161948|NCT02933385|Behavioral|Social Health platform|
161949|NCT02933385|Behavioral|Accelerometer provided|Social Health Platform: employees can challenge themselves or each other.
161950|NCT02933372|Drug|Varenicline|In experiment 1, Patients will take Varenicline, 1 pill per day or 1 pill twice per day, for 10 days. In Experiment 2, patients will take either Varenicline or placebo initially for 3 weeks, then off for 3 weeks, then back on for 3 weeks.
161951|NCT02933372|Radiation|PET Scan|"In Experiment 1, 2 different PET scanning sessions, radiotracers will be injected into the participant's vein through an IV (intravenous catheter or plastic tube inserted in an arm vein). A tracer refers to a small amount of a radioactive substance that does not alter body function.~Experiment 2 does not require any PET scans."
161952|NCT02933372|Other|Evaluation by Investigator|In both arms, the patient will undergo a evaluation of of the participant's parkinsonism, mood, cognition, gait speed, and balance. This will be determined by cognitive testing and medical evaluation by investigator.
161953|NCT02933333|Biological|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
161954|NCT02933333|Biological|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
161955|NCT02933333|Biological|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
161956|NCT02933320|Biological|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or MAD and recommended Phase II dose (RP2D) for evaluation of BI-1206
161957|NCT02933320|Biological|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the Recommended Phase 2 Dose
161958|NCT02933320|Biological|Combination of BI-1206 with Rituximab|An investigation of combination treatment of BI-1206 with Rituximab.
161959|NCT02933307|Device|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
161960|NCT02933307|Device|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
161961|NCT02933294|Procedure|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
161962|NCT02933294|Procedure|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
161963|NCT02933281|Biological|MTBVAC|Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
161964|NCT02933281|Biological|BCG|BCG 5 x 10^5 CFU
161965|NCT02933268|Dietary Supplement|High water intake|High water intake aimed at achieving an urine osmolality < 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
161966|NCT02933268|Other|Ad libitum water intake|Water intake guided by thirst
161967|NCT02933255|Biological|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10^8 infectious units; PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10^9 infectious units.
161968|NCT02933255|Drug|Nivolumab|Nivolumab is to be administered as a flat dose of 240 mg over approximately 60-minutes via IV infusion.
161969|NCT02933242|Radiation|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
161970|NCT02933229|Device|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
161971|NCT02933229|Drug|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.~If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
161972|NCT02933190|Procedure|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
161973|NCT02933177|Behavioral|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
161974|NCT02933177|Behavioral|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.~The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):~Boards of known photographs to recall autobiographical memories~Newspapers to read, talk, associate memories around an article~Massage Oil, refreshing wipes, cream to reconnect with the body~Clay, cookie pieces, washable felt and paper to create shapes, draw.~Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .~Listening to music~Relaxation-Breathing~Cushion, foam balls to vent his energy on secure hardware.~Plush doll or to invest a vector object of affection and empathy~Sensory flash balls that the patient can squeeze, throw, roll.~Games with which the patient can play according to its possibilities."
161975|NCT02933164|Device|Continuous Glucose Monitoring System|Effectiveness and safety of a Continuous Glucose Monitoring System
161976|NCT02933151|Dietary Supplement|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
161977|NCT02933125|Behavioral|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:~The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.~Parenting skill training (PST) for Caregivers:~The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
161978|NCT02933125|Behavioral|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
161979|NCT02933112|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
161980|NCT02933099|Drug|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
161981|NCT02933099|Drug|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
161982|NCT02933086|Other|Specific exercises for lumbar stabilization|The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
161983|NCT02933086|Other|Conventional therapy|The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
161984|NCT02933073|Biological|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
161985|NCT02933060|Other|Normal saline (1000 mL)|
161986|NCT02933060|Other|Control|
161987|NCT02933047|Procedure|Total laparoscopic hysterectomy|
161988|NCT02933047|Procedure|Total laparoscopic hysterectomy|
161989|NCT02933034|Drug|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
161990|NCT02933021|Other|Blood sample taken|
161991|NCT02933021|Other|Answering a lifestyle questionnaire|
161992|NCT02933021|Other|Phone call from researcher|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
161993|NCT02933008|Other|aNMT biofeedback|neuromuscular training intervention that incorporates biofeedback training
161994|NCT02932969|Drug|BMS-986231|
161995|NCT02932969|Drug|BMS-986231 Placebo|
161996|NCT02932956|Genetic|GAP T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:~DL1: 1x10^7/m2~DL2: 3x10^7/m2~DL3: 1x10^8/m2~DL4: 3x10^8/m2~DL5: 1x10^9/m2~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
161997|NCT02932956|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
161998|NCT02932956|Drug|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
161999|NCT02932943|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
162000|NCT02932943|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
162001|NCT02932930|Procedure|QLB bloc|
162004|NCT02932917|Device|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
162005|NCT02932904|Drug|Vortioxetine|Vortioxetine Overencapsulated Tablet
162006|NCT02932904|Drug|Paroxetine|Paroxetine Overencapsulated Tablets.
162007|NCT02932904|Drug|Placebo|Vortioxetine Placebo-matching Capsules.
162008|NCT02932891|Drug|DSXS topical|topical treatment
162009|NCT02932878|Drug|DSXS topical|topical treatment
162010|NCT02932852|Procedure|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
162011|NCT02932852|Procedure|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
162012|NCT02932839|Device|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
162013|NCT02932826|Biological|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml NS
162014|NCT02932826|Drug|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
162015|NCT02932813|Behavioral|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
162016|NCT02932800|Procedure|"Fixation with ballerina technique and flip"|
162017|NCT02932800|Procedure|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
162018|NCT02932800|Other|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
162019|NCT02932787|Device|Height-adjustable workstation|
162020|NCT02932774|Drug|Cetirizine|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
162021|NCT02932774|Drug|Loratadine|Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
162022|NCT02932774|Other|Placebo|Placebo syrup once daily before 10:00 AM for 2 weeks
162023|NCT02932761|Drug|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
162024|NCT02932761|Procedure|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
162025|NCT02932748|Dietary Supplement|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
162026|NCT02932748|Behavioral|Group Phone (GP)|Weight management program delivered via group conference call.
162027|NCT02932748|Dietary Supplement|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
162028|NCT02932748|Behavioral|Individual Phone (IP)|Weight management program delivered via individual phone call.
162029|NCT02932748|Behavioral|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
162030|NCT02932722|Other|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
162031|NCT02932722|Drug|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
162032|NCT02932722|Drug|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
162033|NCT02932709|Behavioral|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
162034|NCT02932696|Other|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately within 3 months after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).~30-minute AIT sessions will occur 5x per week for 4 weeks.~1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
162035|NCT02932683|Device|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
162036|NCT02932670|Other|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
162037|NCT02932657|Other|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
162038|NCT02932644|Other|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
162039|NCT02932644|Other|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
162085|NCT02932332|Other|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
162040|NCT02932631|Other|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.~The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
162041|NCT02932618|Biological|von Willebrand factor (Recombinant)|Lyophilized powder and solvent to prepare solution for injection.
162042|NCT02932618|Biological|Antihemophilic Factor (Recombinant)|Packaged in single boxes with 2 glass vials, with one vial containing the lyophilized ADVATE and the second vial containing the diluent.
162043|NCT02932605|Drug|Placebo|Placebo
162044|NCT02932605|Drug|Cannabidiol|Cannabidiol
162045|NCT02932592|Device|Continuous Glucose Monitoring System (i Pro 2 - Medtronic)|This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
162046|NCT02932579|Other|Pharmacogenomic Testing|Saliva collection (5mL)
162047|NCT02932579|Drug|Ibuprofen|400 mg
162048|NCT02932579|Drug|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
162049|NCT02932579|Drug|acetominophen|650 mg
162050|NCT02932579|Drug|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
162051|NCT02932566|Drug|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
162052|NCT02932566|Drug|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
162053|NCT02932553|Device|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
162054|NCT02932540|Other|change of head position|patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
162055|NCT02932527|Behavioral|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
162056|NCT02932527|Procedure|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
162057|NCT02932527|Procedure|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
162058|NCT02932514|Device|Eversense (Senseonics) Continuous Glucose Monitoring System|"Evaluate accuracy of Eversense CGM System to SMBG Meter.~Compare performance between abdomen and arm insertion sites.~Determine the usability of the Eversense System in a home-use setting for 180 days."
162059|NCT02932501|Procedure|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
162060|NCT02932501|Procedure|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
162061|NCT02932501|Procedure|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
162062|NCT02932488|Drug|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
162063|NCT02932475|Drug|Metformin|1000 mg twice a day
162064|NCT02932475|Drug|Placebo|Delivered to match active drug
162065|NCT02932462|Drug|DSXS|topical product
162066|NCT02932462|Drug|Placebo|topical product
162067|NCT02932436|Drug|Empagliflozin|10 mg per os daily for 12 weeks
162068|NCT02932436|Drug|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
162069|NCT02932423|Other|Control product E|Plain water
162070|NCT02932423|Other|Test product A|Beverage with no sugar but sweetener
162071|NCT02932423|Other|Test product B|Beverage with 22 g/L sugar and sweetener
162072|NCT02932423|Other|Test product C|Beverage with 33 g/L sugar and sweetener
162073|NCT02932423|Other|Test product D|Beverage with 47 g/L sugar and sweetener
162074|NCT02932423|Other|Comparative product F|Beverage with 98 g/L sugar
162075|NCT02932410|Drug|Macitentan|Dispersible tablet; Oral use
162076|NCT02932410|Other|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and i.v./s.c. prostanoids.
162077|NCT02932397|Drug|Intravenous dose of 0.5 mg/kg of propofol|
162078|NCT02932397|Drug|Intravenous dose of 0.05 mL/kg of saline solution|
162079|NCT02932384|Behavioral|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
162080|NCT02932384|Behavioral|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.~Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
162081|NCT02932371|Device|ECOM™.|
162082|NCT02932371|Device|Trans-esophageal echography|
162404|NCT02929901|Dietary Supplement|placebo|placebo plus placebo
260028|NCT02217618|Drug|LY2409021|
162086|NCT02932332|Other|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
162087|NCT02932332|Other|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
162088|NCT02932332|Other|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
162089|NCT02932319|Device|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
162090|NCT02932319|Other|expectative|expectative until the next day befor starting the induction
162091|NCT02932306|Drug|IDP-121 Lotion|Lotion
162092|NCT02932306|Drug|IDP-121 Vehicle Lotion|Vehicle
162093|NCT02932293|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
162094|NCT02932280|Drug|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
162095|NCT02932267|Drug|Adapalene 0.3% / BPO 2.5% gel|Epiduo Forte / Tactupump gel to be applied once a daily at bed time on entire face during 16 weeks
162096|NCT02932254|Drug|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
162097|NCT02932254|Drug|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
162098|NCT02932241|Behavioral|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
162099|NCT02932228|Other|ImPACT|"The ImPACT team offers the following services:~An intensive intake process, including a home visit if deemed appropriate~Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~After-hours access to on-call team member in order to avoid unnecessary emergency care~Optimization of chronic condition management using evidence-based protocols~Navigation of transitions between hospital and home~Coordination of specialty care, including contact with specialists when indicated~Rapid response to signs of health status deterioration or other stressful events~Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
162100|NCT02932215|Drug|lorcaserin|Open label
162101|NCT02932215|Other|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
162102|NCT02932202|Other|Longitudinal Nutritional Counseling|
162103|NCT02932202|Other|Standard Care|
162104|NCT02932189|Device|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
162105|NCT02932176|Device|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
162106|NCT02932176|Device|machine-learning algorithm|
162107|NCT02932150|Drug|TAF|Administered orally once daily
162108|NCT02932150|Drug|Placebo|Administered orally once daily
162109|NCT02932137|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
162110|NCT02932124|Device|mechanical chest compression device|
162111|NCT02932111|Procedure|osteopathic session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
162112|NCT02932111|Procedure|Placebo manipulative session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
162113|NCT02932098|Behavioral|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.~Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
162114|NCT02932098|Behavioral|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
162115|NCT02932098|Behavioral|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
162116|NCT02932085|Device|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
162117|NCT02932059|Behavioral|Metamemory|Metamemory evaluation using a sentence construction strategy
162118|NCT02932046|Dietary Supplement|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
162119|NCT02932033|Procedure|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
162120|NCT02932033|Procedure|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
162121|NCT02932020|Drug|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
162122|NCT02932020|Drug|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
162123|NCT02932020|Device|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
162124|NCT02932020|Drug|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
162405|NCT02929888|Drug|Lysine Acetilsalicilate|
162125|NCT02932007|Drug|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
162126|NCT02931994|Other|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
162127|NCT02931981|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
162128|NCT02931968|Device|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
162129|NCT02931955|Other|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
162130|NCT02931942|Other|blood withdrawn|venous blood sampling
162131|NCT02931929|Drug|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
162132|NCT02931903|Other|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
162133|NCT02931903|Other|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
162134|NCT02931890|Drug|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
162135|NCT02931890|Drug|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
162136|NCT02931890|Drug|Capecitabine|oral capecitabine in arm 1 and 2
162137|NCT02931890|Procedure|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
162138|NCT02931890|Radiation|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
162139|NCT02931890|Drug|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
162140|NCT02931890|Drug|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
162141|NCT02931877|Drug|sevoflurane|
162142|NCT02931877|Drug|propofol|
162143|NCT02931864|Other|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
162144|NCT02931864|Other|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
162145|NCT02931851|Other|ICU Families Website|Professionally developed website for relatives of ICU patients
162146|NCT02931851|Other|Placebo|Standard Information provided online
162147|NCT02931838|Drug|BMS-986165|
162148|NCT02931838|Drug|Placebo for BMS-986165|
162149|NCT02931825|Behavioral|Reminder letter|"The letter will consist in several parts:~Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)~Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up~Request information if they've done their follow-up or if we have incorrect information~Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
162150|NCT02931799|Behavioral|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
162151|NCT02931799|Other|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:~PRO-2 Scale for patients with Crohn's Disease~6-Point Mayo Score for patients with Ulcerative Colitis~Morisky Medication Adherence Scale (MMAS-4)~The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
162152|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
162153|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
162154|NCT02931799|Other|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
162155|NCT02931786|Drug|propofol|propofol, midazolam and atropine administration via intravenous cannula.
162156|NCT02931786|Drug|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
162157|NCT02931773|Device|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
162158|NCT02931760|Device|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
162159|NCT02931760|Device|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
162160|NCT02931747|Dietary Supplement|Placebo|Subjects are received Placebo once daily for 16 weeks.
162161|NCT02931747|Dietary Supplement|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
162406|NCT02929888|Drug|Aspirin|
260076|NCT02217241|Other|Handoff Workshop|
162163|NCT02931734|Drug|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
162164|NCT02931734|Drug|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
162165|NCT02931734|Procedure|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
162166|NCT02931721|Diagnostic Test|MRI|Pelvis MRI
162167|NCT02931708|Other|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
162168|NCT02931695|Other|evaluation of QT interval duration|ECG to evaluation of QT interval duration
162169|NCT02931695|Other|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
162170|NCT02931669|Other|Qualitative Descriptive Study|
162171|NCT02931656|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
162172|NCT02931643|Other|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
162173|NCT02931643|Other|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
162174|NCT02931630|Other|Whey protein powder|60 g of whey protein powder
162175|NCT02931630|Other|Maltodextrin powder|60 g of Maltodextrin powder
162176|NCT02931630|Other|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
162177|NCT02931630|Other|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
162178|NCT02931617|Other|Chest Physiotherapy|
162179|NCT02931617|Device|Post-therapy lung volume measurements|In both intervention groups.
162180|NCT02931604|Device|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
162181|NCT02931591|Drug|Metformin|Metformin is administered as an oral solution
162182|NCT02931591|Drug|Growth Hormone|Growth Hormone- no specific band
162183|NCT02931591|Drug|Placebo|
162184|NCT02931578|Other|Glucose100|
162185|NCT02931578|Other|Glucose50|
162186|NCT02931578|Other|Glucose42|
162187|NCT02931578|Other|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
162188|NCT02931565|Drug|IW-1701|
162189|NCT02931565|Drug|Matching Placebo|
162190|NCT02931552|Behavioral|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
162191|NCT02931539|Drug|Maribavir|Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
162192|NCT02931539|Drug|Ganciclovir|Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
162193|NCT02931539|Drug|Valganciclovir|Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
162194|NCT02931539|Drug|Foscarnet|Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
162195|NCT02931539|Drug|Cidofovir|Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
162196|NCT02931526|Drug|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
162197|NCT02931513|Other|Blood samples|
162198|NCT02931513|Device|Fibroscan|
162199|NCT02931513|Other|Questionnaires|
162200|NCT02931513|Biological|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
162201|NCT02931487|Behavioral|Attentional Bias Modification|Computerized
162202|NCT02931487|Behavioral|Sham Comparator|Computerized
162203|NCT02931474|Drug|Tesamorelin|Growth Hormone-Releasing
162204|NCT02931474|Other|Placebo|
162205|NCT02931461|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
162206|NCT02931448|Device|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
162207|NCT02931435|Procedure|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
162208|NCT02931435|Procedure|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
162209|NCT02931422|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
162210|NCT02931409|Procedure|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
162211|NCT02931409|Procedure|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
162212|NCT02931396|Device|FES|
162213|NCT02931383|Drug|Liraglutide 3 mg (Saxenda)|
162214|NCT02931383|Drug|Liraglutide 3 mg placebo|
162215|NCT02931370|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
162216|NCT02931357|Device|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
162217|NCT02931357|Drug|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
162218|NCT02931344|Dietary Supplement|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
162219|NCT02931318|Behavioral|Nevsehir|The data of the study were collected with the questionnaire
162220|NCT02931305|Drug|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
162221|NCT02931305|Drug|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
162222|NCT02931292|Procedure|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
162223|NCT02931279|Device|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
162224|NCT02931266|Device|PASS MIS®|Posterior mini-invasive osteosynthesis
162225|NCT02931253|Drug|Metformin|Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
162226|NCT02931240|Device|Revivent TC|Treatment of LV scar
162227|NCT02931227|Procedure|temperature obtained by the non-invasive method of zero-heat flux|
162228|NCT02931227|Procedure|esophageal temperature|
162229|NCT02931227|Procedure|intracerebral temperature|
162230|NCT02931227|Procedure|arterial temperature|
162231|NCT02931214|Drug|GMI-1359|
162232|NCT02931214|Drug|Placebo|
162233|NCT02931201|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
162234|NCT02931188|Drug|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
162235|NCT02931188|Drug|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
162236|NCT02931188|Drug|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
162237|NCT02931175|Drug|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
162238|NCT02931162|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
162239|NCT02931162|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
162240|NCT02931149|Drug|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
162241|NCT02931136|Drug|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
162242|NCT02931136|Drug|Placebo|The participants will treatment by the placebo in 52 weeks.
162243|NCT02931123|Drug|lattulose and rifaximine|
162244|NCT02931110|Drug|CBL0137|All dose are on Days 1 and 8 of every 22 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops
162245|NCT02931097|Device|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
162246|NCT02931097|Device|Sham stimulation|
162247|NCT02931084|Other|Rehabilitation|In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
162248|NCT02931084|Procedure|ACL reconstruction|Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
162249|NCT02931071|Drug|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
162250|NCT02931071|Drug|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
162251|NCT02931058|Other|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
163214|NCT02923960|Other|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
162252|NCT02931058|Other|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
162253|NCT02931058|Other|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.~The knee-extension resistance training exercise is performed with an elastic exercise band."
162254|NCT02931045|Drug|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
162255|NCT02931045|Drug|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
162256|NCT02931032|Procedure|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
162257|NCT02931019|Procedure|Intubation|
162258|NCT02931006|Other|water|
162259|NCT02931006|Other|bovine milk|
162260|NCT02930993|Biological|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
162261|NCT02930980|Device|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
162262|NCT02930967|Biological|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
162263|NCT02930954|Drug|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
162264|NCT02930954|Drug|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
162265|NCT02930954|Drug|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
162266|NCT02930941|Drug|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
162267|NCT02930941|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
162268|NCT02930928|Other|Accuracy of weight estimation|Computer based comparison
162269|NCT02930915|Device|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
162270|NCT02930902|Drug|Gemcitabine Hydrochloride|Given IV
162271|NCT02930902|Other|Laboratory Biomarker Analysis|Correlative studies
162272|NCT02930902|Drug|Nab-paclitaxel|Given IV
162273|NCT02930902|Drug|Paricalcitol|Given IV
162274|NCT02930902|Biological|Pembrolizumab|Given IV
162275|NCT02930902|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
162276|NCT02930889|Device|Prostate Artery Embolization|Prostate Artery Embolization
162277|NCT02930876|Behavioral|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
162278|NCT02930863|Other|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
162279|NCT02930863|Behavioral|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
162280|NCT02930850|Device|Rad-67 Pulse oximeter|Noninvasive pulse oximeter that measures hemoglobin
162281|NCT02930837|Drug|alteplase|
162282|NCT02930824|Genetic|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
162283|NCT02930811|Drug|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
162284|NCT02930811|Drug|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.~Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
162285|NCT02930798|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z46-116)"
162286|NCT02930785|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code:Z46-104)"
162287|NCT02930772|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.~(Formulation Code: Z46-100)"
162288|NCT02930759|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-096)
162289|NCT02930746|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-092)
162290|NCT02930733|Drug|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
162292|NCT02930707|Drug|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
162293|NCT02930707|Drug|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
162294|NCT02930694|Drug|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
162295|NCT02930694|Drug|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
162296|NCT02930681|Dietary Supplement|Glucosanol 500mg|
162297|NCT02930681|Dietary Supplement|Placebo|
162298|NCT02930668|Dietary Supplement|Glucosanol 350mg|
162299|NCT02930668|Dietary Supplement|Glucosanol 500mg|
162300|NCT02930668|Dietary Supplement|Placebo|
162301|NCT02930655|Drug|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
162302|NCT02930655|Drug|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
162303|NCT02930642|Behavioral|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
162304|NCT02930642|Other|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
162305|NCT02930629|Device|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia~Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.~The TOF force transducer will be placed on the volar aspect of the thumb.~The TOF Watch leads will be attached to the ECG electrodes.~A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.~Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
162306|NCT02930616|Device|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
162307|NCT02930616|Device|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
162308|NCT02930590|Other|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
162309|NCT02930590|Other|Gel mattress|IsoGel, Stryker, USA
162310|NCT02930590|Other|Basic foam|Standard hospital mattress
162311|NCT02930564|Other|CDED + milk fat and gluten|CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
162312|NCT02930551|Drug|Lidocaine|
162313|NCT02930551|Drug|Isotonic Saline|
162314|NCT02930538|Other|Survey|Completing a survey on RedCap
162315|NCT02930525|Other|High Flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
162316|NCT02930525|Other|Standard respiratory care|Standard respiratory care. Oxygen delivered via low flow nasal cannula, increase of fractions of inspired oxygen to maintain desired oxygenation as defined per protocol.
162317|NCT02930512|Procedure|DXA scan|
162318|NCT02930512|Procedure|pQCT scan|
162319|NCT02930499|Device|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
162320|NCT02930499|Device|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
162321|NCT02930486|Device|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
162322|NCT02930486|Device|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
162323|NCT02930473|Behavioral|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
162324|NCT02930473|Drug|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
162325|NCT02930447|Device|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
162326|NCT02930434|Dietary Supplement|cholecalciferol|Administration of vitamin D3
162327|NCT02930421|Other|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
162328|NCT02930408|Procedure|electrocardiogram|
162329|NCT02930408|Procedure|Echocardiography|
162330|NCT02930395|Procedure|serum S100B assay|
162331|NCT02930382|Other|Baroreflex assessment|
162332|NCT02930369|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
162333|NCT02930356|Other|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
162334|NCT02930356|Other|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
162335|NCT02930343|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
163379|NCT02922894|Procedure|Sham|Room air will be administered instead of episodic hypoxia or supplemental oxygen..
162336|NCT02930343|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
162337|NCT02930343|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
162338|NCT02930343|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
162339|NCT02930343|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
162340|NCT02930343|Drug|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
162341|NCT02930330|Behavioral|INT|"5 min warm-up (40% Pmax*)~30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
162342|NCT02930330|Behavioral|CONT|"5 min warm-up (40% Pmax*)~30 min moderate intensity continuous training (60% Pmax)~10 min cool-down (30% Pmax)~Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
162343|NCT02930317|Drug|Recombinant Factor VIII (50 IU/kg)|
162344|NCT02930317|Drug|Recombinant Factor VIII (On-demand treatment)|
162345|NCT02930304|Other|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
162346|NCT02930304|Other|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
162347|NCT02930304|Other|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
162348|NCT02930265|Drug|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
162349|NCT02930252|Device|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
162350|NCT02930252|Device|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
162351|NCT02930239|Other|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
162352|NCT02930239|Other|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
162353|NCT02930226|Biological|Autologous Freeze Dried Plasma (FDP)|Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
162354|NCT02930226|Biological|Fresh Frozen Plasma (FFP)|Controlled FFP in cohort 3 only
162355|NCT02930200|Behavioral|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
162356|NCT02930200|Behavioral|QuitGuide|NCI QuitGuide Treatment App
162357|NCT02930200|Behavioral|Smart-T|Smart-Treatment App
162358|NCT02930174|Device|noninvasive positive pressure ventilation|Application of various levels of positive pressure
162359|NCT02930161|Drug|Runihol|"Composition of Runihol®:~One tablet contains:~Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
162360|NCT02930161|Other|Placebo|"The composition of the drug in one tablet:~Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.~Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.~Tablet weight enteric coated - 0.695 g"
162361|NCT02930148|Other|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
162362|NCT02930135|Procedure|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
162363|NCT02930122|Drug|Saline (0.9%) and anakinra (150mg)|i.a. administration
162364|NCT02930122|Drug|anakinra (150mg) and Saline (0.9%)|i.a. administration
162365|NCT02930122|Other|Saline intraarticularly|i.a. administration
162366|NCT02930109|Drug|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on days 1, 8 and 15 of each cycle. Triciribine will be infused over 1 hour on days 1, 8, and 15 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
162367|NCT02930109|Drug|Cytarabine|Cytarabine will be given at a dose of 400 mg/m2 as a continuous IV infusion on days 2-6 of each cycle.
162368|NCT02930057|Drug|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
162369|NCT02930057|Procedure|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
162370|NCT02930057|Drug|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
162371|NCT02930044|Other|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
162372|NCT02930044|Other|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
162373|NCT02930044|Drug|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
162374|NCT02930031|Dietary Supplement|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
162375|NCT02930031|Dietary Supplement|Placebo|500 mL orally, daily for eight days following exercise
162376|NCT02930018|Drug|NA-1, 2.6 mg/kg|Single intravenous infusion of NA-1 over 10 ± 1 minutes
162377|NCT02930018|Drug|Placebo|Placebo Comparator: Placebo
162378|NCT02930005|Drug|Meclofenamic acid|
162379|NCT02930005|Drug|Pentosan polysulfate sodium|
162380|NCT02929992|Other|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
162381|NCT02929992|Other|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
162382|NCT02929992|Other|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
162383|NCT02929992|Other|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
162384|NCT02929979|Behavioral|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
162385|NCT02929979|Behavioral|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
162386|NCT02929966|Other|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
162387|NCT02929966|Other|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
162388|NCT02929953|Other|chart review|data from charts and from registries will be compared
162389|NCT02929940|Other|No intervention|No Intervention, observational
162390|NCT02929927|Procedure|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
162391|NCT02929927|Device|PDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60s,then irradiation 120s.
162392|NCT02929927|Drug|tooth disinfection|use 1% iodine to disinfect the crown of the teeth.in order to avoid the outside microbe
162393|NCT02929927|Drug|1%NaOCl|use different concentration Naclo as irrigants
162394|NCT02929927|Drug|2%NaOCl|use different concentration Naclo as irrigants
162395|NCT02929914|Procedure|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
162396|NCT02929914|Procedure|Tooth drying|The tooth was dried with air jet.
162397|NCT02929914|Procedure|Dentin wash with sodium 0.9% saline|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed. The remaining dentin was washed with sodium 0.9% saline. After that a a new dentin collection was performed at another site of the cavity, and teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin(Z350,3M)
162398|NCT02929914|Procedure|Antimicrobial Photodynamic Therapy|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a spoon (1#) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW（medium Wave） power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity.Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin(Z350,3M)
162399|NCT02929914|Drug|sodium 0.9% saline|Dentin is washed with sodium 0.9% saline.
162400|NCT02929914|Device|DENFOTEX PADplus|Dentin is disinfected by using DENFOTEX PADplus.
162401|NCT02929901|Dietary Supplement|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
162402|NCT02929901|Dietary Supplement|caffeine|caffeine plus placebo
162403|NCT02929901|Dietary Supplement|chlorogenic acid|chlorogenic acid plus placebo
162407|NCT02929875|Behavioral|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
162408|NCT02929862|Drug|LYC-55716|For Phase 1, increasing doses of oral 55716 given BID for a 28 day cycle. For Phase 2A, the RP2D will be administered to patients for 28 day cycles.
162409|NCT02929849|Dietary Supplement|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
162410|NCT02929849|Dietary Supplement|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
162411|NCT02929849|Dietary Supplement|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
162412|NCT02929836|Procedure|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
162413|NCT02929836|Procedure|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
162414|NCT02929836|Procedure|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
162415|NCT02929836|Procedure|linear ablation|Right atrial CTI ablation was performed during SR.
162416|NCT02929836|Device|CARTO|3 dimensional mapping system
162417|NCT02929823|Drug|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
162418|NCT02929823|Drug|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
162419|NCT02929823|Drug|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
162420|NCT02929810|Behavioral|sleep extension|
162421|NCT02929810|Behavioral|sleep maintenance|
162422|NCT02929797|Biological|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
162423|NCT02929797|Drug|Gemcitabine|gemcitabine
162424|NCT02929784|Device|Intervention|Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
162425|NCT02929784|Device|Sham|no meaningful stimulation will be given.
162426|NCT02929771|Device|Samsung GearVR|VR with head mounted display (HMD) and headphones. Treatment
162427|NCT02929771|Device|iPad|iPad with headphones. Control
162428|NCT02929758|Behavioral|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
162429|NCT02929745|Procedure|Skin biopsy|Four 4-5 mm punch biopsies of the skin
162430|NCT02929745|Procedure|Blood draw|Blood will be drawn to test for HLA-cw6 status
162431|NCT02929732|Other|Sympathetic nervous activity measurement|Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
162432|NCT02929719|Drug|Test.|gel
162433|NCT02929719|Drug|Aczone Gel 5%|gel
162434|NCT02929719|Drug|Placebo|gel
162435|NCT02929706|Genetic|Pre-genotype NUDT15 and optimize azathioprine dosage|Pre-genotype NUDT15 and optimize azathioprine dosage.The wild type use azathioprine(Imuran，2-2.5mg/kg/d),the CT genotype use half dose of azathioprine（Imuran，1-1.5mg/kg/d).The TT genotype avoid use of azathioprine.
162436|NCT02929693|Drug|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
162437|NCT02929693|Drug|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
162438|NCT02929693|Drug|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
162439|NCT02929667|Drug|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
162440|NCT02929667|Drug|Placebo|Standard 6 weeks titration.
162441|NCT02929654|Device|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
162442|NCT02929654|Device|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
162443|NCT02929654|Device|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
162444|NCT02929628|Device|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
162445|NCT02929615|Other|Hematopoietic stem cell transplantation|
162446|NCT02929589|Drug|Ibuprofen|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
162447|NCT02929589|Drug|Opioid Medication|1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
162448|NCT02929589|Drug|Placebo|800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
162449|NCT02929589|Drug|Ibuprofen + Opioid medication|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
162450|NCT02929576|Drug|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
162451|NCT02929576|Drug|Placebo|
162452|NCT02929576|Drug|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
162453|NCT02929563|Drug|Pantoprazole|
162454|NCT02929563|Drug|Placebo (for pantoprazole)|
162652|NCT02928094|Biological|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
162653|NCT02928081|Procedure|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
162455|NCT02929524|Drug|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
162456|NCT02929524|Drug|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
162457|NCT02929511|Procedure|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
162458|NCT02929511|Procedure|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
162459|NCT02929511|Procedure|Active comparator Protaper multi-file system|
162460|NCT02929498|Drug|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
162461|NCT02929498|Drug|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
162462|NCT02929485|Drug|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
162463|NCT02929485|Drug|Placebo|Placebo (200mg) administered at study visit
162464|NCT02929485|Drug|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
162465|NCT02929472|Behavioral|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
162466|NCT02929472|Behavioral|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
162467|NCT02929459|Dietary Supplement|Riboflavin Dose 1|
162468|NCT02929459|Dietary Supplement|Riboflavin Dose 2|
162469|NCT02929459|Other|Placebo|
162470|NCT02929446|Procedure|Mobilisation|Mobilisation to sit in an armchair
162471|NCT02929446|Procedure|Mobilisation and breathing exercises|Mobilisation to sit in an armchair and breathing exercises with PEP
162472|NCT02929433|Other|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
162473|NCT02929420|Drug|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
162474|NCT02929420|Drug|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
162475|NCT02929407|Drug|FE 204205|"In Part 1 of the trial, each subject will receive increasing IV doses of FE 204205, given once daily as 2 hour infusion, on three consecutive days.~In Part 2 of the trial, each subject will receive a 2 hour IV infusion of the maximum tolerated dose of FE 204205 as defined in Part 1 of the trial."
162476|NCT02929407|Drug|Placebo|In Part 2 of the trial, each subject will receive a 2 hour IV infusion of placebo.
162477|NCT02929394|Drug|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
162478|NCT02929381|Device|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
162479|NCT02929381|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
162480|NCT02929368|Device|PICC implantation under fluoroscopy|PICC Catheter implantation
162481|NCT02929368|Device|PICC Implantation under Sherlock System|PICC Catheter implantation
162482|NCT02929355|Other|carotid assesment by duplex ultrasonography|
162483|NCT02929342|Drug|Pitolisant|
162484|NCT02929342|Radiation|[14C]-Pitolisant|
162485|NCT02929329|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 208 weeks with dose level determined by periodic blood testing
162486|NCT02929329|Drug|Placebo|Oral placebo twice daily for up to 208 weeks
162487|NCT02929316|Drug|Vedolizumab|IV infusion week 0, 2 and 6
162488|NCT02929303|Drug|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
162489|NCT02929290|Drug|BPI-9016M|Four dose cohorts will be evaluated, including 300mg, 450mg, 600mg, 800mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
162490|NCT02929277|Other|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
162491|NCT02929264|Drug|ABX-1431|Capsules, 40 mg, single dose
162492|NCT02929264|Drug|Placebo|Capsules, single dose
162493|NCT02929251|Drug|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
162494|NCT02929251|Drug|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
162495|NCT02929251|Drug|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
162496|NCT02929238|Other|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
162654|NCT02928081|Procedure|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
163634|NCT02921022|Drug|PEGPH20|
162497|NCT02929238|Other|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
162498|NCT02929225|Drug|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals.
162499|NCT02929225|Other|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
162500|NCT02929212|Other|Solid Meal|Subjects will receive solid meals during meal study
162501|NCT02929212|Other|Liquid Meal|Subjects will receive liquid meals, during meal study
162502|NCT02929212|Drug|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
162503|NCT02929212|Other|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
162504|NCT02929212|Other|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
162505|NCT02929199|Other|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
162506|NCT02929199|Other|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
162507|NCT02929186|Behavioral|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
162508|NCT02929186|Behavioral|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
162509|NCT02929173|Other|Allceram|Pressed E-max coping veneered with E-max veneering system
162510|NCT02929173|Other|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
162511|NCT02929160|Procedure|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
162512|NCT02929160|Procedure|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
162513|NCT02929147|Drug|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
162514|NCT02929147|Drug|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
162515|NCT02929147|Drug|Placebo|In the Group 3 the PCA will contain placebo.
162516|NCT02929134|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
162517|NCT02929134|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
162518|NCT02929121|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
162519|NCT02929121|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
162520|NCT02929108|Behavioral|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
162521|NCT02929108|Behavioral|ACCESS|"Intervention will have two components.~Participants will be enrolled in a Secret Facebook group for social support and education~Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
162522|NCT02929095|Drug|dexmedetomidine|
162523|NCT02929095|Drug|midazolam|
162524|NCT02929095|Drug|remifentanil|- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
162525|NCT02929082|Radiation|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
162526|NCT02929069|Behavioral|ESTEEM|ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
162527|NCT02929069|Behavioral|CMHT|CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
162528|NCT02929069|Behavioral|VCT|Voluntary Counselling and Testing (VCT).
162529|NCT02929056|Device|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
162530|NCT02929056|Device|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
162531|NCT02929043|Other|air puffs|
162532|NCT02929030|Device|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
162533|NCT02929017|Other|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
162534|NCT02929017|Other|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
162535|NCT02929004|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
162536|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
162537|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3~Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3~Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2~Bone marrow infusion: Day 0"
163891|NCT02919306|Drug|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
162538|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2~Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL OR daily for a total of 3 doses targeting AUC 3600-6000 (micromole/liter)*minute Days: -7, -6, -5, -4~Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8~Bone marrow infusion: Day 0"
162539|NCT02928978|Drug|Ruxolitinib|ruxolitinib tablet
162540|NCT02928978|Drug|Placebo (for Ruxolitinib)|placebo tablet
162541|NCT02928965|Drug|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
162542|NCT02928965|Drug|Placebo|Matching placebo with appearance of over - encapsulated minocycline
162543|NCT02928952|Behavioral|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
162544|NCT02928939|Other|drug-drug or drug-disease interaction|
162545|NCT02928926|Other|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
162546|NCT02928913|Other|No intervention|
162547|NCT02928900|Behavioral|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
162548|NCT02928887|Other|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
162549|NCT02928874|Behavioral|% COMPX (low ED vs. high ED preload)|
162550|NCT02928874|Behavioral|EAH (low ED vs. high ED snacks)|
162551|NCT02928861|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
162552|NCT02928848|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
162553|NCT02928835|Device|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
162554|NCT02928822|Behavioral|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
162555|NCT02928822|Behavioral|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
162556|NCT02928809|Device|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
162557|NCT02928809|Other|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
162558|NCT02928796|Behavioral|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
162559|NCT02928783|Behavioral|Home-based cardiac rehabilitation|
162560|NCT02928770|Device|Nastent|Use of the device while at home and in the sleep lab
162561|NCT02928757|Other|Complex care clinic as part of the CCKO initiative|"The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families."
162562|NCT02928744|Other|COPD|Plethysmography
162563|NCT02928744|Other|COPD|Forced oscillations
162564|NCT02928731|Other|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
162565|NCT02928731|Other|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
162691|NCT02927873|Biological|RSV vaccine (GSK3389245A) middle dose|2 doses of 0.15 ml of ChAd155 5x10^10 vp administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
167791|NCT02888938|Other|pelvic radiography|
162566|NCT02928718|Procedure|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
162567|NCT02928705|Procedure|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
162568|NCT02928705|Procedure|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
162569|NCT02928692|Drug|Minocycline|
162570|NCT02928692|Drug|Placebo|
162571|NCT02928679|Drug|Liraglutide 3 mg (Saxenda)|
162572|NCT02928679|Drug|Liraglutide 3 mg placebo|
162573|NCT02928666|Other|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
162574|NCT02928653|Dietary Supplement|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
162575|NCT02928640|Device|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
162576|NCT02928627|Other|Analysis of microRNA expression|sample analysis
162577|NCT02928614|Drug|Liraglutide 3 mg (Saxenda)|
162578|NCT02928614|Drug|Liraglutide 3 mg placebo|
162579|NCT02928601|Drug|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
162580|NCT02928601|Drug|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
162581|NCT02928575|Drug|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
162582|NCT02928575|Drug|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
162583|NCT02928575|Radiation|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
162584|NCT02928562|Other|exercise|cyclic exercise, aerobic exercise and resistant training exercise
162585|NCT02928549|Behavioral|semi-structured interviews|
162586|NCT02928536|Other|no intervention|This is an observational study. No intervention is considered
162587|NCT02928523|Drug|Autologous Fecal Microbiota Transplantation|
162588|NCT02928510|Procedure|Biospecimen Collection|Undergo biospecimen collection
162589|NCT02928510|Procedure|Colonoscopy|Undergo colonoscopy
162590|NCT02928510|Procedure|Colposcopic Biopsy|Undergo colposcopic biopsy
162591|NCT02928510|Drug|Idelalisib|Given PO
162592|NCT02928510|Other|Laboratory Biomarker Analysis|Correlative studies
162593|NCT02928510|Other|Pharmacological Study|Correlative studies
162594|NCT02928510|Procedure|Physical Examination|Undergo physical examination
162595|NCT02928510|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
162596|NCT02928497|Device|WATCHMAN LAAC Device Implant|WATCHMAN LAAC Implant
162597|NCT02928497|Drug|Single Antiplatelet Therapy or No Therapy (Control)|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
162598|NCT02928484|Dietary Supplement|Probiotic mix CBP-004019/C|One capsule per day of the probiotic mix CBP-004019/C during one month.
162599|NCT02928484|Dietary Supplement|Placebo|One capsule per day of the placebo (maltodextrin) during one month.
162600|NCT02928471|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
162601|NCT02928458|Drug|Omnipaque|
162602|NCT02928458|Drug|MD-Gastroview|
162603|NCT02928445|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
162604|NCT02928445|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
162605|NCT02928432|Drug|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
162606|NCT02928419|Drug|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
162735|NCT02927496|Drug|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
162607|NCT02928419|Other|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.~Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
162608|NCT02928419|Drug|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
162609|NCT02928406|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) will be administered by intravenous (IV) infusion Q3W.
162610|NCT02928393|Drug|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
162611|NCT02928393|Drug|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
162612|NCT02928380|Device|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
162613|NCT02928380|Device|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
162614|NCT02928367|Other|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
162615|NCT02928367|Other|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
162616|NCT02928367|Other|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
162617|NCT02928354|Drug|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
162618|NCT02928354|Drug|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
162619|NCT02928354|Drug|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
162620|NCT02928341|Other|Improved water supply|
162621|NCT02928328|Drug|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
162622|NCT02928328|Drug|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
162623|NCT02928328|Drug|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
162624|NCT02928315|Drug|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
162625|NCT02928315|Other|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
162626|NCT02928302|Other|TVU CL screening|Transvaginal ultrasound cervical length screening
162627|NCT02928289|Device|VISCO360 ab interno canaloplasty surgery|360 degrees of viscodilation of Schlemm's canal
162628|NCT02928289|Device|Selective Laser Trabeculoplasty (SLT)|360 degrees of selective laser trabeculoplasty
162629|NCT02928276|Other|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
162630|NCT02928263|Other|Non-Interventional|Other
162631|NCT02928250|Dietary Supplement|Carnosine|Patients in intervention group received carnosine capsules orally daily
162632|NCT02928250|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
162633|NCT02928237|Device|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
162634|NCT02928224|Drug|Encorafenib|Orally, once daily.
162635|NCT02928224|Drug|Binimetinib|Orally, twice daily.
162636|NCT02928224|Drug|Cetuximab|Standard of care.
162637|NCT02928224|Drug|Irinotecan|Standard of care.
162638|NCT02928224|Drug|Folinic Acid|Standard of care.
162639|NCT02928224|Drug|5-Fluorouracil|Standard of care.
162640|NCT02928211|Device|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
162641|NCT02928211|Drug|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
162642|NCT02928211|Radiation|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
162643|NCT02928198|Device|ABSORB BVS|
162644|NCT02928185|Behavioral|semi-structured interviews|
162645|NCT02928172|Device|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
162646|NCT02928172|Device|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
162647|NCT02928159|Device|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
162648|NCT02928146|Procedure|Hernia Repair|
162649|NCT02928107|Other|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
162650|NCT02928107|Other|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
162651|NCT02928094|Biological|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
162774|NCT02927249|Drug|Aspirin|Given PO
167792|NCT02888938|Other|pelvic MRI|
162655|NCT02928068|Behavioral|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
162656|NCT02928055|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
162657|NCT02928042|Other|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) and nisin bacteriocin on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
162658|NCT02928029|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
162659|NCT02928029|Drug|Placebo|Matching placebo
162660|NCT02928029|Drug|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
162661|NCT02928029|Drug|Dexamethasone|Dexamethasone is administered orally at 40 mg
162662|NCT02928016|Other|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
162663|NCT02928016|Other|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
162664|NCT02928016|Other|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
162665|NCT02928016|Other|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
162666|NCT02928016|Other|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
162667|NCT02928016|Other|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
162668|NCT02928003|Procedure|Lung surgery|Genetic analysis and questionnaires
162669|NCT02927990|Other|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
162670|NCT02927977|Other|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
162671|NCT02927977|Other|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
162672|NCT02927964|Drug|Ibrutinib|Given PO
162673|NCT02927964|Radiation|Radiation Therapy|Undergo radiation therapy
162674|NCT02927964|Drug|TLR9 Agonist SD-101|Given IT
162675|NCT02927951|Drug|Pregabalin|150mg bid
162676|NCT02927951|Drug|Placebo|150mg bid
162677|NCT02927938|Procedure|Allogeneic HCT|Allogeneic HCT
162678|NCT02927938|Drug|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
162679|NCT02927925|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
162680|NCT02927912|Radiation|Electron Beam Therapy|Undergo IOERT boost
162681|NCT02927912|Procedure|Lumpectomy|Undergo lumpectomy
162682|NCT02927912|Other|Quality-of-Life Assessment|Ancillary studies
162683|NCT02927912|Other|Questionnaire Administration|Ancillary studies
162684|NCT02927912|Radiation|Radiation Therapy|Undergo whole breast radiation therapy
162685|NCT02927912|Procedure|Reconstructive Surgery|Undergo oncoplastic reconstruction
162686|NCT02927899|Other|Survey Administration|Ancillary studies
162687|NCT02927899|Dietary Supplement|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
162688|NCT02927886|Procedure|Per-oral endoscopy pyloromyotomy|
162689|NCT02927886|Procedure|Intrapyloric injection of Botulinum toxin|
162690|NCT02927873|Biological|RSV vaccine (GSK3389245A) low dose|2 doses of 0.5 ml of ChAd155 5x10^9 vp, administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
162692|NCT02927873|Biological|RSV vaccine (GSK3389245A) high dose|2 doses of 0.5 ml of ChAd155 5x10^10 vp administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
162693|NCT02927873|Drug|Placebo LD|2 doses of 0.5 ml administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
162694|NCT02927873|Drug|Placebo MD|2 doses of 0.15 ml administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
162695|NCT02927873|Drug|Placebo HD|2 doses of 0.5 ml administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
162696|NCT02927860|Other|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
162697|NCT02927847|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
162698|NCT02927847|Drug|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
162699|NCT02927847|Behavioral|Behavioral Activation|Participants in the BA+VLNC group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
162700|NCT02927847|Behavioral|Supportive Counseling|Participants in the VLNC Only group will undergo 8 60-minute behavioral sessions (4 pre-quit, 1 on quit day, and 3 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling and health education. Supportive counseling and health education will include empathic listening as well as informational content on topics of exercise, nutrition, sleep and relaxation.
162701|NCT02927834|Drug|6 day Prednisone|6 day prednisone burst
162702|NCT02927834|Drug|Augmentin|Antibiotic augmentin for 3 weeks
162703|NCT02927834|Drug|21 day Prednisone|21 day prednisone burst
162704|NCT02927821|Behavioral|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
162705|NCT02927808|Behavioral|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
162706|NCT02927782|Procedure|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
162707|NCT02927782|Procedure|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
162708|NCT02927769|Biological|Nivolumab|Specified Dose on Specified Days
162709|NCT02927769|Biological|brentuximab vedotin|Specified Dose on Specified Days
162710|NCT02927769|Biological|bendamustine|Specified Dose on Specified Days
162711|NCT02927743|Behavioral|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
162712|NCT02927730|Other|no interventions|no interventions
162713|NCT02927704|Other|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
162714|NCT02927691|Device|EMST|
162715|NCT02927691|Behavioral|smTAP|
162716|NCT02927678|Other|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
162717|NCT02927665|Device|Reshape Integrated Dual Balloon|
162718|NCT02927652|Other|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
162719|NCT02927639|Other|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
162720|NCT02927626|Drug|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
162721|NCT02927626|Drug|Routine medical care|Routine medical care
162722|NCT02927600|Other|Low GI Breakfast|Intake of low GI breakfast
162723|NCT02927600|Other|High GI Breakfast|Intake of high GI breakfast
162724|NCT02927600|Other|Low GI Dinner|Intake of Low GI dinner
162725|NCT02927600|Other|High GI Dinner|Intake of high GI dinner
162726|NCT02927587|Drug|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
162727|NCT02927574|Device|DCB|
162728|NCT02927574|Device|POBA|
162729|NCT02927561|Other|Diabetic Retinopathy screening|Diabetic Retinopathy screening
162730|NCT02927535|Drug|TNF blockers monotherapy|
162731|NCT02927522|Drug|Donepezil|An cholinesterase inhibitor
162732|NCT02927522|Drug|Placebo|
162733|NCT02927509|Drug|TNF alpha blockers|
162734|NCT02927496|Drug|Doxycycline|"Once daily tablet for 6 weeks:~Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)"
162736|NCT02927483|Dietary Supplement|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
162737|NCT02927483|Dietary Supplement|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
162738|NCT02927470|Device|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
162739|NCT02927470|Device|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
162740|NCT02927470|Device|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
162741|NCT02927457|Drug|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
162742|NCT02927457|Drug|Placebo|Subjects will receive matching Placebo topically.
162743|NCT02927444|Biological|NBP606|A single intramuscular injection into the thigh
162744|NCT02927444|Biological|Prevnar13|A single intramuscular injection into the thigh
162745|NCT02927431|Drug|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
162746|NCT02927431|Drug|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
162747|NCT02927431|Drug|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
162748|NCT02927431|Drug|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
162749|NCT02927418|Behavioral|Strength & Conditioning|
162750|NCT02927418|Behavioral|Control|
162751|NCT02927405|Drug|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
162752|NCT02927405|Procedure|TAP Block|a procedure done anesthetize the anterior abdominal wall
162753|NCT02927392|Drug|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
162754|NCT02927379|Drug|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
162755|NCT02927379|Drug|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
162756|NCT02927379|Drug|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
162757|NCT02927366|Drug|QCC374|0.03 mg (2 capsules of 0.015 mg) BID 0.06 mg (1 capsule of 0.06 mg) BID 0.12 mg (2 capsules of 0.06 mg) BID
162758|NCT02927366|Drug|Placebo Matching|"Placebo matching to QCC374:~0.03 mg BID, 0.06 mg BID and 0.12 mg BID"
162759|NCT02927353|Drug|DMB-3113|subcutaneously injected in a single dose of 40 mg.
162760|NCT02927353|Drug|Adalimumab|subcutaneously injected in a single dose of 40 mg.
162761|NCT02927340|Drug|Lorlatinib|
162762|NCT02927327|Device|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.~PET/MR ZTE MRAC"
162763|NCT02927327|Device|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.~PET/MR Q Static (Q. MRAC)"
162764|NCT02927314|Drug|CF102|orally q12h
162765|NCT02927314|Drug|Placebo|orally q12h
162766|NCT02927301|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
162767|NCT02927275|Behavioral|Experimental: Standing Modality|Cognitive performance when standing
162768|NCT02927275|Behavioral|Experimental: Biking Modality|Cognitive performance when biking slowly
162769|NCT02927275|Behavioral|Experimental: Walking Modality|Cognitive performance when walking at 1mph
162770|NCT02927275|Behavioral|No Intervention: Seated Modality|Cognitive performance when sitting.
162771|NCT02927262|Drug|gilteritinib|Tablet to be taken orally once daily.
162772|NCT02927262|Drug|Placebo|Matching placebo tablet to be taken orally once daily.
162773|NCT02927249|Other|Placebo|Given PO
162775|NCT02927236|Other|TMS|TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
162776|NCT02927223|Drug|Atropine|
162777|NCT02927223|Procedure|Exercise treadmill test|
162778|NCT02927210|Drug|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
162779|NCT02927210|Drug|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
162780|NCT02927197|Behavioral|LearningRx cognitive training|A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
162781|NCT02927184|Drug|VK2809|
162782|NCT02927184|Drug|Placebo|
162783|NCT02927171|Other|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
162784|NCT02927145|Biological|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
162785|NCT02927132|Behavioral|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
162786|NCT02927132|Behavioral|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
162787|NCT02927119|Dietary Supplement|iodine|≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
162788|NCT02927080|Drug|ACE-083|Recombinant fusion protein.
162789|NCT02927080|Drug|ACE-083 or placebo|Recombinant fusion protein or normal saline.
162790|NCT02927067|Drug|Maribavir|Participants will receive 400 mg of maribavir BID orally.
162791|NCT02927067|Drug|Valganciclovir|Participants will receive valganciclovir tablets orally.
162792|NCT02927067|Drug|Placebo|Participants will receive placebo tablets matched to either maribavir or valganciclovir.
162793|NCT02927054|Other|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
162794|NCT02927041|Device|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
162795|NCT02927028|Other|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.~On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
162796|NCT02927015|Other|Purple Majesty potato chips|Purple Majesty potato chips
162797|NCT02927015|Other|Mountain Rose potato chips|Mountain Rose potato chips
162798|NCT02927015|Other|White potato chips|White potato chips
162799|NCT02927015|Other|Crackers|Crackers
162800|NCT02927002|Device|Noninvasive brain stimulation|
162801|NCT02926989|Drug|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
162802|NCT02926989|Drug|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
162803|NCT02926976|Drug|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
162804|NCT02926976|Drug|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
162805|NCT02926976|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
162806|NCT02926976|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
162807|NCT02926976|Device|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
162808|NCT02926976|Device|clozapine|clozapine may be used in the treatment of treatment-resistant schizophrenia
162809|NCT02926963|Other|samples collection : hair and skin biopsy|
162810|NCT02926950|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
162811|NCT02926950|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
162812|NCT02926950|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
162813|NCT02926937|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet~Route of administration: oral"
162814|NCT02926937|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
162815|NCT02926924|Device|Wound Vac|a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.
162816|NCT02926924|Other|Standard Dressing|standard dressing with drain tube and bandage
162817|NCT02926911|Other|Guideline Concordant Care|Surgery +/- radiation choice for endocrine therapy
162818|NCT02926911|Other|Active Surveillance|Choice for endocrine therapy
162819|NCT02926898|Drug|ZX008 - 0.2 mg/kg/day|ZX008 - 0.2 mg/kg/day ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/ mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
162820|NCT02926898|Drug|ZX008 - 0.4 mg/kg/day|ZX008 - 0.4 mg/kg/day ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/ mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
162821|NCT02926898|Drug|ZX008 - 20 mg/day maximum dose|ZX008 - 20 mg/day maximum dose ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and
162822|NCT02926898|Drug|Matching Placebo|ZX008 Matching Placebo
162823|NCT02926885|Device|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
162824|NCT02926885|Device|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
162825|NCT02926885|Procedure|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
162826|NCT02926872|Other|There is no intervention in the study|
162827|NCT02926859|Drug|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
162828|NCT02926859|Drug|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
162829|NCT02926846|Drug|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
162830|NCT02926846|Drug|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.~(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
162831|NCT02926833|Biological|axicabtagene ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
162832|NCT02926833|Biological|atezolizumab (anti-PD-L1)|Administered intravenously
162833|NCT02926833|Drug|Cyclophosphamide|Administered intravenously
162834|NCT02926833|Drug|Fludarabine|Administered intravenously
162835|NCT02926820|Behavioral|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
162836|NCT02926807|Other|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
162837|NCT02926807|Other|MDCT|a MDCT to calculate the Agatston score
162838|NCT02926807|Other|biopsy and blood collection|biopsy and blood collection to assess biomarkers
162839|NCT02926794|Behavioral|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
162840|NCT02926794|Behavioral|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
162841|NCT02926794|Behavioral|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
162842|NCT02926794|Behavioral|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
162843|NCT02926781|Device|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
162844|NCT02926768|Drug|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles~Phase 2: CK-101 will be administered daily"
162845|NCT02926755|Procedure|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
162846|NCT02926742|Device|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
162880|NCT02926430|Drug|Placebo|Participants will receive placebo as formulation buffer.
162881|NCT02926417|Procedure|High Density-Electroencephalogram|
162882|NCT02926404|Device|UNiD Rods|Spinal osteosynthesis
167793|NCT02888938|Other|pelvic CT-scan|
162847|NCT02926729|Device|nonlinear microscopy imaging of excised surgical margins|Following standard lumpectomy excision, excised tissue will be imaged with NLM. If invasive cancer or ductal carcinoma in situ (DCIS) is detected on or close to the margin, additional excision may be performed. Following surgery, final margins will be evaluated using paraffin embedded histopathology as per standard procedure. Paraffin embedded histopathology will be used to make a final margin determination.
162848|NCT02926729|Procedure|standard lumpectomy without nonlinear microscopy imaging|Lumpectomy with postoperative paraffin embedded histopathology to make a final margin determination.
162849|NCT02926703|Other|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
162850|NCT02926690|Drug|OTS167PO|Single arm, no competitor
162851|NCT02926677|Behavioral|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
162852|NCT02926677|Behavioral|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
162853|NCT02926677|Behavioral|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
162854|NCT02926677|Device|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
162855|NCT02926664|Other|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
162856|NCT02926651|Drug|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
162857|NCT02926651|Drug|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
162858|NCT02926638|Drug|Erlotinib Hydrochloride|Given PO
162859|NCT02926638|Other|Laboratory Biomarker Analysis|Correlative studies
162860|NCT02926638|Biological|Rilotumumab|Given IV
162861|NCT02926625|Behavioral|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~Children who are getting worse should come back immediately or at any time for a re-assessment~All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~HEW should fill out a loose child assessment form~If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
162862|NCT02926625|Behavioral|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
162863|NCT02926612|Other|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
162864|NCT02926599|Behavioral|Personal Optimization Training|
162865|NCT02926586|Drug|Fludarabine|Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
162866|NCT02926586|Drug|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
162867|NCT02926573|Drug|Gabapentin|
162868|NCT02926573|Drug|Placebo|
162869|NCT02926521|Device|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
162870|NCT02926521|Device|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
162871|NCT02926508|Dietary Supplement|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto‐oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.~Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
162872|NCT02926508|Other|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.~The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.~This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
162873|NCT02926495|Device|eCoin System|Median nerve neurostimulator.
162874|NCT02926482|Behavioral|Prescriber Recruitment Bundle (PRB)|The Prescriber Recruitment Bundle (PRB) is a bundle pharmacotherapy capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) prescriber education forums, c) prescriber-friendly workflow and risk-reduction strategies, d) academic detailing to recruit OUD prescribers, e) telemedicine, and f) organizational leadership and culture to support building OUD pharmacotherapy capacity.
162875|NCT02926469|Device|Virtual Reality|Using Virtual Reality during labor
162876|NCT02926443|Other|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
162877|NCT02926443|Other|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
162878|NCT02926430|Biological|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
162879|NCT02926430|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
162883|NCT02926391|Device|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
162884|NCT02926378|Procedure|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
162885|NCT02926365|Behavioral|ICBT|
162886|NCT02926352|Behavioral|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
162887|NCT02926352|Device|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
162888|NCT02926352|Device|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
162889|NCT02926339|Behavioral|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
162890|NCT02926326|Drug|BCT197|A single dose of BCT197
162891|NCT02926326|Drug|Azithromycin|3 daily doses of Azithromycin
162892|NCT02926313|Other|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
162893|NCT02926300|Biological|stem cells|IV infusion
162894|NCT02926287|Other|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
162895|NCT02926261|Other|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
162896|NCT02926248|Drug|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
162897|NCT02926248|Other|Placebo|
162898|NCT02926235|Drug|Amino Acid|Treatment arm
162899|NCT02926235|Other|Placebo|
162900|NCT02926222|Drug|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
162901|NCT02926222|Drug|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
162902|NCT02926209|Device|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
162903|NCT02926209|Procedure|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
162904|NCT02926196|Drug|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
162905|NCT02926183|Drug|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
162906|NCT02926170|Drug|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
162907|NCT02926170|Drug|acenocumarol|Doses will be adjusted according to INR
162908|NCT02926157|Behavioral|Life Style and Sleep Intervention|
162909|NCT02926144|Device|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
162910|NCT02926144|Device|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
162911|NCT02926131|Other|Blood sampling|"One full capillary tube (50µl blood) will be used to measure the Hct level and the routine SBR using the BR-501 bilirubin meter machine (non-study procedure).~An additional half- filled capillary tube (25µl blood) will be used for the SBR measurement with the Bilistick system"
162912|NCT02926118|Dietary Supplement|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
162913|NCT02926118|Dietary Supplement|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
162914|NCT02926105|Behavioral|T&E Home-based exercise programme|"T&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
162915|NCT02926105|Behavioral|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
162916|NCT02926105|Behavioral|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
162917|NCT02926092|Diagnostic Test|Observation|Observation of progression of disease over time
162918|NCT02926066|Drug|AAV2-hAADC|"Dosage form: Aqueous solution Dose(s): 2.37x10^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect"
162919|NCT02926053|Procedure|Surgical removal of tumor tissue for T cell production|Surgical removal of > 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
162920|NCT02926053|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
162921|NCT02926053|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
162922|NCT02926053|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
163055|NCT02924974|Drug|Lidocaine|sham procedure (s.c. lidocaïne)
162923|NCT02926053|Drug|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
162924|NCT02926040|Procedure|Irreversible electroporation|
162925|NCT02926027|Drug|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
162926|NCT02926027|Drug|placebo|placebo
162927|NCT02926014|Device|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
162928|NCT02926014|Other|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
162929|NCT02926014|Other|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:~Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
162930|NCT02925988|Device|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
162931|NCT02925975|Drug|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
162932|NCT02925975|Device|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
162933|NCT02925975|Procedure|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
162934|NCT02925962|Other|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
162935|NCT02925962|Other|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
162936|NCT02925949|Behavioral|DuoPACT|6 couple-based intervention sessions are administered weekly by a counselor.
162937|NCT02925949|Behavioral|LifeSteps|3 individual-based intervention sessions are administered weekly by a counselor.
162938|NCT02925936|Other|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
162939|NCT02925936|Other|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
162940|NCT02925923|Drug|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, crushed ticagrelor will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
162941|NCT02925923|Drug|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
162942|NCT02925923|Drug|Clopidogrel|
162943|NCT02925910|Device|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
162944|NCT02925897|Behavioral|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
162945|NCT02925884|Device|Gunnar OTC Glasses Condition|Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
162946|NCT02925858|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
162947|NCT02925858|Drug|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
162948|NCT02925845|Device|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
163056|NCT02924961|Device|Triathlon PS total knee system with mobile-bearing|
162949|NCT02925832|Procedure|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
162950|NCT02925832|Drug|Ropivacaine|0.75% ropivacaine soaked sponges
162951|NCT02925832|Drug|Bupivacaine|0.5% bupivacaine soaked sponges
162952|NCT02925832|Drug|Proparacaine|For anaesthetising conjunctiva
162953|NCT02925806|Other|Non-interventional study - retrospective database review|
162954|NCT02925793|Drug|DS107|
162955|NCT02925793|Other|Vehicle cream|
162956|NCT02925780|Device|Resin infiltration|"Teeth selected for this group will be treated with the resin infiltrant Icon according to the manufacturer's instructions. In short, teeth will be isolated with a rubber dam and the labial tooth surface cleaned with non-fluoride prophylactic paste and pumice. After an etching and drying step (to open the lesion surface), Icon will be applied following the manufacturer's instructions and subsequently light cured, followed by polishing.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
162957|NCT02925780|Device|Microabrasion|"The labial surfaces of teeth selected for this group will be isolated and precleaned. Subsequently, the microabrasive material, Opalustre, will be applied according to the manufacturer's instructions, using a rubber cup at low speed (5 times each for 5 seconds). Between each of the applications the surface is washed by flushing water using a syringe.~Digital images are taken before and after the treatment as well as at the follow-up visits (3, 6, 9 and 12 months)."
162958|NCT02925767|Device|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
162959|NCT02925767|Device|308-nm excimer laser|XTRAC, PhotoMedex, US
162960|NCT02925741|Other|Silk-Like Linens|Synthetic moisture-wicking fabric
162961|NCT02925728|Other|Finger-Food|Finger-Food at lunch and having diner
162962|NCT02925728|Other|Without Finger-Food|Without finger-food
162963|NCT02925715|Procedure|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
162964|NCT02925702|Drug|Radium 223 55mBq/Kg every 4 weeks intravenously|Radium-223 55kBq/kg infusion IV every 4 weeks
162965|NCT02925676|Device|hyposafe H02|hypoglycaemia alarm device
162966|NCT02925663|Behavioral|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
162967|NCT02925650|Drug|Posiphen|oral solid dosage form capsule
162968|NCT02925650|Drug|Placebo|oral solid dosage form capsule
162969|NCT02925637|Other|FacoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
162970|NCT02925624|Procedure|Pulmonary vein isolation|
162971|NCT02925611|Drug|Isoflurane|
162972|NCT02925611|Drug|Desflurane|
162973|NCT02925598|Device|I-gel LMA insertion|'I-gel LMA insertion' was done following anesthesia induction.
162974|NCT02925598|Device|AuraGain LMA insertion|'AuraGain LMA insertion' was done following anesthesia induction.
162975|NCT02925598|Device|ETT insertion|'ETT insertion' was done following anesthesia induction.
162976|NCT02925585|Other|Pre/post imaging|
162977|NCT02925572|Other|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
162978|NCT02925559|Drug|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
162979|NCT02925559|Drug|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
162980|NCT02925546|Drug|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
162981|NCT02925546|Drug|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
162982|NCT02925546|Drug|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
162983|NCT02925533|Drug|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
162984|NCT02925533|Drug|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
162985|NCT02925520|Drug|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.~Home Use of Omegaven:~The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
162986|NCT02925507|Other|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
162987|NCT02925494|Drug|Estradiol/Norethindrone Acetate|Oral administration
162988|NCT02925494|Drug|Elagolix|Oral administration
167794|NCT02888925|Other|Mooney test|
162989|NCT02925481|Behavioral|Moderate Online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
162990|NCT02925481|Behavioral|Stretching and toning|Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
162991|NCT02925481|Behavioral|Low dose online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
162992|NCT02925468|Device|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
162993|NCT02925455|Device|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
162994|NCT02925455|Device|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
162995|NCT02925442|Procedure|t-RFA|standard thermal genicular radiofrequency ablation
162996|NCT02925442|Procedure|C-RFA|Cooled radiofrequency ablation
162997|NCT02925442|Procedure|Control|Simulated radiofrequency ablation for placebo controlled group
162998|NCT02925416|Drug|oritavancin|
162999|NCT02925416|Drug|placebo (D5W)|
163000|NCT02925403|Biological|R21/Matrix-M1|
163001|NCT02925403|Other|Saline|
163002|NCT02925377|Behavioral|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
163003|NCT02925377|Behavioral|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
163004|NCT02925364|Radiation|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
163005|NCT02925351|Procedure|Computed Tomography|Undergo PET/CT scan
163006|NCT02925351|Radiation|Fluorine F 18 Clofarabine|Given IV
163007|NCT02925351|Procedure|Positron Emission Tomography|Undergo PET/CT scan
163008|NCT02925338|Other|QOL questionaire|Health assessment questionnaire disability index for rheumatoide polyarthritis questionnair
163009|NCT02925325|Behavioral|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
163010|NCT02925325|Other|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
163011|NCT02925312|Other|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication
163012|NCT02925299|Device|FlorenceM (US) and FlorenceX (UK)|"The automated closed loop system (FlorenceM in US) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Guardian3 CGM and glucose suspend feature.~The automated closed loop system (FlorenceX in UK) will consist of:~The DANA Diabecare R insulin pump (Sooil Development, Korea) incorporating the Dexcom G6 CGM.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
163013|NCT02925299|Device|Insulin pump therapy|Subjects will continue using their own insulin pump for 6 months.
163014|NCT02925286|Other|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
163015|NCT02925273|Other|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.~The scaling of the grasp response is as followed:~Flexion at the distal interphalangeal joint of the hand~Flexion at the proximal interphalangeal joint of the hand~Flexion at the metacarpal-phalangeal joint of the hand"
163016|NCT02925273|Other|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
163057|NCT02924961|Device|Triathlon PS total knee system with fixed-bearing|
163058|NCT02924948|Procedure|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
163059|NCT02924935|Dietary Supplement|L-Histidine|L-Histidine in 500mg capsules taken at a dose of 50mg/kg to maintain high-normal serum histidine levels
163215|NCT02923947|Drug|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
163017|NCT02925260|Other|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
163018|NCT02925247|Behavioral|Adherence to oral anticoagulant treatment|The adherence will be evaluated by biological results
163019|NCT02925234|Drug|Panitumumab|Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
163020|NCT02925234|Drug|Olaparib|Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
163021|NCT02925234|Drug|Dabrafenib|Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
163022|NCT02925234|Drug|Nilotinib|Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
163023|NCT02925234|Drug|Trametinib|Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
163024|NCT02925234|Drug|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
163025|NCT02925234|Drug|Trastuzumab and Pertuzumab (combination treatment)|Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
163026|NCT02925234|Drug|Vemurafenib and Cobimetinib (combination treatment)|Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
163027|NCT02925234|Drug|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
163028|NCT02925234|Drug|Regorafenib|Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
163029|NCT02925234|Drug|Nivolumab|Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
163030|NCT02925208|Other|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
163031|NCT02925195|Dietary Supplement|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
163032|NCT02925195|Drug|Placebo|
163033|NCT02925182|Device|Er,Cr:YSGG Laser|
163034|NCT02925169|Device|CT Scan|CT imaging
163035|NCT02925143|Other|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
163036|NCT02925130|Drug|Salbutamol|Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
163037|NCT02925130|Drug|Placebo|Acute oral intake of a placebo drug
163038|NCT02925117|Drug|ABT-494|Oral tablet
163039|NCT02925117|Drug|Placebo|Oral tablet
163040|NCT02925104|Drug|INC280|
163041|NCT02925078|Device|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with <2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
163042|NCT02925065|Other|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
163043|NCT02925052|Device|Gastric Tube Guide|
163044|NCT02925052|Device|Conventional placement|
163045|NCT02925039|Other|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
163046|NCT02925039|Other|Treatment as usual|Treatment as usual
163047|NCT02925026|Dietary Supplement|Lactoferrin|
163048|NCT02925026|Dietary Supplement|Lysozyme|
163049|NCT02925026|Dietary Supplement|Placebo|
163050|NCT02925013|Procedure|Blood sampling|Blood sampling for lipid profile
163051|NCT02925013|Other|Dietary- Normal western diet|Normal western diet
163052|NCT02925000|Drug|TLC178|TLC178
163053|NCT02924987|Drug|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
163054|NCT02924974|Drug|Morphine|mixed with bupivacaine
163060|NCT02924922|Procedure|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
163061|NCT02924922|Procedure|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
163062|NCT02924922|Device|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
163063|NCT02924922|Device|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
163064|NCT02924922|Drug|Mannitol|
163065|NCT02924909|Drug|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
163066|NCT02924896|Dietary Supplement|Palm olein|60g of palm olein will be given in a milkshake at breakfast
163067|NCT02924896|Dietary Supplement|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
163068|NCT02924896|Dietary Supplement|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
163069|NCT02924883|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion
163070|NCT02924883|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
163071|NCT02924883|Other|Placebo|Placebo matched to atezolizumab
163072|NCT02924870|Other|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
163073|NCT02924870|Other|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
163074|NCT02924857|Device|Chocolate Touch|The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
163075|NCT02924857|Device|Lutonix Drug Coated Balloon|The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
163076|NCT02924831|Other|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
163077|NCT02924831|Other|moxibustion|Stimulating acupoints by using burned moxa
163078|NCT02924831|Other|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
163079|NCT02924818|Other|Clinical assessment|
163080|NCT02924818|Behavioral|questionnaires|
163081|NCT02924818|Other|pulmonary function test|
163082|NCT02924818|Biological|blood test|
163083|NCT02924818|Biological|microbiology|
163084|NCT02924818|Biological|histology|
163085|NCT02924818|Other|imaging|
163086|NCT02924805|Other|Telemedical care|Telemedically guided care based on a standard operating procedure
163087|NCT02924792|Device|Reinfusion - Sternal IO needle|
163088|NCT02924792|Device|Reinfusion - Intravenous needle|
163089|NCT02924779|Other|No intervention|Retrospective observational study
163090|NCT02924766|Drug|Niraparib|Participants will start with niraparib 200 mg once daily.
163091|NCT02924766|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4*60 mg) once daily orally.
163092|NCT02924766|Drug|Abiraterone Acetate|Participants will receive 1000 mg (4*250mg) once daily.
163093|NCT02924766|Drug|Prednisone|Participants will receive 10 mg (1*5 mg twice daily).
163094|NCT02924753|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
163095|NCT02924753|Drug|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
163096|NCT02924753|Biological|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
163128|NCT02924558|Other|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
163129|NCT02924532|Biological|immediate post operative bioassay of Parathyroid Hormone|
163130|NCT02924506|Device|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
163131|NCT02924506|Device|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
163376|NCT02922894|Procedure|Supplemental oxygen|Supplemental oxygen therapy for 6 weeks
163377|NCT02922894|Drug|Trazodone|100mg before bedtime
163097|NCT02924740|Behavioral|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
163098|NCT02924740|Behavioral|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
163099|NCT02924727|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
163100|NCT02924727|Drug|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
163101|NCT02924727|Drug|Placebo of LCZ696|Matching placebo of LCZ696 tablets
163102|NCT02924727|Drug|Placebo of ramipril|Matching placebo of ramipril capsule
163103|NCT02924727|Drug|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
163104|NCT02924727|Drug|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
163105|NCT02924714|Other|Discontinuation of imatinib|
163106|NCT02924701|Other|Blood samples, fibroscan and questionaires|
163107|NCT02924688|Drug|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily [QD] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
163108|NCT02924688|Drug|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
163109|NCT02924688|Drug|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
163110|NCT02924688|Drug|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
163111|NCT02924688|Drug|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
163112|NCT02924688|Drug|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
163113|NCT02924688|Drug|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
163114|NCT02924688|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
163115|NCT02924688|Device|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
163116|NCT02924688|Device|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
163117|NCT02924688|Device|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
163118|NCT02924675|Drug|Pregabalin|150mg daily in three doses during three weeks
163119|NCT02924675|Drug|Placebo|Three doses daily with lactose
163120|NCT02924662|Other|There is no intervention.|
163121|NCT02924649|Procedure|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
163122|NCT02924636|Behavioral|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
163123|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic RFA assisted TE|
163124|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic partial nephrectomy|
163125|NCT02924571|Procedure|Bone Marrow Aspirate Concentrate (BMAC)|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest (BMAC+ ALLOGRAFT) or
163126|NCT02924571|Procedure|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft (BMP). Using the standard technique for anterior lateral fusion, the bone graft from group 1 or 2 will be laid onto the decorticated transverse processes, lateral aspects of the facets, par interarticularis, and onto the facets.
163127|NCT02924558|Other|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
260622|NCT02213159|Drug|Morphine|
163132|NCT02924493|Other|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
163133|NCT02924480|Procedure|Cystectomy|
163134|NCT02924480|Drug|Lidocaine|Patients will receive lidocaine infusion during surgery
163135|NCT02924480|Drug|Saline|Patients will receive saline infusion during surgery
163136|NCT02924467|Behavioral|1 Notice|1 Reminder notification via autodialer
163137|NCT02924467|Behavioral|2 Notices|2 Reminder notifications via autodialer
163138|NCT02924467|Behavioral|3 Notices|3 Reminder notifications via autodialer
163139|NCT02924454|Drug|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
163140|NCT02924454|Drug|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
163141|NCT02924454|Drug|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
163142|NCT02924454|Drug|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
163143|NCT02924441|Other|Lidocaine|Applied to breast skin
163144|NCT02924441|Other|Calming Music|Played during mammography
163145|NCT02924441|Other|No Music|No music played during mammography
163146|NCT02924428|Device|Venus Versa|
163147|NCT02924415|Behavioral|Tele-care support|Psychoeducation treatment based on telemedicine
163148|NCT02924415|Other|Control group|Standard care
163149|NCT02924402|Biological|XmAb13676|Biological
163150|NCT02924389|Drug|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day in combination with Truvada.
163151|NCT02924389|Drug|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
163152|NCT02924389|Drug|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily in combination with Tivicay (dolutegravir).
163153|NCT02924376|Drug|Pemigatinib|Pemigatinibonce a day by mouth for 2 consecutive weeks and 1 week off therapy
163154|NCT02924363|Diagnostic Test|Cardiac MRI with or without contrast dye|MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.
163155|NCT02924363|Diagnostic Test|Blood sample|Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
163156|NCT02924350|Other|Stannous fluoride|"Supervised direct application (Day 0): Participants applied a pea-sized dose of test dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and Home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed each of the 2 qualifying test teeth first, followed by their whole mouth for at least 60 sec. Participants were permitted to rinse with 5 mL tap water (room temperature) for 5 sec. maximum after brushing on supervised brushing (Day 0) and were also permitted to rinse with tap water after brushing on home use (3 days)."
163157|NCT02924350|Other|Sodium monofluorophosphate|"Supervised direct application (Day 0): participants applied a pea-sized dose of control dentifrice to each of the 2 qualifying test teeth using their washed and clean finger to gently rub the dentifrice into the tooth's cervical margin for 60 sec. No rinsing was permitted after treatment.~Supervised brushing (Day 0, before leaving the site) and home use (3 days): after dosing a dry toothbrush with a full strip of dentifrice, participants brushed their whole mouth thoroughly for at least 60 sec. Participants were permitted to rinse with 5mL tap water (room temperature) for 5 sec. maximum after brushing in supervised brushing on Day 0 and were also permitted to rinse with tap water after brushing on home use (3 days)."
163158|NCT02924337|Drug|Placebo|
163159|NCT02924337|Drug|Imeglimin|
163160|NCT02924337|Drug|Moxifloxacin|
163161|NCT02924324|Device|propofol|
163162|NCT02924324|Drug|ropivacaine|
163163|NCT02924324|Behavioral|Wong-Baker FACES® Pain Rating Scale|Nurses will record patient-reported pain scores.
163164|NCT02924324|Behavioral|Post-procedural quality of life (QOL)|
163165|NCT02924311|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
163166|NCT02924298|Behavioral|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
163167|NCT02924285|Procedure|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
163168|NCT02924285|Drug|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:~Antiarrhythmic Drug Amiodarone"
163169|NCT02924272|Drug|Ixazomib|Ixazomib Capsules
163170|NCT02924259|Device|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
163175|NCT02924233|Drug|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).~Sym004 will be administered at different dose-levels via infusion Q2W"
163176|NCT02924233|Drug|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
163177|NCT02924207|Other|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
163178|NCT02924194|Device|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
163179|NCT02924194|Device|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
163180|NCT02924181|Device|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
163181|NCT02924168|Device|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
163182|NCT02924168|Device|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
163183|NCT02924155|Drug|SJP002|
163184|NCT02924155|Drug|Placebo|
163185|NCT02924142|Device|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
163186|NCT02924129|Device|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
163187|NCT02924116|Device|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
163188|NCT02924103|Device|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
163189|NCT02924090|Drug|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
163190|NCT02924090|Drug|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
163191|NCT02924090|Procedure|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
163192|NCT02924090|Procedure|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
163193|NCT02924064|Drug|Teneligliptin 20mg|
163194|NCT02924064|Drug|Placebo|
163195|NCT02924064|Drug|Metformin ≥ 1000 mg|
163196|NCT02924051|Behavioral|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
163197|NCT02924051|Behavioral|Cooking skills and nutritional education|Participants in this group will develop an understanding of healthy food options and healthy food preparation.
163198|NCT02924038|Biological|IMA950|
163199|NCT02924038|Biological|poly-ICLC|
163200|NCT02924038|Biological|Varlilumab|
163201|NCT02924025|Behavioral|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
163202|NCT02924012|Other|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
163203|NCT02924012|Other|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
163204|NCT02924012|Other|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
163205|NCT02923999|Drug|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
163206|NCT02923999|Drug|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
163207|NCT02923999|Drug|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
163208|NCT02923986|Drug|BP1001 (varying dose)|BP1001 (varying dose)
163209|NCT02923986|Drug|BP1001 (fixed dose)|BP1001 (fixed dose)
163210|NCT02923986|Drug|Dasatinib|Dasatinib
163211|NCT02923973|Other|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
163212|NCT02923960|Other|Standard ONS|One serving (237 ml) standard oral nutritional beverage
163213|NCT02923960|Other|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
163216|NCT02923934|Drug|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
163217|NCT02923934|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
163218|NCT02923921|Biological|Pegilodecakin|Pegilodecakin plus FOLFOX
163219|NCT02923921|Drug|FOLFOX|FOLFOX Alone
163220|NCT02923908|Other|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
163221|NCT02923908|Other|Voice Recording|A voice recording will be made for the duration of the tasting period.
163222|NCT02923908|Other|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
163223|NCT02923908|Other|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
163224|NCT02923895|Other|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
163225|NCT02923895|Other|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
163226|NCT02923882|Other|'$100Kitchen and improved cookstove'|
163227|NCT02923869|Drug|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
163228|NCT02923869|Drug|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
163229|NCT02923856|Device|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
163230|NCT02923856|Device|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
163231|NCT02923856|Device|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
163232|NCT02923843|Other|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
163233|NCT02923830|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
163234|NCT02923830|Drug|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
163235|NCT02923817|Biological|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
163236|NCT02923804|Dietary Supplement|Omega-3|3x 1g capsules taken daily for 6 months
163237|NCT02923804|Dietary Supplement|Olive oil|3x 1g capsules taken daily for 6 months
163238|NCT02923791|Biological|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
163239|NCT02923791|Biological|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
163240|NCT02923778|Other|Laboratory Biomarker Analysis|Correlative studies
163241|NCT02923778|Radiation|Radiation Therapy|Undergo radiation therapy
163242|NCT02923778|Biological|Talimogene Laherparepvec|Given IT
163243|NCT02923765|Other|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
163244|NCT02923752|Device|MRI|Contrast-enhanced MRI
163245|NCT02923739|Biological|Bevacizumab|Given IV
163246|NCT02923739|Biological|Emactuzumab|Given IV
163247|NCT02923739|Other|Laboratory Biomarker Analysis|Correlative studies
163248|NCT02923739|Drug|Paclitaxel|Given IV
163249|NCT02923739|Other|Pharmacological Study|Correlative studies
163250|NCT02923726|Device|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
163251|NCT02923726|Device|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
163252|NCT02923700|Biological|Leukocyte-rich PRP intra-articular injections|
163253|NCT02923700|Biological|Leukocyte-poor PRP intra-articular injections|
163254|NCT02923687|Drug|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
163255|NCT02923687|Drug|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
163256|NCT02923674|Behavioral|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
163257|NCT02923674|Behavioral|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
163258|NCT02923674|Behavioral|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).
163259|NCT02923661|Device|CM LOC|
163260|NCT02923661|Device|ball attachment|
163261|NCT02923635|Procedure|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
163262|NCT02923635|Procedure|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
163263|NCT02923622|Other|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
163264|NCT02923622|Other|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
163265|NCT02923622|Other|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
163266|NCT02923609|Biological|Cell Therapy|Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
163267|NCT02923609|Biological|Control Procedure|In the Control Group we will perform transendocardial injections using the same protocol as in the SC Group; stem cell suspension will be substituted with placebo (0.9% saline).
163268|NCT02923596|Procedure|History of prior Surgery|History of prior Surgery will be reviewed
163269|NCT02923596|Radiation|History of Radiation Therapy|History of prior radiation therapy will be reviewed
163270|NCT02923583|Biological|M834|
163271|NCT02923583|Biological|US-Sourced Orencia®|
163272|NCT02923583|Biological|EU-Sourced Orencia®|
163273|NCT02923570|Radiation|Photon intensity modulated radiation therapy (IMRT)|
163274|NCT02923570|Radiation|Proton beam radiotherapy (PBRT)|
163275|NCT02923557|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
163276|NCT02923544|Procedure|YUMI manipulator|
163277|NCT02923531|Drug|X4P-001|X4P-001 will be administered as per the dose and schedule specified in the arm.
163278|NCT02923531|Drug|Nivolumab|Nivolumab will be administered as per the dose and schedule specified in the arm.
163279|NCT02923518|Other|Questionnaire|Observational study without any intervention described under intervention type
163280|NCT02923505|Procedure|polygraphy or polysomnography|
163281|NCT02923492|Behavioral|SafERteens|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
163282|NCT02923479|Device|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
163283|NCT02923479|Other|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
163284|NCT02923479|Other|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
163285|NCT02923479|Device|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
163286|NCT02923479|Device|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
163287|NCT02923466|Biological|VSV-IFNβ-NIS|Intratumoral injection of a single dose of VSV-IFNβ-NIS
163288|NCT02923466|Biological|VSV-IFNβ-NIS and avelumab|Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab
163289|NCT02923453|Dietary Supplement|CNT 2000 American ginseng extract|
163290|NCT02923453|Dietary Supplement|Placebo|
163291|NCT02923440|Biological|blood sample|
163292|NCT02923427|Device|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
163293|NCT02923427|Device|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
163294|NCT02923414|Device|Standard escalating shocks|125 J, 150 J, 200 J
163295|NCT02923414|Device|High energy shock protocol|360 J, 360 J, 360 J.
260783|NCT02211924|Drug|BI 44847|
163296|NCT02923401|Other|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.~Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
163297|NCT02923401|Behavioral|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
163298|NCT02923401|Behavioral|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
163299|NCT02923401|Behavioral|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
163300|NCT02923401|Other|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.~Control Group: Participants receive written materials and counseling by an exercise physiologist."
163301|NCT02923388|Drug|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
163302|NCT02923388|Drug|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
163303|NCT02923388|Drug|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
163304|NCT02923388|Drug|Placebo pill|Placebo pill orally thrice daily for 5 weeks
163305|NCT02923375|Biological|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
163306|NCT02923362|Procedure|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
163307|NCT02923362|Device|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
163308|NCT02923349|Drug|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
163309|NCT02923336|Drug|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
163310|NCT02923323|Device|MRI including DTI , EEG, CGMS|Will be connected to continuous simultaneous systems
163311|NCT02923323|Behavioral|Neurocognitive tests|Will perform multiple tests of neurocognitive functions after lunch
163312|NCT02923310|Biological|Platelets Rich Plasma|
163313|NCT02923310|Biological|Leucocyte - Platelets Rich Plasma|
163314|NCT02923310|Drug|Hialuronic Acid|
163315|NCT02923297|Other|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
163316|NCT02923271|Device|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
163317|NCT02923258|Drug|Docetaxel|20mg/m2/w for 6 weeks
163318|NCT02923258|Drug|Cisplatinum|40mg/m2/w for 6 weeks
163319|NCT02923258|Radiation|IMRT|a total dose of 60Gy in 30 fractions over 6 weeks
163320|NCT02923245|Other|point-of-care ultrasound|
163321|NCT02923232|Device|Accommodative contact lens|Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
163322|NCT02923219|Biological|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
163323|NCT02923206|Device|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
163324|NCT02923193|Device|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
163325|NCT02923193|Drug|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
163326|NCT02923180|Drug|Enoblituzumab|
163378|NCT02922894|Drug|Placebo|One placebo pill before-bedtime
163327|NCT02923167|Device|Robotic-assisted training of the hand|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
163328|NCT02923154|Drug|MT-3995|
163329|NCT02923154|Drug|Placebo|
163330|NCT02923141|Behavioral|Neutral Writing|
163331|NCT02923141|Behavioral|Expressive Writing|
163332|NCT02923141|Behavioral|Contingency Management|
163333|NCT02923128|Drug|Dexmedetomidine|Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
163334|NCT02923128|Drug|Sufentanyl|Sufentanyl(0.06ug.kg-1.h-1) is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
163335|NCT02923128|Drug|Saline|Saline is used to dilute other drugs
163336|NCT02923115|Drug|DS-1040b|injection
163337|NCT02923115|Drug|placebo|0.9% Sodium Chloride Injection
163338|NCT02923102|Dietary Supplement|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
163339|NCT02923102|Dietary Supplement|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
163340|NCT02923089|Other|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163341|NCT02923089|Other|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163342|NCT02923089|Other|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163343|NCT02923089|Other|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163344|NCT02923089|Other|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163345|NCT02923089|Other|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163346|NCT02923089|Other|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163347|NCT02923089|Other|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163348|NCT02923089|Other|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
163349|NCT02923076|Other|CCR5 delta32/delta32 cord blood transplantation|
163350|NCT02923063|Behavioral|Combined Aerobic and Resistance Exercise|Combined aerobic and resistance exercise session thrice weekly for 12 weeks
163351|NCT02923050|Behavioral|Simple Suppers|Theory-based 10-week family meals program
163352|NCT02923037|Procedure|Yoga|Complete guided and home yoga sessions
163353|NCT02923037|Other|tape measurement of arm|Ancillary studies
163354|NCT02923037|Other|Quality-of-Life Assessment|Ancillary studies
163355|NCT02923037|Other|ldex measurement of arms|
163356|NCT02923024|Behavioral|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
163357|NCT02923011|Device|MRgFUS|Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
163358|NCT02923011|Device|CTgRFA|Computed tomography-guided radiofrequency ablation of osteoid osteoma
163359|NCT02922985|Drug|Intravenous acetominophen|One dose if 1 gram intravenous to be given pre-surgery
163360|NCT02922985|Drug|Ketorolac, intramuscular|One dose of 60 mg Intramuscular to be given at time of skin closure
163361|NCT02922985|Drug|Bupivacaine, subcutaneous|Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
163362|NCT02922985|Drug|Normal saline|Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
163363|NCT02922972|Device|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
163364|NCT02922959|Behavioral|TTIP-PRO|TTIP-PRO includes: 1) a 30-minute computer-facilitated telephone intervention delivered by Peer Interventionists; and 2) a mailing which includes a report on the participant's risk factors for experiencing another opioid overdose.
163365|NCT02922959|Drug|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
163366|NCT02922959|Behavioral|information|Written information about opioid overdose and treatment for opioid use disorder.
163367|NCT02922946|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
163368|NCT02922933|Drug|entinostat|HDAC (histone deacetylase inhibitor)
163369|NCT02922933|Dietary Supplement|Omeprazole|Proton pump inhibitor
163370|NCT02922933|Dietary Supplement|Famotidine|Histamine-2 blocker
163371|NCT02922920|Other|Tart cherry juice|16 fl. oz of tart cherry juice
163372|NCT02922920|Other|Placebo|16 fl. oz of placebo
163373|NCT02922907|Dietary Supplement|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
163374|NCT02922907|Dietary Supplement|Placebo for arabinoxylan rice bran|inactive product
163375|NCT02922894|Procedure|Acute episodic hypoxia|The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
163380|NCT02922881|Other|Ulcerative Colitis Diet (UCD)|The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
163381|NCT02922868|Device|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
163382|NCT02922868|Device|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
163383|NCT02922855|Behavioral|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
163384|NCT02922855|Behavioral|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
163385|NCT02922855|Behavioral|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
163386|NCT02922842|Device|Transcutaneous Electrical Nerve Stimulation|
163387|NCT02922816|Biological|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
163388|NCT02922816|Procedure|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
163389|NCT02922816|Procedure|Stool or perirectal swab sampling|Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
163390|NCT02922816|Other|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
163391|NCT02922803|Drug|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
163392|NCT02922803|Drug|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
163393|NCT02922790|Behavioral|standard health information|Subjects will review standard health information
163394|NCT02922790|Behavioral|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
163395|NCT02922790|Behavioral|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
163396|NCT02922777|Drug|BGB324|75 mg/m2 every 21 days
163397|NCT02922777|Drug|Docetaxel|75 mg/m2 given IV every 21 days
163398|NCT02922764|Drug|RGX-104|
163399|NCT02922764|Drug|Nivolumab|
163400|NCT02922764|Drug|Ipilimumab|
163401|NCT02922764|Drug|Docetaxel|
163402|NCT02922764|Drug|Pembrolizumab|
163403|NCT02922764|Drug|Carboplatin|
163404|NCT02922764|Drug|Pemetrexed|
163405|NCT02922751|Other|Liver Stiffness Measurement (LSM)|LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.
163406|NCT02922738|Other|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
163407|NCT02922725|Drug|5-hydroxytryptophan and Creatine|
163408|NCT02922725|Other|Placebo control|
163409|NCT02922712|Drug|NISE|Nise 200mg Max per day in 2 divided doses
163410|NCT02922699|Drug|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
163411|NCT02922699|Drug|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
163412|NCT02922686|Drug|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
163413|NCT02922686|Drug|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
163414|NCT02922686|Drug|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
163415|NCT02922673|Drug|Aspirin|
163416|NCT02922673|Drug|Placebo|
163417|NCT02922660|Drug|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
163418|NCT02922660|Procedure|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
163419|NCT02922660|Procedure|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
163420|NCT02922660|Drug|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2—4 μg/ml in TCI
163421|NCT02922660|Drug|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2—4 ng/ml in TCI
163422|NCT02922647|Device|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
163423|NCT02922647|Device|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
163424|NCT02922634|Other|Mini Cog|short cognitive screen, short Frailty screen
163425|NCT02922608|Other|simulation practice|simulation session
163426|NCT02922595|Device|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
163427|NCT02922595|Device|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.~Intubation will then be peformed"
163428|NCT02922582|Drug|DepoTXA|
163429|NCT02922582|Drug|Tranexamic Acid|
163430|NCT02922569|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
164301|NCT02916615|Other|Low nitrate vegetables|vegetables naturally low in nitrate
163431|NCT02922569|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
163432|NCT02922569|Other|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
163433|NCT02922569|Other|Traumatic Brain Injury Information Session|Ten minutes of viewing traumatic brain injury related news, information, and programs.
163434|NCT02922556|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
163435|NCT02922556|Other|Commercially available computerized training|
163436|NCT02922530|Other|Computerized Plasticity-based Adaptive Cognitive Training|
163437|NCT02922530|Other|Commercially available computerized training|
163438|NCT02922504|Behavioral|Music intervention group|
163439|NCT02922504|Behavioral|Controlled group|
163440|NCT02922491|Dietary Supplement|vitamin E|daily intake of vitamin E
163441|NCT02922491|Dietary Supplement|starch|daily intake of starch (control)
163442|NCT02922478|Radiation|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
163443|NCT02922478|Procedure|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
163444|NCT02922478|Radiation|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
163445|NCT02922478|Procedure|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
163446|NCT02922465|Drug|K-877|
163447|NCT02922465|Drug|Clopidogrel|
163448|NCT02922452|Drug|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
163449|NCT02922452|Drug|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
163450|NCT02922439|Behavioral|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
163451|NCT02922439|Behavioral|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
163452|NCT02922426|Drug|ALKS 3831|Daily dosing for 21 consecutive days
163453|NCT02922426|Drug|Olanzapine|Daily dosing for 21 consecutive days
163454|NCT02922426|Drug|Placebo|Daily dosing for 21 consecutive days
163455|NCT02922413|Biological|Hemin for injection|Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
163456|NCT02922413|Other|Placebo|Saline infusion
163457|NCT02922400|Behavioral|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
163458|NCT02922387|Drug|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
163459|NCT02922387|Behavioral|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
163460|NCT02922374|Drug|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
163461|NCT02922348|Drug|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
163462|NCT02922348|Drug|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
163463|NCT02922335|Behavioral|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
163464|NCT02922335|Behavioral|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
163465|NCT02922322|Other|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
163466|NCT02922309|Behavioral|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
163467|NCT02922309|Behavioral|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
163468|NCT02922283|Device|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
163469|NCT02922283|Procedure|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
163470|NCT02922283|Device|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
163471|NCT02922283|Procedure|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
163644|NCT02920944|Device|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
164302|NCT02916602|Drug|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
163472|NCT02922270|Other|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
163473|NCT02922244|Other|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
163474|NCT02922244|Other|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
163475|NCT02922244|Other|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
163476|NCT02922244|Other|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
163477|NCT02922231|Biological|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
163478|NCT02922205|Device|Endoscopic Linear Cutter Stapler and reloads|Endoscopic Linear Cutter Stapler and reloads
163479|NCT02922192|Drug|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
163480|NCT02922179|Drug|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
163481|NCT02922166|Drug|SRX246|oral capsule
163482|NCT02922166|Drug|Placebo|oral capsule
163483|NCT02922153|Device|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
163484|NCT02922153|Drug|Standard of Care|Institutional SOC for pain management will be followed.
163485|NCT02922140|Behavioral|pharmaceutical care service|
163486|NCT02922127|Drug|Ulipristal Acetate|Daily use of Ulipristal Acetate
163487|NCT02922127|Drug|Combined Oral Contraceptive Pill|Daily use of Oral Contraceptive Pill
163488|NCT02922114|Other|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
163489|NCT02922101|Behavioral|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
163490|NCT02922101|Behavioral|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
163491|NCT02922088|Device|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
163492|NCT02922075|Biological|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
163493|NCT02922075|Biological|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
163494|NCT02922075|Device|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque > 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
163495|NCT02922075|Procedure|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
163496|NCT02922075|Device|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
163497|NCT02922075|Biological|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
163498|NCT02922075|Drug|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
163499|NCT02922075|Device|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
163500|NCT02922075|Other|No soft tissue graft|No soft tissue graft was used
163501|NCT02922062|Other|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
163645|NCT02920944|Device|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
163646|NCT02920931|Drug|Tenofovir disoproxil|
163502|NCT02922062|Other|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
163503|NCT02922062|Other|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
163504|NCT02922049|Other|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
163505|NCT02922036|Device|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
163506|NCT02922023|Device|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
163507|NCT02922023|Other|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
163508|NCT02921997|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
163509|NCT02921997|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
163510|NCT02921997|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
163511|NCT02921984|Drug|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
163512|NCT02921984|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
163513|NCT02921984|Drug|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
163514|NCT02921984|Drug|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
163515|NCT02921971|Drug|SAR156597 (ACT14604)|Pharmaceutical form:Solution Route of administration: Subcutaneous
163516|NCT02921971|Drug|Placebo|Pharmaceutical form:Solution Route of administration: Subcutaneous
163517|NCT02921958|Behavioral|occupational therapy|Family-centered occupational therapy services
163518|NCT02921945|Biological|SCT800|recombinant human coagulation factor VIII
163519|NCT02921932|Dietary Supplement|Ensure, Resource 2.0 and Glucerna|Preoperative nutritional supplement for undernourished patients
163520|NCT02921932|Other|Cognitive Training, Memory Card Game|Preoperative memory card game
163521|NCT02921932|Device|'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc|Inspiratory muscle trainer protocol for strengthening respiratory muscles
163522|NCT02921919|Drug|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
163523|NCT02921906|Other|High protein meal|Breakfast with high protein / low carbohydrate content
163524|NCT02921906|Other|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
163525|NCT02921906|Drug|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
163526|NCT02921906|Other|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
163527|NCT02921893|Drug|Dexamethasone|Given PO
163528|NCT02921893|Drug|Ixazomib Citrate|Given PO
163529|NCT02921893|Other|Laboratory Biomarker Analysis|Correlative studies
163530|NCT02921893|Drug|Lenalidomide|Given PO
163531|NCT02921893|Other|Questionnaire Administration|Ancillary studies
163532|NCT02921880|Other|Cardiac Rehabilitation|
163533|NCT02921867|Other|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
163534|NCT02921854|Other|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
163535|NCT02921841|Behavioral|D*STAR|
163536|NCT02921841|Behavioral|D*HEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
163537|NCT02921789|Drug|Bleselumab|Intravenous infusion
163538|NCT02921789|Drug|Basiliximab|Bolus injections
163539|NCT02921789|Drug|Mycophenolate Mofetil (MMF)|Oral (po) or intravenous (iv) two times a day (bid)
163540|NCT02921789|Drug|Tacrolimus Capsules|Oral (po) or intravenous (iv) if medically indicated
163541|NCT02921789|Drug|Methylprednisone|Oral (po) or intravenous (iv)
163542|NCT02921789|Drug|Prednisone|Oral (po)
163543|NCT02921776|Other|Aim 1 - VidaTalk - post-extubation|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:~Tell me you are tired~Tell me you are having pain~Rate this pain~Tell me there is pain in your back~Tell me your pain is sharp~Ask to see the doctor~Write your favorite color by drawing with your finger~Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.~Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.~Group 1 only:~Patients will be asked about their preferences for customizing the VidaTalk app."
163544|NCT02921776|Other|Aim 2 - VidaTalk - intubated|Usability testing prior to clinical trial. The company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
163647|NCT02920918|Drug|Canagliflozin|
163648|NCT02920918|Drug|Sitagliptin|
163892|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
163545|NCT02921776|Device|Aim 3 - VidaTalk tablet app|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in surveys about the patients hospital stay, if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
163546|NCT02921776|Other|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a common tablet application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
163547|NCT02921763|Drug|Dydrogesterone|
163548|NCT02921750|Device|Exufiber|Gelling fibre dressing
163549|NCT02921750|Device|Aquacel Extra|Gelling fibre dressing
163550|NCT02921737|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
163551|NCT02921724|Device|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:~Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.~Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
163552|NCT02921711|Device|LVIS®|Low-profile Visualized Intraluminal Support device
163553|NCT02921698|Device|FRED®|Flow Re-Direction Endoluminal Device
163554|NCT02921685|Drug|Monalizumab|Four dose levels will be tested.
163555|NCT02921672|Other|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
163556|NCT02921659|Dietary Supplement|Niagen™|nicotinamide riboside chloride, 250mg capsules
163557|NCT02921659|Dietary Supplement|Placebo|silicified microcrystalline cellulose, vegetarian capsule
163558|NCT02921646|Other|Measure of resting energetic expenditure|measure of resting energetic expenditure
163559|NCT02921633|Other|Intervention letter|
163560|NCT02921620|Biological|PRX-102|Intravenous
163561|NCT02921620|Other|Placebo|Intravenous
163562|NCT02921607|Other|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
163563|NCT02921594|Device|Total knee arthroplasty with Vanguard XP|
163564|NCT02921594|Device|Total knee arthroplasty with Vanguard CR|
163565|NCT02921581|Radiation|FDG-PET guided dose painting|
163566|NCT02921568|Device|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
163567|NCT02921568|Device|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
163568|NCT02921555|Drug|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
163569|NCT02921555|Drug|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
163570|NCT02921542|Device|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
163571|NCT02921529|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
163572|NCT02921529|Other|false stimulation|Electrodes were attached to specific acupoints without electric current
163573|NCT02921516|Behavioral|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
163574|NCT02921516|Behavioral|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
163575|NCT02921516|Behavioral|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
163576|NCT02921503|Other|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
163577|NCT02921490|Device|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
163578|NCT02921477|Drug|bosutinib|
163579|NCT02921464|Other|none - registry clinic followup only|
163580|NCT02921451|Device|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
163581|NCT02921438|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
163635|NCT02921009|Device|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
163636|NCT02920996|Drug|Merestinib|Oral, predetermined dosage per protocol, once daily per 28 day treatment cycle
163637|NCT02920983|Device|somofilcon A|contact lens
163638|NCT02920983|Device|nelfilcon A II 2|contact lens
163639|NCT02920983|Device|omafilcon A ll 2|contact lens
163640|NCT02920970|Device|narafilcon A|contact lens
163641|NCT02920970|Device|stenfilcon A|contact lens
163582|NCT02921425|Behavioral|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
163583|NCT02921412|Device|fanfilcon A|contact lens
163584|NCT02921386|Drug|Oral Testosterone Undecanoate|All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods
163585|NCT02921373|Biological|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging."
163586|NCT02921373|Device|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
163587|NCT02921360|Drug|acetylsalicylic acid|
163588|NCT02921347|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
163589|NCT02921334|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
163590|NCT02921295|Device|Sidekick Stubbies|
163591|NCT02921282|Genetic|Genotype dopamine|Laboratory investigations of nicotine reinforcement
163592|NCT02921282|Genetic|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
163593|NCT02921269|Drug|Atezolizumab|Given IV
163594|NCT02921269|Biological|Bevacizumab|Given IV
163595|NCT02921269|Other|Laboratory Biomarker Analysis|Correlative studies
163596|NCT02921256|Drug|Capecitabine|Given PO
163597|NCT02921256|Drug|Fluorouracil|Given IV
163598|NCT02921256|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
163599|NCT02921256|Drug|Leucovorin|Given IV
163600|NCT02921256|Drug|Leucovorin Calcium|Given IV
163601|NCT02921256|Drug|Oxaliplatin|Given IV
163602|NCT02921256|Biological|Pembrolizumab|Given IV
163603|NCT02921256|Drug|Veliparib|Given PO
163604|NCT02921230|Device|Peripheral stenting|stent implantation during the index procedure
163605|NCT02921217|Dietary Supplement|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
163606|NCT02921217|Dietary Supplement|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
163607|NCT02921217|Dietary Supplement|Control|Placebo: 300 mg maltodextrin.
163608|NCT02921204|Other|Vitamin D status|There is no intervention in this study
163609|NCT02921191|Drug|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
163610|NCT02921178|Other|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
163611|NCT02921165|Drug|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
163612|NCT02921165|Drug|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
163613|NCT02921152|Procedure|bone marrow aspiration /trephine biopsy|
163614|NCT02921139|Radiation|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
163615|NCT02921139|Procedure|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
163616|NCT02921100|Procedure|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
163617|NCT02921100|Procedure|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
163618|NCT02921100|Procedure|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
163619|NCT02921100|Device|EUS-guided fine needle|
163620|NCT02921087|Device|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
163621|NCT02921087|Device|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
163622|NCT02921074|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
163623|NCT02921074|Other|Commercially available computerized training|
163624|NCT02921061|Drug|Cladribine|Given IV
163625|NCT02921061|Drug|Cytarabine|Given IV
163626|NCT02921061|Drug|Decitabine|Given IV
163627|NCT02921061|Biological|Filgrastim|Given SC
163628|NCT02921061|Other|Laboratory Biomarker Analysis|Correlative studies
163629|NCT02921061|Drug|Mitoxantrone Hydrochloride|Given IV
163630|NCT02921048|Dietary Supplement|omega-3 fatty acids|
163631|NCT02921035|Drug|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
163632|NCT02921022|Drug|Gemcitabine|
163633|NCT02921022|Drug|Nab-paclitaxel|
163649|NCT02920905|Drug|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
163650|NCT02920905|Drug|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
163651|NCT02920905|Drug|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.~Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
163652|NCT02920892|Drug|AFQ056|Oral suspension (liquid)
163653|NCT02920892|Other|Placebo|Oral suspension (liquid)
163654|NCT02920892|Other|Language Intervention|The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.
163655|NCT02920879|Procedure|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
163656|NCT02920866|Behavioral|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
163657|NCT02920866|Behavioral|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
163658|NCT02920853|Behavioral|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
163659|NCT02920853|Behavioral|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
163660|NCT02920840|Device|Intermittent theta-burst stimulation|see associated arm/group description
163661|NCT02920840|Device|Negative-peak-triggered-TMS|see associated arm/group description
163662|NCT02920840|Device|Open-loop replay TMS|see associated arm/group description
163663|NCT02920827|Combination Product|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
163664|NCT02920827|Combination Product|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
163665|NCT02920814|Other|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
163666|NCT02920801|Drug|saxagliptin|5mg per day for 12 weeks
163667|NCT02920801|Drug|Metformin|1500mg per day for 12 weeks
163668|NCT02920788|Behavioral|Goal-Oriented Attentional Self-Regulation (GOALS)|GOALS is a manualized, therapist-administered cognitive training program that targets executive control functions of applied mindfulness-based attention regulation and goal management strategies and links them to participant-defined real-life goals. In contrast to training via practice on isolated tasks, this training protocol involves application of attention regulation skills and strategies to participant-defined goals in real life, ecologically valid settings. One of the main training aims is to improve self-regulatory control mechanisms as they contribute to goal attainment.
163669|NCT02920788|Other|Brain Health Education (BHE)|BHE group is a formal in-person, active, psycho-educational, control intervention closely matched to GOALS for length, intensity, and contact with a therapist/facilitator. Topics include brain structure, function, sleep, stress, emotion and the brain.
163670|NCT02920788|Device|fMRI|Functional Magnetic Resonance Imaging of the Brain
163671|NCT02920775|Other|Non-interventional study - retrospective database review|
163672|NCT02920762|Other|on-interventional study - retrospective database review|
163673|NCT02920749|Drug|Sevoflurane group A|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
260784|NCT02211924|Drug|Placebo|
163674|NCT02920749|Drug|Sevoflurane group B|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
163675|NCT02920749|Drug|Propofol group C|In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.
163676|NCT02920749|Drug|Propofol group D|In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
163677|NCT02920723|Other|Training|
163678|NCT02920723|Other|Control|
163679|NCT02920710|Drug|Repository Corticotropin Injection|"Initial treatment with 80 units daily for ten days (induction phase)~Maintenance treatment with 80 units twice weekly (maintenance phase)"
163680|NCT02920697|Drug|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
163681|NCT02920684|Other|Passive legs mobilisation|A physiotherapist performs a passive leg movement
163682|NCT02920684|Other|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
163683|NCT02920684|Other|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
163684|NCT02920684|Other|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
163685|NCT02920671|Other|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
163686|NCT02920671|Other|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
163687|NCT02920671|Other|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
163688|NCT02920671|Other|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
163689|NCT02920658|Drug|NAVS Naphthalan|
163690|NCT02920658|Drug|0.05% Betamethasone dipropionate|
163691|NCT02920645|Other|AVM-related ICH|
163692|NCT02920632|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games that are designed to train cognitive functions.
163693|NCT02920632|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games.
163694|NCT02920619|Device|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
163695|NCT02920606|Procedure|Pulpotomy|
163696|NCT02920606|Procedure|Endodontic treatment|
163697|NCT02920593|Drug|Vitamin D3|Vitamin D prophylaxis
163698|NCT02920580|Procedure|Extubation|This is an extubation by removal of endotracheal tube which must be done on the day of randomization or the following day. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
163699|NCT02920580|Procedure|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow prompt extubation to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
163700|NCT02920567|Drug|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
163701|NCT02920567|Drug|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
163702|NCT02920554|Procedure|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
163703|NCT02920554|Procedure|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
163704|NCT02920541|Drug|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
163705|NCT02920528|Drug|Ketamine|sub-dissociative ketamine
163706|NCT02920528|Drug|Placebo|Normal Saline
163707|NCT02920515|Drug|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
163708|NCT02920515|Drug|Zhibo dihuang pills|Traditional Chinese Medicine
163709|NCT02920515|Drug|Dabu ying pills|Traditional Chinese Medicine
163710|NCT02920502|Dietary Supplement|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
163711|NCT02920502|Dietary Supplement|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
163712|NCT02920502|Dietary Supplement|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
163713|NCT02920502|Other|Arm 1: Placebo|One time dose of Placebo
163714|NCT02920489|Drug|Individualized epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
163715|NCT02920489|Drug|Routine epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
163716|NCT02920476|Drug|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest"
163717|NCT02920450|Drug|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period. The dose given in the phase 2 portion will be the MTD determined in the phase Ib portion of the study.~Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
163718|NCT02920450|Drug|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
163719|NCT02920450|Drug|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
163720|NCT02920437|Behavioral|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
163721|NCT02920437|Other|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
163722|NCT02920424|Drug|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
163723|NCT02920424|Drug|Placebo|Subjects will receive matching placebo.
163724|NCT02920411|Other|Pediatopic Treatment Cream|Applied twice a day minimum.
163725|NCT02920411|Other|Pediatopic Body lotion|Applied at libitum.
163726|NCT02920398|Drug|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
163727|NCT02920385|Drug|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
163728|NCT02920385|Drug|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
163729|NCT02920385|Drug|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
163730|NCT02920385|Drug|Placebo|Oral administration once daily together with semaglutide
163731|NCT02920372|Drug|EPOETIN ALFA|
163732|NCT02920359|Drug|LEUPRORELIN ACETATE|
163733|NCT02920333|Procedure|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
163734|NCT02920333|Device|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
163735|NCT02920333|Device|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
163736|NCT02920333|Device|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
163737|NCT02920320|Other|Internet-based self-help program|
163738|NCT02920307|Procedure|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
163739|NCT02920307|Procedure|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
163740|NCT02920307|Procedure|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
163741|NCT02920307|Procedure|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
163742|NCT02920294|Dietary Supplement|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
163743|NCT02920294|Dietary Supplement|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
163744|NCT02920294|Dietary Supplement|Placebo|Acidified dairy drink without ferments
163745|NCT02920281|Other|Polysomnography|
163746|NCT02920268|Other|Dance and yoga intervention|
163747|NCT02920255|Other|Diagnostic|Measurement of spinal tilt
163748|NCT02920242|Drug|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
163749|NCT02920242|Drug|Rifaximin (Xifaxan)|200 mg tablet administered orally
163750|NCT02920242|Drug|Placebo|Matching Placebo tablet administered orally
163751|NCT02920229|Drug|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
163752|NCT02920216|Drug|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
163753|NCT02920203|Genetic|Heart and spleen tissue|genetic sequencing
163754|NCT02920190|Drug|Liraglutide|Interventional, single-group, open label pilot study. The investigators will identify monoclonal gammopathy patients whose antibodies are lipid/VAT targeted (goal is 10 initially as a pilot) and who are overweight/obese (BMI > 27). Eligible patients will be started on Liraglutide up to 1.8 mg sc once daily, as adjunct weight loss treatment for 12 months.
163755|NCT02920177|Drug|platelet-rich plasma injection|platelet-rich plasma injection
163756|NCT02920177|Drug|Kenalog 10 MG/ML Injectable Suspension|4 mL corticosteroid injection
163757|NCT02920164|Device|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
163758|NCT02920164|Device|Placebo acupuncture|Placebo acupuncture with placebo needles
163840|NCT02919579|Other|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
164303|NCT02916602|Drug|HCP0605|amlodipine, Losartan FDC
163759|NCT02920151|Other|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
163760|NCT02920125|Drug|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
163761|NCT02920125|Combination Product|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
163762|NCT02920125|Other|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
163763|NCT02920112|Behavioral|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
163764|NCT02920099|Other|Nutrition Literacy Assessment Instrument (NLAI)|Assessment tool which combines elements of different nutrition literacy tools.
163765|NCT02920086|Behavioral|Nutrition Education Program|"The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~Nutritional education will be provided to ICU patents' families by a dietitian~Tracking of nutritional information by family~Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
163766|NCT02920086|Other|Decision Support Program|"Families will be provided with a web-based decision support tool (My ICU Guide)~Families will meet with the ICU medical team early in ICU stay to review goals of care"
163767|NCT02920060|Drug|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
163768|NCT02920060|Drug|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
163769|NCT02920047|Drug|Fimasartan/Amlodipine|Treatment B
163770|NCT02920047|Drug|Fimasartan + Amlodipine|Treatment A
163771|NCT02920034|Device|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
163772|NCT02920034|Device|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
163773|NCT02920034|Device|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
163774|NCT02920021|Drug|ANB020|ANB020
163775|NCT02920021|Drug|Placebo|Placebo
163776|NCT02920008|Drug|guadecitabine|In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
163777|NCT02920008|Drug|Treatment Choice (TC)|"High intensity: Intermediate or high dose cytarabine (HiDAC).~Low intensity:~LDAC.~Decitabine.~Azacitidine.~Best supportive care only: given according to standard and institutional practice."
163778|NCT02919995|Drug|RPL554|RPL554 suspension administered using a nebuliser
163779|NCT02919995|Drug|Placebo|Placebo solution administered using a nebuliser
163780|NCT02919969|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
163781|NCT02919956|Other|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
163782|NCT02919956|Other|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
163783|NCT02919943|Procedure|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
163784|NCT02919930|Device|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
163785|NCT02919930|Device|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
163786|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
163787|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
163788|NCT02919904|Device|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:~NREM and REM sleep frequency and duration~Duration and number of arousal~Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor~Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer~Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone~Apnea/hypopnea index and respiratory disturbance index"
163789|NCT02919891|Other|Questionnaire|Questionnaires
163790|NCT02919878|Drug|Gemcitabine|Nucleoside analog- Chemotherapy
163791|NCT02919878|Radiation|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
163792|NCT02919878|Drug|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
163841|NCT02919579|Drug|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
163980|NCT02918734|Device|Metal interference screw|ACL reconstruction with metal interference screw
163793|NCT02919865|Device|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.~Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.~All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
163794|NCT02919852|Procedure|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
163795|NCT02919839|Other|non-Interventional|
163796|NCT02919826|Behavioral|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
163797|NCT02919813|Behavioral|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
163798|NCT02919813|Behavioral|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
163799|NCT02919800|Biological|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
163800|NCT02919800|Other|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
163801|NCT02919787|Drug|5-FU|Neoadjuvant treatment
163802|NCT02919787|Drug|Oxaliplatine|Neoadjuvant treatment
163803|NCT02919787|Drug|Irinotecan|Neoadjuvant treatment
163804|NCT02919787|Procedure|Pancreatic surgery|All patients
163805|NCT02919787|Drug|5-FU|Adjuvant treatment
163806|NCT02919787|Drug|Oxaliplatine|Adjuvant treatment
163807|NCT02919787|Drug|Irinotecan|Adjuvant treatment
163808|NCT02919774|Drug|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
163809|NCT02919774|Drug|placebo|matching placebo tablets
163810|NCT02919761|Drug|Acthar|
163811|NCT02919761|Drug|Placebo|
163812|NCT02919748|Other|Choral Singing|Weekly sessions at 1 hour of choral singing.
163813|NCT02919748|Other|Health Education Program|Weekly session at 1 hour of health education talk and group activities
163814|NCT02919735|Drug|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
163815|NCT02919735|Drug|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
163816|NCT02919722|Behavioral|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
163817|NCT02919709|Biological|blood taking|
163818|NCT02919696|Drug|Abemaciclib|Administered orally
163819|NCT02919683|Drug|Nivolumab|
163820|NCT02919683|Drug|Ipilimumab|
163821|NCT02919683|Procedure|Standard of Care Surgery|
163822|NCT02919670|Dietary Supplement|Enterade|
163823|NCT02919670|Dietary Supplement|Placebo|
163824|NCT02919670|Other|Standard Supportive Care|
163825|NCT02919657|Dietary Supplement|Genepro Protein|weekly blood draws to measure blood protein levels
163826|NCT02919657|Dietary Supplement|Whey Protein|weekly blood draws to measure blood protein levels
163827|NCT02919644|Biological|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10_7 autologous dendritic cells loaded with autologous tumor homogenate
163828|NCT02919644|Drug|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
163829|NCT02919631|Drug|Triheptanoin|Anaplerotic dietary oil
163830|NCT02919631|Drug|Placebo oil|Safflower oil
163831|NCT02919618|Radiation|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
163832|NCT02919605|Drug|Single dose of Pentamidine|The patients will come to the hospital to take a single dose of the Pentamidine.
163833|NCT02919605|Drug|Two doses of Pentamidine|The patients will come to the hospital to take two doses of the Pentamidine, in interval of one week between them.
163834|NCT02919605|Drug|Three doses of Pentamidine|The patients will come to the hospital to take three doses of the Pentamidine, in interval of one week between them.
163835|NCT02919592|Device|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
163836|NCT02919592|Device|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. . MemoryShape Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
163837|NCT02919592|Procedure|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, autoplasty, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
163838|NCT02919579|Drug|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
163839|NCT02919579|Drug|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
163981|NCT02918721|Device|Restylane Lidocaine|Intradermal injection
163842|NCT02919553|Procedure|modified wet-suction technique|Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
163843|NCT02919553|Procedure|"Capillary slow pull technique"|The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
163844|NCT02919540|Other|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
163845|NCT02919527|Other|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
163846|NCT02919527|Other|Stretching|Static Stretching performed at the anterior thigh
163847|NCT02919514|Other|Physical training on hard surface.|Physical training on hard surface.
163848|NCT02919514|Other|Physical training on sand surface.|Physical training on sand surface.
163849|NCT02919514|Other|Physical training on soft surface.|Physical training on soft surface.
163850|NCT02919501|Drug|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
163851|NCT02919501|Other|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
163852|NCT02919501|Drug|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
163853|NCT02919488|Other|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
163854|NCT02919488|Other|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
163855|NCT02919475|Drug|JTE-051|Active drug tablets containing JTE-051
163856|NCT02919475|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
163857|NCT02919462|Drug|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
163858|NCT02919462|Drug|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
163859|NCT02919462|Drug|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
163860|NCT02919462|Drug|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
163861|NCT02919462|Drug|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
163862|NCT02919462|Drug|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
163863|NCT02919449|Biological|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
163864|NCT02919449|Biological|Atezolizumab|Atezolizumab will be administered every 3 weeks
163865|NCT02919436|Drug|Tamsulosin|Active drug
163866|NCT02919436|Drug|Placebo|Lactose-filled capsules identical to active drug
163867|NCT02919423|Device|transcranial magnetic stimulation|
163868|NCT02919410|Device|iodophor-impregnated adhesive drapes|
163869|NCT02919410|Other|No adhesive drapes|
163870|NCT02919397|Device|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
163871|NCT02919397|Behavioral|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
163872|NCT02919397|Behavioral|Motivational messaging|Messages sent via smartphone application
163873|NCT02919384|Other|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
163874|NCT02919371|Drug|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
163875|NCT02919371|Drug|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
163876|NCT02919358|Other|Music|
163877|NCT02919358|Other|No music.|This is the control group.
163878|NCT02919345|Drug|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
163879|NCT02919345|Drug|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
163880|NCT02919332|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
163881|NCT02919332|Radiation|Fludeoxyglucose F-18|Given IV
163882|NCT02919332|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
163883|NCT02919319|Drug|ACT-541468 (Formulation A)|Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
163884|NCT02919319|Drug|ACT-541468 (Formulation B)|Soft gelatin capsules for oral administration formulated at the strength of 25 mg
163885|NCT02919319|Drug|Placebo (Formulation A)|Hard capsules matching ACT-541468 Formulation A
163886|NCT02919319|Drug|Placebo (Formulation B)|Soft capsules matching ACT-541468 Formulation B
163887|NCT02919319|Drug|14C-labeled ACT-541468|Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
163888|NCT02919319|Drug|Placebo tracer|Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
163889|NCT02919306|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
163890|NCT02919306|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
163893|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
163894|NCT02919280|Other|Observational Study|The Dallas 2K is a 10-year natural history, longitudinal, prospective study of a cohort of 2,000 participants. There is no medication or non-medication treatment or intervention provided by this study.
163895|NCT02919267|Device|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
163896|NCT02919267|Device|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
163897|NCT02919254|Dietary Supplement|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
163898|NCT02919254|Other|Placebo|Fruit juice cordial containing negligible nitrate
163899|NCT02919241|Behavioral|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
163900|NCT02919241|Behavioral|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
163901|NCT02919228|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
163902|NCT02919215|Behavioral|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
163903|NCT02919202|Procedure|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
163904|NCT02919202|Procedure|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
163905|NCT02919189|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
163906|NCT02919176|Drug|Mirabegron|Mirabegron 50 mg/day
163907|NCT02919176|Drug|Pioglitazone|Pioglitazone 30 mg/day
163908|NCT02919176|Drug|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
163909|NCT02919163|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
163910|NCT02919137|Other|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
163911|NCT02919124|Device|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
163912|NCT02919111|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
163913|NCT02919098|Behavioral|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
163914|NCT02919098|Behavioral|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
163915|NCT02919085|Procedure|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
163916|NCT02919072|Drug|Chloroprocaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
163917|NCT02919072|Drug|Ropivacaine|The 20 mL epidural anaesthetic solution will be administered as follows: 5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 15 mL of the study anaesthetic solution will be administered epidurally. Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered.
163918|NCT02919059|Drug|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
163982|NCT02918721|Device|Restylane|Intradermal injection
163983|NCT02918708|Biological|Synflorix|10-valent pneumococcal conjugate vaccine
163984|NCT02918708|Biological|Prevenar13|13-valent pneumococcal conjugate vaccine
164297|NCT02916628|Device|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
163919|NCT02919059|Drug|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.~On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.~The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
163920|NCT02919046|Biological|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
163921|NCT02919033|Other|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
163922|NCT02919033|Device|Self-management|"Usual care~Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.~All patients receive proficiency training in using the BP tele-monitor, and mobile App."
163923|NCT02919033|Other|PCTM intervention|"Usual care~Self-management~PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.~PCPs and cardiologists receive training of the CareLinker website."
163924|NCT02919020|Other|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
163925|NCT02919020|Other|Resistance exercise|resistance exercise to strengthen lower limbs
163926|NCT02919007|Device|Silk'n HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
163927|NCT02918994|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
163928|NCT02918981|Behavioral|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
163929|NCT02918981|Dietary Supplement|14 g Whey protein|
163930|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine|
163931|NCT02918981|Dietary Supplement|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
163932|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
163933|NCT02918981|Other|Water control|
163934|NCT02918968|Drug|Enzalutamide|Oral
163935|NCT02918968|Drug|Flutamide|Oral
163936|NCT02918968|Other|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
163937|NCT02918955|Procedure|up-front neck dissection|
163938|NCT02918955|Radiation|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
163939|NCT02918955|Drug|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
163940|NCT02918955|Procedure|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
163941|NCT02918929|Drug|EDP 305|
163942|NCT02918929|Drug|Placebo|placebo to match EDP 305
163943|NCT02918916|Other|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
163944|NCT02918916|Other|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
163945|NCT02918903|Procedure|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
163946|NCT02918903|Procedure|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
163947|NCT02918890|Other|Constraint-induced Movement Therapy|
163948|NCT02918890|Other|Hand-arm Bimanual Intensive Therapy|
163949|NCT02918877|Drug|Sevoflurane|Volatile Anesthetic
163950|NCT02918877|Drug|Propofol|Intravenous Anesthetic
164090|NCT02918097|Drug|Risperidone|
163951|NCT02918864|Drug|Oxytocin and social cognitive skills group|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
163952|NCT02918864|Behavioral|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
163953|NCT02918851|Biological|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
163954|NCT02918851|Biological|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
163955|NCT02918851|Biological|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
163956|NCT02918838|Behavioral|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
163957|NCT02918838|Behavioral|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
163958|NCT02918838|Behavioral|Control Group|
163959|NCT02918825|Drug|Olanzapine|Olanzapine
163960|NCT02918825|Drug|Paliperidone|Paliperidone
163961|NCT02918812|Drug|Intracervical lidocaine|Intracervical lidocaine injected at four different points
163962|NCT02918812|Drug|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
163963|NCT02918799|Behavioral|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
163964|NCT02918786|Device|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
163965|NCT02918786|Device|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
163966|NCT02918773|Device|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
163967|NCT02918773|Device|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
163968|NCT02918760|Drug|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
163969|NCT02918760|Other|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
163970|NCT02918747|Drug|pegaspargase|"P-Gemoxd Arm: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.~P-CHOP Arm: 2000U/m2 im on day 2 of each 21 day cycle. Number of Cycles: four."
163971|NCT02918747|Drug|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
163972|NCT02918747|Drug|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
163973|NCT02918747|Drug|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
163974|NCT02918747|Drug|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
163975|NCT02918747|Drug|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
163976|NCT02918747|Drug|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
163977|NCT02918747|Drug|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
163978|NCT02918747|Radiation|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
163979|NCT02918734|Device|Endobutton CL BTB|ACL reconstruction with Endobutton CL BTB
164304|NCT02916589|Dietary Supplement|Diet|
163985|NCT02918682|Other|Exercise - FIRST PHASE|the participants do not need to perform the first phase or can advance to the second phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8 m/s and walking 30 meters without stopping; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO stance for 30 seconds and the Tandem EO stance for more than 5 seconds; 4. Having sitting stability limits with eyes open; 5. In upright position, able to bend the trunk forward, standing parallel to a wall, between 16.5 - 32 cm but stable. For the muscle strength: being able to perform hip flexion with 50% of 1 repetition maximum (RM) for 8 repetitions; hip extension with 50% of 1RM for 8 repetitions; hip abduction without load but at least for 8 repetitions; knee extension with 50% of 1RM for 8 repetitions; knee flexion with 50 % of 1RM for 8 repetitions;
163986|NCT02918682|Other|Exercise - SECOND PHASE|the participants do not need to perform the second phase or can advance to the third phase if they have obtained the following results in the balance and functional tests: 1. Gait speed of 0.8-1 m/s and ability to walk 60 meters; 2. Ability to perform the stand up and sit down test from the chair five times properly within less than 15 seconds; 3. Maintaining the FFEO and FFEC stance for more than 5 seconds and the Tandem EO stance for 10-20 seconds; 4. Having sitting stability limits with eyes closed; 5. Being able to bend the trunk forward, standing parallel to a wall, between 20-32 cm ad being stable. For muscle strength: being able to perform hip flexion with 60% of 1 RM for 8 repetitions; hip extension with 60% of 1RM for 8 repetitions; hip abduction without load but between 8-12 repetitions; knee extension with 60% of 1RM for 8 repetitions; knee flexion with 60% of 1RM for 8 repetitions;
163987|NCT02918682|Other|Exercise - FOURTH PHASE|at the end of the exercise protocol, the participants who have reached the fourth phase must be able to achieve: 1. Gait speed of 0.8-1 m/s and able to walk 90 meters; 2. Stand up and sit down five times from the chair properly within less than 15 seconds; 3. TUG performance less than 14 seconds; 4. Maintenance of 30 seconds in FFEO and FFEC stance, maintenance of 30 seconds in Tandem EO and Tandem EC stance, maintenance of the single-leg stance for more than 21 seconds; 5. Normal sitting stability limits with eyes closed; 6. Bending the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For muscle strength: able to perform hip flexion with 70% of 1 RM for 6-10 repetitions; hip extension with 70% of 1RM for 6-10 repetitions; hip abduction with 40-60% of 1RM for 8-12 repetitions; knee extension with 70% of 1RM for 6-10 repetitions; knee flexion with 70% of 1RM for 6-10 repetitions.
163988|NCT02918682|Other|Exercise - THIRD PHASE|participants do not need to perform the third phase or can advance to the fourth phase if they have obtained: 1 Gait speed of 0.8-1 m/s and walk 90 meters; 2 perform the stand up and sit down five times from the chair properly within less than 15 seconds; 3 Performing the TUG test within less than 14 seconds; 4 Maintaining the FFEO and FFEC stance for 30 seconds, maintaining the Tandem EO and Tandem EC stance for 30 seconds and maintaining the single-leg stance for more than 20 seconds; 5 Having sitting stability limits with eyes closed; 6 In the upright position, to bend the trunk forward, standing parallel to a wall, more than 32 cm and being stable. For the muscle strength test, perform hip flexion with 60 % of 1 RM for 8-12 repetitions; hip extension with 60 % of 1RM for 8-12 repetitions; hip abduction without load or 5% of 1RM for hip abductor and between 8-12 repetitions; knee extension with 60 % of 1RM for 8-12 repetitions; knee flexion with 60 % of 1RM for 8-12 repetitions;
163989|NCT02918669|Radiation|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.~There are no other interventions. It is just a onetime CT post 60 month time point."
163990|NCT02918656|Other|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
163991|NCT02918656|Other|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
163992|NCT02918656|Other|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
163993|NCT02918643|Other|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
163994|NCT02918630|Drug|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
163995|NCT02918630|Drug|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
163996|NCT02918617|Drug|Control toothpaste containing Novamin® technology|
163997|NCT02918617|Drug|Control toothpaste containing 1500 ppm fluoride as MFP|
163998|NCT02918617|Drug|Test toothpaste with nano-HAP (high concentration)|
163999|NCT02918617|Drug|Test toothpaste with nano-HAP (low concentration)|
164000|NCT02918617|Drug|Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3|
164001|NCT02918617|Drug|Control toothpaste without nano-HAP|
164002|NCT02918617|Drug|Test toothpaste with nano-HAP (medium concentration)|
164003|NCT02918617|Drug|Test cream with nano-HAP (higher concentration)|
164004|NCT02918617|Drug|Control cream without nano-HAP|
164005|NCT02918604|Device|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
164006|NCT02918591|Drug|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
164007|NCT02918578|Other|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
164008|NCT02918578|Other|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
164009|NCT02918578|Other|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
260785|NCT02211911|Drug|Bisacodyl|
164010|NCT02918565|Behavioral|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
164011|NCT02918565|Behavioral|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
164012|NCT02918565|Behavioral|Adaptive Goal Support (AGS)|12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
164013|NCT02918565|Behavioral|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
164014|NCT02918552|Drug|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
164015|NCT02918552|Drug|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
164016|NCT02918539|Drug|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
164017|NCT02918526|Device|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
164018|NCT02918513|Behavioral|Wellness Element 1 - Exercise|1. Daily wellness element focusing on Exercise; adherence documented online daily
164019|NCT02918513|Behavioral|Wellness Element 2 - Mindfulness|2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
164020|NCT02918513|Behavioral|Wellness Element 3 - Sleep Hygiene|3. Daily wellness element focusing on sleep hygiene; adherence documented online daily
164021|NCT02918513|Behavioral|Wellness Element 4 - Social Connectedness|4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
164022|NCT02918513|Behavioral|Wellness Element 5 - Nutrition|5. Daily wellness element focusing on Nutrition; adherence documented online daily
164023|NCT02918513|Behavioral|Wellness Element 6 - Wellness Exercises|6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
164024|NCT02918513|Behavioral|Wellness Element 7 - Motivational Messages|7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
164025|NCT02918500|Drug|Nicoderm Patch|Nicotine replacement therapy patch
164026|NCT02918487|Drug|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
164027|NCT02918487|Drug|Placebo|Inactive compound that is similar looking as the intervention
164028|NCT02918474|Other|Decision Aid|Use decision making tool
164029|NCT02918474|Other|Questionnaire Administration|Ancillary studies
164030|NCT02918461|Behavioral|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
164031|NCT02918448|Other|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
164032|NCT02918435|Behavioral|WE CARE|The WE CARE survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household utilities). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
164033|NCT02918422|Other|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
164034|NCT02918409|Drug|Colistin|
164035|NCT02918409|Drug|Tobramycin|
164036|NCT02918396|Device|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as <0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
164037|NCT02918396|Device|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
164038|NCT02918396|Device|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
164039|NCT02918383|Diagnostic Test|Indocyanin Green Dye (ICG)|
164040|NCT02918370|Drug|Aripiprazole|Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.
164041|NCT02918370|Drug|Placebo|Inactive ingredient matching the active comparators in appearance.
164042|NCT02918357|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
164043|NCT02918344|Other|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
164044|NCT02918344|Procedure|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
164045|NCT02918331|Drug|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
164046|NCT02918331|Drug|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
164047|NCT02918331|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
164048|NCT02918318|Drug|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
164049|NCT02918318|Drug|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
164050|NCT02918318|Drug|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
164051|NCT02918318|Drug|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
164052|NCT02918305|Device|PRDS-001 Renal Denervation Ultrasound System|
164053|NCT02918305|Procedure|Sham Procedure|
164054|NCT02918292|Drug|Antithymocyte Globulin (ATG)|Administration of ATG will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.
164055|NCT02918292|Drug|Fludarabine|Fludarabine dose will be 30 mg/m^2 IV daily for 5 days from Day -6 to Day -2.
164056|NCT02918292|Drug|Cyclophosphamide|Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.
164057|NCT02918292|Radiation|Total Body Irradiation (TBI)|TBI is to be delivered in a single dose of 200 cGy on Day -1.
164058|NCT02918292|Procedure|Haplo HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.
164059|NCT02918292|Drug|Tacrolimus|Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.
164060|NCT02918292|Drug|Mycophenolate mofetil (MMF)|MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5.
164061|NCT02918292|Drug|G-CSF|G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is > 1500 for 3 days.
164062|NCT02918279|Drug|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
164063|NCT02918279|Drug|Placebo|Administered once daily subcutaneously (s.c., under the skin)
164064|NCT02918266|Drug|Scopolamine|Scopolamine subcutaneous injection
164065|NCT02918266|Drug|TAK-071|TAK-071 DIC
164066|NCT02918266|Drug|Donepezil|Donepezil over-encapsulated tablet
164067|NCT02918266|Drug|Scopolamine Placebo|Scopolamine placebo-matching subcutaneous injection
164068|NCT02918266|Drug|TAK-071 Placebo|TAK-071 placebo-matching DIC
164069|NCT02918266|Drug|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
164070|NCT02918253|Radiation|targeted focal HDR brachytherapy|
164071|NCT02918253|Radiation|Whole-gland HDR Brachytherapy|Control/Standard of Care
164072|NCT02918240|Procedure|Appointment intervals|
164073|NCT02918240|Device|fixed orthodontic braces|
164074|NCT02918227|Procedure|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
164075|NCT02918201|Drug|Tranexamic Acid|To moisten the innermost wound dressing with diluted tranexamic acid 5 mg/ml.
164076|NCT02918201|Drug|saline|To moisten the innermost wound dressing with saline (0.9% NaCl)
164077|NCT02918188|Drug|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
164078|NCT02918175|Behavioral|mHealth|Personalized step count feedback and medication teaching tool.
164079|NCT02918162|Drug|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
164080|NCT02918162|Drug|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.~Example:~Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
164081|NCT02918149|Other|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
164082|NCT02918149|Device|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
164083|NCT02918136|Device|Adipose-derived stem cell injection|
164084|NCT02918136|Drug|cortisone injection|
164085|NCT02918123|Biological|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
164086|NCT02918110|Drug|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
164087|NCT02918097|Drug|Lithium Carbonate|
164088|NCT02918097|Drug|Sertraline|
164089|NCT02918097|Drug|Nortriptyline|
164091|NCT02918084|Drug|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
164092|NCT02918084|Drug|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
164093|NCT02918071|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
164094|NCT02918058|Other|MedSafer|MedSafer is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedSafer can identify potentially inappropriate medication use and communicate the risk of adverse drug events to the treating team.
164095|NCT02918045|Device|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
164096|NCT02918045|Device|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
164097|NCT02918019|Drug|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
164098|NCT02918019|Drug|Placebo|Placebo matched with MSTT1041A.
164099|NCT02918006|Biological|VXA-A1.1|Enteric coated oral vaccine tablet
164100|NCT02918006|Biological|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
164101|NCT02918006|Other|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
164102|NCT02918006|Other|Saline Solution for Placebo IM Injection|
164103|NCT02917993|Drug|Itacitinib|In Phase 1, itacitinib at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, itacitinib at the recommended dose from Phase 1.
164104|NCT02917993|Drug|Osimertinib|Osimertinib 80 mg once daily (QD)
164105|NCT02917967|Drug|Botulinum toxin injection|"BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.~Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.~A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
164106|NCT02917954|Device|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
164107|NCT02917941|Drug|Ixazomib|Ixazomib capsules
164108|NCT02917941|Drug|Lenalidomide|Lenalidomide capsules
164109|NCT02917941|Drug|Dexamethasone|Dexamethasone Tablets
164110|NCT02917928|Dietary Supplement|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
164111|NCT02917928|Drug|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
164112|NCT02917915|Other|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
164113|NCT02917915|Other|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
164114|NCT02917902|Other|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
164115|NCT02917889|Drug|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
164116|NCT02917889|Drug|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
164117|NCT02917889|Other|Cardiopulmonary test|"assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~."
164118|NCT02917889|Other|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
164119|NCT02917863|Drug|L-Thyroxine (tablet, per os)|
164120|NCT02917863|Drug|L-Thyroxine (oral drops, solution)|
164121|NCT02917850|Procedure|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
164122|NCT02917850|Procedure|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
164123|NCT02917837|Other|Usual QCNL DI utilization report|See arm descriptions.
164124|NCT02917837|Other|New DI utilization report|See arm descriptions.
164125|NCT02917837|Other|Detailing|In-person detailing, usually with a small group of family physicians and a peer (physician) facilitator to discuss the topic over a 30-60 minute period.
164126|NCT02917824|Device|High-intensity IMT|30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
164127|NCT02917824|Device|Low-intensity IMT|30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
164128|NCT02917798|Behavioral|Assessments|
164129|NCT02917785|Device|Karman curettage|
164130|NCT02917772|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)~If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)~If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
164298|NCT02916628|Device|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
260786|NCT02211911|Drug|Sodium picosulfate|
164131|NCT02917746|Drug|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
164132|NCT02917746|Procedure|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
164133|NCT02917733|Drug|LY3039478|Administered orally
164134|NCT02917720|Other|TKI discontinuation|2nd TKI stop after pre-treatment with nilotinib.
164135|NCT02917720|Drug|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
164136|NCT02917707|Other|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
164137|NCT02917681|Other|Two intrathecal MSC injections|
164138|NCT02917668|Other|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
164139|NCT02917668|Other|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > or = 95 %
164140|NCT02917655|Behavioral|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
164141|NCT02917655|Behavioral|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
164142|NCT02917655|Behavioral|Numerical Rating Scales (NRS)|Answer NRS at baseline, 6, 12 and 24 months.
164143|NCT02917655|Behavioral|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
164144|NCT02917655|Behavioral|STS30|Perform the STS30 at baseline, 6, 12 and 24 months.
164145|NCT02917655|Behavioral|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
164146|NCT02917655|Behavioral|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
164147|NCT02917655|Behavioral|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
164148|NCT02917655|Behavioral|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
164149|NCT02917655|Behavioral|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
164150|NCT02917655|Behavioral|Sessions with the physical educators team|Participate in a extra session group with the physical educators
164151|NCT02917655|Behavioral|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
164152|NCT02917655|Behavioral|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
164153|NCT02917642|Device|Ultrasonic Irrigation|Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
164154|NCT02917642|Device|Non-Ultrasonic Irrigation|Syringe and needle irrigation with no-ultrasonic activation
164155|NCT02917629|Other|Laboratory Biomarker Analysis|Correlative studies
164156|NCT02917629|Drug|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
164157|NCT02917629|Other|Pharmacological Study|Correlative studies
164158|NCT02917629|Other|Placebo|Given PO
164159|NCT02917616|Other|Alkaline drinking-water|
164160|NCT02917616|Other|Neutral drinking-water|
164161|NCT02917603|Behavioral|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
164162|NCT02917590|Other|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
164163|NCT02917590|Other|Single-task obstacle crossing training|Obstacle crossing training
164164|NCT02917577|Biological|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
164165|NCT02917577|Biological|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
164166|NCT02917564|Drug|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
164167|NCT02917564|Other|Sham - Participants will not recieve the Triamcinolone Acetonide|Patients will be given a sham.
164168|NCT02917551|Other|7 days of adequate antibiotic treatment|
164169|NCT02917551|Other|14 days of adequate antibiotic treatment|
164170|NCT02917538|Procedure|RFA|Both groups will receive radiofrequency ablation treatment
164171|NCT02917525|Dietary Supplement|Vitamin K2|
164172|NCT02917525|Other|Placebo|
164173|NCT02917512|Drug|HU00701|Cyclosporine 0.01% + 3% trehalose
164174|NCT02917512|Drug|HU007|Cyclosporine 0.02% + 3% trehalose
164175|NCT02917512|Drug|Restasis|Cyclosporine 0.05%
164176|NCT02917512|Drug|Placebo|Vehicle
164177|NCT02917499|Device|TMS|Transcranial magnetic stimulation
164178|NCT02917486|Other|blood sample|
164179|NCT02917473|Behavioral|In-person counseling|"In-person counseling~Sun protection"
164180|NCT02917473|Behavioral|Written advice|Written advice
164181|NCT02917473|Behavioral|Medical skin screening|Medical skin screening
164182|NCT02917460|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
164205|NCT02917213|Other|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
164299|NCT02916615|Other|High nitrate vegetables|vegetables naturally high in nitrate
164300|NCT02916615|Dietary Supplement|Low nitrate vegetables + nitrate|pill containing KNO3
167795|NCT02888925|Other|Benton Face Recognition test|
164183|NCT02917447|Behavioral|DESTRESS-WV|"This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives.~Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. On two occasions, participants will be asked to write about current stressors or hassles. Additionally, on two occasions participants will be asked to write about a traumatic experience and then rewrite it. Participants will be guided in using various coping skills taught in the program during this writing process. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the prog"
164184|NCT02917447|Behavioral|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
164185|NCT02917434|Dietary Supplement|Very Low Energy Diet (VLED)|Very Low Energy Diet (VLED), divided into 4 daily doses, gives any intake of 640 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume VLED. After the strict period food is successively reintroduced during a period of 18 weeks.
164186|NCT02917421|Radiation|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
164187|NCT02917395|Device|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
164188|NCT02917369|Other|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
164189|NCT02917356|Other|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
164190|NCT02917356|Other|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
164191|NCT02917356|Other|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
164192|NCT02917343|Behavioral|mirror therapy and repetitive task training|
164193|NCT02917330|Other|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
164194|NCT02917304|Biological|GC3110A vaccine|0.5mL, Intramuscular
164195|NCT02917291|Drug|FAB117-HC|(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 5 patients in cohort 2 (40 million cells)
164196|NCT02917291|Other|Control group|(Ph 2) No treatment will be administered
164197|NCT02917291|Drug|FAB117-HC|(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
164198|NCT02917278|Dietary Supplement|Meals|High Protein renal-specific meals
164199|NCT02917265|Device|TENS for vagus stimulation|TENS electrodes are applied on an area of the external ear innervated by the auricular branch of the vagus nerve.
164200|NCT02917265|Device|TENS for sham stimulation|TENS electrodes are applied on an area of the external ear devoid of vagus innervation.
164201|NCT02917252|Other|3-hydroxybuturate|Drink of ketone bodies
164202|NCT02917252|Other|Placebo|Drink of saline
164203|NCT02917226|Other|Clinical decision support and monitoring system|
164204|NCT02917213|Other|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
164291|NCT02916667|Other|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
164292|NCT02916654|Dietary Supplement|sucrosomial iron|administration of sucrosomial iron
164206|NCT02917213|Other|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
164207|NCT02917213|Other|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
164208|NCT02917213|Procedure|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
164209|NCT02917213|Other|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
164210|NCT02917213|Other|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
164211|NCT02917200|Drug|Moxifloxacin|Oral route
164212|NCT02917200|Device|DAV132|Oral route
164213|NCT02917200|Other|Negative control|Oral route
164214|NCT02917187|Drug|BIIB074|Administered as specified in the treatment arm
164215|NCT02917187|Drug|Placebo|Matched placebo
164216|NCT02917174|Behavioral|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
164217|NCT02917174|Behavioral|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
164218|NCT02917161|Device|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
164219|NCT02917148|Other|Peripheral Venipuncture or Blood draw from Central Line|
164220|NCT02917135|Device|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
164221|NCT02917122|Device|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
164222|NCT02917122|Drug|Sertraline|Patients will take Sertraline.
164223|NCT02917122|Device|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
164224|NCT02917109|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
164225|NCT02917096|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
164226|NCT02917096|Drug|Fludarabine|Given IV
164227|NCT02917096|Drug|Fludarabine Phosphate|Given IV
164228|NCT02917096|Other|Laboratory Biomarker Analysis|Correlative studies
164229|NCT02917096|Drug|Melphalan|Given IV
164230|NCT02917096|Other|Pharmacological Study|Correlative studies
164231|NCT02917096|Drug|Ruxolitinib|Given PO
164232|NCT02917096|Drug|Ruxolitinib Phosphate|Given PO
164233|NCT02917096|Drug|Sirolimus|Given PO
164234|NCT02917096|Drug|Tacrolimus|Given IV and PO
164235|NCT02917083|Genetic|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10^7 cells/m2. Dose Level Two: 1x10^8 cells/m2. Dose Level Three: 2x10^8 cells/m2."
164236|NCT02917083|Drug|Cyclophosphamide|Patients who are not post autologous transplant will receive three daily doses of cyclophosphamide (Cy: 500mg/m2/day) finishing at least 48 hours before T cell infusion, but no later than 2 weeks prior to infusion of the cells.
164237|NCT02917083|Drug|Fludarabine|Patients who are not post autologous transplant will receive fludarabine (Flu: 30mg/m2/day), finishing at least 48 hours before T cell infusion, but no later than 2 weeks prior to infusion of the cells.
164238|NCT02917070|Other|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
164239|NCT02917057|Drug|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
164240|NCT02917057|Drug|basal insulin|basal insulin tretament in the customary clinical care in USA
164241|NCT02917044|Procedure|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
164293|NCT02916654|Drug|Sulphate iron|administration of sulphate iron
164294|NCT02916641|Drug|Fuzhenghuayu|
164295|NCT02916641|Drug|UDCA|
164296|NCT02916628|Behavioral|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
167796|NCT02888925|Other|Face inversion effect test|
164242|NCT02917044|Device|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
164243|NCT02917044|Procedure|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
164244|NCT02917044|Device|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
164245|NCT02917031|Drug|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
164246|NCT02917031|Drug|Sitagliptin|50 mg or 100 mg, gray capsule
164247|NCT02917031|Drug|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
164248|NCT02917031|Drug|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
164249|NCT02917018|Drug|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
164250|NCT02917005|Drug|Palbociclib|CDK 4/6 inhibitor
164251|NCT02917005|Drug|Exemestane|Aromatase inhibitor
164252|NCT02917005|Drug|Goserelin|LHRH agonist
164253|NCT02916992|Radiation|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
164254|NCT02916992|Genetic|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
164255|NCT02916979|Drug|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
164256|NCT02916979|Drug|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
164257|NCT02916979|Biological|Rabbit ATG|"Rabbit ATG:~Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
164258|NCT02916979|Drug|Methotrexate|"Methotrexate:~Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
164259|NCT02916966|Other|Patient Registry|Patient Registry
164260|NCT02916953|Device|AGN1 Femoral Local Osteo-Enhancement Procedure|A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
164261|NCT02916940|Drug|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
164262|NCT02916927|Drug|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
164263|NCT02916927|Drug|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
164264|NCT02916914|Other|Q2 feeding|Infants are going to be fed every 2 hours
164265|NCT02916901|Drug|CKD-519 200mg|
164266|NCT02916901|Drug|Placebo|
164267|NCT02916888|Other|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
164268|NCT02916888|Other|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
164269|NCT02916862|Dietary Supplement|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
164270|NCT02916862|Combination Product|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
164271|NCT02916862|Dietary Supplement|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
164272|NCT02916862|Combination Product|Placebo + calcium|Participants will consume a supplement without SCF + calcium carbonate (600 mg/day) for 12 months
164273|NCT02916849|Other|Safe Step|Strength and balance exercise-digital version
164274|NCT02916849|Other|OEP|Strength and balance exercise -paper version
164275|NCT02916836|Other|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
164276|NCT02916836|Other|No Use of therapeutic drug conciliation sheet (TDC)|
164277|NCT02916810|Device|Active rTMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
164278|NCT02916810|Device|Sham rTMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
164279|NCT02916797|Other|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
164280|NCT02916771|Drug|Ixazomib|Oral, proteasome inhibitor
164281|NCT02916771|Drug|Lenalidomide|Oral, immunomodulatory agent
164282|NCT02916771|Drug|Dexamethasone|Oral, steroid
164283|NCT02916758|Other|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
164284|NCT02916745|Drug|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length will be delivered.
164285|NCT02916745|Device|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
164286|NCT02916719|Device|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
164287|NCT02916706|Drug|Teneligliptin 20mg|
164288|NCT02916706|Drug|Placebo|
164289|NCT02916693|Drug|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
164290|NCT02916680|Procedure|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
164305|NCT02916576|Device|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).~The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.~Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.~Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.~Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.~The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.~An additional skin puncture will be performed by study personnel with single-use lancing devices."
164306|NCT02916550|Behavioral|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
164307|NCT02916537|Drug|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
164308|NCT02916537|Procedure|Prostatectomy|Radical prostatectomy with lymph node dissection
164309|NCT02916524|Behavioral|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
164310|NCT02916511|Drug|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5
164311|NCT02916511|Drug|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw*5
164312|NCT02916511|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
164313|NCT02916498|Device|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
164314|NCT02916485|Device|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
164315|NCT02916472|Behavioral|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Participants in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the participants' tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
164316|NCT02916472|Behavioral|Stretching|Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Participants will be provided with two different colored resistance bands (lighter colored - easier resistance; darker colored - harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participant by the exercise physiologist before the 12 week program begins.
164317|NCT02916472|Behavioral|Resistance Bands|"Participants randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks.~The resistance band program will include upper body and lower body exercises and will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Participants will start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all participants in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the participants by the exercise physiologist before the 12 week program begins."
164318|NCT02916459|Device|21G EBUS-TBNA needle|
164319|NCT02916459|Device|Flexible 19G EBUS-TBNA needle|
164320|NCT02916446|Biological|Viaskin Peanut 250 mcg|
164321|NCT02916446|Biological|Placebo|
164322|NCT02916433|Drug|Octreotide|
164323|NCT02916420|Drug|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
164324|NCT02916420|Drug|Dexamethasone|≤70 years,40mg/day; >70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
164325|NCT02916407|Drug|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with sevoflurane 2-3 vol%."
164326|NCT02916407|Drug|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.~General anesthesia will maintained with desflurane 6-7vol%."
164327|NCT02916394|Radiation|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
164328|NCT02916381|Procedure|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
164329|NCT02916381|Procedure|General anaesthesia|
164330|NCT02916355|Drug|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
164331|NCT02916355|Drug|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
164332|NCT02916342|Procedure|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
164374|NCT02915952|Other|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
164333|NCT02916342|Procedure|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
164334|NCT02916329|Other|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
164335|NCT02916316|Drug|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
164336|NCT02916290|Drug|Fuzhenghuayu|
164337|NCT02916290|Drug|UDCA|
164338|NCT02916277|Biological|endocan|to look series Endocan level for 5 days in intubated patients
164339|NCT02916264|Procedure|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
164340|NCT02916251|Drug|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
164341|NCT02916251|Drug|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
164342|NCT02916238|Drug|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
164343|NCT02916238|Behavioral|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
164344|NCT02916225|Behavioral|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
164345|NCT02916225|Behavioral|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
164346|NCT02916212|Other|Optimized alarm profiles|
164347|NCT02916199|Device|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
164348|NCT02916186|Biological|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
164349|NCT02916186|Procedure|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
164350|NCT02916173|Drug|Recombinant Human Chorionic Gonadotrophin|250 unit intramuscular
164351|NCT02916173|Drug|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|250 unit intramuscular + 1 mg subcutaneous
164352|NCT02916160|Drug|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
164353|NCT02916147|Drug|Sevoflurane|
164354|NCT02916147|Drug|Propofol|
164355|NCT02916134|Procedure|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
164356|NCT02916134|Drug|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.~The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
164357|NCT02916121|Dietary Supplement|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
164358|NCT02916121|Other|Placebo|placebo
164359|NCT02916108|Other|Reading EEG|EEG recording for 5 minutes (not an intervention)
164360|NCT02916095|Drug|Kanitinib|Oral administration of Kanitinib tablets.
164361|NCT02916082|Procedure|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
164362|NCT02916069|Device|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
164363|NCT02916069|Device|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
164364|NCT02916069|Device|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
164365|NCT02916056|Drug|Azeliragon 5mg|
164366|NCT02916043|Procedure|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
164367|NCT02916030|Dietary Supplement|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
164368|NCT02916004|Device|Measurement of NFR and PDR|Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
164369|NCT02915978|Drug|Fentanyl|Fentanyl delivered via sublingual spray
164370|NCT02915978|Drug|Placebo|Matching placebo delivered via sublingual spray
164371|NCT02915965|Drug|DCX|docetaxel, cisplatin and capecitabine
164372|NCT02915965|Procedure|surgery|Ivor Lewis Esophagectomy
164373|NCT02915952|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
164375|NCT02915939|Behavioral|The Residential Care Transition Module|Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.
164376|NCT02915926|Behavioral|occupational performance coaching|
164377|NCT02915926|Behavioral|standard OT|
164378|NCT02915913|Behavioral|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
164379|NCT02915913|Behavioral|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
164380|NCT02915913|Behavioral|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
164381|NCT02915913|Other|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
164382|NCT02915900|Other|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
164383|NCT02915900|Other|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
164384|NCT02915887|Other|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
164385|NCT02915874|Behavioral|Acceptance and Commitment Therapy|
164386|NCT02915861|Other|Non-invasive eschar samples + blood|EXPa (n=12) will have blood and non-invasive eschar samples collected (consent to study, declined biopsy).
164387|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+blood|EXPb (n=12) will have blood, non-invasive eschar samples, and an eschar biopsy collected (consent to study, draining LN inaccessible).
164388|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|EXPc (n=12) will have blood, non-invasive eschar samples, eschar biopsy, and LN FNA collected (consent to study, draining LN accessible).
164389|NCT02915861|Other|Blood+Skin sample|Controls (EXC, n=12) are healthy individuals, attending hospital for elective/minor surgery or treatment of minor skin injury, and normally reside in a scrub typhus endemic region. Blood and a skin sample will be collected at baseline only.
164390|NCT02915848|Device|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
164391|NCT02915835|Drug|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
164392|NCT02915835|Drug|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
164393|NCT02915822|Procedure|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
164394|NCT02915822|Procedure|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
164395|NCT02915809|Biological|GC3110B vaccine|0.5mL, Intramuscular
164396|NCT02915809|Biological|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
164397|NCT02915796|Biological|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
164398|NCT02915796|Biological|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
164399|NCT02915796|Procedure|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
164400|NCT02915796|Biological|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
164401|NCT02915783|Drug|lenvatinib|4 mg and 10 mg capsules
164402|NCT02915783|Drug|everolimus|5 mg tablets
164403|NCT02915770|Procedure|cholangiojejunostomy|Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage
164404|NCT02915770|Procedure|hepatectomy|
164405|NCT02915770|Device|T-tube|T-tube Drainage
164406|NCT02915757|Device|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.~The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.~Blood sample and clinical assessment"
164415|NCT02915731|Dietary Supplement|Vitamin A supplement|200 000 IU vitamin A (once-off dose), given to participants as part of the national vitamin A supplementation program
164416|NCT02915718|Procedure|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
164417|NCT02915705|Biological|burosumab|solution for subcutaneous (SC) injection
164418|NCT02915705|Drug|oral phosphate|
164419|NCT02915705|Drug|active vitamin D|
164420|NCT02915692|Device|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
164421|NCT02915692|Device|Comparator Silver Coated Catheter|Foley catheter coated with silver
164422|NCT02915679|Other|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:~A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior~Thermal stimulation for pain assessment~Computer game named Cyberball: test of social exclusion~Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.~Routine blood sampling"
164423|NCT02915666|Drug|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
164424|NCT02915666|Drug|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
164425|NCT02915666|Drug|Trametinib|trametinib 2 mg PO daily for 8-week cycles
164426|NCT02915653|Other|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
164427|NCT02915640|Other|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
164428|NCT02915627|Device|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
164429|NCT02915614|Procedure|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
164430|NCT02915601|Drug|Sodium bicarbonate|
164431|NCT02915601|Drug|Placebo|
164432|NCT02915588|Other|early isometric loading after rotator cuff surgery|
164433|NCT02915588|Other|passive motion after rotator cuff surgery|
164434|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<1% risk of CKD), medium (1-10 % risk of CKD) and high (≥10 % risk of CKD). Specific follow-up will be guided by risk status
164435|NCT02915575|Other|Usual Care|Participants will be discharged as per usual ward discharge protocols.
164436|NCT02915562|Other|exercise|
164437|NCT02915549|Other|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
164438|NCT02915549|Other|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
164439|NCT02915536|Other|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
164440|NCT02915523|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACi).
164441|NCT02915523|Drug|avelumab|A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
164442|NCT02915523|Drug|Placebo|A pill containing no active drug ingredient.
164443|NCT02915510|Dietary Supplement|Glycomacropeptide-based protein substitute|
164444|NCT02915497|Behavioral|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
164445|NCT02915484|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
164446|NCT02915471|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
164447|NCT02915445|Biological|CAR-T cells recognizing EpCAM|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
164448|NCT02915432|Biological|3 mg/kg anti-PD-1 mAb JS001 Q2W|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.~If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
164449|NCT02915432|Biological|360 mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 360 mg once every 3 weeks (Q3W). JS001 360 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
164510|NCT02914977|Drug|Daunorubicin|"Agent: Daunorubicin~Dose: 6.75 mg/m2/day~Route: IV~Schedule: Days 1-5~Duration: One cycle"
164549|NCT02914600|Drug|Filgotinib|Tablet(s) administered orally once daily
164550|NCT02914600|Drug|Placebo|Tablet(s) administered orally once daily
164450|NCT02915432|Biological|240mg anti-PD-1 mAb JS001 Q3W|Subjects will receive corresponding regimen of standard first-line chemotherapy combined with JS001 240 mg once every 3 weeks (Q3W). JS001 240 mg Q3W can be administrated after the end of chemotherapy until absence of further benefits judged by the investigator, disease progression, occurrence of intolerable toxicity, investigator's decision, and withdrawal of informed consent by the subject, or death.
164451|NCT02915419|Biological|PRP|platelet rich plasma
164452|NCT02915419|Biological|PRF|PLATELET RICH FIBRIN
164453|NCT02915406|Device|CliniMACs|
164454|NCT02915380|Biological|Evaluation of pituitary endocrine function|"The basal thyroid hormone and test to perform will be: TSH, fT4, fT3.~When available, the following hormones will be tested:~FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality.~Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)"
164455|NCT02915380|Behavioral|Evaluation of clinical outcome|Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.
164456|NCT02915380|Behavioral|Evaluation of neuropsychological function|Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.
164457|NCT02915367|Behavioral|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
164458|NCT02915354|Drug|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
164459|NCT02915328|Device|Filterwire EZ™|
164460|NCT02915328|Device|MO.MA Ultra|
164461|NCT02915328|Device|Stent Roadsaver®|
164462|NCT02915328|Device|Carotid Wallstent|
164463|NCT02915315|Dietary Supplement|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
164464|NCT02915302|Biological|Fluzone Quadrivalent vaccine, No Preservative|0.25-mL (Pediatric Dose), Intramuscular (2016-2017 formulation)
164465|NCT02915302|Biological|Fluzone Quadrivalent vaccine, No Preservative|0.5-mL, Intramuscular (2016-2017 formulation)
164466|NCT02915289|Procedure|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
164467|NCT02915289|Procedure|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
164468|NCT02915276|Procedure|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
164469|NCT02915276|Procedure|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
164470|NCT02915263|Drug|IGIV-C|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
164471|NCT02915263|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
164472|NCT02915250|Drug|BioChaperone® Combo|Injection of BioChaperone® Combo
164473|NCT02915250|Drug|Humalog® Mix25|Injection of Humalog® Mix25
164474|NCT02915250|Drug|Humalog®|Injection of Humalog®
164475|NCT02915250|Drug|Lantus®|Injection of Lantus®
164476|NCT02915250|Drug|Placebo|Injection of 0.9% NaCl
164477|NCT02915237|Dietary Supplement|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
164478|NCT02915237|Dietary Supplement|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
164479|NCT02915224|Drug|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
164480|NCT02915224|Drug|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
164481|NCT02915211|Dietary Supplement|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
164482|NCT02915198|Drug|Metformin XR|"For patients < 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR < 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo."
164483|NCT02915198|Drug|Placebo|"For patients < 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.~For patients 80 years of age or with most recent 30 eGFR < 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
164545|NCT02914652|Drug|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
164546|NCT02914639|Drug|SF0166 Topical Ophthalmic Solution|
164484|NCT02915185|Procedure|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
164485|NCT02915185|Device|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
164486|NCT02915172|Drug|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
164487|NCT02915172|Drug|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
164488|NCT02915159|Biological|Abatacept|
164489|NCT02915159|Other|Placebo|
164490|NCT02915146|Radiation|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
164491|NCT02915133|Procedure|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
164492|NCT02915120|Procedure|Real Pulsed Radiofrequency|"Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C."
164493|NCT02915120|Procedure|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
164494|NCT02915107|Device|BioFreedom|PCI with BioFreedom
164495|NCT02915107|Device|Orsiro|PCI with BioFreedom
164496|NCT02915094|Drug|Anakinra|
164497|NCT02915081|Other|Blue light|"Illumination: High illumination lighting will be instituted with a Day*Light Classic Light (Uplift Technologies, Dartmouth, NS)~Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.~Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
164498|NCT02915068|Behavioral|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
164499|NCT02915055|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
164500|NCT02915055|Drug|standard oxycodone/acetaminophen|
164501|NCT02915042|Drug|Dexmedetomidine|Analgesic Efficacy
164502|NCT02915042|Drug|Placebo|Saline placebo
164503|NCT02915029|Other|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
164504|NCT02915016|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
164505|NCT02915016|Biological|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
164506|NCT02915016|Biological|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.~Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
164507|NCT02915016|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
164508|NCT02915003|Behavioral|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
164509|NCT02914990|Drug|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
164551|NCT02914587|Device|ARTAS System|
164511|NCT02914964|Behavioral|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
164512|NCT02914964|Behavioral|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
164513|NCT02914951|Behavioral|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
164514|NCT02914951|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
164515|NCT02914938|Drug|ME-401|60 mg
164516|NCT02914938|Drug|Rituximab|IV infusion 375 mg/m2
164517|NCT02914938|Drug|Zanubrutinib|160 mg bid
164518|NCT02914925|Device|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
164519|NCT02914899|Behavioral|focus groups|
164520|NCT02914899|Behavioral|in-depth interviews|
164521|NCT02914886|Drug|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
164522|NCT02914886|Drug|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
164523|NCT02914873|Procedure|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
164524|NCT02914860|Device|Cardiac CT|"Cardiac CT - contract enhanced cardiac CT according to standard protocol~D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)~Merge CT and D-SPECT image data to generate SUMO map."
164525|NCT02914860|Procedure|Ablation Procedure|"CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.~High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).~RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)~Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA~Control HFS~At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.~Exit and entrance block confirmation~Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
164526|NCT02914860|Device|D-SPECT|
164527|NCT02914847|Behavioral|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
164528|NCT02914834|Other|Acupuncture|Standardized acupuncture treatment administered for 30 minutes each session
164529|NCT02914834|Other|Non-pain related video health education|Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
164530|NCT02914821|Behavioral|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
164531|NCT02914808|Other|Patients will undergo a lower limb MRI and blood tests|
164532|NCT02914795|Other|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
164533|NCT02914782|Other|Observational Study|
164534|NCT02914769|Drug|Ayahuasca|patients will receive a single dose of ayahuasca.
164535|NCT02914769|Drug|placebo|patients will receive a single dose of a passive placebo.
164536|NCT02914743|Behavioral|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
164537|NCT02914743|Procedure|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
164538|NCT02914704|Device|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
164539|NCT02914691|Drug|Dapagliflozine 10 mg once daily tablet treatment|
164540|NCT02914691|Drug|Placebo identical once daily tablet treatment|
164541|NCT02914678|Other|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
164542|NCT02914665|Drug|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
164543|NCT02914665|Drug|Placebo|Placebo administered intravenously once daily for 7 consecutive days
164544|NCT02914652|Drug|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
164547|NCT02914626|Drug|Intravitreal ranibizumab|Intravitreal ranibizumab injection
164553|NCT02914574|Other|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
164554|NCT02914561|Drug|Filgotinib|Tablet(s) administered orally once daily
164555|NCT02914561|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
164556|NCT02914548|Drug|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
164557|NCT02914548|Drug|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
164558|NCT02914535|Drug|Filgotinib|Tablet(s) administered orally once daily
164559|NCT02914535|Drug|Placebo|Tablet(s) administered orally once daily
164560|NCT02914522|Drug|Filgotinib|Tablet(s) administered orally once daily
164561|NCT02914522|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
164562|NCT02914509|Drug|Travoprost|
164563|NCT02914509|Other|Placebo Vehicle|
164564|NCT02914496|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
164565|NCT02914483|Behavioral|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
164566|NCT02914483|Behavioral|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
164567|NCT02914483|Diagnostic Test|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
164568|NCT02914470|Drug|carbplatin, cyclophophamide, atezolizumab|
164569|NCT02914457|Device|Standard biventricular pacing|Pacing will be performed on one LV electrode pair, (at different locations), and on the tip of the RV-lead.
164570|NCT02914457|Device|MultiSpot simultaneous LV-ventricular pacing (MultiSpot-SYN)|Pacing will be performed on all electrodes on the LV wall and on the tip of the RV-lead simultaneously.
164571|NCT02914457|Device|MultiSpot sequential LV-ventricular pacing (MultiSpot-SEQ)|Pacing will be performed on all electrodes on the LV wall sequentially. The RV-electrode will be paced simultaneously with last paced LV-electrode.
164572|NCT02914431|Device|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The cutting guides also worked as the drilling guide. Several screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The screw holes on the bones prepared by the cutting guides were used as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding screw holes on the plate to the bone. Afterwards, the position of the osteotomized Le Fort I segment was adjusted till all the remaining corresponding screw holes on bone and plate were aligned.
164573|NCT02914418|Device|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for ~200sec and can promote changes in neural activity.
164574|NCT02914405|Drug|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
164575|NCT02914405|Drug|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
164576|NCT02914379|Drug|[¹⁴C]-LY3337641|Administered orally
164577|NCT02914366|Drug|Ambroxol|
164578|NCT02914366|Other|Placebo|
164579|NCT02914353|Drug|EP=7041|Factor X!a Inhibitor
164580|NCT02914353|Drug|Placebo|Normal Saline
164581|NCT02914340|Device|Spiration Valve System|
164582|NCT02914327|Drug|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
164583|NCT02914314|Drug|perampanel|oral suspension
164584|NCT02914301|Device|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
164585|NCT02914301|Device|Placebo|No Mobile App, Usual care
164586|NCT02914288|Other|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
164587|NCT02914275|Biological|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age.
164714|NCT02913287|Dietary Supplement|Aquamin/Aquamin MG|Marine-based nutraceutical
164715|NCT02913287|Other|Maltodextrin Placebo|Maltodextrin Placebo
164716|NCT02913274|Device|Paclitaxel (Taxol) eluting angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.
164588|NCT02914275|Biological|Comparator Quadrivalent Inactivated Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection of the non-dominant arm in children 36 months through 59 months of age.
164589|NCT02914262|Drug|AKB-4924|Comparison of different dosages of AKB-4924
164590|NCT02914262|Other|Placebo|Placebo comparator
164591|NCT02914249|Other|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
164592|NCT02914236|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
164593|NCT02914223|Drug|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
164594|NCT02914210|Device|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
164595|NCT02914210|Other|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
164596|NCT02914197|Other|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
164597|NCT02914184|Biological|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
164598|NCT02914184|Biological|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
164599|NCT02914171|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
164600|NCT02914171|Device|Insertable cardiac monitor|Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
164601|NCT02914158|Drug|Goserelin|
164602|NCT02914158|Drug|Tamoxifen|
164603|NCT02914158|Drug|Aromatase Inhibitors|
164604|NCT02914145|Drug|Dihydroartemisinin-piperaquine|Mass drug administration
164605|NCT02914132|Device|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
164606|NCT02914119|Drug|Rocuronium|
164607|NCT02914119|Drug|Succinylcholine|
164608|NCT02914119|Drug|Cisatracurium|
164609|NCT02914119|Drug|Mivacurium|
164610|NCT02914119|Device|Objective neuromuscular monitoring (acceleromyography)|
164611|NCT02914119|Drug|Sugammadex|
164612|NCT02914119|Drug|Neostigmine|
164613|NCT02914106|Other|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
164614|NCT02914093|Other|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
164615|NCT02914067|Other|Neurocognitive testing|
164616|NCT02914067|Device|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
164617|NCT02914054|Drug|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
164618|NCT02914054|Drug|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
164619|NCT02914028|Procedure|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
164620|NCT02914028|Drug|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
164621|NCT02914015|Procedure|Continous QLB (quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major muscle with catheter insertion and continuous local infusion
164622|NCT02914015|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
164623|NCT02914015|Drug|Ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.~followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
164624|NCT02914015|Drug|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
164850|NCT02912299|Procedure|Skin biopsies|2 3mm skin biopsies will be taken
260787|NCT02211898|Drug|BNS003|
164625|NCT02914002|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
164626|NCT02913989|Other|Smoking habits characterization|
164627|NCT02913976|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
164628|NCT02913976|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
164629|NCT02913963|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
164630|NCT02913963|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
164631|NCT02913950|Other|validation of pediatric stool scale|validation of pediatric stool scale
164632|NCT02913937|Device|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
164633|NCT02913937|Device|Endodontic needle|Endodontic irrigation
164634|NCT02913924|Drug|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
164635|NCT02913924|Drug|Placebo|
164636|NCT02913911|Other|feedback|Sit to stand training with external feedback
164637|NCT02913898|Behavioral|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
164638|NCT02913898|Behavioral|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
164639|NCT02913885|Drug|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
164640|NCT02913885|Drug|fluoride varnish|fluoride inhibit the progression of white spot lesion
164641|NCT02913859|Radiation|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
164642|NCT02913859|Drug|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
164643|NCT02913846|Other|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
164644|NCT02913846|Other|Muscular assessment|An assessment of muscular force will be performed once a week.
164645|NCT02913846|Other|Pre-albumine dosage|Dosage performed once a month.
164646|NCT02913833|Other|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
164647|NCT02913820|Other|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
164648|NCT02913807|Procedure|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
164649|NCT02913807|Procedure|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
164650|NCT02913781|Procedure|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
164651|NCT02913781|Procedure|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
164652|NCT02913768|Drug|Ondansetron|
164653|NCT02913768|Drug|Normal saline|
164654|NCT02913755|Behavioral|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
164655|NCT02913742|Procedure|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
164656|NCT02913729|Radiation|partial breast irradiation|irradiation
164657|NCT02913716|Drug|defactinib|Single oral dose of 400 mg [14C]-defactinib
164658|NCT02913703|Drug|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
164659|NCT02913703|Other|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
164660|NCT02913690|Dietary Supplement|Placebo|2 x 150mg capsules daily
164661|NCT02913690|Dietary Supplement|TRF|2 x 150mg capsules daily
164662|NCT02913677|Dietary Supplement|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
164663|NCT02913664|Drug|Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)"
164664|NCT02913664|Behavioral|Aerobic Exercise Training|Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
164665|NCT02913664|Other|Usual Care|Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
164666|NCT02913664|Behavioral|Stretching Exercise|Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
164667|NCT02913664|Drug|Atorvastatin|
164668|NCT02913651|Device|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
164669|NCT02913625|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
164670|NCT02913625|Other|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
164671|NCT02913612|Drug|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
164672|NCT02913612|Drug|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
164673|NCT02913573|Device|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
164674|NCT02913573|Drug|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
164675|NCT02913547|Device|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
164676|NCT02913534|Radiation|whole brain radiotherapy|
164677|NCT02913521|Drug|Diclofenac Sodium Gel 1%|
164678|NCT02913521|Drug|Voltaren Gel|
164679|NCT02913521|Drug|Placebo|
164680|NCT02913508|Drug|Vedolizumab intravenous injection|Vedolizumab intravenous injection
164681|NCT02913508|Drug|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
164682|NCT02913495|Drug|Vaginal Progesterone|
164683|NCT02913495|Drug|Intramuscular Progesterone|
164684|NCT02913482|Drug|Risdiplam|Risdiplam will be administered orally.
164685|NCT02913469|Drug|Morphine|The patients in group A would be administrated intravenous morphine 5mg
164686|NCT02913469|Drug|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
164687|NCT02913469|Drug|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
164688|NCT02913443|Drug|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
164689|NCT02913430|Drug|Fulvestrant|500mg IM Q28 days
164690|NCT02913430|Drug|Tamoxifen|20mg PO Qdaily
164691|NCT02913430|Drug|Palbociclib|Tamoxifen or Fulvestrant plus palbociclib125mg/day PO on a 21 days on/7 days off schedule
164692|NCT02913417|Device|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert reduced to give 35cGymax to normal liver; second, concurrent ipilimumab 1mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 480 every 2 weeks (immunotherapy part 2) until progression or 3 years
164693|NCT02913417|Drug|ipilimumab|ipilimumab 1mg/kg every 3 weeks x 4
164694|NCT02913417|Drug|nivolumab|nivolumab 1mg/kg every 3 weeks x 4 then 480mg q 4 weeks
164695|NCT02913404|Procedure|ACL Reconstruction|standard surgical procedure
164696|NCT02913404|Procedure|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
164697|NCT02913404|Device|CT scan|a CT scan of bilateral knees will be taken in order to create 3D bone models
164698|NCT02913404|Device|Vicon MX - markers|To track the general body movement -- the reflective markers placed throughout the body will be tracked using conventional optical motion tracking equipment
164699|NCT02913404|Device|Novel's pedar system|To measure pressure distribution under the foot for each participant during the dynamic movement trials.
164700|NCT02913404|Device|instrumented treadmill|This will collect ground reaction forces at 1000 Hz during each movement trial.
164701|NCT02913391|Other|recruitment group (RG)|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
164702|NCT02913391|Other|control group (CG)|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
164703|NCT02913378|Procedure|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
164704|NCT02913378|Procedure|Sling|Conservative treatment with sling and rehabilitation
164705|NCT02913352|Procedure|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
164706|NCT02913352|Procedure|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
164707|NCT02913339|Other|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
164708|NCT02913326|Drug|Dabigatran etexilate|
164709|NCT02913326|Drug|Warfarin|
164710|NCT02913313|Drug|BMS-986207|
164717|NCT02913274|Device|high-pressure angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
164718|NCT02913274|Device|low-pressure balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
164719|NCT02913261|Drug|Ruxolitinib|Tablet for oral use
164720|NCT02913261|Drug|Best Available Therapy (BAT)|Best Available Therapy
164721|NCT02913248|Procedure|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
164722|NCT02913235|Procedure|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
164723|NCT02913222|Other|Rehabilitation|Comparison of two rehabilitation approaches
164724|NCT02913196|Drug|Apalutamide|"Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD"
164725|NCT02913196|Drug|Abiraterone acetate|"Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD"
164726|NCT02913196|Drug|Docetaxel|"Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W"
164727|NCT02913196|Drug|Prednisone|Dose: 5 mg BID
164728|NCT02913183|Drug|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
164729|NCT02913183|Drug|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
164730|NCT02913170|Dietary Supplement|Nattokinase|
164731|NCT02913170|Dietary Supplement|Placebo|
164732|NCT02913157|Drug|Hydroxychloroquine|Orally administered Hydroxychloroquine
164733|NCT02913131|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
164734|NCT02913131|Device|MRI|MRI scan following the pyruvate (13c) injection
164735|NCT02913118|Drug|Andrographolid Sulfonate Injection (AS Injection)|
164736|NCT02913118|Drug|Cephalosporin|
164737|NCT02913118|Drug|Azithromycin, Minocycline or Doxycycline|
164738|NCT02913118|Drug|Amoxicillin-clavulantic acid|
164739|NCT02913118|Drug|Fluoroquinolones|
164740|NCT02913118|Drug|Placebo|
164741|NCT02913105|Drug|LMB763|Hard Gelatin Capsules
164742|NCT02913105|Drug|Placebo|Hard Gelatin Capsule
164743|NCT02913092|Behavioral|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
164744|NCT02913079|Behavioral|Sit-stand desk|
164745|NCT02913079|Behavioral|Sitting desk|
164746|NCT02913066|Other|S-1 concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~33 planning target volume times, 60~66 Gray/28~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1~ 14 days, 21 days for a cycle.
164747|NCT02913066|Other|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~30 planning target volume times, Gross tumor volume of primary tumor60~66 Gray/28~33), synchronous chemotherapy S-1 70 mg/m2 1~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.
164748|NCT02913053|Behavioral|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
164749|NCT02913053|Behavioral|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
164750|NCT02913040|Other|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
164751|NCT02913040|Other|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
164752|NCT02913027|Other|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
164753|NCT02913027|Other|Bimanual Exam|
164754|NCT02913027|Other|Speculum Exam|
164755|NCT02913014|Other|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
164756|NCT02913001|Other|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
164757|NCT02913001|Other|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
164758|NCT02912988|Drug|Letrozole|Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
164759|NCT02912975|Other|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
164840|NCT02912364|Drug|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
164760|NCT02912975|Other|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
164761|NCT02912962|Behavioral|Self-Regulation Intervention adapted from the Alert Program ®|
164762|NCT02912949|Drug|zenocutuzumab (MCLA-128)|full length IgG1 bispecific antibody targeting HER2 and HER3
164763|NCT02912936|Dietary Supplement|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
164764|NCT02912936|Dietary Supplement|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
164765|NCT02912923|Other|Visual + Force Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation."
164766|NCT02912923|Other|Visual + Force + Game Scores Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.~Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.~Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured."
164767|NCT02912910|Other|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
164768|NCT02912910|Other|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
164769|NCT02912897|Biological|Cellular therapy with EBV specific autologous CTL infusion|CTL infusions at D0, M3 and M6
164770|NCT02912884|Drug|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
164771|NCT02912871|Other|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
164772|NCT02912858|Device|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
164773|NCT02912845|Drug|KamRAB - HRIG|wound infiltration or IM injection
164774|NCT02912832|Device|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
164775|NCT02912819|Other|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
164776|NCT02912806|Procedure|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
164777|NCT02912793|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
164778|NCT02912767|Behavioral|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
164779|NCT02912754|Drug|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
164780|NCT02912754|Drug|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
164781|NCT02912741|Drug|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
164782|NCT02912741|Drug|resin infiltration|low viscous light cure resin applied in layers and cured
164783|NCT02912728|Behavioral|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
164784|NCT02912728|Device|Standard CGM|use of CGM alone to assess CGM adherence
164841|NCT02912351|Other|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
164842|NCT02912338|Behavioral|Resistant Training|
164843|NCT02912338|Other|Control Group|
164844|NCT02912325|Dietary Supplement|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
164845|NCT02912312|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated RNI
164846|NCT02912312|Other|Laboratory Biomarker Analysis|Correlative studies
164785|NCT02912715|Device|Paclitaxel releasing angioplasty balloon|Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
164786|NCT02912702|Drug|Pegaspargase|2000U/m2 day5
164787|NCT02912702|Drug|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
164788|NCT02912702|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
164789|NCT02912702|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
164790|NCT02912702|Drug|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
164791|NCT02912702|Drug|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
164792|NCT02912689|Device|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
164793|NCT02912689|Device|Pressure support ventilation|PS during Non-invasive ventilation
164794|NCT02912676|Drug|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. 6-mercaptopurine is reduced by 33% two weeks before addition of 6-thioguanine, while dose of methotrexate is unchanged. Oral 6-thioguanine is then added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
164795|NCT02912663|Drug|Verapamil and Magnesium Sulfate|Single dose strategy will be used
164796|NCT02912663|Other|Placebo|Single matching dosing strategy will be used
164797|NCT02912650|Drug|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
164798|NCT02912650|Drug|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
164799|NCT02912650|Drug|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
164800|NCT02912650|Drug|Placebo|2 caplets of Placebo
164801|NCT02912637|Other|Hyperpolarized Xenon MRI|MRI & MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
164802|NCT02912611|Procedure|Education and Protocol based management|
164803|NCT02912598|Device|Mallinckrodt™ Endobronchial Tube|
164804|NCT02912598|Device|Fuji Uniblocker™|
164805|NCT02912598|Device|ETView VivaSight™-SL+EB|
164806|NCT02912598|Device|COOK© Arndt Endobronchial Blocker|
164807|NCT02912585|Biological|Oropharyngeal administration of own mother's colostrum|
164808|NCT02912585|Other|Oropharyngeal administration of sterile water (placebo)|
164809|NCT02912585|Biological|Oropharyngeal administration of donor human milk|
164810|NCT02912572|Drug|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle lasts 28 days Dosage is determined by physician Premedication Antihistamine and Paracetamol will be administered prior to treatment
164811|NCT02912572|Drug|Talazoparib|Talazoparib will be taken one time per day by mouth Each Cycle lasts 28 days
164812|NCT02912559|Drug|Atezolizumab|Given IV
164813|NCT02912559|Drug|Fluorouracil|Given IV
164814|NCT02912559|Other|Laboratory Biomarker Analysis|Correlative studies
164815|NCT02912559|Drug|Leucovorin Calcium|Given IV
164816|NCT02912559|Drug|Oxaliplatin|Given IV
164817|NCT02912559|Other|Quality-of-Life Assessment|Ancillary studies
164818|NCT02912546|Procedure|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
164819|NCT02912533|Drug|JR-131|
164820|NCT02912520|Drug|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
164821|NCT02912507|Device|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
164822|NCT02912507|Device|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
164823|NCT02912494|Drug|JR-131|
164824|NCT02912494|Drug|Darbepoetin alfa|
164825|NCT02912481|Procedure|posterior tibial artery|
164826|NCT02912481|Procedure|radial artery|
164827|NCT02912481|Procedure|dorsalis pedis artery|
164828|NCT02912468|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
164829|NCT02912468|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
164830|NCT02912468|Drug|Mometasone furoate 50 micrograms|"Pharmaceutical form: Suspension (Nasal spray)~Route of administration: Intranasal"
164831|NCT02912455|Drug|canagliflozin|encapsulated (gelatin capsule).
164832|NCT02912455|Drug|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
164833|NCT02912429|Device|Patellofemoral Arthroplasty|
164834|NCT02912416|Dietary Supplement|Probiotics|
164835|NCT02912416|Dietary Supplement|Placebo|
164836|NCT02912390|Procedure|Cerclage|Macdonald cerclage placed in standard fashion
164837|NCT02912390|Other|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
164838|NCT02912377|Biological|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
164839|NCT02912364|Drug|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
164851|NCT02912299|Other|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
164852|NCT02912299|Other|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
164853|NCT02912286|Device|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
164854|NCT02912286|Device|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
164855|NCT02912286|Device|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
164856|NCT02912273|Other|Baseline Participant Assessment|"Section 1 contains demographic questions~Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months~Section 3 has the participant list all medication~Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)~Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very~Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
164857|NCT02912273|Other|Baseline Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
164858|NCT02912273|Other|Follow-up Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
164859|NCT02912273|Other|Follow-up Healthcare Provider Assessment|"Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
164860|NCT02912273|Other|End-of-study Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions~Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions~Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very~Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
164861|NCT02912273|Other|End-of-study Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)~Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.~Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
164862|NCT02912260|Drug|MGL-3196|
164863|NCT02912260|Drug|Placebo|
164864|NCT02912247|Drug|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
164865|NCT02912247|Drug|adalimumab|adalimumab, 40mg,subcutaneous injection,once
164866|NCT02912234|Drug|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
164867|NCT02912234|Drug|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
164868|NCT02912221|Other|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
164869|NCT02912208|Drug|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
164870|NCT02912208|Other|Placebo|The administration is the same of eltrombopag
164871|NCT02912195|Drug|Intravenous lidocaine|Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
164872|NCT02912195|Drug|Intravenous morphine|Emergency department provider chooses appropriate dose of intravenous morphine
164873|NCT02912182|Drug|Betamethasone|Betamethasone intravenous
164874|NCT02912182|Drug|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
164875|NCT02912182|Drug|Prednisolone|Oral tablets
164876|NCT02912169|Procedure|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
164877|NCT02912169|Biological|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
164878|NCT02912156|Drug|Vaway FC Tablets 200mg (Voriconazole)|
164879|NCT02912156|Drug|VFEND FC Tablets 200mg (Voriconazole)|
164880|NCT02912143|Other|documentation only|
164881|NCT02912130|Dietary Supplement|Protein Supplementation|1.2-1.5g/kg/body weight per day
167797|NCT02888925|Other|Face composite effect test|
164882|NCT02912130|Other|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
164883|NCT02912130|Other|Resistance Exercise|60 minutes per week of progressive resistance training
164884|NCT02912104|Biological|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 2×107 hAEC in 5ml sample is separately injected into ovarian tissue by bilateral ovarian artery infusion.
164885|NCT02912078|Other|Pocket-warming|Pocket-warming of epidural medication
164886|NCT02912078|Other|Standard of Care Labor Epidural|Labor epidural medication administered per standard of care; no pocket warming.
164887|NCT02912052|Drug|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
164888|NCT02912052|Drug|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
164889|NCT02912039|Device|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
164890|NCT02912039|Device|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
164891|NCT02912026|Drug|IV F901318|Metabolic profile AUC 0 to infinity
164892|NCT02912026|Drug|Oral F901318|Metabolic profile AUC 0 to infinity
164893|NCT02912013|Device|Me Mini|Home use hair removal device
164894|NCT02912000|Behavioral|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
164895|NCT02911987|Other|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
164896|NCT02911987|Other|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
164897|NCT02911974|Device|Acquire EUS Biopsy Device|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
164898|NCT02911974|Device|Expect EUS Aspiration Needle|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
164899|NCT02911961|Drug|Acetaminophen|1 gram acetaminophen 4 times a day with at least 6 hour intervals between doses for the 3 days prior to the embolization procedure.
164900|NCT02911948|Drug|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
164901|NCT02911948|Drug|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
164902|NCT02911935|Drug|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
164903|NCT02911935|Drug|Placebo|Placebo suspension
164904|NCT02911922|Device|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
164905|NCT02911922|Device|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.~Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
164906|NCT02911922|Radiation|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
164907|NCT02911909|Device|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
164908|NCT02911909|Other|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
164909|NCT02911883|Device|Optical Coherence Tomography Angiography|
164910|NCT02911870|Drug|SNAC|Oral administration
164911|NCT02911870|Drug|Placebo|Oral administration
164912|NCT02911870|Drug|Moxifloxacin|Oral administration
164913|NCT02911857|Biological|Canakinumab (AIN457)|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
164914|NCT02911844|Drug|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
164915|NCT02911831|Drug|Tranexamic Acid|
164916|NCT02911831|Drug|Sodium Chloride|
164917|NCT02911818|Behavioral|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
164918|NCT02911818|Drug|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
164919|NCT02911818|Other|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet prescribed for 12 weeks.
164920|NCT02911818|Drug|Placebo Oral Tablet|
164921|NCT02911818|Drug|Phentermine 15 MG|
164998|NCT02911194|Dietary Supplement|a1 containing milk|use a1 containing milk
164999|NCT02911181|Other|BIVA measurement|
164922|NCT02911818|Behavioral|Extension Study CMS-recommended lifestyle counseling|4 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
164923|NCT02911805|Behavioral|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
164924|NCT02911805|Behavioral|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
164925|NCT02911792|Drug|Dapagliflozin|SGLT2 inhibitor
164926|NCT02911792|Drug|Metformin|Oral diabetes medicine that helps control blood sugar levels.
164927|NCT02911792|Drug|Glipizide 5 MG|Oral diabetes medicine that helps control blood sugar levels.
164928|NCT02911779|Procedure|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
164929|NCT02911766|Drug|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
164930|NCT02911766|Drug|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
164931|NCT02911766|Drug|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
164932|NCT02911753|Other|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
164933|NCT02911753|Other|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
164934|NCT02911753|Other|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
164935|NCT02911740|Other|Urine LAM Ag test|TB diagnostic assay
164936|NCT02911727|Procedure|Fast-track discharge|As described above
164937|NCT02911714|Drug|Lumason Contrast-Enhanced Ultrasound|In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
164938|NCT02911701|Drug|Acetaminophen|
164939|NCT02911701|Drug|Ibuprofen|
164940|NCT02911688|Drug|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
164941|NCT02911688|Drug|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
164942|NCT02911675|Device|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
164943|NCT02911662|Drug|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
164944|NCT02911662|Drug|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
164945|NCT02911649|Other|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
164946|NCT02911649|Other|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
164947|NCT02911649|Other|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
164948|NCT02911649|Other|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
164949|NCT02911636|Radiation|Pelvic SABR with intra-prostatic SABR|described elsewhere
164950|NCT02911623|Device|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
164951|NCT02911610|Device|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
164952|NCT02911610|Device|Volar plate|surgery of wrist fractures with volar plate
164953|NCT02911597|Drug|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
164954|NCT02911584|Procedure|Laparoscopic procedure|
164955|NCT02911571|Device|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
164956|NCT02911532|Procedure|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
165075|NCT02910518|Drug|Insulin glulisine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
167798|NCT02888925|Other|Cambridge Face Memory Test|
164957|NCT02911519|Other|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
164958|NCT02911519|Other|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
164959|NCT02911506|Other|Polysomnography|
164960|NCT02911493|Behavioral|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
164961|NCT02911493|Behavioral|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
164962|NCT02911480|Drug|Oxytocin|
164963|NCT02911467|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
164964|NCT02911467|Device|MRI|MRI scan following the Pyruvate injection
164965|NCT02911454|Other|Infant formula|
164966|NCT02911441|Behavioral|Cognitive Behavioral Therapy|
164967|NCT02911428|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
164968|NCT02911415|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
164969|NCT02911402|Other|sea sickness questionnaires|
164970|NCT02911389|Other|Home PT via web-based platform|
164971|NCT02911389|Other|Home PT via paper manual|
164972|NCT02911389|Other|outpatient PT|
164973|NCT02911363|Device|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
164974|NCT02911363|Other|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
164975|NCT02911350|Drug|Hormone Suppressors|
164976|NCT02911350|Drug|Paclitaxel|
164977|NCT02911350|Radiation|Radiation Therapy|
164978|NCT02911337|Dietary Supplement|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
164979|NCT02911324|Drug|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
164980|NCT02911324|Behavioral|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
164981|NCT02911311|Drug|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
164982|NCT02911311|Device|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
164983|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
164984|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
164985|NCT02911285|Drug|N-acetylcysteine|1200mg bid (2400mg/day)
164986|NCT02911285|Drug|Placebo|Placebo pills bid
164987|NCT02911285|Behavioral|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
164988|NCT02911272|Device|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
164989|NCT02911272|Drug|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
164990|NCT02911272|Procedure|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
164991|NCT02911272|Device|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
164992|NCT02911259|Device|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
164993|NCT02911259|Device|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
164994|NCT02911233|Biological|Thromboelastograpgy|
164995|NCT02911220|Genetic|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
164996|NCT02911207|Behavioral|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
164997|NCT02911194|Dietary Supplement|a2 milk|replace all milk with a2 milk
260884|NCT02211170|Drug|Placebo|
165000|NCT02911168|Procedure|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
165001|NCT02911168|Procedure|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
165002|NCT02911142|Drug|Lenalidomide|Lenalidomide taken orally, daily at assigned dose level on days 1 to 10, up to 25mg.
165003|NCT02911142|Drug|Rituximab|During cycle 1, rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, rituximab will be administered on day 1 of each cycle.
165004|NCT02911142|Drug|Prednisone|During cycle 1, Prednisone 60 mg/m2 /day PO days 6 to 10. During cycles 2-6, Prednisone 60 mg/m2 /day PO days 1-5.
165005|NCT02911142|Drug|Etopside|During cycle 1, Etoposide 50 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Etoposide 50 mg/m2/day continuous intravenous infusion days 1 to 4.
165006|NCT02911142|Drug|Doxorubicin|During cycle 1, Doxorubicin 10 mg /m2/day continuous intravenous infusion days 6 to 9. During cycles 2-6, Doxorubicin continuous intravenous infusion days 1 to 4.
165007|NCT02911142|Drug|Vincristine|During cycle 1, Vincristine 0.4 mg/m2 /day continuous intravenous infusion days 6 to 9. During cycles 2-6, Vincristine continuous intravenous infusion days 1 to 4.
165008|NCT02911142|Drug|Cyclophosphamide|During cycle 1, Cyclophosphamide 750 mg/m2 day 10. During cycles 2-6, Cyclophosphamide 750 mg/m2 day 5.
165009|NCT02911116|Drug|Ustekinumab|Subcutaneous Injection
165010|NCT02911116|Drug|Ustekinumab|Intravenous Infusion
165011|NCT02911103|Device|DBS surgery|Unilateral thalamic DBS therapy
165012|NCT02911090|Other|Data Registry|Data Registry
165013|NCT02911064|Behavioral|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
165014|NCT02911051|Device|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
165015|NCT02910986|Behavioral|Written educational brochure|Written educational brochure about breast density
165016|NCT02910986|Behavioral|Promotora interaction|Promotora education about breast density
165017|NCT02910973|Device|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
165018|NCT02910973|Device|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
165019|NCT02910960|Device|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
165020|NCT02910960|Device|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
165021|NCT02910947|Procedure|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
165022|NCT02910934|Other|Actellic CS|Indoor residual spray with Actellic CS
165023|NCT02910895|Other|tumor biopsy|biopsy
165024|NCT02910882|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
165025|NCT02910882|Drug|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
165026|NCT02910882|Radiation|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
165027|NCT02910869|Genetic|Pathway Genomics FIT test|
165076|NCT02910518|Drug|Insulin aspart|"Pharmaceutical form: solution~Route of administration: intravenous/subcutaneous"
167799|NCT02888925|Other|Matching different view test|
165028|NCT02910843|Drug|Regorafenib|"Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.~Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
165029|NCT02910843|Drug|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
165030|NCT02910843|Radiation|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
165031|NCT02910843|Procedure|Surgery|6-12 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed (42-84 days after last day of RCT).
165032|NCT02910817|Drug|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
165033|NCT02910817|Other|Placebo|Placebo
165034|NCT02910804|Drug|68Ga-BBN-IRDye800CW|
165035|NCT02910804|Device|PET/NIRF|
165036|NCT02910804|Procedure|PET/NIR fluorescent imaging-guided surgery|
165037|NCT02910791|Procedure|blood draw/skin biopsy|
165038|NCT02910778|Drug|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
165039|NCT02910778|Drug|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
165040|NCT02910778|Drug|Ticagrelor|
165041|NCT02910765|Drug|methylene blue|
165042|NCT02910765|Drug|ozone|
165043|NCT02910765|Other|saline infusion|
165044|NCT02910765|Other|oxygen|
165045|NCT02910752|Drug|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
165046|NCT02910739|Drug|MK-8931|MK-8931 40 mg
165047|NCT02910726|Procedure|Sentinel Lymph Node Biopsy|
165048|NCT02910726|Drug|indocyanine green (ICG)|
165049|NCT02910700|Drug|Dabrafenib|Given PO
165050|NCT02910700|Other|Laboratory Biomarker Analysis|Correlative studies
165051|NCT02910700|Biological|Nivolumab|Given IV
165052|NCT02910700|Other|Pharmacological Study|Correlative studies
165053|NCT02910700|Drug|Trametinib|Given PO
165054|NCT02910687|Other|This is an observational study|
165055|NCT02910661|Other|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last ~90 min. and be audio-recorded. An observer will take field notes.
165056|NCT02910648|Behavioral|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
165057|NCT02910635|Drug|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
165058|NCT02910635|Drug|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
165059|NCT02910635|Drug|Placebo|
165060|NCT02910622|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
165061|NCT02910609|Device|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
165062|NCT02910596|Drug|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
165063|NCT02910596|Device|early bladder training|early bladder training start on 3rd - 5thpostoperative day
165064|NCT02910596|Other|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
165065|NCT02910596|Other|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
165066|NCT02910583|Drug|ibrutinib|ibrutinib 420mg capsules administered orally once daily
165067|NCT02910583|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally once daily
165068|NCT02910583|Drug|venetoclax|venetoclax tablets will be administered orally once daily starting with a 5 week ramp up of 20 mg, 50 mg, 100 mg, 200 mg and 400 mg. After ramp up, venetoclax will be administered at 400 mg.
165069|NCT02910570|Drug|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
165070|NCT02910570|Drug|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
165071|NCT02910544|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
165072|NCT02910531|Dietary Supplement|Alpha lipoic acid|Already mentioned in arm/group descriptions.
165073|NCT02910531|Drug|Placebo|Already mentioned in arm/group descriptions.
165074|NCT02910518|Drug|Insulin glulisine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
165077|NCT02910518|Drug|NPH insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
165078|NCT02910518|Drug|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection~Route of administration: subcutaneous"
165079|NCT02910518|Drug|Glucose|"Pharmaceutical form: solution~Route of administration: intravenous"
165080|NCT02910518|Drug|Heparin|"Pharmaceutical form: solution~Route of administration: intravenous"
165081|NCT02910505|Device|enLighten Laser|Laser for tattoo removal
165082|NCT02910492|Device|enLighten Laser|Nd:YAG dual-pulse duration laser for the treatment of skin rejuvenation
165083|NCT02910479|Device|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
165084|NCT02910479|Device|Rectal thermometer|
165085|NCT02910479|Device|Esophageal thermometer|
165086|NCT02910479|Device|Vital sense capsule thermometer|
165087|NCT02910466|Drug|rhPTH(1-84)|Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 48 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.
165088|NCT02910453|Procedure|Pulmonary lobectomy|
165089|NCT02910440|Drug|DCL-101 vs Golytely|
165090|NCT02910427|Other|Regular salt|Participants eat a regular salt diet.
165091|NCT02910427|Other|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
165092|NCT02910427|Other|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
165093|NCT02910414|Drug|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
165094|NCT02910414|Device|Peregrine System Kit (Sham Procedure)|The Peregrine Catheter is delivered to the renal arteries, but the needles are not deployed and no alcohol is delivered to the perivascular space.
165095|NCT02910401|Biological|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
165096|NCT02910388|Device|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
165097|NCT02910388|Other|LLETZ without colposcopy|Loop procedure without using a colposcope
165098|NCT02910375|Other|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
165099|NCT02910375|Other|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
165100|NCT02910362|Device|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
165101|NCT02910362|Device|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
165102|NCT02910336|Other|Quantitative Sensory Testing|sensory testing profile
165103|NCT02910310|Other|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
165104|NCT02910284|Biological|Observational|
165105|NCT02910245|Drug|Mercaptopurine (Purinethol)|
165106|NCT02910245|Drug|Placebo|
165107|NCT02910245|Drug|Mesalamine|
165108|NCT02910245|Drug|Prednisone|
165109|NCT02910232|Device|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
165110|NCT02910219|Drug|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
165111|NCT02910206|Drug|Etomidate|etomidate is given intravenously
165112|NCT02910206|Drug|propofol|propofol is given intravenously
165113|NCT02910206|Drug|Sufentanil|sufentanil is given intravenously
165114|NCT02910206|Drug|Cisatracurium|Cisatracurium is given intravenously
165115|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
165116|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
165117|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
165118|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
165119|NCT02910154|Dietary Supplement|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
165120|NCT02910154|Behavioral|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
165121|NCT02910154|Drug|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure > 130 and/or low density lipoprotein (LDL) > 2.0.
165122|NCT02910141|Device|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
165123|NCT02910128|Behavioral|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
165124|NCT02910115|Other|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
165125|NCT02910115|Drug|Pitocin|Pitocin is administered intravenously according to the usual protocol.
165126|NCT02910102|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
165127|NCT02910102|Drug|Placebo|once daily, oral, matching tablets
165128|NCT02910089|Behavioral|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
165129|NCT02910076|Drug|Hydroxychloroquine|200 MG Plaquenil three times a day
165130|NCT02910063|Drug|Blinatumomab|Blinatumomab monotherapy
165131|NCT02910050|Drug|Bicalutamide|50mg once a day orally
165132|NCT02910050|Drug|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
165133|NCT02910037|Device|mNGS for pathogen detection|This assay is a laboratory-validated metagenomic test for comprehensive detection of viruses, bacteria, fungi, and parasites in clinical samples.
165134|NCT02910024|Device|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
165135|NCT02910024|Device|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
165136|NCT02910011|Drug|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
165137|NCT02909998|Other|Blood sample|Conservation at the end of the blood sample
165138|NCT02909985|Other|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
165139|NCT02909985|Other|ERG|Participants will undergo electroretinography using both normal settings and infrared as the stimuli.
165140|NCT02909985|Other|VEP|Participants will undergo visual evoke potential tests using both normal settings and infrared as the stimuli.
165141|NCT02909972|Drug|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
165142|NCT02909972|Drug|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
165143|NCT02909959|Drug|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
165144|NCT02909959|Drug|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
165145|NCT02909946|Behavioral|Multi-modal Infection Control Program|"Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).~Hand hygiene education to residents and families (resident-level intervention).~Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).~Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).~Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
165146|NCT02909933|Drug|liraglutide|
165147|NCT02909933|Drug|metformin and liraglutide|
165148|NCT02909920|Other|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
165149|NCT02909920|Other|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
165150|NCT02909907|Drug|Botulinum toxin|Botulinum injections into dominant upper extremity using protocol outlined above.
165151|NCT02909907|Other|Placebo|Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
165152|NCT02909894|Other|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
165153|NCT02909894|Other|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
165154|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
165155|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
165156|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
165157|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
165158|NCT02909881|Behavioral|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
165273|NCT02909036|Drug|Pegfilgrastim|
165159|NCT02909868|Device|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
165160|NCT02909855|Other|No intervention|Participants in this study will not receive any interventions as part of the study.
165161|NCT02909842|Dietary Supplement|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
165162|NCT02909842|Dietary Supplement|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
165163|NCT02909842|Biological|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
165164|NCT02909829|Device|Closed Loop Delivery|Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm.
165165|NCT02909829|Device|Closed Loop Delivery with Meal Detection Module|Closed Loop Delivery with Meal Detection Module Insulin will be delivered by subcutaneous insulin infusion pump. Infusion rates will be changed manually every 10 minutes based on the computer generated recommendation infusion rates, calculated from the glucose levels measured by a real time sensor. The computer generated recommendations are based on a predictive algorithm with an overlying meal detection module which detects missed meals and will increase insulin infusion rates based on a predictive meal detection algorithm
165166|NCT02909829|Device|Conventional Pump Therapy|Insulin will be delivered by subcutaneous insulin infusion pump with participants usual infusion rate
165167|NCT02909803|Other|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
165168|NCT02909803|Other|White Bread|Participants will consume white bread on at least two different test days
165169|NCT02909790|Device|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
165170|NCT02909777|Drug|CUDC-907|
165171|NCT02909764|Other|Low Sodium Group|Breakfast Cereal
165172|NCT02909751|Drug|Epirubicin 90 mg/m2 iv|Max. 3 months
165173|NCT02909751|Drug|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
165174|NCT02909751|Drug|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
165175|NCT02909751|Drug|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
165176|NCT02909751|Drug|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
165177|NCT02909751|Dietary Supplement|Tocotrienol 300 mg x 3 daily|Max. 6 months
165178|NCT02909738|Other|Volunteer to pedal a bicycle|
165179|NCT02909725|Other|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
165180|NCT02909725|Other|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.~Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
165181|NCT02909725|Other|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
165182|NCT02909712|Drug|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:~3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
165183|NCT02909712|Drug|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
165184|NCT02909699|Other|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
165185|NCT02909686|Dietary Supplement|Boswellia Serrata|
165186|NCT02909686|Dietary Supplement|Curcumin|
165187|NCT02909686|Dietary Supplement|Epimedium|
165188|NCT02909686|Dietary Supplement|Fisetin|
165189|NCT02909686|Dietary Supplement|Luteolin|
165190|NCT02909686|Dietary Supplement|Nettle|
165191|NCT02909686|Dietary Supplement|Pycnogenol|
165192|NCT02909686|Dietary Supplement|Reishi Mushroom|
165193|NCT02909686|Dietary Supplement|Resveratrol|
165194|NCT02909686|Dietary Supplement|Placebo|
165195|NCT02909673|Behavioral|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
165196|NCT02909660|Other|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
165197|NCT02909647|Procedure|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
165198|NCT02909647|Procedure|Osteosynthesis|osteosynthesis using volar locking plate
165199|NCT02909621|Dietary Supplement|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
165200|NCT02909621|Other|PLACEBO|
165201|NCT02909608|Other|No interventions / observations only|This is an observational study only
165202|NCT02909595|Device|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter [Extractor Pro RX [M00547000, M00547010, or M00547020]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
165203|NCT02909595|Device|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V [FG-V435P or FG-V425PR]; Olympus Corp., Shang hai,China).
165204|NCT02909582|Procedure|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
165205|NCT02909569|Drug|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
165206|NCT02909556|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
165207|NCT02909543|Other|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
165208|NCT02909530|Device|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
165209|NCT02909530|Device|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
165210|NCT02909517|Other|cSLO imaging|
165211|NCT02909504|Drug|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
165212|NCT02909478|Drug|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
165213|NCT02909478|Drug|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
165214|NCT02909465|Drug|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
165215|NCT02909465|Drug|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
165216|NCT02909465|Drug|placebo|distilled water
165217|NCT02909465|Drug|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
165218|NCT02909452|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
165219|NCT02909452|Drug|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
165220|NCT02909439|Drug|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
165221|NCT02909439|Drug|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
165222|NCT02909426|Device|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
165223|NCT02909426|Device|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
165224|NCT02909413|Drug|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
165225|NCT02909413|Drug|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
165226|NCT02909400|Drug|KH176|
165227|NCT02909400|Drug|placebo|
165228|NCT02909387|Behavioral|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
165229|NCT02909374|Other|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
165230|NCT02909361|Drug|Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
165231|NCT02909348|Drug|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
165232|NCT02909335|Drug|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.~The doses are then adjusted to maintain trough levels :~between 6 and 10 ng / ml during the first 2 months,~between 5 and 8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
165233|NCT02909335|Drug|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.~The doses are then adjusted to maintain trough levels:~between 6 and 10 ng / ml during the first 2 months,~between 5-8 ng / ml from the start of the end M3 and M6,~and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
165234|NCT02909335|Drug|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
165274|NCT02909036|Procedure|Autologous Hematopoietic Progenitor Cell Transplant|
165235|NCT02909335|Drug|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
165236|NCT02909322|Procedure|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
165237|NCT02909322|Procedure|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
165238|NCT02909309|Device|JAWAC system + Capnoline + Spo2|measure mandibular mouvements + etCO2 + pulse oxymetry, respectively
165239|NCT02909296|Procedure|Endoscopic drainage|
165240|NCT02909283|Procedure|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
165241|NCT02909270|Device|Mediclore|to apply mediclore fully around thyroid gland
165242|NCT02909257|Drug|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
165243|NCT02909257|Drug|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
165244|NCT02909244|Biological|Biological sampling|Biological sampling
165245|NCT02909218|Other|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
165246|NCT02909205|Other|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
165247|NCT02909205|Other|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
165248|NCT02909192|Device|Light Therapy Device|
165249|NCT02909179|Other|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
165250|NCT02909166|Drug|aliskiren|
165251|NCT02909153|Drug|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
165252|NCT02909140|Drug|Topical phenylephrine 2.5%|
165253|NCT02909140|Drug|Topical cyclopentolate 1%|
165254|NCT02909140|Drug|Intracameral Lidocaine 1%|
165255|NCT02909140|Drug|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
165256|NCT02909127|Other|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
165257|NCT02909127|Other|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
165258|NCT02909127|Other|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
165259|NCT02909114|Radiation|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.~The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
165260|NCT02909101|Device|Active Cognitive Training (ACT)|Cognitive training games
165261|NCT02909101|Device|Control Training (CON)|Cognitive training games
165262|NCT02909088|Drug|Ecopipam 50mg|
165263|NCT02909088|Drug|Ecopipam 100mg|
165264|NCT02909075|Device|PET/CT scans|
165265|NCT02909075|Device|MRI|
165266|NCT02909062|Device|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
165267|NCT02909062|Behavioral|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
165268|NCT02909049|Drug|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
165269|NCT02909049|Drug|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
165270|NCT02909049|Drug|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
165271|NCT02909049|Drug|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
165272|NCT02909036|Device|Melphalan|
165275|NCT02909023|Biological|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.~The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
165276|NCT02909010|Device|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
165277|NCT02909010|Other|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
165278|NCT02908997|Other|MindMate|A dementia-specific mobile reminding application
165279|NCT02908984|Behavioral|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and of oculomotor function if indicated, and general exercises
165280|NCT02908984|Other|Standard primary health care|The treatment may include pharmacological medication and physiotherapy or no active treatment
165281|NCT02908971|Behavioral|soy based formula at infancy|The intervention is only past history of soy consumption
165282|NCT02908958|Biological|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
165283|NCT02908958|Biological|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
165284|NCT02908945|Drug|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
165285|NCT02908945|Device|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
165286|NCT02908932|Dietary Supplement|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
165287|NCT02908932|Dietary Supplement|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
165288|NCT02908919|Procedure|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
165289|NCT02908906|Drug|JNJ-63723283|JNJ-63723283 will be administered by IV infusion or SC injection.
165290|NCT02908893|Behavioral|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
165291|NCT02908880|Device|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
165292|NCT02908867|Other|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
165293|NCT02908854|Other|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
165294|NCT02908841|Device|Surgicel Snow|
165295|NCT02908841|Other|Standard of Care|
165296|NCT02908828|Dietary Supplement|Calanus oil|
165297|NCT02908828|Dietary Supplement|placebo dietary oil|
165298|NCT02908815|Device|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
165299|NCT02908815|Device|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
165300|NCT02908802|Dietary Supplement|Probiotic|Probiotic
165301|NCT02908802|Dietary Supplement|Placebo|Probiotics capsules without the active ingredient
165302|NCT02908789|Radiation|Antimicrobial photodynamic therapy (aPDT)|Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms.
165303|NCT02908776|Dietary Supplement|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
165304|NCT02908776|Other|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
165305|NCT02908763|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
165306|NCT02908750|Drug|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
165307|NCT02908750|Drug|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
165308|NCT02908737|Device|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
165309|NCT02908711|Drug|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
165351|NCT02908360|Genetic|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
261526|NCT02206568|Drug|URAL|
165310|NCT02908698|Drug|Prednisone|"Total treatment duration: 15 days~Doses are as follows:~5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
165311|NCT02908698|Drug|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
165312|NCT02908685|Drug|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
165313|NCT02908685|Drug|Risdiplam|Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
165314|NCT02908672|Drug|Atezolizumab|Will be administered as per the schedule described in individual arm.
165315|NCT02908672|Drug|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
165316|NCT02908672|Drug|Cobimetinib|Will be administered as per the schedule described in individual arm.
165317|NCT02908672|Drug|Vemurafenib|Will be administered as per the schedule described in individual arm.
165318|NCT02908672|Drug|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
165319|NCT02908646|Procedure|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
165320|NCT02908646|Procedure|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
165321|NCT02908633|Procedure|canaloplasty and phacoemulsification|
165322|NCT02908620|Combination Product|One spray CTY-5339-A|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 28 mg) and 2.0% Tetracaine Hydrochloride (USP = 4 mg). Administered in a single anesthetic spray.
165323|NCT02908620|Drug|One spray CTY-5339-CB|Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
165324|NCT02908620|Combination Product|Two sprays CTY-5339-A|Metered spray bottle with ≈400 uL total spray volume. Contains the active ingredients: 14.0% Benzocaine (USP = 56 mg total) and 2.0% Tetracaine Hydrochloride (USP = 8 mg total). Administered in two anesthetic sprays.
165325|NCT02908620|Drug|One spray CTY-5339-CB in combination with one spray CTY-5339-P (vehicle control: placebo)|A single spray of CTY-5339-CB in a metered spray bottle with ≈200 uL total spray volume, containing the active ingredient: 14.0% Benzocaine (USP = 28 mg). This was administered in combination with a single spray of CTY-5339-P (acting as vehicle control placebo with no active ingredient) in a metered spray bottle with ≈200 uL total spray volume. This combination was used to maintain double-blind conditions. The vehicle control was sprayed outside the circumscribed area to avoid dilution of active drug.
165326|NCT02908607|Device|Thermal imaging|Examination of the cervix by thermal imaging camera
165327|NCT02908594|Device|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
165328|NCT02908581|Drug|Placebo|Administered orally once daily
165329|NCT02908581|Drug|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
165330|NCT02908568|Device|Spring device|Brisk dilatation of fhe mouth.
165331|NCT02908568|Device|Mandible stimulator|Stimulation of fhe mouth.
165332|NCT02908555|Other|No intervention|This is a descriptive study with no intervention
165333|NCT02908542|Genetic|genetic analysis with massively parallel sequencing|
165334|NCT02908529|Drug|Combination product of Atomoxetine and Oxybutynin|Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
165335|NCT02908529|Drug|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
165336|NCT02908516|Drug|Tranexamic Acid|2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
165337|NCT02908516|Drug|Placebo|2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
165338|NCT02908503|Other|Placebo Film|placebo vaginal films
165339|NCT02908490|Drug|Sildenafil|Sildenafil 50 mg once daily
165340|NCT02908490|Other|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
165341|NCT02908477|Radiation|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
165342|NCT02908477|Drug|Docetaxel|15 mg/m2. Experimental arm only.
165343|NCT02908477|Drug|Cisplatin|40 mg/m2. Standard arm only.
165344|NCT02908464|Device|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
165345|NCT02908451|Biological|AbGn-107|Antibody Drug Conjugate
165346|NCT02908438|Drug|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
165347|NCT02908425|Other|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
165348|NCT02908412|Drug|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
165349|NCT02908399|Device|FLIR ONE|
165350|NCT02908373|Other|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
165422|NCT02907853|Behavioral|Contingency Management|as described above
165352|NCT02908347|Drug|MP1032|hard gelatine capsules containing 50 mg MP1032 as active ingredient
165353|NCT02908347|Drug|Placebo|hard gelatine capsules without active ingredient
165354|NCT02908334|Drug|Sertraline|400 mg/day sertraline
165355|NCT02908321|Behavioral|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
165356|NCT02908308|Procedure|Targeted temperature management to 33°C|Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.
165357|NCT02908308|Procedure|Standard care with early treatment of fever|Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
165358|NCT02908295|Drug|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
165359|NCT02908295|Drug|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
165360|NCT02908282|Device|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
165361|NCT02908282|Device|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
165362|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
165363|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative|0.5 mL, Intramuscular
165364|NCT02908269|Biological|Fluzone High-Dose, vaccine, 2016-2017 formulation|0.5 mL, Intramuscular
165365|NCT02908256|Drug|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
165366|NCT02908256|Drug|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
165367|NCT02908243|Other|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
165368|NCT02908230|Behavioral|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
165369|NCT02908230|Behavioral|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
165370|NCT02908230|Behavioral|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
165371|NCT02908217|Drug|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
165372|NCT02908217|Drug|Placebo|6 Intravenous infusions of placebo every 4 weeks.
165373|NCT02908191|Drug|ABI-H0731|
165374|NCT02908191|Drug|Placebo for ABI-H0731|
165375|NCT02908191|Drug|Entecavir|Used to treat adults with chronic hepatitis B virus
165376|NCT02908191|Drug|Tenofovir disoproxil fumarate|Used to treat adults with chronic hepatitis B virus
165377|NCT02908191|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
165378|NCT02908191|Drug|Nucleos(t)ide|Used to treat adults with chronic hepatitis B virus
165379|NCT02908178|Procedure|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
165380|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a continuous schedule|Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
165381|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a sequential schedule|Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
165382|NCT02908152|Dietary Supplement|curcumin|"1500 mg~1 capsule / day for 12 weeks"
165383|NCT02908152|Dietary Supplement|placebo|"1500 mg~1 capsule / day for 12 weeks"
165384|NCT02908139|Device|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
165385|NCT02908139|Device|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
165386|NCT02908126|Drug|Oxytocin|Oxytocin drug
165387|NCT02908113|Behavioral|collection data|
165388|NCT02908113|Behavioral|IRM|
165389|NCT02908100|Drug|GDC-0853 (high dose)|Participants will receive GDC-0853 twice daily, orally every 12 hours starting on Day 1 and ending at Week 48.
165390|NCT02908100|Drug|GDC-0853 (low dose)|Participants will receive GDC-0853 once daily, and matching placebo twice daily, orally, starting on Day 1 and ending at Week 48.
165391|NCT02908100|Drug|Placebo|Participants will receive matching placebo to GDC-0853 tablets twice daily, orally, every 12 hours starting on Day 1 and ending at Week 48.
165392|NCT02908087|Drug|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
165393|NCT02908087|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
165394|NCT02908074|Drug|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
165471|NCT02907424|Dietary Supplement|2 months of treatment|standard 2 months of treatment
165395|NCT02908061|Procedure|Surgery Radical Cystectomy|All surgeries will be performed in an open or laparoscopic fashion.
165396|NCT02908061|Procedure|Ultrapro mesh|Surgery Mesh Placement. All surgeries will be performed in an open or laparoscopic fashion.
165397|NCT02908048|Other|Blood samples|Blood samples collected at varying intervals over a two to three year period.
165398|NCT02908035|Drug|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
165399|NCT02908035|Drug|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
165400|NCT02908022|Device|Electroacupuncture Analgesia|Acupuncture needles will be inserted next to the cuff placed on the leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.
165401|NCT02908022|Device|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
165402|NCT02907996|Drug|Sofosbuvir|400 mg tablet administered orally once daily
165403|NCT02907983|Drug|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
165404|NCT02907983|Drug|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
165405|NCT02907957|Device|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
165406|NCT02907957|Procedure|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
165407|NCT02907944|Behavioral|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.~External Facilitator: Outside content expert who assists site~Local Champion: Site stakeholder who promotes change~Provider Education and Academic Detailing: Provision of unbiased peer education~Stakeholder Engagement: Aligning goals of implementation and those impacted~Tailor Program to Site: Addressing site specific needs based on Aim 1~Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results~Formative Evaluation: Quant. and qual. determination of impact~Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders~Program Marketing: Increase attention to availability of on-site addiction treatment services"
165408|NCT02907931|Other|Point of Care Ultrasound|
165409|NCT02907918|Drug|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
165410|NCT02907918|Drug|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
165411|NCT02907918|Biological|Trastuzumab|Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery.
165412|NCT02907918|Drug|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
165413|NCT02907918|Procedure|Breast surgery|Standard of care
165414|NCT02907918|Procedure|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
165415|NCT02907918|Procedure|Research bone marrow (OPTIONAL)|Baseline and surgery
165416|NCT02907918|Procedure|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
165417|NCT02907918|Genetic|Research blood for germline DNA|Baseline
165418|NCT02907918|Procedure|Blood for detection of circulating tumor cells|Baseline
165419|NCT02907905|Biological|capillary sampling|"After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results"
165420|NCT02907892|Procedure|Glove change|Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
165421|NCT02907866|Device|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
261940|NCT02203643|Drug|Cyclophosphamide|
165423|NCT02907840|Device|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
165424|NCT02907827|Other|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
165425|NCT02907814|Device|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
165426|NCT02907814|Other|Eye Exam|This is a brief, non-contact ocular exam.
165427|NCT02907801|Behavioral|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
165428|NCT02907775|Device|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
165429|NCT02907775|Device|Electrodes|electrodes placed over the radial nerve in radial grove
165430|NCT02907762|Device|Endovascular aneurysm repair EVAR|
165431|NCT02907749|Drug|Spironolactone Pill|spironolactone starts from 40mg once daily and increase every week with a maximum dose as 100mg once daily
165432|NCT02907749|Drug|Carvedilol|carvedilol starts from 6.25mg once daily and increase to 12.5mg once daily in next week if being tolerated
165433|NCT02907749|Drug|Spironolactone and Carvedilol|spironolactone is added when carvedilol has reached the most tolerated dose
165434|NCT02907723|Device|Sleep Recording|the device records movements during patients' sleep
165435|NCT02907710|Drug|Endostar|intravenous infusion
165436|NCT02907710|Drug|DDP|
165437|NCT02907697|Behavioral|Life Steps-Drug Use|
165438|NCT02907697|Behavioral|General Health Education|
165439|NCT02907684|Dietary Supplement|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
165440|NCT02907684|Dietary Supplement|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks~NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
165441|NCT02907671|Procedure|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
165442|NCT02907658|Behavioral|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
165443|NCT02907645|Behavioral|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
165444|NCT02907645|Behavioral|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
165445|NCT02907632|Drug|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age."
165446|NCT02907632|Drug|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
165447|NCT02907619|Biological|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
165448|NCT02907593|Drug|Budesonide in Calfactant|Budesonide in Calfactant
165449|NCT02907580|Behavioral|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
165450|NCT02907580|Behavioral|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
165451|NCT02907567|Drug|CT1812|Active study drug
165452|NCT02907567|Drug|Placebo|non-active study drug
165453|NCT02907554|Drug|cyclosporine A|the intervention group receives 2.5 mg/kg of cyclosporine
165454|NCT02907554|Drug|Placebo|control group receives a placebo
165455|NCT02907541|Other|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
165456|NCT02907541|Other|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
165457|NCT02907541|Other|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
165458|NCT02907528|Biological|Bone|Furcation defect regenerated with bone graft material
165459|NCT02907528|Biological|EMD|Furcation defect regenerated with EMD
165460|NCT02907515|Device|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
165461|NCT02907515|Device|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
165462|NCT02907502|Dietary Supplement|Young-child formula with low protein content|Young-child formula with low protein content
165463|NCT02907502|Dietary Supplement|Young-child formula with protein content similar to that of cow's milk|Young-child formula with protein content similar to that of cow's milk
165464|NCT02907489|Other|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
165465|NCT02907476|Behavioral|Iyengar Yoga|
165466|NCT02907476|Behavioral|Walking|
165467|NCT02907450|Device|TwiCare®.|
165468|NCT02907437|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
165469|NCT02907437|Drug|Placebo|(200 mg/day)
165470|NCT02907437|Other|Probiotics|(450 mg/day)
165472|NCT02907411|Other|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
165473|NCT02907398|Device|Inspire therapy|
165474|NCT02907398|Other|No intervention|
165475|NCT02907385|Device|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
165476|NCT02907372|Other|neuropsychologic evaluation|
165477|NCT02907372|Other|oncogeriatric evaluation|
165478|NCT02907359|Drug|Guadecitabine|Guadecitabine regimen is 60 mg/m2 given SC daily on Days 1-5 in 28-day cycles (delayed as needed to allow blood count recovery). Treatment should be given for at least 6 total cycles in absence of unacceptable toxicity or disease progression requiring alternative therapy.
165479|NCT02907359|Other|Treatment Choice|"BSC: according to standard/institutional practice; includes RBC or platelet transfusions; growth factors, ie, erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.~Low dose cytarabine: 20 mg/m2 SC or IV QD for 14 days in 28-day cycles. Other schedules allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.~Standard Intensive Chemotherapy: recommended 7+3 given as cytarabine 100-200 mg/m2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice include daunorubicin (45-60 mg/m2/day) or idarubicin (9-12 mg/m2/day) or mitoxantrone (8-12 mg/m2/day) by IV infusion. Subjects with complete or partial response after IC induction should receive ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
165480|NCT02907346|Device|CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
165481|NCT02907333|Behavioral|Advice to use condoms|
165482|NCT02907320|Drug|CYCLO 3 ® FORT|
165483|NCT02907320|Drug|MPFF|
165484|NCT02907320|Drug|placebo CYCLO 3 ® FORT|
165485|NCT02907320|Drug|placebo MPFF|
165486|NCT02907307|Device|LactiSal vaginal gel 1%|to be administered daily intravaginally for 6 days
165487|NCT02907307|Device|LactiSal vaginal tablet 50mg|to be administered daily intravaginally for 6 days
165488|NCT02907307|Drug|Clotrimazole vaginal tablet 100mg|to be administered daily intravaginally for 6 days
165489|NCT02907294|Drug|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
165490|NCT02907294|Drug|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
165491|NCT02907294|Drug|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
165492|NCT02907281|Other|Observational|Observational
165493|NCT02907268|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
165494|NCT02907268|Drug|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
165495|NCT02907255|Device|Oximetry monitor|Wireless respiratory monitoring system
165496|NCT02907242|Other|Revealment|Cerebroplacental ratio revealment
165497|NCT02907229|Device|NCVC-CS1|Intervention Description
165498|NCT02907216|Biological|Squarekids|Three doses administered subcutaneously in the upper arm or thigh
165499|NCT02907216|Biological|Rotarix|Two doses administered orally
165500|NCT02907190|Other|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
165501|NCT02907190|Other|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
165502|NCT02907177|Drug|Ponesimod|One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
165503|NCT02907177|Other|Placebo|One tablet of matching placebo administered orally once daily in the morning
165504|NCT02907164|Behavioral|Email invitation|Receive emails encouraging them to sign up
165505|NCT02907164|Behavioral|Social norm|Receive information about how many people have signed up
165506|NCT02907164|Behavioral|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
165507|NCT02907164|Behavioral|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
165508|NCT02907151|Other|Survey|Complete a survey prior to the consultation and a questionnaire after
165509|NCT02907138|Other|Medical Yoga|
165510|NCT02907138|Other|Treatment as Usual (physical therapy)|
165511|NCT02907125|Behavioral|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
165512|NCT02907125|Behavioral|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year."
165550|NCT02906787|Behavioral|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
261941|NCT02203643|Drug|Lenalidomide|
165513|NCT02907125|Behavioral|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
165514|NCT02907112|Behavioral|Meat reduction|Advice, Motivational material and food products provided to participants
165515|NCT02907099|Drug|CXCR4 Antagonist BL-8040|Given SC
165516|NCT02907099|Biological|Pembrolizumab|Given IV
165517|NCT02907099|Other|Pharmacological Study|Correlative studies
165518|NCT02907086|Other|blood collection|
165519|NCT02907073|Drug|BF4|Single IV dose of 9-11 millicurie (mCi) sodium [Fluorine-18] radiolabeled B4^F
165520|NCT02907060|Device|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.~It will be used in accordance with user manual"
165521|NCT02907060|Drug|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).~It will be used in accordance with Summary of Product Characteristics"
165522|NCT02907047|Other|tourniquet inflated|
165523|NCT02907047|Other|tourniquet not inflated|
165524|NCT02907034|Procedure|Virtual reality experimentation sequency (VR)|
165525|NCT02907034|Procedure|Classical narrative approach (CN)|
165526|NCT02907021|Drug|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
165527|NCT02907008|Other|Polysomnography|
165528|NCT02906995|Drug|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.~The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
165529|NCT02906982|Other|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
165530|NCT02906982|Other|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
165531|NCT02906969|Other|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
165532|NCT02906969|Other|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
165533|NCT02906956|Behavioral|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
165534|NCT02906930|Drug|semaglutide|Oral administration once daily.
165535|NCT02906930|Drug|placebo|Oral administration once daily.
165536|NCT02906917|Drug|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
165537|NCT02906917|Drug|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
165538|NCT02906917|Drug|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
165539|NCT02906904|Other|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
165540|NCT02906904|Other|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
165541|NCT02906891|Device|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
165542|NCT02906878|Procedure|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
165543|NCT02906865|Other|Proximal hamstring tendons repair|Proximal hamstring tendons repair
165544|NCT02906839|Other|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
165545|NCT02906826|Device|Video game|Video game operated by performing therapy correctly
165546|NCT02906813|Drug|TAK-935 Tablets|Tablets
165547|NCT02906813|Drug|TAK-935 Oral Solution|Oral solution
165548|NCT02906800|Drug|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
165549|NCT02906787|Behavioral|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
165551|NCT02906774|Biological|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
165552|NCT02906761|Drug|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
165553|NCT02906761|Drug|Placebo|Placebo (2 tablets) twice daily for 6 months
165554|NCT02906748|Procedure|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
165555|NCT02906748|Procedure|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
165556|NCT02906735|Procedure|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
165557|NCT02906722|Drug|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
165558|NCT02906722|Drug|Intravenous placebo|administration once, twice or 3 times per day according to renal function
165559|NCT02906722|Drug|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
165560|NCT02906722|Drug|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
165561|NCT02906709|Drug|Omarigliptin|Omarigliptin, 25 mg orally once weekly
165562|NCT02906709|Drug|Placebo|Placebo to omarigliptin orally once weekly
165563|NCT02906709|Biological|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
165564|NCT02906696|Drug|Bosutinib|Given PO
165565|NCT02906696|Other|Laboratory Biomarker Analysis|Correlative studies
165566|NCT02906683|Drug|TAS-303|Oral administration for 8 weeks, once daily.
165567|NCT02906683|Drug|Placebo|Oral administration for 8 weeks, once daily.
165568|NCT02906670|Drug|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
165569|NCT02906657|Other|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
165570|NCT02906644|Drug|lorcaserin|
165571|NCT02906644|Drug|nicotine patch|
165572|NCT02906644|Drug|placebo lorcaserin|
165573|NCT02906618|Drug|LY3039478|Administered orally
165574|NCT02906618|Drug|3C 15N 2H-LY3039478 IV|Administered IV
165575|NCT02906605|Drug|JNJ-809|JNJ-809 (1*10^9) colony forming units (CFU) given as an infusion.
165576|NCT02906605|Drug|Apalutamide|Apalutamide 240 mg orally daily.
165577|NCT02906579|Drug|Matching Placebo|
165578|NCT02906579|Drug|IW-1973|
165579|NCT02906566|Drug|Retinol|Retinol in the form of vitamin A lotion
165580|NCT02906566|Drug|Placebo|Placebo of Retinol
165581|NCT02906553|Drug|Glyceryl Trinitrate|
165582|NCT02906553|Drug|Placebo|
165583|NCT02906540|Procedure|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
165584|NCT02906540|Procedure|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
165585|NCT02906527|Drug|Non-exposed group|Non-exposed group / Patients receiving VKA
165586|NCT02906527|Drug|Exposed group|Exposed group / Patients receiving DOAC
165587|NCT02906514|Drug|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
165588|NCT02906514|Drug|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
165589|NCT02906501|Procedure|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
165590|NCT02906501|Procedure|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
165591|NCT02906475|Other|standardized skin care regimen|"Application of a standardized daily skin care regimen:~milk lotion once daily and~application of addendum for bathing as needed"
165592|NCT02906462|Other|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
165593|NCT02906462|Other|Usual practices|the centres applies their usual practices
165594|NCT02906449|Behavioral|Meditation Technique|Alertness training or relaxation training
165595|NCT02906436|Device|Xvivo Chamber|
165596|NCT02906423|Other|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
165597|NCT02906410|Other|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
165598|NCT02906410|Other|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
165599|NCT02906397|Drug|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
165751|NCT02905266|Biological|Ipilimumab|-Specified dose on specified days
165600|NCT02906397|Radiation|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
165601|NCT02906384|Radiation|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
165602|NCT02906371|Drug|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
165603|NCT02906371|Drug|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (~ Day -5 to -1) will follow the standard CRS Rx algorithm
165604|NCT02906371|Biological|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of ~1.5 x107 - 5 x109 (~3x105 - 1x108/kg) T cells.
165605|NCT02906358|Behavioral|Community-based pain self-management|
165606|NCT02906358|Behavioral|Clinic-based pain self-management|
165607|NCT02906345|Device|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
165608|NCT02906332|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
165609|NCT02906332|Drug|Lenalidomide|Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.
165610|NCT02906332|Drug|Dexamethasone|Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
165611|NCT02906306|Behavioral|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
165612|NCT02906306|Behavioral|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
165613|NCT02906293|Other|Abdominal acoustic measurement|"On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal."
165614|NCT02906280|Device|EBUS-TBNA needle|tissue sampling
165615|NCT02906267|Other|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
165616|NCT02906254|Other|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
165617|NCT02906254|Other|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
165618|NCT02906241|Behavioral|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
165619|NCT02906241|Behavioral|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
165620|NCT02906228|Radiation|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
165621|NCT02906215|Behavioral|Care Coordination Intervention|cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
165622|NCT02906202|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
165623|NCT02906189|Radiation|MRI|
165624|NCT02906176|Drug|Vfend (voriconazole) intravenous infusion|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
165625|NCT02906176|Drug|Vfend (voriconazole) tablet|Vfend (voriconazole) 200 mg tablet once
165626|NCT02906163|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
165627|NCT02906163|Drug|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
165628|NCT02906150|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
165629|NCT02906150|Drug|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
165630|NCT02906137|Other|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
165631|NCT02906111|Drug|estriol|"Study Group, treated with estriol~Control Group, no drug treatment~Both groups will undergo vaginal surgery for prolapse"
165632|NCT02906111|Procedure|vaginal surgery|Control Group
165633|NCT02906098|Behavioral|Patient centered oral health education|Procedure: The theory-based educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
165634|NCT02906098|Behavioral|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
165635|NCT02906085|Drug|Endothelin-1|
165636|NCT02906085|Drug|Placebo|Isotonic saline
165637|NCT02906072|Behavioral|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
165752|NCT02905253|Drug|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
165638|NCT02906072|Behavioral|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
165639|NCT02906059|Drug|AZD1775|
165640|NCT02906059|Drug|Irinotecan|
165641|NCT02906046|Device|Weight in Lower Limbs|
165642|NCT02906033|Other|New perioperative practice model|The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
165643|NCT02906020|Drug|GZ/SAR402671|Pharmaceutical form:capsule Route of administration: oral
165644|NCT02906020|Drug|Placebo|Pharmaceutical form:capsule Route of administration: oral
165645|NCT02906007|Drug|Bedaquiline|"100 mg oral tablets.~Doses will vary based on the participant's age and weight."
165646|NCT02905994|Drug|Volasertib|Polo-Like Kinase Inhibitor
165647|NCT02905994|Drug|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
165648|NCT02905994|Drug|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
165649|NCT02905994|Procedure|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
165650|NCT02905981|Drug|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
165651|NCT02905981|Drug|Shohl's solution|Shohl's solution will be supplied as 500-mL bottles containing citric acid USP 640 mg/5 mL and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
165652|NCT02905981|Drug|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
165653|NCT02905968|Device|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
165654|NCT02905955|Device|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
165655|NCT02905942|Drug|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
165656|NCT02905942|Drug|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
165657|NCT02905929|Device|ActivPAL inclinometer|Participants will wear a thigh-worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. The device will monitor their sitting and standing time.
165658|NCT02905929|Behavioral|Phone counseling call: Breaking up sitting time|Participants will receive 5 counseling phone calls to check-in on goal setting, strategies, and tools.
165659|NCT02905929|Behavioral|In-person counseling: Breaking up sitting time|Participants will receive 3 in-person health education sessions. At these sessions participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. Participants will also develop action plans, check-in on goal setting, and use of tools at these sessions.
165660|NCT02905929|Behavioral|Phone counseling call: Healthy living|Participants will receive a healthy living educational intervention over the phone, developed and tested by the investigators in previous studies. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
165661|NCT02905929|Other|Tools to prompt standing|Investigators will provide standing desks to participants who spend time sitting at a computer. Additional tools to help prompt standing are mechanical and electronic timers set to interrupt long periods of sitting and cues in the environment such as standing during commercial breaks and phone calls.
165662|NCT02905929|Behavioral|In-person counseling: Healthy living|Control subjects will receive one in-person counseling session about healthy living. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
165663|NCT02905916|Drug|PEG-rhG-CSF|
165664|NCT02905903|Drug|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
165665|NCT02905890|Drug|Norethisterone enantate|Noristerat® 200mg, solution for intramuscular injection given every 8 weeks
165666|NCT02905890|Device|Condoms|Latex male condoms
165667|NCT02905877|Other|Behavioural study|reaching studies and other behavioural studies.
165668|NCT02905864|Drug|Liraglutide 3 mg (Saxenda)|
165669|NCT02905864|Drug|Liraglutide 3 mg placebo|
165670|NCT02905851|Other|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
165671|NCT02905851|Other|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
165672|NCT02905838|Device|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
165673|NCT02905838|Device|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).~All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
165674|NCT02905825|Device|BreathID® Hp System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
165675|NCT02905825|Drug|BreathID® Hp Lab System|Breath will be analyzed for change in carbon 13 content in breath after ingestion of carbon 13 enriched urea
165676|NCT02905825|Diagnostic Test|Stool Test|Each subject was asked to perform a stool test in parallel to the breath test.
165753|NCT02905253|Drug|Placebo|Placebo capsules matching AC-084 capsules
165677|NCT02905812|Other|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
165678|NCT02905799|Drug|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
165679|NCT02905799|Drug|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
165680|NCT02905786|Device|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
165681|NCT02905786|Other|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
165682|NCT02905786|Other|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
165683|NCT02905773|Other|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
165684|NCT02905773|Other|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
165685|NCT02905760|Drug|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
165686|NCT02905760|Drug|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
165687|NCT02905760|Drug|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
165688|NCT02905760|Drug|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
165689|NCT02905747|Behavioral|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
165690|NCT02905734|Drug|Nicotine patch|Single administration of an active treatment (nicotine patch)
165691|NCT02905734|Other|placebo patch|Single administration of a placebo treatment
165692|NCT02905721|Procedure|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
165693|NCT02905708|Device|Air-Activated heating packs|The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
165694|NCT02905708|Device|Forced Air Warming Device|forced air-warming inflatable device applied according to standard hospital protocol.
165695|NCT02905695|Drug|Chirocaine|
165696|NCT02905695|Other|Placebo|
165697|NCT02905682|Drug|Desmopressin|
165698|NCT02905682|Drug|Placebo|
165699|NCT02905669|Device|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
165700|NCT02905656|Behavioral|Brief Advice|Psychoeducation
165701|NCT02905656|Behavioral|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
165702|NCT02905656|Behavioral|Rate Reduction|Reducing the number of cigarettes consumed.
165703|NCT02905656|Drug|Pharmacological|Nicotine Replacement Therapy in the form of gum.
165704|NCT02905656|Behavioral|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
165705|NCT02905643|Other|Study subjects|This study does not include an intervention it is only observational.
165706|NCT02905630|Other|Exercise training|high intensity aerobic interval training
165707|NCT02905604|Device|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
165708|NCT02905604|Device|dmPFC Sham iTBS|Sham iTBS
165709|NCT02905591|Drug|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
165710|NCT02905591|Drug|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered~the dose is 45 mg/m2 (standard dose)~Administered weekly~6 to 7 weeks of therapy, depending on when radiation starts~Standardized dose reductions are used"
165711|NCT02905591|Drug|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.~Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)~Administered weekly~6 to 7 weeks of therapy, depending on when radiation starts~Standard dose reductions are used"
165712|NCT02905591|Drug|Ascorbic Acid|"Administered intravenously~75 grams per infusion; each infusion is about 2 hours~3 infusion per calendar week~The infusion is actively running for at least 20 minutes when radiation begins~May be given while chemotherapy is delayed due to low counts~Dose reductions are not used~Given for 6 to 7 weeks, depending on when radiation starts"
165713|NCT02905578|Drug|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate~given for 3 weeks out of the 4 week cycle~standard dose reductions are used~up to 2 cycles are administered before standard of care CT scan~decision to continue therapy is based disease response to therapy as measured from the CT scan~treatment continues until disease progression is identified"
165714|NCT02905578|Drug|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate~given for 3 weeks out of the 4 week cycle~standard dose reductions are used~up to 2 cycles are administered before standard of care CT scan~decision to continue therapy is based disease response to therapy as measured from the CT scan~treatment continues until disease progression is identified"
165715|NCT02905578|Drug|Pharmacological ascorbate|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine~given 3 times weekly~given for 4 weeks out of the 4 week cycle~no dose reductions are used~up to 2 cycles are administered before standard of care CT scan~decision to continue therapy is based disease response to therapy as measured from the CT scan~treatment continues until disease progression is identified"
165716|NCT02905565|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
165717|NCT02905565|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
165718|NCT02905552|Other|No intervention|
165719|NCT02905539|Drug|Iron Isomaltoside 1000|
165720|NCT02905539|Drug|Ferric Carboxymaltose|
165721|NCT02905526|Behavioral|Contraceptive instant messages|Contraceptive Instant messages
165722|NCT02905526|Other|Mobile phone app|Mobile phone app
165723|NCT02905513|Behavioral|Contraceptive app instant messages|
165724|NCT02905513|Other|Mobile phone app|
165725|NCT02905474|Other|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
165726|NCT02905474|Device|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
165727|NCT02905474|Device|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
165728|NCT02905461|Behavioral|Contraceptive text messages|
165729|NCT02905461|Other|Text messages not about contraception|
165730|NCT02905448|Other|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.~Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.~Herbal beverage two times daily. Dietary fiber supplements is taken three times daily (10-36w) and more high fat whole plant-based foods (avocado, tofu, seeds) Conventional food intake is taken ad libitum and no calorie counts or restrictions will be applied.~From 10 to 36 weeks we added vitamin B12 and EPA+DHA fatty acid"
165731|NCT02905435|Device|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as BTM Dressing) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
165732|NCT02905422|Behavioral|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
165733|NCT02905409|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
165734|NCT02905396|Device|Spinal cord stimulation|implantation of spinal cord stimulator
165735|NCT02905383|Other|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
165736|NCT02905370|Behavioral|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
165737|NCT02905370|Behavioral|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education."
165738|NCT02905357|Device|OCT|Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
165739|NCT02905357|Other|CMR|Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
165740|NCT02905331|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
165741|NCT02905331|Drug|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
165742|NCT02905318|Drug|Palbociclib|125 mg orally on days 1-21 each 28 day cycle
165743|NCT02905305|Device|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
165744|NCT02905305|Device|Contour Advance electrode|Standard Contour Advance electrode
165745|NCT02905292|Other|evaluation and treatment maneuver for BPPV|
165746|NCT02905279|Behavioral|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
165747|NCT02905279|Behavioral|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
165748|NCT02905279|Behavioral|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
165749|NCT02905279|Behavioral|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
165750|NCT02905266|Biological|Nivolumab|-Specified dose on specified days
165756|NCT02905227|Drug|CVT-427 (zolmitriptan inhalation powder)|Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.
165757|NCT02905214|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
165758|NCT02905188|Genetic|GLYCAR T cells|"Five different dosing schedules will be evaluated. Three to six patients will be evaluated on each dosing schedule.~The following dose levels will be evaluated:~DL1: 1x10^7/m2~DL2: 3x10^7/m2~DL3: 1x10^8/m2~DL4: 3x10^8/m2~DL5: 1x10^9/m2~If DLTs are observed on DL1, patients will be enrolled on DL0 at 3x10^6/m2 dose.~The first patient on each dose level has to be 14 days post T-cell infusion before the second patient can be enrolled.~The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
165759|NCT02905188|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
165760|NCT02905188|Drug|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
165761|NCT02905175|Procedure|blood sample|
165762|NCT02905175|Procedure|synovial tissue|synoviocytes from synovial tissue
165763|NCT02905162|Other|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
165764|NCT02905149|Procedure|Serrato|Serratus plane block.
165765|NCT02905149|Procedure|Control|Standard anesthesia
165766|NCT02905136|Other|Fundamental research|serum, whole blood, cerebrospinal fluid
165767|NCT02905123|Behavioral|Check Your Drinking|
165768|NCT02905110|Drug|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
165769|NCT02905110|Drug|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
165770|NCT02905110|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
165771|NCT02905097|Procedure|Knee Replacement|Surgical replacement of arthritic knee with an implant
165772|NCT02905071|Other|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
165773|NCT02905071|Other|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
165774|NCT02905071|Other|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
165775|NCT02905058|Drug|Ketoprofen|oral non-steroidal antiinflammatory drug
165776|NCT02905058|Drug|placebo|
165777|NCT02905045|Drug|Ketoprofen|
165778|NCT02905045|Drug|placebo|
165779|NCT02905032|Behavioral|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
165780|NCT02905019|Biological|R21 with Matrix-M1|Vaccine
165781|NCT02905019|Biological|ChAd63 ME-TRAP|Vaccine
165782|NCT02905019|Biological|MVA ME-TRAP|Vaccine
165783|NCT02905006|Drug|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab.
165784|NCT02905006|Other|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
165785|NCT02904993|Other|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
165786|NCT02904993|Other|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
165787|NCT02904980|Behavioral|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
165788|NCT02904980|Behavioral|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
165789|NCT02904967|Biological|Extra Blood Draw|
165790|NCT02904954|Drug|Durvalumab|Intravenously
165791|NCT02904954|Other|Durvalumab plus SBRT|Intravenously
165792|NCT02904941|Biological|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
165793|NCT02904941|Device|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
165794|NCT02904941|Procedure|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
165795|NCT02904915|Drug|Lidocaine|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
165796|NCT02904915|Other|No analgesia|IUD placement without analgesia.
165797|NCT02904915|Device|Intrauterine device (IUD)|IUD placement with or without paracervical block with 1% lidocaine.
165798|NCT02904902|Drug|adalimumab|Subcutaneous Injection
165799|NCT02904889|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
165800|NCT02904889|Other|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
165873|NCT02904148|Procedure|Shoulder mobilisation|early shoulder mobilisation
166047|NCT02902770|Drug|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
165801|NCT02904876|Radiation|Diffusion Magnetic Resonance Imaging at 6 months|2-year follow-up MRI of patients initiating treatment with Tysabri with anti-JCV antibody positive or negative. Patients enrolled will benefit from diffusion MRI at 6 months, in addition to conventional MRI.
165802|NCT02904863|Biological|Extra blood draw samples|
165803|NCT02904850|Biological|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
165804|NCT02904837|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
165805|NCT02904837|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
165806|NCT02904824|Biological|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
165807|NCT02904824|Biological|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
165808|NCT02904811|Other|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
165809|NCT02904811|Other|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
165810|NCT02904798|Drug|Polypodium Leucotomos|- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
165811|NCT02904785|Device|Extracorporeal Shock Waves|
165812|NCT02904785|Device|Sham Extracorporeal Shock Waves|
165813|NCT02904785|Other|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
165814|NCT02904772|Drug|alipogene tiparvovec|A dose of 1x10(*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
165815|NCT02904772|Drug|Prednisolone|IV bolus methylprednisolone 1mg/kg half hour prior to administration
165816|NCT02904772|Drug|Cyclosporins|Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
165817|NCT02904772|Drug|Mycophenolate mofetil|Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
165818|NCT02904759|Drug|Desmopressin|
165819|NCT02904759|Drug|Placebo|
165820|NCT02904746|Behavioral|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
165821|NCT02904733|Other|mHealth platform|Use of a mHealth platform to inform and empower patient of hies/her own health
165822|NCT02904707|Other|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
165823|NCT02904681|Other|No intervention. Observational and descriptive study|
165824|NCT02904668|Other|self-managmeent program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (…), which were complemented by a problem-based session.
165825|NCT02904655|Other|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
165826|NCT02904642|Behavioral|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
165827|NCT02904642|Behavioral|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
165828|NCT02904629|Behavioral|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
165829|NCT02904629|Other|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
165830|NCT02904616|Device|mobile spectrofluorimeter|
166048|NCT02902770|Drug|Normal Saline Push|Normal Saline Push Placebo
166049|NCT02902757|Procedure|Computed Tomography|Undergo FDG PET/CT
165831|NCT02904577|Other|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
165832|NCT02904564|Drug|MMP with 5-FU|MMP with 5-FU using tattoo device
165833|NCT02904564|Drug|MMP with Saline infusion|MMP with saline infusion using tattoo device
165834|NCT02904551|Procedure|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
165835|NCT02904551|Procedure|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
165836|NCT02904538|Drug|Dexamethasone|
165837|NCT02904538|Drug|isotonic saline|
165838|NCT02904525|Device|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
165839|NCT02904512|Device|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
165840|NCT02904512|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
165841|NCT02904499|Drug|Dabigatran|
165842|NCT02904486|Behavioral|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
165843|NCT02904473|Other|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
165844|NCT02904447|Other|x-ray and pedobar foot pressure mapping|
165845|NCT02904434|Other|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
165846|NCT02904408|Behavioral|psychotherapy|Group psychotherapy
165847|NCT02904395|Other|observational (no intervention)|
165848|NCT02904369|Drug|Emtricitabine|
165849|NCT02904369|Drug|Tenofovir alafenamide|
165850|NCT02904369|Drug|Tenofovir disoproxil|
165851|NCT02904356|Device|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
165852|NCT02904343|Device|domestic hemodialysis machine|WEGO, DBB-27C
165853|NCT02904343|Device|imported hemodialysis machine|Fresenius, 4008s
165854|NCT02904330|Drug|K1-70 intramuscular or K1-70 intravenous|Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
165855|NCT02904304|Drug|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
165856|NCT02904304|Drug|Placebo|01 tablet, orally, every 12 hours.
165857|NCT02904291|Drug|Amlodipine|Patients are tested for their normal prescription amlodipine medication
165858|NCT02904278|Other|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
165859|NCT02904278|Other|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
165860|NCT02904265|Drug|Diazepam|
165861|NCT02904265|Drug|Acetazolamide|
165862|NCT02904252|Other|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F>2).
165863|NCT02904226|Drug|JTX-2011|Specified dose on specified days
165864|NCT02904226|Drug|Nivolumab|Specified dose on specified days
165865|NCT02904226|Drug|Ipilimumab|Specified dose on specified days
165866|NCT02904226|Drug|Pembrolizumab|Specified dose on specified days
165867|NCT02904213|Biological|ComBe Five (Liquid)|
165868|NCT02904200|Device|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
165869|NCT02904200|Device|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
165870|NCT02904187|Other|Positron Emission Tomography (PET)|
165871|NCT02904187|Other|Electroencephalogram (EEG)|
165872|NCT02904174|Behavioral|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question & answer session were included in the group education.
165874|NCT02904122|Other|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
165875|NCT02904109|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
165876|NCT02904109|Drug|Placebo|Once daily oral administration of placebo mannitol for 8 days.
165877|NCT02904096|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
165878|NCT02904083|Behavioral|self assessment of adherence|
165879|NCT02904070|Device|Vaginal swabbing|
165880|NCT02904057|Device|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
165881|NCT02904031|Drug|5-fluorouracil|
165882|NCT02904031|Drug|oxaliplatin|
165883|NCT02904031|Drug|l-leucovorin|
165884|NCT02904031|Drug|panitumumab|
165885|NCT02904018|Other|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
165886|NCT02904005|Other|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.~At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
165887|NCT02903992|Radiation|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
165888|NCT02903979|Other|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
165889|NCT02903979|Other|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
165890|NCT02903966|Drug|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
165891|NCT02903966|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
165892|NCT02903940|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
165893|NCT02903927|Device|Implantation of CT LUCIA IOL|
165894|NCT02903927|Device|Implantation of Acrysof IQ SN60WF IOL|
165895|NCT02903914|Drug|INCB001158|Arginase Inhibitor
165896|NCT02903914|Drug|Pembrolizumab|PD-1 Inhibitor
165897|NCT02903901|Drug|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
165898|NCT02903901|Drug|Placebo|10 mg liquid placebo at 7 pm for 1 week
165899|NCT02903888|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
165900|NCT02903875|Other|Patient therapeutic education (PTE) programme|
165901|NCT02903862|Behavioral|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support & assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
165902|NCT02903862|Device|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
165903|NCT02903849|Behavioral|Drafting Motivational Messages|Write down three motivating messages
165904|NCT02903849|Behavioral|Control Reminders|Receive standard reminders at three points during the challenge
165905|NCT02903849|Behavioral|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
165906|NCT02903836|Drug|Nafithromycin 800 mg 3 days|
165907|NCT02903836|Drug|Nafithromycin 800 mg 5 days|
165908|NCT02903836|Drug|Moxifloxacin 400 mg|
165909|NCT02903823|Drug|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
165910|NCT02903810|Biological|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
165911|NCT02903784|Device|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
165912|NCT02903784|Procedure|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
165913|NCT02903784|Other|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
165950|NCT02903433|Behavioral|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
165951|NCT02903433|Behavioral|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
165914|NCT02903771|Drug|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.~Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
165915|NCT02903771|Drug|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
165916|NCT02903758|Other|cross sectional|
165917|NCT02903745|Other|observational|
165918|NCT02903732|Other|observational|registry
165919|NCT02903719|Drug|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
165920|NCT02903706|Other|Measure of Plasmodium prevalence (PCR)|
165921|NCT02903693|Other|cross sectional|
165922|NCT02903680|Drug|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
165923|NCT02903680|Drug|Placebo group|Normal Saline 0,9% same volume
165924|NCT02903667|Device|Bone grafting|
165925|NCT02903654|Other|observational|
165926|NCT02903641|Behavioral|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
165927|NCT02903641|Behavioral|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
165928|NCT02903628|Behavioral|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
165929|NCT02903615|Other|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
165930|NCT02903615|Other|Standard diet|Standard diabetes diet recommendations
165931|NCT02903602|Behavioral|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
165932|NCT02903602|Behavioral|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
165933|NCT02903589|Other|observational|
165934|NCT02903576|Procedure|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
165935|NCT02903576|Procedure|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
165936|NCT02903563|Other|observational|
165937|NCT02903537|Drug|Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Intranodal administration
165938|NCT02903537|Drug|Interferon-beta|Subcutaneous administration interferon-beta
165939|NCT02903524|Drug|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
165940|NCT02903524|Drug|pirarubicin and cyclophosphamide|
165941|NCT02903511|Drug|Metformin|Monitoring of safety and tolerability
165942|NCT02903511|Drug|Placebo|Monitoring of safety and tolerability
165943|NCT02903498|Drug|UFT|UFT 360mg/m2 qd po d1-14, q3w
165944|NCT02903485|Other|nurses perform presurgical assessement and surveillance during surgery|
165945|NCT02903485|Other|the anesthetic team performs presurgical assessement and surveillance during surgery|
165946|NCT02903459|Other|Transversal Study so there is no intervention|
165947|NCT02903446|Drug|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
165948|NCT02903433|Other|High-intake avocados|Families will receive 14 avocados on a weekly basis.
165949|NCT02903433|Other|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
166050|NCT02902757|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
165952|NCT02903420|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
165953|NCT02903407|Drug|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
165954|NCT02903407|Drug|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
165955|NCT02903407|Drug|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
165956|NCT02903394|Device|mLCI Device|imaging of cervical epithelium using mLCI device
165957|NCT02903381|Drug|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
165958|NCT02903381|Drug|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
165959|NCT02903381|Drug|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
165960|NCT02903368|Drug|Apalutamide|Apalutamide is administered orally once daily up
165961|NCT02903368|Drug|Leuprolide|Leuprolide is administered via injection every 3 months.
165962|NCT02903368|Drug|Prednisone|"Prednisone is administered orally once daily for patients on Abiraterone Acetate Only.~Prednisone is administered orally twice daily for patients on Apalutamide and Abiraterone. Acetate."
165963|NCT02903368|Drug|Abiraterone Acetate|Orally once daily predetermined dose
165964|NCT02903368|Procedure|Radical Prostatectomy|Surgery
165965|NCT02903368|Other|Observation-Post RP|No adjuvant therapy
165966|NCT02903355|Drug|D-methionine|D-methionine, oral liquid suspension
165967|NCT02903355|Drug|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
165968|NCT02903342|Other|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
165969|NCT02903329|Other|Detoxification|Two ways of composing the detoxification protocol
165970|NCT02903316|Procedure|Fluids|
165971|NCT02903303|Other|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :~1st session : contact with the therapist, body scan, basic suggestions~2nd session : hypnosis induction followed by suggestions tu build a safe place~3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)~4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
165972|NCT02903290|Other|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|
165973|NCT02903290|Other|walking track GAITRite,manual dynamometer, and treadmill|
165974|NCT02903264|Other|Gestational diabetes mellitus|
165975|NCT02903251|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
165976|NCT02903251|Other|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
165977|NCT02903238|Drug|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
165978|NCT02903238|Drug|Placebo Oral Tablet|Lactose capsule
165979|NCT02903225|Behavioral|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
165980|NCT02903212|Biological|Autologous apoptotic cells injection|cells injection
165981|NCT02903199|Dietary Supplement|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
165982|NCT02903199|Dietary Supplement|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
165983|NCT02903199|Dietary Supplement|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
165984|NCT02903186|Behavioral|SMS|This is an intervention using short mobile messages (SMS)
165985|NCT02903160|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg PO daily
165986|NCT02903160|Drug|Prednisone|5 mg PO twice a day
165987|NCT02903160|Drug|Radium-223 dichloride|50 kBq/kg IV monthly
165988|NCT02903160|Drug|cabazitaxel|25 mg/m2 IV every 3 weeks
165989|NCT02903160|Drug|Carboplatin|Carboplatin AUC 4 IV every 3 weeks
165990|NCT02903160|Drug|Enzalutamide|160 mg PO daily
165991|NCT02903147|Behavioral|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
165992|NCT02903147|Behavioral|The employer's training|
165993|NCT02903121|Drug|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
165994|NCT02903121|Drug|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
165995|NCT02903121|Drug|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
165996|NCT02903108|Drug|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
165997|NCT02903108|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
165998|NCT02903095|Drug|TD-1439|
165999|NCT02903095|Drug|Placebo|
166000|NCT02903082|Biological|Residue of blood further to NFS|
166001|NCT02903082|Biological|Residue of blood further to preoperative workup|
166002|NCT02903082|Biological|Bone marrow collected during a myelogram carried out for hematological pathology workup|
166003|NCT02903082|Biological|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
167800|NCT02888925|Other|Memorizing and recognition of new faces test|
166004|NCT02903069|Drug|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.~MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.~IV hydration will be given prior to the MRZ infusion."
166005|NCT02903069|Drug|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.~TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
166006|NCT02903069|Radiation|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
166007|NCT02903069|Device|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
166008|NCT02903056|Other|Rett Syndrome|Diagnosis of Rett Syndrome
166009|NCT02903030|Drug|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
166010|NCT02903030|Drug|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
166011|NCT02903017|Drug|Tranexamic acid 5%|Via nasogastric tube, 100 mL
166012|NCT02903017|Drug|Placebo|Via nasogastric tube, 100 mL
166013|NCT02903004|Drug|Trabectedin|
166014|NCT02903004|Drug|Pegylated Liposomal Doxorubicin|
166015|NCT02903004|Drug|Topotecan|
166016|NCT02903004|Drug|Gemcitabine|
166017|NCT02903004|Drug|Weekly Paclitaxel|
166018|NCT02903004|Drug|Carboplatin|
166019|NCT02902978|Drug|E6130|
166020|NCT02902978|Drug|Placebo|E6130 matched placebo
166021|NCT02902965|Drug|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
166022|NCT02902965|Drug|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
166023|NCT02902965|Drug|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects >75 years of age."
166024|NCT02902952|Behavioral|Physical Exercise|An eight week physical exercise intervention
166025|NCT02902952|Behavioral|Control Intervention|An eight week sedentary control intervention
166026|NCT02902939|Device|minimal extracorporeal circulation (MEC)|We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
166027|NCT02902939|Procedure|The cytokines modulations|We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
166028|NCT02902926|Behavioral|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
166029|NCT02902926|Behavioral|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
166030|NCT02902913|Other|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
166031|NCT02902913|Other|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
166032|NCT02902913|Other|D2i0|No oleocanthal and no oleacein
166033|NCT02902913|Drug|Ibuprofen|400 mg of Ibuprofen
166034|NCT02902887|Device|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
166035|NCT02902874|Other|Blood sample|
166036|NCT02902861|Drug|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
166037|NCT02902861|Drug|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
166038|NCT02902835|Behavioral|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
166039|NCT02902835|Behavioral|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
166040|NCT02902822|Procedure|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:~bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~fungal skin infections (tinea corporis, cruris, pedis);~pigmented tumors (melanoma);~non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
166041|NCT02902822|Device|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:~bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);~fungal skin infections (tinea corporis, cruris, pedis);~pigmented tumors (melanoma);~non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).~A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
166042|NCT02902809|Biological|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
166043|NCT02902796|Device|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
166044|NCT02902783|Other|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
166045|NCT02902770|Drug|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
166046|NCT02902770|Drug|Ketorolac Tromethamine|IV ketorolac 30mg push
166051|NCT02902757|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
166052|NCT02902744|Drug|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
166053|NCT02902731|Drug|PLACEBO|
166054|NCT02902731|Drug|ANAKINRA|
166055|NCT02902718|Device|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
166056|NCT02902705|Other|Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)|The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
166057|NCT02902692|Other|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
166058|NCT02902679|Drug|BMS-986177|
166059|NCT02902666|Drug|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
166060|NCT02902666|Drug|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
166061|NCT02902653|Drug|Oral misoprostol|hourly titrated misoprostol
166062|NCT02902653|Drug|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
166063|NCT02902653|Drug|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
166064|NCT02902640|Drug|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
166065|NCT02902640|Drug|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
166066|NCT02902640|Drug|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
166067|NCT02902627|Device|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
166068|NCT02902614|Procedure|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
166069|NCT02902614|Procedure|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
166070|NCT02902601|Drug|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
166071|NCT02902601|Drug|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
166072|NCT02902601|Other|Placebo|Matching placebo to JNJ-54175446
166073|NCT02902588|Other|ICG-PULSION|Intravenous administration of indocyanine green
166074|NCT02902588|Device|LiMON, Pulsion Medical Systems|Application of near infrared light
166075|NCT02902588|Other|Gadolinium (Gadovist, Bayer, Germany)|Injection of gadolinium
166076|NCT02902575|Procedure|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
166077|NCT02902562|Procedure|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
166078|NCT02902562|Procedure|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
166079|NCT02902536|Other|No interventions|
166080|NCT02902523|Drug|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
166081|NCT02902523|Drug|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
166082|NCT02902510|Other|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
166083|NCT02902484|Drug|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
166084|NCT02902471|Other|Forced oscillations measure|
166085|NCT02902458|Other|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
166086|NCT02902445|Biological|rotavirus rapid screen test|According to routine care
166087|NCT02902445|Genetic|polymorphism exploration|from an oral swab collected after parents consent
166088|NCT02902432|Drug|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
166089|NCT02902419|Other|Wound dressing removal.|
166090|NCT02902393|Biological|Thromboelastography|
166091|NCT02902380|Drug|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
166092|NCT02902380|Drug|control group|0.9% saline infusion
166140|NCT02902042|Drug|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
166141|NCT02902042|Drug|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
166142|NCT02902042|Drug|Pembrolizumab alone|200 mg q3w
166093|NCT02902367|Other|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
166094|NCT02902367|Other|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
166095|NCT02902354|Other|Nifedipine for tocolysis|observational
166096|NCT02902341|Dietary Supplement|Nutrition Therapy|Nutrition based on measured caloric needs.
166097|NCT02902341|Dietary Supplement|Control|Standard protocol nutrition based on calculated caloric needs.
166098|NCT02902315|Other|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
166099|NCT02902315|Other|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
166100|NCT02902315|Other|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
166101|NCT02902315|Other|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
166102|NCT02902302|Drug|Ibuprofen 400 mg/10 mL oral suspension|
166103|NCT02902302|Drug|MOMENT 400 mg coated tablet|
166104|NCT02902289|Drug|Ibuprofen 200 mg/5 mL oral suspension|
166105|NCT02902289|Drug|MOMENT 200 mg coated tablet|
166106|NCT02902276|Other|additional blood sample|Two blood samples will be taken at ICU admission
166107|NCT02902250|Procedure|Decompression|vertebral body decompression in compression fracture
166108|NCT02902250|Procedure|vertebroplasty|vertebroplasty in vertebral compression fracture
166109|NCT02902237|Biological|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
166110|NCT02902224|Dietary Supplement|Tap water|300ml tap water via nasogastric tube
166111|NCT02902224|Dietary Supplement|Glucose|300ml tap water with 75g glucose via nasogastric tube
166112|NCT02902224|Dietary Supplement|Fructose|300ml tap water with 25g fructose via nasogastric tube
166113|NCT02902211|Device|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
166114|NCT02902211|Other|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
166115|NCT02902198|Dietary Supplement|Placebo|Tap water 200ml
166116|NCT02902198|Dietary Supplement|Glucose|25g Glucose in 200ml tap water
166117|NCT02902198|Dietary Supplement|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
166118|NCT02902198|Dietary Supplement|Quinine|17mg quinine in 200ml tap water
166119|NCT02902185|Drug|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
166120|NCT02902185|Drug|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
166121|NCT02902172|Drug|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
166122|NCT02902172|Drug|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
166123|NCT02902159|Other|BWW Online Peer Support|Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
166124|NCT02902159|Other|NHS Moodzone Online Information|Directed to access to online information from NHS Moodzone
166125|NCT02902146|Device|Bougie|
166126|NCT02902146|Device|Endotracheal tube|
166127|NCT02902133|Drug|Acetazolamide|Acetazolamide 500 mg twice per day for 5 days
166128|NCT02902120|Drug|Post-transplant Grazoprevir and Elbasvir|Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
166129|NCT02902107|Device|CivaSheet|
166130|NCT02902107|Radiation|Brachytherapy|
166131|NCT02902107|Procedure|surgical resection|
166132|NCT02902094|Device|Drug eluting balloons|
166133|NCT02902094|Device|Non drug eluting balloons|
166134|NCT02902081|Drug|Cannabidiol|
166135|NCT02902081|Drug|Placebo|
166136|NCT02902068|Device|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
166137|NCT02902055|Drug|Neuromuscular Blocking Agents|Neuromuscular blockae
166138|NCT02902055|Drug|Isotonic saline|Placebo
166139|NCT02902042|Drug|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
261942|NCT02203643|Drug|Dexamethasone|
166143|NCT02902029|Drug|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
166144|NCT02902029|Drug|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
166145|NCT02902029|Drug|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
166146|NCT02902016|Drug|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
166147|NCT02902003|Behavioral|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
166148|NCT02901977|Drug|Ramipril|Antihypertensive therapy
166149|NCT02901977|Drug|Doxazosin|Antihypertensive therapy
166150|NCT02901964|Other|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
166151|NCT02901964|Other|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
166152|NCT02901951|Biological|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B vaccine in the deltoid region of the non-dominant arm.
166153|NCT02901938|Procedure|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
166154|NCT02901938|Device|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
166155|NCT02901925|Drug|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
166156|NCT02901899|Drug|Guadecitabine|Given SC
166157|NCT02901899|Other|Laboratory Biomarker Analysis|Correlative studies
166158|NCT02901899|Biological|Pembrolizumab|Given IV
166159|NCT02901886|Behavioral|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
166160|NCT02901873|Device|Electrical Impedance Spectroscopy|
166161|NCT02901860|Other|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
166162|NCT02901847|Other|PAD tailored care|PAD tailored care
166163|NCT02901821|Genetic|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
166164|NCT02901782|Procedure|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
166165|NCT02901769|Other|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
166166|NCT02901756|Dietary Supplement|Antemig|Participants were instructed to take one tablet every morning for three months.
166167|NCT02901743|Other|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
166168|NCT02901730|Procedure|532nm laser group|LPI with 532nm laser.
166169|NCT02901730|Procedure|561nm laser group|LPI with 561nm laser.
166170|NCT02901717|Drug|Mino-Lok|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
166171|NCT02901717|Drug|Antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
166172|NCT02901704|Device|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
262344|NCT02200822|Drug|beta blockers|
166173|NCT02901704|Procedure|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
166174|NCT02901691|Other|musical rhythmic stimulation|
166175|NCT02901678|Device|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
166176|NCT02901665|Other|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
166177|NCT02901652|Device|noninvasive respiratory support devices|
166178|NCT02901639|Other|counseling|
166179|NCT02901626|Device|Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:~Pessary Size Upper diameter, lower diameter~Nulliparous 65 mm, 32 mm~Multiparous 70 mm, 32 mm~Alternative 70 mm, 35 mm"
166180|NCT02901613|Device|Negative-pressure wound therapy|
166181|NCT02901600|Other|Detection of the expression of DMTB1 by immunohistochemistry|
166182|NCT02901587|Drug|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
166183|NCT02901587|Drug|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
166184|NCT02901587|Drug|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
166185|NCT02901574|Device|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
166186|NCT02901574|Device|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
166187|NCT02901574|Behavioral|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
166188|NCT02901561|Drug|misoprostol 200|
166189|NCT02901561|Drug|misoprostol 400|
166190|NCT02901548|Drug|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
166191|NCT02901548|Procedure|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
166192|NCT02901535|Other|Spirometry|Spirometry in baseline
166193|NCT02901535|Other|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
166194|NCT02901535|Other|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
166195|NCT02901535|Other|Spirometry - 20 weeks|Spirometry (20 weeks)
166196|NCT02901522|Other|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
166197|NCT02901522|Other|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
166198|NCT02901522|Other|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
166199|NCT02901522|Other|Teleconsultation|The general practioner received phone call to asthma care.
166200|NCT02901496|Behavioral|Endurance Exercise Training|Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
166201|NCT02901496|Behavioral|Resistance Exercise Training|Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
166202|NCT02901496|Behavioral|No Exercise|Control to exercise
166203|NCT02901496|Drug|Tocilizumab|Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
166204|NCT02901496|Drug|Placebo|Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
166205|NCT02901483|Drug|PEP503|PEP503 will be administered by intratumoral route as slow injection
166206|NCT02901483|Drug|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 with a minimum of accumulated 200 mg/m2 during the 7~8 weeks' radiation period.
166207|NCT02901483|Radiation|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7~8 weeks.
166208|NCT02901457|Other|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
166209|NCT02901431|Drug|Placebo|Participants will receive a matching placebo orally. Approximate treatment duration will be up to 24 weeks.
166293|NCT02900781|Device|Steprite™|Steprite™ Device shoe insert monitoring device
167801|NCT02888925|Other|Memorizing and recognition of new objects test|
166210|NCT02901431|Drug|RO5285119|Participants will receive age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of balovaptan (RO5285119). Approximate treatment duration will be up to 24 weeks (up to 52 additional weeks for those enrolled in the OLE).
166211|NCT02901418|Biological|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
166212|NCT02901405|Device|Negative Pressure Wound Therapy (ActivVAC, KCI)|
166213|NCT02901405|Device|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
166214|NCT02901392|Procedure|AMS-800|Artificial urianry sphincter
166215|NCT02901392|Procedure|ADVANCE/ADVANCEXP|Male sling
166216|NCT02901392|Procedure|VIRTUE|Male sling
166217|NCT02901392|Procedure|INVANCE|Male sling
166218|NCT02901379|Drug|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
166219|NCT02901379|Drug|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
166220|NCT02901366|Drug|14C-FYU-981|14C-FYU-981, (Oral single dosing)
166221|NCT02901353|Device|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
166222|NCT02901340|Dietary Supplement|one to two liters of water daily|
166223|NCT02901327|Procedure|Lumbar Stabilisation Exercise|"McGill protocol starting with:~'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each~'curl-up' exercise 10 repetitions with 7 seconds hold each~'side-bridge' exercise 10 repetitions with 7 seconds hold each~'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
166224|NCT02901327|Procedure|treadmill walk exercise|"Bruce protocol~This include:~'5 minutes warm up' at zero degree inclination.~'20 minutes active exercise with increasing speed and inclination'~'5 minutes cool down'"
166225|NCT02901314|Other|on-demand audio messages of heart failure education themes|
166226|NCT02901301|Drug|Pembrolizumab|200mg, IV, q3weeks, Day 1
166227|NCT02901301|Drug|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
166228|NCT02901301|Drug|Capecitabine|1000mg/m2, PO, BID, Day 1-14
166229|NCT02901301|Drug|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
166230|NCT02901288|Drug|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
166231|NCT02901288|Drug|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
166232|NCT02901288|Drug|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
166233|NCT02901288|Drug|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
166234|NCT02901288|Drug|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
166235|NCT02901275|Drug|Within-subject test of blinded study medications|This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (sugar pill). This study will use a within-subject design, and all participants will serve as their own control. Study medication administration will be randomized within each participant.
166236|NCT02901249|Drug|sertraline|
166237|NCT02901249|Drug|Nortriptyline|
166238|NCT02901249|Drug|Lithium Carbonate|
166239|NCT02901236|Procedure|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
166240|NCT02901236|Drug|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
166241|NCT02901236|Drug|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
166242|NCT02901223|Procedure|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
166243|NCT02901223|Procedure|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
166244|NCT02901210|Procedure|Modified delorme procedure|
166245|NCT02901197|Behavioral|Education and Reminder Posters|See arm description
166246|NCT02901197|Other|Policy Change|See arm description
166247|NCT02901184|Drug|Spironolactone|Treatment with Spironolactone tablets on top of standard care
166248|NCT02901184|Other|Standard care|Standard care does not involve Spironolactone
166249|NCT02901171|Behavioral|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
166250|NCT02901171|Behavioral|ACT group treatment|
166251|NCT02901171|Behavioral|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
166294|NCT02900781|Other|Standard of care|No Device. Standard of care physical therapy
166252|NCT02901145|Drug|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
166253|NCT02901119|Dietary Supplement|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
166254|NCT02901106|Drug|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate~Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
166255|NCT02901080|Device|Alpha Stim AID cranial electrotherapy stimulation|- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
166256|NCT02901080|Behavioral|Pregnancy test|- Pregnancy test x 1 (day 1)
166257|NCT02901080|Other|Anxiety questionnaire|- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
166258|NCT02901080|Other|Quality of life questionnaire|- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
166259|NCT02901080|Other|Work and social questionnaire|- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
166260|NCT02901080|Other|Sleep questionnaire|- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
166261|NCT02901080|Other|Depression questionnaire|- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
166262|NCT02901080|Other|Quality of life and financial questionnaire|- CSRI questionnaire x 3 (day 1, week 12 and week 24)
166263|NCT02901067|Drug|Aspirin and Rosuvastatin|Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
166264|NCT02901067|Drug|Placebo (for Aspirin and Rosuvastatin)|Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
166265|NCT02901054|Drug|Ondansetron|A single 15-min intravenous infusion of ondansetron
166266|NCT02901041|Drug|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
166267|NCT02901041|Behavioral|Take Control|Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.
166268|NCT02901041|Drug|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
166269|NCT02901028|Other|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
166270|NCT02901028|Other|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
166271|NCT02901015|Behavioral|Assessment battery A|"Social cognition tests version A are administered to the patients"
166272|NCT02901015|Behavioral|Assessment battery B|"Social cognition tests version B are administered to the patients"
166273|NCT02901002|Other|Sensory testing in the two hand|spontaneous sensations while watching a hand
166274|NCT02901002|Other|Neuropsychological evaluation|Score to anxiety-depression scale
166275|NCT02900989|Behavioral|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.~The study had to be declared as an interventional study according to French law."
166276|NCT02900976|Biological|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
166277|NCT02900976|Biological|Rituximab|Given IV
166278|NCT02900963|Other|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
166279|NCT02900950|Procedure|Multicolour inking specimens|
166280|NCT02900950|Procedure|Monocolour inking specimens|
166281|NCT02900937|Device|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
166282|NCT02900924|Device|BioMimics 3D Stent|
166283|NCT02900911|Other|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy~Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.~All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
166284|NCT02900911|Other|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
166285|NCT02900898|Other|Dynamic exercise and Mediterranean diet|DE, MD
166286|NCT02900898|Other|Dynamic exercise|DE
166287|NCT02900898|Other|Mediterranean diet|MD
166288|NCT02900898|Other|Control|Control
166289|NCT02900820|Other|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
166290|NCT02900820|Other|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
166291|NCT02900794|Device|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
166292|NCT02900794|Procedure|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
166295|NCT02900768|Behavioral|Exercise|Combination of resistance and aerobic exercises for 100 days.
166296|NCT02900755|Drug|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
166297|NCT02900742|Drug|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
166298|NCT02900742|Drug|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
166299|NCT02900742|Drug|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
166300|NCT02900742|Drug|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
166301|NCT02900742|Drug|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
166302|NCT02900742|Drug|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
166303|NCT02900742|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
166304|NCT02900729|Device|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
166305|NCT02900729|Drug|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
166306|NCT02900716|Drug|DTRMWXHS-12|DTRMWXHS-12
166307|NCT02900716|Drug|DTRM-505|DTRMWXHS-12 and everolimus
166308|NCT02900716|Drug|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
166309|NCT02900703|Biological|stool samples|
166310|NCT02900677|Behavioral|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
166311|NCT02900664|Biological|PDR001|Powder for solution for infusion
166312|NCT02900664|Biological|ACZ885|Solution for injection
166313|NCT02900664|Biological|CJM112|Solution for infusion
166314|NCT02900664|Drug|TMT212|Tablets
166315|NCT02900664|Drug|EGF816|Tablets
166316|NCT02900651|Drug|MAK683|Drug: MAK683
166317|NCT02900638|Behavioral|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
166318|NCT02900612|Other|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
166319|NCT02900612|Other|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
166320|NCT02900612|Other|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
166321|NCT02900599|Other|Observationnal (no intervention)|
166322|NCT02900560|Drug|CC-486|CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
166323|NCT02900560|Biological|Pembrolizumab|Pembrolizumab 200 mg IV every 21 days
166324|NCT02900547|Other|Patients with systolic heart failure|
166325|NCT02900534|Other|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
166326|NCT02900508|Other|Exergaming training|
166327|NCT02900508|Other|Physical therapy intervention|
166328|NCT02900495|Device|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
166329|NCT02900482|Other|Sampling saliva|
166330|NCT02900469|Biological|denosumab|denosumab: 120 mg subcutaneous injection
166331|NCT02900469|Procedure|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
166332|NCT02900443|Drug|Mycophenolate mofetil|
166333|NCT02900443|Drug|Azathioprine|
166334|NCT02900430|Other|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
166335|NCT02900430|Drug|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
166336|NCT02900417|Drug|Sitagliptin|All the patients will receive sitagliptin 100mg daily
166337|NCT02900404|Other|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
166338|NCT02900404|Other|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
166339|NCT02900378|Drug|LCZ696 (Sacubitril/Valsartan)|LCZ696 (sacubitril/valsartan) was available in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
166340|NCT02900378|Drug|Placebo of LCZ696 (Sacubitril/Valsartan)|Placebo of LCZ696 (sacubitril/valsartan) was available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
166341|NCT02900378|Drug|Enalapril|Enalapril was available in 2.5 mg, 5 mg and 10 mg film-coated tablets
166342|NCT02900378|Drug|Placebo of Enalapril|Placebo of Enalapril was available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
166343|NCT02900365|Procedure|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
166344|NCT02900365|Procedure|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
166345|NCT02900352|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
166346|NCT02900352|Drug|Placebo|Placebo
166347|NCT02900339|Device|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
166348|NCT02900326|Other|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
166349|NCT02900326|Other|Mindfulness-based-stress-reduction|
166350|NCT02900326|Other|Both interventions together|
166351|NCT02900326|Other|Vo2max measurements|
166352|NCT02900326|Genetic|Telomerase activity on a blood sample|
166353|NCT02900326|Other|Quality of life (questionnaires)|
166354|NCT02900326|Other|Cerebral IRMf|
166355|NCT02900313|Other|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
166356|NCT02900274|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
166357|NCT02900261|Other|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
166358|NCT02900248|Other|Provider determined|Provider will treat patient as he/she feels best
166359|NCT02900235|Drug|MT-3995|
166360|NCT02900222|Procedure|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
166361|NCT02900209|Other|Influenza Vaccination|
166362|NCT02900196|Other|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
166363|NCT02900196|Other|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
166364|NCT02900183|Drug|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
166365|NCT02900157|Biological|MEDI9090|MEDI9090 will be administered by IV infusion
166366|NCT02900157|Biological|Durvalumab|Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
166367|NCT02900144|Behavioral|Modified Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the modified CBIT protocol. In addition to addressing tics, the treatment in this arm will also directly address ADHD symptoms using CBT for ADHD techniques, and quality of life concerns. The treatment itself will be modified to be more accessible to an ADHD population. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
166368|NCT02900144|Behavioral|Comprehensive Behavioral Intervention for Tics|In this arm, participants will receive the standard CBIT intervention (Piacentini et al 2010). The primary components of CBIT are habit reversal training, relaxation training and a functional interventional to assess the environment for situations/factors that exacerbate or sustain tics. The treatment will consist of twelve 50-min sessions: ten weekly and then two every other week for relapse prevention.
166369|NCT02900131|Drug|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
166370|NCT02900131|Drug|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
166371|NCT02900105|Drug|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
166372|NCT02900092|Drug|Ganaxolone|Participants received ganaxolone
166373|NCT02900079|Device|rapid diagnostic test for malaria antigen|rapid diagnostic test for malaria antigen to be used by travelers when febrile
166374|NCT02900053|Device|tDCS|tDCS for transcranial Direct-Current Stimulation
166375|NCT02900053|Device|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
166376|NCT02900040|Other|kidney transplantation|
166377|NCT02900027|Drug|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
166378|NCT02900027|Drug|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
166379|NCT02900014|Procedure|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
166380|NCT02900001|Procedure|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
166381|NCT02900001|Procedure|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
166382|NCT02899988|Drug|Mirikizumab|Administered SC
166383|NCT02899988|Drug|Placebo|Administered SC
166461|NCT02899351|Device|Respiratory Volume Monitor|
166462|NCT02899338|Drug|BI695501 Prefilled syringe|
166384|NCT02899975|Other|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
166385|NCT02899962|Drug|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
166386|NCT02899962|Drug|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
166387|NCT02899936|Drug|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
166388|NCT02899936|Drug|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
166389|NCT02899923|Other|Data collection|
166390|NCT02899910|Behavioral|Health education|Education on lifestyle changes for treatment of metabolic syndrome
166391|NCT02899910|Behavioral|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
166392|NCT02899897|Device|echocardiography in IV fluid therapy|
166393|NCT02899884|Other|No Intervention|
166394|NCT02899871|Other|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:~If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~serum assays of the anti-TNF administered, as well as screening for associated antibodies."
166395|NCT02899858|Other|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
166396|NCT02899858|Other|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
166397|NCT02899858|Procedure|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
166398|NCT02899858|Other|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
166399|NCT02899858|Other|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
166400|NCT02899858|Other|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
166401|NCT02899845|Other|postural task|
166402|NCT02899845|Other|walk task|
166403|NCT02899832|Device|NIRS|Near Infra Red Spectroscopy
166404|NCT02899819|Other|meconium|The meconium will be sampled in the first 2 days of life
166405|NCT02899806|Other|Written Information|A written information on peridural anesthesia is delivered
166406|NCT02899806|Other|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
166407|NCT02899793|Drug|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
166408|NCT02899780|Device|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
166409|NCT02899754|Behavioral|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
166410|NCT02899754|Behavioral|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
166411|NCT02899741|Drug|Omega-3|1000mg every day for 90 days
166412|NCT02899728|Drug|Carboplatin|Given IV
166413|NCT02899728|Drug|Cediranib|Given PO
166414|NCT02899728|Drug|Cediranib Maleate|Given PO
166415|NCT02899728|Drug|Cisplatin|Given IV
166416|NCT02899728|Drug|Etoposide|Given IV
166417|NCT02899728|Drug|Olaparib|Given PO
166418|NCT02899702|Drug|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
166419|NCT02899702|Drug|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.~The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
166420|NCT02899689|Device|Dilapan|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
166421|NCT02899689|Device|Foley Catheter|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
166422|NCT02899676|Other|neuropsychological testing|
166423|NCT02899676|Other|functional magnetic resonance imaging|
166424|NCT02899676|Other|simple arithmetic operations|
166425|NCT02899650|Other|exercise|acute downhill running
166426|NCT02899637|Device|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
166427|NCT02899637|Device|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
166428|NCT02899624|Biological|Extra blood draw samples|
166429|NCT02899624|Biological|additional tissue samples|
166430|NCT02899611|Drug|Valproate|ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
166431|NCT02899598|Biological|Extra blood draw samples|
166432|NCT02899598|Biological|extra amniotic fluid samples|
166433|NCT02899585|Other|Questionnaires|
166434|NCT02899585|Other|Score|
166435|NCT02899572|Procedure|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
166436|NCT02899559|Behavioral|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
166437|NCT02899533|Drug|[18F] FES|[18F] FES PET/CT scan, imaging tracer
166438|NCT02899520|Other|Reference method|Electrostimulation associated to perineal training
166439|NCT02899520|Other|CMP ® method|Method based on Knowledge and Control of Perineum
166440|NCT02899507|Drug|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
166441|NCT02899494|Other|Antenatal classes|
166442|NCT02899494|Other|Physical and psychic preparation|
166443|NCT02899481|Other|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
166444|NCT02899468|Device|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
166445|NCT02899455|Drug|HGP0904|
166446|NCT02899455|Drug|HGP0608|
166447|NCT02899455|Drug|HGP0816|
166448|NCT02899455|Drug|HGP0904 Placebo|
166449|NCT02899455|Drug|HGP0816 Placebo|
166450|NCT02899442|Other|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
166451|NCT02899403|Other|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
166452|NCT02899390|Behavioral|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.~The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
166453|NCT02899377|Radiation|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
166454|NCT02899377|Radiation|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.~Other Name:11C-MET"
166455|NCT02899377|Procedure|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
166456|NCT02899377|Procedure|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
166457|NCT02899364|Drug|Sodium thiosulfate|see description under experimental arm
166458|NCT02899364|Drug|Sodium chloride 0.9%|see description under placebo comparator arm
166459|NCT02899364|Procedure|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
166460|NCT02899364|Other|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
166464|NCT02899325|Drug|Diagnostic PET/CT scans|These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
166465|NCT02899312|Drug|PSMA PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
166466|NCT02899299|Biological|Nivolumab|
166467|NCT02899299|Biological|Ipilimumab|
166468|NCT02899299|Drug|Pemetrexed|
166469|NCT02899299|Drug|Cisplatin|
166470|NCT02899299|Drug|Carboplatin|
166471|NCT02899286|Biological|PEG-BCT-100|PEGylated recombinant human arginase
166472|NCT02899260|Device|Peanut Exercise Ball|A Peanut shaped exercise ball.
166473|NCT02899247|Procedure|Surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).~The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
166474|NCT02899247|Procedure|No surface sealant|"Device:~Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.~Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.~Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)~7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
166475|NCT02899234|Other|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
166476|NCT02899221|Radiation|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
166477|NCT02899221|Procedure|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
166478|NCT02899195|Drug|Concurrent Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration.
166479|NCT02899195|Drug|Maintenance Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
166480|NCT02899182|Drug|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
166481|NCT02899182|Other|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
166482|NCT02899169|Drug|Realgar-Indigo naturalis formula|
166483|NCT02899169|Drug|all-trans retinoic acid|
166484|NCT02899169|Drug|Arsenic trioxide|
166485|NCT02899169|Drug|Hydroxyurea|
166486|NCT02899156|Drug|Flumazenil|
166487|NCT02899156|Drug|Placebo|0.9% normal saline
166488|NCT02899143|Drug|Antibiotic|Targeted antimicrobial therapy
166489|NCT02899130|Drug|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
166490|NCT02899130|Drug|Placebo|Inactive compound that is similar looking as the intervention
166491|NCT02899117|Other|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
166492|NCT02899104|Drug|Xofigo (Radium-223 dichloride, BAY88-8223|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
166493|NCT02899091|Biological|CB-AC-02|"Stage1:~① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0~② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)~Stage2~① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)~② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)"
166494|NCT02899091|Biological|Placebo|"Stage2:~Placebo on day 0 and on week 4 (repeated injection)"
166495|NCT02899078|Drug|Ibrutinib|Given PO
166496|NCT02899078|Drug|Nivolumab|Given IV
166497|NCT02899065|Diagnostic Test|Procalcitonin|Procalcitonin is a blood test used to differentiate between viral and bacterial infections. This test is expected to aid in determining the best course of treatment for patients enrolled into this arm.
166498|NCT02899065|Other|Pharmacist-Led Education|Pharmacists will interpret the results of the Roche Cobas Liat Flu/RSV assay and procalcitonin test (if available) and provide the treating physician with recommendations for antibiotic therapy based on these results.
166499|NCT02899052|Drug|Carfilzomib|"Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 - 18 within 30 minutes to 4 hours after dexamethasone dosing.~Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16.~Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - 18: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 20 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.~Cycles 2 - 18: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16."
166500|NCT02899052|Drug|Venetoclax|Venetoclax tablet administered orally once daily during Cycles 1-18. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
166501|NCT02899052|Drug|Dexamethasone|Dexamethasone tablet administered orally during Cycles 1 - 18. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
166502|NCT02899039|Biological|extra blood draw samples|
166503|NCT02899026|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
166576|NCT02898350|Device|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
166504|NCT02899026|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
166505|NCT02899026|Drug|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
166506|NCT02899013|Other|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
166507|NCT02899000|Drug|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
166508|NCT02899000|Drug|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets [50 mg], twice daily)
166509|NCT02898974|Behavioral|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
166510|NCT02898961|Drug|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.~In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
166511|NCT02898948|Biological|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
166512|NCT02898922|Biological|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
166513|NCT02898909|Device|nuclear lens fragmentation in 8 pieces|
166514|NCT02898909|Device|nuclear lens fragmentation in 16 pieces|
166515|NCT02898896|Biological|blood test|Additional 21 ml of blood will be collected
166516|NCT02898883|Behavioral|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
166517|NCT02898857|Other|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
166518|NCT02898844|Behavioral|Mixed Diet Condition|One roommate dieted and the other ate normally.
166519|NCT02898844|Behavioral|Both Diet Condition|Both roommates dieted.
166520|NCT02898831|Other|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
166521|NCT02898818|Other|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
166522|NCT02898818|Other|papa smear|Papnicolaou Papa Smear test
166523|NCT02898805|Other|Placebo|
166524|NCT02898805|Other|Prescribed Diet|
166525|NCT02898805|Dietary Supplement|LopiGLIK®|
166526|NCT02898805|Dietary Supplement|Armolipid Plus|
166527|NCT02898792|Drug|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
166528|NCT02898779|Drug|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)~Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.~Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.~Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
166529|NCT02898766|Other|Enteral Nutrition Formula|
166530|NCT02898753|Drug|VAL-1221|VAL-1221 3, 10, or 30 mg/kg as per the dose and schedule specified in the arm group description
166531|NCT02898753|Drug|RhGAA|Active comparator
166532|NCT02898740|Behavioral|Structural exercise|Exercise instruction and encouragement
166533|NCT02898740|Behavioral|Health education|Provision of general information about a variety of health topics
166534|NCT02898727|Other|Local Therapy|"Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).~Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions."
166535|NCT02898701|Behavioral|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
166536|NCT02898688|Behavioral|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
166537|NCT02898688|Behavioral|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
166538|NCT02898688|Behavioral|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
166539|NCT02898688|Behavioral|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
166540|NCT02898675|Device|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
166541|NCT02898675|Device|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
166542|NCT02898662|Drug|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
166543|NCT02898662|Drug|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
166544|NCT02898649|Device|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
166545|NCT02898636|Other|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
166546|NCT02898623|Other|No intervention|Evaluation of performance of immunoassays based on the detection of antibodies directed against Mycobacterium tuberculosis antigen
166547|NCT02898610|Drug|Colchicine|
166548|NCT02898597|Behavioral|Cognitive Behavioral Therapy|Received 8 weekly individualized counseling sessions of cognitive behavioral therapy
166549|NCT02898584|Other|BP Track|
166550|NCT02898571|Dietary Supplement|Placebo|Placebo comparitor
166551|NCT02898571|Dietary Supplement|Vitamin C|Active treatment
166552|NCT02898571|Dietary Supplement|epicatechin|Active treatment
166553|NCT02898558|Behavioral|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
166554|NCT02898558|Device|magnifying lenses|
166555|NCT02898545|Device|SEEQ monitor|An external cardiac rhythm monitor
166556|NCT02898532|Behavioral|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
166557|NCT02898519|Other|cohort|Blood sampling
166558|NCT02898506|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
166559|NCT02898506|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
166560|NCT02898480|Procedure|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
166561|NCT02898467|Other|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
166562|NCT02898467|Other|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
166563|NCT02898454|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
166564|NCT02898454|Drug|Placebo|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
166565|NCT02898454|Drug|Mometasone furoate nasal spray|"Pharmaceutical form: Suspension~Route of administration: Intranasal"
166566|NCT02898441|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
166567|NCT02898428|Device|Continuous glucose monitoring (CGM)|
166568|NCT02898415|Procedure|Liver transplantation|
166569|NCT02898402|Procedure|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
166570|NCT02898376|Other|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment~+/- Additional care according to the specificity of each spa"
166571|NCT02898376|Drug|Pentoxifylline|400 mg bid during at least 6 months
166572|NCT02898376|Drug|Tocopherol acetate|500 mg bid during at least 6 months
166573|NCT02898363|Other|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
166574|NCT02898350|Device|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
166575|NCT02898350|Device|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
166577|NCT02898350|Device|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
166578|NCT02898337|Device|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG~Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
166579|NCT02898324|Other|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
166580|NCT02898311|Device|immediate loading of posterior implants with chairside CAD-CAM composite crown|
166581|NCT02898298|Behavioral|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
166582|NCT02898285|Behavioral|Team sports|Participants will choose from a list of team sports and will be signed up with the team.
166583|NCT02898285|Behavioral|Individual sport condition|Participants will choose from a list of individual sports.
166584|NCT02898285|Behavioral|Night out|"Participants in this group will be asked to go out to have a weekly night out or personal time of choice, such as dinner or a movie (only restrictions are they cannot go do a sport or physical activity and time must be spent without children)."
166585|NCT02898259|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
166586|NCT02898259|Drug|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:~Starting lenalidomide Dose (20mg)~Calculated Creatinine Clearance: >=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle~Calculated Creatinine Clearance: >= 30 and < 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
166587|NCT02898259|Drug|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
166588|NCT02898233|Other|Deprexis|Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
166589|NCT02898233|Device|Active low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
166590|NCT02898233|Device|Sham low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
166591|NCT02898207|Drug|Olaparib|Given PO
166592|NCT02898207|Drug|Onalespib|Given IV
166593|NCT02898194|Other|Survey|Survey that occurs within a focus group led by a moderator
166594|NCT02898181|Device|Tragus stimulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation (TENS) device with electrodes attached to the tragus of the ear.TENS will be applied continuously for 8 hours daily (4 hours twice daily)
166595|NCT02898168|Device|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
166596|NCT02898168|Other|Control|Conventional rehabilitation therapy and gait training without WA.
166597|NCT02898155|Other|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
166598|NCT02898142|Other|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
166599|NCT02898129|Other|Questionnaire|
166600|NCT02898129|Device|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
166601|NCT02898116|Drug|Ensartinib|Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).
166602|NCT02898116|Drug|Durvalumab|During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
166603|NCT02898103|Device|Ultrasound-guided percutaneous peripheral nerve stimulation|Using ultrasound guidance, the small electrical lead is inserted adjacent to a target peripheral nerve through a percutaneously introduced 20-gauge needle. Following needle withdrawal, the percutaneous lead is attached to a miniature stimulator half the size of a business card that is simply adhered to the skin. When activated, the (active) stimulator generates a small electrical current which passes through the insulated leads to the uninsulated lead tip, which activates nerve fibers (placebo stimulators do not generate current).
166604|NCT02898077|Drug|Ramucirumab|Administered IV
166605|NCT02898077|Drug|Paclitaxel|Administered IV
166606|NCT02898077|Drug|Placebo|Administered IV
166638|NCT02897804|Behavioral|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
166728|NCT02897401|Biological|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
166607|NCT02898064|Device|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
166608|NCT02898064|Other|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
166609|NCT02898038|Dietary Supplement|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
166610|NCT02898025|Device|Active Interferential Current|Involves the application of medium frequency alternating currents
166611|NCT02898025|Device|Active Laser|Involves the application of low level laser over the knee
166612|NCT02898025|Device|Placebo Interferential Current|It is a sham interferential therapy
166613|NCT02898025|Device|Placebo Laser|It is a sham laser therapy
166614|NCT02898012|Drug|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
166615|NCT02898012|Drug|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage > grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
166616|NCT02897999|Biological|QBKPN|QBKPN Site Specific Immunomodulators
166617|NCT02897999|Other|Placebo|Placebo
166618|NCT02897986|Drug|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
166619|NCT02897973|Other|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
166620|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Norway|
166621|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
166622|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
166623|NCT02897934|Drug|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
166624|NCT02897908|Procedure|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
166625|NCT02897895|Biological|levels of CNI in whole blood|
166626|NCT02897895|Biological|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
166627|NCT02897882|Other|Lung transplant|Pain evaluation
166628|NCT02897869|Drug|POL7080|7 doses of POL7080 alone over 2.5 days
166629|NCT02897869|Drug|Amikacin|3 doses of Amikacin alone over 2.5 days
166630|NCT02897869|Drug|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
166631|NCT02897856|Drug|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
166632|NCT02897856|Drug|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
166633|NCT02897843|Device|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
166634|NCT02897843|Device|sham tDCS|sham tDCS
166635|NCT02897830|Drug|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
166636|NCT02897830|Drug|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).~Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).~Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
166637|NCT02897830|Drug|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.~Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
166724|NCT02897427|Other|Biomarker Analysis|Complete HPV testing
166639|NCT02897804|Behavioral|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166640|NCT02897804|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
166641|NCT02897804|Behavioral|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166642|NCT02897804|Behavioral|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
166643|NCT02897804|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166644|NCT02897804|Behavioral|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166645|NCT02897804|Behavioral|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166646|NCT02897804|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
166647|NCT02897804|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166648|NCT02897804|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
166649|NCT02897804|Behavioral|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166650|NCT02897804|Behavioral|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
166651|NCT02897804|Behavioral|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166652|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
166653|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166654|NCT02897804|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
166655|NCT02897804|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166656|NCT02897804|Behavioral|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
166657|NCT02897804|Behavioral|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166658|NCT02897804|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
166659|NCT02897804|Behavioral|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166660|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
166661|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166662|NCT02897804|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
166663|NCT02897804|Behavioral|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166664|NCT02897804|Behavioral|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
166665|NCT02897804|Behavioral|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166666|NCT02897804|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
166667|NCT02897804|Behavioral|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166668|NCT02897804|Behavioral|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
166669|NCT02897804|Behavioral|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
166670|NCT02897791|Behavioral|written evaluations|answering questions about pictures and stories
166671|NCT02897778|Drug|Entinostat|Single, supratherapeutic dose of entinostat given orally
166672|NCT02897778|Other|Placebo|Single dose of Placebo containing inactive ingredients matching the appearance of the active product (entinostat).
166673|NCT02897765|Biological|NEO-PV-01|Personal cancer vaccine
166674|NCT02897765|Biological|Nivolumab|monoclonal antibody against PD1
166675|NCT02897765|Other|Adjuvant|immune adjuvant
166676|NCT02897752|Device|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
166677|NCT02897752|Other|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
166678|NCT02897739|Procedure|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
166679|NCT02897739|Biological|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
166680|NCT02897739|Radiation|PET CT|PET study for metabolic pathway study
166681|NCT02897739|Behavioral|Psychological assessment|Assessment by a psychologist
166682|NCT02897726|Drug|NVP-1402|Oral
166683|NCT02897726|Drug|NVP-1402R|Oral
166684|NCT02897713|Other|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
166685|NCT02897713|Other|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
166686|NCT02897700|Drug|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
166725|NCT02897427|Procedure|Biospecimen Collection|Undergo collection of blood and oral gargle samples
166726|NCT02897427|Procedure|Ultrasonography|Undergo transcervical ultrasonography
166727|NCT02897414|Other|Surveillance of state medical examiner databases|
168094|NCT02886273|Other|Group 1|Observation
166687|NCT02897700|Drug|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
166688|NCT02897700|Drug|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
166689|NCT02897687|Behavioral|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
166690|NCT02897687|Behavioral|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
166691|NCT02897674|Dietary Supplement|Palm olein|two thirds of the 30% fat calories will come from palm olein
166692|NCT02897674|Dietary Supplement|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
166693|NCT02897674|Dietary Supplement|soybean oil|two thirds of the 30% fat calories will come from soybean oil
166694|NCT02897661|Procedure|FMT|fecal microbiota transplantation (FMT) via mid-GI
166695|NCT02897661|Drug|Metronidazole|oral adminstration
166696|NCT02897661|Dietary Supplement|EN|via nasal feeding tube
166697|NCT02897648|Drug|Assessment of dermal administration of Beta-Lactams|Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
166698|NCT02897635|Behavioral|Individualized Integrative Medicine Intervention|
166699|NCT02897622|Other|Case management|Case management by Eira unit
166700|NCT02897596|Drug|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
166701|NCT02897596|Drug|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
166702|NCT02897596|Drug|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
166703|NCT02897596|Drug|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
166704|NCT02897583|Procedure|YAG vitreolysis|
166705|NCT02897570|Dietary Supplement|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
166706|NCT02897570|Dietary Supplement|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
166707|NCT02897570|Dietary Supplement|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
166708|NCT02897570|Dietary Supplement|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
166709|NCT02897570|Device|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
166710|NCT02897570|Device|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
166711|NCT02897557|Device|Insulet Artificial Pancreas (AP) System|
166712|NCT02897544|Behavioral|Individualized Manualized Health Education Intervention|
166713|NCT02897531|Procedure|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
166714|NCT02897531|Procedure|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
166715|NCT02897518|Device|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
166716|NCT02897518|Device|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
166717|NCT02897505|Behavioral|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
166718|NCT02897492|Other|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
166719|NCT02897479|Drug|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg or 400mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
166720|NCT02897466|Other|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
166721|NCT02897453|Device|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
166722|NCT02897440|Procedure|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
166723|NCT02897440|Procedure|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
166729|NCT02897401|Biological|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
166730|NCT02897401|Biological|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
166731|NCT02897401|Behavioral|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
166732|NCT02897401|Procedure|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
166733|NCT02897388|Other|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling & promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
166734|NCT02897375|Drug|Carboplatin|Given IV
166735|NCT02897375|Drug|Cisplatin|Given IV
166736|NCT02897375|Drug|Palbociclib|Given PO
166737|NCT02897349|Drug|placebo|
166738|NCT02897349|Drug|linagliptin|
166739|NCT02897349|Drug|background therapy|insulin with or without metformin
166740|NCT02897336|Procedure|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
166741|NCT02897336|Procedure|interlaminar|interlaminar epidural corticosteroid injection
166742|NCT02897323|Other|description|
166743|NCT02897284|Behavioral|Mindfulness 8 weeks|8 sessions of mindfulness
166744|NCT02897284|Behavioral|Mindfulness 2 weeks|2 sessions of mindfulness
166745|NCT02897245|Other|No intervention|
166746|NCT02897232|Other|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
166747|NCT02897219|Drug|ipragliflozin|Oral administration once daily
166748|NCT02897219|Drug|Placebo|Oral administration once daily
166749|NCT02897219|Other|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
166750|NCT02897206|Drug|Imipenem|A wide-spectre antibiotic from the carbapenem group
166751|NCT02897206|Drug|Placebo|An imipenem-matching placebo
166752|NCT02897193|Device|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
166753|NCT02897193|Device|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
166754|NCT02897193|Device|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
166755|NCT02897193|Device|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
166756|NCT02897180|Biological|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
166757|NCT02897180|Biological|Placebo|Capsules containin Placebo
166758|NCT02897167|Genetic|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
166759|NCT02897167|Genetic|Prospective study of fresh samples|Samples of serum and cells will be drawn.
166760|NCT02897154|Diagnostic Test|In-vitro|
166761|NCT02897141|Device|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
166762|NCT02897141|Device|Control App|The attention control group will receive an app which asked them about their symptoms but did not provide symptoms strategies
166763|NCT02897128|Other|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
166764|NCT02897115|Biological|Adalimumab|Administered every other week by subcutaneous injection for up to 48 weeks, depending on participants' disease activity.
166765|NCT02897115|Other|Non-steroidal Anti-inflammatory Drugs (NSAIDs)|ASAS recommended NSAID doses to treat axial spondyloarthritis.
166766|NCT02897102|Behavioral|Training|Training program based on abacus and other activities
166767|NCT02897102|Other|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
166768|NCT02897089|Device|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
166769|NCT02897076|Drug|betamethasone 24 mg|
166770|NCT02897076|Drug|12mg betamethasone +placebo|
166771|NCT02897063|Drug|Droxidopa|Single oral dose 300 mg
166772|NCT02897063|Drug|Midodrine|Single oral dose 10 mg
166773|NCT02897063|Drug|Placebo|sugar pill
166774|NCT02897050|Drug|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
166775|NCT02897050|Drug|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
166776|NCT02897050|Drug|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
166777|NCT02897050|Drug|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
166778|NCT02897050|Drug|Epirubicin|Epirubicin 100mg/m2, iv, d1
166779|NCT02897050|Drug|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
166780|NCT02897037|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
166781|NCT02897037|Drug|heparin|heparin monotherapy
166782|NCT02897024|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
166783|NCT02897011|Drug|Methotrexate|
166784|NCT02896998|Procedure|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
166785|NCT02896998|Procedure|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
166786|NCT02896972|Procedure|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
166787|NCT02896959|Procedure|Arthroscopic rotator cuff repair|
166788|NCT02896946|Radiation|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
166789|NCT02896907|Drug|Oxaliplatin|Given IV
166790|NCT02896907|Drug|Irinotecan Hydrochloride|Given IV
166791|NCT02896907|Drug|Leucovorin Calcium|Given IV
166792|NCT02896907|Drug|Fluorouracil|Given IV
166793|NCT02896907|Dietary Supplement|Ascorbic Acid|Given IV
166794|NCT02896894|Other|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
166795|NCT02896868|Drug|LY3041658|Administered IV.
166796|NCT02896868|Drug|Placebo|Administered IV.
166797|NCT02896855|Drug|Docetaxel|Docetaxel (75-mg/m^2) administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
166798|NCT02896855|Drug|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
166799|NCT02896855|Drug|Placebo|Placebo matched to pertuzumab administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
166800|NCT02896855|Drug|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
166801|NCT02896842|Drug|Posology dose modification|
166802|NCT02896842|Other|active comparator|
166803|NCT02896829|Behavioral|Interruption of the treatment by Imatinib|
166804|NCT02896816|Other|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
166805|NCT02896816|Other|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
166806|NCT02896803|Drug|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
166807|NCT02896790|Other|Interviews with 2 oncologists and 10 patients|
166808|NCT02896790|Other|Interviews with 15 patients|
166809|NCT02896777|Other|Transfer embryo from pH 7.20±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.20±0.02.
166810|NCT02896777|Other|Transfer embryo from pH 7.3±0.02 either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.3±0.02.
166811|NCT02896777|Other|Transfer embryo from pH of 7.4±0.02 on either Day 3 or day 5/6|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.4±0.02 from day 0 to 5/6
166812|NCT02896764|Device|Cone-beam CT|
166813|NCT02896751|Device|3D printed NIV mask|use of 3D printed mask
166814|NCT02896725|Device|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
166815|NCT02896725|Device|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
166816|NCT02896712|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
166817|NCT02896712|Behavioral|Drug Counseling (DC)|The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
168095|NCT02886273|Other|Group 2|Observation
166818|NCT02896712|Behavioral|Contingency Management (CM)|The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
166819|NCT02896712|Drug|Placebo|The placebo capsule will be filled with corn starch and riboflavin.
166820|NCT02896712|Drug|Modafinil|Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
166821|NCT02896699|Behavioral|PrEP Intervention Group|
166822|NCT02896699|Other|Control Group|
166823|NCT02896686|Radiation|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for fascial closure."
166824|NCT02896686|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
166825|NCT02896686|Procedure|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
166826|NCT02896673|Procedure|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT~Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)~Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV~Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time~Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds~Time E: return to adjustment period A"
166827|NCT02896660|Device|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
166828|NCT02896634|Biological|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
166829|NCT02896621|Drug|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
166830|NCT02896621|Drug|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
166831|NCT02896608|Device|measure of neuronal excitability|
166832|NCT02896595|Device|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
166833|NCT02896595|Device|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
166834|NCT02896582|Drug|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
166835|NCT02896582|Drug|Dexamethasone|40 mg D1 to D4 in GA-DHAP
166836|NCT02896582|Drug|Aracytine|2g/m² D1 & D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
166837|NCT02896582|Drug|Cisplatinum|100 mg/m² D1 in GA-DHAP
166838|NCT02896582|Drug|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
166839|NCT02896582|Drug|Melphalan|140 mg/m² D-2 in GA-BEAM
166840|NCT02896582|Drug|Carmustine|300 mg/m² D-7 in GA-BEAM
166841|NCT02896569|Other|Topical combination therapy|
166842|NCT02896556|Device|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
166843|NCT02896543|Other|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
166844|NCT02896530|Other|No intervention. Description study|
166845|NCT02896504|Drug|Exposure: Adjuvant chemotherapy treatment|
166846|NCT02896504|Drug|Exposure: Adjuvant hormonal therapy treatment|
166847|NCT02896491|Radiation|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
166848|NCT02896478|Other|No intervention. Only observational study|
166849|NCT02896465|Other|Oral rehydration solution|
166850|NCT02896465|Other|Zinc|
166851|NCT02896465|Other|Human milk oligosaccharides|
166852|NCT02896465|Other|Breastfeeding|
166853|NCT02896439|Device|Neurophysiological MONITORING|"The neurophysiology team perform:~Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~Establishment of a spacer or forceps in the greater or lesser sciatic notch~Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~At the end of the incision~On the establishment of a spacer or forceps in the greater or lesser sciatic notch~When towing layout~At the end of the intervention"
166854|NCT02896426|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
168096|NCT02886273|Other|Group 3|Observation
166855|NCT02896426|Behavioral|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
166856|NCT02896413|Drug|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
166857|NCT02896413|Drug|Control group|0.9% saline infusion
166858|NCT02896400|Behavioral|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
166859|NCT02896400|Drug|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
166860|NCT02896400|Other|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
166861|NCT02896400|Other|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
166862|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
166863|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
166864|NCT02896361|Device|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
166865|NCT02896348|Device|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
166866|NCT02896348|Other|Conventional therapy|Exercise program established with a therapist (8 sessions under therapist direct supervision and 10 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
166867|NCT02896335|Drug|Palbociclib|
166868|NCT02896322|Radiation|Partial breast irradiation with cyberknife|
166869|NCT02896309|Dietary Supplement|Sodium bicarbonate|
166870|NCT02896309|Dietary Supplement|Sodium chloride|
166871|NCT02896296|Drug|RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose could be adjusted from 100 mg to 300 mg (or the reverse) based on the medical judgment of the investigator.
166872|NCT02896283|Radiation|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
166873|NCT02896283|Radiation|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
166874|NCT02896270|Drug|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
166875|NCT02896257|Other|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
166876|NCT02896244|Other|no intervention|
166877|NCT02896231|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
166878|NCT02896218|Other|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
166879|NCT02896205|Drug|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
166880|NCT02896205|Drug|Placebo|Subjects will be given matching placebo for 6 months
166881|NCT02896192|Drug|Setmelanotide|RM-493 once daily subcutaneous injection
166882|NCT02896192|Drug|Placebo|During the double blind placebo withdrawal period, patients will receive RM-493 or placebo at variable times over an 8 week period in order for patients to serve as their own control.
166883|NCT02896179|Device|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
166884|NCT02896179|Device|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
166885|NCT02896166|Other|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
166886|NCT02896153|Other|Questionnaire|
166887|NCT02896140|Other|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
166888|NCT02896127|Drug|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
166889|NCT02896127|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
166890|NCT02896101|Drug|Pimecrolimus Cream, 1%|
166891|NCT02896101|Drug|Elidel® (pimecrolimus) Cream|
166892|NCT02896101|Drug|Placebo of Pimecrolimus Cream, 1%|
166919|NCT02895828|Other|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
166920|NCT02895828|Other|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
167751|NCT02889328|Drug|Regorafenib|Regorafenib 100mg continuous dosing arm
166893|NCT02896088|Other|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
166894|NCT02896075|Other|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
166895|NCT02896075|Other|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
166896|NCT02896062|Behavioral|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
166897|NCT02896049|Device|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
166898|NCT02896036|Procedure|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
166899|NCT02896036|Procedure|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
166900|NCT02896023|Drug|human menopausal gonadotropin|Induction of ovulation followed by ICSI
166901|NCT02896010|Other|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
166902|NCT02896010|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
166903|NCT02895997|Other|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
166904|NCT02895984|Behavioral|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
166905|NCT02895958|Drug|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
166906|NCT02895945|Biological|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
166907|NCT02895932|Radiation|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
166908|NCT02895919|Other|Culture|culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
166909|NCT02895906|Drug|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
166910|NCT02895893|Behavioral|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
166911|NCT02895880|Behavioral|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
166912|NCT02895880|Behavioral|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
166913|NCT02895867|Other|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
166914|NCT02895867|Other|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
166915|NCT02895867|Other|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
166916|NCT02895854|Radiation|Hypofractionated RT 5 x 7,25 Gy|
166917|NCT02895854|Radiation|LDR-brachytherapy with I125 seeds|
166918|NCT02895841|Other|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
167752|NCT02889302|Drug|KPS-0373|24 weeks
166921|NCT02895815|Combination Product|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit [SRAK-02 kit] and third arm accessory).
166922|NCT02895815|Combination Product|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
166923|NCT02895802|Behavioral|Verbal instructions with picture diagram|verbal instructions and picture diagram
166924|NCT02895802|Behavioral|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
166925|NCT02895802|Behavioral|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
166926|NCT02895802|Behavioral|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
166927|NCT02895763|Other|Form administrations|
166928|NCT02895750|Drug|Metformin|Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
166929|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences|
166930|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences; Claret Sentinel™ Cerebral Protection Systems|
166931|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
166932|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Claret Sentinel™ Cerebral Protection Systems|
166933|NCT02895724|Drug|Medical Oxygen|Hyperbaric oxygen therapy
166934|NCT02895698|Device|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
166935|NCT02895698|Other|Stretching exercises|"The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~Standing self-stretching of the calf muscles.~Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~All stretches were done six times and the duration of each stretch is 30 seconds."
166936|NCT02895685|Other|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
166937|NCT02895672|Drug|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
166938|NCT02895659|Procedure|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
166939|NCT02895646|Other|Collection of blood sample|
166940|NCT02895633|Other|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
166941|NCT02895633|Other|CT scan|With injection of Iomeron 400
166942|NCT02895633|Other|MRI|With injection of gadolinium (Multihance)
166943|NCT02895620|Biological|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
166944|NCT02895607|Procedure|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.~After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
166945|NCT02895555|Procedure|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested aulograft.
166946|NCT02895555|Procedure|Allograft|Approx 50 g of allograft bone in the fused site
166947|NCT02895529|Drug|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters [mL]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
166948|NCT02895529|Drug|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
166949|NCT02895516|Device|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
166950|NCT02895503|Behavioral|Yoga|Participate in yoga
166951|NCT02895503|Behavioral|Support Group Therapy|Participate in emotional support group therapy
166982|NCT02895269|Behavioral|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
166983|NCT02895256|Drug|Any treatment for cluster headache|
167014|NCT02895009|Device|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
166952|NCT02895503|Other|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, & Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
166953|NCT02895503|Other|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
166954|NCT02895490|Other|educational intervention|Receive a DVD containing educational information and communication skills
166955|NCT02895490|Other|communication skills training|Receive a DVD containing educational information and communication skills
166956|NCT02895490|Other|educational intervention|Receive information about the LINC group
166957|NCT02895490|Other|questionnaire administration|Ancillary studies
166958|NCT02895490|Other|quality-of-life assessment|Ancillary studies
166959|NCT02895477|Device|hearing aid|
166960|NCT02895464|Other|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
166961|NCT02895451|Behavioral|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
166962|NCT02895438|Dietary Supplement|gluten|
166963|NCT02895425|Other|Registry (No intervention)|
166964|NCT02895412|Biological|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.~P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
166965|NCT02895399|Other|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
166966|NCT02895386|Device|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
166967|NCT02895386|Other|Sham procedure|Sham procedure + continuing current antihypertensive medications.
166968|NCT02895373|Drug|Alprostadil|5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
166969|NCT02895373|Drug|0.9% sodium chloride solution|continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
166970|NCT02895360|Drug|BAL101553|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2
166971|NCT02895360|Drug|BAL101553 at MTD|BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; treatment with maximum tolerated dose (MTD)
166972|NCT02895347|Behavioral|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
166973|NCT02895334|Behavioral|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
166974|NCT02895321|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
166975|NCT02895321|Other|Colgate, Protection Caries|a fluorine-based toothpaste gels
166976|NCT02895321|Other|Placebo gel|a glycerin and water gel
166977|NCT02895308|Behavioral|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
166978|NCT02895308|Behavioral|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
166979|NCT02895295|Behavioral|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
166980|NCT02895295|Behavioral|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
166981|NCT02895295|Behavioral|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
167091|NCT02894515|Drug|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
166984|NCT02895243|Other|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
166985|NCT02895230|Other|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
166986|NCT02895217|Other|ergocycle|
166987|NCT02895204|Dietary Supplement|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
166988|NCT02895204|Dietary Supplement|Placebo|6g of maltodextrin
166989|NCT02895191|Drug|ulinastatin|Patients will receive the study drugs for 7 to 14 days
166990|NCT02895191|Drug|placebo|Patients will receive the placebo for 7 to 14 days
166991|NCT02895178|Behavioral|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
166992|NCT02895152|Behavioral|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
166993|NCT02895139|Device|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
166994|NCT02895139|Device|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
166995|NCT02895139|Device|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
166996|NCT02895126|Behavioral|"Appui Parental program"|
166997|NCT02895126|Behavioral|Regular parental support|
166998|NCT02895113|Drug|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
166999|NCT02895113|Other|Placebo|Patients in this arm will be treated with placebo
167000|NCT02895100|Drug|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
167001|NCT02895100|Drug|Placebo|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
167002|NCT02895087|Other|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
167003|NCT02895087|Other|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.~At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.~At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
167004|NCT02895074|Procedure|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
167005|NCT02895074|Procedure|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
167006|NCT02895074|Drug|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
167007|NCT02895074|Drug|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
167008|NCT02895061|Drug|Alfacalcidol|Alfacalcidol 1 microgram/capsule
167009|NCT02895035|Drug|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
167010|NCT02895035|Drug|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
167011|NCT02895022|Drug|Lidocaine 2% adrénalinée|
167012|NCT02895022|Device|Epidural catheter|
167013|NCT02895022|Procedure|Caesarean section|
167015|NCT02895009|Device|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
167016|NCT02894996|Drug|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
167017|NCT02894983|Other|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
167018|NCT02894983|Other|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
167019|NCT02894970|Device|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
167020|NCT02894957|Drug|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
167021|NCT02894944|Biological|Theragene®,Ad5-yCD/mutTKSR39rep-ADP|Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
167022|NCT02894931|Dietary Supplement|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
167023|NCT02894931|Dietary Supplement|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
167024|NCT02894931|Dietary Supplement|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
167025|NCT02894931|Dietary Supplement|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
167026|NCT02894931|Other|Control- water|Chilled water flavored with lemon juice as control
167027|NCT02894918|Drug|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
167028|NCT02894905|Drug|AL-335|Participants with various degrees of impaired renal function (mild [Cohort 1], moderate [Cohort 2], severe [Cohort 3]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
167029|NCT02894892|Drug|(A)Bismuth|
167030|NCT02894892|Drug|(B)Bismuth|
167031|NCT02894892|Drug|(C)Bismuth|
167032|NCT02894892|Drug|(D)Esomeprazole and Bismuth|
167033|NCT02894892|Drug|(E)Esomeprazole and Bismuth|
167034|NCT02894892|Drug|(F)Esomeprazole and Bismuth|
167035|NCT02894892|Other|(G)Control|
167036|NCT02894879|Device|BreatheMAX®|"Modify chest physical therapy~oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set~oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
167037|NCT02894879|Other|Routine treatment|"Routine chest physical therapy~Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level~Coughing with splinting 3 times/set~Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
167038|NCT02894866|Device|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
167039|NCT02894853|Genetic|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
167040|NCT02894840|Biological|an inactivated influenza vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
167041|NCT02894840|Other|Placebo|The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
167042|NCT02894827|Biological|Blood sample|
167043|NCT02894827|Other|Flow cytometry|
167044|NCT02894827|Other|western blot|
167045|NCT02894814|Behavioral|One-Stop Dispensing|Use of own medication, review of the patient`s medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
167046|NCT02894814|Behavioral|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
167047|NCT02894788|Other|ICU admission|
167048|NCT02894749|Radiation|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
167049|NCT02894736|Device|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
167050|NCT02894723|Dietary Supplement|L-arginine|30 ml arginoline contains 5 gr l-arginine
167051|NCT02894723|Dietary Supplement|syrup|The same bottle of the experimental group, but without l-arginine
167052|NCT02894710|Drug|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
167053|NCT02894710|Drug|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
167054|NCT02894697|Device|Angiography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
167055|NCT02894697|Device|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
167056|NCT02894684|Drug|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
167057|NCT02894684|Drug|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
167058|NCT02894671|Other|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
167059|NCT02894658|Device|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
167060|NCT02894658|Procedure|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
167061|NCT02894645|Drug|Prednisolone|Oral
167062|NCT02894645|Drug|Dexamethasone|Oral
167063|NCT02894645|Drug|L-Asparaginase|Intramuscular injection
167064|NCT02894645|Drug|Vincristine|Intravenous
167065|NCT02894645|Drug|Methotrexate|Intrathecal/ Intravenous/ Oral
167066|NCT02894645|Drug|Daunorubicin|Intravenous
167067|NCT02894645|Drug|Doxorubicin|Intravenous
167068|NCT02894645|Drug|Cyclophosphamide|Intravenous
167069|NCT02894645|Drug|Cytarabine|Intravenous/ Subcutaneous injection
167070|NCT02894645|Drug|6-Mercaptopurine|Oral
167071|NCT02894645|Drug|Thioguanine|Oral
167072|NCT02894645|Drug|Fludarabine|Intravenous
167073|NCT02894645|Drug|Imatinib|Oral (For BCR-ABL ALL only)
167074|NCT02894632|Device|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
167075|NCT02894606|Drug|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
167076|NCT02894606|Drug|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
167077|NCT02894593|Other|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
167078|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
167079|NCT02894593|Other|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
167080|NCT02894593|Other|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
167081|NCT02894567|Device|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
167082|NCT02894554|Drug|Telbivudine|
167083|NCT02894554|Drug|Lamivudine|
167084|NCT02894541|Drug|CKD-519 100mg|
167085|NCT02894541|Drug|CKD-519 200mg|
167086|NCT02894541|Drug|CKD-519 100mg|
167087|NCT02894541|Drug|CKD-519 200mg|
167088|NCT02894528|Drug|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
167089|NCT02894528|Drug|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
167090|NCT02894515|Drug|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
167092|NCT02894502|Behavioral|Motivational interviewing|The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
167093|NCT02894489|Device|corneal lenses|wear corneal lenses on daily basis
167094|NCT02894489|Device|large diameter lenses|
167095|NCT02894463|Other|questionnaire|
167096|NCT02894450|Other|blood test|bioassay xaban
167097|NCT02894437|Other|qualitative interviews|semi-structured interviews as a conceptual frame work
167098|NCT02894398|Drug|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
167099|NCT02894398|Drug|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
167100|NCT02894398|Drug|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
167101|NCT02894398|Drug|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
167102|NCT02894398|Drug|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
167103|NCT02894385|Drug|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
167104|NCT02894372|Device|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
167105|NCT02894372|Device|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
167106|NCT02894359|Device|cone beam imagery of cervical spine|
167107|NCT02894346|Other|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
167108|NCT02894333|Behavioral|behavioral observation|
167109|NCT02894320|Behavioral|Behavioral observation|
167110|NCT02894307|Drug|Rivaroxaban|In patients with mechanical valves and unstable INR
167111|NCT02894294|Other|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine [SP] + Amodiaquine [AQ]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
167112|NCT02894281|Device|pupillary light reflex|measure with infra-red cameras
167113|NCT02894268|Drug|Doxycycline|Doxycycline 100g po bid
167114|NCT02894268|Drug|Furazolidone|Furazolidone 100mg po bid
167115|NCT02894268|Drug|Esomeprazole|Esomeprazole 20mg po bid
167116|NCT02894268|Drug|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
167117|NCT02894268|Drug|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
167118|NCT02894255|Device|Coronary artery bypass grafting|
167119|NCT02894255|Procedure|Percutaneous coronary intervention|
167120|NCT02894242|Device|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
167121|NCT02894229|Behavioral|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
167122|NCT02894229|Behavioral|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
167123|NCT02894216|Procedure|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
167124|NCT02894203|Behavioral|Mindfulness|
167125|NCT02894203|Behavioral|Yoga|
167126|NCT02894177|Procedure|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
167127|NCT02894164|Other|No intervention|
167128|NCT02894151|Drug|Depot medroxyprogesterone acetate|
167129|NCT02894151|Device|LNG-IUS|
167130|NCT02894138|Drug|alteplase|
167131|NCT02894138|Drug|Placebo|
167132|NCT02894125|Other|SPA Therapy|
167133|NCT02894112|Dietary Supplement|non-fat milk|1 serving of non-fat fluid milk
167134|NCT02894112|Dietary Supplement|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
167135|NCT02894112|Dietary Supplement|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
167136|NCT02894099|Other|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
167137|NCT02894099|Other|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
167175|NCT02893787|Other|Speckle Tracking Echocardiography|Echocardiography analyses
167396|NCT02892019|Drug|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
167138|NCT02894099|Other|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
167139|NCT02894099|Other|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
167140|NCT02894086|Other|database.|
167141|NCT02894073|Device|skin transilluminator|VeinViewer
167142|NCT02894060|Other|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):~2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
167143|NCT02894047|Biological|blood|measurement of CaSR expression levels on synovial fluid monocytes
167144|NCT02894021|Procedure|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
167145|NCT02894021|Procedure|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
167146|NCT02894008|Drug|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
167147|NCT02893995|Drug|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
167148|NCT02893995|Drug|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
167149|NCT02893982|Radiation|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
167150|NCT02893969|Behavioral|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
167151|NCT02893969|Behavioral|Rest|Complete physical rest until asymptomatic.
167152|NCT02893956|Procedure|echocardiography with postural support|
167153|NCT02893956|Procedure|echocardiography with standard condition (usual)|
167154|NCT02893943|Dietary Supplement|Probiotics|
167155|NCT02893943|Dietary Supplement|Placebo|
167156|NCT02893930|Drug|Sapanisertib|Given PO
167157|NCT02893917|Drug|Cediranib|Given PO
167158|NCT02893917|Other|Laboratory Biomarker Analysis|Correlative studies
167159|NCT02893917|Drug|Olaparib|Given PO
167160|NCT02893904|Device|EEG monitoring under propofol|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
167161|NCT02893904|Device|EEG monitoring under sevoflurane|Steady state concentrations periods of Sevoflurane for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
167162|NCT02893891|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
167163|NCT02893891|Procedure|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
167164|NCT02893891|Procedure|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
167165|NCT02893891|Device|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
167166|NCT02893878|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
167167|NCT02893865|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
167168|NCT02893865|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
167169|NCT02893852|Behavioral|standard CO-OP Approach|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
167170|NCT02893852|Behavioral|standard CO-OP Approach plus coaching parents|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
167171|NCT02893839|Other|Prick to prick test|
167172|NCT02893826|Drug|EG-1962 (nimodipine microparticles)|
167173|NCT02893826|Drug|Enteral Nimodipine|
167174|NCT02893800|Device|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
167281|NCT02893046|Other|No intervention|
167176|NCT02893774|Other|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.~Those assessment will use standardized quality of life questionnaire :~QLQ-C30~SWLS (Satisfaction with Life Scale)~PTGI (Post-Traumatic Growth Inventory)~HADS (Hospital Anxiety and Depression Scale)~Brief COPE~MHLCS (Multidimensional Health Locus of Control Scale)"
167177|NCT02893748|Device|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
167178|NCT02893748|Procedure|Colonoscopy|Screening colonoscopy as per standard of care.
167179|NCT02893748|Drug|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
167180|NCT02893735|Other|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
167181|NCT02893735|Other|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
167182|NCT02893722|Drug|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
167183|NCT02893722|Drug|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
167184|NCT02893709|Drug|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
167185|NCT02893696|Other|Various sitting time|Various sitting time
167186|NCT02893683|Other|Paris Visual Learning Test|
167187|NCT02893670|Procedure|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.~Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
167188|NCT02893618|Drug|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
167189|NCT02893579|Behavioral|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
167190|NCT02893579|Behavioral|Delayed SR intervention|Activity tracking only for the first month
167191|NCT02893566|Behavioral|Mi Band Step Challenge|
167192|NCT02893553|Drug|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
167193|NCT02893553|Drug|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
167194|NCT02893553|Drug|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
167195|NCT02893553|Other|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
167196|NCT02893540|Drug|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
167197|NCT02893527|Behavioral|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
167198|NCT02893514|Other|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
167199|NCT02893514|Other|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
167200|NCT02893488|Drug|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
167201|NCT02893488|Drug|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
167202|NCT02893488|Drug|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
167203|NCT02893449|Behavioral|Social adaptation|"Questionnaire to fill-in.~The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
167282|NCT02893033|Device|repetitive transcranial magnetic stimulation|rTMS
167531|NCT02890979|Other|Laboratory Biomarker Analysis|Correlative studies
167204|NCT02893449|Behavioral|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
167205|NCT02893449|Procedure|Deep brain stimulation|
167206|NCT02893436|Procedure|Surgery with tracheal intubation curarisation|
167207|NCT02893423|Drug|Ropivacaine|Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
167208|NCT02893397|Device|Activity Monitor|Wear a fitbit
167209|NCT02893397|Behavioral|Exercise Intervention|Undergo supervised exercise sessions
167210|NCT02893384|Drug|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
167211|NCT02893371|Drug|Lithium Carbonate|Exposure to all dosages and delivery forms.
167212|NCT02893371|Drug|Lamotrigine|Exposure to all dosages and delivery forms.
167213|NCT02893371|Drug|Valproic Acid|Exposure to all dosages and delivery forms.
167214|NCT02893371|Drug|Oxcarbazepine|Exposure to all dosages and delivery forms.
167215|NCT02893371|Drug|Carbamazepine|Exposure to all dosages and delivery forms.
167216|NCT02893371|Drug|Ziprasidone|Exposure to all dosages and delivery forms.
167217|NCT02893371|Drug|Risperidone|Exposure to all dosages and delivery forms.
167218|NCT02893371|Drug|Quetiapine|Exposure to all dosages and delivery forms.
167219|NCT02893371|Drug|Olanzapine|Exposure to all dosages and delivery forms.
167220|NCT02893371|Drug|Aripiprazole|Exposure to all dosages and delivery forms.
167221|NCT02893371|Drug|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
167222|NCT02893371|Drug|Haloperidol|Exposure to all dosages and delivery forms.
167223|NCT02893371|Drug|Perphenazine|Exposure to all dosages and delivery forms.
167224|NCT02893371|Drug|Clozapine|Exposure to all dosages and delivery forms.
167225|NCT02893371|Drug|Asenapine|Exposure to all dosages and delivery forms.
167226|NCT02893371|Drug|Lurasidone|Exposure to all dosages and delivery forms.
167227|NCT02893371|Drug|Paliperidone|Exposure to all dosages and delivery forms.
167228|NCT02893371|Drug|Mirtazapine|Exposure to all dosages and delivery forms.
167229|NCT02893371|Drug|Bupropion|Exposure to all dosages and delivery forms.
167230|NCT02893371|Drug|Desvenlafaxine|Exposure to all dosages and delivery forms.
167231|NCT02893371|Drug|Duloxetine|Exposure to all dosages and delivery forms.
167232|NCT02893371|Drug|Venlafaxine|Exposure to all dosages and delivery forms.
167233|NCT02893371|Drug|Citalopram|Exposure to all dosages and delivery forms.
167234|NCT02893371|Drug|Escitalopram|Exposure to all dosages and delivery forms.
167235|NCT02893371|Drug|Fluoxetine|Exposure to all dosages and delivery forms.
167236|NCT02893371|Drug|Fluvoxamine|Exposure to all dosages and delivery forms.
167237|NCT02893371|Drug|Paroxetine|Exposure to all dosages and delivery forms.
167238|NCT02893371|Drug|Sertraline|Exposure to all dosages and delivery forms.
167239|NCT02893371|Drug|Vilazodone|Exposure to all dosages and delivery forms.
167240|NCT02893371|Drug|Doxepin|Exposure to all dosages and delivery forms.
167241|NCT02893358|Drug|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
167242|NCT02893358|Drug|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
167243|NCT02893345|Behavioral|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
167244|NCT02893345|Other|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
167245|NCT02893332|Radiation|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
167246|NCT02893332|Drug|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
167247|NCT02893319|Behavioral|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
167248|NCT02893306|Biological|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
167249|NCT02893293|Drug|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
167250|NCT02893293|Device|Magentic Resonance Imaging|Both arms will receive MRI
167251|NCT02893280|Drug|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
167357|NCT02892357|Drug|Treatment group|Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
167358|NCT02892357|Drug|Control group|sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
167359|NCT02892344|Drug|QMF149 150/80 μg|QMF149 150/80 μg o.d via Concept1
167252|NCT02893267|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
167253|NCT02893267|Other|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
167254|NCT02893267|Other|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
167255|NCT02893267|Device|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
167256|NCT02893254|Drug|IBI303|12 cycles. IBI303: 40 mg, iH
167257|NCT02893254|Drug|Adalimumab|12 cycles. Adalimumab: 40mg, iH
167258|NCT02893241|Drug|Cafedrine/theodrenaline|
167259|NCT02893241|Drug|Ephedrine|
167260|NCT02893228|Procedure|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
167261|NCT02893228|Drug|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
167262|NCT02893215|Other|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
167263|NCT02893202|Other|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
167264|NCT02893189|Genetic|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
167265|NCT02893176|Drug|macitentan|
167266|NCT02893176|Drug|placebo (for macitentan)|
167267|NCT02893163|Behavioral|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
167268|NCT02893163|Other|Usual Care|Usual Care by Family Doctor
167269|NCT02893150|Behavioral|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).~For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
167270|NCT02893150|Behavioral|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
167271|NCT02893150|Behavioral|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems[47]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
167272|NCT02893137|Device|Optune|For further information see www.optune.com
167273|NCT02893137|Procedure|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
167274|NCT02893124|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
167275|NCT02893111|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
167276|NCT02893098|Drug|Humia inj.|"Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
167277|NCT02893098|Drug|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
167278|NCT02893085|Biological|bile sample analysis|tumor mutation profile tumor genotype
167279|NCT02893085|Biological|biochemical markers, VEGF and MMPs, in bile samples|
167280|NCT02893072|Behavioral|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
167283|NCT02893007|Other|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
167284|NCT02892994|Other|ultrasound|
167285|NCT02892981|Other|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
167286|NCT02892968|Procedure|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
167287|NCT02892968|Procedure|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
167288|NCT02892955|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the MOMENTUM 3 IDE Study.
167289|NCT02892942|Drug|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
167290|NCT02892942|Drug|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
167291|NCT02892942|Drug|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
167292|NCT02892929|Behavioral|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.~Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
167293|NCT02892929|Behavioral|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
167294|NCT02892916|Drug|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
167295|NCT02892916|Drug|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
167296|NCT02892903|Device|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
167297|NCT02892890|Procedure|Muscle Magnetic Resonance Imaging (RMI) evaluation|
167298|NCT02892890|Device|MRI|
167299|NCT02892864|Other|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
167300|NCT02892864|Other|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.~Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
167301|NCT02892851|Device|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :~Parameter setting~Cross-over double-bind (ON/OFF)~Open Phase (ON)"
167302|NCT02892838|Device|mobile bearing knee system for total knee arthroplasty|
167303|NCT02892838|Device|fixed bearing total knee prosthesis|
167304|NCT02892825|Other|Music|headphones with music
167305|NCT02892825|Other|No Music|headphones without music
167306|NCT02892812|Biological|Pneumococcal conjugate vaccine|
167307|NCT02892799|Other|NICOM-Guided Diuresis|NICOM-based assessment of PLR-induced change in cardiac index
167308|NCT02892799|Other|Standard of Care|
167309|NCT02892786|Other|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study~5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery~Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.~Patients will be followed every 3 months for two years."
167310|NCT02892773|Device|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times per therapy session.~Each I.S. therapy session will last about 15 minutes, 3 times per day.~Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
167311|NCT02892773|Device|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.~Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~The 10-breath cycle will be repeated 3 times.~Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.~Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
167312|NCT02892760|Device|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
167313|NCT02892747|Behavioral|Educational Program|
167314|NCT02892734|Biological|Ipilimumab|Given IV
167315|NCT02892734|Other|Laboratory Biomarker Analysis|Correlative studies
167316|NCT02892734|Biological|Nivolumab|Given IV
167360|NCT02892344|Drug|MF 200 μg|MF 200 μg o.d. via Twisthaler®
167395|NCT02892032|Behavioral|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
167753|NCT02889302|Drug|Placebo|24 weeks
167317|NCT02892721|Other|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.~The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
167318|NCT02892708|Procedure|Surgery|partial or complete resection followed by radiotherapy
167319|NCT02892708|Radiation|radiotherapy|radiotherapy after a brain biopsy
167320|NCT02892695|Biological|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
167321|NCT02892682|Other|BLOOD TEST|
167322|NCT02892669|Other|non interventional study|non interventional study
167323|NCT02892643|Procedure|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
167324|NCT02892643|Procedure|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
167325|NCT02892630|Other|No intervention|
167326|NCT02892617|Other|Bacteriological analysis of disc|
167327|NCT02892604|Device|insulin pump to inControl AP platform|Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
167328|NCT02892591|Drug|Cannabis|vaporized plant material
167329|NCT02892591|Drug|Oxycodone|oral capsule
167330|NCT02892591|Drug|Placebo for Cannabis|vaporized placebo plant material
167331|NCT02892591|Drug|Placebo for Oxycodone|oral placebo capsule
167332|NCT02892578|Other|electrocardiogram|
167333|NCT02892565|Other|Blood sample|
167334|NCT02892552|Radiation|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
167335|NCT02892552|Radiation|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
167336|NCT02892539|Radiation|Coronary Angiography|
167337|NCT02892526|Other|Abdominoplasty with exeresis of cutaneous tissue|
167338|NCT02892526|Other|Collection of cutaneous tissue|
167339|NCT02892513|Device|Percutaneous auricular neurostimulation|The Bridge device (manufactured by Key Electronics [Jeffersonville, IN, USA] and distributed by Innovative Health Solutions [Versailles, IN, USA]) provides continual neurostimulation for five days with alternating current.
167340|NCT02892513|Device|Sham percutaneous auricular neurostimulation|Identical in appearance to active, device, but no stimulation will be given.
167341|NCT02892500|Drug|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
167342|NCT02892500|Drug|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
167343|NCT02892487|Other|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
167344|NCT02892474|Procedure|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
167345|NCT02892474|Procedure|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
167346|NCT02892461|Procedure|Umbilical cord milking|As same as that in arm descriptions.
167347|NCT02892448|Other|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels. Patients in all three groups (Unilateral hip resurfacing, bilateral hip resurfacing, and non-metal on metal total hip arthroplasty) will undergo a Cardiac MRI.
167348|NCT02892435|Device|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
167349|NCT02892435|Device|conventional dressing|positioning conventional dressing
167350|NCT02892422|Drug|Lu AF35700|"Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study"
167351|NCT02892409|Drug|Clarithromycin|Clarithromycin tablets
167352|NCT02892409|Drug|Amoxicillin|Amoxicillin capsules
167353|NCT02892409|Drug|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
167354|NCT02892409|Drug|Lansoprazole|Lansoprazole capsules
167355|NCT02892409|Drug|TAK-438|TAK-438 tablets
167356|NCT02892370|Drug|SHR0302|SHR0302 tablets (10 mg)
167789|NCT02888990|Drug|Dasatinib|
167361|NCT02892331|Behavioral|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
167362|NCT02892331|Behavioral|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
167363|NCT02892318|Drug|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
167364|NCT02892318|Drug|Guadecitabine|Guadecitabine 60 mg/m^2 SC on Days 1-5 of every 28-day cycle.
167365|NCT02892305|Procedure|Hepatic Resection or Ablation with Pancreaticoduodenectomy|"Patients will undergo pancreaticoduodenectomy, or the Whipple procedure, which involves removal of the head of the pancreas, the duodenum, and a portion of the stomach, as well as the gallbladder and a portion of the bile duct.~The patient will also undergo a Hepatectomy, the surgical resection or removal of all or part of the liver or Microwave Ablation (MWA) if determined by the surgeon to be the best course of care."
167366|NCT02892279|Other|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
167367|NCT02892266|Other|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
167368|NCT02892253|Device|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
167369|NCT02892240|Other|No intervention. Observational study|
167370|NCT02892227|Procedure|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
167371|NCT02892214|Procedure|Pelvic floor physical therapy|
167372|NCT02892214|Drug|estriol cream (ovestin)|
167373|NCT02892214|Procedure|Low-level-laser therapy|
167374|NCT02892201|Drug|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
167375|NCT02892175|Procedure|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
167376|NCT02892162|Procedure|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
167377|NCT02892149|Drug|vadadustat|Oral tablet
167378|NCT02892149|Drug|darbepoetin alfa|subcutaneous/intravenous
167379|NCT02892123|Drug|ZW25|ZW25 administered IV once weekly, once every 2 weeks, or once every 3 weeks. Part 1: in multiple increasing doses; Part 2: ZW25 given at the MTD, OBD, or an RD identified in Part 1; Part 3: ZW25 given at the MTD, OBD, or an RD combined with one of the selected chemotherapy agents.
167380|NCT02892123|Combination Product|Paclitaxel|Part 3, Treatment Group 1 chemotherapy combination
167381|NCT02892123|Combination Product|Capecitabine|Part 3, Treatment Group 2 chemotherapy combination
167382|NCT02892123|Combination Product|Vinorelbine|Part 3, Treatment Group 3 chemotherapy combination
167383|NCT02892110|Drug|Varenicline|2 mg daily
167384|NCT02892110|Drug|Placebo|2 mg daily
167385|NCT02892097|Device|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
167386|NCT02892097|Device|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
167387|NCT02892097|Behavioral|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
167388|NCT02892084|Device|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
167389|NCT02892084|Device|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
167390|NCT02892071|Drug|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
167391|NCT02892071|Device|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
167392|NCT02892071|Device|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
167393|NCT02892045|Device|MMG|neuromuscular monitoring device
167394|NCT02892032|Behavioral|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
167397|NCT02892019|Drug|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
167398|NCT02892006|Behavioral|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
167399|NCT02891993|Other|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
167400|NCT02891993|Other|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
167401|NCT02891980|Biological|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
167402|NCT02891980|Biological|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
167403|NCT02891967|Other|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
167404|NCT02891967|Other|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
167405|NCT02891954|Drug|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
167406|NCT02891928|Device|Rocker sole shoes|Measure of walk testing Measure of standing position
167407|NCT02891928|Device|Normal shoes|Measure of walk testing Measure of standing position
167408|NCT02891915|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
167409|NCT02891915|Drug|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
167410|NCT02891915|Drug|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
167411|NCT02891915|Other|Placebo|Placebo
167412|NCT02891902|Other|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
167413|NCT02891863|Device|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
167414|NCT02891850|Drug|Adempas (Riociguat, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
167415|NCT02891850|Drug|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
167416|NCT02891850|Drug|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
167417|NCT02891837|Drug|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;~Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
167418|NCT02891837|Other|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;~Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;~Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;~9 mg/kg/hr continuous infusion for up to 48 hours."
167419|NCT02891824|Drug|atezolizumab + avastin + platinum-based chemotherapy|"atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
167420|NCT02891824|Drug|placebo + avastin + platinum-based chemotherapy|"placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression~avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression~platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
167421|NCT02891811|Drug|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
167422|NCT02891811|Drug|Thalidomide|100mg orally on days 1-28 in patients <75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
167423|NCT02891811|Drug|Lenalidomide|25mg p.o. on days 1-21 of each cycle
167532|NCT02890979|Other|Quality-of-Life Assessment|Ancillary studies
167424|NCT02891811|Drug|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients <75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
167425|NCT02891798|Drug|Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
167426|NCT02891798|Drug|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3 for Knee replacements Nerve blocks before surgery of L2-L4 for hip replacements
167427|NCT02891785|Behavioral|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
167428|NCT02891772|Procedure|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
167429|NCT02891759|Other|Alloderm RTU|-Most commonly used acellular dermal matrices
167430|NCT02891759|Other|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
167431|NCT02891759|Procedure|Skin or nipple-sparing mastectomy|-Standard of care
167432|NCT02891759|Other|Breast Q|"15 questions~10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time~Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
167433|NCT02891759|Procedure|Surgery|"To address the tissue expander~Standard of care"
167434|NCT02891746|Other|non invasive sampling|
167435|NCT02891720|Device|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
167436|NCT02891707|Device|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
167437|NCT02891694|Other|in vitro immuno-histo-chemical analysis of corneal epithelium|
167438|NCT02891681|Device|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
167439|NCT02891668|Drug|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
167440|NCT02891655|Other|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
167441|NCT02891642|Device|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
167442|NCT02891629|Device|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
167443|NCT02891616|Drug|fludeoxyglucose F 18|
167444|NCT02891616|Device|Positron emission tomography-computed tomography|
167445|NCT02891616|Drug|18F-fluorothymidine|
167446|NCT02891616|Device|Positron emission tomography-magnetic resonance imaging|
167447|NCT02891603|Drug|Pacritinib|Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
167448|NCT02891603|Drug|Sirolimus|In addition to the study drug, pacritinib, sirolimus and tacrolimus (SIR/TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR/TAC taper. SIR/TAC levels will be monitored according to program standard operating procedures. Dose modifications of SIR/TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
167449|NCT02891603|Drug|Tacrolimus|In addition to the study drug, pacritinib, sirolimus and tacrolimus (SIR/TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR/TAC taper. SIR/TAC levels will be monitored according to program standard operating procedures. Dose modifications of SIR/TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
167450|NCT02891590|Drug|DTRMWXHS-12|
167451|NCT02891577|Procedure|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
167533|NCT02890979|Device|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
167534|NCT02890966|Drug|SHR4640|Day1~Day7:oral administration
167452|NCT02891564|Behavioral|Band Together|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.
167453|NCT02891564|Other|Control Mobile 3D video game|expectancy-matched control game
167454|NCT02891538|Drug|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).*
167455|NCT02891525|Dietary Supplement|50g glucose|
167456|NCT02891525|Dietary Supplement|25g fructose|
167457|NCT02891525|Dietary Supplement|220mg acesulfame-K|
167458|NCT02891525|Dietary Supplement|250mL tap water|
167459|NCT02891512|Other|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
167460|NCT02891512|Other|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
167461|NCT02891512|Other|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
167462|NCT02891499|Procedure|Low-level laser therapy|"Immediate post-operative period (implantation day) Red emission (660 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.~Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 8 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
167463|NCT02891499|Procedure|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
167464|NCT02891486|Procedure|Spinal surgery|Elective spinal surgery performed
167465|NCT02891473|Other|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
167466|NCT02891473|Other|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
167467|NCT02891460|Device|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
167468|NCT02891460|Device|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
167469|NCT02891447|Drug|Cisplatin|Given intraperitoneally
167470|NCT02891447|Drug|Hyperthermic Intraperitoneal Chemotherapy|Undergo HIPEC
167471|NCT02891447|Drug|Mitomycin|Given intraperitoneally
167472|NCT02891434|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
167473|NCT02891434|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
167474|NCT02891434|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
167475|NCT02891421|Behavioral|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
167476|NCT02891421|Other|Standard Care|Standard Care: Participants received standard care
167477|NCT02891408|Drug|Firsocostat|Tablet(s) or Capsule(s) administered orally on Day 1
167478|NCT02891408|Drug|Fenofibrate|Tablet(s) administered orally on Day 1
167479|NCT02891395|Drug|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.~For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
167480|NCT02891382|Behavioral|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
167481|NCT02891382|Behavioral|Goal setting|Goals for weight loss and change in levels of HbA1c
167482|NCT02891382|Behavioral|Companion Support|Patient has a companion/team support partner to support achieving goals.
167483|NCT02891382|Behavioral|Individual Reward|The cash reward is given to the patient with diabetes.
167484|NCT02891382|Behavioral|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
167485|NCT02891369|Other|No intervention. Descriptive study|
167486|NCT02891356|Device|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
167487|NCT02891343|Other|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
167488|NCT02891330|Behavioral|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
167489|NCT02891304|Other|Quarterly Feedback|Learning curves received quarterly vs. annually
167535|NCT02890966|Drug|placebo|Day1~Day7:oral administration
167536|NCT02890953|Drug|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
167790|NCT02888964|Drug|Add-on therapy|Pioglitazone therapy
167490|NCT02891278|Drug|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM."
167491|NCT02891278|Drug|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
167492|NCT02891278|Procedure|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
167493|NCT02891265|Behavioral|Smoking cessation patch|To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
167494|NCT02891252|Procedure|outpatient procedure|
167495|NCT02891239|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
167496|NCT02891226|Drug|Mirikizumab|
167497|NCT02891226|Drug|Placebo|
167498|NCT02891200|Other|Peer support program|The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
167499|NCT02891200|Other|HCP support|Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
167500|NCT02891187|Behavioral|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
167501|NCT02891187|Behavioral|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
167502|NCT02891174|Drug|Ibuprofen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.
167503|NCT02891174|Drug|Acetaminophen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
167504|NCT02891161|Drug|durvalumab|1500 mg Q4 weekly
167505|NCT02891161|Radiation|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
167506|NCT02891148|Drug|BI 690517|
167507|NCT02891135|Other|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
167508|NCT02891109|Biological|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
167509|NCT02891096|Procedure|inspiratory muscle strength|"Measurements:~in- and expiratory muscle strength (5min)~lung function (FVC, FEV1, PEF, PCF) (10 min)~Questionnaires:~ISCoS core data-set~ISCoS pulmonary function data sets~ISCoS quality of life questionnaire~questionnaire on individual respiratory muscle training, regular physical exercise and therapies~individual medication/vaccination and other medical complications will be assessed from patient's medical records~All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
167510|NCT02891083|Drug|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
167511|NCT02891083|Radiation|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)~Dose: 50Gy~Technology: strong tone~Segmentation: conventional segmentation 2Gy/d"
167512|NCT02891083|Other|Control group (Surgery alone)|
167513|NCT02891070|Drug|FS VH S/D 500 s-apr|
167514|NCT02891070|Device|DuraSeal Dural Sealant|
167515|NCT02891057|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-036)
167516|NCT02891044|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-040)
167517|NCT02891031|Drug|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
167518|NCT02891031|Drug|Placebo|500 mg twice daily after meal for 6 weeks
167519|NCT02891018|Device|paclitaxel controlled release balloon catheter Vasoguard TM|
167520|NCT02891018|Device|paclitaxel release coronary balloon catheter SeQuent Please|
167521|NCT02891005|Device|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
167522|NCT02891005|Device|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
167523|NCT02890992|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form: solution Route of administration: subcutaneous injection
167524|NCT02890992|Drug|statins|Pharmaceutical form: tablet Route of administration: oral
167525|NCT02890992|Drug|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
167526|NCT02890992|Drug|cholestyramine|Pharmaceutical form:tablet Route of administration: oral
167527|NCT02890992|Drug|fenofibrate|Pharmaceutical form: tablet Route of administration: oral
167528|NCT02890992|Drug|omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
167529|NCT02890992|Drug|nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
167530|NCT02890979|Other|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
265523|NCT02177448|Drug|BIBR277 low dose|
167537|NCT02890953|Drug|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
167538|NCT02890940|Behavioral|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
167539|NCT02890927|Other|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:~Low risk patients are expected to do well and will not receive co-management.~Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.~High risk patients have an acute geriatric syndrome. The geriatric nurse will visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
167540|NCT02890914|Other|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
167541|NCT02890888|Other|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
167542|NCT02890875|Other|Ethanol lock|
167543|NCT02890875|Other|Heparin lock|
167544|NCT02890849|Other|Liquid biopsy|
167545|NCT02890836|Drug|Antihypertensiva, mainly Metyldopa|
167546|NCT02890823|Drug|Cholecalciferol|
167547|NCT02890810|Other|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
167548|NCT02890810|Other|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
167549|NCT02890797|Radiation|radiology|The investigators propose to performed a chest ultrasound in infants (<24 months) admitted for bronchiolitis with an available chest X-ray
167550|NCT02890784|Drug|dasatinib (SPRYCEL®)|Treatment optimization for patients with chronic myeloid leukemia (CML)
167551|NCT02890771|Procedure|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
167552|NCT02890771|Procedure|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
167553|NCT02890771|Procedure|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
167554|NCT02890758|Biological|Natural Killer (NK) Cells|dose escalation of Natural Killer (NK) Cells from two infusion of 10 x 10^6 cells/kg to 1000 x 10^6 cells/kg dependent on dose limited toxicity
167555|NCT02890758|Biological|ALT803|given at 6mcg/kg weekly for four weeks
167556|NCT02890745|Drug|Empagliflozin|
167557|NCT02890745|Drug|Placebo|
167558|NCT02890732|Device|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
167559|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
167560|NCT02890719|Drug|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
167561|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
167562|NCT02890719|Drug|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
167563|NCT02890719|Drug|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
167564|NCT02890706|Device|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
167565|NCT02890693|Behavioral|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
167566|NCT02890680|Procedure|Platelet-rich fibrin|
167567|NCT02890680|Procedure|Control group|
167568|NCT02890667|Other|Incident cancer|The number of incident cancer cases
167569|NCT02890654|Other|First time measure|"Initial Interview~Initial Survey,~Quality of life Scale~Kinesitherapy Review~Anxiety Scale"
167570|NCT02890654|Other|Second time measure|"Kinesitherapy review~Second survey including numeric scale of pain~Anxiety scale~Scoliosis Research Society 22 quality of life scale"
167571|NCT02890654|Other|Third time measure|"Scoliosis Research Society 22 quality of life Scale~Anxiety scale~Numeric scale of pain~Kinesitherapy review"
167572|NCT02890641|Genetic|Sequencing of paired blood-brain DNA samples|Sequencing of paired blood-brain DNA samples to search for genetic abnormalities
167573|NCT02890615|Behavioral|Depression self-care|Toolkit and coaching
167574|NCT02890602|Drug|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
167744|NCT02889367|Drug|Odalasvir 100 mg|Participants will receive odalasvir 2*50 mg tablet, orally once on Day 1.
167575|NCT02890602|Drug|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
167576|NCT02890589|Device|SYNERGY stent|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
167577|NCT02890589|Device|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.~Stent will be implanted according to manufacturer's and competent authority recommendations."
167578|NCT02890576|Other|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
167579|NCT02890563|Device|Class II Compression Stockings|
167580|NCT02890537|Drug|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
167581|NCT02890537|Drug|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
167582|NCT02890524|Device|night guard|60 days before and after intervention with the night guard
167583|NCT02890524|Device|placebo night guard|60 days before and after intervention with the placebo night guard
167584|NCT02890511|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
167585|NCT02890485|Procedure|Dry Needling|Dry needling consists of small, monofilament needles that are administered directly into the tissue and manipulated to make the muscle relax for pain relief. This technique is used to treat dysfunctions in skeletal muscle and connective tissue to help diminish pain, reduce impairments of body structure and restore function. Dry needling will be performed in the gluteal or the quadriceps muscle groups depending upon group randomization.
167586|NCT02890485|Procedure|Sham Dry Needling|"The same overall procedures will be used as in the true dry needling groups and applied to the same muscle groups (gluteal or quadriceps) depending upon ground randomization. Sham dry needling will be performed using a commercially available sham needling system commonly.This set-up utilizes a blunt tipped needle. When the sham needle is pressed downward, the barrel of the needle retracts into the handle, giving the appearance of insertion of the needle through the skin. This also creates pressure on the subject's skin, increasing the sensation of dry needling. Patients will not be allowed to observe the areas being needled or sham needled."
167587|NCT02890485|Other|Physical Therapy|Physical Therapy and exercise as determined by the examining clinician based on the patients specific impairments and functional limitations. All subjects enrolled in this study will receive an initial physical therapy (PT) evaluation and then 2 additional PT sessions a week a part. Interventions and prescribed home exercises will be specific to the patients' primary individual impairments as determined during the initial PT evaluation. These interventions reflect current evidence, but will not be restrictive to specific exercises; prescribed exercises will be deemed appropriate based on the treating PTs' examination, evaluation, and identification of each patients' primary deficits, impairments, functional limitations, and current literature.
167588|NCT02890459|Other|Prize incentive - Low|Low expected prize value.
167589|NCT02890459|Other|Prize incentive - High|High expected prize value.
167590|NCT02890459|Other|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
167591|NCT02890459|Other|Travel Voucher|Travel voucher to assist with linkage to care.
167592|NCT02890459|Other|Standard care|Includes HIV viral load and treatment adherence counseling.
167593|NCT02890459|Behavioral|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
167594|NCT02890459|Behavioral|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
167595|NCT02890459|Behavioral|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
167596|NCT02890459|Behavioral|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
167597|NCT02890459|Behavioral|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
167598|NCT02890446|Behavioral|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.~Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.~12 sessions--3 times a week for 4 weeks"
167745|NCT02889367|Drug|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
167746|NCT02889367|Drug|Odalasvir 500 mg|Participants will receive odalasvir 10*50 mg tablet, orally once on Day 1.
167599|NCT02890394|Other|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
167600|NCT02890381|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
167601|NCT02890381|Biological|Placebo|Isotonic diluent, administered as nose drops
167602|NCT02890368|Drug|TTI-621 Monotherapy|"TTI-621 (SIRPα-IgG1 Fc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
167603|NCT02890368|Drug|TTI-621 + PD-1/PD-L1 Inhibitor|TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab, avelumab, or atezolizumab administered on Day 1. Subjects in this cohort must have a cancer diagnosis for which a PD-1/PD-L1 inhibitor is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
167604|NCT02890368|Drug|TTI-621 + pegylated interferon-α2a|TTI-621 will be given in combination with pegylated interferon-α2a. Subjects in this cohort must have a cancer diagnosis for which pegylated interferon-α2a is approved by the FDA or listed in the National Comprehensive Cancer Network (NCCN) Guidelines.
167605|NCT02890368|Other|TTI-621 + T-Vec|TTI-621 will be given in combination with talimogene laherparepvec (T-Vec). Subjects in this cohort must have unresectable melanoma.
167606|NCT02890368|Other|TTI-621 + radiation|TTI-621 will be given following radiation to the target plasmacytoma. Subjects in this cohort must have relapsed multiple myeloma with bony or soft tissue plasmacytoma(s).
167607|NCT02890355|Drug|Fluorouracil|Given IV
167608|NCT02890355|Drug|Fluorouracil|Given IV bolus
167609|NCT02890355|Drug|Irinotecan Hydrochloride|Given IV
167610|NCT02890355|Other|Laboratory Biomarker Analysis|Correlative studies
167611|NCT02890355|Drug|Leucovorin Calcium|Given IV
167612|NCT02890355|Drug|Veliparib|Given PO
167613|NCT02890329|Drug|Decitabine|Given IV
167614|NCT02890329|Biological|Ipilimumab|Given IV
167615|NCT02890316|Other|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
167616|NCT02890316|Radiation|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
167617|NCT02890303|Device|Zepto System|Anterior Capsulotomy using the Zepto System.
167618|NCT02890290|Dietary Supplement|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.
167619|NCT02890290|Dietary Supplement|Placebo|Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.
167620|NCT02890277|Device|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
167621|NCT02890277|Drug|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
167622|NCT02890238|Drug|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
167623|NCT02890238|Drug|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
167624|NCT02890238|Drug|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
167625|NCT02890225|Procedure|3 days after|in 3 days after RIRS.
167626|NCT02890225|Procedure|10days after|in10 days after RIRS.
167627|NCT02890225|Procedure|EPVL performed in30days after RIRS|Patients in Group C undergo EPVL in630days after RIRS.
167628|NCT02890212|Dietary Supplement|selenium supplementation|administration of selenium pills (400 micrograms) for randomized subjects
167629|NCT02890212|Dietary Supplement|placebo|administration of placebo pills for randomized subjects
167630|NCT02890199|Drug|Bupivacaine liposomal|
167631|NCT02890199|Drug|Lidocaine|
167632|NCT02890186|Device|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
167633|NCT02890186|Other|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
167634|NCT02890173|Drug|CS-3150|
167635|NCT02890173|Drug|Eplerenone|
167636|NCT02890160|Device|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
167637|NCT02890160|Device|XIENCE|Everolimus Eluting Coronary Stent System
167638|NCT02890108|Dietary Supplement|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
167639|NCT02890108|Dietary Supplement|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
167640|NCT02890095|Procedure|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :~1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.~These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
167747|NCT02889367|Drug|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20*50 mg tablet, orally once on Day 1.
167748|NCT02889354|Behavioral|Cognitive-behavioral therapy|
167749|NCT02889341|Dietary Supplement|DHA|
167641|NCT02890095|Procedure|plastic surgery|"The excision piece will follow the classical pathological circuit.~A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:~measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)~to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.~Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
167642|NCT02890082|Drug|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
167643|NCT02890082|Drug|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~Ovulation induction by OVITRELLE® 250μg.~Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
167644|NCT02890082|Drug|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
167645|NCT02890069|Biological|PDR001|anti-PD1 antibody
167646|NCT02890069|Drug|LCL161|
167647|NCT02890069|Drug|Everolimus|
167648|NCT02890069|Drug|Panobinostat|
167649|NCT02890069|Drug|QBM076|
167650|NCT02890069|Drug|HDM201|
167651|NCT02890056|Behavioral|H2GO!|
167652|NCT02890043|Procedure|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
167653|NCT02890043|Procedure|free-hand surgery|traditional free-hand surgery
167654|NCT02890043|Device|TiRobot system|a robot-assisted spine surgery system
167655|NCT02890030|Behavioral|Questionnaire|"Neurotoxicity~Medications of interest~General health~Family history"
167656|NCT02890017|Other|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.~Postoperative consultation at 1 and 3 months."
167657|NCT02890017|Other|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
167658|NCT02889991|Other|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
167659|NCT02889991|Other|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
167660|NCT02889991|Other|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.~The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
167661|NCT02889991|Other|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:~To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.~Monitor longitudinally taut band, with index and middle fingers.~Percuss with tube and needle placebo (Sham needle) on Infraspinatus.~Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.~Remove the bridles and perform hemostasis with cotton.~We will give end to the technique placebo of dry needling."
167662|NCT02889952|Device|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.~NIR consisted of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
167700|NCT02889679|Procedure|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
167750|NCT02889341|Other|Placebo|
167663|NCT02889939|Other|UC + ETT|"UC: A 3-week UC period, where the participants were not offered any new rehabilitation activities but were allowed to continue their regular treatment for a maximum of 3 hours per week.~ETT: The rehabilitation facilities were located in a climate that allowed and encouraged both indoor and outdoor activities. The ETT was individually tailored. Participants exercised in the same room/place as the other participants in groups of 4-9. Physical exercise was scheduled 3.5-6 hours per day, 5½ days per week for 3 weeks. The training was characterized by repetitive mass practice of gradually increasing difficulty and noncompensatory strategies, such as enforcing use of the affected side.~Beyond scheduled activities, participants were encouraged to physically engage themselves in a challenging outdoor environment."
167664|NCT02889926|Biological|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
167665|NCT02889926|Biological|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
167666|NCT02889913|Other|No intervention only description|No intervention only description
167667|NCT02889900|Drug|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily~Dose reduction for both products is allowed"
167668|NCT02889874|Radiation|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
167669|NCT02889861|Drug|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific TCR fused to anti-CD3
167670|NCT02889848|Other|Saline|Saline injection
167671|NCT02889848|Drug|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
167672|NCT02889835|Device|Supreme Universal Restorative|
167673|NCT02889835|Device|Supreme Flowable Restorative|
167674|NCT02889835|Device|Bulk Fill Flowable Restorative|
167675|NCT02889822|Drug|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd~Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
167676|NCT02889809|Drug|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
167677|NCT02889809|Drug|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
167678|NCT02889809|Drug|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (>=6 year old subjects)
167679|NCT02889809|Drug|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
167680|NCT02889796|Drug|Filgotinib|Tablet(s) administered orally once daily
167681|NCT02889796|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
167682|NCT02889796|Drug|Adalimumab|40 mg/mL administered via subcutaneous injection once every two weeks
167683|NCT02889796|Drug|Placebo to match adalimumab|Administered via subcutaneous injection once every two weeks
167684|NCT02889796|Drug|MTX|Commercially sourced tablet(s) administered orally
167685|NCT02889783|Other|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
167686|NCT02889770|Other|PEEP titration|Exposure to different PEEP levels
167687|NCT02889757|Drug|Acteylcysteine|randomized into three arms
167688|NCT02889744|Device|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
167689|NCT02889718|Device|CONCERT-CL® station|"During cancer surgery (surgery > 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:~Port B = open loop: Analgesic~Port A = closed loop: Hypnotic~Port C = closed loop: Curare"
167690|NCT02889718|Other|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
167691|NCT02889705|Other|Ultrasonographic examination|
167692|NCT02889692|Drug|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
167693|NCT02889692|Drug|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
167694|NCT02889692|Drug|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.~YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
167695|NCT02889692|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
167696|NCT02889692|Drug|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
167697|NCT02889692|Drug|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
167698|NCT02889692|Drug|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
167699|NCT02889679|Procedure|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
265804|NCT02175407|Drug|itraconazole|oral
167701|NCT02889679|Procedure|Standard polypectomy|Standard polypectomy will be performed for diminutive (<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
167702|NCT02889666|Drug|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
167703|NCT02889666|Drug|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
167704|NCT02889666|Drug|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
167705|NCT02889666|Drug|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
167706|NCT02889666|Drug|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
167707|NCT02889666|Drug|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
167708|NCT02889666|Drug|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
167709|NCT02889666|Drug|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
167710|NCT02889653|Drug|Any oral antithrombotics (antiplatelets or anticoagulants)|
167711|NCT02889640|Other|SAGA Innovations|An intensive math tutoring program
167712|NCT02889640|Other|Scale-up tutors|Tutors who have been selected for hire via the one in three-and-a-half randomization process
167713|NCT02889640|Other|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
167714|NCT02889627|Drug|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
167715|NCT02889614|Other|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
167716|NCT02889601|Other|Psycho-behavioural assessment|DAPHNE Scale
167717|NCT02889562|Drug|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
167718|NCT02889562|Drug|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
167719|NCT02889549|Drug|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
167720|NCT02889549|Drug|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
167721|NCT02889536|Other|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
167722|NCT02889523|Drug|Tazemetostat|Tablets 200 mg, to be administrated per os
167723|NCT02889523|Drug|Rituximab|375 mg/m²/dose, D1
167724|NCT02889523|Drug|Cyclophosphamide|750 mg/m²/dose, D1
167725|NCT02889523|Drug|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
167726|NCT02889523|Drug|Doxorubicin|50 mg/m²/dose, D1
167727|NCT02889523|Drug|Prednisolone|40 mg/m2 in the morning D1 to D5
167728|NCT02889510|Drug|liraglutide|7-week subcutaneous liraglutide once daily
167729|NCT02889510|Drug|placebo|7-week subcutaneous placebo once daily
167730|NCT02889497|Biological|the first batch vaccine|
167731|NCT02889497|Biological|the second batch vaccine|
167732|NCT02889497|Biological|the third batch vaccine|
167733|NCT02889484|Procedure|Lumbar disc hernia surgery|
167734|NCT02889471|Procedure|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
167735|NCT02889471|Procedure|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
167736|NCT02889458|Other|Not Provided|
167737|NCT02889445|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
167738|NCT02889432|Drug|Oral Melatonin 10mg|
167739|NCT02889432|Drug|Placebo|
167740|NCT02889419|Device|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
167741|NCT02889406|Behavioral|Motivational intervention|motivational interviewing schema
167742|NCT02889393|Drug|teduglutide|Daily subcutaneous injection of 0.05mg/kg teduglutide
167743|NCT02889380|Drug|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
265805|NCT02175394|Drug|Microgynon®|
167754|NCT02889289|Other|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
167755|NCT02889276|Other|Functional Resistance Training|Supervised group-based Functional Resistance Training
167756|NCT02889276|Behavioral|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
167757|NCT02889250|Device|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
167758|NCT02889237|Dietary Supplement|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
167759|NCT02889237|Dietary Supplement|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
167760|NCT02889237|Dietary Supplement|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
167761|NCT02889224|Other|Obese|
167762|NCT02889224|Procedure|Hypercortisolism|
167763|NCT02889224|Other|Hydrocortisone|
167764|NCT02889224|Other|Control|
167765|NCT02889211|Behavioral|Gambling Task|
167766|NCT02889198|Behavioral|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
167767|NCT02889185|Device|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
167768|NCT02889172|Behavioral|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
167769|NCT02889159|Biological|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
167770|NCT02889159|Biological|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
167771|NCT02889159|Biological|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
167772|NCT02889159|Procedure|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
167773|NCT02889146|Other|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
167774|NCT02889146|Other|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
167775|NCT02889146|Other|Respiratory therapy|Respiratory therapy according to the service routine.
167776|NCT02889133|Drug|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
167777|NCT02889133|Drug|Saline|Salt water IV - 500 mL, one pint normal saline.
167778|NCT02889133|Procedure|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
167779|NCT02889133|Procedure|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
167780|NCT02889107|Other|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
167781|NCT02889094|Other|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
167782|NCT02889081|Other|maternal biological folate level|supplementation status and serum level
167783|NCT02889081|Other|maternal biological Vitamin D level|supplementation status and serum level
167784|NCT02889068|Other|Blood sample|
167785|NCT02889055|Device|patient requiring the MIRUS (mechanical ventilation)|
167786|NCT02889042|Other|MRI and biological assessment|performing a MRI and a biological assessment
167787|NCT02889029|Device|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
167788|NCT02889003|Drug|Pioglitazone + TKI|
167802|NCT02888925|Other|Recognition of celebrities and access to semantic information test|
167803|NCT02888925|Procedure|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
167804|NCT02888912|Other|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
167805|NCT02888912|Other|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
167806|NCT02888899|Behavioral|Biofeedback|
167807|NCT02888899|Drug|Loperamide|
167808|NCT02888899|Drug|Stool bulking agent (sterculia or ispaghula husk)|
167809|NCT02888899|Other|PTNS|
167810|NCT02888886|Other|Questionnaires about food habits and tobacco|
167811|NCT02888886|Other|Spirometry|
167812|NCT02888886|Other|Carotid echography|
167813|NCT02888886|Other|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
167814|NCT02888873|Other|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
167815|NCT02888873|Other|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
167816|NCT02888847|Device|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
167817|NCT02888847|Device|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
167818|NCT02888834|Other|Adverse drug reaction|
167819|NCT02888821|Behavioral|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
167820|NCT02888808|Other|Gastroscopy|Upper gastrointestinal endoscopy procedure
167821|NCT02888795|Drug|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
167822|NCT02888782|Other|Pharmacist Consultation|
167823|NCT02888769|Behavioral|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
167824|NCT02888756|Biological|iHIVARNA-01|Therapeutic vaccination, followed by treatment interruption
167825|NCT02888756|Biological|TriMix|Therapeutic vaccination, followed by treatment interruption
167826|NCT02888756|Biological|Placebo|Therapeutic vaccination, followed by treatment interruption
167827|NCT02888743|Biological|Durvalumab|Given IV
167828|NCT02888743|Radiation|Radiation Therapy|Undergo radiation therapy
167829|NCT02888743|Biological|Tremelimumab|Given IV
167830|NCT02888730|Drug|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
167831|NCT02888730|Drug|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
167832|NCT02888717|Procedure|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.~Slices A and C are sent OSNA analysis~Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.~After the analysis, the report indicates whether the node is:~Free (-): <250 copies~Micrometastatic (+): 250 ≤ - <5,000 copies,~Macrometastatic (++): ≥ 5000 copies."
168092|NCT02886286|Drug|Bupivacaine|Patient-activated intrathecal bolus for incident pain
167833|NCT02888704|Drug|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
167834|NCT02888691|Other|Low carbohydrate diet|
167835|NCT02888691|Other|High carbohydrate diet|
167836|NCT02888678|Behavioral|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
167837|NCT02888678|Behavioral|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
167838|NCT02888665|Drug|Doxorubicin Hydrochloride|Given IV
167839|NCT02888665|Other|Laboratory Biomarker Analysis|Correlative studies
167840|NCT02888665|Biological|Pembrolizumab|Given IV
167841|NCT02888652|Drug|antiplatelet agents(Clopidogrel or Ticagrelor)|Clinical physicians according to patients condition to give different antiplatelet agents(Clopidogrel or Ticagrelor).We only observe clinical curative effect.
167842|NCT02888613|Procedure|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
167843|NCT02888613|Procedure|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).~Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
167844|NCT02888600|Behavioral|Mindfulness Training|Guided mindfulness meditation and stress management training
167845|NCT02888600|Behavioral|Health Education|Guided health education and stress management training
167846|NCT02888574|Drug|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
167847|NCT02888574|Drug|Placebo|Placebo nasal spray
167848|NCT02888561|Drug|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
167849|NCT02888561|Drug|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
167850|NCT02888548|Procedure|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
167851|NCT02888548|Procedure|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
167852|NCT02888535|Other|Internal Medicine consultation|
167853|NCT02888522|Biological|immunomodulation|Immunomodulation depending on chimerism
167854|NCT02888496|Drug|tocilizumab|3 monthly IV infusions in PMR patients
167855|NCT02888457|Other|Nasopharyngeal sampling with a swab|
167856|NCT02888444|Drug|Varenicline|Two 0.5mg tablets taken twice daily
167857|NCT02888444|Behavioral|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
167858|NCT02888444|Drug|Placebo|Two 0.5mg tablets taken twice daily
167859|NCT02888431|Device|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
167860|NCT02888418|Biological|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
167861|NCT02888418|Biological|placebo|
167862|NCT02888405|Other|High-carbohydrate diet|
167863|NCT02888405|Other|Low-carbohydrate diet|
167864|NCT02888392|Other|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
167865|NCT02888392|Dietary Supplement|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
167866|NCT02888379|Drug|TOP1288|
167867|NCT02888379|Drug|Placebo (for TOP1288)|
167868|NCT02888353|Device|Device: MRI|Perform MRI in patients with cardiac devices
167869|NCT02888340|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
167870|NCT02888327|Drug|AL-794|
167871|NCT02888327|Drug|Oseltamivir|
167872|NCT02888327|Drug|Digoxin|
167873|NCT02888327|Drug|Midazolam|
167874|NCT02888327|Drug|Pitavastatin|
167875|NCT02888327|Drug|JNJ-63623872|
167876|NCT02888301|Procedure|Computed Tomography|Undergo 18F-clofarabine PET/CT
167877|NCT02888301|Radiation|Fluorine F 18 Clofarabine|Given IV
167878|NCT02888301|Procedure|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
167998|NCT02887183|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) is supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg twice daily (bid)
168093|NCT02886286|Drug|Opioid|Patient-activated intrathecal bolus for incident pain
167879|NCT02888288|Behavioral|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
167880|NCT02888288|Behavioral|Standard of Care|Standard of Care includes enhanced ART adherence based on clinic protocols and monthly HIV teaching sessions prior to adolescent clinic.
167881|NCT02888275|Drug|Dexmedetomidine|
167882|NCT02888275|Drug|normal saline|
167883|NCT02888249|Other|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
167884|NCT02888236|Drug|LEO 32731|
167885|NCT02888236|Drug|LEO 32731 Placebo|
167886|NCT02888223|Biological|SCT800|
167887|NCT02888223|Biological|Xyntha|
167888|NCT02888210|Device|MD-15 Intraocular Lens|
167889|NCT02888171|Drug|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
167890|NCT02888171|Drug|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
167891|NCT02888158|Other|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
167892|NCT02888158|Other|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
167893|NCT02888132|Procedure|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
167894|NCT02888132|Procedure|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
167895|NCT02888119|Device|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
167896|NCT02888106|Drug|Myrcludex B|5 mg (once a day), 5 mg (twice a day), 10 mg (once a day)
167897|NCT02888106|Drug|PEG IFN alfa-2a|180 μg (once a week)
167898|NCT02888106|Drug|Tenofovir|300 mg, orally, once daily
167899|NCT02888093|Device|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
167900|NCT02888080|Drug|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
167901|NCT02888080|Drug|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
167902|NCT02888067|Drug|Rocuronium bromide 0.5 mg/kg|Moderate neuromuscular blockade with rocuronium bromide
167903|NCT02888067|Drug|Rocuronium bromide 1.0 mg/kg|Deep neuromuscular blockade with rocuronium bromide
167904|NCT02888067|Drug|Sugammadex sodium 2 mg/kg|Reversal with sugammadex sodium
167905|NCT02888067|Drug|Sugammadex sodium 4 mg/kg|Reversal with sugammadex sodium
167906|NCT02888054|Drug|lesinurad/allopurinol 200/300 FDC tablet|
167907|NCT02888054|Drug|lesinurad 200 mg|
167908|NCT02888054|Drug|allopurinol 300 mg|
167909|NCT02888041|Drug|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
167910|NCT02888041|Drug|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
167911|NCT02888028|Procedure|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
167912|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
167913|NCT02888015|Other|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
167914|NCT02888002|Behavioral|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
167915|NCT02887989|Device|Virtual Reality|A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
167916|NCT02887989|Device|Health and Wellness Channel|Relaxing content broadcast passively on the patient in-room television channel.
167917|NCT02887976|Drug|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
167918|NCT02887976|Drug|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
167919|NCT02887950|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
167920|NCT02887950|Dietary Supplement|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
168030|NCT02886819|Other|vibration|Whole body vibration
265806|NCT02175394|Drug|BI 1356|
167921|NCT02887950|Dietary Supplement|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.~Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
167922|NCT02887937|Drug|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
167923|NCT02887924|Device|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
167924|NCT02887898|Device|Automated bolus calculator|
167925|NCT02887898|Other|Education|
167926|NCT02887885|Drug|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
167927|NCT02887872|Other|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
167928|NCT02887859|Biological|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
167929|NCT02887846|Device|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 < 0,40, Pa CO2 < 65 mmHg, pH> 7.20, MAP (mean airway pressure) <7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 < 0.30 at 24 hours and above, free oxygen will be introduced.
167930|NCT02887833|Other|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
167931|NCT02887820|Device|Thromboelastograph|A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
167932|NCT02887807|Drug|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
167933|NCT02887807|Drug|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
167934|NCT02887794|Other|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
167935|NCT02887768|Device|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
167936|NCT02887768|Procedure|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
167937|NCT02887755|Device|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
167938|NCT02887703|Behavioral|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
167939|NCT02887690|Device|Modular Prosthetic Limb|
167940|NCT02887677|Drug|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
167941|NCT02887677|Drug|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
167942|NCT02887664|Procedure|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
167943|NCT02887651|Radiation|Cavity boost radiation|Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
167944|NCT02887638|Other|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:~Analysis of the sitting-posture profile:~o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).~Analysis of the dural profile before and after the provoking task:~o Determination of the dural sensitivity by the use of the slump-test~Analysis of the pain profile before and after the provoking task:~Determination of pressure pain sensitivity by the use of pressure algometry~Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
167945|NCT02887625|Drug|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
167946|NCT02887625|Drug|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c <7.0%
167947|NCT02887612|Other|ctDNA test|
167948|NCT02887599|Procedure|Blood collection|1ml of blood specimen collection
168031|NCT02886806|Other|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
167949|NCT02887586|Other|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
167950|NCT02887573|Drug|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
167951|NCT02887573|Drug|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
167952|NCT02887573|Procedure|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
167953|NCT02887573|Drug|2L PEG|2L PEG are laxatives for experiment group.
167954|NCT02887573|Drug|4L PEG|4L PEG are laxatives in the control group.
167955|NCT02887573|Drug|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
167956|NCT02887573|Drug|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
167957|NCT02887560|Procedure|transoesophageal echocardiography|
167958|NCT02887547|Procedure|micro-osteoperforation|
167959|NCT02887534|Drug|SPARC1401-low dose|SPARC1401- low dose
167960|NCT02887534|Drug|SPARC1401-mid dose|SPARC1401- mid dose
167961|NCT02887534|Drug|SPARC1401-high dose|SPARC1401-high dose
167962|NCT02887534|Drug|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
167963|NCT02887534|Drug|Placebo1401|Placebo
167964|NCT02887521|Other|education|pulmonary rehabilitation participant manual
167965|NCT02887521|Procedure|rehabilitation|pulmonary rehabilitation
167966|NCT02887521|Device|pedometer|receive a pedometer
167967|NCT02887521|Other|education|receive a pamphlet with exercises plus the standard course of care
167968|NCT02887521|Procedure|surgery|patients undergo surgery
167969|NCT02887508|Behavioral|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
167970|NCT02887508|Behavioral|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
167971|NCT02887482|Biological|GLS-5700|GLS 5700 at 2 mg DNA/dose
167972|NCT02887482|Biological|Placebo|
167973|NCT02887469|Drug|3% hypertonic saline|The same as above
167974|NCT02887456|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
167975|NCT02887456|Drug|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
167976|NCT02887443|Drug|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
167977|NCT02887443|Drug|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
167978|NCT02887430|Other|foot reflexology therapy|standard care and foot reflexology
167979|NCT02887404|Other|Spine surgery analgesic pathway|Enhanced pain management care
167980|NCT02887404|Other|Usual Care|Standard of pain management care
167981|NCT02887391|Other|No intervention - observational study|No intervention - observational study
167982|NCT02887378|Device|hot clamps|reusable hot biopsy forceps
167983|NCT02887378|Device|normal clamps|
167984|NCT02887365|Drug|tegafur-uracil|
167985|NCT02887352|Other|assessment of problem-solving ability|
167986|NCT02887339|Other|Training Website|Additional training website can be found at gtextraing.org
167987|NCT02887339|Other|Control|Standard training given by OPOs and GTEx staff
167988|NCT02887313|Drug|mFOLFOX6 with radiation|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4-6 cycles of mFOLFOX6 would be given before surgery.
167989|NCT02887300|Behavioral|Mantra Meditation|"Week 1:~20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.~Week 2:~Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.~Week 3:~20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.~Week 4:~20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
167990|NCT02887287|Drug|EEN|
167991|NCT02887261|Device|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
167992|NCT02887261|Device|Conventional Port|not for power injection for contrast media.
167993|NCT02887248|Drug|nab-paclitaxel|"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.~Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
167994|NCT02887248|Drug|Gemcitabine|Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
167995|NCT02887235|Other|Home Delivered, Medically Tailored Meals (HDTM)|
167996|NCT02887222|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
167997|NCT02887209|Behavioral|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger & Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
168032|NCT02886806|Other|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
167999|NCT02887157|Device|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
168000|NCT02887157|Other|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
168001|NCT02887157|Other|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
168002|NCT02887144|Device|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
168003|NCT02887144|Device|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
168004|NCT02887131|Other|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
168005|NCT02887105|Other|Standard neuropsychological assessment|
168006|NCT02887105|Other|Brain MRI|
168007|NCT02887053|Device|MRI|
168008|NCT02887040|Radiation|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
168009|NCT02887040|Drug|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
168010|NCT02887040|Drug|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
168011|NCT02887027|Behavioral|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
168012|NCT02887014|Procedure|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
168013|NCT02887001|Other|Pharmacist consultation|
168014|NCT02886988|Drug|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
168015|NCT02886988|Drug|normal saline|0.1mlof normal saline will be injected with a 30G needle.
168016|NCT02886975|Behavioral|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
168017|NCT02886962|Biological|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
168018|NCT02886962|Drug|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.~Administration once daily or at the end of each dialysis session, according to the nephrologist choice.~INR monitoring at least once per week"
168019|NCT02886936|Device|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
168020|NCT02886910|Other|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
168021|NCT02886910|Other|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
168022|NCT02886897|Biological|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
168023|NCT02886884|Drug|20 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
168024|NCT02886884|Drug|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
168025|NCT02886871|Behavioral|Step Goal Delivery by Smartphone|
168026|NCT02886858|Device|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
168027|NCT02886858|Device|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
168028|NCT02886845|Genetic|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
168029|NCT02886832|Dietary Supplement|Prostate Health formulation|
168034|NCT02886780|Behavioral|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
168035|NCT02886780|Behavioral|Self-help|
168036|NCT02886767|Other|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
168037|NCT02886754|Behavioral|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
168038|NCT02886754|Behavioral|National e-learning programme only|National e-learning programme (COMPASS)
168039|NCT02886754|Behavioral|Standard simulation|Paper based simulation cases
168040|NCT02886741|Other|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
168041|NCT02886728|Drug|Filgotinib|Tablet(s) administered orally once daily
168042|NCT02886728|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
168043|NCT02886728|Drug|MTX|Capsule(s) administered orally once weekly
168044|NCT02886728|Drug|Placebo to match MTX|Capsule(s) administered orally once weekly
168045|NCT02886715|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.
168046|NCT02886715|Drug|Tazorac®|Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
168047|NCT02886715|Drug|Placebo|Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
168048|NCT02886702|Drug|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
168049|NCT02886702|Drug|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
168050|NCT02886702|Drug|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
168051|NCT02886689|Drug|TNF-alpha antagonist and other biotherapy|
168052|NCT02886676|Drug|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
168053|NCT02886663|Other|stimulation of the blind visual field|
168054|NCT02886650|Procedure|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
168055|NCT02886637|Other|None intervention|
168056|NCT02886624|Drug|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
168057|NCT02886598|Drug|degarelix|
168058|NCT02886585|Drug|Pembrolizumab|
168059|NCT02886585|Radiation|MRI|
168060|NCT02886585|Radiation|PET/CT|
168061|NCT02886585|Procedure|Stereotactic Radiosurgery|
168062|NCT02886572|Radiation|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
168063|NCT02886559|Drug|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
168064|NCT02886546|Procedure|pneumoperitoneum|
168065|NCT02886546|Device|oesophageal Doppler monitor|
168066|NCT02886533|Other|Antithrombotic|Collection of clinical, biological data
168067|NCT02886520|Device|PVDF transobturator tape|
168068|NCT02886520|Device|Polypropylene transobturator tape|
168069|NCT02886507|Dietary Supplement|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
168070|NCT02886507|Dietary Supplement|Placebo|The placebo capsules contain microcrystalline cellulose.
168071|NCT02886494|Drug|BAC|
168072|NCT02886494|Drug|Matched placebo|
168073|NCT02886481|Device|perioperative monitoring|
168074|NCT02886468|Other|skin ultrasound|
168075|NCT02886455|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
168076|NCT02886455|Other|New adhesive strip|This a newly developed adhesive strip.
168077|NCT02886442|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
168078|NCT02886442|Other|New adhesive strip|This is a newly developed adhesive strip
168079|NCT02886429|Drug|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
168080|NCT02886429|Drug|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
168081|NCT02886416|Other|Non interventional study|
168082|NCT02886403|Other|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
168083|NCT02886403|Other|New adhesive strip|A newly developed adhesive strip
168084|NCT02886390|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
168085|NCT02886377|Biological|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
168086|NCT02886364|Behavioral|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
168087|NCT02886351|Drug|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
168088|NCT02886338|Device|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
168089|NCT02886312|Device|Supplemental Oxygen Delivery System|
168097|NCT02886273|Other|Group 4|Observation
168098|NCT02886234|Behavioral|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
168099|NCT02886234|Behavioral|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
168100|NCT02886221|Procedure|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
168101|NCT02886208|Behavioral|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
168102|NCT02886195|Drug|pemetrexed|500mg/m2 ivgtt d1, per three weeks
168103|NCT02886195|Drug|cisplatin|80mg/m2 ivgtt d1, per three weeks
168104|NCT02886195|Drug|Erlotinib|150mg po. every day
168105|NCT02886169|Other|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
168106|NCT02886169|Other|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
168107|NCT02886156|Device|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
168108|NCT02886156|Dietary Supplement|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
168109|NCT02886143|Procedure|Active Voiding Trial|"Nursing protocol:~Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push~Clamp the Foley~Deflate the catheter balloon and remove the catheter from the bladder.~Record the amount of saline that was instilled into the bladder.~Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate~7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
168110|NCT02886143|Procedure|Passive Voiding Trial|"Nursing protocol:~Deflate the catheter balloon and remove the catheter from the bladder.~Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).~5. If the patient has not voided within 5 hours, assist the patient to try to void.~6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.~7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
168111|NCT02886130|Dietary Supplement|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
168112|NCT02886130|Dietary Supplement|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
168113|NCT02886104|Procedure|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
168114|NCT02886104|Device|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
168115|NCT02886078|Procedure|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
168116|NCT02886078|Procedure|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
168117|NCT02886065|Drug|Hiltonol|Intramuscular injection of Hiltonol (1 mg) administered Biweekly at the time of PVX-410 administration
168118|NCT02886065|Drug|Citarinostat|Citarinostat (180 mg) administered orally once daily on days 1-21 every 28 day cycle.
168119|NCT02886065|Drug|Lenalidomide|Lenalidomide (25 mg) administered orally once daily on days 1-21 every 28 day cycle.
168120|NCT02886065|Biological|PVX-410|PVX-410 Biweekly (0.8 mg) via subcutaneous injection
168121|NCT02886052|Behavioral|Therapist guided Internet-CBT for insomnia|
168122|NCT02886052|Other|Active control|
168199|NCT02885467|Procedure|Standard total knee arthroplasty|
267696|NCT02161692|Drug|Cisplatin|
168123|NCT02886039|Other|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
168124|NCT02886026|Device|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
168125|NCT02886026|Device|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
168126|NCT02885987|Device|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
168127|NCT02885974|Drug|Celecoxib|Celecoxib (100 mg daily)
168128|NCT02885974|Drug|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
168129|NCT02885974|Drug|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
168130|NCT02885961|Drug|Dabigatran|Anti-coagulant
168131|NCT02885961|Radiation|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
168132|NCT02885948|Drug|Naloxone|used to block the effects of opioids, especially in overdose
168133|NCT02885948|Drug|Placebo|Placebo, ineffective control arm
168134|NCT02885935|Other|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
168135|NCT02885935|Other|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
168136|NCT02885922|Drug|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
168137|NCT02885909|Device|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
168138|NCT02885909|Procedure|Insulin protocal|Using insulin protocal based on glucose monitor
168139|NCT02885883|Device|MRI 3T|
168140|NCT02885870|Procedure|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
168141|NCT02885857|Drug|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
168142|NCT02885844|Procedure|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
168143|NCT02885844|Procedure|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
168144|NCT02885831|Device|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
168145|NCT02885805|Drug|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
168146|NCT02885805|Drug|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
168147|NCT02885792|Other|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
168148|NCT02885792|Other|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
168149|NCT02885792|Other|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
168150|NCT02885792|Procedure|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
168151|NCT02885766|Drug|PF-114|
168152|NCT02885753|Drug|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
168153|NCT02885753|Drug|5 Fu|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
168154|NCT02885753|Drug|Folinic Acid|400 mg/m² in intravenous
168155|NCT02885753|Drug|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
168156|NCT02885753|Drug|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
168157|NCT02885753|Drug|Bevacizumab|Only for patient RAS mutated : 5 mg/m² at each cycle in intravenous
168158|NCT02885740|Other|Quantification assay of adenosine and methionine cycle metabolites|
168159|NCT02885740|Genetic|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
168160|NCT02885740|Other|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
168161|NCT02885740|Biological|Blood sample|
168162|NCT02885727|Drug|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
168163|NCT02885727|Radiation|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
168164|NCT02885714|Procedure|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
168165|NCT02885714|Procedure|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
168200|NCT02885454|Drug|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
267697|NCT02161692|Drug|Bleomycin|
168166|NCT02885701|Other|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson & Johnson, New Brunswick, NJ) over the incision.
168167|NCT02885701|Other|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
168168|NCT02885701|Other|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
168169|NCT02885688|Dietary Supplement|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
168170|NCT02885688|Procedure|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.~The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
168171|NCT02885675|Other|blood sampling|sample no more than 3ml
168172|NCT02885662|Drug|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
168173|NCT02885649|Drug|Enzalutamide|Given PO
168174|NCT02885649|Other|Laboratory Biomarker Analysis|Correlative studies
168175|NCT02885649|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
168176|NCT02885636|Drug|Albuterol|": Experimental: Inhaled albuterol~2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
168177|NCT02885636|Other|Saline placebo|Saline inhaled through a nebulizer as a single dose
168178|NCT02885610|Biological|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
168179|NCT02885610|Biological|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
168180|NCT02885610|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
168181|NCT02885610|Biological|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
168182|NCT02885597|Drug|Juanbi pill|4g, twice a day, 3month, oral
168183|NCT02885597|Drug|Juanbi pill placebo|4g, twice a day, 3month, oral
168184|NCT02885597|Drug|Methotrexate|5mg, once a week, 3 month, oral
168185|NCT02885584|Device|High frequency percussive ventilation|
168186|NCT02885571|Device|SomnoDent Flex with DentiTrac|
168187|NCT02885558|Drug|Efonidipine|8 weeks treatment with either efonidipine
168188|NCT02885558|Drug|Nifedipine|8 weeks treatment with either nifedipine
168189|NCT02885545|Device|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
168190|NCT02885545|Drug|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
168191|NCT02885532|Other|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
168192|NCT02885519|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
168193|NCT02885519|Behavioral|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
168194|NCT02885506|Drug|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
168195|NCT02885506|Drug|Oral administration of P218 matching placebo|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
168196|NCT02885493|Behavioral|tests|
168197|NCT02885480|Behavioral|questionnaires|
168198|NCT02885467|Procedure|Total knee arthroplasty with Saphenous nerve burial|
168201|NCT02885454|Drug|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
168202|NCT02885454|Drug|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
168203|NCT02885454|Drug|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
168204|NCT02885441|Drug|Ketorolac|Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
168205|NCT02885428|Device|echography|
168206|NCT02885415|Procedure|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
168207|NCT02885402|Other|MRI Sodium ( 23Na )|
168208|NCT02885376|Device|Dentoxol|Mouthrinse
168209|NCT02885376|Device|Placebo|Mouthrinse
168210|NCT02885363|Other|Clinical examination|
168211|NCT02885363|Other|Blood sample|
168212|NCT02885363|Procedure|Echocardiography|
168213|NCT02885350|Drug|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
168214|NCT02885350|Drug|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
168215|NCT02885337|Other|Multi-Modal Frailty Intervention|"Exercise: A Kinesiologist will develop an individualized exercise program and schedule appointments with the patient at home including goal setting discussion. Participants will be offered free YMCA membership.~Cognitive-behavioural Change Strategy(CBCS) and education: CBCS may be an effective way to facilitate coaching strategies to increase participant exercise levels. Throughout the intervention, CBCS and education about exercise, hip or knee arthroplasty and osteoarthritis will be administered.~Protein Supplement: Participants will be provided with 1-2 daily supplements (containing 20 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.~Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.~Medication Review: A geriatrician will review the medications for patients in the intervention arm."
168216|NCT02885337|Other|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the Kinesiologist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.~For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
168217|NCT02885324|Drug|Cabozantinib|Subjects will receive Cabozantinib
168218|NCT02885311|Behavioral|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
168219|NCT02885311|Behavioral|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
168220|NCT02885311|Drug|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
168221|NCT02885311|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
168222|NCT02885311|Other|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
168223|NCT02885298|Procedure|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
168224|NCT02885285|Behavioral|Spinning Class|Spinning Class twice a week for six weeks.
168225|NCT02885285|Behavioral|Yoga Class|Yoga Class twice a week for six weeks.
168226|NCT02885285|Behavioral|Dance Class|Dance Class twice a week for six weeks.
168227|NCT02885285|Other|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
168228|NCT02885272|Procedure|Computed Tomography|Undergo PET/CT scans
168229|NCT02885272|Radiation|Fludeoxyglucose F-18|Given IV
168230|NCT02885272|Procedure|Magnetic Resonance Imaging|Undergo standard of care MRI
168231|NCT02885272|Procedure|Positron Emission Tomography|Undergo PET/CT scans
168232|NCT02885259|Drug|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
168233|NCT02885246|Other|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
168268|NCT02884921|Drug|Paracetamol|Paracetamol
168269|NCT02884921|Drug|Paracetamol|Paracetamol
168234|NCT02885233|Behavioral|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
168235|NCT02885233|Behavioral|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
168236|NCT02885220|Other|Conventional Program|No scheduled intermediate weight loss goals provided to patient
168237|NCT02885220|Other|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
168238|NCT02885207|Biological|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:~Crisis with clinical symptoms indicating focal seizure~& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.~From unknown cause:~No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.~No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.~No argument for metabolic or neurodegenerative genetic epilepsy.~Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).~Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
168239|NCT02885194|Other|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
168240|NCT02885181|Drug|GS-9876|One tablet administered orally once daily
168241|NCT02885181|Drug|Filgotinib|Two tablets administered orally once daily
168242|NCT02885181|Drug|GS-9876 placebo|One tablet administered orally once daily
168243|NCT02885181|Drug|Filgotinib placebo|Two tablets administered orally once daily
168244|NCT02885181|Drug|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
168245|NCT02885168|Drug|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
168246|NCT02885168|Device|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
168247|NCT02885168|Drug|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.~Arterial tension through an invasive approach is measured during the test."
168248|NCT02885168|Biological|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
168249|NCT02885155|Other|Echocardiography|planned at regular intervals
168250|NCT02885155|Other|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
168251|NCT02885142|Procedure|Local excision for early rectal cancer|
168252|NCT02885116|Device|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
168253|NCT02885116|Device|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
168254|NCT02885103|Device|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
168255|NCT02885103|Device|Nebulizer|Inhalation will be done will Nebulizer and via mouth
168256|NCT02885090|Procedure|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
168257|NCT02885077|Device|High-intensity IMT + combined exercise|
168258|NCT02885051|Procedure|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
168259|NCT02885038|Other|Platelet concentrate transfusion|
168260|NCT02885025|Dietary Supplement|Broccoli Sprout Extract|Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
168261|NCT02885025|Drug|fluticasone nasal|fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
168262|NCT02885025|Dietary Supplement|brocooli sprout extract placebo|a tablet similar to the actual broccoli sprout extract though without BSE.
168263|NCT02885025|Drug|normal saline nasal spray|normal saline to replace nasal fluticasone in specific arms of the study
168264|NCT02885012|Drug|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
168265|NCT02884986|Drug|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
168266|NCT02884986|Drug|Placebo|120mg of placebo
168267|NCT02884960|Procedure|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
168271|NCT02884908|Drug|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
168272|NCT02884908|Other|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
168273|NCT02884895|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
168274|NCT02884895|Device|Direct Laryngoscopy|Direct Laryngoscopy
168275|NCT02884882|Other|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
168276|NCT02884869|Device|Intubating Laryngeal Mask|Direct laryngoscopy
168277|NCT02884843|Device|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
168278|NCT02884843|Device|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
168279|NCT02884830|Device|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
168280|NCT02884817|Drug|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
168281|NCT02884817|Other|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
168282|NCT02884817|Other|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
168283|NCT02884791|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
168284|NCT02884778|Diagnostic Test|Detection of pain after nociceptive stimulus|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
168285|NCT02884765|Procedure|Non-surgical|Non-surgical treatment in both condylar fractures
168286|NCT02884765|Procedure|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
168287|NCT02884765|Procedure|Surgical|Surgical treatment in both condylar fractures
168288|NCT02884739|Other|Data collection|
168289|NCT02884726|Drug|BMS-986148|Specified dose on specified days
168290|NCT02884713|Drug|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
168291|NCT02884713|Drug|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
168292|NCT02884713|Drug|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
168293|NCT02884700|Biological|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
168294|NCT02884674|Device|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
168295|NCT02884674|Device|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
168296|NCT02884648|Drug|Bevacizumab|15 mg/kg by vein on Day 1 of every 21-day study cycle.
168297|NCT02884635|Drug|ASP1707|Oral
168298|NCT02884635|Drug|Placebo|Oral
168299|NCT02884635|Drug|Methotrexate|Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
168300|NCT02884622|Other|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
168301|NCT02884622|Other|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
168302|NCT02884596|Drug|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
168335|NCT02884323|Device|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
168336|NCT02884310|Drug|Remifentanil adapted to SPI|
168337|NCT02884310|Drug|Remifentanil fixed|
168303|NCT02884583|Other|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
168304|NCT02884570|Other|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
168305|NCT02884557|Other|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
168306|NCT02884544|Drug|HLD100|Treatment
168307|NCT02884531|Other|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
168308|NCT02884531|Behavioral|Patient Education|Patient education (1/2 day)
168309|NCT02884518|Device|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
168310|NCT02884518|Behavioral|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
168311|NCT02884505|Device|Pupillometry|Measures pupillary dynamics in darkness and light conditions
168312|NCT02884505|Behavioral|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
168313|NCT02884505|Other|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
168314|NCT02884505|Behavioral|Hypersomnia Severity Index|Self-report measure of hypersomnolence
168315|NCT02884492|Drug|18F-THK-5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
168316|NCT02884492|Procedure|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
168317|NCT02884479|Drug|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
168318|NCT02884479|Drug|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
168319|NCT02884466|Behavioral|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
168320|NCT02884453|Drug|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research & Development, LLC and Pharmacyclics Inc.
168321|NCT02884440|Drug|TAP block ropivacaine|
168322|NCT02884440|Drug|TAP block placebo|
168323|NCT02884440|Drug|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
168324|NCT02884427|Device|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
168325|NCT02884427|Device|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
168326|NCT02884427|Device|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
168327|NCT02884414|Device|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
168328|NCT02884401|Device|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
168329|NCT02884388|Procedure|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
168330|NCT02884388|Procedure|general anesthesia|Patients in this group were assigned to receive general anesthesia.
168331|NCT02884375|Other|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :~functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~comorbidities (CIRS G)~polypharmacy (number of medications)~social environment (primary caregiver, support at home, friends , family, living alone)~urinary and/or fecal incontinence"
168332|NCT02884362|Other|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
168333|NCT02884349|Procedure|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
168338|NCT02884297|Drug|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
168339|NCT02884284|Other|clinical biological database collection|
168340|NCT02884271|Procedure|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
168341|NCT02884245|Drug|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
168342|NCT02884232|Procedure|Nasofibroscopy|
168343|NCT02884219|Drug|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
168344|NCT02884219|Other|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
168345|NCT02884219|Drug|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
168346|NCT02884206|Drug|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
168347|NCT02884206|Drug|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
168348|NCT02884206|Drug|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
168349|NCT02884206|Drug|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
168350|NCT02884193|Procedure|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
168351|NCT02884193|Procedure|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
168352|NCT02884193|Procedure|Sham Ice Bag|"Placebo application through an ice bag empty."
168353|NCT02884180|Drug|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
168354|NCT02884180|Drug|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
168355|NCT02884154|Device|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
168356|NCT02884128|Drug|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
168357|NCT02884128|Drug|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
168358|NCT02884128|Drug|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
168359|NCT02884115|Drug|benzathine penicillin|
168360|NCT02884102|Genetic|genetic sequencing|
168361|NCT02884089|Drug|Abemaciclib|Administered orally
168362|NCT02884089|Drug|Metformin|Administered orally
168363|NCT02884089|Drug|Iohexol|Administered intravenously (IV)
168364|NCT02884089|Drug|Placebo|Administered orally
168365|NCT02884063|Procedure|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
168366|NCT02884050|Drug|Topiramate|antiepilepsy drug
168367|NCT02884050|Drug|Placebo|non-active placebo
168368|NCT02884037|Drug|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
168369|NCT02884024|Other|no intervention|there is no intervention in this study
168370|NCT02883998|Other|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
168371|NCT02883998|Other|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
168372|NCT02883985|Radiation|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.~In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
168373|NCT02883972|Other|Intervention letter|Behavioural-insight informed letter template
168374|NCT02883972|Other|Control letter|Invitation letter used by local area last year (updated as required)
168375|NCT02883972|Other|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
168376|NCT02883959|Other|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
168377|NCT02883946|Other|Data collection|
168378|NCT02883933|Other|Data collection|
168379|NCT02883920|Other|Allergy and respiratory functional tests|
168380|NCT02883894|Other|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
168381|NCT02883842|Behavioral|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
168382|NCT02883829|Behavioral|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
168508|NCT02882945|Other|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
168509|NCT02882945|Other|Group B|200 cases of type 2 DM without complications were enrolled in the study.
168596|NCT02882308|Drug|Durvalumab|1500 mg d1
269237|NCT02149628|Drug|Desflurane|
168383|NCT02883829|Behavioral|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
168384|NCT02883816|Other|assessment of lung function|measurement of lung volumes and flow rates of bronchial
168385|NCT02883803|Biological|Injection of mesenchymal stem cells|Injection of mesenchymal stem cells
168386|NCT02883803|Biological|Injection of albumin alone|Injection of albumin alone
168387|NCT02883790|Dietary Supplement|Somnage|Melatonin 1mg, Zinc, Magnesium
168388|NCT02883790|Other|Placebo|Placebo
168389|NCT02883777|Behavioral|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
168390|NCT02883777|Behavioral|Conventional Diet|Conventional diet over 1 year after transplantation.
168391|NCT02883751|Radiation|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
168392|NCT02883751|Procedure|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
168393|NCT02883738|Other|tremor|evaluation of the intensity of the tremor
168394|NCT02883725|Other|data collection|
168395|NCT02883699|Behavioral|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
168396|NCT02883699|Behavioral|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
168397|NCT02883699|Behavioral|Standard resistance training|Machine based hypertrophy training 2 x per week
168398|NCT02883699|Behavioral|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
168399|NCT02883686|Behavioral|Alma|Alma peer-mentoring
168400|NCT02883673|Device|Jada System|It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
168401|NCT02883660|Genetic|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
168402|NCT02883647|Drug|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
168403|NCT02883634|Other|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
168404|NCT02883634|Other|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
168405|NCT02883621|Procedure|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
168406|NCT02883621|Procedure|standard upper endoscopy|standard examination without using a cap
168407|NCT02883608|Procedure|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
168408|NCT02883595|Drug|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
168409|NCT02883595|Other|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
168410|NCT02883582|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
168411|NCT02883582|Device|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
168412|NCT02883569|Procedure|open or endoscopic discectomy|FDA approved surgical procedures
168413|NCT02883569|Procedure|epidural block|epidural block
168414|NCT02883569|Other|exercise|educated exercise
168415|NCT02883569|Drug|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
168416|NCT02883569|Procedure|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
168417|NCT02883569|Procedure|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
168418|NCT02883569|Drug|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
168419|NCT02883569|Procedure|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
168420|NCT02883556|Drug|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
168421|NCT02883543|Drug|icotinib|Icotinib is orally administered three times per day.
168422|NCT02883543|Drug|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
168423|NCT02883543|Radiation|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
168510|NCT02882945|Other|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
168597|NCT02882295|Other|Validation of a handwriting scale|
168424|NCT02883530|Procedure|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1−2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
168425|NCT02883517|Genetic|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
168426|NCT02883504|Procedure|Echo-Doppler examination and left heart catheterization|
168427|NCT02883478|Device|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
168428|NCT02883478|Procedure|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
168429|NCT02883478|Drug|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
168430|NCT02883465|Procedure|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.~a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side~a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
168431|NCT02883452|Biological|Infliximab|
168432|NCT02883439|Drug|MP29-02|local nasal application
168433|NCT02883439|Drug|Fluticasone propionate|local nasal application
168434|NCT02883426|Biological|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
168435|NCT02883426|Biological|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
168436|NCT02883426|Biological|Placebo|Administered by nasal spray
168437|NCT02883413|Behavioral|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
168438|NCT02883413|Behavioral|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
168439|NCT02883400|Drug|Spironolactone|spironolactone 25 mg up to 50 mg
168440|NCT02883387|Other|Preoperative CT angiography|Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
168441|NCT02883387|Other|No Preoperative Imaging|No imaging will be done to map blood vessels prior to surgery
168442|NCT02883374|Drug|Chidamide|
168443|NCT02883361|Behavioral|Motivational enhancement therapy|Counseling meant to enhance motivation and decrease ambivalence about change, including asking open-ended questions, eliciting change-talk, and identifying discrepancies between current behaviour and valued behaviour
168444|NCT02883361|Behavioral|Attention Control|Having participants come into the lab and fill out questionnaires with a researcher in-person
168445|NCT02883335|Other|Observational registry|
168446|NCT02883322|Other|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
168447|NCT02883309|Other|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
168448|NCT02883296|Other|Pelvis Magnetic resonance imaging|
168449|NCT02883283|Procedure|Epidural loading dose|Labor epidural analgesia loading dose
168450|NCT02883283|Device|Epidural catheter|Epidural loading dose via epidural catheter
168451|NCT02883283|Device|Epidural needle|Epidural loading dose via epidural needle
168452|NCT02883270|Device|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
168453|NCT02883270|Other|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
168454|NCT02883257|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
168455|NCT02883244|Device|Soft-Picks Advanced|Soft-picks Advanced will be used once a day to clean interdental sites at home.
168456|NCT02883244|Device|Floss|Floss will be used once a day to clean interdental sites at home.
168457|NCT02883231|Other|taking peripheral blood|taking peripheral blood of no more than 3ml
168458|NCT02883192|Drug|Ondansetron|Zofran 4 mg.
168459|NCT02883192|Drug|Placebo|Placebo
168460|NCT02883179|Drug|lidocaine injection|anhydrous solution
168461|NCT02883179|Drug|lidocaine-prilocaine cream|topical cream
168462|NCT02883166|Drug|abiraterone|integested with a continental breakfast
168511|NCT02882932|Procedure|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
168729|NCT02881086|Drug|Cyclophosphamide|
168463|NCT02883153|Drug|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
168464|NCT02883140|Other|Three-dimensional sialography CBCT and MRI sialography|"MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).~3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
168465|NCT02883127|Behavioral|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:~Watch portion size - to be conscious about the amount of carbohydrates in each meal.~Eat mainly carbohydrates of low glycaemic index.~Reduce the intake of carbohydrate of high glycaemic index.~Watch daily weight changes - aim for the recommended weekly changes.~In addition to the motivational intervention the women are given unchanged routine care."
168466|NCT02883114|Drug|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
168467|NCT02883114|Drug|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
168468|NCT02883101|Behavioral|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :~i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
168469|NCT02883088|Procedure|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
168470|NCT02883075|Other|Supine position|Spinal anesthesia in sitting position then 2 minutes in Supine position after spinal anesthetic administration
168471|NCT02883075|Other|Right lateral position|Spinal anesthesia in sitting position then 2 minutes in the right lateral position after spinal anesthetic administration
168472|NCT02883075|Other|Left lateral position|Spinal anesthesia in sitting position then 2 minutes in the left lateral position after spinal anesthetic administration
168473|NCT02883062|Drug|Atezolizumab|Given IV
168474|NCT02883062|Drug|Carboplatin|Given IV
168475|NCT02883062|Procedure|Lumpectomy|Undergo lumpectomy
168476|NCT02883062|Procedure|Mastectomy|Undergo mastectomy
168477|NCT02883062|Drug|Paclitaxel|Given IV
168478|NCT02883049|Drug|Clofarabine|Given IV
168479|NCT02883049|Drug|Cyclophosphamide|Given IV
168480|NCT02883049|Drug|Cytarabine|Given IT, IV, or SC
168481|NCT02883049|Drug|Dasatinib|Given PO
168482|NCT02883049|Drug|Daunorubicin Hydrochloride|Given IV
168483|NCT02883049|Drug|Dexamethasone|PO or IV
168484|NCT02883049|Drug|Doxorubicin Hydrochloride|Given IV
168485|NCT02883049|Drug|Etoposide|Given IV
168486|NCT02883049|Drug|Hydrocortisone Sodium Succinate|Given IT
168487|NCT02883049|Other|Laboratory Biomarker Analysis|Correlative studies
168488|NCT02883049|Drug|Leucovorin Calcium|Given PO or IV
168489|NCT02883049|Drug|Mercaptopurine|Given PO
168490|NCT02883049|Drug|Methotrexate|Given IT and IV
168491|NCT02883049|Drug|Pegaspargase|Given IV
168492|NCT02883049|Drug|Prednisone|Given PO or IV
168493|NCT02883049|Radiation|Radiation Therapy|Undergo radiation therapy
168494|NCT02883049|Drug|Thioguanine|Given PO
168495|NCT02883049|Drug|Vincristine Sulfate|Given IV
168496|NCT02883036|Other|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
168497|NCT02883036|Other|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
168498|NCT02883023|Other|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
168499|NCT02883023|Drug|Intralesional bleomycin injection|Local intralesional injections with bleomycin
168500|NCT02883010|Device|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
168501|NCT02883010|Other|Standard Care|Care path normally used by the hospital
168502|NCT02882997|Behavioral|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
168503|NCT02882997|Behavioral|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
168504|NCT02882984|Drug|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
168505|NCT02882984|Radiation|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
168506|NCT02882984|Radiation|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
168507|NCT02882971|Behavioral|Pain Assessment|To create an objective observational pain scoring system and validate.
168512|NCT02882919|Behavioral|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
168513|NCT02882893|Drug|Clostridium Botulinum A Toxin|
168514|NCT02882893|Drug|Clostridium Botulinum A Toxin|
168515|NCT02882880|Device|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
168516|NCT02882867|Other|Injuries in Swedish Youth Athletics. The KLUB-study.|
168517|NCT02882854|Drug|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
168518|NCT02882854|Drug|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
168519|NCT02882841|Other|Biopsies, stool and blood collection|
168520|NCT02882828|Drug|switched from Prograf® to Envarsus®|
168521|NCT02882815|Device|IrisFIT PFO Occluder|
168522|NCT02882802|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format.
168523|NCT02882802|Behavioral|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions.
168524|NCT02882789|Drug|LCB01-0371|Cohort1 & 3: Placebo-controlled, Single ascending dose administration
168525|NCT02882789|Drug|LCB01-0371 400mg|Cohort 2: Crossover designed administration
168526|NCT02882776|Dietary Supplement|Ginger drink|Ginger powder dissolved in water
168527|NCT02882763|Other|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
168528|NCT02882750|Other|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
168529|NCT02882750|Other|PS Q18|Patients Satisfaction Questionnaire
168530|NCT02882750|Other|Decision Self-Efficacy Scale|Questionnaire
168531|NCT02882737|Drug|Glucagon before exercise|
168532|NCT02882737|Drug|Glucagon after exercise|
168533|NCT02882737|Drug|Glucagon after resting|
168534|NCT02882724|Behavioral|Exercise|8-week aquatic exercise training program
168535|NCT02882724|Behavioral|Control|Control group did not do the exercise training.
168536|NCT02882711|Drug|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
168537|NCT02882698|Behavioral|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
168538|NCT02882698|Behavioral|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
168539|NCT02882698|Behavioral|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
168540|NCT02882698|Behavioral|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
168541|NCT02882685|Procedure|Roux-en-y gastric bypass|
168542|NCT02882685|Procedure|Single anastomosis gastric bypass|
168543|NCT02882672|Other|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
168544|NCT02882672|Other|Control|They did not do ant exercise training during 8 weeks.
168545|NCT02882659|Biological|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
168546|NCT02882646|Device|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
168547|NCT02882633|Drug|30ml bolus of bupivacaine|Local anesthetic
168548|NCT02882620|Behavioral|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
168592|NCT02882321|Other|Pharmacological Study|Correlative studies
168593|NCT02882308|Drug|Olaparib|50/25 mg BD split x 5 days
168594|NCT02882308|Drug|Cisplatin|60 mg/m^2 d1-d5
168595|NCT02882308|Drug|Olaparib|300 mg BD x 21-28 days.
168549|NCT02882620|Behavioral|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
168550|NCT02882620|Behavioral|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
168551|NCT02882607|Behavioral|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
168552|NCT02882594|Behavioral|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
168553|NCT02882581|Radiation|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
168554|NCT02882568|Biological|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
168555|NCT02882555|Behavioral|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity <10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
168556|NCT02882555|Drug|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
168557|NCT02882555|Drug|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
168558|NCT02882542|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
168559|NCT02882529|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
168560|NCT02882516|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
168561|NCT02882503|Device|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
168562|NCT02882490|Behavioral|Parent Training|
168563|NCT02882490|Other|Supportive Therapy|
168564|NCT02882477|Drug|Deferiprone|
168565|NCT02882477|Drug|Acetylcysteine|
168566|NCT02882477|Drug|Sitagliptin and Metformin|
168567|NCT02882464|Device|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
168568|NCT02882464|Device|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
168569|NCT02882464|Procedure|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
168570|NCT02882451|Dietary Supplement|pinaverium bromide|
168571|NCT02882451|Dietary Supplement|Vitamin C|
168572|NCT02882438|Drug|infected group|Ginkgo Biloba in different dosage forms
168573|NCT02882438|Drug|control group|placebo without Ginkgo Biloba
168574|NCT02882425|Drug|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
168575|NCT02882425|Drug|Selexipag for oral use|Tablet containing 200 µg of selexipag
168576|NCT02882412|Other|observational|
168577|NCT02882399|Other|Shortystrap|
168578|NCT02882386|Other|Strength Training|
168579|NCT02882386|Dietary Supplement|Milk 1%|
168580|NCT02882386|Dietary Supplement|Whey protein concentrate 80 (WPC-80)|
168581|NCT02882386|Dietary Supplement|Microparticulated whey|
168582|NCT02882386|Dietary Supplement|Hydrolyzed whey|
168583|NCT02882386|Dietary Supplement|Native whey|
168584|NCT02882373|Dietary Supplement|Arginine|Given PO
168585|NCT02882373|Drug|Placebo|Given PO
168586|NCT02882360|Device|Kerlix-AMD|Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
168587|NCT02882360|Other|placebo--normal gauze|Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
168588|NCT02882347|Drug|Somatostatin|
168589|NCT02882334|Device|Finger Force Manipulandum|
168590|NCT02882334|Other|Conventional physiotherapy|
168591|NCT02882321|Drug|Oxidative Phosphorylation Inhibitor IACS-010759|Given PO
168598|NCT02882282|Drug|Pembrolizumab|200 mg by vein on Day 1 of a 21 day cycle for 4 cycles.
168599|NCT02882269|Drug|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
168600|NCT02882269|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
168601|NCT02882256|Other|Video discharge instructions|Discharge instructions provided in video form
168602|NCT02882243|Device|FLXfit Cage for fusion|Evaluating patient outcomes and radiographic outcomes
168603|NCT02882230|Drug|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|chemical dosage ARV
168604|NCT02882217|Drug|XC8 (histamine glutarimide)|
168605|NCT02882217|Drug|Placebo|
168606|NCT02882191|Drug|LevoCept|placement of LevoCept IUD
168607|NCT02882165|Other|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.~A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
168608|NCT02882152|Procedure|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
168609|NCT02882152|Procedure|morphine|Intrathecal morphine injection
168610|NCT02882126|Drug|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
168611|NCT02882113|Drug|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
168612|NCT02882100|Biological|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
168613|NCT02882100|Biological|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
168614|NCT02882087|Drug|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
168615|NCT02882087|Drug|RC18 160 mg plus MTX|
168616|NCT02882074|Drug|Human albumin|human albumin 5% during surgery
168617|NCT02882074|Drug|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
168618|NCT02882061|Procedure|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
168619|NCT02882048|Procedure|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
168620|NCT02882048|Other|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
168621|NCT02882035|Other|OFA|
168622|NCT02882022|Device|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
168623|NCT02882009|Drug|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
168624|NCT02882009|Drug|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
168625|NCT02881996|Drug|IV tylenol|IV tylenol given scheduled in addition to standard PCA
168626|NCT02881996|Drug|No IV tylenol|No additional IV Tylenol given
168627|NCT02881996|Drug|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
168628|NCT02881983|Other|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
168629|NCT02881970|Drug|autologous cord blood stem cell|
168630|NCT02881957|Drug|Cholecalciferol|
168631|NCT02881957|Other|Placebo|Oral syrup placebo
168632|NCT02881944|Behavioral|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
168633|NCT02881944|Behavioral|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
168634|NCT02881931|Behavioral|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
168635|NCT02881918|Other|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
168636|NCT02881905|Device|ball attachment|it is attachment part that connects the overdenture to the implant
168637|NCT02881905|Device|cm loc attachment|It is a new attachment made of peek material
168730|NCT02881086|Drug|Fludarabine|
168638|NCT02881892|Other|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
168639|NCT02881879|Biological|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
168640|NCT02881866|Drug|Furosemide|
168641|NCT02881866|Drug|Saline|
168642|NCT02881853|Drug|XmAb7195|
168643|NCT02881853|Drug|Placebo|
168644|NCT02881840|Drug|14C-APD421|
168645|NCT02881827|Radiation|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
168646|NCT02881827|Other|Placebo|Simulation of treatment with the device switched off
168647|NCT02881827|Other|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.~For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
168648|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
168649|NCT02881775|Device|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
168650|NCT02881775|Device|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
168651|NCT02881762|Drug|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
168652|NCT02881749|Radiation|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
168653|NCT02881749|Drug|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
168654|NCT02881736|Other|electroencephalographic,magnetic resonance imaging|
168655|NCT02881723|Procedure|Surgery|
168656|NCT02881723|Radiation|Radio- chemotherapy|
168657|NCT02881710|Other|contrast product used to assess biomarkers variations|
168658|NCT02881697|Other|Adipose tissue sampling|
168659|NCT02881684|Device|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
168660|NCT02881684|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
168661|NCT02881671|Genetic|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
168662|NCT02881658|Dietary Supplement|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
168663|NCT02881658|Dietary Supplement|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
168664|NCT02881645|Behavioral|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
168665|NCT02881632|Device|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
168666|NCT02881619|Drug|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
168667|NCT02881619|Drug|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
168668|NCT02881606|Device|Naso-alveolar molding (NAM)|
168669|NCT02881606|Device|Computer aided design NAM (CAD/NAM)|
168670|NCT02881580|Other|No intervention : descriptive study|
168671|NCT02881567|Drug|Daclizumab|High yield formulation
168672|NCT02881554|Procedure|Computed Tomography|Undergo SC SPECT/CT
168673|NCT02881554|Procedure|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
168674|NCT02881554|Drug|Technetium Tc-99m Sulfur Colloid|Given IV
168675|NCT02881541|Procedure|Enhanced support|
168676|NCT02881541|Procedure|Usual care|
168731|NCT02881086|Drug|Vincristine|
168732|NCT02881086|Drug|Mercaptopurine|
168733|NCT02881086|Drug|VP16|
168677|NCT02881528|Drug|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
168678|NCT02881528|Drug|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
168679|NCT02881515|Other|Low Sodium Diet|Ten days of low sodium diet
168680|NCT02881515|Other|Medium Sodium Diet|Ten days of a medium sodium diet
168681|NCT02881515|Other|High Sodium Diet|Ten days of a high sodium diet
168682|NCT02881502|Other|severe asthma group|No intervention
168683|NCT02881489|Other|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
168684|NCT02881476|Other|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
168685|NCT02881463|Other|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
168686|NCT02881437|Drug|IgHy10|Sub Cutaneous IgHy10 administration
168687|NCT02881411|Other|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
168688|NCT02881411|Other|Fibromyalgia coping skills programme|Exercise, education programme
168689|NCT02881398|Device|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
168690|NCT02881398|Other|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
168691|NCT02881372|Other|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
168692|NCT02881359|Device|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
168693|NCT02881346|Drug|Enstilar®|Once daily application of cutaneous foam to plaques on body and/or extremities
168694|NCT02881333|Genetic|Blood samples|
168695|NCT02881320|Drug|B/F/TAF (Adult Strength)|50/200/25 mg FDC tablets administered orally once daily without regard to food
168696|NCT02881320|Drug|B/F/TAF (Low Dose)|30/120/15 mg FDC tablets administered orally once daily without regard to food
168697|NCT02881307|Dietary Supplement|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
168698|NCT02881307|Behavioral|Dietary Counseling|Dietary Counseling
168699|NCT02881307|Behavioral|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
168700|NCT02881294|Drug|SUVN-G3031|
168701|NCT02881281|Other|educational program for Development of problem-solving skills|
168702|NCT02881281|Other|no education program|no education program
168703|NCT02881268|Other|blood sample|
168704|NCT02881255|Device|Implantable Cardioverter Defibrillator|Patients will be randomized to receive either a subcutaneous or transvenous ICD.
168705|NCT02881242|Other|Laboratory Biomarker Analysis|Correlative studies
168706|NCT02881242|Other|Quality-of-Life Assessment|Ancillary studies
168707|NCT02881242|Drug|Trametinib|Given PO
168708|NCT02881216|Device|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
168709|NCT02881216|Device|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
168710|NCT02881203|Device|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
168711|NCT02881203|Device|RPM|Varian Real-time Position Management (RPM) system
168712|NCT02881190|Drug|RC48-ADC|
168713|NCT02881177|Drug|Oxytocin|40 IU
168714|NCT02881177|Drug|Placebo|40 IU
168715|NCT02881164|Other|Low glycemic index|Subjects intake a low glycemic index breakfast
168716|NCT02881164|Other|High glycemic index|Subjects intake a high glycemic index breakfast
168717|NCT02881151|Device|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
168718|NCT02881138|Drug|RC48-ADC|
168719|NCT02881125|Drug|Nortriptyline Hydrochloride|Given PO
168720|NCT02881125|Drug|Paclitaxel|Given IV
168721|NCT02881112|Device|Provant Therapy System|Treatment with the Provant Therapy System
168722|NCT02881086|Drug|Rituximab|
168723|NCT02881086|Drug|Nelarabine|
168724|NCT02881086|Drug|PEG-Asparaginase|
168725|NCT02881086|Procedure|Cranial irradiation|
168726|NCT02881086|Drug|Imatinib|
168727|NCT02881086|Drug|Idarubicin|
168728|NCT02881086|Drug|Dexamethasone|
168736|NCT02881086|Procedure|Stem cell transplantation|
168737|NCT02881086|Drug|Cytarabine|
168738|NCT02881086|Drug|Vindesine|
168739|NCT02881086|Drug|Adriamycin|
168740|NCT02881086|Drug|Prednisolone|
168741|NCT02881073|Other|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
168742|NCT02881060|Dietary Supplement|Alcohol|
168743|NCT02881060|Dietary Supplement|Placebo|
168744|NCT02881047|Device|ablative fractional laser|
168745|NCT02881047|Other|Biospecimen Collection|
168746|NCT02881034|Drug|Triple therapy|
168747|NCT02881021|Other|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
168748|NCT02881021|Device|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
168749|NCT02881008|Drug|Entecavir|
168750|NCT02881008|Drug|Myrcludex B|
168751|NCT02880995|Device|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
168752|NCT02880995|Behavioral|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
168753|NCT02880995|Drug|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
168754|NCT02880982|Dietary Supplement|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
168755|NCT02880982|Other|Placebo|Weekly oral placebo softgel capsule
168756|NCT02880969|Behavioral|answering questionnaires|
168757|NCT02880956|Drug|ABBV-8E12|ABBV-8E12 solution for IV infusion
168758|NCT02880956|Drug|placebo for ABBV-8E12|placebo solution for IV infusion
168759|NCT02880943|Drug|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.~Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.~Starting dose for phase I will be 55 kBq/kg."
168760|NCT02880930|Dietary Supplement|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
168761|NCT02880917|Device|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
168762|NCT02880917|Device|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
168763|NCT02880917|Other|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
168764|NCT02880904|Other|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
168765|NCT02880891|Procedure|prothetic procedure|splinted crown
168766|NCT02880878|Procedure|Early Surgical Hematoma Evacuation|Early Minimally Invasive Parafascicular Surgery (MIPS)
168767|NCT02880865|Biological|CD-JEV|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
168768|NCT02880865|Biological|MMR|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
168769|NCT02880852|Drug|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
168770|NCT02880839|Device|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
168771|NCT02880839|Device|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
168772|NCT02880839|Device|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
168773|NCT02880826|Behavioral|Measure the culture of safety in the reanimation units|
168774|NCT02880813|Other|Infusion|infusion of nutrients
168775|NCT02880800|Drug|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:~Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
168776|NCT02880800|Drug|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:~Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
168777|NCT02880800|Drug|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
168778|NCT02880800|Drug|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
168779|NCT02880787|Drug|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
169241|NCT02877264|Drug|vapendavir 24 mg/mL oral suspension|
168780|NCT02880787|Device|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
168781|NCT02880774|Other|mandibular nonspecific mobilization|The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
168782|NCT02880774|Other|Ultrasound detuned,|Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
168783|NCT02880761|Procedure|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
168784|NCT02880748|Other|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
168785|NCT02880748|Other|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
168786|NCT02880735|Device|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
168787|NCT02880709|Dietary Supplement|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
168788|NCT02880696|Behavioral|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
168789|NCT02880696|Behavioral|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
168790|NCT02880696|Device|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
168791|NCT02880683|Device|NeuroTronik CANS Therapy System|
168792|NCT02880670|Drug|BMS-986142|
168793|NCT02880657|Dietary Supplement|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
168794|NCT02880657|Dietary Supplement|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
168795|NCT02880631|Device|BAROSTIM NEO™ System|
168796|NCT02880618|Device|Barostim Neo™ System|
168797|NCT02880592|Other|Affinity Allograft|fresh hypothermically stored human amniotic membrane
168798|NCT02880592|Other|Standard of care|offloading, debridement, infection management using appropriate dressings
168799|NCT02880566|Procedure|Scalp block|Full scalp block
168800|NCT02880540|Drug|Fentanyl|
168801|NCT02880540|Drug|Morphine|
168802|NCT02880540|Drug|Dexmedetomidine|
168803|NCT02880527|Other|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :~medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~general practitioners~the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
168804|NCT02880514|Device|PROPEL Mini Sinus Implant|Sinus implant with 370 mcg of mometasone furoate released over 30 days
168805|NCT02880514|Procedure|Balloon Sinus Dilation Alone|
168806|NCT02880501|Device|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
168807|NCT02880475|Drug|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
168808|NCT02880462|Dietary Supplement|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
168809|NCT02880462|Other|placebo|Placebo is made of starch
168810|NCT02880449|Behavioral|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
168811|NCT02880436|Other|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
168812|NCT02880423|Procedure|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .~The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
168813|NCT02880423|Procedure|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
168814|NCT02880410|Device|NeuroBlate System|Laser Interstitial Thermal Therapy
168815|NCT02880410|Drug|Radiation therapy and temozolomide|Radiation therapy and temozolomide
168816|NCT02880397|Drug|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
169449|NCT02875639|Drug|Buyang huanwu decoction|
168817|NCT02880397|Drug|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
168818|NCT02880384|Other|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
168819|NCT02880371|Drug|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
168820|NCT02880371|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
168821|NCT02880345|Drug|PEMBROLIZUMAB|
168822|NCT02880345|Radiation|hypofractionated radiation|
168823|NCT02880332|Other|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
168824|NCT02880332|Other|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
168825|NCT02880332|Other|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
168826|NCT02880319|Drug|Stereotactic Body Radiation Therapy (SBRT)|
168827|NCT02880319|Device|Stereotactic Linear Accelerator|
168828|NCT02880306|Other|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
168829|NCT02880293|Drug|melphalan|melphalan (140 mg/m2 IV on day -7)
168830|NCT02880293|Drug|fludarabine|fludarabine (40 mg/m2/d on days -5 through -2)
168831|NCT02880293|Drug|thiotepa|thiotepa (5 mg/kg IV on day -67)
168832|NCT02880293|Drug|Cyclophosphamide|cyclophosphamide (50 mg/kg IV on day +3 and +4)
168833|NCT02880293|Drug|Mesna|
168834|NCT02880293|Drug|Mycophenolate Mofetil|(15 mg/kg PO/IV TID)
168835|NCT02880293|Drug|Filgrastim|
168836|NCT02880293|Drug|Tacrolimus|
168837|NCT02880280|Drug|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
168838|NCT02880280|Drug|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
168839|NCT02880267|Device|CGM|Glucose challenge during a clinic session to assess CGM performance compared to a laboratory reference measurement.
168840|NCT02880254|Device|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
168841|NCT02880254|Device|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
168842|NCT02880241|Drug|MMV390048|Tablets of 20mg each
168843|NCT02880228|Drug|Dexamethasone|Given PO
168844|NCT02880228|Other|Laboratory Biomarker Analysis|Correlative studies
168845|NCT02880228|Drug|Lenalidomide|Given PO
168846|NCT02880228|Biological|Pembrolizumab|Given IV
168847|NCT02880215|Behavioral|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
168848|NCT02880215|Behavioral|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
168849|NCT02880202|Other|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
168850|NCT02880189|Device|Orbera Intragastric Balloon|The Orbera Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
168851|NCT02880189|Procedure|Endoscopic Ultrasound Guided Core Liver Biopsy|
168852|NCT02880176|Other|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
168853|NCT02880163|Device|ResQFoam|Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
168854|NCT02880150|Other|Stress test|
168855|NCT02880137|Drug|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20 MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
168856|NCT02880137|Procedure|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
168857|NCT02880124|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
270704|NCT02138422|Biological|Placebo|
168858|NCT02880124|Behavioral|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
168859|NCT02880124|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
168860|NCT02880124|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
168861|NCT02880124|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
168862|NCT02880124|Other|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
168863|NCT02880124|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
168864|NCT02880124|Behavioral|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
168865|NCT02880098|Biological|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
168866|NCT02880085|Drug|Local anesthetic|local injection
168867|NCT02880072|Dietary Supplement|phosphate orally|4 different preparations of phosphate
168868|NCT02880059|Device|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
168869|NCT02880033|Drug|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
168870|NCT02880033|Drug|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
168871|NCT02880020|Biological|Ipilimumab|Given IV
168872|NCT02880020|Other|Laboratory Biomarker Analysis|Correlative studies
168873|NCT02880020|Biological|Nivolumab|Given IV
168874|NCT02880007|Radiation|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
168875|NCT02880007|Radiation|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
168876|NCT02880007|Drug|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
168877|NCT02879994|Other|Laboratory Biomarker Analysis|Correlative studies
168878|NCT02879994|Biological|Pembrolizumab|Given IV
168879|NCT02879981|Drug|Guaifenesin|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
168880|NCT02879981|Drug|Sulfamethoxazole|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
168881|NCT02879981|Drug|Trimethoprim|Administration of treatment will be according to treating physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
168882|NCT02879968|Other|Non-interventional study|
168883|NCT02879955|Other|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
168884|NCT02879955|Other|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
168885|NCT02879955|Other|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
168886|NCT02879955|Other|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
168887|NCT02879942|Other|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
168888|NCT02879942|Other|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
168889|NCT02879916|Drug|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
168890|NCT02879916|Drug|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
168891|NCT02879903|Procedure|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.~Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
168892|NCT02879903|Procedure|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
168893|NCT02879903|Procedure|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
168894|NCT02879877|Drug|UCB7858|
168895|NCT02879877|Drug|Placebo|
168928|NCT02879656|Procedure|operative treatment|surgery with volar locking plate with modified Henry's volar approach
168929|NCT02879643|Drug|Marqibo|The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
169450|NCT02875639|Drug|QISHEN YIQI DRIPPING PILLS|
168896|NCT02879864|Device|light therapy|The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning. The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes. The light source should be placed at eye level (distance of about 40 cm). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy. These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
168897|NCT02879864|Device|Usual care|The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before. A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
168898|NCT02879838|Other|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
168899|NCT02879825|Device|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.~Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
168900|NCT02879812|Other|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
168901|NCT02879812|Other|Educational Video for Staff|Dialysis facility staff will watch a ~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
168902|NCT02879812|Other|Educational Video for Patients|Dialysis facilities will receive a ~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
168903|NCT02879812|Other|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and CME will be offered.
168904|NCT02879812|Other|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
168905|NCT02879812|Other|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
168906|NCT02879799|Other|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
168907|NCT02879786|Other|Posturographic tests|
168908|NCT02879786|Other|Questionnaire of motion sickness susceptibility|
168909|NCT02879773|Radiation|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
168910|NCT02879760|Biological|Ad-MAGEA3|Intramuscular injection
168911|NCT02879760|Biological|MG1-MAGEA3|Intravenous infusion
168912|NCT02879760|Biological|Pembrolizumab|Intravenous infusion
168913|NCT02879747|Drug|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
168914|NCT02879734|Other|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
168915|NCT02879721|Drug|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
168916|NCT02879721|Drug|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
168917|NCT02879708|Other|Information Only|Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.
168918|NCT02879708|Other|Information and Facilitation|In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
168919|NCT02879695|Biological|Blinatumomab|Given IV
168920|NCT02879695|Biological|Ipilimumab|Given IV
168921|NCT02879695|Biological|Nivolumab|Given IV
168922|NCT02879682|Procedure|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
168923|NCT02879682|Procedure|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
168924|NCT02879669|Biological|ONCOS-102|
168925|NCT02879669|Drug|Pemetrexed/cisplatin (carboplatin)|
168926|NCT02879669|Drug|Cyclophosphamide|
168927|NCT02879656|Procedure|non-operative treatment|conservative treatment with 5 weeks cast immobilization
276147|NCT02098486|Drug|ceftriaxone|
168930|NCT02879617|Drug|durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
168931|NCT02879604|Other|Compensatory cognitive training|In addition to the usual care, method of compensatory cognitive remediation
168932|NCT02879604|Other|Usual|Usual care
168933|NCT02879591|Other|Social Skills training with Avatar therapist|
168934|NCT02879578|Drug|NBI-98854|
168935|NCT02879565|Other|Semi structured interviews + EEG exams|
168936|NCT02879552|Procedure|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
168937|NCT02879552|Procedure|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
168938|NCT02879539|Device|MP3000 sound coding strategy or ACE strategy with lower stimulation|
168939|NCT02879526|Drug|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
168940|NCT02879513|Drug|Paclitaxel|
168941|NCT02879513|Drug|Cisplatin|
168942|NCT02879513|Drug|Epirubicin|
168943|NCT02879513|Drug|Cyclophosphamide|
168944|NCT02879513|Drug|5-fluoruracil|
168945|NCT02879500|Other|Diet beverages|
168946|NCT02879487|Device|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
168947|NCT02879474|Behavioral|Melanoma scale questionnair|
168948|NCT02879461|Procedure|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
168949|NCT02879448|Device|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
168950|NCT02879448|Device|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
168951|NCT02879435|Drug|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
168952|NCT02879435|Other|Placebo|pre-operative wound infiltration with 10 ml of sterile water
168953|NCT02879422|Genetic|genetic analysis|
168954|NCT02879409|Drug|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
168955|NCT02879409|Drug|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.~Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.~Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
168956|NCT02879409|Drug|Sitagliptin|Oral: 100 mg once daily
168957|NCT02879409|Drug|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
168958|NCT02879409|Drug|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily~Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
168959|NCT02879409|Drug|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
168960|NCT02879409|Drug|human insulin|insulin dosage and administration according to physician
168961|NCT02879396|Behavioral|PA4LE Program|"Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~Patient understanding of red flag indicators of worsening condition and appropriate next steps~Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness & Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
168962|NCT02879383|Procedure|DMR Procedure|The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System
168963|NCT02879383|Procedure|Sham Procedure|The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
168964|NCT02879370|Procedure|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
168965|NCT02879357|Behavioral|Training|"Clinician training~System for patient selection~System of triggering and tracking conversations~Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values~Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
168966|NCT02879344|Other|Blood draw|
168967|NCT02879331|Procedure|10 coils in upper lobes|
168968|NCT02879331|Procedure|15 coils in upper and lower lobes|
168969|NCT02879331|Procedure|cycloergometry|
168970|NCT02879318|Drug|Gemcitabine|
168971|NCT02879318|Drug|Nab-paclitaxel|
168972|NCT02879318|Drug|Durvalumab|
168973|NCT02879318|Drug|Tremelimumab|
169404|NCT02875938|Behavioral|Control|control condition using reading materials without music.
168974|NCT02879305|Drug|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
168975|NCT02879305|Drug|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
168976|NCT02879305|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
168977|NCT02879305|Drug|Iron therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
168978|NCT02879292|Other|Spinal anesthesia|Spinal Anesthesia
168979|NCT02879279|Device|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
168980|NCT02879279|Other|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
168981|NCT02879266|Biological|TetraVax-DV TV005|Contains 10^3 plaque-forming units (PFUs) of rDEN1Δ30, 10^4 PFUs of rDEN2/4Δ30(ME), 10^3 PFUs of rDEN3Δ30/31-7164, and 10^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
168982|NCT02879266|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
168983|NCT02879240|Other|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
168984|NCT02879240|Other|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
168985|NCT02879227|Drug|Cisplatin|Arm cisplatin : 75mg/m2, day n*1 and day n*22, And radiotherapy 50 Gy, 2Gy/f
168986|NCT02879227|Drug|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
168987|NCT02879214|Radiation|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
168988|NCT02879201|Procedure|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
168989|NCT02879188|Other|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
168990|NCT02879188|Other|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
168991|NCT02879162|Drug|Durvalumab|
168992|NCT02879162|Drug|Tremelimumab|
168993|NCT02879149|Device|AUGMENT® Bone Graft|AUGMENT® Bone Graft
168994|NCT02879149|Procedure|Standard of Care|Autologous Bone Graft
168995|NCT02879136|Drug|Methylphenidate|Patient will be randomized to Methylphenidate
168996|NCT02879136|Other|Physical Therapy|All Patients will have standard of care PT used for PD patients
168997|NCT02879136|Drug|Atomoxetine|Patient will be randomized to Atomoxetine
168998|NCT02879110|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
168999|NCT02879110|Other|Placebo|Placebo tablet is composed of starch.
169000|NCT02879097|Biological|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
169001|NCT02879097|Biological|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
169002|NCT02879097|Drug|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
169003|NCT02879097|Drug|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
169004|NCT02879058|Procedure|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
169079|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
169005|NCT02879045|Other|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
169006|NCT02879019|Other|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
169007|NCT02879019|Other|Walking training group|Patients will perform two walking session per week, each consisting of 15*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
169008|NCT02879006|Drug|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
169009|NCT02879006|Drug|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
169010|NCT02879006|Drug|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
169011|NCT02879006|Drug|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
169012|NCT02878993|Device|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
169013|NCT02878980|Behavioral|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
169014|NCT02878980|Other|Laboratory Biomarker Analysis|Correlative studies
169015|NCT02878980|Other|Quality-of-Life Assessment|Ancillary studies
169016|NCT02878980|Other|Questionnaire Administration|Ancillary studies
169017|NCT02878954|Other|No intervention (Observational study)|"160 patients will be recruited to:~Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.~Perform a six-minute walk test Comparison between men and women will be performed."
169018|NCT02878954|Other|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.~In the control session participants will be seated in resting position for 15 minutes."
169019|NCT02878954|Other|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
169020|NCT02878941|Procedure|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
169021|NCT02878928|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
169022|NCT02878915|Device|Ultrasound guided femoral puncture|
169023|NCT02878902|Other|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
169024|NCT02878889|Drug|S-1|
169025|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
169026|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
169027|NCT02878863|Drug|Paeoniflorin + phosphatidylcholine or silymarin|
169028|NCT02878863|Drug|Phosphatidylcholine or silymarin|
169029|NCT02878850|Other|Augmented Blood Pressure|Subjects will have their blood pressure kept in a higher range.
169030|NCT02878837|Drug|Dexmedetomidine|
169031|NCT02878837|Drug|Midazolam|
169032|NCT02878824|Other|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek & Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr & Burt, 2014).~In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
169033|NCT02878824|Other|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray & Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
169034|NCT02878811|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
169035|NCT02878798|Drug|topiramate|Oral topiramate at a target dose of 50mg twice daily.
169036|NCT02878798|Other|Placebo|overencapsulated placebo of identical color, shape and packaging to topiramate
169037|NCT02878785|Drug|Decitabine|DNA methyltransferase inhibitor
169038|NCT02878785|Drug|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
169039|NCT02878772|Drug|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
169040|NCT02878772|Drug|Aspirin|100mg, once daily, oral medication
276148|NCT02098473|Drug|RPC4046|
169041|NCT02878759|Device|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
169042|NCT02878746|Device|Robotic mirror therapy|2-dimensional
169043|NCT02878746|Device|Conventional mirror therapy|2- and 3-dimensional
169044|NCT02878733|Drug|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
169045|NCT02878720|Device|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.~Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy following the real or sham tVNS stimulation"
169046|NCT02878707|Drug|Dexmedetomidine|
169047|NCT02878694|Biological|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
169048|NCT02878681|Drug|Ranibizumab|0.5 mg intravitreal injections
169049|NCT02878681|Drug|Aflibercept|2 mg intravitreal injections
169050|NCT02878668|Procedure|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
169051|NCT02878629|Device|Mandibular Advancement Devices|
169052|NCT02878616|Drug|LFG316|LFG316 single dose
169053|NCT02878616|Drug|IVIG|IVIG single dose
169054|NCT02878603|Biological|caplacizumab|
169055|NCT02878590|Device|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
169056|NCT02878577|Device|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
169057|NCT02878564|Drug|Praziquantel|40 mg/kg, PO (orally administered tablets)
169058|NCT02878551|Other|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
169059|NCT02878538|Drug|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
169060|NCT02878538|Other|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
169061|NCT02878525|Procedure|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
169062|NCT02878525|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
169063|NCT02878512|Procedure|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
169064|NCT02878512|Procedure|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
169065|NCT02878499|Other|polysomnography|
169066|NCT02878486|Device|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
169067|NCT02878486|Behavioral|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
169068|NCT02878486|Device|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
169069|NCT02878473|Procedure|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
169070|NCT02878460|Other|monitoring with ORI + SpO2|"If ORI is equal to 0.00, the FiO2 (or oxygen flow) is not changed. if ORI is ≥ 0.01, Nurses must decrease the FiO2 (or oxygen flow) by 10%, until ORI is =0.~if SpO2 is < lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
169071|NCT02878460|Other|monitoring with SpO2|"If SpO2 is below the upper individualized limit, the FiO2 (or oxygen flow) is not changed.~If SpO2 is equal or above this limit, Nurses must reduce the FiO2 (or oxygen flow) by 10% every 10 minutes until SpO2 is ≤ upper individualized limit, with FiO2≥25 %.~if SpO2 is < lower individualized limit, FiO2 (or oxygen flow) is increased by 10%, if it happens twice, doctors are called."
169072|NCT02878447|Radiation|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
169073|NCT02878421|Device|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
169074|NCT02878421|Other|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
169075|NCT02878421|Other|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
169076|NCT02878408|Genetic|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
169077|NCT02878395|Procedure|Ileocolic resection|
169078|NCT02878382|Other|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
169080|NCT02878369|Procedure|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
169081|NCT02878356|Behavioral|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
169082|NCT02878356|Behavioral|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
169083|NCT02878356|Behavioral|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
169084|NCT02878343|Behavioral|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
169085|NCT02878343|Behavioral|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
169086|NCT02878330|Drug|MEDI8897|A single IM dose of 50 mg on Day 1 of the study.
169087|NCT02878330|Drug|Placebo|A single IM dose of placebo matched to MEDI8897 on Day 1 of the study.
169088|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
169089|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
169090|NCT02878278|Drug|Chidamide BIW|Chidamide is given 30mg, twice a week
169091|NCT02878278|Drug|Chidamide QD|Chidamide is given 10mg,QD
169092|NCT02878265|Dietary Supplement|Vitamin A|Vitamin A supplements
169093|NCT02878265|Dietary Supplement|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
169094|NCT02878265|Dietary Supplement|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
169095|NCT02878239|Other|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
169096|NCT02878239|Other|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
169097|NCT02878226|Procedure|repair of rupture|
169098|NCT02878213|Device|D700 System|Atrial Fibrillation Ablation Procedure
169099|NCT02878200|Biological|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
169100|NCT02878187|Device|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
169101|NCT02878174|Procedure|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
169102|NCT02878161|Drug|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
169103|NCT02878161|Biological|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
169104|NCT02878161|Biological|etanercept|Etanercept :hypodermic injection,25mg/twice a week
169105|NCT02878161|Biological|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
169106|NCT02878161|Drug|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
169107|NCT02878161|Drug|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
169108|NCT02878161|Drug|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
169109|NCT02878148|Device|Diagnostic imaging modalities for suspected renal colic|"All patients with suspected acute uncomplicated renal colic included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.~Imaging examination will be performed according to current guidelines.~Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
169110|NCT02878135|Procedure|fast application|
169111|NCT02878135|Procedure|slow application|
169112|NCT02878122|Procedure|Cancer treatment|Chemotherapy and laparoscopic surgery
169113|NCT02878109|Device|Post-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
169114|NCT02878109|Device|Pre-treatment phase group|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
169115|NCT02878096|Drug|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
169116|NCT02878083|Drug|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
169117|NCT02878083|Drug|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
169118|NCT02878070|Behavioral|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
169119|NCT02878057|Drug|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
169120|NCT02878044|Other|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
276149|NCT02098473|Drug|Placebo|
169121|NCT02878031|Drug|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age <12 months (4 - <10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age <3 years (10 kg - <14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children <5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
169122|NCT02878018|Drug|Qi-Ji Shen-Kang formula; Zhu-Bai formula; Yu-Shen formula|Qi-Ji Shen-Kang formula:15g of field thistle,10g of common edelweiss herb,10g of spreading hedyotis herb,10g ofYunnan manyleaf Paris rhizome,10g of hairyvein agrimonia herb,10g of the root bark of the tree peony,15g of root of red rooted salvia, and 15g ofmembranous mikvetch root.Zhu-Bai formula:10g of glabrous greenbrier rhizome,5g of Chinese atractylodes rhizome,10g of amur corktree bark,10g of common edelweiss her),10g of field thistle,10g of lalang grass rhizome,10g of garden burnet root,5g of longbract cattail pollen,5g of rehmanniae radix, and 5g of Chinese angelica root.Yu-Shen formula:15g of membranous mikvetch root,10g of heterophylla falsestarwort root,10g of field thistle,10g of cogongrass rhizome,10g of spreading hedyotis herb,10g of root of red rooted salvia,10g of fresh root of rehmannia,10g of Asian puccoon,10g of wormwoodlike motherwort herb,10g of common cockscomb inflorescence,10g of gordon euyale,10g of root bark of the tree peony, and 5g of licorice root.
169123|NCT02878018|Drug|angiotensin-converting enzyme (ACE) inhibitor; adrenergic receptor binder (ARB); adrenal cortical hormone; Tripterygium wilfordii polyglycosidium; immunosuppressant|prednisone at a dose of 1-1.5 mg/(kg·d) and Tripterygium wilfordii polyglycosidium at a dose of 1 mg/(kg·d). For each patient, the specific Western medicines used and their doses may be adjusted at the discretion of his or her physician, but the classes cannot be changed.
169124|NCT02878005|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
169125|NCT02878005|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
169126|NCT02877992|Procedure|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
169127|NCT02877979|Drug|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
169128|NCT02877979|Drug|Placebo|
169129|NCT02877966|Dietary Supplement|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
169130|NCT02877966|Other|Placebo|
169131|NCT02877953|Behavioral|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
169132|NCT02877940|Device|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
169133|NCT02877940|Device|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
169134|NCT02877940|Device|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
169135|NCT02877927|Drug|Omadacycline|po tablets
169136|NCT02877927|Drug|Linezolid|po tablets
169137|NCT02877914|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
169138|NCT02877901|Drug|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
169139|NCT02877901|Drug|placebo|one tablet at bed time
169140|NCT02877888|Drug|fluoride varnish 22600ppm|topical application on teeth every 6months
169141|NCT02877875|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
169142|NCT02877875|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
169143|NCT02877875|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
169144|NCT02877862|Behavioral|mAGIC app|7-day app to encourage uptake of genetic counseling
169145|NCT02877849|Device|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
169146|NCT02877836|Other|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
169147|NCT02877823|Behavioral|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
169148|NCT02877823|Behavioral|Control|Healthy Lifestyle Education
169149|NCT02877810|Other|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
169150|NCT02877810|Other|Telephone|Consultations will be given over telephone.
169151|NCT02877797|Device|Cap|cap assisted esophagogastroduodenoscopy
169240|NCT02877264|Drug|vapendavir 264 mg tablet|
277324|NCT02089386|Procedure|Endoscopy|
169152|NCT02877784|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
169153|NCT02877784|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
169154|NCT02877784|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
169155|NCT02877784|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
169156|NCT02877784|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
169157|NCT02877784|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
169158|NCT02877784|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
169159|NCT02877784|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
169160|NCT02877784|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
169161|NCT02877771|Device|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
169162|NCT02877758|Other|Tomorrowlabs cosmeceutical formulation|
169163|NCT02877758|Other|Sham cosmeceutical formulation|
169164|NCT02877745|Other|Stratification, no intervention|
169165|NCT02877732|Device|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
169166|NCT02877732|Other|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
169167|NCT02877732|Other|DEM|Participant will be asked to read list of numbers out loud from a card
169168|NCT02877732|Other|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
169169|NCT02877732|Other|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
169170|NCT02877719|Other|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
169171|NCT02877706|Other|no specific intervention|
169172|NCT02877693|Radiation|Thoracic MRI Scan|is to demonstrate the MRI scan will not adversely affect the functionality of the ICD system. To do so, the ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
169173|NCT02877680|Behavioral|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
169174|NCT02877667|Device|planar acoustic wave device|accessory to laser treatment
169175|NCT02877654|Procedure|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.~One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
169176|NCT02877641|Dietary Supplement|Cholecalciferol|Given PO
169177|NCT02877641|Other|Laboratory Biomarker Analysis|Correlative studies
169178|NCT02877641|Dietary Supplement|Multivitamin|Given PO
169179|NCT02877641|Other|Placebo|Given PO
169180|NCT02877641|Other|Questionnaire Administration|Ancillary studies
169181|NCT02877628|Other|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
169182|NCT02877615|Drug|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
169183|NCT02877615|Drug|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
169184|NCT02877615|Drug|Placebo|Two sachets of placebo twice a day
169185|NCT02877602|Device|MRI|
169186|NCT02877602|Device|Transient Elastography|
169187|NCT02877589|Other|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
169188|NCT02877576|Procedure|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
169189|NCT02877576|Behavioral|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
169190|NCT02877576|Behavioral|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
169191|NCT02877563|Other|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
169192|NCT02877550|Drug|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
169193|NCT02877550|Drug|Venetoclax|p.o. once daily according to dose level (DL) or MTD
169194|NCT02877537|Drug|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
169195|NCT02877537|Procedure|Forced oscillation technique|before and after bronchodilation
169196|NCT02877537|Procedure|Plethysmography|
169197|NCT02877524|Other|Adaptive support ventilation|ASV during NIV
169198|NCT02877524|Other|Pressure support ventilation|PSV during NIV
169199|NCT02877511|Drug|BAY987517|Applied liberally to the skin (Formulation: Y73-161
169200|NCT02877511|Drug|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
169201|NCT02877498|Other|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
169202|NCT02877498|Other|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
169203|NCT02877485|Drug|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
169204|NCT02877485|Drug|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
169205|NCT02877472|Device|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
169206|NCT02877472|Procedure|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
169207|NCT02877459|Device|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
169208|NCT02877433|Device|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
169209|NCT02877433|Device|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
169210|NCT02877420|Other|Non-Technical Skills Training Curriculum|
169211|NCT02877420|Other|Conventional Simulation Training Group|
169212|NCT02877407|Procedure|patient who undergo laparoscopic/robotic-assisted hysteropexy|
169213|NCT02877407|Procedure|patient who undergo vaginal hysterectomy|
169214|NCT02877394|Device|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
169215|NCT02877394|Device|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
169216|NCT02877381|Procedure|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
169217|NCT02877381|Procedure|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
169218|NCT02877368|Other|Computed tomography|
169219|NCT02877355|Drug|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
169220|NCT02877342|Other|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
169221|NCT02877329|Behavioral|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
169222|NCT02877316|Other|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
169223|NCT02877316|Other|safety plan on paper|Standard treatment with safety plan on paper
169224|NCT02877303|Biological|Blinatumomab|Given IV
169225|NCT02877303|Drug|Cyclophosphamide|Given IV
169226|NCT02877303|Drug|Cytarabine|Given IT and IV
169227|NCT02877303|Drug|Dexamethasone|Given PO
169228|NCT02877303|Drug|Doxorubicin Hydrochloride|Given IV
169229|NCT02877303|Other|Laboratory Biomarker Analysis|Correlative studies
169230|NCT02877303|Drug|Mercaptopurine|Given PO
169231|NCT02877303|Drug|Methotrexate|Given IT, IV, and PO
169232|NCT02877303|Biological|Ofatumumab|Given IV
169233|NCT02877303|Drug|Prednisone|Given PO
169234|NCT02877303|Biological|Rituximab|Given IV
169235|NCT02877303|Drug|Vincristine Sulfate|Given IV
169236|NCT02877290|Device|non-invasive ventilation (NIV)|
169237|NCT02877277|Dietary Supplement|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
169238|NCT02877277|Dietary Supplement|Placebo|Oral intake of placebo tablet daily for 56 days
169239|NCT02877264|Drug|vapendavir 132 mg capsule|
169242|NCT02877238|Drug|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
169243|NCT02877238|Drug|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
169244|NCT02877225|Drug|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
169245|NCT02877225|Drug|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
169246|NCT02877212|Drug|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
169247|NCT02877199|Other|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
169248|NCT02877186|Other|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
169249|NCT02877186|Other|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
169250|NCT02877173|Drug|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
169251|NCT02877173|Drug|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
169252|NCT02877160|Drug|AL-794 suspension|
169253|NCT02877160|Drug|AL-794 tablet|
169254|NCT02877147|Other|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
169255|NCT02877134|Drug|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
169256|NCT02877134|Drug|Placebo|Participants will receive placebo Subcutaneously.
169257|NCT02877134|Drug|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
169258|NCT02877095|Drug|Furosemide|subcutaneous furosemide delivered via subcutaneous pump
169259|NCT02877082|Biological|Thymoglobulin|Given IV
169260|NCT02877082|Drug|Bortezomib|Given IV
169261|NCT02877082|Drug|Tacrolimus|Given IV and PO
169262|NCT02877069|Device|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
169263|NCT02877056|Procedure|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
169264|NCT02877043|Procedure|resection pulmonaire|
169265|NCT02877030|Other|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
169266|NCT02877017|Behavioral|Family safety reporting intervention|family safety reporting intervention for families and providers
169267|NCT02877004|Device|3 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatment - at a frequency of 3 times per week for 4 weeks
169268|NCT02877004|Device|2 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatments - at a frequency of 2 times per week for 6 weeks
169269|NCT02877004|Device|1 Low-Level Laser Therapy Treatment Weekly|Receive 12 LLLT treatments - at a frequency of once per week for 12 weeks
169270|NCT02876991|Procedure|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).~Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).~Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
169271|NCT02876978|Genetic|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
169272|NCT02876978|Drug|Fludarabine|30 mg/m^2/day x 4 days
169273|NCT02876978|Drug|Cyclophosphamide|500 mg/m^2/day x 2 days
169274|NCT02876965|Procedure|Muscle Stretching|Subjects completed one stretching session on the main muscle groups of the body weekly.
169275|NCT02876965|Procedure|Physical Exercise|Subjects completed 3 moderate intensity aerobic physical exercise sessions weekly.
169276|NCT02876952|Other|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.~HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
169277|NCT02876952|Other|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.~Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.~Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
169314|NCT02876679|Drug|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
169402|NCT02875938|Behavioral|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
277752|NCT02086175|Drug|Rituximab|
169278|NCT02876952|Other|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
169279|NCT02876952|Other|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
169280|NCT02876939|Other|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
169281|NCT02876939|Other|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
169282|NCT02876926|Behavioral|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
169283|NCT02876926|Behavioral|Home-based testing only|A standard home-based HIV test kit.
169284|NCT02876926|Behavioral|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
169285|NCT02876900|Drug|Low Dose Asenapine maleate transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patch
169286|NCT02876900|Drug|High Dose Asenapine maleate transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patch
169287|NCT02876900|Drug|Placebo|The study will evaluate placebo transdermal patch.
169288|NCT02876887|Drug|Cocoa|
169289|NCT02876887|Drug|Placebo|
169290|NCT02876874|Drug|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
169291|NCT02876861|Procedure|Radical nephroureterectomy|Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
169292|NCT02876861|Procedure|Distal ureterectomy|Distal ureterectomy.
169293|NCT02876861|Drug|Neoadjuvant Chemotherapy|Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
169294|NCT02876848|Other|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~Contact you over the phone or in person to provide medical advice on how to better take your pills,~Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
169295|NCT02876835|Drug|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
169296|NCT02876835|Drug|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
169297|NCT02876835|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
169298|NCT02876835|Drug|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
169299|NCT02876822|Drug|Vitamin D|
169300|NCT02876796|Drug|GS-0976|Capsule(s) administered orally
169301|NCT02876796|Drug|Placebo|Capsule(s) administered orally
169302|NCT02876796|Other|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
169303|NCT02876796|Other|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
169304|NCT02876783|Other|Observational - No intervention|
169305|NCT02876770|Dietary Supplement|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
169306|NCT02876770|Dietary Supplement|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
169307|NCT02876757|Drug|5ARI|Exposure to finasteride/dutasteride
169308|NCT02876744|Other|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
169309|NCT02876731|Device|PET-CT|NaF PET-CT
169310|NCT02876731|Device|MRI|DWMRI
169311|NCT02876718|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
169312|NCT02876705|Other|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
169313|NCT02876692|Device|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
169401|NCT02875964|Device|magnetoencephalogram|Implanting electrode to measure brain activity
169315|NCT02876679|Drug|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
169316|NCT02876679|Drug|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
169317|NCT02876666|Behavioral|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
169318|NCT02876653|Other|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
169319|NCT02876640|Drug|Retinoid 9cUAB30|Given PO
169320|NCT02876640|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection surgery
169321|NCT02876627|Behavioral|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
169322|NCT02876601|Drug|Defibrotide|6.25mg/kg bodyweight over 2h infusion
169323|NCT02876601|Drug|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
169324|NCT02876601|Drug|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
169325|NCT02876588|Other|Unrestricted|Users may open up to 4 patient records at a time.
169326|NCT02876588|Other|Restricted|Users are restricted to open 1 patient record at a time.
169327|NCT02876575|Device|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
169328|NCT02876562|Procedure|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
169329|NCT02876549|Drug|Chloroquine|10 mg/kg on day 0 & 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
169330|NCT02876549|Drug|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
169331|NCT02876549|Drug|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
169332|NCT02876536|Device|TENS|The effect of TENS device will be compared in case and control groups.
169333|NCT02876510|Drug|Fludarabine|Fludarabine infusion
169334|NCT02876510|Drug|Cyclophosphamide|Cyclophosphamide infusion
169335|NCT02876510|Biological|IMA101 product|i.v. infusion of IMA101 product(s).
169336|NCT02876510|Biological|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
169337|NCT02876510|Diagnostic Test|IMADetect|IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.
169338|NCT02876510|Drug|Atezolizumab|Atezolizumab infusion (1200 mg, i.v.) shall be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 6 months after IMA101 infusion.
169339|NCT02876497|Other|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
169340|NCT02876484|Drug|Colesevelam|
169341|NCT02876484|Drug|Chenodeoxycholic Acid|
169342|NCT02876484|Other|Water|
169343|NCT02876471|Other|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
169344|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
169345|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 96 hours) will be performed
169346|NCT02876445|Other|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
169347|NCT02876432|Device|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.~Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
169348|NCT02876432|Drug|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
169349|NCT02876432|Other|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
169350|NCT02876354|Drug|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
169351|NCT02876328|Biological|Ad26.ZEBOV|0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
169352|NCT02876328|Biological|MVA-BN-Filo|0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
169353|NCT02876328|Biological|rVSVΔG-ZEBOV-GP|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
169403|NCT02875938|Behavioral|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
169354|NCT02876328|Biological|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
169355|NCT02876328|Biological|rVSV boost|1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
169356|NCT02876315|Dietary Supplement|Redoxon VI|"Each tablet contains:~Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)~Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
169357|NCT02876315|Dietary Supplement|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
169358|NCT02876302|Drug|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
169359|NCT02876302|Drug|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
169360|NCT02876302|Drug|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
169361|NCT02876302|Drug|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
169362|NCT02876289|Drug|Perampanel|
169363|NCT02876276|Procedure|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
169364|NCT02876250|Drug|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
169365|NCT02876250|Drug|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
169366|NCT02876237|Other|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
169367|NCT02876237|Radiation|Radiotherapy|standard radiotherapy
169368|NCT02876224|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
169369|NCT02876224|Drug|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
169370|NCT02876224|Drug|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
169371|NCT02876211|Drug|Paricalcitol|Paricalcitol 2 capsules/three times per week
169372|NCT02876211|Drug|Epoetin beta|epoetin 1-3 times per week
169373|NCT02876211|Drug|Placebo|Placebo 2 capsules/three times per week
169374|NCT02876198|Device|Gonioscopy|Study of the trabecular structure by gonioscopy
169375|NCT02876185|Other|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
169376|NCT02876172|Drug|MDMA|Two sessions of MDMA-assisted psychotherapy, one with an initial dose of 75 mg and the second with 100 mg MDMA given to a person with PTSD and a significant other without PTSD.
169377|NCT02876172|Behavioral|CBCT|"A three-phase, 15-session, manualized treatment engaging an individual with PTSD and a concerned significant other"
169378|NCT02876159|Biological|2016-2017 Influenza Vaccine|Quadrivalent influenza A/Hemagglutinin Type 1 (H1N1), A/Influenza A virus subtype (A/H3N2) H3N2,and B virus vaccine for Intramuscular (IM) use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
169379|NCT02876146|Drug|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
169380|NCT02876133|Device|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
169381|NCT02876133|Device|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
169382|NCT02876120|Other|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
169383|NCT02876107|Drug|Carboplatin|Given IV
169384|NCT02876107|Other|Laboratory Biomarker Analysis|Correlative studies
169385|NCT02876107|Drug|Paclitaxel|Given IV
169386|NCT02876107|Biological|Panitumumab|Given IV
169387|NCT02876094|Drug|celecoxib|dose-response
169388|NCT02876081|Drug|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
169389|NCT02876055|Drug|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
169390|NCT02876055|Drug|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
169391|NCT02876055|Drug|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
169392|NCT02876042|Device|BAROSTIM NEO™ System|Implantation of the BAROSTIM NEO™ System
169393|NCT02876029|Other|Reference|the reference product used
169394|NCT02876029|Other|Test product|The test Product used
169395|NCT02876016|Device|functional MRI|locate the cerebral bases in functional imaging
169396|NCT02876003|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
169397|NCT02875990|Biological|Blood sample|
169398|NCT02875977|Other|Educational video|A 4-minute educational video describing PFPT
169399|NCT02875977|Other|Educational handout|A 2-page educational handout describing PFPT
169400|NCT02875964|Device|electroencephalogram|Implanting electrode to measure brain activity
169405|NCT02875925|Other|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
169406|NCT02875912|Behavioral|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.~Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.~Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.~Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
169407|NCT02875886|Drug|Amiloride|Combined with hydrochlorothiazide
169408|NCT02875886|Drug|Hydrochlorothiazide|Combined with amiloride
169409|NCT02875886|Other|Low-sodium diet|
169410|NCT02875873|Drug|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
169411|NCT02875873|Drug|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
169412|NCT02875873|Other|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
169413|NCT02875873|Other|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
169414|NCT02875860|Device|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
169415|NCT02875860|Device|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
169416|NCT02875847|Dietary Supplement|HMO1|
169417|NCT02875847|Dietary Supplement|HMO2|
169418|NCT02875847|Dietary Supplement|Dextropur|
169419|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
169420|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
169421|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
169422|NCT02875834|Drug|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
169423|NCT02875821|Drug|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
169424|NCT02875821|Drug|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
169425|NCT02875795|Procedure|automatic speech processing tool|
169426|NCT02875782|Behavioral|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
169427|NCT02875782|Behavioral|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
169428|NCT02875769|Procedure|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
169429|NCT02875769|Drug|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
169430|NCT02875769|Drug|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
169431|NCT02875769|Other|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
169432|NCT02875769|Other|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
169433|NCT02875756|Procedure|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
169434|NCT02875756|Procedure|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
169435|NCT02875743|Drug|Posaconazole|
169436|NCT02875730|Procedure|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
169437|NCT02875730|Procedure|CMRI|Cardiac Magnetic Resonance Imaging
169438|NCT02875717|Drug|Acetylsalicylic acid|
169439|NCT02875717|Drug|low molecular weight heparin|
169440|NCT02875704|Other|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
169441|NCT02875691|Dietary Supplement|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
169442|NCT02875691|Dietary Supplement|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
169443|NCT02875678|Drug|ABX-1431|Single-dose ABX-1431
169444|NCT02875678|Drug|Placebo|Single-dose matching placebo
169445|NCT02875665|Device|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
169446|NCT02875652|Biological|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
169447|NCT02875639|Drug|Yiqi prescription|
169448|NCT02875639|Drug|Huoxue prescription|
169451|NCT02875639|Drug|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
169452|NCT02875639|Drug|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
169453|NCT02875626|Drug|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
169454|NCT02875613|Drug|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
169455|NCT02875600|Other|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
169456|NCT02875587|Drug|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
169457|NCT02875587|Drug|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
169458|NCT02875574|Drug|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
169459|NCT02875574|Other|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
169460|NCT02875561|Device|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
169461|NCT02875561|Device|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
169462|NCT02875548|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
169463|NCT02875535|Behavioral|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
169464|NCT02875522|Other|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
169465|NCT02875483|Other|Expedited Scheduling|Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.
169466|NCT02875483|Other|Standard Scheduling|Scheduling of tubal surgery occurs after completion of post-partum office visit
169467|NCT02875470|Device|Intensiv Perio Set|Diamond burs for root planing
169468|NCT02875470|Device|Gracey curette|
169469|NCT02875457|Drug|apatinib;etoposide and cisplatin|
169470|NCT02875457|Drug|placebo;etoposide and cisplatin|
169471|NCT02875444|Other|Angio-CT|
169472|NCT02875431|Procedure|Patients undergo ACDF or cervical vertebral body replacement|
169473|NCT02875418|Device|EUM|"STUDY DESIGN~Explanation regarding the study and assessing eligibility criteria.~Signing an informed consent.~Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
169474|NCT02875418|Device|Tocodynamometry|"STUDY DESIGN~Explanation regarding the study and assessing eligibility criteria.~Signing an informed consent.~Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
169475|NCT02875405|Procedure|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
169476|NCT02875392|Other|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
169477|NCT02875392|Other|placebo pills|taking placebo pills as if patients are under treatment.
169478|NCT02875379|Procedure|Measurements|Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
169479|NCT02875366|Drug|LUM/IVA|
169480|NCT02875366|Drug|Placebo|
169481|NCT02875353|Device|Doppler Endoscopic Probe|A colon length catheter (probe).
169482|NCT02875340|Drug|VAL401|Risperidone formulated into a liquid lipid filled capsule
169483|NCT02875314|Drug|Induction|vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
169484|NCT02875314|Drug|Single Cycle Intensive Chemotherapy|Carboplatin, thiotepa, etoposide
169485|NCT02875314|Drug|Tandem 3 Cycle Intensive Chemotherapy|Carboplatin, thiotepa
169486|NCT02875301|Behavioral|150 Minutes Week|This group will walk 150 minutes per week. Participants will have 3 supervised exercise sessions per week. A walking duration of 30 minutes will be achieved by the third week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone.
169521|NCT02875054|Behavioral|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
169522|NCT02875041|Device|Transcranial Magnetic Stimulation (TMS)|
169523|NCT02875041|Device|MAGSTIM Rapid2|
169593|NCT02874573|Drug|Normal saline|Placebo
169487|NCT02875301|Behavioral|225 Minutes Week|This group will walk 225 minutes per week. Participants will have 3 supervised exercise sessions per week. A walking duration of 45 minutes will be achieved by the sixth week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone.
169488|NCT02875301|Behavioral|Stretch and Tone|The control condition will focus on improving balance, flexibility, and strength. This group will meet for supervised sessions 3 times per week for 12 months. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions.
169489|NCT02875288|Drug|liposomal bupivicaine|"The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.~The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.~Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine~Route of drug administration; Surgical site infiltration"
169490|NCT02875275|Other|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
169491|NCT02875275|Other|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
169492|NCT02875275|Other|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
169493|NCT02875275|Other|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
169494|NCT02875262|Drug|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
169495|NCT02875262|Other|placebo|placebo (NaCl 0.9%) in equal dose to treatment
169496|NCT02875249|Other|patients stool collection|patients stool collection
169497|NCT02875236|Drug|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
169498|NCT02875236|Drug|Ringer-acetat|Crystalloid used as standard of care.
169499|NCT02875223|Drug|CC-90011|
169500|NCT02875210|Procedure|Laximeter measurement|
169501|NCT02875197|Other|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
169502|NCT02875171|Drug|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
169503|NCT02875158|Procedure|Cyclophotocoagulation protocol|"Intravenous route is installed~Retrobulbar anaesthesia : 50% xylocaine (2%) + 50% bupivicaine~Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)~Pars plana measurement using transillumination (if needed)~Laser treatment applied approximately 1mm post to limbus~Dexamethasone 0,5 mg subconjunctival injection~Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
169504|NCT02875158|Procedure|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
169505|NCT02875158|Procedure|Modified cyclophotocoagulation|2000 mW for 2 seconds.
169506|NCT02875145|Procedure|Cataract surgery|
169507|NCT02875132|Drug|pembrolizumab|pembrolizumab at 200mg IV infusion every 3 weeks
169508|NCT02875119|Drug|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
169509|NCT02875119|Drug|Placebo Gel|Placebo Gel
169510|NCT02875106|Device|12-point-ECG|routine recording will be 300 seconds
169511|NCT02875106|Device|Polar V800|routine recording will be 300 seconds
169512|NCT02875106|Device|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
169513|NCT02875106|Device|Adidas Micoach smart run|routine recording will be 300 seconds
169514|NCT02875106|Device|TomTom Runner Cardio HRM|routine recording will be 300 seconds
169515|NCT02875093|Drug|ADI-PEG 20|Investigational Medicine
169516|NCT02875093|Drug|Cytarabine|low-dose cytarabine 20 mg BID twice daily for 10 days, every 28 days
169517|NCT02875080|Drug|OPC-34712|
169518|NCT02875067|Biological|Pembrolizumab|
169519|NCT02875067|Drug|Lenalidomide|
169520|NCT02875054|Behavioral|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
169524|NCT02875028|Drug|Vorapaxar|10mg-20mg vorapaxar to achieve >80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
169525|NCT02875028|Drug|Placebo|
169526|NCT02875028|Other|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
169527|NCT02875015|Drug|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
169528|NCT02875015|Drug|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
169529|NCT02875015|Procedure|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
169530|NCT02875002|Drug|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m^2, is schedule to increase to 100mg/m^2, and be administered on days 1 and 8 of each 28-day cycle.
169531|NCT02875002|Drug|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m^2 , is scheduled to increase to 1000 mg/m^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
169532|NCT02874989|Drug|Dasatinib + Quercetin|
169533|NCT02874989|Drug|Placebo|
169534|NCT02874976|Device|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
169535|NCT02874976|Device|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
169536|NCT02874976|Device|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
169537|NCT02874976|Device|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
169538|NCT02874963|Procedure|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
169539|NCT02874963|Device|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
169540|NCT02874963|Drug|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
169541|NCT02874950|Other|office exercise training|The exercise group, did 6 months office exercise training.
169542|NCT02874950|Other|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
169543|NCT02874950|Other|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
169544|NCT02874950|Other|Control|Control group did not do any exercise and did not follow any ergonomic modification.
169545|NCT02874937|Drug|Atomoxetine|norepinephrine transporter inhibitor
169546|NCT02874937|Drug|Matching Placebo|matching placebo identical in appearance.
169547|NCT02874924|Drug|Rapamycin|treatment
169548|NCT02874924|Drug|Placebo|control
169549|NCT02874924|Drug|Rapamycin|No placebo control in this substudy group
169550|NCT02874911|Other|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
169551|NCT02874898|Behavioral|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
169552|NCT02874885|Procedure|Blood Draws|"Healthy Participants: Blood (about 2 tablespoons) drawn at 1 time point.~Rectal Cancer Participants: Blood (about 2 tablespoons) drawn 1 time before participant starts treatment.~Blood also drawn:~Just before tumor surgery 1-8 weeks after surgery, or before chemotherapy begins 1-12 weeks after last dose of chemotherapy~year after surgery, OR 1 year after completion of treatment if no surgery~years after surgery, OR 2 years after completion of treatment if no surgery If the disease gets worse during treatment, OR If disease comes back within 6 years after treatment, OR at end of 6 years follow-up."
169553|NCT02874872|Behavioral|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
169554|NCT02874846|Drug|Netarsudil ophthalmic solution 0.02%|Once daily in both eyes (OU) in the evening (PM) for 7 days
169555|NCT02874846|Other|Netarsudil Ophthalmic Solution Vehicle|Once daily in both eyes (OU) in the evening (PM) for 7 days
169556|NCT02874833|Other|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
169557|NCT02874820|Radiation|[11C]BU99008|Baseline and blocked scans
169558|NCT02874820|Drug|Idazoxan|Idazoxan dose up to 80mg
169559|NCT02874807|Drug|Empagliflozin|
169560|NCT02874807|Other|Placebo|
169561|NCT02874794|Drug|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
169562|NCT02874794|Drug|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
169563|NCT02874794|Drug|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
169564|NCT02874794|Drug|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
169565|NCT02874768|Drug|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
169566|NCT02874768|Drug|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
169567|NCT02874755|Other|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
169568|NCT02874742|Drug|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 throughout each 28-day cycle on Cycles 7 through 9. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
169569|NCT02874742|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
169570|NCT02874742|Drug|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
169571|NCT02874742|Drug|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 4 or 8 weeks.
169572|NCT02874729|Procedure|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
169573|NCT02874729|Procedure|Urine collection|Urine will be collected in appropriate sterile holders provided.
169574|NCT02874729|Procedure|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
169575|NCT02874729|Procedure|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
169576|NCT02874716|Other|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
169577|NCT02874703|Other|Cardiac MRI/MRS|
169578|NCT02874690|Drug|Methylphenidate|
169579|NCT02874690|Drug|Placebo|Identical to methylphenidate dispensing with placebo drug
169580|NCT02874677|Other|Effort reeducation program|personalized reeducation program at a load level preceding hyperventilation
169581|NCT02874664|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
169582|NCT02874651|Drug|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
169583|NCT02874651|Drug|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
169584|NCT02874638|Dietary Supplement|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
169585|NCT02874638|Dietary Supplement|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
169586|NCT02874638|Dietary Supplement|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
169587|NCT02874638|Dietary Supplement|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
169588|NCT02874625|Procedure|Dental restoration|
169589|NCT02874612|Other|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
169590|NCT02874599|Procedure|Dental restoration|
169591|NCT02874586|Other|Plasma exchange combination of immunosuppressive regimens|
169592|NCT02874573|Drug|Tocilizumab|Investigational agent
169594|NCT02874547|Behavioral|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
169595|NCT02874534|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
169596|NCT02874534|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
169597|NCT02874521|Other|Intra-dialytic LF-EMS|Electrical muscle stimulation during haemodialysis
169598|NCT02874521|Other|Intra-dialytic cycle training|Cycle training during haemodialysis
169599|NCT02874495|Behavioral|Psychological tests|Related to affective and cognitive dimensions of pain.
169600|NCT02874495|Device|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.~With measure of heart rate variability."
169601|NCT02874495|Behavioral|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
169602|NCT02874469|Other|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).~All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.~The diary will be implemented during the second period of the study within the first 8 hours after admission.~It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
169603|NCT02874456|Other|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
169604|NCT02874443|Other|Knowledge Translation of labor management guidelines|
169605|NCT02874430|Drug|Metformin Hydrochloride|Given orally
169606|NCT02874430|Drug|Doxycycline|Given orally
169607|NCT02874417|Behavioral|CAST psychoeducation|
169608|NCT02874417|Behavioral|PHET|
169609|NCT02874404|Drug|Ibrutinib|Given PO
169610|NCT02874404|Other|Laboratory Biomarker Analysis|Correlative markers
169611|NCT02874404|Drug|PI3K-delta Inhibitor TGR-1202|Given PO
169612|NCT02874378|Drug|Dexmedetomidine|
169613|NCT02874378|Drug|0.9%NaCl solution|
169614|NCT02874365|Procedure|Endoscopic biopsies|intestinal biopsies
169615|NCT02874352|Device|high resolution impedance manometry with Automated Impedance Manometry analysis|
169616|NCT02874339|Device|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
169617|NCT02874339|Device|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
169618|NCT02874326|Drug|Octreotide LAR|
169619|NCT02874313|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
169620|NCT02874313|Drug|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
169621|NCT02874313|Other|Conventional anti-diabetic diet recommendations|
169622|NCT02874300|Other|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
169623|NCT02874300|Other|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
169624|NCT02874287|Drug|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
169625|NCT02874287|Drug|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 20 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
169626|NCT02874274|Behavioral|Standard of Care|
169627|NCT02874274|Behavioral|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
169628|NCT02874261|Device|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
169762|NCT02873377|Other|Smoking Quitline Referral|Fax referral to the State smoking Quitline
281576|NCT02057055|Other|Soap 300000029240|
169629|NCT02874248|Drug|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
169630|NCT02874248|Drug|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
169631|NCT02874248|Drug|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
169632|NCT02874248|Drug|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
169633|NCT02874248|Drug|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
169634|NCT02874235|Behavioral|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
169635|NCT02874235|Behavioral|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
169636|NCT02874222|Other|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
169637|NCT02874209|Other|sodium MRI|
169638|NCT02874196|Procedure|Standard arthrography|
169639|NCT02874196|Procedure|Dual energy arthrography|
169640|NCT02874196|Procedure|Arthro-tomosynthesis|
169641|NCT02874196|Procedure|Arthro-tomography|
169642|NCT02874196|Procedure|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
169643|NCT02874183|Behavioral|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
169644|NCT02874170|Other|Spectroscopy magnetic resonance of phosphorus 31|
169645|NCT02874157|Biological|blood draw|
169646|NCT02874144|Drug|AZ compound|40 mg three times daily po for 12 weeks
169647|NCT02874144|Other|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
169648|NCT02874144|Drug|Intranasal corticosteroid|QD Nasal Spray
169649|NCT02874144|Drug|Placebo|looks like AZ compound, made by same company, double blind. 40 mg three times daily po for 12 weeks
169650|NCT02874131|Behavioral|Behavioral Activation|Behavioral activation
169651|NCT02874131|Behavioral|Cognitive Processing Therapy|Cognitive processing therapy
169652|NCT02874118|Behavioral|Fried scale for frailty assessement|
169653|NCT02874105|Other|Group C: physiotherapy protocol with Conventional physiotherapy.|
169654|NCT02874105|Other|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
169655|NCT02874092|Drug|Ticagrelor|
169656|NCT02874092|Drug|MTX therapy|
169657|NCT02874079|Other|Blood sample and cotton skin swabs|
169658|NCT02874066|Drug|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
169659|NCT02874040|Procedure|Endoresection|Endoresection of the tumor scar
169660|NCT02874040|Procedure|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
169661|NCT02874027|Other|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
169662|NCT02874014|Radiation|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
169663|NCT02873988|Other|bronchial epithelial cell culture|
169664|NCT02873975|Drug|LY2606368|
169665|NCT02873962|Drug|Bevacizumab|"Bevacizumab will be given intravenously at a pre-determined dosage~One dose reduction will be allowed for Bevacizumab"
169666|NCT02873962|Drug|Nivolumab|"Nivolumab injection is to be administered as an IV infusion at a pre-determined dosage.~No dose reductions or escalations will be allowed for Nivolumab"
169667|NCT02873962|Drug|Rucaparib|"Rucaparib will be taken orally twice daily on days 1-14 at a pre-determined dosage.~Three dose reductions will be allowed for Rucaparib."
169668|NCT02873949|Biological|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment~In non-periodontitis individuals: 2 samples from 1 site"
169669|NCT02873949|Biological|Saliva samples (1ml)|
169670|NCT02873949|Other|Etiologic treatment|education on oral hygiene, scaling and root planing
169671|NCT02873949|Other|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
169672|NCT02873936|Drug|Filgotinib|Tablet(s) administered orally once daily
169673|NCT02873936|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
169674|NCT02873936|Drug|csDMARDs|csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
169675|NCT02873923|Other|No intervention|No intervention : meta analysis from patients in old clinical trials, but no specific inclusion for this project
169676|NCT02873910|Dietary Supplement|IQP-AS-119|
169677|NCT02873910|Dietary Supplement|Placebo|
169678|NCT02873897|Dietary Supplement|Session A: Experimental products (selected enriched products)|
169679|NCT02873897|Dietary Supplement|Experimental session: to select enriched products|
169680|NCT02873897|Dietary Supplement|Session B: Control (standard products without enrichment)|
169681|NCT02873897|Dietary Supplement|Control session|
169682|NCT02873884|Behavioral|Case-management|
169683|NCT02873871|Device|Standardized compressive dressing|Standardized compressive dressing
169684|NCT02873871|Device|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
169685|NCT02873858|Other|smell and taste tests|
169686|NCT02873845|Other|Preliminary validation of the COBQoL questionnaire|
169687|NCT02873832|Biological|Blood sample|
169688|NCT02873832|Other|Flow cytometry|
169689|NCT02873832|Other|western blot|
282525|NCT02049528|Drug|CC-122|CC-122
169690|NCT02873819|Drug|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
169691|NCT02873819|Drug|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
169692|NCT02873819|Drug|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
169693|NCT02873819|Drug|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
169694|NCT02873819|Drug|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
169695|NCT02873806|Procedure|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
169696|NCT02873806|Drug|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
169697|NCT02873806|Device|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
169698|NCT02873806|Drug|Tobramycin|"Topical antibiotic (tobramycin):~1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
169699|NCT02873806|Drug|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~Week 1: 1 drop four (4) times per day in the study eye~Week 2: 1 drop three (3) times per day in the study eye~Week 3: 1 drop two (2) times per day in the study eye~Week 4: 1 drop one (1) time per day in the study eye"
169700|NCT02873793|Genetic|Extraction of total RNA from healthy and tumour tissues|
169701|NCT02873767|Drug|PR1|"Active substance: UCB4019~Route of Administration: subcutaneously"
169702|NCT02873767|Other|PL1|"Active substance: Placebo~Concentration: 0.9 % saline~Route of Administration: subcutaneously"
169703|NCT02873754|Behavioral|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
169704|NCT02873754|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
169705|NCT02873754|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
169706|NCT02873754|Drug|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
169707|NCT02873754|Drug|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
169708|NCT02873754|Drug|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
169709|NCT02873741|Procedure|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
169710|NCT02873741|Procedure|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
169711|NCT02873741|Procedure|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
169712|NCT02873741|Procedure|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
169713|NCT02873728|Procedure|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
169714|NCT02873728|Other|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
169715|NCT02873715|Behavioral|Family-based treatment|Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 30 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
169716|NCT02873715|Behavioral|Usual Care|Usual care is a treatment that is normally provided to patients in pediatric offices by a pediatrician, physician assistant, or other primary care staff.
169717|NCT02873702|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
169718|NCT02873702|Drug|Lansoprazole|Lansoprazole capsules.
169719|NCT02873702|Drug|Placebo|Dexlansoprazole placebo-matching capsules.
169720|NCT02873689|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule
169721|NCT02873689|Drug|Placebo|Dexlansoprazole placebo-matching capsules
169763|NCT02873377|Behavioral|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
283568|NCT02041533|Drug|Carboplatin|
169722|NCT02873676|Behavioral|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
169723|NCT02873676|Behavioral|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
169724|NCT02873676|Behavioral|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
169725|NCT02873676|Behavioral|control|The intervention involve dietary pattern modification and protein intake standardization
169726|NCT02873663|Procedure|Plasma and head hair collection|Plasma and head hair collection
169727|NCT02873650|Drug|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
169728|NCT02873637|Device|under sartorial catheter|
169729|NCT02873637|Device|femoral catheter|
169730|NCT02873624|Procedure|Laparoscopic cholecystectomy|
169731|NCT02873611|Device|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
169732|NCT02873611|Procedure|genicular ablation procedure|
169733|NCT02873598|Drug|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
169734|NCT02873598|Radiation|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
169735|NCT02873585|Device|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
169736|NCT02873585|Device|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
169737|NCT02873572|Behavioral|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
169738|NCT02873572|Behavioral|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:~psychiatric assesment and~registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
169739|NCT02873559|Drug|testosterone|Testosterone supplemented in 5 months
169740|NCT02873559|Other|Progressive muscle training|Progressive muscle training during 4 months
169741|NCT02873546|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
169742|NCT02873533|Other|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
169743|NCT02873520|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
169744|NCT02873520|Biological|Precision Cell Immunotherapy|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
169745|NCT02873507|Other|MRI of donor liver prior to transplant|MRI of the on ice donor liver within the transport cooler on its way to the operating room
169746|NCT02873494|Device|PHYSIOFLOW - PF05 Lab1TM|
169747|NCT02873481|Behavioral|Centering Pregnancy Care plus Yoga (CPC+Y)|Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
169748|NCT02873468|Drug|Florence 30 μg/mL|10 mL, oral, twice a day.
169749|NCT02873468|Drug|Florence 60 μg/mL|10 mL, oral, twice a day.
169750|NCT02873468|Drug|Florence 90 μg/mL|10 mL, oral, twice a day.
169751|NCT02873468|Other|Placebo|10 mL, oral, twice a day.
169752|NCT02873455|Other|Short video clip including the circumstance of operation theater, and surgeon's interview|
169753|NCT02873442|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
169754|NCT02873442|Biological|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline~+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
169755|NCT02873416|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
169756|NCT02873416|Biological|Precision Cells|Precision Cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
169757|NCT02873403|Device|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
169758|NCT02873403|Device|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
169759|NCT02873390|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
169760|NCT02873377|Drug|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
169761|NCT02873377|Drug|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
169764|NCT02873364|Drug|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
169765|NCT02873364|Drug|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
169766|NCT02873351|Drug|carbidopa-levodopa 25-100 mg|included in arm description
169767|NCT02873351|Drug|placebo for carbidopa-levodopa 25-100 mg|included in arm description
169768|NCT02873338|Drug|CX-01|4 mg/kg IV bolus followed by doses of 0.125, or 0.25 mg/kg/hr given on days 1 through 7 with standard induction therapy, on days 1 through 5 or 7 with standard re-induction therapy, and on days 1, 3 and 5 with standard consolidation therapy
169769|NCT02873338|Drug|Idarubicin|12 mg/m2/day by slow (10 to 15 minutes) IV injection daily on days 1, 2 and 3 of induction therapy, and on days 1 and 2 of re-induction therapy
169770|NCT02873338|Drug|Cytarabine|"100 mg/m2/day by continuous IV infusion on days 1 through 7 of induction therapy, and on days 1 through 5 of re-induction therapy~1.0 g/m2 IV infusion given over 3 hours every 12 hours on days 1, 3, and 5 of consolidation therapy"
169771|NCT02873325|Other|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
169772|NCT02873312|Device|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:~An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.~An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.~A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
169773|NCT02873299|Other|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
169774|NCT02873299|Other|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
169775|NCT02873286|Biological|MVA-BN-RSV|MVA-mBN294B
169776|NCT02873286|Other|Placebo|Tris Buffered Saline, sterile
169777|NCT02873273|Drug|Dexamethasone|Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
169778|NCT02873260|Biological|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^4.3 PFU/mL of rDEN2/4Δ30(ME), 10^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
169779|NCT02873260|Biological|rDEN3Δ30|Administered at a dose of 10^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
169780|NCT02873260|Biological|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
169781|NCT02873234|Drug|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
169782|NCT02873234|Drug|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
169783|NCT02873221|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
169784|NCT02873221|Drug|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
169785|NCT02873221|Drug|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
169786|NCT02873208|Drug|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
169787|NCT02873195|Drug|Atezolizumab|Given IV
169788|NCT02873195|Biological|Bevacizumab|Given IV
169789|NCT02873195|Drug|Capecitabine|Given PO
169790|NCT02873195|Other|Laboratory Biomarker Analysis|Correlative studies
169791|NCT02873195|Other|Placebo|Given IV
169792|NCT02873182|Device|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
169793|NCT02873169|Other|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
169794|NCT02873156|Drug|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
169795|NCT02873156|Drug|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
169796|NCT02873143|Other|No intervention|No intervention
169797|NCT02873130|Behavioral|Telepractice Global Voice Prevention Model|
169798|NCT02873130|Behavioral|In-person Global Voice Prevention Model|
169799|NCT02873130|Behavioral|Telepractice, Vocal Hygiene and Vocal Education|
169800|NCT02873117|Other|Prostate biopsy, prostatectomy or prostate resection|Collection of prostate examination
169801|NCT02873104|Device|truSculpt rf device|radiofrequency device
169802|NCT02873091|Procedure|Epidural analgesia|
169803|NCT02873091|Procedure|Continuous epidural infusion|
169804|NCT02873091|Procedure|Intermittent epidural bolus|
169805|NCT02873091|Drug|ropivacaine|
169806|NCT02873091|Drug|sufentanil|
169807|NCT02873078|Behavioral|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
169808|NCT02873065|Drug|Ilaprazole|
169809|NCT02873065|Drug|Esoprazole|
169810|NCT02873052|Device|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
169880|NCT02872441|Biological|blood sample|One blood sample of 50 milliliter 24 hours after the inclusion
169811|NCT02873026|Drug|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
169812|NCT02873000|Behavioral|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
169813|NCT02872974|Other|GDM|Exposure to GDM during fetal life
169814|NCT02872948|Genetic|Diagnostic|
169815|NCT02872935|Drug|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
169816|NCT02872935|Drug|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
169817|NCT02872922|Other|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
169818|NCT02872909|Device|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
169819|NCT02872896|Procedure|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
169820|NCT02872883|Procedure|Expectant management|
169821|NCT02872883|Procedure|Minimal Vaginal examinations (only when necessary)|
169822|NCT02872883|Procedure|Active management|
169823|NCT02872883|Procedure|Routine vaginal examinations|
169824|NCT02872870|Behavioral|auditory lexical decision task|
169825|NCT02872870|Device|electroencephalogram|
169826|NCT02872857|Drug|Placebo|Placebo will match drug capsules.
169827|NCT02872857|Drug|8mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
169828|NCT02872857|Drug|12mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
169829|NCT02872831|Device|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
169830|NCT02872831|Device|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
169831|NCT02872818|Drug|17β estradiol hemihydrate|4mg/kg/day for 20 days
169832|NCT02872818|Drug|Metformin|50 mg/kg/day last 10 days
169833|NCT02872818|Drug|medroxyprogesterone acetate|1mg/kg/day last 10 days
169834|NCT02872805|Other|PEPFAR Enhanced Standard of Care (PESCA)|Standardized materials will be provided to PEPFAR supported clinical sites to assist clinic teams with supporting patients in the transition from pediatric to adult medical care
169835|NCT02872805|Behavioral|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
169836|NCT02872792|Device|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
169837|NCT02872792|Other|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
169838|NCT02872779|Procedure|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
169839|NCT02872766|Device|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
169840|NCT02872753|Biological|ACP|Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
169841|NCT02872753|Other|Standard Meniscectomy|Patients will receive standard arthroscopic meniscectomy
169842|NCT02872740|Procedure|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
169843|NCT02872740|Procedure|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
169881|NCT02872428|Drug|Valproic Acid|By infusion over 1 hour
169882|NCT02872428|Drug|Isotonic saline solution|By infusion over 1 hour
169883|NCT02872415|Biological|Blood puncture site|Blood puncture site
169970|NCT02871856|Diagnostic Test|Low dose CT|low-dose screening CT of chest for lung cancer detection
170224|NCT02870049|Behavioral|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
169844|NCT02872727|Other|Respiratoy health, biological investigations|Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
169845|NCT02872714|Drug|pemigatinib|Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
169846|NCT02872714|Drug|pemigatinib|Pemigatinib once a day by mouth continuously.
169847|NCT02872701|Drug|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
169848|NCT02872701|Device|Near infrared camera imaging system|Near infrared camera imaging system
169849|NCT02872688|Other|GanedenBC30|
169850|NCT02872675|Dietary Supplement|HOST-DM059|"Experimental Supplement: HOST-DM059.~Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
169851|NCT02872675|Dietary Supplement|Maltodextrin|Placebo Comparator: Maltodextrin.
169852|NCT02872649|Drug|Dabigatran|
169853|NCT02872649|Drug|Phenprocoumon|
169854|NCT02872636|Device|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
169855|NCT02872623|Radiation|Enterography-MRI without enteroclysis|
169856|NCT02872623|Radiation|enteroCT with enteroclysis|
169857|NCT02872610|Behavioral|Self-help Online|"The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager."
169858|NCT02872597|Drug|Ipratropium|
169859|NCT02872597|Drug|0.9% Sodium Chloride|
169860|NCT02872597|Drug|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
169861|NCT02872597|Drug|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
169862|NCT02872584|Drug|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
169863|NCT02872571|Drug|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
169864|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|Decision Aid
169865|NCT02872558|Other|Usual Care|Usual Care
169866|NCT02872545|Procedure|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
169867|NCT02872545|Procedure|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
169868|NCT02872545|Procedure|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
169869|NCT02872532|Procedure|Testicular tissue cryopreservation|Testicular tissue will be removed
169870|NCT02872519|Drug|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|Given by IV
169871|NCT02872519|Procedure|Positron Emission Tomography|Undergo scan
169872|NCT02872519|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
169873|NCT02872506|Drug|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
169874|NCT02872506|Procedure|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
169875|NCT02872493|Procedure|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
169876|NCT02872480|Other|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
169877|NCT02872467|Drug|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
169878|NCT02872467|Other|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
169879|NCT02872454|Behavioral|Text Messaging|Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities—cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)—for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
170092|NCT02870972|Drug|BCX7353|Plasma kallikrein inhibitor
169884|NCT02872402|Behavioral|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
169885|NCT02872402|Behavioral|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
169886|NCT02872389|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
169887|NCT02872389|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
169888|NCT02872363|Other|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:~'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
169889|NCT02872363|Other|Intervention B - Priority|"SMS reminder with 'Priority' message:~'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
169890|NCT02872350|Device|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
169891|NCT02872337|Behavioral|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
169892|NCT02872337|Behavioral|Group Preoperative Education Session (per the standard of care)|
169893|NCT02872324|Other|Procurement questionnaires|
169894|NCT02872311|Biological|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
169895|NCT02872311|Biological|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
169896|NCT02872311|Biological|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
169897|NCT02872311|Biological|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
169898|NCT02872298|Device|Targeted Lung Denervation (TLD)|The Nuvaira Lung Denervation System, manufactured by Nuvaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
169899|NCT02872285|Drug|Drug: LYC-30937-EC|
169900|NCT02872285|Drug|Placebo|
169901|NCT02872272|Drug|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
169902|NCT02872259|Drug|BGB324+pembrolizumab|Combination
169903|NCT02872259|Drug|BGB324+dabrafenib and trametinib|Combination
169904|NCT02872259|Drug|pembrolizumab|Monotherapy
169905|NCT02872259|Drug|dabrafenib and trametinib|Combination
169906|NCT02872246|Drug|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
169907|NCT02872246|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
169908|NCT02872233|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
169909|NCT02872233|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
169910|NCT02872220|Drug|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
169911|NCT02872220|Drug|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
169912|NCT02872220|Drug|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
169913|NCT02872220|Drug|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride [NaCl]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
169914|NCT02872207|Drug|BAY 987516 (Y65-122)|5 µL in one eye
169915|NCT02872207|Drug|BAY 987516 (Y65-118)|5 µL in one eye
169916|NCT02872207|Drug|Control|5 uL in other eye
169917|NCT02872194|Drug|BAY987516, Y55-170|10 uL in one eye
169918|NCT02872194|Drug|BAY987516, X72-151|10 uL in one eye
169919|NCT02872194|Drug|BAY987516, Y49-034|10 uL in one eye
169920|NCT02872194|Drug|Standard shampoo mixture (control)|10 uL in one eye
169921|NCT02872181|Procedure|Supine|Placed in Supine position
169922|NCT02872181|Procedure|Left uterine displacement|Placed in 15 degrees left uterine displacement
169923|NCT02872168|Other|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
169924|NCT02872155|Other|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
169925|NCT02872155|Drug|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
169926|NCT02872155|Drug|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
169927|NCT02872142|Biological|Albutein 5%|Plasma exchange will be performed using Albutein 5% as the replacement solution. Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the subject.
169928|NCT02872116|Drug|Nivolumab|Specified dose on specified days
169929|NCT02872116|Drug|Ipilimumab|Specified dose on specified days
169930|NCT02872116|Drug|Oxaliplatin|Specified dose on specified days
169931|NCT02872116|Drug|Capecitabine|Specified dose on specified days
169932|NCT02872116|Drug|Leucovorin|Specified dose on specified days
169933|NCT02872116|Drug|Fluorouracil|Specified dose on specified days
169934|NCT02872103|Drug|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
169935|NCT02872103|Drug|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
169936|NCT02872090|Drug|Indacaterol|inhalation
169937|NCT02872090|Drug|Glycopyrronium|inhalation
169938|NCT02872090|Drug|Tiotropium|inhalation
169939|NCT02872090|Drug|Placebo|
169940|NCT02872090|Procedure|photoplethysmography|inhalation
169941|NCT02872077|Other|Auricular acupuncture|
169942|NCT02872064|Drug|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
169943|NCT02872051|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.~Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
169944|NCT02872051|Other|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).~Mental health care is provided according to a stepped care model with the following treatment modalities:~Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment~Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
169945|NCT02872038|Drug|Cefepime|Cefepime intraperitoneal continuous dosing
169946|NCT02872038|Drug|Cefazolin plus Ceftazidime|
169947|NCT02872025|Drug|Pembrolizumab|
169948|NCT02872012|Device|Cryoanesthesia device|The study will be carried out in patients receiving bilateral injections. One eye will be anesthetized using the cryoanesthesia device, developed at the University of Michigan. This has been assessed to be a Non-significant Risk device.
169949|NCT02872012|Drug|Lidocaine|Lidocaine applied to the non-cryoanesthesia eye.
169950|NCT02871999|Device|Acupuncture therapy|
169951|NCT02871999|Procedure|Laparoscopic Surgery|
169952|NCT02871986|Drug|Routine transdermal oestrogen patch|Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
169953|NCT02871973|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
169954|NCT02871973|Behavioral|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
169955|NCT02871960|Procedure|Robotic and Laparoscopic Colectomy|
169956|NCT02871934|Genetic|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
169957|NCT02871921|Behavioral|Conversational Engagement|Examine whether increasing social interaction through face-to-face (video chat) conversations could improve cognitive function, targeting seniors aged 75 and older who are socially isolated
169958|NCT02871908|Drug|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 twice daily 2 x 10^8
169959|NCT02871908|Drug|Placebo|Placebo
169960|NCT02871882|Radiation|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA [diethylenetriaminepentaacetic acid] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
169961|NCT02871882|Other|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
169962|NCT02871882|Drug|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
169963|NCT02871882|Other|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
169964|NCT02871869|Drug|vindesine|3 mg/㎡ (maximum dosage: <4mg), d1, 21 d as a cycle, for 4～6 cycles
169965|NCT02871869|Drug|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
169966|NCT02871869|Drug|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
169967|NCT02871869|Drug|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
169968|NCT02871869|Drug|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
169969|NCT02871869|Drug|Rituximab|375mg/㎡,one day before CHOP protocol
169971|NCT02871843|Drug|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
169972|NCT02871843|Radiation|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
169973|NCT02871843|Drug|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
169974|NCT02871843|Drug|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
169975|NCT02871830|Behavioral|Physical Activity|15 mins physical activity per day within the school setting.
169976|NCT02871817|Other|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
169977|NCT02871804|Procedure|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
169978|NCT02871804|Procedure|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
169979|NCT02871791|Drug|Palbociclib|
169980|NCT02871791|Drug|Everolimus|
169981|NCT02871791|Drug|Exemestane|
169982|NCT02871778|Drug|VX-371|
169983|NCT02871778|Drug|Hypertonic Saline|
169984|NCT02871778|Drug|Placebo (0.17% saline)|
169985|NCT02871778|Drug|Ivacaftor|
169986|NCT02871765|Other|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
169987|NCT02871752|Behavioral|Health promotion|mindfulness-based stress reduction
169988|NCT02871739|Behavioral|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
169989|NCT02871739|Behavioral|DA viewing|Participants will receive 3 decisions aids to review.
169990|NCT02871739|Behavioral|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
169991|NCT02871726|Device|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy
169992|NCT02871713|Other|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
169993|NCT02871713|Other|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
169994|NCT02871700|Behavioral|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
169995|NCT02871700|Behavioral|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
169996|NCT02871700|Behavioral|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
169997|NCT02871687|Drug|Simvastatin|Simvastatin 40 mg daily
169998|NCT02871687|Drug|Pravastatin|Pravastatin 80 mg daily
169999|NCT02871687|Other|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
170000|NCT02871674|Behavioral|Good Night Project|The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
170001|NCT02871661|Drug|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
170002|NCT02871661|Other|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
170003|NCT02871661|Device|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
170004|NCT02871648|Drug|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
170005|NCT02871648|Drug|Fludrocortisone|Fludrocortisone 0.1 mg
170006|NCT02871648|Drug|Eplerenone|Epleronone 100 mg
170007|NCT02871635|Drug|BI 695501|
170008|NCT02871635|Drug|HUMIRA|
170009|NCT02871622|Device|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
170010|NCT02871609|Other|Stent examination, urinary analysis, USSQ questionnaire|
170011|NCT02871596|Other|Placebo|A combination of maltodextrins and red and blue food colors.
170012|NCT02871596|Dietary Supplement|Flavonoids|A combination of blueberry extract, black current extract, and black rice extract.
170093|NCT02870972|Drug|Placebo|
170013|NCT02871596|Dietary Supplement|Flavonoids+Prebiotics|A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
170014|NCT02871583|Procedure|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
170015|NCT02871583|Procedure|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
170016|NCT02871570|Drug|Rivipansel|A single dose of IV Rivipansel over 20 minutes
170017|NCT02871544|Other|BNP and NGAL|
170018|NCT02871531|Procedure|Pneumatic retinopexy|
170019|NCT02871531|Procedure|Vitrectomy|
170020|NCT02871518|Drug|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
170021|NCT02871518|Drug|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
170022|NCT02871505|Drug|Benzathine Penicillin G|
170023|NCT02871492|Drug|Pritelivir 5% w/w ointment|
170024|NCT02871492|Drug|Pritelivir ointment matching placebo|
170025|NCT02871492|Drug|Zovirax® cream|
170026|NCT02871479|Drug|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
170027|NCT02871479|Drug|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
170028|NCT02871479|Drug|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
170029|NCT02871466|Drug|stem cells infusion|
170030|NCT02871453|Device|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
170031|NCT02871453|Other|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
170032|NCT02871440|Drug|Omega 3|
170033|NCT02871440|Drug|Optive Advanced|
170034|NCT02871440|Drug|Optive|
170035|NCT02871427|Drug|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
170036|NCT02871414|Behavioral|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
170037|NCT02871414|Behavioral|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
170038|NCT02871401|Drug|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
170039|NCT02871401|Drug|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
170040|NCT02871388|Behavioral|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
170041|NCT02871375|Device|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
170042|NCT02871375|Device|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
170043|NCT02871362|Dietary Supplement|IQP-AS-118|Take one a day
170044|NCT02871362|Dietary Supplement|Placebo|Take one a day
170045|NCT02871349|Drug|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
170046|NCT02871349|Drug|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
170047|NCT02871349|Device|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
170048|NCT02871336|Other|Data collection|
170049|NCT02871323|Biological|Durvalumab|Given IV
170050|NCT02871323|Other|Laboratory Biomarker Analysis|Correlative studies
170051|NCT02871310|Dietary Supplement|IQP-AS-118|1 tablet in the morning
170052|NCT02871310|Dietary Supplement|Placebo|1 tablet in the morning
170053|NCT02871297|Drug|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
170054|NCT02871284|Behavioral|Exercise|
170055|NCT02871271|Dietary Supplement|IQP-AS-121|
170056|NCT02871258|Device|The MetaNeb® System|
170057|NCT02871245|Procedure|Laparoscopic Surgery|
170058|NCT02871245|Device|Acupuncture treatment|
170059|NCT02871232|Other|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
170060|NCT02871219|Drug|Lenalidomide|Given PO
170061|NCT02871219|Biological|Obinutuzumab|Given IV
170062|NCT02871206|Biological|Fluad|
170063|NCT02871206|Biological|Fluzone|
170064|NCT02871193|Drug|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
170065|NCT02871193|Drug|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
170066|NCT02871193|Other|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
170222|NCT02870062|Other|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
170067|NCT02871180|Dietary Supplement|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
170068|NCT02871180|Other|No late night snack|Patient consumed no nutrients at late night.
170069|NCT02871167|Procedure|Controlled ovarian hyperstimulation (COH)|"After information and consent, patients are addressed to a reproductive medicine center.~The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation."
170070|NCT02871167|Procedure|Oocyte/embryo freezing|Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
170071|NCT02871154|Other|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
170072|NCT02871141|Procedure|electroconvulsive therapy|electroconvulsive therapy
170073|NCT02871141|Drug|Antidepressant|Antidepressant
170074|NCT02871128|Dietary Supplement|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
170075|NCT02871128|Dietary Supplement|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
170076|NCT02871128|Drug|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
170077|NCT02871115|Other|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
170078|NCT02871115|Other|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
170079|NCT02871102|Procedure|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
170080|NCT02871089|Device|Closed-loop system (Florence M or CamAPS FX)|"The automated closed-loop system (FlorenceM) will consist of:~Sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite/Guardian 3 real time CGM and glucose suspend feature.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.~The automated closed-loop system (CamAPS FX) will consist of:~Dana R or RS insulin pump~Dexcom G6 real-time CGM~CamAPS FX App on an unlocked android smartphone.~Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
170081|NCT02871089|Other|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.~Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
170082|NCT02871076|Device|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
170083|NCT02871050|Other|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
170084|NCT02871037|Drug|PF-05221304|Single or repeated, escalating dose of PF-05221304
170085|NCT02871037|Other|Placebo|single or repeated dose of placebo
170086|NCT02871024|Device|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
170087|NCT02871011|Drug|Nitric Oxide|Delivered as a footbath
170088|NCT02871011|Drug|Water|Delivered as a footbath
170089|NCT02870998|Other|Active learning|1-day continuing education activity consisting of a lecture on patient education.
170090|NCT02870998|Other|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
170091|NCT02870985|Device|Coronary Stent|
170094|NCT02870946|Procedure|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
170095|NCT02870946|Procedure|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
170096|NCT02870933|Biological|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
170097|NCT02870920|Drug|Tremelimumab|
170098|NCT02870920|Drug|Durvalumab|
170099|NCT02870920|Other|Best Supportive Care|
170100|NCT02870907|Other|Observation|no post operative chemotherapy
170101|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
170102|NCT02870907|Drug|Vincristine|1, 5 mg/m²/d, IV at D1.
170103|NCT02870907|Radiation|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
170104|NCT02870907|Drug|Carboplatin|160 mg/m²/d, IV from D1 to D5.
170105|NCT02870907|Drug|Vincristine|1,5 mg/m²/d, IV at D22 and D26
170106|NCT02870907|Drug|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
170107|NCT02870907|Drug|Carboplatin|560 mg/m²/d, IV at D1.
170108|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV from D1 to D5
170109|NCT02870907|Drug|Carboplatin|160 mg/m²/d,IV from D1 to D5
170110|NCT02870907|Drug|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
170111|NCT02870907|Drug|Vincristine|1,5 mg/m²/d), IV at D22
170112|NCT02870907|Drug|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
170113|NCT02870907|Procedure|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
170114|NCT02870907|Drug|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
170115|NCT02870907|Drug|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
170116|NCT02870907|Drug|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
170117|NCT02870907|Procedure|Peripheral bood stem cell transplantation|at D0
170118|NCT02870868|Behavioral|Slow breathing|Slow breathing techniques from yoga
170119|NCT02870855|Drug|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
170120|NCT02870842|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
170121|NCT02870842|Other|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
170122|NCT02870829|Drug|menaquinone-7|Oral supplement given post dialysis 3x/week
170123|NCT02870816|Procedure|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
170124|NCT02870816|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
170125|NCT02870816|Procedure|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
170126|NCT02870790|Drug|TDF/FTC|one pill daily
170127|NCT02870777|Other|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
170128|NCT02870764|Drug|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
170129|NCT02870764|Drug|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
170130|NCT02870764|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
170131|NCT02870751|Biological|TW11681 or TW10722|
170132|NCT02870738|Procedure|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
170133|NCT02870738|Drug|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
170134|NCT02870725|Behavioral|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
170135|NCT02870712|Procedure|Suture of perineum|suture of the tear to obtain hemostasis
170136|NCT02870712|Procedure|hemostatis by digital compression|Digital compression of the tear to obtain hemostasis
170137|NCT02870699|Device|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
170138|NCT02870699|Device|Placebo excipient|film forming excipient solution
170139|NCT02870686|Procedure|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
170140|NCT02870686|Procedure|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
170141|NCT02870673|Drug|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
170142|NCT02870673|Drug|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
170273|NCT02869698|Device|Hybride electrode|
170143|NCT02870673|Device|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
170144|NCT02870673|Device|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
170145|NCT02870660|Other|Registry|
170146|NCT02870647|Other|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
170147|NCT02870634|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
170148|NCT02870608|Other|lung and liver elastography measurement of fetus|
170149|NCT02870595|Device|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
170150|NCT02870595|Device|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
170151|NCT02870582|Drug|Donafenib|treatment drug
170152|NCT02870582|Drug|Placebo|Best support treatment
170153|NCT02870569|Drug|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
170154|NCT02870569|Drug|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
170155|NCT02870556|Device|cervical epidural analgesia|
170156|NCT02870543|Drug|Phytolacca decandra|Treatment of bruxism
170157|NCT02870543|Drug|Melissa officinalis|Treatment of bruxism
170158|NCT02870543|Drug|Phyt.decandra + Melissa offic.|Treatment of bruxism
170159|NCT02870530|Procedure|division-less gastric bypass|in division-less gastric bypass, the investigators will do the gastric bypass without division of the stomach into 2 part (pouch part and the rest of the stomach that still connected to the duodenum) but the pouch which will anatomised with the small intestine is excluded from within, in comparison to standard mini-gastric bypass so that we try to decrease the cost of stapler and its complication
170160|NCT02870530|Procedure|mini-gastric bypass|classic laparoscopic mini-gastric bypass as described by Rutledge
170161|NCT02870517|Other|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have <60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
170162|NCT02870517|Other|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
170163|NCT02870504|Procedure|Corneoscleral limbus group|Laser spot locates on the corneoscleral limbus
170164|NCT02870504|Procedure|one spot group|Laser spot locates on one spot away from the corneoscleral limbus
170165|NCT02870504|Procedure|two spots group|Laser spot locates on two spots away from the corneoscleral limbus
170166|NCT02870491|Behavioral|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
170167|NCT02870491|Behavioral|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
170168|NCT02870478|Drug|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
170169|NCT02870465|Procedure|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
170170|NCT02870452|Behavioral|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
170171|NCT02870452|Behavioral|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
170172|NCT02870439|Other|Blood drawn|
170173|NCT02870426|Procedure|Frontal Craniotomy and retrieval of OBs|For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique. For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
170174|NCT02870426|Procedure|OB Retrieval During Anterior Cranial Surgery|Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure. In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
170175|NCT02870413|Behavioral|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
170176|NCT02870400|Drug|REGN2477|Participants will receive ascending doses of REGN2477
170177|NCT02870400|Drug|Placebo|Participants will receive matching placebo
170178|NCT02870387|Other|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
170223|NCT02870049|Behavioral|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
170274|NCT02869698|Device|Macro electrode|
170275|NCT02869685|Radiation|radiotherapy|
170179|NCT02870387|Other|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
170180|NCT02870374|Behavioral|Answering specific quality of life questionnaire in kidneys transplantation population|
170181|NCT02870361|Drug|intranasal insulin|
170182|NCT02870361|Drug|Placebo|
170183|NCT02870348|Biological|Alpha-1 MP|Weekly intravenous infusions of 60 mg/kg Alpha-1 MP
170184|NCT02870335|Other|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
170185|NCT02870335|Other|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
170186|NCT02870322|Behavioral|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
170187|NCT02870322|Behavioral|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
170188|NCT02870309|Biological|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
170189|NCT02870296|Behavioral|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
170190|NCT02870283|Drug|Lithium|
170191|NCT02870283|Drug|Valproic Acid|
170192|NCT02870283|Drug|Carbamazepine|
170193|NCT02870270|Other|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
170194|NCT02870257|Other|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
170195|NCT02870257|Other|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
170196|NCT02870244|Biological|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.~Subjects in Cohort 1 will receive 7.5 x 10^6/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 2 will receive 2.5 x 10^7/kg TIL 1383I TCR transduced T cells.~Subjects in Cohort 3 will receive 7.5 x 10^7/kg TIL 1383I TCR transduced T cells."
170197|NCT02870231|Drug|NNC9204-0530|Once-daily subcutaneous (s.c., under the skin) administration.
170198|NCT02870231|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration.
170199|NCT02870231|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration
170200|NCT02870218|Drug|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
170201|NCT02870218|Drug|Nicotine discrimination thresholds|Measure of nicotine thresholds for detecting and recognizing the addictive, rewarding effects of smoking.
170202|NCT02870205|Drug|GSP 301 NS|2 spray in each nostril twice daily for 14 days
170203|NCT02870205|Drug|GOM-NS|2 spray in each nostril twice daily for 14 days
170204|NCT02870205|Drug|GMM-2 NS|2 spray in each nostril twice daily for 14 days
170205|NCT02870205|Drug|GSP 301 placebo NS|2 spray in each nostril twice daily for 14 days
170206|NCT02870192|Procedure|Laparoscopic ventral mesh rectopexy|Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
170207|NCT02870179|Device|Pulse Oximeter|Measurement of physiological parameters
170208|NCT02870166|Other|blood sample|
170209|NCT02870153|Drug|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
170210|NCT02870153|Drug|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
170211|NCT02870140|Device|SUPRAFLEX|Percutaneous Coronary Intervention
170212|NCT02870140|Device|XIENCE|Percutaneous Coronary Intervention
170213|NCT02870127|Other|blood sample|
170214|NCT02870101|Diagnostic Test|Nucleic acid amplification test 1 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
170215|NCT02870101|Diagnostic Test|Nucleic acid amplification test 2 for NG and CT|A combination test using target amplification to detect RNA from NG and CT.
170216|NCT02870101|Diagnostic Test|Nucleic acid amplification test 3 for NG and CT|A combination test using real-time PCR to detect DNA from NG and CT.
170217|NCT02870088|Behavioral|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
170218|NCT02870088|Behavioral|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
170219|NCT02870075|Behavioral|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
170220|NCT02870075|Behavioral|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
170221|NCT02870062|Other|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
170225|NCT02870049|Behavioral|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
170226|NCT02870049|Behavioral|Usual care|Usual care: FIT kit delivery as part of usual care
170227|NCT02870036|Drug|Simmitecan|
170228|NCT02870036|Drug|5-fluorouracil and Leucovorin Calcium|
170229|NCT02870036|Drug|Thalidomide|
170230|NCT02870023|Other|Balance training|
170231|NCT02870023|Other|Strength training|
170232|NCT02870010|Biological|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
170233|NCT02870010|Radiation|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
170234|NCT02869997|Device|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
170235|NCT02869984|Drug|Ramosetron|
170236|NCT02869971|Device|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
170237|NCT02869971|Drug|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
170238|NCT02869958|Other|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
170239|NCT02869958|Other|Written action plan|
170240|NCT02869945|Genetic|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
170241|NCT02869945|Other|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
170242|NCT02869945|Other|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
170243|NCT02869932|Radiation|Lung CT scan|Lung CT scan without injection
170244|NCT02869919|Other|AKI|Vitamin D levels
170245|NCT02869906|Other|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
170246|NCT02869893|Drug|Secretin|
170247|NCT02869880|Other|Enhanced Pre-Consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision—parent, patient, healthcare provider and research staff.
170248|NCT02869880|Other|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial
170249|NCT02869867|Other|refrigerated cushion|refrigerated cushion
170250|NCT02869854|Behavioral|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
170251|NCT02869854|Behavioral|PAP|Physical Activity on Prescription, after 3 months a new prescription
170252|NCT02869841|Drug|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
170253|NCT02869841|Drug|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
170254|NCT02869841|Drug|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
170255|NCT02869841|Other|Placebo|No rectus sheath analgesia
170256|NCT02869828|Device|Monitoring by arterial catheter and Spot-on|
170257|NCT02869828|Device|Monitoring by oesophagal probe and Spot-on|
170258|NCT02869815|Procedure|ICG+Methylene Blue|"ICG+Methylene Blue Arm:~One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
170259|NCT02869802|Procedure|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
170260|NCT02869802|Other|Serial Collection of Plasma and Serum and Urine Samples|Participants will undergo serial collection of plasma and serum samples at baseline and every 4 weeks until radiological disease progression is confirmed using RECIST 1.1. BC Cancer participants will undergo urine sample collection at baseline and at end of treatment.
170261|NCT02869789|Drug|Nivolumab in combination with Ipilimumab|Specified dose on specified days
170262|NCT02869776|Behavioral|Questionnaire|Behavioral questionnaires
170263|NCT02869776|Procedure|Rapid finger stick|HIV and HCV testing through rapid finger stick
170264|NCT02869776|Procedure|Venipuncture|HIV and HCV testing through venipuncture
170265|NCT02869763|Dietary Supplement|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
170266|NCT02869763|Dietary Supplement|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
170267|NCT02869763|Dietary Supplement|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
170268|NCT02869737|Device|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
170269|NCT02869724|Other|Weekly divided delivery|
170270|NCT02869724|Other|Monthly divided delivery|
170271|NCT02869711|Other|Health care quality management|
170272|NCT02869698|Procedure|Spectral Dynamic Imaging|
170276|NCT02869672|Biological|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
170277|NCT02869672|Biological|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
170278|NCT02869659|Behavioral|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 & 2 & 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
170279|NCT02869659|Behavioral|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
170280|NCT02869646|Procedure|Procedure: Acupuncture|Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
170281|NCT02869646|Procedure|Procedure: Sham acupuncture|Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
170282|NCT02869633|Drug|Ibrutinib|Given by mouth
170283|NCT02869633|Other|Laboratory Biomarker Analysis|Correlative studies
170284|NCT02869620|Other|Data collection|
170285|NCT02869607|Other|Data collection|
170286|NCT02869594|Other|Data collection|
170287|NCT02869581|Other|Data collection|
170288|NCT02869568|Other|Data collection|
170289|NCT02869555|Other|Data collection|
170290|NCT02869542|Other|Data collection|
170291|NCT02869529|Other|Data collection|
170292|NCT02869516|Other|Clinical data collection|
170293|NCT02869503|Other|Data collection|
170294|NCT02869490|Other|Data collection|
170295|NCT02869477|Other|Data collection|
170296|NCT02869464|Other|Imaging-Ultrasound|Abdominal Ultrasound
170297|NCT02869464|Other|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
170298|NCT02869464|Genetic|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
170299|NCT02869451|Drug|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
170300|NCT02869451|Drug|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
170301|NCT02869451|Drug|Nicotine polacrilex|Initiated at smoking quit date.
170302|NCT02869451|Drug|nicotine lozenge|Initiated at smoking quit date.
170303|NCT02869451|Behavioral|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
170304|NCT02869451|Behavioral|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
170305|NCT02869438|Drug|Benralizumab|Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
170306|NCT02869438|Other|Placebo|Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
170307|NCT02869425|Drug|arbaclofen ER Tablets|arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
170308|NCT02869425|Drug|Placebo for arbaclofen ER tablets|matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
170309|NCT02869412|Other|Computer-Assisted Intervention|Use BCG website
170310|NCT02869412|Other|Computer-Assisted Intervention|Use passive website
170311|NCT02869412|Other|Quality-of-Life Assessment|Ancillary studies
170312|NCT02869412|Other|Questionnaire Administration|Ancillary studies
170313|NCT02869399|Dietary Supplement|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):~avoid or limit alcoholic drinks (2 drinks men, 1 drink women)~increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)~eat mostly food of plant origin~eat lean meat, limit intake of red meat and avoid processed meat~increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams~avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
170314|NCT02869386|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
170315|NCT02869386|Procedure|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
170316|NCT02869373|Behavioral|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
170317|NCT02869347|Drug|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
170318|NCT02869347|Drug|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
170319|NCT02869334|Device|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
170320|NCT02869334|Device|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
170321|NCT02869334|Behavioral|Auditory Remediation|Computer program designed to improve discrimination between sounds
170322|NCT02869334|Behavioral|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
170323|NCT02869321|Drug|Fentanyl|
170324|NCT02869321|Drug|Morphine Sulfate|
170325|NCT02869321|Drug|Fentanyl placebo|
170326|NCT02869321|Drug|Morphine Sulfate placebo|
170328|NCT02869308|Drug|stannous pyrophosphate|Injection of 1ml Angiocis
170329|NCT02869308|Drug|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
170330|NCT02869308|Device|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
170331|NCT02869308|Device|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
170332|NCT02869295|Drug|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
170333|NCT02869282|Other|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
170334|NCT02869282|Other|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
170335|NCT02869269|Device|Early stage|patients who classed as clinical stage 1 and 2
170336|NCT02869269|Device|Late stage|patients who classed as clinical stage 3 and 4
170337|NCT02869256|Other|Practices evaluation|Practices evaluation
170338|NCT02869243|Drug|hrBMP4|"Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.~Catheters will be placed during a second procedure a few days later based upon the patient's condition.~Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters."
170339|NCT02869230|Procedure|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
170340|NCT02869230|Procedure|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
170341|NCT02869217|Drug|Cyclophosphamide|
170342|NCT02869217|Biological|TBI-1301|
170343|NCT02869217|Drug|Fludarabine|
170344|NCT02869204|Other|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
170345|NCT02869204|Dietary Supplement|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
170346|NCT02869204|Dietary Supplement|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
170347|NCT02869204|Dietary Supplement|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
170348|NCT02869165|Drug|Premarin vaginal cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
170349|NCT02869165|Drug|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
170350|NCT02869152|Other|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
170351|NCT02869152|Other|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
170352|NCT02869152|Other|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
170353|NCT02869152|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
170354|NCT02869152|Procedure|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
170355|NCT02869152|Procedure|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
170356|NCT02869139|Other|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
170357|NCT02869139|Other|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
170358|NCT02869126|Procedure|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient~Stress conventional acquisition with D.SPECT camera 20 min after injection~60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)~double isotope acquisition 5 min after thallium-201 injection~injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection~rest conventional acquisition 20 min later"
170359|NCT02869126|Drug|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first~For tomoscintigraphy"
170360|NCT02869126|Drug|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)~For tomoscintigraphy"
170361|NCT02869113|Drug|BAY98751 (Y65-110)|10 µL in one eye
170362|NCT02869113|Drug|BAY 98751 (Y65-102)|10 µL in one eye
170363|NCT02869113|Drug|BAY 98751 (Y65-106)|10 µL in one eye
170364|NCT02869113|Drug|Standard shampoo mixture (Control)|10 µL in other eye
170365|NCT02869100|Other|Blood sample|
170366|NCT02869100|Procedure|Sodium fluoride Positron Emission Tomography|
170367|NCT02869100|Other|Magnetic Resonance Imaging|
170368|NCT02869100|Other|Radiography|
170369|NCT02869087|Device|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
170370|NCT02869074|Genetic|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
170371|NCT02869061|Procedure|Liposuction|
170372|NCT02869061|Procedure|Transurethral bladder neck resection.|
170373|NCT02869061|Biological|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
170374|NCT02869061|Other|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
170410|NCT02868814|Drug|Pregabalin Release Tablets|
170411|NCT02868814|Drug|Pregabalin Release Tablets|
170375|NCT02869035|Drug|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
170376|NCT02869035|Drug|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
170377|NCT02869022|Drug|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
170378|NCT02869022|Drug|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
170379|NCT02869022|Procedure|organ perfusion for heart transplantation|
170380|NCT02869009|Drug|clopidogrel|
170381|NCT02869009|Drug|Aspirin|
170382|NCT02868996|Drug|Recombinant human tissue kallikrein|Intravenous DM199
170383|NCT02868983|Other|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:~A. Identification B. Assessment C. Treatment D. Surveillance"
170384|NCT02868970|Biological|Meningococcal B|Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
170385|NCT02868970|Biological|High-Dose TIV|Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.
170386|NCT02868970|Biological|Tdap (tetanus-diphtheria-acellular pertussis)|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
170387|NCT02868970|Biological|Meningococcal ACWY|Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.
170388|NCT02868970|Biological|Herpes Zoster|Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).
170389|NCT02868970|Biological|Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)|Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.
170390|NCT02868957|Other|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
170391|NCT02868957|Device|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
170392|NCT02868957|Device|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
170393|NCT02868944|Drug|experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).|
170394|NCT02868944|Drug|control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.|
170395|NCT02868931|Behavioral|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.~The program is delivered by certified and specially trained diabetes educators."
170396|NCT02868918|Drug|biodentine|tricalcium silicate cement used to replace the carious dentin
170397|NCT02868918|Drug|glass ionomer cement|high viscosity glass ionomer used as a base material
170398|NCT02868918|Device|DigoraH optium|digital Xray for follow up
170399|NCT02868905|Procedure|Blood sample|
170400|NCT02868892|Drug|Pemetrexed|Pemetrexed 500 mg/m2
170401|NCT02868879|Other|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
170402|NCT02868866|Behavioral|Immediate Intervention|Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
170403|NCT02868853|Behavioral|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
170404|NCT02868853|Behavioral|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
170405|NCT02868853|Behavioral|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
170406|NCT02868840|Behavioral|Tai Chi exercise|exercise twice a week each for one hour
170407|NCT02868840|Behavioral|symptom management|sending text message weekly to manage symptoms related to stroke
170408|NCT02868827|Drug|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
170409|NCT02868827|Other|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
170413|NCT02868801|Drug|Placebo|same intervention as the experimental group
170414|NCT02868801|Drug|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
170415|NCT02868801|Drug|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
170416|NCT02868801|Drug|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
170417|NCT02868788|Dietary Supplement|dietary fiber|
170418|NCT02868775|Procedure|cystoscopy, bladder hydrodistention and bladder biopsy|
170419|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
170420|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
170421|NCT02868736|Device|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
170422|NCT02868723|Other|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
170423|NCT02868710|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
170424|NCT02868697|Drug|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
170425|NCT02868697|Drug|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4`-methylenebis[tetrahydro-1,1,1`,1`-tetraoxide], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
170426|NCT02868671|Other|acupuncture|
170427|NCT02868671|Other|sham acupuncture|
170428|NCT02868658|Biological|Blood sampling|
170429|NCT02868658|Other|Nasal swab|
170430|NCT02868645|Biological|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
170431|NCT02868632|Drug|MEDI4736|anti-PD-L1 human monoclonal antibody
170432|NCT02868632|Drug|Tremelimumab|anti-CTLA4 human monoclonal antibody
170433|NCT02868632|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
170434|NCT02868619|Other|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
170435|NCT02868619|Other|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
170436|NCT02868619|Other|R-CMAS scale|Evaluate the anxiety
170437|NCT02868606|Other|Physiologic Insulin Therapy|
170438|NCT02868606|Other|Sliding-Scale Insulin Therapy|
170439|NCT02868593|Other|Pharyngeal swab|
170440|NCT02868580|Drug|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
170441|NCT02868567|Drug|dalfampridine|Pill open label
170442|NCT02868554|Device|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
170443|NCT02868554|Device|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
170444|NCT02868541|Other|Naso pharyngeal swab|
170445|NCT02868528|Genetic|chromosome screening with NGS technology|
170446|NCT02868515|Other|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
170447|NCT02868502|Device|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
170448|NCT02868502|Device|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
170449|NCT02868502|Device|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
170450|NCT02868502|Device|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
170451|NCT02868489|Dietary Supplement|LactoWise®|blend of bacillus coagulans and galactomannans
170452|NCT02868489|Other|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium carbonate)
170453|NCT02868450|Biological|Blood Sample|
170454|NCT02868437|Device|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
170455|NCT02868424|Drug|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
170456|NCT02868411|Other|Rectal Swab|
170457|NCT02868385|Drug|4x Praziquantel|Four consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, and 6.
170458|NCT02868385|Drug|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
170459|NCT02868372|Drug|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
170460|NCT02868359|Other|No Intervention|The study is observational.
170461|NCT02868346|Other|Anal swab|
170462|NCT02868320|Other|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.~Weekly reminder messages of blood glucose testing."
170463|NCT02868320|Other|Instruction booklet|General detailed instructions addressing the same SMS categories.
170464|NCT02868307|Behavioral|Answering questionnaire|
170465|NCT02868294|Device|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
170466|NCT02868281|Drug|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
170467|NCT02868281|Drug|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
170468|NCT02868268|Other|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
170469|NCT02868255|Procedure|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
170470|NCT02868242|Drug|LDV/SOF|Tablet(s) administered orally once daily
170471|NCT02868229|Drug|COR-001|
170472|NCT02868229|Other|Placebo|
170473|NCT02868216|Behavioral|anger management training|
170474|NCT02868203|Device|OCT|OCT after stent implantation
170475|NCT02868203|Device|eLuting stent|
170476|NCT02868190|Device|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
170477|NCT02868177|Dietary Supplement|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
170478|NCT02868177|Dietary Supplement|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
170479|NCT02868164|Drug|Fecal Microbiota Transplantation|The recipient will receive healthy donor, prepared fecal installations through a Naso-gastric tube, 100 ml once a month for 6 month.
170480|NCT02868164|Drug|Standard Treatment|Standard Treatment
170481|NCT02868164|Other|Weight Reduction|routine exercise for weight reduction
170482|NCT02868151|Drug|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
170483|NCT02868151|Drug|Zinc acetate|Zinc acetate 50mg tablets orally twice daily for entire period of cancer treatment
170484|NCT02868125|Radiation|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
170485|NCT02868112|Other|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
170486|NCT02868112|Other|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
170487|NCT02868099|Drug|Romiplostim|
170488|NCT02868099|Drug|Placebo|
170489|NCT02868086|Device|OCT B-scans|
170490|NCT02868086|Device|OCT angiography|
170491|NCT02868073|Biological|VXA-G1.1-NN (high dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high dose.
170492|NCT02868073|Other|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
170493|NCT02868073|Biological|VXA-G1.1-NN (low dose) Oral Vaccine Tablet|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the low dose.
170494|NCT02868060|Drug|Romiplostim|
170495|NCT02868047|Procedure|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
170496|NCT02868034|Behavioral|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
170497|NCT02868034|Behavioral|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
170498|NCT02868034|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
170499|NCT02868034|Behavioral|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
170500|NCT02868021|Device|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
170501|NCT02868021|Behavioral|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
170502|NCT02868021|Behavioral|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
170503|NCT02868021|Behavioral|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
170504|NCT02868021|Behavioral|Self-assessed function|Using the Late Life Function and Disability Instrument.
170505|NCT02868021|Procedure|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
170506|NCT02868021|Device|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
170507|NCT02868021|Device|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
170508|NCT02868021|Behavioral|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
170509|NCT02868008|Procedure|Microsurgical resection of brain AVMs|fMRI guided microsurgical resection of brain AVMs
170510|NCT02867995|Device|Eye Drop Aid|Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
170511|NCT02867982|Procedure|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
170512|NCT02867982|Procedure|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
170513|NCT02867982|Drug|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
170514|NCT02867982|Device|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
170515|NCT02867982|Radiation|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
170516|NCT02867969|Other|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
170517|NCT02867956|Drug|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
170518|NCT02867956|Drug|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
170519|NCT02867943|Other|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
170520|NCT02867930|Drug|Dexmedetomidine|drug for moderate sedation in trans-esophageal echocardiography
170521|NCT02867930|Drug|Ketofol(ketamine+propofol)|drug for moderate sedation in trans-esophageal echocardiography
170522|NCT02867917|Drug|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
170523|NCT02867917|Drug|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
170524|NCT02867917|Drug|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
170525|NCT02867904|Drug|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
170526|NCT02867904|Drug|Marcaine (4ml 0.5%, injection)|Control
170527|NCT02867878|Drug|Adenosine|
170528|NCT02867878|Drug|Saline solution|
170529|NCT02867865|Drug|Gemcitabine|Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles
170530|NCT02867865|Drug|Cisplatin|Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles
170531|NCT02867865|Radiation|Chemoradiation|Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).
170532|NCT02867865|Procedure|PETCECT|All the patients will undergo PETCECT to rule out metastatic disease
170533|NCT02867865|Procedure|Laparoscopy|Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
170534|NCT02867852|Drug|Abiraterone acetate|Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 [CYP17]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
170535|NCT02867839|Drug|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
170536|NCT02867839|Drug|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
170537|NCT02867826|Device|Cap|Cap-assisted endoscopy
170538|NCT02867813|Biological|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
170539|NCT02867800|Drug|Diphenhydramine|"(Standard of Care) Premedication~Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
170540|NCT02867800|Drug|Acetaminophen|"(Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
170541|NCT02867800|Drug|Methylprednisolone|"(Standard of Care) Premedication~Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
170542|NCT02867800|Drug|Meperidine|"(Standard of Care) Premedication~Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
170543|NCT02867800|Drug|Alemtuzumab|"(Standard of Care) Immunosuppression~Alemtuzumab:~A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
170544|NCT02867800|Drug|Thymoglobulin|"(Standard of Care) Immunosuppression~Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
170545|NCT02867800|Drug|Fludarabine|"(Standard Conditioning Regimen)~Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
170546|NCT02867800|Drug|Melphalan|"(Standard Conditioning Regimen)~Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
170547|NCT02867800|Drug|Thiotepa|"(Standard Conditioning Regimen)~Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
170548|NCT02867800|Drug|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
170549|NCT02867800|Drug|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor~Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
170550|NCT02867800|Drug|Methotrexate|"(Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
170551|NCT02867800|Drug|Abatacept|"(Investigational)~Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
170552|NCT02867800|Procedure|Marrow infusion|"(Standard)~A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
170553|NCT02867800|Drug|Sirolimus|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
170554|NCT02867800|Drug|Mycophenolate Mofetil|"(Standard GVHD Prophylaxis)~Calcineurin inhibitor (cyclosporine or tacrolimus or with permission of the sponsor: sirolimus or mycophenolate mofetil (MMF)) administration will commence no later than day -2 (at least 36 hours before the stem cell infusion); cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml. This range assumes monitoring by mass spectrometry. If an immunoassay is used instead, the equivalent range for that immunoassay should be used."
170555|NCT02867787|Drug|Botox arm|
170556|NCT02867774|Behavioral|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.~The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.~The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
170557|NCT02867761|Drug|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
170558|NCT02867761|Drug|Placebo|27.5/15.6 mcg placebo
170559|NCT02867748|Procedure|TVT-Abbrevo|
170560|NCT02867748|Procedure|Serasis|
170561|NCT02867735|Drug|LKA651|Interventional
170562|NCT02867735|Other|Sham Comparator|
170563|NCT02867722|Drug|aminolevulinic acid HCl|Drug will be administered to consented patients
170564|NCT02867709|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
170565|NCT02867709|Drug|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
170566|NCT02867696|Other|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
170567|NCT02867696|Behavioral|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.~The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.~Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.~Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
170568|NCT02867683|Other|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
170569|NCT02867670|Device|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
170570|NCT02867657|Behavioral|Mindfulness|Five days MBSR curriculum with meditation and yoga
170571|NCT02867644|Other|standard care|Patients coming for preoperative breast assessment will have standard care.
170572|NCT02867644|Other|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
170624|NCT02867189|Other|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
283569|NCT02041533|Drug|Paclitaxel|
170573|NCT02867631|Behavioral|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
170574|NCT02867618|Drug|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
170575|NCT02867618|Drug|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
170576|NCT02867605|Dietary Supplement|Hyaluronan|
170577|NCT02867592|Drug|Cabozantinib|Given IV
170578|NCT02867592|Drug|Cabozantinib S-malate|Given PO
170579|NCT02867592|Other|Pharmacological Study|Correlative studies
170580|NCT02867579|Behavioral|"evaluation of the child quality attachment (Strange situation)"|
170581|NCT02867566|Drug|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
170582|NCT02867566|Drug|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
170583|NCT02867553|Drug|rituximab|
170584|NCT02867553|Radiation|Multi-fields radiotherapy|
170585|NCT02867540|Other|MRI enterography|
170586|NCT02867514|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
170587|NCT02867488|Other|Soybean oil in salad dressing|
170588|NCT02867475|Other|Physical activity motivation|Physical activity motivation
170589|NCT02867462|Other|Standard care|standard care
170590|NCT02867462|Other|manipulator consultation radiotherapy added to standard care|
170591|NCT02867449|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
170592|NCT02867449|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
170593|NCT02867436|Other|Gluten-free diet|
170594|NCT02867423|Device|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
170595|NCT02867410|Other|No intervention|
170596|NCT02867397|Drug|Teysuno (S1) in combination with epirubicin and oxaliplatin|
170597|NCT02867384|Drug|Obinutuzumab|B cell depletion
170598|NCT02867384|Drug|Placebo|Placebo
170599|NCT02867371|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
170600|NCT02867358|Drug|KT07 Capsule|
170601|NCT02867358|Other|Placebo|
170602|NCT02867345|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
170603|NCT02867345|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
170604|NCT02867345|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
170605|NCT02867332|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
170606|NCT02867332|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
170607|NCT02867332|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
170608|NCT02867319|Biological|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
170609|NCT02867306|Drug|ASP1707|Oral
170610|NCT02867306|Drug|methotrexate (MTX)|Oral
170611|NCT02867293|Procedure|ultrasound guided ascitic fluid drainage|
170612|NCT02867293|Procedure|operative drainage of ascites through small skin incision after induction of anesthesia|
170613|NCT02867293|Device|ultrasound|
170614|NCT02867280|Drug|Sorafenib|red round tablet
170615|NCT02867267|Drug|Thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
170616|NCT02867267|Other|Placebo|Subcutaneous injections of 1.6 mg twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
170617|NCT02867241|Behavioral|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
170618|NCT02867241|Behavioral|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
170619|NCT02867228|Other|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
170620|NCT02867215|Other|Barley bread|120g barley bread per day for 3 weeks.
170621|NCT02867215|Other|Wheat bread|120g wheat bread per day for 3 weeks.
170622|NCT02867202|Device|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
170623|NCT02867202|Device|Intrauterine contraceptive device|After the completion of hysteroscopic adhesiolysis, copper IUD was inserted into the uterine cavity and removed after at the second time of hysteroscopy.
170625|NCT02867176|Drug|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
170626|NCT02867176|Drug|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
170627|NCT02867163|Drug|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
170628|NCT02867150|Device|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system~UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
170629|NCT02867137|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
170630|NCT02867124|Drug|XR-NTX|Vivitrol
170631|NCT02867124|Other|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
170632|NCT02867124|Other|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
170633|NCT02867111|Device|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
170634|NCT02867111|Other|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
170635|NCT02867111|Procedure|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
170636|NCT02867098|Drug|XmAb5871|
170637|NCT02867085|Other|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
170638|NCT02867072|Procedure|Open appendectomy|
170639|NCT02867072|Procedure|Laparoscopic appendectomy|
170640|NCT02867059|Drug|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
170641|NCT02867046|Drug|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
170642|NCT02867033|Procedure|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
170643|NCT02867033|Other|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
170644|NCT02867033|Procedure|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
170645|NCT02867033|Procedure|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
170646|NCT02867033|Other|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
170647|NCT02867033|Procedure|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
170648|NCT02867020|Drug|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
170649|NCT02867020|Drug|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
170650|NCT02867020|Drug|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
170651|NCT02867020|Drug|Prednisone|Subjects will receive prednisone 10mg/day.
170652|NCT02867007|Drug|KHK2455|oral dosing
170653|NCT02867007|Drug|Mogamulizumab|i.v. administration
170654|NCT02866994|Behavioral|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
170655|NCT02866994|Behavioral|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
170656|NCT02866981|Other|Observation|
170657|NCT02866968|Procedure|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
170658|NCT02866955|Drug|Estramustine|140mg/4 caps/day
170659|NCT02866955|Drug|Tamoxifen|20mg/day
170660|NCT02866942|Drug|Administration of Live attenuated influenza vaccine (LAIV)|
170661|NCT02866929|Procedure|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
170662|NCT02866929|Device|Orthodontics|Self-ligation brackets in upper and lower teeth
170663|NCT02866929|Drug|Mucograft|Porcine naturally cross-linked collagen matrix
170664|NCT02866916|Drug|SXL01|
170665|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
170666|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
170667|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
170668|NCT02866890|Device|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
170669|NCT02866877|Other|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
170670|NCT02866864|Other|Animal allergy +|Allergic symptom occurs when subject contact animal
170671|NCT02866864|Other|Animal allergy -|Allergic symptom does not occur when subject contact animal
170672|NCT02866851|Other|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
170673|NCT02866838|Drug|Tranexamic acid|intravenous
170674|NCT02866838|Drug|Saline 0.9%|intravenous
170675|NCT02866825|Biological|IFX-1|
170676|NCT02866825|Biological|Placebo|
170677|NCT02866812|Other|questionnaires assessing the state of fatigue, depression and anxiety|
170678|NCT02866799|Other|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
170679|NCT02866799|Other|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
170680|NCT02866786|Drug|Metformin|
170681|NCT02866786|Drug|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
170682|NCT02866773|Behavioral|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
170683|NCT02866773|Behavioral|PA2: Education sessions, Reminders|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior~Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
170684|NCT02866773|Behavioral|PA3: Education sessions, Whataps group|"The intervention includes two components:~Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.~Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
170685|NCT02866773|Behavioral|PA4: Education sessions|"The intervention includes one component only:~- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
170686|NCT02866773|Behavioral|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.~- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
170687|NCT02866773|Behavioral|HD2: Education sessions, Reminders|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
170688|NCT02866773|Behavioral|HD3:Education sessions, Whataps group|"The intervention includes two components:~Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.~Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
170689|NCT02866773|Behavioral|HD4: Education sessions|"The intervention includes one component only:~- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
170690|NCT02866747|Radiation|Hypofractionated stereotactic radiation therapy|
170691|NCT02866747|Drug|Durvalumab|
170692|NCT02866734|Other|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
170693|NCT02866734|Other|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
170694|NCT02866734|Other|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
170774|NCT02866175|Drug|Prasugrel|prasugrel 5mg or 10 mg once-daily
170775|NCT02866175|Drug|ticagrelor|ticagrelor 90 mg twice-daily
170695|NCT02866721|Biological|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of hMSCs: 1 x 10^6, 3 x 10^6 or 5 x 10^6 hMSCs/kg body weight during Visit 2. A traditional 3+3 design will be utilized.~Allogeneic MSCs will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common CFTR mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of CF lung infection and inflammation."
170696|NCT02866708|Device|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
170697|NCT02866695|Drug|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
170698|NCT02866682|Drug|Prograf|Brand Drug for the duration of the study.
170699|NCT02866682|Drug|Tacrolimus|Generic
170700|NCT02866669|Behavioral|Practice Facilitation|ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
170701|NCT02866669|Behavioral|Peer Coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
170702|NCT02866669|Behavioral|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
170703|NCT02866656|Other|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
170704|NCT02866656|Device|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
170705|NCT02866643|Drug|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
170706|NCT02866643|Drug|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
170707|NCT02866630|Biological|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
170708|NCT02866617|Device|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
170709|NCT02866604|Procedure|Sterofundin|
170710|NCT02866604|Procedure|0.9% saline|
170711|NCT02866591|Other|mammography according to an auto-compression procedure|
170712|NCT02866591|Other|mammography according to a standard procedure|
170713|NCT02866591|Other|questionary|
170714|NCT02866578|Procedure|Open lung protective ventilation strategy|
170715|NCT02866565|Drug|adipose-derived regenerative cells (ADRCs)|
170716|NCT02866552|Drug|Stromal Vascular fraction|
170717|NCT02866552|Drug|Ringer lactate|
170718|NCT02866539|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
170719|NCT02866539|Drug|Placebo|Similar looking inactive powder
170720|NCT02866526|Other|Patient questionnaire|quantitative and qualitative data collection will be proposed.
170721|NCT02866513|Other|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
170722|NCT02866500|Behavioral|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
170723|NCT02866487|Procedure|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
170724|NCT02866474|Dietary Supplement|population living at home with meals on wheels|
170725|NCT02866474|Dietary Supplement|population living in an EHPAD|
170726|NCT02866461|Other|No treatment|Observation
170727|NCT02866448|Drug|Vehicle control|Described in arm
170728|NCT02866448|Drug|Isoquercetin|Described in arm
170729|NCT02866448|Drug|Aspirin|Described in arm
170730|NCT02866448|Drug|Isoquercetin plus Aspirin|Described in arm
170731|NCT02866435|Drug|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
170732|NCT02866435|Drug|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
170733|NCT02866435|Drug|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
170734|NCT02866422|Other|No Intervention|Observational Study: No intervention
170735|NCT02866409|Procedure|scalp block|"In this group following nerves were blocked-~Supra-orbital nerve~Supra-trochlear nerve~Zygomatico-temporal nerve~Auriculo-temporal nerve~Posterior auricular branches of the greater auricular Nerve~The greater, lesser, and third occipital nerves"
170736|NCT02866409|Procedure|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
170737|NCT02866409|Drug|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
170738|NCT02866409|Drug|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
170776|NCT02866162|Genetic|High-throughput exome sequencing|
170777|NCT02866149|Biological|Blood sampling|Up to 5 blood samplings can be performed at different time points
170904|NCT02865356|Drug|Placebo|topical vehicle solution
170739|NCT02866396|Drug|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
170740|NCT02866396|Other|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
170741|NCT02866383|Drug|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
170742|NCT02866383|Drug|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
170743|NCT02866383|Radiation|Radiotherapy|15 Gy x 1 fraction given on day 1
170744|NCT02866370|Drug|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
170745|NCT02866370|Drug|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
170746|NCT02866370|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
170747|NCT02866370|Drug|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
170748|NCT02866370|Drug|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
170749|NCT02866370|Drug|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days*~* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
170750|NCT02866357|Other|No intervention|Just collection of nasopharyngeal aspirate for assessment
170751|NCT02866344|Procedure|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
170752|NCT02866344|Procedure|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
170753|NCT02866331|Drug|G-CSF (Leucostim)|
170754|NCT02866331|Biological|CB (autologous cord blood)|
170755|NCT02866331|Drug|Placebo (Normal saline)|
170756|NCT02866318|Device|Echocardiography|
170757|NCT02866305|Procedure|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
170758|NCT02866305|Procedure|Chest tube insertion|Conventional chest tube insertion.
170759|NCT02866305|Drug|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
170760|NCT02866305|Radiation|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
170761|NCT02866292|Other|Pelvic floor muscle and sexual function evaluation|"PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.~The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.~Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain."
170762|NCT02866279|Device|Etonogestrel Contraceptive Implant|Women will be randomized to the TIMING of implant placement
170763|NCT02866266|Other|Retrospective database review|
170764|NCT02866253|Drug|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
170765|NCT02866240|Device|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
170766|NCT02866227|Drug|TOL-463|TOL-463 vaginal gel
170767|NCT02866227|Drug|TOL-463|TOL-463 vaginal insert
170768|NCT02866214|Drug|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
170769|NCT02866214|Drug|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
170770|NCT02866201|Other|Rectal swab|
170771|NCT02866188|Device|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
170772|NCT02866175|Drug|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
170773|NCT02866175|Drug|Clopidogrel|Clopidogrel 75 mg once-daily
170778|NCT02866149|Procedure|Tumor sampling|One tumor sampling can be performed, if applicable
170779|NCT02866149|Other|Stool sampling|Up to 5 blood samplings can be performed at different time points
170780|NCT02866136|Drug|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
170781|NCT02866136|Drug|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
170782|NCT02866136|Drug|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
170783|NCT02866136|Drug|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
170784|NCT02866136|Device|Laser (local treatment)|
170785|NCT02866136|Device|cryoapplication (local treatment)|
170786|NCT02866136|Radiation|I125 radioactive plaques (local treatment)|
170787|NCT02866136|Drug|intravitreal Melphalan (local treatment)|
170788|NCT02866123|Other|ultrasonography|
170789|NCT02866123|Radiation|pulmonary radiography|
170790|NCT02866110|Behavioral|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
170791|NCT02866110|Device|MRI|Echo-planar Imaging of brain BOLD signal
170792|NCT02866097|Other|mHealth inventory management|Improved stock management of iCCM commodities using the DHIS2 mHealth platform
170793|NCT02866097|Other|Supportive supervision|Strengthening of supportive supervision using DHIS2
170794|NCT02866097|Other|ICCM current standard of care|ICCM implementation as per current practice without mHealth interventions
170795|NCT02866084|Device|Device|"The following parameters will be set for active treatments using the CVS Device:~A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.~The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
170796|NCT02866071|Drug|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
170797|NCT02866071|Drug|Placebo-Comparator|50mg IN Placebo
170798|NCT02866058|Procedure|Cesarean Section|
170799|NCT02866045|Procedure|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
170800|NCT02866045|Procedure|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
170801|NCT02866032|Drug|MOB015B|
170802|NCT02866032|Drug|Ciclopirox 80 mg/g|
170803|NCT02866019|Device|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month [4 weeks]; cell sheet culture period, 0.5 month [16 days]; transplantation period, assessment/follow-up period, 6 months [24 weeks])
170804|NCT02866006|Drug|BVAC-C|BVAC-C IV injection at 0, 4, 8th weeks.
170805|NCT02865993|Other|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
170806|NCT02865993|Other|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
170807|NCT02865980|Other|clove extract|in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
170808|NCT02865980|Other|Betadine|in control group, will be washed the Catheter with Betadine
170809|NCT02865967|Other|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
170810|NCT02865967|Other|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
170811|NCT02865954|Device|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
170812|NCT02865941|Dietary Supplement|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
170813|NCT02865941|Dietary Supplement|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
170814|NCT02865941|Dietary Supplement|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
170815|NCT02865928|Drug|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
170816|NCT02865928|Drug|Normal Saline|Same injection technique as intervention arm with normal saline
170817|NCT02865915|Drug|MLE4901 40mg|
170818|NCT02865915|Drug|Placebo|Placebo to match active drug
170819|NCT02865902|Device|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
170820|NCT02865889|Procedure|Laparoscopy in Gynecologic Oncologic Indications|
170821|NCT02865889|Procedure|Conventional surgery (abdominal radical surgery)|
170822|NCT02865876|Procedure|Accelerated Corneal Cross-linking|All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
170823|NCT02865863|Dietary Supplement|Eurycomalongifoliawater extract (Physta®)|
170824|NCT02865863|Dietary Supplement|Placebo|
170825|NCT02865863|Dietary Supplement|Multivitamin|
170826|NCT02865850|Drug|vadadustat|oral tablet
170827|NCT02865850|Drug|Darbepoetin alfa|subcutaneous/intravenous
170828|NCT02865837|Other|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.~Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.~Right after, a scanner is performed with urinary catheter declamping and emptied bladder.~Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.~Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
170829|NCT02865824|Drug|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
170830|NCT02865824|Drug|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
170831|NCT02865811|Drug|Pembrolizumab|"Please see Arms for description."
170832|NCT02865811|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Please see Arms for description."
170833|NCT02865785|Drug|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
170834|NCT02865785|Drug|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
170835|NCT02865759|Behavioral|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
170836|NCT02865746|Drug|Bethametasone|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
170837|NCT02865746|Drug|Placebo|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
170838|NCT02865733|Drug|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
170839|NCT02865733|Drug|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
170840|NCT02865720|Drug|CINRYZE 500 U|IV infusion administered twice weekly
170841|NCT02865720|Drug|CINRYZE 1000 U|IV infusion administered twice weekly
170842|NCT02865707|Dietary Supplement|Synergy-1|Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).
170843|NCT02865707|Dietary Supplement|Maltodextrin|Maltodextrin is carbohydrate adsorbed in the small bowel.
170844|NCT02865694|Other|Cascade|
170845|NCT02865681|Drug|Menopur|Nasal versus injectable
170846|NCT02865681|Drug|Synarel|nasal
170847|NCT02865681|Drug|HCG trigger|injectable
170848|NCT02865681|Drug|Clomiphene citrate|oral
170849|NCT02865681|Drug|Letrozole|Oral
170850|NCT02865668|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
170851|NCT02865668|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
170852|NCT02865668|Drug|Metformin Extended Release (XR)|Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
170853|NCT02865655|Procedure|Hysteroscopic|
170854|NCT02865642|Drug|Serotonin Uptake Inhibitors|
170855|NCT02865642|Drug|Placebo|
170856|NCT02865629|Drug|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for Week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 1200 mg PO evening for Week 3, and then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
170857|NCT02865616|Drug|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
170858|NCT02865616|Drug|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
170859|NCT02865603|Behavioral|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
170860|NCT02865590|Device|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
170861|NCT02865590|Device|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
170862|NCT02865564|Dietary Supplement|Lactobacillus reuteri DSM 17938|
170863|NCT02865564|Dietary Supplement|Placebo|
170864|NCT02865564|Drug|ampicillin and gentamicin|
170865|NCT02865551|Device|Foley catheter|Extended bladder catheterization after epidural anesthesia.
170866|NCT02865551|Device|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
170867|NCT02865551|Drug|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
170868|NCT02865538|Drug|NT-814|
170869|NCT02865538|Drug|Placebo (for NT-814)|
170870|NCT02865512|Procedure|thoracic epidural catheterization|thoracic epidural catheterization for the management of postoperative pain
170871|NCT02865499|Drug|acarbose|acarbose treatment with meals
170872|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
170873|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
170874|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
170875|NCT02865473|Drug|Pilocarpine|topical instillation into the study eye
170876|NCT02865460|Drug|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
170877|NCT02865460|Drug|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
170878|NCT02865447|Device|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
170879|NCT02865434|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
170880|NCT02865434|Procedure|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
170881|NCT02865434|Procedure|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
170882|NCT02865434|Procedure|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
170883|NCT02865434|Procedure|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
170884|NCT02865434|Procedure|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
170885|NCT02865434|Procedure|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
170886|NCT02865434|Procedure|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
170887|NCT02865434|Procedure|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
170888|NCT02865434|Procedure|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
170889|NCT02865434|Procedure|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
170890|NCT02865434|Procedure|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
170891|NCT02865434|Procedure|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
170892|NCT02865434|Procedure|Planar Image with both Hands in Field of View|Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
170893|NCT02865421|Drug|stem cells|adipose tissue derived stromal vascular fraction
170894|NCT02865421|Drug|platelet rich plasma|platelet rich plasma transplanted in bald area at a distance
170895|NCT02865408|Dietary Supplement|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
170896|NCT02865408|Dietary Supplement|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
170897|NCT02865408|Dietary Supplement|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
170898|NCT02865395|Drug|Belladonna and Opium Suppository|
170899|NCT02865395|Procedure|Rectal Exam|
170900|NCT02865382|Procedure|white light was used for colonoscopy withdrawal|
170901|NCT02865382|Procedure|OE mode was used for colonoscopy withdrawal|
170902|NCT02865369|Drug|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
170903|NCT02865356|Drug|Cyclosporine 5% solution|topical solution
170905|NCT02865343|Device|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
170906|NCT02865343|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
170907|NCT02865330|Other|Registry|National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
170908|NCT02865304|Drug|endostar|
170909|NCT02865291|Device|ForConti device|
170910|NCT02865278|Other|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
170911|NCT02865265|Procedure|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.~An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
170912|NCT02865252|Other|MWM Treatment|
170913|NCT02865252|Other|MWM Sham|
170914|NCT02865239|Procedure|Position for the 3.0 Tesla in Magnetic Resonance Imaging|"Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.~This examination is then extended by 10 minutes without additional injection of contrast medium"
170915|NCT02865226|Other|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
170916|NCT02865226|Other|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
170917|NCT02865213|Device|OBA|"The intrusion of posterior teeth using removable appliance OBA."
170918|NCT02865213|Device|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
170919|NCT02865213|Device|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
170920|NCT02865200|Other|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.
170921|NCT02865200|Other|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.~Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
170922|NCT02865187|Dietary Supplement|Vitamin D|Vitamin D 600IU/day
170923|NCT02865187|Drug|Hormonal contraception|Hormonal contraceptives
170924|NCT02865174|Drug|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
170925|NCT02865174|Drug|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
170926|NCT02865174|Drug|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
170927|NCT02865161|Drug|NISELAT|NISELAT 600MG BD
170928|NCT02865148|Behavioral|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
170929|NCT02865135|Drug|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A*02 positive patients.
170930|NCT02865122|Drug|NTRA-9620|Oral daily dose
170931|NCT02865122|Drug|Placebo|Oral daily dose
170932|NCT02865109|Drug|Nusinersen|Administered by intrathecal injection
170933|NCT02865083|Device|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
170934|NCT02865070|Device|Skin Sensor|Wireless vitals monitor
170935|NCT02865057|Procedure|Vaginal assessment|Vaginal assessment of position prior to delivery
170936|NCT02865044|Other|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
170937|NCT02865044|Other|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
283570|NCT02041533|Drug|Pemetrexed|
170938|NCT02865031|Drug|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
170939|NCT02865018|Drug|cetirizine|
170940|NCT02865005|Drug|Dapsone 5.0% Gel (SEEGPharm)|Topical Gel
170941|NCT02865005|Other|Placebo|Topical Gel
170942|NCT02865005|Drug|Dapsone 5.0% Gel (Allergan)|Topical Gel
170943|NCT02864992|Drug|Tepotinib|Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
170944|NCT02864966|Device|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
170945|NCT02864953|Drug|BIIB093|Administered as specified in the treatment arm.
170946|NCT02864953|Drug|Placebo|Administered as specified in the treatment arm.
170947|NCT02864940|Device|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
170948|NCT02864940|Device|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
170949|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
170950|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
170951|NCT02864914|Drug|Empagliflozin|drug
170952|NCT02864914|Drug|DPP-4 inhibitors|drug
170953|NCT02864901|Drug|KSL-W|Plaque reducing gum
170954|NCT02864901|Drug|Chewing Gum Placebo|
170955|NCT02864888|Radiation|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
170956|NCT02864888|Drug|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
170957|NCT02864888|Drug|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
170958|NCT02864875|Drug|Fibrinogen concentrate|Receive fibrinogen concentrate 50mg/kg of body weight after randomization
170959|NCT02864862|Device|Immediate implant|
170960|NCT02864862|Biological|SCTG|
170961|NCT02864862|Biological|ADM|
170962|NCT02864849|Drug|Oxaliplatin|
170963|NCT02864849|Drug|Capecitabine|
170964|NCT02864849|Radiation|Intensity modulated radiotherapy|
170965|NCT02864849|Procedure|Total mesorectal excision|
170966|NCT02864836|Procedure|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
170967|NCT02864823|Procedure|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
170968|NCT02864810|Drug|[18F]GP1|[18F]GP1 PET/CT imaging for detecting thromboembolism
170969|NCT02864797|Other|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
170970|NCT02864784|Drug|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
170971|NCT02864784|Other|Placebo|
170972|NCT02864758|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
170973|NCT02864758|Drug|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
170974|NCT02864758|Drug|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
170975|NCT02864745|Device|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
170976|NCT02864745|Other|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
170977|NCT02864732|Other|Rehabilitation exercises|
170978|NCT02864732|Device|Electrical Stimulation|
170979|NCT02864719|Other|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
170980|NCT02864706|Drug|Everolimus|"All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used."
170981|NCT02864706|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
170982|NCT02864706|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
170983|NCT02864706|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
170984|NCT02864693|Device|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
170985|NCT02864693|Device|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
170986|NCT02864680|Other|Electroretinography|
171547|NCT02860234|Procedure|Total Mesorectal Excision|
170987|NCT02864680|Other|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
170988|NCT02864680|Other|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
170989|NCT02864680|Other|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
170990|NCT02864680|Other|CAST (cannabis abuse screening test)|
170991|NCT02864680|Other|PANSS (Positive And Negative Symptoms Scale) test|
170992|NCT02864680|Other|Delayed Matching to Sample (DMS) test|
170993|NCT02864680|Other|Spatial Working Memory (SWM) test|
170994|NCT02864680|Other|Rapid Visual Information Processing (RVP) test|
170995|NCT02864680|Other|Test for attentional performance (TAP) / Divided Attention|
170996|NCT02864680|Other|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
170997|NCT02864654|Procedure|ADRC injection|10 mL of autologous ADRC suspension will be injected intramuscularly
170998|NCT02864654|Other|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
170999|NCT02864654|Procedure|Liposuction|
171000|NCT02864641|Behavioral|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
171001|NCT02864628|Biological|MVA-BN-RSV|MVA-mBN294B
171002|NCT02864628|Other|Placebo|Tris Buffered Saline
171003|NCT02864615|Radiation|SBRT|Dose and schedule will be depended on metastases location.
171004|NCT02864602|Drug|IV dexamethasone|An infusion of IV dexamethasone
171005|NCT02864589|Behavioral|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
171006|NCT02864589|Behavioral|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual & workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
171007|NCT02864576|Behavioral|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Aerobic Exercise:~12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching."
171008|NCT02864576|Behavioral|Cognitive Remediation_Health Promotion|"Cognitive Remediation:~The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.~Health Promotion:~12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse."
171009|NCT02864563|Procedure|Blood sampling|"Blood sample at diagnosis to evaluate MYCN amplification in plasma.~In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
171010|NCT02864550|Drug|Doxycycline|doxycycline 100mg orally daily
171011|NCT02864550|Other|Placebo|placebo capsule identical in appearance, taste, and size to the capsule provided to the intervention group
171012|NCT02864537|Other|Training|Patients were trained to measure INR and dose warfarin
171013|NCT02864524|Other|Manipulative and Massage Therapy|
171014|NCT02864524|Other|Exercise Program|
171015|NCT02864511|Procedure|Nefertiti lift|
171016|NCT02864498|Drug|DS107|
171017|NCT02864498|Drug|Placebo|
171548|NCT02860234|Behavioral|Quality of Life Questionnaires|
171018|NCT02864485|Procedure|live donor liver transplantation|live donor liver transplantation
171019|NCT02864472|Procedure|PDT|PDT and ranibizumab
171020|NCT02864472|Drug|Ranibizumab|Ranibizumab
171021|NCT02864472|Drug|ranibizumab PRN|ranibizumab PRN
171022|NCT02864459|Other|Muscular ultrasound|Muscular ultrasound is done before extubation
171023|NCT02864420|Other|Home hospitalization|
171024|NCT02864420|Other|Inpatient Hospitalization|
171025|NCT02864407|Drug|Vahelva Respimat(Tiotropium + Olodaterol)|2.5 microgram and 2.5 microgram 2 puffs comprise one medicinal dose
171026|NCT02864394|Biological|pembrolizumab 2 mg/kg|IV infusion
171027|NCT02864394|Drug|Docetaxel 75 mg/m^2|IV infusion
171028|NCT02864381|Drug|Andecaliximab|800 mg administered via intravenous (IV) infusion every 2 weeks
171029|NCT02864381|Drug|Nivolumab|3 mg/kg administered via intravenous (IV) infusion every 2 weeks
171030|NCT02864368|Drug|5-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m^2/day on days 1-5 of each 28 day cycle
171031|NCT02864368|Drug|21-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
171032|NCT02864368|Biological|PEP-CMV|500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered in the right groin and, 2 hours later, 500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered in the left groin
171033|NCT02864368|Drug|Tetanus-Diphtheria booster|At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
171034|NCT02864368|Drug|Tetanus Pre-Conditioning|All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
171035|NCT02864355|Device|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
171036|NCT02864342|Device|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
171037|NCT02864342|Device|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.~The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
171038|NCT02864316|Drug|Nivolumab|
171039|NCT02864303|Other|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
171040|NCT02864290|Drug|ASP1235|intravenous (IV) infusion
171041|NCT02864277|Procedure|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
171042|NCT02864277|Procedure|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.~Preoperative Management Interoperative Management Postoperative Management Post discharge"
171043|NCT02864264|Drug|BMS-986184|
171044|NCT02864264|Drug|Placebo matching BMS-986184|
171045|NCT02864251|Biological|Nivolumab|
171046|NCT02864251|Biological|Ipilimumab|
171047|NCT02864251|Drug|Pemetrexed|
171048|NCT02864251|Drug|Cisplatin|
171049|NCT02864251|Drug|Carboplatin|
171050|NCT02864238|Other|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
171051|NCT02864225|Device|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
171052|NCT02864225|Device|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
171088|NCT02863926|Biological|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
171089|NCT02863913|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
283881|NCT02039063|Drug|E6011 5 mg/kg|
171053|NCT02864225|Device|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
171054|NCT02864199|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
171055|NCT02864199|Drug|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
171056|NCT02864186|Device|control|Women wont use support bra 24 hours a days for six months
171057|NCT02864186|Device|surgical support bra|Women will use surgical support bra 24 hours a day for six months
171058|NCT02864186|Device|common support bra|Women will use common support bra 24 hours a day for six months
171059|NCT02864173|Genetic|Whole genome small nucleotide polymorphism genotyping|
171060|NCT02864160|Behavioral|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
171061|NCT02864160|Behavioral|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
171062|NCT02864147|Drug|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
171063|NCT02864147|Drug|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
171064|NCT02864121|Other|all patients included in IDAHO study|
171065|NCT02864095|Drug|Tranexamic acid (TXA)|IV and topical administration
171066|NCT02864095|Drug|Epinephrine|
171067|NCT02864082|Drug|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
171068|NCT02864082|Drug|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
171069|NCT02864082|Drug|Vehicle|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001.
171070|NCT02864069|Behavioral|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
171071|NCT02864069|Behavioral|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
171072|NCT02864069|Behavioral|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
171073|NCT02864056|Other|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
171074|NCT02864043|Device|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
171075|NCT02864043|Procedure|esophagogastroduodenoscopy (EGD)|Standard of care EGD
171076|NCT02864030|Drug|ERIBULIN MESYLATE|"Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.~The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin."
171077|NCT02864017|Procedure|Enteral nutrition|
171078|NCT02864017|Dietary Supplement|L-Citrulline|
171079|NCT02864017|Dietary Supplement|Placebo|
171080|NCT02864004|Drug|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
171081|NCT02864004|Other|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
171082|NCT02863991|Drug|ONC201|ONC201
171083|NCT02863978|Other|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.~Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
171084|NCT02863952|Other|Single photon emission computed tomography myocardial perfusion imaging|
171085|NCT02863952|Device|novel cadmium-zinc-telluride (CZT) SPECT cameras|
171086|NCT02863939|Device|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
171087|NCT02863939|Other|exercise|
171131|NCT02863562|Other|Placebo Kinesio taping|
171132|NCT02863549|Device|MitraClip in tricuspid valve|MitraClip in tricuspid valve
171090|NCT02863913|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
171091|NCT02863913|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
171092|NCT02863900|Other|cohort of BC of each subtypes|
171093|NCT02863887|Behavioral|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
171094|NCT02863874|Device|VicrylPlus®|Suture
171095|NCT02863874|Device|Vicryl®|Suture
171096|NCT02863861|Drug|Dexmedetomidine-ketamine|
171097|NCT02863861|Drug|propofol-ketamine|
171098|NCT02863848|Dietary Supplement|OraftiR inulin‐type fructans|
171099|NCT02863848|Dietary Supplement|Placebo|maltodextrin
171100|NCT02863835|Other|EIT|All participants will have continuous monitoring of EIT whilst self venting
171101|NCT02863835|Other|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
171102|NCT02863822|Behavioral|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
171103|NCT02863822|Behavioral|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
171104|NCT02863809|Drug|Riboflavin|Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.
171105|NCT02863809|Drug|Dextran|Dextran is used to increase the viscosity of the solution.
171106|NCT02863809|Device|UVA Light Source|Avedro's KXL® System is a UVA irradiation system that uses a light emitting diode (LED) to deliver a dose of UVA light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
171107|NCT02863783|Device|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
171108|NCT02863770|Other|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
171109|NCT02863744|Procedure|coronally advanced flap with subepithelial connective tissue graft|"Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.~The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.~The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
171110|NCT02863731|Other|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
171111|NCT02863731|Other|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
171112|NCT02863718|Drug|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
171113|NCT02863718|Drug|Placebo|Placebo 420mg daily
171114|NCT02863705|Drug|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
171115|NCT02863705|Drug|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
171116|NCT02863679|Drug|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
171117|NCT02863653|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
171118|NCT02863640|Device|Color retinography|
171119|NCT02863640|Device|Optical coherence tomography|
171120|NCT02863640|Device|Fundus autofluorescence imaging|
171121|NCT02863627|Other|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
171122|NCT02863614|Drug|Ibuprofen 600 mg|
171123|NCT02863614|Drug|Lorazepam 1 mg|
171124|NCT02863614|Drug|Placebo|
171125|NCT02863588|Biological|seropositive for Toxoplasma gondii|blood sample
171126|NCT02863575|Drug|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
171127|NCT02863575|Drug|Ibuprofen|Ibuprofen capsule
171128|NCT02863575|Drug|Placebo|Placebo treatment
171129|NCT02863562|Other|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
171130|NCT02863562|Other|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
171133|NCT02863536|Device|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
171134|NCT02863523|Behavioral|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
171135|NCT02863510|Device|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
171136|NCT02863497|Behavioral|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
171137|NCT02863484|Other|surgery|pealing of the outer layer of the cavernous sinus
171138|NCT02863471|Drug|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
171139|NCT02863445|Drug|Levonorgestrel-based emergency contraception 1.5 mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
171140|NCT02863445|Drug|Levonorgestrel-based emergency contraception 3.0mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
171141|NCT02863419|Drug|semaglutide|Oral semaglutide once-daily.
171142|NCT02863419|Drug|liraglutide|Subcutaneous (s.c.) injection once-daily.
171143|NCT02863419|Drug|placebo|Placebo once-daily.
171144|NCT02863406|Other|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
171145|NCT02863393|Other|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
171146|NCT02863380|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
171147|NCT02863380|Device|Individualized rTMS (transcranial magnetic stimulation)|
171148|NCT02863380|Device|Classical rTMS (transcranial magnetic stimulation)|
171149|NCT02863380|Device|Classical tDCS (transcranial direct current stimulation)|
171150|NCT02863367|Drug|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
171151|NCT02863367|Drug|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
171152|NCT02863354|Drug|Aflibercept|Intravitreal injection
171153|NCT02863341|Other|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
171154|NCT02863328|Drug|semaglutide|Oral administration once-daily.
171155|NCT02863328|Drug|empagliflozin|Oral administration once-daily.
171156|NCT02863315|Device|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).~In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)~In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
171157|NCT02863302|Other|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
171158|NCT02863276|Procedure|Intensified insulin therapy|
171159|NCT02863263|Device|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
171160|NCT02863263|Device|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
171161|NCT02863198|Device|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
171162|NCT02863185|Drug|Pitavastatin|
171163|NCT02863185|Drug|Atorvastatin|
171164|NCT02863172|Behavioral|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.~Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
171165|NCT02863172|Procedure|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
171166|NCT02863159|Device|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
171167|NCT02863133|Device|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
171168|NCT02863120|Drug|liposomal bupivacaine|
171169|NCT02863120|Drug|bupivacaine HCl|
171170|NCT02863120|Drug|Ropivacaine|
171171|NCT02863120|Drug|Saline|
171172|NCT02863107|Behavioral|Questionnaires|Participants complete questionnaires about work, family history, medical history, and health habits. Questions are about quality of life, well-being, concerns they may have, as well as the types of health care and follow-up care they are receiving.
171173|NCT02863107|Procedure|Blood Draw|About 2 tablespoons blood collected 1 time.
171174|NCT02863094|Device|transcranial magnetic stimulation|
171175|NCT02863081|Other|Survey|Administered to healthcare providers
171176|NCT02863081|Other|interview|Administered to patients and LAR (i.e., interviews)
171177|NCT02863068|Drug|Topical Sodium Nitrite|"Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention."
171178|NCT02863068|Other|Placebo|Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
171179|NCT02863055|Drug|Nintedanib|Nintedanib 200 mg administered twice daily
171180|NCT02863055|Drug|Placebo|Matching placebo administered twice daily
171181|NCT02863042|Procedure|Repair Deltoid Tendon|
171182|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
171183|NCT02863029|Procedure|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
171184|NCT02863016|Device|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
171185|NCT02862977|Drug|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
171186|NCT02862977|Drug|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
171187|NCT02862964|Other|identify L4/L5|"For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.~The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.~The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
171188|NCT02862938|Drug|NT-501 ECT implant|NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
171189|NCT02862938|Other|Sham|Sham surgery
171190|NCT02862925|Procedure|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
171191|NCT02862912|Drug|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
171192|NCT02862912|Drug|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
171193|NCT02862912|Drug|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
171194|NCT02862912|Drug|Saline|Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml
171195|NCT02862899|Device|Thermowire|
171196|NCT02862886|Other|myometrium biopsy|
171197|NCT02862873|Procedure|Spinal anaesthesia|
171198|NCT02862873|Drug|Ondansetron|
171199|NCT02862873|Other|saline solution|
171200|NCT02862860|Biological|blood sample|
171201|NCT02862860|Biological|urine sample|
171202|NCT02862860|Device|installation of Holter|
171203|NCT02862847|Other|stool samples|
171204|NCT02862834|Genetic|High-throughput exome sequencing|
171205|NCT02862821|Other|HR-EEG|
171206|NCT02862795|Procedure|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
171207|NCT02862782|Drug|hCG (Ovitrelle 250 mcg mcg - Merck Serono)|
171208|NCT02862782|Drug|hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)|
171209|NCT02862769|Drug|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
171210|NCT02862769|Drug|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
171211|NCT02862756|Other|diffusion-weighted MRI and clinical examination|
171212|NCT02862743|Other|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
171213|NCT02862730|Device|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
171297|NCT02862054|Procedure|splenectomy|
283882|NCT02039063|Drug|E6011 10 mg/kg|
171214|NCT02862730|Device|Subject's insulin pump|Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
171215|NCT02862730|Device|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
171216|NCT02862730|Device|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
171217|NCT02862704|Biological|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
171218|NCT02862691|Drug|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
171219|NCT02862691|Drug|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
171220|NCT02862678|Other|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
171221|NCT02862665|Drug|iron isomaltoside 1000 (Monofer®)|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
171222|NCT02862665|Drug|normal saline 100 ml|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
171223|NCT02862652|Other|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
171224|NCT02862639|Device|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
171225|NCT02862639|Device|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
171226|NCT02862613|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
171227|NCT02862613|Biological|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
171228|NCT02862600|Drug|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
171229|NCT02862600|Device|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
171230|NCT02862587|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
171231|NCT02862587|Biological|precision cells|precision cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
171232|NCT02862574|Drug|Andecaliximab|Administered via subcutaneous injection once weekly
171233|NCT02862574|Drug|Placebo|Administered via subcutaneous injection once weekly
171234|NCT02862574|Drug|Methotrexate|Administered orally weekly as part of the participant's current treatment regimen
171235|NCT02862574|Drug|TNF Inhibitor|An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, etanercept, or golimumab.
171236|NCT02862561|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
171237|NCT02862561|Biological|Precision Cells|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
171238|NCT02862548|Drug|TAF|25 mg tablet administered orally once daily
171239|NCT02862548|Drug|TDF|Tablet administered orally once daily
171240|NCT02862548|Drug|Other approved antivirals|Other approved antivirals (such as lamivudine, entecavir, or immunoglobulin antihepatitis B) administered per local practice
171241|NCT02862535|Drug|Andecaliximab|Administered via intravenous (IV) infusion every 3 weeks
171242|NCT02862535|Drug|S-1|Administered orally twice daily for the first 14 days of the 21 day cycle
171243|NCT02862535|Drug|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
171244|NCT02862535|Drug|Oxaliplatin|Administered via IV infusion on Day 1 of each 21-day cycle
171245|NCT02862535|Drug|Nivolumab|Administered via IV infusion every 2 weeks
171246|NCT02862522|Other|Questionnaire of overall health|The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
171247|NCT02862509|Drug|Budesonide nasal instillation|
171248|NCT02862509|Drug|Normal saline nasal instillation|
171249|NCT02862483|Drug|Tamsulosin 0.2mg|
171250|NCT02862483|Drug|Tadalafil 5mg|
171251|NCT02862483|Drug|Placebo for Tamsulosin|
171252|NCT02862457|Drug|Epacadostat 25 mg|25 mg tablet administered orally, twice a day (BID) on Days 1-5 and Days 8-28 of Cycle 1 (28-day Cycle) and Days 1-21 of Cycles 2 through 35 (21-day Cycles) for epacadostat cohort and on Days 1-21 of Cycles 1 through 35 (21-day Cycles) for epacadostat + pembrolizumab cohort.
171253|NCT02862457|Drug|Epacadostat 100 mg|100 mg tablet administered orally, twice a day (BID) on Days 1-5 and Days 8-28 of Cycle 1 (28-day Cycle) and Days 1-21 of Cycles 2 through 35 (21-day Cycles) for epacadostat cohort and on Days 1-21 of Cycles 1 through 35 (21-day Cycles) for epacadostat + pembrolizumab cohort.
171254|NCT02862457|Drug|Epacadostat 300 mg|300 mg tablet administered orally, twice a day (BID) on Days 1-5 and Days 8-28 of Cycle 1 (28-day Cycle) and Days 1-21 of Cycles 2 through 35 (21-day Cycles) for epacadostat cohort and on Days 1-21 of Cycles 1 through 35 (21-day Cycles) for epacadostat + pembrolizumab cohort.
171255|NCT02862457|Biological|pembrolizumab 200 mg|Administered as an intravenous (IV) infusion on Day 8 of Cycle 1 (28 days) and Day 1 of Cycles 2 through 35 (21-day Cycles) for epacadostat cohort and on Day 1 of Cycles 1 through 35 (21-day Cycles) for epacadostat + pembrolizumab cohort .
171256|NCT02862457|Drug|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of Cycles 1 through 4
171257|NCT02862457|Drug|Carboplatin Area Under the Curve (AUC)5|Administered as an IV infusion on Day 1 of Cycles 1 through 4
171258|NCT02862457|Drug|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of Cycles 1 through 4
171259|NCT02862457|Drug|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of Cycles 1 through 4
171260|NCT02862457|Drug|Carboplatin AUC6|Administered as an IV infusion on Day 1 of Cycles 1 through 4
171261|NCT02862444|Other|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
171262|NCT02862431|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
171263|NCT02862431|Drug|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
171264|NCT02862418|Other|UTE MRI|One MRI with UTE settings will be acquired.
171265|NCT02862405|Other|vision tests|
171266|NCT02862379|Behavioral|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
171267|NCT02862366|Other|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
171268|NCT02862353|Biological|blood sample|15 ml of blood
171269|NCT02862340|Genetic|Genetic test|
171270|NCT02862327|Drug|intravenous dexamethasone|intravenous injection of dexamethasone
171271|NCT02862327|Drug|intravenous placebo|intravenous injection of placebo
171272|NCT02862327|Drug|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
171273|NCT02862327|Other|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
171274|NCT02862314|Biological|Blood sample|
171275|NCT02862301|Biological|blood sample|
171276|NCT02862288|Device|Microwave ablation with Acculis Accu2i pMTA Applicator|
171277|NCT02862275|Drug|Atezolizumab|Given IV
171278|NCT02862275|Other|Laboratory Biomarker Analysis|Correlative studies
171279|NCT02862262|Device|ARIES Bordetella Assay|
171280|NCT02862249|Biological|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
171281|NCT02862249|Biological|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
171282|NCT02862236|Drug|Hypericum perforatum extract|250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
171283|NCT02862223|Dietary Supplement|Neoprinol|
171284|NCT02862210|Drug|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
171285|NCT02862210|Drug|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
171286|NCT02862171|Drug|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
171287|NCT02862158|Device|FDT visual field|
171288|NCT02862158|Device|Standard HVF|
171289|NCT02862145|Drug|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
171290|NCT02862145|Drug|Dexamethasone|Premedication during the week of treatment
171291|NCT02862132|Drug|Vedolizumab|
171292|NCT02862119|Procedure|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
171293|NCT02862119|Other|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
171294|NCT02862106|Biological|εPA-44|subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
171295|NCT02862093|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
171296|NCT02862067|Other|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
171298|NCT02862041|Device|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
171299|NCT02862041|Device|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
171300|NCT02862028|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
171301|NCT02862015|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
171302|NCT02862015|Drug|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
171303|NCT02862002|Other|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
171304|NCT02862002|Other|Standard care|patients receiving standard care of cancer pain.
171305|NCT02861989|Other|qualitative study|
171306|NCT02861976|Other|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
171307|NCT02861963|Procedure|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
171308|NCT02861963|Procedure|Systemic-to-pulmonary artery shunts|"Modified Blalock-Taussig shunt performed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side. Central Shunt performed between ascending part of aorta and main pulmonary artery."
171309|NCT02861950|Drug|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
171310|NCT02861950|Drug|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
171311|NCT02861937|Procedure|non surgical periodontal therapy|
171312|NCT02861924|Other|microcirculatory responses|"The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.~measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP)."
171313|NCT02861911|Other|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
171314|NCT02861911|Device|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
171315|NCT02861898|Drug|Intra-arterial Cetuximab|
171316|NCT02861898|Drug|Intra-arterial Mannitol|
171317|NCT02861885|Other|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
171318|NCT02861859|Drug|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
171319|NCT02861859|Drug|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
171320|NCT02861846|Biological|profile of CSF biomarkers of AD|dosage of biomarker of AD
171321|NCT02861833|Other|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
171322|NCT02861820|Device|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
171323|NCT02861807|Device|Brain stimulation with mindfulness-based relapse prevention|Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
171324|NCT02861794|Procedure|GMK Sphere|Total Knee Replacement
171325|NCT02861781|Other|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
171326|NCT02861768|Biological|Pharyngeal swab|
171327|NCT02861755|Behavioral|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
171328|NCT02861755|Behavioral|5-week Emotion Reporting|
171329|NCT02861742|Other|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
171330|NCT02861742|Behavioral|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
171331|NCT02861742|Behavioral|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
171332|NCT02861742|Behavioral|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
171333|NCT02861742|Behavioral|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
171334|NCT02861742|Behavioral|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
171335|NCT02861729|Other|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
171336|NCT02861729|Other|IPS e.max|lithium disilicate partial coverage restorations
171540|NCT02860260|Other|Cerebral MRI|
171541|NCT02860234|Drug|Oxaliplatin|
171337|NCT02861716|Drug|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
171338|NCT02861716|Drug|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
171339|NCT02861716|Drug|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
171340|NCT02861703|Behavioral|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
171341|NCT02861690|Drug|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
171342|NCT02861690|Drug|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
171343|NCT02861677|Other|pharmaceutical care|
171344|NCT02861664|Other|Stannous fluoride (SnF2)|Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF
171345|NCT02861664|Other|Sodium monofluorophosphate (SMFP)|Dentifrice containing 1400 ppm fluoride as SMFP
171346|NCT02861651|Other|DNA sequencing|
171347|NCT02861638|Device|Experimental group|Video of the exercises
171348|NCT02861638|Device|Control group|video of nature scenes
171349|NCT02861638|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
171350|NCT02861625|Behavioral|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
171351|NCT02861612|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
171352|NCT02861599|Other|proprioceptive therapy|
171353|NCT02861599|Other|speech therapy|
171354|NCT02861586|Biological|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
171355|NCT02861586|Biological|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
171356|NCT02861586|Biological|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
171357|NCT02861586|Biological|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
171358|NCT02861573|Biological|Pembrolizumab 200 mg|IV Q3W
171359|NCT02861573|Drug|Olaparib 400 mg|Eight 50-mg capsules PO BID
171360|NCT02861573|Drug|Docetaxel 75 mg/m^2|IV Q3W
171361|NCT02861573|Drug|Prednisone 5 mg|One 5-mg tablet PO BID
171362|NCT02861573|Drug|Enzalutamide 160 mg|Four 40-mg capsules, four 40-mg tablets, or two 80-mg tablets PO QD
171363|NCT02861573|Other|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
171364|NCT02861573|Drug|Olaparib 300 mg|Two 150-mg tablets PO BID
171365|NCT02861573|Drug|Abiraterone acetate 1000 mg|Two 500-mg or four 250-mg tablets PO QD
171366|NCT02861560|Other|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
171367|NCT02861547|Other|death|
171368|NCT02861534|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
171369|NCT02861534|Drug|Placebo for Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
171370|NCT02861521|Device|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
171371|NCT02861521|Device|Sham|Sham shoe modification
171372|NCT02861508|Other|Point-of-care ultrasound|
171373|NCT02861508|Other|Usual care|
171374|NCT02861495|Device|Humeral Compression/Distraction (CD) Nail|Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
171375|NCT02861482|Device|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
171376|NCT02861482|Drug|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
171377|NCT02861482|Drug|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
171378|NCT02861482|Drug|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
171542|NCT02860234|Drug|Capecitabine|
171379|NCT02861482|Procedure|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
171380|NCT02861482|Procedure|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
171381|NCT02861482|Procedure|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
171382|NCT02861482|Procedure|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
171383|NCT02861482|Procedure|Hysterectomy|Hysterectomy with all the above measures not working
171384|NCT02861482|Drug|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
171385|NCT02861469|Other|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
171386|NCT02861456|Other|Standard Model of Care|
171387|NCT02861456|Other|Alternative Model of Care|
171388|NCT02861443|Behavioral|practice of colonic irrigation|
171389|NCT02861430|Procedure|Immunochemistry and molecular biology on sentinel lymph node specimen|
171390|NCT02861417|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplantation
171391|NCT02861417|Drug|Busulfan|Given IV
171392|NCT02861417|Drug|Cyclophosphamide|Given IV
171393|NCT02861417|Drug|Fludarabine|Given IV
171394|NCT02861417|Drug|Fludarabine Phosphate|Given IV
171395|NCT02861417|Other|Laboratory Biomarker Analysis|Correlative studies
171396|NCT02861417|Drug|Mycophenolate Mofetil|Given PO
171397|NCT02861417|Other|Pharmacological Study|Correlative studies
171398|NCT02861417|Drug|Tacrolimus|Given IV or PO
171399|NCT02861417|Drug|Thiotepa|Given IV
171400|NCT02861404|Genetic|skin flakes collection|viral status assessment of skin flakes
171401|NCT02861391|Device|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
171402|NCT02861378|Drug|Phentolamine mesylate|Injection of 1ml at lidocaine injection site
171403|NCT02861378|Drug|Water|Injection of 1ml of physiologic saline water at injection site
171404|NCT02861352|Other|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
171405|NCT02861339|Device|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
171406|NCT02861326|Device|Gracey Curettes|
171407|NCT02861313|Device|CM LOC attachment|CM LOC attachment
171408|NCT02861313|Device|ball attachment|Ball attachment
171409|NCT02861300|Drug|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
171410|NCT02861300|Drug|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
171411|NCT02861287|Other|Economic evaluation|
171412|NCT02861274|Device|pacemaker|
171413|NCT02861261|Drug|1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
171414|NCT02861261|Drug|1. Berberine placebo tablets ; 2. ProMetS probiotics powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;~4g (2 strips) of ProMetS probiotics powder administered orally every night"
171415|NCT02861261|Drug|1. Berberine hydrochloride tablets; 2. Probiotics placebo powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;~2 strips of probiotics placebo powder administered orally every night"
171416|NCT02861261|Drug|1. Berberine placebo tablets; 2. Probiotics placebo powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;~2 strips of probiotics placebo powder administered orally every night"
171417|NCT02861248|Procedure|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60−90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50−80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8−16 weeks.
171418|NCT02861235|Other|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
171419|NCT02861235|Other|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
171420|NCT02861235|Other|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
171421|NCT02861235|Other|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
171422|NCT02861235|Other|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
171423|NCT02861235|Other|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
171424|NCT02861222|Drug|Doxorubicin|
171425|NCT02861209|Other|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
171426|NCT02861196|Procedure|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
171543|NCT02860234|Radiation|intensity modulated radiotherapy|
171427|NCT02861183|Device|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
171428|NCT02861183|Device|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
171429|NCT02861170|Behavioral|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
171430|NCT02861157|Behavioral|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
171431|NCT02861144|Other|Ma ka hana ka ̒ike|Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
171432|NCT02861144|Other|Hanapū Provider Toolbox|Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
171433|NCT02861131|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
171434|NCT02861131|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
171435|NCT02861118|Other|No Intervention|
171436|NCT02861105|Drug|LMWH|LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
171437|NCT02861105|Other|0.9% saline solution|0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
171438|NCT02861079|Device|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
171439|NCT02861079|Drug|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
171440|NCT02861066|Behavioral|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
171441|NCT02861053|Other|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
171442|NCT02861053|Other|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
171443|NCT02861040|Other|Laboratory Biomarker Analysis|Correlative studies
171444|NCT02861040|Other|Pharmacological Study|Correlative studies
171445|NCT02861040|Drug|Vincristine Sulfate Liposome|Given IV
171446|NCT02861040|Drug|Volasertib|Given IV
171447|NCT02861027|Procedure|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
171448|NCT02861027|Procedure|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
171449|NCT02861014|Biological|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
171450|NCT02861001|Device|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
171451|NCT02861001|Device|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
171452|NCT02860988|Behavioral|MCCC treatment|Participants receive newly supported grant services to enhance fatherhood and parenting among individuals with substance use issues.
171453|NCT02860975|Other|Inhaled Nitrogen|"To create the correct gas mixture, nitrogen tanks or membrane technology nitrogen generators will be utilized.~Humidified, high flow, hypoxic gas by nasal cannula will allow the participant to walk short distances, eat, execute basic personal needs (e.g., use of toilette, washing, bathing etc.), or take breaks from wearing the mask."
171454|NCT02860962|Drug|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
171455|NCT02860949|Drug|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
171544|NCT02860234|Procedure|DRE-Endoscopy-MRI-CEA|
171456|NCT02860949|Procedure|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
171457|NCT02860949|Procedure|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
171458|NCT02860936|Drug|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
171459|NCT02860923|Drug|Exenatide|
171460|NCT02860923|Drug|Placebo|
171461|NCT02860910|Behavioral|Cognitive Behavioral Group Therapy|
171462|NCT02860897|Drug|Premarin|Vaginal estrogen cream
171463|NCT02860897|Drug|Vagifem|Vaginal estrogen tablet
171464|NCT02860884|Procedure|liver biopsy|
171465|NCT02860884|Other|infrared spectroscopy|
171466|NCT02860871|Other|infrared spectroscopy|
171467|NCT02860858|Biological|Intravitreous aflibercept injection|
171468|NCT02860845|Device|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
171469|NCT02860845|Drug|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
171470|NCT02860845|Drug|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
171471|NCT02860819|Drug|Veliparib|Veliparib 250mg BID, continuously
171472|NCT02860819|Drug|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
171473|NCT02860819|Drug|Carboplatin|Carboplatin AUC = 4, day 1
171474|NCT02860806|Drug|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
171475|NCT02860806|Drug|Placebo|Intravenous infusion of matching placebo.
171476|NCT02860793|Other|Bone marrow aspiration|
171477|NCT02860793|Other|Blood sampling|
171478|NCT02860780|Drug|prexasertib|Administered IV
171479|NCT02860780|Drug|ralimetinib|Administered orally
171480|NCT02860754|Other|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
171481|NCT02860741|Behavioral|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
171482|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
171483|NCT02860728|Behavioral|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
171484|NCT02860715|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
171485|NCT02860715|Drug|Placebo|This is the placebo of GX-I7 described above.
171486|NCT02860702|Other|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
171487|NCT02860702|Other|Human/Bovine Milk|Bovine milk derived fortification
171488|NCT02860689|Other|using questionnaires - International Index Erectile Function|using questionnaires
171489|NCT02860676|Drug|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
171490|NCT02860663|Dietary Supplement|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
171491|NCT02860663|Dietary Supplement|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
171492|NCT02860663|Dietary Supplement|25OHD|10 ug/d of vitamin D3 for 6 weeks
171493|NCT02860650|Biological|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9*10^10 viral particles (vp).
171494|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5*10^8 infectious units (Inf U).
171495|NCT02860650|Biological|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5*10^10 vp.
171496|NCT02860650|Biological|Placebo|IM injection of 0.9 percent saline.
171497|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1*10^8 Inf U.
171498|NCT02860637|Other|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
171499|NCT02860624|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
171500|NCT02860624|Drug|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
171501|NCT02860572|Other|follow-up without intervention|
171502|NCT02860572|Other|fluid bolus|
171503|NCT02860559|Biological|TBX-1400|Hematopoietic stem cells transplantation
171504|NCT02860546|Drug|TAS-102|One Arm Only (of TAS 102 plus nivolumab)
171505|NCT02860546|Drug|nivolumab|One Arm Only (of TAS 102 plus nivolumab)
171506|NCT02860533|Device|cuff device|Measurement of blood pressure during stress testing with cuff device
171507|NCT02860533|Device|iphone|Measurement of blood pressure during stress testing with iPhone
171508|NCT02860507|Drug|sugammadex|
171509|NCT02860507|Drug|Neostigmine|
171510|NCT02860507|Drug|Glycopyrrolate|
171545|NCT02860234|Procedure|Nonoperative Management|
171546|NCT02860234|Procedure|Local Excision|
171511|NCT02860494|Drug|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
171512|NCT02860494|Drug|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
171513|NCT02860481|Procedure|blood sample for FSHR analysis|
171514|NCT02860481|Procedure|blood sample for FSHR analysis|
171515|NCT02860468|Other|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
171516|NCT02860468|Other|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
171517|NCT02860455|Device|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)~Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
171518|NCT02860455|Device|CO-oximeter|"COHb measurement (Active Comparator)~Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
171519|NCT02860442|Behavioral|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
171520|NCT02860442|Other|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 4-, 8-, and 12-month follow-up assessments.
171521|NCT02860429|Drug|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
171522|NCT02860429|Drug|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
171523|NCT02860403|Procedure|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
171524|NCT02860390|Other|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
171525|NCT02860390|Other|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
171526|NCT02860377|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. ~At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
171527|NCT02860377|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
171528|NCT02860364|Procedure|Hypothermic circulatory arrest|During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
171529|NCT02860325|Device|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
171530|NCT02860325|Device|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
171531|NCT02860312|Behavioral|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
171532|NCT02860312|Behavioral|Non-exercising group|Patients are having their usual physical activity
171533|NCT02860299|Drug|citrate 4%|
171534|NCT02860299|Drug|unfractionated heparin|
171535|NCT02860299|Biological|blood sample|
171536|NCT02860286|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
171537|NCT02860273|Device|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
171538|NCT02860273|Device|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
171539|NCT02860260|Biological|Blood samples|
171549|NCT02860221|Drug|Tranexamic acid (TXA)|IV and topical administration
171550|NCT02860221|Drug|Epinephrine|
171551|NCT02860208|Procedure|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
171552|NCT02860195|Other|oral dose of alcohol|
171553|NCT02860195|Device|alcotest|
171554|NCT02860195|Biological|blood samples|
171555|NCT02860195|Device|Transdermal monitor|
171556|NCT02860182|Other|measure the elastic properties of aortic wall|
171557|NCT02860169|Behavioral|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
171558|NCT02860130|Drug|Prismocitrate 18|Modality of CVVHDF
171559|NCT02860130|Other|No Anticoagulation|Modality of CVVHDF
171560|NCT02860117|Drug|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
171561|NCT02860117|Drug|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
171562|NCT02860104|Device|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
171563|NCT02860091|Drug|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
171564|NCT02860078|Device|Ultrasound|Location and function of sacral epidural space with ultrasound
171565|NCT02860078|Device|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
171566|NCT02860065|Drug|CPC-201|solifenacin and donepezil
171567|NCT02860065|Other|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
171568|NCT02860052|Drug|SB208 2%|Apply once daily to one or both feet for 14 days
171569|NCT02860052|Drug|SB208 4%|Apply once daily to one or both feet for 14 days
171570|NCT02860052|Drug|SB208 16%|Apply once daily to one or both feet for 14 days
171571|NCT02860052|Drug|Vehicle Gel|Apply once daily to one or both feet for 14 days
171572|NCT02860039|Biological|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
171573|NCT02860039|Biological|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
171574|NCT02860039|Other|Laboratory Biomarker Analysis|Correlative studies
171575|NCT02860026|Other|Marketed cow's milk-based infant formula|
171576|NCT02860026|Other|Cow's milk-based infant formula with added nutrients|
171577|NCT02860013|Device|Telemedicine|
171578|NCT02860000|Drug|Alisertib|Given PO
171579|NCT02860000|Drug|Fulvestrant|Given IM
171580|NCT02860000|Other|Laboratory Biomarker Analysis|Correlative studies
171581|NCT02859987|Procedure|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
171582|NCT02859987|Procedure|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
171583|NCT02859987|Device|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
171584|NCT02859974|Behavioral|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.~Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.~Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
171585|NCT02859961|Drug|PRO 140 (350 mg)|PRO 140 350 mg (175 mg/mL) SC injection per week
171586|NCT02859961|Drug|PRO 140 (525 mg)|PRO 140 525 mg (175 mg/mL) SC injection per week
171587|NCT02859961|Drug|PRO 140 (700 mg)|PRO 140 700 mg (175 mg/mL) SC injection per week
171588|NCT02859948|Drug|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
171589|NCT02859935|Behavioral|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
171590|NCT02859922|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
171591|NCT02859922|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
171592|NCT02859909|Biological|BT595|
171593|NCT02859896|Drug|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule~Route of administration: oral"
171594|NCT02859896|Drug|Calcitriol|"Pharmaceutical form: capsule~Route of administration: oral"
171595|NCT02859883|Device|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
171596|NCT02859870|Device|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
171597|NCT02859857|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
171598|NCT02859844|Device|Transcutaneous Tibial Nerve Stimulation (TTNS)|
171599|NCT02859831|Other|water samples|
171600|NCT02859818|Other|therapeutic education program|
171601|NCT02859805|Other|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
171602|NCT02859792|Drug|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
171603|NCT02859792|Drug|Placebo|placebo capsules 25 or 50 mg
171604|NCT02859792|Biological|Blood Samples|v1;v2;v3;v4
171605|NCT02859779|Behavioral|education programs|
283883|NCT02039063|Drug|E6011 15 mg/kg|
171606|NCT02859766|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
171607|NCT02859753|Other|Percutaneous Radiofrequency Ablation|
171608|NCT02859753|Other|Percutaneous Microwave Ablation|
171609|NCT02859740|Other|SIGAM Questionnaire|
171610|NCT02859727|Drug|CDZ173|140 mg/day
171611|NCT02859714|Other|screening data|
171612|NCT02859701|Drug|AK002|IV AK002
171613|NCT02859701|Other|Placebo|
171614|NCT02859688|Genetic|pyrosequencing|
171615|NCT02859688|Genetic|Methylome|
171616|NCT02859675|Other|triangular test|metabolic state, impedance measurement, potential flavours evoked by sucrose,
171617|NCT02859675|Biological|blood sampling|sampling of 2 mL
171618|NCT02859675|Other|Questionnaires|Stunkard, PrefQuest
171619|NCT02859662|Procedure|ruptured aortic aneurysm|All patients with ruptured abdominal aortic aneurysm may be included in this study, whatever the surgical treatment.
171620|NCT02859649|Behavioral|neuropsychological test|neuropsychological test
171621|NCT02859610|Other|research on interactions between portal hypertension and microparticles|
171622|NCT02859597|Device|High flow nasal cannula|High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.
171623|NCT02859584|Biological|Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|
171624|NCT02859571|Drug|Oxytocin|
171625|NCT02859558|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants will receive one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food.
171626|NCT02859545|Behavioral|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
171627|NCT02859545|Behavioral|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
171628|NCT02859532|Radiation|elastography SWIRE|
171629|NCT02859519|Drug|MOB015B|
171630|NCT02859519|Drug|MOB015B Vehicle|
171631|NCT02859506|Other|Respiratory quotient|
171632|NCT02859506|Other|Olfactory liking|
171633|NCT02859493|Device|Saccharomyces cerevisiae|
171634|NCT02859493|Device|Placebo|
171635|NCT02859480|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
171636|NCT02859480|Drug|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
171637|NCT02859467|Other|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles~Inhibitory Treatment Techniques:~Release Technique of the trapezius muscle.~Release Technique for scalene muscles.~Technique suboccipital inhibition.~Technique hands crossed for induction dorsal superficial fascia."
171638|NCT02859467|Other|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
171639|NCT02859454|Drug|Avelumab|Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.
171640|NCT02859441|Drug|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5 with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 (Micro)L, which correlates to 0.5 mg of dry ranibizumab.
171641|NCT02859441|Drug|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
171642|NCT02859415|Drug|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
171643|NCT02859402|Drug|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
171644|NCT02859402|Drug|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
171645|NCT02859376|Dietary Supplement|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
171646|NCT02859363|Genetic|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
171647|NCT02859350|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
171648|NCT02859350|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
171649|NCT02859350|Other|Normal Saline|0.9% Sodium chloride
171650|NCT02859350|Biological|PfSPZ Challenge (for PfSPZ-CVac)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
171651|NCT02859337|Drug|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
171652|NCT02859337|Drug|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
171653|NCT02859324|Drug|CC-122|
171654|NCT02859324|Drug|Nivolumab|
171655|NCT02859311|Drug|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
171656|NCT02859298|Device|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
171657|NCT02859285|Other|Placebo vulvar cream|
171658|NCT02859285|Other|Estradiol vulvar cream|
171659|NCT02859259|Drug|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
171660|NCT02859259|Drug|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
171661|NCT02859246|Drug|Mucinex®|Mucinex®
171662|NCT02859233|Other|Lack of hyperhydration|
171663|NCT02859220|Other|Determination of PTH following|"Determination of PTH following:~in group 1: intact PTH Elecsys Roche"
171664|NCT02859220|Other|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
171665|NCT02859207|Drug|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
171666|NCT02859194|Procedure|Veno-veno-arterial ECMO|
171667|NCT02859181|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
171668|NCT02859168|Behavioral|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
171669|NCT02859168|Device|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
171670|NCT02859155|Procedure|Multivisceral en bloc resection surgery|Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
171671|NCT02859142|Drug|Chantix|Chantix given alongside standard smoking cessation treatment
171672|NCT02859142|Behavioral|Behavioral Counseling Sessions|One-to-one behavioral counseling sessions with a trained therapist
171673|NCT02859142|Drug|NicodermCQ|Nicotine patches provided over 12 week participation
171674|NCT02859129|Drug|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
171675|NCT02859129|Drug|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
171676|NCT02859129|Drug|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
171677|NCT02859129|Drug|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
171678|NCT02859116|Procedure|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
171679|NCT02859103|Drug|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
171680|NCT02859090|Procedure|tonsillectomy|
171681|NCT02859090|Biological|blood sample|
171682|NCT02859077|Drug|EGFR-TKI|EGFR-TKI (gefitinib)
171683|NCT02859077|Drug|Chemotherapy（pemetrexed/gemcitabine）|Chemotherapy (pemetrexed/gemcitabine)
171684|NCT02859077|Drug|Chemotherapy（carboplatin）|Chemotherapy（carboplatin）
171685|NCT02859064|Drug|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
171686|NCT02859064|Device|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
171687|NCT02859051|Device|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
171688|NCT02859038|Procedure|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
171689|NCT02859038|Procedure|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
171690|NCT02859025|Biological|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
171691|NCT02859025|Biological|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
171692|NCT02859025|Biological|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
171693|NCT02859012|Drug|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
171694|NCT02859012|Other|Observation|this group is observational ones.
171695|NCT02858999|Drug|PAD-VCD|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
171696|NCT02858986|Procedure|3D laparoscopy|
171697|NCT02858986|Procedure|4K laparoscopy|
171698|NCT02858973|Drug|Q203|
171699|NCT02858973|Drug|Placebo|
171700|NCT02858960|Device|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
171701|NCT02858960|Device|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
171702|NCT02858947|Procedure|Aelite Flo|Microhybrid flowable composite
171703|NCT02858947|Procedure|x-tra base|Bulk-fill flowable composite
171704|NCT02858934|Radiation|Tomotherapy|"Dose prescription:~Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).~Target volumes:~Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.~Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.~CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.~Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
171705|NCT02858921|Drug|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
171706|NCT02858921|Drug|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
171707|NCT02858921|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
171708|NCT02858908|Drug|Tideglusib|Tideglusib for oral suspension,
171709|NCT02858895|Drug|MDNA55|MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the pseudomonas exotoxin A (PE).
171710|NCT02858882|Other|Screening|Screening of elite swimmers
171711|NCT02858869|Biological|Pembrolizumab|Given IV
171712|NCT02858869|Radiation|Stereotactic Radiosurgery|Undergo SRS
171713|NCT02858856|Drug|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
171714|NCT02858843|Drug|lumacaftor-ivacaftor|Drug given for cystic fibrosis
171715|NCT02858830|Other|High fat mixed meal|
171716|NCT02858817|Drug|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
171717|NCT02858817|Biological|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
171718|NCT02858817|Other|NaCl 0,9%|0.9% NaCl solution for injection
171719|NCT02858804|Drug|Etoposide|50 mg/m2, IV d1-4
171720|NCT02858804|Drug|Doxorubicin|10 mg/m2, IV, d1-4
171721|NCT02858804|Drug|Dexamethasone|30 mg/d, d1-5
171722|NCT02858804|Drug|Vincristine|0.4 mg/m2, IV, d1-4
171723|NCT02858804|Drug|Cyclophosphamide|750 mg/m2 ,d5
171724|NCT02858804|Drug|Cytarabine|2g/m2, q12h, d1
171725|NCT02858804|Drug|Cisplatin|100mg/ m2,IV, d1
171726|NCT02858804|Drug|Rituximab|375 mg/m2 IV, d1
171727|NCT02858804|Drug|Thalidomide|50-150mg/d, po, d1-28
171728|NCT02858804|Drug|Prednisone|0.5mg/Kg, po, qod
171729|NCT02858778|Other|Early order of palliative care consultation|
171730|NCT02858765|Other|Application of white polychromatic light for 2h30 at different times of day|
171731|NCT02858752|Other|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
171732|NCT02858752|Other|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
171733|NCT02858752|Other|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
171734|NCT02858752|Other|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
171735|NCT02858752|Other|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
171736|NCT02858739|Device|BIOFREEDOM STENT|
171737|NCT02858726|Drug|CR845 0.5 mcg/kg|IV medication delivered three times/week
171738|NCT02858726|Drug|CR845 1 mcg/kg|IV medication delivered three times/week
171739|NCT02858726|Drug|CR845 1.5mcg/kg|IV medication delivered three times/week
171740|NCT02858726|Drug|Placebo|IV medication delivered three times/week
171741|NCT02858713|Drug|Calcipotriene + Betamethasone Dipropionate|Participants received Calcipotriene + Betamethasone Dipropionate once daily when needed for the entire study period.
171742|NCT02858713|Device|App|App named MyPso SmarTopTM Version 1.0 (LEO Pharma) was used for 28 days by participants in the intervention arm.
171743|NCT02858700|Biological|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
171744|NCT02858687|Other|Nasopharyngeal swab|
171745|NCT02858674|Other|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
171746|NCT02858674|Other|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
171747|NCT02858661|Other|Nasopharyngeal swab|
171748|NCT02858648|Behavioral|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
171749|NCT02858648|Behavioral|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
171750|NCT02858635|Other|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
171751|NCT02858622|Drug|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
171752|NCT02858622|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
171753|NCT02858622|Drug|perfalgan|intravenous paracetamol
171754|NCT02858622|Drug|fentanyl|
171755|NCT02858609|Other|Nasopharyngeal Swab|
171756|NCT02858596|Dietary Supplement|Semi-solid feed (Terumo PG soft)|
171757|NCT02858596|Dietary Supplement|Liquid feed (Meibalance)|
171758|NCT02858583|Procedure|CC+SI|chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
171759|NCT02858583|Procedure|3:1 C:V|During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
171760|NCT02858570|Biological|MenCC-BIO Vaccine|The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.
171761|NCT02858570|Biological|Combined - CRM197|The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
171762|NCT02858557|Behavioral|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
171763|NCT02858557|Behavioral|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
171764|NCT02858544|Other|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
171765|NCT02858544|Other|ImPACT|Patient- completed computerized neurocognitive test battery
171766|NCT02858531|Other|data retrieval|data retrieval with the Hospital Information System
171767|NCT02858518|Other|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
171768|NCT02858505|Drug|27 mg elemental iron|
171769|NCT02858505|Drug|54 mg elemental iron|
171770|NCT02858492|Drug|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
171771|NCT02858492|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
171772|NCT02858479|Other|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
171773|NCT02858479|Other|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.~stimulations for 6 seconds"
171774|NCT02858479|Radiation|MRI scan|"2 sessions for 10 minutes :~11 controls stimulations for 6 s each spaced 20 s without stimulation.~11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
171775|NCT02858466|Radiation|MRI scan|
171776|NCT02858453|Drug|AQX-1125 100 mg|Synthetic SHIP1 activator
171777|NCT02858453|Drug|AQX-1125 200 mg|Synthetic SHIP1 activator
171778|NCT02858453|Drug|Placebo|Appearance and weight matched placebo tablets
171779|NCT02858440|Biological|Infanrix-IPV/Hib|Subjects receive Infanrix-IPV/Hib three-dose primary vaccination course at 3, 4.5 and 6 months of age and a booster dose at 18 months of age. The vaccine is administered intramuscularly into the upper side of the thigh on the right/left side.
171780|NCT02858427|Behavioral|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.~Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.~Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.~Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
171781|NCT02858427|Behavioral|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
171782|NCT02858427|Behavioral|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
171783|NCT02858427|Behavioral|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
171784|NCT02858414|Other|additional blood sample|
171785|NCT02858401|Drug|Vesatolimod|Tablet(s) administered orally once every 2 weeks
171786|NCT02858401|Drug|Placebo|Tablet(s) administered orally once every 2 weeks
171787|NCT02858401|Drug|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
171788|NCT02858388|Device|Sinuclean Nebules 45|Nebulization of solution
171789|NCT02858388|Other|Saline solution|Nebulization of solution
171790|NCT02858362|Drug|ezutromid|oral suspension
171791|NCT02858349|Behavioral|No intervention|No intervention
171792|NCT02858349|Behavioral|High-intensity interval training|High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
171793|NCT02858336|Behavioral|NEA|Neutral Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 45 kcal/kg LBM day.
171794|NCT02858336|Behavioral|DEA|Deficient Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 20 kcal/kg LBM day.
171795|NCT02858310|Biological|E7 TCR cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
171796|NCT02858310|Drug|Aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
171797|NCT02858310|Drug|Fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
171798|NCT02858310|Drug|Cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
171799|NCT02858297|Drug|Glucosamine sulfate|Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
171800|NCT02858297|Drug|triamcinolone acetonide|Topical corticosteroid
171801|NCT02858284|Device|TUG|Therapeutic Ultrasound for Glaucoma
171802|NCT02858284|Device|Sham|
171803|NCT02858271|Drug|AKB-9778 subcutaneous injection|
171804|NCT02858258|Drug|R-CHOP/R-DHAP|Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
171805|NCT02858258|Drug|Ibrutinib (Induction)|Ibrutinib: only in cycle 1,3,5 on Day 1-19
171806|NCT02858258|Drug|ASCT conditioning|"ASCT conditioning THAM or BEAM, stratified per site before trial activation at site~THAM (TBI (total body irradiation), Ara-C, Melphalan) or~BEAM (BCNU, Etoposide, Cytarabine, Melphalan)"
171807|NCT02858258|Drug|Ibrutinib (Maintenance)|Ibrutinib (Maintenance), daily 560 mg for 2 years;
171808|NCT02858245|Other|No intervention - registry|
171809|NCT02858232|Biological|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
171810|NCT02858219|Drug|Botulinum Toxin Type A|
171811|NCT02858219|Other|Saline solution|
171812|NCT02858219|Other|Indexes|Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
171813|NCT02858206|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
171814|NCT02858206|Drug|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
171815|NCT02858206|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
171816|NCT02858206|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
171817|NCT02858206|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
171818|NCT02858193|Drug|1.35 g SCMC- lys powder|1.35 g SCMC- lys powder for oral solution
171819|NCT02858193|Drug|Fluifort® syrup|SCMC-lys Syrup 90 mg/ml
171820|NCT02858180|Drug|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
171821|NCT02858167|Device|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
171822|NCT02858154|Other|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
171823|NCT02858154|Other|Oxygen by Cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to control sleep apnea and desaturations
171824|NCT02858141|Other|Data collection|
171825|NCT02858128|Other|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
171826|NCT02858115|Other|Fluid challenge|100 ml of crystalloid was infused over 1-min
171827|NCT02858115|Other|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
171828|NCT02858102|Behavioral|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
171829|NCT02858076|Drug|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
171830|NCT02858076|Procedure|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
171831|NCT02858050|Device|Portal-724 MEMs Cap|
171832|NCT02858037|Combination Product|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
171833|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and no tampons|Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
171834|NCT02858024|Drug|Dapivirine Vaginal Ring-004 with tampons|followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
171835|NCT02858024|Drug|Dapivirine Vaginal Ring-004 with no menses|Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
171836|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and same ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
171837|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and new ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
171838|NCT02858011|Other|Cash distribution during first 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
171839|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during first 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
171840|NCT02858011|Dietary Supplement|Preventive Nutrition Packages during last 12 months|Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)
171841|NCT02858011|Other|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
171842|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
171843|NCT02857998|Drug|HMPL-523|Oral administration, once daily
171844|NCT02857985|Device|3D RA|3D RA is realised just after angioplasty.
171845|NCT02857985|Device|MRI|MRI is realised between 24h and 96h post angioplasty.
171846|NCT02857972|Device|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
171847|NCT02857959|Drug|Benzathine Penicillin G|
171848|NCT02857946|Drug|Prevaglip (linagliptin)|1 tablet contains 5 mg linagliptin
171849|NCT02857946|Drug|Trajenta (linagliptin)|1 tablet contains 5 mg linagliptin
171850|NCT02857933|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
171851|NCT02857920|Drug|Bevacizumab|7.5 mg/kg IV every 3 weeks (continuous)
171852|NCT02857920|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfusion in 3 times, i.v.
171853|NCT02857907|Other|Blood sample|A blood sample is performed one year after kidney transplantation.
171854|NCT02857881|Procedure|De-epithelization and therapeutic photokeratectomy|
171855|NCT02857868|Drug|ABL001|
171856|NCT02857855|Procedure|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
171857|NCT02857855|Procedure|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
171858|NCT02857842|Drug|Prednisolone|
171859|NCT02857829|Dietary Supplement|CAF+|CAF+ will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (1 mg), and cobalamin (20 mg).
171860|NCT02857829|Dietary Supplement|Caffeine-alone|Caffeine (100 mg)
171861|NCT02857829|Other|Placebo|Rice flour
171862|NCT02857816|Device|NURO System PTNM Therapy|
171863|NCT02857803|Procedure|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
171864|NCT02857803|Procedure|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
171865|NCT02857803|Procedure|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
171866|NCT02857777|Drug|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
171903|NCT02857491|Drug|sham|sham intravitreal injection before vitrectomy
283884|NCT02039050|Drug|Tiotropium|
171867|NCT02857751|Behavioral|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
171868|NCT02857738|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
171869|NCT02857738|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
171870|NCT02857725|Drug|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
171871|NCT02857725|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
171872|NCT02857712|Drug|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
171873|NCT02857686|Procedure|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
171874|NCT02857686|Procedure|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
171875|NCT02857673|Behavioral|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
171876|NCT02857673|Behavioral|Active Control Group|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
171877|NCT02857660|Other|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
171878|NCT02857660|Dietary Supplement|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
171879|NCT02857647|Behavioral|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
171880|NCT02857634|Device|Cellvizio dual band|Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
171881|NCT02857608|Drug|Lymphoseek|
171882|NCT02857595|Behavioral|Online Behavioral Weight Loss program|
171883|NCT02857595|Behavioral|Weight Loss Nomogram|
171884|NCT02857595|Behavioral|Bite Counter|
171885|NCT02857582|Biological|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
171886|NCT02857582|Drug|Vancomycin|Active comparator to treatment with ACHIM
171887|NCT02857582|Drug|Metronidazole|Primary treatment for C diff in all treatment arms
171888|NCT02857569|Drug|Ipilimumab IT|
171889|NCT02857569|Drug|Ipilimumab IV|
171890|NCT02857569|Drug|Nivolumab IV|
171891|NCT02857556|Biological|Blood sample|
171892|NCT02857556|Other|Retinal photography:|
171893|NCT02857556|Other|dialyse|
171894|NCT02857543|Other|Plant-Based Diet|
171895|NCT02857543|Other|American Heart Association Diet|
171896|NCT02857543|Other|Mediterranean Diet|
171897|NCT02857530|Drug|rhTPO|rhTPO
171898|NCT02857530|Drug|placebo|without rhTPO
171899|NCT02857517|Drug|conbercept|0.05ml conbercept
171900|NCT02857504|Device|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
171901|NCT02857504|Device|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
171902|NCT02857491|Drug|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
171904|NCT02857491|Procedure|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
171905|NCT02857478|Drug|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
171906|NCT02857478|Drug|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
171907|NCT02857465|Drug|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
171908|NCT02857465|Drug|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
171909|NCT02857465|Drug|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
171910|NCT02857465|Drug|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
171911|NCT02857452|Other|SLA Questionnaire|
171912|NCT02857452|Other|Lupus Qol Questionnaire|
171913|NCT02857439|Other|Standard diagnostic item list|All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
171914|NCT02857426|Drug|Nivolumab|
171915|NCT02857400|Other|current standard of care|connection documentation faxed to GP (General practitioner) on the day of patient's discharge
171916|NCT02857400|Other|CREDO standard of care|"organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP"
171917|NCT02857387|Biological|blood sample withdrawn|
171918|NCT02857374|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
171919|NCT02857374|Drug|Fluorescein Sodium Injection|Given IV
171920|NCT02857374|Other|Laboratory Biomarker Analysis|Correlative studies
171921|NCT02857374|Procedure|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
171922|NCT02857361|Drug|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
171923|NCT02857348|Behavioral|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
171924|NCT02857348|Behavioral|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
171925|NCT02857335|Behavioral|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
171926|NCT02857322|Other|Accompanying patient's specific perioperative|
171927|NCT02857309|Device|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
171928|NCT02857309|Drug|Optimal medical therapy|OMT using standard heart failure (HF) drugs
171929|NCT02857296|Other|interview and observation|
171930|NCT02857283|Other|Ozone|Subject will be exposed to a concentration of ozone for 6.5 hours
171931|NCT02857283|Other|Filtered Air|Subject will be exposed to filtered clean air
171932|NCT02857283|Device|Health and Exposure Tracker (HET)|Ozone and heart rate tracker
171933|NCT02857270|Drug|LY3214996|Administered orally
171934|NCT02857270|Drug|Midazolam|Administered orally
171935|NCT02857270|Drug|Abemaciclib|Administered orally
171936|NCT02857270|Drug|Nab-paclitaxel|Administered IV
171937|NCT02857270|Drug|Gemcitabine|Administered IV
171938|NCT02857270|Drug|Encorafenib|Administered orally
171939|NCT02857270|Drug|Cetuximab|Administered IV
171940|NCT02857257|Biological|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
171941|NCT02857244|Drug|Duloxetine|Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.
171942|NCT02857244|Drug|Donepezil|Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.
171943|NCT02857244|Drug|Modafinil|Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil & duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
171944|NCT02857218|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
171945|NCT02857218|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
171946|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
171947|NCT02857192|Biological|Blood samples|
171948|NCT02857179|Procedure|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
172002|NCT02856724|Drug|PGE2|10 mg PGE2 vaginal ovul(Propess)
171949|NCT02857166|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
171950|NCT02857153|Drug|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
171951|NCT02857153|Drug|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
171952|NCT02857153|Procedure|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
171953|NCT02857153|Procedure|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
171954|NCT02857127|Behavioral|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
171955|NCT02857114|Other|massage|
171956|NCT02857101|Other|dosage of calprotectin|
171957|NCT02857088|Behavioral|olfactory assessment|determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
171958|NCT02857088|Behavioral|image visualization|20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
171959|NCT02857088|Behavioral|psychophysiological assessment|during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
171960|NCT02857075|Other|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
171961|NCT02857062|Device|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
171962|NCT02857049|Other|Oral nutritional supplements (ONS) degustation|
171963|NCT02857036|Other|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
171964|NCT02857036|Behavioral|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
171965|NCT02857023|Behavioral|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
171966|NCT02857010|Biological|Allogenic mesenchymal stem cells|Cell therapy
171967|NCT02857010|Other|Placebo|Serum without stem cells
171968|NCT02856997|Drug|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
171969|NCT02856958|Procedure|Nerve decompression|
171970|NCT02856958|Other|Non-operative|Physical therapy
171971|NCT02856932|Other|Conventional high viscosity glass ionomer|Dental restorative material
171972|NCT02856932|Other|Glass ionomer with glass hybrid technology|Dental restorative material
171973|NCT02856919|Drug|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
171974|NCT02856906|Other|occlusal adjustment|
171975|NCT02856893|Drug|Osimertinib|Osimertinib 60 or 40 mg daily until progression
171976|NCT02856893|Drug|Gefitinib|Gefitinib 250mg daily until progression
171977|NCT02856880|Other|Test zinc-IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
171978|NCT02856880|Other|Test zinc non- IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
171979|NCT02856880|Other|Positive control|Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
171980|NCT02856880|Other|SLS negative control|Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
171981|NCT02856880|Other|non-SLS negative control|Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
171982|NCT02856867|Drug|Nintedanib|
171983|NCT02856867|Drug|Fluorouracil|
171984|NCT02856867|Drug|Leucovorin|
171985|NCT02856867|Drug|Oxaliplatin|
171986|NCT02856867|Drug|Placebo|
171987|NCT02856854|Drug|EMB-001|EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)
171988|NCT02856854|Drug|Placebo|EMB-001 matched placebo
171989|NCT02856854|Drug|Cocaine IV|Cocaine administered at doses of 20 and 40mg
171990|NCT02856854|Drug|Saline IV|Cocaine matched placebo
171991|NCT02856828|Device|DIE|digital image enhancement
171992|NCT02856815|Biological|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10^9 ~ 2 x 10^10 lymphocytes / 60kg adult) for 1 hour
171993|NCT02856802|Drug|DFN-02|
171994|NCT02856802|Other|DFN-02 Placebo|
171995|NCT02856789|Other|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
171996|NCT02856789|Other|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
171997|NCT02856789|Other|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
171998|NCT02856789|Other|Specialized hemostasis tests|Coagulation factors
171999|NCT02856776|Dietary Supplement|Vitamin D3|Vitamin D provided in capsule form
172000|NCT02856750|Drug|Gabapentin|Gabapentin 300 mg three times daily x30 days
172001|NCT02856737|Other|eye masks and earplugs|Materials similar to those offered on long commercial flights
172003|NCT02856711|Behavioral|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
172004|NCT02856698|Drug|Midazolam|Dose use according to the product technical sheet
172005|NCT02856698|Drug|Morphine|Dose use according to the product technical sheet
172006|NCT02856685|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
172007|NCT02856672|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
172008|NCT02856672|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
172009|NCT02856633|Device|Vitaliti|
172010|NCT02856620|Other|Observational only|Observational only
172011|NCT02856607|Other|determine the prognosis of threated patients according to the clinical care pathway.|
172012|NCT02856594|Drug|Dexmedetomidine|Dexmedetomidine
172013|NCT02856594|Drug|Placebo|Placebo
172014|NCT02856581|Drug|Varenicline|Given PO
172015|NCT02856581|Drug|Placebo|Given PO
172016|NCT02856581|Other|Tobacco Cessation Counseling|Complete counseling session
172017|NCT02856568|Drug|Cisplatin|Given IV
172018|NCT02856568|Drug|Gemcitabine Hydrochloride|Given IV
172019|NCT02856568|Other|Laboratory Biomarker Analysis|Correlative studies
172020|NCT02856568|Other|Pharmacological Study|Correlative studies
172021|NCT02856568|Drug|Ricolinostat|Given PO
172022|NCT02856555|Drug|GS-0976|Capsule(s) administered orally once daily
172023|NCT02856555|Drug|Placebo|Capsule(s) administered orally once daily
172024|NCT02856542|Drug|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
172025|NCT02856529|Other|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
172026|NCT02856529|Other|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
172027|NCT02856516|Other|Boost Glucose Control (A)|Oral nutrition supplement
172028|NCT02856516|Other|Boost Glucose Control (B)|Oral nutrition supplement
172029|NCT02856516|Other|Boost Original|Oral nutrition supplement
172030|NCT02856503|Drug|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
172031|NCT02856477|Biological|urine analysis|a sample of urine is collected during 8 hours.
172032|NCT02856464|Other|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
172033|NCT02856464|Other|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
172034|NCT02856451|Biological|Nivolumab|Specified dose on specified days
172035|NCT02856438|Drug|Elotuzumab|Specified dose on specified days
172036|NCT02856438|Drug|Lenalidomide|Specified dose on specified days
172037|NCT02856438|Drug|Dexamethasone|Specified dose on specified days
172038|NCT02856425|Drug|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
172039|NCT02856425|Drug|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
172040|NCT02856412|Other|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
172041|NCT02856412|Other|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
172042|NCT02856386|Dietary Supplement|polyphenol supplement|8 mL once daily
172043|NCT02856373|Procedure|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
172044|NCT02856360|Other|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
172045|NCT02856360|Other|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
172046|NCT02856347|Other|18F-DOPA|Injection of 18F-DOPA and PET / CT-scan assessment
172047|NCT02856308|Device|Hairstetics hair implant device|
172048|NCT02856295|Drug|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
172049|NCT02856282|Drug|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
172050|NCT02856269|Dietary Supplement|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
172051|NCT02856256|Dietary Supplement|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
172052|NCT02856243|Drug|new antiviral therapy|
172053|NCT02856230|Device|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
172173|NCT02855307|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
172054|NCT02856217|Procedure|tunneling|In this arm of the study which is Peritoneal tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum)
172055|NCT02856217|Procedure|non-tunneling|In this arm of the study which is Peritoneal non-tunneling group in SCP, standard minimal invasive sacrocolpopexy procedure will be performed. Placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
172056|NCT02856204|Other|Cytology Specimen Collection Procedure|Undergo collection of blood
172057|NCT02856204|Other|Laboratory Biomarker Analysis|Correlative studies
172058|NCT02856191|Other|Holter|
172059|NCT02856178|Drug|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
172060|NCT02856178|Drug|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
172061|NCT02856165|Device|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 > 94%.
172062|NCT02856165|Device|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 > 94% (up to a maximum of 2l/min).
172063|NCT02856152|Drug|GDC-0276 capsule|Three 90 milligram [mg] capsules of GDC-0276 administered orally.
172064|NCT02856152|Drug|GDC-0276 tablets|Three 90 mg GDC-0276 tablets administered orally.
172065|NCT02856126|Procedure|Hepatic arterial infusion chemotherapy|
172066|NCT02856126|Procedure|Transarterial chemoembolization|
172067|NCT02856126|Drug|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
172068|NCT02856126|Drug|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
172069|NCT02856126|Drug|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
172070|NCT02856113|Drug|Alogliptin Benzoate|Alogliptin benzoate Tablets.
172071|NCT02856113|Drug|Placebo|Alogliptin benzoate placebo-matching Tablets.
172072|NCT02856100|Drug|18F DCFPyL- Radiopharmaceutical|
172073|NCT02856087|Drug|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
172074|NCT02856087|Drug|Naloxone|naloxone infusion
172075|NCT02856087|Drug|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
172076|NCT02856087|Drug|Normal Saline|normal saline infusion
172077|NCT02856074|Biological|prise de sang|
172078|NCT02856074|Other|quality of life questionnaire|
172079|NCT02856061|Behavioral|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
172080|NCT02856048|Drug|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
172081|NCT02856035|Other|Neural feedback plus FES and motor training|Neural feedback involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; 46 additional motor learning sessions without brain neural feedback will be provided in Phase III.
172082|NCT02856022|Device|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.~After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
172083|NCT02856022|Procedure|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
172084|NCT02856009|Other|completion of a quality of life questionnaire|
172085|NCT02855996|Other|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
172086|NCT02855983|Procedure|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
172087|NCT02855970|Other|completion of a quality of life questionnaire|
172088|NCT02855957|Other|Free α-Hb pool analysis|
283885|NCT02039050|Drug|Aclidinium|
172089|NCT02855944|Drug|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
172090|NCT02855944|Drug|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice daily
172091|NCT02855931|Procedure|Middle turbinate resection|
172092|NCT02855918|Other|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :~A clinical assessment by psychiatrist~Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits…~A neuropsychological assessment for the evaluations of cognitive performances~A routine blood sampling to the realization of a standard blood test~A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
172093|NCT02855905|Other|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
172094|NCT02855892|Other|Placebo|
172095|NCT02855892|Drug|GV1001|
172096|NCT02855879|Other|Collection of biological data|
172097|NCT02855879|Other|Collection of clinical data|
172098|NCT02855866|Procedure|thyroidectomy|
172099|NCT02855866|Other|cryotherapy|
172100|NCT02855866|Drug|cortisone aerosol|
172101|NCT02855866|Drug|Dexamethasone acetate|
172102|NCT02855866|Drug|paracetamol|
172103|NCT02855853|Other|serious game et virtual reality|
172104|NCT02855853|Other|Nintendo Wii|
172105|NCT02855840|Other|completion of the quality of life questionnaire|
172106|NCT02855814|Other|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
172107|NCT02855801|Other|constant exercise|
172108|NCT02855801|Other|cryotherapy|
172109|NCT02855801|Other|intermittent exercise|
172110|NCT02855788|Drug|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
172111|NCT02855775|Other|additional blood sample|blood sample every 3 weeks
172112|NCT02855762|Other|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
172113|NCT02855749|Procedure|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
172114|NCT02855736|Behavioral|Positive Psychology|"Gratitude Journal (Emmons and Stern, 2013)~Every evening, patients have to write down the things they feel grateful about."
172115|NCT02855736|Behavioral|Placebo (food journal)|"Food journal (i.e. alimentary list):~Patients have to write down the list of foods eaten during the day."
172116|NCT02855723|Other|Surgery: GS strategy|sentinel node biopsy
172117|NCT02855723|Other|Surgery: Classic strategy|systematic lymphadenectomy
172118|NCT02855710|Other|Rhythm workers training Perceptive timing|Perceptive timing training
172119|NCT02855710|Other|Rhythm workers training sensorimotor timing|Sensorimotor timing training
172120|NCT02855710|Other|No Rhythm workers training|No training
172121|NCT02855697|Drug|Olaparib|300 mg taken twice daily, equivalent to a total daily dose of 600 mg
172122|NCT02855697|Drug|Cediranib|20mg dose of cediranib was selected for this study
172123|NCT02855697|Drug|Platinum-based Chemotherapy|1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
172124|NCT02855684|Drug|Insulin glargine (U300)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
172125|NCT02855684|Drug|Insulin glargine|"Pharmaceutical form: solution~Route of administration: subcutaneous"
172126|NCT02855684|Drug|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet~Route of administration: oral"
172127|NCT02855671|Device|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
172128|NCT02855658|Drug|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
172129|NCT02855658|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
172130|NCT02855645|Drug|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
172131|NCT02855645|Drug|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
172132|NCT02855632|Drug|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
172133|NCT02855632|Drug|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
172134|NCT02855632|Drug|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
172135|NCT02855632|Other|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
172171|NCT02855307|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
172136|NCT02855619|Procedure|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
172137|NCT02855619|Procedure|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
172138|NCT02855619|Procedure|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.~This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
172139|NCT02855567|Device|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
172140|NCT02855554|Other|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
172141|NCT02855541|Device|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
172142|NCT02855528|Device|Tin Filter|
172143|NCT02855515|Procedure|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
172144|NCT02855502|Drug|Prednisolone|
172145|NCT02855502|Drug|Placebo|
172146|NCT02855489|Behavioral|Attitudes Only|
172147|NCT02855489|Behavioral|Norms Only|
172148|NCT02855489|Behavioral|Perceived Behavioral Control Only|
172149|NCT02855489|Behavioral|Intentions Only|
172150|NCT02855489|Behavioral|Three Constructs|
172151|NCT02855489|Behavioral|Four Constructs|
172152|NCT02855450|Drug|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution three times a day (TID) for 8 weeks of treatment.
172153|NCT02855450|Drug|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution times a day (TID) for 8 weeks of treatment.
172154|NCT02855437|Device|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. Following completion of 26 week IVR period participants will crossover to RheumPro arm.
172155|NCT02855437|Device|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. Following completion of 26 week RheumPro period participants will crossover to IVR arm."
172156|NCT02855424|Other|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
172157|NCT02855424|Other|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
172158|NCT02855411|Drug|PF-04958242|0.15 mg or 0.5 mg, twice daily (BID) for 12 weeks, capsule
172159|NCT02855411|Drug|placebo|placebo, twice daily (BID) for 12 weeks, capsule
172160|NCT02855372|Procedure|Lung transplantation|
172161|NCT02855359|Drug|denintuzumab mafodotin|SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
172162|NCT02855359|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
172163|NCT02855359|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
172164|NCT02855359|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
172165|NCT02855359|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
172166|NCT02855359|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
172167|NCT02855346|Combination Product|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
172168|NCT02855346|Combination Product|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
172169|NCT02855333|Other|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
172170|NCT02855320|Other|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
172172|NCT02855307|Device|Insulin pump|Patient's insulin pump will be used to infuse insulin.
172174|NCT02855307|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
172175|NCT02855307|Other|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
172176|NCT02855294|Drug|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
172177|NCT02855268|Drug|SAR339375|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous injection
172178|NCT02855268|Drug|Placebo|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous injection
172179|NCT02855255|Behavioral|NHS 1-1 smoking cessation programme.|Smoking cessation using cognitive behavioural therapy/motivational interviewing
172180|NCT02855255|Behavioral|Group smoking cessation programme|Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
172181|NCT02855242|Behavioral|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
172182|NCT02855242|Other|Controls Group|Subjects not participating in any lifestyle counseling
172183|NCT02855216|Other|Manual technique of sub-occipital inhibition|
172184|NCT02855216|Other|Self-treatment by way of Occipivot®|
172185|NCT02855203|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|18-20Gy in 1 fraction
172186|NCT02855203|Drug|Pembrolizumab|Pembrolizumab at a dose of 200mg IV, 3-weekly will be delivered for a duration of 6 months, commencing 5 days (+/- 3 days) from the last dose of SABR.
172187|NCT02855190|Other|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
172188|NCT02855177|Drug|Placebo|Placebo as suspension administered every 8 hours, with food
172189|NCT02855177|Drug|PF-06427878|500 mg suspension administered every 8 hours, with food
172190|NCT02855164|Drug|Tropifexor (LJN452)|Comparison of different doses of drug
172191|NCT02855164|Drug|Placebo|Comparator
172192|NCT02855138|Drug|oral isotretinoin|
172193|NCT02855125|Drug|TAS-114|TAS-114 is a modulator of 5-fluorouracil (5-FU).
172194|NCT02855125|Drug|S-1|S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
172195|NCT02855112|Biological|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
172196|NCT02855099|Other|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
172197|NCT02855086|Biological|Cetuximab|Administered intravenously (IV)
172198|NCT02855086|Drug|Cetuximab-IRDye 800CW|Administered intravenously (IV)
172199|NCT02855086|Procedure|Tumor resection|Standard of care treatment
172200|NCT02855073|Biological|ReJoinTM|adipose derived mesenchymal progeinitor cells
172201|NCT02855073|Drug|Sodium Hyaluronate|Sodium Hyaluronate Injection
172202|NCT02855060|Device|Pelvic Binder|
172203|NCT02855034|Other|Blood samples|Blood samples for dosage: copeptin and protein S100B
172204|NCT02855021|Other|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.~Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.~These tests do not require discontinuation of Parkinson's disease treatment."
172205|NCT02855008|Behavioral|STEPS|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius and are determining whether they are willing to participate and have eligible homes. We will randomize additional agencies for participation. Within each agency we then, (1) determine homes that that meet criteria and, by gender, randomize to STEPS or attention-control condition. Individuals with ID and staff are recruited after randomization. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in STEPS.
172206|NCT02855008|Behavioral|Food for Life|Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius and are determining whether they are willing to participate and have eligible homes. We will randomize additional agencies for participation. Within each agency we then, (1) determine homes that that meet criteria and, by gender, randomize to STEPS or attention-control condition. Individuals with ID and staff are recruited after randomization. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in Food for Life.
172207|NCT02854995|Procedure|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
172248|NCT02854579|Biological|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
172249|NCT02854579|Biological|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
172250|NCT02854566|Device|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
172251|NCT02854553|Procedure|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
172376|NCT02853487|Device|Actigraphy|An actigraph from Philips
172208|NCT02854995|Procedure|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.[5] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
172209|NCT02854982|Procedure|therapeutic management of the prostate Cancer as usual|
172210|NCT02854969|Behavioral|Device: Anapphylaxis|
172211|NCT02854956|Behavioral|Neuropsychological, cognitive and behavioral assessment|"The assessment includes mainly :~The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient~The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient~The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).~The Vineland adaptive behavioral scale which allow to assess the adaptive behavior~The Nisonger child behavior rating form which allow to assess the behavior disorders~Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.~Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component."
172212|NCT02854930|Other|questioning|
172213|NCT02854904|Drug|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
172214|NCT02854904|Drug|Placebo|Placebo controlled
172215|NCT02854891|Other|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
172216|NCT02854878|Device|The Lucy ultrasonic comb models A and B combined with the LucyGel|
172217|NCT02854865|Other|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
172218|NCT02854839|Biological|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
172219|NCT02854826|Other|SAFE Care model of care|"SAFE Care Model Site Intervention:~Endorse best practices for frail patients;~Identify frail patients promptly using multi-dimensional screening and assessments;~Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;~Develop electronic health record templates for patient-centered interprofessional frailty notes;~Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.~Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
172220|NCT02854800|Drug|varenicline|Participants will follow the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
172221|NCT02854787|Drug|Phenylephrine|A bolus of 100 mcg
172222|NCT02854787|Drug|Norepinephrine|A bolus of 0,2 mcg/kg
172223|NCT02854774|Behavioral|Muscle activation exercises|Activation of either muscles activating the knee or hip.
172224|NCT02854761|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
172225|NCT02854748|Drug|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
172226|NCT02854748|Drug|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
172227|NCT02854748|Drug|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
172228|NCT02854735|Other|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
172229|NCT02854722|Drug|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.~Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
172230|NCT02854722|Drug|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
172231|NCT02854709|Behavioral|Sleep extension|Sleep extension by 1 hour for 2 weeks
172232|NCT02854696|Procedure|Islet graft|Patients will be transplanted with pancreatic islet cells
172233|NCT02854696|Drug|best medical care|Patients will continue their insulin treatment
172234|NCT02854683|Drug|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
172235|NCT02854683|Dietary Supplement|Oral Rehydration Solution|1 liter of ORS solution given by mouth
172236|NCT02854670|Drug|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
172237|NCT02854657|Behavioral|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
172238|NCT02854644|Other|additional blood sample|
172239|NCT02854631|Drug|Selonsertib|18 mg tablet administered orally once daily
172240|NCT02854631|Drug|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
172241|NCT02854631|Drug|Placebo|Selonsertib placebo tablet administered orally once daily
172242|NCT02854618|Other|additional blood sample|
172243|NCT02854605|Drug|GS-9674|Tablet administered orally once daily
172244|NCT02854605|Drug|Placebo to match GS-9674|Tablet(s) administered orally once daily
172245|NCT02854592|Drug|rtPA|intravenous thrombolysis with rtPa
172246|NCT02854592|Drug|urokinase|intravenous thrombolysis with urokinase
172247|NCT02854579|Biological|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
172252|NCT02854553|Procedure|rectus sheath block|ultrasound guided rectus sheath block
172253|NCT02854540|Device|Hydrogel electrode-based iontophoresis|Hydrogel was administered through iontophoresis, a process of transdermal drug delivery by use of a voltage gradient on the skin.
172254|NCT02854527|Drug|Digoxin|single dose
172255|NCT02854527|Drug|Furosemide|single dose
172256|NCT02854527|Drug|Metformin|single dose
172257|NCT02854527|Drug|Rosuvastatin|single dose
172258|NCT02854527|Drug|Digoxin|0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
172259|NCT02854527|Drug|Furosemide|1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
172260|NCT02854527|Drug|Metformin hydrochloride|10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
172261|NCT02854527|Drug|Rosuvastatin|10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
172262|NCT02854514|Procedure|Aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
172263|NCT02854488|Drug|Yervoy|
172264|NCT02854475|Procedure|Venous blood collection|weekly within two weeks
172265|NCT02854475|Procedure|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
172266|NCT02854462|Behavioral|Language comprehension intervention|
172267|NCT02854462|Behavioral|Counting intervention|
172268|NCT02854436|Drug|Niraparib|Participants will receive 300 mg niraparib (3 capsules*100 mg) orally once daily.
172269|NCT02854423|Device|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
172270|NCT02854410|Dietary Supplement|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
172271|NCT02854410|Dietary Supplement|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
172272|NCT02854397|Other|blood sample|
172273|NCT02854371|Drug|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.~Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
172274|NCT02854371|Drug|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
172275|NCT02854358|Drug|mixed powder of A. digitata and M. sylvestris|
172276|NCT02854358|Drug|Hypozalix spray (artificial saliva)|Hypozalix spray (artificial saliva)
172277|NCT02854345|Device|Tomoscintigraphic parathyroid imaging on a CZT camera|
172278|NCT02854332|Device|tDCS session|Direct current transcranial magnetic stimulation
172279|NCT02854332|Device|rTMS session|Repetitive transcranial magnetic stimulation.
172280|NCT02854319|Device|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
172281|NCT02854306|Procedure|Bariatric surgery|With mindfulness programm
172282|NCT02854306|Procedure|Bariatric surgery|Without mindfulness programm
172283|NCT02854293|Other|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.~Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
172284|NCT02854280|Biological|Pedalling exercise on a cycle ergometer|At 80% of the maximal aerobic power, until exhaustion
172285|NCT02854280|Biological|Isolated contractions of the quadriceps|Until exhaustion
172286|NCT02854254|Device|peripherally inserted central catheter|peripherally inserted central catheter
172287|NCT02854254|Device|peripherally venous access|standard over-the-needle intravenous catheter
172288|NCT02854241|Procedure|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
172289|NCT02854241|Procedure|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.~DWI using multishot and T2 map are not included for initial MR reading."
172290|NCT02854241|Procedure|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
172291|NCT02854215|Other|Collection of additional data with questionnaires|"questionnaires for quality of life measurements: QLQC30; QLQ-OV28~questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.~These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up)."
172292|NCT02854202|Other|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
172293|NCT02854202|Other|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
172294|NCT02854202|Other|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
172295|NCT02854189|Device|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
172296|NCT02854176|Procedure|Somatosensory electrical stimulation|
172297|NCT02854176|Procedure|Control|
172374|NCT02853500|Device|Traditional Delivery|Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
172298|NCT02854163|Drug|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
172299|NCT02854150|Genetic|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
172300|NCT02854137|Drug|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
172301|NCT02854137|Drug|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
172302|NCT02854124|Procedure|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
172303|NCT02854111|Other|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
172304|NCT02854111|Other|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
172305|NCT02854085|Behavioral|Art Therapy|The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.
172306|NCT02854085|Behavioral|Music Reminiscence Activity|Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
172307|NCT02854072|Drug|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
172308|NCT02854072|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
172309|NCT02854072|Drug|Capecitabine|Capecitabine 830 mg/m^2 will be orally given in the morning and evening (total dose of 1660 mg/m^2) for 21 days followed by 7 days' rest.
172310|NCT02854059|Biological|IdeS (0.25 mg/kg)|Single i.v. infusion of IdeS (0.25 mg/kg). Following an evaluation of efficacy and safety in the first 3 patients the dose may be increased in the following 3 patients to 0.5 mg/kg.
172311|NCT02854059|Biological|IdeS (0.50 mg/kg)|Single i.v. infusion of IdeS (0.50 mg/kg).
172312|NCT02854046|Other|Calcific Uremic Arteriolopathy|
172313|NCT02854007|Device|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
172314|NCT02853981|Device|Harmonic scalpel|a method for liver parenchymal transection
172315|NCT02853981|Device|Kelly clamp crush technique|a method for liver parenchymal transection
172316|NCT02853968|Procedure|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
172317|NCT02853955|Device|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
172318|NCT02853942|Biological|Autologous adipose stem cell therapy|
172319|NCT02853942|Drug|Mecobalamin|
172320|NCT02853929|Biological|Infanrix hexa|All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
172321|NCT02853916|Dietary Supplement|500 mg InSea2®|
172322|NCT02853916|Dietary Supplement|250 mg InSea2®|
172323|NCT02853916|Dietary Supplement|Placebo|
172324|NCT02853903|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
172325|NCT02853890|Other|Questionnaires during hospitalization for delivery|Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
172326|NCT02853877|Behavioral|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
172327|NCT02853864|Drug|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
172328|NCT02853864|Drug|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
172329|NCT02853864|Drug|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
172330|NCT02853864|Drug|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
172331|NCT02853864|Drug|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
172332|NCT02853851|Other|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
172372|NCT02853526|Drug|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
172373|NCT02853500|Device|Surefire|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
172333|NCT02853838|Other|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.~During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
172334|NCT02853838|Other|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.~The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
172335|NCT02853838|Other|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
172336|NCT02853825|Behavioral|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
172337|NCT02853812|Other|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
172338|NCT02853799|Other|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"Placement of feeding tube stomach (oral- or naso-gastric tube)~Randomized to receive either continuous feeding or intermittent feeding first. Once at goal nutrition for 4 hours, enter first 4-hour data collection interval. Next proceed with cross-over and complete a 4-hour washout period with the feed type. Finally enter second 4-hour data collection period. To enter into the first data collection period, the patient would require an insulin infusion.~There will be five blood glucose checks in each data collection period.~If two blood glucose concentrations are above 180 mg/dl then a regular insulin infusion will be initiated."
172339|NCT02853799|Dietary Supplement|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
172340|NCT02853786|Behavioral|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
172341|NCT02853786|Other|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
172342|NCT02853773|Other|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
172343|NCT02853773|Other|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
172344|NCT02853773|Other|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
172345|NCT02853760|Behavioral|walking|
172346|NCT02853760|Device|Treadmill|
172347|NCT02853747|Behavioral|high-intensity-interval-training|12 weeks of walking-based HIIT training
172348|NCT02853734|Other|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
172349|NCT02853734|Other|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
172350|NCT02853721|Other|iPTH|iPTH assay six hours after surgery
172351|NCT02853721|Other|no dosage of iPTH|Ca and P on postoperative day 1 and 2
172352|NCT02853682|Biological|plasma|assesment of glycocalyx protein
172353|NCT02853669|Procedure|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
172354|NCT02853669|Procedure|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
172355|NCT02853643|Drug|ASN002|Single dose study with food effect
172356|NCT02853630|Drug|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
172357|NCT02853630|Drug|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
172358|NCT02853617|Biological|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
172359|NCT02853617|Biological|AV0328 - Cohort 2|Cohort 2 will receive 30 µg to be given as an IM injection
172360|NCT02853617|Biological|AV0328 - Cohort 3|Cohort 3 will receive 75 µg to be given as an IM injection
172361|NCT02853617|Biological|AV0328 - Cohort 4|Cohort 4 will receive 150 µg to be given as an IM injection
172362|NCT02853604|Drug|ADXS11-001|
172363|NCT02853604|Drug|Placebo|
172364|NCT02853591|Procedure|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
172365|NCT02853578|Drug|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;~1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
172366|NCT02853565|Drug|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
172367|NCT02853552|Drug|Misoprostol|800mcg misoprostol taken sublingually
172368|NCT02853539|Drug|Denosumab|Subcutaneous injection of Denosumab
172369|NCT02853526|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
172370|NCT02853526|Drug|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
172371|NCT02853526|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
172375|NCT02853500|Drug|Doxorubicin|Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
172377|NCT02853487|Other|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
172378|NCT02853474|Behavioral|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm."
172379|NCT02853474|Other|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
172380|NCT02853474|Other|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
172381|NCT02853461|Other|Sonication|Ultrasound bath (40 kHz, 1 W/cm2, 1 min) of bearing components of the prosthesis in sterile conditions.
172382|NCT02853461|Other|Microbiological analysis|Plating the sonicates on agar plates.
172383|NCT02853448|Device|Novel Blood Drawing Apparatus|
172384|NCT02853435|Drug|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
172385|NCT02853435|Drug|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
172386|NCT02853435|Drug|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
172387|NCT02853396|Other|Cognitive Behaviour Therapy|
172388|NCT02853396|Other|Psychoeducation|
172389|NCT02853370|Drug|Bendamustine and Rituximab|
172390|NCT02853357|Other|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
172391|NCT02853357|Other|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
172392|NCT02853357|Other|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
172393|NCT02853344|Biological|Pembrolizumab|IV infusion
172394|NCT02853331|Biological|Pembrolizumab|Intravenous infusion
172395|NCT02853331|Drug|Axitinib|Oral tablet
172396|NCT02853331|Drug|Sunitinib|Oral capsule
172397|NCT02853318|Biological|Bevacizumab|Given IV
172398|NCT02853318|Drug|Cyclophosphamide|Given PO
172399|NCT02853318|Other|Laboratory Biomarker Analysis|Correlative studies
172400|NCT02853318|Biological|Pembrolizumab|Given IV
172401|NCT02853305|Biological|Pembrolizumab|IV infusion
172402|NCT02853305|Drug|Cisplatin|IV infusion
172403|NCT02853305|Drug|Carboplatin|IV infusion
172404|NCT02853305|Drug|Gemcitabine|IV infusion
172405|NCT02853292|Biological|urine collection|
172406|NCT02853279|Behavioral|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:~70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT~Where WR is work rate, LT is lactate threshold)~Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
172407|NCT02853279|Behavioral|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
172408|NCT02853266|Other|laboratory biomarker analysis|Archived serum samples are analysed for measurement of biomarker NCRA
172430|NCT02853071|Drug|standard practice|standard practice
172431|NCT02853058|Radiation|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
172432|NCT02853058|Radiation|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
172433|NCT02853045|Drug|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
172434|NCT02853045|Drug|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
172474|NCT02852707|Behavioral|Not exposed|People not engaged in regular sports competition/exercise training.
172409|NCT02853253|Dietary Supplement|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
172410|NCT02853253|Dietary Supplement|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
172411|NCT02853240|Procedure|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
172412|NCT02853227|Other|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
172413|NCT02853214|Genetic|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
172414|NCT02853188|Other|venous thromboembolism|
172415|NCT02853162|Radiation|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
172416|NCT02853149|Behavioral|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
172417|NCT02853149|Behavioral|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
172418|NCT02853149|Behavioral|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
172419|NCT02853136|Drug|Fluvoxamine|single dose
172420|NCT02853136|Drug|BI 409306|low single dose
172421|NCT02853136|Drug|BI 409306|medium or high dose
172422|NCT02853123|Drug|Tiotropium|fixed dose combination once daily
172423|NCT02853123|Drug|Olodaterol|fixed dose combination once daily
172424|NCT02853123|Drug|Tiotropium|
172425|NCT02853110|Radiation|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
172426|NCT02853097|Other|Cytology Specimen Collection Procedure|Undergo blood collection
172427|NCT02853097|Other|Laboratory Biomarker Analysis|Correlative studies
172428|NCT02853084|Drug|HL2351|The dose will be adjusted based on disease activities
172429|NCT02853071|Drug|Estramustine|
172435|NCT02853032|Device|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
172436|NCT02853032|Device|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
172437|NCT02853032|Device|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
172438|NCT02853019|Other|Electroencephalogram|electrophysiological measurements (evoked potentials) based on neural activity when visualizing stimuli
172439|NCT02853019|Behavioral|Cognitive tasks|- clinical scales and subjective assessments of emotional and motivational stimuli
172440|NCT02853019|Behavioral|subjective evaluation scales|- clinical scales and subjective assessments of emotional and motivational stimuli
172441|NCT02853006|Biological|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
172442|NCT02853006|Procedure|Biopsy|
172443|NCT02853006|Procedure|Excised tissues|
172444|NCT02852980|Other|gestational diabetes women|No intervention.
172445|NCT02852967|Drug|KD025|
172446|NCT02852967|Drug|Placebo tablet|
172447|NCT02852941|Device|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
172448|NCT02852941|Device|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
172449|NCT02852915|Procedure|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
172450|NCT02852876|Drug|ASP2151|Oral
172451|NCT02852876|Drug|Placebo|Oral
172452|NCT02852863|Other|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
172453|NCT02852837|Drug|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
172454|NCT02852824|Drug|BI 655130|
172455|NCT02852824|Drug|Placebo|
172456|NCT02852811|Other|Group education|Intervention involving two education session with topics common in menopause transition.
172457|NCT02852798|Drug|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
172458|NCT02852785|Behavioral|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
172459|NCT02852785|Behavioral|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
172460|NCT02852785|Behavioral|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
172461|NCT02852785|Behavioral|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
172462|NCT02852772|Behavioral|Cognitive function tests|
172463|NCT02852759|Procedure|Selective Cold|The volunteers of intervention group will undergo Selective Cold treatment below 10 degree celsius to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The electroacupuncture is conducted by commercially available device. Hyperinsulinemic euglycemic clamp, glucose tolerance test, blood parameter measurements, and PTC-CT scans will be conducted before and after the intervention. The participants will be instructed to maintain their normal behavior and calorie intake.
172464|NCT02852759|Device|Electroacupuncture|Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region to patients.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
172465|NCT02852746|Behavioral|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
172466|NCT02852733|Other|end-of-life emergencies' management|
172467|NCT02852720|Drug|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
172468|NCT02852720|Procedure|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
172469|NCT02852720|Procedure|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
172470|NCT02852720|Procedure|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
172471|NCT02852720|Device|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
172472|NCT02852707|Behavioral|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
172473|NCT02852707|Behavioral|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
172475|NCT02852694|Drug|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children <20kg: 1x 5mg) is recommended.
172476|NCT02852694|Drug|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients < 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
172477|NCT02852694|Drug|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
172478|NCT02852681|Drug|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
172479|NCT02852668|Other|Power Training|This experimental groups underwent an intervention period of power training
172480|NCT02852668|Other|Strength Training|This experimental groups underwent an intervention period of strength training
172481|NCT02852655|Drug|MK-3475|
172482|NCT02852642|Other|Exercise|Plyometric training
172483|NCT02852629|Other|observational study|
172484|NCT02852616|Behavioral|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
172485|NCT02852577|Drug|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
172486|NCT02852577|Drug|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
172487|NCT02852564|Drug|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
172488|NCT02852551|Drug|PAT-1251|
172489|NCT02852551|Drug|Placebo|
172490|NCT02852538|Behavioral|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
172491|NCT02852525|Device|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
172492|NCT02852512|Procedure|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
172493|NCT02852499|Other|Urine sampling|
172494|NCT02852499|Other|Carry a GPS and BET|
172495|NCT02852499|Other|Carry pollution sensor|
172496|NCT02852499|Other|Sampling at the maternity|
172497|NCT02852499|Other|Self-questionnaires|
172498|NCT02852499|Other|Sampling in partum period|Meconium and a strand of hair.
172499|NCT02852486|Drug|Pioglitazone|30 mg/day, orally, for 3 months, before imatinib discontinuation
172500|NCT02852486|Other|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
172501|NCT02852473|Other|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
172502|NCT02852460|Other|rapid recovery|
172503|NCT02852434|Drug|Lidocaine Gel (2%)|
172504|NCT02852434|Drug|Lidocaine Paracervical Block (1%)|
172505|NCT02852421|Procedure|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
172506|NCT02852421|Procedure|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
172507|NCT02852408|Procedure|Laparoscopic cholecystectomy|
172508|NCT02852395|Drug|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
172509|NCT02852395|Drug|Placebo|Oral dose; appearance matched to JNJ-48816274
172510|NCT02852382|Drug|Bupivacaine|In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.
172511|NCT02852382|Drug|morphine patient controlled analgesia|End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
172546|NCT02852044|Behavioral|Exercise|One hour of cycling at 50% of maximal power output
172547|NCT02852044|Other|Dorsal Hand Vein Cannulation (heated hand technique)|
172548|NCT02852044|Other|Venous Cannulation|
172549|NCT02852031|Other|Collaborative Learning Network|
172512|NCT02852369|Behavioral|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.~The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
172513|NCT02852356|Device|MIRI-TL Incubator|MIRI-TL Timelapse incubator
172514|NCT02852330|Device|SA16 research software|Software for measurement of voltage tomography intraoperatively.
172515|NCT02852330|Device|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
172516|NCT02852291|Behavioral|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
172517|NCT02852291|Behavioral|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
172518|NCT02852278|Other|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
172519|NCT02852265|Drug|Etonogestrel contraceptive implant|Place nexplanon
172520|NCT02852252|Drug|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
172521|NCT02852252|Drug|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
172522|NCT02852239|Drug|dabrafenib|Single dose dabrafenib 100 mg
172523|NCT02852226|Other|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
172524|NCT02852226|Behavioral|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
172525|NCT02852226|Behavioral|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
172526|NCT02852213|Drug|AAV2-hAADC|"Subjects will be enrolled sequentially into 2 dose groups, Group 1 followed by Group 2. Initially, up to 3 subjects initially will be enrolled in Group 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as an infusate volume of up to 160 μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Group 2 may commence after the last subject in Group 1 is treated and followed through Month 3 post-surgery, with the approval of the data safety monitoring board (DSMB).~The final safety and clinical outcome assessments will be performed 1 year post-surgery. A follow-up analysis will be performed for 2 years post-surgery. Thereafter, subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates."
172527|NCT02852200|Other|SEGAm|
172528|NCT02852187|Device|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
172529|NCT02852187|Device|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
172530|NCT02852174|Behavioral|Mindfulness meditation training|Mindfulness meditation training
172531|NCT02852161|Device|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
172532|NCT02852148|Device|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
172533|NCT02852135|Device|LMA Proseal|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.
172534|NCT02852135|Device|LMA Supreme|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
172535|NCT02852122|Drug|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA > 20 ng/mL, or Gleason score 8-10, or clinical stage >T2c) would be included.
172536|NCT02852096|Other|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
172537|NCT02852096|Other|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
172538|NCT02852083|Drug|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
172539|NCT02852083|Drug|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
172540|NCT02852083|Drug|Treosulfan|Treosulfan 250 mg twice daily, p.o.
172541|NCT02852083|Drug|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
172542|NCT02852070|Procedure|bronchoalveolar lavage 120ml|120mL sterile saline solution instilled into the distal bronchial tree in 3 times
172543|NCT02852070|Procedure|bronchoalveolar lavage 60ml|60mL sterile saline solution instilled into the distal bronchial tree in 3 times
172544|NCT02852057|Drug|timolol maleate and dorzolamide hydrochloride|Timolol maleate and dorzolamide hydrochloride loaded contact lenses
172545|NCT02852044|Behavioral|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
284522|NCT02034591|Drug|Apixaban|
172550|NCT02852018|Genetic|Identification of genetic polymorphisms|
172551|NCT02852005|Biological|MVA/HIV62B vaccine|1×10^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
172552|NCT02852005|Biological|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
172553|NCT02852005|Biological|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
172554|NCT02851992|Device|GTS cementless stem|Total Hip Arthroplasty
172555|NCT02851979|Other|Olfactory stimulations|"Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.~Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance."
172556|NCT02851966|Procedure|mTESE|mTESE time may be postponed or advanced.
172557|NCT02851953|Device|Aqueduct-100|
172558|NCT02851940|Procedure|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
172559|NCT02851940|Procedure|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
172560|NCT02851927|Procedure|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
172561|NCT02851927|Procedure|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
172562|NCT02851914|Drug|"Tricyclic Antidepressants (TCA)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
172563|NCT02851914|Drug|"Selective Serotonin Uptake Inhibitors (SSRI)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
172564|NCT02851888|Drug|Ropivacaine|Iliac fascia block was performed in the experimental group with a single shot of Ropavicaine.
172565|NCT02851888|Other|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
172566|NCT02851888|Procedure|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
172567|NCT02851875|Other|Registry|
172568|NCT02851849|Drug|LGD-6972-5 mg|5 mg LGD-6972 QD
172569|NCT02851849|Drug|LGD-6972-10 mg|10 mg LGD-6972 QD
172570|NCT02851849|Drug|LGD-6972-15 mg|15 mg LGD-6972 QD
172571|NCT02851849|Other|Placebo|Placebo QD
172572|NCT02851836|Behavioral|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.~This evaluation takes approximately 1hour."
172573|NCT02851823|Device|Periodontal curettes|
172574|NCT02851823|Device|Er-YAG+Nd-YAG lasers|
172575|NCT02851810|Behavioral|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
172576|NCT02851810|Behavioral|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
172577|NCT02851810|Behavioral|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
172578|NCT02851810|Behavioral|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
172579|NCT02851810|Behavioral|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
172580|NCT02851797|Drug|givinostat|suspension of givinostat (10 mg/mL)
172581|NCT02851797|Drug|placebo|suspension manufactured to mimic givinostat
172582|NCT02851784|Biological|adoptive immunotherapy|HCC (D ≤5 cm, fewer than three tumors) patients were treated with radical MWA and 4-6 courses of immunotherapy with CIK every year.The immunotherapy were started at 2 weeks, 4 weeks, 6 weeks, 10 weeks, 14 weeks, 18 weeks and then every 12 weeks after MWA. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were injected into the abdominal cavity. CIK was infused intravenously.
172583|NCT02851784|Procedure|MWA|ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
172584|NCT02851771|Other|Nasopharyngeal Swab|
172585|NCT02851758|Other|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected or infused into the ischemic myocardium
172586|NCT02851745|Drug|Linagliptin|
172587|NCT02851745|Drug|Placebo|
172588|NCT02851732|Behavioral|Quality Improvement Intervention|The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports
172589|NCT02851719|Other|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
172590|NCT02851719|Other|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
172591|NCT02851693|Device|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
172592|NCT02851693|Device|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
172593|NCT02851680|Biological|blood samples|
172594|NCT02851667|Behavioral|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
172595|NCT02851654|Device|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
172596|NCT02851641|Procedure|"pushed mono-canaliculonasal intubation"|
172597|NCT02851628|Device|Alternative sizing model based trial mask|A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
172598|NCT02851628|Device|Prototype Full Face Mask|A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
172599|NCT02851615|Behavioral|SCThrive Intervention for Adolescents with SCD|Chronic Disease Self-Management Program
172600|NCT02851602|Biological|Blood sample|
172601|NCT02851589|Biological|PCAR-019 (anti-CD19 CAR-T cells)|
172602|NCT02851576|Other|Infusion of ADV specific T cells|Cell engineering
172603|NCT02851537|Other|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
172604|NCT02851524|Other|posturography|
172605|NCT02851511|Behavioral|Cognitive Training|Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
172606|NCT02851511|Device|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
172607|NCT02851511|Device|tDCS (sham stimulation)|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
172608|NCT02851511|Behavioral|Educational Training|Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
172609|NCT02851498|Other|Food product: high-protein pasta and cereal|
172610|NCT02851485|Drug|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
172611|NCT02851485|Drug|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
172612|NCT02851485|Drug|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
172613|NCT02851472|Drug|Inhaled Nitric Oxide|Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems adapted specifically for this study.
172614|NCT02851472|Drug|Placebo|Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems specifically adapted for this study.
172615|NCT02851459|Behavioral|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
172616|NCT02851459|Behavioral|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
172617|NCT02851459|Behavioral|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.~Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
172618|NCT02851459|Behavioral|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.~Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
172619|NCT02851459|Behavioral|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
172620|NCT02851459|Behavioral|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
172621|NCT02851446|Other|measure dyspnoea> Borg 7|
172622|NCT02851433|Drug|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
172623|NCT02851433|Drug|total intravenous anaesthesia with Propofol.|
172624|NCT02851420|Other|spectroscopy|
172625|NCT02851407|Drug|Defibrotide|
172626|NCT02851407|Other|Best Supportive Care|
172627|NCT02851394|Drug|Levobupivacaine|
172628|NCT02851394|Drug|levobupivacaine|
172629|NCT02851394|Drug|tramadol|
172630|NCT02851381|Drug|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:~Dose: 35 mg/kg~Route: IV over one hour following completion of gemcitabine infusion~Schedule:~Days 1, 8, and 15~Please note that Day 8 infusion will on be completed during the first treatment cycle"
172631|NCT02851368|Device|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
172632|NCT02851368|Drug|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
174111|NCT02839720|Other|Laboratory Biomarker Analysis|Correlative studies
172633|NCT02851316|Other|Whole Body Vibration|Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
172634|NCT02851303|Drug|Morphine|Morphine wean protocol as described in arm description
172635|NCT02851303|Drug|Methadone|Methadone wean protocol as described in arm description
172636|NCT02851290|Procedure|Caudal block anesthesia|After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
172637|NCT02851290|Procedure|Dorsal penile nerve block anesthesia|After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
172638|NCT02851277|Drug|ASP0892 Intradermal|Intradermal injection
172639|NCT02851277|Drug|ASP0892 Intramuscular|Intramuscular injection
172640|NCT02851277|Drug|Placebo Intradermal|Intradermal injection
172641|NCT02851277|Drug|Placebo Intramuscular|Intramuscular injection
172642|NCT02851238|Other|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
172643|NCT02851225|Other|telemedicine transmission of biological results|telemedicine transmission of biological informations
172644|NCT02851212|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
172645|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
172646|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
172647|NCT02851212|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
172648|NCT02851199|Device|Electroencephalography|Electroencephalograph recording following hyperventilation in different participant's body postures
172649|NCT02851186|Device|Acupuncture|
172650|NCT02851186|Device|Sham acupuncture|
172651|NCT02851173|Device|LLLT|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
172652|NCT02851173|Device|Placebo|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
172653|NCT02851160|Other|semi-structured interview conducted by a clinical psychologist|semi-structured interview conducted by a clinical psychologist
172654|NCT02851160|Other|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
172655|NCT02851147|Device|SL-D301|Slit Lamp
172656|NCT02851147|Device|DC-4|Digital Camera Attachment
172657|NCT02851147|Device|SL-3G|Slit Lamp
172658|NCT02851134|Genetic|genetic analysis|genetic (Whole Exome Sequencing )
172659|NCT02851134|Biological|blood and stools samples|biological collection
172660|NCT02851121|Other|Sensorial stimulations|
172661|NCT02851121|Other|Experimental protocols|
172662|NCT02851121|Behavioral|Emotional protocols|
172663|NCT02851121|Other|Protocol with a spatial dimension|
172664|NCT02851108|Drug|Methylene Blue|50 patients will receive methylene blue
172665|NCT02851108|Drug|Primaquine|50 patients will receive primaquine
172666|NCT02851095|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
172667|NCT02851095|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
172668|NCT02851095|Drug|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
172669|NCT02851082|Other|Endurance training program|"Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.~A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases."
172670|NCT02851056|Biological|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered.~Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered."
172671|NCT02851056|Procedure|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
172672|NCT02851056|Biological|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
172673|NCT02851056|Drug|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
284568|NCT02034292|Drug|Placebo|
172674|NCT02851043|Device|pneuRIP (breathing with resistance)|subjects are given a resistance element to breath through
172675|NCT02851043|Device|Respitrace system (Carefusion) (breathing without resistance)|subjects are asked to breath normally
172676|NCT02851030|Behavioral|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
172677|NCT02851017|Other|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
172678|NCT02851004|Drug|BBI608(Napabucasin)|"1 cycle is 21days.~BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day.~[Additional cohort to the Phase II part] Oral administration at a dose of 240mg mg BID, every day~The therapy will be repeated until meeting the discontinuation criteria."
172679|NCT02851004|Drug|Pembrolizumab|"1 cycle is 21days.~Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle~[Additional cohort to the Phase II part] Administration at a dose of 200 mg/body on Day 1 of each cycle.~The therapy will be repeated until meeting the discontinuation criteria."
172680|NCT02850991|Radiation|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
172681|NCT02850991|Radiation|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
172682|NCT02850978|Drug|Spiolto|
172683|NCT02850965|Drug|BI 695501|
172684|NCT02850965|Drug|Humira|
172685|NCT02850952|Other|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
172686|NCT02850939|Behavioral|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
172687|NCT02850926|Other|Soccer head gear|Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
172688|NCT02850913|Drug|Doxycycline|"115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.~Treatment will be initiated in hospital but will be continued at home.~Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.~Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
172689|NCT02850913|Other|Placebo|- Placebo (matching capsules containing no active ingredients)
172690|NCT02850900|Behavioral|Internet Survey|Weekly survey will be emailed, subjects should complete them
172691|NCT02850887|Other|general endotracheal anesthesia|sedation with the use of endotracheal intubation
172692|NCT02850887|Other|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
172693|NCT02850874|Procedure|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
172694|NCT02850874|Procedure|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.~Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
172695|NCT02850874|Drug|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
172696|NCT02850861|Device|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
172697|NCT02850848|Drug|Entigin Film Coated Tablet 0.5mg|
172698|NCT02850848|Drug|(Baraclude 0.5mg Tablets|
172699|NCT02850835|Other|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
172700|NCT02850822|Drug|Demethylation drug|Demethylation drug,such as Decitabine
172701|NCT02850822|Drug|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
174112|NCT02839720|Drug|Selumetinib|Given PO
172702|NCT02850796|Behavioral|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
172703|NCT02850796|Other|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
172704|NCT02850783|Procedure|89Zr-nanocoll and Indocyanine Green|
172705|NCT02850770|Behavioral|Pedometers and Walking Logs|Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
172706|NCT02850770|Behavioral|Phone Messaging|Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
172707|NCT02850770|Behavioral|Family/Friend Support|Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
172708|NCT02850757|Device|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
172709|NCT02850757|Device|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
172710|NCT02850744|Drug|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
172711|NCT02850731|Device|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
172712|NCT02850718|Drug|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
172713|NCT02850718|Drug|Oral Sildenafil|50 mg oral sildenafil (Viagra)
172714|NCT02850692|Other|measure of endothelial function|Arterial tone index measured by EndoPAT®. Patient should neither eat nor drink at least 4 hours before exam and should neither smoke 3 hours before the exam.
172715|NCT02850692|Biological|Blood sample|21 ml of blood to measure : hepatic workup, complete blood count (CBC), platelets, prothrombin time (PT), activated partial thromboplastin time (aPTT), C-reactive protein (CRP), lipid test, ionograms, creatinine, tissue plasminogen activator factor (tPA), plasminogen activator inhibitor-1 (PAI-1), tissue factor pathway inhibitor (TFPI), Willebrand factor, soluble thrombomodulin, blood levels of endoglin and syndecan. And level beta human chorionic gonadotropin (beta-HCG) for woman only.
172716|NCT02850692|Other|Hepatic elastography|Hepatic elastography by Fibrocan®. Patient should neither eat nor drink at least 2 hours before exam. 10 successive measurements are made.
172717|NCT02850692|Diagnostic Test|Injected abdominal CT|"Patient should neither eat nor drink at least 4 hours before exam.~The examination is not realized if an abdominal scan or an MRI was performed in the five years prior to the day of the visit."
172718|NCT02850666|Behavioral|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
172719|NCT02850653|Biological|PCR : 16S ribosomal DNA and real-time targeted PCR|
172720|NCT02850653|Biological|Sampling of aqueous humour|
172721|NCT02850627|Drug|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
172722|NCT02850627|Drug|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
172723|NCT02850614|Behavioral|gaming application to encourage physical activity|
172724|NCT02850614|Device|FitBit|
172725|NCT02850601|Drug|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
172726|NCT02850588|Procedure|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
172727|NCT02850588|Procedure|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
172728|NCT02850575|Device|Mpact Double Mobility cup|
172729|NCT02850562|Behavioral|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
172730|NCT02850562|Behavioral|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
172731|NCT02850549|Other|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
172732|NCT02850536|Biological|anti-CEA CAR-T cells|Gene modified patient T cells
172733|NCT02850523|Other|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
172734|NCT02850510|Behavioral|Brief Incredible Years parent training|The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
172735|NCT02850497|Device|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
172736|NCT02850484|Drug|Budesonide|Inhaled corticosteroid
172737|NCT02850484|Drug|Formoterol|Long Acting Beta Agonist (LABA)
173283|NCT02846272|Procedure|Observation|Observation of MRI changes in subjects
172738|NCT02850471|Device|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
172739|NCT02850458|Device|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
172740|NCT02850445|Drug|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
172741|NCT02850445|Other|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
172742|NCT02850445|Other|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
172743|NCT02850445|Other|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
172744|NCT02850432|Procedure|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
172745|NCT02850432|Other|Conservative treatment|rehabilitation with medical therapy
172746|NCT02850419|Drug|ThermoDox (Thermally Sensitive Liposomal Doxorubicin)|A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
172747|NCT02850419|Radiation|Radiation Therapy|A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
172748|NCT02850419|Device|Superficial Hyperthermia|Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
172749|NCT02850406|Drug|GBT440|GBT440 will be administered as oral capsules
172750|NCT02850393|Other|Functional magnetic resonance imaging|
172751|NCT02850393|Behavioral|behavioral measures|
172752|NCT02850393|Other|physiological measurements|
172753|NCT02850380|Other|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
172754|NCT02850367|Dietary Supplement|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
172755|NCT02850367|Dietary Supplement|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
172756|NCT02850367|Dietary Supplement|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
172757|NCT02850367|Dietary Supplement|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
172758|NCT02850367|Biological|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
172759|NCT02850367|Biological|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
172760|NCT02850354|Other|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
172761|NCT02850341|Device|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
172762|NCT02850328|Other|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~Rate of force development~Electromyographic activity~Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~Maximum voluntary activation capacity (%VA): %VA = (1-[torque superimposed twitch/torque resting twitch])*100%."
172763|NCT02850315|Device|optimal coherence tomography|
172764|NCT02850302|Other|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
172765|NCT02850302|Other|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
172766|NCT02850289|Drug|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
172767|NCT02850289|Drug|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
172768|NCT02850276|Drug|Pyridostigmine|
172769|NCT02850263|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
172770|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
172771|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
172772|NCT02850250|Drug|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
172773|NCT02850224|Behavioral|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
172774|NCT02850211|Drug|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
172775|NCT02850211|Drug|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
172776|NCT02850211|Drug|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
172777|NCT02850198|Device|scalp electroacupuncture|
172778|NCT02850198|Device|sham scalp electroacupuncture|
172779|NCT02850185|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
172780|NCT02850185|Device|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
172781|NCT02850185|Drug|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
172782|NCT02850172|Behavioral|Walk, Eat, & Breathe|"Walking exercise: 3 times per week, 20~30 mins per section~Eat: nutritional assessment and advice weekly~Inspiratory muscle training: twice every day, 7 days a week, 6~8 weeks before surgery"
172783|NCT02850159|Device|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
172784|NCT02850159|Device|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
172785|NCT02850146|Drug|18F-AV-1451|
172786|NCT02850133|Other|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
172787|NCT02850120|Procedure|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
172788|NCT02850120|Procedure|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
172789|NCT02850120|Procedure|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
172790|NCT02850107|Device|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
172791|NCT02850107|Device|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
172792|NCT02850107|Device|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
172793|NCT02850107|Device|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
172794|NCT02850107|Device|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
172795|NCT02850094|Behavioral|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
172796|NCT02850081|Drug|Statin|"Standard of care treatment (one of four):~Simvastatin (to 40mg without amlodipine)~Simvastatin (to 20 mg if currently on amlodipine)~Atorvastatin (to 80mg)~Rosuvastatin (to 20mg)"
172797|NCT02850081|Drug|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules"
172798|NCT02850081|Other|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
172799|NCT02850068|Device|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
172800|NCT02850055|Other|Conventional Physiotherapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home."
172801|NCT02850055|Other|Specific Manual Therapy|"Leaflet care and health habits of the temporomandibular joint.~Program of cranio-cervical and temporomandibular exercises.~Massage of the cervical muscles and self care document for home.~Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
172802|NCT02850042|Behavioral|Occupation-based practice (OBP)|
172803|NCT02850042|Behavioral|Modified-constraint induced therapy (m-CIT)|
172804|NCT02850029|Other|Observational study, no intervention|
172805|NCT02850016|Drug|3BNC117|Intravenous Infusion of 3BNC117
172806|NCT02850016|Drug|Romidepsin|Intravenous Infusion of Romidepsin
172807|NCT02850003|Drug|IDP-120 Gel|Gel
172808|NCT02849990|Drug|Abiraterone Acetate|Given PO
172809|NCT02849990|Drug|Apalutamide|Given PO
172810|NCT02849990|Drug|Degarelix|Given SC
172811|NCT02849990|Drug|Indomethacin|Given PO
172812|NCT02849990|Other|Laboratory Biomarker Analysis|Correlative study
172813|NCT02849990|Drug|Prednisone|Given PO
172814|NCT02849951|Drug|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
173326|NCT02845921|Other|control|no intervention has been done
172815|NCT02849951|Drug|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
172816|NCT02849938|Device|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
172817|NCT02849925|Drug|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
172818|NCT02849912|Other|questionnaire|
172819|NCT02849899|Drug|Vildagliptin|"Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).~In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).~Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.~The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin."
172820|NCT02849899|Drug|Placebo|The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
172821|NCT02849886|Drug|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
172822|NCT02849886|Drug|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~Grade ≥3 toxicity attributable to GMC."
172823|NCT02849873|Drug|IDP-123 Lotion|Lotion
172824|NCT02849873|Drug|Tazorac Cream|Cream
172825|NCT02849860|Drug|IDP-121 Lotion|Lotion
172826|NCT02849834|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
172827|NCT02849821|Other|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
172828|NCT02849821|Other|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H&E).
172829|NCT02849795|Other|bone densitometry|
172830|NCT02849795|Other|questionnaires|
172831|NCT02849795|Other|biological analyses|
172832|NCT02849782|Drug|Fampridine|Oral intake of 10 mg twice daily
172833|NCT02849769|Device|Implant of an MR-conditional Tachy device system|
172834|NCT02849756|Other|older in intensive care unit|It is an observational study with no intervention.
172835|NCT02849743|Drug|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
172836|NCT02849743|Drug|Placebo (for Syntocinon)|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
172837|NCT02849730|Device|Fentanyl/ropivacaine based Epi-PCA|Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
172838|NCT02849717|Behavioral|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
172839|NCT02849704|Drug|Creon36™|Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
172840|NCT02849678|Drug|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
172841|NCT02849678|Drug|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.~At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
172842|NCT02849665|Other|Kangaroo Position|
172843|NCT02849652|Behavioral|ATTOC Intervention|ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
172844|NCT02849652|Behavioral|UC Intervention|Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
172845|NCT02849639|Other|Placebo|Participants will receive educational materials, but will not receive MTM.
174113|NCT02839720|Drug|Selumetinib Sulfate|Given PO
172846|NCT02849639|Other|Medication Therapy Management (MTM)|Participants will receive MTM in addition to the educational materials.
172847|NCT02849639|Drug|Scopolamine patch|At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
172848|NCT02849626|Drug|Perampanel|E2007
172849|NCT02849613|Other|Adipose Derived Stem Cells|
172850|NCT02849613|Other|Vehicle media|
172851|NCT02849587|Drug|cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
172852|NCT02849561|Other|Therapeutic hypothermia|With a mattress at 4°C to reach a central temperature at 33,5°C.
172853|NCT02849561|Device|Synchronized Intermittent Mandatory Ventilation|Constant volume 6 ml/kg
172854|NCT02849561|Other|Electroencephalography|
172855|NCT02849561|Device|Pupillary light reflex surveillance|With Neurolight® device.
172856|NCT02849561|Device|Transcranial Doppler|Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
172857|NCT02849548|Drug|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
172858|NCT02849548|Other|placebo|Pill with inactive ingredients
172859|NCT02849535|Behavioral|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
172860|NCT02849522|Procedure|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.~The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.~NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
172861|NCT02849522|Procedure|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
172862|NCT02849522|Procedure|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
172863|NCT02849522|Procedure|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
172864|NCT02849509|Drug|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
172865|NCT02849509|Drug|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
172866|NCT02849496|Drug|Atezolizumab|Given IV
172867|NCT02849496|Drug|Olaparib|Given PO
172868|NCT02849496|Other|Questionnaire Administration|Ancillary studies
172869|NCT02849483|Drug|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
172870|NCT02849483|Drug|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
172871|NCT02849470|Procedure|Intradermal Injection in hair loss|Comparative Injection of Control (PRP & Acel) in hair loss; 2) Intradermal Injection in hair loss
172872|NCT02849470|Procedure|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
172873|NCT02849470|Procedure|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
172874|NCT02849470|Procedure|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
172875|NCT02849470|Procedure|MatriStem Matrix (ACell) - Current Standard of Care|
172876|NCT02849470|Procedure|HD-PRP (High Density Platelet Rich Plasma)|
172877|NCT02849470|Procedure|Emulsified AD-tSVF|
172878|NCT02849470|Procedure|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
172879|NCT02849457|Drug|Vigabatrin|Subjects randomized to vigabatrin in Arm A will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study (Arm B) and continue to be followed until 36 months of age.
172880|NCT02849457|Drug|Placebo|Subjects randomized to placebo in Arm A will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study (Arm B) and continue to be followed until 36 months of age.
172881|NCT02849444|Other|Anti-myeloma treatment at physician discretion|non Interventional Study
172882|NCT02849431|Behavioral|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
172883|NCT02849418|Drug|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
172884|NCT02849418|Drug|Placebo|Placebo injection contains sodium chloride (0.9 milligrams [mg]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
172885|NCT02849405|Device|MHRC: Metabolic Hyperspectral Retinal Camera|Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
172886|NCT02849392|Other|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
172887|NCT02849379|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
172888|NCT02849379|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
172889|NCT02849366|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
172890|NCT02849366|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
172891|NCT02849353|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
172892|NCT02849353|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
172893|NCT02849340|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
172894|NCT02849340|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
172895|NCT02849327|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
172896|NCT02849327|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
172897|NCT02849314|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
172898|NCT02849314|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
172899|NCT02849301|Device|Arabin cervical pessary|
172900|NCT02849288|Device|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
172901|NCT02849275|Other|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
172902|NCT02849275|Other|Probiotic Treatment|Probiotic treatment, consumed once daily, over 4-5 weeks.
172903|NCT02849262|Drug|Omiganan (CLS001) topical gel|
172904|NCT02849262|Drug|Vehicle topical gel|
172905|NCT02849249|Biological|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
172906|NCT02849236|Drug|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles"
172907|NCT02849236|Drug|Placebo|20 mL saline 0.9%
172908|NCT02849223|Device|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
172909|NCT02849223|Device|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
172910|NCT02849210|Biological|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
172911|NCT02849197|Procedure|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
172912|NCT02849184|Drug|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
172913|NCT02849184|Other|Placebo|Placebo once daily before bedtime.
172914|NCT02849171|Device|PET scan|
172915|NCT02849171|Radiation|C-Choline|
172916|NCT02849158|Other|Biopsy|Rectoscopy with biopsy
172917|NCT02849145|Biological|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
172918|NCT02849132|Drug|Entecavir|oral entecavir 0.5mg daily for 5 years
172919|NCT02849119|Procedure|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
172920|NCT02849106|Procedure|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
172921|NCT02849093|Other|Non-invasive OCT imaging|Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
172922|NCT02849080|Drug|semaglutide|Oral administration once-daily.
172923|NCT02849080|Drug|sitagliptin|Oral administration once-daily.
172924|NCT02849067|Other|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
172925|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
172926|NCT02849054|Device|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
172927|NCT02849054|Device|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
172928|NCT02849054|Device|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
172929|NCT02849054|Device|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
172930|NCT02849041|Device|medical imaging|Low-dose CT-scanner
172931|NCT02849041|Biological|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
172932|NCT02849041|Procedure|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
172933|NCT02849028|Behavioral|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
172934|NCT02849015|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
172935|NCT02849015|Biological|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
172936|NCT02849002|Device|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
172937|NCT02848989|Other|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
172938|NCT02848976|Other|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
172939|NCT02848963|Drug|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
172940|NCT02848950|Drug|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
172941|NCT02848937|Device|Bath with citrate|bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
172942|NCT02848937|Device|Bath with citrate and Ca_eq|bath with citrate and Ca_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
172943|NCT02848924|Other|No intervention|
172944|NCT02848911|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
172945|NCT02848898|Device|Equistasi|
172946|NCT02848898|Other|Placebo|
172947|NCT02848885|Other|Active TDCS|Participants will receive active tDCS stimulation.
172948|NCT02848885|Other|Sham TDCS|Participants will receive sham tDCS stimulation
172949|NCT02848859|Behavioral|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
172950|NCT02848859|Behavioral|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
172951|NCT02848846|Device|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.~During this phases the patient will perform different task requiring the use of the robotic hand."
172952|NCT02848833|Drug|JARDIANCE 10mg|T2DM with JARDIANCE 10mg
172953|NCT02848833|Drug|JARDIANCE 25mg|MT2DM with JARDIANCE 25mgax
172954|NCT02848820|Drug|Augmentin + Gentamicin|Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours
172955|NCT02848820|Procedure|Appendectomy|Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
172956|NCT02848807|Dietary Supplement|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
172957|NCT02848794|Drug|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
172958|NCT02848781|Device|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
172959|NCT02848781|Procedure|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
172960|NCT02848768|Drug|Sunitinib|
172961|NCT02848755|Device|Cranial ultrasonography|
172962|NCT02848742|Device|Dermal Cooling System|Dermal cryotherapy
172963|NCT02848729|Drug|Acetaminophen (APAP) tablets|
172964|NCT02848729|Drug|IV acetaminophen (APAP)|
172965|NCT02848729|Drug|IV morphine|
172966|NCT02848716|Procedure|Surgery followed with chemoradiation|"Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.~Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy."
173000|NCT02848443|Drug|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
173327|NCT02845908|Drug|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
172967|NCT02848716|Radiation|Standard chemoradiation|"patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.~Concurrent platinum-based chemotherapy will be given with definitive radiation therapy."
172968|NCT02848716|Radiation|chemoradiation|
172969|NCT02848703|Device|Magnetic Resonance Imaging (MRI)|
172970|NCT02848703|Device|phosphorus-31 Magnetic Resonance Spectroscopy|
172971|NCT02848703|Device|sodium-23 MRI|
172972|NCT02848690|Behavioral|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
172973|NCT02848690|Other|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
172974|NCT02848677|Behavioral|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
172975|NCT02848677|Behavioral|usual care|usual care of hypertensive patients.
172976|NCT02848664|Device|Dysphagia retraining with device|Patients used the device for 60 trials of retraining swallowing at home each day and also had the device turned on throughout the day in automatic mode to intermittently trigger every few minutes to trigger a swallow for saliva control
172977|NCT02848651|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit (up to approximately 3 years).
172978|NCT02848625|Other|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
172979|NCT02848612|Drug|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
172980|NCT02848599|Drug|morphine|
172981|NCT02848599|Drug|levobupivacaine|
172982|NCT02848586|Other|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
172983|NCT02848586|Behavioral|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
172984|NCT02848586|Other|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
172985|NCT02848560|Drug|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
172986|NCT02848547|Behavioral|Text Messaging via Short Message Service|
172987|NCT02848534|Biological|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
172988|NCT02848508|Drug|Metformin|
172989|NCT02848495|Genetic|Non-Interventional|
172990|NCT02848482|Device|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
172991|NCT02848482|Procedure|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
172992|NCT02848482|Drug|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
172993|NCT02848469|Dietary Supplement|1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid|
172994|NCT02848456|Procedure|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
172995|NCT02848456|Procedure|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
172996|NCT02848456|Procedure|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
172997|NCT02848443|Drug|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
172998|NCT02848443|Drug|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
172999|NCT02848443|Drug|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
173328|NCT02845908|Drug|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
173001|NCT02848430|Dietary Supplement|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
173002|NCT02848417|Drug|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
173003|NCT02848417|Drug|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
173004|NCT02848417|Other|Placebo|"Placebo liquid 120 ml per/ bottle~Placebo capsules 60 capsules per bottle 400 mg /cap~With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
173005|NCT02848404|Device|Categorical Language Fluency Smartphone Application|4 weeks' training
173006|NCT02848391|Other|Environmental|hypobaric flight simulation
173007|NCT02848365|Device|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
173008|NCT02848352|Other|Placebo nasal spray|
173009|NCT02848352|Other|Film Sequence|
173010|NCT02848339|Drug|aspirin|aspirin desensitization
173011|NCT02848326|Drug|Atogepant|Atogepant capsule.
173012|NCT02848326|Drug|Placebo-matching Atogepant|Placebo-matching atogepant capsule.
173013|NCT02848313|Drug|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
173014|NCT02848300|Drug|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
173015|NCT02848300|Drug|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
173016|NCT02848287|Drug|normal saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
173017|NCT02848287|Drug|ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
173018|NCT02848261|Behavioral|Developmental Demands|Education and training related to use of CGM in this age group
173019|NCT02848261|Behavioral|Distress Reduction|Education and training on reducing distress
173020|NCT02848261|Behavioral|Remote Monitoring|Education and training on the use of remote monitoring
173021|NCT02848261|Behavioral|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
173022|NCT02848261|Behavioral|No intervention|No intervention - serves as the control group
173023|NCT02848248|Drug|SGN-CD123A|Intravenous infusion in 3-week cycles
173024|NCT02848235|Other|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
173025|NCT02848222|Device|Bruder Moist Heat Compress|
173026|NCT02848222|Other|Washcloth|
173027|NCT02848209|Procedure|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
173028|NCT02848209|Procedure|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
173029|NCT02848209|Procedure|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
173030|NCT02848196|Radiation|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
173031|NCT02848183|Drug|Cytarabine|
173032|NCT02848183|Drug|Idarubicin|
173033|NCT02848183|Drug|Mitoxantrone|
173034|NCT02848183|Drug|Etoposide|
173035|NCT02848183|Procedure|Hematopoietic stem cell transplantation|
173036|NCT02848170|Drug|CS-3150|CS-3150 2.5mg, oral
173037|NCT02848170|Drug|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
173038|NCT02848157|Drug|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
173039|NCT02848157|Drug|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
173040|NCT02848157|Drug|Ropivacaine|
173041|NCT02848144|Other|blood samples|
173042|NCT02848144|Other|Collection of nosocomial infections|
173043|NCT02848131|Drug|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
173044|NCT02848131|Drug|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
173045|NCT02848118|Device|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
173046|NCT02848118|Other|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
173047|NCT02848105|Drug|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
173329|NCT02845908|Drug|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
174114|NCT02839707|Drug|Atezolizumab|Given IV
173048|NCT02848092|Behavioral|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
173049|NCT02848092|Other|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
173050|NCT02848079|Drug|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
173051|NCT02848066|Procedure|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
173052|NCT02848053|Other|no intervention|
173053|NCT02848040|Other|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
173054|NCT02848027|Biological|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
173055|NCT02848014|Behavioral|Writing task|
173056|NCT02848001|Drug|CC-90009|CC-90009
173057|NCT02847988|Device|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
173058|NCT02847988|Device|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
173059|NCT02847975|Dietary Supplement|Sodium nitrate|Sodium nitrate will be ingested orally
173060|NCT02847962|Other|Corn Soy Blend Plus (CSB+)|
173061|NCT02847962|Other|Corn Soy Blend 14 (CSB14)|
173062|NCT02847962|Other|White Sorghum Cowpea Blend Variety 1|
173063|NCT02847962|Other|White Sorghum Cowpea Blend Variety 2|
173064|NCT02847962|Other|Red Sorghum Cowpea Blend|
173065|NCT02847962|Other|White Sorghum Soy Blend|
173066|NCT02847949|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein
173067|NCT02847936|Procedure|vicryl plus suture|episiotomy with triclosan-coated sutures
173068|NCT02847936|Procedure|vicryl suture|episiotomy with non antibacterial coated suture
173069|NCT02847923|Other|Presentation of alternative communication application|At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.
173070|NCT02847923|Other|Familiarization with the software interface|At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it
173071|NCT02847923|Other|Test of the software|"Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option."
173072|NCT02847923|Other|Answer the questionnaire|After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
173073|NCT02847910|Procedure|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
173074|NCT02847910|Procedure|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
173075|NCT02847897|Device|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
173076|NCT02847884|Biological|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
173077|NCT02847871|Behavioral|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:~Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.~Perform a nutritional assessment by a dietician followed by appropriate care management.~Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.~At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;~Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
173078|NCT02847858|Behavioral|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
173079|NCT02847845|Dietary Supplement|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
173330|NCT02845895|Other|Caregiver dedicated|Organization of nutrition screening with the help of a caregiver
173080|NCT02847845|Dietary Supplement|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
173081|NCT02847832|Other|Standardized transvaginal ultrasound examination|
173082|NCT02847819|Device|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
173083|NCT02847806|Biological|Estradiol (Insulin sensitivity)|
173084|NCT02847806|Biological|Testosterone (Insulin sensitivity)|
173085|NCT02847793|Behavioral|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
173086|NCT02847793|Behavioral|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
173087|NCT02847780|Device|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
173088|NCT02847780|Device|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
173089|NCT02847767|Procedure|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
173090|NCT02847754|Other|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
173091|NCT02847741|Other|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
173092|NCT02847715|Device|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
173093|NCT02847702|Drug|VM902A 200-mg Capsules|Taken orally with food twice daily
173094|NCT02847702|Drug|VM902A 400-mg Capsules|Taken orally with food twice daily
173095|NCT02847702|Drug|Naproxen 500-mg Capsules|Taken orally with food twice daily
173096|NCT02847702|Drug|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
173097|NCT02847689|Behavioral|Language Treatment|Recording of a mother's voice reading a children's storybook.
173098|NCT02847689|Behavioral|Control Treatment|Standard of Care
173099|NCT02847676|Procedure|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
173100|NCT02847663|Device|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
173101|NCT02847663|Other|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
173102|NCT02847650|Drug|Placebo|
173103|NCT02847650|Drug|PF-06649751|
173104|NCT02847637|Drug|Emicizumab|Participants will receive emicizumab prophylaxis at the specified dose subcutaneously until the end of the study (maximum up to 2 years).
173105|NCT02847624|Drug|tolvaptan|
173106|NCT02847611|Device|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
173107|NCT02847598|Drug|BIIB059|Administered as specified in the treatment arm.
173108|NCT02847598|Drug|Placebo|Administered as specified in the treatment arm.
173109|NCT02847585|Dietary Supplement|Water-soluble Ubiquinol|10 mg/kg BW/d, by oral drops
173110|NCT02847572|Procedure|Cataract Surgery|All patients wil be having intraocular lens surgery
173111|NCT02847559|Biological|Bevacizumab|Given IV
173112|NCT02847559|Procedure|Electric Field Therapy|Undergo electric field therapy using Optune device
173113|NCT02847559|Device|NovoTTF-200A Device|Undergo electric field therapy using Optune device
173114|NCT02847559|Procedure|Quality-of-Life Assessment|Ancillary studies
173115|NCT02847546|Device|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
173116|NCT02847533|Procedure|blood sample|blood sample for concentration levels of inflammatory markers
173117|NCT02847533|Behavioral|psychometric scales|Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
173118|NCT02847520|Behavioral|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
173119|NCT02847494|Drug|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
173120|NCT02847494|Drug|Dexamethasone|dexamethasone 10mg intramuscular injection
173121|NCT02847494|Drug|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
173122|NCT02847481|Procedure|fecal microbiota transplantation|fecal microbiota transplantation
173123|NCT02847481|Drug|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
173124|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
173125|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
173331|NCT02845895|Other|Classic strategy|Classic organization with the training of the department team
173126|NCT02847468|Other|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
173127|NCT02847468|Other|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
173128|NCT02847455|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
173129|NCT02847455|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
173130|NCT02847455|Drug|10 mg Rabeprazole|one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
173131|NCT02847442|Drug|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
173132|NCT02847442|Drug|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
173133|NCT02847429|Drug|Crenolanib|
173134|NCT02847429|Drug|Placebo|
173135|NCT02847416|Device|BreatheMAX breathing device|
173136|NCT02847403|Drug|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
173137|NCT02847403|Other|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
173138|NCT02847390|Other|Education intervention|The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes superuser educational curriculum focused on delivering safe, evidence-based diabetes care in the hospital setting. The physician educational curriculum will consist of 10 case-based modules taught to internal medicine residents at two academic hospitals and taught to hospitalists at two academic hospitals and one community hospital. The nursing educational curriculum will consistent of 12 case-based modules taught to unit-based nurses at two academic hospitals and one community hospital. These educational interventions will be delivered over a 6-month time frame from August 2016-April 2017.
173139|NCT02847377|Other|Injection of [18F]-ODS2004436 radiotracer|
173140|NCT02847364|Dietary Supplement|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
173141|NCT02847351|Dietary Supplement|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).~Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
173142|NCT02847338|Drug|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
173143|NCT02847338|Drug|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
173144|NCT02847338|Drug|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
173145|NCT02847338|Drug|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
173146|NCT02847325|Drug|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
173147|NCT02847325|Drug|Placebo capsules|Placebo capsules
173148|NCT02847312|Other|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
173149|NCT02847312|Other|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
173150|NCT02847312|Other|Control|Control are matched with energy and insoluable fibre.
173151|NCT02847299|Device|"increase of cough peak flow (Astral ventilator)"|instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
173152|NCT02847286|Drug|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
173153|NCT02847286|Drug|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
173154|NCT02847286|Drug|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
173155|NCT02847260|Drug|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
173156|NCT02847247|Drug|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
173226|NCT02846740|Behavioral|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
173372|NCT02845596|Drug|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
286540|NCT02018601|Procedure|BRILMA|
173157|NCT02847208|Other|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
173158|NCT02847195|Device|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
173159|NCT02847182|Biological|Cord Blood Infusion|
173160|NCT02847182|Biological|Placebo|
173161|NCT02847169|Device|filcon IV1 toric lens|toric contact lens
173162|NCT02847169|Device|ocufilcon D toric lens|toric contact lens
173163|NCT02847156|Other|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
173164|NCT02847143|Drug|nasal oxytocin or placebo|nasal administration of oxytocin or palcebo 45 min befor fMRI session
173165|NCT02847143|Device|fMRI|FMRI during emotional image visualization
173166|NCT02847143|Behavioral|Attachement scale interview (ASI)|this scale is used to determine the attachement style of each participant
173167|NCT02847143|Behavioral|psychometric scales|self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
173168|NCT02847130|Other|Informational Intervention|Participate in focus group
173169|NCT02847130|Other|Interview|Undergo one-on-one interviews
173170|NCT02847130|Other|Medical Chart Review|Review of medical chart
173171|NCT02847130|Other|Questionnaire Administration|Ancillary studies
173172|NCT02847117|Other|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
173173|NCT02847104|Other|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
173174|NCT02847104|Other|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
173175|NCT02847091|Drug|Ipragliflozin|Oral administration, 50mg once daily
173176|NCT02847091|Drug|Insulin|Patients are receiving insulin therapy from at least 12 weeks before Visit 1 (is allowed ±10% dose modification if clinically needed, and is reduced within a 20% to 40% range at Visit 1 and then is controlled up to Visit 8 based on criteria of this study).
173177|NCT02847078|Device|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
173178|NCT02847078|Device|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
173179|NCT02847052|Other|Non interventional study|
173180|NCT02847039|Genetic|Blood samples|Blood samples at baseline.
173181|NCT02847026|Biological|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
173182|NCT02847026|Biological|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
173183|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
173184|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
173185|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
173186|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
173187|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
173188|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
173189|NCT02847013|Drug|TAP block w Liposomal bupivacaine|TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)
173190|NCT02847013|Procedure|TAP block w normal saline|TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)
174115|NCT02839707|Biological|Bevacizumab|Given IV
173191|NCT02847000|Drug|Tetrahydrouridine|"Starting dose is by weight:~THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
173192|NCT02847000|Drug|Decitabine|"Starting dose is by weight:~DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested ~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules.~Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
173193|NCT02846987|Drug|Abemaciclib|
173194|NCT02846974|Device|Pulse oximeter|A pulse oximeter will be used for calibration
173195|NCT02846948|Other|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
173196|NCT02846935|Drug|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested ~60 minutes after THU capsules.
173197|NCT02846935|Drug|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
173198|NCT02846909|Drug|Progesterone|400mg progesterone pessaries
173199|NCT02846883|Biological|MSC's|Intravenous infusion of 1 million allogeneic MSCs/kg.
173200|NCT02846883|Biological|MSC's|Intravenous infusion of 3 million allogeneic MSCs/kg
173201|NCT02846883|Drug|Placebo|Intravenous infusion of Plasmalyte A (placebo)
173202|NCT02846870|Other|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
173203|NCT02846870|Other|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
173204|NCT02846857|Other|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
173205|NCT02846857|Other|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
173206|NCT02846857|Other|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
173207|NCT02846857|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
173208|NCT02846857|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
173209|NCT02846857|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
173210|NCT02846857|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
173211|NCT02846831|Other|12-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 12 days.~Participants will have been previously shown how to use the study insulin pump."
173212|NCT02846831|Other|12-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 12 days."
173213|NCT02846831|Device|Insulin pump|Tandem Diabetes Care
173214|NCT02846831|Device|Continuous glucose monitoring system|Dexcom G5 Platinum
173215|NCT02846831|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
173216|NCT02846818|Procedure|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
173217|NCT02846805|Procedure|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
173218|NCT02846792|Biological|Nivolumab|Given IV
173219|NCT02846792|Drug|Plinabulin|Given IV
173220|NCT02846779|Other|Low intensity|Low intensity telepharmacy outreach
173221|NCT02846779|Other|Moderate intensity|Moderate intensity telepharmacy outreach
173222|NCT02846779|Other|High intensity|High intensity telepharmacy outreach
173223|NCT02846766|Drug|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
173224|NCT02846753|Procedure|trans catheter heart valve replacement|trans catheter heart valve replacement
173225|NCT02846740|Device|Alpha-Stim®.|cranial electrical stimulation
173227|NCT02846727|Device|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
173228|NCT02846714|Behavioral|FLARE|
173229|NCT02846701|Drug|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
173230|NCT02846675|Biological|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
173231|NCT02846675|Biological|Placebo|a Placebo treatment without SVF cells
173232|NCT02846662|Behavioral|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
173233|NCT02846649|Behavioral|PIER|Daily text message queries with tailored support
173234|NCT02846623|Drug|Atezolizumab|Given IV
173235|NCT02846623|Other|Laboratory Biomarker Analysis|Correlative studies
173236|NCT02846623|Biological|Obinutuzumab|Given IV
173237|NCT02846623|Drug|Venetoclax|Given PO
173238|NCT02846597|Procedure|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
173239|NCT02846584|Biological|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
173240|NCT02846571|Biological|Human Pancreatic Islet Transplantation|Human Pancreatic Islet Transplantation in the Eye Anterior Chamber of legally blind Diabetic Patients with a Stable Kidney Transplant
173241|NCT02846558|Other|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
173242|NCT02846558|Behavioral|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
173243|NCT02846558|Device|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
173244|NCT02846545|Biological|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
173245|NCT02846545|Biological|Placebo|Matching Placebo to golimumab
173246|NCT02846532|Drug|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to <8 kilogram (kg) will receive 2.2 milligram (mg); 8 to <10 kg will receive 3.2 mg; 10 to<12 kg will receive 3.4 mg; 12 to <20 will receive 4.0 mg and 20 to <30 will receive 5.0 mg.
173247|NCT02846532|Drug|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
173248|NCT02846519|Drug|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
173249|NCT02846519|Drug|Rifampin|2 capsules (300 mg each) of rifampin.
173250|NCT02846506|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
173251|NCT02846506|Drug|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
173252|NCT02846506|Drug|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
173253|NCT02846506|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
173254|NCT02846493|Drug|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
173255|NCT02846493|Drug|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
173256|NCT02846480|Other|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
173257|NCT02846480|Other|surgical treatment|Surgical correction of POP.
286802|NCT02016482|Other|Placebo|
173258|NCT02846480|Other|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
173259|NCT02846467|Other|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
173260|NCT02846467|Other|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
173261|NCT02846454|Other|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
173262|NCT02846454|Other|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
173263|NCT02846441|Procedure|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
173264|NCT02846428|Drug|5-Fluorouracil|5-FU will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
173265|NCT02846428|Drug|Capecitabine|Capecitabine will be administered at 900 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
173266|NCT02846428|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
173267|NCT02846428|Drug|Docetaxel|Docetaxel will be administered at 100 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
173268|NCT02846428|Drug|Epirubicin|Epirubicin will be administered at 100 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
173269|NCT02846415|Behavioral|Play Intervention for Dementia|"8 weekly session, 45-75 minutes each~Play with toys~Sessions will be facilitated by a play specialist, trained play assistants, and centre staff."
173270|NCT02846402|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
173271|NCT02846389|Other|Moderate Exercise|Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
173272|NCT02846376|Drug|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
173273|NCT02846376|Drug|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
173274|NCT02846363|Other|public awareness campaign|"The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:~3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately~A leaflet on stroke will be created~3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page~Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).~A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)~On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently"
173275|NCT02846350|Behavioral|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
173276|NCT02846337|Procedure|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.~Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.~Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
173277|NCT02846337|Procedure|ENHANCED MEDICAL TREATMENT|"Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample~Medical care adjustment in order to apply European and American guidance for chronic heart failure care~Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed~Physical rehabilitation suggestions by a physiologist~Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
173278|NCT02846324|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
173279|NCT02846324|Drug|Placebo|Placebo capsules
173280|NCT02846311|Device|Flu Test|
173281|NCT02846298|Biological|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
173282|NCT02846285|Other|No intervention|
175701|NCT02827721|Device|multiple breath washout test|
173284|NCT02846246|Other|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
173285|NCT02846246|Other|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
173286|NCT02846233|Drug|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
173287|NCT02846233|Drug|basal insulin|The participant will continue with the basal insulin.
173288|NCT02846233|Drug|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
173289|NCT02846233|Drug|Metformin|The participant will continue with metformin.
173290|NCT02846220|Behavioral|Overcoming Immunity to Change health coaching|
173291|NCT02846207|Drug|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
173292|NCT02846207|Drug|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
173293|NCT02846207|Drug|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
173294|NCT02846207|Drug|placebo|Dextrin,oral administration, twice one day, for 12weeks.
173295|NCT02846194|Behavioral|brief guided imagery|
173296|NCT02846181|Drug|[14C]-SK-1405|
173297|NCT02846155|Other|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
173298|NCT02846155|Drug|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
173299|NCT02846155|Drug|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
173300|NCT02846142|Drug|PTI-428|
173301|NCT02846142|Other|Placebo|
173302|NCT02846142|Drug|ethinyl estradiol and levonorgestrel|
173303|NCT02846116|Other|Prosthetic crown|
173304|NCT02846103|Other|Biological samples|blood and tumor tissue samples
173305|NCT02846090|Drug|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
173306|NCT02846077|Other|No intervention. Observation only|No intervention. Observation only
173307|NCT02846064|Procedure|Autograft of cryopreserved ovarian tissue|Orthotopic transplantation
173308|NCT02846051|Procedure|venous mapping|clinical examination + doppler echo
173309|NCT02846025|Dietary Supplement|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
173310|NCT02846025|Dietary Supplement|Folate and placebo|rich diet aministracao folate and placebo
173311|NCT02846025|Dietary Supplement|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
173312|NCT02846012|Other|CSCM2|
173313|NCT02845999|Biological|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10^6 ; 8.10^6 and 12.10^6 cells/kg of recipient body weight
173314|NCT02845999|Biological|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
173315|NCT02845999|Drug|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
173316|NCT02845999|Drug|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
173317|NCT02845999|Drug|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
173318|NCT02845986|Procedure|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
173319|NCT02845986|Drug|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
173320|NCT02845973|Biological|gut microbiota|
173321|NCT02845960|Behavioral|rapid recovery|rapid recovery
173322|NCT02845947|Behavioral|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
173323|NCT02845934|Other|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
173324|NCT02845921|Other|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
173325|NCT02845921|Other|leg wrapping|Esmarch bandage is used to wrap each lower limb
173332|NCT02845882|Drug|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
173333|NCT02845882|Drug|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
173334|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
173335|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
173336|NCT02845882|Drug|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
173337|NCT02845882|Drug|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
173338|NCT02845882|Drug|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
173339|NCT02845869|Device|THOR Laser LX2 System|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
173340|NCT02845869|Device|Sham Therapy|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
173341|NCT02845856|Drug|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
173342|NCT02845856|Biological|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
173343|NCT02845843|Drug|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
173344|NCT02845843|Drug|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
173345|NCT02845817|Other|Qualitative research|Semi-structured interviews
173346|NCT02845804|Device|Alpine|
173347|NCT02845791|Behavioral|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
173348|NCT02845778|Drug|Melatonin|Each sachet contains 0.5 g
173349|NCT02845765|Device|Dynamic Vessel Analyzer (DVA)|
173350|NCT02845765|Drug|Phosphodiesterase type 5 Inhibitor (PDE5I)|
173351|NCT02845752|Drug|Stiolto Respimat|Oral inhalation spray
173352|NCT02845752|Drug|Placebo Respimat|Oral inhalation spray
173353|NCT02845739|Other|Kidney transplanted patients|
173354|NCT02845726|Other|Stent examination, urinary analysis, USSQ questionnaire|
173355|NCT02845713|Drug|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
173356|NCT02845700|Behavioral|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
173357|NCT02845700|Behavioral|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
173358|NCT02845674|Drug|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
173359|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
173360|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
173361|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
173362|NCT02845648|Drug|anticholinergic|Initial anticholinergic therapy to all patients
173363|NCT02845635|Other|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
173364|NCT02845622|Dietary Supplement|Hazelnut|This dietary supplement contains 30 g of hazelnut.
173365|NCT02845622|Dietary Supplement|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
173366|NCT02845622|Dietary Supplement|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
173367|NCT02845622|Dietary Supplement|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
173368|NCT02845622|Dietary Supplement|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
173369|NCT02845609|Drug|Sialic Acid-Extended Release|Oral drug of Sialic acid
173370|NCT02845596|Drug|cyclosporine|cyclosporine
173371|NCT02845596|Procedure|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
173373|NCT02845596|Drug|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
173374|NCT02845596|Drug|methotrexate|methotrexate
173375|NCT02845596|Drug|fludarabine|fludarabine
173376|NCT02845596|Drug|cyclophosphamide|cyclophosphamide
173377|NCT02845596|Radiation|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
173378|NCT02845596|Procedure|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
173379|NCT02845570|Other|68Ga-DOTANOC PET/MRI|
173380|NCT02845570|Other|18F-FDG PET/MRI|
173381|NCT02845557|Other|OGTT and IVGTT tests|
173382|NCT02845544|Other|Pilates-based exercises|
173383|NCT02845531|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
173384|NCT02845531|Drug|Optimal Medical Therapy|
173385|NCT02845518|Procedure|Cardiac magnetic resonance imaging|"RV contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.~Right atrial pressure, pulmonary artery pressures and cardiac index will be measured with RHC as currently recommended, therefore performing RHC will not be considered as an intervention but as a routine practice"
173386|NCT02845505|Other|Intravascular Ultrasound, coronary computed tomography angiography|
173387|NCT02845492|Other|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
173388|NCT02845492|Other|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
173389|NCT02845479|Other|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
173390|NCT02845466|Biological|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
173391|NCT02845466|Device|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
173392|NCT02845466|Device|Placebo Dressing|Inactive wound dressing.
173393|NCT02845453|Drug|Quetiapine|Participants will be randomly assigned Quetiapine and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
173394|NCT02845453|Drug|Placebo|Participants will be randomly assigned to placebo and will be titrated to the maximum daily dose over three weeks and then enter a dose maintenance phase for weeks 4 through 8 of the study.
173395|NCT02845440|Other|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
173396|NCT02845440|Other|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
173397|NCT02845440|Other|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
173398|NCT02845427|Device|closed suction drain|using closed suction drain system postoperative
173399|NCT02845427|Procedure|no suction drain|the surgical wound will be closed with no suction drain
173400|NCT02845414|Drug|CD133KDEL (dCD133KDEL)|Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
173401|NCT02845401|Other|Stop NA therapy|Cases will stop antiviral therapy
173402|NCT02845388|Drug|Sildenafil citrate|
173403|NCT02845388|Drug|estradiol valerate|
173404|NCT02845375|Drug|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
173405|NCT02845375|Drug|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
173406|NCT02845375|Drug|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
173407|NCT02845362|Other|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
173408|NCT02845349|Drug|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
173409|NCT02845349|Drug|Placebo|A placebo comparator will be used in one subset of patients.
173410|NCT02845336|Drug|Celecoxib|celecoxib 100mg PO twice per day for 3 months
173411|NCT02845336|Drug|artificial tears|Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
173412|NCT02845323|Drug|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
173413|NCT02845323|Drug|Nivolumab monotherapy|Two cycles of Nivolumab alone
289227|NCT01996657|Drug|Warfarin|
173414|NCT02845310|Procedure|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV < 10% - MAP >65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP > 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
173415|NCT02845310|Procedure|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
173416|NCT02845297|Drug|pembrolizumab|Intravenous pembrolizumab
173417|NCT02845297|Drug|Azacitadine|Intravenous or subcutaneous
173418|NCT02845284|Behavioral|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
173419|NCT02845284|Behavioral|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
173420|NCT02845271|Drug|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
173421|NCT02845271|Drug|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
173422|NCT02845271|Drug|acetaminophen or paracetamol|"Pharmaceutical form: tablet~Route of administration: oral"
173423|NCT02845271|Drug|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule~Route of administration: oral"
173424|NCT02845271|Drug|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet~Route of administration: oral"
173425|NCT02845258|Procedure|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):~This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.~In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
173426|NCT02845245|Other|3D printed plastic model prototype|
173427|NCT02845245|Other|3D CT scan|
173428|NCT02845245|Other|Plain film radiographs|
173429|NCT02845232|Other|Transfusion|The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
173430|NCT02845219|Drug|semaglutide|Oral administration once daily alone or together with oral contraceptive.
173431|NCT02845219|Drug|SNAC|Oral administration once daily together with oral contraceptive.
173432|NCT02845219|Drug|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
173433|NCT02845206|Procedure|Patient specific cutting blocks|'MyKnee' Instrumentation
173434|NCT02845206|Procedure|Conventional cutting blocks|Standard Instrumentation
173435|NCT02845193|Device|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
173436|NCT02845193|Device|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
173437|NCT02845193|Device|CAD/NAM|computer aided design NAM
173438|NCT02845180|Procedure|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
173439|NCT02845167|Other|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
173440|NCT02845154|Other|bolus purge|complete and uninterrupted purge
173441|NCT02845154|Other|Intermittent purge|intermittent portal purge
173442|NCT02845141|Procedure|Actifuse|bone tunnel filled with Actifuse
173443|NCT02845141|Procedure|bone graft|bone graft to fill bone tunnel
173444|NCT02845115|Device|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
173445|NCT02845115|Device|optimized implantation with laser velocimetry|
173446|NCT02845102|Other|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
173447|NCT02845076|Other|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
173448|NCT02845063|Behavioral|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
173449|NCT02845063|Behavioral|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
173450|NCT02845063|Genetic|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
173451|NCT02845050|Drug|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
173452|NCT02845050|Drug|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:~Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion~Cisplatin (70 mg/m²) on Day 2, every 21 days~4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
173453|NCT02845050|Procedure|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
173454|NCT02845037|Drug|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
173455|NCT02845037|Drug|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
173456|NCT02845024|Drug|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
173457|NCT02845024|Drug|placebo Group|Oral placebo was taken within 15 days
173458|NCT02845011|Device|Audiovisual compression feedback|The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a handheld device consisting of three components. The rescuer-side has a red palm-sized push-button with a pictogram illustrating proper use. The center unit is composed of a stable plastic base containing an arrangement of springs, and the patient-side consists of liquid-absorbent polyurethane foam. Application of 400 ± 30 Newtons of force results in an audible click alerting the rescuer to cease compression, and an additional click on decompression alerts the rescuer to resume compression.
173459|NCT02845011|Other|Standard Manual Chest Compression|Cardiopulmonary resuscitation according to published international guidelines.
173460|NCT02844998|Behavioral|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
173461|NCT02844998|Drug|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
173462|NCT02844985|Other|No Intervention|
173463|NCT02844946|Behavioral|Acceptance and Commitment Therapy|Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
173464|NCT02844933|Drug|Cannabidiol|Oral solution
173465|NCT02844933|Drug|Placebo|Matching oral solution
173466|NCT02844920|Device|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
173467|NCT02844907|Drug|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
173468|NCT02844907|Drug|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
173469|NCT02844907|Other|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
173470|NCT02844894|Drug|Dexmedetomidine|
173471|NCT02844894|Drug|Esmolol|
173472|NCT02844894|Drug|Placebo|normal saline
173473|NCT02844881|Drug|Apatinib|Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
173474|NCT02844881|Biological|MASCT|Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
173475|NCT02844868|Device|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
173476|NCT02844868|Device|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
173477|NCT02844855|Behavioral|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
173478|NCT02844842|Biological|Allergovac Poliplus|
173479|NCT02844829|Other|Prostate MRI|MRI of the prostate prior to prostate biobsy
173480|NCT02844816|Drug|Atezolizumab|Given IV
173481|NCT02844803|Drug|Combination of Metformin + S. Baicalensis|the combination therapy for 8 weeks
173482|NCT02844803|Drug|Combination of Metformin + Placebo|the metformin single therapy for 8 weeks
173483|NCT02844790|Drug|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
173484|NCT02844777|Drug|Placebo|200 mg applied once-daily for 28 days
173485|NCT02844777|Drug|5% VDA-1102|200 mg applied once-daily for 28 days
173486|NCT02844777|Drug|10% VDA-1102|200 mg applied once-daily for 28 days
173516|NCT02844556|Other|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
292488|NCT01971385|Drug|Placebo solution|
173487|NCT02844764|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Day 7, 14 and 30 [PRP]
173488|NCT02844751|Biological|[StroMed + platelet rich plasma (PRP)]|[Day 0] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
173489|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
173490|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
173491|NCT02844738|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Days 7 and 14 [PRP]
173492|NCT02844725|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
173493|NCT02844725|Drug|Placebo|water for injection
173494|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
173495|NCT02844699|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
173496|NCT02844699|Drug|Placebo|5% infusion solution of dextrose (glucose)
173497|NCT02844686|Other|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
173498|NCT02844673|Drug|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
173499|NCT02844673|Device|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
173500|NCT02844660|Biological|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
173501|NCT02844660|Other|Standard of Care|moist wound therapy and offloading
173502|NCT02844647|Other|Hyperpolarized Pyruvate (13C)|MRI contrast agent
173503|NCT02844634|Drug|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
173504|NCT02844634|Drug|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
173505|NCT02844634|Drug|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
173506|NCT02844621|Drug|Omeprazole|20mg orally once daily
173507|NCT02844608|Other|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
173508|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
173509|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.~Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
173510|NCT02844582|Drug|Cabazitaxel|Given IV
173511|NCT02844582|Drug|Prednisone|Given PO
173512|NCT02844569|Device|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
173513|NCT02844569|Device|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
173514|NCT02844569|Device|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
173515|NCT02844556|Procedure|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
175702|NCT02827721|Device|body plethysmography|
173517|NCT02844543|Device|EYE-SYNC eye-tracking device|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
173518|NCT02844543|Other|SCAT-3|The Symptom subtest of SCAT-3 assessment tool will be administered to participants.
173519|NCT02844543|Device|Desktop Eye-Tracker|Eye movements are recorded with an eye tracking system (Desktop Eye-Tracker, Eyelink CR, SR Research) with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
173520|NCT02844530|Drug|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.~A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).~From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
173521|NCT02844530|Drug|chemotherapy/ immunotherapy|
173522|NCT02844517|Device|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
173523|NCT02844504|Behavioral|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
173524|NCT02844504|Behavioral|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
173525|NCT02844491|Other|additional biological samples|blood and tissue samples
173526|NCT02844478|Behavioral|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
173527|NCT02844478|Behavioral|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
173528|NCT02844465|Device|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
173529|NCT02844452|Device|Acupuncture|Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
173530|NCT02844452|Device|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
173531|NCT02844439|Drug|Tesevatinib|
173532|NCT02844426|Drug|bifid triple viable capsule and pectin|
173533|NCT02844426|Drug|maltodextrin|
173534|NCT02844413|Other|aerobic interval training|In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
173535|NCT02844400|Device|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
173536|NCT02844400|Other|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
173537|NCT02844387|Dietary Supplement|L-arginine hydrochloride solution|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
173538|NCT02844387|Other|Placebo|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
173539|NCT02844374|Other|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
173540|NCT02844361|Other|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
173541|NCT02844361|Other|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
173542|NCT02844348|Other|Hypnosis session|
173543|NCT02844335|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
173544|NCT02844335|Biological|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
173545|NCT02844322|Drug|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
173546|NCT02844322|Drug|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
173547|NCT02844309|Drug|Thalidomide|thalidomide 50-150 mg per night
173548|NCT02844296|Behavioral|Video about exercise|Video about short-bout exercise will be played for the participants.
173549|NCT02844296|Behavioral|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
173550|NCT02844296|Behavioral|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
173551|NCT02844296|Behavioral|Video about diet|Video about healthy diet will be played for the participants.
173552|NCT02844296|Behavioral|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
173553|NCT02844296|Behavioral|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
173554|NCT02844283|Drug|Ad-HGF|
173555|NCT02844283|Other|0.9% NaCl|
173556|NCT02844270|Device|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
173557|NCT02844244|Behavioral|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
173558|NCT02844231|Other|Single-photon emission computed tomography|
173559|NCT02844218|Other|Age of patient|"Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~Improvement of Treatments Over Time~Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)"
173560|NCT02844205|Other|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
173561|NCT02844179|Drug|HTBZ|
173562|NCT02844166|Other|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
173563|NCT02844166|Other|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
173564|NCT02844153|Other|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
173565|NCT02844140|Procedure|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
173566|NCT02844127|Procedure|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
173567|NCT02844114|Drug|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
173568|NCT02844114|Drug|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
173569|NCT02844114|Drug|Chemotherapy|iv.30 minutes
173570|NCT02844101|Device|GT3X Actigraph accelerometer.|
173571|NCT02844088|Other|Meningococcus C conjugate vaccine|
173572|NCT02844075|Drug|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.~Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.~Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
173573|NCT02844062|Biological|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
173574|NCT02844062|Drug|cyclophosphamide|250 mg/m^2 d1-3
173575|NCT02844062|Drug|Fludarabine|25mg/m^2 d1-3
173576|NCT02844049|Device|Deep Brain Stimulation|surgical procedure
173577|NCT02844036|Procedure|Percutaneous angioplasty|
173578|NCT02844036|Procedure|Balloon angioplasty|
173579|NCT02844036|Procedure|Right heart catheterization|
173580|NCT02844036|Procedure|Echocardiography|
173581|NCT02844036|Other|A six-minute walking test|
173582|NCT02844036|Procedure|Functional respiratory investigations|
173583|NCT02844036|Procedure|Pulmonary tomography or pulmonary angiography|
173584|NCT02844036|Other|Biological parameters|
173585|NCT02844023|Behavioral|Clinical evaluation|With questionnaire.
175703|NCT02827708|Drug|semaglutide|Oral administration once daily.
173586|NCT02844023|Other|Paraclinical evaluation|Symptom inflammatory, biomarkers.
173587|NCT02844023|Device|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
173588|NCT02844023|Other|Ophthalmologic examination|
173589|NCT02844023|Biological|Dosage of biomarkers|Control patients.
173590|NCT02844010|Other|weighing|
173591|NCT02843997|Genetic|Endophenotype and sequencing|Draw an endophenotype and genetic study
173592|NCT02843984|Drug|Lactoferrin|
173593|NCT02843971|Device|Intraocular pressure measurement with the Sensimed triggerfish Device|
173594|NCT02843958|Device|HEMOPTIC|
173595|NCT02843945|Device|Directional Brachytherapy Source Implant|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
173596|NCT02843932|Other|functional brain MRI|functional imagery during motor-perception tasks
173597|NCT02843919|Other|Electroencephalography and Electrocardiography|
173598|NCT02843906|Procedure|Lombar Punction|cerebrospinal fluid testing at screening and M36
173599|NCT02843906|Radiation|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
173600|NCT02843906|Radiation|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
173601|NCT02843906|Other|Psychiatric tests|
173602|NCT02843906|Other|Neuropsychological Tests|done at screening, M12, M24 and M36
173603|NCT02843906|Genetic|Apolipoprotein (ApoE) detection|ApoE detection done at screening
173604|NCT02843893|Device|Measure the minimum intensity of a painful stimulation|With Neurolight device.
173605|NCT02843867|Other|blood sample|36 ml of blood sample at D0 and 1 year after transplantation
173606|NCT02843841|Other|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
173607|NCT02843828|Device|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
173608|NCT02843828|Other|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
173609|NCT02843815|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
173610|NCT02843815|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
173611|NCT02843802|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
173612|NCT02843802|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
173613|NCT02843789|Drug|Tocilizumab|
173614|NCT02843776|Other|Questionnaires completion|
173615|NCT02843763|Other|Blood sample|Blood sample (28 ml)
173616|NCT02843750|Behavioral|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:~Breathing Awareness~Upper and Lower Extremity Exercise.~Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve~Practice at home"
173617|NCT02843750|Other|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
173618|NCT02843737|Other|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
173619|NCT02843724|Other|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
173620|NCT02843724|Other|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
173621|NCT02843711|Genetic|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
173622|NCT02843698|Drug|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
173623|NCT02843698|Drug|Normal saline|Normal saline
173624|NCT02843685|Drug|Drotrecogin alfa activated|
173625|NCT02843672|Procedure|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.~Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
173626|NCT02843672|Procedure|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
173627|NCT02843659|Drug|BMS-931699|Specified dose on specified days
173628|NCT02843659|Drug|BMS-986142|Specified dose on specified days
173629|NCT02843659|Drug|Placebo|Specified dose on specified days
173630|NCT02843646|Device|Walk Aide training|
173631|NCT02843633|Device|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
173632|NCT02843633|Drug|Dual Antiplatelet Therapy|a combination of aspirin and a P2Y12 platelet receptor inhibitor
173633|NCT02843620|Dietary Supplement|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
173634|NCT02843620|Other|Placebo|Excipients only
173635|NCT02843607|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
173636|NCT02843607|Biological|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
173637|NCT02843594|Procedure|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
173638|NCT02843594|Procedure|Standard Phaco Control|
173639|NCT02843581|Device|Cryosurgery|Argon-helium cryosurgical system
173640|NCT02843581|Biological|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
173641|NCT02843568|Other|Laboratory Biomarker Analysis|Correlative studies
173642|NCT02843568|Radiation|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
173643|NCT02843568|Radiation|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
173644|NCT02843568|Procedure|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
173645|NCT02843542|Device|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
173646|NCT02843542|Device|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
173647|NCT02843529|Other|Altoida: neuropsychological, MRI, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects. In both Prodromal and Preclinical AD subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.~Data collection at 6, 12, 24 and 36 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both Prodromal and Preclinical AD subjects."
173648|NCT02843516|Other|No intervention|No intervention
173649|NCT02843503|Device|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
173650|NCT02843503|Device|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
173651|NCT02843503|Device|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
173652|NCT02843490|Drug|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
173653|NCT02843477|Device|ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure < 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
173654|NCT02843464|Other|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
173655|NCT02843451|Drug|Milk Thistle|
173656|NCT02843451|Drug|Placebo|
173657|NCT02843438|Other|Fluorescein angiography|
173658|NCT02843438|Other|Dilated fundus examination|
173659|NCT02843438|Biological|Toxoplasmosis serology|
173660|NCT02843438|Drug|Anti-toxoplasmosis treatment|
173661|NCT02843438|Drug|Anti-inflammatory treatments|
173662|NCT02843438|Other|Puncture in anterior chamber|
173663|NCT02843425|Other|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
173664|NCT02843425|Other|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
173665|NCT02843412|Procedure|choose two tumor tissue paraffin blocks|
173666|NCT02843386|Drug|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :~One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.~Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
173667|NCT02843386|Other|Intensive surveillance|"Intensive surveillance~Total duration: 3 years.~liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
173668|NCT02843373|Device|TMS|
173669|NCT02843347|Procedure|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
173670|NCT02843334|Biological|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
173671|NCT02843321|Biological|T-cell infusion, influenza vaccination|Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
173672|NCT02843308|Behavioral|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
173673|NCT02843295|Other|blood samples|
173674|NCT02843282|Behavioral|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
173675|NCT02843269|Behavioral|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
173676|NCT02843256|Device|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
173677|NCT02843230|Radiation|Avastin|
173678|NCT02843230|Radiation|Lomustine|
173679|NCT02843230|Radiation|Temozolomide|
173680|NCT02843230|Device|MRI|
173681|NCT02843230|Device|MRS|
173682|NCT02843230|Device|DSC|
173683|NCT02843217|Behavioral|Lifestyle, screening|
173684|NCT02843204|Drug|Nivolumab|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
173685|NCT02843204|Biological|NK immunotherapy|Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
173686|NCT02843191|Drug|Chemotherapy|5-FU, Leucovorine, and Oxaliplatin (FOLFOX regimen)
173687|NCT02843178|Behavioral|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
173688|NCT02843165|Drug|CBI|Approved CBIs (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
173689|NCT02843165|Radiation|CBI plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
173690|NCT02843126|Drug|Trastuzumab|Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
173691|NCT02843126|Biological|NK immunotherapy|For each procedure, 10 billion cells will be infused for 4 times
173692|NCT02843113|Behavioral|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
173693|NCT02843100|Other|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
173694|NCT02843100|Other|Crohn's Disease Exclusion Diet|a limited whole food diet
173695|NCT02843100|Other|Partial Enteral Nutrition|25-50% of Energy from formula
173696|NCT02843100|Other|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
173697|NCT02843074|Drug|elotuzumab|Given intravenously (IV)
173698|NCT02843074|Drug|Lenalidomide|Given by IV
173699|NCT02843074|Drug|Dexamethasone|Given orally (PO) or by IV
173700|NCT02843074|Procedure|autologous stem cell transplantation|
173701|NCT02843061|Drug|Rituximab|
173702|NCT02843061|Biological|NK immunotherapy|Each time 10 billion cells, 4 times in all,i.v.
173703|NCT02843048|Behavioral|Exercise training program|"Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance."
173704|NCT02843048|Behavioral|Standard medical care|Standard follow-up medical care following bariatric surgery
173705|NCT02843035|Drug|GZ402671|
173706|NCT02843022|Behavioral|standardized electronic messages|supportive and educational short messages
173707|NCT02843022|Behavioral|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
173708|NCT02843022|Behavioral|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
173709|NCT02843009|Behavioral|Resistance Exercise Training|Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
173710|NCT02843009|Dietary Supplement|Supplementation|Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
173711|NCT02842983|Drug|Esmolol|conventional management plus esmolol infusion
173712|NCT02842957|Behavioral|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
173713|NCT02842944|Device|open loop weaning group (Beacon)|mechanical ventilation following advice from the Beacon Caresystem
173714|NCT02842944|Other|Routine care|Standardized routine care
173715|NCT02842931|Drug|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
173716|NCT02842931|Drug|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
173717|NCT02842931|Drug|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
173718|NCT02842931|Drug|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
173719|NCT02842918|Procedure|Spinal Manual Therapy|
173720|NCT02842918|Procedure|Spinal Range of Motion|
173721|NCT02842905|Other|Fitting Audiologist completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the fitting Audiologist
173722|NCT02842905|Other|Participant's Physician completion|Phase II of the COSI (Client Oriented Scale of Improvement) questionnaire completed in a scheduled visit with the Participant's Physician
173723|NCT02842892|Other|Tissue stiffness|
173724|NCT02842879|Other|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
173725|NCT02842866|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
173726|NCT02842866|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined|0.5 mL, Intramuscular
173727|NCT02842853|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (Lot 1)
173728|NCT02842853|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (Lot 2)
173729|NCT02842853|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (Lot 3)
173730|NCT02842853|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
173731|NCT02842840|Behavioral|Patient-based intervention|
173732|NCT02842840|Behavioral|Family based intervention|
173733|NCT02842840|Other|Routine counseling|
173734|NCT02842827|Drug|IMG-7289|LSD1 inhibitor
173735|NCT02842827|Drug|All-trans retinoic acid|Derivative of Vitamin A, differentiating agent.
173736|NCT02842814|Other|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
173737|NCT02842814|Drug|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
173738|NCT02842814|Drug|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
173739|NCT02842801|Other|Hip manipulation|High-amplitude and low-velocity thrust mobilization
173740|NCT02842788|Procedure|Prone positioning|Turning the patient face down for several consecutive hours
173741|NCT02842775|Other|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
173742|NCT02842762|Device|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
173743|NCT02842762|Procedure|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
173744|NCT02842762|Device|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
173745|NCT02842762|Device|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
173746|NCT02842749|Drug|everolimus|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
173747|NCT02842736|Device|Cerene(R) Cryotherapy Device|
173748|NCT02842723|Radiation|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
173749|NCT02842710|Device|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
173750|NCT02842697|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
173751|NCT02842697|Procedure|CTA|Three-dimensional hepatic vein-portal vein model constructed with CTA images
173752|NCT02842697|Procedure|Doppler ultrasound|Portal vein velocity measured by Doppler ultrasound
173753|NCT02842684|Device|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
173754|NCT02842671|Other|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
173755|NCT02842658|Other|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
173756|NCT02842658|Other|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
173757|NCT02842632|Other|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
173799|NCT02842359|Drug|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
173800|NCT02842346|Other|ultrasonography|
173801|NCT02842333|Other|Additional biological samples|Blood samples
173802|NCT02842320|Other|biological samples|bone marrow and blood
173758|NCT02842632|Other|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
173759|NCT02842619|Biological|BonoFill-II|"Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.~Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling."
173760|NCT02842606|Other|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
173761|NCT02842593|Behavioral|Lower-repetition, heavier-load|8-12 reps/set at ~80% 1 repetition maximum
173762|NCT02842593|Behavioral|Higher-repetition, lighter-load|20-25 reps/set at ~30% 1 repetition maximum
173763|NCT02842580|Drug|5 FLUOROURACYL|"Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days."
173764|NCT02842580|Drug|acide folinique|200 mg/m² if Elvorine
173765|NCT02842580|Drug|irinotecan|"Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
173766|NCT02842580|Drug|Oxaliplatin|"Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days."
173767|NCT02842580|Drug|capécitabine|For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
173768|NCT02842580|Drug|bevacizumab|Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
173769|NCT02842567|Drug|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
173770|NCT02842567|Drug|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
173771|NCT02842554|Other|EPT|
173772|NCT02842554|Drug|Drug Placebo Administration|
173773|NCT02842554|Other|C|No Intervention
173774|NCT02842541|Drug|EBI-031|
173775|NCT02842528|Behavioral|Diagnostic Interview for Genetic Studies|
173776|NCT02842528|Behavioral|Family Informant Schedule and Criteria|
173777|NCT02842528|Behavioral|Temperament and Character Inventory|
173778|NCT02842528|Behavioral|Barratt Impulsiveness Scale|
173779|NCT02842528|Behavioral|Wisconsin Card Sorting Test|
173780|NCT02842528|Genetic|blood sample withdrawn|
173781|NCT02842515|Other|teeth avulsion|
173782|NCT02842502|Procedure|Collection of supernumerary biopsies during skin graft pellet procedure|
173783|NCT02842489|Procedure|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
173784|NCT02842489|Procedure|left lateral horizontal position|patients will be horizontally positioned on their left side
173785|NCT02842476|Device|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
173786|NCT02842476|Device|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
173787|NCT02842476|Device|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
173788|NCT02842463|Other|2 times : 6-minute stepper test with a rest of 20min between each test.|
173789|NCT02842450|Device|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
173790|NCT02842450|Other|definitions only|
173791|NCT02842437|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
173792|NCT02842437|Other|normal saline|receive matching placebo (equal volume of normal saline)
173793|NCT02842424|Drug|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
173794|NCT02842398|Behavioral|Balance Master|
173795|NCT02842398|Behavioral|Customary Care|
173796|NCT02842385|Other|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
173797|NCT02842359|Drug|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
173798|NCT02842359|Drug|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
173803|NCT02842307|Procedure|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
173804|NCT02842307|Procedure|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
173805|NCT02842307|Procedure|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
173806|NCT02842294|Drug|Bevacizumab|
173807|NCT02842281|Other|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
173808|NCT02842281|Other|Maltodextrin|Polysaccharide produced from starch
173809|NCT02842268|Drug|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
173810|NCT02842255|Device|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
173811|NCT02842242|Drug|MYK-461|
173812|NCT02842190|Device|NIPPV|after ekstubation
173813|NCT02842177|Procedure|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
173814|NCT02842177|Procedure|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
173815|NCT02842177|Radiation|Transvaginal ultrasound|
173816|NCT02842177|Device|Cu-IUD|
173817|NCT02842164|Other|Tension group|
173818|NCT02842164|Other|No tension group|
173819|NCT02842164|Other|Foley catheter Balloon|
173820|NCT02842151|Procedure|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
173821|NCT02842151|Device|ACRYSOF® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
173822|NCT02842151|Device|Topcon® KR-1W Wave-Front Analyzer|Wavefront and topography system used to obtain autorefraction data
173823|NCT02842138|Biological|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
173824|NCT02842125|Drug|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic capecitabine
173825|NCT02842125|Drug|Xeloda|Oral metronomic chemotherapeutic agent
173826|NCT02842125|Drug|Keytruda|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
173827|NCT02842125|Drug|Opdivo|Antineoplastic, Monoclonal Antibody; PD-1/PD-L1 Inhibitors
173828|NCT02842112|Other|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.~Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.~Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
173829|NCT02842099|Drug|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
173830|NCT02842099|Drug|X|Capecitabine
173831|NCT02842086|Drug|F/TAF|200/25 mg tablet administered orally once daily
173832|NCT02842086|Drug|F/TDF|200/300 mg tablet administered orally once daily
173833|NCT02842086|Drug|F/TAF Placebo|Tablet administered orally once daily
173834|NCT02842086|Drug|F/TDF Placebo|Tablet administered orally once daily
173835|NCT02842073|Drug|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
173836|NCT02842073|Drug|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
173837|NCT02842060|Behavioral|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
173868|NCT02841826|Radiation|Transvaginal ultrasound|
173869|NCT02841813|Other|No intervention|No intervention
173870|NCT02841800|Device|'Intra-luminal radiofrequency ablation (Habib EndoHPB)|endobiliary radiofrequency ablation device
173871|NCT02841787|Behavioral|iCBT for late life depression|
173872|NCT02841774|Drug|Pravastatin|40mg daily (Weeks 2 - 14)
174116|NCT02839707|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
296784|NCT01939002|Drug|naproxen|
173838|NCT02842060|Behavioral|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
173839|NCT02842047|Behavioral|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
173840|NCT02842047|Behavioral|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
173841|NCT02842047|Behavioral|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
173842|NCT02842034|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
173843|NCT02842021|Drug|S2G6T-1|Twice a day topical cream
173844|NCT02842021|Drug|S2G6T-2|Twice a day topical cream
173845|NCT02842021|Drug|S2G6T-3|Twice a day topical cream
173846|NCT02842021|Drug|S2G6T-4|Twice a day topical cream
173847|NCT02842008|Behavioral|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
173848|NCT02841995|Drug|KD025|
173849|NCT02841982|Procedure|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
173850|NCT02841982|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
173851|NCT02841982|Device|PAJUNK StimuLong|
173852|NCT02841982|Drug|single dose ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.~given immediately after the correct position of the tip of the needle has been verified."
173853|NCT02841982|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5~2mg, lock time: 10min, 1h limitation: 6~8mg
173854|NCT02841969|Other|Electrolysed water|Irrigation of wound using electrolysed water
173855|NCT02841969|Other|Prontosan|Irrigation of wound using Prontosan
173856|NCT02841956|Other|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
173857|NCT02841956|Other|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis & building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms & changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy & treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
173858|NCT02841956|Other|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
173859|NCT02841956|Other|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
173860|NCT02841930|Other|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
173861|NCT02841904|Device|Confocal LASER Endomicroscopy|Patients scheduled for bladder endoscopic surgery under general anesthesia are offered to be included in our study. The suspicious mucosal areas are marked then examined with CLE. Tissue samples are taken based on the usual standard criterias. The samples are evaluated microscopically and compared with the results of the CLE technique. A single surgeon performs all surgeries. Biopsies are anlysed by a pathologist from Herlev and Gentofte Hospital's Pathology Department, which is affiliated CLE- study.
173862|NCT02841891|Device|Sylys® Surgical Sealant|Standard Stapled Anastomosis Colectomy Procedure with the addition of Sylys® Surgical Sealant
173863|NCT02841891|Procedure|Stapled Anastomosis Colectomy Procedure|Standard Stapled Anastomosis Colectomy Procedure without the addition of Sylys® Surgical Sealant
173864|NCT02841878|Genetic|Analysis on colorectal biopsy|
173865|NCT02841839|Drug|Stannous Fluoride|
173866|NCT02841826|Other|IUD|
173867|NCT02841826|Other|Uterine sounding|
296884|NCT01938261|Drug|paracetamol|
173873|NCT02841774|Drug|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK <+1.5 x ULN, and LDL-c is >60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
173874|NCT02841761|Drug|Midalozam|Syrup for oral use
173875|NCT02841761|Drug|ACT-132577|Capsules for oral use
173876|NCT02841748|Drug|Pembrolizumab|200mg, every three weeks, iv, x 1 year
173877|NCT02841748|Drug|Placebo|iv, every three weeks, x 1 year
173878|NCT02841735|Device|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
173879|NCT02841735|Device|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
173880|NCT02841735|Device|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
173881|NCT02841722|Procedure|ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)|8 additional blood samples
173882|NCT02841709|Drug|ACT-541468|Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
173883|NCT02841709|Drug|Placebo|Capsules for oral administration matching the ACT-541468 capsules
173884|NCT02841696|Device|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
173885|NCT02841683|Behavioral|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
173886|NCT02841670|Device|InFo - Instant Focus (c) lens implantation|
173887|NCT02841631|Genetic|HPV status and typing of tissue|HPV status and typing of tissue
173888|NCT02841618|Other|High Linoleic Acid Healthy Cookies|
173889|NCT02841618|Other|High Oleic Acid Healthy Cookies|
173890|NCT02841605|Procedure|Rectosigmoidoscopy with colonic biopsies|Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
173891|NCT02841605|Procedure|Colonoscopy with colonic biopsies|Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
173892|NCT02841592|Other|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
173893|NCT02841592|Other|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
173894|NCT02841579|Drug|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
173895|NCT02841566|Other|questionnaire|
173896|NCT02841540|Drug|H3B-8800|H3B-8800 by mouth once daily at specified doses.
173897|NCT02841527|Procedure|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
173898|NCT02841527|Procedure|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
173899|NCT02841527|Procedure|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
173900|NCT02841514|Device|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
173901|NCT02841514|Other|OTC toothpaste and an unoperated Y10 device|
173902|NCT02841501|Genetic|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
173903|NCT02841488|Procedure|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
173904|NCT02841488|Drug|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
173905|NCT02841488|Drug|Ropivacaine|
173906|NCT02841488|Device|Perineural catheter|
173907|NCT02841475|Other|Charlson comorbidity index|Charlson comorbidity index
173908|NCT02841462|Device|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
173909|NCT02841449|Behavioral|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
173910|NCT02841449|Behavioral|Rehydrated|Participants rehydrate after the heat tent procedure
173911|NCT02841436|Device|Irreversible Electroporation (IRE) System|
173912|NCT02841423|Procedure|neuropsychological test battery|
173913|NCT02841410|Other|Magnetic Resonance Imaging|
173914|NCT02841384|Other|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
173915|NCT02841384|Other|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
173916|NCT02841371|Radiation|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
173917|NCT02841358|Biological|Blood sampling|
173918|NCT02841358|Biological|Biopsy|
174117|NCT02839707|Other|Quality-of-Life Assessment|Ancillary studies
175704|NCT02827708|Drug|placebo|Oral administration once daily.
173919|NCT02841345|Other|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.~In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.~In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.~In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
173920|NCT02841332|Drug|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).~Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
173921|NCT02841332|Other|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :~Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )~magnetic resonance imagery spectroscopy sequence~Perfusion magnetic resonance imagery sequence~Diffusion magnetic resonance imagery sequence"
173922|NCT02841332|Drug|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
173923|NCT02841332|Other|Clinical examination|"During the examination, the following parameters will be checked :~Neurological examination~Corticotherapy prescribed~General status of patient (world health organization score)~Weight and height~Control of arterial pressure~Chirurgical and medical history~Concomitant treatment"
173924|NCT02841319|Other|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
173925|NCT02841306|Drug|Ursodeoxycholic Acid|
173926|NCT02841293|Other|Utility Cost evaluation|Medical consequences in terms of quality-adjusted life year and costs within the first year. quality-adjusted life year will be estimated using EQ-5D-3L scale
173927|NCT02841293|Other|Clinical and medical parameters|"Cumulative dose and time duration of pain medication~Pain evaluation~Time to complete healing~Duration of nursing requirements after discharge~Perineal hernia symptomatic or not"
173928|NCT02841280|Drug|Chlorthalidone|This is a forced-titration study and the study drug or placebo will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
173929|NCT02841280|Drug|Placebo|This is a forced-titration study and the study drug or placebo will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
173930|NCT02841267|Drug|PF 06252616|
173931|NCT02841254|Other|Non interventional study|
173932|NCT02841241|Drug|Esmolol|Esmolol infusion
173933|NCT02841228|Radiation|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
173934|NCT02841215|Drug|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
173935|NCT02841215|Drug|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
173936|NCT02841202|Drug|oral contraceptive pills|
173937|NCT02841189|Device|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
173938|NCT02841176|Other|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
173939|NCT02841176|Biological|Golimumab|Participants will start monthly Golimumab after their baseline visit
173940|NCT02841163|Drug|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
173941|NCT02841163|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
173942|NCT02841163|Procedure|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
173943|NCT02841163|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
299800|NCT01916252|Drug|Melphalan|
173944|NCT02841163|Procedure|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
173945|NCT02841150|Drug|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4*140 milligram (mg), capsules.
173946|NCT02841150|Drug|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1*560 mg, tablet.
173947|NCT02841137|Drug|Progesterone|comparison of different dosages of drug towards the active comparator
173948|NCT02841124|Other|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
173949|NCT02841098|Other|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
173950|NCT02841098|Drug|Optimal medical therapy alone|Optimal medical therapy alone
173951|NCT02841085|Genetic|Genetic sample|Blood sample or saliva collection
173952|NCT02841059|Procedure|LSH|laparoscopic subtotal hysterectomy: LSH
173953|NCT02841059|Procedure|CLSH|laparoscopic cervical ligament sparing hysterectomy: CLSH
173954|NCT02841059|Procedure|LAVH|laparoscopic assisted vaginal hysterectomy: LAVH
173955|NCT02841046|Device|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
173956|NCT02841046|Device|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
173957|NCT02841033|Drug|daratumumab|Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
173958|NCT02841020|Procedure|Additional biopsy|• Patients in the experimental group receive the additional biopsy for non-neoplastic disease during the same procedure before the biopsy of the renal mass (with potential for direct benefit to the patient by revealing non-neoplastic renal disease).
173959|NCT02841007|Device|geko neuromuscular electrostimulation device|
173960|NCT02840994|Biological|CV301|
173961|NCT02840994|Biological|Pembrolizumab|
173962|NCT02840994|Biological|Nivolumab|
173963|NCT02840955|Device|Staphefekt SA.100|
173964|NCT02840955|Other|Placebo|
173965|NCT02840942|Behavioral|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
173966|NCT02840942|Behavioral|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
173967|NCT02840929|Procedure|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
173968|NCT02840929|Drug|Esomeprazole|
173969|NCT02840916|Procedure|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
173970|NCT02840916|Procedure|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
173971|NCT02840903|Drug|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
173972|NCT02840890|Procedure|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
173973|NCT02840890|Procedure|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
173974|NCT02840877|Behavioral|DOT Adherence Monitoring|Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
173975|NCT02840864|Device|Sonography assisted breast surgery|
173976|NCT02840851|Device|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
173977|NCT02840851|Device|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
173978|NCT02840812|Drug|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
173979|NCT02840799|Drug|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
173980|NCT02840799|Drug|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
173981|NCT02840786|Device|plaque excision system|
173982|NCT02840786|Device|Stent|
173983|NCT02840773|Other|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
173984|NCT02840773|Other|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
173985|NCT02840773|Other|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
173986|NCT02840773|Other|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
174408|NCT02837653|Behavioral|Physical Activity Counselling|
173987|NCT02840773|Other|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
173988|NCT02840760|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
173989|NCT02840734|Other|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
173990|NCT02840721|Drug|PF-06480605|PF-06480605 500 mg IV Q2W x 7 Doses
173991|NCT02840708|Drug|Sargramostim|
173992|NCT02840695|Drug|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
173993|NCT02840669|Procedure|Cardiac magnetic resonance imaging (CMR)|
173994|NCT02840669|Procedure|Exercise-stress test|
173995|NCT02840669|Procedure|Echocardiography (ECHO)|
173996|NCT02840669|Procedure|Cardiac-related blood studies|
173997|NCT02840656|Other|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
173998|NCT02840656|Other|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
173999|NCT02840643|Behavioral|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
174000|NCT02840643|Behavioral|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
174001|NCT02840630|Other|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
174002|NCT02840617|Drug|Indocyanine Green (ICG)|
174003|NCT02840591|Drug|Ramelteon|
174004|NCT02840591|Drug|Citicoline|
174005|NCT02840565|Drug|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
174006|NCT02840565|Drug|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
174007|NCT02840552|Drug|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
174008|NCT02840539|Drug|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim|"Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle~Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older~Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle~Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles"
174009|NCT02840526|Procedure|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
174010|NCT02840526|Drug|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
174011|NCT02840526|Drug|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
174012|NCT02840526|Drug|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
174013|NCT02840526|Drug|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
174014|NCT02840526|Drug|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
174015|NCT02840526|Device|Intubation|Intratracheal intubation with a single lumen endotracheal tube
174016|NCT02840526|Drug|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
174017|NCT02840526|Drug|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
174018|NCT02840526|Drug|Ketonal|100 mg ketoprofen intravenously every 12 hours
174019|NCT02840526|Drug|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
174020|NCT02840513|Other|Smartphone app/CO self-monitoring|Smartphone app and carbon monoxide self-monitoring (personal device)
174021|NCT02840500|Other|No intervention|No intervention
174022|NCT02840487|Biological|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
174023|NCT02840474|Biological|VRC-HIVMAB080-00-AB|VRCOlLS is an investigational human monoclonal antibody targeted to the CD4 binding site of HIV-l.
174024|NCT02840474|Biological|VRCHIVMAB075 00 AB|VRCOlLS is an investigational human monoclonal antibody targeted to the CD4 binding site of HIV-l.
174025|NCT02840461|Drug|Ivermectin Cream, 1%|
174026|NCT02840461|Drug|Placebo/Vehicle cream|
174027|NCT02840435|Behavioral|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
174107|NCT02839785|Drug|Placebo|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
174108|NCT02839772|Other|Current skin care regimen plus 2% glycerine added to soaking water|
174109|NCT02839772|Other|Current skin care regimen|
174110|NCT02839759|Other|TELLYHealth|Educational videos and questions.
174028|NCT02840435|Behavioral|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
174029|NCT02840422|Device|ARTHRUM H 2%|ARTHRUM H 2%
174030|NCT02840409|Drug|Vinblastine|
174031|NCT02840409|Drug|Bevacizumab|
174032|NCT02840396|Device|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
174033|NCT02840396|Device|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
174034|NCT02840383|Other|Delayed Intervention|Schools not receiving intervention until two years after implementation.
174035|NCT02840383|Other|Intervention|intervention at the beginning of study.
174036|NCT02840370|Device|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
174037|NCT02840370|Device|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
174038|NCT02840357|Other|Purple Wheat Convenience Bars|Whole grain convenience bars manufactured with purple wheat
174039|NCT02840357|Other|Control Wheat Convenience Bars|Whole grain convenience bars manufactured with ordinary wheat
174040|NCT02840344|Behavioral|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
174041|NCT02840344|Behavioral|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
174042|NCT02840331|Drug|St. John's Wort|Single oral doses (900 milligram) 2-4 hours before laparoscopy
174043|NCT02840331|Device|Photodynamic diagnostic and therapy|Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
174044|NCT02840318|Other|Compassion Intervention|See arm description
174045|NCT02840305|Other|Evaluation of visual function|
174046|NCT02840305|Other|Magnetic Resonance Imaging|
174047|NCT02840279|Drug|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
174048|NCT02840279|Drug|Placebo|
174049|NCT02840253|Device|NIRS|
174050|NCT02840240|Drug|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
174051|NCT02840240|Drug|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
174052|NCT02840227|Procedure|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
174053|NCT02840227|Procedure|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
174054|NCT02840214|Device|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
174055|NCT02840214|Device|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
174056|NCT02840188|Other|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
174057|NCT02840175|Drug|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
174058|NCT02840175|Drug|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
174059|NCT02840175|Drug|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
174060|NCT02840175|Drug|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
174061|NCT02840162|Drug|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
174062|NCT02840162|Drug|Placebo|
174063|NCT02840149|Drug|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
174064|NCT02840136|Drug|Piperacillin-tazobactam combination product|
174065|NCT02840136|Drug|Meropenem|
174066|NCT02840136|Drug|Ceftazidime|
174067|NCT02840123|Biological|Autologous dendritic cells|
174068|NCT02840110|Other|ACTR T Cell Product|
174069|NCT02840097|Drug|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
174070|NCT02840097|Drug|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
174071|NCT02840084|Device|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
299959|NCT01914926|Drug|Diltiazem|
174072|NCT02840071|Other|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
174073|NCT02840058|Other|Biological samples|blood and tumor tissue samples
174074|NCT02840058|Drug|Anti PD1/PDL1 treatment|
174075|NCT02840045|Device|high-density electroencephalography|Musical stimulation during electroencephalography recording
174076|NCT02840019|Device|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
174077|NCT02840019|Procedure|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
174078|NCT02840006|Procedure|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
174079|NCT02840006|Procedure|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
174080|NCT02839993|Device|tDCS|
174081|NCT02839993|Behavioral|training|
174082|NCT02839967|Other|Photobiomodulation|Intraoral photobiomodulation is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of photobiomodulation in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
174083|NCT02839967|Other|Photobiomodulation placebo|The volunteers will be subjected to the same Group intervention, Photobiomodulation and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
174084|NCT02839954|Biological|anti-MUC1 CAR-pNK cells|
174085|NCT02839941|Drug|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
174086|NCT02839941|Drug|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
174087|NCT02839941|Drug|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
174088|NCT02839941|Drug|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
174089|NCT02839928|Drug|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
174090|NCT02839928|Device|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
174091|NCT02839928|Drug|EMLA|
174092|NCT02839915|Drug|Folinic Acid|Capsule form, taken twice a day with a max dose of 50 mg
174093|NCT02839915|Other|Placebo|Inactive placebo comparator
174094|NCT02839902|Drug|TAK-085|Omega-3-acid ethyl esters (TAK-085) capsule
174095|NCT02839902|Other|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
174096|NCT02839889|Drug|Naloxegol|Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
174097|NCT02839889|Drug|Placebo|Placebo once daily for two weeks, followed by two week open-label period
174098|NCT02839876|Drug|Intravenous acetaminophen|Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
174099|NCT02839876|Drug|Oral acetaminophen|Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
174100|NCT02839850|Device|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
174101|NCT02839837|Behavioral|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
174102|NCT02839837|Device|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
174103|NCT02839824|Procedure|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
174104|NCT02839811|Procedure|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
174105|NCT02839798|Device|NEST (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
174106|NCT02839785|Drug|Ibuprofen|the child will take orally 30 minutes before each session of physiotherapy 10mg/kg of Ibuprofen (not to exceed 400 mg) in liquid form or placebo.
174118|NCT02839694|Drug|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
174119|NCT02839694|Drug|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
174120|NCT02839694|Drug|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
174121|NCT02839681|Drug|Anetumab Ravtansine|Administered intravenously (IV) every 3 weeks
174122|NCT02839681|Device|Blood test|Research blood test for eligibility
174123|NCT02839668|Drug|Lidocaine|Continuous infusion of lidocaine
174124|NCT02839668|Drug|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
174125|NCT02839668|Drug|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
174126|NCT02839668|Drug|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
174127|NCT02839668|Drug|Tramadol|administration of tramadol for postoperative analgesia
174128|NCT02839668|Drug|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
174129|NCT02839668|Drug|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
174130|NCT02839668|Device|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
174131|NCT02839655|Device|Da Vinci Xi|
174132|NCT02839642|Drug|Rivastigmine|
174133|NCT02839642|Drug|Placebo|
174134|NCT02839629|Other|Non-Interventional|
174135|NCT02839616|Procedure|orthotopic liver transplantation|
174136|NCT02839590|Device|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
174137|NCT02839590|Device|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
174138|NCT02839590|Device|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
174139|NCT02839590|Device|STARflo|Suprachoroidal Shunt Surgery (STARflo)
174140|NCT02839590|Device|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
174141|NCT02839590|Device|iStent implant|Trans-trabecular meshwork implants (iStent implant).
174142|NCT02839590|Device|Kahook Dual Blade|It removes part of the trabecular meshwork
174143|NCT02839577|Drug|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and~• 40 ml saline around the tendon."
174144|NCT02839577|Drug|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
174145|NCT02839564|Procedure|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
174146|NCT02839564|Procedure|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
174147|NCT02839551|Procedure|simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
174148|NCT02839538|Procedure|Local Infiltration|Injection at perianal region with ropivacaine 0.75%(20ml)
174149|NCT02839538|Procedure|Subarachnoidal block|Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
174150|NCT02839525|Dietary Supplement|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
174151|NCT02839525|Dietary Supplement|Isolate whey protein|23g of protein of whey protein
174152|NCT02839525|Dietary Supplement|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
174153|NCT02839525|Other|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
174154|NCT02839512|Device|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
174155|NCT02839499|Device|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
174156|NCT02839499|Other|autonomy scale (ADL and AGGIR)|autonomy data
174157|NCT02839499|Other|various activity scale (IADL)|activity of life data
174158|NCT02839486|Other|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
174159|NCT02839486|Other|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
174160|NCT02839473|Device|Castalie water spray|
174161|NCT02839473|Device|Hydrogel Hydrosorb®|
174162|NCT02839460|Procedure|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
174163|NCT02839447|Other|no intervention|
174164|NCT02839434|Procedure|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
174165|NCT02839421|Drug|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
174166|NCT02839408|Dietary Supplement|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
174167|NCT02839408|Drug|Azithromycin|Tablet containing 500mg Azithromicyn
174168|NCT02839408|Other|Talc powder|Sachet containing talc powder and tablet containing talc powder
174169|NCT02839408|Procedure|Periodontal treatment Scaling and root planning|
174170|NCT02839395|Other|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
174171|NCT02839395|Other|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
174172|NCT02839395|Other|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
174409|NCT02837653|Other|Therapeutic Exercise for LBP|
174173|NCT02839382|Other|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
174174|NCT02839382|Other|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
174175|NCT02839382|Other|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
174176|NCT02839369|Other|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
174177|NCT02839369|Other|walking under varies conditions|walking on electronic walkway under different conditions
174178|NCT02839356|Drug|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
174179|NCT02839356|Drug|normal saline|20-mL irrigation with physiological saline over the entire papilla
174180|NCT02839343|Radiation|radiation therapy|
174181|NCT02839343|Procedure|surgery|
174182|NCT02839343|Drug|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
174183|NCT02839343|Drug|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
174184|NCT02839330|Biological|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
174185|NCT02839330|Biological|Placebo|Placebo: Saline injection
174186|NCT02839317|Biological|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
174187|NCT02839304|Device|Cryoablation System|Pulmonary Vein Isolation, Posterior Wall Isolation. May Include Mitral Line ablation, AF Driver ablation, and Cavo-tricuspid Isthmus ablation as indicated
174188|NCT02839291|Other|quality of life questionaries|
174189|NCT02839291|Drug|intravenous or oral bone antiresorptive treatments|
174190|NCT02839278|Biological|Blood sample|
174191|NCT02839265|Drug|FLT3 Ligand Therapy (CDX-301)|See Arm 1 descriptions
174192|NCT02839265|Radiation|Stereotactic Body Radiotherapy (SBRT)|See Arm 1 descriptions
174193|NCT02839252|Behavioral|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
174194|NCT02839239|Dietary Supplement|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
174195|NCT02839239|Dietary Supplement|Drops with vitamin D3|Oil suspension with vitamin D3
174196|NCT02839226|Drug|AR/101|
174197|NCT02839226|Drug|Placebo|
174198|NCT02839213|Drug|Hyoscine Butyl bromide|
174199|NCT02839213|Drug|Saline|
174200|NCT02839200|Drug|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
174201|NCT02839200|Drug|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
174202|NCT02839200|Drug|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
174203|NCT02839200|Drug|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
174204|NCT02839200|Drug|Placebo 1|Placebo capsules matching ACT-541468 capsules
174205|NCT02839200|Drug|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
174206|NCT02839187|Radiation|Neuroimaging|AV45-positron emission tomography
174207|NCT02839161|Biological|Na-GST-1/Alhydrogel|
174208|NCT02839161|Biological|Na-APR-1 (M74)/Alhydrogel|
174209|NCT02839161|Biological|Hepatitis B Vaccine|
174210|NCT02839148|Dietary Supplement|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.~The control children will receive routine clinical care but no FS or PS."
174211|NCT02839135|Drug|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
174212|NCT02839135|Drug|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
174213|NCT02839122|Drug|Tadalafil|
174214|NCT02839122|Drug|Dutasteride|
174215|NCT02839096|Drug|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
174216|NCT02839096|Drug|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
174217|NCT02839083|Other|Thoracic Paravertebral group|Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
174218|NCT02839083|Other|Pecs II group|Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
174219|NCT02839070|Other|Sleep/Wake Schedule|Timing of sleep and wake
174220|NCT02839057|Procedure|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
174221|NCT02839057|Procedure|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
174222|NCT02839044|Dietary Supplement|Menaquinone-7|
174223|NCT02839044|Dietary Supplement|Placebo|
174224|NCT02839031|Behavioral|"CBT (Cognitive-Behavioral Therapy)"|
174225|NCT02839031|Behavioral|Control (telephonic support without CBT content)|
174226|NCT02839005|Other|Continuous suture with polyglecaprone 25|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
174227|NCT02839005|Other|Continuous suture with polyamide (nylon)|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
174410|NCT02837653|Other|Superficial Thermotherapy|
174228|NCT02838992|Drug|Rabbit ATG, (Genzyme)|ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
174229|NCT02838992|Drug|Cy|Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
174230|NCT02838992|Drug|CsA|CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
174231|NCT02838992|Biological|Cord blood|Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
174232|NCT02838979|Dietary Supplement|L-glutamine|Oral Glutamine for 2 weeks at dose of 0.4mg/kg/day in three divided daily doses
174233|NCT02838979|Dietary Supplement|Maltodextrin|Oral maltodextrin as described for the active agent: 2 weeks at dose of 0.4mg/kg/day in three divided daily doses.
174234|NCT02838966|Dietary Supplement|Nestle IMPACT Advanced Recovery|
174235|NCT02838966|Dietary Supplement|Nestle Boost High Protein Drink|
174236|NCT02838953|Behavioral|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
174237|NCT02838940|Procedure|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
174238|NCT02838940|Drug|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
174239|NCT02838927|Other|No intervention|No intervention
174240|NCT02838914|Procedure|radiofrequency ablation (RFCA)|Patients undergo radiofrequency ablation (RFCA)
174241|NCT02838901|Drug|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
174242|NCT02838901|Drug|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
174243|NCT02838888|Device|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
174244|NCT02838875|Procedure|Blood samples|After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
174245|NCT02838849|Dietary Supplement|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
174246|NCT02838849|Dietary Supplement|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
174247|NCT02838836|Procedure|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
174248|NCT02838823|Biological|humanized anti-PD-1 monoclonal antibody toripalimab|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
174249|NCT02838810|Drug|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
174250|NCT02838810|Drug|Nucleoside analogues|Nucleoside analogues
174251|NCT02838797|Drug|RQ-00000010|orally administered serotonin 4 receptor partial agonist
174252|NCT02838797|Drug|Placebo|oral acetate buffer
174253|NCT02838784|Other|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
174254|NCT02838784|Procedure|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
174255|NCT02838771|Other|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
174256|NCT02838771|Other|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
174257|NCT02838758|Device|Cryoablation|A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
174258|NCT02838758|Drug|Lidocaine|Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
174259|NCT02838758|Drug|Saline|Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
174260|NCT02838745|Drug|Pemetrexed|
174261|NCT02838745|Drug|Cisplatin|
174262|NCT02838732|Dietary Supplement|L-carnitine|
174263|NCT02838719|Drug|Perineural Dexamethasone acetate|
174264|NCT02838719|Drug|Intravenous dexamethasone acetate|
174265|NCT02838706|Procedure|Surgery for hip fracture|
174266|NCT02838693|Procedure|Not applicable. This is an observational study.|Not applicable. This is an observational study.
174267|NCT02838680|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
174268|NCT02838667|Procedure|Standard of Care plus Nephrology Care|
174269|NCT02838654|Procedure|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
174270|NCT02838641|Device|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
174271|NCT02838628|Drug|KX2-391|KX2-391 Ointment will be applied once daily for X consecutive days
174272|NCT02838615|Procedure|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
175705|NCT02827695|Behavioral|SMASK|Medication adherence and BP monitoring
174273|NCT02838602|Radiation|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
174274|NCT02838602|Radiation|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
174275|NCT02838589|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
174276|NCT02838589|Drug|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
174277|NCT02838576|Drug|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
174278|NCT02838576|Drug|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
174279|NCT02838563|Other|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
174280|NCT02838550|Behavioral|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
174281|NCT02838550|Behavioral|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
174282|NCT02838537|Drug|Exposure to Triptan|
174283|NCT02838537|Drug|Exposure to Ergot|
174284|NCT02838511|Other|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
174285|NCT02838511|Other|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
174286|NCT02838498|Device|ERCP Mechanical Simulator (EMS)|Hands on EMS training
174287|NCT02838485|Other|Mirror|The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.
174288|NCT02838485|Other|Imagery|The subject will be asked to imagine performing hand movements.
174289|NCT02838472|Drug|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
174290|NCT02838446|Procedure|Cognitive Therapy|"Graded Motor Imagery has three stages:~Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
174291|NCT02838433|Other|biological samples|blood and tissue samples
174292|NCT02838420|Drug|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
174293|NCT02838420|Drug|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
174294|NCT02838407|Other|BAL fluid sampling|Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
174295|NCT02838407|Other|Nasopharyngeal swab sampling|1 swab, Day 0
174296|NCT02838394|Procedure|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
174297|NCT02838394|Other|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
174298|NCT02838381|Other|Additional biological samples|blood and tissue samples
174299|NCT02838355|Device|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
174300|NCT02838355|Other|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
174301|NCT02838342|Drug|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
174302|NCT02838342|Drug|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
174303|NCT02838329|Other|warming of ropivacaine for BT|
174304|NCT02838329|Drug|Ropivicaine|
174305|NCT02838316|Drug|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
174306|NCT02838303|Other|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
174307|NCT02838303|Other|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
174308|NCT02838290|Other|Induction|Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
174309|NCT02838290|Other|Control group|Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
174310|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
174311|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
174312|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
176287|NCT02823197|Other|Active transport lesson|
174313|NCT02838264|Drug|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
174314|NCT02838264|Drug|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
174315|NCT02838251|Other|No intervention|
174316|NCT02838238|Drug|Capecitabine|
174317|NCT02838238|Drug|Placebo|
174318|NCT02838225|Drug|Docetaxel, Doxorubicin|
174319|NCT02838225|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|
174320|NCT02838212|Drug|adverse drug reaction|drug-related death
174321|NCT02838199|Device|SAPIEN 3|
174322|NCT02838199|Procedure|SAVR|
174323|NCT02838186|Procedure|retroflexion|examination of the right colon with scope retroflexion
174324|NCT02838186|Procedure|forward view|examination of the right colon in forward view
174325|NCT02838173|Procedure|serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)|
174326|NCT02838173|Procedure|tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)|
174327|NCT02838173|Procedure|serratus plane bloc : placebo|
174328|NCT02838173|Procedure|tissue infiltration : placebo|
174329|NCT02838160|Behavioral|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
174330|NCT02838160|Behavioral|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
174331|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
174332|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
174333|NCT02838147|Device|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
174334|NCT02838147|Device|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
174335|NCT02838134|Other|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when post-tetanic count (PTC) is more than 0 and titrated towards PTC 1-2.
174336|NCT02838134|Other|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
174337|NCT02838121|Drug|Aclasta|Aclasta once annually for 2 years
174338|NCT02838121|Drug|Placebo|No IV aclasta
174339|NCT02838095|Behavioral|Nap|A 1-hour daytime nap opportunity
174340|NCT02838082|Behavioral|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
174341|NCT02838082|Behavioral|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
174342|NCT02838069|Biological|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
174343|NCT02838069|Biological|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
174344|NCT02838069|Other|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
174345|NCT02838056|Drug|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
174346|NCT02838043|Dietary Supplement|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
174347|NCT02838030|Drug|L-arginine|3 gr per day
174348|NCT02838030|Drug|Placebo (for L-arginine)|3 gr per day
174349|NCT02838030|Drug|acetylsalicylic acid|3 gr per day
174350|NCT02838017|Device|Tissue Adhesive|
174351|NCT02838017|Device|Sterile strips|
174352|NCT02838004|Device|IOL MINI WELL READY|IOL MINI WELL READY
174353|NCT02837991|Drug|CDX-014|
174354|NCT02837978|Drug|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid)，adjusted by its concentration in blood or due to patient response. Then may titer down until the endpoint.
174355|NCT02837978|Drug|MTX|MTX：5mg to 15mg, po, once per week (Qw) until the endpoint or adjusted due to unacceptable toxicity develops.
174356|NCT02837965|Drug|treatment with topical superpotent corticosteroid therapy|
174357|NCT02837965|Drug|treatment with systemic therapy (methotrexate)|
174358|NCT02837965|Drug|treatment systemic therapy (prednisone)|
174359|NCT02837965|Drug|treatment with systemic therapy (prednisone)|
174360|NCT02837965|Drug|treatment with systemic therapy (doxycycline)|
174361|NCT02837952|Drug|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
174362|NCT02837952|Drug|Placebo|Placebo
174363|NCT02837939|Drug|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:~Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug~To be administered subcutaneously as follows:~12 doses TF in total:~3 x TF in first week: day 1,3,5~2 x TF in week 2: day 8 , 11~1 xTF in week 3 and 4 : day 15, 22~1 x TF once a month up to 6 month"
174364|NCT02837939|Drug|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:~3 doses in first week: day 1,3,5~2 doses in week 2: day 8 , 11~1 dose in week 3 and 4 : day 15, 22~1 dose once a month up to 6 month"
174365|NCT02837926|Other|questionnaire|
174366|NCT02837926|Biological|Gardasil vaccine|
174367|NCT02837926|Biological|Cervarix®|
174368|NCT02837913|Device|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
174369|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
174370|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
174371|NCT02837887|Behavioral|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
174372|NCT02837874|Procedure|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
174373|NCT02837874|Procedure|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
174374|NCT02837861|Drug|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of approximately 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
174375|NCT02837861|Other|Routine Nutritional Support|Enteral nutrition as tolerated.
174376|NCT02837848|Procedure|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
174377|NCT02837848|Procedure|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
174378|NCT02837835|Drug|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
174379|NCT02837835|Drug|ceftazidime|20 mg/kg over 30 min every 8 h
174380|NCT02837822|Device|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
174381|NCT02837822|Procedure|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
174382|NCT02837809|Radiation|Low dose CT|annual CT vs biennial CT
174383|NCT02837796|Procedure|transobturator tape|
174384|NCT02837783|Drug|Linaclotide|Oral, once daily
174385|NCT02837783|Drug|Placebo|Oral, one daily
174386|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
174387|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
174388|NCT02837770|Drug|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
174389|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
174390|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
174391|NCT02837770|Drug|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
174392|NCT02837757|Other|Biological samples|blood and tumor tissue samples
174393|NCT02837744|Device|Axiostat®|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.~Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
174394|NCT02837744|Device|Standard Institutional Care Product|Band Size: 24 x 4 cm Cotton Gauze size : 5 x 5 cm
174395|NCT02837731|Device|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
174396|NCT02837718|Procedure|bupivakain % 0,5|Bupivacaine 0,5% The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
174397|NCT02837705|Other|blood draw|
174398|NCT02837692|Drug|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
174399|NCT02837692|Drug|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
174400|NCT02837692|Drug|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
174401|NCT02837692|Drug|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
174402|NCT02837679|Other|Geriatric Follow up|
174403|NCT02837666|Dietary Supplement|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
174404|NCT02837666|Other|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
174405|NCT02837666|Other|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
174406|NCT02837666|Other|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
174407|NCT02837666|Other|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
301972|NCT01899794|Drug|Oxytrol|
174411|NCT02837640|Drug|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
174412|NCT02837627|Other|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
174413|NCT02837614|Drug|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
174414|NCT02837614|Drug|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
174415|NCT02837614|Procedure|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
174416|NCT02837614|Drug|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
174417|NCT02837601|Device|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
174418|NCT02837588|Device|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
174419|NCT02837575|Biological|VCL-HB01|Investigational Product
174420|NCT02837575|Other|Phosphate-buffered saline|Placebo
174421|NCT02837562|Other|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
174422|NCT02837549|Other|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
174423|NCT02837536|Other|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
174424|NCT02837536|Other|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
174425|NCT02837510|Behavioral|Standard smoking cessation counseling|Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
174426|NCT02837497|Other|ICU-RESUS CPR Improvement Bundle|"Point-of-care CPR training~Post-cardiac arrest educational debriefings"
174427|NCT02837484|Other|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
174428|NCT02837471|Device|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.~Participants have access to a personal account created online and can record the daily steps count and physical activity.~Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
174429|NCT02837458|Device|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
174430|NCT02837458|Device|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
174431|NCT02837445|Device|PHC ON|Eligible patients randomized after optimization phase to PHC ON for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
174432|NCT02837445|Device|PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 6 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
174433|NCT02837432|Drug|Hydrocortisone acetate|
174434|NCT02837432|Drug|Placebo|
174435|NCT02837419|Behavioral|Health related Quality of life EQ-5D|Quality of Care
174436|NCT02837393|Procedure|Ureteral catheterization|During ureteral catheterization, urine samples will be obtain from each kidney
174437|NCT02837380|Drug|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
174438|NCT02837380|Drug|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
174540|NCT02836522|Behavioral|Assessment of Health-Related Quality|Demographic Questionnaire, ANCHOR HRSI, FACT-G, MDASI, Patient ECOG PS, PGIC
174439|NCT02837367|Dietary Supplement|Administration of supplements containing methyl-donors|Administration of supplements containing methyl-donors: betaine, 5-MTHF (L-5-methyltetrahydrofolate), Vitamin B12, choline bitartrate, ALA (alfa-linolenic acid), EPA (eicosapentaenoic acid), DHA(docosahexaenoic acid)
174440|NCT02837354|Other|No intervention|
174441|NCT02837341|Device|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
174442|NCT02837328|Drug|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
174443|NCT02837328|Drug|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
174444|NCT02837315|Behavioral|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.
174445|NCT02837315|Behavioral|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
174446|NCT02837315|Behavioral|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
174447|NCT02837302|Drug|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
174448|NCT02837289|Other|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
174449|NCT02837289|Other|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
174450|NCT02837263|Radiation|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.~SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
174451|NCT02837263|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
174452|NCT02837250|Behavioral|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
174453|NCT02837250|Behavioral|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
174454|NCT02837237|Drug|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.~In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
174455|NCT02837224|Device|The Situate Detection System|The Situate Detection System for locating surgical sponges
174456|NCT02837211|Behavioral|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.~The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.~From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
174457|NCT02837211|Behavioral|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.~Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
174458|NCT02837198|Drug|FYU-981|
174459|NCT02837198|Drug|Topiroxostat|
174460|NCT02837185|Procedure|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
174461|NCT02837185|Other|Physiological measures|These include TMS and EMG measurements
174541|NCT02836509|Drug|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
176288|NCT02823197|Other|Active transport lesson and Facebook group|
174462|NCT02837172|Other|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.~Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
174463|NCT02837159|Other|mHealth application|Dietary and physical activity recommendations trough a mobile application
174464|NCT02837146|Biological|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
174465|NCT02837146|Drug|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
174466|NCT02837133|Behavioral|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
174467|NCT02837107|Dietary Supplement|Mind Master|80ml Mind Master / day for 8 weeks
174468|NCT02837107|Dietary Supplement|Placebo|80ml a look-alike Placebo / day for 8 weeks
174469|NCT02837094|Drug|C19-A3 GNP|C19A3 GNP intradermal microinjectable solution of human C19A3 proinsulin peptide coupled to gold.
174470|NCT02837081|Other|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
174471|NCT02837081|Other|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
174472|NCT02837068|Device|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
174473|NCT02837068|Device|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
174474|NCT02837055|Device|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
174475|NCT02837055|Device|conventional intubation|patients are intubated with a conventional endotracheal tube
174476|NCT02837042|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
174477|NCT02837029|Other|Laboratory Biomarker Analysis|Correlative studies
174478|NCT02837029|Biological|Nivolumab|Given IV
174479|NCT02837029|Radiation|Yttrium Y 90 Glass Microspheres|Given IA
174480|NCT02837016|Device|Wearable biofeedback|
174481|NCT02837016|Behavioral|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
174482|NCT02837003|Drug|Aspirin|Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
174483|NCT02837003|Drug|Thienopyridine|Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
174484|NCT02836990|Device|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
174485|NCT02836990|Device|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
174486|NCT02836977|Drug|tegafur-uracil|Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
174487|NCT02836964|Device|Dental Implant|Dental implant
174488|NCT02836951|Other|Withdrawal of blood and CSF|Withdrawal of blood and CSF
174489|NCT02836938|Other|Collection of exhaled breath volatile organic compounds|
174490|NCT02836925|Drug|Ledipasvir+Sofosbuvir|"Patients with genotype 1 or genotype 4 Ledipasvir 90 mg + Sofosbuvir 400 mg~12 weeks in previously untreated infected patients~24 weeks for previously treated patients with uncertain subsequent retreatment options"
174491|NCT02836925|Drug|Sofosbuvir+Velpatasvir|"Patients with genotype 2 or genotype 3 Sofosbuvir 400 mg + Velpatasvir 100 mg~· 12 weeks of treatment"
174492|NCT02836912|Other|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
174493|NCT02836899|Drug|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
174494|NCT02836899|Other|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
174495|NCT02836873|Drug|Bexagliflozin|Bexagliflozin tablet, 20 mg
174496|NCT02836873|Drug|Placebo|Placebo (inactive) tablet to match the active comparator
174497|NCT02836860|Other|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
174498|NCT02836847|Procedure|biological test|mutation and signal pathway activation status analysis
174499|NCT02836847|Drug|GEMOX|Conventional chemotherapy:gemcitabine and oxaliplatin
174500|NCT02836847|Drug|Cetuximab|
174501|NCT02836847|Drug|Trastuzumab|
174502|NCT02836847|Drug|Gefitinib|
174503|NCT02836847|Drug|Lapatinib|
174504|NCT02836847|Drug|Everolimus|
174505|NCT02836847|Drug|Sorafenib|
174506|NCT02836847|Drug|Crizotinib|
174507|NCT02836834|Biological|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
174508|NCT02836821|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
174509|NCT02836821|Drug|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
174542|NCT02836509|Drug|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
175209|NCT02831478|Drug|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
174510|NCT02836808|Behavioral|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
174511|NCT02836795|Biological|humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
174512|NCT02836782|Procedure|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
174513|NCT02836769|Behavioral|Rehabilitation Consult (RC)|The RC was designed to foster key contributors to self management in the participants. The RC is administered by a rehabilitation professional and consists of an initial one-hour face-to-face consult and follow-up appointment(s) 2-12 weeks later, either telephone or face-to-face. The initial consult consists of orientation, consultation, goal-setting, teaching cognitive strategies, introduction to online resources/action planning/planning coping responses, review/implementation intentions/scheduling follow-up. The follow-up consists of a reminder, reorientation, checking of progress on goals and plans, re-planning as necessary, and discharge or scheduling of further follow-up as necessary.
174514|NCT02836743|Drug|Circadin|Slow-release melatonin
174515|NCT02836743|Drug|Placebo|
174516|NCT02836730|Procedure|Low back pain surgery|
174517|NCT02836717|Device|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
174518|NCT02836704|Drug|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous injection"
174519|NCT02836704|Drug|metformin|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
174520|NCT02836704|Drug|acarbose|"Pharmaceutical form: table or capsule~Route of administration: oral administration"
174521|NCT02836691|Device|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
174522|NCT02836678|Biological|Ridge splitting, immediate implant, Nanobone with PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~Alloplast bone graft material (Nanobone)~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
174523|NCT02836678|Biological|Ridge splitting, immediate implantand PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).~PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
174524|NCT02836665|Procedure|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
174525|NCT02836652|Device|HeartMate II (HMII)|Left Ventricular Assist Device
174526|NCT02836652|Drug|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
174527|NCT02836652|Drug|acetylsalicylic acid (ASA) therapy|(81mg/day)
174528|NCT02836639|Drug|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
174529|NCT02836639|Drug|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
174530|NCT02836639|Drug|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
174531|NCT02836626|Procedure|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
174532|NCT02836626|Procedure|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
174533|NCT02836613|Biological|Galcanezumab|Administered SC
174534|NCT02836600|Drug|LY3039478|Administered orally
174535|NCT02836587|Behavioral|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
174536|NCT02836574|Biological|Neo-Kidney Augment (NKA)|Autologous selected renal cells (SRC).
174537|NCT02836561|Other|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
174538|NCT02836548|Drug|Vorinostat|vorinostat 360 milligram once daily
174539|NCT02836535|Behavioral|qualitative interviews|
174543|NCT02836496|Drug|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
174544|NCT02836496|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
174545|NCT02836496|Drug|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
174546|NCT02836496|Drug|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
174547|NCT02836483|Drug|LCB01-0371 800mg, QD|Oral administration
174548|NCT02836483|Drug|LCB01-0371 400mg, BID|Oral administration
174549|NCT02836483|Drug|LCB01-0371 800mg, BID|Oral administration
174550|NCT02836483|Drug|Tubes 3~5Tablet, QD|Oral administration
174551|NCT02836483|Drug|Zyvox 600mg, BID|Oral administration
174552|NCT02836470|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
174553|NCT02836470|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
174554|NCT02836457|Drug|ELIQUIS (APIXABAN)|
174555|NCT02836431|Drug|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
174556|NCT02836431|Drug|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
174557|NCT02836431|Drug|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
174558|NCT02836418|Drug|ATYR1940|ATYR1940 at a dose no greater than 3.0 mg/kg administered via IV infusion over 90 minutes once weekly.
174559|NCT02836405|Device|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
174560|NCT02836392|Behavioral|Questionnaire|
174561|NCT02836379|Other|No intervention|No intervention
174562|NCT02836353|Drug|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
174563|NCT02836353|Drug|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
174564|NCT02836340|Drug|2-Iminobiotin|The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
174565|NCT02836327|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging
174566|NCT02836314|Other|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
174567|NCT02836314|Other|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
174568|NCT02836301|Behavioral|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
174569|NCT02836301|Behavioral|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots…a missed opportunity.
174570|NCT02836301|Behavioral|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
174571|NCT02836288|Drug|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
174572|NCT02836288|Other|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
174573|NCT02836275|Other|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
174574|NCT02836262|Device|HIT Hip Replacement System|HIT Hip Replacement System
174575|NCT02836249|Drug|TAF|TAF 25 mg tablet administered orally once daily
174576|NCT02836249|Drug|TDF|TDF 300 mg tablet administered orally once daily
174577|NCT02836249|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
174578|NCT02836249|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
174579|NCT02836236|Drug|TAF|TAF 25 mg tablet administered orally once daily
174580|NCT02836236|Drug|TDF|TDF 300 mg tablet administered orally once daily
174581|NCT02836236|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
174582|NCT02836236|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
174583|NCT02836223|Device|Interdental cleaning device|Water Flosser
174584|NCT02836223|Device|Manual Tooth brush|Control
174585|NCT02836210|Device|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
174665|NCT02835612|Other|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
174823|NCT02834390|Drug|Cytarabine|"[Induction period] Once-daily intravenous injection of 100 mg/m2 cytarabine on day 1 to 7.~[Consolidation period] Twice-daily intravenous injection of 3.0 g/m2 cytarabine at 12-hour intervals on day 1, 3, and 5."
174586|NCT02836197|Behavioral|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
174587|NCT02836184|Drug|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
174588|NCT02836184|Drug|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
174589|NCT02836171|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
174590|NCT02836171|Drug|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
174591|NCT02836158|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
174592|NCT02836145|Other|Differentiation of hiPSCs to skeletal muscle progenitors|
174593|NCT02836132|Behavioral|Weight Watchers Online|
174594|NCT02836132|Behavioral|Experience Success Virtual Reality Platform|
174595|NCT02836106|Other|Butter|Butter with jam and three slices of bread
174596|NCT02836106|Other|Cheese|Cheese with jam and three slices of bread
174597|NCT02836106|Other|Whipped cream|Whipped cream with jam and three slices of bread
174598|NCT02836106|Other|Sour cream|Sour cream with jam and three slices of bread
174599|NCT02836093|Behavioral|FACIT-Fatigue 52-point questionnaire|
174600|NCT02836080|Behavioral|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
174601|NCT02836080|Other|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
174602|NCT02836067|Behavioral|Counseling|Smoking cessation counseling
174603|NCT02836067|Other|Smoking Cessation drugs|Medication to aid smoking cessation
174604|NCT02836067|Procedure|Bronchoscopy|Bronchoscopy
174605|NCT02836067|Procedure|Blood Draw|Screening and research blood draws
174606|NCT02836067|Behavioral|Questionnaires|Behavioral questionnaires
174607|NCT02836054|Procedure|lumbar puncture (LP)|
174608|NCT02836054|Procedure|brain MRI|
174609|NCT02836041|Behavioral|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):~In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
174610|NCT02836041|Device|actigraph|This device reliably measures sleep by monitoring the child's motion.
174611|NCT02836028|Drug|Talazoparib|Talazoparib monotherapy 1mg/day orally
174612|NCT02836028|Drug|Temozolomide|temozolomide 37.5 mg/m2 on days 1-5 of each cycle
174613|NCT02836015|Behavioral|Shared Medical Visit|The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
174614|NCT02836002|Drug|Sulfadoxine-pyrimethamine (low dose)|- subcurative regimen (500mg/25mg)
174615|NCT02836002|Drug|Piperaquine (low dose)|- subcurative regimen (480 mg)
174616|NCT02836002|Drug|Sulfadoxine-pyrimethamine (high dose)|- curative regimen (1000mg/50mg)
174617|NCT02836002|Drug|Piperaquine (high dose)|- curative regimen (960 mg)
174618|NCT02836002|Biological|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
174619|NCT02836002|Drug|Atovaquone-proguanil|- curative regimen: 1000/400 mg, for 3 days
174620|NCT02835989|Other|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
174621|NCT02835976|Drug|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
174622|NCT02835963|Other|Data collection|Usual data collection
174821|NCT02834403|Drug|Enteric-coated aspirin|non-steroidal anti-inflammatory drug
175229|NCT02831361|Drug|Gemigliptin|
302097|NCT01898819|Drug|saline|
174623|NCT02835950|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
174624|NCT02835937|Other|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
174625|NCT02835924|Drug|Regorafenib|
174626|NCT02835898|Other|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
174627|NCT02835885|Device|Digitmer High Voltage Stimulator model DS7A TENS unit|
174628|NCT02835872|Other|dietary fiber|Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
174629|NCT02835859|Other|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
174630|NCT02835859|Other|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
174631|NCT02835846|Drug|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
174632|NCT02835833|Drug|Nintedanib|Nintedanib will be given twice daily at either 150 mg or 200 mg.
174633|NCT02835833|Drug|Bevacizumab|Bevacizumab will be given at 15 mg/kg
174634|NCT02835820|Dietary Supplement|Ketogenic Diet|12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
174635|NCT02835807|Behavioral|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
174636|NCT02835807|Behavioral|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
174637|NCT02835794|Drug|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
174638|NCT02835794|Drug|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
174639|NCT02835794|Drug|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
174640|NCT02835781|Other|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
174641|NCT02835768|Other|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
174642|NCT02835755|Other|Educational Intervention|Receive standard HPV and HPV vaccine information
174643|NCT02835755|Other|Educational Intervention|Receive mHealth HPV vaccine intervention
174644|NCT02835755|Other|Survey Administration|Ancillary studies
174645|NCT02835742|Drug|Sargramostim|
174646|NCT02835742|Drug|Placebo|
174647|NCT02835729|Drug|Idarubicin|Chemotherapy
174648|NCT02835729|Drug|Cytarabine|Chemotherapy
174649|NCT02835729|Drug|Indoximod Freebase|IDO pathway inhibitor
174650|NCT02835729|Drug|Indoximod HCL F1|IDO pathway inhibitor
174651|NCT02835729|Drug|Indoximod HCL F2|IDO pathway inhibitor
174652|NCT02835716|Drug|roflumilast|DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
174653|NCT02835716|Biological|ustekinumab|STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body
174654|NCT02835703|Procedure|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
174655|NCT02835690|Biological|Pembrolizumab|IV infusion
174656|NCT02835677|Behavioral|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
174657|NCT02835664|Dietary Supplement|Nicotinamide Riboside (Niagen)|
174658|NCT02835664|Dietary Supplement|Placebo|
174659|NCT02835651|Dietary Supplement|Palmitic acid|Experimental products are enriched with C16:0
174660|NCT02835651|Dietary Supplement|Stearic acid|Experimental products are enriched with C18:0
174661|NCT02835638|Device|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
174662|NCT02835625|Radiation|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
174663|NCT02835625|Radiation|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
174664|NCT02835612|Other|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
174666|NCT02835586|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
174667|NCT02835560|Drug|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
174668|NCT02835560|Drug|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
174669|NCT02835547|Other|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
174670|NCT02835534|Drug|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
174671|NCT02835534|Drug|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
174672|NCT02835521|Procedure|Reception|
174673|NCT02835521|Drug|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
174674|NCT02835508|Drug|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
174675|NCT02835508|Drug|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
174676|NCT02835508|Drug|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
174677|NCT02835495|Behavioral|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
174678|NCT02835495|Behavioral|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
174679|NCT02835482|Procedure|Femtolaser surgery|
174680|NCT02835482|Procedure|Phacoemulsification|
174681|NCT02835469|Drug|Menotrophin|
174682|NCT02835456|Device|Sharklet Catheter insertion|
174683|NCT02835456|Device|Silicone Foley Catheter insertion|
174684|NCT02835443|Device|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
174685|NCT02835430|Procedure|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
174686|NCT02835430|Procedure|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
174687|NCT02835404|Drug|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
174688|NCT02835404|Radiation|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
174689|NCT02835404|Radiation|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
174690|NCT02835391|Device|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
174691|NCT02835391|Device|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
174692|NCT02835391|Procedure|Electrocautery/Diatermy|Procedure for the control of bleeding
174693|NCT02835378|Other|No intervention|
174694|NCT02835352|Other|Essential oils massages|
174695|NCT02835352|Other|Oil massages|
174696|NCT02835339|Drug|Magnesium sulfate 4g loading dose, 1g/hr infusion|
174697|NCT02835339|Drug|Magnesium sulfate 6g loading dose, 2g/hr infusion|
174698|NCT02835326|Behavioral|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
174699|NCT02835326|Behavioral|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
174700|NCT02835313|Behavioral|FAST|Subjects participate in fast walking training 3x/week for 12 weeks.
174701|NCT02835313|Behavioral|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
174702|NCT02835313|Behavioral|SAM|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
174703|NCT02835300|Behavioral|CampAir|CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.
174704|NCT02835300|Behavioral|Information and Referral|The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
175230|NCT02831361|Drug|Gemigliptin placebo|
174705|NCT02835287|Other|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
174706|NCT02835274|Device|BSC Deep Brain Stimulation System with Directional Lead|
174707|NCT02835261|Other|Sleep Restriction|Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
174708|NCT02835248|Other|Fall Detection|All participants will wear a device configured to detect falls.
174709|NCT02835235|Drug|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
174710|NCT02835235|Drug|placebo|Administered daily subcutaneously (s.c., under the skin)
174711|NCT02835222|Drug|Cytarabine|Given IV
174712|NCT02835222|Drug|Daunorubicin Hydrochloride|Given IV
174713|NCT02835222|Drug|Selinexor|Given PO
174714|NCT02835209|Other|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
174715|NCT02835183|Device|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
174716|NCT02835183|Device|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
174717|NCT02835170|Biological|Autologous immunoglobulin|Autologous immunoglobulin (total IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
174718|NCT02835170|Other|Placebo|"Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).~(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)"
174719|NCT02835157|Drug|Balanced salt solution|Balanced salt solutions as boluses of 20 ml/kg would be administered.
174720|NCT02835157|Drug|Normal saline|Normal saline as boluses of 20 ml/kg would be administered
174721|NCT02835144|Other|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
174722|NCT02835144|Other|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
174723|NCT02835131|Drug|Pasireotide|
174724|NCT02835118|Drug|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
174725|NCT02835118|Drug|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
174726|NCT02835105|Drug|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
174727|NCT02835105|Drug|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
174728|NCT02835092|Other|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 & 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
174729|NCT02835092|Other|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 & 2 & 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
174730|NCT02835092|Other|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
174731|NCT02835079|Drug|Tamoxifen|
174732|NCT02835066|Other|Integrated Fitness Assessment|Undergo function/fitness assessment
174733|NCT02835066|Procedure|Psychosocial Assessment and Care|Undergo psychosocial health assessments
174734|NCT02835066|Procedure|Quality-of-Life Assessment|Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
174735|NCT02835053|Other|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
174736|NCT02835040|Other|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
174737|NCT02835040|Other|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
174738|NCT02835027|Procedure|Open versus endovascular surgery|Treatment for acute ischemia
174739|NCT02835014|Behavioral|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
174740|NCT02835014|Behavioral|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
174741|NCT02835014|Behavioral|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
174742|NCT02835001|Procedure|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
174743|NCT02835001|Device|Lung Volume Reduction Coil (HEAT-LVRC)|Bronchoscopy with Heat-LVRC
174744|NCT02834975|Drug|Pembrolizumab|Pembrolizumab on Day 1, every 21 days per protocol.
174745|NCT02834975|Drug|Paclitaxel|Paclitaxel on Day 1, every 21 days per protocol.
174746|NCT02834975|Drug|Carboplatin|Carboplatin every 21 days per protocol.
174747|NCT02834962|Procedure|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
174748|NCT02834962|Procedure|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
174749|NCT02834949|Behavioral|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
174750|NCT02834949|Behavioral|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
174751|NCT02834949|Behavioral|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
174752|NCT02834936|Drug|pyrotinib|
174753|NCT02834923|Behavioral|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
174754|NCT02834923|Behavioral|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
174755|NCT02834910|Other|collection of bacterial sample|
174756|NCT02834897|Radiation|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
174757|NCT02834884|Genetic|Biomarker assessment|Predictive and prognostic biomarker assessment
174758|NCT02834884|Diagnostic Test|NGS, IHC|Diagnostic tests to check eligibility for a specific targeted trial
174759|NCT02834871|Device|Electromyogram|
174760|NCT02834858|Biological|Umbilical Cord Mesenchymal Stem Cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
174761|NCT02834858|Biological|saline|
174762|NCT02834845|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
174763|NCT02834845|Drug|Desflurane|Desflurane %6-8 for general anesthesia maintenance
174764|NCT02834832|Device|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
174765|NCT02834819|Drug|3% Nebulized Hypertonic Saline|
174766|NCT02834806|Device|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
174767|NCT02834793|Drug|Placebo|Participants will receive matching placebo in Randomization phase.
174768|NCT02834793|Drug|Perampanel|Participants will receive perampanel in Randomization phase, open-label Extension A, and open-label Extension B.
174769|NCT02834780|Drug|H3B-6527|H3B-6527 by mouth once or twice daily at specified doses.
174770|NCT02834767|Device|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
174771|NCT02834767|Device|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
174772|NCT02834754|Drug|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
174773|NCT02834754|Drug|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
174774|NCT02834741|Drug|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
174775|NCT02834728|Behavioral|telephone interview|
174776|NCT02834715|Dietary Supplement|Stevia rebaudiana liquid extract|Sweetener made of liquid stevia self administered daily for 30 days
174822|NCT02834390|Drug|quizartinib|[Induction period] Once-daily repeated oral administration day 8 to day 21. [Consolidation period] Once-daily repeated oral administration day 6 to day 19.
174824|NCT02834390|Drug|Idarubicin|Either Idarubicin or Daunorubicin will be used [Induction period] Once-daily intravenous injection of 12 mg/m2 idarubicin on day 1 to 3.
174777|NCT02834702|Device|Sinew acupuncture|The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.
174778|NCT02834702|Device|Sham acupuncture|The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
174779|NCT02834689|Behavioral|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
174780|NCT02834689|Behavioral|Seated Control|Sitting for 50 minutes
174781|NCT02834676|Drug|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
174782|NCT02834663|Drug|Lucentis|
174783|NCT02834650|Other|Cardiac MRI with contrast|Cardiac MRI
174784|NCT02834650|Other|Cardiac MRI without contrast|Cardiac MRI
174785|NCT02834650|Other|Blood Test|Hematocrit, Creatinine, Troponin, BNP
174786|NCT02834650|Other|Heart Rate|Holter Monitor
174787|NCT02834650|Other|Pulmonary Function Test|Pulmonary Function Test
174788|NCT02834650|Other|Genetic Testing|Genetic Testing
174789|NCT02834650|Other|Repeat MRI scan|Repeat MRI scan
174790|NCT02834637|Drug|bivalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
174791|NCT02834637|Drug|nonavalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
174792|NCT02834624|Drug|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
174793|NCT02834624|Drug|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
174794|NCT02834611|Drug|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
174795|NCT02834598|Device|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
174796|NCT02834585|Other|Ultrasound|
174797|NCT02834572|Behavioral|All About Me|Assessment and algorithm to determine recommended HIV testing approach
174798|NCT02834572|Behavioral|Control|HIV testing information
174799|NCT02834559|Drug|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
174800|NCT02834559|Drug|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
174801|NCT02834546|Biological|Sorafenib plasma concentration 4 weeks after treatment initiation|Sorafenib plasma concentrations will be assessed at 4, 8 and 16 weeks by high performance liquid chromatography. The pharmacology Unit of Bordeaux university hospital (Pr Molimard) is a French Center of reference for the dosage of TKI in the plasma
174802|NCT02834533|Device|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
174803|NCT02834507|Drug|Placebo|Matching placebo capsules
174804|NCT02834507|Drug|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
174805|NCT02834507|Drug|Comtan®|Capsules containing entacapone 200 mg
174806|NCT02834507|Drug|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
174807|NCT02834494|Procedure|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
174808|NCT02834494|Biological|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
174809|NCT02834481|Device|ANI/NIPE|ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
174810|NCT02834468|Drug|DEX Combined With RTX, CSA and IVIG|The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
174811|NCT02834455|Device|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
174812|NCT02834455|Device|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
174813|NCT02834442|Drug|MT-7117|
174814|NCT02834442|Drug|Placebo|
174815|NCT02834416|Behavioral|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
174816|NCT02834416|Behavioral|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
174817|NCT02834403|Drug|L-NMMA|Nitric oxide synthase inhibitor
174818|NCT02834403|Drug|Docetaxel|Mitotic inhibitor, cytotoxic
174819|NCT02834403|Drug|Amlodipine|Long-acting calcium channel blocker
174820|NCT02834403|Drug|Pegfilgrastim|Colony-stimulating factor
174825|NCT02834390|Drug|Daunorubicin|Either Idarubicin or Daunorubicin will be used [Induction period] Once-daily intravenous injection of 60mg/m2 daunorubicin on day 1 to 3.
174826|NCT02834377|Other|Treatment algorithm targeting individual cardiac output|
174827|NCT02834364|Drug|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
174828|NCT02834364|Drug|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
174829|NCT02834351|Other|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.~the activity of the complex 1 is analyzed and compared between the 2 groups."
174830|NCT02834338|Device|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
174831|NCT02834325|Procedure|mechanical ventilation|
174832|NCT02834312|Drug|Estetrol|All treatments (E4 [2.5 mg, 5 mg, 10 mg, 15 mg] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
174833|NCT02834312|Drug|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
174834|NCT02834299|Behavioral|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
174835|NCT02834299|Behavioral|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
174836|NCT02834299|Behavioral|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
174837|NCT02834286|Drug|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
174838|NCT02834286|Drug|Eltrombopag|Eltrombopag 50 mg PO days 1-28
174839|NCT02834286|Drug|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
174840|NCT02834273|Behavioral|stroke education workshops|
174841|NCT02834260|Drug|Dexamethasone implant OZURDEX|
174842|NCT02834247|Drug|TAK-659|TAK-659 Tablets
174843|NCT02834247|Drug|Nivolumab|Nivolumab intravenous infusion
174844|NCT02834234|Genetic|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
174845|NCT02834221|Device|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
174846|NCT02834221|Other|Anatomical landmark guided puncture|Anatomical landmark puncture
174847|NCT02834208|Other|MRI (Magnetic resonance imaging)|
174848|NCT02834208|Genetic|Polymorphism (SNP in DNA)|
174849|NCT02834208|Genetic|quantitative measures of mRNA|
174850|NCT02834208|Other|Neuropsychological assessment|
174851|NCT02834182|Behavioral|IRMf|
174852|NCT02834182|Behavioral|Mini International Neuropsychiatric Interview|
174853|NCT02834182|Behavioral|Positive And Negative Syndrom Scale|
174854|NCT02834182|Behavioral|Young Mania Rating Scale|
174855|NCT02834182|Behavioral|Hamilton Depression Scale|
174856|NCT02834169|Other|Non interventional|Data collection
174857|NCT02834156|Other|LP in a seated position then LP in a lying position|
174858|NCT02834156|Other|LP in a lying position then LP in a seated position|
174859|NCT02834143|Other|No intervention|The is no intervention. This study is a descriptive one
174860|NCT02834130|Behavioral|Evaluation of psychological and psychopathological|
174861|NCT02834117|Other|natural cycle|Ovulation is not induced by drugs
174862|NCT02834117|Drug|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
174863|NCT02834104|Device|RMI|
174864|NCT02834104|Other|myocardial biopsy|
174865|NCT02834104|Biological|blood sample|
174866|NCT02834091|Procedure|Hypnoanalgesia|
174867|NCT02834078|Dietary Supplement|BGG|
174868|NCT02834078|Other|Placebo|
174869|NCT02834065|Device|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
174870|NCT02834052|Drug|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
174871|NCT02834052|Drug|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18"
174872|NCT02834039|Procedure|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
174873|NCT02834039|Procedure|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
174874|NCT02834026|Other|Cicloergometry training|
174875|NCT02834026|Other|No Cicloergometry training|
174876|NCT02834013|Procedure|Biospecimen Collection|Undergo optional collection of biopsy tissue and blood
174877|NCT02834013|Biological|Ipilimumab|Given IV
174878|NCT02834013|Biological|Nivolumab|Given IV
176425|NCT02822131|Drug|sevelamer, sodium bicarbonate, sodium chloride|
174879|NCT02834000|Device|LiDCO rapid™ CNAP monitoring|LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
174880|NCT02833987|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
174881|NCT02833987|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
174882|NCT02833987|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
174883|NCT02833987|Drug|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
174884|NCT02833974|Drug|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
174885|NCT02833974|Drug|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
174886|NCT02833961|Device|Magnetic resonance imaging|
174887|NCT02833948|Drug|Acetylicsalicylic acid|"Drug: Acetylsalicylic acid:~75 - 100 mg OD (for first 90 days only in arm 1)"
174888|NCT02833948|Drug|Clopidogrel|Drug: Clopidogrel 75 mg OD for first 90 days
174889|NCT02833948|Drug|Rivaroxaban|"Drug: Rivaroxaban (Xarelto):~10 mg OD (once-daily)"
174890|NCT02833935|Behavioral|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
174891|NCT02833922|Behavioral|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
174892|NCT02833909|Other|surgery|
174893|NCT02833896|Genetic|surgery|
174894|NCT02833883|Drug|Enzalutamide|
174895|NCT02833883|Drug|CC-115|
174896|NCT02833870|Behavioral|Musical intervention|
174897|NCT02833870|Behavioral|Non-musical (cooking) intervention|
174898|NCT02833870|Behavioral|Control with no intervention|
174899|NCT02833857|Drug|Etelcalcetide|A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
174900|NCT02833844|Drug|Repatha (Evolocumab)|Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM)
174901|NCT02833844|Drug|Placebo|Dose of subcutaneous Repatha (Evolocumab) Matching Placebo every 4 weeks (QM)
174902|NCT02833844|Drug|Repatha (Evolocumab)|Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM)
174903|NCT02833831|Drug|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
174904|NCT02833831|Drug|Placebo|Matching Placebo will be administered.
174905|NCT02833831|Drug|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
174906|NCT02833818|Dietary Supplement|CAKE-intervention|Increased protein and energy supplementation and conversations
174907|NCT02833818|Dietary Supplement|CAKE-control|nutrition according to established procedures
174908|NCT02833805|Drug|Thymoglobulin|Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
174909|NCT02833805|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
174910|NCT02833805|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
174911|NCT02833805|Radiation|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
174912|NCT02833805|Drug|Tacrolimus|Start on Day 5 through Day 365
174913|NCT02833805|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
174914|NCT02833792|Drug|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
174915|NCT02833792|Other|Placebo|Intravenous administration
174916|NCT02833779|Other|Individual exercises|
174917|NCT02833779|Other|Group exercises|
174918|NCT02833766|Drug|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
174919|NCT02833753|Drug|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.~Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy"
174920|NCT02833740|Device|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
174921|NCT02833727|Other|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
174922|NCT02833701|Dietary Supplement|Ascorbic Acid|Given IV
174923|NCT02833701|Biological|Bevacizumab|Given intravenously (IV)
174924|NCT02833701|Other|Laboratory Biomarker Analysis|Correlative studies
174925|NCT02833701|Other|Quality-of-Life Assessment|Ancillary studies
174926|NCT02833688|Drug|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
174927|NCT02833688|Drug|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
174928|NCT02833662|Other|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
174929|NCT02833649|Device|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
174930|NCT02833636|Procedure|ACEF score|
174931|NCT02833623|Behavioral|Short-message-based Re-education|
174932|NCT02833623|Behavioral|conventional education|
174933|NCT02833610|Drug|Denosumab Q4W|
174934|NCT02833584|Drug|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
174935|NCT02833584|Drug|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
174936|NCT02833558|Device|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
174937|NCT02833558|Procedure|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
174938|NCT02833545|Device|Ozone gas|Injection of ozone gas intra articularly
174939|NCT02833545|Drug|Steroid injection|Injection of steroids (diprospan) intra articularly
174940|NCT02833532|Device|Volus/Powerfill|Maximum: 22ml
174941|NCT02833519|Behavioral|group exercise|"Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.~The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).~The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.~The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.~A weekly supportive email."
174942|NCT02833506|Other|Laboratory Biomarker Analysis|Correlative studies
174943|NCT02833506|Biological|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
174944|NCT02833506|Drug|Sirolimus|Given PO
174945|NCT02833480|Drug|Fluticasone group|
174946|NCT02833480|Drug|Budesonide group|
174947|NCT02833480|Drug|Formoterol group|
174948|NCT02833454|Procedure|direct insertion anterior cruciate ligament reconstruction|ACL reconstruction based on direct insertion of ACL.
174949|NCT02833454|Procedure|single bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using single bundle technique
174950|NCT02833454|Procedure|double bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using double bundle technique
174951|NCT02833441|Behavioral|Peer Support|
174952|NCT02833428|Device|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.~• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
174953|NCT02833415|Drug|[U-13C3] glycerol|Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
174954|NCT02833415|Drug|Empagliflozin|Active drug
174955|NCT02833415|Drug|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
174956|NCT02833402|Device|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
174957|NCT02833389|Drug|Placebo|UTTR1147A matching placebo will be administered SC.
174958|NCT02833389|Drug|UTTR1147A|UTTR1147A will be administered SC.
174959|NCT02833376|Other|alcohol antisepsis|
174960|NCT02833376|Other|chlorhexidine antisepsis|
174961|NCT02833350|Drug|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
174962|NCT02833350|Drug|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
174963|NCT02833350|Drug|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
174964|NCT02833350|Drug|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
174965|NCT02833350|Drug|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
174966|NCT02833337|Radiation|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
174967|NCT02833324|Behavioral|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
174968|NCT02833324|Behavioral|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
174969|NCT02833324|Other|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
175418|NCT02829879|Drug|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
174970|NCT02833311|Behavioral|Computer Tablet Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a computer tablet.
174971|NCT02833311|Behavioral|Paper and Pencil Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a paper-pencil diary.
174972|NCT02833311|Behavioral|Standard Treatment Control Group|Participants will first meet once with a health education specialist. During this meeting the health education specialist will provide general information about engaging in healthy behaviors. Information will primarily focus on the benefits of engaging in healthy behaviors and safety precautions. Participants will then receive weekly follow-up phone calls to discuss various health topics.
174973|NCT02833298|Behavioral|Automated reminders|At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
174974|NCT02833298|Behavioral|Patient navigation|The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
174975|NCT02833272|Behavioral|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
174976|NCT02833246|Other|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
174977|NCT02833246|Other|usual care|
174978|NCT02833233|Procedure|Cryoablation|
174979|NCT02833233|Drug|Ipilimumab|
174980|NCT02833233|Drug|Nivolumab|
174981|NCT02833220|Device|Single-Pulse Transcranial Magnetic Stimulation|Single-pulse Transcranial Magnetic Stimulation activates neurons within the cortex of the brain by way of electromagnetic induction. This causes a small, focused electric field to become present in the brain, which activates the neurons.
174982|NCT02833207|Drug|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.~Details under study description."
174983|NCT02833207|Drug|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.~Details under study description."
174984|NCT02833181|Device|BIS monitor|Monitoring circadian variation of EEG
174985|NCT02833168|Other|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
174986|NCT02833168|Device|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
174987|NCT02833155|Drug|Entinostat|Given PO
174988|NCT02833155|Drug|Exemestane|Given PO
174989|NCT02833142|Drug|BIIB033 (opicinumab)|
174990|NCT02833116|Drug|Betamethasone|
174991|NCT02833116|Drug|Dexamethasone|
174992|NCT02833103|Drug|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
174993|NCT02833103|Drug|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
174994|NCT02833090|Procedure|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
174995|NCT02833077|Device|JUVÉDERM VOLUMA® XC|JUVÉDERM VOLUMA® XC is injected into the chin at a volume determined by the investigator. Eligible participants in the JUVÉDERM VOLUMA® XC arm may receive a touch-up treatment of JUVÉDERM VOLUMA® XC injected into the chin at a volume determined by the investigator. The maximum total volume administered is up to 4 mL.
174996|NCT02833064|Radiation|Non-contrast magnetic resonance imaging|
174997|NCT02833064|Other|Biological sampling|Blood, urine, stool and breath sampling and analysis
174998|NCT02833038|Drug|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
174999|NCT02833038|Drug|Normal saline|the same bolus and infusion volumes of normal saline
175000|NCT02833025|Device|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
175001|NCT02833012|Drug|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
175002|NCT02833012|Drug|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
175003|NCT02833012|Drug|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
175004|NCT02833012|Drug|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
175005|NCT02832999|Drug|sub cutaneous liraglutide|Liraglutide 1.2mg/day
175006|NCT02832999|Drug|Oral Vildagliptin|Vildagliptin 50mg/day
175007|NCT02832986|Other|Medical Questionary|"The medical questionary will contain :~Date of initial infection by Herpes zoster~Localisation~Severity~Presence of postherpetic pain~Postherpetic pain Intensity~Postherpetic pain duration~Antiviral treatment~History of chronic pathologies~Concomitant treatment"
175008|NCT02832973|Drug|Spironolactone|Spironolactone 25 mg
175009|NCT02832973|Drug|Furosemide,|Furosemide 20-40 mg
175010|NCT02832973|Drug|Amiloride|Amiloride 5 mg
175011|NCT02832973|Drug|Ramipril|Ramipril 5-10 mg
175012|NCT02832973|Drug|Bisoprolol|Bisoprolol 5-10 mg
175072|NCT02832544|Drug|Rivaroxaban (20 mg)|Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
175073|NCT02832544|Drug|Vitamin K antagonists (VKA)|
175419|NCT02829866|Device|AMIStem-H|
175013|NCT02832960|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
175014|NCT02832960|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
175015|NCT02832947|Drug|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
175016|NCT02832934|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
175017|NCT02832934|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
175018|NCT02832921|Behavioral|cognitive training by virtual reality|
175019|NCT02832921|Behavioral|watching a scientific TV documentary|
175020|NCT02832921|Device|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking—i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill—places greater demand on cognitive resources than a single task."
175021|NCT02832908|Other|Change from semi-seated position to supine|from semi-seated position (30°) to lying position
175022|NCT02832895|Other|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
175023|NCT02832882|Procedure|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
175024|NCT02832882|Procedure|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
175025|NCT02832869|Other|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
175026|NCT02832869|Other|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
175027|NCT02832856|Behavioral|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
175028|NCT02832856|Behavioral|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
175029|NCT02832830|Radiation|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
175030|NCT02832830|Radiation|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
175031|NCT02832817|Device|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
175032|NCT02832804|Device|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
175033|NCT02832791|Procedure|QUADRICEPS TENDON|Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured
175074|NCT02832531|Drug|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~Left atrial enlargement ≥ 5.5 cm, OR~Left atrial spontaneous echo contrast OR~Left atrial thrombus OR~Frequent ectopic atrial activity (>1000/24 hours) on Holter ECG."
175075|NCT02832531|Drug|Aspirin|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:~Left atrial enlargement ≥ 5.5 cm, OR~Left atrial spontaneous echo contrast OR~Left atrial thrombus OR~Frequent ectopic atrial activity (>1000/24 hours) on Holter ECG."
175034|NCT02832791|Procedure|HAMSTRING TENDON|"Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.~Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.~A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper"
175035|NCT02832778|Drug|Efavirenz|Efavirenz 400mg
175036|NCT02832778|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
175037|NCT02832778|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
175038|NCT02832778|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
175039|NCT02832778|Drug|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)
175040|NCT02832765|Radiation|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
175041|NCT02832765|Radiation|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
175042|NCT02832765|Radiation|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
175043|NCT02832765|Radiation|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
175044|NCT02832752|Procedure|ECPR Protocol|The regional protocol is activated for eligible patients who remain pulseless after 3 cycles of resuscitation, and intubation. The hospital team is activated at this time, which includes the emergency department team, a perfusionist, and a cardiovascular surgeon. A mechanical CPR device (Lucas chest compression device) is applied at this time and the patient is transported to hospital. The goal times from first professional CPR to ECMO flows is < 60 minutes, and from emergency department (ED) arrival to ECMO flows < 30 minutes.
175045|NCT02832739|Device|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==> www.senaca.ch
175046|NCT02832726|Dietary Supplement|Vitamin B12|
175047|NCT02832713|Drug|Botulinum toxin A ( BoNT-A)|Intra-articular injection of BoNT-A
175048|NCT02832713|Device|Hyaluronic acid (HA)|Intra-articular injection of Hyaluronic acid
175049|NCT02832700|Dietary Supplement|Casein glycomacropeptide|
175050|NCT02832700|Dietary Supplement|Placebo|
175051|NCT02832687|Drug|Acetaminophen|patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. <50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
175052|NCT02832687|Drug|normal saline|100mL of normal saline every 4 hours to a maximum administration of 400mL
175053|NCT02832674|Device|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
175054|NCT02832648|Dietary Supplement|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
175055|NCT02832635|Drug|TMZ|TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy
175056|NCT02832635|Radiation|WBRT with avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.
175057|NCT02832635|Radiation|WBRT without avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
175058|NCT02832622|Device|MPP|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
175059|NCT02832622|Device|BiV/MPP|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
175060|NCT02832622|Device|BiV|MPP OFF at the 12-month study visit and for at least three continuous months prior to 12-month assessment (i.e., BiV pacing ON for months 10-12)
175061|NCT02832622|Device|Other Pacing|Other pacing schemes not covered above (Retrospective categorization implemented based on the usage of MPP or BiV pacing for 12 months)
175062|NCT02832609|Other|Supine|measurements after 30 minutes in complete supine position
175063|NCT02832596|Drug|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
175064|NCT02832596|Procedure|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
175065|NCT02832583|Device|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
175066|NCT02832570|Drug|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
175067|NCT02832570|Drug|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
175068|NCT02832557|Other|Salivary collection|Collection of saliva via swab for miRNA processing
175069|NCT02832557|Other|Vineland Adaptive Behavior Scale-II Assessment|
175070|NCT02832557|Other|Medical history questionaire|
175071|NCT02832557|Other|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
175076|NCT02832505|Other|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
175077|NCT02832492|Behavioral|pupil near response|
175078|NCT02832466|Other|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
175079|NCT02832453|Behavioral|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
175080|NCT02832453|Behavioral|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
175081|NCT02832453|Behavioral|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
175082|NCT02832440|Other|Exercise programmes|
175083|NCT02832414|Behavioral|Intensive weight loss program|behavioral and dietary supplement
175084|NCT02832401|Drug|Caffeine|
175085|NCT02832401|Drug|Placebo|
175086|NCT02832375|Drug|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
175087|NCT02832375|Drug|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
175088|NCT02832362|Drug|Carbomer 980|Test product containing 0.5% carbomer 980 gel
175089|NCT02832362|Other|Placebo|Reference product containing vehicle without 0.5% carbomer 980 gel
175090|NCT02832349|Other|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
175091|NCT02832336|Drug|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
175092|NCT02832336|Drug|Fiber|Fiber will be used as placebo.
175093|NCT02832323|Biological|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
175094|NCT02832310|Procedure|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
175095|NCT02832297|Other|Vectra DA|
175096|NCT02832297|Other|Usual Care|
175097|NCT02832284|Device|iNod System|The iNod System is intended for use for diagnostic ultrasound imaging and ultrasound-guided fine needle aspiration (FNA) of extramural and submucosal lesions of the tracheobronchial tree.
175098|NCT02832271|Drug|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
175099|NCT02832271|Drug|Placebo|Placebo
175100|NCT02832232|Other|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
175101|NCT02832232|Other|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.~And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
175102|NCT02832232|Other|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
175103|NCT02832219|Dietary Supplement|Molecular hydrogen|
175104|NCT02832219|Dietary Supplement|Placebo|
175105|NCT02832206|Procedure|hybrid ablation|Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
175106|NCT02832180|Drug|OC containing EE and NET|
175107|NCT02832180|Drug|BMS-986142|
175108|NCT02832167|Biological|Nivolumab|Specified dose on specified days
175109|NCT02832154|Other|Internet-Based Intervention|Complete online PA program
175110|NCT02832154|Procedure|Quality-of-Life Assessment|Ancillary studies
175111|NCT02832154|Other|Questionnaire Administration|Ancillary studies
175112|NCT02832141|Procedure|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
175113|NCT02832141|Procedure|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
175114|NCT02832128|Drug|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
175115|NCT02832128|Drug|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
175116|NCT02832115|Drug|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
175117|NCT02832115|Drug|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
175118|NCT02832102|Procedure|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
175119|NCT02832089|Drug|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
175120|NCT02832076|Procedure|Subcutaneous negative suction drain for 10 days|
175121|NCT02832076|Procedure|No subcutaneous drain|
175122|NCT02832063|Biological|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
175123|NCT02832063|Biological|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
175124|NCT02832050|Behavioral|Play therapy|See previous description of play therapy intervention arm.
175125|NCT02832050|Behavioral|Standard of care|See previous description of comparator arm.
175126|NCT02832037|Drug|BI 425809 dose 1|
175127|NCT02832037|Drug|BI 425809 dose 2|
175128|NCT02832037|Drug|BI 425809 dose 3|
175129|NCT02832037|Drug|BI 425809 dose 4|
175130|NCT02832037|Drug|Placebo|
175131|NCT02832024|Device|plaque excision system|
175132|NCT02832024|Device|stent|
175133|NCT02832024|Device|Balloon|
175134|NCT02832011|Dietary Supplement|olive oil|The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.
175135|NCT02832011|Dietary Supplement|Eoprotin|Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.
175136|NCT02831998|Drug|ZuraPrep|Apply topically.
175137|NCT02831998|Drug|ChloraPrep|Apply topically.
175138|NCT02831998|Drug|ZP Vehicle|Apply topically.
175139|NCT02831985|Procedure|general practice follow-up|Post-surgery follow-up by general practitioner
175140|NCT02831985|Procedure|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
175141|NCT02831972|Drug|AG120|
175142|NCT02831972|Drug|Itraconazole|
175143|NCT02831959|Device|NovoTTF-100M device|
175144|NCT02831959|Other|Best Standard of Care|
175145|NCT02831946|Device|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
175146|NCT02831946|Device|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
175147|NCT02831933|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
175148|NCT02831933|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
175149|NCT02831933|Radiation|SBRT|Low-dose SBRT
175150|NCT02831933|Drug|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
175151|NCT02831920|Other|CEUS and targeted biopsies|
175152|NCT02831920|Other|MRI and targeted biopsies|
175153|NCT02831907|Procedure|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
175154|NCT02831894|Drug|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
175155|NCT02831894|Drug|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
175156|NCT02831894|Drug|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
175157|NCT02831868|Device|HAVAI|implantation of the HAVAI device to correct the IMA angle
175158|NCT02831855|Drug|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
175159|NCT02831855|Drug|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.~During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
175160|NCT02831855|Drug|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
175161|NCT02831842|Drug|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
175162|NCT02831842|Drug|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
175163|NCT02831842|Drug|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
175164|NCT02831829|Other|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
175165|NCT02831829|Other|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
175166|NCT02831816|Drug|ZuraPrep|Apply topically.
175167|NCT02831816|Drug|ChloraPrep|Apply topically.
175168|NCT02831816|Drug|ZP Vehicle|Apply topically.
175169|NCT02831803|Dietary Supplement|Walnuts|28 gm/day in single-serve package
175170|NCT02831803|Dietary Supplement|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
175205|NCT02831517|Drug|Placebo|Matched Placebo
175206|NCT02831491|Drug|Ramucirumab|Administered IV
175207|NCT02831491|Drug|Docetaxel|Administered IV
175208|NCT02831478|Drug|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
175171|NCT02831790|Other|Fontan Education Videos|"The intervention will consist of three brief (~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:~Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.~Anticoagulation~Prolonged pleural drainage"
175172|NCT02831777|Device|non-invasive blood pressure monitor|Equivalence of CareTaker blood pressure to classical sphygmomanometry
175173|NCT02831764|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
175174|NCT02831764|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
175175|NCT02831764|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
175176|NCT02831751|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
175177|NCT02831751|Biological|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
175178|NCT02831751|Biological|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
175179|NCT02831751|Biological|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
175180|NCT02831738|Dietary Supplement|Polydextrose|Polydextrose 12 g
175181|NCT02831738|Dietary Supplement|Control Treatment|no polydextrose
175182|NCT02831712|Dietary Supplement|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
175183|NCT02831686|Drug|Selinexor|
175184|NCT02831686|Drug|Ixazomib|
175185|NCT02831686|Drug|Dexamethasone|
175186|NCT02831673|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
175187|NCT02831673|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
175188|NCT02831673|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
175189|NCT02831660|Drug|idarucizumab|
175190|NCT02831647|Dietary Supplement|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
175191|NCT02831634|Procedure|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
175192|NCT02831621|Behavioral|lifestyle intervention (diet OR diet+exercise)|diet or diet+fitness training
175193|NCT02831608|Biological|Influenza vaccine|
175194|NCT02831608|Biological|Placebo|
175195|NCT02831595|Device|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
175196|NCT02831582|Dietary Supplement|Omega-3 Fatty Acid|Given PO.
175197|NCT02831582|Other|Placebo|Given PO.
175198|NCT02831569|Drug|Loxoprofen sodium|
175199|NCT02831569|Drug|Methocarbamol|
175200|NCT02831543|Drug|Motireb 5/100 mg|
175201|NCT02831543|Drug|Mosapride citrate|
175202|NCT02831543|Drug|Placebo|
175203|NCT02831530|Drug|Abemaciclib|
175204|NCT02831517|Drug|BIIB074|Administered as specified in the treatment arm
175210|NCT02831465|Behavioral|Healthy Subjects|Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
175211|NCT02831452|Other|pelvic floor muscle strength evaluation|
175212|NCT02831439|Behavioral|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
175213|NCT02831439|Behavioral|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
175214|NCT02831439|Behavioral|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
175215|NCT02831426|Device|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
175216|NCT02831426|Device|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
175217|NCT02831413|Behavioral|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
175218|NCT02831413|Behavioral|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
175219|NCT02831400|Behavioral|Walking test|Walking test to increase cardiac output, maximum 12 minutes
175220|NCT02831400|Behavioral|Standard Meal|After the walking test, volunteers eat a standard warm meal
175221|NCT02831387|Drug|P-321 Ophthalmic Solution|P-321 Ophthalmic Solution 0.017%
175222|NCT02831387|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
175223|NCT02831374|Drug|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
175224|NCT02831374|Procedure|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
175225|NCT02831374|Biological|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
175226|NCT02831374|Procedure|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
175227|NCT02831374|Procedure|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
175228|NCT02831374|Drug|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
175231|NCT02831361|Drug|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
175232|NCT02831361|Procedure|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.~the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
175233|NCT02831335|Other|MRI|Perform MRI studies
175234|NCT02831335|Other|MRI|Perform MRI studies
175235|NCT02831335|Other|MRI|Perform MRI studies
175236|NCT02831335|Other|Group 4|Perform MRI studies
175237|NCT02831322|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
175238|NCT02831309|Behavioral|Light-Intensity Condition|The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
175239|NCT02831309|Behavioral|Moderate-Intensity Condition|The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
175240|NCT02831309|Behavioral|High-Intensity Condition|The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
175241|NCT02831309|Behavioral|Sedentary Condition|The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
175242|NCT02831283|Drug|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
175243|NCT02831283|Drug|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
175244|NCT02831283|Procedure|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
175245|NCT02831270|Procedure|Acute normovolemic hemodilution (ANH)|
175246|NCT02831270|Drug|hydroxyethyl starch (HES 130/0.6)|
175247|NCT02831257|Drug|AZD2014|
175248|NCT02831244|Device|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
175249|NCT02831231|Drug|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
175250|NCT02831231|Drug|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
175251|NCT02831218|Procedure|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
175252|NCT02831218|Procedure|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
175253|NCT02831218|Procedure|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
175254|NCT02831218|Procedure|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
175255|NCT02831205|Device|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
175256|NCT02831205|Device|everolimus-eluting cobalt-chromium (Xience) stent|
175257|NCT02831192|Biological|microtransplantation|HLA mismatched donor mobilized prepheral stem cell infusion
175258|NCT02831179|Drug|Capecitabine|Given PO
175259|NCT02831179|Drug|Temozolomide|Given PI
175260|NCT02831179|Drug|Veliparib|given PO
175261|NCT02831179|Other|Pharmacological Study|Correlative studies
175262|NCT02831179|Other|Laboratory Biomarker Analysis|Correlative studies
175263|NCT02831166|Procedure|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
175290|NCT02831023|Drug|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
175291|NCT02831023|Drug|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
175292|NCT02830997|Device|Stereotactic guidance system|
175490|NCT02829177|Drug|Placebo|
175264|NCT02831166|Procedure|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
175265|NCT02831153|Procedure|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
175266|NCT02831140|Behavioral|Early exercises|"In postoperative phase:~Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
175267|NCT02831140|Behavioral|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
175268|NCT02831140|Behavioral|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
175269|NCT02831140|Behavioral|commun interventions|"In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.~In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall~, preservation of Serratus anterior and the front part of Latissimus Dorsi ).~In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
175270|NCT02831127|Other|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
175271|NCT02831127|Other|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
175272|NCT02831114|Other|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
175273|NCT02831101|Drug|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
175274|NCT02831101|Drug|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
175275|NCT02831088|Drug|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
175276|NCT02831088|Drug|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
175277|NCT02831088|Drug|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
175278|NCT02831075|Biological|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
175279|NCT02831075|Biological|saline|
175280|NCT02831062|Other|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
175281|NCT02831049|Behavioral|Retrieval-extinction|Retrieval-extinction
175282|NCT02831049|Behavioral|Extinction|extinction
175283|NCT02831049|Behavioral|Retrieval|Retrieval
175284|NCT02831036|Other|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
175285|NCT02831036|Other|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
175286|NCT02831036|Other|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
175287|NCT02831023|Drug|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
175288|NCT02831023|Drug|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
175289|NCT02831023|Drug|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
175293|NCT02830984|Procedure|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
175294|NCT02830984|Procedure|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
175295|NCT02830971|Procedure|Doing Different ICU techniques and skills|
175296|NCT02830958|Device|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
175297|NCT02830958|Other|No intervention|No intervention. Uses of an ordinary tape
175298|NCT02830945|Behavioral|Motivational Interviewing Intervention Arm|
175299|NCT02830945|Other|Control Brochure Arm|
175300|NCT02830932|Biological|VXA-RSV-f Tablets (high dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
175301|NCT02830932|Other|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
175302|NCT02830932|Biological|VXA-RSV-f Tablets (low dose)|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the low dose
175303|NCT02830919|Drug|Glucosamine and chondroitin sulfate combination (Eurofarma)|
175304|NCT02830919|Drug|Glucosamine and chondroitin sulfate combination (Zodic)|
175305|NCT02830906|Drug|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
175306|NCT02830906|Drug|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
175307|NCT02830893|Device|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
175308|NCT02830893|Behavioral|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
175309|NCT02830880|Drug|FACBC PET-CT|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
175310|NCT02830880|Other|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or Bone scan will be performed to correlate imaging findings.
175311|NCT02830854|Other|Molecular Hydrogen|
175312|NCT02830841|Device|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
175313|NCT02830841|Device|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
175314|NCT02830828|Other|Investigation of precision pinch grip control|
175315|NCT02830802|Other|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
175316|NCT02830802|Other|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash."
175317|NCT02830789|Dietary Supplement|Calcium Carbonate|
175318|NCT02830789|Dietary Supplement|Calcium Citrate|
175319|NCT02830789|Dietary Supplement|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
175320|NCT02830789|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
175321|NCT02830776|Drug|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
175322|NCT02830763|Dietary Supplement|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
175323|NCT02830750|Procedure|Ablation|
175324|NCT02830737|Procedure|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
175325|NCT02830737|Procedure|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
175326|NCT02830724|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W infused simultaneously with Mesna 15 mg/kg /day over 1 hr x 2 days.
175327|NCT02830724|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
175328|NCT02830724|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum 9 doses).
175329|NCT02830724|Biological|Anti-hCD70 CAR transduced PBL|Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes.
175330|NCT02830711|Other|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
175368|NCT02830256|Other|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
175826|NCT02826681|Drug|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
175331|NCT02830685|Device|DTI with Acellular Dermal Matrix (CELLIS® Breast)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
175332|NCT02830685|Device|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
175333|NCT02830672|Procedure|Surgical release A1 pulley for Trigger finger of the hand|
175334|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
175335|NCT02830633|Procedure|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
175336|NCT02830633|Procedure|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
175337|NCT02830620|Other|Dosage of chimiokines|
175338|NCT02830607|Device|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
175339|NCT02830594|Radiation|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
175340|NCT02830594|Other|Laboratory Biomarker Analysis|Correlative studies
175341|NCT02830594|Biological|Pembrolizumab|Given IV
175342|NCT02830568|Procedure|open donor nephrectomy|open donor nephrectomy
175343|NCT02830568|Procedure|standard and hand-assisted laparoscopic donor nephrectomy|standard and hand-assisted laparoscopic donor nephrectomy
175344|NCT02830568|Procedure|laparoscopic robotic-assisted nephrectomy|laparoscopic robotic-assisted nephrectomy
175345|NCT02830542|Drug|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
175346|NCT02830542|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
175347|NCT02830529|Behavioral|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
175348|NCT02830529|Behavioral|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
175349|NCT02830516|Other|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
175350|NCT02830503|Procedure|Feeding tube daily replacement|Feeding tubes replaced once a day in the first week of life.
175351|NCT02830490|Other|functional tests|Test-retest reliability of physical function in hemodialysis patients
175352|NCT02830477|Biological|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973|unmodified, full length recombinant FVIII
175353|NCT02830438|Device|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
175354|NCT02830425|Other|No intervention|
175355|NCT02830412|Other|Postoperative nausea and vomiting (PONV) reminder|The postoperative nausea and vomiting (PONV) electronic reminder will be programmed to assess the patient risk for PONV according to the risk factors identified by Apfel and Koivuranta. The PONV risk assessment and current guidelines will be displayed electronically for patients randomized to receive the reminder.
175356|NCT02830399|Device|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
175357|NCT02830399|Device|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
175358|NCT02830386|Device|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
175359|NCT02830373|Device|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
175360|NCT02830360|Drug|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
175361|NCT02830360|Procedure|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
175362|NCT02830347|Drug|Amoxicillin|Extraction
175363|NCT02830347|Procedure|Extraction|Extraction of third molars
175364|NCT02830321|Other|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
175365|NCT02830295|Other|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
175366|NCT02830282|Other|Blood Collection|
175367|NCT02830269|Device|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
175369|NCT02830243|Drug|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
175370|NCT02830243|Drug|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
175371|NCT02830230|Drug|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
175372|NCT02830204|Device|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
175373|NCT02830165|Other|Laboratory Biomarker Analysis|Correlative studies
175374|NCT02830165|Other|Quality-of-Life Assessment|Ancillary studies
175375|NCT02830165|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
175376|NCT02830152|Device|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
175377|NCT02830152|Drug|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
175378|NCT02830139|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
175379|NCT02830139|Procedure|Radical colorectal resection|radical colorectal resection with lymphadenectomy
175380|NCT02830139|Drug|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
175381|NCT02830139|Drug|Normal saline , Cisplatin , 5-Fu|
175382|NCT02830126|Other|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
175383|NCT02830113|Procedure|non-surgical periodontal treatment|One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
175384|NCT02830100|Other|Healthy volunteers|Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
175385|NCT02830100|Device|MRI|
175386|NCT02830087|Procedure|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
175387|NCT02830074|Behavioral|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
175388|NCT02830074|Behavioral|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
175389|NCT02830061|Other|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
175390|NCT02830048|Drug|Glibenclamide|
175391|NCT02830035|Procedure|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
175392|NCT02830035|Procedure|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
175393|NCT02830022|Other|physiological explorations|
175394|NCT02830009|Other|Urines samples|24-hour urines will be collected
175395|NCT02830009|Other|Blood sample|
175396|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
175397|NCT02829996|Drug|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
175398|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
175399|NCT02829996|Drug|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
175400|NCT02829996|Drug|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
175401|NCT02829983|Drug|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
175402|NCT02829983|Drug|Placebo|Use of placebo tablets twice a day for 3 days.
175403|NCT02829983|Other|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
175404|NCT02829970|Behavioral|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention & Alcohol Disorders (BAAAD).
175405|NCT02829970|Behavioral|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
175406|NCT02829957|Drug|Apixaban|10mg BID for 7 days, then 5mg BID for three months
175407|NCT02829957|Drug|Rivaroxaban|15mg BID for 7 days, then 20mg daily for three months
175408|NCT02829944|Drug|Ropivacaine|
175409|NCT02829944|Drug|Ketorolac|
175410|NCT02829944|Drug|Placebo|
175411|NCT02829931|Radiation|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
175412|NCT02829931|Drug|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
175413|NCT02829931|Drug|Bevacizumab|Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
175414|NCT02829931|Drug|Ipilimumab|Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
175415|NCT02829918|Drug|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 mg Q4W from 17 weeks to end of study.
175416|NCT02829892|Device|Light therapy|14-days exposure with an innovative ambient light
175417|NCT02829879|Drug|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
175420|NCT02829853|Genetic|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo & HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
175421|NCT02829840|Drug|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.~Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.~Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
175422|NCT02829840|Drug|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.~Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
175423|NCT02829840|Behavioral|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).~If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
175424|NCT02829827|Drug|Radiprodil|Radiprodil at individualized doses.
175425|NCT02829814|Drug|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
175426|NCT02829814|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
175427|NCT02829801|Behavioral|AAT and cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.~Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...)."
175428|NCT02829801|Behavioral|Cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.~Then, the same cognitive stimulation in the AAT arm will be offered."
175429|NCT02829788|Other|Non interventional|Peroperative data collection
175430|NCT02829775|Drug|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
175431|NCT02829775|Drug|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
175432|NCT02829762|Other|Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance|Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
175433|NCT02829749|Device|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
175434|NCT02829749|Procedure|Control|traditional mitral valve repair performed under cardiac arrest
175435|NCT02829736|Procedure|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
175436|NCT02829736|Procedure|Standard post-operative chest tube|A regular chest tube is left in the pleura.
175437|NCT02829736|Procedure|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
175438|NCT02829723|Drug|BLZ945|
175439|NCT02829723|Drug|PDR001|
175440|NCT02829710|Behavioral|Nurse-driven sedation protocol|The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
175441|NCT02829697|Drug|Ropivacaine|Perineural injection.
175442|NCT02829684|Other|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
175443|NCT02829671|Other|Clinical and biological assessment|Blood sample, clinical assessment with quetsionnaires
175444|NCT02829658|Behavioral|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
175445|NCT02829658|Other|No intervention|No intervention
175446|NCT02829645|Other|Clinical assessment|Clinical assessment with questionnaires
175827|NCT02826681|Drug|Placebo (Normal Saline)|Normal Saline Solution
175447|NCT02829632|Behavioral|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
175448|NCT02829632|Behavioral|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
175449|NCT02829632|Behavioral|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
175450|NCT02829606|Other|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
175451|NCT02829606|Other|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
175452|NCT02829593|Other|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
175453|NCT02829580|Procedure|Echocardiography|Measures by Doppler and study of endothelial function
175454|NCT02829567|Behavioral|Motivational interviewing|
175455|NCT02829541|Drug|BIIB068|Administered as specified in the treatment arm.
175456|NCT02829541|Drug|Placebo|Administered as specified in the treatment arm
175457|NCT02829528|Behavioral|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
175458|NCT02829515|Procedure|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
175459|NCT02829502|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
175460|NCT02829502|Drug|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
175461|NCT02829476|Biological|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
175462|NCT02829463|Radiation|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
175463|NCT02829450|Other|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
175464|NCT02829437|Other|Treatment for EST|Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)
175465|NCT02829424|Drug|Methotrexate|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
175466|NCT02829424|Drug|Methotrexate Placebo|Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
175467|NCT02829411|Behavioral|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
175468|NCT02829411|Behavioral|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
175469|NCT02829398|Procedure|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
175470|NCT02829385|Drug|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)~Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
175471|NCT02829372|Drug|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
175472|NCT02829359|Drug|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
175473|NCT02829346|Drug|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
175474|NCT02829346|Drug|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
175475|NCT02829333|Other|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
175476|NCT02829333|Other|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
175477|NCT02829320|Drug|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
175478|NCT02829320|Drug|Iron|Subjects will receive supplemental iron therapy if ferritin is <=100 ng/mL and TSAT is <=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
175479|NCT02829307|Drug|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
175480|NCT02829294|Device|E002 - cerumen removal aid|topical treatment
175481|NCT02829281|Drug|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
175482|NCT02829281|Drug|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
175483|NCT02829281|Drug|Saline|Joint injection of Saline
175484|NCT02829268|Drug|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.~There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
175485|NCT02829255|Other|altitude exposure|altitude exposure
175486|NCT02829242|Device|NIRS Monitoring (SenSmart Monitor)|
175487|NCT02829229|Behavioral|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials & 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
175488|NCT02829190|Device|Magnetic Resonance Imaging (MRI),|Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
175489|NCT02829177|Drug|Allopurinol|
175491|NCT02829151|Drug|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
175492|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
175493|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
175494|NCT02829138|Genetic|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
175495|NCT02829138|Behavioral|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
175496|NCT02829099|Drug|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
175497|NCT02829086|Other|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
175498|NCT02829086|Other|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
175499|NCT02829086|Other|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
175500|NCT02829073|Device|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
175501|NCT02829073|Device|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
175502|NCT02829060|Drug|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
175503|NCT02829060|Drug|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
175504|NCT02829060|Drug|Ampicillin 2g|Peri-operative dose: 2 grams, IV
175505|NCT02829060|Drug|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
175506|NCT02829060|Drug|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
175507|NCT02829060|Drug|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
175508|NCT02829047|Device|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
175509|NCT02829034|Drug|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
175510|NCT02829034|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks
175511|NCT02829021|Device|FLIR ThermaCAM P-65|Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
175512|NCT02829008|Drug|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
175513|NCT02829008|Drug|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
175514|NCT02828995|Other|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:~The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.~The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.~Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
175515|NCT02828982|Device|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
175516|NCT02828982|Device|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
175517|NCT02828969|Other|Phone call or physical consultation|
175518|NCT02828943|Behavioral|IMT with High Resistance EMT|
175519|NCT02828943|Behavioral|IMT with Low Resistance EMT|
175520|NCT02828930|Drug|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
175521|NCT02828930|Drug|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
175522|NCT02828930|Drug|[13C]-radiolabeled Idasanutlin|[13C]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
175523|NCT02828930|Drug|[14C]-radiolabeled Idasanutlin|[14C]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
175524|NCT02828917|Device|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
175525|NCT02828891|Device|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
175526|NCT02828878|Biological|Allogeneic MPBC transplantation from matched related donor|
175527|NCT02828865|Device|Irreversible Electroporation (IRE) System|
175566|NCT02828553|Other|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
175567|NCT02828540|Drug|HT047 High-dose group|HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
175528|NCT02828852|Other|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.~In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
175529|NCT02828839|Procedure|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
175530|NCT02828826|Other|telephone coaching|
175531|NCT02828800|Other|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith & Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
175532|NCT02828787|Other|MRI|"The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.~The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.~The phases will be carried out in this order in each participant. They will be separated at least one night."
175533|NCT02828774|Other|there will be no intervention.|this study is observational, procedure are done in vitro and on animal models.
175534|NCT02828761|Device|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
175535|NCT02828761|Procedure|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
175536|NCT02828748|Other|no intervention in patients treatment, only biopsy taken|
175537|NCT02828735|Device|respiration assessment|Respiration Breathing Exercise
175538|NCT02828722|Other|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).~Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
175539|NCT02828722|Other|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.~Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
175540|NCT02828709|Device|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
175541|NCT02828696|Device|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
175542|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
175543|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
175544|NCT02828670|Biological|blood sample|
175545|NCT02828670|Procedure|spleen sample|
175546|NCT02828644|Device|EVO|videogame-like digital therapy
175547|NCT02828631|Device|Macintosh laryngoscope|
175548|NCT02828631|Device|McGrath videolaryngoscope|
175549|NCT02828631|Device|Pentax videolaryngoscope|
175550|NCT02828618|Procedure|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
175551|NCT02828618|Procedure|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
175552|NCT02828618|Procedure|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
175553|NCT02828618|Procedure|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
175554|NCT02828618|Drug|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
175555|NCT02828605|Device|Virtual Interactive Platform (VIP) Transplant|
175556|NCT02828592|Drug|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
175557|NCT02828592|Drug|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 & -5)
175558|NCT02828592|Radiation|Total Body Irradiation|300 cGy x1 dose (Day -1)
175559|NCT02828592|Drug|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
175560|NCT02828592|Drug|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
175561|NCT02828579|Procedure|Bariatric surgery|Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
175562|NCT02828566|Drug|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
175563|NCT02828566|Drug|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
175564|NCT02828566|Drug|IN saline 0.9%|Intranasal 0.9% normal saline
175565|NCT02828566|Drug|IV saline 0.9%|Intravenous 0.9% normal saline
175568|NCT02828540|Drug|HT047 Low-dose group|HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
175569|NCT02828540|Drug|Placebo|placebo having the same appearance as HT047 Tab. 250mg
175570|NCT02828527|Other|Observational|
175571|NCT02828501|Procedure|Spinal Manipulation|A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
175572|NCT02828488|Other|No intervention|It is a descriptive study. No intervention
175573|NCT02828475|Other|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
175574|NCT02828475|Behavioral|Standard Care|Previous standard of care based on surgeon judgement alone.
175575|NCT02828462|Other|CAPRI|
175576|NCT02828449|Behavioral|therapeutic education program|
175577|NCT02828436|Device|Precision Spectra System|Spinal Cord Stimulation
175578|NCT02828436|Behavioral|Exercise Intervention|Standard Exercise
175579|NCT02828423|Procedure|EMD|Regenerative surgery with EMD
175580|NCT02828423|Procedure|BC|Regenerative surgery with BC
175581|NCT02828410|Dietary Supplement|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
175582|NCT02828397|Drug|REGN2222|
175583|NCT02828384|Other|low fodmap diet|dietary teaching
175584|NCT02828384|Dietary Supplement|Psyllium|7.1g of psyllium daily
175585|NCT02828371|Device|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
175586|NCT02828371|Other|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
175587|NCT02828358|Drug|Azacitidine|Given IV
175588|NCT02828358|Drug|Cyclophosphamide|Given IV
175589|NCT02828358|Drug|Cytarabine|Given IV, SC, IT
175590|NCT02828358|Drug|Daunorubicin|Given IV
175591|NCT02828358|Drug|Daunorubicin Hydrochloride|Given IV
175592|NCT02828358|Drug|Dexamethasone|Given PO, NG, IV
175593|NCT02828358|Drug|Hydrocortisone Sodium Succinate|Given IT
175594|NCT02828358|Other|Laboratory Biomarker Analysis|Correlative studies
175595|NCT02828358|Drug|Leucovorin|Given PO, IV
175596|NCT02828358|Drug|Leucovorin Calcium|Given PO, IV
175597|NCT02828358|Drug|Mercaptopurine|Given PO, NG
175598|NCT02828358|Drug|Methotrexate|Given IT, IV, PO
175599|NCT02828358|Drug|Pegaspargase|Given IV
175600|NCT02828358|Other|Pharmacological Study|Correlative studies
175601|NCT02828358|Drug|Prednisolone|Given PO, NG
175602|NCT02828358|Drug|Thioguanine|Given PO, NG
175603|NCT02828358|Drug|Vincristine|Given IV
175604|NCT02828358|Drug|Vincristine Sulfate|Given IV
175605|NCT02828345|Other|Specimen Collection|
175606|NCT02828332|Other|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
175607|NCT02828332|Other|Quality of life|Evaluation of the quality of life and comorbidities
175608|NCT02828319|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
175609|NCT02828306|Other|Patient Specific Implant|Implantation of Patient Specific Implant
175610|NCT02828293|Other|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
175611|NCT02828280|Device|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
175612|NCT02828280|Device|Traditional mask|A traditional air inflated facemark used to ventilate patients
175613|NCT02828267|Behavioral|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
175614|NCT02828267|Behavioral|Standard Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.
175615|NCT02828267|Behavioral|Personalized Booster|This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
175616|NCT02828254|Drug|PRI-724|
175617|NCT02828241|Drug|DFD-04 Ointment|
175618|NCT02828241|Other|Placebo Ointment|
175619|NCT02828228|Drug|Vitamin D 1200 IU|Vitamin D 1200 IU once a day for 26 weeks
175620|NCT02828228|Drug|Placebo|placebo once a day for 26 weeks
175621|NCT02828215|Device|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.~The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
175622|NCT02828202|Other|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
175623|NCT02828202|Other|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
175697|NCT02827734|Device|multiple breath washout tests|
175698|NCT02827734|Device|impulse oscillometry|
175624|NCT02828202|Other|Quality of life|Specific questionnaires (FACT-M, EUROQUOL) at inclusion, every 3 months and before each new systemic therapy.
175625|NCT02828189|Other|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 6 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
175626|NCT02828189|Behavioral|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
175627|NCT02828189|Other|Therapeutic exercise-Physiotherapy|"15 minutes of exercise in step with moderate intensity (80% of maximum heart rate).~Force-resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk. The exercises included in the program as resistance will own body weight and exercised by the partners. In the exercises with your own body weight, intensity depend on the perception of effort that has the performer herself, and on that basis the number of repetitions will be established. In resisted exercises in pairs, you will be prompted to assistant exercising adequate strength so that the performer can perform the number of repetitions without problems.~Stretches corresponding muscle groups involved (upper limbs, lower limbs and trunk)."
175628|NCT02828176|Procedure|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.~these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
175629|NCT02828176|Procedure|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
175630|NCT02828176|Procedure|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
175631|NCT02828176|Procedure|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
175632|NCT02828163|Other|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
175633|NCT02828163|Drug|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
175634|NCT02828150|Dietary Supplement|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure [Harris-Benedict] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI >30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
175635|NCT02828124|Biological|BMS-986183|specified dose on specified days
175636|NCT02828124|Biological|Nivolumab|specified dose on specified days
175637|NCT02828111|Drug|Patidegib|
175638|NCT02828111|Drug|Vehicle gel|
175639|NCT02828098|Drug|Part 1: BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
175640|NCT02828098|Drug|Part 2: BO-112|"BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year."
175641|NCT02828085|Biological|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
175642|NCT02828072|Other|SKY therapy|slow breathing
175643|NCT02828072|Drug|usual drug therapy|
175644|NCT02828059|Drug|Ropivacaine|Surgical wound Infiltration over 48 hours
175645|NCT02828046|Biological|M281|
175646|NCT02828046|Other|Placebo|
175647|NCT02828033|Drug|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
175648|NCT02828020|Drug|Ubrogepant|50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
175649|NCT02828020|Drug|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
175650|NCT02828007|Device|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
175651|NCT02827994|Other|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.~Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
175652|NCT02827968|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
175653|NCT02827955|Device|Gamma Knife® radiosurgery bilateral|
175654|NCT02827942|Drug|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
175655|NCT02827942|Drug|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
175699|NCT02827734|Device|body plethysmography|
175700|NCT02827721|Device|impulse oscillometry|
175656|NCT02827942|Drug|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
175657|NCT02827942|Drug|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
175658|NCT02827942|Drug|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
175659|NCT02827929|Behavioral|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
175660|NCT02827916|Device|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
175661|NCT02827916|Device|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
175662|NCT02827916|Device|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
175663|NCT02827903|Drug|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
175664|NCT02827903|Drug|Metformin + placebo|Group II: Metformin + placebo,
175665|NCT02827903|Drug|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
175666|NCT02827890|Drug|Januvia Tab. 100mg|Januvia Tab. 100mg*1T/day for 5days, QD, PO
175667|NCT02827890|Drug|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg*1T/day for 5 dyas, QD, PO
175668|NCT02827877|Radiation|Copper Cu 64-DOTA-Trastuzumab|Given IV
175669|NCT02827877|Other|Laboratory Biomarker Analysis|Correlative studies
175670|NCT02827877|Biological|Pertuzumab|Given IV
175671|NCT02827877|Procedure|Positron Emission Tomography|Undergo PET
175672|NCT02827877|Procedure|Therapeutic Conventional Surgery|Undergo surgery
175673|NCT02827877|Biological|Trastuzumab|Given IV
175674|NCT02827864|Behavioral|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
175675|NCT02827864|Behavioral|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
175676|NCT02827864|Behavioral|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
175677|NCT02827851|Procedure|Liposuction|
175678|NCT02827851|Other|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
175679|NCT02827851|Other|Intraarticular administration of autologous SVF|
175680|NCT02827838|Biological|Durvalumab|Given IV
175681|NCT02827838|Other|Laboratory Biomarker Analysis|Correlative studies
175682|NCT02827838|Procedure|Therapeutic Conventional Surgery|Undergo surgery
175683|NCT02827825|Other|No intervention|No intervention. It's a study on retrospective Data
175684|NCT02827812|Other|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
175685|NCT02827812|Other|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
175686|NCT02827812|Other|Home-Based telemedicine program|"A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.~A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
175687|NCT02827799|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
175688|NCT02827799|Behavioral|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
175689|NCT02827786|Device|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
175690|NCT02827773|Other|Talking Pill Bottle|Made by Talking Rx
175691|NCT02827760|Dietary Supplement|Synergy1|Inulin type fructans
175692|NCT02827760|Dietary Supplement|Maltodextrin|
175693|NCT02827747|Other|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
175694|NCT02827747|Other|Placebo|Placebo pill
175695|NCT02827747|Dietary Supplement|Centrum|Centrum
175696|NCT02827747|Combination Product|Dietary Sources|From dietary sources of vitamins.
175706|NCT02827695|Behavioral|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
175707|NCT02827682|Device|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
175708|NCT02827682|Device|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
175709|NCT02827669|Behavioral|One Drop Experts Program|
175710|NCT02827669|Behavioral|One Drop Experts Program + Apple Watch|
175711|NCT02827656|Drug|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
175712|NCT02827656|Drug|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
175713|NCT02827643|Drug|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
175714|NCT02827643|Other|TDF/3TC or FTC/EFV|arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
175715|NCT02827630|Other|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
175716|NCT02827630|Other|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
175717|NCT02827617|Drug|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
175718|NCT02827578|Drug|Tamsulosin|Tamsulosin
175719|NCT02827578|Drug|Solifenacin|Solifenacin
175720|NCT02827578|Drug|Solifenacin placebo|Solifenacin placebo
175721|NCT02827565|Other|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
175722|NCT02827552|Other|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
175723|NCT02827539|Device|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
175724|NCT02827539|Device|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
175725|NCT02827526|Drug|Ketamine|
175726|NCT02827526|Drug|Control|
175727|NCT02827513|Drug|CTN SR1|
175728|NCT02827513|Drug|CTN XR1|
175729|NCT02827513|Drug|CTN XR2|
175730|NCT02827513|Drug|CTN XR3|
175731|NCT02827500|Drug|ivabradine|Active Comparator: ivabradine
175732|NCT02827500|Other|Usual Care|Placebo Comparator: usual care
175733|NCT02827487|Drug|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
175734|NCT02827487|Drug|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
175735|NCT02827487|Drug|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
175736|NCT02827487|Drug|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
175737|NCT02827487|Procedure|IUD|IUD insertion
175738|NCT02827474|Other|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
175739|NCT02827474|Other|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
175740|NCT02827435|Drug|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
175741|NCT02827422|Other|not provided|
175742|NCT02827409|Procedure|Short Delay Cord Clamping|Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
175743|NCT02827409|Procedure|Extended Delay Cord Clamping|Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
175744|NCT02827396|Behavioral|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.~Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
175745|NCT02827383|Behavioral|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
175746|NCT02827370|Behavioral|Behavioral Dietary Intervention|Receive dietary counseling
175747|NCT02827357|Other|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
175748|NCT02827344|Biological|blood sample collection for CTC and MDSC analysis|"Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,~Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC~Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
175749|NCT02827331|Other|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~Benzodiazepine derivatives (N05BA)~Benzodiazepine derivatives (N05CD)~Benzodiazepine related drugs (N05CF)"
175750|NCT02827331|Other|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~Antipsychotics (N05A)~Antiepileptics with the exception of clonazepam (N03)~Drugs used for alcohol dependance (N07BB)~Drugs used for opioids dependance (N07BC)"
175751|NCT02827331|Other|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
175752|NCT02827331|Other|Administrative and medical data|"Gender~Birthdate~Department of residence~City of residence~Vital status (month and date of death)~Affiliation to Universal Health Coverage~Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates~Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)~Data collected from medicalisation program of information system and private and public home care structures~Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
175753|NCT02827318|Dietary Supplement|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
175754|NCT02827318|Dietary Supplement|Glucose|75g Glucose (high glycaemic load intervention)
175755|NCT02827318|Dietary Supplement|Sweetened water|Sweetened water will be used as a control
175756|NCT02827305|Drug|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
175757|NCT02827305|Procedure|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
175758|NCT02827292|Other|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.~A proper silent operative room environment will be maintained."
175759|NCT02827292|Other|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
175760|NCT02827292|Procedure|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
175761|NCT02827279|Other|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
175762|NCT02827266|Drug|Epoetin beta|Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
175763|NCT02827253|Device|MRI|MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
175764|NCT02827240|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
175765|NCT02827227|Biological|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
175766|NCT02827201|Drug|FOLFIRI.3|For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
175767|NCT02827201|Drug|nab-paclitaxel+ gemcitabine|For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
175768|NCT02827188|Other|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
175769|NCT02827175|Other|blood sample|
175770|NCT02827136|Drug|Lidocaine patch and hypafix|Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
175771|NCT02827136|Drug|hypafix|Appliance of hypafix on both shoulder tip after anesthetic induction
175772|NCT02827123|Device|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
175773|NCT02827123|Drug|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
175774|NCT02827110|Device|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
175775|NCT02827110|Device|pentax-airway scope|Tracheal intubation using pentax-AWS
175776|NCT02827110|Procedure|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
175777|NCT02827097|Drug|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
175778|NCT02827097|Drug|denogan|administration of denogan
175779|NCT02827084|Device|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
175780|NCT02827084|Device|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
175781|NCT02827058|Device|G25 pencil point needle|
175782|NCT02827058|Device|G27 pencil point needle|
175783|NCT02827045|Device|Vestibular test|
175784|NCT02827032|Device|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
175785|NCT02827019|Other|questionnaire|a questionnaire made puerperium the 2nd day of life during the interview with the parents on the basis of a semi-structured interview about the progress of the birth and the immediate postpartum period using the memories of parents
175786|NCT02827006|Procedure|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
175982|NCT02825485|Procedure|Voiding cystourethrogram|
175787|NCT02826993|Device|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
175788|NCT02826980|Other|questionnaire|Patients consultant in gynecology in the service of Doctor Sauvanet, for whom a diagnosis of endometriosis has been established (clinical history and imaging tests confirming the diagnosis) will be offered to fill a self-administered questionnaire during their consultation
175789|NCT02826967|Procedure|Colonic Irrigation|
175790|NCT02826954|Other|Upper airway assessment, including nasal biopsy|
175791|NCT02826941|Other|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
175792|NCT02826941|Other|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
175793|NCT02826928|Biological|blood sample withdrawn|
175794|NCT02826915|Device|Near Infra Red Spectroscopy (NIRS)|
175795|NCT02826915|Device|Electroencephalogram (EEG)|
175796|NCT02826902|Drug|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
175797|NCT02826902|Drug|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
175798|NCT02826889|Device|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
175799|NCT02826889|Device|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
175800|NCT02826876|Drug|Topical use|Topical use of Ropivacaine in laparoscopic surgery
175801|NCT02826876|Other|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
175802|NCT02826876|Other|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
175803|NCT02826863|Drug|ZX008 - 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
175804|NCT02826863|Drug|ZX008 - 0.2 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
175805|NCT02826863|Drug|Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
175806|NCT02826850|Procedure|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
175807|NCT02826850|Procedure|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
175808|NCT02826837|Drug|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.~Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.~A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day~Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
175809|NCT02826798|Drug|VBI-1501A|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
175810|NCT02826798|Drug|VBI-1501A|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
175811|NCT02826798|Drug|VBI-1501A|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
175812|NCT02826798|Drug|VBI-1501|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
175813|NCT02826798|Drug|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
175814|NCT02826785|Behavioral|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
175815|NCT02826772|Drug|GT0918|anti-tumor activity
175816|NCT02826759|Other|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
175817|NCT02826746|Drug|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
175818|NCT02826746|Drug|Normal saline|the same bolus and infusion volumes of normal saline
175819|NCT02826733|Device|Electroencephalogram (EEG)|
175820|NCT02826733|Device|Near Infra Red Spectroscopy (NIRS)|
175821|NCT02826733|Device|magnetic resonance imaging (MRI)|
175822|NCT02826720|Other|No intervention was applied|No intervention was applied
175823|NCT02826707|Behavioral|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
175824|NCT02826694|Genetic|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
175825|NCT02826694|Genetic|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
175828|NCT02826668|Other|Ultrasound|A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
175829|NCT02826655|Device|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
175830|NCT02826642|Drug|IDH305|
175831|NCT02826629|Device|Manual dexterity|Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
175832|NCT02826629|Device|Oculomotor movements|Oculomotor movements during behavioral task will be recorded using a video-oculography device
175833|NCT02826629|Device|TMS coupled to EMG recording|The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
175834|NCT02826629|Other|Psychopathological evaluations|
175835|NCT02826629|Other|Neuropsychological evaluations|
175836|NCT02826616|Drug|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
175837|NCT02826603|Drug|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
175838|NCT02826603|Drug|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
175839|NCT02826590|Other|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
175840|NCT02826590|Other|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
175841|NCT02826577|Drug|Pregnenolone 175mg|Single Dose 175mg
175842|NCT02826577|Drug|Pregnenolone 400mg|Single Dose 400mg
175843|NCT02826577|Drug|Placebo|Single Dose
175844|NCT02826564|Drug|pembrolizumab|
175845|NCT02826551|Drug|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
175846|NCT02826551|Other|Ice|
175847|NCT02826551|Drug|Percocet|
175848|NCT02826551|Device|Knee Brace and Crutches|
175849|NCT02826538|Device|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
175850|NCT02826538|Device|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
175851|NCT02826525|Drug|AZD4076|Investigational product
175852|NCT02826525|Drug|Placebo|Control
175853|NCT02826512|Drug|Niraparib|niraparib 300 mg QD continuously
175854|NCT02826499|Device|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
175855|NCT02826499|Other|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
175856|NCT02826486|Drug|BL-8040|BL-8040 subcutaneous(SC) injections
175857|NCT02826486|Drug|Pembrolizumab|pembrolizumab will be given as a 30-minute IV infusion
175858|NCT02826486|Drug|Chemotherapy of Onivyde|• IV Onivyde® followed by IV leucovorin (LV), followed by IV fluorouracil (5-FU), every 2 weeks.
175859|NCT02826473|Other|BRAINCHECK|Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
175860|NCT02826434|Biological|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
175861|NCT02826434|Biological|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
175862|NCT02826434|Drug|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
175863|NCT02826421|Device|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
175864|NCT02826421|Device|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
175865|NCT02826421|Device|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
175866|NCT02826421|Device|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
175867|NCT02826408|Drug|Rabeprazole sodium|WIll study effect of the medication on palpittions
175868|NCT02826408|Drug|Pacebo|Placebo comparison to active treatment
175869|NCT02826395|Drug|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
175870|NCT02826382|Drug|[68Ga]P15-041|Imaging by Positron Emission Tomography after injection of [68Ga]P15-041
175871|NCT02826369|Other|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.~The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
175872|NCT02826343|Drug|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
175873|NCT02826343|Drug|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
175874|NCT02826343|Drug|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
175875|NCT02826330|Other|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
175876|NCT02826317|Procedure|preoperative and postoperative setting|Preoperative assessment will consist on collecting demographic data as well as the presence preoperative chronic pain and its localization, preoperative opioid, gabapentin or pregabalin consumption. In postoperative, we will collect the following data: type of anesthesia, intra operative ketamine administration, type and total dose of opioid administered during surgery. Pain will be evaluated at least 2 hours after the surgery within the same day (D0) and then at day 2 (D2), 1 (M1) and 2 months (M2) after the surgery. Pain will be assessed using a 10-point NPS. If NPS >0, neuropathic pain will be diagnosed on the basis of DN4 questionnaire. NCPSP is defined by NPS >0 and positive DN4 (DN4 ≥ 4 /10) (11). APSNP and CPSNP are defined by D0/D2 DN4≥ 4/10 and M1/M2 DN4≥ 4/10, respectively.
175877|NCT02826304|Procedure|Vaginal hysterectomy|"All the cases were performed by the same surgical team~Incision is made at the anterior cervical lip below the bladder reflection~Anterior peritoneal entry .~Douglas pouch entry.~The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .~Uterine artery clamping division and ligation~After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy~Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).~Hemostasis~The vaginal vault is closed after insertion of intraperitoneal drain and"
175878|NCT02826304|Procedure|Laparoscopic assisted vaginal hysterectomy|"Uterine manipulator was inserted through the cervix to mobilize the uterus~Veress needle was inserted through the base of the umbilicus~creation of pneumoperitoneum~Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars~The round and the utero-ovarian ligament are coagulated and divided.~Dissection through the vesico-uterine space to displace bladder away from the cervix.~Uterine artery was coagulated and divided laparoscopically~anterior colpotomy over the cup of the uterine elevator.~Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
175879|NCT02826291|Device|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
175880|NCT02826278|Other|External genitalia measurements in female newborns|
175881|NCT02826265|Device|multiple breath washout test (MBW)|
175882|NCT02826265|Device|impulse oscillometry (IOS)|
175883|NCT02826265|Device|body plethysmography (BP)|
175884|NCT02826265|Device|quantitative computed tomography (qCT)|ultra-low-dose qCT
175885|NCT02826252|Drug|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
175886|NCT02826252|Device|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
175887|NCT02826239|Device|multiple breath washout test (MBW)|measured in upright and supine position
175888|NCT02826226|Device|multiple-breath-washout test|
175889|NCT02826226|Drug|Bronchodilator Agents|
175890|NCT02826213|Device|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
175891|NCT02826213|Device|Waves perfusion device|Renal Perfusion with Waves perfusion device
175892|NCT02826200|Drug|Acenocoumarol|Standard of care plus oral anticoagulant therapy (acenocoumarol)
175893|NCT02826200|Other|Standard of care|Standard of care
175894|NCT02826187|Other|Early complications data|"Early complications of interest are :~New arthroplasty for any reason~Related to the implant :~Wrong position of the implant~Early displacement of the implant~Related to the intervention :~Hematoma~Dislocation (or not causing the resumption of joint replacement)~Deep vein thrombosis~Pulmonary embolism~Acute Infection"
175895|NCT02826187|Other|Late stage complications data|"Late complications taken into account are:~New arthroplasty for any reason~Aseptic loosening~Delayed hypersensitivity reaction type IV~Solid Tumors~Recurrent dislocation (causing or not the resumption of joint replacement)~Allergic reactions of any kind~Chronic infection"
175896|NCT02826187|Other|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
175897|NCT02826187|Other|Efficacity|Efficacity as evaluated by Harris HIP score
175898|NCT02826187|Other|Radiographic evaluation|Bone reaction visible in radiography
175899|NCT02826174|Procedure|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
175900|NCT02826174|Procedure|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
175901|NCT02826174|Drug|Anti-Rejection Agents|Anti-Rejection Agents for both groups
175902|NCT02826174|Drug|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
175983|NCT02825472|Behavioral|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
175984|NCT02825459|Behavioral|Abstinence from e-cigarettes|Abrupt cessation for 6 days
175903|NCT02826161|Drug|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
175904|NCT02826161|Drug|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
175905|NCT02826148|Other|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
175906|NCT02826135|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
175907|NCT02826122|Device|Pai APP|Prescription: Target 100 PAI Points per week
175908|NCT02826122|Device|FitBit APP|Prescription: Target daily 10.000 steps
175909|NCT02826109|Device|PeriAcryl®90 HV|
175910|NCT02826096|Behavioral|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
175911|NCT02826083|Dietary Supplement|XXS|
175912|NCT02826083|Dietary Supplement|non-XXS|
175913|NCT02826070|Drug|Telbivudine|Telbivudine, 600mg, oral, daily
175914|NCT02826070|Drug|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
175915|NCT02826070|Other|off-treatment follow-up|
175916|NCT02826057|Other|Targeted temperature management (33 degree Celsius)|
175917|NCT02826044|Drug|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
175918|NCT02826031|Drug|Sodium Hyaluronate Injection|
175919|NCT02826031|Drug|DICL-SR|
175920|NCT02826018|Drug|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
175921|NCT02826018|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
175922|NCT02826005|Device|MRI|
175923|NCT02825992|Device|AcQMap System|3D imaging and mapping system for cardiac chambers
175924|NCT02825979|Procedure|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
175925|NCT02825979|Drug|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
175926|NCT02825966|Device|LifeVest|Wearable Cardioverter Defibrillator
175927|NCT02825953|Drug|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
175928|NCT02825953|Device|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
175929|NCT02825953|Device|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
175930|NCT02825953|Device|Neopuff|Fisher and Paykel, Auckland, New Zealand
175931|NCT02825953|Device|neonatal ventilator|GE Healthcare, Madison, USA
175932|NCT02825940|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
175933|NCT02825940|Drug|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m^2 on Days 1 and 8.
175934|NCT02825940|Drug|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m^2 on Day 1.
175935|NCT02825927|Other|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
175936|NCT02825914|Dietary Supplement|Casein glycomacropeptide (CGMP)|
175937|NCT02825914|Dietary Supplement|Placebo|
175938|NCT02825901|Dietary Supplement|Placebo|
175939|NCT02825901|Dietary Supplement|Djulis-Buckwheat|
175940|NCT02825901|Dietary Supplement|Buckwheat|
175941|NCT02825875|Drug|18F DCFPyL- Radiopharmaceutica|
175942|NCT02825862|Behavioral|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
176032|NCT02825108|Drug|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
176033|NCT02825108|Procedure|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
175943|NCT02825862|Behavioral|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
175944|NCT02825849|Biological|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
175945|NCT02825836|Drug|M7583|All participants who received M7583 80/160 mg or 300 mg or 600 mg or 900 mg PiC orally OD or 300 mg BID in fasted state for 28 days in each 28 day cycle until disease progression, withdrawal of consent, or discontinuation from the study.
175946|NCT02825823|Dietary Supplement|Ketone Salt|
175947|NCT02825823|Dietary Supplement|Placebo|
175948|NCT02825810|Behavioral|Cervical motor control|Intervention will consist in a tailored exercise training following a previous published motor control protocol
175949|NCT02825797|Drug|3BNC117|Intravenous infusion of 3BNC117
175950|NCT02825797|Drug|10-1074|Intravenous infusion of 10-1074
175951|NCT02825797|Other|Analytical treatment interruption|Analytical treatment interruption
175952|NCT02825797|Drug|Placebo|Intravenous infusion of placebo (sterile saline)
175953|NCT02825784|Dietary Supplement|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
175954|NCT02825771|Behavioral|Caring Contacts Messages|Text messages expressing care and support are sent following initial meeting on the following schedule: next day, 6 weekly, 9 bi-weekly, 7 monthly; one each on birthday, holiday, and seasonal (total of 25)
175955|NCT02825771|Behavioral|Usual Care|Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
175956|NCT02825758|Dietary Supplement|ZestiVits|"The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.~The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation."
175957|NCT02825745|Dietary Supplement|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
175958|NCT02825719|Drug|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
175959|NCT02825719|Other|Placebo pills|Placebo pills will be prescribed
175960|NCT02825719|Drug|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
175961|NCT02825719|Drug|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
175962|NCT02825706|Other|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
175963|NCT02825693|Procedure|Conventional cataract surgery (phacoemulsification)|
175964|NCT02825693|Procedure|Femtosecond laser assisted cataract surgery|
175965|NCT02825680|Other|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
175966|NCT02825680|Other|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model of Change, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool
175967|NCT02825667|Other|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
175968|NCT02825641|Drug|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~Induction of labor on presentation at the delivery room.~Induction of labor after 24 hours of rupture of membranes."
175969|NCT02825641|Drug|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:~Induction of labor on presentation at the delivery room.~Induction of labor after 24 hours of rupture of membranes."
175970|NCT02825628|Drug|Osteodex|formulation: solution for infusion route of administration: intravenous infusion
175971|NCT02825615|Procedure|Radial artery cannulation|Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
175972|NCT02825589|Device|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
175973|NCT02825576|Drug|Sugammadex|Sugammadex 2mg/kg given for reversal agent
175974|NCT02825576|Drug|Neostigmine/Glycopyrrolate|Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
175975|NCT02825563|Drug|Anlotinib|in the fasting state
175976|NCT02825563|Drug|Anlotinib|in the high fat diet
175977|NCT02825550|Device|Taiwan ACE Beads|Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
175978|NCT02825537|Device|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
175979|NCT02825537|Other|No use of compression stocking|No use of compression stocking
175980|NCT02825524|Device|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
175981|NCT02825498|Device|Contact force guided RFA|Contact force guided RFA during Atrial Flutter ablation procedure.
176118|NCT02824458|Drug|Placebo|
175985|NCT02825446|Procedure|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
175986|NCT02825446|Procedure|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.~Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
175987|NCT02825433|Other|No intervention, only ventilation monitoring|
175988|NCT02825420|Drug|trabectedin|
175989|NCT02825407|Dietary Supplement|Oral physiology|
175990|NCT02825394|Other|anti-Xa activity point-of-care testing (aXa-POCT)|
175991|NCT02825394|Other|ecarin clotting time point-of-care testing (ECT-POCT)|
175992|NCT02825368|Biological|MMR|0.5 mL, subcutaneous
175993|NCT02825368|Biological|Tdap|0.5 mL, intramuscular
175994|NCT02825368|Other|Diphtherinum®|
175995|NCT02825368|Other|Pertussinum®|
175996|NCT02825368|Other|Tetanotxicum®|
175997|NCT02825368|Other|Morbilinum®|
175998|NCT02825368|Other|Ourlianum®|
175999|NCT02825368|Other|Sterile saline|0.5 mL, intramuscular
176000|NCT02825368|Other|Sugar pellets|
176001|NCT02825342|Drug|Citalopram|
176002|NCT02825329|Device|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
176003|NCT02825316|Behavioral|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
176004|NCT02825316|Behavioral|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
176005|NCT02825303|Other|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
176006|NCT02825290|Drug|Choriogonadotropin alfa|
176007|NCT02825290|Drug|Triptorelin acetate|
176008|NCT02825277|Device|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
176009|NCT02825264|Device|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
176010|NCT02825251|Drug|Faster-acting insulin aspart|Injected s.c. /subcutaneously (under the skin)
176011|NCT02825251|Drug|insulin aspart|Injected s.c. /subcutaneously (under the skin)
176012|NCT02825238|Other|Supervised exercise program|
176013|NCT02825225|Other|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
176014|NCT02825225|Procedure|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
176015|NCT02825212|Drug|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
176016|NCT02825199|Dietary Supplement|Caffeine|capsule: 300mg caffeine
176017|NCT02825199|Dietary Supplement|Non caffeine|capsule: placebo (maize starch)
176018|NCT02825186|Drug|Loteprendol etabonate 0.5%|Steroid eye drops used after strabismus surgery.
176019|NCT02825186|Drug|Dexamethasone 0.1%|
176020|NCT02825173|Device|Seal-G|"Intervention:~Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
176021|NCT02825160|Drug|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
176022|NCT02825147|Drug|Pegaspargase|
176023|NCT02825147|Drug|Methotrexate|
176024|NCT02825147|Drug|Dexamethasone|
176025|NCT02825147|Drug|Etoposide|
176026|NCT02825147|Radiation|radiotherapy|
176027|NCT02825134|Device|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
176028|NCT02825134|Device|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
176029|NCT02825121|Device|Monitoring Neuromuscular Blockade the Flexor Hallucis|
176030|NCT02825121|Device|Monitoring Neuromuscular Blockade adductor of the thumb.|
176031|NCT02825108|Drug|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
176119|NCT02824445|Device|individualized Transcranial Magnetic Stimulation|
176034|NCT02825095|Procedure|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
176035|NCT02825095|Procedure|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
176036|NCT02825095|Procedure|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
176037|NCT02825095|Drug|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
176038|NCT02825095|Procedure|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
176039|NCT02825082|Procedure|Abdominal emergency surgery|all abdominal emergency surgery procedures
176040|NCT02825069|Other|Early introduction of solid foods|Early introduction of solid foods
176041|NCT02825056|Drug|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
176042|NCT02825056|Drug|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
176043|NCT02825043|Device|High-Flow Nasal Cannula|This is a humidified oxygen delivery system.
176044|NCT02825030|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation-SR15-78_Y73-167).
176045|NCT02825017|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm*2 test application.(Formulation-SR15-79_Y73-161)
176046|NCT02825004|Behavioral|Psychological Intervention|
176047|NCT02824991|Procedure|detection of local twitch response intensities during dry needling|
176048|NCT02824965|Drug|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
176049|NCT02824965|Biological|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
176050|NCT02824952|Drug|Tagrisso|taking orally everyday for 6 or 12 weeks.
176051|NCT02824939|Other|Transversus Abdominis Plane (TAP) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
176052|NCT02824939|Other|Quadratus Lumborum (QL) Block|0.5 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
176053|NCT02824926|Drug|Dapaconazole|
176054|NCT02824926|Drug|Ketoconazole|
176055|NCT02824913|Drug|P-321 Ophthalmic Solution|
176056|NCT02824913|Drug|P-321 Ophthalmic Solution placebo|
176057|NCT02824900|Device|Vibration stimuli to neck muscles|
176058|NCT02824900|Device|Vibration stimuli to hand|
176059|NCT02824900|Behavioral|conventional physiotherapy|
176060|NCT02824887|Other|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
176061|NCT02824887|Other|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
176062|NCT02824874|Drug|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg*1T/day for 5days, QD, PO
176063|NCT02824874|Drug|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg*1T/day for 5 dyas, QD, PO
176064|NCT02824861|Behavioral|Bemobile|
176065|NCT02824848|Behavioral|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
176066|NCT02824848|Behavioral|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
176067|NCT02824835|Procedure|biopsy during colonoscopy|sampling the lesion with forcept biopter
176068|NCT02824796|Behavioral|Schema Parent Behavioral Training|A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)
176069|NCT02824796|Behavioral|Parent Behavioral Training|A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
176070|NCT02824770|Behavioral|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
176071|NCT02824770|Drug|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
176072|NCT02824770|Drug|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
176073|NCT02824770|Procedure|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
176074|NCT02824744|Device|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
176075|NCT02824744|Device|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
176076|NCT02824731|Radiation|Radiation with protons|
176077|NCT02824731|Radiation|Radiation with photons|
176078|NCT02824718|Drug|Teriparatide|human recombinant parathormone
176079|NCT02824718|Drug|Thiazide|Diuretic
176080|NCT02824718|Drug|Potassium sparing diuretic|Diuretic
176081|NCT02824718|Drug|Alfacalcidol|Belongs to the class of vitamin D and analogues
176082|NCT02824705|Procedure|Congenital Heart Disease Surgery|Stool and blood sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
176083|NCT02824692|Device|heart lungs and abdomen ultrasound|
176084|NCT02824679|Drug|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
176085|NCT02824679|Drug|saline|0.9%normal saline
176120|NCT02824432|Drug|TAK-085|TAK-085 capsules
176121|NCT02824419|Drug|Methionine|Subject undergoes imaging studies with FDG and with methionine.
176086|NCT02824666|Drug|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).~Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
176087|NCT02824666|Radiation|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of [18F]Fallypride [5-6 mCi being the typical range of injected dose].
176088|NCT02824653|Biological|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
176089|NCT02824640|Behavioral|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
176090|NCT02824640|Behavioral|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
176091|NCT02824627|Drug|Oxytocin|A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
176092|NCT02824627|Drug|Placebo|Inactive substance administered in volume equivalent to volume administered in active treatment arm.
176093|NCT02824614|Dietary Supplement|E967-Xylitol|
176094|NCT02824614|Dietary Supplement|E968-Erythritol|
176095|NCT02824601|Device|Laser|1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP
176096|NCT02824601|Drug|Calcium hydroxide|2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
176097|NCT02824588|Behavioral|Working Memory Training|Training mental flexibility
176098|NCT02824588|Behavioral|Internet use|Used as control for time spent on computer
176099|NCT02824575|Drug|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
176100|NCT02824575|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
176101|NCT02824575|Drug|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 & 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
176102|NCT02824562|Behavioral|Intervention|The intervention group will receive treatment as usual plus a chronic pain self-management program which includes six one-on-one sessions facilitated by a trained interventionist and six group sessions facilitated by a trained interventionist and a peer. A peer is an HIV-infected patient living with chronic pain, who has completed all ten of the one-on-one sessions offered, received training to co-facilitate the six group sessions with the interventionist, and is successfully self-managing his/her chronic pain.
176103|NCT02824562|Behavioral|Control|"The control group will receive treatment as usual. The treatment as usual or control group refers to the standard of care that patients receive for their chronic pain. This standard of care allows patients to discuss chronic pain with their providers at their discretion. Although highly variable, providers can recommend and prescribe pharmacologic (e.g., opioid and other pain medication), non-pharmacologic (e.g., physical therapy, referral to psychology) approaches for pain. This study will not interfere in any way with usual care. No additional treatment will be provided to participants allocated to the control group."
176104|NCT02824549|Device|FreeStyle Libre Flash Glucose Monitoring|
176105|NCT02824536|Drug|3BNC117|Intravenous Infusion of 3BNC117
176106|NCT02824536|Drug|10-1074|Intravenous Infusion of 10-1074
176107|NCT02824536|Drug|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
176108|NCT02824523|Drug|aspirin|
176109|NCT02824510|Other|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
176110|NCT02824510|Other|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
176111|NCT02824510|Drug|Insulin aspart, glargine and detemir|
176112|NCT02824497|Other|No intervention. It's a description study|
176113|NCT02824484|Behavioral|GWDP|"In each writing session participants are asked to:~Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude~Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.~Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
176114|NCT02824484|Behavioral|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
176115|NCT02824471|Other|SCD Group|No Intervention. Use of discard blood/tissue
176116|NCT02824458|Drug|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
176117|NCT02824458|Drug|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
176122|NCT02824419|Drug|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
176123|NCT02824406|Drug|Acetazolamide|Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.
176124|NCT02824393|Biological|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
176125|NCT02824380|Drug|DA-4001 H|5% minoxidil / high dose of finasteride
176126|NCT02824380|Drug|DA-4001 L|5% minoxidil / low dose of finasteride
176127|NCT02824367|Behavioral|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
176128|NCT02824354|Drug|Nalmefene (Selincro®) 18 mg tablet|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
176129|NCT02824354|Drug|placebo|Evaluate the efficacy, tolerability and safety of nalmefene for reduction of alcohol consumption (reduction of the number of monthly heavy drinking days, and daily total alcohol consumption) in alcohol-dependent patients with alcoholic compensated cirrhosis.
176130|NCT02824341|Device|fMRI|
176131|NCT02824315|Drug|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
176132|NCT02824315|Drug|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
176133|NCT02824315|Drug|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
176134|NCT02824302|Other|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
176135|NCT02824289|Behavioral|Sun Safe Workplaces Program|The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
176136|NCT02824289|Behavioral|Attention Control|Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
176137|NCT02824276|Drug|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
176138|NCT02824276|Drug|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
176139|NCT02824263|Device|CPAP withdrawal|CPAP is discontinued for 3 nights.
176140|NCT02824250|Behavioral|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
176141|NCT02824237|Device|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
176142|NCT02824224|Drug|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
176143|NCT02824224|Drug|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
176144|NCT02824211|Device|Right Dose System|Automated titration of oxygen system during exertion
176145|NCT02824198|Biological|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
176146|NCT02824198|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
176147|NCT02824185|Device|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
176148|NCT02824172|Other|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
176149|NCT02824172|Other|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
176150|NCT02824159|Other|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
176151|NCT02824159|Other|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
176152|NCT02824159|Other|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
176153|NCT02824159|Other|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
176154|NCT02824159|Genetic|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
176155|NCT02824159|Genetic|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
176156|NCT02824159|Other|Biological statement|"The following parameters will be assessed :~Complete blood count~Hemoglobin~Hepatic enzymes~Creatinine clearance~Lactate dehydrogenase rate~Total bilirubin rate~Cluster of differentiation 4 T lymphocytes rate~Total gamma-globulins rate"
176204|NCT02823821|Other|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
176205|NCT02823808|Drug|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
176157|NCT02824159|Other|Clinical examination|"The clinical examination are composed by :~Weigh, Height and body mass index measurement~Clinical state of patient during examination~Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)~Presence of B symptomatology~Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
176158|NCT02824146|Other|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
176159|NCT02824133|Drug|AZD4547|80 mg bd (per os)
176160|NCT02824120|Other|Comedy|patients will watch comedy film
176161|NCT02824120|Other|Documentary|patients will watch a documentary film
176162|NCT02824107|Biological|blood sample|
176163|NCT02824107|Behavioral|questionnaires for psychosocial factors|
176164|NCT02824094|Drug|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
176165|NCT02824081|Biological|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
176166|NCT02824068|Drug|glucosidase alfa|Long-term use in an observational study of licenced drug
176167|NCT02824055|Drug|Placebo|Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
176168|NCT02824055|Drug|RO5545965|Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
176169|NCT02824042|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
176170|NCT02824042|Drug|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
176171|NCT02824029|Drug|Ibrutinib|Given PO
176172|NCT02824029|Other|Laboratory Biomarker Analysis|Correlative studies
176173|NCT02824029|Other|Pharmacological Study|Correlative studies
176174|NCT02824016|Biological|biological sample|T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
176175|NCT02824016|Radiation|supraclavicular irradiation|Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
176176|NCT02824003|Drug|ISIS-GCGRRx|once weekly dosing for 13 weeks
176177|NCT02824003|Drug|Placebo|once weekly dosing for 13 weeks
176178|NCT02823990|Biological|TG4010|Given SC
176179|NCT02823990|Biological|Nivolumab|Given IV
176180|NCT02823977|Drug|Ketamine|Blinded study drug administered to experimental arm
176181|NCT02823977|Drug|Dexmedetomidine|Open-label study drug administered to both arms
176182|NCT02823977|Drug|Normal saline|Blinded comparator administered to control arm
176183|NCT02823964|Drug|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
176184|NCT02823951|Drug|Rebif|
176185|NCT02823951|Drug|Tecfidera|
176186|NCT02823938|Other|existing database on data collection.|This is an observational study on an existing database.
176187|NCT02823925|Drug|Pamidronate or Zoledronate|
176188|NCT02823912|Drug|Capsaicin|
176189|NCT02823912|Drug|Magnesia calcinada|
176190|NCT02823899|Biological|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
176191|NCT02823899|Biological|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
176192|NCT02823886|Other|MRI at D7|The infarct size measured on MRI at 7 days.
176193|NCT02823886|Biological|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
176194|NCT02823873|Device|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
176195|NCT02823860|Other|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
176196|NCT02823847|Behavioral|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
176197|NCT02823847|Device|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
176198|NCT02823847|Behavioral|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.~Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation."
176199|NCT02823847|Procedure|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
176200|NCT02823847|Procedure|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
176201|NCT02823847|Procedure|Oral Biopsy|Premalignant and malignant oral lesions [PMOL]) still present 2 weeks after oral exam are biopsied.
176202|NCT02823834|Device|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
176203|NCT02823821|Other|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
176247|NCT02823470|Device|activated smart device|
176248|NCT02823470|Device|de-activated smart device|
176206|NCT02823808|Drug|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
176207|NCT02823795|Behavioral|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
176208|NCT02823782|Other|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
176209|NCT02823782|Other|neuropsychological assessment|
176210|NCT02823769|Device|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
176211|NCT02823769|Device|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
176212|NCT02823756|Procedure|Physical Therapy|Exercise, education, spinal manipulation
176213|NCT02823743|Drug|Aspirin|Daily medication
176214|NCT02823743|Drug|Placebo|Daily intake
176215|NCT02823730|Other|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
176216|NCT02823691|Drug|Lanreotide and Metformin|Lanreotide and Metformin
176217|NCT02823678|Procedure|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
176218|NCT02823665|Drug|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
176219|NCT02823665|Drug|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
176220|NCT02823652|Other|Counseling|Undergo usual care
176221|NCT02823652|Other|Genetic Counseling|Complete remote counseling
176222|NCT02823652|Other|Genetic Testing|Undergo germline testing
176223|NCT02823652|Other|Internet-Based Intervention|Complete on-line genetic education
176224|NCT02823652|Other|Survey Administration|Ancillary studies
176225|NCT02823639|Procedure|Transcranial direct current stimulation|
176226|NCT02823626|Drug|Spironolactone and patiromer|High dose spironolactone with or without patiromer based on the patient's baseline potassium
176227|NCT02823613|Dietary Supplement|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
176228|NCT02823613|Dietary Supplement|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
176229|NCT02823600|Device|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
176230|NCT02823587|Other|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
176231|NCT02823587|Other|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
176232|NCT02823574|Biological|Nivolumab|
176233|NCT02823574|Biological|Ipilimumab|
176234|NCT02823574|Other|Placebo|
176235|NCT02823561|Dietary Supplement|Garcinia mangostana|
176236|NCT02823561|Behavioral|Control group|
176237|NCT02823548|Drug|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
176238|NCT02823548|Drug|Placebo|Placebo
176239|NCT02823535|Behavioral|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
176240|NCT02823522|Other|Patients recruitment|Between July and November 2016, the patients included in the previous retrospective study were contacted by phone, mail and e-mail and invited to come back to the respective clinics where they had been initially diagnosed as NCWS patients: the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (province of Agrigento).
176241|NCT02823509|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation-SR15-68_R84-089)
176242|NCT02823496|Other|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
176243|NCT02823496|Other|Untreated skin|One site is patched without treatment as control
176244|NCT02823483|Other|Sunscreen Lotion (BAY987521)|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
176245|NCT02823483|Other|Untreated Skin|This site is patched without treatment as irradiated control
176246|NCT02823470|Drug|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
176249|NCT02823457|Behavioral|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
176250|NCT02823444|Other|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.~Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
176251|NCT02823431|Drug|lidocaine gel|
176252|NCT02823431|Other|Plain aqueous gel|
176253|NCT02823418|Procedure|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
176254|NCT02823418|Procedure|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
176255|NCT02823405|Drug|X4P-001|X4P-001 100 mg capsules, administered orally, continuous daily dosing
176256|NCT02823405|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
176257|NCT02823392|Other|DBMV|the occurrence of at least two following events which were requiring application of CPAP with opening airway maneuvers, requiring oropharyngeal airway, requiring two-person bag mask ventilation, unable to perform bag mask ventilation or presence of desaturation (SpO2 < 95%).
176258|NCT02823379|Behavioral|Physical Activity|A Smartphone delivered physical activity program
176259|NCT02823379|Behavioral|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
176260|NCT02823366|Drug|Fenofibrate|
176261|NCT02823366|Drug|UDCA|
176262|NCT02823353|Drug|Fenofibrate|
176263|NCT02823353|Drug|UDCA|
176264|NCT02823340|Device|Fractional microneedle RF(United, Peninsula Medical, China)|
176265|NCT02823327|Genetic|Laboratory Biomarker Analysis|Correlative studies
176266|NCT02823327|Other|Medical Chart Review|Medical chart review is performed
176267|NCT02823314|Device|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
176268|NCT02823314|Device|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
176269|NCT02823301|Behavioral|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
176270|NCT02823288|Other|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:~Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.~Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.~Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
176271|NCT02823275|Other|Functional mobilisation|functional mobilisation
176272|NCT02823275|Other|Short term plaster cast fixation|2 weeks cast immobilisation
176273|NCT02823262|Other|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
176274|NCT02823262|Other|Usual Care|
176275|NCT02823249|Dietary Supplement|1.56 g L-Tryptophan|
176276|NCT02823249|Dietary Supplement|1.56 g L-Leucine|
176277|NCT02823249|Dietary Supplement|50 g Xylitol|
176278|NCT02823249|Dietary Supplement|75 g Erythritol|
176279|NCT02823249|Dietary Supplement|75 g Glucose|
176280|NCT02823249|Dietary Supplement|Tap water|
176281|NCT02823249|Dietary Supplement|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
176282|NCT02823249|Device|Nasogastric Tube|
176283|NCT02823236|Drug|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
176284|NCT02823236|Drug|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
176285|NCT02823236|Drug|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
176286|NCT02823223|Device|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
176289|NCT02823184|Biological|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
176290|NCT02823171|Drug|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
176291|NCT02823171|Drug|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
176292|NCT02823158|Procedure|Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)|"Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.~Best medical treatment is applied in combination with GPi-DBS."
176293|NCT02823158|Procedure|Best medical treatment|Patients will receive optimized medical treatment according to published evidence based guidelines.
176294|NCT02823145|Drug|ZX008 (Fenfluramine Hydrochloride)|
176295|NCT02823132|Biological|blood sample|
176296|NCT02823119|Device|Mini-hysteroscopy|Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.
176297|NCT02823119|Device|Conventional Office Hysteroscopy|. Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
176298|NCT02823106|Drug|Verapamil and Citicoline|Single dosing strategy will be used.
176299|NCT02823106|Other|Placebo|Single matching dosing strategy will be used.
176300|NCT02823080|Drug|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
176301|NCT02823067|Other|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
176302|NCT02823054|Device|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
176303|NCT02823041|Behavioral|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
176304|NCT02823041|Behavioral|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
176305|NCT02823041|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
176306|NCT02823041|Behavioral|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
176307|NCT02823028|Drug|NRT|8-weeks of study provided NRT patch, and 8-weeks of study provided NRT gum of varying strengths or 8-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
176308|NCT02823028|Behavioral|Web Guide|"A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules."
176309|NCT02823028|Behavioral|Tweet2Quit|"A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group."
176310|NCT02823002|Procedure|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
176311|NCT02823002|Procedure|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
176312|NCT02823002|Procedure|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
176313|NCT02823002|Procedure|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
176314|NCT02823002|Procedure|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
176315|NCT02823002|Procedure|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
176316|NCT02823002|Drug|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
176317|NCT02823002|Drug|Buffer|Sodium Bicarbonate
176426|NCT02822118|Drug|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
176427|NCT02822118|Drug|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
176433|NCT02822040|Other|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
176318|NCT02822989|Device|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
176319|NCT02822989|Device|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
176320|NCT02822950|Drug|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
176321|NCT02822937|Drug|Methylphenidate|Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
176322|NCT02822937|Drug|Triazolam|Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
176323|NCT02822937|Other|Project: EVO|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
176324|NCT02822937|Drug|Placebo|Sugar pill
176325|NCT02822924|Procedure|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
176326|NCT02822911|Behavioral|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.~Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
176327|NCT02822911|Procedure|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
176328|NCT02822911|Procedure|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
176329|NCT02822911|Procedure|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
176330|NCT02822898|Drug|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
176331|NCT02822898|Drug|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
176332|NCT02822885|Radiation|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
176333|NCT02822859|Device|Wright nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
176334|NCT02822859|Device|Bennett-Twin nebulizer|Puritan Bennett Corp., Carlsbad, CA, USA
176335|NCT02822859|Device|Aeroneb Solo|Aerogen Ltd., Galway, Ireland
176336|NCT02822846|Other|lung ultrasound|
176337|NCT02822833|Procedure|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
176338|NCT02822820|Device|Ligasure-Covidien|Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
176339|NCT02822820|Device|RoBi forceps-Karl Storz|Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
176340|NCT02822807|Biological|Blood sampling|
176341|NCT02822794|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
176342|NCT02822794|Drug|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
176343|NCT02822781|Other|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
176344|NCT02822768|Procedure|Packing|The patient will receive packing as part of their wound care
176345|NCT02822768|Other|No packing|The patient will not receive packing as part of their wound care
176346|NCT02822755|Other|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
176347|NCT02822742|Drug|DE-117 ophthalmic solution|
176348|NCT02822742|Drug|Latanoprost ophthalmic solution 0.005%|
176349|NCT02822729|Drug|DE-117 ophthalmic solution|
176350|NCT02822729|Drug|Timolol ophthalmic solution|
176428|NCT02822105|Biological|the H3N2 M2SR monovalent influenza vaccine|The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
176429|NCT02822105|Other|Placebo|saline
176611|NCT02820688|Procedure|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
176351|NCT02822716|Procedure|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
176352|NCT02822716|Device|Ultrasound|
176353|NCT02822703|Device|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
176354|NCT02822703|Device|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
176355|NCT02822690|Other|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
176356|NCT02822664|Behavioral|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
176357|NCT02822664|Behavioral|Healthy subjects|cerebral MRI and/or cerebral PET imaging
176358|NCT02822664|Device|PET/MRI|
176359|NCT02822651|Biological|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
176360|NCT02822651|Other|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
176361|NCT02822638|Other|STEMI PATIENT Cohort|PCI
176362|NCT02822625|Drug|QUTENZA®|
176363|NCT02822625|Other|hypnotic message|
176364|NCT02822625|Other|music therapy|
176365|NCT02822612|Device|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
176366|NCT02822599|Drug|RiaStAP|To decrease post-operative bleeding volume.
176367|NCT02822599|Drug|Saline|Placebo consisting of normal saline 0.9%
176368|NCT02822586|Radiation|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
176369|NCT02822586|Drug|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
176370|NCT02822573|Drug|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
176371|NCT02822573|Drug|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
176372|NCT02822560|Device|pEVAR|percutaneous femoral access using a suture-mediated closure device
176373|NCT02822560|Procedure|open femoral access|cutdown to femoral artery and surgical closure
176374|NCT02822547|Drug|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
176375|NCT02822534|Drug|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
176376|NCT02822521|Other|Mobile Application|A mobile health application that asks daily questions about participants' pain, function, and disease activity.
176377|NCT02822521|Other|Population Management System|Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
176378|NCT02822508|Drug|BLI801 Laxative|BLI801 oral laxative
176379|NCT02822508|Drug|BLI801 Placebo|BLI801 oral laxative placebo
176380|NCT02822495|Biological|tabelecleucel|Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
176381|NCT02822482|Drug|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
176382|NCT02822482|Drug|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
176383|NCT02822469|Other|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.~The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
176430|NCT02822092|Drug|Risperidone or Aripiprazole (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
176431|NCT02822066|Procedure|Electroporation|Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
176432|NCT02822053|Procedure|US-guided laser ablation for refractory neoplasms|
176384|NCT02822469|Device|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
176385|NCT02822456|Procedure|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
176386|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
176387|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
176388|NCT02822430|Other|Pain scales|"Visual analogic scale of pain~Pain behaviour scale~Short-FormHealth Survey (SF-36)~Clinical Global impression~Mini International Neuropsychiatric Interview (MINI)"
176389|NCT02822404|Dietary Supplement|Urinary and blood sample for Cystaine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
176390|NCT02822391|Other|observation|
176391|NCT02822378|Dietary Supplement|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
176392|NCT02822378|Dietary Supplement|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
176393|NCT02822378|Dietary Supplement|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
176394|NCT02822365|Procedure|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
176395|NCT02822365|Device|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
176396|NCT02822365|Procedure|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
176397|NCT02822352|Other|Chromoendoscopy|High definition virtual chromoendoscopy
176398|NCT02822339|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z12-030)
176399|NCT02822326|Biological|CD19-CAR-T2 Cells|
176400|NCT02822313|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-76_V27-006)
176401|NCT02822300|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-74_R84-086)
176402|NCT02822287|Drug|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
176403|NCT02822274|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-70_R84-064)
176404|NCT02822261|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-66_R84-088)
176405|NCT02822248|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-64-R84-070)
176406|NCT02822235|Other|No Intervention|
176407|NCT02822222|Drug|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
176408|NCT02822222|Drug|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
176409|NCT02822209|Behavioral|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
176410|NCT02822209|Behavioral|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
176411|NCT02822209|Behavioral|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
176412|NCT02822209|Behavioral|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
176413|NCT02822196|Drug|Lidocaine|Local Anesthesia using 1% Lidocaine
176414|NCT02822196|Drug|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
176415|NCT02822183|Other|Online Survey|
176416|NCT02822170|Other|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
176417|NCT02822157|Drug|Olaparib|
176418|NCT02822157|Drug|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
176419|NCT02822144|Drug|Etomidate|
176420|NCT02822144|Drug|Succinylcholine|
176421|NCT02822144|Drug|Propofol|
176422|NCT02822144|Drug|Remifentanil|
176423|NCT02822144|Drug|Lidocaine|
176424|NCT02822131|Dietary Supplement|sodium phosphate|
176434|NCT02822027|Drug|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
176435|NCT02822027|Drug|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
176436|NCT02822014|Other|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
176437|NCT02822001|Drug|Sugammadex|Sugammadex is a relatively new compound, a gamma--‐cyclodextrin molecule that forms an 8--‐membered ring. When administered to patients who received rocuronium--‐induced neuromuscular block, sugammadex binds free plasma rocuronium irreversibly, lowering the plasma concentration of free rocuronium. This promotes diffusion of free rocuronium from the neuromuscular junction back into the plasma, where the free rocuronium is again encapsulated. This removal of rocuronium from the neuromuscular junction reverses the neuromuscular block more rapidly and effectively than traditional anticholinesterases (neostigmine).
176438|NCT02822001|Drug|Placebo|The patient's trachea will be then extubated, and postoperative anesthetic care will proceed as per usual routine.
176439|NCT02822001|Device|Train-of-Four Monitoring|This involves delivery of small electrical impulses from a nerve stimulator via surface ECG electrodes to a peripheral nerve (usually the ulnar nerve at the wrist) and measuring the muscle contraction in the innervated muscle (usually the adductor pollicis muscle or the thumb. This testing is used routinely in many centers in awakening patients in the PACU, and it is not associated with any adverse effects or patient discomfort.
176440|NCT02822001|Device|ExSpiron Respiratory Volume Monitoring|The ExSpiron is a non-invasive and safe device cleared by the FDA for monitoring MV, TV and RR. The device requires the application of monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.In the proposed trial, we use the ExSpiron to assess the respiratory effects of residual NMB and the effects of sugammadex reversal in decreasing the incidence of pulmonary complications (CREs).
176441|NCT02821988|Device|External fetal monitor for Nonstress test|
176442|NCT02821988|Device|Ultrasonography for Biophysical profile|
176443|NCT02821975|Other|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
176444|NCT02821962|Behavioral|Sedentary prompts from a VTAP device|
176445|NCT02821949|Biological|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
176446|NCT02821936|Procedure|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
176447|NCT02821923|Dietary Supplement|E967-Xylitol|24g xylitol/d
176448|NCT02821923|Dietary Supplement|E968-Erythritol|36g erythritol/d
176449|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
176450|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
176451|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
176452|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
176453|NCT02821910|Drug|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
176454|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
176455|NCT02821897|Procedure|Target-controlled intravenous anaesthesia|
176456|NCT02821897|Procedure|Total anaesthesia|
176457|NCT02821884|Device|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
176458|NCT02821884|Device|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
176459|NCT02821884|Device|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
176460|NCT02821871|Drug|SP2086|
176461|NCT02821871|Dietary Supplement|high fat diet|
176462|NCT02821858|Drug|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
176463|NCT02821858|Drug|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
176464|NCT02821858|Drug|Placebo|Matching placebo will be administered.
176612|NCT02820688|Drug|Bupivacaine 0.167%|
176465|NCT02821845|Behavioral|Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control, members of this group will be trained at slow gait speeds,
176466|NCT02821832|Procedure|blood draw|blood draw
176467|NCT02821832|Radiation|PET/CT|Radiographic biomarkers using PET/CT as an early marker of treatment response and possibly as a marker for relapse at the end of treatment are being examined. The FDG-PET/CT scan will be performed at a facility local to the study site. The CT portion of the scan will be done without contrast and will be limited to the chest. Subjects will consent to receive a maximum of 4 FDG-PET/CT scans during the study baseline, 1 month, EOT, and at recurrence); however the vast majority of subjects will only receive 2-3 scans. The same scanner at each location will be used for subjects receiving subsequent scans as was used on their first scan. Subjects will be fully briefed with regard to what to expect and any precautions highlighted.
176468|NCT02821832|Procedure|induced sputum|Sputum induction, if necessary during the study, will take place in a designated area. Hypertonic saline will be administered via the mouthpiece of a nebulizer to induce expectoration.
176469|NCT02821819|Other|Random start ovarian stimulation|Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
176470|NCT02821819|Drug|Gonadotrophins|Urinary FSH 150-225 IU/d
176471|NCT02821819|Drug|GnRH antagonist|Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
176472|NCT02821819|Drug|GnRH agonist|GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
176473|NCT02821793|Other|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
176474|NCT02821793|Other|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
176475|NCT02821754|Drug|Durvalumab|Flat dose of 1500 mg every 4 weeks.
176476|NCT02821754|Drug|Tremelimumab|Flat dose of 75 mg every 4 weeks for up to 4 doses.
176477|NCT02821754|Procedure|TACE|TACE will be performed on Day 36 (+/-96hrs).
176478|NCT02821754|Procedure|RFA|RFA will be performed on Day 36 (+/-96hrs).
176479|NCT02821754|Procedure|Cryoablation|Cryoablation will be performed on Day 36 (+/-96hrs).
176480|NCT02821728|Dietary Supplement|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
176481|NCT02821728|Other|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
176482|NCT02821715|Drug|Active comparator: Modafinil + placebo|
176483|NCT02821715|Drug|THN102 300/3|
176484|NCT02821715|Drug|THN102 300/27|
176485|NCT02821702|Device|Vaginal ultrasound|
176486|NCT02821702|Biological|Blood sample|
176487|NCT02821689|Drug|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
176488|NCT02821676|Procedure|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
176489|NCT02821676|Procedure|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
176490|NCT02821663|Behavioral|vocal intervention|10 x 60 min. sessions of vocal intervention
176491|NCT02821650|Other|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
176492|NCT02821637|Other|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
176493|NCT02821637|Behavioral|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
176494|NCT02821637|Other|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
176495|NCT02821624|Drug|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
176496|NCT02821624|Drug|Placebo|Placebo
176497|NCT02821611|Behavioral|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
176498|NCT02821598|Other|Upper Limb pattern with flexion - abduction - external rotation|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
176537|NCT02821338|Drug|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
176538|NCT02821325|Other|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.~2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
176613|NCT02820688|Drug|Bupivacaine 0.125%|
176614|NCT02820688|Drug|Prilocaine 0.66%|
176499|NCT02821598|Other|Lower Limb pattern with flexion - adduction - external rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
176500|NCT02821598|Other|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
176501|NCT02821598|Other|Lifting to the right|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
176502|NCT02821598|Other|Sit to Stand|"Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times."
176503|NCT02821585|Behavioral|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
176504|NCT02821572|Biological|blood sample|
176505|NCT02821572|Procedure|spleen sample|
176506|NCT02821559|Drug|TOMOX|
176507|NCT02821559|Drug|Bevacizumab|Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
176508|NCT02821546|Drug|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
176509|NCT02821533|Procedure|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
176510|NCT02821533|Drug|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
176511|NCT02821520|Drug|conbercept|At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.
176512|NCT02821520|Procedure|Initial PDT|At baseline PDT with verteporfin is administered initially.And thereafter PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
176513|NCT02821520|Procedure|Delayed PDT|PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
176514|NCT02821507|Drug|sirolimus and cyclophosphamide|
176515|NCT02821494|Biological|Hespecta|A dose escalation of Amplivant® conjugated peptide
176516|NCT02821481|Dietary Supplement|Beta-alanine|
176517|NCT02821481|Dietary Supplement|Placebo|
176518|NCT02821481|Behavioral|Muscular endurance exercise|
176519|NCT02821468|Drug|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
176520|NCT02821468|Drug|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
176521|NCT02821455|Procedure|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
176522|NCT02821442|Device|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
176523|NCT02821442|Device|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
176524|NCT02821429|Other|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
176525|NCT02821416|Biological|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
176526|NCT02821416|Other|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
176527|NCT02821403|Device|clear lens with regular coating|
176528|NCT02821403|Device|regular coating lens with yellow tint|
176529|NCT02821403|Device|clear lens with blue-light blocking coating|
176530|NCT02821390|Drug|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
176531|NCT02821390|Drug|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
176532|NCT02821377|Drug|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
176533|NCT02821377|Drug|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
176534|NCT02821377|Procedure|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
176535|NCT02821364|Other|Advanced Life Support|IV FLUIDS, INTUBATION
176536|NCT02821351|Device|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
176539|NCT02821312|Drug|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
176540|NCT02821312|Drug|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
176541|NCT02821299|Other|Laryngeal transplantation|Laryngeal transplantation
176542|NCT02821286|Other|Observational study|Blood sampling
176543|NCT02821273|Other|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
176544|NCT02821273|Other|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
176545|NCT02821247|Drug|VEGF-Trap-Eye (BAY86-5321)|standard treatment patterns as decided by the physician
176546|NCT02821234|Other|MRI|
176547|NCT02821182|Radiation|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).~A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated >48h and <96h."
176548|NCT02821169|Drug|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
176549|NCT02821169|Drug|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
176550|NCT02821143|Other|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
176551|NCT02821143|Other|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).~The aim is to define and formalize:~Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.~Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.~Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.~In case of medical worsening :~Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
176552|NCT02821117|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.~During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.~Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
176553|NCT02821091|Other|Interactive Dynamic Balance Training|
176554|NCT02821078|Other|4D flow imaging sequence|4D flow imaging sequence
176555|NCT02821065|Device|Telus Health Remote Patient Monitoring|
176556|NCT02821052|Drug|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
176557|NCT02821026|Procedure|Omental Islet transplant|The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
176558|NCT02821026|Drug|Anti-Thymocyte Globulin|
176559|NCT02821026|Drug|Mycophenolate mofetil|
176560|NCT02821026|Drug|Tacrolimus|
176561|NCT02821026|Drug|Etanercept|
176562|NCT02821026|Drug|Sirolimus|Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
176563|NCT02821013|Drug|Intermittent PD-1 inhibitor therapy|
176564|NCT02821013|Drug|Continuous PD-1 inhibitor therapy|
176565|NCT02821000|Biological|Pembrolizumab|Intravenous infusion
176566|NCT02820987|Drug|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
176567|NCT02820987|Drug|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
176568|NCT02820987|Drug|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
176569|NCT02820961|Drug|entinostat|An orally available histone deacetylases inhibitor (HDAC)
176570|NCT02820961|Drug|exemestane|Aromatase inhibitor
176571|NCT02820948|Drug|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
176572|NCT02820935|Drug|CC-220|
176573|NCT02820935|Drug|Rifampin|
176574|NCT02820935|Drug|Itraconazole|
176575|NCT02820922|Procedure|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
176606|NCT02820740|Device|NeuroBlate System|Laser Interstitial Thermal Therapy
176607|NCT02820714|Drug|BLI801 Laxative|BLI801 Laxative
176608|NCT02820701|Procedure|OMT|Osteopathic Manipulative Treatment to low back region
176609|NCT02820688|Drug|Bupivacaine 0.25%|
176576|NCT02820909|Procedure|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
176577|NCT02820909|Procedure|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (> 3 punctures), a conversion to ultrasound guidance will be done.~In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
176578|NCT02820896|Drug|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
176579|NCT02820896|Drug|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
176580|NCT02820883|Biological|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
176581|NCT02820883|Biological|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
176582|NCT02820883|Biological|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
176583|NCT02820870|Behavioral|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
176584|NCT02820857|Drug|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
176585|NCT02820857|Drug|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
176586|NCT02820844|Drug|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
176587|NCT02820844|Drug|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
176588|NCT02820844|Drug|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
176589|NCT02820844|Other|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
176590|NCT02820844|Other|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
176591|NCT02820844|Other|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
176592|NCT02820844|Other|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
176593|NCT02820805|Other|Meal Skipping|No meal
176594|NCT02820805|Other|French fries|50g of available carbohydrates meal
176595|NCT02820805|Other|Mashed potatoes|50g of available carbohydrates meal
176596|NCT02820805|Other|Hash browns|50g of available carbohydrates meal
176597|NCT02820805|Other|Rice|50g of available carbohydrates meal
176598|NCT02820805|Other|Beans|50g of available carbohydrates meal
176599|NCT02820792|Procedure|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
176600|NCT02820792|Device|LMA ProtectorTM|
176601|NCT02820792|Device|Ambu AuraGainTM|
176602|NCT02820779|Device|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
176603|NCT02820753|Behavioral|EHR + Text|Text reminders to promote adherence
176604|NCT02820753|Behavioral|EHR + Portal|Engage portal to promote adherence and medication knowledge.
176605|NCT02820753|Behavioral|EHR + Text + Portal|See if texting and portal use promote adherence more than each element alone.
176616|NCT02820688|Device|Ultrasound|All nerve blocks will be performed with ultrasound guidance
176617|NCT02820675|Other|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
176618|NCT02820675|Other|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
176619|NCT02820662|Other|RETCAM|
176620|NCT02820662|Biological|Blood samples|
176621|NCT02820649|Other|Sleep deprivation|40 hours of continuous wakefullness
176622|NCT02820636|Behavioral|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual & 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication & trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
176623|NCT02820636|Behavioral|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
176624|NCT02820623|Behavioral|Self-report|
176625|NCT02820623|Behavioral|Chart-Stimulated Recall|
176626|NCT02820623|Behavioral|Behavioral Rehearsal|
176627|NCT02820610|Drug|Dexmedetomidine|2 mg/kg bupivacaine 25% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
176628|NCT02820610|Drug|Magnesium Sulfate|2 mg/kg bupivacaine 25% and 50 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
176629|NCT02820610|Drug|Normal saline 0.9 %|2 mg/kg bupivacaine 25% diluted in normal saline 0.9 % will instilled into the peritoneal cavity.
176630|NCT02820597|Device|ClariFix device|
176631|NCT02820584|Biological|GSC-loaded autologous dendritic cells|
176632|NCT02820558|Drug|Substance P|
176633|NCT02820545|Other|Sociological interview|A sociological interview will be performed with each patient by a sociologist, during their hospital stay
176634|NCT02820545|Other|Self-administrated questionnaire|Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
176635|NCT02820532|Device|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
176636|NCT02820519|Drug|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
176637|NCT02820506|Procedure|SLN mapping and removal of PET-positive lymph nodes|Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
176638|NCT02820493|Drug|vedolizumab|
176639|NCT02820480|Device|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.~Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
176640|NCT02820467|Device|fluorescence angiography|Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
176641|NCT02820454|Drug|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
176642|NCT02820454|Radiation|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
176643|NCT02820441|Drug|Zopiclone|
176644|NCT02820441|Drug|Placebo|
176645|NCT02820428|Other|Healthy participants|Semi-structured interview
176646|NCT02820415|Other|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
176647|NCT02820389|Procedure|Optical colonoscopy|Patients with suspected colorectal cancer in this group will undergo Optical Colonoscopy as the initial imaging modality.
176648|NCT02820389|Procedure|CTC|Patients with suspected colorectal cancer in this group will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan, i.e. patients with medium to large polyps or colorectal cancer will undergo Optical Colonoscopy as the second imaging test.
176649|NCT02820376|Other|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
176650|NCT02820363|Device|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™|G applied to bony voids."
176651|NCT02820363|Procedure|SOC treatment|surgical repair of tibial fracture
176652|NCT02820350|Device|SCD-F40|CRRT with SCD
176653|NCT02820324|Drug|Oliceridine|
176654|NCT02820324|Drug|Placebo|
176655|NCT02820324|Drug|Morphine|
176656|NCT02820311|Drug|TD-4208 175 mcg|via nebulizer
176657|NCT02820311|Drug|TD-4208 700 mcg|via nebulizer
176658|NCT02820311|Drug|Placebo for TD-4208|via nebulizer
176659|NCT02820311|Drug|Moxifloxacin 400 mg|oral
176660|NCT02820298|Drug|Bexagliflozin|Bexagliflozin tablet, 20 mg
176661|NCT02820285|Other|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
176948|NCT02818166|Procedure|Mitral valve surgery|Right mini-thoracotomy mitral valve replacement/repair.
176662|NCT02820285|Other|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
176663|NCT02820285|Other|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting~)"
176664|NCT02820272|Procedure|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
176665|NCT02820272|Procedure|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
176666|NCT02820272|Procedure|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
176667|NCT02820259|Drug|Tacrolimus|
176668|NCT02820246|Other|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
176669|NCT02820194|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
176670|NCT02820194|Procedure|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
176671|NCT02820181|Device|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
176672|NCT02820181|Device|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
176673|NCT02820155|Drug|RGN1016|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
176674|NCT02820155|Drug|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
176675|NCT02820129|Device|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
176676|NCT02820129|Device|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
176677|NCT02820116|Drug|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
176678|NCT02820103|Behavioral|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
176679|NCT02820103|Behavioral|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
176680|NCT02820103|Behavioral|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
176681|NCT02820077|Device|Hemospray (Endoscopic treatment with hemostatic powder)|Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
176682|NCT02820064|Procedure|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
176683|NCT02820051|Device|Transcutaneous CO2 monitor|Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
176684|NCT02820051|Drug|Midazolam|The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
176685|NCT02820051|Drug|Propofol|The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
176686|NCT02820051|Drug|Nalbuphine|The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
176687|NCT02820051|Drug|Lidocaine|Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
176688|NCT02820038|Behavioral|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
176689|NCT02820038|Behavioral|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
176949|NCT02818153|Other|Self questionnaire for allergic rhinitis control|
176690|NCT02820038|Behavioral|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
176691|NCT02820025|Drug|doxapram|
176692|NCT02820025|Other|saline|
176693|NCT02820012|Other|Scoliosis|Questionnaires, radiography
176694|NCT02819999|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
176695|NCT02819999|Drug|Cisplatin|
176696|NCT02819999|Drug|Etoposide|
176697|NCT02819986|Behavioral|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
176698|NCT02819973|Other|Educational Video1|
176699|NCT02819973|Other|Educational Video 2|
176700|NCT02819973|Other|Usual Care 3|
176701|NCT02819960|Drug|PROBIO-FIX INUM®|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
176702|NCT02819960|Drug|Placebo|Maltodextrin
176703|NCT02819947|Other|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
176704|NCT02819934|Drug|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
176705|NCT02819921|Drug|Desvenlafaxine succinate 100mg|Pristiq 100mg
176706|NCT02819921|Drug|Desvenlafaxine succinate 50mg|Pristiq 50mg
176707|NCT02819921|Drug|Placebo|Placebo
176708|NCT02819908|Drug|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
176709|NCT02819908|Drug|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
176710|NCT02819895|Other|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
176711|NCT02819882|Other|No intervention|
176712|NCT02819869|Drug|Statin and Metformin use|
176713|NCT02819856|Drug|Placebo|0 mg SPI-1005 bid po x 21d
176714|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
176715|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
176716|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
176717|NCT02819843|Drug|TALIMOGENE LAHERPAREPVEC (TVEC)|
176718|NCT02819843|Radiation|Hypofractionated Radiotherapy|
176719|NCT02819830|Behavioral|Exercise Intervention|Combined strength and aerobic exercise
176720|NCT02819817|Drug|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
176721|NCT02819817|Other|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
176722|NCT02819804|Drug|Dasatinib|Given PO
176723|NCT02819804|Other|Laboratory Biomarker Analysis|Correlative studies
176724|NCT02819804|Biological|Nivolumab|Given IV
176725|NCT02819804|Other|Pharmacological Study|Correlative studies
176726|NCT02819791|Other|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
176727|NCT02819791|Behavioral|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:~learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.~the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .~the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
176728|NCT02819778|Procedure|usual care|
176729|NCT02819778|Procedure|S100B|
176730|NCT02819752|Drug|Pembrolizumab|Pembrolizumab
176731|NCT02819752|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
176732|NCT02819752|Drug|Chemotherapy|Chemotherapy - Standard Treatment
176733|NCT02819739|Drug|medical oxygen|
176734|NCT02819726|Biological|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
176735|NCT02819726|Biological|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
176736|NCT02819726|Biological|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
176737|NCT02819726|Biological|Rituxan/SAIT101|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
176738|NCT02819713|Other|ultrasound gel|
176739|NCT02819713|Other|Instillagel|
176740|NCT02819700|Behavioral|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
176741|NCT02819687|Drug|RDX5791|
176742|NCT02819687|Drug|Placebo|
176743|NCT02819661|Device|SOMNOTOUCH RESP|Ventilatory effort recorder
176744|NCT02819661|Procedure|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
176745|NCT02819661|Drug|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
176746|NCT02819648|Drug|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
176747|NCT02819648|Other|Control|Milk Tablet
176748|NCT02819635|Drug|Placebo|Tablet
176749|NCT02819635|Drug|Updacitinib (ABT-494)|Tablet
176750|NCT02819609|Procedure|myomectomy|Myomectomy as part of routine clinical care
176751|NCT02819609|Procedure|endometrial ablation|Endometrial ablation as part of routine clinical care
176752|NCT02819609|Procedure|uterine artery embolization|Uterine artery embolization as part of routine clinical care
176753|NCT02819609|Procedure|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
176754|NCT02819596|Drug|Savolitinib|
176755|NCT02819596|Drug|MEDI4736|
176756|NCT02819596|Drug|Tremelimumab|
176757|NCT02819583|Biological|PCAR-019 (anti-CD19 CAR-T cells)|
176758|NCT02819570|Drug|I.V cefuroxime 750 mg*3/d for 2 days|
176759|NCT02819570|Drug|I.V ampicillin 2 gram x4/d for 2 days|
176760|NCT02819570|Drug|P.O cefuroxime 500 mgx2/d for 5 days|
176761|NCT02819570|Drug|P.O roxithromycin 150 mg*2/d for 7 days|
176762|NCT02819570|Drug|P.O moxypen 500 mgx3/d for 5 days|
176763|NCT02819557|Drug|Ataluren|Ataluren
176764|NCT02819544|Drug|Sodium chloride administration|Sodium chloride administration
176765|NCT02819544|Drug|Ropivacaine administration|Ropivacaine administration
176766|NCT02819531|Device|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
176767|NCT02819531|Device|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
176768|NCT02819531|Device|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
176769|NCT02819518|Biological|Pembrolizumab|IV infusion
176770|NCT02819518|Drug|Nab-paclitaxel|IV infusion
176771|NCT02819518|Drug|Paclitaxel|IV infusion
176772|NCT02819518|Drug|Gemcitabine|IV infusion
176773|NCT02819518|Drug|Carboplatin|IV infusion
176774|NCT02819518|Drug|Normale Saline Solution|IV infusion
176775|NCT02819505|Dietary Supplement|beta-alanine|
176776|NCT02819505|Dietary Supplement|Placebo|
176777|NCT02819479|Drug|25% Mannitol|"Route of administration:~In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
176778|NCT02819479|Drug|Low-dose Intra-arterial Bevacizumab|"Route of administration:~In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery."
176779|NCT02819466|Device|3D echography|ultrasound visualization of the stomach in fasting patients.
176780|NCT02819453|Drug|Methylprednisolone|Patients with acute respiratory distress syndrome needed treat with methylprednisolone, which determined by two clinicians.
176781|NCT02819440|Drug|Tadalafil|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
176782|NCT02819440|Drug|Placebo|100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
176783|NCT02819427|Device|Near Infra Red Spectroscopy (NIRS)|
176784|NCT02819427|Device|Electroencephalography (EEG)|Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
176785|NCT02819414|Drug|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
176786|NCT02819414|Other|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
176787|NCT02819401|Other|pediatric formula|high-fiber enteral formula
176788|NCT02819388|Behavioral|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
176789|NCT02819375|Drug|Propofol|1 mg/kg propofol
176790|NCT02819375|Drug|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
176791|NCT02819375|Drug|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
176792|NCT02819362|Device|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
176793|NCT02819349|Behavioral|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
176881|NCT02818621|Drug|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
177171|NCT02816567|Drug|placebo - isotonic saline serum|
177172|NCT02816567|Drug|sufentanil|
176794|NCT02819336|Device|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.~Let the patient lie down on lateral decubitus.~The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.~The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)~After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)~The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
176795|NCT02819336|Device|Sham electroacupuncture|"Let the patient lie down on lateral decubitus.~The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally & SP11 and SP6 bilaterally.~The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.~The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.~The practitioner should have at least 1-year clinical experiences.~The procedure will be repeated 10 times (once a session) within 21 days."
176796|NCT02819323|Drug|PEG-ELS|polyethylene glycol based bowel preparation
176797|NCT02819323|Drug|BLI800|BLI800 bowel preparation
176798|NCT02819310|Drug|BLI400 Laxative|oral laxative
176799|NCT02819297|Drug|BLI400 Laxative|Oral laxative
176800|NCT02819297|Drug|BLI400 Placebo|BLI400 Placebo
176801|NCT02819284|Drug|KPI-121 0.25% Ophthalmic Suspension|
176802|NCT02819284|Drug|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
176803|NCT02819271|Drug|CXL-1427 Ascending Dose|
176804|NCT02819271|Other|Placebo|
176805|NCT02819271|Drug|CXL-1427 Descending Dose|
176806|NCT02819258|Other|Endodontic treatment|
176807|NCT02819245|Procedure|posterior correction and fusion|
176808|NCT02819232|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
176809|NCT02819219|Dietary Supplement|Supplemental|participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.
176810|NCT02819219|Other|Exercise Intervention|Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
176811|NCT02819206|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
176812|NCT02819193|Other|raw mother's own milk|Infants receive mother's own milk before day 7.
176813|NCT02819180|Biological|Butantan Influenza Trivalent, Fragmented and Inactivated vaccine|
176814|NCT02819167|Other|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
176815|NCT02819154|Behavioral|phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay|"phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay. Investigators will use :~Questionnaire SF 36: Only the first two questions of the SF-36 are used exploring the felt quality of life at the time of the telephone call and in comparison with the period before hospitalization in intensive care.~Stress Assessment Questionnaire posttraumatic (Revised Impact of Event Scale, IES-R)~ADL: Assessment of independence in activities of daily life"
176816|NCT02819141|Drug|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
176817|NCT02819128|Other|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
176818|NCT02819128|Other|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
176819|NCT02819115|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
176820|NCT02819102|Drug|BCX7353 and probes|
176821|NCT02819089|Drug|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
176822|NCT02819089|Other|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
176823|NCT02819076|Other|pain scale|
176824|NCT02819050|Device|NCPAP|Nasal Continuous Positive Airway Pressure
176825|NCT02819037|Procedure|gas chromatography|
176826|NCT02819037|Procedure|Stool analysis for detection of malabsorption|
176827|NCT02819024|Drug|Dexamethasone|Given PO BID
176828|NCT02819024|Device|Device for PET|Undergo 18F-FLT PET scan
176829|NCT02819024|Other|Laboratory Biomarker Analysis|Correlative studies
176830|NCT02819024|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET scan
176831|NCT02819011|Device|MBB AFO|Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO
176832|NCT02819011|Other|Control|Subjects will be provided with a pair of New Balance 813 shoes
176833|NCT02818998|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
176834|NCT02818985|Drug|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
176835|NCT02818985|Drug|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
176836|NCT02818985|Drug|Saline|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
176837|NCT02818972|Device|RelayPro|Endovascular treatment with investigational device.
176838|NCT02818959|Device|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
176839|NCT02818946|Device|MRI|Detection of cancer by MRI for pathologic nipple discharge
176882|NCT02818608|Device|Functional Electrical Stimulation (FES)|Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
177173|NCT02816567|Procedure|laparoscopic surgery|
176840|NCT02818920|Drug|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 & 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles~-Note: Standard radiation therapy in selected patients for standard clinical indications"
176841|NCT02818907|Other|Additional biological samples|blood and tumor tissue samples
176842|NCT02818894|Drug|Lidocaine|Spinal anesthesia administered prior to participant's THA
176843|NCT02818894|Drug|Bupivacaine|Spinal anesthesia administered prior to participant's THA
176844|NCT02818881|Other|High-speed yoga|
176845|NCT02818881|Other|Low-speed yoga|
176846|NCT02818868|Drug|apixisaban|
176847|NCT02818855|Procedure|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.~The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
176848|NCT02818855|Drug|Collagen Matrix|A new collagen membrane
176849|NCT02818855|Procedure|Subepithelial connective tissue graft|Connective tissue graft
176850|NCT02818842|Other|Primary Health Insurance Fund data|"Data collected are:~First and last name of mother~Age~Mother's date of birth~Theorical date of beginning of pregnancy~Childbirth date"
176851|NCT02818842|Other|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :~First and last name of the mother~Mother's birth date~Mother Obstetric history~Course of pregnancy~Drug exposure (name, decision period)~Medical termination of pregnancy (date, cause ...)~Malformations (description, test results, gender of the child,~Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
176852|NCT02818842|Other|Mother and child protection data collection|"Date collected are :~Name and surname of Mother~Date of birth of the mother~Obstetric history of the mother (the first certificate to 8 days)~Course of pregnancy (1st certificate to 8 days)~Birth data (1 certificate to 8 days)~Child gender,~Age of the child at the time of the review,~Weight, height and head circumference of the child~American Pediatric Gross Assessment Record (1 certificate to 8 days)~Neonatal diseases (1 certificate to 8 days)~Birth defects (1 certificate to 8 days)~Death (age at death)~History (certificates at 9 and 24 months)~Current diseases (certificates at 9 and 24 months)~Psychomotor development (certificates at 9 and 24 months).~Date of drugs issue~Amount of drug issued~Type of feeding (1 certificate to 8 days)"
176853|NCT02818842|Other|Medicalisation Program of Information Systems data|"Data collected are :~First and last name of the mother~Mother's birth date~History of abortions (date and cause)"
176854|NCT02818829|Other|Collection of biological samples|Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
176855|NCT02818816|Drug|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
176856|NCT02818816|Other|Carboxymethylcellulose Eye Drops|Ocular lubricants
176857|NCT02818803|Other|Propolis|
176858|NCT02818803|Drug|Miconazole|
176859|NCT02818790|Behavioral|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
176860|NCT02818790|Behavioral|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
176861|NCT02818777|Drug|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.~A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
176862|NCT02818764|Procedure|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
176863|NCT02818764|Procedure|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
176864|NCT02818764|Device|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
176865|NCT02818764|Device|Cerebral blood flow and oxygen extraction fraction|NIRS measurement of Cerebral blood flow and cerebral tissue oxygen concentration.
176866|NCT02818751|Drug|Escitalopram|Patients being randomized to receive escitalopram.
176867|NCT02818751|Other|Placebo|Patients being randomized to receive placebo.
176868|NCT02818738|Drug|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
176869|NCT02818738|Other|Placebo|matching verum
176870|NCT02818725|Drug|Chemotherapy|METHOTREXATE 30 mg/m2 on day 1 VINBLASTINE 3 mg/m2 on day 2 DOXORUBICIN 30 mg/m2 on day 2 CISPLATIN 70 mg/m2 on day 2
176871|NCT02818725|Drug|panitumumab|PANITUMUMAB 6 mg/kg on day 2
176872|NCT02818699|Dietary Supplement|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
176873|NCT02818699|Dietary Supplement|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
176874|NCT02818686|Drug|TD-1473|
176875|NCT02818686|Drug|Placebo|
176876|NCT02818673|Radiation|labelled human serumalbumin (125-I, Séralb®CisBio)|Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
176877|NCT02818673|Radiation|labelled albumin (99m-Tc, Vasculocis®, Cisbio)|intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
176878|NCT02818660|Drug|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
176879|NCT02818647|Procedure|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
176880|NCT02818634|Procedure|Harvesting rib cartilage|
176883|NCT02818608|Device|Combination of Transcranial direct brain stimulation (tDCS) and FES|Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
176884|NCT02818595|Device|electroencephalogram (HR-EEG)|
176885|NCT02818595|Device|Near Infra Red Spectroscopy (NIRS)|
176886|NCT02818582|Drug|GS-5734|Daily GS-5734 or placebo delivered intravenously (IV) for 5 days
176887|NCT02818582|Other|Placebo Comparator|Placebo delivered intravenously (IV) for 5 days.
176888|NCT02818569|Drug|Dexmedetomidine|Oral form
176889|NCT02818569|Other|Saline Placebo|Saline Placebo
176890|NCT02818556|Drug|Restalyne Silk|
176891|NCT02818556|Drug|Belotero Balance|
176892|NCT02818543|Drug|LYC-30937|
176893|NCT02818530|Device|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
176894|NCT02818530|Device|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
176895|NCT02818517|Other|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
176896|NCT02818517|Other|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
176897|NCT02818504|Other|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
176898|NCT02818491|Drug|Placebo|Normal saline 0.9% in 2 mls
176899|NCT02818491|Drug|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
176900|NCT02818491|Drug|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
176901|NCT02818491|Drug|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
176902|NCT02818491|Drug|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
176903|NCT02818491|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 20 mls
176904|NCT02818478|Other|Reporting of patient reported outcome measures|Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
176905|NCT02818465|Other|Vascular calcifications by Xray|
176906|NCT02818465|Other|Vascular calcifications by tomodentimetry|
176907|NCT02818465|Biological|Blood sample withdrawn|
176908|NCT02818452|Other|Oatmeal + OatWell28XF|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
176909|NCT02818452|Other|Oatmeal|
176910|NCT02818452|Other|Hot cereal|
176911|NCT02818439|Other|evaluation of frailty|
176912|NCT02818426|Drug|UCPVax|
176913|NCT02818413|Other|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
176914|NCT02818400|Procedure|composite tissue allotransplantation|
176915|NCT02818387|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
176916|NCT02818387|Drug|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
176917|NCT02818387|Drug|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
176918|NCT02818374|Device|oral accessibility spatula (SAB)|
176919|NCT02818361|Drug|Topical tripterygium gel|
176920|NCT02818361|Drug|Placebo gel|
176921|NCT02818348|Drug|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
176922|NCT02818348|Drug|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
176923|NCT02818335|Drug|LY3023414 Reference Fasted|Administered Orally
176924|NCT02818335|Drug|LY3023414 Test Fasted|Administered Orally
176925|NCT02818335|Drug|LY3023414 Test Fed|Administered Orally
176926|NCT02818322|Device|telemedical monitoring ( T)|
176927|NCT02818322|Device|classic monitoring|
176928|NCT02818309|Drug|Lesogaberan|120 mg bid
176929|NCT02818309|Drug|Placebo|Placebo
176930|NCT02818296|Behavioral|Active IU CBM-I|
176931|NCT02818296|Behavioral|Control CBM-I|
176932|NCT02818283|Other|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
176933|NCT02818283|Other|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
176934|NCT02818270|Drug|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
176935|NCT02818270|Drug|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
176936|NCT02818257|Other|Strip A|Adhesive strip A
176937|NCT02818257|Other|Strip B|Adhesive strip B
176938|NCT02818257|Other|Strip C|Adhesive strip C
176939|NCT02818244|Device|Fit Bit Blaze Heart Rate Monitoring Device|
176940|NCT02818244|Device|Garmin Forerunner 235 Heart Rate Monitoring Device|
176941|NCT02818244|Device|Tom Tom Spark Cardio Heart Rate Monitoring Device|
176942|NCT02818244|Device|Apple Watch Heart Rate Monitoring Device|
176943|NCT02818244|Device|Scosche Rhythm + Heart Rate Monitor|
176944|NCT02818231|Other|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
176945|NCT02818218|Procedure|Liver Transplant|liver transplant recipient surgery
176946|NCT02818205|Other|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
176947|NCT02818179|Radiation|THERMOGRAPHY IMAGING|
176950|NCT02818140|Procedure|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
176951|NCT02818140|Procedure|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
176952|NCT02818140|Drug|Ropivacaine|
176953|NCT02818140|Drug|Saline|
176954|NCT02818140|Device|Ultrasound|
176955|NCT02818127|Procedure|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
176956|NCT02818114|Behavioral|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
176957|NCT02818101|Behavioral|Hypnosis session|
176958|NCT02818088|Behavioral|n-Back (Cognitive Training)|
176959|NCT02818075|Other|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
176960|NCT02818075|Other|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
176961|NCT02818062|Biological|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
176962|NCT02818049|Procedure|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
176963|NCT02818036|Drug|Naltrexone|
176964|NCT02818036|Drug|Placebo|
176965|NCT02818023|Drug|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
176966|NCT02818023|Drug|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.~One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
176967|NCT02818023|Drug|Cobimetinib|Cobimetinib will be given at 20 mg once daily, 40 mg once daily, or 60 mg once daily. Treatment with cobimetinib will commence on the same day. Cobimetinib will be given daily for 21 days, then held for 7 days.
176968|NCT02818010|Other|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
176969|NCT02817984|Biological|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
176970|NCT02817971|Behavioral|Enhanced feedback|Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
176971|NCT02817971|Behavioral|Standard feedback|Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
176972|NCT02817958|Drug|Chemotherapy TIP|Paclitaxel, ifosfamide, and cisplatin
176973|NCT02817945|Drug|68Ga-NOTA-3P-TATE-RGD|68Ga-NOTA-3P-TATE-RGD were injected into the patients before the PET/CT scans
176974|NCT02817932|Drug|Ranolazine|
176975|NCT02817906|Drug|ITI-007|
176976|NCT02817906|Drug|Placebo|
176977|NCT02817880|Device|rTMS|
176978|NCT02817880|Device|tDCS|
176979|NCT02817880|Device|tsDCS|
176980|NCT02817867|Device|tDCS|Transcranial direct current stimulation (tDCS)
176981|NCT02817867|Device|TMS|Transcranial magnetic stimulation
176982|NCT02817867|Device|tDCS + TMS|Association between tDCS and TMS.
176983|NCT02817854|Procedure|Measure PCT, CRP and WBC at admission|Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done
176984|NCT02817854|Procedure|Measure PCT, CRP and WBC 1 day after admission|Measure PCT, CRP and WBC at one day after admission for acute diverticulitis
176985|NCT02817854|Procedure|Measure PCT, CRP and WBC 2 days after admission|Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
176986|NCT02817841|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
176987|NCT02817828|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
176988|NCT02817815|Device|Electrocardiogram (ECG)|
176989|NCT02817815|Biological|Blood sampling from the cephalic vein|
176990|NCT02817815|Biological|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
176991|NCT02817815|Biological|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
176992|NCT02817815|Procedure|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
176993|NCT02817815|Biological|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
176994|NCT02817802|Device|Magmaris|PCI (Magmaris)
176995|NCT02817789|Drug|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
176996|NCT02817789|Drug|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
176997|NCT02817776|Device|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
176998|NCT02817763|Procedure|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
176999|NCT02817763|Procedure|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
177000|NCT02817763|Drug|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
177001|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
177002|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
177003|NCT02817724|Device|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
177004|NCT02817724|Other|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
177005|NCT02817698|Drug|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
177006|NCT02817685|Other|3 months|
177007|NCT02817685|Other|6 months|
177008|NCT02817685|Other|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
177009|NCT02817672|Behavioral|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
177010|NCT02817672|Behavioral|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
177011|NCT02817659|Drug|Glucagon|Glucagon infusion
177012|NCT02817646|Other|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
177013|NCT02817646|Dietary Supplement|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
177014|NCT02817633|Drug|TSR-022|TSR-022 is a humanized monoclonal IgG4 antibody binds to TIM3
177015|NCT02817633|Drug|TSR-042, an anti-PD-1 antibody|TSR-042 is a humanized monoclonal IgG4 antibody binds to PD-1
177016|NCT02817633|Drug|TSR-033, an anti-LAG-3 antibody|TSR-033 is a humanized monoclonal IgG4 antibody binds to Lag 3
177017|NCT02817620|Dietary Supplement|Spirulysat®|
177018|NCT02817620|Dietary Supplement|Placebo|
177019|NCT02817607|Procedure|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.~A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
177020|NCT02817568|Other|Drawing Blood|Drawing Blood for genetic analysis
177021|NCT02817555|Drug|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin > 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
177022|NCT02817555|Drug|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin >150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
177023|NCT02817542|Device|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
177024|NCT02817529|Device|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
177025|NCT02817529|Device|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
177026|NCT02817516|Drug|TAK-828|TAK-828 solution.
177027|NCT02817516|Drug|Placebo|TAK-828 placebo-matching solution.
177028|NCT02817503|Drug|Standard BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
177029|NCT02817503|Drug|Moderate BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
177030|NCT02817503|Drug|Intensive BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
177031|NCT02817490|Other|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.~The program includes theoretical information, practical cases, and discussions between participants and professionals.~It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
177032|NCT02817477|Drug|Ketamine Hydrochloride|Delivered intranasally using an atomizer
177033|NCT02817477|Drug|Morphine|Delivered either as an IM injection or a slow IV bolus
177034|NCT02817464|Drug|TV-46046 - 400 mg/mL|A single subcutaneous injection in the abdomen of TV-46046 - 400 mg/mL
177035|NCT02817464|Drug|TV-46046 - 200 mg/mL|A single subcutaneous injection in the abdomen of TV-46046 - 200 mg/mL
177036|NCT02817464|Drug|TV-46046 - 300 mg/mL (if warranted)|A single subcutaneous injection in the abdomen of TV-46046 - 300 mg/mL (if warranted)
177037|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
177038|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
177039|NCT02817438|Behavioral|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
177040|NCT02817425|Drug|SOX Sequential S-1|8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
177041|NCT02817425|Drug|SOX|S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle
177042|NCT02817425|Drug|TEGAFOX Sequential S-1.|6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
177043|NCT02817412|Behavioral|Go/No-Training|
177044|NCT02817412|Behavioral|Stop-Signal Training|
177045|NCT02817412|Behavioral|Dot-Probe Paradigm|
177046|NCT02817412|Behavioral|Generic Response Training|
177047|NCT02817399|Device|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
177048|NCT02817399|Device|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
177049|NCT02817399|Procedure|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
177050|NCT02817386|Other|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
177051|NCT02817373|Other|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
177052|NCT02817360|Drug|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
177053|NCT02817360|Other|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
177054|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
177055|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
177056|NCT02817347|Drug|piperacillin 2% + tazobactam 0.25%|
177057|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5%|
177058|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0%|
177059|NCT02817334|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
177060|NCT02817321|Procedure|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
177220|NCT02816112|Drug|Neupogen|Granulocyte-colony stimulating factor
177061|NCT02817321|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
177062|NCT02817321|Device|PAJUNK Contiplex S Catheter|
177063|NCT02817321|Drug|single dose ropivacaine|"2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total~given immediately after the correct position of the tip of the needle has been confirmed"
177064|NCT02817321|Drug|continuously infusion of ropivacaine|"0.2% ropivacaine, pulse dosadge: 0.125ml/kg/pulse, 1pulse/h at a rate of 6ml/minutes~given through the catheter inserted in the T8 paravertebral space following the single dose"
177065|NCT02817321|Drug|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
177066|NCT02817308|Other|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
177067|NCT02817295|Other|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
177068|NCT02817282|Other|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
177069|NCT02817269|Other|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
177070|NCT02817269|Other|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
177071|NCT02817256|Dietary Supplement|Vitamins and Minerals|Multivitamins and Minerals supplementation
177072|NCT02817243|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
177073|NCT02817243|Drug|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
177074|NCT02817230|Drug|Statin|
177075|NCT02817217|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
177076|NCT02817217|Drug|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
177077|NCT02817204|Behavioral|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
177078|NCT02817204|Behavioral|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
177079|NCT02817191|Drug|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
177080|NCT02817191|Drug|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
177081|NCT02817178|Other|Additional biological samples|blood and tumor tissue samples
177082|NCT02817165|Dietary Supplement|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
177083|NCT02817165|Other|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
177084|NCT02817152|Procedure|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
177085|NCT02817152|Device|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
177086|NCT02817139|Device|TDCS|
177087|NCT02817126|Procedure|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
177088|NCT02817126|Procedure|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
177089|NCT02817113|Drug|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
177090|NCT02817113|Drug|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
177091|NCT02817113|Drug|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
177092|NCT02817100|Drug|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
177134|NCT02816814|Other|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
177135|NCT02816801|Other|Butler-Program 2.0|Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
177093|NCT02817100|Drug|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food [Continental breakfast])
177094|NCT02817100|Drug|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
177095|NCT02817087|Device|repetitive Transcranial Magnetic Stimulation -On|Cap worn on the scalp will deliver active Repetitive Transcranial Magnetic Stimulation to specific parts of the brain
177096|NCT02817087|Device|repetitive Transcranial Magnetic Stimulation -Off|Cap worn on the scalp will no delivery of the Repetitive Transcranial Magnetic Stimulation to any part of the, referred to as a sham or inactive study treatment.
177097|NCT02817074|Behavioral|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
177098|NCT02817074|Behavioral|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
177099|NCT02817061|Device|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
177100|NCT02817048|Device|chest tube|
177101|NCT02817048|Procedure|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
177102|NCT02817048|Procedure|VATS with chest tube placement|
177103|NCT02817035|Device|noninvasive mechanical ventilation|To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
177104|NCT02817022|Other|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
177105|NCT02817009|Behavioral|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
177106|NCT02817009|Behavioral|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
177107|NCT02817009|Behavioral|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
177108|NCT02816996|Procedure|Hand-holding|Subject will have their hand held.
177109|NCT02816996|Procedure|Stress Ball|Subject will be given a stress ball to hold.
177110|NCT02816983|Radiation|SBRT|
177111|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
177112|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
177113|NCT02816957|Drug|nigella sativ|nigella sativa powder (2 gm/day) for 3 consecutive months.
177114|NCT02816944|Procedure|EUS-guided laser ablation for refractory neoplasms|
177115|NCT02816918|Device|Extraluminal use of Univent bronchial Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .~So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
177116|NCT02816918|Device|Innerluminal use Univent bronchial Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
177117|NCT02816905|Drug|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
177118|NCT02816905|Drug|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
177119|NCT02816905|Drug|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
177120|NCT02816879|Procedure|Cytology Specimen Collection Procedure|Undergo anal cytology collection
177121|NCT02816879|Other|Laboratory Biomarker Analysis|Correlative studies
177122|NCT02816866|Other|empowered primary care model|mode of survivorship care
177123|NCT02816866|Other|specialty survivor clinic|mode of survivorship care
177124|NCT02816853|Drug|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
177125|NCT02816853|Drug|Placebo|Matching placebo will be administered.
177126|NCT02816853|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
177127|NCT02816840|Radiation|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
177128|NCT02816840|Radiation|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
177129|NCT02816827|Dietary Supplement|AG-01|Product to increase mental alertness
177130|NCT02816827|Dietary Supplement|AG-05|Product to increase mental alertness
177131|NCT02816827|Dietary Supplement|AG-06|Product to increase mental alertness
177132|NCT02816827|Dietary Supplement|AG-07|Product to increase mental alertness
177133|NCT02816814|Other|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
177170|NCT02816567|Drug|NMBA - cisatracurium|
177136|NCT02816788|Behavioral|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
177137|NCT02816775|Device|Macintosh Laryngoscope|After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
177138|NCT02816775|Device|McGRATH Videolaryngoscope|After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
177139|NCT02816762|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
177140|NCT02816762|Drug|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
177141|NCT02816762|Other|Diet|Conventional anti-diabetic diet recommendations
177142|NCT02816749|Procedure|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
177143|NCT02816749|Procedure|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
177144|NCT02816736|Drug|LCZ696|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.~Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.~The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively."
177145|NCT02816736|Drug|valsartan|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.~Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.~Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.~Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.~The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets)."
177146|NCT02816736|Drug|LCZ696 placebo|LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
177147|NCT02816736|Drug|valsartan placebo|Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
177148|NCT02816723|Behavioral|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
177149|NCT02816723|Behavioral|Brain Health|Brain Health Education
177150|NCT02816710|Drug|Conbercept|Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
177151|NCT02816697|Other|CEASE|"Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)~CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits"
177152|NCT02816697|Other|Usual Care Tobacco Treatment Services|
177153|NCT02816684|Behavioral|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
177154|NCT02816684|Behavioral|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
177155|NCT02816671|Device|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
177156|NCT02816658|Other|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
177157|NCT02816658|Other|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
177158|NCT02816645|Procedure|Magnetic Resonance Imaging (MRI)|
177159|NCT02816632|Other|mRI|Neural bases of feedbacks' influence on decision making processes
177160|NCT02816632|Other|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
177161|NCT02816619|Behavioral|Personalized Physical Activity coaching program|
177162|NCT02816619|Behavioral|Free practice of physical activity|
177163|NCT02816606|Procedure|Flexible reamers|These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
177164|NCT02816606|Procedure|70-degree arthroscope|Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
177165|NCT02816593|Drug|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
177166|NCT02816593|Drug|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
177167|NCT02816593|Drug|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
177168|NCT02816580|Other|Blood collection|
177169|NCT02816567|Drug|propofol|
177174|NCT02816554|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
177175|NCT02816554|Biological|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
177176|NCT02816554|Biological|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
177177|NCT02816554|Biological|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
177178|NCT02816541|Other|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
177179|NCT02816541|Other|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
177180|NCT02816541|Other|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
177181|NCT02816528|Behavioral|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
177182|NCT02816502|Behavioral|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
177183|NCT02816502|Behavioral|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
177184|NCT02816489|Device|Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA|(passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
177185|NCT02816489|Device|Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA|(conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
177186|NCT02816476|Drug|Daratumumab|
177187|NCT02816463|Device|Ambu AuraGain|
177188|NCT02816463|Device|LMA Supreme|
177189|NCT02816450|Behavioral|Water Intake|
177190|NCT02816437|Biological|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
177191|NCT02816424|Behavioral|Teens Exploring and Managing Prevention Options (TEMPO)|
177192|NCT02816411|Dietary Supplement|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.~Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
177193|NCT02816411|Dietary Supplement|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
177194|NCT02816398|Device|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
177195|NCT02816385|Procedure|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
177196|NCT02816385|Procedure|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
177197|NCT02816372|Other|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
177198|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
177199|NCT02816346|Biological|Shigella sonnei 53G|"Investigational Product: Shigella sonnei strain 53G (Lot 1794) Mode of Administration: Delivered with sodium bicarbonate orally after a 90 minute fast.~Dose: 500-1500 cfu (doses were to be increased or lowered based on results of preceding cohorts)"
177200|NCT02816320|Other|Hospitalization|Patients who were hospitalized in acute care
177201|NCT02816307|Other|blood samples|
177202|NCT02816294|Behavioral|Housing Prescription|
177203|NCT02816268|Other|Pulmonary vein isolation|
177204|NCT02816255|Device|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
177205|NCT02816255|Device|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
177206|NCT02816242|Other|concept map teaching|teaching anatomy using concept map to improve critical thinking
177207|NCT02816242|Other|traditional teaching|teaching anatomy using lecture
177208|NCT02816229|Device|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
177209|NCT02816216|Behavioral|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
177210|NCT02816203|Device|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
177211|NCT02816190|Procedure|prone position|
177212|NCT02816177|Other|Telemedicine|
177213|NCT02816177|Other|Usual Care|
177214|NCT02816164|Drug|Neupogen|Subcutaneous injections
177215|NCT02816151|Drug|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
177216|NCT02816151|Drug|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
177217|NCT02816138|Drug|Nicotine|Open-label transdermal nicotine patch
177218|NCT02816125|Dietary Supplement|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
177219|NCT02816112|Drug|Ciprofloxacin|Antibiotic
177221|NCT02816099|Biological|Prise de sang|
177222|NCT02816086|Other|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
177223|NCT02816073|Device|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
177224|NCT02816060|Procedure|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
177225|NCT02816047|Other|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
177226|NCT02816034|Behavioral|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
177227|NCT02816034|Behavioral|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
177228|NCT02816021|Drug|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
177229|NCT02816021|Drug|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
177230|NCT02816008|Behavioral|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
177231|NCT02816008|Behavioral|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
177232|NCT02815995|Drug|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
177233|NCT02815995|Drug|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
177234|NCT02815982|Behavioral|NOURISH-T|Overweight/obesity family intervention
177235|NCT02815982|Behavioral|Enhanced Usual Care|Publicly available overweight/obesity materials
177236|NCT02815969|Other|vena punction|vena punction and urine collection
177237|NCT02815956|Device|percutaneous tibial nerve stimulation|
177238|NCT02815956|Device|Placebo|
177239|NCT02815943|Procedure|biliopancreatic diversion with duodenal switch|
177240|NCT02815943|Procedure|sleeve gastrectomy|
177241|NCT02815943|Other|liquid meal|will be consumed over 30 minutes with [U-13C]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
177242|NCT02815943|Radiation|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
177243|NCT02815943|Other|[7,7,8,8-2H]-palmitate|i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to 360 min.
177244|NCT02815943|Device|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
177245|NCT02815930|Other|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
177246|NCT02815917|Drug|[18F]FTP PET/CT|All PET/CT imaging sessions will include an injection of [18F]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of [18F]FTP in healthy volunteers and cocaine-dependent volunteers.
177247|NCT02815904|Other|Yakson touch|Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\infant to relieve their pain or to calm them down.
177248|NCT02815904|Other|Conventional handling|Positioning of preterm infants for optimal physiological development
177249|NCT02815904|Other|Kinesthetic stimulation|For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
177250|NCT02815904|Other|Kangaroo Mother Care|Providing skin to skin human touch
177251|NCT02815878|Behavioral|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
177252|NCT02815865|Device|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
177253|NCT02815865|Device|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
177254|NCT02815865|Drug|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
177255|NCT02815852|Other|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women <40 years the typical imaging presentation pattern of malignancies observed in women> 40 years are confirmed.
177256|NCT02815839|Drug|SHR4640|
177257|NCT02815839|Drug|Placebo|
177258|NCT02815826|Other|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
177259|NCT02815826|Other|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
177307|NCT02815475|Dietary Supplement|Turmeric powder|
177308|NCT02815462|Other|FAMFACESG|- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
177309|NCT02815462|Other|Control|- Usual hospital Care
177629|NCT02813083|Other|No intervention (observational)|No intervention (observational)
177260|NCT02815813|Behavioral|PeerFIT|The 12-month PeerFIT intervention consists of a 6-month intensive phase including: (a) once weekly 60-minute group weight management and exercise session led by a lifestyle coach; (b) once weekly one-hour physical activity session delivered in community settings; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change. Participants then transition to a 6-month lower intensity phase in which the 90-minute weight management sessions are discontinued. The groups will be conducted as open groups with a minimum of 4 and maximum of 18 participants at any given time.
177261|NCT02815813|Behavioral|BEAT|Participants in BEAT will receive monthly individual lifestyle sessions delivered by a lifestyle coach including education, guidance, and support for self-monitoring behaviors (i.e., daily self-weighing and tracking daily steps) during the first six months of the study, plus text message reminders and encouragement for self-monitoring weight loss behaviors during the entire 12-month study period. Participants will receive materials with tips and strategies for healthy eating and increasing physical activity. They will also be given a wearable activity tracker (i.e., Fitbit Zip) to use with instructions for using the device. The first session with the lifestyle coach will be in person and thereafter by phone.
177262|NCT02815800|Dietary Supplement|ETHNODYNE VISIO|
177263|NCT02815787|Drug|SP2086|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
177264|NCT02815787|Drug|Glyburide|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
177265|NCT02815774|Drug|SP2086|all subjects were given SP2086 50mg only one time.
177266|NCT02815761|Other|NO intervention, just observation|No intervention.
177267|NCT02815748|Drug|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
177268|NCT02815735|Device|comfilcon A|contact lens
177269|NCT02815735|Device|lotrafilcon B|contact lens
177270|NCT02815722|Drug|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
177271|NCT02815722|Drug|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
177272|NCT02815709|Drug|Oliceridine|
177273|NCT02815709|Drug|Placebo|
177274|NCT02815709|Drug|Morphine|
177275|NCT02815696|Device|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
177276|NCT02815670|Drug|Idarucizumab|
177277|NCT02815657|Drug|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
177278|NCT02815657|Drug|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
177279|NCT02815644|Drug|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
177280|NCT02815631|Device|Cardiogoniometry (CGM)|
177281|NCT02815631|Device|Fractional Flow Reserve (FFR)|
177282|NCT02815618|Device|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
177283|NCT02815592|Drug|BMS-986012|
177284|NCT02815592|Drug|Cisplatin|
177285|NCT02815592|Drug|Etoposide|
177286|NCT02815592|Drug|Platinum|
177287|NCT02815592|Drug|Carboplatin|
177288|NCT02815579|Other|Shamba Maisha Intervention|A) A microcredit loan (~$140) B) Agricultural implements to be purchased with the loan C) Education in financial management and sustainable farming practices
177289|NCT02815566|Drug|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
177290|NCT02815566|Drug|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
177291|NCT02815553|Procedure|Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|
177292|NCT02815553|Procedure|Direct Transthoracic Cardiac Tumor Laser Ablation Therapy|
177293|NCT02815540|Procedure|12-Lead ECG|Subjects will be monitored while on cannabidiol with a 12-Lead ECG and/or Holter monitoring
177294|NCT02815540|Drug|Cannabidiol|Subjects who are planning to take state dispensed medical cannabidiol, or are already taking state dispensed medical cannabidiol.
177295|NCT02815527|Other|Fresubin intensive|Enteral nutrition containing a high protein concentration
177296|NCT02815501|Biological|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
177297|NCT02815488|Drug|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
177298|NCT02815488|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
177299|NCT02815488|Drug|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
177300|NCT02815488|Drug|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
177301|NCT02815488|Drug|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
177302|NCT02815488|Drug|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
177303|NCT02815488|Drug|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
177304|NCT02815488|Drug|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
177305|NCT02815475|Dietary Supplement|Placebo comparator|
177306|NCT02815475|Dietary Supplement|Curcumin|
177310|NCT02815462|Other|FAMFACESG|- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
177311|NCT02815462|Other|FAMFACESG|"For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.~For high and moderate risk patients & have complex nursing and / or high functional needs, PNs will refer these patients for THC.~For mild risk patients, PNs will refer them to care coordinator."
177312|NCT02815462|Other|FAMFACESG|- For low risk patients, PNs will continue usual hospital care.
177313|NCT02815449|Other|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
177314|NCT02815449|Other|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
177315|NCT02815449|Other|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
177316|NCT02815436|Other|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
177317|NCT02815436|Other|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
177318|NCT02815423|Biological|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
177319|NCT02815423|Biological|Percutaneous|Percutaneous injection
177320|NCT02815410|Drug|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
177321|NCT02815397|Drug|Metformin|given in addition to standard of care treatment
177322|NCT02815371|Procedure|Needle Acupuncture|See above
177323|NCT02815371|Procedure|Laser Acupuncture|See above
177324|NCT02815371|Procedure|Sham Laser Acupuncture|See above
177325|NCT02815358|Other|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
177326|NCT02815358|Other|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
177327|NCT02815345|Device|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
177328|NCT02815332|Drug|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
177329|NCT02815332|Drug|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
177330|NCT02815332|Drug|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
177331|NCT02815319|Drug|Dexamethasone|Steroid prophylaxis
177332|NCT02815306|Device|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
177333|NCT02815293|Drug|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
177334|NCT02815293|Drug|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
177335|NCT02815280|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
177336|NCT02815280|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
177337|NCT02815267|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
177338|NCT02815267|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
177339|NCT02815254|Other|High intensity functional exercise|
177340|NCT02815254|Other|Low intensity functional exercise|
177341|NCT02815241|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-046)
177342|NCT02815228|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-034)
177343|NCT02815215|Procedure|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
177344|NCT02815215|Procedure|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
177345|NCT02815202|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z12-034)
177346|NCT02815189|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
177347|NCT02815189|Drug|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
177348|NCT02815176|Other|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
177349|NCT02815163|Other|Empowerment education|"admission (1 hour)~▪partnership~2 ds after THR (30-45min)~listening~dialogue~reflection~action~feedback~2 WKs after THR (30 min)~listening~dialogue~reflection~action~feedback~6 WKs after THR (30 min)~listening~dialogue~reflection~action~feedback~10 WKs after THR (30 min)~listening~dialogue~reflection~action~feedback"
177350|NCT02815150|Dietary Supplement|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
177351|NCT02815137|Other|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
177352|NCT02815124|Other|Standard of Care|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
177353|NCT02815124|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
177354|NCT02815111|Drug|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
177355|NCT02815111|Drug|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
177356|NCT02815111|Drug|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
177357|NCT02815111|Drug|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
177358|NCT02815085|Other|RecoverLINK technology|HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
177359|NCT02815072|Other|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
177360|NCT02815059|Drug|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
177361|NCT02815059|Drug|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
177362|NCT02815059|Drug|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
177363|NCT02815046|Drug|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
177364|NCT02815046|Device|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
177365|NCT02815033|Drug|Enzalutamide|
177366|NCT02815033|Procedure|11C or 18F-Choline PET/CT|
177367|NCT02815033|Procedure|Whole body MRI|
177368|NCT02815033|Procedure|Bone scan|
177369|NCT02815020|Other|Boot Camp Translation - community-participatory process|Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
177370|NCT02815007|Drug|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
177371|NCT02814994|Behavioral|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
177372|NCT02814994|Behavioral|low tidal volume|ventilation ventilated with low tidal volume
177373|NCT02814968|Drug|Enzalutamide|
177374|NCT02814968|Device|18-FDG PET/CT|
177375|NCT02814968|Device|Whole body MRI|
177376|NCT02814968|Device|Bone scan|
177377|NCT02814942|Device|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
177378|NCT02814916|Drug|Dalbavancin single dose|"Dalbavancin, weight-adjusted dose, up to 1500mg. Intravenous (IV) administration.~Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used."
177379|NCT02814916|Drug|Dalbavancin two dose|"Dalbavancin, weight-adjusted dose, up to 1000mg. Intravenous (IV) administration, with second dalbavancin weight-adjusted dose, up to 500mg.~Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used."
177380|NCT02814916|Drug|Comparator|"Course of either vancomycin not to exceed a total daily dose of 4000 mg;or oxacillin; or flucloxacillin not to exceed a total daily dose of 2000 mg. Intravenous (IV) administration. Possible oral switch after at least 72 hours from oxacillin or flucloxacillin to oral cefadroxil, or from IV vancomycin to oral clindamycin (for MRSA).~Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.~Additional comparator drugs may be used, if an alternate comparator regimen is indicated by local susceptibility patterns."
177381|NCT02814890|Procedure|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
177382|NCT02814890|Procedure|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
177383|NCT02814877|Other|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
177384|NCT02814864|Drug|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale>2) will receive Mesenchymal Stromal Cell (MSC) injections
177385|NCT02814851|Device|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
177386|NCT02814851|Device|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
177421|NCT02814604|Other|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
177719|NCT02812368|Drug|Clonidine|
177387|NCT02814851|Device|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
177388|NCT02814851|Device|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
177389|NCT02814838|Drug|Ladarixin|Ladarixin oral capsule
177390|NCT02814838|Drug|Placebo|Placebo oral capsule
177391|NCT02814825|Other|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
177392|NCT02814812|Procedure|CT scan|
177393|NCT02814799|Other|bone removal|
177394|NCT02814786|Radiation|MRI scanner|"This examination is divided in 2 parts:~Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.~Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome."
177395|NCT02814786|Other|Gait analysis|For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
177396|NCT02814773|Other|questionnaires|
177397|NCT02814760|Other|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:~Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms~Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
177398|NCT02814747|Other|quantitive study: 500 patients likely to be candidates for HTS|
177399|NCT02814747|Other|qualitative study: 30 patients who have benefited from HTS|
177400|NCT02814721|Device|Sonic Window ultrasound device|
177401|NCT02814708|Biological|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow‐up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST‐1 binding Ab titer of < 20 to > 40 or a 4‐fold increase in TSST‐1 binding Ab titer .
177402|NCT02814695|Dietary Supplement|Vit E 1|
177403|NCT02814695|Dietary Supplement|Vit E 2|
177404|NCT02814695|Dietary Supplement|Vit E 3|
177405|NCT02814695|Dietary Supplement|YE 1|
177406|NCT02814695|Dietary Supplement|YE 2|
177407|NCT02814695|Dietary Supplement|YE 3|
177408|NCT02814695|Dietary Supplement|Vit C 1|
177409|NCT02814695|Dietary Supplement|Vit C 2|
177410|NCT02814695|Dietary Supplement|Vit C 3|
177411|NCT02814669|Drug|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
177412|NCT02814669|Drug|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
177413|NCT02814656|Drug|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
177414|NCT02814656|Drug|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
177415|NCT02814643|Drug|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
177416|NCT02814643|Drug|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
177417|NCT02814643|Drug|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
177418|NCT02814630|Biological|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
177419|NCT02814617|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.68 g|Cordyceps sinensis mycelium culture extract 1.68 g
177420|NCT02814617|Dietary Supplement|Placebo|
177422|NCT02814591|Device|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
177423|NCT02814578|Other|Optical coherent tomography|comparative method for BVS
177424|NCT02814578|Other|IntraVascular UltraSound|The method of goldstandard for decision stent choice
177425|NCT02814565|Drug|Cyclobenzaprine HCl|Cyclobenzaprine HCl extended-release capsules
177426|NCT02814565|Drug|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules
177427|NCT02814552|Other|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
177428|NCT02814552|Other|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
177429|NCT02814526|Behavioral|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
177430|NCT02814526|Behavioral|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
177431|NCT02814513|Device|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
177432|NCT02814513|Device|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
177433|NCT02814513|Device|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
177434|NCT02814513|Device|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
177435|NCT02814513|Device|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
177436|NCT02814500|Drug|DP-R212|Investigational product is prescribed to all of randomized subjects
177437|NCT02814500|Drug|Amlodipine|Investigational product is prescribed to all of randomized subjects
177438|NCT02814500|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
177439|NCT02814474|Other|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
177440|NCT02814474|Other|Saline|Infusion of 0.9 % saline
177441|NCT02814461|Drug|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
177442|NCT02814461|Radiation|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
177443|NCT02814448|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
177444|NCT02814448|Device|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
177445|NCT02814448|Device|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
177446|NCT02814435|Other|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
177447|NCT02814435|Other|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
177448|NCT02814409|Drug|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|
177449|NCT02814409|Drug|Intravenous Tenecteplase|
177450|NCT02814383|Other|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
177451|NCT02814357|Other|Control (market standard)|
177452|NCT02814357|Other|wheat flour|
177453|NCT02814357|Other|chickpea flour|
177454|NCT02814357|Other|guar gum|
177455|NCT02814357|Other|barley|
177456|NCT02814344|Device|Electrohysterography|
177457|NCT02814331|Device|multimodal high-resolution EEG-NIRS|
177458|NCT02814318|Biological|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
177459|NCT02814305|Behavioral|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
177460|NCT02814305|Behavioral|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
177509|NCT02813850|Device|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
177461|NCT02814279|Procedure|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
177462|NCT02814279|Procedure|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
177463|NCT02814279|Drug|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
177464|NCT02814279|Drug|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
177465|NCT02814266|Other|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
177466|NCT02814266|Other|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
177467|NCT02814240|Other|NMR|
177468|NCT02814240|Biological|Blood samples|
177469|NCT02814240|Other|fibroscan|
177470|NCT02814227|Device|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
177471|NCT02814214|Device|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
177472|NCT02814201|Behavioral|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
177473|NCT02814188|Other|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
177474|NCT02814188|Other|Placebo Beverage|750 ml of an artificially-sweetened beverage
177475|NCT02814175|Drug|methotrexate (MTX)|
177476|NCT02814175|Biological|adalimumab|
177477|NCT02814149|Procedure|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
177478|NCT02814149|Procedure|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
177479|NCT02814136|Procedure|Ablation|
177480|NCT02814123|Other|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
177481|NCT02814110|Drug|Granulocyte colony-stimulating factor (Filgrastim)|Drug administration
177482|NCT02814097|Drug|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
177483|NCT02814097|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
177484|NCT02814084|Device|Bilateral Internal Mammary Artery grafts|Sternal Wound Edge Oxygenation in patients undergoing Coronary Artery bypass surgery with Bilateral Internal Mammary Artery grafts
177485|NCT02814084|Device|Prevena|The Prevena wound management system applies negative pressure to the closed wound for up to 7 days and is associated with lower rates of surgical site infection.
177486|NCT02814071|Other|Early enteral feeding|Early enteral feeding as per description
177487|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
177488|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
177489|NCT02814019|Drug|Idebenone 150 mg film-coated tablets|
177490|NCT02814019|Drug|placebo|
177491|NCT02814006|Other|health educational video|visualization of health educational video
177492|NCT02813993|Other|Health educational video|
177493|NCT02813980|Other|There are no interventions. This is a prospective observational study.|
177494|NCT02813967|Radiation|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
177495|NCT02813967|Radiation|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
177496|NCT02813967|Drug|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
177497|NCT02813954|Device|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
177498|NCT02813941|Other|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
177499|NCT02813941|Other|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
177500|NCT02813941|Other|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
177501|NCT02813928|Genetic|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
177502|NCT02813915|Device|NICOM|Use of NICOM and PLR to obtain patient fluid status
177503|NCT02813902|Drug|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
177504|NCT02813902|Other|Sugar Pill|A pill that appears similar to the supplement
177505|NCT02813889|Device|SmarToyGym|"We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.~A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture."
177506|NCT02813876|Other|Enhanced recovery protocol|
177507|NCT02813863|Drug|SP2086|
177508|NCT02813863|Drug|Metformin|
177510|NCT02813837|Biological|CD19CART|Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
177511|NCT02813824|Drug|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
177512|NCT02813824|Drug|Placebo (for Aspirin 300)|Daily dose during 4 years
177513|NCT02813824|Drug|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
177514|NCT02813824|Drug|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
177515|NCT02813798|Drug|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
177516|NCT02813785|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
177517|NCT02813785|Drug|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 21-day cycle.
177518|NCT02813772|Dietary Supplement|Milk formula NAN Sensitive, Nestle|Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
177519|NCT02813772|Dietary Supplement|Milk formula Optipro, Nestle|Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
177520|NCT02813759|Other|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
177521|NCT02813759|Other|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
177522|NCT02813746|Dietary Supplement|Fitness program|
177523|NCT02813746|Behavioral|Stop smoking|
177524|NCT02813746|Procedure|Endometrial fluid collection|
177525|NCT02813733|Procedure|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
177526|NCT02813720|Radiation|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.~It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
177527|NCT02813707|Other|QoL questionnaire regarding the long term complication|Micronutrients evaluation
177528|NCT02813694|Drug|lefamulin|antibacterial agent
177529|NCT02813694|Drug|Moxifloxacin|antibacterial agent
177530|NCT02813681|Procedure|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
177531|NCT02813681|Procedure|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
177532|NCT02813681|Procedure|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
177533|NCT02813668|Behavioral|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 7% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
177534|NCT02813655|Drug|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
177535|NCT02813655|Drug|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.~All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
177536|NCT02813642|Biological|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
177537|NCT02813642|Biological|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
177538|NCT02813642|Procedure|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
177539|NCT02813629|Device|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.~PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
177540|NCT02813603|Procedure|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
177541|NCT02813590|Other|Ascitic fluid puncture|
177542|NCT02813590|Other|Skin swaps from puncture side|
177543|NCT02813590|Other|Stool samples|
177544|NCT02813577|Device|Lutonix® 035 Drug Coated Balloon PTA Catheter|Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
177545|NCT02813564|Behavioral|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
177546|NCT02813551|Drug|Torsemide|
177547|NCT02813551|Drug|Placebo|
177548|NCT02813538|Drug|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
177549|NCT02813538|Other|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
177550|NCT02813525|Other|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
177551|NCT02813512|Drug|ADSCs|Autologous ADSCs
177552|NCT02813499|Other|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
177553|NCT02813486|Biological|Biological: GC3111 vaccine|0.5mL, Intramuscular
177554|NCT02813486|Biological|Biological: Boostrix® vaccine|0.5mL, Intramuscular
177555|NCT02813473|Radiation|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
177556|NCT02813473|Radiation|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
177557|NCT02813460|Drug|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
177558|NCT02813460|Drug|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
177559|NCT02813460|Drug|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
177560|NCT02813460|Drug|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
177561|NCT02813460|Drug|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
177562|NCT02813460|Drug|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
177563|NCT02813460|Drug|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
177564|NCT02813460|Drug|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
177565|NCT02813460|Drug|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
177566|NCT02813460|Drug|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
177567|NCT02813460|Drug|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
177568|NCT02813460|Drug|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
177569|NCT02813447|Drug|Sertraline|
177570|NCT02813447|Drug|Placebo|
177571|NCT02813434|Biological|florbetapir|18F-AV-45 or 18F-Florbetapir
177572|NCT02813421|Device|CGM Informed|
177573|NCT02813395|Device|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
177574|NCT02813395|Device|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
177575|NCT02813382|Drug|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
177576|NCT02813382|Drug|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
177577|NCT02813382|Drug|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
177578|NCT02813369|Drug|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
177579|NCT02813369|Drug|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
177580|NCT02813356|Drug|naloxegol|non-interventional study where naloxegol is prescribed during normal clinical practice
177581|NCT02813356|Drug|non-PAMORA|non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
177628|NCT02813096|Other|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
177582|NCT02813343|Device|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
177583|NCT02813330|Other|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
177584|NCT02813330|Other|saline injection|Saline injection in two points of low back pain
177585|NCT02813304|Behavioral|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
177586|NCT02813304|Behavioral|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
177587|NCT02813291|Device|tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex."
177588|NCT02813291|Device|sham tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:~- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex."
177589|NCT02813278|Dietary Supplement|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
177590|NCT02813278|Other|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra & Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
177591|NCT02813265|Drug|KPI-121 0.25% Ophthalmic Suspension|
177592|NCT02813265|Drug|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
177593|NCT02813252|Genetic|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
177594|NCT02813239|Other|hCG|Oocyte maturation with hCG
177595|NCT02813239|Other|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
177596|NCT02813226|Other|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
177597|NCT02813213|Procedure|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
177598|NCT02813213|Procedure|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
177599|NCT02813200|Drug|Seretide® Diskus® 500/550 μg|Every day during 7 days
177600|NCT02813200|Drug|Ultibro® Breezhaler® 110/50 μg|Every day during 7 days
177601|NCT02813200|Drug|Spiriva® Respimat® 2,5 μg|Every day during 7 days
177602|NCT02813187|Biological|cellular and tissue based therapy|
177603|NCT02813187|Procedure|debridement|
177604|NCT02813187|Procedure|advanced wound therapy|
177605|NCT02813187|Dietary Supplement|Nutritional screening|
177606|NCT02813174|Behavioral|Compassionate Mind Training from Compassion-Focused Therapy|
177607|NCT02813161|Biological|cellular and tissue based therapy|
177608|NCT02813161|Device|negative pressure wound therapy|
177609|NCT02813161|Procedure|debridement|
177610|NCT02813161|Procedure|advanced wound therapy|
177611|NCT02813161|Dietary Supplement|Nutritional screening|
177612|NCT02813161|Device|off-loading|
177613|NCT02813161|Device|Hyperbaric oxygen Therapy|
177614|NCT02813148|Drug|Naloxegol|Non-interventional study of drug utilization
177615|NCT02813135|Drug|Ribociclib|
177616|NCT02813135|Drug|Topotecan|
177617|NCT02813135|Drug|Temozolomide|
177618|NCT02813135|Drug|Everolimus|
177619|NCT02813135|Drug|AZD1775|
177620|NCT02813135|Drug|Carboplatin|
177621|NCT02813135|Drug|Olaparib|
177622|NCT02813135|Drug|Irinotecan|
177623|NCT02813135|Drug|Nivolumab|
177624|NCT02813135|Drug|Enasidenib|
177625|NCT02813135|Drug|Lirilumab|
177626|NCT02813122|Device|x-ray|x-ray for the detection of leaks and bleeding
177627|NCT02813096|Drug|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.~Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
177630|NCT02813070|Drug|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
177631|NCT02813057|Procedure|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
177632|NCT02813057|Procedure|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
177633|NCT02813044|Drug|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
177634|NCT02813044|Drug|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
177635|NCT02813031|Other|Functional meat products|
177636|NCT02813031|Other|Traditional meat products|
177637|NCT02813018|Procedure|0.2 ml/kg of 0.2% ropivacaine|In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
177638|NCT02813018|Procedure|0.2mg/kg of Normal Saline|In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
177639|NCT02813005|Procedure|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
177640|NCT02813005|Procedure|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
177641|NCT02812992|Drug|Nab-paclitaxel|
177642|NCT02812992|Drug|Gemcitabine|
177643|NCT02812992|Other|Best Supportive Care|
177644|NCT02812979|Device|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
177645|NCT02812979|Device|Mask|Usual nebulization of salbutamol with mask
177646|NCT02812979|Device|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
177647|NCT02812966|Device|Lutonix|Drug Coated Balloons
177648|NCT02812966|Device|IN.PACT|Drug Coated Balloons
177649|NCT02812940|Drug|Everolimus|GvHD prophylaxis
177650|NCT02812927|Device|Edelvaiss Multiline-8|Optimised infusion line
177651|NCT02812927|Device|Standard infusion line|
177652|NCT02812914|Other|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
177653|NCT02812914|Behavioral|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
177654|NCT02812914|Behavioral|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
177655|NCT02812901|Procedure|cardiac surgery scheduled in the morning|cardiac surgery scheduled in the morning
177656|NCT02812901|Procedure|cardiac surgery scheduled in the afternoon|cardiac surgery scheduled in the afternoon
177657|NCT02812888|Drug|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
177658|NCT02812875|Drug|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.~Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: mesothelioma, melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
177659|NCT02812862|Drug|Ultibro/ Breezhaler|LABA/ LAMA combination therapy a combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent
177660|NCT02812849|Drug|Cu-64 DOTATATE|
177661|NCT02812836|Device|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
177662|NCT02812823|Device|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
177663|NCT02812810|Device|active rTMS|
177664|NCT02812810|Device|sham rTMS|
177665|NCT02812784|Device|Nephrocheck TM|
177666|NCT02812771|Drug|Efinaconazole|Solution
177667|NCT02812758|Device|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
177668|NCT02812745|Device|recording of cardiac output|
177669|NCT02812745|Device|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
177670|NCT02812732|Behavioral|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.~Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3&4. Action Plans are developed in Session 5. Sessions 6&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
177671|NCT02812719|Drug|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.~This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
177672|NCT02812719|Drug|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.~This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
177673|NCT02812706|Drug|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
177674|NCT02812693|Drug|Imatinib Mesylate|Given PO
177675|NCT02812693|Other|Laboratory Biomarker Analysis|Correlative studies
177676|NCT02812693|Biological|Pembrolizumab|Given IV
177677|NCT02812680|Other|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
177678|NCT02812667|Drug|Nivolumab + Plinabulin|
177679|NCT02812654|Drug|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
177680|NCT02812654|Drug|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
177681|NCT02812654|Radiation|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
177682|NCT02812641|Drug|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If <= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If > 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
177683|NCT02812641|Drug|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
177684|NCT02812641|Drug|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
177685|NCT02812628|Procedure|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
177686|NCT02812628|Procedure|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
177687|NCT02812615|Dietary Supplement|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
177688|NCT02812615|Dietary Supplement|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
177689|NCT02812615|Drug|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
177690|NCT02812615|Behavioral|Nutritional counselling|Parents/caregivers will be given nutritional counselling
177691|NCT02812615|Dietary Supplement|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
177692|NCT02812602|Drug|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
177693|NCT02812602|Drug|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
177694|NCT02812589|Other|Diffusion tensor imaging (DTI) in Breast MRI|
177695|NCT02812563|Other|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
177696|NCT02812550|Procedure|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
177697|NCT02812537|Other|patients with conduct disorders|interview with a specialist
177698|NCT02812524|Drug|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
177699|NCT02812511|Procedure|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
177700|NCT02812498|Other|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
177701|NCT02812498|Other|Standard|Group of patients followed in a traditional way
177702|NCT02812472|Other|Treadmill training with functional electrical stimulation|
177703|NCT02812472|Other|Treadmill training without functional electrical stimulation|
177704|NCT02812459|Other|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
177705|NCT02812459|Other|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
177706|NCT02812446|Other|IAI infection|
177707|NCT02812446|Other|Staphylococcus aureus nasal carriage infection|
177708|NCT02812433|Drug|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
177709|NCT02812433|Drug|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
177710|NCT02812420|Biological|Durvalumab|Given IV
177711|NCT02812420|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy with pelvic lymph node dissection
177712|NCT02812420|Biological|Tremelimumab|Given IV
177713|NCT02812407|Device|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.~The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second~At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds~And at 20 cm"
177714|NCT02812394|Drug|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
177715|NCT02812394|Drug|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
177716|NCT02812394|Drug|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
177717|NCT02812381|Procedure|KT|to aplicate neuromuscular bandage technique(KT)
177718|NCT02812381|Procedure|SCS|To aplicate strain-counterstrain above trigger point
177720|NCT02812368|Drug|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
177721|NCT02812355|Drug|Heparin|
177722|NCT02812342|Drug|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
177723|NCT02812329|Behavioral|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
177724|NCT02812316|Device|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
177725|NCT02812303|Other|Centralized support for population health management activities|
177726|NCT02812290|Procedure|Lung transplant biopsy bites.|In the second phase of the study, two biopsy bites from the same patient will be collected to assess tissue sampling variability.
177727|NCT02812264|Behavioral|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
177728|NCT02812264|Behavioral|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
177729|NCT02812264|Behavioral|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
177730|NCT02812264|Behavioral|scale|Connected scale that will transfer weight information to app
177731|NCT02812251|Drug|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
177732|NCT02812251|Drug|Placebo|Matching placebo will be administered.
177733|NCT02812238|Dietary Supplement|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of placebo pills.
177734|NCT02812238|Drug|Placebo|Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
177735|NCT02812225|Device|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
177736|NCT02812212|Device|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
177737|NCT02812212|Device|diuretic renography|diuretic renography to measure the cortical transit time.
177738|NCT02812199|Device|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
177739|NCT02812199|Drug|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
177740|NCT02812199|Procedure|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
177741|NCT02812186|Procedure|deep neuromuscular blockade|"After induction and intubation, the patient will be maintained in a deep (post-tetanic count, one or two twitches) neuromuscular block (NMB), obtained with an intubating dose of rocuronium of 0.6 mg/kg followed by a continuous infusion. The initial infusion rate will be set at 0.6 mg/kg/h. To minimize any type of carry-over effects, after the completion of the deep NMB 20 minute period, a transition period of approximately 10-15 minutes will begin. During this transition period the rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade."
177742|NCT02812186|Procedure|moderate neuromuscular blockade|"After induction and intubation, the patient will be maintained in a deep (post-tetanic count, one or two twitches) neuromuscular block (NMB), obtained with an intubating dose of rocuronium of 0.6 mg/kg followed by a continuous infusion. The initial infusion rate will be set at 0.6 mg/kg/h. To minimize any type of carry-over effects, after completion of the moderate NMB 20 minute period, a transition period of approximately 10-15 min will begin. During this transition period the rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB."
177743|NCT02812186|Drug|Rocuronium|
177744|NCT02812173|Device|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
177745|NCT02812173|Device|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
177746|NCT02812173|Device|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
177747|NCT02812160|Device|Spatz3 Adjustable Balloon|An adjustable intragastric balloon for weight loss that can have the balloon volume increased or decrease as needed
177748|NCT02812147|Drug|L-DOPS|Added as described in the Arm/Group Descriptions.
177749|NCT02812147|Drug|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
177750|NCT02812121|Drug|umbilical cord blood mesenchymal stem cells|
177751|NCT02812108|Device|intracranial stent, flow diverter and coils|
177752|NCT02812095|Procedure|Refeeding|when amount of feeding reach to 120mL/kg a day,
177753|NCT02812082|Other|web-based patient education|
177754|NCT02812082|Behavioral|questionnaire|
177755|NCT02812069|Device|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
177756|NCT02812056|Drug|Alisertib|"Dose Escalation Phase:~Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
177878|NCT02811120|Other|venepuncture only|single venepuncture
177757|NCT02812056|Drug|TAK-228|"Dose Escalation Phase:~Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.~Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
177758|NCT02812043|Device|1,064nm Long-pulsed Nd:YAG|Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
177759|NCT02812043|Drug|Amorolfine|Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
177760|NCT02812030|Other|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
177761|NCT02812017|Behavioral|Thirty Million Words- Well Baby|Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
177762|NCT02812017|Other|Safety Starts at Home|A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
177763|NCT02812004|Device|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.~For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
177764|NCT02811991|Drug|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
177765|NCT02811991|Drug|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
177766|NCT02811991|Drug|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose<25mg/4h.
177767|NCT02811978|Drug|Bortezomib|Participants will receive 1.3 mg/m^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
177768|NCT02811978|Drug|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
177769|NCT02811965|Other|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
177770|NCT02811965|Other|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
177771|NCT02811965|Device|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
177772|NCT02811965|Device|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
177773|NCT02811965|Device|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
177774|NCT02811965|Device|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
177775|NCT02811952|Other|without intervention|without intervention
177776|NCT02811939|Drug|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
177777|NCT02811939|Drug|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
177778|NCT02811939|Drug|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
177779|NCT02811939|Drug|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
177780|NCT02811913|Other|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions~session 1 - High frequency rTMS targeting contralesional sensory cortex~session 2 - Low frequency rTMS~session 3 - sham rTMS"
177781|NCT02811900|Procedure|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
177782|NCT02811900|Procedure|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
177783|NCT02811900|Procedure|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
177784|NCT02811900|Procedure|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
177785|NCT02811887|Behavioral|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
177786|NCT02811887|Other|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
177836|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
177837|NCT02811484|Drug|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
177946|NCT02810600|Other|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
177787|NCT02811887|Behavioral|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.~The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
177788|NCT02811874|Behavioral|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
177789|NCT02811874|Behavioral|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
177790|NCT02811861|Drug|lenvatinib|
177791|NCT02811861|Drug|everolimus|
177792|NCT02811861|Drug|pembrolizumab|
177793|NCT02811861|Drug|Sunitinib|
177794|NCT02811822|Drug|GMI-1271|
177795|NCT02811809|Drug|Apalutamide|Apalutamide 240 mg (4 60mg tablets) daily
177796|NCT02811809|Drug|IHT|Leuprolide 3-month depot 22.5 intramuscular dose
177797|NCT02811796|Other|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
177798|NCT02811783|Drug|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
177799|NCT02811783|Drug|Placebo Lotion|Topical TID for 2 weeks
177800|NCT02811770|Other|kidney biopsy|
177801|NCT02811757|Procedure|tenotomy|
177802|NCT02811757|Procedure|tenodesis|
177803|NCT02811744|Drug|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
177804|NCT02811731|Drug|CKD-330 16/5mg - B|
177805|NCT02811731|Drug|Candesartan 16mg and Amlodipine 5mg|
177806|NCT02811718|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
177807|NCT02811718|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
177808|NCT02811705|Other|Quality of life|Quality of life
177809|NCT02811692|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
177810|NCT02811679|Drug|Blinatumomab|Blinatumomab is a bispecific t cell engaging antibody targeting CD19 and CD3 approved for B cell acute lymphoblastic leukemia
177811|NCT02811666|Device|Assessment of sarcopenia by CT-Scan|
177812|NCT02811666|Device|hand gauge|
177813|NCT02811653|Device|Brain MRI|
177814|NCT02811653|Other|neuropsychological evaluation|
177815|NCT02811653|Biological|Blood|
177816|NCT02811640|Other|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
177817|NCT02811627|Drug|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
177818|NCT02811627|Device|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
177819|NCT02811614|Procedure|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
177820|NCT02811614|Procedure|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
177821|NCT02811614|Procedure|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
177822|NCT02811601|Procedure|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
177823|NCT02811588|Device|Non-invasive ventilation|
177824|NCT02811575|Other|Biopsy|Ileon and colon biopsy
177825|NCT02811562|Device|manikin|
177826|NCT02811562|Device|fiberoptic bronchoscope|
177827|NCT02811562|Device|pentax-airwayscope|
177828|NCT02811549|Device|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode, HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode or the HiRes™ Ultra Implant with the HiFocus™ Mid‐Scala electrode will be implanted in adults with eligible hearing profile.
177829|NCT02811536|Device|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
177830|NCT02811523|Drug|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
177831|NCT02811510|Drug|Placebo|Placebo pill (no active cannabinoids)
177832|NCT02811510|Drug|Dronabinol|10 mg capsule of Dronabinol will be administered orally.
177833|NCT02811497|Drug|Azacitidine|
177834|NCT02811497|Drug|Durvalumab|
177835|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
177877|NCT02811133|Drug|Inositol|Subjects will receive inositol
177838|NCT02811484|Behavioral|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
177839|NCT02811458|Behavioral|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
177840|NCT02811432|Other|Kangaroo mother care|Skin-to-skin care (target: at least 18 hours per day)
177841|NCT02811432|Other|Standard care|Incubator or radiant warmer until neonate meets stability criteria; once stable (WHO indication for KMC certain), the baby can transition to routine (intermittent) KMC
177842|NCT02811419|Device|i-scan|examination will be performed with i-scan digital enhancement
177843|NCT02811419|Device|standard high-definition white light|examination will be performed with high-definition white light
177844|NCT02811406|Procedure|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
177845|NCT02811406|Biological|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.~If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
177846|NCT02811393|Other|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
177847|NCT02811380|Device|BIP CVC|BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
177848|NCT02811380|Device|Uncoated Standard CVC|Standard CVC catheterization for venous access during and after elective large surgery
177849|NCT02811367|Device|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
177850|NCT02811354|Drug|AZD9291|oral administration as a single daily dose of 80 mg
177851|NCT02811341|Drug|Scopolamine Hydrobromide|
177852|NCT02811341|Drug|normal saline|
177853|NCT02811315|Other|Observational. Non interventional study|Observational. Non interventional study
177854|NCT02811302|Device|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
177855|NCT02811289|Drug|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
177856|NCT02811289|Other|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
177857|NCT02811289|Radiation|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
177858|NCT02811289|Radiation|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
177859|NCT02811289|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
177860|NCT02811289|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
177861|NCT02811289|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
177862|NCT02811276|Other|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
177863|NCT02811263|Drug|Normal saline placebo|Equal volume of normal saline to be used as placebo
177864|NCT02811263|Drug|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
177865|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 8 Gy|
177866|NCT02811250|Radiation|Stereotactic radiotherapy 5 x 8 Gy|
177867|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 10 Gy|
177868|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 12 Gy|
177869|NCT02811237|Other|HESTIA|"Management based on the HESTIA rule:~If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.~In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
177870|NCT02811237|Other|sPESI|"Management based on the simplified PESI score:~If the sPESI score =0, the proposed management will be outpatient care.~In the other cases, the patient will receive in-hospital care.~Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
177871|NCT02811198|Other|No intervention|
177872|NCT02811185|Drug|[F-18]-Fludeoxyglucose|Radiopharmaceutical imaging agent
177873|NCT02811172|Other|BEhavior of biomarkers during pregnanCy and lactatiOn|
177874|NCT02811159|Drug|Telapristone acetate|Telapristone acetate, orally, once daily for three 18-weeks courses separated by an ODI.
177875|NCT02811146|Device|Bilevel Positive Pressure Airway|Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week
177876|NCT02811146|Other|Heart rehabilitation|Heart rehabilitation, for 12 weeks, 3 times a week
177879|NCT02811107|Other|Questionnaires|Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
177880|NCT02811094|Other|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
177881|NCT02811081|Procedure|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
177882|NCT02811081|Procedure|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
177883|NCT02811081|Procedure|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
177884|NCT02811068|Other|venepuncture|single venepuncture
177885|NCT02811055|Biological|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
177886|NCT02811055|Procedure|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
177887|NCT02811055|Device|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
177888|NCT02811055|Procedure|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
177889|NCT02811055|Drug|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
177890|NCT02811055|Drug|Administration of placebo|Administration of placebo once per day during 14 days
177891|NCT02811042|Device|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
177892|NCT02811042|Device|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
177893|NCT02811029|Behavioral|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
177894|NCT02811016|Drug|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
177895|NCT02811016|Drug|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
177896|NCT02811016|Drug|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
177897|NCT02811003|Device|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
177898|NCT02810990|Drug|Bosutinib|"Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 > 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
177899|NCT02810977|Device|Ultrasound|Ultrasound assessment of gastric content and volume
177900|NCT02810964|Drug|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
177901|NCT02810964|Drug|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
177902|NCT02810951|Genetic|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional collagen VII. FCX-007 cell suspension is injected intradermally.
177903|NCT02810938|Device|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
177904|NCT02810925|Procedure|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
177905|NCT02810925|Procedure|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
177906|NCT02810925|Dietary Supplement|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
177907|NCT02810925|Dietary Supplement|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
177908|NCT02810912|Other|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
177909|NCT02810899|Drug|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
177910|NCT02810899|Drug|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
177911|NCT02810886|Drug|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
177912|NCT02810873|Device|Positron Emission Mammography|Undergo PEM Positron Emission Mammography scan
177913|NCT02810873|Device|Positron Emission Tomography|Undergo PET Positron Emission Tomography scan
177914|NCT02810873|Radiation|Fludeoxyglucose F-18|Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
177915|NCT02810873|Drug|Copper Cu 64 TP3805|Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
177916|NCT02810860|Procedure|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
177917|NCT02810847|Device|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
177918|NCT02810834|Behavioral|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).~The intervention will run over two school years (approximately 16 months)"
177919|NCT02810834|Behavioral|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.~The intervention will run over two school years (approximately 16 months)"
177920|NCT02810808|Procedure|1+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.
177921|NCT02810808|Procedure|3+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.
177922|NCT02810808|Drug|Ranibizumab|Ranibizumab — a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
177923|NCT02810795|Other|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
177924|NCT02810782|Drug|Phenobarbital|Phenobarbital per os
177925|NCT02810782|Drug|Chlorpromazine|Chlorpromazine per os
177926|NCT02810782|Drug|Morphine|Morphine per os
177927|NCT02810769|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
177928|NCT02810769|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
177929|NCT02810769|Dietary Supplement|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
177930|NCT02810756|Drug|New Pazopanib formulation|
177931|NCT02810743|Drug|ddAC-CP-Olaparib|ddAC-CP-Olaparib
177932|NCT02810743|Drug|ddAC-mini CTC|ddAC - mini CTC
177933|NCT02810730|Procedure|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
177934|NCT02810717|Device|theta-burst stimulation using a MagPro X1000|TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.
177935|NCT02810717|Device|sham stimulation using a MagPro X1000|Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
177936|NCT02810704|Drug|Enteric Coated Aspirin|
177937|NCT02810704|Drug|Warfarin|
177938|NCT02810704|Drug|Rivaroxaban|
177939|NCT02810691|Dietary Supplement|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
177940|NCT02810691|Dietary Supplement|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
177941|NCT02810678|Other|Latent Tuberculosis Infection program evaluation & diagnosis|
177942|NCT02810665|Behavioral|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
177943|NCT02810652|Other|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
177944|NCT02810652|Other|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
177945|NCT02810626|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
177947|NCT02810587|Drug|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
177948|NCT02810574|Behavioral|Cognitive training|
177949|NCT02810574|Device|Noninvasive brain stimulation (active)|Neuroconn DC-STIMULATOR PLUS
177950|NCT02810574|Device|Noninvasive brain stimulation (sham)|Neuroconn DC-STIMULATOR PLUS
177951|NCT02810561|Other|No Intervention|No intervention was completed with this study.
177952|NCT02810548|Procedure|OFD alone|Periodontal surgical cleaning procedure
177953|NCT02810548|Drug|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
177954|NCT02810548|Drug|Nanohydroxyapatite|Synthetic bone graft
177955|NCT02810535|Other|Observation|"Visit 1:~Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~Completion of a Health Questionnaire~Lung function testing with spirometry~Skin prick test~Visit 2:~Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~Measurement of nitric oxide in expired air (FeNO)~Taking nasal secretion samples with a cotton carrier for 15 min~Nasal provocation test with dust mite~Blood sample collection to define blood count, IgE and specific IgE"
177956|NCT02810522|Device|OneTouch Select® Plus Glucose Test Strips|
177957|NCT02810496|Genetic|blood collection for mutation characterization|
177958|NCT02810483|Drug|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
177959|NCT02810483|Drug|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.~Dose of study:~200mg for 5 weeks.~Decrease phase:~The 9th week, 100mg for 4 days then 50mg for 3 days."
177960|NCT02810470|Dietary Supplement|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
177961|NCT02810470|Dietary Supplement|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
177962|NCT02810457|Drug|FKB238 (bevacizumab)|
177963|NCT02810457|Drug|Avastin (bevacizumab)|
177964|NCT02810457|Drug|Paclitaxel|
177965|NCT02810457|Drug|Carboplatin|
177966|NCT02810444|Biological|BT595|
177967|NCT02810418|Drug|LMB-100|"Arms A1 and A2 (short infusion): Administered IV on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles~Arms B1 and B2 (continuous infusion): Administered IV for 24,48, 72 or 96 hours continuously on the first 1 - 4 days or 24 hour infusions on days 1 and 4 (depending on dose level) of each 21 day cycle for a maximum of 2 cycles"
177968|NCT02810418|Drug|Nab-Paclitaxel|Administered IV on days 1, and 8 of each 21 day cycle for a maximum of 2 cycles
177969|NCT02810418|Device|Mesothelin Expression|Research blood test for Arm B1 eligibility
177970|NCT02810392|Drug|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
177971|NCT02810392|Drug|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
177972|NCT02810379|Procedure|written informed consent|
177973|NCT02810379|Procedure|video+written informed consent|
177974|NCT02810366|Other|Physician versus Computer Coded Verbal Autopsy|Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
177975|NCT02810353|Device|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
177976|NCT02810353|Device|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
177977|NCT02810340|Biological|MCV-5 with adjuvant|
177978|NCT02810340|Biological|MCV-5 without adjuvant|
177979|NCT02810340|Biological|Menactra|
177980|NCT02810327|Genetic|Genetic Sequencing|Sequencing of the SERPINA1 gene
177981|NCT02810314|Behavioral|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
177982|NCT02810314|Other|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
177983|NCT02810301|Other|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
177984|NCT02810301|Other|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
177985|NCT02810288|Behavioral|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.~The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
177986|NCT02810275|Drug|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
177987|NCT02810275|Drug|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
177988|NCT02810262|Other|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
177989|NCT02810249|Other|No intervention used|
177990|NCT02810236|Procedure|Ultrasound|Ultrasound will be performed.
177991|NCT02810236|Behavioral|Discussion|Radiologist will discuss with the patient the findings on mammogram.
177992|NCT02810223|Biological|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
177993|NCT02810210|Other|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
177994|NCT02810210|Other|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.~This exam is part of current medical practice for other groups."
177995|NCT02810197|Behavioral|Psychopathological assessment|
177996|NCT02810197|Behavioral|Neuropsychological assessment|
177997|NCT02810197|Device|Functional magnetic resonance imaging (fMRI)|
177998|NCT02810184|Radiation|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
177999|NCT02810171|Behavioral|Cognitive Behavioral Therapy|A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
178000|NCT02810171|Behavioral|Relaxation Therapy|An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
178001|NCT02810132|Drug|Metformin|See above
178002|NCT02810132|Drug|Placebo|See above
178003|NCT02810119|Drug|LO2A|
178004|NCT02810119|Drug|Placebo|
178005|NCT02810093|Other|retrospective medical records analyze|Ten thousand medical records (between years 2000 and 2016) will be analyzed
178006|NCT02810067|Procedure|Tunnel + AlloDerm|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).
178007|NCT02810067|Procedure|Tunnel + Novomatrix|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
178008|NCT02810054|Procedure|Minimally Invasive Surgical Techniques (MIST)|Using minimally invasive surgical techniques.
178009|NCT02810054|Procedure|Enamel Matrix Derivative (EMD)|Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
178010|NCT02810041|Dietary Supplement|yoghurts enriched with XXS|
178011|NCT02810041|Dietary Supplement|yoghurts non enriched with XXS|
178012|NCT02810028|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
178013|NCT02810015|Drug|Botulinum Toxin Type A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
178014|NCT02810002|Device|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
178015|NCT02810002|Device|Control infantry boot|Training: infantry basic training in the control boots
178016|NCT02809989|Drug|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
178017|NCT02809976|Drug|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
178018|NCT02809963|Drug|Eplerenone|50 mg tablets, oral use.
178019|NCT02809963|Drug|Placebo|50 mg tablets, oral use
178020|NCT02809950|Other|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
178021|NCT02809950|Other|control group|NPO from midnight of the day before surgery
178022|NCT02809937|Drug|dexmedetomidine|low-dose dexmedetomidine infusion
178023|NCT02809937|Drug|placebo|normal saline infusion
178024|NCT02809924|Other|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
178025|NCT02809924|Other|Video training|Video describing endotracheal intubation
178026|NCT02809911|Device|Provant|
178027|NCT02809898|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
178028|NCT02809885|Biological|Hepatitis E serology|
178029|NCT02809872|Other|Diagnostic Thoracic Ultrasound|
178030|NCT02809859|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
178031|NCT02809846|Device|Quell|
178032|NCT02809846|Device|Sham Quell|
178033|NCT02809833|Drug|Tocilizumab|Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
178034|NCT02809820|Drug|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
178035|NCT02809820|Drug|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
178036|NCT02809807|Other|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
178037|NCT02809807|Device|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
178038|NCT02809794|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
178039|NCT02809781|Biological|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
178040|NCT02809781|Drug|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
178041|NCT02809768|Drug|Avatrombopag|
178042|NCT02809768|Drug|Fluconazole|
178043|NCT02809768|Drug|Itraconazole|
178044|NCT02809768|Drug|Rifampin|
178045|NCT02809755|Drug|4% Lidocaine|
178046|NCT02809755|Other|Saline|
178047|NCT02809742|Drug|Ropivacaine|Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
178048|NCT02809729|Drug|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
178049|NCT02809729|Drug|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
178050|NCT02809729|Procedure|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
178051|NCT02809729|Other|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
178052|NCT02809716|Other|Biomarker Analysis|Correlative studies
178053|NCT02809716|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
178054|NCT02809703|Other|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
178055|NCT02809690|Device|CAT|Undergo 18F-FMAU PET/CT
178056|NCT02809690|Drug|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
178057|NCT02809690|Other|Laboratory Biomarker Analysis|Correlative studies
178058|NCT02809690|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
178059|NCT02809690|Device|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
178060|NCT02809690|Device|Ultrasound|Undergo TRUS-guided biopsy
178061|NCT02809677|Drug|Escitalopram|Escitalopram (ESC) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 5mg PO QD for 4 weeks. Increase to 10mg PO QD at Week 4 (if needed). Increase to 20mg PO QD at Week 8 (if needed).
178062|NCT02809677|Drug|Venlafaxine XR|Venlafaxine Extended Release (VEN XR) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 75mg PO QD for 4 weeks. Increase at Week 4 to 150mg PO QD (if needed). Increase at Week 8 to 300mg PO QD (if needed).
178063|NCT02809677|Drug|Bupropion XR|Bupropion Extended Release (BUP XR) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 150mg PO QD for 4 weeks. Increase at Week 4 to 300mg PO QD (if needed). Increase at Week 8 to 450mg PO QD (if needed).
178064|NCT02809677|Drug|Sertraline|Sertraline (SERT) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 50mg PO QD for 4 weeks. Increase at Week 4 to 100mg PO QD (if needed). Increase at Week 8 to 200mg PO QD (if needed).
178065|NCT02809677|Drug|Mirtazapine|Mirtazapine (MIRT) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 15mg PO qHS for 4 weeks. Increase at Week 4 to 30mg PO qHS (if needed). Increase at Week 8 to 45mg PO qHS (if needed).
178066|NCT02809677|Drug|Buspirone|"Buspirone (BUSP) as an augmenting agent for the Major Depressive Disorder (MDD).~Dose titration schedule: begin at Week 24 of the study (if needed) at 10mg PO QD for 3 days, then 10mg PO BID for 4 weeks. Increase at Week 28 (if needed) to 15mg PO BID. Increase at Week 32 (if needed) to 20mg PO BID."
178067|NCT02809677|Drug|Quetiapine|"Quetiapine (QUET) as an augmenting agent for the Major Depressive Disorder (MDD).~Dose titration schedule: begin at Week 24 of the study (if needed) at 25mg PO qHS for 4 weeks. Increase at Week 28 (if needed) to 50mg PO qHS. Increase at Week 32 (if needed) to 100mg PO qHS."
178068|NCT02809677|Drug|Aripiprazole|Aripiprazole as an augmenting agent for the Major Depressive Disorder (MDD) for non-response patients at Week 48 of study. Dose titration schedule: begin at Week 48 (if needed) at 2mg PO QD for 4 weeks.
178069|NCT02809677|Drug|Lithium|Lithium as an augmenting agent for the Major Depressive Disorder (MDD) for non-response patients at Week 48 of study. Dose titration schedule: begin at Week 48 (if needed) at 300mg PO qHS for 4 weeks.
178070|NCT02809651|Device|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
178071|NCT02809638|Other|ultrasound elastography|
178072|NCT02809612|Behavioral|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
178073|NCT02809599|Behavioral|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
178074|NCT02809586|Behavioral|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
178075|NCT02809586|Behavioral|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
178076|NCT02809573|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
178077|NCT02809573|Drug|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m^2 in 5 minutes after chidamide administration
178078|NCT02809573|Drug|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m^2 soon after cyclophosphamide administration.
178079|NCT02809573|Drug|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m^2 after adriacin administration.
178080|NCT02809573|Drug|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
178081|NCT02809560|Procedure|Induced sputum method using hypertonic serum|Collection of expectoration in sterile vial, conserved in ice all along the examination
178082|NCT02809547|Device|Dried Blood Spot device|
178083|NCT02809534|Drug|Anlotinib|Anlotinib p.o. qd
178084|NCT02809521|Other|Activity Liking|
178085|NCT02809508|Dietary Supplement|Oily fish|A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
178086|NCT02809508|Dietary Supplement|Poultry|A selection of poultry, mainly chicken, provided for dinner and lunch
178087|NCT02809495|Other|use of app in smartphone|
178088|NCT02809482|Other|Eucaloric feeding|3 days of a diet designed to maintain energy balance
178089|NCT02809482|Other|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
178090|NCT02809469|Drug|apixaban dose reduction|Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
178091|NCT02809456|Drug|Nicorandil|oral intake
178092|NCT02809443|Biological|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
178093|NCT02809430|Device|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
178094|NCT02809404|Drug|Everolimus|
178095|NCT02809391|Device|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
178096|NCT02809391|Device|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
178097|NCT02809378|Drug|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
178098|NCT02809378|Drug|sevoflurane|Inhalational anesthetics Halogenated.
178099|NCT02809378|Drug|remifentanil|ultra-short acting opioid anesthetics
178100|NCT02809378|Drug|pentothal sodium|intra-venous anesthetics for anesthesia induction
178101|NCT02809378|Drug|propofol|intra-venous anesthetics for anesthesia induction and maintenance
178102|NCT02809365|Device|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
178103|NCT02809365|Device|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
178104|NCT02809352|Biological|Human papillomavirus genotyping|
178105|NCT02809339|Other|Questionnaires|
178106|NCT02809326|Behavioral|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
178107|NCT02809326|Behavioral|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
178108|NCT02809326|Behavioral|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
178109|NCT02809313|Dietary Supplement|Treatment Gingivitis with Probiotic|gingivitis treatment (scaling and coronary polish) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months
178110|NCT02809313|Other|Treatment Gingivitis conventional|gingivitis treatment (scaling and coronary polish) and one sachet containing Placebo (talc powder) per day during 3 months
178111|NCT02809300|Biological|blood collection|
178112|NCT02809287|Procedure|Jackknife posture|patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
178113|NCT02809274|Other|questionnaires|• Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
178114|NCT02809261|Procedure|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
178115|NCT02809261|Procedure|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
178116|NCT02809261|Drug|Normal Saline|Normal saline is safe for perineural injection.
178117|NCT02809261|Drug|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
178118|NCT02809248|Device|ZES|stent implantation (zotarolimus eluting stent)
178119|NCT02809248|Device|BMS|stent implantation (bare metal stent)
178120|NCT02809235|Dietary Supplement|coconut oil|3 tablespoons per day of supplemental coconut oil
178121|NCT02809222|Other|Samples|Blood samples
178122|NCT02809222|Other|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
178123|NCT02809196|Behavioral|1: Tailored SMS program implicating friend and mother|
178124|NCT02809196|Behavioral|2: Standardized SMS program implicating friend and mother|
178125|NCT02809196|Behavioral|3: Tailored SMS program implicating friend, not mother|
178126|NCT02809196|Behavioral|4: Standardized SMS program implicating friend, not mother|
178127|NCT02809196|Behavioral|5: Tailored SMS program implicating mother, not friend|
178128|NCT02809196|Behavioral|6: Standardized SMS program implicating mother, not friend|
178129|NCT02809196|Behavioral|7: Tailored SMS program not implicating mother or friend|
178130|NCT02809196|Behavioral|8: Standardized SMS program not implicating mother or friend|
178131|NCT02809196|Behavioral|9: No SMS program|
178132|NCT02809183|Drug|Placebo|oral suspension
178133|NCT02809183|Drug|TRC101|oral suspension
178134|NCT02809170|Dietary Supplement|Arginine|Arginine is an amino acids
178135|NCT02809170|Dietary Supplement|Citrulline|Citrulline is an amino acid
178136|NCT02809144|Procedure|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
178137|NCT02809131|Drug|polymixin/bacitracin|Antibacterial irrigation
178138|NCT02809131|Drug|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
178139|NCT02809131|Drug|Saline|Saline irrigation
178140|NCT02809118|Drug|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
178141|NCT02809118|Drug|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
178142|NCT02809118|Other|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
178143|NCT02809105|Drug|linaclotide|Oral administration once daily
178144|NCT02809105|Drug|Placebo|Oral administration once daily
178145|NCT02809092|Biological|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.~Other Names:~Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m^2 by vein on Days -6, -5, -4, -3, and -2.~Other Names:~Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
178146|NCT02809079|Drug|Mycophenolate mofetil|Mycophenolate mofetil 500mg Bid
178147|NCT02809079|Drug|Prednisone|prednisone 10mg Qd
178148|NCT02809066|Other|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;~50 gr kashkaval cheese,~400 ml milk and~150 gr yogurt for each day."
178149|NCT02809053|Biological|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
178150|NCT02809053|Biological|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
178151|NCT02809040|Other|Electrocardiogram/Echocardiography|"Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.~Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart."
178188|NCT02808767|Drug|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
179121|NCT02801669|Drug|placebo|Placebo orally administered once daily.
178152|NCT02809040|Other|Portable digital auscultation|"Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.~Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation"
178153|NCT02809027|Drug|Ginger|
178154|NCT02809027|Drug|Placebo|
178155|NCT02809014|Other|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
178156|NCT02809014|Other|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
178157|NCT02809014|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
178158|NCT02809014|Other|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
178159|NCT02809001|Procedure|Fat grafting|In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
178160|NCT02808988|Procedure|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
178161|NCT02808988|Procedure|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
178162|NCT02808988|Other|zoledronic acid|5 mg/year zoledronic acid (i.v.)
178163|NCT02808975|Drug|Adalimumab|Weekly subcutaneous injection
178164|NCT02808975|Drug|Placebo|Weekly subcutaneous injection
178165|NCT02808962|Procedure|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
178166|NCT02808949|Drug|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
178167|NCT02808936|Procedure|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
178168|NCT02808936|Procedure|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
178169|NCT02808923|Other|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
178170|NCT02808923|Other|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
178171|NCT02808910|Behavioral|Nudged to eat less added salt and more other seasonings|
178172|NCT02808910|Behavioral|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
178173|NCT02808910|Behavioral|Nudged to eat more vegetables|
178174|NCT02808910|Behavioral|Nudged to eat smaller portions|
178175|NCT02808910|Behavioral|Nudged to eat less calorie-dense food|
178176|NCT02808897|Device|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (FR) to 32 FR shall be used for the single anterior mediastinal chest tube.
178177|NCT02808897|Device|Active Clearance Technology drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum with one (1) standard chest tube. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 FR to 32 FR shall be used for the single anterior mediastinal chest tube.
178178|NCT02808884|Genetic|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
178179|NCT02808871|Drug|Pirfenidone|Pirfenidone three times daily (2403 mg) for 52 weeks
178180|NCT02808871|Drug|Placebo|Placebo three times daily for 52 weeks
178181|NCT02808845|Other|microalbuminuria|
178182|NCT02808832|Behavioral|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
178183|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
178184|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
178185|NCT02808806|Other|real-time audio-visual feedback|real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
178186|NCT02808793|Drug|AK002|
178187|NCT02808767|Drug|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
178189|NCT02808754|Procedure|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic > 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
178190|NCT02808741|Drug|F901318 SDD|Pharmacokinetics area under curve
178191|NCT02808741|Drug|F901318 IR|Pharmacokinetics area under curve
178192|NCT02808741|Drug|F901318 IR Fasting|Pharmacokinetics area under curve
178193|NCT02808741|Drug|F901318 IR Fed|Pharmacokinetics area under curve
178194|NCT02808728|Drug|Pain Cocktail with Exparel|pain cocktail: bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.
178195|NCT02808728|Drug|Pain Cocktail with Ropivacaine|pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
178196|NCT02808715|Other|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
178197|NCT02808702|Behavioral|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
178198|NCT02808689|Behavioral|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
178199|NCT02808689|Other|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
178200|NCT02808689|Other|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
178201|NCT02808676|Dietary Supplement|Vitamin D3|Dose: 10000 IU, three times per week, orally.
178202|NCT02808676|Other|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
178203|NCT02808676|Other|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
178204|NCT02808676|Other|placebo D3|matching placebo for Vitamin D3
178205|NCT02808676|Other|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
178206|NCT02808676|Other|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
178207|NCT02808663|Biological|fecal calprotectin concentration|
178208|NCT02808663|Biological|blood collection|
178209|NCT02808650|Other|Laboratory Biomarker Analysis|Correlative studies
178210|NCT02808650|Other|Pharmacological Study|Correlative studies
178211|NCT02808650|Drug|Prexasertib|Given IV
178212|NCT02808637|Other|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
178213|NCT02808637|Other|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
178214|NCT02808637|Other|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
178215|NCT02808637|Other|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
178216|NCT02808624|Drug|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
178217|NCT02808611|Drug|propranolol|Reduction of the ANS response
178218|NCT02808611|Drug|Placebo|
178219|NCT02808598|Behavioral|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
178220|NCT02808585|Drug|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
178221|NCT02808585|Drug|Placebo Injection|Four weekly subcutaneous injections of placebo.
178222|NCT02808572|Biological|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
178223|NCT02808572|Biological|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
178224|NCT02808572|Procedure|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
178329|NCT02807753|Other|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
178225|NCT02808559|Device|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
178226|NCT02808533|Drug|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
178227|NCT02808533|Other|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
178228|NCT02808507|Other|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
178229|NCT02808468|Behavioral|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
178230|NCT02808455|Drug|Pacritinib 400 mg Capsule (Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
178231|NCT02808455|Drug|Pacritinib 80 mg Solution (Treatment B)|A single 80-mg oral solution dose of pacritinib
178232|NCT02808442|Biological|UCART19|
178233|NCT02808429|Drug|Atacicept 25 mg|Subject will receive Atacicept 25 milligram (mg) once weekly as a subcutaneous (SC) injection for 72 weeks.
178234|NCT02808429|Drug|Atacicept 75 mg|Subject will receive Atacicept 75 mg once weekly as an SC injection for 72 weeks.
178235|NCT02808429|Drug|Placebo|Subject will receive matching Placebo to atacicept once weekly as an SC injection for 72 weeks.
178236|NCT02808429|Drug|Atacicept 25 mg|Subject will receive Atacicept 25 mg once weekly as an SC injection for 156 weeks.
178237|NCT02808429|Drug|Atacicept 75 mg|Subject will receive Atacicept 75 mg once weekly as an SC injection for 156 weeks
178238|NCT02808429|Drug|Atacicept 150 mg|Subject will receive Atacicept 150 mg once weekly as an SC injection for 156 weeks.
178239|NCT02808429|Drug|Placebo|Subject will receive matching Placebo to atacicept once weekly as an SC injection for 156 weeks.
178240|NCT02808416|Biological|Personalized cellular vaccine|"Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen mRNA pulsed cellular vaccines.~Other Names:~• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine"
178241|NCT02808403|Other|No intervention|No intervention; observation of routine medical care
178242|NCT02808390|Drug|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
178243|NCT02808390|Drug|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
178244|NCT02808390|Drug|Placebo|Placebo BID for 8 Weeks
178245|NCT02808377|Other|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
178246|NCT02808364|Biological|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
178247|NCT02808351|Drug|Berberine|
178248|NCT02808338|Device|Philips BiPAP AutoSV Advanced System One|Auto SV Auto Servo Ventilation is a mode of positive airway pressure used to treat obstructive and complex central sleep apnea. This devices is FDA approved and will be set according to a predetermined setting.
178249|NCT02808338|Device|Modified Philips BiPAP ASV|This Modified BiPAP ASV will be set to a predetermined setting. This is the investigational device.
178250|NCT02808338|Device|ResMed S7 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
178251|NCT02808338|Device|ResMed S9 VPAP Adapt|This device is FDA approved and will be set to predetermined setting.
178252|NCT02808325|Drug|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
178253|NCT02808325|Drug|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
178254|NCT02808312|Drug|GS-9674 (30 mg)|GS-9674 30 mg (3 x 10 mg tablet) orally
178255|NCT02808312|Drug|GS-9674 (10 mg)|GS-9674 10 mg (1 x 10 mg tablet) orally
178256|NCT02808299|Other|HBV infection history|HBV infection history or HBV carriers
178257|NCT02808286|Behavioral|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
178258|NCT02808286|Behavioral|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
178259|NCT02808273|Drug|Bemiparine|Bemiparine 3500 UI as antithrombotic according to a protocol for prevention of postoperative deep venous thrombosis
178260|NCT02808247|Drug|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH & Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
178261|NCT02808247|Drug|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
178262|NCT02808234|Procedure|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
178263|NCT02808234|Other|Nucel|Allograft derived from human amnion and amniotic fluid
178264|NCT02808208|Biological|Adipose Derived Mesenchymal Stem Cells (AMSC)|This group will receive Autologous stem cells derived from own fat biopsy.
178265|NCT02808195|Other|Constraint-induced therapy|
178266|NCT02808195|Other|kinect-based constraint-induced therapy|
178267|NCT02808182|Drug|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
178268|NCT02808182|Other|[7,7,8,8-2H]-palmitate|using i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to +360 min
178269|NCT02808182|Other|[U-13C]-palmitate|oral administration of [U-13C]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
178270|NCT02808182|Procedure|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
178271|NCT02808182|Other|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
178272|NCT02808156|Other|unilateral upper limbs intensive training|The unimanual intensive training group focuses on the training of the more affected arm and restraint the less affected arm.
178273|NCT02808156|Other|bilateral upper limbs intensive training|The bimanual intensive training focuses activities that required the use of both hands.
178274|NCT02808143|Biological|BCG Solution|Given intravesically
178275|NCT02808143|Other|Laboratory Biomarker Analysis|Correlative studies
178276|NCT02808143|Biological|Pembrolizumab|Given intravesically
178277|NCT02808143|Other|Pharmacological Study|Correlative studies
178278|NCT02808130|Other|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
178279|NCT02808117|Dietary Supplement|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.~One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
178280|NCT02808104|Drug|mazindol|
178281|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
178282|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
178283|NCT02808091|Radiation|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
178284|NCT02808078|Device|Gait training with augmented reality|20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
178285|NCT02808078|Device|Standard training|20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
178286|NCT02808065|Drug|Tacrolimus|Administered dose were individualized according to their own prescription
178287|NCT02808065|Drug|Mycophenolate mofetil|Administered dose were individualized according to their own prescription
178288|NCT02808052|Drug|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
178289|NCT02808039|Other|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
178290|NCT02808026|Drug|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
178291|NCT02808013|Drug|NDS-446|
178292|NCT02808013|Drug|Placebo|
178293|NCT02808000|Device|BIP Foley (latex) or BIP Foley -silicone|
178294|NCT02808000|Device|Standard catheter|
178295|NCT02807987|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
178296|NCT02807974|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
178297|NCT02807961|Drug|ELX-02|Synthetic aminoglycoside
178298|NCT02807961|Drug|Placebo|Placebo comparator
178299|NCT02807948|Device|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
178300|NCT02807935|Device|Optical coherence tomography imaging|
178301|NCT02807922|Drug|Zopiclone|
178302|NCT02807922|Drug|Placebo|
178303|NCT02807909|Drug|BMS-986177|
178304|NCT02807909|Drug|Itraconazole|
178305|NCT02807909|Drug|Diltiazem ER|
178306|NCT02807883|Drug|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
178307|NCT02807883|Procedure|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
178308|NCT02807870|Drug|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
178309|NCT02807870|Behavioral|Parental training|Weekly parental training conducted by behavioral psychologists.
178310|NCT02807870|Other|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
178311|NCT02807870|Drug|Placebo pill|Placebo pill during 8 weeks.
178312|NCT02807857|Procedure|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
178313|NCT02807844|Drug|MCS110|
178314|NCT02807844|Drug|PDR001|
178315|NCT02807831|Behavioral|Executive functions training|Daily training of executive functions via activities to develop auto-regulation, attention and memory.
178316|NCT02807831|Behavioral|Language skills training|Daily training of language skills via activities to develop phonological awareness and vocabulary.
178317|NCT02807831|Other|Regular school curriculum|Ministry of Education national school curriculum.
178318|NCT02807818|Behavioral|Home visiting Program for Young Pregnant Women|
178319|NCT02807805|Drug|Abiraterone Acetate|Given PO
178320|NCT02807805|Drug|Niclosamide|Given PO
178321|NCT02807805|Drug|Prednisone|Given PO
178322|NCT02807792|Device|Perianal access device|Perianal access device
178323|NCT02807779|Drug|Dexamethasone infusion|Patients will receive dexamethasone infusion following plain balloon angioplasty
178324|NCT02807779|Device|Drug coated balloon|Patients will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
178325|NCT02807766|Behavioral|Behavior modification|Each group has 30 subjects and experiences six months' training.
178326|NCT02807766|Behavioral|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
178327|NCT02807766|Behavioral|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
178328|NCT02807766|Behavioral|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
178330|NCT02807753|Other|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
178331|NCT02807740|Other|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
178332|NCT02807740|Other|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
178333|NCT02807727|Drug|Intralipid 20%|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
178334|NCT02807727|Drug|Modified Ringers Lactate|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
178335|NCT02807701|Procedure|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy~dissection~reconstruction"
178336|NCT02807701|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
178337|NCT02807688|Behavioral|Health Promotion Intervention|"The intervention package consists of the following elements:~i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
178338|NCT02807675|Drug|CVT-301, LIP|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
178339|NCT02807675|Other|Placebo|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
178340|NCT02807662|Behavioral|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
178341|NCT02807649|Dietary Supplement|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
178342|NCT02807649|Dietary Supplement|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
178343|NCT02807649|Dietary Supplement|Placebo Comparator: Placebo|Two tablets consume daily with meal.
178344|NCT02807636|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
178345|NCT02807636|Drug|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
178346|NCT02807636|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
178347|NCT02807636|Other|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
178348|NCT02807636|Drug|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
178349|NCT02807623|Drug|Ibuprofen|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
178350|NCT02807623|Behavioral|Compound Exercise of Push-ups|The participants will perform an exercise intervention of push-ups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
178351|NCT02807623|Drug|oral placebo|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
178352|NCT02807610|Drug|Inj Etomidate|Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0`.2mg kg-1 and IV Fentanyl 2ug kg-1.
178353|NCT02807610|Drug|Injection Propofol|Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
178354|NCT02807610|Drug|Placebo for Propofol|After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
178355|NCT02807597|Drug|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
178356|NCT02807597|Device|Cancer Vision Goggles|-Surgeon will wear during surgery
178357|NCT02807597|Procedure|Surgery|-Standard of care
178358|NCT02807584|Device|ELECT|
178359|NCT02807571|Procedure|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
178360|NCT02807558|Drug|SY-1425 (tamibarotene)|Continuous days 1-28 of a 28-day cycle of SY-1425 at 6 mg/m2/day orally divided into twice a day dosing.
178361|NCT02807558|Drug|azacitidine|75 mg/m2/day IV or SC days 1-7 of a 28 day cycle in combination with SY-1425.
178362|NCT02807558|Drug|Daratumumab|16 mg/kg/day IV starting on Cycle 1 Day 1 weekly for 8 weeks, followed by dosing every two weeks for 16 weeks, followed by dosing every 4 weeks in combination with SY-1425.
178363|NCT02807545|Behavioral|Scoliosis Specific Exercises|
178364|NCT02807532|Other|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
178365|NCT02807532|Other|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
178366|NCT02807519|Genetic|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
178367|NCT02807506|Device|Mobile Service Robot|The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
178368|NCT02807493|Device|Occlusal Support Device|Bite plate
178369|NCT02807493|Other|Control|Control group
178370|NCT02807480|Behavioral|Exposure-based therapy|Exposure-based therapy
178371|NCT02807480|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
178372|NCT02807480|Behavioral|Computer-based behavioral assessment|Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
178373|NCT02807480|Behavioral|Surveys and Interviews|Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
178374|NCT02807480|Device|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
178375|NCT02807480|Device|Electroencephalography (EEG)|Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
178376|NCT02807467|Drug|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
178377|NCT02807467|Drug|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
178378|NCT02807454|Drug|Daratumumab|
178379|NCT02807454|Drug|Durvalumab|
178380|NCT02807454|Drug|Pomalidomide|
178381|NCT02807454|Drug|Dexamethasone|
178382|NCT02807441|Drug|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
178383|NCT02807428|Drug|AYX1 Injection 660 mg/6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)
178384|NCT02807428|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
178385|NCT02807415|Drug|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
178386|NCT02807389|Drug|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
178387|NCT02807376|Device|Surgeon's 'standard of care' stapler|
178388|NCT02807376|Device|Ethicon Powered Vascular Stapler|
178389|NCT02807363|Drug|Leuprolide Oral Tablet 4-mg QD|4-mg oral tablet once daily for 28 consecutive days.
178390|NCT02807363|Drug|Leuprolide Oral Tablet 4-mg BID|4-mg oral tablet twice daily for 28 consecutive days.
178391|NCT02807363|Drug|Leuprolide Depot|3.75 mg intramuscular depot injection
178392|NCT02807363|Drug|Leuprolide Oral Tablet 10-mg BID|10-mg oral tablet twice daily for 28 consecutive days.
178393|NCT02807350|Device|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
178394|NCT02807350|Device|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
178395|NCT02807337|Drug|Caphosol|
178396|NCT02807337|Drug|0,9% NaCl|
178397|NCT02807324|Other|Venapunction|The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
178398|NCT02807298|Drug|4%articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
178399|NCT02807298|Drug|2% Lignocaine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
178400|NCT02807298|Drug|Epinephrine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
178401|NCT02807285|Drug|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
178402|NCT02807272|Drug|Tipifarnib|Oral tablet
178441|NCT02806986|Biological|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
178442|NCT02806973|Drug|Nasal Glucagon|Administered intranasally.
178443|NCT02806960|Drug|LY900018|Administered intranasally.
178444|NCT02806947|Drug|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
178403|NCT02807259|Behavioral|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
178404|NCT02807246|Biological|Maflor®, Mamsel Pharmaceuticals, Turkey|"Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)~Other Name: Maflor®"
178405|NCT02807246|Other|drops of saline|Dietary Supplement: Breast milk +drops of saline
178406|NCT02807220|Drug|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
178407|NCT02807207|Drug|A: 400 mg pacritinib|Treatment A
178408|NCT02807207|Other|B: Placebo|Treatment B
178409|NCT02807207|Drug|C: 400 mg moxifloxacin|Treatment C
178410|NCT02807194|Other|spinal anesthesia|
178411|NCT02807194|Other|general anesthesia|
178412|NCT02807194|Procedure|lumbar disc herniation|
178413|NCT02807181|Drug|Cisplatin-gemcitabine|Systemic chemotherapy
178414|NCT02807181|Device|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
178415|NCT02807168|Other|NT-proBNP (Cardiac Biomarkers)|
178416|NCT02807155|Behavioral|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
178417|NCT02807155|Behavioral|Transition Empowerment Program + Diabetes Wellness Council|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
178418|NCT02807155|Behavioral|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
178419|NCT02807142|Biological|NC 1 cell therapy|All patients will be treated with NC1
178420|NCT02807129|Biological|blood withdrawn|
178421|NCT02807129|Biological|urine collection|
178422|NCT02807116|Drug|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
178423|NCT02807116|Drug|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
178424|NCT02807116|Drug|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
178425|NCT02807103|Drug|Rituximab|1 g intravenous pulse at day1 and day15
178426|NCT02807103|Drug|Placebo-rituximab|intravenous pulses at day1 and day15
178427|NCT02807103|Drug|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
178428|NCT02807103|Drug|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
178429|NCT02807090|Other|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
178430|NCT02807090|Other|Circular dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
178431|NCT02807077|Drug|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
178432|NCT02807064|Drug|Bifidobacteria|0.5 ml per os all days for 2 months
178433|NCT02807064|Drug|placebo|0,5 ml per os all days for 2 months
178434|NCT02807051|Drug|Pacritinib|Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
178435|NCT02807051|Drug|Clarithromycin|Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
178436|NCT02807051|Drug|Pacritinib and Clarithromycin|On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
178437|NCT02807038|Procedure|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
178438|NCT02807012|Other|Nursing educational intervention|"The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.~The control group could have ou not the usual care guidelines provide by health services that have access."
178439|NCT02806999|Drug|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
178440|NCT02806999|Drug|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
178445|NCT02806947|Drug|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
178446|NCT02806934|Procedure|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
178447|NCT02806921|Device|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
178448|NCT02806908|Drug|JZP-110|
178449|NCT02806908|Drug|Placebo|
178450|NCT02806895|Drug|JZP-110|
178451|NCT02806895|Drug|Placebo|
178452|NCT02806882|Drug|Ceftaroline fosamil|600mg IV infusion
178453|NCT02806869|Drug|Single dose of ibuprofen (800 mg tablet)|
178454|NCT02806869|Dietary Supplement|Pulmocare, two 8.0 oz (236.6 mL) cans|
178455|NCT02806856|Device|tDCS neuroConn|Cathodal on M1
178456|NCT02806856|Device|Sham stimulation|Sham
178457|NCT02806843|Device|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
178458|NCT02806830|Drug|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
178459|NCT02806817|Drug|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
178460|NCT02806817|Drug|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
178461|NCT02806817|Other|Normal saline|Use saline as placebo
178462|NCT02806804|Biological|one dose test vaccine|
178463|NCT02806804|Biological|one dose commercially available trivalent influenza vaccine|
178464|NCT02806804|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
178465|NCT02806791|Drug|FILGRASTIM|
178466|NCT02806778|Other|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
178467|NCT02806778|Other|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
178468|NCT02806765|Dietary Supplement|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol every day for 6 months
178469|NCT02806765|Other|Control|Placebo in Softgel form
178470|NCT02806752|Drug|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
178471|NCT02806752|Drug|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
178472|NCT02806739|Dietary Supplement|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
178473|NCT02806739|Dietary Supplement|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
178474|NCT02806726|Device|iDesign 1.3-PRESBY treatment|Software used to calculate the LASIK treatment profile including a presbyopic correction component for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
178475|NCT02806726|Device|iDesign 1.3 treatment|Software used to calculate the LASIK treatment profile for the iDesign Advanced Wavescan Studio™ System within the Star S4 IR™ Excimer Laser System.
178476|NCT02806713|Drug|Phenazopyridine|
178477|NCT02806713|Other|no Phenazopyridine|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
178478|NCT02806700|Behavioral|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
178479|NCT02806687|Drug|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.~Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
178480|NCT02806687|Drug|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
178481|NCT02806674|Device|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
178526|NCT02806336|Behavioral|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
178527|NCT02806336|Behavioral|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
178528|NCT02806323|Other|Yoga practice|
178529|NCT02806310|Other|Blood draw|blood sampling for biomarker levels
178482|NCT02806674|Device|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
178483|NCT02806661|Procedure|Vagus nerve-preserving Robot-assisted Gastrectomy|
178484|NCT02806661|Procedure|Conventional Robot-assisted Gastrectomy|
178485|NCT02806648|Drug|Palbociclib|Palbociclib
178486|NCT02806635|Behavioral|OurRelationship|
178487|NCT02806635|Behavioral|PREP Online|
178488|NCT02806609|Other|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
178489|NCT02806609|Other|immersion in water at room temperature|immersion in water at room temperature
178490|NCT02806609|Other|active recovery - running|active recovery
178491|NCT02806609|Other|rest in the chair|rest in the chair
178492|NCT02806596|Drug|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
178493|NCT02806583|Other|structured support groups|Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
178494|NCT02806570|Device|Mitral valve repair|
178495|NCT02806557|Device|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
178496|NCT02806544|Drug|Tamoxifen|Tamoxifen 20mg by mouth daily
178497|NCT02806531|Biological|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
178498|NCT02806518|Procedure|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
178499|NCT02806505|Drug|Peginterferon alfa-2a|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
178500|NCT02806492|Other|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP <60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
178501|NCT02806492|Other|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
178502|NCT02806492|Other|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
178503|NCT02806492|Other|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
178504|NCT02806492|Other|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
178505|NCT02806479|Other|Observational: Arrhythmogenic Substrate|
178506|NCT02806466|Procedure|Fiberoptic bronchoscopy|
178507|NCT02806453|Dietary Supplement|thickened formula|
178508|NCT02806453|Dietary Supplement|Mg alginate|
178509|NCT02806453|Behavioral|reassurance with lifestyle changes|
178510|NCT02806440|Drug|Low dose naltrexone|Active comparator
178511|NCT02806440|Drug|Placebo|Placebo comparator
178512|NCT02806427|Other|Enteral Formula|
178513|NCT02806414|Drug|Ivermectin|
178514|NCT02806401|Device|landmark|
178515|NCT02806401|Device|US_Ax|
178516|NCT02806375|Procedure|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
178517|NCT02806375|Drug|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
178518|NCT02806375|Drug|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
178519|NCT02806375|Drug|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
178520|NCT02806375|Drug|Ruxolitinib|Days -8 through -2 15 mg tid
178521|NCT02806375|Drug|Ruxolitinib|Days +5 through +100: 7.5 mg bid
178522|NCT02806362|Drug|Ombitasvir/paritaprevir/ritonavir|Tablet
178523|NCT02806349|Dietary Supplement|American Ginseng|herb
178524|NCT02806349|Dietary Supplement|Konjac-glucomannan fiber blend|Blend of 2 viscous fibers: konjac mannan and xanthan
178525|NCT02806349|Dietary Supplement|Control|Fiber matched control for intervention (corn starch and wheat bran)
178530|NCT02806297|Procedure|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
178531|NCT02806297|Procedure|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
178532|NCT02806284|Biological|PPSV23, Act-HIB|"described in Arm description"
178533|NCT02806271|Behavioral|Worry Postponement|"In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate."
178534|NCT02806271|Behavioral|Worry Monitoring|For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
178535|NCT02806258|Radiation|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
178536|NCT02806258|Drug|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
178537|NCT02806245|Other|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~Atrial sensing- right ventricular pacing 10 min.~5 min no pacing (washout).~Atrial sensing - biventricular pacing 10 min.~5 min no pacing (washout).~Intrinsic rhythm~5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
178538|NCT02806232|Drug|Biltricide (racemate praziquantel) oral tablets|Biltricide (600 mg tablet) was administered to participants at a dose of 20 mg/kg in Part 1, Cohort 1 and at a dose of 40mg/kg in Part 1, Cohort 2.
178539|NCT02806232|Drug|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) (150) mg was administered at a dose of 40 mg/kg in Part 1, Cohort 3 and at a dose of 60 mg/kg in Part 1, Cohort 4.
178540|NCT02806232|Drug|Levo Praziquantel ODT|Levo PZQ (150 mg) was administered at a dose of 30 mg/kg in Part 1 Cohort 5, 45 mg/kg Part 1 Cohort 6, 60 mg/kg Part 1 Cohort 7, 50 mg/kg Part 2 Cohort 8, and 50 mg/kg Part 2 Cohort 9.
178541|NCT02806219|Device|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
178542|NCT02806219|Device|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
178543|NCT02806206|Drug|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
178544|NCT02806206|Drug|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
178545|NCT02806193|Procedure|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.~Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
178546|NCT02806180|Procedure|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
178547|NCT02806180|Procedure|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
178548|NCT02806167|Other|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
178549|NCT02806154|Other|DEXA|The appendicular muscle mass measured by DEXA
178550|NCT02806141|Drug|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
178551|NCT02806141|Drug|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
178552|NCT02806128|Drug|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
178553|NCT02806115|Procedure|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
178554|NCT02806115|Drug|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
178555|NCT02806115|Device|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
178556|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
178557|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
178558|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
178559|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
178560|NCT02806089|Device|Handheld dynamometer|Evaluation of muscle strength
178561|NCT02806089|Biological|Creatinine index|Evaluation of muscle mass using plasma creatinine level
178562|NCT02806089|Device|Electrical bioimpedance analysis|Evaluation of lean body mass
178563|NCT02806089|Other|"Voorrips score questionnaire"|Evaluation of physical activity
178564|NCT02806089|Biological|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
178565|NCT02806076|Procedure|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
178566|NCT02806076|Procedure|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
178567|NCT02806063|Procedure|intraoperative samples|
178568|NCT02806050|Drug|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
178569|NCT02806050|Device|FES PET|all patients will have a FES PET at baseline
178570|NCT02806050|Drug|Letrozole|all patients will be treated with Letrozole daily until progression
178571|NCT02806024|Drug|Tranexamic Acid|
178572|NCT02806024|Drug|Placebo Drug|50 cc Normal Saline IV
178573|NCT02805998|Behavioral|Web-based CBT-I|
178574|NCT02805998|Other|Treatment as Usual|
178575|NCT02805985|Device|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
178576|NCT02805972|Drug|Naloxone|4 mg / 0.1 ml
178577|NCT02805972|Drug|Placebo|0.1 ml
178578|NCT02805959|Device|MTS2|
178579|NCT02805946|Drug|posaconazole|iv versus oral
178580|NCT02805920|Drug|Bupivacaine|comparison of different volumes-dosages of 0.25% Bupivacaine
178581|NCT02805907|Drug|Calcifediol|
178582|NCT02805907|Drug|Placebo|
178583|NCT02805894|Drug|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
178584|NCT02805894|Drug|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy & IMRT treatment
178585|NCT02805881|Device|Neurolief system|Non-invasive cephalic neurostimulation device
178586|NCT02805868|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
178587|NCT02805868|Other|Laboratory Biomarker Analysis|Correlative studies
178588|NCT02805868|Biological|Siltuximab|Given IV
178589|NCT02805855|Drug|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
178590|NCT02805842|Drug|Tacrolimus BID|Administration of Tacrolimus BID
178591|NCT02805842|Drug|Advagraf QD|administration of Advagraf QD
178592|NCT02805829|Drug|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
178593|NCT02805803|Other|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
178594|NCT02805790|Drug|Elamipretide|40 mg elamipretide administered once daily subcutaneously
178595|NCT02805790|Drug|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
178596|NCT02805764|Device|Homeoblock|A removable, functional dental appliance to be worn nightly for 1 year Pending 510(k) clearance for the use of reducing snoring and mild to moderate obstructive sleep apnea in adults. A class II medical device.
178597|NCT02805751|Device|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
178598|NCT02805751|Other|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
178599|NCT02805751|Other|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
178600|NCT02805738|Drug|CKD-390|CKD-390 1 Tablet (48 weeks)
178601|NCT02805738|Drug|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
178602|NCT02805725|Drug|Phase 1: Trabectedin|"A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)~Patients will be allocated 4 doses of Trabectedin following a 3 + 3 design:"
178603|NCT02805725|Drug|Phase 2: Trabectedin|All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial.
178604|NCT02805725|Drug|Phase 1: Cyclophosphamide|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
178605|NCT02805725|Drug|Phase 2: Cyclophosphamide|All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
178606|NCT02805712|Other|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
178607|NCT02805712|Other|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
178696|NCT02804945|Biological|Mesenchymal Stem Cells (MSCs)|Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1.
178697|NCT02804932|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g/day) for 8 weeks
178608|NCT02805699|Drug|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
178609|NCT02805699|Drug|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
178610|NCT02805686|Device|spectral domain optical coherence tomography|
178611|NCT02805686|Device|multifocal electroretinogram|
178612|NCT02805673|Procedure|Osteopathy|
178613|NCT02805660|Drug|mocetinostat|Mocetinostat oral capsule, administered three times weekly in combination with durvalumab
178614|NCT02805660|Drug|durvalumab|Durvalumab 1500mg intravenously administered in 28 day cycles in combination with mocetinostat
178615|NCT02805634|Other|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
178616|NCT02805634|Device|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
178617|NCT02805608|Drug|Injection of 68Ga-NOTA-AE105|One injection intravenously of 68Ga-NOTA-AE105
178618|NCT02805608|Drug|Injection of 18F-FDG|One injection intravenously of 18F-FDG
178619|NCT02805608|Device|Positron Emission Tomography and CT|Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
178620|NCT02805608|Device|Positron Emission Tomography and MRI|Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
178621|NCT02805595|Drug|23.4% Hypertonic saline|
178622|NCT02805595|Drug|Saline|
178623|NCT02805582|Drug|10ml ropivacain 0.5%|Ultrasound guided nerve block
178624|NCT02805569|Device|articulating stylet|patient who intubated with articulating stylet
178625|NCT02805569|Device|conventional stylet|patient who intubated with conventional stylet
178626|NCT02805556|Drug|BMS-663068|Single oral dose of BMS-663068
178627|NCT02805556|Drug|BMS-626529|Single intravenous dose of [13C]BMS 626529
178628|NCT02805543|Device|Color doppler imaging|
178629|NCT02805530|Other|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
178630|NCT02805530|Other|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
178631|NCT02805530|Radiation|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
178632|NCT02805530|Other|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
178633|NCT02805517|Device|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
178634|NCT02805504|Drug|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
178635|NCT02805504|Drug|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
178636|NCT02805491|Other|meconium|to evaluate internal exposure to pesticide
178637|NCT02805491|Other|self questionnaires to parents|to evaluate external exposure to pesticide
178638|NCT02805478|Other|There is no intervention|This is a prospective observational cohort study without any intervention
178639|NCT02805465|Device|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
178640|NCT02805465|Device|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
178641|NCT02805452|Drug|Succinate of Solifenacin|
178642|NCT02805452|Drug|Placebo of Succinate of Solifenacin|
178643|NCT02805439|Drug|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
178644|NCT02805439|Drug|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
178645|NCT02805439|Drug|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
178646|NCT02805426|Drug|Tranexamic Acid|
178647|NCT02805426|Drug|Placebo|
178648|NCT02805426|Drug|Misoprostol|
178649|NCT02805413|Other|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10…). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9…). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
178741|NCT02804607|Other|questionnaire|
178650|NCT02805400|Other|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.~For these methods only commercially available CE marked devices will be used."
178651|NCT02805387|Dietary Supplement|Treatment|Bicarbonate was ingested
178652|NCT02805374|Drug|ASP1517|Oral
178653|NCT02805348|Drug|Bixalomer|Oral
178654|NCT02805335|Device|KTFIX PLUS|
178655|NCT02805322|Device|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
178656|NCT02805322|Device|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
178657|NCT02805322|Device|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
178658|NCT02805309|Behavioral|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
178659|NCT02805309|Behavioral|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
178660|NCT02805309|Behavioral|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
178661|NCT02805296|Other|Light irradiance|Comparison of double vs. single phototherapy
178662|NCT02805270|Other|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
178663|NCT02805257|Drug|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
178664|NCT02805257|Other|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
178665|NCT02805244|Drug|JTZ-951, 14C-JTZ-951|
178666|NCT02805231|Other|Vitamin D receptor polymorphic analysis|
178667|NCT02805218|Drug|PEG-rhG-CSF|
178668|NCT02805205|Drug|PEG-rhG-CSF|
178669|NCT02805192|Device|Size Measurement by a Smart phone App|
178670|NCT02805179|Radiation|High Dose Radiation|Radiation will be delivered once daily for a total of 30 fractions, five days per week.
178671|NCT02805179|Drug|Temozolomide|Patients will receive concurrent temozolomide (75 mg/m^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
178672|NCT02805166|Drug|PEG-rhG-CSF|
178673|NCT02805153|Drug|PEG-rhG-CSF|
178674|NCT02805153|Drug|rhG-CSF|
178675|NCT02805140|Behavioral|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
178676|NCT02805140|Behavioral|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
178677|NCT02805140|Behavioral|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
178678|NCT02805101|Drug|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
178679|NCT02805101|Drug|MTA|MTA is going to be used as the sealing agent for the perforation.
178680|NCT02805088|Other|Electroencephalographic recordings|
178681|NCT02805088|Other|neuropsychological evaluation|
178682|NCT02805088|Other|clinical evaluation of symptoms|
178683|NCT02805075|Other|Fructooligosaccharide|Given PO
178684|NCT02805075|Other|Laboratory Biomarker Analysis|Correlative studies
178685|NCT02805062|Procedure|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
178686|NCT02805062|Procedure|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
178687|NCT02805049|Drug|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
178688|NCT02805036|Device|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
178689|NCT02805036|Device|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
178690|NCT02805023|Biological|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
178691|NCT02805023|Biological|Control medium|Intramuscular injections - single treatment session
178692|NCT02805010|Drug|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
178693|NCT02805010|Other|Placebo|On Day 1, subjects will receive a single SC dose of placebo
178694|NCT02804984|Genetic|ICUS|
178695|NCT02804958|Procedure|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
178698|NCT02804932|Other|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 8 weeks
178699|NCT02804919|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
178700|NCT02804906|Behavioral|Home-based physical therapy|"Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed."
178701|NCT02804906|Behavioral|Usual Care|"Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions)."
178702|NCT02804893|Procedure|VATS|Thorax thoracoscopic surgery (lobectomy)
178703|NCT02804893|Procedure|RATS|Thorax robotic surgery (lobectomy)
178704|NCT02804880|Behavioral|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
178705|NCT02804880|Behavioral|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
178706|NCT02804880|Behavioral|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
178707|NCT02804880|Other|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
178708|NCT02804880|Other|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
178709|NCT02804880|Behavioral|Brief advice|Very brief, minimal and general smoking cessation advice
178710|NCT02804880|Other|12-page booklet|12-page smoking cessation self-help booklet
178711|NCT02804867|Procedure|Online questionnaire and self-administered blood spot|
178712|NCT02804854|Drug|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
178713|NCT02804841|Dietary Supplement|Cholecalciferol -Vitamin D3|
178714|NCT02804841|Other|Placebo -gel capsule containing no vitamin D.|
178715|NCT02804828|Dietary Supplement|Individualized mitochondrial cocktail|
178716|NCT02804828|Dietary Supplement|Arctic cod liver oil capsules|
178717|NCT02804828|Dietary Supplement|Placebo|
178718|NCT02804815|Drug|Aspirin 100mg|Aspirin 100mg
178719|NCT02804815|Drug|Aspirin 300mg|Aspirin 300mg
178720|NCT02804815|Drug|Placebo 100mg|Placebo 100mg
178721|NCT02804815|Drug|Placebo 300mg|Placebo 300mg
178722|NCT02804802|Other|questionnaire|dietary habits and physical activity questionnaire
178723|NCT02804776|Drug|Gefitinib|250mg oral daily for 4 weeks
178724|NCT02804763|Drug|Placebo|Solution for infusion, 0,9% saline
178725|NCT02804763|Drug|Dapirolizumab pegol (DZP)|Solution for infusion
178726|NCT02804750|Drug|CORT125134|
178727|NCT02804737|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
178728|NCT02804724|Other|No intervention|
178729|NCT02804711|Biological|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
178730|NCT02804711|Biological|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
178731|NCT02804711|Biological|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
178732|NCT02804711|Biological|Placebo|
178733|NCT02804698|Behavioral|Education intervention|13-week educational and physical activity intervention
178734|NCT02804685|Other|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
178735|NCT02804659|Other|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
178736|NCT02804646|Drug|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
178737|NCT02804646|Drug|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
178738|NCT02804633|Drug|IV Acetaminophen|1 gram every 6 hours
178739|NCT02804633|Drug|Placebo|100 ml of normal saline every 6 hours
178740|NCT02804620|Behavioral|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
178742|NCT02804594|Drug|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
178743|NCT02804594|Drug|Placebo|placebo taken three times daily
178744|NCT02804581|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
178745|NCT02804568|Drug|ALKS 3831|Oral capsule, daily administration
178746|NCT02804555|Other|Oxygen|Oxygen administration
178747|NCT02804542|Other|Observational|
178748|NCT02804542|Other|Retrospective review|
178749|NCT02804529|Device|Veress needle|
178750|NCT02804516|Behavioral|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
178751|NCT02804516|Behavioral|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
178752|NCT02804503|Behavioral|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
178753|NCT02804503|Behavioral|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
178754|NCT02804503|Behavioral|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
178755|NCT02804490|Dietary Supplement|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
178756|NCT02804490|Dietary Supplement|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
178757|NCT02804490|Dietary Supplement|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
178758|NCT02804451|Device|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
178759|NCT02804451|Device|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
178760|NCT02804451|Device|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
178761|NCT02804451|Device|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
178762|NCT02804425|Other|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
178763|NCT02804412|Other|Control group|This is the control group with 14 h treatment over 10 workdays.
178764|NCT02804412|Other|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
178765|NCT02804412|Other|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
178766|NCT02804399|Drug|PF-06463922|100 mg oral dose on day 1 in period 1 and on day 8 in period 2
178767|NCT02804399|Drug|rifampin|600 mg QD from day 1 to day 12 in period 2.
178768|NCT02804386|Drug|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
178769|NCT02804373|Drug|Oxytocin (OXT) continuous|Administration of 24 IU of oxytocin daily during 28 days
178770|NCT02804373|Drug|Placebo|Placebo daily during 28 days
178771|NCT02804373|Drug|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
178772|NCT02804373|Drug|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
178773|NCT02804360|Device|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
178774|NCT02804347|Device|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
178775|NCT02804347|Device|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
178776|NCT02804347|Other|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A & B, RAVLT
178777|NCT02804334|Procedure|Psychiatric Questionnaires|
178778|NCT02804334|Procedure|Blood draw|
178779|NCT02804308|Behavioral|Combined Training|
178780|NCT02804295|Other|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
178781|NCT02804282|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
178782|NCT02804269|Other|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
178783|NCT02804269|Other|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
178784|NCT02804256|Other|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
178785|NCT02804243|Device|nasal high flow therapy|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
178786|NCT02804230|Device|MRgFUS Ablation of Epileptic Foci|MR-Guided Focused Ultrasound
178787|NCT02804217|Other|Genetic: mutation profile|
178788|NCT02804204|Drug|Anti-TNF|
178789|NCT02804191|Drug|LO2A|eye drop solution.
178790|NCT02804191|Drug|Saline|Placebo
178791|NCT02804178|Drug|ATR-101|
178876|NCT02803489|Device|medical device intervention|
178792|NCT02804165|Genetic|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
178793|NCT02804152|Behavioral|CBT for Chronic Pain in Pregnancy|"The content will be included in 8 weekly sessions, i.e., sessions 1-3 (Education on chronic pain, Theories of pain and diaphragmatic breathing and Progressive muscle relaxation and visual imagery), sessions 4 and 5 (Automatic thoughts and pain and Cognitive restructuring), sessions 7, 8 and 10 (Pleasant activity scheduling, Time-based pacing and Sleep hygiene), sessions 6 and 9 (Stress management and Anger management). Following this content, 1-2 sessions will be dedicated to review and reinforcement of key concepts or addressing any stuck points as well as cover content in session 11 (Relapse Prevention). The last session of therapy would include a review of achievements and commitment to continued application of CBT for chronic pain in participants daily lives."
178794|NCT02804139|Other|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
178795|NCT02804139|Other|Standard Care|Standard Care after C-section with no additional physical therapy.
178796|NCT02804126|Procedure|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
178797|NCT02804126|Procedure|QL (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
178798|NCT02804126|Drug|Bupivacaine|In both groups (TAP&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
178799|NCT02804126|Device|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
178800|NCT02804126|Drug|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
178801|NCT02804126|Drug|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
178802|NCT02804126|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
178803|NCT02804126|Drug|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
178804|NCT02804113|Device|Supera Peripheral Stent System|
178805|NCT02804087|Device|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
178806|NCT02804087|Other|Sham Implantation|Sham Implantation
178807|NCT02804074|Other|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
178808|NCT02804074|Other|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
178809|NCT02804061|Behavioral|NELIP|
178810|NCT02804048|Other|superficial heat pelvic floor muscle|Superficial heat application in the pelvic floor muscle
178811|NCT02804048|Other|superficial heat low back|Superficial heat application in the low back
178812|NCT02804048|Other|Pelvic Floor Muscle Training|Pelvic floor muscle training exercises
178813|NCT02804048|Other|Manual therapy in iliopsoas, diaphragm and piriformis|Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes
178814|NCT02804048|Other|Intra Vaginal Manual therapy|Intra Vaginal Manual therapy in the pelvic floor muscles
178815|NCT02804048|Other|Electromyographic biofeedback|Electromyographic biofeedback in the pelvic floor muscles
178816|NCT02804035|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
178817|NCT02804022|Device|VPIA analgesia|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
178818|NCT02804022|Drug|Morphine|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
178819|NCT02803996|Drug|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
178820|NCT02803996|Drug|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
178821|NCT02803983|Procedure|Pediatric hip plate|Children were treated with pediatric hip plate.
178822|NCT02803983|Procedure|Cannulated screw|Children were treated with cannulated screw.
178823|NCT02803957|Device|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
178824|NCT02803957|Device|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
178825|NCT02803944|Drug|Azithromycin|
178826|NCT02803931|Device|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
178827|NCT02803931|Device|12-lead ECG|
178828|NCT02803918|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
178829|NCT02803918|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
178830|NCT02803918|Drug|Basal Insulin|"Pharmaceutical form: solution~Route of administration: subcutaneous"
178831|NCT02803918|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
178832|NCT02803905|Biological|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
179021|NCT02802462|Behavioral|HIT|3-minute intervals at 40% and 80%VO 2max
178833|NCT02803892|Drug|rapamycin|Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
178834|NCT02803892|Drug|Vildagliptin|Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
178835|NCT02803892|Drug|Placebo 1|Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
178836|NCT02803892|Drug|Placebo 2|Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
178837|NCT02803879|Device|Cardiogoniometry|
178838|NCT02803866|Behavioral|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
178839|NCT02803853|Behavioral|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
178840|NCT02803840|Radiation|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
178841|NCT02803827|Other|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
178842|NCT02803827|Biological|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
178843|NCT02803827|Other|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
178844|NCT02803814|Procedure|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
178845|NCT02803814|Procedure|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
178846|NCT02803801|Behavioral|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
178847|NCT02803788|Drug|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
178848|NCT02803775|Device|CRT Algorithm|Programming based on Electrogram measurement
178849|NCT02803762|Drug|Pacritinib|400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
178850|NCT02803749|Drug|Buspirone|
178851|NCT02803749|Drug|Placebo|
178852|NCT02803736|Device|acupuncture|Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
178853|NCT02803723|Procedure|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
178854|NCT02803723|Procedure|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
178855|NCT02803710|Other|Microbiological study|
178856|NCT02803697|Other|Patients|
178857|NCT02803684|Other|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
178858|NCT02803671|Device|TFU-NIRS|
178859|NCT02803671|Device|NIRS|
178860|NCT02803671|Device|EEG|
178861|NCT02803658|Behavioral|smoking behavior|
178862|NCT02803658|Biological|Sperm collection|
178863|NCT02803645|Biological|blood sample|
178864|NCT02803632|Behavioral|questionnaires|
178865|NCT02803632|Device|actigraphic recording|
178866|NCT02803593|Behavioral|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
178867|NCT02803567|Behavioral|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
178868|NCT02803554|Other|Plasma|Blood plasma from donors aged 25 years or younger
178869|NCT02803541|Behavioral|12 day mainstream summer camp experience|see arm description
178870|NCT02803528|Drug|Biodentine|Biodentine is going to be used as the direct pulp capping material
178871|NCT02803528|Drug|MTA|MTA is going to be used as the direct pulp capping material in the second group
178872|NCT02803515|Biological|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
178873|NCT02803502|Device|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
178874|NCT02803502|Device|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
178875|NCT02803502|Device|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
178877|NCT02803463|Procedure|open appendectomy with peritoneal closure|open appendectomy with peritoneal closure under general anesthesia for acute appendicitis
178878|NCT02803463|Procedure|open appendectomy without peritoneal closure|open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
178879|NCT02803450|Procedure|Epidural needle|Medication administration via epidural needle.
178880|NCT02803450|Procedure|Catheter Administration|Medication administration via epidural catheter.
178881|NCT02803450|Procedure|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
178882|NCT02803437|Drug|Radium-223 dichloride (Xofigo, BAY 88-8223)|Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
178883|NCT02803424|Other|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
178884|NCT02803424|Other|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
178885|NCT02803398|Other|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann & Rauscher).
178886|NCT02803385|Other|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
178887|NCT02803385|Other|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
178888|NCT02803372|Other|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
178889|NCT02803372|Other|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
178890|NCT02803359|Procedure|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
178891|NCT02803346|Other|Circulating blood (leukocytes)|mHLA-DR measurement (in vitro)
178892|NCT02803333|Other|No Intervention|
178893|NCT02803320|Drug|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
178894|NCT02803307|Drug|TLC599|Single dose via intra-articular injection
178895|NCT02803294|Procedure|transcatheter aortic valve replacement|
178896|NCT02803281|Other|Frailty Assessment|Various physiologic and frailty assessment tests
178897|NCT02803268|Drug|MT-8554 low dose|
178898|NCT02803268|Drug|MT-8554 middle dose|
178899|NCT02803268|Drug|MT-8554 high dose|
178900|NCT02803268|Drug|Placebo|
178901|NCT02803255|Device|MAHI Exo-II|
178902|NCT02803242|Other|Patient Reported Outcomes|
178903|NCT02803229|Drug|Adderall-XR|
178904|NCT02803229|Drug|Matched placebo|matched placebo provided for placebo arm
178905|NCT02803216|Drug|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
178906|NCT02803216|Drug|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
178907|NCT02803216|Drug|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
178908|NCT02803203|Drug|osimertinib|
178909|NCT02803203|Drug|Bevacizumab|
178910|NCT02803190|Behavioral|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
178911|NCT02803190|Behavioral|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
178912|NCT02803177|Biological|BMC2012|
178913|NCT02803177|Device|beta-TCP Chronos® Synthes|
178914|NCT02803164|Device|Wound Vacuum-assisted dressing|Management of chronic open chest wounds with V-AD assisted dressing.
178915|NCT02803151|Radiation|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
178916|NCT02803138|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
178917|NCT02803138|Drug|Dasabuvir|Tablet
178918|NCT02803138|Drug|Ribavirin|Tablet
179022|NCT02802462|Behavioral|MCT|sustained 60%VO 2max
178919|NCT02803138|Behavioral|Patient support program|Supportive services provided to participants included reminder calls, emails, text messages, a Care Coach, and educational/informational materials.
178920|NCT02803125|Behavioral|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
178921|NCT02803125|Behavioral|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
178922|NCT02803112|Procedure|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
178923|NCT02803099|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number-SR15-63-Z13-084).
178924|NCT02803073|Drug|Testosterone|Testosterone Cypionate Intramuscular injections will be administered weekly
178925|NCT02803073|Drug|Normal Saline|Normal Saline Intramuscular injections will be administered weekly
178926|NCT02803060|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formaulation number- SR15-62 -Z15-038).
178927|NCT02803047|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation number - SR15-61-Z15-034).
178928|NCT02803034|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number- SR15-60-Z15-030).
178929|NCT02803021|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - SR15-47-Z13-076)
178930|NCT02803008|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation number - SR15-46-Z13-072)
178931|NCT02802995|Drug|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
178932|NCT02802969|Procedure|Surgery|"The operative approach and operating time will be performed according to neurosurgical practices (for head and neck) or surgical orthopaedic team (for sacrum) depending on the location, the extension and the relationship of the lesion to critical structures.~The surgery can be macroscopically complete or incomplete."
178933|NCT02802969|Radiation|Protontherapy|Radiotherapy will be done with the Cyclotron, for a total dose of 78 Gray Relative Biological Effective (Gy RBE) - 70 Gy RBE to the tumor bed and macroscopic volume and 8 Gy RBE to the the hypoxic component volume, delivered in 39 fractions spread over 67 days.
178934|NCT02802969|Drug|18F FAZA|FAZA PET/CT, in order to target the hypoxic zones
178935|NCT02802956|Other|Daily Life Promotion Program|Daily Life Promotion Program
178936|NCT02802956|Other|general rehabilitation treatment|general rehabilitation treatment
178937|NCT02802943|Biological|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 300 μg each of 5 HLA class I and 4 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 30 different peptides restricted by the 6 most common HLA class I allotypes (A*01, A*02, A*03, A*24, B*07, B*08) and 4 HLA class II peptides. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
178938|NCT02802943|Drug|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
178939|NCT02802930|Drug|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
178940|NCT02802930|Drug|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
178941|NCT02802930|Drug|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
178942|NCT02802930|Drug|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride [NaCl]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
178943|NCT02802917|Drug|SPF 50 Y49 091 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
178944|NCT02802917|Drug|SPF 50 X15 158 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
178945|NCT02802917|Drug|SPF 50 X15 160 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
178946|NCT02802917|Drug|SPF 50 X57 162 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
178947|NCT02802917|Other|J & J baby shampoo, X46 046 (control)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
178948|NCT02802904|Other|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
178949|NCT02802904|Other|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
179118|NCT02801695|Drug|Citrulline|Citrulline supplementation
178950|NCT02802904|Other|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
178951|NCT02802878|Device|Hybrid Training using Electrodes and Joint Motion Sensors|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).~A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
178952|NCT02802878|Device|Isokinetic Training with Isokinetic Dynamometer|Low intensity exercises completed using isokinetic dynamometer (HUMAC NORM, Computer Sports Medicine Inc. (CSMi), Stoughton, MA) in isokinetic mode at approximately 40%1 RM.
178953|NCT02802865|Drug|Clomiphene|
178954|NCT02802865|Drug|Letrozole|
178955|NCT02802852|Device|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
178956|NCT02802852|Drug|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
178957|NCT02802839|Device|Virtual Reality|
178958|NCT02802826|Behavioral|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
178959|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
178960|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
178961|NCT02802800|Other|Plyometric training|Plyometric exercises
178962|NCT02802787|Other|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
178963|NCT02802774|Other|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
178964|NCT02802774|Other|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
178965|NCT02802774|Other|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
178966|NCT02802748|Drug|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
178967|NCT02802748|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
178968|NCT02802735|Drug|Apremilast|
178969|NCT02802735|Drug|Placebo|
178970|NCT02802722|Dietary Supplement|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
178971|NCT02802722|Biological|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
178972|NCT02802722|Radiation|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
178973|NCT02802722|Other|Symptom questionnaire|Symptom questionnaire for recent symptom history
178974|NCT02802722|Other|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
178975|NCT02802709|Device|SB-061|delivered via intra-articular injection
178976|NCT02802709|Other|Placebo|Placebo
178977|NCT02802696|Drug|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
178978|NCT02802696|Drug|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
178979|NCT02802683|Drug|Bupivacaine|spinal anesthesia with hyperbaric bupivacaine
178980|NCT02802683|Drug|Levobupivacaine|spinal anesthesia with isobaric levobupivacaine
178981|NCT02802683|Drug|Phenylephrine|continous infusion of phenylephrine
178982|NCT02802683|Drug|normal saline|continous infusion of normal saline
178983|NCT02802670|Drug|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of [14C]-labeled GDC-0810 on Day 1.
178984|NCT02802657|Procedure|Treat-and-Extend regimen|For the T&E regimen,we recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
178985|NCT02802657|Procedure|Pro Re Nata|For the PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
178986|NCT02802657|Drug|Conbercept|
178987|NCT02802644|Drug|Sitagliptin|Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
179119|NCT02801695|Drug|Placebo|Placebo
178988|NCT02802644|Drug|Non DPP-4 Inhibitor|This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
178989|NCT02802631|Drug|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
178990|NCT02802631|Other|Placebo|Placebo - Normal Saline
178991|NCT02802618|Other|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
178992|NCT02802605|Drug|Bemiparin|Bemiparin subcutaneus administration
178993|NCT02802592|Drug|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
178994|NCT02802592|Drug|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
178995|NCT02802579|Radiation|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
178996|NCT02802579|Radiation|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
178997|NCT02802579|Radiation|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
178998|NCT02802566|Dietary Supplement|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
178999|NCT02802566|Dietary Supplement|Standard prenatal vitamin|Standard prenatal vitamin
179000|NCT02802553|Device|SmartGoggle|SmartGoggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
179001|NCT02802553|Other|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
179002|NCT02802553|Device|SPY Elite|Previously validated fluorescence detection system. Will be used to look at the same regions as the SmartGoggles to confirm sensitivity
179003|NCT02802553|Device|gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
179004|NCT02802553|Other|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
179005|NCT02802540|Drug|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
179006|NCT02802540|Drug|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
179007|NCT02802527|Procedure|Percutaneous Tracheostomy|
179008|NCT02802514|Drug|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
179009|NCT02802514|Drug|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
179010|NCT02802514|Drug|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
179011|NCT02802514|Drug|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
179012|NCT02802501|Drug|Tafenoquine|This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
179013|NCT02802501|Drug|Matched-Placebo for Tafenoquine|This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
179014|NCT02802501|Drug|Primaquine|This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
179015|NCT02802501|Drug|Matched-Placebo for Primaquine|This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
179016|NCT02802501|Drug|Dihydroartemisinin-piperaquine (DHA-PQP)|This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing <75 kg, 3 tablets will be administered per day. For subjects weighing >=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
179017|NCT02802501|Drug|ACT plus PQ (Rescue medication)|Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
179018|NCT02802501|Drug|PQ (End of study treatment)|Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
179019|NCT02802488|Procedure|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.~Thombus will be diagnosed according to the standard of care."
179020|NCT02802475|Biological|vena punction|
179023|NCT02802449|Drug|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
179024|NCT02802449|Drug|Placebo|
179025|NCT02802436|Procedure|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
179026|NCT02802423|Drug|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
179027|NCT02802410|Device|IQ-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
179028|NCT02802410|Device|Kinesiotape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
179029|NCT02802410|Other|No-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
179030|NCT02802397|Other|Self-administered questionnaire and blood and urine samples|Self-administered questionnaire and blood and urine samples
179031|NCT02802371|Behavioral|Psychosocial intervention|Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
179032|NCT02802371|Other|Pharmaceutical care and psychosocial support|"Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process."
179033|NCT02802358|Procedure|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
179034|NCT02802345|Drug|Nintedanib|
179035|NCT02802345|Drug|Placebo|
179036|NCT02802345|Drug|Sildenafil|
179037|NCT02802332|Behavioral|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
179038|NCT02802319|Device|Porcine Xenograft (Zcore)|Ridge preservation bone grafting after tooth extraction
179039|NCT02802319|Device|Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting after tooth extraction
179040|NCT02802306|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
179041|NCT02802293|Device|repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
179042|NCT02802293|Device|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
179043|NCT02802280|Other|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)~This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.~Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
179044|NCT02802267|Drug|Inecalcitol|vitamin D receptor agonist
179045|NCT02802267|Drug|Placebo Oral Tablet|placebo
179046|NCT02802254|Behavioral|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
179047|NCT02802254|Device|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
179048|NCT02802241|Drug|placebo|
179049|NCT02802241|Dietary Supplement|peppermint oil|
179050|NCT02802228|Drug|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
179051|NCT02802228|Drug|Placebo|matched placebo delivered as infusion and oral capsule
179052|NCT02802215|Drug|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
179053|NCT02802215|Drug|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
179054|NCT02802189|Other|Exercise programme|"Endurance and Resistant training exercise program (Duration: 45 minutes)~Muscle retraining of longus colli and endurance training of the deep cervical flexors.~Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).~Active ROM exercises for the neck muscles~Upper limbs exercises with resistant bands~Stretching exercises for the neck and upper limbs muscles"
179055|NCT02802189|Other|Integrated Neuromuscular Inhibition Technique application.|"Integrated Neuromuscular Inhibition Technique application.~(Duration: 15min)~The protocol was applied to the following muscles:~Upper border of the trapezius muscle~sternocleidomastoid~levator scapulae muscle~splenius capitis muscle~Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:~Ischemic compression~Muscle energy technique~Strain-counterstrain technique"
179056|NCT02802176|Device|INVOcell device|intra-vaginal culture of embryos using INVOcell device
179057|NCT02802176|Other|Traditional IVF|traditional culture of embryos in-vitro
179058|NCT02802163|Drug|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.~Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
179059|NCT02802163|Drug|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m^2 or 36 mg/m^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
179060|NCT02802163|Drug|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.~Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
179061|NCT02802163|Drug|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
179062|NCT02802150|Dietary Supplement|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
179063|NCT02802150|Dietary Supplement|Soy Bean Oil;placebo(4g/day)|parallel design
179064|NCT02802137|Drug|tafluprost|
179065|NCT02802137|Drug|tafluprost and dorzolamide/timolol|
179066|NCT02802124|Radiation|carbon-ion radiotherapy for tumor away from GI|
179067|NCT02802124|Radiation|carbon-ion radiotherapy for tumor adjacent to GI|
179068|NCT02802111|Drug|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
179069|NCT02802111|Drug|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
179070|NCT02802098|Drug|Durvalumab|Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
179071|NCT02802098|Drug|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
179072|NCT02802085|Device|VEGA Knee|TKA
179073|NCT02802072|Device|Enterprise stent implantation|Enterprise stent system (Johnson & Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
179074|NCT02802072|Drug|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
179075|NCT02802059|Drug|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
179076|NCT02802059|Drug|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administered within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).~Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administered within 10 days (1 ampoule per day)."
179077|NCT02802046|Radiation|Computed tomographic angiography of coronary artery|
179078|NCT02802020|Device|Pancreatic fully-covered self-expanding metal stent (FCSEMS)|The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
179079|NCT02802007|Device|Elipse Intragastric Balloon|
179080|NCT02801994|Device|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
179081|NCT02801981|Drug|GSK2230672|It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
179082|NCT02801981|Drug|Placebo|It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
179083|NCT02801968|Procedure|Tap block|
179084|NCT02801968|Other|intravenous analgesia|
179085|NCT02801955|Procedure|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
179086|NCT02801955|Procedure|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
179087|NCT02801942|Procedure|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
179120|NCT02801669|Drug|Du-176b|DU-176b orally administered at a dose of 15 mg once daily.
179088|NCT02801942|Procedure|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
179089|NCT02801942|Procedure|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
179090|NCT02801942|Other|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
179091|NCT02801929|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - SR15-72_V27-010).
179092|NCT02801916|Other|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
179093|NCT02801916|Other|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
179094|NCT02801916|Other|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
179095|NCT02801916|Other|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
179096|NCT02801903|Drug|SB204 4%|Topically Once Daily (AM)
179097|NCT02801890|Biological|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
179098|NCT02801877|Behavioral|IntelliCare|
179099|NCT02801877|Behavioral|Hub App with the Recommender System|
179100|NCT02801877|Behavioral|Coaching|
179101|NCT02801864|Device|Real tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
179102|NCT02801864|Device|Sham tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
179103|NCT02801864|Other|Intensive Speech Therapy|Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
179104|NCT02801851|Behavioral|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
179105|NCT02801838|Drug|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
179106|NCT02801825|Procedure|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
179107|NCT02801825|Procedure|Real-time ultrasound-guided out-of-plane femoral artery cannulation.|Real-time ultrasound-guided out-of-plane femoral artery cannulation.
179108|NCT02801812|Device|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
179109|NCT02801799|Drug|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.~The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.~The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).~We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
179110|NCT02801786|Drug|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
179111|NCT02801786|Drug|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
179112|NCT02801786|Drug|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
179113|NCT02801773|Dietary Supplement|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
179114|NCT02801773|Other|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
179115|NCT02801747|Behavioral|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
179116|NCT02801734|Other|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
179117|NCT02801721|Other|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
179122|NCT02801656|Biological|Fecal Microbiota Transplantation|Oral, encapsulated FMT
179123|NCT02801656|Drug|Vancomycin|Vancomycin po 125 mg qid x 10 days
179124|NCT02801656|Biological|Fecal Microbiota Transplantation Placebo|Matching placebo to FMT
179125|NCT02801656|Drug|Vancomycin Placebo|Matching placebo to Vancomycin
179126|NCT02801630|Device|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
179127|NCT02801617|Drug|PRO-067|1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
179128|NCT02801617|Drug|GAAP Ofteno®|1 drop QD during 30 days Active comparator, reference medication.
179129|NCT02801591|Procedure|Conventional ovarian stimulation proctol without rhGH|
179130|NCT02801578|Drug|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
179131|NCT02801565|Drug|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
179132|NCT02801552|Device|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
179133|NCT02801539|Device|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
179134|NCT02801539|Device|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
179135|NCT02801526|Drug|CKD-330 16/5mg - A|
179136|NCT02801526|Drug|Candesartan 16mg and Amlodipine 5mg|
179137|NCT02801513|Behavioral|Brief Mindfulness Training|Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice
179138|NCT02801513|Behavioral|Resting Control Training|Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
179139|NCT02801500|Device|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
179140|NCT02801500|Procedure|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
179141|NCT02801487|Radiation|CIRT with concurrent chemo arm|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3~5mm. Cisplatin (40mg/m^2) monotherapy will be given weekly along with radiotherapy.
179142|NCT02801474|Procedure|direct fracture reduction and fixation|In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
179143|NCT02801474|Procedure|indirect fracture reduction and fixation|In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
179144|NCT02801461|Device|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
179145|NCT02801448|Drug|sulforaphane|sulforaphane-containing broccoli sprout extracts
179146|NCT02801448|Drug|Placebo|Maltodextrine-based placebo without sulforaphane
179147|NCT02801435|Drug|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
179148|NCT02801435|Drug|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
179149|NCT02801435|Drug|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
179150|NCT02801435|Drug|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
179151|NCT02801435|Drug|Placebo|Topical administration for twice daily
179152|NCT02801422|Other|fMRI|
179153|NCT02801409|Drug|Combined Epi-GA|Thoracic epidural catheterization will be performed according the surgical incision site. General anesthesia will be induced and maintained as in the control group, combined with epidural anesthesia which will be maintained with 0.5% ropivacaine during surgery.
179154|NCT02801409|Drug|PCEA|Patient-controlled epidural analgesia (0.12% ropivacaine and 0.5 ug/ml sufentanil) will be provided after surgery.
179155|NCT02801409|Drug|GA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with intravenous (propofol), inhalational (sevoflurane), or combined intravenous-inhalational anesthetics. Opioids and muscle relaxants will be administered when considered necessary.
179156|NCT02801409|Drug|PCIA|Patient-controlled intravenous analgesia (0.5 mg/ml morphine) will be provided after surgery.
179157|NCT02801396|Device|Etafilcon A Design 1 (Test 1)|
179158|NCT02801396|Device|Etafilcon A Design 2 (Test 2)|
179159|NCT02801396|Device|Etafilcon A (Control)|
179160|NCT02801383|Drug|Yallaferon®， the recombinant human interferon α-2b gel|
179161|NCT02801383|Other|gel without active ingredient|
179162|NCT02801370|Drug|12 mg ciprofloxacin|Single administration of OTO-201
179163|NCT02801370|Drug|Sham Control|Simulated, single adminstration
179164|NCT02801357|Drug|lofexidine administration in subjects seeking buprenorphine dose reduction|
179165|NCT02801344|Dietary Supplement|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
179166|NCT02801344|Dietary Supplement|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
179167|NCT02801344|Dietary Supplement|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
179168|NCT02801344|Other|Controlled-diet|the diet containing 0.8 g protein /kg/day
179169|NCT02801331|Device|Stochastic Vibrotactile Stimulation (SVS)|The infants isolette mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle vibrations and sounds during mattress stimulations.
179170|NCT02801318|Procedure|Polysomnography|
179171|NCT02801305|Drug|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
179172|NCT02801305|Drug|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
179173|NCT02801305|Drug|Vaseline|This is used as the topical placebo agent.
179174|NCT02801292|Drug|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
179175|NCT02801279|Other|Conventional bilateral arm training|The Kinect-based bilateral arm training focuses activities that required the use of both hands by using Kinect game.
179176|NCT02801279|Other|Kinect-based bilateral arm training|The conventional bilateral arm training focuses activities that required the use of both hands.
179177|NCT02801266|Behavioral|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
179178|NCT02801240|Other|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
179179|NCT02801227|Drug|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
179180|NCT02801227|Drug|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
179181|NCT02801214|Other|fMRI|
179182|NCT02801201|Drug|Midazolam|
179183|NCT02801201|Drug|Bupivacaine|
179184|NCT02801188|Drug|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
179185|NCT02801188|Drug|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
179186|NCT02801175|Procedure|Pulmonary vein isolation|
179187|NCT02801162|Device|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
179188|NCT02801162|Device|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
179189|NCT02801149|Procedure|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
179190|NCT02801136|Behavioral|CBT for PNES|
179191|NCT02801136|Behavioral|Supportive Therapy|
179192|NCT02801123|Behavioral|Mindfulness Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
179193|NCT02801123|Behavioral|Tai Chi/Qigong (TCQ) for Cancer Patients|"TCQ involves a series of slow specific movements or forms done in a meditative fashion. It is purported that focusing the mind solely on the movements of the form helps to bring about a state of mental calm and clarity. The practice itself has been separated from its martial arts roots and is widely taught as a health behavior practice and exercise. Qigong exercises generally have three components: a posture (whether moving or stationary), breathing techniques, and mental focus on guiding qi through the body. Our program, developed specifically for a cancer patient population, incorporates simple Tai Chi elements within a healing framework stemming from Qigong principles."
179194|NCT02801097|Drug|RRx-001|
179195|NCT02801097|Drug|Irinotecan|
179196|NCT02801084|Behavioral|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.~Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Floats 3 & 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.~Each float will occur approximately 1 to 7 days apart."
179197|NCT02801071|Drug|15g L-citrulline daily p.o.|
179198|NCT02801071|Drug|Placebo|
179199|NCT02801058|Other|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
179200|NCT02801045|Behavioral|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:~humanistic phenomenological focus~transpersonal therapeutic bound~transdisciplinarity in the artistic approach~integrative-relational specialized counseling of the grief, loss and trauma aspects."
179201|NCT02801032|Drug|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
179269|NCT02800525|Device|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
179639|NCT02797665|Drug|corticosteroids|prednisone 0.6mg/kg/d
179202|NCT02801032|Drug|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention."
179203|NCT02801019|Other|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
179204|NCT02801019|Other|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
179205|NCT02801006|Device|stenfilcon A|contact lens
179206|NCT02801006|Device|etafilcon A|contact lens
179207|NCT02800980|Procedure|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
179208|NCT02800980|Procedure|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
179209|NCT02800967|Dietary Supplement|Pure Aronia juice|Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
179210|NCT02800967|Dietary Supplement|Aronia juice-based beverage|Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
179211|NCT02800967|Dietary Supplement|Placebo beverage|A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
179212|NCT02800954|Biological|blood samples|
179213|NCT02800954|Biological|Bone marow samples|
179214|NCT02800941|Drug|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
179215|NCT02800928|Drug|CERC-501|CERC-501
179216|NCT02800928|Drug|Placebo|Placebo
179217|NCT02800915|Other|Service innovation with focus on interdisciplinary collaboration|The follow- up is performed via telemedicine to the patient in his or her own home, and in cooperation with the local health care workers.
179218|NCT02800902|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
179219|NCT02800902|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
179220|NCT02800902|Drug|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
179221|NCT02800889|Drug|Pixantrone|Pixantrone
179222|NCT02800876|Other|CT-acquisition|
179223|NCT02800863|Device|Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)|Electrical stimulation of the DRG using the Axium™ Neurostimulator System
179224|NCT02800863|Device|Dorsal Root Ganglion (DRG) Stimulation (Proclaim™ Neurostimulator System)|Electrical Stimulation of the DRG using the Proclaim™ Neurostimulator System.
179225|NCT02800850|Behavioral|Bright Light|
179226|NCT02800850|Behavioral|Placebo Light|
179227|NCT02800824|Drug|Budesonide|
179228|NCT02800824|Drug|Uceris|
179229|NCT02800811|Drug|FR104|GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
179230|NCT02800811|Drug|Placebo|The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
179231|NCT02800798|Other|Preeclampsia positive|
179232|NCT02800785|Drug|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
179233|NCT02800785|Procedure|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
179234|NCT02800772|Dietary Supplement|acetic acid|
179235|NCT02800772|Dietary Supplement|saline|
179236|NCT02800759|Dietary Supplement|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
179237|NCT02800759|Dietary Supplement|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
179238|NCT02800759|Dietary Supplement|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
179239|NCT02800759|Dietary Supplement|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
179240|NCT02800746|Drug|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
179241|NCT02800746|Drug|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
179242|NCT02800733|Dietary Supplement|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
179243|NCT02800733|Dietary Supplement|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
179244|NCT02800720|Behavioral|Meditation Awareness Training|8 Week Meditation Intervention
179245|NCT02800720|Behavioral|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
179246|NCT02800707|Other|Sucralose|Sweetner
179247|NCT02800707|Other|Stevia|Sweetner
179248|NCT02800694|Drug|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
179249|NCT02800681|Other|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.~The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
179250|NCT02800681|Other|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
179251|NCT02800681|Other|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
179252|NCT02800681|Other|Other general interviewer ratings|1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
179253|NCT02800668|Device|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
179254|NCT02800655|Device|Digital Health Feedback System|"This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.~Other Names:~DHFS"
179255|NCT02800642|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The recommended dose for intravitreal aflibercept is 2 mg equivalent to 50 μL. Study treatment will be administered at baseline and at monthly intervals until stabilization of disease. When stability is achieved, the treatment interval can be extended based on visual and anatomic outcomes as judged by the treating investigator.
179256|NCT02800629|Dietary Supplement|Modified Citrus Pectin|MCP versus placebo
179257|NCT02800629|Dietary Supplement|Placebo|
179258|NCT02800616|Other|The Healthy Primary School of the Future|In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.
179259|NCT02800616|Behavioral|The Physical Activity School|In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
179260|NCT02800603|Behavioral|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
179261|NCT02800590|Drug|ABP-700|
179262|NCT02800577|Device|General Practitioner Emotional Test Battery (GP-ETB)|The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
179263|NCT02800564|Behavioral|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
179264|NCT02800564|Behavioral|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
179265|NCT02800551|Radiation|dose-intensified image-guided SBRT using simultaneous integrated boost|
179266|NCT02800551|Radiation|External 3-dimensional conformal radiotherapy (3D-CRT)|
179267|NCT02800538|Dietary Supplement|intragastric infusion of nutrient|Intragastric infusion of nutrient that can be widely found in daily food or placebo.
179268|NCT02800525|Device|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
179675|NCT02797470|Drug|Cytarabine|
179676|NCT02797470|Drug|Etoposide|
179270|NCT02800512|Procedure|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
179271|NCT02800512|Procedure|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally—by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
179272|NCT02800486|Drug|Intra-arterial Cetuximab|
179273|NCT02800486|Drug|Intra-arterial Mannitol|
179274|NCT02800486|Radiation|Hypofractionated re-irradiation|
179275|NCT02800473|Device|Strorz (commercial)|
179276|NCT02800473|Device|CyPaM2 (experimental)|
179277|NCT02800460|Procedure|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
179278|NCT02800447|Drug|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1~14
179279|NCT02800447|Drug|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
179280|NCT02800434|Procedure|hand allograft|
179281|NCT02800408|Other|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
179282|NCT02800408|Other|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
179283|NCT02800408|Other|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
179284|NCT02800395|Procedure|Malnutrition screening and perioperative nutritional support|"Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~Implementation of an adapted nutritional support based on ESPEN Guidelines"
179285|NCT02800382|Other|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
179286|NCT02800369|Biological|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
179287|NCT02800356|Procedure|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.~The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
179288|NCT02800343|Procedure|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
179289|NCT02800330|Drug|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
179290|NCT02800330|Drug|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
179291|NCT02800330|Drug|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
179292|NCT02800317|Procedure|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
179293|NCT02800278|Other|observational|describe bone status and outcome of odontoid fracture
179294|NCT02800265|Dietary Supplement|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
179295|NCT02800252|Drug|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
179296|NCT02800252|Drug|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
179297|NCT02800252|Drug|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
179298|NCT02800239|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
179299|NCT02800226|Device|10Hz|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
179300|NCT02800226|Device|iTBS|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
179301|NCT02800213|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
179302|NCT02800213|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
179303|NCT02800200|Procedure|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
179464|NCT02798926|Device|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
179304|NCT02800200|Device|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
179305|NCT02800187|Device|ESWT|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
179306|NCT02800174|Device|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
179307|NCT02800174|Drug|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
179308|NCT02800161|Drug|Trehalose|Trehalose 70g/die
179309|NCT02800161|Drug|Maltose|Maltose 70g/die
179310|NCT02800148|Drug|Azelaic acid foam|
179311|NCT02800148|Drug|Azelaic acid foam|
179312|NCT02800148|Drug|Azelaic acid foam - Placebo|
179313|NCT02800135|Drug|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
179314|NCT02800096|Behavioral|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
179315|NCT02800096|Behavioral|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
179316|NCT02800083|Drug|Pitolisant (BF2.649)|
179317|NCT02800083|Drug|Placebo|
179318|NCT02800070|Biological|Lentivirus Alpha-gal A transduced stem cells|
179319|NCT02800044|Device|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
179320|NCT02800031|Device|Transvaginal ultrasonography|
179321|NCT02800018|Other|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
179322|NCT02800005|Device|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
179323|NCT02800005|Other|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
179324|NCT02799992|Procedure|689 nm Laser Treatment of the Macula|
179325|NCT02799992|Procedure|Half Dose Photodynamic Therapy|
179326|NCT02799979|Device|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
179327|NCT02799966|Device|Myndmove|20 sessions of 1 hour treatments with the MyndMove device (functional electrical stimulation) to the muscles of the upper limb(s), conducted 3 to 5 times per week, over 4 to 7 weeks.
179328|NCT02799953|Device|Technology-based self-management model|Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
179329|NCT02799927|Procedure|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
179330|NCT02799927|Procedure|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
179331|NCT02799914|Device|Sinus-Venous stent (Optimed GmbH)|Stent implantation
179332|NCT02799901|Biological|Nivolumab|Injection of nivolumab
179333|NCT02799901|Radiation|hypofractionned radiotherapy|radiation
179334|NCT02799888|Drug|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
179335|NCT02799888|Drug|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
179465|NCT02798913|Drug|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
179336|NCT02799888|Drug|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
179337|NCT02799888|Drug|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m^2 on day +1, and 10 mg/m^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10^9/L.
179338|NCT02799875|Other|Higher permissive hypercapnia|"pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;~pH ≥ 7.20 from a capillary or arterial blood sample;"
179339|NCT02799875|Other|Lower Permissive Hypercapnia|"pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;~pH ≥ 7.25 from a capillary or arterial blood sample;"
179340|NCT02799862|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
179341|NCT02799862|Drug|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
179342|NCT02799849|Other|Sleep and metabolism assessment|
179343|NCT02799836|Device|Blindfold|Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
179344|NCT02799823|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
179345|NCT02799797|Procedure|ultrasound guided long axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
179346|NCT02799797|Procedure|ultrasound guided short axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
179347|NCT02799797|Device|Philip CX 50 Ultrasound Scanner|The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
179348|NCT02799797|Device|PAJUNK Contiplex S Catheter|
179349|NCT02799797|Drug|Ropivocaine|0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
179350|NCT02799797|Drug|rescue sulfentanil given postoperatively as PICA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
179351|NCT02799784|Drug|UMEC/VI|ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
179352|NCT02799784|Drug|TIO/OLO|TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
179353|NCT02799784|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
179354|NCT02799758|Drug|NK-104-CR|NK-104-CR 8 mg for 52 weeks
179355|NCT02799758|Drug|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
179356|NCT02799758|Drug|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
179357|NCT02799758|Drug|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
179358|NCT02799745|Drug|Enzalutamide|Oral
179359|NCT02799745|Other|Active Surveillance|
179360|NCT02799706|Drug|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
179361|NCT02799706|Drug|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
179362|NCT02799706|Radiation|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
179363|NCT02799680|Biological|allogeneic CART-33|allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
179364|NCT02799667|Device|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
179365|NCT02799667|Device|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
179366|NCT02799641|Drug|Diazepam|5 mg Diazepam
179367|NCT02799641|Drug|Lidocaine|2 ml of 2% lidocaine
179368|NCT02799641|Other|Placebo pill|Placebo pill
179369|NCT02799641|Other|Placebo injection|Placebo injection
179370|NCT02799628|Behavioral|intervention|intervention with recommendation and therapist introduction
179371|NCT02799628|Other|placebo|low back pain education, and physical therapy 3 times per week
179372|NCT02799615|Drug|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
179373|NCT02799602|Drug|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
179374|NCT02799602|Drug|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
179375|NCT02799602|Drug|Docetaxel|As prescribed by the treating physician.
179636|NCT02797691|Other|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
179376|NCT02799602|Drug|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone [LHRH] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
179377|NCT02799589|Drug|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
179378|NCT02799589|Drug|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
179379|NCT02799589|Drug|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
179380|NCT02799576|Device|Curved needle|In this arm, the curved block needle will be used for regional blockade
179381|NCT02799563|Other|Coach, Preselected number of cases|
179382|NCT02799563|Other|Coach, Self-selected number of cases|
179383|NCT02799563|Other|No coach, Preselected number of cases|
179384|NCT02799563|Other|No coach, Self-selected number of cases|
179385|NCT02799550|Biological|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
179386|NCT02799537|Other|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
179387|NCT02799524|Other|comparison of screening scales|Concordance degrees Assessment of each of 2 scales ( HADS and GDS ) from the DSM- V , for diagnostic confirmation of major depressive episodes in elderly patients with cancer or haematological malignancies
179388|NCT02799511|Biological|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
179389|NCT02799498|Device|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
179390|NCT02799498|Other|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
179391|NCT02799498|Drug|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
179392|NCT02799485|Other|Laboratory Biomarker Analysis|Correlative studies
179393|NCT02799485|Other|Pharmacological Study|Correlative studies
179394|NCT02799485|Behavioral|Quality-of-Life Assessment|Ancillary studies
179395|NCT02799485|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
179396|NCT02799472|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
179397|NCT02799472|Drug|Placebo|0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
179398|NCT02799472|Drug|MTX|Capsule, tablet or liquid administered orally or as SC injection.
179399|NCT02799472|Drug|Folic (or folinic) acid|Capsule, tablet or liquid and will be administered orally.
179400|NCT02799459|Procedure|General anaesthesia|the patient will receive a general anaesthesia do proceed at her conization
179401|NCT02799459|Procedure|Hypnosis in conization|this is the experimental treatment which is allocated to the experimental group
179402|NCT02799446|Drug|Reslizumab|Reslizumab 3mg/kg intravenous (IV)
179403|NCT02799446|Drug|Placebo|Matching Placebo intravenous (IV)
179404|NCT02799433|Behavioral|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
179405|NCT02799433|Behavioral|Usual services|Control condition
179406|NCT02799420|Device|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
179407|NCT02799420|Device|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
179408|NCT02799407|Other|ResearchKit Consent|Multi-tiered consent form using the Apple ResearchKit Platform.
179409|NCT02799394|Other|Activity modification, exercises and gradual return to sport|
179410|NCT02799381|Drug|ABT-SLV187|Dose levels will be individually optimized.
179411|NCT02799381|Drug|optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications will be individually optimized to their maximum therapeutic effect.
179412|NCT02799368|Drug|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
179413|NCT02799368|Drug|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
179414|NCT02799355|Drug|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
179415|NCT02799316|Other|HBV core antibodies testing. • Real time PCR testing.|"HBV core antibodies testing in HBV surface antigen negative patients.~Real time PCR testing for those having positive HBc antibodies."
179416|NCT02799303|Device|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
179417|NCT02799303|Other|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
179418|NCT02799290|Biological|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
179419|NCT02799290|Biological|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
179420|NCT02799277|Drug|Testosterone|Effect of testosterone on moral decision making
179421|NCT02799277|Drug|Placebo|Effect of testosterone on moral decision making
179422|NCT02799264|Drug|Cabotegravir 30 mg|Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
179423|NCT02799251|Other|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
179424|NCT02799238|Biological|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
179425|NCT02799238|Radiation|radiotherapy|Radiotherapy 5 days/week for 6 weeks
179426|NCT02799238|Drug|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
179427|NCT02799212|Drug|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
179428|NCT02799212|Drug|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
179429|NCT02799186|Procedure|blood sample for genetic analysis|
179430|NCT02799173|Biological|RANKL/OPG ratio|
179431|NCT02799173|Device|bone densitometry|
179432|NCT02799173|Device|fan beam CT scan|
179433|NCT02799173|Device|Doppler ultrasound|
179434|NCT02799147|Procedure|Allogeneic stem cell transplantation|
179435|NCT02799147|Drug|Fludarabine monophosphate|
179436|NCT02799147|Drug|Busulfan|
179437|NCT02799147|Drug|Bendamustine|
179438|NCT02799134|Drug|Dexamethasone|
179439|NCT02799134|Drug|Vitamin C|
179440|NCT02799121|Device|ReGenerCell™ Autologous Cell Harvesting Device|
179441|NCT02799108|Device|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
179442|NCT02799108|Device|fMRI|fMRI acquisition under the same stimulation conditions
179443|NCT02799095|Drug|ALKS 4230|Intravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
179444|NCT02799095|Drug|ALKS 4230 + pembrolizumab|IV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
179445|NCT02799082|Drug|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
179446|NCT02799082|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
179447|NCT02799069|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
179448|NCT02799069|Drug|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
179449|NCT02799069|Drug|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
179450|NCT02799056|Device|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines at the eighth intercostal space in the mid-axillary line. The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
179451|NCT02799043|Procedure|Standard PVI|Standard PVI procedure without FIRMap.
179452|NCT02799043|Procedure|FIRM-Guided Procedure and PVI|
179453|NCT02799030|Drug|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
179454|NCT02799030|Drug|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
179455|NCT02799030|Drug|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
179456|NCT02799017|Other|Intensive Phonology Treatment|Phonology based reading, writing, and naming therapy.
179457|NCT02799017|Other|Intensive SFA Treatment|Semantic based reading, writing, and naming therapy.
179458|NCT02798991|Drug|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
179459|NCT02798991|Drug|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
179460|NCT02798978|Drug|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
179461|NCT02798978|Drug|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
179462|NCT02798965|Biological|serodiagnosis|
179463|NCT02798952|Biological|Engerix-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
179637|NCT02797678|Device|Powersleep|Participants will receive 5 nights of stimulation
179466|NCT02798913|Drug|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
179467|NCT02798900|Other|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
179468|NCT02798900|Device|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
179469|NCT02798887|Procedure|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
179470|NCT02798874|Drug|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
179471|NCT02798874|Drug|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
179472|NCT02798861|Device|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 1 to 3 months post-transplant in the liver recipient.
179473|NCT02798848|Device|Tablet computer|iPad
179474|NCT02798835|Drug|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
179475|NCT02798835|Drug|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
179476|NCT02798835|Drug|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
179477|NCT02798835|Drug|Bupivacaine|Used in spinal anesthetic
179478|NCT02798835|Drug|Fentanyl|May or may not be used in spinal anesthetic
179479|NCT02798835|Drug|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
179480|NCT02798835|Drug|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
179481|NCT02798822|Procedure|Rapid maxillary expansion|When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
179482|NCT02798809|Other|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
179483|NCT02798796|Device|MRI|All patients will be submitted to MRI
179484|NCT02798770|Other|No Intervention Foreseen|
179485|NCT02798757|Drug|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
179486|NCT02798744|Drug|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
179487|NCT02798744|Behavioral|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
179488|NCT02798744|Drug|Placebo|Placebo once daily for the duration of the study (24 weeks)
179489|NCT02798718|Dietary Supplement|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
179490|NCT02798692|Biological|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
179491|NCT02798692|Biological|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
179492|NCT02798692|Biological|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
179493|NCT02798692|Biological|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
179494|NCT02798666|Other|High intensity exercise training|Exercise training using sprint interval exercise
179495|NCT02798666|Other|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
179496|NCT02798653|Drug|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
179497|NCT02798653|Drug|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
179498|NCT02798653|Drug|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
179499|NCT02798640|Device|Celliant|100% Celliant garment
179500|NCT02798640|Device|Control|Control Garment
179501|NCT02798627|Drug|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
179502|NCT02798627|Drug|placebo|Placebo pills identical in appearance to the NS2359 will be provided
179503|NCT02798614|Device|10-day cast|Removal of plaster cast fixation 10 days after reduction
179504|NCT02798601|Other|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
179505|NCT02798588|Radiation|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)->8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
179506|NCT02798575|Device|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
179507|NCT02798562|Device|Native and dynamic contrast-enhanced CT|
179508|NCT02798549|Other|blood draw|blood draw of 150ml, twice
179509|NCT02798536|Drug|LMB-100|Administered IV on days 1, 3 and 5 of a 21 day cycle for up to 4 cycles(Arms A1 and A2) or 2 cycles (Arms B1 and B2)
179510|NCT02798536|Drug|nab-paclitaxel|Arms B1 and B2 only. Administered IV on days 1 and 8 of each 21 day cycle for up to 6 cycles
179511|NCT02798523|Drug|Methylprednisolone sodium succinate(Solu-Medrol)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.~125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
179512|NCT02798523|Drug|Topical methylprednisolone (Advantan emulsion 0 /1%)|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearylether, polyoxyethylene alcohol-21-stearylether, benzyl alcohol, disodium edetate, glycerol, and purified water.
179513|NCT02798510|Radiation|Concurrent Chemoradiotherapy|
179514|NCT02798510|Drug|capecitabine|
179515|NCT02798510|Drug|gemcitabine|
179516|NCT02798497|Other|Serum and Blood samples|
179517|NCT02798484|Device|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
179518|NCT02798471|Drug|Edoxaban|15 or 30 mg tablets for participants 12 years of age to <18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
179519|NCT02798471|Drug|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
179520|NCT02798458|Device|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
179521|NCT02798458|Procedure|Endoscopic Mucosal Resection|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
179522|NCT02798445|Other|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
179523|NCT02798445|Other|CONTROL|Multilayer bandages and wound care
179524|NCT02798432|Procedure|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
179525|NCT02798432|Device|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
179526|NCT02798419|Drug|DFD05 Cream|
179527|NCT02798419|Drug|Active01 Cream|
179528|NCT02798406|Biological|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
179529|NCT02798406|Biological|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
179530|NCT02798393|Other|Infrared Phototherapy|Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).
179531|NCT02798393|Other|Sham|
179532|NCT02798380|Drug|HTS-519 Insert|Maximum feasible dose of HTS-519 Insert per diseased nail
179533|NCT02798367|Behavioral|CBT-I plus placebo|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)
179534|NCT02798367|Drug|CBT-I plus Melatonin 3 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
179535|NCT02798367|Drug|CBT-I plus Melatonin 5 mg|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
179536|NCT02798354|Behavioral|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
179537|NCT02798341|Other|Biospecimen Collection|
179538|NCT02798328|Device|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
179539|NCT02798302|Other|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
179540|NCT02798289|Device|Oculeve Intranasal Neurostimulator|Neurostimulation device
179677|NCT02797470|Other|Laboratory Biomarker Analysis|Correlative studies
179541|NCT02798276|Procedure|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
179542|NCT02798276|Other|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
179543|NCT02798263|Other|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
179544|NCT02798263|Other|Acupuncture|30 minutes of classical acupuncture using predefined points.
179545|NCT02798263|Other|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
179546|NCT02798250|Other|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
179547|NCT02798250|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
179548|NCT02798250|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
179549|NCT02798250|Device|Dexcom G4 Platinum glucose sensor|
179550|NCT02798250|Device|Accu Chek Combo insulin pump|
179551|NCT02798237|Other|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.~Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
179552|NCT02798237|Other|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
179553|NCT02798224|Behavioral|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
179554|NCT02798224|Behavioral|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
179555|NCT02798211|Drug|Secukinumab|300 mg
179556|NCT02798211|Drug|Secukinumab|150 mg
179557|NCT02798211|Other|Placebo|Placebo
179558|NCT02798198|Other|T2DM|T2DM without DKD
179559|NCT02798172|Drug|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
179560|NCT02798159|Drug|TD0025|
179561|NCT02798159|Drug|Sildenafil Citrate 50mg|
179562|NCT02798146|Other|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
179563|NCT02798133|Procedure|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
179564|NCT02798133|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
179565|NCT02798120|Drug|SB204 4%|Open label, topical SB204 4%
179566|NCT02798107|Drug|idarucizumab|drug
179567|NCT02798081|Behavioral|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
179568|NCT02798068|Drug|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
179569|NCT02798055|Drug|Bosentan group|
179570|NCT02798042|Other|Urine Sample|We plan to collect a urine sample during the pre-surgical visit.
179571|NCT02798029|Radiation|Frameless Fractionated Stereotactic Radiation Therapy|Undergo FFSRT
179572|NCT02798016|Procedure|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
179573|NCT02798016|Procedure|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
179574|NCT02798003|Other|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
179575|NCT02797977|Drug|SRA737, gemcitabine, cisplatin|
179576|NCT02797977|Drug|SRA737, gemcitabine|
179638|NCT02797678|Device|Sham Powersleep|Participants will receive 5 nights of no stimulation
179577|NCT02797964|Drug|SRA737|SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
179578|NCT02797951|Drug|Galcanezumab|Administered SQ
179579|NCT02797938|Device|Taper guard tube|Taper guard tube was intubated
179580|NCT02797938|Device|Cylindrical tube|Cylindrical tube was intubated
179581|NCT02797925|Other|Training|Long slow strength training of the tendon for 3 months to improve function
179582|NCT02797912|Other|No intervention|
179583|NCT02797899|Device|Platelet Rich Fibrin|Native growth factors
179584|NCT02797886|Other|FES + VOL|Electrical stimulation is applied in concert with the subject's volitional movement.
179585|NCT02797886|Other|FES|Electrical stimulation is applied to the subject while they are asked to do nothing.
179586|NCT02797886|Other|VOL|The subject initiates and completes the movement without electrical stimulation.
179587|NCT02797873|Other|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
179588|NCT02797873|Other|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
179589|NCT02797873|Behavioral|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
179590|NCT02797873|Other|SCID-II|See Detailed Study Description.
179591|NCT02797873|Other|SDQ|See Detailed Study Description.
179592|NCT02797873|Other|ASRS|See Detailed Study Description.
179593|NCT02797873|Other|AQ|See Detailed Study Description.
179594|NCT02797873|Other|TAS-20|See Detailed Study Description.
179595|NCT02797873|Other|Raven's SPM|See Detailed Study Description.
179596|NCT02797873|Other|Reading ability|See Detailed Study Description.
179597|NCT02797873|Other|Ishihara's tests for colour deficiency|See Detailed Study Description.
179598|NCT02797873|Other|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
179599|NCT02797873|Other|Brown-ADD|See Detailed Study Description.
179600|NCT02797873|Other|MFQ|See Detailed Study Description.
179601|NCT02797873|Other|STAI-T|See Detailed Study Description.
179602|NCT02797873|Other|BIS|See Detailed Study Description.
179603|NCT02797873|Other|DAWBA|See Detailed Study Description.
179604|NCT02797873|Other|STAI-S|See Detailed Study Description.
179605|NCT02797873|Other|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
179606|NCT02797873|Other|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
179607|NCT02797873|Behavioral|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
179608|NCT02797873|Other|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
179609|NCT02797873|Other|Structural T2 MRI scan|See Detailed Study Description.
179610|NCT02797873|Other|DTI MRI scan|See Detailed Study Description and Outcome Measures.
179611|NCT02797873|Other|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
179612|NCT02797860|Drug|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
179613|NCT02797847|Drug|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
179614|NCT02797847|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
179615|NCT02797834|Procedure|Endometrial fluid collection|
179616|NCT02797821|Drug|Asfotase alfa|
179617|NCT02797808|Drug|Sertraline|Impact of sertraline on functional brain connectivity
179618|NCT02797808|Other|No Intervention|Healthy control non-intervention
179619|NCT02797795|Drug|NEV801|Dose Escalation
179620|NCT02797782|Other|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
179621|NCT02797769|Drug|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
179622|NCT02797769|Drug|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
179623|NCT02797756|Procedure|Esophago-gastro-duodenoscopy (EGD) with biopsy|
179624|NCT02797756|Procedure|Esophageal Impedance Monitoring (EIM)|
179625|NCT02797743|Other|Whole blood|"Adults ≥18 yrs of age: up to 50 mL (5 tubes)~Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
179626|NCT02797730|Behavioral|art-therapy sessions|
179627|NCT02797717|Radiation|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
179628|NCT02797717|Drug|Vincristine|ARM A and ARM B
179629|NCT02797717|Drug|Etoposide|ARM B , 100mg/m2/day
179630|NCT02797717|Drug|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
179631|NCT02797717|Drug|Doxorubicin|ARM B , 25mg/m2
179632|NCT02797717|Drug|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
179633|NCT02797717|Drug|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
179634|NCT02797704|Drug|Aflibercept|Eylea (aflibercept) Injection is a prescription medicine administered by injection into the eye.
179635|NCT02797691|Other|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
179640|NCT02797665|Procedure|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
179641|NCT02797652|Procedure|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
179642|NCT02797652|Procedure|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
179643|NCT02797639|Other|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.~In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
179644|NCT02797639|Other|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
179645|NCT02797626|Procedure|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
179646|NCT02797613|Behavioral|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
179647|NCT02797600|Behavioral|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
179648|NCT02797600|Other|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
179649|NCT02797587|Drug|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
179650|NCT02797587|Drug|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
179651|NCT02797587|Drug|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
179652|NCT02797587|Drug|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
179653|NCT02797587|Drug|Cytisine Placebo|Multi-daily dosing for 25 days.
179654|NCT02797587|Drug|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
179655|NCT02797574|Procedure|Punch Biopsy at a Lesional Site|
179656|NCT02797574|Procedure|Punch Biopsy at a Non- Lesional site|
179657|NCT02797561|Other|5 year Follow-up|
179658|NCT02797548|Drug|Aspirin only|Aspirin only during surgery
179659|NCT02797548|Drug|No antiplatelet therapy|No antiplatelet therapy will be during surgery
179660|NCT02797535|Procedure|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
179661|NCT02797522|Drug|ARC-521 Injection|
179662|NCT02797522|Other|Placebo|0.9% normal saline
179663|NCT02797522|Drug|antihistamine|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.
179664|NCT02797522|Drug|acetaminophen|Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).
179665|NCT02797522|Drug|entecavir|Participants take entecavir OR tenofovir daily throughout the study.
179666|NCT02797522|Drug|tenofovir|Participants take entecavir OR tenofovir daily throughout the study.
179667|NCT02797509|Behavioral|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
179668|NCT02797496|Other|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
179669|NCT02797496|Other|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
179670|NCT02797483|Other|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
179671|NCT02797483|Other|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
179672|NCT02797483|Other|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
179673|NCT02797470|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
179674|NCT02797470|Drug|Carmustine|
179678|NCT02797470|Biological|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
179679|NCT02797470|Drug|Melphalan|
179680|NCT02797470|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
179681|NCT02797457|Procedure|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
179682|NCT02797457|Procedure|Prosthetic forehands|Prosthetic forehands
179683|NCT02797444|Other|semi-structured interviews|
179684|NCT02797431|Drug|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR>2.5 or platelet count < 35,000
179685|NCT02797431|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
179686|NCT02797418|Behavioral|Cognitive remediation program|"Comparison between a cognitive remediation program (Cognitus and Me) (groupe 1) and a training group of fine motor skills (group 2)"
179687|NCT02797405|Radiation|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
179688|NCT02797392|Behavioral|Lifestyle intervention|1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
179689|NCT02797379|Other|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
179690|NCT02797366|Radiation|Proton radiotherapy|
179691|NCT02797353|Other|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
179692|NCT02797340|Other|Blood draws and urine samples for metformin concentration measurements|
179693|NCT02797340|Drug|Metformin|
179694|NCT02797314|Other|Bone biopsies|Bone biopsies
179695|NCT02797301|Other|synthetic test|The children performed the synthetic test with no time restriction.
179696|NCT02797301|Other|computerised test|The children performed the computerised test with no time restriction.
179697|NCT02797275|Drug|Albuterol|Beta agonist respiratory inhaler
179698|NCT02797275|Drug|Placebo|respiratory inhaler with no medication
179699|NCT02797262|Device|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
179700|NCT02797249|Drug|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
179701|NCT02797249|Other|Blank|Routine examination during pregnancy.
179702|NCT02797236|Biological|SF2a-TT15 vaccine|
179703|NCT02797236|Biological|SF2a-TT15 vaccine + adjuvant|
179704|NCT02797236|Biological|Placebo|
179705|NCT02797236|Biological|Placebo + adjuvant|
179706|NCT02797223|Behavioral|Semi-structured interviews|Qualitative phenomenological study. Data collection will be done through semi-structured interviews. Each interview will last between 60 and 90 minutes. It will be the same researcher who interviewed and analyze them.
179707|NCT02797210|Device|Continuous theta-burst stimulation|
179708|NCT02797197|Procedure|handgrip strength test|
179709|NCT02797197|Drug|chemotherapy|
179710|NCT02797184|Drug|KNO3, potassium nitrate|Potassium nitrate (KNO3) will be given orally in 2 gelatin capsules, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are 10 mmol and 20 mmol KNO3.
179711|NCT02797171|Biological|VRC01|Administered by intravenous (IV) infusion
179712|NCT02797171|Biological|VRC01LS|Administered by intravenous (IV) infusion
179713|NCT02797158|Procedure|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
179714|NCT02797145|Drug|Digoxin dose-adjusted|Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
179715|NCT02797145|Drug|Standard dose|the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
179716|NCT02797132|Drug|LUM/IVA|
179717|NCT02797119|Drug|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
179718|NCT02797119|Drug|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
179719|NCT02797119|Drug|Saline Solution (TA0)|
179720|NCT02797106|Other|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
179721|NCT02797080|Drug|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m².
179722|NCT02797067|Drug|indomethacin suppository|100mg rectal indomethacin 30min before ESWL
179723|NCT02797067|Drug|Glycerin Suppository|30min before ESWL
179724|NCT02797054|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
179725|NCT02797054|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
179726|NCT02797054|Behavioral|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
179727|NCT02797041|Drug|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
179728|NCT02797028|Dietary Supplement|Anthocyanidins capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
179729|NCT02797028|Dietary Supplement|Placebo capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
179730|NCT02797028|Drug|Allopurinol|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
179731|NCT02797015|Drug|RPC1063|Oral capsule daily
179732|NCT02797002|Other|Assessment|
179733|NCT02796989|Dietary Supplement|Wheat bran|20 g each day
179734|NCT02796989|Dietary Supplement|Placebo|20 g each day
179735|NCT02796976|Other|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
179736|NCT02796963|Behavioral|Crowdsourced intervention|The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
179737|NCT02796963|Behavioral|Traditional intervention campaign|The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, Community-Based Organization (CBO), and partners. These are typically designed by experts and social marketing companies.
179738|NCT02796950|Drug|Acipimox|P.o. administration of 250 mg acipimox
179739|NCT02796937|Biological|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
179740|NCT02796924|Device|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
179741|NCT02796911|Drug|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
179742|NCT02796911|Drug|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
179743|NCT02796898|Drug|SM88 (Cohort 1)|"Tyrosine Isomers - 230 mg qd~Phenytoin - 50 mg qd.~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
179744|NCT02796898|Drug|SM88 (Cohort 2)|"Tyrosine Isomers - 460 mg (230 mg bid)~Phenytoin - 50 mg qd~Methoxsalen - 10 mg qd~Sirolimus - 0.5 mg qd"
179745|NCT02796885|Other|no intervention - observational study|
179746|NCT02796872|Dietary Supplement|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
179747|NCT02796872|Dietary Supplement|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
179748|NCT02796872|Dietary Supplement|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
179749|NCT02796872|Dietary Supplement|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
179750|NCT02796859|Drug|Siltuximab|Investigational agent
179751|NCT02796859|Drug|normal saline|Placebo
179752|NCT02796833|Drug|SMOFlipid20%|
179753|NCT02796820|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
179754|NCT02796807|Drug|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
179755|NCT02796794|Dietary Supplement|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
179756|NCT02796794|Other|enteral nutrition only|These are the patients receiving enteral nutrition
179757|NCT02796781|Biological|Lung stem cells|
179758|NCT02796768|Other|3D US Scanning|3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
179759|NCT02796768|Other|2D US Scanning|2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
179760|NCT02796755|Drug|Riluzole|Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
179761|NCT02796755|Drug|Placebo|Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
179762|NCT02796742|Other|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
179763|NCT02796729|Procedure|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
179764|NCT02796729|Drug|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
179765|NCT02796729|Drug|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
179766|NCT02796716|Device|Testing on new technology called Accelerate ID/AST system|
179767|NCT02796703|Dietary Supplement|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
179768|NCT02796703|Dietary Supplement|Placebo|2 cc of milk will be given to control group
179769|NCT02796690|Other|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
179770|NCT02796677|Drug|Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Inhalation powder
179771|NCT02796677|Drug|Aclidinium bromide 400 μg (AB 400 μg)|Inhalation powder
179772|NCT02796677|Drug|Formoterol fumarate 12 μg (FF 12 μg)|Inhalation powder
179773|NCT02796677|Other|Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Inhalation powder
179774|NCT02796677|Drug|Tiotropium 18 μg (TIO 18 μg)|Powder in capsules for oral inhalation
179775|NCT02796677|Other|Placebo to TIO 18 μg|Powder in capsules for oral inhalation
179776|NCT02796664|Dietary Supplement|Ginseng|2grams twice per day (0.5gram/capsule, 2capsuels twice a day) for 12months
179777|NCT02796664|Dietary Supplement|Placebo|2grams twice per day (0.5gram/capsule, 2capsuels twice a day) for 12months
179778|NCT02796651|Drug|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
179779|NCT02796651|Drug|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
179780|NCT02796651|Drug|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
179781|NCT02796651|Drug|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
179782|NCT02796651|Drug|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
179783|NCT02796638|Device|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
179784|NCT02796625|Other|Painful Stimuli|warm or painful heat administration
179785|NCT02796612|Other|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
179786|NCT02796612|Behavioral|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
179787|NCT02796612|Behavioral|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
179788|NCT02796599|Device|Non invasive ventilation during exercise with facial or nasal mask.|Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
179789|NCT02796586|Other|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
179790|NCT02796573|Behavioral|cognitive behavioural therapy|
179791|NCT02796560|Drug|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
179792|NCT02796560|Drug|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
179793|NCT02796547|Drug|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
179794|NCT02796547|Other|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
179795|NCT02796534|Other|Diagnosis of sleep apnea by oxymetry|
179796|NCT02796521|Other|dietary counseling|Patients received individualized nutritional counseling encouraging them for enrichment
179797|NCT02796521|Other|nutritional workshop with enrichment during a meal|Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
179798|NCT02796508|Behavioral|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
179799|NCT02796508|Behavioral|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
179800|NCT02796495|Device|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
179979|NCT02795117|Drug|Ivermectin (reference)|
179980|NCT02795117|Drug|Placebo|
179801|NCT02796482|Dietary Supplement|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
179802|NCT02796469|Drug|Pentoxifylline|
179803|NCT02796469|Drug|Corticosteroid|
179804|NCT02796469|Drug|Placebo|
179805|NCT02796456|Other|blood sample|
179806|NCT02796443|Procedure|Laparoscopic cholecystectomy (LC)|Removal of the gallbladder via a minimally invasive approach
179807|NCT02796430|Other|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
179808|NCT02796430|Other|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
179809|NCT02796417|Behavioral|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
179810|NCT02796417|Behavioral|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
179811|NCT02796404|Device|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
179812|NCT02796404|Other|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
179813|NCT02796391|Drug|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.~Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.~Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
179814|NCT02796391|Behavioral|One on One Counseling|All participants will receive One on One Counseling.
179815|NCT02796378|Drug|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
179816|NCT02796378|Drug|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
179817|NCT02796378|Drug|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
179818|NCT02796365|Other|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
179819|NCT02796352|Drug|High dose bolus interleukin-2 (HD IL2)|"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).~The planned treatment consists of 3 courses (6 cycles) of HD IL-2."
179820|NCT02796339|Dietary Supplement|Mastiha|
179821|NCT02796339|Dietary Supplement|Placebo|
179822|NCT02796326|Device|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
179823|NCT02796313|Behavioral|DASH Groceries + Weekly Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
179824|NCT02796313|Behavioral|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $30 grocery order for 8 weeks.
179825|NCT02796300|Device|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
179826|NCT02796300|Device|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
179827|NCT02796287|Procedure|achieving a neuropsychological examination in the acute amnesic phase|achieving a neuropsychological examination in the acute phase in addition to the normal protocole
179828|NCT02796287|Procedure|Neurological consultation with neuropsychological evaluation|Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase
179829|NCT02796287|Radiation|MRI|Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
179830|NCT02796261|Drug|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
179831|NCT02796261|Drug|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
179832|NCT02796261|Drug|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
179833|NCT02796248|Other|cross-sectional survey|This is an observation study. Participants will complete a survey at one occasion. Participants are also invited to do a A1c mail-in capillary test.
179834|NCT02796235|Other|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
179835|NCT02796209|Drug|Atomexetine|Upon completion of the 4-week treatment period (period 1), the investigator or research nurse will instruct the subject to discontinue the study medication for 1 week (wash-out period). After this period, the subject will complete the second 4-week treatment period (period 2).
180017|NCT02794870|Biological|Placebo|Isotonic diluent, administered as nose drops
179836|NCT02796209|Drug|Placebo|Upon completion of the 4-week treatment period (period 1), the investigator or research nurse will instruct the subject to discontinue the study medication for 1 week (wash-out period). After this period, the subject will complete the second 4-week treatment period (period 2).
179837|NCT02796196|Other|Medical Chart Review|Review of medical chart
179838|NCT02796196|Device|Monitoring Device|Wearable physical activity monitoring device
179839|NCT02796196|Procedure|Physical Therapy|Undergo primarily self-directed physical therapy
179840|NCT02796183|Drug|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
179841|NCT02796170|Drug|Dapagliflozin|5mg pill taken once daily
179842|NCT02796170|Drug|Sulfonylurea|Subjects may take any of the sulfonlyurea medications, titration will be done per standard of care.
179843|NCT02796170|Drug|Placebo|5mg pill taken once daily- placebo of Dapagliflozin
179844|NCT02796157|Device|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
179845|NCT02796157|Device|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
179846|NCT02796144|Drug|Lorcaserin|Max dose of 10 mg BID
179847|NCT02796144|Drug|Metformin|Max dose of 1,000 mg BID
179848|NCT02796144|Drug|Placebo|Matching placebos will be administered for each drug.
179849|NCT02796131|Drug|RDX5791|
179850|NCT02796131|Drug|Placebo|Placebo
179851|NCT02796118|Drug|ASP2151|Oral
179852|NCT02796118|Drug|Placebo|Oral
179853|NCT02796105|Drug|Progevera|
179854|NCT02796105|Drug|Orgalutran|
179855|NCT02796092|Device|Fibered platinum coils|
179856|NCT02796092|Device|Vascular plugs|
179857|NCT02796079|Biological|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
179858|NCT02796079|Biological|saline|saline injections
179859|NCT02796066|Drug|Vehicle|Applied once a day
179860|NCT02796066|Drug|TSN2898|Applied once a day
179861|NCT02796066|Drug|TSN2898|Applied once a day
179862|NCT02796066|Drug|TSN2898|Applied once a day
179863|NCT02796053|Drug|TAB08|The TAB08 will be administered intravenously, by infusion.
179864|NCT02796053|Other|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
179865|NCT02796040|Device|MRI|
179866|NCT02796027|Other|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:~peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing~HCT using CTR with Rapid Testing~ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
179867|NCT02796001|Biological|human rhinovirus|human rhinovirus
179868|NCT02795988|Biological|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
179869|NCT02795988|Drug|Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.|Chemotherapy will consist of: cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle), or (in Phase 2 only) oxaliplatin, by intravenous administration at 130 mg/m2 on Day 1 of each cycle and capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle).
179870|NCT02795962|Other|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
179871|NCT02795949|Drug|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
179872|NCT02795949|Drug|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
179873|NCT02795936|Procedure|Cardiac rehabilitation|Perform exercise prescription for 12 weeks
179874|NCT02795910|Behavioral|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
179875|NCT02795910|Behavioral|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
179876|NCT02795884|Drug|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
179877|NCT02795884|Drug|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
179878|NCT02795871|Behavioral|Neuropsychological and cognitive assessment|
179879|NCT02795858|Drug|Ramucirumab|
179880|NCT02795858|Drug|Somatostatin Analog|
180018|NCT02794857|Drug|NP001|
180019|NCT02794857|Drug|Placebo|
179881|NCT02795845|Dietary Supplement|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
179882|NCT02795845|Other|Placebo|capsule without active ingredient
179883|NCT02795832|Drug|ZPL-5212372 1% w/w Ointment BID|
179884|NCT02795832|Drug|Placebo Ointment BID|
179885|NCT02795819|Drug|AR-42|AR-42 tablets were taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment was interrupted during the cycle, the cycle was to be extended
179886|NCT02795819|Drug|Pazopanib|Pazopanib tablets were taken orally once daily continuously during each 4-week treatment cycle. There were no scheduled breaks in pazopanib therapy
179887|NCT02795793|Drug|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
179888|NCT02795793|Procedure|Appendectomy group (Operative management, OM)|
179889|NCT02795780|Drug|18F-AV-1451|
179890|NCT02795767|Drug|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
179891|NCT02795754|Drug|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
179892|NCT02795754|Drug|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
179893|NCT02795754|Drug|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
179894|NCT02795754|Drug|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
179895|NCT02795754|Drug|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
179896|NCT02795741|Device|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
179897|NCT02795728|Other|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
179898|NCT02795728|Other|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
179899|NCT02795715|Device|tDCS|
179900|NCT02795715|Behavioral|training|
179901|NCT02795702|Device|tDCS|
179902|NCT02795702|Behavioral|training|
179903|NCT02795676|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
179904|NCT02795676|Biological|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
179905|NCT02795663|Device|NIRS EEG HR recording|NIRS EEG HR recording
179906|NCT02795650|Drug|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
179907|NCT02795650|Drug|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
179908|NCT02795637|Drug|dasotraline|dasotraline 8mg capsule/day
179909|NCT02795624|Procedure|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
179910|NCT02795624|Procedure|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
179911|NCT02795624|Procedure|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
179912|NCT02795611|Behavioral|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
179913|NCT02795611|Behavioral|regular occupational therapy|regular occupational therapy
179914|NCT02795611|Other|intervention done outside our hospital|intervention done outside our hospital
179915|NCT02795598|Procedure|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
179916|NCT02795598|Procedure|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.~15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
179917|NCT02795585|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
179918|NCT02795572|Dietary Supplement|Vitamin D|Vitamin D 2000 IU oral once daily
179919|NCT02795572|Dietary Supplement|Vitamin B6|Vitamin B6 100 mg oral once daily
179920|NCT02795572|Dietary Supplement|Vitamin B12|Vitamin B12 100 mcg oral once daily
179921|NCT02795572|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
179922|NCT02795559|Other|Glucose|75g glucose dissolved in 300ml water
179923|NCT02795559|Other|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
179924|NCT02795559|Other|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
179925|NCT02795546|Drug|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
179926|NCT02795546|Biological|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
180094|NCT02794272|Device|tDCS|
180095|NCT02794272|Device|sham-tDCS|
180096|NCT02794259|Device|tDCS|
179927|NCT02795533|Behavioral|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:~A medical examination~Quality of life questionnaires~Neuropsychological test~All instruments have been translated into Norwegian and validated and tested in clinical practice."
179928|NCT02795520|Drug|OTS167IV|
179929|NCT02795507|Device|Rehabit-Tec System|Device with visual and kinesthetic feedback
179930|NCT02795507|Device|Rehabit-Tec System|Device without visual and kinesthetic feedback
179931|NCT02795507|Behavioral|conventional exercises|
179932|NCT02795494|Behavioral|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
179933|NCT02795494|Behavioral|ASK-P questionnaire at baseline|Patient-reported activity level score
179934|NCT02795494|Behavioral|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
179935|NCT02795468|Procedure|Radial arterial cannulation|Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
179936|NCT02795455|Behavioral|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
179937|NCT02795455|Behavioral|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
179938|NCT02795455|Dietary Supplement|meal replacement shake|
179939|NCT02795442|Other|Even protein|5 day intake of even protein 3 day rotating menu.
179940|NCT02795442|Other|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
179941|NCT02795429|Drug|PDR001|PDR001 will be administered intravenously
179942|NCT02795429|Drug|INC280|INC280 will be administered orally
179943|NCT02795416|Drug|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
179944|NCT02795403|Other|blood draw of 150ml, twice|
179945|NCT02795390|Drug|Chinese herbal medicine|
179946|NCT02795390|Drug|Placebo|
179947|NCT02795364|Procedure|Structural Image Guidance|Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
179948|NCT02795364|Procedure|Metabolic Image Guidance|Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
179949|NCT02795351|Drug|Sildenafil|Single oral administration of active or placebo one week apart
179950|NCT02795351|Drug|Placebo|
179951|NCT02795338|Procedure|brain mapping|pre-operative and intra-operative brain mapping to identify eloquent areas
179952|NCT02795325|Drug|DCR-PH1|IV infusion of DCR-PH1
179953|NCT02795325|Other|Placebo|
179954|NCT02795312|Behavioral|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
179955|NCT02795299|Drug|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
179956|NCT02795299|Drug|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
179957|NCT02795299|Drug|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
179958|NCT02795299|Drug|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
179959|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
179960|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
179961|NCT02795286|Device|Artis Haemodialysis Machine w/o ASIST Software|
179962|NCT02795273|Drug|Grass-SPIRE|
179963|NCT02795273|Drug|Placebo|
179964|NCT02795260|Biological|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
179965|NCT02795260|Biological|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
179966|NCT02795247|Procedure|Anterior Cruciate Ligament Reconstruction|
179967|NCT02795234|Other|Blood samples|
179968|NCT02795208|Procedure|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
179969|NCT02795195|Radiation|CIRT arm (3GyE per fraction)|Four dose levels (54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
179970|NCT02795182|Drug|BGB-3111|
179971|NCT02795182|Drug|BGB-A317|
179972|NCT02795156|Drug|afatinib|40 mg orally (p.o.) once daily for each 28-day cycle
179973|NCT02795156|Drug|regorafenib|160 mg p.o. once daily for the first 21-days of each 28-day
179974|NCT02795156|Drug|Cabozantinib|60 mg p.o. once daily for each 28-day cycle
179975|NCT02795143|Drug|Isotretinoin|
179976|NCT02795143|Other|Placebo|
179977|NCT02795130|Procedure|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
179978|NCT02795117|Drug|Ivermectin|
180097|NCT02794259|Device|sham-tDCS|
179981|NCT02795104|Behavioral|Educational Intervention via brochure|"Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures"
179982|NCT02795104|Behavioral|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
179983|NCT02795104|Behavioral|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
179984|NCT02795091|Other|manual cleaning|manual clean the rag and floor towel
179985|NCT02795091|Device|machine clean|machine clean the rag and floor towel
179986|NCT02795078|Drug|conservative treatment|
179987|NCT02795078|Procedure|Aneurysms clipping|
179988|NCT02795078|Procedure|Interventional embolization forAneurysms|
179989|NCT02795078|Procedure|stenting for stenosis|
179990|NCT02795065|Drug|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
179991|NCT02795065|Drug|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
179992|NCT02795052|Procedure|Intravenous BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous.
179993|NCT02795052|Procedure|Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intranasal (lower 1/3 of nasal passages).
179994|NCT02795039|Drug|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
179995|NCT02795039|Drug|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
179996|NCT02795026|Procedure|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
179997|NCT02795026|Procedure|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
179998|NCT02794987|Device|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
179999|NCT02794974|Other|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
180000|NCT02794974|Other|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
180001|NCT02794974|Other|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
180002|NCT02794961|Biological|CD22 CAR-T|Autologous CAR-T cells with average 1*10^6 cells/kg body weight
180003|NCT02794948|Other|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province
180004|NCT02794948|Dietary Supplement|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province.
180005|NCT02794935|Other|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
180006|NCT02794935|Other|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
180007|NCT02794922|Drug|Neurovit Forte|
180008|NCT02794922|Drug|Corn Starch|
180009|NCT02794909|Device|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
180010|NCT02794896|Drug|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
180011|NCT02794896|Drug|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
180012|NCT02794883|Biological|Durvalumab|Given IV
180013|NCT02794883|Other|Laboratory Biomarker Analysis|Correlative Studies
180014|NCT02794883|Procedure|Surgical Procedure|Undergo surgical tumor resection
180015|NCT02794883|Biological|Tremelimumab|Given IV
180016|NCT02794870|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
180020|NCT02794844|Drug|Genotype Guided PPI Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
180021|NCT02794818|Behavioral|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
180022|NCT02794805|Device|¹³C-Octanoate Breath Test|Octanoate Breath Test to be performed on subjects with suspected HCC
180023|NCT02794792|Drug|Ipragliflozin L-proline|Oral
180024|NCT02794792|Drug|Metformin|Oral
180025|NCT02794792|Drug|Placebo|Oral
180026|NCT02794779|Drug|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
180027|NCT02794766|Drug|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
180028|NCT02794766|Drug|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
180029|NCT02794766|Drug|Placebo|Placebo 1 gum each 12 hours for 10 days
180030|NCT02794753|Behavioral|Working memory training|
180031|NCT02794753|Behavioral|Game|
180032|NCT02794740|Drug|X0002|External Spray
180033|NCT02794740|Drug|Placebo|External Spray
180034|NCT02794727|Device|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
180035|NCT02794727|Device|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
180036|NCT02794714|Drug|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
180037|NCT02794714|Drug|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
180038|NCT02794701|Other|People with silicosis|
180039|NCT02794688|Procedure|Ductal lavage therapy|"Patient lies in supine position, with routine sterilizing and draping procedure.~Local anesthesia with 2ml lidocaine (1%) around the nipple.~Identification of 4-5 openings of the lactiferous ducts from the nipple.~Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.~Start the infusion pump with 15ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.~The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.~Repeat step 1-6 every other day for 2 weeks.~Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed."
180040|NCT02794675|Drug|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
180041|NCT02794662|Procedure|Oxygen Environment|FiO2 delivered by servo-controlled incubator
180042|NCT02794662|Procedure|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
180043|NCT02794623|Device|Tinnitus masking|Tinnitus masking via CI system
180044|NCT02794610|Drug|Tacrolimus|Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.
180045|NCT02794597|Behavioral|Intervention|a brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing.
180046|NCT02794584|Drug|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
180047|NCT02794584|Procedure|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
180048|NCT02794584|Procedure|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
180049|NCT02794571|Drug|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle in combination with MTIG7192A. Combination treatment may continue until disease progression or loss of clinical benefit.
180050|NCT02794571|Drug|MTIG7192A|Several dose levels will be evaluated for MTIG7192A administered as a single agent and in combination with atezolizumab. MTIG7192A will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent MTIG7192A may receive combination treatment with MTIG7192A plus atezolizumab. Combination treatment may continue until disease progression or loss of clinical benefit.
180051|NCT02794558|Device|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.~Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
180052|NCT02794545|Procedure|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
180053|NCT02794532|Procedure|High-flow nasal cannula|Oxygenation will be done via a high-flow nasal cannula
180054|NCT02794519|Drug|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
180098|NCT02794246|Biological|CART-19 cells|
180099|NCT02794233|Other|Impedance measurements|Refer to study description
180100|NCT02794220|Device|CN electronic cigarette 10 mg|Inhalation
180055|NCT02794519|Drug|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
180056|NCT02794519|Drug|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
180057|NCT02794506|Drug|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
180058|NCT02794506|Drug|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
180059|NCT02794493|Drug|Traditional Chinese Medicine Formula LC09|
180060|NCT02794493|Other|Placebo|
180061|NCT02794480|Device|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
180062|NCT02794480|Device|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
180063|NCT02794480|Device|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
180064|NCT02794467|Drug|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
180065|NCT02794467|Drug|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
180066|NCT02794454|Other|HeezOn Ultra-1|
180067|NCT02794454|Other|HeezOn Ultra-2|
180068|NCT02794454|Other|Placebo|
180069|NCT02794441|Drug|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
180070|NCT02794441|Other|Placebo|Matched oral solution
180071|NCT02794428|Drug|Eflornithine|Eflornithine*, 2 tablets, Oral, Daily for 18 months
180072|NCT02794428|Other|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
180073|NCT02794415|Other|Community-based exercise|"Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for ~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.~Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly."
180074|NCT02794402|Drug|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
180075|NCT02794402|Behavioral|Placebo|Placebo once weekly injections sc
180076|NCT02794389|Drug|N-acetyl cysteine|
180077|NCT02794389|Drug|Placebo|
180078|NCT02794376|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|
180079|NCT02794376|Behavioral|Waiting Period|
180080|NCT02794363|Biological|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
180081|NCT02794350|Device|Cochlear implant|
180082|NCT02794337|Radiation|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
180083|NCT02794337|Procedure|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
180084|NCT02794337|Drug|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
180085|NCT02794324|Procedure|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
180086|NCT02794324|Procedure|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.
180087|NCT02794324|Procedure|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
180088|NCT02794324|Device|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
180089|NCT02794311|Other|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
180090|NCT02794298|Device|Transcranial direct current stimulation (tDCS)|
180091|NCT02794298|Device|sham-tDCS|
180092|NCT02794285|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
180093|NCT02794285|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
180101|NCT02794220|Device|CN electronic cigarette 15 mg|Inhalation
180102|NCT02794220|Device|Nicorette Inhalator 15 mg|Inhalation
180103|NCT02794220|Other|Cigarette|Inhalation
180104|NCT02794194|Other|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
180105|NCT02794194|Other|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
180106|NCT02794168|Drug|VAS203|Treatment
180107|NCT02794168|Drug|Saline|Placebo
180108|NCT02794155|Drug|HDV Insulin Lispro|HDV Insulin Lispro: ~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
180109|NCT02794155|Drug|Insulin LISPRO|Insulin Lispro: no bound insulin
180110|NCT02794142|Procedure|renal transplantation|
180111|NCT02794129|Other|Functional Magnetic Resonance Imaging|
180112|NCT02794116|Procedure|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
180113|NCT02794116|Procedure|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
180114|NCT02794103|Device|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
180115|NCT02794090|Behavioral|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
180116|NCT02794090|Behavioral|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
180117|NCT02794077|Drug|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
180118|NCT02794064|Device|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
180119|NCT02794051|Behavioral|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
180120|NCT02794038|Device|Soberlink Cellular Device|BAC breath analyzer
180121|NCT02794038|Device|BACtrack S80 Pro|BAC breath analyzer
180122|NCT02794025|Drug|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm < HR < 100 bpm within 72 hours).~Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
180123|NCT02794025|Drug|natural saline|Control group also received natural saline via a micro pump,
180124|NCT02793999|Device|Near-Infrared Spectroscopy (NIRS)|
180125|NCT02793986|Drug|propofol|For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
180126|NCT02793986|Drug|dexmedetomidine|For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
180127|NCT02793973|Device|shoe lifts|
180128|NCT02793960|Drug|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
180129|NCT02793947|Drug|Ropivacaine|400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
180130|NCT02793947|Drug|Epinephrine|0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
180131|NCT02793947|Drug|Morphine|5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
180132|NCT02793947|Drug|0.9% sodium chloride solution|36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
180222|NCT02793323|Other|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
180223|NCT02793323|Other|IV placebo|100 ml IV saline
180440|NCT02791737|Other|Questionnaire Administration|Ancillary studies
180133|NCT02793934|Other|Scales|"For stroke patients there are used scales:~Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia~For patients after THR:~The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
180134|NCT02793934|Other|New model of rehabilitation|
180135|NCT02793934|Other|Old model of rehabilitation|
180136|NCT02793934|Other|ICF reader|
180137|NCT02793921|Behavioral|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise, monitored on-site. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety.
180138|NCT02793908|Drug|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
180139|NCT02793908|Drug|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
180140|NCT02793895|Device|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
180141|NCT02793895|Other|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
180142|NCT02793882|Drug|18F-Fluorocholine PET/CT|
180143|NCT02793856|Drug|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
180144|NCT02793856|Other|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
180145|NCT02793843|Drug|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
180146|NCT02793843|Drug|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
180147|NCT02793843|Other|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
180148|NCT02793830|Other|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application—BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
180149|NCT02793830|Other|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
180150|NCT02793817|Drug|KPI-121 1% Ophthalmic Suspension dosed BID|
180151|NCT02793817|Drug|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
180152|NCT02793804|Device|Oraquick (made in Thailand)|
180153|NCT02793791|Procedure|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
180154|NCT02793778|Drug|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
180155|NCT02793778|Drug|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
180156|NCT02793765|Drug|Docetaxel|
180157|NCT02793765|Biological|Sipuleucel-T|
180158|NCT02793752|Other|Age|Maternal Age
180159|NCT02793739|Procedure|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
180160|NCT02793726|Procedure|NMR|
180191|NCT02793544|Drug|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).~Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.~Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
180161|NCT02793713|Procedure|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
180162|NCT02793687|Drug|MEXIDOL® (ethylmethylhydroxypyridine succinate)|
180163|NCT02793687|Other|Placebo|
180164|NCT02793674|Device|Fisher & Paykel high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
180165|NCT02793674|Device|Vapotherm high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
180166|NCT02793661|Device|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
180167|NCT02793661|Other|Control|Hydration protocol following ESC Guidelines 2014
180168|NCT02793648|Drug|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
180169|NCT02793648|Drug|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
180170|NCT02793648|Drug|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
180171|NCT02793635|Device|Indego Powered Exoskeleton|Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
180172|NCT02793622|Drug|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
180173|NCT02793622|Drug|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
180174|NCT02793609|Other|Intervention is to let patient to go home.|Intervention is to let patient to go home.
180175|NCT02793609|Other|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
180176|NCT02793596|Other|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
180177|NCT02793583|Drug|TGR-1202 + Ublituximab|
180178|NCT02793583|Drug|TGR-1202|
180179|NCT02793583|Drug|TGR-1202 + Ublituximab + Bendamustine|
180180|NCT02793570|Other|observational|
180181|NCT02793557|Drug|FOL-005|Intradermal injection of 50 μl solution
180182|NCT02793557|Other|Placebo|
180183|NCT02793544|Drug|Fludarabine|"Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).~The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).~creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
180184|NCT02793544|Drug|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
180185|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy on Day -1|"200 cGy TBI is administered in a single fraction on Day -1.~Radiation sources, dose rates, and shielding follow institutional practice."
180186|NCT02793544|Procedure|Infusion of non-T-cell depleted bone marrow on Day 0|"On Day 0, the harvested bone marrow is infused.~Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.~The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
180187|NCT02793544|Drug|Busulfan|"Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM*min (Perkins et al., 2012))~Busulfan dosing is based on adjusted IBW (Appendix K)"
180188|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
180189|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.~Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Hydration prior to Cy may be given according to institutional guideline.~Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
180190|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"200cGy TBI is administered in twice daily on Days -3, -2, and -1.~Radiation sources, dose rates, and shielding follow institutional practice."
180224|NCT02793323|Other|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
180225|NCT02793310|Procedure|DMEK|The intervention group will receive cornea transplantation by DMEK
180192|NCT02793544|Drug|Sirolimus|"Sirolimus dosing is based on adjusted IBW (Appendix K).~Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.~For subjects ≥ 18 years old:~A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.~For subjects < 18 years old:~A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.~Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
180193|NCT02793544|Drug|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).~An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
180194|NCT02793544|Drug|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.~Additional G-CSF may be administered as warranted."
180195|NCT02793544|Drug|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
180196|NCT02793544|Drug|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
180197|NCT02793544|Drug|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.~Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
180198|NCT02793544|Drug|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.~Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
180199|NCT02793531|Other|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
180200|NCT02793518|Behavioral|psychological tests|
180201|NCT02793505|Drug|metformin|This is not an intervention but an observed exposure.
180202|NCT02793505|Drug|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
180203|NCT02793492|Device|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
180204|NCT02793466|Drug|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
180205|NCT02793453|Other|periodontal smears|
180206|NCT02793440|Other|cortivazol treatment|
180207|NCT02793440|Other|lumbar traction|
180208|NCT02793427|Biological|blood sample collection|
180209|NCT02793401|Device|Hıgh İntensity Laser (HILT)|HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
180210|NCT02793401|Device|Ultrasound|BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
180211|NCT02793401|Device|Hotpack|All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
180212|NCT02793401|Device|Transcutaneous electrical nerve stimulation|All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
180213|NCT02793401|Other|Therapeutic exercises|All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
180214|NCT02793401|Other|Balneotherapy|All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
180215|NCT02793388|Drug|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
180216|NCT02793388|Drug|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
180217|NCT02793375|Drug|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
180218|NCT02793375|Drug|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, and the day after surgery, with pain scores and amount of opioid pain medication required measured postoperatively.
180219|NCT02793349|Device|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
180220|NCT02793323|Other|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
180221|NCT02793323|Other|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
180226|NCT02793310|Procedure|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
180227|NCT02793297|Other|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
180228|NCT02793297|Other|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
180229|NCT02793297|Other|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
180230|NCT02793284|Radiation|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
180231|NCT02793271|Behavioral|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
180232|NCT02793271|Behavioral|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
180233|NCT02793258|Device|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.~Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
180234|NCT02793245|Other|Questionnaire|Questionnaire on their main characteristics : age, gender, height, weight, smoking
180235|NCT02793245|Other|Simplified pulmonary function test|
180236|NCT02793232|Drug|PF-06751979 single dose|PF-06751979 administered as a single dose suspension in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 200 mg, 400 mg, 700 mg, 200 mg fed (these doses are subject to change based on emerging data).
180237|NCT02793232|Drug|Placebo single dose|Matched Placebo suspension administered as single dose
180238|NCT02793232|Drug|PF-06751979 multiple ascending dose|PF-06751979 suspension administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are mg, 100 mg, 200 mg, 340 mg (these are subject to change based on emerging data).
180239|NCT02793232|Drug|Placebo multiple ascending dose|Matched placebo suspension administered daily for 14 consecutive days.
180240|NCT02793232|Drug|PF-06751979 multiple dose|PF-06751979 suspension administered daily for 14 consecutive days. The planned dose level is 340 mg (this is subject to change based on emerging data).
180241|NCT02793232|Drug|Placebo multiple elderly dose|Multiple dose administration to Healthy Elderly Subjects (Placebo)
180242|NCT02793219|Biological|Sipuleucel-T|
180243|NCT02793219|Drug|Docetaxel|
180244|NCT02793206|Device|Imaging|
180245|NCT02793193|Dietary Supplement|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
180246|NCT02793193|Dietary Supplement|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
180247|NCT02793193|Drug|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
180248|NCT02793193|Dietary Supplement|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
180249|NCT02793167|Device|AKI alert|
180250|NCT02793154|Drug|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate >=6 hours apart)
180251|NCT02793154|Drug|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
180252|NCT02793141|Other|No intervention|No intervention will be administered
180253|NCT02793128|Drug|MitoGel™ instillations|Treatment with MitoGel™ once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate CR will be treated with MitoGel™ once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
180254|NCT02793115|Behavioral|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
180255|NCT02793115|Behavioral|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
180256|NCT02793115|Behavioral|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
180436|NCT02791737|Behavioral|Exercise Intervention|Complete individualized exercise program
180257|NCT02793115|Behavioral|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
180258|NCT02793115|Behavioral|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
180259|NCT02793102|Other|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
180260|NCT02793102|Other|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
180261|NCT02793102|Other|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
180262|NCT02793089|Other|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
180263|NCT02793076|Other|Bollywood Dance|8 week Bollywood Dance Program
180264|NCT02793063|Other|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
180265|NCT02793050|Drug|Trabectedin|Collection of data on the clinical use of Trabectedin
180266|NCT02793037|Device|Zirconia resin bonded bridge|
180267|NCT02793024|Behavioral|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
180268|NCT02793011|Drug|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
180269|NCT02793011|Drug|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
180270|NCT02792998|Drug|IW-1701|IW-1701 Tablet
180271|NCT02792998|Drug|Placebo|Matching Placebo Tablet
180272|NCT02792985|Behavioral|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.~An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
180273|NCT02792985|Behavioral|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.~Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
180274|NCT02792972|Other|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
180275|NCT02792972|Other|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
180276|NCT02792959|Device|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
180277|NCT02792959|Device|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
180278|NCT02792946|Drug|Acebrophylline|
180279|NCT02792933|Procedure|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
180280|NCT02792933|Procedure|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
180281|NCT02792920|Device|CoCr-EES|
180282|NCT02792907|Device|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.~Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
180437|NCT02791737|Other|Laboratory Biomarker Analysis|Correlative studies
180283|NCT02792894|Behavioral|Family networks program|Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
180284|NCT02792881|Procedure|Laparoscopic total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
180285|NCT02792868|Other|24 h urines analyses|patient collects urines during 24h
180286|NCT02792855|Device|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
180287|NCT02792855|Device|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
180288|NCT02792842|Drug|ART-123 (High Frequency)|intravenous drip infusion
180289|NCT02792842|Drug|ART-123 (Low Frequency)|intravenous drip infusion
180290|NCT02792842|Drug|Placebo|intravenous drip infusion
180291|NCT02792829|Drug|Lenvatinib|All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
180292|NCT02792816|Drug|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
180293|NCT02792803|Drug|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
180294|NCT02792803|Drug|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
180295|NCT02792803|Drug|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
180296|NCT02792777|Other|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo software for coding and analysis.
180297|NCT02792777|Other|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:~Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.~Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.~Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.~Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
180298|NCT02792751|Device|Bispectral Index Monitorisation (BIS)|Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients
180299|NCT02792751|Other|Ramsey Sedation Scale|Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
180300|NCT02792738|Behavioral|hypnosis|
180301|NCT02792725|Drug|Abemaciclib|Administered orally
180302|NCT02792712|Drug|Ticagrelor|Ticagrelor 180 mg LD，then 90 mg BID
180303|NCT02792712|Drug|Clopidogrel|Clopidogrel 300 mg LD，then 75 mg QD
180304|NCT02792699|Drug|ABP 798|Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
180305|NCT02792699|Drug|Rituximab (US)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
180306|NCT02792699|Drug|Rituximab (EU)|Supplied as a 10 mg/mL liquid concentrate for IV administration.
180307|NCT02792686|Drug|ABX464|Single Administration
180308|NCT02792673|Other|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
180309|NCT02792673|Other|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
180310|NCT02792673|Other|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
180311|NCT02792673|Device|Labotect embryo transfer catheter|
180312|NCT02792660|Device|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
180313|NCT02792647|Drug|Placebo|Administered orally
180314|NCT02792647|Drug|IX-01|Administered orally
180315|NCT02792634|Procedure|Sleeve-Gastrectomy, Roux en Y gastric bypass|
180316|NCT02792621|Dietary Supplement|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
180317|NCT02792621|Dietary Supplement|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
180318|NCT02792608|Behavioral|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
180319|NCT02792595|Other|Negative Control|Untreated area
180320|NCT02792595|Other|Positive Control|High SPF Standard P3/SPF 15
180321|NCT02792595|Other|Test Product A|Yosemite Falls (Forte Day SPF upgrade) Variant A
180322|NCT02792595|Other|Test Product B|Yosemite Falls (Forte Day SPF upgrade) Variant B
180323|NCT02792595|Other|Test Product C|Yosemite Falls (Forte Day SPF upgrade) Variant C
180324|NCT02792595|Other|Test Product D|Yosemite Falls (Forte Day SPF upgrade) Variant D
180325|NCT02792595|Other|Test Product E|Yosemite Falls (Forte Day SPF upgrade) Variant E
180326|NCT02792595|Other|Test Product F|Yosemite Falls (Forte Day SPF upgrade) Variant F
180327|NCT02792595|Other|Test Product G|Yosemite Falls (Forte Day SPF upgrade) Variant G
180328|NCT02792595|Other|Test Product H|Yosemite Falls (Forte Day SPF upgrade) Variant H
180329|NCT02792582|Radiation|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
180330|NCT02792582|Procedure|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
180331|NCT02792569|Procedure|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
180332|NCT02792556|Device|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
180333|NCT02792543|Device|Entéromate™|Chyme reinfusion (the experimental treatment) consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
180334|NCT02792543|Drug|parenteral nutrition|Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
180335|NCT02792530|Other|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
180336|NCT02792517|Drug|Erenumab|A single dose of erenumab administered in the abdomen.
180337|NCT02792517|Drug|Ethynil Estradiol/Norgestimate Oral Contraceptive|Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
180338|NCT02792491|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
180339|NCT02792465|Drug|CFI-402257|
180340|NCT02792426|Drug|Research ENDS S-TA-U001|
180341|NCT02792426|Drug|Nicorette Inhalator|
180342|NCT02792413|Drug|Denosumab|
180343|NCT02792413|Drug|NaCl (placebo)|
180344|NCT02792400|Drug|LY2403021|Glucagon receptor antagonist
180345|NCT02792400|Drug|LY2403021 placebo|
180346|NCT02792400|Procedure|Standardised liquid meal|
180347|NCT02792400|Drug|Linagliptin|DPP-4-inhibitor
180348|NCT02792400|Drug|Linagliptin placebo|
180349|NCT02792400|Drug|Empagliflozin|SGLT2-inhibitor
180350|NCT02792400|Drug|Empagliflozin placebo|
180351|NCT02792387|Other|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
180352|NCT02792374|Other|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
180353|NCT02792361|Procedure|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
180354|NCT02792348|Other|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
180355|NCT02792335|Drug|apixaban|
180356|NCT02792335|Drug|dabigatran|
180357|NCT02792335|Drug|rivaroxaban|
180358|NCT02792335|Drug|warfarin|
180359|NCT02792322|Device|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
180360|NCT02792309|Behavioral|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
180361|NCT02792296|Other|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
180362|NCT02792283|Biological|whole blood collection|
180363|NCT02792270|Other|Caloric Restriction Diet|"A nutritional supplement called Scandishake (Nutridrinks, Perivale, UK) will be used for 3 days before surgery.~- Scandishake will be mixed with 8 oz of whole fat cow milk, whole fat lactaid milk, almond milk or soy milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is: 45% fat, 46% carbohydrate, and 8% protein."
180364|NCT02792257|Drug|Dronabinol (Marinol®)|5mg -10mg daily dose
180365|NCT02792257|Drug|Placebo|Daily dose
180438|NCT02791737|Procedure|Physical Therapy|Complete individualized exercise program
180366|NCT02792231|Drug|Ofatumumab subcutaneous injection|Patients randomized to the ofatumumab arm will receive subcutaneous injections of ofatumumab every 4 weeks
180367|NCT02792231|Drug|Placebo orally matching to teriflunomide|Placebo orally, matching in appearance to teriflunomide, administered once daily
180368|NCT02792231|Drug|Teriflunomide orally|Patients randomized to the teriflunomide arm will take teriflunomide orally once daily
180369|NCT02792231|Drug|Placebo subcutaneous injection matching to ofatumumab|Placebo-containing syringes, matching in appearance to syringes containing ofatumumab, administered every 4 weeks
180370|NCT02792218|Drug|Ofatumumab subcutaneous injection|Patients randomized to the ofatumumab arm will receive subcutaneous injections of ofatumumab every 4 weeks
180371|NCT02792218|Drug|Placebo orally matching to teriflunomide|Placebo orally, matching in appearance to teriflunomide, administered once daily
180372|NCT02792218|Drug|Teriflunomide orally|Patients randomized to the teriflunomide arm will take teriflunomide orally once daily
180373|NCT02792218|Drug|Placebo subcutanous injection matching to ofatumumab|Placebo-containing syringes, matching in appearance to syringes containing ofatumumab, administered every 4 weeks
180374|NCT02792205|Other|Non interventional study|no intervention
180375|NCT02792192|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
180376|NCT02792192|Biological|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
180377|NCT02792179|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of [18F]RO6958948 injected will be less than or equal to (</=) 10 micrograms (µg), injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie [mCi]).
180378|NCT02792166|Procedure|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
180379|NCT02792166|Procedure|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
180380|NCT02792153|Drug|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
180381|NCT02792140|Drug|Naltrexone|one week
180382|NCT02792140|Other|Placebo|one week
180383|NCT02792127|Behavioral|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
180384|NCT02792114|Drug|Cyclophosphamide|
180385|NCT02792114|Biological|Mesothelin-targeted T cells|
180386|NCT02792114|Drug|AP1903|
180387|NCT02792088|Drug|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
180388|NCT02792088|Drug|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
180389|NCT02792075|Other|5-year Follow-up|
180390|NCT02792062|Drug|TAK-385 40 mg|TAK-385 40 mg tablet
180391|NCT02792049|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
180392|NCT02792049|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
180393|NCT02792036|Drug|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
180394|NCT02792036|Drug|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
180395|NCT02792036|Procedure|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
180396|NCT02792036|Procedure|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
180397|NCT02792023|Other|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
180398|NCT02792023|Device|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
180399|NCT02792023|Device|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
180400|NCT02792010|Device|Hip cartilage MRI|Hip cartilage MRI
180401|NCT02791997|Other|Neuropsychological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
180402|NCT02791997|Other|Neurophysiological tests|Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
180403|NCT02791984|Device|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.~Measure of peak velocity before and after the fluid challenge"
180439|NCT02791737|Other|Quality-of-Life Assessment|Ancillary studies
180404|NCT02791971|Behavioral|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:~Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.~Printed materials for recipients to keep and/or share with friends.~Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.~Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
180405|NCT02791971|Behavioral|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
180406|NCT02791958|Drug|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
180407|NCT02791958|Drug|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
180408|NCT02791958|Drug|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
180409|NCT02791945|Behavioral|Medical Management Counseling|Brief alcohol counseling
180410|NCT02791945|Drug|N-acetylcysteine|Experimental supplement
180411|NCT02791945|Drug|Placebo|Placebo comparator
180412|NCT02791932|Behavioral|Exercise|See description above.
180413|NCT02791919|Drug|Cytarabine|Given IV or IT
180414|NCT02791919|Biological|Filgrastim|Given IV or SC
180415|NCT02791919|Drug|Fludarabine Phosphate|Given IV
180416|NCT02791919|Other|Laboratory Biomarker Analysis|Correlative studies
180417|NCT02791919|Other|Pharmacological Study|Correlative studies
180418|NCT02791919|Drug|WEE1 Inhibitor AZD1775|Given PO
180419|NCT02791906|Drug|ISMN|
180420|NCT02791906|Dietary Supplement|Vitamin C|
180421|NCT02791893|Device|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
180422|NCT02791893|Device|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
180423|NCT02791880|Procedure|Transcatheter Aortic Valve Replacement|The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
180424|NCT02791867|Drug|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
180425|NCT02791841|Behavioral|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
180426|NCT02791841|Behavioral|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).~AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
180427|NCT02791841|Behavioral|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
180428|NCT02791815|Drug|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
180429|NCT02791815|Drug|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
180430|NCT02791789|Other|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
180431|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.~Collection of patient's radiographic and clinical parameters"
180432|NCT02791763|Drug|1 to 4 mg tablets of GSK1278863|7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
180433|NCT02791763|Drug|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
180434|NCT02791763|Drug|Epoetin beta pegol|An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
180435|NCT02791750|Other|questionnary of quality of life|
180441|NCT02791724|Behavioral|Desiconnect|Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
180442|NCT02791724|Other|CAU|Care as Usual
180443|NCT02791711|Other|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological markers, questionary of quality of use of HFNC by the physician, questionary of evaluation of adverse events with HFNC
180444|NCT02791685|Behavioral|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
180445|NCT02791685|Behavioral|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
180446|NCT02791685|Behavioral|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
180447|NCT02791672|Behavioral|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
180448|NCT02791659|Radiation|Automatic beam adjustment function|The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
180449|NCT02791646|Behavioral|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
180450|NCT02791646|Behavioral|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
180451|NCT02791633|Other|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
180452|NCT02791620|Device|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
180453|NCT02791594|Drug|Pembrolizumab|
180454|NCT02791581|Diagnostic Test|Cardiac MRI|"Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months."
180455|NCT02791568|Procedure|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
180456|NCT02791568|Procedure|MRI Scan|MR imaging will take approximately 30 minutes.
180457|NCT02791568|Drug|Ferumoxytol|A subset of subjects will complete MRI imaging with ferumoxytol as a contrast agent at the 24-28 week visit. A nurse will administer ferumoxytol in a hospital triage with pulse and blood pressure monitoring and fetal heart monitoring. The pharmacy will prepare the infusion and deliver to triage. Subjects will arrive at the obstetric triage unit for ferumoxytol injection three days prior to their scheduled ferumoxytol MRI study. In the triage, the nurse will obtain baseline vital signs and fetal heart rate. The IV Ferumoxytol infusion will be 30 minutes and atients will be monitored at 5 to 15-minute intervals. Three days after the ferumoxytol infusion, at 24-26 weeks gestation, subjects will have blood/urine collected, undergo a 30 minute ultrasound, a 30 minute MRI, an adverse event review, and medical record review. The MRI scanning procedure will be conducted at WIMR and will last approximately 30-60 minutes.
180458|NCT02791529|Procedure|Electrocautery|Skin incision performed by electrocautery
180459|NCT02791529|Procedure|Scalpel|Skin incision performed by scalpel
180460|NCT02791516|Drug|Romosozumab|Administered by subcutaneous injection once a month (QM)
180461|NCT02791516|Drug|Placebo|Administered by subcutaneous injections once a month
180462|NCT02791503|Procedure|Irreversible electroporation (IRE)|IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
180463|NCT02791503|Procedure|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
180464|NCT02791490|Drug|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
180465|NCT02791490|Drug|Placebo|Oral tablet, once daily at approximately the same time each day
180466|NCT02791490|Drug|Metformin IR|All participants will take Met-IR as background medication. Initially, they will take 1 x 500 mg tablet Met-IR b.i.d. (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR b.i.d. (2000 mg/day).
180467|NCT02791477|Device|Attune FB PS knee arthroplasty|
180468|NCT02791464|Behavioral|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
180469|NCT02791451|Device|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
180470|NCT02791438|Drug|TAK-536 2.5 mg|TAK-536 2.5 mg granules + TAK-536 5, 10, 20 mg tablets
180471|NCT02791438|Drug|TAK-536 5 mg|TAK-536 5, 10, 20, 40 mg tablets
180472|NCT02791425|Device|Brain Computer Interface (BCI) device|A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
180473|NCT02791425|Other|Communication picture board|The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
180474|NCT02791412|Procedure|percutaneous coronary intervention or coronary-artery bypass graft|
180475|NCT02791399|Behavioral|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
180476|NCT02791373|Drug|Vinorelbine|Mobilisation Chemotherapy
180477|NCT02791373|Drug|Gemcitabine|Mobilisation Chemotherapy
180478|NCT02791360|Other|Brain MRI|
180479|NCT02791347|Other|Nutrition Intervention|
180480|NCT02791334|Drug|LY3300054|Administered IV
180481|NCT02791334|Drug|Ramucirumab|Administered IV
180482|NCT02791334|Drug|Abemaciclib|Administered orally
180483|NCT02791334|Drug|Merestinib|Administered orally
180484|NCT02791334|Drug|LY3321367|Administered IV
180485|NCT02791321|Other|ADS severity|Evaluation of the ADS severity with the CARS scale
180486|NCT02791321|Other|Adaptative and intellectual functioning|Evaluation with IQ and Vineland II scale
180487|NCT02791321|Other|Psychiatric and somatic comorbidities|Evaluation with the Reiss, DSQIID and CIRS Scales
180488|NCT02791308|Drug|Pimecrolimus Cream 1% (Valeant)|
180489|NCT02791308|Drug|Vehicle cream|
180490|NCT02791308|Drug|Pimecrolimus Cream, 1%|
180491|NCT02791295|Other|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
180492|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
180493|NCT02791269|Drug|Peginterferon alfa-2a|180 mcg SC injection QW for 48 weeks.
180494|NCT02791256|Drug|Ribavirin|
180495|NCT02791256|Drug|peginterferon alfa-2a|
180496|NCT02791243|Drug|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
180497|NCT02791243|Drug|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
180498|NCT02791243|Drug|Negative Control|0.9% aqueous NaCl
180499|NCT02791230|Drug|Tafamidis|Soft gel capsules administered once a day for 60 months
180500|NCT02791204|Device|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
180501|NCT02791204|Device|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
180502|NCT02791191|Drug|LY3202626|Administered orally
180503|NCT02791191|Drug|Placebo|Administered orally
180504|NCT02791178|Procedure|Optical coherence tomography (OCT)|Special camera to study part of your heart that was affected
180505|NCT02791178|Procedure|Index of microcirculatory resistance (IMR)|Special wire to study part of your heart that was affected
180506|NCT02791178|Other|Cardiac MRI|Special scanner if the heart to assess the damage of your heart
180507|NCT02791139|Other|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
180508|NCT02791139|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
180509|NCT02791139|Other|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
180510|NCT02791139|Other|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
180511|NCT02791139|Other|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
180512|NCT02791139|Other|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
180513|NCT02791126|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
180514|NCT02791126|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
180515|NCT02791113|Other|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
180516|NCT02791100|Behavioral|Promotion of chicken eggs|Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
180704|NCT02789774|Procedure|Posterior fusion C1-C2|Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.
180517|NCT02791087|Other|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
180518|NCT02791087|Other|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
180519|NCT02791074|Other|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
180520|NCT02791074|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
180521|NCT02791074|Other|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
180522|NCT02791061|Other|Cardiovascular Magnetic Resonance Imagine (MRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
180523|NCT02791061|Other|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
180524|NCT02791061|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
180525|NCT02791048|Behavioral|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.~This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
180526|NCT02791035|Drug|Oral administration of Ipragliflozin|
180527|NCT02791022|Device|SPYDER ECG sensor|
180528|NCT02791009|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
180529|NCT02791009|Other|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
180530|NCT02791009|Other|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
180531|NCT02791009|Other|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
180532|NCT02791009|Other|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
180533|NCT02791009|Other|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
180534|NCT02790996|Drug|Vancomycin|Vancomycin is an antibiotic used to treat a number of bacterial infections.It is recommended intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant S. aureus.
180535|NCT02790970|Device|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
180536|NCT02790970|Other|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
180537|NCT02790957|Drug|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
180538|NCT02790957|Drug|Placebo|Single injection of an equal volume of NaCl solution
180539|NCT02790944|Genetic|Multi-gene Next Generation Sequencing Panel|Participants will have genetic testing
180540|NCT02790931|Other|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
180541|NCT02790918|Other|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
180542|NCT02790918|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
180543|NCT02790892|Behavioral|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
180544|NCT02790879|Other|Transition pediatric - adult|
180545|NCT02790866|Behavioral|LuCaS Decision Aid|Web-based Lung Cancer Screening Decision Aid
180546|NCT02790866|Behavioral|NCI Website|NCI Website on Lung Cancer Screening
180547|NCT02790853|Procedure|Biopsy|Undergo brush biopsy and incisional biopsy
180548|NCT02790853|Procedure|Fluorescence Imaging|Undergo PS2.1/PS3 imaging
180549|NCT02790853|Procedure|High-Resolution Microendoscopy|Undergo HRME imaging
180550|NCT02790853|Drug|Proflavine Hemisulfate|Applied on mucosa
180551|NCT02790840|Drug|Omeprazole|20 mg oral capsules administered once daily for 10 days
180552|NCT02790840|Drug|Omeprazole|40 mg oral capsules administered twice daily for 10 days
180553|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
180554|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
180555|NCT02790827|Behavioral|CETA|CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.
180556|NCT02790827|Behavioral|Treatment as usual|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
180557|NCT02790814|Device|Moyo strap-on|Continous measurements
180558|NCT02790814|Device|Hand-held fetoscope|Intermittent measurements
180559|NCT02790801|Other|observation|observation
180560|NCT02790788|Drug|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
180561|NCT02790788|Drug|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
180562|NCT02790775|Drug|Anti-VEGF in quadrant 1|
180563|NCT02790775|Drug|Anti-VEGF in quadrant 2|
180564|NCT02790775|Drug|Anti-VEGF in quadrant 3|
180565|NCT02790775|Drug|Anti-VEGF in quadrant 4|
180566|NCT02790762|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
180567|NCT02790749|Procedure|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
180568|NCT02790749|Procedure|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
180569|NCT02790736|Drug|propranolol|active treatment
180570|NCT02790736|Drug|Placebo|inactive pill
180571|NCT02790723|Drug|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the Research Institute at Nationwide Children's Hospital.
180572|NCT02790710|Drug|Propanolol|Active treatment
180573|NCT02790710|Drug|Placebo|
180574|NCT02790697|Other|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
180575|NCT02790684|Drug|DS-8500a|
180576|NCT02790671|Drug|DS-8500a|DS-8500a 25mg tablet
180577|NCT02790671|Drug|Itraconazole|200mg itraconazole
180578|NCT02790658|Dietary Supplement|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
180579|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
180580|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
180581|NCT02790645|Other|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
180582|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
180583|NCT02790632|Drug|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
180584|NCT02790632|Drug|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
180585|NCT02790619|Device|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
180586|NCT02790619|Device|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
180587|NCT02790606|Device|Covera(TM) Vascular Covered Stent|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
180588|NCT02790593|Device|Juxta-Cures™|Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
180589|NCT02790593|Device|Standard Compression|Compression bandaging
180590|NCT02790593|Device|PicoPress®|Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
180591|NCT02790593|Device|Silhoutte® 3D wound imaging system|Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
180705|NCT02789774|Procedure|Rigid cervical collar|External immobilization of cervical spine in a rigid collar for 12 weeks.
180706|NCT02789761|Dietary Supplement|High-flavanol milk choocolate|
180592|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
180593|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide~Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
180594|NCT02790567|Other|HEP score|"The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.~The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia."
180595|NCT02790567|Other|4Ts score|The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
180596|NCT02790567|Other|ID-PaGIA test|The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
180597|NCT02790567|Other|HIT-Ab(PF4-H) test|The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
180598|NCT02790554|Device|Moyo strap-on|Continous monitoring
180599|NCT02790554|Device|Hand-held Doppler|Intermittent monitoring
180600|NCT02790541|Device|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
180601|NCT02790528|Drug|Atorvastatin|20mg QD
180602|NCT02790528|Drug|Placebo|Placebo drug will be administered.
180603|NCT02790515|Drug|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
180604|NCT02790515|Drug|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
180605|NCT02790515|Drug|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
180606|NCT02790515|Drug|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
180607|NCT02790515|Drug|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
180608|NCT02790515|Drug|Melphalan|Given IV prior to transplant on Days -2 and -1.
180609|NCT02790515|Drug|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
180610|NCT02790515|Drug|Rituximab|Given IV prior to transplant on Day -1.
180611|NCT02790515|Drug|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
180612|NCT02790515|Drug|Thiotepa|Given IV prior to transplant on Day -3.
180613|NCT02790515|Biological|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
180614|NCT02790515|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
180615|NCT02790515|Drug|Sirolimus|Given orally (PO) starting Day 0. The dose will be tapered off over two weeks starting on Day +42 in the absence of GVHD.
180616|NCT02790502|Device|Food Photography Application©|Group testing RFPM as method of recording plate waste
180617|NCT02790489|Dietary Supplement|Valedia|
180618|NCT02790476|Other|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
180619|NCT02790463|Behavioral|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
180620|NCT02790450|Drug|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
180621|NCT02790437|Drug|IdeS|One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.
180622|NCT02790437|Procedure|Kidney transplantation|Performed following IdeS treatment
180623|NCT02790424|Device|Imaging devices|technological adjustment tests
180624|NCT02790411|Device|Imaging devices|technological adjustment tests
180625|NCT02790411|Device|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
180707|NCT02789761|Dietary Supplement|Low-flavanol milk chocolate|
180626|NCT02790398|Behavioral|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
180627|NCT02790398|Behavioral|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
180628|NCT02790385|Device|Negative Pressure Wound Therapy|
180629|NCT02790385|Other|Standard Gauze Treatment|
180630|NCT02790372|Other|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
180631|NCT02790359|Other|Air|Group of patients who would receive air insufflation
180632|NCT02790359|Other|Carbon dioxide|Group of patients who would receive carbon dioxide insufflation
180633|NCT02790346|Procedure|arthrodesis talonavicular|
180634|NCT02790346|Procedure|tendon gestures|
180635|NCT02790333|Procedure|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
180636|NCT02790333|Procedure|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
180637|NCT02790307|Device|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
180638|NCT02790294|Device|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
180639|NCT02790281|Procedure|Blood sampling|Blood sample collected at a single visit
180640|NCT02790268|Procedure|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
180641|NCT02790255|Other|Cold air|
180642|NCT02790255|Other|Cold water|
180643|NCT02790229|Other|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
180644|NCT02790229|Other|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
180645|NCT02790216|Procedure|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
180646|NCT02790203|Drug|Celecoxib|NSAIDS
180647|NCT02790203|Drug|Placebo|Placebo
180648|NCT02790190|Other|Radiotherapy dose|
180649|NCT02790177|Drug|Hyaluronic Acid|
180650|NCT02790177|Drug|NORMAL SALINE|
180651|NCT02790164|Drug|Esmeron|Neuromuscular Blockade
180652|NCT02790164|Drug|Saline|Normal Saline
180653|NCT02790151|Behavioral|Standard Therapy|Learning and practicing Memory strategies
180654|NCT02790151|Behavioral|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
180655|NCT02790138|Drug|Vedolizumab|Vedolizumab IV infusion
180656|NCT02790138|Drug|Ciprofloxacin|Ciprofloxacin Tablets
180657|NCT02790138|Drug|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion
180658|NCT02790125|Drug|BMS-986166|
180659|NCT02790125|Drug|Placebo matching BMS-986166|
180660|NCT02790112|Other|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty."
180661|NCT02790099|Drug|Bupivacaine|Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
180662|NCT02790099|Drug|Morphine|0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
180663|NCT02790073|Drug|SNF472|SNF472 for calciphylaxis
180664|NCT02790047|Device|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
180665|NCT02790047|Other|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes~Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes~Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale < 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.~Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
180666|NCT02790047|Other|Health education|"Health education include~Knowledge of COPD disease~Smoking status and smoking cessation~Medication correctly~Self dyspnea management~Basic nutrition for COPD"
180667|NCT02790047|Other|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include~Control breathing~Pursed lip breathing (PLB)~Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique~Force expiratory technique (FET) with low to medium lung volume~Huffing or coughing"
180703|NCT02789787|Procedure|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
180668|NCT02790047|Drug|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below~Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)~Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)~Xanthine derivative (sustained release theophylline)~Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)~Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)~Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)~Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
180669|NCT02790034|Drug|Sarizotan|2 to 10 mg per day of Sarizotan followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
180670|NCT02790034|Drug|Placebo|placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
180671|NCT02790021|Procedure|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
180672|NCT02789995|Procedure|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
180673|NCT02789982|Drug|β-adrenergic blocker propranolol|
180674|NCT02789982|Behavioral|Treatment as usual|
180675|NCT02789969|Drug|Hydromorphone|Hydromorphone 15mcg/kg IV
180676|NCT02789969|Drug|Fentanyl|Fentanyl 1.5mcg/kg IV
180677|NCT02789956|Device|Internal vs. external cad cam co/cr framework|
180678|NCT02789943|Procedure|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
180679|NCT02789930|Other|"Device: Accuracy of a program and the anesthesia tape (Anästhesie-Lineal)"|Computer based comparison of the two devices based on collected patient data
180680|NCT02789917|Other|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
180681|NCT02789917|Other|Triple Therapy|"HAS-BLED-Score <3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
180682|NCT02789904|Other|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
180683|NCT02789891|Procedure|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
180684|NCT02789891|Procedure|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
180685|NCT02789878|Drug|Goserelin|Androgen Deprivation Therapy
180686|NCT02789878|Drug|Prednisone|Corticosteroid
180687|NCT02789878|Drug|Abiraterone|CYP17 inhibitor
180688|NCT02789878|Drug|Apalutamide|Androgen-receptor antagonist
180689|NCT02789865|Drug|Ertapenem, Levofloxacin and Metronidazole|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
180690|NCT02789865|Procedure|Endoscopic retrograde appendicitis therapy (ERAT)|The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
180691|NCT02789865|Procedure|Appendectomy|The patients will receive laparoscopic appendectomy according to standard routines.
180692|NCT02789852|Device|Orthosis|use orthosis
180693|NCT02789839|Procedure|Blood test|Blood test of 30mL
180694|NCT02789839|Procedure|Medullar test|Medullar test for 2-5mL and a smear
180695|NCT02789826|Procedure|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
180696|NCT02789826|Procedure|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
180697|NCT02789813|Drug|Valproic Acid|Once oral administration of 500mg before exposure therapy.
180698|NCT02789813|Drug|Placebo|Once oral administration of 500mg before exposure therapy.
180699|NCT02789813|Behavioral|Fear reactivation|Fear reactivation before exposure therapy.
180700|NCT02789813|Behavioral|No fear reactivation|No fear reactivation before exposure therapy.
180701|NCT02789800|Behavioral|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
180702|NCT02789787|Procedure|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
180708|NCT02789748|Device|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
180709|NCT02789735|Device|Active laser therapy|Laser therapy at predetermined sites
180710|NCT02789735|Device|Sham laser therapy|Sham therapy at predetermined sites
180711|NCT02789722|Other|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
180712|NCT02789722|Other|Placebo|Take 3 capsules, 3 times daily for 28 days.
180713|NCT02789709|Procedure|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
180714|NCT02789696|Other|Diagnosis of acromegaly|Biological analysis of IGF-1
180715|NCT02789683|Other|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
180716|NCT02789683|Other|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
180717|NCT02789683|Other|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
180718|NCT02789670|Other|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
180719|NCT02789657|Drug|paclitaxel|80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
180720|NCT02789657|Drug|Trastuzumab|Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
180721|NCT02789657|Drug|Pertuzumab|every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.
180722|NCT02789657|Drug|Carboplatin|AUC 2 administered weekly with no planned treatment breaks
180723|NCT02789657|Procedure|Breast surgery|breast conserving or mastectomy
180724|NCT02789657|Drug|AC|"doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles"
180725|NCT02789644|Drug|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
180726|NCT02789631|Other|assessment|
180727|NCT02789618|Other|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
180728|NCT02789618|Other|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
180729|NCT02789618|Other|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
180730|NCT02789605|Drug|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
180731|NCT02789605|Drug|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
180732|NCT02789592|Drug|Melatonin PR|For experimental treatment of RBD
180733|NCT02789592|Drug|Clonazepam|For experimental treatment of RBD
180734|NCT02789592|Drug|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
180735|NCT02789592|Drug|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
180736|NCT02789579|Drug|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
180737|NCT02789579|Drug|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
180738|NCT02789579|Drug|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
180739|NCT02789566|Drug|Primaquine|Primaquine 30 mg taken after meal in the morning.
180740|NCT02789553|Other|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
180741|NCT02789553|Other|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
180742|NCT02789527|Drug|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
180743|NCT02789527|Genetic|Genotyping|DNA sampling from a saliva sample
180744|NCT02789501|Device|4% citrate lock solution regimen|(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
180840|NCT02788760|Device|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
180889|NCT02788318|Other|Brain samples|Collected in patients died
180745|NCT02789501|Device|TauroLock lock solution regimen|After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
180746|NCT02789488|Dietary Supplement|Fenugreek seeds extract 500 mg|Furocyst one caps BID
180747|NCT02789475|Drug|Amlodipine|Amlodipine administration
180748|NCT02789475|Drug|Rosuvastatin|Rosuvastatin administration
180749|NCT02789462|Procedure|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
180750|NCT02789449|Other|assessment of DLNO and DLCO|
180751|NCT02789436|Drug|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
180752|NCT02789436|Other|Placebo lozenges|Twice daily, for 28 days
180753|NCT02789423|Procedure|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
180754|NCT02789410|Drug|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
180755|NCT02789410|Drug|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
180756|NCT02789397|Drug|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
180757|NCT02789397|Drug|Placebo Administration|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
180758|NCT02789384|Other|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.~For each patient:~Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~Blood samples will be obtained for genetic profiling and assessment of markers.~The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.~All patients should be managed according to the usual medical practices."
180759|NCT02789371|Procedure|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
180760|NCT02789371|Procedure|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
180761|NCT02789358|Other|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
180762|NCT02789358|Other|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
180763|NCT02789358|Device|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
180764|NCT02789358|Drug|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
180765|NCT02789358|Device|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
180766|NCT02789345|Drug|Ramucirumab|Administered IV
180767|NCT02789345|Drug|Necitumumab|Administered IV
180768|NCT02789345|Drug|Osimertinib|Administered orally
180769|NCT02789332|Drug|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
180770|NCT02789332|Drug|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
180771|NCT02789332|Drug|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
180772|NCT02789332|Procedure|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
180773|NCT02789332|Other|Stratification|Hormone-receptor status (HR+ vs HR-) Age < 40 years vs >= 40 years
180774|NCT02789319|Device|Blood Glucose Meter Systems|
180775|NCT02789306|Procedure|Epidemiological study on the incidence of peri-implantitis|Clinical and radiographic examination in the routine based protocol
180776|NCT02789293|Device|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
180777|NCT02789280|Behavioral|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
180778|NCT02789280|Other|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
180779|NCT02789267|Other|Regular dietary support|Systematic and regular dietary support after radiotherapy
180841|NCT02788747|Drug|4 mg elamipretide|Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
180842|NCT02788747|Drug|40 mg elamipretide|Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
180890|NCT02788318|Other|Skin samples|Collected in patients died
180780|NCT02789254|Biological|FLYSYN|"Cohort 1:~Patient 1-3: FLYSYN 0.5 mg/m² body surface area (BSA) day 1~Cohort 2:~Patient 4-6: FLYSYN 0.5 mg/m² body surface area (BSA) day 1 FLYSYN 1.0 mg/m² BSA day 2~Cohort 3:~Patient 7-9: FLYSYN 0.5 mg/m² body surface area (BSA) day 1, FLYSYN 4.5 mg/m² BSA day 2~Cohort 4:~Patient 10-12 and 13-28*: FLYSYN 0.5 mg/m² body surface area (BSA) day 1, FLYSYN 14.5** mg/m² BSA day 2 * If the maximum tolerated dose (MTD) is reached in Cohorts 1-3, the respective cohort will be expanded by additional 16 patients for assessment of efficacy.~** The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
180781|NCT02789241|Biological|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
180782|NCT02789241|Other|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
180783|NCT02789228|Biological|Tumor associated antigen lymphocytes (TAA-CTL)|Pediatric and adult patients who have high-risk solid tumors with known positivity for one or more Tumor Antigen Associated (TAA) (WT1, PRAME and/or survivin) will be eligible to receive Tumor Antigen Associated Cytotoxic T Lymphocytes (TAA CTL). The goal of this cell infusion will be to initiate an immune response against solid tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
180784|NCT02789215|Behavioral|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
180785|NCT02789202|Other|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
180786|NCT02789202|Other|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
180787|NCT02789189|Drug|nedaplatin and gemcitabine|
180788|NCT02789176|Other|Surveys|Regarding development, epilepsy, and family impact
180789|NCT02789176|Other|EEG|
180790|NCT02789163|Device|Ultrasound|breast ultrasound; hand held and automated volume breast scanner
180791|NCT02789150|Drug|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
180792|NCT02789150|Drug|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
180793|NCT02789124|Other|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
180794|NCT02789111|Drug|Alvimopan|Alviimopan 12 mg twice daily up to 15 doses
180795|NCT02789111|Drug|Placebo|Placebo twice daily up to 15 doses
180796|NCT02789098|Other|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
180797|NCT02789085|Device|ULF TENS stimulation|
180798|NCT02789072|Other|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).~On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
180799|NCT02789059|Other|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
180800|NCT02789046|Procedure|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
180801|NCT02789033|Drug|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
180802|NCT02789033|Drug|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
180803|NCT02789033|Drug|Placebo|placebo
180804|NCT02789020|Drug|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
180805|NCT02789020|Other|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
180806|NCT02789020|Device|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
180807|NCT02789020|Device|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
180808|NCT02789020|Other|Physical Function Performance Test|This test will be performed at baseline and one year.
180843|NCT02788747|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
180884|NCT02788370|Other|Constant work load cycling test|"Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include~sever breathlessness (>5 /10 score of modified Borg scale)~leg fatigue (can not maintain speed between 50 to 60 rpm)~Hear rate (HR) >80 % age-predicted maximum HR~Exercise time up to 10 minutes~Other symptom that stated by American thoracic Society(2002)"
180809|NCT02789007|Other|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).~Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
180810|NCT02788994|Device|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.~The system has been designed to allow:~stable fracture synthesis for fast rehabilitation and early mobilization~an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
180811|NCT02788994|Device|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.~This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
180812|NCT02788981|Drug|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
180813|NCT02788981|Other|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
180814|NCT02788981|Drug|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
180815|NCT02788968|Other|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
180816|NCT02788955|Behavioral|Dietary counselling|
180817|NCT02788955|Other|Dietary Protein|
180818|NCT02788942|Procedure|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
180819|NCT02788929|Device|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
180820|NCT02788916|Other|No Intervention|
180821|NCT02788903|Other|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
180822|NCT02788890|Procedure|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
180823|NCT02788890|Procedure|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
180824|NCT02788890|Procedure|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
180825|NCT02788877|Drug|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
180826|NCT02788864|Drug|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
180827|NCT02788864|Drug|Placebo|"Stage 1: Parasite Clearance~Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days~Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days~Stage 2: Forest trip~• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
180828|NCT02788851|Drug|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
180829|NCT02788851|Behavioral|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
180830|NCT02788825|Procedure|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
180831|NCT02788812|Procedure|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
180832|NCT02788812|Procedure|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
180833|NCT02788799|Other|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
180834|NCT02788799|Other|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
180835|NCT02788786|Drug|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
180836|NCT02788786|Drug|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
180837|NCT02788786|Drug|Salt and Water|salt and water mix oral rinse
180838|NCT02788773|Drug|Durvalumab|
180839|NCT02788773|Drug|Tremelimumab|
180885|NCT02788357|Drug|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
180844|NCT02788734|Other|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
180845|NCT02788721|Drug|GLPG2451 single dose|GLPG2451 oral suspension, single ascending doses, daily
180846|NCT02788721|Drug|Placebo|Placebo, oral suspension, daily
180847|NCT02788708|Drug|Lenvatinib Mesylate|Given PO
180848|NCT02788708|Drug|Paclitaxel|Given IV
180849|NCT02788708|Other|Pharmacological Study|Correlative studies
180850|NCT02788682|Genetic|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
180851|NCT02788656|Device|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
180852|NCT02788656|Drug|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
180853|NCT02788656|Drug|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
180854|NCT02788656|Drug|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
180855|NCT02788643|Biological|biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection|
180856|NCT02788630|Behavioral|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
180857|NCT02788617|Device|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
180858|NCT02788604|Other|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
180859|NCT02788604|Other|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
180860|NCT02788591|Drug|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
180861|NCT02788591|Drug|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
180862|NCT02788552|Drug|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
180863|NCT02788539|Behavioral|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
180864|NCT02788526|Procedure|Adjuvant TACE|1~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
180865|NCT02788526|Procedure|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
180866|NCT02788513|Drug|BI 425809 dose 1|
180867|NCT02788513|Drug|BI 425809 dose 2|
180868|NCT02788513|Drug|BI 425809 dose 3|
180869|NCT02788513|Drug|BI 425809 dose 4|
180870|NCT02788513|Drug|Placebo|
180871|NCT02788500|Other|Incidence of sports-related injuries and illnesses|The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
180872|NCT02788487|Device|Tongue retaining device|Tongue retaining device is used for 3 weeks
180873|NCT02788487|Device|CPAP|CPAP is used for 3 weeks
180874|NCT02788474|Drug|nintedanib|
180875|NCT02788474|Drug|placebo|
180876|NCT02788461|Radiation|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
180877|NCT02788461|Radiation|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
180878|NCT02788448|Device|VIVASURE CLOSURE DEVICE|Large hole closure device
180879|NCT02788435|Behavioral|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
180880|NCT02788422|Other|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
180881|NCT02788422|Other|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
180882|NCT02788409|Other|Not applicable for study|Provide external perspective on background second primary cancer incidence rates for REASSURE study.
180883|NCT02788370|Device|a conical positive expiratory pressure device|The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
180886|NCT02788357|Drug|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
180887|NCT02788344|Other|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
180891|NCT02788305|Drug|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
180892|NCT02788292|Drug|Acetylcysteine|See arm description
180893|NCT02788279|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
180894|NCT02788279|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
180895|NCT02788279|Drug|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
180896|NCT02788266|Procedure|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
180897|NCT02788266|Procedure|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
180898|NCT02788266|Procedure|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
180899|NCT02788240|Drug|Peg GCSF|
180900|NCT02788240|Biological|20% Albumin|
180901|NCT02788240|Dietary Supplement|Nutrition|
180902|NCT02788240|Other|Bowel wash|
180903|NCT02788240|Drug|Terlipressin 1- 4mg,if indicated|
180904|NCT02788240|Drug|Meropenem or Imepenem, if indicated|
180905|NCT02788240|Drug|Placebo|
180906|NCT02788227|Biological|rVSV-Zebov GP vaccine|initial vaccination for all participants, one-to-one randomization at Month 18 to receive booster vaccination or no booster.
180907|NCT02788201|Drug|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocinm, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
180908|NCT02788201|Other|COXEN|The COXEN algorithm will be used to determine the next best therapy from among 75 FDA approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
180909|NCT02788188|Biological|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
180910|NCT02788188|Other|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
180911|NCT02788175|Biological|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
180912|NCT02788162|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - X71-144)
180913|NCT02788149|Device|Ultrasound Exam|Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
180914|NCT02788149|Device|Polysomnography|"Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as >50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.~Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:~Non-OSA : < 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr."
180915|NCT02788136|Drug|human chorionic gonadotropin|At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
180916|NCT02788123|Drug|bismuth tripotassium dicitrate|oral
180917|NCT02788123|Drug|pantoprazole|oral
180918|NCT02788110|Other|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
180919|NCT02788110|Other|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
181396|NCT02784639|Other|Plasma Analysis of circulating cell free DNA|
180920|NCT02788097|Procedure|Progesterone supplementation|artificial frozen embryo transfers
180921|NCT02788071|Dietary Supplement|FMT capsules|25 capsules per day for 12 days
180922|NCT02788071|Dietary Supplement|FMT placebo|25 capsules per day for 12 days
180923|NCT02788058|Drug|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
180924|NCT02788058|Radiation|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
180925|NCT02788045|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
180926|NCT02788045|Biological|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5mL injection administered intramuscularly.
180927|NCT02788045|Biological|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
180928|NCT02788045|Drug|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
180929|NCT02788032|Other|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
180930|NCT02788019|Drug|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
180931|NCT02788006|Drug|Regorafenib 160 mg|
180932|NCT02787993|Behavioral|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
180933|NCT02787980|Biological|Additional taking blood|Additional blood collection of 1 ml during the biological workup usually done.
180934|NCT02787967|Drug|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
180935|NCT02787967|Drug|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
180936|NCT02787954|Procedure|TACE|Procedure for giving chemotherapy directly to tumor cells.
180937|NCT02787954|Procedure|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
180938|NCT02787954|Procedure|MWA|Using heat to kill tumor cells.
180939|NCT02787954|Procedure|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
180940|NCT02787941|Behavioral|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.~Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
180941|NCT02787928|Drug|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
180942|NCT02787915|Biological|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
180943|NCT02787902|Behavioral|Communication|Behavioral weight management program adapted for mother-daughter dyads with communication skills training
180944|NCT02787902|Behavioral|Standard|Behavioral weight management program adapted for mother-daughter dyads without communication skills training
180945|NCT02787889|Other|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
180946|NCT02787889|Other|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
180947|NCT02787876|Drug|Pegteograstim|
180948|NCT02787863|Biological|Prevenar 13|Conjugate 13 serotype pneumococcal vaccine
180949|NCT02787863|Biological|Immunovac|Vaccine against Staphylococcus aureus, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli.
180950|NCT02787863|Drug|Polioxidonium|Polioxidonium. Immunomodulatory drug. Increases the body's resistance against local and generalized infections. The basis of the mechanism of immunomodulating effect of Polyoxidonium is a direct impact on faguoqitirute cells and natural killer cells, and stimulation of antibody production. Active ingredient: anoxemia bromide (polyoxidonium).
180951|NCT02787863|Biological|Pneumo-23|Polysaccharide 23-valent pneumococcal vaccine.
180952|NCT02787850|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
180953|NCT02787824|Drug|Iron Sucrose Supplement|
180954|NCT02787811|Device|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
180955|NCT02787798|Drug|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
180956|NCT02787798|Drug|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
180957|NCT02787798|Procedure|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
180958|NCT02787785|Device|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
180959|NCT02787772|Procedure|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
180960|NCT02787759|Other|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
180961|NCT02787759|Other|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
180962|NCT02787746|Drug|Donepezil|Eligible patients is treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d，the patient can reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who cannot endure the 10mg/d titration of 2nd time and then back to 5mg/d or discontinuance of Aricept® should be regarded as to quit the study. There will be a visting at week 0, the end of week 4 and the end of week 20 ,respectively.
180963|NCT02787733|Dietary Supplement|Citrus flavonoid|Daily dose of 500mg divided over two capsules
180964|NCT02787733|Dietary Supplement|Placebo|Daily dose of 500mg divided over two capsules
180965|NCT02787720|Other|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
180966|NCT02787720|Other|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
180967|NCT02787707|Drug|Persumac|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
180968|NCT02787707|Drug|lactose|2.7 grams Lactose every 8 hour
180969|NCT02787694|Other|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
180970|NCT02787694|Device|treadmill|
180971|NCT02787681|Device|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
180972|NCT02787668|Other|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO <10%; fat >65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
180973|NCT02787668|Other|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
180974|NCT02787655|Behavioral|Aerobic exercise|stationary bicycling
180975|NCT02787655|Behavioral|Cognitive training|20 minutes of cognitive training using Mindfit program
180976|NCT02787642|Drug|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
180977|NCT02787642|Radiation|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
180978|NCT02787629|Procedure|Simultaneous Intubation|Intubation with GlideScope and ETT inserted simultaneously
180979|NCT02787629|Procedure|Standard Intubation|Intubation with GlideScope inserted first and ETT insertion after the GlideScope view is obtained
180980|NCT02787616|Genetic|buccal swab|cheek swab for DNA sampling
180981|NCT02787603|Other|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels < 0,25ng/mL OR PCT > 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
180982|NCT02787590|Drug|Simvastatin|
180983|NCT02787590|Drug|Matched Placebo (for Simvastatin)|
180984|NCT02787577|Behavioral|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
180985|NCT02787564|Behavioral|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
180986|NCT02787551|Drug|Insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
180987|NCT02787551|Drug|liraglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
180988|NCT02787551|Drug|exenatide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
180989|NCT02787551|Drug|exenatide extended-release|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
180990|NCT02787551|Drug|albiglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
180991|NCT02787551|Drug|dulaglutide|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
180992|NCT02787551|Drug|Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)|Pharmaceutical form: tablet Route of administration: oral If previously taken, doses to remain stable through the study.
181032|NCT02787226|Drug|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
181033|NCT02787226|Drug|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
181158|NCT02786329|Drug|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
180993|NCT02787538|Behavioral|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
180994|NCT02787538|Behavioral|Control group (Online medication guide)|Standard online medication guide.
180995|NCT02787525|Other|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.~The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
180996|NCT02787512|Device|Stent|Endoscopic biliary stent insertion
180997|NCT02787499|Procedure|HIV-1 RNA Resistance Testing|Perform drug resistance on enrollment to guide management of virologic failure
180998|NCT02787486|Other|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
180999|NCT02787473|Drug|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
181000|NCT02787473|Drug|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
181001|NCT02787473|Radiation|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
181002|NCT02787473|Drug|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
181003|NCT02787460|Behavioral|Behavioral Text Messages|
181004|NCT02787447|Drug|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
181005|NCT02787447|Radiation|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
181006|NCT02787447|Drug|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
181007|NCT02787434|Other|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
181008|NCT02787421|Device|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
181009|NCT02787408|Device|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
181010|NCT02787395|Procedure|shoulder dislocation self reduction|shoulder dislocation self reduction using one of three methods in the study
181011|NCT02787382|Device|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls~EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
181012|NCT02787369|Drug|ACY-1215|
181013|NCT02787369|Drug|Ibrutinib|
181014|NCT02787369|Drug|Idelalisib|
181015|NCT02787356|Drug|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
181016|NCT02787356|Drug|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
181017|NCT02787330|Behavioral|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
181018|NCT02787330|Behavioral|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
181019|NCT02787317|Drug|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
181020|NCT02787317|Drug|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
181021|NCT02787304|Drug|SHP626|5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
181022|NCT02787304|Drug|Placebo|Matching placebo
181023|NCT02787291|Device|Ellipse VR ICD and Durata/Optisure lead|Non-diagnostic MRI Scan sequence of head and chest
181024|NCT02787278|Drug|SP-8203 High dose|High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
181025|NCT02787278|Drug|SP-8203 Low dose|Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
181026|NCT02787278|Drug|Placebo|Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
181027|NCT02787265|Device|spinal cord stimulation|
181028|NCT02787252|Device|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
181029|NCT02787239|Drug|HLX01|
181030|NCT02787239|Drug|Rituximab|
181031|NCT02787239|Drug|CHOP|
181034|NCT02787187|Procedure|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
181035|NCT02787187|Procedure|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
181036|NCT02787174|Other|Asthma Medication Adherence Education|
181037|NCT02787161|Device|Hemodiafiltration|High volume online HDF
181038|NCT02787161|Device|Hemodialysis|High-flux HD
181039|NCT02787148|Behavioral|Cognitive behavioral therapy|
181040|NCT02787135|Behavioral|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
181041|NCT02787122|Behavioral|CBT-E|Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
181042|NCT02787122|Behavioral|Treatment as Usual|Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
181043|NCT02787109|Biological|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
181044|NCT02787109|Biological|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
181045|NCT02787109|Biological|Placebo|Saline
181046|NCT02787096|Device|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
181047|NCT02787083|Drug|Mirabegron|
181048|NCT02787083|Drug|Placebo|
181049|NCT02787070|Drug|PQ supervised|
181050|NCT02787070|Drug|PQ unsupervised|
181051|NCT02787057|Drug|vancomycin|IP vancomycin 1g every 5 days
181052|NCT02787057|Drug|moxifloxacin|oral moxifloxacin 400mg QD
181053|NCT02787057|Drug|ceftazidime|IP ceftazidime 1g QD
181054|NCT02787044|Biological|High Dose Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine
181055|NCT02787044|Biological|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine
181056|NCT02787031|Procedure|Neuraxial anesthesia|
181057|NCT02787031|Procedure|General anesthesia|
181058|NCT02787018|Drug|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
181059|NCT02787018|Drug|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
181060|NCT02787018|Drug|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
181061|NCT02787005|Biological|Pembrolizumab|Intravenous infusion
181062|NCT02787005|Drug|Enzalutamide|Oral capsules
181063|NCT02786992|Drug|Misoprostol|
181064|NCT02786992|Drug|Oxytocin|
181065|NCT02786992|Drug|Carbetocin|
181066|NCT02786992|Drug|Placebo|
181067|NCT02786979|Drug|Beraprost|Oral
181068|NCT02786979|Drug|Aspirin|Oral
181069|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
181070|NCT02786953|Behavioral|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
181071|NCT02786940|Device|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
181072|NCT02786927|Drug|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
181073|NCT02786927|Drug|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
181074|NCT02786927|Other|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
181075|NCT02786927|Other|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
181076|NCT02786901|Drug|Loteprednol Etabonate Ophthalmic Gel dosed TID|Gel
181077|NCT02786901|Drug|Loteprednol Etabonate Ophthalmic Gel dosed BID|Gel
181078|NCT02786901|Drug|Vehicle Gel dosed TID|Gel
181079|NCT02786901|Drug|Vehicle Gel dosed BID|Gel
181080|NCT02786875|Other|low Glycemic Index Mediterranean diet|All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
181081|NCT02786875|Other|Mediterranean diet|General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
181082|NCT02786875|Behavioral|Moderate physical activity|Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
181083|NCT02786875|Behavioral|Basic physical activity|General recommendations for physical activity
181084|NCT02786875|Dietary Supplement|high level Vitamin D|Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
181085|NCT02786875|Dietary Supplement|normal level Vitamin D|Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
181086|NCT02786862|Other|independent ventilation|comparison conventional and independent 1:1 ventilation
181087|NCT02786849|Other|neuromuscular electrical stimulation of high frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).~The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.~In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating."
181088|NCT02786849|Other|neuromuscular electrical stimulation of low frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.~Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.~The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.~In each session there will be a warm-up period, training and slowdown."
181089|NCT02786836|Drug|13C-Methacetin|"The test substrate in this study, ¹³C-methacetanilide solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.~The nasal or intubated breath sampling ID circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
181090|NCT02786823|Dietary Supplement|Folic acid|tab. Folic acid 5 mg
181091|NCT02786823|Dietary Supplement|Vitamin B12|tab. Vitamin B12 500 mcg
181092|NCT02786823|Drug|Oral hypoglycemic agents [Metformin +/- Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~Sulfonylurea~Metformin~Metformin plus Sulfonylurea"
181093|NCT02786810|Drug|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
181094|NCT02786797|Behavioral|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
181095|NCT02786797|Behavioral|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
181096|NCT02786784|Other|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
181097|NCT02786771|Device|Spire|
181098|NCT02786771|Device|Muse headband|
181099|NCT02786732|Biological|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
181100|NCT02786732|Biological|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
181101|NCT02786732|Biological|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
181102|NCT02786732|Biological|Placebo|Placebo administered subcutaneously
181103|NCT02786719|Drug|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
181104|NCT02786719|Drug|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
181105|NCT02786719|Drug|Cisplatin|Cycle 3+5 (given daily x 4 days)
181106|NCT02786719|Drug|Etoposide|Cycle 3+5 (given daily for 3 days)
181107|NCT02786719|Drug|Vincristine|Cycle 4+6 (given daily for 3 days)
181108|NCT02786719|Drug|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
181109|NCT02786719|Drug|Doxorubicin|Cycle 4+6 (given daily for 3 days)
181110|NCT02786719|Drug|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
181111|NCT02786706|Device|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
181112|NCT02786680|Behavioral|stroop test in condition DBS off|Patients were evaluated in DBS Off
181113|NCT02786680|Behavioral|stroop test in condition DBS on|Patients were evaluated in DBS On
181114|NCT02786667|Drug|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
181115|NCT02786667|Drug|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
181116|NCT02786641|Drug|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
181117|NCT02786641|Drug|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
181118|NCT02786641|Drug|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
181119|NCT02786641|Radiation|IMRT|IMRT for all patients
181120|NCT02786641|Drug|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
181157|NCT02786329|Drug|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
181193|NCT02786017|Biological|Conventional therapy|Patients will receive the conventional therapy.
181121|NCT02786628|Other|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
181122|NCT02786615|Behavioral|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
181123|NCT02786602|Genetic|pyrosequencing|
181124|NCT02786589|Biological|Blood-stage infection of P. vivax|Each patient will be vaccinated with P. vivax-infected red blood cells containing approximately 0.3-1×10^7 Plasmodium parasites.And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples.The treatment will last at least 12 weeks from the day of finding the Plasmodium from peripheral blood and will be terminated by chloroquine phosphate or Artemisinin compound preparation or Artesunate injection.
181125|NCT02786550|Drug|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
181126|NCT02786550|Other|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
181127|NCT02786537|Drug|sofosbuvir/ledipasvir|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
181128|NCT02786537|Drug|ombitasvir/paritaprevir/ritonavir (Phase 1 only)|(Phase 1 only) Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) for 12 to 24 weeks (treatment duration and use of ribavirin as per HCV provider)
181129|NCT02786537|Drug|elbasvir/grazoprevir|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks with or without RBV
181130|NCT02786537|Drug|Dasabuvir|250 mg daily for 12 to 24 weeks
181131|NCT02786524|Behavioral|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
181132|NCT02786511|Drug|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
181133|NCT02786498|Drug|Vitamin D3|
181134|NCT02786498|Other|Placebo|
181135|NCT02786485|Biological|rivogenlecleucel|T cells transduced with iCasp safety switch
181136|NCT02786485|Drug|Rimiducid|administered to treat GVHD
181137|NCT02786472|Behavioral|Online Bystander Training|Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
181138|NCT02786472|Behavioral|Online Substance Abuse Training|Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
181139|NCT02786472|Behavioral|In-Person Bystander Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
181140|NCT02786472|Behavioral|In-Person Combination Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
181141|NCT02786459|Device|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
181142|NCT02786459|Device|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
181143|NCT02786459|Device|SPECT-CT|Used as a comparative to ProxiScan.
181144|NCT02786446|Drug|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
181145|NCT02786446|Drug|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
181146|NCT02786446|Drug|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
181147|NCT02786433|Other|conventional physiotherapy|
181148|NCT02786433|Other|Virtual Reality with X- Box Kinect®|
181149|NCT02786407|Drug|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
181150|NCT02786407|Drug|Placebo|In these studies,patients received placebo administered to 20 injection sites
181151|NCT02786394|Behavioral|REACH|REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
181152|NCT02786368|Behavioral|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
181153|NCT02786368|Behavioral|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
181154|NCT02786355|Other|Frova bougie|Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
181155|NCT02786342|Procedure|blood sample collection|
181156|NCT02786329|Drug|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
181159|NCT02786329|Drug|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
181160|NCT02786316|Other|HIT program|HIT program for the rehabilitation of persons with NSCLBP
181161|NCT02786316|Other|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
181162|NCT02786303|Device|Whole-body diffusion- weighted MRI|
181163|NCT02786290|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
181164|NCT02786277|Other|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
181165|NCT02786264|Drug|Dexmedetomidine|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start.
181166|NCT02786264|Drug|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start.
181167|NCT02786264|Drug|Fentanyl and/or Midazolam|A fentanyl / midazolam dominant anesthetic will be defined as monitored anesthesia care in the presence of fentanyl or midazolam and in the absence of a propofol or dexmedetomidine infusion.
181168|NCT02786251|Other|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
181169|NCT02786251|Other|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (~26-28oC).
181170|NCT02786238|Behavioral|Standard Behavioral Treatment (SBT)|See description of treatment arm.
181171|NCT02786238|Behavioral|Acceptance-Based Treatment (ABT)|See description of treatment arm. **Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.**
181172|NCT02786225|Behavioral|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
181173|NCT02786225|Behavioral|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
181174|NCT02786212|Drug|Dexmedetomidine|
181175|NCT02786212|Drug|Normal Saline|
181176|NCT02786160|Dietary Supplement|HMO|
181177|NCT02786160|Dietary Supplement|Dextropur|
181178|NCT02786147|Other|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.~Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.~Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
181179|NCT02786147|Other|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
181180|NCT02786147|Other|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
181181|NCT02786147|Other|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
181182|NCT02786134|Radiation|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
181183|NCT02786134|Radiation|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
181184|NCT02786108|Procedure|left gastric artery embolization|
181185|NCT02786108|Behavioral|healthy diet and exercise|
181186|NCT02786082|Drug|20mg Azilsartan Tablets|Strength: 20mg, oral administration 1 tablet/ day
181187|NCT02786082|Drug|40mg Azilsartan Tablets|Strength: 40mg, oral administration 1 tablet/ day
181188|NCT02786069|Drug|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
181189|NCT02786056|Other|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
181190|NCT02786043|Drug|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
181191|NCT02786030|Behavioral|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
181192|NCT02786030|Behavioral|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
181241|NCT02785692|Radiation|Radiation|preoperative Radiotherapy/ IMRT
181194|NCT02786017|Biological|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5*10^8.
181195|NCT02786004|Device|Full Field Digital Mammography|
181196|NCT02786004|Device|Digital Breast Tomosynthesis|
181197|NCT02785991|Procedure|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
181198|NCT02785978|Drug|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring"
181199|NCT02785978|Other|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):~Controlled environment tests (series of tasks of everyday life)"
181200|NCT02785978|Other|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):~Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
181201|NCT02785978|Device|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
181202|NCT02785978|Other|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
181203|NCT02785965|Device|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
181204|NCT02785965|Behavioral|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
181205|NCT02785952|Biological|Ipilimumab|Given IV
181206|NCT02785952|Other|Laboratory Biomarker Analysis|Correlative studies
181207|NCT02785952|Biological|Nivolumab|Given IV
181208|NCT02785952|Other|Quality-of-Life Assessment|Ancillary studies
181209|NCT02785952|Other|Questionnaire Administration|Ancillary studies
181210|NCT02785939|Drug|Docetaxel|Given IV (arm II closed to accrual 12/18/2015)
181211|NCT02785939|Other|Laboratory Biomarker Analysis|Correlative studies
181212|NCT02785939|Drug|Palbociclib|Given PO
181213|NCT02785913|Other|Laboratory Biomarker Analysis|Correlative studies
181214|NCT02785913|Drug|Taselisib|Given PO
181215|NCT02785900|Drug|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
181216|NCT02785900|Drug|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
181217|NCT02785900|Drug|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
181218|NCT02785900|Drug|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
181219|NCT02785887|Other|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
181220|NCT02785874|Drug|Statin|Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
181221|NCT02785861|Behavioral|supervision of physical activity|
181222|NCT02785861|Behavioral|distance supervised physical activity|
181223|NCT02785848|Other|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
181224|NCT02785822|Drug|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
181225|NCT02785822|Drug|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
181226|NCT02785809|Other|Pausing oral contraceptive|
181227|NCT02785796|Other|CV4|
181228|NCT02785796|Other|SHAM TECHNIQUE|
181229|NCT02785783|Device|Standard colonoscopy|
181230|NCT02785783|Device|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
181231|NCT02785770|Drug|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
181232|NCT02785770|Drug|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
181233|NCT02785770|Drug|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
181234|NCT02785757|Other|Thrombin Generation Assay|
181235|NCT02785744|Other|Gaucher disease DNA mutation analysis|
181236|NCT02785731|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
181237|NCT02785731|Procedure|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
181238|NCT02785731|Procedure|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
181239|NCT02785718|Other|Global Haemostasis assays|
181240|NCT02785705|Biological|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
181242|NCT02785679|Dietary Supplement|cow's milk formula|addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
181243|NCT02785666|Drug|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
181244|NCT02785666|Behavioral|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
181245|NCT02785653|Drug|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
181246|NCT02785653|Drug|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
181247|NCT02785640|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|Prompt group
181248|NCT02785627|Other|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
181249|NCT02785614|Drug|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
181250|NCT02785614|Drug|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
181251|NCT02785601|Drug|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
181252|NCT02785588|Device|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
181253|NCT02785575|Other|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
181254|NCT02785562|Other|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
181255|NCT02785549|Drug|Ibuprofen|600 mg/8hours
181256|NCT02785549|Drug|Acetaminophen|1 g/8 hours
181257|NCT02785549|Drug|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
181258|NCT02785536|Behavioral|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
181259|NCT02785536|Behavioral|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
181260|NCT02785523|Drug|Ganoderma Spore Lipids|
181261|NCT02785523|Drug|Placebo|
181262|NCT02785523|Drug|Chemotherapy|
181263|NCT02785497|Other|Control group|will be turn on the equipment, positioning the patient but no put intensity
181264|NCT02785497|Other|Treatment group|This group will receive electrostimulation
181265|NCT02785484|Other|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
181266|NCT02785484|Other|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
181267|NCT02785471|Behavioral|Screening for Mental Health only|Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
181268|NCT02785471|Behavioral|Screening for Mental Health & Man Therapy|"Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience."
181269|NCT02785458|Behavioral|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
181270|NCT02785445|Device|Dip.io Home Based Dipstick Analyzer|"First intervention (assigned to the All participants arm)."
181271|NCT02785445|Device|ACON U500 Mission® U500 Urine Analyzer|"Second intervention (assigned to the All participants arm)."
181299|NCT02785237|Device|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
181779|NCT02781766|Other|Thrombin generation measurement.|
181272|NCT02785432|Device|Pre program low level laser|Phase 1 is an intervention only phase (LLLT or Sham) with no additional elements of the pain program (PT, counseling). Intervention will be completed at the Outpatient Physical Therapy Clinic in the School of Health Professions. Intervention will take place in the rooms that are appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
181273|NCT02785432|Device|Program low level laser|"Laser intervention (LLLT): Clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint.~Sham laser intervention (Sham): same protocol in time, application, and areas of treatment as stated above except laser unit will not discharge any photonic energy."
181274|NCT02785419|Behavioral|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
181275|NCT02785406|Drug|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
181276|NCT02785406|Drug|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
181277|NCT02785393|Drug|Sugar Pill|The administration of a sugar pill
181278|NCT02785393|Drug|Doxazosin|The administration of the Doxazosin medication
181279|NCT02785380|Procedure|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
181280|NCT02785380|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
181281|NCT02785367|Procedure|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.~The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
181282|NCT02785341|Other|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
181283|NCT02785341|Other|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
181284|NCT02785341|Other|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
181285|NCT02785328|Other|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
181286|NCT02785328|Other|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
181287|NCT02785328|Other|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
181288|NCT02785315|Behavioral|rehabilitation & remediation approach|The rehabilitation & remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
181289|NCT02785315|Behavioral|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
181290|NCT02785289|Device|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
181291|NCT02785276|Device|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
181292|NCT02785276|Drug|Ropivacaine|Commonly used local anaesthetic drug
181293|NCT02785276|Other|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
181294|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 6 weeks.|
181295|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 5 weeks.|
181296|NCT02785250|Other|DPX-Survivac|SubQ injection
181297|NCT02785250|Drug|Cyclophosphamide|PO BID
181298|NCT02785250|Drug|Epacadostat (INCB024360)|PO BID
181397|NCT02784639|Other|Tumor tissue analysis of circulating cell free DNA|
181300|NCT02785237|Device|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
181301|NCT02785224|Drug|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
181302|NCT02785211|Behavioral|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
181303|NCT02785198|Device|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
181304|NCT02785185|Drug|IDP-122 Vehicle Lotion|Vehicle
181305|NCT02785185|Drug|IDP-122 Vehicle Cream|Vehicle
181306|NCT02785185|Drug|IDP-122 Lotion|Lotion
181307|NCT02785185|Drug|Ultravate Cream|Cream
181308|NCT02785172|Drug|IDP-118 Vehicle Lotion|Vehicle
181309|NCT02785172|Drug|IDP-118 Vehicle Cream|Vehicle
181310|NCT02785172|Drug|IDP-118 Lotion|Lotion
181311|NCT02785172|Drug|Ultravate Cream|Cream
181312|NCT02785159|Drug|IDP-118 Lotion|Lotion
181313|NCT02785159|Drug|Tazorac Cream|Cream
181314|NCT02785159|Drug|IDP-118 Vehicle Lotion|Lotion
181315|NCT02785159|Drug|IDP-118 Vehicle Cream|Cream
181316|NCT02785146|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
181317|NCT02785146|Drug|Oxaliplatin|85 mg/m², ivdrip, D1
181318|NCT02785146|Drug|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
181319|NCT02785146|Drug|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
181320|NCT02785133|Device|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
181321|NCT02785133|Drug|Normal Saline Solution|150 ml of 0.9% Sodium Chloride Solution
181322|NCT02785133|Device|Peripheral Catheterization|"20-gauge 1.0 catheter"
181323|NCT02785120|Drug|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
181324|NCT02785107|Behavioral|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
181325|NCT02785094|Behavioral|Observation|Observation of Participants' behaviour
181326|NCT02785068|Drug|MM-151|Oligoclonal antibody
181327|NCT02785068|Drug|nal-IRI|Nanoliposomal irinotecan
181328|NCT02785068|Drug|Leucovorin|folinic acid
181329|NCT02785068|Drug|5-FU|Chemotherapy
181330|NCT02785055|Procedure|Thoracic Epidural Placement|Thoracic Epidural Placement
181331|NCT02785055|Drug|Bupivacaine 0.05%|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
181332|NCT02785055|Drug|Hydromorphone 0.01mg/mL|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
181333|NCT02785042|Device|Heidelberg Spectralis OCT|OCT imaging
181334|NCT02785029|Device|OCT|
181335|NCT02785003|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
181336|NCT02785003|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
181337|NCT02785003|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
181338|NCT02785003|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
181339|NCT02785003|Drug|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
181340|NCT02784990|Biological|Lipase, amylase and CRP (C-reactive protein) dosages|
181341|NCT02784977|Device|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
181342|NCT02784977|Device|Intraoral device (IOD)|Treatment of OSA with IOD
181343|NCT02784977|Procedure|Uvuloplasty|Uvuloplasty
181344|NCT02784977|Other|Conservative treatment|No active intervention
181345|NCT02784964|Biological|Elixcyte 8 ml|ADSC 6.4*10^7 cells, allogeneic injection
181346|NCT02784964|Device|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
181347|NCT02784964|Biological|Elixcyte 4 ml|ADSC 3.2*10^7 cells, allogeneic injection
181348|NCT02784964|Biological|Elixcyte 2 ml|ADSC 1.6*10^7 cells, allogeneic injection
181349|NCT02784951|Drug|Red blood cells (0Rh D-neg)|Fresh produced RBC
181350|NCT02784951|Drug|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
181351|NCT02784951|Drug|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
181393|NCT02784665|Device|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.~100 microns light spot size, 0.05 seconds duration, 80 ~ 200 milliwatts of power"
181394|NCT02784652|Drug|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
181352|NCT02784938|Behavioral|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
181353|NCT02784925|Device|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure~and has proven to be an accurate technique to measure subcutaneous fat thickness."
181354|NCT02784899|Drug|iloprost|"20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
181355|NCT02784899|Drug|normal saline|"20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
181356|NCT02784886|Biological|Women at high risk of MAP|Blood sample
181357|NCT02784873|Other|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
181358|NCT02784860|Drug|Lidocaine|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
181359|NCT02784860|Drug|normal saline|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
181360|NCT02784847|Drug|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
181361|NCT02784834|Drug|dimethyl fumarate|
181362|NCT02784821|Drug|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
181363|NCT02784821|Other|Gastric fluid|Microbiome, metabolome, and inflammatory mediators will be evaluated using gastric aspirate.
181364|NCT02784821|Other|Breast milk|Microbiome, metabolome, and inflammatory mediators will be evaluated using mother's breast milk.
181365|NCT02784821|Other|Stool samples|Microbiome, metabolome, and inflammatory mediators will be evaluated using infant's stool.
181366|NCT02784821|Drug|Antibiotics - pre-emptive|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
181367|NCT02784821|Other|Skin swabs|The neonate's microbiome will be evaluated using infant's skin swab.
181368|NCT02784808|Drug|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
181369|NCT02784808|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
181370|NCT02784795|Drug|LY3039478|Administered orally
181371|NCT02784795|Drug|Taladegib|Administered orally
181372|NCT02784795|Drug|Abemaciclib|Administered orally
181373|NCT02784795|Drug|Cisplatin|Administered IV
181374|NCT02784795|Drug|Gemcitabine|Administered IV
181375|NCT02784795|Drug|Carboplatin|Administered IV
181376|NCT02784795|Drug|LY3023414|Administered orally
181377|NCT02784782|Device|Orthesis|
181378|NCT02784782|Behavioral|No orthesis|
181379|NCT02784769|Other|measurement of skin autofluorescence|
181380|NCT02784769|Other|skin biopsy collection|
181381|NCT02784756|Device|Quantiferon-CMV assay|
181382|NCT02784743|Drug|''albendazole'' and ''ivermectin''|annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
181383|NCT02784730|Procedure|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
181384|NCT02784730|Procedure|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
181385|NCT02784717|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
181386|NCT02784704|Drug|Eravacycline|
181387|NCT02784704|Drug|Meropenem|
181388|NCT02784704|Drug|Placebo|
181389|NCT02784691|Device|Feeligreen patch|
181390|NCT02784678|Procedure|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
181391|NCT02784678|Device|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
181392|NCT02784665|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
181395|NCT02784652|Radiation|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions,
181398|NCT02784626|Drug|Dexmedetomidine|Intraoperative sedation using dexmedetomidine
181399|NCT02784626|Drug|Propofol|Intraoperative sedation using propofol
181400|NCT02784613|Drug|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
181401|NCT02784600|Device|Bioinductive implant|
181402|NCT02784587|Procedure|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
181403|NCT02784561|Drug|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously [i.v.], days -10 to -8)
181404|NCT02784561|Drug|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
181405|NCT02784561|Drug|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
181406|NCT02784561|Drug|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
181407|NCT02784561|Drug|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
181408|NCT02784548|Other|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
181409|NCT02784535|Drug|Atomoxetine|norepinephrine transporter inhibitor
181410|NCT02784535|Drug|Placebo|placebo
181411|NCT02784522|Device|locking compression plate group|Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique
181412|NCT02784522|Device|conventional locking plate group|Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
181413|NCT02784496|Other|Long-term Follow-up|Undergo follow-up assessment
181414|NCT02784496|Other|Quality-of-Life Assessment|Ancillary studies
181415|NCT02784496|Drug|Ruxolitinib|Given PO
181416|NCT02784483|Drug|Atezolizumab (1200mg via IV infusion)|
181417|NCT02784470|Device|gastroduodenal stent placement|
181418|NCT02784470|Procedure|gastrojejunostomy|
181419|NCT02784457|Drug|Cetrorelix|
181420|NCT02784444|Drug|MSDC-0602K|MSDC-0602K capsules
181421|NCT02784444|Drug|Placebo|Placebo capsules
181422|NCT02784418|Procedure|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
181423|NCT02784418|Procedure|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
181424|NCT02784392|Drug|Ulimorelin|Active
181425|NCT02784392|Drug|Metoclopramide|Comparator
181426|NCT02784353|Behavioral|Perioperative rehabilitation program|"Perioperative rehabilitation program~preoperative rehabilitation : 2 weeks prior to operation~postoperative rehabilitation : 3 months after operation"
181427|NCT02784353|Behavioral|Conventional|conventional perioperative management without rehabilitation program
181428|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone IV drip
181429|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
181430|NCT02784340|Drug|Saline (IV fluids)|IV fluids 500 cc saline infusion
181431|NCT02784340|Drug|Bupivicaine and Fentany|
181432|NCT02784340|Device|25G spinal needles|
181433|NCT02784327|Drug|PRF110|
181434|NCT02784314|Procedure|Robotic-Assisted Radical Prostatectomy|
181435|NCT02784314|Procedure|Laparoscopic Radical Prostatectomy|
181436|NCT02784301|Device|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
181437|NCT02784301|Behavioral|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
181438|NCT02784301|Behavioral|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
181439|NCT02784288|Procedure|Neck Dissection|All patients will undergo neck dissection.
181440|NCT02784288|Procedure|Transoral Surgery of Primary Site|Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
181441|NCT02784288|Radiation|Radiation|Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
181442|NCT02784288|Drug|Carboplatin|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
181443|NCT02784288|Drug|Paclitaxel|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
181444|NCT02784275|Drug|Cyclo-Z|
181445|NCT02784275|Drug|Placebo|
181446|NCT02784262|Drug|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
181447|NCT02784249|Procedure|Goniotomy|Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
181448|NCT02784249|Device|Trabecular Micro-Bypass Stent|Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
181449|NCT02784249|Procedure|Cataract Extraction|Cataract extraction via Phaco and PCIOL implant.
181450|NCT02784236|Device|telemedicine|The study population corresponds to patients> 18 and <65 years with DM1 of> 1 year of evolution, and treated with MDI HbA1c> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
181451|NCT02784223|Device|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
181452|NCT02784210|Drug|Methylprednisolone|1000mg/day for 5 days
181453|NCT02784210|Drug|Methylprednisolone|1000mg/day for 3 days
181454|NCT02784197|Device|Phase Signal Recorder|The cPSTA System is a medical device system that uses passive tomography to analyze a patient's phase space data to identify the presence of significant coronary artery disease. The cPSTA System consists of several components that work together to obtain, transmit, analyze the data, and display the results, including the Phase Signal Acquisition System (PSAQ System), which is the Phase Signal Recorder (PSR) and the Phase Signal Data Repository (PSDR); analytical software; and secure web portal. For this study only the PSAQ System is used by the clinical site for the purposes of acquiring and transmitting the signal.
181455|NCT02784171|Drug|Cisplatin|
181456|NCT02784171|Drug|Pemetrexed|
181457|NCT02784171|Drug|Pembrolizumab|
181458|NCT02784158|Drug|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
181459|NCT02784145|Dietary Supplement|Resistant starch|
181460|NCT02784145|Other|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
181461|NCT02784132|Other|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
181462|NCT02784119|Procedure|temporary porto-caval shunt|temporary porto-caval shunt
181463|NCT02784106|Drug|Placebo|Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
181464|NCT02784106|Drug|M2951|Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
181465|NCT02784106|Drug|M2951|Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
181466|NCT02784093|Drug|Gastrograﬁn|
181467|NCT02784093|Procedure|enemas|
181468|NCT02784080|Other|HLA-alloantibodies exposure|"Following analyzes will be done:~LABScreen® Mixed, One Lambda, CA LABScreen® Single Antigen, One Lambda, CA C1qScren™, One Lambda, CA PE-conjugated IgG3 antibody"
181469|NCT02784067|Drug|Sucraid|Study drug
181470|NCT02784067|Drug|Placebo|Sucraid placebo
181471|NCT02784054|Drug|Carboplatin|
181472|NCT02784054|Drug|Etoposide|
181473|NCT02784054|Drug|Cyclophosphamide|
181474|NCT02784054|Drug|Bleomycin|
181475|NCT02784054|Drug|Thiotepa|
181476|NCT02784054|Drug|Melphalan|
181477|NCT02784054|Radiation|Reduced dose radiotherapy|
181478|NCT02784041|Drug|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
181479|NCT02784041|Drug|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
181480|NCT02784028|Other|SGM-101|Administration of SGM-101 prior surgery
181481|NCT02784015|Drug|Cisplatin|
181482|NCT02784015|Drug|Etoposide|
181483|NCT02784015|Drug|Doxorubicin|
181484|NCT02784015|Drug|Cyclophosphamide|
181485|NCT02784015|Drug|Ifosfamide|
181486|NCT02784015|Drug|Carboplatin|
181487|NCT02784015|Radiation|Radiotherapy|
181488|NCT02784015|Drug|Thiotepa|
181489|NCT02784015|Drug|Melphalan|
181490|NCT02784002|Drug|Ridinilazole|
181491|NCT02784002|Drug|Fidaxomicin|
181492|NCT02783989|Other|white wine|A dietary beverage: a market white wine, 13º alcohol
181493|NCT02783989|Dietary Supplement|tyrosol|tyrosol in capsules
181494|NCT02783976|Drug|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
181495|NCT02783963|Device|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
181496|NCT02783950|Other|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
181497|NCT02783937|Biological|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:~Phase A:~Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.~Phase B:~Injection of saline SC injection twice daily for five consecutive days."
181498|NCT02783937|Drug|Saline|Injection of saline SC injection twice daily for five consecutive days
181499|NCT02783924|Drug|Cholecalciferol|Vitamin D preparation
181500|NCT02783924|Drug|Placebo|placebo
181501|NCT02783911|Device|MTA|Mineral Trioxide Aggregate grey paste
181502|NCT02783911|Drug|Ferric Sulfate|Ferric Sulfate paste
181503|NCT02783898|Device|AliveCor Heart Monitor|Smart phone based ECG event recorder
181504|NCT02783885|Drug|immunotherapy|
181505|NCT02783859|Drug|Amoxicillin-clavulanic Acid|
181506|NCT02783859|Drug|Placebo (for Amoxicillin-clavulanic Acid)|
181507|NCT02783846|Other|normal saline|receive equal volume of normal saline
181508|NCT02783846|Drug|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
181509|NCT02783846|Drug|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
181510|NCT02783833|Drug|MMV390048 40mg|
181511|NCT02783833|Drug|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
181512|NCT02783820|Drug|MMV390048 40 mg|
181513|NCT02783820|Drug|Placebo to match MMV390048 40 mg|
181514|NCT02783820|Drug|MMV390048 80 mg|
181515|NCT02783820|Drug|Placebo to match MMV390048 80 mg|
181516|NCT02783820|Drug|MMV390048 120 mg|
181517|NCT02783820|Drug|Placebo to match MMV390048 120 mg|
181518|NCT02783807|Device|Eyenez Retinal Camera v200|
181519|NCT02783807|Device|Volk Pictor Ret 1|
181520|NCT02783794|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
181521|NCT02783794|Drug|Placebo|Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
181522|NCT02783781|Procedure|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.~Blood sample collection Urine sample collection"
181523|NCT02783768|Device|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
181524|NCT02783768|Other|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
181525|NCT02783768|Drug|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
181526|NCT02783768|Drug|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
181527|NCT02783755|Behavioral|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
181528|NCT02783742|Behavioral|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
181529|NCT02783729|Drug|Lemborexant|Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
181530|NCT02783729|Drug|Lemborexant|Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
181531|NCT02783729|Drug|Lemborexant-matched placebo|Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
181532|NCT02783729|Drug|Zolpidem tartrate|Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
181533|NCT02783729|Drug|Zolpidem-matched placebo|Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
181534|NCT02783716|Device|Cardiac Resynchronization Therapy Implantation|An implanted cardiac resynchronization device is a medical device used in cardiac resynchronization therapy (CRT). It resynchronizes the contractions of the heart's ventricles by sending tiny electrical impulses to the heart muscle, which can help the heart pump blood throughout the body more efficiently.
181535|NCT02783716|Device|Implantable Cardioverter-defibrillator (ICD)|An implantable cardioverter-defibrillator (ICD) — a pager-sized device — is placed in the chest to reduce risk of dying if the lower chambers of the heart (ventricles) go into a dangerous rhythm and stop beating effectively
181536|NCT02783703|Dietary Supplement|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
181537|NCT02783690|Radiation|Hypofractionation|40 Gy (RBE) in 15 daily fractions
181538|NCT02783677|Procedure|Percutaneous balloon angioplasty|
181634|NCT02782897|Drug|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
181539|NCT02783664|Other|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
181540|NCT02783651|Other|Other|No intervention other than routine medical care
181541|NCT02783638|Drug|YHD1119|2 by 2
181542|NCT02783638|Drug|Lyrica|2 by 2
181543|NCT02783625|Drug|Romidepsin|
181544|NCT02783625|Drug|Bortezomib|
181545|NCT02783625|Drug|duvelisib|
181546|NCT02783612|Other|glucose buddy application|
181547|NCT02783599|Drug|Olaratumab|Administered IV
181548|NCT02783599|Drug|Doxorubicin|Administered IV
181549|NCT02783599|Radiation|External Beam Radiotherapy|
181550|NCT02783586|Procedure|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
181551|NCT02783586|Procedure|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
181552|NCT02783586|Drug|Bupivacaine|20 ml of bupivacaine with adrenaline
181553|NCT02783586|Device|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
181554|NCT02783573|Drug|Lanabecestat|Administered orally
181555|NCT02783573|Drug|Placebo|Administered orally
181556|NCT02783560|Behavioral|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
181557|NCT02783560|Behavioral|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
181558|NCT02783547|Drug|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.~SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
181559|NCT02783534|Device|Verum acupuncture|"Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
181560|NCT02783534|Device|Sham acupuncture|We use a non-insertive sham control produced by Asia-med Company in Germany—the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
181561|NCT02783534|Behavioral|Usual care|Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
181562|NCT02783521|Behavioral|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
181563|NCT02783521|Behavioral|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
181564|NCT02783508|Drug|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
181565|NCT02783508|Drug|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.~In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.~If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
181566|NCT02783495|Behavioral|Device: iPad|All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention. At the end of the baseline visit, subjects will be lent an iPad to take home (or will be assisted in the installation of the ReMind app on their personal iPad) and instructed in the use of the ReMind app (and more basic iPad skills, if necessary). Subjects will review the intervention schedule (approximately 3 hours per week). Testing will be repeated 3 months after the baseline visit (i.e., immediately after the intervention) and 9 months after the baseline visit (i.e., 6 months after completion of the intervention), both time-points including a new MRI.
181567|NCT02783482|Biological|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
181568|NCT02783469|Genetic|Identification of genetic causes of diabetic neuropathic pain|
181569|NCT02783456|Procedure|Noise|The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
181570|NCT02783456|Procedure|Silence|The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
181571|NCT02783443|Other|General anesthesia|General anesthesia
181572|NCT02783443|Other|Regional anesthesia|Regional anesthesia
181573|NCT02783430|Drug|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
181574|NCT02783430|Drug|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
181575|NCT02783430|Drug|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
181576|NCT02783417|Other|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
181577|NCT02783404|Drug|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
181578|NCT02783404|Drug|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate"
181579|NCT02783391|Device|ECoG and intracortical electrodes|
181580|NCT02783378|Drug|Gaviscon Syrup|
181581|NCT02783365|Behavioral|Photo-elicitation and online group support|See above information.
181582|NCT02783352|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
181583|NCT02783352|Procedure|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
181584|NCT02783326|Other|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
181585|NCT02783313|Device|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
181586|NCT02783313|Other|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
181587|NCT02783300|Drug|GSK3326595.|The capsules will be of Opaque White for 100 mg and Opaque Light Green for 25 mg. The tablets will be of white to almost white film coated 100 mg tablets with no markings. The capsules and tablets will be administered orally with water (approximately 200 mL) at approximately the same time of day (+/- 4 hours) with no food or antacids for 1 hour before and 2 hours after each dose.
181588|NCT02783287|Behavioral|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
181589|NCT02783287|Behavioral|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
181590|NCT02783274|Device|Actis Total Hip System|Total Hip Replacement and Hemi-hip Replacement
181591|NCT02783261|Other|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
181592|NCT02783235|Other|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
181593|NCT02783222|Drug|Nab-paclitaxel|comparison of different dosages of drug
181594|NCT02783209|Procedure|Cataract surgery|
181595|NCT02783196|Drug|Liraglutide|In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
181596|NCT02783196|Drug|Placebo|In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
181597|NCT02783183|Drug|YHD1119|2 by 2
181598|NCT02783183|Drug|Lyrica|2 by 2
181599|NCT02783170|Biological|Tetanus, Diphtheria, and Pertussis Vaccine|
181600|NCT02783170|Biological|2016-2017 Quadrivalent Inactivated Influenza Vaccine|
181601|NCT02783170|Biological|2017-2018 Quadrivalent Inactivated Influenza Vaccine|
181602|NCT02783157|Device|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
181603|NCT02783157|Device|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
181604|NCT02783144|Procedure|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
181605|NCT02783144|Other|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
181606|NCT02783144|Drug|TAP Block and Dexamethasone i.v.|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
181607|NCT02783131|Device|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
181608|NCT02783118|Other|Self administered online CBT|"The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~The Emotional Pulse exercise~The Sticky Notes exercise~The Find Irrational Thoughts~The Change Irrational Thoughts"
181609|NCT02783105|Other|Musical intervention|
181610|NCT02783105|Other|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
181611|NCT02783092|Drug|Cannabidiol|Oral solution of cannabidiol 200 mg / mL dissolved in corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
181612|NCT02783092|Drug|Placebo|The placebo will be an oral solution of corn oil. Titration period: 5 mg / kg / day up to 25 mg / kg / day. Maintenance period: highest dose obtained during the titration period (maximum of 25 mg/kg / day)
181613|NCT02783079|Behavioral|CBT|
181614|NCT02783079|Behavioral|MBSR|
181615|NCT02783066|Device|Offloading boot : PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
181616|NCT02783053|Drug|Metformin|Metformin vs no metformin
181617|NCT02783040|Drug|Midazolam|
181618|NCT02783040|Drug|Warfarin|
181619|NCT02783040|Drug|Omeprazole|
181620|NCT02783040|Drug|Midazolam|
181621|NCT02783040|Drug|Digoxin|
181622|NCT02783040|Drug|BI 425809|
181623|NCT02783027|Behavioral|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
181624|NCT02782988|Other|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
181625|NCT02782975|Drug|aducanumab|
181626|NCT02782949|Drug|Curcumin|Given PO
181627|NCT02782949|Other|Laboratory Biomarker Analysis|Correlative studies
181628|NCT02782949|Other|Placebo|Given PO
181629|NCT02782949|Other|Quality-of-Life Assessment|Ancillary studies
181630|NCT02782936|Other|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).~Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
181631|NCT02782936|Device|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
181632|NCT02782923|Device|STISIM driving simulator|This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
181633|NCT02782910|Device|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
182052|NCT02779751|Drug|Abemaciclib|Administered orally
181635|NCT02782897|Other|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
181636|NCT02782871|Device|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
181637|NCT02782858|Drug|GNbAC1|Monthly IV repeated dose
181638|NCT02782858|Drug|Placebo|Monthly IV repeated dose
181639|NCT02782845|Drug|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
181640|NCT02782845|Drug|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
181641|NCT02782845|Drug|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
181642|NCT02782819|Drug|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
181643|NCT02782819|Drug|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
181644|NCT02782806|Device|Masimo Rad-67 Pulse Oximeter|Noninvasive pulse oximeter
181645|NCT02782793|Procedure|Endoscopic Mucosal Resection|
181646|NCT02782780|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
181647|NCT02782767|Other|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
181648|NCT02782767|Other|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
181649|NCT02782754|Drug|Carboplatin|
181650|NCT02782754|Drug|Etoposide|
181651|NCT02782754|Drug|Cyclophosphamide|
181652|NCT02782754|Drug|Bleomycin|
181653|NCT02782754|Radiation|Reduced dose of radiotherapy|
181654|NCT02782741|Drug|avalglucosidase alfa(GZ402666)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
181655|NCT02782741|Drug|alglucosidase alfa (GZ419829)|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
181656|NCT02782728|Behavioral|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
181657|NCT02782728|Behavioral|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
181658|NCT02782715|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
181659|NCT02782715|Procedure|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
181660|NCT02782702|Drug|Botulism Toxin Treatment|Injection of 50 UI of botulism toxin for treated zone
181661|NCT02782689|Device|Kit Biflex|Two-layer reusable compression system
181662|NCT02782689|Device|Profore|Four-layer compression system
181663|NCT02782676|Device|Investigational Healon5 OVD|ophthalmic viscosurgical device
181664|NCT02782676|Device|Healon5 OVD|ophthalmic viscosurgical device
181665|NCT02782663|Drug|ABT-494|Oral use
181666|NCT02782650|Other|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
181667|NCT02782637|Other|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.~a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
181668|NCT02782624|Drug|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
181669|NCT02782624|Drug|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
181742|NCT02782091|Behavioral|Multiple Errands Test (MET)|1 hour assessment in an unknown district with 2 independent raters.
181743|NCT02782078|Biological|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
181744|NCT02782065|Other|Not an interventional study|
182053|NCT02779751|Drug|Pembrolizumab|Administered IV
181670|NCT02782611|Behavioral|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
181671|NCT02782598|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
181672|NCT02782585|Other|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
181673|NCT02782585|Other|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
181674|NCT02782585|Other|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
181675|NCT02782572|Other|Exercise|Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
181676|NCT02782559|Drug|Sildenafil|
181677|NCT02782559|Drug|Placebo|Color and size matched to active drug (sildenafil)
181678|NCT02782546|Drug|Fludarabine|-Standard of care
181679|NCT02782546|Drug|Cyclophosphamide|-Standard of care
181680|NCT02782546|Radiation|Single dose total body irradiation|-Standard of care
181681|NCT02782546|Procedure|Graft cell infusion|-Day 0
181682|NCT02782546|Drug|Tacrolimus|-GVHD prophylaxis
181683|NCT02782546|Drug|Mycophenolate mofetil|-GVHD prophylaxis
181684|NCT02782546|Drug|G-CSF|-Continue until neutrophil engraftment as per institutional guidelines
181685|NCT02782546|Procedure|CIML NK cell infusion|-Day +7
181686|NCT02782546|Drug|ALT-803|-Start approximately 4 hours after CIML NK cell infusion
181687|NCT02782546|Procedure|Leukapheresis|-Day +6
181688|NCT02782533|Device|Deep Brain Stimulation V3|
181689|NCT02782520|Drug|Ringer Lactate (10ml/kg) fluid expansion|
181690|NCT02782520|Drug|Hypertonic saline (3ml/kg) fluid expansion|
181691|NCT02782507|Behavioral|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon & Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.~Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
181692|NCT02782494|Other|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
181693|NCT02782481|Drug|ND0612|
181694|NCT02782481|Drug|Placebo|
181695|NCT02782468|Drug|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m^2 intravenous infusion.
181696|NCT02782468|Drug|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m^2 intravenous infusion.
181697|NCT02782468|Drug|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m^2 intravenous infusion.
181698|NCT02782468|Drug|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m^2 intravenous infusion.
181699|NCT02782468|Drug|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m^2 intravenous or subcutaneous formulation.
181700|NCT02782455|Drug|Flavonoids|Daflon is administered
181701|NCT02782455|Drug|CDobi|Calcium dobesylate is administered
181702|NCT02782442|Behavioral|Structured Cognitive Training & PRIME|The treatment condition-- 30-35 hours of CT over 16 weeks (~2 hours per week) in a structured program of 10 hours of social cognition exercises followed by 30 hours of auditory processing exercises, combined with the personalized PRIME coaching application
181703|NCT02782442|Behavioral|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 30-35 hours of games over 16 weeks (~2 hours per week), combined with the personalized PRIME coaching application.
181704|NCT02782429|Drug|Ketamine|
181705|NCT02782429|Other|Saline|
181706|NCT02782416|Other|Examination of latent tuberculosis|
181707|NCT02782403|Drug|Axitinib|Given PO
181708|NCT02782403|Drug|Bosutinib|Given PO
181709|NCT02782403|Other|Laboratory Biomarker Analysis|Correlative studies
181710|NCT02782390|Other|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans & Innes, 2010).
181711|NCT02782390|Other|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
181712|NCT02782351|Biological|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
181713|NCT02782338|Drug|Voltaren ophtha 0.1%|All study patients will be treated with Voltaren ophtha 0.1% after cataract surgery
181714|NCT02782325|Biological|Active FMT, then open label FMT|Endoscopic application of OpenBiome FMT Lower Delivery followed by 2 weeks of treatment with OpenBiome FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
181715|NCT02782325|Biological|Placebo FMT, then open label FMT|Endoscopic application of Placebo FMT Lower Delivery followed by 2 weeks of treatment with Placebo FMT Capsules G3 with follow-up at week 4, 8, 16 and 24 after inclusion. In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension after at least 10 day of antibiotic therapy with an additional endoscopic FMT followed by 2 weeks of oral FMT. Follow-up will occur in open label at week 4, 8, 16 and 24 after open label FMT.
181716|NCT02782312|Drug|ICS+LABA|Seretide is inhaled for one year
181717|NCT02782312|Other|routine therapy|routine therapy for one year
181718|NCT02782299|Other|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
181719|NCT02782286|Drug|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
181720|NCT02782286|Drug|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
181721|NCT02782273|Drug|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
181722|NCT02782273|Drug|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
181723|NCT02782260|Drug|Dipyridamole|
181724|NCT02782260|Drug|Placebo|
181725|NCT02782247|Device|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.~It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal < 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis >11.5kPa. It cannot be used in patients with ascites."
181726|NCT02782247|Device|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
181727|NCT02782234|Behavioral|Contract management|
181728|NCT02782221|Drug|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
181729|NCT02782221|Drug|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
181730|NCT02782208|Drug|Acipimox|Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
181731|NCT02782208|Drug|Placebo|Placebo is administered 4 times previous to and during the investigation day.
181732|NCT02782208|Drug|GH substitution|GH substitution as usually
181733|NCT02782208|Other|GH pause|GH substitution pause two days prior to the experimental day
181734|NCT02782182|Drug|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
181735|NCT02782169|Drug|Pregabalin|Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
181736|NCT02782169|Drug|Placebo|Matching placebo capsule with excipient to match Pregabalin
181737|NCT02782156|Other|Process evaluation|Adherence to screening and action algorithm
181738|NCT02782130|Behavioral|Epic Allies App Intervention|"The Epic Allies app addresses barriers to ART adherence through:~Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.~Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.~A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.~Users progress through Epic Allies' virtual world, creating allies with other users.~The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy."
181739|NCT02782130|Behavioral|Epic Allies - Control Branch|Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
181740|NCT02782117|Device|Luminopia VR Device|Luminopia VR Device is a digital therapeutic that allows patients to watch videos with therapeutic modifications applied.
181741|NCT02782104|Drug|Esketamine Nasal Spray|Open-Label Induction Phase: Participants will self-administer with esketamine nasal spray twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer esketamine nasal spray (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer esketamine nasal spray (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
181778|NCT02781779|Device|AQUACEL® AG|AQUACEL® AG wound dressings
181745|NCT02782052|Drug|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:~Placebo (P; sterile 0.9% sodium chloride solution)~Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
181746|NCT02782052|Drug|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:~Placebo (P; sterile 0.9% sodium chloride solution)~Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
181747|NCT02782052|Drug|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:~Placebo (P; sterile 0.9% sodium chloride solution)~Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone~Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
181748|NCT02782026|Device|Exhaled Breath Olfactory Signature (Artificial Nose)|
181749|NCT02782000|Other|lessons,long-term supervision and message|
181750|NCT02782000|Other|lessons,short-term supervision and message|
181751|NCT02781987|Other|chronic pancreatitis|patients with chronic pancreatitis
181752|NCT02781974|Other|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
181753|NCT02781961|Other|cellvizio|pCLE during gastroscopy
181754|NCT02781948|Device|Optical Coherence Tomography|
181755|NCT02781935|Procedure|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
181756|NCT02781922|Genetic|Autologous cardiac stem cells (JRM-001)|3x 10^5 cells/kg, single treatment
181757|NCT02781909|Drug|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
181758|NCT02781909|Drug|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
181759|NCT02781896|Device|pacing catheter|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
181760|NCT02781896|Device|valve delivery guidewire|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
181761|NCT02781883|Drug|BP1001 in combination with decitabine|BP1001 in combination with decitabine
181762|NCT02781870|Procedure|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
181763|NCT02781870|Procedure|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
181764|NCT02781857|Other|No intervention|
181765|NCT02781844|Drug|25mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice-daily regimen (12 hours apart) of two 25mcg doses without calcium in cohort 1 and with calcium in cohort 3.
181766|NCT02781844|Drug|50mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as twice daily regimen (12 hours apart) of two 50mcg doses without calcium in cohort 2 and with calcium in cohort 4
181767|NCT02781844|Drug|100mcg rhPTH(1-84)|Participants will receive rhPTH(1-84) as once-daily regimen of one 100 mcg dose without calcium in cohort 1 and 2 and with calcium in cohort 3 and 4 in the morning.
181768|NCT02781831|Procedure|Standard rehab|Standard hospital based rehabilitation for patients with stroke
181769|NCT02781831|Device|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
181770|NCT02781818|Drug|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
181771|NCT02781818|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
181772|NCT02781818|Drug|Normal Saline|Normal saline 0.1 mL will be administered intralesionally at the selected site.
181773|NCT02781805|Drug|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
181774|NCT02781792|Drug|Temozolomide|-Given standard of care
181775|NCT02781792|Other|Functional Assessment of Cancer Therapy - Brain|"23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire [2] that includes 27 items.~Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)~The sleep portion of this questionnaire consists of 17 questions about sleeping patterns and the ability to rate severity of insomnia."
181776|NCT02781792|Other|ActTrust Condor Instrument Watch|-Will be required to wear 24 hours per day and will only be removed at specified data collection time points
181777|NCT02781779|Device|Silverlon®|Silverlon wound dressings
181780|NCT02781753|Biological|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
181781|NCT02781753|Biological|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
181782|NCT02781740|Device|Continous Positive Air Pressure Device|
181783|NCT02781727|Drug|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
181784|NCT02781727|Drug|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
181785|NCT02781714|Behavioral|Two-way SMS|"SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.~Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:~Male partner invited to enroll/enrolled~Male partner not invited to enroll~Unpartnered"
181786|NCT02781701|Device|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.~Therefore, participants will work out about 20 minutes a day for 6 weeks."
181787|NCT02781688|Behavioral|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.~Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.~Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
181788|NCT02781675|Other|Dietary Intervention|3 wk dietary intervention with prescribed menus and ~50% foods provided.
181789|NCT02781662|Behavioral|Pharmacist Home-Visit|
181790|NCT02781649|Drug|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
181791|NCT02781649|Drug|Ribavirin|Ribavirin 1200 mg/d (> 75 kg) or 1000 mg/d (< 75 kg) by mouth daily in two divided doses
181792|NCT02781649|Drug|Sofosbuvir|Sofosbuvir 400 mg daily
181793|NCT02781636|Device|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
181794|NCT02781623|Procedure|MRI|
181795|NCT02781610|Drug|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
181796|NCT02781597|Drug|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
181797|NCT02781597|Drug|Placebo|Patients will receive 0.9% normal saline
181798|NCT02781584|Drug|SEL|Administered orally once daily
181799|NCT02781584|Drug|Firsocostat|Administered orally once daily
181800|NCT02781584|Drug|Cilofexor|Administered orally once daily
181801|NCT02781584|Drug|Fenofibrate|Administered orally once daily
181802|NCT02781584|Drug|Vascepa|Administered orally two times daily
181803|NCT02781571|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
181804|NCT02781558|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
181805|NCT02781558|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
181806|NCT02781519|Drug|THC|Active THC (0.015mg/kg) administered over 10 minutes
181807|NCT02781519|Drug|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
181808|NCT02781506|Drug|Nivolumab|Nivolumab IV, 3 mg/kg q2 weeks
181809|NCT02781506|Radiation|SAbR|SAbR (1-3 lesions)
181810|NCT02781493|Drug|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
181811|NCT02781493|Drug|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
181812|NCT02781480|Biological|AAV RPE65|Comparison of different dosages of AAV RPE65
181813|NCT02781467|Biological|PNK-007|
181814|NCT02781467|Drug|Cyclophosphamide|
181815|NCT02781467|Drug|Fludarabine|
181816|NCT02781467|Drug|Human recombinant Interleukin-2 (rhIL-2)|
181817|NCT02781454|Drug|Mexiletine|
181818|NCT02781454|Drug|Placebo|
181819|NCT02781441|Behavioral|Question prompt list (QPL)|
181820|NCT02781441|Behavioral|Education brochure of Groupe Français des Myélodysplasies|
181821|NCT02781415|Procedure|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
181822|NCT02781415|Drug|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
182054|NCT02779751|Drug|Anastrozole|Administered orally
181823|NCT02781402|Procedure|4 weeks of Aerobic Training|The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 75-80% of their maximum heart rate. The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 75-80% HR max. The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
181824|NCT02781376|Other|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
181825|NCT02781376|Other|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
181826|NCT02781363|Other|Thoracic ultrasound|
181827|NCT02781363|Other|CXR|
181828|NCT02781350|Other|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
181829|NCT02781350|Dietary Supplement|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
181830|NCT02781324|Procedure|Posterior Spinal Fusion|
181831|NCT02781324|Device|Ultrasonic Bone Scalpel|
181832|NCT02781311|Drug|Setipiprant|Setipiprant tablets, orally, BID for 24 weeks.
181833|NCT02781311|Drug|Placebo|Placebo tablets, orally, BID for 24 weeks.
181834|NCT02781311|Drug|Finasteride|Finasteride tablet, orally, once daily for 24 weeks.
181835|NCT02781298|Dietary Supplement|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
181836|NCT02781298|Dietary Supplement|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
181837|NCT02781272|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
181838|NCT02781272|Procedure|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
181839|NCT02781272|Procedure|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
181840|NCT02781259|Procedure|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
181841|NCT02781259|Drug|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
181842|NCT02781259|Device|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
181843|NCT02781246|Drug|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
181844|NCT02781233|Other|Progressive resistance training|Progressive resistance training program
181845|NCT02781233|Other|Normal daily activities|Usual daily activities
181846|NCT02781194|Device|3M™ Bair Hugger™|forced-air warming blanket
181847|NCT02781194|Device|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
181848|NCT02781181|Device|CAS with CPD|using a neuroprotection device
181849|NCT02781181|Other|CAS without CPD|No Neuroprotection
181850|NCT02781168|Device|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
181851|NCT02781155|Other|Moxibustion|Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
181852|NCT02781142|Other|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied two times a week for 8 weeks. The first one and/or two sessions will be performed in the clinic, the other will be performed at the patients' home with a video-conference telerehabilitation technique.
181853|NCT02781129|Other|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
181877|NCT02780934|Other|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
181878|NCT02780921|Procedure|prehabilitation|
181879|NCT02780921|Other|nutritional support|
182055|NCT02779738|Drug|Merestinib|Administered orally
181854|NCT02781103|Other|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
181855|NCT02781103|Other|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
181856|NCT02781090|Behavioral|PSFW+|PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
181857|NCT02781090|Behavioral|AHA|The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
181858|NCT02781090|Drug|Nicotine polacrilex|All participants, in both study arms, will be offered a 3-month supply of nicotine patches
181859|NCT02781077|Procedure|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
181860|NCT02781064|Drug|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
181861|NCT02781064|Drug|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
181862|NCT02781051|Behavioral|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
181863|NCT02781051|Device|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
181864|NCT02781051|Behavioral|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
181865|NCT02781051|Other|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
181866|NCT02781038|Behavioral|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
181867|NCT02781038|Behavioral|Control|Subjects in this group will not receive the pamphlet
181868|NCT02781025|Other|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
181869|NCT02780999|Device|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
181870|NCT02780999|Device|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
181871|NCT02780986|Behavioral|Female entertainment worker intervention group|"The following summarises the content of each session:~Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.~Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.~Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.~Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
181872|NCT02780986|Behavioral|Heterosexual men intervention group|"This will be delivered via 3 main activities:~Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.~Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.~Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
181873|NCT02780973|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
181874|NCT02780960|Device|HPV self-testing|Patients will perform HPV testing themselves at home.
181875|NCT02780947|Procedure|Ventricular tachycardia substrate ablation|"Study protocol~Baseline programmed ventricular stimulation performed from the LV~High density endocardial LV mapping using CARTO® 3 System~Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
181876|NCT02780934|Other|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
184268|NCT02763475|Drug|Fludarabine|25mg/m2 iv daily on day -5 to -1
181880|NCT02780908|Other|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
181881|NCT02780908|Other|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
181882|NCT02780895|Drug|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.~For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.~To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.~After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
181883|NCT02780882|Drug|Pasireotide|
181884|NCT02780869|Device|HEMOBLAST Bellows|
181885|NCT02780869|Device|Absorbable gelatin sponge, USP with thrombin|
181886|NCT02780856|Device|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and a black & white and luminescent image of each tooth taken. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
181887|NCT02780843|Other|Computerized Tomography|Standard Operational Plan at admission: CT and CT-angiography
181888|NCT02780843|Other|Magnetic Resonance Imaging|Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
181889|NCT02780830|Drug|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
181890|NCT02780830|Drug|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
181891|NCT02780817|Other|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
181892|NCT02780817|Other|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
181893|NCT02780804|Drug|Entinostat|Given PO
181894|NCT02780804|Other|Laboratory Biomarker Analysis|Correlative studies
181895|NCT02780804|Other|Pharmacological Study|Correlative studies
181896|NCT02780791|Other|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
181897|NCT02780791|Other|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
181898|NCT02780778|Drug|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
181899|NCT02780778|Drug|Docetaxel|chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
181900|NCT02780765|Device|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
181901|NCT02780765|Device|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
181902|NCT02780752|Drug|hymecromone|hymecromone treatment as described
181903|NCT02780739|Behavioral|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
181904|NCT02780739|Behavioral|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills & Skills; and Cool-down/stretch.
181905|NCT02780739|Behavioral|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
181944|NCT02780544|Device|incubator|staying in incubator during eye examination.
181945|NCT02780544|Drug|Sucrose|oral sucrose before eye examination
181946|NCT02780518|Device|Airvo|Applying high flow nasal oxygen
182011|NCT02780128|Drug|Ribociclib|"Group 1: Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.~Group 2B: Participants will take ribociclib once per day orally for Days 8-21 of a 21-day cycle."
181906|NCT02780739|Device|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
181907|NCT02780739|Device|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
181908|NCT02780739|Behavioral|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
181909|NCT02780726|Drug|ASP1517|Oral
181910|NCT02780713|Drug|AZD9496 (Reference)|AZD9496 (Reference)
181911|NCT02780713|Drug|AZD9496 Variant A|AZD9496 Variant A.
181912|NCT02780713|Drug|AZD9496 Variant B|AZD9496 Variant B
181913|NCT02780713|Drug|AZD9496 Variant C|AZD9496 Variant C
181914|NCT02780713|Drug|AZD9496 Variant D|AZD9496 Variant D
181915|NCT02780700|Drug|Nintedanib|
181916|NCT02780700|Drug|Capecitabine|
181917|NCT02780687|Drug|Afatinib|
181918|NCT02780674|Biological|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
181919|NCT02780674|Biological|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
181920|NCT02780661|Device|Denture Cleanser Daily Use Period|One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
181921|NCT02780661|Device|Denture Cleanser Weekly Use Period|One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
181922|NCT02780661|Other|Water|A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
181923|NCT02780648|Radiation|Stereotactic Body Radiation|
181924|NCT02780635|Behavioral|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
181925|NCT02780635|Behavioral|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
181926|NCT02780622|Drug|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
181927|NCT02780622|Drug|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
181928|NCT02780609|Drug|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
181929|NCT02780609|Drug|Melphalan|Melphalan 100 mg/m^2 IV over 30-45 minutes.
181930|NCT02780609|Drug|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1).
181931|NCT02780609|Procedure|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
181932|NCT02780609|Drug|Fosaprepitant|Fosaprepitant at 150 mg IV on days -3 and -2.
181933|NCT02780596|Other|Item1|Does CHILD NAME often wake one or more times during the night?
181934|NCT02780596|Other|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
181935|NCT02780596|Other|Item3|Do you think CHILD'S SLEEP is a problem?
181936|NCT02780596|Other|Item4|Do you think CHILD NAME has a sleep problem?
181937|NCT02780596|Other|Item5|Do you have any concerns about CHILD NAME'S sleep?
181938|NCT02780583|Drug|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
181939|NCT02780583|Drug|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
181940|NCT02780570|Procedure|Small Volume Plasma Exchange|Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
181941|NCT02780557|Behavioral|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
181942|NCT02780557|Behavioral|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
181943|NCT02780544|Behavioral|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
181947|NCT02780505|Drug|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.~The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
181948|NCT02780505|Drug|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.~The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
181949|NCT02780492|Other|Set of assessment tools|
181950|NCT02780479|Drug|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
181951|NCT02780479|Drug|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
181952|NCT02780453|Device|Negative pressure dressing|
181953|NCT02780453|Device|Standard wound dressing|
181954|NCT02780440|Behavioral|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
181955|NCT02780440|Behavioral|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
181956|NCT02780440|Behavioral|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
181957|NCT02780427|Drug|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.25 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
181958|NCT02780401|Other|Laboratory Biomarker Analysis|Correlative studies
181959|NCT02780401|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
181960|NCT02780401|Biological|Sargramostim|Given ID
181961|NCT02780388|Drug|VIB4920|Participants will receive a single IV dose of VIB4920 Q2W from Day 1 up to 12 weeks.
181962|NCT02780388|Other|Placebo|Participants will receive a single IV dose of placebo matched to VIB4920 Q2W from Day 1 up to 12 weeks.
181963|NCT02780375|Procedure|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
181964|NCT02780362|Drug|Prodactariv|1 tablet contains 60 mg Daclatasvir
181965|NCT02780362|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
181966|NCT02780349|Device|WIRION|Embolic Protection System
181967|NCT02780336|Other|No intervention.|Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
181968|NCT02780323|Drug|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
181969|NCT02780323|Drug|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
181970|NCT02780323|Drug|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
181971|NCT02780323|Drug|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
181972|NCT02780310|Drug|Lenvatinib|
181973|NCT02780284|Behavioral|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise
181974|NCT02780271|Behavioral|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
181975|NCT02780271|Behavioral|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
181976|NCT02780271|Behavioral|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
181977|NCT02780258|Device|Restylane Silk|
181978|NCT02780245|Drug|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
181979|NCT02780245|Procedure|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
181980|NCT02780232|Behavioral|Cuida tu animo / Care for your mood|"CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.~Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:~What is 'CUIDA TU ÁNIMO': Description and definition of the program~Psycho-educational information: Information about depression, its treatment, and opportunities for prevention~How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback~Forums.~Blog.~Appointment (Chat or Phone call).~Contact."
182009|NCT02780128|Other|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
181981|NCT02780219|Other|stable amino acid infusion|stable isotopes Such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
181982|NCT02780219|Other|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
181983|NCT02780219|Other|24-hour post exercise amino acid infusion|stable isotopes such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
181984|NCT02780206|Other|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
181985|NCT02780193|Drug|Omegaven|Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
181986|NCT02780180|Drug|QGC001|
181987|NCT02780180|Drug|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
181988|NCT02780167|Drug|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
181989|NCT02780167|Drug|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
181990|NCT02780167|Drug|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
181991|NCT02780167|Drug|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
181992|NCT02780167|Drug|Placebo|Placebo QD for 12 weeks
181993|NCT02780154|Biological|PfSPZ (7G8) Challenge|PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
181994|NCT02780154|Biological|PfSPZ (NF54) Challenge|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
181995|NCT02780141|Drug|roxadustat|Oral
181996|NCT02780128|Procedure|Biopsy|Needle or incisional tumor biopsy
181997|NCT02780128|Drug|Ceritinib|Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
181998|NCT02780128|Drug|Trametinib|Participants will take trametinib once per day orally for Days 1-14 of a 21-day cycle.
181999|NCT02780128|Drug|HDM201|Participants will take HDM201 orally on Day 1 and Day 8 of a 28-day cycle.
182000|NCT02780128|Genetic|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
182001|NCT02780128|Procedure|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
182002|NCT02780128|Radiation|X-ray|Participants will have x-rays of the wrist and leg.
182003|NCT02780128|Procedure|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
182004|NCT02780128|Other|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
182005|NCT02780128|Other|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
182006|NCT02780128|Other|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
182007|NCT02780128|Other|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
182008|NCT02780128|Behavioral|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
182010|NCT02780128|Other|Echocardiogram|The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
182012|NCT02780115|Drug|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
182013|NCT02780115|Drug|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
182014|NCT02780115|Drug|AGN-199201 Vehicle|Vehicle to AGN-199201
182015|NCT02780115|Drug|AGN-190584 Vehicle|Vehicle to AGN-190584
182016|NCT02780102|Other|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
182017|NCT02780102|Drug|Ritalin|2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
182018|NCT02780102|Other|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
182019|NCT02780076|Other|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
182020|NCT02780063|Other|Lenstar Biometer|uses optical principles (laser interferometry) to measure axial length, measuring distance from the corneal apex to the retinal RPE. In addition to axial length, it also measures corneal thickness, anterior chamber depth, lens thickness, radii of curvature of flat and steep meridian, axis of flat meridian, white to white distance, and pupil diameter.
182021|NCT02780050|Other|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.~After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
182022|NCT02780037|Behavioral|Regulatory frame: prevention|Exercise program presented as preventing deterioration.
182023|NCT02780037|Behavioral|Regulatory frame: promotion|Exercise program presented as promoting improvement.
182024|NCT02780037|Behavioral|Regulatory frame: not implied|Exercise program presented without implied consequences.
182025|NCT02780024|Drug|Metformin|Metformin,
182026|NCT02780011|Drug|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
182027|NCT02780011|Drug|Alsertib|Aurora A kinase inhibitor
182028|NCT02779998|Other|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
182029|NCT02779998|Other|Standard oxygen therapy with facial mask|
182030|NCT02779985|Dietary Supplement|Lycium Barbarum mixed meal|This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
182031|NCT02779985|Dietary Supplement|Control mixed meal|This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
182032|NCT02779972|Other|Echo stress test|Echo stress test
182033|NCT02779959|Drug|Prochlorperazine|
182034|NCT02779946|Device|Fibro Scan|
182035|NCT02779946|Genetic|PNPLA3|
182036|NCT02779933|Other|Epidemiology od HAP|no intervention
182037|NCT02779920|Procedure|per oral pylorotomy|The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
182038|NCT02779907|Other|No Intervention|No interventions planned for this observational study
182039|NCT02779894|Other|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
182040|NCT02779881|Dietary Supplement|Extensively hydrolyzed casein formula plus LGG|
182041|NCT02779868|Dietary Supplement|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
182042|NCT02779868|Dietary Supplement|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
182043|NCT02779855|Biological|Talimogene laherparepvec|Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
182044|NCT02779855|Drug|Paclitaxel|Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m^2.
182045|NCT02779842|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. formulation number SR15-39-Z12-002.
182046|NCT02779829|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. Formulation number SR15-40-Z12-006.
182047|NCT02779816|Device|Pen device|Adaptive pen device
182048|NCT02779803|Procedure|EC-IC bypass|To determine if cerebral revascularization via STA to MCA bypass to improve cerebral hemodynamics, cognitive function, and quality of life in a defined subgroup of symptomatic carotid occlusion patients.
182049|NCT02779790|Other|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
182050|NCT02779777|Drug|Tipifarnib|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
182051|NCT02779764|Drug|roxadustat|Oral
182056|NCT02779725|Behavioral|SCC|Automated self-management coaching paired to symptom reports during daily symptom monitoring call
182057|NCT02779725|Behavioral|Nurse Practitioner|Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
182058|NCT02779725|Behavioral|DSS|A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
182059|NCT02779725|Behavioral|AT|An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
182060|NCT02779725|Behavioral|Symptom Severity|Automated patient-reporting of 11 common cancer treatment symptoms
182061|NCT02779712|Procedure|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
182062|NCT02779712|Procedure|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
182063|NCT02779699|Drug|AL2846|AL2846 p.o. qd
182064|NCT02779673|Other|Yoghurt drink containing plant stanol as esters|
182065|NCT02779673|Other|Yoghurt drink without plant stanol as esters|
182066|NCT02779660|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
182067|NCT02779660|Procedure|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
182068|NCT02779647|Behavioral|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). The total of sessions was 144, the minimum number of sessions to consider valid that a child has completed the intervention was 115 (80%) in order to perform the minimum level of physical activity recommended for their ages. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
182069|NCT02779634|Drug|ubiquinol|Ubiquinol three times daily
182070|NCT02779634|Drug|Placebo|Sugar pill three times daily
182071|NCT02779621|Procedure|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
182072|NCT02779621|Procedure|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
182073|NCT02779608|Drug|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
182074|NCT02779608|Drug|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
182075|NCT02779595|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
182076|NCT02779582|Drug|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
182077|NCT02779582|Drug|Placebo|pill with no effect
182078|NCT02779569|Drug|decitabine|
182079|NCT02779556|Other|ACP Living with Diabetes Guide|American Colleges of Physicians (ACP) Living Well with Diabetes Guide
182080|NCT02779556|Other|ADA Living Well with Diabetes Workbook|American Diabetes Association (ADA) Living Well with Diabetes Workbook
182081|NCT02779543|Device|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
182082|NCT02779543|Device|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
182083|NCT02779543|Device|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
182084|NCT02779530|Drug|Diclofenac|50 mg po, b.i.d for 6 days
182085|NCT02779530|Other|Placebo|Placebo po, b.i.d. for 6 days
182086|NCT02779517|Other|Mobile Service Robot Survey|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
182139|NCT02779153|Drug|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
182087|NCT02779517|Other|Mobile Service Robot Survey for Patients|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
182088|NCT02779491|Behavioral|5-a-day fruit and vegetable mobile phone application|5-a-day fruit and vegetable mobile phone application
182089|NCT02779478|Procedure|Bronchoscopy|
182090|NCT02779465|Drug|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
182091|NCT02779439|Biological|Virus specific CTLs|Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
182092|NCT02779426|Behavioral|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
182093|NCT02779413|Drug|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
182094|NCT02779400|Device|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
182095|NCT02779387|Drug|Goserelin Acetate|
182096|NCT02779374|Other|Autologous bone marrow transplantation|Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
182097|NCT02779361|Dietary Supplement|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (*), 10:30 am, 13:00 pm (*), 15:30 pm, 18:00 pm (*), 20:30 pm on day 7.~One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (*)."
182098|NCT02779348|Drug|BIA 3-202|Nebicapone tablets 200 mg
182099|NCT02779348|Drug|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
182100|NCT02779335|Other|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
182101|NCT02779322|Procedure|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
182102|NCT02779322|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
182103|NCT02779309|Procedure|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
182104|NCT02779296|Other|2-Octyl Cyanoacrylate Glue|topical
182105|NCT02779283|Drug|Cyclophosphamide|Given IV
182106|NCT02779283|Drug|Cytarabine|Given IV
182107|NCT02779283|Drug|Dasatinib|Given PO
182108|NCT02779283|Drug|Dexamethasone|Given PO
182109|NCT02779283|Drug|Doxorubicin Hydrochloride|Given IV
182110|NCT02779283|Drug|Idarubicin|Given IV
182111|NCT02779283|Drug|Idelalisib|Given PO
182112|NCT02779283|Device|In Vitro Kinase Inhibitor Assay|Correlative studies
182113|NCT02779283|Drug|Leucovorin Calcium|Given IV
182114|NCT02779283|Drug|Methotrexate|Given IV
182115|NCT02779283|Drug|Methylprednisolone Sodium Succinate|Given IV
182116|NCT02779283|Drug|Ponatinib Hydrochloride|Given PO
182117|NCT02779283|Biological|Rituximab|Given IV
182118|NCT02779283|Drug|Ruxolitinib Phosphate|Given PO
182119|NCT02779283|Drug|Sorafenib Tosylate|Given PO
182120|NCT02779283|Drug|Sunitinib Malate|Given PO
182121|NCT02779283|Drug|Vincristine Sulfate|Given IV
182122|NCT02779270|Drug|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.~Formulation: V27-104"
182123|NCT02779270|Drug|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
182124|NCT02779257|Drug|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
182125|NCT02779257|Drug|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
182126|NCT02779244|Procedure|Early Weight bearing + Cam Boot|Patients will be transitioned to weight bearing as tolerated in a cam boot.
182127|NCT02779244|Procedure|Non-Weight Bearing + Cam Boot|Subject will be transitioned to non weight bearing cam boot, standard treatment.
182128|NCT02779231|Other|Bi-directional texting|
182129|NCT02779218|Procedure|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
182130|NCT02779218|Procedure|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
182131|NCT02779218|Procedure|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
182132|NCT02779205|Procedure|adipose tissue sample|adipose tissue sample
182133|NCT02779192|Drug|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
182134|NCT02779192|Drug|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
182135|NCT02779192|Drug|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
182136|NCT02779179|Procedure|Periodontal treatment|"Mechanical debridement (scaling, root planning, subgingival curettage)~Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).~Antiseptic mouthrinses, gel or dentifrice~Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
182137|NCT02779166|Drug|Celecoxib|Received 400mg celecoxib prior to surgery
182138|NCT02779166|Drug|placebo|
182226|NCT02778386|Other|Placebo Capsule|Two patients in Cohort 3 & 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
182227|NCT02778373|Dietary Supplement|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
182140|NCT02779153|Drug|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
182141|NCT02779140|Biological|NTM-1632|Monoclonal antibody mixture of XB10, XB18, and XB23
182142|NCT02779140|Other|Placebo|Placebo
182143|NCT02779127|Other|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
182144|NCT02779127|Other|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
182145|NCT02779127|Other|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
182146|NCT02779127|Other|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
182147|NCT02779127|Other|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
182148|NCT02779114|Drug|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
182149|NCT02779114|Other|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
182150|NCT02779114|Other|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
182151|NCT02779101|Drug|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
182152|NCT02779088|Other|exercise and nutrition|Exercise:muscle strengthening exercise Nutrition: 7.2 g branched chain amino acid every day and 1200 mg Ca+800 IU Vitamin D3
182153|NCT02779075|Drug|Saline|Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
182154|NCT02779075|Drug|Exendin-9,39|Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
182155|NCT02779062|Other|Interview|Interview
182156|NCT02779049|Other|Blood examination|blood sampling
182157|NCT02779036|Procedure|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
182158|NCT02779036|Procedure|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
182159|NCT02779023|Behavioral|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
182160|NCT02779010|Behavioral|Hand washing with soap and Health education|Health education on key environmental variables and hand washing with soap
182161|NCT02778997|Procedure|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
182162|NCT02778984|Device|QuadraLite masks|The intervention is identical in the two group
182163|NCT02778984|Other|standard mask|
182164|NCT02778971|Drug|[18F]Flutemetamol|amyloid PET imaging with [18F]Flutemetamol and subsequent modification of diagnosis and management
182165|NCT02778958|Drug|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
182166|NCT02778958|Drug|ibuprofen|"iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
182167|NCT02778945|Drug|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
182168|NCT02778945|Drug|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
182169|NCT02778919|Drug|KLH-2109|
182170|NCT02778919|Drug|Placebo|
182171|NCT02778919|Drug|Leuprorelin acetate|
182172|NCT02778906|Drug|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
182173|NCT02778906|Drug|Placebo|Administration of the comparator s.c. weekly in comparable to verum
182174|NCT02778893|Drug|Conmana|125mg three times a day (TID) continuously
182175|NCT02778893|Drug|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
182176|NCT02778880|Drug|Ketamine|
182177|NCT02778880|Drug|Fentanyl|
182178|NCT02778867|Other|elimination diet therapy|1FED: milk elimination 6FED: milk, egg, wheat, soy, fish/shellfish, and tree nuts/peanut elimination
182179|NCT02778867|Drug|Flovent|Flovent (fluticasone propionate): swallowed glucocorticoid
182180|NCT02778854|Genetic|detection of driver mutation|participants are received gene detection via the liquid biopsy
182181|NCT02778841|Other|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
182228|NCT02778373|Dietary Supplement|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
182229|NCT02778373|Other|Placebo: Water|
182182|NCT02778828|Drug|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
182183|NCT02778815|Other|Kindness for Mums|
182184|NCT02778789|Drug|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
182185|NCT02778789|Drug|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
182186|NCT02778776|Drug|Metformin|Metfomin in tablet presentation of 500 mg
182187|NCT02778776|Dietary Supplement|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
182188|NCT02778776|Other|Placebo of agave inulin|Calcinated magnesia powder
182189|NCT02778776|Other|Metformin placebo|Calcinated magnesia tablet
182190|NCT02778763|Drug|CBLB612|4 μg CBLB612 SQ
182191|NCT02778763|Drug|Placebo|
182192|NCT02778750|Procedure|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
182193|NCT02778737|Behavioral|ACT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.~Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
182194|NCT02778737|Behavioral|CBT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.~Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.~Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
182195|NCT02778711|Drug|secukinumab|anti-IL-17
182196|NCT02778698|Dietary Supplement|Omegaven|
182197|NCT02778685|Other|Laboratory Biomarker Analysis|Correlative studies
182198|NCT02778685|Drug|Letrozole|Given PO
182199|NCT02778685|Drug|Palbociclib|Given PO
182200|NCT02778685|Biological|Pembrolizumab|Given IV
182201|NCT02778672|Other|Thermal imaging of infant's chest with a mobile phone|
182202|NCT02778659|Drug|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
182203|NCT02778659|Drug|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
182204|NCT02778594|Drug|BIA 3-202|nebicapone 50 mg tablets; oral use
182205|NCT02778594|Drug|Placebo|Nebicapone matching placebo tablets
182206|NCT02778594|Drug|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
182207|NCT02778581|Dietary Supplement|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
182208|NCT02778581|Dietary Supplement|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
182209|NCT02778581|Dietary Supplement|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
182210|NCT02778568|Behavioral|Resistance training|Resistance training exercises
182211|NCT02778568|Behavioral|Control|Stretching exercises
182212|NCT02778555|Behavioral|Questionnaires|
182213|NCT02778542|Behavioral|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
182214|NCT02778542|Behavioral|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
182215|NCT02778529|Device|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
182216|NCT02778516|Dietary Supplement|Sodium Restriction|
182217|NCT02778503|Other|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
182218|NCT02778503|Other|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
182219|NCT02778477|Drug|PF-06423264|Multiple ascending dose of PF-06423264
182220|NCT02778477|Other|Placebo|Multiple dose of placebo
182221|NCT02778451|Other|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
182222|NCT02778425|Procedure|PSE|Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches of diseases.It has been demonstrated to effectively increase hematologic indices in cirrhotic patients with splenomegaly. This is particularly valuable amongst those cirrhotic patients who are not viable candidates for splenectomy.
182223|NCT02778399|Drug|Placebo|Placebo tablets for oral administration once daily
182224|NCT02778399|Drug|OBE2109|OBE2109 tablets for oral administration once daily
182225|NCT02778386|Drug|N-Methanocarbathymidine|Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.
182264|NCT02778048|Other|US (ultra sound)|Assessment of the sphincter
182230|NCT02778360|Device|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.~The training is personalized according to patient's characteristics."
182231|NCT02778360|Drug|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
182232|NCT02778334|Other|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~patients who return home and~patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3)."
182233|NCT02778321|Device|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.~The data collected :~Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)~Data on the CI:~Monitoring Results scope ICU Neurovascular.~Presence palpitations~Treatment influencing the rate (beta-blockers or antiarrhythmic)~Data on cardiac monitoring:~A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
182234|NCT02778308|Drug|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
182235|NCT02778282|Other|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
182236|NCT02778269|Device|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
182237|NCT02778269|Device|Dexcom G4-System|Continuous Glucose Monitoring
182238|NCT02778256|Device|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
182239|NCT02778256|Device|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
182240|NCT02778243|Biological|steroids concentrations determination|
182241|NCT02778230|Dietary Supplement|Pea Fiber|Snacks (2 baked goods) fortified with 5 g pea hull fiber
182242|NCT02778230|Dietary Supplement|Control|Snacks (2 baked goods) without fiber fortification.
182243|NCT02778217|Procedure|Culture media renwal|
182244|NCT02778204|Drug|Maraviroc|"For Cohort 1: 8 mg/kg oral solution as a single dose.~For Cohort 2: 8 mg/kg oral solution given twice daily."
182245|NCT02778191|Drug|cisplatin|100 mg/m2 day 1, 22 and 43
182246|NCT02778191|Drug|carboplatin|carboplatin 300-350 mg/m2 day 1, 22 and 43
182247|NCT02778191|Drug|5-FU|5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
182248|NCT02778178|Drug|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
182249|NCT02778178|Drug|Placebo|20 mL saline 0.9%, per side
182250|NCT02778178|Device|ultrasound|
182251|NCT02778165|Other|MyCaRe (my cardiac recovery Android application)|Application & Fitbit Flex activity monitor
182252|NCT02778152|Device|Laser depilation|Laser depilation of natal cleft (pilonidal region)
182253|NCT02778126|Drug|[¹⁴C]Prexasertib|Administered IV Infusion
182254|NCT02778126|Drug|Prexasertib|Administered IV Infusion
182255|NCT02778113|Drug|Nasal Glucagon|Administered intranasally.
182256|NCT02778113|Drug|Glucagon|Administered SC.
182257|NCT02778100|Drug|Nasal Glucagon|Administered intranasally.
182258|NCT02778100|Drug|Oxymetazoline|Administered intranasally.
182259|NCT02778087|Behavioral|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
182260|NCT02778087|Behavioral|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
182261|NCT02778074|Behavioral|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
182262|NCT02778074|Behavioral|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
182263|NCT02778048|Other|MRI (magnetic resonance imaging)|Assessment of the sphincter
182265|NCT02778048|Other|FLIP (functional lumen imaging probe)|Assessment of the sphincter
182266|NCT02778048|Other|HRAM (high resolution anal manometry)|Assessment of the sphincter
182267|NCT02778035|Device|Dorsomedial prefrontal rTMS|Dorsomedial prefrontal rTMS, bilateral, iTBS, 600 pulses per hemisphere, 120% RMT, 2 sessions at 0, 30, or 60 min inter-session interval
182268|NCT02778022|Behavioral|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
182269|NCT02778009|Radiation|iDEXA Scan|Subjects will receive pre study and post study scans to assess body mass composition
182270|NCT02778009|Other|Wellness Lectures|Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
182271|NCT02778009|Other|Exercise intervention|Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
182272|NCT02778009|Other|Activity monitor|Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
182273|NCT02777996|Device|Low Dose Computed Tomography|Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
182274|NCT02777983|Behavioral|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
182275|NCT02777970|Drug|Tramadol Hydrochloride/Dexketoprofen Trometamol|
182276|NCT02777970|Drug|Tramadol Hydrochloride/Paracetamol|
182277|NCT02777970|Drug|Placebo|
182278|NCT02777944|Behavioral|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
182279|NCT02777931|Drug|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
182280|NCT02777931|Drug|Placebo|Matching placebo capsules
182281|NCT02777918|Behavioral|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
182282|NCT02777905|Behavioral|Mindfulness Based Cognitive Therapy|
182283|NCT02777892|Other|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
182284|NCT02777879|Procedure|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
182285|NCT02777866|Drug|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
182286|NCT02777866|Drug|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
182287|NCT02777853|Dietary Supplement|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
182288|NCT02777853|Dietary Supplement|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
182289|NCT02777840|Device|face mask oxygen|oxygen given by face mask as per routine practice
182290|NCT02777840|Device|High flow oxygen|High flow oxygen given via optiflo machine / device
182291|NCT02777827|Drug|Abediterol 0.156 μg|Dry powder for inhalation
182292|NCT02777827|Drug|Abediterol 2.5 μg|Dry powder for inhalation
182293|NCT02777827|Drug|Abediterol 0.05 μg|Pressurised metered-dose inhaler
182294|NCT02777827|Drug|Abediterol 0.156 μg|Pressurised metered-dose inhaler
182295|NCT02777827|Drug|Abediterol 2.5 μg|Pressurised metered-dose inhaler
182296|NCT02777827|Other|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
182297|NCT02777814|Drug|Entecavir|anti hepatitis B virus
182298|NCT02777801|Drug|Entecavir|anti-HBV
182299|NCT02777788|Drug|JinFuKang|treated with chemotherapy
182300|NCT02777788|Drug|XingZaoRuanJian|treated with chemotherapy
182301|NCT02777788|Drug|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
182362|NCT02777294|Behavioral|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
182363|NCT02777281|Behavioral|Shoulder pain and SCI|Shoulder pain and SCI
182364|NCT02777281|Behavioral|Shoulder pain and able bodies|
182365|NCT02777268|Drug|Infacort|Multi-particulate granules
182366|NCT02777268|Drug|Hydrocortisone|Tablet
182302|NCT02777775|Procedure|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:~The skin area will be cleaned~The skin area will be numbed (by either a numbing cream or a tiny numbing shot)~Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.~A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.~Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
182303|NCT02777762|Behavioral|Fun First|8 weekly interactive small-group sessions with a health coach
182304|NCT02777762|Behavioral|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
182305|NCT02777749|Drug|Bupivacaine|15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection
182306|NCT02777736|Drug|Methotrexate|i.v. or intrathecal CNS prophylaxis
182307|NCT02777723|Drug|Xenobella|Hypotonic 0.3% Sodium Hyaluronate
182308|NCT02777723|Drug|Isotonic 0.3% Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
182309|NCT02777710|Drug|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
182310|NCT02777710|Drug|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
182311|NCT02777697|Other|chronic pain|
182312|NCT02777684|Other|Qualitative study|
182313|NCT02777671|Drug|BIA 2-093|
182314|NCT02777671|Drug|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
182315|NCT02777645|Other|Growth, feeding evaluation|Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions
182316|NCT02777632|Procedure|Living donor liver transplantation|
182317|NCT02777619|Drug|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
182318|NCT02777619|Drug|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
182319|NCT02777619|Drug|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
182320|NCT02777619|Drug|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
182321|NCT02777619|Drug|Propofol|
182322|NCT02777606|Drug|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3 days in the treatment group.
182323|NCT02777593|Device|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
182324|NCT02777580|Drug|Tenecteplase|Half dose Tenecteplase
182325|NCT02777580|Drug|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
182326|NCT02777580|Procedure|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
182327|NCT02777580|Procedure|Primary PCI|Primary PCI accoring to local standards
182328|NCT02777554|Drug|Apremilast|
182329|NCT02777541|Dietary Supplement|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
182330|NCT02777541|Dietary Supplement|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
182331|NCT02777528|Device|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
182332|NCT02777528|Procedure|Revascularization Procedure|Revascularization procedure of the great vessel
182333|NCT02777515|Behavioral|using electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:~A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)~measurement of blood pressure~An electrocardiogram~A Holter-ECG 10 minutes~A transthoracic echocardiogram"
182334|NCT02777489|Drug|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
182335|NCT02777476|Device|B-Lite- Light Weight Breast Implants|
183139|NCT02771587|Dietary Supplement|Alcohol|Multiple oral dose of alcohol
182336|NCT02777463|Other|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 1000 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 3.0T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
182337|NCT02777450|Procedure|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
182338|NCT02777437|Drug|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
182339|NCT02777424|Drug|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
182340|NCT02777424|Biological|Fresh Frozen Plasma|Pooled collection of plasma from donors
182341|NCT02777411|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
182342|NCT02777411|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
182343|NCT02777411|Biological|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
182344|NCT02777411|Biological|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
182345|NCT02777411|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
182346|NCT02777411|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
182347|NCT02777411|Biological|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
182348|NCT02777398|Procedure|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
182349|NCT02777398|Procedure|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
182350|NCT02777385|Drug|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
182351|NCT02777385|Drug|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
182352|NCT02777385|Radiation|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
182353|NCT02777372|Drug|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine LH Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
182354|NCT02777359|Procedure|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
182355|NCT02777346|Device|Absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
182356|NCT02777346|Device|Non absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.~Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
182357|NCT02777333|Behavioral|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
182358|NCT02777320|Drug|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
182359|NCT02777320|Drug|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
182360|NCT02777307|Other|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
182361|NCT02777294|Behavioral|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
185114|NCT02757391|Biological|Pembrolizumab|Given IV
182367|NCT02777242|Combination Product|Testosterone enanthate auto-injector|SC injections of QST 50 mg or 75 mg or 100 mg
182368|NCT02777229|Drug|Dolutegravir 50 mg|1 tablet once a day
182369|NCT02777229|Drug|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
182370|NCT02777229|Drug|Efavirenz 200 mg|2 tablets once a day
182371|NCT02777216|Device|ConfidenHT system|ConfidenHT Medical system
182372|NCT02777203|Device|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag.
182373|NCT02777190|Drug|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
182374|NCT02777164|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
182375|NCT02777151|Drug|REGN3470-3471-3479|
182376|NCT02777151|Drug|Placebo|
182377|NCT02777138|Other|Maintaining a normal daily living lifestyle|participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
182378|NCT02777125|Device|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
182379|NCT02777125|Device|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
182380|NCT02777112|Other|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
182381|NCT02777112|Other|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
182382|NCT02777112|Other|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
182383|NCT02777099|Procedure|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
182384|NCT02777099|Procedure|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
182385|NCT02777086|Behavioral|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
182386|NCT02777073|Drug|Farxiga|Single dose of dapagliflozin
182387|NCT02777073|Drug|Victoza|Single dose of Liraglutide
182388|NCT02777073|Drug|Placebo|Single dose of generic placebo
182389|NCT02777060|Procedure|Exergame|Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
182390|NCT02777060|Procedure|Home based balance training|Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
182391|NCT02777047|Other|Anticoagulation Coordinated Care|see above
182392|NCT02777034|Other|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.~Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.~Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
182393|NCT02777034|Other|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.~Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.~Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
182394|NCT02777008|Drug|CTP-543|
182395|NCT02777008|Drug|Placebo for CTP-543|
182396|NCT02776995|Other|Thermography imaging|Thermography imaging of the treated - irradiated body area.
182397|NCT02776982|Procedure|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
182398|NCT02776982|Procedure|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
182399|NCT02776982|Procedure|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
182400|NCT02776982|Procedure|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
182868|NCT02773368|Drug|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
182401|NCT02776956|Drug|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
182402|NCT02776956|Drug|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
182403|NCT02776943|Biological|umbilical cord mesenchymal stem cells|
182404|NCT02776943|Device|Hyaluronic acid|
182405|NCT02776917|Drug|Cirmtuzumab + Paclitaxel|Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
182406|NCT02776904|Other|Immediate Post-concussion Assessment and Cognitive Testing|
182407|NCT02776904|Other|Psychomotor Vigilance Task|
182408|NCT02776891|Drug|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and standardized uptake value (SUV) calculation.
182409|NCT02776878|Drug|dasatinib|
182410|NCT02776865|Drug|suprascapular nerve block|4ml 2% xylocaine
182411|NCT02776865|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
182412|NCT02776852|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: SR15-43-Y65-158)
182413|NCT02776839|Device|Mobile sensing|
182414|NCT02776813|Biological|ACTR087|
182415|NCT02776813|Biological|rituximab|
182416|NCT02776800|Device|Allevyn Life|
182417|NCT02776800|Device|Foam dressing with an integrated adhesive border|Foam dressing normally used by the home health agency
182418|NCT02776761|Biological|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
182419|NCT02776761|Biological|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
182420|NCT02776761|Biological|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
182421|NCT02776748|Drug|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
182422|NCT02776735|Drug|Sarilumab|Pharmaceutical form:Solution Route of administration: Subcutaneous
182423|NCT02776722|Other|fructose, allulose, tagatose, or sorbose|Single-bolus feeding of fructose, allulose, tagatose, or sorbose given together with a reference carbohydrate(s) compared with the same reference carbohydrate(s) alone for acute feeding trials or chronic feeding of fructose, allulose, tagatose, or sorbose provided in substitution for other reference carbohydrates or added to a control diet compared with the reference carbohydrate(s) alone or the control diet alone for chronic feeding trials.
182424|NCT02776709|Procedure|ERCP with cholangioscopy|
182425|NCT02776696|Device|Advanced Hybrid Closed Loop System|
182426|NCT02776696|Device|Hybrid Closed Loop System|
182427|NCT02776683|Drug|BI 695502|
182428|NCT02776683|Drug|Avastin|
182429|NCT02776670|Other|Propylene glycol, 0.6% eye drops|
182430|NCT02776670|Other|Lubricant eye drops|
182431|NCT02776657|Other|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
182432|NCT02776657|Device|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
182433|NCT02776657|Procedure|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
182434|NCT02776631|Device|Pinloc|Internal fixation device
182435|NCT02776631|Device|Hansson Pins (LIH)|Internal fixation device
182436|NCT02776618|Procedure|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
182437|NCT02776605|Drug|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
182438|NCT02776605|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
182439|NCT02776605|Drug|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
182440|NCT02776605|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
182441|NCT02776605|Drug|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
182442|NCT02776605|Drug|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
182443|NCT02776605|Drug|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
182444|NCT02776605|Drug|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
182445|NCT02776605|Drug|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
182446|NCT02776605|Drug|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
182447|NCT02776605|Drug|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
182448|NCT02776605|Procedure|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
182449|NCT02776605|Procedure|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
182450|NCT02776592|Other|Cow's milk-based formula with added nutrients|
182451|NCT02776592|Other|Cow's milk-based formula|
182452|NCT02776579|Other|Girls-only resistance training|
182521|NCT02776007|Device|Self-Measurement Blood Glucose|Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
182522|NCT02775994|Drug|Canakinumab|interleukin beta (IL-1) antagonist
182523|NCT02775981|Drug|RX0041-002|
182524|NCT02775968|Drug|Cephalosporins and Macrolide Antibiotics|The intervention drugs are prescribed by treating caregiver.
182525|NCT02775955|Drug|RX0041|Active
182453|NCT02776566|Other|Patient Self-Monitoring vs Anticoagulation Clinic|"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.~Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
182454|NCT02776553|Other|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
182455|NCT02776553|Behavioral|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
182456|NCT02776553|Behavioral|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
182457|NCT02776540|Drug|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
182458|NCT02776540|Drug|Aspirin|there's another group will receive 400 mg Aspirin
182459|NCT02776527|Drug|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
182460|NCT02776514|Drug|Triamcort|Fluoroscopic guided injection in the knee joint
182461|NCT02776514|Drug|Platelet-rich-plasma|
182462|NCT02776514|Drug|Suplasyn1|
182463|NCT02776514|Drug|Placebo|
182464|NCT02776501|Drug|Coppertone (BAY987521)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: Y49-103)
182465|NCT02776488|Drug|Glucose|Less than one fifth of one ounce of glucose mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of standard brain chemistry analyses.
182466|NCT02776488|Drug|Lactate|Less than two thirds of an ounce of lactate mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of the standard brain chemistry analyses.
182467|NCT02776488|Drug|Beta-hydroxybutyrate|Less than one tenth of one ounce of hydroxybutyrate mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of the standard brain chemistry analyses.
182468|NCT02776475|Procedure|Sacral neuromodulation device turned off|Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
182469|NCT02776462|Device|EyeBox CNS|
182470|NCT02776436|Drug|Dexamethasone|Dose of prophylactic dexamethasone will be reduced for all patients
182471|NCT02776436|Drug|Prednisone|standard prednisone 5 mg bid for patients with prostate cancer
182472|NCT02776423|Procedure|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
182473|NCT02776410|Behavioral|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
182474|NCT02776397|Dietary Supplement|Vitamin E|Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.
182475|NCT02776397|Other|Placebo|Placebo arm
182476|NCT02776384|Other|Observational study|
182477|NCT02776371|Drug|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.
182478|NCT02776371|Drug|Sequential therapy|H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.
182479|NCT02776358|Other|High Fidelity Simulation|"A HFS session for an asthma attack require:~a 5 minutes briefing session: case and equipments presentation and choice of participants~15 minutes of actual simulation~40 minutes of debriefing~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
182480|NCT02776358|Other|Video case|"a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.~A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.~Also, another test will be done after 7 days of the course."
182481|NCT02776345|Other|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
182943|NCT02772822|Drug|SCT400 plus CHOP|
182482|NCT02776345|Other|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
182483|NCT02776345|Other|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
182484|NCT02776332|Procedure|Manual Expression of Breastmilk|Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
182485|NCT02776319|Device|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
182486|NCT02776319|Device|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
182487|NCT02776306|Other|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
182488|NCT02776293|Behavioral|Relaxation|
182489|NCT02776293|Behavioral|Music|
182490|NCT02776280|Other|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
182491|NCT02776267|Device|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
182492|NCT02776254|Other|START|Point of care testing for rapid ART initiation
182493|NCT02776254|Other|CAG|Community Adherence Group
182494|NCT02776254|Other|UAG|Urban Adherence Group
182495|NCT02776254|Other|FAST-TRACK|Prescription refill only
182496|NCT02776241|Other|water|
182497|NCT02776228|Drug|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
182498|NCT02776228|Drug|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
182499|NCT02776215|Drug|tasimelteon|Melatonin receptor agonist
182500|NCT02776202|Drug|Fludarabine monophosphate|"The HSCT preparative regimen will consist of~Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5~Fludarabine: 35 mg/m2/day IV on Days -8 through -4~Melphalan: 140 mg/m2 IV on Day -3~Rest on Day -2 and -1~Day 0 is the day of transplant~GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
182501|NCT02776189|Drug|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
182502|NCT02776189|Drug|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
182503|NCT02776189|Drug|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
182504|NCT02776176|Procedure|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
182505|NCT02776176|Procedure|Traditional Program|traditional standard protocol
182506|NCT02776163|Drug|Cisplatin|Cisplatin 80mg/m^2，D1-3，2 cycles
182507|NCT02776163|Drug|Docetaxel|Docetaxel 70mg/m^2，D1，2 cycles
182508|NCT02776163|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
182509|NCT02776137|Drug|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
182510|NCT02776137|Radiation|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
182511|NCT02776124|Dietary Supplement|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
182512|NCT02776111|Other|Blood Sample|A one time blood sample will be provided.
182513|NCT02776059|Drug|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
182514|NCT02776059|Drug|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
182515|NCT02776046|Drug|High FiO2|High FiO2 with a perioperative open lung strategy
182516|NCT02776046|Drug|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
182517|NCT02776033|Drug|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
182518|NCT02776033|Drug|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
182519|NCT02776020|Device|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
182520|NCT02776007|Device|Libre Flash CGMS|
182663|NCT02774902|Drug|Clarithromycin|Clarithromycin tablets
182526|NCT02775942|Biological|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
182527|NCT02775942|Biological|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
182528|NCT02775942|Biological|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
182529|NCT02775942|Biological|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
182530|NCT02775929|Drug|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
182531|NCT02775929|Drug|ART|ART for HIV-1 infected partners
182532|NCT02775916|Drug|CDZ173|
182533|NCT02775916|Drug|Placebo|
182534|NCT02775903|Drug|Azacitidine|
182535|NCT02775903|Drug|Durvalumab|
182536|NCT02775890|Behavioral|Eating wild game shot with lead bullets|Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (>85 grams).
182537|NCT02775877|Drug|Letrozole|
182538|NCT02775877|Drug|clomiphene|
182539|NCT02775877|Drug|HMG|
182540|NCT02775864|Drug|Antipsychotic|New initiation of any antipsychotic medication
182541|NCT02775864|Drug|Antidepressant|New initiation of any antidepressant medications
182542|NCT02775864|Drug|Benzodiazepine|New initiation of any benzodiazepine
182543|NCT02775864|Drug|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
182544|NCT02775851|Biological|Pembrolizumab|Given IV
182545|NCT02775851|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
182546|NCT02775838|Drug|Indocyanine green|perioperative application of Indocyanine green (ICG)
182547|NCT02775825|Other|survey|
182548|NCT02775812|Drug|Cisplatin|Given IV
182549|NCT02775812|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
182550|NCT02775812|Other|Laboratory Biomarker Analysis|Correlative studies
182551|NCT02775812|Biological|Pembrolizumab|Given IV
182552|NCT02775799|Other|Registration|Registration according to approved data sets
182553|NCT02775786|Other|MRIs with and without intravenous contrast (up to 2)|Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
182554|NCT02775773|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
182555|NCT02775773|Drug|Oxytocin|2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
182556|NCT02775760|Behavioral|Cardiovascular endurance|Physical exercise at the Boston University Fitness and Recreation Center
182557|NCT02775760|Behavioral|Strength, balance, and flexibility|Physical exercise at the Boston University Fitness and Recreation Center
182558|NCT02775747|Biological|platelet rich plasma gel|Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
182559|NCT02775747|Biological|saline|64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
182560|NCT02775734|Drug|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
182561|NCT02775734|Drug|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
182562|NCT02775721|Other|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
182563|NCT02775721|Other|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
182564|NCT02775721|Other|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
182565|NCT02775721|Other|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
182566|NCT02775721|Other|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
182567|NCT02775708|Device|Pillcam endoscopy system|
182568|NCT02775695|Drug|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
182569|NCT02775630|Procedure|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
182739|NCT02774343|Behavioral|Contingency Management|Prize-based contingency management for attendance
182570|NCT02775617|Drug|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
182571|NCT02775617|Drug|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
182572|NCT02775617|Drug|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
182573|NCT02775604|Behavioral|Home-Based Video|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
182574|NCT02775604|Behavioral|Paper Checklist|A paper checklist for fall hazards in the home will be completed by the participants based on standardized verbal instruction.
182575|NCT02775591|Drug|DA-9701|DA-9701 30mg Tablet
182576|NCT02775591|Drug|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
182577|NCT02775578|Procedure|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
182578|NCT02775578|Procedure|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
182579|NCT02775578|Procedure|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
182580|NCT02775565|Device|AngioVac|
182581|NCT02775552|Behavioral|A&T community-based interventions|"Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:~- Increase mothers' knowledge about adequate child feeding practices~Interpersonal communication delivered by agricultural extension workers to:~- Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding~Community mobilization activities to:~Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)~Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)~Raise awareness of adequate child feeding during fasting among family and community members (church sermons)~Enhanced training of government health and agricultural extension workers in infant and young child feeding to:~Improve their ability to provide timely and appropriate information and support to mothers and families"
182582|NCT02775552|Behavioral|Mass media|Radio campaign - radio drama series, spots, and jingles
182583|NCT02775539|Drug|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
182584|NCT02775539|Drug|Placebo|
182585|NCT02775526|Procedure|TOT|70 patients
182586|NCT02775526|Procedure|TVT|70 patients
182587|NCT02775526|Procedure|Burch Colposuspension|70 patients
182588|NCT02775500|Drug|apremilast|Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
182589|NCT02775474|Drug|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
182590|NCT02775474|Drug|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
182591|NCT02775448|Drug|Carduus marianus 6cH|
182592|NCT02775448|Drug|Carduus marianus 12cH|
182593|NCT02775448|Drug|Carduus marianus 30cH|
182594|NCT02775448|Drug|Placebo|
182595|NCT02775448|Behavioral|Exercise|aerobic exercise, 30 minutes, daily
182596|NCT02775448|Other|Diet|1600 calories
182597|NCT02775435|Biological|Pembrolizumab|IV infusion
182598|NCT02775435|Drug|Paclitaxel|IV infusion
182599|NCT02775435|Drug|Nab-paclitaxel|IV infusion
182600|NCT02775435|Drug|Carboplatin|IV infusion Carboplatin dose should not to exceed 900 mg.
182601|NCT02775435|Drug|Saline placebo for pembrolizumab|IV infusion
182602|NCT02775422|Biological|Serological Test s for the Virus Chicken Pox Virus|
182603|NCT02775409|Procedure|Subcutaneous placement|The tissue expander will be placed above the muscle.
182604|NCT02775409|Procedure|Submuscular placement|The tissue expander will be placed below the muscle
182605|NCT02775396|Device|Spectacle lens|Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
182606|NCT02775383|Other|Therapeutic|Observational Study
182607|NCT02775370|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
182608|NCT02775357|Behavioral|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
182609|NCT02775357|Behavioral|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
182610|NCT02775344|Device|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
182611|NCT02775331|Other|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
182612|NCT02775331|Other|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
182944|NCT02772822|Drug|Rituximab plus CHOP|
182613|NCT02775318|Procedure|Stellate Ganglion Block|Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
182614|NCT02775318|Drug|Bupivacaine|10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
182615|NCT02775318|Procedure|Transcranial Doppler|The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
182616|NCT02775318|Procedure|Digital Subtraction Angiography|Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
182617|NCT02775305|Behavioral|Frail|"Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .~Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.~Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.~Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques."
182618|NCT02775292|Biological|Aldesleukin|Given SC
182619|NCT02775292|Drug|Cyclophosphamide|Given IV
182620|NCT02775292|Drug|Fludarabine Phosphate|Given IV
182621|NCT02775292|Other|Laboratory Biomarker Analysis|Correlative studies
182622|NCT02775292|Biological|Nivolumab|Given IV
182623|NCT02775292|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
182624|NCT02775292|Biological|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
182625|NCT02775292|Procedure|Positron Emission Tomography|Correlative studies
182626|NCT02775266|Other|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
182627|NCT02775266|Procedure|Scaling and Root planing|Scaling and root planing will be done at baseline.
182628|NCT02775253|Other|Chronic cold acclimation|
182629|NCT02775240|Drug|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
182630|NCT02775240|Drug|Maribavir|200mg twice a day for 8 days
182631|NCT02775240|Drug|Dextromethorphan|30 mg oral dose
182632|NCT02775227|Drug|Hydrocortisone|
182633|NCT02775227|Drug|Pasireotide|
182634|NCT02775214|Device|Video Laryngoscopy|
182635|NCT02775201|Procedure|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
182636|NCT02775201|Procedure|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
182637|NCT02775188|Device|interACTION|
182638|NCT02775188|Other|Standard of Care Physical Therapy|
182639|NCT02775175|Behavioral|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
182640|NCT02775162|Device|Normothermic Machine Perfusion (NMP)|
182641|NCT02775162|Other|Standard of Care (Ice)|
182642|NCT02775149|Other|Collection of saliva samples|Collection of saliva samples
182643|NCT02775149|Other|Visual detection of BEWE-index|Visual detection of BEWE-index
182644|NCT02775136|Device|HS-1000 recording|
182645|NCT02775123|Device|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
182646|NCT02775110|Other|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
182647|NCT02775097|Device|OCT|OCT for all Arms
182648|NCT02775084|Dietary Supplement|Fish Oil|4 capsules twice daily with food for 6 weeks
182649|NCT02775084|Dietary Supplement|Olive Oil|4 capsules twice daily with food for 6 weeks
182650|NCT02775058|Device|synergoss Pxx|dental grafting
182651|NCT02775045|Other|Observation Period|8 week observational period
182652|NCT02775032|Behavioral|Advance care planning conversations between patients and their GP|
182653|NCT02775019|Dietary Supplement|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
182654|NCT02775019|Dietary Supplement|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
182655|NCT02775006|Drug|Docetaxel|75mg/m2
182656|NCT02775006|Drug|Erlotinib|150mg/day
182657|NCT02774993|Drug|Doxycycline|
182658|NCT02774993|Drug|placebo|
182659|NCT02774980|Behavioral|Recurrent depression|
182660|NCT02774967|Procedure|root coverage|Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
182661|NCT02774954|Behavioral|Change the Cycle|See previous response
182662|NCT02774902|Drug|TAK-438|TAK-438 tablets
182664|NCT02774889|Behavioral|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:~Fall prevention tips~Fall prevention exercise videos with narrations for proper technique and safety precautions~Guest expert videos with online access to the guest expert to ask questions~Tools to set exercise goals, get reminders and track progress~Access to a fall prevention specialist for personal feedback and suggested group homework~Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)~Fall prevention resources"
182665|NCT02774876|Device|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
182666|NCT02774876|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
182667|NCT02774876|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
182668|NCT02774876|Other|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
182669|NCT02774863|Other|Home passages|Three home passages between the 2nd and 3rd months of follow up.
182670|NCT02774837|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg once daily for 96 weeks
182671|NCT02774837|Drug|Telbivudine|Telbivudine oral tablets 600mg once daily for 96 weeks
182672|NCT02774811|Drug|Prostaglandin analogue|Topical therapy
182673|NCT02774811|Procedure|Selective laser trabeculoplasy|Laser therapy into drainage angle
182674|NCT02774811|Device|laser|
182675|NCT02774785|Device|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
182676|NCT02774759|Device|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
182677|NCT02774759|Behavioral|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.~Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
182678|NCT02774759|Behavioral|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
182679|NCT02774759|Behavioral|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
182680|NCT02774759|Behavioral|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
182681|NCT02774759|Behavioral|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
182682|NCT02774759|Behavioral|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
182683|NCT02774746|Other|35-week delivery|Induction at 35 weeks gestational age
182684|NCT02774746|Other|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
182685|NCT02774733|Device|spirometer;Intraocular pressure;Color doppler imaging|
182686|NCT02774720|Behavioral|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
182687|NCT02774720|Behavioral|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
182688|NCT02774694|Device|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
182689|NCT02774681|Procedure|Cognitive Assessment|Ancillary studies
182690|NCT02774681|Drug|Palbociclib|Given PO
182691|NCT02774681|Procedure|Quality-of-Life Assessment|Ancillary studies
182692|NCT02774681|Biological|Trastuzumab|Given IV
182693|NCT02774668|Other|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.~The amount of weight loss caused by these two meal plans is not expected to differ."
182694|NCT02774668|Other|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
182695|NCT02774655|Device|Pai APP|prescribed 100 PAI weekly
182696|NCT02774655|Device|FitBit APP|prescribed 10000 steps daily
182818|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
182819|NCT02773745|Behavioral|Aquatic Prehab|Pool therapy
182697|NCT02774642|Behavioral|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
182698|NCT02774642|Behavioral|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
182699|NCT02774629|Other|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
182700|NCT02774616|Device|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
182701|NCT02774616|Device|Plexa ICD lead|predefined follow-up schedule
182702|NCT02774603|Other|Aquatic Locomotor Training|
182703|NCT02774603|Other|Land Locomotor Training|
182704|NCT02774590|Drug|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
182705|NCT02774577|Other|whole body vibration training in vibrating platform in young|
182706|NCT02774577|Other|whole body vibration training in vibrating platform in elderly|
182707|NCT02774564|Drug|BIA 3-202|Nebicapone tablets 50 mg, oral administration
182708|NCT02774564|Drug|Placebo|Nebicapone matching placebo tablets
182709|NCT02774564|Drug|Sinemet®|Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
182710|NCT02774551|Behavioral|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
182711|NCT02774538|Other|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.~A second oral brushing up to 18 months will be performed during a standard follow-up visit."
182712|NCT02774525|Behavioral|Reinforcement for drug & alcohol abstinence|
182713|NCT02774525|Behavioral|Parenting intervention|
182714|NCT02774525|Behavioral|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug & alcohol screening plus support for personal goal setting
182715|NCT02774512|Drug|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
182716|NCT02774499|Drug|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
182717|NCT02774499|Drug|Placebo|equivalent volume (5mL) of syrup given preoperatively
182718|NCT02774486|Device|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
182719|NCT02774460|Drug|Zestril®|Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
182720|NCT02774460|Drug|Atacand®|Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
182721|NCT02774460|Drug|Norvasc®|Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
182722|NCT02774460|Drug|Hydrochlorthiazide®|Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
182723|NCT02774460|Drug|Treatment X|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
182724|NCT02774460|Drug|Treatment Y|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
182725|NCT02774460|Drug|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
182726|NCT02774447|Procedure|ileostoma closure|The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
182727|NCT02774434|Device|JM-105|Measurement of TcB via the JM-105 device
182728|NCT02774421|Drug|Trastuzumab after SubQ GM-CSF|
182729|NCT02774421|Drug|Trastuzumab in combination with SubQ GM-CSF|
182730|NCT02774408|Device|Saturation sensitive backup ventilation|
182731|NCT02774382|Drug|Vancomycin|Already incl. in arm description
182732|NCT02774382|Drug|Fecal microbiota transplantation|Already incl. in arm description
182733|NCT02774382|Drug|Rectal bacteriotherapy|Already incl. in arm description
182734|NCT02774369|Behavioral|Physical exercise|Individualized aerobic intervention program
182735|NCT02774369|Behavioral|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
182736|NCT02774343|Drug|Pioglitazone|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
182737|NCT02774343|Drug|Placebo|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
182738|NCT02774343|Behavioral|Therapy|Cognitive-behavioral therapy 1 hour per week
182740|NCT02774330|Other|Policy|This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
182741|NCT02774317|Biological|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
182742|NCT02774304|Device|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
182743|NCT02774304|Device|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
182744|NCT02774291|Biological|Aldesleukin|Given IV
182745|NCT02774291|Biological|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
182746|NCT02774291|Drug|Cyclophosphamide|Given IV
182747|NCT02774291|Biological|Filgrastim|Given SC
182748|NCT02774291|Drug|Fludarabine Phosphate|Given IVPB
182749|NCT02774291|Other|Laboratory Biomarker Analysis|Correlative studies
182750|NCT02774278|Drug|Erlotinib|Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
182751|NCT02774265|Drug|VTE prophylaxis with Enoxaparin 30mg BID|Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
182752|NCT02774265|Drug|VTE prophylaxis with Aspirin 81mg BID|Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
182753|NCT02774252|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation number - Y49-103)
182754|NCT02774239|Drug|Human normal immunoglobulin G (IgG)|"Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.~Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner."
182755|NCT02774226|Drug|Tetrahydrobiopterin (BH4)|12 week intervention
182756|NCT02774226|Dietary Supplement|Antioxidant Cocktail|12 week intervention
182757|NCT02774213|Other|Questionnaires completion|
182758|NCT02774213|Other|Clinical Pain Assessments|
182759|NCT02774200|Drug|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
182760|NCT02774187|Drug|Sorafenib|administration of Sorafenib
182761|NCT02774187|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
182762|NCT02774187|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
182763|NCT02774161|Other|Ultrasound Tomography|Undergo B-mode ultrasound imaging
182764|NCT02774148|Drug|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
182765|NCT02774148|Drug|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
182766|NCT02774135|Other|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
182767|NCT02774122|Device|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
182768|NCT02774122|Device|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
182769|NCT02774109|Dietary Supplement|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
182770|NCT02774109|Dietary Supplement|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
182771|NCT02774109|Procedure|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
182772|NCT02774109|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
182773|NCT02774096|Drug|xenon|
182774|NCT02774083|Behavioral|Feuerstein Program|Mediated learning cognitive enhancement program
182775|NCT02774083|Behavioral|Adler Program|Social and emotional group program
182776|NCT02774070|Radiation|Plain X-ray|antero-posterior, lateral neutral, flexion, extension and open-mouth views
182777|NCT02774070|Radiation|Magnetic resonance imaging|Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
182778|NCT02774057|Drug|Captafer®|"2 pills daily. Contains~Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
182779|NCT02774057|Drug|Iron Sulfate|195 mg Iron supplement
182820|NCT02773732|Drug|Ciprofloxacin|"Ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.~Dose Level 0 Ciprofloxacin 750 mg Dose Level +1 Ciprofloxacin 1000 mg Dose Level -1 Ciprofloxacin 500 mg"
182821|NCT02773732|Drug|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
182822|NCT02773719|Other|True Biofield therapy|
182823|NCT02773719|Other|Fake Biofield therapy|
182780|NCT02774044|Drug|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
182781|NCT02774044|Drug|Survanta|
182782|NCT02774031|Device|Aisys with Et control|
182783|NCT02774031|Device|Aisys conventional|
182784|NCT02774031|Device|Flow-i with ACG|
182785|NCT02774031|Device|Flow-i conventional|
182786|NCT02774018|Behavioral|Mindfulness-Based Stress Reduction (MBSR) program|
182787|NCT02774005|Drug|Idebenone|
182788|NCT02773992|Behavioral|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
182789|NCT02773979|Drug|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
182790|NCT02773979|Biological|PfSPZ (NF54) Challenge|Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.
182791|NCT02773979|Other|Placebo|Placebo
182792|NCT02773966|Radiation|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
182793|NCT02773966|Radiation|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
182794|NCT02773953|Device|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
182795|NCT02773953|Device|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
182796|NCT02773940|Device|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
182797|NCT02773927|Drug|Metformin|Metformin in tablet presentation of 500 mg
182798|NCT02773927|Dietary Supplement|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
182799|NCT02773927|Other|Placebo of agave inulin|Calcinated magnesia powder
182800|NCT02773927|Other|Metformin placebo|Calcinated magnesia tablet
182801|NCT02773914|Other|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
182802|NCT02773901|Device|HS-1000|
182803|NCT02773888|Device|HS-1000|
182804|NCT02773875|Device|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
182805|NCT02773862|Device|HS-1000|
182806|NCT02773849|Biological|INSTILADRIN|
182807|NCT02773836|Other|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
182808|NCT02773823|Behavioral|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
182809|NCT02773810|Other|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
182810|NCT02773797|Drug|IN-DEX 1.0 mcg/kg, intranasal saline|
182811|NCT02773797|Drug|IN-DEX 1.5 mcg/kg, intranasal saline|
182812|NCT02773797|Drug|Placebo - Saline|
182813|NCT02773784|Other|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
182814|NCT02773771|Dietary Supplement|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive >3g of HMB/ day.
182815|NCT02773771|Dietary Supplement|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
182816|NCT02773771|Dietary Supplement|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
182817|NCT02773758|Other|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
186084|NCT02750254|Radiation|Single dose total body irradiation|
182824|NCT02773706|Other|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
182825|NCT02773706|Other|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
182826|NCT02773693|Behavioral|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
182827|NCT02773693|Behavioral|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
182828|NCT02773693|Behavioral|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
182829|NCT02773680|Device|"electrical impedance tomography"|One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
182830|NCT02773654|Other|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
182831|NCT02773654|Other|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
182832|NCT02773641|Drug|Botulinum Toxin Type A|
182833|NCT02773641|Drug|Sterile Saline Solution|
182834|NCT02773628|Device|Acar'up system|
182835|NCT02773628|Device|Acar'up placebo system|
182836|NCT02773615|Procedure|Cardiac computed tomography|Non-invasive CT scan of the heart
182837|NCT02773602|Drug|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
182838|NCT02773602|Drug|Clonidine|2 μg/kg of clonidine in 1 ml saline
182839|NCT02773602|Drug|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
182840|NCT02773589|Procedure|Peroral endoscopic myotomy|Peroral endoscopic myotomy
182841|NCT02773576|Drug|Risperidone implant|
182842|NCT02773563|Other|EUS with air insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation
182843|NCT02773563|Other|EUS with CO2 insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
182844|NCT02773550|Drug|Bortezomib|Low dose of bortezomib
182845|NCT02773550|Drug|Melphalan|
182846|NCT02773550|Drug|Prednisone|
182847|NCT02773537|Drug|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
182848|NCT02773537|Drug|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
182849|NCT02773537|Drug|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
182850|NCT02773524|Drug|Regorafenib|Regorafenib is the experimental intervention in this study. Regorafenib will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
182851|NCT02773524|Other|Placebo|Placebo (matching in appearance to regorafenib) made of microcrystalline cellulose, will be self-administered by participants at 160mg (4 x 40mg tablets) orally once daily on days 1-21 of each 28 day cycle plus best supportive care until progression or prohibitive toxicity as defined by the protocol.
182852|NCT02773511|Procedure|Surgical treatment|Closed reduction and Kirschner wire fixation
182853|NCT02773498|Procedure|conventional TESE|usual procedure for sperm extraction
182854|NCT02773498|Procedure|Micro TESE|procedure of extraction is performed under the operating microscope
182855|NCT02773485|Radiation|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
182856|NCT02773485|Drug|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
182857|NCT02773472|Device|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
182858|NCT02773472|Drug|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
182859|NCT02773459|Drug|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
182860|NCT02773446|Biological|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
182861|NCT02773433|Other|Proportional Assist Ventilation|
182862|NCT02773420|Procedure|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
182863|NCT02773407|Drug|Azithromycin|
182864|NCT02773407|Drug|Co-trimoxazole|
182865|NCT02773381|Drug|semaglutide|Oral administration once-daily.
182866|NCT02773381|Drug|placebo|Oral administration once-daily.
182867|NCT02773368|Drug|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
186085|NCT02750254|Drug|Melphalan|
182869|NCT02773355|Drug|liraglutide 3.0 mg|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
182870|NCT02773329|Other|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
182871|NCT02773329|Other|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
182872|NCT02773316|Drug|MR902|
182873|NCT02773316|Drug|IR morphine sulphate|
182874|NCT02773303|Device|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
182875|NCT02773303|Device|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
182876|NCT02773290|Biological|Romiplostim|Weekly SC administration
182877|NCT02773277|Other|head-impulse testing|all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
182878|NCT02773264|Device|Ultrasound|Ultrasound Elastography of soft tissue and organ lesions
182879|NCT02773251|Drug|hyaluronic acid-carboxymethylcellulose|
182880|NCT02773238|Procedure|Computed Tomography|Undergo FDG PET/CT
182881|NCT02773238|Procedure|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
182882|NCT02773238|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
182883|NCT02773238|Other|Laboratory Biomarker Analysis|Correlative studies
182884|NCT02773238|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
182885|NCT02773238|Radiation|Radiation Therapy|Undergo functional avoidance radiation therapy
182886|NCT02773238|Procedure|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m Undergo Tc-99m sulfur colloid SPECT/CT
182887|NCT02773238|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
182888|NCT02773238|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo Tc-99m sulfur colloid
182889|NCT02773225|Drug|Eltrombopag|"CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> partial or complete remission Eltrombopag and slow tapering of CSA~12 month after therapy start --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
182890|NCT02773225|Drug|Placebo (for Eltrombopag)|"CSA + Placebo, evaluation after three month therapy start regarding dose escalation~6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --> dose escalation~12 month after start of eltrombopag --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
182891|NCT02773212|Drug|d-amphetamine|Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
182892|NCT02773212|Behavioral|Contingency management|Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
182893|NCT02773212|Drug|Placebo (for d-amphetamine)|60 mg of riboflavin and cornstarch as needed.
182894|NCT02773199|Other|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
182895|NCT02773199|Other|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
182896|NCT02773199|Drug|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
182897|NCT02773186|Other|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
182898|NCT02773173|Procedure|IPP in colorectal laparoscopic surgery|Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
182899|NCT02773173|Procedure|SPP in colorectal laparoscopic surgery|A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
182900|NCT02773160|Other|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
182901|NCT02773160|Other|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
182902|NCT02773160|Other|Control group|Subjects will receive no feedback during the learning phase of a motor control task
182903|NCT02773147|Drug|Cyanocobalamin|
182904|NCT02773147|Drug|Folate|
182905|NCT02773147|Drug|Pyridoxine|
182906|NCT02773134|Other|Brace Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
186086|NCT02750254|Drug|Granulocyte-colony stimulating factor|
182907|NCT02773134|Other|Control Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.~Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
182908|NCT02773121|Behavioral|Physical Activity|Trainer-guided at-home behavioral intervention
182909|NCT02773095|Other|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
182910|NCT02773082|Device|Reclaim™ DBS Therapy|The Medtronic Reclaim DBS Therapy is indicated for bilateral stimulation of the anterior limb of the internal capsule, AIC, as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
182911|NCT02773069|Behavioral|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
182912|NCT02773056|Device|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
182913|NCT02773056|Device|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
182914|NCT02773056|Device|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
182915|NCT02773043|Device|CZT SPECT camera|
182916|NCT02773030|Drug|CC-220|CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.
182917|NCT02773030|Drug|Dexamethasone|Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
182918|NCT02773030|Drug|Daratumumab|Daratumumab (DARA) 16mg/kg by intravenous infusion on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.
182919|NCT02773030|Drug|Bortezomib (BTZ)|Bortezomib 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.
182920|NCT02773030|Drug|Carfilzomib|Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.
182921|NCT02773017|Drug|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
182922|NCT02773017|Drug|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
182923|NCT02773017|Drug|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
182924|NCT02773004|Other|EPClin genomic test|
182925|NCT02772991|Other|troponin measurement|Cardiac catheterization (for patients with >50% lesions) or discharge or in patients with intermediate risk.
182926|NCT02772978|Drug|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
182927|NCT02772978|Drug|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
182928|NCT02772965|Drug|Methotrexate|"Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to <40 kg, and 10 mg for children 20 to <30 kg.~A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).~A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
182929|NCT02772965|Other|Sugar pill (placebo)|"Placebo for methotrexate: The weekly dose will mimic that of methotrexate.~Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).~A 1 mg dose of folic acid per day will be provided to maintain blinding.~Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 156 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
182930|NCT02772952|Other|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
182931|NCT02772952|Other|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
182932|NCT02772939|Device|Renal sympathetic denervation (RDN)|Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
182933|NCT02772926|Dietary Supplement|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
182934|NCT02772926|Dietary Supplement|Placebo|Placebo 900 mg per day
182935|NCT02772900|Other|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
182936|NCT02772900|Other|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
182937|NCT02772887|Dietary Supplement|L-Citrulline|amino acid supplement
182938|NCT02772887|Other|Placebo|placebo
182939|NCT02772874|Other|No intervention|No intervention
182940|NCT02772861|Dietary Supplement|Amino Acid Supplement - One dose|20gr
182941|NCT02772861|Dietary Supplement|3-Methylhistidine|120mgr
182942|NCT02772835|Device|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
182945|NCT02772809|Device|Haptic Robot Therapy with Games|Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
182946|NCT02772796|Drug|SENS-218|Oral Administration
182947|NCT02772783|Other|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of ~90 is achieved by using corn syrup as a carbohydrate source.
182948|NCT02772783|Other|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of ~40 is achieved by using uncooked corn starch as a carbohydrate source.
182949|NCT02772783|Drug|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
182950|NCT02772783|Drug|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are > 400 mg/dl or < 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
182951|NCT02772770|Other|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
182952|NCT02772770|Procedure|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
182953|NCT02772770|Procedure|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
182954|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
182955|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
182956|NCT02772757|Behavioral|standard hearing aid fitting|standard hearing aid, face-to-face fitting
182957|NCT02772757|Behavioral|coupler-based fitting|coupler-based fitting using average RECDs
182958|NCT02772757|Behavioral|coupler-based fitting|coupler-based fitting using measured RECDs
182959|NCT02772744|Drug|Daclatasvir 60 MG Oral Tablet [Daklinza]|Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
182960|NCT02772744|Drug|Sofosbuvir 400 MG Oral Tablet [Sovaldi]|Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
182961|NCT02772744|Drug|Ribavirin Oral Product|Ribavirin (twice-daily) dosed according to body weight (<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
182962|NCT02772731|Procedure|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
182963|NCT02772731|Procedure|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
182964|NCT02772718|Drug|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
182965|NCT02772718|Drug|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
182966|NCT02772718|Drug|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
182967|NCT02772718|Drug|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
182968|NCT02772692|Behavioral|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
183140|NCT02771587|Dietary Supplement|Energy drink|Multiple oral dose of energy drink
183625|NCT02768116|Procedure|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
182969|NCT02772679|Biological|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10^6 cells. The second cohort will receive 20x10^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
182970|NCT02772666|Device|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
182971|NCT02772666|Other|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
182972|NCT02772653|Other|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
182973|NCT02772653|Other|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
182974|NCT02772653|Other|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
182975|NCT02772653|Other|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
182976|NCT02772653|Other|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
182977|NCT02772653|Other|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
182978|NCT02772640|Drug|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:~morning -> evening evening -> morning"
182979|NCT02772627|Drug|Nebicapone|Nebicapone 100 mg tablets; oral route.
182980|NCT02772627|Drug|Placebo|Placebo tablets; oral route.
182981|NCT02772614|Drug|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
182982|NCT02772601|Drug|Caffeine|
182983|NCT02772601|Drug|Warfarin|
182984|NCT02772601|Drug|Omeprazole|
182985|NCT02772601|Drug|Metoprolol|
182986|NCT02772601|Drug|Midazolam|
182987|NCT02772601|Drug|Risankizumab|
182988|NCT02772588|Drug|ARN-509|
182989|NCT02772588|Drug|Abiraterone|
182990|NCT02772588|Drug|Leuprolide|
182991|NCT02772588|Radiation|stereotactic, ultra-fractionated radiotherapy|
182992|NCT02772575|Procedure|Hepatic trans-arterial embolization (TAE)|
182993|NCT02772575|Device|MRI/CT scan|
182994|NCT02772575|Procedure|biopsy|
182995|NCT02772575|Other|blood draw|
182996|NCT02772562|Biological|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
182997|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study, all participants are subject to a set of three visual stimulus conditions.~Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).~VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals."
182998|NCT02772523|Other|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
182999|NCT02772510|Device|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
183000|NCT02772510|Device|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
183001|NCT02772497|Drug|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
183002|NCT02772484|Device|HS-1000|
183003|NCT02772471|Device|HS-1000|
183004|NCT02772458|Other|Dodecanoate acid and saline|Test drink
183005|NCT02772445|Behavioral|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
183006|NCT02772432|Behavioral|Relaxation Response Resiliency Training for Parents of SPLD|
183007|NCT02772419|Drug|benralizumab|SC administration
183008|NCT02772419|Drug|benralizumab|SC administration
183009|NCT02772419|Drug|Placebo|SC administration
183010|NCT02772406|Device|Linked Color Imaging|
183011|NCT02772406|Device|white light imaging|
183012|NCT02772380|Device|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
183013|NCT02772367|Procedure|skin punch biopsy|
183014|NCT02772354|Procedure|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
183015|NCT02772354|Drug|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg"
183016|NCT02772354|Drug|Verapamil|Verapamil 20-240 mg
183017|NCT02772354|Device|NAVI-STAR® RMT ThermoCool|
183018|NCT02772341|Device|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
183019|NCT02772341|Other|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
183020|NCT02772328|Behavioral|Peer Mentor|comparison of communication training to equal attention control
183021|NCT02772315|Other|omics|diagnostic procedures applying omics results
183022|NCT02772302|Device|mindBEAGLE EEG-based brain-computer interface|
183778|NCT02766946|Other|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
183023|NCT02772289|Biological|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
183024|NCT02772289|Biological|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
183025|NCT02772289|Biological|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
183026|NCT02772276|Drug|MB-102|4 µmol/kg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
183027|NCT02772276|Drug|Iohexol|5 mL of a 647 mg/mL solution administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds
183028|NCT02772276|Device|QuantumLeap|Optical Renal Function Monitor (ORFM)
183029|NCT02772276|Device|Radiance|Optical Renal Function Monitor (ORFM)
183030|NCT02772276|Device|Brilliance|Optical Renal Function Monitor (ORFM)
183031|NCT02772263|Other|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
183032|NCT02772250|Behavioral|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
183033|NCT02772250|Behavioral|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
183034|NCT02772237|Biological|Riboflavin|Riboflavin 400mg daily
183035|NCT02772237|Biological|Placebo|
183036|NCT02772224|Device|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
183037|NCT02772224|Device|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
183038|NCT02772211|Drug|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
183039|NCT02772211|Drug|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
183040|NCT02772211|Drug|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:~Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~Week 7: Day 43-49 - 750mg/d, three pills per day~Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
183041|NCT02772198|Biological|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
183042|NCT02772185|Device|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
183043|NCT02772185|Device|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
183044|NCT02772185|Behavioral|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
183045|NCT02772185|Behavioral|placebo CT|Videos (short films) will be presented during the neurostimulation
183046|NCT02772172|Device|Surgical Template|
183047|NCT02772159|Drug|TD-4208|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
183048|NCT02772146|Device|CLS UF|One single ultrafiltration session of 10 hours.
183049|NCT02772133|Procedure|Primary PCI|
183141|NCT02771587|Dietary Supplement|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
183142|NCT02771574|Drug|Exendin (9-39)|
183050|NCT02772120|Drug|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
183051|NCT02772120|Drug|Intramuscular Progesterone|Progesterone—25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
183052|NCT02772107|Drug|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
183053|NCT02772107|Drug|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
183054|NCT02772107|Radiation|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
183055|NCT02772107|Radiation|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
183056|NCT02772094|Biological|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.~Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
183057|NCT02772081|Combination Product|LISA combination product (Curosurf+catheter CHF6440)|Curosurf administration through brief catheterisation
183058|NCT02772081|Drug|Curosurf through conventional administration (endotracheal tube)|Curosurf through conventional administration (endotracheal tube)
183059|NCT02772068|Drug|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
183060|NCT02772068|Other|Exercise|
183061|NCT02772055|Other|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
183062|NCT02772055|Other|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
183063|NCT02772042|Other|Intervention Group|
183064|NCT02772042|Other|Control Group|
183065|NCT02772029|Drug|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
183066|NCT02772016|Drug|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
183067|NCT02772003|Biological|DNA Plasmid Encoding Interleukin-12 INO-9012|Given IM
183068|NCT02772003|Biological|Electroporation-Mediated Plasmid DNA Vaccine Therapy|Undergo electroporation
183069|NCT02772003|Biological|HCV DNA Vaccine INO-8000|Given IM
183070|NCT02772003|Other|Laboratory Biomarker Analysis|Correlative studies
183071|NCT02772003|Other|Quality-of-Life Assessment|Ancillary studies
183072|NCT02771990|Device|Sham transcranial direct current stimulation|sham stimulation
183073|NCT02771990|Device|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
183074|NCT02771977|Other|Drug-specific alert|A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
183075|NCT02771964|Other|Quality of life survey|"All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.~The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey."
183076|NCT02771951|Behavioral|"Lights of Change"|
183077|NCT02771951|Behavioral|Usual Care|
183078|NCT02771938|Other|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
183079|NCT02771925|Drug|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.~All patients will receive standard of care treatment."
183080|NCT02771925|Drug|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
183081|NCT02771912|Drug|Propofol|Propofol and excipients
183082|NCT02771912|Drug|Placebo|Qualitative composition of Propofol lipuro 2% excipients
183083|NCT02771899|Device|spineEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
183084|NCT02771899|Device|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
183134|NCT02771613|Other|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
183135|NCT02771613|Other|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
183136|NCT02771600|Device|Buzzy|See arm description
183137|NCT02771600|Drug|Topical anaesthetic cream|See arm description
183278|NCT02770508|Drug|emtricitabine-tenofovir(FTC/TDF)|
183085|NCT02771886|Behavioral|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.~Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
183086|NCT02771873|Behavioral|Integrated cardiovascular disease risk management.|Health promotion intervention
183087|NCT02771860|Drug|denosumab|60mg sc
183088|NCT02771860|Drug|Placebo|identical syringe
183089|NCT02771860|Dietary Supplement|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
183090|NCT02771847|Behavioral|survey|anonym survey is given to people
183091|NCT02771834|Other|Biomechanical analysis|
183092|NCT02771834|Other|Kiphosis analysis|
183093|NCT02771834|Other|Vitamin D level|
183094|NCT02771821|Other|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.~Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
183095|NCT02771808|Other|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
183096|NCT02771795|Drug|Herceptin (trastuzumab)|Intravenous administration
183097|NCT02771795|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
183098|NCT02771782|Biological|BCG vaccine (SSI)|
183099|NCT02771782|Biological|TDaP-IPV vaccine|
183100|NCT02771769|Other|blood draw|Participants will have a venous blood draw of ~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
183101|NCT02771756|Dietary Supplement|zhen qishen capsule and Oral Supplement of Yuyikang|
183102|NCT02771756|Dietary Supplement|zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo|
183103|NCT02771756|Radiation|chemotherapy|
183104|NCT02771756|Other|nutrition education|
183105|NCT02771743|Drug|Cisplatin|
183106|NCT02771743|Drug|Doxorubicin|
183107|NCT02771743|Drug|Etoposide|
183108|NCT02771743|Drug|Cyclophosphamide|
183109|NCT02771743|Drug|Ifosfamide|
183110|NCT02771743|Drug|Carboplatin|
183111|NCT02771743|Procedure|Tandem HDCT/auto-SCT|
183112|NCT02771743|Radiation|Radiotherapy|
183113|NCT02771743|Drug|Interleukin-2|
183114|NCT02771743|Drug|Isotretinoin|
183115|NCT02771743|Radiation|MIBG|
183116|NCT02771730|Biological|Ad4-mgag|A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
183117|NCT02771730|Biological|Ad4-EnvC150|A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
183118|NCT02771730|Other|Placebo Comparator|Oral sucrose capsules
183119|NCT02771730|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
183120|NCT02771717|Drug|Budesonide (Pulmicort)|Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
183121|NCT02771717|Drug|Placebo - dummy inhaler|Placebo - dummy inhaler to be taken 1 puff twice daily.
183122|NCT02771704|Other|Silver Diamine fluoride|
183123|NCT02771704|Other|Potassium iodide|
183124|NCT02771704|Other|Chlorhexidine|
183125|NCT02771704|Other|Silver diamine fluoride and potassium iodide|
183126|NCT02771704|Other|Physiological saline|
183127|NCT02771691|Other|Mentalization-Based Group Therapy for Adolescents|
183128|NCT02771665|Other|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
183129|NCT02771652|Behavioral|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
183130|NCT02771652|Other|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
183131|NCT02771639|Procedure|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
183132|NCT02771626|Drug|CB-839|Glutaminase inhibitor
183133|NCT02771626|Drug|Nivolumab|PD-1 inhibitor
183138|NCT02771587|Dietary Supplement|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
183279|NCT02770495|Other|blood sample|
183143|NCT02771561|Procedure|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
183144|NCT02771548|Procedure|Anterior Cruciate Ligament Reconstruction|
183145|NCT02771535|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
183146|NCT02771535|Behavioral|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
183147|NCT02771522|Device|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black & white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
183148|NCT02771509|Drug|ANG-3777|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
183149|NCT02771509|Drug|Placebo|
183150|NCT02771496|Other|Other: observational only- no intervention|Other: observational only- no intervention
183151|NCT02771470|Drug|Probiotics|Microbial composition using probiotic
183152|NCT02771470|Drug|placebo|Microbiota modulation using placebo
183153|NCT02771457|Drug|Infliximab at weeks 0,2, and 6|
183154|NCT02771457|Drug|Infliximab at weeks 0,4, and 8|
183155|NCT02771457|Drug|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
183156|NCT02771444|Device|Tomo Assessment|A four-view tomosynthesis examination
183157|NCT02771431|Other|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
183158|NCT02771418|Drug|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
183159|NCT02771418|Drug|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
183160|NCT02771418|Procedure|Elective carotid endarterectomy|
183161|NCT02771405|Drug|Sofosbuvir|Sofosbuvir 400 mg orally once daily
183162|NCT02771405|Drug|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
183163|NCT02771405|Drug|Simeprevir|Simeprevir 150 mg orally once daily
183164|NCT02771405|Drug|daclatasvir|Daclatasvir 60 mg orally once daily
183165|NCT02771405|Drug|Ledipasvir|Ledipasvir 90 mg orally once daily
183166|NCT02771392|Drug|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
183167|NCT02771392|Other|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
183168|NCT02771379|Drug|Idebenone|Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
183169|NCT02771366|Drug|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
183170|NCT02771366|Other|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
183171|NCT02771353|Radiation|WT_vDIBH|
183172|NCT02771353|Radiation|VMAT_FB|
183173|NCT02771340|Biological|ICON-1|Intravitreal injection of ICON-1
183174|NCT02771327|Device|CPAP plus Gas|
183175|NCT02771327|Device|ventimask plus gas|
183176|NCT02771314|Drug|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
183177|NCT02771301|Biological|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
183178|NCT02771288|Device|Bioresorbable Vascular Scaffold|
183179|NCT02771275|Device|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
183180|NCT02771262|Other|Pulmonary Rehabilitation|
183181|NCT02771249|Drug|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
183182|NCT02771249|Drug|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
183183|NCT02771249|Drug|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
183184|NCT02771249|Dietary Supplement|Pyridoxine|
183185|NCT02771210|Biological|AIN457/Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
183186|NCT02771210|Drug|AIN457/Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
183187|NCT02771197|Drug|Fludarabine|
183188|NCT02771197|Drug|Melphalan|
183189|NCT02771197|Drug|Pembrolizumab|
183280|NCT02770482|Biological|spinal fluid collection|
183826|NCT02766608|Drug|BFF MDI 160/9.6 μg|Blinded Treatment
183190|NCT02771184|Device|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
183191|NCT02771171|Radiation|CT Scan|CT imaging
183192|NCT02771158|Drug|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
183193|NCT02771158|Drug|placebo|placebo will be administered to double blind the study
183194|NCT02771145|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
183195|NCT02771145|Device|Soft contact lenses (SCL)|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
183196|NCT02771145|Device|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
183197|NCT02771132|Behavioral|"12-hr IMPower empowerment self defense course"|"The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack."
183198|NCT02771132|Behavioral|12-hr Source of Strength for boys|The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.
183199|NCT02771132|Behavioral|Life-skills course|A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
183200|NCT02771106|Other|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
183201|NCT02771093|Drug|Trelagliptin|Trelagliptin 100 mg tablet
183202|NCT02771093|Drug|Alogliptin|Alogliptin 25 mg tablet
183203|NCT02771080|Procedure|Cardiac surgery|
183204|NCT02771067|Procedure|Fluid infusion|Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
183205|NCT02771054|Drug|TAF/FTC|Change of nucleoside backbone
183206|NCT02771041|Procedure|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
183207|NCT02771028|Behavioral|Emotional Freedom Techniques|
183208|NCT02771015|Device|Mepilex Border®|randomization
183209|NCT02771015|Device|Cosmopor steril®|randomization
183210|NCT02771002|Device|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
183211|NCT02770989|Procedure|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
183212|NCT02770976|Device|Increasing and decreasing NAVA levels with 10-min intervals|
183213|NCT02770963|Procedure|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.~A Huatuo Brand needle (0.3*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
183214|NCT02770963|Procedure|Sham acupuncture|"Specially designed sham needles (0.3*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).~The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
183215|NCT02770950|Drug|Zushima plaster with high dose|Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
183216|NCT02770950|Drug|Zushima plaster with low dose|Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
183217|NCT02770950|Drug|Indometacin Cataplasms|Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
183218|NCT02770937|Other|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
183219|NCT02770937|Other|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) on a box trainer.
183220|NCT02770937|Device|Simbionix|
183221|NCT02770924|Device|AT LISA TRI TORIC|phacoemulsification with IOL implantation
183222|NCT02770924|Device|AT LISA TRI|phacoemulsification with IOL implantation
183223|NCT02770911|Procedure|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
183224|NCT02770911|Procedure|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
183465|NCT02769221|Device|Rigid video stylet|
183225|NCT02770898|Behavioral|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
183226|NCT02770885|Drug|Dulaglutide|Treatment with dulaglutide for 3 weeks.
183227|NCT02770885|Drug|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
183228|NCT02770872|Other|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
183229|NCT02770859|Procedure|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle [esophagus] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle & sphincter of the LES for the treatment of achalasia
183230|NCT02770846|Procedure|Immediate loading|
183231|NCT02770846|Procedure|Delayed loading|
183232|NCT02770833|Other|Fish and carbohydrats with low or high GI|
183233|NCT02770833|Other|Veal and carbohydrats with low or high GI|
183234|NCT02770820|Biological|Aldesleukin|Given SC
183235|NCT02770820|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
183236|NCT02770820|Other|Laboratory Biomarker Analysis|Correlative studies
183237|NCT02770807|Drug|EDS-EP dose range of ~5-10 mg DSP/infusion|infusion
183238|NCT02770807|Drug|EDS-EP dose range of ~14-22 mg DSP/infusion|infusion
183239|NCT02770807|Drug|Placebo|infusion
183240|NCT02770794|Drug|Infliximab|Discontinue infliximab; receive Infliximab when relapse
183241|NCT02770781|Other|Exercise regimen|Subjects will receive a personal exercise regimen based on their health history and individual capability.
183242|NCT02770768|Drug|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
183243|NCT02770768|Drug|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
183244|NCT02770729|Drug|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
183245|NCT02770729|Drug|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
183246|NCT02770716|Drug|Terlipressin|Each 6 mL vial contains 1 mg lyophilized terlipressin acetate and 10 mg mannitol in sterile 0.9% sodium chloride solution
183247|NCT02770716|Other|Placebo Comparator|11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution
183248|NCT02770703|Device|DynaMesh visible mesh|Implantation of a MRI visible mesh
183249|NCT02770690|Drug|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
183250|NCT02770690|Drug|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
183251|NCT02770690|Drug|placebo|apply normal saline before propofol iv injection
183252|NCT02770677|Other|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
183253|NCT02770664|Drug|Placebo|Placebo
183254|NCT02770664|Drug|LC28-0126 Dose A|LC28-0126 Dose A
183255|NCT02770664|Drug|LC28-0126 Dose B|LC28-0126 Dose B
183256|NCT02770664|Drug|LC28-0126 Dose C|LC28-0126 Dose C
183257|NCT02770651|Device|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
183258|NCT02770651|Device|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
183259|NCT02770638|Device|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
183260|NCT02770638|Device|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
183261|NCT02770625|Drug|ISU302|60 U/kg given intravenously
183262|NCT02770612|Other|Prescribed opioids|Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
183263|NCT02770599|Other|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
183264|NCT02770586|Device|Breast PET|imaging of the breast using the Breast PET system
183265|NCT02770573|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
183266|NCT02770573|Other|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
183267|NCT02770573|Other|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
183268|NCT02770560|Device|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
183269|NCT02770547|Device|Low Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
183270|NCT02770547|Device|High Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
183271|NCT02770534|Procedure|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
183272|NCT02770521|Drug|Treprostinil|Administered SC.
183273|NCT02770521|Drug|Placebo|Administered SC.
183274|NCT02770521|Drug|LY900014|Administered SC.
183275|NCT02770521|Drug|Insulin Lispro|Administered SC.
183276|NCT02770508|Drug|darunavir/ritonavir|
183277|NCT02770508|Drug|Lamivudine|
183281|NCT02770469|Behavioral|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
183282|NCT02770469|Behavioral|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
183283|NCT02770456|Dietary Supplement|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
183284|NCT02770456|Dietary Supplement|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
183285|NCT02770456|Dietary Supplement|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
183286|NCT02770443|Drug|withdrawal|withdrawal of beta blocker and ACE inhibitors
183287|NCT02770443|Drug|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
183288|NCT02770430|Biological|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
183289|NCT02770430|Drug|conventional treatment|"Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
183290|NCT02770417|Dietary Supplement|beta-alanine|Patients receive beta-alanine
183291|NCT02770417|Dietary Supplement|placebo|Patients receive placebo
183292|NCT02770417|Other|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
183293|NCT02770404|Drug|Nafithromycin|100, 200, or 400 mg of nafithromycin
183294|NCT02770404|Drug|Placebo|IV matching placebo
183295|NCT02770391|Drug|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
183296|NCT02770391|Drug|ARN-509|ARN-509, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. ARN-509 will be initiated the same day patients receive their leuprolide acetate injection.
183297|NCT02770391|Procedure|Radical prostatectomy|
183298|NCT02770378|Drug|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
183299|NCT02770378|Drug|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
183300|NCT02770378|Drug|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
183301|NCT02770378|Drug|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
183302|NCT02770378|Drug|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
183303|NCT02770378|Drug|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
183304|NCT02770378|Drug|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
183305|NCT02770378|Drug|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
183306|NCT02770378|Drug|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
183307|NCT02770378|Drug|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
183308|NCT02770365|Drug|estrace cream (Perrigo)|
183309|NCT02770365|Drug|estrace cream (Reference)|
183310|NCT02770365|Drug|Placebo cream|
183311|NCT02770326|Biological|Fecal Microbiota Transplantation (FMT)|
183312|NCT02770313|Behavioral|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
183313|NCT02770300|Device|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
183314|NCT02770300|Device|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
183466|NCT02769221|Device|Video laryngoscope|
183827|NCT02766608|Drug|FF MDI 9.6 μg|Blinded Treatment
183315|NCT02770287|Device|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
183316|NCT02770274|Drug|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
183317|NCT02770274|Drug|Aspirin|Monotherapy with aspirin 100 mg once daily
183318|NCT02770261|Drug|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
183319|NCT02770261|Drug|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
183320|NCT02770261|Drug|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
183321|NCT02770261|Drug|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
183322|NCT02770261|Drug|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
183323|NCT02770261|Drug|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
183324|NCT02770248|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
183325|NCT02770248|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
183326|NCT02770235|Other|DE assessment|by a validated self-administered questionnaire: Index International erectile function (IIEF-15)
183327|NCT02770235|Other|AGE measurement|By AGE-ReaderTM
183328|NCT02770222|Drug|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
183329|NCT02770222|Drug|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
183330|NCT02770222|Drug|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
183331|NCT02770209|Biological|biomimetic cartilage matrix + autologous chondrocytes|
183332|NCT02770209|Procedure|arthroscopic debridement|
183333|NCT02770209|Procedure|microfracture surgery|
183334|NCT02770196|Behavioral|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
183335|NCT02770183|Device|Imacor|"In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.~During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive."
183336|NCT02770170|Drug|BI 655064 dose 1|
183337|NCT02770170|Drug|BI 655064 dose 2|
183338|NCT02770170|Drug|BI 655064 dose 3|
183339|NCT02770170|Drug|Placebo|
183340|NCT02770157|Drug|DA-3002|
183341|NCT02770157|Drug|Genotropin®|
183342|NCT02770144|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
183343|NCT02770144|Behavioral|Access to Referral to Social Services|
183344|NCT02770118|Behavioral|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
183345|NCT02770118|Behavioral|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
183346|NCT02770118|Behavioral|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
183347|NCT02770105|Other|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
183348|NCT02770105|Other|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
183349|NCT02770105|Other|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
183350|NCT02770105|Other|Placebo|Oral administration of 200ml of distilled water
183351|NCT02770092|Other|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
183352|NCT02770066|Device|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)~Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician~Antiplatelet therapy (usually standard)~Cholesterol-lowering drugs (usually standard)~Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)~Smoking cessation, diet and physical activity (usually standard)"
183353|NCT02770053|Procedure|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
183354|NCT02770040|Drug|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
183355|NCT02770027|Drug|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
183828|NCT02766608|Drug|BD MDI 320 μg|Blinded Treatment
183356|NCT02770027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
183357|NCT02770014|Drug|Erlotinib|
183358|NCT02769962|Drug|CRLX101|"CRLX101 IV Q 2weeks Day 1 and Day 15, administered in 28 day cycles, until disease progression or development of intolerable side effects~Plus olaparib (PO days 3-13* and days 17-26*) administered in 28 day cycle, until disease progression or development of intolerable side effects.~P1: Dose Escalation P2: RP2~(* On days 13 and 26, only one dose of olaparib will be administered in the morning)"
183359|NCT02769962|Drug|olaparib|"olaparib (PO days 3-13* and days 17-26* administered in 28 day cycles, until disease progression or development of intolerable side effects~Plus CRLX101 (IV Q 2weeks, Day 1 and Day 15) administered in 28 day cycles, until disease progression or development of intolerable side effects~P1: Dose Escalation P2: RP2D~(* On days 13 and 26, only one dose of olaparib will be administered in the morning)"
183360|NCT02769936|Drug|D-cycloserine|100 mg D-cycloserine administered orally as encapsulated pill
183361|NCT02769936|Other|Placebo|Placebo administered orally as encapsulated pill
183362|NCT02769923|Device|Westpharma ID adapter|device used for administering intradermal injection
183363|NCT02769923|Device|Star ID syringe|device used for administering intradermal injection
183364|NCT02769923|Device|BCG NS|syringe used for administering intradermal injection
183365|NCT02769910|Drug|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
183366|NCT02769910|Drug|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
183367|NCT02769910|Other|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
183368|NCT02769897|Behavioral|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
183369|NCT02769884|Device|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
183370|NCT02769871|Behavioral|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
183371|NCT02769871|Behavioral|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
183372|NCT02769858|Device|Light therapy|Light therapy glasses
183373|NCT02769845|Drug|Hydroxyurea|drug to be administered
183374|NCT02769845|Procedure|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
183375|NCT02769832|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1, 8 q 21 days
183376|NCT02769832|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, day 1, 8 q 21 days
183377|NCT02769819|Device|Flexible fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia~Glottic visualization will be evaluated by direct laryngoscopy.~The endotracheal tube will be loaded onto the scope after silicon spray lubrication~Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position~With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.~Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
183378|NCT02769806|Procedure|MRI|
183379|NCT02769793|Drug|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
183380|NCT02769793|Drug|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
183381|NCT02769767|Genetic|Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.|The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
183382|NCT02769754|Device|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
183383|NCT02769754|Other|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
183384|NCT02769741|Other|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
183385|NCT02769741|Other|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
183386|NCT02769728|Device|EndoBarrier|implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
183387|NCT02769715|Device|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
183388|NCT02769715|Other|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
183389|NCT02769702|Drug|Acthar|Acthar 80 IU SC twice a week
183390|NCT02769689|Drug|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
183391|NCT02769689|Drug|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
183392|NCT02769689|Drug|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
183393|NCT02769689|Drug|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
183394|NCT02769676|Other|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
183395|NCT02769676|Other|usual care|Participants in the usual care arm will receive no additional interventions.
183396|NCT02769663|Behavioral|questionnaires and neuropsychological assessments|
183397|NCT02769650|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
183398|NCT02769650|Drug|Optimal medicamentous treatment|
183399|NCT02769650|Procedure|Stress-MRI|A standard stress-MRI test with adenosine
183400|NCT02769637|Drug|PPI treatment|PPI treatment or no PPI treatment
183401|NCT02769624|Drug|Treprostinil|A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
183402|NCT02769624|Drug|Placebo|3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
183403|NCT02769611|Drug|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
183404|NCT02769598|Device|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
183405|NCT02769585|Behavioral|Self-hypnosis|Self-hypnosis
183406|NCT02769585|Behavioral|CDE training|standard CDE training for an obese diabetic
183407|NCT02769572|Other|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
183408|NCT02769572|Drug|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
183409|NCT02769572|Drug|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
183410|NCT02769572|Other|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
183411|NCT02769559|Procedure|Reduction mammaplasty|Surgical removal of excess breast tissue
183412|NCT02769546|Other|Surveys|
183413|NCT02769533|Drug|OTL0038|
183414|NCT02769533|Drug|Benadryl|
183415|NCT02769533|Device|intraoperative imaging|
183416|NCT02769520|Drug|Pembrolizumab|200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
183417|NCT02769507|Device|DC Stimulator PLUS (NeuroConn)|
183418|NCT02769494|Drug|Mesalazine Sustained-Release Tablets|Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
183419|NCT02769494|Drug|Riboflavin Sodium Phosphate Injection|gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
183420|NCT02769481|Drug|Bexagliflozin|20 mg, tablet
183421|NCT02769481|Drug|Placebo for Bexagliflozin|20 mg inactive tablet to match active comparator
183422|NCT02769481|Drug|Glimepiride|2, 4 or 6 mg, capsule
183423|NCT02769481|Drug|Placebo for Glimepiride|2, 4 or 6 mg inactive capsule to match the active comparator
183424|NCT02769468|Other|The Back|
183425|NCT02769468|Other|Chest|
183426|NCT02769468|Other|Left Axilla|
183467|NCT02769208|Device|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
183542|NCT02768688|Other|Brain connectivity and physiology|MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
183829|NCT02766608|Drug|Symbicort® TBH 400/12 μg BID|Open Label
183427|NCT02769455|Other|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.~The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
183428|NCT02769455|Other|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.~The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.~The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
183429|NCT02769442|Device|Terumo SurFlash Plus catheter|
183430|NCT02769442|Device|BD Insyte Autoguard catheter|
183431|NCT02769429|Device|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
183432|NCT02769429|Device|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
183433|NCT02769416|Other|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
183434|NCT02769403|Device|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:~Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
183435|NCT02769403|Other|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
183436|NCT02769403|Other|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
183437|NCT02769403|Other|Sick Days|Sick days during the 12 week study period will be collected
183438|NCT02769403|Other|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) & Physician Assistants [advance practice clinicians], and nurses) and will be linked to the consented research participant.
183439|NCT02769390|Drug|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
183440|NCT02769390|Drug|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
183441|NCT02769390|Drug|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
183442|NCT02769377|Device|Breeze2 glucometer|Breeze2 glucometer for self-monitoring of blood glucose
183443|NCT02769377|Device|Breeze2 glucometer and H2|Breeze2 glucometer and Health2Sync Mobile App for data transfer
183444|NCT02769351|Device|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
183445|NCT02769338|Other|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
183446|NCT02769325|Drug|Atropine|IV atropine 0.1%, 10 ml
183447|NCT02769325|Drug|Placebo|IV saline, 10 ml
183448|NCT02769325|Drug|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
183449|NCT02769325|Drug|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
183450|NCT02769325|Drug|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
183451|NCT02769325|Drug|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
183452|NCT02769325|Drug|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
183453|NCT02769325|Drug|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
183454|NCT02769312|Device|Theta burst stimulation|Theta burst transcranial magnetic stimulation
183455|NCT02769312|Device|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
183456|NCT02769299|Radiation|Radiation Therapy|less than 1 Gy with protons to 4-8 Gy with photons
183457|NCT02769286|Drug|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
183458|NCT02769273|Device|Percutaneous Transluminal Angioplasty|
183459|NCT02769260|Other|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
183460|NCT02769247|Drug|Naproxen|Oral naproxen vs placebo
183461|NCT02769247|Drug|Lidocaine|Intrauterine lidocaine vs normal saline
183462|NCT02769247|Drug|placebo|either normal saline or empty oral capsule
183463|NCT02769234|Procedure|ERP/EEG test|The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
183464|NCT02769234|Procedure|Psychometric testing|Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
183468|NCT02769182|Device|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
183469|NCT02769182|Behavioral|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
183470|NCT02769169|Drug|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
183471|NCT02769169|Drug|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
183472|NCT02769143|Other|Whole-Body Vibration|Will be performed six months of WBV exercises
183473|NCT02769143|Other|Pilates|Will be performed six months of Pilates exercises
183474|NCT02769130|Drug|Losartan|Losartan is given for 12 months
183475|NCT02769117|Procedure|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm or clavicle fractures
183476|NCT02769117|Procedure|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm or clavicle fractures
183477|NCT02769104|Drug|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
183478|NCT02769104|Drug|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks*4cycles
183479|NCT02769091|Drug|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
183480|NCT02769091|Drug|Placebo|
183481|NCT02769078|Drug|dabigatran|
183482|NCT02769078|Drug|rivaroxaban|
183483|NCT02769078|Drug|apixaban|
183484|NCT02769078|Drug|warfarin|
183485|NCT02769065|Drug|TAK-071|TAK-071 capsules
183486|NCT02769065|Drug|Donepezil|Donepezil over-encapsulated tablet
183487|NCT02769065|Drug|TAK-071 Placebo|TAK-071 placebo-matching capsules
183488|NCT02769065|Drug|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
183489|NCT02769052|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
183490|NCT02769039|Other|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit & sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
183491|NCT02769013|Other|Pre-treatment follow up|No active intervention; medical support provided if needed
183492|NCT02769013|Other|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
183493|NCT02769013|Other|Post treatment follow up|No active intervention; medical support provided if needed.
183494|NCT02769013|Other|Olfactometer experiment|No active intervention; medical support provided if needed.
183495|NCT02769000|Radiation|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
183496|NCT02769000|Radiation|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
183497|NCT02768987|Behavioral|Bright 1 Bodies|A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
183498|NCT02768974|Drug|OPRX-106|Oral delivery, once daily.
183499|NCT02768961|Drug|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
183500|NCT02768961|Drug|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.~Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
183501|NCT02768948|Drug|telmisartan during 6 months|telmisartan during 6 months
183502|NCT02768948|Drug|Losartan during 6 months|Losartan during 6 months
183503|NCT02768948|Procedure|blood sample|blood sample
183504|NCT02768935|Procedure|blood sample|blodd sample at 12 months
183505|NCT02768922|Other|Aphasia telerehabilitation|Speech and language therapy delivered by speech-language pathologist via computer and telemedicine
183506|NCT02768922|Other|Standard face-to-face aphasia rehabilitation|Speech and language therapy delivered by speech-language pathologist face-to-face (treatment as usual)
183507|NCT02768909|Device|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
183508|NCT02768909|Other|Survey & Physical Exam|2. Perform a oriented survey for risk factors and a complete physical exam.
183509|NCT02768909|Other|Chest X-ray|Perform anteroposterior chest X-ray
183510|NCT02768909|Other|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
183541|NCT02768701|Drug|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
183623|NCT02768129|Device|sham transcranial direct current stimulation|sham stimulation
183511|NCT02768909|Device|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
183512|NCT02768909|Device|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
183513|NCT02768909|Device|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
183514|NCT02768909|Device|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.~Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
183515|NCT02768896|Behavioral|Baseline|Patients will walk naturally with EEG measuring brain waves
183516|NCT02768896|Behavioral|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
183517|NCT02768896|Behavioral|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
183518|NCT02768896|Behavioral|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
183519|NCT02768883|Behavioral|Respira Sano|The intervention is all three components: clinic + home + community.
183520|NCT02768870|Device|Harpoon Artificial ePTFE Chords|It is anticipated that use of the Harpoon device could achieve similar outcomes to open cardiac surgery while decreasing the invasiveness of mitral valve repair.
183521|NCT02768857|Behavioral|Sensorimotor reeducation programs|
183522|NCT02768844|Device|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by Wyss Institute, Harvard University, Cofab Design LLC) to provide gentle vibrations and sounds during mattress stimulations.
183523|NCT02768844|Other|Control|Absence of mattress Stochastic Vibratory Stimulation (SVS)
183524|NCT02768831|Other|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
183525|NCT02768831|Other|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
183526|NCT02768818|Dietary Supplement|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
183527|NCT02768818|Dietary Supplement|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
183528|NCT02768805|Biological|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
183529|NCT02768805|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
183530|NCT02768805|Biological|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
183531|NCT02768792|Drug|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
183532|NCT02768779|Other|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
183533|NCT02768766|Drug|Selumetinib|"100mg, 125mg, 150mg, 175mg, 200mg or 225mg of oral capsules~An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK) or MAPK/extracellular-signal-regulated kinase (ERK) kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
183534|NCT02768753|Procedure|The Axillary Bilateral-breast Approach|
183535|NCT02768753|Procedure|The bilateral Axillo-breast Approach|
183536|NCT02768740|Drug|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
183537|NCT02768727|Drug|Xenon|drug given in concentrations of 0% to 60% over period of 2 hours
183538|NCT02768714|Drug|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
183539|NCT02768714|Drug|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
183540|NCT02768701|Drug|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
183624|NCT02768116|Procedure|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
183543|NCT02768688|Drug|Dexmedetomidine|Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
183544|NCT02768675|Device|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
183545|NCT02768662|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
183546|NCT02768649|Drug|RBP-7000|Sequential dosing of each cohort
183547|NCT02768649|Drug|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
183548|NCT02768636|Dietary Supplement|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
183549|NCT02768623|Other|Pharmacist led Asthma Management|
183550|NCT02768623|Other|Pharmacist Intervention (when requested by patient)|
183551|NCT02768610|Drug|Dexmedetomidine|
183552|NCT02768610|Drug|Normal Saline|
183553|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
183554|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
183555|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
183556|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
183557|NCT02768571|Drug|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation
183558|NCT02768571|Drug|Placebo|Placebo- saline 100 ml/day * 21 days with rehabilitation
183559|NCT02768558|Radiation|Thoracic RT|High-precision radiation therapy
183560|NCT02768558|Drug|Cisplatin|Anti-cancer alkylating agent
183561|NCT02768558|Drug|Etoposide|Cytotoxic agent
183562|NCT02768558|Drug|Nivolumab|Anti-PD-1 targeted immunotherapy
183563|NCT02768558|Other|Placebo|0.9% Sodium Chloride solution or 5% Dextrose solution
183564|NCT02768545|Drug|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
183565|NCT02768532|Drug|Vedolizumab|"During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.~Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed."
183566|NCT02768519|Drug|OTS167IV|diluted to final concentration with cherry syrup
183567|NCT02768519|Other|Cherry syrup|
183568|NCT02768493|Drug|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
183569|NCT02768493|Drug|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
183570|NCT02768480|Other|Primary Care|Patients will be followed by primary care team according to the usual health system routine.
183571|NCT02768480|Other|Phone Calls Support and Primary Care|Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
183572|NCT02768467|Procedure|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
183573|NCT02768467|Procedure|No Stitches|Subject will not receive stitches post buccal mucosa removal.
183574|NCT02768454|Drug|medical review of controlled broad-spectrum antibiotics|medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
183575|NCT02768441|Drug|Dexamphetamine|Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
183576|NCT02768428|Other|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
183577|NCT02768415|Drug|Apatinib|
183578|NCT02768415|Drug|Oral Vinorelbine|
183579|NCT02768402|Device|Caisson TMVR System|Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
183580|NCT02768389|Drug|Bevacizumab|Subjects receive Bevacizumab as standard of care
183581|NCT02768389|Behavioral|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (< 20gm/day).
183582|NCT02768376|Drug|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
183583|NCT02768376|Drug|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
183584|NCT02768363|Biological|aglatimagene besadenovec|Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
183585|NCT02768363|Biological|placebo|Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
183586|NCT02768363|Drug|valacyclovir|Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
183587|NCT02768350|Procedure|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
183588|NCT02768350|Procedure|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
183589|NCT02768337|Drug|Afatinib|
183590|NCT02768337|Radiation|2 Gy targeted radiotherapy|
183591|NCT02768337|Radiation|4 Gy targeted radiotherapy|
183592|NCT02768311|Procedure|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
183593|NCT02768311|Procedure|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
183594|NCT02768311|Procedure|hand files k-files|Procedure: hand files k-files
183595|NCT02768298|Drug|LCZ696|LCZ696 50 mg, 100 mg or 200 mg film-coated tablets
183596|NCT02768298|Drug|enalapril|Enalapril 2.5mg, 5 mg and 10 mg film-coated tablets
183597|NCT02768298|Drug|Enalapril matching placebo|Placebo to enalapril 2.5mg, 5 mg and 10 mg film-coated tablets
183598|NCT02768298|Drug|LCZ696 matching placebo|Placebo to LCZ696 50mg, 100mg and 200mg film-coated tablets
183599|NCT02768285|Procedure|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
183600|NCT02768272|Device|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
183601|NCT02768272|Procedure|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
183602|NCT02768246|Device|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
183603|NCT02768246|Device|Face Mask|Classic face mask
183604|NCT02768233|Behavioral|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
183605|NCT02768220|Drug|empagliflozin|Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
183606|NCT02768220|Drug|linagliptin|Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
183607|NCT02768207|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
183608|NCT02768207|Drug|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
183609|NCT02768194|Device|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
183610|NCT02768194|Other|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
183611|NCT02768194|Other|Mineral water|Commercially available mineral water
183612|NCT02768181|Behavioral|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
183613|NCT02768181|Dietary Supplement|Nutrient supplement to pregnant women (PNS)|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.~Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA ~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
183614|NCT02768181|Dietary Supplement|Nutrienr supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).~Dose: 2 sachets ~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
183615|NCT02768168|Drug|dezocine|receive dezocine 0.1 mg/kg
183616|NCT02768168|Other|normal saline|receive matching placebo (equal volume of normal saline)
183617|NCT02768155|Other|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
183618|NCT02768155|Other|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
183619|NCT02768155|Other|Placebo Control|Normal Saline
183620|NCT02768142|Other|Natural cesarean delivery|Natural cesarean delivery
183621|NCT02768142|Other|Standard cesarean delivery|Standard cesarean delivery
183622|NCT02768129|Device|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
183626|NCT02768103|Behavioral|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
183627|NCT02768090|Device|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
183628|NCT02768077|Drug|Melatonin(Circadin®)|
183629|NCT02768077|Drug|Placebo|
183630|NCT02768064|Device|temporary pacemaker insertion|Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
183631|NCT02768051|Procedure|AF Ablation|
183632|NCT02768038|Other|Observational|Blood, stool ja biopsy specimens
183633|NCT02768025|Other|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
183634|NCT02768025|Other|NRT, counselling|Nicotine Replacement Therapy, counselling
183635|NCT02768012|Behavioral|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
183636|NCT02767999|Drug|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
183637|NCT02767999|Drug|Placebo|cellulose placebo per day from D0 to D90
183638|NCT02767999|Radiation|fMRI|functional resting state MRI
183639|NCT02767973|Other|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
183640|NCT02767947|Drug|Luliconazole Cream 1%|Luliconazole cream will be applied per schedule specified in the arm.
183641|NCT02767947|Drug|Vehicle Cream|Vehicle cream will be applied per schedule specified in the arm.
183642|NCT02767934|Other|Laboratory Biomarker Analysis|Correlative studies
183643|NCT02767934|Biological|Pembrolizumab|Given IV
183644|NCT02767921|Other|Cytology Specimen Collection Procedure|Correlative studies
183645|NCT02767921|Other|Laboratory Biomarker Analysis|Correlative studies
183646|NCT02767921|Procedure|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
183647|NCT02767921|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
183648|NCT02767921|Procedure|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
183649|NCT02767908|Other|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
183650|NCT02767895|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
183651|NCT02767882|Drug|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
183652|NCT02767882|Drug|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
183653|NCT02767869|Drug|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
183654|NCT02767869|Drug|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
183655|NCT02767856|Device|IO-therapy Glasses|
183656|NCT02767843|Device|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
183657|NCT02767830|Behavioral|Excercise and Nutrition Program|
183658|NCT02767817|Procedure|Stereotactic Hematoma Evacuation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.
183659|NCT02767817|Biological|MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
183660|NCT02767817|Biological|Injectable Collagen Scaffold with MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
183661|NCT02767804|Drug|X-396 (ensartinib)|oral ALK inhibitor
183662|NCT02767804|Drug|crizotinib|oral ALK inhibitor
183663|NCT02767791|Other|Acupuncture|Acupuncture
183664|NCT02767791|Other|Auriculotherapy|Auriculotherapy
183707|NCT02767492|Drug|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
183708|NCT02767479|Drug|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
183665|NCT02767778|Device|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
183666|NCT02767778|Device|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
183667|NCT02767765|Drug|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
183668|NCT02767752|Dietary Supplement|T-ChOS|
183669|NCT02767752|Drug|Gemcitabine|
183670|NCT02767752|Dietary Supplement|Placebo|
183671|NCT02767752|Drug|Capecitabine|
183672|NCT02767739|Behavioral|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
183673|NCT02767726|Device|non-invasive multimodal imaging|
183674|NCT02767713|Drug|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
183675|NCT02767713|Other|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
183676|NCT02767700|Genetic|NGS|Next generation sequencing
183677|NCT02767687|Other|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
183678|NCT02767674|Drug|Rituximab|375 mg/m2 IVD day0
183679|NCT02767674|Drug|Gemcitabine|Gemcitabine 1 g/m2 IVD day 1
183680|NCT02767674|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IVD day1
183681|NCT02767674|Drug|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IVD d1
183682|NCT02767674|Drug|Epirubicin Injectable Product|Epirubicin 35 mg/m2 IVD d1
183683|NCT02767674|Drug|Vindesine|Vindesine 2 mg IVP d1
183684|NCT02767674|Drug|Prednisone|Prednisone 40mg/m2 PO d1-5
183685|NCT02767661|Drug|Capecitabine|Capecitabine, 625mg/m2, orally twice daily (continuously)
183686|NCT02767661|Drug|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
183687|NCT02767648|Other|proteomic urine analysis|proteomic urine analysis
183688|NCT02767635|Drug|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
183689|NCT02767635|Drug|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
183690|NCT02767635|Drug|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
183691|NCT02767622|Procedure|Liver transplantation|
183692|NCT02767609|Device|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
183693|NCT02767596|Drug|Lixisenatide|
183694|NCT02767596|Drug|Basal insulins|patients are on basal insulin treatment
183695|NCT02767583|Device|Exams|Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
183696|NCT02767570|Other|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
183697|NCT02767570|Other|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
183698|NCT02767557|Drug|Tocilizumab|Intravenous infusion
183699|NCT02767557|Drug|Gemcitabine|Intravenous infusion
183700|NCT02767557|Drug|nab-Paclitaxel|Intravenous infusion,
183701|NCT02767544|Procedure|Vaginal wound local analgesia after laparoscopic hysterectomy|
183702|NCT02767531|Drug|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
183703|NCT02767518|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
183704|NCT02767505|Other|gastric bypass|Type of surgery: gastric bypass
183705|NCT02767505|Other|Sleeve gastrectomy|Typ of surgery: sleeve gastrectomy
183706|NCT02767492|Device|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
183709|NCT02767479|Drug|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
183710|NCT02767466|Procedure|Physical therapy and robotic assisted gait training|
183711|NCT02767453|Procedure|Wound drainage|Experimental portion removing/draining blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
183712|NCT02767453|Procedure|Total Shoulder Arthroplasty|"Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible. Shoulder prosthesis is a standard artificial device to replace both components of the ball and socket joint during TSA."
183713|NCT02767440|Behavioral|Families on Track Intervention|Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
183714|NCT02767427|Device|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
183715|NCT02767427|Other|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
183716|NCT02767414|Device|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
183717|NCT02767414|Device|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
183718|NCT02767414|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
183719|NCT02767401|Device|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
183720|NCT02767401|Drug|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
183721|NCT02767375|Drug|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 & 2 , IA，q4-6 Weeks
183722|NCT02767375|Procedure|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
183723|NCT02767362|Drug|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
183724|NCT02767349|Drug|MNK-155|2 or 3 tablets initial dose, followed by two tablets every twelve hours
183725|NCT02767336|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
183726|NCT02767323|Device|rTMS|excitatory 5Hz rTMS will be used
183727|NCT02767323|Device|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
183728|NCT02767310|Drug|Rosuvastatin 20 mg film-coated tablets|Single oral dose of 20 mg
183729|NCT02767310|Drug|Crestor 20 mg film-coated tablets|Single oral dose of 20 mg
183730|NCT02767297|Drug|FDL169|
183731|NCT02767284|Device|UCST-V1|A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.
183732|NCT02767284|Device|UCST-V2|A refined version of the UCST-V1 that randomizes frequency order.
183733|NCT02767284|Device|UCST-V3|A version that utilises eye-tracking technology to make the measurements more accurate.
183734|NCT02767284|Device|Quick-CSF (QCSF)|A fast contrast sensitivity measurement method using a Bayesian algorithm.
183735|NCT02767284|Device|Pelli-Robson|A standard method developed using a Sloan-letter chart with decreasing contrast.
183736|NCT02767284|Device|Optec 6500|A standard test using sinusoidal gratings to measure the contrast sensitivity function.
183737|NCT02767271|Drug|Luliconazole Cream 1%|Luliconazole cream will be applied topically per schedule specified in the arms.
183738|NCT02767258|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
183739|NCT02767258|Device|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
183740|NCT02767245|Drug|Thiamine|Thiamine IV 100 mg/day
183741|NCT02767232|Drug|Recombinant tissue plasminogen activator (rt-PA)|Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
184078|NCT02764879|Procedure|scaling and root planing|
183742|NCT02767232|Drug|Standard Anticoagulation Therapy|Standard anticoagulation determined by physician for a period of 3-6 months
183743|NCT02767219|Drug|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
183744|NCT02767219|Drug|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
183745|NCT02767219|Drug|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
183746|NCT02767193|Biological|DCV3|"Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4"
183747|NCT02767193|Biological|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
183748|NCT02767193|Biological|Placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4
183749|NCT02767193|Biological|Placebo with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
183750|NCT02767167|Other|Semi-skimmed cow's milk|430ml of semi-skimmed cow's milk / day for 12 weeks
183751|NCT02767154|Device|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
183752|NCT02767154|Device|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
183753|NCT02767141|Behavioral|Coping Strategies|Coping strategies for households in the US with food insecurity
183754|NCT02767128|Drug|Triferic|
183755|NCT02767128|Drug|Fer-In-Sol|
183756|NCT02767128|Drug|Shohl's solution|
183757|NCT02767115|Dietary Supplement|2% GSE mucoadhesive gel|2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
183758|NCT02767115|Other|GSE free mucoadhesive gel|GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
183759|NCT02767102|Other|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
183760|NCT02767102|Other|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
183761|NCT02767089|Drug|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
183762|NCT02767089|Drug|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
183763|NCT02767076|Procedure|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
183764|NCT02767076|Device|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
183765|NCT02767063|Drug|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.
183766|NCT02767063|Drug|Avelumab|10mg/kg every 2 weeks, for a maximum of 8 IV infusions over a 4 months' period. (If MR4.5 is acheived by the first 3 months the 7th and 8th infusions will be omitted)
183767|NCT02767037|Device|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
183768|NCT02767037|Genetic|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
183769|NCT02767024|Drug|Sodium nitroprusside|Sodium nitroprusside is a medication used to lower blood pressure.
183770|NCT02767024|Drug|Dobutamine|Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.
183771|NCT02767024|Drug|Furosemide|Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
183772|NCT02767011|Other|Tele-Health Electronic Monitoring (THEM)|Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
183773|NCT02766998|Procedure|Preserved umbilical vein as shunt/conduit|All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
183774|NCT02766972|Procedure|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
183775|NCT02766959|Other|Observational study|
183776|NCT02766946|Device|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
183777|NCT02766946|Device|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
183779|NCT02766946|Other|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
183780|NCT02766907|Device|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
183781|NCT02766894|Device|EEG monitoring|EEG will be performed. Data obtained will be analyzed using software. Anesthesiologists will enter their assumption in a blinded fashion and data obtained will be compared with EEG data
183782|NCT02766868|Drug|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
183783|NCT02766855|Drug|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
183784|NCT02766842|Procedure|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
183785|NCT02766842|Procedure|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
183786|NCT02766842|Device|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
183787|NCT02766842|Device|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
183788|NCT02766829|Procedure|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
183789|NCT02766829|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
183790|NCT02766816|Biological|Part 1 study - BBio bOPV|A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
183791|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 1|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
183792|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 2|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
183793|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 3|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
183794|NCT02766816|Biological|Part 2 study - Licensed bOPV|Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
183795|NCT02766816|Biological|Part 1 study - Licensed bOPV|A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
183796|NCT02766803|Drug|Simvastatin and micronized trans-resveratrol|
183797|NCT02766790|Dietary Supplement|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
183798|NCT02766790|Other|Placebo|Placebo, an inactive formulation
183799|NCT02766777|Drug|Lubiprostone|
183800|NCT02766764|Drug|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
183801|NCT02766764|Drug|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
183802|NCT02766764|Drug|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
183803|NCT02766764|Drug|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
183804|NCT02766751|Behavioral|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
183805|NCT02766751|Behavioral|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
183806|NCT02766738|Other|GrACE program|to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
183807|NCT02766738|Other|GrACE + gait|to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
183808|NCT02766725|Drug|preparation F12 sildenafil in situ gel|in situ vaginal gel
183809|NCT02766725|Drug|preparation F2 sildenafil in situ gel|in situ vaginal gel
183810|NCT02766725|Drug|placebo gel|vaginal gel
183811|NCT02766712|Procedure|Pace During 1st Half of Lesion|
183812|NCT02766712|Procedure|Pace During 2nd Half of Lesion|
183813|NCT02766699|Drug|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
183814|NCT02766686|Radiation|Radiotherapy with protons|
183815|NCT02766686|Radiation|Radiotherapy with photons|
183816|NCT02766673|Drug|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
183817|NCT02766673|Drug|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
183818|NCT02766660|Device|Optical Coherence Tomography|All groups were measured by optical coherence tomography.
183819|NCT02766647|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
183820|NCT02766647|Biological|US-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
183821|NCT02766634|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
183822|NCT02766634|Biological|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
183823|NCT02766621|Biological|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
183824|NCT02766621|Drug|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
183825|NCT02766608|Drug|BFF MDI 320/9.6 μg|Blinded Treatment
183830|NCT02766595|Other|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
183831|NCT02766582|Drug|Pembrolizumab|IV every 21 days at 200 mg
183832|NCT02766582|Drug|Carboplatin|IV every 21 days
183833|NCT02766582|Drug|Paclitaxel|IV infusion (80mg/m2) every 7 days for 6 cycles
183834|NCT02766569|Device|ASD closure with the Occlutech Flex II ASD closure device|Monitoring of possible device related side effects with a minumum of 1 year follow-up.
183835|NCT02766556|Drug|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
183836|NCT02766556|Procedure|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
183837|NCT02766556|Drug|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
183838|NCT02766543|Device|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
183839|NCT02766530|Other|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
183840|NCT02766517|Drug|Capsaicin|Administered topically
183841|NCT02766504|Device|airway ultrasound|airway assessment using ultrasound
183842|NCT02766491|Other|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
183843|NCT02766491|Other|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.~For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
183844|NCT02766478|Drug|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
183845|NCT02766478|Drug|Placebo|A placebo pill will be taken orally for 12 weeks.
183846|NCT02766465|Drug|Busulfan|Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.
183847|NCT02766465|Drug|Fludarabine|Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2).
183848|NCT02766465|Drug|r-ATG|r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg).
183849|NCT02766465|Procedure|Hematopoietic Cell Transplant|Day 0 is the day of transplantation.
183850|NCT02766465|Drug|Tacrolimus|Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.
183851|NCT02766465|Drug|Methotrexate|Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2.
183852|NCT02766465|Procedure|Standard of Care|Continue to receive standard of care treatment per patient's SCD physician.
183853|NCT02766452|Behavioral|"You and your child in the recovery room DVD"|
183854|NCT02766452|Behavioral|Standard pre-operative preparation|Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
183855|NCT02766439|Drug|etanercept|25-mg etanercept injection subcutaneously twice a week
183856|NCT02766426|Behavioral|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
183857|NCT02766400|Behavioral|Guided Training|
183858|NCT02766400|Behavioral|Directed Training|
183859|NCT02766387|Other|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
183860|NCT02766374|Behavioral|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.~The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
183861|NCT02766374|Behavioral|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
183862|NCT02766361|Behavioral|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
183863|NCT02766361|Other|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
183864|NCT02766348|Drug|gemcitabine|gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
183865|NCT02766348|Biological|DC-CTL|8×10^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
183866|NCT02766348|Drug|cisplatinum|cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
183867|NCT02766335|Drug|Docetaxel|Given IV
183868|NCT02766335|Biological|Durvalumab|Given IV
183869|NCT02766335|Other|Laboratory Biomarker Analysis|Correlative studies
183870|NCT02766322|Other|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
183871|NCT02766322|Other|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
183872|NCT02766322|Other|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
183873|NCT02766322|Other|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
183874|NCT02766309|Other|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker & Gandeck, 2002).
183875|NCT02766296|Behavioral|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
183876|NCT02766296|Behavioral|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
183877|NCT02766283|Drug|iodinated contrast agents|Intravascular application
183878|NCT02766270|Drug|Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
183879|NCT02766270|Radiation|Radiotherapy|
183880|NCT02766257|Procedure|Anesthesia for ambulatory paediatric surgery|
183881|NCT02766244|Device|ICG/SPY|indocyanine green fluorescence imaging
183882|NCT02766244|Drug|Antibiotic Ointment|Antibiotic ointment
183883|NCT02766231|Device|Physica CR|Cruciate tretaining total knee replacement
183884|NCT02766231|Device|Physica PS|Posterior Stabilized total knee replacement
183885|NCT02766192|Drug|Ketamine|
183886|NCT02766192|Behavioral|TIMBER Psychotherapy|
183887|NCT02766192|Drug|Placebo (normal saline)|
183888|NCT02766179|Device|CPAP|CPAP is used for 6 weeks
183889|NCT02766179|Device|Somnoguard|Somnoguard is used for 6 weeks
183890|NCT02766140|Drug|SHR1020 plus Docetaxel|SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks
183891|NCT02766140|Drug|Placebo plus Docetaxel|Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks
183892|NCT02766127|Other|Veritise Flow|Self-adhering composite
183893|NCT02766127|Other|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
183894|NCT02766127|Other|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
183895|NCT02766127|Other|Flor-Opal® Varnish|fluoride-based varnish
183896|NCT02766114|Procedure|Carpal tunnel release through Mini Transverse Approach|Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
183897|NCT02766101|Behavioral|Aerobic Exergaming PE Curriculum|Sustained aerobic exercise.
183898|NCT02766101|Behavioral|Standard PE|Non-aerobic skill building.
183899|NCT02766088|Procedure|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
183900|NCT02766075|Behavioral|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait & Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
183901|NCT02766062|Other|metabolic syndrome|metabolic syndrome
183902|NCT02766049|Biological|DC|Autologous dendritic cells (3x10e7)
183903|NCT02766049|Biological|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
183904|NCT02766049|Biological|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
183905|NCT02766036|Drug|Propolis|Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
183906|NCT02766036|Drug|Placebo|Patients will receive 500 mg / day of the placebo in the form of tablets split in two daily doses
183907|NCT02766023|Biological|Lactobacillus crispatus CTV-05|LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
183908|NCT02766023|Drug|Metronidazole|Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
183909|NCT02766023|Other|Placebo|Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
183910|NCT02766010|Device|TensorTip|Non Invasive screening of various physiological and hematological parameters.
186087|NCT02750254|Procedure|Stem cell transplant|
183911|NCT02765997|Biological|Unmanipulated UCB|Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
183912|NCT02765997|Biological|SR-1 UCB|SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
183913|NCT02765984|Device|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
183914|NCT02765971|Other|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
183915|NCT02765971|Drug|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
183916|NCT02765971|Drug|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
183917|NCT02765958|Device|portable ECG devise|
183918|NCT02765945|Other|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
183919|NCT02765932|Procedure|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
183920|NCT02765932|Procedure|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
183921|NCT02765919|Radiation|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
183922|NCT02765919|Radiation|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
183923|NCT02765906|Other|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics & Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
183924|NCT02765906|Other|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
183925|NCT02765893|Other|No Foley|Patients will have Foley catheter removed 6 hours post-op.
183926|NCT02765880|Other|fMRI|Connectivity between the areas related to information processing over time and the areas activated during the rest activity. We will verify whether the activation anomalies observed during time tasks predict anomalies in spontaneous activity dynamics.
183927|NCT02765880|Other|EEG|link between EEG response anomalies related to information processing over time and response anomalies recorded during rest activity. We will check whether anomalies in EEG oscillatory responses during time tasks predict anomalies during the rest task.
183928|NCT02765867|Drug|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
183929|NCT02765854|Drug|Dexamethasone|Given PO
183930|NCT02765854|Drug|Ixazomib|Given PO
183931|NCT02765854|Drug|Lenalidomide|Given PO
183932|NCT02765841|Drug|Lomitapide|
183933|NCT02765828|Other|Observational study|The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
183934|NCT02765815|Drug|Liposomal bupivacaine, 266mg|
183935|NCT02765815|Drug|Bupivacaine 0.5 % with Epinephrine|
183936|NCT02765815|Drug|Ketorolac 30mg|
183937|NCT02765815|Drug|Morphine 10mg|
183938|NCT02765815|Drug|Bupivacaine 0.25% with Epinephrine|
183939|NCT02765802|Drug|Peginterferon Lambda-1A|
183940|NCT02765789|Device|Immunoadsorption (Immunosorba)|Immunoadsorption as an alternative to plasma exchange
183941|NCT02765776|Other|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.~In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
183942|NCT02765763|Drug|2-Minute Reveal Masque|
183943|NCT02765763|Drug|24/7 Barrier Repair Cream|
183944|NCT02765763|Drug|8-in-1 BioSerum|
183945|NCT02765763|Drug|Null Formula 2-Minute Reveal Masque|
183946|NCT02765763|Drug|Null Formula 24/7 Barrier Repair Cream|
183947|NCT02765763|Drug|Null Formula 8-in-1 BioSerum|
184390|NCT02762643|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
183948|NCT02765750|Behavioral|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60."
183949|NCT02765750|Behavioral|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40."
183950|NCT02765750|Behavioral|No message|The headphones will be placed on patient's ears but no message will be played.
183951|NCT02765737|Other|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
183952|NCT02765737|Device|Mepilex Ag|
183953|NCT02765724|Drug|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
183954|NCT02765685|Device|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
183955|NCT02765685|Other|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers."
183956|NCT02765672|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
183957|NCT02765672|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
183958|NCT02765672|Behavioral|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
183959|NCT02765672|Behavioral|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
183960|NCT02765672|Behavioral|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
183961|NCT02765672|Behavioral|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
183962|NCT02765672|Procedure|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
183963|NCT02765672|Procedure|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
183964|NCT02765672|Procedure|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
183965|NCT02765672|Procedure|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
183966|NCT02765672|Procedure|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
183967|NCT02765659|Behavioral|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
183968|NCT02765659|Behavioral|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
183969|NCT02765659|Behavioral|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
183970|NCT02765646|Device|Coronary stent procedure (CSP)|
183971|NCT02765633|Drug|Cangrelor|
183972|NCT02765620|Other|drug&radiation|"Early treatment response assessment: using baseline data and early follow-up data~Evaluate treatment response: using baseline data, early follow-up data and final data~Compare PERCIST to RECIST criteria: correlation analysis~Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
183973|NCT02765607|Procedure|Heart surgery|
183974|NCT02765594|Drug|Hydroxychloroquine Sulfate|200mg bid
183975|NCT02765594|Drug|Valsartan|160mg qd
183976|NCT02765581|Device|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
184079|NCT02764879|Other|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
184080|NCT02764866|Other|Sleep testing|Home sleep testing
184263|NCT02763501|Procedure|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
183977|NCT02765581|Device|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany—the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
183978|NCT02765581|Behavioral|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
183979|NCT02765568|Behavioral|High Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
183980|NCT02765568|Behavioral|Moderate Intensity Continuous Exercise Training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
183981|NCT02765568|Behavioral|Nordic Walking|Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
183982|NCT02765555|Drug|RBP-7000|Single dose
183983|NCT02765542|Other|Automated disease assessment & self-care support phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
183984|NCT02765529|Procedure|Blood sampling|
183985|NCT02765516|Other|Plant sterols|2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
183986|NCT02765516|Other|Placebo|Identical margarine without additional plant sterols to be consumed for 28 days
183987|NCT02765503|Radiation|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
183988|NCT02765490|Drug|AL-335|AL-335 800 mg (2*400) tablet will be administered once daily.
183989|NCT02765490|Drug|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
183990|NCT02765490|Drug|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
183991|NCT02765451|Behavioral|interventions of the Cancéropôle Nord-Ouest|"During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,....."
183992|NCT02765438|Device|BOBO|"Each subject will play four games with the BOBO system."
183993|NCT02765425|Device|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
183994|NCT02765412|Other|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
183995|NCT02765412|Other|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
183996|NCT02765412|Other|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
183997|NCT02765412|Other|Academic Detailing|All sites will be offered an academic detailing approach to implementation of Lung Decision Precsion. A trained detailer will travel to all sites who agree to a visit. The detailer will meet with individual primary care providers whenever possible, and groups of providers as necessary. He will present evidence for a risk-based approach to screening and how to use the tool with patients to make tailored screening recommendations.
183998|NCT02765399|Drug|Liraglutide|
183999|NCT02765399|Drug|Placebo|
184000|NCT02765386|Device|Hybrid fittings for cochlear implant recipients|
184001|NCT02765373|Drug|Exemestane|
184002|NCT02765373|Drug|Letrozole|
184003|NCT02765373|Drug|Anastrozole|
184004|NCT02765360|Other|Treatment Group|"Participants will be established on the randomised mode of ventilation and will have continuous assessment of the following during the assessment period:~Electrical impedance tomography~EMGpara~SpO2~tcCO2~Pneumotachography~End-tidal CO2 monitoring"
184005|NCT02765347|Drug|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
184006|NCT02765347|Drug|Insulin|For arm 2, just accept insulin for 24 weeks
184007|NCT02765334|Device|nBETTER|60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
184008|NCT02765321|Behavioral|Healthy lifestyle promotion|Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
184151|NCT02764307|Device|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
184264|NCT02763501|Procedure|non-closure of mesenteric defects|Mesenteric defects are left open
184009|NCT02765295|Device|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
184010|NCT02765295|Device|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
184011|NCT02765282|Device|Algorithm based programming using Kinesia-based assessment|DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
184012|NCT02765269|Device|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
184013|NCT02765256|Drug|Fluconazole|400mg orally once daily (Day 1-14)
184014|NCT02765256|Drug|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
184015|NCT02765256|Drug|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
184016|NCT02765256|Drug|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
184017|NCT02765256|Drug|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
184018|NCT02765256|Drug|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
184019|NCT02765243|Biological|Anti-GD2 CART|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
184020|NCT02765217|Drug|Lactobacillus reuteri DSM 17938|Comparison the effects of L. reuteri and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
184021|NCT02765217|Drug|Placebo|Comparison the effects of L. reuteri and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
184022|NCT02765217|Drug|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
184023|NCT02765204|Drug|Dapagliflozin|
184024|NCT02765204|Drug|Saxagliptin|
184025|NCT02765204|Drug|Glucose|
184026|NCT02765191|Drug|Norepinephrine|Norepinephrine will be titrated to achieve a MAP of 60-65 mmHg and 75-80 mmHg respectively.
184027|NCT02765191|Drug|Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 10 minutes will be administered
184028|NCT02765178|Other|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
184029|NCT02765178|Other|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
184030|NCT02765178|Other|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
184031|NCT02765178|Other|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
184032|NCT02765178|Other|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
184033|NCT02765165|Drug|USL311|Administered once weekly in a 21-day cycle
184034|NCT02765165|Drug|USL311|Administered once daily in a 21-day cycle
184035|NCT02765165|Drug|USL311|Administered once daily in a 42-day cycle
184036|NCT02765165|Drug|Lomustine|Administered once every 6 weeks in a 42-day cycle
184037|NCT02765152|Other|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
184038|NCT02765152|Other|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
184039|NCT02765152|Other|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
184152|NCT02764294|Other|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started about 10-15 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
184040|NCT02765139|Behavioral|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
184041|NCT02765139|Other|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
184042|NCT02765126|Biological|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
184043|NCT02765126|Biological|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
184044|NCT02765113|Procedure|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
184045|NCT02765113|Procedure|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.~Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.~MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
184046|NCT02765100|Drug|Minocycline|In various models of neurodegenerative disease, minocycline has demonstrated neurorestorative as well as neuroprotective properties.
184047|NCT02765087|Other|Medical History|Oriented Survey and complete physical exam.
184048|NCT02765087|Device|E-Nose|Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
184049|NCT02765087|Other|Chest CT|
184050|NCT02765087|Other|Pleural Fluid Analysis|Cytomorphology Cytochemistry Adenosine Deaminase Value
184051|NCT02765074|Drug|subcutaneous tocilizumab|162 mg subcutaneous, once a week during 12 months
184052|NCT02765048|Behavioral|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
184053|NCT02765035|Device|C-Leg 4|Microprocessor Controlled Knee
184054|NCT02765035|Device|C-Leg 3|Microprocessor Controlled Knee
184055|NCT02765022|Device|Clip closure|Complete clip closure of secondary lesions after the endoscopic mucosal resection
184056|NCT02765022|Procedure|No clip closure|Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
184057|NCT02765009|Drug|diuretics|Used to reduce fluid overload as evidenced by weight gain
184058|NCT02765009|Drug|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
184059|NCT02765009|Other|fluid restriction|Used to reduce fluid overload
184060|NCT02765009|Device|renal replacement|Used to reduce fluid overload in patients with renal replacement
184061|NCT02764996|Device|Acupuncture|
184062|NCT02764983|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
184063|NCT02764983|Behavioral|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
184064|NCT02764983|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
184065|NCT02764983|Behavioral|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
184066|NCT02764983|Behavioral|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
184067|NCT02764983|Behavioral|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
184068|NCT02764983|Procedure|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
184069|NCT02764983|Other|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
184070|NCT02764970|Drug|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
184071|NCT02764957|Dietary Supplement|green coffee extract|
184072|NCT02764957|Dietary Supplement|placebo|
184073|NCT02764944|Procedure|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
184074|NCT02764931|Other|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
184075|NCT02764905|Behavioral|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
184076|NCT02764892|Drug|V81444|Single oral dose of V81444
184077|NCT02764879|Dietary Supplement|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
184081|NCT02764853|Behavioral|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
184082|NCT02764853|Behavioral|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed
184083|NCT02764840|Other|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
184084|NCT02764840|Other|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
184085|NCT02764827|Biological|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
184086|NCT02764814|Other|Cryopreserved amniotic membrane|subjects will receive cryopreserved amniotic membrane
184087|NCT02764801|Drug|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
184088|NCT02764801|Device|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
184089|NCT02764788|Other|Specific auriculotherapy|Specific auriculotherapy with needles
184090|NCT02764788|Other|non-specific auriculotherapy|non-specific auriculotherapy with needles
184091|NCT02764788|Other|seed auriculotherapy|non-specific auriculotherapy with seeds
184092|NCT02764775|Device|Headpod|Adaptive equipment to assist with active head movements
184093|NCT02764762|Drug|Vedolizumab|Vedolizumab intravenous infusion.
184094|NCT02764762|Drug|Adalimumab|Adalimumab injection for subcutaneous use.
184095|NCT02764762|Drug|Methotrexate|Methotrexate oral tablets.
184096|NCT02764749|Dietary Supplement|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
184097|NCT02764749|Dietary Supplement|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
184098|NCT02764736|Drug|Atorvastatin|Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
184099|NCT02764723|Drug|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
184100|NCT02764723|Drug|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
184101|NCT02764710|Drug|Amoxicillin-Potassium Clavulanate Combination|"Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.~Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7."
184102|NCT02764697|Drug|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
184103|NCT02764684|Drug|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
184104|NCT02764671|Biological|10μg/0.5ml recombinant hepatitis B vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
184105|NCT02764658|Device|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
184106|NCT02764658|Other|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
184107|NCT02764658|Other|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
184108|NCT02764645|Device|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.~The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
184109|NCT02764645|Device|22Fr curved Cannula|arterial cannula for use in cardiac surgery
184110|NCT02764632|Procedure|Digital facilitation|
184111|NCT02764619|Drug|Spironolactone|
184112|NCT02764619|Drug|Placebo|
184113|NCT02764606|Biological|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
184114|NCT02764593|Drug|Nivolumab|Anti-PD-1 targeted immunotherapy
184115|NCT02764593|Drug|Cisplatin|Anti-cancer alkylating agent
184116|NCT02764593|Drug|Cetuximab|Epidermal Growth Factor Receptor (EGFR) antagonist
184117|NCT02764593|Radiation|IMRT|High-precision radiotherapy
184118|NCT02764567|Other|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
184119|NCT02764541|Drug|Letrozole|
184120|NCT02764541|Drug|Tamoxifen|
184121|NCT02764541|Drug|Palbociclib|
184122|NCT02764541|Drug|Endocrine Therapy|
184193|NCT02763956|Other|Placebo|Intradiscal saline injection
184265|NCT02763488|Device|DelfiPTS tourniquet system|
184123|NCT02764528|Behavioral|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
184124|NCT02764528|Behavioral|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
184125|NCT02764528|Behavioral|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
184126|NCT02764515|Drug|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
184127|NCT02764515|Drug|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
184128|NCT02764502|Device|Pressure Gauge Manometer|Identification of epidural space
184129|NCT02764489|Biological|FEIBA|Anti-inhibitor Coagulant Complex Nanofiltered (activated prothrombin complex concentrate [APCC]), FEIBA NF.
184130|NCT02764476|Other|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
184131|NCT02764476|Other|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
184132|NCT02764463|Device|Fiber Reinforced Composite Fixed Partial Dentures|All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
184133|NCT02764450|Device|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
184134|NCT02764450|Device|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
184135|NCT02764437|Biological|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
184136|NCT02764424|Device|NIPE (MDoloris®)|Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
184137|NCT02764411|Drug|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
184138|NCT02764385|Other|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
184139|NCT02764385|Other|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
184140|NCT02764372|Behavioral|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
184141|NCT02764372|Behavioral|Exergames|Participants played exergames existent in the Wii game console
184142|NCT02764359|Drug|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
184143|NCT02764346|Behavioral|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
184144|NCT02764346|Behavioral|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
184145|NCT02764333|Biological|TPIV200|
184146|NCT02764333|Biological|Durvalumab|
184147|NCT02764320|Other|Treatment Strategy|Both arms will initiate or optimize preventive medications. Subjects in the Discontinuation arm will stop overused medications and use an alternative rescue medication(s) with a limited frequency. Subjects in the Preventive Therapy Only arm will initiate or optimize preventive medications without immediately discontinuing the overused medication.
184148|NCT02764307|Device|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
184149|NCT02764307|Device|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
184150|NCT02764307|Device|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
184262|NCT02763514|Dietary Supplement|3 g Placebo|
184266|NCT02763488|Other|Standard physical therapy|
184153|NCT02764294|Other|Stress Ball Group|"Music group was given stress ball into both their palms about 10-15 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
184154|NCT02764294|Other|DVD Group|DVD group was started to be watched a DVD of their choise about 10-15 minutes before cystoscopy and continued during the whole procedure.
184155|NCT02764281|Drug|MEDA|"Methotrexate, 3.0g/m2/d iv, day 1~Etoposide, 100mg/m2 iv, day 2 to day 4~Dexamethasone, 40mg/d iv, day 1 to day 4~Pegaspargase, 2500IU/m2/d im, day 4~The MEDA chemotherapy will be repeated every 3 weeks."
184156|NCT02764281|Procedure|Auto-HSCT|Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
184157|NCT02764268|Drug|Apatinib|
184158|NCT02764242|Other|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
184159|NCT02764242|Other|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
184160|NCT02764229|Drug|LYC-30937-EC|LYC-30937-EC 25 mg by mouth once daily
184161|NCT02764216|Radiation|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
184162|NCT02764203|Other|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
184163|NCT02764203|Device|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
184164|NCT02764190|Behavioral|I-ACT with Check Yourself|
184165|NCT02764177|Dietary Supplement|Protein drink|The protein drink was administered during this trial
184166|NCT02764177|Dietary Supplement|Carbohydrate drink|The carbohydrate drink was administered in this trial
184167|NCT02764164|Device|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
184168|NCT02764151|Drug|PF-06840003|Daily Oral PF-06840003
184169|NCT02764138|Behavioral|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
184170|NCT02764125|Drug|Stalevo|levodopa/carbidopa/entacapone
184171|NCT02764125|Drug|levodopa MR|levodopa MR/carbidopa/ODM-104
184172|NCT02764099|Behavioral|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
184173|NCT02764086|Radiation|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
184174|NCT02764073|Device|Bioimpedance spectroscopy|The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
184175|NCT02764073|Device|Lung Ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts (with a distance 7 mm between 2 artifacts). The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
184176|NCT02764073|Device|Echocardiography|All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
184177|NCT02764060|Device|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
184178|NCT02764060|Device|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
184179|NCT02764047|Dietary Supplement|Probiotic|L. acidophilus 10⁹, B. lactis 10⁹
184180|NCT02764034|Device|Low level Laser diode machine|wavelength 635 Low level diode laser power control time control Continuous mode
184181|NCT02764021|Dietary Supplement|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
184182|NCT02764021|Dietary Supplement|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
184183|NCT02764008|Drug|Bupivacaine|20 ml %0,25 bupivacaine
184184|NCT02764008|Device|Ultrasound|
184185|NCT02763995|Behavioral|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
184186|NCT02763982|Other|Physical evaluation|
184187|NCT02763969|Drug|BMS-986202|
184188|NCT02763969|Drug|Placebo|
184189|NCT02763969|Drug|Interferon alpha-2a recombinant|
184190|NCT02763969|Drug|Famotidine|
184191|NCT02763969|Drug|Ustekinumab|
184192|NCT02763956|Device|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
184194|NCT02763943|Behavioral|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
184195|NCT02763930|Other|Control diet|
184196|NCT02763930|Other|Milk diet|
184197|NCT02763930|Other|GABA-rich cheese diet|
184198|NCT02763917|Device|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
184199|NCT02763917|Device|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
184200|NCT02763904|Dietary Supplement|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
184201|NCT02763904|Other|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
184202|NCT02763891|Other|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
184203|NCT02763891|Other|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
184204|NCT02763878|Procedure|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
184205|NCT02763878|Procedure|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
184206|NCT02763865|Device|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.~Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
184207|NCT02763865|Device|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
184208|NCT02763852|Drug|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
184209|NCT02763852|Drug|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
184210|NCT02763852|Drug|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
184211|NCT02763839|Drug|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
184212|NCT02763839|Drug|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
184213|NCT02763839|Drug|Sinemet 25/100|Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp & Dohme) tablets; oral route.
184214|NCT02763826|Device|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
184215|NCT02763813|Device|Herbst (propulsion type oral appliance)|Oral appliance
184216|NCT02763813|Device|Retention type appliance (ORM)|
184217|NCT02763800|Drug|BIA 3-202|BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
184218|NCT02763800|Drug|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
184219|NCT02763787|Drug|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
184220|NCT02763787|Drug|Placebo|Identical placebo
184221|NCT02763774|Other|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
184222|NCT02763774|Other|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
184267|NCT02763475|Drug|cyclophosphamide|60mg/kg by vein on day -6
184223|NCT02763774|Other|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
184224|NCT02763761|Drug|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
184225|NCT02763761|Drug|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
184226|NCT02763748|Procedure|Laparoscopic endoscopy combined surgery|
184227|NCT02763748|Procedure|laparoscopic and endoscopic cooperative surgery|
184228|NCT02763748|Procedure|Single-arch laparoscopic and endoscopic cooperative surgery|
184229|NCT02763735|Drug|11C acetate|Radiopharmaceutical
184230|NCT02763722|Other|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
184231|NCT02763696|Other|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
184232|NCT02763683|Radiation|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
184233|NCT02763670|Other|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)~At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).~At 6 and 18 months, one cardiology consultation~At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
184234|NCT02763670|Other|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.~According to these recommendations, the patient should see his cardiologist at least once a year.~Usual practices are:~An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency~At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
184235|NCT02763657|Other|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
184236|NCT02763644|Drug|LFG316 active drug|LFG316
184237|NCT02763644|Other|Standard of care treatment|SoC (site specific)
184238|NCT02763631|Other|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
184239|NCT02763631|Other|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
184240|NCT02763631|Other|Sham Comparator: Stand Care Arm|No change will be made to participants care
184241|NCT02763618|Other|Neurofeedback|Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.
184242|NCT02763618|Other|Placebo Neurofeedback training|The placebo training will be a previously recorded Neurofeedback session of a participant in group A
184243|NCT02763605|Other|no intervention|
184244|NCT02763592|Drug|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
184245|NCT02763592|Other|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
184246|NCT02763579|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab intravenous infusion was administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
184247|NCT02763579|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
184248|NCT02763579|Drug|Etoposide|Etoposide intravenous infusion was administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
184249|NCT02763579|Drug|Placebo|Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
184250|NCT02763566|Drug|Abemaciclib|Administered orally
184251|NCT02763566|Drug|Anastrozole|Administered orally
184252|NCT02763566|Drug|Letrozole|Administered orally
184253|NCT02763566|Drug|Placebo|Administered orally
184254|NCT02763566|Drug|Fulvestrant|Administered intramuscularly
184255|NCT02763553|Dietary Supplement|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
184256|NCT02763553|Dietary Supplement|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
184257|NCT02763540|Procedure|Lung cryobiopsy|Transbronchial cryobiopsy
184258|NCT02763527|Behavioral|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
184259|NCT02763527|Behavioral|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
184260|NCT02763514|Dietary Supplement|3 g PronovaPure 150:500 EE EU|
184261|NCT02763514|Dietary Supplement|3 g PronovaPure 500:200 EE EU|
184269|NCT02763475|Procedure|NK cell infusion|"First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy~Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
184270|NCT02763475|Drug|IL-2|1x10^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
184271|NCT02763449|Behavioral|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
184272|NCT02763436|Procedure|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
184273|NCT02763423|Procedure|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
184274|NCT02763410|Other|PRBC transfusion|
184275|NCT02763397|Device|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
184276|NCT02763397|Device|DBS|DBS will be switched off
184277|NCT02763384|Drug|BL-8040|
184278|NCT02763384|Drug|Nelarabine|
184279|NCT02763371|Other|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
184280|NCT02763371|Other|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
184281|NCT02763358|Device|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
184282|NCT02763345|Device|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
184283|NCT02763345|Other|Standard care|
184284|NCT02763332|Other|Upper trunk group (UTG)|This bandage was placed over the upper trapezius muscle.
184285|NCT02763332|Other|Global trunk group (GTG)|This bandage was placed globally along the back
184286|NCT02763319|Drug|Rituximab (RTX)|Rituximab: Dose: 375 mg/m2 IV
184287|NCT02763319|Drug|MOR208|MOR208: MOR208 dose: 12 mg/kg intravenously (IV)
184288|NCT02763319|Drug|Bendamustine (BEN)|
184289|NCT02763306|Device|Dermal Cooling System|Treatment with dermal cooling system.
184290|NCT02763293|Other|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
184291|NCT02763280|Dietary Supplement|Ginseng extract 1g|Ginseng extract 1g, parallel design
184292|NCT02763280|Dietary Supplement|Ginseng extract 3g|Ginseng extract 3g, parallel design
184293|NCT02763280|Dietary Supplement|Placebo|placebo, parallel design
184294|NCT02763267|Other|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant [4-14 weeks gestation] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at delivery)
184295|NCT02763254|Biological|baltaleucel-T|Autologous EBV-specific T cells
184296|NCT02763241|Drug|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
184297|NCT02763241|Drug|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
184298|NCT02763228|Behavioral|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
184299|NCT02763228|Behavioral|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
184300|NCT02763228|Behavioral|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
184301|NCT02763228|Behavioral|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
184302|NCT02763228|Behavioral|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
184303|NCT02763228|Behavioral|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
184304|NCT02763228|Behavioral|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
184305|NCT02763202|Other|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:~(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
184306|NCT02763189|Other|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
184307|NCT02763189|Other|Self-study|All subjects will receive self-study
184308|NCT02763163|Behavioral|Sun exposure routine|
184309|NCT02763150|Behavioral|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
184310|NCT02763150|Other|Health Promotion|The health promotion group will receive education on healthy eating and activity
184311|NCT02763137|Drug|Standard LD/CD|LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
184312|NCT02763137|Drug|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
184313|NCT02763124|Procedure|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
184314|NCT02763111|Drug|BCD-085|
184315|NCT02763111|Other|Placebo|
184316|NCT02763098|Drug|Remi 0.1|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
184317|NCT02763098|Drug|Remi 0.2|.Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
184318|NCT02763098|Drug|Remi 0.3|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
184319|NCT02763085|Device|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
184320|NCT02763072|Device|Picosecond Q-switched Laser|One Enlighten treatment
184321|NCT02763072|Device|KTP Laser|Up to four Excel V treatments
184322|NCT02763059|Drug|Ibuprofen 600 mg|This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
184323|NCT02763059|Drug|Dexamethasone 4 mg|This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
184324|NCT02763059|Drug|Placebo|This group receives 1 hour before surgery placebo.
184325|NCT02763059|Drug|Acetaminophen 1000 mg|A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
184326|NCT02763046|Biological|AIN457/Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. every 4 weeks
184327|NCT02763046|Biological|AIN457/Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. every 4 weeks
184328|NCT02763046|Drug|AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab|Induction: 4x Secukinumab Placebo s.c. weekly Maintenance: Secukinumab Placebo s.c. every 4 weeks until Week 16 followed by 150 mg Secukinumab s.c. weekly for 4 weeks
184329|NCT02763033|Drug|Bob's Red Mill®|Standard bone marrow transplant (BMT) diet + potato-based starch
184330|NCT02763033|Other|Starch Placebo|Standard bone marrow transplant (BMT) diet + corn-based starch
184331|NCT02763020|Other|Fruit extracts high in polyphenols|
184332|NCT02763020|Other|placebo|
184333|NCT02763007|Drug|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
184334|NCT02763007|Drug|alogliptin|nesina add on metformin
184335|NCT02763007|Drug|pioglitazone|actos add on metformin
184336|NCT02762994|Drug|BCD-085|
184337|NCT02762994|Other|Placebo|
184338|NCT02762981|Drug|CORT125134 with nab-paclitaxel|CORT125134 is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.
184339|NCT02762968|Dietary Supplement|Placebo|Placebo capsules similar to the experimental treatments.
184340|NCT02762968|Dietary Supplement|HMB|Capsules containing calcium HMB.
184341|NCT02762968|Dietary Supplement|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
184342|NCT02762955|Biological|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
184343|NCT02762955|Biological|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
184344|NCT02762942|Drug|Misoprostol|Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
184345|NCT02762942|Device|Foley catheter|Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
184346|NCT02762929|Drug|HTX-011A|
184347|NCT02762929|Drug|Saline|
184348|NCT02762929|Drug|HTX-011B|
184349|NCT02762929|Drug|HTX-002|
184350|NCT02762929|Drug|Bupivacaine Hydrochloride Injection|
184351|NCT02762929|Drug|HTX-009|
184352|NCT02762916|Other|Selfmanage with the help of telemedicine program|"The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.~Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme"
184353|NCT02762903|Procedure|TSA with tenotomy technique|Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
184354|NCT02762903|Procedure|TSA with lesser tuberosity osteotomy technique|Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
184355|NCT02762903|Device|Shoulder prosthesis|"Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device."
184356|NCT02762890|Drug|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
184357|NCT02762890|Drug|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
184358|NCT02762864|Other|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
184359|NCT02762864|Drug|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
184360|NCT02762864|Drug|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
184361|NCT02762851|Other|Sterile saline|0.5 ml dose injected intramuscularly
184362|NCT02762851|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
184363|NCT02762838|Biological|BCD-055|BCD-055 is infliximab biosimilar
184364|NCT02762838|Biological|Remicade®|
184365|NCT02762838|Drug|Methotrexate|All patients will receive methotrexate in a dose from 10 to 25 mg per week.
184366|NCT02762838|Drug|Folic acid|All patients will receive folic acid in a dose of 5 mg per week.
184367|NCT02762825|Behavioral|HIIT|HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
184368|NCT02762825|Behavioral|MCT|MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
184369|NCT02762812|Biological|BCD-055|
184370|NCT02762812|Biological|Remicade®|
184371|NCT02762799|Biological|Leucostim®|Leucostim® is filgrastim biosimilar.
184372|NCT02762799|Biological|Neupogen®|
184373|NCT02762786|Behavioral|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
184374|NCT02762773|Procedure|non-dissection of inferior rectus sheath|Non-dissection of inferior rectus sheath
184375|NCT02762773|Procedure|control|Dissection of inferior and superior aspect of the rectus sheath
184376|NCT02762760|Biological|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
184377|NCT02762760|Biological|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
184378|NCT02762747|Procedure|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
184379|NCT02762734|Other|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
184380|NCT02762708|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
184381|NCT02762708|Behavioral|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
184382|NCT02762708|Drug|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
184383|NCT02762708|Drug|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
184384|NCT02762695|Other|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.~The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
184385|NCT02762695|Other|Usual Care|Usual Care at Primary Health Care Center
184386|NCT02762669|Drug|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
184387|NCT02762656|Drug|Lidocaine|Lidocaine drip during surgery
184388|NCT02762643|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
184389|NCT02762643|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
184391|NCT02762630|Device|Carestream Health Inc. weight bearing cone beam CT scanner|
184392|NCT02762617|Drug|Tenofovir disoproxil fumarate intravaginal ring|The TDF IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of 86% (w/w) TDF and 14% (w/w) sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
184393|NCT02762617|Drug|Placebo intravaginal ring (IVR)|The Placebo IVR is formulated using preformed flexible tubing, comprised of biomedical medical grade hydrophilic, aliphatic polyurethane, and an inner core compartment comprised of sodium chloride. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
184394|NCT02762604|Behavioral|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
184395|NCT02762604|Behavioral|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
184396|NCT02762591|Drug|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
184397|NCT02762578|Drug|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
184398|NCT02762578|Drug|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
184399|NCT02762565|Device|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
184400|NCT02762552|Device|Transcranial-holter monitoring|Transcranial holter with an 4 hour-recording
184401|NCT02762539|Drug|omega-3 enriched SMOF lipid emusion|
184402|NCT02762526|Procedure|Lipoabdominoplasty|
184403|NCT02762513|Drug|Axitinib|
184404|NCT02762500|Drug|LYC-30937-EC|
184405|NCT02762500|Drug|Placebo|
184406|NCT02762487|Device|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
184407|NCT02762474|Drug|nab-paclitaxel group|Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
184408|NCT02762461|Procedure|IVF or ICSI|
184409|NCT02762448|Drug|Daclatasvir+ Asunaprevir|HCV clearance and complete regression of NHL by ASV+ DCV
184410|NCT02762435|Other|sham|light touch at established points on hand and wrist
184411|NCT02762435|Other|control|no contact with the subject
184412|NCT02762435|Other|acupressure|moderate pressure at established points on hand and wrist
184413|NCT02762422|Other|Phlebotomy|Removal of 500 cc of blood via forearm vein
184414|NCT02762409|Other|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
184415|NCT02762409|Other|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
184416|NCT02762383|Drug|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
184417|NCT02762370|Drug|FX006 32 mg|Single 5 mL IA injection
184418|NCT02762370|Drug|TCA IR 40 mg|Single 1 mL IA injection
184419|NCT02762357|Device|Novosyn® Quick|Episiotomy closure
184420|NCT02762344|Drug|heparin|routinary heparin administration during coronary angiography/PCI
184421|NCT02762331|Drug|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
184422|NCT02762331|Drug|Placebo|Placebo intervention
184423|NCT02762318|Other|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:~Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.~A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.~For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
184424|NCT02762305|Other|RSVP Bone Builders Group Exercise|
184425|NCT02762292|Device|Measurement of work of breathing using indirect calorimeter|"Preparation:~Patient baseline characteristics will be collected.~Connection of the Indirect Calorimeter to the respiratory circuit.~Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.~Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.~End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
184426|NCT02762279|Other|esophageal and pleural pressure measurement|Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
184427|NCT02762266|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
184428|NCT02762266|Procedure|Transarterial Chemoembolization|Undergo TACE
184429|NCT02762266|Drug|embolic agent|". Acceptable embolic agents include:~Gelatin sponge (gelfoam)~Polyvinyl alcohol (PVA) particles~Microspheres / Embolic beads"
184430|NCT02762266|Drug|lipiodol|
184431|NCT02762253|Drug|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
184432|NCT02762240|Other|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
184433|NCT02762240|Other|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
184434|NCT02762227|Device|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
184435|NCT02762227|Device|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
184436|NCT02762227|Procedure|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
184437|NCT02762214|Device|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).~After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
184438|NCT02762214|Other|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.~Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
184439|NCT02762201|Procedure|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.~Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).~Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
184440|NCT02762201|Procedure|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
184441|NCT02762188|Device|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.~Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
184442|NCT02762149|Device|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
184443|NCT02762136|Drug|placebo|
184444|NCT02762136|Drug|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
184445|NCT02762123|Drug|BMS-986142 200mg|
184446|NCT02762123|Drug|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
184447|NCT02762123|Drug|BMS-986142 350mg|
184448|NCT02762097|Procedure|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
184449|NCT02762097|Procedure|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
184450|NCT02762097|Drug|normal saline|Normal saline would be injected into uterine cavity to delineate defects
184451|NCT02762084|Drug|Patidegib|
184452|NCT02762084|Drug|Vehicle gel|
184453|NCT02762071|Drug|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
184454|NCT02762071|Drug|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
186088|NCT02750254|Drug|Azacitidine|
184455|NCT02762058|Device|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
184456|NCT02762058|Procedure|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
184457|NCT02762045|Biological|Ad5-gag|Ad5-gag is used as vaccine in all arms.
184458|NCT02762045|Biological|Placebo|Preservation Solution is used as control in all arms.
184459|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
184460|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
184461|NCT02762032|Drug|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
184462|NCT02762019|Device|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
184463|NCT02762019|Device|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
184464|NCT02762006|Drug|Durvalumab|Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
184465|NCT02762006|Drug|Tremelimumab|Tremelimumab is a CTLA-4 monoclonal antibody.
184466|NCT02761993|Biological|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
184467|NCT02761993|Drug|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
184468|NCT02761980|Drug|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
184469|NCT02761980|Drug|Ibuprofen 250 mg|Ibuprofen 250 mg
184470|NCT02761980|Drug|Acetaminophen 500 mg|1 APAP 500 mg caplet
184471|NCT02761980|Drug|Placebo|Placebo tablet
184472|NCT02761967|Behavioral|Physical activity|Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
184473|NCT02761928|Other|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
184474|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 1)|Patients in Dose Level1 will receive 1x10^7 1RG-CART/m^2 on Day 0 (intravenously).
184475|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 2)|Patients in Dose Level 2 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 on Day 0.
184476|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 3)|Patients in Dose Level 3 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 on Day 0.
184477|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 4)|Patients in Dose Level 4 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 on Day 0.
184478|NCT02761915|Drug|Cyclophosphamide|
184479|NCT02761915|Drug|Fludarabine|
184480|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 5)|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 on Day 0 .
184481|NCT02761889|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
184482|NCT02761889|Procedure|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
184483|NCT02761889|Device|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
184484|NCT02761889|Device|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
184485|NCT02761876|Behavioral|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
184486|NCT02761876|Behavioral|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
184487|NCT02761876|Behavioral|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
184542|NCT02761369|Device|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
185659|NCT02753452|Behavioral|Residential Immersive Life Skills programming|
184488|NCT02761863|Other|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.~The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).~The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
184489|NCT02761837|Behavioral|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
184490|NCT02761837|Behavioral|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
184491|NCT02761824|Other|Camp Discovery|Activities included physical, social, emotional, sensory and spiritual activities.
184492|NCT02761811|Device|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
184493|NCT02761798|Device|Automated Mobile Interactive Audiometer|iPad game
184494|NCT02761746|Behavioral|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
184495|NCT02761733|Behavioral|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
184496|NCT02761720|Other|No Intervention|
184497|NCT02761707|Other|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
184498|NCT02761707|Other|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
184499|NCT02761707|Other|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
184500|NCT02761707|Other|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
184501|NCT02761694|Drug|ARQ 751|During dose escalation, subjects received ARQ 751 orally every day at dose levels specified for the respective dose cohort for a 28-day cycle During dose expansion, subjects will receive ARQ 751 orally at 75mg every day on a 28-day cycle.
184502|NCT02761694|Drug|ARQ 751 and fulvestrant|Subjects will receive ARQ 751 orally every day at dose levels specified for the respective dose cohort for a 28-day cycle in combination with fulvestrant (500 mg administered intramuscularly) on Days 1 & 15 of Cycle 1 and Day 1 on all subsequent cycles for each 28-day cycle.
184503|NCT02761694|Drug|ARQ 751 and paclitaxel|ARQ 751 will be administered every day orally at dose levels specified for the respective dose cohort for a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2), once a week on Day 1, 8 &15 for three consecutive weeks followed by one week off of each 28-day cycle.
184504|NCT02761681|Behavioral|ACT-CL Web-based guided self-help|
184505|NCT02761681|Behavioral|Control Web-based guided self-help|
184506|NCT02761668|Procedure|ParS+Ortho 4W|Orthodontics 4 weeks post surgical
184507|NCT02761668|Procedure|ParS+Ortho 6M|Orthodontics 6 months post surgical
184508|NCT02761655|Behavioral|Memory Strategies|Memory strategies on encoding retention, retrieval, execution and monitoring
184509|NCT02761642|Drug|Epoetin Beta|All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
184510|NCT02761629|Drug|Peg-Interferon Alpha-2A|Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
184511|NCT02761629|Drug|Ribavirin|Ribavirin will be administered as either 1000 milligrams (mg) (2*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing less than (<) 75 kilograms (kg) or as 1200 mg (3*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing greater than or equal to (>/=) 75 kg.
184512|NCT02761616|Other|eBC treated participants|No intervention administered in this retrospective observational study.
184543|NCT02761356|Other|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
185660|NCT02753452|Behavioral|Non-residential life skills programming|
184513|NCT02761603|Behavioral|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
184514|NCT02761603|Behavioral|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
184515|NCT02761590|Other|Circuit training protocol|The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
184516|NCT02761577|Drug|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
184517|NCT02761577|Drug|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
184518|NCT02761564|Other|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
184519|NCT02761564|Other|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
184520|NCT02761551|Behavioral|Reminder notifications via autodialer|
184521|NCT02761538|Behavioral|AVIITAM|"The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.~.~."
184522|NCT02761525|Other|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
184523|NCT02761525|Other|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
184524|NCT02761512|Drug|CJ-12420 50 mg QD|CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
184525|NCT02761512|Drug|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
184526|NCT02761512|Drug|Lansoprazole 30 mg QD|Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
184527|NCT02761499|Device|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
184528|NCT02761486|Drug|Aspirin|325mg aspirin per day
184529|NCT02761486|Drug|Placebo|placebo in matching capsules
184530|NCT02761473|Other|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
184531|NCT02761473|Other|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
184532|NCT02761460|Drug|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
184533|NCT02761447|Other|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
184534|NCT02761447|Other|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
184535|NCT02761434|Other|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
184536|NCT02761434|Other|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
184537|NCT02761421|Other|observation study|observation study
184538|NCT02761395|Procedure|Al-hijamah|"Strict sterilization of selected anatomical sites.~Suction using sterile plastic disposable sucking cups~Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
184539|NCT02761395|Drug|Deferasirox|20-40 mg/kg/day orally
184540|NCT02761382|Other|Mindfulness-based psychological treatment|
184541|NCT02761382|Other|Non-specific psychological treatment|
184544|NCT02761343|Other|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
184545|NCT02761330|Drug|Ketamine|Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
184546|NCT02761330|Procedure|Electroconvulsive Therapy|Dose of the ECT charge will be determined during titration session prior to randomization.
184547|NCT02761317|Drug|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
184548|NCT02761317|Drug|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
184549|NCT02761317|Drug|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
184550|NCT02761304|Procedure|Ultrasound|
184551|NCT02761291|Drug|Gemcitabine|Gemcitabine will be administrated 600~1250 mg/m^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m^2. If no subject suffered the dose limit toxicity, 1000 mg/m^2 and even 1250 mg/m^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m^2, the 600 mg/m^2 will be started.
184552|NCT02761291|Drug|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
184553|NCT02761291|Drug|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and < 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
184554|NCT02761278|Procedure|Endometrial biopsy|
184555|NCT02761265|Procedure|Surgical intervention|Surgery to correct spinal deformity
184556|NCT02761265|Other|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
184557|NCT02761252|Drug|Bilastine 20mg|
184558|NCT02761252|Drug|Montelukast 10mg|
184559|NCT02761252|Drug|Placebo Bilastine 20mg|
184560|NCT02761252|Drug|Placebo Montelukast 10mg|
184561|NCT02761239|Device|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
184562|NCT02761226|Procedure|Platform Matched Design (Group A)|10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)
184563|NCT02761226|Procedure|Platform Switching Design (Group B)|10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
184564|NCT02761213|Drug|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
184565|NCT02761213|Drug|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
184566|NCT02761187|Other|No Intervention|
184567|NCT02761174|Drug|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
184568|NCT02761174|Other|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
184569|NCT02761161|Drug|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
184570|NCT02761161|Behavioral|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
184571|NCT02761122|Procedure|Human biological samples|"Blood sample~Skin or mucosal brushing~Skin or mucosal biopsy"
184572|NCT02761096|Device|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.~Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.~An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.~After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
184573|NCT02761096|Other|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
184574|NCT02761083|Device|Novosyn® Quick|Eye surgery
184575|NCT02761083|Device|Vicryl® Rapid|Eye surgery
184576|NCT02761070|Drug|Temozolomide|
184577|NCT02761070|Drug|Bevacizumab|
184578|NCT02761057|Drug|Cabozantinib|Given PO
184579|NCT02761057|Drug|Cabozantinib S-malate|Given PO
184580|NCT02761057|Drug|Crizotinib|Given PO
184581|NCT02761057|Drug|Savolitinib|Given PO
184582|NCT02761057|Drug|Sunitinib|Given PO
184583|NCT02761057|Drug|Sunitinib Malate|Given PO
184584|NCT02761018|Behavioral|Behavioral: Fitness Tracker|will use a fitness tracker but will not be able to see other participant's data
184585|NCT02761018|Behavioral|Fitness Tracker|will use a fitness tracker and will be able to see other member's daily and weekly results
184630|NCT02760667|Drug|Cisplatinum|Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
184631|NCT02760667|Drug|Docetaxel|Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
184632|NCT02760667|Drug|Carboplatin|Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)
184586|NCT02761005|Drug|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
184587|NCT02760992|Drug|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
184588|NCT02760992|Drug|Oral Baclofen|10 mg tablet
184589|NCT02760979|Drug|Denosumab|Denosumab treatment one year after surgery
184590|NCT02760979|Drug|Placebo|Serum one year after surgery
184591|NCT02760966|Other|Alcohol 70º|
184592|NCT02760966|Other|Soap|
184593|NCT02760953|Procedure|Cryoablation|Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
184594|NCT02760953|Drug|Epirubicin|Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
184595|NCT02760940|Drug|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
184596|NCT02760927|Device|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
184597|NCT02760901|Drug|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
184598|NCT02760901|Drug|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
184599|NCT02760901|Drug|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
184600|NCT02760901|Drug|saline|saline hydration 2500 ml before cisplatin therapy
184601|NCT02760901|Drug|Cisplatin|patients with tumours already prescribed cisplatin
184602|NCT02760888|Drug|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
184603|NCT02760888|Drug|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
184604|NCT02760888|Drug|Placebo|Women will receive a Placebo 1 hour before the procedure
184605|NCT02760875|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
184606|NCT02760862|Drug|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
184607|NCT02760862|Drug|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
184608|NCT02760849|Other|Laboratory Biomarker Analysis|Correlative studies
184609|NCT02760849|Procedure|Oophorectomy|Undergo ISDO
184610|NCT02760849|Other|Quality-of-Life Assessment|Ancillary studies
184611|NCT02760849|Procedure|Salpingectomy|Undergo ISDO
184612|NCT02760849|Procedure|Salpingo-Oophorectomy|Undergo RRSO
184613|NCT02760823|Drug|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
184614|NCT02760823|Drug|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
184615|NCT02760810|Device|Marketed Contact Lens|Narafilcon A
184616|NCT02760797|Drug|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
184617|NCT02760797|Drug|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
184618|NCT02760784|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
184619|NCT02760771|Other|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
184620|NCT02760771|Other|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
184621|NCT02760758|Drug|CDI-31244|NNI
184622|NCT02760758|Drug|Placebo|no active ingredients
184623|NCT02760745|Other|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
184624|NCT02760732|Device|drug eluting balloon; cutting balloon|Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.
184625|NCT02760732|Device|drug eluting stent|with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
184626|NCT02760719|Drug|nebulized 3% hypertonic solution|already described
184627|NCT02760706|Device|Computed Tomography scan|
184628|NCT02760680|Device|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
184629|NCT02760680|Other|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
184633|NCT02760667|Procedure|Transoral Robotic Assisted Surgery|TORS will be performed for the patients who responded to the induction treatment (80% reduction)
184634|NCT02760654|Device|Proactive Self Management Program for Effects of Cancer Treatment|
184635|NCT02760641|Other|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
184636|NCT02760641|Other|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
184637|NCT02760628|Behavioral|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
184638|NCT02760628|Behavioral|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
184639|NCT02760615|Drug|Caffeine|Caffeine tablets
184640|NCT02760615|Drug|Losartan|Losartan tablets
184641|NCT02760615|Drug|Omeprazole|Omeprazole capsules
184642|NCT02760615|Drug|Dextromethorphan|Dextromethorphan capsules
184643|NCT02760615|Drug|Midazolam|Midazolam syrup
184644|NCT02760615|Drug|Vedolizumab|Vedolizumab solution for IV infusion
184645|NCT02760602|Drug|Solanezumab|Administered IV
184646|NCT02760602|Drug|Placebo|Administered IV
184647|NCT02760576|Drug|BAY 987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
184648|NCT02760563|Drug|BAY 987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application (Formulation number V26-160)
184649|NCT02760550|Other|No intervention|Participants of all three groups completed a questionnaire.
184650|NCT02760537|Behavioral|Lay Health Worker Intervention|Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.
184651|NCT02760537|Behavioral|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
184652|NCT02760524|Behavioral|NET Intervention|Neuro-emotional Technique
184653|NCT02760511|Dietary Supplement|Anthocyanin|Capsules with different anthocyanin content
184654|NCT02760511|Dietary Supplement|Placebo|Placebo capsules
184655|NCT02760498|Drug|cemiplimab|
184656|NCT02760485|Drug|itacitinib|Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
184657|NCT02760485|Drug|ibrutinib|
184658|NCT02760472|Drug|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
184659|NCT02760472|Drug|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
184660|NCT02760459|Drug|Dexamethasone|
184661|NCT02760459|Drug|Normal saline solution|
184662|NCT02760446|Behavioral|CAM-ICU.fr|Neuropsychological testing
184663|NCT02760433|Drug|Olokizumab q4w|
184664|NCT02760433|Drug|Olokizumab q2w|
184665|NCT02760433|Drug|Placebo q2w|
184666|NCT02760420|Drug|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
184667|NCT02760420|Drug|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
184668|NCT02760407|Drug|Olokizumab 64mg q4w|
184669|NCT02760407|Drug|Olokizumab 64mg q2w|
184670|NCT02760407|Drug|Adalimumab 40mg q2w|
184671|NCT02760407|Drug|Placebo q2w|
184672|NCT02760394|Device|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
184673|NCT02760381|Device|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
184674|NCT02760368|Drug|Olokizumab q4w|
184675|NCT02760368|Drug|Olokizumab q2w|
184676|NCT02760368|Drug|Placebo q2w|
184677|NCT02760355|Drug|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
184678|NCT02760355|Drug|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks.
184679|NCT02760342|Drug|peficitinib|Oral
184680|NCT02760342|Drug|Metformin|Oral
184681|NCT02760329|Procedure|Blood draw|Biomarkers analyses
184682|NCT02760329|Procedure|Urine|Biomarker analyses
184683|NCT02760329|Procedure|Lung function measurements|FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
184684|NCT02760329|Procedure|Fractional Exhaled Nitric Oxide (FENO)|Measures level of exhaled nitric oxide.
184685|NCT02760316|Drug|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
184686|NCT02760316|Drug|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
184687|NCT02760316|Drug|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
184688|NCT02760316|Drug|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
184689|NCT02760316|Drug|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
184690|NCT02760316|Drug|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
184691|NCT02760316|Drug|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
184692|NCT02760316|Drug|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
184693|NCT02760316|Drug|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
184694|NCT02760303|Behavioral|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
184695|NCT02760303|Behavioral|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
184696|NCT02760303|Behavioral|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
184697|NCT02760290|Procedure|Extraperitoneal cesarean section|
184698|NCT02760290|Procedure|Intraperitoneal cesarean section|
184699|NCT02760277|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
184700|NCT02760277|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
184701|NCT02760277|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
184702|NCT02760277|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
184703|NCT02760264|Drug|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
184704|NCT02760264|Drug|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
184705|NCT02760264|Drug|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
184706|NCT02760264|Drug|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
184707|NCT02760251|Drug|romiplostim|
184708|NCT02760238|Other|Observational|
184709|NCT02760225|Drug|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
184710|NCT02760225|Device|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
184711|NCT02760212|Device|Radial Shockwave Therapy|5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.
184712|NCT02760212|Other|Placebo Comparator: Group 2 - Placebo Group|5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
184713|NCT02760199|Drug|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
184714|NCT02760199|Device|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
184715|NCT02760186|Procedure|Altitude Exposure|Altitude Exposure
184716|NCT02760173|Other|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
184717|NCT02760160|Other|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) [114, 217, 343, 500, 619, 848].
184718|NCT02760147|Device|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
184719|NCT02760147|Device|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
184720|NCT02760147|Device|PEEP Over Level|PEEP Level upward by 50%, 2 hours
184721|NCT02760147|Device|PEEP Under Level|PEEP Level downward by 50%, 2 hours
184722|NCT02760134|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
184723|NCT02760121|Drug|Acetazolamide|
184724|NCT02760121|Drug|Methazolamide|
184725|NCT02760121|Drug|Placebo|
184726|NCT02760095|Drug|3 mg zinc sulfate supplement|
184727|NCT02760095|Drug|0.5 mg of 13C10-retinyl-acetate|
184728|NCT02760082|Other|Qualitative evaluation|
184729|NCT02760069|Drug|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
184730|NCT02760069|Drug|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
184731|NCT02760069|Drug|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
184732|NCT02760069|Drug|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
184733|NCT02760056|Drug|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
184734|NCT02760056|Drug|Placebo|Patient will receive a matching placebo to take twice daily for one week.
184735|NCT02760043|Drug|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
184736|NCT02760043|Other|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
184737|NCT02760043|Drug|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
184738|NCT02760030|Drug|Fulvestrant|Given IM
184739|NCT02760030|Other|Laboratory Biomarker Analysis|Correlative studies
184740|NCT02760030|Drug|Palbociclib|Given PO
184741|NCT02760030|Other|Questionnaire Administration|Correlative studies
184742|NCT02760017|Drug|B. forficata|
184743|NCT02760017|Drug|Placebo|
184744|NCT02760004|Behavioral|PRogram In Support of Moms (PRISM)|"PRogram In Support of Moms Toolkit with Stepped Care Algorithms~Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform~Customization of depression screening for each practice~Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)~Employ psychoeducation and Motivational Interviewing to engage patients with depression~medical assistant champion and psychiatrist contact bi-weekly to review cases~Stepped care treatment to depression screening/assessment"
184745|NCT02760004|Behavioral|Enhanced Usual Care group (Access to MCPAP for Moms)|"30-60 minute presentation on perinatal depression~Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns~Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation~Access to assessment and treatment protocols in Provider Toolkit~Resource provision/referrals"
184746|NCT02759991|Drug|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
184747|NCT02759991|Drug|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
184748|NCT02759978|Other|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
184749|NCT02759939|Other|Video + Prompt Card|"A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?~A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
184750|NCT02759939|Other|Decision Aids + Training|"Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.~A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
184751|NCT02759926|Drug|Denatonium benzoate|
184752|NCT02759926|Drug|Quinine hydrochloride|
184753|NCT02759926|Drug|Tap water|
184754|NCT02759913|Procedure|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
184755|NCT02759900|Device|Non-thermal, atmospheric plasma|Non-thermal, atmospheric plasma treatment of affected area
184756|NCT02759887|Procedure|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
184757|NCT02759887|Other|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
184758|NCT02759887|Other|caregiver questionnaire|
184759|NCT02759887|Procedure|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
184760|NCT02759887|Procedure|MRI|Magnetic resonance imaging of the head and brain.
184761|NCT02759887|Procedure|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
184762|NCT02759887|Procedure|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
184763|NCT02759887|Procedure|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
184764|NCT02759874|Device|specialized breathalyzer w face recognition technology|
184765|NCT02759861|Drug|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
184766|NCT02759835|Drug|osimertinib|Single daily dose of osimertinib until progression. The starting dose of osimertinib will be 80 mg per day for patients without leptomeningeal disease and 160 mg per day for those with leptomeningeal disease at baseline.
184767|NCT02759835|Other|LAT|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
184768|NCT02759822|Procedure|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
184769|NCT02759809|Other|Pasteurized donor human breastmilk|
184770|NCT02759809|Other|Preterm formula|
184771|NCT02759796|Procedure|Tailoring the flap according to clinical assessment|After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
185661|NCT02753439|Drug|Geistlich Bio Oss|Extraction of Impacted 3rd Molars,
184772|NCT02759796|Procedure|Tailoring the flap according to ICG Angiography assessment|After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
184773|NCT02759783|Radiation|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
184774|NCT02759783|Other|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
184775|NCT02759770|Other|no intervention|
184776|NCT02759757|Other|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
184777|NCT02759757|Other|Placebo|A micropore tape will be used as placebo
184778|NCT02759744|Device|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
184779|NCT02759731|Drug|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg PO QD
184780|NCT02759718|Biological|Chromogranin A|The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
184781|NCT02759692|Device|TEST Contact Lens|
184782|NCT02759692|Device|CONTROL Contact Lens|
184783|NCT02759679|Other|Human breath samples|
184784|NCT02759666|Drug|SHR3162|SHR3162 capsule(s) is administered orally QD.
184785|NCT02759640|Drug|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
184786|NCT02759627|Other|Robotic-Assisted Gait Training|"There were three intervention arms in this study,~Robotic-Assisted Gait Training,~Conventional Training,~Combined Training."
184787|NCT02759614|Drug|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
184788|NCT02759614|Drug|Erlotinib|Erlotinib 150mg, orally once a day
184789|NCT02759601|Drug|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
184790|NCT02759588|Biological|GL-ONC1 alone, or in combination with chemotherapy with or without bevacizumab|GL-ONC1 is a genetically-engineered oncolytic vaccinia virus, which is administered via intraperitoneal infusion as multiple doses.
184791|NCT02759575|Drug|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
184792|NCT02759575|Radiation|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
184793|NCT02759575|Drug|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
184794|NCT02759562|Drug|Andecaliximab|Administered via subcutaneous injection
184795|NCT02759562|Drug|Placebo|Administered via subcutaneous injection
184796|NCT02759549|Behavioral|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
184797|NCT02759549|Other|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
184798|NCT02759549|Behavioral|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
184799|NCT02759536|Radiation|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
184800|NCT02759510|Drug|Norepinephrine|Hypotension (systolic BP <80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
184801|NCT02759510|Drug|Phenylephrine|Hypotension (systolic BP <80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
184802|NCT02759497|Other|serum amyloid A level|serum amyloid A level (SAA)
184803|NCT02759484|Behavioral|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
184804|NCT02759484|Behavioral|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
184805|NCT02759471|Device|comfilcon A sphere lens (control)|contact lens
184806|NCT02759471|Device|comfilcon A asphere lens (test)|contact lens
184807|NCT02759458|Device|Smith & Nephew Healicoil Anchor|
184808|NCT02759458|Device|Smith & Nephew Twinfix Anchor|
184809|NCT02759445|Other|routine treatment|No intervention, only observation and describing
184810|NCT02759432|Other|High-intensity interval exercise training|
184811|NCT02759419|Drug|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
184812|NCT02759406|Device|coronary stent|
184813|NCT02759393|Drug|Dexlansoprazole|receiving 8-week PPI
184814|NCT02759393|Drug|Lansoprazole|receiving 8-week PPI
184815|NCT02759380|Other|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
184816|NCT02759367|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
184817|NCT02759354|Other|Blood Sample|Blood sample at approx. 4 years of age
184818|NCT02759341|Other|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
184819|NCT02759341|Other|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
184820|NCT02759341|Other|State-Trait Anxiety Inventory form Y (STAI-Y)|
184821|NCT02759341|Other|SF-36 Health-Related Quality of Life|
184822|NCT02759341|Other|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
184823|NCT02759328|Behavioral|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
184824|NCT02759328|Behavioral|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
184825|NCT02759315|Drug|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
184826|NCT02759315|Drug|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
184827|NCT02759263|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
184828|NCT02759250|Drug|ARGX-110|
184829|NCT02759237|Device|CoreValve System Family|"Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.~Delivery Catheter System: ACCUTRAK & EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.~Loading System: Compression Loading System & EnVeo R Loading System - Used to load the TAV onto the delivery system"
184830|NCT02759224|Drug|BRI-1501|
184831|NCT02759224|Drug|Lafutidine|
184832|NCT02759224|Drug|Irsogladine maleate|
184833|NCT02759211|Other|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
184834|NCT02759211|Other|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
184835|NCT02759198|Drug|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
184836|NCT02759198|Drug|Celecoxib|Drug: Celecoxib 200mg
184837|NCT02759198|Drug|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
184838|NCT02759185|Drug|High THC Marijuana|Three weeks of smoking marijuana containing more THC than CBD, with amount smoked limited to no more than 1.8 g per day.
184839|NCT02759185|Drug|High CBD Marijuana|Three weeks of smoking marijuana containing more CBD than THC, with amount smoked limited to no more than 1.8 g per day.
184840|NCT02759185|Drug|High THC/high CBD marijuana|Three weeks of smoking marijuana containing equal amounts of THC and CBD, with smoking limited to no more than 1.8 g per day.
184841|NCT02759185|Drug|Placebo marijuana|Three weeks of smoking marijuana with low levels of THC and CBD, with smoking limited to no more than 1.8 per day.
184842|NCT02759172|Behavioral|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
184843|NCT02759159|Procedure|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
184844|NCT02759159|Procedure|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
184845|NCT02759146|Other|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
184846|NCT02759146|Other|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
184847|NCT02759133|Device|Metal wire|Localization technique for breast surgery using metal wire
184848|NCT02759133|Device|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
184950|NCT02758496|Other|MeRT Efficacy Chart Review|There will be not intervention. This is a chart review.
185662|NCT02753426|Drug|Doxycycline|Doxycycline 20mg capsule by mouth, twice a day for 30 days.
184849|NCT02759120|Drug|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight < 50 kilograms or 100mg twice daily if weight > 50 kilograms for up to 36 months
184850|NCT02759120|Other|No Intervention: Standard of Care|Standard of care
184851|NCT02759107|Drug|LY3298176|Administered SC
184852|NCT02759107|Drug|Placebo|Administered SC
184853|NCT02759107|Drug|Dulaglutide|Administered SC
184854|NCT02759094|Device|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
184855|NCT02759081|Device|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
184856|NCT02759081|Procedure|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
184857|NCT02759068|Behavioral|sounds and odors|presentation of sounds and odors
184858|NCT02759055|Other|Clinical Decision Support|an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
184859|NCT02759042|Drug|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
184860|NCT02759029|Drug|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk~concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk~bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk~levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
184861|NCT02759016|Drug|BI 836826|
184862|NCT02759016|Drug|Ibrutinib|Standard of Care
184863|NCT02759003|Procedure|Nightime NIV initiation|In-hospital vs home
184864|NCT02758990|Dietary Supplement|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
184865|NCT02758990|Dietary Supplement|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
184866|NCT02758990|Dietary Supplement|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
184867|NCT02758990|Dietary Supplement|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
184868|NCT02758990|Dietary Supplement|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
184869|NCT02758990|Dietary Supplement|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
184870|NCT02758990|Other|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (~91 grams) per day.
184871|NCT02758990|Other|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (~30 grams) per day.
184872|NCT02758990|Dietary Supplement|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
184873|NCT02758990|Other|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
184874|NCT02758990|Device|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
184875|NCT02758990|Other|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
184876|NCT02758977|Procedure|ALPPS|For detailed information please refer to description of experimental arm
184877|NCT02758977|Procedure|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
184878|NCT02758964|Other|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
184879|NCT02758951|Other|Perioperative systemic therapy|Neoadjuvant systemic therapy should start within four weeks after randomisation. Adjuvant systemic therapy should start within twelve weeks after CRS-HIPEC. In case of unacceptable toxicity or contraindications to oxaliplatin or irinotecan in the neoadjuvant setting, CAPOX or FOLFOX may be switched to FOLFIRI and vice versa. In case of unacceptable toxicity or contraindications to oxaliplatin in the adjuvant setting, CAPOX of FOLFOX may be switched to fluoropyrimidine monotherapy. Dose reduction, prohibited concomitant care, permitted concomitant care, and strategies to improve adherence are not specified a priori, but left to the discretion of the treating medical oncologist. Perioperative systemic therapy can be prematurely discontinued due to radiological or clinical disease progression, unacceptable toxicity, physicians decision, or at patients request.
184880|NCT02758951|Combination Product|Perioperative CAPOX-bevacizumab|Four three-weekly neoadjuvant and adjuvant cycles of CAPOX (130 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 1000 mg/m2 BSA of capecitabine, orally twice daily on days 1-14), with bevacizumab (7.5 mg/kg body weight, IV on day 1) added to the first three neoadjuvant cycles.
184881|NCT02758951|Combination Product|Perioperative FOLFOX-bevacizumab|Six two-weekly neoadjuvant and adjuvant cycles of FOLFOX (85 mg/m2 body-surface area [BSA] of oxaliplatin, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2), with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
184882|NCT02758951|Combination Product|Perioperative FOLFIRI-bevacizumab|Six two-weekly neoadjuvant cycles of FOLFIRI (180 mg/m2 body-surface area [BSA] of irinotecan, intravenously [IV] on day 1; 400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) and either four three-weekly (capecitabine (1000 mg/m2 BSA, orally twice daily on days 1-14) or six two-weekly (400 mg/m2 BSA of leucovorin, IV on day 1; 400/2400 mg/m2 BSA of bolus/continuous 5-fluorouracil, IV on day 1-2) adjuvant cycles of fluoropyrimidine monotherapy, with bevacizumab (5 mg/kg body weight, IV on day 1) added to the first four neoadjuvant cycles.
184951|NCT02758483|Other|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
184883|NCT02758951|Procedure|CRS-HIPEC, experimental arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after completion of neoadjuvant systemic therapy, and at least six weeks after the last administration of bevacizumab in order to minimise the risk of bevacizumab-related postoperative complications.
184884|NCT02758951|Procedure|CRS-HIPEC, control arm|CRS-HIPEC is performed according to the Dutch protocol in all study centres. The choice of HIPEC medication (oxaliplatin or mitomycin C) is left to the discretion of the treating physician, since neither one has a favourable safety or efficacy. CRS-HIPEC should be performed within six weeks after randomisation.
184885|NCT02758938|Other|Urologic biofeedback software|All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
184886|NCT02758925|Drug|Rituximab|375mg/m2 IV day 1
184887|NCT02758925|Drug|Bendamustine|90mg/m2 IV day 1-2
184888|NCT02758925|Drug|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
184889|NCT02758912|Drug|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
184890|NCT02758886|Behavioral|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
184891|NCT02758886|Behavioral|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
184892|NCT02758886|Behavioral|Observing human-animal interaction|Participants watched others participate in petting dogs and cats, while they waited in line for 10 minutes. Participants did not physically touch any animals during this time.
184893|NCT02758873|Genetic|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
184894|NCT02758873|Genetic|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
184895|NCT02758873|Other|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
184896|NCT02758860|Procedure|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
184897|NCT02758847|Device|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
184898|NCT02758847|Device|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
184899|NCT02758821|Other|No CRP will be measured onsite|No CRP will be measured onsite
184900|NCT02758821|Other|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 20mg/L.
184901|NCT02758821|Other|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 40mg/L.
184902|NCT02758795|Dietary Supplement|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
184903|NCT02758795|Dietary Supplement|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
184904|NCT02758782|Biological|Golimumab|
184905|NCT02758782|Drug|Celecoxib|
184906|NCT02758769|Biological|ORENCIA Subcutaneous Injection|
184907|NCT02758756|Other|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
184908|NCT02758756|Other|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
184909|NCT02758743|Drug|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
184910|NCT02758743|Drug|Placebo|Placebo with no active substance will not have the effect on intervention device.
184911|NCT02758730|Biological|AFFITOPE® PD01A + Adjuvant|s.c. injection
184912|NCT02758730|Biological|Adjuvant without active component|s.c. injection
184913|NCT02758717|Drug|Brentuximab Vedotin|Given IV
184914|NCT02758717|Other|Laboratory Biomarker Analysis|Correlative studies
184915|NCT02758717|Biological|Nivolumab|Given IV
184916|NCT02758704|Other|High stress|Generation of a stressful environment during a neonatal intubation procedure.
184917|NCT02758704|Other|Low stress|Absence of stressful stimuli during neonatal intubation procedure
184918|NCT02758704|Other|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
184919|NCT02758691|Drug|Intranasal Insulin|All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
184920|NCT02758691|Drug|Intranasal Saline|All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
184921|NCT02758678|Biological|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
184922|NCT02758665|Drug|ibrutinib|
184923|NCT02758665|Drug|obinutuzumab|
184924|NCT02758665|Drug|venetoclax|
184925|NCT02758639|Behavioral|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
184926|NCT02758626|Drug|ataluren|Powder formulation
184927|NCT02758626|Drug|Placebo|Powder formulation
184928|NCT02758613|Drug|Baricitinib|Administered orally.
184929|NCT02758613|Drug|Placebo|Administered orally.
184930|NCT02758600|Other|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
184931|NCT02758587|Drug|Defactinib|cross reference with arm/group descriptions
184932|NCT02758587|Drug|Pembrolizumab|cross reference with arm/group descriptions
184933|NCT02758574|Procedure|CDT without ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
184934|NCT02758574|Procedure|CDT with ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
184935|NCT02758561|Behavioral|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.~The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.~During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
184936|NCT02758548|Procedure|Blood sample|Fingerprick and venous
184937|NCT02758548|Device|POCT device|Investigational device
184938|NCT02758535|Device|coaxial renal biopsy|In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.
184939|NCT02758535|Device|noncoaxial renal biopsy|In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
184940|NCT02758522|Drug|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
184941|NCT02758522|Drug|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
184942|NCT02758522|Drug|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
184943|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin|
184944|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
184945|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
184946|NCT02758509|Drug|Ledipasvir/Sofosbuvir|
184947|NCT02758509|Drug|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
184948|NCT02758509|Drug|Daclatasvir+Sofosbuvir|
184949|NCT02758509|Drug|Simeprevir+Sofosbuvir|
184952|NCT02758483|Other|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
184953|NCT02758470|Drug|Acetazolamide|250 mg, taken orally three times per day
184954|NCT02758470|Drug|Methazolamide|100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.
184955|NCT02758470|Other|Placebo|A placebo will be taken three times per day
184956|NCT02758457|Device|dental crowns|
184957|NCT02758444|Dietary Supplement|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
184958|NCT02758444|Dietary Supplement|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
184959|NCT02758444|Dietary Supplement|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
184960|NCT02758444|Dietary Supplement|MNP without Zn|Same as above except MNP will not contain Zn
184961|NCT02758431|Drug|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
184962|NCT02758431|Drug|Placebo Gel|Placebo gel packet applied daily for 28 days.
184963|NCT02758431|Drug|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
184964|NCT02758431|Drug|Testosterone Gel|Testosterone Gel applied daily for 28 days
184965|NCT02758431|Drug|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
184966|NCT02758418|Other|TAO|"TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.~The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive."
184967|NCT02758405|Drug|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
184968|NCT02758405|Drug|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
184969|NCT02758405|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
184970|NCT02758392|Drug|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
184971|NCT02758392|Drug|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
184972|NCT02758392|Drug|Placebo|Participants will receive placebo on Day 1.
184973|NCT02758379|Device|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
184974|NCT02758366|Drug|Doxorubicin|
184975|NCT02758353|Drug|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
184976|NCT02758340|Drug|Misoprostol|Women would be given misoprostol tablet by mouth
184977|NCT02758340|Device|foley's balloon catheter|foley's balloon catheter would be inserted through vagina into cervix.
184978|NCT02758327|Drug|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
184979|NCT02758314|Other|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
184980|NCT02758301|Device|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
184981|NCT02758288|Other|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
184982|NCT02758288|Other|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
184983|NCT02758275|Behavioral|Teaching: Individual (5606)|"Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:~Behavior Modification (4360) Promotion of a behavior change.~Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.~Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.~Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.~Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.~Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles."
184984|NCT02758262|Device|Noninvasive brain stimulation|
184985|NCT02758249|Drug|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
184986|NCT02758249|Drug|propofol|patients are anesthetized by using propofol infusion
184987|NCT02758236|Other|No Intervention|No Intervention
184988|NCT02758223|Biological|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
184989|NCT02758210|Device|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
184990|NCT02758210|Device|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
185115|NCT02757378|Procedure|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
184991|NCT02758197|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
184992|NCT02758184|Device|ROTEM-based coagulation monitoring|
184993|NCT02758171|Drug|Empagliflozin|
184994|NCT02758171|Drug|Linagliptin|
184995|NCT02758158|Device|Tri-modal imaging|This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
184996|NCT02758145|Other|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.~After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.~The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
184997|NCT02758132|Biological|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
184998|NCT02758132|Drug|Enzalutamide|160 mg enzalutamide by mouth daily
184999|NCT02758132|Drug|Abiraterone|1000 mg abiraterone by mouth daily
185000|NCT02758132|Drug|Prednisone|5 mg prednisone by mouth twice daily
185001|NCT02758119|Other|Serious Game|
185002|NCT02758119|Other|Online course|
185003|NCT02758106|Device|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
185004|NCT02758106|Device|placebo intervention|CCPT for 15 minutes then sputum suction.
185005|NCT02758093|Behavioral|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
185006|NCT02758093|Other|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
185007|NCT02758080|Other|Matching on the basis of molecular analysis|
185008|NCT02758080|Other|Matching on the basis of physician's choice|
185009|NCT02758067|Drug|brexpiprazole|2- 4 mg/day, tablets, oral, 28-weeks
185010|NCT02758067|Drug|risperidone|4-6 mg/day, tablets, oral, 28-weeks
185011|NCT02758054|Behavioral|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
185012|NCT02758041|Device|Sebacia Microparticles|
185013|NCT02758028|Behavioral|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention."
185014|NCT02758015|Other|Standardized Meal|
185015|NCT02758015|Dietary Supplement|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
185016|NCT02758015|Dietary Supplement|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
185017|NCT02758015|Dietary Supplement|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
185018|NCT02758002|Procedure|Firm ablation for transitional AF rotors|Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
185019|NCT02757989|Other|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
185020|NCT02757976|Device|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. Device implantation will be performed within 10 working days of randomization. Conscious sedation or general anesthesia can be used for the implant procedure. The device will be implanted in a facility that has the capacity to perform coronary sinus venography at the time of implantation. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum (R wave > 7 mV, pacing threshold < 1.5 V at a pulse-width of 0.5 ms). The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches, avoiding the LV apex and scar region identified by pre-implant imaging.
185021|NCT02757976|Device|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, placed in the same time frame, and will have RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach, using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Special care will be taken to avoid the LV apex and transmural scar identified by pre-implant imaging.
185277|NCT02756208|Biological|1.0 mL FLSC Vaccine Group|FLSC vaccine 300 mcg (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
185022|NCT02757963|Other|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score >=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
185023|NCT02757963|Other|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score >=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
185024|NCT02757950|Biological|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
185025|NCT02757937|Behavioral|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
185026|NCT02757937|Other|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
185027|NCT02757924|Other|Infant formula supplemented with prebiotics|Sole source nutrition
185028|NCT02757911|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
185029|NCT02757898|Drug|Biotin-Labeled Red Blood Cells (RBCs)|"500mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
185030|NCT02757885|Procedure|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) matched donor through a central venous catheter.
185031|NCT02757885|Procedure|Bone Marrow Harvest (Donation)|The donation of bone marrow is a surgical procedure in which bone marrow is removed from the back of both of the hip bones through a large, hollow needle. At least two small cuts (less than ¼ inch) will be made in the skin to put the needle into the bone. Many small samples are collected through the needle into syringes. The total amount of marrow take will be up to ¼ ounce of marrow per pound. Bone marrow harvest is done under general anesthesia. Participants will be in the hospital for 8 to 10 hours.
185032|NCT02757885|Drug|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing >125% ideal body weight.
185033|NCT02757885|Drug|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing >125% ideal body weight.
185034|NCT02757885|Drug|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing > 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
185035|NCT02757885|Drug|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
185036|NCT02757885|Other|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
185037|NCT02757885|Radiation|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
185038|NCT02757872|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
185039|NCT02757872|Drug|Omega-3 Fatty acids|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
185040|NCT02757872|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
185041|NCT02757872|Dietary Supplement|Fish oil placebo|Fish oil placebo
185042|NCT02757859|Procedure|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
185043|NCT02757859|Other|Lavage|Receive extensive intraoperative peritoneal saline (EIPL-S) lavage
185072|NCT02757664|Other|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
186857|NCT02744092|Drug|Dalteparin|Anticoagulation therapy.
185044|NCT02757833|Other|A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.|Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
185045|NCT02757820|Device|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
185046|NCT02757820|Device|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
185047|NCT02757820|Device|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
185048|NCT02757807|Behavioral|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
185049|NCT02757794|Other|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
185050|NCT02757794|Other|standard remediation|A speech therapy and / or academic support is realized.
185051|NCT02757781|Behavioral|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
185052|NCT02757768|Drug|Mirabegron|Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
185053|NCT02757768|Drug|Placebo|Participants received initial dose of 25 mg of matching placebo (oral tablet) which was increased to 50 mg after 4 weeks.
185054|NCT02757768|Drug|Tamsulosin Hydrochloride|Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
185055|NCT02757755|Biological|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
185056|NCT02757755|Biological|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
185057|NCT02757755|Biological|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
185058|NCT02757755|Biological|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
185059|NCT02757729|Drug|PAC-14028 cream 0.1%|Topical application
185060|NCT02757729|Drug|PAC-14028 cream 0.3%|Topical application
185061|NCT02757729|Drug|PAC-14028 cream 1.0%|Topical application
185062|NCT02757729|Drug|PAC-14028 cream vehicle|Topical application
185063|NCT02757716|Other|Questionnaire|Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and exercise and drug addiction prior, 6 months and 24 months after surgery.
185064|NCT02757703|Drug|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
185065|NCT02757703|Drug|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
185066|NCT02757703|Drug|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
185067|NCT02757703|Device|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
185068|NCT02757690|Device|3-dimensional distal pancreatectomy|3D laparoscopy
185069|NCT02757690|Device|2-dimensional distal pancreatectomy|2D laparoscopy
185070|NCT02757677|Device|Optical Coherence Tomography based Angiography|A contrast-free, noninvasive technology to identify blood vessels in the eye
185071|NCT02757664|Device|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
185111|NCT02757391|Biological|Aldesleukin|Given SC
185112|NCT02757391|Drug|Cyclophosphamide|Given IV
185113|NCT02757391|Other|Laboratory Biomarker Analysis|Correlative studies
185073|NCT02757664|Device|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
185074|NCT02757651|Drug|Hydrogen Peroxide|Hydrogen Peroxide
185075|NCT02757638|Other|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
185076|NCT02757625|Drug|Dexmedetomidine hydrochloride|"45 weeks CGA to < 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~6 years old to < 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state"
185077|NCT02757612|Radiation|laser diode|laser diode
185078|NCT02757599|Other|Ultrasound training|Training on the transvaginal ultrasound simulator.
185079|NCT02757586|Genetic|shRNA|Using shRNA interfered the expression of the gene of CLL
185080|NCT02757573|Procedure|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
185081|NCT02757560|Other|SFA diet|SFA versus control diet
185082|NCT02757560|Other|MUFA diet|MUFA versus control diet
185083|NCT02757560|Other|CARB diet|CARB versus control diet
185084|NCT02757547|Device|Transcranial magnetic stimulation - Placebo Arm|Each seizure patient (subject) will receive 5 days in a row the placebo (sham) magnetic stimulation using the placebo (sham) coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total. The placebo coil produces the same noise and movement as an active coil, but doesn't deliver any magnetic stimulation.
185085|NCT02757547|Device|Transcranial magnetic stimulation - Active Arm|Each seizure patient (subject) will receive 5 days in a row of active magnetic stimulation using the active TMS coil of the STM9000 Transcranial Magnetic Stimulator. This involves magnetic stimulation at 90% of the resting motor threshold at 1 Hz in three 500-pulse blocks, separated by 10-minute breaks for 1500 pulses total.
185086|NCT02757534|Drug|Domperidone|The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
185087|NCT02757521|Drug|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
185088|NCT02757521|Drug|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
185089|NCT02757508|Dietary Supplement|protein powder supplement|
185090|NCT02757508|Dietary Supplement|Vitamins/minerals|
185091|NCT02757495|Drug|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
185092|NCT02757482|Other|training|
185093|NCT02757469|Drug|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
185094|NCT02757456|Behavioral|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
185095|NCT02757456|Other|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
185096|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
185097|NCT02757443|Drug|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
185098|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
185099|NCT02757443|Drug|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
185100|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
185101|NCT02757443|Drug|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
185102|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
185103|NCT02757443|Drug|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
185104|NCT02757430|Procedure|Cardiac Ablation|
185105|NCT02757417|Drug|sodium fluorescein|
185106|NCT02757417|Drug|phenazopyridine|
185107|NCT02757404|Drug|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
185108|NCT02757404|Drug|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
185109|NCT02757404|Drug|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
185110|NCT02757391|Biological|Adoptive Immunotherapy|Undergo CD8 +T cell therapy
185116|NCT02757378|Procedure|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
185117|NCT02757365|Drug|aspirin|
185118|NCT02757365|Drug|Levofloxacin|
185119|NCT02757352|Drug|Ixekizumab|Administered SC
185120|NCT02757352|Drug|Placebo|Administered SC
185121|NCT02757326|Drug|ABC294640|
185122|NCT02757313|Drug|Low dose THC marijuana|
185123|NCT02757313|Drug|High dose THC marijuana|
185124|NCT02757313|Drug|Placebo marijuana|
185125|NCT02757300|Device|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
185126|NCT02757300|Device|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
185127|NCT02757287|Drug|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~- Quality of Life questionnaire the day after the bolus"
185128|NCT02757261|Device|Laser|Low-level laser therapy administrated to acupoints
185129|NCT02757261|Device|Occlusal splint|Occlusal splint with expander
185130|NCT02757261|Device|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
185131|NCT02757248|Drug|Volasertib|Volasertib 75-150mg/m2 given intravenously on days 1 and 8
185132|NCT02757248|Drug|Romidepsin|Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
185133|NCT02757235|Procedure|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
185134|NCT02757235|Procedure|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
185135|NCT02757222|Radiation|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.~CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
185136|NCT02757222|Radiation|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.~CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.~Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.~PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.~All patients receive concurrent platinum chemotherapy."
185137|NCT02757209|Device|Spiromax (budesonide/formoterol)|"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"
185138|NCT02757209|Device|Turbohaler (budesonide/formoterol)|Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
185139|NCT02757209|Device|Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)|Diskus® inhaler(50mcg salmeterol&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
185140|NCT02757196|Drug|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
185141|NCT02757196|Drug|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
185142|NCT02757183|Device|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
185143|NCT02757170|Device|Thromboelastography|Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
185144|NCT02757157|Behavioral|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
185145|NCT02757157|Behavioral|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.~During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
185146|NCT02757144|Drug|DWP14012|DWP14012 tablets
185147|NCT02757144|Drug|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
185148|NCT02757144|Drug|Esomeprazole|Nexium®
185234|NCT02756533|Other|Telemonitoring of daily parameters recorded by NIV|"Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.~Recommendations will be transferred to the patient within 36 hours."
185149|NCT02757131|Other|Ambulation|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.~In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale."
185150|NCT02757118|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
185151|NCT02757118|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
185152|NCT02757105|Drug|BEKINDA|
185153|NCT02757105|Drug|Placebo|
185154|NCT02757092|Other|Pulmonary Rehabilitation|smoking cession, breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, and chest physical therapy for 6 weeks.
185155|NCT02757079|Drug|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
185156|NCT02757066|Drug|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
185157|NCT02757066|Drug|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
185158|NCT02757066|Drug|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
185159|NCT02757053|Device|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
185160|NCT02757040|Drug|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
185161|NCT02757040|Drug|ibrutinib|ibrutinib
185162|NCT02757027|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
185163|NCT02757027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
185164|NCT02757014|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - R84-087)
185165|NCT02757001|Other|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.~Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
185166|NCT02756988|Drug|Coppertone (BAY987704)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: X71-109)
185167|NCT02756975|Device|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
185168|NCT02756975|Device|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
185169|NCT02756962|Drug|Cytarabine|
185170|NCT02756962|Procedure|Allogeneic stem cell transplant|
185171|NCT02756962|Procedure|Bone marrow aspiration|"Baseline~Approximately 30 days after cytotoxic induction therapy~End of treatment"
185172|NCT02756962|Procedure|Punch skin biopsy|"The first will be obtained with the initial blood and bone marrow collections, whenever possible.~The second will be obtained at the time of re-biopsy to confirm remission."
185173|NCT02756949|Other|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
185174|NCT02756949|Device|Smartphone|
185175|NCT02756936|Drug|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
185176|NCT02756936|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
185177|NCT02756910|Device|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
185178|NCT02756897|Drug|Ibrutinib|Given PO
185179|NCT02756897|Other|Laboratory Biomarker Analysis|Correlative studies
185180|NCT02756897|Other|Pharmacological Study|Correlative studies
185181|NCT02756897|Drug|Venetoclax|Given PO
185182|NCT02756884|Biological|LoFU and aADSC|Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.
185183|NCT02756884|Biological|adipose derived stem cells|control arm will only received the adipose derived stem cells.
185184|NCT02756871|Other|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
185185|NCT02756858|Drug|ANAVEX2-73|
185186|NCT02756845|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
185187|NCT02756832|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets
185188|NCT02756819|Drug|Azilsartan Medoxomil|Azilsartan medoxomil tablets
185189|NCT02756806|Device|Picosecond Q-switched laser|Each subject will receive up to 6 laser treatments.
185190|NCT02756793|Radiation|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
185191|NCT02756793|Other|Standard of Care Treatment|"May include:~Continue with current systemic agent(s)~Observation~Switch to next-line treatment~Palliative radiotherapy is allowed in this arm."
185192|NCT02756780|Other|Tenovus Cancer Choir|Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
185193|NCT02756767|Other|Survey|
185194|NCT02756754|Device|Radiofrequency ablation|The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
185195|NCT02756741|Drug|ALBUMIN|Albumin in two different doses
185196|NCT02756728|Biological|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
185197|NCT02756728|Other|High dose melphalan|High dose melphalan (HDM)
185198|NCT02756728|Other|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
185199|NCT02756715|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
185200|NCT02756715|Drug|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
185201|NCT02756702|Device|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
185202|NCT02756689|Other|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
185203|NCT02756689|Other|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
185204|NCT02756676|Procedure|Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
185205|NCT02756663|Drug|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
185206|NCT02756663|Drug|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
185207|NCT02756663|Drug|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
185208|NCT02756650|Drug|drug administration|monthly canakinumab will be administered
185209|NCT02756624|Drug|AC-170 0.24%|
185210|NCT02756624|Drug|AC-170 Vehicle|
185211|NCT02756611|Drug|Venetoclax|Tablets
185212|NCT02756598|Drug|Sufentanil I|bolus dose of sufentanil 1 microgram/kg
185213|NCT02756598|Drug|Sufentanil II|bolus dose of sufentanil 0.5 microgram/kg
185214|NCT02756598|Drug|Propofol I|Continued dose of propofol 0.03 mg/kg/min
185215|NCT02756598|Drug|Propofol II|Continued dose of propofol 0.06 mg/kg/min
185216|NCT02756585|Radiation|ct perfusion|computed tomography perfusion of the head
185217|NCT02756572|Drug|Cladribine|Given IV
185218|NCT02756572|Drug|Cyclosporine|Given PO
185219|NCT02756572|Drug|Cytarabine|Given IV
185220|NCT02756572|Biological|Filgrastim|Given SC
185221|NCT02756572|Drug|Fludarabine Phosphate|
185222|NCT02756572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
185223|NCT02756572|Other|Laboratory Biomarker Analysis|Correlative studies
185224|NCT02756572|Drug|Melphalan|Given IV
185225|NCT02756572|Drug|Mitoxantrone Hydrochloride|Given IV
185226|NCT02756572|Drug|Mycophenolate Mofetil|Given PO
185227|NCT02756572|Other|Questionnaire Administration|Ancillary studies
185228|NCT02756572|Drug|Sirolimus|Given PO
185229|NCT02756572|Radiation|Total-Body Irradiation|Undergo TBI
185230|NCT02756572|Drug|Melphalan Hydrochloride|Given IV
185231|NCT02756546|Drug|Cyclophosphamide|
185232|NCT02756546|Drug|Hydroxychloroquine|
185233|NCT02756546|Drug|Hydrocortisone|
185276|NCT02756208|Biological|0.5 mL Placebo Group|Placebo sterile saline 0.5 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168
186858|NCT02744092|Drug|Enoxaparin|Anticoagulation therapy.
185235|NCT02756533|Other|Placebo|Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
185236|NCT02756520|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
185237|NCT02756507|Behavioral|video-based transdiagnostic REBT|The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
185238|NCT02756507|Behavioral|Wait list|Delayed intervention
185239|NCT02756494|Biological|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
185240|NCT02756468|Other|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
185241|NCT02756455|Other|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
185242|NCT02756442|Other|Respiratory disorder assessment during sleep|
185243|NCT02756429|Other|blood samples|Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
185244|NCT02756416|Device|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
185245|NCT02756416|Device|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
185246|NCT02756416|Device|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
185247|NCT02756403|Drug|Azithromycin|500 mg
185248|NCT02756403|Drug|Doxycycline|200 mg
185249|NCT02756403|Drug|Metronidazole|500 mg
185250|NCT02756403|Drug|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
185251|NCT02756390|Behavioral|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
185252|NCT02756390|Behavioral|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
185253|NCT02756390|Behavioral|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
185254|NCT02756377|Drug|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
185255|NCT02756377|Drug|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
185256|NCT02756364|Drug|Fulvestrant|Fulvestrant IM injection
185257|NCT02756364|Drug|MLN0128|MLN0128 capsule
185258|NCT02756351|Device|CytaCoat Nasal Prong|
185259|NCT02756351|Device|Inspiration Healthcare Inspire nCPAP Nasal Prong|
185260|NCT02756338|Device|BioMonitor 2 Insertable Cardiac Monitor|
185261|NCT02756325|Device|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
185262|NCT02756312|Other|IV Anesthesia|The patients will receive intravenous anesthesia
185263|NCT02756312|Other|IH anesthesia|The patients will receive inhalation anesthesia
185264|NCT02756299|Other|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
185265|NCT02756299|Other|Standard Support|General information about OSA and PAP treatment at baseline
185266|NCT02756286|Other|NAT electroencephalography (EEG) test|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
185267|NCT02756273|Device|bridge device|
185268|NCT02756273|Device|no bridge device|
185269|NCT02756247|Drug|Buparlisib|
185270|NCT02756247|Drug|Ibrutinib|
185271|NCT02756221|Dietary Supplement|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
185272|NCT02756221|Other|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
185273|NCT02756208|Biological|0.25 mL FLSC Vaccine Group|FLSC vaccine 75 mcg (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
185274|NCT02756208|Biological|0.25 mL Placebo Group|Placebo saline 0.25 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168
185275|NCT02756208|Biological|0.5 mL FLSC Vaccine Group|FLSC vaccine 150 mcg (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
185658|NCT02753465|Procedure|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
185278|NCT02756208|Biological|1.0 mL Placebo Group|Placebo sterile saline 1.0 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168
185279|NCT02756182|Device|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP & AC measurements
185280|NCT02756169|Other|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
185281|NCT02756143|Behavioral|Exercise|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
185282|NCT02756130|Drug|Birinapant|Given IV
185283|NCT02756130|Drug|Carboplatin|Given IV
185284|NCT02756130|Other|Laboratory Biomarker Analysis|Correlative studies
185285|NCT02756130|Other|Pharmacological Study|Correlative studies
185286|NCT02756117|Drug|L-Lysine|
185287|NCT02756117|Drug|Normal (0.9%) Saline|
185288|NCT02756104|Other|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
185289|NCT02756104|Other|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
185290|NCT02756091|Other|No study-specific intervention|
185291|NCT02756078|Device|TEST Contact Lens|
185292|NCT02756078|Device|CONTROL Contact Lens|
185293|NCT02756065|Other|no intervention|no intervention is used
185294|NCT02756052|Device|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
185295|NCT02756052|Device|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
185296|NCT02756026|Dietary Supplement|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
185297|NCT02756013|Drug|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
185298|NCT02756013|Drug|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
185299|NCT02756000|Procedure|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
185300|NCT02756000|Procedure|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
185301|NCT02755987|Drug|ANG1005|
185302|NCT02755961|Behavioral|Dietary education|
185303|NCT02755961|Behavioral|Education on phosphate binder use|
185304|NCT02755948|Biological|RSV A Memphis 37|Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
185305|NCT02755948|Biological|Influenza A/California/04/2009|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
185306|NCT02755935|Device|Cochlear Nucleus CI532|cochlear implantation
185307|NCT02755922|Biological|Application of autologous mesenchymal stem cells|within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
185308|NCT02755909|Behavioral|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
185309|NCT02755896|Radiation|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
185310|NCT02755896|Radiation|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
185311|NCT02755883|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
185312|NCT02755883|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
185313|NCT02755870|Other|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class
185314|NCT02755870|Other|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
185315|NCT02755857|Drug|Lozanoc|65 mg
185316|NCT02755844|Drug|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).~One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
185317|NCT02755844|Drug|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
185318|NCT02755844|Drug|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
185319|NCT02755831|Device|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
185320|NCT02755831|Other|Pre-natal care|Standard Pre-Natal Care
185321|NCT02755818|Drug|Heparin|This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
185322|NCT02755805|Behavioral|CO-OP|
185323|NCT02755805|Behavioral|Attention Control|
185324|NCT02755792|Behavioral|Calligraphy Training|
185325|NCT02755792|Behavioral|iPad Training|
185326|NCT02755753|Drug|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
185327|NCT02755753|Drug|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
185328|NCT02755753|Drug|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
185329|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
185330|NCT02755727|Procedure|Platelet Rich Plasma Injection|See Arms
185331|NCT02755727|Procedure|Open Surgical Release|See arms
185332|NCT02755714|Drug|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
185333|NCT02755701|Drug|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
185334|NCT02755701|Drug|Placebo|Placebo will be administered in the same way
185335|NCT02755688|Procedure|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
185336|NCT02755688|Procedure|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
185337|NCT02755675|Other|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
185338|NCT02755662|Device|Mandibular Retention Device|
185339|NCT02755649|Drug|Dupilumab|
185340|NCT02755649|Drug|Placebo|
185341|NCT02755636|Behavioral|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
185342|NCT02755636|Other|Usual care|Primary care as usual
185343|NCT02755623|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
185344|NCT02755623|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|
185345|NCT02755610|Other|PD Product Check List|PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
185346|NCT02755597|Drug|Placebo|Tablet
185347|NCT02755597|Drug|Bortezomib|Solution for subcutaneous injection
185348|NCT02755597|Drug|Dexamethasone|Tablet
185349|NCT02755597|Drug|Venetoclax|Tablet
185350|NCT02755558|Behavioral|Low energy density|Low energy density milk served
185351|NCT02755558|Behavioral|High energy density|High energy density milk served
185352|NCT02755558|Behavioral|Small portion|Small portion of milk served
185353|NCT02755558|Behavioral|Large portion|Large portion of milk served
185354|NCT02755545|Drug|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
185355|NCT02755545|Drug|Product B (salicylic acid)|Product B applied topically to affected area of the skin 1 to 3 times daily
185356|NCT02755532|Drug|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==>140.1 m/z. The methodology was validated according to the international FDA recommendations.
185357|NCT02755532|Drug|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==>140.1 m/z. The methodology was validated according to the international FDA recommendations.
185358|NCT02755506|Device|endobronchial ultrasound elastography|Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
185359|NCT02755493|Behavioral|Sleep deprivation|
185360|NCT02755480|Device|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
185361|NCT02755467|Device|KTP laser|Dual Wavelength Laser Emitting 532 nm Laser Energy
185362|NCT02755454|Device|Perfusion CT Imaging|
185363|NCT02755428|Biological|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
185364|NCT02755415|Device|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
185365|NCT02755415|Other|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
185366|NCT02755402|Device|Xpert HCV Viral load|HCV viral load testing
185367|NCT02755402|Device|Transient elastography|Evaluation of liver fibrosis
185368|NCT02755389|Drug|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
185369|NCT02755389|Drug|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
185370|NCT02755389|Drug|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
185371|NCT02755376|Biological|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
185372|NCT02755376|Biological|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
185373|NCT02755376|Procedure|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
185374|NCT02755363|Other|osteopathic manual therapy|"suboccipital decompression - atlanto-occipital joint relaxation technique.~deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.~thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.~stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
185375|NCT02755363|Other|control group|"manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.~manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
185376|NCT02755350|Drug|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
185377|NCT02755324|Biological|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
185378|NCT02755311|Procedure|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
185379|NCT02755311|Procedure|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
185380|NCT02755311|Drug|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
185381|NCT02755311|Drug|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
185382|NCT02755311|Drug|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
185383|NCT02755311|Other|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
185384|NCT02755298|Drug|Acetazolamide|
185385|NCT02755298|Drug|Placebo|
185386|NCT02755272|Drug|Pembrolizumab|IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
185387|NCT02755272|Drug|Carboplatin|IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
185388|NCT02755272|Drug|Gemcitabine|IV infusion of 800 mg/m^2 given on days one and eight of each 21 day treatment cycle.
185389|NCT02755259|Drug|Acetazolamide|
185390|NCT02755259|Drug|Placebo|
185391|NCT02755246|Dietary Supplement|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
185392|NCT02755246|Dietary Supplement|Placebo supplementation|3 months of placebo intake (3 capsules/day)
185573|NCT02753998|Device|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
185574|NCT02753998|Procedure|Conventional angioplasty|
185393|NCT02755233|Other|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
185394|NCT02755220|Device|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
185395|NCT02755194|Other|No intervention|This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
185396|NCT02755181|Behavioral|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
185397|NCT02755168|Procedure|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
185398|NCT02755168|Procedure|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
185399|NCT02755155|Drug|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
185400|NCT02755155|Drug|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
185401|NCT02755142|Biological|Gliolan|
185402|NCT02755129|Other|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
185403|NCT02755129|Other|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
185404|NCT02755129|Other|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
185405|NCT02755129|Other|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
185406|NCT02755129|Other|Reveal LINQ accelerometer|Walking exercises test
185407|NCT02755129|Other|3D accelerometer|Walking exercises test
185408|NCT02755116|Drug|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
185409|NCT02755116|Drug|Placebo|placebo by mouth prior to anesthetic induction
185410|NCT02755103|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
185411|NCT02755090|Drug|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
185412|NCT02755090|Drug|IV Saline|
185413|NCT02755077|Procedure|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
185414|NCT02755064|Drug|Erythromycin lactobionate|In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
185415|NCT02755064|Drug|Placebo IV|In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
185416|NCT02755064|Drug|[13C]-Spirulina|The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
185417|NCT02755064|Drug|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
185418|NCT02755064|Drug|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
185419|NCT02755051|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:~Sleep education~Sleep scheduling, limit setting, and stimulus control~Teaching relaxation strategies and other adaptive coping skills~Parenting strategies (differential attention, rewards, consequences)~Identification of maladaptive & adaptive cognitions~Problem solving & communication skills~Sleep restriction; bright light to change circadian rhythms~Review gains and plan for long-term maintenance"
185420|NCT02755025|Other|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
185421|NCT02754999|Drug|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
185422|NCT02754986|Other|Analysis of the holter electrocardiogram|
185575|NCT02753985|Other|Survey|
185423|NCT02754973|Behavioral|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability.
185424|NCT02754973|Behavioral|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The placebo activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet which will be conducted for 30 minutes.The participants will also receive a 30-minute English tutorial session with the research assistants in each home visit.
185425|NCT02754960|Drug|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
185426|NCT02754960|Drug|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
185427|NCT02754934|Other|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
185428|NCT02754921|Procedure|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
185429|NCT02754921|Procedure|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
185430|NCT02754908|Behavioral|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
185431|NCT02754908|Behavioral|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
185432|NCT02754895|Other|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
185433|NCT02754895|Other|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.~Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
185434|NCT02754882|Drug|Bevacizumab|Avastin® 15 mg/kg IV every 3 weeks on Day 1
185435|NCT02754882|Drug|SB8|SB8 15 mg/kg IV every 3 weeks on Day 1
185436|NCT02754882|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
185437|NCT02754882|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
185438|NCT02754856|Biological|Durvalumab|Given IV
185439|NCT02754856|Other|Laboratory Biomarker Analysis|Correlative studies
185440|NCT02754856|Procedure|Therapeutic Conventional Surgery|Undergo liver surgery
185441|NCT02754856|Biological|Tremelimumab|Given IV
185442|NCT02754843|Device|Phonak's equivalent newly developped power BTE|
185443|NCT02754843|Device|Equivalent competitor device|
185444|NCT02754830|Drug|LY3303560 - IV|Administered IV
185445|NCT02754830|Drug|Saline Solution - IV|Administered IV
185446|NCT02754830|Drug|LY3303560 - SC|Administered SC
185447|NCT02754817|Drug|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
185448|NCT02754804|Device|Biomechanic parameters|recording of biomechanic parameters and surface electromyography at the thigh and calf level throughout the walking period, in PAD patients .
185449|NCT02754791|Device|Steripath|A device that diverts the first 2 ml of blood drawn in order to reduce contamination
185450|NCT02754791|Device|Soluprep|Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
185451|NCT02754778|Behavioral|conditional workout|6 month of regular conditional workout 1-3 times a weak
185452|NCT02754765|Drug|Bedaquiline|
185453|NCT02754765|Drug|Delamanid|
185454|NCT02754765|Drug|Clofazimine|
185455|NCT02754765|Drug|Levofloxacin|
185456|NCT02754765|Drug|Moxifloxacin|
185457|NCT02754765|Drug|Linezolid|
185458|NCT02754765|Drug|Pyrazinamide|
185459|NCT02754765|Drug|Control arm MDR-TB regimen, consistent with WHO guidelines|Control arm MDR-TB regimen, consistent WHO guidelines
185460|NCT02754752|Procedure|Electro-Acupuncture|Participants receive up to 10 electro-acupuncture sessions over 4 weeks. Fixed core points used for the treatment of PMPS and supplemented by the addition of other fixed points based on location of pain and the one additional symptom causing the patients the most problems (i.e., fatigue, sleep disturbance, or mood problems).
185461|NCT02754752|Procedure|Sham Electro-Acupuncture|Participants receive up to 10 electro-acupuncture sessions over 4 weeks using slightly different techniques. Fixed core points used for the treatment of PMPS and supplemented by the addition of other fixed points based on location of pain and the one additional symptom causing the patients the most problems (i.e., fatigue, sleep disturbance, or mood problems).
185462|NCT02754752|Other|Standard of Care|Participants in WLC group receive standard medical care as prescribed by their oncologists/primary care physicians.
185463|NCT02754752|Behavioral|Questionnaires|"Questionnaires completed at baseline, week 4, and week 8 regarding participant's pain, arm and shoulder movement, fatigue, mood, their expectations about treatment, partner/caregiver support, and quality of life.~Questionnaire completed during weeks 1 - 3 regarding participant's level of pain."
185464|NCT02754739|Drug|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
185465|NCT02754739|Drug|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
185466|NCT02754739|Behavioral|Nutritional education only|Only nutritional education by a nutritionist
185467|NCT02754726|Drug|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
185468|NCT02754726|Drug|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
185469|NCT02754726|Drug|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
185470|NCT02754726|Drug|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
185471|NCT02754726|Drug|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
185472|NCT02754700|Other|Neuromuscular Training|Standardized, comprehensive neuromuscular training
185473|NCT02754700|Other|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
185474|NCT02754700|Other|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
185475|NCT02754687|Drug|Placebo|Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
185476|NCT02754687|Drug|11βmethyl nortestosterone dodecylcarbonate|Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
185477|NCT02754674|Procedure|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
185478|NCT02754661|Device|COLON Capsule endoscopy|
185479|NCT02754661|Device|Computed Tomographic Colonography|
185480|NCT02754648|Procedure|laparoscopic ovarian endometriotic cyst|
185481|NCT02754635|Other|Induction of labour|Induction of labour
185482|NCT02754635|Other|Expectant management|Expectant management
185483|NCT02754622|Other|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
185484|NCT02754609|Other|Gluten micro-challenge|From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
185485|NCT02754609|Other|Inadvertent gluten challenge|From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
185486|NCT02754609|Other|Moderate gluten challenge|From week 36 to week 42, all participants will be on gluten 2g/day.
185487|NCT02754609|Other|Liberal diet|From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
185488|NCT02754609|Other|Necator americanus-hookworm larvae L3-10|A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
185489|NCT02754609|Other|Tabasco® Sauce|Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
185490|NCT02754609|Other|Necator americanus-hookworm larvae L3-20|A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
185491|NCT02754609|Other|Gluten free diet|From week 0 to week 12, all participants will be on a gluten free diet.
185492|NCT02754596|Drug|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
185493|NCT02754596|Drug|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
185494|NCT02754596|Drug|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
185495|NCT02754583|Behavioral|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction and maintenance, hygiene and sanitation education and promotion, community-based hygiene promotion workers, household wash stations, household WASH education books, household soap distribution, and a hygiene curriculum for primary schools.
185496|NCT02754583|Behavioral|Standard of care WASH intervention|Stand of care WASH arm
185497|NCT02754583|Drug|Azithromycin|20mg/kg
185498|NCT02754583|Drug|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
185499|NCT02754583|Other|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
185500|NCT02754583|Drug|Albendazole|
185501|NCT02754570|Drug|Pilocarpine|Pilocarpine will be administered 4 times in addition to latanoprost.
185502|NCT02754557|Other|Breath Focused Meditation|"During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
185503|NCT02754557|Other|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
185504|NCT02754544|Procedure|Direct Electrocortical Stimulation|Undergo direct electrocortical stimulation
185505|NCT02754544|Other|Electrocorticography|Undergo electrocorticography
185506|NCT02754531|Device|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
185507|NCT02754531|Other|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
185508|NCT02754518|Drug|Entresto|
185509|NCT02754505|Other|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
185510|NCT02754505|Other|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
185511|NCT02754492|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
185512|NCT02754479|Device|Nd:YAG laser|Treatment of lower extremity spider veins
185513|NCT02754466|Other|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
185514|NCT02754466|Other|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
185515|NCT02754453|Behavioral|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
185516|NCT02754440|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
185517|NCT02754427|Behavioral|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
185518|NCT02754427|Behavioral|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
185519|NCT02754414|Procedure|Apheresis platelet collection|A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
185520|NCT02754414|Other|Refrigerated storage of apheresis platelets in PAS/plasma|The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
185521|NCT02754414|Radiation|Infusion of aliquot of autologous radiolabeled platelets|Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
185522|NCT02754414|Other|In vitro tests|Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
185523|NCT02754401|Other|16 Items|Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
185524|NCT02754401|Other|PSI|The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
185525|NCT02754375|Procedure|rTMS|
185526|NCT02754362|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
185527|NCT02754362|Biological|Peptide Vaccine|"Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.~Vaccine Consists of:~EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg"
185528|NCT02754362|Drug|Poly-ICLC as immune adjuvant|Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
185529|NCT02754362|Drug|Keyhole limpet hemocyanin (KLH)|Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
185530|NCT02754349|Device|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
185531|NCT02754336|Behavioral|Cogmed Robomemo, working memory training|
185532|NCT02754336|Behavioral|Othmer, neurofeedback|
185533|NCT02754323|Device|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
185534|NCT02754310|Other|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
185535|NCT02754310|Other|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
185576|NCT02753972|Behavioral|Mindful Eating and Living|8 week mindfulness skills intervention
185577|NCT02753972|Behavioral|Active Weight Loss Control|8 week active weight loss control group
185536|NCT02754297|Drug|177Lu-Octreotate|"The induction course will consist in 4 cycles at 8-10 weeks intervals.~Concomitant amino acids will be administered for renal protection.~Intra-arterial LuTate administration will be allowed in suitable cases.~Dosimetry will be based on quantitative SPECT/CT imaging.~In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
185537|NCT02754284|Biological|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
185538|NCT02754284|Biological|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
185539|NCT02754271|Other|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
185540|NCT02754258|Drug|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
185541|NCT02754258|Drug|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
185542|NCT02754232|Other|Telemedical training|Intervention will involve resistance training and anaerobic training
185543|NCT02754219|Drug|Evogliptin|DPP4-inhibitor, Evogliptin
185544|NCT02754193|Other|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
185545|NCT02754180|Drug|Gemcitabine|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
185546|NCT02754180|Radiation|TS-1 with radiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
185547|NCT02754167|Biological|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
185548|NCT02754167|Biological|PRS-080-Placebo#001|Placebo comparator
185549|NCT02754154|Drug|Warfarin|
185550|NCT02754154|Drug|Apixaban|
185551|NCT02754154|Drug|Dabigatran|
185552|NCT02754154|Drug|Rivaroxaban|
185553|NCT02754141|Biological|BMS-986179|Specified dose on specified days
185554|NCT02754141|Biological|Nivolumab|Specified dose on specified days
185555|NCT02754141|Biological|rHuPH20|Specified dose on specified days
185556|NCT02754128|Behavioral|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
185557|NCT02754128|Behavioral|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
185558|NCT02754115|Other|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
185559|NCT02754102|Other|Sunscreen Spray- Liquid (BAY987516)|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
185560|NCT02754089|Drug|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
185561|NCT02754089|Drug|Placebo|500 mg twice daily after meals for 6 weeks
185562|NCT02754076|Drug|BMN 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
185563|NCT02754063|Device|PbtO2 probes|PbtO2/ICP/CPP-directed therapy according to international recommendations
185564|NCT02754063|Other|No PbtO2 probes|ICP/CPP-directed therapy according to international recommendations
185565|NCT02754050|Device|Tandem Snare|
185566|NCT02754037|Radiation|FDG-PET|FDG-PET has been utilized in multiple disease processes that have inflammation as the key driver of the disease and has found potentials to be used for imaging of steatohepatitis. Dynamic PET acquires images at multiple time points and enables parametric imaging of FDG kinetics, providing fundamental quantitative information about the kinetic process of glucose metabolism in the liver tissue. Our group at UC Davis has developed a novel kernel-based dynamic (KBD) PET imaging method. The resulting KBD PET method has demonstrated a five-fold gain in signal-to-noise ratio (SNR) when tested on a small group of patients with breast cancer. With this substantial SNR gain, the study group believes the approach has great potential to allow accurate characterization of FDG kinetics in the liver.
185567|NCT02754037|Radiation|MRI-PDFF|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
185568|NCT02754024|Procedure|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
185569|NCT02754024|Procedure|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
185570|NCT02754024|Device|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
185571|NCT02754011|Drug|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
185572|NCT02753998|Device|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
186859|NCT02744092|Drug|Fondaparinux|Anticoagulation therapy.
185578|NCT02753959|Other|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
185579|NCT02753959|Other|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:~Electrical impedance tomography (EIT)~EMGpara~SpO2~tcCO2~Respiratory inductance plethysmography~EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention~Interventions will be set as follows with a 30 minute washout period between modes:~Manual techniques only~MIE at low pressure (+30 to -30)~MIE at high pressure (+60 to -60)"
185580|NCT02753946|Drug|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
185581|NCT02753946|Drug|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
185582|NCT02753933|Other|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
185583|NCT02753933|Other|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
185584|NCT02753920|Other|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
185585|NCT02753920|Device|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
185586|NCT02753907|Dietary Supplement|Low LA|Individuals who replaced 10 mL soy oil with one apple
185587|NCT02753907|Dietary Supplement|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
185588|NCT02753894|Drug|ASP1585|Oral
185589|NCT02753881|Drug|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
185590|NCT02753881|Drug|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
185591|NCT02753868|Behavioral|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
185592|NCT02753868|Procedure|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
185593|NCT02753855|Drug|Telavancin|A single dose of telavancin as a 1-hour intravenous infusion
185594|NCT02753842|Device|Fitted condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy.~Participants will receive 5 fitted condoms in plain aluminum foils, identifiable only by a two-digit number printed on the foil. Participants will also receive ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
185595|NCT02753842|Device|Thin condoms|"Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick.~Participants will receive 5 thin condoms in plain aluminum foils, identifiable only by a two-digit number printed on the foil. Participants will also receive ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
185596|NCT02753842|Device|Standard condoms|"Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick.~Participants will receive 5 thin condoms in plain aluminum foils, identifiable only by a two-digit number printed on the foil. Participants will also receive ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
185597|NCT02753829|Procedure|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
185598|NCT02753829|Procedure|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.~It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
185599|NCT02753829|Other|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
185600|NCT02753816|Drug|Tranexamic Acid|
185601|NCT02753816|Drug|Placebo Comparator|
185602|NCT02753803|Drug|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
185603|NCT02753803|Drug|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
185604|NCT02753803|Drug|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
185605|NCT02753803|Drug|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
185606|NCT02753803|Drug|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
185657|NCT02753465|Procedure|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
185607|NCT02753803|Drug|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
185608|NCT02753790|Radiation|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume [PTV] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.~Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.~Gross disease which has received prior radiosurgery will receive 30 Gy."
185609|NCT02753777|Other|Questionnaires|
185610|NCT02753764|Drug|AZD7624|
185611|NCT02753764|Drug|prednisone|oral prednisone 20 mg bid for one week
185612|NCT02753764|Drug|Placebo|
185613|NCT02753751|Other|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
185614|NCT02753738|Drug|Escitalopram|Tablet 10mg, 21 days
185615|NCT02753738|Drug|Placebo|Tablet, 21 days
185616|NCT02753738|Other|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
185617|NCT02753738|Behavioral|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
185618|NCT02753738|Behavioral|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
185619|NCT02753725|Drug|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
185620|NCT02753725|Drug|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
185621|NCT02753712|Drug|Fluticasone/Formoterol BAI|
185622|NCT02753712|Drug|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
185623|NCT02753699|Drug|Alisporivir|Intervention of interest; follow-up after ALV-active study
185624|NCT02753686|Drug|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
185625|NCT02753686|Drug|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
185626|NCT02753673|Behavioral|qualitative interviews with patients|
185627|NCT02753673|Behavioral|questionnaires|
185628|NCT02753660|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
185629|NCT02753660|Procedure|Pendant position|Subjects were set on pendant position before spinal anesthesia begun.
185630|NCT02753647|Drug|Rituximab|
185631|NCT02753647|Drug|Cyclophosphamide|
185632|NCT02753647|Drug|Doxorubicin|
185633|NCT02753647|Drug|Vincristine|
185634|NCT02753647|Drug|Prednisone|
185635|NCT02753647|Drug|Chidamide|
185636|NCT02753634|Behavioral|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
185637|NCT02753621|Behavioral|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
185638|NCT02753621|Behavioral|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
185639|NCT02753608|Other|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
185640|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m2 or 1.1 mg/m2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
185641|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m2 or 1.1 mg/m2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
185642|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m2 as IV infusion on Day 1 and 8 of 21-day cycle
185643|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 μg/kg or 1.6 μg/kg as IV infusion on Day -1 and 7 of 21-day cycle
185644|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 μg/kg or 1.6 μg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
185645|NCT02753582|Dietary Supplement|SOD+Gliadin Capsule|
185646|NCT02753582|Dietary Supplement|Placebo|
185647|NCT02753569|Other|Imaging - DW-MRI|
185648|NCT02753569|Radiation|FDG PET-CT|
185649|NCT02753543|Drug|Chidamide|
185650|NCT02753530|Drug|Arimoclomol|2 200mg pills taken 3 times per day during breakfast, early afternoon and at bedtime
185651|NCT02753530|Other|Placebo|2 matched placebo pills to be taken 3 times per day during breakfast, early afternoon and at bedtime
185652|NCT02753517|Device|Hepatobiliary scintigraphy|hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
185653|NCT02753504|Drug|CKD-519|
185654|NCT02753504|Drug|placebo|
185655|NCT02753491|Behavioral|Motivational short interview|New designed motivational short interview model
185656|NCT02753478|Other|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.~Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
185663|NCT02753426|Drug|Placebo (for Doxycycline)|Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
185664|NCT02753413|Biological|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
185665|NCT02753413|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
185666|NCT02753400|Drug|emixustat hydrochloride|Tablet for oral administration
185667|NCT02753400|Other|Placebo|Placebo tablets for oral administration contain only inactive ingredients
185668|NCT02753387|Drug|Chlorhexidine|4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
185669|NCT02753387|Device|NaCl 0.9 %|4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
185670|NCT02753361|Procedure|Ultrasound guidance|In the second arm, ultrasound will be used to guide the regional block
185671|NCT02753348|Other|Echocardiography|
185672|NCT02753348|Other|Blood analysis from umbilical cord blood|
185673|NCT02753348|Other|ECG|
185674|NCT02753348|Other|Measurement of oxygen saturation|
185675|NCT02753335|Behavioral|GMI and Desensitization|"Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.~Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials."
185676|NCT02753335|Behavioral|Desensitization|Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
185677|NCT02753322|Other|Dual task training|Balance and walking exercises with simultaneously engaging in attention demanding tasks
185678|NCT02753322|Other|Single-task training|Balance and walking exercises and and attention demanding task performed separately
185679|NCT02753322|Other|Limbs exercise|Stretching and strengthening exercises
185680|NCT02753309|Drug|Sirolimus|
185681|NCT02753283|Drug|denosumab|Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
185682|NCT02753283|Drug|Placebo|Semi-annual saline injection
185683|NCT02753283|Dietary Supplement|Calcium and Vitamin D|Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
185684|NCT02753270|Procedure|Short catheter|Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
185685|NCT02753270|Procedure|Long catheter preceded by tumescence|Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
185686|NCT02753257|Other|Non-Interventional|Non-Interventional
185687|NCT02753244|Other|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
185688|NCT02753244|Other|iPad Apps|Commercially available iPad game applications
185689|NCT02753231|Behavioral|Low physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
185690|NCT02753231|Behavioral|High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
185691|NCT02753231|Behavioral|Low and High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
185692|NCT02753231|Behavioral|Conventional physical activity program|One Physical Education sessions / week
185693|NCT02753218|Drug|Midazolam|
185694|NCT02753218|Drug|LEO 32731|
185695|NCT02753205|Drug|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
185696|NCT02753205|Drug|normal saline|infusion of normal saline
185697|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
185698|NCT02753179|Other|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
185699|NCT02753179|Other|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
185700|NCT02753179|Other|VEMPs & VEMPo|VEMPs & VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
185701|NCT02753179|Other|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
185702|NCT02753179|Other|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
185745|NCT02752867|Drug|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
185703|NCT02753166|Drug|Dexamethasone|After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
185704|NCT02753153|Procedure|Control surgical protocol|"A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.~The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0)."
185705|NCT02753153|Procedure|Test surgical protocol|The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.
185706|NCT02753153|Procedure|Socket preservation|"An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied."
185707|NCT02753140|Drug|Cetuximab|
185708|NCT02753140|Radiation|radiation|
185709|NCT02753140|Drug|Docetaxel|
185710|NCT02753140|Drug|Cisplatin|
185711|NCT02753127|Drug|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
185712|NCT02753127|Drug|Fluorouracil|
185713|NCT02753127|Drug|Leucovorin|
185714|NCT02753127|Drug|Irinotecan|
185715|NCT02753127|Drug|Bevacizumab|
185716|NCT02753114|Drug|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
185717|NCT02753114|Drug|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
185718|NCT02753101|Drug|[18F]-FTC-146|10 mCi± 1 mCi of [18F]FTC-146 intravenously
185719|NCT02753088|Drug|BCD-063|
185720|NCT02753088|Drug|Copaxone-Teva|
185721|NCT02753088|Drug|Placebo|
185722|NCT02753075|Device|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
185723|NCT02753075|Device|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
185724|NCT02753075|Other|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
185725|NCT02753075|Drug|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
185726|NCT02753062|Drug|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
185727|NCT02753049|Behavioral|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
185728|NCT02753036|Drug|Paclitaxel|ovarian: carboplatin + paclitaxel breast: epirubicin + cyclophosphamide + paclitaxel
185729|NCT02753023|Other|no intervention|No intervention related
185730|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.
185731|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..
185732|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
185733|NCT02752997|Other|Pharmacist discharge medication services|Included in arm descriptions
185734|NCT02752971|Drug|Bupivacaine|
185735|NCT02752971|Drug|Sodium diclofenac|
185736|NCT02752958|Drug|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
185737|NCT02752945|Other|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
185738|NCT02752945|Other|Usual care|Usual care afforded by local CAMHS services
185739|NCT02752932|Other|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
185740|NCT02752919|Drug|Galunisertib|Administered orally
185741|NCT02752906|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
185742|NCT02752906|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
185743|NCT02752880|Drug|YH1 group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
185744|NCT02752880|Drug|placebo group|Participants were randomly assigned 1:1 to receive either YH1 or placebo for 12 consecutive weeks.
185822|NCT02752243|Drug|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
185746|NCT02752867|Other|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
185747|NCT02752854|Other|pain threshold measurement|pressure algometer
185748|NCT02752841|Dietary Supplement|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
185749|NCT02752828|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
185750|NCT02752828|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
185751|NCT02752828|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: oral"
185752|NCT02752815|Drug|Rituximab|
185753|NCT02752815|Drug|Cyclophosphamide|
185754|NCT02752815|Drug|Epirubicin|
185755|NCT02752815|Drug|Vincristine|
185756|NCT02752815|Drug|Prednisone|
185757|NCT02752802|Device|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
185758|NCT02752776|Drug|Secukinumab|Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
185759|NCT02752763|Drug|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
185760|NCT02752763|Drug|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
185761|NCT02752750|Other|MRI|MR imaging (MRI) at 3 Tesla
185762|NCT02752724|Drug|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
185763|NCT02752724|Drug|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
185764|NCT02752711|Procedure|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
185765|NCT02752698|Procedure|Micro Hand S robotic surgery|30 patients undergo Micro Hand S robotic surgeries
185766|NCT02752698|Procedure|laparoscopic surgery|30 patients undergo laparoscopic surgeries
185767|NCT02752685|Drug|Pembrolizumab|
185768|NCT02752685|Drug|Nab-Paclitaxel|
185769|NCT02752659|Procedure|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
185770|NCT02752646|Drug|nepafenac 0.3%|Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
185771|NCT02752646|Drug|ketorolac|Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
185772|NCT02752633|Drug|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
185773|NCT02752633|Drug|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
185774|NCT02752620|Other|Osteopathic Manipulative Treatment|
185775|NCT02752620|Other|Exercise Therapy|
185776|NCT02752594|Biological|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
185777|NCT02752594|Other|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
185778|NCT02752581|Device|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
185779|NCT02752581|Device|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
185780|NCT02752568|Procedure|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
185781|NCT02752568|Procedure|assisted hatching|using Octax laser 20120644-laser 5452
185782|NCT02752568|Procedure|controlled ovarian hyperstimulation|using merional&/ or fostimon doses individualized as judged by patient age & ovarian reserve & monitored by follicular size & serum estradiol
185783|NCT02752555|Other|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
185784|NCT02752542|Behavioral|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
185785|NCT02752542|Drug|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
185786|NCT02752529|Drug|Tacrolimus（FK506）|
185787|NCT02752516|Drug|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
185788|NCT02752503|Drug|Nalmefene|
185789|NCT02752490|Drug|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
185790|NCT02752490|Drug|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
185791|NCT02752477|Drug|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
185792|NCT02752477|Drug|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
185793|NCT02752464|Behavioral|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
185794|NCT02752464|Behavioral|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
185795|NCT02752451|Other|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
185796|NCT02752451|Other|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
185797|NCT02752451|Other|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
185798|NCT02752438|Device|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
185799|NCT02752425|Device|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
185800|NCT02752412|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
185801|NCT02752412|Drug|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
185802|NCT02752412|Drug|Metformin|"Pharmaceutical form: tablet~Route of administration: oral"
185803|NCT02752386|Behavioral|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
185804|NCT02752373|Device|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
185805|NCT02752360|Procedure|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
185806|NCT02752360|Procedure|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
185807|NCT02752347|Device|Surface EMG device|measuring the muscles activity using surface EMG device
185808|NCT02752334|Drug|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
185809|NCT02752321|Device|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
185810|NCT02752308|Drug|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
185811|NCT02752308|Procedure|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
185812|NCT02752308|Drug|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
185813|NCT02752308|Drug|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
185814|NCT02752308|Drug|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
185815|NCT02752308|Drug|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
185816|NCT02752308|Procedure|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
185817|NCT02752295|Behavioral|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
185818|NCT02752295|Behavioral|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
185819|NCT02752282|Other|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
185820|NCT02752282|Other|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
185821|NCT02752256|Drug|Tissue Plasminogen Activator|
185823|NCT02752230|Procedure|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
185824|NCT02752230|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
185825|NCT02752217|Other|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
185826|NCT02752217|Other|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
185827|NCT02752204|Drug|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
185828|NCT02752204|Drug|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
185829|NCT02752191|Drug|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
185830|NCT02752191|Drug|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
185831|NCT02752178|Other|MA|Monoaminergic antidepressant use
185832|NCT02752178|Other|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
185833|NCT02752165|Other|TEAM-ED|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
185834|NCT02752165|Other|Enhanced Usual Care|Report of symptoms to primary care physician
185835|NCT02752152|Behavioral|Computer-assisted counseling|The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
185836|NCT02752152|Behavioral|On-demand counseling|The counselor only invites the participants to ask questions about HIV and other STIs.
185837|NCT02752152|Behavioral|Standard counseling|The counselor gives face-to-face general information/education
185838|NCT02752152|Behavioral|Appointment + reminder|Has an appointment and receive reminders for further testing
185839|NCT02752152|Behavioral|Reminder|Only receive reminders for further testing
185840|NCT02752152|Behavioral|No appointment and no reminder|No appointment and no reminders for further testing
185841|NCT02752126|Radiation|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
185842|NCT02752126|Radiation|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
185843|NCT02752113|Drug|Empagliflozin and Linagliptin|Empagliflozin and Linagliptin
185844|NCT02752113|Drug|Metformin and Insulin sc|Metformin and Insulin sc
185845|NCT02752100|Procedure|Percutaneous transluminal angioplasty|
185846|NCT02752087|Drug|LY900014|Administered SC
185847|NCT02752074|Drug|pembrolizumab + epacadostat|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
185848|NCT02752074|Drug|pembrolizumab + placebo|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)~Placebo will be administered orally daily starting at Day 1 (Week 1)"
185849|NCT02752061|Other|Potlako intervention|"Multicomponent intervention including:~provider training on early detection and diagnostic approaches to cancer~patient education on importance of obtaining timely cancer diagnosis~provision of a patient navigator to facilitate diagnosis and entry into care~provision of transportation support to vulnerable patients"
185850|NCT02752048|Drug|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
185851|NCT02752048|Drug|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
185852|NCT02752035|Drug|gilteritinib|Tablet, oral
185853|NCT02752035|Drug|azacitidine|Subcutaneous injection or intravenous infusion
185854|NCT02752009|Procedure|Axillary Lymph Node Sampling Clip|
185855|NCT02751996|Drug|SB 9200|SB 9200
185856|NCT02751996|Drug|Placebo|
185857|NCT02751996|Drug|Tenofovir|
185858|NCT02751983|Behavioral|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
185859|NCT02751983|Other|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
185860|NCT02751970|Procedure|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
185861|NCT02751970|Procedure|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
185862|NCT02751970|Procedure|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
185863|NCT02751970|Procedure|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
185864|NCT02751970|Procedure|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
185865|NCT02751957|Behavioral|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
185866|NCT02751944|Dietary Supplement|NEM|Dietary supplement for the support of joint health.
185867|NCT02751944|Dietary Supplement|Placebo|Placebo
185868|NCT02751931|Drug|Mirabegron|Oral
185869|NCT02751918|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.
185870|NCT02751918|Drug|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.
185871|NCT02751905|Drug|BIIB074|Administered orally as specified in treatment arm
185872|NCT02751892|Behavioral|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
185873|NCT02751866|Dietary Supplement|Berry fruit powder OR nutritional ketosis|Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
185874|NCT02751866|Dietary Supplement|Placebo powder OR higher carbohydrate|Daily supplementation with placebo powder OR higher carbohydrate intake
185875|NCT02751853|Device|Conductance catheter|Continuous online measurements of left ventricular pressure and volume using conductance catheters
185876|NCT02751840|Dietary Supplement|Caffeine|200 mg of caffeine capsule before RMR measurement
185877|NCT02751840|Dietary Supplement|Placebo|Placebo capsule (starch) before RMR measurement
185878|NCT02751840|Other|Coffee|9 grams of black coffee in boiling water consumed before RMR measurement
185879|NCT02751840|Other|Decaffeinated|9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
185880|NCT02751827|Other|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics~One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
185881|NCT02751801|Other|no intervention|
185882|NCT02751762|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ).|Not required
185883|NCT02751762|Other|Psychiatric Research Interview for Substance and Mental Disorders, adapted for assessing addiction to opioid analgesics (PRISM-5-Op).|Not required
185884|NCT02751762|Other|Events in Medical Records|Not required
185885|NCT02751749|Behavioral|Unified Protocol|
185886|NCT02751736|Dietary Supplement|CJLP243|Perioperative administration till postoperative weeks 3
185887|NCT02751736|Dietary Supplement|Placebo|Perioperative administration till postoperative weeks 3
185888|NCT02751723|Other|validated questionnaires|
185889|NCT02751710|Other|Whole-body FDG PET-CT alone|FDG PET-CT imaging
185890|NCT02751671|Procedure|POCUS|The use of Point-of-care ultrasound before urine sample procedure
185891|NCT02751671|Procedure|Standard|Urine sampling procedure without prior ultrasound
185892|NCT02751658|Other|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
185893|NCT02751645|Procedure|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
185894|NCT02751632|Behavioral|Support and Problem Solving Therapy|Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
185895|NCT02751632|Behavioral|Cognitive Behavioural Case Management|CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
185896|NCT02751632|Drug|Fluoxetine|Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
185897|NCT02751632|Drug|Placebo|Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
185898|NCT02751632|Behavioral|3-monthly monitoring|Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
185899|NCT02751619|Drug|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
185900|NCT02751619|Drug|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
185901|NCT02751606|Drug|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
185902|NCT02751606|Device|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
185903|NCT02751606|Device|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
185904|NCT02751593|Drug|Dexamethasone|dexamethasone 40mg/d for 4 days
185905|NCT02751580|Other|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
185906|NCT02751580|Other|Questionnaire Administration|Ancillary studies
185907|NCT02751567|Other|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
185908|NCT02751567|Other|Untreated skin|One site is patched without treatment as control
185909|NCT02751541|Drug|Sunscreen Sport Spray (BAY987519)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
185910|NCT02751541|Other|Untreated Skin|This site is patched without treatment as irradiated control.
185911|NCT02751528|Biological|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
185912|NCT02751515|Other|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
185913|NCT02751515|Other|Untreated skin|One site is patched without treatment as control
185914|NCT02751502|Device|m2 Bimanual Arm Trainer (BAT)|Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
185915|NCT02751489|Other|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
185916|NCT02751476|Other|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
185917|NCT02751476|Other|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
185918|NCT02751476|Device|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
185919|NCT02751476|Other|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
185920|NCT02751463|Drug|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
185921|NCT02751463|Other|Untreated skin|One site is patched without treatment as control
185922|NCT02751450|Device|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
185923|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
185924|NCT02751437|Dietary Supplement|Arginine|
185925|NCT02751424|Drug|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
185926|NCT02751424|Drug|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
185927|NCT02751411|Device|micro-enema with Promelaxin|The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
185928|NCT02751411|Drug|Macrogol 4000|Stool softener
185929|NCT02751398|Drug|Dapagliflozin 10mg|
185930|NCT02751398|Drug|Placebo 10mg|Matching placebo for dapagliflozin 10 mg
185931|NCT02751385|Drug|Microgynon|
185932|NCT02751385|Drug|Nintedanib|
185933|NCT02751372|Drug|BAY 987517|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
185934|NCT02751372|Other|Untreated Skin|This site is patched without treatment as irradiated control
185935|NCT02751359|Drug|Cannabidiol|200, 400, or 800 mg Cannabidiol
185936|NCT02751359|Drug|Placebo|0 mg Cannabidiol
185937|NCT02751333|Procedure|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
185938|NCT02751333|Procedure|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
185939|NCT02751333|Device|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
185940|NCT02751333|Device|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
185941|NCT02751320|Drug|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
185942|NCT02751320|Drug|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
185943|NCT02751320|Drug|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
185944|NCT02751320|Other|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
185945|NCT02751320|Drug|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
185946|NCT02751320|Drug|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
185947|NCT02751307|Drug|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
185948|NCT02751307|Drug|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
185949|NCT02751294|Drug|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
185950|NCT02751294|Drug|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
185951|NCT02751294|Drug|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
185952|NCT02751281|Procedure|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
185953|NCT02751281|Procedure|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
185954|NCT02751268|Drug|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
185955|NCT02751268|Drug|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
186081|NCT02750254|Radiation|Fractionated total body irradiation|
185956|NCT02751255|Drug|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
185957|NCT02751229|Behavioral|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session~Considering pros and cons of disclosing:~hurtful and helpful attitudes about mental illness~identify beliefs participants hold about themselves~explore five-step process to challenge their personally hurtful beliefs~weigh pros and cons of coming out in order to facilitate a decision on whether to disclose~Different ways to disclose:~different levels of (non-) disclosure and how to weigh the cons and pros~disclosure via social media versus disclosing face to face~how to find people that are better to disclose to than others and how to 'test them out'~participants will discuss how others might respond to their disclosure and how that will affect them~Telling your story:~how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
185958|NCT02751216|Other|EEG recording + pain protocol|
185959|NCT02751203|Behavioral|Make Safe Happen App|The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
185960|NCT02751190|Procedure|Totally ExtraPeritoneal (TEP) repair|
185961|NCT02751190|Procedure|TransAbdominal PrePeritoneal (TAPP) repair|
185962|NCT02751190|Procedure|Open anterior mesh repair|
185963|NCT02751190|Procedure|Open Anterior Non Mesh|
185964|NCT02751190|Procedure|Combined anterior and posterior repair|
185965|NCT02751190|Procedure|Open preperitoneal mesh repair|
185966|NCT02751177|Genetic|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
185967|NCT02751164|Other|Day/time of admission to the critical care unit|
185968|NCT02751151|Other|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
185969|NCT02751138|Procedure|Surgery|Tumor resection
185970|NCT02751125|Drug|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
185971|NCT02751112|Biological|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
185972|NCT02751099|Other|transplanted patients|bone biopsy, echocardiogram, blood samples
185973|NCT02751086|Procedure|Robotic Gastrectomy|Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
185974|NCT02751086|Procedure|Laparoscopic Gastrectomy|Minimally invasive surgical approach performed through traditional laparoscopy.
185975|NCT02751060|Other|No intervention|
185976|NCT02751047|Other|manual ventilation|Facemask ventilation is performed by manual bagging with reservoir bag.
185977|NCT02751047|Other|Pressure controlled mechanical ventilation|Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
185978|NCT02751034|Device|Neuramis® Deep Lidocaine|HA filler
185979|NCT02751034|Device|Restylane® PERLANE-L|HA filler
185980|NCT02751021|Other|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
185981|NCT02751021|Other|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
185982|NCT02750995|Biological|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
185983|NCT02750995|Drug|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
185984|NCT02750982|Other|Laughter Therapy|Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
185985|NCT02750969|Device|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
185986|NCT02750969|Other|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.~tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
185987|NCT02750969|Procedure|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.~the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
185988|NCT02750969|Other|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
185989|NCT02750956|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
186082|NCT02750254|Drug|Busulfan|
185990|NCT02750943|Drug|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
185991|NCT02750943|Drug|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
185992|NCT02750930|Drug|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
185993|NCT02750930|Device|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
185994|NCT02750917|Drug|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
185995|NCT02750917|Drug|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
185996|NCT02750904|Behavioral|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.~Includes four in person and four phone visits.~Therapy information is withheld to protect the integrity of the study."
185997|NCT02750904|Behavioral|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
185998|NCT02750891|Drug|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
185999|NCT02750878|Other|Informational Handout|
186000|NCT02750865|Behavioral|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
186001|NCT02750852|Procedure|Total hip arthroplasty, blood loss analysis|Data analysis about blood loss in total hip replacement
186002|NCT02750839|Procedure|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
186003|NCT02750826|Other|Health Education Program|
186004|NCT02750826|Other|Weight Loss Intervention|
186005|NCT02750813|Device|Delefilcon A contact lenses|
186006|NCT02750813|Device|Senofilcon A contact lenses|
186007|NCT02750800|Biological|Adalimumab|Pre-filled syringe or pen, administered by subcutaneous injection
186008|NCT02750800|Behavioral|AbbVie Care 2.0|Supportive services provided to participants included reminder calls, emails, text messages, nursing services, dietician, and psychological support. An adalimumab starter pack, injection guide, digital and print educational materials were also provided.
186009|NCT02750787|Other|Nutritional Study Product|Two 220 ml servings per day
186010|NCT02750774|Behavioral|Low-glycemic index group|"The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity."
186011|NCT02750774|Other|Standard Care Group|Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
186012|NCT02750761|Drug|Tedizolid Phosphate (IV)|
186013|NCT02750761|Drug|Tedizolid Phosphate (oral suspension)|
186014|NCT02750748|Drug|Naltrexone|
186015|NCT02750748|Other|Intravail|
186016|NCT02750722|Device|Flutter®|Acute exercise with Flutter® breathing therapy.
186017|NCT02750722|Device|No Flutter®|Acute exercise without Flutter® breathing therapy.
186018|NCT02750709|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
186019|NCT02750709|Drug|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
186020|NCT02750709|Drug|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
186021|NCT02750696|Drug|Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
186022|NCT02750696|Drug|Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
186023|NCT02750670|Drug|Obinutuzumab|Type II anti-CD20 monoclonal antibody
186024|NCT02750670|Drug|Gemcitabine|Antineoplastic agent
186025|NCT02750670|Drug|Dexamethasone|Corticosteroid
186026|NCT02750670|Drug|Cisplatin|Antineoplastic Agent
186027|NCT02750657|Genetic|Molecular Profiling|Whole Genome Sequencing
186028|NCT02750631|Other|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
186029|NCT02750618|Biological|Burosumab|solution for subcutaneous injection
186030|NCT02750605|Device|DEB|Intervention with drug eluting balloon.
186031|NCT02750605|Device|POBA|Intervention with old technology as comparison
186032|NCT02750592|Drug|Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
186033|NCT02750579|Procedure|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
186034|NCT02750566|Procedure|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
186035|NCT02750566|Other|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
186036|NCT02750553|Drug|SHR0534|
186037|NCT02750553|Drug|Placebo|
186038|NCT02750540|Drug|Tenofovir enema|
186039|NCT02750540|Other|Saline enema|
186040|NCT02750514|Biological|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
186041|NCT02750514|Drug|Dasatinib|
186042|NCT02750514|Biological|Relatlimab|
186043|NCT02750514|Biological|Ipilimumab|
186044|NCT02750514|Drug|BMS-986205|Specified dose on specified days
186045|NCT02750501|Device|RELiZORB (immobilized lipase) cartridge|Hydrolyzing fats from enteral formula, ex vivo, with in-line enteral feed RELiZORB (immobilized lipase) cartridge
186046|NCT02750501|Other|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
186047|NCT02750488|Drug|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
186048|NCT02750488|Other|Untreated skin|One site is patched without treatment as control
186049|NCT02750475|Drug|Sunscreen Sport Lotion (BAY987516)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
186050|NCT02750475|Other|Untreated Skin|This site is patched without treatment as irradiated control
186051|NCT02750462|Other|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
186052|NCT02750462|Other|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
186053|NCT02750449|Drug|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
186054|NCT02750449|Other|Untreated skin|This site is patched without treatment as control
186055|NCT02750436|Device|Ultrasound guided|This group will be treated using an ultrasound imaging device
186056|NCT02750436|Device|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
186057|NCT02750423|Procedure|DHCA+RCP|During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
186058|NCT02750423|Procedure|MHCA + SACP|During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
186059|NCT02750410|Drug|Dulaglutide|Administered subcutaneously (SC)
186060|NCT02750410|Drug|Placebo|Administered SC
186061|NCT02750384|Drug|DSM265 50% SDD granules|Single oral dose 400 mg
186062|NCT02750384|Drug|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
186063|NCT02750371|Other|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
186064|NCT02750358|Drug|Enzalutamide|
186065|NCT02750358|Behavioral|assessment|
186066|NCT02750345|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
186067|NCT02750345|Drug|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
186068|NCT02750345|Drug|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
186069|NCT02750332|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
186070|NCT02750319|Drug|Amiodarone|
186071|NCT02750319|Drug|N-Acetylcysteine|
186072|NCT02750319|Drug|Placebo|
186073|NCT02750306|Drug|Suvorexant|10 mg tablet (may be increased to 20 mg tablet)
186074|NCT02750306|Drug|Placebo|Placebo to suvorexant
186075|NCT02750293|Drug|Cholecalciferol|Vitamin D preparation
186076|NCT02750293|Drug|Placebo|placebo
186077|NCT02750280|Device|MatriStem® [Urinary Bladder Matrix (UBM)]|Porcine derived urinary bladder extracellular matrix
186078|NCT02750280|Device|Mepilex® [Silicone foam dressing]|primary wound dressing
186079|NCT02750267|Device|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
186080|NCT02750254|Drug|Fludarabine|
186089|NCT02750241|Behavioral|Active video game-based intervention|"Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.~Participate in self-paced home sessions~Monitor daily, weekly, and monthly steps using Wii Fit Meter~Feedback on physical activity and physical function"
186090|NCT02750241|Behavioral|Pedometer|"Attend 3 monthly UTMB Breast Cancer Support Group Sessions~Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)~Feedback on physical activity and physical function"
186091|NCT02750215|Drug|Capmatinib (INC280)|treatment with Capmatinib (INC280)
186092|NCT02750202|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
186093|NCT02750202|Biological|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
186094|NCT02750189|Other|Direct cost|Money spent to treat COPD in medical institute based on HIRA
186095|NCT02750189|Other|Indirect cost|extra-expanses excluding hospital fees
186096|NCT02750176|Other|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
186097|NCT02750163|Drug|paracetamol|Paracetamol will be given to febrile septic patients
186098|NCT02750150|Drug|Freezed-dried plasma|early transfusion of 4 units of freezed dried plasma
186099|NCT02750150|Drug|Fresh-frozen plasma|
186100|NCT02750137|Drug|Tetracaine|Application of Ametop prior to intravenous cannulation
186101|NCT02750124|Device|Cobas PCR Female swab sample Packet|The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
186102|NCT02750124|Other|Routine practice|The standard, annual renewed invitation to cervical screening.
186103|NCT02750098|Other|Glucose measurement|"Elective cataract surgery~Blood glucose measurement - glucometer~Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer~Perioperative Hemoglobin A1c level - blood laboratory test"
186104|NCT02750072|Procedure|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
186105|NCT02750072|Procedure|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
186106|NCT02750059|Drug|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
186107|NCT02750059|Drug|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
186108|NCT02750046|Procedure|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
186109|NCT02750033|Device|Multimodal Spectroscopy (MMS)|surgical margin assessment with multimodal optical spectroscopy (MMS) device
186110|NCT02750020|Other|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
186111|NCT02750007|Drug|HS-20004|
186112|NCT02749994|Drug|Rosuvastatin|
186113|NCT02749994|Drug|Ezetimibe|
186114|NCT02749981|Procedure|blood and tissue sampling|
186115|NCT02749968|Drug|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
186116|NCT02749968|Drug|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
186117|NCT02749955|Behavioral|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
186118|NCT02749955|Behavioral|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
186119|NCT02749942|Device|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
186120|NCT02749942|Device|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
186121|NCT02749929|Other|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
186122|NCT02749929|Other|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
186123|NCT02749916|Other|Methods of carotid wall imaging|
186124|NCT02749903|Drug|enzalutamide|oral
186125|NCT02749890|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
186126|NCT02749890|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
186127|NCT02749890|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet~Route of administration: Oral"
186128|NCT02749877|Behavioral|Working Memory Training|(Training Details already described above)
186129|NCT02749877|Behavioral|Physical Training|(Training Details already described above)
186176|NCT02749461|Procedure|heel stick|Consecutive routine blood sampling heel sticks
186130|NCT02749851|Device|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
186131|NCT02749851|Device|MRI - IUGR|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy. The objective of this ancillary arm is to further test the sensitivity of placental magnetic resonance imaging to detect abnormal perfusion and oxygenation in confirmed cases of IUGR between gestational ages 28 to 36 weeks.
186132|NCT02749825|Drug|Trelstar|As labeled
186133|NCT02749825|Drug|Lupron|As labeled
186134|NCT02749825|Drug|Zoladex|As labeled
186135|NCT02749812|Device|Constant Continuous Positive Airway Pressure|
186136|NCT02749812|Device|Automatic continuous Positive Airway Pressure|
186137|NCT02749799|Drug|DFD-01|
186138|NCT02749786|Other|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
186139|NCT02749773|Device|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
186140|NCT02749760|Other|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
186141|NCT02749760|Other|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
186142|NCT02749747|Drug|Sulpiride use|50mg sulpiride once a day use for 60 days
186143|NCT02749747|Drug|Placebo|50mg placebo once a day use for 60 days
186144|NCT02749734|Procedure|Subretinal transplantation|Transplant hESC-RPE into subretinal space of patients with macular degeneration
186145|NCT02749721|Drug|vortioxetine|
186146|NCT02749708|Drug|IRX5183|IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 [DL1] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
186147|NCT02749695|Drug|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
186148|NCT02749695|Other|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
186149|NCT02749669|Other|Qualitative research|Semi-structured Interviews
186150|NCT02749656|Drug|0.25% Desoximetasone cream (Topoxy®)|apply on the scalp psoriasis lesion twice a day
186151|NCT02749656|Drug|0.25% Desoximetasone cream (Topicorte®)|apply on the scalp psoriasis lesion twice a day
186152|NCT02749656|Drug|Placebo|apply on the scalp psoriasis lesion twice a day
186153|NCT02749643|Device|Vibrotactile feedback system|
186154|NCT02749630|Drug|Placebo|Matching placebo to UTTR1147A administered intravenously
186155|NCT02749630|Drug|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
186156|NCT02749617|Drug|apixaban|2.5 mg PO BID
186157|NCT02749604|Procedure|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
186158|NCT02749604|Procedure|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
186159|NCT02749591|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
186160|NCT02749591|Other|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
186161|NCT02749591|Other|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
186162|NCT02749591|Other|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
186163|NCT02749578|Drug|Atorvastatin|
186164|NCT02749578|Drug|MGL-3196|
186165|NCT02749552|Behavioral|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
186166|NCT02749539|Device|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
186167|NCT02749539|Procedure|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
186168|NCT02749526|Drug|"Endostar"|30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
186169|NCT02749526|Drug|Liposo|135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
186170|NCT02749526|Drug|cisplatin|25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
186171|NCT02749526|Drug|Gimeracil and Oteracil Potassium （Tegafur）|40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
186172|NCT02749513|Drug|Itraconazole|
186173|NCT02749500|Other|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
186174|NCT02749500|Device|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
186175|NCT02749487|Other|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
186177|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
186178|NCT02749435|Other|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
186179|NCT02749422|Diagnostic Test|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
186180|NCT02749409|Drug|Parecoxib|
186181|NCT02749409|Drug|Morphine|
186182|NCT02749396|Drug|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
186183|NCT02749396|Drug|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
186184|NCT02749396|Drug|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
186185|NCT02749396|Drug|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
186186|NCT02749396|Drug|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
186187|NCT02749396|Drug|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
186188|NCT02749396|Other|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
186189|NCT02749383|Drug|PAC-14028 cream 0.3%|Topical application
186190|NCT02749383|Drug|PAC-14028 cream 1.0%|Topical application
186191|NCT02749383|Drug|PAC-14028 cream vehicle|Topical application
186192|NCT02749370|Drug|Etanercept|Administered subcutaneously twice weekly for 12 weeks then once weekly for an additional 12 weeks.
186193|NCT02749357|Device|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.~The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
186194|NCT02749357|Device|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
186195|NCT02749344|Other|FET after endometrial preparation|Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
186196|NCT02749331|Drug|AdVince|Virus solution for infusion in intrahepatic artery
186197|NCT02749318|Genetic|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
186198|NCT02749305|Other|Collection of patient-reported outcome measures|Pre- and posto-perative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
186199|NCT02749292|Drug|Rituximab|re-dosing dependent on interventional arm parameter.
186200|NCT02749266|Other|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
186201|NCT02749266|Other|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
186202|NCT02749253|Other|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
186203|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
186204|NCT02749227|Drug|Pasireotide LAR|"Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained."
186205|NCT02749214|Other|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
186206|NCT02749214|Other|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
186207|NCT02749201|Device|Gastrisail|Light Intensity and gastric wall thickness assessment
186208|NCT02749188|Other|Bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
186209|NCT02749175|Device|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
186210|NCT02749175|Device|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
187105|NCT02742441|Drug|122-0551 Foam|Topical Foam containing active drug
186211|NCT02749162|Drug|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
186212|NCT02749162|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
186213|NCT02749162|Drug|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
186214|NCT02749162|Drug|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
186215|NCT02749162|Drug|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
186216|NCT02749136|Drug|Preoperative modified FOLFIRINOX and postoperative gemcitabine|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles~Oxaliplatin IV 85 mg/m2 Day (D) 1~Irinotecan IV 180 mg/m2 D1~5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2~Leucovorin IV 400 mg/m2 D1~Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"
186217|NCT02749123|Drug|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
186218|NCT02749123|Drug|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
186219|NCT02749123|Drug|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
186220|NCT02749110|Device|Vaginal self-sampling brush|Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
186221|NCT02749097|Drug|SHR0534|
186222|NCT02749097|Drug|Placebo|
186223|NCT02749084|Biological|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).~Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.~The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.~T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.~Release Criteria of Treg cell preparation will be defined.~The product will be infused into the recipient through a venous catheter."
186224|NCT02749071|Procedure|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
186225|NCT02749071|Device|EndoStim stimulation for first six months of study|Lower esophageal stimulation
186226|NCT02749071|Device|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
186227|NCT02749071|Device|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
186228|NCT02749058|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
186229|NCT02749058|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
186230|NCT02749045|Radiation|SPECT imaging|myocardial perfusion imaging
186231|NCT02749032|Other|Mixed meal test|Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
186232|NCT02749032|Drug|Vildagliptin|Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
186233|NCT02749032|Drug|Sitagliptin|The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
186234|NCT02749032|Drug|Placebo|Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
186235|NCT02749032|Drug|Metformin|For patients continuing with pre-existing metformin treatment, 1000 mg film coated tablets from commercial sources. In half of the patients (stratum: metformin as background medication), metformin was administered orally twice daily at 1000 mg of active compound during of after breakfast and dinner.
186236|NCT02749032|Other|Diet and exercise|Patients treated their diabetes mellitus type 2 with diet/exercise only
186237|NCT02749019|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
186238|NCT02749006|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
186239|NCT02749006|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
186240|NCT02748993|Drug|PAC-14028 Cream 0.1%|Topical application
186241|NCT02748993|Drug|PAC-14028 Cream 0.3%|Topical application
186242|NCT02748993|Drug|PAC-14028 Cream 1.0%|Topical application
186243|NCT02748993|Drug|PAC-14028 Cream Vehicle|Topical application
186244|NCT02748967|Drug|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
186245|NCT02748967|Drug|Placebo|Participant will receive single dose of Placebo on Day 1.
186278|NCT02748759|Other|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
186246|NCT02748954|Behavioral|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
186247|NCT02748954|Behavioral|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
186248|NCT02748954|Behavioral|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
186249|NCT02748954|Behavioral|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
186250|NCT02748954|Behavioral|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
186251|NCT02748941|Device|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque~Description of different modalities:~HITS quantification~Ultrasound examinations:~Ulceration >2 mm~Plaque thickness~GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop~CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)~High Resolution MRI:~Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated~Quantification of shear stresses (Pa) on the surface of the plaque~mi-RNA identification and quantification"
186252|NCT02748928|Device|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
186253|NCT02748915|Other|Electrophysiological and psychoacoustic tests|
186254|NCT02748902|Drug|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
186255|NCT02748889|Drug|Carboplatin|Standard chemotherapy
186256|NCT02748889|Drug|Etoposide|Standard chemotherapy
186257|NCT02748889|Biological|MPDL3280A|Experimental biologic
186258|NCT02748876|Other|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
186259|NCT02748863|Drug|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
186260|NCT02748863|Drug|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
186261|NCT02748863|Drug|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
186262|NCT02748850|Biological|blood sample|a blood sample 20 milliliter
186263|NCT02748850|Biological|Stem cell donation|The volume of stem cells remained in the tube is recovered
186264|NCT02748837|Drug|ERY974|
186265|NCT02748811|Other|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
186266|NCT02748798|Drug|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
186267|NCT02748798|Drug|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
186268|NCT02748798|Drug|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
186269|NCT02748798|Drug|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
186270|NCT02748798|Device|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
186271|NCT02748798|Device|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
186272|NCT02748798|Device|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
186273|NCT02748785|Drug|Methotrexate|Methotrexate will be continued
186274|NCT02748785|Biological|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
186275|NCT02748772|Drug|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
186276|NCT02748772|Drug|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
186277|NCT02748759|Device|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
186279|NCT02748746|Device|Bio Impedance Analysis Measurement|Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.
186280|NCT02748746|Device|Tissue Dielectric Constant Measurement|In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.
186281|NCT02748733|Other|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
186282|NCT02748733|Other|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
186283|NCT02748720|Other|RFM (device) Visible|Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
186284|NCT02748707|Drug|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
186285|NCT02748707|Drug|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
186286|NCT02748707|Drug|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
186287|NCT02748707|Other|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
186288|NCT02748694|Drug|TAK-041|TAK-041 suspension.
186289|NCT02748694|Drug|TAK-041|TAK-041 tablet.
186290|NCT02748694|Drug|TAK-041 Placebo|TAK-041 placebo-matching suspension.
186291|NCT02748681|Device|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
186292|NCT02748668|Other|Blood specimen collection|
186293|NCT02748655|Other|Alkaline ionized water|
186294|NCT02748655|Other|Tap water|
186295|NCT02748642|Drug|BITS7201A|BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
186296|NCT02748642|Drug|Placebo|Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
186297|NCT02748629|Device|Covidien Parietex ProGrip Self-Fixating Mesh|
186298|NCT02748629|Device|Lightweight Polypropylene Mesh (<38g/m2 after absorption)|Serag Wiessner SERAMESH® PA 15x10 cm
186299|NCT02748616|Drug|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
186300|NCT02748590|Device|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
186301|NCT02748577|Other|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
186302|NCT02748577|Other|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
186303|NCT02748564|Biological|Aldesleukin|Given IV
186304|NCT02748564|Other|Laboratory Biomarker Analysis|Correlative studies
186305|NCT02748564|Biological|Pembrolizumab|Given IV
186306|NCT02748551|Procedure|Laparoscopic procedures|Laparoscopic surgery
186307|NCT02748551|Procedure|Open Surgery|Open surgery
186308|NCT02748525|Other|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
186309|NCT02748525|Biological|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
186310|NCT02748512|Drug|FAI insert|
186311|NCT02748499|Other|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
186312|NCT02748499|Other|Control|Participants maintain their daily acitvities.
186313|NCT02748486|Behavioral|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
186314|NCT02748486|Behavioral|Group discussion|Group discussion of current events
186315|NCT02748486|Behavioral|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
186316|NCT02748473|Other|Pilates Exercises program|"The volunteers were divided in two groups:~Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.~The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.~Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.~After the 24 sessions, both groups were retested with the same measured methods of the baseline."
186317|NCT02748473|Other|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
186318|NCT02748473|Other|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
186364|NCT02748135|Drug|TB-403 50mg/kg|bi-weekly intravenous doses of TB-403 50mg/kg
186319|NCT02748447|Device|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
186320|NCT02748434|Other|Lipohypertrophy|
186321|NCT02748434|Other|Normal Subcutaneous Tissue|
186322|NCT02748421|Procedure|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
186323|NCT02748421|Procedure|Conventional Microscope|macular membrane dissection without OCT RESCAN
186324|NCT02748408|Device|SMS femoral stem|
186325|NCT02748395|Drug|Triamcinolone|
186326|NCT02748395|Other|Placebo|
186327|NCT02748395|Drug|Lidocaine|
186328|NCT02748382|Other|higher chloride crystalloid|Normal saline
186329|NCT02748382|Other|higher chloride albumin|5% Octalbin
186330|NCT02748382|Other|lower chloride crystalloid|Ringers Lactate
186331|NCT02748382|Other|lower chloride albumin|5% Plasbumin
186332|NCT02748369|Drug|Somatostatin|Somatostatin infusion to create a low insulin state.
186333|NCT02748369|Drug|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
186334|NCT02748356|Drug|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
186335|NCT02748343|Device|allograft bone|Use of the allograft bone to treat the bone defect in patients
186336|NCT02748343|Device|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
186337|NCT02748330|Drug|Ticagrelor|Ticagrelor
186338|NCT02748330|Drug|Clopidogrel|Clopidogrel
186339|NCT02748330|Drug|Aspirin|Acetylsalicylic acid
186340|NCT02748317|Drug|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
186341|NCT02748304|Other|control|just follow up
186342|NCT02748304|Drug|sorafenib|sorafenib 400mg bid po
186343|NCT02748304|Drug|aspirin|aspirin 100mg qd po
186344|NCT02748291|Other|Walking|"The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).~Participants will be provided with a pedometer and daily diary to record step counts.~Weekly scores will be collected via telephone contact.~Followup questionnaires will be at 6, 12 and 24 months."
186345|NCT02748291|Other|Department of Health Physical Activity Guidelines|"Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.~Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.~Adults should also undertake physical activity to improve muscle strength on at least two days a week.~All adults should minimise the amount of time spent being sedentary (sitting) for extended periods."
186346|NCT02748278|Procedure|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
186347|NCT02748278|Procedure|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
186348|NCT02748265|Drug|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
186349|NCT02748265|Drug|Sevoflurane|Volatile maintenance anesthesia
186350|NCT02748265|Drug|Propofol|Intravenous maintenance anesthesia
186351|NCT02748252|Other|stroke center referral|
186352|NCT02748239|Behavioral|MEDIAS 2 CT|The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
186353|NCT02748239|Behavioral|Current CT program|The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
186354|NCT02748226|Procedure|endovascular treatment|endovascular treatment
186355|NCT02748213|Drug|Xeloda|Participants will receive oral Xeloda, 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle.
186356|NCT02748213|Drug|Taxotere|Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
186357|NCT02748213|Drug|Herceptin|Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
186358|NCT02748200|Radiation|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
186359|NCT02748187|Other|CBASP|Interpersonal psychotherapy for chronic depression
186360|NCT02748174|Behavioral|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
186361|NCT02748161|Procedure|DEB-TACE|Transarterial chemoembolization with doxorubicin-eluting beads.
186362|NCT02748148|Other|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
186363|NCT02748135|Drug|TB-403 20mg/kg|bi-weekly intravenous doses of TB-403 20mg/kg
186365|NCT02748135|Drug|TB-403 100mg/kg|bi-weekly intravenous doses of TB-403 100mg/kg
186366|NCT02748135|Drug|TB-403 175mg/kg|bi-weekly intravenous doses of TB-403 175mg/kg
186367|NCT02748122|Other|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
186368|NCT02748109|Behavioral|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
186369|NCT02748109|Behavioral|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
186370|NCT02748096|Procedure|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
186371|NCT02748096|Procedure|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
186372|NCT02748083|Device|tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.
186373|NCT02748083|Device|Sham tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
186374|NCT02748070|Drug|Prednisone|
186375|NCT02748070|Drug|Flonase|
186376|NCT02748057|Drug|Ezetimibe|
186377|NCT02748057|Drug|Rosuvastatin|
186378|NCT02748044|Device|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
186379|NCT02748031|Procedure|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
186380|NCT02748018|Device|670G Insulin Pump|Medtronic 670G Hybrid Closed Loop (HCL) ambulatory insulin pump system
186381|NCT02748018|Device|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
186382|NCT02748005|Dietary Supplement|Fenugreek seeds extract 500 mg|one cap once a day
186383|NCT02747979|Other|hemodialysis only|hemodialysis treatment only
186384|NCT02747979|Other|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
186385|NCT02747979|Other|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
186386|NCT02747953|Drug|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
186387|NCT02747940|Drug|flunarizine and/or pregabalin|
186388|NCT02747927|Biological|Takeda's Tetravalent Dengue Vaccine Candidate|TDV subcutaneous injection
186389|NCT02747927|Drug|TDV Placebo|Takeda's TDV placebo-matching vaccine
186390|NCT02747914|Device|Transcranial magnetic stimulation|
186391|NCT02747914|Other|Conventional exercise|
186392|NCT02747901|Other|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
186393|NCT02747901|Other|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
186394|NCT02747888|Genetic|•Referral to Genetic Counselor, if indicated|
186395|NCT02747875|Drug|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
186396|NCT02747875|Drug|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
186397|NCT02747862|Other|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP [i.e. identifiable APC mutation], and/or a compatible family history or personal adenoma burden of > 50 adenomas).~The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
186436|NCT02747498|Procedure|Procedure with linear ablation in addiction to pulmonary vein isolation|
186398|NCT02747849|Device|TENS|Placebo had stimulator placed on hand. Active comparator had stimulator placed on foot. Amount of time, intensity, threshold voltage, pulsewidth and frequency remained the same for both arms.
186399|NCT02747836|Other|Ultrasound of the wrist|using sound waves to create images capturing the movement of the SSCT and flexor tendon and transformation of the median nerve in the wrist
186400|NCT02747823|Biological|CBT124|1 mg/kg IV infusion
186401|NCT02747823|Biological|EU Sourced Avastin®|1 mg/kg IV infusion
186402|NCT02747823|Biological|US Sourced Avastin®|1 mg/kg IV infusion
186403|NCT02747810|Device|NewTENS Design|This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
186404|NCT02747797|Drug|Lucitanib|10 mg orally daily
186405|NCT02747784|Behavioral|Cognitive training program RehaCom®|Cognitive training program RehaCom®
186406|NCT02747771|Behavioral|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
186407|NCT02747758|Device|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
186408|NCT02747758|Device|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
186409|NCT02747758|Device|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
186410|NCT02747745|Behavioral|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits & phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
186411|NCT02747732|Drug|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.~Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
186412|NCT02747719|Behavioral|Light and exercise|Exposure to light and exercise
186413|NCT02747706|Behavioral|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
186414|NCT02747680|Other|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
186415|NCT02747654|Genetic|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
186416|NCT02747641|Procedure|Pixel CO2 Laser System|
186417|NCT02747628|Drug|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
186418|NCT02747628|Drug|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
186419|NCT02747628|Drug|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
186420|NCT02747615|Other|transfused pre-operatively donated autologous blood.|
186421|NCT02747615|Drug|intravenous tranexamic acid (TXA) infusion|
186422|NCT02747615|Other|transfused only allogeneic blood.|
186423|NCT02747602|Drug|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
186424|NCT02747602|Drug|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
186425|NCT02747602|Drug|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
186426|NCT02747589|Procedure|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
186427|NCT02747563|Other|Blood test (PSA)|Measurement of blood PSA levels
186428|NCT02747550|Procedure|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
186429|NCT02747550|Procedure|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
186430|NCT02747537|Drug|Sorafenib|
186431|NCT02747537|Drug|Irinotecan|
186432|NCT02747524|Other|Vita Mamba peanut butter paste|
186433|NCT02747511|Drug|Haloperidol|
186434|NCT02747511|Drug|Placebo|
186435|NCT02747498|Procedure|Procedure with circumferential pulmonary vein isolation|
186437|NCT02747485|Device|Cardiac MRI|
186438|NCT02747485|Biological|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
186439|NCT02747485|Procedure|myocardial biopsy|
186440|NCT02747485|Genetic|blood samples|extract DNA to look for genomic mutations associated with the disease.
186441|NCT02747472|Drug|GIP-A|GIP receptor antagonist
186442|NCT02747472|Drug|GIP(1-42)|GIP receptor agonist
186443|NCT02747472|Other|Saline|Placebo
186444|NCT02747459|Behavioral|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
186445|NCT02747446|Dietary Supplement|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
186446|NCT02747433|Device|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
186447|NCT02747433|Device|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
186448|NCT02747420|Device|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
186449|NCT02747420|Device|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
186450|NCT02747407|Biological|Hepatitis A Vaccine|
186451|NCT02747407|Other|Laboratory Biomarker Analysis|Correlative studies
186452|NCT02747407|Biological|Tetanus Toxoid Vaccine|
186453|NCT02747407|Biological|Trivalent Influenza Vaccine|
186454|NCT02747394|Other|Working Memory Training|
186455|NCT02747381|Dietary Supplement|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
186456|NCT02747368|Device|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
186457|NCT02747342|Drug|SHR3680; SHR3162|"SHR3680 will be administered orally in dose escalation/expansion phase,~SHR3680 will be administered orally at a fixed dose together with SHR3162 in combination phase."
186458|NCT02747329|Device|BuMA Supreme™ stent|
186459|NCT02747329|Device|Xience V/Prime stent|
186460|NCT02747316|Other|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
186461|NCT02747316|Other|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
186462|NCT02747303|Procedure|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
186463|NCT02747290|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
186464|NCT02747264|Device|eRAPID|eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
186465|NCT02747251|Other|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
186466|NCT02747251|Other|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
186467|NCT02747238|Device|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
186468|NCT02747238|Procedure|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
186469|NCT02747238|Procedure|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
186851|NCT02744105|Dietary Supplement|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
186470|NCT02747225|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
186471|NCT02747212|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
186472|NCT02747199|Device|SYNERGY stent|
186473|NCT02747199|Device|BVS ABSORB scaffold|
186474|NCT02747186|Drug|Lidocaine|Intraoral maxillary field block
186475|NCT02747160|Behavioral|Managing Anxiety from Cancer (MAC)|The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
186476|NCT02747147|Device|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
186477|NCT02747134|Behavioral|Emotion Regulation and Mindfulness skills|
186478|NCT02747121|Behavioral|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
186479|NCT02747108|Behavioral|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
186480|NCT02747108|Behavioral|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
186481|NCT02747095|Device|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
186482|NCT02747082|Procedure|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
186483|NCT02747069|Device|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
186484|NCT02747069|Device|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
186485|NCT02747056|Other|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
186486|NCT02747056|Other|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
186487|NCT02747056|Other|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
186488|NCT02747043|Drug|ABP 798|375 mg/m2, IV (in the vein)
186489|NCT02747043|Drug|Rituximab|375 mg/m2, IV (in the vein)
186490|NCT02747030|Drug|Ocriplasmin intravenously|Retinal vein cannulation with Ocriplasmin infusion
186491|NCT02747004|Drug|Abemaciclib|Administered orally
186492|NCT02747004|Drug|Tamoxifen|Administered orally
186493|NCT02747004|Drug|Prophylactic Loperamide|Administered orally
186494|NCT02746991|Drug|Sham Injection|
186495|NCT02746991|Drug|FAI Insert|
186496|NCT02746978|Other|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
186497|NCT02746978|Other|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
186498|NCT02746965|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
186499|NCT02746965|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
186500|NCT02746965|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
186501|NCT02746952|Biological|UCART19|
186502|NCT02746939|Behavioral|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
186503|NCT02746926|Drug|tafamidis|
186504|NCT02746913|Device|Urodynamics|Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.
186505|NCT02746913|Device|Pessary|A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
186506|NCT02746900|Procedure|Cervical cerclage|McDonald cervical cerclage
186507|NCT02746887|Other|Preterm/term cohort|
186508|NCT02746874|Procedure|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
186509|NCT02746874|Procedure|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
186510|NCT02746861|Behavioral|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
186511|NCT02746848|Biological|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
186512|NCT02746835|Other|Exercise program for fall prevention|"Set of exercises to improve the following parameters:~balance, endurance, muscle strength, flexibility."
186513|NCT02746809|Device|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:~Evolut 34R Transcatheter Aortic Valve (TAV)~EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath~EnVeo R Loading System (LS)"
186514|NCT02746796|Drug|ONO-4538|
186515|NCT02746796|Drug|Oxaliplatin|
186516|NCT02746796|Drug|Tegafur- Gimeracil-Oteracil potassium|
186517|NCT02746796|Drug|Capecitabine|
186518|NCT02746796|Drug|Placebo|
186519|NCT02746783|Drug|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
186520|NCT02746783|Drug|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
186521|NCT02746770|Other|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
186522|NCT02746757|Other|Remote conditioning|
186523|NCT02746757|Drug|Exendin 9-39|
186524|NCT02746744|Drug|Rituximab|Infusion of Mabthera/Rituximab every 6 months
186525|NCT02746744|Drug|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
186526|NCT02746744|Drug|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
186527|NCT02746731|Other|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.~Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
186528|NCT02746731|Other|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
186529|NCT02746718|Other|Blood sample|A blood sample for CPK dosage and pompe disease test
186530|NCT02746705|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
186531|NCT02746705|Device|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
186532|NCT02746705|Behavioral|Cognitive Training Program|
186533|NCT02746692|Other|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).~Total duration 15 minutes circle training: 20s workout, 10 rest"
186534|NCT02746692|Other|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
186852|NCT02744092|Drug|Rivaroxaban|Anticoagulation therapy.
186535|NCT02746679|Other|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
186536|NCT02746666|Behavioral|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
186537|NCT02746653|Device|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
186538|NCT02746640|Procedure|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
186539|NCT02746627|Behavioral|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
186540|NCT02746627|Behavioral|Education|Educational materials on diabetes management
186541|NCT02746614|Other|Psychomotor Therapy|Psychomotor Therapy
186542|NCT02746601|Behavioral|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
186543|NCT02746588|Other|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
186544|NCT02746575|Drug|metoprolol|
186545|NCT02746562|Procedure|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
186546|NCT02746549|Other|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
186547|NCT02746536|Other|Slow chest compression|"During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.~A standardized verbal command will be given: Exhale all the air."
186548|NCT02746536|Other|No slow chest compression|"The patient will remain seated at rest for one minute after the 6MST. A standardized verbal command will be given: Exhale all the air."
186549|NCT02746523|Other|Sensory Organization Test|Balance and proprioception test
186550|NCT02746523|Genetic|Biomarkers|Blood, urine, and saliva biomarkers
186551|NCT02746523|Other|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
186552|NCT02746523|Other|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
186553|NCT02746523|Other|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
186554|NCT02746510|Genetic|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
186555|NCT02746497|Procedure|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.~Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
186556|NCT02746484|Other|Ability platform program|The Ability program is an at home participant-tailored and technology-enhanced platform a) delivering tablet-based intensive (five days/a week for six weeks) motor and cognitive activities; b) monitoring from remote vital and physical health parameters (i.e., weight, Heart Rate, O2 saturation, daily steps, sleep activity).
186557|NCT02746484|Other|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
186558|NCT02746471|Device|Reveal LINQ|
186559|NCT02746458|Other|Blood Flow Restriction|Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.
186560|NCT02746458|Device|Delfi PTSII Tourniquet System|
186561|NCT02746445|Other|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
186562|NCT02746432|Drug|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
186563|NCT02746419|Device|Vessix|Renal denervation using radio-ablation
186564|NCT02746406|Device|Peritron+|Peritron+ device to measure intravesical pressure
186565|NCT02746393|Other|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
186566|NCT02746393|Other|211 Information Sheet|Receive a printed list of community resources to address social needs.
186567|NCT02746380|Drug|LBAL|Adalimumab
186568|NCT02746380|Drug|Humira®|Adalimumab
186569|NCT02746367|Other|Diagnostic test (LDT)|Proteomic assay
186570|NCT02746354|Other|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
186571|NCT02746328|Drug|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
186572|NCT02746315|Drug|HS-20004|
186573|NCT02746315|Drug|Placebo|
186574|NCT02746302|Drug|HS-20004|
186575|NCT02746302|Drug|Placebo|
186853|NCT02744092|Drug|Apixaban|Anticoagulation therapy.
186576|NCT02746276|Drug|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
186577|NCT02746276|Drug|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
186578|NCT02746263|Drug|IV acetaminophen|
186579|NCT02746263|Drug|Oral acetaminophen|
186580|NCT02746263|Drug|Morphine|Patient controlled analgesia
186581|NCT02746250|Drug|Amitriptyline|The investigator recruits patients who have already discussed and agreed to the amitriptyline treatment with their physician. The patients start the treatment after the investigator have measured them once.
186582|NCT02746237|Drug|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
186583|NCT02746237|Drug|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
186584|NCT02746224|Procedure|Initially dissection of inferior mesenteric vein|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
186585|NCT02746224|Procedure|Initially dissection of inferior mesenteric artery|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
186586|NCT02746224|Procedure|Latero-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
186587|NCT02746224|Procedure|Termino-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
186588|NCT02746211|Biological|High Titre Influenza virus|High Titre Influenza virus
186589|NCT02746211|Biological|Medium - High Influenza virus|Medium - High Influenza virus
186590|NCT02746211|Biological|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
186591|NCT02746211|Biological|Low titre|Low titre
186592|NCT02746198|Other|probiotic dairy drink|
186593|NCT02746198|Other|acidified milk|
186594|NCT02746185|Drug|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
186595|NCT02746185|Drug|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
186596|NCT02746172|Device|Cochlear implant with in-situ audiometry|
186597|NCT02746159|Device|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
186598|NCT02746146|Other|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
186599|NCT02746133|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
186600|NCT02746107|Other|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
186601|NCT02746094|Device|8 bi-weekly LIESWT sessions|"LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy~The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.~In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.~mJ = millijoule."
186602|NCT02746081|Drug|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
186603|NCT02746068|Drug|AXS-02|
186604|NCT02746068|Drug|Placebo|
186605|NCT02746042|Drug|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
186606|NCT02746042|Drug|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
186607|NCT02746029|Other|Clinical examination|
186608|NCT02746016|Other|Infant Formula supplemented with Oligosaccharides|sole source nutrition
186609|NCT02746003|Other|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
186610|NCT02745990|Drug|Recombinant human erythropoietin|rhEPO is administered 500IU/kg, intravenously within 72h after birth, and every other day up to 32 weeks of corrected age.
186611|NCT02745990|Drug|Normal saline|Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
186612|NCT02745977|Other|Dairy Free Diet|Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
186613|NCT02745964|Device|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
186614|NCT02745964|Device|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
186615|NCT02745951|Other|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
186616|NCT02745951|Other|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
186617|NCT02745925|Drug|Ibuprofen|
186618|NCT02745912|Drug|Naltrexone/Bupropion|Naltrexone/Bupropion extended-release tablets.
186619|NCT02745912|Drug|Metformin|Metformin immediate-release tablet.
186620|NCT02745899|Dietary Supplement|Cow milk|Ingestion of 240 ml cow milk
186621|NCT02745899|Dietary Supplement|Soy milk|Ingestion of 240 ml soy milk
186622|NCT02745886|Drug|metformin 0.85 twice daily for 6 months|
186623|NCT02745886|Behavioral|Calorie restriction|
186624|NCT02745873|Drug|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
186625|NCT02745860|Drug|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
186626|NCT02745860|Drug|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
186627|NCT02745847|Radiation|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
186628|NCT02745834|Other|Gait analysis|Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
186629|NCT02745821|Device|Pressure Wire Certus, St. Jude Medical, USA|FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
186630|NCT02745808|Biological|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
186631|NCT02745808|Biological|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
186632|NCT02745795|Behavioral|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
186633|NCT02745795|Behavioral|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
186634|NCT02745782|Other|Observational Study|Observational Study
186635|NCT02745769|Drug|Ramucirumab|Administered IV
186636|NCT02745769|Drug|Merestinib|Administered orally
186637|NCT02745769|Drug|Abemaciclib|Administered orally
186638|NCT02745756|Procedure|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
186639|NCT02745756|Biological|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
186640|NCT02745743|Drug|BAY1251152|Weekly infusion of BAY1251152 in 21-day cycles.
186641|NCT02745730|Other|Glucose|
186642|NCT02745730|Other|Fructose|
186643|NCT02745730|Other|Sucralose|
186644|NCT02745730|Other|Allulose|
186645|NCT02745717|Drug|Thymoglobulin|administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
186646|NCT02745717|Procedure|Cord blood|transfusion of one unit of at least 4/6 HLA loci matched cord blood.
186647|NCT02745717|Drug|Cyclosporine Oral Product|administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
186648|NCT02745704|Drug|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
186649|NCT02745691|Other|Surgery|Thoracic surgery for lung cancer
186650|NCT02745691|Other|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
186651|NCT02745691|Other|Targeted therapy|New targeted therapies for lung cancer
186652|NCT02745691|Other|Immunotherapy|New immunotherapies for lung cancer
186653|NCT02745678|Drug|Thermosensitive gel rectal formulation|
186654|NCT02745665|Other|flow mediated dilation (endothelial function)|
186655|NCT02745665|Other|ABPI|
186656|NCT02745665|Other|Pulse wave velocity and augmentation index|
186657|NCT02745665|Other|blood pressure|
186658|NCT02745665|Other|ramp test|
186659|NCT02745652|Device|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
186660|NCT02745652|Device|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
186709|NCT02745184|Biological|Lung stem cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
186854|NCT02744092|Drug|Edoxaban|Anticoagulation therapy.
186855|NCT02744092|Drug|Dabigatran|Anticoagulation therapy.
186661|NCT02745639|Radiation|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
186662|NCT02745639|Drug|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
186663|NCT02745626|Device|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
186664|NCT02745613|Other|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
186665|NCT02745600|Device|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
186666|NCT02745587|Radiation|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
186667|NCT02745574|Procedure|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
186668|NCT02745574|Procedure|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
186669|NCT02745561|Drug|Endostatins|Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
186670|NCT02745561|Drug|Oxaliplatin|Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
186671|NCT02745561|Radiation|Radiotherapy|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
186672|NCT02745535|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|
186673|NCT02745522|Drug|Oxytocin|
186674|NCT02745522|Drug|Placebo|
186675|NCT02745509|Other|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
186676|NCT02745496|Procedure|TRUS Biopsy|Standard of Care Treatment
186677|NCT02745496|Procedure|TRUS/FUSION Biopsy|Interventional Treatment
186678|NCT02745483|Device|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
186679|NCT02745470|Drug|Lixisenatide|Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
186680|NCT02745470|Other|Placebo|Normal saline injection before performing fMRI
186681|NCT02745444|Dietary Supplement|low-calorie formula diet|
186682|NCT02745444|Dietary Supplement|protein-restricted diet|
186683|NCT02745431|Drug|Oxytocin|
186684|NCT02745431|Drug|Placebo|
186685|NCT02745405|Other|Fat Suit|Participants wear a fat suit.
186686|NCT02745405|Other|Control Condition|Participants wear same clothing as intervention, but in their own size.
186687|NCT02745392|Drug|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
186688|NCT02745392|Drug|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
186689|NCT02745379|Procedure|BFPSCs+ DFDBA+ PRF|
186690|NCT02745379|Procedure|DFDBA + PRF|
186691|NCT02745366|Procedure|BFPSC+FDBA+PRF|
186692|NCT02745366|Procedure|FDBA+PRF|
186693|NCT02745353|Drug|naloxegol|
186694|NCT02745340|Other|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
186695|NCT02745314|Other|Frailty measurement|Frailty measurement under Fried at el criteria
186696|NCT02745314|Other|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
186697|NCT02745301|Other|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
186698|NCT02745288|Procedure|inferior alveolar nerve block|"A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.~The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood."
186699|NCT02745275|Behavioral|Peer-led Health Education|Peer-led health education
186700|NCT02745262|Other|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
186701|NCT02745249|Behavioral|Maternal Nutrition Behavior change|
186702|NCT02745236|Other|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
186703|NCT02745236|Other|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
186704|NCT02745223|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
186705|NCT02745223|Drug|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
186706|NCT02745210|Device|magnetic resoance imaging|acquisition of 13C spectroscopy in the brain
186707|NCT02745197|Dietary Supplement|Nutritional Supplement|Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
186708|NCT02745197|Dietary Supplement|Placebo|Participants will take 2 capsules, containing a placebo, 3 times per day.
186710|NCT02745171|Other|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
186711|NCT02745145|Drug|Abituzumab 1500 mg|Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
186712|NCT02745145|Drug|Abituzumab 500 mg|Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
186713|NCT02745145|Drug|Placebo|Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
186714|NCT02745132|Other|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.~Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.~Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)~(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
186715|NCT02745119|Drug|Lampalizumab|Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
186716|NCT02745106|Procedure|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
186717|NCT02745106|Device|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
186718|NCT02745106|Device|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:~punction of right jugular vein with Seldinger technique, introducer placement~insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.~positioning of swan-ganz catheter in pulmonary artery~direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)~calculating of indirect parameters (pulmonary vascular resistance)"
186719|NCT02745093|Drug|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
186720|NCT02745093|Drug|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
186721|NCT02745080|Biological|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
186722|NCT02745080|Biological|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
186723|NCT02745067|Behavioral|enhanced cognitive behavioral therapy|
186724|NCT02745054|Other|mgt of bleeding concerns/complications of oral anticoagulants|observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only
186725|NCT02745041|Drug|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]~FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
186726|NCT02745041|Other|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]~FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
186727|NCT02745028|Dietary Supplement|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
186728|NCT02745015|Procedure|non-surgical periodontal treatment|full-mouth scaling and root planing
186729|NCT02745002|Device|navigated bronchoscopy|
186730|NCT02744989|Device|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental group will receive the active stimulation: Intensity = 2 mA. Sequence duration = 20 minutes (ramp ud/ramp down 30 seconds). Total number of sessions = 10 (sessions twice daily for 5 days)
186731|NCT02744989|Device|Sham tDCS|The control group will receive the sham stimulation (placebo) following the same regimen. Sham stimulation consists of a 20 minutes session including 1 minute active stimulation (ramp up/ramp down 30 seconds, 2 mA) at the beginning and ending of the sessions.
186732|NCT02744976|Drug|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
186733|NCT02744976|Behavioral|Lifestyle recommendations|Standard lifestyle recommendations
186734|NCT02744963|Other|Free and convenient medicine access|
186735|NCT02744950|Procedure|Pulley stitches|
186736|NCT02744950|Procedure|Intermediate Repair|
186737|NCT02744937|Drug|Aspirin|aspirin is continued by its regular dosing
186783|NCT02744625|Drug|Propofol for light sedation|Propofol for light sedation
186784|NCT02744612|Drug|Brentuximab Vedotin|Given IV
186738|NCT02744924|Behavioral|Physical activity intervention|"The intervention is comprised of 5 steps:~Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals~Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails~Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.~Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.~Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
186739|NCT02744911|Device|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
186740|NCT02744911|Behavioral|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
186741|NCT02744911|Behavioral|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
186742|NCT02744898|Drug|Carboplatin AUC|
186743|NCT02744898|Drug|Abraxane|100mg/m2
186744|NCT02744885|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
186745|NCT02744885|Dietary Supplement|Placebo Comparator: Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
186746|NCT02744872|Drug|Felodipine|Felodipine 10 mg once daily or identical placebo
186747|NCT02744872|Drug|Placebo|Placebo
186748|NCT02744859|Other|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
186749|NCT02744846|Drug|Antibiotics exposure|
186750|NCT02744833|Drug|GMI-1271|
186751|NCT02744833|Drug|Enoxaparin Sodium (Lovenox®)|
186752|NCT02744820|Drug|GMC-252-L-Lysine Salt|1 dose by oral route, once a day, 28 days
186753|NCT02744820|Other|Placebo|Matching doses by oral route, once a day, 28 days
186754|NCT02744807|Other|Chronic endometritis|with or without Chronic endometritis
186755|NCT02744794|Device|Dermal Cooling System|Treatment with cryotherapy.
186756|NCT02744781|Device|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
186757|NCT02744768|Drug|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
186758|NCT02744768|Drug|Blinatumomab|"Upon induction:~patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
186759|NCT02744755|Biological|Adalimumab - GP2017|Adalimumab - GP2017
186760|NCT02744755|Biological|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
186761|NCT02744742|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
186762|NCT02744742|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
186763|NCT02744742|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
186764|NCT02744742|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
186765|NCT02744729|Drug|99mTc-3PRGD2|For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
186766|NCT02744716|Drug|Aspirin|low dose of Aspirin after operation
186767|NCT02744716|Device|intrauterine balloon|insert intrauterine balloon after operation
186768|NCT02744703|Drug|total-etch adhesive|comparator use of total-etch adhesive
186769|NCT02744703|Drug|CAPE-T|experimental group
186770|NCT02744703|Drug|self-etch adhesive|comparator use of total-etch adhesive
186771|NCT02744703|Drug|CAPE-S|experimental group
186772|NCT02744690|Drug|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
186773|NCT02744677|Device|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
186774|NCT02744664|Procedure|Cryotherapy|After entering the group subject receive Cryotherapy on lung cancer
186775|NCT02744664|Drug|Icotinib|After Cryotherapy, subjects begin Icotinib administration
186776|NCT02744651|Device|EUS-FNA|"Please note the text in section Arm description"
186777|NCT02744651|Device|EUS-Endodrill biopsy|"Please note the text in section Arm description"
186778|NCT02744638|Other|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
186779|NCT02744638|Other|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
186780|NCT02744638|Drug|Arilin|2 tablets Arilin 500mg for 7 days
186781|NCT02744625|Drug|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
186782|NCT02744625|Drug|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
186786|NCT02744599|Device|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
186787|NCT02744586|Behavioral|Strengthening Our Vows (SOV)|"Participants, led by a counselor, will discuss options to keep HIV from entering their relationship including both sex partners remaining monogamous, using condoms every time they have sex with outside partners, and being tested together with outside partners to ensure they are HIV negative (Together HIV Free Plan). Participants will discuss options in the event of an outside exposure to HIV including abstaining from having sex with their spouse or by using condoms every time they have sex with their spouse until they can be retested for HIV after 30 days (Protecting my Spouse Plan).~Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners."
186788|NCT02744586|Behavioral|Good Health Package Plus (GHPP)|Participants, led by a counselor, will discuss how to prevent, screen, and treat neglected tropical diseases (helminths and schistosomiasis), non-communicable diseases (hypertension and diabetes) and diarrheal diseases through basic hygiene and sanitation. The facilitator will demonstrate proper handwashing techniques and chlorination of water and discuss diet and lifestyle changes. Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will also be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.
186789|NCT02744560|Dietary Supplement|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
186790|NCT02744547|Dietary Supplement|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
186791|NCT02744534|Drug|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.~Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
186792|NCT02744534|Procedure|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.~The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.~This biopsy process is estimated to take about 10 minutes."
186793|NCT02744534|Procedure|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
186794|NCT02744521|Other|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
186795|NCT02744508|Drug|palonosetron|
186796|NCT02744508|Drug|palonosetron with dexamethasone|
186797|NCT02744495|Drug|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
186798|NCT02744495|Drug|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
186799|NCT02744482|Drug|risedronate|risedrante tablet (75 mg)
186800|NCT02744482|Drug|placebo|risedrante placebo tablet (75 mg)
186801|NCT02744469|Other|No intervention (observational study)|
186802|NCT02744456|Drug|Losartan|An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
186803|NCT02744456|Drug|Amlodipine|A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
186804|NCT02744456|Drug|Hydrochlorothiazide|A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
186805|NCT02744443|Dietary Supplement|Leucine|
186806|NCT02744443|Dietary Supplement|Placebo|
186807|NCT02744430|Drug|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
186808|NCT02744430|Other|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
186809|NCT02744417|Behavioral|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
186810|NCT02744417|Procedure|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
186811|NCT02744417|Drug|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
186812|NCT02744417|Drug|bupropion hydrochloride|bupropion hydrochloride 150mg
186813|NCT02744417|Drug|Varenicline|Varenicline 0,5mg
186814|NCT02744404|Device|POC EID|
186815|NCT02744391|Drug|Levodopa|
186816|NCT02744378|Drug|Tacrolimus 0.1%|This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
186817|NCT02744378|Drug|Clobetasol 0.05%|This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
186818|NCT02744365|Other|Observational|"All women of the biobank have provided:~blood samples (plasma, serum and Buffy-coat)~urine samples~demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)~mean arterial blood pressure~ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)~access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
186819|NCT02744352|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
186820|NCT02744352|Drug|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
186821|NCT02744339|Drug|Riociguat|Adempas up-titrated to max. 1.5mg TID
186822|NCT02744339|Drug|Placebo|Placebo sham-titrated TID
186823|NCT02744326|Behavioral|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
186824|NCT02744300|Behavioral|BABI-2 Lifestyle Intervention|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
186825|NCT02744287|Biological|BPX-601|Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/Cluster Designation (CD)40 (iMC) co-stimulatory domain
186826|NCT02744287|Drug|Rimiducid|Dimerizer infusion to activate the iMC of the BPX-601 cells for improved proliferation and persistence
186827|NCT02744274|Other|Verum acupuncture|"Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi."
186828|NCT02744248|Drug|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
186829|NCT02744248|Drug|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
186830|NCT02744235|Device|Polysomnography Data|
186831|NCT02744235|Device|Jawbone UP®|
186832|NCT02744235|Device|Fitbit Charge ®|
186833|NCT02744222|Biological|BCD-054 180 mcg|180 mcg intramuscularly once every two weeks
186834|NCT02744222|Biological|Avonex®|30 mcg intramuscularly once a week
186835|NCT02744222|Biological|BCD-054 240 mcg|240 mcg intramuscularly once every two weeks
186836|NCT02744222|Other|Placebo|intramuscularly once a week (0,5 ml)
186837|NCT02744196|Biological|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
186838|NCT02744196|Drug|Placebo|Placebo solution will look identical to the Acellbia solution.
186839|NCT02744196|Drug|Methotrexate|
186840|NCT02744183|Behavioral|Exercise|Moderate intensity exercise
186841|NCT02744183|Behavioral|Breakfast|Breakfast consumption
186842|NCT02744183|Behavioral|Maintain habitual habits|Normal physical activity and dietary behaviors maintained
186843|NCT02744170|Device|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
186844|NCT02744170|Device|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
186845|NCT02744170|Device|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
186846|NCT02744157|Behavioral|Longterm effects after a structured lifestyle program|present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
186847|NCT02744131|Drug|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
186848|NCT02744131|Drug|Metformin 1500mgs per day|
186849|NCT02744118|Other|5A's Model|"The adapted 5A's model will include the following elements:~Ask the patient about their marijuana use~Advise every patient to quit/reduce marijuana use using clear, specific personalized advice~Assess factors affecting choice of behavior and behavior change~Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient~Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
186850|NCT02744118|Other|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:~Balance~Boundaries~Communication"
186856|NCT02744092|Drug|Warfarin|Anticoagulation therapy.
186860|NCT02744079|Behavioral|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
186861|NCT02744079|Behavioral|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
186862|NCT02744066|Device|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
186863|NCT02744053|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
186864|NCT02744053|Other|Laboratory Biomarker Analysis|Correlative studies
186865|NCT02744053|Radiation|Scintimammography|Undergo MBI
186866|NCT02744053|Drug|Technetium Tc-99m Sestamibi|Given via injection
186867|NCT02744040|Drug|ART initiation at time of HIV diagnosis|Immediate ART initiation
186868|NCT02744040|Drug|ART at 24 weeks|ART initiation 24 weeks after enrollment
186869|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)|Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories [TWIST]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
186870|NCT02744027|Other|Heavy Weighted T2 Imaging (T2W)|Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
186871|NCT02744027|Other|Lymph Node Access|"The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.~Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite."
186872|NCT02744014|Behavioral|Add-on Therapy for Axial Spondyloarthritis|
186873|NCT02744001|Other|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
186874|NCT02743988|Drug|Oxygen|Adapt inspired oxygen to achieve desired SpO2 target range
186875|NCT02743975|Drug|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
186876|NCT02743962|Device|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
186877|NCT02743962|Other|Routine physiotherapy control|This group will receive standard specialist physiotherapy intervention for bladder pain syndrome as stated in the arm descriptor, and will not use the therapeutic wand.
186878|NCT02743949|Drug|Vonoprazan|Vonoprazan over-encapsulated capsules
186879|NCT02743949|Drug|Esomeprazole|Esomeprazole over-encapsulated tablets
186880|NCT02743949|Drug|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
186881|NCT02743936|Device|Nasal cannula|Placement of nasal cannula under non-invasive positive pressure ventilation mask
186882|NCT02743936|Device|Non-invasive positive pressure ventilation|Non-invasive positive pressure ventilation
186883|NCT02743923|Drug|carboplatin|AUC 6
186884|NCT02743923|Drug|paclitaxel|200mg/m2
186885|NCT02743923|Drug|Bevacizumab|15 mg/kg
186886|NCT02743923|Drug|Pemetrexed|500 mg/m2
186887|NCT02743923|Drug|cisplatin|75 mg/m2
186888|NCT02743910|Other|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
186889|NCT02743910|Other|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available)
186890|NCT02743897|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
186891|NCT02743897|Drug|Mavyret|Mavyret (glecaprevir 100 mg and pibrentasvir 40 mg) is taken by mouth for 8 weeks. Study subjects with treatment failure will be provided an alternative DAA + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
186892|NCT02743884|Device|Esophageal Warming|30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
186893|NCT02743884|Device|Esophageal Cooling|30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
186894|NCT02743871|Biological|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
186895|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
186896|NCT02743871|Biological|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
186897|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
186898|NCT02743871|Biological|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
186899|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
186900|NCT02743871|Biological|PF-06817024|Subjects will be given 2 doses intravenously
186901|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
186902|NCT02743871|Biological|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
186903|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
186904|NCT02743858|Other|Bilateral arm measurements|will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder, and the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements.
186905|NCT02743858|Other|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
186906|NCT02743858|Behavioral|Quality of Life Questionnaire|
186907|NCT02743832|Procedure|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
186908|NCT02743832|Procedure|Resection for primary lesion|Resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
186909|NCT02743819|Drug|Pembrolizumab and Ipilimumab combination|
186910|NCT02743806|Drug|Vedolizumab|Vedolizumab IV infusion
186911|NCT02743793|Procedure|Blood Draw|
186912|NCT02743780|Drug|MGV354 ophthalmic suspension|
186913|NCT02743780|Drug|MGV354 placebo|Inactive ingredients used as placebo comparator
186914|NCT02743767|Procedure|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
186915|NCT02743754|Other|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
186916|NCT02743754|Other|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
186917|NCT02743741|Drug|Lutetium-177 Octreotate|Radiopharmaceutical
186918|NCT02743728|Device|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
186919|NCT02743728|Device|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
186920|NCT02743728|Behavioral|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
186921|NCT02743715|Device|Active tDCS (transcranial direct current stimulation)|An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
186922|NCT02743715|Device|Sham tDCS|The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
186923|NCT02743702|Other|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:~supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times~lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side~sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing~diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications~in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times~exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
186924|NCT02743702|Other|USUAL THERAPIES|
186925|NCT02743663|Procedure|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
186926|NCT02743663|Procedure|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
186927|NCT02743663|Procedure|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach ~2%. Each test in duplicate and average is calculated.
186928|NCT02743663|Procedure|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
186929|NCT02743663|Procedure|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
186930|NCT02743663|Drug|salbutamol|Given during bronchodilator response.
186931|NCT02743663|Procedure|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
186932|NCT02743663|Procedure|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
186933|NCT02743663|Procedure|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
186934|NCT02743663|Procedure|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
187106|NCT02742441|Drug|Vehicle Foam|Topical Foam containing no active drug
186935|NCT02743650|Dietary Supplement|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
186936|NCT02743637|Drug|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
186937|NCT02743624|Procedure|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
186938|NCT02743611|Biological|BPX-701|autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch
186939|NCT02743611|Drug|Rimiducid|dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity
186940|NCT02743598|Drug|Liraglutide|
186941|NCT02743585|Device|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in < 1 - 1.5 hours
186942|NCT02743585|Device|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
186943|NCT02743572|Other|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
186944|NCT02743572|Other|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
186945|NCT02743572|Other|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
186946|NCT02743572|Other|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
186947|NCT02743559|Device|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
186948|NCT02743546|Drug|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
186949|NCT02743546|Drug|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
186950|NCT02743520|Device|The Lifestar Act III|
186951|NCT02743494|Drug|Nivolumab|Specified dose on specified days
186952|NCT02743494|Other|Placebo|Specified dose on specified days
186953|NCT02743455|Drug|ISA-720|
186954|NCT02743455|Biological|MVA Smallpox Vaccine|MVA (Modified Vaccinia Ankara) Smallpox Vaccine is a highly attenuated live vaccinia virus.
186955|NCT02743455|Biological|MVA-BN Yellow Fever Vaccine|
186956|NCT02743455|Other|Placebo|Placebo
186957|NCT02743455|Biological|YF Vax 17D Strain|
186958|NCT02743442|Device|da Vinci® Si™|
186959|NCT02743429|Drug|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days."
186960|NCT02743416|Other|ECG screening (Zenicor-ECG) for atrial fibrillation|Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
186961|NCT02743403|Device|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
186962|NCT02743403|Device|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
186963|NCT02743403|Device|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
186964|NCT02743390|Biological|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
186965|NCT02743390|Other|Saline|Saline for 2 hours (250mL)
186966|NCT02743377|Other|PET|
186967|NCT02743377|Other|MRI|
186968|NCT02743364|Other|Laboratory Biomarker Analysis|Correlative studies
186969|NCT02743364|Other|Placebo|Given PO
186970|NCT02743364|Other|Quality-of-Life Assessment|Ancillary studies
186971|NCT02743364|Other|Questionnaire Administration|Ancillary studies
186972|NCT02743364|Drug|Simvastatin|Given PO
186973|NCT02743351|Biological|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
186974|NCT02743351|Biological|Control Arm|Untreated mobilized peripheral blood (mPB) cells
186975|NCT02743338|Behavioral|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
186976|NCT02743338|Behavioral|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
186977|NCT02743338|Behavioral|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
186978|NCT02743325|Procedure|SVT ablation by ALARA protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The usage of CartoUnivuTM allows a seamless combination of a fluoro image and Carto® 3 System maps into a single view.
186979|NCT02743325|Procedure|SVT ablation by conventional protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The convention Ablation procedure works without a 3D navigation System.
186980|NCT02743312|Device|Torso Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
186981|NCT02743312|Device|Sham Weights|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
186982|NCT02743312|Device|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
186983|NCT02743299|Device|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
186984|NCT02743286|Behavioral|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
186985|NCT02743286|Behavioral|Walking breaks|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
186986|NCT02743286|Behavioral|Stand more|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
186987|NCT02743260|Drug|pitavastatin|
186988|NCT02743260|Drug|Metformin|
186989|NCT02743260|Drug|digoxin|
186990|NCT02743260|Drug|Adefovir|
186991|NCT02743260|Drug|sitagliptin|
186992|NCT02743247|Drug|Tacrolimus|
186993|NCT02743247|Drug|Mycophenolate mofetil|
186994|NCT02743234|Other|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
186995|NCT02743234|Drug|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
186996|NCT02743234|Drug|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
186997|NCT02743221|Drug|Trifluridine/tipiracil + bevacizumab|Patients were treated withTrifluridine/tipiracil + bevacizumab regimen until they met a discontinuation criterion.
186998|NCT02743221|Drug|Capecitabine + bevacizumab|Patients were treated with capecitabine+ bevacizumab regimen until they met a discontinuation criterion.
186999|NCT02743208|Device|Short stem hip arthroplasty (SHA)|Furlong Evolution femoral stem
187000|NCT02743208|Device|Total hip arthroplasty (THA)|Furlong H-A.C. femoral stem
187001|NCT02743195|Dietary Supplement|Polyphenol/prebiotic blend|
187002|NCT02743182|Drug|Pegylated interferon alfa-2a|
187003|NCT02743169|Other|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
187004|NCT02743156|Procedure|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
187005|NCT02743156|Procedure|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
187006|NCT02743143|Behavioral|Exercise therapy|
187007|NCT02743143|Other|Follow-up care as usual|
187008|NCT02743130|Dietary Supplement|Blackcurrant Nectar|Consumption of a single dose (300 ml)
187009|NCT02743130|Dietary Supplement|Lingonberry Nectar|Consumption of a single dose (300 ml)
187010|NCT02743130|Dietary Supplement|Reference|Consumption of a single dose (300 ml)
187011|NCT02743117|Biological|Monovalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
187012|NCT02743117|Other|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
187013|NCT02743104|Drug|Ketamine|
187014|NCT02743104|Drug|Propofol|
187015|NCT02743104|Drug|midazolam and atropine|
187016|NCT02743104|Drug|Lidocaine|
187017|NCT02743078|Drug|Bevacizumab|Vascular endothelial growth factor A (VEGF-A) angiogenesis inhibitor
187018|NCT02743078|Device|TTFields|Tumor treating low intensity, intermediate frequency electric fields
187019|NCT02743065|Device|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
187020|NCT02743052|Drug|Anticoagulation treatment.|Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
187021|NCT02743039|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
187057|NCT02742766|Drug|GSK3008356|This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
187058|NCT02742766|Drug|Placebo|This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
187142|NCT02742155|Behavioral|Comparison|Behavioral: Information only
187143|NCT02742142|Other|water as placebo|topical application of water as a placebo in the control arm
187022|NCT02743026|Behavioral|FOXY|This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
187023|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI|
187024|NCT02743013|Drug|CHF 5993 100/6/12,5 DPI Test 1|
187025|NCT02743013|Drug|CHF 5993 100/6/12,5 DPI Test 2|
187026|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI replicate|
187027|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber|
187028|NCT02742987|Drug|Ticagrelor|Ticagrelor 90 mg twice daily
187029|NCT02742987|Drug|Clopidogrel|Clopidogrel 150 mg once daily
187030|NCT02742987|Drug|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
187031|NCT02742974|Device|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
187032|NCT02742961|Other|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
187033|NCT02742948|Drug|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
187034|NCT02742935|Biological|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
187035|NCT02742922|Behavioral|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
187036|NCT02742909|Drug|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
187037|NCT02742909|Drug|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
187038|NCT02742896|Other|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.~The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
187039|NCT02742883|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
187040|NCT02742870|Other|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.~The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
187041|NCT02742857|Biological|BQ-A Peptide Extract|BQ-A Peptide Extract
187042|NCT02742857|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells
187043|NCT02742857|Device|Transcranial Laser Therapy|Transcranial Laser Therapy
187044|NCT02742857|Device|Median Nerve Stimulator|Median Nerve Stimulator
187045|NCT02742844|Biological|APZ2 application|Application of IMP on patients wound.
187046|NCT02742831|Behavioral|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:~Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.~Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.~Problem solving techniques.~Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.~Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.~Reflection, repeat behavioral chain analysis. Update crisis plan."
187047|NCT02742831|Other|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
187048|NCT02742818|Device|Upper body blanket, Bair Hugger|Patients undergoing LEA and EVAR will use this device
187049|NCT02742818|Device|Underbody blanket, Bair Hugger|Patients undergoing LEA and EVAR will use this device
187050|NCT02742805|Dietary Supplement|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
187051|NCT02742805|Dietary Supplement|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
187052|NCT02742805|Drug|Omalizumab|Standard of care dose.
187053|NCT02742792|Other|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
187054|NCT02742792|Other|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
187055|NCT02742779|Drug|GDC-0310|Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
187056|NCT02742779|Drug|Placebo|Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
187256|NCT02741388|Drug|Cisplatin|
187059|NCT02742753|Other|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
187060|NCT02742740|Behavioral|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
187061|NCT02742727|Biological|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
187062|NCT02742714|Device|PillCam SBC system|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
187063|NCT02742701|Other|diagnosis|Measurement of glycosuria
187064|NCT02742688|Dietary Supplement|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
187065|NCT02742688|Dietary Supplement|Placebo|Placebo(4g/day)
187066|NCT02742675|Drug|Bicalutamide|Given orally
187067|NCT02742675|Drug|goserelin acetate|Given subcutaneously or as an injection
187068|NCT02742675|Drug|flutamide|Given orally
187069|NCT02742675|Drug|leuprolide acetate|Given subcutaneously or as an injection
187070|NCT02742675|Drug|triptorelin|Given subcutaneously or as an injection
187071|NCT02742675|Procedure|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
187072|NCT02742662|Device|Wearable technology, smartscale|
187073|NCT02742662|Behavioral|Smartphone applications|
187074|NCT02742662|Behavioral|Standard Weight Management Visits|
187075|NCT02742649|Drug|Fixed Combination|Continuous elution from the ocular insert.
187076|NCT02742649|Drug|Bimatoprost|Continuous elution from the ocular insert. This is an active control arm.
187077|NCT02742649|Drug|Timolol|Continuous elution from the ocular insert. This is an active control arm.
187078|NCT02742649|Device|Placebo Segment|One segment of placebo (no drug product)
187079|NCT02742649|Drug|Timolol 0.5%|0.5% timolol drops twice daily.
187080|NCT02742636|Device|Foley catheter|The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
187081|NCT02742623|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
187082|NCT02742610|Behavioral|Mindfulness with Contingency Management|
187083|NCT02742610|Behavioral|Active Control|
187084|NCT02742597|Behavioral|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
187085|NCT02742584|Procedure|Cough Stress Test|Varying bladder volumes during cough stress test.
187086|NCT02742571|Other|non applicable|
187087|NCT02742558|Biological|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
187088|NCT02742558|Biological|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
187089|NCT02742545|Behavioral|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
187090|NCT02742532|Drug|Oxytocin|Intranasal oxytocin 40 IU
187091|NCT02742532|Drug|Placebo|Intranasal saline solution
187092|NCT02742519|Drug|ivacaftor|
187093|NCT02742519|Drug|Placebo|
187094|NCT02742506|Other|Electroencephalography (EEG)|EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
187095|NCT02742493|Other|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
187096|NCT02742493|Other|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
187097|NCT02742493|Other|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
187098|NCT02742480|Drug|Dabigatran|
187099|NCT02742480|Drug|Acenocoumarol|
187100|NCT02742467|Drug|Perindopril plus Amlodipine|Group 1
187101|NCT02742467|Drug|Perindopril plus Hydrochlorothiazide|Group 2
187102|NCT02742467|Drug|Amlodipine plus Hydrochlorothiazide|Group 3
187103|NCT02742454|Procedure|Standard 30-60 Seconds Cord Clamping|The infant will be stimulated to breathe after birth. If the infant is not breathing well, the cord will be clamped at 30 seconds. If the baby is breathing well, the cord will be clamped at 60 seconds. Ventilatory assistance will be given after cord clamping.
187104|NCT02742454|Procedure|VentFirst 120 Seconds Cord Clamping|The infant will be stimulated to breathe after birth. If the infant is not breathing well, Positive Pressure Ventilation by face mask will be given starting at 30 seconds. If the baby is breathing well, Continuous Positive Airway Pressure (CPAP by face mask) will be given starting at 30 seconds. The cord will be clamped at 120 seconds.
187107|NCT02742428|Device|Systematic ascites evacuation|Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
187108|NCT02742428|Procedure|Acute paracentesis.|Evacuation of a large (>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
187109|NCT02742428|Behavioral|Interview.|Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
187110|NCT02742428|Behavioral|Quality of life.|Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
187111|NCT02742428|Behavioral|Nutritional status.|Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
187112|NCT02742415|Behavioral|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
187113|NCT02742402|Other|Diagnostic imaging|Abdominal ultrasound, followed by abdominal computed tomography when necessary
187114|NCT02742402|Other|Observation|Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.
187115|NCT02742389|Other|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
187116|NCT02742376|Other|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
187117|NCT02742376|Other|Floor|A marked path on the floor where the subject is instructed to walk.
187118|NCT02742376|Other|Kyboot shoes|Special shoes will be worn by the subject.
187119|NCT02742363|Other|Collecting data|
187120|NCT02742350|Device|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
187121|NCT02742324|Drug|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
187122|NCT02742324|Drug|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
187123|NCT02742311|Procedure|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
187124|NCT02742298|Device|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
187125|NCT02742298|Other|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
187126|NCT02742285|Drug|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
187127|NCT02742259|Device|Blood Draw|Blood draws only - non-diagnostic, non-treatment
187128|NCT02742246|Behavioral|Individual clinician-provided CBT|Individual clinician-provided CBT
187129|NCT02742246|Behavioral|CBT4CBT|CBT computer program assisted therapy
187130|NCT02742233|Drug|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment"
187131|NCT02742233|Drug|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment"
187132|NCT02742220|Other|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
187133|NCT02742220|Other|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
187134|NCT02742207|Other|Electrical atrial fibrillation Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
187135|NCT02742207|Other|Cardioversion|Electrical cardioversion for patients admitted for Atrial Fibrillation
187136|NCT02742194|Dietary Supplement|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
187137|NCT02742194|Dietary Supplement|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
187138|NCT02742181|Drug|Alvimopan|Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
187139|NCT02742181|Other|Control Group|Standard postoperative care
187140|NCT02742168|Radiation|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.~Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
187141|NCT02742155|Behavioral|Play2Sleep|Behavioral: Video self-modelling
187144|NCT02742142|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
187145|NCT02742129|Drug|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
187146|NCT02742129|Drug|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
187147|NCT02742116|Genetic|DNA screening before Pregnancy|"Saliva/swab shall be collected from couple for Hereditary Disease DNA screening test. Blood sample shall be taken by venipuncture of women for Fragile X carrier screening A pre-test questionnaire will be conducted to assess subject's knowledge, views and preferences in receiving expanded carrier screening, choice of having concurrent or sequential screening, factors affecting their choices, anxiety level, and their willingness to pay for the test.~A post-test self-administered questionnaire shall be filled in by the patient on receiving the test results.~Couples who receive a screen positive result shall be subsequently referred to Queen Mary Hospital for joint counselling by clinical geneticist and gynaecologist. This consultation shall be audiotaped or videotaped."
187148|NCT02742103|Biological|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
187149|NCT02742103|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
187150|NCT02742090|Drug|TGR-1202|
187151|NCT02742077|Device|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
187152|NCT02742064|Other|Cogito Companion Mobile Phone Application|
187153|NCT02742051|Drug|Everolimus|Neoadjuvant endocrine therapy
187154|NCT02742051|Drug|Letrozole|Neoadjuvant endocrine therapy
187155|NCT02742051|Drug|Fluorouracil|Neoadjuvant chemotherapy
187156|NCT02742051|Drug|Epirubicin|Neoadjuvant chemotherapy
187157|NCT02742051|Drug|Cyclophosphamide|Neoadjuvant chemotherapy
187158|NCT02742038|Other|Fluoride varnish plus education|Biannual varnish every 6 month/ 24 months plus educational component
187159|NCT02742025|Other|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
187160|NCT02742025|Other|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
187161|NCT02742025|Other|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
187162|NCT02742025|Procedure|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
187163|NCT02742012|Other|the study is observational|the study is observational
187164|NCT02741986|Other|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.~The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
187165|NCT02741973|Other|Yoga|
187166|NCT02741973|Other|School sport|
187167|NCT02741960|Drug|metformin|500 mg metformin three times daily
187168|NCT02741960|Drug|placebo|500 mg placebo three times daily
187169|NCT02741947|Drug|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
187170|NCT02741947|Drug|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
187171|NCT02741921|Device|VivaSight DL|intubation using VivaSight DL tube
187172|NCT02741921|Device|conventional double-lumen tube|intubation using conventional double-lumen tube
187173|NCT02741908|Behavioral|Calorie counting diet|
187174|NCT02741908|Behavioral|Fixed diet plan|
187175|NCT02741895|Behavioral|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
187176|NCT02741882|Other|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
187177|NCT02741869|Device|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
187178|NCT02741856|Drug|Carboplatin|For more information please see the arm descriptions section.
187179|NCT02741856|Drug|Paclitaxel|For more information please see the arm descriptions section.
187180|NCT02741856|Drug|Cisplatin|For more information please see the arm descriptions section.
187181|NCT02741856|Drug|Capecitabine|For more information please see the arm descriptions section.
187182|NCT02741856|Radiation|Radiotherapy|For more information please see the arm descriptions section.
187183|NCT02741843|Behavioral|Patient Education|
187184|NCT02741817|Drug|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
187185|NCT02741804|Dietary Supplement|BBH-1001 Brain Health Supplement|Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
187186|NCT02741804|Other|Lifestyle Intervention|All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
187257|NCT02741388|Drug|Cytarabine|
187258|NCT02741388|Drug|Gemcitabine|
187187|NCT02741804|Dietary Supplement|Brain Health Placebo|Treatment with placebo consisting of soybean oil
187188|NCT02741791|Drug|AXS-05|AXS-05 taken daily for 6 weeks.
187189|NCT02741791|Drug|Bupropion|Buproprion taken daily for 6 weeks.
187190|NCT02741778|Procedure|Minimally invasive group|In this group, all manipulations are finished by laparoscopy and thoracoscopy.
187191|NCT02741778|Procedure|Open group|Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
187192|NCT02741765|Behavioral|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
187193|NCT02741765|Other|Real rTMS|Subjects will participate in a combination of rTMS
187194|NCT02741765|Behavioral|Supervised aerobic exercise|
187195|NCT02741752|Procedure|Decortication|cortical bone perforation
187196|NCT02741739|Drug|REGN1033|
187197|NCT02741726|Device|acupoint stimulation|Electric stimulation was given through electrode attached to acupoints
187198|NCT02741726|Device|no stimulation|patients were only attached electrodes without electric current
187199|NCT02741713|Procedure|"PECS Pectoralis 1 and 2 Blocks"|"An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects."
187200|NCT02741713|Procedure|Interscalene Block|An interscalene block will be performed on the subjects.
187201|NCT02741713|Procedure|Sham Block|
187202|NCT02741713|Drug|Solution for Injection in Interscalene Block|20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
187203|NCT02741713|Drug|Solution for Injection in Sham Block|Lidocaine 1%
187204|NCT02741713|Drug|Solution for Injection PECS Blocks|10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
187205|NCT02741700|Behavioral|Improvement of Medication Adherence|The investigators have developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management. The objective of this study is to assess the efficacy of a novel storytelling intervention in Veteran's own voices to improve medication adherence and patient outcomes in African-American Veterans with gout.
187206|NCT02741687|Drug|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) > 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
187207|NCT02741687|Drug|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
187208|NCT02741687|Drug|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
187209|NCT02741687|Drug|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
187210|NCT02741687|Drug|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
187211|NCT02741687|Drug|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change~Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day~Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day~Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
187212|NCT02741674|Procedure|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
187213|NCT02741674|Procedure|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
187214|NCT02741674|Procedure|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
187215|NCT02741661|Other|No intervention. Observational study|No intervention
187216|NCT02741648|Device|Near Infrared Spectroscopy|INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
187217|NCT02741622|Behavioral|High aerobic intensity training (HIT)|One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
187218|NCT02741622|Behavioral|Long slow distance training (LSD)|One training session, long slow distance training (LSD) at 70 % of the HRmax
187219|NCT02741609|Device|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
187220|NCT02741596|Drug|DX-2930|Participants who rollover from the DX-2930-03 study will receive 300 milligram (mg) DX-2930 subcutaneous injection at Day 0 followed by second dose following the first HAE attack and then once in every 2 weeks until the end of the treatment period (up to 924 days). A wash-out period of a minimum of 10 days and a maximum of 18 days is required between subsequent administrations.
187221|NCT02741596|Drug|DX-2930|Participants who were not participants in DX-2930-03 will receive 300 milligram (mg) DX-2930 subcutaneous injection once in every 2 weeks until the end of the treatment period (up to 924 days).
187222|NCT02741583|Other|altitude rehabilitation program|altitude exposure
187223|NCT02741583|Other|rehabilitation program|Rehabilitation at low altitude
187224|NCT02741570|Biological|Nivolumab|
187225|NCT02741570|Biological|Ipilimumab|
187226|NCT02741570|Drug|Cetuximab/Erbitux|
187227|NCT02741570|Drug|Cisplatin/Platinol|
187228|NCT02741570|Drug|Carboplatin/Paraplatin|
187229|NCT02741570|Drug|Fluorouracil/Adrucil|
187230|NCT02741557|Drug|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
187231|NCT02741557|Drug|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
187232|NCT02741557|Drug|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
187233|NCT02741531|Other|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
187234|NCT02741531|Other|saline solution|Saline solution will be used to partially fill patients' bladders
187235|NCT02741518|Biological|Fecal Microbiota Transplantation|This is pre-screened fecal material that has been encapsulated
187236|NCT02741518|Other|Placebo|These are capsules that have no fecal material in them.
187237|NCT02741505|Device|Actigraph|Participants will be asked to wear an actigraph
187238|NCT02741492|Procedure|Transversus Abdominis Plane Block|Continuous Nerve Block
187239|NCT02741492|Procedure|Sham Block|Continuous Sham Catheter
187240|NCT02741479|Other|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
187241|NCT02741466|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. Formulation number - SR16-01.
187242|NCT02741453|Procedure|Standard Practice|
187243|NCT02741453|Procedure|Bilateral IJ Ultrasound Scanning|
187244|NCT02741427|Other|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
187245|NCT02741427|Other|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
187246|NCT02741427|Other|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
187247|NCT02741414|Device|The result of H pylori culture based on gram staining and enzyme activity testing|This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
187248|NCT02741414|Device|The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole|The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
187249|NCT02741414|Device|The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing|The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
187250|NCT02741401|Other|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
187251|NCT02741401|Other|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
187252|NCT02741388|Drug|selinexor|
187253|NCT02741388|Drug|Rituximab|
187254|NCT02741388|Drug|Dexamethasone|
187255|NCT02741388|Drug|Oxaliplatin|
187259|NCT02741375|Device|Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)|All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
187260|NCT02741362|Other|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
187261|NCT02741362|Other|Lipoaspiration|
187262|NCT02741336|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The~￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
187263|NCT02741336|Behavioral|Self-Monitoring|
187264|NCT02741323|Drug|Maraviroc|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR < 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
187265|NCT02741323|Drug|Placebo|"Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR < 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).~Once GFR is greater than or equal to 30, the dose should be returned to the non-renal dosage. If GFR is consistently fluctuating (especially immediately post-transplant), the site investigator may choose when to resume normal dosing of study product based on clinical assessment of stability."
187266|NCT02741310|Drug|Placebo|Administered by intravenous infusion
187267|NCT02741310|Drug|Sumatriptan|Administered by two 6 mg subcutaneous injections 1 hour apart on day 2 and day 5
187268|NCT02741310|Drug|Erenumab|Administered by intravenous infusion
187269|NCT02741297|Device|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
187270|NCT02741284|Drug|Room air|
187271|NCT02741284|Drug|10L Oxygen by nonrebreather mask|
187272|NCT02741271|Drug|MF MDI 100 mcg BID (Open Label)|Eligible participants will receive open-label MF MDI 100 mcg BID during a 2-week run-in period.
187273|NCT02741271|Drug|MF/F MDI 100/10 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF/F MDI 100/10 mcg BID.
187274|NCT02741271|Drug|MF MDI 100 mcg BID|After a 2 week run-in on open-label MF MDI 100 mcg BID, eligible participants will receive double-blinded treatment with MF MDI 100 mcg BID.
187275|NCT02741271|Drug|Albuterol/Salbutamol PRN|Participants may use study-provided short-acting beta agonist (SABA), albuterol/salbutamol, as needed (PRN) for the relief of asthma symptoms.
187276|NCT02741271|Drug|Prednisone/Prednisolone|Participants may use a systemic corticosteroid (prednisone/prednisolone) for acute asthma worsening per investigator discretion.
187277|NCT02741258|Device|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
187278|NCT02741258|Drug|skin cream|cream to treat skin erythema due to radiotherapy
187279|NCT02741245|Drug|Ezetimibe 10 mg|
187280|NCT02741245|Drug|Rosuvastatin 2.5 mg|
187281|NCT02741245|Drug|Placebo for Ezetimibe|
187282|NCT02741245|Drug|Placebo for Rosuvastatin|
187283|NCT02741232|Drug|Lidocaine 1% with epinephrine 1/400000|
187284|NCT02741232|Other|sham block|
187285|NCT02741219|Drug|Normal saline|Control Group receives normal saline bolus after delivery
187286|NCT02741219|Drug|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
187287|NCT02741219|Drug|Sufentanil|sufentanil PCA after surgery
187288|NCT02741219|Drug|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
187289|NCT02741206|Behavioral|Bellevue ROSE Intervention|
187290|NCT02741206|Behavioral|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
187291|NCT02741206|Behavioral|One Psycho-education session and usual, standard of care Control|
187292|NCT02741193|Device|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).~single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
187293|NCT02741180|Other|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
187294|NCT02741180|Other|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
187295|NCT02741167|Procedure|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
187296|NCT02741154|Drug|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
187297|NCT02741154|Drug|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
187298|NCT02741154|Drug|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
187299|NCT02741154|Drug|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
187300|NCT02741141|Other|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol."
187301|NCT02741141|Other|Classical partograph|Classical partograph used as standard care
187302|NCT02741128|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
187303|NCT02741128|Biological|Placebo (NaCl 0.9%) vaccine group|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
187304|NCT02741115|Drug|Udenafil|Active drug
187305|NCT02741115|Drug|Placebo|Matching Placebo
187306|NCT02741102|Procedure|Uterine Transplant|Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
187307|NCT02741089|Procedure|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.~The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
187308|NCT02741076|Drug|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Structured discontinuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
187309|NCT02741076|Drug|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)|Continuation of opioid therapy (morphine sulfate ER, oxycodone ER, oxymorphone ER)
187310|NCT02741063|Behavioral|screen low autistic subjects|screen subjects with low ASQ score
187311|NCT02741063|Behavioral|screen high autistic subjects|screen subjects with high ASQ score
187312|NCT02741063|Drug|oxytocin|intranasal administration of oxytocin (24 IU)
187313|NCT02741063|Drug|placebo|intranasal administration of placebo (24 IU)
187314|NCT02741050|Behavioral|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
187315|NCT02741050|Behavioral|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
187316|NCT02741037|Behavioral|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
187317|NCT02741037|Behavioral|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
187318|NCT02741037|Other|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
187319|NCT02741024|Drug|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
187320|NCT02741024|Drug|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
187321|NCT02741011|Other|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
187322|NCT02740985|Drug|AZD4635|AZD4635 will be administered orally as a nanosuspension on a continuous schedule in Arms A, B, C, D, E, F, G, H, I, J, K, KD, and L. The AZD4635 nanoparticle drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing. In Arms CA, CB, and CC AZD4635 will be administered as 25 mg or 50 mg capsules.
187323|NCT02740985|Drug|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
187324|NCT02740985|Drug|Abiraterone Acetate|"Abiraterone acetate 1000 mg PO QD will be given with prednisone BID. The patient must receive abiraterone/prednisone according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary abiraterone/ prednisone dose modifications may follow institutional standard practice.~Abiraterone acetate is supplied in 250 mg tablets."
187378|NCT02740647|Drug|Placebo|50 ml of 0.9% sodium chloride three times a day
187379|NCT02740634|Drug|F-18 AV 1451|Tau binding agent
187380|NCT02740634|Drug|C-11 PiB|Amyloid binding agent
187826|NCT02737150|Procedure|Local anesthesia with conscious sedation|
187325|NCT02740985|Drug|Enzalutamide|"Enzalutamide 160 mg PO QD will be dosed per the approved package insert. The patient must receive enzalutamide according to the prescribing information during the DLT assessment period, Cycle 1 and Cycle 2. After Cycle 2 necessary enzalutamide dose modifications may follow institutional standard practice.~Enzalutamide is supplied as 40 mg soft gelatin capsules."
187326|NCT02740985|Drug|Oleclumab|Oleclumab 1500 mg will be given by IV infusion on Days 1 and 15 of each cycle.
187327|NCT02740985|Drug|Docetaxel|"Patients in Cohort CC will receive docetaxel 75 mg/m² by IV infusion according to institutional standards of practice on Day 1 of each treatment cycle. If a patient's body surface area is greater than 2.2 m², the docetaxel dose will be adjusted to a body surface area of 2.2 m².~The patient should be pre-medicated with oral dexamethasone 8 mg (or equivalent) twice daily starting the day prior to treatment for a total of 3 days, or according to institutional standards of practice."
187328|NCT02740972|Drug|NS-065/NCNP-01|
187329|NCT02740972|Drug|Placebo|
187330|NCT02740959|Drug|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
187331|NCT02740959|Drug|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
187332|NCT02740946|Other|Exercise therapy|5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
187333|NCT02740933|Drug|Demeclocycline|
187334|NCT02740920|Drug|Pembrolizumab|
187335|NCT02740920|Procedure|CT Scan|
187336|NCT02740907|Procedure|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
187337|NCT02740894|Drug|Gefitinib|
187338|NCT02740881|Other|Counselor Training Methods|
187339|NCT02740868|Drug|Xenon-129|Xenon gas to be inhaled by research participants
187340|NCT02740868|Device|Magnetic Resonance Imaging|Lung imaging will be performed for participants using MRI for all 3 arms
187341|NCT02740868|Device|Lung Clearance Index|Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
187342|NCT02740855|Device|Alcomed 3011®|Endtidal ethanol measurement
187343|NCT02740842|Behavioral|Interpersonal behavioral change communication|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
187344|NCT02740842|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
187345|NCT02740829|Drug|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
187346|NCT02740829|Drug|Intranasal placebo|Placebo
187347|NCT02740816|Other|Comparative blood analysis|Collection of menstrual blood and systemic blood
187348|NCT02740803|Other|Sodium fluoride toothpaste 1,450 ppmF|
187349|NCT02740803|Other|sodium monofluorophosphate toothpaste 1,450 ppmF|
187350|NCT02740803|Other|stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF|
187351|NCT02740803|Other|sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF|
187352|NCT02740803|Other|Amine fluoride toothpaste 1,400 ppmF|
187353|NCT02740803|Other|Non-fluoridated toothpaste 0 ppmF|
187354|NCT02740790|Biological|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
187355|NCT02740790|Biological|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
187356|NCT02740777|Biological|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
187357|NCT02740764|Other|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
187358|NCT02740751|Dietary Supplement|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
187359|NCT02740738|Device|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
187360|NCT02740738|Device|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
187361|NCT02740725|Other|Patching Therapy|Occlusion of a dominant eye with better best corrected visual acuity
187362|NCT02740725|Device|Interactive Binocular Treatment System|Dissociation of two eyes with more foveal stimulation to the amblyopic eye
187363|NCT02740712|Drug|Caffeine|200 mg (4 x 50mg) Tablet
187364|NCT02740712|Drug|Warfarin|10 mg (2 x 5mg) Tablet
187365|NCT02740712|Drug|Omeprazole|40 mg Tablet
187366|NCT02740712|Drug|Midazolam|5 mg/mL
187367|NCT02740712|Drug|digoxin|.25 mg Tablet
187368|NCT02740712|Drug|Vitamin K|10 mg Tablet
187369|NCT02740712|Drug|Rucaparib|200 & 300 mg tablet
187370|NCT02740699|Drug|Rosuvastatin|Participants will receive 20-40 mg once daily
187371|NCT02740699|Drug|Atorvastatin|Participants will receive 40-80 mg once daily
187372|NCT02740686|Other|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
187373|NCT02740673|Device|Driving simulator|Patients are asked to use a driving simulator to test their driving skills
187374|NCT02740660|Drug|Caffeine 100mg / Albuterol 4mg|
187375|NCT02740660|Drug|Placebo|
187376|NCT02740660|Behavioral|Family weight management counseling|
187377|NCT02740647|Drug|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
187381|NCT02740608|Device|OrganOx metra|Normothermic Machine Liver Perfusion
187382|NCT02740595|Other|one time exposure to e-cig with nicotine|one time exposure to e-cig vapor with nicotine
187383|NCT02740595|Other|one time exposure to e-cig without nicotine|one time exposure to e-cig without nicotine
187384|NCT02740595|Other|one time exposure to empty e-cig|one time exposure to empty e-cig (sham control
187385|NCT02740582|Drug|Tolcapone|
187386|NCT02740582|Drug|Placebo|
187387|NCT02740569|Other|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
187388|NCT02740556|Other|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
187389|NCT02740556|Device|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
187390|NCT02740556|Other|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
187391|NCT02740543|Drug|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
187392|NCT02740543|Drug|Placebo|
187393|NCT02740530|Device|Magstim® Rapid 2 machine|See Arms description
187394|NCT02740491|Other|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
187395|NCT02740465|Behavioral|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
187396|NCT02740465|Behavioral|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
187397|NCT02740452|Device|ligamys technique|Ligamys technique (device) or standard technique
187398|NCT02740452|Other|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
187399|NCT02740439|Other|Avocado|The intervention meals will contain 1 large avocado.
187400|NCT02740439|Other|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
187401|NCT02740426|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
187402|NCT02740400|Procedure|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
187403|NCT02740400|Procedure|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
187404|NCT02740387|Drug|OTO-104|
187405|NCT02740374|Device|ROTEM|ROTEM coagulation assessment and guided transfusion management.
187406|NCT02740374|Other|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
187407|NCT02740361|Behavioral|Deprexis, DeprexisPlus|Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
187408|NCT02740348|Behavioral|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
187409|NCT02740348|Behavioral|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
187410|NCT02740335|Drug|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
187411|NCT02740335|Drug|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
187412|NCT02740322|Procedure|Hum Test|The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.
187413|NCT02740322|Procedure|Weber Test|Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.
187414|NCT02740322|Device|Audiogram|A standard audiogram will be administered by an audiologist.
187415|NCT02740309|Behavioral|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
187416|NCT02740309|Behavioral|Treatment as usual|Facilitated community referral for mental health treatment
187417|NCT02740296|Other|No intervention|
187418|NCT02740283|Behavioral|glycemic monitoring|
187419|NCT02740283|Dietary Supplement|dietary guide|
187420|NCT02740270|Drug|GWN323|
187421|NCT02740270|Drug|PDR001|
187422|NCT02740257|Other|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
187423|NCT02740244|Device|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
187424|NCT02740244|Device|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
187425|NCT02740231|Drug|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
187426|NCT02740231|Device|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
187427|NCT02740218|Other|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
187428|NCT02740205|Other|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
187429|NCT02740192|Procedure|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
187430|NCT02740192|Procedure|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
187431|NCT02740192|Drug|Ropivacaine|Ropivacaine was used for the periarticular injection
187432|NCT02740192|Drug|Bupivacaine|Bupivacaine was used for the periarticular injection
187433|NCT02740179|Drug|Eplerenone|Eplerenone 50mg by mouth twice daily
187434|NCT02740179|Drug|Placebo|Placebo by mouth twice daily
187435|NCT02740179|Behavioral|Lifestyle Modification|Counseling regarding diet and healthy activity
187436|NCT02740166|Drug|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
187437|NCT02740153|Other|No Intervention Given|
187438|NCT02740127|Procedure|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
187439|NCT02740127|Drug|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
187440|NCT02740127|Drug|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
187441|NCT02740127|Drug|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
187442|NCT02740127|Drug|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
187443|NCT02740127|Drug|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
187444|NCT02740127|Behavioral|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
187445|NCT02740114|Drug|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
187446|NCT02740114|Drug|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
187447|NCT02740114|Drug|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
187448|NCT02740114|Behavioral|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
187449|NCT02740114|Behavioral|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
187450|NCT02740101|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
187451|NCT02740101|Drug|placebo treatment|intranasal administration of placebo (40 IU)
187452|NCT02740088|Other|Imaging test: 18F-NaF PET/CT|18F-NaF PET/CT as an imaging test
187453|NCT02740062|Device|NIBS system for evaluation and non invasive current stimulation|
187454|NCT02740049|Drug|VR588|Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
187455|NCT02740036|Device|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
187456|NCT02740023|Device|Hearing Aid (Phonak Audéo V90-13)|Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
187457|NCT02740023|Device|Hearing Aid (Successor of Phonak Audéo V90-13)|The successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90-13 will be fitted to the participants individual Hearing loss.
187458|NCT02740010|Device|EDOF Mini WELL Ready IOL|implant
187459|NCT02739997|Drug|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
187460|NCT02739997|Drug|metronidazole 500 mg|metronidazole 500 mg administered as an IV infusion
187827|NCT02737150|Procedure|General anesthesia|
187461|NCT02739984|Biological|Evolocumab|Administered by subcutaneous injection with an automated mini doser
187462|NCT02739984|Drug|Placebo to Evolocumab|Administered by subcutaneous injection with an automated mini doser
187463|NCT02739971|Behavioral|Low AGEs diet|Oral and written instructions on how to reduce AGEs in diet, mainly by changing cooking methods in addition to standard of care dietary guidance for type 2 diabetes
187464|NCT02739971|Behavioral|Standard of care dietary guidance for Type 2 diabetes|Oral and written instructions for standard of care dietary guidance for type 2 diabetes
187465|NCT02739958|Drug|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
187466|NCT02739958|Drug|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
187467|NCT02739945|Procedure|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
187468|NCT02739906|Drug|BioChaperone Human Insulin (HinsBet®)|BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
187469|NCT02739906|Drug|Insulin Lispro (Humalog®)|Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
187470|NCT02739906|Drug|Regular human insulin (Huminsulin® Normal)|Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
187471|NCT02739893|Procedure|Scope Guide Assist|"Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy."
187472|NCT02739893|Procedure|Standard procedure for colonoscopy|
187473|NCT02739880|Device|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule~The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .~Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
187474|NCT02739841|Other|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
187475|NCT02739841|Other|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
187476|NCT02739828|Biological|Adalimumab|Adalimumab
187477|NCT02739815|Drug|Normal Saline containing a prophylactic Antibiotic 1 g|500 ml of normal saline containing a prophylactic Antibiotic 1 g.
187478|NCT02739815|Drug|Tranexamic Acid|Tranexamic acid
187479|NCT02739802|Drug|Coppertone(BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.Formulation number - SR16-02.
187480|NCT02739789|Device|tDCS|tDCS
187481|NCT02739789|Device|Sham tDCS|Sham tDCS
187482|NCT02739776|Device|Thermographic imaging|Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
187483|NCT02739763|Biological|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
187484|NCT02739750|Other|No intervention|There is no intervention for this study. It is a MRS.
187485|NCT02739737|Other|Blinded manuscript|Blinded version of sham manuscript
187486|NCT02739737|Other|Unblinded manuscript|Unblinded version of sham manuscript
187487|NCT02739724|Procedure|Adnexal surgery|
187488|NCT02739711|Drug|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
187489|NCT02739698|Drug|Paclitaxel|
187490|NCT02739698|Procedure|Radical surgery-peritonectomy|
187491|NCT02739685|Device|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
187492|NCT02739685|Device|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
187493|NCT02739672|Drug|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
187494|NCT02739672|Drug|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
187495|NCT02739672|Drug|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
187496|NCT02739659|Device|carbon-ion radiotherapy|
187497|NCT02739646|Device|Functional MRI scan|7.0 Tesla functional MRI scan
187498|NCT02739633|Drug|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
187499|NCT02739633|Drug|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
187500|NCT02739620|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
187610|NCT02738723|Drug|EP|Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
187501|NCT02739607|Behavioral|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
187502|NCT02739594|Drug|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
187503|NCT02739594|Drug|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
187504|NCT02739581|Procedure|Endoscopic Variceal Ligation|
187505|NCT02739581|Drug|Non selective beta blocker|
187506|NCT02739581|Other|Placebo|
187507|NCT02739568|Drug|Pitolisant (BF2.649)|
187508|NCT02739568|Drug|Placebo|
187509|NCT02739555|Device|Thermal destruction with radiofrequency or laser|
187510|NCT02739555|Drug|Acide Zoledronique MEDAC|
187511|NCT02739542|Drug|Tecfidera|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
187512|NCT02739542|Drug|Placebo|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
187513|NCT02739529|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
187514|NCT02739516|Drug|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
187515|NCT02739516|Drug|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
187516|NCT02739516|Drug|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
187517|NCT02739503|Device|Ultrasound|Patients will receive ultrasound in the ultrasound unit at Hillel Yaffe Medical Center within 10 days before onset of induced or spontaneous labors. The ultrasound team has been trained in FHC , Estimated Fetal Weight (EFW) and Biparietal Diameter (BPD) measurement .Optimal ultrasound measurements of FHC and BPD will be obtained. The average of 3 fetal head circumference measurements will be recorded. Investigators consider the FHC and BPD to be optimal when a clear outline of the entire fetal skull is measured, and the landmarks (the thalamus, cavum septum pellucidum and choroid plexus in the atrium of the lateral ventricles) are visualized. Subsequent information of labor outcome as well as normal head circumference ,post-delivery will be obtained from maternal and neonatal medical records.
187518|NCT02739490|Procedure|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
187519|NCT02739477|Drug|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).~Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.~Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
187520|NCT02739464|Other|Exercise + SOC PT/OT|
187521|NCT02739464|Other|SOC PT/OT|
187522|NCT02739451|Procedure|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~low-flow oxygen [including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask]~or medium-flow oxygen [Venturi masks and medium-flow facemasks]"
187523|NCT02739451|Procedure|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher&Paykel, Courtaboeuf, France).
187524|NCT02739438|Other|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
187525|NCT02739438|Other|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
187526|NCT02739438|Other|Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
187527|NCT02739425|Device|Sentimag Device|The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
187528|NCT02739412|Biological|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
187529|NCT02739399|Drug|Phenylephrine|Intravenous administration
187530|NCT02739386|Biological|Ipilimumab|Intravenous monoclonal antibody injection
187531|NCT02739373|Drug|BMS-986189|
187532|NCT02739373|Other|Placebo|
187533|NCT02739360|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
187534|NCT02739347|Device|Active Trans-cranial direct-current stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
187535|NCT02739347|Device|Sham Trans-cranial direct current stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
187536|NCT02739334|Behavioral|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
187537|NCT02739334|Behavioral|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
187538|NCT02739321|Device|Sound to Sleep System|Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
187611|NCT02738710|Procedure|transumbilical incision|incision within umbilicus
188279|NCT02734004|Drug|Bevacizumab|Bevacizumab
187539|NCT02739308|Other|Proprioceptive Training|In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
187540|NCT02739308|Other|Control Group|The control group will not make the intervention and will continue with usual training fencing.
187541|NCT02739295|Drug|recombinant granulocyte - colony stimulating factor|
187542|NCT02739295|Drug|NaCl 0.9%|
187543|NCT02739282|Other|Systematic therapeutic drug monitoring|Blood samples with antiepileptic drug level measurement
187544|NCT02739269|Other|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
187545|NCT02739269|Other|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
187546|NCT02739256|Procedure|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
187547|NCT02739243|Behavioral|Tailored group intervention (PREPARE)|
187548|NCT02739243|Behavioral|Individual treatment as usual|
187549|NCT02739230|Drug|Exparel|
187550|NCT02739230|Drug|On-Q pain intra-articular catheter|
187551|NCT02739217|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
187552|NCT02739204|Drug|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
187553|NCT02739191|Device|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
187554|NCT02739178|Other|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
187555|NCT02739165|Drug|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
187556|NCT02739165|Drug|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
187557|NCT02739139|Dietary Supplement|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
187558|NCT02739126|Procedure|Radial EBUS biopsy|Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
187559|NCT02739126|Device|Types of Radial Ultrasound probes|The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
187560|NCT02739100|Drug|Triferic|
187561|NCT02739087|Procedure|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
187562|NCT02739087|Device|Magnetic resonance imaging|
187563|NCT02739061|Behavioral|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
187564|NCT02739061|Drug|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
187565|NCT02739061|Other|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
187566|NCT02739035|Drug|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
187567|NCT02739035|Drug|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
187568|NCT02739022|Behavioral|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
187569|NCT02739009|Drug|MOR106 single ascending doses, intravenous|
187570|NCT02739009|Drug|Placebo single ascending doses, intravenous|
187571|NCT02739009|Drug|MOR106 multiple ascending doses, intravenous|
187572|NCT02739009|Drug|Placebo multiple intravenous administrations|
187573|NCT02738996|Behavioral|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
187574|NCT02738996|Behavioral|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
187575|NCT02738996|Behavioral|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
187576|NCT02738983|Drug|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
187577|NCT02738983|Radiation|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
187578|NCT02738970|Drug|Trastuzumab|Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
187579|NCT02738970|Drug|Pertuzumab|Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
187607|NCT02738736|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
187608|NCT02738723|Radiation|SBRT|40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
187580|NCT02738957|Behavioral|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
187581|NCT02738944|Behavioral|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
187582|NCT02738944|Behavioral|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.~If a patient does not engage in treatment (<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
187583|NCT02738931|Drug|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
187584|NCT02738931|Drug|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
187585|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
187586|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
187587|NCT02738918|Drug|Nulojix (Belatacept)|Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
187588|NCT02738905|Drug|Rifaximin|One 550 mg tablet taken orally two times a day.
187589|NCT02738879|Drug|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
187590|NCT02738879|Drug|Placebo to sitagliptin|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
187591|NCT02738879|Drug|Metformin|At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
187592|NCT02738879|Drug|Metformin XR|At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
187593|NCT02738879|Drug|Insulin glargine|Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
187594|NCT02738866|Drug|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
187595|NCT02738866|Drug|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
187596|NCT02738853|Device|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of severe symptomatic aortic stenosis in subjects who are considered at high through extreme risk for surgical aortic valve replacement.
187597|NCT02738840|Procedure|MRI scan|MRI scan
187598|NCT02738827|Procedure|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
187599|NCT02738814|Drug|propofol|When severe emergence agitation(PAED > 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
187600|NCT02738801|Drug|GLPG1690 group 1|600 mg GLPG1690 q.d., administered as oral capsules
187601|NCT02738801|Drug|Placebo group 2|Oral capsules matching those of GLPG1690 group 1
187602|NCT02738788|Other|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).~Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.~After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
187603|NCT02738775|Biological|Ublituximab|
187604|NCT02738775|Drug|Placebo|
187605|NCT02738762|Other|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
187606|NCT02738749|Device|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
187609|NCT02738723|Radiation|IMRT|45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.
187612|NCT02738710|Procedure|Infra umbilical incision|incision about 1 cm below umbilicus
187613|NCT02738697|Drug|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
187614|NCT02738697|Procedure|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
187615|NCT02738671|Behavioral|Cognitive assessment|
187616|NCT02738671|Other|functional magnetic resonance imaging|
187617|NCT02738671|Other|olfactory function measurement|
187618|NCT02738671|Procedure|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
187619|NCT02738658|Device|Bioresorbable vascular scaffold|
187620|NCT02738658|Device|Everolimus-eluting stent|
187621|NCT02738645|Other|pneumonia|
187622|NCT02738632|Drug|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
187623|NCT02738632|Drug|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
187624|NCT02738632|Drug|Placebo for Hydrochlorothiazide|
187625|NCT02738619|Drug|Vitamin D3|1600 UI
187626|NCT02738619|Drug|placebo|placebo
187627|NCT02738606|Drug|Chemotherapy|
187628|NCT02738606|Other|Laboratory Biomarker Analysis|Correlative studies
187629|NCT02738606|Procedure|Metastasectomy|Undergo lung metastasectomy
187630|NCT02738606|Other|Quality-of-Life Assessment|Ancillary studies
187631|NCT02738606|Procedure|Therapeutic Conventional Surgery|Undergo hepatectomy
187632|NCT02738580|Drug|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
187633|NCT02738580|Drug|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
187634|NCT02738567|Procedure|patients undergoing surgery or medical procedure|
187635|NCT02738554|Other|Treatment cessation|Cessation of nucleoside analogue therapy following European Association for the Study of the Liver guidelines
187636|NCT02738541|Drug|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
187637|NCT02738541|Drug|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
187638|NCT02738528|Other|Mental practice and brushing guidance in patients with Parkinson Disease|
187639|NCT02738515|Drug|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
187640|NCT02738515|Drug|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
187641|NCT02738502|Drug|darunavir monotherapy|darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
187642|NCT02738489|Biological|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
187643|NCT02738476|Procedure|Patellofemoral arthroplasty|
187644|NCT02738450|Biological|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
187645|NCT02738450|Biological|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
187646|NCT02738450|Biological|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
187647|NCT02738437|Device|Kryptonite-bone cement|
187648|NCT02738424|Other|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
187649|NCT02738398|Radiation|FDG PET/CT|
187650|NCT02738385|Behavioral|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
187651|NCT02738385|Behavioral|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
187652|NCT02738372|Other|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
187653|NCT02738359|Procedure|optical colonoscopy|optical colonoscopy
187654|NCT02738359|Procedure|colon capsule endoscopy|colon capsule endoscopy
187655|NCT02738359|Diagnostic Test|fecal immunological test (FIT)|fecal immunological test (FIT)
187656|NCT02738346|Drug|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
187657|NCT02738346|Drug|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
187658|NCT02738346|Drug|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
187659|NCT02738346|Device|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
187660|NCT02738333|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
187661|NCT02738333|Drug|SOF|400 mg tablet administered orally once daily
187662|NCT02738333|Drug|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
187663|NCT02738320|Other|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
187664|NCT02738307|Other|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
187665|NCT02738294|Device|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
187666|NCT02738268|Device|Low-level laser therapy|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
187667|NCT02738268|Device|sham laser|
187668|NCT02738255|Device|Varnum mouthpiece|
187669|NCT02738242|Device|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
187670|NCT02738229|Drug|Valacyclovir|
187671|NCT02738229|Drug|placebo|
187672|NCT02738216|Behavioral|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
187673|NCT02738216|Behavioral|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
187674|NCT02738203|Drug|Vaginal 2% Lidocaine|Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
187675|NCT02738203|Drug|Surgical Lubricant Jelly|Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
187676|NCT02738190|Drug|Albumin|Albumin 5% added to blood priming solution
187677|NCT02738190|Biological|Fresh Frozen Plasma|Fresh Frozen Plasma added to blood priming solution
187678|NCT02738177|Drug|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
187679|NCT02738177|Drug|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
187680|NCT02738177|Drug|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) & 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
187681|NCT02738151|Drug|Insulin glargine, 300U/mL|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).
187682|NCT02738151|Drug|Insulin degludec, 100 U/mL|"Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 80 to 100 mg/dL (4.4 to 5.6 mmol/L).~Route of administration: subcutaneous"
187683|NCT02738151|Drug|Non-insulin anti-diabetic treatment|Background therapy: Oral Anti diabetics Drugs (OADs), Glucagon-like peptide-1 (GLP-1) receptor agonist.
187684|NCT02738138|Drug|ABT-493 coformulated with ABT-530|Tablet
187685|NCT02738112|Device|Encore System|Hyo-mandibular suspension
187686|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
187687|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
187688|NCT02738073|Drug|Control: Saline|
187689|NCT02738073|Drug|Tranexamic Acid|
187690|NCT02738060|Dietary Supplement|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.~Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
187691|NCT02738034|Other|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
187692|NCT02738021|Behavioral|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
187693|NCT02738008|Drug|ARC-520 Injection|IV injection
187694|NCT02738008|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
187695|NCT02738008|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
187696|NCT02738008|Drug|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
187697|NCT02737995|Drug|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
187698|NCT02737982|Procedure|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
187699|NCT02737969|Device|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
187700|NCT02737943|Drug|Moist Exposed Burn Ointment (MEBO)|is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.
187701|NCT02737943|Drug|Zagazig|Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
187702|NCT02737930|Drug|Fluoxetine|
187703|NCT02737930|Drug|Placebo|
187704|NCT02737917|Other|Oxygen|15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.
187705|NCT02737917|Other|Standard of care|Rapid sequence intubation
187706|NCT02737904|Other|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
187707|NCT02737904|Other|Usual care|Personalised in-patient rehabilitation programme
187708|NCT02737891|Drug|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
187709|NCT02737891|Drug|Placebo|
187710|NCT02737878|Behavioral|Aerobic Training|Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
187711|NCT02737878|Behavioral|Resistance Training|Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
187712|NCT02737878|Behavioral|Balance and Tone Training|Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
187713|NCT02737878|Behavioral|Balance and Tone Program|Six months of four times a week stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
187714|NCT02737865|Drug|Sonazoid|Sonazoid: Commercially available contrast material for ultrasonography
187715|NCT02737865|Device|Superb-Microvascular imaging|Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
187716|NCT02737852|Device|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
187717|NCT02737839|Other|Stepping On Education Program|
187718|NCT02737839|Other|Home visit|
187719|NCT02737839|Other|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
187720|NCT02737839|Other|Mini-Balance Evaluation Systems Test|"The Mini-BESTest includes 14-items that assess balance across four domains: 1) anticipatory postural adjustments, 2) reactive postural responses, 3) sensory orientation, and 4) stability in gait. Each item is rated on a 0-2 scale with 0 indicating poor balance and 2 indicating no impairment. The total possible score on the Mini-BESTest is 28 points~Balance testing will take approximately 15 minutes."
187721|NCT02737839|Other|GAITRite|"Gait will be assessed using the 4.87-m GAITRite~The GAITRite is a computerized mat that allows for measurement of spatiotemporal measures (e.g., gait velocity, stride length) of gait. We will measure gait in the following conditions: 1) comfortable forward, 2) fast-as-possible, and 3) dual-task. For comfortable forward, participants will be asked to walk at their self-perceived normal pace. For fast-as-possible, participants will be asked to walk as quickly and safely as possible. For dual-task, participants will be asked to walk at their comfortable pace forward while saying as many words that begin with a letter given to them just prior to the start of the trial. Participants will complete five trials of each condition. Gait testing will take approximately 15 minutes."
187755|NCT02737605|Drug|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
187756|NCT02737605|Drug|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
187757|NCT02737592|Device|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
187783|NCT02737423|Drug|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
187722|NCT02737839|Other|Precise measure of movement testing|We will conduct additional movement-based testing with participants wearing small, portable sensors (APDM, Inc., Portland, OR). These sensors allow for precise measurement of movement characteristics. The sensors will be worn on the outside of clothing and will be placed on the following body locations: 1) sternum, 2) low back, 3) right wrist, 4) left wrist, 5) right ankle, and 6) left ankle. The participants will wear these sensors during the following movement tasks: 1) Two Minute Walk Test, 2) Timed Up & Go, 3) Dual Timed Up & Go, 4) Stand and Walk (SAW), and 5) 360 Degree Turn test. These sensors will allow for capture of precise measures postural sway, arm swing, gait variability, and many other variables the proposed movement tasks.
187723|NCT02737826|Drug|Buprenorphine - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol.
187724|NCT02737826|Drug|Gabapentin - Phase II|Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
187725|NCT02737826|Drug|Placebo - Phase II|Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
187726|NCT02737826|Drug|Buprenorphine taper - Phase II|Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
187727|NCT02737813|Drug|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
187728|NCT02737813|Drug|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
187729|NCT02737800|Procedure|endometrioma aspiration|Transvaginal ultrasound guided aspiration
187730|NCT02737800|Drug|GnRh agonist ( Decapeptyl )|3 monthly doses of Decapeptyl 7.5mg intramuscular
187731|NCT02737800|Procedure|standard long stimulation protocol|Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size &serum estradiol.
187732|NCT02737787|Biological|WT1 Vaccine|
187733|NCT02737787|Drug|Nivolumab|
187734|NCT02737774|Drug|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
187735|NCT02737774|Drug|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
187736|NCT02737761|Behavioral|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
187737|NCT02737748|Drug|TWB-103 add-on Tegaderm|TWB-103 is the primary therapeutics with the use of Tegaderm as a wound-site protection
187738|NCT02737748|Drug|Placebo+Tegaderm|Placebo to TWB-103 with the use of Tegaderm as a wound-site protection
187739|NCT02737735|Drug|standard chemotherapy medicine combined with Chinese herbs|
187740|NCT02737735|Drug|standard chemotherapy medicine|
187741|NCT02737722|Drug|Bisphosphocin Nu-3|
187742|NCT02737722|Drug|Placebo|
187743|NCT02737709|Drug|Paclitaxel and Carboplatin regimen|Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
187744|NCT02737696|Behavioral|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
187745|NCT02737696|Behavioral|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
187746|NCT02737670|Drug|Sulodexide|25 mg morning and evening for 40 days
187747|NCT02737670|Drug|Placebo|1 tablet morning and evening for 40 days
187748|NCT02737644|Other|observation|This is an observational study
187749|NCT02737631|Device|"Trojan Chameleon Personal Lubricant"|
187750|NCT02737618|Device|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
187751|NCT02737605|Drug|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
187752|NCT02737605|Drug|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
187753|NCT02737605|Drug|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
187754|NCT02737605|Drug|Oral Placebo|Participants will receive matching placebo orally.
187825|NCT02737150|Device|Edwards Sapien 3|
187758|NCT02737579|Procedure|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
187759|NCT02737566|Behavioral|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
187760|NCT02737566|Other|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
187761|NCT02737553|Procedure|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
187762|NCT02737553|Procedure|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
187763|NCT02737527|Procedure|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
187764|NCT02737527|Device|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
187765|NCT02737527|Device|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
187766|NCT02737527|Device|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
187767|NCT02737527|Drug|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
187768|NCT02737527|Procedure|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
187769|NCT02737527|Procedure|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
187770|NCT02737514|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
187771|NCT02737514|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
187772|NCT02737514|Procedure|water exchange|Water will infused and removed during insertion phase of colonoscopy
187773|NCT02737501|Drug|Brigatinib|Brigatinib will be administered orally to eligible participants with locally advanced or metastatic ALK+NSCLC naive to ALK inhibitors at a dose of 90 mg QD for 7 days, then 180 mg QD, continuously, until disease progression, unacceptable toxicity, withdrawal of consent or death.
187774|NCT02737501|Drug|Crizotinib|Crizotinib will be administered to eligible participants with locally advanced or metastatic ALK+ NSCLC naive to ALK inhibitors as 250 mg orally BID, until disease progression, unacceptable toxicity, withdrawal of consent or death.
187775|NCT02737488|Behavioral|Trauma Systems Therapy (TST)|Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.
187776|NCT02737488|Behavioral|Treatment as Usual (TAU)|"Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.~The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency."
187777|NCT02737475|Drug|BMS-986178|Specified dose on specified days
187778|NCT02737475|Drug|Nivolumab|Specified dose on specified days
187779|NCT02737475|Drug|Ipilimumab|Specified dose on specified days
187780|NCT02737462|Drug|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
187781|NCT02737436|Drug|Intranasal Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
187782|NCT02737436|Drug|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
187784|NCT02737410|Behavioral|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
187785|NCT02737397|Drug|JMI-001 (SJP-304 and SJP-223)|
187786|NCT02737397|Drug|SJP-304|
187787|NCT02737397|Drug|SJP-223|
187788|NCT02737397|Drug|placebo|
187789|NCT02737384|Biological|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.~Conditioning regimen:~Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2~Graft: CD34+ cells positively selected cells from PBSC of the donor~Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
187790|NCT02737371|Drug|F901318 Dose level A oral|Adverse events days 1-10
187791|NCT02737371|Drug|Placebo dose level A oral|Placebo adverse events days 1-10
187792|NCT02737371|Drug|F901318 Dose level B oral|F901318 adverse events days 1-10
187793|NCT02737371|Drug|Placebo dose level B oral|Placebo adverse events days 1-10
187794|NCT02737371|Drug|F901318 Dose level C oral|F901318 adverse events days 1-10
187795|NCT02737371|Drug|Placebo Dose level C oral|Placebo adverse events days 1-10
187796|NCT02737358|Drug|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
187797|NCT02737358|Other|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
187798|NCT02737345|Other|Rotem|
187799|NCT02737332|Drug|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) Compared to SoluMatrix™ Abiraterone Acetate 500 mg
187800|NCT02737332|Drug|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ Abiraterone Acetate 500 mg Compared to Zytiga® 1,000 mg (4 x 250 mg qd)
187801|NCT02737319|Drug|Rosuvastatin|40 mg of rosuvastatin before angioplasty
187802|NCT02737306|Drug|PRO 140|Two 1 mL injections, 175mg/ml each, of PRO 140 to opposite sides of the abdomen.
187803|NCT02737293|Other|Control Diet|4-week intake of Control Diet 5 day rotating menu
187804|NCT02737293|Other|Med Diet|4-week intake of Med Diet 5 day rotating menu
187805|NCT02737293|Other|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
187806|NCT02737280|Device|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher & Paykel Healthcare) device
187807|NCT02737280|Device|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
187808|NCT02737267|Behavioral|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
187809|NCT02737267|Behavioral|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
187810|NCT02737254|Drug|Oxytocin|40 IU/ML nasal spray. One administration: children <40kg administer 12IU, children >40kg administer 24IU.
187811|NCT02737254|Drug|Placebo|NaCl 0,9 % nasal spray.
187812|NCT02737254|Other|Secure CBM training|Children are trained to interpret ambiguous maternal behavior in a secure way.
187813|NCT02737254|Other|Neutral CBM training|Children receive a training unrelated to the interpretation of maternal behavior.
187814|NCT02737241|Procedure|Low power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 50W holmium laser energy.
187815|NCT02737241|Procedure|High power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 100W holmium laser energy.
187816|NCT02737228|Drug|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
187817|NCT02737228|Drug|Gemcitabine|1000 mg/m^2 intravenously every week three times per cycle (4 weeks)
187818|NCT02737228|Drug|Erlotinib|100 mg per oral daily per cycle (4 weeks)
187819|NCT02737215|Device|CPAP|patients will receive CPAP therapy with Auto-CPAP
187820|NCT02737202|Drug|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
187821|NCT02737189|Procedure|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
187822|NCT02737189|Drug|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
187823|NCT02737176|Other|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
187824|NCT02737150|Device|CoreValve Evolut R|
187828|NCT02737137|Procedure|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
187829|NCT02737137|Procedure|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
187830|NCT02737124|Drug|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
187831|NCT02737124|Other|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
187832|NCT02737111|Behavioral|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
187833|NCT02737111|Behavioral|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
187834|NCT02737111|Behavioral|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
187835|NCT02737111|Behavioral|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
187836|NCT02737111|Behavioral|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
187837|NCT02737098|Other|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
187838|NCT02737098|Other|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
187839|NCT02737085|Biological|Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells|Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
187840|NCT02737072|Drug|LY2510924|Administered SQ
187841|NCT02737072|Drug|Durvalumab|Administered IV
187842|NCT02737059|Drug|Naloxegol|25mg daily
187843|NCT02737059|Drug|Codeine|30mg 4 times daily
187844|NCT02737059|Drug|codeine placebo|4 times daily (placebo will be made to match the codeine)
187845|NCT02737059|Drug|naloxegol placebo|placebo will match naloxegol, given daily
187846|NCT02737046|Drug|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
187847|NCT02737046|Drug|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
187848|NCT02737046|Drug|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
187849|NCT02737046|Drug|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
187850|NCT02737033|Drug|Rhodiola|Rhodiola rosea 800mg
187851|NCT02737033|Drug|Placebo|innocuous pill manufactured to mimic Rhodiola
187852|NCT02737020|Drug|Rhodiola|Rhodiola rosea 200mg pill up to four times a day
187853|NCT02737020|Drug|Placebo|up to four times a day
187854|NCT02737007|Drug|[14C]-GSK3191607|[14C]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of [14C]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of [14C] radioactivity.
187855|NCT02736994|Drug|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
187856|NCT02736994|Drug|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
187857|NCT02736994|Other|Water|Water
187971|NCT02736032|Procedure|Embryo transfer|The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy
188311|NCT02733705|Drug|propofol|propofol infusion
187858|NCT02736981|Behavioral|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
187859|NCT02736981|Behavioral|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
187860|NCT02736981|Behavioral|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
187861|NCT02736968|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
187862|NCT02736968|Other|Placebo|Placebo
187863|NCT02736955|Drug|Valbenazine|
187864|NCT02736942|Procedure|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
187865|NCT02736942|Procedure|TaTME|Transanal Total Mesorectal Excision
187866|NCT02736929|Behavioral|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
187867|NCT02736916|Radiation|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
187868|NCT02736916|Radiation|Conventional PCI|LD-SCLC patients with conventional PCI
187869|NCT02736903|Behavioral|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
187870|NCT02736903|Behavioral|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
187871|NCT02736890|Drug|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
187872|NCT02736890|Drug|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
187873|NCT02736877|Procedure|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
187874|NCT02736877|Procedure|Conventional Microscope|corneal transplantation guided by Conventional Microscope
187875|NCT02736851|Other|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.~At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
187876|NCT02736838|Device|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
187877|NCT02736838|Device|Laser Doppler|
187878|NCT02736825|Device|Ultherapy®|Focused ultrasound energy delivered below the surface of the skin
187879|NCT02736825|Device|Standard transducer|Commercially available transducer designed to deliver focused ultrasound energy below the surface of the skin, delivering one line of treatment at a time.
187880|NCT02736825|Device|Simulines transducer|New transducer designed to deliver focused ultrasound energy below the surface of the skin, delivering two lines of treatment simultaneously.
188585|NCT02731651|Procedure|open hysterectomy|Hysterectomy with laparotomy incision.
187881|NCT02736812|Biological|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are~Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~Usual pre-hospital care according to recommendations in best practices~Administration of FLYP"
187882|NCT02736812|Biological|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are~Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)~Usual pre-hospital care according to recommendations in best practices~Administration of Normale Saline Solution"
187883|NCT02736799|Device|Sham vibrating capsule|Sham device without vibration
187884|NCT02736799|Device|Vibrant Capsule (1 vibration)|1 vibration/min
187885|NCT02736799|Device|Vibrant Capsule (3 vibration)|3 vibration/min
187886|NCT02736799|Device|Vibrant Capsule (5 vibration)|5 vibration/min
187887|NCT02736773|Other|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
187888|NCT02736760|Drug|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.~5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
187889|NCT02736760|Procedure|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
187890|NCT02736747|Other|Cryotherapy|
187891|NCT02736747|Other|Placebo|
187892|NCT02736734|Drug|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
187893|NCT02736721|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
187894|NCT02736708|Device|probe based confocal laser endomicroscopy|real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
187895|NCT02736695|Drug|F-18 AV 1451|Tau binding agent
187896|NCT02736682|Drug|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
187897|NCT02736682|Drug|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
187898|NCT02736669|Behavioral|Energy Reduction|
187899|NCT02736656|Drug|SPN-812 ER|
187900|NCT02736630|Other|body temperature|intermittant tympanic temperature measurement during surgery
187901|NCT02736617|Drug|Ibrutinib|Given PO
187902|NCT02736617|Other|Laboratory Biomarker Analysis|Correlative studies
187903|NCT02736617|Biological|Obinutuzumab|Given IV
187904|NCT02736604|Drug|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
187905|NCT02736604|Drug|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
187906|NCT02736604|Device|laryngeal mask airway (LMA Supreme Size 3/4|
187907|NCT02736604|Drug|sevoflurane|
187908|NCT02736591|Drug|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
187909|NCT02736591|Drug|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
187910|NCT02736591|Drug|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
187911|NCT02736591|Drug|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
187912|NCT02736578|Drug|Cetuximab-IRDye800|Administered intravenously (IV) at 50 or 100 mg
187913|NCT02736578|Drug|Cetuximab|Administered as a 100 mg IV loading dose
187914|NCT02736565|Biological|pbi-shRNA™ EWS/FLI1 Type 1 LPX|
187915|NCT02736552|Drug|S-1 for 6 months|6 months S-1 after D2 resection
187916|NCT02736552|Drug|S-1 for 1 year|1 year S-1 after D2 resection
187917|NCT02736539|Drug|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
187918|NCT02736539|Drug|Placebo|Placebo treatment
187919|NCT02736526|Procedure|recession or resection of the horizontal extraocular muscles|
187920|NCT02736513|Drug|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
187921|NCT02736500|Drug|28 GBq 177Lu-DOTATATE|Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
187922|NCT02736500|Drug|22 GBq 177Lu-DOTATATE|Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
187923|NCT02736487|Device|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
188802|NCT02730117|Device|Mechanical ventilator|Invasive or noninvasive form of respiratory support
187924|NCT02736487|Device|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
187925|NCT02736474|Drug|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
187926|NCT02736474|Drug|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
187927|NCT02736474|Drug|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
187928|NCT02736474|Drug|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
187929|NCT02736461|Procedure|Floor repair surgery|
187930|NCT02736448|Drug|Capecitabine|oral low dose of capecitabine
187931|NCT02736448|Drug|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
187932|NCT02736448|Drug|SS-LAR|long acting octreotide or lanreotide
187933|NCT02736435|Device|Magnetic Resonance Guided High Intensity Focused Ultrasound|Direct treatment of uterine fibroids with MR-HIFU
187934|NCT02736435|Drug|leuprolide acetate for depot suspension|Treatment of uterine fibroids with leuprolide acetate prior to MR-HIFU
187935|NCT02736422|Other|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
187936|NCT02736409|Drug|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
187937|NCT02736409|Drug|Placebo|Matching Placebo dose
187938|NCT02736396|Other|fMRI|Functional MRI scan to be performed
187939|NCT02736396|Other|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
187940|NCT02736344|Device|BioNIR Ridaforolimus Eluting Coronary Stent|
187941|NCT02736331|Dietary Supplement|Treatment 1|Treatment 1 Beverage
187942|NCT02736331|Dietary Supplement|Treatment 2|Treatment 2 Beverage
187943|NCT02736318|Other|processed osteochondral allograft|
187944|NCT02736305|Drug|Regorafenib|Once a day for 21 days in a 28 days cycle
187945|NCT02736292|Behavioral|Mindfulness Practices for Healthcare Professionals|
187946|NCT02736279|Drug|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
187947|NCT02736266|Drug|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
187948|NCT02736240|Biological|7-valent pneumococcal conjugate vaccine|
187949|NCT02736240|Biological|13-valent pneumococcal polysaccharide conjugate vaccine|
187950|NCT02736227|Drug|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
187951|NCT02736214|Behavioral|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
187952|NCT02736201|Device|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
187953|NCT02736201|Other|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
187954|NCT02736188|Drug|Aceneuramic Acid Extended-Release Tablets|
187955|NCT02736175|Drug|Dexamethasone|
187956|NCT02736175|Other|Placebo Vehicle|
187957|NCT02736162|Other|No treatment (intervention) was administered|
187958|NCT02736149|Drug|ubenimex|
187959|NCT02736136|Behavioral|joint observation and video feedback|
187960|NCT02736123|Drug|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
187961|NCT02736123|Drug|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
187962|NCT02736084|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
187963|NCT02736071|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
187964|NCT02736071|Drug|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
187965|NCT02736071|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
187966|NCT02736071|Drug|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
187967|NCT02736058|Device|Trans- abdominal sonography|
187968|NCT02736058|Device|Trans-vaginal sonography|
187969|NCT02736058|Procedure|post-operative pathological specimen examination|
187970|NCT02736045|Device|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
187972|NCT02736032|Procedure|Serum Estradiol and Progesterone levels|Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation
187973|NCT02736032|Drug|GnRH agonist|GnRH agonist given on day 21 of the cycle preceding the embryo transfer
187974|NCT02736032|Drug|External Estradiol|Estradiol started on day1 of the cycle for endometrial prepartaion
187975|NCT02736032|Drug|Progesterone|progesterone as luteal phase support start after endometrium is well prepared
187976|NCT02736019|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
187977|NCT02736019|Drug|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
187978|NCT02736019|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
187979|NCT02736019|Drug|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
187980|NCT02736006|Other|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.~In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
187981|NCT02735980|Drug|Prexasertib|Administered IV
187982|NCT02735967|Other|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
187983|NCT02735967|Device|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
187984|NCT02735954|Other|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
187985|NCT02735928|Device|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 7.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
187986|NCT02735915|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
187987|NCT02735902|Drug|Vitamin K antagonist or direct oral anticoagulant treatment|"The Vitamin K antagonist or direct oral anticoagulant treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended if the treatment is AVK.~The Direct oral anticoagulant treatment : Apixaban 5 mg x2 or 2.5 mg X2, Edoxaban 30 ou 60 mg"
187988|NCT02735902|Drug|Aspirin|"Daily dose is between 75 mg and 100 mg.~Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."
187989|NCT02735889|Other|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
187990|NCT02735889|Other|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
187991|NCT02735889|Other|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
187992|NCT02735876|Drug|acalabrutinib|
187993|NCT02735876|Drug|ibrutinib|
187994|NCT02735876|Drug|rituximab|
187995|NCT02735863|Drug|ABX464|50 mg or 150mg once daily for 28 days
187996|NCT02735863|Drug|Placebo|ABX464 matching placebo
187997|NCT02735850|Drug|L19-IL2|L19-IL2 added to SBRT
187998|NCT02735850|Radiation|SBRT|
187999|NCT02735850|Other|No intervention|
188000|NCT02735837|Drug|Doxycycline Group|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
188001|NCT02735837|Drug|placebo topical gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
188002|NCT02735824|Procedure|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
188003|NCT02735824|Procedure|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
188004|NCT02735824|Procedure|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
188005|NCT02735811|Device|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
188006|NCT02735798|Drug|MM-302|
188007|NCT02735798|Drug|Trastuzumab|
188008|NCT02735785|Behavioral|Harnessing Online Peer Education (HOPE) Social Media Intervention|
188009|NCT02735772|Procedure|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
188010|NCT02735759|Device|Photoacoustic flow cytometry device|The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
188011|NCT02735746|Radiation|4D Computed Tomography (CT)|The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.
188012|NCT02735746|Radiation|Cone Beam CT|Daily cone beam CT imaging at each radiation treatment visit, as part of standard care
189005|NCT02728687|Drug|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
188013|NCT02735746|Radiation|Low-dose Cinefluorography|A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.
188014|NCT02735746|Device|Pulmonary Function Tests|"Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.~Research PFTs will be conducted at 4 and 12-months post radiation therapy"
188015|NCT02735733|Device|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
188016|NCT02735720|Other|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
188017|NCT02735720|Other|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
188018|NCT02735707|Drug|Hydrocortisone|50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
188019|NCT02735707|Drug|Ceftriaxone|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
188020|NCT02735707|Drug|Moxifloxacin or Levofloxacin|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
188021|NCT02735707|Drug|Piperacillin tazobactam|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
188022|NCT02735707|Drug|Ceftaroline|"The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.~Ceftaroline is not available at commencement."
188023|NCT02735707|Drug|Amoxicillin Clavulanate|The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
188024|NCT02735707|Drug|Macrolide administered for 3 days|"The dosing of and route of administration is not protocolised, the following guidance is provided:~Initial IV administration of a macrolide is strongly preferred~The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
188025|NCT02735707|Drug|Macrolide administered for up to 14 days|"The dosing of and route of administration is not protocolised, the following guidance is provided:~Initial IV administration of a macrolide is strongly preferred~The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.~The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted."
188026|NCT02735694|Drug|Cycloserine|Capsule containing 250 mg of Cycloserine
188027|NCT02735694|Drug|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
188028|NCT02735681|Procedure|meibomian gland probing|Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.
188029|NCT02735681|Procedure|Left eye Meibomian Gland Probing Control Group|There will be no probing in the left eye. This will be used as a control for the right eye.
188030|NCT02735668|Other|Shoulder Conventional Exercises|"The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~Mobilisation Joint Exercises.~Isometrics and Resisted Exercises (elastic bands)."
188031|NCT02735668|Other|Multimodal Physiotherapy|"The protocol consists in:~Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included."
188032|NCT02735668|Other|Scapular exercises|"The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation."
188033|NCT02735668|Behavioral|Therapeutic Education|"The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases."
188034|NCT02735655|Other|Physician's opinion|To get physician's opinion about the current global state of gastrointestinal endoscopy training programs and to identify the unmet needs and how to improve it through a web based questionnaire.
188035|NCT02735642|Behavioral|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
188036|NCT02735642|Behavioral|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
188037|NCT02735642|Behavioral|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
188071|NCT02735395|Procedure|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
188038|NCT02735642|Behavioral|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
188039|NCT02735642|Behavioral|High Risk Negative Cohort (N=185)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=185). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
188040|NCT02735642|Other|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).~All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
188041|NCT02735629|Drug|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
188042|NCT02735629|Drug|CX1739 - 600 mg|CX1739 - 600 mg
188043|NCT02735629|Drug|CX1739 - 900 mg|CX1739 - 900 mg
188044|NCT02735629|Drug|Placebo|Placebo to 300 mg CX1739
188045|NCT02735603|Drug|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
188046|NCT02735603|Other|Placebo|Naltrexone/bupropion placebo-matching tablets.
188047|NCT02735603|Drug|Moxifloxacin|Moxifloxacin tablet.
188048|NCT02735590|Drug|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
188049|NCT02735590|Drug|Rifapentine|Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
188050|NCT02735577|Drug|Disulfiram|Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
188051|NCT02735564|Procedure|Bariatric Surgery|
188052|NCT02735551|Drug|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
188053|NCT02735551|Other|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
188054|NCT02735551|Other|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
188055|NCT02735538|Procedure|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
188056|NCT02735538|Procedure|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
188057|NCT02735525|Device|Smartphone monitoring|Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
188058|NCT02735512|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
188059|NCT02735512|Other|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
188060|NCT02735499|Drug|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
188061|NCT02735486|Dietary Supplement|Ginger drink|300 ml ginger drink
188062|NCT02735486|Dietary Supplement|Placebo: Super pure water|Placebo: Super pure water
188063|NCT02735473|Drug|Choline bitartrate|
188064|NCT02735473|Drug|Placebo|
188065|NCT02735460|Device|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
188066|NCT02735434|Behavioral|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
188067|NCT02735434|Other|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
188068|NCT02735421|Drug|Adapalene 0.3% / BPO 2.5% gel|
188069|NCT02735421|Drug|Vehicle gel|
188070|NCT02735408|Other|Kinesiotape (KT)|
188072|NCT02735395|Drug|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
189252|NCT02726997|Drug|Carboplatin|Given IV
188073|NCT02735395|Drug|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
188074|NCT02735395|Drug|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
188075|NCT02735395|Drug|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
188076|NCT02735395|Drug|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
188077|NCT02735395|Other|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
188078|NCT02735395|Other|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
188079|NCT02735395|Other|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
188080|NCT02735395|Other|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
188081|NCT02735382|Behavioral|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
188082|NCT02735382|Behavioral|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
188083|NCT02735369|Drug|2% OC-10X|2% OC-10X
188084|NCT02735369|Drug|Placebo Comparator|Placebo
188085|NCT02735356|Drug|Itraconazole|Applied topically
188086|NCT02735356|Other|Placebo|Applied topically
188087|NCT02735343|Drug|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
188088|NCT02735343|Drug|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
188089|NCT02735330|Procedure|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
188090|NCT02735330|Procedure|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
188091|NCT02735330|Procedure|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
188092|NCT02735317|Drug|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade ＞ 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
188093|NCT02735317|Drug|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade ＞ 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
188094|NCT02735304|Other|Impression intervention|The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
188095|NCT02735291|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
188096|NCT02735278|Other|different test paradigms|
188097|NCT02735265|Behavioral|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
188098|NCT02735265|Behavioral|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
188099|NCT02735252|Other|Systemic therapy|Systemic therapy is selected by the physician and is not restricted by the study. Molecular testing will be performed on tissue and blood to identify patterns and relationships with clinical outcomes in each group.
188100|NCT02735239|Drug|Durvalumab|
188101|NCT02735239|Drug|Tremelimumab|
188102|NCT02735239|Drug|Oxaliplatin|IV administered Chemotherapy
188103|NCT02735239|Drug|Capecitabine|orally-administered chemotherapy
188104|NCT02735239|Radiation|Radiotherapy|
188105|NCT02735239|Drug|Paclitaxel|IV administered Chemotherapy
188106|NCT02735239|Drug|Carboplatin|IV administered Chemotherapy
188107|NCT02735239|Drug|5-fluorouracil (5-FU)|IV administered Chemotherapy
188108|NCT02735239|Drug|Leucovorin|orally-administered chemo-protective agent
188109|NCT02735239|Drug|docetaxel|IV administered Chemotherapy
188110|NCT02735226|Other|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
188193|NCT02734732|Drug|Ciprofloxacin|
188194|NCT02734719|Device|Bonestim|
188195|NCT02734706|Dietary Supplement|LRC™ capsule|Twice per day (BID), 9 weeks
188196|NCT02734706|Other|Placebo capsule|Twice per day (BID), 9 weeks
188111|NCT02735213|Device|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250~400 milliWatts of power(50% threshold power),150~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
188112|NCT02735213|Device|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55~60 milliwatts of power, 18~27 spots,the laser area is the corresponding leakage on mid-phase FA.
188113|NCT02735200|Drug|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
188114|NCT02735200|Other|Application of Aloe vera gel|"aloe vera gel will be applied~Dosage: 1 gram Duration: 120 days Frequency: Daily"
188115|NCT02735187|Device|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
188116|NCT02735187|Drug|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
188117|NCT02735174|Device|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
188118|NCT02735174|Other|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
188119|NCT02735174|Behavioral|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
188120|NCT02735174|Other|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
188121|NCT02735161|Other|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
188122|NCT02735161|Other|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
188123|NCT02735148|Other|Body Weight Supported Treadmill Training|"There were three intervention arms in this study,~Body Weight Supported Treadmill Training,~Conventional Training and~Combined Training."
188124|NCT02735135|Device|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
188125|NCT02735135|Device|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
188126|NCT02735135|Device|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
188127|NCT02735135|Device|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
188128|NCT02735122|Drug|acetaminophen Tablet|2 test acetaminophen 500 mg tablets
188129|NCT02735122|Drug|acetaminophen Caplet|2 commercial acetaminophen 500 mg caplets
188130|NCT02735122|Drug|ibuprofen Liquid-filled capsule|2 commercial ibuprofen 200 mg Liquid-filled capsules
188131|NCT02735122|Drug|Placebo Tablet|2 placebo tablets
188132|NCT02735122|Drug|Placebo Caplet|2 placebo caplets
188133|NCT02735122|Drug|Placebo Liquid-filled capsule|2 placebo Liquid-filled capsules
188134|NCT02735109|Other|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
188135|NCT02735109|Procedure|biopsy normal area|biopsy done to compare with abnormal area
188136|NCT02735096|Device|EquiCue (Intraoral Electronic Balance Aid)|When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
188137|NCT02735083|Biological|UCART19/ALLO-501 follow-up|UCART19/ALLO-501 will not be administered during the study period. Patients who will be rolled-over from the parent study to this long term follow-up study, have previously received UCART19/ALLO-501 but also a lymphodepletion regimen with: fludarabine and cyclophosphamide with or without alemtuzumab or ALLO-647. The roll-over occurs at the end of the parent study, or at any time after UCART19/ALLO-501 administration, in case of premature discontinuation from the parent study.
188138|NCT02735070|Drug|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
188139|NCT02735070|Drug|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
188140|NCT02735057|Drug|Carboplatin|
188141|NCT02735044|Drug|Insulin glargine,300 U/mL|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 milligram/deciliter (mg/dL) (5.0 to 7.2 millimol per liter [mmol/L])
188142|NCT02735044|Drug|Insulin glargine (100 units /mL)|Subcutaneous injection in the morning or evening using a prefilled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L)
188143|NCT02735044|Drug|Background therapy|Fast-acting mealtime insulin analogs
188144|NCT02735031|Drug|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
188145|NCT02735031|Drug|Placebo|6 weeks treatment with placebo on top of insulin treatment
188146|NCT02735018|Drug|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
188147|NCT02735018|Drug|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
188148|NCT02735005|Other|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.~The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
188197|NCT02734693|Drug|dasotraline 4mg|dasotraline 4mg/day
188198|NCT02734693|Other|Placebo|placebo/day
188199|NCT02734680|Radiation|Concurrent chemoradiotherapy(CCRT)|Radiation and take gemcitabine(GEM)
189006|NCT02728687|Drug|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
188149|NCT02734992|Behavioral|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hour. The control group will receive the ACT intervention following the completion of the 3-months follow-up assessment of the treatment group. Participants in both groups will complete primary and secondary outcome scales, as well as ACT process effects scales at pre, post and 3-months follow-up. The treatment group only will be also assessed at 6 and 12-months follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou & Karekla, 2015). Techniques will focus on key ACT processes aiming at promoting psychological flexibility for the head pain experience.
188150|NCT02734992|Behavioral|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of the 3 months follow-up assessment of the ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
188151|NCT02734979|Device|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
188152|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
188153|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
188154|NCT02734966|Drug|Tiopronin Injection|Tiopronin Injection 200mg OD
188155|NCT02734953|Drug|Nitric Oxide|Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
188156|NCT02734940|Drug|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
188157|NCT02734940|Drug|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
188158|NCT02734940|Drug|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
188159|NCT02734940|Drug|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
188160|NCT02734940|Drug|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
188161|NCT02734927|Other|realization of computerized exercises|
188162|NCT02734914|Device|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
188163|NCT02734914|Device|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
188164|NCT02734901|Dietary Supplement|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
188165|NCT02734901|Dietary Supplement|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
188166|NCT02734901|Dietary Supplement|Placebo|1x daily intake of 600 mL raspberry deprived supplement
188167|NCT02734888|Other|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
188168|NCT02734875|Other|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
188169|NCT02734862|Drug|CD101|Intravenous antifungal therapy
188170|NCT02734862|Drug|Caspofungin|Intravenous antifungal therapy
188171|NCT02734862|Drug|Fluconazole|oral antifungal therapy
188172|NCT02734862|Drug|intravenous placebo|normal saline
188173|NCT02734862|Drug|oral placebo|microcrystalline cellulose
188174|NCT02734849|Drug|AK001 low dose|A low dose of AK001 will be administered as multiple doses
188175|NCT02734849|Drug|AK001 high dose|A high dose of AK001 will be administered as multiple doses
188176|NCT02734849|Drug|Placebo|Placebo will be administered as multiple doses
188177|NCT02734836|Device|Balloon Angioplasty|
188178|NCT02734836|Other|Optical Coherence Tomography|
188179|NCT02734823|Other|Cytology Specimen Collection Procedure|Undergo collection of serum
188180|NCT02734823|Other|Laboratory Biomarker Analysis|Correlative studies
188181|NCT02734823|Other|Questionnaire Administration|Ancillary studies
188182|NCT02734823|Procedure|Ultrasonography|Undergo transvaginal pelvic ultrasonography
188183|NCT02734810|Drug|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
188184|NCT02734784|Procedure|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
188185|NCT02734784|Procedure|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
188186|NCT02734771|Drug|Brentuximab vedotin|
188187|NCT02734771|Drug|Rituximab|
188188|NCT02734771|Drug|Cyclophosphamide|
188189|NCT02734771|Drug|Doxorubicin|
188190|NCT02734771|Drug|Prednisone|
188191|NCT02734745|Device|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
188192|NCT02734732|Drug|Trimethoprim/Sulfamethoxazole|
188200|NCT02734680|Radiation|Stereotactic Radiotherapy(SBRT)|Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
188201|NCT02734680|Drug|S-1|Taking S-1 orally after radiation
188202|NCT02734667|Device|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
188203|NCT02734654|Procedure|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
188204|NCT02734628|Drug|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
188205|NCT02734628|Drug|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
188206|NCT02734615|Drug|LSZ102|LSZ102
188207|NCT02734615|Drug|LEE011|LEE011
188208|NCT02734615|Drug|BYL719|BYL719
188209|NCT02734602|Drug|Ketamine|Ketamine will be administered after the initial PET scan.
188210|NCT02734602|Behavioral|Cognitive Testing|Verbal and computer assessments will be given.
188211|NCT02734602|Radiation|PET|PET scan will involve infusion of a radiotracer.
188212|NCT02734602|Device|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale.
188213|NCT02734589|Other|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
188214|NCT02734589|Other|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
188215|NCT02734589|Other|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
188216|NCT02734576|Device|Venous Sinus Stenting|
188217|NCT02734563|Other|Collagen turnover|Type IV and V collagen synthesis and breakdown
188218|NCT02734550|Other|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
188219|NCT02734550|Other|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
188220|NCT02734537|Drug|Cisplatin|Given IV
188221|NCT02734537|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
188222|NCT02734537|Other|Laboratory Biomarker Analysis|Correlative studies
188223|NCT02734524|Biological|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell ＞1×10^9，q28d*4
188224|NCT02734524|Drug|Taxol|135-175mg/m2,q28d*4
188225|NCT02734524|Drug|Carboplatin|AUC=5,q28d*4
188226|NCT02734511|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
188227|NCT02734498|Device|Electroconvulsive Treatment (ECT) Right Unilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed unilateral on the right side.
188228|NCT02734498|Device|Electroconvulsive Treatment (ECT) - Bilateral|Intervention is electroconvulsive treatment (ECT) involves a brief electrical stimulation of the brain while the patient is under anesthesia. Performed Bilateral.
188229|NCT02734485|Device|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.~Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
188230|NCT02734485|Device|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
188231|NCT02734472|Other|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
188232|NCT02734459|Drug|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
188233|NCT02734446|Drug|Reuterin D3 drops|5 drops/day for 3 months
188234|NCT02734446|Other|Placebo|5 drops/day for 3 months
188235|NCT02734433|Drug|Pexidartinib|
188236|NCT02734420|Drug|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
188274|NCT02734056|Other|Music|Listening to music that the patient likes
188275|NCT02734056|Other|Control|Control
188276|NCT02734017|Other|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
188277|NCT02734004|Drug|Olaparib|Olaparib
188237|NCT02734420|Drug|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
188238|NCT02734420|Device|Laser|
188239|NCT02734407|Procedure|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
188240|NCT02734407|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
188241|NCT02734394|Behavioral|Exercise|Cardiovascular and resistance exercise training
188242|NCT02734381|Other|Elderly patients|Elderly patients who visited the Emergency Department
188243|NCT02734368|Drug|Hyperpolarized Helium-3|
188244|NCT02734355|Drug|Telmisartan 80 mg and amlodipine 5 mg|
188245|NCT02734355|Drug|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
188246|NCT02734342|Other|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo & Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
188247|NCT02734329|Procedure|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
188248|NCT02734329|Procedure|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
188249|NCT02734316|Other|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
188250|NCT02734290|Drug|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
188251|NCT02734290|Drug|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
188252|NCT02734290|Drug|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
188253|NCT02734251|Dietary Supplement|Relora|750 mg/day
188254|NCT02734251|Dietary Supplement|Placebo|
188255|NCT02734238|Drug|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
188256|NCT02734238|Drug|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
188257|NCT02734225|Other|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
188258|NCT02734225|Other|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
188259|NCT02734225|Other|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
188260|NCT02734212|Behavioral|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
188261|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
188262|NCT02734186|Drug|Praziquantel|Anthelminthic
188263|NCT02734173|Drug|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
188264|NCT02734160|Drug|Galunisertib|Administered orally
188265|NCT02734160|Drug|Durvalumab|Administered IV
188266|NCT02734147|Drug|Ascorbic Acid|
188267|NCT02734147|Other|Normal Saline|
188268|NCT02734134|Procedure|One-stage exchange joint replacement surgery|
188269|NCT02734134|Procedure|Two-stage exchange joint replacement surgery|
188270|NCT02734121|Behavioral|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~Social worker (30 mins): values clarification exercise~Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
188271|NCT02734108|Device|Transcranial direct current stimulation|Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
188272|NCT02734095|Device|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
188273|NCT02734069|Drug|Carboplatin|Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
188278|NCT02734004|Drug|MEDI4736|MEDI4736
188280|NCT02733991|Device|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.~Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
188281|NCT02733991|Device|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
188282|NCT02733978|Device|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
188283|NCT02733965|Other|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.~Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).~These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
188284|NCT02733965|Other|No Pharmaceutical Consultations|
188285|NCT02733952|Drug|Tranexamic Acid|
188286|NCT02733952|Procedure|Pericervical Tourniquet|
188287|NCT02733939|Device|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:~leaves the home without notice, since this might occur in a moment of disorientation;~leaves a water tap open;~forgets something on the stove;~gets out of bed during the night and doesn't come back within a certain time interval;~never goes to the bathroom in 24 hours;~never opens refrigerator door in 24 hours.~Depending on the personal choice of the study participants, the kit will also :~automatically turn on a light to help avoid a fall during the night;~alert the caregiver when the temperature in the house falls or rises excessively;~act as burglar alarm in some areas of the home."
188288|NCT02733926|Other|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
188289|NCT02733900|Procedure|femoral head removal|
188290|NCT02733887|Device|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
188291|NCT02733887|Device|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
188292|NCT02733887|Radiation|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
188293|NCT02733874|Drug|Compound Clobetasol Propionate Ointment|
188294|NCT02733874|Drug|Calcipotriol Betamethasone Ointment|
188295|NCT02733848|Drug|Creon|"Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.~Formulations come in different fixed dose combinations as follows:~Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units~Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units~Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units~Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units~Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units"
188296|NCT02733848|Other|Diet|A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
188297|NCT02733848|Other|Placebo|Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
188298|NCT02733835|Drug|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
188299|NCT02733822|Drug|Naloxone|
188300|NCT02733809|Drug|Sorafenib|Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
188301|NCT02733783|Device|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
188302|NCT02733770|Procedure|Laparoscopic sleeve gastrectomy|Doppler ultrasound.
188303|NCT02733770|Procedure|Laparoscopic mini gastric bypass|Doppler ultrasound.
188304|NCT02733757|Drug|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
188305|NCT02733744|Biological|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
188306|NCT02733731|Drug|Chinese Herbal Compound Ointment|
188307|NCT02733731|Drug|Estriol|
188308|NCT02733718|Device|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
188309|NCT02733705|Other|Control|normal saline IV
188310|NCT02733705|Drug|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
188312|NCT02733692|Behavioral|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
188313|NCT02733679|Drug|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
188314|NCT02733679|Drug|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
188315|NCT02733666|Procedure|Absorbable screw group|Open reduction was performed and one absorbable screw was used for fixation in the experimental group
188316|NCT02733653|Device|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
188317|NCT02733640|Drug|Pantoprazole|pantoprazole 40 mg once-daily
188318|NCT02733640|Drug|Ranitidine|ranitidine 150 mg twice-daily
188319|NCT02733627|Drug|BI 1467335 low dose|
188320|NCT02733627|Drug|BI 1467335 medium dose|
188321|NCT02733627|Drug|BI 1467335 high dose|
188322|NCT02733627|Drug|Placebo|
188323|NCT02733614|Drug|SRX246|novel V1a receptor antagonist
188324|NCT02733614|Drug|Placebo|matching placebo
188325|NCT02733601|Other|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
188326|NCT02733588|Drug|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
188327|NCT02733575|Other|Compassion Focused Therapy|Up to 26 sessions of Compassion Focused Therapy
188328|NCT02733549|Other|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.~Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
188329|NCT02733536|Device|Standard endotracheal tube|1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
188330|NCT02733536|Device|C-MAC|C-MAC introduced with a h size 3 blade.
188331|NCT02733523|Behavioral|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
188332|NCT02733510|Drug|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
188333|NCT02733497|Procedure|Sympathectomy|Resection of ganglia at T3 level
188334|NCT02733497|Procedure|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
188335|NCT02733484|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
188336|NCT02733484|Dietary Supplement|Placebo|the patients in this arm will receive placebo intervention
188337|NCT02733471|Drug|Lidocaine|
188338|NCT02733471|Drug|Placebo|Placebo
188339|NCT02733458|Drug|GELAD|Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
188340|NCT02733458|Radiation|Radiotherapy|Radiotherapy: 50-56Gy
188341|NCT02733445|Drug|dasatinib|
188342|NCT02733445|Drug|nilotinib|
188343|NCT02733432|Drug|CD101 Vaginal Gel (3%)|CD101 Vaginal Gel (3%) intravaginally applied topical gel on Days 1 and 2
188344|NCT02733432|Drug|CD101 External gel (1%)|CD101 external gel (1%) applied topically twice daily over 72 hours as needed
188345|NCT02733432|Drug|CD101 Vaginal Ointment (6%)|CD101 vaginal ointment (6%) intravaginally applied topical ointment on Day 1
188346|NCT02733432|Drug|CD101 External ointment (1%)|CD101 external ointment (1%) applied topically twice daily over 72 hours as needed
188347|NCT02733432|Drug|Fluconazole|oral fluconazole (150mg) on Day 1
188348|NCT02733419|Drug|Enfuvirtide|Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
188349|NCT02733419|Drug|Optimized background antiretroviral regimen (OB)|Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
188350|NCT02733406|Other|Target Controlled Infusion|
188351|NCT02733406|Other|Velocity Controlled Infusion|
188352|NCT02733393|Procedure|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
188353|NCT02733393|Drug|lidocaine|
188354|NCT02733380|Drug|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
188355|NCT02733380|Drug|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
188356|NCT02733380|Drug|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
188357|NCT02733380|Drug|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
188358|NCT02733380|Drug|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
188359|NCT02733367|Drug|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
188360|NCT02733354|Device|watch viedo|
188361|NCT02733341|Drug|Cangrelor|
188362|NCT02733341|Drug|Ticagrelor|
188363|NCT02733328|Procedure|CPB Surgery|
188364|NCT02733315|Behavioral|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
188365|NCT02733302|Behavioral|Hope theory|Adapted Physical Activity
188366|NCT02733276|Other|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
188367|NCT02733276|Other|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
188368|NCT02733263|Dietary Supplement|15 g RMD|15 grams of resistant maltodextrin
188369|NCT02733263|Dietary Supplement|25 g RMD|25 grams of resistant maltodextrin
188370|NCT02733263|Dietary Supplement|0 g RMD|0 grams of resistant maltodextrin
188371|NCT02733250|Biological|Pembrolizumab|200mg IV Day 1 of each 21 cycles
188372|NCT02733250|Drug|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
188373|NCT02733237|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
188374|NCT02733237|Drug|placebo treatment|intranasal administration of placebo (40 IU)
188375|NCT02733211|Device|MD- Logic Closed Loop System|Closed Loop System
188376|NCT02733211|Device|sensor augmented pump therapy|Sensor augmented pump therapy
188377|NCT02733198|Other|Prognosis-guided therapy|
188378|NCT02733185|Drug|disodium EDTA|
188379|NCT02733185|Dietary Supplement|Oral Multi Vitamins/Minerals (OMVM)|
188380|NCT02733185|Drug|Placebo disodium EDTA|
188381|NCT02733185|Dietary Supplement|Placebo Oral Multi Vitamins/Minerals (OMVM)|
188382|NCT02733159|Drug|pembrolizumab|anti PD-1
188383|NCT02733146|Other|cardiac arrest|
188384|NCT02733133|Drug|Testagen® TDS Testosterone 5% HypoSpray®|Topically applied Testosterone Hormone Replacement Lotion
188385|NCT02733120|Other|stable isotope infusion|stable isotopes such as 15N2, TRP, 2H3-Leucine, L-[2H3]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-[Guanido-15N2]-Arginine, L-[ureido-13C-2H2]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
188386|NCT02733107|Drug|Apatinib|Apatinib, 250mg daily, po, continue until disease progression
188387|NCT02733107|Drug|Etoposide|Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
188388|NCT02733094|Drug|Secukinumab|
188389|NCT02733081|Procedure|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
188390|NCT02733068|Biological|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
188391|NCT02733068|Biological|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
188392|NCT02733055|Other|posturographic evaluation|subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
188393|NCT02733042|Drug|Durvalumab|
188394|NCT02733042|Drug|Lenalidomide|
188395|NCT02733042|Drug|Rituximab|
188396|NCT02733042|Drug|Ibrutinib|
188397|NCT02733042|Drug|Bendamustine|
188398|NCT02733029|Drug|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
188399|NCT02733029|Device|contrast enhanced ultrasonography|
188400|NCT02733003|Behavioral|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues.
188401|NCT02732990|Behavioral|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
188402|NCT02732977|Other|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
188403|NCT02732964|Other|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
188404|NCT02732964|Other|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
188405|NCT02732951|Drug|BI 1026706|
188406|NCT02732951|Drug|Placebo|
188407|NCT02732938|Drug|PF-04136309|PF-04136309 oral dosing
188408|NCT02732938|Drug|Nab-paclitaxel|Nab-paclitaxel IV dosing
188409|NCT02732938|Drug|Gemcitabine|Gemcitabine IV dosing
188410|NCT02732925|Device|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment~Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.~Below is a list of the conservative management they will be managed by their Doctor:~Bisphosphonates~Pain relief~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy"
188411|NCT02732925|Procedure|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.~Concomitant treatment with bisphosphonates~Pain relief as required~Systemic chemotherapy for Myeloma disease~Bed rest~Radiotherapy~Physiotherapy"
188412|NCT02732912|Device|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
188413|NCT02732912|Device|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
188414|NCT02732912|Drug|Zopiclone|This night sedation will be given to any patient requesting it, in either group
188415|NCT02732899|Drug|Sirolimus|
188416|NCT02732899|Drug|EYLEA|
188417|NCT02732886|Device|Medifoam®|Foam Dressing
188418|NCT02732886|Device|Betafoam®|Foam dressing including Betadine iodine
188419|NCT02732873|Device|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
188420|NCT02732860|Other|Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
188421|NCT02732847|Other|A delayed prescription dated 2 days after clinical office visit|
188422|NCT02732847|Drug|Usual Dated|
188423|NCT02732834|Behavioral|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
188424|NCT02732834|Behavioral|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
188425|NCT02732834|Behavioral|Audio recordings of clinical consultations|
188426|NCT02732834|Behavioral|Questionnaire|Patients will fill out a questionnaire about their perceived stigma and satisfaction with their clinician's communication.
188427|NCT02732834|Behavioral|2-hour empathic communication skills training|2-hour empathic communication skills training
188428|NCT02732834|Behavioral|Standardized Patient Assessments|pre-training SPA, post-training SPA
188429|NCT02732834|Behavioral|Training evaluation|Clinicians will complete an evaluation assessing the empathic communication training module.
188430|NCT02732834|Behavioral|Patient recruitment|6 of the clinician's patients (3 pre-training, 3 post-training) will be recruited to complete brief surveys assessing clinician communication
188431|NCT02732821|Procedure|Gastric Per Oral Endoscopic Myotomy|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
188432|NCT02732808|Drug|Ovulation stimulation|"Double stimulation in 2 phases:~Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.~Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection."
188433|NCT02732795|Other|Morphine pharmacokinetic evaluation|Each group received morphine and blood drawn to evaluate morphine PK
188434|NCT02732782|Other|Isometric exercise|
188435|NCT02732782|Other|Eccentric exercise|
188436|NCT02732769|Device|GammaKnifePerfexion®|neurosurgery
188437|NCT02732769|Device|GammaKnifeIcon®|neurosurgery
188438|NCT02732769|Device|Efficast®|Thermoformed mask
188439|NCT02732769|Device|MRI|
188440|NCT02732756|Behavioral|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
188441|NCT02732756|Behavioral|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
188442|NCT02732743|Dietary Supplement|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
188443|NCT02732730|Drug|Truvada|400 women who accept to initiate PrEP
188444|NCT02732717|Other|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.~Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
188445|NCT02732704|Device|JenaValve Pericardial TAVR System|TAVR with JenaValve Pericardial Valve and Delivery System
188446|NCT02732691|Device|JenaValve Pericardial TAVR System|Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.
188447|NCT02732678|Drug|PROPRANOLOL|
188448|NCT02732639|Drug|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
188449|NCT02732626|Procedure|radiofrequency ablation|
188450|NCT02732613|Device|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
188451|NCT02732600|Other|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
188452|NCT02732587|Drug|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
188453|NCT02732574|Device|Oscilatory Positive Expiratory Pressure (OPEP) device|OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
188454|NCT02732574|Device|SHAM Device Group|SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
188455|NCT02732561|Device|Alpha Stim device|cranial electrotherapy stimulation device
188456|NCT02732561|Device|Sham device|Sham device
188457|NCT02732548|Other|Negative Pressure Wound Therapy (NPWT)|
188458|NCT02732548|Other|MIRODERM Application(s)|
188459|NCT02732548|Other|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
188460|NCT02732535|Procedure|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
188461|NCT02732522|Drug|Sublingual misoprostol|
188462|NCT02732522|Drug|Vaginal misoprostol|
188463|NCT02732496|Behavioral|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
188464|NCT02732496|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
188465|NCT02732483|Drug|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
188466|NCT02732470|Other|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
188467|NCT02732431|Other|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
188468|NCT02732418|Drug|Depo-Provera CI|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
188469|NCT02732418|Drug|Depo-subQ 104|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
188470|NCT02732405|Drug|MK5172 /MK8742|tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
188471|NCT02732392|Procedure|standard lymphadenectomy|
188472|NCT02732392|Procedure|lymphadenectomy radio-isotope method|
188473|NCT02732379|Procedure|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
188474|NCT02732379|Procedure|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
188475|NCT02732379|Procedure|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
188476|NCT02732379|Procedure|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
188477|NCT02732366|Behavioral|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
188478|NCT02732366|Other|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
188479|NCT02732353|Dietary Supplement|Minced beef|Cow meat protein supplement
188480|NCT02732353|Dietary Supplement|Hydrolyzed beef|Cow meat protein supplement
188481|NCT02732340|Procedure|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
188482|NCT02732327|Drug|CAZ-AVI|Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
188483|NCT02732327|Drug|Vancomycin|15 mg/kg
188484|NCT02732327|Drug|Linezolid|600 mg
188485|NCT02732327|Drug|Cefepime|2 g
188486|NCT02732327|Drug|Meropenem|1 g
188487|NCT02732327|Drug|Piperacillin/tazobactam|4.5 g
188488|NCT02732314|Drug|Investigational OTC Cream|
188489|NCT02732314|Other|Cosmetic Eczema Cream|
188490|NCT02732314|Drug|0.05% Desonide Cream|
188491|NCT02732314|Other|Placebo Cream|
188492|NCT02732288|Dietary Supplement|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
188493|NCT02732275|Drug|DS-3201b|
188494|NCT02732262|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
189007|NCT02728674|Other|Person in the case is a male.|Person in the case is a male.
188495|NCT02732262|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
188496|NCT02732262|Drug|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
188497|NCT02732249|Drug|Esomeprazole|Given 30 min before morning and evening meals
188498|NCT02732249|Drug|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
188499|NCT02732249|Drug|Clarithromycin|Given 30 min after morning and evening meals
188500|NCT02732249|Drug|Metronidazole|Given 30 min after meals or at bedtime
188501|NCT02732236|Other|Rituximab|Cohort observation study
188502|NCT02732223|Dietary Supplement|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
188503|NCT02732223|Dietary Supplement|Control treatment|placebo supplements
188504|NCT02732197|Drug|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
188505|NCT02732197|Drug|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
188506|NCT02732184|Drug|Co-ArgI-PEG modified human arginase I|
188507|NCT02732171|Other|Plasma/Buffy Coat|3 x 10ml EDTA Tube
188508|NCT02732171|Other|Serum|1 x 8.5ml Serum Separator Tube
188509|NCT02732171|Other|Bone Marrow Aspirate|1 x 10ml EDTA Tube
188510|NCT02732158|Other|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
188511|NCT02732145|Diagnostic Test|"Three Rings Vulvoscopy (TRIV)"|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during Three Rings Vulvoscopy technique (TRIV Form Data). Assessing of the data by the Vulvoscopy Index and the N-S-P Scheme."
188512|NCT02732145|Procedure|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
188513|NCT02732132|Drug|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
188514|NCT02732132|Drug|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
188515|NCT02732119|Drug|Ribociclib|supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
188516|NCT02732119|Drug|Everolimus|supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
188517|NCT02732119|Drug|Exemestane|supplied in 25 mg tablets taken orally, daily for 28 day cycle
188518|NCT02732093|Procedure|stellate block|
188519|NCT02732093|Drug|Na.Cl 0.9% (placebo)|
188520|NCT02732093|Drug|lidocaine 2%|
188521|NCT02732080|Device|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
188522|NCT02732080|Device|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
188523|NCT02732067|Other|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
188524|NCT02732054|Biological|Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]|Different HBV vaccine regimen in each group
188525|NCT02732015|Drug|Dexamethasone|Given IV
188526|NCT02732015|Drug|Doxorubicin|Given IV
188527|NCT02732015|Drug|Doxorubicin Hydrochloride|Given IV
188528|NCT02732015|Drug|Fosaprepitant Dimeglumine|Given IV
188529|NCT02732015|Drug|Ifosfamide|Given IV
188530|NCT02732015|Other|Laboratory Biomarker Analysis|Correlative studies
188531|NCT02732015|Drug|Mesna|Given IV
188532|NCT02732015|Drug|Ondansetron|Given IV
188533|NCT02732015|Other|Questionnaire Administration|Ancillary studies
188534|NCT02732015|Drug|Rolapitant|Given PO
188535|NCT02732015|Drug|Rolapitant Hydrochloride|Given PO
188536|NCT02732015|Drug|Vincristine Sulfate|Given IV
188537|NCT02732002|Procedure|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
188538|NCT02731976|Other|Dietary intervention|
188539|NCT02731963|Drug|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
188540|NCT02731950|Drug|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
188541|NCT02731937|Device|GE Healthcare Revolution CT Scanner (CT Scanner)|Raw CT Scan Data
188542|NCT02731924|Procedure|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
188543|NCT02731911|Drug|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
188544|NCT02731885|Drug|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
188545|NCT02731885|Drug|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
188586|NCT02731651|Procedure|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
189008|NCT02728674|Other|Person in the case is a female.|Person in the case is a female.
188546|NCT02731872|Device|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.~Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
188547|NCT02731859|Device|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
188548|NCT02731846|Drug|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
188549|NCT02731846|Drug|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
188550|NCT02731846|Drug|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
188551|NCT02731846|Device|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
188552|NCT02731846|Drug|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
188553|NCT02731833|Other|stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
188554|NCT02731833|Other|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
188555|NCT02731820|Dietary Supplement|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
188556|NCT02731820|Dietary Supplement|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
188557|NCT02731820|Dietary Supplement|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
188558|NCT02731820|Dietary Supplement|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
188559|NCT02731807|Dietary Supplement|Dose A: TA-65 24mg, powder|
188560|NCT02731807|Dietary Supplement|Dose B: TA-65, 8mg, powder|
188561|NCT02731807|Dietary Supplement|Dose C: TA-65 3.2mg, capsule|
188562|NCT02731807|Dietary Supplement|Dose D: TA-65 8mg, capsule|
188563|NCT02731807|Dietary Supplement|Dose E: TA-65 32mg, capsule|
188564|NCT02731794|Device|left ventricular assist|In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
188565|NCT02731794|Procedure|Biventricular assist|In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
188566|NCT02731781|Other|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
188567|NCT02731768|Behavioral|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
188568|NCT02731768|Behavioral|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
188569|NCT02731768|Device|Fitbit Zip|
188570|NCT02731768|Device|Digital body weight scale|
188571|NCT02731755|Other|Oat|The study oat intervention products will consist of 67.7g oatflake and 22.5g oatbran concentrate.
188572|NCT02731755|Other|Control|60g cream of rice
188573|NCT02731742|Biological|MK-1966|MK-1966 administered as an intravenous (IV) infusion
188574|NCT02731742|Drug|SD-101|SD-101 administered as an intratumoral (IT) injection
188575|NCT02731729|Drug|ipilimumab|
188576|NCT02731729|Drug|nivolumab|
188577|NCT02731716|Behavioral|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
188578|NCT02731716|Behavioral|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
188579|NCT02731716|Behavioral|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
188580|NCT02731703|Device|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
188581|NCT02731690|Drug|Aceneuramic Acid Extended-Release|oral tablets
188582|NCT02731677|Other|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
188583|NCT02731664|Biological|GLP-1|Intravenous infusion of GLP-1
188584|NCT02731664|Biological|Intravenous saline|Control
189253|NCT02726997|Biological|Durvalumab|Given IV
188587|NCT02731638|Drug|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
188588|NCT02731638|Drug|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
188589|NCT02731625|Other|Kettlebell training|Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
188590|NCT02731625|Other|Army Physical Readiness Training|Army Physical Readiness Training per Army Field Manual 7-22
188591|NCT02731612|Drug|lurasidone|Atypical Antipsychotic
188592|NCT02731612|Other|Placebo|Inactive substance
188593|NCT02731599|Procedure|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
188594|NCT02731586|Drug|Allogenic Mesenchymal stem cells|Allogenic mesenchymal stem cells are introduced during placement of dental implants.
188595|NCT02731573|Drug|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
188596|NCT02731573|Procedure|Open heart surgery|Subject will undergo open heart surgery according to standard of care
188597|NCT02731560|Drug|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.~This was done either by a specialist nurse or a trained doctor."
188598|NCT02731547|Behavioral|Education Against Tobacco School-Based Intervention|
188599|NCT02731534|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
188600|NCT02731534|Drug|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
188601|NCT02731521|Device|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
188602|NCT02731521|Device|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
188603|NCT02731508|Device|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
188604|NCT02731495|Dietary Supplement|EGCG|EGCG (Epigallocatechin -3-gallate)
188605|NCT02731495|Dietary Supplement|Placebo (deionized water)|
188606|NCT02731482|Other|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.~Aerobic training in stepping training.~Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.~Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
188607|NCT02731482|Other|Control Group|"The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.~Participants will not receive any supervised physical training.~Once a week, patients will receive a phone call to provide support and general advice."
188608|NCT02731469|Biological|BCD-131|
188609|NCT02731469|Biological|Mircera®|
188610|NCT02731469|Biological|Aranesp®|
188611|NCT02731456|Other|altitude exposure|altitude exposure
188612|NCT02731443|Procedure|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
188613|NCT02731443|Procedure|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
188614|NCT02731430|Drug|intrathecal morphine|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
188615|NCT02731430|Drug|intrathecal saline|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
188616|NCT02731417|Other|acupuncture|Acupuncture for women with post partum urinary retention
188617|NCT02731417|Device|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
188618|NCT02731404|Procedure|HFJV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
188619|NCT02731404|Procedure|IPPV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
188620|NCT02731391|Procedure|Pelvic floor reconstruction（with or without mesh）|
188621|NCT02731378|Drug|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
188622|NCT02731378|Drug|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
188623|NCT02731378|Drug|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
188624|NCT02731378|Drug|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
188665|NCT02731066|Other|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
188666|NCT02731066|Other|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
188625|NCT02731365|Device|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
188626|NCT02731352|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o. in differentiated thyroid cancer
188627|NCT02731339|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
188628|NCT02731339|Behavioral|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
188629|NCT02731339|Behavioral|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
188630|NCT02731339|Behavioral|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
188631|NCT02731326|Device|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
188632|NCT02731326|Behavioral|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
188633|NCT02731313|Biological|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
188634|NCT02731300|Device|tDCS|brain stimulation by cathodal electrode at motor cortex
188635|NCT02731287|Drug|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
188636|NCT02731287|Drug|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
188637|NCT02731274|Other|Regular physical activity in Motor memory consolidation|After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
188638|NCT02731261|Other|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
188639|NCT02731248|Other|Prospective screening study|Prospective screening study in newborns
188640|NCT02731235|Other|High-intensity training|high intensity training 5 days a week for 12 weeks
188641|NCT02731235|Drug|prophylactic stroke medication|Usual care medication for stroke prophylaxis
188642|NCT02731235|Behavioral|Recommendations for lifestyle changes|Advise on diet, alcohol, smoking and exercise
188643|NCT02731222|Other|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
188644|NCT02731209|Device|urinary catheter|
188645|NCT02731196|Behavioral|Exercise Intervention|Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
188646|NCT02731183|Procedure|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
188647|NCT02731170|Behavioral|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
188648|NCT02731157|Drug|Rejuvesol|
188649|NCT02731157|Procedure|Blood transfusion|Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
188650|NCT02731144|Other|Peptamen intense|
188651|NCT02731144|Other|Novasource senior|
188652|NCT02731131|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
188653|NCT02731131|Drug|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
188654|NCT02731118|Dietary Supplement|Salovum|AF-enriched egg yolk
188655|NCT02731118|Dietary Supplement|Placebo|egg yolk
188656|NCT02731105|Drug|Acnatac® Gel left face|topical application
188657|NCT02731105|Drug|Epiduo® Gel right face|topical application
188658|NCT02731105|Drug|Acnatac® Gel right face|topical application
188659|NCT02731105|Drug|Epiduo® Gel left face|topical application
188660|NCT02731092|Dietary Supplement|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
188661|NCT02731079|Device|Covidien iDrive|Surgery performed with Covidien powered stapler
188662|NCT02731079|Device|Ethicon Echilon|Surgery performed with Ethicon powered stapler
188663|NCT02731066|Other|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
188664|NCT02731066|Other|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
188667|NCT02731053|Behavioral|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
188668|NCT02731040|Drug|Bisphosphonate|
188669|NCT02731014|Other|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
188670|NCT02731014|Other|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
188671|NCT02731014|Other|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
188672|NCT02731014|Other|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
188673|NCT02731001|Radiation|Proton therapy|
188674|NCT02731001|Radiation|Photon therapy|
188675|NCT02730988|Behavioral|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
188676|NCT02730975|Drug|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
188677|NCT02730975|Drug|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
188678|NCT02730975|Drug|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
188679|NCT02730962|Drug|Vancomycin|Vancomycin 3 times a day for 7 days
188680|NCT02730962|Other|Placebo|Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
188681|NCT02730962|Drug|Neomycin|Neomycin 3 times a day for 1 day
188682|NCT02730962|Drug|Clindamycin|Clindamycin 3 times a day for 5 days
188683|NCT02730962|Procedure|Fecal Microbiota Transplantation|FMT conducted via colonoscopy
188684|NCT02730949|Dietary Supplement|D-chiro-inositol|Treated group
188685|NCT02730949|Dietary Supplement|Folic Acid|Control group
188686|NCT02730936|Device|Antimicrobial Hernia Repair Device|hernia repair
188687|NCT02730923|Drug|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone~Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.~Route of Administration Oral~Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))~Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
188688|NCT02730923|Drug|Anastrozole|"Therapeutic Class Aromatase inhibitor~Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.~Route of Administration Oral~Dosage regimen~1 mg tablet once a day~Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
188689|NCT02730910|Other|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
188690|NCT02730910|Other|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
188691|NCT02730897|Procedure|Central/Peripheral|Central versus peripheral location of the primary tumor
188692|NCT02730884|Drug|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
188693|NCT02730884|Behavioral|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
188694|NCT02730871|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
188695|NCT02730871|Drug|Brinzolamide/brimonidine vehicle|Inactive ingredients used as placebo comparator
188696|NCT02730871|Drug|Travoprost 0.004%/timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
188697|NCT02730858|Behavioral|Palliative and Oncology Care|Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.
188698|NCT02730858|Behavioral|Standard Oncology Care|Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
188699|NCT02730845|Drug|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
188700|NCT02730845|Drug|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
188701|NCT02730832|Other|Questionnaires completed at D0|
188702|NCT02730832|Other|Questionnaires completed at D15 (test-retest for 30 patients)|
188703|NCT02730819|Drug|Illuminate Cream|Topical compound applied daily
189009|NCT02728674|Other|Symptom in the case is breathlessness.|Symptom in the case is breathlessness.
188704|NCT02730806|Behavioral|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
188705|NCT02730793|Drug|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
188706|NCT02730793|Drug|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
188707|NCT02730793|Drug|Nasal Placebo|Placebo (nasal saline twice per day)
188708|NCT02730780|Dietary Supplement|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
188709|NCT02730780|Dietary Supplement|High-Salt Diet|The high-salt diet (7 days) consists of each subjects usual diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
188710|NCT02730767|Behavioral|partially supervised exercise intervention|
188711|NCT02730741|Drug|Lcr restituo® sachet|symptomatic treatment of diarrhoea
188712|NCT02730741|Drug|Placebo|
188713|NCT02730728|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
188714|NCT02730728|Drug|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
188715|NCT02730728|Drug|5ml bolus of 0.5% ropivicaine|Local anesthetic
188716|NCT02730715|Drug|Basiliximab|Periodic blood collection to monitor Treg cells
188717|NCT02730715|Drug|Thymoglobulin|Periodic blood collection to monitor Treg cells
188718|NCT02730702|Device|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
188719|NCT02730689|Drug|DP-R207|
188720|NCT02730689|Drug|Rosuvastatin|
188721|NCT02730689|Drug|Ezetimibe|
188722|NCT02730676|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
188723|NCT02730676|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
188724|NCT02730663|Device|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
188725|NCT02730650|Other|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
188726|NCT02730637|Other|Early nephrologist consultation|
188727|NCT02730624|Drug|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
188728|NCT02730598|Device|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to ~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
188729|NCT02730598|Device|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
188730|NCT02730585|Biological|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
188731|NCT02730572|Drug|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
188732|NCT02730572|Drug|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
188733|NCT02730572|Drug|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
188734|NCT02730559|Other|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
188735|NCT02730546|Drug|Carboplatin|Given IV
188736|NCT02730546|Procedure|Computed Tomography|Undergo CT scan
188737|NCT02730546|Drug|Fluorouracil|Given IV
188738|NCT02730546|Other|Laboratory Biomarker Analysis|Correlative studies
188739|NCT02730546|Drug|Leucovorin Calcium|Given IV
188740|NCT02730546|Drug|Oxaliplatin|Given IV
188741|NCT02730546|Drug|Paclitaxel|Given IV
188742|NCT02730546|Biological|Pembrolizumab|Given IV
188743|NCT02730546|Procedure|Positron Emission Tomography|Undergo PET scan
188744|NCT02730546|Radiation|Radiation Therapy|Undergo radiation therapy
188745|NCT02730546|Procedure|Therapeutic Conventional Surgery|Undergo curative-intent surgery
188746|NCT02730533|Drug|Esomeprazole|Proton pump inhibitor
188747|NCT02730533|Drug|No PPI treatment|No PPI treatment before ESD procedure
188748|NCT02730520|Other|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
188801|NCT02730117|Device|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
189172|NCT02727660|Drug|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
188749|NCT02730507|Device|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
188750|NCT02730507|Device|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
188751|NCT02730494|Device|Lcr Regenerans® vaginal capsules|
188752|NCT02730494|Device|Lcr Regenerans® vaginal tablet|
188753|NCT02730481|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
188754|NCT02730455|Drug|natalizumab|Administered as specified in the treatment arm
188755|NCT02730455|Drug|Placebo|Matched placebo
188756|NCT02730442|Drug|F901318|Administration of F901318 intravenously
188757|NCT02730442|Drug|Fluconazole|Oral administration
188758|NCT02730429|Drug|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
188759|NCT02730429|Drug|Letrozole|Letrozole is standard of care in both arms
188760|NCT02730416|Drug|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
188761|NCT02730403|Other|Treatment As Usual|
188762|NCT02730377|Drug|liraglutide|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
188763|NCT02730377|Drug|alpha-glucosidase inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
188764|NCT02730377|Drug|DPP-4 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
188765|NCT02730377|Drug|meglitinides|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
188766|NCT02730377|Drug|SGLT-2 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
188767|NCT02730377|Drug|sulphonylurea|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
188768|NCT02730377|Drug|thiazolidinediones|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
188769|NCT02730364|Drug|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
188770|NCT02730351|Drug|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
188771|NCT02730351|Drug|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
188772|NCT02730351|Drug|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
188773|NCT02730351|Drug|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
188774|NCT02730338|Behavioral|High intensity aerobic and resistance training|
188775|NCT02730338|Behavioral|Psychosocial support|
188776|NCT02730325|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
188777|NCT02730325|Other|Placebo|
188778|NCT02730312|Biological|XmAb14045|Administered IV weekly up to 8 weeks, with or without induction dosing
188779|NCT02730299|Drug|NiCord® (omidubicel)|
188780|NCT02730299|Other|Cord Blood Unit|Cord blood unit
188781|NCT02730286|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
188782|NCT02730273|Device|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
188783|NCT02730260|Behavioral|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
188784|NCT02730260|Behavioral|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
188785|NCT02730247|Drug|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
188786|NCT02730247|Drug|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
188787|NCT02730234|Device|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
188788|NCT02730208|Drug|Tezacaftor/Ivacaftor|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
188789|NCT02730208|Drug|Ivacaftor|IVA 150 mg tablet.
188790|NCT02730208|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
188791|NCT02730208|Drug|Placebo|Placebo matched to IVA tablet.
188792|NCT02730195|Drug|Pioglitazone|Given PO
188793|NCT02730195|Drug|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
188794|NCT02730182|Other|altitude exposure|altitude exposure
188795|NCT02730169|Drug|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
188796|NCT02730169|Drug|Placebo|Capsules will be taken weekly for a maximum of 24 weeks
188797|NCT02730156|Other|Altitude exposure|Altitude exposure
188798|NCT02730143|Other|Altitude exposure|Altitude exposure
188799|NCT02730130|Drug|Pembrolizumab|
188800|NCT02730130|Radiation|Radiotherapy|
188803|NCT02730117|Drug|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
188804|NCT02730117|Drug|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
188805|NCT02730091|Drug|Letrozole|Letrozole 2.5 mg daily
188806|NCT02730091|Drug|Anastrozole|anastrozole 1 mg daily
188807|NCT02730091|Drug|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
188808|NCT02730078|Behavioral|VEMOFIT|The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
188809|NCT02730078|Behavioral|Attention-meetings (AG)|Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
188810|NCT02730065|Behavioral|Structured Aerobic Dance Training Group|Systematic physical activity
188811|NCT02730065|Behavioral|Stretching plus education|Weekly group based stretching with psychoeducation and health education
188812|NCT02730052|Device|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
188813|NCT02730052|Device|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
188814|NCT02730039|Behavioral|workshop|
188815|NCT02730039|Behavioral|follow-up calls & webinars|
188816|NCT02730039|Behavioral|assessments|
188817|NCT02730026|Drug|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
188818|NCT02730026|Drug|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
188819|NCT02730013|Behavioral|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.~In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
188820|NCT02730000|Procedure|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
188821|NCT02730000|Procedure|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
188822|NCT02729987|Behavioral|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
188823|NCT02729974|Procedure|ROTEM|rapid testing of blood clot formation
188824|NCT02729974|Procedure|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
188825|NCT02729961|Drug|Brentuximab Vedotin|Given IV
188826|NCT02729961|Drug|Ceritinib|Given PO
188827|NCT02729961|Other|Laboratory Biomarker Analysis|Correlative studies
188828|NCT02729961|Other|Pharmacological Study|Correlative studies
188829|NCT02729948|Other|Survey Administration|Ancillary studies
188830|NCT02729948|Device|Tethered Capsule Endoscope|Undergo TCE
188831|NCT02729935|Drug|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
188832|NCT02729935|Drug|Placebo|An equal volume of saline
188833|NCT02729922|Device|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
188834|NCT02729909|Drug|Lubiprostone|Lubiprostone capsules
188835|NCT02729909|Drug|Placebo|Lubiprostone placebo-matching capsules
188836|NCT02729896|Drug|Atezolizumab [TECENTRIQ]|"Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment.~NOTE: Atezolizumab treatment has been discontinued in all participants currently on study treatment."
188837|NCT02729896|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
188923|NCT02729272|Procedure|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
188838|NCT02729896|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
188839|NCT02729896|Drug|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
188840|NCT02729883|Other|Quality-of-Life Assessment|Ancillary studies
188841|NCT02729883|Other|Questionnaire Administration|Complete interviews
188842|NCT02729883|Procedure|Supportive Care|Receive patient navigation via the Take the Fight strategists
188843|NCT02729870|Drug|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
188844|NCT02729870|Other|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
188845|NCT02729857|Dietary Supplement|SFA muffin|Muffin rich in saturated fat.
188846|NCT02729857|Dietary Supplement|PUFA muffin|Muffin rich in polyunsaturated fat.
188847|NCT02729831|Behavioral|Interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
188848|NCT02729831|Behavioral|Video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
188849|NCT02729831|Behavioral|Provider Report|A short report that includes the patients' goals and treatment preferences
188850|NCT02729805|Drug|Saline|10ml bolus injection of saline followed by intravenous infusion of saline during the operation
188851|NCT02729805|Drug|Ketamine 0.5mg/kg|0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
188852|NCT02729805|Drug|Ketamine 0.75mg/kg|0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
188853|NCT02729792|Device|rTMS|intermittent theta burst stimulation (iTBS)
188854|NCT02729779|Other|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
188855|NCT02729779|Other|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
188856|NCT02729766|Other|Induced hypotonic hyponatremia - SIAD model|
188857|NCT02729766|Drug|Empagliflozin 25mg Tbl|
188858|NCT02729766|Drug|Placebo P-Tablet|
188859|NCT02729753|Device|CryoBalloon™ Full Ablation System|Tissue Ablation using CryoBalloon™ Full Ablation System
188860|NCT02729753|Device|CryoBalloon™ Swipe Ablation System|Tissue Ablation using CryoBalloon™ Swipe Ablation System
188861|NCT02729740|Device|Penumbra Smart Coil|
188862|NCT02729740|Device|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
188863|NCT02729727|Device|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
188864|NCT02729714|Drug|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
188865|NCT02729714|Drug|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
188866|NCT02729701|Drug|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
188867|NCT02729688|Device|customized pressure guide bandage|"Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.~For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level."
188868|NCT02729688|Device|Ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
188892|NCT02729506|Procedure|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
188924|NCT02729272|Procedure|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
188869|NCT02729675|Other|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F&V fresh.
188870|NCT02729675|Behavioral|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
188871|NCT02729675|Behavioral|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
188872|NCT02729662|Drug|Tolvaptan|"Before administration of tolvaptan~TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)~24-hour urine collection・Hematology/urinalysis: Once/year~Physical findings: Blood pressure and medical interview at ambulatory visit~Hospitalization for education and examination at the start of tolvaptan administration~24-hour urine collection・Hematology/urinalysis・Inulin clearance~Physical findings: Body weight, blood pressure~Adverse Events~After administration of tolvaptan~TKV・Liver capacity・inulin clearance: Once/year~24-hour urine collection: Once/6 months~Hematology/urinalysis: Once/month in principle~Physical findings: Blood pressure and medical interview at ambulatory visit~Adverse Events"
188873|NCT02729649|Device|ArmAssist robotic training|
188874|NCT02729649|Other|Conventional therapy|
188875|NCT02729649|Other|Extended conventional therapy|
188876|NCT02729636|Device|multi-pad functional electrical stimulation (FES)|"Treatment includes two automated phases: optimization of stimulation parameters and application during the walk.~Optimization of stimulation parameters: The stimulator generates short bursts of electrical impulses and sends them to each of the 16 pads of the multi-pad electrode. Each pad is the same size. Pads are sorted in two rows by 8 pads. Common anode is placed under the knee. Based on FES-induced foot movements, automated algorithm suggests parameters which are evaluated by medical doctor/therapist.~Assisted walking: During assisted walking, pattern for plantar flexion is activated in push off phase and pattern for dorsiflexion in swing phase of the gait."
188877|NCT02729636|Other|Conventional therapy|2. All study subjects received the conventional stroke rehabilitation program of physiotherapy based on the neurodevelopmental facilitation approach and occupational therapy focused on activities of daily living during the treatment for 60 min a day, 5 days a week, for 4-weeks. Conventional therapy was given by trained therapists and consisted of the following strategies: strategies to joint mobilization and range of motion exercises; exercises to improve strength; strategies to manage spasticity; exercises for increase range of motion, compensatory strategy; strategies to improve balance, and mobility.
188878|NCT02729623|Drug|Kite Systems cannaHALER cannabis Inhaler.|
188879|NCT02729610|Device|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
188880|NCT02729610|Device|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
188881|NCT02729597|Other|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
188882|NCT02729597|Other|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
188883|NCT02729597|Other|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
188884|NCT02729597|Other|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
188885|NCT02729571|Biological|MTBVAC|Live-attenuated tuberculosis vaccine
188886|NCT02729571|Biological|BCG|Commercially available live-attenuated tuberculosis vaccine
188887|NCT02729558|Radiation|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
188888|NCT02729545|Other|Tung's acupuncture|The study took Tung's acupoints as main acupuncture points, which were Fuke, Huanchao, Tianhuang, Renhuang, as well as the traditional acupoints Guanyuan (CV4) and Zigong (EX-CA1).
188889|NCT02729545|Drug|Cyproterone acetate/ethinylestradiol (CPA/EE)|Cyproterone acetate/ethinylestradiol (CPA/EE) contains 2mg cyproterone acetate (an anti-androgenic progestin) and 0.035mg ethinylestradiol (CPA/EE). The pills were administered for 21 days consecutively. The patients then stopped taking the pills for seven days and, on the eighth day, continued to take the pills again for three menstrual cycles (28 day cycles).
188890|NCT02729532|Device|Xpert|The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
188891|NCT02729519|Procedure|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
188925|NCT02729272|Device|Monopolar ESD|
188926|NCT02729272|Device|Ultrasonic ESD|
188893|NCT02729506|Procedure|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.~The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
188894|NCT02729493|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
188895|NCT02729480|Device|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
188896|NCT02729467|Drug|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
188897|NCT02729467|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
188898|NCT02729467|Drug|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
188899|NCT02729454|Other|Mental practice and physical therapy|
188900|NCT02729454|Other|physical therapy|
188901|NCT02729441|Drug|ramipril|Comparison of two renin angiotensin aldosterone inhibitors
188902|NCT02729441|Drug|perindopril|Comparison of two renin angiotensin aldosterone inhibitors
188903|NCT02729428|Device|MRI|Participants will undergo an MRI scan
188904|NCT02729415|Procedure|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
188905|NCT02729415|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
188906|NCT02729415|Other|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
188907|NCT02729402|Other|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
188908|NCT02729389|Behavioral|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
188909|NCT02729389|Behavioral|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
188910|NCT02729376|Drug|galeterone|
188911|NCT02729363|Behavioral|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention.
188912|NCT02729363|Behavioral|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
188913|NCT02729350|Behavioral|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
188914|NCT02729350|Behavioral|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
188915|NCT02729337|Behavioral|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
188916|NCT02729324|Drug|Medical Radiation Protectants (FORRAD®)|Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
188917|NCT02729324|Drug|Trolamine (Biafine)|Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
188918|NCT02729311|Behavioral|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
188919|NCT02729298|Drug|TP-0903|Novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers
188920|NCT02729285|Drug|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
188921|NCT02729285|Drug|placebo|On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
188922|NCT02729285|Procedure|scleral buckle|Surgical procedure of scleral buckle under retrobulbar block anesthesia
189000|NCT02728713|Procedure|Sham/Placebo|A laying on of hands with no actual treatment being performed.
188927|NCT02729259|Behavioral|Virtual Reality Snowworld|The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
188928|NCT02729259|Behavioral|Virtual Reality slides of nature|The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
188929|NCT02729259|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
188930|NCT02729246|Procedure|Laparoscopic Gastric Bypass|
188931|NCT02729233|Other|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
188932|NCT02729220|Other|Bronchoscopy|Sampling of airways
188933|NCT02729207|Drug|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
188934|NCT02729194|Drug|Pazopanib|
188935|NCT02729194|Other|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
188936|NCT02729181|Device|DRX9000|
188937|NCT02729168|Biological|Human rabies vaccine|
188938|NCT02729155|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
188939|NCT02729155|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
188940|NCT02729155|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
188941|NCT02729155|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
188942|NCT02729142|Procedure|Tibial cortical density evaluation|Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
188943|NCT02729129|Other|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
188944|NCT02729129|Other|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
188945|NCT02729116|Drug|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
188946|NCT02729116|Drug|Ertapenem|Patients are given IV ertapenem for 14 days
188947|NCT02729103|Drug|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
188948|NCT02729090|Other|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
188949|NCT02729090|Other|Device: treadmill Train_Comb_aerobic|Device: treadmill Train_Comb_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train_Comb_aerobic
188950|NCT02729077|Device|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
188951|NCT02729064|Drug|Humulin R|Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
188952|NCT02729064|Drug|Normal Saline|Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
188953|NCT02729051|Drug|FF/UMEC/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
188954|NCT02729051|Drug|FF/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
188955|NCT02729051|Drug|UMEC|This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
188956|NCT02729051|Drug|Placebo|This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
188957|NCT02729051|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
188958|NCT02729038|Drug|Gepotidacin|Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
188959|NCT02729025|Drug|Evolocumab|Administered subcutaneously once a month using an autoinjector/pen.
188960|NCT02729025|Drug|Placebo|Administered subcutaneously once a month using an autoinjector/pen.
188961|NCT02729012|Drug|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
188962|NCT02729012|Other|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
188963|NCT02728999|Procedure|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
189001|NCT02728700|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
189002|NCT02728700|Other|Laboratory Biomarker Analysis|Correlative studies
189003|NCT02728700|Drug|Mycophenolate Mofetil|Given IV
189004|NCT02728700|Drug|Sirolimus|Given PO
188964|NCT02728999|Procedure|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.~After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
188965|NCT02728986|Device|Profore|Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice
188966|NCT02728986|Device|Coban2|Coban2 compression system + standard regimen for wound care according to investigator's choice
188967|NCT02728973|Other|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
188968|NCT02728960|Procedure|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
188969|NCT02728947|Drug|ROTIGOTINE|1 week at each dose
188970|NCT02728934|Biological|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
188971|NCT02728934|Biological|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
188972|NCT02728934|Biological|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
188973|NCT02728921|Drug|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
188974|NCT02728921|Drug|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
188975|NCT02728908|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100
188976|NCT02728895|Drug|Vedolizumab|Vedolizumab Injection.
188977|NCT02728882|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
188978|NCT02728869|Biological|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1[8]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
188979|NCT02728869|Biological|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
188980|NCT02728869|Biological|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7[5]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A[8]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
188981|NCT02728856|Other|Sunscreen Spray SPF50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
188982|NCT02728856|Other|Shampoo Control|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
188983|NCT02728856|Other|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
188984|NCT02728843|Drug|Deferiprone|600 mg tablets
188985|NCT02728843|Drug|Placebo|Tablets that match the deferiprone tablets in appearance
188986|NCT02728830|Drug|Pembrolizumab|Pembrolizumab 200mg IV
188987|NCT02728817|Procedure|End-cephalic vein to side-radial artery fistula creation|"Circumferential dissection of the cephalic vein (4-5cm long)~Longitudinal arteriotomy (~10mm)~End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
188988|NCT02728817|Procedure|RADAR fistula creation|"Dissection of the anterior-medial aspect of the cephalic vein (~15mm) without grasping or clamping the venous wall~Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips~Ligation and section of the radial artery (distal)~Longitudinal venotomy (~10mm)~End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
188989|NCT02728804|Other|Quality-of-Life Assessment|Complete questionnaire
188990|NCT02728804|Other|Questionnaire Administration|Complete questionnaires
188991|NCT02728778|Drug|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
188992|NCT02728778|Procedure|Acupuncture|Application of acupuncture into the forehead
188993|NCT02728765|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
188994|NCT02728752|Drug|Octagam 10%|Patients to be treated with Octagam 10%
188995|NCT02728752|Other|Placebo|Patients to be treated with a Placebo
188996|NCT02728739|Procedure|Transthoracic Echocardiogram (TTE) Assesment|Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (>30 pg/ ml) for grading of MR severity within 7 days.
188997|NCT02728726|Drug|sugammadex|
188998|NCT02728726|Drug|Placebo|
188999|NCT02728713|Procedure|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
189173|NCT02727660|Drug|FF MDI (PT005) 9.6 μg|Blinded Treatment
189010|NCT02728674|Other|Symptom in the case is pain.|Symptom in the case is pain.
189011|NCT02728661|Behavioral|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
189012|NCT02728661|Behavioral|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
189013|NCT02728648|Drug|Oxycodone|Pain Management
189014|NCT02728635|Other|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
189015|NCT02728635|Procedure|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
189016|NCT02728635|Other|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
189017|NCT02728622|Drug|Tamoxifen|endocrine treatment
189018|NCT02728622|Drug|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
189019|NCT02728609|Device|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
189020|NCT02728609|Device|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
189021|NCT02728596|Other|Preventive Intervention|Receive PP-CSF
189022|NCT02728596|Other|Quality-of-Life Assessment|Ancillary studies
189023|NCT02728596|Other|Questionnaire Administration|Ancillary studies
189024|NCT02728583|Dietary Supplement|Margarine enriched with plant sterols and fish oil|
189025|NCT02728583|Dietary Supplement|Placebo margarine|
189026|NCT02728570|Other|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
189027|NCT02728570|Other|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
189028|NCT02728557|Behavioral|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
189029|NCT02728557|Behavioral|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
189030|NCT02728544|Other|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
189031|NCT02728531|Drug|Bendamustine|
189032|NCT02728531|Drug|Rituximab|
189033|NCT02728531|Drug|Cytarabine|
189034|NCT02728531|Drug|Pegfilgrastim|
189035|NCT02728531|Procedure|Leukapheresis|
189036|NCT02728531|Drug|Filgrastim|
189037|NCT02728531|Procedure|Autologous stem cell transplant|
189038|NCT02728518|Drug|Nebulized Amikacin|400mg twice daily nebulized amikacin
189039|NCT02728518|Drug|Intravenous Amikacin|20mg/kg once daily intravenous amikacin
189040|NCT02728505|Drug|SinuSurf irrigation twice daily|
189041|NCT02728505|Drug|NeilMed Sinus rinse irrigation twice daily|
189042|NCT02728492|Drug|Quisinostat|
189043|NCT02728492|Drug|Paclitaxel|
189044|NCT02728492|Drug|Carboplatin|
189045|NCT02728492|Drug|Gemcitabine|
189046|NCT02728492|Drug|Cisplatin|
189047|NCT02728466|Dietary Supplement|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
189048|NCT02728466|Dietary Supplement|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
189049|NCT02728466|Dietary Supplement|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
189050|NCT02728453|Drug|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
189051|NCT02728453|Drug|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
189052|NCT02728440|Drug|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
189053|NCT02728427|Device|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
189054|NCT02728427|Device|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
189055|NCT02728414|Dietary Supplement|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
189056|NCT02728414|Dietary Supplement|placebo|the patients in this arm will receive placebo intervention
189057|NCT02728388|Drug|aminolevulinic acid|"Drug: Levulan Kerastick~Drug: Topical placebo~Device: Omnilux Revive~Procedure: Photodynamic therapy~Other: Tumor growth rate measurements"
189058|NCT02728375|Other|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
189059|NCT02728375|Other|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
189060|NCT02728349|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
189061|NCT02728336|Procedure|Cardiac MRI|
189062|NCT02728323|Drug|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
189063|NCT02728323|Drug|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
189064|NCT02728310|Drug|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
189065|NCT02728310|Drug|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
189066|NCT02728297|Procedure|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
189067|NCT02728284|Procedure|cardiovascular MRI (CMR)|CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients
189068|NCT02728284|Procedure|Conventional Cardiologic Evaluation|ECG (gating), and respiratory motion effects
189069|NCT02728271|Biological|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.~Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
189070|NCT02728258|Drug|Copanlisib|Given IV
189071|NCT02728258|Other|Laboratory Biomarker Analysis|Correlative studies
189072|NCT02728245|Drug|Dienogest|Dienogest 2mg po qd
189073|NCT02728245|Drug|Placebo drug|Placebo 1 table po qd
189074|NCT02728245|Procedure|Surgery|conservative surgery without intent to oophorectomy
189075|NCT02728232|Procedure|internal iliac artery ligation|
189076|NCT02728232|Procedure|Cesarean Hysterectomy|
189077|NCT02728219|Procedure|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
189078|NCT02728219|Procedure|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
189079|NCT02728206|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
189080|NCT02728193|Procedure|RFA|
189081|NCT02728193|Procedure|MWV|
189082|NCT02728193|Procedure|PEI|Percutaneous ethanol injection
189083|NCT02728180|Drug|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
189084|NCT02728180|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
189085|NCT02728167|Device|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
189086|NCT02728154|Other|Blood Sample|One tablespoon of blood will be drawn once during the study.
189087|NCT02728154|Other|Stool Sample|One stool sample will be collected.
189088|NCT02728141|Other|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
189089|NCT02728141|Other|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
189090|NCT02728115|Biological|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
189091|NCT02728115|Biological|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. All participants will receive a total of 3 intravenous administration, one every 30 days.
189174|NCT02727647|Drug|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
189175|NCT02727647|Drug|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
189092|NCT02728102|Procedure|Tumor Cell Collection|Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
189093|NCT02728102|Procedure|Autologous Stem Cell Transplant|Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
189094|NCT02728102|Drug|Melphalan|Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m^2 at the schedule and timing according to institutional practices.
189095|NCT02728102|Procedure|Leukapheresis|Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
189096|NCT02728102|Biological|Myeloma vaccine|The target dose is 3 x 10^6 fusion cells per vaccine. A minimum of 3 x 10^6 total fusion cells will be required to proceed with vaccine administration. Patients who have <3 x 10^6 total fusion cells will not proceed with vaccination. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
189097|NCT02728102|Drug|GM-CSF|100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
189098|NCT02728102|Drug|Lenalidomide|Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
189099|NCT02728089|Drug|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
189100|NCT02728076|Radiation|Phase II - Preoperative Radiation followed by Lumpectomy.|Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
189101|NCT02728063|Dietary Supplement|Lactibiane Tolerance|probiotics
189102|NCT02728050|Drug|Cladribine|Given IV
189103|NCT02728050|Drug|Cytarabine|Given IV
189104|NCT02728050|Biological|Filgrastim|Given SC
189105|NCT02728050|Other|Laboratory Biomarker Analysis|Correlative studies
189106|NCT02728050|Drug|Mitoxantrone Hydrochloride|Given IV
189107|NCT02728050|Other|Quality-of-Life Assessment|Ancillary studies
189108|NCT02728050|Drug|Sorafenib Tosylate|Given PO
189109|NCT02728050|Drug|Mitoxantrone|Given IV
189110|NCT02728050|Drug|Sorafenib|Given PO
189111|NCT02728037|Procedure|Magnesium-Based Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate."
189112|NCT02728037|Procedure|Lidocaine-Only Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine."
189113|NCT02728037|Drug|lidocaine|
189114|NCT02728037|Drug|magnesium sulfate, bicarbonate, dextrose.|
189115|NCT02728024|Other|Missing items, Errors in Completion, Difficulties|
189116|NCT02728011|Other|Scientific Brain Training (SBT)|Cognitive training
189117|NCT02728011|Other|Tetris|
189118|NCT02727998|Drug|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
189119|NCT02727998|Drug|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
189120|NCT02727985|Procedure|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
189121|NCT02727972|Behavioral|Cognitive Testing|Verbal assessments as well as computer testing.
189122|NCT02727972|Other|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.
189215|NCT02727374|Other|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
189216|NCT02727374|Behavioral|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
189217|NCT02727361|Radiation|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
189254|NCT02726997|Other|Laboratory Biomarker Analysis|Correlative studies
189123|NCT02727972|Radiation|PET|High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB, ABP688, or SV2A.
189124|NCT02727946|Other|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
189125|NCT02727920|Dietary Supplement|Energy drink|
189126|NCT02727920|Other|Placebo|placebo drink
189127|NCT02727907|Drug|BCD-033 (interferon beta 1a)|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
189128|NCT02727907|Drug|Rebif (interferon beta 1a)|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
189129|NCT02727907|Drug|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
189130|NCT02727881|Drug|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
189131|NCT02727881|Drug|Placebo Ophthalmic solution|Placebo Ophthalmic solution
189132|NCT02727881|Drug|ranibizumab|ranibizumab
189133|NCT02727868|Genetic|blood samples|
189134|NCT02727855|Biological|Shanchol|Oral Cholera Vaccine
189135|NCT02727842|Device|CP950 Sound Processor|An off-the-ear processor configuration with identical functionality to the commercially approved CP910/920 processor
189136|NCT02727842|Device|Wireless programming pod|The CP950 Sound Processor will be programmed by the wireless programming pod, which is needed as the interface to commercially approved programming software
189137|NCT02727829|Device|pefusion index measurement|perfusion index measurement using massimo radical 7 device
189138|NCT02727816|Device|filcon IV I (BC 8.6)|control lens
189139|NCT02727816|Device|filcon IV I (BC 8.7)|control lens
189140|NCT02727816|Device|ocufilcon D|test lens
189141|NCT02727816|Device|methafilcon A (BC 8.6)|control lens
189142|NCT02727816|Device|methafilcon A (BC 8.7)|control lens
189143|NCT02727816|Device|somofilcon A|test lens
189144|NCT02727803|Biological|Allogeneic Natural Killer Cell Line NK-92|Given IV
189145|NCT02727803|Biological|Anti-Thymocyte Globulin|Given IV
189146|NCT02727803|Drug|Busulfan|Given IV
189147|NCT02727803|Drug|Clofarabine|Given IV
189148|NCT02727803|Drug|Cyclophosphamide|Given IV
189149|NCT02727803|Drug|Fludarabine Phosphate|Given IV
189150|NCT02727803|Other|Laboratory Biomarker Analysis|Correlative studies
189151|NCT02727803|Drug|Melphalan|Given IV
189152|NCT02727803|Biological|Rituximab|Given IV
189153|NCT02727803|Radiation|Total-Body Irradiation|Undergo total body irradiation
189154|NCT02727803|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplantation
189155|NCT02727790|Device|Stimulator|
189156|NCT02727777|Drug|TAK228|Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
189157|NCT02727777|Other|Blood Sugar Testing|Participant given a glucometer to check pre-dose blood sugar levels at home every day.
189158|NCT02727764|Genetic|ART-I02|Single Intra-articular injection in the carpometacarpal (CMC), metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
189159|NCT02727751|Drug|Tenapanor|
189160|NCT02727738|Dietary Supplement|Selenium|Selenium 80 mg bid for 90 days
189161|NCT02727738|Drug|Methimazole|Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values <10 pg/ml, 10-15 pg/ml, >15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
189162|NCT02727725|Other|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
189163|NCT02727712|Procedure|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4)program
189164|NCT02727712|Device|Transesophageal Echocardiography（TEE）|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;~Goal-directed fluid management"
189165|NCT02727712|Device|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6~7ml/kg, joint use of PEEP)
189166|NCT02727712|Drug|Anesthesia drugs during the surgery|"Bilateral thoracic paravertebral block before induction of anesthesia;~Fast channel anesthesia • Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01~0.04ug/kg•min, Sevoflurane 0.5~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
189167|NCT02727712|Procedure|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml*2)program
189168|NCT02727699|Drug|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
189169|NCT02727699|Drug|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
189170|NCT02727686|Other|Water Load (WL) Post-Operative Day 1|Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
189171|NCT02727660|Drug|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
189176|NCT02727634|Other|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
189177|NCT02727621|Drug|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
189178|NCT02727621|Drug|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
189179|NCT02727608|Drug|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
189180|NCT02727595|Device|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
189181|NCT02727569|Device|New visual field algorithm with DLS|Mathematical model (software based) to derive retinal sensitivity.
189182|NCT02727569|Device|SITA algorithm|Mathematical model (software based) to derive retinal sensitivity. Commercially available.
189183|NCT02727569|Device|New visual field algorithm with MMDT|Mathematical model (software based) to derive retinal sensitivity.
189184|NCT02727556|Behavioral|visual images|
189185|NCT02727543|Other|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
189186|NCT02727530|Other|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
189187|NCT02727530|Other|ADVICES|Advices for parents to improve the management of infant colic
189188|NCT02727517|Procedure|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
189189|NCT02727517|Procedure|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
189190|NCT02727504|Device|Electrocardiogram|ECG at inclusion and M12
189191|NCT02727504|Device|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
189192|NCT02727504|Device|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
189193|NCT02727504|Biological|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
189194|NCT02727504|Device|Cardiac MRI|Cardiac MRI at inclusion
189195|NCT02727504|Device|Cardiac scanner|Cardiac scanner at inclusion
189196|NCT02727504|Other|6-minutes walking test|6-minutes walking test at inclusion and M12
189197|NCT02727504|Other|Duke Activity Score|Duke Activity Score at inclusion and M12
189198|NCT02727491|Drug|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
189199|NCT02727491|Drug|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
189200|NCT02727478|Other|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
189201|NCT02727465|Other|Meningitis cases|None - blood draw only
189202|NCT02727452|Other|Skin-to-skin contact|
189203|NCT02727439|Other|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
189204|NCT02727426|Other|Low Salt (LS) diet|Intake of less than 2.3 g of salt per day for 7 days.
189205|NCT02727426|Other|High Salt (HS) diet|Intake of 11.2 g of salt per day for 7 days.
189206|NCT02727413|Procedure|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
189207|NCT02727413|Other|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
189208|NCT02727387|Drug|TEMIRI|Window therapy frontline for VHR patients
189209|NCT02727387|Drug|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
189210|NCT02727387|Drug|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
189211|NCT02727387|Drug|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
189212|NCT02727387|Drug|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
189213|NCT02727387|Drug|BUMEL|Consolidation phase
189214|NCT02727387|Drug|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
189218|NCT02727361|Other|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
189219|NCT02727348|Procedure|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
189220|NCT02727348|Procedure|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
189221|NCT02727322|Drug|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
189222|NCT02727322|Drug|Placebo|Placebo
189223|NCT02727309|Drug|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
189224|NCT02727296|Drug|sevoflurane|General anesthesia with sevoflurane
189225|NCT02727296|Drug|propofol|General anesthesia with propofol
189226|NCT02727283|Drug|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
189227|NCT02727283|Drug|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
189228|NCT02727270|Other|No Intervention - Observational Study|No Intervention - Observational Study
189229|NCT02727257|Procedure|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
189230|NCT02727244|Procedure|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
189231|NCT02727231|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
189232|NCT02727231|Device|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
189233|NCT02727218|Procedure|Chest tube removal|chest tube removal post thoracoscopic surgery
189234|NCT02727205|Drug|Rotigotine Transdermal System|
189235|NCT02727192|Device|CPAP|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
189236|NCT02727179|Procedure|Liver resection|The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
189237|NCT02727166|Dietary Supplement|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
189238|NCT02727166|Dietary Supplement|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
189239|NCT02727153|Other|"Ultra E.R.A.S."|
189240|NCT02727153|Other|Classic E.R.A.S.|
189241|NCT02727140|Behavioral|Yoga with Asana (yoga postures)|Yoga intervention consisting of asana, breathing and relaxation, meditation
189242|NCT02727140|Behavioral|Yoga without Asana (yoga postures)|Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
189243|NCT02727114|Other|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® & VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
189244|NCT02727101|Drug|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
189245|NCT02727088|Procedure|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
189246|NCT02727088|Procedure|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
189247|NCT02727062|Other|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed.~Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.~Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period."
189248|NCT02727049|Other|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
189249|NCT02727036|Dietary Supplement|Pumpkin seed oil|1 gram capsule of Pumpkin seed oil.
189250|NCT02727036|Dietary Supplement|Pumpkin seeds|4.1 grams (1½ teaspoons/~0.15ounces) of pumpkin seeds
189251|NCT02727023|Other|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
189255|NCT02726997|Drug|Paclitaxel|Given IV
189256|NCT02726997|Other|Pharmacological Study|Correlative studies
189257|NCT02726997|Other|Quality-of-Life Assessment|Ancillary studies
189258|NCT02726984|Drug|18F-sodium fluoride PET/MR|18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
189259|NCT02726971|Drug|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
189260|NCT02726945|Device|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
189261|NCT02726945|Other|Placebo|Placebo Control
189262|NCT02726932|Other|No intervention, merely observational|
189263|NCT02726919|Drug|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
189264|NCT02726906|Behavioral|Moderate-aerobic walking|
189265|NCT02726906|Radiation|Positron Emission Tomography (PET) scan|Radioligand that binds to proteins using a PET/CT scanner.
189266|NCT02726906|Behavioral|Healthy living education|
189267|NCT02726906|Device|Physical activity monitor|Wrist device that will track daily physical activity
189268|NCT02726893|Other|no intervention|
189269|NCT02726880|Behavioral|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
189270|NCT02726880|Behavioral|Referral for care|Referral for mental health issues and family support services
189271|NCT02726867|Drug|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
189272|NCT02726867|Drug|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
189273|NCT02726867|Drug|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
189274|NCT02726867|Drug|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
189275|NCT02726854|Drug|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
189276|NCT02726841|Procedure|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
189277|NCT02726841|Procedure|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
189278|NCT02726828|Drug|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
189279|NCT02726828|Drug|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
189280|NCT02726828|Drug|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
189281|NCT02726815|Other|Questionnaire|Questionnaire based study using a symptom assessment tool
189282|NCT02726802|Other|physical therapy vs. primary care interventions|Subjects with acute (< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
189283|NCT02726789|Drug|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
189284|NCT02726789|Drug|pegylated interferon|immunotherapy
189285|NCT02726789|Drug|entecavir|local generic entecavir
189286|NCT02726776|Other|Suspension in a harness|
189287|NCT02726776|Other|Climbing|
189288|NCT02726763|Device|Transcranial Direct Current Stimulation (tDCS)|
189289|NCT02726763|Behavioral|Questionnaires|
189290|NCT02726750|Procedure|Blood Collection|Blood (about 1-2 tablespoons) collected for biomarker and routine tests and to check the status of the disease.
189291|NCT02726737|Drug|sodium bicarbonate|
189292|NCT02726737|Drug|Lidocaine|
189293|NCT02726737|Drug|sterile distilled water|
189294|NCT02726724|Other|5 observers|
189295|NCT02726724|Other|1 observer|
189296|NCT02726711|Drug|Trimethaphan|Trimethaphan will be infused (0.5 - 4.0 mg IV)
189297|NCT02726711|Drug|Placebo|0.5 - 4.0 mg IV to be infused
189298|NCT02726685|Other|respiratory training.|breathing exercise.
189299|NCT02726685|Other|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
189300|NCT02726672|Device|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
189301|NCT02726659|Drug|Celecoxib|Adjunct celecoxib
189302|NCT02726659|Drug|Placebo|Adjunct placebo
189303|NCT02726646|Drug|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
189304|NCT02726646|Procedure|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
189305|NCT02726646|Drug|Placebo|The application of 1 mg of microspheres placebo
189306|NCT02726620|Procedure|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
189355|NCT02726581|Drug|Dexamethasone|Specified dose on specified days, PO
189356|NCT02726568|Drug|Icotinib|375 mg Tid (1125 mg per day) until intracranial PD.
190146|NCT02721121|Procedure|circumferential pulmonary vein isolation|
189307|NCT02726620|Procedure|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
189308|NCT02726620|Procedure|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
189309|NCT02726620|Procedure|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
189310|NCT02726620|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
189311|NCT02726620|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
189312|NCT02726620|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
189313|NCT02726620|Device|Pager system|The mobile pager system through which alerts can be sent
189314|NCT02726620|Procedure|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
189315|NCT02726620|Procedure|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
189316|NCT02726620|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
189317|NCT02726620|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
189318|NCT02726620|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
189319|NCT02726620|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
189320|NCT02726620|Drug|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
189321|NCT02726620|Drug|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
189322|NCT02726620|Drug|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
189323|NCT02726620|Drug|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
189324|NCT02726620|Drug|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
189325|NCT02726620|Drug|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
189326|NCT02726620|Drug|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
189327|NCT02726620|Drug|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
189328|NCT02726620|Drug|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
189329|NCT02726620|Drug|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
189330|NCT02726620|Drug|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
189331|NCT02726620|Drug|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
189332|NCT02726620|Drug|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
189333|NCT02726620|Drug|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
189334|NCT02726620|Drug|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
189335|NCT02726620|Drug|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
189336|NCT02726620|Drug|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
189337|NCT02726620|Drug|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
189338|NCT02726620|Drug|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
189339|NCT02726620|Drug|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
189340|NCT02726620|Drug|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
189341|NCT02726620|Drug|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
189342|NCT02726620|Drug|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
189343|NCT02726620|Drug|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
189344|NCT02726620|Drug|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
189345|NCT02726620|Drug|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
189346|NCT02726620|Drug|Procaine|Local anesthetic used for central neuraxial anesthesia.
189347|NCT02726620|Drug|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
189348|NCT02726620|Drug|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
189349|NCT02726620|Drug|Articaine|Local anesthetic used for central neuraxial anesthesia.
189350|NCT02726607|Behavioral|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
189351|NCT02726607|Behavioral|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
189352|NCT02726581|Biological|Nivolumab|Specified dose on specified days, IV (intravenous)
189353|NCT02726581|Biological|Elotuzumab|Specified dose on specified days, IV
189354|NCT02726581|Drug|Pomalidomide|Specified dose on specified days, PO (by mouth)
189357|NCT02726568|Radiation|SRS|If intracranial PD, then the subjects get stereotatic radiosurgery （30Gy/3f) combined with Icotinib 375mg Tid.
189358|NCT02726555|Drug|Red yeast rice and atorvastatin|Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
189359|NCT02726555|Drug|Atorvastatin alone|Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
189360|NCT02726542|Drug|somatropin|Norditropin (growth hormone) given by injection using a pen-device
189361|NCT02726529|Behavioral|Brighter Bites|
189362|NCT02726529|Behavioral|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
189363|NCT02726516|Dietary Supplement|PRJ-205|1 sachet per day
189364|NCT02726516|Other|Placebo|1 sachet per day
189365|NCT02726503|Drug|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.~The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
189366|NCT02726490|Drug|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
189367|NCT02726490|Drug|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
189368|NCT02726477|Drug|Wuling San|Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.
189369|NCT02726477|Drug|placebo|Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
189370|NCT02726451|Other|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
189371|NCT02726451|Other|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
189372|NCT02726438|Drug|Debio 1450|Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
189373|NCT02726425|Behavioral|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians & peer leaders lasting ~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
189374|NCT02726412|Procedure|Acute vs elective|non-intverention study
189375|NCT02726399|Drug|Ramucirumab|Ramucirumab 8mg/kg administered intravenously on days 1 and 8 ever 21 days
189376|NCT02726399|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
189377|NCT02726399|Drug|Capecitabine|Capecitabine 850mg/m2 will be added, taken orally twice a day for fourteen days (days 1 through 14) followed by a 7 day rest period
189378|NCT02726399|Drug|Cisplatin|Cisplatin 80mg/m2 administered as an IV infusion every 21 days
189379|NCT02726386|Drug|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
189380|NCT02726373|Other|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
189381|NCT02726360|Behavioral|survey|The ILR Scale, a non-English language proficiency self-assessment.
189382|NCT02726360|Behavioral|Audio record|Audio record the initial visits between patients and their treating physician
189383|NCT02726347|Biological|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
189384|NCT02726334|Drug|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
189385|NCT02726334|Drug|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).~BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).~FOLFIRI components:~Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)~FOLFIRI Cycles are repeated every 14 days."
189386|NCT02726308|Drug|Dexamethasone|5 mg I.V. Dexamethasone just before induction
189387|NCT02726308|Drug|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
189388|NCT02726308|Drug|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
189389|NCT02726295|Drug|E. coli Nissle 1917(Mutaflor®)|
189390|NCT02726295|Drug|Placebo|
189391|NCT02726269|Drug|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
189392|NCT02726269|Drug|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
189393|NCT02726230|Behavioral|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
190519|NCT02718170|Procedure|Plate and Screw Fixation|
189394|NCT02726217|Behavioral|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
189395|NCT02726217|Behavioral|Standard of Care Reminders and Self Assessments|
189396|NCT02726204|Other|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
189397|NCT02726204|Other|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
189398|NCT02726204|Other|Path Assistance and Gravity Elimination|
189399|NCT02726191|Behavioral|Spatial Match Exercise|
189400|NCT02726191|Behavioral|Temporal Sequence Reconstruction Exercise|
189401|NCT02726191|Behavioral|Token Task Exercise|
189402|NCT02726191|Behavioral|Story Recall Exercise|
189403|NCT02726191|Behavioral|Sample-Match (Within Modality) Exercise|
189404|NCT02726191|Behavioral|Pair-Match (Across-Modality) Exercise|
189405|NCT02726191|Behavioral|Triad-FiguresExercise|
189406|NCT02726191|Behavioral|Monster Garden Exercise|
189407|NCT02726191|Behavioral|Memory Match Exercise|
189408|NCT02726191|Behavioral|Memory Matrix Exercise|
189409|NCT02726191|Behavioral|Familiar Faces Exercises|
189410|NCT02726191|Behavioral|Lost in Migration Exercise|
189411|NCT02726191|Behavioral|Playing Koi Exercise|
189412|NCT02726178|Drug|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
189413|NCT02726178|Drug|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
189414|NCT02726152|Procedure|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
189415|NCT02726152|Procedure|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
189416|NCT02726126|Drug|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
189417|NCT02726113|Drug|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
189418|NCT02726113|Other|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
189419|NCT02726100|Behavioral|SMARTHealth Diabetes|SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
189420|NCT02726087|Procedure|ministernotomy|"Partial upper J hemisternotomy trough 4th right intercostal space)"
189421|NCT02726087|Procedure|Full sternotomy|Conventional full median sternotomy
189422|NCT02726074|Drug|Perampanel|
189423|NCT02726061|Behavioral|Internet-based psychological support|A behavioral therapy called Problem Solving Therapy, conflict management training, and stress management training will be administered via an interactive multimedia program (PATH) to participants referred from their Employee Assistance Program and the general public for the management of depression, stress, and conflict.
189424|NCT02726048|Device|Simplus/Eson|Released product Simplus and Eson masks
189425|NCT02726035|Drug|Naltrexone|oral naltrexone 50 mg daily
189426|NCT02726035|Other|Placebo|oral placebo (appearing identical to naltrexone) once daily
189427|NCT02726022|Drug|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
189428|NCT02726022|Drug|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
189429|NCT02726009|Drug|Degarelix|
189430|NCT02725996|Biological|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
189431|NCT02725996|Other|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
189432|NCT02725983|Behavioral|SPT consultation|
189433|NCT02725983|Device|SOPROCARE®|
189434|NCT02725970|Other|survey|Cross-sectional survey
189435|NCT02725957|Drug|Trehalose for IV Infusion|
189436|NCT02725957|Drug|Saline 0.9% IV|
189437|NCT02725944|Device|Implantation of ICRM|All patients will be implanted with ICRM in order to detect an occult PAF.
189438|NCT02725931|Behavioral|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
189439|NCT02725918|Drug|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
189440|NCT02725918|Drug|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
189441|NCT02725905|Behavioral|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
189473|NCT02725710|Drug|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
189474|NCT02725710|Drug|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
189442|NCT02725905|Behavioral|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
189443|NCT02725892|Other|NIS observational stud|NIS observational study : Epidemiologic registry
189444|NCT02725866|Drug|Paritaprevir/ritonavir/ombitasvir|Co-formulated tablet
189445|NCT02725866|Drug|Dasabuvir|Tablet
189446|NCT02725866|Drug|Ribavirin|Tablet
189447|NCT02725853|Device|tDCS|Application of 1.5 mA tDCS for 30 minutes
189448|NCT02725853|Device|sham tDCS|Application of sham tDCS for 30 minutes
189449|NCT02725853|Behavioral|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
189450|NCT02725853|Behavioral|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
189451|NCT02725840|Radiation|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
189452|NCT02725840|Radiation|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
189453|NCT02725840|Procedure|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
189454|NCT02725840|Procedure|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
189455|NCT02725827|Other|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
189456|NCT02725827|Other|Control medium|The usual embryo transfer medium used in the study centres.
189457|NCT02725814|Other|24% Sucrose Solution|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
189458|NCT02725801|Device|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
189459|NCT02725801|Device|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
189460|NCT02725788|Device|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
189461|NCT02725788|Device|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
189462|NCT02725775|Dietary Supplement|100% Florida OJ|
189463|NCT02725775|Dietary Supplement|Placebo Equicaloric Orange Drink|
189464|NCT02725762|Device|LT-300 Active (PBM)|
189465|NCT02725762|Device|LT-300 Inactive (Sham)|
189466|NCT02725749|Radiation|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
189467|NCT02725749|Other|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
189468|NCT02725749|Radiation|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.~Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.~The participants performed the exercises three times a week for eight weeks."
189469|NCT02725736|Drug|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:~Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
189470|NCT02725736|Drug|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:~Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
189471|NCT02725723|Device|Therm-AppTM TH, thermographic camera|
189472|NCT02725723|Drug|epidural injection|
189476|NCT02725684|Other|Observational study, no intervention|Observational study, no intervention
189477|NCT02725671|Device|Explorer|ECG device which records comprehensive voltage potential data in the myocardium
189478|NCT02725658|Device|DOSI|Breast tissue properties scanning
189479|NCT02725645|Other|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
189480|NCT02725632|Device|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
189481|NCT02725619|Behavioral|CBT|
189482|NCT02725619|Behavioral|PST|
189483|NCT02725606|Biological|Pegylated Recombinant Human G-CSF|subcutaneous
189484|NCT02725606|Biological|GW003|subcutaneous
189485|NCT02725593|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
189486|NCT02725593|Drug|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
189487|NCT02725580|Genetic|AT-GTX-501|Subjects with diagnosis of CLN6 Batten disease will receive a single dose of AT-GTX-501 (scAAV9.CB.CLN6).
189488|NCT02725567|Drug|ivacaftor|
189489|NCT02725554|Device|StimRelieve Halo System|The StimRelieve Halo System is intended as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic migraine as defined by the Third edition of the International Classification of headache disorders (ICDH-3). The system provides treatment by delivering small controlled electrical pulses to the occipital and supraorbital nerves, as it has been shown that for chronic migraine headaches the response to combined systems appears to be substantially better than occipital nerves stimulation alone.
189490|NCT02725541|Drug|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
189491|NCT02725528|Drug|collagenase injection|injection
189492|NCT02725528|Procedure|limited palmar fasciectomy|surgery
189493|NCT02725515|Biological|XmAb5871|
189494|NCT02725515|Biological|Placebo to match XmAb5871|
189495|NCT02725502|Drug|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
189496|NCT02725502|Drug|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
189497|NCT02725489|Biological|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
189498|NCT02725489|Drug|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
189499|NCT02725476|Biological|XmAb5871|
189500|NCT02725463|Device|Labyrinth Devices MVI™ Multichannel Vestibular Implant|
189501|NCT02725450|Behavioral|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
189502|NCT02725450|Behavioral|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
189503|NCT02725437|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection
189504|NCT02725437|Biological|Placebo|0.5 mL intramuscular injection
189505|NCT02725424|Drug|S-1|Her-2 Positive patients with SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), po,Bid， d1-14 Every 3weeks.
189506|NCT02725424|Drug|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), PO,BID， d1-14 Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks.
189507|NCT02725424|Drug|Oxaliplatin|HER-2 Negative Patients：SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), PO,BID， d1-14 Every 3 weeks
189508|NCT02725424|Drug|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks
189509|NCT02725411|Drug|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
189510|NCT02725411|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
189511|NCT02725411|Biological|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
189512|NCT02725411|Drug|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
189513|NCT02725411|Biological|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
189514|NCT02725398|Drug|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
189515|NCT02725398|Drug|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
189516|NCT02725398|Drug|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
189517|NCT02725385|Other|Laboratory Biomarker Analysis|Correlative studies
189518|NCT02725385|Other|Physiologic Testing|Undergo Trier Social Stress Test
189519|NCT02725385|Other|Questionnaire Administration|Complete questionnaire
189520|NCT02725372|Drug|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
189521|NCT02725372|Drug|Placebo|Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
189522|NCT02725359|Drug|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
189523|NCT02725359|Drug|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
189524|NCT02725359|Drug|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
189525|NCT02725359|Drug|Saline|USG guided SCPB with saline bilaterally 10 ml each side
189526|NCT02725346|Procedure|Acromioplasty with planning|
189527|NCT02725346|Procedure|Acromioplasty without planning|
189528|NCT02725333|Procedure|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
189529|NCT02725307|Device|Noninvasive pulse wave analysis sensor, ECG-sensor|Noninvasive pulse wave sensors and ECG-sensors are attached
189530|NCT02725294|Other|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
189531|NCT02725281|Other|Stress ball|The patients in this group were given stress ball into their both palms 5 min before the lithotripsy and told to squeeze the ball whenever they would like until end of the process. This ball was medium hard and has been made of high quality silicon.
189532|NCT02725281|Other|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
189533|NCT02725268|Drug|Paclitaxel|Paclitaxel intravenous solution
189534|NCT02725268|Drug|MLN0128|MLN0128 capsules
189535|NCT02725268|Drug|MLN1117|MLN1117 capsules
189536|NCT02725255|Dietary Supplement|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
189537|NCT02725255|Drug|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
189538|NCT02725255|Dietary Supplement|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
189539|NCT02725242|Drug|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
189540|NCT02725242|Drug|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
189541|NCT02725229|Procedure|parasternal block|parasternal block and PCA for sternotomy pain
189542|NCT02725229|Device|TENS group|TENS and PCA for sternotomy pain
189543|NCT02725229|Device|control group|PCA for sternotomy pain
189544|NCT02725203|Behavioral|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
189545|NCT02725190|Behavioral|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
189546|NCT02725190|Behavioral|Normal sleep night|Normal sleep at home before trial.
189547|NCT02725177|Drug|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks~Initial treatment with 80 units daily for ten days (induction phase)~Maintenance treatment with 80 units twice weekly (maintenance phase)"
189548|NCT02725177|Drug|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
189549|NCT02725164|Drug|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
189550|NCT02725164|Drug|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
189551|NCT02725164|Drug|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
189552|NCT02725164|Drug|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
189553|NCT02725138|Dietary Supplement|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
189554|NCT02725138|Other|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
189555|NCT02725125|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
189556|NCT02725112|Drug|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
189557|NCT02725112|Drug|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
189558|NCT02725112|Drug|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
189559|NCT02725112|Drug|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
189560|NCT02725112|Drug|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
189561|NCT02725112|Drug|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
189562|NCT02725099|Drug|Chewing Ticagrelor|180 mg Chewing Ticagrelor
189563|NCT02725099|Drug|Oral Ticagrelor|180 mg oral Ticagrelor
189564|NCT02725086|Drug|Leucostim®|
189565|NCT02725086|Drug|Neupogen®|
189566|NCT02725073|Procedure|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter [MAJ-1419; Olympus America, Center Valley, Pa., USA]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research & Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
189567|NCT02725060|Drug|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every ~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
189568|NCT02725060|Drug|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every ~3 min until heart rate increases by 25 bpm. This intervention is optional.
189569|NCT02725060|Radiation|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
189570|NCT02725060|Procedure|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
189571|NCT02725060|Procedure|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
189572|NCT02725060|Procedure|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
189573|NCT02725060|Procedure|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
189574|NCT02725060|Other|Rebreathing test|Cardiac output will be measured using the rebreathing technique (Innocor)
189575|NCT02725060|Other|Assessment of splanchnic capacitance|Splanchnic capacitance will be assessed using cpap and body impedance to construct pressure volume curves
189576|NCT02725060|Procedure|microneurography|microneurography will be measured in the peroneal nerve to assess sympathetic activity.
189577|NCT02725047|Other|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
189578|NCT02725047|Other|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
189579|NCT02725034|Device|Standard endoscopy|
189580|NCT02725034|Device|High definition endoscopy with Optic Enhancement|
189581|NCT02725021|Behavioral|Education Against Tobacco school-based intervention by medical students|
189582|NCT02725008|Drug|Dexamethasone|
189583|NCT02725008|Drug|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
189584|NCT02724969|Behavioral|MILK or Text4Baby text message intervention|MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
189585|NCT02724956|Device|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
189586|NCT02724956|Device|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
189619|NCT02724735|Drug|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
189587|NCT02724956|Device|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
189588|NCT02724943|Behavioral|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
189589|NCT02724943|Behavioral|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
189590|NCT02724943|Behavioral|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
189591|NCT02724943|Behavioral|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
189592|NCT02724943|Behavioral|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
189593|NCT02724930|Behavioral|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
189594|NCT02724917|Drug|APN1125|Oral solid dose form of APN1125
189595|NCT02724917|Drug|Placebo|Placebo to match
189596|NCT02724904|Procedure|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
189597|NCT02724904|Drug|Fludarabine|Standard Treatment
189598|NCT02724904|Drug|Thiotepa|Standard Treatment
189599|NCT02724904|Drug|Methotrexate|IV Bolus
189600|NCT02724891|Other|paper form|questionnaires in paper form
189601|NCT02724891|Other|web/smartphone form|questionnaires in web/smartphone
189602|NCT02724878|Drug|Bevacizumab|Monoclonal antibody that binds circulating vascular endothelial growth factor
189603|NCT02724878|Drug|Atezolizumab|Monoclonal antibody that binds programmed death ligand-1
189604|NCT02724865|Device|Somnodent® (Oral appliance therapy)|
189605|NCT02724865|Device|Herbst® (Oral appliance therapy)|
189606|NCT02724852|Biological|0.5 ml of MMR vaccine|Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
189607|NCT02724839|Behavioral|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Two non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (first phase) and monthly (second phase). Participants will participate in only one phase.
189608|NCT02724839|Device|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 8 months
189609|NCT02724826|Behavioral|Qigong therapy|Medical qigong
189610|NCT02724826|Behavioral|Exercise therapy|Regular exercise
189611|NCT02724813|Behavioral|Cognitive Orientation to Occupational Preformance (COOP)|
189612|NCT02724800|Behavioral|CBTI|28 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
189613|NCT02724800|Behavioral|BBTI|28 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
189614|NCT02724787|Behavioral|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
189615|NCT02724774|Behavioral|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
189616|NCT02724761|Drug|Racemic Epinephrine|1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
189617|NCT02724761|Drug|Placebo (for racemic epinephrine)|0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
189618|NCT02724748|Behavioral|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
189620|NCT02724722|Behavioral|Assigned intervention|a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
189621|NCT02724722|Behavioral|No intervention|a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
189622|NCT02724709|Procedure|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
189623|NCT02724709|Procedure|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
189624|NCT02724683|Device|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
189625|NCT02724683|Behavioral|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
189626|NCT02724683|Behavioral|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
189627|NCT02724683|Device|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
189628|NCT02724683|Other|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
189629|NCT02724670|Radiation|IGRT|MR-based IGRT
189630|NCT02724657|Other|Buteyko Method|Intervention will be held twice a week during 3 weeks.
189631|NCT02724644|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
189632|NCT02724644|Biological|Placebo Comparator|
189633|NCT02724631|Device|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
189634|NCT02724618|Drug|Curcumin|120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
189635|NCT02724618|Radiation|RT|EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
189636|NCT02724618|Drug|Placebo|Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
189637|NCT02724605|Biological|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
189638|NCT02724605|Biological|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
189639|NCT02724592|Device|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
189640|NCT02724592|Device|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
189641|NCT02724579|Drug|Cisplatin|Given IV
189642|NCT02724579|Drug|Cyclophosphamide|Given IV
189643|NCT02724579|Other|Laboratory Biomarker Analysis|Correlative studies
189644|NCT02724579|Drug|Lomustine|Given PO
189645|NCT02724579|Radiation|Radiation Therapy|Undergo craniospinal radiation therapy
189646|NCT02724579|Drug|Vincristine|Given IV or via minibag
189647|NCT02724579|Drug|Vincristine Sulfate|Given IV or via minibag
189648|NCT02724566|Drug|apelin|Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
189649|NCT02724566|Drug|placebo|2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
189650|NCT02724553|Device|Acrylic lens implantation|
189651|NCT02724540|Device|Bland Embolization|Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
189652|NCT02724540|Combination Product|Transarterial chemoembolization|Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
189653|NCT02724540|Combination Product|Drug Eluting Beads Embolization|CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
189654|NCT02724527|Drug|Cavosonstat|CFTR modulator that stabilizes CFTR
189655|NCT02724527|Drug|Placebo|Matched Placebo capsule
189656|NCT02724514|Other|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
189657|NCT02724501|Behavioral|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
189658|NCT02724501|Procedure|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
189659|NCT02724475|Procedure|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
189660|NCT02724475|Procedure|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
189661|NCT02724462|Behavioral|Smartphone-delivered Intervention (SmartQuit)|The experimental arm includes an intervention using a novel smartphone smoking cessation app.
189662|NCT02724462|Behavioral|: Smartphone-delivered Intervention (Standard of care app)|The control intervention uses a standard of care smartphone smoking cessation app.
189663|NCT02724449|Device|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
189664|NCT02724436|Procedure|TACE|
189665|NCT02724436|Procedure|radioembolization with Y-90|radioembolization with Y-90
189666|NCT02724423|Drug|NRL-1|
189667|NCT02724410|Drug|home intravenous ertapenem|see arm description
189668|NCT02724410|Drug|home oral amoxicillin-clavulanate|see arm description
190661|NCT02717156|Other|Laboratory Biomarker Analysis|Correlative studies
189669|NCT02724410|Device|peripheral inserted central Catheter|All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.
189670|NCT02724397|Device|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
189671|NCT02724397|Device|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
189672|NCT02724384|Device|MOE Plasma Delivery System A|Plasma treatment
189673|NCT02724384|Device|MOE Plasma Delivery System B|Plasma treatment
189674|NCT02724371|Device|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
189675|NCT02724358|Procedure|TACE|iodized oil (5ml) + Pirarubicin (20mg)
189676|NCT02724358|Drug|Rg3|20mg, BID, maintained though Month 12.
189677|NCT02724358|Other|TACE + Rg3|
189678|NCT02724358|Procedure|protective therapy|standard liver protective therapy
189679|NCT02724332|Drug|Rapamycin|2mg,po,bid
189680|NCT02724319|Device|SpartanRX|A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
189681|NCT02724306|Behavioral|Active Lifestyle Programme|
189682|NCT02724293|Drug|pregabaline 300 mg once.|patients received pregabaline 300 mg 2 hours pre-operatively.
189683|NCT02724293|Drug|pregabaline 300 mg twice.|patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
189684|NCT02724293|Drug|pregabaline 600 mg once.|patients received pregabaline 600 mg 2 hours pre-operatively.
189685|NCT02724293|Drug|placebo|patients received placebo
189686|NCT02724280|Device|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
189687|NCT02724280|Device|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
189688|NCT02724267|Biological|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
189689|NCT02724254|Drug|AP611074 5% gel|
189690|NCT02724254|Drug|AP611074 matching placebo|
189691|NCT02724241|Other|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
189692|NCT02724241|Other|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
189693|NCT02724241|Other|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
189694|NCT02724228|Drug|BMN 111|BMN 111 will be administered subcutaneously daily.
189695|NCT02724215|Device|Sleep Apnea Screening (Out of Center Polysomnography Device)|
189696|NCT02724202|Drug|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
189697|NCT02724202|Drug|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
189698|NCT02724189|Device|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
189699|NCT02724189|Other|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
189700|NCT02724176|Drug|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
189701|NCT02724163|Drug|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
189702|NCT02724163|Drug|Liposomal daunorubicin|Anthracycline
189703|NCT02724163|Drug|Mitoxantrone|DNA-reactive agent
189704|NCT02724163|Drug|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
189705|NCT02724163|Drug|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
189706|NCT02724163|Drug|Busulfan|Alkylsulfonate
189707|NCT02724163|Drug|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
189708|NCT02724150|Drug|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
189709|NCT02724150|Drug|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
189710|NCT02724137|Behavioral|Fitbit®|Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
189711|NCT02724137|Other|Physical Therapy Rehab|Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
189712|NCT02724124|Other|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
189713|NCT02724124|Other|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
189714|NCT02724124|Other|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
189715|NCT02724124|Other|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
189716|NCT02724124|Other|Control|No intervention
189717|NCT02724111|Drug|sufficient dose of rocuronium|
189718|NCT02724111|Drug|sugammadex 10 min after position change|
189719|NCT02724098|Drug|Dexmedetomidine|
189720|NCT02724085|Drug|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
189721|NCT02724072|Device|Thoraflex™ Hybrid Device|Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
189722|NCT02724059|Procedure|EBUS with elastography followed by TBNA|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
189723|NCT02724046|Drug|Ciprofloxacin|Single-dose oral ciprofloxacin
189724|NCT02724033|Procedure|regional nerve block|regional nerve block
189725|NCT02724033|Drug|Antiemetic|Antiemetic
189726|NCT02724020|Drug|Everolimus|Everolimus Capsules.
189727|NCT02724020|Drug|MLN0128|MLN0128 Capsules.
189728|NCT02724020|Drug|MLN1117|MLN1117 Capsules.
189729|NCT02723994|Drug|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
189730|NCT02723994|Drug|Asparaginase Erwinia Chrysanthemi|
189731|NCT02723994|Drug|Cyclophosphamide|
189732|NCT02723994|Drug|Cytarabine|
189733|NCT02723994|Drug|Dexamethasone|
189734|NCT02723994|Drug|Doxorubicin|
189735|NCT02723994|Drug|Leucovorin Calcium|
189736|NCT02723994|Drug|Mercaptopurine|
189737|NCT02723994|Drug|Methotrexate|
189738|NCT02723994|Drug|Pegaspargase|
189739|NCT02723994|Drug|Prednisone|
189740|NCT02723994|Drug|Thioguanine|
189741|NCT02723994|Drug|Vincristine Sulfate|
189742|NCT02723981|Device|COMBO-Stent|The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
189743|NCT02723981|Drug|Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
189744|NCT02723981|Device|Any drug eluting stent oder bare metal sent|Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
189745|NCT02723981|Drug|ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
189746|NCT02723968|Other|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
189747|NCT02723968|Procedure|HGPIV diagnosis test|
189748|NCT02723968|Procedure|HOMAR-IR diagnosis test|
189749|NCT02723955|Drug|GSK3359609 IV infusion|GSK3359609 diluted product will be administered as an IV infusion to subjects Q3W.
189750|NCT02723955|Drug|GSK3174998 IV infusion|GSK3174998 diluted product will be administered as an IV infusion to subjects Q3W.
189751|NCT02723955|Drug|Pembrolizumab 200 mg IV infusion|Pembrolizumab 200 mg will be administered as an IV infusion to subjects Q3W.
189752|NCT02723955|Drug|Docetaxel 75 milligrams per square meters (mg/m^2) IV infusion|Docetaxel 75 mg/m^2 diluted product will be administered as an IV infusion to subjects Q3W.
189753|NCT02723955|Drug|Pemetrexed 500 mg/m^2 plus Carboplatin area under the curve (AUC) 4-6 mg/mL per minute IV infusion|Pemetrexed 500 mg/m^2 diluted product in combination with Carboplatin AUC 4-6 milligram per milliliter (mg/mL) per minute (diluted product), will be administered as an IV infusion to subjects Q3W.
189754|NCT02723955|Drug|Paclitaxel 200 mg/m^2 plus Carboplatin AUC 4-6 mg/mL per minute IV infusion|Paclitaxel 200 mg/m^2 diluted product in combination with Carboplatin AUC 4-6 mg/mL per minute (diluted product), will be administered as an IV infusion to subjects Q3W.
189755|NCT02723955|Drug|Gemcitabine 1250 mg/m^2 plus Carboplatin AUC 4-6 mg/mL per minute IV infusion|Gemcitabine 1250 mg/m^2 diluted product in combination with Carboplatin AUC 4-6 mg/mL per minute (diluted product), will be administered as an IV infusion to subjects Q3W.
189756|NCT02723955|Drug|Fluorouracil (5-FU) 1000 mg/m^2 plus carboplatin or cisplatin|Carboplatin AUC 4-6 mg/mL per minute or cisplatin at 100 mg/m^2 will be combined with 5-FU at 1000 mg/m^2/day will be administered as an IV infusion to subjects Q3W.
189757|NCT02723942|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
189758|NCT02723929|Device|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
189759|NCT02723929|Device|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.~Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
189760|NCT02723916|Behavioral|ezParent Program|Tablet-based behavioral parent training program.
189761|NCT02723916|Behavioral|Health-e Kids Control App|Tablet based health promotion information App
189762|NCT02723903|Drug|Deanxit|we use Deanxit for the patient with anxiety
189763|NCT02723903|Drug|Prozac|we use Prozac for the patient with depression
189764|NCT02723903|Procedure|coronary artery disease treatment|including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
189765|NCT02723890|Device|Tyto Device|
189766|NCT02723877|Drug|PQR309|Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
189767|NCT02723877|Drug|Eribulin|non.taxane microtubule dynamics inhibitor
189768|NCT02723864|Drug|Veliparib + VX-970 + Cisplatin|ATR protein kinase is central to the DNA damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. PARP plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor VX-970 synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a BRCA null phenotype, and potentiation of the antitumor activity of cisplatin.
189769|NCT02723851|Device|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
189770|NCT02723838|Biological|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
189771|NCT02723838|Drug|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
189772|NCT02723838|Drug|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
189773|NCT02723825|Procedure|Closed reduction|Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed
189774|NCT02723825|Procedure|Open reduction|Open reduction and internal fixation
189775|NCT02723812|Biological|GCFLU® Influenza vaccine (Split virion, Inactivated)|
189776|NCT02723799|Behavioral|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
189777|NCT02723799|Other|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
189778|NCT02723786|Biological|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
189779|NCT02723786|Drug|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
189780|NCT02723773|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
189781|NCT02723760|Drug|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.~For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
189782|NCT02723747|Other|myocardial perfusion with magnetic resonance imaging|
189783|NCT02723734|Other|Decipher® Testing|Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
189784|NCT02723721|Drug|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
189785|NCT02723708|Other|Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
189786|NCT02723695|Other|Evaluation of postural performances|Postural tests
189787|NCT02723682|Other|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
189788|NCT02723669|Drug|AR10|effervescent tablet
189789|NCT02723669|Drug|acetylcysteine|oral solution
189790|NCT02723656|Behavioral|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
189791|NCT02723656|Behavioral|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
189792|NCT02723630|Drug|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level <12%~Treatment 2: reference* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level >26%"
189793|NCT02723617|Other|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
189794|NCT02723617|Other|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
189795|NCT02723617|Other|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
189796|NCT02723617|Other|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
189859|NCT02723136|Device|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
189797|NCT02723604|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
189798|NCT02723591|Drug|Tacrolimus|Oral
189799|NCT02723591|Drug|Tacrolimus immediate release|Oral
189800|NCT02723578|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
189801|NCT02723578|Drug|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
189802|NCT02723552|Behavioral|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
189803|NCT02723539|Drug|MBN-101|Topical application
189804|NCT02723539|Drug|Placebo|Topical application
189805|NCT02723526|Other|Blood drawing|
189806|NCT02723513|Other|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
189807|NCT02723500|Device|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
189808|NCT02723487|Drug|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
189809|NCT02723487|Drug|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
189810|NCT02723474|Device|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
189811|NCT02723461|Drug|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
189812|NCT02723461|Drug|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
189813|NCT02723448|Drug|aclarubicin|Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
189814|NCT02723435|Drug|Midostaurin|Given PO
189815|NCT02723422|Procedure|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
189816|NCT02723422|Procedure|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
189817|NCT02723409|Procedure|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
189818|NCT02723409|Procedure|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
189819|NCT02723409|Procedure|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
189820|NCT02723409|Procedure|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
189821|NCT02723409|Procedure|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
189822|NCT02723383|Drug|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
189823|NCT02723383|Drug|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
189824|NCT02723370|Behavioral|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
190012|NCT02722018|Drug|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
189825|NCT02723357|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
189826|NCT02723357|Behavioral|Access to Social Service Referrals|Access to referrals for common social needs.
189827|NCT02723344|Dietary Supplement|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
189828|NCT02723344|Other|Sunflower and medium chain triglyceride oils|Placebo
189829|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for R-PDAC Patients|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
189830|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for BR-PDAC Patients|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
189831|NCT02723318|Behavioral|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
189832|NCT02723318|Behavioral|Access to Referrals to Social Services|
189833|NCT02723305|Other|No intervention|
189834|NCT02723292|Behavioral|TOP|
189835|NCT02723292|Behavioral|Control intervention|
189836|NCT02723279|Behavioral|EPNS|Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
189837|NCT02723279|Drug|TT|Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
189838|NCT02723266|Behavioral|STOPPING-GDM|Educational counseling and skills building Intervention
189839|NCT02723253|Radiation|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement > 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
189840|NCT02723253|Drug|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
189841|NCT02723240|Drug|NUC-3373|
189842|NCT02723227|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
189843|NCT02723227|Behavioral|Referral to Social Services|
189844|NCT02723214|Procedure|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
189845|NCT02723201|Drug|TAK-020 Captisol Oral Solution|TAK-020 solution.
189846|NCT02723201|Drug|TAK-020 CCT|TAK-020 co-crystal tablet
189847|NCT02723201|Drug|TAK-020 SDT|TAK-020 Solid dispersion tablet.
189848|NCT02723201|Drug|TAK-020 IRT|TAK-020 immediate release tablet.
189849|NCT02723201|Drug|TAK-020 CCT|TAK-020 co-crystal tablet.
189850|NCT02723201|Drug|TAK-020 Solid Formulation|TAK-020 solid formulation
189851|NCT02723188|Device|Sham stimulation (1.5 milliampere,30 seconds)|
189852|NCT02723188|Device|DC stimulation (1.5 milliampere, 20 minutes)|
189853|NCT02723188|Device|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
189854|NCT02723175|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
189855|NCT02723162|Drug|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
189856|NCT02723162|Drug|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
189857|NCT02723162|Drug|Placebo|Matched placebo
189858|NCT02723149|Behavioral|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
189860|NCT02723123|Other|Recording of cardio-respiratory signals|Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
189861|NCT02723110|Other|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
189862|NCT02723110|Other|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
189863|NCT02723097|Behavioral|3 RP|
189864|NCT02723084|Drug|ABT-493/ABT-530|Co-formulated tablet
189865|NCT02723084|Drug|sofosbuvir (SOF)|Tablet
189866|NCT02723084|Drug|ribavirin (RBV)|Capsule
189867|NCT02723071|Drug|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
189868|NCT02723058|Behavioral|ICMHM|ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
189869|NCT02723045|Procedure|Open Lichtenstein Hernioplasty|
189870|NCT02723045|Procedure|Laparoscopic TEP Hernioplasty|
189871|NCT02723032|Device|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
189872|NCT02723019|Behavioral|Volunteer Peer Mentor+Behavioral Hlth Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
189873|NCT02723006|Drug|TAK-580|TAK-580 tablets
189874|NCT02723006|Drug|TAK-202|TAK-202 infusion
189875|NCT02723006|Drug|vedolizumab|vedolizumab infusion
189876|NCT02723006|Drug|nivolumab|nivolumab infusion
189877|NCT02723006|Drug|ipilimumab|ipilimumab infusion
189878|NCT02722993|Dietary Supplement|Probiotics|
189879|NCT02722993|Dietary Supplement|Placebo|
189880|NCT02722980|Dietary Supplement|Placebo|The intervention consists of capsules containing placebo.
189881|NCT02722980|Dietary Supplement|: Probiotic capsules|The intervention consists of capsules containing probiotics.
189882|NCT02722967|Drug|Aripiprazole + IEM (Ingestible Event Marker)|Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
189883|NCT02722954|Drug|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
189884|NCT02722954|Drug|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
189885|NCT02722941|Drug|Panobinostat|Maintenance therapy dosing as outlined in Cohorts A and B.
189886|NCT02722928|Other|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
189887|NCT02722915|Procedure|fMRI|collection of functional brain data for 1 hour per day
189888|NCT02722915|Behavioral|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 & 4; controls without AVH: Days 2 & 3)
189889|NCT02722915|Other|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
189890|NCT02722915|Other|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
189891|NCT02722915|Other|SF36|questionnaire about life quality after 1 week during a telephone interview
189892|NCT02722902|Drug|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane."
189893|NCT02722902|Dietary Supplement|IntraLipid|Lipid emulsion for infusion
189894|NCT02722902|Dietary Supplement|Placebo|Saline will be used as placebo
189895|NCT02722876|Other|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
189896|NCT02722876|Other|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
189897|NCT02722850|Behavioral|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
189898|NCT02722837|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
189899|NCT02722824|Device|Electro-stimulation|
189900|NCT02722824|Other|Placebo|
189901|NCT02722811|Drug|Etanercept|etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
189902|NCT02722811|Other|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 8 weeks
189903|NCT02722798|Drug|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
190009|NCT02722070|Device|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
190662|NCT02717156|Biological|Pembrolizumab|Given IV
189904|NCT02722785|Behavioral|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum [1-RM] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
189905|NCT02722772|Drug|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
189906|NCT02722772|Other|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
189907|NCT02722759|Other|hemoglobin measurement|
189908|NCT02722746|Drug|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
189909|NCT02722746|Drug|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
189910|NCT02722733|Drug|G-CSF (filgrastim)|
189911|NCT02722733|Drug|Cytosine arabinoside with G-CSF (filgrastim)|
189912|NCT02722720|Procedure|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
189913|NCT02722720|Procedure|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
189914|NCT02722707|Device|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
189915|NCT02722694|Drug|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
189916|NCT02722694|Other|Placebo|Subjects received weekly SC placebo injections for 24 weeks
189917|NCT02722694|Drug|Methotrexate|All Subjects received backup Methotrexate treatment.
189918|NCT02722681|Procedure|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
189919|NCT02722681|Procedure|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
189920|NCT02722668|Drug|Fludarabine|Both Arms: 30 mg/m^2 IV over 1 hour Day -6 to Day -2
189921|NCT02722668|Drug|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
189922|NCT02722668|Drug|MMF|"Both Arms:~Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, do not stop MMF."
189923|NCT02722668|Drug|Sirolimus|"Both Arms:~Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.~Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
189924|NCT02722668|Radiation|TBI|Both Arms: 200 cGy on Day -1
189925|NCT02722668|Biological|Umbilical cord blood cell infusion|Both Arms: Day 0
189926|NCT02722668|Biological|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
189927|NCT02722642|Biological|Bronchial basal cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
189928|NCT02722629|Procedure|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
190010|NCT02722044|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
189929|NCT02722616|Device|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
189930|NCT02722616|Device|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
189931|NCT02722616|Drug|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
189932|NCT02722603|Drug|gabapentin|75 mg/ml gabapentin syrup
189933|NCT02722603|Drug|tramadol|100 mg/ml tramadol oral drops
189934|NCT02722603|Other|placebo tramadol|placebo tramadol oral drops
189935|NCT02722603|Other|placebo gabapentin|placebo gabapentin syrup
189936|NCT02722577|Procedure|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
189937|NCT02722564|Behavioral|self estimation of breath alcohol content|
189938|NCT02722564|Device|breath alcohol content as measured by Alco Sensor IV device|
189939|NCT02722564|Other|drink a beer|drink a beer, repeat until breath alcohol content 0.1
189940|NCT02722551|Device|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
189941|NCT02722538|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
189942|NCT02722525|Procedure|Magnetic Resonance Imaging|Undergo treadmill stress CMR
189943|NCT02722525|Behavioral|Exercise Intervention|Complete treadmill exercise
189944|NCT02722525|Radiation|Gadopentetate Dimeglumine|Undergo gadopentetate dimeglumine perfusion MRI
189945|NCT02722525|Procedure|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
189946|NCT02722525|Behavioral|Exercise Intervention|Complete resistive lower extremity exercise
189947|NCT02722525|Procedure|Spectroscopy|Undergo skeletal muscle PMRS
189948|NCT02722525|Other|Laboratory Biomarker Analysis|Correlative studies
189949|NCT02722512|Biological|Heat Shock Protein Peptide Complex-96 (HSPPC-96)|The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
189950|NCT02722512|Procedure|Tumor Resection|Clinically-indicated removal of the tumor
189951|NCT02722512|Radiation|Radiation|Focal Radiation Therapy
189952|NCT02722499|Behavioral|Financial Incentive Augmented Education and Skills Training|The intervention is based on the IMB model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Subjects will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes
189953|NCT02722486|Device|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
189954|NCT02722486|Other|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
189955|NCT02722473|Biological|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
189956|NCT02722473|Biological|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
189957|NCT02722447|Drug|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
189958|NCT02722447|Drug|Placebo|Placebo for 6 weeks
189959|NCT02722434|Other|Laboratory Biomarker Analysis|Correlative studies
189960|NCT02722434|Other|MC5-A Scrambler Therapy|Undergo Scrambler therapy
189961|NCT02722434|Other|Questionnaire Administration|Ancillary studies
189962|NCT02722434|Other|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
189963|NCT02722421|Drug|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
189964|NCT02722421|Drug|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
189965|NCT02722408|Drug|Gemcabene 300 mg|1-300 mg tablet, QD, 28 days
189966|NCT02722408|Drug|Gemcabene 600 mg|2-300 mg tablets, QD, 28 days
189967|NCT02722408|Drug|Gemcabene 900 mg|3-300 mg tablets, QD, 28 days
190011|NCT02722044|Device|Autoinjector|Subcutaneous administration
189968|NCT02722382|Other|Patient-Centered Kidney Transitions Care|In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
189969|NCT02722369|Drug|Gemcitabine|Chemotherapy
189970|NCT02722369|Drug|Carboplatin|Chemotherapy
189971|NCT02722369|Drug|Etoposide|Chemotherapy
189972|NCT02722369|Drug|Hydroxychloroquine|Maintenance Agent
189973|NCT02722356|Drug|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
189974|NCT02722343|Drug|Tenofovir intravaginal ring|The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
189975|NCT02722343|Drug|Truvada|The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
189976|NCT02722330|Device|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
189977|NCT02722317|Behavioral|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
189978|NCT02722304|Biological|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
189979|NCT02722304|Biological|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
189980|NCT02722304|Biological|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
189981|NCT02722304|Biological|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
189982|NCT02722304|Biological|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
189983|NCT02722291|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
189984|NCT02722278|Drug|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
189985|NCT02722278|Drug|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.~Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
189986|NCT02722265|Drug|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
189987|NCT02722252|Device|Embryoscope|
189988|NCT02722252|Device|Embryo culture system without incorporated camera|
189989|NCT02722239|Drug|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
189990|NCT02722239|Drug|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
189991|NCT02722239|Drug|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
189992|NCT02722226|Other|Simulation|High fidelity simulation based sedation learning program
189993|NCT02722226|Device|Airway management|Workshop on using airway management and oxygenation devices.
189994|NCT02722226|Behavioral|Crisis resource management|Learning crisis resource management principles
189995|NCT02722213|Behavioral|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
189996|NCT02722200|Drug|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
189997|NCT02722200|Other|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
189998|NCT02722187|Procedure|subinguinal microscopic varicocelectomy|
189999|NCT02722187|Procedure|laparoscopic varicocelectomy|
190000|NCT02722161|Drug|[14C]BI 1482694|
190001|NCT02722148|Device|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
190002|NCT02722135|Drug|Volasertib|
190003|NCT02722122|Drug|AIR DNase™|
190004|NCT02722109|Other|No intervention|No intervention will be done
190005|NCT02722096|Drug|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
190006|NCT02722096|Drug|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
190007|NCT02722083|Drug|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
190008|NCT02722083|Drug|Placebo|placebo tablet, single dose, orally
190013|NCT02722018|Drug|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
190014|NCT02722005|Behavioral|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
190015|NCT02722005|Behavioral|Access to referral to social services|Access to referral to a host of social services.
190016|NCT02721992|Other|No intervention|No intervention
190017|NCT02721979|Drug|Apalutamide|Given PO
190018|NCT02721979|Other|Laboratory Biomarker Analysis|Correlative studies
190019|NCT02721979|Other|Quality-of-Life Assessment|Ancillary studies
190020|NCT02721979|Other|Questionnaire Administration|Ancillary studies
190021|NCT02721966|Biological|AIN457|Anti IL-17a monoclonal antibody
190022|NCT02721966|Drug|AIN457 Placebo|Placebo matching AIN457
190023|NCT02721953|Dietary Supplement|Butyrate|Butyrate
190024|NCT02721953|Other|Placebo|Placebo
190025|NCT02721940|Procedure|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
190026|NCT02721940|Biological|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
190027|NCT02721940|Biological|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
190028|NCT02721940|Drug|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
190029|NCT02721940|Drug|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
190030|NCT02721927|Other|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
190031|NCT02721914|Procedure|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive an amount of eight sessions that will be applied within five weeks; four massotherapy sessions and another 4 of H.A.G. The three first weeks one session of each methodology will be applied, starting always with massotherapy (with sessions on Mondays and Thursdays or on Tuesdays and Fridays). On the fourth week a session of massotherapy will be applied on the same day as usual. And, finally, on the fifth week a session of H.A.G will be applied on the same day as massotherapy is applied.
190032|NCT02721914|Procedure|GROUP RECEIVING MASSOTHERAPY|"The sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~Massotherapy technics will be applied all over the back, covering the thoracolumbar area as well as upper areas reaching the cervix and occiput.~In particular, posterosuperior iliac spines, iliac crests, ribs, shoulder girdle and the entire spine (sacral bone- lumbar area-backbones-cervical vertebrae) and its attached tissues will be worked down.~Massotherapy protocol will be applied by the physical therapist, always respecting the postural ergonomics. This enables the verticality of the body (avoiding the slopes) which makes work much easier thanks to the inertia triggered by the load transfer in the lower extremities in both sagittal and horizontal plane."
190033|NCT02721914|Procedure|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|"The subjects of this group will receive a total of 8 sessions of 30 minutes each; sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.~The techniques applied are an assembly of rhythm, postural and breathing exercises that have to be done in a systematically. The physical therapist will check that all of the group subjects have assimilated properly the H.A.G and the breathing patterns from the exercises protocol. If they have, then the practical session which comprises 6 hypopressive exercises, can be started.~The subjects must remain in each position between 10 and 30 seconds and repeat the exercise three times, with a rest period among each that will last at least 20 seconds."
190034|NCT02721901|Behavioral|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
190035|NCT02721901|Behavioral|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
190036|NCT02721888|Drug|Liraglutide|
190037|NCT02721888|Drug|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|
190038|NCT02721888|Biological|Blood sample|
190039|NCT02721888|Other|Kinetic substudy (10 patients)|
190040|NCT02721875|Drug|Volasertib|
190041|NCT02721875|Drug|Volasertib|
190042|NCT02721875|Drug|Azacitidine|
190043|NCT02721862|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
190044|NCT02721862|Drug|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
190117|NCT02721316|Other|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
190045|NCT02721862|Radiation|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
190046|NCT02721849|Behavioral|Yoga for adolescents|12 week hatha yoga course for adolescents
190047|NCT02721849|Behavioral|Yoga for parents|12 week hatha yoga course
190048|NCT02721836|Behavioral|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
190049|NCT02721836|Behavioral|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
190050|NCT02721823|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
190051|NCT02721823|Behavioral|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
190052|NCT02721810|Behavioral|Consideration of 3-month functional prognosis|
190053|NCT02721797|Procedure|Orthopaedic & Gynaecology surgery|Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
190054|NCT02721784|Device|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
190055|NCT02721784|Radiation|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
190056|NCT02721771|Procedure|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
190057|NCT02721758|Behavioral|Brief Motivational Intervention|
190058|NCT02721745|Behavioral|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
190059|NCT02721745|Device|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
190060|NCT02721745|Device|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
190061|NCT02721732|Other|Laboratory Biomarker Analysis|Correlative studies
190062|NCT02721732|Biological|Pembrolizumab|Given IV
190063|NCT02721732|Other|Questionnaire Administration|Ancillary studies
190064|NCT02721706|Other|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h <50%, serum albumin <3 g/dl, body mass index <18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
190065|NCT02721693|Device|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
190066|NCT02721680|Other|Internal Awareness Training Program|
190067|NCT02721680|Other|External Awareness Training Program|
190068|NCT02721667|Device|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
190069|NCT02721667|Other|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
190070|NCT02721654|Drug|Plasma-Lyte 148®|Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution & when administered intravenously it is a source of water, electrolytes & calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water & electrolytes or as an alkalinising agent.
190071|NCT02721654|Drug|0.9% sodium chloride|The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile & non-pyrogenic solution & is indicated for extracellular fluid replacement & in the management of metabolic alkalosis in the presence of fluid loss, & for restoring or maintaining the concentration of sodium & chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailability (absorption) of the active components is complete (100 per cent).
190072|NCT02721641|Drug|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
190073|NCT02721628|Procedure|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
190074|NCT02721628|Procedure|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
190075|NCT02721628|Device|Femtosecond laser|Use in the epic-keratoplasty surgery
190076|NCT02721615|Procedure|Insertion of intra spinal sub dural pressure monitor|
190077|NCT02721615|Procedure|Insertion of sub dural microdialysis probe|
190078|NCT02721602|Behavioral|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
190079|NCT02721589|Drug|SHR-1210|PD-1 antibody
190080|NCT02721576|Drug|Sodium Glycididazole|Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
190081|NCT02721563|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
190082|NCT02721563|Drug|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
190083|NCT02721550|Drug|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
190084|NCT02721537|Dietary Supplement|Nicotinamide Riboside|Three capsules, twice per day for 84 days
190085|NCT02721537|Other|Matching placebo|Three matching capsules, twice per day for 84 days
190086|NCT02721524|Procedure|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
190087|NCT02721511|Drug|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
190088|NCT02721498|Procedure|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
190089|NCT02721498|Other|Rest period|A 30-60 minute of resting
190090|NCT02721485|Other|Ringer's Lactate|After a 1 week run in half of participating hospitals will be crossed over to using Ringer's Lactate as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
190091|NCT02721485|Other|Normal Saline|After a 1 week run in half of participating hospitals will be crossed over to using Normal Saline as 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
190092|NCT02721472|Procedure|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
190093|NCT02721472|Procedure|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, Annexin A5, RNA and TSP1
190094|NCT02721459|Drug|XL888|"Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.~Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW."
190095|NCT02721459|Drug|Vemurafenib|Vemurafenib 720 mg by mouth twice a day (BID)
190096|NCT02721459|Drug|Cobimetinib|Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.
190097|NCT02721446|Behavioral|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
190098|NCT02721446|Behavioral|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
190099|NCT02721446|Behavioral|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
190100|NCT02721446|Behavioral|Incentive + Salience|Combined message of incentive plus salience.
190101|NCT02721433|Drug|Pamidronate|Bone-targeted agent as standard of care
190102|NCT02721433|Drug|Denosumab|Bone-targeted agent as standard of care
190103|NCT02721433|Drug|Zoledronate|Bone-targeted agent as standard of care
190104|NCT02721420|Drug|dihydroartemisinin-piperaquine|
190105|NCT02721420|Other|message(SMS) reminder|
190106|NCT02721420|Other|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
190107|NCT02721420|Other|short message(SMS) reminder|
190108|NCT02721407|Drug|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
190109|NCT02721394|Behavioral|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
190110|NCT02721381|Behavioral|ImPACT Online|ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
190111|NCT02721368|Device|Neuramis® Volume Lidocaine|hyaluronic acid filler
190112|NCT02721368|Device|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
190113|NCT02721355|Dietary Supplement|GastimunHP|Health food supplement containing specific IgY against urease of H. pylori
190114|NCT02721342|Drug|Ramipril, Irbesartan and Atorvastin|
190115|NCT02721329|Device|APAP|Automatic Continuous Positive Airway Pressure
190116|NCT02721329|Device|APAP with SensAwake|Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
190118|NCT02721303|Dietary Supplement|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
190119|NCT02721303|Procedure|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
190120|NCT02721303|Procedure|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
190121|NCT02721290|Procedure|Femoral nerve block using Ultrasound and neurostimulator|
190122|NCT02721290|Procedure|Femoral nerve block using Ultrasound|
190123|NCT02721290|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
190124|NCT02721277|Drug|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
190125|NCT02721264|Biological|Fecal Microbiota Transplant|
190126|NCT02721264|Other|Standard Medical Treatment|
190127|NCT02721251|Behavioral|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
190128|NCT02721251|Behavioral|Weight Loss|16 week. the goal is 10% weight loss.
190129|NCT02721251|Behavioral|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
190130|NCT02721238|Biological|20% Albumin|
190131|NCT02721238|Other|Plasmalyte|
190132|NCT02721225|Dietary Supplement|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
190133|NCT02721225|Dietary Supplement|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
190134|NCT02721212|Device|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.~Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
190135|NCT02721212|Other|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).~Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.~The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
190136|NCT02721199|Other|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
190137|NCT02721186|Drug|MDA with DHAp and SLD Primaquine|
190138|NCT02721173|Drug|Tazarotene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
190139|NCT02721173|Drug|Adapalene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
190140|NCT02721160|Other|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.~Table: Incentivized indicators~CHW level~nb of cases screened and referred to HC for acute malnutrition (AM)~nb of classes promoting good nutrition~HC level~nb of cases screened and cared for severe and moderate AM~nb of growth follow-ups~Hospital level~nb of treated severe AM cases with complications~length of the stay~All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
190141|NCT02721147|Behavioral|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
190142|NCT02721147|Behavioral|Living Healthy Together|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
190143|NCT02721147|Behavioral|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
190144|NCT02721147|Behavioral|Behavioral, Psychological or Informational Intervention|Receive educational information and support
190145|NCT02721134|Other|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
190147|NCT02721121|Procedure|Linear ablation in addiction to circumferential pulmonary vein isolation|
190148|NCT02721108|Behavioral|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
190149|NCT02721108|Behavioral|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
190150|NCT02721095|Other|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
190151|NCT02721095|Other|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
190152|NCT02721082|Behavioral|Opt Out Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for all participants.
190153|NCT02721082|Drug|Nicotine Replacement Therapy|Unless they Opt Out all participants will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
190154|NCT02721082|Behavioral|Opt In Treatment Program|Tobacco Treatment (UKanQuit) staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.
190155|NCT02721082|Drug|Nicotine Replacement Therapy|Participants ready to quit will be provided with a 14 day supply of the nicotine patch and nicotine mini-lozenges or nicotine gum, depending on study related criteria.
190156|NCT02721069|Drug|NRL-1|
190157|NCT02721056|Radiation|NBTXR3, IL or IA injection + SBRT|Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be maximum 45 Gy, delivered as three fractions of 15 Gy each max, over 5 to 7 days (45 Gy, 3x15 Gy, over 5 to 7 days).
190158|NCT02721043|Biological|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
190159|NCT02721043|Drug|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
190160|NCT02721043|Drug|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
190161|NCT02721017|Device|Cryoanalgesia|
190162|NCT02721017|Drug|Thoracic epidural (ropivicaine, fentanyl)|Epidural infusion was begun with with 0.1% ropivicaine and 2 mg/cc fentanyl.
190163|NCT02721004|Drug|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
190164|NCT02720991|Drug|Mifepristone|200 mg of oral mifepristone
190165|NCT02720991|Drug|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
190166|NCT02720978|Drug|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
190167|NCT02720978|Drug|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.~Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
190168|NCT02720965|Other|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
190169|NCT02720952|Drug|Infacort®|dry granule formulation of hydrocortisone
190170|NCT02720926|Drug|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
190171|NCT02720926|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
190172|NCT02720926|Drug|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
190173|NCT02720913|Device|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
190174|NCT02720913|Procedure|Standard Suture Tying|Standard Suture Tying
190175|NCT02720900|Dietary Supplement|B-GOS|1.8 g/day for 6 weeks
190176|NCT02720900|Dietary Supplement|Maltodextrin|1.8 g/day for 6 weeks
190177|NCT02720887|Procedure|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
190178|NCT02720874|Behavioral|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
190179|NCT02720874|Behavioral|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
190180|NCT02720874|Behavioral|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
190351|NCT02719574|Drug|FT-2102|FT-2102 will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
190352|NCT02719574|Drug|Azacitidine|azacitidine will be administered per site's standard of care
190181|NCT02720874|Behavioral|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
190182|NCT02720874|Behavioral|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
190183|NCT02720861|Genetic|DNA sequencing|withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
190184|NCT02720848|Device|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
190185|NCT02720848|Device|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
190186|NCT02720822|Drug|Placebo|Treatment with placebo is given as one double-blind capsule in the morning.
190187|NCT02720822|Drug|Morphine Sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
190188|NCT02720822|Drug|Plus laxative (Docusate with senna)|If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
190189|NCT02720822|Drug|Plus placebo laxative|If the patients are taking placebo, a placebo laxative will be offered.
190190|NCT02720822|Device|FitBit charge HR (Accelerometer)|A Fitbit will be worn by patients during week 1 and week 3.
190191|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
190192|NCT02720783|Drug|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
190193|NCT02720783|Drug|Placebo plus Econazole nitrate 150 mg vaginal pessary|
190194|NCT02720783|Drug|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
190195|NCT02720783|Drug|Placebo vaginal pessary|
190196|NCT02720770|Drug|norditropine simplex|
190197|NCT02720757|Drug|Spiolto Respimat|Tiotropium bromide + Olodaterol
190198|NCT02720744|Drug|Sodium Oxybate|
190199|NCT02720744|Drug|Placebo|
190200|NCT02720718|Device|Stratafix|
190201|NCT02720718|Device|Vicryl|
190202|NCT02720705|Drug|Dexmedetomidine|oral dexmedetomidine
190203|NCT02720705|Drug|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
190204|NCT02720692|Drug|N1539|
190205|NCT02720692|Drug|Intravenous Placebo|
190206|NCT02720666|Drug|K-001|In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
190207|NCT02720653|Procedure|Endoscopic sinus surgery|
190208|NCT02720640|Device|Implant 'on' vs implant 'off'|Single group assignment
190209|NCT02720627|Drug|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
190210|NCT02720614|Radiation|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
190211|NCT02720601|Drug|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
190212|NCT02720575|Other|Consumption of capsule/bread with vitamin D|
190213|NCT02720549|Procedure|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
190214|NCT02720549|Procedure|valvular surgery with bypass|valvular surgery with bypass
190215|NCT02720536|Drug|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
190216|NCT02720523|Drug|Placebo|Tablets taken orally once a day
190217|NCT02720523|Drug|Upadacitinib|Tablets taken orally once a day
190218|NCT02720510|Drug|Revlimid|Revlimid was used with dexamethasone to treat patients with multiple myeloma
190219|NCT02720510|Drug|Velcade|Velcade was a proteasome inhibitor indicated for treatment of patients with multiple myeloma
190220|NCT02720510|Drug|dexamethasone|Dexamethasone was a steroid used to treat patients with multiple myeloma.
190221|NCT02720510|Drug|Farydak|FARYDAK® (panobinostat) capsules was a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
190222|NCT02720497|Behavioral|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
190223|NCT02720497|Behavioral|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
190224|NCT02720484|Other|Laboratory Biomarker Analysis|Correlative studies
190225|NCT02720484|Drug|Nivolumab|Given IV
190226|NCT02720471|Drug|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
190227|NCT02720471|Drug|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
190228|NCT02720458|Other|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
190229|NCT02720458|Behavioral|Short-term simple self-help program|"The short-term simple self-help program consists in:~Restriction of time in bed~Stimulus control instructions~The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
190230|NCT02720445|Drug|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
190231|NCT02720445|Drug|Placebo Patch|Matching placebo patches worn during waking hours.
190232|NCT02720432|Other|CIMT|Constraint-induced movement therapy
190233|NCT02720432|Other|HABIT|hand-arm bimanual intensive training
190234|NCT02720432|Other|baby-massage|instructions for baby-massage
190235|NCT02720406|Drug|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
190236|NCT02720406|Drug|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
190237|NCT02720406|Drug|Nebulized Ketamine 2mg/kg|Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
190238|NCT02720406|Drug|saline placebo|Saline 0.9% given by nebulizer before anesthesia and iv after anesthesia and before surgery.
190239|NCT02720393|Other|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
190240|NCT02720393|Other|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
190241|NCT02720380|Other|Buteyko|Intervention will be held twice a week during 3 weeks.
190242|NCT02720380|Other|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
190243|NCT02720367|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.
190244|NCT02720354|Other|[11C]‑DMDPA|
190245|NCT02720341|Device|ARMin|single sessions of about one hour each
190246|NCT02720328|Biological|Blood samples for DOAC measurement|
190247|NCT02720315|Procedure|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
190248|NCT02720302|Behavioral|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
190249|NCT02720302|Behavioral|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
190250|NCT02720289|Other|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
190251|NCT02720289|Other|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
190252|NCT02720276|Other|Training after acute stroke|Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
190253|NCT02720263|Drug|ASP4345|Oral
190254|NCT02720263|Drug|Matching Placebo|Oral
190255|NCT02720250|Dietary Supplement|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
190256|NCT02720250|Dietary Supplement|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
190257|NCT02720237|Behavioral|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
190258|NCT02720237|Behavioral|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
190259|NCT02720237|Behavioral|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
190260|NCT02720224|Drug|Estetrol|15 mg [14C]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
190261|NCT02720211|Device|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
190262|NCT02720211|Device|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
190263|NCT02720198|Drug|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
190264|NCT02720198|Drug|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
190265|NCT02720185|Drug|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
190266|NCT02720185|Procedure|Conventional Surgery|Undergo surgery
190267|NCT02720185|Other|Laboratory Biomarker Analysis|Correlative studies
190268|NCT02720172|Behavioral|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
190269|NCT02720172|Other|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
190270|NCT02720159|Device|Percutaneous Osseintegrated Prosthesis|
190271|NCT02720133|Biological|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.~All these tests should be practice before, during and after Ramadan fasting for comparison."
190272|NCT02720120|Drug|Ocrelizumab|Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
190273|NCT02720120|Drug|Placebo|Participants will receive single IV infusion of placebo.
190274|NCT02720107|Drug|fingolimod|
190275|NCT02720094|Drug|Cabotegravir tablets|30 mg tablets
190276|NCT02720094|Drug|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
190277|NCT02720094|Drug|TDF/FTC placebo tablets|
190278|NCT02720094|Drug|CAB placebo tablets|
190279|NCT02720094|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
190280|NCT02720094|Drug|Placebo for CAB LA|Administered as one 3 mL IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
190281|NCT02720081|Drug|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
190282|NCT02720081|Drug|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
190283|NCT02720081|Drug|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
190284|NCT02720081|Drug|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
190285|NCT02720068|Biological|MK-4280|IV infusion
190286|NCT02720068|Biological|Pembrolizumab|IV infusion
190287|NCT02720068|Drug|Oxaliplatin|IV infusion
190288|NCT02720068|Drug|Irinotecan|IV infusion
190289|NCT02720068|Drug|Leucovorin (Calcium Folinate)|IV infusion
190290|NCT02720068|Drug|Fluorouracil [5-FU]|IV infusion
190291|NCT02720068|Biological|MK-4280A|IV infusion
190292|NCT02720055|Other|Psychological workbook|
190293|NCT02720055|Other|Basic information workbook|Basic rehabilitation information that represents current practice.
190294|NCT02720042|Device|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)
190295|NCT02720029|Device|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
190296|NCT02720016|Behavioral|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
190297|NCT02720016|Behavioral|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 8 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
190298|NCT02720016|Behavioral|PTSD Family Education (PFE)|Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist?s office.
190299|NCT02720003|Device|LTX DCB|Treatment with a drug-coated balloon
190300|NCT02719990|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
190301|NCT02719977|Drug|CX5461|
190302|NCT02719964|Other|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
190303|NCT02719964|Other|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
190304|NCT02719964|Other|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
190305|NCT02719951|Drug|[18F]FPEB PET imaging|PET exam
190306|NCT02719951|Other|Biological samples|blood sample and urine sample
190307|NCT02719951|Other|MRI|MRI exam
190308|NCT02719938|Behavioral|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
190309|NCT02719925|Other|Mg(+)|"1,5 L per day during 30 days~No livestyle counseling"
190310|NCT02719925|Other|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
190311|NCT02719912|Device|mitral valve replacement|transcatheter mitral valve replacement
190312|NCT02719886|Device|Ultrasound|Estimation of fetal weight by ultrasound
190313|NCT02719873|Other|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
190314|NCT02719860|Dietary Supplement|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
190315|NCT02719860|Dietary Supplement|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
190316|NCT02719860|Dietary Supplement|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
190317|NCT02719847|Procedure|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
190318|NCT02719834|Drug|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
190319|NCT02719834|Other|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
190320|NCT02719821|Behavioral|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.~Device: Actiwatch-2 (Philips Respironics)"
190321|NCT02719808|Drug|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
190322|NCT02719808|Drug|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
190323|NCT02719808|Drug|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
190324|NCT02719808|Drug|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
190325|NCT02719795|Drug|Ropivacaine|Local injection of local anesthetic into the fascial spaces
190326|NCT02719795|Drug|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
190327|NCT02719782|Biological|Biological: TCR-T|Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
190328|NCT02719756|Drug|Metformin|Metformin tablets 1000 mg
190329|NCT02719756|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets
190330|NCT02719756|Drug|Metformin up-titration|
190331|NCT02719743|Biological|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
190332|NCT02719730|Behavioral|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
190333|NCT02719717|Device|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
190334|NCT02719704|Behavioral|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
190335|NCT02719704|Behavioral|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
190336|NCT02719691|Drug|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
190337|NCT02719691|Drug|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
190338|NCT02719678|Other|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
190339|NCT02719665|Dietary Supplement|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:~Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
190340|NCT02719665|Dietary Supplement|SPM Softgel, Dose-Modality|Phase 1b Dose-Finding oral softtel SPM administration of two different doses (2 softgel vs 4 softgel) Days 0 to 5: 2 SPM softgel; Days 6 to 21: Washout, no SPM administration; Days 22 to 26: 4 SPM softgel; Days 27-42: Washout, no SPM administration
190341|NCT02719665|Dietary Supplement|Placebo Softgel|Days 43-47: 4 Placebo softgel; Day 48-64 Washout
190342|NCT02719613|Drug|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
190343|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
190344|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
190345|NCT02719613|Drug|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
190346|NCT02719613|Drug|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
190347|NCT02719600|Behavioral|Virtual reality|Evaluation of observational motor learning using virtual reality
190348|NCT02719587|Procedure|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
190349|NCT02719587|Procedure|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
190350|NCT02719587|Procedure|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
190353|NCT02719574|Drug|Cytarabine|low-dose cytarabine will be administered per site's standard of care
190354|NCT02719561|Behavioral|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
190355|NCT02719548|Device|Soft edge oval - Hard oval - Modified PF breast shield|"Treatment order:~soft-edge oval breast shield~Hard oval breast shield~modified PersonalFit breast shield"
190356|NCT02719548|Device|Modified PF breast shield - Soft edge oval - Hard oval|"modified PersonalFit breast shield~soft-edge oval breast shield~Hard oval breast shield"
190357|NCT02719548|Device|Hard oval - Soft edge oval - Modified PF breast shield|"Hard oval breast shield~soft-edge oval breast shield~modified PersonalFit breast shield"
190358|NCT02719535|Other|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
190359|NCT02719522|Device|Pipeline™ Flex Embolization Device with Shield Technology™|"Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.~The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot."
190360|NCT02719509|Procedure|Cardiac Ultrasound|
190361|NCT02719496|Drug|IBEROGAST|
190362|NCT02719483|Device|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
190363|NCT02719483|Procedure|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
190364|NCT02719470|Behavioral|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
190365|NCT02719457|Other|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
190366|NCT02719457|Other|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
190367|NCT02719431|Drug|Warfarin|
190368|NCT02719431|Drug|K-877|
190369|NCT02719418|Drug|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
190370|NCT02719405|Dietary Supplement|Lactobacillus GG|Lactobacillus GG
190371|NCT02719405|Dietary Supplement|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
190372|NCT02719405|Dietary Supplement|Amino Acid Formula|Amino Acid Formula
190373|NCT02719392|Dietary Supplement|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
190374|NCT02719392|Drug|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
190375|NCT02719392|Other|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
190376|NCT02719379|Biological|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
190377|NCT02719340|Procedure|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
190378|NCT02719327|Drug|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
190379|NCT02719327|Other|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
190380|NCT02719314|Drug|Glucocorticoid treatment|Glucocorticoid treatment
190381|NCT02719288|Biological|CLARIX® CORD 1K graft|
190382|NCT02719275|Behavioral|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
190383|NCT02719262|Device|installing ventilation in the workplace|Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
190384|NCT02719249|Other|Dried blood spot test|
190385|NCT02719236|Procedure|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.~Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.~Once the final implants are in situ, the hip is reduced and assessed."
190467|NCT02718521|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
190468|NCT02718521|Drug|0.9% sodium chloride ﬂuid administration|
190469|NCT02718521|Drug|isosorbide dinitrate|
190473|NCT02718482|Drug|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
190386|NCT02719236|Procedure|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.~A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.~The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.~When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
190387|NCT02719223|Device|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
190388|NCT02719210|Biological|High Volume Plasma Exchange|
190389|NCT02719210|Drug|Hypertonic 3% saline|
190390|NCT02719210|Drug|Mannitol|
190391|NCT02719210|Device|Elective positive pressure ventilation|
190392|NCT02719197|Drug|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
190393|NCT02719197|Drug|Placebo|Placebo capsules matching AC-083 capsules
190394|NCT02719171|Drug|risankizumab|Risankizumab administered by SC injection
190395|NCT02719171|Drug|placebo for risankizumab|Placebo for risankizumab administered by SC injection
190396|NCT02719158|Drug|6 mg ciprofloxacin|Single administration of OTO-201
190397|NCT02719158|Drug|12 mg ciprofloxacin|Single administration of OTO-201
190398|NCT02719158|Other|Sham|
190399|NCT02719132|Drug|Dapagliflozin|Dapagliflozin, 10 mg
190400|NCT02719132|Drug|Metformin|Metformin, up to 2500 mg
190401|NCT02719119|Procedure|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
190402|NCT02719119|Procedure|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
190403|NCT02719106|Device|Ultimaster stent|
190404|NCT02719093|Drug|recombinant FSH|Subcutaneous injection
190405|NCT02719054|Behavioral|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.~B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
190406|NCT02719041|Other|Immunohistochemistry staining method|
190407|NCT02719028|Drug|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
190408|NCT02719028|Drug|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
190409|NCT02719015|Drug|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10^11 vp. Subsequently enrolled patients injected at the same dose of 1x10^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have >/=2 injectable lesions, at the same injection dose of 1x10^10 up to three separate sites/lesions if patients have > 3 injectable lesions.~Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
190410|NCT02719015|Drug|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
190411|NCT02719002|Device|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
190412|NCT02718989|Device|Transcutaneous Electrical Stimulation|TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
190413|NCT02718989|Device|10Kilohertz (KHz)|10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
190414|NCT02718989|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
190415|NCT02718976|Procedure|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
190416|NCT02718976|Procedure|Ultrasound guided lumbar plexus block (Shamrock)|
190417|NCT02718976|Drug|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
190418|NCT02718963|Device|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
190419|NCT02718950|Drug|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
190420|NCT02718937|Drug|BTA-C585 oral capsule|
190421|NCT02718937|Drug|Matching placebo capsules|
190422|NCT02718911|Drug|LY3022855|Administered IV
190423|NCT02718911|Drug|Durvalumab|Administered IV
190424|NCT02718911|Drug|Tremelimumab|Administered IV
190425|NCT02718898|Drug|Ixekizumab|Administered SC
190426|NCT02718898|Drug|Placebo|Administered SC
190427|NCT02718885|Dietary Supplement|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
190428|NCT02718885|Dietary Supplement|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
190470|NCT02718508|Behavioral|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
190471|NCT02718495|Drug|PTI-428|
190429|NCT02718872|Behavioral|Tobacco cessation online training|"The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules."
190430|NCT02718859|Biological|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
190431|NCT02718859|Procedure|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
190432|NCT02718846|Drug|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
190433|NCT02718846|Drug|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
190434|NCT02718833|Drug|Elotuzumab|
190435|NCT02718833|Drug|Pomalidomide|
190436|NCT02718833|Drug|Bortezomib|
190437|NCT02718833|Drug|Dexamethasone|
190438|NCT02718820|Drug|Docetaxel|Docetaxel 75mg/m2; q21
190439|NCT02718820|Drug|Pembrolizumab|Pembrolizumab 200mg, q21
190440|NCT02718807|Other|RP model explanation and questionnaire|Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
190441|NCT02718794|Procedure|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
190442|NCT02718794|Procedure|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
190443|NCT02718781|Behavioral|Health talk|Health talk on zero-time exercise.
190444|NCT02718781|Behavioral|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
190445|NCT02718781|Device|Handgrip|This is a home-based equipment
190446|NCT02718755|Drug|Fludarabine|"Induction Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle."
190447|NCT02718755|Drug|Cytarabine|"Induction Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.~Consolidation Phase:~2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle."
190448|NCT02718755|Drug|Erwinase|"Induction Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.~Consolidation Phase:~25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle."
190449|NCT02718742|Other|Laboratory Biomarker Analysis|Correlative studies
190450|NCT02718742|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
190451|NCT02718742|Other|Quality-of-Life Assessment|Ancillary studies
190452|NCT02718729|Procedure|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
190453|NCT02718716|Drug|UCB7665|"Intervention Type: Biological/Vaccine~Pharmaceutical Form: Powder for solution for infusion~Concentration: 100 mg/ml - Route of Administration:~Subcutaneous infusion"
190454|NCT02718703|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
190455|NCT02718690|Device|TENS|TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
190456|NCT02718690|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
190457|NCT02718677|Drug|Refacto AF|Observational - Non-Interventional Study
190458|NCT02718664|Other|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
190459|NCT02718638|Other|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
190460|NCT02718625|Biological|Santyl|Collagenase ointment applied topically
190461|NCT02718625|Biological|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
190462|NCT02718599|Drug|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
190463|NCT02718599|Drug|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
190464|NCT02718560|Behavioral|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
190465|NCT02718547|Drug|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
190466|NCT02718521|Procedure|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
190472|NCT02718495|Drug|Placebo|
190474|NCT02718482|Drug|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
190475|NCT02718469|Biological|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
190476|NCT02718469|Biological|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
190477|NCT02718469|Biological|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
190478|NCT02718469|Biological|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
190479|NCT02718456|Behavioral|Expedited CD4 testing|
190480|NCT02718456|Behavioral|Supplemental peer counseling|
190481|NCT02718443|Drug|VXM01|Oral immunotherapy targeting VEGFR2
190482|NCT02718430|Drug|VXM01|Oral immunotherapy targeting VEGFR2
190483|NCT02718417|Drug|carboplatin|Given Q3W during chemotherapy phase
190484|NCT02718417|Drug|paclitaxel|Investigator choice of weekly or Q3W during chemotherapy phase
190485|NCT02718417|Drug|Avelumab|Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
190486|NCT02718417|Drug|Avelumab|Given as single agent in maintenance portion Q2W
190487|NCT02718404|Procedure|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.~At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI."
190488|NCT02718404|Drug|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
190489|NCT02718404|Procedure|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
190490|NCT02718391|Biological|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
190491|NCT02718378|Drug|estetrol|
190492|NCT02718378|Drug|placebo|
190493|NCT02718365|Procedure|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
190494|NCT02718365|Procedure|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
190495|NCT02718352|Other|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
190496|NCT02718339|Behavioral|Intensive counseling|
190497|NCT02718326|Drug|Intravitreal aflibercept injection [IAI]|
190498|NCT02718326|Drug|Sham|
190499|NCT02718300|Drug|Parsaclisib|Up to 3 oral once a day (QD) doses of parsaclisib. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
190500|NCT02718300|Drug|Parsaclisib|Two recommended oral QD doses of parsaclisib. Once daily doses of parsaclisib will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
190501|NCT02718300|Drug|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of parsaclisib.
190502|NCT02718300|Drug|Parsaclisib|20 mg oral QD dose of parsaclisib for 8 weeks. After 8 weeks patients will take either 20 mg once weekly or 5 mg once daily.
190503|NCT02718300|Drug|Parsaclisib|"2 dose strategies will be compared:~5 mg parsaclisib beginning on Day 1 until end of treatment.~20 mg oral QD dose of parsaclisib for 8 weeks; after 8 weeks patients will take 5 mg once daily."
190504|NCT02718287|Behavioral|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
190505|NCT02718287|Behavioral|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
190506|NCT02718274|Device|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
190507|NCT02718274|Other|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
190508|NCT02718261|Drug|Pantoprazole|
190509|NCT02718261|Drug|Saline 0.9% (matching placebo)|
190510|NCT02718248|Device|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
190511|NCT02718248|Behavioral|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
190512|NCT02718235|Other|Overall survival|Observation of overall and disease free survival
190513|NCT02718222|Device|Post-partum IUD|The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
190514|NCT02718209|Device|Mid-Infrared Spectroscopy with ATR|
190515|NCT02718196|Behavioral|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
190516|NCT02718183|Other|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
190517|NCT02718183|Other|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
190518|NCT02718170|Procedure|Buried Intramedullary K-wire Fixation|
190520|NCT02718157|Device|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
190521|NCT02718144|Drug|Estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
190522|NCT02718131|Device|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
190523|NCT02718131|Procedure|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
190524|NCT02718118|Device|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
190525|NCT02718118|Device|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
190526|NCT02718105|Genetic|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
190527|NCT02718092|Device|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
190528|NCT02718092|Device|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
190529|NCT02718079|Biological|Plasma Exchange|
190530|NCT02718079|Other|Management of cerebral edema/intracranial hypertension:|
190531|NCT02718079|Other|Transfer to Intensive Care Unit|
190532|NCT02718079|Drug|Prophylactic Antibiotics|
190533|NCT02718079|Other|Intubation of trachea|
190534|NCT02718079|Other|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
190535|NCT02718079|Other|Volume Replacement|
190536|NCT02718079|Other|Pressor Support|
190537|NCT02718079|Drug|N-acetyl-L-cysteine|
190538|NCT02718079|Other|Correction of metabolic parameters|
190539|NCT02718079|Dietary Supplement|Correction of nutrition|
190540|NCT02718066|Drug|HBI-8000 in combination with nivolumab|"Phase 1b: HBI-8000, orally, twice a week, dose escalation 20mg, 30mg, 40mg; in combination with nivolumab 240mg intravenous infusion every 2 weeks.~Phase 2: HBI-8000 MTD or 40mg; in combination with nivolumab in accordance with the manufacturer package insert and institution's prescribing practice."
190541|NCT02718053|Other|L-stiff|spasticity measurement with Lokomat
190542|NCT02718053|Other|Ashworth|spasticity measurement with Ashworth scale
190543|NCT02718040|Device|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
190544|NCT02718014|Other|scaling and root planing (srp)|
190545|NCT02718001|Device|Edwards EVOQUE Transcatheter Mitral Valve Replacement System|Replacement of the mitral valve through a transcatheter approach
190546|NCT02717988|Drug|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
190547|NCT02717988|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
190548|NCT02717975|Procedure|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
190549|NCT02717975|Procedure|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
190550|NCT02717962|Drug|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
190551|NCT02717949|Drug|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
190552|NCT02717949|Drug|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
190553|NCT02717949|Drug|Ribavirin|ribavirin 1200 mg given orally in divided dose for those >75kg and 1000 mg in divided dose for those <75 kg.
190554|NCT02717936|Procedure|Immunohistochemistry using Pancytokeratin Staining|
190555|NCT02717923|Other|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
190556|NCT02717910|Behavioral|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
190557|NCT02717910|Behavioral|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
190558|NCT02717897|Other|No intervention|This study is not interventional
190559|NCT02717884|Drug|tranylcypromine|"TCP p.o., daily either 20, 40**, 60**, 80** mg/day, (28d/cycle)~**TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
190560|NCT02717884|Drug|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
190561|NCT02717884|Drug|cytarabine|40mg s.c. (days 1-10)
190562|NCT02717871|Device|PACK-CXL|"Local anesthesia~- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times~Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer~Corneal scrape~Hypo-osmolaric riboflavin solution~- Apply one drop every 2 minutes for 20 minutes~UV-A irradiation~3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)~Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.~Additional postoperative treatment~Homatropin or Scopolamin, if anterior chamber reaction~Systemic NSAID/NSAR, if substantial pain~Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
190563|NCT02717871|Drug|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.~Initial empiric topical antibiotic therapy (eye drops or ocular ointment):~1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
190564|NCT02717871|Drug|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
190565|NCT02717871|Drug|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
190566|NCT02717871|Drug|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
190567|NCT02717858|Drug|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
190568|NCT02717858|Drug|placebo|Injected s.c./subcutaneously (under the skin) once daily.
190569|NCT02717845|Device|Ellipse|diagnostic CT scan imaging
190570|NCT02717845|Device|Tomofix|diagnostic CT scan imaging
190571|NCT02717832|Drug|hyperinsulinemic-euglycemic clamp|
190572|NCT02717819|Dietary Supplement|Protein|Daily intake of supplement
190573|NCT02717819|Dietary Supplement|Placebo|Daily intake of supplement
190574|NCT02717819|Other|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
190575|NCT02717819|Dietary Supplement|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
190576|NCT02717806|Behavioral|PATHway|Patients will use the PATHway platform for 6 months
190577|NCT02717793|Other|Strength testing|"isometric muscle strength~1RM measurement of muscle strength"
190578|NCT02717780|Drug|Fentanyl and sevoflurane|
190579|NCT02717780|Drug|Remifentanil and desflurane|
190580|NCT02717767|Other|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
190581|NCT02717754|Drug|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
190582|NCT02717754|Drug|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
190583|NCT02717741|Drug|tafetinib|
190584|NCT02717728|Procedure|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.~Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.~Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
190585|NCT02717728|Procedure|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.~Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.~Device: Dressing~Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
190586|NCT02717715|Behavioral|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
190587|NCT02717689|Other|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
190588|NCT02717676|Procedure|Episiotomy|episiotomy will be done after crowning of the fetal head
190589|NCT02717663|Behavioral|Adaptive Goals|Prescribed goals change daily based on participant's performance
190590|NCT02717663|Behavioral|Static Goals|Prescribed goals remain the same throughout study
190591|NCT02717663|Behavioral|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
190592|NCT02717663|Behavioral|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
190593|NCT02717650|Other|A-STEP|"Study A) Study A) Development of new exercise test protocol and Observational Feasibility/Safety Study (no comparator).~Feasibility/safety of a newly designed, incremental, maximal, standardised step test in adults with Cystic Fibrosis."
190594|NCT02717650|Other|A-STEP (New Protocol)|Study B) Validation Study (random allocation of test order). Validity of an incremental, maximal, standardised incremental step test with breath-by-breath gas analysis using portable metabolic measurement equipment against CPET.
190595|NCT02717650|Other|Comparator: CPET cycle ergometer (Gold Standard)|"Study B) Validation study (random allocation of test order) Gold standard CPET. An incremental, maximal standardised cycle ergometer exercise test (performed as per published protocol) using portable metabolic measurement equipment."
190596|NCT02717624|Drug|Acalabrutinib in combination with BR|
190597|NCT02717624|Drug|Acalabrutinib in combination with VR|
190598|NCT02717611|Drug|ACP-196 (acalabrutinib)|
190599|NCT02717598|Procedure|cold snare polypectomy|CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.
190600|NCT02717598|Procedure|hot snare polypectomy|HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
190601|NCT02717585|Device|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
190602|NCT02717572|Radiation|Fludeoxyglucose F 18|
190603|NCT02717572|Device|Positron Emission Tomography|
190604|NCT02717572|Device|Computerized Tomography|
190605|NCT02717572|Device|Magnetic Resonance Imaging|
190606|NCT02717546|Device|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
190607|NCT02717533|Other|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
190608|NCT02717520|Device|EQUIA Forte and Tetric EvoCeram|"GC cavity conditioner (20% polyacrylic acid) will be applied for 10 sec, rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 min 30 sec after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat will be applied to the surfaces and light cured with D-light for 20 sec.~Enamel will be etched with 37% orthophosphoric acid for 10 sec. After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (1200 mW/cm2, slow mode) for 10 sec. The composite resin will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece and polished."
190609|NCT02717507|Drug|Carvedilol|Given PO
190610|NCT02717507|Other|Laboratory Biomarker Analysis|Correlative studies
190611|NCT02717507|Other|Pharmacogenomic Study|Correlative studies
190612|NCT02717507|Other|Pharmacological Study|Correlative studies
190613|NCT02717507|Other|Placebo|Given PO
190614|NCT02717507|Other|Quality-of-Life Assessment|Ancillary studies
190615|NCT02717507|Other|Questionnaire Administration|Ancillary studies
190616|NCT02717494|Biological|PPV-23|PPV-23 is a polysaccharide PNC vaccine, licensed in Brazil, that is directed against 23 serotypes.
190617|NCT02717494|Biological|PCV-10|PCV-10 is a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
190618|NCT02717494|Other|NaCl|NaCl is the placebo for the study against which the two vaccines will be compared during pregnancy.
190619|NCT02717481|Device|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
190620|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
190621|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
190622|NCT02717455|Drug|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.~STRATUM 2: Non-progressed DIPG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
190623|NCT02717442|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
190624|NCT02717442|Drug|Placebo|Single intratympanic injection of placebo
190625|NCT02717429|Behavioral|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
190663|NCT02717156|Procedure|Positron Emission Tomography|Correlative studies
190664|NCT02717156|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
190665|NCT02717130|Drug|Aripiprazole|
190626|NCT02717429|Behavioral|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
190627|NCT02717416|Device|Endo-Clot|After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
190628|NCT02717416|Device|Hemoclip|After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist.
190629|NCT02717403|Behavioral|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
190630|NCT02717403|Behavioral|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
190631|NCT02717403|Behavioral|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
190632|NCT02717403|Behavioral|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
190633|NCT02717390|Behavioral|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
190634|NCT02717390|Behavioral|Texts for Child Safety (TCS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
190635|NCT02717377|Behavioral|physical activity|
190636|NCT02717364|Drug|Yervoy|
190637|NCT02717351|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-07)
190638|NCT02717338|Behavioral|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
190639|NCT02717338|Behavioral|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
190640|NCT02717338|Behavioral|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
190641|NCT02717325|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-08)
190642|NCT02717299|Device|Verasense|Verasense will collect balancing data on all patients in this trial.
190643|NCT02717286|Procedure|restorative|It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
190644|NCT02717273|Drug|standard|peri-operative antibiotic regimen only
190645|NCT02717273|Drug|extended|extended three-day course of antibiotics
190646|NCT02717273|Other|liver transplant|orthotopic liver transplantation
190647|NCT02717260|Device|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
190648|NCT02717247|Device|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).~100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
190649|NCT02717247|Device|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
190650|NCT02717234|Other|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
190651|NCT02717221|Other|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
190652|NCT02717208|Biological|HL036|
190653|NCT02717208|Biological|Vehicle|
190654|NCT02717195|Drug|Risperidone|4-6 mg/day, encapsulated tablets, orally
190655|NCT02717195|Drug|Olanzapine|15-20 mg/day, encapsulated tablets, orally
190656|NCT02717195|Drug|Lu AF35700|10 mg/day, encapsulated tablets, orally
190657|NCT02717195|Drug|Lu AF35700|20 mg/day, encapsulated tablets, orally
190658|NCT02717182|Other|interviews|interviews
190659|NCT02717169|Device|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
190660|NCT02717156|Procedure|Computed Tomography|Correlative studies
190666|NCT02717117|Other|Soup meal|Soup meal as above
190667|NCT02717091|Drug|FOLFIRINOX|
190668|NCT02717091|Drug|gemcitabine + nab-paclitaxel|
190669|NCT02717078|Other|Diet Therapy|The intervention for both study groups will be a change in diet.
190670|NCT02717065|Other|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
190671|NCT02717065|Other|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
190672|NCT02717052|Drug|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
190673|NCT02717052|Drug|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH~Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
190674|NCT02717052|Drug|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
190675|NCT02717052|Drug|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
190676|NCT02717052|Other|PILOT Study II: PET1|[11C]DASB PET
190677|NCT02717052|Other|PILOT Study II: PET2|[11C]DASB PET
190678|NCT02717052|Other|Main Study: PET1|[11C]DASB PET
190679|NCT02717052|Other|Main Study: PET2|[11C]DASB PET
190680|NCT02717052|Other|PILOT Study I: PET1|[11C]DASB PET
190681|NCT02717052|Other|PILOT Study I: PET2|[11C]DASB PET
190682|NCT02717052|Drug|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
190683|NCT02717052|Drug|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma~Dosis: 0.80mg/kg bodyweight i.v. over 50"
190684|NCT02717052|Other|PILOT Study III: PET1|[11C]DASB PET
190685|NCT02717052|Other|PILOT Study III: PET2|[11C]DASB PET
190686|NCT02717039|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
190687|NCT02717026|Device|Optical coherence tomography|Sections including the retinal vasculature will be taken.
190688|NCT02717026|Device|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
190689|NCT02717026|Device|Fundus photography|30 and 50 degree fundus images
190690|NCT02717013|Dietary Supplement|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
190691|NCT02717013|Dietary Supplement|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
190692|NCT02716987|Drug|TAK-831|TAK-831 Suspension
190693|NCT02716987|Drug|[18F]PGM299|[18F]PGM299 Injection
190694|NCT02716974|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
190695|NCT02716974|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
190696|NCT02716974|Drug|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
190697|NCT02716974|Procedure|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
190698|NCT02716974|Radiation|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
190699|NCT02716961|Drug|Gemcitabine, cisplatin|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
190700|NCT02716948|Other|Laboratory Biomarker Analysis|Correlative studies
190701|NCT02716948|Biological|Nivolumab|Given IV
190702|NCT02716948|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
190703|NCT02716935|Dietary Supplement|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
190704|NCT02716935|Dietary Supplement|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
190705|NCT02716922|Procedure|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
190706|NCT02716909|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
190707|NCT02716896|Radiation|Radiation and chemoradiation|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
190708|NCT02716896|Procedure|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
190709|NCT02716883|Procedure|AMT|"The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.~In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed."
190710|NCT02716870|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
190711|NCT02716857|Drug|Oxycodone extended-release|
190712|NCT02716857|Drug|Placebo of oxycodone extended-release|
190713|NCT02716844|Other|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
190714|NCT02716831|Behavioral|Nutritional Counseling & Acceptance-based Therapy|
190715|NCT02716831|Behavioral|Cognitive Behavioral Therapy for Eating Disorders|
190716|NCT02716818|Drug|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
190717|NCT02716818|Drug|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
190718|NCT02716805|Drug|Tremelimumab|Tremelimumab was administered as an intravenous (IV) infusion over 60 ± 5 minutes at a fixed dose of 75 mg, regardless of weight.
190719|NCT02716805|Drug|Durvalumab|"Durvalumab was administered as an IV infusion over 60 ± 5 minutes at a fixed dose of 1500 mg for subjects weighing > 30 kg. If a subject's body weight dropped to ≤ 30 kg on study, the subject was dosed at 600 mg for as long as the body weight remained ≤ 30 kg.~When applicable, the durvalumab infusion was to start at least 60 minutes after the end of the tremelimumab infusion."
190720|NCT02716805|Biological|Prevnar-13|Prevnar-13 was administered as an intramuscular injection. The Prevnar-13 dose and the tremelimumab dose were to be separated by a minimum of 48 hours.
190721|NCT02716805|Drug|Melphalan|Melphalan was administered as an IV infusion according to institutional standard of care and local prescribing information.
190722|NCT02716792|Drug|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
190723|NCT02716779|Drug|Pegylated Interferon (PEG-IFN) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
190724|NCT02716779|Drug|Placebo|Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
190725|NCT02716779|Drug|Ribavirin|Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
190726|NCT02716766|Drug|Sorafenib|PO
190727|NCT02716766|Drug|Capecitabine|PO
190728|NCT02716766|Drug|Oxaliplatin|IV
190729|NCT02716753|Biological|seminal plasma|
190730|NCT02716753|Biological|Physiological NaCL solution|
190731|NCT02716740|Dietary Supplement|Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week|After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
190732|NCT02716727|Device|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
190733|NCT02716727|Device|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
190734|NCT02716714|Drug|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
190735|NCT02716714|Drug|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
190736|NCT02716701|Behavioral|Exercise Group|
190737|NCT02716701|Other|Control Group|
190738|NCT02716701|Other|wristband activity tracker|
190739|NCT02716688|Drug|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to four cycles.
190740|NCT02716688|Radiation|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8 Gy to a total dose of 50.4 Gy.
190741|NCT02716675|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
190742|NCT02716675|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
190743|NCT02716662|Dietary Supplement|Axona|medical powder, supplement food
190744|NCT02716649|Other|No intervention|
190745|NCT02716636|Procedure|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
190746|NCT02716623|Other|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
190747|NCT02716623|Behavioral|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
190748|NCT02716610|Drug|INH 69 U (low)|inhaled human insulin
190749|NCT02716610|Drug|INH 69 U (high)|inhaled human insulin
190750|NCT02716610|Drug|INH 139 U|inhaled human insulin
190751|NCT02716610|Drug|INH 208 U|inhaled human insulin
190752|NCT02716610|Drug|LIS 18 U|subcutaneous insulin lispro
190753|NCT02716597|Drug|25% Albumin|
190754|NCT02716597|Drug|Placebo|
190755|NCT02716584|Behavioral|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
190756|NCT02716584|Behavioral|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
190757|NCT02716571|Other|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.~Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
190758|NCT02716558|Other|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
190759|NCT02716558|Other|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
190760|NCT02716545|Device|balloon assisted enteroscopy|Patients with recurrent bleeding (>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
190761|NCT02716532|Dietary Supplement|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
190762|NCT02716519|Biological|Santyl|Collagenase ointment applied topically once per day for up to six weeks
190763|NCT02716519|Other|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
190764|NCT02716506|Procedure|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
190765|NCT02716493|Behavioral|Telerehabilitation program|"The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.~Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.~In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions"
190766|NCT02716480|Behavioral|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
190767|NCT02716480|Behavioral|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
190768|NCT02716467|Other|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
190769|NCT02716467|Radiation|Radiotherapy|All participants will receive treatment by radiotherapy
190770|NCT02716454|Procedure|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
190771|NCT02716441|Device|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
190772|NCT02716428|Drug|Faldaprevir|
190773|NCT02716428|Drug|TD-6450|
190774|NCT02716428|Drug|Ribavirin|
190775|NCT02716415|Drug|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~regular diaper changing,~gentle cleansing~application of the trial ointment"
190776|NCT02716415|Drug|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.~The regimen includes:~regular diaper changing,~gentle cleansing~application of the trial ointment"
190777|NCT02716402|Radiation|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
190778|NCT02716389|Other|Zebris CMS 70|
190779|NCT02716389|Other|3-D Bulls Eye Spirit Meter|
190780|NCT02716376|Device|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
190781|NCT02716363|Device|Rotational Atherectomy by Rotablator|
190782|NCT02716350|Dietary Supplement|B-GOS|comparison versus placebo
190783|NCT02716350|Dietary Supplement|Maltodextrin|placebo
190784|NCT02716337|Dietary Supplement|Addition of human milk fortifiers according to human milk analysis|
190785|NCT02716324|Behavioral|Care Manager CM)|The CM was an individual responsible for communicating and coordinating ADHD care. The CM established rapport with families and communicated with them every 3 months or more frequently if needed to assess treatment use, identify new concerns, and help problem-solve. The CM also communicated with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
190786|NCT02716324|Other|ADHD Portal|The ADHD portal was a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment were measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents were encouraged to consult with their children when completing the tool.
190787|NCT02716311|Drug|Afatinib|
190788|NCT02716311|Drug|Cetuximab|
190789|NCT02716298|Device|fanfilcon A|contact lens
190790|NCT02716298|Device|lotrafilcon B|contact lens
190791|NCT02716285|Drug|Ileocolonic release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
190792|NCT02716285|Drug|Placebo|Placebo capsule, containing microcrystalline cellulose
190793|NCT02716285|Drug|Small intestinal release peppermint oil|Peppermint oil, menthae piperitae aetheroleum
190794|NCT02716272|Drug|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
190795|NCT02716272|Drug|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
190796|NCT02716259|Procedure|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
190797|NCT02716259|Procedure|Supragingival prophylaxis|Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
190798|NCT02716246|Biological|ABO-102|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
190799|NCT02716233|Drug|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
190800|NCT02716233|Drug|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
190801|NCT02716220|Device|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
190802|NCT02716207|Device|CyberKnife|Radiation Therapy
190803|NCT02716194|Biological|BAX 826|
190804|NCT02716194|Biological|Octocog alfa|
190805|NCT02716181|Device|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
190806|NCT02716181|Device|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
190807|NCT02716168|Other|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
190808|NCT02716142|Drug|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
190809|NCT02716142|Drug|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
190810|NCT02716129|Drug|Morphine|38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
190811|NCT02716129|Drug|Morphine plus Nalbuphine|39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
190812|NCT02716116|Drug|TAK-788|TAK-788 capsules.
190813|NCT02716103|Other|blood collection|
190814|NCT02716103|Other|bone marrow collection|
190815|NCT02716090|Drug|Adapalene and Benzoyl peroxide Dalap Duo®|
190816|NCT02716090|Drug|Adapalene and Benzoyl peroxide Epiduo®|
190817|NCT02716077|Radiation|FDG PET/CT imaging|
190818|NCT02716064|Behavioral|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
190819|NCT02716051|Device|MRI|Whole body MRI with cardiac and pulmonary synchronization
190820|NCT02716051|Device|PET|
190821|NCT02716038|Drug|MPDL3280A|MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
190822|NCT02716038|Drug|Carboplatin|Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin area under the curve (AUC)=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
190823|NCT02716038|Drug|Nab-paclitaxel|Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
190824|NCT02716025|Procedure|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
190825|NCT02716012|Drug|MTL-CEBPA|"Intravenous administration into a vein (peripheral or central) on day 1, 8 and 15 of each 28-day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
190826|NCT02715999|Procedure|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
190827|NCT02715999|Procedure|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
190828|NCT02715986|Device|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
190829|NCT02715973|Dietary Supplement|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
190830|NCT02715973|Dietary Supplement|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
190831|NCT02715960|Drug|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
190832|NCT02715947|Drug|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
190833|NCT02715934|Other|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
190834|NCT02715934|Other|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
190835|NCT02715921|Other|Tele-exercise|
190836|NCT02715908|Drug|LBEC0101|Etanercept 50mg
190837|NCT02715895|Dietary Supplement|Friso|Friso formula feeding on demand for 3 months
190838|NCT02715895|Dietary Supplement|Wyeth|Wyeth formula feeding on demand for 3 months
190839|NCT02715895|Dietary Supplement|Breast milk|Breast milk feeding on demand
190840|NCT02715882|Drug|CBLB502|
190841|NCT02715882|Drug|Placebo|
190842|NCT02715869|Drug|A pharmacologic cardiac preconditioning (Sevoflurane)|A Patients are anaesthetized by Sevoflurane more than 1 mac.
190843|NCT02715869|Procedure|B ischeamic preconditioning|B ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
190844|NCT02715856|Other|Monitoring Device|Undergo surgical wound and physical activity monitoring
190845|NCT02715856|Other|Physical Activity Measurement|Undergo physical activity measurement
190846|NCT02715856|Other|Quality-of-Life Assessment|Ancillary studies
190847|NCT02715856|Other|Questionnaire Administration|Ancillary studies
190848|NCT02715856|Procedure|Standard Follow-Up Care|Undergo standard follow-up care
190849|NCT02715856|Other|Survey Administration|Ancillary studies
190850|NCT02715843|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
190851|NCT02715830|Procedure|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
190852|NCT02715817|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance and gaite in post-stroke patients.
190853|NCT02715817|Other|Conventional therapeutic exercises|It is the use of the conventional therapeutic exercises for rehabilitation of balance and gait in post-stroke patients.
190854|NCT02715817|Other|Virtual Rehabilitation and Conventional Therapeutic Exercise|It is the use of the conventional exercises and of the NW for rehabilitation of balance and gait in post-stroke patients.
190855|NCT02715804|Other|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
190856|NCT02715804|Drug|Placebo|Matching placebo for PEGPH20
190857|NCT02715804|Drug|nab-Paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
190858|NCT02715804|Drug|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
190859|NCT02715791|Behavioral|TAP-HC-DM|"Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.~Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.~Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.~Clinicians will see and triage the reports, and may follow up on various aspects identified."
190860|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
190861|NCT02715765|Device|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
190910|NCT02715531|Drug|Cisplatin|Cisplatin will be administered as 80 mg/m^2 IV over 120 minutes q3w (Group E2).
190911|NCT02715518|Device|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.~FFR-guided strategy arm~Angiography-guided strategy arm"
190912|NCT02715505|Drug|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
190913|NCT02715492|Drug|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
190914|NCT02715492|Procedure|TACE|Trans arterial chemoembolization
190862|NCT02715765|Device|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
190863|NCT02715765|Device|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
190864|NCT02715752|Dietary Supplement|Gene-Eden-VIR/Novirin|
190865|NCT02715739|Other|No intervention|
190866|NCT02715726|Drug|Alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
190867|NCT02715726|Drug|Placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
190868|NCT02715726|Drug|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
190869|NCT02715726|Drug|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
190870|NCT02715726|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
190871|NCT02715726|Drug|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
190872|NCT02715726|Drug|simvastatin|Pharmaceutical form:tablet Route of administration: oral
190873|NCT02715700|Drug|Methadone|Methadone 20 to 200 mg (10 mg/mL if oral solution concentrate) oral tablet once per day.
190874|NCT02715700|Drug|Doravirine|Doravirine 100 mg oral tablet once per day.
190875|NCT02715687|Drug|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
190876|NCT02715687|Drug|Placebo|Will receive 30 days treatment with oral placebo of 200mg
190877|NCT02715674|Device|Plasti-med TRIFLO|
190878|NCT02715674|Device|BIPAP VISION|
190879|NCT02715674|Device|Plasti-med oxygen therapy mask|
190880|NCT02715661|Other|exercise|six-month interval of exercise
190881|NCT02715648|Drug|Phenazopyridine|
190882|NCT02715635|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
190883|NCT02715635|Dietary Supplement|Concentrate beetroot Juice|140 ml containing ~8 mmol of inorganic nitrate
190884|NCT02715635|Dietary Supplement|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
190885|NCT02715622|Procedure|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
190886|NCT02715609|Drug|Disulfiram|
190887|NCT02715609|Drug|Copper Gluconate|
190888|NCT02715609|Procedure|Surgery|
190889|NCT02715609|Radiation|Radiation|
190890|NCT02715609|Drug|Temozolomide|
190891|NCT02715596|Dietary Supplement|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
190892|NCT02715596|Other|Placebo|placebo in 15 cc emulsion stick-pack
190893|NCT02715583|Drug|11C-Acetate|
190894|NCT02715583|Drug|Ra-223 therapy|
190895|NCT02715570|Drug|PC945 - single doses|Safety and tolerability of single doses
190896|NCT02715570|Drug|Placebo - single doses|Safety and tolerability of single doses
190897|NCT02715570|Drug|PC945 - repeat doses|Safety and tolerability of repeat doses
190898|NCT02715570|Drug|Placebo - repeat doses|Safety and tolerability of repeat doses
190899|NCT02715557|Behavioral|Relapse prevention program|The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
190900|NCT02715544|Other|Healthy lifestyle|The families will receive a designed for these purposes intervention
190901|NCT02715544|Other|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
190902|NCT02715531|Drug|5-FU|5-FU (400 mg/m^2) will be administered as an IV bolus, followed by 2400 mg/m^2 by continuous IV infusion over 46 (± 1) hours, q2w.
190903|NCT02715531|Drug|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group E2, and Arm F) or 840 mg q2w (Arm B, Arm C, and Groups E1 and E3).
190904|NCT02715531|Drug|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group F1) or 10 mg/kg q2w (Arm B).
190905|NCT02715531|Drug|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
190906|NCT02715531|Drug|Leucovorin|Leucovorin 200 mg/m^2 L-isomer form or 400 mg/m^2 D,L-racemic form will be administered IV over 120 (± 15) minutes, q2w.
190907|NCT02715531|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
190908|NCT02715531|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 will be administered IV over 120 (± 5) minutes q2w.
190909|NCT02715531|Drug|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m^2) twice daily on Days 1-4 of a 21-day cycle.
190915|NCT02715479|Drug|Dolutegravir|Dolutegravir
190916|NCT02715479|Drug|BMS955176|BMS955176
190917|NCT02715466|Drug|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
190918|NCT02715466|Drug|Balanced electrolyte solution|Sterofundin ISO
190919|NCT02715453|Other|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):~Nutritional evaluation and intervention after randomization and regularly during follow-up~Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year~Psychiatrist or psychologist assistance for 1 year after discharge"
190920|NCT02715440|Drug|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
190921|NCT02715427|Other|Conventional care|
190922|NCT02715427|Other|Enhanced recovery|
190923|NCT02715414|Behavioral|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
190924|NCT02715414|Behavioral|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
190925|NCT02715401|Drug|HCP1303|
190926|NCT02715401|Drug|HGP1201|
190927|NCT02715401|Drug|HIP1402|
190928|NCT02715388|Device|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
190929|NCT02715375|Device|CREON2000A|
190930|NCT02715375|Device|Sham|
190931|NCT02715362|Drug|TAI-GPC3-CART cells|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
190932|NCT02715349|Behavioral|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
190933|NCT02715336|Drug|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
190934|NCT02715323|Other|Cross-sectional study|
190935|NCT02715297|Radiation|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
190936|NCT02715284|Biological|dostarlimab|Dostarlimab (also known as TSR-042) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
190937|NCT02715271|Procedure|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
190938|NCT02715258|Drug|Bexagliflozin|20 mg, tablet
190939|NCT02715258|Drug|Placebo|20 mg tablet to match active comparator
190940|NCT02715245|Procedure|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
190941|NCT02715232|Drug|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
190942|NCT02715232|Drug|Lynestrenol|2-3 tablets/day, if menstruation still occurs
190943|NCT02715232|Drug|Cyproterone Acetate|25mg daily
190944|NCT02715232|Drug|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
190945|NCT02715232|Drug|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
190946|NCT02715219|Other|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
190947|NCT02715206|Behavioral|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
190948|NCT02715206|Behavioral|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
190949|NCT02715206|Behavioral|control|control group continues to teach whatever prevention curriculum they were using prior to study
190950|NCT02715193|Biological|REMD-477|
190951|NCT02715193|Biological|Placebo Comparator|
190991|NCT02714855|Drug|Apixaban|
190992|NCT02714842|Drug|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
190952|NCT02715180|Radiation|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
190953|NCT02715167|Drug|Budesonide novolizer|
190954|NCT02715167|Drug|Placebo|
190955|NCT02715154|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
190956|NCT02715154|Drug|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
190957|NCT02715141|Behavioral|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
190958|NCT02715128|Device|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
190959|NCT02715115|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
190960|NCT02715115|Drug|Placebo|Strawberry flavored solution and Water for Injection
190961|NCT02715089|Genetic|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
190962|NCT02715076|Other|Ambient Temperature 19°C|Ambient Temperature 19°C
190963|NCT02715076|Other|Ambient Temperature 21°C|Ambient Temperature 21°C
190964|NCT02715076|Other|Ambient Temperature 23°C|Ambient Temperature 23°C
190965|NCT02715076|Device|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
190966|NCT02715076|Other|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
190967|NCT02715063|Behavioral|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
190968|NCT02715063|Behavioral|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
190969|NCT02715063|Behavioral|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
190970|NCT02715063|Other|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
190971|NCT02715050|Device|Active or Placebo Phototherapy (MR4)|
190972|NCT02715037|Other|Throat swabbing|
190973|NCT02715024|Drug|Tamsulosin|Oral
190974|NCT02715024|Drug|Solifenacin|Oral
190975|NCT02715011|Drug|JNJ-63709178|Intravenous infusion of JNJ-63709178 dosed every two weeks or more frequently. The duration of each treatment cycle is 21-35 days.
190976|NCT02714998|Drug|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
190977|NCT02714998|Procedure|salpingectomy|Laparoscopic unilateral salpingectomy
190978|NCT02714972|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
190979|NCT02714959|Drug|Proleukin|
190980|NCT02714946|Device|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
190981|NCT02714946|Device|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
190982|NCT02714933|Other|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
190983|NCT02714920|Other|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
190984|NCT02714907|Device|Cortrium C3 device|Data is read from Cortrium C3 monitor
190985|NCT02714907|Device|Holter device|Date is read from Holter device
190986|NCT02714894|Drug|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
190987|NCT02714881|Drug|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
190988|NCT02714881|Radiation|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
190989|NCT02714868|Behavioral|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
190990|NCT02714868|Behavioral|Matched Comparison|Participants set goal to try a new activity in the community
190993|NCT02714842|Drug|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
190994|NCT02714842|Drug|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
190995|NCT02714842|Drug|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
190996|NCT02714829|Device|Inject BMP|Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.
190997|NCT02714829|Device|ExcelOS-inject|Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
190998|NCT02714803|Behavioral|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
190999|NCT02714803|Behavioral|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
191000|NCT02714803|Behavioral|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
191001|NCT02714777|Device|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
191002|NCT02714751|Behavioral|Daily asynchronies information|
191003|NCT02714738|Procedure|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
191004|NCT02714725|Drug|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
191005|NCT02714725|Drug|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
191006|NCT02714725|Drug|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
191007|NCT02714712|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
191008|NCT02714699|Drug|diclofenac potassium|patients will take oral diclofenac potassium; two tablets (cataflam 25 mg) and one tablet placebo one hour before the procedure
191009|NCT02714699|Drug|hyoscine butyl bromide|patients will take oral hyoscine-N- butyl bromide; 2 tablets (buscopan 10 mg) one hour before the procedure
191010|NCT02714699|Drug|placebo|patients will take oral placebo; 2 tablets one hour before the procedure
191011|NCT02714686|Behavioral|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
191012|NCT02714673|Drug|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
191013|NCT02714660|Other|none, observational study|
191014|NCT02714647|Behavioral|Attentional prime|
191015|NCT02714647|Behavioral|Sham prime|
191016|NCT02714634|Drug|Methotrexate + biologic administration|"Methotrexate + adalimumab or~Methotrexate + certolizumab or~Methotrexate + etanercept or~Methotrexate + golimumab or~Methotrexate + infliximab or~Methotrexate + abatacept or~Methotrexate + rituximab or~Methotrexate + tocilizumab"
191017|NCT02714634|Drug|methotrexate + salazopyrine + hydroxychloroquine administration|
191018|NCT02714621|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
191019|NCT02714608|Drug|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
191020|NCT02714608|Drug|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
191021|NCT02714608|Drug|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
191022|NCT02714595|Drug|S-649266|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function).
191023|NCT02714595|Drug|Best Available Therapy|Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
191024|NCT02714582|Behavioral|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson & Mangino 2006).
191025|NCT02714569|Drug|LY3202328|Administered orally
191026|NCT02714569|Drug|Placebo|Administered orally
191027|NCT02714569|Drug|Atorvastatin|Administered orally
191028|NCT02714569|Drug|Simvastatin|Administered orally
191029|NCT02714556|Other|Physiologic measures of lung function|"Respiratory function tests:~Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)"
191030|NCT02714543|Drug|aloevera juice|aloevera juice to drink twice daily for 3 months.
191031|NCT02714543|Drug|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
191032|NCT02714543|Drug|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
191033|NCT02714543|Drug|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
191034|NCT02714543|Drug|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
191035|NCT02714530|Drug|Erlotinib|Tarceva daily during radiotherapy course
191036|NCT02714530|Radiation|Radiation|Radiotherapy
191037|NCT02714517|Other|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
191038|NCT02714517|Other|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
191039|NCT02714504|Drug|Voriconazole or posaconazole|Azole with activity against molds
191040|NCT02714491|Other|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
191041|NCT02714491|Other|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
191042|NCT02714491|Other|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
191043|NCT02714478|Device|equistasi|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
191044|NCT02714478|Device|placebo|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
191045|NCT02714465|Other|hyperbaric oxygen therapy|hyperbaric oxygen therapy
191046|NCT02714452|Behavioral|Person-centred care|Person-centred and thriving promoting care
191047|NCT02714439|Drug|Proflavine|Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
191048|NCT02714439|Procedure|High-Resolution Microendoscopy (HRME)|High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
191049|NCT02714426|Behavioral|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) psychoeducation, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
191050|NCT02714426|Other|Brain health|Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
191051|NCT02714413|Dietary Supplement|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
191052|NCT02714413|Dietary Supplement|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
191053|NCT02714413|Other|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
191054|NCT02714400|Drug|Venlafaxine|Venlafaxine 50mg before sleep
191055|NCT02714400|Drug|Placebo|One piece of placebo before sleep
191056|NCT02714387|Other|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
191057|NCT02714374|Biological|GL-ONC1|"Dose and Regimen:~Single dose group: Cohort 1 dose is 1 × 109 pfu~Multiple dose groups:~Cohort 2 dose is 1 × 109 pfu × 5 consecutive days~Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days~Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.~Route: GL-ONC1 is delivered as a bolus IV injection."
191058|NCT02714361|Dietary Supplement|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
191059|NCT02714361|Other|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
191060|NCT02714348|Other|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
191061|NCT02714322|Biological|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
191062|NCT02714322|Biological|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
191063|NCT02714309|Dietary Supplement|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
191064|NCT02714309|Other|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
191065|NCT02714309|Other|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
191066|NCT02714309|Other|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
191067|NCT02714296|Drug|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
191068|NCT02714296|Dietary Supplement|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
191069|NCT02714283|Drug|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
191070|NCT02714283|Drug|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
191071|NCT02714270|Procedure|modified partograph|
191072|NCT02714270|Procedure|paperless partograph|
191073|NCT02714257|Behavioral|Enhanced Usual Care plus Exercise Coaching|"For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.~Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.~For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation."
191074|NCT02714244|Other|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
191075|NCT02714231|Drug|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
191076|NCT02714231|Drug|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
191077|NCT02714218|Biological|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
191078|NCT02714218|Biological|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
191079|NCT02714218|Biological|Nivolumab 1 mg/kg IV|
191080|NCT02714218|Biological|Ipilimumab 3 mg/kg IV|
191081|NCT02714218|Biological|Nivolumab 6 mg/kg IV|A dose of 240mg is identical to a dose of 3mg/kg, therefore 6mg/kg is approximately equal to ~ 480mg.
191082|NCT02714205|Drug|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
191083|NCT02714205|Drug|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
191084|NCT02714192|Other|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
191085|NCT02714179|Drug|Paracetamol was given intravenously in both group at different times|
191086|NCT02714166|Other|Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
191087|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
191088|NCT02714153|Device|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
191089|NCT02714140|Behavioral|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all EXISTING HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
191090|NCT02714140|Behavioral|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select 3 PB-HCT options that are less preferred than the common option
191091|NCT02714140|Behavioral|Economic incentive|Participants will be re-contacted three months after being offered PB-HCT options. Participants will be reminded of the options, and offered an incentive to present for testing using any of the PB-HCT options or the common option.
191092|NCT02714140|Behavioral|PB-HCT ++|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible ENHANCED HIV testing options for each participant and select those 3 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the three options over the common option.
191093|NCT02714140|Behavioral|SMS Reminder|Participants will receive an SMS reminder to test.
191094|NCT02714127|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
191095|NCT02714127|Other|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
191096|NCT02714114|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
191097|NCT02714114|Other|Blood draw|One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
191098|NCT02714101|Other|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
191099|NCT02714088|Other|Novel high-intensity interval training|
191100|NCT02714075|Other|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
191101|NCT02714075|Other|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
191102|NCT02714075|Other|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
191103|NCT02714075|Other|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
191104|NCT02714075|Other|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
191105|NCT02714075|Other|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
191106|NCT02714062|Drug|Placebo|po once daily
191107|NCT02714062|Drug|VI-0521 Mid Dose|po once daily
191108|NCT02714062|Drug|VI-0521 Top Dose|po once daily
191109|NCT02714049|Behavioral|sex therapy|60 minutes each time, in person or on the telephone
191110|NCT02714049|Drug|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
191111|NCT02714036|Drug|ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration16. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
191112|NCT02714023|Procedure|Normal Saline|Intra-operative irrigation with normal saline
191113|NCT02714023|Procedure|Sterile Water|Intra-operative irrigation with sterile water
191114|NCT02714010|Drug|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
191115|NCT02714010|Radiation|whole brain radiotherapy|30Gy/10F
191116|NCT02713997|Drug|etanercept|50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
191117|NCT02713997|Drug|Alpha 1-Antitrypsin|90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
191118|NCT02713984|Biological|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
191119|NCT02713971|Device|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
191120|NCT02713971|Other|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
191121|NCT02713958|Other|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
191122|NCT02713958|Other|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
191123|NCT02713945|Drug|Simvastatin|Experimental drug administrated orally
191124|NCT02713945|Drug|Placebo|Treatment for the control group
191125|NCT02713932|Device|Transcatheter aortic valve implantation|
191126|NCT02713919|Behavioral|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
191127|NCT02713906|Device|X-Ray Knee Guide group|
191128|NCT02713893|Drug|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
191129|NCT02713893|Drug|Placebo plus Econazole nitrate 1% intravaginal cream|
191130|NCT02713893|Drug|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
191131|NCT02713893|Drug|Placebo intravaginal cream|
191132|NCT02713867|Biological|Nivolumab|
191133|NCT02713854|Procedure|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
191134|NCT02713841|Drug|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
191135|NCT02713841|Drug|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
191136|NCT02713828|Drug|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).~Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
191137|NCT02713828|Drug|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response [PR] or Complete Response [CR]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
191138|NCT02713815|Radiation|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by Theta-burst stimulation (TBS), once a day
191139|NCT02713815|Radiation|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 4 weeks by sham Theta-burst stimulation (TBS), once a day
191140|NCT02713802|Drug|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
191141|NCT02713802|Drug|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
191142|NCT02713789|Drug|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
191143|NCT02713789|Drug|Placebo (PBS-20% sucrose)|
191144|NCT02713776|Drug|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
191145|NCT02713776|Drug|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
191146|NCT02713763|Drug|Sunitinib|Sunitinib 37.5 mg/day
191199|NCT02713373|Other|Laboratory Biomarker Analysis|Correlative studies
191200|NCT02713373|Biological|Pembrolizumab|Given IV
191201|NCT02713360|Behavioral|Cognitive Therapy|
191333|NCT02712476|Drug|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
191147|NCT02713750|Other|reversible contraceptive methods|"Consistent male condom use only~Consistent female condom use only~Hormonal contraception, combined oral contraceptive pills and male/female condom~Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~Hormonal contraception , progestin only hormonal implant and male/female condom~Intrauterine device and male/female condom"
191148|NCT02713737|Device|heated humidified high-flow nasal cannula|HFNC device (Airvo™, Fisher＆Paykel, Auckland, New Zealand) with a heated circuit (Fisher＆Paykel,900PT501) and nasal cannula(optiflow TM,Fisher＆Paykel). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) > 92%.
191149|NCT02713737|Device|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 > 92%.
191150|NCT02713724|Behavioral|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
191151|NCT02713724|Behavioral|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
191152|NCT02713711|Radiation|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
191153|NCT02713711|Procedure|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
191154|NCT02713711|Procedure|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
191155|NCT02713698|Drug|Propofol|"The whole anaesthetic procedure is standard except for additional body composition assessment with Body Composition Monitor - BCM (Fresenius Medical Care, Germany) and arterial blood samples collection.~In all included patients, propofol will be started at 2000mg/h until LOC, defined by loss of eye-lash reflex and loss of response to name calling. During surgery propofol infusion will be guided by targeted BIS values between 40 and 60.~Arterial blood samples will be obtained immediately after LOC and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
191156|NCT02713685|Procedure|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
191157|NCT02713685|Procedure|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
191158|NCT02713672|Other|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
191159|NCT02713659|Behavioral|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
191160|NCT02713659|Behavioral|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
191161|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
191162|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
191163|NCT02713620|Biological|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
191164|NCT02713607|Drug|Doxycycline|Given doxycycline to acne subjects
191165|NCT02713594|Behavioral|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
191166|NCT02713594|Other|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
191167|NCT02713581|Biological|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
191168|NCT02713568|Other|Ultrasound examination|"Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.~Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.~For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin."
191334|NCT02712476|Drug|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
191169|NCT02713568|Other|Magnetic resonance examination|"MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.~Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031*Fetal Body Volume = MR imaging weight (g) developed by Baker.~General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.~For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99."
191170|NCT02713555|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
191171|NCT02713555|Procedure|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
191172|NCT02713542|Device|ACP|Autologous Conditioned Plasma
191173|NCT02713542|Other|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
191174|NCT02713529|Biological|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
191175|NCT02713516|Other|Virtual Reality|Use of virtual reality to deliver exposure therapy
191176|NCT02713503|Other|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
191177|NCT02713503|Other|VisionCoach|Visual field evaluation using VisionCoach
191178|NCT02713490|Drug|EXPAREL|EXPAREL and bupivacaine HCl
191179|NCT02713490|Drug|Bupivacaine|Single dose of bupivacaine HCl 0.5%
191180|NCT02713477|Drug|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution~Route of administration: subcutaneous"
191181|NCT02713477|Drug|Insulin glargine HOE901|"Pharmaceutical form: solution~Route of administration: subcutaneous"
191182|NCT02713477|Drug|Placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
191183|NCT02713464|Behavioral|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
191184|NCT02713451|Drug|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).~This management of FiO2 will be done until extubation of the patient."
191185|NCT02713438|Behavioral|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
191186|NCT02713438|Behavioral|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
191187|NCT02713438|Behavioral|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).~Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
191188|NCT02713438|Behavioral|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.~The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
191189|NCT02713425|Device|Entertaining Video Game|Children between 7 & 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
191190|NCT02713412|Other|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
191191|NCT02713412|Other|Water|300ml water
191192|NCT02713399|Device|Optical Coherence Tomography|
191193|NCT02713386|Drug|Carboplatin|Given IV
191194|NCT02713386|Drug|Paclitaxel|Given IV
191195|NCT02713386|Drug|Ruxolitinib|Given PO
191196|NCT02713386|Drug|Ruxolitinib Phosphate|Given PO
191197|NCT02713386|Procedure|Therapeutic Conventional Surgery|Undergo TRS
191198|NCT02713373|Biological|Cetuximab|Given IV
191202|NCT02713347|Behavioral|ADAPT Intervention|"The intervention includes 3 components:~nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
191203|NCT02713334|Behavioral|survey|
191204|NCT02713334|Behavioral|semi-structured interview|
191205|NCT02713282|Drug|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
191206|NCT02713269|Procedure|Thermal Ablation Procedure|Thermal ablation procedure performed before spine stereotactic radiosurgery. Thermal ablation heats tumor tissue using a laser, and helps to shrink the tumor by destroying tumor cells.
191207|NCT02713269|Radiation|Stereotactic Spine Radiosurgery (SSRS)|Treatment delivered in 1 or 3 fractions per treating physician. One fraction: Gross tumor volume (GTV) prescribed to 24 or 18 Gy in a single fraction depending on the tumor histology. Radioresistant histologies such as renal cell carcinoma, sarcoma and melanoma treated to 24 Gy, and radiosensitive tumor such as breast cancer and non-small lung cancer treated to 18 Gy. Clinical target volume (CTV) prescribed to 16 Gy in a single fraction. Three fractions: GTV prescribed to 24 or 27 Gy in 3 fractions, and the CTV prescribed to 21 Gy in 3 fractions.
191208|NCT02713269|Behavioral|Symptom Questionnaires|Symptom questionnaires completed at baseline and at follow up months 1, 3, 6, 9, 12, then every 6 months.
191209|NCT02713256|Drug|CFZ533|CFZ533 intravenously over approximately one hour
191210|NCT02713243|Drug|LJN452|Capsules containing LJN452
191211|NCT02713243|Drug|Placebo to LJN452|Capsules containing placebo to LJN452
191212|NCT02713230|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension,133 mg in 10 mL expanded with normal saline to 20 mL
191213|NCT02713230|Drug|Placebo|Normal saline in 20 mL.
191214|NCT02713217|Other|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
191215|NCT02713217|Other|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
191216|NCT02713204|Drug|REGN910-3|
191217|NCT02713204|Drug|Intravitreal Aflibercept Injection (IAI)|
191218|NCT02713191|Drug|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
191219|NCT02713191|Drug|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
191220|NCT02713191|Other|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
191221|NCT02713191|Drug|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
191222|NCT02713191|Drug|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
191223|NCT02713178|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
191224|NCT02713178|Drug|Placebo|Normal saline.
191225|NCT02713165|Other|Raisins|Participants will consume 84g of raisins per day for 14 days.
191226|NCT02713139|Drug|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
191227|NCT02713139|Drug|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
191228|NCT02713139|Drug|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
191229|NCT02713126|Drug|Placebo Solution|Placebo capsule administered orally, taken every 4 hours or 3 times per day during waking hours for 12 weeks
191230|NCT02713126|Drug|Oral Sodium Nitrite|Oral Sodium Nitrite, 40 mg administered orally, taken every 4 hours or 3 times per day during waking hours for 12 weeks
191231|NCT02713126|Device|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
191232|NCT02713126|Other|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
191233|NCT02713113|Drug|sugammadex reversal of neuromuscular blockade|
191234|NCT02713100|Behavioral|level of agitation|psychological pain
191235|NCT02713087|Drug|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
191236|NCT02713087|Drug|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
191237|NCT02713074|Drug|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
191238|NCT02713074|Drug|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
191239|NCT02713061|Drug|TAK-850|TAK-850 injection
191240|NCT02713048|Other|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
191294|NCT02712749|Device|Sound with Binaural Beats|Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
191335|NCT02712476|Drug|placebo|mannitol alone is compared with placebo
191611|NCT02710630|Drug|Dabigatran etexilate tablet E1|
191241|NCT02713035|Behavioral|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
191242|NCT02713022|Device|DEXA Scan|
191243|NCT02713022|Behavioral|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
191244|NCT02713009|Dietary Supplement|Pregnancy multi-vitamin (including 10μg vitamin D3)|
191245|NCT02713009|Dietary Supplement|10μg vitamin D3|
191246|NCT02713009|Dietary Supplement|0μg vitamin D (placebo)|
191247|NCT02712996|Drug|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
191248|NCT02712996|Drug|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
191249|NCT02712983|Drug|TIP|TIP dose regimen
191250|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
191251|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
191252|NCT02712983|Drug|TIP|TIP dose regimen
191253|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
191254|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
191255|NCT02712983|Drug|TIP|TIP dose regimen
191256|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
191257|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
191258|NCT02712970|Procedure|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of <1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
191259|NCT02712970|Procedure|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
191260|NCT02712970|Procedure|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
191261|NCT02712970|Procedure|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
191262|NCT02712957|Drug|NEO6860|TRPV1 antagonist
191263|NCT02712957|Drug|NEO6860 placebo|Inactive substance
191264|NCT02712957|Drug|Naproxen|NSAID
191265|NCT02712957|Drug|Naproxen placebo|inactive substance
191266|NCT02712944|Drug|Testosterone|Testosterone
191267|NCT02712944|Drug|Saline|Placebo
191268|NCT02712918|Behavioral|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
191269|NCT02712918|Other|Standard Care|Treatment as usual at the ward
191270|NCT02712905|Drug|INCB059872|"Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth."
191271|NCT02712905|Drug|all-trans retinoic acid (ATRA)|
191272|NCT02712905|Drug|azacitidine|
191273|NCT02712905|Drug|nivolumab|
191274|NCT02712892|Genetic|Non Interventional Study|
191275|NCT02712866|Drug|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
191276|NCT02712853|Other|Saliva collection|Collection of saliva via swab for miRNA processing
191277|NCT02712853|Other|Vineland Adaptive Behavior Scale-II Assessment|
191278|NCT02712840|Procedure|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
191279|NCT02712840|Procedure|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
191280|NCT02712827|Procedure|Progrip|Self-fixating mesh
191281|NCT02712827|Procedure|Non-Progrip|Non self-fixating mesh with the use of glue
191282|NCT02712814|Drug|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
191283|NCT02712814|Procedure|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
191284|NCT02712814|Procedure|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
191285|NCT02712801|Drug|Zidovudine|Dose will be adjusted according to the child's weight.
191286|NCT02712801|Drug|Nevirapine|Dose will be adjusted according to the child's weight.
191287|NCT02712801|Drug|Lamivudine|Dose will be adjusted according to the child's weight.
191288|NCT02712801|Drug|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
191289|NCT02712788|Drug|Milrinone|
191290|NCT02712788|Drug|Placebo|
191291|NCT02712775|Drug|Minocycline (yes/no)|
191292|NCT02712775|Drug|Placebo|Saline
191293|NCT02712762|Other|Cross-sectional study|
191295|NCT02712749|Device|Sound without Binaural Beats|Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
191296|NCT02712736|Other|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
191297|NCT02712723|Drug|Letrozole|Nonsteroidal aromatase inhibitor
191298|NCT02712723|Drug|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
191299|NCT02712723|Drug|Placebo|Placebo for ribociclib
191300|NCT02712710|Device|functional knee brace|The functional knee brace for OA can decrease abnormal varus torque by external force.
191301|NCT02712697|Drug|WM (Shentong Granules)|Shentong Granules with Prednisone
191302|NCT02712697|Drug|Hormone (prednisone)|Oral prednisone
191303|NCT02712684|Procedure|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
191304|NCT02712671|Radiation|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
191305|NCT02712671|Procedure|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
191306|NCT02712671|Procedure|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
191307|NCT02712671|Procedure|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
191308|NCT02712671|Other|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
191309|NCT02712671|Procedure|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
191310|NCT02712658|Drug|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
191311|NCT02712658|Drug|Placebo|
191312|NCT02712619|Drug|Metformin|
191313|NCT02712593|Dietary Supplement|Niagen™ 100|
191314|NCT02712593|Dietary Supplement|Niagen™ 300|
191315|NCT02712593|Dietary Supplement|Niagen™ 1000|
191316|NCT02712593|Other|Placebo|
191317|NCT02712580|Device|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
191318|NCT02712580|Device|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
191319|NCT02712580|Device|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
191320|NCT02712580|Device|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
191321|NCT02712567|Drug|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
191322|NCT02712554|Drug|CL-108|7.5 mg/325 mg/12.5 mg tablet
191323|NCT02712554|Drug|M366|7.5 mg/325 mg tablet
191324|NCT02712554|Drug|Placebo|
191325|NCT02712528|Drug|remifentanil-based|
191326|NCT02712528|Drug|sevoflurane-sufentanil balanced|
191327|NCT02712515|Procedure|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
191328|NCT02712515|Device|Ad-Tech Medical Instrumentation Corp. electrodes/subdural strips|Ad-Tech Medical Instrumentation Corp. electrodes are intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
191329|NCT02712515|Device|FHC Guideline 4000+ system and/or Medtronic RC+S|Brain signals will be recorded using the clinical Participants in this group with Parkinson's disease will be undergoing deep brain stimulation implantation surgery as part of the standard of care. In addition, the Ad-Tech Medical Instrumentation Corp. device will be used to test responses with wireless sensors placed on the participant's arms, which can record EMG activity. Brain signals will be recorded using the clinical FHC Guideline 4000+ system and/or Medtronic RC+S devices, which are capable of recording during stimulation.
191330|NCT02712502|Drug|Levofloxacin|"Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.~Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
191331|NCT02712502|Drug|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.~• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
191332|NCT02712489|Other|No intervention|
191336|NCT02712437|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
191337|NCT02712424|Biological|DAR-901|
191338|NCT02712424|Biological|Sterile saline placebo|
191339|NCT02712411|Drug|HCP1303|
191340|NCT02712411|Drug|HGP1201|
191341|NCT02712411|Drug|HIP1402|
191342|NCT02712398|Device|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
191343|NCT02712385|Other|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
191344|NCT02712385|Device|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
191345|NCT02712385|Procedure|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
191346|NCT02712385|Behavioral|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
191347|NCT02712372|Drug|AZD4831|AZD4831 1-50 mg/g oral suspension
191348|NCT02712372|Drug|AZD4831 placebo|AZD4831 placebo oral suspension
191349|NCT02712359|Other|Blood sample collection|A blood sample (~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
191350|NCT02712346|Drug|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
191351|NCT02712346|Drug|Placebo|One inactive pill daily for twelve weeks
191352|NCT02712333|Behavioral|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
191353|NCT02712333|Behavioral|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
191354|NCT02712320|Drug|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
191355|NCT02712307|Drug|Phenoxymethylpenicillin|
191356|NCT02712294|Other|Neuromuscular Electrical Stimulation|
191357|NCT02712281|Behavioral|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.~The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
191358|NCT02712281|Behavioral|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.~Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
191359|NCT02712268|Other|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
191360|NCT02712255|Behavioral|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
191361|NCT02712255|Behavioral|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient."
191395|NCT02712021|Other|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
191396|NCT02712008|Drug|REGN910-3|Co-formulation for intravitreal (IVT) injection consisting of REGN910 (nesvacumab) and REGN3 (aflibercept)
191397|NCT02712008|Drug|Intravitreal Aflibercept Injection (IAI)|
191434|NCT02711826|Procedure|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
191435|NCT02711813|Drug|TAB08|biologic
191436|NCT02711813|Other|Placebo|
191612|NCT02710630|Drug|Dabigatran etexilate tablet D1|
191362|NCT02712255|Behavioral|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
191363|NCT02712255|Behavioral|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
191364|NCT02712242|Other|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
191365|NCT02712242|Other|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
191366|NCT02712242|Other|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
191367|NCT02712229|Behavioral|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.~Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
191368|NCT02712216|Procedure|Laparoscopy|Determine best port sites to insert bariatric trocars
191369|NCT02712203|Biological|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
191370|NCT02712190|Device|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
191371|NCT02712177|Biological|4CMenb|
191372|NCT02712177|Biological|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
191373|NCT02712177|Biological|conjugated pneumococcal vaccine|
191374|NCT02712177|Biological|MMRV|
191375|NCT02712164|Device|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
191376|NCT02712164|Device|Tegaderm|Standard of care for STSG donor sites.
191377|NCT02712151|Procedure|Abdominal Wall Block|bilateral TAP and RS blocks.
191378|NCT02712151|Procedure|Surgical infiltration|distributed between the 4 laparoscopic port sites.
191379|NCT02712151|Drug|Sterile saline|Placebo injection
191380|NCT02712151|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
191381|NCT02712151|Device|Ultrasound|For nerve localization
191382|NCT02712151|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
191383|NCT02712125|Drug|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
191384|NCT02712125|Drug|Placebo|placebo vaginal tablets once daily until delivery
191385|NCT02712112|Drug|Imatinib Mesylate|
191386|NCT02712086|Other|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
191387|NCT02712073|Other|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
191388|NCT02712060|Other|No intervention|
191389|NCT02712047|Drug|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
191390|NCT02712047|Drug|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
191391|NCT02712047|Drug|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
191392|NCT02712034|Behavioral|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:~Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.~The latest information about addiction and recovery support, monitoring prompts, and peer and family support.~Advice on where to go for help and on how to make the best use of health and human services; and~A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.~A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
191393|NCT02712034|Other|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
191394|NCT02712021|Other|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
191613|NCT02710630|Drug|Dabigatran etexilate tablet C1|
191398|NCT02711995|Drug|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
191399|NCT02711995|Drug|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
191400|NCT02711982|Procedure|Optic canal and optic nerve sheath decompression|within 5 days from trauma
191401|NCT02711982|Drug|methylprednisolone|within 5 days from trauma
191402|NCT02711969|Drug|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
191403|NCT02711956|Drug|ZEN003694|
191404|NCT02711956|Drug|Enzalutamide|
191405|NCT02711943|Drug|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
191406|NCT02711917|Drug|MAC 0.5|0.5 MAC Sevoflurane
191407|NCT02711917|Drug|MAC 0.75|0.75 MAC Sevoflurane
191408|NCT02711917|Drug|MAC 1.0|1.0 MAC Sevoflurane
191409|NCT02711917|Drug|Propofol|Propofol consumption
191410|NCT02711917|Drug|Etomidate|Etomidate consumption
191411|NCT02711917|Drug|Rocuronium|Consumption of Rocuronium
191412|NCT02711904|Drug|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:~20 years old - 6.0 mcg/Kg/h~30 years old - 5.7 mcg/Kg/h~40 years old - 5.3 mcg/kg/h~50 years old - 5.0 mcg/kg/h~60 years old - 4.6 mcg/kg/h~70 years old - 4.3 mcg/kg/h~80 years old - 4.0 mcg kg/h."
191413|NCT02711904|Drug|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:~The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.~The remifentanil dose was adjusted according to the randomization:~20 years old - 9.0 mcg/Kg/h~30 years old - 8.5 mcg/Kg/h~40 years old - 8.0 mcg/kg/h~50 years old - 7.5 mcg/kg/h~60 years old - 7.0 mcg/kg/h~70 years old - 6.5 mcg/kg/h~80 years old - 6.0 mcg kg/h."
191414|NCT02711891|Drug|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
191415|NCT02711891|Drug|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
191416|NCT02711878|Behavioral|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
191417|NCT02711878|Behavioral|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
191418|NCT02711878|Behavioral|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
191419|NCT02711865|Biological|IGF1R antibody MK0646|
191420|NCT02711865|Other|Saline solution|
191421|NCT02711852|Drug|Duvelisib|Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg. Subjects will take duvelisib until disease progression or unacceptable toxicity.
191422|NCT02711839|Dietary Supplement|Commercial diabetic formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
191423|NCT02711839|Dietary Supplement|White sweet potato formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
191424|NCT02711826|Biological|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 550 ± 450 x 10^6 polyTregs.
191425|NCT02711826|Drug|Everolimus|
191426|NCT02711826|Drug|Tacrolimus|
191427|NCT02711826|Drug|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
191428|NCT02711826|Drug|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
191429|NCT02711826|Drug|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
191430|NCT02711826|Drug|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
191431|NCT02711826|Procedure|Biopsy, Kidney|
191432|NCT02711826|Procedure|Blood Draw|
191433|NCT02711826|Procedure|Leukapheresis|
191437|NCT02711800|Drug|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
191438|NCT02711787|Device|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
191439|NCT02711787|Device|Control group|Physiotherapy and occupational therapy.
191440|NCT02711787|Device|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
191441|NCT02711774|Device|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
191442|NCT02711761|Device|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
191443|NCT02711748|Device|electrostimulation|Electrostimulation using manual defibrillator
191444|NCT02711748|Device|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
191445|NCT02711735|Biological|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
191446|NCT02711735|Biological|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
191447|NCT02711722|Device|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA~Blood gas analysis~Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
191448|NCT02711722|Device|PScli1|Pressure support set by clinicians prior to inclusion
191449|NCT02711722|Device|PScli2|Pressure support at the same level as prior to the study
191450|NCT02711709|Other|Frailty Measurements|"A frailty index will be determined as a combination of factors.~An older adult is considered physically vulnerable when they experience:~muscle weakness~fatigue~low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.~This will be collected at baseline, 3, 6 and 12 months."
191451|NCT02711709|Other|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
191452|NCT02711709|Other|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
191453|NCT02711709|Other|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
191454|NCT02711696|Behavioral|GCED, Gluten Contamination Elimination Diet|"A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED)."
191455|NCT02711683|Drug|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
191456|NCT02711683|Drug|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
191457|NCT02711670|Drug|chlorthalidone|
191458|NCT02711670|Drug|Hydrochlorothiazide|
191459|NCT02711657|Other|Fibrocyte measurement and lung function test.|
191460|NCT02711644|Behavioral|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
191461|NCT02711644|Behavioral|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
191462|NCT02711631|Behavioral|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
191463|NCT02711618|Device|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
191464|NCT02711605|Device|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
191465|NCT02711592|Genetic|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
191466|NCT02711579|Drug|Celecoxib|
191467|NCT02711579|Drug|Placebo|
191503|NCT02711293|Other|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice). In addition, participants who state that they have access to a plot of land or garden to grow vegetables receive a pack of seeds (amaranth, cowpea, or pumpkin) at enrolment.
191504|NCT02711280|Drug|Sevoflurane|
191468|NCT02711566|Device|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
191469|NCT02711566|Device|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
191470|NCT02711553|Drug|Ramucirumab|Administered IV
191471|NCT02711553|Drug|Merestinib|Administered orally
191472|NCT02711553|Drug|Cisplatin|Administered IV
191473|NCT02711553|Drug|Gemcitabine|Administered IV
191474|NCT02711553|Drug|Placebo Oral|Administered orally
191475|NCT02711553|Drug|Placebo IV|Administered IV
191476|NCT02711540|Procedure|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
191477|NCT02711527|Other|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
191478|NCT02711527|Other|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
191479|NCT02711501|Procedure|Laser-assisted surgery.|laser-assisted surgery
191480|NCT02711501|Procedure|conventional surgery by blade|conventional surgery
191481|NCT02711488|Behavioral|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.~The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
191482|NCT02711462|Drug|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
191483|NCT02711462|Drug|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
191484|NCT02711449|Drug|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
191485|NCT02711449|Drug|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
191486|NCT02711436|Device|Computed Tomography Scan|
191487|NCT02711436|Device|Fast Magnetic Resonance Imaging|
191488|NCT02711423|Drug|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
191489|NCT02711423|Drug|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
191490|NCT02711410|Drug|Clopidogrel|
191491|NCT02711397|Other|Observational study|Comparison excretion levels of gluten immunogenic peptides
191492|NCT02711371|Other|fMRI|
191493|NCT02711358|Drug|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
191494|NCT02711358|Drug|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
191495|NCT02711345|Drug|LTT462|ERK Inhibitor
191496|NCT02711332|Other|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
191497|NCT02711332|Other|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
191498|NCT02711319|Device|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
191499|NCT02711319|Device|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)~For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
191500|NCT02711306|Dietary Supplement|Glucomannan noodle|The participants received two servings (400 g) of GMN every day to replace their daily carbohydrate intake for 4 weeks.
191501|NCT02711306|Dietary Supplement|Placebo noodle|In the placebo noodle diet, the participants received the same amount of noodles without glucomannan for 4 weeks.
191502|NCT02711293|Other|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home (maintaining patients' prior clinic visit frequency) to deliver ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count >350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been >350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than 12 months ago.
191506|NCT02711267|Drug|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
191507|NCT02711267|Drug|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
191508|NCT02711267|Drug|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
191509|NCT02711267|Drug|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
191510|NCT02711267|Drug|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
191511|NCT02711267|Procedure|OFM|Sampling method for interstitial fluid
191512|NCT02711267|Device|OFM Probe|Sampling probe used during OFM
191513|NCT02711267|Device|OFM Pump|Pump used to operate OFM probes
191514|NCT02711241|Drug|Dipyrone|1 gram by slow IV infusion
191515|NCT02711241|Drug|Papaverine|80 mg by slow intravenous infusion
191516|NCT02711228|Biological|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
191517|NCT02711215|Diagnostic Test|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
191518|NCT02711215|Drug|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
191519|NCT02711215|Drug|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
191520|NCT02711215|Drug|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
191521|NCT02711202|Drug|MabCampath,|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
191522|NCT02711202|Drug|Remicade|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
191523|NCT02711202|Drug|Sirolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
191524|NCT02711202|Drug|Tacrolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
191525|NCT02711189|Drug|Oxytocin|Oxytocin nasal spray given in dose 80
191526|NCT02711189|Other|Placebo|
191527|NCT02711176|Drug|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
191528|NCT02711176|Drug|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
191529|NCT02711176|Drug|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
191530|NCT02711176|Drug|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
191531|NCT02711176|Drug|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
191532|NCT02711176|Drug|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
191533|NCT02711163|Dietary Supplement|Extensively Hydrolyzed formula|
191534|NCT02711163|Dietary Supplement|Amino acid formula|
191535|NCT02711150|Device|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
191536|NCT02711137|Drug|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 1), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 2).
191537|NCT02711137|Drug|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose (Part 3), with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts (Part 4).
191538|NCT02711137|Drug|Gemcitabine|Standard of Care (SOC) agents
191539|NCT02711137|Drug|Paclitaxel|Standard of Care (SOC) agents
191540|NCT02711137|Drug|Rucaparib|Standard of Care (SOC) agents
191541|NCT02711137|Drug|Abiraterone|Standard of Care (SOC) agents
191542|NCT02711137|Drug|Ruxolitinib|Standard of Care (SOC) agents
191543|NCT02711137|Drug|Azacitidine|Standard of Care (SOC) agents
191544|NCT02711111|Device|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
191545|NCT02711111|Device|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
191546|NCT02711098|Biological|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
191547|NCT02711098|Biological|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
191548|NCT02711085|Other|No intervention|No intervention - observational study
191549|NCT02711072|Drug|control group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
191550|NCT02711072|Drug|infiltration group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
191551|NCT02711059|Procedure|parathyroidectomy|surgical treatment of hyperparathyroidism
191552|NCT02711046|Procedure|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
191553|NCT02711033|Procedure|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
191554|NCT02711033|Procedure|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
191555|NCT02711020|Behavioral|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
191556|NCT02711020|Behavioral|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
191557|NCT02711007|Drug|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
191558|NCT02710994|Drug|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
191559|NCT02710994|Drug|Losec|Losec 40 mg
191560|NCT02710981|Drug|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
191561|NCT02710981|Drug|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
191562|NCT02710968|Device|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
191563|NCT02710955|Dietary Supplement|Thickened infant formula|
191564|NCT02710942|Behavioral|SPHERE|
191565|NCT02710942|Behavioral|PRISM|
191566|NCT02710916|Device|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
191567|NCT02710903|Procedure|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
191568|NCT02710890|Drug|Lacosamide|"Pharmaceutical form: solution for infusion~Concentration: 10 mg/ml~Route of Administration: intravenous"
191569|NCT02710877|Device|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
191570|NCT02710877|Other|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
191571|NCT02710877|Drug|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
191572|NCT02710877|Drug|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
191573|NCT02710877|Drug|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
191574|NCT02710851|Biological|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
191575|NCT02710851|Biological|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
191576|NCT02710851|Biological|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.~All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
191577|NCT02710851|Biological|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
191578|NCT02710838|Device|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
191614|NCT02710630|Drug|Dabigatran etexilate tablet B1|
191615|NCT02710630|Drug|Dabigatran etexilate tablet A1|
191579|NCT02710825|Other|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.~When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
191580|NCT02710825|Other|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
191581|NCT02710812|Procedure|Local Excision or Wait-and-See|"Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).~The following principles should be respected:~A gross margin of at least 0.5 cm;~full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;~determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist."
191582|NCT02710799|Other|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
191583|NCT02710799|Other|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
191584|NCT02710786|Procedure|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
191585|NCT02710773|Other|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
191586|NCT02710773|Other|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
191587|NCT02710760|Other|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
191588|NCT02710760|Other|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
191589|NCT02710747|Genetic|CYP2C9;VKORC1|
191590|NCT02710734|Drug|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
191591|NCT02710734|Drug|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
191592|NCT02710734|Drug|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
191593|NCT02710734|Drug|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
191594|NCT02710734|Radiation|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
191595|NCT02710734|Procedure|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
191596|NCT02710734|Drug|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
191597|NCT02710734|Drug|Mitomycin C|Intravenous on day 1 with radiation treatment
191598|NCT02710721|Other|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
191599|NCT02710721|Other|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
191600|NCT02710708|Drug|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
191601|NCT02710695|Behavioral|Control|This group will receive a standardized 10 minute discussion.
191602|NCT02710695|Behavioral|Intervention|This group will receive a standardized 10 minute discussion
191603|NCT02710682|Procedure|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.~Skin disinfection; Local anesthesia (lidocaine 1%).~Skin incision, slightly anterior to lateral epicondyle.~Exposure of the plane between the tendon and fascia.~Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.~Excision of diseased tissue of the ECRB tendon.~ECRL tendon is sutured back to the fascia. The skin is closed.~Patient is monitored for 30 minutes after procedure."
191604|NCT02710682|Device|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.~Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.~Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.~Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.~Patient monitored for 30 minutes, before being discharged."
191605|NCT02710669|Drug|(R)-propafenone|
191606|NCT02710669|Drug|(S)-Propafenone|
191607|NCT02710669|Drug|Placebo|
191608|NCT02710656|Device|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
191609|NCT02710656|Device|Standard PTA|Percutaneous angioplasty performed with a standard balloon
191610|NCT02710643|Drug|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
191616|NCT02710630|Drug|Dabigatran etexilate capsule|
191617|NCT02710617|Device|Blood glucose monitoring systems for point-of-care-testing|
191618|NCT02710604|Drug|CMX157|tablet
191619|NCT02710604|Drug|TDF|300mg tablet
191620|NCT02710591|Drug|Rimeporide|"Cohort 1:~50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight > 30kg at Baseline~Cohort 2:~100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight > 30kg at Baseline~Cohort 3:~150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight > 30kg at Baseline~Cohort 4:~200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight > 30kg at Baseline"
191621|NCT02710578|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
191622|NCT02710578|Drug|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
191623|NCT02710565|Other|Cohort|Obtaining additional EBUS TBNA samples for cell culture
191624|NCT02710552|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
191625|NCT02710552|Drug|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
191626|NCT02710539|Drug|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
191627|NCT02710539|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
191628|NCT02710526|Drug|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
191629|NCT02710513|Dietary Supplement|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
191630|NCT02710500|Drug|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
191631|NCT02710487|Behavioral|REMSA|Awakening from REM sleep during the last hour of the sleep period
191632|NCT02710487|Behavioral|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
191633|NCT02710474|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
191634|NCT02710474|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
191635|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
191636|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
191637|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
191638|NCT02710448|Drug|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
191639|NCT02710435|Device|Neovasc Reducer System|An aid in the management of chronic refractory angina pectoris
191640|NCT02710422|Biological|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
191641|NCT02710422|Behavioral|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
191642|NCT02710422|Other|PSA Measurement|Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
191643|NCT02710422|Behavioral|Sexual History Inventory for Men|SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
191644|NCT02710409|Biological|Quadrivalent influenza vaccine|0.5 ml/vial, one dose, intramuscular injection on day 0
191645|NCT02710409|Biological|Trivalent influenza vaccine A|0.5 ml/vial, one dose, intramuscular injection on day 0
191646|NCT02710409|Biological|Trivalent influenza vaccine B|0.5 ml/vial, one dose, intramuscular injection on day 0
191647|NCT02710396|Drug|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.~Pembrolizumab 200 mg will be administered IV every 3 weeks."
191648|NCT02710396|Drug|Carboplatin|Carboplatin AUC = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
191649|NCT02710396|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
191650|NCT02710396|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab
191651|NCT02710357|Procedure|Mandibular Overdenture|Placement of an implant in the mandibular midline.
191652|NCT02710357|Procedure|Mandibular complete denture|No intervention. Maintenance of the dentures will be done when needed.
191653|NCT02710344|Behavioral|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
191654|NCT02710331|Drug|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
191655|NCT02710331|Drug|Placebo|Control: no alcohol, administered for ~80 minutes.
191656|NCT02710331|Drug|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
191657|NCT02710331|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
191658|NCT02710318|Behavioral|Electronic immunization alert|Immunization alert in the electronic health record
191659|NCT02710305|Drug|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
191660|NCT02710305|Drug|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
191661|NCT02710292|Device|Delefilcon A contact lenses|
191662|NCT02710292|Device|Narafilcon A contact lenses|
191663|NCT02710279|Behavioral|Trier Social Stress Test (TSST)|"For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days."
191664|NCT02710279|Device|smartphone|
191665|NCT02710266|Drug|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
191666|NCT02710266|Drug|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
191667|NCT02710266|Drug|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
191668|NCT02710253|Radiation|External Beam Radiation Therapy|Undergo EBRT
191669|NCT02710253|Other|Laboratory Biomarker Analysis|Correlative studies
191670|NCT02710253|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
191671|NCT02710240|Drug|Indocyanine Green (ICG)|
191672|NCT02710240|Radiation|intraoperative near-infrared (NIR)|
191673|NCT02710227|Other|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
191674|NCT02710214|Drug|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
191675|NCT02710214|Drug|Placebo|Once-daily dosing of placebo for 8 weeks
191676|NCT02710201|Behavioral|Descriptive Social Norm|
191677|NCT02710201|Behavioral|Descriptive-plus-Injunctive Social Norm|
191678|NCT02710188|Drug|HTL0009936 modified release|HTL0009936 modified release
191679|NCT02710188|Drug|HTL0009936 immediate release|HTL0009936 immediate release
191680|NCT02710175|Other|serum TSH level|
191681|NCT02710162|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
191682|NCT02710162|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
191683|NCT02710162|Device|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
191684|NCT02710162|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
191685|NCT02710162|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
191686|NCT02710162|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
191687|NCT02710162|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
191688|NCT02710162|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
191689|NCT02710162|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
191690|NCT02710162|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
191691|NCT02710162|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
191885|NCT02708875|Other|Glucose Challenge|Glucose drink (50g glucose)
191692|NCT02710162|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
191693|NCT02710149|Biological|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
191694|NCT02710136|Biological|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).~Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
191695|NCT02710123|Other|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
191696|NCT02710123|Other|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
191697|NCT02710110|Device|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
191698|NCT02710110|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
191699|NCT02710110|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
191700|NCT02710110|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
191701|NCT02710110|Other|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
191702|NCT02710110|Device|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
191703|NCT02710110|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
191704|NCT02710097|Drug|Active inhaled cannabis|"~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
191705|NCT02710097|Drug|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
191706|NCT02710097|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
191707|NCT02710097|Drug|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
191708|NCT02710084|Drug|Oxytocin|Intranasal oxytocin
191709|NCT02710084|Drug|Saline|Placebo
191710|NCT02710071|Drug|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
191711|NCT02710071|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
191712|NCT02710058|Behavioral|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
191713|NCT02710045|Biological|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
191714|NCT02710045|Biological|DTP Vaccine at 9 months of age|Single intramuscular (i.m.) dose of diphtheria-tetanus-whole cell pertussis vaccine (Serum Institute of India Ltd.) into the thigh at 9 months of age
191715|NCT02710045|Biological|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
191716|NCT02710032|Behavioral|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
191717|NCT02710032|Behavioral|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
191718|NCT02710019|Other|Back to Reality Series video games|Back to Reality Series are a psycho-educational video games that address the emotional harms associated with underage substance use. They also help youth learn how and where to seek help for mental health and addictions problems.
191719|NCT02710019|Other|Control video games|The control video game will consist of digital puzzles and memory mini-games. The control games will not have any content related to mental health and addictions problems
192243|NCT02706405|Drug|Cyclophosphamide|Given IV
191720|NCT02710006|Procedure|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
191721|NCT02709993|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
191722|NCT02709980|Behavioral|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
191723|NCT02709980|Behavioral|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
191724|NCT02709967|Other|Material support|Writing materials
191725|NCT02709967|Other|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
191726|NCT02709967|Behavioral|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
191727|NCT02709954|Drug|Active inhaled delta-9-THC|"Low dose THC (~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
191728|NCT02709954|Drug|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
191729|NCT02709954|Drug|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
191730|NCT02709954|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
191731|NCT02709941|Other|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
191732|NCT02709941|Other|Placebo|
191733|NCT02709928|Drug|TD-0714|
191734|NCT02709928|Drug|Placebo|
191735|NCT02709915|Other|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
191736|NCT02709915|Other|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
191737|NCT02709902|Drug|Adapalene/BP gel, 0.3%/2.5%|Gel
191738|NCT02709902|Drug|EPIDUO® FORTE|Gel
191739|NCT02709902|Drug|Placebo|Gel
191740|NCT02709889|Drug|Rovalpituzumab tesirine|
191741|NCT02709876|Biological|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
191742|NCT02709863|Drug|Sevoflurane|1-1.5 MAC, inhalation route, during operation
191743|NCT02709863|Drug|Desflurane|1-1.5 MAC, inhalation route, during operation
191744|NCT02709863|Drug|Propofol|6-10 mg/kg/h, iv infusion, during operation
191745|NCT02709850|Drug|IONIS ANGPTL3-LRx|
191746|NCT02709850|Drug|Placebo (0.9%NaCl, water, riboflavin)|
191747|NCT02709837|Other|Nutritional|
191748|NCT02709824|Drug|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
191749|NCT02709824|Drug|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
191750|NCT02709811|Drug|Electrochemotherapy|
191751|NCT02709798|Drug|Shenfu Injection|
191752|NCT02709798|Drug|5% Glucose Injection|
191753|NCT02709785|Drug|SmartMouth Clinical DDS mouthrinse|Subjects use SmartMouth Clinical DDS mouth rinse for six weeks.
191754|NCT02709785|Drug|0.12% chlorhexidine rinse|Subjects use chlorhexidine mouth rinse for six weeks.
191755|NCT02709785|Drug|Placebo rinse|Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
191756|NCT02709772|Behavioral|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
192244|NCT02706405|Biological|Durvalumab|Given IV
192245|NCT02706405|Drug|Fludarabine Phosphate|Given IV
191757|NCT02709759|Behavioral|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
191758|NCT02709759|Behavioral|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
191759|NCT02709759|Behavioral|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
191760|NCT02709746|Drug|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
191761|NCT02709746|Drug|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
191762|NCT02709746|Drug|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
191763|NCT02709746|Other|Placebo|Encapsulated tablet
191764|NCT02709733|Behavioral|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
191765|NCT02709720|Drug|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
191766|NCT02709720|Drug|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
191767|NCT02709720|Drug|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
191768|NCT02709720|Drug|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
191769|NCT02709720|Radiation|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
191770|NCT02709707|Device|Blood glucose monitor|
191771|NCT02709694|Other|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
191772|NCT02709681|Other|Physician standard-of-care in SCD patients|
191773|NCT02709668|Dietary Supplement|Enlyte|gel cap of reduced B vitamins
191774|NCT02709668|Other|placebo|identical to Enlyte
191775|NCT02709655|Drug|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
191776|NCT02709655|Drug|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
191777|NCT02709655|Drug|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).~Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
191778|NCT02709655|Other|Placebo|Encapsulated tablet, orally
191779|NCT02709642|Behavioral|Deposit Contract|"A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer."
191780|NCT02709629|Behavioral|Individualized and adaptive computerized cognitive training|
191781|NCT02709629|Behavioral|Active control|
191782|NCT02709616|Biological|Personalized cellular vaccine|Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.
191783|NCT02709603|Drug|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
191784|NCT02709603|Drug|placebo|oral placebo; 2 tablets 30 minutes before the procedure
191785|NCT02709590|Drug|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
191786|NCT02709590|Drug|placebo|patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
191787|NCT02709577|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
191788|NCT02709577|Other|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
191789|NCT02709564|Drug|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
191790|NCT02709564|Drug|placebo 400 sublingual|patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
191791|NCT02709551|Behavioral|HRV_Bfb|
191792|NCT02709551|Behavioral|MBI|
191793|NCT02709551|Behavioral|MBI_HRV_Bfb|
191794|NCT02709538|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 spray in each nostril twice daily for 52 weeks
191795|NCT02709538|Drug|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
191796|NCT02709538|Drug|GSP 301 Placebo NS pH 7.0|2 spray in each nostril twice daily for 52 weeks
191797|NCT02709525|Drug|hyaluronic acid|
191798|NCT02709525|Other|Placebo|
191799|NCT02709512|Drug|ADI-PEG 20 plus Pem Cis|Investigational Drug in combination approved standard of care treatment for this indication
191800|NCT02709512|Other|Placebo plus Pem Cis|Placebo in combination approved standard of care treatment for this indication
191801|NCT02709499|Device|0J LLLT|perform with the machine off
191802|NCT02709499|Device|6J LLLT|irradiation will be perform with 4J
191803|NCT02709486|Drug|Tanezumab|2.5 mg
191804|NCT02709486|Drug|Tanezumab|5 mg
191805|NCT02709486|Drug|Placebo|Placebo
192246|NCT02706405|Other|Laboratory Biomarker Analysis|Correlative studies
192247|NCT02706405|Other|Pharmacological Study|Correlative studies
191806|NCT02709473|Drug|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
191807|NCT02709473|Drug|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
191808|NCT02709473|Drug|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
191809|NCT02709460|Procedure|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
191810|NCT02709460|Procedure|Cervical occlusion|Cervical occlusion of the uterine artery
191811|NCT02709447|Behavioral|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
191812|NCT02709447|Behavioral|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
191813|NCT02709434|Behavioral|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
191814|NCT02709434|Other|Standard care|Usual IBD management
191815|NCT02709395|Device|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
191816|NCT02709382|Drug|Cefepime and Tazobactam combination|
191817|NCT02709369|Device|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
191818|NCT02709356|Dietary Supplement|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
191819|NCT02709356|Dietary Supplement|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
191820|NCT02709343|Drug|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
191821|NCT02709343|Drug|Placebo|Placebo product visually very similar to mesenchymal stromal cells
191822|NCT02709330|Drug|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
191823|NCT02709330|Other|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
191824|NCT02709317|Behavioral|Prevention Intervention|
191825|NCT02709317|Behavioral|Brief Intervention|
191826|NCT02709304|Drug|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
191827|NCT02709304|Drug|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
191828|NCT02709291|Behavioral|behavioral parent training|Parents receive up to 6 sessions of the Family Check-Up program
191829|NCT02709291|Behavioral|interventionist training|Interventionists are trained in the delivery of the Family Check-Up program and deliver sessions to families in their community
191830|NCT02709278|Biological|BCG|BCG SSI (Groups 1A, 1B, 1C and 1D) & BCG Bulgaria (InterVax) (Groups 2A, 2B, 2C, 2D and 2E)
191831|NCT02709278|Other|Saline placebo|Saline placebo
191832|NCT02709265|Drug|amikacin/fosfomycin|single aerosolized dose
191833|NCT02709252|Device|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
191834|NCT02709239|Dietary Supplement|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
191835|NCT02709239|Dietary Supplement|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
191836|NCT02709226|Radiation|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD (provided no DLT) with a maximum of 21 evaluable patients enrolled.
191837|NCT02709213|Diagnostic Test|Diagnostic|Determination of pathogens and faecal calprotectin in the stools
191838|NCT02709200|Drug|Dexmedetomidine|
191839|NCT02709187|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
191840|NCT02709187|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
191841|NCT02709187|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
191842|NCT02709174|Procedure|blood draw|blood draw
191843|NCT02709161|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
191883|NCT02708888|Other|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
191844|NCT02709161|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
191845|NCT02709148|Device|Activa PC+S|DBS
191846|NCT02709122|Device|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
191847|NCT02709109|Drug|VX-371|
191848|NCT02709109|Drug|Saline|
191849|NCT02709109|Drug|Placebo|
191850|NCT02709109|Drug|Orkambi|
191851|NCT02709096|Drug|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
191852|NCT02709096|Drug|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
191853|NCT02709083|Drug|Dasatinib|Given orally
191854|NCT02709083|Drug|Imatinib Mesylate|Given orally
191855|NCT02709083|Drug|Nilotinib|Given orally
191856|NCT02709070|Procedure|resection|hepatectomy for HCC
191857|NCT02709070|Procedure|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
191858|NCT02709057|Behavioral|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
191859|NCT02709044|Drug|Ringer lactate|
191860|NCT02709031|Drug|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,~Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
191861|NCT02709031|Drug|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
191862|NCT02709018|Drug|losartan|Angiotensin receptor blocker (ARB)
191863|NCT02709018|Drug|Placebo|Placebo
191864|NCT02709005|Drug|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
191865|NCT02709005|Other|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
191866|NCT02708992|Drug|Azithromycin|
191867|NCT02708992|Drug|Cefixime|
191868|NCT02708979|Other|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
191869|NCT02708979|Other|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
191870|NCT02708966|Drug|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
191871|NCT02708966|Drug|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
191872|NCT02708953|Procedure|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
191873|NCT02708953|Procedure|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
191874|NCT02708940|Other|Participatory technology development|Creating mobile support tools by patients and their therapists
191875|NCT02708940|Other|Usual Care|Usual care as part of the UCLA PHP and IOP programs
191876|NCT02708927|Other|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
191877|NCT02708927|Other|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
191878|NCT02708914|Biological|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
191879|NCT02708914|Biological|Eprex|Eprex® is chosen as the comparator.
191880|NCT02708901|Dietary Supplement|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
191881|NCT02708901|Dietary Supplement|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
191882|NCT02708888|Other|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
191884|NCT02708875|Other|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
191886|NCT02708862|Device|Preoxygenation|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed below, the exhaled oxygen content will be measured. All participants were enrolled in a single arm in which they underwent 4 interventions in series: 1) Simple mask at 60 L/min for 3 minutes 2) Non-rebreather at 60 L/min for 3 min 3) Non-rebreather at 15 L/min for 3 minutes 4) Bag valve mask at 15 L/min for 3 minutes
191887|NCT02708849|Drug|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
191888|NCT02708849|Drug|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
191889|NCT02708849|Drug|Placebo|oral dose placebo
191890|NCT02708836|Procedure|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
191891|NCT02708836|Device|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
191892|NCT02708836|Device|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
191893|NCT02708836|Procedure|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
191894|NCT02708836|Procedure|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
191895|NCT02708836|Procedure|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
191896|NCT02708836|Procedure|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
191897|NCT02708836|Procedure|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
191898|NCT02708823|Other|CogCheck application|The application is administered once to all study participants.
191899|NCT02708810|Device|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
191900|NCT02708810|Radiation|80 Gy Radiation|
191901|NCT02708797|Other|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
191902|NCT02708797|Other|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
191903|NCT02708771|Drug|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
191904|NCT02708771|Drug|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
191905|NCT02708758|Behavioral|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
191906|NCT02708745|Behavioral|Intervention Survey|
191907|NCT02708745|Behavioral|Placebo Survey|
191908|NCT02708719|Procedure|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
191909|NCT02708706|Drug|hyaluronic acid (hyruan)|2cc hyaluronic acid
191910|NCT02708706|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
191911|NCT02708693|Drug|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort)
191912|NCT02708693|Device|thermoplastic wrist splint|thermoplastic wrist splint with wrist placed in a neutral position
191913|NCT02708693|Drug|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
191914|NCT02708680|Drug|entinostat|An orally available histone deacetylases inhibitor (HDAC)
191915|NCT02708680|Drug|atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
191916|NCT02708680|Drug|Placebo|A pill containing no active drug ingredient
191917|NCT02708654|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
191918|NCT02708654|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
191919|NCT02708654|Behavioral|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
192248|NCT02706392|Other|Laboratory Biomarker Analysis|Correlative studies
192249|NCT02706392|Biological|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
191920|NCT02708654|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
191921|NCT02708641|Drug|pembrolizumab|200 mg IV given every three weeks
191922|NCT02708628|Drug|extract of allium cepae, allantoin and heparin|prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
191923|NCT02708628|Procedure|Scar excision|Scar excision in second c-section
191924|NCT02708615|Other|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
191925|NCT02708602|Genetic|β2AR polymorphism|
191926|NCT02708589|Dietary Supplement|probiotic|
191927|NCT02708589|Other|Placebo|
191928|NCT02708576|Biological|NGM313|
191929|NCT02708576|Other|Placebo|
191930|NCT02708563|Procedure|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
191931|NCT02708563|Procedure|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
191932|NCT02708550|Behavioral|Participatory Organizational Intervention|
191933|NCT02708537|Biological|PRGF in candidates for sperm donors|PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
191934|NCT02708524|Device|Senofilcon C Contact Lens|
191935|NCT02708524|Device|Comfilcon A Contact Lens|
191936|NCT02708524|Device|Lotrafilcon B Contact Lens|
191937|NCT02708524|Device|Samfilcon A Contact Lens|
191938|NCT02708511|Diagnostic Test|Computed Tomography|Undergo PET/CT
191939|NCT02708511|Drug|Copper Cu 64-DOTA B-Fab|Given IV
191940|NCT02708511|Other|Laboratory Biomarker Analysis|Correlative studies
191941|NCT02708511|Other|Pharmacological Study|Correlative studies
191942|NCT02708511|Diagnostic Test|Positron Emission Tomography|Undergo PET/CT
191943|NCT02708498|Behavioral|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
191944|NCT02708485|Other|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
191945|NCT02708472|Device|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
191946|NCT02708459|Device|surgically inserted Transversus abdominus plane catheter|at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
191947|NCT02708459|Drug|Intravenous morphine|Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
191948|NCT02708459|Drug|Bupevecaine|
191949|NCT02708459|Drug|Dexmedetomedine|
191950|NCT02708446|Drug|Mifepristone|200mg oral mifepristone to both study arms
191951|NCT02708446|Drug|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
191952|NCT02708446|Drug|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
191953|NCT02708433|Drug|Lidocaine|Lidocaine
191954|NCT02708420|Device|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
191955|NCT02708420|Device|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
191956|NCT02708407|Procedure|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
191957|NCT02708394|Drug|olanzapine|atypical antipsychotic
191958|NCT02708394|Drug|placebo|placebo control
191959|NCT02708381|Other|Screening|Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
191960|NCT02708368|Other|blood withdrawal|3 times
191961|NCT02708355|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
191962|NCT02708355|Drug|Placebo|Placebo capsules
191963|NCT02708329|Procedure|T-provisional stenting|Standard endovascular T-provisional stenting technique
191964|NCT02708329|Procedure|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
192084|NCT02707497|Drug|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
191965|NCT02708329|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
191966|NCT02708316|Genetic|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
191967|NCT02708303|Other|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.~Data collected from the questionnaire will be entered into a database that will be maintained for future research."
191968|NCT02708290|Other|MITA imagination exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.
191969|NCT02708277|Device|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
191970|NCT02708277|Device|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
191971|NCT02708264|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
191972|NCT02708251|Drug|glyceryl trinitrate cream|
191973|NCT02708251|Drug|lidocaine cream|
191974|NCT02708251|Drug|placebo cream|
191975|NCT02708238|Dietary Supplement|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
191976|NCT02708238|Dietary Supplement|Lactobacillus reuteri DSM 17938 (108 CFU)|
191977|NCT02708238|Drug|Simethicone|
191978|NCT02708225|Behavioral|medical clown|a medical clown will assist the child during the performance of pulmonary function test
191979|NCT02708212|Procedure|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
191980|NCT02708186|Drug|Nelotanserin|once daily, oral, 20-mg tablets
191981|NCT02708186|Drug|Placebo|once daily, oral, matching tablets
191982|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
191983|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
191984|NCT02708160|Drug|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
191985|NCT02708160|Drug|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
191986|NCT02708160|Drug|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
191987|NCT02708147|Other|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
191988|NCT02708147|Other|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
191989|NCT02708121|Behavioral|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
191990|NCT02708121|Other|Comparator Intervention|Participants informed that they have access to weight loss treatment.
191991|NCT02708108|Behavioral|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
191992|NCT02708108|Behavioral|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
191993|NCT02708095|Drug|Baricitinib|Administered orally
191994|NCT02708095|Drug|Placebo|Administered orally
191995|NCT02708082|Device|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
192085|NCT02707497|Drug|Placebo|The control group will not use any platelet-increased drugs.
192352|NCT02705534|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
191996|NCT02708069|Other|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
191997|NCT02708069|Other|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
191998|NCT02708056|Drug|Sugammadex|
191999|NCT02708043|Other|Flexible-Laryngeal Mask Airway|
192000|NCT02708030|Other|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
192001|NCT02708030|Other|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
192002|NCT02708030|Other|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
192003|NCT02708017|Procedure|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
192004|NCT02708017|Procedure|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
192005|NCT02708004|Drug|ACT-132577|Formulated in capsules in 2 different strengths; 2 capsules per day
192006|NCT02708004|Other|Placebo|Matching active drug
192007|NCT02707991|Behavioral|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
192008|NCT02707978|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
192009|NCT02707965|Drug|Oxcarbmazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192010|NCT02707965|Drug|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192011|NCT02707965|Drug|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192012|NCT02707965|Drug|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192013|NCT02707965|Drug|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192014|NCT02707965|Drug|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192015|NCT02707965|Drug|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192016|NCT02707965|Drug|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
192017|NCT02707952|Drug|ABT-493/ABT-530|Co-formulated tablet
192018|NCT02707952|Drug|OBV/PTV/r|Co-formulated tablet
192019|NCT02707939|Other|Observation|Patients will be observed before and after they receive anesthesia
192020|NCT02707926|Drug|Anti-HIV Agents|Therapy to treat HIV infection
192021|NCT02707913|Drug|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
192022|NCT02707913|Drug|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
192023|NCT02707900|Drug|Vorinostat|"At Step 2 (Enrollment) - subjects receive two paired oral doses of Vorinostat (VOR) 400 mg.~Step 5 - Approximately 7- 10 days after the 4th dose of AGS-004 in Step 4 (Visit 11), ten (10) doses of VOR 400 mg will be administered at 72 hour intervals.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
192024|NCT02707900|Biological|AGS-004|"Step 4 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 10-7 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.~Steps 6 - 7 & EOS visit - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 6) followed by 10 doses of VOR 400 mg PO (Step 7)."
192025|NCT02707887|Behavioral|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
192026|NCT02707887|Behavioral|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
192027|NCT02707887|Behavioral|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
192028|NCT02707874|Drug|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
192029|NCT02707874|Drug|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
192030|NCT02707861|Drug|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
192031|NCT02707861|Drug|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
192032|NCT02707848|Other|No intervention|
192033|NCT02707835|Other|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
192034|NCT02707835|Other|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
192035|NCT02707835|Other|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
192036|NCT02707822|Other|Clinical and genetic factors|
192037|NCT02707809|Drug|Dexmedetomidine|Dexmedetomidine infusion
192038|NCT02707796|Procedure|Hemicolectomy|
192039|NCT02707783|Device|Bioresorbable vascular scaffold (BVS) implantation|
192040|NCT02707770|Other|Pulmonary Rehabilitation|
192041|NCT02707757|Drug|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
192042|NCT02707757|Drug|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
192043|NCT02707744|Other|no intervention|
192044|NCT02707731|Procedure|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
192045|NCT02707718|Biological|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
192046|NCT02707705|Device|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :~The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
192126|NCT02707237|Other|Verbal counseling|Verbal counseling done by physician
194831|NCT02687191|Biological|PF-05230907|PF-05230907 IV bolus injection
192047|NCT02707705|Device|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.~Data collected :~T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency~T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects~T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects~T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
192048|NCT02707705|Procedure|Disinfection|The ear is disinfected by applying Chlorhexidine®.
192049|NCT02707692|Biological|Fluarix|Intramuscular injection with Fluarix® .
192050|NCT02707692|Biological|Pneumovax|Intramuscular injection with Pneumovax.
192051|NCT02707692|Other|Placebo|Intramuscular injection with sterile saline (placebo).
192052|NCT02707679|Other|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
192053|NCT02707679|Other|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
192054|NCT02707679|Other|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
192055|NCT02707679|Other|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
192056|NCT02707666|Drug|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
192057|NCT02707666|Drug|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
192058|NCT02707653|Drug|Misoprostol|400 mcg sublingual misoprostol
192059|NCT02707640|Drug|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
192060|NCT02707640|Drug|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
192061|NCT02707640|Drug|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
192062|NCT02707627|Device|Ablative fractional carbon dioxide laser therapy (AFCL)|AFCL is a new form of treatment for hypertrophic burn scars.
192063|NCT02707627|Procedure|Standard Scar Management (SSM)|SSM may include any of the following: range of motion exercises, massage, custom fit pressure garments, and silicone sheeting.
192064|NCT02707627|Device|Pulsed Dye Laser (PDL)|PDL is a new form of treatment for hypertrophic burn scars.
192065|NCT02707614|Procedure|Robotic vs open prostastectomy|robotic minimal invasive surgery
192066|NCT02707601|Drug|E/C/F/TAF|150/150/200/10 mg fixed dose combination (FDC) tablet administered orally once daily
192067|NCT02707601|Drug|F/R/TAF|200/25/25 mg FDC tablet administered orally once daily
192068|NCT02707601|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
192069|NCT02707588|Drug|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
192070|NCT02707588|Drug|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.~Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
192071|NCT02707588|Radiation|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
192072|NCT02707575|Drug|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
192073|NCT02707562|Drug|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
192074|NCT02707562|Drug|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
192075|NCT02707562|Drug|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
192076|NCT02707549|Drug|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
192077|NCT02707549|Drug|0.9% sodium chloride|
192078|NCT02707536|Procedure|Socket grafting with PRF|Extraction with socket grafting using PRF.
192079|NCT02707536|Procedure|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
192080|NCT02707523|Drug|Azithromycin 10 mg|
192081|NCT02707523|Drug|Azithromycin 20mg|
192082|NCT02707523|Drug|Placebo|
192083|NCT02707510|Other|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
192394|NCT02705287|Other|Vitamin D dynamics-pregnant|tracer dose of deuterated vitamin D3
192086|NCT02707484|Drug|Thalidomide (100mg)|Patients were randomly assigned to receive a four-month course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
192087|NCT02707484|Drug|Thalidomide (50mg)|Patients were randomly assigned to receive a four-month course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
192088|NCT02707484|Drug|placebo|Patients were randomly assigned to receive a four-month course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
192089|NCT02707471|Behavioral|SM-AET|self-management for improving adherence and reducing symptom interference (SM-AET)
192090|NCT02707471|Behavioral|general health education|general health education intervention that focuses on improving overall health.
192091|NCT02707458|Drug|Probucol|"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."
192092|NCT02707445|Drug|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
192093|NCT02707432|Behavioral|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
192094|NCT02707419|Device|Experimental group|Video of the exercises
192095|NCT02707419|Device|Control group|video of nature scenes
192096|NCT02707419|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
192097|NCT02707406|Other|NEOX®CORD 1K|use of human tissue product wound covering
192098|NCT02707406|Other|standard of care|standard wound coverings
192099|NCT02707393|Drug|Fludarabine|infusion
192100|NCT02707393|Drug|Thiotepa|infusion
192101|NCT02707393|Drug|Melphalan|infusion
192102|NCT02707393|Drug|ATG|infusion
192103|NCT02707393|Drug|Cyclosporine A|infusion, orally if possible
192104|NCT02707393|Drug|Mycophenolate mofetil|infusion
192105|NCT02707393|Biological|bone marrow or peripheral blood stem cells|infusion
192106|NCT02707380|Other|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
192107|NCT02707380|Other|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
192108|NCT02707367|Behavioral|Recovery Roadmap (RR)|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. Participants in the RR intervention will use the tool in Year 2, Quarter 1 (Y2Q1), Y2Q2, and Y2Q3. There are 3 components:~Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.~Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.~Coaching & Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
192109|NCT02707367|Behavioral|Illness Management and Recovery (IMR)|IMR is an established evidence-based practice that helps people set meaningful goals for themselves, acquire information and skills to develop more mastery over their psychiatric illness, and make progress towards their own personal recovery. For this study, the IMR intervention will arise from established use of the intervention in enrolled programs.
192110|NCT02707354|Device|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
192111|NCT02707328|Drug|Gemcitabine|
192112|NCT02707328|Drug|nab-paclitaxel|
192113|NCT02707328|Radiation|CyberKnife|
192114|NCT02707315|Drug|Gemcitabine|
192115|NCT02707315|Radiation|Stereotactic Radiosurgery|
192116|NCT02707302|Device|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
192117|NCT02707302|Procedure|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
192118|NCT02707276|Device|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
192119|NCT02707276|Device|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment.
192120|NCT02707263|Drug|intravenous continuous infusion of heparin (IV UFH)|
192121|NCT02707263|Drug|Subcutaneous Heparin|
192122|NCT02707250|Drug|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
192123|NCT02707250|Drug|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
192124|NCT02707250|Drug|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
192125|NCT02707250|Drug|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
192127|NCT02707237|Other|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
192128|NCT02707224|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
192129|NCT02707224|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
192130|NCT02707224|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
192131|NCT02707211|Biological|Anti-oxLDL IgM antibody|Immunization
192132|NCT02707198|Drug|kefir|4 ounces of kefir 3 times a day, with or without food.
192133|NCT02707185|Behavioral|Simulation-Based Training|An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
192134|NCT02707172|Behavioral|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
192135|NCT02707172|Behavioral|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
192136|NCT02707159|Drug|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
192137|NCT02707146|Behavioral|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
192138|NCT02707146|Other|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
192139|NCT02707146|Device|iPad|
192140|NCT02707133|Other|No intervention|
192141|NCT02707120|Drug|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
192142|NCT02707120|Drug|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
192143|NCT02707107|Drug|Intravenous infusions of WCK 5222|
192144|NCT02707107|Drug|Placebo|
192145|NCT02707094|Device|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
192146|NCT02707094|Other|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
192147|NCT02707081|Drug|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
192148|NCT02707081|Drug|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
192149|NCT02707081|Drug|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
192150|NCT02707081|Drug|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
192151|NCT02707068|Behavioral|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
192152|NCT02707055|Drug|PF-05190457|Ghrelin Receptor Inverse Agonist
192153|NCT02707055|Behavioral|MI-VF|Motivational Interviewing with Video
192154|NCT02707055|Other|Placebo|Placebo
192155|NCT02707055|Other|Counseling|Counselling Support
192156|NCT02707042|Drug|Amoxicillin|Amoxicillin (Amoxil (Registered Trademark)): Each capsule of Amoxil, with royal blue opaque cap and pink opaque body, contains 500 mg amoxicillin as the trihydrate. The cap and body of the 500-mg capsule are imprinted with the product name AMOXIL and 500.
192157|NCT02707042|Drug|Azithromycin|Azithromycin (Zithromax (Registered Trademark)): Tablets for oral administration are provided as red film-coated, oval-shaped tablets that contain 250 mg of azithromycin as the monohydrate. The tablets are engraved with Pfizer and 306 .
192158|NCT02707016|Other|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
192159|NCT02707016|Other|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
192160|NCT02706990|Device|Physica KR|Kinematic retaining total knee implant
192161|NCT02706990|Device|Physica PS|Posterior stabilized total knee implant
192162|NCT02706977|Drug|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
192163|NCT02706977|Drug|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
192212|NCT02706626|Drug|brigatinib|Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
192213|NCT02706613|Behavioral|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
192214|NCT02706613|Behavioral|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
192164|NCT02706977|Device|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
192165|NCT02706977|Other|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
192166|NCT02706977|Other|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
192167|NCT02706964|Device|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
192168|NCT02706964|Device|Magnetic resonance imaging|A brain MRI will be performed.
192169|NCT02706964|Device|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
192170|NCT02706951|Drug|Methotrexate|Oral capsule
192171|NCT02706951|Drug|Upadacitinib|Oral tablet
192172|NCT02706951|Drug|Upadacitinib matching placebo|Oral tablet
192173|NCT02706951|Drug|Methotrexate matching placebo|Oral capsule
192174|NCT02706938|Other|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
192175|NCT02706938|Other|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
192176|NCT02706925|Drug|BI 443651|
192177|NCT02706925|Drug|Placebo|
192178|NCT02706912|Behavioral|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
192179|NCT02706899|Drug|vadastuximab talirine|Intravenous (IV) push every 4 weeks
192180|NCT02706899|Drug|Azacitidine|75 mg/m^2 given intravenously or subcutaneously for 7 days every 4 weeks
192181|NCT02706899|Drug|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A, IV push every 4 weeks
192182|NCT02706886|Drug|Lumasiran|Single or multiple doses of ALN-GO1 by subcutaneous (sc) injection
192183|NCT02706886|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
192184|NCT02706873|Drug|Upadacitinib|Oral tablet
192185|NCT02706873|Drug|Methotrexate|Oral capsule
192186|NCT02706873|Drug|Methotrexate Matching Placebo|Oral capsule
192187|NCT02706873|Drug|Upadacitinib Matching Placebo|Oral Tablet
192188|NCT02706860|Drug|Atorvastatin|
192189|NCT02706847|Drug|Placebo|Matching tablets taken orally once a day
192190|NCT02706847|Drug|Upadacitinib|Tablets taken orally once a day
192191|NCT02706834|Drug|TAK-828|TAK-828 oral solution
192192|NCT02706834|Drug|Placebo|TAK-828 placebo-matching oral solution
192193|NCT02706821|Dietary Supplement|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
192194|NCT02706821|Dietary Supplement|Placebo|Placebo, crossover design
192195|NCT02706808|Dietary Supplement|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
192196|NCT02706808|Dietary Supplement|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
192197|NCT02706795|Biological|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
192198|NCT02706782|Drug|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
192199|NCT02706769|Drug|Placebo|Study medication contains blinded placebo
192200|NCT02706769|Drug|Paracetamol|Study medication contains blinded paracetamol
192201|NCT02706756|Other|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
192202|NCT02706756|Other|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
192203|NCT02706756|Other|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
192204|NCT02706756|Other|Supervised neglect|Monitoring of group without formal intervention.
192205|NCT02706730|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
192206|NCT02706717|Drug|Visibiome|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
192207|NCT02706717|Drug|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
192208|NCT02706704|Drug|Adalimumab|
192209|NCT02706691|Drug|BGJ398|Given by mouth (oral)
192210|NCT02706678|Drug|Tacrolimus sustained-release capsule|Oral
192211|NCT02706665|Other|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
192215|NCT02706600|Behavioral|myCOPD|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.~Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.~Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.~A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
192216|NCT02706600|Behavioral|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
192217|NCT02706587|Device|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
192218|NCT02706587|Device|Sham control|No electrostimulation
192219|NCT02706561|Behavioral|questionnaires|
192220|NCT02706561|Behavioral|three in-person sessions|
192221|NCT02706561|Behavioral|monthly phone calls|
192222|NCT02706561|Behavioral|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
192223|NCT02706561|Behavioral|Enhanced Monitoring and Education (EME)|
192224|NCT02706548|Behavioral|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
192225|NCT02706548|Behavioral|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association & American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
192226|NCT02706535|Drug|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
192227|NCT02706535|Drug|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
192228|NCT02706535|Drug|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
192229|NCT02706522|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
192230|NCT02706522|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
192231|NCT02706509|Drug|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
192232|NCT02706509|Behavioral|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
192233|NCT02706509|Device|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
192234|NCT02706483|Drug|Plecanatide|
192235|NCT02706470|Drug|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
192236|NCT02706470|Drug|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
192237|NCT02706457|Other|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
192238|NCT02706444|Device|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
192239|NCT02706444|Device|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
192240|NCT02706431|Procedure|Hyperventilation|
192241|NCT02706418|Procedure|Clinical Massage Therapy|
192242|NCT02706405|Biological|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Given IV
192250|NCT02706379|Other|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
192251|NCT02706353|Drug|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.~Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
192252|NCT02706353|Drug|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
192253|NCT02706340|Other|No intervention - observational study only|
192254|NCT02706327|Device|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
192255|NCT02706327|Device|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
192256|NCT02706327|Other|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
192257|NCT02706301|Behavioral|Telephone-Based Coping Skills Training (CST)|
192258|NCT02706288|Other|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose 7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
192259|NCT02706275|Other|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
192260|NCT02706262|Other|Metabolically abnormal obese - Mediterranean diet|The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.
192261|NCT02706262|Other|Metabolically abnormal obese - Low carbohydrate ketogenic diet|The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.
192262|NCT02706262|Other|Metabolically abnormal obese - Plant-based, very-low-fat diet|The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 to 8 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
192263|NCT02706249|Drug|Enoxaparin|
192264|NCT02706236|Drug|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
192265|NCT02706236|Drug|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
192266|NCT02706223|Other|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
192267|NCT02706223|Other|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
192268|NCT02706197|Device|OxyChip|The OxyChip is an investigational device to assess oxygen level in tissues, when measured with Electron Paramagnetic Resonance (EPR).
192269|NCT02706184|Drug|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
192270|NCT02706184|Drug|Placebo|Placebo
192271|NCT02706171|Radiation|CyberKnife|
192272|NCT02706158|Dietary Supplement|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
192273|NCT02706158|Behavioral|balanced diet|participants will get a balanced diet according to pregnancy stage
192274|NCT02706145|Other|Social norming campaign|community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
192275|NCT02706132|Biological|Mesenchymal Stem Cells(MSCs)|Six doses of 1*10^6/kg body weight MSCs are given, intravenously.
192276|NCT02706119|Drug|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
192277|NCT02706119|Drug|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
192278|NCT02706106|Device|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
192279|NCT02706093|Other|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at ~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
192280|NCT02706093|Other|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
192281|NCT02706093|Other|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax [25min; ~150kcals; 4d/wk]
192282|NCT02706093|Other|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax [15min; ~90kcals; 4d/wk]
192283|NCT02706080|Other|emergency|
192284|NCT02706067|Drug|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent [%] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
192285|NCT02706054|Other|saline|The patients received an IM injection of saline near the nerve root (periradicular)
192286|NCT02706054|Drug|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
192287|NCT02706041|Procedure|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
192288|NCT02706041|Procedure|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
192289|NCT02706028|Device|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
192290|NCT02706028|Device|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
192291|NCT02706015|Drug|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
192292|NCT02706015|Drug|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
192293|NCT02706002|Device|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
192294|NCT02706002|Procedure|hip prosthesis|all patients in the study will undergo hip prosthesis
192295|NCT02705989|Drug|BMS-986195|Specified dose on specified day
192296|NCT02705989|Other|Placebo|Specified dose on specified day
192297|NCT02705976|Other|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
192298|NCT02705976|Other|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
192299|NCT02705963|Drug|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
192300|NCT02705963|Drug|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
192301|NCT02705963|Drug|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
192302|NCT02705950|Drug|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
192303|NCT02705950|Other|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
192304|NCT02705937|Other|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
192305|NCT02705937|Device|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
192306|NCT02705924|Behavioral|psychoeducation|"Participants will attend conferences where experts present the state of the art in various domains:~Latest knowledge in oncogenetics~Recommendations and morbidity of prophylactic breast surgeries and annexectomy~Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits~How to perform the periodic breast screening~Assisted medical procreation and embryo selection~Importance of nutrition and physical activity as risk modulator~Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?~Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.~The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist."
192307|NCT02705911|Other|Isometric handgrip exercise|Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
192308|NCT02705911|Other|Aerobic endurance training|To perform 150 minutes extra/week at moderate aerobic intensity
192309|NCT02705898|Behavioral|LPA+Fitbit|
192310|NCT02705898|Behavioral|HEC|
192311|NCT02705885|Dietary Supplement|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
192312|NCT02705885|Dietary Supplement|Placebo IgY|Placebo IgY
192313|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
192472|NCT02704650|Procedure|fluid sample|taking a vaginal fluid sample
192314|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
192315|NCT02705859|Drug|Copanlisib|Copanlisib is supplied as lyophilized preparation in a 6mL injection vial. The total amount of copanlisib per vial is 60mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered first over 60 minutes followed by the infusion of trastuzumab.
192316|NCT02705859|Drug|Trastuzumab|Trastuzumab IV weekly (4mg/kg on Cycle 1 Day 1 followed by 2 mg/kg IV weekly from Day 8).
192317|NCT02705820|Drug|Pembrolizumab|Switch maintenance pembrolizumab treatment
192318|NCT02705807|Drug|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen [pH] 10.2 - 10.8 diluent) for Injection.
192319|NCT02705807|Drug|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
192320|NCT02705781|Device|smARTrack Feeding Tube System|
192321|NCT02705768|Drug|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
192322|NCT02705768|Drug|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
192323|NCT02705755|Drug|TD-9855|
192324|NCT02705755|Drug|Placebo|
192325|NCT02705742|Biological|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
192326|NCT02705729|Device|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
192327|NCT02705729|Device|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
192328|NCT02705716|Other|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
192329|NCT02705716|Other|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
192330|NCT02705703|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
192331|NCT02705690|Device|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:~The phone is kept stable against the lower back of the participant using the belt.~The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.~These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
192332|NCT02705664|Drug|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
192333|NCT02705664|Drug|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
192334|NCT02705664|Drug|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
192335|NCT02705651|Drug|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
192336|NCT02705638|Drug|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
192337|NCT02705638|Drug|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
192338|NCT02705625|Drug|MIV-711|MIV-711 administered orally once daily
192339|NCT02705625|Drug|Placebo|Placebo manufactured to mimic MIV-711 capsule.
192340|NCT02705612|Drug|Cisplatin|
192341|NCT02705612|Radiation|External Beam Radiation Therapy|
192342|NCT02705612|Radiation|Internal Radiation Therapy|
192343|NCT02705612|Drug|nimotuzumab|
192344|NCT02705586|Behavioral|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
192345|NCT02705573|Drug|Mannitol|In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
192346|NCT02705560|Other|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
192347|NCT02705560|Other|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
192348|NCT02705560|Other|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
192349|NCT02705547|Drug|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
192350|NCT02705534|Drug|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
192351|NCT02705534|Drug|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
192353|NCT02705521|Device|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
192354|NCT02705508|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
192355|NCT02705508|Drug|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
192356|NCT02705508|Drug|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
192357|NCT02705508|Radiation|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
192358|NCT02705495|Other|acupuncture|"Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture."
192359|NCT02705495|Drug|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
192360|NCT02705482|Biological|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
192361|NCT02705482|Biological|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
192362|NCT02705482|Biological|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
192363|NCT02705469|Drug|ZEN003694|
192364|NCT02705456|Procedure|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
192365|NCT02705456|Procedure|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.~Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
192366|NCT02705443|Other|No Intervention|Standard of Care Only
192367|NCT02705430|Dietary Supplement|EPA and DHA capsules of 2 g/day|EPA and DHA capsules of 2 g/day
192368|NCT02705430|Behavioral|Stress management phone application (Eco Fusion Mentally)|Stress management phone application (Eco Fusion Mentally)
192369|NCT02705430|Behavioral|life style program using a mobile phone (Eco Mentally and NewMe)|life style program using a mobile phone (Eco Mentally and NewMe)
192370|NCT02705430|Device|mobile phone|mobile phone
192371|NCT02705417|Procedure|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
192372|NCT02705417|Procedure|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
192373|NCT02705417|Procedure|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
192374|NCT02705417|Procedure|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
192375|NCT02705417|Procedure|arteriovenous graft placement|surgical placement of arteriovenous graft
192376|NCT02705404|Genetic|Multifocal Tissue Banking|
192377|NCT02705378|Drug|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
192378|NCT02705378|Drug|naloxegol|Intervention would be given by OG or NG tube
192379|NCT02705365|Other|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
192380|NCT02705365|Other|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
192381|NCT02705352|Drug|5-Fluorouracil|Treatment medication
192382|NCT02705352|Other|Normal saline|Placebo
192383|NCT02705339|Drug|Rociletinib|
192384|NCT02705339|Procedure|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
192385|NCT02705339|Procedure|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
192386|NCT02705326|Device|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
192387|NCT02705313|Drug|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
192388|NCT02705300|Drug|Irinotecan 165 mg/m2 iv|Max. 4 months
192389|NCT02705300|Drug|Oxaliplatin 85 mg/m2 iv|Max. 4 months
192390|NCT02705300|Drug|Calcium folinate 200 mg/m2 iv|Max. 6 months
192391|NCT02705300|Drug|5-fluorouracil 3200 mg/m2|Max. 6 months
192392|NCT02705300|Dietary Supplement|Tocotrienol|Max. 2 years or at the discretion of the investigator
192393|NCT02705300|Drug|Placebo|Max. 2 years or at the discretion of the investigator
192395|NCT02705287|Other|Vitamin D dynamics-nonpregnant|tracer dose of deuterated vitamin D3
192396|NCT02705287|Other|Delivery-placental transfer|tracer dose of deuterated vitamin D3 to women in late gestation
192397|NCT02705287|Other|Delivery-Vitamin D|women will be dosed with deuterated vitamin D3 at term when they come in for their pre-surgical appointments prior to their scheduled c-section
192398|NCT02705287|Other|Delivery-25(OH) Vitamin D|women will be dosed with deuterated 25(OH)D3 when they come in for their pre-surgical appointments
192399|NCT02705274|Drug|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.~Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
192400|NCT02705274|Procedure|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
192401|NCT02705261|Behavioral|cognitive-behavior therapy|Internet based program to support parents in developing strategies to help their children
192402|NCT02705222|Procedure|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
192403|NCT02705222|Procedure|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
192404|NCT02705209|Other|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
192405|NCT02705209|Other|Placebo Cataplasm|Poultice of Kaolin and Water
192406|NCT02705196|Genetic|delolimogene mupadenorepvec|oncolytic virus encoding TMZ-CD40L and 4-1BBL
192407|NCT02705196|Drug|gemcitabine|chemotherapy
192408|NCT02705196|Drug|nab-paclitaxel|chemotherapy
192409|NCT02705196|Biological|atezolizumab|anti-PD-L1 antibody
192410|NCT02705183|Radiation|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
192411|NCT02705170|Procedure|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
192412|NCT02705157|Procedure|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
192413|NCT02705157|Radiation|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
192414|NCT02705144|Other|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
192415|NCT02705131|Device|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
192416|NCT02705131|Device|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
192417|NCT02705118|Device|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
192418|NCT02705118|Device|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
192419|NCT02705105|Biological|Mogamulizumab + Nivolumab|i.v. administration
192420|NCT02705092|Other|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
192421|NCT02705092|Other|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
192422|NCT02705079|Other|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
192423|NCT02705066|Dietary Supplement|Citicoline supplement|
192424|NCT02705066|Dietary Supplement|Placebo supplement|Cellulose
192425|NCT02705053|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
192426|NCT02705053|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
192427|NCT02705040|Other|Normal|bone mineral density T>=-1.0
192428|NCT02705040|Other|Osteopenia|bone mineral density -1.0>T>=-2.5
192429|NCT02705040|Other|Osteoporosis|bone mineral density T<-2.5
192430|NCT02705027|Device|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
192431|NCT02705014|Drug|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
192432|NCT02705001|Other|all admissions except accident and emergency|No additional intervention, retrospective study
192433|NCT02704988|Procedure|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
192434|NCT02704988|Procedure|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
192435|NCT02704975|Device|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
192436|NCT02704975|Device|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
192437|NCT02704962|Drug|full-dose olanzapine|trifluoperazine 5mg/d
192438|NCT02704949|Radiation|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
192439|NCT02704949|Radiation|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
192440|NCT02704923|Drug|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
192441|NCT02704923|Drug|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
192442|NCT02704910|Behavioral|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
192443|NCT02704897|Other|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
192444|NCT02704884|Dietary Supplement|probiotic soy milk|
192445|NCT02704871|Other|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
192446|NCT02704858|Drug|Perillyl alcohol|Intranasal administration
192447|NCT02704832|Other|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
192448|NCT02704819|Other|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
192449|NCT02704819|Other|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
192450|NCT02704819|Other|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
192451|NCT02704819|Other|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
192452|NCT02704819|Other|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
192453|NCT02704793|Other|Bilateral 1 Hz Cerebellar rTMS|900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
192454|NCT02704793|Other|Sham (electrical stimulation)|900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
192455|NCT02704780|Drug|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
192456|NCT02704767|Drug|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
192457|NCT02704767|Drug|Tarceva|
192458|NCT02704767|Drug|Placebo|
192459|NCT02704754|Drug|suvorexant|First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
192460|NCT02704754|Other|placebo|Pill with inactive ingredients
192461|NCT02704741|Device|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
192462|NCT02704728|Other|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
192463|NCT02704728|Other|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
192464|NCT02704715|Procedure|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
192465|NCT02704702|Drug|Fimasartan|
192466|NCT02704702|Drug|Rosuvastatin|
192467|NCT02704702|Drug|Fimasartan + Rosuvastatin|
192468|NCT02704689|Device|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
192469|NCT02704676|Other|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
192470|NCT02704663|Procedure|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
192471|NCT02704663|Procedure|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
192473|NCT02704637|Device|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
192474|NCT02704624|Dietary Supplement|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
192475|NCT02704624|Other|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
192476|NCT02704611|Device|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
192477|NCT02704611|Device|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
192478|NCT02704598|Drug|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
192479|NCT02704598|Drug|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
192480|NCT02704585|Device|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
192481|NCT02704585|Device|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
192482|NCT02704572|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection.
192483|NCT02704559|Drug|DWC20155|
192484|NCT02704559|Drug|DWC20156|
192485|NCT02704546|Drug|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
192486|NCT02704546|Drug|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
192487|NCT02704533|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
192488|NCT02704533|Biological|PfSPZ Challenge (NF54)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
192489|NCT02704533|Biological|PfSPZ Challenge (7G8)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
192490|NCT02704533|Other|Normal saline|0.9% sodium chloride
192491|NCT02704520|Drug|Capecitabine|Coated tablet. Systemic chemotherapy
192492|NCT02704520|Drug|Oxaliplatin|Concentrate for Solution for Infusion. Systemic chemotherapy
192493|NCT02704520|Drug|5-fluorouracil|Infusion. Systemic chemotherapy
192494|NCT02704520|Drug|Folinic Acid|Solution for infusion.
192495|NCT02704507|Drug|Triamcinolone|topical application nightly to half the face for 4 weeks
192496|NCT02704507|Drug|Tretinoin|topical application nightly for 8 weeks
192497|NCT02704507|Drug|Emollient|topical application nightly to half the face for 4 weeks
192498|NCT02704494|Drug|Resveratrol|Resveratrol 500mg daily
192499|NCT02704494|Drug|Placebo|Placebo 1 capsule daily
192500|NCT02704494|Drug|Losartan|Losartan 12.5mg daily
192501|NCT02704481|Drug|Mifepristone|200mg oral mifepristone
192502|NCT02704481|Drug|Misoprostol|800mcg buccal misoprostol
192503|NCT02704481|Drug|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
192504|NCT02704481|Drug|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
192505|NCT02704468|Other|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
192506|NCT02704429|Drug|PRN1008|Part A: PRN1008, oral dose, 12 weeks; Part B: PRN1008, oral dose 24 weeks
192507|NCT02704416|Procedure|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
192508|NCT02704403|Drug|Elafibranor|
192509|NCT02704403|Drug|Placebo|
192510|NCT02704390|Drug|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
192511|NCT02704377|Other|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
192512|NCT02704377|Procedure|Dual X-ray Absorptiometry|Undergo iDXA
192513|NCT02704377|Other|Laboratory Biomarker Analysis|Correlative studies
192514|NCT02704377|Other|Quality-of-Life Assessment|Ancillary studies
192515|NCT02704377|Other|Questionnaire Administration|Ancillary studies
192516|NCT02704364|Biological|NGM282|
192517|NCT02704364|Other|Placebo|
192518|NCT02704351|Procedure|Surgery|Sugammadex to reverse neuromuscular blockade
192519|NCT02704338|Biological|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
192520|NCT02704325|Biological|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
192521|NCT02704325|Other|PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
192522|NCT02704312|Radiation|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
192523|NCT02704299|Biological|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
192524|NCT02704286|Behavioral|Internet-Based Osteoarthritis Risk Calculator|The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
192525|NCT02704286|Behavioral|Generic osteoarthritis information|Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
192526|NCT02704260|Genetic|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
192527|NCT02704247|Device|CARDIOSPACE System|"autonomic nervous system test~tilt test~ultrasound exploration at rest (heart / vessels)~laser doppler + iontophoresis test~sub-maximal exercise test"
192528|NCT02704234|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
192529|NCT02704234|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
192530|NCT02704221|Behavioral|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
192531|NCT02704221|Behavioral|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
192532|NCT02704221|Behavioral|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
192533|NCT02704208|Behavioral|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
192534|NCT02704208|Behavioral|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
192535|NCT02704195|Procedure|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
192536|NCT02704195|Procedure|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
192537|NCT02704182|Device|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
192538|NCT02704182|Device|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
192539|NCT02704169|Other|Spatially registered endoscopy|
192540|NCT02704156|Device|Cyberknife|Radiation therapy
192541|NCT02704143|Other|combination of Cyberknife with S-1|Radiation therapy combined with chemotherapy
192542|NCT02704130|Device|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
192543|NCT02704130|Procedure|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
192544|NCT02704117|Device|Transcranial Magentic Stimulation|This is a form of mild brain stimulation delivered noninvasively. The device delivers pulses of magnetic energy through a coil placed on the scalp. The treatment takes 41 seconds, and takes place for ten sessions, Monday through Friday, over the course of two weeks
192545|NCT02704104|Device|AC5 Topical Hemostatic Device|Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient
192546|NCT02704091|Drug|Smecta|
192547|NCT02704091|Drug|Smecta placebo|
192548|NCT02704078|Device|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
192549|NCT02704078|Device|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
192550|NCT02704052|Drug|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
192551|NCT02704052|Drug|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
192552|NCT02704026|Other|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
192553|NCT02704013|Drug|Oxybutynin|Anticholinergic
192554|NCT02704000|Behavioral|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
192555|NCT02703987|Other|Fermented infant milk formula|
192556|NCT02703987|Other|Non-fermented infant milk formula|
192557|NCT02703974|Behavioral|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~A raised concrete platform (built to child height)~A plastic container with a lid and spigot~Soap~The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
192558|NCT02703974|Behavioral|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:~A raised concrete platform (built to child height)~A plastic container with a lid and spigot~Soap~The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
192777|NCT02702609|Device|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
192559|NCT02703974|Behavioral|Nudge|"A nudge will be built in each randomly selected school and will consist of:~Connecting latrines to the handwashing station via paved pathways that are painted bright colors~Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations~The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
192560|NCT02703974|Behavioral|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:~Importance of handwashing~Method of handwashing~Critical times of handwashing~Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.~The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
192561|NCT02703961|Drug|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
192562|NCT02703961|Drug|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
192563|NCT02703961|Radiation|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
192564|NCT02703961|Radiation|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
192565|NCT02703961|Drug|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
192566|NCT02703948|Device|Restylane Silk with Lidocaine|
192567|NCT02703935|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
192568|NCT02703935|Behavioral|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
192569|NCT02703922|Other|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
192570|NCT02703909|Drug|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
192571|NCT02703909|Device|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
192572|NCT02703896|Drug|Drug either PPIS or H2RA and prokinetics|"Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups~Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )~Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)~Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)~Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)~Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)~Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)~Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)~Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)~Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)~Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)"
192573|NCT02703896|Procedure|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
192574|NCT02703883|Device|BWST|BWST (six weeks, 3 times/week)
192575|NCT02703870|Device|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
192576|NCT02703870|Device|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
192577|NCT02703870|Behavioral|VRT|Vision restoration training, 10 sessions, 20 minutes
192578|NCT02703857|Drug|cefoxitin|Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing
192579|NCT02703844|Device|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
192580|NCT02703844|Device|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
192581|NCT02703831|Procedure|Dual attending|Two attending spine surgeons perform surgery
192582|NCT02703831|Procedure|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
192583|NCT02703818|Device|Senza|Spinal Cord Stimulation
192584|NCT02703805|Other|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
192585|NCT02703805|Other|Standard YMCA membership|A 12 week standard YMCA membership.
192586|NCT02703779|Drug|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
192587|NCT02703779|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
192588|NCT02703779|Drug|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
192589|NCT02703766|Behavioral|overfeeding induced weight gain|
192590|NCT02703753|Behavioral|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
192591|NCT02703740|Device|Hyaluronic acid dermal filler with lidocaine 0.3%|injection in labial fold of a dermal filler
192670|NCT02703220|Other|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
192592|NCT02703727|Behavioral|Extended polymedication check|"Behavioral: Medication review~Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
192593|NCT02703714|Drug|Pembrolizumab|200 mg given IV
192594|NCT02703714|Drug|Sargramostim|250 µg given SC
192595|NCT02703701|Behavioral|Physician at triage|A physician embedded at triage
192596|NCT02703701|Other|Usual Care|No physician at triage
192597|NCT02703688|Behavioral|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
192598|NCT02703688|Other|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
192599|NCT02703675|Device|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
192600|NCT02703662|Device|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
192601|NCT02703662|Device|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
192602|NCT02703649|Drug|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
192603|NCT02703636|Drug|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
192604|NCT02703623|Drug|Abiraterone Acetate|Given PO
192605|NCT02703623|Drug|Apalutamide|Given PO
192606|NCT02703623|Drug|Cabazitaxel|Given IV
192607|NCT02703623|Drug|Carboplatin|Given IV
192608|NCT02703623|Biological|Ipilimumab|Given IV
192609|NCT02703623|Other|Laboratory Biomarker Analysis|Correlative studies
192610|NCT02703623|Drug|Prednisone|Given PO
192611|NCT02703610|Drug|Oxycodone/acetaminophen|Patients will be discharged home with a 3 day supply of oxycodone/acetaminophen
192612|NCT02703610|Drug|Ibuprofen/acetaminophen|Patients will be discharged home with a 3 day supply of ibuprofen/acetaminophen
192613|NCT02703597|Behavioral|Surveys|Baseline survey includes questions related to smoking behavior and attitude toward smoking, as well as demographic questions. Psychosocial surveys and social network surveys also completed.
192614|NCT02703597|Behavioral|Focus Group|Participants engage in audio recorded group discussions that work to improve upon the online health programs.
192615|NCT02703597|Behavioral|ASPIRE|Participants engage in four 40-minute sessions of A Smoking Prevention Interactive Experience (ASPIRE) spread over a period of 4 weeks. During ASPIRE use, participants face a laptop computer and individually watch videos and engage in computer-based activities related to the negative effects of smoking.
192616|NCT02703597|Behavioral|GSA-ASPIRE|Participants engage in four 45-minute sessions of ASPIRE conducted over a period of four weeks. During each session, after every 9 minutes of ASPIRE use, participants engage in a 3-minute game-based social activities (GSA), for a total of 5 GSAs. During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSA activities contain games about the effects of smoking.
192617|NCT02703584|Drug|Buseralin|
192618|NCT02703584|Other|Placebo|
192619|NCT02703584|Drug|pregnyl|
192620|NCT02703571|Drug|ribociclib|
192621|NCT02703571|Drug|Trametinib|
192622|NCT02703558|Drug|Phenazopyridine|
192623|NCT02703558|Drug|Fluorescein|
192624|NCT02703532|Behavioral|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.~If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.~Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.~Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
192625|NCT02703532|Behavioral|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
192626|NCT02703532|Behavioral|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.~Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
192627|NCT02703519|Procedure|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
192628|NCT02703506|Other|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
192629|NCT02703506|Other|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
192630|NCT02703493|Radiation|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
192631|NCT02703480|Biological|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
192632|NCT02703480|Biological|Ti-mesh|Titanium mesh
192633|NCT02703454|Procedure|FIRM-guided RF ablation|
192634|NCT02703454|Procedure|Conventional RF ablation|
192635|NCT02703441|Other|Tablet computer|Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
192636|NCT02703415|Drug|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
192637|NCT02703415|Drug|Tramadol|caudal block with tramadol 1 mg/kg
192638|NCT02703402|Other|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
192639|NCT02703402|Other|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
192640|NCT02703389|Behavioral|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
192641|NCT02703389|Behavioral|Pamphlet|Contains same information as video.
192642|NCT02703376|Drug|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
192643|NCT02703363|Drug|Minocycline|
192644|NCT02703363|Drug|Celecoxib|
192645|NCT02703363|Drug|Placebo|
192646|NCT02703350|Drug|LY900014|Administered subcutaneously (SC)
192647|NCT02703350|Drug|Insulin Lispro|Administered SC
192648|NCT02703337|Drug|LY900014|Administered subcutaneously (SC)
192649|NCT02703337|Drug|Insulin Lispro|Administered SC
192650|NCT02703324|Drug|LY900014|Administered subcutaneously (SC)
192651|NCT02703324|Drug|Insulin Lispro|Administered SC
192652|NCT02703311|Device|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
192653|NCT02703298|Drug|TRX-818 capsules|
192654|NCT02703285|Other|Sound|task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
192655|NCT02703272|Drug|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m^2 /329 mg/m^2 per day) during part 1 and part 2.
192656|NCT02703272|Drug|Rituximab|Participants will receive a cumulative dose of rituximab 750 mg/m^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
192657|NCT02703272|Drug|Ifosfamide|Participants will receive a cumulative dose of Ifosfamide 9 g/m^2 and 10 g/m^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
192658|NCT02703272|Drug|Carboplatin|Participants will receive a cumulative dose of carboplatin 635 mg/m^2 and 800 mg/m^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
192659|NCT02703272|Drug|Etoposide|Participants will receive a cumulative dose of etoposide 300 mg/m^2 in part 1 and part 2 as a part of RICE regimen per cycle.
192660|NCT02703272|Drug|Vincristine|Participants will receive a cumulative dose of vincristine 1.6 mg/m^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
192661|NCT02703272|Drug|Idarubicin|Participants will receive a cumulative dose of idarubicin 20 mg/m^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
192662|NCT02703272|Drug|Dexamethasone|Participants will receive a cumulative dose of dexamethasone 100 mg/m^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
192663|NCT02703259|Drug|Gabapentin|
192664|NCT02703259|Drug|Acetaminophen|
192665|NCT02703259|Drug|Celecoxib|
192666|NCT02703246|Procedure|abdominal morcellation|patients will be randomized to receive abdominal morcellation
192667|NCT02703246|Procedure|vaginal morcellation|patients will be randomized to receive vaginal morcellation
192668|NCT02703233|Drug|Nitrous Oxide|
192669|NCT02703233|Other|Oxygen|
192776|NCT02702609|Device|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
194832|NCT02687178|Drug|Canrenone 50 vs canrenone 100 mg|
192671|NCT02703220|Drug|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
192672|NCT02703220|Drug|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
192673|NCT02703207|Device|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
192674|NCT02703207|Device|NIPPV and /or oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
192675|NCT02703194|Drug|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
192676|NCT02703194|Drug|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
192677|NCT02703181|Drug|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
192678|NCT02703181|Drug|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
192679|NCT02703155|Device|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
192680|NCT02703142|Procedure|Patients after esophagectomy|postoperative endoscopic evaluation
192681|NCT02703129|Other|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
192682|NCT02703116|Behavioral|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
192683|NCT02703116|Behavioral|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
192684|NCT02703103|Other|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
192685|NCT02703103|Device|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
192686|NCT02703090|Drug|Remifentanil|
192687|NCT02703090|Drug|Normal saline|
192688|NCT02703077|Procedure|Spyglass|Endoscopic direct view of the bile ducts
192689|NCT02703077|Procedure|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
192690|NCT02703077|Procedure|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
192691|NCT02703077|Procedure|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
192692|NCT02703064|Dietary Supplement|Furocyst|Furocyst caps BD
192693|NCT02703051|Drug|GMI-1271|
192694|NCT02703051|Drug|Filgrastim|
192695|NCT02703051|Drug|Placebo Injection|
192696|NCT02703051|Drug|Placebo Infusion|
192697|NCT02703025|Dietary Supplement|GCB-70|green coffee bean extract
192698|NCT02703012|Other|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
192699|NCT02702999|Device|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
192700|NCT02702999|Device|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
192701|NCT02702986|Procedure|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
192702|NCT02702986|Device|Laser|
192703|NCT02702973|Other|Observe the fundus characteristics after therapy.|
192704|NCT02702960|Procedure|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for >3 wks
192705|NCT02702960|Radiation|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
192706|NCT02702960|Procedure|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
192707|NCT02702960|Drug|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
192708|NCT02702960|Drug|Mesna|administered on Days 3 and 4 with PTCy
192709|NCT02702960|Drug|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
192710|NCT02702960|Drug|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
192711|NCT02702960|Drug|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
192712|NCT02702960|Drug|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
192713|NCT02702960|Drug|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
192714|NCT02702960|Drug|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
192715|NCT02702947|Dietary Supplement|Prunus domestica extract|Prosman 1 capsule twice a day
192716|NCT02702934|Other|Test meal|Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
192717|NCT02702921|Device|Surgeon's 'standard of care' stapler|
192718|NCT02702921|Device|Ethicon Powered Vascular Stapler|
192719|NCT02702895|Behavioral|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
192720|NCT02702882|Dietary Supplement|Fenugreek Seeds Extract|Furosap one caps OD
192721|NCT02702869|Procedure|cleft lip repair|
192722|NCT02702869|Procedure|cleft palate repair|
192723|NCT02702869|Procedure|oronasal fistula repair|
192724|NCT02702869|Procedure|pharyngoplasty|
192725|NCT02702869|Procedure|gingivoperiosteoplasty|
192726|NCT02702869|Procedure|LeFort-1 maxillary repositioning|
192727|NCT02702869|Procedure|rhinoplasty|
192728|NCT02702869|Procedure|myringotomy and tympanostomy tube placement|
192729|NCT02702869|Other|speech therapy|
192730|NCT02702869|Procedure|orthodontia|
192731|NCT02702869|Procedure|presurgical orthopedics|
192732|NCT02702856|Other|ExoIntelliScore Prostate|
192733|NCT02702843|Procedure|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
192734|NCT02702843|Procedure|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
192735|NCT02702830|Other|Cardiopulmonary Exercise Testing|Undergo CPET
192736|NCT02702830|Device|Magnetic Resonance Imaging|Undergo MRI
192737|NCT02702817|Drug|Naproxen|pale blue oval tablets
192738|NCT02702817|Drug|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
192739|NCT02702804|Other|High Intensity Interval Training|High Intensity Interval Training
192740|NCT02702791|Behavioral|Telecoaching|Pedeometer based goals and telecoaching support
192741|NCT02702791|Other|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
192742|NCT02702778|Drug|Delayed-Release (DR) Prednisone|delayed release prednisone
192743|NCT02702778|Drug|Immediate Release (IR) Prednisone|standard prednisone
192744|NCT02702765|Procedure|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
192745|NCT02702765|Procedure|Ultrasound|Ultrasound is a non-invasive procedure
192746|NCT02702765|Drug|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.~The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
192747|NCT02702765|Procedure|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
192748|NCT02702765|Procedure|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
192749|NCT02702752|Other|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
192750|NCT02702739|Drug|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
192751|NCT02702726|Other|Congee and juice with coconut gel|25g coconut oleogel
192752|NCT02702726|Other|Congee and juice with coconut oil|25g coconut oil
192753|NCT02702726|Other|Congee and juice with sunflower gel|25g sunflower oleogel
192754|NCT02702726|Other|Congee and juice with sunflower oil|25g sunflower oil
192755|NCT02702713|Dietary Supplement|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
192756|NCT02702713|Dietary Supplement|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
192757|NCT02702713|Dietary Supplement|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
192758|NCT02702713|Dietary Supplement|Bakery placebo|Bakery placebo: Biscuits without enrichment
192759|NCT02702713|Dietary Supplement|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
192760|NCT02702713|Dietary Supplement|Egg placebo|Egg placebo: Frozen pancakes without enrichment
192761|NCT02702700|Drug|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
192762|NCT02702700|Drug|Verteporfin|Visudyne® IV 3 mg/m2
192763|NCT02702700|Device|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of <10mWcm2.
192764|NCT02702687|Behavioral|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
192765|NCT02702687|Behavioral|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
192766|NCT02702674|Drug|propranolol|propranolol 20 mg given before induction of labor
192767|NCT02702674|Drug|placebo|starch tablet containing no active drug material given before induction of labor
192768|NCT02702674|Drug|Oxytocin|intravenous infusion of oxytocin
192769|NCT02702661|Procedure|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
192770|NCT02702661|Procedure|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
192771|NCT02702661|Drug|Levobupivacaine|Levobupivacaine 0.125% - 40ml
192772|NCT02702648|Drug|AC-082|Hard gelatin capsules for oral administration
192773|NCT02702648|Drug|Placebo|Matched placebo capsules for oral administration
192774|NCT02702635|Procedure|DCE MRI of the brain|An MRI of the brain including a DCE sequence
192775|NCT02702622|Other|Provitamin A-biofortified transgenic bananas|
192778|NCT02702596|Other|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
192779|NCT02702596|Behavioral|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
192780|NCT02702596|Behavioral|Standard Education|The the use of a pamphlet to educate people about depression.
192781|NCT02702570|Behavioral|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
192782|NCT02702557|Other|Elastic Band Exercises|
192783|NCT02702544|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
192784|NCT02702544|Device|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
192785|NCT02702531|Device|FloShield Defogging and Cleaning System|
192786|NCT02702518|Drug|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
192787|NCT02702518|Drug|Vehicle|Drug vehicle 4 times a day for 8 weeks
192788|NCT02702505|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
192789|NCT02702505|Other|ProRoot MTA|Control group
192790|NCT02702492|Drug|KPT-9274|
192791|NCT02702492|Drug|KPT-9274 & Niacin ER|
192792|NCT02702479|Other|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
192793|NCT02702479|Other|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
192794|NCT02702466|Other|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
192795|NCT02702453|Behavioral|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
192796|NCT02702440|Other|Liquid calories from sugars|
192797|NCT02702427|Biological|virus-specific T-Cells|infusion
192798|NCT02702414|Biological|Pembrolizumab|
192799|NCT02702401|Biological|Pembrolizumab|IV infusion
192800|NCT02702401|Drug|Placebo|0.90% w/v sodium chloride IV infusion
192801|NCT02702401|Other|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
192802|NCT02702388|Drug|Lenvatinib|Lenvatinib capsule.
192803|NCT02702388|Drug|Lenvatinib matching placebo|Lenvatinib matching placebo capsule.
192804|NCT02702375|Other|Fructose-containing Sugars|
192805|NCT02702362|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
192806|NCT02702349|Other|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
192807|NCT02702336|Behavioral|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
192808|NCT02702323|Drug|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
192809|NCT02702323|Procedure|TACE|one times every 4-6 weeks.
192810|NCT02702310|Other|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
192811|NCT02702310|Other|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
192812|NCT02702297|Other|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
192813|NCT02702284|Behavioral|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
192814|NCT02702284|Behavioral|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
192815|NCT02702271|Device|WATCHMAN FLX|Left atrial appendage closure with WATCHMAN FLX
192860|NCT02701959|Dietary Supplement|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~3 mg nitrate derived).
192902|NCT02701673|Drug|Busulfan|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
192816|NCT02702258|Behavioral|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
192817|NCT02702245|Dietary Supplement|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
192818|NCT02702245|Dietary Supplement|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
192819|NCT02702245|Other|Placebo Comparator: Control|75 g pure glucose.
192820|NCT02702232|Other|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
192821|NCT02702219|Behavioral|Mobility of the hamstrings muscles|
192822|NCT02702206|Drug|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
192823|NCT02702206|Drug|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
192824|NCT02702206|Drug|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
192825|NCT02702193|Behavioral|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
192826|NCT02702180|Drug|molgramostim|molgramostim nebuliser solution
192827|NCT02702180|Drug|placebo|placebo nebuliser solution
192828|NCT02702167|Device|High-frequency rTMS|10 Hz active stimulation, once daily
192829|NCT02702167|Device|Low-frequency rTMS|1 Hz active stimulation, once daily
192830|NCT02702167|Device|Sham rTMS|Sham stimulation, once daily
192831|NCT02702154|Device|High-frequency rTMS|20 Hz active stimulation, twice daily
192832|NCT02702154|Device|Low-frequency rTMS|1 Hz active stimulation, twice daily
192833|NCT02702154|Device|Sham rTMS|Sham stimulation, twice daily
192834|NCT02702141|Drug|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
192835|NCT02702128|Drug|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
192836|NCT02702128|Drug|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
192837|NCT02702115|Biological|SB-318|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
192838|NCT02702102|Drug|11C-PBR28|Up to 20 millicuries
192839|NCT02702089|Procedure|Rectal cancer surgery|Rectal cancer resection
192840|NCT02702076|Drug|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
192841|NCT02702076|Drug|Placebo|Continuous subcutaneous infusion of placebo during waking day
192842|NCT02702063|Other|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
192843|NCT02702063|Procedure|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
192844|NCT02702063|Other|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
192845|NCT02702050|Other|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
192846|NCT02702050|Other|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
192847|NCT02702037|Dietary Supplement|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
192848|NCT02702037|Other|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
192849|NCT02702024|Procedure|Double uterine incision technique in uterus preserving surgery for placenta percreta|
192850|NCT02702011|Drug|empagliflozin medium dose|
192851|NCT02702011|Drug|empagliflozin low dose|
192852|NCT02702011|Drug|empagliflozin high dose|
192853|NCT02702011|Drug|placebo|
192854|NCT02701998|Behavioral|mHealth-Enhance Physical Activity Intervention|
192855|NCT02701998|Other|Physical Activity Intervention|
192856|NCT02701985|Drug|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
192857|NCT02701985|Drug|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
192858|NCT02701972|Device|BACE Device|Implanted BACE device
192859|NCT02701959|Dietary Supplement|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~530 mg nitrate derived).
192901|NCT02701686|Behavioral|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
194834|NCT02687152|Other|N-hydroxy-nor-L-arginine|
192861|NCT02701946|Procedure|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
192862|NCT02701946|Procedure|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
192863|NCT02701933|Drug|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
192864|NCT02701933|Drug|Saline|Saline, intravenous infusion
192865|NCT02701920|Device|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
192866|NCT02701920|Device|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
192867|NCT02701920|Device|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
192868|NCT02701920|Device|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
192869|NCT02701920|Other|parental feedback|Questionnaire
192870|NCT02701920|Other|healthcare provider feedback|Questionnaire
192871|NCT02701907|Other|Blood sampling|
192872|NCT02701894|Dietary Supplement|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
192873|NCT02701881|Device|Long stenting using drug-eluting stent (Zilver PTX)|Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
192874|NCT02701881|Device|Spot stenting using drug-eluting stent (Zilver PTX)|Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
192875|NCT02701855|Behavioral|Cognitive tests|"Cognitive tests include:~The MMSE (Mini Mental State Examination)~Free and Cued Selective Recall Reminding Test (FCSRT).~Executive functions (fluencies, TMT A and B, span).~Tests of verbal fluency (literal and category)~Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)~The Clinical Dementia Rating Scale~The IADL scale evaluates autonomy.~Geriatric Depression screening Scale (GDS)"
192876|NCT02701855|Biological|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
192877|NCT02701855|Radiation|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
192878|NCT02701855|Other|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
192879|NCT02701842|Device|ImPACT Online/Paper Pencil Tests|
192880|NCT02701842|Device|ImPACT Online|
192881|NCT02701829|Other|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
192882|NCT02701829|Other|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
192883|NCT02701829|Other|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
192884|NCT02701816|Device|innova stent (Boston scientific)|
192885|NCT02701803|Device|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
192886|NCT02701777|Drug|Seromycin|100mg pill of Seromycin by mouth will be administered
192887|NCT02701777|Device|STDP|noninvasive magnetic or electrical stimulation will be applied to the brain
192888|NCT02701777|Other|Training|following the directions of the researcher the participant will be asked to perform specific repetitive movements using their hand, arm or leg .
192889|NCT02701777|Drug|Dextromethorphan|150mg of DExtromethorphan pill will be administered
192890|NCT02701777|Drug|Seromycin Placebo|placebo pill will be administered
192891|NCT02701777|Drug|Dextromethorphan Placebo|placebo pill will be administered
192892|NCT02701777|Device|Sham STDP|noninvasive magnetic or electrical sham stimulation will be applied to the brain
192893|NCT02701764|Drug|Pregabalin|
192894|NCT02701764|Drug|Placebo|
192895|NCT02701751|Other|Exercise session|A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
192896|NCT02701738|Dietary Supplement|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
192897|NCT02701725|Device|CRI status|Measurement of CRI
192898|NCT02701712|Radiation|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
192899|NCT02701699|Biological|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
192900|NCT02701686|Behavioral|quit immediately (QI)|advise to quit immediately using the AWARD model
192903|NCT02701673|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
192904|NCT02701673|Drug|Glutamine|Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
192905|NCT02701673|Drug|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
192906|NCT02701673|Drug|Belinostat|Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
192907|NCT02701673|Drug|Azacitidine|Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
192908|NCT02701673|Drug|Gemcitabine|Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
192909|NCT02701673|Drug|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
192910|NCT02701673|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
192911|NCT02701660|Device|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
192912|NCT02701647|Device|Repetitive transcranial magnetic stimulation (rTMS)|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric field in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim Rapid magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
192913|NCT02701647|Other|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Participants will maintain the maximum speed achieved for the rest of the session or adjusted as needed. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
192914|NCT02701634|Drug|ENTO|Tablets administered orally
192915|NCT02701634|Drug|Placebo|Tablets administered orally
192916|NCT02701621|Other|MIRT-AT|Aquatic therapy
192917|NCT02701621|Other|MIRT|Land-based Therapy
192918|NCT02701608|Drug|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients >70kg)
192919|NCT02701608|Drug|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients >70kg)
192920|NCT02701608|Procedure|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
192921|NCT02701595|Drug|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients >70kg)
192922|NCT02701595|Procedure|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
192923|NCT02701582|Drug|Phenylephrine|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) < 13 and Cardiac Index is >=2.2 Phenylephrine is administered
192924|NCT02701582|Drug|Epinephrine|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) < 13 and Cardiac Index is < 2.2 Epinephrine is administered
192925|NCT02701582|Other|Albumin|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
192926|NCT02701582|Other|Voluven|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
192927|NCT02701582|Other|Normal Saline|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
192928|NCT02701582|Other|Packed Red Blood Cells|if Mean arterial pressure (MAP) is < = 65, Stroke volume variation (SVV) > = 13, fluids are administered --OR-- if Mean arterial pressure (MAP) is > 65, Stroke volume variation (SVV) > = 13 and Cardiac Index is <2.2 fluids are administered.
192929|NCT02701582|Device|FloTrac Monitor|FloTrac monitor is connected for all patients, but only visible to the anesthesiologist for half. Based on a decision tree and the data from monitor, choices of interventions are used.
192930|NCT02701569|Other|Rebound exercise|Repeated jumping on a mini trampoline was administered
192931|NCT02701556|Device|Complete MPS|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
192932|NCT02701556|Device|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
192933|NCT02701543|Device|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
192934|NCT02701543|Device|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
192935|NCT02701530|Behavioral|Targeted smoking cessation|Smoking cessation program developed in cooperation with and aimed at smokers with low education.
192936|NCT02701517|Drug|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
192937|NCT02701517|Drug|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
192938|NCT02701491|Dietary Supplement|Ginger|ginger
192939|NCT02701491|Other|Placebo|Placebo
192975|NCT02701270|Dietary Supplement|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
194835|NCT02687139|Drug|18F-DCFPyL|
192940|NCT02701478|Drug|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
192941|NCT02701465|Other|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
192942|NCT02701465|Other|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
192943|NCT02701452|Other|COAGO|blood samples for haemostasis and hormonal data
192944|NCT02701439|Device|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~Abbreviated demographic and clinical evaluation~TB history and evaluation~Obtain three sputum samples - one early morning sample and two spot samples~HIV testing (and CD4 if positive)~Chest radiograph~Small membrane filtration intervention will be administered to both arms"
192945|NCT02701426|Behavioral|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
192946|NCT02701413|Device|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
192947|NCT02701413|Device|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
192948|NCT02701400|Biological|Durvalumab|Given IV
192949|NCT02701400|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
192950|NCT02701400|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
192951|NCT02701400|Biological|Tremelimumab|Given IV
192952|NCT02701387|Device|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
192953|NCT02701387|Device|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
192954|NCT02701374|Drug|TRK-700|
192955|NCT02701374|Drug|Placebo|
192956|NCT02701361|Behavioral|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
192957|NCT02701361|Behavioral|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
192958|NCT02701361|Behavioral|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
192959|NCT02701348|Other|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
192960|NCT02701348|Drug|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
192961|NCT02701348|Procedure|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
192962|NCT02701348|Other|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
192963|NCT02701335|Device|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
192964|NCT02701335|Device|Gloreha device|Robotic assisted passive mobilization.
192965|NCT02701335|Device|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
192966|NCT02701322|Behavioral|Medical clown|
192967|NCT02701309|Device|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
192968|NCT02701296|Drug|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
192969|NCT02701296|Drug|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
192970|NCT02701283|Device|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
192971|NCT02701283|Device|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
192972|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
192973|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
192974|NCT02701270|Dietary Supplement|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
194875|NCT02686775|Behavioral|Standard care|
192976|NCT02701257|Device|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
192977|NCT02701257|Device|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
192978|NCT02701257|Drug|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
192979|NCT02701257|Drug|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
192980|NCT02701257|Device|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
192981|NCT02701257|Device|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
192982|NCT02701244|Radiation|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
192983|NCT02701231|Device|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
192984|NCT02701231|Drug|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
192985|NCT02701231|Device|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
192986|NCT02701218|Procedure|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
192987|NCT02701205|Biological|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
192988|NCT02701205|Biological|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
192989|NCT02701205|Drug|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
192990|NCT02701192|Other|Coccygectomy|Patient receiving coccygectomy surgery.
192991|NCT02701179|Drug|Lignocaine 1% concentration solution|
192992|NCT02701179|Drug|Lignocaine 2% concentration solution|
192993|NCT02701166|Drug|Bezafibrate|bezafibrate 400mg per day
192994|NCT02701166|Drug|Placebo|placebo 400mg per day
192995|NCT02701153|Procedure|Conventional Surgery|Undergo surgery
192996|NCT02701153|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
192997|NCT02701153|Other|Laboratory Biomarker Analysis|Correlative studies
192998|NCT02701153|Other|Questionnaire Administration|Ancillary studies
192999|NCT02701140|Procedure|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
193000|NCT02701140|Procedure|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
193001|NCT02701140|Procedure|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
193002|NCT02701140|Procedure|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
193003|NCT02701140|Procedure|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
193004|NCT02701127|Drug|Oral niacinamide, 1 gram daily|
193005|NCT02701127|Drug|Oral niacinamide, 3 gram daily|
193006|NCT02701127|Drug|Placebo|
193007|NCT02701114|Procedure|Proximal Adductor Canal Block|Continuous Nerve Block
193008|NCT02701114|Procedure|Distal Adductor Canal Block|Continuous Nerve Block
193009|NCT02701101|Device|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
193010|NCT02701101|Other|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
193011|NCT02701088|Drug|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
193048|NCT02700828|Drug|Hydrocortisone|4 * 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
194936|NCT02686346|Drug|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
193012|NCT02701088|Radiation|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
193013|NCT02701075|Device|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
193014|NCT02701075|Device|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
193015|NCT02701062|Device|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
193016|NCT02701062|Drug|Anticoagulation Therapy|Anticoagulation Therapy - Standard of Care at the discretion of the Investigator.
193017|NCT02701049|Other|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
193018|NCT02701023|Drug|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
193019|NCT02701010|Behavioral|Structured training and leaflet|"The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group."
193020|NCT02701010|Behavioral|Structured training|"The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group."
193021|NCT02701010|Behavioral|Leaflet|"The patients who were given only educational leaflet were included in this group."
193022|NCT02701010|Behavioral|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
193023|NCT02700997|Device|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
193024|NCT02700984|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
193025|NCT02700984|Procedure|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
193026|NCT02700971|Procedure|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
193027|NCT02700958|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
193028|NCT02700958|Procedure|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
193029|NCT02700945|Device|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
193030|NCT02700932|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
193031|NCT02700919|Drug|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
193032|NCT02700919|Drug|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
193033|NCT02700906|Drug|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
193034|NCT02700906|Drug|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
193035|NCT02700893|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
193036|NCT02700893|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
193037|NCT02700880|Device|LifeVest|LifeVest monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
193038|NCT02700867|Device|NIO|Intraosseous access device NIO (Defibtech)
193039|NCT02700854|Other|5% carbon-dioxide inhalation|5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE > -5 mmol/L in arterial blood gas samples
193040|NCT02700841|Drug|Melphalan|Given IV
193041|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
193042|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
193043|NCT02700841|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
193044|NCT02700841|Biological|Tetanus Toxoid Vaccine|Given IM
193045|NCT02700841|Biological|Therapeutic Autologous Lymphocytes|Via infusion
193046|NCT02700841|Biological|Trivalent Influenza Vaccine|Given IM
193047|NCT02700841|Biological|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|Given SC
193049|NCT02700828|Drug|Placebo|4 * 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
193050|NCT02700815|Drug|Diclofenac|
193051|NCT02700815|Drug|Capsaicin|
193052|NCT02700815|Drug|Placebo|
193053|NCT02700802|Other|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
193054|NCT02700789|Procedure|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
193055|NCT02700776|Other|Phlebotomy - Blood sampling for GP88 at MM|Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
193056|NCT02700776|Procedure|SOC Tissue biopsy|standard of care tissue biopsy if clinically indicated.
193057|NCT02700763|Other|[18F]dabrafenib molecular imaging|A [18F]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
193058|NCT02700750|Device|OCT exam|OCT exam
193059|NCT02700737|Other|Image-based simulation modelling|"The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset)."
193060|NCT02700737|Other|Imaging parameters currently recommended by clinical practice guidelines|"The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset)."
193061|NCT02700724|Other|Immediate Surgery|
193062|NCT02700724|Other|Observation|
193063|NCT02700724|Procedure|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
193064|NCT02700711|Drug|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
193065|NCT02700711|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
193066|NCT02700711|Drug|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
193067|NCT02700685|Dietary Supplement|Pycnogenol|Dietary supplement, standardised extract of French maritime Pine bark. This group receives a nutritional supplement for a period of 10 weeks.
193068|NCT02700685|Drug|Methylphenidate|Standard pharmaceutical treatment for ADHD, slow release.
193069|NCT02700685|Other|Placebo|Placebo treatment (identical capsules containing excipients only)
193070|NCT02700672|Other|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
193071|NCT02700659|Other|Cxbladder|Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
193072|NCT02700646|Behavioral|Developmental recommendations|
193073|NCT02700646|Behavioral|Standard care|standard care
193074|NCT02700633|Device|Pacemaker|
193075|NCT02700620|Behavioral|Internet-delivered CBT|Guided internet treatment
193076|NCT02700607|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
193077|NCT02700607|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
193078|NCT02700594|Other|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
193079|NCT02700581|Procedure|low PEEP conventional ventilation|
193080|NCT02700581|Procedure|moderate PEEP conventional ventilation|
193081|NCT02700581|Procedure|low PEEP protective ventilation|
193082|NCT02700581|Procedure|moderate PEEP protective ventilation|
193083|NCT02700568|Drug|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
193084|NCT02700542|Other|Integrated Pest Management|One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
193085|NCT02700529|Drug|ubenimex|
193086|NCT02700529|Other|placebo|
193087|NCT02700503|Behavioral|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
193088|NCT02700490|Behavioral|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
193089|NCT02700477|Dietary Supplement|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
193090|NCT02700477|Other|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
193091|NCT02700464|Device|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
193092|NCT02700464|Procedure|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
193162|NCT02699853|Other|Questionnaire Administration|Ancillary studies
193093|NCT02700451|Drug|Ketorolac|Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
193094|NCT02700451|Drug|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
193095|NCT02700451|Drug|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
193096|NCT02700438|Drug|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
193097|NCT02700438|Procedure|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
193098|NCT02700425|Device|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
193099|NCT02700412|Drug|Epidiolex|The titration of CBD will start with a dose of 5 mg/kg/day given in two divided doses and titrated by 5 mg/kg/2 weeks up to 25 mg/kg/day; in some patients additional titration by 5mg/kg/day every 2 weeks up to 50mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI
193100|NCT02700399|Device|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
193101|NCT02700399|Device|Traditional tilt table from Rehab-Care|Traditional tilt table
193102|NCT02700386|Combination Product|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
193103|NCT02700373|Drug|PDC-APB|
193104|NCT02700373|Drug|Placebo|
193105|NCT02700360|Dietary Supplement|high-fat diet|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.
193106|NCT02700360|Drug|EC-18|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
193107|NCT02700347|Drug|Pyrazinamide|
193108|NCT02700347|Drug|Allopurinol|
193109|NCT02700334|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
193110|NCT02700334|Drug|Placebo|one per day before breakfast during 12 weeks.
193111|NCT02700321|Device|OPTIFLOW/ AIRVO|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
193112|NCT02700321|Procedure|STANDARD Face Mask|"Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
193113|NCT02700308|Device|Kyphoplasty|Placement and inflation of balloon prior to cement injection
193114|NCT02700308|Device|Conventional vertebroplasty|Conventional vertebroplasty
193115|NCT02700295|Device|Orthokeratology lens|
193116|NCT02700282|Behavioral|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
193117|NCT02700269|Other|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
193118|NCT02700256|Behavioral|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
193119|NCT02700243|Behavioral|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
193120|NCT02700230|Procedure|Computed Tomography|Undergo CT scan
193121|NCT02700230|Other|Laboratory Biomarker Analysis|Correlative studies
193122|NCT02700230|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
193123|NCT02700230|Other|Quality-of-Life Assessment|Ancillary studies
193124|NCT02700230|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT imaging
193125|NCT02700217|Procedure|Bupivacaine and Diamorphine|
193126|NCT02700217|Procedure|Remifentanil, Propofol and Cistracurium|
193127|NCT02700217|Procedure|Bupivacaine and Rectus Sheath injection|
193128|NCT02700204|Device|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
193163|NCT02699853|Procedure|Radical Cystectomy|Undergo RRC
193164|NCT02699853|Procedure|Radical Cystectomy|Undergo ORC
193129|NCT02700204|Device|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
193130|NCT02700191|Device|uCor|
193131|NCT02700178|Other|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
193132|NCT02700165|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments. Cryolipolysis is the technology of the non-invasive treatments.
193133|NCT02700152|Device|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
193134|NCT02700139|Device|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
193135|NCT02700113|Other|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
193136|NCT02700100|Device|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.~The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:~Tetralogy of Fallot~Truncus Arteriosus~Pulmonary Atresia~Transposition of Great Arteries with Ventricular Septal Defect (VSD)~Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes~The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
193137|NCT02700087|Drug|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
193138|NCT02700087|Drug|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
193139|NCT02700074|Other|No Intervention|Intervention is not a part of this study.
193140|NCT02700061|Procedure|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
193141|NCT02700061|Procedure|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
193142|NCT02700048|Drug|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
193143|NCT02700048|Drug|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
193144|NCT02700035|Other|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
193145|NCT02700022|Drug|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
193146|NCT02700009|Behavioral|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
193147|NCT02700009|Other|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
193148|NCT02699996|Other|Questionnaire Administration|Complete interview
193149|NCT02699996|Behavioral|Telephone-Based Intervention|Complete the self management + peer mentoring intervention with videoconferencing
193150|NCT02699983|Behavioral|Behavioral Dietary Intervention|Use SparkPeople web-based program
193151|NCT02699983|Behavioral|Exercise Intervention|Use Fitbit monitor and SparkPeople web-based program
193152|NCT02699983|Device|Activity Monitoring Device|Wear Fitbit activity monitoring device
193153|NCT02699957|Procedure|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
193154|NCT02699944|Device|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
193155|NCT02699931|Device|Electric3D|Oral-B 3D with orthodontic head
193156|NCT02699931|Device|Manual|Oral-B orthodontic
193157|NCT02699918|Procedure|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
193158|NCT02699905|Other|phlebotomy|phlebotomy
193159|NCT02699892|Drug|Rituximab|Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
193160|NCT02699879|Drug|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
193161|NCT02699866|Device|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
193165|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
193166|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
193167|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
193168|NCT02699827|Drug|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
193169|NCT02699827|Drug|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
193170|NCT02699827|Drug|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
193171|NCT02699814|Behavioral|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
193172|NCT02699801|Drug|propofol|propofol for post-sternal closure sedation
193173|NCT02699801|Drug|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
193174|NCT02699788|Device|Multifunction Cardiogram|
193175|NCT02699775|Other|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
193176|NCT02699762|Other|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
193177|NCT02699749|Drug|TAK-931|TAK-931 oral capsules.
193178|NCT02699723|Drug|Arsenic Trioxide|Given PO
193179|NCT02699723|Drug|Itraconazole|Given PO
193180|NCT02699723|Other|Laboratory Biomarker Analysis|Correlative studies
193181|NCT02699710|Drug|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
193182|NCT02699710|Drug|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
193183|NCT02699710|Drug|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
193184|NCT02699710|Drug|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
193185|NCT02699697|Radiation|External Beam Radiation Therapy|Undergo EBRT
193186|NCT02699697|Radiation|Palliative Radiation Therapy|Undergo EBRT
193187|NCT02699697|Other|Quality-of-Life Assessment|Ancillary studies
193188|NCT02699697|Other|Questionnaire Administration|Ancillary studies
193189|NCT02699684|Device|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
193190|NCT02699684|Device|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
193191|NCT02699684|Device|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
193192|NCT02699684|Device|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
193193|NCT02699684|Device|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
193194|NCT02699671|Device|Bioresorbable Vascular Scaffold|
193195|NCT02699658|Drug|Levofloxacin|
193196|NCT02699645|Drug|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 capsule taken orally once daily for 36 months
193197|NCT02699645|Drug|Placebo|1 capsule taken orally once daily for 36 months
193198|NCT02699619|Device|Pinloc|3 hook pins interlocked in plate.
193199|NCT02699619|Device|2 Hansson pins|2 isolated hook pins.(Without plate)
193200|NCT02699606|Drug|Erdafitinib|Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
193201|NCT02699593|Device|Test Contact Lens|
193202|NCT02699593|Device|Control Contact Lens|
193203|NCT02699580|Device|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
193204|NCT02699580|Procedure|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
193205|NCT02699567|Other|No intervention|
193206|NCT02699554|Procedure|Single-event multilevel surgery|
193207|NCT02699541|Behavioral|Diabetes Self-Management Education|"This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.~Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight."
193208|NCT02699528|Drug|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
193209|NCT02699515|Drug|MSB0011359C|Subjects with metastatic or locally advanced solid tumors will receive intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
193210|NCT02699502|Other|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
193248|NCT02699164|Other|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
193211|NCT02699489|Procedure|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
193212|NCT02699489|Procedure|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
193213|NCT02699476|Behavioral|Psycho-Social Therapy|
193214|NCT02699476|Device|Cognitive Behavioral Computer Training|
193215|NCT02699476|Behavioral|Interactive Trainer-Subject Sessions|
193216|NCT02699476|Device|Active Control Games|
193217|NCT02699463|Device|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
193218|NCT02699463|Other|Control Group|Standard sleep hygiene counseling as per published guidelines
193219|NCT02699450|Drug|Faricimab|Faricimab will be administered by IVT injection in the study eye.
193220|NCT02699450|Drug|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
193221|NCT02699437|Other|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
193222|NCT02699424|Radiation|External radiation therapy|
193223|NCT02699411|Device|Dry needling|dry needling Travell and Simons
193224|NCT02699411|Other|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
193225|NCT02699398|Behavioral|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
193226|NCT02699398|Behavioral|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
193227|NCT02699385|Other|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
193228|NCT02699385|Drug|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
193229|NCT02699385|Drug|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
193230|NCT02699372|Drug|Placebo|
193231|NCT02699372|Drug|RO6889450|
193232|NCT02699359|Device|HS-1000 recording|
193233|NCT02699346|Device|HS-1000 recording|
193234|NCT02699320|Other|Complications|Not involved
193235|NCT02699307|Behavioral|Counseling|OT led counseling
193236|NCT02699294|Other|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
193237|NCT02699294|Other|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
193238|NCT02699294|Other|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
193239|NCT02699281|Drug|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
193240|NCT02699281|Drug|Placebo|um-PEA like placebo twice a day
193241|NCT02699268|Other|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
193242|NCT02699242|Device|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
193243|NCT02699216|Device|Electrical Stimulation of the Retina|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
193244|NCT02699203|Behavioral|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
193245|NCT02699203|Behavioral|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
193246|NCT02699177|Device|CBF measurements|CBF measurements
193247|NCT02699164|Device|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
193249|NCT02699164|Other|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
193250|NCT02699151|Drug|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
193251|NCT02699151|Procedure|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
193252|NCT02699151|Other|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
193253|NCT02699138|Drug|Trazodone|100mg of trazodone to be administered orally once.
193254|NCT02699138|Drug|Placebo|Compounded sugar pill
193255|NCT02699138|Device|Epiglottic catheter|Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
193256|NCT02699125|Drug|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
193257|NCT02699125|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
193258|NCT02699112|Other|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
193259|NCT02699099|Dietary Supplement|Vitamin A|Oral administration of Vitamin A (1 dose)
193260|NCT02699099|Biological|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
193261|NCT02699099|Biological|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
193262|NCT02699099|Biological|Stamaril|Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
193263|NCT02699086|Drug|PDC-1421 Capsule|PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
193264|NCT02699073|Drug|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.~Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
193265|NCT02699060|Procedure|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|The procedure should be performed on an empty stomach standard technique of anesthesia;10% lidocaine solution). The examination includes analysis of esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects (erosions, ulcers, strictures, hemorrhages), as well as the appearance of the gastric and duodenal mucosa. . The modified Savary-Miller classification of esophagitis will be used to characterize changes in the esophageal mucosa. For morphological research and monocyte/macrophage phenotype assessment biopsy sampling of distal esophagus will be performed.
193266|NCT02699060|Procedure|24-h esophageal pH-impedance test with manometry-control of pH-transducer|"Procedure of pH impedancemetry includes intranasal introduction of a probe into oesophagus and connection of the probe with the recording device and 24-hour wearing of the probe.~Installation of the probe is carried out on an empty stomach. 24-h pH-impedance monitoring will be done in both distal oesophagus and in the stomach according to standard of practice. Esophageal pH sensor will be positioned 5 cm above the manometrically located border of the lower esophageal sphincter. Measurement with a second pH sensor in the stomach, 10cm below the lower esophageal sphincter in order to monitor intragastric acidity will be done as a standard routine procedure.~Standard measuring parameters will be collected: percent of time when pH is less than 4, total number of reflux episodes, number of acid and alkaline reflux episodes, duration of longest reflux episode."
193267|NCT02699047|Dietary Supplement|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
193268|NCT02699047|Dietary Supplement|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
193269|NCT02699034|Procedure|ablation for typical atrial flutter|
193270|NCT02699034|Device|Vision-MR ablation catheter|
193271|NCT02699008|Drug|Clopidogrel|Antiplatelet agent
193272|NCT02699008|Drug|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
193273|NCT02698995|Drug|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
193274|NCT02698995|Drug|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
193275|NCT02698995|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
193276|NCT02698995|Drug|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
193277|NCT02698995|Drug|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
193278|NCT02698982|Device|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
193279|NCT02698982|Procedure|moderate risk surgery|
193280|NCT02698969|Drug|Sugammadex|
193281|NCT02698969|Device|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
193282|NCT02698969|Drug|Neostigmine|
193283|NCT02698969|Drug|Atropine|
193284|NCT02698969|Device|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
193285|NCT02698969|Drug|Rocuronium|Rocuronium will be administered 0.6 mg*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
193286|NCT02698969|Drug|Fentanyl|Fentanest will be administered 2 mcg*kg-1 at the induction of general anesthesia and titrated 0.5 mcg*kg-1 every 30 minutes
193287|NCT02698969|Drug|Propofol|Propofol will be administered 2 mg*kg-1 at the induction of general anesthesia
193288|NCT02698969|Drug|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
193289|NCT02698956|Device|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
193290|NCT02698943|Procedure|Phacoemulsification|Phacoemulsification for cataract extraction with Envista MX-60 implantation
193291|NCT02698930|Drug|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
193292|NCT02698930|Drug|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
193293|NCT02698917|Other|Low normal PaCO2|4.5-4.7 kPa
193294|NCT02698917|Other|High normal PaCO2|5.8-6.0 kPa
193295|NCT02698917|Other|Low normal PaO2|10-15 kPa
193296|NCT02698917|Other|High normal PaO2|20-25 kPa
193297|NCT02698917|Other|Low normal MAP|65-75 mmHg
193298|NCT02698917|Other|High normal MAP|80-100 mmHg
193299|NCT02698904|Behavioral|Guided Relaxation Technique|
193300|NCT02698904|Other|Documentary Movie|
193301|NCT02698891|Drug|Paclitaxel|
193302|NCT02698891|Drug|Neulasta|
193303|NCT02698891|Drug|Cyclophosphamide|
193304|NCT02698891|Drug|Doxorubicin|
193305|NCT02698878|Dietary Supplement|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
193306|NCT02698878|Other|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
193307|NCT02698878|Device|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
193308|NCT02698852|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
193309|NCT02698839|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
193310|NCT02698839|Device|BuMA™|Stent platform: stainless steel
193311|NCT02698826|Other|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas [ABG] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value <100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
193312|NCT02698813|Biological|umbilical cord mesenchymal stem cells and hyaluronic acid|
193313|NCT02698813|Drug|hyaluronic acid|
193314|NCT02698800|Device|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
193315|NCT02698800|Device|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
193316|NCT02698761|Other|Comprehensive Care Plan|"Care Plan~Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.~Other Medications. All medications will be given during daytime hours, if possible.~Pain Psychology.~Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.~Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.~Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).~Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
193317|NCT02698748|Drug|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
193318|NCT02698748|Drug|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
193319|NCT02698735|Drug|Gentamicin|Gentamicin was either formulated into a 0.1% ointment or solutions for injection were purchased directly from suppliers.
193320|NCT02698735|Drug|Placebo|There are two placebos used in this study. The ointment vehicle (same as used to formulate gentamicin) and vehicle solution for injection.
193321|NCT02698722|Other|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
193322|NCT02698709|Other|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
193323|NCT02698696|Other|ECo program|
193324|NCT02698696|Other|CRT program|
193325|NCT02698696|Other|Supportive psychotherapy|
193326|NCT02698683|Other|lymphocyte count|lymphocyte count
193327|NCT02698670|Device|Rhythmia mapping system|A 3-D Cardiac Mapping system
193328|NCT02698670|Device|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
193329|NCT02698657|Drug|ASP5094|Intravenous (IV)
193330|NCT02698657|Drug|Placebo|Intravenous (IV)
193478|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
193331|NCT02698644|Drug|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
193332|NCT02698631|Procedure|Conventional AF ablation|"Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).~Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins."
193333|NCT02698631|Procedure|LGE-MRI guided AF ablation|"Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).~Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.~In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed."
193334|NCT02698618|Procedure|Diagnostic|"Pre-PCI and treatment:~At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.~At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
193335|NCT02698618|Drug|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence [Body Mass Index (BMI) ≥30 kg/m2] with the implementation of a dedicated randomization list.
193336|NCT02698618|Procedure|PCI|"Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated~PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.~Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
193337|NCT02698605|Device|Usability test study of the MirrorPath|"The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.~A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch."
193338|NCT02698592|Device|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
193339|NCT02698592|Device|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
193340|NCT02698592|Device|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
193341|NCT02698579|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
193342|NCT02698566|Drug|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
193343|NCT02698553|Drug|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
193344|NCT02698553|Drug|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
193345|NCT02698540|Other|Nutritional Supplement|High calorie, high protein peptide based
193346|NCT02698527|Drug|Non-Buffered Lidocaine|Active comparator
193347|NCT02698527|Drug|Buffered Lidocaine|Experimental, additIon of Sodium Bicarbonate to Lidocaine
193348|NCT02698514|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
193349|NCT02698514|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
193350|NCT02698501|Drug|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
193351|NCT02698501|Drug|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
193352|NCT02698488|Procedure|Morphology|
193353|NCT02698488|Procedure|Morphology and Mass Spectroscopy|
193479|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
193354|NCT02698475|Drug|Ustekinumab 0.75 mg/kg|Participants weighing less than (<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
193355|NCT02698475|Drug|Ustekinumab 45 mg|Participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
193356|NCT02698475|Drug|Ustekinumab 90 mg|Participants weighing >100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
193357|NCT02698462|Other|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
193358|NCT02698449|Procedure|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
193359|NCT02698449|Procedure|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
193360|NCT02698449|Procedure|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
193361|NCT02698449|Procedure|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
193362|NCT02698449|Radiation|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
193363|NCT02698436|Device|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
193364|NCT02698436|Drug|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
193365|NCT02698423|Device|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
193366|NCT02698423|Other|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
193367|NCT02698410|Drug|Lanreotide (Autogel formulation) and Temozolomide|
193368|NCT02698371|Device|G1-Control: Futurabond®DC-SE (FBDC_SE)|Futurabond®DC (FBDC) adhesive by self-etch (SE) mode bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
193369|NCT02698371|Device|G2-Control: Futurabond®DC_SE_EE|Futurabond®DC adhesive by self-etch mode with selective enamel etching (FBDC-SE-EE) bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
193370|NCT02698371|Device|G3: Futurabond® U - ER (FBU_ER)|FuturabondU® (FBU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
193371|NCT02698371|Device|G4: Futurabond® U - SE (FBU_SE)|FuturabondU® (FBU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
193372|NCT02698371|Device|G5: Adhese® Universal - ER (ADU_ER)|Adhese®Universal (ADU) adhesive by etch-and-rinse (ER) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
193373|NCT02698371|Device|G6: Adhese® Universal - SE (ADU_SE)|Adhese®Universal (ADU) adhesive by self-etch (SE) mode, bonding in NCCls restorations, was randomly assigned to premolar or molar teeth ensuring that this adhesive/mode is only apllied once in each participant.
193374|NCT02698358|Device|Epic stent (Boston Scientific)|
193375|NCT02698345|Device|drug-eluting balloon (In.PACT Admiral, Medtronic)|
193376|NCT02698332|Device|Algorithm for UTI|The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
193377|NCT02698319|Behavioral|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
193378|NCT02698306|Drug|Dexamethasone|Dexamethasone
193379|NCT02698306|Drug|Diclofenac Sodium|Diclofenac Sodium
193380|NCT02698293|Drug|Gliolan|orally, 40 mg/kg 4-6 hours prior to light application
193381|NCT02698293|Drug|Vitamin D3 cholecalciferol)|Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
193382|NCT02698293|Other|Photodynamic Therpay|"Approximately 4-6 hours after photosensitizer administration, activating light will be applied.~The target mucosal lesion will be identified based on the initial clinical evaluation. Treatment light will be generated using a Modulight ML7710-630-6K diode laser, This laser produces up to 6W total power, with a peak wavelength of 630nm and 90% of laser power within 630-633 nm.~The light fluence (doses) will be 50 and 100 Joules per square centimeter."
193383|NCT02698280|Drug|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
193384|NCT02698280|Drug|Nimustine|Nimustine is administered intravenously at 90mg/m^2 to 110mg/m^2 every 6 weeks.
193385|NCT02698267|Drug|BIIB074|Administered as specified in the treatment arm
193386|NCT02698267|Drug|Itraconazole|200 mg twice daily [BID] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
193387|NCT02698254|Biological|Bevacizumab|
193388|NCT02698254|Other|Quality-of-Life Assessment|Ancillary studies
193389|NCT02698254|Radiation|Radiation Therapy|Undergo radiation therapy with conventional fractionation
194522|NCT02689388|Procedure|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
193390|NCT02698241|Device|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
193391|NCT02698228|Drug|Bupivacaine (femoral nerve block)|0.5% bupivacaine
193392|NCT02698228|Drug|Morphine|Intravenous injection of 0.1mg/kg of morphine
193393|NCT02698228|Device|Ultrasound|
193394|NCT02698215|Drug|Varenicline|Varenicline 1 mg twice daily
193395|NCT02698215|Drug|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
193396|NCT02698202|Device|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
193397|NCT02698189|Drug|MK-8628 Dose 20 mg|Administered as an oral capsule twice a day for 21 consecutive days per cycle.
193398|NCT02698176|Drug|MK-8628|Administered as an oral capsule in a fasted state
193399|NCT02698163|Device|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
193400|NCT02698163|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
193401|NCT02698150|Device|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
193402|NCT02698124|Drug|Decitabine|
193403|NCT02698111|Drug|Donafenib|donafenib 200mg，bid
193404|NCT02698098|Drug|Methadone|
193405|NCT02698085|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
193406|NCT02698085|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
193407|NCT02698072|Other|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
193408|NCT02698072|Device|Dry needling|Dry needling needle AGUPUNT®
193409|NCT02698072|Device|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
193410|NCT02698059|Device|iNAP® Sleep Therapy System (iNAP)|The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
193411|NCT02698046|Dietary Supplement|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
193412|NCT02698046|Dietary Supplement|Placebo starch|200mg of placebo starch three times a day for 4 months
193413|NCT02698033|Drug|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
193414|NCT02698033|Other|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
193415|NCT02698020|Procedure|Room-air|Provision of room-air
193416|NCT02698007|Device|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
193417|NCT02697994|Other|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
193418|NCT02697994|Other|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
193419|NCT02697981|Behavioral|nutrition counseling|nutrition counseling and guidance.
193420|NCT02697968|Device|Electroacupuncture|
193421|NCT02697955|Drug|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
193422|NCT02697955|Other|Placebo|9 mg sodium chloride pr. ml (0,9 %)
193423|NCT02697942|Other|cognitive training|The investigators will provide participants with tablets to play brain games through Lumosity.
193424|NCT02697942|Other|exercise training|The investigators will provide participants with foot peddlers.
193425|NCT02697929|Drug|sugammadex|
193426|NCT02697929|Drug|Neostigmine|
193427|NCT02697916|Drug|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
193428|NCT02697903|Dietary Supplement|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
193429|NCT02697903|Dietary Supplement|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
193430|NCT02697890|Device|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
193431|NCT02697890|Device|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
193432|NCT02697877|Drug|Regadenoson|
193433|NCT02697864|Drug|tafamidis|
193434|NCT02697851|Drug|Microgynon 30®|
193435|NCT02697851|Drug|Evotaz®|
193436|NCT02697838|Drug|Apatinib|Apatinib (850 mg qd p.o.) until disease progression or intolerable toxicity or refused by the patients.
193480|NCT02697461|Other|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
194644|NCT02688530|Drug|IV Dexamethasone 8mg|
193437|NCT02697838|Drug|Paclitaxel-based chemotherapeutic regimens|"Paclitaxel-based chemotherapeutic regimens including:~The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~The PF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.~Paclitaxel 80mg/m2 d1，d8，d15，repeating the cycle every 28 days~other paclitaxel-based regimens"
193438|NCT02697825|Procedure|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
193439|NCT02697812|Procedure|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
193440|NCT02697799|Behavioral|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
193441|NCT02697799|Behavioral|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
193442|NCT02697786|Device|Transcranial doppler|Prolonged de airing to decrease the number of MES
193443|NCT02697773|Other|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
193444|NCT02697773|Biological|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
193445|NCT02697773|Biological|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
193446|NCT02697760|Radiation|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
193447|NCT02697747|Other|Education|Educational intervention in the use of ultrasound to identify landmarks
193448|NCT02697734|Drug|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg. Each strength has a unique size and color. The osilodrostat 1 mg, 5 mg, 10 mg and 20 mg film coated tablets are approximately 6 mm, 7 mm, 9 mm, and 11 mm respectively in diameter and pale yellow, yellow, pale orange brown and light brown respectively in color.
193449|NCT02697734|Drug|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg. Each strength has a unique size and color.
193450|NCT02697721|Behavioral|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
193451|NCT02697721|Other|Control with delayed intervention|Control with delayed intervention
193452|NCT02697708|Dietary Supplement|Potassium control diet|No additional potassium.
193453|NCT02697708|Dietary Supplement|Potassium gluconate diet|1000 mg K from potassium gluconate.
193454|NCT02697708|Dietary Supplement|Potato Diet|1000 mg K from potatoes.
193455|NCT02697708|Dietary Supplement|French Fries Diet|1000 mg K from French Fries.
193456|NCT02697695|Other|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
193457|NCT02697682|Biological|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
193458|NCT02697669|Other|18F-FDG PET|Imaging
193459|NCT02697656|Behavioral|IPS|Individualized job support provided by an employment specialist
193460|NCT02697656|Behavioral|Self-help|Self-help resources on obtaining employment and coping with chronic pain
193461|NCT02697656|Behavioral|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
193462|NCT02697643|Behavioral|BHCDS-based recommendations|
193463|NCT02697643|Behavioral|Non-tailored recommendations|
193464|NCT02697630|Drug|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
193465|NCT02697630|Drug|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
193466|NCT02697617|Drug|Pioglitazone|Pioglitazone
193467|NCT02697617|Drug|Placebo|Placebo
193468|NCT02697591|Drug|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
193469|NCT02697565|Behavioral|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
193470|NCT02697565|Behavioral|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
193471|NCT02697552|Drug|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly [BIW].
193472|NCT02697539|Other|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
193473|NCT02697539|Other|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
193474|NCT02697526|Other|Terumo|
193475|NCT02697526|Other|Tensoplast|
193476|NCT02697513|Behavioral|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
193477|NCT02697487|Other|No treatment|This is an observational study with no intervention.
193481|NCT02697461|Other|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
193482|NCT02697448|Drug|propofol|Participant receives propofol as anesthetic for cardiac ablation.
193483|NCT02697448|Drug|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
193484|NCT02697435|Other|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
193485|NCT02697435|Other|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
193486|NCT02697422|Other|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
193487|NCT02697409|Behavioral|Education Against Tobacco intervention|
193488|NCT02697396|Behavioral|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
193489|NCT02697396|Other|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
193490|NCT02697396|Other|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
193491|NCT02697383|Drug|Ixazomib (MLN9708)|
193492|NCT02697383|Drug|Dexamethasone|
193493|NCT02697370|Drug|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
193494|NCT02697357|Behavioral|Psychosocial Instruments|
193495|NCT02697357|Behavioral|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
193496|NCT02697344|Drug|Dexamethasone|Given PO
193497|NCT02697344|Other|Laboratory Biomarker Analysis|Correlative studies
193498|NCT02697344|Drug|Lenalidomide|Given PO
193499|NCT02697344|Other|Pharmacological Study|Correlative studies
193500|NCT02697344|Drug|R-(-)-Gossypol Acetic Acid|Given PO
193501|NCT02697331|Drug|Progesterone|"women will receive progesterone capsules containing 100mg of progesterone per tablet . it will be used by the patient as one tablet per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 weeks and stopped at the end of 34 weeks"
193502|NCT02697331|Other|Placebo|"omen will receive placebo tablets twice a day . it will be used by the patient as one tablet per vagina twice per day .~women will be showed how to use tablets . medication will be started at 20 weeks and stopped at the end of 34 weeks"
193503|NCT02697318|Drug|Timolol maleate 0.5% ophthalmic solution|
193504|NCT02697305|Dietary Supplement|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
193505|NCT02697305|Dietary Supplement|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
193506|NCT02697305|Other|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
193507|NCT02697292|Drug|Intravenous Immunoglobulin|GAMUNEX-C is the brand name for Intravenous Immunoglobulin, and is clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration.
193508|NCT02697292|Drug|Placebo/Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents.
193509|NCT02697279|Procedure|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I&D technique with or without packing utilizing a standard I&D kit.
193510|NCT02697279|Procedure|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I&D kit and the cuff of a sterile glove for a loop device.
193511|NCT02697266|Other|No intervention|This is an observational study.
193512|NCT02697253|Drug|Exendin 9-39 and Sitagliptin|"Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 90 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg tablet at 0700 hours."
193513|NCT02697253|Drug|Placebo|"Infusion of 0.9% saline solution (placebo infusion) for 60 minutes. An average of 18.2mg will be infused in a forearm vein during an oral glucose (30g) preload.~100mg Placebo tablet will be administered at 2200 hours the night before the visit. The day of the visit, the patient will take another 100mg placebo tablet at 0700 hours."
193514|NCT02697240|Drug|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
193515|NCT02697227|Behavioral|Behavioral Intervention|Receive BATS counseling
193516|NCT02697227|Other|Laboratory Biomarker Analysis|Correlative studies
193517|NCT02697227|Drug|Nicotine Patch|Receive nicotine patch
193518|NCT02697227|Other|Questionnaire Administration|Ancillary studies
193519|NCT02697227|Behavioral|Smoking Cessation Intervention|Receive standard smoking cessation counseling
194937|NCT02686346|Drug|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
193520|NCT02697214|Device|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
193521|NCT02697214|Device|Apple Watch|Apple Watch heart rate monitoring device compared to ECG and Polar H7
193522|NCT02697214|Device|Mio Fuse|Mio Fuse heart rate monitoring device compared to ECG and Polar H7
193523|NCT02697214|Device|Basis Peak|Basis Peak heart rate monitoring device compared to ECG and Polar H7
193524|NCT02697201|Drug|Intralipid|0.55 ml/kg/h
193525|NCT02697201|Drug|Saline|0.55 ml/kg/h for
193526|NCT02697188|Drug|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
193527|NCT02697188|Drug|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
193528|NCT02697175|Device|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
193529|NCT02697175|Other|No Live Video-Colposcopy|The TV will be shut off during colposcopy
193530|NCT02697162|Device|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
193531|NCT02697162|Device|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
193532|NCT02697162|Drug|Octenidine chloride|Antiseptic
193533|NCT02697149|Radiation|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
193534|NCT02697149|Radiation|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
193535|NCT02697136|Drug|CER-001|Recombinant human apoA-I/phospholipid complexes
193536|NCT02697136|Drug|Placebo|0.9% Sodium Chloride Injection, USP
193537|NCT02697123|Other|antepartum and postpartum|This is a prospective observational cohort study.
193538|NCT02697110|Behavioral|Edutainment based intervention|Edutainment intervention package
193539|NCT02697084|Other|anal cancer|Anal cancer patients with TEP TDM
193540|NCT02697071|Drug|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
193541|NCT02697071|Drug|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
193542|NCT02697058|Biological|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
193543|NCT02697058|Drug|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
193544|NCT02697045|Drug|Aripiprazole 400mg LAI|Aripiprazole 400mg, IM, Once a month
193545|NCT02697032|Drug|Bicalutamide|150mg
193546|NCT02697032|Procedure|FDHT PET|PET scan
193547|NCT02697019|Behavioral|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
193548|NCT02697006|Drug|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
193549|NCT02696993|Procedure|Cognitive Assessment|Ancillary studies
193550|NCT02696993|Biological|Ipilimumab|Given IV
193551|NCT02696993|Other|Laboratory Biomarker Analysis|Correlative studies
193552|NCT02696993|Biological|Nivolumab|Given IV
193553|NCT02696993|Radiation|Stereotactic Radiosurgery|Undergo SRS
193554|NCT02696993|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
193555|NCT02696980|Device|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
193556|NCT02696967|Drug|CLR325|CLR325 Concentrate for solution for infusion
193557|NCT02696967|Other|Placebo|Normal saline
193558|NCT02696954|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
193559|NCT02696954|Drug|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
193560|NCT02696954|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks
193561|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks
193562|NCT02696954|Drug|Primaquine|Primaquine on Day 0 Washout period: more than 1 week
193563|NCT02696954|Drug|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
193564|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine + Primaquine|Artemether-lumefantrine Day 0, 1 and 2 + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: more than 6 weeks
193565|NCT02696954|Drug|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0
193566|NCT02696941|Drug|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
193567|NCT02696941|Drug|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
193568|NCT02696928|Drug|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
193569|NCT02696928|Drug|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
193570|NCT02696928|Drug|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
193571|NCT02696915|Drug|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
193572|NCT02696915|Drug|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
193573|NCT02696915|Device|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
194645|NCT02688517|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
193574|NCT02696915|Drug|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
193575|NCT02696902|Drug|MEDI3902|Active
193576|NCT02696902|Other|Placebo|Placebo
193577|NCT02696889|Procedure|ROSE-1 Protocol|A bone marrow aspiration will be performed under anesthesia in preparation for a diagnostic laparoscopy for full evaluation of the pelvic anatomy. Following laparoscopy, injection of BMSCs into the right ovary will occur.
193578|NCT02696876|Device|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
193579|NCT02696876|Procedure|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
193580|NCT02696863|Behavioral|questionnaire|
193581|NCT02696850|Drug|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
193582|NCT02696850|Drug|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
193583|NCT02696837|Device|ETT|
193584|NCT02696837|Device|Proseal LMA|
193585|NCT02696837|Drug|Rocuronium|
193586|NCT02696837|Other|No Muscle Relaxant|
193587|NCT02696837|Drug|Rocuronium|
193588|NCT02696824|Behavioral|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
193589|NCT02696811|Dietary Supplement|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
193590|NCT02696811|Dietary Supplement|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
193591|NCT02696798|Drug|Ixekizumab|Administered SC
193592|NCT02696798|Drug|Placebo|Administered SC
193593|NCT02696785|Drug|Ixekizumab|Administered SC
193594|NCT02696785|Drug|Placebo|Administered SC
193595|NCT02696785|Drug|Adalimumab|Administered SC
193596|NCT02696772|Other|Energy intake|
193597|NCT02696759|Other|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
193598|NCT02696746|Other|Observation|No intervention
193599|NCT02696733|Device|Ultrasound|Ultrasound-guided obturator nerve localization
193600|NCT02696733|Drug|lidocaine 2%|local anesthetic used to block the obturator nerve
193601|NCT02696733|Drug|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
193602|NCT02696720|Drug|Lidocaine|
193603|NCT02696720|Other|Sham|
193604|NCT02696707|Procedure|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
193605|NCT02696707|Procedure|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
193606|NCT02696694|Other|Progesterone 25-75|Impact of serum progesterone concentrations [25-75] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
193607|NCT02696694|Other|Progesterone <25, >75|Impact of serum progesterone concentrations (<25, >75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
193608|NCT02696681|Behavioral|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
193609|NCT02696668|Other|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
193610|NCT02696668|Other|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:~Limits of stability training with eyes open / eyes closed~Self induced movement strategies with eyes open / eyes closed~Gaze stability exercises in sitting / standing / walking~Sensory integration~Habituation exercises"
193611|NCT02696655|Behavioral|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
193612|NCT02696642|Drug|Anetumab ravtansine (BAY94-9343)|All subjects will receive anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
193613|NCT02696629|Procedure|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
193614|NCT02696629|Device|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
193615|NCT02696629|Behavioral|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
193616|NCT02696616|Drug|BI 655088|
193617|NCT02696616|Drug|Placebo|
193690|NCT02696174|Other|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
194646|NCT02688517|Other|Laboratory Biomarker Analysis|Correlative studies
193618|NCT02696603|Behavioral|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
193619|NCT02696603|Behavioral|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
193620|NCT02696603|Behavioral|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
193621|NCT02696603|Behavioral|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test [Corsi, P.M. (1972)] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
193622|NCT02696603|Behavioral|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
193623|NCT02696603|Behavioral|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
193624|NCT02696603|Other|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
193625|NCT02696590|Dietary Supplement|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
193626|NCT02696577|Drug|Low dose aspirin|
193627|NCT02696577|Drug|Omega 3|
193628|NCT02696564|Drug|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
193629|NCT02696564|Drug|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
193630|NCT02696551|Other|Medical education|
193631|NCT02696538|Other|Functional Gait Assessment|Balance assessment
193632|NCT02696538|Other|mini-Balance Evaluation Systems Test|Balance assessment
193633|NCT02696538|Other|Berg Balance Scale|Balance assessment
193634|NCT02696512|Drug|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
193635|NCT02696512|Device|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
193636|NCT02696512|Dietary Supplement|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
193637|NCT02696512|Other|Standard of Care|Standard of Care treatment
193638|NCT02696499|Drug|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
193639|NCT02696499|Drug|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
193640|NCT02696486|Behavioral|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
193641|NCT02696473|Dietary Supplement|Carrot|
193642|NCT02696460|Procedure|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
193643|NCT02696460|Procedure|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
193644|NCT02696447|Biological|Biomarkers assays|D-Dimer assays, C-reactive protein, blood platelets assays
193645|NCT02696434|Drug|Naltrexone|daily dosing
193646|NCT02696434|Drug|Placebo|daily dosing
193647|NCT02696434|Drug|Buprenorphine|daily dosing
193648|NCT02696408|Device|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.~If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
193649|NCT02696408|Device|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.~If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
193650|NCT02696395|Device|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
193651|NCT02696395|Device|DePuy Corail® femoral stem + Deltamotion® acetabular component|
193652|NCT02696382|Behavioral|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
193653|NCT02696382|Behavioral|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
193654|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:200,000|
193655|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:80,000|
193656|NCT02696356|Biological|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
193657|NCT02696343|Device|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
193658|NCT02696343|Device|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
193659|NCT02696330|Drug|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
193660|NCT02696330|Drug|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
193661|NCT02696330|Drug|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
193662|NCT02696317|Device|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
193663|NCT02696317|Device|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
193664|NCT02696304|Other|Adipose tissu repartition|absorptiometry,
193665|NCT02696304|Other|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
193666|NCT02696304|Other|Preadipocyte quantification and adipose tissue inflamation|biopsy
193667|NCT02696304|Other|Inflamation blood markers quantification|blood drawn,
193668|NCT02696291|Drug|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
193669|NCT02696291|Drug|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
193670|NCT02696291|Drug|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
193671|NCT02696291|Drug|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
193672|NCT02696291|Drug|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
193673|NCT02696291|Drug|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
193674|NCT02696278|Other|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
193675|NCT02696278|Other|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
193676|NCT02696278|Other|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
193677|NCT02696265|Procedure|CFAE guided ablation|CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.
193678|NCT02696265|Procedure|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
193679|NCT02696239|Device|V-lock suture|
193680|NCT02696239|Device|Vicryl Suture|
193681|NCT02696239|Device|Lapra-Ty II|
193682|NCT02696226|Drug|SAVR Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
193683|NCT02696226|Drug|SAVR Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
193684|NCT02696226|Drug|TAVR Warfarin and clopidogrel|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
193685|NCT02696226|Drug|TAVR Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
193686|NCT02696213|Other|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
193687|NCT02696213|Other|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
193688|NCT02696200|Device|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
193689|NCT02696187|Behavioral|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
193691|NCT02696161|Other|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
193692|NCT02696161|Other|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
193693|NCT02696148|Drug|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
193694|NCT02696148|Drug|placebo|For subcutaneous (s.c., under the skin) injection once daily.
193695|NCT02696122|Procedure|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
193696|NCT02696122|Procedure|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
193697|NCT02696109|Behavioral|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
193698|NCT02696109|Behavioral|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
193699|NCT02696096|Other|FMRI|all participants will complete 2 FMRIs
193700|NCT02696096|Drug|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
193701|NCT02696083|Device|Provant Therapy System|
193702|NCT02696070|Device|Provant Therapy System|
193703|NCT02696057|Other|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
193704|NCT02696057|Other|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
193705|NCT02696044|Drug|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
193706|NCT02696031|Drug|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
193707|NCT02696031|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
193708|NCT02696031|Drug|Secukinumab|150 mg Secukinumab s.c. monthly
193709|NCT02696031|Drug|Secukinumab|Dose escalation to 300mg at Year 2
193710|NCT02696018|Device|Ultrasonography|Ultrasonographic assessment of the diaphragm function
193711|NCT02696005|Other|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
193712|NCT02695992|Drug|Metoprolol|Dosage 100 mg o.d.
193713|NCT02695992|Drug|Diltiazem|Dosage 360 mg o.d.
193714|NCT02695966|Procedure|Whipples Surgery|Whipples Surgery
193715|NCT02695940|Drug|LEO 124249 ointment 30 mg/g|
193716|NCT02695940|Other|LEO 124249 ointment vehicle|
193717|NCT02695927|Device|Computer rehabilitation glasses|
193718|NCT02695914|Drug|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
193719|NCT02695901|Drug|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
193720|NCT02695901|Drug|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
193721|NCT02695888|Behavioral|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
193722|NCT02695888|Behavioral|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
193723|NCT02695875|Procedure|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
193724|NCT02695875|Procedure|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.~The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
193725|NCT02695862|Drug|Terlipressin|
193761|NCT02695628|Diagnostic Test|Computed Tomography|Undergo [18F] FMISO PET/CT
193762|NCT02695628|Diagnostic Test|Positron Emission Tomography|Undergo [18F] FMISO PET/CT
193763|NCT02695602|Procedure|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
193764|NCT02695602|Procedure|Submucous Resection with non powered instrument|
193765|NCT02695576|Procedure|Lumbar Fusion Surgery|Interbody fusion with fixation
194021|NCT02693496|Other|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
193726|NCT02695836|Other|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
193727|NCT02695836|Other|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
193728|NCT02695836|Other|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
193729|NCT02695836|Other|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
193730|NCT02695836|Other|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
193731|NCT02695823|Device|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.~Search of any neurological complication during the 5 postoperative days."
193732|NCT02695810|Drug|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
193733|NCT02695810|Drug|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
193734|NCT02695810|Behavioral|Exercise|Interval training, 5 times per week, 30 min per session
193735|NCT02695797|Other|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
193736|NCT02695797|Drug|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
193737|NCT02695784|Dietary Supplement|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
193738|NCT02695771|Drug|Mitomycin C|Cancer chemotherapeutic agent
193739|NCT02695771|Drug|Gemcitabine|Cancer chemotherapeutic agent
193740|NCT02695758|Procedure|Interscalene brachial plexus block|
193741|NCT02695758|Procedure|bupivacaine extended-release liposome injection|
193742|NCT02695745|Drug|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
193743|NCT02695745|Drug|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
193744|NCT02695745|Drug|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
193745|NCT02695745|Drug|Capsaicin|1% administered topically
193746|NCT02695732|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
193747|NCT02695732|Device|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
193748|NCT02695719|Drug|Placebo|Lubiprostone placebo-matching capsules
193749|NCT02695719|Drug|Lubiprostone|Lubiprostone capsules
193750|NCT02695706|Device|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
193751|NCT02695693|Behavioral|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
193752|NCT02695693|Behavioral|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
193753|NCT02695693|Behavioral|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
193754|NCT02695693|Behavioral|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
193755|NCT02695654|Drug|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
193756|NCT02695654|Drug|Clonidine|Clonidine 100 mcg
193757|NCT02695641|Drug|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
193758|NCT02695641|Drug|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
193759|NCT02695628|Drug|18F-Fluoromisonidazole|Undergo [18F] FMISO PET/CT
193760|NCT02695628|Procedure|Arterial Embolization|Undergo transcatheter arterial embolization
193766|NCT02695576|Other|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
193767|NCT02695576|Other|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
193768|NCT02695563|Drug|Lactoferrin|
193769|NCT02695550|Drug|CT-707|
193770|NCT02695537|Drug|Epidiolex|In some patients additional titration by 5 mg/kg/day every 2 weeks up to 50 mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI
193771|NCT02695524|Other|Scapula-focused exercises|
193772|NCT02695524|Other|Motor control exercises|
193773|NCT02695511|Other|Caloric restriction|25% caloric restriction below baseline energy requirement
193774|NCT02695498|Other|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class [9 total classes.] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
193775|NCT02695498|Other|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
193776|NCT02695485|Procedure|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
193777|NCT02695472|Drug|80 Milligrams NSI-189|Orally Administered
193778|NCT02695472|Drug|Placebo|Orally administered
193779|NCT02695472|Drug|40 Milligrams NSI-189|Orally Administered
193780|NCT02695459|Drug|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
193781|NCT02695446|Drug|Minocycline|Oral extended release minocycline
193782|NCT02695433|Dietary Supplement|Active|Active Treatment Diet Plan
193783|NCT02695433|Dietary Supplement|Control|Control Diet Plan
193784|NCT02695420|Drug|25 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID
193785|NCT02695420|Drug|Placebo|Drug: n/a Subjects will receive Placebo BID
193786|NCT02695420|Drug|37.5 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID up to week 4 or week 8 and 25 mg or 37.5 mg BID after week 4 or week 8, based on week 2 PK
193787|NCT02695420|Drug|50 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID up to week 4 or week 8 and 25 mg or 50 mg BID after week 4 or week 8, based on week 2 PK
193788|NCT02695407|Other|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
193789|NCT02695407|Other|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
193790|NCT02695381|Drug|Etodolac-lidocaine topical patch|Once daily
193791|NCT02695381|Drug|Placebo|Once daily
193792|NCT02695368|Device|Novaerus NV800 on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through. The air-cleaner has to have been turned on for at least 2 days prior to the surgical intervention.
193793|NCT02695368|Device|Novaerus NV800 off|The machine decribed above is running but the plasma filter chamber isn't active, i.e. the placebo group.
193794|NCT02695368|Device|Novaerus NV800 on or off|Patients with multiple surgeries that have been operated during both periods when the apparatus has been on and off will belong to this mixed group.
193795|NCT02695355|Drug|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
193796|NCT02695342|Behavioral|Home balance exercise program|
193797|NCT02695329|Device|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
193798|NCT02695316|Other|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
193799|NCT02695316|Other|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
193800|NCT02695316|Other|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
193801|NCT02695316|Other|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
193802|NCT02695303|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
193803|NCT02695290|Drug|Afatinib|
193804|NCT02695277|Device|AtriCure Bipolar System|
193805|NCT02695277|Device|Standard Endocardial Ablation with Catheter|
193806|NCT02695277|Device|AtriClip® PRO LAA Exclusion System|
193807|NCT02695277|Device|Endocardial Ablation with Catheter|
193808|NCT02695277|Device|Repeated Endocardial ablation(s)|
193809|NCT02695264|Device|HS-1000 recording|
193810|NCT02695251|Other|low AGE meal|Patients will receive a low AGE (eggs) meal
193811|NCT02695251|Other|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
193812|NCT02695238|Procedure|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
193882|NCT02694601|Dietary Supplement|Control|4-hour visit with no caffeine is given during a standardize breakfast follow by repeated blood sampling.
193813|NCT02695225|Behavioral|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
193814|NCT02695225|Behavioral|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
193815|NCT02695212|Drug|Apremilast|"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
193816|NCT02695199|Procedure|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
193817|NCT02695199|Procedure|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
193818|NCT02695186|Procedure|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
193819|NCT02695160|Biological|SB-FIX|Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
193820|NCT02695147|Procedure|TAVI|
193821|NCT02695134|Other|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
193822|NCT02695108|Other|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
193823|NCT02695108|Other|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
193824|NCT02695069|Procedure|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
193825|NCT02695043|Behavioral|RRTBIMS|TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
193826|NCT02695043|Behavioral|Multimedia Multicultural Educational Program for TBI (MMEPT)|
193827|NCT02695030|Device|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
193828|NCT02695017|Device|Iso inertial|
193829|NCT02695017|Device|Conventional machine|
193830|NCT02695004|Drug|DKF-310|
193831|NCT02695004|Drug|Placebo|
193832|NCT02694991|Other|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
193833|NCT02694978|Drug|Ferumoxytol|
193834|NCT02694978|Drug|FCM|
193835|NCT02694965|Other|observational|
193836|NCT02694952|Biological|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
193837|NCT02694952|Biological|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
193838|NCT02694939|Behavioral|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
193839|NCT02694939|Behavioral|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
193840|NCT02694926|Other|Education|During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
193841|NCT02694913|Other|Non Interventional|This is a non therapeutic, pilot study.
193842|NCT02694900|Other|Manually chest compressions|Chest compressions performed manually without any device
193843|NCT02694900|Device|Cardiopump|Chest compressions performed with Cardiopump
193844|NCT02694900|Device|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
193845|NCT02694874|Drug|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
193846|NCT02694874|Drug|Placebo|This is the placebo control
193847|NCT02694848|Drug|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
194019|NCT02693522|Drug|Eutropin|Subcutaneous injection
193848|NCT02694848|Drug|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
193849|NCT02694835|Device|Delefilcon A contact lenses with UV Absorber|
193850|NCT02694835|Device|Delefilcon A contact lenses|
193851|NCT02694822|Drug|AGEN1884|anti-CTLA-4 antibody
193852|NCT02694809|Drug|Conjugated Estrogens/Bazedoxifene|Given PO
193853|NCT02694809|Other|Laboratory Biomarker Analysis|Correlative studies
193854|NCT02694809|Other|Pharmacological Study|Correlative studies
193855|NCT02694809|Other|Placebo|Given PO
193856|NCT02694809|Procedure|Quality-of-Life Assessment|Ancillary studies
193857|NCT02694809|Other|Questionnaire Administration|Ancillary studies
193858|NCT02694796|Behavioral|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
193859|NCT02694783|Biological|PyVST|Ex vivo generated polyomavirus-specific T cells from HLA-matched donor.
193860|NCT02694783|Other|No Intervention|No Intervention
193861|NCT02694770|Biological|Neihulizumab Treatment|Monoclonal antibody
193862|NCT02694770|Biological|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
193863|NCT02694757|Device|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
193864|NCT02694744|Drug|patiromer|8.4 g/day starting dose, administered orally
193865|NCT02694731|Behavioral|Mobile application intervention (Device: Smartphone)|Consists of the app described in the arm description.
193866|NCT02694718|Drug|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m^2 bid orally on Days 1-14, and at a dose of 825mg/m^2 bid on Days 22-35 and 43-56.
193867|NCT02694718|Drug|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m^2/d intravenously on Day 1 and 50mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
193868|NCT02694705|Device|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
193869|NCT02694705|Device|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
193870|NCT02694705|Device|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
193871|NCT02694692|Procedure|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
193872|NCT02694692|Behavioral|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
193873|NCT02694679|Behavioral|CBNH|The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
193874|NCT02694666|Other|Controlled whole-body vibration training|The intervention is an 8-week program
193875|NCT02694653|Drug|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
193876|NCT02694653|Drug|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
193877|NCT02694640|Behavioral|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
193878|NCT02694640|Behavioral|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
193879|NCT02694640|Behavioral|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
193880|NCT02694627|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
193881|NCT02694614|Behavioral|smartphone-assisted dietary coaching|
193883|NCT02694601|Dietary Supplement|Caffeine low dose|4-hour visit with a dose of 2.5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
193884|NCT02694601|Dietary Supplement|Caffeine high dose|4-hour visit with a dose of 5 mg/kg of caffeine is given during a standardize breakfast follow by repeated blood sampling.
193885|NCT02694588|Drug|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
193886|NCT02694588|Drug|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
193887|NCT02694562|Device|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
193888|NCT02694549|Device|CaveoVasc|
193889|NCT02694536|Drug|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
193890|NCT02694536|Drug|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
193891|NCT02694523|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
193892|NCT02694523|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
193893|NCT02694523|Drug|placebo for risankizumab|Placebo risankizumab administered by subcutaneous (SC) injection
193894|NCT02694523|Biological|placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection
193895|NCT02694510|Other|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
193896|NCT02694497|Other|Chlamydia care as usual|
193897|NCT02694484|Other|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
193898|NCT02694471|Behavioral|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
193899|NCT02694458|Other|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
193900|NCT02694458|Other|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
193901|NCT02694445|Other|observation|The study is non-interventional.
193902|NCT02694432|Behavioral|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
193903|NCT02694432|Behavioral|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
193904|NCT02694419|Device|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
193905|NCT02694406|Device|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
193906|NCT02694393|Drug|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
193907|NCT02694367|Other|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
193908|NCT02694354|Drug|BI 685509|
193909|NCT02694354|Drug|Placebo|
193910|NCT02694341|Procedure|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
193911|NCT02694341|Device|Bakri Balloon|uterine compression balloon
193912|NCT02694328|Drug|ALKS 3831|Daily dosing
193913|NCT02694328|Drug|Olanzapine|Daily dosing
193914|NCT02694315|Other|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
193915|NCT02694315|Other|cervical length|measuring cervical length by trans-vaginal ultrasound
193916|NCT02694302|Device|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
193917|NCT02694302|Device|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
193918|NCT02694289|Drug|Metformin|Treatment/continuation of metformin therapy during admission
193919|NCT02694289|Drug|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
193920|NCT02694276|Behavioral|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
194311|NCT02691052|Other|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
194312|NCT02691026|Drug|Pembrolizumab|
193921|NCT02694263|Drug|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
193922|NCT02694263|Drug|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
193923|NCT02694263|Drug|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
193924|NCT02694263|Drug|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
193925|NCT02694263|Drug|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
193926|NCT02694250|Device|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
193927|NCT02694237|Behavioral|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
193928|NCT02694237|Behavioral|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
193929|NCT02694237|Behavioral|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
193930|NCT02694224|Drug|vismodegib|Smo inhibitor
193931|NCT02694224|Drug|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
193932|NCT02694224|Drug|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
193933|NCT02694224|Drug|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
193934|NCT02694211|Behavioral|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
193935|NCT02694198|Other|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
193936|NCT02694185|Other|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
193937|NCT02694172|Other|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
193938|NCT02694146|Drug|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
193939|NCT02694146|Drug|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
193940|NCT02694133|Procedure|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
193941|NCT02694133|Procedure|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
193942|NCT02694107|Other|Proprioceptive exercises|
193943|NCT02694107|Other|Control|
193944|NCT02694094|Dietary Supplement|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for > 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
193945|NCT02694081|Procedure|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
193946|NCT02694081|Procedure|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
193947|NCT02694068|Other|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
193948|NCT02694068|Other|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
194313|NCT02691013|Drug|Ramelteon|
194314|NCT02691013|Drug|Placebo|
193949|NCT02694055|Other|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package.
193950|NCT02694055|Other|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to an iCCM service delivery package to patients that visit them at their work post.
193951|NCT02694055|Other|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
193952|NCT02694055|Other|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
193953|NCT02694055|Other|Training of primary health centre staff|"Health center staff will receive targeted training in~Integrated management of childhood illness~Diagnosis and treatment of simple and severe cases of malaria~Helping babies breathe~Managing post-partum haemorrhage~Gestational dating using frontal height, last menstrual period and ultrasound~Family planning counselling and administration of long-acting contraceptives~Pharmacy stock management~Health center management"
193954|NCT02694042|Behavioral|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
193955|NCT02694029|Device|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing.
193956|NCT02694029|Device|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry.
193957|NCT02694016|Procedure|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
193958|NCT02694003|Behavioral|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
193959|NCT02693990|Radiation|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
193960|NCT02693977|Procedure|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
193961|NCT02693964|Other|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
193962|NCT02693951|Drug|Cefotiam|Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
193963|NCT02693938|Device|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
193964|NCT02693938|Device|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
193965|NCT02693912|Procedure|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
193966|NCT02693899|Other|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
193967|NCT02693886|Other|doctor experience|
193968|NCT02693873|Behavioral|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.~EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
193969|NCT02693860|Drug|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute.
194020|NCT02693509|Other|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
194435|NCT02690012|Other|Magnesium Citrate|Magnesium Citrate
193970|NCT02693860|Drug|89Zr−J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO−huJ591 with 89Zr is achieved by the addition of 89Zr−oxalate to the DFO−huJ591 in ammonium acetate buffer.
193971|NCT02693834|Device|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
193972|NCT02693834|Device|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
193973|NCT02693821|Drug|Gabapentin|gabapentin 300 mg per day, orally during 30 days
193974|NCT02693821|Other|Placebo|Placebo 300 mg per day, orally during 30 days
193975|NCT02693808|Procedure|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
193976|NCT02693808|Procedure|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
193977|NCT02693795|Other|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
193978|NCT02693795|Other|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
193979|NCT02693782|Dietary Supplement|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
193980|NCT02693782|Dietary Supplement|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
193981|NCT02693769|Drug|fluticasone propionate/formoterol fumarate breath actuated inhaler|
193982|NCT02693769|Drug|Indacaterol maleate / glycopyrronium bromide capsules|
193983|NCT02693756|Other|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:~Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
193984|NCT02693743|Device|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
193985|NCT02693717|Other|Laboratory Biomarker Analysis|Correlative studies
193986|NCT02693717|Drug|Pemetrexed Disodium|Given IV
193987|NCT02693704|Device|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
193988|NCT02693691|Device|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
193989|NCT02693678|Other|Massage|
193990|NCT02693678|Device|DIathermy|
193991|NCT02693678|Device|Sham diathermy|
193992|NCT02693665|Behavioral|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
193993|NCT02693652|Biological|CVI-HBV-002|"Investigational product: CVI-HBV-002~Dose: 20ug or 40ug~Frequency: 3 or 6 times~Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months~Administration route: Intramuscular injection"
193994|NCT02693626|Behavioral|intensive cessation message|Mobile phone-based text message （three to five messages per day） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
193995|NCT02693626|Behavioral|Not intensive cessation message|Mobile phone-based text message （three to five messages per week） interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
193996|NCT02693613|Drug|ASP1517|Oral
193997|NCT02693613|Drug|Kremezin®|Oral
193998|NCT02693600|Procedure|Ligamentoplasty with partial trapeziectomy|
193999|NCT02693600|Procedure|Ligamentoplasty with total trapeziectomy|
194000|NCT02693587|Drug|Misodel and Angusta|
194001|NCT02693574|Drug|Clarithromycin|
194002|NCT02693574|Drug|Levofloxacin|
194003|NCT02693561|Behavioral|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
194004|NCT02693561|Behavioral|Self-Help Book|Reading the self-help book.
194005|NCT02693535|Drug|Crizotinib|drug
194006|NCT02693535|Drug|Palbociclib|drug
194007|NCT02693535|Drug|Sunitinib|drug
194008|NCT02693535|Drug|Temsirolimus|drug
194009|NCT02693535|Drug|Trastuzumab and Pertuzumab|drug
194010|NCT02693535|Drug|Vemurafenib and Cobimetinib|drug
194011|NCT02693535|Drug|Regorafenib|drug
194012|NCT02693535|Drug|Olaparib|drug
194013|NCT02693535|Drug|Pembrolizumab|drug
194014|NCT02693535|Drug|Nivolumab and Ipilimumab|drug
194015|NCT02693535|Drug|Abemaciclib|drug
194016|NCT02693535|Drug|Afatinib|drug
194017|NCT02693535|Drug|Talazoparib|drug
194018|NCT02693522|Drug|somatropin|Subcutaneous injection
194022|NCT02693483|Drug|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
194023|NCT02693470|Drug|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
194024|NCT02693457|Procedure|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
194025|NCT02693457|Procedure|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
194026|NCT02693444|Drug|Lidocaine|
194027|NCT02693444|Drug|Saline|
194028|NCT02693431|Other|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.~The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.~At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
194029|NCT02693418|Drug|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
194030|NCT02693418|Drug|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
194031|NCT02693418|Drug|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
194032|NCT02693418|Drug|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
194033|NCT02693405|Other|Executive functions|measures of executive functioning with tasks
194034|NCT02693405|Other|social cognition|measures of socio-cognitive functioning with tasks
194035|NCT02693405|Other|quality of life|measures of quality of life with questionnaires
194036|NCT02693392|Drug|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents~Sulfonylurea based oral hypoglycemic agents~Metformin based oral hypoglycemic agents~Metformin plus Sulfonylurea based oral hypoglycemic agents"
194037|NCT02693392|Dietary Supplement|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
194038|NCT02693379|Device|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.~Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
194039|NCT02693366|Biological|Autologous Cell Transplantation|Endovascular infusion of bone marrow derived cells in both renal arteries.
194040|NCT02693340|Biological|sampling|"• Sampling period(s):~Blood: W0, W6, W14, W30 and W52 and relapse.~Biopsies and fecal: W0, W14 and M52 and relapse."
194041|NCT02693327|Other|Biological Sample|A one time sample will be collected.
194042|NCT02693327|Other|Blood Sample|A one time blood sample will be collected.
194043|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
194044|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
194045|NCT02693314|Dietary Supplement|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
194046|NCT02693301|Other|Exercise program|
194047|NCT02693288|Procedure|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
194048|NCT02693275|Device|Quotient® System iPad Test|See arm/group description
194049|NCT02693262|Device|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
194050|NCT02693262|Device|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
194051|NCT02693236|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
194052|NCT02693223|Other|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
194053|NCT02693210|Drug|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
194054|NCT02693210|Drug|Methotrexate|Participants will receive >= 10 mg/week methotrexate orally up to 24 weeks
194055|NCT02693210|Other|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
194056|NCT02693210|Other|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
194057|NCT02693210|Other|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
194058|NCT02693210|Drug|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
194059|NCT02693197|Drug|T-817MA|A single oral dose of 448 mg
194060|NCT02693184|Other|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
194061|NCT02693184|Other|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
194062|NCT02693171|Drug|Dinutuximab|Unituxin was administered along with cytokines according to the prescribing information
194063|NCT02693145|Other|Anti-Retroviral Treatment and Access to Services (ARTAS)|Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
194064|NCT02693132|Behavioral|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
194065|NCT02693132|Behavioral|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
194066|NCT02693132|Behavioral|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
194067|NCT02693119|Drug|elamipretide (MTP-131) 1% topical ophthalmic solution|
194068|NCT02693119|Drug|Vehicle topical ophthalmic solution|
194069|NCT02693106|Dietary Supplement|Dietary supplement|Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated (5 g of leucine, 3.6 g of butyrate, 7.2 g of butyrate, 5 g of octanoate, 10 g of octanoate, 1.95 g of carnitine or 65 g of butter fraction rich in MCT) follow by a period of 4-hour with multiple blood sampling.
194070|NCT02693093|Drug|NI-03|
194071|NCT02693093|Drug|Placebo|
194072|NCT02693080|Device|CAPP-Seq|Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.
194073|NCT02693080|Drug|Isovue-200|Contrast agent
194074|NCT02693080|Radiation|Computed Tomography Perfusion Imaging|
194075|NCT02693067|Drug|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
194076|NCT02693054|Device|HALO|Laser Treatment
194077|NCT02693041|Drug|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
194078|NCT02693041|Drug|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
194079|NCT02693028|Drug|Probiotic lozenges|The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
194080|NCT02693028|Drug|Placebo lozenges|The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
194081|NCT02693028|Drug|Probiotic capsules|The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
194082|NCT02693028|Drug|Placebo capsules|The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
194083|NCT02693028|Drug|Probiotic chewing gum|The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
194084|NCT02693002|Drug|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
194085|NCT02693002|Drug|Placebo|inactive ingredient
194086|NCT02692989|Procedure|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
194087|NCT02692976|Biological|mDC vaccination|Intranodal mDC vaccination
194088|NCT02692976|Biological|pDC vaccination|Intranodal pDC vaccination
194089|NCT02692976|Biological|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
194090|NCT02692963|Biological|BCG vaccination|BCG vaccine InterVax
194091|NCT02692950|Other|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
194092|NCT02692950|Behavioral|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
194093|NCT02692937|Procedure|Neurolysis|
194094|NCT02692937|Other|Traditional neck-specific exercise program|
194095|NCT02692859|Biological|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
194096|NCT02692833|Other|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
194097|NCT02692820|Dietary Supplement|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
194098|NCT02692820|Other|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
194099|NCT02692807|Procedure|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
194100|NCT02692781|Drug|MOD-6031|
194101|NCT02692781|Other|Placebo control|
194102|NCT02692768|Other|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
194103|NCT02692768|Other|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
194104|NCT02692768|Other|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
194105|NCT02692755|Drug|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
194106|NCT02692742|Drug|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
194107|NCT02692742|Drug|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
194108|NCT02692729|Procedure|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
194109|NCT02692729|Procedure|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
194110|NCT02692716|Drug|semaglutide|For oral use once daily.
194111|NCT02692716|Drug|placebo|For oral use once daily.
194112|NCT02692703|Drug|glecaprevir/pibrentasvir|Tablet; glecaprevir coformulated with pibrentasvir
194113|NCT02692690|Device|Stimulette r4x|
194114|NCT02692677|Drug|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
194115|NCT02692664|Device|Endovascular aorto-iliac repair|
194116|NCT02692651|Drug|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
194117|NCT02692651|Drug|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
194118|NCT02692638|Procedure|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
194119|NCT02692638|Procedure|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
194120|NCT02692625|Dietary Supplement|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
194121|NCT02692625|Dietary Supplement|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
194122|NCT02692599|Biological|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
194123|NCT02692599|Biological|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
194124|NCT02692586|Device|FlowTriever System|
194125|NCT02692573|Other|positioning|prone positioning for the initial 5 minutes of life
194126|NCT02692573|Other|positioning|supine positioning for the initial 5 minutes of life
194127|NCT02692560|Behavioral|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
194128|NCT02692560|Other|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Kaiser Permanente Washington enrollees.
194129|NCT02692547|Device|Hybrid-logic closed loop system|All patients get to wear the pump
194130|NCT02692534|Other|Urine cocaine negative|Preoperative urine cocaine negative
194131|NCT02692534|Other|Urine cocaine positive|Preoperative urine cocaine positive
194132|NCT02692521|Dietary Supplement|Human Milk|
194133|NCT02692482|Device|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
194134|NCT02692482|Procedure|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
194135|NCT02692469|Procedure|Duodenal Switch|Bariatric procedure
194136|NCT02692469|Procedure|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
194137|NCT02692456|Device|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
194138|NCT02692456|Device|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
194139|NCT02692443|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
194140|NCT02692443|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
194141|NCT02692430|Other|No intervention is studied|
194142|NCT02692417|Device|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
194143|NCT02692391|Drug|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
194144|NCT02692391|Drug|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
194145|NCT02692378|Drug|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
194146|NCT02692365|Procedure|Magnetic Resonance + hemodynamic + infusion of gadolinium|
194147|NCT02692352|Other|Goal Management Training|Goal Management training, 8 sessions of 2 hours
194148|NCT02692352|Other|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
194149|NCT02692339|Drug|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
194150|NCT02692339|Drug|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
194151|NCT02692326|Procedure|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies < 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
194152|NCT02692313|Drug|Epinephrine|Dose response of epinephrine infusion
194153|NCT02692313|Other|Saline infusion|Placebo
194154|NCT02692300|Procedure|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram or MASIMO or Medline monitors
194155|NCT02692287|Device|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
194156|NCT02692261|Procedure|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
194157|NCT02692261|Procedure|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
194158|NCT02692248|Drug|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
194159|NCT02692248|Drug|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
194160|NCT02692248|Drug|Gemcitabine|Gemcitabine 1000 mg/msq IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
194161|NCT02692248|Drug|Oxaliplatin|Oxaliplatin 100 mg/msq (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
194162|NCT02692248|Drug|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
194163|NCT02692235|Dietary Supplement|carnitine|1500 mg/d l-carnitine-l-tartrate
194164|NCT02692235|Dietary Supplement|placebo|isonitrogenous
194165|NCT02692222|Other|Calculation of PPV and CO with two methods|
194166|NCT02692209|Device|FFDM Plus DBT|"FFDM + DBT Images~FujiFilm Aspire Cristalle System"
194167|NCT02692209|Device|FFDM Alone|FFDM Alone Images
194168|NCT02692196|Device|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
194169|NCT02692170|Biological|CVI-HBV-001|"Investigational product: CVI-HBV-001~Dose: 5, 10, 20 or 40ug~Frequency: 3 times~Vaccination schedule: at 0, 1, 6 months~Administration route: Intramuscular injection"
194170|NCT02692170|Biological|Conventional Hepatitis B vaccine (20 μg)|"Active comparator: Conventional Hepatitis B vaccine (20 μg)~Dose: 20ug~Frequency: 3 times~Vaccination schedule: at 0, 1, 6 months~Administration route: Intramuscular injection"
194171|NCT02692157|Drug|Placebo|Placebo for Neurokinin 1,3 antagonist
194172|NCT02692157|Drug|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
194173|NCT02692157|Drug|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
194174|NCT02692157|Drug|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
194175|NCT02692144|Other|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
194176|NCT02692105|Radiation|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
194177|NCT02692105|Radiation|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
194178|NCT02692079|Procedure|T-PRF|Flap Surgery
194179|NCT02692079|Procedure|Allograft|Flap Surgery
194180|NCT02692066|Biological|varicella vaccine|
194181|NCT02692053|Biological|blood sampling|additional blood sampling (volume: 18 mL)
194182|NCT02692040|Drug|G3215|Gut hormone analogue
194183|NCT02692040|Drug|Placebo|0.9% saline
194184|NCT02692027|Other|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.~In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
194185|NCT02692027|Other|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.~Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
194186|NCT02692001|Other|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
194187|NCT02691988|Other|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
194188|NCT02691988|Other|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
194189|NCT02691975|Drug|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
194190|NCT02691962|Device|Xen Matrix AB|Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
194191|NCT02691949|Drug|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
194192|NCT02691936|Device|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
194193|NCT02691936|Drug|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
194194|NCT02691923|Drug|Fluorescein|
194195|NCT02691923|Drug|Fluorescein + ALA|
194196|NCT02691910|Drug|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
194197|NCT02691910|Drug|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
194198|NCT02691897|Drug|Melatonin|Melatonin 3mg once daily at bedtime
194199|NCT02691897|Drug|Placebo|Placebo 1 tablet once daily at bedtime
194200|NCT02691884|Procedure|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
194201|NCT02691871|Drug|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
194202|NCT02691871|Drug|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
194203|NCT02691871|Drug|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
194204|NCT02691858|Drug|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
194205|NCT02691858|Drug|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
194206|NCT02691845|Behavioral|BA (brief advice)|
194207|NCT02691845|Behavioral|SHE (supervised and home-based exercise)|
194208|NCT02691845|Behavioral|HE (health education)|
194209|NCT02691845|Behavioral|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
194210|NCT02691832|Device|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
194211|NCT02691819|Device|single stent and embedded balloon angioplasty|
194212|NCT02691806|Other|experimental protocol|"first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.~second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors."
194213|NCT02691793|Drug|Sunitinib|sunitinib 37.5mg QD
194214|NCT02691780|Drug|Sorafenib|
194215|NCT02691767|Drug|pazopanib|
194216|NCT02691754|Other|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
194217|NCT02691741|Device|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
194218|NCT02691741|Device|AT LISA® tri IOL|Trifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
194219|NCT02691728|Drug|LDV/SOF FDC|
194220|NCT02691715|Procedure|Endometrial saline plus curettage|
194221|NCT02691715|Procedure|Endometrial curettage|
194436|NCT02689999|Drug|Dexrabeprazole 10 mg Enteric-Coated Tablets|
194222|NCT02691702|Drug|PF-05251749|Multiple ascending doses of PF-05251749 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
194223|NCT02691702|Drug|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
194224|NCT02691689|Other|Genetic testing|Genetic testing by DNA sequencing on blood samples after DNA extraction
194225|NCT02691676|Drug|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
194226|NCT02691676|Drug|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
194227|NCT02691663|Dietary Supplement|Oral bicarbonate supplementation|
194228|NCT02691663|Dietary Supplement|Placebo|
194229|NCT02691598|Drug|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
194230|NCT02691585|Other|Music Intervention|A raga will be played for 10 minutes & data collected.
194231|NCT02691572|Procedure|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
194232|NCT02691572|Drug|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
194233|NCT02691572|Drug|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
194234|NCT02691572|Procedure|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
194235|NCT02691572|Procedure|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
194236|NCT02691572|Procedure|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients` abdomen.
194237|NCT02691572|Procedure|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
194238|NCT02691572|Drug|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
194239|NCT02691572|Drug|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
194240|NCT02691572|Procedure|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
194241|NCT02691559|Device|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
194242|NCT02691546|Other|blood sample collection|
194243|NCT02691533|Drug|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
194244|NCT02691533|Drug|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
194245|NCT02691533|Drug|No Lipid Emulsion/Placebo|
194246|NCT02691507|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
194247|NCT02691507|Drug|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
194248|NCT02691494|Drug|Elagolix|Elagolix for 6-month Treatment
194249|NCT02691494|Drug|Placebo for Estradiol/Norethindrone Acetate|Placebo for 6-month Treatment
194250|NCT02691494|Drug|Estradiol/Norethindrone Acetate|Estradiol/Norethindrone Acetate for 6-month Treatment
194251|NCT02691494|Drug|Placebo for Elagolix|Placebo for 6-month Treatment
194252|NCT02691481|Dietary Supplement|Oatmeal breakfast|
194253|NCT02691481|Dietary Supplement|Glucerna formula|
194254|NCT02691481|Dietary Supplement|Ultra Glucose Control formula|
194255|NCT02691468|Device|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
194256|NCT02691468|Device|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
194257|NCT02691455|Device|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
194258|NCT02691455|Procedure|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
194259|NCT02691455|Device|Ahmed Model FP7 Flexible Plate|
194260|NCT02691455|Device|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
194261|NCT02691442|Drug|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
194262|NCT02691442|Drug|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
194263|NCT02691442|Drug|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
194264|NCT02691429|Other|Acai dye 10%|dye to be used during chromovitrectomy in humans
194265|NCT02691416|Drug|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
194266|NCT02691416|Drug|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
194267|NCT02691403|Drug|levo-bupivacaine|
194268|NCT02691403|Drug|normal saline|
194269|NCT02691390|Device|dTMS|dTMS to ACC
194270|NCT02691390|Device|dTMS|SHAM - no stimulation
194271|NCT02691377|Device|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
194272|NCT02691377|Device|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
194273|NCT02691364|Procedure|Blood withdrawal|
194437|NCT02689986|Drug|Bendamustine, Rituximab|Bendamustine, Rituximab
194274|NCT02691351|Other|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment~Regimen~Response Evaluation~SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
194275|NCT02691338|Other|EEG|EEG analysis
194276|NCT02691338|Other|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
194277|NCT02691325|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
194278|NCT02691325|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
194279|NCT02691325|Drug|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
194280|NCT02691312|Device|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
194281|NCT02691299|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
194282|NCT02691299|Drug|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
194283|NCT02691273|Behavioral|cellular application treating diabetes using breathing technique|
194284|NCT02691260|Behavioral|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
194285|NCT02691260|Behavioral|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
194286|NCT02691260|Behavioral|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
194287|NCT02691247|Biological|CLBS03 Low Dose|
194288|NCT02691247|Biological|CLBS03 High Dose|
194289|NCT02691247|Biological|Placebo|
194290|NCT02691234|Device|Extracorporeal Shockwave Therapy and debridement|
194291|NCT02691234|Other|debridement and cleaning|
194292|NCT02691221|Behavioral|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
194293|NCT02691208|Other|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
194294|NCT02691208|Other|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
194295|NCT02691195|Drug|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
194296|NCT02691195|Drug|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
194297|NCT02691182|Drug|SPN-810|
194298|NCT02691169|Drug|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
194299|NCT02691156|Other|Bilirubin Binding Capacity|Laboratory assay of bilirubin binding capacity
194300|NCT02691156|Other|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
194301|NCT02691156|Other|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
194302|NCT02691143|Other|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
194303|NCT02691130|Biological|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
194304|NCT02691130|Biological|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
194305|NCT02691130|Biological|Saline|0.9% NaCl in double distilled water
194306|NCT02691117|Drug|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
194307|NCT02691104|Device|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
194308|NCT02691104|Device|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
194309|NCT02691078|Other|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
194310|NCT02691065|Drug|Integrase Inhibitor|
194315|NCT02691000|Device|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
194316|NCT02691000|Device|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
194317|NCT02690987|Drug|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.~The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of ~130-190 pg/mL."
194318|NCT02690987|Biological|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. GMP-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).~The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of ~13-19 ng/mL."
194319|NCT02690987|Biological|Saline|The placebo visit will involve an intravenous infusion of normal saline.
194320|NCT02690974|Drug|LCZ696 (sacubitril/valsartan)|All patients were treated with the LCZ696 (sacubitril and valsartan) tablets
194321|NCT02690961|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
194322|NCT02690961|Drug|placebo multiple doses|
194323|NCT02690948|Biological|Pembrolizumab|Given IV
194324|NCT02690948|Drug|Vismodegib|Given PO
194325|NCT02690935|Drug|2LALERG|Homeopathic drug
194326|NCT02690935|Drug|Placebo|Placebo
194327|NCT02690922|Drug|Dasatinib|100mg (d1-d84)
194328|NCT02690922|Drug|prednisone|60mg/m2 d1-24
194329|NCT02690922|Drug|dexamethasone|10mg/d 3-7days
194330|NCT02690922|Drug|methotrexate|3g/m2 1day
194331|NCT02690909|Device|Redy™ Renal Denervation System|Renal Denervation System
194332|NCT02690896|Behavioral|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
194333|NCT02690896|Behavioral|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
194334|NCT02690883|Drug|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
194335|NCT02690883|Drug|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG <10.0mmol/L.
194336|NCT02690870|Drug|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
194337|NCT02690870|Drug|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
194338|NCT02690857|Drug|Docosahexaenoic acid|
194339|NCT02690857|Drug|Sunflower Oil|
194340|NCT02690844|Drug|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
194341|NCT02690844|Drug|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
194342|NCT02690844|Drug|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
194343|NCT02690831|Other|Inspiratory Muscle training (IMT)|Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
194344|NCT02690831|Other|IMT + Manual Therapy and Motor Control Exercise|IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
194345|NCT02690831|Device|Powerbreathe|
194346|NCT02690818|Behavioral|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
194347|NCT02690805|Device|MR-compatible scinti-mammography (MRI-SMM) system|
194348|NCT02690792|Other|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
194349|NCT02690792|Dietary Supplement|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
194350|NCT02690779|Other|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
194351|NCT02690779|Other|Routine Care Instructions|patients will follow routine care and instructions
194352|NCT02690766|Behavioral|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
194353|NCT02690753|Procedure|A protocol tailored to individual risk factors|
194354|NCT02690753|Device|The Prevalon® Turn and Position System 2.0|
194355|NCT02690753|Device|Comfort Shield® barrier cream cloths|
194356|NCT02690740|Other|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
194357|NCT02690727|Drug|RP6530|Single oral dose
194358|NCT02690714|Biological|Plasminogen (Human) intravenous|Prometic Plasminogen (Human) intravenous infusion given as single dose of 6.6 mg/kg in Segment 1 and repeat doses in Segments 2 and 3.
194480|NCT02689687|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
194359|NCT02690701|Drug|Secukinumab 300 mg|"Secukinumab 300 mg was provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab consisted of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occurred on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
194360|NCT02690701|Biological|Placebo|"Placebo was provided in 1 mL prefilled syringe. Each placebo dose consisted of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients were switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive.~The patients (or caregivers) self-injected each dose at the study site under the supervision of site personnel when injections occured on days of study visits.~The injections not occurring on days of study visits were done by the patients (or caregivers) at home."
194361|NCT02690688|Device|determination of dynamic preload variables|
194362|NCT02690675|Dietary Supplement|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
194363|NCT02690662|Behavioral|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
194364|NCT02690649|Other|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
194365|NCT02690636|Radiation|radiotherapy|daily fractions, five fractions per week.
194366|NCT02690623|Other|Pediatric hospitalist program|In-house hospitalists available at all hours
194367|NCT02690623|Other|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
194368|NCT02690610|Procedure|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
194369|NCT02690597|Other|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
194370|NCT02690584|Behavioral|Metacognitive therapy|
194371|NCT02690571|Other|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
194372|NCT02690558|Drug|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pembrolizumab with gemcitabine and cisplatin prior to cystectomy
194373|NCT02690545|Biological|ATLCAR.CD30 cells|For Phase Ib, in adults and separately in children, two doses will be investigated: 1x10^8 cells/m^2 and 2x10^8 cells/m^2. Phase II patients will receive the dose level decided upon in Phase I.
194374|NCT02690519|Drug|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
194375|NCT02690519|Drug|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
194376|NCT02690506|Drug|Placebo|
194377|NCT02690506|Drug|Pregabalin|
194378|NCT02690493|Procedure|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
194379|NCT02690493|Other|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
194380|NCT02690493|Other|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
194381|NCT02690480|Drug|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
194382|NCT02690480|Drug|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
194383|NCT02690480|Drug|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
194384|NCT02690467|Device|Insupen G34x3,5mm|
194385|NCT02690467|Device|Insupen G32x4mm|
194386|NCT02690441|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
194387|NCT02690441|Behavioral|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
194388|NCT02690441|Behavioral|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
194389|NCT02690428|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
194390|NCT02690415|Procedure|Antibiotics Given|Patients who's treating physician prescribed antibiotics
194391|NCT02690415|Procedure|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
194392|NCT02690402|Behavioral|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
194393|NCT02690389|Drug|Flumazenil|used alone or with acupuncture
194394|NCT02690389|Procedure|Acupuncture|used alone or with flumazenil
194395|NCT02690376|Device|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
194396|NCT02690350|Drug|U3-1784|Solution for solution in 5% dextrose for infusion, intravenously administered every 2 weeks (q2w) as a 250 mL IV, along with colestyramine or equivalent if clinically indicated
194397|NCT02690337|Drug|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
194398|NCT02690324|Behavioral|cognitive stress (serial 7)|
194399|NCT02690311|Device|smartphone display|
194400|NCT02690298|Device|ExSpiron|Non-Invasive respiratory volume monitoring
194401|NCT02690285|Drug|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
194402|NCT02690285|Other|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
194403|NCT02690272|Behavioral|Psychic processes|Quantitative and qualitative aprroche of the psychic process
194404|NCT02690259|Procedure|Sentinel node procedure|Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
194405|NCT02690246|Other|questionnaire|a questionnaire based study
194406|NCT02690233|Procedure|Elective Surgery|Elective laparoscopic inguinal hernia repair
194407|NCT02690220|Device|TiLOOP® PRO Plus A|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
194408|NCT02690207|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
194409|NCT02690194|Device|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
194410|NCT02690194|Device|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
194411|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 .
194412|NCT02690168|Behavioral|Fasting|72 hour fasting
194413|NCT02690155|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
194414|NCT02690155|Drug|VKA (Vitamin K antagonist)|As prescribed by treating physicians
194415|NCT02690142|Drug|Placebo|Single dose i.v.
194416|NCT02690142|Drug|ABY-035 i.v.|Single dose i.v.
194417|NCT02690142|Drug|ABY-035 s.c.|Single dose s.c.
194418|NCT02690129|Drug|Vaginal Progesteron|
194419|NCT02690116|Other|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
194420|NCT02690116|Other|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 8 weeks, with a recommended home practice time of 2 1/2 hours each week.
194421|NCT02690116|Other|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60-minute class per week for the 8 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
194422|NCT02690103|Drug|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
194423|NCT02690103|Dietary Supplement|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
194424|NCT02690103|Drug|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
194425|NCT02690077|Procedure|Family-Centered Cesarean|Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
194426|NCT02690077|Procedure|Traditional Cesarean|Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
194427|NCT02690064|Dietary Supplement|Acute Antioxidant|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
194428|NCT02690064|Dietary Supplement|Chronic Antioxidant|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
194429|NCT02690064|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
194430|NCT02690051|Device|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
194431|NCT02690038|Drug|Intravenous immunoglobulin (IVIG)|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
194432|NCT02690038|Drug|Normal Saline|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.~Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
194433|NCT02690025|Drug|ZP1848|
194434|NCT02690012|Other|Magnesium Oxide|Magnesium Oxide
194438|NCT02689973|Behavioral|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
194439|NCT02689973|Behavioral|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools."
194440|NCT02689973|Behavioral|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools."
194441|NCT02689960|Drug|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
194442|NCT02689947|Device|Restylane Silk|
194443|NCT02689934|Dietary Supplement|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
194444|NCT02689934|Dietary Supplement|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
194445|NCT02689921|Drug|Exemestane|Aromatase inhibitor
194446|NCT02689921|Drug|Letrozole|Aromatase inhibitor
194447|NCT02689921|Drug|Anastrozole|Aromatase inhibitor
194448|NCT02689921|Drug|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
194449|NCT02689921|Drug|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
194450|NCT02689921|Drug|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
194451|NCT02689908|Radiation|computed tomography|low dose protocol of thorax ct
194452|NCT02689895|Other|modified directly administered anti-retroviral therapy (mDAART)|As described before
194453|NCT02689882|Dietary Supplement|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
194454|NCT02689869|Drug|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
194455|NCT02689869|Drug|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
194456|NCT02689856|Drug|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
194457|NCT02689856|Drug|Placebo control|Vehicle cream alone
194458|NCT02689856|Drug|Hydrocortisone acetate|hydrocortisone alone
194459|NCT02689856|Drug|Lidocaine hydrochloride|lidocaine alone
194460|NCT02689843|Drug|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
194461|NCT02689843|Drug|Metformin|Metformin 500mg three times daily
194462|NCT02689843|Drug|Pioglitazone|Pioglitazone 30mg once daily
194463|NCT02689830|Device|Bead Block|Prostate embolization
194464|NCT02689817|Device|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
194465|NCT02689804|Drug|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
194466|NCT02689804|Drug|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
194467|NCT02689791|Dietary Supplement|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
194468|NCT02689778|Drug|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
194469|NCT02689778|Drug|Placebo|Identical tablets without active substance
194470|NCT02689765|Dietary Supplement|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
194471|NCT02689765|Dietary Supplement|Placebo|Placebo capsules is identically packaged.
194472|NCT02689752|Drug|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
194473|NCT02689739|Procedure|venous duplex ultrasound|Venous duplex ultrasound
194474|NCT02689726|Drug|GTL001+|
194475|NCT02689726|Drug|Aldara|5% imiquimod cream
194476|NCT02689713|Drug|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
194477|NCT02689713|Drug|Topical Sterile Water Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
194478|NCT02689700|Other|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
194479|NCT02689687|Behavioral|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
194520|NCT02689401|Drug|Ferumoxytol|
194521|NCT02689401|Device|MRI 3T scanner|
194938|NCT02686346|Drug|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
194481|NCT02689687|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
194482|NCT02689687|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
194483|NCT02689635|Other|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
194484|NCT02689635|Other|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
194485|NCT02689622|Other|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
194486|NCT02689622|Other|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
194487|NCT02689622|Other|physical performance|Activities of Daily Living and physical performance
194488|NCT02689609|Radiation|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
194489|NCT02689596|Drug|Oxytocin|
194490|NCT02689596|Other|Placebo|
194491|NCT02689583|Biological|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin > Clarithromycin > Levofloxacin >Tetracycline > Furazolidone > Metronidazole.
194492|NCT02689583|Genetic|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
194493|NCT02689583|Dietary Supplement|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
194494|NCT02689570|Other|observational|no interventions; observational study
194495|NCT02689557|Other|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
194496|NCT02689544|Other|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
194497|NCT02689544|Other|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
194498|NCT02689544|Other|Control|The control group volunteers no received intervention
194499|NCT02689518|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
194500|NCT02689505|Drug|BI 836880|
194501|NCT02689479|Procedure|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
194502|NCT02689479|Biological|11C-5-HTP|150-400 MBq [11C]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
194503|NCT02689479|Procedure|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
194504|NCT02689479|Procedure|Mixed-Meal Tolerance Test (MMTT)|
194505|NCT02689479|Procedure|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
194506|NCT02689479|Procedure|Glomerular Filtration Rate Testing|
194507|NCT02689479|Procedure|Blood draw|
194508|NCT02689453|Biological|IL-15 plus alemtuzumab|rhIL-15 by s.c. injection Monday-Friday over two weeks; followed by alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
194509|NCT02689440|Drug|Dasatinib|Given PO
194510|NCT02689440|Other|Laboratory Biomarker Analysis|Correlative studies
194511|NCT02689440|Drug|Venetoclax|Given PO
194512|NCT02689427|Procedure|Axillary Lymph Node Dissection|Undergo axillary lymph node dissection
194513|NCT02689427|Drug|Enzalutamide|Given PO
194514|NCT02689427|Other|Laboratory Biomarker Analysis|Correlative studies
194515|NCT02689427|Procedure|Lymph Node Biopsy|Undergo lymph node biopsy
194516|NCT02689427|Drug|Paclitaxel|Given IV
194517|NCT02689427|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of primary tumor
194518|NCT02689414|Procedure|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
194519|NCT02689414|Procedure|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
194523|NCT02689375|Device|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
194524|NCT02689362|Drug|Evogliptin|1 tablet per day
194525|NCT02689362|Drug|Sitagliptin|1 tablet per day
194526|NCT02689362|Drug|Placebo Evogliptin|1 tablet per day
194527|NCT02689362|Drug|Placebo Sitagliptin|1 tablet per day
194528|NCT02689349|Device|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
194529|NCT02689336|Biological|Erlotinib|
194530|NCT02689336|Drug|Temozolomide|
194531|NCT02689323|Device|repeated transcranial magnetic stimulation|
194532|NCT02689310|Other|Leptospermum scoparium honey|No information available- PI left- study being withdrawn.
194533|NCT02689310|Other|Standard of Care Treatment|No information available- PI left- study being withdrawn.
194534|NCT02689297|Other|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
194535|NCT02689297|Other|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
194536|NCT02689284|Biological|Margetuximab plus pembrolizumab|margetuximab in combination with pembrolizumab; combination treatment is administered once every 21-day cycle
194537|NCT02689271|Other|MRI|VERDICT diffusion-weighted microstructure imaging sequence
194538|NCT02689258|Drug|HTX-011B|
194539|NCT02689258|Drug|Placebo|
194540|NCT02689258|Drug|HTX-011A|
194541|NCT02689258|Drug|HTX-002|
194542|NCT02689258|Drug|Bupivicaine HCl|
194543|NCT02689245|Drug|Tenofovir|
194544|NCT02689245|Drug|Fecal Microbiota Transplantation (FMT)|
194545|NCT02689232|Biological|Fresh Frozen Plasma|
194546|NCT02689232|Biological|Platelets Concentrate|
194547|NCT02689232|Biological|Cryo Precitipitate|
194548|NCT02689219|Drug|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
194549|NCT02689206|Drug|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
194550|NCT02689206|Drug|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
194551|NCT02689193|Other|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
194552|NCT02689180|Drug|Placebo|Replacement of furosemide by placebo
194553|NCT02689180|Drug|Furosemide|Maintenance of furosemide on usual doses
194554|NCT02689167|Drug|Sunitinib|
194555|NCT02689154|Device|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
194556|NCT02689141|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
194557|NCT02689141|Drug|Ofatumumab|"Induction:~Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.~Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.~Cycle 1-8: Day 1 1000 mg i.v."
194558|NCT02689141|Drug|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
194559|NCT02689115|Other|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
194560|NCT02689102|Device|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
194561|NCT02689089|Drug|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
194562|NCT02689076|Other|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
194563|NCT02689076|Other|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
194564|NCT02689063|Drug|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
194565|NCT02689063|Drug|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
194566|NCT02689063|Drug|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
194567|NCT02689063|Drug|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
194568|NCT02689050|Device|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
194569|NCT02689037|Procedure|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
194570|NCT02689037|Drug|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
194571|NCT02689024|Drug|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
194572|NCT02689024|Drug|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
194573|NCT02689024|Drug|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
194574|NCT02689024|Drug|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
194575|NCT02689024|Drug|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
194576|NCT02689024|Drug|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
194577|NCT02689024|Drug|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
194578|NCT02689024|Drug|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
194579|NCT02689024|Drug|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
194580|NCT02689024|Drug|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
194581|NCT02689011|Procedure|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
194582|NCT02689011|Procedure|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
194583|NCT02688998|Device|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
194584|NCT02688985|Drug|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
194585|NCT02688985|Procedure|Lumbar Puncture|Participants will receive LP as specified in individual arms.
194586|NCT02688985|Drug|Methyloprednisolone|Participants will receive 100 mg of IV methylprenisolone (or an equivalent) prior to ocrelizumab infusion.
194587|NCT02688985|Drug|Antihistamine|Participants will receive an antihistamine, such as diphenhydramine, prior to ocrelizumab infusion.
194588|NCT02688972|Other|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
194589|NCT02688972|Other|Control group|The volunteers stayed in rest about 10 minutes
194590|NCT02688959|Behavioral|Tai Chi|
194591|NCT02688959|Behavioral|Exercise|
194592|NCT02688946|Other|Not provided|
194593|NCT02688933|Drug|HOE901-U300 (Insulin Glargine 300 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
194594|NCT02688933|Drug|Lantus (Insulin Glargine 100 U/ml)|Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
194595|NCT02688933|Drug|Mandated back ground therapy|Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
194596|NCT02688920|Procedure|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
194597|NCT02688907|Drug|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first & second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
194598|NCT02688894|Other|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.~Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
194599|NCT02688881|Drug|sirolimus|Rapamune
194600|NCT02688868|Device|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
194601|NCT02688855|Device|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
194602|NCT02688855|Device|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
194603|NCT02688842|Device|Rapamycin target-eluting coronary stent systems (38mm)|
194604|NCT02688829|Device|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
194605|NCT02688816|Device|Xpert HPV|Point-of-care HPV DNA PCR test
194606|NCT02688816|Device|OncoE6|Point-of-care E6 oncoprotein test
194607|NCT02688803|Drug|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
194608|NCT02688803|Drug|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
194609|NCT02688803|Drug|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
194610|NCT02688790|Drug|Dalbavancin|
194647|NCT02688491|Drug|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
194648|NCT02688478|Other|Phthalate|Delivered by inhalation on day 1 of the triad
194649|NCT02688478|Other|Filtered Air|Delivered by inhalation on day 1 of the triad
194650|NCT02688478|Other|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
194651|NCT02688465|Drug|Apomorphine|
194652|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
194611|NCT02688777|Behavioral|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
194612|NCT02688764|Drug|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
194613|NCT02688764|Drug|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.~During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
194614|NCT02688751|Radiation|time-resolved CT Angiography|A multi-phase contrast CT
194615|NCT02688751|Procedure|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
194616|NCT02688738|Drug|Doxycycline|
194617|NCT02688725|Device|post mastectomy ultrasound|post mastectomy ultrasound
194618|NCT02688712|Drug|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
194619|NCT02688712|Drug|Capecitabine|Antimetabolite chemotherapy
194620|NCT02688712|Drug|Fluorouracil|Antimetabolite chemotherapy
194621|NCT02688712|Procedure|Tumor specific mesorectal excision|Tumor specific mesorectal excision
194622|NCT02688699|Procedure|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.~Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
194623|NCT02688686|Biological|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
194624|NCT02688673|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
194625|NCT02688660|Other|MRI Scans|
194626|NCT02688647|Drug|KD025|
194627|NCT02688647|Drug|Standard of Care|Treatment/Drug determined by each subject's prescribing physician
194628|NCT02688634|Drug|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
194629|NCT02688621|Behavioral|Internet Only|18 month behavioral weight loss intervention delivered online
194630|NCT02688621|Behavioral|Internet + Incentives|18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
194631|NCT02688608|Drug|Pembrolizumab|200 mg IV once every 3 weeks
194632|NCT02688595|Device|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
194633|NCT02688595|Other|General anesthesia|Scheduled operation under general anesthesia
194634|NCT02688582|Other|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
194635|NCT02688569|Behavioral|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
194636|NCT02688556|Drug|cyclosporine|
194637|NCT02688556|Drug|vehicle of OTX-101|
194638|NCT02688543|Procedure|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
194639|NCT02688543|Radiation|radiofrequency ablation|
194640|NCT02688543|Device|ultrasound|
194641|NCT02688530|Drug|IV Saline|
194642|NCT02688530|Drug|IV Dexamethasone 4mg|
194643|NCT02688530|Drug|IV Dexamethasone 6mg|
194653|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
194654|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
194655|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
194656|NCT02688439|Other|Sciatic Nerve block|
194657|NCT02688439|Other|Leg raised 30°|
194658|NCT02688439|Other|Distal tourniquet placed on the lower part of the leg|
194659|NCT02688439|Other|Leg in a neutral position|
194660|NCT02688426|Device|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
194661|NCT02688426|Device|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
194662|NCT02688413|Device|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
194663|NCT02688413|Other|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
194664|NCT02688400|Drug|Diacerein|
194665|NCT02688400|Drug|Celecoxib|
194666|NCT02688400|Drug|Placebo|
194667|NCT02688387|Drug|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
194668|NCT02688387|Drug|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
194669|NCT02688374|Other|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
194670|NCT02688374|Other|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
194671|NCT02688374|Other|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
194672|NCT02688361|Drug|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
194673|NCT02688361|Drug|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
194674|NCT02688348|Other|Quality-of-Life Assessment|Ancillary studies
194675|NCT02688348|Other|Questionnaire Administration|Ancillary studies
194676|NCT02688335|Device|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
194677|NCT02688322|Drug|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
194678|NCT02688309|Drug|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
194679|NCT02688309|Procedure|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
194680|NCT02688309|Procedure|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
194681|NCT02688296|Device|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
194682|NCT02688283|Other|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
194683|NCT02688270|Drug|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
194684|NCT02688270|Drug|Vehicle (placebo)|Vehicle administered topically
194685|NCT02688257|Other|MRI|Functional magnetic resonance imaging
194686|NCT02688257|Other|Ultrasound|Optoacoustic imaging
194687|NCT02688244|Procedure|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
194688|NCT02688244|Procedure|No irrigation|Suction only, using suction device
194725|NCT02688023|Drug|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
194726|NCT02688010|Behavioral|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
194689|NCT02688231|Other|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
194690|NCT02688231|Other|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
194691|NCT02688218|Behavioral|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
194692|NCT02688218|Behavioral|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
194693|NCT02688205|Other|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
194694|NCT02688205|Device|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
194695|NCT02688192|Behavioral|Exercise Intervention|Participate in fitness program
194696|NCT02688192|Behavioral|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
194697|NCT02688192|Device|Monitoring Device|Wear an electronic accelerometer
194698|NCT02688192|Other|Quality-of-Life Assessment|Ancillary studies
194699|NCT02688166|Other|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
194700|NCT02688153|Device|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR & CABG.
194701|NCT02688153|Device|Stented aortic bioprostheses|In comparison to control valves available on the market.
194702|NCT02688140|Drug|Arsenic trioxide|
194703|NCT02688140|Drug|Idarubicin|
194704|NCT02688140|Drug|Cytarabine|
194705|NCT02688140|Drug|Tretinoin|
194706|NCT02688140|Drug|Mitoxantrone|
194707|NCT02688140|Drug|Mercaptopurine|
194708|NCT02688140|Drug|Methotrexate|
194709|NCT02688127|Drug|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
194710|NCT02688114|Procedure|Baseline surveillance endoscopy|All study participants will undergo endoscopy with NinePoint NvisionVLE volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
194711|NCT02688114|Procedure|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
194712|NCT02688114|Procedure|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
194713|NCT02688114|Procedure|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
194714|NCT02688114|Procedure|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, NinePoint NvisionVLE volumetric laser endomicroscopy, and biopsies.
194715|NCT02688101|Drug|DpC|iron chelator
194716|NCT02688088|Drug|Drug Cocktail|Administered orally
194717|NCT02688088|Drug|Abemaciclib|Administered orally
194718|NCT02688075|Other|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
194719|NCT02688062|Biological|NeuroRegen Scaffold with BMMCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
194720|NCT02688062|Procedure|Surgical intradural decompression and adhesiolysis|Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
194721|NCT02688049|Biological|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
194722|NCT02688049|Biological|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
194723|NCT02688036|Radiation|hypofractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
194724|NCT02688036|Radiation|conventionally fractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
194727|NCT02687997|Other|poligraphy|Sleep study
194728|NCT02687984|Drug|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
194833|NCT02687165|Drug|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
194729|NCT02687971|Drug|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
194730|NCT02687958|Drug|Everolimus|Maintenance therapy
194731|NCT02687945|Procedure|Outpatient physiotherapy|
194732|NCT02687945|Procedure|Self-guided physiotherapy|
194733|NCT02687932|Drug|LCZ696|
194734|NCT02687932|Drug|Valsartan|
194735|NCT02687919|Other|Modified Paleo diet|Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
194736|NCT02687906|Drug|Vabomere|Vabomere (meropenem-vaborbactam) for IV injection
194737|NCT02687893|Behavioral|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
194738|NCT02687893|Behavioral|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
194739|NCT02687880|Procedure|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
194740|NCT02687867|Drug|Dabigatran (Pradaxa)|As prescribed by treating physicians
194741|NCT02687867|Drug|Vitamin K antagonist|As prescribed by treating physicians
194742|NCT02687854|Drug|Apixaban|As prescribed by treating physicians
194743|NCT02687854|Drug|Vitamin K antagonist|As prescribed by treating physicians
194744|NCT02687841|Drug|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
194745|NCT02687841|Drug|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
194746|NCT02687815|Drug|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
194747|NCT02687815|Drug|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
194748|NCT02687802|Other|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
194749|NCT02687789|Other|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
194750|NCT02687789|Other|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
194751|NCT02687763|Biological|ProQuad|"2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:~to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.~to participate in the three (3) antibody titer blood draws."
194752|NCT02687750|Device|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
194753|NCT02687737|Procedure|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
194754|NCT02687737|Procedure|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
194755|NCT02687737|Procedure|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
194756|NCT02687737|Behavioral|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
194757|NCT02687724|Drug|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
194758|NCT02687698|Other|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
194759|NCT02687685|Other|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
194787|NCT02687451|Drug|Placebo|Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
194788|NCT02687438|Device|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
194789|NCT02687438|Other|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
194790|NCT02687425|Drug|Pioglitazone|15mg/day,po
194791|NCT02687425|Drug|imatinib mesylate|400mg/day,po
194760|NCT02687685|Other|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
194761|NCT02687672|Biological|Stem Cell Transplantation|Transplantation of autologous stem cells
194762|NCT02687659|Device|TEMIS system|Wearing TEMIS system over the day during one week
194763|NCT02687646|Drug|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.~Subjects will receive four sequential IV dose of Mesenchymal stem cells.~Sequential doses:~Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
194764|NCT02687633|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
194765|NCT02687607|Device|WEB Aneurysm Embolization System|
194766|NCT02687594|Drug|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
194767|NCT02687581|Device|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
194768|NCT02687581|Device|patch|6-hour of eye patch on the fellow eye
194769|NCT02687568|Other|EEG monitoring|Value of EEG monitoring as adjunct to standard monitoring
194770|NCT02687555|Behavioral|Cognitive Bias Modification of Appraisals (CBM-App)|
194771|NCT02687555|Behavioral|Peripheral Vision Task (control condition)|
194772|NCT02687542|Drug|Placebo|Placebo
194773|NCT02687542|Drug|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
194774|NCT02687542|Drug|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
194775|NCT02687542|Drug|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
194776|NCT02687542|Drug|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
194777|NCT02687529|Device|CST001|
194778|NCT02687516|Behavioral|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
194779|NCT02687516|Behavioral|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
194780|NCT02687503|Dietary Supplement|Probiotic|All children will receive a daily dose of probiotic (10⁹ cfu of L.acidophilus NCFM and B. lactis, Bi-07), a commercially available probiotic. Parents will give probiotic in 1 ounce of milk or water once a day for 30 days in an open label fashion.
194781|NCT02687490|Drug|Abraxane|125 mg/m2, D1, D8, D15
194782|NCT02687477|Procedure|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
194783|NCT02687477|Procedure|Sham procedure|patient in the sham group will receive sham procedure
194784|NCT02687464|Other|Non-operative treatment|"will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement (a total course of 10 days of antibiotics (intravenous and oral). They will be discharged home once they meet a standardized set of criteria to be used in all centers.~The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results."
194785|NCT02687464|Procedure|Appendectomy|"will undergo laparoscopic appendectomy within 18 hours of randomization and will receive intravenous antibiotics per each site's standard care, from the time of randomization and post-operatively according to a defined and standardized treatment regimen based on consensus for this trial.~Children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group and are not specified by the study."
194786|NCT02687451|Drug|Oxymorphone HCl|Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
194792|NCT02687412|Procedure|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
194793|NCT02687412|Procedure|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
194794|NCT02687412|Procedure|bowel preparation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
194795|NCT02687412|Procedure|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
194796|NCT02687412|Procedure|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
194797|NCT02687412|Procedure|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
194798|NCT02687412|Procedure|Postoperative glycaemic control|Postoperative glycaemic control;
194799|NCT02687412|Procedure|postoperative nausea and vomiting (PONV) control;|
194800|NCT02687412|Procedure|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
194801|NCT02687412|Procedure|pre-operative fasting at least 8h|
194802|NCT02687412|Procedure|bowel preparation for traditional surgery|Oral bowel preparations or mechanical bowl until liquid stool
194803|NCT02687412|Procedure|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
194804|NCT02687399|Other|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
194805|NCT02687399|Biological|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
194806|NCT02687386|Drug|Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)|EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
194807|NCT02687373|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
194808|NCT02687373|Other|Normal Saline|0.9% Sodium chloride
194809|NCT02687360|Device|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
194810|NCT02687360|Device|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
194811|NCT02687347|Drug|oral methadone|Oral methadone is the study drug
194812|NCT02687347|Drug|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
194813|NCT02687334|Drug|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
194814|NCT02687321|Other|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
194815|NCT02687308|Procedure|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
194816|NCT02687308|Procedure|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
194817|NCT02687295|Dietary Supplement|Thylakoids|
194818|NCT02687295|Other|Control|
194819|NCT02687282|Other|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
194820|NCT02687269|Drug|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
194821|NCT02687269|Drug|Placebo|Patients receive Placebo twice daily in the three days before surgery
194822|NCT02687256|Device|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
194823|NCT02687256|Device|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
194824|NCT02687256|Drug|Heparin|
194825|NCT02687243|Device|Interactive Virtual Application|Online application via tablet
194826|NCT02687230|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
194827|NCT02687230|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
194828|NCT02687217|Drug|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
194829|NCT02687204|Drug|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
194830|NCT02687204|Drug|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
194836|NCT02687139|Procedure|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
194837|NCT02687126|Device|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
194838|NCT02687113|Device|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
194839|NCT02687100|Drug|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
194840|NCT02687100|Drug|Placebo|patients will receive 8 mL of saline without any drug
194841|NCT02687087|Device|Visco-ease|19.6 mg/mL of LMS-611
194842|NCT02687087|Device|Placebo|Physiological Saline
194843|NCT02687074|Device|HFNC|patients treated with high flow nasal cannula
194844|NCT02687074|Device|NIV|patients treated with noninvasive ventilation
194845|NCT02687048|Behavioral|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
194846|NCT02687048|Behavioral|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
194847|NCT02687035|Device|TAVR with SAPIEN S3 valve|Transcatheter aortic valve replacement
194848|NCT02687022|Device|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
194849|NCT02687022|Device|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
194850|NCT02687009|Drug|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
194851|NCT02686996|Dietary Supplement|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
194852|NCT02686996|Other|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
194853|NCT02686983|Drug|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
194854|NCT02686944|Biological|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells, suspension for intratumoral injection
194855|NCT02686918|Other|Advanced Practice Nurse consultation|
194856|NCT02686905|Dietary Supplement|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
194857|NCT02686905|Dietary Supplement|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
194858|NCT02686905|Dietary Supplement|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
194859|NCT02686905|Dietary Supplement|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
194860|NCT02686905|Dietary Supplement|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
194861|NCT02686905|Dietary Supplement|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
194862|NCT02686879|Device|Multifocal contact lenses|
194863|NCT02686879|Device|Single vision contact lenses|
194864|NCT02686866|Device|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
194865|NCT02686866|Device|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
194866|NCT02686866|Device|hand grip strength|
194867|NCT02686853|Drug|Liposomal amphotericin B|
194868|NCT02686840|Drug|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).~Paracetamol, eight hourly, will be provided as analgesic or antipyretic.~A specimen bottle to collect the POC if passed out.~Two pairs of disposable gloves.~Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
194869|NCT02686840|Drug|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.~Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
194870|NCT02686827|Drug|Paricalcitol|Vitamin D3 analogue
194871|NCT02686827|Drug|Placebo (for paricalcitol)|Injection fluid to mimic paricalcitol injection
194872|NCT02686814|Device|17mm MDT-2215 aortic valve bioprosthesis|
194873|NCT02686788|Drug|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
194874|NCT02686775|Behavioral|Patient coach|
194876|NCT02686762|Drug|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
194877|NCT02686762|Drug|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
194878|NCT02686762|Drug|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
194879|NCT02686749|Device|Catheter Ablation|"During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF."
194880|NCT02686749|Drug|FDA approved anti arrhythmic drug|Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
194881|NCT02686736|Behavioral|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
194882|NCT02686723|Other|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
194883|NCT02686710|Drug|Sevoflurane|
194884|NCT02686710|Drug|Propofol|
194885|NCT02686697|Drug|L-Carnosine|
194886|NCT02686697|Drug|Placebo|
194887|NCT02686697|Behavioral|Cognitive Training|Cognitive Training for 2 weeks
194888|NCT02686684|Drug|Dimethyl fumarate|
194889|NCT02686671|Other|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
194890|NCT02686658|Drug|Zimura|Zimura Dose Administration 1
194891|NCT02686658|Drug|Zimura|Zimura Dose Administration 2
194892|NCT02686658|Other|Sham|Sham Administration 1
194893|NCT02686658|Drug|Zimura|Zimura Dose Administration 3
194894|NCT02686658|Drug|Zimura|Zimura Dose Administration 4
194895|NCT02686658|Other|Sham|Sham Administration 2
194896|NCT02686645|Biological|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
194897|NCT02686645|Drug|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
194898|NCT02686645|Drug|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
194899|NCT02686645|Drug|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
194900|NCT02686632|Behavioral|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
194901|NCT02686619|Drug|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
194902|NCT02686619|Drug|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
194903|NCT02686619|Drug|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2*500mg tablets or 4*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
194904|NCT02686619|Drug|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
194905|NCT02686619|Drug|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
194906|NCT02686606|Dietary Supplement|Vital 1.5|Oral nutritional supplement
194907|NCT02686606|Dietary Supplement|Ensure Plus|Oral nutritional supplement
194908|NCT02686606|Dietary Supplement|elemental 028|Oral nutritional supplement
194909|NCT02686606|Other|water|water
194910|NCT02686593|Drug|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
194911|NCT02686580|Biological|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
194912|NCT02686567|Procedure|with TDT|a transanal drainage tube insert from the anus after laparoscopic anterior resection and double-stapling technique anastomosis were finished. And it will be retaind for 5-7days
194913|NCT02686567|Procedure|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
194914|NCT02686554|Other|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
194939|NCT02686333|Other|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
194940|NCT02686307|Procedure|ICD Implant|Implantation of an implantable cardioverter/defibrillator
194941|NCT02686294|Drug|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
194942|NCT02686294|Drug|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
194943|NCT02686281|Drug|GMC-252-L-Lysine|
194915|NCT02686541|Device|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.~Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).~During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
194916|NCT02686528|Other|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
194917|NCT02686528|Other|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
194918|NCT02686515|Device|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
194919|NCT02686515|Device|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
194920|NCT02686502|Behavioral|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
194921|NCT02686489|Other|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher & Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
194922|NCT02686489|Other|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
194923|NCT02686476|Drug|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
194924|NCT02686463|Procedure|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
194925|NCT02686463|Procedure|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
194926|NCT02686437|Other|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
194927|NCT02686411|Behavioral|Participant Questionnaires|"Participants complete 2 questionnaires about satisfaction and impression of care received in the PCU, how much distress experienced in past week, and level of comfort with being transferred to the PCU. Questionnaires take about 15 minutes to complete.~Two (2) weekdays after completion of first set of questionnaires, 2 questionnaires completed about overall satisfaction and impression of care received in the PCU, and how much distress experienced in the past few days. One (1) questionnaire asks comparison of care received with the palliative care consult, to the care received in the PCU. These questionnaires should also take about 15 minutes to complete."
194928|NCT02686411|Behavioral|Caregiver Questionnaires|"Caregiver completes questionnaire about their demographic information. It should take about 5-10 minutes to complete.~Caregiver then completes 2 questionnaires about their overall satisfaction and impression of care their family member or friend received in the PCU, how much distress experienced in past week, and level of comfort felt with family member/friend being transferred to the PCU. These questionnaires should take about 15 minutes to complete.~Two (2) weekdays after completion of first set of questionnaires, same questionnaires completed about overall satisfaction and impression of care their family member or friend received in the PCU and how much distress experienced in the past few days. One (1) questionnaire asks caregiver to compare the care their family member or friend received with the palliative care consult, to the care their family member/friend received in the PCU. These questionnaires should take also about 15 minutes to complete."
194929|NCT02686398|Biological|Fluad|
194930|NCT02686398|Biological|Agrippal|
194931|NCT02686385|Drug|Prednisolone|
194932|NCT02686385|Drug|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
194933|NCT02686372|Other|Biological: HBV antigen specific TCR redirected T cell|Subjects will receive escalating doses of HBV antigen specific TCR redirected T cell infusion.
194934|NCT02686359|Biological|sample|
194935|NCT02686346|Drug|Brentuximab Vedotin|"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
194945|NCT02686255|Other|complete blood count|complete blood count during follow up in the heart institute
194946|NCT02686242|Procedure|spinal anesthesia|bupivacaine injected by spinal puncture
194947|NCT02686242|Procedure|general anesthesia|general anesthesia with intubation
194948|NCT02686229|Other|no interventions|
194949|NCT02686216|Drug|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
194950|NCT02686203|Device|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).~The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
194951|NCT02686190|Other|Luxtherapy|
194952|NCT02686177|Drug|Liraglutide|
194953|NCT02686177|Drug|Metformin or sulfonylurea|
194954|NCT02686164|Drug|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
194955|NCT02686164|Drug|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
194956|NCT02686151|Drug|Letrozole|used after oocyte retrieval
194957|NCT02686151|Drug|Polygeline|used after oocyte retrieval
194958|NCT02686151|Drug|Sodium Chloride|used after oocyte retrieval
194959|NCT02686151|Drug|dexamethasone|used after oocyte retrieval
194960|NCT02686138|Drug|Tenapanor|
194961|NCT02686138|Drug|Placebo|
194962|NCT02686125|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
194963|NCT02686099|Device|SternaLock 360|Sternal closure with SternaLock 360
194964|NCT02686099|Device|Wire Cerclage|Sternal closure with standard wire cerclage
194965|NCT02686086|Device|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
194966|NCT02686086|Device|Standard hospital jet nebuliser|"The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications"
194967|NCT02686086|Drug|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
194968|NCT02686060|Device|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
194969|NCT02686047|Device|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
194970|NCT02686047|Device|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
194971|NCT02686034|Device|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
194972|NCT02686034|Device|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
194973|NCT02686021|Drug|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
194974|NCT02686021|Drug|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
194975|NCT02686021|Drug|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
194976|NCT02686008|Drug|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
194977|NCT02685995|Device|VectorFlow TDC|TDC insertion with VectorFlow will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
194978|NCT02685995|Device|Palindrome TDC|TDC insertion with Palindrome will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
195264|NCT02683837|Drug|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
194979|NCT02685982|Device|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.~In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
194980|NCT02685969|Procedure|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
194981|NCT02685956|Device|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
194982|NCT02685943|Behavioral|Psychotherapy|
194983|NCT02685930|Behavioral|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
194984|NCT02685917|Procedure|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
194985|NCT02685917|Procedure|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
194986|NCT02685904|Biological|ENIA11|
194987|NCT02685904|Biological|Placebo|
194988|NCT02685891|Other|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
194989|NCT02685891|Other|sham condition|in the sham condition, no tones will be played
194990|NCT02685865|Device|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
194991|NCT02685865|Device|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
194992|NCT02685852|Drug|Exenatide|Exenatide at a dose of 5 mcg
194993|NCT02685852|Drug|Acarbose|Acarbose at a dose of 25 mg
194994|NCT02685852|Drug|Placebo|Placebo
194995|NCT02685839|Device|Intelligent POWER Rehabilitation Cluster Machine|
194996|NCT02685839|Other|general physical therapy|
194997|NCT02685826|Drug|Durvalumab|single use vials administered via intravenous infusion
194998|NCT02685826|Drug|Lenalidomide|capsules for oral administration
194999|NCT02685826|Drug|Dexamethasone|tablets for oral administration
195000|NCT02685787|Behavioral|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
195001|NCT02685787|Behavioral|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.~Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
195002|NCT02685774|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
195003|NCT02685774|Drug|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
195004|NCT02685761|Procedure|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
195005|NCT02685761|Procedure|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
195006|NCT02685748|Drug|Aspirin|1000 mg pd in two doses
195007|NCT02685748|Drug|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
195008|NCT02685748|Drug|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
195009|NCT02685735|Drug|Gabapentin|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
195010|NCT02685735|Drug|Placebo|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
195011|NCT02685722|Biological|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
195012|NCT02685722|Other|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
195013|NCT02685709|Drug|Octreotide capsules|Octreotide capsules 40mg/day, 60mg/day, 80mg/day
195014|NCT02685709|Drug|Injectable Somatostatin Analogs (octreotide or lanreotide)|Octreotide - 10, 20, 30mg. Lanreotide 60,90, 120mg.
195015|NCT02685709|Drug|Cabergoline|Cabergoline - 3.5mg/week
195062|NCT02685397|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
195016|NCT02685696|Device|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
195017|NCT02685696|Device|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
195018|NCT02685683|Drug|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of >50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI <7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
195019|NCT02685670|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
195020|NCT02685670|Drug|Fludarabine|
195021|NCT02685670|Drug|Cyclophosphamide|
195022|NCT02685657|Drug|Drug: Selumetinib|
195023|NCT02685657|Drug|Doxorubicin|
195024|NCT02685657|Drug|Cyclophosphamide|
195025|NCT02685657|Drug|Docetaxel|
195026|NCT02685644|Procedure|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
195027|NCT02685631|Other|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
195028|NCT02685618|Drug|Iloprost|
195029|NCT02685618|Drug|Saline|
195030|NCT02685618|Device|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
195031|NCT02685618|Device|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
195032|NCT02685605|Procedure|Standard surgery (neuronavigation-guided)|
195033|NCT02685605|Radiation|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
195034|NCT02685605|Radiation|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
195035|NCT02685605|Drug|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
195036|NCT02685592|Drug|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
195037|NCT02685579|Other|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
195038|NCT02685566|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
195039|NCT02685566|Device|FFDM|FujiFilm Aspire Cristalle System
195040|NCT02685553|Device|NIR|Laparoscopic use of NIR
195041|NCT02685514|Device|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
195042|NCT02685501|Other|no intervention|
195043|NCT02685488|Device|Transcranial Ultrasound Power|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
195044|NCT02685488|Device|Transcranial Ultrasound Sham|"Transcranial ultrasound will be used without power for a sham condition."
195045|NCT02685475|Drug|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
195046|NCT02685462|Drug|Rosuvastatin|
195047|NCT02685462|Drug|Atorvastatin|
195048|NCT02685462|Drug|Simvastatin|
195049|NCT02685462|Drug|Digoxin|
195050|NCT02685462|Drug|Caffeine|
195051|NCT02685449|Drug|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
195052|NCT02685449|Drug|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
195053|NCT02685449|Drug|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
195054|NCT02685436|Drug|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
195055|NCT02685423|Behavioral|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
195056|NCT02685423|Behavioral|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
195057|NCT02685410|Other|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
195058|NCT02685397|Drug|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
195059|NCT02685397|Drug|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
195060|NCT02685397|Drug|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
195061|NCT02685397|Drug|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
195178|NCT02684435|Drug|Perflutren lipid microsphere|Dosing per approved package label
195063|NCT02685384|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
195064|NCT02685371|Behavioral|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
195065|NCT02685358|Behavioral|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
195066|NCT02685358|Behavioral|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
195067|NCT02685345|Drug|DS-8500a 25 mg|
195068|NCT02685345|Drug|DS-8500a 75 mg|
195069|NCT02685345|Drug|placebo|
195070|NCT02685332|Radiation|Stereotactic Radiation|Stereotactic Body Partial Breast irradiation Cohort 1: 22.5 Gy Cohort 2: 25 Gy Cohort 3: 27.5 Gy Cohort 4: 30 Gy
195071|NCT02685319|Procedure|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
195072|NCT02685306|Biological|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
195073|NCT02685306|Drug|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
195074|NCT02685293|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
195075|NCT02685293|Drug|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
195076|NCT02685280|Device|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
195077|NCT02685267|Drug|Docetaxel|
195078|NCT02685267|Drug|Enzalutamide|
195079|NCT02685267|Drug|Prednisone|
195080|NCT02685254|Behavioral|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
195081|NCT02685254|Other|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
195082|NCT02685228|Drug|Decitabine|decitabine 5mg/m2,d1-d5;
195083|NCT02685228|Drug|Gemcitabine|gemcitabine 1.0g/m2, d8,d15,d22
195084|NCT02685202|Device|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
195085|NCT02685189|Other|Previous exposure to stannsoporfin|No intervention in this protocol
195086|NCT02685176|Device|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)|A heater (STK Heatpac) will be used in the active warming arms of the study.
195087|NCT02685176|Other|No heat|No active heating provided post cooling
195088|NCT02685163|Other|Antioxidant ice-cream|Narutal Antioxidant ice-cream
195089|NCT02685163|Other|Control Ice-cream|Natural Control Ice-cream
195090|NCT02685150|Device|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
195091|NCT02685150|Drug|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
195092|NCT02685150|Other|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
195093|NCT02685137|Drug|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
195094|NCT02685137|Other|Sham Injection|nothing
195095|NCT02685124|Dietary Supplement|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
195096|NCT02685111|Drug|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
195097|NCT02685111|Drug|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
195098|NCT02685098|Biological|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2 and/or gender mismatched allogeneic MSCs above the site of amputation and into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective lower extremity major amputation at a randomized time of 3, 7, 14, or 21 days before surgery.
195099|NCT02685085|Drug|Misoprostol ( Prostaglandin E2)|
195100|NCT02685085|Device|Foley's catheter|
195101|NCT02685072|Drug|Progesterone (200 mgs BID)|Transdermal Nicotine Patch (TNP) + Progesterone
195102|NCT02685072|Drug|Placebo|TNP + Placebo
195103|NCT02685059|Drug|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
195104|NCT02685059|Drug|Placebo|"Placebo i.v. every 4 weeks~As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:~Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by~MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
195105|NCT02685059|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
195106|NCT02685059|Drug|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
195107|NCT02685059|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
195108|NCT02685046|Drug|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
195109|NCT02685033|Drug|Dalbavancin|
195110|NCT02685033|Drug|Comparator|
195111|NCT02685020|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
195112|NCT02685020|Biological|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
195113|NCT02685020|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
195114|NCT02685007|Other|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
195115|NCT02684994|Behavioral|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
195116|NCT02684968|Procedure|Colorectal surgery|
195117|NCT02684955|Device|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
195118|NCT02684955|Device|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
195119|NCT02684942|Drug|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
195120|NCT02684942|Drug|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
195121|NCT02684929|Dietary Supplement|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
195122|NCT02684916|Procedure|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.~The parents and the child are unaware of group allocation."
195123|NCT02684916|Procedure|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
195124|NCT02684903|Behavioral|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
195125|NCT02684877|Other|Questionnaire|
195126|NCT02684864|Other|Non-interventional|
195127|NCT02684851|Drug|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
195128|NCT02684851|Drug|Placebo|Placebo
195129|NCT02684825|Device|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
195130|NCT02684812|Drug|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
195131|NCT02684799|Drug|Cenicriviroc|
195132|NCT02684799|Drug|Omeprazole|
195133|NCT02684799|Drug|Famotidine|
195134|NCT02684786|Drug|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
195135|NCT02684786|Procedure|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
195179|NCT02684422|Other|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
195180|NCT02684409|Drug|PROT-CL-NP101-015.01|
195181|NCT02684396|Drug|TAK-648|TAK-648 Solution
195182|NCT02684396|Drug|TAK-648 Placebo|TAK-648 placebo-matching solution
195136|NCT02684786|Drug|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
195137|NCT02684773|Procedure|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
195138|NCT02684773|Procedure|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
195139|NCT02684760|Drug|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
195140|NCT02684747|Other|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
195141|NCT02684747|Other|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
195142|NCT02684721|Other|8-week home-based exercise programme|8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
195143|NCT02684708|Drug|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
195144|NCT02684708|Drug|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
195145|NCT02684695|Other|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
195146|NCT02684695|Other|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
195147|NCT02684682|Behavioral|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
195148|NCT02684682|Behavioral|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
195149|NCT02684682|Behavioral|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
195150|NCT02684669|Drug|Naloxone|active drug infusion
195151|NCT02684669|Drug|Normal saline|placebo comparator
195152|NCT02684656|Procedure|Hemodialysis|Hemodialysis >/=4h
195153|NCT02684656|Procedure|Hemodiafiltration|Hemodiafiltration >/=4h, > 20l convection
195154|NCT02684643|Other|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
195155|NCT02684643|Other|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
195156|NCT02684643|Other|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
195157|NCT02684630|Device|Trima Accel System|Platelet Apheresis Procedure
195158|NCT02684617|Biological|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35
195159|NCT02684617|Drug|dinaciclib|dinaciclib 7 mg/m^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35
195160|NCT02684591|Drug|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
195161|NCT02684591|Drug|Placebo|Placebo
195162|NCT02684578|Drug|Metformin|
195163|NCT02684565|Dietary Supplement|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
195164|NCT02684565|Dietary Supplement|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
195165|NCT02684552|Device|Non invasive ventilation|Training on treadmill with Non invasive ventilation
195166|NCT02684552|Device|Oxygen|Training on treadmill with oxygen
195167|NCT02684539|Device|tilt table Erigo®|tilting table with onset of syncope
195168|NCT02684526|Procedure|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
195169|NCT02684526|Procedure|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
195170|NCT02684513|Dietary Supplement|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
195171|NCT02684513|Dietary Supplement|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
195172|NCT02684500|Device|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
195173|NCT02684487|Drug|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
195174|NCT02684487|Drug|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
195175|NCT02684474|Biological|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
195176|NCT02684461|Drug|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
195177|NCT02684448|Procedure|Inguinal Hernia Repair|Inguinal (unilateral or bilateral) hernia repair
195183|NCT02684383|Biological|rDEN3∆30|10^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
195184|NCT02684383|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
195185|NCT02684370|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
195186|NCT02684370|Drug|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
195187|NCT02684370|Drug|ustekinumab|Ustekinumab administered by subcutaneous (SC) injection
195188|NCT02684370|Drug|placebo for ustekinumab|Placebo for ustekinumab administered by subcutaneous (SC) injection
195189|NCT02684357|Drug|risankizumab|Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
195190|NCT02684357|Drug|ustekinumab|Ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
195191|NCT02684357|Drug|placebo for risankizumab|Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
195192|NCT02684357|Drug|placebo for ustekinumab|Placebo for ustekinumab pre-filled syringe, administered by subcutaneous (SC) injection
195193|NCT02684344|Drug|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
195194|NCT02684344|Other|Education|Education about signs and symptoms of urinary retention
195195|NCT02684331|Other|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
195196|NCT02684331|Other|Echocardiography|Standard measurements and strain.
195197|NCT02684331|Other|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
195198|NCT02684318|Drug|PM01183 + olaparib|
195199|NCT02684305|Drug|Administration of Propess|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
195200|NCT02684305|Device|balloon|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
195201|NCT02684305|Drug|Intravenous oxytocin infusion|"History taking and physical examination including cervical length~Eligibility assessment~Explanation regarding the study protocol~Signed informed consent (at VAS<3)~Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.~Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
195202|NCT02684292|Biological|pembrolizumab|IV infusion
195203|NCT02684292|Biological|brentuximab vedotin|IV infusion
195204|NCT02684279|Drug|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
195205|NCT02684266|Drug|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
195206|NCT02684253|Drug|Nivolumab|
195207|NCT02684253|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
195208|NCT02684240|Drug|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
195209|NCT02684240|Other|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
195210|NCT02684227|Drug|Carboplatin|Given IV
195211|NCT02684227|Drug|Enzalutamide|Given PO
195212|NCT02684227|Other|Laboratory Biomarker Analysis|Correlative studies
195213|NCT02684227|Drug|Paclitaxel|Given IV
195214|NCT02684227|Other|Pharmacological Study|Correlative studies
195215|NCT02684214|Behavioral|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
195261|NCT02683850|Dietary Supplement|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
195216|NCT02684214|Behavioral|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
195217|NCT02684201|Device|Boston Scientific Stimulator Lead|A Boston Scientific PMA P030017 spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
195218|NCT02684188|Behavioral|Enhanced rural discharge and transition|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
195219|NCT02684175|Device|Remote CI Counseling|The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
195220|NCT02684175|Other|In-Person CI Counseling|The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
195221|NCT02684162|Biological|Donor Lymphocytes|Given IV
195222|NCT02684162|Drug|Guadecitabine|Given SC
195223|NCT02684162|Other|Laboratory Biomarker Analysis|Correlative studies
195224|NCT02684149|Procedure|relational touch|
195225|NCT02684136|Drug|suvorexant|suvorexant 20 mg taken before sleep
195226|NCT02684136|Drug|placebo|placebo taken before sleep
195227|NCT02684123|Drug|Apremilast|Subjects will get drug or placebo
195228|NCT02684123|Drug|Placebo|
195229|NCT02684097|Drug|Tralokinumab|All groups will receive study drug every two weeks for 24 weeks.
195230|NCT02684097|Drug|Placebo|Matching placebo given every two weeks for 24 weeks
195231|NCT02684084|Drug|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
195232|NCT02684084|Drug|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
195233|NCT02684071|Drug|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
195234|NCT02684071|Drug|topotecan|To be administered in conjunction with methotrexate
195235|NCT02684071|Drug|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
195236|NCT02684058|Drug|dabrafenib|dabrafenib oral, twice daily.
195237|NCT02684058|Drug|trametinib|trametinib oral, once daily.
195238|NCT02684058|Drug|Carboplatin with vincristine|Chemotherapy of carboplatin with vincristine - LGG only
195239|NCT02684032|Drug|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
195240|NCT02684032|Drug|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
195241|NCT02684032|Drug|Letrozole|Letrozole at 2.5 mg daily
195242|NCT02684032|Drug|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
195243|NCT02684019|Drug|Dexmedetomidine|added to propofol sedation
195244|NCT02684019|Drug|Magnesium Sulphate|added to propofol sedation
195245|NCT02684006|Drug|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
195246|NCT02684006|Drug|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
195247|NCT02684006|Drug|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
195248|NCT02683993|Device|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
195249|NCT02683980|Device|Lumenis Pulse P120H and Xpeeda side firing fiber|
195250|NCT02683967|Procedure|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
195251|NCT02683941|Drug|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression, death, or unacceptable toxicity
195252|NCT02683941|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
195253|NCT02683928|Biological|GBR 830|
195254|NCT02683928|Biological|Placebo|
195255|NCT02683915|Procedure|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
195256|NCT02683902|Device|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
195257|NCT02683902|Behavioral|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
195258|NCT02683902|Device|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
195259|NCT02683889|Drug|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
195260|NCT02683863|Drug|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
195262|NCT02683837|Drug|Remifentanil|
195263|NCT02683837|Device|Pupillometry|Pupillary diameter measured every 5 minutes
195265|NCT02683824|Diagnostic Test|Computed Tomography|Undergo CT scan
195266|NCT02683824|Other|Laboratory Biomarker Analysis|Correlative studies
195267|NCT02683824|Diagnostic Test|PET/MRI scan|Undergo PET/MRI scan
195268|NCT02683824|Drug|[18F]FP-R01-MG-F2|radioactive tracer
195269|NCT02683811|Behavioral|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
195270|NCT02683798|Dietary Supplement|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
195271|NCT02683798|Dietary Supplement|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
195272|NCT02683785|Drug|GSK3196165|GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
195273|NCT02683785|Drug|Placebo|Matching placebo will be administered as above.
195274|NCT02683772|Device|Astral|Astral ventilator
195275|NCT02683759|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)~Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
195276|NCT02683759|Drug|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
195277|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
195278|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
195279|NCT02683746|Drug|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
195280|NCT02683746|Drug|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
195281|NCT02683733|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
195282|NCT02683733|Drug|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
195283|NCT02683720|Dietary Supplement|ONS|randomized clinical trial involving different ONS strategies
195284|NCT02683707|Other|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
195285|NCT02683707|Drug|Fentanyl|IV peri-procedural analgesia
195286|NCT02683707|Drug|Lidocaine|Local Anesthetic
195287|NCT02683707|Drug|Midazolam|IV sedation
195288|NCT02683694|Device|iOCT|the number of subjects that can be peeled without dye are assessed
195289|NCT02683668|Combination Product|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
195290|NCT02683668|Combination Product|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
195291|NCT02683668|Combination Product|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
195292|NCT02683655|Drug|Apatinib|Apatinib 500mg qd p.o.
195293|NCT02683655|Drug|Apatinib|Apatinib 750mg qd p.o.
195294|NCT02683629|Biological|NTCELL Implantation|NTCELL Implantation
195295|NCT02683629|Other|Sham Surgery|Sham Surgery
195296|NCT02683616|Device|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
195297|NCT02683603|Drug|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
195298|NCT02683603|Drug|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
195299|NCT02683603|Drug|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
195300|NCT02683603|Drug|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
195301|NCT02683603|Drug|AS colistin and imipenem|IV imipenem 1 g three times per day.
195302|NCT02683603|Drug|IV colistin and imipenem|IV imipenem 1 g three times per day
195303|NCT02683590|Device|Ceramic Implant|The replacement of the sternum by a ceramic implant
195304|NCT02683577|Drug|telotristat etiprate|
195305|NCT02683564|Drug|BOW015|monoclonal antibody against TNF-alpha
195306|NCT02683564|Drug|Remicade|monoclonal antibody against TNF-alpha
195307|NCT02683551|Procedure|Sutureless Thyroidectomy|Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Device which will be used is decided according to current availability in the operating room. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
195308|NCT02683538|Device|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
195309|NCT02683525|Drug|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
195310|NCT02683512|Other|No intervention|This is an observational study that consists of data abstraction.
195380|NCT02682953|Drug|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
195311|NCT02683499|Procedure|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
195312|NCT02683486|Device|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
195313|NCT02683486|Device|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
195314|NCT02683460|Procedure|Patella resurfacing|
195315|NCT02683460|Procedure|Patella retention|
195316|NCT02683447|Other|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
195317|NCT02683434|Device|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
195318|NCT02683421|Drug|Tilmanocept|
195319|NCT02683408|Other|placebo|inactive placebo
195320|NCT02683408|Dietary Supplement|diosmiplex|diosmiplex is an FDA regulated medical food product
195321|NCT02683395|Drug|PLX51107|
195322|NCT02683382|Device|Moisturizing Eye Product in Liquid Formula|Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
195323|NCT02683369|Dietary Supplement|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~15 mg of Vitamin C~400 mcg of Folate~30 mcg Vitamin of B-12~26 mg of Iron~125 mg of Beet Root"
195324|NCT02683356|Other|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
195325|NCT02683356|Other|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
195326|NCT02683330|Behavioral|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
195327|NCT02683317|Dietary Supplement|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
195328|NCT02683317|Dietary Supplement|sunflower oil|Sunflower similar to the excipient used in experimental group
195329|NCT02683304|Biological|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
195330|NCT02683304|Device|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
195331|NCT02683291|Drug|sirolimus|
195332|NCT02683291|Drug|tacrolimus|
195333|NCT02683291|Drug|mycophenolate|
195334|NCT02683291|Drug|Prednisone|Prednisone 30mg/day
195335|NCT02683291|Drug|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
195336|NCT02683291|Drug|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
195337|NCT02683278|Behavioral|Cognitive-behavioral|Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
195338|NCT02683278|Behavioral|Mindfulness-acceptance|Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
195339|NCT02683278|Other|Pain Education|Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
195340|NCT02683265|Drug|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
195341|NCT02683265|Drug|Placebo|Placebo capsules
195342|NCT02683252|Other|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
195343|NCT02683239|Drug|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
195344|NCT02683239|Drug|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
195345|NCT02683226|Drug|Vipdomet|
195346|NCT02683226|Drug|Incresync|
195347|NCT02683213|Drug|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
195348|NCT02683213|Drug|Placebo|Matching placebo.
195349|NCT02683200|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
195350|NCT02683200|Radiation|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
195351|NCT02683187|Drug|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
195381|NCT02682953|Procedure|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
195568|NCT02681471|Device|bipolar resectoscope TURis|
195352|NCT02683187|Drug|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
195353|NCT02683174|Device|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
195354|NCT02683174|Biological|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
195355|NCT02683161|Drug|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
195356|NCT02683161|Behavioral|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
195357|NCT02683161|Behavioral|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
195358|NCT02683148|Drug|DHEA|
195359|NCT02683148|Other|FACT-67 validated survey|"Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2~7 questions with answers ranging from 0=Not At All to 4 = Very Much."
195360|NCT02683135|Behavioral|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
195361|NCT02683135|Behavioral|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
195362|NCT02683135|Behavioral|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning ~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
195363|NCT02683109|Drug|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
195364|NCT02683109|Drug|Placebo|
195365|NCT02683109|Drug|Tiotropium|
195366|NCT02683109|Drug|Olodaterol|
195367|NCT02683096|Other|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
195368|NCT02683083|Biological|[131I]-SGMIB Anti-HER2 VHH1|
195369|NCT02683070|Procedure|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
195370|NCT02683070|Drug|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
195371|NCT02683057|Other|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
195372|NCT02683044|Procedure|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
195373|NCT02683031|Other|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
195374|NCT02683018|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
195375|NCT02683018|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
195376|NCT02683005|Drug|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
195377|NCT02682992|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
195378|NCT02682979|Other|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
195379|NCT02682966|Radiation|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
195382|NCT02682953|Drug|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
195383|NCT02682940|Device|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
195384|NCT02682927|Drug|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
195385|NCT02682927|Drug|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
195386|NCT02682901|Drug|Cycloset|Cycloset 1.6 -3.2 mg/day
195387|NCT02682901|Drug|Placebo|Non-active placebo for cycloset
195388|NCT02682888|Behavioral|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
195389|NCT02682888|Drug|Oxytocin|intranasal administration of oxytocin
195390|NCT02682888|Drug|Placebo|intranasal administration of placebo
195391|NCT02682862|Drug|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
195392|NCT02682862|Drug|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
195393|NCT02682836|Behavioral|Walk with Ease|
195394|NCT02682823|Device|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
195395|NCT02682823|Drug|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3 (Days 0, 14, and 28). The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
195396|NCT02682810|Device|DNA PCR HIV diagnostic test|standard of care
195397|NCT02682810|Device|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
195398|NCT02682784|Drug|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
195399|NCT02682784|Drug|Placebo|
195400|NCT02682771|Device|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
195401|NCT02682771|Device|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
195402|NCT02682771|Procedure|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
195403|NCT02682758|Drug|Xenon|Wash-in of xenon for maintenance of anaesthesia
195404|NCT02682745|Drug|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
195405|NCT02682745|Drug|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
195406|NCT02682732|Procedure|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
195407|NCT02682719|Drug|LCZ696|
195408|NCT02682719|Drug|Valsartan|
195409|NCT02682719|Other|Placebo to LCZ696|
195410|NCT02682719|Other|Placebo to Valsartan|
195411|NCT02682693|Drug|Denosumab|Denosumab 120 mg every 4 weeks for 6 cycles
195412|NCT02682693|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
195413|NCT02682693|Drug|Epirubicin|Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
195414|NCT02682693|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
195415|NCT02682693|Drug|Carboplatin|Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
195416|NCT02682693|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
195417|NCT02682693|Drug|Pertuzumab|Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
195418|NCT02682680|Drug|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
195419|NCT02682680|Drug|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
195420|NCT02682654|Device|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
195421|NCT02682654|Device|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
195422|NCT02682641|Drug|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
195423|NCT02682641|Drug|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
195424|NCT02682628|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
195425|NCT02682602|Device|DePuy Synthes total hip arthroplasty|
195426|NCT02682602|Radiation|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
195427|NCT02682602|Radiation|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
195428|NCT02682589|Procedure|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
195531|NCT02681757|Device|Mepitel Ag|used for variable/experimental group under soft cast
195532|NCT02681744|Behavioral|Resistance Training|24-weeks of progressive strength training
195429|NCT02682589|Procedure|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
195430|NCT02682576|Procedure|Brachial artery ultrasound imaging|
195431|NCT02682563|Drug|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
195432|NCT02682563|Drug|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
195433|NCT02682550|Procedure|blood drawing|blood drawing
195434|NCT02682524|Drug|Pelubiprofen CR 45mg tab.|
195435|NCT02682524|Drug|Aceclofenac 100mg tab.|
195436|NCT02682511|Drug|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
195437|NCT02682511|Drug|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
195438|NCT02682498|Drug|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
195439|NCT02682498|Drug|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
195440|NCT02682485|Drug|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
195441|NCT02682485|Procedure|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
195442|NCT02682485|Drug|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
195443|NCT02682472|Other|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
195444|NCT02682459|Drug|Lisinopril|
195445|NCT02682446|Drug|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen [lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week]
195446|NCT02682433|Device|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
195447|NCT02682433|Device|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
195448|NCT02682420|Device|everlinQ endoAVF System|
195449|NCT02682407|Biological|OMS721|Biological: OMS721
195450|NCT02682407|Other|Vehicle (D5W)|5% Dextrose in water
195451|NCT02682381|Drug|Teduglutide 0.05mg/kg|0.05 mg/kg
195452|NCT02682381|Drug|Teduglutide 0.025 mg/kg|0.025 mg/kg
195453|NCT02682381|Other|Standard of Care|Observational cohort for the 24-week treatment period and 4 week follow-up.
195454|NCT02682368|Diagnostic Test|Point of Care Ultrasound by Surgeons (POCUSS)|"POCUSS-1. To identify the gallbladder and it's contents, complications and perform measurements, elicit sonographic Murphy.~POCUSS-2: To perform focused left lower quadrant sonography and identify bowel wall thickness, diverticulae, measure the colonic wall thickness, assess pericolic fat and detect possible complications; evaluate sensibility on graded compression."
195455|NCT02682368|Diagnostic Test|Radiology report|Radiologist report compared to the point of care ultrasound impression.
195456|NCT02682368|Procedure|Surgery-Intra-operative findings|Intra-operative findings compared to the previously performed point of care ultrasound.
195457|NCT02682342|Other|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
195458|NCT02682329|Other|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
195459|NCT02682329|Other|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
195460|NCT02682316|Other|dry gauze|
195461|NCT02682316|Device|The Prevena Incision Management System|
195462|NCT02682303|Device|Elastic Bandage (Idealplast C®)|"Elastic bandage~One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).~For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish"
195463|NCT02682303|Device|Pretape cramer® (non standarized tape)|"Pretape cramer® was used.~The individual is in supine position keeping the foot and ankle in a neutral position.~The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.~This is the only intervention carried out in this group."
195464|NCT02682290|Other|Expectoration and measurement of sputum rheological properties|
195465|NCT02682277|Device|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
195466|NCT02682277|Other|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
195467|NCT02682264|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
195468|NCT02682251|Other|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
195469|NCT02682238|Drug|BBI-4000, 15%|
195470|NCT02682238|Other|Vehicle gel|
195471|NCT02682225|Drug|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
195472|NCT02682225|Drug|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
195473|NCT02682225|Drug|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
195474|NCT02682225|Drug|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
195475|NCT02682225|Drug|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
195476|NCT02682212|Other|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
195477|NCT02682186|Drug|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.~Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.~In the other group, sterilization, sheating and US are performed but the needle is not inserted."
195478|NCT02682173|Other|MR Abdomen|
195479|NCT02682160|Other|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
195480|NCT02682147|Drug|Hypoxia administration study group|scan completed after 5 minutes of breathing in hypoxic air
195481|NCT02682147|Drug|Hyperoxia administration study group|scan completed after up to 15 minutes of breathing in hyperoxic air
195482|NCT02682147|Drug|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging.
195483|NCT02682134|Drug|xylocaine|First group were given xylocaine
195484|NCT02682134|Drug|Dexamethasone|Second group were given Dexamethasone
195485|NCT02682134|Drug|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
195486|NCT02682121|Drug|Metformin|Metformin 850 mg twice daily
195487|NCT02682121|Drug|Placebo|Placebo twice daily
195488|NCT02682108|Device|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
195489|NCT02682082|Procedure|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
195490|NCT02682082|Drug|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
195533|NCT02681718|Behavioral|Community health worker education|Diabetes self-management education by community health workers
195534|NCT02681718|Behavioral|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
195854|NCT02679326|Device|Therapeutic ultrasound|
195491|NCT02682069|Device|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
195492|NCT02682056|Device|Microneedle patch|The microneedle patch will collect interstitial fluid to be tested for glucose level. The microneedles are made from biocompatible polymers or metal. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
195493|NCT02682056|Device|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
195494|NCT02682056|Device|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
195495|NCT02682043|Device|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.~The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.~Parents will keep a log of what days they use the toy car, where and for how long."
195496|NCT02682030|Device|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
195497|NCT02682030|Device|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
195498|NCT02682017|Other|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
195499|NCT02682017|Other|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
195500|NCT02682004|Other|leptin, serotonin and adiponectin level|
195501|NCT02682004|Other|leptin,serotonin, adiponectin level|
195502|NCT02681991|Drug|Renamezin capsule|
195503|NCT02681978|Drug|Ivabradine|Ivabradine 5 mg twice daily
195504|NCT02681978|Drug|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
195505|NCT02681965|Behavioral|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
195506|NCT02681952|Drug|Renamezin capsule|
195507|NCT02681952|Drug|Kremezin granule|
195508|NCT02681939|Drug|Tulsi(Ocimum sanctum Linn.) capsules|
195509|NCT02681926|Procedure|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
195510|NCT02681913|Drug|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
195511|NCT02681900|Behavioral|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
195512|NCT02681900|Behavioral|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
195513|NCT02681887|Drug|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
195514|NCT02681887|Drug|Placebo|placebo tablet identical to circadian
195515|NCT02681874|Behavioral|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
195516|NCT02681874|Behavioral|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
195517|NCT02681861|Drug|ASP6294 Intravenous|Intravenous (IV)
195518|NCT02681861|Drug|ASP6294 Subcutaneous|Subcutaneous (SC)
195519|NCT02681861|Drug|Placebo Intravenous|Intravenous (IV)
195520|NCT02681861|Drug|Placebo Subcutaneous|Subcutaneous (SC)
195521|NCT02681848|Drug|Varenicline|Smoking cessation medication
195522|NCT02681848|Drug|Nicotine replacement therapy|
195523|NCT02681835|Device|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
195524|NCT02681835|Device|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
195525|NCT02681809|Drug|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
195526|NCT02681809|Drug|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
195527|NCT02681809|Drug|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
195528|NCT02681796|Drug|Bupivacaine|
195529|NCT02681783|Drug|aflibercept|Therapeutic/Pharmacological Classification: VEGF - Anti-neovascularization agent Route(s) of Administration: Intravitreal Injection Dosage Form: Solution 40 mg/ml Proposed Indication: Treatment of Pigment Epithelial Detachments (PEDs) associated with neovascular Age-related Macular Degeneration (nAMD), Central serous chorioretinopathy (CSR), and idiopathic Poplypoidal Choroidal Vasculopathy (iPCV).
195530|NCT02681757|Device|triple antibiotic ointment dressing|used for control group under soft cast
195567|NCT02681471|Device|monopolar resectoscope|
195535|NCT02681705|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
195536|NCT02681705|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
195537|NCT02681692|Device|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
195538|NCT02681679|Drug|0.1% bromfenac ophthalmic solution|
195539|NCT02681679|Procedure|femtosecond laser cataract surgery|
195540|NCT02681666|Dietary Supplement|Dietary intervention|Sessions will be spent with patients discussing the FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and how to use this diet to treat their Irritable Bowel Syndrome.
195541|NCT02681666|Behavioral|Irritable Bowel Syndrome eating awareness training|A type of meditation about their eating habits.
195542|NCT02681653|Drug|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
195543|NCT02681653|Drug|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
195544|NCT02681640|Other|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
195545|NCT02681640|Device|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
195546|NCT02681627|Other|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
195547|NCT02681627|Other|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
195548|NCT02681614|Device|Uronav guided biopsy|All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia. Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum.
195549|NCT02681614|Device|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
195550|NCT02681601|Dietary Supplement|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
195551|NCT02681601|Other|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
195552|NCT02681601|Dietary Supplement|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.~OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.~Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
195553|NCT02681588|Procedure|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
195554|NCT02681575|Behavioral|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
195555|NCT02681562|Drug|olaparib|
195556|NCT02681549|Drug|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4 (or alternative cycles if bevacizumab is held during these cycles). Three weeks constitutes one cycle.
195557|NCT02681536|Drug|Triptorelin|
195558|NCT02681536|Drug|Combined oral contraceptive pills|
195559|NCT02681536|Drug|HMG|
195560|NCT02681523|Drug|Eribulin|
195561|NCT02681510|Drug|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
195562|NCT02681510|Drug|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
195563|NCT02681510|Drug|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
195564|NCT02681484|Behavioral|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
195565|NCT02681471|Other|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
195566|NCT02681471|Other|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
195569|NCT02681458|Other|Direct Examination|It was an observational study and subjects received their routine treatment.
195570|NCT02681445|Device|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
195571|NCT02681432|Drug|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
195572|NCT02681432|Procedure|No HIPEC|Cytoreductive surgery without HIPEC
195573|NCT02681419|Procedure|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
195574|NCT02681419|Procedure|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
195575|NCT02681406|Behavioral|ACHESS|Smartphone based additions focused application, encouraging social support
195576|NCT02681406|Behavioral|TMC|Brief telephone monitoring and counseling
195577|NCT02681393|Behavioral|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
195578|NCT02681393|Behavioral|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
195579|NCT02681380|Other|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
195580|NCT02681380|Other|Control group|No session will be planned for the participants.
195581|NCT02681367|Other|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
195582|NCT02681354|Other|Biorescue training|
195583|NCT02681328|Other|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
195584|NCT02681328|Other|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
195585|NCT02681328|Other|Afirma GSC|Afirma GSC molecular test on collected thyroid tissue
195586|NCT02681328|Other|ThyroSeq v.3|ThyroSeq v.3 molecular test on collected thyroid tissue
195587|NCT02681315|Device|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
195588|NCT02681315|Device|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
195589|NCT02681302|Drug|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
195590|NCT02681302|Drug|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
195591|NCT02681289|Other|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
195592|NCT02681276|Procedure|Irrigation with 3% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
195593|NCT02681276|Procedure|Irrigation with 0.5% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
195594|NCT02681263|Drug|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
195595|NCT02681250|Procedure|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
195596|NCT02681250|Procedure|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
195597|NCT02681237|Drug|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
195598|NCT02681237|Drug|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
195599|NCT02681224|Other|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
195600|NCT02681224|Other|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
195601|NCT02681224|Other|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
195602|NCT02681224|Other|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
195603|NCT02681211|Other|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
195604|NCT02681211|Drug|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
195605|NCT02681211|Drug|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
195606|NCT02681211|Drug|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
195607|NCT02681211|Drug|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:~Ketorolac 0.5mg/kg, max 30mg~Metoclopramide 0.1 mg/kg, max 10mg~Diphenhydramine 1mg/kg, max 50mg~Normal saline fluid bolus 20mL/kg, max 1000mL"
195608|NCT02681198|Drug|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
195609|NCT02681198|Drug|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
195610|NCT02681185|Other|Virtual Care|"Virtual Care consists of the following services and resources:~Have a virtual consult through online methods or telephone with one of the study endocrinologists~Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods~Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic~Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
195611|NCT02681185|Other|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
195612|NCT02681172|Drug|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
195613|NCT02681172|Procedure|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
195614|NCT02681146|Other|Multimodal intervention|Educational advice + physiotherapist treatment
195615|NCT02681133|Other|Epidemiological study Survey|
195616|NCT02681120|Procedure|Biopsy|
195617|NCT02681120|Procedure|Blood draw|
195618|NCT02681120|Procedure|Mammogram|
195619|NCT02681120|Procedure|MRI|
195620|NCT02681107|Radiation|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
195621|NCT02681094|Drug|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
195622|NCT02681094|Drug|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
195623|NCT02681094|Drug|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
195624|NCT02681094|Drug|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
195625|NCT02681081|Other|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
195626|NCT02681081|Other|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
195627|NCT02681081|Other|Control|Normal food intake
195628|NCT02681068|Other|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
195629|NCT02681055|Drug|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
195630|NCT02681042|Procedure|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
195631|NCT02681042|Device|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
195632|NCT02681029|Procedure|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
195633|NCT02681029|Procedure|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
195634|NCT02681016|Device|"DES Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
195635|NCT02681016|Device|"DES Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
195636|NCT02681016|Procedure|Coronary angioplasty|
195637|NCT02680990|Behavioral|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
195638|NCT02680990|Other|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
195639|NCT02680977|Other|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
195640|NCT02680977|Other|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
195705|NCT02680548|Drug|4mg/cc methylprednisolone acetate injectable suspension USP|
195641|NCT02680977|Other|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
195642|NCT02680977|Drug|LD+DDCI|Levodopa plus Benserazide
195643|NCT02680977|Drug|LD-DDCI|Levodopa without any DDCI
195644|NCT02680977|Other|Placebo|Groundnuts powder
195645|NCT02680951|Drug|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
195646|NCT02680951|Drug|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
195647|NCT02680951|Drug|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses~Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
195648|NCT02680951|Drug|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses~Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
195649|NCT02680951|Drug|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.~Cytarabine dose defined by age:~30 mg for patients age 1 - 1.99~50 mg for patients age 2 - 2.99~70 mg for patients ≥3 years of age~The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
195650|NCT02680938|Drug|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~The duration of the third stage of labor by stopwatch.~Hemoglobin (Hb) difference before and 12 h after delivery.~The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
195651|NCT02680938|Drug|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.~- The two groups will be compared in the following terms:~The duration of the third stage of labor by stopwatch.~Hemoglobin (Hb) difference before and 12 h after delivery.~The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
195652|NCT02680925|Procedure|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
195653|NCT02680925|Procedure|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
195654|NCT02680912|Device|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
195655|NCT02680912|Device|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
195656|NCT02680899|Behavioral|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
195657|NCT02680886|Device|Novosyn® Quick|Skin closure
195658|NCT02680873|Other|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
195659|NCT02680847|Drug|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
195660|NCT02680834|Device|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
195661|NCT02680834|Device|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
195662|NCT02680821|Procedure|ALL reconstruction (Anterolateral ligament)|
195663|NCT02680821|Procedure|ACL revision (Anterior cruciate ligament )|
195664|NCT02680808|Drug|Midazolam with F901318|Pharmacokinetics of midazolam with F901318
195665|NCT02680795|Drug|Belinostat IV|"Cohort A:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort B:~Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion.~Cohort C:~Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
195666|NCT02680782|Drug|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
195667|NCT02680769|Dietary Supplement|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
195668|NCT02680769|Other|Placebo|This group will take a placebo
195669|NCT02680756|Drug|Ferric Maltol|
195670|NCT02680756|Drug|Ferric Carboxy Maltose|
195671|NCT02680743|Other|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
195672|NCT02680730|Behavioral|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
195673|NCT02680717|Drug|Clobetasol|ointment, twice daily (alternating weeks)
195674|NCT02680717|Drug|Calcipotriene|ointment, twice daily
195675|NCT02680717|Drug|Tacrolimus|ointment, 0.1%, twice daily
195676|NCT02680704|Other|PEEP titrated mechanical ventilation|Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set > 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
195677|NCT02680691|Other|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
195678|NCT02680691|Other|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
195679|NCT02680678|Other|Colloid Preload|preload infusion
195680|NCT02680678|Other|colloid co-load|co-load infusion
195681|NCT02680678|Other|Crystalloid preload|preload infusion
195682|NCT02680678|Other|Crystalloid Co-load|co-load infusion
195683|NCT02680639|Device|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
195684|NCT02680626|Drug|Magnesium Sulfate|Given via transversus abdominis plane block
195685|NCT02680626|Drug|Ropivacaine|Given via transversus abdominis plane block
195686|NCT02680613|Behavioral|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
195687|NCT02680613|Behavioral|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
195688|NCT02680600|Drug|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
195689|NCT02680600|Other|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
195690|NCT02680600|Other|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
195691|NCT02680600|Other|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
195692|NCT02680600|Other|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
195693|NCT02680600|Other|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
195694|NCT02680600|Other|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
195695|NCT02680587|Radiation|SBRT|SBRT (1-5 fractions) will be administered.
195696|NCT02680587|Drug|DCFPyL-PET/MRI or -PT/CT|Estimate the proportion of DCFPyL-PET/MRI or -PET/CT positive sites that are positive for new or progressive metastatic disease by bone scan at 6-months from SBRT and vice versa
195697|NCT02680587|Other|Observational (no SBRT)|These patient will not receive SBRT. They will be observed.
195698|NCT02680574|Drug|vadadustat|oral tablet
195699|NCT02680574|Drug|darbepoetin alfa|Subcutaneous
195700|NCT02680561|Drug|Fluticasone Propionate MDPI|
195701|NCT02680561|Drug|Fluticasone Propionate/Salmeterol MDPI|
195702|NCT02680561|Drug|Fluticasone propionate/salmeterol|
195703|NCT02680548|Drug|0.9% saline|
195704|NCT02680548|Drug|0.25% bupivacaine hydrochloride injectable suspension USP|
195706|NCT02680535|Device|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
195707|NCT02680522|Other|Exercise|exercise training with virtual reality in videogame
195708|NCT02680509|Procedure|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
195709|NCT02680496|Device|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
195710|NCT02680496|Other|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
195711|NCT02680496|Other|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
195712|NCT02680470|Device|Virtual observed therapy|Virtual Observation of participants taking their medication
195713|NCT02680457|Drug|Insulin Degludec|10 IU SC every 24 hours for 6 days
195714|NCT02680457|Drug|Insulin Glargine|10 IU SC every 24 hours for 6 days
195715|NCT02680444|Behavioral|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
195716|NCT02680444|Behavioral|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
195717|NCT02680444|Behavioral|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
195718|NCT02680431|Other|Blood sample|10 mL venous blood sample for analysis of plasma
195719|NCT02680418|Drug|FDL169|
195720|NCT02680405|Procedure|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
195721|NCT02680405|Procedure|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
195722|NCT02680405|Procedure|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
195723|NCT02680392|Procedure|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.~The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.~The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
195724|NCT02680392|Drug|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.~To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
195725|NCT02680379|Drug|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
195726|NCT02680379|Drug|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
195727|NCT02680366|Device|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
195728|NCT02680366|Device|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
195729|NCT02680353|Procedure|Bilateral superficial cervical plexus block|A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
195730|NCT02680340|Procedure|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
195731|NCT02680314|Drug|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
195732|NCT02680301|Drug|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
195733|NCT02680301|Drug|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
195734|NCT02680288|Drug|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
195735|NCT02680288|Drug|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
195736|NCT02680288|Other|Oral Placebo|Oral inert treatment
195737|NCT02680275|Drug|Dead Sea Peloid Gel|intravaginally
195738|NCT02680262|Behavioral|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
195739|NCT02680262|Behavioral|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.~The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
195740|NCT02680262|Behavioral|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
195741|NCT02680249|Drug|CTP-656|
195742|NCT02680236|Other|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use~At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
195743|NCT02680223|Device|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
195744|NCT02680223|Device|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
195745|NCT02680210|Other|Questionnaires and cognitive measures|
195746|NCT02680197|Drug|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
195747|NCT02680184|Drug|CMP-001|CMP-001 will be administered as per the dose and schedule specified in the respective arms.
195748|NCT02680184|Drug|Pembrolizumab|Pembrolizumab will be administered as per the schedule specified in the respective arms.
195749|NCT02680171|Behavioral|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
195750|NCT02680171|Other|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
195751|NCT02680158|Device|Oculeve Intranasal|Oculeve device, intranasal (test) application for approximately 3 minutes.
195752|NCT02680158|Device|Sham|Sham device (control), intranasal application for approximately 3 minutes.
195753|NCT02680158|Device|Oculeve Extranasal|Oculeve device, extranasal (control) application for approximately 3 minutes.
195754|NCT02680145|Device|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
195755|NCT02680132|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
195756|NCT02680132|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
195757|NCT02680119|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
195758|NCT02680119|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
195759|NCT02680106|Device|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous dressing is thus created.
195760|NCT02680106|Device|JELONET|The patient's DSW will be dressed by JELONET
195761|NCT02680093|Other|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.~additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
195762|NCT02680080|Drug|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
195763|NCT02680080|Dietary Supplement|Grapefruit group|one liter of fresh pink-grapefruit juice
195764|NCT02680067|Drug|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
195765|NCT02680067|Device|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
195766|NCT02680054|Drug|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
195767|NCT02680041|Drug|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
195768|NCT02680028|Device|targon pft nail|
195769|NCT02680015|Behavioral|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
195770|NCT02680002|Biological|7.5 mcg H5N1 (stored as monobulk)|
195771|NCT02680002|Biological|15 mcg H5N1 (stored as monobulk)|
195772|NCT02680002|Biological|90 mcg H5N1 (stored as monobulk)|
195773|NCT02680002|Biological|90 mcg H5N1 (stored in vials)|
195774|NCT02680002|Other|MF59|
195775|NCT02680002|Other|MF59 (stored as monobulk)|
195776|NCT02679989|Behavioral|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
195777|NCT02679989|Behavioral|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
195778|NCT02679976|Device|etafilcon A|Marketed Multifocal Contact Lens
195779|NCT02679963|Drug|Olaparib|
195780|NCT02679963|Drug|Placebo|
195781|NCT02679950|Genetic|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
195782|NCT02679937|Behavioral|Fit4Duty|Small (<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
195783|NCT02679937|Other|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
195784|NCT02679924|Device|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
195785|NCT02679924|Other|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
195786|NCT02679911|Drug|Loceryl NL|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
195787|NCT02679911|Drug|Ciclopirox NL|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
195788|NCT02679898|Other|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
195789|NCT02679898|Other|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
195790|NCT02679859|Other|BNP guided medical therapy optimisation|
195791|NCT02679846|Other|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
195792|NCT02679833|Dietary Supplement|Placebo|Toothpaste not containing the vitamin.
195793|NCT02679833|Dietary Supplement|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
195794|NCT02679820|Device|Copper T intrauterine device|
195795|NCT02679807|Biological|Bifidobacterium animalis subsp. lactis Bl-04|
195796|NCT02679807|Other|sucrose|
195797|NCT02679794|Behavioral|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
195798|NCT02679794|Behavioral|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
195799|NCT02679781|Drug|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
195800|NCT02679781|Drug|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
195801|NCT02679768|Behavioral|Circadian Reinforcement Therapy|Circadian reinforcement therapy plus electronical monitoring. Circadian reinforcement therapy is a specialized psychoeducation working with strengthening of circadian rhythms.
195802|NCT02679768|Behavioral|Standard treatment|Standard treatment plus electronical monitoring
195803|NCT02679755|Drug|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
195804|NCT02679755|Drug|Letrozole|2.5 mg/d tablets orally on a continuous regimen
195805|NCT02679742|Dietary Supplement|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
195806|NCT02679742|Dietary Supplement|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
195807|NCT02679729|Drug|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
195808|NCT02679729|Drug|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
195809|NCT02679729|Other|Placebo|inactive substance
195810|NCT02679716|Other|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
195811|NCT02679703|Device|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
195812|NCT02679703|Device|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
195852|NCT02679339|Drug|CNTX-2022 (lidocaine gel, 40%)|
195853|NCT02679339|Drug|Placebo|
195813|NCT02679703|Other|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
195814|NCT02679690|Behavioral|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
195815|NCT02679690|Behavioral|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
195816|NCT02679677|Device|Whole Body Vibration|The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
195817|NCT02679664|Drug|Rosuvastatin|20 mg tablet of rosuvastatin
195818|NCT02679651|Other|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
195819|NCT02679651|Other|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
195820|NCT02679651|Other|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
195821|NCT02679638|Other|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
195822|NCT02679638|Other|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
195823|NCT02679625|Device|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
195824|NCT02679599|Other|B-MOBILE-CARDIAC smartphone application|
195825|NCT02679599|Behavioral|Cardiac rehabilitation as usual|
195826|NCT02679586|Device|Diffusion weighted MRI|
195827|NCT02679573|Drug|Delafloxacin|Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
195828|NCT02679573|Drug|Moxifloxacin|Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
195829|NCT02679573|Drug|Linezolid|Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
195830|NCT02679560|Drug|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
195831|NCT02679560|Drug|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
195832|NCT02679547|Other|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
195833|NCT02679534|Other|hand massage|
195834|NCT02679534|Other|hand holding|
195835|NCT02679534|Other|application of unscented hypoallergenic cream|
195836|NCT02679534|Other|environmental adjustments|
195837|NCT02679521|Device|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
195838|NCT02679521|Device|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
195839|NCT02679508|Drug|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
195840|NCT02679508|Drug|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
195841|NCT02679495|Behavioral|Active measures of lifestyle modification|
195842|NCT02679469|Drug|nalmefene hydrochloride 10 mg|
195843|NCT02679456|Drug|SCY-078|
195844|NCT02679456|Drug|Fluconazole|
195845|NCT02679443|Dietary Supplement|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
195846|NCT02679430|Device|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
195847|NCT02679417|Behavioral|exercise|12 weeks of aerobic or resistant exercise
195848|NCT02679378|Device|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
195849|NCT02679365|Procedure|lower segment cesarean section and double lock closure of rectus sheath|
195850|NCT02679365|Procedure|lower segment cesarean section and continuous non-locking closure of rectus sheath|
195851|NCT02679352|Device|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
195855|NCT02679313|Device|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
195856|NCT02679300|Other|Virtual reality exercise group|
195857|NCT02679300|Other|Conventional exercise group (control group)|
195858|NCT02679287|Device|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
195859|NCT02679274|Drug|Placebo|Intermittent intramuscular injections of saline (males and females).
195860|NCT02679274|Drug|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
195861|NCT02679261|Drug|Atorvastatin|Oral administration atorvastatin 20 mg per day
195862|NCT02679261|Drug|Placebo|Oral administration placebo
195863|NCT02679248|Dietary Supplement|Neo40 Daily®|
195864|NCT02679248|Dietary Supplement|Placebo|
195865|NCT02679235|Drug|Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
195866|NCT02679222|Dietary Supplement|Supplementation|coconut oil and MCT oils (60-40, tricaprylin and triheptanoate)
195867|NCT02679209|Biological|Demineralized bone matrix in putty form|it is a type of bone graft from human cadavers.
195868|NCT02679209|Biological|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
195869|NCT02679196|Drug|KA2237|PI3 Kinase p110β/δ inhibitor
195870|NCT02679183|Dietary Supplement|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
195871|NCT02679183|Other|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
195872|NCT02679170|Drug|Crizotinib|Treatment with crizotinib following routine clinical practice
195873|NCT02679144|Drug|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study.
195874|NCT02679131|Drug|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
195875|NCT02679118|Device|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
195876|NCT02679105|Drug|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
195877|NCT02679105|Drug|ALK diluent|0,3% human albumin
195878|NCT02679092|Drug|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
195879|NCT02679092|Drug|Mifepristone|200 mg PO on the day prior to D&E
195880|NCT02679092|Device|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
195881|NCT02679079|Drug|NBI-98854|
195882|NCT02679079|Drug|Placebo|
195883|NCT02679066|Device|Sugar-tong splint|Plaster immobilization including the elbow
195884|NCT02679066|Device|Short forearm cast|Fiberglass immobilization with elbow free
195885|NCT02679053|Behavioral|Aerobic exercise|
195886|NCT02679053|Behavioral|Placebo control|
195887|NCT02679040|Procedure|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
195888|NCT02679040|Drug|Chemotherapy|Chemotherapy treatment
195889|NCT02679040|Radiation|Radiation therapy|Radiation therapy
195890|NCT02679027|Other|Protrude tongue maximally and upward (PTMU)|The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
195891|NCT02679027|Other|Protrude tongue maximally and downward (PTMD)|The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
195892|NCT02679014|Drug|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
195893|NCT02679014|Drug|RO5459072|With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
195894|NCT02679001|Drug|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
195895|NCT02678988|Device|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter [mg/mL]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
195896|NCT02678988|Device|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
195897|NCT02678988|Drug|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
195898|NCT02678975|Drug|Disulfiram|Disulfiram 400 mg daily
195899|NCT02678975|Dietary Supplement|Copper|nutritional supplement with copper, 2 mg daily
195900|NCT02678975|Drug|Alkylating Agents|Alkylating antineoplastic agent
195901|NCT02678962|Device|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
196013|NCT02678182|Drug|Rucaparib|600mg PO twice daily
195902|NCT02678962|Device|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
195903|NCT02678962|Device|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
195904|NCT02678962|Device|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
195905|NCT02678962|Device|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
195906|NCT02678962|Device|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
195907|NCT02678949|Drug|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
195908|NCT02678949|Drug|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
195909|NCT02678949|Drug|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
195910|NCT02678936|Biological|PRP|Application of platelet-rich plasma during surgery
195911|NCT02678923|Drug|MDCO-216|
195912|NCT02678923|Drug|Placebo|
195913|NCT02678910|Procedure|Ovarian Cryopreservation|The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
195914|NCT02678897|Drug|Oxynorm on-demand|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
195915|NCT02678897|Drug|Oxynorm via PCA|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)~If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.~Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
195916|NCT02678884|Drug|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
195917|NCT02678871|Device|Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)
195918|NCT02678871|Device|WATCHMAN|LAA closure with the WATCHMAN device
195919|NCT02678858|Behavioral|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
195920|NCT02678858|Behavioral|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
195921|NCT02678845|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
195922|NCT02678819|Device|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
195923|NCT02678806|Radiation|Postoperative radiotherapy|The radiotherapy group received prophylactic radiotherapy 1 month after operation. All the patients in the experimental group were treated with 6 to 8 MV X-ray, intensity-modulated irradiation (IMRT) technique, which was divided into 4-5 fields, 2Gy/25 times. 5f/W, total dose 50Gy
195967|NCT02678455|Biological|TV005 vaccine|Delivered by subcutaneous injection; contains 10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31, and 10^3 PFU of rDEN4Δ30.
195968|NCT02678455|Biological|Placebo|Delivered by subcutaneous injection
196154|NCT02677220|Device|CI532 cochlear implant|
195924|NCT02678806|Drug|Postoperative TACE|In the intervention group, TACE was performed in January and March after operation. The femoral artery puncture was performed by Seldinger method, and the cannula was intubated to the hepatic artery by DSA. Then, 50 mg of lobaplatin plus 4 mg of raltitrexed was injected into the vascular artery. The embolic agent was selected as 38.0. % super liquefied iodine solution and / or gelatin sponge particles, the dose is maintained at 5 ~ 20ml. At the end of treatment, a DSA examination again confirmed that the tumor was completely occluded.
195925|NCT02678793|Drug|CNTX-4975|
195926|NCT02678780|Drug|Lenvatinib|
195927|NCT02678767|Drug|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
195928|NCT02678754|Other|No intervention required, purely observational|
195929|NCT02678741|Drug|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
195930|NCT02678728|Drug|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion until 12 hrs of aortic cross clamp off
195931|NCT02678728|Drug|normal saline|IV loading and infusion of same volume of normal saline after induction until 12 hrs of aortic cross clamp off
195932|NCT02678715|Device|Solubrux®|prefabricated device adaptable by temperature
195933|NCT02678715|Device|Customized Appliance|customized device fabricated in the dental laboratory
195934|NCT02678715|Device|Somatics®|standard device
195935|NCT02678702|Behavioral|CBT-I|CBT-I
195936|NCT02678702|Behavioral|Treatment as usual|Treatment as usual
195937|NCT02678689|Biological|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
195938|NCT02678689|Device|Intraventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
195939|NCT02678676|Other|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
195940|NCT02678676|Other|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
195941|NCT02678663|Procedure|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
195942|NCT02678663|Procedure|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
195943|NCT02678650|Drug|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
195944|NCT02678650|Drug|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
195945|NCT02678637|Other|MRI and muscle dynamometer|
195946|NCT02678624|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
195947|NCT02678611|Dietary Supplement|Basis 250|
195948|NCT02678611|Dietary Supplement|Basis 500|
195949|NCT02678611|Dietary Supplement|Placebo|
195950|NCT02678598|Drug|Micafungin|Intravenous
195951|NCT02678585|Drug|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
195952|NCT02678585|Drug|Lidocaine|53 patients received intravenous regional lidocaine
195953|NCT02678572|Combination Product|Melphalan/HDS|Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
195954|NCT02678559|Other|tee measurement|
195955|NCT02678559|Other|flotrac measurement|
195956|NCT02678559|Other|clearsight measurement|
195957|NCT02678546|Other|Other|case review of diagnosed disease
195958|NCT02678533|Drug|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
195959|NCT02678533|Drug|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
195960|NCT02678520|Radiation|3-D Conformal Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
195961|NCT02678520|Radiation|Intensity Modulated Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.~The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
195962|NCT02678520|Drug|Casodex, Zoladex , Lupron|"Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.~Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.~Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months."
195963|NCT02678507|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
195964|NCT02678494|Other|Neurofeedback training|
195965|NCT02678481|Device|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
195966|NCT02678481|Device|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
196012|NCT02678182|Drug|Trastuzumab|6mg/kg on day 1 cycle every 21 days
195969|NCT02678442|Device|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
195970|NCT02678442|Device|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
195971|NCT02678429|Device|Change DBS programming|Patient will change thier settings to move from one group to the other to trial the other DBS settings
195972|NCT02678416|Drug|IV Acetaminophen|IV formulation
195973|NCT02678416|Drug|IV Morphine|IV formulation
195974|NCT02678416|Other|Placebo tablet|tablet
195975|NCT02678416|Drug|Acetaminophen tablets|oral formulation
195976|NCT02678416|Other|IV Placebo|IV formulation
195977|NCT02678403|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
195978|NCT02678403|Device|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
195979|NCT02678390|Dietary Supplement|MCT supplement|30 g of MCT per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.
195980|NCT02678390|Dietary Supplement|MCT supplement + physical exercise|30 g of MCT per day in combination with 30 minutes of aerobic exercise (70% to 80% HRMax) per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.
195981|NCT02678377|Drug|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
195982|NCT02678377|Drug|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
195983|NCT02678364|Dietary Supplement|Control eggs|Control eggs containing no additional vitamin D beyond norm
195984|NCT02678364|Dietary Supplement|Vitamin D3 eggs|Vitamin D3-biofortified eggs
195985|NCT02678364|Dietary Supplement|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
195986|NCT02678351|Drug|gallium Ga 68-PSMA|Undergo gallium Ga 68-PSMA PET/MRI
195987|NCT02678351|Procedure|Magnetic Resonance Imaging|Undergo gallium Ga 68-PSMA PET/MRI
195988|NCT02678351|Procedure|Positron Emission Tomography|Undergo gallium Ga 68-PSMA PET/MRI
195989|NCT02678338|Drug|Hu5F9-G4|
195990|NCT02678325|Other|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
195991|NCT02678325|Other|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
195992|NCT02678312|Drug|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), 50 mg, 100 mg, 200 mg dosage strengths
195993|NCT02678312|Drug|Enalapril|Enalapril will be open label in Part 1 and double blind in Part 2
195994|NCT02678312|Drug|Placebo of LCZ696|
195995|NCT02678312|Drug|Placebo of Enalapril|
195996|NCT02678299|Drug|PREBEN|
195997|NCT02678286|Drug|N1539|
195998|NCT02678286|Drug|Intravenous Placebo|
195999|NCT02678273|Other|Intervention group|"The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents~."
196000|NCT02678260|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
196001|NCT02678247|Device|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
196002|NCT02678247|Device|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
196003|NCT02678234|Drug|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
196004|NCT02678221|Drug|Sildenafil citrate|
196005|NCT02678221|Drug|Aspirin|
196006|NCT02678208|Drug|Tranexamic Acid|
196007|NCT02678208|Drug|5% glucose|
196008|NCT02678195|Drug|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
196009|NCT02678195|Drug|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
196010|NCT02678182|Drug|Capecitabine|1250 mg/m2/day, 21 day cycle
196011|NCT02678182|Drug|MEDI4736|IV treatment on days 1&15 of 28 day cycle
196014|NCT02678169|Device|Penumbra Aspiration System|Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
196015|NCT02678156|Device|Lyoplant Onlay|
196016|NCT02678143|Drug|Alemtuzumab|
196017|NCT02678143|Drug|Cyclophosphamide|
196018|NCT02678143|Drug|Mycophenolate mofetil|
196019|NCT02678143|Drug|Sirolimus|
196020|NCT02678143|Drug|Fludarabine|
196021|NCT02678143|Radiation|Total body irradiation|
196022|NCT02678143|Procedure|Hematopoietic stem cell transplant|
196023|NCT02678130|Device|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
196024|NCT02678130|Device|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
196025|NCT02678117|Drug|Pregabalin & Placebo|
196026|NCT02678117|Drug|Magnesium sulphate & Placebo|
196027|NCT02678117|Drug|Pregabalin & Magnesium sulphate|
196028|NCT02678117|Drug|Placebo|
196029|NCT02678104|Procedure|Tooth extraction|Tooth removal
196030|NCT02678104|Drug|Chlorhexidine mouth wash|Chlorhexidine mouth wash
196031|NCT02678104|Drug|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
196032|NCT02678091|Device|Ultrasound exam with Doppler|Ultrasound exam of the orbit
196033|NCT02678078|Procedure|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
196034|NCT02678065|Device|InPact Admiral DEB|
196035|NCT02678052|Drug|Vedolizumab|Vedolizumab exposure
196036|NCT02678052|Biological|Other Biological Agent|Other Biological Agent exposure
196037|NCT02678039|Device|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
196038|NCT02678039|Procedure|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
196039|NCT02678026|Device|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
196040|NCT02678013|Procedure|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
196041|NCT02678013|Procedure|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
196042|NCT02678000|Drug|LHW090|LHW090 is orally administered
196043|NCT02678000|Drug|Placebo|Matching placebo of LHW090
196044|NCT02677987|Device|Intervention systematic light exposure|
196045|NCT02677987|Device|Comparison systematic light exposure|
196046|NCT02677974|Device|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
196047|NCT02677961|Other|Observation|
196048|NCT02677948|Drug|Pacritinib|
196049|NCT02677948|Drug|Ibrutinib|
196050|NCT02677935|Other|Community education programs|
196051|NCT02677922|Drug|AG-120|
196052|NCT02677922|Drug|Azacitidine|
196053|NCT02677922|Drug|AG-221|
196054|NCT02677909|Device|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
196055|NCT02677896|Drug|Enzalutamide|Oral
196056|NCT02677896|Drug|Placebo|Oral
196057|NCT02677883|Other|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
196058|NCT02677883|Other|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
196059|NCT02677870|Drug|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
196060|NCT02677870|Other|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
196061|NCT02677857|Behavioral|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
196062|NCT02677844|Drug|Abemaciclib|Administered orally
196063|NCT02677844|Drug|Placebo|Administered orally
196064|NCT02677844|Drug|Loperamide|Administered orally
196065|NCT02677805|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
196066|NCT02677805|Drug|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
196067|NCT02677792|Behavioral|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
196068|NCT02677779|Procedure|CO2 laser|Single session of CO2 laser debridement
196069|NCT02677779|Procedure|traditional surgery|Single session of traditional debridement
196070|NCT02677766|Other|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
196071|NCT02677766|Other|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
196072|NCT02677753|Radiation|Fluoroscopy|
196073|NCT02677740|Device|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention.
196074|NCT02677740|Device|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention.
196075|NCT02677727|Other|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
196076|NCT02677714|Radiation|99mTc-rhAnnexin V-128|
196077|NCT02677701|Drug|azithromycin|500mg tablet over-encapsulated to match placebo
196078|NCT02677701|Drug|placebo (for azithromycin)|
196079|NCT02677701|Drug|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
196080|NCT02677688|Biological|Autologous EBV specific CTL infusion|
196081|NCT02677675|Behavioral|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
196082|NCT02677662|Other|Diesel Exhaust|Dilute diesel exhaust
196083|NCT02677662|Other|Filtered air|Filtered air
196084|NCT02677649|Other|cranberry|the effect of cranberry on the gut microbiota
196085|NCT02677649|Other|placebo|the effect of placebo on the gut microbiota
196086|NCT02677636|Drug|MSRD-100|MSRD-100 is a topical gel.
196087|NCT02677636|Drug|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
196088|NCT02677623|Drug|Pyridium|
196089|NCT02677623|Drug|Sodium Fluorescein|
196090|NCT02677623|Drug|Mannitol|
196091|NCT02677623|Other|Normal Saline|
196092|NCT02677610|Drug|MSRD-100|MSRD-100 is a topical gel.
196093|NCT02677610|Drug|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
196094|NCT02677597|Drug|Cisplatin Combined With S-1|
196095|NCT02677597|Drug|Cisplatin Combined With Paclitaxel|
196096|NCT02677584|Drug|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
196097|NCT02677584|Drug|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
196098|NCT02677571|Procedure|Paravertebral Thoracic block|
196099|NCT02677571|Procedure|Pectorals nerve block|
196100|NCT02677571|Drug|Levobupivacaine 0.25%|
196101|NCT02677571|Drug|Morphine|
196102|NCT02677558|Other|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
196103|NCT02677545|Drug|Ticagrelor|
196104|NCT02677545|Drug|Clopidogrel|
196105|NCT02677545|Drug|Aspirin|
196106|NCT02677532|Drug|Paracetamol|1 g every 8 hours
196107|NCT02677532|Drug|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
196108|NCT02677532|Drug|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
196109|NCT02677532|Drug|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
196110|NCT02677532|Drug|Morphine|Intravenous slow bolus of 10 mg morphine
196111|NCT02677532|Device|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
196112|NCT02677532|Device|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
196113|NCT02677532|Drug|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
196114|NCT02677532|Drug|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
196115|NCT02677519|Drug|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
196116|NCT02677506|Procedure|Supraclavicular|Brachial plexus block with supraclavicular approach
196117|NCT02677506|Procedure|Infraclavicular|Brachial plexus block with infraclavicular approach
196118|NCT02677493|Biological|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
196119|NCT02677493|Biological|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
196120|NCT02677493|Biological|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
196121|NCT02677480|Dietary Supplement|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
196122|NCT02677480|Dietary Supplement|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
196123|NCT02677467|Biological|Blood-pressure variability|Day to Night Blood pressure variability
196124|NCT02677454|Device|Flash Glucose Monitor|
196125|NCT02677441|Procedure|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
196126|NCT02677441|Procedure|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
196127|NCT02677428|Behavioral|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
196128|NCT02677428|Behavioral|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
196129|NCT02677415|Other|Intravenous anesthetics|
196130|NCT02677415|Other|local anesthesia|
196131|NCT02677415|Other|Controlled ventilation|
196132|NCT02677415|Other|Spontaneous breathing|
196133|NCT02677402|Other|immersion|
196134|NCT02677389|Other|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
196135|NCT02677389|Other|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
196136|NCT02677389|Device|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
196137|NCT02677389|Other|Quality-of-Life Assessment|Ancillary studies
196138|NCT02677389|Other|Questionnaire Administration|Ancillary studies
196139|NCT02677376|Other|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a secon NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
196140|NCT02677363|Other|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
196141|NCT02677350|Drug|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
196142|NCT02677337|Other|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
196143|NCT02677337|Other|Educational Program|
196144|NCT02677324|Drug|ABT199|Oral BCL-2 antagonist
196145|NCT02677311|Procedure|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
196146|NCT02677311|Procedure|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
196147|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
196148|NCT02677298|Drug|Placebo|Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
196149|NCT02677285|Other|Different type of wound|
196150|NCT02677272|Other|Appropriateness of NH resident's transfer to ED|
196151|NCT02677259|Drug|17-beta estradiol|
196152|NCT02677259|Drug|Micronized progesterone|
196153|NCT02677246|Drug|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils > 0,5x10(9)/L and chimerism ≥ 10% of donor origin.~Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.~Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.~Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
196155|NCT02677207|Drug|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
196156|NCT02677207|Drug|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
196157|NCT02677194|Device|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
196158|NCT02677194|Other|Control device|Device without any LED exposition
196159|NCT02677181|Drug|ATG|rabbit ATG（Sanofi）
196160|NCT02677181|Drug|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
196161|NCT02677181|Drug|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
196162|NCT02677181|Drug|Methotrexate|short-term methotrexate
196163|NCT02677168|Device|cNEP|continuous negative external pressure
196164|NCT02677155|Radiation|Radiotherapy|Radiotherapy 8 Gy single dose
196165|NCT02677155|Biological|Rituximab|Intranodal injection 5 mg
196166|NCT02677155|Biological|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
196167|NCT02677155|Biological|GM-CSF|Subcutaneous injection of 50 ug
196168|NCT02677155|Biological|Pembrolizumab|Intravenous infusion of 200 mg
196169|NCT02677142|Behavioral|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
196170|NCT02677142|Behavioral|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
196171|NCT02677129|Other|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
196172|NCT02677116|Drug|Olaratumab|Olaratumab administered IV.
196173|NCT02677116|Drug|Doxorubicin|Doxorubicin administered IV.
196174|NCT02677116|Drug|Vincristine|Vincristine administered IV.
196175|NCT02677116|Drug|Irinotecan|Irinotecan administered IV.
196176|NCT02677116|Drug|Ifosfamide|Ifosfamide administered IV.
196177|NCT02677103|Device|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
196178|NCT02677103|Procedure|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
196179|NCT02677103|Procedure|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
196180|NCT02677090|Drug|Placebo (including Maltodextrin)|
196181|NCT02677090|Drug|Dose 1 - Promitor®|
196182|NCT02677090|Drug|Dose 2 - Promitor®|
196183|NCT02677090|Drug|Dose 3 - Promitor®|
196184|NCT02677077|Drug|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
196185|NCT02677064|Other|assessments|Thus, a prospective observational study in which all newly diagnosed or newly relapsed acute leukemia patients would be registered close to the beginning of induction or re-induction therapy would allow us to follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
196186|NCT02677051|Drug|Sulforaphane|Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
196187|NCT02677051|Drug|Placebo|
196188|NCT02677038|Drug|Olaparib|Given PO
196189|NCT02677025|Behavioral|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
196190|NCT02677025|Behavioral|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
196191|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the RESOLVE TM technique
196192|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Cytori PureGraft TM technique
196193|NCT02677012|Procedure|Autologous Fat Graft|Undergo AFG using the Coleman technique
196194|NCT02677012|Procedure|Reconstructive Surgery|Undergo reconstructive surgery
196195|NCT02676999|Procedure|Implantation of a Scheker total distal radioulnar joint prosthesis|
196196|NCT02676986|Drug|Enzalutamide|Anti-androgen
196197|NCT02676986|Drug|Exemestane|Hormonal therapy (Licenced)
196198|NCT02676973|Procedure|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
196234|NCT02676700|Behavioral|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
196199|NCT02676973|Procedure|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
196200|NCT02676973|Procedure|Uphold™ LITE|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
196201|NCT02676960|Other|MRI without sedation|
196202|NCT02676947|Drug|Tocilizumab|
196203|NCT02676934|Device|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
196204|NCT02676908|Other|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
196205|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 25 μg|Two injections of the study vaccine were administered 28 days apart.
196206|NCT02676895|Biological|GVGH S. sonnei (1790GAHB) vaccine 100 μg|Two injections of the study vaccine were administered 28 days apart.
196207|NCT02676895|Biological|Menveo|One injection of Menveo was administered in subjects in the Control Group.
196208|NCT02676895|Biological|Boostrix|One injection of Boostrix was administered in subjects in the Control Group.
196209|NCT02676882|Dietary Supplement|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
196210|NCT02676869|Drug|IMP321 (eftilagimod alpha)|"Part A: Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks~Part B: Single subcutaneous injections of 30 mg of IMP321 administered every 2 weeks"
196211|NCT02676869|Drug|Pembrolizumab|Administered according to the approved label.
196212|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3*10^8/kg/once.
196213|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3*10^8/kg/once.
196214|NCT02676856|Drug|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
196215|NCT02676856|Drug|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
196216|NCT02676843|Drug|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
196217|NCT02676830|Drug|K-312 100 mg|Single oral dose
196218|NCT02676830|Drug|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) [14C] given as a 5-ml IV push over 2 minutes
196219|NCT02676804|Other|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.~Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own."
196220|NCT02676791|Drug|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
196221|NCT02676778|Drug|E7777|
196222|NCT02676765|Drug|Allergen|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
196223|NCT02676765|Drug|Placebo|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
196224|NCT02676752|Procedure|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
196225|NCT02676752|Other|Questionnaire Administration|Completion of questionnaires
196226|NCT02676752|Procedure|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
196227|NCT02676739|Drug|Adderall XR|
196228|NCT02676726|Procedure|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
196229|NCT02676726|Procedure|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
196230|NCT02676713|Drug|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
196231|NCT02676713|Drug|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.~All are made into granules."
196232|NCT02676713|Drug|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
196233|NCT02676713|Drug|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
197480|NCT02667275|Other|Vehicle Solution|Placebo
196235|NCT02676700|Behavioral|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
196236|NCT02676687|Procedure|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
196237|NCT02676687|Procedure|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
196238|NCT02676674|Drug|Dose 1|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
196239|NCT02676674|Drug|Dose 2|Subjects with vitamin D deficiency will be given 300,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
196240|NCT02676648|Behavioral|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
196241|NCT02676648|Behavioral|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
196242|NCT02676648|Behavioral|Text messages|We will send participants text messages, to support intervention adherence.
196243|NCT02676648|Behavioral|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
196244|NCT02676635|Behavioral|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
196245|NCT02676622|Drug|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.~Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
196246|NCT02676622|Other|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.~Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
196247|NCT02676622|Drug|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)~Cyclophosphamide iv: 50 mg/kg iv over 2 hours~Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours~r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
196248|NCT02676622|Other|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.~Day +5: start Filgrastim (G-csf) subcutaneous injections~Hospitalization in isolation room for 4-5 weeks"
196249|NCT02676622|Drug|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is > 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.~Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
196250|NCT02676609|Device|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
196251|NCT02676596|Drug|K-312 10 mg QD|
196252|NCT02676596|Drug|K-312 25 mg QD|
196253|NCT02676596|Drug|K-312 50 mg QD|
196254|NCT02676596|Drug|K-312 100 mg QD|
196255|NCT02676596|Drug|K-312 200 mg QD|
196256|NCT02676596|Drug|K-312 400 mg QD|
196257|NCT02676596|Other|Placebo|
196258|NCT02676583|Procedure|Tonsillectomy|Closure or not closure of tonsil fossa
196259|NCT02676557|Device|Exposed to the high pressure during the surgery|
196260|NCT02676544|Device|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
196261|NCT02676531|Other|Exercise|Walking meditation exercise program
196262|NCT02676518|Other|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
196263|NCT02676505|Behavioral|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
196264|NCT02676505|Behavioral|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
196265|NCT02676492|Other|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
196266|NCT02676492|Other|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
196267|NCT02676479|Device|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use~Use of a tenaculum or cervical stitch is required~Use of saline to wash the cervix is required~Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
196483|NCT02675023|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
196268|NCT02676466|Dietary Supplement|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
196269|NCT02676466|Drug|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
196270|NCT02676466|Other|Corn Oil (Fish oil Placebo)|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
196271|NCT02676466|Other|Cellulose Based (Losartan Placebo)|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
196272|NCT02676453|Other|Intervention|Dental hygienist support
196273|NCT02676440|Other|Treatment|F13/T38
196274|NCT02676440|Other|Comparator|M26
196275|NCT02676427|Procedure|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
196276|NCT02676414|Behavioral|Interactive hypertension education program of the DHL©|
196277|NCT02676401|Drug|MT-3995 Low|
196278|NCT02676401|Drug|MT-3995 Middle|
196279|NCT02676401|Drug|MT-3995 High|
196280|NCT02676388|Procedure|Freeze-dried, Capsulized FMT|
196281|NCT02676388|Procedure|Fresh FMT|
196282|NCT02676375|Drug|Combination Bupropion + NRTs|
196283|NCT02676375|Other|Extended Treatment|
196284|NCT02676375|Other|Home Visits & Calls|
196285|NCT02676375|Drug|Monotherapy|
196286|NCT02676362|Other|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
196287|NCT02676349|Drug|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
196288|NCT02676349|Radiation|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
196289|NCT02676349|Procedure|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
196290|NCT02676349|Drug|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
196291|NCT02676336|Dietary Supplement|Violet™ Molecular Iodine (I2)|
196292|NCT02676336|Other|Placebo|
196293|NCT02676323|Drug|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
196294|NCT02676323|Drug|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m^2/dose over 30 minutes, daily for 5 days (days 8-12).
196295|NCT02676323|Drug|Cytarabine|Cytarabine will be given IV, 2 gram/m^2/dose over 4 hours, daily for 5 days (days 8-12).
196296|NCT02676323|Drug|Intrathecal Triples|Given intrathecally (IT).
196297|NCT02676323|Drug|Leucovorin|Leucovorin (5 mg/m^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
196298|NCT02676310|Drug|Bimatoprost|
196299|NCT02676297|Drug|tiotropium|four inhalations
196300|NCT02676284|Device|Durolane SJ|single dose injection
196301|NCT02676271|Procedure|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
196302|NCT02676258|Device|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
196303|NCT02676258|Device|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
196304|NCT02676245|Behavioral|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
196305|NCT02676245|Behavioral|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
196306|NCT02676232|Behavioral|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
196307|NCT02676219|Other|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
196308|NCT02676219|Other|Water|
196309|NCT02676206|Other|Classical music|Classical music will be played over the headphones
196310|NCT02676193|Behavioral|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
196311|NCT02676180|Other|Group|
196312|NCT02676167|Behavioral|PrEP Intervention|
196313|NCT02676154|Drug|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
196314|NCT02676141|Other|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
196315|NCT02676128|Behavioral|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
196316|NCT02676128|Behavioral|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
196317|NCT02676115|Other|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
196318|NCT02676115|Other|Medipore Tape|"One layer of Medipore tape will be placed across the incision.~Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.~When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
196319|NCT02676102|Behavioral|Control Group|Generic Video about organ donation
196320|NCT02676102|Behavioral|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
196321|NCT02676102|Behavioral|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
196322|NCT02676089|Drug|CHF 5993 200/6/12.5 µg|
196323|NCT02676089|Drug|CHF 1535 200/6 µg|
196324|NCT02676089|Drug|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
196325|NCT02676076|Drug|CHF 5993 100/6/12.5 µg|
196326|NCT02676076|Drug|CHF 1535 100/6 µg|
196327|NCT02676050|Other|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
196328|NCT02676050|Device|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
196329|NCT02676050|Device|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
196330|NCT02676037|Device|foot pressure plate form|
196331|NCT02676024|Device|Knowledge-based cognitive aid|"Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid reader)."
196332|NCT02676024|Device|Cognitive aids with roles defined (CARD)|"Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid reader)."
196333|NCT02676024|Device|Integrated cognitive aids|"Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid reader."
196334|NCT02676011|Drug|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
196335|NCT02676011|Drug|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
196336|NCT02676011|Drug|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
196337|NCT02676011|Drug|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
196338|NCT02676011|Drug|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
196339|NCT02676011|Drug|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
196340|NCT02675998|Drug|Tenapanor|
196341|NCT02675998|Drug|Placebo|
196342|NCT02675985|Other|Physical Therapy|Early Intensive Physical therapy in the ICU
196343|NCT02675959|Drug|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
196344|NCT02675946|Drug|CGX1321|
196345|NCT02675946|Drug|Pembrolizumab|
196346|NCT02675933|Behavioral|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
196347|NCT02675920|Drug|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
196348|NCT02675907|Drug|N1539|
196349|NCT02675907|Drug|Intravenous Placebo|
196350|NCT02675894|Device|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
196351|NCT02675894|Device|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
196352|NCT02675881|Device|DSM|Monopolar RFA using dual switching mode (DSM)
196353|NCT02675881|Device|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
196354|NCT02675868|Drug|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
196355|NCT02675868|Drug|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
196356|NCT02675868|Drug|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
196357|NCT02675868|Drug|Placebo|NaCl 0.9% infusion
196358|NCT02675855|Other|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
196359|NCT02675855|Procedure|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
196360|NCT02675855|Device|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
196361|NCT02675842|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
196625|NCT02673840|Drug|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
196362|NCT02675842|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
196363|NCT02675829|Drug|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
196364|NCT02675816|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
196365|NCT02675803|Biological|VAY736|VAY736 treatment
196366|NCT02675803|Biological|VAY736 placebo|VAY736 placebo
196367|NCT02675790|Drug|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
196368|NCT02675790|Drug|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
196369|NCT02675777|Other|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:~Identification of a clinical champion and Local Implementation Team.~Participatory Design.~Training primary care providers and Medical Assistants.~EHR clinical decision support tools~Weekly facilitated Local Implementation Team meetings.~Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.~Learning sessions for primary care providers during implementation.~Social worker use of an EHR registry with weekly supervision.~Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
196370|NCT02675764|Other|Vibration|peripheral vibration at the wrist skin at an imperceptible level
196371|NCT02675764|Other|Placebo (for vibration)|No peripheral vibration at the wrist skin
196372|NCT02675764|Behavioral|therapy|standardized hand therapy program
196373|NCT02675751|Device|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
196374|NCT02675738|Other|good clinical practice|
196375|NCT02675725|Device|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.~When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
196376|NCT02675712|Other|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
196377|NCT02675699|Behavioral|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.~OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
196378|NCT02675699|Behavioral|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
196379|NCT02675673|Procedure|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
196380|NCT02675673|Procedure|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
196381|NCT02675660|Dietary Supplement|L-Homoarginine|125 mg L-homoarginine once daily
196382|NCT02675660|Drug|Placebo|placebo capsules once daily
196383|NCT02675647|Drug|Heparin, IV route, based on patients body weights (UI/kg)|
196384|NCT02675647|Procedure|Cardiopulmonary bypass|
196385|NCT02675647|Drug|Protamin administration|
196386|NCT02675634|Device|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
196387|NCT02675634|Device|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
196388|NCT02675634|Device|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
196389|NCT02675621|Other|Phenolic Beverage|
196390|NCT02675608|Biological|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
196391|NCT02675582|Other|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
196392|NCT02675569|Procedure|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
196393|NCT02675569|Procedure|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
196394|NCT02675556|Drug|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells
196395|NCT02675556|Drug|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
196396|NCT02675543|Device|Vitreous Tamponade with Silicone Oil|
198119|NCT02662491|Dietary Supplement|Placebo|
196397|NCT02675530|Drug|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"
196398|NCT02675517|Drug|Spiolto Respimat|Tiotropium bromide + Olodaterol
196399|NCT02675504|Other|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
196400|NCT02675491|Drug|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
196401|NCT02675478|Drug|AC220|
196402|NCT02675465|Drug|ATB200|
196403|NCT02675465|Drug|AT2221|
196404|NCT02675452|Drug|AMG 176|Study Drug
196405|NCT02675452|Drug|Dexamethasone|Non-investigational product
196406|NCT02675452|Drug|Carfilzomib|Non-investigational product
196407|NCT02675452|Drug|Azacitidine|Non-investigational product
196408|NCT02675439|Drug|ADU-S100|
196409|NCT02675439|Biological|ipilimumab|
196410|NCT02675426|Drug|Placebo|Oral tablets matching upadacitinib
196411|NCT02675426|Drug|Upadacitinib|Tablets for oral administration
196412|NCT02675413|Drug|Dimethyl Fumarate|Open-label
196413|NCT02675400|Drug|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
196414|NCT02675400|Behavioral|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
196415|NCT02675400|Drug|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
196416|NCT02675387|Device|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
196417|NCT02675387|Drug|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
196418|NCT02675374|Drug|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
196419|NCT02675374|Drug|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
196420|NCT02675361|Behavioral|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
196421|NCT02675348|Dietary Supplement|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
196422|NCT02675348|Dietary Supplement|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
196423|NCT02675348|Dietary Supplement|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
196424|NCT02675335|Drug|Sitagliptin|
196425|NCT02675335|Drug|Placebo|
196426|NCT02675322|Drug|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
196427|NCT02675322|Other|Placebo|Placebo with no chemical effects.
196428|NCT02675309|Drug|MT-8554|
196429|NCT02675309|Drug|rosuvastatin|
196430|NCT02675309|Drug|simvastatin|
196431|NCT02675283|Device|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
196432|NCT02675270|Behavioral|Phonological|This treatment involves picture viewing and word repetition.
196433|NCT02675270|Behavioral|Orthographic|This treatment involves picture viewing, reading, and writing.
196434|NCT02675270|Behavioral|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
196435|NCT02675270|Behavioral|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
196436|NCT02675270|Behavioral|Untrained|These words are not trained during the treatment phase.
196437|NCT02675257|Behavioral|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
196438|NCT02675257|Behavioral|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
196439|NCT02675257|Behavioral|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
196440|NCT02675257|Behavioral|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
196441|NCT02675257|Behavioral|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
196442|NCT02675257|Behavioral|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
196443|NCT02675257|Behavioral|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
196444|NCT02675257|Behavioral|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
196445|NCT02675257|Behavioral|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
196446|NCT02675257|Behavioral|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
196447|NCT02675257|Behavioral|Sports, activities and exercise|Education on sports, activities and exercise
196448|NCT02675257|Behavioral|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
196449|NCT02675257|Behavioral|Diabetes complications|Education on diabetes complications
196450|NCT02675257|Behavioral|Social aspects of living with diabetes|Education on social aspects of living with diabetes
196451|NCT02675244|Procedure|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
196452|NCT02675244|Procedure|MVS|MVS will be performed using standard surgical techniques
196453|NCT02675231|Drug|Abemaciclib|Administered Orally
196454|NCT02675231|Drug|Trastuzumab|Administered IV
196455|NCT02675231|Drug|Fulvestrant|Administered IM
196456|NCT02675231|Drug|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
196457|NCT02675218|Other|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
196458|NCT02675205|Drug|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
196459|NCT02675205|Drug|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
196460|NCT02675205|Drug|aspirin|
196461|NCT02675192|Other|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
196462|NCT02675179|Device|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
196463|NCT02675179|Device|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
196464|NCT02675166|Other|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
196465|NCT02675153|Drug|Sirolimus|Sirolimus 2mg daily will be given to subjects by oral for six months.
196466|NCT02675153|Drug|5-ASA, Prednisone, Azathioprine or Remicade|5-ASA, Prednisone, Azathioprine and Remicade are traditional treatments according to associated guidelines
196467|NCT02675140|Drug|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
196468|NCT02675140|Drug|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
196469|NCT02675127|Drug|Daktavira|1 tablet contains 60 mg Daclatasvir
196470|NCT02675127|Drug|Daklinza|1 tablet contains 60 mg Daclatasvir
196471|NCT02675114|Procedure|Surgical aortic valve replacement (SAVR)|SAVR with a commercially available bioprosthetic valve.
196472|NCT02675114|Device|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
196473|NCT02675101|Other|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
196474|NCT02675101|Other|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
196475|NCT02675101|Other|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
196476|NCT02675088|Radiation|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
196477|NCT02675088|Radiation|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
196478|NCT02675049|Drug|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
196479|NCT02675049|Drug|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
196480|NCT02675049|Drug|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
196481|NCT02675049|Drug|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
196482|NCT02675036|Procedure|Tooth extraction|
199167|NCT02655354|Behavioral|Care Management|
196484|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
196485|NCT02674997|Biological|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
196486|NCT02674984|Drug|BB-12 with LGG|Multistrain probiotic
196487|NCT02674984|Drug|Placebo|
196488|NCT02674971|Behavioral|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
196489|NCT02674958|Drug|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
196490|NCT02674945|Device|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
196491|NCT02674932|Behavioral|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
196492|NCT02674932|Behavioral|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
196493|NCT02674932|Behavioral|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
196494|NCT02674919|Other|Nordic Hamstring|
196495|NCT02674919|Other|Control|
196496|NCT02674906|Drug|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
196497|NCT02674906|Drug|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
196498|NCT02674893|Drug|Liraglutide|
196499|NCT02674893|Other|Observation alone|
196500|NCT02674880|Drug|HMW-HA|Aerolized administration b.i.d.
196501|NCT02674880|Other|Placebo|Standard therapy
196502|NCT02674867|Other|Blood draw|
196503|NCT02674854|Drug|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop daily in the evening (PM) in both eyes (OU)
196504|NCT02674854|Drug|Netarsudil (AR-13324) ophthalmic solution 0.02%|1 drop daily in the evening (PM) in both eyes (OU)
196505|NCT02674854|Drug|Latanoprost ophthalmic solution 0.005%|1 drop daily in the evening (PM) in both eyes (OU)
196506|NCT02674841|Other|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
196507|NCT02674841|Other|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
196508|NCT02674841|Other|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
196509|NCT02674828|Behavioral|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
196510|NCT02674828|Other|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
196511|NCT02674815|Other|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
196512|NCT02674789|Behavioral|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
196513|NCT02674776|Drug|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
196514|NCT02674776|Drug|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
196515|NCT02674763|Drug|IMGN779|
196516|NCT02674750|Drug|CUDC-907|
196517|NCT02674737|Drug|dexmedetomidine, tramadol and flurbiprofen|
196518|NCT02674737|Drug|tramadol and flurbiprofen|
196519|NCT02674724|Other|Gym Group|"Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.~The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets."
196552|NCT02674477|Other|Treatment as Usual (TAU)|Standard treatment comprises a psychiatrist-led interdisciplinary team as well as face-to-face group counseling for substance use and skills for improving general mental health. There will be no change to the routine care (treatment at usual [TAU]) provided to patients on the service.
196520|NCT02674724|Other|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
196521|NCT02674724|Other|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
196522|NCT02674711|Behavioral|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
196523|NCT02674698|Other|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
196524|NCT02674698|Other|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
196525|NCT02674698|Other|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
196526|NCT02674698|Other|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
196527|NCT02674672|Device|VenaTech® (VenaTech Retrievable Filter)|
196528|NCT02674659|Behavioral|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session will be held for around 15 minutes.
196529|NCT02674659|Behavioral|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
196530|NCT02674646|Radiation|Radiotherapy|Radiation as indicated by the cancer diagnosis
196531|NCT02674646|Device|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
196532|NCT02674633|Device|AKL-T01|Videogame-like digital therapy
196533|NCT02674633|Device|AKL-T09|Videogame-like digital therapy
196534|NCT02674620|Other|Aerobic Exercise|Patients are treated with progressive exercise
196535|NCT02674607|Dietary Supplement|Spirulina|
196536|NCT02674581|Drug|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
196537|NCT02674568|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
196538|NCT02674555|Drug|radio-labeled naquotinib|Oral administration
196539|NCT02674555|Drug|naquotinib|Oral administration
196540|NCT02674542|Other|In-depth interviews|"Future family planning intentions and beliefs~Family planning experiences and beliefs:~Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise"
196541|NCT02674542|Other|Focus Group|"Future family planning intentions and beliefs~Family planning experiences and beliefs:~Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise"
196542|NCT02674529|Drug|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
196543|NCT02674529|Drug|Placebo|Placebo
196544|NCT02674516|Device|Transcranial direct current stimulation|
196545|NCT02674516|Device|Sham transcranial direct current stimulation|
196546|NCT02674503|Behavioral|Walking|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
196547|NCT02674503|Behavioral|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
196548|NCT02674490|Device|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
196549|NCT02674490|Behavioral|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
196550|NCT02674490|Device|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
196551|NCT02674477|Device|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
196620|NCT02673879|Other|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
196553|NCT02674464|Behavioral|Provider Audit-Feedback, Stratified by Race and Ethnicity|Transparent and timely access to and review of clinical performance data are among the key elements of successful improvement activities. For this reason, the RICH LIFE Project provides the health systems with the logic to build practice and provider level HTN dashboards, support in building the dashboard, and education in utilizing the dashboard. The practice dashboard provides a display of the percentage of patients achieving BP control, defined as <140/90 mm Hg for the overall practice, while the provider dashboard provides a display of the percentage of patients achieving BP control for each provider's patient panel. Both the practice and provider Dashboards stratify hypertension performance data by race (White, non-Hispanic; Black, non-Hispanic; and All Hispanic) to help practice administration and clinicians evaluate differences between races and ethnicities in BP control rates. New reports are generated at least quarterly and will display data from the previous 3 months.
196554|NCT02674464|Behavioral|Blood Pressure Measurement Standardization|"All adult medicine staff at participating study practices receive standardized, evidence-based, best practices BP measurement training. Aspects of the training include proper patient preparation and positioning, how use of an automated BP measurement device, and executing a screen and confirm protocol when measuring patients' blood pressures."
196555|NCT02674464|Behavioral|System Level Leadership Intervention|"This System-Level Leadership intervention aims to create a learning network through an inter-organizational approach to promote health equity and reduce CVD disparities. Elements of the system-level leadership intervention, then, include: 1) an introductory session during the kick-off event (baseline); 2) a quarterly 1 hour content call with a presentation on leading for equity and discussion among system-level leaders, community organization leaders, and interested practice champions in the CC/Stepped care arm conducted via conference call/webinar; and 3) monthly coaching calls for the system and practice level leaders, CMs, and CHWs in the CC/stepped care arm to discuss the interventions, while they are actively engaged in the intervention phase."
196556|NCT02674464|Behavioral|Collaborative Care Team Intervention|The collaborative care intervention creates a collaborative care team that, at a minimum, consists of PCP, RN or LCSW care manager, and community health worker. The collaborative care team develops the medical management plan in partnership with patients; 2) uses care coordination to maximize interaction of the patients' PCPs with other care providers addressing medication management, patient self-management, and psychosocial support on a regular, consistent basis; and 3) determines patient access to CHW support and subspecialty consultations.
196557|NCT02674464|Behavioral|Community Health Worker Referral|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
196558|NCT02674464|Behavioral|Specialist Care Consultation|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
196559|NCT02674451|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
196560|NCT02674438|Other|Risk stratification and transitional care intervention|"Intervention consists of 2 components:~Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores, where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores~Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
196561|NCT02674425|Device|Dark Adaptometer|
196562|NCT02674412|Drug|Buspirone|
196563|NCT02674412|Drug|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
196564|NCT02674399|Drug|JointStem|
196565|NCT02674399|Drug|Synvisc-One|
196566|NCT02674386|Drug|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
196567|NCT02674360|Behavioral|SDM Training|
196568|NCT02674347|Drug|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
196569|NCT02674347|Drug|Placebo|IV matching the Investigational drug
196570|NCT02674334|Device|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
196571|NCT02674334|Device|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
196572|NCT02674321|Drug|SD-809|
196573|NCT02674308|Drug|Vedolizumab|
196574|NCT02674308|Other|Other Biologic Agents|Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
196575|NCT02674295|Drug|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
196576|NCT02674295|Drug|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
196577|NCT02674282|Procedure|ACL reconstruction|ACL reconstruction with hamstrings autograft.
196578|NCT02674269|Drug|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
196579|NCT02674269|Drug|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
196580|NCT02674269|Device|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
196581|NCT02674256|Drug|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
196582|NCT02674256|Other|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
196583|NCT02674243|Drug|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
196584|NCT02674243|Drug|Talc|In this group, Talc will be used as pleurodesis substance
196585|NCT02674217|Procedure|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
196621|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
196622|NCT02673866|Drug|DS-1971a|
196586|NCT02674204|Drug|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
196587|NCT02674204|Drug|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
196588|NCT02674191|Device|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
196589|NCT02674191|Procedure|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
196590|NCT02674191|Procedure|Administration of , Mepivacaine-l|local anesthesia
196591|NCT02674191|Procedure|BETADINE povidone-iodine 10%|a local disinfectant
196592|NCT02674191|Drug|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
196593|NCT02674191|Drug|(Cataflam 25mg), are prescribed post-operatively|an analgesic
196594|NCT02674178|Procedure|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days~Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm [18]~Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
196595|NCT02674165|Behavioral|HART|Skills based sexual education intervention plus PTSD awareness
196596|NCT02674152|Drug|BI 836880|
196597|NCT02674139|Device|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
196598|NCT02674126|Behavioral|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
196599|NCT02674126|Behavioral|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
196600|NCT02674113|Drug|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
196601|NCT02674113|Drug|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
196602|NCT02674100|Other|Registry|
196603|NCT02674074|Device|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
196604|NCT02674061|Biological|pembrolizumab|IV infusion
196605|NCT02674048|Other|Metvix|
196606|NCT02674035|Procedure|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
196607|NCT02674022|Dietary Supplement|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
196608|NCT02674009|Drug|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
196609|NCT02673996|Drug|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
196610|NCT02673996|Drug|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
196611|NCT02673983|Procedure|Endoscopic full-thickness biopsy|
196612|NCT02673957|Other|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
196613|NCT02673944|Device|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
196614|NCT02673931|Drug|Byetta (Lilly, Exenatide)|See description of arms
196615|NCT02673931|Drug|Conoxia (AGA, oxygen)|See description arms
196616|NCT02673931|Drug|20% Human Albumin|
196617|NCT02673918|Other|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.~On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
196618|NCT02673905|Other|Tissue Engineered Product|Implantation of tissue engineered products
196619|NCT02673892|Other|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
196623|NCT02673866|Drug|placebo|
196624|NCT02673866|Drug|pregabalin|pregabalin
196626|NCT02673840|Drug|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
196627|NCT02673827|Other|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
196628|NCT02673814|Biological|durvalumab|
196629|NCT02673814|Biological|bavituximab|
196630|NCT02673801|Other|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
196631|NCT02673788|Other|observation without intervention in this follow up study|observation without intervention in this follow up study
196632|NCT02673775|Other|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
196633|NCT02673775|Other|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
196634|NCT02673749|Drug|RP-G28|Study drug taken orally
196635|NCT02673749|Other|Placebo|Placebo taken orally
196636|NCT02673736|Drug|PLX73086|
196637|NCT02673723|Drug|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
196638|NCT02673723|Drug|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
196639|NCT02673710|Other|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
196640|NCT02673697|Device|Perceval valve|Sutureless Aortic Biological Valve
196641|NCT02673697|Device|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
196642|NCT02673684|Device|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
196643|NCT02673684|Device|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
196644|NCT02673671|Device|G-Tech Myoelectric recording device|A minimum of three patches are placed on the abdomen of the patient to record myoelectric activity.
196645|NCT02673658|Behavioral|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
196646|NCT02673658|Behavioral|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
196647|NCT02673645|Other|SAGA Innovations|An intensive math tutoring program.
196648|NCT02673632|Drug|Merional ®|Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 < 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
196649|NCT02673619|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
196650|NCT02673619|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2
196651|NCT02673606|Drug|Estradiol 2Mg Tablet|one 2 mg dose of estradiol (obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
196652|NCT02673606|Drug|Estradiol 4Mg Tablet|two 2 mg pills estradiol(obtained from Estrace® Tablets, 2.0 mg estradiol tablets, USP, Warner Chilcott),
196653|NCT02673606|Drug|Placebo Pills|inactive placebo pills
196654|NCT02673593|Drug|DS102|
196655|NCT02673593|Drug|Placebo|
196656|NCT02673580|Other|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
196657|NCT02673580|Other|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
196658|NCT02673567|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
196659|NCT02673567|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
196660|NCT02673567|Drug|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
196661|NCT02673567|Drug|Placebo|Matching Placebo
196662|NCT02673554|Drug|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
196663|NCT02673554|Drug|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
196664|NCT02673554|Procedure|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
196665|NCT02673554|Procedure|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l)
196736|NCT02672943|Other|non-rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
196666|NCT02673541|Device|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
196667|NCT02673541|Device|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
196668|NCT02673528|Procedure|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
196669|NCT02673515|Behavioral|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
196670|NCT02673502|Dietary Supplement|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
196671|NCT02673502|Dietary Supplement|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
196672|NCT02673489|Drug|DCV|
196673|NCT02673489|Drug|SOF|
196674|NCT02673489|Drug|RBV|
196675|NCT02673476|Drug|ALS-008176|ALS-008176 tablets
196676|NCT02673476|Drug|Placebo|Identical placebo tablets
196677|NCT02673463|Drug|Spironolactone|25 mg once daily
196678|NCT02673463|Drug|Placebo|Visually identical to spironolactone, once daily
196679|NCT02673437|Other|This is a non-interventional study|This is a non-interventional study
196680|NCT02673424|Procedure|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm~* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
196681|NCT02673424|Procedure|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm~* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden >70%)"
196682|NCT02673411|Device|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
196683|NCT02673398|Other|Comprehensive Geriatric Assessment|Ancillary studies
196684|NCT02673398|Other|Laboratory Biomarker Analysis|Correlative studies
196685|NCT02673398|Drug|Neratinib|Given PO
196686|NCT02673398|Other|Pharmacological Study|Correlative studies
196687|NCT02673385|Other|Brazelton scale|
196688|NCT02673372|Drug|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
196689|NCT02673372|Drug|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
196690|NCT02673359|Drug|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
196691|NCT02673359|Procedure|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
196692|NCT02673333|Drug|Pembrolizumab|
196693|NCT02673320|Procedure|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
196694|NCT02673320|Procedure|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
196695|NCT02673307|Behavioral|1 chewing gum over 45 minutes|
196696|NCT02673294|Other|balance virtual rehabilitation|
196697|NCT02673281|Other|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
196698|NCT02673281|Other|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
196699|NCT02673268|Procedure|Mastectomy|
196700|NCT02673268|Device|Da Vinci Robot Xi|
196701|NCT02673255|Biological|Tetanus and Diphtheria (Td) Vaccine|
196702|NCT02673242|Device|Threshold IMT Philips Respironics|Inspiratory muscle training
196703|NCT02673229|Drug|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
196704|NCT02673229|Drug|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
196705|NCT02673216|Other|No intervention|
196737|NCT02672930|Device|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
196738|NCT02672917|Biological|MVT-5873|MVT-5873 is administered weekly by IV infusion. Dose will be increased during the study in order to define the MTD
196739|NCT02672904|Device|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
196706|NCT02673203|Device|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
196707|NCT02673203|Behavioral|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
196708|NCT02673177|Procedure|robot-assisted total mesorectal excision|The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
196709|NCT02673177|Procedure|laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
196710|NCT02673164|Biological|CSCC_ASC|The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
196711|NCT02673151|Procedure|Computed Tomography|Undergo 68Ga-PSMA PET/CT
196712|NCT02673151|Drug|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC|Given IV
196713|NCT02673151|Other|Laboratory Biomarker Analysis|Correlative studies
196714|NCT02673151|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA PET/CT
196715|NCT02673138|Drug|canagliflozin|basal interruption with canagliflozin
196716|NCT02673138|Other|basal interruption without canagliflozin|basal interruption
196717|NCT02673125|Genetic|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
196718|NCT02673112|Behavioral|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
196719|NCT02673112|Behavioral|Light stretching (LS)|Brief daily stretching routine.
196720|NCT02673099|Procedure|HDF online|Hemodialysis by the HDF online method
196721|NCT02673086|Other|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
196722|NCT02673086|Other|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
196723|NCT02673073|Other|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.~Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
196724|NCT02673073|Other|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
196725|NCT02673060|Drug|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
196726|NCT02673047|Biological|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
196727|NCT02673021|Procedure|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
196728|NCT02673008|Biological|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
196729|NCT02672995|Radiation|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:~Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
196730|NCT02672995|Drug|bevacizumab|"Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
196731|NCT02672982|Other|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
196732|NCT02672982|Other|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
196733|NCT02672969|Device|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).~Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
196734|NCT02672956|Procedure|Ten mm trocar|
196735|NCT02672943|Behavioral|Rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.
196740|NCT02672904|Device|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
196741|NCT02672891|Device|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.~(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
196742|NCT02672878|Device|Bioresorbable vascular scaffold|
196743|NCT02672865|Drug|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
196744|NCT02672852|Drug|Risankizumab|Risankizumab administered by subcutaneous injection
196745|NCT02672852|Drug|Placebo|Placebo for risankizumab administered by subcutaneous injection
196746|NCT02672839|Drug|LGD-6972 Solution|15 mg of LGD-6972
196747|NCT02672839|Drug|LGD-6972 Capsules|15 mg LGD-6972
196748|NCT02672826|Procedure|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
196749|NCT02672813|Procedure|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
196750|NCT02672800|Behavioral|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
196751|NCT02672787|Behavioral|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
196752|NCT02672787|Behavioral|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
196753|NCT02672774|Procedure|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
196754|NCT02672774|Device|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
196755|NCT02672761|Behavioral|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
196756|NCT02672761|Behavioral|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
196757|NCT02672761|Behavioral|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
196758|NCT02672761|Behavioral|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
196759|NCT02672748|Other|Garden|Two years of financial and technical home gardening support for new gardeners
196760|NCT02672735|Other|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
196761|NCT02672722|Drug|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
196762|NCT02672722|Other|Exercise|
196763|NCT02672722|Other|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
196764|NCT02672709|Drug|apixaban|
196765|NCT02672696|Device|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
196766|NCT02672670|Behavioral|Experimental: Intervention group---coping-oriented supportive programme|
196767|NCT02672670|Behavioral|Active Comparator: Comparison group---a didactic talk (usual care)|
196768|NCT02672644|Device|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
196769|NCT02672644|Device|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
196770|NCT02672631|Other|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
196771|NCT02672631|Other|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
196772|NCT02672631|Other|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
196773|NCT02672605|Other|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
196774|NCT02672592|Drug|Anakinra|Anakinra 100mg s.c. bid
196775|NCT02672592|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
196776|NCT02672566|Drug|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
196777|NCT02672566|Other|Usual care|Patients will all benefit from the usual care
196778|NCT02672553|Device|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
196779|NCT02672553|Device|Stented Aortic Bioprostheses|In comparison to control valves available on the market undergoing FS-AVR
196780|NCT02672540|Drug|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
196781|NCT02672540|Drug|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
196782|NCT02672527|Drug|Trabectedin|
196783|NCT02672527|Drug|Dexamethasone|
196784|NCT02672514|Device|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
196785|NCT02672514|Device|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
196786|NCT02672501|Drug|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences
196787|NCT02672488|Drug|Sorafenib|Standard treatment for advanced HCC
196788|NCT02672488|Drug|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
196789|NCT02672475|Drug|Galunisertib|Given PO
196790|NCT02672475|Other|Laboratory Biomarker Analysis|Correlative studies
196791|NCT02672475|Drug|Paclitaxel|Given IV
196792|NCT02672462|Device|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
196793|NCT02672449|Radiation|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
196794|NCT02672436|Drug|ENERGI-F703|Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
196795|NCT02672436|Drug|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
196796|NCT02672423|Drug|Abemaciclib Capsules (Reference Formulation)|Administered orally
196797|NCT02672423|Drug|Abemaciclib Tablet (Test Formulation)|Administered orally
196798|NCT02672397|Behavioral|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
196799|NCT02672384|Procedure|Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )|Dental examination Study exams (oral and blood sample collection)
196800|NCT02672371|Device|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
196801|NCT02672371|Device|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
196802|NCT02672358|Drug|Dabrafenib|Oral Dabrafenib 150 mg BID
196803|NCT02672358|Drug|Trametinib|Oral Trametinib 2 mg QD
196804|NCT02672345|Drug|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
196805|NCT02672332|Drug|SB204 4%|Once daily
196806|NCT02672332|Drug|Vehicle Gel|Placebo comparator
196844|NCT02672033|Radiation|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
196845|NCT02672033|Other|Laboratory Biomarker Analysis|Correlative studies
196846|NCT02672033|Procedure|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
196847|NCT02672020|Biological|omics identity card|
199168|NCT02655354|Drug|Fluoxetine|Anti-depressant
196807|NCT02672319|Procedure|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
196808|NCT02672306|Biological|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
196809|NCT02672306|Biological|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
196810|NCT02672293|Drug|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
196811|NCT02672280|Device|Medical Collagen Membrane with MSC|
196812|NCT02672280|Device|Medical Collagen Membrane|
196813|NCT02672267|Biological|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
196814|NCT02672267|Other|Placebo|Lactated Ringer's Solution
196815|NCT02672254|Radiation|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
196816|NCT02672241|Drug|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
196817|NCT02672241|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
196818|NCT02672228|Device|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
196819|NCT02672215|Behavioral|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
196820|NCT02672215|Behavioral|generic advice|general, non-tailored web-based generic advice with tips
196821|NCT02672202|Drug|Duloxetine|"60 mg/d - twice before surgery and once a day for post operative days 3-7~30 mg/d - once a day for post operative days 1-2"
196822|NCT02672202|Drug|Pregabalin|"75 mg/d - twice a day for post operative days 1-2~150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
196823|NCT02672202|Drug|Placebo|"non-active - twice before surgery~non-active - twice a day for post operative days 1-7"
196824|NCT02672189|Behavioral|EVA-Online|Internet-based cognitive behavioral therapy
196825|NCT02672176|Behavioral|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
196826|NCT02672176|Behavioral|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
196827|NCT02672163|Procedure|CABG surgery|Elective CABG surgery
196828|NCT02672163|Procedure|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
196829|NCT02672150|Behavioral|Core|
196830|NCT02672150|Behavioral|Enhanced|
196831|NCT02672137|Behavioral|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
196832|NCT02672111|Drug|CAM2038 q1w or q4w exposure to SL BPN/NX|
196833|NCT02672111|Drug|CAM2038 q1w or q4w new to BPN treatment|
196834|NCT02672098|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
196835|NCT02672098|Drug|Carboplatin|"Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C)."
196836|NCT02672085|Procedure|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
196837|NCT02672085|Procedure|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
196838|NCT02672072|Other|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
196839|NCT02672072|Other|questionnaire to define the presence of job strain at 6 months|
196840|NCT02672072|Other|questionnaire to define the presence of job strain at 12 months|
196841|NCT02672059|Other|Observation|No intervention
196842|NCT02672046|Other|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
196843|NCT02672033|Radiation|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
196848|NCT02672007|Device|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
196849|NCT02671994|Other|G8 screening|
196850|NCT02671994|Other|Geriatric assessment|
196851|NCT02671968|Device|Continuous Glucose Monitoring System|
196852|NCT02671955|Drug|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
196853|NCT02671942|Drug|Roflumilast|
196854|NCT02671942|Drug|Placebo|
196855|NCT02671929|Behavioral|self-help program|Access to the internet-based self-help program
196856|NCT02671929|Behavioral|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
196857|NCT02671916|Behavioral|questionnaire|Investigation on all study patients, no Intervention, no groups
196858|NCT02671903|Device|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
196859|NCT02671890|Drug|Disulfiram|Given PO
196860|NCT02671890|Drug|Gemcitabine Hydrochloride|Given IV
196861|NCT02671890|Other|Laboratory Biomarker Analysis|Correlative studies
196862|NCT02671890|Other|Placebo|Given PO
196863|NCT02671877|Procedure|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
196864|NCT02671864|Other|1: incretin-based therapy|
196865|NCT02671864|Other|2: other antidiabetic|
196866|NCT02671851|Drug|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
196867|NCT02671851|Drug|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
196868|NCT02671838|Behavioral|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
196869|NCT02671825|Drug|PUR0200|PUR0200 dry powder inhalation
196870|NCT02671825|Drug|Reference Product|Dry Powder Inhalation Reference Product
196871|NCT02671799|Device|VenTouch System Implant|The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
196872|NCT02671786|Other|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories & 15-17 gms of proteins.
196873|NCT02671773|Drug|Inhaled corticosteroid dose/type|
196874|NCT02671760|Drug|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
196875|NCT02671760|Drug|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
196876|NCT02671760|Drug|Placebo|Placebo
196877|NCT02671747|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
196878|NCT02671734|Behavioral|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
196879|NCT02671721|Other|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
196880|NCT02671721|Other|Transpulmonary Pressure|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
196881|NCT02671708|Drug|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
196882|NCT02671708|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
196883|NCT02671708|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
196884|NCT02671695|Drug|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
196885|NCT02671695|Drug|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
196886|NCT02671682|Procedure|Immunoadsorption|
196887|NCT02671682|Procedure|Plasmapheresis|
196888|NCT02671669|Behavioral|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
196889|NCT02671669|Behavioral|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:~Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.~Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
196923|NCT02671305|Procedure|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
196890|NCT02671656|Device|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
196891|NCT02671630|Other|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
196892|NCT02671617|Other|High intensity interval training (HIIT)|Preoperative HIIT protocol.
196893|NCT02671591|Behavioral|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
196894|NCT02671591|Behavioral|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
196895|NCT02671578|Drug|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
196896|NCT02671565|Drug|Hyaluronic Acid injections|
196897|NCT02671552|Drug|Perflutren Protein-Type A Microspheres|Given IV
196898|NCT02671552|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
196899|NCT02671539|Genetic|rAAV2.REP1|single subretinal injection
196900|NCT02671526|Other|Computerized plasticity-based adaptive cognitive training|
196901|NCT02671513|Drug|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
196902|NCT02671500|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
196903|NCT02671487|Behavioral|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
196904|NCT02671474|Other|4-dimensional volume-rendered computed tomography|
196905|NCT02671461|Drug|BMS-986141|
196906|NCT02671461|Drug|Aspirin|
196907|NCT02671461|Other|Placebo|
196908|NCT02671448|Behavioral|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
196909|NCT02671448|Behavioral|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
196910|NCT02671448|Behavioral|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
196911|NCT02671435|Combination Product|Intervention|Biological: Durvalumab Biological: Monalizumab Biological: Cetuximab
196912|NCT02671409|Other|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
196913|NCT02671396|Behavioral|Virtual reality based intervention|Virtual reality based balance training
196914|NCT02671396|Behavioral|Conventional intervention|Conventional balance training
196915|NCT02671383|Drug|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
196916|NCT02671383|Drug|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
196917|NCT02671370|Other|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
196918|NCT02671357|Procedure|ERAMIP|Minimally invasive pancreaticoduodenectomy with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
196919|NCT02671344|Other|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
196920|NCT02671331|Procedure|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
196921|NCT02671318|Drug|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
196922|NCT02671318|Drug|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
196924|NCT02671305|Procedure|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
196925|NCT02671292|Behavioral|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
196926|NCT02671292|Other|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
196927|NCT02671279|Dietary Supplement|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
196928|NCT02671266|Drug|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
196929|NCT02671266|Drug|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
196930|NCT02671253|Procedure|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
196931|NCT02671227|Drug|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
196932|NCT02671227|Drug|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
196933|NCT02671214|Other|Control|100 g high fibre flour
196934|NCT02671214|Other|Active 2|98 g high fibre flour + 2 g guar gum
196935|NCT02671214|Other|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
196936|NCT02671214|Other|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
196937|NCT02671214|Other|Active 5|96 g high fibre flour + 4 g guar gum
196938|NCT02671214|Other|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
196939|NCT02671214|Other|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
196940|NCT02671214|Other|Active 8|94 g high fibre flour + 6 g guar gum
196941|NCT02671214|Other|Active 9|98 g high fibre flour + 2 g konjac mannan
196942|NCT02671214|Other|Active 10|96 g high fibre flour + 4 g konjac mannan
196943|NCT02671214|Other|Active 11|100 g low fibre flour
196944|NCT02671214|Other|Active 1|85 g high fibre flour + 15 g legume flour
196945|NCT02671201|Other|Education|Different methods in education of emergency ultrasound
196946|NCT02671188|Drug|GSK3050002|The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
196947|NCT02671188|Drug|Placebo|Normal saline (0.9% sodium chloride) will be used as placebo.
196948|NCT02671175|Drug|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
196949|NCT02671175|Drug|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
196950|NCT02671162|Drug|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
196951|NCT02671162|Drug|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
196952|NCT02671149|Dietary Supplement|Water|Participants will receive two cups of 150ml plain water
196953|NCT02671136|Device|Hyperbaric Oxygen therapy|
196954|NCT02671136|Other|Conventional Wound Therapies|
196955|NCT02671123|Procedure|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
196956|NCT02671123|Procedure|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
196957|NCT02671110|Behavioral|Transforming Your Life|See Transforming Your Life Arm
196958|NCT02671110|Behavioral|Diabetes Prevention Program|See Diabetes Prevention Program Arm
196959|NCT02671097|Drug|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
196960|NCT02671097|Drug|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
196961|NCT02671084|Drug|sevoflurane|
199169|NCT02655354|Drug|Fluvoxamine|Anti-depressant
196962|NCT02671071|Behavioral|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
196963|NCT02671058|Drug|Cortenema|Hydrocortisone Administered as a Liquid Enema
196964|NCT02671058|Drug|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
196965|NCT02671045|Genetic|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
196966|NCT02671045|Genetic|Genomic profile by other methods|Genomic profiling by other testing methods.
196967|NCT02671032|Device|Nucleus CI532 cochlear implant|
196968|NCT02671019|Behavioral|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
196969|NCT02671006|Other|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
196970|NCT02670993|Behavioral|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
196971|NCT02670993|Behavioral|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
196972|NCT02670980|Device|Intelligent Retinal Implant System|
196973|NCT02670967|Dietary Supplement|Soluble Fibre|
196974|NCT02670954|Drug|Dexmedetomidine, tramadol and flurbiprofen|
196975|NCT02670954|Drug|tramadol and flurbiprofen|
196976|NCT02670941|Drug|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
196977|NCT02670941|Drug|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
196978|NCT02670941|Drug|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
196979|NCT02670941|Drug|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
196980|NCT02670928|Behavioral|Lifestyle intervention|Patients of active group were assigned to receive activities of the program for life style changes. Patients in control group were managed in frames of routine clinical practice. No any investigational drug therapy was used.
196981|NCT02670915|Drug|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
196982|NCT02670915|Drug|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
196983|NCT02670915|Drug|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
196984|NCT02670902|Behavioral|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
196985|NCT02670902|Behavioral|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program, as well as three telephone recovery check-up calls post-discharge.
196986|NCT02670876|Behavioral|Anti-bullying intervention|"The title of each session were as follows :~Introduction of intervention and setting rules, building rapport~Understanding school bullying (The definition of school bullying and proper coping strategies)~Empathy of others ( Practice of understanding victims of school bullying)~Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~Communication skills enhancement~Increasing self esteem"
196987|NCT02670863|Other|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
196988|NCT02670863|Other|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
196989|NCT02670850|Other|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
196990|NCT02670837|Device|Cellutome Epidermal Harvesting System|
196991|NCT02670824|Drug|CN-105|Single and multiple intravenous (IV) doses of CN-105
196992|NCT02670824|Drug|Placebo|Normal Saline
196993|NCT02670811|Dietary Supplement|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
196994|NCT02670811|Dietary Supplement|Acidified milk|150 mL daily of artificially acidified milk
196995|NCT02670798|Procedure|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
196996|NCT02670785|Drug|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
196997|NCT02670785|Drug|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
196998|NCT02670772|Drug|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
196999|NCT02670772|Drug|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
197085|NCT02670096|Drug|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
197086|NCT02670083|Drug|Crenezumab|Crenezumab will be administered by IV infusion q4w for 100 weeks.
197000|NCT02670759|Drug|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
197001|NCT02670759|Drug|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
197002|NCT02670733|Procedure|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
197003|NCT02670720|Drug|avoralstat|
197004|NCT02670707|Drug|Cytarabine|Cytarabine 100 mg/m^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
197005|NCT02670707|Drug|Vinblastine/prednisone|"Vinblastine 6 mg/m^2/dose IV push weekly~Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
197006|NCT02670681|Behavioral|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
197007|NCT02670668|Other|Mutation analysis|
197008|NCT02670655|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
197009|NCT02670655|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
197010|NCT02670655|Drug|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
197011|NCT02670655|Device|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
197012|NCT02670655|Device|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
197013|NCT02670642|Drug|Esomeprazole|Proton pump inhibitor
197014|NCT02670629|Procedure|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
197015|NCT02670629|Procedure|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
197016|NCT02670616|Drug|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
197017|NCT02670616|Drug|Rituximab|375 mg/m2 IV, day 1
197018|NCT02670616|Drug|Cyclophosphamide|750 mg/m2 IV day 1
197019|NCT02670616|Drug|Doxorubicin|50 mg/m2 IV day 1
197020|NCT02670616|Drug|vincristine|1.4 mg/m2 IV on day 1
197021|NCT02670616|Drug|Prednisolone|100mg per day on day 1-5
197022|NCT02670603|Drug|EVONAIL® solution|
197023|NCT02670590|Behavioral|diet|diet
197024|NCT02670564|Genetic|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).~For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
197025|NCT02670564|Other|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).~Blood sampling:~->For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion~->For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.~For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:~-> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
197026|NCT02670551|Drug|Cariprazine|
197027|NCT02670551|Drug|Placebo|
197028|NCT02670538|Drug|Cariprazine|Cariprazine capsule one per day orally.
197029|NCT02670538|Drug|Placebo|Matching placebo capsule one per day orally.
197030|NCT02670525|Genetic|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
197031|NCT02670512|Device|Telehome Monitoring|
197032|NCT02670499|Device|CPM|Used to aid in recovery from TKR
197033|NCT02670499|Device|GAPFLEX|Used to aid in the recovery of TKR
197034|NCT02670486|Other|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
197035|NCT02670473|Device|fanfilcon A (test)|contact lens
197036|NCT02670460|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
197037|NCT02670447|Procedure|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
197038|NCT02670434|Drug|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
197039|NCT02670434|Drug|Placebo|Placebo daily for 12 weeks
197040|NCT02670434|Drug|Livalo|Livalo® IR daily from week 12 to week 52
197087|NCT02670083|Drug|Placebo|Placebo will be administered as IV infusion q4w for 100 weeks.
197041|NCT02670421|Behavioral|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
197042|NCT02670421|Behavioral|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
197043|NCT02670421|Behavioral|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
197044|NCT02670408|Procedure|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.
197045|NCT02670395|Drug|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
197046|NCT02670395|Drug|Placebo|Placebo solution will be administered orally.
197047|NCT02670382|Dietary Supplement|EPA|10 week supplementation
197048|NCT02670382|Dietary Supplement|DHA|10 week supplementation
197049|NCT02670382|Dietary Supplement|sunflower oil|10 week supplementation
197050|NCT02670369|Behavioral|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
197051|NCT02670356|Dietary Supplement|Fish oil|two 750 mg/capsules/day
197052|NCT02670356|Dietary Supplement|Krill oil|one 300 mg capsule/day
197053|NCT02670343|Drug|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
197054|NCT02670330|Drug|SD-101-6.0 cream|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
197055|NCT02670317|Drug|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
197056|NCT02670317|Drug|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
197057|NCT02670317|Drug|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
197058|NCT02670304|Drug|letrozole|letrozole from the day of oocyte retrieval for 5 days
197059|NCT02670304|Drug|Aspirin|aspirin from the day of oocyte retrieval for 5 days
197060|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
197061|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
197062|NCT02670265|Dietary Supplement|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
197063|NCT02670265|Dietary Supplement|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
197064|NCT02670252|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
197065|NCT02670252|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
197066|NCT02670252|Radiation|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
197067|NCT02670239|Procedure|normothermic ex vivo lung perfusion|
197068|NCT02670226|Other|Samples|Blood samples, muscle biopsy
197069|NCT02670213|Drug|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
197070|NCT02670200|Behavioral|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
197071|NCT02670187|Biological|GLS-5300|
197072|NCT02670174|Other|Traditional training|
197073|NCT02670174|Other|Separate kinetic chain training|
197074|NCT02670174|Other|Integrated kinetic chain training|
197075|NCT02670161|Drug|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
197076|NCT02670148|Procedure|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
197077|NCT02670135|Drug|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
197078|NCT02670135|Drug|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
197079|NCT02670122|Device|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
197080|NCT02670109|Drug|Carmustine|300mg/m2, IV, in 3 hours, during day -4
197081|NCT02670109|Drug|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
197082|NCT02670109|Drug|Carboplatin|1400/m2, IV, in 1 hour, during day -3
197083|NCT02670109|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
197084|NCT02670109|Drug|Busulfan|16mg/kg, Oral, during day -4
197088|NCT02670070|Drug|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
197089|NCT02670057|Procedure|Transnasal SPG block|
197090|NCT02670044|Drug|Cobimetinib|Cobimetinib will be administered orally daily on Days 1-21 of each 28-day treatment cycle.
197091|NCT02670044|Drug|Idasanutlin|Idasanutlin will be administered orally daily or twice daily on Days 1-5 of each 28 day treatment cycle.
197092|NCT02670044|Drug|Venetoclax|Venetoclax will be administered orally daily on Days 1-28 of each 28 day treatment cycle.
197093|NCT02670031|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
197094|NCT02670031|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
197095|NCT02670031|Other|Electrocardiogram|To examine specific function of the heart.
197096|NCT02670031|Device|Ambulatory Blood Pressure Monitoring|A 24-hour test.
197097|NCT02670018|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets, for 1 day
197098|NCT02670018|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets, for 1day
197099|NCT02669992|Procedure|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
197100|NCT02669992|Procedure|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
197101|NCT02669979|Other|Intervention|Professional oral care
197102|NCT02669966|Procedure|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
197103|NCT02669953|Drug|Aflibercept|
197104|NCT02669927|Other|Observational|
197105|NCT02669914|Drug|MEDI4736|
197106|NCT02669901|Behavioral|Naloxone Auto-Injector|Naloxone auto-injector is the only product FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
197107|NCT02669888|Drug|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
197108|NCT02669888|Drug|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
197109|NCT02669875|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
197110|NCT02669875|Drug|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
197111|NCT02669862|Drug|A-101 Solution 40|
197112|NCT02669862|Drug|A-101 Solution 45|
197113|NCT02669862|Drug|Vehicle Solution|
197114|NCT02669849|Drug|VX-210|
197115|NCT02669849|Drug|Placebo|
197116|NCT02669836|Procedure|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
197117|NCT02669836|Procedure|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
197118|NCT02669823|Other|None, treatment as actual best practice|
197119|NCT02669810|Drug|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
197120|NCT02669810|Device|Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)|
197121|NCT02669797|Behavioral|In-home Visits and Food Preparation Activities|"Families will participate in twelve in-home education activities. The visits will focus on family meal quality (dietary, interpersonal) and quantity (meal frequency) factors found in prior studies to be associated with child weight and weight-related behaviors. Eight of the visits (every other week) will be delivered by a CHW and will last 90 minutes. Additionally ,a family meal food preparation activity will occur to help support families in learning skills to increase family meal quality and quantity. On weeks opposite of the in-home education visits with a CHW, families will be given a Try it Yourself activity to reinforce the messages (e.g., use family meals as a family connection time) and skills (e.g., recipe that requires families to steam vegetables) taught by the CHW during the in-home education visits."
197122|NCT02669797|Behavioral|Ecological Momentary Intervention|Parents will receive daily EMI messages regarding suggestions for increasing meal quality/quantity via a smartphone application, based on the stress level and source of stress they reported earlier in the day. Specifically, parents will receive two push notifications in the morning to report their stress level and type/source of stress (e.g., work, children, finances). Then, based on the reported stress level and source of stress, parents will be texted tips/ideas for carrying out a nutritionally and emotionally healthful family meal the same night, in the face of stress. If parents report no stress on their EMI measure earlier in the day, they will be provided with a menu of options regarding what type of meal tip they would prefer later in the day (e.g., recipe ideas, meal prep tips, mealtime conversation starters. Parents will be able to respond to the EMI messages indicating preferred tips so that EMI tips become more meaningful/relevant to the needs of each family.
197123|NCT02669797|Behavioral|Feedback on Video-recorded Family Meals|Parents will video-record and upload via an iPad (study provided) one family meal every other week, which will be watched by intervention staff. Using Motivational Interviewing, CHWs will give specific feedback on how to adapt negative mealtime behaviors and provide reinforcement for positive behaviors seen in the videos, based on a validated interpersonal coding tool called the Iowa Family Interaction Rating Scales (IFIRS). Additionally, feedback will be given on the dietary healthfulness of the meal, based on a validated coding tool called the Healthfulness of Meal Index (HOM). After feedback, family members will be taught specific skills to improve their family meal processes and behaviors that vary from food preparation skills, to increasing healthful food options at meals, or role-playing family interactions to improve the emotional atmosphere at the meal. Families will also set SMART goals at each visit regarding family meal quality and quantity.
197124|NCT02669797|Behavioral|Maintenance|After 16 weeks, EMI family meal tips for all arms will be reduced to only the days in which parent's report their highest stress levels. Stress profiles will be created for each parent in order to tailor the EMI family meals tips to days in which they experience their highest levels of stress. For example, during the 16-weeks of EMI, a parent may report their highest stress levels on Tuesdays and Thursdays. The stress profile that would be created for the parent during the maintenance phase would include receiving text messages only on Tuesdays and Thursdays. The parent would then receive these EMI family meal tips only on Tuesdays and Thursdays throughout the 8-week maintenance phase..
197125|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 40mL|The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
197126|NCT02669784|Drug|Low Dose Contrast (Omnipaque) 50 mL|The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
197127|NCT02669771|Drug|enzalutamide|oral
197128|NCT02669758|Drug|ALKS 3831|Tablets were administered for daily dosing
197129|NCT02669732|Drug|DS-8500a|tablets
197130|NCT02669732|Drug|placebo|tablets
197131|NCT02669719|Biological|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
197132|NCT02669719|Drug|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
197133|NCT02669706|Drug|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
197134|NCT02669693|Dietary Supplement|bread without olives|
197135|NCT02669693|Dietary Supplement|bread with olives|
197136|NCT02669680|Drug|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
197137|NCT02669680|Other|Standard therapy|
197138|NCT02669667|Drug|MEDI9314|single dose of MEDI9314
197139|NCT02669667|Drug|placebo|single dose of placebo
197140|NCT02669654|Other|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
197141|NCT02669641|Dietary Supplement|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
197142|NCT02669628|Procedure|Surgical technique|Laparoscopic surgery
197143|NCT02669628|Procedure|Alcohol sclerotherapy|US-guided sclerotherapy
197144|NCT02669615|Drug|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m^2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
197145|NCT02669589|Drug|Heparin|
197146|NCT02669589|Drug|Citrate|
197147|NCT02669576|Behavioral|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
197148|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
197149|NCT02669563|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
197150|NCT02669563|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
197151|NCT02669563|Drug|[13N]ammonia|IV injection of [13N]ammonia
197152|NCT02669563|Drug|[11C]HED|IV injection of [11C]HED
197153|NCT02669550|Device|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
197154|NCT02669550|Device|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
197155|NCT02669537|Device|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
197156|NCT02669524|Drug|LY2409021|
197157|NCT02669524|Drug|LY2409021 placebo|
197158|NCT02669524|Procedure|OGTT|
197159|NCT02669524|Procedure|IIGI|
197160|NCT02669524|Procedure|Standardised liquid meal|
197161|NCT02669511|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
197162|NCT02669498|Procedure|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
197163|NCT02669485|Drug|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
197164|NCT02669485|Device|Fluorescence imaging|
197165|NCT02669472|Other|Environmental Intervention|Intervention sites received regularly-scheduled, discount, fresh F&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
197202|NCT02669173|Drug|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
197203|NCT02669173|Drug|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
197204|NCT02669160|Device|PC Innowalk|
197166|NCT02669472|Behavioral|Educational Intervention|Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
197167|NCT02669472|Behavioral|Control|We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
197168|NCT02669459|Drug|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
197169|NCT02669459|Procedure|LLETZ|surgical treatment for CIN, current gold standard
197170|NCT02669446|Device|Medical devices|
197171|NCT02669446|Device|traditional household remedy|
197172|NCT02669433|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
197173|NCT02669433|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
197174|NCT02669433|Drug|Placebo|once daily, oral, matching tablets
197175|NCT02669420|Procedure|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
197176|NCT02669407|Procedure|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
197177|NCT02669407|Drug|regional nerve block with a local anesthetic (Lidocaine)|
197178|NCT02669394|Behavioral|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
197179|NCT02669394|Behavioral|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
197180|NCT02669381|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
197181|NCT02669368|Drug|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
197182|NCT02669368|Drug|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
197183|NCT02669368|Drug|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
197184|NCT02669368|Drug|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
197185|NCT02669342|Device|Radiance™ Clear Sharklet® Silicone Foley Catheter|
197186|NCT02669342|Device|Silicone Foley Catheter|
197187|NCT02669329|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
197188|NCT02669303|Drug|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
197189|NCT02669303|Drug|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
197190|NCT02669290|Other|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
197191|NCT02669290|Other|Non-guided|LV lead placement will be conventional posterolateral placement
197192|NCT02669277|Drug|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
197193|NCT02669277|Drug|standard IVIG product|to compare efficacy and safety with the minipool IVIG
197194|NCT02669264|Drug|ADCT-402|Intravenous infusion
197195|NCT02669251|Drug|MPH966|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"
197196|NCT02669238|Device|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
197197|NCT02669238|Drug|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
197198|NCT02669225|Radiation|[18F]florbetaben|PET radiotracer to image Amyloid beta
197199|NCT02669199|Biological|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
197200|NCT02669186|Drug|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
197201|NCT02669186|Drug|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
197205|NCT02669160|Device|Conventional passive stander|
197206|NCT02669134|Other|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
197207|NCT02669121|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV: 15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum as Al(OH)3, administered as 0.5 mL intramuscularly (IM)
197208|NCT02669121|Biological|NoV vaccine placebo|NoV vaccine placebo-matching solution [saline (0.9% sodium chloride)] administered as 0.5 mL intramuscularly (IM)
197209|NCT02669108|Device|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
197210|NCT02669095|Device|Investigational Contact Lenses (Test)|
197211|NCT02669095|Device|Marketed Contact Lenses (Control)|
197212|NCT02669082|Drug|Ramelteon|Ramelteon tablets
197213|NCT02669069|Device|PS1|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are synchronous with the tones.
197214|NCT02669069|Device|PS2|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
197215|NCT02669069|Device|PS3|Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
197216|NCT02669056|Other|5-HT measurement|
197217|NCT02669056|Other|cerebral MRI|
197218|NCT02669056|Other|Video recording|
197219|NCT02669056|Other|EEG|
197220|NCT02669056|Other|growth curves|
197221|NCT02669056|Other|ASQ questionnaire|
197222|NCT02669043|Drug|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
197223|NCT02669030|Drug|suvorexant|an FDA-approved sleep aid
197224|NCT02669030|Drug|Placebo|control group
197225|NCT02669017|Drug|ADCT-402|intravenous infusion
197226|NCT02669004|Drug|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
197227|NCT02669004|Drug|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
197228|NCT02668978|Device|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
197229|NCT02668978|Procedure|Standard surgical technique|Lung resuturing or restapling
197230|NCT02668965|Procedure|Intrauterine hCG (pregnyl)|
197231|NCT02668952|Drug|0.9% Normal Saline (0.9% Sodium Chloride) injection|
197232|NCT02668952|Drug|Isolyte S injection|
197233|NCT02668926|Drug|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
197234|NCT02668926|Drug|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
197235|NCT02668926|Drug|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
197236|NCT02668913|Other|Diagnostic analysis|Molecular profiling
197237|NCT02668900|Behavioral|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
197238|NCT02668887|Behavioral|Quality of Life, status of employment|
197239|NCT02668874|Device|Isolite® technique|The Isolite technique utilizes a flexible plastic dental adapter to separate the cheek and tongue prior to sealant application.
197240|NCT02668874|Device|Cotton Roll technique|A cotton roll is placed between the cheek and tongue prior to sealant application
197241|NCT02668861|Drug|Vitamin D|Vitamin D 4000IU/day for 8 weeks
197242|NCT02668861|Drug|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
197243|NCT02668861|Other|placebo|placebo for 8 weeks
197244|NCT02668848|Dietary Supplement|water|If USG>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
197245|NCT02668835|Device|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
197246|NCT02668835|Genetic|Non intervention-Genetic testing|
197247|NCT02668822|Drug|ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)|Medicated vaginal ring
197248|NCT02668822|Drug|Placebo vaginal ring|Placebo vaginal ring
197249|NCT02668822|Drug|Ibuprofen|Ibuprofen 400-mg tablets, to be taken orally, were provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may have taken 400 mg every 4 hours as needed for pelvic pain/cramping.
197281|NCT02668640|Biological|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
197250|NCT02668809|Other|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
197251|NCT02668809|Other|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
197252|NCT02668809|Other|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
197253|NCT02668809|Other|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
197254|NCT02668809|Other|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
197255|NCT02668809|Other|Varnish application|"1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish."
197256|NCT02668809|Other|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
197257|NCT02668809|Other|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
197258|NCT02668796|Drug|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
197259|NCT02668796|Drug|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
197260|NCT02668796|Drug|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
197261|NCT02668783|Drug|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
197262|NCT02668783|Drug|Placebo vaginal ring|Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
197263|NCT02668783|Drug|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
197264|NCT02668770|Drug|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
197265|NCT02668770|Drug|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
197266|NCT02668757|Behavioral|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
197267|NCT02668744|Behavioral|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
197268|NCT02668718|Radiation|Adjuvant radiotherapy|The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
197269|NCT02668705|Other|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
197270|NCT02668692|Drug|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
197271|NCT02668692|Drug|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
197272|NCT02668679|Procedure|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
197273|NCT02668679|Device|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
197274|NCT02668679|Biological|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
197275|NCT02668679|Other|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
197276|NCT02668666|Drug|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
197277|NCT02668666|Drug|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
197278|NCT02668653|Drug|Chemotherapy|
197279|NCT02668653|Drug|Quizartinib|
197280|NCT02668653|Drug|Placebo|
197282|NCT02668627|Procedure|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
197283|NCT02668614|Device|WR-22 model microwave sensor|
197284|NCT02668588|Drug|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
197285|NCT02668588|Drug|extended release of placebo|1 intramuscular injection of extended release of placebo
197286|NCT02668575|Behavioral|Supportive Care Intervention|Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
197287|NCT02668562|Procedure|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
197288|NCT02668562|Procedure|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
197289|NCT02668549|Other|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
197290|NCT02668536|Drug|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
197291|NCT02668536|Device|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
197292|NCT02668523|Device|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
197293|NCT02668510|Biological|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
197294|NCT02668510|Drug|Normal saline|placebo injection of normal saline immediately following shockwave therapy
197295|NCT02668497|Drug|Botulinum Toxin Type A|
197296|NCT02668484|Device|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
197297|NCT02668484|Device|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
197298|NCT02668471|Procedure|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
197299|NCT02668471|Procedure|traditional method|Radial artery catheters will be placed by the palpation technique only.
197300|NCT02668458|Procedure|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
197301|NCT02668458|Procedure|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
197302|NCT02668445|Other|Standard meal containing low or high carbohydrate content|
197303|NCT02668432|Drug|Amiodarone|Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.
197304|NCT02668419|Device|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
197305|NCT02668419|Other|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure >15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as >200 mmHg; 6) a rise in diastolic blood pressure during exercise >110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
197306|NCT02668406|Other|Venous blood sampling (2 timepoints) (Phase A and B)|8.5ml at Day 1 + 8.5ml at Day 5
197307|NCT02668406|Other|Venous blood sampling (1 timepoint) (Phase A and B)|8.5ml at Day 1
197308|NCT02668406|Other|Voided urine sampling (first sample) (Phase A)|At least 20ml upon confirmation of being part of one of the 3 study groups
197309|NCT02668406|Other|Voided urine sampling (second sample) (Phase A)|At least 20ml during routine hospital stay or routine follow-up visit
197310|NCT02668393|Drug|Docetaxel|
197311|NCT02668393|Drug|Nintedanib|Low Dose
197312|NCT02668393|Drug|Nintedanib|Medium dose
197313|NCT02668393|Drug|Nintedanib|High dose
197314|NCT02668393|Drug|Nintedanib|Continuous high dose
197315|NCT02668367|Drug|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
197316|NCT02668367|Drug|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
197317|NCT02668341|Other|non-interventional|non-interventional survey study
197318|NCT02668328|Behavioral|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
197319|NCT02668315|Biological|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
197408|NCT02667795|Other|Monitored walking based exercise|Monitored walking based exercise
197320|NCT02668302|Combination Product|Steroid-eluting sinus implant|PROPEL (Intersect ENT, Inc., Menlo Park, CA), containing 370μg of mometasone furoate gradually released over 30 days
197321|NCT02668302|Other|Post-op standard of care|Post-op standard of care including debridement, irrigation, and/or topical steroids
197322|NCT02668289|Other|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
197323|NCT02668289|Other|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
197324|NCT02668289|Other|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
197325|NCT02668289|Other|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
197326|NCT02668289|Other|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
197327|NCT02668289|Other|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
197328|NCT02668289|Other|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
197329|NCT02668289|Procedure|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
197330|NCT02668289|Other|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
197331|NCT02668276|Other|Standard NCCN counseling|
197332|NCT02668276|Other|Standard NCCN counseling and Oncotype DX results|
197333|NCT02668263|Procedure|Surgery alone|Surgery
197334|NCT02668263|Procedure|Surgery and Drain(s)|Drains inserted as per standard practice
197335|NCT02668263|Procedure|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
197336|NCT02668250|Procedure|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
197337|NCT02668250|Procedure|Usual Care|Patients receive the usual care.
197338|NCT02668237|Other|OptiPAC|Molecular and urinary tests.
197339|NCT02668237|Other|Usual care|Antibiotics for prevention.
197340|NCT02668224|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
197341|NCT02668224|Other|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
197342|NCT02668211|Device|PROFEMUR Preserve Classic Femoral Components|
197343|NCT02668198|Device|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
197344|NCT02668198|Device|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
197345|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
197346|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine the area of prior EMR site.
197347|NCT02668198|Procedure|Biopsy|Biopsy to assess any evidence of residual neoplasia via standard histopathology assessment
197348|NCT02668185|Drug|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
197349|NCT02668185|Drug|Placebo|Placebo
197350|NCT02668172|Drug|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
197351|NCT02668172|Drug|Pegvisomant|only in combination with pasireotide LAR
197352|NCT02668159|Dietary Supplement|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
197353|NCT02668159|Dietary Supplement|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
197354|NCT02668159|Dietary Supplement|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
197355|NCT02668159|Dietary Supplement|Placebo|7 tablets of placebos administered prior to one the OGTT
197356|NCT02668146|Drug|Perampanel|Study drug will be administered to study subjects
197357|NCT02668146|Drug|Placebo|Placebo will be administered to study subjects
197358|NCT02668133|Dietary Supplement|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
197359|NCT02668133|Dietary Supplement|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS) added during manufacturing
197360|NCT02668133|Dietary Supplement|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
197361|NCT02668133|Dietary Supplement|1 mg isotopically enriched 68Zn|administered intravenously
197362|NCT02668107|Other|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
197363|NCT02668094|Drug|Lidocaine|
197364|NCT02668094|Drug|Pregabalin|
197365|NCT02668094|Drug|propofol|
197366|NCT02668081|Procedure|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
197367|NCT02668081|Procedure|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
197368|NCT02668068|Procedure|large volume whole-lung lavage (WLL)|Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
197449|NCT02667496|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
197369|NCT02668068|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
197370|NCT02668055|Biological|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
197371|NCT02668042|Biological|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
197372|NCT02668029|Drug|oxygen|information already included in arm/group descriptions.
197373|NCT02668029|Drug|medical air|Placebo
197374|NCT02668016|Drug|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
197375|NCT02668016|Other|Placebo|Placebo tablets taken orally once daily for one month
197376|NCT02668003|Behavioral|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
197377|NCT02667990|Other|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
197378|NCT02667990|Other|standard stiletto|standard stiletto without insole
197379|NCT02667990|Other|comfy trainer|comfy trainer
197380|NCT02667977|Other|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
197381|NCT02667977|Other|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
197382|NCT02667964|Other|spiroergometry|Spiroergometry on a bicycle ergometer
197383|NCT02667951|Other|A home-based caregiver-training program|This training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
197384|NCT02667938|Drug|HCP1303 capsule 5/0.2mg|
197385|NCT02667938|Drug|HCP1303 capsule 5/0.4mg|
197386|NCT02667938|Drug|HGP1201|
197387|NCT02667938|Drug|HCP1303 capsule 5/0.2mg placebo|
197388|NCT02667938|Drug|HCP1303 capsule 5/0.4mg placebo|
197389|NCT02667938|Drug|HGP1201 placebo|
197390|NCT02667925|Drug|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
197391|NCT02667912|Procedure|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to segmental branches renal artery in a number of points distributed along the length and circumference of the vessels in order to ablate renal nerve plexus
197392|NCT02667912|Procedure|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode (Symplicity Flex; Medtronic, Inc.) is used for stepwise radiofrequency energy delivery to the main trunk of renal artery in a number of points equally distributed along its length and circumference in order to ablate renal nerve plexus
197393|NCT02667899|Device|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
197394|NCT02667899|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
197395|NCT02667899|Other|Routine treatment|Means without above additional treatment.
197396|NCT02667886|Drug|X4P-001|Continuous, oral, once-daily dosing
197397|NCT02667886|Drug|axitinib|Continuous, oral, twice-daily dosing
197398|NCT02667873|Drug|SL-801|SL-801 is a small molecule inhibitor of the nuclear export protein Exportin-1 (XPO1).
197399|NCT02667860|Procedure|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
197400|NCT02667860|Procedure|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
197401|NCT02667860|Device|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
197402|NCT02667860|Device|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
197403|NCT02667834|Behavioral|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
197404|NCT02667834|Behavioral|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
197405|NCT02667821|Other|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
197406|NCT02667808|Other|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
197407|NCT02667808|Other|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
197478|NCT02667288|Drug|A-101 Solution|
197409|NCT02667782|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
197410|NCT02667782|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
197411|NCT02667769|Other|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose <55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
197412|NCT02667756|Other|Non-interventional|
197413|NCT02667743|Drug|Paclitaxel Micelles for Injection|
197414|NCT02667743|Drug|Paclitaxel Injection|
197415|NCT02667743|Drug|Cisplatin|
197416|NCT02667730|Drug|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
197417|NCT02667730|Drug|Naproxen|naproxen 500mg twice daily for 7 days
197418|NCT02667730|Drug|Celecoxib|celecoxib 100mg twice daily
197419|NCT02667730|Other|physiotherapy only|physiotherapy only (no drug)
197420|NCT02667717|Behavioral|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
197421|NCT02667717|Behavioral|Usual care|Patients will have the usual care as an intervention.
197422|NCT02667704|Drug|Bosentan|
197423|NCT02667704|Drug|Nintedanib|
197424|NCT02667691|Dietary Supplement|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
197425|NCT02667691|Dietary Supplement|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
197426|NCT02667691|Other|caloric restriction|Caloric recommendation reduced by 20%
197427|NCT02667678|Biological|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
197428|NCT02667652|Procedure|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
197429|NCT02667652|Procedure|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
197430|NCT02667639|Biological|RPH-104|Anti-IL-1 Mab
197431|NCT02667639|Other|Sodium chloride Sterile Injection 0.9% w/v|Sterile saline solution
197432|NCT02667626|Other|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
197433|NCT02667626|Other|Control|Web-based resource lists and text-based study adherence reminders
197434|NCT02667613|Other|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
197435|NCT02667613|Other|Control|Usual customary care
197436|NCT02667587|Drug|Nivolumab|
197437|NCT02667587|Drug|Temozolomide|
197438|NCT02667587|Radiation|Radiotherapy|
197439|NCT02667587|Other|Nivolumab Placebo|
197440|NCT02667574|Drug|ERIVEDGE|
197441|NCT02667561|Drug|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
197442|NCT02667561|Drug|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
197443|NCT02667561|Drug|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
197444|NCT02667561|Drug|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
197445|NCT02667548|Procedure|PCI|percutaneous coronary intervention
197446|NCT02667535|Drug|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.~Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
197447|NCT02667522|Behavioral|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
197448|NCT02667496|Drug|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
197450|NCT02667496|Drug|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
197451|NCT02667483|Drug|DS-5141b|DS-5141b, Subcutaneous injection
197452|NCT02667470|Drug|Solifenacin|Oral
197453|NCT02667457|Radiation|99mTc-rhAnnexin V-128|
197454|NCT02667444|Drug|SB204 4%|Applied topically once daily
197455|NCT02667444|Drug|Vehicle Gel|Applied topically one daily
197456|NCT02667418|Drug|Fidaxomicin|200 mg PO twice daily for 10 days
197457|NCT02667418|Drug|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
197458|NCT02667418|Drug|Vancomycin|125 mg PO for times daily for 10 days
197459|NCT02667405|Procedure|Hot Pack|Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
197460|NCT02667405|Procedure|Whirlpool|Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
197461|NCT02667392|Procedure|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
197462|NCT02667392|Procedure|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
197463|NCT02667379|Other|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
197464|NCT02667366|Behavioral|Tel-PT|
197465|NCT02667366|Behavioral|TAU and text messages|
197466|NCT02667353|Procedure|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) < 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
197467|NCT02667353|Drug|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
197468|NCT02667353|Drug|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
197469|NCT02667340|Dietary Supplement|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game & at halftime)
197470|NCT02667340|Other|Placebo|0.7 g glucose per kg body mass in two ingestions (before game & at halftime)
197471|NCT02667327|Drug|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
197472|NCT02667327|Other|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
197473|NCT02667314|Behavioral|Jigsaw puzzles|"Intervention period 1: Participants are asked to solve jigsaw puzzles at home 6 times per week for at least 1 hour over a period of 5 weeks.~Intervention period 2 (voluntary): Participants receive the possibility to solve jigsaw puzzles free-of-charge at home for a period of at least 3 month before the 1.5-year follow-up."
197474|NCT02667314|Behavioral|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)
197475|NCT02667301|Device|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
197476|NCT02667301|Device|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
197477|NCT02667301|Device|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
197481|NCT02667262|Other|Algorithm to identify patients experiencing opioid abuse/addiction|
197482|NCT02667249|Other|clinical pathway|implementation of a standardized clinical pathway
197483|NCT02667236|Drug|A-101 Solution|Active Drug
197484|NCT02667236|Other|Vehicle Solution|Placebo
197485|NCT02667223|Biological|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
197486|NCT02667223|Biological|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
197487|NCT02667223|Biological|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
197488|NCT02667223|Biological|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
197489|NCT02667223|Biological|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
197490|NCT02667210|Other|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
197491|NCT02667197|Other|Algorithm to determine overdose from opioid abuse|
197492|NCT02667184|Dietary Supplement|Low FODMAP Oral Nutrition Supplement|
197493|NCT02667171|Behavioral|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).~Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
197494|NCT02667171|Behavioral|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.~Educations consists same information as for the control group."
197495|NCT02667158|Other|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
197496|NCT02667145|Other|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
197497|NCT02667119|Behavioral|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.~Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
197498|NCT02667119|Behavioral|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
197499|NCT02667106|Drug|RX0041-2|Pharmacokinetic study
197500|NCT02667080|Other|2-7 days of Sexual abstinence|2-7 days of Sexual abstinence
197501|NCT02667080|Other|2 hours of sexual abstinence|2 hours of sexual abstinence
197502|NCT02667067|Device|Simplify Disc|Simplify Disc at one level in the cervical spine.
197503|NCT02667067|Device|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®|C Disc trial."
197504|NCT02667054|Drug|RX0041 4%|Anesthetic
197505|NCT02667054|Drug|Placebo|Placebo Comparator
197506|NCT02667054|Drug|RX0041 8%|Anesthetic
197507|NCT02667041|Device|NeuroQore rTMS Device|
197508|NCT02667028|Procedure|PCI|percutaneous coronary intervention
197509|NCT02667015|Behavioral|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
197510|NCT02667002|Procedure|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
197511|NCT02667002|Procedure|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
197512|NCT02667002|Other|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
197513|NCT02666989|Drug|placebo|2 placebo pills twice a day
197514|NCT02666976|Drug|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
197515|NCT02666963|Drug|RTA 901 Capsules, 10 or 40 mg|
197516|NCT02666963|Drug|Placebo|
197517|NCT02666950|Drug|Cytarabine|Given SC
197518|NCT02666950|Other|Laboratory Biomarker Analysis|Correlative studies
197519|NCT02666950|Other|Pharmacological Study|Correlative studies
197520|NCT02666950|Other|Quality-of-Life Assessment|Ancillary studies
197521|NCT02666950|Other|Questionnaire Administration|Ancillary studies
197522|NCT02666950|Drug|WEE1 Inhibitor AZD1775|Given PO
199170|NCT02655354|Drug|Paroxetine|Anti-depressant
197523|NCT02666924|Dietary Supplement|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
197524|NCT02666924|Other|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
197525|NCT02666911|Procedure|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
197526|NCT02666911|Procedure|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
197527|NCT02666898|Drug|GA101|"Part 1 :6 cycles~Obinutuzumab/GA101:~First cycle:~D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v~Cycle 2 to 6 (every 28 days) :~D1 of every cycle: 1000 mg i.v PART 2 4 cycles~-patients have BM MRD >10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1"
197528|NCT02666898|Drug|Ibrutinib|"Part 1 :6 cycles~Cycle 2 to 6 (every 28 days) :Ibrutinib:~D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles~patients in CR with BM MRD < 10-4 : Ibrutinib alone 420mg daily~patients with BM MRD >10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine"
197529|NCT02666898|Drug|Cyclophosphamide|"PART 2 :~patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine"
197530|NCT02666898|Drug|Fludarabine|"PART 2 :~patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide"
197531|NCT02666885|Radiation|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
197532|NCT02666872|Behavioral|Motivational interviewing|
197533|NCT02666859|Device|Virtual Reality|During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
197534|NCT02666846|Drug|Ibuprofen|Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).
197535|NCT02666846|Drug|Diclofenac|Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
197536|NCT02666846|Drug|Methyl-salicylate / Menthol|Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
197537|NCT02666846|Drug|Placebo|The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
197538|NCT02666833|Device|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
197539|NCT02666820|Procedure|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
197540|NCT02666820|Procedure|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
197541|NCT02666807|Dietary Supplement|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
197542|NCT02666807|Dietary Supplement|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
197543|NCT02666794|Drug|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
197544|NCT02666794|Drug|Epidural sufentanil|10 mcg
197545|NCT02666794|Procedure|Placement of the epidural catheter|Placement of the epidural catheter
197546|NCT02666794|Drug|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
197547|NCT02666794|Drug|Intrathecal morphine|60 mcg
197548|NCT02666794|Procedure|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
197549|NCT02666794|Drug|Intrathecal sufentanil|5 mcg
197585|NCT02666508|Other|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
197550|NCT02666781|Other|ApneaLink Plus, BIA Device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
197551|NCT02666768|Drug|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
197552|NCT02666742|Drug|Apixaban|Apixaban is a blood thinning drug, also called an anticoagulant. Apixaban is approved by the U.S. Food and Drug Administration (FDA) for the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
197553|NCT02666742|Drug|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
197554|NCT02666729|Procedure|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
197555|NCT02666729|Procedure|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
197556|NCT02666716|Drug|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
197557|NCT02666703|Device|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
197558|NCT02666703|Drug|Methylprednisolone|
197559|NCT02666690|Device|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
197560|NCT02666664|Drug|ETC-1002|ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
197561|NCT02666664|Drug|Placebo|Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
197562|NCT02666651|Drug|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
197563|NCT02666651|Other|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
197564|NCT02666638|Other|Control Volunteers|MRI on up to a 7T scanner without contrast.
197565|NCT02666638|Other|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
197566|NCT02666625|Procedure|saliva samples|
197567|NCT02666625|Procedure|blood samples|
197568|NCT02666612|Procedure|Blood samples|
197569|NCT02666599|Radiation|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.~Resected pieces will be analysed histologically."
197570|NCT02666586|Other|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
197571|NCT02666586|Other|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
197572|NCT02666586|Other|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
197573|NCT02666586|Other|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
197574|NCT02666586|Other|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
197575|NCT02666573|Device|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
197576|NCT02666573|Other|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
197577|NCT02666560|Device|Auditory Cueing|Auditory cueing set at different frequency rates
197578|NCT02666547|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
197579|NCT02666547|Radiation|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
197580|NCT02666547|Radiation|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
197581|NCT02666534|Drug|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
197582|NCT02666534|Device|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
197583|NCT02666534|Drug|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
197584|NCT02666534|Device|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
197586|NCT02666508|Other|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
197587|NCT02666495|Other|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement & stabilisation; phase 2 - developing trust & understanding; phase 3 - developing awareness & acceptance; phase 4 - testing change & strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
197588|NCT02666482|Behavioral|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
197589|NCT02666469|Other|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
197590|NCT02666469|Other|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
197591|NCT02666469|Device|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
197592|NCT02666456|Other|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
197593|NCT02666443|Drug|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
197594|NCT02666443|Drug|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
197595|NCT02666443|Drug|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
197596|NCT02666430|Drug|Mylan's insulin glargine|
197597|NCT02666430|Drug|Lantus®|
197598|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
197599|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
197600|NCT02666404|Other|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
197601|NCT02666391|Biological|umbilical cord mesenchymal stem cells|
197602|NCT02666378|Other|Cardiac Magnetic Resonance Imaging (CMR)|Subjects will be recruited for observational cardiac magnetic resonance imaging.
197603|NCT02666378|Other|Echocardiogram (ECHO)|Subjects will undergo a research echocardiogram if a clinical echocardiogram has not already been ordered.
197604|NCT02666365|Procedure|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
197605|NCT02666365|Procedure|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
197606|NCT02666352|Drug|Uprifosbuvir|A single dose of uprifosbuvir 450 mg (given as three 150-mg tablets) taken by mouth.
197607|NCT02666352|Drug|Ruzasvir|A single dose of ruzasvir 60 mg (given as six 10-mg capsules) taken by mouth.
197608|NCT02666339|Other|Usual care|Usual care : drug therapy, nurse and physician consultations.
197609|NCT02666339|Behavioral|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
197610|NCT02666326|Procedure|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is <9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is <14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
197611|NCT02666313|Behavioral|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.~Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
197612|NCT02666300|Other|TaperGuard ETT|tracheal intubation with TaperGuard ETT
197613|NCT02666287|Drug|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
197614|NCT02666287|Drug|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
197615|NCT02666287|Drug|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
197616|NCT02666287|Drug|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
197617|NCT02666287|Drug|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
197618|NCT02666235|Procedure|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
197619|NCT02666235|Procedure|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
197620|NCT02666222|Device|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
197621|NCT02666209|Drug|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
197622|NCT02666209|Drug|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
197623|NCT02666209|Drug|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
197624|NCT02666209|Drug|Dexamethasone|steroid given at physician discretion on a 28 day cycles
197625|NCT02666196|Drug|DAA-I|
197626|NCT02666196|Drug|Placebo|
197627|NCT02666183|Behavioral|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
197628|NCT02666183|Behavioral|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
197629|NCT02666183|Behavioral|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
197630|NCT02666170|Drug|Alpha-lipoic acid|
197631|NCT02666157|Drug|Dabigatran etexilate|this drug is administered twice per day for the entire study period
197632|NCT02666157|Drug|Rivaroxaban|this drug is administered once per day for the entire study period
197633|NCT02666157|Drug|Apixaban|this drug is administered twice per day for the entire study period
197634|NCT02666144|Device|Spectralis OCT|Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
197635|NCT02666118|Procedure|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
197636|NCT02666118|Procedure|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
197637|NCT02666118|Procedure|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
197638|NCT02666118|Procedure|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
197639|NCT02666105|Drug|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
197640|NCT02666092|Other|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
197641|NCT02666092|Biological|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
197642|NCT02666079|Device|LightPath® Imaging System.|Intra-operative use of the LightPath® Imaging System.
197643|NCT02666053|Drug|BMS-663068|BMS-663068
197644|NCT02666040|Device|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
197645|NCT02666040|Device|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
197646|NCT02666040|Procedure|Detecting the mode of admission to hospital|Ordinary admission or day surgery
197647|NCT02666040|Procedure|Duration of surgery|Time operating room
197648|NCT02666040|Procedure|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
197649|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
197650|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
197651|NCT02666014|Drug|Sugammadex|Reversal of neuromuscular blockade
197652|NCT02666014|Drug|Neostigmine|Reversal of neuromuscular blockade
197653|NCT02666001|Drug|BMS-663068|BMS-663068
197654|NCT02666001|Drug|Methadone|Methadone
197655|NCT02666001|Drug|Buprenorphine and Norbuprenorphine|Buprenorphine and Norbuprenorphine
197656|NCT02665988|Device|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
197657|NCT02665988|Device|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
197658|NCT02665975|Behavioral|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
197659|NCT02665975|Behavioral|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
197660|NCT02665962|Other|Perioperative Caloric Restriction Program|
197661|NCT02665936|Drug|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
197662|NCT02665936|Drug|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
197663|NCT02665936|Drug|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
197664|NCT02665923|Other|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
197665|NCT02665910|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
197666|NCT02665910|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
197667|NCT02665884|Other|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
197668|NCT02665871|Biological|one dose of Influenza Vaccine|
197669|NCT02665871|Biological|one dose of Influenza Vaccine|
197670|NCT02665871|Biological|placebo|
197671|NCT02665871|Biological|placebo|
197672|NCT02665858|Other|OCT Imaging|
197673|NCT02665845|Drug|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
197674|NCT02665845|Drug|Corticosteroids|Corticosteroids will be given to all patients.
197675|NCT02665832|Drug|DWJ1351|
197676|NCT02665832|Drug|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
197677|NCT02665819|Other|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
197678|NCT02665806|Drug|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
197679|NCT02665806|Drug|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
197680|NCT02665793|Other|DBPCFC to peanut cookie|
197681|NCT02665793|Other|Single-dose DBPCFC to peanut flour|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
197682|NCT02665793|Other|Single-dose DBPCFC to peanut butter|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
197683|NCT02665780|Procedure|Periodontal debridement|teeth cleaning
197684|NCT02665780|Other|Cetylpyridium chloride|mouthrinse
197685|NCT02665767|Device|Smartphone-based Telesonography|The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
197686|NCT02665754|Biological|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
197687|NCT02665754|Biological|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
197688|NCT02665754|Drug|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
197689|NCT02665741|Device|Olympus transparent cap|distal colonscope attachment
197690|NCT02665741|Device|Medivators Endocuff|distal colonscope attachment
197691|NCT02665741|Device|Control|No distal colonoscope attachments
197692|NCT02665728|Drug|BLI400 Laxative|
197693|NCT02665715|Other|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
197694|NCT02665715|Other|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
197695|NCT02665702|Drug|NVB|25mg/m2 ，D1，8
197696|NCT02665702|Drug|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
197697|NCT02665702|Drug|Endostar|15mg/d，d1-d7 civ
197698|NCT02665689|Drug|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
197699|NCT02665663|Device|medical device|
197700|NCT02665650|Biological|AFM13|
197701|NCT02665650|Biological|Pembrolizumab|
197702|NCT02665637|Drug|Trastuzumab|Each patient may receive single dose by intravenous infusion
197703|NCT02665624|Drug|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
197704|NCT02665624|Drug|Senna alone|comparison of bowel cleansing and patient comfort.
197705|NCT02665611|Behavioral|intervention for improvement of adherence|intervention for improvement of adherence
197706|NCT02665611|Behavioral|treatment as usual|The control group will be treated according to the usual stadard of care.
197707|NCT02665585|Procedure|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
197708|NCT02665572|Behavioral|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
197709|NCT02665533|Drug|Dexamethasone|Dexamethasone 8 mg
197710|NCT02665533|Drug|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
197711|NCT02665520|Procedure|liposuction for retrieval of own stem cells from fat cells|
197712|NCT02665507|Device|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
197713|NCT02665507|Device|Sham|Hand held laser that emits no LLLI
197714|NCT02665481|Behavioral|MBSR|
197715|NCT02665481|Behavioral|Exercise|
197716|NCT02665481|Behavioral|Health Education|
197717|NCT02665468|Behavioral|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
197718|NCT02665468|Behavioral|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
197719|NCT02665455|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (pre-meals and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
197720|NCT02665442|Device|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
197721|NCT02665429|Behavioral|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
197722|NCT02665416|Drug|Selicrelumab|Selicrelumab will be provided as concentrate for solution to be administered via SC injection or IV infusion.
197723|NCT02665416|Drug|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
197724|NCT02665416|Drug|Bevacizumab|Bevacizumab will be administered via IV infusion.
197725|NCT02665403|Other|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
197726|NCT02665403|Other|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
197727|NCT02665390|Procedure|Percutaneous cryoablation|Percutaneous cryoablation
197728|NCT02665377|Drug|ANP|
197729|NCT02665364|Biological|IFN-Kinoid|
197730|NCT02665364|Other|Placebo|
197731|NCT02665364|Other|ISA 51|
197732|NCT02665351|Drug|Peramivir|The two regimens of Peramivir were compared
197733|NCT02665338|Device|Transcranial Magnetic Stimulation|
197734|NCT02665325|Drug|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
197735|NCT02665286|Drug|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
197736|NCT02665286|Drug|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
197737|NCT02665286|Drug|Naproxen|Naproxen 500mg PO BID x 7 days
199171|NCT02655354|Drug|Setraline|Anti-depressant
197738|NCT02665286|Drug|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
197739|NCT02665273|Procedure|Greater occipital nerve block|Bilateral greater occipital nerve block
197740|NCT02665273|Drug|Bupivacaine|0.5 cc of 0.5% bupivacaine injected intradermally
197741|NCT02665260|Drug|Cantharidin|cantharidin 0.7% topical liquid
197742|NCT02665260|Drug|Placebo|Placebo topical liquid
197743|NCT02665260|Device|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
197744|NCT02665247|Behavioral|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
197745|NCT02665247|Other|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
197746|NCT02665234|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
197747|NCT02665234|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
197748|NCT02665221|Other|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
197749|NCT02665221|Drug|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
197750|NCT02665208|Other|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
197751|NCT02665208|Drug|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
197752|NCT02665208|Behavioral|Text Message Intervention (TMI)|
197753|NCT02665195|Other|saliva specimen|
197754|NCT02665195|Behavioral|questionnaire|
197755|NCT02665182|Behavioral|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
197756|NCT02665169|Behavioral|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
197757|NCT02665169|Other|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
197758|NCT02665156|Procedure|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
197759|NCT02665143|Drug|nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
197760|NCT02665143|Drug|AML induction (placebo)|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Nintedanib or placebo will be added at day 8 and continued until end of cycle.
197761|NCT02665130|Other|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
197762|NCT02665130|Other|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
197763|NCT02665117|Drug|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
197764|NCT02665117|Drug|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
197765|NCT02665117|Drug|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
197766|NCT02665104|Device|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
197767|NCT02665091|Behavioral|Peer Education Program|
197768|NCT02665078|Other|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
197769|NCT02665065|Drug|Iomab-B|
197770|NCT02665065|Drug|Conventional Care|
197771|NCT02665065|Procedure|HCT|
197772|NCT02665052|Device|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
197773|NCT02665052|Device|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
197774|NCT02665052|Behavioral|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
197775|NCT02665039|Drug|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:~280 mg/m2 in patients with GFR 40-60 ml/min~250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min"
197776|NCT02665039|Drug|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
197777|NCT02665039|Drug|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
197778|NCT02665026|Procedure|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
197779|NCT02665013|Behavioral|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
197780|NCT02665013|Behavioral|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
197781|NCT02665000|Procedure|Structured training programme|Participants will undergo 5-days training sessions
197782|NCT02664987|Other|Patients receiving cancer pain treatment|
197783|NCT02664974|Dietary Supplement|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.~Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.~Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
197784|NCT02664974|Other|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.~Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
197785|NCT02664961|Drug|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
197786|NCT02664961|Drug|Bevacizumab|Bevacizumab will be dosed every two weeks.
197787|NCT02664948|Procedure|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
197788|NCT02664935|Drug|AZD4547|FGFR Inhibitor
197789|NCT02664935|Drug|Vistusertib|MTORC1/2 Inhibitor
197790|NCT02664935|Drug|Palbociclib|CDK4/6 Inhibitor
197791|NCT02664935|Drug|Crizotinib|ALK/MET/ROS1 Inhibitor
197792|NCT02664935|Drug|Selumetinib|MEK Inhibitor
197793|NCT02664935|Drug|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
197794|NCT02664935|Drug|AZD5363|AKT Inhibitor
197795|NCT02664935|Drug|Osimertinib|EGFRm+ T790M+ Inhibitor
197796|NCT02664935|Drug|Durvalumab|Anti-PDL1
197797|NCT02664935|Drug|Sitravatinib|VEGFR Inhibitor
197798|NCT02664922|Drug|Propofol|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
197799|NCT02664922|Drug|Ketamine|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures."
197800|NCT02664922|Drug|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
197801|NCT02664922|Drug|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
197802|NCT02664909|Drug|Tranexamic Acid|
197803|NCT02664909|Drug|Placebo (saline)|
197804|NCT02664896|Other|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
197805|NCT02664896|Other|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
197806|NCT02664883|Procedure|Computed Tomography|Correlative studies
197807|NCT02664883|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
197808|NCT02664883|Other|Laboratory Biomarker Analysis|Correlative studies
197809|NCT02664883|Procedure|Magnetic Resonance Imaging|Correlative studies
197810|NCT02664870|Procedure|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
197811|NCT02664870|Procedure|Arthroplasty|Total hip, shoulder, or knee arthroplasty
197812|NCT02664857|Drug|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
197813|NCT02664857|Drug|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
197814|NCT02664844|Behavioral|Physical activity|
197815|NCT02664805|Drug|LEO 124249 ointment|Ointment
197816|NCT02664805|Drug|LEO 124249 ointment vehicle|Ointment vehicle
197817|NCT02664792|Other|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
197818|NCT02664779|Other|Arrhythmia diagnosis with the 10 steps method|
197819|NCT02664779|Other|Arrhythmia diagnosis with the 6 steps method|
197820|NCT02664779|Other|Arrhythmia diagnosis with the 4 steps method|
197875|NCT02664350|Behavioral|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
197821|NCT02664766|Behavioral|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
197822|NCT02664753|Drug|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.~Day 1: a first bolus of 6g of L-Carnitine is administered with a syringe driver of 50 ml.~Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each syringes~For the next 46 days, patients will take oral doses of L-Carnitine as follows:~< à 60kg : 2g/day > 60kg : 3g/day If the patient leaves the hospital before D10, oral treatment can be initiated at the end of the hospitalization"
197823|NCT02664753|Drug|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).~Day 1: 1 50ml syringe driver of 50 ml isotonic saline solution . Day 2 to Day 10 : Two syringe drivers of 50 ml of isotonic saline solution are prepared each day, one during the morning and one during the evening."
197824|NCT02664740|Drug|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
197825|NCT02664740|Drug|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
197826|NCT02664727|Behavioral|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
197827|NCT02664727|Behavioral|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
197828|NCT02664714|Other|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
197829|NCT02664701|Other|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
197830|NCT02664701|Other|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
197831|NCT02664701|Other|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
197832|NCT02664701|Other|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
197833|NCT02664688|Other|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
197834|NCT02664688|Other|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
197835|NCT02664675|Procedure|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
197836|NCT02664675|Procedure|Open Flap Debridement|"After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.~Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap."
197837|NCT02664662|Other|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
197838|NCT02664649|Drug|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].~- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
197839|NCT02664649|Drug|Standard of care|VKA or Antiplatelet therapy
197840|NCT02664636|Procedure|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.~This is part of routine care."
197876|NCT02664350|Genetic|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
197918|NCT02664012|Other|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
197841|NCT02664636|Procedure|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.~This is part of routine care."
197842|NCT02664636|Procedure|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
197843|NCT02664623|Procedure|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
197844|NCT02664623|Procedure|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
197845|NCT02664610|Behavioral|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
197846|NCT02664597|Procedure|ADNEXMR Scoring System|Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
197847|NCT02664597|Other|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
197848|NCT02664571|Device|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.~Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
197849|NCT02664571|Device|MRI scan|Subjects will have an MRI scan at inclusion.
197850|NCT02664571|Biological|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
197851|NCT02664558|Drug|ubenimex|
197852|NCT02664558|Other|placebo|
197853|NCT02664545|Device|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
197854|NCT02664545|Procedure|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
197855|NCT02664532|Other|Miller group|Miller blade was used for laryngoscopy
197856|NCT02664532|Other|Macintosh group|Macintosh blade was used for laryngoscopy
197857|NCT02664519|Behavioral|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
197858|NCT02664506|Behavioral|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
197859|NCT02664493|Drug|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
197860|NCT02664480|Other|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
197861|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
197862|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
197863|NCT02664454|Other|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice~Interactive educational seminar Primary care"
197864|NCT02664441|Drug|Exenatide|Weekly injections of active drug.
197865|NCT02664441|Drug|placebo|Weekly placebo injections
197866|NCT02664428|Dietary Supplement|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
197867|NCT02664428|Dietary Supplement|Control|A daily dose of about 90 gram will be given for 8 weeks
197868|NCT02664415|Biological|VRC01|40 mg/kg; administered IV
197869|NCT02664415|Biological|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
197870|NCT02664389|Genetic|Genetic analysis|Sequencing of 200 selected genes in the different study populations
197871|NCT02664376|Other|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:~Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).~Walking speed measurement~Hand grip test~A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.~Data regarding the geriatric characteristics of this sarcopenic population will be collected."
197872|NCT02664363|Biological|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
197873|NCT02664350|Genetic|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
197874|NCT02664350|Behavioral|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
197958|NCT02663700|Other|Placebo|Placebo
197877|NCT02664337|Other|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
197878|NCT02664337|Other|Standard treatment information|Participants will receive information pertaining to one of the 12 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
197879|NCT02664311|Device|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
197880|NCT02664311|Device|Conventional ventilation|Conventional ventilator - control arm
197881|NCT02664285|Other|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
197882|NCT02664285|Other|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
197883|NCT02664272|Procedure|Total Hip Arthroplasty|
197884|NCT02664259|Procedure|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
197885|NCT02664259|Procedure|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
197886|NCT02664259|Procedure|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
197887|NCT02664246|Device|percutaneous coronary intervention|
197888|NCT02664233|Behavioral|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
197889|NCT02664220|Drug|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.~1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
197890|NCT02664220|Procedure|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
197891|NCT02664207|Procedure|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
197892|NCT02664194|Device|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
197893|NCT02664194|Procedure|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
197894|NCT02664181|Drug|Nivolumab|Nivolumab will be given at 3mg/kg by IV every two weeks until progression
197895|NCT02664181|Drug|oral decitabine|oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
197896|NCT02664181|Drug|Tetrahydrouridine|Oral THU ~10 mg/kg twice weekly on consecutive days
197897|NCT02664168|Device|Aquacel Ag Surgical Dressing|
197898|NCT02664168|Device|Single-Use Negative Pressure Wound Therapy (PICO)|
197899|NCT02664155|Drug|Apixaban|Direct Oral Anticoagulant
197900|NCT02664155|Drug|Rivaroxaban|Direct Oral Anticoagulant
197901|NCT02664155|Drug|Heparin|Standard Of Care
197902|NCT02664155|Drug|VKA|Standard Of Care
197903|NCT02664142|Procedure|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
197904|NCT02664142|Procedure|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
197905|NCT02664142|Drug|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
197906|NCT02664129|Other|Video self-observation|Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
197907|NCT02664129|Other|Non Self video observation|Patients will not watch the video of them in acute decompensation phase.
197908|NCT02664116|Drug|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
197909|NCT02664116|Drug|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
197910|NCT02664103|Drug|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
197911|NCT02664077|Drug|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
197912|NCT02664077|Drug|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
197913|NCT02664064|Behavioral|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
197914|NCT02664051|Drug|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom"
197915|NCT02664051|Drug|placebo|100mg 4x2 daily mannitol
197916|NCT02664038|Behavioral|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
197917|NCT02664025|Procedure|vaginal examination simulator|
198002|NCT02663388|Procedure|gastric bypass, sleeve, gastric banding|
197919|NCT02664012|Other|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
197920|NCT02664012|Other|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
197921|NCT02664012|Other|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
197922|NCT02664012|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
197923|NCT02663999|Drug|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
197924|NCT02663986|Behavioral|Organizational Skills Training (OST) Intervention|
197925|NCT02663960|Other|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
197926|NCT02663960|Other|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
197927|NCT02663947|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
197928|NCT02663934|Behavioral|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
197929|NCT02663934|Behavioral|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
197930|NCT02663921|Other|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:~Immediately after the light exposure;~30 minutes after light exposure; and~1 hour after light exposure."
197931|NCT02663921|Other|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography~Visual Clinical Assessment~Spectroscopy~Colorimetry"
197932|NCT02663908|Drug|Degarelix|
197933|NCT02663908|Drug|Leuprolide|
197934|NCT02663895|Drug|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
197935|NCT02663882|Behavioral|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
197936|NCT02663882|Behavioral|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
197937|NCT02663856|Other|observational|Self assessment of ageing transition using a frailty index through MySAwH app
197938|NCT02663843|Device|i-gel airway|Fibreoptic intubation via i-gel airway device
197939|NCT02663843|Device|air-Q airway|Fibreoptic intubation via air-Q airway device
197940|NCT02663830|Drug|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
197941|NCT02663830|Drug|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
197942|NCT02663817|Device|CT Scan|
197943|NCT02663804|Device|Total Knee Arthroplasty|
197944|NCT02663778|Behavioral|Strength training|weight lifting to increase muscle strength
197945|NCT02663778|Behavioral|Endurance training|treadmill walking to increase endurance
197946|NCT02663778|Behavioral|Flexibility training|stretches to improve flexibility
197947|NCT02663778|Behavioral|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
197948|NCT02663778|Behavioral|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
197949|NCT02663752|Procedure|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
197950|NCT02663752|Drug|Deferasirox|Patients are already on commercial deferasirox before entering the study.
197951|NCT02663739|Device|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
197952|NCT02663726|Other|Yoga|10 weekly 75-min sessions of specialised yoga
197953|NCT02663726|Behavioral|Written advice|Written advice about physical activity
197954|NCT02663713|Drug|Ticagrelor|Ticagrelor 60mg twice daily
197955|NCT02663713|Drug|Clopidogrel|Clopidogrel 75 mg once daily
197956|NCT02663700|Drug|Artesunate|Four tablets of 50mg each, totaling 200mg will be given in a single calendar day
197957|NCT02663700|Biological|PfSPZ Vaccine|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
197959|NCT02663687|Drug|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
197960|NCT02663687|Drug|Placebo|Subjects will receive matching placebo
197961|NCT02663687|Drug|SHP623|SHP623
197962|NCT02663687|Drug|Placebo|Placebo
197963|NCT02663674|Drug|Fluconazole|Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
197964|NCT02663674|Other|Placebo|Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
197965|NCT02663661|Procedure|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
197966|NCT02663661|Other|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
197967|NCT02663635|Device|Safe'N'Sound|
197968|NCT02663622|Drug|CD24Fc|Acute GVHD prophylaxis
197969|NCT02663622|Drug|Methotrexate|Acute GVHD prophylaxis
197970|NCT02663622|Drug|Tacrolimus|Acute GVHD prophylaxis
197971|NCT02663622|Drug|Placebo|100 ml saline IV infusion.
197972|NCT02663609|Other|No intervention|No treatment (intervention) was administered.
197973|NCT02663596|Drug|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
197974|NCT02663583|Behavioral|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
197975|NCT02663583|Behavioral|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.~TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
197976|NCT02663583|Behavioral|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
197977|NCT02663570|Drug|Melatonin|
197978|NCT02663544|Other|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
197979|NCT02663544|Other|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
197980|NCT02663544|Other|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
197981|NCT02663531|Device|DVA|
197982|NCT02663531|Device|FDOCT|
197983|NCT02663531|Device|Pattern ERG|
197984|NCT02663531|Device|Optical Coherence Tomography|
197985|NCT02663518|Drug|TTI-621|Monotherapy
197986|NCT02663518|Drug|TTI-621 plus Rituximab|Combination therapy
197987|NCT02663518|Drug|TTI-621 plus Nivolumab|Combination therapy
197988|NCT02663505|Procedure|Patients receiving the surgery planned for them|"For each patient the following potential influence (risk) factors are documented:~sex, urgency of the operation, BMI, age, ASA classification, preconditions, physical fitness, Hb value.~In phase 2 only selected influence factors will be recorded.~No intervention will be performed apart from the surgery planned for each patient."
197989|NCT02663492|Device|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
197990|NCT02663492|Drug|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
197991|NCT02663479|Dietary Supplement|Cardiopressin|
197992|NCT02663479|Dietary Supplement|Placebo|
197993|NCT02663466|Procedure|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
197994|NCT02663453|Drug|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
197995|NCT02663453|Drug|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
197996|NCT02663440|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
197997|NCT02663440|Biological|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
197998|NCT02663440|Drug|Temozolomide|Temozolomide
197999|NCT02663427|Device|serological examination and gastroscope|
198000|NCT02663414|Device|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
198001|NCT02663401|Behavioral|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
198003|NCT02663375|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
198004|NCT02663362|Other|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
198005|NCT02663349|Behavioral|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
198006|NCT02663336|Other|Comparison ABPM with OBPM|No interventions
198007|NCT02663323|Device|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the treatment of de-novo coronary artery lesions.
198008|NCT02663310|Procedure|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
198009|NCT02663310|Procedure|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
198010|NCT02663297|Drug|ATLCAR.CD30 cells|"Three dose levels will be evaluated:~Group One, 2x10^7 cells/m^2 (maximum dose 5x10^7 cells)~Group Two, 1x10^8 cells/m^2 (maximum dose 2.5x10^8 cells)~Group Three, 2x10^8 cells/m^2 (maximum dose 5x10^8 cells)"
198011|NCT02663284|Drug|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
198012|NCT02663271|Drug|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
198013|NCT02663271|Device|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
198014|NCT02663271|Other|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
198015|NCT02663271|Other|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
198016|NCT02663258|Drug|Pembrolizumab|
198017|NCT02663245|Other|Intervention 1|"Diabetes specific consultation~Basic training in clinical guidelines~Platform of communication for professionals~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.~7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
198018|NCT02663245|Other|Intervention 2|"7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.~Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.~Basic training in clinical guidelines.~Platform of communication for professionals.~Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
198019|NCT02663219|Behavioral|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
198020|NCT02663206|Procedure|peroral endoscopic myotomy|peroral endoscopic myotomy
198021|NCT02663206|Procedure|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
198022|NCT02663193|Other|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
198023|NCT02663180|Behavioral|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
198024|NCT02663180|Behavioral|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
198025|NCT02663167|Behavioral|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
198026|NCT02663154|Drug|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
198027|NCT02663154|Drug|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
198028|NCT02663141|Drug|Losartan|
198029|NCT02663141|Drug|Intravitreal bevacizumab|
198030|NCT02663141|Drug|Placebo|
198031|NCT02663128|Drug|Lanabecestat|Administered orally
198032|NCT02663115|Other|Biopsy of the diaphragmatic muscle|
198033|NCT02663115|Other|Skeletal muscle biopsy|
198034|NCT02663102|Other|Data collection|Safety monitoring and evaluation: ‒ Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. ‒ Recording of SAEs throughout the study period for each subject.
198035|NCT02663089|Drug|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of [14C]-GSK961081 (approximately 6.2 kilobecquerel [kBq]) intravenously as a single dose over 1 hour.
198036|NCT02663089|Drug|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of [14C]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
198037|NCT02663089|Drug|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
198038|NCT02663063|Device|SSP treatment|SSP treatment 5 times a week
198039|NCT02663050|Other|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
198040|NCT02663050|Drug|NSAID's|twice a daily
198041|NCT02663024|Biological|idursulfase beta|IV, weekly infusion for 24 weeks
198042|NCT02663024|Biological|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
198043|NCT02663011|Other|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
198044|NCT02662985|Drug|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.~Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose will be administered as 2 × PFS injections."
198045|NCT02662985|Drug|Placebo|Secukinumab placebo provided in a 1 mL PFS for s.c. injection.
198046|NCT02662972|Drug|Botulinum Toxin Type A|
198047|NCT02662959|Drug|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
198048|NCT02662946|Procedure|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
198049|NCT02662946|Procedure|No angiography|Extension of resection based on subjective measures
198050|NCT02662933|Other|Bedside assessment|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.~Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
198051|NCT02662920|Other|No Intervention|
198052|NCT02662907|Procedure|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
198053|NCT02662907|Behavioral|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
198054|NCT02662907|Device|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
198055|NCT02662907|Device|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
198056|NCT02662907|Behavioral|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
198057|NCT02662907|Drug|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
198058|NCT02662894|Drug|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
198059|NCT02662894|Drug|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
198060|NCT02662894|Drug|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
198061|NCT02662894|Drug|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
198062|NCT02662881|Device|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
198063|NCT02662881|Device|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
198064|NCT02662855|Other|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
198065|NCT02662855|Drug|Favipiravir|oral administration of Favipiravir tablets
198066|NCT02662842|Device|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
198067|NCT02662842|Device|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
198068|NCT02662829|Behavioral|Community-based intervention|
198069|NCT02662829|Other|Standard of care|
198070|NCT02662816|Device|Proton magnetic resonance spectroscopy (1H MRS)|
198071|NCT02662816|Other|a protein rich breakfast at home|
198072|NCT02662816|Other|a protein rich lunch at the Clinical Investigation Center|
198073|NCT02662803|Other|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
198074|NCT02662803|Other|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
198075|NCT02662790|Other|Doppler|
198076|NCT02662777|Device|Eso-SPONGE® vacuum treatment|
198077|NCT02662764|Drug|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for 24 hours and up to 72 hours
198078|NCT02662751|Other|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.~Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
198117|NCT02662491|Dietary Supplement|Vitamin D|
198118|NCT02662491|Dietary Supplement|Calcium|
198079|NCT02662751|Device|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.~LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
198080|NCT02662738|Dietary Supplement|Natural fruit extract|
198081|NCT02662738|Other|Placebo|
198082|NCT02662738|Other|Glucose solution|
198083|NCT02662725|Drug|IPILIMUMAB|
198084|NCT02662725|Radiation|Stereotactic radiosurgery|
198085|NCT02662712|Drug|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
198086|NCT02662712|Drug|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
198087|NCT02662686|Other|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
198088|NCT02662686|Other|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
198089|NCT02662673|Device|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
198090|NCT02662660|Drug|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
198091|NCT02662660|Drug|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
198092|NCT02662660|Drug|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
198093|NCT02662647|Drug|Decitabine 20 mg/m²/day for 5 days|
198094|NCT02662634|Biological|AGS-003-LNG|autologous dendritic cell immunotherapy
198095|NCT02662634|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
198096|NCT02662634|Drug|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
198097|NCT02662634|Drug|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
198098|NCT02662634|Drug|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
198099|NCT02662634|Drug|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
198100|NCT02662634|Radiation|Radiation Therapy|Causes DNA strand breaks.
198101|NCT02662621|Other|blood samples|
198102|NCT02662621|Other|Urine samples|
198103|NCT02662608|Drug|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
198104|NCT02662595|Other|SMS reminder message|
198105|NCT02662595|Other|Voice call + SMS message|
198106|NCT02662582|Drug|Reldesemtiv|Oral
198107|NCT02662582|Drug|Placebo|Oral
198108|NCT02662569|Biological|Evolocumab|Administered by subcutaneous injection
198109|NCT02662569|Drug|Atorvastatin|Administered orally once a day
198110|NCT02662569|Other|Placebo|Placebo to evolocumab administered by subcutaneous injection
198111|NCT02662556|Drug|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
198112|NCT02662530|Drug|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
198113|NCT02662504|Device|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.~After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
198114|NCT02662504|Procedure|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
198115|NCT02662504|Drug|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
198116|NCT02662491|Dietary Supplement|Vitamin D and calcium|
198120|NCT02662478|Procedure|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
198121|NCT02662465|Procedure|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
198122|NCT02662452|Drug|GLPG2222 single dose|single ascending doses, oral suspension
198123|NCT02662452|Drug|Placebo single dose|single doses, oral suspension, matching placebo
198124|NCT02662452|Drug|GLPG2222 multiple doses|multiple ascending doses, daily for 14 days, oral suspension
198125|NCT02662452|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral suspension, matching placebo
198126|NCT02662439|Device|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
198127|NCT02662426|Drug|Lingdancao granules|4 packs per time (3g/pack), three times per day
198128|NCT02662426|Drug|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
198129|NCT02662426|Drug|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
198130|NCT02662426|Drug|analogous Lingdancao granules|4 packs per time, three times per day
198131|NCT02662413|Other|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
198132|NCT02662400|Biological|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
198133|NCT02662387|Device|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
198134|NCT02662387|Other|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
198135|NCT02662374|Drug|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
198136|NCT02662374|Drug|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
198137|NCT02662374|Drug|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
198138|NCT02662374|Device|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
198139|NCT02662374|Drug|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
198140|NCT02662348|Drug|Recombinant Human Interleukin-2|Given SC
198141|NCT02662348|Drug|HER2Bi-Armed T Cells|Given IV
198142|NCT02662335|Other|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
198143|NCT02662335|Other|Questionnaire Administration|Ancillary studies
198144|NCT02662335|Procedure|Standard Follow-Up Care|Undergo standard follow-up care
198145|NCT02662322|Other|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
198146|NCT02662322|Other|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
198147|NCT02662322|Other|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
198148|NCT02662322|Other|peripheral intravenous catheterization|peripheral intravenous catheterization
198149|NCT02662309|Drug|MPDL3280A|Intravenous infusion
198150|NCT02662296|Drug|Ibrutinib|Given PO
198151|NCT02662296|Drug|Idelalisib|Given PO
198152|NCT02662283|Drug|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
198153|NCT02662283|Drug|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
198154|NCT02662257|Drug|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
198155|NCT02662257|Drug|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).~Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
198156|NCT02662244|Device|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
198157|NCT02662231|Procedure|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
198158|NCT02662205|Other|Psychotherapy Group|Traditional process group
198159|NCT02662205|Other|Yoga class|Yin yoga class
198160|NCT02662205|Other|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
198161|NCT02662192|Other|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
198162|NCT02662192|Other|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
198163|NCT02662179|Other|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
198164|NCT02662179|Other|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
198165|NCT02662179|Other|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
198166|NCT02662179|Other|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
198167|NCT02662166|Device|MR imaging|3 T MRI of the urinary bladder
198168|NCT02662153|Other|Database review to evaluate opioid overdose and death|Database review to evaluate opioid overdose and death
198169|NCT02662140|Behavioral|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.~Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
198170|NCT02662127|Device|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
198171|NCT02662114|Other|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
198172|NCT02662101|Device|Exsalt SD7, Exsalt T7 Wound Dressing|
198173|NCT02662088|Procedure|laparoscopic-lavage|
198174|NCT02662075|Device|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
198175|NCT02662062|Drug|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
198176|NCT02662062|Drug|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
198177|NCT02662062|Radiation|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
198178|NCT02662036|Drug|Bupivicaine HCL|
198179|NCT02662036|Drug|Liposomal bupivacaine|
198180|NCT02662023|Drug|perineural ropivacaine administration|
198181|NCT02661997|Behavioral|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
198182|NCT02661997|Behavioral|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
198183|NCT02661971|Drug|Docetaxel|Docetaxel 50 mg/m², d1
198184|NCT02661971|Drug|Oxaliplatin|Oxaliplatin 85 mg/m², d1
198185|NCT02661971|Drug|Calciumfolinat|Leucovorin 200 mg/m², d1
198186|NCT02661971|Drug|5-Fluorouracil|5-FU 2600 mg/m², d1
198187|NCT02661971|Biological|Ramucirumab|Ramucirumab 8mg/kg, d1
198188|NCT02661958|Drug|S6G5T-3|once a day topical cream
198189|NCT02661958|Drug|S6G5T-1|once a day topical cream
198190|NCT02661958|Drug|S6G5T-5|once a day topical cream
198191|NCT02661958|Drug|S6G5T-6|once a day topical cream
198192|NCT02661958|Drug|S6G5T-7|once a day topical cream
198193|NCT02661958|Drug|S6G5T-8|once a day topical cream
198194|NCT02661945|Device|Near focus with narrow band imaging|
198195|NCT02661932|Drug|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.~Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
198230|NCT02661672|Device|Apollo Device|The Apollo system has been cleared for the controlled aspiration of soft tissue and/or fluid during endoscopically guided neurosurgery of the ventricular system.
198196|NCT02661919|Device|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
198197|NCT02661906|Other|SKY|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
198198|NCT02661893|Drug|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
198199|NCT02661893|Drug|Rifampin|Oral dose of rifampin 600 mg (2*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5 to 12.
198200|NCT02661880|Behavioral|preferred music|listening to preferred music choices
198201|NCT02661867|Behavioral|delivery|delivery either vaginal or by cesarean section
198202|NCT02661854|Biological|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
198203|NCT02661854|Biological|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
198204|NCT02661854|Biological|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
198205|NCT02661854|Biological|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
198206|NCT02661854|Biological|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
198207|NCT02661854|Biological|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
198208|NCT02661854|Biological|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
198209|NCT02661854|Biological|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
198210|NCT02661854|Biological|Subcutaneous placebo|Comparison between placebo and active group
198211|NCT02661854|Biological|Sublingual placebo|Comparison between placebo and active group
198212|NCT02661841|Other|LI-Guided Therapy|Preemptive treatment according to LI monitoring
198213|NCT02661841|Other|Heart Failure Guidelines|Treatment according to clinical signs
198214|NCT02661828|Other|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
198215|NCT02661828|Other|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
198216|NCT02661815|Drug|Paclitaxel|Please see arm/group description.
198217|NCT02661815|Drug|Ricolinostat|Please see arm/group description.
198218|NCT02661815|Drug|Bevacizumab|Please see arm/group description.
198219|NCT02661802|Other|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
198220|NCT02661789|Drug|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
198221|NCT02661789|Drug|Placebo|Injection of saline
198222|NCT02661750|Drug|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.~Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.~Step 1: 51 g MiraLAX* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.~Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
198223|NCT02661737|Device|YVOIRE volume s|
198224|NCT02661724|Behavioral|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
198225|NCT02661711|Drug|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.~Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
198226|NCT02661698|Dietary Supplement|Omega-3 oil: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
198227|NCT02661698|Dietary Supplement|Placebo|3 x 1 g capsules Placebo: olive oil
198228|NCT02661698|Dietary Supplement|Omega-3 oil: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
198229|NCT02661685|Biological|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
198231|NCT02661672|Device|Artemis Device|The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump. The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.
198232|NCT02661659|Biological|Multipeptide vaccine S-588210|
198233|NCT02661646|Device|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
198234|NCT02661633|Device|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
198235|NCT02661633|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
198236|NCT02661620|Device|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7.5 year post op telephone call to assess stem status and adverse events.
198237|NCT02661607|Procedure|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
198238|NCT02661607|Device|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
198239|NCT02661607|Procedure|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
198240|NCT02661594|Drug|APD421 5 mg|Therapeutic dose of amisulpride
198241|NCT02661594|Drug|APD421 40 mg|Supra-therapeutic dose of amisulpride
198242|NCT02661594|Drug|Moxifloxacin|Positive control for assay sensitivity
198243|NCT02661594|Drug|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
198244|NCT02661581|Behavioral|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
198245|NCT02661555|Other|Aerobic exercise|
198246|NCT02661542|Drug|FF-10502-01|
198247|NCT02661529|Procedure|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
198248|NCT02661529|Procedure|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.~Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
198249|NCT02661529|Other|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
198250|NCT02661529|Other|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
198251|NCT02661503|Drug|Bleomycin|
198252|NCT02661503|Drug|Etoposide|
198253|NCT02661503|Drug|Doxorubicin|
198254|NCT02661503|Drug|Cyclophosphamide|
198255|NCT02661503|Drug|Vincristine|
198256|NCT02661503|Drug|Procarbazine|
198257|NCT02661503|Drug|Prednisone|
198258|NCT02661503|Drug|Brentuximab Vedotin|
198259|NCT02661503|Drug|Dacarbazine|
198260|NCT02661503|Drug|Dexamethasone|
198261|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
198262|NCT02661490|Drug|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
198263|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
198264|NCT02661477|Drug|pegylated interferon alfa 2|
198265|NCT02661477|Other|Placebo|0,9% natrium chlorine solution
198266|NCT02661464|Biological|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
198267|NCT02661464|Biological|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
198268|NCT02661451|Device|SAPIEN 3 THV|
198269|NCT02661451|Biological|Optimal Heart Failure Therapy|
198270|NCT02661438|Drug|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
198271|NCT02661425|Other|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
198272|NCT02661386|Device|Motility Procedure|The use of esophageal manometry device during general anesthesia
198273|NCT02661373|Drug|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.
198274|NCT02661373|Drug|Cobicistat|Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
198275|NCT02661360|Behavioral|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
198276|NCT02661360|Behavioral|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
198277|NCT02661347|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
198278|NCT02661347|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
198279|NCT02661334|Dietary Supplement|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
198280|NCT02661334|Dietary Supplement|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
198281|NCT02661321|Other|No intervention was used in this study, this was an observational study|
198282|NCT02661308|Device|Litebook|
198283|NCT02661295|Drug|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and < 50% and ferritin ≥ 200 and < 500 ng/ml after a 2 week wash out period.
198284|NCT02661282|Biological|Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes|Given IV
198285|NCT02661282|Other|Laboratory Biomarker Analysis|Correlative studies
198286|NCT02661282|Drug|Temozolomide|Given PO
198287|NCT02661282|Procedure|Therapeutic Conventional Surgery|Undergo surgery
198288|NCT02661269|Device|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
198289|NCT02661269|Device|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
198290|NCT02661256|Device|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
198291|NCT02661256|Dietary Supplement|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
198292|NCT02661243|Device|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
198293|NCT02661230|Device|COGNIPLUS|"Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest."
198294|NCT02661217|Drug|LCZ696|The target dose of LCZ696 is 200 mg twice daily. Starting dose of LCZ696 is either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.
198295|NCT02661204|Device|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
198296|NCT02661191|Drug|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
198297|NCT02661178|Drug|emodepside (BAY 44-4400)|
198298|NCT02661178|Drug|placebo|
198299|NCT02661152|Drug|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
198300|NCT02661126|Drug|MK-3682B|FDC oral tablet containing 225 mg uprifosbuvir + 50 mg grazoprevir + 30 mg ruzasvir.
198301|NCT02661100|Drug|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
198302|NCT02661100|Biological|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
198303|NCT02661100|Biological|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
198304|NCT02661087|Procedure|Hysteroscopic resection with bipolar energy|
198305|NCT02661087|Procedure|Hysteroscopic resection with monopolar energy|
198306|NCT02661074|Other|Questionnaire|"A questionnaire will be completed in order to collect data on:~Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),~Occupational and/or domestic exposure to fish."
198307|NCT02661061|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
198308|NCT02661061|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
198345|NCT02660840|Drug|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
198309|NCT02661048|Device|CyberHeart System|The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
198310|NCT02661035|Drug|Allopurinol|300 mg/day (for peds -150 mg/m^2/day), day -6 and continue through day 0 or longer if clinically indicated
198311|NCT02661035|Drug|Fludarabine|30 mg/m^2 IV over 1 hour, day -6, -5, -4, -3 and -2
198312|NCT02661035|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
198313|NCT02661035|Drug|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
198314|NCT02661035|Radiation|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
198315|NCT02661035|Drug|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.~An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.~Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.~The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:~Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.~Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
198316|NCT02661035|Drug|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.~MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, MMF will continue as long as clinically indicated."
198317|NCT02661035|Biological|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
198318|NCT02661035|Biological|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
198319|NCT02661022|Drug|SL-401/ Pomalidomide/ Dexamethasone|
198320|NCT02660983|Drug|Donepezil hydrochloride|
198321|NCT02660983|Drug|Donepezil matching placebo|
198322|NCT02660983|Drug|Donepezil hydrochloride|
198323|NCT02660970|Other|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
198324|NCT02660970|Other|Placebo-band|Children will have to wear a 'placebo-wristband'
198325|NCT02660970|Drug|Iberogast|Children will have to take Iberogast drops
198326|NCT02660970|Other|Placebo-drops|Children will have to take placebo-drops
198327|NCT02660957|Behavioral|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
198328|NCT02660957|Other|placebo comparator|suggest a healthy life style as a placebo comparator
198329|NCT02660944|Drug|RSLV-132|RNase-Fc fusion protein
198330|NCT02660944|Drug|Placebo|Saline placebo
198331|NCT02660931|Other|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
198332|NCT02660918|Drug|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
198333|NCT02660918|Other|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
198334|NCT02660905|Drug|E/C/F/TAF;|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
198335|NCT02660905|Drug|Ledipasvir-Sofosbuvir|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
198336|NCT02660892|Dietary Supplement|Protein intake|"Oral consumption of eight hourly experimental meals~4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~4 isotopically labeled experimental meals."
198337|NCT02660879|Other|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
198338|NCT02660879|Other|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
198339|NCT02660866|Drug|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
198340|NCT02660866|Drug|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
198341|NCT02660840|Drug|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
198342|NCT02660840|Drug|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
198343|NCT02660840|Drug|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
198344|NCT02660840|Drug|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
198346|NCT02660840|Drug|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
198347|NCT02660827|Device|Insulin Pump|Closed Loop Algorithm
198348|NCT02660814|Other|Non-surgical periodontal treatment|"SRP under local anaesthesia, in a total of 2-3 clinical visits.~Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
198349|NCT02660814|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
198350|NCT02660801|Procedure|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
198351|NCT02660801|Procedure|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
198352|NCT02660788|Other|Standard Reminder Postcard|
198353|NCT02660788|Other|Family Physician Reminder Letter|
198354|NCT02660775|Behavioral|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task (TREF)~for theory of mind : Movie for the assessment of social cognition ( MASC-VF)~for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia~for self assessment : Self - assessment of social cognition (ACSo)"
198355|NCT02660775|Behavioral|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:~for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels~for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type~for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score~for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )~for empathy : Empathy quotient (EQ)~for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
198356|NCT02660775|Behavioral|Healthy controls|only social cognitive measures
198357|NCT02660762|Drug|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
198358|NCT02660762|Drug|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
198359|NCT02660762|Drug|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
198360|NCT02660762|Drug|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
198361|NCT02660762|Drug|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
198362|NCT02660762|Drug|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
198363|NCT02660762|Drug|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
198364|NCT02660762|Drug|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
198365|NCT02660762|Drug|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
198366|NCT02660762|Drug|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
198367|NCT02660762|Drug|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
198368|NCT02660762|Drug|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
198369|NCT02660762|Drug|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
198370|NCT02660736|Drug|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
198371|NCT02660736|Drug|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
198372|NCT02660736|Drug|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
198373|NCT02660736|Drug|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
198374|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
198375|NCT02660710|Drug|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
198376|NCT02660697|Procedure|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
198377|NCT02660684|Drug|Prograf|Injection or oral
198378|NCT02660684|Drug|Methotrexate|Injection
198379|NCT02660684|Drug|Cyclosporine|Injection or oral
198380|NCT02660671|Behavioral|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
198381|NCT02660671|Behavioral|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
198382|NCT02660671|Behavioral|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
198383|NCT02660658|Drug|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
198384|NCT02660645|Drug|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
198385|NCT02660645|Device|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
198386|NCT02660632|Other|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
198387|NCT02660632|Other|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
198388|NCT02660619|Other|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
198389|NCT02660606|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
198390|NCT02660593|Dietary Supplement|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
198391|NCT02660580|Drug|MSB11022|Participants received MSB11022 drug subcutaneously MSB11022 (Core Treatment Period), MSB11022 (Extended Treatment Period) and EU-Humira/MSB11022 arm.
198392|NCT02660580|Drug|Humira®|Participants received EU-Humira subcutaneously in EU-Humira, EU-Humira/EU-Humira and EU-Humira/MSB11022 arm.
198393|NCT02660567|Procedure|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
198394|NCT02660554|Other|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
198395|NCT02660541|Device|Betafoam|Comparison between 2 medical devices
198396|NCT02660541|Device|Allevyn Silver Dressing|Comparison between 2 medical devices
198397|NCT02660528|Drug|Tocilizumab|Subcutaneous tocilizumab
198398|NCT02660515|Procedure|Additional wrist arthroscopy|
198399|NCT02660515|Procedure|ORIF|
198400|NCT02660502|Drug|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
198401|NCT02660502|Drug|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
198402|NCT02660502|Drug|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
198403|NCT02660502|Drug|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
198404|NCT02660489|Drug|OC459|
198405|NCT02660489|Drug|Placebo|
198406|NCT02660489|Other|Rhinovirus|Inoculation with rhinovirus serotype 16
198407|NCT02660463|Other|"Registration of the diagnosis CTEPH"|Registration of risk factors for thromboembolic events
198408|NCT02660450|Other|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
198409|NCT02660450|Other|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
198410|NCT02660450|Other|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
198411|NCT02660437|Other|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; ~30min).
198412|NCT02660424|Drug|VX-150|
198413|NCT02660424|Drug|Placebo|
198414|NCT02660411|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
198415|NCT02660411|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
198416|NCT02660398|Procedure|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
198417|NCT02660385|Behavioral|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
198418|NCT02660385|Behavioral|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
198419|NCT02660372|Drug|Imonogas|Simethicone 120 mg in gel capsules
198420|NCT02660372|Drug|Espumisan|Simethicone 40 mg in gel capsules
198421|NCT02660359|Biological|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
198422|NCT02660359|Biological|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
198423|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
198424|NCT02660359|Drug|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
198425|NCT02660346|Drug|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
198426|NCT02660346|Drug|Vancomycin|Control Arm Treatment
198427|NCT02660346|Drug|Ceftaroline|Study Arm Treatment
198428|NCT02660333|Dietary Supplement|Placebo|Maltodextrin - 11g/day
198429|NCT02660333|Dietary Supplement|Prebiotic|Fructooligosaccharide - 11g/day
198430|NCT02660333|Dietary Supplement|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 11g/day
198431|NCT02660320|Device|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
198432|NCT02660320|Device|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
198433|NCT02660307|Other|PROGRESS group|
198434|NCT02660294|Biological|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
198435|NCT02660281|Radiation|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
198436|NCT02660281|Drug|Fludarabine|Fludarabine
198437|NCT02660281|Drug|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
198438|NCT02660281|Drug|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
198439|NCT02660281|Drug|Busulfan|Busulfan
198440|NCT02660281|Drug|Melphalan|Melphalan
198441|NCT02660281|Procedure|Stem Cell Infusion|Stem cell infusion
198442|NCT02660281|Drug|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
198443|NCT02660281|Drug|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
198444|NCT02660281|Drug|Thiotepa|Thiotepa
198445|NCT02660268|Other|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
198446|NCT02660255|Drug|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
198447|NCT02660242|Drug|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).
198448|NCT02660242|Other|Glucose Tabs|Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
198449|NCT02660242|Other|Basal Insulin Reduction|Basal insulin reduction to 50% 5 minutes before the start of exercise.
198450|NCT02660229|Drug|Oxycodone Hydrochloride|Oxycodone injection
198451|NCT02660229|Drug|Morphine Sulphate|Morphine sulphate injection
198452|NCT02660203|Procedure|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.~The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
198453|NCT02660190|Drug|hexaminoavolunate|
198454|NCT02660190|Procedure|WL cystoscopy|
198455|NCT02660177|Drug|Metamizole|metamizole IV administration
198456|NCT02660164|Device|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
198457|NCT02660151|Device|Hyper-CL™ lens|
198458|NCT02660151|Device|Regular soft contact lens|
198459|NCT02660151|Drug|Salt solution|
198460|NCT02660138|Biological|Botulinum toxin type A|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
198461|NCT02660138|Biological|Botulinum toxin type A|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
198462|NCT02660138|Drug|Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
198463|NCT02660138|Drug|Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
198464|NCT02660125|Procedure|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
198465|NCT02660112|Drug|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
198466|NCT02660099|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
198467|NCT02660086|Behavioral|Personalized nutrition feedback|Automated personalized nutrition feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
198468|NCT02660073|Device|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
198469|NCT02660073|Device|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
198470|NCT02660060|Drug|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
198471|NCT02660060|Drug|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH & Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
198472|NCT02660047|Drug|Liraglutide|"Drug: Liraglutide~Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
198473|NCT02660047|Drug|Liraglutide - Placebo|"Drug: Liraglutide - Placebo~Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
198474|NCT02660034|Biological|tislelizumab|
198475|NCT02660034|Drug|pamiparib|
198476|NCT02660008|Drug|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
198477|NCT02660008|Drug|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
198478|NCT02659995|Other|No intervention|No interventions will be performed on these patients.
198479|NCT02659943|Biological|Anti-CD19-CAR T cells|Dose-escalation trial starting dose: 0.66x106 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
198480|NCT02659943|Drug|Cyclophosphamide|300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3
198481|NCT02659943|Drug|Fludarabine|30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
198482|NCT02659930|Drug|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
198483|NCT02659930|Drug|pomalidomide|pomalidomide once a day, days 1- 21 of a 28-day cycle, at the dose levels described in dose escalation plan
198484|NCT02659917|Other|Glass ionomer|Application of preventive agent
198485|NCT02659917|Other|Glass ionomer cement|Application of preventive agent
198486|NCT02659917|Other|-Glass ionomer-|Atraumatic Restorative Treatment
198487|NCT02659917|Other|-Glass ionomer cement-|Atraumatic Restorative Treatment
198488|NCT02659904|Other|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
198489|NCT02659904|Other|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
198490|NCT02659891|Biological|IVIg|
198491|NCT02659891|Other|Placebo|
198492|NCT02659878|Procedure|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
198493|NCT02659865|Drug|Placebo|Administered orally
198494|NCT02659865|Drug|LY3039478 original formulation|Administered orally
198495|NCT02659865|Drug|LY3039478 new formulation|Administered orally
198496|NCT02659852|Procedure|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
198497|NCT02659852|Procedure|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
198498|NCT02659839|Other|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
198499|NCT02659826|Device|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
198500|NCT02659826|Device|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
198571|NCT02659410|Other|Heat stress (25) + DCM|4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
198572|NCT02659410|Other|Heat stress (30) + DCM|4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
198814|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
198815|NCT02657889|Drug|niraparib|
198501|NCT02659826|Device|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
198502|NCT02659826|Device|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
198503|NCT02659826|Device|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
198504|NCT02659826|Device|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
198505|NCT02659826|Device|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
198506|NCT02659813|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
198507|NCT02659800|Other|Laboratory Biomarker Analysis|Correlative studies
198508|NCT02659800|Biological|NT-I7|Given IM
198509|NCT02659800|Other|Placebo|Given IM
198510|NCT02659787|Drug|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
198511|NCT02659787|Drug|Placebo|Placebo
198512|NCT02659774|Behavioral|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
198513|NCT02659774|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
198514|NCT02659774|Behavioral|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
198515|NCT02659774|Behavioral|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
198516|NCT02659774|Behavioral|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
198517|NCT02659774|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
198518|NCT02659761|Drug|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
198519|NCT02659748|Dietary Supplement|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
198520|NCT02659748|Dietary Supplement|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
198521|NCT02659735|Drug|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
198522|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
198523|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
198524|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
198525|NCT02659722|Device|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
198526|NCT02659709|Device|Interest in medical education through social media|Measuring interest in social media technology designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
198527|NCT02659683|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
198528|NCT02659683|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
198529|NCT02659657|Drug|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
198573|NCT02659410|Other|Heat stress (21) + TOL (dermal)|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
198574|NCT02659410|Other|Heat stress (25) + TOL (dermal)|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
198816|NCT02657889|Biological|pembrolizumab|
198530|NCT02659644|Drug|Oral L-citrulline|There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
198531|NCT02659631|Drug|PF-06671008|Dose Escalation Phase - Part 1
198532|NCT02659631|Drug|PF-06671008|Dose Expansion Phase - Part 2
198533|NCT02659605|Procedure|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
198534|NCT02659605|Procedure|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
198535|NCT02659592|Procedure|transplantation of ovarian tissue|operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
198536|NCT02659579|Behavioral|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
198537|NCT02659579|Behavioral|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
198538|NCT02659553|Procedure|steatosis|Liver Transplantation with graft steatosis
198539|NCT02659540|Drug|Ipilimumab|
198540|NCT02659540|Drug|Nivolumab|
198541|NCT02659540|Radiation|Radiotherapy|
198542|NCT02659527|Drug|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
198543|NCT02659527|Device|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
198544|NCT02659514|Drug|Poziotinib|Supplied as oral tablets, administered daily for each 21 days cycle.
198545|NCT02659501|Drug|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
198546|NCT02659501|Drug|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
198547|NCT02659501|Drug|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
198548|NCT02659501|Drug|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
198549|NCT02659501|Drug|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
198550|NCT02659488|Drug|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
198551|NCT02659475|Drug|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
198552|NCT02659462|Other|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
198553|NCT02659449|Device|made to measure compression gloves|Patients achieve tests with compression glove
198554|NCT02659449|Device|Compression bandaging|Patients achieve tests with compression bandaging
198555|NCT02659449|Other|Free Hands|Patients achieve tests without device
198556|NCT02659436|Other|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
198557|NCT02659436|Other|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
198558|NCT02659423|Behavioral|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
198559|NCT02659423|Behavioral|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
198560|NCT02659423|Behavioral|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
198561|NCT02659410|Other|Heat stress (21)|4h exposure to heat (WBGT of 21°C), no solvent
198562|NCT02659410|Other|Heat stress (25)|4h exposure to heat (WBGT of 25°C), no solvent
198563|NCT02659410|Other|Heat stress (30)|4h exposure to heat (WBGT of 30°C), no solvent
198564|NCT02659410|Other|Heat Stress (21) +TOL|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
198565|NCT02659410|Other|Heat stress (25) + TOL|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
198566|NCT02659410|Other|Heat stress (21) + TOL|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
198567|NCT02659410|Other|Heat stress (21) + ACE|4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
198568|NCT02659410|Other|Heat stress (25) + ACE|4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
198569|NCT02659410|Other|Heat stress (30) + ACE|4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
198570|NCT02659410|Other|Heat stress (21) + DCM|4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
199172|NCT02655354|Drug|Citalopram|Anti-depressant
198575|NCT02659410|Other|Heat stress (30) + TOL (dermal)|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
198576|NCT02659397|Drug|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
198577|NCT02659397|Drug|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
198578|NCT02659397|Drug|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
198579|NCT02659384|Drug|Bevacizumab|
198580|NCT02659384|Drug|atezolizumab|
198581|NCT02659384|Drug|acetylsalicylic acid|
198582|NCT02659384|Drug|placebo|
198583|NCT02659371|Dietary Supplement|Low energy diet|
198584|NCT02659358|Device|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
198585|NCT02659345|Behavioral|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
198586|NCT02659345|Behavioral|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
198587|NCT02659332|Device|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
198588|NCT02659319|Behavioral|Family Lifestyle (FL)|12-week Family Food & Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
198589|NCT02659319|Behavioral|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
198590|NCT02659319|Behavioral|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
198591|NCT02659306|Drug|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
198592|NCT02659293|Drug|Lenalidomide|"Cycle 1: 15 mg days 1-21~Cycles 2-4: 25 mg days 1-21 if tolerated, otherwise continue at lower dose~Cycles 5 and beyond: best tolerated dose days 1-21"
198593|NCT02659293|Drug|Carfilzomib|"Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8,9 of cycle 1) will be al12,lowed at the treating physician's discretion.~Cycle 2-4: 36 mg/m2 if tolerated Days 1, 2, 8, 9, 15, 16~Cycles 5-8 (patients that are MRD- and have no risk factors at the end of cycle 6) and Cycle 5 - 36 (for MRD+ patients and high risk patients at the end of cycle 6): best tolerated dose Days 1, 2, 15, 16"
198594|NCT02659293|Drug|Dexamethasone|"Cycles 1 - 4: 20 mg PO or IV per dose Days 1, 8, 15, 22~Cycles 5+: 20 mg or best tolerated dose PO or IV per dose Days 1, 8, 15, 22"
198595|NCT02659293|Drug|Lenalidomide (Control)|"Cycles 1-4: Days 1-28. Lenalidomide will begin at a dose of 10 mg PO daily (2 capsules per day). After three months, the dose will be increased, provided ANC ≥ 1,000/µL, platelet count ≥ 75,000/µL, and all nonhematologic toxicity is ≤ grade 1, to 15 mg PO daily (3 capsules per day).~Cycles 5 and beyond: best tolerated dose days 1-28"
198596|NCT02659280|Other|Adjunct Therapy|"Store and Forward Tele-heath"
198597|NCT02659280|Other|Standard of Care|Standard of Care Outpatient Physical Therapy
198598|NCT02659267|Behavioral|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
198599|NCT02659254|Device|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
198600|NCT02659241|Drug|Adavosertib|Given PO
198601|NCT02659241|Other|Laboratory Biomarker Analysis|Correlative studies
198602|NCT02659228|Device|EEG recording|EEG recording with anesthetic (DIPRIVAN)
198603|NCT02659228|Drug|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
198604|NCT02659215|Device|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
198605|NCT02659215|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
198606|NCT02659202|Device|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
198607|NCT02659176|Procedure|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
198608|NCT02659176|Procedure|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
199026|NCT02656316|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
198609|NCT02659163|Behavioral|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
198610|NCT02659163|Behavioral|mHealth scale|A wireless scale used by participants to measure and record daily weight.
198611|NCT02659163|Behavioral|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
198612|NCT02659163|Behavioral|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
198613|NCT02659163|Behavioral|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
198614|NCT02659163|Behavioral|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
198615|NCT02659150|Drug|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
198616|NCT02659137|Other|HV measurement|Electrophysiology (EP) study during the TAVI procedure
198617|NCT02659124|Device|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
198618|NCT02659124|Procedure|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
198619|NCT02659111|Other|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
198620|NCT02659111|Other|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
198621|NCT02659098|Drug|CNTO 2476 3.0 x 10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
198622|NCT02659098|Device|Subretinal Delivery System|Participants will receive CNTO 2476 by using the Delivery System.
198623|NCT02659085|Drug|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
198624|NCT02659085|Procedure|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
198625|NCT02659059|Biological|Nivolumab|Specified Dose on Specified Days
198626|NCT02659059|Biological|Ipilimumab|Specified Dose on Specified Days
198627|NCT02659059|Drug|Carboplatin|Specified Dose on Specified Days
198628|NCT02659059|Drug|Cisplatin|Specified Dose on Specified Days
198629|NCT02659059|Drug|Paclitaxel|Specified Dose on Specified Days
198630|NCT02659059|Drug|Pemetrexed|Specified Dose on Specified Days
198631|NCT02659033|Drug|ceftriaxone|ceftriaxone (1 gram per day)
198632|NCT02659033|Drug|Cefotaxime|cefotaxime (1 gram every 8 hours)
198633|NCT02659020|Drug|Olaratumab|Administered IV
198634|NCT02659020|Drug|Gemcitabine|Administered IV
198635|NCT02659020|Drug|Docetaxel|Administered IV
198636|NCT02659020|Drug|Placebo|Administered IV
198637|NCT02659007|Other|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
198638|NCT02658994|Behavioral|Thinking Healthy Program Peer Delivered Plus|
198639|NCT02658994|Other|Enhanced Usual Care|
198640|NCT02658981|Biological|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
198641|NCT02658981|Biological|Anti-PD-1|Given IV
198642|NCT02658981|Other|Pharmacological Study|Correlative Studies
198643|NCT02658981|Other|Laboratory Biomarker Analysis|Correlative Studies
198644|NCT02658981|Biological|Anti-CD137|Given IV
198645|NCT02658968|Drug|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
198646|NCT02658955|Procedure|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
198647|NCT02658942|Procedure|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
198648|NCT02658942|Procedure|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
198649|NCT02658929|Biological|bb2121|bb2121
198650|NCT02658916|Drug|BIIB092|Same dose as corresponding CN002003 study panel.
198651|NCT02658903|Device|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
198652|NCT02658903|Device|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
198653|NCT02658890|Drug|BMS-986205|
198654|NCT02658890|Drug|Nivolumab|
198655|NCT02658890|Drug|Ipilimumab|
198695|NCT02658708|Other|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
199027|NCT02656303|Biological|ublituximab|ublituximab IV infusion
198656|NCT02658877|Drug|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
198657|NCT02658877|Drug|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
198658|NCT02658864|Drug|lafutidine|comparison of different doses, sex and medication conditions
198659|NCT02658851|Device|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
198660|NCT02658838|Drug|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
198661|NCT02658838|Drug|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
198662|NCT02658838|Drug|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
198663|NCT02658838|Drug|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
198664|NCT02658825|Drug|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
198665|NCT02658825|Drug|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
198666|NCT02658825|Drug|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
198667|NCT02658825|Drug|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
198668|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
198669|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
198670|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
198671|NCT02658825|Drug|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
198672|NCT02658812|Other|Laboratory Biomarker Analysis|Correlative studies
198673|NCT02658812|Biological|Talimogene Laherparepvec|Given IT
198674|NCT02658799|Drug|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
198675|NCT02658799|Drug|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.~Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
198676|NCT02658773|Drug|lidocaine-Prilocaine cream|
198677|NCT02658773|Drug|placebo cream|
198678|NCT02658760|Drug|Dexmedetomidine|dexmedetomidine plus placebo
198679|NCT02658760|Drug|Bupivacaine|dexmedetomidine and Bupivacaine
198680|NCT02658747|Other|No intervention|No intervention administered in this study
198681|NCT02658734|Drug|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
198682|NCT02658721|Drug|Lidocaine|
198683|NCT02658721|Drug|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
198684|NCT02658721|Drug|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
198685|NCT02658721|Drug|Fentanyl|If the patient had a VAS score of >4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
198686|NCT02658721|Drug|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.~In case of bradycardia (HR <50/min), 0.5 mg intravenous atropine was administered."
198687|NCT02658721|Drug|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
198688|NCT02658721|Drug|Diclofenac sodium|The patients with a VAS score of >4 were administered with 75 mg diclofenac sodium via intramuscular route.
198689|NCT02658721|Drug|Ephedrine|In the event of hypotension (systolic arterial pressure <90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
198690|NCT02658721|Drug|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
198691|NCT02658708|Other|Bright blue-green light using light visor cap|
198692|NCT02658708|Other|Dim red light using light visor cap|
198693|NCT02658708|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
198694|NCT02658708|Other|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
198809|NCT02657928|Drug|Letrozole|Given PO
198810|NCT02657928|Drug|Ribociclib|Given PO
198696|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
198697|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
198698|NCT02658708|Diagnostic Test|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
198699|NCT02658708|Diagnostic Test|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
198700|NCT02658708|Other|Horne-Ostberg Morningness-Eveningness Questionnaire|
198701|NCT02658708|Other|Daily Fatigue and Sleep Log|"Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness~Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)"
198702|NCT02658682|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
198703|NCT02658682|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
198704|NCT02658669|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
198705|NCT02658669|Behavioral|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
198706|NCT02658656|Device|ReWalk 6.0|Exoskeletal Assisted Walking Device
198707|NCT02658643|Procedure|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
198708|NCT02658643|Procedure|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
198709|NCT02658630|Device|Robot + TTT exercise|The intervention will be completed 3x/week for 12 weeks. The training progression will be sequential with 4 weeks completed on the wrist robot, followed by 4 weeks on the shoulder-elbow robot and completing with 4 weeks alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
198710|NCT02658604|Other|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
198711|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean protein concentrate|Protein concentrate treatment
198712|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean protein isolate|Protein isolate treatment
198713|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean starch|Starch treatment
198714|NCT02658591|Dietary Supplement|Crackers/pasta with added faba bean flour|Flour treatment
198715|NCT02658591|Dietary Supplement|Crackers/pasta with no faba bean fraction|Control treatment
198716|NCT02658578|Procedure|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
198717|NCT02658565|Procedure|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
198718|NCT02658552|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
198719|NCT02658526|Behavioral|anesthesia - surgery|
198720|NCT02658513|Other|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
198721|NCT02658513|Other|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
198722|NCT02658500|Dietary Supplement|Infant Formula|
198723|NCT02658500|Dietary Supplement|breast milk|
198724|NCT02658487|Drug|Cytarabine|Given IV
198725|NCT02658487|Drug|Vosaroxin|Given IV
198726|NCT02658474|Behavioral|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
198727|NCT02658461|Drug|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed >1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
198728|NCT02658448|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
198729|NCT02658435|Drug|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
198811|NCT02657915|Drug|Placebo|Administered as specified in the treatment arm.
198730|NCT02658435|Drug|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
198731|NCT02658422|Drug|Test Montelukast|Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
198732|NCT02658422|Drug|Reference Montelukast|Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
198733|NCT02658409|Biological|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
198734|NCT02658409|Biological|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
198735|NCT02658396|Drug|GO-203-2C|
198736|NCT02658396|Drug|Bortezomib|
198737|NCT02658383|Other|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
198738|NCT02658383|Other|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
198739|NCT02658370|Device|animated home-based exercises (Wii-fit)|
198740|NCT02658370|Procedure|conventional home-based exercise program|
198741|NCT02658357|Drug|Risperidone Implant|
198742|NCT02658344|Biological|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml), 1 time injection
198743|NCT02658344|Drug|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
198744|NCT02658292|Drug|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
198745|NCT02658292|Drug|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
198746|NCT02658279|Drug|Pembrolizumab|
198747|NCT02658266|Behavioral|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
198748|NCT02658253|Biological|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
198749|NCT02658253|Biological|GLA-SE|2.56 µg of GLA content
198750|NCT02658253|Biological|Alhydrogel|0.85 mg og Aluminium content
198751|NCT02658253|Biological|Placebo|0.9% Na cl
198752|NCT02658240|Drug|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
198753|NCT02658240|Drug|Epinephrine|0.5 mg epinephrine
198754|NCT02658214|Drug|paclitaxel + carboplatin|IV infusion
198755|NCT02658214|Drug|carboplatin + etoposide|IV infusion
198756|NCT02658214|Drug|gemcitabine + carboplatin|IV infusion
198757|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
198758|NCT02658214|Drug|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
198759|NCT02658214|Biological|durvalumab|IV infusion
198760|NCT02658214|Biological|tremelimumab|IV infusion
198761|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
198762|NCT02658214|Drug|cisplatin + 5-fluorouracil (5FU)|IV infusion
198763|NCT02658201|Device|MRI|Ultrafast MRI to assess constipation
198764|NCT02658188|Drug|ASP8825|Oral
198765|NCT02658175|Drug|Volanesorsen|300 mg volanesorsen
198766|NCT02658162|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
198767|NCT02658162|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
198768|NCT02658149|Drug|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
198769|NCT02658149|Drug|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
198770|NCT02658149|Drug|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
198771|NCT02658149|Drug|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
198772|NCT02658149|Drug|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
198773|NCT02658136|Other|Cardiac Computed tomography|
198774|NCT02658123|Other|Pre-operative education (standard of care)|
198775|NCT02658123|Other|Home health care visits (standard of care)|
198776|NCT02658123|Other|Follow-up post-operative visits|
198777|NCT02658123|Other|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
198778|NCT02658123|Other|Healthcare Utilization Form|"Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized~Form allows patient to record reason for visit and date of visit"
198779|NCT02658123|Other|The City of Hope QOL Survey for Ostomy Patients|"Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.~Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem."
198780|NCT02658123|Other|Phone call with CWOCN or PA|
198781|NCT02658110|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
198782|NCT02658110|Other|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
198812|NCT02657915|Drug|BIIB033 100mg/Kg|Administered as specified in the treatment arm.
198813|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail|
198783|NCT02658110|Other|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
198784|NCT02658097|Drug|Pembrolizumab|200mg Pembrolizumab by IV infusion
198785|NCT02658097|Radiation|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
198786|NCT02658084|Drug|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
198787|NCT02658084|Drug|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
198788|NCT02658058|Other|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
198789|NCT02658058|Other|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
198790|NCT02658058|Other|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
198791|NCT02658045|Device|Standard Oximeter|Oxygen saturation will be measured by standard oximeter
198792|NCT02658045|Device|Oxitone oximeter|Oxygen saturation will be measured by Oxitone oximeter
198793|NCT02658032|Behavioral|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
198794|NCT02658032|Behavioral|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
198795|NCT02658032|Other|standard care|
198796|NCT02658019|Drug|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
198797|NCT02658019|Procedure|Peripheral Blood Sample (optional)|Peripheral blood sample, if available, for biomarkers collected at during screening, every 12 weeks while on treatment, and at the end of treatment visit.
198798|NCT02658019|Genetic|Tumor Tissue Collection (optional)|Tissue sample (archival or newly obtained), if available, collected during screening.
198799|NCT02658006|Procedure|Cardiac surgery|All cardiac surgery procedures
198800|NCT02657993|Behavioral|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.~Participants will be asked to complete questionnaires over a period of 12 months."
198801|NCT02657993|Behavioral|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.~Participants will be asked to complete questionnaires over a period of 12 months."
198802|NCT02657980|Device|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
198803|NCT02657980|Device|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
198804|NCT02657954|Behavioral|CCT|10-week Compensatory Cognitive Training
198805|NCT02657954|Behavioral|HCE|10-week Holistic Cognitive Education
198806|NCT02657941|Behavioral|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
198807|NCT02657941|Behavioral|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
198808|NCT02657928|Other|Laboratory Biomarker Analysis|Correlative studies
198817|NCT02657876|Biological|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
198818|NCT02657863|Procedure|Urine collection and blood draw|
198819|NCT02657850|Other|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
198820|NCT02657850|Other|head neck self reporting|head and neck patient self reports dysphagia symptoms
198821|NCT02657850|Other|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
198822|NCT02657824|Other|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
198823|NCT02657811|Device|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
198824|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
198825|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
198826|NCT02657785|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
198827|NCT02657759|Dietary Supplement|CARDICHOL|
198828|NCT02657759|Dietary Supplement|PLACEBO|
198829|NCT02657746|Other|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
198830|NCT02657733|Device|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.~Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
198831|NCT02657733|Device|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.~Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
198832|NCT02657733|Device|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
198833|NCT02657720|Device|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
198834|NCT02657720|Device|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
198835|NCT02657720|Device|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
198836|NCT02657707|Device|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
198837|NCT02657707|Device|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
198838|NCT02657694|Drug|Sofosbuvir+Ledipasvir|DAA medication treatment
198839|NCT02657694|Drug|Sofosbuvir+Daclatasvir|DAA medication treatment
198840|NCT02657694|Drug|Sofosbuvir+Velpatasvir|DAA medication treatment
198841|NCT02657681|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
198842|NCT02657681|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
198843|NCT02657668|Behavioral|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
198844|NCT02657655|Device|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
199028|NCT02656303|Drug|TGR-1202|TGR-1202 oral daily dose
199173|NCT02655354|Drug|Venlafaxine|Anti-depressant
198845|NCT02657629|Other|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
198846|NCT02657629|Other|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
198847|NCT02657616|Drug|vitamin-k-antagonists|
198848|NCT02657616|Drug|Novel oral anticoagulants|
198849|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (LAX)
198850|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (SAX)
198851|NCT02657603|Procedure|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
198852|NCT02657603|Procedure|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
198853|NCT02657577|Other|There is no intervention|There is no intervention
198854|NCT02657564|Drug|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
198855|NCT02657551|Drug|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
198856|NCT02657538|Other|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
198857|NCT02657538|Other|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
198858|NCT02657538|Device|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
198859|NCT02657538|Other|Visual examination and bitewing (BW) radiography|established diagnostic methods
198860|NCT02657512|Drug|rivaroxaban|rivaroxaban 40 mg/day (1 day)
198861|NCT02657512|Drug|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
198862|NCT02657499|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
198863|NCT02657486|Drug|BGJ398|
198864|NCT02657473|Drug|tobramycin inhalation solution|
198865|NCT02657473|Drug|Saline 0.9% inhalation solution|
198866|NCT02657460|Biological|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
198867|NCT02657460|Drug|cisplatin|cisplatin is a traditional drug for lung cancer
198868|NCT02657447|Drug|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
198869|NCT02657447|Drug|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
198870|NCT02657434|Drug|Atezolizumab|Participants will receive IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
198871|NCT02657434|Drug|Carboplatin|Participants will receive IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
198872|NCT02657434|Drug|Cisplatin|Participants will receive IV infusion of 75 mg/m^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
198873|NCT02657434|Drug|Pemetrexed|Participants will receive IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
198874|NCT02657421|Procedure|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
198875|NCT02657408|Drug|BI 1026706|
198876|NCT02657408|Drug|Placebo|
198877|NCT02657395|Device|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
198878|NCT02657382|Behavioral|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
198879|NCT02657382|Other|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
198880|NCT02657369|Drug|Lenvatinib 24 mg|
198881|NCT02657356|Drug|Placebo capsules|
198882|NCT02657356|Drug|Bardoxolone methyl capsules|
198883|NCT02657343|Drug|Ribociclib|
198884|NCT02657343|Drug|T-DM1|
198885|NCT02657343|Drug|Trastuzumab|
198886|NCT02657343|Drug|Fulvestrant|
198887|NCT02657330|Drug|SBP-101|Subcutaneous drug, escalating dose cohorts
198888|NCT02657317|Behavioral|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
198889|NCT02657317|Other|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
198890|NCT02657304|Behavioral|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
198891|NCT02657304|Other|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
198892|NCT02657291|Drug|Ropivacaine|Local anesthetic
198893|NCT02657291|Device|Ultrasound|Ultrasound guided block
198894|NCT02657278|Procedure|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
198895|NCT02657265|Device|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
198896|NCT02657265|Device|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
198897|NCT02657252|Drug|Glucose|Sclerotherapy of telangiectasis in one lower limb.
198898|NCT02657252|Drug|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
198899|NCT02657239|Behavioral|MOVE UP|Weight management behavioral program
198900|NCT02657213|Device|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
198901|NCT02657213|Device|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
198902|NCT02657200|Other|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
198903|NCT02657187|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
198904|NCT02657187|Drug|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
198905|NCT02657174|Device|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
198906|NCT02657174|Device|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
198907|NCT02657161|Biological|RABIPUR®|Biological rabies vaccine
198908|NCT02657161|Biological|PIKA rabies vaccine|Biological rabies vaccine
198909|NCT02657161|Biological|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
198910|NCT02657148|Drug|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
198911|NCT02657148|Drug|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
198912|NCT02657135|Behavioral|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
198913|NCT02657135|Other|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
198914|NCT02657135|Other|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
198915|NCT02657135|Other|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
198916|NCT02657135|Other|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
198917|NCT02657135|Other|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
198918|NCT02657135|Other|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
198919|NCT02657122|Drug|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
198920|NCT02657122|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
198921|NCT02657122|Drug|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
198922|NCT02657122|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
198923|NCT02657109|Other|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
198924|NCT02657096|Procedure|Hybenx treatment (device)|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
198925|NCT02657096|Procedure|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
198926|NCT02657083|Device|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
198927|NCT02657083|Device|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).~New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.~The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.~During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
198928|NCT02657070|Behavioral|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
198929|NCT02657070|Behavioral|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
198930|NCT02657057|Device|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
198931|NCT02657057|Device|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
198932|NCT02657044|Procedure|EMR|
198933|NCT02657044|Procedure|ESD|
198934|NCT02657031|Drug|Prochlorperazine|prochlorperazine 10 mg IV
198935|NCT02657031|Drug|Ketamine|Ketamine 0.3 mg/kg IV
198936|NCT02657031|Drug|Diphenhydramine|Diphenhydromine 25 mg IV
198937|NCT02657031|Drug|Ondansetron|Ondansetron 4 mg IV
198938|NCT02657031|Drug|Normal Saline|Normal Saline 500 cc IV Bolus
198939|NCT02657018|Device|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
198940|NCT02657018|Other|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
198941|NCT02657005|Drug|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
198942|NCT02656992|Device|Inspiratory muscle training group|
198943|NCT02656979|Drug|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
198944|NCT02656966|Device|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
198945|NCT02656953|Device|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
198946|NCT02656953|Device|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
198947|NCT02656940|Dietary Supplement|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
198948|NCT02656940|Dietary Supplement|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
198949|NCT02656940|Dietary Supplement|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
198950|NCT02656927|Behavioral|Yoga Condition|
198951|NCT02656914|Drug|Irlanda-2-Association|Take 10 mL every 12 hours (2x/day), oral route.
198952|NCT02656914|Drug|Placebo|Take 10 mL every 12 hours (2x/day), oral route.
198953|NCT02656901|Device|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
198954|NCT02656901|Device|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
199163|NCT02655367|Other|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
198955|NCT02656901|Device|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
198956|NCT02656901|Device|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
198957|NCT02656888|Drug|Irlanda-1-Association|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
198958|NCT02656888|Drug|Placebo|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route. For children 12 to 17 years old: take 10 mL every 12 hours (2x/day), oral route.
198959|NCT02656875|Drug|TRV130|
198960|NCT02656862|Other|No intervention|
198961|NCT02656849|Drug|BAY 1000394|
198962|NCT02656836|Other|Home tonometry, diagnostic study|Evaluating intraocular pressure
198963|NCT02656823|Device|ANKYLOS C/X 6.6 mm|
198964|NCT02656810|Drug|Teriparatide|Single subcutaneous injection
198965|NCT02656797|Drug|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
198966|NCT02656784|Behavioral|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
198967|NCT02656784|Behavioral|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
198968|NCT02656771|Device|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
198969|NCT02656758|Behavioral|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
198970|NCT02656745|Device|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones & engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
198971|NCT02656732|Biological|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
198972|NCT02656732|Procedure|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
198973|NCT02656719|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
198974|NCT02656719|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
198975|NCT02656706|Drug|Ipilumumab|
198976|NCT02656706|Drug|Nivolumab|
198977|NCT02656693|Behavioral|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
198978|NCT02656693|Behavioral|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
198979|NCT02656680|Behavioral|FB + Friends|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. In wave 1, participants will be able to invite their friends who are also interested in losing weight. In wave 2, the study team will keep recruitment open for this condition to allow enrollment through week 8.
198980|NCT02656680|Behavioral|FB Only|Participants will receive a weight loss intervention delivered in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
198981|NCT02656667|Device|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
198982|NCT02656667|Device|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
198983|NCT02656667|Other|Conventional pulmonary rehabilitation|excercise training on treadmill
198984|NCT02656654|Other|Whole-body compression|
199164|NCT02655367|Other|Milled oats|Test meal consisting of 264g porridge made with milled oats
198985|NCT02656641|Behavioral|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
198986|NCT02656641|Behavioral|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
198987|NCT02656628|Device|Dynamic Locking Screw 3.7mm and 5.0mm|Treatment with DLS and locked plate constructs (small or large fragments)
198988|NCT02656615|Drug|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
198989|NCT02656602|Other|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
198990|NCT02656589|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
198991|NCT02656589|Drug|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
198992|NCT02656576|Procedure|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
198993|NCT02656576|Procedure|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
198994|NCT02656563|Radiation|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
198995|NCT02656550|Procedure|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
198996|NCT02656537|Device|EnSite™ HD Grid Catheter mapping system|
198997|NCT02656524|Drug|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
198998|NCT02656511|Drug|Dolutegravir|Dolutegravir 50 mg PO daily
198999|NCT02656511|Drug|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
199000|NCT02656498|Drug|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
199001|NCT02656485|Drug|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
199002|NCT02656485|Drug|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
199003|NCT02656472|Drug|Tranexamic acid|"TXA Loading dose: 31 mg/kg diluted to 2 ml/kg NS (in syringe)~31 x _______kg = _______ mg TXA (max: 930mg)~2 x _______ kg = _______ ml NS (max: 60 ml)~TXA infusion: 14 mg/kg hour = 1 ml/kg/hour (6 hour bag) (Max rate of infusion = 30ml/hr)~14 x ______ kg = _____mg x 6 = ______ mg TXA (max: 2,520mg)~1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)~TXA second bolus in 1 ml/kg NS~< 16 kg: TXA 45 mg in 1 ml/kg NS = _______ml NS~16-30 kg: TXA 90 mg in 1 ml/kg NS = _______ml NS~> 30 kg: TXA 120 mg 1 ml/kg NS = _______ml NS (max 30ml)"
199004|NCT02656472|Drug|Epsilon Aminocaproic Acid|"Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS~75 x _______kg = _______ mg EACA (max: 2,250mg)~2x _______ kg = _______ ml NS (max 60ml)~Aminocaproic acid infusion: 75 mg/kg hour = 1 ml/kg/hour (6 hour bag)~75 x ______ kg = _____mg x 6 = ______ mg EACA (max: 13,500 mg)~1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)~Aminocaproic acid second bolus: 75 mg/kg in 1ml/kg NS~75 x _______kg = _______ mg EACA (max: 2,250mg)~1 x _______ kg = _______ ml NS (max 30 ml)"
199005|NCT02656459|Other|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
199006|NCT02656446|Device|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
199007|NCT02656446|Device|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
199008|NCT02656433|Device|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
199009|NCT02656433|Other|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
199010|NCT02656420|Drug|Broccoli Sprout-derived Beverage|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebos.
199011|NCT02656420|Drug|Placebos|Placebo as comparison to broccoli sprout-derived beverages
199012|NCT02656407|Device|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
199013|NCT02656394|Drug|GL101|Topical Gel
199014|NCT02656394|Drug|Placebo|Placebo topical gel
199015|NCT02656368|Device|SEBORRHEAMEDIS Face Cream|SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
199016|NCT02656355|Other|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
199017|NCT02656355|Other|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
199018|NCT02656342|Drug|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
199019|NCT02656342|Drug|Placebo|Predicted to have no enhancing effect
199020|NCT02656329|Drug|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
199021|NCT02656329|Device|Implantable Cardioverter Defibrillator|In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.
199022|NCT02656329|Drug|Thyroid blocking|Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
199023|NCT02656329|Drug|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
199024|NCT02656329|Device|Implantable Cardioverter Defibrillator|All participants allocated to the SoC (control) group underwent ICD implantation.
199025|NCT02656316|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
199029|NCT02656290|Device|Edwards Pericardial Aortic Bioprosthesis Model 11000A|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position; a trileaflet bioprosthesis comprised of bovine pericardium
199030|NCT02656277|Other|Decision Tool|
199031|NCT02656277|Other|Information on Shoulder Dislocation|
199032|NCT02656251|Drug|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
199033|NCT02656251|Drug|placebo|Use of placebo every 12 hours for 04 days
199034|NCT02656251|Drug|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
199035|NCT02656225|Drug|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
199036|NCT02656225|Drug|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
199037|NCT02656212|Drug|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
199038|NCT02656212|Drug|Placebo|Placebo pill, taken orally, one pill/day in the morning
199039|NCT02656199|Procedure|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
199040|NCT02656186|Dietary Supplement|Pre-intervention|First 2-weeks : keeping routine dietary habit
199041|NCT02656186|Dietary Supplement|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
199042|NCT02656173|Drug|Mirabegron|Oral tablet
199043|NCT02656173|Drug|Placebo|Oral tablet
199044|NCT02656173|Drug|Tamsulosin|Oral tablet
199045|NCT02656160|Drug|Placebo|Placebo 3 hrs before sleep
199046|NCT02656160|Drug|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
199047|NCT02656147|Biological|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
199048|NCT02656134|Procedure|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
199049|NCT02656134|Genetic|Molecular analysis.|DNA analysis
199050|NCT02656121|Drug|Vitamin D|6000 IU of vitamin D3
199051|NCT02656121|Drug|Ovulatory Agent|only Clomophine Citrate
199052|NCT02656108|Procedure|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
199053|NCT02656108|Procedure|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
199054|NCT02656095|Drug|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
199055|NCT02656082|Drug|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
199056|NCT02656069|Drug|G-Pen (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
199057|NCT02656069|Drug|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
199058|NCT02656056|Other|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
199059|NCT02656043|Drug|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
199060|NCT02656043|Drug|Placebo|
199061|NCT02656030|Other|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
199062|NCT02656030|Other|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
199063|NCT02656030|Other|usual care|usual care, 2 time per week, 6 weeks duration
199064|NCT02656017|Drug|Metformin|Monitoring of tolerability and symptoms.
199065|NCT02656017|Other|Placebo|Monitoring of tolerability and symptoms.
199066|NCT02656004|Other|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
199067|NCT02656004|Other|Control Session|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
199068|NCT02655991|Behavioral|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
199069|NCT02655991|Behavioral|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
199070|NCT02655978|Other|Magnetic Resonance Imaging|
199071|NCT02655965|Drug|Ropivacaine|Ropivacaine 3.5 mg/ml
199072|NCT02655965|Drug|Clonidine|Clonidine 5µg/ml
199073|NCT02655965|Drug|Sodium Chloride|Sodium Chloride 0.9 %
199074|NCT02655952|Drug|Foxy-5|
199075|NCT02655939|Dietary Supplement|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
199076|NCT02655939|Dietary Supplement|Placebo|Fructose,Orange flavor and sucralose
199077|NCT02655926|Procedure|Deep Brain Stimulation|Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
199078|NCT02655913|Drug|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
199079|NCT02655913|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
199080|NCT02655913|Other|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
199081|NCT02655900|Other|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
199082|NCT02655887|Device|VENOVO™ Venous Stent|VENOVO™ Venous stent placement
199083|NCT02655874|Biological|Influenza vaccine|Administered at day 1
199084|NCT02655874|Biological|Influenza vaccine|Administered at day 180
199085|NCT02655874|Biological|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
199086|NCT02655861|Other|Observation|
199087|NCT02655848|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
199088|NCT02655848|Procedure|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
199089|NCT02655848|Procedure|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
199090|NCT02655835|Behavioral|Internet Mindfulness Meditation|
199091|NCT02655835|Behavioral|Access|
199092|NCT02655822|Drug|CPI-444|100 mg orally twice daily for the first 14 days of each 28-day cycle.
199093|NCT02655822|Drug|CPI-444|100 mg orally twice daily for 28 days of each 28-day cycle.
199094|NCT02655822|Drug|CPI-444|200 mg orally once daily for the first 14 days of each 28-day cycle.
199095|NCT02655822|Drug|CPI-444 + atezolizumab|CPI-444 orally in combination with atezolizumab intravenously.
199096|NCT02655822|Drug|CPI-444|Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
199097|NCT02655809|Radiation|Fluoroscopic examination|
199098|NCT02655796|Device|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
199099|NCT02655783|Other|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
199100|NCT02655783|Other|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
199101|NCT02655770|Drug|Liraglutide|
199102|NCT02655770|Drug|Placebo|
199103|NCT02655757|Drug|Sitagliptin|5 mg, 1 tablet per day for 12 months
199104|NCT02655757|Drug|Placebo|Placebo,1 tablet per day for 12 months
199105|NCT02655744|Radiation|Standard treatment protocol with combined chemoradiation|
199106|NCT02655731|Device|PVI with HeartLight|Catheter ablation
199107|NCT02655718|Other|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
199108|NCT02655718|Device|MRI|
199109|NCT02655705|Drug|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
199110|NCT02655705|Drug|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
199111|NCT02655692|Drug|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
199112|NCT02655692|Drug|Placebo|This is a saline placebo/non-active solution.
199113|NCT02655679|Drug|VTP-38543|VTP-38543 topical cream
199114|NCT02655679|Other|Vehicle with Transcutol®P|Vehicle matching VTP-38543 cream with Transcutol®P
199115|NCT02655679|Other|Vehicle without Transcutol®P|Vehicle matching VTP-38543 cream without Transcutol®P
199116|NCT02655653|Drug|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
199117|NCT02655653|Drug|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
199118|NCT02655640|Other|Questionnaires|Questionnaires will be provided to patients
199119|NCT02655627|Other|Internet based exercise training|
199120|NCT02655627|Other|group exercise training|
199121|NCT02655627|Other|Physical activity counselling via a brochure|
199122|NCT02655614|Drug|GDC-0134|GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
199123|NCT02655614|Drug|Placebo|Placebo matching to GDC-0134
199124|NCT02655614|Drug|Rabeprazole|Rabeprazole 20 mg twice daily orally
199125|NCT02655614|Drug|Midazolam|2mg of liquid formulation of midazolam orally
199126|NCT02655614|Drug|Caffeine|100 mg tablet or solution of caffeine orally
199165|NCT02655354|Behavioral|Motivational Interviewing|
199166|NCT02655354|Behavioral|Cognitive Behavioral Therapy Elements|
199127|NCT02655601|Drug|BMX-001|BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.
199128|NCT02655601|Radiation|Radiation Therapy|RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy.
199129|NCT02655601|Drug|Temozolomide|Initially, temozolomide (TMZ) will be dosed at 75 mg/m2 orally daily for 42 days. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles.
199130|NCT02655588|Behavioral|Interactive Media-Based Problems Solving Treatment|
199131|NCT02655575|Behavioral|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
199132|NCT02655575|Behavioral|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
199133|NCT02655562|Drug|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO＜25ppb were given placebo (p.o., 10mg, qd).~Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO＜25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
199134|NCT02655549|Biological|Px563L, RPA563, or placebo|Two intramuscular injections
199135|NCT02655536|Drug|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
199136|NCT02655536|Drug|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
199137|NCT02655523|Drug|Triamcinolone|1 mL of 40 mg of Triamcinolone
199138|NCT02655523|Drug|Dexamethasone|1 mL of 4mg of Dexamethasone
199139|NCT02655523|Drug|Normal Saline|1 mL of preservative free normal saline
199140|NCT02655523|Drug|Bupivacaine|2 mL of 0.5% bupivacaine
199141|NCT02655510|Drug|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
199142|NCT02655497|Behavioral|Cognitive training|
199143|NCT02655497|Behavioral|Psychosocial education|
199144|NCT02655484|Device|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
199145|NCT02655471|Drug|"Raltegravir and Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
199146|NCT02655458|Drug|Elotuzumab|"The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
199147|NCT02655458|Drug|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
199148|NCT02655458|Other|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
199149|NCT02655458|Other|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
199150|NCT02655445|Procedure|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
199151|NCT02655445|Procedure|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
199152|NCT02655445|Procedure|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
199153|NCT02655432|Device|Spot photoscreener|Screening of vision problem through an automated device
199154|NCT02655432|Procedure|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
199155|NCT02655432|Procedure|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
199156|NCT02655419|Drug|ATM-AVI|"Cohort 1:~(Creatinine clearance > 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance > 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
199157|NCT02655419|Drug|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
199158|NCT02655406|Other|Class 2 compression stockings|
199159|NCT02655393|Dietary Supplement|AMAZ-02|
199160|NCT02655380|Drug|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
199161|NCT02655380|Drug|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
199162|NCT02655380|Drug|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
199174|NCT02655354|Drug|Duloxetine|Anti-depressant
199175|NCT02655354|Drug|Mirtazapine|Anti-depressant
199176|NCT02655354|Drug|Diphenhydramine|Sleep medication
199177|NCT02655354|Drug|Trazodone|Sleep medication
199178|NCT02655354|Drug|Prazosin|Sleep medication
199179|NCT02655341|Device|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
199180|NCT02655341|Procedure|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
199181|NCT02655341|Procedure|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
199182|NCT02655341|Procedure|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
199183|NCT02655328|Other|blood sample|blood sample
199184|NCT02655328|Other|urine sample|urine sample
199185|NCT02655315|Drug|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
199186|NCT02655315|Drug|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
199187|NCT02655302|Other|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
199188|NCT02655302|Other|Lung function measure|Measure lung function and follow it during 4 years
199189|NCT02655289|Device|Modulated TENS|"Frequency: 100 Hz~Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity~Mode: intensity modulation (40% decrease every 0.5 seconds)~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
199190|NCT02655289|Device|Placebo TENS|"Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)~Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.~Mode: continuous~TENS device: ARTROSTIM® SELECT~Channels: 2~Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
199191|NCT02655276|Other|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
199192|NCT02655276|Other|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
199193|NCT02655263|Drug|Somatropin|Somatropin infusion (Genotropin®)
199194|NCT02655263|Other|Ketone bodies|ketone bodies infusion
199195|NCT02655250|Other|Microbiome|
199196|NCT02655237|Drug|Relugolix|Relugolix tablets
199197|NCT02655237|Drug|Relugolix Placebo|Relugolix placebo-matching tablets
199198|NCT02655237|Drug|Leuprorelin|Leuprorelin injection
199199|NCT02655237|Drug|Leuprorelin Placebo|Leuprorelin placebo-matching injections
199200|NCT02655224|Drug|Relugolix|Relugolix Tablets
199201|NCT02655224|Drug|Relugolix placebo|Relugolix placebo-matching tablets
199202|NCT02655211|Procedure|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
199203|NCT02655211|Procedure|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
199204|NCT02655211|Other|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
199205|NCT02655198|Drug|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
199206|NCT02655172|Other|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
199207|NCT02655172|Other|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
199208|NCT02655146|Drug|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
199209|NCT02655146|Drug|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
199210|NCT02655146|Drug|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
199211|NCT02655146|Drug|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
199212|NCT02655133|Drug|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
199213|NCT02655133|Drug|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
199214|NCT02655120|Procedure|Drilling|
199215|NCT02655120|Biological|Bone Marrow +BMP7|
199216|NCT02655081|Dietary Supplement|high arginine nutritional supplement (Nestle's Impact AR)|Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
199217|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
199218|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.~During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).~The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings"
199219|NCT02655055|Procedure|high frequency voluntary apheresis blood donation|
199220|NCT02655029|Drug|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
199221|NCT02655016|Drug|Niraparib|Niraparib vs Placebo 2:1 ratio
199222|NCT02655016|Drug|Placebo|
199223|NCT02655003|Other|TIME|
199224|NCT02655003|Other|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
199225|NCT02654990|Drug|panobinostat capsules|20mg, 10mg or 15mg (for dose reductions only)
199226|NCT02654990|Drug|bortezomib injection|1.3mg/m2 sub-cutaneous administration; Cycle 1-4: 2 weeks on/1 week off twice a week for patients <=75 years at time of screening; once a week for patient > 75 years Cycle 5+: once a week for all patients
199227|NCT02654990|Drug|dexamethasone tablets|pre and 24h after BTZ administration; patients <= 75 years at time of screening: 20mg/dose patients > 75 years: 10mg/dose
199228|NCT02654977|Drug|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
199229|NCT02654964|Drug|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
199230|NCT02654951|Other|Visual Feedback|"The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible."
199231|NCT02654951|Other|Force Feedback|"A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.~The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.~The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible."
199232|NCT02654938|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
199233|NCT02654938|Drug|Placebo|5% infusion solution of dextrose
199234|NCT02654925|Procedure|Adipose Tissue Biopsy|
199235|NCT02654912|Drug|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
199236|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
199237|NCT02654899|Other|Placebo|Placebo
199238|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
199239|NCT02654886|Other|Resistance Exercise Training|"Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months~Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months"
199240|NCT02654860|Drug|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
199241|NCT02654860|Drug|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
199242|NCT02654860|Drug|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
199243|NCT02654847|Drug|Norepinephrine|
199244|NCT02654847|Drug|Normal Saline|0.9% sodium chloride solution, used as a diluent.
199245|NCT02654834|Other|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
199246|NCT02654821|Biological|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
199247|NCT02654821|Procedure|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
199248|NCT02654821|Procedure|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
199283|NCT02654535|Other|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
199284|NCT02654522|Drug|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
199285|NCT02654509|Biological|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
199249|NCT02654808|Device|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
199250|NCT02654808|Device|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
199251|NCT02654795|Radiation|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
199252|NCT02654782|Drug|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
199253|NCT02654782|Drug|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
199254|NCT02654769|Drug|Ingenol Mebutate (Picato®)|Brand product
199255|NCT02654769|Drug|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
199256|NCT02654769|Drug|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
199257|NCT02654743|Dietary Supplement|Sulforaphane|Children with ASD will receive Sulforaphane in this study
199258|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
199259|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
199260|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
199261|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
199262|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
199263|NCT02654717|Drug|DFD-07 Cream|
199264|NCT02654717|Drug|Placebo Cream|
199265|NCT02654704|Biological|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
199266|NCT02654678|Drug|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
199267|NCT02654665|Behavioral|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
199268|NCT02654665|Drug|Liraglutide|GLP-1 agonist
199269|NCT02654652|Dietary Supplement|Symbiotic|Intervention will consist of the adminitration of symbiotic product twice a day during seven days after surgical treatment
199270|NCT02654652|Dietary Supplement|Maltodextrin|Intervention will consist of the adminitration of placebo product twice a day during seven days after surgical treatment
199271|NCT02654639|Drug|TAS-102|TAS-102 Twice a day by mouth day 1-5 and 8-12
199272|NCT02654639|Drug|Bevacizumab|Bevacizumab by intravenous infusion once every 14 days
199273|NCT02654626|Drug|KBP-7072|Drug Intervention
199274|NCT02654626|Other|Placebo|
199275|NCT02654613|Other|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
199276|NCT02654587|Drug|OSE2101|
199277|NCT02654587|Drug|Docetaxel|
199278|NCT02654587|Drug|Pemetrexed|
199279|NCT02654574|Other|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
199280|NCT02654561|Drug|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
199281|NCT02654561|Drug|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
199282|NCT02654548|Other|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
199286|NCT02654496|Other|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
199287|NCT02654483|Drug|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
199288|NCT02654483|Other|Placebo|Matching tablets to VPD-737 tablets without active drug
199289|NCT02654470|Device|Watchman FLX|Patients who are receiving the Watchman FLX device
199290|NCT02654457|Procedure|Women with Breast Cancer|IVD Study
199291|NCT02654431|Procedure|Breast Cancer patient|Samples
199292|NCT02654431|Procedure|Cancer patients|Samples
199293|NCT02654418|Procedure|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
199294|NCT02654405|Dietary Supplement|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
199295|NCT02654405|Other|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
199296|NCT02654392|Dietary Supplement|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
199297|NCT02654392|Dietary Supplement|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils) every day for 5 weeks
199298|NCT02654379|Biological|Rituximab|Rituximab use in non-oncology indications
199299|NCT02654366|Behavioral|Risk Reduction Group|"The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.~The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support."
199300|NCT02654353|Procedure|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
199301|NCT02654327|Device|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
199302|NCT02654314|Drug|Melatonin|
199303|NCT02654301|Dietary Supplement|Test 1|sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
199304|NCT02654301|Dietary Supplement|Test 2|sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
199305|NCT02654301|Dietary Supplement|Test 3|sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
199306|NCT02654301|Dietary Supplement|Control|sucrose 50 g + deionized water 100 g
199307|NCT02654288|Other|gemcitabine-based chemotherapy|
199308|NCT02654275|Other|Proprioceptive Intervention|
199309|NCT02654249|Device|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
199310|NCT02654249|Procedure|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
199311|NCT02654249|Device|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
199312|NCT02654249|Device|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
199313|NCT02654236|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
199314|NCT02654236|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
199315|NCT02654223|Biological|MG56 Mannosylated 60 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 60 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
199316|NCT02654223|Biological|MG56 Mannosylated 100 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 100 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
199317|NCT02654223|Biological|MG56 Mannosylated 300 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 300 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
199318|NCT02654223|Biological|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
199319|NCT02654223|Biological|MG56 Mannosylated 60 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 60 MTU(Mannosylated Therapeutic Units)/ml sublingual
199320|NCT02654223|Biological|MG56 Mannosylated 100 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 100 MTU(Mannosylated Therapeutic Units)/ml sublingual
199321|NCT02654223|Biological|MG56 Mannosylated 300 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 300 MTU(Mannosylated Therapeutic Units)/ml sublingual
199322|NCT02654223|Biological|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 MTU(Mannosylated Therapeutic Units)/ml sublingual
199323|NCT02654223|Biological|Subcutaneous placebo|Comparison between placebo and active group
199324|NCT02654223|Biological|Sublingual placebo|Comparison between placebo and active group
199325|NCT02654210|Other|No Intervention|No Intervention
199326|NCT02654184|Procedure|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
199373|NCT02653911|Other|Sham-acupuncture group|Hwato Brand, Suzhou Medical Appliance Factory, China
199327|NCT02654184|Procedure|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
199328|NCT02654171|Drug|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
199329|NCT02654171|Drug|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
199330|NCT02654158|Drug|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
199331|NCT02654158|Drug|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day~1~3 years old: 20mL each time and three times a day~4~6 years old: 20mL each time and four times a day~7~12 years old: 20mL each time and five times a day"
199332|NCT02654145|Drug|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
199333|NCT02654145|Drug|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
199334|NCT02654145|Drug|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
199335|NCT02654132|Drug|Elotuzumab|
199336|NCT02654132|Drug|Pomalidomide|
199337|NCT02654132|Drug|Dexamethasone|
199338|NCT02654119|Drug|Cyclophosphamide|Given IV
199339|NCT02654119|Other|Laboratory Biomarker Analysis|Correlative studies
199340|NCT02654119|Drug|Paclitaxel|Given IV
199341|NCT02654119|Biological|Trastuzumab|Given IV
199342|NCT02654106|Radiation|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions＜2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
199343|NCT02654106|Drug|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2*5d, q28d, 6cycles
199344|NCT02654093|Drug|Cholecalciferol|
199345|NCT02654093|Drug|Raloxifene|
199346|NCT02654093|Drug|Cholecalciferol and Raloxifene co-administration|
199347|NCT02654080|Biological|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
199348|NCT02654080|Biological|rVSV HIV envC vaccine|1 × 10^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
199349|NCT02654080|Biological|Placebo|"Sodium Chloride for Injection, USP 0.9%;~At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.~At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
199350|NCT02654067|Procedure|photograph|photograph of airway
199351|NCT02654054|Drug|Elagolix|Elagolix for 6-month Treatment
199352|NCT02654054|Drug|Placebo for Estradiol/Norethindrone Acetate|Placebo for 6-month Treatment
199353|NCT02654054|Drug|Estradiol/Norethindrone Acetate|Estradiol/Norethindrone Acetate for 6-month Treatment
199354|NCT02654054|Drug|Placebo for Elagolix|Placebo for 6-month Treatment
199355|NCT02654041|Drug|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
199356|NCT02654028|Procedure|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
199357|NCT02654028|Other|Control group|These group of patients will not receive autotransfusion before or after liver resection.
199358|NCT02654015|Device|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
199359|NCT02654015|Other|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
199360|NCT02654002|Drug|GS-9674|GS-9674 tablets administered orally
199361|NCT02654002|Drug|Placebo|GS-9674 placebo tablets administered orally
199362|NCT02653989|Biological|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
199363|NCT02653976|Drug|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
199364|NCT02653963|Drug|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
199365|NCT02653950|Procedure|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
199366|NCT02653950|Procedure|Traditional septoplasty|septoplasty under direct vision
199367|NCT02653937|Drug|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:~Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
199368|NCT02653924|Other|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
199369|NCT02653924|Other|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
199370|NCT02653924|Other|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
199371|NCT02653924|Other|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
199372|NCT02653911|Other|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China
199374|NCT02653898|Drug|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
199375|NCT02653898|Drug|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
199376|NCT02653898|Drug|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
199377|NCT02653898|Drug|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
199378|NCT02653885|Other|Red red cell distribution width|Results from hemogram
199379|NCT02653872|Drug|AZD7986|Oral solution, single dose, dilution from concentrate
199380|NCT02653872|Drug|Verapamil|Extended release tablet for oral use
199381|NCT02653872|Drug|Itraconazole|Oral solution
199382|NCT02653872|Drug|Diltiazem|Extended release capsule
199383|NCT02653846|Procedure|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
199384|NCT02653846|Procedure|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
199385|NCT02653833|Drug|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
199386|NCT02653833|Other|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
199387|NCT02653820|Other|Reflexology|
199388|NCT02653807|Other|mobilization with movement|manual therapy intervention
199389|NCT02653807|Other|osteopathic mobilization|manual therapy intervention
199390|NCT02653781|Behavioral|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
199391|NCT02653781|Behavioral|control group|The control group will have contents exposed solely from the dialogue-exhibition.
199392|NCT02653781|Behavioral|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
199393|NCT02653781|Behavioral|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
199394|NCT02653768|Behavioral|Stepped Exercise Program|"STEP 1: Participants have access to an internet-based exercise program for knee OA.~STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.~STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit"
199395|NCT02653768|Behavioral|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
199396|NCT02653755|Device|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
199397|NCT02653742|Drug|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
199398|NCT02653742|Drug|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
199399|NCT02653729|Behavioral|cognitive behaviour therapy|
199400|NCT02653729|Drug|Espidone|
199401|NCT02653729|Drug|Olepra|
199402|NCT02653729|Drug|Donu|
199403|NCT02653716|Behavioral|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
199404|NCT02653716|Behavioral|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
199405|NCT02653703|Other|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
199406|NCT02653703|Other|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
199407|NCT02653677|Other|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
199408|NCT02653664|Behavioral|PsychoEducation|Condition #1
199409|NCT02653664|Behavioral|Self-Hypnosis Training|Condition #2
199410|NCT02653664|Behavioral|Mindfulness Meditation|Condition #3
199411|NCT02653651|Drug|Ketamine|Ketamine infused at 0.1 mg/kg/hour
199412|NCT02653651|Drug|Lidocaine|Lidocaine infused at 1 mg/kg/hour
199413|NCT02653651|Drug|Placebo|An equal volume of saline
199414|NCT02653638|Other|Control|"Transcranial Doppler~Blood Pressure~Heart Rate~Oxygen Saturation"
199415|NCT02653638|Drug|Indomethacin|"Transcranial Doppler~Blood Pressure~Heart Rate~Oxygen Saturation"
199416|NCT02653625|Drug|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning.
199417|NCT02653612|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
199418|NCT02653599|Drug|TTP273|
199419|NCT02653599|Drug|Placebo|
199420|NCT02653586|Other|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
199421|NCT02653573|Behavioral|Coaching|Self-management education
199422|NCT02653560|Drug|Potassium chloride powder|
199423|NCT02653560|Drug|Potassium magnesium Citrate (KMgCit)|
199424|NCT02653560|Drug|Potassium citrate powder|
199425|NCT02653560|Drug|Placebo|
199426|NCT02653547|Other|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
199427|NCT02653547|Other|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
199428|NCT02653547|Other|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
199429|NCT02653547|Other|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
199430|NCT02653534|Behavioral|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
199431|NCT02653521|Radiation|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
199432|NCT02653508|Behavioral|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
199433|NCT02653508|Behavioral|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
199434|NCT02653495|Biological|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
199435|NCT02653482|Drug|Dapagliflozin|
199436|NCT02653482|Drug|Dapagliflozin matching placebo|
199437|NCT02653469|Other|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
199438|NCT02653469|Other|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
199439|NCT02653456|Device|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
199440|NCT02653443|Biological|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
199441|NCT02653443|Biological|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
199442|NCT02653430|Procedure|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
199443|NCT02653417|Drug|RAD1901|RAD1901
199444|NCT02653417|Other|Placebo|Placebo
199445|NCT02653404|Other|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
199446|NCT02653391|Drug|Elamipretide 1.0% Ophthalmic Solution|Each subject will receive one drop of Elamipretide 1.0% ophthalmic solution in the randomly selected study eye BID and one drop of vehicle ophthalmic solution BID in the fellow control eye.
199447|NCT02653391|Drug|Elamipretide 3.0% Ophthalmic Solution|A group of subjects will receive one drop of Elamipretide 3.0% ophthalmic solution in both eyes BID
199448|NCT02653378|Behavioral|DIET|25% Energy Depletion by Diet only for 3 Days
199449|NCT02653378|Behavioral|EX|25% Energy Depletion by Exercise only for 3 Days
199450|NCT02653365|Device|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
199478|NCT02653196|Drug|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
199479|NCT02653196|Drug|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
199480|NCT02653196|Drug|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
199481|NCT02653196|Drug|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
199451|NCT02653352|Behavioral|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
199452|NCT02653339|Drug|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
199453|NCT02653339|Drug|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.~The control group patients are treated with Loratadine by oral, 10mg QD"
199454|NCT02653326|Device|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
199455|NCT02653326|Procedure|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
199456|NCT02653326|Behavioral|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
199457|NCT02653326|Other|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
199458|NCT02653326|Drug|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
199459|NCT02653313|Drug|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."
199460|NCT02653300|Biological|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
199461|NCT02653287|Behavioral|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary. Participants receive 6 consecutive monthly group sessions, beginning shortly after randomization focusing on the following topics: introduction to physical activity; fruits/vegetables; motivation; lifestyle physical activity; healthy diet; and enhancing your environment. The 1 hour sessions are interactive so participants can share information and support each other.
199462|NCT02653287|Other|Control|The control group will receive 6 group educational sessions focusing on SLE disease management. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Sessions will be didactic followed by a brief question and answer period and last about 1 hour. A nurse practitioner will be responsible for conducting the group sessions. Control arm participants receive 4 individual phone calls checking in with participants regarding questions about the study or from the group sessions, each lasting about 10-15 minutes. They occur shortly before first group session, then at 1.5, 3, and 6 months.
199463|NCT02653274|Other|Breakfast porridge|220 kcal breakfast porridge served with 240 mL glass of water
199464|NCT02653261|Drug|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
199465|NCT02653261|Drug|Placebo|An equal volume of saline
199466|NCT02653248|Radiation|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
199467|NCT02653235|Biological|Salmonella typhi vaccination|
199468|NCT02653235|Biological|Placebo|
199469|NCT02653222|Procedure|Renal sympathicolysis|
199470|NCT02653222|Procedure|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
199471|NCT02653222|Radiation|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
199472|NCT02653222|Biological|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
199473|NCT02653209|Drug|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
199474|NCT02653209|Drug|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
199475|NCT02653209|Drug|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
199476|NCT02653196|Procedure|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
199477|NCT02653196|Drug|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
199482|NCT02653196|Drug|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
199483|NCT02653196|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
199484|NCT02653196|Drug|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age > 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
199485|NCT02653196|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
199486|NCT02653183|Device|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing. Duration of treatment: Total 5 days included the day of surgery and 4 post-operative days.
199487|NCT02653183|Device|Experimental: Mepilex Border Post-Op|"Aquacel Surgical is a sterile, one piece post-operative dressing.Duration of treatment:~Total 5 days included the day of surgery and 4 post-operative days."
199488|NCT02653170|Other|SCM|"One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:~Biopsychosocial assessment of patient and caregiver needs.~Set up appointments.~Assist scheduling appointments with primary care physician and other medical providers.~Promote medication adherence through medication tool kits, pill organizers and other aids.~Facilitate patient and caregiver engagement and activation.~Facilitate access to social and community services."
199489|NCT02653170|Other|SCM and VSSP|"SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:~Biopsychosocial assessment of patient and caregiver needs.~Set up appointments.~Assist scheduling appointments with primary care physician and other medical providers.~Promote medication adherence through medication tool kits, pill organizers and other aids.~Facilitate patient and caregiver engagement and activation.~Facilitate access to social and community services.~VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:~Contact list of care team members.~Access to hospital patient portal.~Stroke education materials, resources, and guidelines.~Access to Michigan 2-1-1 services.~Medication information and adherence tools.~Patient and Caregiver support networks."
199490|NCT02653157|Other|MDR-GNB|
199491|NCT02653144|Drug|Ropivacaine|local anesthetics adjuvants. Ropivacaine 0.5% 20ml. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
199492|NCT02653144|Drug|Dexmedetomidine|local anesthetics adjuvants. 75mcg of dexmedetomidine. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
199493|NCT02653144|Drug|Dexamethasone|local anesthetics adjuvants. 4mg dexamethasone. pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
199494|NCT02653131|Drug|Dipeptidyl peptidase-4 inhibitor|
199495|NCT02653118|Biological|V503|
199496|NCT02653118|Biological|GARDASIL|
199497|NCT02653105|Biological|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
199498|NCT02653092|Drug|Insulin|
199499|NCT02653092|Drug|Intralipid|
199500|NCT02653092|Drug|Dextrose|
199501|NCT02653092|Drug|Heparin|
199502|NCT02653092|Drug|GnRH|
199503|NCT02653092|Procedure|Hyperinsulinemic Euglycemic Clamp|
199504|NCT02653079|Other|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
199505|NCT02653066|Other|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
199506|NCT02653066|Other|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
199507|NCT02653040|Other|Dynamic lighting|"Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:~07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity"
199508|NCT02653027|Drug|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
199509|NCT02653027|Other|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
199510|NCT02653014|Drug|KBP-5074|
199511|NCT02653001|Other|Stool sample collection|Collection of complete stool sample
199512|NCT02652988|Other|Active-tDCS|Active home-based tDCS applied at home.
199513|NCT02652988|Other|Sham-tDCS|Sham home-based tDCS applied at home.
199514|NCT02652975|Procedure|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
199515|NCT02652975|Procedure|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
199516|NCT02652975|Procedure|24hour blood pressure|24 hour blood pressure measurement
199517|NCT02652975|Procedure|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
199701|NCT02651779|Other|Closed reduction and plasterimmobilisation|
199518|NCT02652975|Biological|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).~Further more urine samples to determine possible systemic impact of cardiovascular disease.~We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.~Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
199519|NCT02652962|Device|Gelesis200|3 capsules each containing 0.70 g
199520|NCT02652962|Other|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
199521|NCT02652949|Device|Valiant Evo Thoracic Stent Graft|
199522|NCT02652936|Drug|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
199523|NCT02652936|Drug|Placebo comparator|AF-130 matching placebo capsule
199524|NCT02652923|Drug|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
199525|NCT02652910|Drug|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
199526|NCT02652897|Procedure|Exposure to glioma resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
199527|NCT02652897|Procedure|Exposure to colon resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
199528|NCT02652884|Drug|phosphate and betamethasone acetate, 2 mL.|single dose of intramuscular depot corticosteroid
199529|NCT02652884|Drug|saline 0.9% NaCl|single dose of intramuscular placebo
199530|NCT02652871|Drug|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.~Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
199531|NCT02652871|Drug|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.~Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
199532|NCT02652871|Drug|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.~Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
199533|NCT02652858|Procedure|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
199534|NCT02652845|Behavioral|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
199535|NCT02652832|Device|non invasive brain stimulation|non invasive brain stimulation
199536|NCT02652819|Drug|FG-4592|
199537|NCT02652819|Drug|Placebo|
199538|NCT02652806|Drug|FG-4592|
199539|NCT02652806|Drug|Epoetin Alfa|
199540|NCT02652793|Drug|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
199541|NCT02652793|Drug|Lamivudine|Lamivudine 300 mg once dailly
199542|NCT02652780|Genetic|GS010|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
199543|NCT02652780|Device|Sham Intravitreal Injection|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.~Sham-treated Eyes: One eye of each subject will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
199544|NCT02652767|Genetic|GS010|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
199545|NCT02652767|Device|Sham Intravitreal Injection|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.~Sham-treated Eyes: One eye of each subject will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
199659|NCT02652091|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
199660|NCT02652091|Device|BETACONNECT device|Used to apply Betaseron.
199546|NCT02652754|Drug|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
199547|NCT02652741|Drug|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
199548|NCT02652728|Drug|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
199549|NCT02652715|Other|Laboratory Biomarker Analysis|Correlative studies
199550|NCT02652715|Other|Quality-of-Life Assessment|Ancillary studies
199551|NCT02652715|Other|Questionnaire Administration|Ancillary studies
199552|NCT02652715|Dietary Supplement|Salvia hispanica Seed|Given PO
199553|NCT02652702|Procedure|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
199554|NCT02652702|Procedure|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
199555|NCT02652689|Radiation|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
199556|NCT02652676|Procedure|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
199557|NCT02652676|Device|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
199558|NCT02652650|Drug|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
199559|NCT02652650|Drug|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
199560|NCT02652650|Drug|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
199561|NCT02652637|Drug|neomycin, metronidazole, polyethylene glycol (PEG)|
199562|NCT02652624|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
199563|NCT02652624|Drug|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
199564|NCT02652624|Drug|ATV|ATV 300 mg capsules administered orally once daily with food
199565|NCT02652624|Drug|RTV|RTV 100 mg tablets administered orally once daily with food
199566|NCT02652624|Drug|FTC/TDF|200/300 mg tablet administered orally once daily with food
199567|NCT02652624|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
199568|NCT02652611|Procedure|SI Screw Removal Surgery|
199569|NCT02652611|Procedure|Non-screw removal treatment (non-operative management)|
199570|NCT02652598|Drug|Tolcapone|
199571|NCT02652585|Drug|Naltrexone|
199572|NCT02652585|Drug|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
199573|NCT02652572|Drug|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
199574|NCT02652559|Device|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
199575|NCT02652559|Device|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
199576|NCT02652559|Device|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
199577|NCT02652559|Other|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
199578|NCT02652559|Other|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
199579|NCT02652546|Drug|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
199580|NCT02652546|Drug|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
199581|NCT02652546|Drug|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
199582|NCT02652546|Drug|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
199583|NCT02652533|Device|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
199699|NCT02651792|Drug|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
199584|NCT02652520|Procedure|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
199585|NCT02652507|Drug|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
199586|NCT02652507|Drug|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
199587|NCT02652481|Device|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:~Device Name Device Model Number Pulse Generators Phase I and II Phase II Only * CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ( dual chamber) ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads~* May only be used internationally outside the US"
199588|NCT02652468|Drug|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
199589|NCT02652468|Drug|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
199590|NCT02652468|Drug|Cyclophosphamide|Given IV for 2 days
199591|NCT02652468|Radiation|Total nodal irradiation|Undergo total lymphoid irradiation
199592|NCT02652468|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
199593|NCT02652468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
199594|NCT02652468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
199595|NCT02652468|Drug|Mycophenolate Mofetil|Given PO
199596|NCT02652468|Drug|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10^5 cells/kg ideal BW of the patient
199597|NCT02652468|Biological|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the patient
199598|NCT02652455|Drug|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
199599|NCT02652455|Procedure|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
199600|NCT02652455|Drug|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
199601|NCT02652455|Drug|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
199602|NCT02652455|Drug|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
199603|NCT02652455|Biological|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
199604|NCT02652455|Drug|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
199605|NCT02652442|Behavioral|Gaze stability exercises|Gaze stability exercises include adaptation and substitution exercises. Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Substitution exercises specifically attempt to facilitate use of alternative strategies, rather than teaching the specific strategies. For example, during active eye-head exercise, a large eye movement to a target is made prior to the head moving to the target, potentially facilitating preprogrammed eye movements.
199606|NCT02652442|Behavioral|Centrifugation|Participants will be rotated in a darkened rotary chair booth with 1 ear positioned 7-8 cm off-axis and the other ear positioned on-axis. Following a 5-minute rest period, the procedure will be repeated with the opposite ear positioned off-axis. Participants will receive 10 sessions in a 4-week period.
199607|NCT02652442|Behavioral|Balance rehabilitation|All participants will perform balance and gait exercises and will be provided a written home exercise program consisting of exercises designed to improve postural stability and mobility with progressively more challenging tasks.
199608|NCT02652429|Drug|Inhaled Nitric Oxide|
199609|NCT02652416|Drug|BI 1026706|oral administration
199610|NCT02652416|Drug|Placebo|placebo
199611|NCT02652403|Device|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:~Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
199612|NCT02652403|Device|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
199613|NCT02652390|Drug|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
199614|NCT02652390|Drug|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
199615|NCT02652390|Other|Saline|2 mL saline + 1 mL lidocaine
199616|NCT02652377|Drug|EDP-494|10, 100 and 200 mg capsules
199617|NCT02652377|Drug|Placebo|placebo to match EDP-494
199661|NCT02652078|Device|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
199618|NCT02652351|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
199619|NCT02652338|Dietary Supplement|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
199620|NCT02652338|Dietary Supplement|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
199621|NCT02652325|Drug|Saline|
199622|NCT02652325|Drug|Povidone-Iodine|
199623|NCT02652325|Drug|5% Povidone-Iodine USP swabs|
199624|NCT02652312|Drug|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
199625|NCT02652312|Drug|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
199626|NCT02652312|Procedure|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
199627|NCT02652312|Procedure|fentanyl|1.5 μg/kg intraoperative
199628|NCT02652312|Procedure|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
199629|NCT02652312|Procedure|Atracurium|0.5 mg/kg IV for endotracheal intubation
199630|NCT02652312|Procedure|diclofenac sodium|1 mg/kg for postoperative analgesia
199631|NCT02652312|Procedure|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
199632|NCT02652299|Biological|Synovial biopsy|Synovial tissue for analysis and biobank.
199633|NCT02652286|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
199634|NCT02652273|Drug|Abatacept|Abatacept 125mg/ml
199635|NCT02652260|Drug|MK-1439A - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded period
199636|NCT02652260|Drug|MK-1439A - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; also an additional 96 weeks during the Open-Label extension period 1; and also a maximum total duration of treatment of 228 weeks during the Open-Label extension period 2.
199637|NCT02652260|Drug|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded period
199638|NCT02652260|Drug|Placebo to ATRIPLA™|A single placebo to ATRIPLA™ tablet administered orally, once daily for 12 weeks during the Blinded period
199639|NCT02652260|Drug|Placebo to MK-1439A|A single placebo to MK-1439A tablet administered orally, once daily for 12 weeks during the Blinded period
199640|NCT02652247|Procedure|molecular analysis of exhaled breath condensate|
199641|NCT02652247|Procedure|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
199642|NCT02652247|Procedure|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
199643|NCT02652234|Drug|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
199644|NCT02652234|Drug|Chemotherapy|
199645|NCT02652221|Device|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
199646|NCT02652208|Behavioral|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
199647|NCT02652208|Behavioral|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
199648|NCT02652195|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
199649|NCT02652195|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
199650|NCT02652169|Drug|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
199651|NCT02652169|Drug|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
199652|NCT02652169|Drug|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
199653|NCT02652169|Other|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
199654|NCT02652156|Drug|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
199655|NCT02652156|Drug|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
199656|NCT02652156|Drug|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
199657|NCT02652143|Device|AneVivo (Medical device for in vivo culture of embryos)|
199658|NCT02652143|Other|comparator for embryo culture in vitro|
199700|NCT02651779|Procedure|Open reduction and internal plate fixation|
199662|NCT02652065|Other|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
199663|NCT02652065|Other|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
199664|NCT02652065|Other|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
199665|NCT02652065|Other|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
199666|NCT02652052|Drug|Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
199667|NCT02652052|Other|Standard of Care - Observation Only|Control Arm - Observation only
199668|NCT02652052|Drug|Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
199669|NCT02652039|Other|Questionnaires|Questionnaires
199670|NCT02652026|Procedure|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
199671|NCT02652026|Procedure|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
199672|NCT02652013|Other|cognitive evaluation|
199673|NCT02652000|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
199674|NCT02651987|Drug|Lanreotide autogel 120 mg|
199675|NCT02651974|Behavioral|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
199676|NCT02651974|Behavioral|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
199677|NCT02651974|Behavioral|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
199678|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
199679|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
199680|NCT02651948|Procedure|Transperineal, MRI-guided, prostate biopsy|
199681|NCT02651948|Procedure|Transrectal prostate biopsy (TRB):|
199682|NCT02651935|Device|Intellivent ASV|Automated Invasive mechanical ventilation and weaning strategy
199683|NCT02651909|Other|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
199684|NCT02651896|Radiation|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.~For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).~Image guidance with cone beam CT will be mandatory before every treatment fraction."
199685|NCT02651883|Behavioral|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
199686|NCT02651883|Behavioral|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
199687|NCT02651870|Drug|Candesartan 16mg|
199688|NCT02651870|Drug|Amlodipine 5mg|
199689|NCT02651870|Drug|Amlodipine 10mg|
199690|NCT02651857|Device|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
199691|NCT02651857|Device|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
199692|NCT02651844|Drug|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).~Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
199693|NCT02651831|Other|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
199694|NCT02651831|Other|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
199695|NCT02651818|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
199696|NCT02651805|Device|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
199697|NCT02651805|Other|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
199698|NCT02651792|Drug|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
199702|NCT02651766|Procedure|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
199703|NCT02651753|Drug|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
199704|NCT02651753|Drug|CKD-337|Test Drug: CKD-337
199705|NCT02651740|Drug|Rifaximin|400mg tid* 3d
199706|NCT02651740|Procedure|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
199707|NCT02651727|Drug|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
199708|NCT02651727|Drug|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
199709|NCT02651727|Drug|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
199710|NCT02651714|Drug|Tradipitant|
199711|NCT02651714|Drug|Placebo|
199712|NCT02651701|Procedure|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
199713|NCT02651688|Drug|Placebo|One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
199714|NCT02651688|Drug|Enclomiphene|Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
199715|NCT02651675|Biological|AAV directed hLDLR gene therapy|A novel adeno-associated viral (AAV) vector with human low-density lipoprotein receptor (hLDLR) gene
199716|NCT02651662|Drug|cemiplimab|Multiple dose levels administered IV Q2W
199717|NCT02651662|Drug|REGN1979|Single dose level of cemiplimab and multiple dose levels of REGN1979 administered IV
199718|NCT02651649|Device|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
199719|NCT02651636|Drug|myo-inositol,alpha-lipoic acid and folic acid|
199720|NCT02651623|Drug|Sertraline|Multiple doses of sertraline for 14 days
199721|NCT02651623|Drug|Moxifloxacin|A single dose of 400 mg Moxifloxacin
199722|NCT02651623|Drug|Drug - Placebo|Placebo administered for 14 days
199723|NCT02651610|Biological|Bavituximab|Biological: bavituximab
199724|NCT02651610|Drug|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
199725|NCT02651597|Other|Oatmeal|
199726|NCT02651584|Drug|CAM2038 SC injection|
199727|NCT02651584|Drug|SL BPN/NX tabs|
199728|NCT02651584|Drug|placebo SC injections|
199729|NCT02651584|Drug|SL placebo tablets|
199730|NCT02651558|Device|Experimental: OBPM 2015-MD-0022 - CHEST|"At the onset of general anesthesia:~continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
199731|NCT02651558|Device|Experimental: OBPM 2015-MD-0022 - CHEST & FINGER|"At the onset of general anesthesia:~continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~continuous estimates of optical blood pressure values at the chest (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
199732|NCT02651558|Device|Experimental: OBPM 2015-MD-0022 - FINGER|"At the onset of general anesthesia:~continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)~continuous estimates of optical blood pressure values at the fingertip (optical blood pressure system, via Swissmedic approved OBPM measuring device 2015-MD-0022 developed by CSEM)~will be recorded."
199733|NCT02651532|Device|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
199734|NCT02651519|Drug|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
199735|NCT02651519|Drug|saline|stellate-ganglion block with saline
199736|NCT02651506|Procedure|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
199737|NCT02651506|Procedure|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
199738|NCT02651493|Device|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
199739|NCT02651480|Dietary Supplement|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
199740|NCT02651480|Dietary Supplement|Control Group|Unrestricted diet with no instruction.
199741|NCT02651467|Other|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
199742|NCT02651467|Other|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
199743|NCT02651467|Other|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
199744|NCT02651454|Drug|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
199745|NCT02651454|Drug|Jowiseungcheung-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
199746|NCT02651454|Drug|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
199747|NCT02651441|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
199748|NCT02651441|Drug|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
199749|NCT02651441|Biological|D-CIK|8×10^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
199750|NCT02651428|Drug|Neutrolin|Neutrolin® or heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
199751|NCT02651428|Drug|Heparin|Neutrolin® or heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
199752|NCT02651415|Drug|Regorafenib|"Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.~Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is <30% fat, ~300-550 calories."
199753|NCT02651415|Drug|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
199754|NCT02651402|Behavioral|FRIENDS for Life|Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
199755|NCT02651402|Behavioral|Adapted FRIENDS|Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
199756|NCT02651402|Behavioral|Train-the-Trainer|Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
199757|NCT02651402|Behavioral|Train-the-Trainer Plus|Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
199758|NCT02651376|Combination Product|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3*10E8 MNCs/kg body at baseline, week 1 and 2.
199759|NCT02651350|Drug|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
199760|NCT02651350|Drug|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
199761|NCT02651337|Device|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
199762|NCT02651324|Drug|Ketamine|
199763|NCT02651324|Other|Placebo|
199764|NCT02651311|Other|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
199765|NCT02651311|Drug|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
199766|NCT02651311|Drug|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
199767|NCT02651298|Device|Fractional Co2-laser|laser treatment
199768|NCT02651285|Other|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
199769|NCT02651285|Other|Control|incubation of IVF embryos with a medium without G-CSF
199770|NCT02651272|Drug|macitentan|10mg macitentan tablets
199771|NCT02651259|Drug|Rifapentine (RPT)|900 mg of RPT
199772|NCT02651259|Drug|Isoniazid (INH)|900 mg of INH
199773|NCT02651259|Dietary Supplement|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
199774|NCT02651246|Other|data collection|
199775|NCT02651233|Other|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
199776|NCT02651220|Drug|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
199777|NCT02651220|Drug|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
199778|NCT02651220|Drug|placebo gel|vehicle used as placebo
200311|NCT02647086|Drug|Metoprolol|Cytochrome P450 substrate
199779|NCT02651207|Other|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
199780|NCT02651194|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
199781|NCT02651181|Device|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
199782|NCT02651168|Biological|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
199783|NCT02651155|Drug|Lubiprostone|Lubiprostone capsules
199784|NCT02651155|Drug|Placebo|Lubiprostone placebo-matching capsules
199785|NCT02651142|Procedure|Patients receive SLNB|Patients receive sentinel lymph node biopsy
199786|NCT02651129|Other|Noise measurement|We will be measuring noise levels in the operating room
199787|NCT02651116|Drug|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
199788|NCT02651116|Drug|Placebo|10 mL Placebo
199789|NCT02651116|Device|Cough recording device|FDA approved device validated for use in adults and children
199790|NCT02651103|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
199791|NCT02651090|Drug|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
199792|NCT02651064|Other|HIP|
199793|NCT02651051|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
199794|NCT02651051|Other|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
199795|NCT02651038|Drug|Micafungin|Measurement of PK
199796|NCT02651025|Other|Resistance Exercise Program|"During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6."
199797|NCT02650999|Drug|Pembrolizumab|200mg intravenously (IV)
199798|NCT02650986|Drug|Cyclophosphamide|Given IV
199799|NCT02650986|Other|Laboratory Biomarker Analysis|Correlative studies
199800|NCT02650986|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
199801|NCT02650986|Biological|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
199802|NCT02650973|Drug|CHS-1701|
199803|NCT02650973|Drug|Pegfilgrastim|
199804|NCT02650947|Dietary Supplement|Sucralose|Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
199805|NCT02650947|Dietary Supplement|Placebo|Consumption of empty capsule everyday for 4 weeks
199806|NCT02650934|Procedure|Percutanous coronary intervention|
199807|NCT02650921|Device|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
199808|NCT02650895|Biological|CD24Fc|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
199809|NCT02650895|Drug|Saline|0.9% sodium chloride
199810|NCT02650882|Procedure|Device POWERbreathe|
199811|NCT02650869|Dietary Supplement|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
199812|NCT02650869|Dietary Supplement|Breast milk|Normal breast milk will be given as part of standard care
199813|NCT02650856|Drug|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
199814|NCT02650856|Biological|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
199815|NCT02650843|Other|DAT SPECT imaging|
199816|NCT02650817|Drug|RAD1901|RAD1901, a novel selective ER degrader (SERD)
199817|NCT02650804|Drug|BPM31510 Nanosuspension Injection|
199818|NCT02650804|Drug|Gemcitabine|
199819|NCT02650791|Drug|Tranexamic Acid|
199820|NCT02650778|Procedure|Breast ultrasound|automated whole breast ultrasound
199821|NCT02650765|Other|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
199822|NCT02650752|Drug|Lapatinib in Tandem With Capecitabine|
199823|NCT02650739|Procedure|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
199824|NCT02650726|Dietary Supplement|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
199825|NCT02650726|Other|Placebo|placebo 320mg daily for 24 weeks
199826|NCT02650713|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
199827|NCT02650713|Drug|RO6958688|"RO6958688 is administered by IV infusion~In Part IA: RO6958688 is administered weekly (QW) on days 1,8 and 15 of each 21-day cycle.~In Part 1b: RO6958688 is administered weekly (QW) or every 3 weeks (Q3W). Cohort A: RO6958688 starting dose will be 100 mg either QW or Q3W.~Step Up dose cohorts: RO6958688 starting dose will be 40mg and increase with each administration up to the MTD or 1200 mg whichever is lower."
199828|NCT02650700|Radiation|spleen radiation|In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
199829|NCT02650687|Procedure|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
199830|NCT02650674|Other|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
199831|NCT02650674|Other|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
199832|NCT02650674|Other|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
199833|NCT02650674|Other|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
199834|NCT02650674|Other|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
199835|NCT02650674|Other|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
199836|NCT02650661|Behavioral|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.~The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
199837|NCT02650661|Behavioral|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
199838|NCT02650661|Behavioral|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
199839|NCT02650661|Behavioral|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).~Booklets are provided at 0-, 2-, and 4-month after the enrollment."
199840|NCT02650648|Drug|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight<70kg) or 1500mg/m^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
199841|NCT02650648|Biological|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
199842|NCT02650648|Biological|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over ~30-90 minutes
199843|NCT02650648|Drug|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10^5 U/m^2/day.
199844|NCT02650635|Drug|Cyclophosphamide|Given IV
199845|NCT02650635|Other|Laboratory Biomarker Analysis|Correlative studies
199846|NCT02650635|Biological|Pegfilgrastim|Given SC
199847|NCT02650635|Other|Pharmacological Study|Correlative studies
199848|NCT02650635|Drug|TLR8 Agonist VTX-2337|Given SC
199849|NCT02650622|Procedure|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
199850|NCT02650609|Drug|Methylprednisolone|
199851|NCT02650609|Drug|Placebo|
199852|NCT02650596|Drug|GLP-1|Liraglutide were taken daily for 3 months
199853|NCT02650596|Drug|Placebo|Placebo were taken daily for 3 months
199854|NCT02650583|Other|Educational Intervention|Receive Enhancing Connections Program
199855|NCT02650583|Other|Questionnaire Administration|Ancillary studies
199856|NCT02650557|Procedure|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
199857|NCT02650544|Drug|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
199858|NCT02650544|Drug|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
199859|NCT02650518|Other|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
199860|NCT02650518|Device|Catheter Change|Urinary catheter change once randomization is complete.
199861|NCT02650505|Drug|LEO 43204|
199862|NCT02650505|Drug|LEO 43204 Vehicle|
199863|NCT02650492|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
199864|NCT02650479|Drug|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
199865|NCT02650479|Drug|Placebo|6 hour IV infusion.
199866|NCT02650479|Drug|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
199867|NCT02650479|Drug|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
199868|NCT02650466|Device|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
199869|NCT02650453|Procedure|Deep venous reconstruction|PTA & stenting with/without endophlebectomy and/or arteriovenous fistula creation
199944|NCT02649751|Drug|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
199870|NCT02650440|Procedure|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
199871|NCT02650440|Procedure|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
199872|NCT02650427|Drug|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
199873|NCT02650414|Biological|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB|
199874|NCT02650401|Drug|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
199875|NCT02650388|Behavioral|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
199876|NCT02650375|Drug|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
199877|NCT02650362|Other|fMRI|
199878|NCT02650349|Other|fMRI|
199879|NCT02650336|Drug|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
199880|NCT02650310|Device|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
199881|NCT02650297|Other|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
199882|NCT02650297|Device|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
199883|NCT02650284|Device|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
199884|NCT02650284|Device|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
199885|NCT02650271|Drug|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
199886|NCT02650271|Drug|Lamivudine|Patients will be received lamivudine (100 mg/d) after 3 days of liver resection.
199887|NCT02650245|Dietary Supplement|EAS Myoplex Protein Drink + 10gm lactulose|
199888|NCT02650232|Device|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
199889|NCT02650232|Procedure|Orthostatic test|"For each arm we will proceed to an orthostatic test day one and day two with :~10 minutes in supine position~10 minutes in sitting position~5 minutes in standing position~5 minutes in supine position"
199890|NCT02650232|Device|Finapres Nova device (FMS system)|
199891|NCT02650219|Genetic|genetic analyses|
199892|NCT02650206|Drug|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
199893|NCT02650206|Other|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
199894|NCT02650193|Drug|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
199895|NCT02650180|Device|Soberlink Cellular Device|Alcohol Breath Analyzer
199896|NCT02650167|Biological|Colostrum feeding|
199897|NCT02650167|Biological|formula for preterm infants|
199898|NCT02650141|Drug|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
199899|NCT02650141|Drug|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
199900|NCT02650128|Device|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
199901|NCT02650102|Drug|Risperidone|a kind of antipsychotics
199902|NCT02650102|Drug|Olanzapine|a kind of antipsychotics
199903|NCT02650102|Drug|Quetiapine|a kind of antipsychotics
199904|NCT02650102|Drug|Aripiprazole|a kind of antipsychotics
199905|NCT02650102|Drug|Ziprasidone|a kind of antipsychotics
199945|NCT02649751|Drug|Placebo|The placebo treatment is lactose capsule.
200012|NCT02649231|Behavioral|Psychological Therapy|Manualised relapse prevention based CBT
199906|NCT02650089|Other|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
199907|NCT02650089|Other|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
199908|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
199909|NCT02650076|Drug|SK-1405|
199910|NCT02650063|Drug|DE-117|
199911|NCT02650050|Radiation|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
199912|NCT02650037|Procedure|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
199913|NCT02650011|Other|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
199914|NCT02649998|Drug|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
199915|NCT02649998|Drug|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
199916|NCT02649985|Drug|[F-18]PBR06|PET radiopharmaceutical
199917|NCT02649972|Drug|Cobimetinib|Cobimetinib will be administered at a dose of 60mg daily for 21 days on, then 7 days off, in a 28 day treatment cycle. Patients will have the option to discontinue treatment after 12 cycles and will be monitored for disease relapse for an additional 12 months. In the event that disease relapse occurs within the 12 month monitoring period, patients will restart treatment and continue on study. Upon restarting, the assessment schedule will restart at rechallenge cycle 1(RC-1) and all assessments will occur at the frequency and intervals. Cycle 1 Day 15 visits will not be required for patients that restart treatment after relapse. Participants will re-sign consent upon rechallenging.
199918|NCT02649959|Drug|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
199919|NCT02649946|Device|Covera Vascular Covered Stent following PTA|Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
199920|NCT02649946|Procedure|Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon|Treatment of stenoses with PTA only
199921|NCT02649933|Device|Watch PAT 200|screening of OSA with Watch PAT 200
199922|NCT02649920|Device|Cervical ripening balloon|
199923|NCT02649920|Drug|Dinoprostone|
199924|NCT02649907|Dietary Supplement|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
199925|NCT02649907|Other|Nutritional counseling|nutritional counseling for healthy eating behaviour
199926|NCT02649907|Dietary Supplement|formula diet|formula diet to help weight loss
199927|NCT02649894|Device|Active Comparator: Approved Uncoated PleurX Indwelling Pleural Catheter|
199928|NCT02649894|Device|Experimental: Silver Nitrate Coated Indwelling Pleural Catheter (SNCIPC)|
199929|NCT02649881|Procedure|The heart subject will undergo OCT|
199930|NCT02649868|Radiation|TAE|Transarterial embolization
199931|NCT02649868|Radiation|RFA|Thermal ablation
199932|NCT02649868|Device|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
199933|NCT02649855|Biological|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
199934|NCT02649855|Biological|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
199935|NCT02649855|Drug|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
199936|NCT02649842|Device|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
199937|NCT02649829|Biological|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:~four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.~four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.~B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
199938|NCT02649803|Behavioral|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
199939|NCT02649790|Drug|KPT-8602|
199940|NCT02649764|Drug|Cytarabine|Given IV
199941|NCT02649764|Drug|Fludarabine Phosphate|Given IV
199942|NCT02649764|Other|Laboratory Biomarker Analysis|Correlative studies
199943|NCT02649764|Drug|Prexasertib|Given IV
200446|NCT02646254|Other|del nido cardioplegia|
199946|NCT02649738|Procedure|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
199947|NCT02649725|Behavioral|patient's satisfaction|Questionnaire based measurement.
199948|NCT02649712|Device|biliary stent|Self-expandable biliary nitinol alloys stent
199949|NCT02649699|Other|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
199950|NCT02649686|Drug|Durvalumab|
199951|NCT02649686|Drug|Trastuzumab|
199952|NCT02649673|Drug|LCL161|
199953|NCT02649673|Drug|Topotecan|Topotecan will also be administered orally. Patients in DL 1 will receive topotecan at 1.8 mg/m2 per day for the first 5 days of each 21-day cycle. Patients in DL 2 will receive topotecan at 2.3 mg/m2 per day for the first 5 days of each 21-day cycle. The maximum dose for topotecan will not exceed 2.3 mg/m2 per day in this study.
199954|NCT02649673|Drug|Pegylated GCSF (PEG-GCSF)|Pegylated GCSF (PEG-GCSF) (e.g. pegfilgrastim) on-body injector (OBI) or daily GCSF (e.g. filgrastim) will be given according to institutional policy after Day 5 of topotecan. Because patients treated with topotecan are at high risk of developing febrile neutropenia, GCSF will be given in the prophylactic setting.
199955|NCT02649647|Procedure|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus.
199956|NCT02649647|Procedure|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus.
199957|NCT02649634|Behavioral|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
199958|NCT02649634|Behavioral|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
199959|NCT02649621|Biological|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
199960|NCT02649608|Drug|Lu AE04621|Low dose of Lu AE04621 on Day 1 followed by a medium dose of Lu AE04621 on Day 2, and a a high dose of Lu AE04621 on Day 3. If deemed appropriate the dosing period may be extended to 4 days. Oral solution, single dose
199961|NCT02649595|Other|Red Cross Respite care|See detailed description.
199962|NCT02649582|Biological|Dendritic cell vaccine plus temozolomide chemotherapy|"When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):~Leukocyte apheresis ± 1 week before chemoradiation (for DC vaccine production)~Chemoradiation (standard treatment): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)~Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly for 3 weeks, starting 1 week after radiotherapy~Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days (max. 12 months) starting 1 week after induction immunotherapy + DC on day 21 of every 28-day cycle"
199963|NCT02649569|Device|Monitoring Device|Wear activity monitor
199964|NCT02649569|Other|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
199965|NCT02649556|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
199966|NCT02649556|Other|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.~The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
199967|NCT02649543|Procedure|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
199968|NCT02649543|Procedure|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
199969|NCT02649543|Procedure|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
199970|NCT02649530|Drug|WNT974|
199971|NCT02649517|Procedure|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
199972|NCT02649504|Drug|Rituximab|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
199973|NCT02649504|Drug|Dexamethasone|Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
199974|NCT02649504|Drug|Mycophenolate mofetil|Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
200595|NCT02645123|Device|TENS|Enraf-Nonius Sonopuls 692
199975|NCT02649504|Drug|Placebo|Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
199976|NCT02649491|Other|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
199977|NCT02649478|Drug|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
199978|NCT02649478|Drug|Placebo|
199979|NCT02649478|Drug|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
199980|NCT02649465|Drug|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
199981|NCT02649465|Drug|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
199982|NCT02649452|Other|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
199983|NCT02649439|Biological|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopopoxvirus
199984|NCT02649439|Biological|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
199985|NCT02649426|Device|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
199986|NCT02649426|Device|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
199987|NCT02649413|Drug|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
199988|NCT02649387|Drug|Ibrutinib|Given PO
199989|NCT02649387|Other|Laboratory Biomarker Analysis|Correlative studies
199990|NCT02649374|Behavioral|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
199991|NCT02649361|Drug|Anlotinib|Anlotinib p.o. qd
199992|NCT02649361|Drug|Placebo|Placebo p.o. qd
199993|NCT02649348|Behavioral|pre-operative prehabilitation|To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
199994|NCT02649335|Drug|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
199995|NCT02649335|Procedure|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
199996|NCT02649322|Device|J-Tip|"After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector."
199997|NCT02649322|Device|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
199998|NCT02649309|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
199999|NCT02649309|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
200000|NCT02649309|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
200001|NCT02649309|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
200002|NCT02649296|Other|Skanlab bodywave|The intervention will be done twice a week
200003|NCT02649283|Device|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
200004|NCT02649283|Procedure|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
200005|NCT02649270|Biological|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
200006|NCT02649257|Procedure|cataract surgery|
200007|NCT02649257|Device|intraocular lens (MC 6125 AS)|
200008|NCT02649257|Device|capsular tension ring (CTR 13/11)|
200009|NCT02649244|Behavioral|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
200010|NCT02649231|Drug|Ketamine|0.8 mg/kg ketamine
200011|NCT02649231|Drug|Placebo|0.9% saline
200013|NCT02649231|Behavioral|Alcohol Education|Simple education about alcohol effects
200014|NCT02649218|Biological|QGE031|QGE031
200015|NCT02649205|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
200016|NCT02649192|Biological|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
200017|NCT02649192|Dietary Supplement|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
200018|NCT02649192|Other|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
200019|NCT02649179|Drug|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
200020|NCT02649179|Drug|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
200021|NCT02649166|Device|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
200022|NCT02649166|Device|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
200023|NCT02649153|Drug|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
200024|NCT02649153|Drug|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
200025|NCT02649140|Dietary Supplement|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
200026|NCT02649127|Behavioral|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
200027|NCT02649127|Behavioral|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity [i. e., >60% of oxygen uptake reserve (VO2R)], and a time of 20-25 minutes each bout of training
200028|NCT02649127|Behavioral|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
200029|NCT02649114|Behavioral|Cognitive-Behavioural Therapy|
200030|NCT02649114|Behavioral|Compassion-Focused Therapy|
200031|NCT02649101|Drug|Thalidomide|Thalidomide tablet 100mg qn po.
200032|NCT02649101|Drug|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
200033|NCT02649088|Device|Microscan|It allows to look at sublingual microcirculation
200034|NCT02649088|Device|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
200035|NCT02649075|Other|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
200036|NCT02649075|Other|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
200037|NCT02649062|Biological|NGM282|
200038|NCT02649062|Other|Placebo|
200039|NCT02649049|Other|there is no intervention|
200040|NCT02649010|Device|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
200041|NCT02648997|Drug|Nivolumab - 240 mg|240 mg every 2 weeks
200042|NCT02648997|Drug|Ipilimumab - 3 mg/kg|3 mg/kg every 3 weeks
200043|NCT02648997|Drug|Nivolumab - 480 mg|480 mg once every 4 weeks
200044|NCT02648997|Drug|Nivolumab - 1 mg/kg|1 mg/kg every 3 weeks
200045|NCT02648997|Radiation|External Beam RT|IMRT, 3D-CRT, or proton-beam radiation therapy
200046|NCT02648984|Other|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
200047|NCT02648971|Procedure|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
200048|NCT02648971|Procedure|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
200360|NCT02646748|Drug|itacitinib|Itacitinib tablets administered orally once daily.
200049|NCT02648958|Drug|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
200050|NCT02648958|Drug|normal saline|The control group received the normal saline infusion
200051|NCT02648945|Other|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
200052|NCT02648932|Biological|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
200053|NCT02648932|Procedure|Matched Unrelated Donor Transplant|
200054|NCT02648919|Drug|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
200055|NCT02648906|Drug|Choline alfoscerate|
200056|NCT02648906|Drug|Placebo|
200057|NCT02648893|Other|Multiple biofortified food crops (MBFC-Exp)|Meals from three biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
200058|NCT02648893|Other|Commercially available non-fortified food crops (MBFC-C)|This arm will consume meals based on three commercially available (non-biofortified) food crops three times per day, six days per week, for 9 months.
200059|NCT02648880|Behavioral|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
200060|NCT02648880|Other|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
200061|NCT02648867|Device|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
200062|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
200063|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
200064|NCT02648841|Radiation|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
200065|NCT02648841|Drug|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
200066|NCT02648841|Drug|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
200067|NCT02648828|Other|Clinical deterioration|Patients at risk of clinical deterioration
200068|NCT02648815|Procedure|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
200069|NCT02648815|Procedure|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
200070|NCT02648802|Procedure|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
200071|NCT02648802|Procedure|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
200072|NCT02648776|Drug|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
200073|NCT02648750|Behavioral|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
200074|NCT02648737|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch & Craske, 2009; Craske, 2010).
200075|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
200076|NCT02648724|Drug|Sym015|Sym015 is a mixture of two monoclonal antibodies which specifically bind to non-overlapping epitopes in the extracellular domain of MET.
200077|NCT02648711|Drug|CRLX101|infusion CRLX101 weekly
200078|NCT02648711|Drug|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
200079|NCT02648711|Drug|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
200080|NCT02648698|Drug|Antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
200081|NCT02648672|Drug|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
200082|NCT02648672|Drug|Placebo|
200083|NCT02648659|Drug|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
200084|NCT02648659|Drug|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
200085|NCT02648659|Drug|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
200086|NCT02648659|Drug|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
200087|NCT02648646|Other|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
200088|NCT02648633|Radiation|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
200089|NCT02648633|Drug|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
200090|NCT02648633|Drug|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
200091|NCT02648620|Device|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
200092|NCT02648620|Procedure|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
200093|NCT02648607|Device|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
200094|NCT02648594|Device|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
200095|NCT02648581|Drug|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
200096|NCT02648568|Behavioral|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
200097|NCT02648568|Behavioral|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
200098|NCT02648555|Behavioral|Daily walking|Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
200099|NCT02648555|Behavioral|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.~Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
200100|NCT02648542|Other|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
200101|NCT02648542|Device|transcranial direct current stimulation|Low-current electrical brain stimulation
200102|NCT02648542|Other|Combined CAS and tDCS|Combined auditory and electrical stimulation
200103|NCT02648542|Other|Sham stimulation|Sham stimulation
200104|NCT02648529|Procedure|MRI|"Patients are investigated with the following sequences:~High-resolution 3D T1-weighted anatomical MRI.~DTI with 48 directions (to examine white matter)"
200186|NCT02648009|Drug|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
200105|NCT02648529|Procedure|functional MRI (fMRI)|"fMRI investigations will be focused on :~language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~Social cognition: investigations on social cognition skills~Memory :~Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
200106|NCT02648529|Behavioral|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
200107|NCT02648516|Combination Product|Conventional plus AAIT|Participants will receive ART and taken i.v., at a dose of 2-3*10E8 MNCs/kg body at baseline, week 1 and 2.
200108|NCT02648503|Drug|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
200109|NCT02648503|Drug|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
200110|NCT02648490|Drug|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
200111|NCT02648490|Drug|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
200112|NCT02648490|Drug|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
200113|NCT02648490|Drug|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
200114|NCT02648490|Drug|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
200115|NCT02648477|Drug|Anastrozole|Given PO
200116|NCT02648477|Drug|Doxorubicin Hydrochloride|Given IV
200117|NCT02648477|Drug|Exemestane|Given PO
200118|NCT02648477|Other|Laboratory Biomarker Analysis|Correlative studies
200119|NCT02648477|Drug|Letrozole|Given PO
200120|NCT02648477|Biological|Pembrolizumab|Given IV
200121|NCT02648464|Drug|Hydroxychloroquine|
200122|NCT02648464|Drug|Placebo|
200123|NCT02648451|Dietary Supplement|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
200124|NCT02648438|Drug|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
200125|NCT02648438|Drug|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
200126|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
200127|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
200128|NCT02648438|Drug|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
200129|NCT02648425|Drug|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
200130|NCT02648425|Drug|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
200131|NCT02648425|Drug|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;~Or~Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
200132|NCT02648412|Drug|ketamine|bolus 1 mg/kg
200133|NCT02648412|Procedure|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
200134|NCT02648399|Procedure|surgery：BCND（bilateral central lymph node dissection）|
200135|NCT02648399|Procedure|surgery：UCND（unilateral central lymph node dissection）|
200136|NCT02648386|Procedure|Laparoscopic surgery|Completely resected rectal tumor.
200137|NCT02648386|Device|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
200138|NCT02648386|Biological|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
200139|NCT02648386|Biological|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
200140|NCT02648373|Behavioral|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
200141|NCT02648373|Other|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
200142|NCT02648360|Behavioral|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
200143|NCT02648347|Drug|vadadustat|oral tablet
200144|NCT02648347|Drug|darbepoetin alfa|Subcutaneous
200145|NCT02648334|Device|IN.PACT drug coated balloon|
200146|NCT02648334|Device|Lutonix drug coated balloon|
200147|NCT02648321|Behavioral|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
200148|NCT02648321|Behavioral|Health Education|General education about healthy lifestyle and diet.
200187|NCT02648009|Drug|Gadolinium|MRI with Gadolinium
200149|NCT02648308|Behavioral|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
200150|NCT02648295|Procedure|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
200151|NCT02648282|Drug|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX for a total of 8 doses.
200152|NCT02648282|Drug|GVAX|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of eight doses.
200153|NCT02648282|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine for a total of 8 doses.
200154|NCT02648282|Radiation|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX).
200155|NCT02648269|Drug|SEL-110|
200156|NCT02648269|Biological|SEL-212|
200157|NCT02648269|Biological|SEL-037|
200158|NCT02648256|Other|Polymerase Chain Reaction on Oropharyngeal rinse|
200159|NCT02648243|Behavioral|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
200160|NCT02648230|Device|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
200161|NCT02648230|Device|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
200162|NCT02648217|Drug|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
200163|NCT02648217|Drug|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
200164|NCT02648204|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
200165|NCT02648204|Drug|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
200166|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active."
200167|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive."
200168|NCT02648178|Device|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
200169|NCT02648165|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
200170|NCT02648165|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
200171|NCT02648165|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
200172|NCT02648152|Device|Osteoarthritis|Total Hip Arthroplasty
200173|NCT02648139|Drug|Dentifrice|3x/day for 7 days.
200174|NCT02648126|Procedure|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.~The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
200175|NCT02648113|Procedure|Restrictive transfusion|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
200176|NCT02648113|Procedure|Liberal transfusion|transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL
200177|NCT02648113|Biological|red blood transfusion|
200178|NCT02648100|Other|biomarker study|
200179|NCT02648087|Device|With and without SDB|Screening of sleep-disordered breathing (SDB)
200180|NCT02648074|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
200181|NCT02648074|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
200182|NCT02648048|Drug|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
200183|NCT02648048|Drug|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
200184|NCT02648035|Biological|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
200185|NCT02648022|Behavioral|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
200188|NCT02647996|Procedure|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
200189|NCT02647983|Drug|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
200190|NCT02647970|Behavioral|PUFA‒Cys/Met diet|Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
200191|NCT02647970|Behavioral|SFA+Cys/Met diet|Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
200192|NCT02647957|Procedure|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
200193|NCT02647944|Drug|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
200194|NCT02647944|Drug|Placebo|
200195|NCT02647931|Behavioral|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
200196|NCT02647918|Drug|Sotagliflozin|Single dose
200197|NCT02647918|Drug|Sotagliflozin|2 single doses
200198|NCT02647905|Device|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
200199|NCT02647892|Drug|lidocaine|local anesthesia
200200|NCT02647892|Drug|sodium bicarbonate|additional drug added to lidocaine
200201|NCT02647866|Drug|KHK4083|IV Infusion
200202|NCT02647866|Drug|Placebo|IV Infusion
200203|NCT02647853|Drug|TAT4 Gel concentration A|
200204|NCT02647853|Drug|TAT4 Gel concentration B|
200205|NCT02647853|Drug|Placebo|
200206|NCT02647840|Behavioral|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
200207|NCT02647827|Other|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
200208|NCT02647827|Device|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
200209|NCT02647827|Drug|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
200210|NCT02647814|Behavioral|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
200211|NCT02647801|Behavioral|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
200212|NCT02647788|Drug|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
200213|NCT02647788|Drug|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
200214|NCT02647775|Procedure|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
200215|NCT02647775|Procedure|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
200216|NCT02647762|Drug|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
200217|NCT02647762|Drug|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
200218|NCT02647762|Drug|Placebo|Placebo tablets, 1mg BID for 12 weeks
200219|NCT02647762|Drug|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
200220|NCT02647749|Device|Cardioinsight® mapping system|
200221|NCT02647749|Other|Conventional method without non-invasive mapping|
200222|NCT02647736|Other|Hypertonic saline infusion|
200223|NCT02647723|Dietary Supplement|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
200307|NCT02647086|Drug|Midazolam|Cytochrome P450 substrate
200224|NCT02647723|Dietary Supplement|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
200225|NCT02647710|Behavioral|PHAT Life Intervention|HIV Prevention behavioral health intervention
200226|NCT02647710|Behavioral|Health Promotion Control|Behavioral health intervention control
200227|NCT02647697|Drug|Radiprodil oral|"Active Substance: Radiprodil~Pharmaceutical Form: dry granules for oral suspension~Concentration: 30 mg~Route of Administration: oral use"
200228|NCT02647684|Behavioral|Self-Directed Triple P|10 Week Triple P Self directed workbook
200229|NCT02647671|Drug|Aquamin®|90 days of Aquamin
200230|NCT02647671|Drug|Calcium Carbonate|90 days of Calcium Carbonate
200231|NCT02647671|Drug|Placebo|90 days of placebo
200232|NCT02647658|Behavioral|Guideline Based Care plus Psychologically Informed Physical Therapy|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
200233|NCT02647658|Behavioral|Guideline Based Care (GBC)|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
200234|NCT02647645|Device|Transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of 20 minutes each for 6 sessions over two weeks simultaneously with cognitive training.
200235|NCT02647645|Procedure|Cognitive training|Computer delivered intervention designed to improve cognitive speed and executive functioning for a period of 20 minutes each for 6 sessions over two weeks.
200236|NCT02647645|Device|Sham transcranial direct current stimulation|Direct current stimulation at a current of 1.5 mA with anode at F3 (left dorsolateral prefrontal cortex) and cathode at Fp2 (right frontal pole) for a period of one minute to simulate active treatment applied in 6 sessions over two weeks.
200237|NCT02647632|Drug|Grazoprevir/Elbasvir|
200238|NCT02647632|Drug|Sofosbuvir|
200239|NCT02647632|Drug|Ribavirin|
200240|NCT02647619|Drug|Xiapex|Injection of collagenase of primary dupytren cord
200241|NCT02647619|Procedure|Needle aponeurotomy|26 G needle multiple perforation tecqnique with local anesthetic
200242|NCT02647606|Procedure|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
200243|NCT02647606|Device|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
200244|NCT02647606|Device|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
200245|NCT02647606|Device|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
200246|NCT02647567|Other|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
200247|NCT02647567|Other|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
200248|NCT02647554|Drug|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
200249|NCT02647554|Drug|Placebo|matching placebo every 8 hours for 10 days
200250|NCT02647541|Dietary Supplement|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
200251|NCT02647528|Device|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
200252|NCT02647528|Device|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
200253|NCT02647515|Drug|ranibizumab|
200254|NCT02647502|Other|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
200255|NCT02647489|Biological|PAMVAC|
200256|NCT02647489|Biological|Alhydrogel|
200257|NCT02647489|Biological|GLA-SE|
200258|NCT02647489|Biological|GLA-LSQ|
200259|NCT02647489|Other|Placebo|
200260|NCT02647476|Dietary Supplement|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
200261|NCT02647476|Dietary Supplement|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
200262|NCT02647463|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|
200263|NCT02647450|Other|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
200264|NCT02647437|Drug|Levetiracetam|
200265|NCT02647437|Drug|Placebo|
200266|NCT02647424|Drug|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
200267|NCT02647424|Drug|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
200268|NCT02647398|Behavioral|Vigorous aerobic training|Supervised vigorous aerobic training
200269|NCT02647385|Drug|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.~Interventions: include pain assessment, inflammatory response and opioid consumption."
200270|NCT02647372|Procedure|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
200271|NCT02647372|Procedure|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
200272|NCT02647359|Drug|Ataluren|Ataluren oral suspension will be administered as per the dose and schedule specified in the respective arms.
200273|NCT02647359|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
200274|NCT02647346|Device|Daily use of podimetrics smart-foot mat|
200308|NCT02647086|Drug|Omeprazole|Cytochrome P450 substrate
200309|NCT02647086|Drug|Warfarin|Cytochrome P450 substrate
200310|NCT02647086|Drug|Caffeine|Cytochrome P450 substrate
200275|NCT02647333|Dietary Supplement|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
200276|NCT02647333|Dietary Supplement|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
200277|NCT02647320|Drug|Sitagliptin 100 mg|Two sitagliptin 50 mg tablets, over-encapsulated to provide a once-daily dose of 100 mg, for oral administration
200278|NCT02647320|Drug|DS-8500a 25mg|DS-8500a 25mg tablet for oral administration
200279|NCT02647320|Drug|Placebo Tablet|Placebo matching DS-8500a tablet for oral administration
200280|NCT02647320|Drug|Placebo Capsule|Placebo matching sitagliptin over-capsule for oral administration
200281|NCT02647307|Drug|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
200282|NCT02647294|Dietary Supplement|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
200283|NCT02647294|Other|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
200284|NCT02647281|Drug|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
200285|NCT02647281|Drug|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
200286|NCT02647268|Drug|Oxytocin|Oxytocin, 10-5M solution
200287|NCT02647268|Drug|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
200288|NCT02647255|Procedure|Plasma Exchange (PE)|PE treatment>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
200289|NCT02647255|Drug|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
200290|NCT02647242|Behavioral|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
200291|NCT02647229|Other|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
200292|NCT02647229|Other|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
200293|NCT02647216|Behavioral|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
200294|NCT02647216|Behavioral|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
200295|NCT02647203|Drug|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
200296|NCT02647190|Drug|Erwinia Chrysanthemi asparaginase|
200297|NCT02647177|Other|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
200298|NCT02647151|Drug|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
200299|NCT02647151|Drug|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.~skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
200300|NCT02647138|Other|white noise|exposure to white noise
200301|NCT02647125|Drug|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
200302|NCT02647125|Radiation|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
200303|NCT02647112|Other|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
200304|NCT02647099|Drug|Acetylsalicylic acid|
200305|NCT02647099|Drug|Placebo|
200306|NCT02647086|Drug|Dupilumab|
200312|NCT02647073|Device|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
200313|NCT02647047|Procedure|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
200314|NCT02647047|Procedure|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
200315|NCT02647047|Procedure|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
200316|NCT02647047|Procedure|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
200317|NCT02647047|Drug|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
200318|NCT02647047|Drug|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
200319|NCT02647047|Drug|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
200320|NCT02647047|Drug|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
200321|NCT02647047|Drug|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
200322|NCT02647047|Drug|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
200323|NCT02647034|Other|no intervention|no intervention
200324|NCT02647021|Behavioral|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
200325|NCT02647021|Behavioral|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
200326|NCT02647008|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
200327|NCT02646995|Dietary Supplement|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
200328|NCT02646995|Dietary Supplement|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
200329|NCT02646982|Drug|Placebo|A matched placebo will be given once daily for 12 months.
200330|NCT02646982|Drug|Candesartan|Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP>110 mm Hg, DBP>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
200331|NCT02646969|Dietary Supplement|Formula regimen 1|
200332|NCT02646969|Dietary Supplement|Formula regimen 2|
200333|NCT02646956|Other|sweeteners|Participants tasted a variety of nutritive and nonnutritive sweeteners
200334|NCT02646930|Procedure|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
200335|NCT02646917|Device|SkinPen|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
200336|NCT02646904|Drug|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
200337|NCT02646904|Drug|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
200338|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 15 mcg|
200339|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 30 mcg|
200340|NCT02646891|Biological|Placebo|
200341|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 90 mcg|
200342|NCT02646878|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
200343|NCT02646865|Behavioral|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
200344|NCT02646865|Behavioral|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol
200345|NCT02646852|Drug|PLX038|
200346|NCT02646839|Device|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
200347|NCT02646826|Other|Placebo|Subjects are treated with Placebo tablets
200348|NCT02646826|Drug|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
200349|NCT02646826|Drug|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
200350|NCT02646826|Drug|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
200351|NCT02646813|Procedure|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
200352|NCT02646813|Procedure|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
200353|NCT02646800|Drug|Micafungin|Injection
200354|NCT02646787|Behavioral|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
200355|NCT02646787|Behavioral|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
200356|NCT02646774|Drug|Micafungin|Injection
200357|NCT02646761|Device|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
200358|NCT02646761|Other|Standard of Care Physical Therapy|Physical therapy rehabilitation program
200359|NCT02646748|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
200361|NCT02646748|Drug|INCB050465|INCB050465 tablets administered orally once daily.
200362|NCT02646735|Drug|Fulvestrant 500 mg|Fulvestrant 500mg will be given monthly.
200363|NCT02646735|Drug|Exemestane 25 mg|Exemestane 25mg will be given once daily.
200364|NCT02646709|Drug|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
200365|NCT02646709|Drug|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
200366|NCT02646709|Drug|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
200367|NCT02646709|Drug|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
200368|NCT02646696|Other|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
200369|NCT02646683|Drug|vedolizumab|
200370|NCT02646670|Drug|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
200371|NCT02646670|Drug|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
200372|NCT02646670|Drug|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
200373|NCT02646670|Drug|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
200374|NCT02646657|Drug|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
200375|NCT02646644|Other|Metastasized intestinal NET|This is an observational study
200376|NCT02646631|Other|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
200377|NCT02646631|Behavioral|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
200378|NCT02646631|Behavioral|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
200379|NCT02646631|Other|Educational Materials|Printed educational materials on the management of epilepsy
200380|NCT02646618|Behavioral|Get Social|Online-delivered weight loss intervention
200381|NCT02646618|Behavioral|Traditional|Group-delivered weight loss intervention
200382|NCT02646618|Device|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
200383|NCT02646605|Other|depression screening|Patient Health Questionnaire
200384|NCT02646592|Drug|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
200385|NCT02646592|Drug|sevoflurane or propofol|
200386|NCT02646579|Procedure|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
200387|NCT02646579|Procedure|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
200388|NCT02646566|Drug|APD421|
200389|NCT02646566|Drug|Placebo|
200390|NCT02646553|Other|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
200391|NCT02646540|Drug|Tolvaptan 30 mg + IV Diuretics|Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
200392|NCT02646540|Drug|Metolazone 5 mg + IV Diuretics|Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
200393|NCT02646540|Drug|2.5 times the Diuretics Dose|Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
200394|NCT02646527|Behavioral|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
200395|NCT02646514|Device|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
200396|NCT02646514|Device|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
200397|NCT02646501|Drug|Antiarrhythmic drug|Antiarrhythmic drug
200398|NCT02646501|Procedure|percutaneous stellate ganglion block (PSGB)|percutaneous stellate ganglion block (PSGB)
200399|NCT02646488|Behavioral|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
200400|NCT02646488|Behavioral|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
200401|NCT02646488|Behavioral|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
200402|NCT02646488|Behavioral|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
200403|NCT02646488|Behavioral|Standard Care Regimen 9 Months|
200404|NCT02646488|Behavioral|Standard Care Regimen 12 Months|
200405|NCT02646488|Behavioral|Standard Care Regimen 15 Months|
200406|NCT02646488|Behavioral|Standard Care Regimen 18 Months|
200407|NCT02646488|Behavioral|Standard Care Regimen 21 Months|
200408|NCT02646488|Behavioral|Standard Care Regimen 24 Months|
200409|NCT02646488|Behavioral|Standard Care Regimen 27 Months|
200410|NCT02646488|Behavioral|Follow Up Post Intervention 21 Months|
200411|NCT02646488|Behavioral|Follow Up Post Intervention 24 Months|
200412|NCT02646488|Behavioral|Follow Up Post Intervention 27 Months|
200413|NCT02646488|Behavioral|Follow Up Post Intervention 30 Months|
200414|NCT02646488|Behavioral|Follow Up Post Intervention 33 Months|
200415|NCT02646475|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
200416|NCT02646475|Drug|Saline|Normal saline will be used as a placebo comparator.
200417|NCT02646449|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
200418|NCT02646449|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
200419|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
200420|NCT02646436|Other|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
200421|NCT02646423|Behavioral|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
200422|NCT02646410|Other|FPD+NDOT|
200423|NCT02646410|Other|FPD+DOT|
200424|NCT02646410|Other|DDD+NDOT|Door to door delivery + non directly observed treatment
200425|NCT02646410|Other|DDD+DOT|Door to door delivery + directly observed treatment
200426|NCT02646397|Drug|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
200427|NCT02646397|Drug|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
200428|NCT02646397|Drug|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
200429|NCT02646384|Procedure|Ovarian tissue cryopreservation|Ovarian tissue will be removed
200430|NCT02646371|Biological|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
200431|NCT02646371|Biological|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
200432|NCT02646358|Drug|Vepoloxamer|
200433|NCT02646345|Procedure|Surgical checklist|Use of the World Health Organization Surgical checklist
200434|NCT02646332|Drug|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
200435|NCT02646332|Drug|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
200436|NCT02646319|Other|Laboratory Biomarker Analysis|Correlative studies
200437|NCT02646319|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
200438|NCT02646319|Other|Quality-of-Life Assessment|Ancillary studies
200439|NCT02646306|Other|shoulder proprioceptive rehabilitation tool|"Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object."
200440|NCT02646280|Other|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
200441|NCT02646280|Other|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
200442|NCT02646267|Drug|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
200443|NCT02646267|Drug|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
200444|NCT02646267|Drug|dabigatran etexilate|110mg, twice a day, oral
200445|NCT02646254|Other|blood cardioplegia|
200447|NCT02646241|Procedure|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
200448|NCT02646241|Procedure|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB & unroofing biopsy.
200449|NCT02646228|Other|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.~Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
200450|NCT02646215|Device|Threshold inspiratory muscle training|Inspiratory muscle training
200451|NCT02646202|Procedure|Sclerotherapy|Injection of varices
200452|NCT02646202|Procedure|Band ligation|endoscopic banding of varices
200453|NCT02646202|Procedure|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
200454|NCT02646189|Drug|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
200455|NCT02646189|Drug|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
200456|NCT02646189|Drug|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
200457|NCT02646176|Behavioral|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
200458|NCT02646163|Drug|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.~(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
200459|NCT02646150|Procedure|Magnetic Resonance Perfusion Imaging|
200460|NCT02646137|Drug|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
200461|NCT02646137|Procedure|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
200462|NCT02646137|Procedure|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
200463|NCT02646124|Drug|Naproxen|Naproxen 500mg by mouth two times a day, #20
200464|NCT02646124|Drug|Placebo|28 placebo capsules
200465|NCT02646124|Drug|Diazepam|Diazepam 5mg capsules, 1-2 tabs by mouth two times a day, #28
200466|NCT02646111|Drug|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
200467|NCT02646111|Drug|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
200468|NCT02646111|Drug|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
200469|NCT02646098|Procedure|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
200470|NCT02646085|Drug|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
200471|NCT02646072|Drug|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
200472|NCT02646059|Other|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
200473|NCT02646059|Other|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
200474|NCT02646046|Behavioral|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
200475|NCT02646046|Behavioral|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
200476|NCT02646020|Drug|Aprepitant|aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
200477|NCT02646020|Drug|Desloratadine|Desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
200478|NCT02646020|Drug|Placebo of aprepitant|Placebo of aprepitant 125mg d1, 80mg d3 and d5; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
200479|NCT02646020|Drug|Placebo of desloratadine|Placebo of desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
200480|NCT02646007|Biological|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
200481|NCT02645994|Device|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
200482|NCT02645994|Device|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
200483|NCT02645981|Drug|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
200484|NCT02645981|Drug|Sorafenib|Control
200485|NCT02645942|Dietary Supplement|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
200486|NCT02645942|Dietary Supplement|Placebo|Placebo daily for 8 weeks
200487|NCT02645929|Behavioral|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
200488|NCT02645916|Drug|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
200489|NCT02645916|Drug|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
200490|NCT02645903|Drug|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
200491|NCT02645903|Drug|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
200492|NCT02645890|Drug|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
200493|NCT02645890|Drug|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
200494|NCT02645877|Procedure|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
200495|NCT02645864|Drug|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
200496|NCT02645864|Drug|Irinotecan|150mg/m^2 i.v. q2w
200497|NCT02645851|Drug|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
200498|NCT02645851|Device|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
200499|NCT02645851|Device|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
200500|NCT02645851|Other|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
200501|NCT02645838|Behavioral|Motivational interviewing|1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
200502|NCT02645799|Drug|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
200503|NCT02645799|Drug|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
200504|NCT02645773|Device|non-ablative laser|non-abaltive laser pre, immediate and post wounding
200505|NCT02645760|Other|Core stabilization exercise|7-weeks of core stabilization exercise
200506|NCT02645760|Other|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
200507|NCT02645747|Drug|Aflibercept (Eylea, BAY86-5321)|"Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency."
200508|NCT02645734|Drug|bevacizumab|1.25 mg of bevacizumab is injected
200509|NCT02645734|Drug|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
200510|NCT02645734|Drug|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
200511|NCT02645721|Behavioral|Extended self-help program with guidance|See arm description for Experimental
200512|NCT02645721|Behavioral|Briefer Self-help program, no guidance|See arm description for Active Comparator
200513|NCT02645721|Behavioral|WL: Extended self-help program, choice of guidance intensity|See arm description for Waiting list.
200514|NCT02645708|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
200515|NCT02645708|Procedure|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
200516|NCT02645695|Device|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
200596|NCT02645123|Procedure|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
202413|NCT02632058|Other|Cognitive Behavioral Therapy|
200517|NCT02645695|Device|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
200518|NCT02645682|Device|anti-infection CVC|
200519|NCT02645682|Device|normal CVC|
200520|NCT02645669|Procedure|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
200521|NCT02645669|Procedure|Control site|Only Scaling and Root planing was done.
200522|NCT02645656|Drug|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
200523|NCT02645643|Other|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
200524|NCT02645630|Other|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
200525|NCT02645630|Other|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
200526|NCT02645630|Other|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
200527|NCT02645617|Drug|Varnish|Topical application to the teeth
200528|NCT02645591|Procedure|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
200529|NCT02645591|Biological|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
200530|NCT02645591|Behavioral|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
200531|NCT02645578|Device|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
200532|NCT02645565|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
200533|NCT02645565|Drug|Azathioprine|azathioprine will be given at 2 mg/kg.
200534|NCT02645565|Drug|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
200535|NCT02645552|Drug|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
200536|NCT02645552|Other|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
200537|NCT02645539|Device|intravascular ventricular assist system (iVAS)|A mechanical circulatory support device using the principles of counterpulsation.
200538|NCT02645526|Other|Woolen cap|
200539|NCT02645513|Behavioral|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
200540|NCT02645513|Behavioral|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
200541|NCT02645513|Behavioral|Control|No text message reminders
200542|NCT02645500|Behavioral|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
200543|NCT02645500|Behavioral|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
200544|NCT02645487|Radiation|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size <= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy >1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy >2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy >3-4cm: 15 Gy; + 3 Gy incremental escalation up to 21 Gy
200545|NCT02645474|Procedure|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
200546|NCT02645474|Procedure|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
200547|NCT02645474|Drug|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
200548|NCT02645461|Drug|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
200549|NCT02645461|Drug|Riluzole|Riluzole 50 mg twice daily
200550|NCT02645448|Other|Resistance Exercise|"Control Session~Resistance exercise at different intensities (40%1RM or 80%1RM)~Duration of effect"
200551|NCT02645435|Procedure|hip replacement|Total hip replacement
200552|NCT02645409|Drug|OTL38|OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
200553|NCT02645409|Device|Intraoperative fluorescence imaging system|
200597|NCT02645123|Procedure|swedish type massage|petrissage, effleurage, tapotement
200598|NCT02645123|Procedure|static hamstring stretch|static hamstring stretching
200599|NCT02645123|Procedure|sham treatment|touching of the skin overlying the lumbar area
200554|NCT02645383|Device|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
200555|NCT02645383|Device|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
200556|NCT02645370|Drug|Danzhen|
200557|NCT02645370|Drug|Topiramate|
200558|NCT02645357|Other|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
200559|NCT02645357|Other|Control group|control group
200560|NCT02645344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
200561|NCT02645344|Behavioral|Sensory Cueing (SC)|
200562|NCT02645344|Behavioral|Conventional Rehabilitation|
200563|NCT02645331|Behavioral|Remind-to-move|
200564|NCT02645331|Behavioral|Modified constraint induced movement therapy|
200565|NCT02645331|Behavioral|Conventional rehabilitation|
200566|NCT02645305|Biological|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
200567|NCT02645292|Device|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
200568|NCT02645292|Device|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
200569|NCT02645279|Other|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
200570|NCT02645279|Drug|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
200571|NCT02645266|Drug|Aflibercept Injection [Eylea]|Subjects will be administered 2.0mg Aflibercept intraocular injection each month for 5 consecutive months. After the 5th month, the serum cytokine levels in blood work will be assessed as well as patients's visual acuity, and eye pressures. Upon completion of the trial, patients will resume receiving the usual standard of care.
200572|NCT02645253|Drug|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
200573|NCT02645253|Drug|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
200574|NCT02645253|Drug|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
200575|NCT02645253|Drug|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
200576|NCT02645253|Drug|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
200577|NCT02645240|Drug|Heparin injection|Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
200578|NCT02645227|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
200579|NCT02645227|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
200580|NCT02645227|Procedure|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
200581|NCT02645214|Other|Non-antiseptic scrubs|
200582|NCT02645214|Other|Antiseptic scrubs|
200583|NCT02645201|Dietary Supplement|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
200584|NCT02645201|Other|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
200585|NCT02645188|Other|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
200586|NCT02645175|Dietary Supplement|TW1025|20ml, 3 times per day (daily dose: 60 ml)
200587|NCT02645175|Dietary Supplement|Placebo|20ml, 3 times per day (daily dose: 60 ml)
200588|NCT02645162|Behavioral|Community-based Preschool|"Preschool sessions in community-based preschool~Run by trained community youth leaders from the same village."
200589|NCT02645149|Drug|Standard therapy or clinical trial|Patients with BRAF V600 and NRAS mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
200590|NCT02645149|Drug|Matched targeted therapy|Patients with tumour found to be BRAF and NRAS wild type will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for BRAF / NRAS wild type melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour as listed above.
200591|NCT02645149|Drug|Trametinib and / or supportive care|Patients with BRAF and NRAS wild type tumour for whom there is no actionable genetic aberration in tumour tissue following extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
200592|NCT02645136|Other|Pilates|Pilates exercises
200593|NCT02645136|Other|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
200594|NCT02645136|Other|Control|
200600|NCT02645110|Device|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
200601|NCT02645110|Device|Tap water|Washing hand with water alone in comparison to hand washing with soap
200602|NCT02645097|Procedure|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
200603|NCT02645084|Other|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
200604|NCT02645071|Behavioral|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
200605|NCT02645058|Procedure|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
200606|NCT02645058|Procedure|ESWL|Treatment by extracorporeal shock waves lithotripsy
200607|NCT02645058|Device|Rigid and flexible ureteroscope|
200608|NCT02645058|Device|Lithotripter|
200609|NCT02645058|Device|Holmium laser|
200610|NCT02645058|Device|Basket for fragment removal|
200611|NCT02645058|Procedure|General or spinal anesthesia|
200612|NCT02645058|Drug|Intravenous pain medication|If required by the patient
200613|NCT02645058|Device|X-ray|To focus the stone
200614|NCT02645058|Device|Ultrasound|To focus the stone
200615|NCT02645032|Biological|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
200616|NCT02645032|Biological|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
200617|NCT02645032|Biological|VAXIGRIP®|"Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)~*Participants less than 9 years of age, who have not been vaccinated for flu before, will receive a second dose of flu-vaccine after the last follow-up visit of last participant in their age cohort."
200618|NCT02645019|Device|Cuffed ETT or LMA|
200619|NCT02645006|Behavioral|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
200620|NCT02645006|Behavioral|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
200621|NCT02644993|Radiation|Proton therapy|
200622|NCT02644980|Drug|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
200623|NCT02644980|Drug|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
200624|NCT02644980|Device|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
200625|NCT02644980|Drug|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
200626|NCT02644980|Drug|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
200627|NCT02644980|Other|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
200628|NCT02644967|Drug|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
200629|NCT02644967|Drug|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
200630|NCT02644967|Drug|Pembrolizumab|Drug: Pembrolizumab Administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks beginning on Week 2.
200631|NCT02644954|Drug|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
200632|NCT02644954|Drug|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
200633|NCT02644954|Drug|Topical Coal tar|Topical coal tar to be applied once daily
200634|NCT02644954|Drug|Topical calcipotriol|Topical calcipotriol to be applied once daily
200635|NCT02644941|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
200636|NCT02644941|Device|ePTFE graft|Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
200637|NCT02644915|Drug|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
200638|NCT02644915|Drug|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.~Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg"
200639|NCT02644902|Other|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
200640|NCT02644902|Other|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
200752|NCT02644187|Device|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
202414|NCT02632045|Drug|LEE-011|600 mg capsule (3x 200 mg capsules)
200641|NCT02644876|Drug|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
200642|NCT02644876|Drug|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
200643|NCT02644863|Drug|Paclitaxel|Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
200644|NCT02644863|Biological|DC-CIK|Antigen-sensitized DC-CIK 8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
200645|NCT02644863|Drug|Cisplatin|Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
200646|NCT02644837|Device|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
200647|NCT02644837|Device|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
200648|NCT02644837|Device|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
200649|NCT02644837|Device|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
200650|NCT02644837|Device|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
200651|NCT02644837|Device|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
200652|NCT02644837|Device|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
200653|NCT02644837|Device|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
200654|NCT02644824|Device|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
200655|NCT02644811|Drug|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
200656|NCT02644811|Drug|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
200657|NCT02644811|Procedure|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
200658|NCT02644811|Drug|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
200659|NCT02644811|Drug|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
200660|NCT02644811|Device|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
200661|NCT02644811|Device|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
200662|NCT02644798|Other|Gene polymorphism|Samples of gene polymorphism in ARDS patients and patients with ARDS risk factors
200663|NCT02644785|Drug|protamine|Protamine infusion exposures
200664|NCT02644759|Biological|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
200665|NCT02644746|Device|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
200666|NCT02644746|Device|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
200667|NCT02644733|Procedure|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
200668|NCT02644733|Procedure|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
200753|NCT02644187|Device|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
200998|NCT02642380|Drug|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
200669|NCT02644720|Procedure|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
200670|NCT02644720|Procedure|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
200671|NCT02644720|Drug|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
200672|NCT02644720|Device|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
200673|NCT02644720|Device|monofocal intraocular lens (IOL) (Tecnis ZCB)|
200674|NCT02644707|Dietary Supplement|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
200675|NCT02644707|Other|Placebo|The group will be randomized to receive placebo (control group) for 6 months
200676|NCT02644694|Drug|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
200677|NCT02644681|Procedure|Aortic Aneurysm, Thoracic surgery|
200678|NCT02644668|Drug|CK-2127107 150 mg|
200679|NCT02644668|Drug|Placebo|
200680|NCT02644668|Drug|CK-2127107 450 mg|
200681|NCT02644655|Biological|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
200682|NCT02644642|Other|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
200683|NCT02644629|Drug|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
200684|NCT02644629|Drug|Ketamine (1st phase)|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
200685|NCT02644629|Drug|Ketamine (2st phase)|Patients failing to achieve response (<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
200686|NCT02644616|Drug|tolvaptan+torasemide|tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
200687|NCT02644616|Drug|placebo+torasemide|placebo 15mg/d po(10 days) +torasemide 20mg/d iv
200688|NCT02644603|Procedure|Enhanced Recovery After Surgery|"Before operation:~Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.~In operation:~Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.~After operation:~Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
200689|NCT02644590|Drug|Melatonin|Detailed in arm description
200690|NCT02644577|Drug|Metformin|
200691|NCT02644577|Other|Starch|
200692|NCT02644564|Other|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
200693|NCT02644551|Drug|CELEXT07|
200694|NCT02644551|Drug|Penlac|
200695|NCT02644551|Other|vehicle solution|
200696|NCT02644538|Drug|PegIFN alfa-2a|chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA <1000copies/ml, and HBsAg<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
200697|NCT02644525|Drug|Imatinib Mesylate|Imatinib is a small molecule inhibitor which was US Food and Drug Administration (FDA) -approved for chronic myelogenous leukemia (CML) in 2001 which acts on the protein product of the Philadelphia chromosome, Bcr-Abl.
200698|NCT02644525|Drug|Placebo|Placebo pills
200699|NCT02644499|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
200700|NCT02644499|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
200701|NCT02644499|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
200702|NCT02644499|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
200703|NCT02644499|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
200704|NCT02644486|Drug|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
200705|NCT02644486|Drug|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
200706|NCT02644486|Drug|Irbesartan|Irbesartan 300mg/d
200707|NCT02644473|Drug|Tranexamic Acid|
200708|NCT02644473|Drug|Normal saline|Control
200709|NCT02644460|Drug|Abemaciclib|
200710|NCT02644447|Biological|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
200711|NCT02644447|Biological|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
200750|NCT02644213|Other|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):~simulated road march using a virtual reality environment without additional load~simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.~without physical or cognitive load (without march, waiting between performance evaluations) as control."
200712|NCT02644434|Procedure|Conventional Strategy|"Jailed wire technique: Both MV and SB are wired. The MV is stented with wire protection in SB. The SB is not further treated unless there is threatened SB closure, severe ostial pinching of SB (>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A. If one of these criteria exists, the SB would be rewired and a kissing balloon inflation is undertaken.~Provisional two-stent strategy: Lesion preparation and MV stenting are the same as the jailed wire technique. Provisional T stenting of the SB could be undertaken if one of the following criteria exists after SB rewiring and a kissing balloon inflation is undertaken: threatened SB closure, severe ostial pinching of SB (>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A."
200713|NCT02644434|Procedure|Intentional strategy|"Jailed balloon technique: The technique has been detailed in previous studies. A monorail balloon that is angiographically sized to approximate the Side Branch (SB) vessel diameter is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard kissing balloon technique no matter there is SB compromise or not.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which stenting SB before MV stenting."
200714|NCT02644421|Drug|VVZ-149|
200715|NCT02644421|Drug|Lidocaine|
200716|NCT02644421|Drug|Placebo|
200717|NCT02644408|Drug|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
200718|NCT02644408|Radiation|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
200719|NCT02644408|Other|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
200720|NCT02644395|Drug|Chlorthalidone|Drug
200721|NCT02644395|Drug|Amlodipine|Drug
200722|NCT02644382|Other|qualitative data collection|qualitative data collection
200723|NCT02644382|Other|survey|survey pre and post-surgical consult
200724|NCT02644382|Other|decision aid|web-based decision aid post-surgical consult
200725|NCT02644369|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
200726|NCT02644356|Behavioral|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
200727|NCT02644343|Device|Custom Sound|Custom Sound is the programming software used to program Nucleus cochlear implants.
200728|NCT02644330|Procedure|transthoracic device closure|minimally invasive transthoracic device closure
200729|NCT02644330|Procedure|surgical repair|surgical repair with cardiopulmonary bypass
200730|NCT02644317|Device|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
200731|NCT02644304|Drug|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
200732|NCT02644304|Drug|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
200733|NCT02644304|Other|Placebo|placebo(half tablet) every 3 days (4 doses).
200734|NCT02644291|Drug|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
200735|NCT02644278|Drug|VX-984 120 mg + PLD 40 mg/m^2|Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
200736|NCT02644278|Drug|VX-984 240 mg + PLD 40 mg/m^2|Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
200737|NCT02644278|Drug|VX-984 480 mg + PLD 40 mg/m^2|Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
200738|NCT02644278|Drug|VX-984 720 mg + PLD 40 mg/m^2|Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m^2.
200739|NCT02644252|Drug|Day 1: Cisplatin 75 mg/m2|
200740|NCT02644252|Drug|Day 1: Vinorelbine 25 mg/m2|
200741|NCT02644252|Drug|Day 8: Capsule vinorelbine 50 mg/m2|
200742|NCT02644252|Drug|Day 1: Carboplatin AUC=5|
200743|NCT02644252|Drug|Day 1: Vinorelbine 30 mg/m2|
200744|NCT02644252|Drug|Day 8: Capsule vinorelbine 60 mg/m2|
200745|NCT02644252|Dietary Supplement|Tocotrienol 300 mg x 3 daily until progression|
200746|NCT02644252|Drug|Placebo 1 capsule x 3 daily until progression|
200747|NCT02644239|Dietary Supplement|ketogenic diet|Ketogenic diet with high fat (90%)
200748|NCT02644226|Other|Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
200749|NCT02644226|Other|Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
200751|NCT02644200|Device|Gelatin tannate|
200754|NCT02644187|Drug|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
200755|NCT02644174|Procedure|Bariatric Surgery|
200756|NCT02644161|Procedure|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
200757|NCT02644161|Procedure|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
200758|NCT02644161|Drug|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
200759|NCT02644161|Other|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
200760|NCT02644161|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
200761|NCT02644148|Procedure|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
200762|NCT02644148|Procedure|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
200763|NCT02644135|Drug|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
200764|NCT02644135|Drug|Halo Placebo|Three sprays per use, total = 9 sprays per day
200765|NCT02644122|Drug|SF1126|
200766|NCT02644109|Dietary Supplement|Phytosterol|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
200767|NCT02644109|Dietary Supplement|Placebo|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.~Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.~Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
200768|NCT02644096|Other|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
200769|NCT02644083|Drug|Dimethyl fumarate|
200770|NCT02644070|Device|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
200771|NCT02644070|Device|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
200772|NCT02644070|Device|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
200773|NCT02644057|Drug|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
200774|NCT02644057|Drug|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
200775|NCT02644044|Drug|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
200776|NCT02644031|Procedure|mtwo rotary system|post-treatment pain after using mtwo rotary system
200777|NCT02644031|Procedure|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
200778|NCT02644031|Procedure|hand files|post-treatment pain after using hand files
200779|NCT02644018|Drug|Imidazolyl ethanamide pentandioic acid|
200780|NCT02644018|Drug|placebo|
200810|NCT02643719|Behavioral|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
200811|NCT02643719|Drug|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:~Topiramate 25mg tabs (with a plan to increase to 100mg)"
200812|NCT02643719|Drug|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
200781|NCT02644005|Device|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG & Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
200782|NCT02643992|Other|DOAC concentration measurement|
200783|NCT02643979|Drug|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
200784|NCT02643979|Drug|Propofol|100mg of Propofol
200785|NCT02643979|Drug|Saline|1mL of saline
200786|NCT02643966|Device|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
200787|NCT02643953|Behavioral|Incentives|1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
200788|NCT02643953|Behavioral|Community|1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
200789|NCT02643927|Behavioral|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
200790|NCT02643927|Behavioral|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
200791|NCT02643914|Drug|Nicotine|
200792|NCT02643914|Device|MR Compatible Nicotine Delivery Device|
200793|NCT02643901|Biological|GW003|single SC injection
200794|NCT02643875|Device|Orthokeratology|It is a kind of rigid permeable lens.
200795|NCT02643862|Drug|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
200796|NCT02643862|Drug|Placebo|Placebo
200797|NCT02643849|Device|The Spanner Temporary Prostatic Stent|
200798|NCT02643836|Device|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
200799|NCT02643823|Biological|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
200800|NCT02643823|Drug|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
200801|NCT02643810|Other|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
200802|NCT02643797|Behavioral|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
200803|NCT02643784|Drug|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.~Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
200804|NCT02643784|Other|Control|"Randomized Treatment Period (Day 1 through Day 14):~No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
200805|NCT02643771|Procedure|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
200806|NCT02643758|Device|Bifocal soft contact lenses|
200807|NCT02643745|Procedure|Nephrology Intervention|"pre-operative study:~Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.~Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.~optimise the patient' s overall condition with a pre-operative strategy:~Obesity control~Control protein, caloric, salt intake~Stop smoking~Good glycemic control~Start ACEI/ARA II if there is proteinuria~Start additional antihypertensive drug if required~Start hypolipemic treatment if required~Start hyperuricemia treatment if required~Start AAS, clopidogrel if it is necessary (prophylaxis)~Phosphate control~Anemia control~Metabolic acidosis correction"
200808|NCT02643732|Drug|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
200809|NCT02643732|Drug|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
200813|NCT02643719|Drug|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
200814|NCT02643693|Other|P3L|"Ad libitum use for a maximum of three hours.~P3L delivers, on average, 80 µg of nicotine per puff under Health Canada Intense smoking regime."
200815|NCT02643693|Other|VUSE|"Ad libitum use for a maximum of three hours.~VUSE delivers, on average, 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime."
200816|NCT02643693|Other|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
200817|NCT02643680|Device|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
200818|NCT02643680|Device|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
200819|NCT02643667|Drug|Ibrutinib|
200820|NCT02643667|Procedure|Blood samples for PSA and immune assays|
200821|NCT02643667|Procedure|Radical prostatectomy|-Standard of care
200822|NCT02643654|Drug|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
200823|NCT02643654|Drug|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
200824|NCT02643641|Biological|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
200825|NCT02643641|Biological|Placebo|Placebo contains aluminum hydroxide only
200826|NCT02643628|Procedure|Microneedling|
200827|NCT02643628|Device|Microneedling followed by Bellafill treatment|
200828|NCT02643615|Device|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
200829|NCT02643615|Device|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
200830|NCT02643615|Drug|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
200831|NCT02643615|Drug|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
200832|NCT02643602|Other|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
200833|NCT02643602|Other|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
200834|NCT02643589|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
200835|NCT02643576|Behavioral|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
200836|NCT02643576|Behavioral|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
200837|NCT02643576|Behavioral|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
200838|NCT02643563|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
200839|NCT02643563|Drug|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
200840|NCT02643563|Drug|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
200841|NCT02643550|Biological|Monalizumab|
200842|NCT02643550|Biological|Cetuximab|
200843|NCT02643550|Biological|Anti-PD(L)1|
200844|NCT02643524|Behavioral|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
200845|NCT02643524|Behavioral|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
200846|NCT02643511|Radiation|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
200847|NCT02643498|Radiation|Stereotactic Body Radiotherapy (SBRT)|
200848|NCT02643485|Procedure|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
200849|NCT02643472|Behavioral|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
200850|NCT02643472|Behavioral|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
200851|NCT02643459|Behavioral|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
200852|NCT02643446|Biological|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
200853|NCT02643446|Biological|OPV|"OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.~OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7."
200854|NCT02643433|Biological|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
200855|NCT02643433|Biological|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
200856|NCT02643420|Drug|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle.
200857|NCT02643420|Drug|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle.
200858|NCT02643407|Drug|Docetaxel|60mg/m2
200859|NCT02643407|Drug|Nedaplatin|80mg/m2
200860|NCT02643407|Drug|Cisplatin|75mg/m2
200861|NCT02643394|Drug|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
200862|NCT02643394|Drug|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
200863|NCT02643381|Drug|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
200864|NCT02643381|Drug|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
200865|NCT02643381|Procedure|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
200866|NCT02643381|Device|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
200867|NCT02643368|Biological|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
200868|NCT02643368|Biological|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
200869|NCT02643368|Biological|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
200870|NCT02643368|Biological|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
200871|NCT02643355|Drug|Olanzapine|
200872|NCT02643355|Drug|Clonidine|
200873|NCT02643342|Device|Orthokeratology|
200874|NCT02643329|Drug|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
200875|NCT02643329|Drug|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
200876|NCT02643316|Drug|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
200996|NCT02642393|Drug|Placebo|capsules containing ~500 mg of lactose and appearing indistinguishable from inosine capsules
200877|NCT02643316|Drug|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
200878|NCT02643303|Drug|Durvalumab|
200879|NCT02643303|Drug|Tremelimumab|
200880|NCT02643303|Drug|Poly ICLC|
200881|NCT02643290|Device|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
200882|NCT02643277|Behavioral|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
200883|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
200884|NCT02643264|Other|rTMS 10 Hz targeting the insula|Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
200885|NCT02643264|Other|Sham rTMS|Sham stimulation with the same regimen as active treatment
200886|NCT02643251|Drug|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
200887|NCT02643251|Drug|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
200888|NCT02643238|Device|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
200889|NCT02643212|Drug|Rivaroxaban|
200890|NCT02643212|Drug|Placebo|
200891|NCT02643186|Drug|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
200892|NCT02643186|Procedure|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
200893|NCT02643173|Other|Volatile anesthetics|
200894|NCT02643173|Other|Intravenous anesthetics|
200895|NCT02643160|Other|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
200896|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
200897|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
200898|NCT02643147|Drug|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
200899|NCT02643134|Procedure|extracorporeal shockwave lithotripsy|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
200900|NCT02643134|Device|External Physical Vibration Lithecbole|Multi-dimensional physical harmonic vibration inertial guidance technology
200901|NCT02643121|Other|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
200902|NCT02643108|Procedure|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.0 - 3.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
200903|NCT02643095|Device|scleral contact lens|Scleral contact lens
200904|NCT02643082|Drug|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
200905|NCT02643082|Drug|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
200906|NCT02643069|Other|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
200907|NCT02643056|Drug|Panitumumab|IV administration every 2 weeks
200908|NCT02643043|Other|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
200909|NCT02643030|Behavioral|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
200910|NCT02643030|Behavioral|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
200911|NCT02643017|Drug|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
200912|NCT02643017|Drug|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
200913|NCT02643004|Device|Senofilcon A|contact lens
200914|NCT02643004|Device|Stenfilcon A|contact lens
200915|NCT02642991|Device|Study Test contact lens|
200916|NCT02642991|Device|comfilcon A contact lens|
200999|NCT02642367|Device|McGrath videolaryngoscope|without use of stylet
200917|NCT02642978|Procedure|RSRCLM|The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
200918|NCT02642978|Procedure|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
200919|NCT02642965|Drug|Cytarabine|Given IT or IV
200920|NCT02642965|Biological|Filgrastim|Given SC or IV
200921|NCT02642965|Drug|Fludarabine Phosphate|Given IV
200922|NCT02642965|Other|Laboratory Biomarker Analysis|Correlative studies
200923|NCT02642965|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
200924|NCT02642965|Other|Pharmacological Study|Correlative studies
200925|NCT02642952|Other|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
200926|NCT02642939|Drug|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
200927|NCT02642926|Procedure|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
200928|NCT02642926|Procedure|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
200929|NCT02642913|Drug|Enzalutamide|
200930|NCT02642913|Drug|Enzalutamide with Sorafenib|
200931|NCT02642900|Procedure|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
200932|NCT02642900|Drug|Nystatin 100.000 units|Control group treated with nystatin
200933|NCT02642887|Procedure|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
200934|NCT02642874|Drug|Methocarbamol|Methocarbamol twice daily
200935|NCT02642874|Drug|Calcium Carbonate|Calcium carbonate twice daily
200936|NCT02642861|Drug|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
200937|NCT02642861|Drug|Calcium Carbonate|Calcium carbonate for 2 weeks
200938|NCT02642848|Procedure|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
200939|NCT02642848|Procedure|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
200940|NCT02642848|Procedure|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
200941|NCT02642835|Procedure|vaginal wall mesh|retrospective review of case series
200942|NCT02642809|Drug|Pembrolizumab|
200943|NCT02642809|Radiation|Brachytherapy|
200944|NCT02642809|Procedure|Endoscopic biopsy|
200945|NCT02642809|Procedure|Computed tomography-guided biopsy|
200946|NCT02642809|Procedure|Peripheral blood collection|
200947|NCT02642796|Device|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.~Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
200948|NCT02642783|Behavioral|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
200949|NCT02642783|Behavioral|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
200950|NCT02642770|Device|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
200951|NCT02642757|Behavioral|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
200952|NCT02642757|Other|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
200953|NCT02642744|Other|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
200954|NCT02642718|Drug|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
200955|NCT02642718|Other|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
200956|NCT02642705|Other|High intensity interval training N|Exercise training and ambient air breathing
200957|NCT02642705|Other|High intensity interval training H|Exercise training and hypoxic breathing
200958|NCT02642705|Other|Constant load exercise training N|Exercise training and ambient air breathing
200959|NCT02642705|Other|Constant load exercise training H|Exercise training and hypoxic breathing
200960|NCT02642705|Other|Hypoxic conditioning at rest|Hypoxic breathing at rest
200961|NCT02642705|Other|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
200962|NCT02642692|Procedure|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
200963|NCT02642692|Procedure|Hamstring Graft|Acl reconstruction with hamstring graft
200964|NCT02642679|Device|Opticell Ag|Opticell Ag+ applied to STSG donor site
200997|NCT02642380|Drug|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
201080|NCT02641847|Drug|docetaxel|
200965|NCT02642666|Behavioral|Children's Yoga|"Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme."
200966|NCT02642653|Drug|Lovastatin|Once per day dosing
200967|NCT02642653|Other|Placebo|Once per day dosing
200968|NCT02642640|Dietary Supplement|melatonin|5 mg of melatonin per os.
200969|NCT02642640|Drug|placebo|
200970|NCT02642627|Device|Bellafill|
200971|NCT02642614|Drug|BI 1026706|
200972|NCT02642614|Drug|Placebo|
200973|NCT02642614|Drug|Placebo|For blinding purposes
200974|NCT02642601|Drug|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
200975|NCT02642588|Dietary Supplement|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
200976|NCT02642562|Drug|Iron (III) isomaltoside 1000|
200977|NCT02642549|Behavioral|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
200978|NCT02642536|Behavioral|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
200979|NCT02642536|Behavioral|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
200980|NCT02642523|Drug|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
200981|NCT02642523|Drug|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
200982|NCT02642523|Other|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
200983|NCT02642510|Other|Structured Education DVD + Verbal Teaching|"The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.~Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects."
200984|NCT02642510|Other|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
200985|NCT02642497|Drug|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
200986|NCT02642497|Drug|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
200987|NCT02642497|Drug|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
200988|NCT02642484|Drug|Gabapentin|Gapapentin twice daily
200989|NCT02642484|Drug|Calcium Carbonate|calcium carbonate twice daily
200990|NCT02642471|Procedure|no systematic pelvic lymphadenectomy|systematic pelvic lymphadenectomy is omitted in surgical treatment
200991|NCT02642445|Device|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
200992|NCT02642432|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
200993|NCT02642419|Drug|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)~Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)~Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg~Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.~Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
200994|NCT02642419|Drug|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
200995|NCT02642393|Drug|Inosine|capsules containing 500 mg of inosine
201000|NCT02642367|Device|McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)|use of stylet
201001|NCT02642367|Drug|rocuronium|tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
201002|NCT02642354|Device|Study Test contact lens|
201003|NCT02642354|Device|comfilcon A contact lens|
201004|NCT02642341|Device|Study Test contact lens|
201005|NCT02642341|Device|comfilcon A contact lens|
201006|NCT02642328|Other|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
201007|NCT02642328|Other|Control|Continuous aerobic exercise at 65% of VO2Max
201008|NCT02642315|Drug|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
201009|NCT02642302|Behavioral|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
201010|NCT02642302|Behavioral|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
201011|NCT02642302|Behavioral|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
201012|NCT02642289|Dietary Supplement|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
201013|NCT02642289|Dietary Supplement|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
201014|NCT02642289|Other|Placebo|Innocuous substance
201015|NCT02642276|Other|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
201016|NCT02642263|Drug|Carbetocin|Postpartum uterotonic drug
201017|NCT02642250|Drug|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
201018|NCT02642250|Drug|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
201019|NCT02642237|Biological|Fluenz|intranasal inoculation with Fluenz
201020|NCT02642237|Other|placebo|
201021|NCT02642237|Other|LPS|
201022|NCT02642224|Behavioral|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
201023|NCT02642211|Procedure|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
201024|NCT02642198|Device|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
201025|NCT02642185|Procedure|Microwave ablation|CT-guided percutaneous ablation of 1-5, <31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
201026|NCT02642185|Procedure|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
201027|NCT02642172|Dietary Supplement|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
201028|NCT02642172|Dietary Supplement|Placebo|Participants will consume 16 g/day maltodextrin
201029|NCT02642159|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
201030|NCT02642159|Drug|Statins|Statins at stable dose without other LMT as clinically indicated.
201031|NCT02642159|Drug|Ezetimibe|Pharmaceutical form: tablet Route of administration: oral
201032|NCT02642159|Drug|Fenofibrate|Pharmaceutical form: tablet Route of administration: oral
201033|NCT02642159|Drug|Nicotinic acid|Pharmaceutical form: tablet Route of administration: oral
201034|NCT02642159|Drug|Omega-3 fatty acids|Pharmaceutical form: tablet Route of administration: oral
201035|NCT02642159|Drug|Antihyperglycemic Drug|Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
201036|NCT02642146|Drug|Calcium Channel Blockers|
201037|NCT02642146|Drug|Phosphodiesterase Inhibitors|
201038|NCT02642146|Drug|Endothelin receptor blocker|
201039|NCT02642146|Drug|Prostanoids|
201040|NCT02642146|Drug|Other vasodilator|
201081|NCT02641847|Drug|doxorubicin or epirubicin|
201082|NCT02641847|Drug|cyclophosphamide|
201083|NCT02641847|Drug|gemcitabine|
201084|NCT02641847|Drug|cisplatin|
201085|NCT02641834|Other|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
201086|NCT02641834|Other|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
201087|NCT02641821|Drug|Nifedipine GITS|
201133|NCT02641509|Device|NBI during polypectomy|NBI to perform the polipectomy
201041|NCT02642133|Procedure|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
201042|NCT02642120|Device|"Dental device Laboraide"|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
201043|NCT02642107|Radiation|Elective neck irradiation|Whole neck irradiation is given in the positive neck. Elective neck irradiation of Level II,III,Va lymph node area is given in negative neck, and Level IV,Vb and Supraclavicular fossa lymph node area were not irradiated in negative neck.
201044|NCT02642107|Radiation|Whole neck irradiation|Whole neck irradiation is given regardless of negative neck or positive neck
201045|NCT02642094|Drug|Rapamycin|Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
201046|NCT02642055|Behavioral|Neuro+ Attention Training|Attention training program with Neuro+ software
201047|NCT02642055|Other|Treatment as Usual|Continuation of current ADHD treatment
201048|NCT02642042|Drug|Docetaxel|Given IV
201049|NCT02642042|Other|Laboratory Biomarker Analysis|Correlative studies
201050|NCT02642042|Drug|Trametinib|Given PO
201051|NCT02642029|Device|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
201052|NCT02642029|Device|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
201053|NCT02642029|Device|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
201054|NCT02642016|Biological|CDX-0158 (formerly known as KTN-0158)|Single agent CDX-0158 until unacceptable toxicity or progressive disease
201055|NCT02642003|Drug|Granulocyte Colony Stimulating Factor|
201056|NCT02641990|Drug|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
201057|NCT02641990|Drug|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
201058|NCT02641951|Other|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
201059|NCT02641951|Other|Pecs II block|Ultrasound guided Pecs II block
201060|NCT02641938|Drug|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
201061|NCT02641938|Drug|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
201062|NCT02641925|Procedure|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
201063|NCT02641925|Procedure|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
201064|NCT02641912|Other|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
201065|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.~At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
201066|NCT02641899|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
201067|NCT02641899|Drug|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
201068|NCT02641899|Drug|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
201069|NCT02641899|Drug|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
201070|NCT02641899|Drug|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
201071|NCT02641899|Drug|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
201072|NCT02641886|Drug|Jian Pi Yi Shen Hua Tan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
201073|NCT02641886|Other|the placebo group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
201074|NCT02641873|Drug|BBI608|240 mg twice daily (480 mg total daily dose)
201075|NCT02641873|Drug|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
201076|NCT02641873|Drug|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
201077|NCT02641873|Drug|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
201078|NCT02641873|Drug|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
201079|NCT02641860|Biological|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
201088|NCT02641808|Other|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
201089|NCT02641808|Other|no follicular flushing|
201090|NCT02641795|Device|Minimally invasive robotic cochlear implantation|
201091|NCT02641782|Drug|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
201092|NCT02641782|Drug|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
201093|NCT02641782|Drug|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
201094|NCT02641782|Drug|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
201095|NCT02641782|Drug|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
201096|NCT02641769|Biological|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
201097|NCT02641756|Other|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
201098|NCT02641743|Dietary Supplement|Inslow|carbohydrate adjusted liquid food using palatinose as the major carbohydrate (>50%)
201099|NCT02641743|Dietary Supplement|standard balanced formula|
201100|NCT02641730|Drug|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
201101|NCT02641730|Drug|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
201102|NCT02641717|Other|vaginal swab|
201103|NCT02641704|Behavioral|Multidisciplinary program|Coordinated multidisciplinary program
201104|NCT02641691|Radiation|Radiation|
201105|NCT02641691|Drug|Oxaliplatin|
201106|NCT02641691|Drug|Leucovorin|
201107|NCT02641691|Drug|Fluorouracil|
201108|NCT02641678|Device|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
201109|NCT02641665|Procedure|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
201110|NCT02641652|Drug|Sertraline|25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
201111|NCT02641652|Drug|Placebo|1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
201112|NCT02641639|Drug|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
201113|NCT02641639|Drug|Placebo|Saline for infusion
201114|NCT02641626|Procedure|Urgent Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
201115|NCT02641626|Procedure|Deferred Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
201116|NCT02641613|Procedure|retroclavicular block|retroclavicular block for forearm or hand surgery
201117|NCT02641613|Procedure|supraclavicular block|supraclavicular block for forearm or hand surgery
201118|NCT02641600|Device|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
201119|NCT02641600|Device|Placebo stockings|Placebo stocking with pressure applied to the legs
201120|NCT02641587|Other|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
201121|NCT02641587|Other|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
201122|NCT02641574|Other|compare complication|
201123|NCT02641561|Drug|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
201124|NCT02641561|Drug|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
201125|NCT02641561|Drug|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
201126|NCT02641561|Drug|Placebo|Placebo would be a suppository 50 mg x 2
201127|NCT02641548|Device|Sock of silicone|
201128|NCT02641548|Other|Heel cream|
201129|NCT02641535|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
201130|NCT02641535|Device|BC membrane protective garment|
201131|NCT02641535|Device|NBC mask|
201132|NCT02641522|Drug|Siltuximab|Single infusion of siltuximab (11 mg/kg)
201134|NCT02641509|Device|no NBI during polypectomy|no NBI to perform the polypectomy
201135|NCT02641496|Behavioral|CBT-OSA|CBT-OSA is a new cognitive behavioral therapy which focuses on changing behaviors and thoughts to help individuals adjust to using a CPAP machine.
201136|NCT02641496|Behavioral|Sleep Education|The Sleep Education treatment will include information, facts, and videos on sleep, cardiovascular disease, PTSD, and proper sleep hygiene.
201137|NCT02641483|Other|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
201138|NCT02641470|Dietary Supplement|DA9301 (Vaccinium uliginosum extract)|
201139|NCT02641470|Dietary Supplement|Placebo|
201140|NCT02641457|Drug|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
201141|NCT02641457|Drug|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
201142|NCT02641444|Procedure|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
201143|NCT02641444|Procedure|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
201144|NCT02641444|Procedure|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
201145|NCT02641431|Procedure|mapping/ablation|Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
201146|NCT02641431|Drug|Ajmaline|Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
201147|NCT02641431|Procedure|ablation|Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.
201148|NCT02641431|Procedure|mapping|A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
201149|NCT02641418|Other|Supervised exercise programme|supervised exercise programme
201150|NCT02641405|Device|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
201151|NCT02641405|Device|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
201152|NCT02641392|Drug|GED-0301|Mongersen
201153|NCT02641392|Other|Placebo|Placebo
201154|NCT02641379|Drug|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\n
201155|NCT02641379|Drug|Ribavirin|Ribavirin is available as 200 mg tablets
201156|NCT02641366|Device|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
201157|NCT02641366|Procedure|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
201158|NCT02641366|Procedure|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
201159|NCT02641353|Drug|Apremilast|30 mg tablet
201160|NCT02641353|Drug|Apremilast Oral Suspension|30 mg oral suspension
201161|NCT02641340|Drug|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
201162|NCT02641340|Drug|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
201163|NCT02641327|Device|EarlySense (Passive monitoring)|Passive contact-free monitoring
201164|NCT02641314|Drug|metronomic therapy|"Propranolol 0.5 mg/kgxd p.o. day 1,~mg/kgxd p.o. day 2,~mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day~Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day~Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose~Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose~Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
201165|NCT02641301|Drug|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
201166|NCT02641288|Drug|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
201167|NCT02641288|Drug|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
201168|NCT02641275|Other|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
201243|NCT02640638|Behavioral|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
201169|NCT02641249|Device|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
201170|NCT02641236|Drug|Vancomycin-polymyxin B|
201171|NCT02641223|Device|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
201172|NCT02641210|Procedure|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
201173|NCT02641210|Drug|Albendazole|All participants took Albendazole 400 mg before the intervention.
201174|NCT02641197|Device|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.~Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
201175|NCT02641171|Other|Specimen sampling|exhaled air samples blood samples fecal samples
201176|NCT02641158|Other|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
201177|NCT02641158|Behavioral|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
201178|NCT02641145|Radiation|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
201179|NCT02641145|Device|MRI|Cardiac MRI with gadolinium contrast.
201180|NCT02641145|Radiation|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
201181|NCT02641132|Drug|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
201182|NCT02641132|Procedure|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
201183|NCT02641106|Other|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
201184|NCT02641106|Other|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
201185|NCT02641093|Drug|Pembrolizumab|Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
201186|NCT02641093|Procedure|Surgery|gross total surgical resection
201187|NCT02641093|Radiation|Radiation Therapy|60-66 Gy over 6 weeks
201188|NCT02641093|Drug|Cisplatin|Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
201189|NCT02641080|Drug|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
201190|NCT02641080|Device|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
201191|NCT02641067|Drug|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
201192|NCT02641054|Drug|CVXL-0107|
201193|NCT02641054|Drug|Placebo|
201194|NCT02641054|Drug|Levodopa|
201195|NCT02641041|Biological|BIIB033|single or multiple dose
201196|NCT02641041|Other|Placebo|single or multiple dose
201197|NCT02641028|Drug|CERC-501|CERC-501
201198|NCT02641028|Drug|Placebo|Placebo
201199|NCT02641002|Drug|CC-90002|Monoclonal Ab to CD47
201200|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
201201|NCT02640989|Biological|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
201202|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
201203|NCT02640976|Drug|Human menopausal gonadotrophin (HMG)|[Merional® 75 IU ampoules, IBSA institut]
201204|NCT02640976|Drug|GnRH antagonist Cetrorelix|[Cetrotide® 0.25 mg syringes, Merck Serono]
201205|NCT02640976|Drug|Human chorionic gonadotrophin (hCG)|[Choriomon® 5000 IU ampoules, IBSA institut]
201206|NCT02640963|Other|Exercise|to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
201207|NCT02640963|Other|Control|to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
201208|NCT02640950|Device|NeuroStar TMS|Transcranial Magnetic Stimulation
201209|NCT02640924|Radiation|Proton radiotherapy|
201210|NCT02640924|Procedure|Radiofrequency Ablation|
201211|NCT02640898|Radiation|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
201212|NCT02640898|Radiation|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
201213|NCT02640885|Device|Foley's cather ballon|
201214|NCT02640846|Drug|Norepinephrine|Norepinephrine will be given to the patient due to septic shock. After the inclusion we will change the dose of Norepinephrine to achieve 3 different MAP-levels, 60 mmHg, 75 mmHg and 90 mmHg.
201215|NCT02640846|Drug|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
201216|NCT02640846|Drug|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
201217|NCT02640833|Drug|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
201218|NCT02640833|Drug|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
201219|NCT02640820|Drug|Sensitizing DPCP Ointment|Sensitization
201220|NCT02640820|Drug|Treatment DPCP Ointment|Treatment
201221|NCT02640807|Drug|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) >2.5 or platelet count < 35,000
201222|NCT02640807|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
201223|NCT02640794|Drug|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
201224|NCT02640794|Drug|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
201225|NCT02640781|Procedure|self-expandable metal stent insertion(covered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal covered stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
201226|NCT02640781|Procedure|self-expandable metal stent insertion(uncovered stent)|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery uncovered catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
201227|NCT02640768|Other|educational training|implementation of a structured educational program for physicians and nurses
201228|NCT02640755|Drug|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
201229|NCT02640755|Drug|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
201230|NCT02640755|Drug|Fulvestrant|Hormonal Agent
201231|NCT02640755|Drug|Paclitaxel|Taxane
201232|NCT02640729|Drug|Nelotanserin|once daily, oral, 20-mg tablets
201233|NCT02640729|Drug|Placebo|once daily, oral, matching tablets
201234|NCT02640716|Behavioral|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
201235|NCT02640716|Behavioral|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
201236|NCT02640703|Biological|Infanrix + Prevenar 13|Different time of application
201237|NCT02640690|Behavioral|Trauma Sensitive Yoga Intervention|(10) 1-hour sessions of trauma sensitive yoga
201238|NCT02640690|Behavioral|Cognitive Processing Therapy-Cognitive Only|(12) 1.5 hour sessions of cognitive processing therapy
201239|NCT02640677|Biological|4CMenB|This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
201240|NCT02640664|Drug|Ranibizumab|0.2 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
201241|NCT02640664|Drug|Ranibizumab|0.1 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
201242|NCT02640651|Device|DC-Stimulator (PLUS version)|transcranial direct current stimulation
201286|NCT02640313|Drug|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
202415|NCT02632045|Drug|Fulvestrant|500 mg injection
201244|NCT02640625|Dietary Supplement|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
201245|NCT02640612|Drug|BI 695501|
201246|NCT02640599|Other|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
201247|NCT02640599|Other|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
201248|NCT02640586|Device|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
201249|NCT02640573|Drug|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
201250|NCT02640560|Other|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
201251|NCT02640560|Other|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
201252|NCT02640534|Drug|Enzalutamide|Enzalutamide 160 mg od until disease progression
201253|NCT02640534|Drug|Metformin|850 mg bid until disease progression
201254|NCT02640521|Behavioral|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
201255|NCT02640508|Drug|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
201256|NCT02640508|Drug|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
201257|NCT02640495|Drug|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
201258|NCT02640482|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
201259|NCT02640482|Drug|Placebo for ABT-493/ABT-530|tablet
201260|NCT02640469|Other|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:~scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
201261|NCT02640469|Other|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
201262|NCT02640469|Other|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
201263|NCT02640456|Biological|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
201264|NCT02640456|Procedure|Type of surgery|Surgical approach and complications.
201265|NCT02640456|Biological|Biochemistry|Amylase concentration i pus aspirates.
201266|NCT02640456|Biological|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
201267|NCT02640443|Drug|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
201268|NCT02640430|Device|standard treatment|20 minutes, twice a day for 10 sessions
201269|NCT02640430|Device|Free Aspire|20 minutes, twice a day for 10 sessions
201270|NCT02640417|Drug|Nucleotides + B12|Oral treatment with either Nucleotides + Vitamin B12
201271|NCT02640417|Drug|B Vitamins|Oral treatment with vitamins B1, B6, and B12
201272|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
201273|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular.
201274|NCT02640391|Other|colonoscopy|
201275|NCT02640378|Other|NO intervention|This study was a cross-sectional study. It had no intervention.
201276|NCT02640365|Drug|MM-398|unresectable Advanced non-colorectal cancer
201277|NCT02640365|Drug|Irinotecan|unresectable metastatic colorectal cancer
201278|NCT02640365|Drug|Leucovorin (LV)|unresectable metastatic colorectal cancer
201279|NCT02640365|Drug|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
201280|NCT02640365|Drug|bevacizumab|unresectable metastatic colorectal cancer
201281|NCT02640365|Drug|MM-398|unresectable metastatic colorectal cancer
201282|NCT02640352|Dietary Supplement|Probi Defendum|
201283|NCT02640352|Dietary Supplement|Placebo|
201284|NCT02640326|Other|No Foley Urinary Catheter|No Foley urinary catheter will be put in place during the operation
201285|NCT02640326|Other|Standard of care Foley urinary catheter insertion|A Foley urinary catheter will be put in place during the operation
201463|NCT02639026|Drug|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
201287|NCT02640300|Drug|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
201288|NCT02640287|Biological|Blood or bone marrow samples|
201289|NCT02640274|Behavioral|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
201290|NCT02640274|Other|Usual care|
201291|NCT02640248|Device|Cuff ETT|
201292|NCT02640235|Device|CELSTAT|
201293|NCT02640235|Device|Surgicel Original|
201294|NCT02640222|Drug|VKA|
201295|NCT02640222|Drug|Apixaban|
201296|NCT02640222|Drug|dabigatran|
201297|NCT02640222|Drug|rivaroxaban|
201298|NCT02640209|Biological|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
201299|NCT02640196|Device|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
201300|NCT02640196|Device|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
201301|NCT02640196|Device|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
201302|NCT02640196|Device|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
201303|NCT02640183|Drug|EMLA|
201304|NCT02640183|Other|Placebo|
201305|NCT02640170|Other|Registry|
201306|NCT02640157|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
201307|NCT02640157|Drug|Sofosbuvir|Tablet
201308|NCT02640157|Drug|Daclatasvir|Tablet
201309|NCT02640144|Drug|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
201310|NCT02640144|Drug|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
201311|NCT02640131|Behavioral|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
201312|NCT02640131|Behavioral|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
201313|NCT02640131|Behavioral|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
201314|NCT02640118|Drug|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
201315|NCT02640118|Drug|Lixisenatide-Placebo|
201316|NCT02640118|Other|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
201317|NCT02640105|Other|Neurological clinical examination|Diagnostic and description of cluster headache
201318|NCT02640105|Other|Psychological clinical examination|Scale and questionnaires
201319|NCT02640105|Other|Questionnaires|Psychopathological and cognitive questionnaires
201320|NCT02640105|Other|Blood sample|Blood sample for DNA collection
201321|NCT02640105|Other|Endothelial function measurement|Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
201322|NCT02640092|Drug|[18F]GTP1|Participants will receive [18F]GTP1 as per the schedule specified in the arm description.
201323|NCT02640079|Behavioral|Cognitive behavioral therapy|
201324|NCT02640066|Other|acupuncture|
201325|NCT02640053|Procedure|Cryotherapy|Applied topically
201326|NCT02640053|Drug|Paclitaxel|Given IV
201327|NCT02640053|Other|Quality-of-Life Assessment|Ancillary studies
201328|NCT02640053|Other|Questionnaire Administration|Ancillary studies
201329|NCT02640040|Device|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
201330|NCT02640040|Device|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
201331|NCT02640040|Procedure|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
201332|NCT02640027|Procedure|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
201333|NCT02640014|Dietary Supplement|Milk|Milk Oral immunotherapy
201334|NCT02639975|Drug|PBF-677|once daily oral administration
201335|NCT02639975|Drug|Placebo|once daily oral administration
201336|NCT02639962|Radiation|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
201337|NCT02639949|Behavioral|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
201338|NCT02639949|Behavioral|Standard Care|
201339|NCT02639923|Procedure|Drawing of 7ml peripheral blood|puncture peripheral vein
201340|NCT02639910|Biological|tafasitamab|tafasitamab (MOR208) dose: 12 mg/kg intravenous infusion
201341|NCT02639910|Drug|Idelalisib|Idelalisib dose: 150 mg twice daily orally
201342|NCT02639910|Drug|Venetoclax|Venetoclax dose: 400 mg once daily orally
201343|NCT02639897|Other|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
201344|NCT02639884|Device|SedLine EEG|
201345|NCT02639884|Device|RRa monitoring|
201346|NCT02639858|Drug|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
201347|NCT02639832|Device|LiquidBiopsy®, NK VueTM|The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.
201348|NCT02639819|Drug|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
201349|NCT02639806|Drug|Sevoflurane|
201350|NCT02639806|Drug|Lidocaine|
201351|NCT02639793|Procedure|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
201352|NCT02639780|Other|protein expression pattern of packed red blood cells|the proteome of packed red blood cells will be assessed at predefined time points
201353|NCT02639767|Drug|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m^2 for pemetrexed in combination with 75 mg/m^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
201354|NCT02639767|Radiation|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
201355|NCT02639767|Device|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
201356|NCT02639754|Behavioral|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
201357|NCT02639754|Behavioral|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
201358|NCT02639741|Drug|Melatonin|Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
201359|NCT02639741|Drug|Vitamin C|Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
201360|NCT02639741|Other|Placebo|Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
201361|NCT02639728|Other|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
201362|NCT02639728|Other|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
201363|NCT02639728|Other|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
201364|NCT02639702|Drug|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
201365|NCT02639689|Device|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.~Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
201366|NCT02639676|Other|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
201367|NCT02639663|Device|dental device|"Leboride~Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control~Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
201368|NCT02639650|Drug|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
201369|NCT02639650|Drug|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
201370|NCT02639650|Drug|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
201371|NCT02639650|Drug|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
201372|NCT02639650|Drug|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
201373|NCT02639650|Drug|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
201374|NCT02639650|Drug|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
201375|NCT02639650|Drug|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
201376|NCT02639637|Drug|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
201377|NCT02639637|Drug|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
201492|NCT02638805|Drug|ITCA 650 Osmotic Mini Pump 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
201378|NCT02639637|Drug|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
201379|NCT02639637|Drug|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
201380|NCT02639637|Drug|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
201381|NCT02639624|Drug|Low bicarbonate dialysate First|
201382|NCT02639624|Drug|Normal bicarbonate dialysate First|
201383|NCT02639624|Drug|Normal bicarbonate dialysate|
201384|NCT02639624|Drug|Low bicarbonate dialysate|
201385|NCT02639611|Other|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
201386|NCT02639611|Other|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
201387|NCT02639598|Drug|Flunarizine|"as in arm descriptions"
201388|NCT02639598|Drug|Topiramate|"as in arm descriptions"
201389|NCT02639585|Drug|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
201390|NCT02639572|Biological|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
201391|NCT02639572|Biological|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
201392|NCT02639559|Drug|BL-8040|
201393|NCT02639559|Procedure|Leukapheresis|
201394|NCT02639559|Procedure|Hematopoietic cell transplant|
201395|NCT02639546|Drug|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
201396|NCT02639533|Drug|Pregabalin|Pregabalin 150 mg PO, single dose.
201397|NCT02639533|Other|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
201398|NCT02639520|Drug|Canephron® N|2 tablets 3 times a day for 7 days
201399|NCT02639520|Drug|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
201400|NCT02639520|Drug|Canephron® N-placebo|2 tablets 3 times a day for 7 days
201401|NCT02639520|Drug|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
201402|NCT02639507|Procedure|Vitrectomy|
201403|NCT02639494|Device|Self-Centering Guide Catheter|
201404|NCT02639481|Behavioral|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
201405|NCT02639481|Device|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
201406|NCT02639481|Device|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
201407|NCT02639468|Device|Stroke Volume estimation using electrical impedance tomography|
201408|NCT02639455|Behavioral|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
201409|NCT02639442|Device|ClearRing™|
201410|NCT02639429|Drug|Vaginal Misoprostol|
201411|NCT02639429|Device|Foley Balloon + Vaginal Misoprostol|
201412|NCT02639416|Dietary Supplement|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
201413|NCT02639416|Dietary Supplement|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
201414|NCT02639416|Other|Standard management|Standard management with F-100 and/or RUTF
201415|NCT02639403|Radiation|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
201416|NCT02639390|Device|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
201493|NCT02638805|Drug|ITCA 650 Osmotic Mini Pump 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
201417|NCT02639390|Other|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
201418|NCT02639377|Drug|Chlorhexidine gluconate|
201419|NCT02639377|Drug|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
201420|NCT02639364|Device|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
201421|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
201422|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 25 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
201423|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 50 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
201424|NCT02639351|Biological|Investigational MenC-CRM adjuavnted with 100 ug of LHD153R|IM vaccination of 1 dose of 0.5 mL
201425|NCT02639351|Biological|Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)|IM vaccination of 1 dose of 0.5 mL
201426|NCT02639338|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
201427|NCT02639338|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
201428|NCT02639286|Drug|ISIS 304801|300 mg or placebo administered as SC
201429|NCT02639286|Drug|Placebo|Placebo administered via SC
201430|NCT02639273|Drug|Nalmefene|
201431|NCT02639273|Other|Placebo|
201432|NCT02639260|Drug|N-acetyl-mannosamine (ManNAc)|dose escalation
201433|NCT02639247|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
201434|NCT02639247|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
201435|NCT02639234|Biological|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
201436|NCT02639234|Drug|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
201437|NCT02639221|Drug|PXT002331|
201438|NCT02639208|Other|PatientsLikeMe (PLM)|
201439|NCT02639195|Other|Treatment|Retrospective chart review of patients treated with manual therapy.
201440|NCT02639182|Drug|AGS-16C3F|Intravenous (IV) infusion
201441|NCT02639182|Drug|Axitinib|Oral
201442|NCT02639169|Other|Music Therapy|apply live music through the techniques of music therapy
201443|NCT02639156|Dietary Supplement|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
201444|NCT02639143|Drug|ticagrelor|
201445|NCT02639143|Drug|Clopidogrel|
201446|NCT02639130|Drug|Exendin [9-39]|Exendin [9-39] at 350 and 500 pmol/kg/min for infusion as challenge agent
201447|NCT02639130|Drug|Placebo|Placebo infusion as challenge agent
201448|NCT02639117|Drug|Vismodegib|Vismodegib 150 mgs po qd for 3 months
201449|NCT02639104|Radiation|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;~The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography~If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis~The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
201450|NCT02639104|Other|Electromyography|"Serratus anterior needle electromyography:~The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
201451|NCT02639091|Drug|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).~In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
201452|NCT02639091|Drug|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
201453|NCT02639091|Drug|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
201454|NCT02639078|Drug|TD-0714|One time dosing in capsule formulation
201455|NCT02639078|Drug|Placebo Comparator|One time dosing in capsule formulation
201456|NCT02639065|Drug|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
201457|NCT02639052|Drug|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
201458|NCT02639052|Drug|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
201459|NCT02639039|Drug|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
201460|NCT02639039|Procedure|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
201461|NCT02639026|Radiation|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
201462|NCT02639026|Drug|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
201464|NCT02639013|Procedure|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
201465|NCT02639000|Procedure|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
201466|NCT02638987|Device|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
201467|NCT02638974|Other|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
201468|NCT02638961|Other|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
201469|NCT02638961|Other|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
201470|NCT02638961|Other|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
201471|NCT02638948|Drug|BMS-986142|BMS986142 specific dose on specific days
201472|NCT02638948|Drug|Placebo|Placebo of BMS-986142 specific dose on specific days
201473|NCT02638948|Drug|Methotrexate|Methotrexate specific dose on specific days
201474|NCT02638935|Device|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
201475|NCT02638922|Drug|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
201476|NCT02638909|Drug|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
201477|NCT02638896|Drug|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
201478|NCT02638896|Drug|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
201479|NCT02638896|Drug|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will take sulfasalazine (2g/d) from week12 to week48.
201480|NCT02638896|Drug|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
201481|NCT02638870|Drug|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
201482|NCT02638857|Procedure|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
201483|NCT02638857|Biological|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
201484|NCT02638857|Drug|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
201485|NCT02638857|Drug|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
201486|NCT02638857|Drug|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
201487|NCT02638857|Biological|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
201488|NCT02638831|Drug|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
201489|NCT02638831|Drug|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
201490|NCT02638818|Procedure|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
201491|NCT02638818|Procedure|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
201609|NCT02637973|Drug|Placebo|once daily
201494|NCT02638805|Drug|Metformin|Stable dose for at least 3 months (at least 1000 mg/day)
201495|NCT02638805|Drug|Liraglutide|Stable dose for at least 3 months (at least 1.2 mg/day)
201496|NCT02638792|Behavioral|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
201497|NCT02638792|Behavioral|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
201498|NCT02638779|Biological|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
201499|NCT02638766|Drug|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
201500|NCT02638753|Other|education|Patients will be educated about pain neurophysiology.
201501|NCT02638753|Other|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
201502|NCT02638740|Procedure|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
201503|NCT02638740|Procedure|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
201504|NCT02638727|Drug|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
201505|NCT02638727|Drug|placebo|This group treat with placebo dayley
201506|NCT02638714|Biological|Stem Cells|Intervention: Transplantation of autologous purified stem cells
201507|NCT02638701|Drug|Infliximab|Please see protocol for details.
201508|NCT02638688|Other|ultrasound|
201509|NCT02638675|Behavioral|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
201510|NCT02638675|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
201511|NCT02638675|Behavioral|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
201512|NCT02638662|Other|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
201513|NCT02638649|Procedure|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
201514|NCT02638649|Device|ultrasound|
201515|NCT02638636|Behavioral|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
201516|NCT02638623|Drug|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
201517|NCT02638623|Drug|Placebo|No additional fluids will be administered
201518|NCT02638610|Device|Cochet-Bonnet aesthesiometer|"The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.~This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface."
201519|NCT02638597|Drug|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
201520|NCT02638597|Behavioral|smoking cessation counseling|smoking cessation counseling
201521|NCT02638584|Drug|Ilaprazole|Ilaprazole 10mg 2tablets once a day(1 times / day), before breakfast
201522|NCT02638584|Drug|Rabeprazole|Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
201523|NCT02638571|Other|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
201524|NCT02638558|Other|written + oral explanation|
201525|NCT02638558|Other|written explanation|
201526|NCT02638545|Drug|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
201527|NCT02638532|Procedure|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
201610|NCT02637960|Drug|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
201528|NCT02638519|Other|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
201529|NCT02638519|Other|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
201530|NCT02638519|Drug|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
201531|NCT02638519|Device|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
201532|NCT02638506|Drug|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
201533|NCT02638506|Other|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
201534|NCT02638480|Device|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
201535|NCT02638467|Drug|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
201536|NCT02638467|Procedure|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.~The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.~The goal is to transplant > 3 x 106 CD34+ cells/kg BW recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow"
201537|NCT02638467|Drug|Bone Marrow cells|
201538|NCT02638454|Procedure|Acute Resistance Exercise|1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
201539|NCT02638441|Other|hospital anxiety and depression scale|Detection of infertility effect on emotional status
201540|NCT02638428|Procedure|CancerSCAN™|Targeted deep sequencing
201541|NCT02638428|Drug|Ifosfamide|
201542|NCT02638428|Drug|Carboplatin|
201543|NCT02638428|Drug|Etoposide|
201544|NCT02638428|Drug|Fludarabine|
201545|NCT02638428|Drug|Cytarabine|
201546|NCT02638428|Drug|Pazopanib|
201547|NCT02638428|Drug|Sorafenib|
201548|NCT02638428|Drug|Axitinib|
201549|NCT02638428|Drug|Crizotinib|
201550|NCT02638428|Drug|Dasatinib|
201551|NCT02638428|Drug|Erlotinib|
201552|NCT02638428|Drug|Everolimus|
201553|NCT02638428|Drug|Imatinib|
201554|NCT02638428|Drug|Ruxolitinib|
201555|NCT02638428|Drug|Vandetanib|
201556|NCT02638428|Drug|Vemurafenib|
201557|NCT02638428|Drug|Trastuzumab|
201558|NCT02638415|Procedure|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.~Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.~Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
201559|NCT02638415|Other|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
201560|NCT02638415|Drug|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
201561|NCT02638389|Drug|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
201562|NCT02638376|Radiation|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|"KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.~PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off."
201563|NCT02638376|Procedure|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|"The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.~This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.~The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.~A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution."
201564|NCT02638363|Behavioral|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
201611|NCT02637960|Drug|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
201742|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
201565|NCT02638350|Device|Strategy with lung ultrasound|"Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.~Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.~At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema."
201566|NCT02638337|Drug|Ospemifene|60 mg tablet
201567|NCT02638337|Drug|Placebo|Tablet identical to the ospemifene tablet without drug
201568|NCT02638324|Device|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
201569|NCT02638298|Device|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
201570|NCT02638298|Other|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
201571|NCT02638285|Drug|LH|
201572|NCT02638285|Drug|HCG|
201573|NCT02638285|Drug|Clomiphene|
201574|NCT02638272|Procedure|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
201575|NCT02638259|Drug|GP2015|Enbrel comparator
201576|NCT02638246|Behavioral|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
201577|NCT02638246|Behavioral|Internet-delivered, non-contingent incentives + Motivational Interviewing|
201578|NCT02638233|Drug|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
201579|NCT02638207|Drug|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
201580|NCT02638194|Other|Active smoking of Tobacco Hookah for 2 hours|
201581|NCT02638194|Other|Exposure to tobacco hookah second hand smoke|
201582|NCT02638194|Other|Visit a win bar|Participants will visit a wine bar for food and/or drinks
201583|NCT02638181|Procedure|trabeculectomy|
201584|NCT02638168|Drug|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
201585|NCT02638168|Drug|Placebo|inert placebo ingredient
201586|NCT02638142|Drug|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
201587|NCT02638142|Drug|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
201588|NCT02638129|Drug|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
201589|NCT02638129|Drug|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
201590|NCT02638116|Drug|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
201591|NCT02638116|Drug|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
201592|NCT02638103|Drug|Fremanezumab|Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
201593|NCT02638103|Drug|Placebo|Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.
201594|NCT02638090|Drug|Vorinostat|Administered per treatment arm guidelines.
201595|NCT02638090|Drug|Pembrolizumab|Administered per treatment arm guidelines.
201596|NCT02638064|Procedure|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
201597|NCT02638051|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
201598|NCT02638051|Dietary Supplement|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
201599|NCT02638051|Drug|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
201600|NCT02638038|Drug|INT131|INT- 131
201601|NCT02638025|Device|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
201602|NCT02638012|Drug|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
201603|NCT02638012|Other|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
201604|NCT02637999|Drug|PEG IFN alfa-2a|
201605|NCT02637999|Drug|Myrcludex B|
201606|NCT02637986|Dietary Supplement|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
201607|NCT02637986|Other|Placebo - capsule with no active ingredient|2 capsules will be given per day
201608|NCT02637973|Drug|Empagliflozin|25 mg once daily
201612|NCT02637947|Device|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
201613|NCT02637947|Device|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
201614|NCT02637934|Drug|[18F]FluorThanatrace|
201615|NCT02637934|Radiation|PET/CT imaging sessions|
201616|NCT02637921|Other|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
201617|NCT02637921|Other|Ambulatory|Participants hava a standardized activity level throughout the intervention
201618|NCT02637921|Other|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
201619|NCT02637921|Other|Bed Rest|Participants remain on supine bed rest throughout the intervention
201620|NCT02637921|Other|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
201621|NCT02637908|Behavioral|Mindfulness training|6-weeks of group-based mindfulness training for parents
201622|NCT02637895|Drug|Placebo|
201623|NCT02637895|Drug|Vortioxetine|
201624|NCT02637882|Other|Ear plug|The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
201625|NCT02637882|Other|Eye mask|The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
201626|NCT02637882|Other|Mixed intervention (ear plug and eye mask)|The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
201627|NCT02637869|Other|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
201628|NCT02637856|Drug|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
201629|NCT02637843|Device|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
201630|NCT02637830|Other|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
201631|NCT02637830|Other|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
201632|NCT02637830|Other|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
201633|NCT02637804|Device|stenfilcon A|contact lens
201634|NCT02637804|Device|narafilcon A|contact lens
201635|NCT02637804|Device|delefilcon A|contact lens
201636|NCT02637791|Device|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
201637|NCT02637778|Dietary Supplement|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
201638|NCT02637778|Dietary Supplement|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
201639|NCT02637765|Behavioral|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
201640|NCT02637752|Behavioral|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
201641|NCT02637739|Device|hysteroscope|Women of PUL with β-hCG > 1000 IU/L or abnormal β-hCG trend (increase < 66% or decrease < 15%) were offered HSC.
201642|NCT02637726|Drug|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
201643|NCT02637726|Drug|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
201644|NCT02637726|Drug|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
201645|NCT02637726|Device|EEG Monitoring|Maintaining a bispectral index between 45 and 55
201646|NCT02637726|Drug|Remifentanil|Remifentanil at discretion of the anesthesiologist
201741|NCT02637050|Other|Standard of care|At the discretion of the attending physician.
201647|NCT02637713|Procedure|Radiofrequency energy to the LES|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter it is approved for the management of GRED.
201648|NCT02637700|Drug|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
201649|NCT02637700|Drug|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
201650|NCT02637687|Drug|Larotrectinib (Vitravki, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
201651|NCT02637674|Procedure|Uterus Transplant|
201652|NCT02637661|Other|earlobe crease positive|
201653|NCT02637661|Other|earlobe crease negative|
201654|NCT02637648|Drug|Sodium Oxybate|parallel Group administration
201655|NCT02637648|Drug|Placebo|parallel Group administration
201656|NCT02637635|Procedure|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
201657|NCT02637635|Procedure|Expander prosthesis|breast reconstruction with expander prosthesis.
201658|NCT02637622|Other|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
201659|NCT02637622|Other|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
201660|NCT02637609|Other|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
201661|NCT02637609|Other|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
201662|NCT02637596|Procedure|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
201663|NCT02637583|Drug|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
201664|NCT02637583|Drug|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
201665|NCT02637570|Dietary Supplement|Hibiscus tea|
201666|NCT02637570|Dietary Supplement|green tea|
201667|NCT02637570|Dietary Supplement|placebo (dextrose)|
201668|NCT02637557|Drug|IW-3718|
201669|NCT02637557|Drug|Matching Placebo|
201670|NCT02637557|Drug|PPI|All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium sesquihydrate, rabeprazole or rabeprazole sodium) during the study.
201671|NCT02637544|Other|acupuncture|classical acupuncture therapy
201672|NCT02637531|Drug|IPI-549|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
201673|NCT02637531|Drug|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
201674|NCT02637518|Other|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
201675|NCT02637505|Procedure|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
201676|NCT02637505|Procedure|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
201677|NCT02637492|Other|Collection of clinical signs and symptoms|Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
201678|NCT02637479|Device|GammaKnife®|
201679|NCT02637479|Device|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
201680|NCT02637479|Device|MRI|
201681|NCT02637466|Drug|Vortioxetine|
201682|NCT02637453|Procedure|CPVI|patients with circumferential pulmonary vein isolation （CPVI）
201683|NCT02637453|Procedure|CPVI+ALA|patients with circumferential pulmonary vein isolation（CPVI）and additional linear ablation perpendicular to the PV ostium （ALA）
201684|NCT02637440|Procedure|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
201685|NCT02637440|Procedure|Angio guided PCI|Patients receive PCI without FFR measurement
201686|NCT02637427|Biological|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
201687|NCT02637414|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
201688|NCT02637401|Behavioral|Dialectical Behaviour Therapy|
201689|NCT02637388|Dietary Supplement|Oatwell28 Oatwell Original Powder|
201690|NCT02637388|Dietary Supplement|Control Breakfast|Isocaloric breakfast without added beta-glucans
201691|NCT02637375|Drug|Ganetespib|
201692|NCT02637375|Drug|Paclitaxel|
201693|NCT02637375|Drug|Doxorubicin|
201694|NCT02637375|Drug|Cyclophosphamide|
201695|NCT02637362|Procedure|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
201696|NCT02637362|Procedure|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
201697|NCT02637362|Procedure|Metatarsal block|A metatarsal block will be performed using a standardised technique
201698|NCT02637362|Procedure|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
201699|NCT02637349|Behavioral|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
201700|NCT02637349|Behavioral|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
201701|NCT02637336|Device|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
201702|NCT02637336|Device|Aerobic exercise|aerobic exercise of moderate intensity
201703|NCT02637336|Device|Aromatherapy|inhalation of eucalyptus essential oil
201704|NCT02637323|Drug|FX006 32 mg|Single 5 mL IA injection
201705|NCT02637323|Drug|TCA IR 40|Single 1 mL IA injection
201706|NCT02637310|Drug|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
201707|NCT02637310|Drug|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
201708|NCT02637297|Procedure|Hypnotherapy|Undergo hypnotherapy
201709|NCT02637297|Other|Questionnaire Administration|Ancillary studies
201710|NCT02637284|Drug|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.~Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
201711|NCT02637284|Drug|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
201712|NCT02637271|Other|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
201713|NCT02637271|Other|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
201714|NCT02637258|Other|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
201715|NCT02637245|Other|No intervention|No intervention
201716|NCT02637232|Other|Mirvaso® / Onreltea TM|
201717|NCT02637206|Drug|GSK2894512 Cream|GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
201718|NCT02637206|Drug|Vehicle Cream|Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
201719|NCT02637206|Drug|Empty Patch|Empty patches without any ingredients will be used as negative control.
201720|NCT02637193|Drug|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
201721|NCT02637193|Drug|Moxifloxacin|400 mg single dose moxifloxacin
201722|NCT02637193|Drug|Drug - placebo|Placebo administered for 16 days
201723|NCT02637180|Drug|anti-osteoporotic medication|check previous information
201724|NCT02637167|Drug|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
201725|NCT02637167|Drug|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
201726|NCT02637154|Behavioral|Motivational Interviewing|Motivational Interviewing method
201727|NCT02637154|Behavioral|Standard Education|Standard Education material will be used
201728|NCT02637141|Biological|AMG 714|A fully human anti-IL-15 monoclonal antibody
201729|NCT02637141|Biological|Placebo|Placebo comparator
201730|NCT02637128|Drug|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
201731|NCT02637128|Drug|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
201732|NCT02637115|Dietary Supplement|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
201733|NCT02637115|Dietary Supplement|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
201734|NCT02637115|Dietary Supplement|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
201735|NCT02637115|Dietary Supplement|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
201736|NCT02637102|Other|Not applicable - observational study|
201737|NCT02637076|Drug|Xyrem|single 3.0 gram dose
201738|NCT02637063|Behavioral|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
201739|NCT02637063|Behavioral|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
201740|NCT02637063|Other|Usual care|No intervention beyond participants' own medical care.
201743|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
201744|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
201745|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
201746|NCT02637024|Radiation|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
201747|NCT02637024|Radiation|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
201748|NCT02636972|Drug|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:~Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
201749|NCT02636959|Other|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
201750|NCT02636946|Drug|Bimatoprost SR|Up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose A administrations at Day 4 and Week 16 (Stage 2).
201751|NCT02636946|Drug|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
201752|NCT02636946|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
201753|NCT02636946|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
201754|NCT02636933|Other|Lung Function Assessment|Lung Function Assessment
201755|NCT02636920|Other|Therapeutic Education to the Patient (TEP)|"Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.~Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.~Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.~Assessing of the knowledges acquired by patients."
201756|NCT02636907|Drug|BI 695501 Autoinjector|
201757|NCT02636907|Drug|BI 695501 Prefilled syringe|
201758|NCT02636894|Device|Restylane Silk|
201759|NCT02636881|Procedure|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
201760|NCT02636881|Procedure|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
201761|NCT02636868|Drug|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
201762|NCT02636868|Drug|nCPAP|Nasal CPAP
201763|NCT02636842|Drug|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
201764|NCT02636829|Other|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
201765|NCT02636829|Other|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL *.~* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
201766|NCT02636816|Drug|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
201767|NCT02636803|Drug|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
201768|NCT02636803|Drug|albendazole|group receives one 400 mg dose of albendazole
201769|NCT02636790|Procedure|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
201770|NCT02636777|Other|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
201771|NCT02636764|Other|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
201772|NCT02636764|Device|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
201773|NCT02636764|Device|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
201774|NCT02636764|Device|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
201775|NCT02636764|Device|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
201776|NCT02636751|Behavioral|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
201777|NCT02636751|Device|Walking aid adjustment|Walking aid adjustment
201778|NCT02636751|Behavioral|Information about pain control|General information about pain control, such as ice application and medication usage
201779|NCT02636738|Device|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
201909|NCT02635711|Behavioral|Adapted Taekwondo training|Adapted Taekwondo training for beginners
201780|NCT02636725|Drug|Axitinib|Twice daily dosing of axitinib alone for the first 7 days, followed by concurrent axitinib administered twice daily at 5 mg PO twice daily, plus intravenous administration of pembrolizumab every 21 days. Intrapatient dose escalation of axitinib will be performed following an initial safety lead-in of 5 patients.
201781|NCT02636725|Drug|Pembrolizumab|Pembrolizumab 200 mg flat dose shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
201782|NCT02636725|Procedure|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
201783|NCT02636725|Procedure|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
201784|NCT02636712|Device|ImageReady™ MR Conditional Pacing System|
201785|NCT02636699|Biological|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
201786|NCT02636699|Biological|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
201787|NCT02636686|Drug|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
201788|NCT02636673|Procedure|Sigmoid Resection|
201789|NCT02636647|Biological|Fecal transplant|
201790|NCT02636634|Other|imaging|
201791|NCT02636621|Device|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
201792|NCT02636621|Other|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
201793|NCT02636595|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
201794|NCT02636582|Other|Laboratory Biomarker Analysis|Correlative studies
201795|NCT02636582|Drug|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
201796|NCT02636582|Biological|Sargramostim|Given ID
201797|NCT02636569|Drug|topical diclofenac daily|"Topical diclofenac will be applied daily for 30 days. Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from one actinic keratosis, one sun exposed area and one not sun exposed area. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have three biopsies taken; one AK, one sun exposed, and one non sun exposed."
201798|NCT02636569|Drug|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from three locations at the baseline visit. The biopsy will be taken from, one actinic keratosis, one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.~After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
201799|NCT02636556|Radiation|concurrent chemoradiation|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w*4.
201800|NCT02636543|Other|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
201801|NCT02636543|Other|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
201802|NCT02636530|Behavioral|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
201803|NCT02636530|Behavioral|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
201804|NCT02636517|Biological|Fecal Microbiota Transplant|Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
201805|NCT02636504|Device|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
201806|NCT02636491|Device|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
201807|NCT02636491|Device|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
201808|NCT02636478|Other|questionnaire for travel habits|questionnaire has been used to collect information about travelling
201809|NCT02636465|Other|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
201810|NCT02636452|Other|cardiopulmonary exercise test|
201811|NCT02636439|Behavioral|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
201812|NCT02636439|Behavioral|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
201813|NCT02636426|Drug|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
201910|NCT02635711|Behavioral|Control|Daily jogging
201814|NCT02636413|Drug|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
201815|NCT02636413|Dietary Supplement|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
201816|NCT02636400|Other|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
201817|NCT02636387|Drug|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and if <50 % improvement then increase to three 0.2 mg tablets at bedtime for 14 days
201818|NCT02636387|Drug|Placebo|Sugar pill manufactured to mimic 0.2 pill of desmopressin. Take two pills at bedtime, if no improvement in 14 days then will take 3 pills at bedtime for an additional 14 days
201819|NCT02636374|Behavioral|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
201820|NCT02636361|Drug|LY900014|Administered subcutaneously (SC)
201821|NCT02636361|Drug|Insulin lispro|Administered SC
201822|NCT02636348|Dietary Supplement|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
201823|NCT02636348|Dietary Supplement|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
201824|NCT02636335|Device|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
201825|NCT02636322|Drug|Cyclophosphamide|Given IV
201826|NCT02636322|Drug|Doxorubicin Hydrochloride|Given IV
201827|NCT02636322|Drug|Etoposide|Given IV
201828|NCT02636322|Drug|Ibrutinib|Given PO
201829|NCT02636322|Drug|Lenalidomide|Given PO
201830|NCT02636322|Drug|Prednisone|Given PO
201831|NCT02636322|Biological|Rituximab|Given IV
201832|NCT02636322|Drug|Vincristine Sulfate|Given IV
201833|NCT02636309|Behavioral|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
201834|NCT02636296|Other|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
201835|NCT02636296|Other|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
201836|NCT02636283|Drug|Entresto|Oral pills
201837|NCT02636283|Drug|Placebo group|The placebo pills
201838|NCT02636270|Drug|Increlex|Treat PAPP-A2 deficient patients with Increlex
201839|NCT02636257|Procedure|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
201840|NCT02636257|Procedure|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
201841|NCT02636244|Drug|SHAPE Gel|
201842|NCT02636231|Drug|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
201843|NCT02636231|Radiation|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
201844|NCT02636218|Drug|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
201845|NCT02636218|Drug|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
201846|NCT02636205|Device|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
201847|NCT02636192|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study.
201848|NCT02636179|Other|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
201849|NCT02636166|Other|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
201850|NCT02636166|Other|Professional pregnancy test|Alere Professional use pregnancy test
201851|NCT02636166|Other|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
201852|NCT02636153|Other|normal diet|Diet containing 1500mg of phosphorus
201853|NCT02636153|Other|restricted phosphate diet|Diet containing 500mg of phosphorus
201854|NCT02636140|Other|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
201855|NCT02636127|Other|blood samples|"one blood sample will be done for dosage and role of Fractalkine in the serum.~- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."
201856|NCT02636114|Procedure|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
201857|NCT02636101|Drug|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
201858|NCT02636088|Drug|Cetuximab|
201907|NCT02635737|Device|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
201859|NCT02636049|Drug|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
201860|NCT02636036|Biological|enadenotucirev|
201861|NCT02636036|Biological|nivolumab|
201862|NCT02636023|Device|SPhENo-Cardiograph|SPhENo-Cardiograph
201863|NCT02636010|Drug|Pembrolizumab|
201864|NCT02635997|Drug|antiresorptive therapy|
201865|NCT02635984|Drug|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
201866|NCT02635984|Drug|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
201867|NCT02635971|Procedure|Transcatheter arterial infusion|
201868|NCT02635971|Procedure|Intravenous chemotherapy|
201869|NCT02635971|Drug|Gemcitabine|
201870|NCT02635971|Drug|Oxaliplatin|
201871|NCT02635945|Drug|PBF-680|
201872|NCT02635945|Drug|Placebo|
201873|NCT02635932|Device|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
201874|NCT02635932|Device|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
201875|NCT02635919|Device|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
201876|NCT02635906|Other|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
201877|NCT02635906|Other|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
201878|NCT02635893|Drug|D-Cycloserine|100 mg of Seromycin by mouth will be administered
201879|NCT02635893|Drug|Placebo|placebo pill will be administered instead of medication by mouth
201880|NCT02635893|Other|Training|walking around a designated track at different speeds both forward and backward
201881|NCT02635893|Other|Stimulation|magnetic stimulation and electrical stimulation may be applied
201882|NCT02635893|Other|Placebo Stimulation|this is a fake stimulation that is administered but will be unknow to the subject.
201883|NCT02635880|Device|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
201884|NCT02635867|Drug|Resin-modified calcium silicate - TheraCal LC|
201885|NCT02635867|Drug|Calcium hydroxide - Dycal|
201886|NCT02635867|Drug|Resin-based dentin bonding agent|
201887|NCT02635854|Other|Septic choc group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
201888|NCT02635854|Other|Orthopedic surgery group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
201889|NCT02635841|Drug|Deferiprone|Deferiprone oral solution (80 mg/mL)
201890|NCT02635828|Drug|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
201891|NCT02635828|Drug|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
201892|NCT02635828|Drug|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
201893|NCT02635815|Procedure|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
201894|NCT02635802|Drug|Remifentanil|"a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time ＞1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min."
201895|NCT02635802|Drug|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
201896|NCT02635802|Drug|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time ＞1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
201897|NCT02635802|Drug|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
201898|NCT02635789|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
201899|NCT02635789|Drug|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
201900|NCT02635776|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
201901|NCT02635776|Biological|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
201902|NCT02635763|Procedure|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
201903|NCT02635763|Procedure|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
201904|NCT02635750|Drug|BI 409306|
201905|NCT02635750|Drug|Donepezil low dose|
201906|NCT02635750|Drug|Donepezil high dose|
201911|NCT02635698|Other|Optifast|medically-supervised weight management program
201912|NCT02635698|Other|Food-Based|low-energy, low-fat diet
201913|NCT02635685|Other|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
201914|NCT02635672|Drug|BAY 1251152|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
201915|NCT02635659|Other|Encapsulated nutrients|
201916|NCT02635659|Other|Placebo|
201917|NCT02635646|Other|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:~nutritional counseling,~physical activity counseling,~psychological counseling,~metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
201918|NCT02635646|Other|individual approach|"individual approach that includes:~nutritional and physical activity counseling in individual appointments,~metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
201919|NCT02635633|Device|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7*(DEF-DM1) [DEF = distance over EF; DM1 = distance over M1]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
201920|NCT02635607|Drug|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
201921|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
201922|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels＞600 pg/ml; and (iii) serum LH levels＞10 IU/l.
201923|NCT02635607|Drug|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
201924|NCT02635607|Drug|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
201925|NCT02635594|Dietary Supplement|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
201926|NCT02635594|Other|Placebo|1000mg cellulose + 475mg L-tartaric acid
201927|NCT02635581|Device|Delta TT acetabular cup|
201928|NCT02635568|Other|Cannabis Use|Observational Study
201929|NCT02635555|Drug|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
201930|NCT02635542|Drug|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
201931|NCT02635542|Drug|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
201932|NCT02635529|Procedure|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
201933|NCT02635529|Procedure|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
201934|NCT02635516|Device|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
201935|NCT02635503|Procedure|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
201936|NCT02635503|Procedure|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
201937|NCT02635477|Behavioral|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
201938|NCT02635477|Behavioral|Control|Behavioral: actigraphy device, step count measurement only
201939|NCT02635464|Biological|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
202416|NCT02632045|Drug|Placebo|600 mg capsule (3x 200 mg capsules)
201940|NCT02635464|Biological|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
201941|NCT02635464|Procedure|CABG|Patients underwent CABG alone.
201942|NCT02635438|Drug|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
201943|NCT02635438|Drug|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
201944|NCT02635425|Procedure|7 eggs collection|vaginal US
201945|NCT02635425|Procedure|Full eggs collection|vaginal US
201946|NCT02635412|Other|Scheduled timing of delivery|
201947|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
201948|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
201949|NCT02635386|Drug|Exenatide once weekly (EQW )|2 mg SC injection every 7 days
201950|NCT02635386|Drug|Dapagliflozin (DAPA)|One pill (10 mg) by mouth daily (QD) in am
201951|NCT02635386|Drug|EQW plus DAPA|2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
201952|NCT02635386|Drug|Dapagliflozin plus Glucophage (MET ER)|DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
201953|NCT02635386|Drug|Phentermine /Topiramate (PHEN/ TRP) ER|PHEN 3.75/TRP ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TRP ER 46mg- 1 pill by mouth once daily in am
201954|NCT02635360|Drug|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
201955|NCT02635360|Radiation|Brachytherapy|Radiation is done for standard clinical care purposes.
201956|NCT02635360|Drug|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
201957|NCT02635347|Procedure|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
201958|NCT02635347|Device|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
201959|NCT02635334|Drug|Montelukast 10 mg orally|
201960|NCT02635334|Other|Placebo|
201961|NCT02635308|Behavioral|"Unilaterally Biased Resistance Training / MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
201962|NCT02635295|Behavioral|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
201963|NCT02635282|Drug|intranasal ketamine|
201964|NCT02635282|Drug|intranasal fentanyl|
201965|NCT02635282|Drug|intranasal midazolam|
201966|NCT02635269|Other|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
201967|NCT02635256|Radiation|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
201968|NCT02635243|Drug|SAR438544|"Pharmaceutical form:solution~Route of administration: subcutaneous"
201969|NCT02635243|Drug|r-glucagon|"Pharmaceutical form:solution~Route of administration: subcutaneous"
201970|NCT02635243|Drug|insulin|"Pharmaceutical form:solution~Route of administration: intravenous"
201971|NCT02635230|Drug|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
201972|NCT02635217|Device|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
201973|NCT02635217|Device|room air insufflation|using standard care room air will be infused on demand
201974|NCT02635217|Procedure|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
201975|NCT02635217|Procedure|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
201976|NCT02635204|Drug|DFD06 Cream|Twice daily topical application for 14 days.
201977|NCT02635204|Drug|Vehicle Cream|Twice daily topical application for 14 days.
201978|NCT02635191|Drug|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
201979|NCT02635191|Drug|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
202017|NCT02634840|Procedure|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
202018|NCT02634827|Drug|Decitabine|Given IV
202019|NCT02634827|Other|Laboratory Biomarker Analysis|Correlative studies
202020|NCT02634827|Drug|Midostaurin|Given PO
203504|NCT02624973|Drug|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
201980|NCT02635178|Other|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to the psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
201981|NCT02635178|Other|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
201982|NCT02635165|Device|Thoracic osteosyntheses with Stracos|
201983|NCT02635152|Behavioral|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
201984|NCT02635152|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
201985|NCT02635139|Behavioral|Breakfast skipping|18h fasting period in the morning
201986|NCT02635139|Behavioral|Dinner skipping|18h fasting period in the evening
201987|NCT02635113|Device|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
201988|NCT02635100|Other|CPAP machine with MNT algorithm|"The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:~Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.~Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.~Five days with standard auto titration.~MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days."
201989|NCT02635087|Device|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
201990|NCT02635074|Drug|Cytarabine|Given IV
201991|NCT02635074|Drug|Ibrutinib|Given PO
201992|NCT02635074|Drug|Idarubicin|Given IV
201993|NCT02635061|Drug|ACY-241|
201994|NCT02635061|Drug|Nivolumab|
201995|NCT02635048|Procedure|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
201996|NCT02635048|Procedure|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
201997|NCT02635035|Drug|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
201998|NCT02635035|Drug|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
201999|NCT02635009|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo PCI using 3DCRT
202000|NCT02635009|Other|Cognitive Assessment|Ancillary studies
202001|NCT02635009|Radiation|Intensity-Modulated Radiation Therapy|Undergo PCI with HA using IMRT
202002|NCT02635009|Other|Laboratory Biomarker Analysis|Correlative studies
202003|NCT02635009|Other|Quality-of-Life Assessment|Ancillary studies
202004|NCT02634983|Drug|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
202005|NCT02634983|Drug|Placebo|Matching placebo
202006|NCT02634970|Drug|Ranibizumab|0.5 mg, intravitreal injection
202007|NCT02634957|Behavioral|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
202008|NCT02634944|Diagnostic Test|Vestibular Ocular Motor Screening Tool (VOMS)|Vestibular Ocular Motor Screening Tool (VOMS)
202009|NCT02634931|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
202010|NCT02634918|Other|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
202011|NCT02634905|Other|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
202012|NCT02634905|Other|Phone Call|
202013|NCT02634892|Device|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
202014|NCT02634879|Behavioral|Incentive Change|
202015|NCT02634853|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
202016|NCT02634853|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
202021|NCT02634814|Device|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
202022|NCT02634814|Other|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
202023|NCT02634814|Device|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
202024|NCT02634801|Drug|Fumaric Acid Esters|Administered orally
202025|NCT02634801|Drug|Methotrexate|Administered orally
202026|NCT02634801|Drug|Ixekizumab|Administered SC
202027|NCT02634788|Drug|Buprenorphine|Buprenorphine sublingual spray delivered via single 100 μL spray
202028|NCT02634788|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
202029|NCT02634775|Other|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
202030|NCT02634749|Other|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
202031|NCT02634749|Other|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
202032|NCT02634749|Other|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
202033|NCT02634736|Device|Exergame plus usual treatment|An individualised [i.e. frequency and duration will be set according to each participant's baseline levels] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
202034|NCT02634723|Biological|Octocog alfa (recombinant human coagulation factor VIII)|
202035|NCT02634710|Radiation|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
202036|NCT02634697|Behavioral|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
202037|NCT02634684|Drug|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
202038|NCT02634684|Drug|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
202039|NCT02634671|Other|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
202040|NCT02634671|Other|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
202041|NCT02634671|Other|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
202042|NCT02634658|Other|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
202043|NCT02634658|Other|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
202044|NCT02634658|Other|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
202110|NCT02634242|Other|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
202111|NCT02634229|Genetic|blood sample|
202112|NCT02634216|Dietary Supplement|Capros|250 mg BID
202045|NCT02634645|Procedure|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
202046|NCT02634645|Procedure|Esophagectomy|The esophagus is surgically removed
202047|NCT02634645|Drug|Chemotherapy|Chemical substances are used to treat cancer
202048|NCT02634645|Radiation|Radiation|Cancer cells are destroyed by radiation therapy.
202049|NCT02634632|Behavioral|Choosing to write advance directives|
202050|NCT02634619|Procedure|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
202051|NCT02634619|Procedure|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
202052|NCT02634606|Drug|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
202053|NCT02634606|Drug|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
202054|NCT02634606|Drug|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
202055|NCT02634593|Behavioral|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
202056|NCT02634580|Biological|Evolocumab|Administered by subcutaneous injection
202057|NCT02634580|Drug|Ezetimibe|Tablet for oral administration
202058|NCT02634580|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
202059|NCT02634580|Drug|Placebo Ezetimibe|Tablet for oral administration
202060|NCT02634567|Behavioral|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
202061|NCT02634541|Drug|Adalimumab|Biologic drug
202062|NCT02634541|Other|PET/CT imaging|PET/CT imaging
202063|NCT02634528|Drug|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
202064|NCT02634528|Drug|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
202065|NCT02634515|Drug|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
202066|NCT02634515|Drug|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
202067|NCT02634502|Procedure|radiofrequency ablation|
202068|NCT02634502|Drug|S-1|
202069|NCT02634489|Drug|Tamsulosin HCl|Oral
202070|NCT02634489|Drug|Solifenacin Succinate|Oral
202071|NCT02634489|Drug|EC905|Oral
202072|NCT02634476|Behavioral|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
202073|NCT02634476|Behavioral|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
202074|NCT02634463|Drug|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
202075|NCT02634463|Other|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
202208|NCT02633540|Radiation|IMRT Radiation|Radiation to Larynx
202209|NCT02633527|Drug|Placebo|
202210|NCT02633527|Drug|SPN-812 ER, Low Dose|
202211|NCT02633527|Drug|SPN-812 ER, Low-Medium Dose|
202076|NCT02634463|Drug|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent [eq.] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
202077|NCT02634463|Drug|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
202078|NCT02634450|Device|Alere q|
202079|NCT02634437|Drug|Ulipristal acetate|
202080|NCT02634424|Device|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
202081|NCT02634411|Drug|8 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days."
202082|NCT02634411|Drug|15 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).~Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days."
202083|NCT02634385|Procedure|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
202084|NCT02634385|Procedure|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
202085|NCT02634372|Behavioral|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
202086|NCT02634372|Behavioral|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
202087|NCT02634359|Device|EarlySense home device|Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
202088|NCT02634359|Procedure|Vaginal ultrasound|Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
202089|NCT02634359|Procedure|Blood Test|Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
202090|NCT02634346|Drug|ALK3831|Daily dosing
202091|NCT02634346|Drug|Olanzapine|Daily dosing
202092|NCT02634346|Drug|Placebo|Daily dosing
202093|NCT02634333|Procedure|Prompt Sham|A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
202094|NCT02634333|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
202095|NCT02634333|Procedure|Deferred laser|Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met
202096|NCT02634333|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
202097|NCT02634320|Drug|Aripiprazole Lauroxil|Monthly IM injection
202098|NCT02634307|Drug|ALKS 8700|Capsules taken twice daily
202099|NCT02634294|Drug|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
202100|NCT02634281|Drug|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
202101|NCT02634281|Drug|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
202102|NCT02634268|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
202103|NCT02634255|Drug|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
202104|NCT02634255|Drug|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
202105|NCT02634255|Drug|Propofol|
202106|NCT02634255|Drug|Fentanyl|
202107|NCT02634255|Other|Ringer Lactate|
202108|NCT02634255|Device|Acceleromyography device|
202109|NCT02634242|Other|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
202212|NCT02633527|Drug|SPN-812 ER, High-Medium Dose|
202213|NCT02633527|Drug|SPN-812 ER, High Dose|
202113|NCT02634203|Procedure|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
202114|NCT02634203|Drug|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
202115|NCT02634190|Other|Thinprep® LBC|liquid based cytology
202116|NCT02634190|Other|APTIMA® HPV Assay|in vitro diagnostic test
202117|NCT02634190|Other|HR HC2® HPV DNA|in vitro diagnostic test
202118|NCT02634190|Other|Colposcopy|Colposcopy
202119|NCT02634177|Genetic|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
202120|NCT02634177|Other|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
202121|NCT02634164|Dietary Supplement|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
202122|NCT02634164|Dietary Supplement|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
202123|NCT02634164|Dietary Supplement|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
202124|NCT02634151|Drug|Gemcabene 600 mg|2-300 mg tablets, 1 placebo tablet, QD, 84 days
202125|NCT02634151|Drug|Placebo|Placebo, 3 tabs QD, 84 days
202126|NCT02634138|Device|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
202127|NCT02634099|Device|blood measurement|Hemoglobin measurement
202128|NCT02634099|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
202129|NCT02634099|Device|hemoCue|non invasive method of hemoglobin measurement
202130|NCT02634073|Drug|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
202131|NCT02634073|Drug|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
202132|NCT02634060|Device|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
202133|NCT02634047|Device|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
202134|NCT02634047|Device|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
202135|NCT02634034|Drug|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
202136|NCT02634034|Drug|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
202137|NCT02634034|Drug|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
202138|NCT02634021|Drug|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
202139|NCT02634021|Drug|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
202140|NCT02634008|Drug|Paritaprevir/ritonavir/ombitasvir|
202141|NCT02634008|Drug|Dasabuvir|
202142|NCT02634008|Drug|Ribavirin|
202143|NCT02634008|Drug|Glecaprevir/pibrentasvir|
202144|NCT02633995|Procedure|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
202145|NCT02633969|Drug|Indomethacin Capsules low dose|
202146|NCT02633969|Drug|Indomethacin Capsules high dose|
202147|NCT02633956|Drug|Obeticholic Acid|Once a day (QD) by mouth (PO)
202148|NCT02633956|Drug|Atorvastatin|"Initiate treatment with Atorvastatin at Week 4 visit with a dose of 10 mg once daily (QD) by mouth (PO).~Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 visit if 10 mg daily is tolerated.~Atorvastatin may be titrated up or down at Week 12 visit as clinically indicated."
202149|NCT02633956|Drug|Placebo|Once a day (QD) by mouth (PO)
202150|NCT02633943|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
202151|NCT02633930|Drug|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
202152|NCT02633930|Drug|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
202153|NCT02633930|Drug|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
202214|NCT02633514|Drug|Cisplatin|25mg/m2,iv gtt,d1-3
202215|NCT02633514|Drug|Etoposide|75mg/m2,iv gtt,d1-3
202216|NCT02633514|Radiation|radiotherapy|60Gy/30Fx
203554|NCT02624661|Drug|Glycerol|
202154|NCT02633930|Drug|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
202155|NCT02633930|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
202156|NCT02633917|Behavioral|Motor control exercises|exercises to strength the lumbar musculature and control the posture
202157|NCT02633917|Behavioral|Standard exercises|general exercises
202158|NCT02633904|Procedure|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
202159|NCT02633904|Procedure|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
202160|NCT02633891|Behavioral|Balance exercise|tailored balance exercise program
202161|NCT02633891|Behavioral|Standard care|general health education and fall prevention classes
202162|NCT02633878|Drug|Chinese Herbal Medicine plus Progesterone Capsules|"New Shoutai Pill Granules plus Micronized Progesterone Capsules"
202163|NCT02633878|Drug|Chinese Herbal Medicine Placebo plus Progesterone Capsules Placebo|"New Shoutai Pill Granules Placebo plus Micronized Progesterone Capsules Placebo"
202164|NCT02633878|Drug|Chinese Herbal Medicine plus Progesterone Capsules Placebo|"New Shoutai Pill Granules plus Micronized Progesterone Capsules Placebo"
202165|NCT02633878|Drug|Chinese Herbal Medicine Placebo plus Micronized Progesterone|"New Shoutai Pill Granules Placebo plus Micronized Progesterone Capsules"
202166|NCT02633852|Drug|Aflibercept|
202167|NCT02633839|Drug|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
202168|NCT02633839|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
202169|NCT02633813|Drug|Naftifine hydrochloride 2%|Topical application for two weeks
202170|NCT02633813|Drug|Placebo|Topical application for two weeks
202171|NCT02633813|Drug|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
202172|NCT02633800|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
202173|NCT02633800|Drug|Cetuximab|Cetuximab 400 mg/mg/m^2 IV loading dose, followed by 250 mg/m^2 weekly
202174|NCT02633800|Drug|Cisplatin|Cisplatin at 100 mg/m^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
202175|NCT02633800|Drug|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
202176|NCT02633800|Drug|Placebo|Placebo to match patritumab
202177|NCT02633787|Biological|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
202178|NCT02633774|Drug|Propafenone|AAD(antiarrhythmic drug)
202179|NCT02633774|Drug|Apixaban|anti-coagulation
202180|NCT02633761|Drug|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
202181|NCT02633761|Drug|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
202182|NCT02633761|Drug|Misoprostol 200mcg|Buccal misoprostol 200mcg
202183|NCT02633748|Behavioral|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
202184|NCT02633735|Behavioral|appy-cds|See description under arm/group section
202185|NCT02633722|Behavioral|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
202186|NCT02633722|Behavioral|Lifestyle Intervention D|Time limiting feeding (12-9pm)
202187|NCT02633709|Drug|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
202188|NCT02633709|Other|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
202189|NCT02633709|Drug|Risdiplam|Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
202190|NCT02633696|Drug|silybin phosphatidylcholine|
202191|NCT02633696|Drug|Legalón SIL|
202192|NCT02633683|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
202193|NCT02633670|Device|Hemopatch|
202194|NCT02633670|Device|No Hemopatch|
202195|NCT02633657|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
202196|NCT02633644|Device|Harmony System|Percutaneous neuromodulation of the aortic wall
202197|NCT02633618|Biological|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
202198|NCT02633618|Biological|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
202199|NCT02633605|Device|First Sense Medical®|
202200|NCT02633592|Other|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
202201|NCT02633592|Other|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
202202|NCT02633579|Drug|erythromycin lactobionate|intravenous administration of erythromycin
202203|NCT02633579|Drug|Atropine|intravenous administration of atropine
202204|NCT02633579|Drug|Erythromycin with atropine|intravenous administration of erythromycin with saline
202205|NCT02633579|Drug|Saline|intravenous administration of saline
202206|NCT02633566|Device|Plantar orthoses|
202207|NCT02633553|Radiation|adjuvant radiotherapy|50Gy/25Fx
202217|NCT02633501|Drug|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
202218|NCT02633501|Drug|Gadobenate dimeglumine|Single IV bolus injection at a rate of 2 mL/second
202219|NCT02633501|Device|MRI|
202220|NCT02633488|Drug|Placebos|A 12 week single blind placebos
202221|NCT02633488|Drug|metformin|A 12 week single blind metformin
202222|NCT02633475|Genetic|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
202223|NCT02633462|Procedure|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
202224|NCT02633462|Drug|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
202225|NCT02633449|Behavioral|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks
202226|NCT02633449|Device|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
202227|NCT02633449|Device|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
202228|NCT02633436|Other|SLC1A5 expression|To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
202229|NCT02633423|Procedure|Use of PEEP before and after CPB|PEEP will be set in order to reach an airway pressure of 5 cmH2O
202230|NCT02633423|Procedure|No use of PEEP before and after CPB(ZEEP)|No PEEP will be used
202231|NCT02633423|Procedure|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB
202232|NCT02633423|Procedure|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
202233|NCT02633410|Procedure|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
202234|NCT02633397|Drug|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
202235|NCT02633397|Drug|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
202236|NCT02633384|Other|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
202237|NCT02633384|Other|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
202238|NCT02633371|Drug|Oxybutynin 3% gel|
202239|NCT02633358|Device|Therapeutic hypothermia group|Therapeutic hypothermia
202240|NCT02633345|Dietary Supplement|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
202241|NCT02633345|Dietary Supplement|Placebo|Placebo tablets
202242|NCT02633319|Behavioral|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
202243|NCT02633319|Other|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
202244|NCT02633306|Device|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
202245|NCT02633293|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
202246|NCT02633267|Behavioral|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
202247|NCT02633267|Behavioral|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
202248|NCT02633254|Device|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
202249|NCT02633241|Drug|Dexmedetomidine-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
202250|NCT02633228|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
202251|NCT02633215|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
202408|NCT02632110|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20 mW/cm2 for 8 minutes 20 seconds
202252|NCT02633202|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
202253|NCT02633202|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
202254|NCT02633189|Drug|Erlotinib|given orally 150 mg daily
202255|NCT02633189|Drug|Bevacizumab|15 mg/kg intravenously every 21 days.
202256|NCT02633176|Drug|Cetuximab|400 mg/m^2 intravenously on day 1,then 250 mg/m^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m^2 intravenously every week concurrent with radiotherapy.
202257|NCT02633176|Drug|Cisplatin|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m^2 intravenously every week concurrent with radiotherapy.
202258|NCT02633176|Drug|Docetaxel|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
202259|NCT02633176|Drug|Capecitabine|1000mg/m^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
202260|NCT02633176|Radiation|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
202261|NCT02633163|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
202262|NCT02633163|Drug|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution.
202263|NCT02633163|Drug|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
202264|NCT02633150|Other|Supplementation with red grapes polyphenol|
202265|NCT02633137|Drug|Lenalidomide|
202266|NCT02633137|Drug|R-CHOP|"Rituximab 375 mg/m^2 IVPB with premedications Day 1~Cyclophosphamide 750 mg/m^2 IVPB Day 1~Doxorubicin 50 mg/m^2 IVP Day 1~Vincristine 1.4 mg/m^2 IVP (capped at 2 mg) Day 1~Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
202267|NCT02633137|Drug|high-dose cytarabine (HIDAC)|
202268|NCT02633124|Device|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
202269|NCT02633124|Device|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
202270|NCT02633111|Other|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
202271|NCT02633111|Other|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
202272|NCT02633111|Device|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
202273|NCT02633098|Drug|Artesunate 200mg|Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery
202274|NCT02633098|Drug|Placebo|Matched placebo PO OD for 14 days prior to colorectal resection surgery
202275|NCT02633085|Device|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
202276|NCT02633072|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
202277|NCT02633059|Drug|Dexamethasone|Given PO
202278|NCT02633059|Drug|Idasanutlin|Given PO
202279|NCT02633059|Drug|Ixazomib Citrate|Given PO
202280|NCT02633059|Other|Laboratory Biomarker Analysis|Correlative studies
202281|NCT02633059|Other|Pharmacological Study|Correlative studies
202282|NCT02633046|Drug|Acthar 80 U 3x/week|Acthar 80 U 3x/week
202283|NCT02633046|Other|Placebo|Placebo 2x/week
202284|NCT02633046|Drug|Acthar 80 U 2x/week|Acthar 80 U 2x/week
202285|NCT02633033|Drug|H.P. Acthar® Gel (repository corticotropin injection)|
202286|NCT02633020|Biological|AMG 714|A fully human anti-IL-15 monoclonal antibody
202287|NCT02633020|Biological|Placebo|
202288|NCT02633007|Drug|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
202289|NCT02633007|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
202290|NCT02633007|Other|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
202291|NCT02632994|Drug|LY2503029|Administered orally.
202292|NCT02632981|Other|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
202293|NCT02632981|Other|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
202294|NCT02632968|Procedure|Pinhole surgery with and without buttons|
202295|NCT02632955|Drug|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
202296|NCT02632955|Procedure|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
202409|NCT02632097|Procedure|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:~0.5 ml of cyanoacrylate glue is used for mesh fixation"
202297|NCT02632942|Procedure|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:~60% or greater diameter of the main AVF~50% diameter of AVF with at least one more av>40% in diameter.~50% in diameter and divides into branches of same size.~av likely to interfere with cannulation on physical examination.~>30% in diameter and associated with stenosis at site of origin."
202298|NCT02632942|Procedure|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
202299|NCT02632916|Drug|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
202300|NCT02632916|Drug|Denosumab|Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
202301|NCT02632903|Drug|Zoledronic acid|
202302|NCT02632877|Drug|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
202303|NCT02632877|Drug|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
202304|NCT02632864|Radiation|Proton arm|Proton beam therapy
202305|NCT02632838|Device|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
202306|NCT02632825|Device|Nasal High Flow|Nasal High Flow Therapy
202307|NCT02632812|Drug|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
202308|NCT02632812|Drug|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
202309|NCT02632812|Drug|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
202310|NCT02632799|Device|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
202311|NCT02632799|Device|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
202312|NCT02632799|Device|CPAP|Nsal CPAP 5cm H2o by face mask
202313|NCT02632786|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
202314|NCT02632786|Drug|Placebo|Saline Bag
202315|NCT02632773|Behavioral|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
202316|NCT02632773|Behavioral|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
202317|NCT02632760|Drug|Ferric carboxymaltose|treatment for Iron deficient anaemia
202318|NCT02632760|Drug|Placebo|placebo - no active drug
202319|NCT02632747|Drug|Empagliflozin|Empagliflozin will be taken once daily
202320|NCT02632747|Drug|Placebo (matching empagliflozin)|Placebo will be taken once daily
202321|NCT02632747|Drug|ramipril|Ramipril will be taken once or twice daily
202322|NCT02632734|Device|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
202323|NCT02632734|Device|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
202324|NCT02632721|Drug|Decitabine|
202325|NCT02632721|Drug|BI 836858|BI 836858 weekly i.v. infusion
202326|NCT02632708|Drug|AG-120|
202327|NCT02632708|Drug|AG-221|
202328|NCT02632708|Drug|cytarabine|
202329|NCT02632708|Drug|daunorubicin|
202330|NCT02632708|Drug|idarubicin|
202331|NCT02632708|Drug|mitoxantrone|
202332|NCT02632708|Drug|etoposide|
202333|NCT02632695|Device|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
202334|NCT02632669|Radiation|Hemi gland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre - treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine 125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks,3,6,9,12,18,24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
202335|NCT02632656|Other|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
202336|NCT02632643|Behavioral|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
202880|NCT02628990|Other|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
202337|NCT02632630|Drug|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
202338|NCT02632630|Dietary Supplement|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
202339|NCT02632630|Drug|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
202340|NCT02632630|Dietary Supplement|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
202341|NCT02632617|Other|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
202342|NCT02632604|Behavioral|Computerized cognitive training|40 hours of a computerized cognitive training, given 1 hour daily
202343|NCT02632604|Behavioral|Computer games|
202344|NCT02632578|Biological|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
202345|NCT02632565|Drug|Lidocaine|
202346|NCT02632565|Drug|Saline|
202347|NCT02632552|Behavioral|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
202348|NCT02632552|Behavioral|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions and brief outpatient texting
202349|NCT02632539|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
202350|NCT02632539|Procedure|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
202351|NCT02632526|Drug|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
202352|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
202353|NCT02632526|Drug|AZD5718 placebo oral suspension|Single and multiple doses
202354|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
202355|NCT02632513|Device|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
202356|NCT02632500|Other|Quality of chest compressions|
202357|NCT02632487|Behavioral|Exercise|Center-based walking + balance, stretching, and light resistance
202358|NCT02632487|Behavioral|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
202359|NCT02632474|Drug|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
202360|NCT02632461|Behavioral|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
202361|NCT02632461|Behavioral|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
202362|NCT02632461|Behavioral|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
202363|NCT02632448|Drug|LY2880070|Capsules
202364|NCT02632448|Drug|Gemcitabine|50 to 600 milligrams per square meter of body surface area (mg/m2)
202365|NCT02632435|Device|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
202366|NCT02632435|Device|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
202367|NCT02632422|Other|Daily acute intermittent hypoxia (dAIH)|Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes which include intervals of 1.5 minute hypoxia (FIO2=0.10±0.02, i.e. 10% O2) and 1 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
202368|NCT02632422|Other|dSHAM|Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02). Participants will receive 5 consecutive days of daily room air (dSHAM).
202369|NCT02632422|Other|Walking|"Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes.~Walking practice will incorporate 5 walking-related tasks:~walking balance (e.g., walking with turns)~skilled walking tasks (e.g., negotiating obstacles)~walking with secondary task (e.g., walking and talking)~endurance~speed"
202370|NCT02632409|Biological|Nivolumab|
202371|NCT02632409|Other|Placebo|
202372|NCT02632396|Drug|Ixazomib|Given PO
202373|NCT02632396|Biological|Rituximab|Given IV
202410|NCT02632097|Procedure|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
202411|NCT02632071|Drug|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
202412|NCT02632071|Drug|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.~100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
202374|NCT02632383|Device|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:~Contact your health care provider (ask questions, set the agenda for the next clinical visit)~My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)~Chatroom~Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)~Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)~Tips packages (Receive a tip about alcohol, drivers license etc.)~To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)~Reminder"
202375|NCT02632370|Drug|Gliolan®|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
202376|NCT02632370|Procedure|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
202377|NCT02632357|Other|Spinal Manipulation|
202378|NCT02632344|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
202379|NCT02632331|Drug|ASP8825|Oral
202380|NCT02632318|Device|Light|30 minutes of dawn simulation
202381|NCT02632305|Drug|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
202382|NCT02632292|Device|Absorb GT1|Bioresorbable vascular scaffold
202383|NCT02632292|Device|Promus|Everolimus-eluting stent
202384|NCT02632279|Dietary Supplement|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
202385|NCT02632279|Dietary Supplement|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
202386|NCT02632279|Device|Stimulator ON|Participants will be tested while their stimulator is turned ON
202387|NCT02632279|Device|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
202388|NCT02632266|Dietary Supplement|Powder HMF|powder human milk fortifier
202389|NCT02632266|Dietary Supplement|Liquid HMF|Liquid human milk fortifier
202390|NCT02632253|Procedure|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
202391|NCT02632253|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
202392|NCT02632240|Other|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
202393|NCT02632227|Procedure|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
202394|NCT02632214|Other|fMRI measure|
202395|NCT02632201|Biological|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
202396|NCT02632201|Biological|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
202397|NCT02632188|Procedure|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
202398|NCT02632188|Biological|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
202399|NCT02632175|Biological|Adalimumab|every other week or weekly subcutaneous injection
202400|NCT02632162|Other|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
202401|NCT02632149|Device|PINS Vagus Nerve Stimulator|
202402|NCT02632136|Drug|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
202403|NCT02632136|Drug|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
202404|NCT02632110|Drug|ALA|20% ALA applied to face prior to light treatment
202405|NCT02632110|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
202406|NCT02632110|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10 mW/cm2 for 16 minutes 40 seconds
202407|NCT02632110|Procedure|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
202417|NCT02632032|Drug|Insulin|"Monitoring insulin therapy of campers based on their usual regimen (one of the following):~premixed insulin in the morning and evening,~premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,~regular insulin in the morning and afternoon, and premixed insulin in the evening.~Education of campers on different aspects of diabetes care:~monitoring of blood glucose~injection of insulin~adaptation of insulin doses according to blood glucose and during exercise~correction of hypoglycemia~dietary advice"
202418|NCT02632019|Drug|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
202419|NCT02632019|Biological|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.~PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
202420|NCT02632006|Biological|PIK-PD-1 cells|"DC cell suspension (1×10*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
202421|NCT02632006|Biological|DC-PMAT|"DC cell suspension (1×10*7 DC+ physiological saline~+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
202422|NCT02631993|Radiation|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320−400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2−1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3−5 times each week.
202423|NCT02631980|Drug|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
202424|NCT02631980|Drug|IV placebo|Intravenous 0.9% saline (250 ml)
202425|NCT02631967|Procedure|Kono anastomosis|Kono anastomosis
202426|NCT02631967|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
202427|NCT02631954|Drug|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
202428|NCT02631954|Drug|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
202429|NCT02631941|Drug|Z7200|
202430|NCT02631941|Drug|Symbicort Turbohaler|
202431|NCT02631941|Drug|Z7200 with charcoal|
202432|NCT02631941|Drug|Symbicort Turbohaler with charcoal|
202433|NCT02631941|Drug|Symbicort Turbohaler replicate|
202434|NCT02631928|Drug|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
202435|NCT02631928|Drug|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
202436|NCT02631902|Behavioral|Exercise|Community-based exercise program with 3 weekly exercise sessions
202437|NCT02631902|Behavioral|Dietary intervention|Community-based dietary intervention program
202438|NCT02631889|Device|Transcollation technology|The use transcollation technology for dissection during lung surgery
202439|NCT02631889|Device|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
202440|NCT02631876|Drug|IMGN853|
202441|NCT02631876|Drug|Paclitaxel|
202442|NCT02631876|Drug|Pegylated Liposomal Doxorubicin|
202443|NCT02631876|Drug|Topotecan|
202444|NCT02631863|Drug|Aminolaevulinic acid|Aminolaevulinic acid with illumination
202445|NCT02631863|Drug|Placebo|Placebo with illumination
202446|NCT02631850|Behavioral|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
202447|NCT02631850|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
202448|NCT02631850|Behavioral|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
202449|NCT02631850|Behavioral|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
202450|NCT02631837|Procedure|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
202451|NCT02631837|Procedure|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
202452|NCT02631824|Procedure|open reduction and internal fixation|Open reduction and internal fixation using an intramedullary nail
202453|NCT02631824|Device|TFNA|Trochanteric Femoral Nail Advance
202454|NCT02631824|Device|Augmentation (Cement)|Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
202455|NCT02631811|Other|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
202456|NCT02631798|Dietary Supplement|Food grade dye mucosal staining|mucosal staining with food grade dye
202500|NCT02631538|Drug|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
202457|NCT02631785|Other|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
202458|NCT02631772|Drug|Sofosbuvir/Ledipasvir x 12 weeks|
202459|NCT02631772|Drug|Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks|
202460|NCT02631759|Drug|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
202461|NCT02631759|Drug|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .~The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.~The decay phase takes place in two phases:~A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)~Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
202462|NCT02631746|Other|Laboratory Biomarker Analysis|Correlative studies
202463|NCT02631746|Biological|Nivolumab|Given IV
202464|NCT02631746|Other|Pharmacogenomic Study|Correlative studies
202465|NCT02631733|Drug|Ferumoxytol|Given IV
202466|NCT02631733|Other|Laboratory Biomarker Analysis|Correlative studies
202467|NCT02631733|Drug|Liposomal Irinotecan|Given IV
202468|NCT02631733|Procedure|Magnetic Resonance Imaging|Undergo MRI
202469|NCT02631733|Drug|Veliparib|Given PO
202470|NCT02631720|Procedure|Blood Draw|
202471|NCT02631720|Procedure|Bronchoscopy|
202472|NCT02631707|Other|High protein diet|The intervention diet is higher in protein than the control diet.
202473|NCT02631694|Drug|Propranolol|Intake of propranolol pill (40 milligram)
202474|NCT02631694|Drug|Placebo|Intake of placebo pill (40 milligram)
202475|NCT02631694|Other|Carbon dioxide|Inhalation of 35% carbon dioxide
202476|NCT02631694|Other|Compressed air|Inhalation of air
202477|NCT02631681|Behavioral|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
202478|NCT02631668|Drug|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
202479|NCT02631668|Drug|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
202480|NCT02631668|Drug|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
202481|NCT02631655|Other|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
202482|NCT02631642|Drug|HMPL-689|selective PI3Kδ inhibitor
202483|NCT02631642|Drug|HMPL-689 placebo|placebo of HMPL-689
202484|NCT02631629|Other|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
202485|NCT02631629|Other|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
202486|NCT02631616|Drug|Somatostatin|Monthly injections of Somatostatin
202487|NCT02631603|Drug|Placebo|Administer Placebo as anti-inflammatory
202488|NCT02631603|Drug|Prednisolone|Administer Prednisolone as anti-inflammatory
202489|NCT02631590|Drug|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
202490|NCT02631590|Drug|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
202491|NCT02631590|Drug|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
202492|NCT02631577|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
202493|NCT02631577|Drug|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
202494|NCT02631577|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
202495|NCT02631551|Drug|GSP 301 NS|FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
202496|NCT02631551|Drug|Olopatadine HCl NS|2 sprays in each nostril twice daily for 14 days
202497|NCT02631551|Drug|Mometasone furoate NS|2 sprays in each nostril twice daily for 14 days
202498|NCT02631551|Drug|GSP 301 Placebo NS|2 sprays in each nostril twice daily for 14 days
202499|NCT02631538|Drug|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
202501|NCT02631538|Drug|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
202502|NCT02631538|Drug|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
202503|NCT02631525|Drug|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
202504|NCT02631525|Drug|Propofol|Total intravenous anesthesia based on propofol
202505|NCT02631512|Device|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
202506|NCT02631512|Device|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
202507|NCT02631499|Procedure|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
202508|NCT02631499|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
202509|NCT02631499|Drug|lipiodol|lipiodol is a kind of embolization material used in TACE
202510|NCT02631486|Other|Physiotherapy|Passive exercises, active exercises, strengthening, stretching
202511|NCT02631473|Drug|50mg NANO-efavirenz|OD
202512|NCT02631473|Drug|400mg NANO-Lopinavir|BID
202513|NCT02631473|Drug|200mg NANO-Lopinavir|BID
202514|NCT02631473|Drug|100mg Ritonavir|BID
202515|NCT02631473|Drug|300mg NANO-Efavirenz|OD
202516|NCT02631473|Drug|600mg Sustiva|OD
202517|NCT02631473|Drug|200mg NANO-Efavirenz|OD
202518|NCT02631473|Drug|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
202519|NCT02631473|Drug|+/- 200mg NANO-Lopinavir|BID
202520|NCT02631473|Drug|+/- 200mg ritonavir NORVIR|BID
202521|NCT02631473|Drug|400mg Sustiva|
202522|NCT02631460|Drug|S1 80-120 mg/d|d1, every 3 weeks
202523|NCT02631460|Drug|pemetrexed 500 mg/m2|d1, every 3 weeks
202524|NCT02631460|Drug|carboplatin AUC=5|d1, every 3 weeks
202525|NCT02631447|Drug|LGX818|LGX818 450 mg p.o. od
202526|NCT02631447|Drug|MEK162|MEK162 45 mg p.o. bid
202527|NCT02631447|Drug|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
202528|NCT02631447|Drug|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
202529|NCT02631434|Procedure|sit-to-stand test|
202530|NCT02631434|Procedure|six-minutes walking test|
202531|NCT02631421|Procedure|Blood Sampling|
202532|NCT02631421|Other|Cardiac MRI|
202533|NCT02631408|Drug|Vancomycin|Locally, intrawound applied vancomycin powder
202534|NCT02631395|Other|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
202535|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
202536|NCT02631382|Procedure|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).~In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
202537|NCT02631369|Device|Heidelberg Spectralis OCT device|
202538|NCT02631356|Drug|Ringer's lactate solution|
202539|NCT02631356|Drug|Succinylated gelatin|
202540|NCT02631343|Behavioral|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
202541|NCT02631343|Other|Essential newborn care|
202542|NCT02631330|Other|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
202543|NCT02631317|Behavioral|Advance hospital notification by EMS|Advance hospital notification by EMS
202544|NCT02631317|Behavioral|stroke team notification|stroke team notification
202545|NCT02631317|Behavioral|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
202546|NCT02631317|Behavioral|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
202547|NCT02631317|Behavioral|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
202548|NCT02631304|Procedure|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
202549|NCT02631291|Behavioral|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
202550|NCT02631291|Behavioral|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
202551|NCT02631278|Device|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
202552|NCT02631265|Other|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
202553|NCT02631265|Other|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
202554|NCT02631265|Other|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
202555|NCT02631252|Drug|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
202556|NCT02631252|Drug|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
202557|NCT02631252|Drug|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
202558|NCT02631239|Drug|Methotrexate|1g/m2/d IV *1d
202559|NCT02631239|Drug|Etoposide|200mg/d PO *3d
202560|NCT02631239|Drug|Dexamethasone|40mg/d PO *3d
202561|NCT02631239|Drug|Pegaspargase|2500IU/m2/d IM *1d
202562|NCT02631239|Radiation|Radiotherapy|50-56Gy
202563|NCT02631200|Behavioral|Advance care plan|Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
202564|NCT02631187|Device|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
202565|NCT02631174|Drug|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
202566|NCT02631161|Other|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
202567|NCT02631161|Other|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
202568|NCT02631148|Drug|Melatonin|2mg controlled release melatonin tablet
202569|NCT02631148|Drug|Placebo|placebo tablet identical to circadin
202570|NCT02631135|Drug|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
202571|NCT02631135|Drug|Propofol|BIS values were arranged 40-60 until the end of operation
202572|NCT02631135|Drug|Dexmedetomidine|0.5 microgram/kg infusion, no changes
202573|NCT02631135|Drug|Rocuronium|0.5 mg/kg iv for intubation, no change
202574|NCT02631122|Procedure|Supraclavicular vs Retroclavicular Nerve Block|An ultrasound-guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% ropivicaine will be performed on patients scheduled for lower arm surgery; 25 ml to be delivered to the brachial plexus and 5 ml to the intercostal nerve
202575|NCT02631109|Drug|Pegaspargase|2000U/m2 day5
202576|NCT02631109|Drug|doxorubicin|25mg/m2 day1
202577|NCT02631109|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
202578|NCT02631109|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
202579|NCT02631096|Drug|ARB-001467|An IV infusion of ARB-001467
202580|NCT02631096|Other|Placebo|An IV infusion of placebo
202581|NCT02631083|Other|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
202582|NCT02631070|Drug|Luspatercept|
202583|NCT02631070|Other|Placebo|
202584|NCT02631057|Drug|Dabigatran|Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day
202585|NCT02631057|Drug|Warfarin|Warfarin tablet (adjustment by each patients)
202586|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with JCAR017 therapy. Treatment will include lymphodepleting chemotherapy followed by one dose of JCAR017 administered by intravenous (IV) injection.
202587|NCT02631044|Biological|JCAR017 (lisocabtagene maraleucel) 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017.
202588|NCT02631031|Drug|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
202589|NCT02631018|Behavioral|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
202590|NCT02631018|Behavioral|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
202591|NCT02631005|Other|"Walk With Ease"|Six-week walking program
202592|NCT02630992|Drug|Amoxicillin-Clavulanate potassium|
202593|NCT02630979|Behavioral|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
202594|NCT02630966|Drug|Vedolizumab|Vedolizumab 300 mg IV infusion
202595|NCT02630966|Drug|Placebo|0.9% sodium chloride IV infusion
202637|NCT02630706|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
202638|NCT02630706|Drug|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
202744|NCT02629991|Drug|Matched Placebo|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
202596|NCT02630953|Behavioral|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
202597|NCT02630953|Behavioral|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
202598|NCT02630927|Drug|AG-519|AG519 will be tested.
202599|NCT02630927|Drug|Placebo|Placebo will be tested.
202600|NCT02630914|Device|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
202601|NCT02630901|Drug|PRX003|
202602|NCT02630901|Other|Placebo|
202603|NCT02630888|Drug|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
202604|NCT02630888|Drug|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
202605|NCT02630875|Drug|A4250|A4250
202606|NCT02630862|Drug|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
202607|NCT02630862|Drug|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
202608|NCT02630849|Procedure|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
202609|NCT02630849|Procedure|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
202610|NCT02630836|Drug|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
202611|NCT02630836|Procedure|Surgical treatment|Isolated endomedullary nailing
202612|NCT02630823|Drug|MK-3475|
202613|NCT02630823|Procedure|Surgical resection (standard of care)|
202614|NCT02630823|Drug|Paclitaxel (standard of care)|
202615|NCT02630823|Drug|Carboplatin (standard of care)|
202616|NCT02630823|Radiation|Radiation (standard of care)|
202617|NCT02630823|Procedure|Endometrial biopsy|
202618|NCT02630823|Procedure|Peripheral blood draw|
202619|NCT02630810|Other|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
202620|NCT02630810|Other|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
202621|NCT02630797|Dietary Supplement|Blueberry Baseline|Before the study beginning, eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. A total of 150 days will be required for the equilibration of tracer in the body i.e. elimination from soft tissue and deposition in the bone. After equilibration, a baseline period of 42 days will occur, during which no blueberry products will be provided.
202622|NCT02630797|Dietary Supplement|Blueberry Low|One food or beverage product containing freeze-dried blueberry powder equivalent to 0.75 cups of fresh blueberries will be provided daily for 42 days.
202623|NCT02630797|Dietary Supplement|Blueberry Medium|Two food or beverage products containing freeze-dried blueberry powder equivalent to 1.5 cups of fresh blueberries will be provided daily for 42 days.
202624|NCT02630797|Dietary Supplement|Blueberry High|Four food or beverage products containing freeze-dried blueberry powder equivalent to 3 cups of fresh blueberries will be provided daily for 42 days.
202625|NCT02630784|Procedure|Non-Invasive Ventilation with Homecare ventilator|
202626|NCT02630784|Procedure|Non-Invasive Ventilation with ICU ventilator|
202627|NCT02630771|Procedure|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
202628|NCT02630758|Behavioral|Mindfulness-based Yoga|See study arm description.
202629|NCT02630758|Behavioral|Walking Control Condition|See study arm description.
202630|NCT02630745|Procedure|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
202631|NCT02630745|Procedure|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
202632|NCT02630732|Behavioral|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
202633|NCT02630732|Behavioral|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
202634|NCT02630719|Drug|Timolol eye drops|eye drops
202635|NCT02630719|Drug|Artificial tears|Placebo drop
202636|NCT02630706|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
202639|NCT02630706|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
202640|NCT02630706|Drug|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
202641|NCT02630693|Drug|Palbociclib 100mg|100mg PO daily
202642|NCT02630693|Drug|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
202643|NCT02630693|Drug|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
202644|NCT02630680|Drug|Eziclen®/Izinova®|
202645|NCT02630667|Other|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
202646|NCT02630667|Other|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
202647|NCT02630667|Other|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
202648|NCT02630654|Other|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
202649|NCT02630641|Drug|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
202650|NCT02630628|Drug|Tacrolimus|Dosage: start at 2mg twice a day, then taper as per protocol
202651|NCT02630628|Drug|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
202652|NCT02630615|Other|Blood draw|Whole blood will be collected using standard phlebotomy procedures
202653|NCT02630602|Dietary Supplement|Functional goat cheese|60 g per day during 12 weeks
202654|NCT02630602|Dietary Supplement|Control cheese|60 g per day during 12 weeks
202655|NCT02630589|Device|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
202656|NCT02630576|Device|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
202657|NCT02630563|Drug|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
202658|NCT02630563|Drug|Cyclosporine|Cyclosporine will be administered as per center practice.
202659|NCT02630563|Drug|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
202660|NCT02630550|Device|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
202661|NCT02630550|Device|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
202662|NCT02630524|Behavioral|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
202663|NCT02630511|Drug|Mannitol|
202664|NCT02630511|Drug|Methacholine|
202665|NCT02630511|Drug|Placebo|
202666|NCT02630511|Other|Rest|
202667|NCT02630511|Other|Exercise|
202668|NCT02630498|Procedure|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
202669|NCT02630485|Behavioral|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
202670|NCT02630485|Dietary Supplement|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
202671|NCT02630485|Drug|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
202672|NCT02630472|Drug|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
202673|NCT02630472|Drug|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
202674|NCT02630459|Drug|Placebo|Placebo Comparator
202675|NCT02630459|Drug|Erenumab|Investigational Product was dosed once monthly (QM) by subcutaneous injections at day 1 and weeks 4, 8, 12, 16, and 20.
202676|NCT02630446|Other|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
202677|NCT02630433|Procedure|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
202678|NCT02630433|Procedure|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
202679|NCT02630420|Drug|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
202680|NCT02630407|Biological|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
202681|NCT02630407|Other|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
202682|NCT02630394|Drug|Azithromycin|
202683|NCT02630381|Device|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (~500 bar) and short rise time (~20 ns), which are followed by a longer low-magnitude negative wave (~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.~Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
202684|NCT02630368|Drug|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
202685|NCT02630368|Drug|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
202686|NCT02630368|Drug|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
202687|NCT02630355|Other|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
202688|NCT02630342|Behavioral|Mock MRI scanner|Using a mock scanner for preparation for MRI
202689|NCT02630342|Behavioral|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
202690|NCT02630342|Behavioral|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
202691|NCT02630342|Behavioral|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
202692|NCT02630329|Procedure|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
202693|NCT02630329|Procedure|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
202694|NCT02630316|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
202695|NCT02630316|Drug|Placebo|Placebo administered four times daily
202696|NCT02630303|Device|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.~All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
202697|NCT02630303|Device|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.~All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
202698|NCT02630290|Drug|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
202699|NCT02630290|Drug|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
202700|NCT02630277|Drug|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
202701|NCT02630264|Drug|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL~E10A preparation:~Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.~Swirl gently. Do NOT shake.~Method of administration~E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.~After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.~Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
202702|NCT02630264|Drug|Paclitaxel injection|"Specification:~30mg/5mL,~Usage:~160mg/m2 on day 3, according to instruction."
202703|NCT02630264|Drug|Cisplatin injection|"Specification:~20mg~Usage:~Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
202879|NCT02628990|Other|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
202704|NCT02630251|Drug|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
202705|NCT02630238|Dietary Supplement|Branched-Chain Amino Acid Supplementation|All participants will partake in the same diet & exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
202706|NCT02630238|Other|Placebo|All participants will partake in the same diet & exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
202707|NCT02630238|Other|Exercise|Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
202708|NCT02630238|Other|Diet|Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
202709|NCT02630225|Behavioral|Critical Time Intervention|"The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:~Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.~Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.~Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers."
202710|NCT02630225|Other|Treatment as Usual|"Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:~All necessary medical care and scheduled follow-ups with subspecialty services~Evaluation by social work with referral to appropriate community services~Screening for alcohol use~Discharge planning services~Financial counseling"
202711|NCT02630225|Behavioral|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
202712|NCT02630225|Other|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
202713|NCT02630199|Drug|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
202714|NCT02630199|Drug|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
202715|NCT02630186|Drug|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
202716|NCT02630186|Drug|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
202717|NCT02630173|Procedure|Scaling and root planing|Scaling and root planing was done in both the groups
202718|NCT02630173|Other|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
202719|NCT02630160|Drug|Bupivacaine hydrochloride|Intraarticular infusion with bupivacaine
202720|NCT02630160|Other|Physiological Saline|Intraarticular infusion physiological serum
202721|NCT02630147|Other|Vanilla scent|"A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).~In addition, a 3-hour polysomnography will be done in a sub-sample on the morning following the night recording with vanilla solution."
202722|NCT02630134|Other|These patients receive the Baeta device and take it home|
202723|NCT02630121|Drug|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
202724|NCT02630121|Drug|Placebo|Proportion of the subjects with 50% reduction in AHI.
202725|NCT02630108|Procedure|Thermal Ablation|Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.
202726|NCT02630108|Drug|EADM|EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
202727|NCT02630108|Drug|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
202728|NCT02630108|Other|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
202729|NCT02630095|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
202730|NCT02630095|Device|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
202731|NCT02630082|Procedure|Circumcision|
202732|NCT02630082|Procedure|Flexible sigmoidoscopy|
202733|NCT02630069|Drug|CDP-choline|CDP-choline 500mg once a day for 12 weeks
202734|NCT02630069|Drug|Placebo|Placebo 500mg once a day for 12 weeks
202735|NCT02630069|Behavioral|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
202736|NCT02630043|Drug|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
202737|NCT02630043|Drug|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
202738|NCT02630030|Drug|Ixazomib|Given PO
202739|NCT02630017|Drug|methylphenidate|double-blind, counter-balanced administration
202740|NCT02630017|Drug|Placebo|double-blind, counter-balanced administration
202741|NCT02630004|Drug|Melatonin oral gel 3%|
202742|NCT02630004|Drug|Placebo oral gel|
202743|NCT02629991|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
202745|NCT02629978|Procedure|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
202746|NCT02629965|Drug|tiotropium|fixed dose combination
202747|NCT02629965|Drug|olodaterol|fixed dose combination
202748|NCT02629965|Drug|tiotropium|
202749|NCT02629952|Other|Blueberry Tea|Blueberry Tea
202750|NCT02629939|Behavioral|course for learning CPR|
202751|NCT02629926|Other|GH Replacement (NutropinAq®)|GH Replacement continued.
202752|NCT02629926|Other|No additional treatment|GH Replacement not continued.
202753|NCT02629913|Device|mementor somnium|
202754|NCT02629913|Other|wait list|delayed access to mementor somnium
202755|NCT02629900|Behavioral|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
202756|NCT02629887|Device|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
202757|NCT02629887|Device|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
202758|NCT02629887|Device|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
202759|NCT02629874|Drug|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
202760|NCT02629874|Drug|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
202761|NCT02629874|Drug|Placebo|
202762|NCT02629861|Drug|Fremanezumab|"Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site."
202763|NCT02629861|Drug|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
202764|NCT02629848|Drug|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
202765|NCT02629848|Drug|Placebo|Motesanib placebo-matching tablets
202766|NCT02629848|Drug|Paclitaxel|Paclitaxel IV
202767|NCT02629848|Drug|Carboplatin|Carboplatin IV
202768|NCT02629835|Other|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
202769|NCT02629835|Other|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
202770|NCT02629822|Drug|MK-1439A|A single FDC tablet of MK-1439 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg will be administered orally, once daily for up to 96 weeks. For some participants who continue into the study extension, study treatment will continue for an additional 96 weeks, approximately, through a total of approximately 192 weeks of treatment.
202771|NCT02629809|Drug|Cyclophosphamide|Given IV
202772|NCT02629809|Drug|Fludarabine Phosphate|Given IV
202773|NCT02629809|Drug|Ibrutinib|Given PO
202774|NCT02629809|Other|Laboratory Biomarker Analysis|Correlative studies
202775|NCT02629809|Biological|Obinutuzumab|Given IV
202776|NCT02629796|Other|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
202777|NCT02629783|Other|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
202778|NCT02629783|Other|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
202779|NCT02629783|Drug|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
202780|NCT02629770|Drug|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
202781|NCT02629757|Drug|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
202782|NCT02629744|Drug|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
202783|NCT02629744|Device|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
202784|NCT02629731|Device|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
202785|NCT02629718|Drug|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
202786|NCT02629718|Procedure|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
202787|NCT02629705|Dietary Supplement|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
202788|NCT02629705|Dietary Supplement|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
202789|NCT02629692|Drug|K0706|Oral administration
202790|NCT02629692|Drug|Placebo|Part A only
202791|NCT02629679|Behavioral|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
202792|NCT02629679|Behavioral|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
202793|NCT02629666|Behavioral|ERS and/or Self-management Strategies|
202794|NCT02629653|Device|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
202795|NCT02629640|Other|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
202796|NCT02629640|Other|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
202797|NCT02629640|Other|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
202798|NCT02629640|Other|Blood or buccal sample|Codon-129 genotyping; storage for future research.
202799|NCT02629640|Other|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
202800|NCT02629627|Dietary Supplement|Conjugated linoleic acid/Leucine|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal during 12 weeks.
202801|NCT02629627|Drug|Metformin|Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 12 weeks
202802|NCT02629627|Dietary Supplement|Placebo of ACL/Leucine|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) during 12 weeks.
202803|NCT02629627|Other|Placebo of Metformin|homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
202804|NCT02629614|Device|Cala ONE Device|The Cala ONE device is a wrist-worn stimulator which applies transcutaneous electrical stimulation non-invasively to the median and radial nerves of an individual through disposable hydrogel electrodes.
202805|NCT02629601|Behavioral|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
202806|NCT02629601|Behavioral|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
202807|NCT02629601|Behavioral|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
202808|NCT02629601|Behavioral|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
202809|NCT02629601|Behavioral|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
202810|NCT02629588|Behavioral|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
202811|NCT02629575|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
202812|NCT02629562|Biological|B12019 and Neulasta|GCSF, Growth Colony Stimulating Factor
202813|NCT02629549|Drug|OTL38|Infusion of OTL38 prior to surgery
202814|NCT02629536|Drug|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
202815|NCT02629523|Drug|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
202816|NCT02629510|Drug|Tachosil|
202817|NCT02629497|Dietary Supplement|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
202818|NCT02629497|Dietary Supplement|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
202819|NCT02629484|Other|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
202820|NCT02629471|Behavioral|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
202821|NCT02629458|Procedure|Treatment by Surgical resection|
202822|NCT02629458|Procedure|Stereotactic Ablative Radiotherapy (SABR)|
202823|NCT02629445|Device|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
202824|NCT02629419|Drug|Amphotericin B|Lipid crystal nano-particle formulation of amphotericin B
202825|NCT02629406|Other|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
202826|NCT02629393|Drug|ORGN001 (formerly ALXN1101)|
202827|NCT02629380|Biological|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
202828|NCT02629380|Procedure|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
202829|NCT02629367|Drug|Vorapaxar|
202830|NCT02629367|Drug|Asprin|
202831|NCT02629367|Drug|Clopidogrel|
202832|NCT02629354|Drug|Ibuprofen|
202833|NCT02629354|Drug|Caffeine|
202834|NCT02629354|Drug|Ibuprofen|
202835|NCT02629341|Dietary Supplement|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:~Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
202836|NCT02629341|Dietary Supplement|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
202837|NCT02629328|Device|CardioCel|Treatment with CardioCel implant
202838|NCT02629315|Other|Carnoy's solution|
202839|NCT02629315|Other|10% neutral buffered formaldehyde|
202840|NCT02629302|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
202841|NCT02629302|Other|standard therapy|standard physiotherapy, speech therapy and occupational therapy
202842|NCT02629289|Drug|HSP-130|
202843|NCT02629289|Drug|US-approved Neulasta|
202844|NCT02629289|Drug|EU-approved Neulasta|
202845|NCT02629276|Other|neurodynamic testing|
202846|NCT02629263|Dietary Supplement|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
202847|NCT02629250|Procedure|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR <100 bpm, Hb >8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV >10% or blood loss >250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
202848|NCT02629250|Procedure|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
202849|NCT02629237|Other|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
202850|NCT02629224|Drug|ASP8825|Oral
202851|NCT02629211|Device|NaviAid™ AB|NaviAid™ AB Procedure
202852|NCT02629159|Drug|Placebo for Adalimumab|Administered by subcutaneous injection once every other week
202853|NCT02629159|Drug|Adalimumab|Administered by subcutaneous injection once every other week
202854|NCT02629159|Drug|Placebo for Upadacitinib|Tablets taken orally once a day
202855|NCT02629159|Drug|Upadacitinib|Tablets taken orally once a day
202856|NCT02629146|Drug|Midazolam|
202857|NCT02629146|Drug|Fentanyl|
202858|NCT02629146|Drug|Isotonic saline|
202859|NCT02629133|Behavioral|SHE Program|The SHE program is specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It is also tailored to participants' alcohol or substance use status, and designed to reach participants across levels of motivation for change. The content of SHE is theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
202860|NCT02629120|Drug|Campath|a humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complementmediated lysis and antibodydependent cellular toxicity. for this study, being used as part of the conditioning regimen. Given IV (dose escalation) over 5 days per package insert and and standard of practice
202861|NCT02629120|Drug|Busulfan IV|an alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of the conditioning regimen for its myelosuppressive properties. Given IV over 2 or 3 days depending on donor cells (sibling vs. unrelated donors) per package insert and standard of practice
202862|NCT02629120|Drug|Sirolimus|
202863|NCT02629120|Drug|cyclophosphamide|Cyclophosphamide is an antineoplastic and for this study being used for its immunosuppresive mechanism of action. Patient will be given Cyclophosphamide 50 mg/kg/d IV per package insert and standand of care on Day +3 and 4 after receiving the cells
202864|NCT02629094|Drug|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
202865|NCT02629081|Other|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
202866|NCT02629068|Behavioral|PURPOSE|"The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.~Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together"
202867|NCT02629055|Other|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
202868|NCT02629042|Procedure|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
202869|NCT02629042|Drug|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
202870|NCT02629029|Procedure|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
202871|NCT02629029|Device|Computed tomography angiography (CTA)|
202872|NCT02629016|Other|Mindfulness|
202873|NCT02629016|Other|Wellness|
202874|NCT02629003|Drug|[11C]Cimbi-36|
202875|NCT02629003|Drug|[11C]Cimbi-36-5|
202876|NCT02628990|Other|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
202877|NCT02628990|Other|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
202878|NCT02628990|Other|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
202881|NCT02628977|Behavioral|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
202882|NCT02628977|Behavioral|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
202883|NCT02628964|Device|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
202884|NCT02628951|Drug|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
202885|NCT02628951|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
202886|NCT02628938|Other|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
202887|NCT02628938|Other|Miswak stick|Miswak stick twice a day for 7 days
202888|NCT02628938|Other|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
202889|NCT02628925|Device|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
202890|NCT02628912|Other|blood draw|
202891|NCT02628912|Behavioral|study questionnaire|
202892|NCT02628912|Other|cardiopulmonary exercise testing (CPET)|
202893|NCT02628912|Other|DXA (dual-energy x-ray absorptiometry) scan|
202894|NCT02628899|Device|Transfemoral TAVR|
202895|NCT02628899|Device|SAVR|
202896|NCT02628886|Biological|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
202897|NCT02628886|Biological|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
202898|NCT02628886|Other|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
202899|NCT02628873|Device|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
202900|NCT02628860|Drug|Ferinject (Ferric Carboxymaltose)|"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .~Study drug may be administered as IV drip infusion or IV undiluted bolus injection."
202901|NCT02628847|Drug|sildenafil citrate|
202902|NCT02628847|Drug|Placebo|
202903|NCT02628834|Other|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
202904|NCT02628834|Other|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
202905|NCT02628821|Other|Preterm Infants treated with non-invasive ventilation.|
202906|NCT02628795|Behavioral|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
202907|NCT02628795|Other|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
202908|NCT02628782|Device|InSeal's Vascular Closure Device|
202909|NCT02628769|Drug|Solithromycin|
202910|NCT02628769|Drug|Placebo|
202911|NCT02628756|Procedure|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
202912|NCT02628743|Drug|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
202913|NCT02628730|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
202914|NCT02628730|Device|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
202915|NCT02628704|Drug|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
202916|NCT02628704|Drug|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
202917|NCT02628704|Drug|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
202918|NCT02628704|Drug|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
202919|NCT02628691|Other|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
202920|NCT02628678|Dietary Supplement|FOS|
202921|NCT02628665|Drug|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
202922|NCT02628665|Device|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
202923|NCT02628652|Dietary Supplement|GOS|
202924|NCT02628652|Dietary Supplement|GLOS|
202925|NCT02628652|Dietary Supplement|FOS|
202926|NCT02628639|Device|high-density electroencephalography|
202927|NCT02628626|Drug|Colesevelam|Patients who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
202928|NCT02628626|Drug|Clonidine|Patients who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
202929|NCT02628626|Other|Placebo|Placebo will be identical in appearance to the active drug.
202930|NCT02628613|Drug|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations
202931|NCT02628613|Drug|Paclitaxel plus Epirubicin|standard neoadjuvant chemotherapy
202932|NCT02628600|Drug|LAI 590 mg|LAI 590 mg QD: administered by inhaling drug product that had been aerosolized in an investigational eFlow nebulizer over approximately 14 minutes
202933|NCT02628600|Drug|Multi-drug regimen|Multidrug antimycobacterial regimen from study INS-212
202934|NCT02628587|Drug|Generic clopidogrel|"Comparison of different brands of clopidogrel:~*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
202935|NCT02628587|Drug|Patent clopidogrel|"Comparison of different brands of clopidogrel:~*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
202936|NCT02628574|Drug|TRX518 monotherapy|comparison of different (ascending) doses of TRX518 monotherapy
202937|NCT02628574|Drug|TRX518 with gemcitabine|comparison of different (ascending) doses of TRX518 in combination with gemcitabine
202938|NCT02628574|Drug|TRX518 with pembrolizumab|comparison of different (ascending) doses of TRX518 in combination with pembrolizumab
202939|NCT02628574|Drug|TRX518 with nivolumab|comparison of different (ascending) doses of TRX518 in combination with nivolumab
202940|NCT02628561|Device|Transcranial direct current stimulation|
202941|NCT02628561|Behavioral|Constraint-Induced Movement Therapy|
202942|NCT02628548|Behavioral|Cognitive training program|8 week cognitive training program
202943|NCT02628535|Biological|MGD009|B7-H3 x CD3 DART protein
202944|NCT02628522|Other|ADRCs therapy|Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
202945|NCT02628522|Device|Celution|Adipose derived regenerative cell isolation
202946|NCT02628522|Device|Tulip cannulas|Lipoaspiration
202947|NCT02628522|Other|20mL Lidocaine 2% and Epinephrine 1:100 000|Infiltration prior to liposuction
202948|NCT02628509|Device|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
202949|NCT02628496|Drug|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
202950|NCT02628496|Device|Confocal laser microlaryngoscopy|
202951|NCT02628496|Procedure|Biopsy (standard of care)|
202952|NCT02628496|Procedure|KTP laser photoablation (standard of care)|
202953|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
202954|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
202955|NCT02628470|Procedure|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
202956|NCT02628470|Procedure|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
202957|NCT02628470|Procedure|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
202958|NCT02628457|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
202959|NCT02628444|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
202960|NCT02628444|Biological|Placebo (NaCl 0.9%)|0.5 mL, Subcutaneous
202961|NCT02628431|Device|Elfi tech monitor|
202962|NCT02628418|Other|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
202963|NCT02628418|Device|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:~A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);~7 min of a number sequence (counting from one to five);~A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)~A sequence of wave-like finger movements (7 min)~A sequence of fist opening/closing (7 min)~A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
202964|NCT02628418|Other|Specific hand rehabilitation performed by physiotherapist|"The activities were:~Flexion-extension of the fingers (10 min);~Thumb opposition with the other fingers keeping the forearm in supine position (10 min);~Adduction and abduction of the fingers (10 min);~Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
202965|NCT02628405|Drug|Carboplatin|Given IV
202966|NCT02628405|Drug|Etoposide|Given IV
202967|NCT02628405|Drug|Ifosfamide|Given IV
202968|NCT02628405|Other|Laboratory Biomarker Analysis|Correlative studies
202969|NCT02628405|Drug|Lenalidomide|Given PO
202970|NCT02628405|Biological|Rituximab|Given IV
202971|NCT02628392|Drug|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
202972|NCT02628392|Drug|Sitagliptin|capsules
202973|NCT02628392|Drug|placebo|matching DS-8500a tablets and sitagliptin capsules
203063|NCT02627677|Drug|ponatinib 30 mg QD|ponatinib 30 mg, taken orally once daily
203064|NCT02627677|Drug|ponatinib 15 mg QD|ponatinib 15 mg, taken orally once daily
203065|NCT02627677|Drug|nilotinib 400 mg BID|nilotinib 400 mg, taken orally twice daily
203066|NCT02627664|Other|observational study|natural history of non dopaminergic signs
203154|NCT02627131|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
202974|NCT02628366|Other|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the nurse will set the dialysate temperature 0.5 to 0.9 °C below each patient's body temperature (measured before starting the hemodialysis treatment) to a minimum of 35.5°C.
202975|NCT02628353|Dietary Supplement|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
202976|NCT02628353|Dietary Supplement|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
202977|NCT02628340|Other|Ex-vivo analysis|
202978|NCT02628301|Dietary Supplement|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
202979|NCT02628301|Other|Normocaloric diet|Normocaloric diet
202980|NCT02628288|Device|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
202981|NCT02628275|Behavioral|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
202982|NCT02628275|Behavioral|Light physical activity|40-55% maximum heart rate for 150min/week
202983|NCT02628262|Procedure|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
202984|NCT02628249|Dietary Supplement|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
202985|NCT02628249|Dietary Supplement|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
202986|NCT02628249|Dietary Supplement|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
202987|NCT02628249|Dietary Supplement|Essential amino acids|Essential amino acids modeled after egg protein.
202988|NCT02628249|Dietary Supplement|Non essential amino acids|Non essential amino acids modeled after egg protein.
202989|NCT02628236|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
202990|NCT02628236|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
202991|NCT02628223|Procedure|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
202992|NCT02628223|Device|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
202993|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
202994|NCT02628197|Dietary Supplement|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
202995|NCT02628197|Procedure|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
202996|NCT02628184|Other|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
202997|NCT02628171|Other|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
202998|NCT02628171|Other|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
202999|NCT02628158|Procedure|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
203000|NCT02628145|Behavioral|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
203001|NCT02628145|Behavioral|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
203002|NCT02628132|Drug|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
203003|NCT02628132|Drug|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
203067|NCT02627651|Other|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
203068|NCT02627638|Other|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
203004|NCT02628119|Procedure|Intra-procedural access flow|"Intra-procedure access flow technique:~Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
203005|NCT02628119|Procedure|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
203006|NCT02628106|Drug|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
203007|NCT02628093|Device|THUNDERBEAT|Tissue dissection and vessels ligation
203008|NCT02628093|Device|LIGASURE|Tissue dissection and vessels ligation
203009|NCT02628080|Drug|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
203010|NCT02628067|Biological|pembrolizumab|intravenous infusion
203011|NCT02628054|Biological|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
203012|NCT02628054|Biological|Placebo|Saline injection given 7 days apart
203013|NCT02628041|Radiation|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.~The catheters are removed at the end of the procedure."
203014|NCT02628041|Radiation|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.~A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
203015|NCT02628028|Drug|LY3337641|Administered orally
203016|NCT02628028|Drug|Placebo|Administered orally
203017|NCT02628002|Device|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
203018|NCT02628002|Device|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
203019|NCT02627989|Drug|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
203020|NCT02627989|Drug|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
203021|NCT02627976|Device|Compression vest, Thuasne|Wearing a compression 4 days/weel with a minumum of 6 hours per day
203022|NCT02627963|Drug|tivozanib hydrochloride|tivozanib hydrochloride
203023|NCT02627963|Drug|Sorafenib|Sorafenib
203024|NCT02627950|Drug|Morphinhydrochloricum|5 mg morphine intravenously
203025|NCT02627950|Drug|Metoclopramide|10 mg MCP intravenously
203026|NCT02627950|Drug|Ticagrelor|180 mg ticagrelor orally
203027|NCT02627950|Drug|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
203028|NCT02627911|Device|Diabeloop System|Insulin delivery
203029|NCT02627911|Device|Continuous Glucose Monitoring|
203030|NCT02627911|Device|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
203031|NCT02627911|Dietary Supplement|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
203032|NCT02627898|Drug|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
203033|NCT02627898|Drug|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
203034|NCT02627885|Behavioral|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
203035|NCT02627885|Other|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
203036|NCT02627859|Device|Durolane SJ|1ml single intra-articular injection in ankle
203037|NCT02627846|Device|EVLA|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
203069|NCT02627625|Drug|Tiotropium|4 inhalations
203070|NCT02627612|Behavioral|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
204629|NCT02616783|Drug|3TC|Tablet administered orally
203038|NCT02627846|Device|ClariVein®|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
203039|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
203040|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
203041|NCT02627846|Drug|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
203042|NCT02627846|Drug|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
203043|NCT02627833|Other|observation|Record lung function, Lung clearance index, inflammatory status
203044|NCT02627820|Drug|Isis 420915/GSK 299872|Open label study in comparison to historic control.
203045|NCT02627807|Radiation|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
203046|NCT02627807|Radiation|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
203047|NCT02627807|Drug|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
203048|NCT02627807|Drug|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
203049|NCT02627807|Drug|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
203050|NCT02627807|Drug|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
203051|NCT02627794|Device|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
203052|NCT02627794|Device|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
203053|NCT02627768|Drug|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
203054|NCT02627755|Device|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
203055|NCT02627755|Device|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
203056|NCT02627742|Device|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
203057|NCT02627729|Device|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
203058|NCT02627729|Device|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
203059|NCT02627716|Procedure|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.~The booklet outlines four avenues to consider:~Contact details / contact person~Treatment and current follow-ups~Medical care in the event of a crisis~Practical aid in the event of a crisis~Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
203060|NCT02627703|Other|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
203061|NCT02627690|Other|islet transplanted|islet transplantation
203062|NCT02627690|Other|non islet transplanted|no islet transplantation (for a non nephrologic reason)
203071|NCT02627612|Behavioral|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
203072|NCT02627599|Device|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
203073|NCT02627586|Other|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
203074|NCT02627586|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
203075|NCT02627573|Procedure|Unrelated allogeneic stem cell transplantation|
203076|NCT02627573|Drug|Busulfan|
203077|NCT02627573|Drug|Fludarabine monophosphate|
203078|NCT02627573|Drug|Tacrolimus|
203079|NCT02627573|Drug|Mycophenolate mofetil|
203080|NCT02627573|Drug|Cyclophosphamide|
203081|NCT02627573|Drug|Thymoglobulin|
203082|NCT02627560|Drug|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
203083|NCT02627560|Drug|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
203084|NCT02627547|Behavioral|Normal training|5-10 hours of endurance training each week
203085|NCT02627547|Behavioral|De-training|No training
203086|NCT02627534|Procedure|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
203087|NCT02627534|Procedure|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
203088|NCT02627521|Procedure|PRU guided CABG|Coronary Artery Bypass Surgery
203089|NCT02627521|Procedure|CABG per standard of care|Coronary Artery Bypass Surgery
203090|NCT02627521|Device|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
203091|NCT02627521|Drug|Ticagrelor|Ticagrelor administration prior to randomization
203092|NCT02627508|Drug|Pregnenolone|orally administered Pregnenolone capsules
203093|NCT02627508|Drug|Placebo|orally administered placebo capsules
203094|NCT02627495|Device|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
203095|NCT02627482|Device|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.~The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
203096|NCT02627469|Behavioral|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
203097|NCT02627469|Device|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
203098|NCT02627469|Device|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
203099|NCT02627456|Biological|PfSPZ Vaccine|PfSPZ Vaccine contains aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites. PfSPZ Vaccine will be delivered by DVI in the pilot and main phases of the study. Participants will receive either 1 or 3 injections.
203100|NCT02627456|Biological|PfSPZ Challenge Material|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites used for CHMI trials. PfSPZ Challenge is not radiated, thus it is fully infections. It will be administered via DVI to participants in Arm 1c and 1d.
203101|NCT02627456|Drug|PBS and HSA Diluent|The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). Vials of sterile PBS (1.6ml) and HSA (0.5ml) will be shipped to the clinical site, where diluent composed of PBS and HSA is prepared. HSA is a licensed product which is approved for parenteral, IV administration to humans. The HSA lots are extensively tested to ensure that it is free of infectious agents as listed in the CoA and is approved for use by the Food and Drug Administration(FDA).
203102|NCT02627456|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be procured in the US and shipped to Mali at ambient temperature. Like the product, normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe.
203103|NCT02627456|Drug|Coartem|Artemether/lumefantrine (coartem) is a licensed antimalarial in the US and Mali for use for uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Artemether /lumefantrine is a Category C pregnancy drug. Thus all female participants will undergo pregnancy testing prior to receiving this drug.
203155|NCT02627118|Device|FRESENIUS 160NR|2 MONTHS OF DIALYSIS WITH THE FRESENIUS 160NR DIALYZER
203104|NCT02627456|Drug|ASAQ|"ASAQ is a fixed dose artemisinin based combination therapy that is indicated and approved for the management of uncomplicated P. falciparum malaria. It has been shown to be as effective as artemether~/lumefantrine when taken at a once/day dosage."
203105|NCT02627443|Drug|ATR Kinase Inhibitor M6620|Given IV
203106|NCT02627443|Drug|Carboplatin|Given IV
203107|NCT02627443|Drug|Gemcitabine|Given IV
203108|NCT02627443|Drug|Gemcitabine Hydrochloride|Given IV
203109|NCT02627443|Other|Laboratory Biomarker Analysis|Correlative studies
203110|NCT02627443|Other|Pharmacological Study|Correlative studies
203111|NCT02627430|Drug|Hsp90 Inhibitor AT13387|Given IV
203112|NCT02627430|Other|Laboratory Biomarker Analysis|Correlative studies
203113|NCT02627430|Other|Pharmacological Study|Correlative studies
203114|NCT02627430|Drug|Talazoparib|Given PO
203115|NCT02627417|Drug|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
203116|NCT02627417|Drug|"Prednisone (Cortancyl®) alone followed by monitoring and standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
203117|NCT02627417|Drug|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
203118|NCT02627404|Other|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
203119|NCT02627404|Device|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
203120|NCT02627391|Other|Early surgical aortic valve replacement|
203121|NCT02627391|Other|Delayed Surgical aortic valve replacement|
203122|NCT02627378|Other|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
203123|NCT02627378|Other|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
203124|NCT02627365|Behavioral|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
203125|NCT02627352|Procedure|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
203126|NCT02627326|Procedure|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
203127|NCT02627313|Device|GammaPod Tumour Bed Boost|Single fraction Tumour Bed boost of 8Gy in 1 Fraction
203128|NCT02627300|Drug|Octanorm 16.5%|
203129|NCT02627287|Device|FlexPen®|For subcutaneously (s.c. under the skin) injection.
203130|NCT02627287|Device|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
203131|NCT02627287|Drug|placebo|For subcutaneously (s.c. under the skin) injection
203132|NCT02627274|Drug|RO6874281|RO6874281 will be administered as per the schedule specified under arm description.
203133|NCT02627274|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified under arm description.
203134|NCT02627274|Drug|Cetuximab|Cetuximab will be administered as per the schedule specified under arm description.
203135|NCT02627261|Biological|blood samples and bone marrow aspirates will be collected|Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
203136|NCT02627248|Drug|Huaier Granule|20g tid, orally
203137|NCT02627248|Drug|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
203138|NCT02627248|Drug|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
203139|NCT02627248|Drug|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
203140|NCT02627235|Behavioral|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
203141|NCT02627235|Behavioral|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
203142|NCT02627222|Other|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
203143|NCT02627222|Other|White cassava|Conventional white cassava
203144|NCT02627209|Other|spectrophotometric assay|measurement of enzyme activity in the serum
203145|NCT02627209|Other|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
203146|NCT02627196|Device|BAROSTIM NEO® System|
203147|NCT02627196|Drug|Medical Management|
203148|NCT02627183|Procedure|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
203149|NCT02627183|Behavioral|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
203150|NCT02627170|Device|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
203151|NCT02627157|Device|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
203152|NCT02627144|Drug|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
203153|NCT02627144|Drug|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
203156|NCT02627118|Device|NIPRO ELISIO-15H|2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
203157|NCT02627105|Behavioral|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
203158|NCT02627105|Behavioral|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
203159|NCT02627092|Other|Copper linen exposure|Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
203160|NCT02627079|Other|Daily SMS text messaging|
203161|NCT02627066|Behavioral|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
203162|NCT02627066|Behavioral|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
203163|NCT02627053|Drug|rivaroxaban|
203164|NCT02627040|Device|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
203165|NCT02627040|Device|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
203166|NCT02627027|Drug|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
203167|NCT02627027|Drug|CKD-395 0.25/750mg|oral administration
203168|NCT02627014|Other|Manual therapy|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
203169|NCT02627014|Other|Home physical therapy|once a day: 15 minutes
203170|NCT02627014|Other|Manual therapy in cervical region|"6 treatments: 2 treatments for week~1 treatment = 30 minutes"
203171|NCT02627014|Other|Home physical therapy in cervical region|once a day: 15 minutes
203172|NCT02627001|Device|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
203173|NCT02627001|Device|Bag Valve Mask|Conventional bag valve mask
203174|NCT02626988|Behavioral|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
203175|NCT02626962|Drug|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
203176|NCT02626962|Drug|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
203177|NCT02626949|Behavioral|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
203178|NCT02626949|Behavioral|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
203179|NCT02626936|Other|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
203180|NCT02626936|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
203181|NCT02626936|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
203182|NCT02626936|Device|Dexcom G4 Platinum glucose sensor|
203183|NCT02626936|Device|Accu Chek Combo insulin pump|
203184|NCT02626897|Device|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
203185|NCT02626897|Device|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
203186|NCT02626884|Drug|Ibrutinib|
203187|NCT02626858|Device|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
203188|NCT02626845|Drug|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
203189|NCT02626845|Other|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
203190|NCT02626832|Other|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
203191|NCT02626819|Behavioral|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
203224|NCT02626507|Drug|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
205962|NCT02607423|Drug|Gemcitabine Hydrochloride|Given IV
203192|NCT02626819|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
203193|NCT02626780|Device|GID SVF-2|Comparison of the number of hairs before and after treatment of autologous adipose-derived SVF as a percentage increase or decrease in growth.
203194|NCT02626767|Other|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
203195|NCT02626754|Drug|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
203196|NCT02626741|Dietary Supplement|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
203197|NCT02626741|Behavioral|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
203198|NCT02626728|Procedure|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
203199|NCT02626715|Drug|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
203200|NCT02626715|Drug|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
203201|NCT02626702|Other|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
203202|NCT02626689|Other|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
203203|NCT02626689|Other|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
203204|NCT02626676|Other|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
203205|NCT02626650|Other|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
203206|NCT02626637|Other|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
203207|NCT02626611|Drug|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
203208|NCT02626611|Drug|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
203209|NCT02626598|Device|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
203210|NCT02626585|Procedure|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
203211|NCT02626572|Drug|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
203212|NCT02626572|Drug|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
203213|NCT02626572|Drug|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
203214|NCT02626572|Drug|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
203215|NCT02626559|Drug|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
203216|NCT02626546|Procedure|Major surgical procedure|observation of postoperative outcomes
203217|NCT02626533|Procedure|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
203218|NCT02626520|Drug|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
203219|NCT02626520|Drug|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
203220|NCT02626520|Radiation|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
203221|NCT02626520|Procedure|Definitive resection|Definitive surgical resection of primary tumor
203222|NCT02626507|Drug|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
203223|NCT02626507|Drug|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
203225|NCT02626507|Drug|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
203226|NCT02626494|Drug|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
203227|NCT02626494|Drug|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
203228|NCT02626481|Drug|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
203229|NCT02626481|Drug|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
203230|NCT02626455|Drug|Copanlisib (BAY80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days.
203231|NCT02626455|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
203232|NCT02626455|Drug|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
203233|NCT02626455|Drug|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
203234|NCT02626455|Drug|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
203235|NCT02626455|Drug|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
203236|NCT02626455|Drug|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
203237|NCT02626455|Drug|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
203238|NCT02626442|Other|Exercise|6 month group exercise class
203239|NCT02626429|Dietary Supplement|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
203240|NCT02626416|Device|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
203241|NCT02626403|Device|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
203242|NCT02626403|Device|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
203243|NCT02626390|Other|Frequent instructions/feedback and an Internal Focus of Attention|
203244|NCT02626390|Other|Minimal instructions/feedback and an External Focus of Attention|
203245|NCT02626377|Behavioral|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
203246|NCT02626377|Other|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
203247|NCT02626364|Drug|crenolanib|single-agent crenolanib at 100 mg PO TID
203248|NCT02626351|Other|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: [1] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; [2] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; [3] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; [4] Follow up.
203249|NCT02626351|Other|Baseline data collection (active comparator)|Endpoint data collection only
203250|NCT02626338|Drug|Crenolanib|
203251|NCT02626338|Drug|Mitoxantrone|
203252|NCT02626338|Drug|Cytarabine|
203253|NCT02626338|Drug|Etoposide|
203257|NCT02626325|Other|High-carbohydrate or High-monounsaturated fat diets|
203258|NCT02626312|Other|Laboratory Biomarker Analysis|Correlative studies
203259|NCT02626312|Procedure|Magnetic Resonance Imaging|Correlative studies
203260|NCT02626312|Radiation|Radiation Therapy|Undergo radiation therapy
203261|NCT02626312|Other|Survey Administration|Ancillary studies
203262|NCT02626299|Drug|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
203263|NCT02626299|Drug|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
203264|NCT02626299|Other|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
203265|NCT02626286|Other|HIV quarterly global care|
203266|NCT02626273|Radiation|weight loss|
203267|NCT02626260|Other|adhesive strip|Adhesive strip with a standard adhesive base
203268|NCT02626247|Dietary Supplement|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
203269|NCT02626247|Other|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
203270|NCT02626234|Drug|INC280|
203271|NCT02626234|Drug|digoxin|
203272|NCT02626234|Drug|rosuvastatin|
203273|NCT02626221|Other|Non Interventional Study|Non Interventional Study
203274|NCT02626208|Device|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
203275|NCT02626195|Dietary Supplement|nutritional support program|"Nutritional support program is briefly described below.~Interval: 5-10 days Contents: admission is required~Calories: 30-35Kg, via enteral or parenteral~Protein: 1.2-1.5g/Kg~Lipid : 1-1.5g/Kg~Mineral and vitamins supply~Blood glucose control~Daily monitoring by dietician and specialized nurse"
203276|NCT02626182|Drug|sildenafil|active sildenafil
203277|NCT02626182|Drug|placebo|sugar pill that looks like sildenafil tablets
203278|NCT02626169|Drug|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
203279|NCT02626169|Drug|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
203280|NCT02626156|Device|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
203281|NCT02626156|Device|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
203282|NCT02626143|Other|Investigational nutrient-rich whey protein formula|
203283|NCT02626143|Other|Cow's milk based formula|
203284|NCT02626130|Procedure|Cryosurgery|Undergo cryoablation
203285|NCT02626130|Other|Laboratory Biomarker Analysis|Correlative studies
203286|NCT02626130|Procedure|Therapeutic Conventional Surgery|Undergo surgery
203287|NCT02626130|Biological|Tremelimumab|Given IV
203288|NCT02626117|Device|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
203289|NCT02626117|Device|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
203290|NCT02626104|Dietary Supplement|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
203291|NCT02626104|Dietary Supplement|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
203292|NCT02626091|Procedure|Left-sided colonic resection|"During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.~In any case, the resection will be performed according to the surgeon's appreciation."
203293|NCT02626078|Other|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
203294|NCT02626065|Biological|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
203295|NCT02626065|Drug|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
203296|NCT02626052|Behavioral|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
203297|NCT02626052|Behavioral|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
203298|NCT02626052|Behavioral|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
203299|NCT02626052|Procedure|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
203300|NCT02626052|Procedure|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
203301|NCT02626052|Procedure|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
203302|NCT02626026|Drug|GS-4059|GS-4059 capsules administered orally
203303|NCT02626026|Drug|Placebo|GS-4059 placebo administered orally
203304|NCT02626000|Drug|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
203305|NCT02626000|Biological|Pembrolizumab|Administered as a 30-minute intravenous infusion at a dose of 200 mg Q3W
203306|NCT02625987|Procedure|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
203307|NCT02625987|Procedure|Separated stitches|Appendectomy wound closure with a separated stitches.
203308|NCT02625974|Drug|Nifurtimox (Lampit, BAYA2502)|"For pediatric subjects with body weight ≤ 40 kg: dosage 10 to 20 mg/kg/day in three divided doses.~For pediatric subjects with body weight > 40 kg: 8 - 10 mg/kg/day in three divided doses.~60 days of nifurtimox treatment"
203309|NCT02625974|Drug|Placebo|Matching placebo
203310|NCT02625961|Biological|pembrolizumab|
203311|NCT02625948|Drug|Tranexamic Acid|
203312|NCT02625922|Drug|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
203313|NCT02625922|Drug|Placebo|Matching placebo i.v infusion
203314|NCT02625909|Drug|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
203315|NCT02625909|Drug|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
203316|NCT02625896|Behavioral|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
203317|NCT02625883|Other|Interview|Interview by validated Quality-of-life-questionnaire
203318|NCT02625870|Drug|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
203319|NCT02625870|Drug|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
203320|NCT02625857|Biological|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU]) and at a higher dose in Cohort 1B (1x10^9 CFU).
203321|NCT02625857|Biological|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
203322|NCT02625844|Other|No intervention|No intervention administered in this study.
203323|NCT02625831|Other|Biological analysis|"Biological analysis :~ficolin-3~anti-ficolin 3 antibodies~anti-C1q antibodies"
203324|NCT02625805|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
203325|NCT02625805|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
203326|NCT02625805|Drug|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
203327|NCT02625792|Drug|Endo-Clot(TM)|After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
203328|NCT02625779|Drug|Valproate and Placebo|
203329|NCT02625779|Drug|Valproate and Cytidine-containing Drug|
203330|NCT02625779|Drug|Valproate and Creatine-containing Drug|
203331|NCT02625766|Procedure|LC fracture surgical fixation|
203332|NCT02625766|Procedure|LC fracture non-operative management|
203333|NCT02625753|Drug|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
203334|NCT02625753|Drug|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
203335|NCT02625753|Drug|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
203336|NCT02625740|Device|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
203337|NCT02625740|Device|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
203338|NCT02625740|Device|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
203339|NCT02625740|Drug|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
203340|NCT02625740|Procedure|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
203341|NCT02625727|Other|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
203342|NCT02625727|Other|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
203343|NCT02625714|Drug|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
203344|NCT02625714|Drug|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
203345|NCT02625701|Procedure|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
203346|NCT02625701|Procedure|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
203347|NCT02625688|Other|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
203348|NCT02625688|Other|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
203349|NCT02625688|Other|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
203350|NCT02625675|Other|Ultrasound scan|
203351|NCT02625636|Drug|SAR438544|"Pharmaceutical form: solution~Route of administration: subcutaneous"
203352|NCT02625636|Drug|placebo|"Pharmaceutical form: solution~Route of administration: subcutaneous"
203353|NCT02625636|Drug|r-glucagon|"Pharmaceutical form: solution~Route of administration: subcutaneous"
203354|NCT02625623|Drug|Avelumab|Avelumab will be administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
203355|NCT02625623|Drug|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m ^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
203356|NCT02625623|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
203357|NCT02625623|Other|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC will be administered once every 3 weeks.
203358|NCT02625610|Drug|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
203359|NCT02625610|Drug|Oxaliplatin|"Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.~Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
203360|NCT02625610|Drug|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
203361|NCT02625610|Drug|Leucovorin|"Induction Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
203362|NCT02625610|Drug|Capecitabine|"Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
203363|NCT02625610|Other|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care will be administered per institutional guidelines and subjects will visit the clinic every 3 weeks.
203364|NCT02625610|Drug|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
203365|NCT02625610|Drug|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
203366|NCT02625610|Drug|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
203367|NCT02625610|Drug|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
203368|NCT02625597|Device|Cotton Pellet|
203369|NCT02625597|Device|Polytetrafluoroethylene Tape|
203370|NCT02625597|Device|Synthetic Foam|
203371|NCT02625597|Device|Polyvinylsiloxane|
203372|NCT02625584|Behavioral|Reading Together - Pausing for Reading|
203373|NCT02625584|Behavioral|Reading Together - Dialogic Reading|
203374|NCT02625584|Behavioral|Reading Together - Shared Reading Control|
203375|NCT02625571|Behavioral|Phase-based treatment of sexual behavior problems of children|
203376|NCT02625558|Drug|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
203377|NCT02625558|Drug|Placebo|Placebo given three times a day
203378|NCT02625545|Device|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
203379|NCT02625532|Procedure|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
203380|NCT02625532|Procedure|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
203381|NCT02625519|Drug|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
203382|NCT02625519|Drug|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
203383|NCT02625506|Drug|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
203384|NCT02625506|Drug|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
203385|NCT02625493|Other|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
203386|NCT02625480|Biological|KTE-X19|
203387|NCT02625480|Drug|Fludarabine|Administered intravenously
203388|NCT02625480|Drug|Cyclophosphamide|Administered intravenously
203389|NCT02625467|Procedure|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
203390|NCT02625467|Procedure|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
203391|NCT02625467|Drug|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
203392|NCT02625454|Drug|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
203393|NCT02625454|Drug|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
203394|NCT02625441|Drug|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
203395|NCT02625441|Drug|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
203396|NCT02625428|Drug|Optison|
203397|NCT02625415|Device|Vitamin B6 cream|Topical Vitamin B6 cream
203398|NCT02625415|Device|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
203399|NCT02625402|Behavioral|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
203400|NCT02625402|Behavioral|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
203401|NCT02625389|Drug|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
203402|NCT02625376|Dietary Supplement|Resvega|Dietary supplementation with Resvega BD
203403|NCT02625376|Dietary Supplement|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
203404|NCT02625376|Dietary Supplement|placebo|Dietary supplementation with a placebo BD
203405|NCT02625363|Other|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
203406|NCT02625363|Other|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
203407|NCT02625363|Other|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
203408|NCT02625363|Other|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
203409|NCT02625363|Other|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes~First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
203410|NCT02625350|Other|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
203411|NCT02625350|Other|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
203412|NCT02625350|Other|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
203413|NCT02625337|Drug|Pembrolizumab|
203414|NCT02625337|Drug|Dabrafenib|
203415|NCT02625337|Drug|Trametinib|
203416|NCT02625337|Procedure|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
203417|NCT02625337|Procedure|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
203418|NCT02625324|Device|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
203419|NCT02625311|Procedure|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
203420|NCT02625298|Device|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
203421|NCT02625298|Device|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
203422|NCT02625272|Procedure|Group A|The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
203423|NCT02625259|Drug|TAK-117|TAK-117 capsules
203424|NCT02625259|Drug|Lansoprazole|Lansoprazole capsules
203425|NCT02625259|Drug|TAK-117|TAK-117 tablets
203426|NCT02625246|Biological|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
203427|NCT02625233|Device|senofilcon C|
203428|NCT02625233|Device|comfilcon A|
203429|NCT02625220|Device|Prototype toric lens senofilcon A|Investigational prototype
203430|NCT02625207|Drug|Maraviroc (Part 1)|300 mg twice daily x 5 days
203431|NCT02625207|Drug|Maraviroc (Part 2)|150 mg once daily x 10 days
203432|NCT02625207|Drug|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
203433|NCT02625194|Drug|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
203434|NCT02625181|Procedure|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
203435|NCT02625181|Procedure|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
203436|NCT02625181|Procedure|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
203437|NCT02625181|Procedure|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
203438|NCT02625181|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
203439|NCT02625181|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
203440|NCT02625181|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
203441|NCT02625181|Procedure|Elective surgery|Surgical procedures that are scheduled and not an emergency.
203442|NCT02625181|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
203443|NCT02625181|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
203444|NCT02625181|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
203445|NCT02625181|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
203446|NCT02625181|Drug|Scopolamine|Prophylactic antiemetic
203447|NCT02625181|Drug|Droperidol|Prophylactic antiemetic & rescue antiemetic
203448|NCT02625181|Drug|Haloperidol|Prophylactic antiemetic & rescue antiemetic
203449|NCT02625181|Drug|Dexamethasone|Prophylactic antiemetic & rescue antiemetic
203450|NCT02625181|Drug|Promethazine|Prophylactic antiemetic & rescue antiemetic
203451|NCT02625181|Drug|Meclizine|Prophylactic antiemetic & rescue antiemetic
203452|NCT02625181|Drug|Aprepitant|Prophylactic antiemetic & rescue antiemetic
203453|NCT02625181|Drug|Metoclopramide|Rescue antiemetic
203454|NCT02625181|Drug|Fentanyl|Analgesic drug / Opioid
203455|NCT02625181|Drug|Sufentanil|Analgesic drug / Opioid
203456|NCT02625181|Drug|Alfentanil|Analgesic drug / Opioid
203457|NCT02625181|Drug|Remifentanil|Analgesic drug / Opioid
203458|NCT02625181|Drug|Morphine|Analgesic drug / Opioid
203459|NCT02625181|Drug|Meperidine|Analgesic drug / Opioid
203460|NCT02625181|Drug|Hydromorphone|Analgesic drug / Opioid
203461|NCT02625181|Drug|Methadone|Analgesic drug / Opioid
203462|NCT02625181|Drug|Oxycodone|Analgesic drug / Opioid
203463|NCT02625181|Drug|Oxymorphone|Analgesic drug / Opioid
203464|NCT02625181|Drug|Hydrocodone|Analgesic drug / Opioid
203465|NCT02625181|Drug|Ketamine|Analgetic / Analgesic drug
203466|NCT02625181|Drug|Ondansetron|Prophylactic antiemetic & rescue antiemetic
203467|NCT02625181|Drug|Granisetron|Prophylactic antiemetic & rescue antiemetic
203468|NCT02625181|Drug|Dolasetron mesylate|Prophylactic antiemetic & rescue antiemetic
203469|NCT02625181|Drug|Palonosetron|Prophylactic antiemetic & rescue antiemetic
203470|NCT02625181|Drug|Tropisetron|Prophylactic antiemetic & rescue antiemetic
203471|NCT02625181|Drug|Ramosetron|Prophylactic antiemetic & rescue antiemetic
203472|NCT02625168|Drug|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
203473|NCT02625168|Drug|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
203474|NCT02625155|Other|Urine diagnostic testing as SOC, drug regimen changes per SOC|
203475|NCT02625155|Other|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
203476|NCT02625142|Other|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
203477|NCT02625129|Other|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
203478|NCT02625103|Procedure|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
203479|NCT02625103|Drug|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
203480|NCT02625090|Drug|UCB0942|"Active Substance: UCB0942~Pharmaceutical form: Film-coated tablet~Concentration: 25 mg, 100 mg or 200 mg~Route of Administration: oral"
203481|NCT02625077|Procedure|Laparoscopic gastroesophageal valvuloplasty|
203482|NCT02625077|Procedure|Laparoscopic Toupet fundoplication|
203483|NCT02625064|Other|Blood samples collection before treatment|
203484|NCT02625064|Other|Blood samples collection after treatment|
203485|NCT02625064|Other|laboratory biomarker proteomic analysis|
203486|NCT02625051|Procedure|Ureteroscopy|Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
203487|NCT02625051|Procedure|Percutaneous nephrolithotomy|Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
203488|NCT02625051|Device|Ureteral stent (double-J stent)|After ureteroscopy (URS) is done and stone clearance is achieved, a 4.6 french ureteral stent is routinely placed at the end of the procedure to drain the kidney for 1-3 weeks.
203489|NCT02625051|Device|Percutaneous nephrostomy tube|At the end of the percutaneous nephrolithotomy (PNL) procedure, a 10 french Cope loop percutaneous nephrostomy tube is placed in all patients to drain the kidney for 1-2 days.
203490|NCT02625038|Device|EUDAMED CIV-14-03-011940|
203491|NCT02625025|Procedure|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
203492|NCT02625025|Procedure|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.~Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
203493|NCT02625025|Procedure|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
203494|NCT02624999|Biological|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
203495|NCT02624999|Drug|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
203496|NCT02624986|Drug|Idasanutlin|Participants will receive idasanutlin film-coated tablets at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation will occur in at least 50-mg increments, and daily dosages greater than or equal to (>/=) 400 mg will be split into twice daily dosing.
203497|NCT02624986|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 Cycle=28 days). For eligible participants with FL, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month for a maximum of up to 24 months.
203498|NCT02624986|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants may be given at a dose of 375 mg/m^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
203499|NCT02624973|Drug|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
203500|NCT02624973|Drug|Neoadjuvant letrozole (postmenopausal women)|
203501|NCT02624973|Drug|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
203502|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide|
203503|NCT02624973|Drug|Neoadjuvant docetaxel|
203505|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
203506|NCT02624973|Drug|Neoadjuvant olaparib|
203507|NCT02624973|Drug|Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)|
203508|NCT02624973|Procedure|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
203509|NCT02624973|Radiation|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
203510|NCT02624973|Drug|Adjuvant trastuzumab|
203511|NCT02624973|Drug|Adjuvant letrozole (postmenopausal women)|
203512|NCT02624973|Drug|Adjuvant tamoxifen + goserelin (premenopausal women)|
203513|NCT02624973|Drug|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
203514|NCT02624973|Drug|Adjuvant Epirubicin+ Cyclophosphamide|
203515|NCT02624960|Device|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
203516|NCT02624947|Biological|RSV F vaccine with adjuvant|
203517|NCT02624947|Biological|Formulation buffer|
203518|NCT02624921|Other|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
203519|NCT02624908|Drug|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
203520|NCT02624908|Drug|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
203521|NCT02624882|Procedure|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:~Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins~Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
203522|NCT02624882|Procedure|Negative rapid GAS test|Usual care
203523|NCT02624869|Biological|evolocumab (AMG 145)|Administered by subcutaneous injection
203524|NCT02624856|Drug|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
203525|NCT02624856|Drug|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
203526|NCT02624843|Drug|Benzyl Alcohol Lotion 5%|White topical lotion
203527|NCT02624843|Drug|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
203528|NCT02624843|Drug|Placebo|White topical lotion
203529|NCT02624830|Drug|Sulfonylurea|See Arm description.
203530|NCT02624817|Drug|Sulfonylurea|See Arm description.
203531|NCT02624804|Genetic|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated lymphocytes"
203532|NCT02624791|Device|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
203533|NCT02624791|Device|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
203534|NCT02624791|Other|No contact lenses|simulated driving tests
203535|NCT02624778|Biological|LY3002813|Administered IV
203536|NCT02624778|Drug|Placebo|Administered IV
203537|NCT02624765|Drug|Digoxin (monotherapy)|Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day
203538|NCT02624765|Drug|Sotalol (monotherapy)|Oral dose: 80 mg TID or 120 mg BID (240 mg/day)
203539|NCT02624765|Drug|Flecainide (monotherapy)|Oral dose: 100 mg TID (300 mg/day)
203540|NCT02624765|Drug|Digoxin (dual therapy)|Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day
203541|NCT02624765|Drug|Sotalol (dual therapy)|Oral dose: 160 mg BID (320 mg/day)
203542|NCT02624765|Drug|Flecainide (dual therapy)|Oral dose:100 mg TID (300 mg/day)
203543|NCT02624752|Dietary Supplement|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
203544|NCT02624726|Drug|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in <5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
203545|NCT02624726|Drug|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
203546|NCT02624726|Drug|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
203547|NCT02624726|Drug|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
203548|NCT02624713|Behavioral|obesity treatment|"Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.~Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.~Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
203549|NCT02624700|Drug|Pemetrexed|Treatment schedule is administered on day 1 of each 21-day cycle by Intravenous infusion over 10 minutes with a dose of 375 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
203550|NCT02624700|Drug|Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 21-day cycle with a dose of 200 mg.
203551|NCT02624687|Behavioral|Intervention|Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
203552|NCT02624687|Other|No intervention|No contact control
203553|NCT02624674|Device|Multi-spectral Imaging Device (MSID)|
203555|NCT02624648|Behavioral|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
203556|NCT02624648|Behavioral|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
203557|NCT02624648|Behavioral|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
203558|NCT02624648|Drug|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
203559|NCT02624648|Drug|Placebo|They will receive a capsule of Placebo twice a day for 120 days
203560|NCT02624635|Other|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
203561|NCT02624635|Other|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ [1.0278 - (0.0278 x number of repetitions)] as was used by (Shirazi et al., 2007).
203562|NCT02624622|Procedure|Chlorhexidine application to cord by mother|
203563|NCT02624622|Procedure|Chlorhexidine application by CHW|
203564|NCT02624609|Other|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
203565|NCT02624609|Other|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
203566|NCT02624596|Drug|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
203567|NCT02624596|Drug|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
203568|NCT02624570|Drug|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
203569|NCT02624557|Drug|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
203570|NCT02624544|Drug|esomeprazole|esomex 40 mg twice daily
203571|NCT02624544|Drug|desonide|topical corticosteroid desonid 0,1% b.i.d
203572|NCT02624531|Drug|Taxane|NACT and Fertility-sparing Treatment Strategy
203573|NCT02624531|Procedure|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
203574|NCT02624518|Drug|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Imaging with PET/MRI
203575|NCT02624518|Procedure|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
203576|NCT02624518|Procedure|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
203577|NCT02624505|Drug|90 mcg Reference Product|Drug: 90 mcg Reference Product
203578|NCT02624505|Drug|180 mcg Reference Product|Drug: 180 mcg of Reference Product
203579|NCT02624505|Drug|90 mcg Test Product|Drug: 90 mcg of Test Product
203580|NCT02624505|Drug|Placebo|Placebo Product
203581|NCT02624492|Drug|BI 836826|
203582|NCT02624492|Drug|GemOx|
203583|NCT02624492|Drug|Rituximab|
203584|NCT02624492|Drug|GemOx|
203585|NCT02624479|Drug|Sodium thiosulfate|oral administration of thiosulfate
203586|NCT02624466|Other|CKD progress|CKD progress
203587|NCT02624453|Drug|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
203588|NCT02624453|Drug|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
203589|NCT02624440|Drug|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
203590|NCT02624440|Drug|Clarithromycin|P.o. clarithromycin 250 mg twice daily
203591|NCT02624440|Drug|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
203592|NCT02624440|Drug|Observation|Observation without prophylactic antibiotic
203593|NCT02624427|Device|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
203594|NCT02624414|Device|PillCam® COLON 2 Capsule Endoscopy|
203595|NCT02624401|Drug|Dexmedetomidine|Intravenous infusion
203596|NCT02624401|Drug|Propofol|Intravenous infusion
203597|NCT02624401|Drug|S-ketamine|Intravenous infusion
203598|NCT02624401|Drug|Sevoflurane|Inhalation
203599|NCT02624401|Drug|Placebo|Intravenous infusion of saline (Ringer's Acetate)
203600|NCT02624388|Drug|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
203601|NCT02624388|Drug|Placebo|Pill that contains no medicine
203602|NCT02624375|Drug|Zoster Vaccine Live|
203603|NCT02624362|Behavioral|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
203604|NCT02624362|Behavioral|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
203605|NCT02624362|Other|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
203606|NCT02624349|Drug|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
203607|NCT02624336|Other|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
203608|NCT02624336|Other|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
203609|NCT02624336|Other|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
203610|NCT02624323|Procedure|Real-time ultrasound-guided central vein catheterization.|
203611|NCT02624310|Drug|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
203612|NCT02624310|Drug|Placebo|
203613|NCT02624297|Other|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
203614|NCT02624284|Device|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).~Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
203615|NCT02624271|Other|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
203616|NCT02624258|Biological|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
203617|NCT02624245|Other|Conventional Physical Therapy|
203618|NCT02624219|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
203619|NCT02624219|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
203620|NCT02624219|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
203621|NCT02624206|Dietary Supplement|Juice A|Subjects to be given juice daily for 3 weeks.
203622|NCT02624206|Dietary Supplement|Juice B|Subjects to be given juice daily for 3 weeks.
203623|NCT02624193|Behavioral|MBSR Program|Mindfulness-based stress reduction, as described previously.
203624|NCT02624193|Behavioral|HT Program|Health education curriculum, as described previously
203625|NCT02624180|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
203626|NCT02624180|Drug|Placebo|A substance containing no medication
203627|NCT02624167|Drug|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
203628|NCT02624167|Drug|Placebo|Patients will be given oral dose of matching Placebo
203629|NCT02624154|Procedure|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
203630|NCT02624141|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
203631|NCT02624128|Drug|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
203632|NCT02624128|Drug|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
203633|NCT02624128|Drug|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
203634|NCT02624102|Behavioral|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
203635|NCT02624102|Behavioral|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
203636|NCT02624102|Drug|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
203637|NCT02624089|Drug|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
203638|NCT02624089|Drug|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
203639|NCT02624076|Other|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
203640|NCT02624076|Other|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
203641|NCT02624063|Drug|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
203642|NCT02624063|Drug|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
203643|NCT02624050|Drug|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
203684|NCT02623777|Dietary Supplement|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
203644|NCT02624050|Drug|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
203645|NCT02624037|Other|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
203646|NCT02624011|Behavioral|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
203647|NCT02623998|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
203648|NCT02623998|Drug|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
203649|NCT02623998|Behavioral|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
203650|NCT02623985|Device|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
203651|NCT02623985|Device|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
203652|NCT02623985|Device|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
203653|NCT02623972|Drug|Eribulin|administered IV for 4 cycles
203654|NCT02623972|Drug|Adriamycin|administered IV with cyclophosphamide for 4 cycles
203655|NCT02623972|Drug|Cyclophosphamide|administered IV with adriamycin for 4 cycles
203656|NCT02623959|Behavioral|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
203657|NCT02623959|Drug|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
203658|NCT02623959|Drug|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
203659|NCT02623959|Other|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
203660|NCT02623959|Drug|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
203661|NCT02623959|Behavioral|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
203662|NCT02623933|Radiation|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
203663|NCT02623920|Drug|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
203664|NCT02623920|Drug|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
203665|NCT02623920|Drug|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
203666|NCT02623881|Device|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
203667|NCT02623881|Drug|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
203668|NCT02623868|Drug|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
203669|NCT02623868|Drug|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
203670|NCT02623868|Drug|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
203671|NCT02623855|Behavioral|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
203672|NCT02623855|Behavioral|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
203673|NCT02623855|Device|Pedometry|Participants will record their daily pedometry.
203674|NCT02623855|Behavioral|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
203675|NCT02623842|Device|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
203676|NCT02623829|Drug|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
203677|NCT02623829|Drug|Saline|1ml of normal saline will be administered
203678|NCT02623816|Drug|Optimal Dosing of Omeprazole|Omeprazole 20 mg
203679|NCT02623803|Drug|Lidocaine|
203680|NCT02623803|Drug|Placebo D5W|
203681|NCT02623790|Other|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
203682|NCT02623790|Other|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
203683|NCT02623790|Other|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
203685|NCT02623777|Dietary Supplement|Short chain fatty acids|Short chain fatty acids administered
203686|NCT02623751|Drug|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally adminitered once daily."
203687|NCT02623751|Drug|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.~Exemestane will be orally adminitered once daily."
203688|NCT02623738|Drug|Placebo ophthalmic solution|
203689|NCT02623738|Drug|DE-117 ophthalmic solution low|
203690|NCT02623738|Drug|DE-117 ophthalmic solution high|
203691|NCT02623738|Drug|Latanoprost ophthalmic solution 0.005%|
203692|NCT02623725|Biological|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
203693|NCT02623725|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
203694|NCT02623712|Other|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
203695|NCT02623712|Other|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
203696|NCT02623699|Drug|BIIB067|Part A, B and C
203697|NCT02623699|Other|Placebo|Part A, B and C
203698|NCT02623686|Other|Aroma Therapy Massage and Inhalation Patch|
203699|NCT02623673|Drug|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
203700|NCT02623660|Device|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.~All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
203701|NCT02623660|Other|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
203702|NCT02623660|Device|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
203703|NCT02623647|Radiation|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
203704|NCT02623634|Behavioral|Position, waveform|different positions and waveform
203705|NCT02623621|Drug|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
203706|NCT02623608|Other|Reference breakfast|A high fat, high calorie breakfast
203707|NCT02623608|Other|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
203708|NCT02623608|Other|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
203709|NCT02623608|Other|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
203710|NCT02623608|Other|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
203711|NCT02623595|Radiation|Stereotactic body radiotherapy|A type of radiation therapy
203712|NCT02623595|Drug|rhGM-CSF|Immune modulating agents
203713|NCT02623582|Biological|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
203714|NCT02623582|Drug|Cyclophosphamide|Given IV
203715|NCT02623569|Drug|Ivabradine|Not Provided
203716|NCT02623569|Drug|Atenolol|Not Provided
203717|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
203718|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
203719|NCT02623543|Device|OrthoK|
203720|NCT02623530|Other|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
203721|NCT02623504|Drug|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
203722|NCT02623504|Drug|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
203723|NCT02623491|Drug|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
203724|NCT02623491|Drug|Placebo|Participants will receive matching placebo.
203725|NCT02623478|Drug|Insulin Lispro|Administered subcutaneously (SC)
203726|NCT02623465|Drug|Insulin Lispro|Administered subcutaneously (SC)
203727|NCT02623452|Drug|Insulin Lispro|Administered subcutaneously (SC)
203728|NCT02623439|Drug|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
203729|NCT02623426|Drug|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
203772|NCT02623075|Biological|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
203730|NCT02623426|Drug|Intravitreal Methotrexate 400 µg|Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
203731|NCT02623426|Drug|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
203732|NCT02623387|Procedure|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
203733|NCT02623374|Behavioral|self-help CBT intervention (SHCBT)|See 'Arms' section
203734|NCT02623361|Drug|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
203735|NCT02623361|Drug|Sham Block|Sham Block by saline injection
203736|NCT02623348|Behavioral|pedometer|pedometer-based physical activity recommendations
203737|NCT02623335|Other|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
203738|NCT02623322|Drug|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
203739|NCT02623322|Drug|Placebo|Placebo will be administered as a single dose by IV administration.
203740|NCT02623309|Procedure|Allogeneic (Allo) hematopoietic stem cell transplantation|
203741|NCT02623296|Drug|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
203742|NCT02623296|Drug|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
203743|NCT02623296|Drug|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
203744|NCT02623283|Other|No intervention given|Participants will have a full dental examination but no operative intervention
203745|NCT02623270|Device|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
203746|NCT02623270|Device|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
203747|NCT02623257|Other|mutation detection|
203748|NCT02623257|Other|ARMS|
203749|NCT02623257|Genetic|ctDNA analysis|
203750|NCT02623244|Procedure|Laparoscopic oophorocystectomy or oophorectomy|
203751|NCT02623231|Drug|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
203752|NCT02623231|Drug|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
203753|NCT02623218|Device|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
203754|NCT02623218|Device|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
203755|NCT02623205|Drug|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission.
203756|NCT02623205|Drug|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders.
203757|NCT02623192|Other|Patients who have performed the ARDS pulmonary function test|
203758|NCT02623179|Other|culture versus Molecular diagnostics|Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
203759|NCT02623153|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
203760|NCT02623153|Drug|capecitabine|capecitabine of 1000 mg/m2
203761|NCT02623153|Drug|S1|S1 of 40 mg/m2
203762|NCT02623153|Drug|Docetaxel|docetaxel 40 mg/m2
203763|NCT02623140|Device|Biofreedom|PCI with Biofreedom stent
203764|NCT02623140|Device|Orsiro|PCI with Orsiro stent
203765|NCT02623127|Drug|Sunitinib|
203766|NCT02623114|Drug|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
203767|NCT02623114|Drug|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
203768|NCT02623101|Device|Reflectance confocal microscopy|Non-invasive imaging of the lesion
203769|NCT02623101|Procedure|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
203770|NCT02623101|Procedure|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
203771|NCT02623088|Other|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
203773|NCT02623062|Drug|Compound Sodium Alginate Oral Suspension sachet|Contents of 2 sachets taken four times daily for 7 days
203774|NCT02623062|Drug|Matched placebo|Contents of 2 sachets taken four times daily for 7 days
203775|NCT02623049|Other|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
203776|NCT02623036|Drug|Equivalent dose enalapril|Chronotherapy with enalapril.
203777|NCT02623036|Drug|Equivalent dose lisinopril|Chronotherapy with lisinopril
203778|NCT02623023|Drug|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
203779|NCT02623023|Other|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
203780|NCT02623010|Drug|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
203781|NCT02622997|Other|Refrigerated|Self-sample taken and refrigerated immediately then stored in laboratory at -20oC until testing
203782|NCT02622997|Other|Incubated at 25oC for 1 week|Self-sample taken and refrigerated immediately then incubated at 25oC for 1 week in laboratory then at -20oC until testing
203783|NCT02622997|Other|Incubated at 25oC for 2 weeks|Self-sample taken and refrigerated immediately then incubated at 25oC for 2 weeks in laboratory then at -20oC until testing
203784|NCT02622984|Behavioral|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
203785|NCT02622984|Behavioral|SBIRT|"Face to face standard intervention considered treatment as usual."
203786|NCT02622971|Other|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
203787|NCT02622971|Other|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
203788|NCT02622958|Drug|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).~Dosing is sex-specific:~Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
203789|NCT02622958|Other|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).~Dosing is sex-specific:~Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg~Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
203790|NCT02622945|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
203791|NCT02622945|Device|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
203792|NCT02622932|Drug|Anlotinib and 14C-labeled Anlotinib|oral
203793|NCT02622906|Drug|Pasireotide|60 mg per month of the Pasireotide during 6 months
203794|NCT02622906|Drug|Placebo|Vehicule injection per month during 6 months
203795|NCT02622893|Drug|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
203796|NCT02622893|Drug|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
203797|NCT02622880|Dietary Supplement|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
203798|NCT02622880|Dietary Supplement|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an `immune-enhancing` feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
203799|NCT02622867|Other|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
203800|NCT02622867|Dietary Supplement|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
203801|NCT02622854|Procedure|plasma exchange|see arm description
203802|NCT02622854|Drug|conservative treatment|see arm description
203803|NCT02622841|Procedure|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
203804|NCT02622828|Behavioral|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
203805|NCT02622802|Drug|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
203806|NCT02622802|Drug|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
203807|NCT02622802|Drug|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
203808|NCT02622789|Other|Pilates Exercises|Pilates method based stability exercise intervention
203809|NCT02622776|Other|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
203810|NCT02622763|Biological|Tolerogenic Dendritic Cells|Intralesional administration
203811|NCT02622750|Procedure|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
203812|NCT02622750|Procedure|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
203813|NCT02622737|Other|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
203814|NCT02622737|Device|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
203815|NCT02622737|Device|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
203816|NCT02622724|Drug|Interferon beta-1a|Investigational drug
203817|NCT02622724|Drug|Placebo|Placebo for investigational drug
203818|NCT02622711|Behavioral|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
203819|NCT02622711|Behavioral|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
203820|NCT02622711|Behavioral|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
203821|NCT02622711|Behavioral|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
203822|NCT02622698|Dietary Supplement|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
203823|NCT02622698|Other|Placebo|Placebo- Patients did not take any protein supplementation after surgery
203824|NCT02622685|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
203825|NCT02622685|Drug|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
203826|NCT02622685|Drug|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
203827|NCT02622685|Drug|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
203828|NCT02622672|Dietary Supplement|water-soluble ubiquinol|100 mg/d
203829|NCT02622672|Dietary Supplement|Placebo|glycerin.soy-lecithin, and water
203830|NCT02622659|Drug|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day~1~3 years old: 10mL each time and three times a day~4~6 years old: 10mL each time and four times a day~7~12 years old: 10mL each time and five times a day"
203831|NCT02622659|Drug|Xiaoer Jiebiao Oral Liquid|"1~2 years old: 5mL each time and twice a day~3~5 years old: 5mL each time and three times a day~6~14 years old: 10mL each time and twice a day"
203832|NCT02622646|Drug|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~Describe PK parameters in patients on prophylaxis treatment with Advate®~Analyze differences in PK parameters in non-controlled vs well controlled patients~Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
203833|NCT02622633|Device|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
203834|NCT02622607|Drug|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
203835|NCT02622594|Drug|Aminolevulinic Acid (ALA)|
203836|NCT02622594|Device|Environ Cosmetic Roller|
203837|NCT02622594|Device|BLU-U IIlluminator|
203838|NCT02622581|Other|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
203839|NCT02622568|Drug|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
203840|NCT02622568|Procedure|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
203841|NCT02622555|Drug|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
203842|NCT02622542|Device|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
203843|NCT02622542|Other|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
203844|NCT02622529|Other|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
203871|NCT02622295|Behavioral|High-frequency active-resisted stance training|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit high muscle forces. Subjects will train for 16 weeks.
203845|NCT02622516|Other|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
203846|NCT02622516|Other|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.~The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
203847|NCT02622503|Drug|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
203848|NCT02622490|Other|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
203849|NCT02622477|Drug|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
203850|NCT02622464|Other|micro injection of SVF in vocal cords|
203851|NCT02622451|Behavioral|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
203852|NCT02622451|Behavioral|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
203853|NCT02622438|Other|Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.|
203854|NCT02622425|Dietary Supplement|Placebo|maltodextrin
203855|NCT02622425|Dietary Supplement|PD01|Carotenoid-producing Bacillus strain PD01
203856|NCT02622412|Other|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
203857|NCT02622412|Other|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
203858|NCT02622399|Behavioral|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
203859|NCT02622386|Drug|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
203860|NCT02622386|Other|Placebo|Matching placebo capsule taken daily for 12 weeks.
203861|NCT02622373|Device|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
203862|NCT02622334|Drug|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
203863|NCT02622334|Drug|Placebo|Matching placebo formulation will be administered in Part A.
203864|NCT02622334|Drug|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
203865|NCT02622321|Drug|Emicizumab|Emicizumab will be administered at a loading dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously (SC) for the first 4 weeks followed by a maintenance dose of 1.5 mg/kg/week SC up to the end of study.
203866|NCT02622321|Drug|rFVIIa|Participants will continue to receive rFVIIa.
203867|NCT02622321|Drug|aPCC|Participants will continue to receive aPCC.
203868|NCT02622308|Device|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
203869|NCT02622295|Behavioral|Single-session high-frequency active-resisted stance|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit high muscle forces.
203870|NCT02622295|Behavioral|Single-session low-frequency active-resisted stance|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit low muscle forces.
204021|NCT02621359|Drug|Levofloxacin|Levofloxacin 500 mg once daily
204022|NCT02621359|Drug|Doxycyclin|Doxycyclin 100 mg twice daily
203872|NCT02622295|Behavioral|Low-frequency active-resisted stance training|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit low muscle forces. Subjects will train for 16 weeks.
203873|NCT02622282|Other|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
203874|NCT02622282|Other|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
203875|NCT02622282|Other|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
203876|NCT02622269|Device|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
203877|NCT02622269|Device|Standard compression device|Compression of the abdomen with the standard compression device
203878|NCT02622256|Behavioral|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team & may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
203879|NCT02622243|Drug|Tiotropium|long acting muscarinic antagonist
203880|NCT02622243|Drug|glycopyrronium|long acting muscarinic antagonist
203881|NCT02622243|Device|Respimat|inhaler device used to deliver active tiotropium or placebo
203882|NCT02622243|Device|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
203883|NCT02622230|Drug|Mianhuahua Flavonoids Tablets|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
203884|NCT02622230|Drug|Placebo|Placebo to match with experimental groups
203885|NCT02622217|Behavioral|Sleep deprivation|
203886|NCT02622204|Procedure|Corrective osteotomy|corrective osteotomy for varus alignment
203887|NCT02622191|Device|Spectral domain Optical Coherence Tomography|Undilated peripapillary circular optic nerve scans and horizontal and vertical SD-OCT B-scan images centered on the fovea were acquired using Spectralis Heidelberg Retinal Angiography (HRA)+OCT (Heidelberg Engineering GmbH, Heidelberg, Germany).
203888|NCT02622178|Diagnostic Test|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
203889|NCT02622178|Diagnostic Test|Visual evoked potential|Visual evoked potential is a means of objectively testing visual field by viewing a computer monitor at 1 meter with a square black/white checkerboard pattern reversal stimulus. Electrodes are placed on the head and face to monitor Electroencephalogram (EEG) activity during testing. Output parameters from VEP system include amplitude and latency measures for each stimuli.
203890|NCT02622165|Behavioral|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
203891|NCT02622152|Procedure|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
203892|NCT02622152|Procedure|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
203893|NCT02622152|Procedure|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
203894|NCT02622152|Procedure|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
203895|NCT02622152|Procedure|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
203896|NCT02622139|Device|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
203897|NCT02622126|Drug|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
203898|NCT02622126|Drug|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
203899|NCT02622126|Drug|Morphine|Sub arachnoid 200 meg morphine
203900|NCT02622126|Drug|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
203901|NCT02622126|Drug|Ephedrine|If severe hypotension (fall of > 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
203902|NCT02622126|Drug|Atropine|Bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
203903|NCT02622113|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
203904|NCT02622113|Drug|Insulin|
203905|NCT02622100|Device|Bioresorbable Vascular Scaffold|
204023|NCT02621359|Drug|Omeprazole|Omeprazole 40 mg twice daily
204024|NCT02621346|Behavioral|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
203906|NCT02622087|Behavioral|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
203907|NCT02622074|Biological|Pembrolizumab|IV infusion
203908|NCT02622074|Drug|Nab-paclitaxel|IV infusion
203909|NCT02622074|Drug|Anthracycline (doxorubicin)|IV injection
203910|NCT02622074|Drug|Cyclophosphamide|IV infusion
203911|NCT02622074|Drug|Carboplatin|IV infusion
203912|NCT02622074|Drug|Paclitaxel|IV infusion
203913|NCT02622048|Behavioral|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
203914|NCT02622035|Behavioral|Provision of information|Information about fruit and vegetable feeding for children framed in gain vs. loss manner
203915|NCT02622035|Behavioral|Emotion induction|Film clip designed to induce anger or fear
203916|NCT02622022|Drug|Morphine hydrochloride|
203917|NCT02622022|Other|Placebo|
203918|NCT02622009|Procedure|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
203919|NCT02621996|Device|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
203920|NCT02621996|Device|containment nest|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
203921|NCT02621983|Behavioral|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
203922|NCT02621983|Behavioral|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
203923|NCT02621970|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
203924|NCT02621970|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1
203925|NCT02621970|Drug|Docetaxel|Docetaxel 60mg/m2, D1
203926|NCT02621970|Drug|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
203927|NCT02621970|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
203928|NCT02621957|Drug|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
203929|NCT02621957|Drug|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
203930|NCT02621944|Drug|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
203931|NCT02621944|Other|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
203932|NCT02621944|Other|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
203933|NCT02621944|Behavioral|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
203934|NCT02621931|Drug|Fremanezumab|Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration. The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
203935|NCT02621931|Drug|Placebo|Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
203936|NCT02621918|Other|Progressive resistance training|
203937|NCT02621918|Other|Aerobic training|
203938|NCT02621918|Other|Placebo training|
203939|NCT02621905|Drug|Sporanox|At least 2 capsules twice a day for 3 weeks
203940|NCT02621905|Drug|Lozanoc|At least 2 capsules twice a day for 3 weeks
203941|NCT02621892|Drug|Tenapanor|
203942|NCT02621892|Drug|Placebo|
203943|NCT02621879|Procedure|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
203944|NCT02621866|Device|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
203945|NCT02621866|Device|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of <500nm, but permits visible light to pass.
203946|NCT02621853|Device|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
203947|NCT02621840|Behavioral|Mandatory On-Site Pre-Admission Testing|
205963|NCT02607423|Drug|Pemetrexed Disodium|Given IV
203948|NCT02621827|Other|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
203949|NCT02621814|Dietary Supplement|Low glycation formula feeding|Formula feeding on demand for 3 months
203950|NCT02621814|Dietary Supplement|Commercially common formula feeding|Formula feeding on demand for 3 months
203951|NCT02621801|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
203952|NCT02621788|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
203953|NCT02621775|Behavioral|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
203954|NCT02621775|Behavioral|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
203955|NCT02621775|Other|Waiting list|The patients are followed by their General Practitioners without change in treatment .
203956|NCT02621762|Device|Magnesium|Magnesium in dialysate increased
203957|NCT02621762|Device|Bicarbonate|Bicarbonate in dialysate increased
203958|NCT02621749|Device|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
203959|NCT02621736|Other|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
203960|NCT02621710|Other|Questionnaire 3 months post-operatively|
203961|NCT02621697|Other|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
203962|NCT02621697|Other|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
203963|NCT02621684|Other|Community Health Activities Model Program for Seniors (CHAMPS)|"Physical activity questionnaire for older adults~Asks about activities in the past 4 weeks~41 questions and asks to notate how long the activity took"
203964|NCT02621684|Other|Lifetime Total Physical Activity Questionnaire|"Questions about leisure time (27) and household activities (5)~Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years"
203965|NCT02621684|Other|Expanded Prostate Cancer Index Composite (EPIC)|"Measures urinary and sexual function before and after prostate cancer treatment~7 questions about urinary function~9 questions about sexual function"
203966|NCT02621684|Other|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
203967|NCT02621684|Other|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
203968|NCT02621684|Other|Questionnaire regarding behavior/lifestyle changes since diagnosis|
203969|NCT02621684|Other|12 week Walking Program|
203970|NCT02621684|Other|12 week Resistance Training Program|
203971|NCT02621671|Behavioral|Cognitive interview|
203972|NCT02621671|Other|Survey|
203973|NCT02621658|Other|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
203974|NCT02621658|Other|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
203975|NCT02621645|Procedure|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
203976|NCT02621645|Procedure|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
203977|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
203978|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
203979|NCT02621645|Device|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
203980|NCT02621632|Device|(Socknleg)To done of a novel compression system|To done a novel compression system.
203981|NCT02621619|Drug|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
203982|NCT02621619|Drug|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
203983|NCT02621606|Drug|[11C]MK-6884|IV bolus dose of ~370 MBq [11C]MK-6884
203984|NCT02621593|Device|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
203985|NCT02621580|Device|Pan-Retinal Photocoagulation|"Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment."
203986|NCT02621567|Device|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
203987|NCT02621567|Device|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
203988|NCT02621554|Dietary Supplement|resveratrol supplementation|6 months of resveratrol supplementation
203989|NCT02621554|Dietary Supplement|Placebo|6 months of placebo intake
203990|NCT02621541|Device|PET/CT|
203991|NCT02621528|Device|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
203992|NCT02621515|Drug|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
203993|NCT02621502|Dietary Supplement|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
203994|NCT02621502|Dietary Supplement|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
203995|NCT02621502|Dietary Supplement|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
203996|NCT02621502|Dietary Supplement|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
203997|NCT02621502|Dietary Supplement|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.~Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:~In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.~In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
203998|NCT02621489|Drug|Bydureon|2 mg Once Weekly
203999|NCT02621489|Drug|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
204000|NCT02621489|Drug|Metformin|Metformin 1g BID
204001|NCT02621476|Behavioral|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
204002|NCT02621476|Behavioral|Usual care|Usual care
204003|NCT02621463|Device|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
204004|NCT02621450|Biological|standart dialysis|dialysate sodium consentration 140 mEq
204005|NCT02621450|Biological|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
204006|NCT02621437|Other|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
204007|NCT02621437|Other|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):~pain questionnaire with digital scale,~quality of life survey: SF-12~HAD (Hospital and Anxiety Depression) questionnaire"
204008|NCT02621424|Device|RTMS|stimulation of the brain with magnetic pulses
204009|NCT02621424|Device|sham|sham noise to block the sound of stimulation
204010|NCT02621411|Drug|Substance use|Patients are found use of substances by preoperative screen
204011|NCT02621398|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
204012|NCT02621398|Drug|Carboplatin|Given IV
204013|NCT02621398|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
204014|NCT02621398|Other|Laboratory Biomarker Analysis|Correlative studies
204015|NCT02621398|Drug|Paclitaxel|Given IV
204016|NCT02621398|Biological|Pembrolizumab|Given IV
204017|NCT02621385|Drug|tradipitant|test agent
204018|NCT02621385|Drug|Midazolam|substrate for drug-drug interaction assessment
204019|NCT02621372|Other|platelet count|Correlation of esophageal varices with platelet count
204020|NCT02621359|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily
204025|NCT02621346|Behavioral|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
204026|NCT02621346|Behavioral|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
204027|NCT02621333|Biological|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
204028|NCT02621333|Drug|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
204029|NCT02621320|Dietary Supplement|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
204030|NCT02621320|Dietary Supplement|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
204031|NCT02621307|Dietary Supplement|Salba|
204032|NCT02621307|Dietary Supplement|Flax|
204033|NCT02621307|Dietary Supplement|Control|
204034|NCT02621294|Other|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-[1-13C] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
204035|NCT02621281|Device|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
204036|NCT02621281|Device|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
204037|NCT02621268|Drug|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
204038|NCT02621255|Drug|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
204039|NCT02621255|Drug|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
204040|NCT02621242|Procedure|Upper endoscopy|Upper endoscopy with biopsies
204041|NCT02621242|Procedure|Anoscopy|Anoscopy with biopsies
204042|NCT02621242|Drug|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
204043|NCT02621190|Drug|cabazitaxel|25mg/m2 q3w
204044|NCT02621177|Biological|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
204045|NCT02621177|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
204046|NCT02621164|Biological|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
204047|NCT02621164|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
204048|NCT02621151|Biological|Pembrolizumab|
204049|NCT02621151|Procedure|Transurethral Resection of Bladder Tumor|
204050|NCT02621151|Drug|Gemcitabine|
204051|NCT02621151|Radiation|External Beam Radiation Therapy|
204052|NCT02621125|Dietary Supplement|Fertilix|daily supplementation
204053|NCT02621125|Other|Placebo|Placebo
204054|NCT02621112|Biological|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
204055|NCT02621112|Biological|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
204056|NCT02621112|Biological|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
204057|NCT02621099|Device|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
204058|NCT02621086|Dietary Supplement|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
204059|NCT02621073|Drug|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
204060|NCT02621073|Device|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
204061|NCT02621060|Drug|Placebo|Placebo: 1200 mg per day for three months
204062|NCT02621060|Drug|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
204063|NCT02621047|Drug|Alectinib|Participants will receive alectinib as per the dosage schedule mentioned in arm description.
204064|NCT02621034|Procedure|Control|K-file hand instrumentation
204065|NCT02621034|Procedure|Reciproc|reciprocating rotary instrument
204066|NCT02621034|Procedure|One shape|full rotation protocol
204067|NCT02621021|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg /day over 1 hour X 2 days.
204068|NCT02621021|Drug|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
204069|NCT02621021|Drug|Aldeslaukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
204070|NCT02621021|Drug|Pembrolizumab|(Cohort 1, Arm 2 and Cohort 2) On day -2, and days 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days) following cell infusion: Pembrolizumab 2mg/kg IV over approximately 30 minutes. (Cohort 1, Arm 1 Retreatment) 4 doses every 3 weeks (+/- 2 days): Pembrolizumab 2mg/kg IV over approximately 30 minutes.
204071|NCT02621021|Biological|young TIL|Day 0: Cells will be administered intravenously (IV) on the Patient Care Unit over 20-30 minutes.
204122|NCT02620722|Device|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
204072|NCT02621008|Other|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
204073|NCT02620995|Drug|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
204074|NCT02620995|Other|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
204075|NCT02620982|Device|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
204076|NCT02620969|Other|Blood and dialysate sampling|Blood and dialysate sampling
204077|NCT02620956|Other|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
204078|NCT02620930|Device|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
204079|NCT02620904|Drug|Mifepristone|
204080|NCT02620904|Drug|placebo|
204081|NCT02620891|Device|helium oxygen mixture|
204082|NCT02620878|Device|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
204083|NCT02620878|Other|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
204084|NCT02620865|Biological|Aldesleukin|Given SC
204085|NCT02620865|Biological|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
204086|NCT02620865|Drug|Fluorouracil|Given IV
204087|NCT02620865|Drug|Gemcitabine Hydrochloride|Given IV
204088|NCT02620865|Drug|Irinotecan Hydrochloride|Given IV
204089|NCT02620865|Other|Laboratory Biomarker Analysis|Correlative studies
204090|NCT02620865|Drug|Leucovorin Calcium|Given IV
204091|NCT02620865|Drug|Oxaliplatin|Given IV
204092|NCT02620865|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
204093|NCT02620865|Biological|Sargramostim|Given SC
204094|NCT02620852|Other|Complete a health questionnaire|Complete a health history questionnaire.
204095|NCT02620852|Genetic|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
204096|NCT02620852|Other|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
204097|NCT02620852|Other|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
204098|NCT02620839|Drug|Alpelisib|Given PO
204099|NCT02620839|Drug|Cisplatin|Given IV
204100|NCT02620826|Procedure|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
204101|NCT02620826|Procedure|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
204102|NCT02620813|Drug|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
204103|NCT02620813|Drug|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
204104|NCT02620800|Drug|5FU|5 fluorouracil (5-FU) (180 mg/m^2/day for 14 days) by CIVI via ambulatory pump
204105|NCT02620800|Drug|nab-paclitaxel|nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
204106|NCT02620800|Drug|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
204107|NCT02620800|Drug|calcium leucovorin|calcium leucovorin (20 mg/m^2) IV bolus, on Days 1, 8, 15
204108|NCT02620800|Drug|oxaliplatin|oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15
204109|NCT02620787|Drug|Tedizolid|
204110|NCT02620787|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
204111|NCT02620774|Drug|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
204112|NCT02620774|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
204113|NCT02620761|Drug|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
204114|NCT02620761|Drug|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
204115|NCT02620748|Drug|Tranexamic Acid|
204116|NCT02620748|Other|Saline Solution|
204117|NCT02620735|Device|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
204118|NCT02620735|Behavioral|Exercise Only|12 week exercise program
204119|NCT02620735|Behavioral|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
204120|NCT02620735|Behavioral|Health Coaching|10 over the phone health coaching sessions.
204121|NCT02620722|Device|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
204123|NCT02620709|Behavioral|Hula intervention|Hula and heart health education
204124|NCT02620696|Drug|netazepide|
204125|NCT02620683|Drug|Lidocaine|See above
204126|NCT02620670|Behavioral|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
204127|NCT02620657|Other|Non interventional study|Non interventional study
204128|NCT02620644|Device|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
204129|NCT02620631|Drug|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
204130|NCT02620631|Drug|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
204131|NCT02620618|Drug|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
204132|NCT02620605|Drug|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
204133|NCT02620605|Drug|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
204134|NCT02620592|Drug|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
204135|NCT02620592|Drug|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
204136|NCT02620579|Drug|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
204137|NCT02620579|Drug|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
204138|NCT02620579|Behavioral|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
204139|NCT02620579|Behavioral|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
204140|NCT02620566|Procedure|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
204141|NCT02620566|Procedure|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
204142|NCT02620553|Drug|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
204143|NCT02620553|Other|Oral Placebo|Oral Placebo is given orally daily
204144|NCT02620540|Device|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
204145|NCT02620514|Behavioral|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
204146|NCT02620514|Behavioral|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
204147|NCT02620514|Behavioral|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
204148|NCT02620514|Behavioral|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
204149|NCT02620501|Drug|Lidocaine|topical lidocaine
204150|NCT02620501|Drug|Placebo|0.45% Normal Saline
204151|NCT02620488|Behavioral|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
204218|NCT02620007|Drug|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
205996|NCT02607202|Drug|nab-paclitaxel|
204152|NCT02620475|Device|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
204153|NCT02620462|Device|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
204154|NCT02620449|Other|Diet|Participants will be fed a low-additive diet as the primary intervention
204155|NCT02620436|Other|Core Mother Shelter Model|"Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.~Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.~Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
204156|NCT02620423|Biological|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
204157|NCT02620423|Drug|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
204158|NCT02620423|Drug|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
204159|NCT02620423|Drug|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
204160|NCT02620423|Drug|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
204161|NCT02620423|Drug|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
204162|NCT02620423|Drug|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
204163|NCT02620410|Device|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
204164|NCT02620384|Drug|Experimental: Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
204165|NCT02620384|Drug|Experimental: Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
204166|NCT02620371|Procedure|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.~We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
204167|NCT02620358|Other|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
204168|NCT02620358|Other|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
204169|NCT02620345|Drug|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature~Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.~1tablet/24 hours/day (to 4 weeks after postpartum)"
204170|NCT02620345|Drug|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature~Fibroids/ Women of Reproductive age ( discovered fibroids )~1tablet/24 hours/day ( from discovered fibroids through 6 months)"
204171|NCT02620332|Drug|MultiPepT1De injection|A mix of peptides
204172|NCT02620332|Other|Placebo|Water for injection
204173|NCT02620319|Device|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
204174|NCT02620306|Drug|Fimsartan 60mg~120mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
204175|NCT02620306|Drug|Fimsartan 60mg~120mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
204295|NCT02619448|Drug|Paclitaxel|chemotherapy
204176|NCT02620306|Drug|Losartan 50mg~100mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
204177|NCT02620306|Drug|Losartan 50mg~100mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
204178|NCT02620293|Device|Eczema Repair Emollient|An Emollient
204179|NCT02620280|Drug|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
204180|NCT02620280|Drug|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
204181|NCT02620280|Drug|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
204182|NCT02620280|Procedure|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
204183|NCT02620280|Drug|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
204184|NCT02620267|Device|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
204185|NCT02620241|Other|sitting position|
204186|NCT02620228|Device|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
204187|NCT02620215|Device|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
204188|NCT02620215|Drug|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
204189|NCT02620189|Drug|Anti-TNF Biologics Therapy|
204190|NCT02620176|Device|Transcutaneous vagal nerve stimulation|Trans-auricular vagal nerve stimulation
204191|NCT02620163|Drug|telmisartan/amlodipine 40/5mg|
204192|NCT02620163|Drug|YH22162 40/5/12.5 mg|
204193|NCT02620163|Drug|telmisartan/amlodipine 80/5mg|
204194|NCT02620163|Drug|YH22162 80/5/25 mg|
204195|NCT02620163|Drug|telmisartan/amlodipine 40/5mg placebo|
204196|NCT02620163|Drug|YH22162 40/5/12.5 mg placebo|
204197|NCT02620163|Drug|telmisartan/amlodipine 80/5mg placebo|
204198|NCT02620163|Drug|YH22162 80/5/25 mg placebo|
204199|NCT02620150|Drug|Escitalopram|10 week trial
204200|NCT02620150|Other|Placebo|10 week trial
204201|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
204202|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
204203|NCT02620124|Drug|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
204204|NCT02620124|Drug|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
204205|NCT02620111|Dietary Supplement|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
204206|NCT02620111|Dietary Supplement|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
204207|NCT02620098|Other|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
204208|NCT02620085|Procedure|blood sampling|blood sampling
204209|NCT02620072|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
204210|NCT02620072|Other|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
204211|NCT02620059|Behavioral|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
204212|NCT02620046|Drug|Vedolizumab SC|Vedolizumab SC 108 mg injection QW
204213|NCT02620033|Behavioral|Yoga therapy|
204214|NCT02620020|Drug|Fasinumab|Participants received fasinumab SC or IV, Q4W or Q8W.
204215|NCT02620020|Drug|placebo|Participants received placebo matching to fasinumab SC or IV, Q4W or Q8W.
204216|NCT02620007|Drug|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
204217|NCT02620007|Drug|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
205997|NCT02607202|Drug|Carboplatin|
204219|NCT02620007|Drug|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
204220|NCT02619994|Drug|Linezolid|
204221|NCT02619994|Drug|Delamanid|
204222|NCT02619994|Drug|Levofloxacin|
204223|NCT02619994|Drug|Pyrazinamide|
204224|NCT02619994|Drug|Locally-used WHO-approved MDR-TB regimen in Korea|
204225|NCT02619981|Procedure|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
204226|NCT02619981|Drug|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
204227|NCT02619968|Other|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
204228|NCT02619955|Other|samples with DNA|
204229|NCT02619942|Procedure|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
204230|NCT02619942|Procedure|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
204231|NCT02619929|Drug|Vinorelbine oral|
204232|NCT02619916|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
204233|NCT02619916|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
204234|NCT02619903|Procedure|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
204235|NCT02619890|Other|Brain Glioma Registry|
204236|NCT02619877|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
204237|NCT02619877|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
204238|NCT02619864|Drug|AZD2014|
204239|NCT02619851|Biological|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
204240|NCT02619851|Device|Conventional Therapy|Typical therapy conducted for burn injury patients
204241|NCT02619838|Device|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
204242|NCT02619825|Device|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
204243|NCT02619825|Device|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
204244|NCT02619812|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
204245|NCT02619812|Drug|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
204246|NCT02619812|Other|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
204247|NCT02619799|Drug|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
204248|NCT02619799|Drug|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
204249|NCT02619786|Drug|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
204250|NCT02619773|Procedure|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
204251|NCT02619760|Drug|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
204252|NCT02619760|Drug|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
204253|NCT02619747|Drug|Compound Sodium Alginate Oral Suspension sachet|
204254|NCT02619747|Drug|Matched placebo|
204255|NCT02619734|Biological|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
204256|NCT02619721|Device|PINS SNS|
204257|NCT02619708|Behavioral|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
204258|NCT02619695|Drug|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
204259|NCT02619682|Drug|Ixazomib Citrate|Given PO
204260|NCT02619682|Other|Laboratory Biomarker Analysis|Correlative studies
204261|NCT02619682|Drug|Lenalidomide|Given PO
204262|NCT02619669|Drug|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
205998|NCT02607202|Drug|Gemcitabine|
204263|NCT02619669|Drug|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
204264|NCT02619656|Procedure|CO2 insufflation|Patients were randomized to insufflation with CO2.
204265|NCT02619656|Procedure|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
204266|NCT02619643|Device|Transcranial Magnetic Stimulation (Magstim)|
204267|NCT02619630|Drug|nelarabine|"Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil >1 Giga/Liter~for a maximum of 5 blocks"
204268|NCT02619617|Drug|SOM230|The study will evaluate SOM230 vs Placebo
204269|NCT02619617|Drug|Placebo|The study will evaluate SOM230 vs Placebo
204270|NCT02619604|Other|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
204271|NCT02619591|Other|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
204272|NCT02619578|Other|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
204273|NCT02619578|Other|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
204274|NCT02619578|Drug|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
204275|NCT02619578|Other|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
204276|NCT02619565|Other|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
204277|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
204278|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
204279|NCT02619552|Drug|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
204280|NCT02619539|Procedure|plasma fibrinogen measurement|plasma fibrinogen measurement
204281|NCT02619526|Drug|Nebivolol|Nebivolol 10mg, once a day
204282|NCT02619526|Drug|Carvedilol|Carvedilol 25mg, twice a day
204283|NCT02619513|Drug|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
204284|NCT02619513|Drug|Ropivacaine|Group GE\GT\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
204285|NCT02619513|Device|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
204286|NCT02619500|Other|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
204287|NCT02619500|Other|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
204288|NCT02619500|Other|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
204289|NCT02619500|Other|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
204290|NCT02619487|Other|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
204291|NCT02619487|Other|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
204292|NCT02619474|Other|Whiteboard|"On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.~The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.~Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning."
204293|NCT02619461|Other|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
204294|NCT02619448|Drug|Carboplatin|chemotherapy
204296|NCT02619448|Radiation|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
204297|NCT02619435|Drug|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
204298|NCT02619422|Other|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
204299|NCT02619409|Drug|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
204300|NCT02619409|Drug|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
204301|NCT02619409|Drug|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
204302|NCT02619409|Drug|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
204303|NCT02619409|Drug|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
204304|NCT02619396|Procedure|Combination 1 of RF power and LSI on LA posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
204305|NCT02619396|Procedure|Combination 2 of RF power and LSI on LA posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
204306|NCT02619396|Procedure|Combination 3 of RF power and LSI on LA posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
204307|NCT02619396|Procedure|Combination 4 of RF power and LSI on LA posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
204308|NCT02619383|Device|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
204309|NCT02619370|Behavioral|Conversation card game|
204310|NCT02619370|Behavioral|Active Control|
204311|NCT02619357|Device|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
204312|NCT02619357|Device|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
204313|NCT02619357|Device|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
204314|NCT02619357|Device|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
204315|NCT02619357|Device|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
204316|NCT02619357|Other|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
204317|NCT02619357|Other|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
204318|NCT02619357|Other|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
204319|NCT02619331|Procedure|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
204320|NCT02619318|Behavioral|Balancing Everyday Life (BEL)|
204321|NCT02619318|Behavioral|Care as usual (generally standard occupational therapy)|
204322|NCT02619305|Other|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
204323|NCT02619292|Behavioral|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
204324|NCT02619279|Other|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
204325|NCT02619266|Other|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
204326|NCT02619266|Other|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
204327|NCT02619266|Drug|Megestrol Acetate|Megestrol Acetate 160mg tablet
204328|NCT02619266|Drug|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
204329|NCT02619253|Drug|Pembrolizumab|
204330|NCT02619253|Drug|Vorinostat|
204331|NCT02619240|Procedure|bronchoscopy|performance of bronchoscopy with BAL
204332|NCT02619227|Other|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
204333|NCT02619214|Drug|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
204334|NCT02619214|Drug|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
204335|NCT02619201|Drug|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
204336|NCT02619201|Drug|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
204337|NCT02619188|Other|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
204338|NCT02619188|Other|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
204339|NCT02619188|Other|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
204340|NCT02619188|Other|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
204341|NCT02619175|Device|Stroke Subjects Perturbation-Based Balance Training|
204342|NCT02619175|Device|Stroke Subjects Weight Shifting and Gait training|
204343|NCT02619162|Drug|Nintedanib|Tablets of 100 mg. or 150 mg.
204344|NCT02619162|Drug|Letrozole|Tablet of 2.5 mg.
204345|NCT02619149|Drug|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
204346|NCT02619149|Drug|Saline solution|Saline iv as placebo control
204347|NCT02619136|Procedure|Transfusion|Red Blood Cell Transfusion
204348|NCT02619123|Other|Tailored screening according to breast density|Different interval of mammography screening according to breast density
204349|NCT02619123|Other|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
204350|NCT02619110|Other|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
204351|NCT02619110|Other|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
204352|NCT02619097|Drug|Pegol-sihematide injection|single dose
204353|NCT02619084|Procedure|STN DBS|Bilateral STN DBS
204354|NCT02619071|Procedure|Tumor sampling|Bone marrow aspirate, blood sampling
204355|NCT02619071|Biological|Constiutional DNA sampling|Buccal swab or Hair follicles
204356|NCT02619058|Biological|NKT cells|autologous natural killer T cell
204357|NCT02619045|Other|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:~telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),~specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),~actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
204358|NCT02619032|Drug|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
204359|NCT02619032|Drug|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
204360|NCT02619019|Drug|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
204361|NCT02619019|Drug|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
204362|NCT02619019|Drug|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
204363|NCT02619006|Other|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
204364|NCT02618993|Procedure|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
204365|NCT02618980|Other|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
204366|NCT02618967|Biological|AMG 570|7 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
204367|NCT02618967|Biological|AMG 570 Matching Placebo|7 dose levels of Placebo administered as single dose subcutaneous in healthy volunteers.
204368|NCT02618954|Other|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
204369|NCT02618941|Biological|AFFITOPE® PD01A|s.c. injection
204370|NCT02618915|Genetic|DTX101|solution for IV infusion
204371|NCT02618902|Biological|tolerogenic dendritic cells (tolDC)|dose-escalation
204372|NCT02618889|Behavioral|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
204373|NCT02618876|Drug|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
204374|NCT02618876|Drug|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
204375|NCT02618863|Device|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
204376|NCT02618850|Procedure|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
204377|NCT02618850|Drug|first-line chemotherapy|as prescribed by oncologist
204378|NCT02618837|Procedure|Downstream strategy|"At diagnosis:~Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel~Pre-procedure:~Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.~In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor~At the time of PCI, the loading doses required (according to randomization):~Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months~Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel* daily for at least 12 months~If subject is >75 years old or <60 kg, daily dose of prasugrel should be 5mg"
204444|NCT02618226|Device|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
204379|NCT02618837|Procedure|Upstream strategy|"At the time of diagnosis:~Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.~Pre-procedure:~All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.~Peri- and post-procedure:~For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.~All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF)."
204380|NCT02618824|Drug|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
204381|NCT02618824|Other|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
204382|NCT02618785|Procedure|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
204383|NCT02618772|Drug|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
204384|NCT02618772|Drug|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
204385|NCT02618759|Drug|DSXS|active treatment
204386|NCT02618759|Drug|Placebo|placebo treatment
204387|NCT02618746|Other|Telerehabilitation|
204388|NCT02618746|Other|Hospital based Rehabilitation|
204389|NCT02618733|Drug|Ticagrelor|90mg, twice a day
204390|NCT02618733|Drug|Clopidogrel|75mg, once a day
204391|NCT02618720|Drug|ornidazole|
204392|NCT02618720|Drug|Placebo|
204393|NCT02618707|Other|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
204394|NCT02618694|Procedure|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
204395|NCT02618694|Procedure|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, & Ihara, 2012; Linos, 2005; George & Kavoussi, 2010).
204396|NCT02618668|Drug|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
204397|NCT02618668|Drug|Propofol|2 mg/kg I.V
204398|NCT02618655|Other|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
204399|NCT02618642|Radiation|Piler light phototherapy|"Piler light + red filter: phototherapy, 10 treatment sessions,10 minutes for one session Piler light + blue filter: phototherapy, 10 treatment sessions,10 minutes for one session Piler light without a filter: phototherapy, 10 treatment sessions, 10 minutes for one session~Piler light + red filter: 10 people Piler light + blue filter: 10 people Piler light without a filter: 10 people"
204400|NCT02618629|Drug|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
204401|NCT02618616|Drug|ZPL-3893787|
204402|NCT02618616|Drug|Placebo|
204403|NCT02618603|Drug|Botulinum toxin A|
204404|NCT02618603|Drug|Triamcinolone Acetonide|
204405|NCT02618577|Drug|Edoxaban|"Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
204406|NCT02618577|Drug|ASA|ASA 100 mg tablets or Placebo
204407|NCT02618564|Drug|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
204480|NCT02617914|Procedure|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
204552|NCT02617355|Device|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
204408|NCT02618551|Procedure|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.~Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)~A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
204409|NCT02618525|Other|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
204410|NCT02618525|Other|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
204411|NCT02618512|Drug|SBC-103|SBC-103 is a recombinant human alpha-N-acetylglucosaminidase (rhNAGLU). Patients were started with low dose of SBC-103 for 12 weeks and then will escalate to a higher dose.
204412|NCT02618499|Drug|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
204413|NCT02618486|Procedure|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
204414|NCT02618473|Other|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
204415|NCT02618460|Device|Non contrast-enhanced magnetic resonance imaging|
204416|NCT02618447|Device|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
204417|NCT02618447|Procedure|Portal vein embolization|
204418|NCT02618434|Drug|SPN-810|
204419|NCT02618434|Drug|Placebo|
204420|NCT02618408|Drug|SPN-810|
204421|NCT02618408|Drug|Placebo|
204422|NCT02618395|Drug|SPARC001A|
204423|NCT02618395|Drug|SPARC001B|
204424|NCT02618395|Drug|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
204425|NCT02618382|Drug|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
204426|NCT02618369|Device|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
204427|NCT02618356|Drug|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage <1.25 m2 80 mg/d~1.25m2 — <1.5 m2 100 mg/d~1.5 m2 120 mg/d"
204428|NCT02618343|Drug|IPA|IPA Aromatherapy for the experimental arm
204429|NCT02618343|Drug|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
204430|NCT02618330|Device|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
204431|NCT02618317|Drug|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
204432|NCT02618317|Drug|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
204433|NCT02618317|Drug|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
204434|NCT02618304|Drug|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
204435|NCT02618291|Other|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
204436|NCT02618291|Other|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
204437|NCT02618278|Other|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
204438|NCT02618265|Procedure|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
204439|NCT02618265|Procedure|traditional management|aspirin or clopidogrel monotherapy or double treatment for
204440|NCT02618265|Procedure|website platform management|second prevention based on website platform management
204441|NCT02618252|Device|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
204442|NCT02618252|Device|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
204443|NCT02618239|Dietary Supplement|Bimuno Galacto-oligo-saccharide|
204445|NCT02618213|Device|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
204446|NCT02618213|Device|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
204447|NCT02618200|Device|3D prostate ultrasound|
204448|NCT02618187|Drug|SER-287|
204449|NCT02618187|Drug|Placebo|
204450|NCT02618187|Drug|Placebo Pre-Treat|
204451|NCT02618187|Drug|Vancomycin Pre-Treat|
204452|NCT02618174|Behavioral|Neutral Control Condition|Message about age of University of Birmingham
204453|NCT02618174|Behavioral|Food-based Control Condition|Message about variety of vegetables in the world
204454|NCT02618174|Behavioral|Health Condition|Message about the health benefits of eating vegetables
204455|NCT02618174|Behavioral|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
204456|NCT02618174|Behavioral|Liking Social Norm|Message suggesting most people like eating vegetables
204457|NCT02618161|Radiation|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
204458|NCT02618161|Radiation|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
204459|NCT02618148|Drug|ESTROGEN HERBALS 21|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
204460|NCT02618148|Drug|ESTROGEN HERBALS 28|"Applies to the following strengths:~17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
204461|NCT02618135|Other|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
204462|NCT02618135|Other|Control Group|"Participants will wait for 8 weeks before training intervention begins.~Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
204463|NCT02618109|Biological|Collection of blood samples|Collection of blood samples
204464|NCT02618096|Drug|Oxytocin|
204465|NCT02618096|Drug|Dinoprostone|
204466|NCT02618096|Procedure|Membrane sweeping|
204467|NCT02618083|Device|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
204468|NCT02618070|Other|Yogurt|
204469|NCT02618057|Drug|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
204470|NCT02618057|Drug|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
204471|NCT02618031|Procedure|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA directly at the site of the clot.
204472|NCT02618018|Procedure|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
204473|NCT02618005|Dietary Supplement|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
204474|NCT02617979|Other|SAFECARE at Home customized lessons|
204475|NCT02617953|Device|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
204476|NCT02617953|Device|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
204477|NCT02617953|Device|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.~auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
204478|NCT02617940|Other|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.~Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
204479|NCT02617940|Other|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
204481|NCT02617901|Radiation|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.~Radiographs and DXA will be read in random and varied order."
204482|NCT02617888|Radiation|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
204483|NCT02617875|Other|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
204484|NCT02617875|Other|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
204485|NCT02617862|Procedure|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
204486|NCT02617862|Device|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
204487|NCT02617862|Device|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
204488|NCT02617849|Drug|Pembrolizumab|200 mg IV every 3 weeks
204489|NCT02617849|Drug|Carboplatin|AUC=6, every 3 weeks x 4
204490|NCT02617849|Drug|Paclitaxel|175 mg/m2, every 3 weeks x 4
204491|NCT02617823|Procedure|lateral position|patients placed on their left side after epidural catheter insertion
204492|NCT02617810|Drug|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
204493|NCT02617810|Drug|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
204494|NCT02617810|Drug|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
204495|NCT02617797|Device|Radiofrequecy|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
204496|NCT02617797|Device|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
204497|NCT02617784|Drug|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
204498|NCT02617771|Drug|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
204499|NCT02617758|Drug|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
204500|NCT02617758|Drug|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
204501|NCT02617745|Other|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
204502|NCT02617732|Drug|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.~The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
204503|NCT02617732|Drug|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.~The placebo group patients are treated with placebo by oral, 5 pills three times a day"
204504|NCT02617706|Device|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
204505|NCT02617693|Behavioral|lifestyle intervention|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform. The intervention consists of a combination of behaviour change counselling and support through six contact-points with CHPs (community health promoter) and access to a personalised mobile application.
204506|NCT02617693|Other|standard antenatal care|Standard of care for pre-pregnancy health. Subjects will be reminded of their endpoint measurement visit towards the end of the intervention period through a phone call.
204507|NCT02617680|Drug|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
204508|NCT02617680|Drug|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
204509|NCT02617667|Drug|Cyclosporine A|topical ocular, eye drops
204510|NCT02617667|Drug|Placebo|topical ocular, eye drops
204511|NCT02617654|Drug|Liraglutide|Treatment with liraglutide for 52 weeks
204512|NCT02617654|Drug|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
204513|NCT02617641|Behavioral|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
204514|NCT02617641|Behavioral|Publicly available websites|"Le Programme de marche (Institut de Cardiologie de Montréal)~L'activité physique (Institut de Cardiologie de Montréal)~L'activité physique (Fondation des maladies du cœur et de l'AVC)~Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)~Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
204515|NCT02617628|Drug|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
204516|NCT02617615|Drug|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
204517|NCT02617615|Drug|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
204518|NCT02617602|Procedure|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:~Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;~cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:~decreased heart rate (HR): dobutamine, dopamine;~normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
204519|NCT02617602|Other|Control|
204520|NCT02617589|Drug|Nivolumab|
204521|NCT02617589|Drug|Temozolomide|
204522|NCT02617589|Radiation|Radiotherapy|
204523|NCT02617563|Device|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
204524|NCT02617550|Drug|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
204525|NCT02617550|Drug|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets [o.d.].
204526|NCT02617550|Drug|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat [trough] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat [peak] or placebo) on day 13, day 27 and day 41
204527|NCT02617537|Drug|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
204528|NCT02617537|Drug|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
204529|NCT02617524|Device|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
204530|NCT02617511|Dietary Supplement|Omega-3 Supplementation|
204531|NCT02617511|Dietary Supplement|Placebo|
204532|NCT02617498|Device|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
204533|NCT02617498|Device|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
204534|NCT02617485|Drug|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
204535|NCT02617485|Drug|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
204536|NCT02617485|Drug|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
204537|NCT02617485|Drug|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
204538|NCT02617485|Drug|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
204539|NCT02617472|Device|Pelvic floor exerciser|Daily exercise using the study device
204540|NCT02617459|Drug|Levobetaxolol eye drops|one drop per time; twice daily
204541|NCT02617459|Drug|Betaxolol eye drops|one drop per time; twice daily
204542|NCT02617446|Drug|placebo|
204543|NCT02617446|Drug|Istaroxime|
204544|NCT02617433|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
204545|NCT02617420|Device|Propeller Health Monitoring Device|
204546|NCT02617407|Other|Livionex® Dental Gel|Dental Plaque, Gingivitis and Oral Microbiome Control.
204547|NCT02617407|Other|PreviDent 5000 plus/Tom's of Maine Children's toothpaste|Dental Plaque, Gingivitis and Oral Microbiome Control.
204548|NCT02617394|Other|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
204549|NCT02617394|Other|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
204550|NCT02617381|Other|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
204551|NCT02617355|Device|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
204584|NCT02617121|Drug|Ramosetron|ramosetron 0.3 mg iv at end of surgery
204553|NCT02617355|Device|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
204554|NCT02617355|Device|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
204555|NCT02617355|Device|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
204556|NCT02617342|Behavioral|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
204557|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
204558|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
204559|NCT02617316|Other|Barefoot|barefoot running test was 20 minutes.
204560|NCT02617316|Other|In shoes|In shoes test was 20 minutes.
204561|NCT02617303|Procedure|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 3 months and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
204562|NCT02617303|Procedure|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
204563|NCT02617290|Drug|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
204564|NCT02617290|Drug|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
204565|NCT02617277|Drug|AZD1775|AZD1775 (adavosertib) is available in capsules for oral administration.
204566|NCT02617277|Drug|MEDI4736|MEDI4736 (durvalumab) will be administered by IV infusion.
204567|NCT02617264|Procedure|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
204568|NCT02617251|Other|No intervention|
204569|NCT02617238|Other|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
204570|NCT02617225|Behavioral|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.~DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
204571|NCT02617225|Behavioral|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
204572|NCT02617212|Procedure|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
204573|NCT02617212|Device|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
204574|NCT02617212|Device|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
204575|NCT02617199|Drug|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
204576|NCT02617199|Drug|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
204577|NCT02617186|Procedure|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
204578|NCT02617186|Procedure|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
204579|NCT02617173|Device|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
204580|NCT02617160|Device|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
204581|NCT02617160|Other|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
204582|NCT02617134|Biological|anti-MUC1 CAR-T cells|
204583|NCT02617121|Drug|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
204585|NCT02617121|Drug|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
204586|NCT02617108|Device|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
204587|NCT02617095|Device|T2762|One drop in each eye 3 to 6 times daily
204588|NCT02617095|Device|Optive|One drop in each eye 3 to 6 times daily
204589|NCT02617082|Radiation|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
204590|NCT02617069|Biological|botulinum toxin injection|
204591|NCT02617069|Biological|0.9% normal saline injection|
204592|NCT02617069|Device|Implantable loop recorder|
204593|NCT02617043|Radiation|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
204594|NCT02617017|Drug|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
204595|NCT02617017|Drug|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
204596|NCT02616991|Procedure|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
204597|NCT02616965|Drug|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
204598|NCT02616965|Drug|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
204599|NCT02616952|Dietary Supplement|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
204600|NCT02616952|Behavioral|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
204601|NCT02616939|Other|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
204602|NCT02616926|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
204603|NCT02616926|Procedure|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
204604|NCT02616926|Procedure|RFA|RFA will be performed 1 week after TACE.
204605|NCT02616913|Other|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
204606|NCT02616913|Other|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
204607|NCT02616913|Other|Placebo|Each subject consumes placebo in one of 3 treatment periods
204608|NCT02616900|Device|eSight Eyewear|primary intervention
204609|NCT02616887|Radiation|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
204610|NCT02616874|Drug|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
204611|NCT02616874|Drug|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
204612|NCT02616861|Drug|IW-1973|IW-1973 Tablet
204613|NCT02616861|Drug|Matching Placebo Tablet|Matching placebo tablet
204614|NCT02616848|Drug|Everolimus|
204615|NCT02616848|Drug|Eribulin|
204616|NCT02616835|Device|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
204617|NCT02616835|Device|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
204618|NCT02616822|Dietary Supplement|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
204619|NCT02616822|Other|Placebo|Used for placebo substance single dose
204620|NCT02616809|Other|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
204621|NCT02616809|Other|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
204622|NCT02616809|Other|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
204623|NCT02616809|Other|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
204624|NCT02616796|Behavioral|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
204625|NCT02616783|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
204626|NCT02616783|Drug|TDF|300 mg tablet administered orally once daily
204627|NCT02616783|Drug|FTC|200 mg capsule administered orally once daily
204628|NCT02616783|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
204630|NCT02616783|Drug|Third agent|"Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)~Drug classes:~Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV~Pharmacokinetic enhancer: COBI~Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~Integrase inhibitors: RAL and DTG"
204631|NCT02616770|Drug|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
204632|NCT02616770|Drug|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
204633|NCT02616770|Drug|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
204634|NCT02616770|Drug|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
204635|NCT02616770|Drug|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
204636|NCT02616770|Drug|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
204637|NCT02616757|Device|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
204638|NCT02616744|Drug|Ibandronic acid|150 mg per month oral ibandronate
204639|NCT02616744|Drug|Placebo|1 oral capsule of placebo per month
204640|NCT02616731|Drug|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
204641|NCT02616731|Drug|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
204642|NCT02616718|Radiation|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
204643|NCT02616692|Drug|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
204644|NCT02616666|Drug|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
204645|NCT02616666|Drug|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
204646|NCT02616653|Procedure|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
204647|NCT02616640|Drug|Durvalumab|
204648|NCT02616640|Drug|Pomalidomide|
204649|NCT02616640|Drug|Dexamethasone|
204650|NCT02616614|Drug|Onexton|Topical gel for treating acne
204651|NCT02616614|Drug|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
204652|NCT02616614|Drug|Placebo|Vehicle gel used as a placebo
204653|NCT02616601|Drug|Generic Fluorouracil Cream|Topical cream, generic formulation of the brand product.
204654|NCT02616601|Drug|Carac® (Fluorouracil) Cream|Topical cream, brand product.
204655|NCT02616601|Drug|Vehicle Cream|Topical cream, placebo. Has no active ingredient.
204656|NCT02616588|Behavioral|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
204657|NCT02616562|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) once-weekly.
204658|NCT02616562|Drug|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
204659|NCT02616549|Behavioral|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
204660|NCT02616536|Other|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
204661|NCT02616523|Drug|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
204662|NCT02616523|Drug|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
204663|NCT02616523|Other|placebo|The participants will be given infusion of normal saline intravenously.
204664|NCT02616523|Drug|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
204665|NCT02616510|Procedure|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
204666|NCT02616497|Drug|Aspirin|COX-1 inhibitor
204667|NCT02616497|Drug|Triflusal|COX-1 inhibitor
204668|NCT02616484|Drug|Dichloroacetate (DCA)|"Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr."
205233|NCT02612480|Drug|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
204669|NCT02616484|Other|Placebo|Participants will receive the same volume of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
204670|NCT02616484|Genetic|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status.
204671|NCT02616471|Dietary Supplement|High-fat cheese|
204672|NCT02616471|Dietary Supplement|Low-fat cheese|
204673|NCT02616471|Dietary Supplement|No-cheese/carbohydrate|
204674|NCT02616458|Other|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
204675|NCT02616458|Other|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
204676|NCT02616445|Drug|UE2343|"UE2343~10mg, 20, 35mg~twice daily for 9 days"
204677|NCT02616445|Drug|Placebo|"10mg, 20, 35mg~twice daily for 9 days"
204678|NCT02616445|Drug|Placebo|"Cross-over study~single dose administered twice (on day 1 and day 8)~study duration 17 days"
204679|NCT02616445|Drug|UE2343|"Cross-over study~UE2343~single dose administered twice (on day 1 and day 8)~study duration 17 days"
204680|NCT02616445|Drug|UE2343|"UE2343~twice daily for 3 days~single dose on day 4"
204681|NCT02616432|Device|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
204682|NCT02616419|Device|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
204683|NCT02616419|Drug|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
204684|NCT02616406|Device|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
204685|NCT02616393|Drug|Tesevatinib|
204686|NCT02616367|Drug|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
204687|NCT02616367|Drug|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
204688|NCT02616354|Drug|Imipenem|Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
204689|NCT02616341|Behavioral|Team ERP (T-ERP) Intervention|
204690|NCT02616341|Behavioral|Treatment as Usual (TAU)|
204691|NCT02616328|Other|No intervention|No intervention administered in this study
204692|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
204693|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
204694|NCT02616302|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
204695|NCT02616289|Other|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
204696|NCT02616276|Other|Control breakfast|It consists of 350 ml of water at room temperature.
204697|NCT02616276|Other|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
204698|NCT02616276|Other|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
204699|NCT02616263|Other|Foot exercise|
204700|NCT02616263|Other|Shoulder exercise|
204701|NCT02616250|Drug|Brimonidine 0.33% gel (Br)|
204702|NCT02616250|Other|CD07805/47 (Br) placebo gel|
204703|NCT02616250|Drug|Ivermectin 1% cream (IVM)|
204704|NCT02616250|Other|CD5024 (IVM) placebo cream|
204705|NCT02616237|Behavioral|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
204706|NCT02616224|Other|No intervention|No intervention was administered in this study.
204707|NCT02616198|Other|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
204737|NCT02616042|Other|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
204738|NCT02616029|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
205999|NCT02607176|Drug|Heweizhixie capsule|3 #, Tid, Oral for 3 days
204708|NCT02616198|Other|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
204709|NCT02616198|Other|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
204710|NCT02616198|Other|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
204711|NCT02616185|Biological|PF-06755992|PF-06755992 will be administered on Day 1 of each cycle. Two dose levels will be evaluated.
204712|NCT02616185|Biological|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
204713|NCT02616185|Device|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
204714|NCT02616185|Biological|Tremelimumab|PF-06753388 will be administered every 28 days.
204715|NCT02616185|Drug|Sunitinib|Sunitinib will be taken daily. Up to three dose levels may be evaluated to determine the MTD when given in combination with the PrCa VBIR.
204716|NCT02616185|Biological|PF-06801591|PF-06801591 will be administered every 28 days.
204717|NCT02616172|Genetic|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
204718|NCT02616159|Other|Oatmeal|
204719|NCT02616146|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
204720|NCT02616146|Drug|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
204721|NCT02616133|Other|chart abstraction|abstraction of breast cancer patients with de-identified data
204722|NCT02616120|Drug|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
204723|NCT02616120|Drug|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
204724|NCT02616107|Other|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~Becoming a Cancer Caregiver [role, changes, challenges, adjusting, self-care]~Basics of Cancer Caregiving [physical, functional, emotional, social, & spiritual support; treatment timeline worksheet]~Caregiver's Role in Managing Patient Care [who/what is involved; health care professionals worksheet]~Managing Cancer Symptoms and Side Effects [common symptoms/side effects; maintaining health; nutrition & exercise; medication management worksheet]~Care Options: [information on curative, palliative and hospice care]~Talking About Goals of Care [information on goals of care conversations]~Managing Transitions [defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet]"
204725|NCT02616107|Other|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
204726|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
204727|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
204728|NCT02616081|Other|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
204729|NCT02616081|Other|Indwelling Catheter|Indwelling catheterization is a standard of care.
204730|NCT02616081|Other|Bladder Surgery|Bladder surgery is a standard of care.
204731|NCT02616068|Drug|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
204732|NCT02616068|Drug|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
204733|NCT02616068|Drug|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
204734|NCT02616068|Drug|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
204735|NCT02616055|Drug|tesevatinib|
204736|NCT02616042|Other|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
204739|NCT02616016|Device|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
204740|NCT02616003|Drug|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
204741|NCT02616003|Other|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
204742|NCT02616003|Dietary Supplement|Caloric diet with 800 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
204743|NCT02615990|Device|Erigo Pro|Verticalization table with two integrated robotic devices for leg movement and cyclic loading
204744|NCT02615990|Other|Standard Physical Therapy|Patients receive standard physical therapy.
204745|NCT02615977|Behavioral|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
204746|NCT02615977|Behavioral|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).~Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
204747|NCT02615964|Radiation|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
204748|NCT02615951|Other|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
204749|NCT02615938|Drug|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
204750|NCT02615938|Other|Placebo|Apply Placebo not to modify lysosomal pH
204751|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation
204752|NCT02615912|Other|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
204753|NCT02615912|Other|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
204754|NCT02615912|Other|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
204755|NCT02615912|Other|Silwet* DA-63 (Momentive) 1.5%|
204756|NCT02615912|Other|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
204757|NCT02615912|Other|Water (control)|
204758|NCT02615899|Other|Matched: Targeted (specific) balance exercise interventions|
204759|NCT02615899|Other|Mismatched: Untargeted (non-specific) balance exercise interventions|
204760|NCT02615886|Other|Observational Control|Participants will be observed and not provided any dietary supplementation.
204761|NCT02615886|Dietary Supplement|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
204762|NCT02615873|Drug|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
204763|NCT02615860|Other|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
204764|NCT02615860|Procedure|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
204765|NCT02615847|Drug|Memantinhydrochlorid|"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.~The study drug will be taken once a day per os, during 12 month."
204766|NCT02615834|Procedure|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
204767|NCT02615821|Behavioral|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
204768|NCT02615808|Other|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
206165|NCT02605824|Drug|0.9% saline|Normal saline is a placebo agent.
204769|NCT02615795|Device|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
204770|NCT02615782|Drug|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
204771|NCT02615769|Behavioral|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
204772|NCT02615769|Behavioral|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
204773|NCT02615756|Behavioral|Exercise|
204774|NCT02615743|Behavioral|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
204775|NCT02615743|Device|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
204776|NCT02615730|Drug|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
204777|NCT02615730|Drug|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
204778|NCT02615717|Behavioral|Attention Bias Modification|comparison of treatment versus control
204779|NCT02615704|Device|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
204780|NCT02615704|Device|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
204781|NCT02615704|Device|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
204782|NCT02615704|Device|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
204783|NCT02615691|Biological|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
204784|NCT02615678|Device|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
204785|NCT02615665|Procedure|Hepatic resection|Removal of a part of the liver during surgery
204786|NCT02615652|Other|no intervention|no intervention, observational study
204787|NCT02615639|Biological|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells & Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
204788|NCT02615639|Drug|Entecavir|0.5mg tablet every night by mouth
204789|NCT02615639|Drug|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells & IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
204790|NCT02615639|Drug|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
204791|NCT02615639|Drug|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells & Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
204792|NCT02615639|Drug|Telbivudine|Telbivudine 600mg tablet every day by mouth
204793|NCT02615626|Procedure|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
204794|NCT02615613|Other|Low Acceptability Meal|
204795|NCT02615613|Other|High acceptability meal|
204796|NCT02615600|Device|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
204797|NCT02615587|Drug|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
204798|NCT02615574|Biological|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
204799|NCT02615574|Drug|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
204800|NCT02615561|Device|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
204801|NCT02615561|Other|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
204802|NCT02615561|Other|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
204803|NCT02615548|Other|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
204869|NCT02615067|Drug|99mTc-MIP-1404 Injection|A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.
205234|NCT02612480|Drug|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
204804|NCT02615548|Other|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
204805|NCT02615535|Device|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
204806|NCT02615535|Device|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
204807|NCT02615522|Device|BPK-S Integration|
204808|NCT02615509|Radiation|Imaging on experimental tomo device|The system used for imaging in the experimental arm is the Philips MicroDose tomography system. The system used for imaging in the active comparator is a standard FFDM system
204809|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
204810|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
204811|NCT02615483|Other|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.~The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
204812|NCT02615470|Behavioral|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
204813|NCT02615470|Other|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
204814|NCT02615457|Drug|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
204815|NCT02615444|Dietary Supplement|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
204816|NCT02615444|Dietary Supplement|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
204817|NCT02615431|Other|MitraClip Intervention|
204818|NCT02615418|Device|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
204819|NCT02615405|Dietary Supplement|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 & 2.
204820|NCT02615405|Dietary Supplement|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 & 2.
204821|NCT02615405|Dietary Supplement|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
204822|NCT02615392|Behavioral|Park Prescription|Please refer to the information included in the arm description.
204823|NCT02615379|Device|EPIFLO|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
204824|NCT02615366|Drug|Tranexamic Acid|
204825|NCT02615366|Drug|Placebo|
204826|NCT02615353|Behavioral|Intensive Lifestyle Intervention|6-months of lifestyle education
204827|NCT02615353|Other|Usual Care Control|Medical visit and dietary counseling
204828|NCT02615340|Drug|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
204829|NCT02615340|Drug|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
204830|NCT02615327|Dietary Supplement|8 g Polydextrose|8g of Polydextrose
204831|NCT02615327|Dietary Supplement|12 g Polydextrose|12 g of Polydextrose
204832|NCT02615327|Dietary Supplement|16 g Polydextrose|16 g of Polydextrose
204833|NCT02615327|Dietary Supplement|Placebo|0 g of Polydextrose
204834|NCT02615314|Procedure|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
204835|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
204836|NCT02615301|Dietary Supplement|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
204870|NCT02615067|Diagnostic Test|Whole-Body Planar and pelvic SPECT/CT scan|A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
204837|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
204838|NCT02615301|Dietary Supplement|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
204839|NCT02615288|Dietary Supplement|Vitamin D3|
204840|NCT02615275|Device|SECA mBCA|Body composition assessed at baseline, weekly throughout RT during clinic visits, and after completion of treatment at the 10-12 week follow up.
204841|NCT02615275|Procedure|X-Ray Imaging|Computed tomography (CT) or positron emission tomography (PET) scan performed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.
204842|NCT02615275|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.
204843|NCT02615275|Radiation|Radiation Therapy|Radiation treatment administered per treating physician for 6-7 weeks. Total prescribed dose is 60-70 Gy in 30-35 fx at 2.0-2.2 Gy/fx prescribed to the PTV. Radiation planned and delivered using intensity modulated radiation therapy (IMRT), volumetric arc therapy (VMAT), and/or three-dimensional conformal radiation therapy (3DCRT).
204844|NCT02615262|Drug|Dexamethasone|
204845|NCT02615262|Drug|Placebo|0.9% Sodium Chloride
204846|NCT02615249|Biological|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
204847|NCT02615236|Device|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
204848|NCT02615236|Procedure|Clinical diagnosis|diagnosis of OASIS clinically
204849|NCT02615223|Procedure|cryoablation|Cryoablation therapy
204850|NCT02615223|Drug|Bicalutamide|bicalutamide
204851|NCT02615223|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
204852|NCT02615210|Device|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
204853|NCT02615197|Behavioral|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
204854|NCT02615197|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
204855|NCT02615184|Drug|Dexlansoprazole|Dexlansoprazole capsules
204856|NCT02615184|Drug|Placebo|Dexlansoprazole placebo-matching capsules
204857|NCT02615171|Behavioral|Comprehensive Dietary Self-Monitoring; Device: smartphone; Other: physical activity|The intervention includes Facebook-delivered weight loss counseling and the use of MyFitnessPal, a comprehensive diet and exercise self-monitoring app. The intervention will last for 12 weeks. In addition to weight loss counseling in a private Facebook group, participants will be encouraged to use the self-monitoring app to enter everything they eat and do for exercise during the intervention period (12 weeks). Participants will receive a daily calorie goal directly from the app. Participants will receive a Fitbit scale to take their weight weekly and at assessments.
204858|NCT02615171|Behavioral|Simple Dietary Self-Monitoring; Device: smartphone; Other: physical activity|Arm: Active Comparator: Simple Dietary Self-Monitoring he intervention includes Facebook-delivered weight loss counseling and the use of Slip Buddy, an app created by the investigative team that only requires users to record instances of overeating by hitting a single button and then indicate the overeating trigger and stress and hunger levels. The intervention will last for 12 weeks. In addition to the weight loss counseling, participants will be asked to use the Slip Buddy app during the intervention period (12 weeks). Participants will receive a Fitbit scale to take their weight weekly and at assessments.
204859|NCT02615158|Behavioral|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
204860|NCT02615158|Behavioral|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
204861|NCT02615158|Behavioral|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
204862|NCT02615132|Behavioral|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
204863|NCT02615119|Drug|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
204864|NCT02615119|Drug|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
204865|NCT02615106|Drug|Endostar|7.5 mg/m2/day, day 1-14
204866|NCT02615106|Radiation|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
204867|NCT02615080|Drug|CRD007|
204868|NCT02615080|Drug|Placebo|
206166|NCT02605811|Drug|temozolomide|
204871|NCT02615054|Device|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
204872|NCT02615054|Device|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
204873|NCT02615041|Drug|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
204874|NCT02615041|Drug|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and~1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
204875|NCT02615041|Drug|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.~Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
204876|NCT02615028|Other|Closed eyes double-leg stance|Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
204877|NCT02615015|Other|Blood draw|
204878|NCT02615002|Drug|Piromelatine|
204879|NCT02615002|Drug|Placebo|
204880|NCT02614989|Procedure|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
204881|NCT02614976|Device|Padding|"Padding webrill (Covidian) TM 6"
204882|NCT02614963|Drug|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
204883|NCT02614963|Drug|placebo|Irritable bowel syndrome patients treated with placebo
204884|NCT02614950|Other|Treatment interruption|
204885|NCT02614937|Drug|ranibizumab|0.5 mg IVT ranibizumab
204886|NCT02614937|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
204887|NCT02614924|Device|Flexible fibreoptic scope|Patient intubated using fibreoptic scope
204888|NCT02614924|Device|Pentax AWS videolaryngoscope|Patient intubated using Pentax AWS videolaryngoscope
204889|NCT02614911|Other|Biological sampling|Biological sampling including blood, feces, biopsies...
204890|NCT02614898|Other|Clinical assessments and laboratory tests.|Clinical assessments and laboratory tests required at a minimum monthly. Frequency is increased at enrollment and any time there is a change in Soliris® regimen. Treatment for aHUS is observational and remains at the discretion of the treating physician.
204891|NCT02614885|Device|RFA|Radiofrequency ablation of the cavity walls of a simulated lumpectomy in the excised prophylactic mastectomy tissue.
204892|NCT02614872|Drug|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) [GLASSIA®] add-on pharmacotherapy and Institution standard of care (SOC)
204893|NCT02614859|Drug|Bicalutamide|Bicalutamide 50 mg daily beginning at cycle 3 to cycle 8
204894|NCT02614859|Drug|Metformin and Bicalutamide|Metformin 1000mg twice a day Bicalutamide 50 mg daily beginning at cycle 3
204895|NCT02614846|Drug|Hetrombopag Olamine|
204896|NCT02614833|Biological|IMP321 (eftilagimod alpha)|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
204897|NCT02614833|Drug|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
204898|NCT02614833|Drug|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
204899|NCT02614820|Procedure|Remote Ischemic Preconditioning Training Apparatus|
204900|NCT02614807|Dietary Supplement|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
204901|NCT02614794|Drug|tucatinib|300 mg orally twice daily
204902|NCT02614794|Drug|capecitabine|1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
204903|NCT02614794|Drug|trastuzumab|8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
204904|NCT02614794|Drug|placebo|Oral dose twice daily
204905|NCT02614768|Device|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received CE certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
204906|NCT02614742|Drug|SFX-01|An intervention releasing sulforaphane.
204907|NCT02614742|Drug|Placebo|Placebo otherwise identical to Active product
204908|NCT02614729|Other|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
204909|NCT02614729|Other|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
204910|NCT02614729|Other|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
204911|NCT02614729|Other|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
204912|NCT02614716|Drug|LY3090106|Administered SC
204913|NCT02614716|Drug|Placebo|Administered SC
204914|NCT02614703|Drug|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
204915|NCT02614703|Other|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
204916|NCT02614690|Procedure|No Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
204917|NCT02614690|Procedure|Univalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
204918|NCT02614690|Procedure|Bivalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
204919|NCT02614664|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
204920|NCT02614651|Procedure|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.~The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
204921|NCT02614651|Procedure|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
204922|NCT02614651|Procedure|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.~The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
204923|NCT02614651|Procedure|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).~The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
204924|NCT02614651|Device|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
204925|NCT02614638|Other|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
204926|NCT02614638|Other|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
204927|NCT02614612|Drug|Itacitinib (200 mg)|
204928|NCT02614612|Drug|Itacitinib (300 mg)|
204929|NCT02614612|Drug|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
204930|NCT02614599|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
204931|NCT02614599|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
204932|NCT02614586|Drug|TAK-058|TAK-058 oral solution.
204933|NCT02614586|Drug|Ondansetron|Ondansetron capsule.
204934|NCT02614586|Drug|TAK-058 Placebo|TAK-058 placebo-matching, solution.
204935|NCT02614586|Drug|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
204976|NCT02614300|Other|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
204977|NCT02614300|Other|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
204978|NCT02614300|Other|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
204979|NCT02614287|Drug|Galcanezumab|Administered SC
204980|NCT02614274|Dietary Supplement|Nutraceutical joint health formulation|A Proprietary Blend
204981|NCT02614261|Drug|Galcanezumab|Administered SC
204982|NCT02614261|Drug|Placebo|Administered SC
204983|NCT02614248|Other|Organic, Unrefined Coconut Oil|
204936|NCT02614573|Device|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.~If capillary INR is <2 or >3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.~If capillary INR is > 4, then verification by venous measure and refer to general practitioner."
204937|NCT02614560|Drug|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
204938|NCT02614560|Drug|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
204939|NCT02614560|Drug|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
204940|NCT02614560|Drug|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
204941|NCT02614547|Drug|SAGE-547|
204942|NCT02614547|Drug|Placebo|
204943|NCT02614534|Drug|MITOMYCIN-C 40 mg|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women) plus HIPEC with Mytomicin C for 60 minutes.
204944|NCT02614534|Procedure|Proactive cytoreductive surgery|Proactive cytoreductive surgery: Tumoral cytoreductive surgery + apendicectomy + total omentectomy + round hepatic ligament + oophorectomy (postmenopausian women)
204945|NCT02614521|Other|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
204946|NCT02614508|Drug|Buparlisib|Given PO
204947|NCT02614508|Drug|Ibrutinib|Given PO
204948|NCT02614508|Biological|Ofatumumab|Given IV
204949|NCT02614495|Drug|Surufatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
204950|NCT02614482|Drug|Fesoterodine|Administer medication to patients with overactive bladder
204951|NCT02614469|Drug|Inosine|Inosine, 1000 mg
204952|NCT02614456|Drug|interferon-gamma and nivolumab|
204953|NCT02614443|Other|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
204954|NCT02614443|Other|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
204955|NCT02614443|Other|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
204956|NCT02614430|Other|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
204957|NCT02614417|Other|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
204958|NCT02614404|Drug|Imatinib|Experimental drug
204959|NCT02614404|Drug|Dihydroartemisinin-piperaquine|Standard of care
204960|NCT02614391|Other|Active distraction using a tablet|Playing a videogame using a computer tablet
204961|NCT02614391|Other|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
204962|NCT02614378|Procedure|air insufflation|modulated air insufflation of the ear canal
204963|NCT02614378|Procedure|placebo|no air will be introduced in the ear canal
204964|NCT02614365|Behavioral|Aerobic exercise|Cardiovascular fitness
204965|NCT02614365|Behavioral|Stretch exercise|Muscle stretch
204966|NCT02614352|Drug|Atorvastatin + Candesartan|
204967|NCT02614352|Drug|AG1502|
204968|NCT02614339|Drug|metformin|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 47 months (total 48months including the adjustment period).
204969|NCT02614339|Drug|control|The patients of this group are treated according to NCCN guideline for stage II high-risk/ III colorectal cancer.
204970|NCT02614326|Behavioral|Autobiographical Memory Flexibility (MemFlex) training|As in experimental arm description
204971|NCT02614326|Behavioral|Psychoeducation|As in experimental arm description
204972|NCT02614313|Procedure|Open breath test with fructose|Open randomised fructose 35g during breath test
204973|NCT02614313|Procedure|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
204974|NCT02614313|Procedure|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
204975|NCT02614313|Procedure|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
204984|NCT02614248|Other|Medline Remedy Phytoplex Z-Guard Skin Protectant|
204985|NCT02614235|Device|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
204986|NCT02614222|Device|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
204987|NCT02614209|Device|In Vitro diagnostic tests|Prospective blood collection
204988|NCT02614196|Drug|Galcanezumab|Administered SC
204989|NCT02614196|Drug|Placebo|Administered SC
204990|NCT02614183|Drug|Galcanezumab|Administered SC
204991|NCT02614183|Drug|Placebo|Administered SC
204992|NCT02614170|Other|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
204993|NCT02614157|Procedure|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
204994|NCT02614157|Device|labeled line|
204995|NCT02614131|Drug|LY2599666|Administered SC
204996|NCT02614131|Drug|Solanezumab|Administered IV
204997|NCT02614131|Drug|Placebo SC|Administered SC
204998|NCT02614131|Drug|Placebo IV|Administered IV
204999|NCT02614118|Drug|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
205000|NCT02614118|Drug|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
205001|NCT02614118|Drug|Placebo|placebo 45 minutes before root canal treatment
205002|NCT02614105|Procedure|Pelvic floor muscle training|16 weeks of group-based exercise
205003|NCT02614105|Procedure|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
205004|NCT02614105|Other|Control|Brief information only
205005|NCT02614092|Behavioral|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
205006|NCT02614079|Device|DSSEP|Collision testing after the placement of SCS leads
205007|NCT02614066|Biological|KTE-X19|
205008|NCT02614066|Drug|Cyclophosphamide|Administered intravenously
205009|NCT02614066|Drug|Fludarabine|Administered intravenously
205010|NCT02614053|Device|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI & spHB
205011|NCT02614040|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
205012|NCT02614040|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
205013|NCT02614027|Other|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
205014|NCT02614027|Other|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
205015|NCT02614014|Behavioral|Cognitive-behavior interventional program|
205016|NCT02614001|Device|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
205017|NCT02614001|Other|post-stroke rehabilitation program|
205018|NCT02613988|Radiation|Radiation|
205019|NCT02613988|Device|3 Tesla magnetic resonance imaging|
205020|NCT02613988|Device|Chemical exchange saturation transfer MRI|
205021|NCT02613988|Device|Diffusion weighted MRI|
205022|NCT02613988|Device|Dynamic contrast enhancement MRI|
205023|NCT02613988|Device|Dynamic susceptibility contrast MRI|
205024|NCT02613975|Device|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
205025|NCT02613962|Procedure|biopsy or surgical resection of tumor and blood sampling|
205026|NCT02613949|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
205027|NCT02613936|Device|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
205028|NCT02613936|Behavioral|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
205029|NCT02613923|Behavioral|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
205030|NCT02613923|Behavioral|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
205031|NCT02613923|Procedure|Blood Draw|blood sample measured for stress and sleep markers
205032|NCT02613923|Other|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
205033|NCT02613923|Other|Insomnia Severity Index (ISI)|
205034|NCT02613923|Other|SF-12 quality of life survey|
205035|NCT02613910|Drug|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
205036|NCT02613910|Drug|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
205037|NCT02613910|Drug|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
205038|NCT02613910|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
205183|NCT02612844|Drug|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
205039|NCT02613897|Drug|Saxagliptin|Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
205040|NCT02613897|Drug|Dapagliflozin|Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
205041|NCT02613897|Drug|Placebo|Placebo
205042|NCT02613884|Drug|Treatment|
205043|NCT02613871|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
205044|NCT02613845|Other|no intervention|
205045|NCT02613832|Other|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
205046|NCT02613832|Other|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
205047|NCT02613819|Radiation|SABR|"Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy."
205048|NCT02613806|Drug|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
205049|NCT02613806|Drug|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
205050|NCT02613780|Procedure|Crosslinking|corneal collagen crosslinking with riboflavin
205051|NCT02613780|Procedure|Photorefractive keratectomy|
205052|NCT02613780|Device|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
205053|NCT02613767|Other|Protein meal|Ingestion of protein
205054|NCT02613767|Other|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
205055|NCT02613754|Behavioral|Contingency Management|See arm description.
205056|NCT02613754|Behavioral|Treatment as Usual|See arm description
205057|NCT02613741|Other|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
205058|NCT02613728|Behavioral|Accelerated Recovery Plan|
205059|NCT02613728|Behavioral|Early Discharge|
205060|NCT02613728|Other|Telemedicine|
205061|NCT02613728|Behavioral|Standard Enhanced Care|
205062|NCT02613715|Dietary Supplement|Blackberry juice with 12% ethanol|
205063|NCT02613715|Dietary Supplement|Blackberry juice|
205064|NCT02613702|Procedure|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
205065|NCT02613702|Procedure|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
205066|NCT02613702|Procedure|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
205067|NCT02613689|Behavioral|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
205068|NCT02613689|Behavioral|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
205069|NCT02613676|Device|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
205070|NCT02613676|Other|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
205071|NCT02613663|Procedure|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
205072|NCT02613663|Procedure|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
205113|NCT02613351|Device|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
205073|NCT02613650|Drug|MEK162 and mFOLFIRI|"MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily"
205074|NCT02613637|Other|Registry|
205075|NCT02613598|Drug|Bortezomib|
205076|NCT02613598|Drug|Ruxolitinib|
205077|NCT02613585|Other|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
205078|NCT02613572|Drug|alpha lipoic acid|
205079|NCT02613572|Drug|Placebo|
205080|NCT02613559|Biological|TK001|Intravitreal Injection
205081|NCT02613546|Behavioral|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:~evaluation session;~sessions of psychoeducation about the CBT model~5 sessions of cognitive restructuring 2 sessions of preventing relapse"
205082|NCT02613546|Behavioral|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
205083|NCT02613533|Other|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to laser peripheral iridotomy (LPI) surgery and Intra-ocular pressure (IOP) is tested every 15 min before and after surgical procedure
205084|NCT02613520|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
205085|NCT02613520|Other|Normal Saline|0.9% Sodium chloride
205086|NCT02613520|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
205087|NCT02613507|Drug|Nivolumab|
205088|NCT02613507|Drug|Docetaxel|
205089|NCT02613494|Drug|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
205090|NCT02613494|Drug|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
205091|NCT02613494|Other|Placebo|Placebo twice daily, increasing to placebo three times daily
205092|NCT02613481|Drug|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
205093|NCT02613468|Other|collection of periodontal records|"Clinic attachment level~Probing depth~Gingival index~Plaque index~Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
205094|NCT02613468|Other|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
205095|NCT02613468|Other|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
205096|NCT02613455|Procedure|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
205097|NCT02613455|Drug|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
205098|NCT02613455|Drug|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
205099|NCT02613429|Behavioral|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
205100|NCT02613429|Behavioral|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
205101|NCT02613416|Drug|Denosumab|monthly subcutaneous injections
205102|NCT02613403|Drug|MK-3682B|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
205103|NCT02613403|Drug|Ribavirin|Ribavirin 200 mg capsules, taken twice daily by mouth as part of a weight-based dosing regimen. Depending on participant body weight, total daily dose of Ribavirin may be 800, 1000, 1200 or 1400 mg per day.
205104|NCT02613390|Procedure|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
205105|NCT02613390|Behavioral|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
205106|NCT02613377|Other|Blood transfusion|
205107|NCT02613364|Behavioral|Behavioral Intervention|Undergo yoga intervention
205108|NCT02613364|Other|Cognitive Intervention|Undergo CBT-I intervention
205109|NCT02613364|Other|Educational Intervention|Receive health education
205110|NCT02613364|Other|Laboratory Biomarker Analysis|Correlative studies
205111|NCT02613364|Device|Monitoring Device|Correlative studies
205112|NCT02613364|Other|Quality-of-Life Assessment|Ancillary studies
205114|NCT02613338|Device|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
205115|NCT02613325|Device|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
205116|NCT02613325|Procedure|Standard of care surgical excision|
205117|NCT02613325|Device|Single cell photoacoustic microscopy|
205118|NCT02613286|Procedure|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
205119|NCT02613286|Procedure|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
205120|NCT02613273|Behavioral|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
205121|NCT02613273|Behavioral|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
205122|NCT02613260|Behavioral|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
205123|NCT02613247|Device|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
205124|NCT02613234|Device|cathode tDCS|"At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
205125|NCT02613234|Device|Sham cathode tDCS|"At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.~At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
205126|NCT02613221|Drug|Panitumumab + TAS-102|panitumumab + TAS-102 combination therapy
205127|NCT02613208|Drug|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
205128|NCT02613208|Drug|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
205129|NCT02613195|Drug|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
205130|NCT02613182|Drug|NEOD001|NEOD001
205131|NCT02613169|Drug|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
205132|NCT02613156|Procedure|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson & Johnson, USA), a laparoscopic linear cutter stapler (Johnson & Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
205133|NCT02613130|Drug|Stannous fluoride toothpaste|
205134|NCT02613130|Drug|Potassium nitrate toothpaste|
205135|NCT02613117|Device|Potassium Oxalate Gel|Self applied
205136|NCT02613117|Device|Potassium Oxalate Liquid|Professionally Applied
205137|NCT02613117|Drug|Stannous fluoride paste|SnF2 Paste
205138|NCT02613104|Other|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
205139|NCT02613104|Other|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
205140|NCT02613104|Other|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
205141|NCT02613104|Other|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
205142|NCT02613091|Drug|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
205181|NCT02612857|Drug|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
205182|NCT02612844|Drug|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
205184|NCT02612831|Procedure|Early bariatric surgery|
205143|NCT02613078|Behavioral|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
205144|NCT02613078|Dietary Supplement|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
205145|NCT02613078|Behavioral|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
205146|NCT02613065|Dietary Supplement|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
205147|NCT02613065|Dietary Supplement|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
205148|NCT02613052|Drug|normal saline|10 mL of normal saline agitated prior to IV administration
205149|NCT02613052|Drug|human albumin|10 mL of 5% albumin agitated prior to IV administration
205150|NCT02613052|Drug|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
205151|NCT02613039|Drug|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
205152|NCT02613026|Drug|Pirarubicin|
205153|NCT02613026|Drug|Docetaxel|
205154|NCT02613026|Drug|Cyclophosphamide|
205155|NCT02613013|Device|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
205156|NCT02613013|Device|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
205157|NCT02613013|Drug|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
205158|NCT02613013|Procedure|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
205159|NCT02613013|Drug|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
205160|NCT02613013|Procedure|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
205161|NCT02613000|Other|No intervention|
205162|NCT02612987|Behavioral|Internet-based Cognitive Behaviour Therapy (iCBT)|
205163|NCT02612974|Biological|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
205164|NCT02612961|Other|3mL of normal saline from the pink sodium chloride bullet|
205165|NCT02612961|Other|Sham Comparator of 3mL normal saline|
205166|NCT02612948|Drug|Quetiapine|escalating dose to prevent delerium.
205167|NCT02612935|Device|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
205168|NCT02612922|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
205169|NCT02612922|Drug|Placebo|Placebo administered orally twice daily for five days
205170|NCT02612909|Biological|IVACFLU-A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine was produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
205171|NCT02612909|Biological|Placebo|Includes 4.500mg sodium chloride, 0.685 mg sodium phosphate dibasic dihydrate, and 0.186 mg sodium phosphate monobasic dihydrate.
205172|NCT02612896|Drug|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
205173|NCT02612896|Behavioral|Health education|in all study arms, using village meetings, posters, pamphlets.
205174|NCT02612870|Device|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
205175|NCT02612870|Device|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
205176|NCT02612870|Device|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
205177|NCT02612870|Device|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
205178|NCT02612870|Device|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
205179|NCT02612857|Drug|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
205180|NCT02612857|Drug|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
205185|NCT02612831|Procedure|Delayed bariatric surgery|
205187|NCT02612805|Other|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
205188|NCT02612805|Other|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
205189|NCT02612805|Other|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
205190|NCT02612792|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
205191|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
205192|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
205193|NCT02612779|Drug|Elotuzumab|
205194|NCT02612779|Drug|Pomalidomide|
205195|NCT02612779|Drug|Dexamethasone|
205196|NCT02612779|Drug|Nivolumab|
205197|NCT02612766|Dietary Supplement|Pure, uncontaminated oats|
205198|NCT02612753|Procedure|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
205199|NCT02612753|Device|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
205200|NCT02612753|Device|tDCs|
205201|NCT02612740|Procedure|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
205202|NCT02612740|Device|granules of deproteinized bovine bone (Bio-Oss)|
205203|NCT02612727|Device|Filtered-sunlight phototherapy|Infants will receive >= four hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using Air Blue 80 window tinting film.
205204|NCT02612727|Device|Intensive phototherapy|Infants will receive >= four hours per day of intensive phototherapy for 1 to 10 days.
205205|NCT02612714|Drug|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
205206|NCT02612701|Other|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
205207|NCT02612701|Other|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
205208|NCT02612701|Other|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
205209|NCT02612701|Other|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
205210|NCT02612688|Behavioral|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
205211|NCT02612675|Other|ONS|
205212|NCT02612662|Drug|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
205213|NCT02612662|Drug|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
205214|NCT02612649|Drug|Ramosetron|Oral
205215|NCT02612636|Other|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
205216|NCT02612636|Other|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
205217|NCT02612623|Drug|Gefapixant|Gefapixant tablets administered by mouth twice daily for 8 weeks
205218|NCT02612623|Drug|Placebo (for gefapixant)|Matching placebo to gefapixant tablets administered by mouth twice daily for 8 weeks
205219|NCT02612610|Drug|Gefapixant|Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
205220|NCT02612610|Drug|Placebo (for gefapixant)|
205221|NCT02612597|Other|Bedrest|
205222|NCT02612597|Other|Exercise Training|
205223|NCT02612584|Device|Pinhole Soft Contact Lens apply for presbyopia|
205224|NCT02612558|Drug|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed.
205225|NCT02612545|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
205226|NCT02612545|Drug|Mefloquine (MQ)|ACT partner drug
205227|NCT02612532|Device|ReCIVA breath sampler|Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
205228|NCT02612519|Device|Alfapump|Implantation of Alfapump
205229|NCT02612519|Device|TIPS|Implantation of TIPS
205230|NCT02612506|Drug|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
205231|NCT02612506|Drug|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
205232|NCT02612493|Other|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
205235|NCT02612480|Drug|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
205236|NCT02612480|Drug|Placebo|7 day treatment with placebo
205237|NCT02612467|Other|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.~Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
205238|NCT02612467|Other|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
205239|NCT02612454|Drug|Dupilumab|
205240|NCT02612441|Device|real Acupuncture Needles|Acupuncture needles
205241|NCT02612441|Device|sham Acupuncture Needles|sham Acupuncture Needles
205242|NCT02612428|Biological|ELAD System|An extracorporeal human hepatic cell-based liver treatment
205243|NCT02612428|Other|Standard of Care (Control)|Standard medical treatment as defined by the protocol
205244|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
205245|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
205246|NCT02612402|Device|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
205247|NCT02612402|Device|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
205248|NCT02612389|Other|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
205249|NCT02612363|Drug|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation~Analgesia~Propofol at lowest dosage.~Dose range: 0.1- 0.7 u/kg/hour~Target RASS score of -2 to +1~Supplemental other sedatives at lowest effective dose"
205250|NCT02612350|Genetic|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
205251|NCT02612337|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
205252|NCT02612337|Drug|Placebo|Single intratympanic injection of placebo
205253|NCT02612324|Behavioral|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
205254|NCT02612324|Behavioral|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
205255|NCT02612311|Biological|Obinutuzumab|Obinutuzumab: IV infusion
205256|NCT02612311|Biological|Ublituximab|Ublituximab: IV infusion
205257|NCT02612311|Drug|TGR-1202|TGR-1202: Oral daily dose
205258|NCT02612311|Drug|Chlorambucil|Chlorambucil: Oral dose
205259|NCT02612298|Drug|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
205260|NCT02612298|Drug|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
205261|NCT02612285|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
205262|NCT02612272|Drug|Ketorolac|intra-articular ketorolac
205263|NCT02612272|Drug|Betamethasone|intra-articular betamethasone
205264|NCT02612259|Dietary Supplement|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
205265|NCT02612259|Other|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
205266|NCT02612246|Drug|GLPG1972 single ascending doses|single dose, oral solution
205267|NCT02612246|Drug|Placebo single dose|single dose, oral solution, matching placebo
205268|NCT02612246|Drug|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
205269|NCT02612246|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
205270|NCT02612233|Drug|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
205271|NCT02612220|Procedure|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
205272|NCT02612220|Other|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
205273|NCT02612207|Device|Bilirubin Binding Capacity by hematofluorometry|
205274|NCT02612194|Drug|Crizotinib|All arms will receive crizotinib.
205275|NCT02612181|Drug|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
205276|NCT02612168|Device|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
205277|NCT02612155|Biological|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
205278|NCT02612155|Biological|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
205279|NCT02612142|Behavioral|physical exercise|endurance-training or stretching (sham exercise)
205280|NCT02612129|Drug|arimoclomol|
205281|NCT02612129|Drug|Placebo|
205282|NCT02612116|Drug|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
205283|NCT02612116|Drug|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
205284|NCT02612116|Drug|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
205285|NCT02612090|Dietary Supplement|Active Treatment Beverage|Strawberry
205286|NCT02612090|Dietary Supplement|Placebo Treatment Beverage|Placebo
205287|NCT02612077|Other|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
205288|NCT02612077|Drug|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
205289|NCT02612064|Device|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
205290|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
205291|NCT02612051|Drug|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
205292|NCT02612051|Drug|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
205293|NCT02612051|Radiation|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of [18F]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
205294|NCT02612038|Device|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
205295|NCT02612038|Device|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
205296|NCT02612025|Behavioral|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
205297|NCT02612012|Radiation|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
205298|NCT02611999|Behavioral|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
205299|NCT02611999|Behavioral|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
205300|NCT02611986|Device|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
205301|NCT02611986|Device|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
205302|NCT02611973|Other|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
205303|NCT02611973|Other|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
205304|NCT02611973|Other|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
205305|NCT02611973|Drug|Hydroxyurea treatment (HU)|HU maintenance
205306|NCT02611960|Biological|Pembrolizumab|IV infusion
205307|NCT02611960|Drug|Capecitabine|oral tablet
205308|NCT02611960|Drug|Gemcitabine|IV infusion
205309|NCT02611960|Drug|Docetaxel|IV infusion
205310|NCT02611947|Radiation|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
205311|NCT02611934|Procedure|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
205312|NCT02611921|Drug|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
205313|NCT02611921|Drug|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
205314|NCT02611908|Drug|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
205315|NCT02611908|Drug|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
205316|NCT02611895|Biological|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
205317|NCT02611882|Drug|Ga-68 labeled HBED-CC PSMA|The imaging agent (Ga-68 HBED-CC PSMA) will be administered on an outpatient basis. It will be administered a single time intravenously prior to the PET/CT imaging. The one-time nominal injected dose will be 3 to 7 millicurie (mCi) containing 10 - 25 μg Ga-68 HBED-CC PSMA.
205318|NCT02611882|Device|Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/CT scan includes two parts: a PET scan and a CT scan. The CT portion of the scan produces a 3-D image that shows a patient's anatomy. The PET scan demonstrates function and what's occurring on a cellular level. The PET scan is unique because it images the radiation emitted from the patient while the CT records anatomical x-rays, showing the same area from another perspective
205319|NCT02611882|Device|Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)|Patient shall begin imaging between 55 and 70 minutes after the injection of the radiopharmaceutical. A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Coverage for the scan will extend from the patients vertex through the mid thighs. We will use 4 minute acquisitions per bed position for PET imaging.
205320|NCT02611869|Procedure|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
205321|NCT02611869|Procedure|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
205322|NCT02611843|Behavioral|Peer-Supported Web CBT|
205323|NCT02611843|Behavioral|Self-Managed Web CBT|
205324|NCT02611830|Drug|Vedolizumab IV 300 mg|
205325|NCT02611830|Drug|Placebo IV|
205326|NCT02611830|Drug|Vedolizumab SC 108 mg|
205327|NCT02611830|Drug|Placebo SC|
205328|NCT02611817|Drug|Vedolizumab SC 108 mg|Vedolizumab SC Injection.
205329|NCT02611817|Drug|Placebo|Vedolizumab placebo-matching SC injection.
205330|NCT02611817|Drug|Vedolizumab IV 300 mg|Vedolizumab IV Injection.
205331|NCT02611804|Drug|Diclofenac sodium|
205332|NCT02611804|Drug|Diclofenac sodium|
205333|NCT02611804|Drug|Placebo|
205334|NCT02611791|Device|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
205335|NCT02611791|Device|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
205336|NCT02611778|Biological|ranibizumab|
205337|NCT02611765|Drug|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
205338|NCT02611765|Drug|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
205339|NCT02611752|Drug|CAM2038|CAM2038 subcutaneous injection
205340|NCT02611739|Device|Medi-Port|Treatment
205341|NCT02611739|Device|Medi-Port|Control
205342|NCT02611726|Other|Acupuncture|Acupuncture
205343|NCT02611700|Drug|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
205344|NCT02611700|Drug|Paclitaxel|175mg/m^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
205345|NCT02611700|Drug|Cisplatin|60mg/m^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
205346|NCT02611700|Drug|Placebo|400mg,day1,weekly,until disease progression or toxicity
205347|NCT02611687|Drug|pitolisant|Tablet
205348|NCT02611687|Drug|Placebo|Tablet
205349|NCT02611661|Device|PET/MRI|
205350|NCT02611661|Radiation|Percutaneous ablation|
205351|NCT02611661|Radiation|Stereotactic body radiotherapy|
205352|NCT02611648|Other|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
205353|NCT02611648|Other|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
205354|NCT02611635|Drug|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205355|NCT02611635|Drug|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205356|NCT02611635|Drug|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205357|NCT02611635|Drug|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
206167|NCT02605811|Radiation|prophylaxis cranial radiotherapy|2
205358|NCT02611635|Drug|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205359|NCT02611635|Drug|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205360|NCT02611622|Behavioral|LUMA ENT™|
205361|NCT02611622|Other|Survey|Demographic and Patient Satisfaction Survey
205362|NCT02611609|Biological|MultiStem|
205363|NCT02611609|Biological|MultiStem|
205364|NCT02611609|Biological|Placebo|
205365|NCT02611596|Drug|Ranolazine|24 weeks of the assigned medication
205366|NCT02611596|Drug|Placebo|Placebo for 24 weeks
205367|NCT02611583|Device|TENS|Transcutaneous Electrical Nerve Stimulation
205368|NCT02611557|Procedure|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
205369|NCT02611544|Behavioral|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
205370|NCT02611544|Behavioral|Survivorship Education|6-week survivorship education group (SE; n=32)
205371|NCT02611544|Behavioral|Enhanced Usual Care|enhanced usual care (EUC; n=26)
205372|NCT02611531|Behavioral|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
205373|NCT02611531|Behavioral|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
205374|NCT02611518|Drug|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
205375|NCT02611518|Drug|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
205376|NCT02611518|Drug|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
205377|NCT02611505|Drug|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
205378|NCT02611492|Drug|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
205379|NCT02611492|Drug|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
205380|NCT02611492|Drug|Aracytine (Ara C)|Age<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
205381|NCT02611492|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils > 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
205382|NCT02611492|Drug|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
205383|NCT02611492|Drug|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
205384|NCT02611492|Drug|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
205385|NCT02611492|Drug|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
205386|NCT02611492|Drug|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
205387|NCT02611466|Drug|ASP7962|Participants receive ASP7962 100 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
205388|NCT02611466|Drug|Naproxen|Participants receive naproxen 500 mg orally twice daily, in the morning and evening with or without food (approximately 12 hours).
205389|NCT02611466|Drug|Placebo|Participants receive matching placebo orally twice daily, in the morning and evening with or without food (approximately 12 hours).
205390|NCT02611453|Other|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
205391|NCT02611440|Behavioral|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.~Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.~HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
205392|NCT02611427|Behavioral|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
205393|NCT02611427|Behavioral|Education|The education group will receive information about safe physical activity.
205394|NCT02611414|Device|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
205395|NCT02611414|Device|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
205475|NCT02610881|Behavioral|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
205631|NCT02609646|Drug|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
205396|NCT02611401|Behavioral|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.~The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
205397|NCT02611401|Behavioral|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.~This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
205398|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
205399|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
205400|NCT02611388|Device|fake stimulation|Patients were only attached electrodes without electric current
205401|NCT02611375|Other|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
205402|NCT02611375|Other|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
205403|NCT02611375|Other|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
205404|NCT02611362|Behavioral|IMB Gaming Intervention|
205405|NCT02611336|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
205406|NCT02611323|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
205407|NCT02611323|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
205408|NCT02611323|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
205409|NCT02611323|Drug|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
205410|NCT02611310|Other|No intervention|No intervention administered in this study.
205411|NCT02611297|Procedure|Cryoprobe|
205412|NCT02611284|Procedure|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
205413|NCT02611284|Procedure|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.~After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2< 0.35; for a target Oxygen Saturation (SpO2) of >90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
205414|NCT02611271|Other|Monitoring of antibiotic drug removal|No study specific intervention will be performed
205415|NCT02611258|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
205476|NCT02610868|Drug|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
206168|NCT02605798|Drug|Elbanovir|1 tablet contains 400 mg sofosbuvir
205416|NCT02611245|Drug|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
205417|NCT02611232|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
205418|NCT02611232|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
205419|NCT02611219|Other|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"38 question questionnaire~Answers range from 1=all of the time to 5=none of the time"
205420|NCT02611219|Other|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"38 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
205421|NCT02611219|Other|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
205422|NCT02611219|Other|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
205423|NCT02611219|Other|General Health Module-Baseline Parent Report-School Age (5-12 years)|"34 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
205424|NCT02611219|Other|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"34 question questionnaire about child~49 question questionnaire about parent~Answers range from 1-all of the time to 5=none of the time"
205425|NCT02611219|Other|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
205426|NCT02611219|Other|SCT Daily Activity Log|"Uses Fitbit Flex~Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
205427|NCT02611219|Other|The Functional Independence Measure for Children|"18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards~Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
205428|NCT02611219|Other|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
205429|NCT02611219|Other|3-Minute Step Test|"Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after~Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
205430|NCT02611219|Other|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"7 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
205431|NCT02611219|Other|HSCT Module-Follow Child-Self Report (5-12 years)|"10 question questionnaire about child~Answers range from 1=all of the time to 5=none of the time"
205432|NCT02611219|Other|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"7 question questionnaire about child~49 question questionnaire about parent~Answers range from 1=all of the time to 5=none of the time"
205433|NCT02611219|Other|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"7 question questionnaire about child~49 question questionnaire about parent~Answers range from 1=all of the time to 5=none of the time"
205434|NCT02611206|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.
205435|NCT02611193|Procedure|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
205436|NCT02611193|Procedure|Simulated manipulative treatment|Simulated Manipulative Treatment
205437|NCT02611180|Procedure|Skin punch biopsy|
205438|NCT02611180|Procedure|Peripheral blood draw|
205439|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
205440|NCT02611154|Drug|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
205477|NCT02610855|Procedure|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
205478|NCT02610855|Other|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
205479|NCT02610855|Device|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
205672|NCT02609386|Drug|Indomethacin|Method of Administration: Indomethacin is administered orally for 21 days.
205441|NCT02611141|Procedure|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack & Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
205442|NCT02611128|Other|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
205443|NCT02611102|Dietary Supplement|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
205444|NCT02611089|Procedure|Tissue biopsy|Sampling of tissue as described.
205445|NCT02611076|Behavioral|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
205446|NCT02611076|Behavioral|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
205447|NCT02611063|Drug|fostamatinib|100mg qd, 150mg qd, or 100mg bid
205448|NCT02611050|Behavioral|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
205449|NCT02611050|Behavioral|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
205450|NCT02611037|Drug|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
205451|NCT02611037|Drug|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m^2).
205452|NCT02611037|Drug|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
205453|NCT02611037|Other|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
205454|NCT02611024|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4mg vials
205455|NCT02611024|Drug|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
205456|NCT02611011|Device|Congo Red Test (GV-005)|The GV-005 is a simple test has been developed to detect unfolded or misfolded proteins in urine.
205457|NCT02610985|Device|3-D laparoscopy|3-D laparoscopy
205458|NCT02610985|Device|2-D laparoscopy|2-D laparoscopy
205459|NCT02610972|Device|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
205460|NCT02610959|Other|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
205461|NCT02610959|Other|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
205462|NCT02610946|Behavioral|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
205463|NCT02610946|Behavioral|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
205464|NCT02610933|Drug|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
205465|NCT02610933|Dietary Supplement|Vitamin K2|Vitamin K2 supplementation
205466|NCT02610920|Procedure|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
205467|NCT02610920|Drug|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
205468|NCT02610907|Other|Buffer|The sleeve contains phosphate buffered saline buffer
205469|NCT02610907|Other|Own output|The sleeve contains the subject own ileal effluent
205470|NCT02610907|Other|simulated output|The sleeve contains simulated output
205471|NCT02610894|Other|mHealth application (PoCAH)|Participants will have unlimited access to the mHealth app via iPad Mini for 5 days post-operatively to aid in pain management
205472|NCT02610894|Other|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
205473|NCT02610881|Dietary Supplement|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
205474|NCT02610881|Dietary Supplement|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
205480|NCT02610855|Other|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
205481|NCT02610842|Other|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
205482|NCT02610829|Dietary Supplement|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
205483|NCT02610816|Other|1 Food Elimination Diet|Participants eliminate milk from the diet for 12 weeks
205484|NCT02610816|Other|4 Food Elimination Diet|Participants eliminate milk, egg, wheat, soy from the diet for 12 weeks
205485|NCT02610816|Other|4 Food Elimination Diet (post 1FED failure)|Participants that fail to respond to 1FED in phase 1 eliminate milk, egg, wheat, soy from the diet for 12 weeks in Phase 2
205486|NCT02610816|Drug|Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)|Participants that fail to respond to 4FED in phase 1 administer swallowed glucocorticosteroids (Flovent HFA) 800 mcg twice daily for 12 weeks in Phase 2
205487|NCT02610777|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
205488|NCT02610777|Drug|Pevonedistat|Pevonedistat intravenous infusion.
205489|NCT02610764|Procedure|Blood Test for CTC evaluation|
205490|NCT02610738|Behavioral|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
205491|NCT02610725|Other|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
205492|NCT02610712|Drug|Ketamine|
205493|NCT02610699|Other|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
205494|NCT02610699|Other|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
205495|NCT02610686|Drug|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
205496|NCT02610673|Device|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
205497|NCT02610647|Drug|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
205498|NCT02610647|Other|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
205499|NCT02610647|Other|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
205500|NCT02610647|Other|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.~After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
205501|NCT02610621|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
205502|NCT02610608|Other|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
205503|NCT02610595|Drug|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
205504|NCT02610582|Drug|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
205505|NCT02610569|Device|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
205506|NCT02610569|Device|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
205507|NCT02610556|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
205508|NCT02610556|Drug|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
205509|NCT02610556|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
205510|NCT02610556|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
205511|NCT02610543|Drug|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
205512|NCT02610543|Drug|Placebo|Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
205513|NCT02610530|Procedure|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
205514|NCT02610530|Procedure|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
205515|NCT02610530|Other|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
205536|NCT02610335|Other|Test group|"spinal mobility reeducation on Huber platform during 2 weeks,~patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~exercises on cycle ergometer or walking on treadmill : to continue at home."
205674|NCT02609386|Drug|Omeprazole|Method of Administration: Omeprazole is administered orally for 21 days
205516|NCT02610517|Behavioral|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
205517|NCT02610517|Behavioral|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
205518|NCT02610504|Device|Durolane|single injection of 3ml
205519|NCT02610491|Dietary Supplement|Hesperidin|Citrus peel extract
205520|NCT02610491|Dietary Supplement|Placebo|Cellulose
205521|NCT02610452|Other|Clown therapy|"The clowns intervene by twos: a game takes place.~The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.~The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.~The original game proposal is adjusted according to mutual empathy with those present.~The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.~The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
205522|NCT02610439|Other|Laboratory Biomarker Analysis|Correlative studies
205523|NCT02610426|Other|Laboratory Biomarker Analysis|Correlative studies
205524|NCT02610413|Other|Laboratory Biomarker Analysis|Correlative studies
205525|NCT02610400|Combination Product|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) > 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
205526|NCT02610400|Combination Product|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
205527|NCT02610400|Combination Product|rfMDA|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):~(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) > 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
205528|NCT02610387|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
205529|NCT02610387|Device|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
205530|NCT02610374|Other|Agrarian Diet|A diet higher in carbohydrates and lower in fats and sugars
205531|NCT02610374|Other|Western-type Diet|A diet higher in fats and lower in carbohydrates
205532|NCT02610361|Drug|BGB-283|"In the dose escalation part(phase 1a): the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In dose expansion phase(Phase 1b): Patients will be assigned to different groups based on their tumor types"
205533|NCT02610348|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
205534|NCT02610348|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
205535|NCT02610335|Other|Control group (C)|"kyphosis reeducation on Huber platform during 2 weeks,~patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),~flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),~exercises on cycle ergometer or walking on treadmill : to continue at home."
205673|NCT02609386|Dietary Supplement|Zinc-containing multivitamin|Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
205537|NCT02610322|Behavioral|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
205538|NCT02610322|Behavioral|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and <30% of energy as total fat.
205539|NCT02610309|Behavioral|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
205540|NCT02610296|Drug|QPI-1002|IV injection
205541|NCT02610296|Other|Placebo|isotonic saline
205542|NCT02610283|Drug|QPI-1002|IV injection
205543|NCT02610283|Drug|Placebo|isotonic saline
205544|NCT02610270|Dietary Supplement|2 Gums|760 mg DHA
205545|NCT02610270|Dietary Supplement|3 Gums|1140 mg DHA
205546|NCT02610257|Device|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.~Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
205547|NCT02610244|Other|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
205548|NCT02610231|Drug|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
205549|NCT02610218|Other|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
205550|NCT02610205|Other|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
205551|NCT02610192|Device|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
205552|NCT02610179|Dietary Supplement|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
205553|NCT02610179|Dietary Supplement|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
205554|NCT02610166|Behavioral|Game|"In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom."
205555|NCT02610166|Other|Usual Care|Children in usual care group receive standard medical care.
205556|NCT02610153|Drug|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
205557|NCT02610140|Drug|Anetumab ravtansine (BAY 94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
205558|NCT02610140|Drug|Vinorelbine|Starting dose: 30mg/m² administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
205559|NCT02610127|Biological|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
205627|NCT02609672|Other|Exercise|A biomechanical exercise program shown to decrease joint loading was administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
205560|NCT02610114|Other|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
205561|NCT02610114|Other|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
205562|NCT02610101|Other|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
205563|NCT02610101|Other|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
205564|NCT02610101|Other|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
205565|NCT02610088|Drug|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
205566|NCT02610088|Drug|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
205567|NCT02610075|Drug|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
205568|NCT02610062|Drug|AGS67E|Intravenous (IV) infusion
205569|NCT02610049|Behavioral|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson & Chard (11/2010)
205570|NCT02610049|Behavioral|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson & Chard (11/2010)
205571|NCT02610049|Behavioral|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson & Chard (1/2010) CPT + Art Therapy of mixed individual techniques
205572|NCT02610023|Other|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
205573|NCT02610023|Other|Laboratory Biomarker Analysis|Correlative studies
205574|NCT02610023|Device|Spectroscopy|Undergo resonance Raman spectroscopy
205575|NCT02610010|Drug|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
205576|NCT02610010|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
205577|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
205578|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
205579|NCT02609997|Drug|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
205580|NCT02609997|Device|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
205581|NCT02609997|Drug|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
205582|NCT02609984|Biological|CMB305|CMB305 is a sequential combination of two investigational study agents, LV305 and G305, with each agent given at different times over several weeks or months.
205583|NCT02609984|Biological|atezolizumab|Atezolizumab is known as a checkpoint inhibitor (CPI) or immune checkpoint controller. It is a programmed cell death ligand 1 (PD-L1) inhibitor also known as MPDL3280A.
205584|NCT02609971|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
205585|NCT02609958|Drug|Varlitinib|"varlitinib tablets with:~starting dose: 300mg BID~target dose: 400mg BID~dose modification by investigator allowed between 200mg BID to 500mg BID"
205586|NCT02609945|Drug|zolmitriptan|Oral Tablet and Nasal Spray
205587|NCT02609945|Drug|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
205588|NCT02609932|Drug|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
205589|NCT02609919|Drug|Gadoteric Acid|MRI Contrast Agent
205590|NCT02609906|Device|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
205628|NCT02609672|Other|No Exercise|A no exercise (control) group maintained their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
205629|NCT02609659|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
205630|NCT02609659|Drug|ribavirin|Tablet
205591|NCT02609906|Device|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
205592|NCT02609893|Other|modified directly observed therapy (mDOT)|
205593|NCT02609893|Other|unobserved dosing|
205594|NCT02609893|Other|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
205595|NCT02609880|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
205596|NCT02609880|Behavioral|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
205597|NCT02609867|Device|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
205598|NCT02609854|Device|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
205599|NCT02609854|Device|Sham Device|Inactive ultrasound device
205600|NCT02609841|Device|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
205601|NCT02609828|Drug|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
205602|NCT02609815|Drug|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
205603|NCT02609815|Drug|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
205604|NCT02609802|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
205605|NCT02609802|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
205606|NCT02609789|Drug|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
205607|NCT02609789|Drug|Placebo|0.9 percent (%) normal saline.
205608|NCT02609776|Drug|JNJ-61186372|The first cohort of participants will receive IV infusions of JNJ-61186372 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of JNJ-61186372 at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and JNJ-61186372 at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.
205609|NCT02609776|Drug|JNJ-61186372|Participants will receive IV infusion of JNJ-61186372 as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
205610|NCT02609776|Drug|Lazertinib|Lazertinib will be administered in combination with JNJ-61186372 at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day JNJ-61186372 treatment cycle.
205611|NCT02609750|Other|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
205612|NCT02609750|Other|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
205613|NCT02609737|Device|PET/CT Imaging|
205614|NCT02609737|Radiation|68Ga-DOTA-JR11|
205615|NCT02609737|Radiation|177Lu-DOTA-JR11|
205616|NCT02609724|Other|Information|During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
205617|NCT02609724|Other|Skin care|The skin is hydrated during the session. If wounds are present, the wound is cared.
205618|NCT02609724|Other|Compression therapy|During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
205619|NCT02609724|Other|Fluoroscopy-guided MLD|Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
205620|NCT02609724|Other|Traditional MLD|Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
205621|NCT02609724|Other|Placebo MLD|During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
205622|NCT02609711|Drug|Candesartan cilexetil|
205623|NCT02609698|Device|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
205624|NCT02609698|Drug|3 months DAPT|
205625|NCT02609698|Drug|6 months DAPT|
205626|NCT02609685|Other|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
206169|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
205632|NCT02609646|Drug|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
205633|NCT02609646|Drug|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
205634|NCT02609646|Drug|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
205635|NCT02609633|Device|Accu-Chek® CONNECT DMS|SMBG will be performed during the 6-month study using the Accu-Chek® Aviva CONNECT monitoring device, and corresponding Smartphone app and online tracking tool.
205636|NCT02609633|Device|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek® CONNECT DMS).
205637|NCT02609620|Device|Peristaltic Feeding Tube|
205638|NCT02609620|Device|ConvaTec Levin Duodenal Tube|
205639|NCT02609607|Drug|Bisacodyl|Rectal suppository
205640|NCT02609607|Other|Placebo|Rectal suppository
205641|NCT02609594|Other|Weekly application of Amnioband|Weekly application of Amnioband.
205642|NCT02609594|Other|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
205643|NCT02609594|Other|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
205644|NCT02609581|Drug|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
205645|NCT02609555|Procedure|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
205646|NCT02609542|Other|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
205647|NCT02609529|Other|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
205648|NCT02609529|Other|Placebo|
205649|NCT02609516|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
205650|NCT02609503|Drug|Pembrolizumab|Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
205651|NCT02609503|Radiation|Intensity Modulated Radiation Therapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
205652|NCT02609490|Drug|Azilsartan tablets|20mg/tablet
205653|NCT02609490|Drug|Azilsartan placebo tablets|placebo tablet
205654|NCT02609490|Drug|Olmesartan medoxomil tablets|20mg/tablet
205655|NCT02609490|Drug|olmesartan medoxomil placebo tablets|placebo tablet
205656|NCT02609477|Drug|Istradefylline|Istradefylline 40, 80, 160 mg
205657|NCT02609477|Drug|Phentermine 45 mg|Phentermine 45 or 90 mg
205658|NCT02609477|Other|Placebo|Placebo
205659|NCT02609464|Device|Interrupted Knotted Sutures|
205660|NCT02609464|Device|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
205661|NCT02609451|Procedure|Ileostomy closure|Ileostomy closure at a different time point
205662|NCT02609438|Behavioral|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
205663|NCT02609438|Behavioral|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
205664|NCT02609425|Device|Stratafix PGA Suture|Subject leak Stricture rates post procedure
205665|NCT02609412|Other|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
205666|NCT02609412|Other|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
205667|NCT02609412|Device|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
205668|NCT02609399|Drug|Oseltamivir|Oral
205669|NCT02609399|Drug|Peramivir|"IV~Note: Subjects admitted to the hospital directly from the ED Enrollment Visit may receive more doses at the discretion of the treating physician."
205670|NCT02609386|Biological|IRX-2|Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.
205671|NCT02609386|Drug|Cyclophosphamide|Method of Administration: Cyclophosphamide is administered once by IV
205675|NCT02609373|Behavioral|Sleep intervention|"Session 1: Intervener & participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.~Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.~Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.~Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.~Booster sessions: At 8 & 10 months: reinforcement, question answering, encouragement and monitoring."
205676|NCT02609360|Other|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
205677|NCT02609360|Other|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
205678|NCT02609360|Other|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
205679|NCT02609347|Other|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
205680|NCT02609347|Other|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
205681|NCT02609334|Drug|CRD007|One single dose given 3 hours prior to Mannitol challenge
205682|NCT02609334|Other|Placebo|One single dose given 3 hours prior to Mannitol challenge
205683|NCT02609321|Procedure|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
205684|NCT02609321|Procedure|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
205685|NCT02609308|Other|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
205686|NCT02609308|Procedure|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
205687|NCT02609295|Dietary Supplement|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
205688|NCT02609295|Dietary Supplement|ALA group|1.2 g (two capsules) of perilla oil
205689|NCT02609282|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|
205690|NCT02609269|Other|Decipher Prostate Cancer Classifier|The Decipher Prostate Cancer Classifier (Decipher Test) is a genomic test that predicts the probability of high-grade disease, metastasis and prostate cancer specific mortality for men with prostate cancer and is commercially available through GenomeDx Biosciences' CLIA & CAP certified laboratory in San Diego, CA
205691|NCT02609269|Other|Decipher Genomics Resource Information Database (GRID)|The Decipher GRID (GRID) is the world's largest research use only (RUO), clinically annotated urologic cancer genomic expression database, built up over 8 years of US and international research conducted using the Decipher® (Decipher) test platform. The GRID currently consists of genomic data comprised of 1.4M data points per patient from more than 20,000 prostate and bladder cancer patients, including those from published retrospective clinical studies that have been annotated with comprehensive treatment and outcomes data. It is anticipated that the GRID will also contain data from several other types of cancer in the future.
205692|NCT02609256|Procedure|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
205693|NCT02609256|Other|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
205694|NCT02609243|Behavioral|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
205695|NCT02609230|Drug|ONC-201|
205696|NCT02609217|Other|Questionnaires and interviews|
205697|NCT02609204|Diagnostic Test|Diopsys NOVA|Healthy Controls will have both eyes tested by the Diopsys NOVA machine using Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
205698|NCT02609191|Device|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
205699|NCT02609191|Device|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
205700|NCT02609191|Device|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
205701|NCT02609178|Procedure|FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
205702|NCT02609178|Procedure|AVR|the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
205703|NCT02609165|Drug|rhNGF 180 µg/ml eye drops solution|eye drops
205704|NCT02609165|Drug|vehicle eye drops|placebo
205821|NCT02608385|Drug|Pembrolizumab|Pembrolizumab (200 mg) given every 3 weeks.
205822|NCT02608372|Other|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
205823|NCT02608372|Other|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
206170|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
205705|NCT02609152|Drug|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
205706|NCT02609152|Drug|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
205707|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
205708|NCT02609139|Drug|PF-06650833|100mg modified release tablet administered under fasted conditions
205709|NCT02609139|Drug|PF-06650833|20mg modified release tablet administered under fasted conditions
205710|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
205711|NCT02609139|Drug|PF-06650833|100mg modified released tablet administered with high fat meal food intake
205712|NCT02609139|Drug|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
205713|NCT02609126|Drug|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
205714|NCT02609126|Drug|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
205715|NCT02609113|Device|Strong Magnetic Wristband|
205716|NCT02609113|Device|Weaker Magnetic Wristband|
205717|NCT02609100|Procedure|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
205718|NCT02609100|Procedure|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
205719|NCT02609100|Device|1.0 X 2.5 cm 'pill' containing a camera|
205720|NCT02609087|Drug|Sevoflurane|
205721|NCT02609087|Drug|Propofol|
205722|NCT02609074|Procedure|Minimally invasive internal fixation surgeries|
205723|NCT02609074|Device|CPC/rhBMP-2 micro-scaffolds|
205724|NCT02609074|Device|CPC paste|
205725|NCT02609061|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
205726|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
205727|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
205728|NCT02609048|Drug|Placebo Comparator|Placebo Capsule (2 taken once daily)
205729|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
205730|NCT02609048|Drug|Experimental: Seladelpar / MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
205731|NCT02609035|Behavioral|Telephonic prompt|
205732|NCT02609022|Biological|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose."
205733|NCT02609022|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
205734|NCT02609009|Other|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
205735|NCT02609009|Other|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
205736|NCT02608996|Drug|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
205737|NCT02608996|Drug|Placebo|For comparison to elucidate the true effect of nesiritide
205738|NCT02608983|Dietary Supplement|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
205739|NCT02608983|Dietary Supplement|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
205740|NCT02608983|Dietary Supplement|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
205741|NCT02608970|Drug|BMS-986177|
205742|NCT02608970|Other|Placebo|
205743|NCT02608957|Device|Latella Knee Implant System|
205744|NCT02608944|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
205745|NCT02608944|Drug|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
205746|NCT02608944|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
205747|NCT02608944|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
205748|NCT02608944|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
205749|NCT02608931|Drug|Dronabinol|
205750|NCT02608931|Other|Placebo|placebo
205751|NCT02608918|Drug|BMS-955176|
205824|NCT02608372|Other|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
205904|NCT02607800|Drug|SOF/VEL/VOX|400/100/100 mg tablet administered orally once daily with food
206389|NCT02604446|Drug|Oxycodone|
205752|NCT02608905|Drug|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
205753|NCT02608905|Drug|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
205754|NCT02608892|Behavioral|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
205755|NCT02608879|Procedure|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
205756|NCT02608879|Procedure|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
205757|NCT02608879|Device|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
205758|NCT02608879|Drug|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
205759|NCT02608866|Radiation|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
205760|NCT02608866|Radiation|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
205761|NCT02608853|Other|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
205762|NCT02608840|Other|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
205763|NCT02608840|Other|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
205764|NCT02608827|Device|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
205765|NCT02608827|Other|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
205766|NCT02608814|Procedure|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
205767|NCT02608814|Other|Ultrasound|
205768|NCT02608788|Drug|S.L.®|"1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
205769|NCT02608788|Drug|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
205770|NCT02608788|Drug|Acular®|"5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
205771|NCT02608788|Drug|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
205772|NCT02608775|Device|Metrodoloris Medical System|Application of a skin electrode
205773|NCT02608775|Device|Aisys® care station, Acertys|Standard photoplethysmography
205774|NCT02608762|Radiation|standard adjuvant local radiation therapy or cranial radiation therapy|
205775|NCT02608749|Behavioral|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
205776|NCT02608749|Behavioral|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
205777|NCT02608749|Behavioral|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
205778|NCT02608736|Drug|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
205905|NCT02607800|Drug|SOF/VEL|400/100 mg tablet administered orally once daily with or without food
206390|NCT02604446|Drug|Placebo|
205779|NCT02608736|Drug|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
205780|NCT02608723|Device|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
205781|NCT02608723|Device|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
205782|NCT02608723|Device|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
205783|NCT02608710|Drug|RDEA3170 4.5 mg|
205784|NCT02608710|Drug|RDEA3170 6 mg|
205785|NCT02608710|Drug|RDEA3170 12 mg|
205786|NCT02608697|Drug|CAT-2054|
205787|NCT02608697|Drug|Placebo|
205788|NCT02608697|Drug|Atorvastatin|
205789|NCT02608684|Drug|Pembrolizumab|Pembrolizumab IV solution
205790|NCT02608684|Drug|Gemcitabine|Gemcitabine IV solution
205791|NCT02608684|Drug|Cisplatin|Cisplatin IV solution
205792|NCT02608671|Procedure|Skin adhesive tape|
205793|NCT02608658|Other|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:~Obtain demographic information, as will past medical history and medications.~Perform a physical examination.~Collect samples for labs~Administer the Chronic Liver Disease Questionnaire (CLDQ)~Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~Perform a physical examination~Collect and record returned investigational product~Dispense investigational product and instruct again regarding use~Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~Perform a physical examination.~Collect samples for labs~Administer the Chronic Liver Disease Questionnaire (CLDQ)~Perform a lactulose breath test"
205794|NCT02608632|Device|Renal denervation guided by HFS|
205795|NCT02608632|Device|Renal denervation as standard procedure|
205796|NCT02608619|Radiation|F-choline PET Scan|
205797|NCT02608619|Device|FDG-PET|
205798|NCT02608619|Procedure|biopsy|
205799|NCT02608606|Drug|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
205800|NCT02608593|Procedure|Strattice|Implant based reconstruction with strattice cover of part or all of implant
205801|NCT02608580|Other|Survey|
205802|NCT02608554|Behavioral|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
205803|NCT02608554|Behavioral|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
205804|NCT02608541|Other|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
205805|NCT02608528|Radiation|[18F]fluoroglucose(FDG)|
205806|NCT02608502|Biological|RSV-F Vaccine|
205807|NCT02608502|Biological|Phosphate Buffer Placebo|
205808|NCT02608489|Drug|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
205809|NCT02608489|Drug|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
205810|NCT02608476|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
205811|NCT02608476|Drug|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
205812|NCT02608463|Device|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
205813|NCT02608450|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
205814|NCT02608450|Drug|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
205815|NCT02608437|Drug|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
205816|NCT02608437|Drug|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
205817|NCT02608424|Device|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
205818|NCT02608411|Drug|ARQ197|
205819|NCT02608398|Other|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
205820|NCT02608385|Radiation|Stereotactic body radiotherapy (SBRT)|Patients will receive 3 or 5 doses of SBRT to the chosen metastases.
205825|NCT02608359|Drug|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
205826|NCT02608346|Procedure|Blood sampling|"Patients will have a blood draw at each visit to the hospital,~with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam~with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
205827|NCT02608333|Behavioral|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
205828|NCT02608333|Behavioral|control group|"heteregenous as usual community intervention"
205829|NCT02608320|Drug|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
205830|NCT02608320|Drug|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
205831|NCT02608320|Drug|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
205832|NCT02608320|Drug|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
205833|NCT02608320|Drug|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
205834|NCT02608320|Drug|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
205835|NCT02608294|Device|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
205836|NCT02608294|Device|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
205837|NCT02608281|Device|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
205838|NCT02608268|Drug|MBG453|anti human TIM-3 monoclonal antibody
205839|NCT02608268|Drug|PDR001|anti-human PD-1 monoclonal antibody
205840|NCT02608255|Other|blood samples|
205841|NCT02608242|Drug|YH22189|
205842|NCT02608242|Drug|Twynsta 80/10mg|
205843|NCT02608242|Drug|Crestor 20mg|
205844|NCT02608229|Drug|BVD-523|
205845|NCT02608229|Drug|Nab-paclitaxel|
205846|NCT02608229|Drug|Gemcitabine|
205847|NCT02608229|Procedure|Tumor biopsy|
205848|NCT02608216|Drug|[18F]FLT|[18F]FLT PET/CT scan, imaging tracer
205849|NCT02608216|Device|PET/CT|[18F]FLT PET/CT scan
205850|NCT02608216|Drug|ribociclib|therapeutic
205851|NCT02608216|Drug|paclitaxel|therapeutic
205852|NCT02608203|Drug|[68Ga]-DOTANOC PET/CT|
205853|NCT02608190|Behavioral|Working memory training|See protocol
205854|NCT02608177|Drug|Linagliptin|Receives 4 weeks of study drug linagliptin
205855|NCT02608177|Drug|Glipizide|Receives 4 weeks of study drug glipizide
205856|NCT02608164|Dietary Supplement|3000IU(75μg) vitamin D3|
205857|NCT02608151|Other|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
205858|NCT02608151|Other|massage without oil|
205859|NCT02608138|Other|Iodine status among portuguese school children|
205860|NCT02608125|Drug|PRN1371|
205861|NCT02608112|Drug|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
205862|NCT02608112|Drug|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
205863|NCT02608099|Drug|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
205901|NCT02607826|Procedure|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
205902|NCT02607813|Drug|LXH254|pan-RAF inhibitor
205864|NCT02608099|Drug|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
205865|NCT02608086|Behavioral|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
205866|NCT02608086|Behavioral|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
205867|NCT02608073|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
205868|NCT02608073|Drug|Cisplatin|Participants will receive cisplatin, 100 mg/m^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
205869|NCT02608060|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
205870|NCT02608034|Drug|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
205871|NCT02608034|Drug|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
205872|NCT02608034|Drug|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 960 mg BID for at least 40 conseutive days.
205873|NCT02608008|Device|Data analysis|data parameters Analysis
205874|NCT02607995|Behavioral|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
205875|NCT02607982|Drug|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
205876|NCT02607982|Drug|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
205877|NCT02607982|Radiation|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
205878|NCT02607969|Other|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
205879|NCT02607956|Drug|DTG|50 mg tablets administered orally, once daily, without regard to food
205880|NCT02607956|Drug|F/TAF|200/25 mg tablets administered orally, once daily, without regard to food
205881|NCT02607956|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally, once daily, without regard to food
205882|NCT02607956|Drug|DTG Placebo|Tablets administered orally, once daily, without regard to food
205883|NCT02607956|Drug|F/TAF Placebo|Tablets administered orally, once daily, without regard to food
205884|NCT02607956|Drug|B/F/TAF Placebo|Tablets administered orally, once daily, without regard to food
205885|NCT02607943|Drug|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
205886|NCT02607943|Drug|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
205887|NCT02607930|Drug|ABC/DTG/3TC|600/50/300 mg tablets administered orally, once daily, without regard to food
205888|NCT02607930|Drug|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
205889|NCT02607930|Drug|ABC/DTG/3TC Placebo|Tablets administered orally, once daily, without regard to food
205890|NCT02607930|Drug|B/F/TAF Placebo|Tablets administered orally, once daily, without regard to food
205891|NCT02607917|Other|Mass Media plus clinic intervention.|
205892|NCT02607917|Other|Media|
205893|NCT02607904|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
205894|NCT02607891|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
205895|NCT02607891|Drug|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
205896|NCT02607865|Drug|semaglutide|Oral administration once-daily
205897|NCT02607865|Drug|sitagliptin|Oral administration once-daily
205898|NCT02607865|Drug|placebo|Oral administration once-daily
205899|NCT02607852|Device|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
205900|NCT02607839|Biological|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
205903|NCT02607813|Drug|PDR001|Biological: PDR001 anti-PD1 antibody
205906|NCT02607787|Behavioral|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
205907|NCT02607787|Other|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
205908|NCT02607774|Drug|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
205909|NCT02607774|Drug|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
205910|NCT02607761|Other|Video|Video-Audio Media
205911|NCT02607748|Other|18F-NaF PET and coronary CTA imaging|
205912|NCT02607735|Drug|SOF/VEL/VOX|400/100/100 mg fixed dose-combination (FDC) tablet administered orally once daily with food
205913|NCT02607735|Drug|Placebo|Tablet administered orally once daily with food
205914|NCT02607722|Drug|Nintedanib|
205915|NCT02607709|Procedure|Lymphadenectomy in conjugation with nephroureterectomy|"Lymphadenectomy (intervention group only):~Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively."
205916|NCT02607709|Procedure|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
205917|NCT02607696|Drug|Zolpidem Hemitartarate|
205918|NCT02607683|Drug|XAF5 (concentration A: 0.1%)|
205919|NCT02607683|Drug|XAF5 (concentration B: 0.035%)|
205920|NCT02607683|Drug|Matching placebo|
205921|NCT02607670|Drug|TAT4 Gel|
205922|NCT02607670|Drug|Matching placebo|
205923|NCT02607657|Drug|Eplerenone 25 mg|
205924|NCT02607657|Drug|Eplerenone 50 mg|
205925|NCT02607657|Drug|Eplerenone 100 mg|
205926|NCT02607657|Drug|Eplerenone 50 mg twice a day|
205927|NCT02607657|Drug|Eplerenone 25 mg twice a day|
205928|NCT02607644|Device|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
205929|NCT02607644|Device|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
205930|NCT02607631|Drug|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
205931|NCT02607618|Drug|Iclaprim|Experimental treatment
205932|NCT02607618|Drug|Vancomycin|Active comparator
205933|NCT02607592|Drug|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
205934|NCT02607592|Drug|nadaplatin+pemetrexed|nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
205935|NCT02607579|Drug|Exparel|
205936|NCT02607579|Drug|Ropivacaine|
205937|NCT02607566|Behavioral|Yoga|
205938|NCT02607566|Behavioral|Standard Exercise Program|twice weekly aerobic exercise program, 60 minutes for 12 weeks
205939|NCT02607553|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
205940|NCT02607540|Other|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
205941|NCT02607540|Other|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
205942|NCT02607540|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
205943|NCT02607527|Device|Mitral Valve IRIS Ring|Transcatheter implantation of the IRIS
205944|NCT02607514|Behavioral|hyperthermic yoga|heated yoga, 90-minutes
205945|NCT02607501|Device|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
205946|NCT02607488|Drug|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
205947|NCT02607488|Drug|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
205948|NCT02607488|Drug|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
205949|NCT02607488|Drug|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.~All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
205950|NCT02607475|Device|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
205951|NCT02607475|Device|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
205952|NCT02607462|Biological|PRP|
205953|NCT02607462|Other|Placebo|
205954|NCT02607449|Drug|FS-1|FS-1 is a liquid solution for internal intake and has antimicrobial and antibacterial activities.
205955|NCT02607449|Drug|Placebo|Placebo without any active pharmaceutical ingredients
205956|NCT02607436|Drug|Sarpogrelate|Sarpogrelate
205957|NCT02607436|Drug|Aspirin|Aspirin
205958|NCT02607423|Drug|Cisplatin|Given IV
205959|NCT02607423|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
205960|NCT02607423|Drug|Docetaxel|Given IV
205961|NCT02607423|Radiation|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
205964|NCT02607423|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
205965|NCT02607410|Drug|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
205966|NCT02607410|Drug|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
205967|NCT02607384|Behavioral|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
205968|NCT02607384|Behavioral|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
205969|NCT02607384|Other|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
205970|NCT02607371|Other|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205971|NCT02607371|Other|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205972|NCT02607371|Other|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205973|NCT02607371|Other|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205974|NCT02607371|Other|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
205975|NCT02607358|Other|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
205976|NCT02607345|Dietary Supplement|Zusto|25gr
205977|NCT02607345|Dietary Supplement|Glucomedics®|25gr
205978|NCT02607332|Drug|Paclitaxel|
205979|NCT02607319|Drug|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
205980|NCT02607306|Drug|insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
205981|NCT02607306|Drug|insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
205982|NCT02607306|Drug|liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
205983|NCT02607293|Drug|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
205984|NCT02607293|Drug|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
205985|NCT02607293|Drug|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
205986|NCT02607280|Drug|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7,5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
205987|NCT02607267|Other|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
205988|NCT02607254|Drug|Pregabalin|Pregabalin will be given to the patients, starting at 75 mg BID and increased weekly to reach 225 mg BID for 8 weeks. During withdrawal phase, dose of pregabalin will be kept the same for patients who are randomized to the pregabalin withdrawal group.
205989|NCT02607254|Drug|Placebo|Placebo will be given to the patients that are randomized to placebo during withdrawal phase.
205990|NCT02607241|Device|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
205991|NCT02607241|Device|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR > 0.8, residual diameter stenosis < 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis > 40% or FFR < 0.8).
205992|NCT02607228|Drug|GS-5829|GS-5829 tablet administered orally once daily
205993|NCT02607228|Drug|Enzalutamide|Enzalutamide capsules administered orally once daily
205994|NCT02607215|Drug|Vinorelbine|25 mg/m2, D1, D8
205995|NCT02607215|Drug|DDP|75 mg/m2, D1
206000|NCT02607163|Drug|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
206001|NCT02607163|Drug|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
206002|NCT02607150|Other|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
206003|NCT02607137|Behavioral|Health Education|Information on healthy living style in relation to physical activity
206004|NCT02607124|Drug|Ribociclib|
206005|NCT02607111|Drug|Dalteparin|
206006|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
206007|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
206008|NCT02607072|Drug|Placebo|
206009|NCT02607059|Other|Registry|
206010|NCT02607046|Other|Exercise training|The exercise program includes supervised treadmill walking and home-based walking exercise.
206011|NCT02607046|Other|NMES|This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
206012|NCT02607033|Other|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
206013|NCT02607033|Other|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
206014|NCT02607020|Other|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:~1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
206015|NCT02607020|Other|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
206016|NCT02607007|Other|2% M.F. Milk|
206017|NCT02607007|Other|White Bread|
206018|NCT02607007|Other|Strawberry Jam|
206019|NCT02607007|Other|31% M.F. Cheddar Cheese|
206020|NCT02607007|Other|2% M.F. Plain Greek yogurt|
206021|NCT02607007|Other|Soy Beverage|
206022|NCT02607007|Other|Water|
206023|NCT02606994|Drug|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
206024|NCT02606994|Drug|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
206025|NCT02606994|Drug|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
206026|NCT02606981|Device|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
206027|NCT02606981|Device|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
206028|NCT02606955|Device|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
206029|NCT02606942|Other|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
206030|NCT02606916|Radiation|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
206031|NCT02606916|Drug|DDP|DDP(25 mg/m2.qw) for six weeks.
206032|NCT02606916|Drug|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
206033|NCT02606903|Drug|BI 695501 prefilled syringe|
206034|NCT02606903|Drug|BI 695501 autoinjector|
206035|NCT02606890|Other|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
206036|NCT02606877|Drug|nintedanib|
206037|NCT02606877|Drug|pirfenidone|
206038|NCT02606864|Drug|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
206039|NCT02606838|Device|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
206040|NCT02606825|Other|Registry of AML patients > 60 years|
206041|NCT02606812|Dietary Supplement|Traditional-food|Intake of ethnic local food
206042|NCT02606799|Device|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
206043|NCT02606786|Other|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
206044|NCT02606773|Drug|Ascorbic Acid|Ascorbic acid in different ways and doses
206045|NCT02606760|Drug|P-3073|
206046|NCT02606760|Drug|Vehicle of P-3073|
206047|NCT02606734|Device|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
206048|NCT02606708|Radiation|Accelerated intensity modulated radiation therapy (AIMRT)|
206049|NCT02606695|Device|NuvaMap O.R.|Clinical imaging software used to assess intraoperative spinal alignment
206050|NCT02606695|Device|NuvaMap|Clinical imaging software used to assess spinal alignment
206051|NCT02606682|Drug|NPT200-11|Single doses of NPT200-11capsules, orally administered
206052|NCT02606682|Drug|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
206053|NCT02606669|Dietary Supplement|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
206054|NCT02606643|Procedure|Slight traction|Slight traction will be applied to the balloon catheter
206055|NCT02606643|Procedure|Foley Catheter to no traction|Foley Catheter to no traction
206056|NCT02606630|Drug|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
206057|NCT02606617|Drug|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
206058|NCT02606617|Drug|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
206059|NCT02606604|Device|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
206060|NCT02606591|Procedure|Electroencephalograph|EEG performed at beginning and end of school year.
206061|NCT02606591|Behavioral|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
206062|NCT02606591|Other|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
206063|NCT02606578|Other|Questionnaires|"The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.~At your clinical follow-up visits (~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.~You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back."
206064|NCT02606565|Biological|Intervention arm: 4% chlorhexidine|See previous description
206065|NCT02606552|Drug|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
206066|NCT02606552|Drug|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
206067|NCT02606552|Device|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
206068|NCT02606539|Procedure|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
206069|NCT02606539|Drug|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
206070|NCT02606526|Biological|BCG at birth|See previous description
206071|NCT02606526|Biological|Control arm: Delayed BCG|See previous description
206072|NCT02606513|Other|MR Urography; CT Urography|
206073|NCT02606500|Drug|Elonva|"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). Gonadotropin-releasing hormone (GnRH) antagonist will be used to prevent premature luteinizing hormone (LH) surge. Additional daily doses of 200 IU of recombinant follicle stimulating hormone (rFSH) will be used if necessary. Human chorionic gonadotropin (hCG) will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. Cumulus cell (CC) samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.~The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age > 38 years."
206074|NCT02606461|Drug|Selinexor|Selinexor 60mg
206075|NCT02606461|Drug|Placebo|
206076|NCT02606448|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
206077|NCT02606448|Procedure|Femoral nerve block|Pre-operative femoral nerve block
206078|NCT02606448|Drug|Ropivicaine|Ropivicaine was used in all femoral nerve blocks
206079|NCT02606435|Procedure|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
206080|NCT02606435|Device|thrombus aspiration|thrombus aspiration with export catheter
206081|NCT02606422|Device|Active HD-tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
206160|NCT02605850|Dietary Supplement|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
206082|NCT02606422|Device|Sham plus Speech-Language Therapy|Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
206083|NCT02606409|Drug|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
206084|NCT02606409|Drug|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
206085|NCT02606396|Procedure|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
206086|NCT02606396|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
206087|NCT02606396|Procedure|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
206088|NCT02606383|Drug|Dapaconazole|
206089|NCT02606383|Drug|Ketoconazole|
206090|NCT02606370|Other|Unstable shoe|Wearing Unstable shoes during 1 month
206091|NCT02606357|Drug|INSULIN GLARGINE|"Pharmaceutical form:Solution~Route of administration: Subcutaneous"
206092|NCT02606344|Other|Mico-finance based intervention|
206093|NCT02606331|Procedure|Piezosurgery|Corticotomy cuts will be performed by this technique.
206094|NCT02606331|Radiation|ER:YAG laser|Corticotomy cuts will be performed by this technique.
206095|NCT02606318|Other|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
206096|NCT02606318|Other|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
206097|NCT02606305|Drug|IMGN853|
206098|NCT02606305|Drug|Bevacizumab|
206099|NCT02606305|Drug|Carboplatin|
206100|NCT02606305|Drug|Pegylated Liposomal Doxorubicin|
206101|NCT02606305|Drug|Pembrolizumab|
206102|NCT02606305|Drug|Bevacizumab+Carboplatin|
206103|NCT02606292|Procedure|Photoacoustic endoscopy|
206104|NCT02606292|Procedure|Endoscopic ultrasound (standard of care)|
206105|NCT02606292|Procedure|Endoscopic surgery (standard of care)|
206106|NCT02606279|Drug|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
206107|NCT02606279|Other|Placebo|
206108|NCT02606266|Drug|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
206109|NCT02606253|Drug|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
206110|NCT02606253|Drug|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
206111|NCT02606253|Drug|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
206112|NCT02606240|Device|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
206113|NCT02606227|Behavioral|Financial incentive|Vouchers
206114|NCT02606227|Other|No financial incentive|No financial intervention
206115|NCT02606214|Drug|TBA-354|
206116|NCT02606214|Drug|TBA-354 Placebo|
206117|NCT02606201|Other|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.~All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.~During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
206118|NCT02606188|Device|Modified High-flow nasal cannula|Modified High-flow nasal cannula
206119|NCT02606188|Device|nasal cannula|Conventional oxygen therap
206120|NCT02606175|Other|Taking questionnaires and tests|"At predefined timepoints:~2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)~1 test for medication adherence: BAASIS~1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)~1 test about medication knowledge"
206121|NCT02606149|Behavioral|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
206122|NCT02606149|Behavioral|Standard of information|
206123|NCT02606136|Drug|pamrevlumab (FG-3019)|pamrevlumab (FG-3019), 10 mg/mL, single dose vials
206161|NCT02605850|Dietary Supplement|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
206162|NCT02605837|Drug|Oral Budesonide Suspension (OBS)|Oral Budesonide Suspension (OBS) 10 milliliter (ml) of 0.2 milligram per milliliter (mg/ml) twice daily up to 16 weeks.
206163|NCT02605837|Drug|Placebo|Oral dose of 10 ml of placebo matched with the experimental drug.
206164|NCT02605824|Drug|n-acetylcystine|NAC is a mucolytic drug.
206124|NCT02606123|Drug|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.~Part 1:~Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.~Part 2:~The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
206125|NCT02606097|Drug|regorafenib|
206126|NCT02606084|Drug|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
206127|NCT02606071|Device|CRT-D|HF patients treated in clinical practice with a CRT-D device
206128|NCT02606058|Procedure|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
206129|NCT02606045|Drug|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
206130|NCT02606045|Drug|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
206131|NCT02606032|Drug|Metronidazole|active comparator
206132|NCT02606032|Drug|Doxycycline|active comparator
206133|NCT02606032|Drug|Terbinafine|active comparator
206134|NCT02606032|Drug|Placebo|identical placebos to all antibiotics
206135|NCT02606006|Behavioral|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
206136|NCT02606006|Behavioral|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
206137|NCT02605993|Biological|Ravulizumab|All treatments were given as IV infusions.
206138|NCT02605980|Behavioral|Sedentary time|
206139|NCT02605967|Drug|PDR001|PDR001 is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
206140|NCT02605967|Drug|Investigator choice of chemotherapy|commonly used chemotherapy as per investigator's choice
206141|NCT02605954|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
206142|NCT02605954|Drug|ABC/3TC|600/300 mg tablets administered orally once daily
206143|NCT02605954|Drug|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:~ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~DRV+COBI or DRV/COBI FDC~darunavir (DRV; Prezista®) + RTV~lopinavir/ritonavir (LPV/r; Kaletra®)~atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~efavirenz (EFV; Sustiva®)~etravirine (ETR; Intelence®)~nevirapine (NVP; Viramune®)~rilpivirine (RPV; Edurant®)~dolutegravir (DTG; Tivicay®)~raltegravir (RAL; Isentress®)~fosamprenavir (FPV; Lexiva®) + RTV~saquinavir (SQV; Invirase®) + RTV~ATV (no booster)~Drug classes:~Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~Pharmacokinetic enhancer: COBI~Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~Integrase inhibitors: RAL and DTG"
206144|NCT02605928|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
206145|NCT02605915|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
206146|NCT02605915|Drug|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter*min (mg/mL*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
206147|NCT02605915|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
206148|NCT02605915|Drug|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
206149|NCT02605915|Drug|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
206150|NCT02605915|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
206151|NCT02605915|Drug|Doxorubicin|Doxorubicin will be administered at 60 mg/m^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
206152|NCT02605915|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
206153|NCT02605902|Behavioral|(i)Comprehensive Behavioral Intervention for Tics|
206154|NCT02605902|Behavioral|internet-delivered psychoeducation and relaxation training|
206155|NCT02605889|Other|Laser acupuncture|Laser acupuncture
206156|NCT02605876|Device|Whole body vibration|
206157|NCT02605876|Device|Local muscle vibration|
206158|NCT02605863|Drug|Enzalutamide|160 mg by mouth daily for 12 months
206159|NCT02605850|Other|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
206171|NCT02605785|Drug|F-18 AV 1451|Tau PET scan
206172|NCT02605772|Drug|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
206173|NCT02605772|Drug|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
206174|NCT02605772|Drug|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
206175|NCT02605759|Device|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
206176|NCT02605746|Drug|ceritinib 750mg|
206177|NCT02605733|Device|EEG|amplitude integrated electroencephalography
206178|NCT02605733|Device|NIRS|regional tissue oximetry
206179|NCT02605720|Drug|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
206180|NCT02605707|Drug|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
206181|NCT02605694|Drug|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
206182|NCT02605694|Drug|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
206183|NCT02605694|Drug|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)~Cyclophosphamide (750 mg/m2)~Doxorubicin hydrochloride (50 mg/m2)~Vincristine sulfate (1.4 mg/m2) (2 mg maximum)~Rituximab (375 mg/m2)"
206184|NCT02605694|Drug|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
206185|NCT02605668|Behavioral|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
206186|NCT02605668|Behavioral|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
206187|NCT02605655|Drug|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
206188|NCT02605655|Other|Placebo|Instant noodles without drug
206189|NCT02605642|Drug|CT-P13|biosimilar infliximab
206190|NCT02605629|Other|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
206191|NCT02605629|Other|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
206192|NCT02605616|Drug|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
206193|NCT02605616|Other|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
206194|NCT02605590|Drug|AIR DNase|
206195|NCT02605590|Drug|Placebo|
206196|NCT02605577|Procedure|new systemic nutrition management protocol|a new established systemic nutrition management protocol
206197|NCT02605564|Other|Gluten Free Diet|Gluten Free Diet
206198|NCT02605564|Other|Placebo|Placebo No intervention, standard T1DM diet
206199|NCT02605551|Procedure|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:~OM Occipitomastoid release technique~Sub-Occipital Release Technique~Rib Raising Technique~Rotatory stimulation of posterior Chapman's Reflexes~Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
206200|NCT02605551|Behavioral|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
206201|NCT02605538|Biological|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
206202|NCT02605525|Biological|SM101|Human soluble recombinant Fcγ Receptor IIB
206203|NCT02605525|Other|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
206204|NCT02605512|Other|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
206205|NCT02605499|Other|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
206206|NCT02605486|Drug|Palbociclib|
206207|NCT02605486|Drug|Bicalutamide|
206208|NCT02605460|Drug|Busulfan|12mg/kg, Oral, divided in 4 days, 3mg/kg/day Oral, during days -7, -6, -5 y -4.
206209|NCT02605460|Drug|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
206210|NCT02605460|Drug|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
206211|NCT02605460|Procedure|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
206212|NCT02605447|Drug|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
206213|NCT02605447|Device|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
206485|NCT02603861|Drug|LY3154207|LY3154207 administered orally.
206214|NCT02605434|Drug|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
206215|NCT02605434|Drug|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
206216|NCT02605434|Drug|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
206217|NCT02605434|Drug|Placebo- Sinemet|Placebo for Sinemet tables
206218|NCT02605421|Drug|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
206219|NCT02605421|Drug|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
206220|NCT02605421|Drug|Melphalan|Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
206221|NCT02605421|Drug|Etoposide|Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
206222|NCT02605421|Drug|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
206223|NCT02605421|Biological|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
206224|NCT02605421|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC > 2000/μL for 3 consecutive days.
206225|NCT02605408|Device|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
206226|NCT02605408|Procedure|Phacoemulsification|Removal of the cataractous lens
206227|NCT02605395|Drug|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
206228|NCT02605395|Drug|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
206229|NCT02605382|Drug|Chlorhexidine gluconate|
206230|NCT02605382|Drug|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
206231|NCT02605369|Behavioral|Intervention arm: An integrated package|See description in previous column
206232|NCT02605356|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
206233|NCT02605356|Drug|Placebo|
206234|NCT02605356|Drug|Bortezomib|
206235|NCT02605356|Drug|Dexamethasone|
206236|NCT02605343|Other|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
206237|NCT02605330|Procedure|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
206238|NCT02605317|Other|WhatsApp|Consultations used WhatsApp Messenger
206239|NCT02605304|Drug|Ledipasvir/sofosbuvir|Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
206240|NCT02605304|Drug|Ribavirin|"Based on weight at entry:~For weight <75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally."
206241|NCT02605291|Other|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
206242|NCT02605291|Other|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
206243|NCT02605291|Other|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
206244|NCT02605291|Other|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
206245|NCT02605291|Other|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
206246|NCT02605278|Other|Clinical program for pain and depression|Already described
206247|NCT02605278|Other|Control|Care as usual
206248|NCT02605265|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
206249|NCT02605265|Drug|Capecitabine|
206250|NCT02605265|Drug|Irinotecan|
206251|NCT02605265|Drug|Oxaliplatin|
206252|NCT02605252|Drug|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
206253|NCT02605239|Drug|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
206254|NCT02605226|Procedure|Cryoablation therapy|Cryoablation therapy
206255|NCT02605226|Radiation|External beam radiation therapy|External beam radiation therapy
206256|NCT02605226|Drug|bicalutamide|bicalutamide
206257|NCT02605226|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
206258|NCT02605213|Drug|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
206259|NCT02605213|Drug|Placebo|Placebo for control Group of primary sclerosing vhlangitis
206260|NCT02605200|Behavioral|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
206261|NCT02605200|Behavioral|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
206262|NCT02605187|Other|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
206263|NCT02605187|Other|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
206264|NCT02605187|Drug|Ibuprofen|Ibuprofen 600mg po q6h
206265|NCT02605187|Drug|Acetaminophen|Acetaminophen 650mg po q6h
206266|NCT02605187|Drug|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
206267|NCT02605187|Drug|Morphine (low)|Intrathecal morphine dose 50mcg
206268|NCT02605187|Drug|Morphine (med)|Intrathecal morphine dose 150mcg
206269|NCT02605187|Drug|Morphine (high)|Intrathecal morphine 300mcg
206270|NCT02605174|Drug|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
206271|NCT02605174|Drug|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
206272|NCT02605174|Drug|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
206273|NCT02605174|Drug|Placebo|Two placebo tablets to match lasmiditan doses.
206274|NCT02605148|Dietary Supplement|Gluten free diet|Gluten free diet during 18 months.
206275|NCT02605148|Dietary Supplement|Omega 3 fatty acid|Omega 3 fatty acid
206276|NCT02605148|Dietary Supplement|Vitamin D|Vitamin D 800 U/day
206277|NCT02605148|Dietary Supplement|Probiotics|Probiotics
206278|NCT02605135|Device|Continued Pessary Use|Pessary Fitting
206279|NCT02605122|Drug|Solithromycin|
206280|NCT02605122|Drug|Standard of Care|Age- and weight-based dosing as appropriate per sites standard of care.
206281|NCT02605109|Other|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
206282|NCT02605096|Procedure|MRI|Magnetic Resonance Imaging Scan
206283|NCT02605096|Procedure|X-ray|X-ray exam (conventional radiography)
206284|NCT02605083|Drug|eFT508|Will be given orally once or twice daily. Each treatment cycle = 21 days.
206285|NCT02605070|Drug|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.~From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.~At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
206286|NCT02605057|Drug|LEO 80185 gel|
206287|NCT02605057|Drug|Dovobet(r) Ointment|
206288|NCT02605044|Drug|Masitinib (AB1010)|
206289|NCT02605044|Drug|FOLFIRI|
206290|NCT02604992|Drug|Treatment A|Dronabinol oral solution, under fed conditions
206291|NCT02604992|Drug|Treatment B|Dronabinol oral capsule, under fed conditions
206292|NCT02604992|Drug|Treatment C|Dronabinol oral capsule, under fasted conditions
206293|NCT02604966|Drug|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
206294|NCT02604966|Drug|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
206295|NCT02604953|Diagnostic Test|Short Duration Transient Visual Evoked Potential (SDtVEP)|Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
206296|NCT02604953|Diagnostic Test|Pattern electroretinogram (PERG)|Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
206297|NCT02604940|Drug|Dexmedetomidine|1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure
206298|NCT02604940|Drug|Normal Saline|60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
206299|NCT02604927|Dietary Supplement|Beta-alanine|
206300|NCT02604927|Dietary Supplement|Dextrose|
206301|NCT02604914|Drug|ND0612|Subcutaneous solution
206302|NCT02604914|Drug|LCIG|Intrajejunal Gel
206303|NCT02604901|Behavioral|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR*S (BI). BI was considered an active intervention method.
206304|NCT02604901|Behavioral|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
206305|NCT02604888|Other|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
206306|NCT02604875|Other|observation|blood sampling during 24 hours
206307|NCT02604862|Other|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
206308|NCT02604849|Drug|Neomycin|
206309|NCT02604849|Drug|Streptomycin|
206310|NCT02604849|Drug|Gentamicins|
206311|NCT02604836|Drug|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
206312|NCT02604823|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
206313|NCT02604810|Biological|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
206314|NCT02604810|Biological|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
206315|NCT02604797|Drug|Nalbuphine|patient-controlled intravenous analgesia
206316|NCT02604797|Drug|Sufentanil|patient-controlled intravenous analgesia
206317|NCT02604797|Drug|flurbiprofen axetil|patient-controlled intravenous analgesia
206318|NCT02604797|Drug|ramosetron|patient-controlled intravenous analgesia
206319|NCT02604784|Drug|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) fixed repeated dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Standard dosage of drugs for each PIPAC: Cisplatin (7.5 mg/m²) + Doxorubicin (1.5 mg/m²) or Oxaliplatin (92 mg/m²) The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
206320|NCT02604784|Drug|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) increasing single dose|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. Escalating dosage of drugs for PIPAC: Cisplatin + Doxorubicin (from 15 mg/m² + 3 mg/m² to 100 mg/m² + 30 mg/m²) or Oxaliplatin (from 92 mg/m² to 300mg/m²).The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters.
206321|NCT02604758|Behavioral|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
206322|NCT02604732|Procedure|Laparoscopic inguinal hernia repair|
206323|NCT02604719|Drug|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
206324|NCT02604706|Device|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
206325|NCT02604706|Device|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
206326|NCT02604706|Behavioral|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
206327|NCT02604693|Other|Nothing|No interventions will be administered.
206328|NCT02604680|Drug|BLI1100-1|BLI1100-1 Topical gel
206329|NCT02604680|Drug|BLI1100-2|BLI1100-2 Topical gel
206330|NCT02604680|Drug|BLI1100-3|BLI1100-3 Topical gel
206331|NCT02604680|Drug|BLI1100-4|BLI1100-4 Topical gel
206332|NCT02604680|Drug|Placebo|Placebo - Topical gel
206333|NCT02604667|Other|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.~Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.~Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
206334|NCT02604667|Other|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
206335|NCT02604654|Drug|Yiqitongluo granule|administered after dissolved
206336|NCT02604641|Dietary Supplement|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
206337|NCT02604641|Dietary Supplement|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
206338|NCT02604641|Dietary Supplement|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
206339|NCT02604628|Behavioral|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
206340|NCT02604615|Drug|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
206341|NCT02604615|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
206342|NCT02604615|Radiation|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
206343|NCT02604602|Other|blood exam|laboratory test
206344|NCT02604589|Drug|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
206345|NCT02604589|Procedure|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
206346|NCT02604589|Drug|bupivicaine 0.25%|Low Dose analgesia
206347|NCT02604589|Drug|bupivicaine 0.5%|High dose analgesia
206348|NCT02604576|Drug|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
206349|NCT02604576|Drug|Bromopride 10 mg|Bromopride 10 mg
206350|NCT02604563|Other|Cognitive Assessment|-Baseline and no more frequently than every 6 months until death
206351|NCT02604563|Other|Activities of Daily Living Questionnaire|"10 items about daily functional status~Baseline and no more frequently than every 6 months until death"
206352|NCT02604563|Other|Instrumental Activities of Daily Living, subscale of the OARS|"7 items about daily functional status~Baseline and no more frequently than every 6 months until death"
206353|NCT02604563|Other|Karnofsky Self-reported Performance Rating Scale|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
206354|NCT02604563|Other|Number of Falls|"1 item about daily functional status~Baseline and no more frequently than every 6 months until death"
206355|NCT02604563|Other|Physical Health Section, subscale of the OARS|"13 items about comorbidity~Baseline and no more frequently than every 6 months until death"
206356|NCT02604563|Other|MOS Social Activity Survey|"4 items about social activity~Baseline and no more frequently than every 6 months until death"
206357|NCT02604563|Other|Unintentional Weight Loss|"2 items about nutrition~Baseline and no more frequently than every 6 months until death"
206358|NCT02604563|Genetic|Peripheral Blood Draw|-Baseline and no more frequently than every 6 months until death
206359|NCT02604563|Genetic|Buccal Swab|"Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~Baseline and no more frequently than every 6 months until death"
206360|NCT02604563|Other|Heart Health and Smoking History from BRFSS questionnaire|"7 items about heart health and smoking history~Baseline and no more frequently than every 6 months until death"
206361|NCT02604563|Other|Gait Speed|"Research coordinator will test gait speed~Baseline and no more frequently than every 6 months until death"
206362|NCT02604563|Other|Grip Strength|"Research coordinator will test grip strength~Baseline and no more frequently than every 6 months until death"
206363|NCT02604563|Other|Height and Weight measurements|-Baseline and no more frequently than every 6 months until death
206364|NCT02604563|Other|Blood pressure measurement|-Baseline and no more frequently than every 6 months until death
206365|NCT02604563|Procedure|Optional bone marrow biopsy|-1 optional bone marrow biopsy
206366|NCT02604550|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
206367|NCT02604550|Drug|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
206368|NCT02604550|Drug|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
206369|NCT02604537|Drug|Celestone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml celestone OR
206370|NCT02604537|Drug|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
206371|NCT02604524|Device|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
206372|NCT02604524|Other|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
206373|NCT02604511|Drug|Ibrutinib|
206374|NCT02604498|Drug|Nemonoxacin|Single dose 500mg oral
206375|NCT02604485|Drug|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
206376|NCT02604485|Drug|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
206377|NCT02604485|Drug|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
206378|NCT02604485|Drug|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
206379|NCT02604472|Other|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
206380|NCT02604472|Other|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
206381|NCT02604459|Device|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
206382|NCT02604459|Device|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
206383|NCT02604459|Procedure|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
206384|NCT02604459|Procedure|General anesthesia|General anesthesia will be used in both groups
206385|NCT02604459|Drug|propofol|propofol per protocol
206386|NCT02604459|Drug|fentanyl|fentanyl per protocol
206387|NCT02604459|Drug|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
206388|NCT02604446|Drug|Tapentadol|
206391|NCT02604446|Drug|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
206392|NCT02604433|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
206393|NCT02604433|Other|Placebo|Placebo, Subcutaneous, every 21 days.
206394|NCT02604420|Drug|eculizumab|
206395|NCT02604407|Drug|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
206396|NCT02604407|Other|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
206397|NCT02604407|Drug|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
206398|NCT02604394|Procedure|Rheolytic Thrombectomy|"RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).~The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:~The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.~The disposable pump connects to a bag of heparinized saline.~The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,"
206399|NCT02604394|Procedure|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
206400|NCT02604381|Dietary Supplement|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
206401|NCT02604381|Other|Placebo|
206402|NCT02604368|Drug|SC411|Soft gelatin capsule
206403|NCT02604368|Drug|Placebo|Soft gelatin capsule
206404|NCT02604355|Other|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
206405|NCT02604355|Drug|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
206406|NCT02604342|Drug|Alectinib|Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
206407|NCT02604342|Drug|Docetaxel|Participants will receive docetaxel at a dose of 75 mg/m^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
206408|NCT02604342|Drug|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
206409|NCT02604329|Device|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).~Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).~Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
206410|NCT02604316|Other|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
206411|NCT02604316|Other|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
206412|NCT02604303|Other|No Intervention|No intervention; prospective observational study
206413|NCT02604290|Device|Kinesio Taping method|"The tape is applied depending on the physical examination:~Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.~Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.~Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
206414|NCT02604290|Device|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
206415|NCT02604277|Behavioral|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
206416|NCT02604277|Behavioral|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
206417|NCT02604277|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MSBR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
206418|NCT02604277|Behavioral|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education & Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education & Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
206486|NCT02603861|Drug|Placebo|Placebo administered orally.
206419|NCT02604264|Device|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
206420|NCT02604251|Device|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
206421|NCT02604251|Device|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
206422|NCT02604238|Drug|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc [LMWH], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing <50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
206423|NCT02604225|Drug|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
206424|NCT02604225|Drug|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
206425|NCT02604212|Drug|ARC-520|
206426|NCT02604212|Other|Placebo|
206427|NCT02604212|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
206428|NCT02604212|Drug|antihistamine|All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
206429|NCT02604212|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
206430|NCT02604199|Drug|ARC-520 Injection|ARC-520 Injection was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
206431|NCT02604199|Other|placebo|Placebo was administered concomitantly, IV with 0.9% normal saline using an infusion rate of 0.4 mL/min for study treatment and 3.6 mL/min for saline.
206432|NCT02604199|Drug|entecavir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
206433|NCT02604199|Drug|tenofovir|All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.
206434|NCT02604199|Drug|antihistamine|All participants will be pretreated with an oral antihistamine, administered 2 hours (±30 minutes) pre-dose. The antihistamine used should in general be an H1>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.
206435|NCT02604186|Other|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
206436|NCT02604186|Other|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
206437|NCT02604173|Drug|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
206438|NCT02604173|Drug|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
206439|NCT02604173|Drug|Placebo|Placebo pill and sham inhaler
206440|NCT02604160|Drug|LY3113593|Administered by slow intravenous (IV) infusion.
206441|NCT02604160|Drug|Placebo|Administered by slow intravenous (IV) infusion.
206442|NCT02604147|Device|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
206443|NCT02604147|Device|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
206444|NCT02604134|Procedure|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
206445|NCT02604134|Drug|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
206446|NCT02604134|Drug|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
206447|NCT02604121|Device|Orcellex® Rovers brush|transepithelial brushing
206448|NCT02604108|Behavioral|Physical Exercise|"The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
206487|NCT02603861|Drug|Modafinil|Modafinil administered orally.
206449|NCT02604108|Behavioral|Healthy Diet|"The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.~The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
206450|NCT02604095|Dietary Supplement|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
206451|NCT02604082|Other|Vibrocompression (VB)|Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
206452|NCT02604082|Other|Hyperinflation (HMV)|Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
206453|NCT02604082|Other|HMV+VB|Association between Vibrocompression and Hyperinflation with mechanical ventilator
206454|NCT02604069|Device|Continuous Glucose Monitor|
206455|NCT02604056|Behavioral|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
206456|NCT02604056|Behavioral|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
206457|NCT02604043|Other|pH monitoring|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
206458|NCT02604043|Other|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
206459|NCT02604030|Other|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
206460|NCT02604017|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
206461|NCT02604004|Drug|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
206462|NCT02604004|Drug|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
206463|NCT02603991|Procedure|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
206464|NCT02603991|Drug|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
206465|NCT02603978|Behavioral|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
206466|NCT02603978|Behavioral|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
206467|NCT02603978|Behavioral|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
206468|NCT02603965|Radiation|Copper Cu 64 TP3805|Given IV
206469|NCT02603965|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
206470|NCT02603965|Procedure|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
206471|NCT02603965|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
206472|NCT02603965|Other|Laboratory Biomarker Analysis|Correlative studies
206473|NCT02603952|Drug|Oseltamivir|75 mg capsules orally BID from Day 1 to Day 5.
206474|NCT02603952|Drug|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered as a single IV infusion of 750 mg or 3000 mg on Day 1.
206475|NCT02603952|Drug|Placebo|Placebo is salt-water solution containing no active ingredients and administered as a single IV infusion on Day 1.
206476|NCT02603939|Procedure|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
206477|NCT02603926|Drug|Allopregnanolone|Allopregnanolone is an endogenous inhibitory pregnane neurosteroid. It is synthesized from progesterone, and is a potent positive allosteric modulator of the action of γ-aminobutyric acid at GABAA receptor. Subjects will receive up to 12 infusions in the study. Subjects will all begin with 2.0 mg dosage. If tolerated, the next infusion will be 4.0 mg, and if that is tolerated, the next infusion will be 6.0 mg. Subject infusions will remain stable at the highest dosage tolerated for the remainder of the study. Each infusion will consist of 2.0 mg, 4.0 mg, or 6.0 mg aliquots of the 0.5 mg/ml allopregnanolone in 6% sulfobutylether-β-cyclodextrin with 0.9% sodium chloride injection solution.
206478|NCT02603900|Drug|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
206479|NCT02603900|Drug|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
206480|NCT02603900|Device|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
206481|NCT02603900|Device|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
206482|NCT02603887|Other|Laboratory Biomarker Analysis|Correlative studies
206483|NCT02603887|Biological|Pembrolizumab|Given IV
206484|NCT02603874|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
206488|NCT02603848|Drug|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
206489|NCT02603848|Drug|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
206490|NCT02603835|Device|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
206491|NCT02603822|Dietary Supplement|12C mannitol|12C mannitol 100 mg
206492|NCT02603822|Drug|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
206493|NCT02603822|Dietary Supplement|13C mannitol|13C mannitol 100 mg
206494|NCT02603822|Dietary Supplement|Lactulose|lactulose 1 g
206495|NCT02603809|Drug|ACT-132577|ACT-132577 administered as capsules orally once a day (o.d.) for 8 weeks
206496|NCT02603809|Drug|Lisinopril|20 mg capsules orally o.d. for 8 weeks
206497|NCT02603809|Other|Placebo|Placebo matching ACT-132577 and placebo matching lisinopril capsules will be administered concomitantly orally o.d. for 8 weeks
206498|NCT02603796|Other|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
206499|NCT02603783|Other|Capsaicin|capsaicin 1,5 mg
206500|NCT02603783|Other|Placebo|0,9% saline 75 ml
206501|NCT02603770|Drug|XueZhiKang|
206502|NCT02603770|Drug|Lovastatin|
206503|NCT02603757|Dietary Supplement|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
206504|NCT02603744|Biological|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
206505|NCT02603718|Other|Rehabilitation treatment|
206506|NCT02603705|Drug|Oxycodone extended-release|
206507|NCT02603692|Other|PROMIS-QOL|PROMIS questionnaires completed every 3 months for up to 2 years.
206508|NCT02603679|Drug|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
206509|NCT02603679|Drug|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
206510|NCT02603679|Drug|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
206511|NCT02603679|Drug|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
206512|NCT02603666|Device|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
206513|NCT02603653|Device|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
206514|NCT02603640|Device|MRI scanning|
206515|NCT02603614|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
206516|NCT02603614|Drug|Placebo|Placebo control
206517|NCT02603601|Behavioral|Mind-body lifestyle intervention|
206518|NCT02603601|Behavioral|Standard lifestyle intervention|
206519|NCT02603588|Procedure|active sphenopalatine ganglion acupuncture|"The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
206520|NCT02603588|Procedure|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
206521|NCT02603575|Drug|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
206522|NCT02603575|Drug|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
206523|NCT02603575|Drug|Sulfanilamides|1.92g q8h
206524|NCT02603562|Biological|ATYR1940|ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg using intrapatient dose escalation. The dose level in this study will not exceed 3.0 mg/kg
206525|NCT02603562|Biological|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
206526|NCT02603549|Other|Pituitary panel will be drawn pre-op and post-op for all patients.|
206527|NCT02603536|Other|WelTel|An evidence-based, text messaging solution for improving patient adherence.
206528|NCT02603523|Behavioral|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
206529|NCT02603510|Drug|SAR342434|"Pharmaceutical form:solution~Route of administration: subcutaneous"
206530|NCT02603510|Drug|insulin lispro|"Pharmaceutical form:solution~Route of administration: subcutaneous"
206531|NCT02603497|Drug|ASP015K|oral
206532|NCT02603471|Other|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
206533|NCT02603471|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
206534|NCT02603458|Drug|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
206535|NCT02603458|Drug|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
206536|NCT02603445|Drug|BCL201|
206537|NCT02603445|Drug|Idelalisib|
206538|NCT02603432|Biological|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
206539|NCT02603432|Other|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
206540|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
206541|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
206542|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
206543|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
206544|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
206545|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
206546|NCT02603406|Drug|erythropoietin|
206547|NCT02603393|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
206548|NCT02603393|Drug|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
206549|NCT02603393|Drug|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
206550|NCT02603380|Other|No intervention|This is an observational study. No intervention will be given.
206551|NCT02603367|Other|Communication Intervention|Undergo communication coaching
206552|NCT02603367|Other|Educational Intervention|Receive COMFORT communication curriculum
206553|NCT02603367|Other|Psychosocial Support for Caregiver|Undergo communication coaching
206554|NCT02603367|Other|Questionnaire Administration|Complete questionnaires
206555|NCT02603354|Drug|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
206556|NCT02603341|Radiation|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
206557|NCT02603341|Radiation|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
206558|NCT02603328|Drug|Atorvastatin|40-80 mg OD
206559|NCT02603328|Other|Placebo|inactive
206560|NCT02603315|Other|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
206561|NCT02603302|Radiation|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
206562|NCT02603302|Procedure|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
206563|NCT02603289|Device|Invisalign|
206564|NCT02603276|Dietary Supplement|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
206565|NCT02603276|Dietary Supplement|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
206566|NCT02603276|Dietary Supplement|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
206567|NCT02603263|Other|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
206568|NCT02603237|Other|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
206569|NCT02603237|Other|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
206570|NCT02603224|Drug|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
206571|NCT02603224|Drug|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
206572|NCT02603211|Device|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
206573|NCT02603198|Drug|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
206574|NCT02603198|Drug|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
206575|NCT02603185|Drug|Hemay007|
206576|NCT02603185|Drug|placebo|
206577|NCT02603172|Drug|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
206578|NCT02603159|Drug|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
206579|NCT02603159|Radiation|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
206580|NCT02603146|Drug|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
206581|NCT02603146|Drug|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
206582|NCT02603133|Behavioral|Three Good Things|"In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others."
206654|NCT02602613|Device|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
206583|NCT02603133|Behavioral|Gratitude|In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
206584|NCT02603133|Behavioral|Random Acts of Kindess|In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
206585|NCT02603133|Behavioral|Awe|This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
206586|NCT02603133|Behavioral|1 Good Chat|This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
206587|NCT02603120|Drug|ABC/DTG/3TC|600/50/300 mg FDC tablets administered orally once daily without regard to food
206588|NCT02603120|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
206589|NCT02603120|Drug|ABC/DTG/3TC Placebo|Tablets administered orally once daily without regard to food
206590|NCT02603120|Drug|B/F/TAF Placebo|Tablets administered orally once daily without regard to food
206591|NCT02603107|Drug|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
206592|NCT02603107|Drug|ATV|300 mg capsule administered orally once daily with food
206593|NCT02603107|Drug|DRV|800 mg tablet administered orally once daily with food
206594|NCT02603107|Drug|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
206595|NCT02603107|Drug|ATV/co|300/150 mg FDC tablet administered orally once daily with food
206596|NCT02603107|Drug|DRV/co|800/150 mg FDC tablet administered orally once daily with food
206597|NCT02603107|Drug|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
206598|NCT02603107|Drug|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
206599|NCT02603107|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
206600|NCT02603094|Procedure|clear fluid ingestion|drinking of clear fluid in preoperative period
206601|NCT02603081|Drug|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
206602|NCT02603068|Drug|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
206603|NCT02603055|Biological|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
206604|NCT02603055|Biological|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
206605|NCT02603029|Other|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
206606|NCT02603029|Other|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
206607|NCT02603016|Drug|GLSE compound|
206608|NCT02603016|Drug|Maitake mushroom extract compound|
206609|NCT02603016|Drug|Ginseng compound|
206610|NCT02603003|Drug|JinFuKang|po.tid.30ml
206611|NCT02603003|Drug|Cisplatin|According to the individual patient's condition
206612|NCT02603003|Drug|Pemetrexed|According to the individual patient's condition
206613|NCT02602990|Device|SQUID™|
206614|NCT02602977|Other|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
206615|NCT02602977|Other|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.~1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.~Single-dose RIPC consists of 1 dose of RIPC as described above"
206616|NCT02602977|Biological|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group [n=10], single-dose RIPC group [n=10] and control group [n=10]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
206617|NCT02602964|Other|Deep neuromsucular block|Deep or standard neuromuscular block
206618|NCT02602951|Other|Pilot MRI program|Pilot MRI program
206619|NCT02602951|Other|MRI with 4D Flow sequence|MRI with 4D Flow sequence
206620|NCT02602938|Drug|Aspirin|Take aspirin (100mg) orally once a day for 2 months
206621|NCT02602925|Other|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
206622|NCT02602925|Other|Usual care|Usual care
206655|NCT02602600|Drug|Liraglutide|"Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.~Weight maintenance diet for 2 weeks"
206656|NCT02602587|Biological|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
207188|NCT02598947|Other|Manual therapy|Exercise and manual therapy
206623|NCT02602912|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
206624|NCT02602899|Procedure|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
206625|NCT02602886|Behavioral|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
206626|NCT02602873|Other|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
206627|NCT02602860|Radiation|[11C]UCB-J|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 20 mCi~Route of Administration: iv"
206628|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 10 mg/ml~Route of Administration: iv"
206629|NCT02602860|Drug|Levetiracetam|"Pharmaceutical form: Sterile solution for intravenous infusion~Concentration: 100 mg/ml~Route of Administration: iv"
206630|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Tablets for oral intake~Concentration: 25 mg~Route of Administration: oral"
206631|NCT02602847|Biological|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
206632|NCT02602834|Other|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
206633|NCT02602834|Other|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
206634|NCT02602795|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
206635|NCT02602795|Behavioral|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
206636|NCT02602769|Diagnostic Test|Transcriptome profiling|The investigators will obtain blood to extract peripheral mononuclear cells. These cells will be used to generate patient specific hypothalamic cells that will be used for transcriptome profiling.
206637|NCT02602756|Radiation|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
206638|NCT02602743|Drug|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
206639|NCT02602743|Drug|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
206640|NCT02602743|Drug|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
206641|NCT02602730|Behavioral|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
206642|NCT02602730|Behavioral|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
206643|NCT02602717|Other|lymph nodes cyto-punction|
206644|NCT02602704|Drug|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
206645|NCT02602704|Drug|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day) for 48 weeks
206646|NCT02602691|Other|AlloMap®|
206647|NCT02602691|Procedure|Endomyocardial biopsies|
206648|NCT02602678|Procedure|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
206649|NCT02602678|Procedure|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
206650|NCT02602665|Procedure|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
206651|NCT02602665|Procedure|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
206652|NCT02602652|Biological|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
206653|NCT02602639|Device|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
206657|NCT02602587|Biological|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
206658|NCT02602574|Other|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
206659|NCT02602561|Dietary Supplement|HMB|
206660|NCT02602561|Dietary Supplement|Placebo|
206661|NCT02602548|Other|Culture|Specimens will be obtained and sent to the lab for cultures.
206662|NCT02602535|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
206663|NCT02602535|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
206664|NCT02602522|Drug|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
206665|NCT02602522|Drug|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
206666|NCT02602509|Drug|Celecoxib|
206667|NCT02602509|Drug|Rifampicin|
206668|NCT02602509|Drug|Pyrazinamide|
206669|NCT02602496|Other|Fruits and Vegetables|5 servings of fruits or vegetables
206670|NCT02602496|Other|Whole Grain|3 servings of whole grain
206671|NCT02602496|Other|Control|3 servings of refined grain
206672|NCT02602483|Drug|Ibuprofen|
206673|NCT02602483|Drug|Magnesium|
206674|NCT02602483|Drug|Ascorbic Acid|
206675|NCT02602483|Drug|Placebo|
206676|NCT02602470|Drug|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser & Moisturizing
206677|NCT02602470|Drug|Azelaic Acid Cream|Azelaic Acid Cream 20%
206678|NCT02602470|Drug|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
206679|NCT02602470|Drug|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
206680|NCT02602470|Drug|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
206681|NCT02602470|Drug|Metronidazole Lotion|Metronidazole Lotion 0,75%
206682|NCT02602470|Drug|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
206683|NCT02602457|Behavioral|moderate-intensity continuous exercise training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
206684|NCT02602457|Behavioral|high-intensity interval training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
206685|NCT02602444|Drug|ticagrelor|180 mg loading dose
206686|NCT02602431|Device|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
206687|NCT02602431|Device|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
206688|NCT02602431|Device|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
206689|NCT02602431|Device|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
206690|NCT02602418|Other|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
206691|NCT02602418|Other|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
206692|NCT02602392|Behavioral|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
206693|NCT02602392|Behavioral|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
206694|NCT02602379|Other|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
206695|NCT02602366|Other|HEC Placebo Gel|
206696|NCT02602366|Other|Placebo Vaginal Insert|
206697|NCT02602366|Other|Placebo Vaginal Film|
206698|NCT02602366|Other|Placebo Intravaginal ring (IVR)|
206699|NCT02602353|Drug|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
206700|NCT02602353|Drug|Placebo Patch|One Placebo Patch applied daily for 3 days
206701|NCT02602353|Drug|No Treatment|No Treatment for 3 days
206702|NCT02602340|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
206703|NCT02602327|Drug|Tas-102|Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
206704|NCT02602327|Device|SIR-Sphere|20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
206705|NCT02602314|Drug|Imatinib|
206706|NCT02602314|Drug|Nilotinib|
206707|NCT02602301|Drug|Oxytocin|different oxytocin diluents and effect on fetal bilirubin&sodium levels.
206708|NCT02602288|Behavioral|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
206709|NCT02602288|Behavioral|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
206710|NCT02602288|Behavioral|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
206711|NCT02602288|Device|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
206712|NCT02602288|Device|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
206713|NCT02602288|Drug|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
206714|NCT02602275|Drug|Neurexan®|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the experimantal arm participants will receive verum on DAY1/PERIOD 1 and will receive placebo on DAY2/PERIOD 2.
206715|NCT02602275|Other|Placebo|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the comparator arm participants will receive placebo on DAY1/PERIOD 1 and will receive verum on DAY2/PERIOD 2.
206716|NCT02602262|Other|HIV-infected deceased donor organ|HIV-infected deceased donor organ transplant
206717|NCT02602249|Biological|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
206718|NCT02602249|Biological|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
206719|NCT02602236|Device|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
206720|NCT02602223|Device|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
206721|NCT02602223|Device|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
206722|NCT02602210|Drug|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
206723|NCT02602210|Drug|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
206724|NCT02602197|Drug|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
206725|NCT02602197|Drug|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
206726|NCT02602184|Drug|AR/101|
206727|NCT02602184|Drug|Placebo|
206728|NCT02602171|Other|Oldenburger sentence test, localization test|
206729|NCT02602158|Dietary Supplement|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
206730|NCT02602158|Dietary Supplement|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Optional study pending interim analysis:~Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
206731|NCT02602145|Other|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a standard post-operative contrast-enhanced CTA of the lower extremities at 6 months after stenting.
206732|NCT02602132|Procedure|Clamping|To clamp before the removal of short-term indwelling urethral catheters
206733|NCT02602119|Drug|OTL38|Infusion of OTL38 prior to surgery
206734|NCT02602106|Behavioral|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
206735|NCT02602093|Procedure|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
207189|NCT02598934|Drug|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
206736|NCT02602093|Procedure|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
206737|NCT02602067|Combination Product|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
206738|NCT02602054|Procedure|Surgical treatment|Standard left thoracotomy
206739|NCT02602054|Drug|Control group|"- Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days"
206740|NCT02602041|Other|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
206741|NCT02602028|Drug|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
206742|NCT02602002|Drug|Remifentanil|IV
206743|NCT02602002|Drug|Placebo|Placebo
206744|NCT02601989|Drug|Tadalafil|
206745|NCT02601989|Drug|Placebo|Per oral intake of placebo for six weeks
206746|NCT02601976|Drug|Peginterferon alfa-2a|PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
206747|NCT02601976|Drug|Ribavirin|Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
206748|NCT02601963|Drug|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
206749|NCT02601963|Drug|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
206750|NCT02601963|Drug|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
206751|NCT02601950|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
206752|NCT02601937|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
206753|NCT02601924|Drug|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
206754|NCT02601924|Other|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
206755|NCT02601911|Drug|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
206756|NCT02601911|Drug|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
206757|NCT02601911|Other|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
206758|NCT02601898|Device|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
206759|NCT02601898|Drug|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
206760|NCT02601885|Drug|ABT-555|Intravenous Infusion
206761|NCT02601885|Other|Placebo|Intravenous Infusion
206762|NCT02601859|Drug|Lithium Carbonate|
206763|NCT02601846|Other|No intervention|This is an observational study, without any specific intervention.
206764|NCT02601833|Device|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
206765|NCT02601833|Procedure|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
206766|NCT02601807|Device|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
206767|NCT02601807|Device|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
206768|NCT02601794|Behavioral|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
206769|NCT02601781|Procedure|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
206770|NCT02601781|Device|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
206771|NCT02601768|Device|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
206772|NCT02601755|Behavioral|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
206773|NCT02601755|Behavioral|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
206774|NCT02601742|Other|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
206775|NCT02601742|Other|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
206776|NCT02601716|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
206777|NCT02601716|Biological|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
206778|NCT02601716|Biological|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
206779|NCT02601703|Drug|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
206780|NCT02601703|Drug|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
206781|NCT02601703|Drug|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
206782|NCT02601690|Other|Blood Sampling|
206783|NCT02601677|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
206784|NCT02601677|Drug|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
206785|NCT02601664|Procedure|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
206786|NCT02601664|Procedure|Conventional PCI|Conventional PCI
206787|NCT02601651|Drug|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
206788|NCT02601651|Drug|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
206789|NCT02601638|Other|Demographics and Health History Questionnaire|
206790|NCT02601638|Other|Pre-Class Laryngectomy Survey|
206791|NCT02601638|Behavioral|Counseling session with speech pathologist|
206792|NCT02601638|Behavioral|Total Laryngectomy Preoperative Education Class|
206793|NCT02601638|Other|Day of Hospital Discharge Laryngectomy Survey|
206794|NCT02601638|Other|Day of Discharge Practicum|
206795|NCT02601638|Other|Laryngectomy Education Study Exit Survey|
206796|NCT02601625|Drug|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
206797|NCT02601625|Drug|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
206798|NCT02601625|Drug|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
206799|NCT02601625|Drug|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
206800|NCT02601625|Drug|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
206801|NCT02601625|Drug|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
206802|NCT02601612|Biological|D46cpΔM2-2 vaccine|Delivered as nose drops
206803|NCT02601612|Biological|Placebo|Delivered as nose drops
206804|NCT02601599|Behavioral|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
206805|NCT02601586|Drug|PR Oxycodone|PR Oxycodone
206806|NCT02601586|Drug|Levodopa|Levodopa
206807|NCT02601586|Drug|Oxycodone Placebo|Placebo of PR Oxycodone
206808|NCT02601586|Drug|Levodopa placebo|
206809|NCT02601573|Drug|Grazoprevir|GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken q.d. by mouth in the morning.
206810|NCT02601573|Drug|Elbasvir|EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.
206811|NCT02601573|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).
206812|NCT02601573|Drug|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
206813|NCT02601560|Biological|MEDI6012|Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
206814|NCT02601560|Biological|Placebo SC|Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.
206815|NCT02601560|Biological|Placebo IV|Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
206852|NCT02601222|Drug|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
206816|NCT02601547|Device|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
206817|NCT02601534|Behavioral|Zero-time Exercise|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve physical activity habit.
206818|NCT02601534|Behavioral|Healthy Eating|a knowledge and motivation enhancement session at baseline, an experience sharing session at 3 months, a family gathering session at 6 months, and a holistic health session at 12 months (not a part of cRCT, for the collection of feedback only) as well as biweekly/monthly mobile messages to improve dietary habit.
206819|NCT02601521|Behavioral|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:~Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.~The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.~Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
206820|NCT02601521|Behavioral|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
206821|NCT02601508|Drug|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
206822|NCT02601508|Drug|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine & Glycopyrrolate
206823|NCT02601495|Behavioral|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
206824|NCT02601482|Behavioral|CON|
206825|NCT02601482|Behavioral|IW-60|
206826|NCT02601482|Behavioral|IW-45|
206827|NCT02601469|Drug|DSXS|twice daily for 28 days
206828|NCT02601443|Device|Cervical Pessary|
206829|NCT02601430|Other|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
206830|NCT02601417|Other|Ignoring result of bile culture|Patients in the trial arm will do bile cultures which will not be considered when choosing antibiotics.
206831|NCT02601404|Device|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
206832|NCT02601391|Behavioral|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
206833|NCT02601378|Drug|LXS196|LXS196 as a single agent
206834|NCT02601378|Drug|LXS196 and HDM201|LXS196 in combination with HDM201
206835|NCT02601365|Drug|Sargramostim 0.04 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
206836|NCT02601365|Drug|Sargramostim 0.2mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
206837|NCT02601365|Drug|Sargramostim 1 mcg/kg/dose|The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
206838|NCT02601339|Procedure|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
206839|NCT02601326|Procedure|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
206840|NCT02601326|Procedure|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
206841|NCT02601313|Biological|KTE-X19|
206842|NCT02601313|Drug|Cyclophosphamide|Administered intravenously
206843|NCT02601313|Drug|Fludarabine|Administered intravenously
206844|NCT02601300|Drug|GED-0301|
206845|NCT02601287|Biological|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
206846|NCT02601274|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
206847|NCT02601261|Other|At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires|"Some of these questionnaires will have to be completed every day and others every other day:~The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.~The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.~The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.~The short questionnaire on critical events occurring during the day,~The short questionnaire with obstetric anamnesis."
206848|NCT02601248|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
206849|NCT02601235|Drug|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
206850|NCT02601235|Drug|Afrin|2 pumps in each nostril every 12 hours.
206851|NCT02601222|Drug|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
207190|NCT02598921|Radiation|three dimensional ultrasound|
206853|NCT02601222|Drug|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
206854|NCT02601209|Drug|Pazopanib|Given PO
206855|NCT02601209|Drug|Pazopanib Hydrochloride|Given PO
206856|NCT02601209|Drug|Sapanisertib|Given PO
206857|NCT02601196|Drug|Ulipristal acetate|"Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.~Another IVF cycle."
206858|NCT02601170|Biological|Platelet-Rich Plasma Intra-Articular Injection|
206859|NCT02601170|Drug|Hyaluronic Acid Viscosupplementation|
206860|NCT02601157|Device|CX-ISAR|Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
206861|NCT02601157|Device|Orsiro|Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, abluminal coatings with biodegradable polymer.
206862|NCT02601157|Drug|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
206863|NCT02601157|Drug|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
206864|NCT02601144|Device|Deep Brain Stimulation|Deep Brain Stimulation
206865|NCT02601131|Biological|Platelet transfusion|
206866|NCT02601118|Other|Micro Expression Training Tool|The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
206867|NCT02601105|Drug|Centella Asiatica|1% Centella Asiatica in lipoderm
206868|NCT02601105|Drug|Placebo Vehicle Cream|Lipoderm cream
206869|NCT02601092|Procedure|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.~No drugs or devices will be used."
206870|NCT02601092|Procedure|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.~No drugs or devices will be used."
206871|NCT02601079|Device|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
206872|NCT02601079|Device|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
206873|NCT02601066|Device|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
206874|NCT02601053|Other|Dull movie|A dull movie (duration approximately 90 minutes)
206875|NCT02601053|Other|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
206876|NCT02601053|Other|Heart rate measurement|Heart rate measurement using a actiheart device
206877|NCT02601040|Biological|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-16 years \6.50 lgCCID50/ml in adults aged 17 up to 65 years old
206878|NCT02601040|Biological|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \320EU/Vial in children aged 3-16 years \640EU/Vial in adults aged 17 up to 65 years old\boost at month 6\two-dose
206879|NCT02601040|Biological|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
206880|NCT02601027|Procedure|TAP block|
206881|NCT02601027|Device|Nimbus Infusion Pump IV Administration|
206882|NCT02601027|Drug|bupivacaine infusion|
206883|NCT02601027|Drug|acetominophen|
206884|NCT02601027|Drug|Hydromorphone|
206885|NCT02601027|Drug|Oxycodone|
206886|NCT02601027|Drug|Ondansetron|
206887|NCT02601014|Biological|Ipilimumab|Given IV
206888|NCT02601014|Other|Laboratory Biomarker Analysis|Correlative studies
206889|NCT02601014|Biological|Nivolumab|Given IV
206890|NCT02601001|Drug|AMG 423|Omecamtiv mecarbil at 25 mg and 37.5 mg
206891|NCT02601001|Drug|AMG 423|Omecamtiv mercabil at 25 mg and 50 mg
206892|NCT02601001|Drug|Placebo|Placebo Comparator
206893|NCT02600988|Drug|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
206894|NCT02600988|Drug|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
206895|NCT02600975|Biological|R21 with ASO1B|R21 with ASO1B
206896|NCT02600949|Drug|Imiquimod|Applied topically
206897|NCT02600949|Other|Laboratory Biomarker Analysis|Correlative studies
206898|NCT02600949|Biological|Pembrolizumab|Given IV
206899|NCT02600949|Biological|Synthetic Tumor-Associated Peptide Vaccine Therapy|Given SC
206900|NCT02600936|Device|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
206901|NCT02600923|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
206902|NCT02600923|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
206903|NCT02600897|Drug|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
206904|NCT02600897|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
206905|NCT02600897|Drug|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
206906|NCT02600897|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
206907|NCT02600884|Behavioral|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
206908|NCT02600884|Behavioral|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
206909|NCT02600871|Drug|Provodine|
206910|NCT02600871|Procedure|Incision and Drainage|
206911|NCT02600858|Behavioral|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
206912|NCT02600845|Device|ACCU-CHEK|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK Aviva Connect Blood Glucose Monitoring System, ACCU-CHEK Connect Diabetes Management App, and ACCU-CHEK Connect Online Diabetes Management System.
206913|NCT02600832|Behavioral|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
206914|NCT02600832|Behavioral|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
206915|NCT02600819|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablets administered orally once daily
206916|NCT02600819|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily
206917|NCT02600806|Drug|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are < 0.5 ng/ml
206918|NCT02600806|Drug|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are >= 0.5 ng/ml.
206919|NCT02600793|Drug|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
206920|NCT02600780|Drug|Febuxostat|Comparison of two anti-hyperuricemic molecules
206921|NCT02600780|Drug|Allopurinol|Comparison of two anti-hyperuricemic molecules
206922|NCT02600767|Drug|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
206923|NCT02600754|Behavioral|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
206924|NCT02600754|Behavioral|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
206925|NCT02600741|Other|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
206926|NCT02600741|Other|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
206927|NCT02600741|Drug|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
206928|NCT02600741|Drug|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206929|NCT02600741|Drug|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206930|NCT02600741|Drug|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206931|NCT02600741|Drug|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206932|NCT02600741|Drug|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206933|NCT02600741|Drug|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206934|NCT02600741|Drug|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206935|NCT02600741|Drug|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206936|NCT02600741|Drug|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206937|NCT02600741|Drug|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206938|NCT02600741|Drug|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206939|NCT02600741|Drug|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206940|NCT02600741|Drug|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206941|NCT02600741|Drug|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206942|NCT02600741|Drug|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206943|NCT02600741|Drug|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206944|NCT02600741|Drug|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206945|NCT02600741|Drug|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206946|NCT02600741|Drug|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206947|NCT02600741|Drug|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
206948|NCT02600728|Behavioral|Experimental Training|"The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.~Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.~Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement."
206949|NCT02600728|Behavioral|Control Training|"The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.~Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.~Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.~Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided."
206950|NCT02600715|Drug|Onabotulinumtoxin A (BoNT)|
206951|NCT02600715|Drug|belladonna|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
206952|NCT02600715|Drug|Morphine|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
206953|NCT02600715|Drug|Placebo|matching placebo to B&O suppository
206954|NCT02600715|Drug|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
206955|NCT02600702|Other|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
206956|NCT02600702|Other|Physical modalities|
206957|NCT02600689|Behavioral|Physical exercise training|
206958|NCT02600689|Behavioral|Cognitive exercise training|
206959|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
206960|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
206961|NCT02600650|Dietary Supplement|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
206962|NCT02600650|Dietary Supplement|Placebo Comparator|Daily administration of Placebo Comparator
206963|NCT02600637|Behavioral|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
206964|NCT02600637|Behavioral|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
206965|NCT02600611|Drug|iclaprim|Experimental treatment
206966|NCT02600611|Drug|vancomycin|Active comparator
206967|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
206968|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
206969|NCT02600585|Biological|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
206970|NCT02600585|Biological|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
206971|NCT02600572|Other|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
206972|NCT02600572|Other|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
206973|NCT02600559|Drug|OTO-201 (ciprofloxacin)|
207053|NCT02599844|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
206974|NCT02600533|Procedure|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
206975|NCT02600520|Drug|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
206976|NCT02600520|Drug|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
206977|NCT02600520|Drug|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
206978|NCT02600507|Drug|ITI-007|
206979|NCT02600507|Drug|Placebo|
206980|NCT02600494|Drug|ITI-007|
206981|NCT02600494|Drug|Placebo|
206982|NCT02600481|Procedure|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
206983|NCT02600481|Procedure|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
206984|NCT02600468|Drug|Orencia|
206985|NCT02600455|Drug|Orencia|
206986|NCT02600442|Other|non interventional study|
206987|NCT02600429|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
206988|NCT02600429|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
206989|NCT02600416|Other|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
206990|NCT02600403|Diagnostic Test|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a machine that scans eyes and has the capability of measuring thickness of various layers of the retina and nerve fiber layer (NFL).
206991|NCT02600403|Diagnostic Test|Visual evoked potential (VEP)|Visual Evoked Potential (VEP) is an imaging system that measures electrical activity from the eye to the brain by using electrodes placed on forehead and back of the head similar to electroencephalogram (EEG).
206992|NCT02600403|Diagnostic Test|Humphrey Visual Field (HVF)|Humphrey Visual Field (HVF) is a test done to evaluate how much peripheral (side) vision has been lost due to glaucoma.
206993|NCT02600390|Biological|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
206994|NCT02600377|Other|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
206995|NCT02600351|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
206996|NCT02600351|Drug|RBV|Tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
206997|NCT02600338|Other|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
206998|NCT02600325|Drug|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
206999|NCT02600312|Device|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
207000|NCT02600299|Behavioral|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
207001|NCT02600299|Behavioral|Usual Care|Usual Care
207002|NCT02600286|Drug|EllaOne|"5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
207003|NCT02600286|Drug|EllaOne placebo|"5 mg/per os of EllaOne every day through 12 months.~10 mg/per os of EllaOne every day through 12 months.~EllaOne placebo/per os every day through 12 months."
207004|NCT02600273|Other|Usual brand cigarettes|Usual brand cigarettes
207005|NCT02600273|Other|Lower nicotine content cigarettes|SPECTRUM research cigarettes
207006|NCT02600273|Other|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
207007|NCT02600273|Other|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
207008|NCT02600260|Drug|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
207009|NCT02600260|Other|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
207010|NCT02600247|Drug|Duloxetine|"Experimental: Duloxetine group~Phase I (preemptive): 1day before operation (30mg for 1 day)~Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)~Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon~Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
207011|NCT02600247|Drug|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week~Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
207012|NCT02600234|Device|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
207013|NCT02600234|Other|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
207014|NCT02600208|Biological|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
207052|NCT02599844|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
207015|NCT02600195|Behavioral|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
207016|NCT02600182|Device|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
207017|NCT02600169|Drug|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
207018|NCT02600156|Procedure|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
207019|NCT02600130|Biological|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
207020|NCT02600130|Biological|Placebo|via peripheral intravenous infusion
207021|NCT02600117|Drug|Tenofovir disoproxil fumarate|300 mg, oral, once a day
207022|NCT02600104|Device|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
207023|NCT02600091|Behavioral|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
207024|NCT02600078|Device|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
207025|NCT02600078|Other|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
207026|NCT02600078|Other|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
207027|NCT02600078|Other|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
207028|NCT02600065|Other|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
207029|NCT02600052|Other|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
207030|NCT02600052|Device|treadmill|AEROBIC TRAINING
207031|NCT02600039|Other|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
207032|NCT02600039|Device|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
207033|NCT02600026|Device|DriveCam|Video event monitoring device
207034|NCT02600026|Behavioral|Feedback|Video feedback intervention
207035|NCT02600000|Radiation|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
207036|NCT02600000|Device|Cardiopulmonary test|Assessment of maximal functional capacity
207037|NCT02600000|Device|AVD-Glittre Test|Evaluation of submaximal functional capacity after inspiratory muscle training.
207038|NCT02600000|Device|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
207039|NCT02599987|Device|POWERbreathe® Classic Light|Inspiratory Muscle Training
207040|NCT02599961|Drug|UX007|UX007 is a liquid intended for oral (PO) administration.
207041|NCT02599948|Other|no intervention|
207042|NCT02599935|Dietary Supplement|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
207043|NCT02599935|Other|standard treatment|No other than standard treatment
207044|NCT02599935|Other|educational structured counseling|Nutritional counseling leaded to patient and caregivers
207045|NCT02599922|Biological|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
207046|NCT02599896|Biological|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
207047|NCT02599896|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
207048|NCT02599883|Radiation|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
207049|NCT02599870|Genetic|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
207050|NCT02599857|Device|CONCOR smartphone application|
207051|NCT02599844|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
207054|NCT02599844|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
207055|NCT02599844|Drug|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
207056|NCT02599831|Device|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
207057|NCT02599831|Device|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
207058|NCT02599831|Device|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
207059|NCT02599818|Behavioral|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
207060|NCT02599805|Device|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
207061|NCT02599792|Drug|CTP-656|
207062|NCT02599792|Drug|Placebo for CTP-656|
207063|NCT02599792|Drug|Kalydeco|
207064|NCT02599779|Drug|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
207065|NCT02599779|Radiation|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
207066|NCT02599766|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
207067|NCT02599766|Other|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
207068|NCT02599753|Drug|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
207069|NCT02599740|Other|Natural fruit extract|Natural fruit extract consumed with rice
207070|NCT02599740|Other|Assumed active|Assumed key active consumed with rice
207071|NCT02599740|Other|Placebo|Rice only
207072|NCT02599727|Other|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
207073|NCT02599727|Other|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
207074|NCT02599714|Drug|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
207075|NCT02599714|Drug|Palbociclib|cyclin dependent kinase inhibitor
207076|NCT02599714|Drug|Fulvestrant|Fulvestrant hormonal therapy as background
207077|NCT02599701|Drug|Gabapentin|A single dose Gabapentin 300mg at bedtime.
207078|NCT02599701|Drug|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
207079|NCT02599688|Other|None in this study|No intervention in this study.
207080|NCT02599675|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
207081|NCT02599675|Dietary Supplement|Placebo|Olive oil, encapsuled
207082|NCT02599662|Radiation|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
207083|NCT02599662|Radiation|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
207084|NCT02599662|Radiation|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
207085|NCT02599649|Drug|Lirilumab|3 mg/kg by vein every 4 weeks.
207086|NCT02599649|Drug|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
207087|NCT02599649|Drug|Azacitidine|75 mg/m^2 by vein for 7 days of a 28 day cycle.
207088|NCT02599636|Other|None intervention|Investigators will study the usual medical assistance
207089|NCT02599623|Procedure|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
207090|NCT02599623|Procedure|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
207185|NCT02598973|Behavioral|Exercise|Aerobic walking
207091|NCT02599610|Other|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
207092|NCT02599610|Device|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
207093|NCT02599597|Behavioral|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
207094|NCT02599597|Behavioral|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
207095|NCT02599584|Behavioral|precritical staff|free pre critical scenario team staff
207096|NCT02599571|Other|Very low nicotine content cigarettes|Cigarettes containing a reduced amount of nicotine
207097|NCT02599571|Other|Conventional nicotine content cigarettes|Cigarettes containing a normal amount of nicotine
207098|NCT02599558|Device|Cytosponge|Patients undergoing the six food elimination diet will be monitored through the diet with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
207099|NCT02599558|Other|Diet|Investigators will reintroduce 1 of the six food for two weeks, then another for two weeks. Participant will return for the cytosponge procedure which will help the Investigator to direct which foods will be add or removed for the next two to four weeks. This will be repeated until all six foods have been reintroduced back into the participants diet.
207100|NCT02599558|Other|Phone call|The study coordinator will call the participant two weeks after the participate has added in one of the six foods as directed by the Investigator, completing a short questionnaire (esophageal eosinophilic Activity Index Pro) EEsAI Pro.
207101|NCT02599558|Other|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline, two weeks after a food has been added to the diet and at the final visit.
207102|NCT02599532|Drug|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
207103|NCT02599493|Drug|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
207104|NCT02599480|Drug|mirabegron|50 mg daily during 12 months
207105|NCT02599480|Procedure|Echocardiography|Echocardiography
207106|NCT02599480|Procedure|Cardiac MRI|Cardiac MRI
207107|NCT02599480|Procedure|Maximal exercise capacity|Maximal exercise capacity
207108|NCT02599480|Procedure|Blood sampling|Blood sampling for study assessments and future exploratory studies.
207109|NCT02599480|Procedure|Endothelial function measurement|EndoPAT assessment
207110|NCT02599480|Radiation|18FDG-PET|PET scanning for beige/brown fat activation
207111|NCT02599467|Other|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
207112|NCT02599454|Drug|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
207113|NCT02599454|Radiation|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
207114|NCT02599415|Device|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
207115|NCT02599402|Drug|Nivolumab|
207116|NCT02599402|Drug|Ipilimumab|
207117|NCT02599389|Device|Drug-coated balloons|
207118|NCT02599389|Device|Excimer Laser|
207119|NCT02599376|Device|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
207120|NCT02599363|Drug|Ribociclib (LEE011)|
207121|NCT02599363|Drug|Paclitaxel|
207122|NCT02599337|Drug|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
207123|NCT02599337|Drug|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
207124|NCT02599324|Drug|Ibrutinib|
207125|NCT02599324|Drug|Everolimus|
207126|NCT02599324|Drug|Docetaxel|
207127|NCT02599324|Drug|Paclitaxel|
207128|NCT02599324|Drug|Cetuximab|
207129|NCT02599324|Drug|Pembrolizumab|
207130|NCT02599311|Device|transvaginal synthetic mesh|transvaginal synthetic mesh
207131|NCT02599311|Drug|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
207132|NCT02599298|Device|Continuous Positive Airway Therapy|
207133|NCT02599298|Behavioral|Sleep-Study Guided Multidisciplinary Therapy|
207134|NCT02599285|Device|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
207135|NCT02599285|Device|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
207136|NCT02599272|Other|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
207186|NCT02598960|Drug|BMS-986156|
207187|NCT02598960|Drug|Nivolumab|
207137|NCT02599272|Other|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
207138|NCT02599272|Other|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
207139|NCT02599259|Device|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
207140|NCT02599233|Other|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
207141|NCT02599233|Other|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 & 7.
207142|NCT02599233|Other|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
207143|NCT02599207|Biological|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
207144|NCT02599194|Drug|18F-FSPG|Administered intravenously (IV)
207145|NCT02599194|Drug|18F-FDG|Administered intravenously (IV)
207146|NCT02599181|Other|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland.
207147|NCT02599168|Drug|Propofol|
207148|NCT02599168|Drug|Dexmedetomidine|
207149|NCT02599168|Drug|Placebo (normal saline)|
207150|NCT02599155|Drug|Crystalloid|normal saline administration for volume expansion in hypovolemic status
207151|NCT02599155|Drug|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
207152|NCT02599142|Device|Group A: Closed-face shell|As for arm description
207153|NCT02599142|Device|Group B: Open-face shell|As for arm description
207154|NCT02599129|Drug|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
207155|NCT02599129|Drug|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
207156|NCT02599116|Other|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
207157|NCT02599116|Other|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
207158|NCT02599103|Other|Fat-free milkshake|participants drinks a fat-free milk shakes
207159|NCT02599103|Other|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
207160|NCT02599103|Other|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
207161|NCT02599103|Other|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
207162|NCT02599103|Other|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
207163|NCT02599103|Other|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
207164|NCT02599103|Other|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
207165|NCT02599103|Other|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
207166|NCT02599103|Other|Tallow|participants drinks the milk shakes prepared from 60g of tallow
207167|NCT02599103|Other|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
207168|NCT02599090|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
207169|NCT02599090|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
207170|NCT02599090|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
207171|NCT02599077|Drug|Dienogest|patients assigned to this treatment receive 2 milligrams per day
207172|NCT02599077|Drug|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
207173|NCT02599064|Drug|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
207174|NCT02599051|Device|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
207175|NCT02599051|Device|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
207176|NCT02599038|Dietary Supplement|Serine supplementation|Serine supplementation (200 mg/kg/day)
207177|NCT02599025|Device|Innowalk cycling system|Innowalk is a unique, motorized medical device
207178|NCT02599025|Device|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
207179|NCT02599012|Drug|Ferinject®|intravenous Ferinject 1000mg injection
207180|NCT02598999|Drug|ALX-009|Solution for inhalation administered through nebulization
207181|NCT02598999|Drug|OSCN-|Solution for inhalation administered through nebulization
207182|NCT02598999|Drug|bLF|Solution for inhalation administered through nebulization
207183|NCT02598999|Drug|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
207184|NCT02598986|Dietary Supplement|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
207191|NCT02598921|Device|Office hysteroscopy|
207192|NCT02598908|Diagnostic Test|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
207193|NCT02598895|Drug|Carboplatin|Given IV
207194|NCT02598895|Drug|Docetaxel|Given IV
207195|NCT02598895|Other|Laboratory Biomarker Analysis|Correlative studies
207196|NCT02598882|Device|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
207197|NCT02598882|Device|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
207198|NCT02598869|Drug|Triamcinolone Acetonide|injection of triamcinolone acetonide
207199|NCT02598856|Drug|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
207200|NCT02598856|Drug|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
207201|NCT02598856|Drug|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
207202|NCT02598856|Drug|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
207203|NCT02598843|Other|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB) 2 weeks FWB out of cast, with 1cm heel raise~Followed by course of physiotherapy"
207204|NCT02598843|Other|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance.~2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance.~2 weeks in Rebound walking boot with foot in neutral with immediate but gradual weaning out off boot. At 8 weeks, remove boot completely and allow FWB out of boot.~Physiotherapy, commenced 4 weeks after initiation of treatment, involves: NWB early active plantar/dorsiflexion to neutral and active inversion/eversion below neutral. At 8 weeks after initiation of treatment, physiotherapy is expanded to include slow dorsiflexion stretching, graduated resistance exercises (open and closed kinetic chain) and proprioception and gait retraining."
207205|NCT02598830|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
207206|NCT02598830|Dietary Supplement|Placebo|Olive oil, encapsuled
207207|NCT02598817|Other|Standard Infant Formula|Standard Infant Formula containing High Sn-2
207208|NCT02598804|Other|5 educational workshop|
207209|NCT02598804|Other|written information booklet|
207210|NCT02598791|Other|IIGI+GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
207211|NCT02598791|Other|IIGI+GLP-1|glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
207212|NCT02598791|Other|IIGI+NaCl (placebo)|i.v. NaCl during isoglycemia
207213|NCT02598791|Other|OGTT|50 g oral glucose tolerance test
207214|NCT02598791|Other|IIGI+GIP+GLP-1|i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
207215|NCT02598778|Drug|Chlorhexidine gluconate (.12%)|30 second oral rinse of 10mL of solution
207216|NCT02598778|Drug|Sodium Fluoride (.05%)|30 second oral rinse of 10mL of solution
207217|NCT02598778|Other|Coconut Oil|30 second oral rinse of 10mL of solution
207218|NCT02598778|Other|Deionized water|30 second oral rinse of 10mL of solution
207219|NCT02598765|Procedure|Standard Trabeculectomy|Fornix-based trabeculectomy with a 3x4 mm scleral flap.
207220|NCT02598765|Procedure|Microtrabeculectomy|Fornix-based trabeculectomy with a 2x2 mm scleral flap.
207221|NCT02598752|Other|Symptom-limited cardiopulmonary exercise test (CPET)|
207222|NCT02598752|Other|Resting assessment of cardiac function by echocardiography|
207223|NCT02598752|Other|Post-exercise assessment of cardiac function by echocardiography|
207224|NCT02598752|Other|Pulmonary function|
207225|NCT02598752|Behavioral|Patient-reported outcomes questionnaire|
207226|NCT02598739|Other|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.~It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).~The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
207227|NCT02598739|Other|Waiting list for the exercises|
207228|NCT02598726|Drug|Curcumin|Given PO
207229|NCT02598726|Other|Laboratory Biomarker Analysis|Correlative studies
207230|NCT02598726|Dietary Supplement|Piperine Extract (Standardized)|Given PO
207231|NCT02598726|Other|Quality-of-Life Assessment|Ancillary studies
207232|NCT02598713|Drug|Aspiration Marker|Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
207233|NCT02598687|Drug|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
207234|NCT02598687|Other|HX4 scan|HX 4 scan day 1 and day 8
207235|NCT02598687|Drug|Carboplatin|2mg/ml/min
207236|NCT02598687|Drug|Paclitaxel|50 mg/m2
207237|NCT02598687|Radiation|Radiotherapy|23 x 1.8 Gy
207238|NCT02598687|Procedure|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
207239|NCT02598674|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
207285|NCT02598362|Drug|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
207240|NCT02598674|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
207241|NCT02598674|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
207242|NCT02598674|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
207243|NCT02598674|Drug|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
207244|NCT02598661|Drug|Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
207245|NCT02598661|Drug|Placebo|Matching Placebo to Imetelstat will be administered.
207246|NCT02598648|Other|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
207247|NCT02598648|Other|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
207248|NCT02598635|Drug|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels <20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
207249|NCT02598635|Drug|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
207250|NCT02598622|Drug|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
207251|NCT02598622|Drug|Placebo|Placebo is taken 2 times a day for days 1 through 21.
207252|NCT02598609|Behavioral|Education program for NICU caregivers|"standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~multicenter sharing of strategies to prevent adverse events in the NICU"
207253|NCT02598596|Biological|Pegloticase|Pegloticase, IV
207254|NCT02598596|Drug|Azathioprine|Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
207255|NCT02598583|Biological|ALXN1210|
207256|NCT02598570|Drug|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
207257|NCT02598557|Drug|Exemestane|Given PO
207258|NCT02598557|Other|Laboratory Biomarker Analysis|Correlative studies
207259|NCT02598557|Other|Pharmacological Study|Correlative studies
207260|NCT02598557|Other|Placebo|Given PO
207261|NCT02598557|Other|Quality-of-Life Assessment|Ancillary studies
207262|NCT02598557|Other|Questionnaire Administration|Ancillary studies
207263|NCT02598557|Procedure|Therapeutic Conventional Surgery|Undergo surgery
207264|NCT02598544|Other|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
207265|NCT02598518|Behavioral|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
207266|NCT02598518|Behavioral|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
207267|NCT02598505|Drug|Indacaterol|
207268|NCT02598505|Drug|Placebo|
207269|NCT02598492|Other|arterial blood gas|Just record clinical lab data
207270|NCT02598479|Other|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
207271|NCT02598466|Drug|Abatacept|
207272|NCT02598453|Drug|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
207273|NCT02598440|Drug|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
207274|NCT02598440|Drug|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
207275|NCT02598427|Drug|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
207276|NCT02598427|Drug|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
207277|NCT02598414|Procedure|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
207278|NCT02598414|Procedure|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
207279|NCT02598414|Device|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
207280|NCT02598401|Other|observation|Observational study with no intervention
207281|NCT02598388|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles).
207282|NCT02598388|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units).
207283|NCT02598388|Biological|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
207284|NCT02598375|Other|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
207569|NCT02596243|Biological|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
207286|NCT02598349|Radiation|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
207287|NCT02598349|Drug|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
207288|NCT02598349|Procedure|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
207289|NCT02598349|Behavioral|FACT-Hep questionnaire|The FACT-Hep questionnaire is specific to those with gastrointestinal cancers focusing on hepatobiliary and pancreatic cancer.
207290|NCT02598336|Device|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
207291|NCT02598336|Device|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
207292|NCT02598323|Device|ultrasound|
207293|NCT02598310|Drug|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
207294|NCT02598310|Drug|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
207295|NCT02598297|Drug|Ruxolitinib|5 mg tablet for oral use
207296|NCT02598297|Drug|Ruxolitinib Placebo|5 mg placebo tablet for oral use
207297|NCT02598284|Other|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
207298|NCT02598284|Other|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).~Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
207299|NCT02598258|Other|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
207300|NCT02598245|Device|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
207301|NCT02598245|Device|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
207302|NCT02598232|Device|1,414nm Nd:YAG Laser System|It has high absorption coefficient in water and a short pulse width.
207303|NCT02598219|Drug|Pre-operative SN mapping with radionucleide|"Preparation : four 1ml syringe (Nanocis, or Nanocoll, or Rotop-nanoHSA) are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.~Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.~Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
207304|NCT02598219|Drug|Intra-operative SN mapping with patent V blue dye|"Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.~Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.~SN are detected by direct visualization of blue colored lymphatics and node"
207305|NCT02598219|Drug|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.~2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible~3- SN detection by near-infrared fluorescence imaging"
207306|NCT02598219|Procedure|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)~Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)~Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
207307|NCT02598219|Procedure|Current initial staging protocols|Current French initial staging protocols
207308|NCT02598206|Drug|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.~Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
207309|NCT02598193|Drug|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
207310|NCT02598193|Drug|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
207311|NCT02598180|Device|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
207312|NCT02598141|Biological|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
207313|NCT02598141|Biological|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
207314|NCT02598128|Device|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
207315|NCT02598128|Device|Placebo|Sham device
207316|NCT02598115|Other|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
207317|NCT02598102|Drug|Diclofenac sodium|Diclofenac for pain relief
207318|NCT02598102|Drug|Placebo|Placebo for comparison
207319|NCT02598089|Biological|Trivalent Seasonal Influenza Vaccine|
207320|NCT02598089|Other|Placebo|0.5 mL of phosphate buffered saline
207321|NCT02598076|Behavioral|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
207322|NCT02598076|Behavioral|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
207323|NCT02598063|Drug|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
207324|NCT02598063|Drug|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
207325|NCT02598063|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
207326|NCT02598050|Other|Mini Cog|Cognitive screen
207327|NCT02598037|Dietary Supplement|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
207328|NCT02598024|Behavioral|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
207329|NCT02598024|Behavioral|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
207330|NCT02598011|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
207331|NCT02598011|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
207332|NCT02597998|Drug|14C-BI 409306|
207333|NCT02597985|Other|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
207334|NCT02597985|Other|Usual Care|
207335|NCT02597972|Device|Fracture repair|
207336|NCT02597972|Device|Fracture repair with joint replacement|
207337|NCT02597946|Drug|afatinib|
207338|NCT02597946|Drug|paclitaxel|
207339|NCT02597933|Drug|Nintedanib|
207340|NCT02597933|Drug|Placebo|
207341|NCT02597907|Drug|aprepitant|aprepitant 80 mg is given to all patients before surgery
207342|NCT02597907|Drug|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
207343|NCT02597907|Drug|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
207344|NCT02597894|Procedure|Biopsy of Prostate|Undergo biopsy
207345|NCT02597894|Other|Laboratory Biomarker Analysis|Correlative studies
207346|NCT02597868|Drug|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
207347|NCT02597868|Procedure|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
207348|NCT02597855|Drug|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
207407|NCT02597478|Behavioral|Phone Call|Thirty days study visit participant called by study staff. This call should last about 10 minutes.
207349|NCT02597855|Drug|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
207350|NCT02597842|Device|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
207351|NCT02597829|Drug|Certolizumab Pegol|Subcutaneous Injection
207352|NCT02597816|Radiation|Three dimensional ultrasound|
207353|NCT02597803|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
207354|NCT02597803|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
207355|NCT02597777|Other|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
207356|NCT02597777|Other|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
207357|NCT02597764|Behavioral|Diaphragmatic Breathing|
207358|NCT02597764|Behavioral|Standard Urotherapy|
207359|NCT02597751|Behavioral|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
207360|NCT02597738|Other|Fresh tissue biopsy|Fresh tissue biopsy will be collected.
207361|NCT02597738|Other|Blood/Urine Sample Collection|A one time blood sample will be collected.
207362|NCT02597712|Drug|YF476|gastrin receptor antagonist
207363|NCT02597712|Drug|YF476 placebo|placebo
207364|NCT02597699|Drug|Remifentanil + Lidocaïne|
207365|NCT02597699|Drug|Sufentanil + Lidocaïne|
207366|NCT02597686|Behavioral|SD-PB training|
207367|NCT02597673|Other|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
207368|NCT02597673|Device|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
207369|NCT02597673|Device|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
207370|NCT02597660|Drug|Somatropin|Active drug
207371|NCT02597660|Drug|Bacteriostatic saline|Placebo, the diluent used to reconstitute somatropin
207372|NCT02597660|Other|Progressive exercise program|Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
207373|NCT02597660|Procedure|Patellar tendon biopsy|Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
207374|NCT02597647|Biological|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
207375|NCT02597647|Other|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
207376|NCT02597634|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
207377|NCT02597634|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
207378|NCT02597621|Other|no intervention|no intervention
207379|NCT02597608|Behavioral|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
207408|NCT02597465|Drug|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
207409|NCT02597465|Drug|Reference1507|Investigators choice including chemotherapy or supportive therapy
207616|NCT02595892|Drug|Gemcitabine|Given IV
207380|NCT02597608|Dietary Supplement|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
207381|NCT02597608|Behavioral|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
207382|NCT02597608|Dietary Supplement|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
207383|NCT02597608|Behavioral|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
207384|NCT02597608|Dietary Supplement|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
207385|NCT02597608|Other|UPPR: Control|No interventions provided.
207386|NCT02597595|Other|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
207387|NCT02597582|Procedure|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
207388|NCT02597569|Behavioral|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.~The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
207389|NCT02597556|Drug|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
207390|NCT02597556|Drug|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
207391|NCT02597543|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
207392|NCT02597543|Drug|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
207393|NCT02597543|Procedure|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
207394|NCT02597530|Device|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
207395|NCT02597517|Device|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
207396|NCT02597504|Other|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
207397|NCT02597504|Device|Quick Test|Quick Test, computerized test will be administered to all subjects.
207398|NCT02597491|Behavioral|TLC monthly|Tobacco longitudinal care monthly
207399|NCT02597491|Behavioral|TLC quarterly|Tobacco longitudinal care quarterly
207400|NCT02597491|Behavioral|MTM|Medication management therapy
207401|NCT02597491|Behavioral|4 week assessment|4 week assessment
207402|NCT02597491|Behavioral|8 week assessment|8 week assessment
207403|NCT02597478|Drug|Fentanyl Sublingual Spray|"Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.~High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test."
207404|NCT02597478|Procedure|Shuttle Walk Test|Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
207405|NCT02597478|Behavioral|Questionnaires|Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
207406|NCT02597478|Behavioral|Mental Ability Tests|After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
207410|NCT02597452|Device|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
207411|NCT02597439|Drug|Omega-3 fatty acids|
207412|NCT02597439|Other|Placebo|
207413|NCT02597413|Procedure|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
207414|NCT02597400|Drug|Metformin|"Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;~Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
207415|NCT02597400|Drug|HMS5552|"Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;~HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
207416|NCT02597387|Drug|Mitoxantrone HCL Liposome Injection|
207417|NCT02597374|Device|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
207418|NCT02597361|Drug|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
207419|NCT02597361|Drug|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
207420|NCT02597348|Procedure|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
207421|NCT02597335|Radiation|Spectro-MRI|Spectro-MRI for D-2HG detection
207422|NCT02597335|Other|Dosage of free circulating plasmatic DNA|
207423|NCT02597335|Other|Dosage of D-2HG in the urine|
207424|NCT02597322|Drug|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
207425|NCT02597309|Drug|Canagliflozin|
207426|NCT02597283|Device|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
207427|NCT02597283|Device|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
207428|NCT02597257|Drug|Lidocaine HCl|lidocaine continuous infusion
207429|NCT02597257|Drug|Normal saline|Normal saline continuous infusion
207430|NCT02597244|Device|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
207431|NCT02597231|Dietary Supplement|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
207432|NCT02597231|Other|Placebo|Patients in this group will receive a matching placebo pill.
207433|NCT02597205|Behavioral|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
207434|NCT02597192|Other|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
207435|NCT02597192|Other|oral hygiene products without Bacillus|products without Bacillus
207436|NCT02597166|Drug|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
207437|NCT02597153|Drug|Mitoxantrone HCL Liposome Injection|
207438|NCT02597140|Drug|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
207439|NCT02597140|Drug|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
207440|NCT02597140|Drug|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
207441|NCT02597127|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
207442|NCT02597127|Drug|Normal Saline|Saline (sterile, normal, 0.9%) solution given as SC injections
207443|NCT02597114|Drug|AGT-181|intravenous infusion over 3-4 hours
207444|NCT02597101|Drug|Metformin|background drug
207445|NCT02597101|Drug|saxagliptin|background drug
207446|NCT02597101|Drug|AZD9668|study drug
207447|NCT02597101|Drug|placebo|placebo for AZD9668 to be added to background drugs
207448|NCT02597088|Other|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
207449|NCT02597075|Other|standard therapy + physical activity program|
207450|NCT02597075|Other|standard therapy|
207451|NCT02597062|Drug|Carfilzomib|
207452|NCT02597062|Drug|Cyclophosphamide|
207453|NCT02597062|Drug|Dexamethasone|
207454|NCT02597049|Drug|Dulaglutide|Administered SC
207455|NCT02597049|Drug|Placebo|Administered SC
207456|NCT02597049|Drug|SGLT2 inhibitor|Administered orally as standard of care for type 2 diabetes
207457|NCT02597049|Drug|Metformin|Administered orally as standard of care for type 2 diabetes
207458|NCT02597036|Drug|LY3127804|Administered IV
207459|NCT02597036|Drug|Ramucirumab|Administered IV
207460|NCT02597036|Drug|Paclitaxel|Administered IV
207461|NCT02597023|Drug|MitoQ|Mitoquinone pill, 20 mg/day
207462|NCT02597023|Drug|Placebo|Placebo pill with inert excipient, 1 time/day
207463|NCT02597010|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
207464|NCT02597010|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
207465|NCT02596997|Drug|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
207466|NCT02596984|Drug|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
207467|NCT02596971|Drug|Atezolizumab|Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
207468|NCT02596971|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
207469|NCT02596971|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
207470|NCT02596971|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 50 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
207471|NCT02596971|Drug|Obinutuzumab|Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
207472|NCT02596971|Drug|Prednisone|Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
207473|NCT02596971|Drug|Vincristine|Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
207474|NCT02596971|Drug|Rituximab|Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.
207475|NCT02596958|Drug|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
207476|NCT02596945|Drug|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
207477|NCT02596932|Other|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL or < 60mg/dL
207478|NCT02596932|Other|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL or < 60 mg/dL
207479|NCT02596919|Other|photography|photography of meibomian glands
207480|NCT02596906|Device|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.
207481|NCT02596906|Device|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
207482|NCT02596893|Drug|GED-0301|
207483|NCT02596893|Drug|Placebo|
207484|NCT02596880|Drug|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
207485|NCT02596880|Drug|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
207486|NCT02596880|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
207487|NCT02596867|Drug|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
207488|NCT02596854|Device|Neurological MRI|Neurological MRI image collection
207489|NCT02596828|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
207490|NCT02596828|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
207491|NCT02596828|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
207492|NCT02596828|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
207617|NCT02595892|Drug|Gemcitabine Hydrochloride|Given IV
207493|NCT02596815|Procedure|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
207494|NCT02596815|Device|Goniometer|
207495|NCT02596802|Device|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
207496|NCT02596789|Device|"TMS Magpro®, Magventure Inc device"|
207497|NCT02596776|Procedure|Fat biopsy|up to 16 biopsy samples will be taken from each subject
207498|NCT02596776|Drug|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
207499|NCT02596776|Other|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
207500|NCT02596763|Drug|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
207501|NCT02596750|Device|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
207502|NCT02596750|Device|Sham microneedle Roller|Flat roller without microneedles
207503|NCT02596737|Behavioral|wittyFit concept|
207504|NCT02596724|Other|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
207505|NCT02596711|Drug|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
207506|NCT02596711|Behavioral|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
207507|NCT02596711|Other|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
207508|NCT02596711|Behavioral|Health Education and Handouts|Participants receive general health education and handouts.
207509|NCT02596711|Behavioral|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
207510|NCT02596711|Behavioral|Counseling Sessions|Participants attend 3 counseling sessions during the study.
207511|NCT02596685|Procedure|Bronchoscopy|Undergo bronchoscopy
207512|NCT02596685|Other|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
207513|NCT02596685|Other|Laboratory Biomarker Analysis|Correlative studies
207514|NCT02596685|Other|Questionnaire Administration|Ancillary studies
207515|NCT02596672|Behavioral|The friendly walking group|A 12 week peer led walking group for adults and older adults (> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
207516|NCT02596659|Procedure|Radial extracorporeal shock wave therapy (rESWT)|Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.
207517|NCT02596659|Procedure|sham shockwave therapy|Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.
207518|NCT02596659|Procedure|Physical therapy|The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
207519|NCT02596646|Procedure|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
207520|NCT02596646|Procedure|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
207521|NCT02596633|Behavioral|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
207522|NCT02596620|Drug|Nexium|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
207523|NCT02596620|Drug|Amolin|Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
207524|NCT02596620|Drug|Cravit|Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
207525|NCT02596620|Drug|Flagyl|Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
207526|NCT02596594|Device|fetal nutrition port system|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
207527|NCT02596581|Other|non-surgical periodontal treatment|scaling and root planing were performed
207528|NCT02596568|Device|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
207568|NCT02596256|Drug|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
207529|NCT02596568|Other|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
207530|NCT02596555|Drug|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
207531|NCT02596542|Other|Water immersion|Different temperatures of cold water immersion will be assessed
207532|NCT02596529|Device|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
207533|NCT02596529|Other|NO Fixation|NO Fixation of the posterior malleolus.
207534|NCT02596503|Drug|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
207535|NCT02596503|Drug|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
207536|NCT02596503|Other|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
207537|NCT02596490|Behavioral|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.~Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.~Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
207538|NCT02596490|Behavioral|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.~Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
207539|NCT02596490|Behavioral|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
207540|NCT02596477|Drug|Vepoloxamer|
207541|NCT02596477|Other|5% dextrose in water|
207542|NCT02596451|Drug|Diclofenac Sodium gel, 1%|
207543|NCT02596451|Drug|Voltaren® Gel|
207544|NCT02596451|Drug|Placebo|
207545|NCT02596438|Other|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
207546|NCT02596425|Procedure|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
207547|NCT02596425|Procedure|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
207548|NCT02596425|Procedure|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
207549|NCT02596412|Other|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
207550|NCT02596399|Drug|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
207551|NCT02596399|Drug|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
207552|NCT02596386|Procedure|sialometry|potassium evaluation
207553|NCT02596386|Procedure|blood test|potassium evaluation
207554|NCT02596373|Drug|Mitoxantrone Hydrochloride Liposome Injection|
207555|NCT02596360|Drug|Pulmodexane® 30mg|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
207556|NCT02596360|Drug|lactose|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
207557|NCT02596347|Procedure|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
207558|NCT02596347|Procedure|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
207559|NCT02596334|Drug|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
207560|NCT02596334|Drug|dolutegravir|
207561|NCT02596321|Drug|Mitizax|Allergen extract
207562|NCT02596321|Drug|Placebo|Placebo tablet
207563|NCT02596308|Biological|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
207564|NCT02596282|Procedure|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine <1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.~Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
207565|NCT02596269|Drug|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
207566|NCT02596269|Drug|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
207567|NCT02596256|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
207570|NCT02596243|Biological|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
207571|NCT02596217|Drug|ABBV-066|SC injection
207572|NCT02596217|Drug|ABBV-066|IV infusion
207573|NCT02596217|Drug|Placebo|SC injection (stage 1)
207574|NCT02596217|Drug|Placebo|IV infusion (stage 2)
207575|NCT02596204|Other|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
207576|NCT02596204|Device|FitBit|All subjects will wear a FitBit activity monitor.
207577|NCT02596191|Other|Clinical evaluation|
207578|NCT02596191|Other|electrophysiological record|
207579|NCT02596191|Other|Muscle MRI|
207580|NCT02596191|Other|blood samples analysis|
207581|NCT02596178|Device|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
207582|NCT02596165|Device|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
207583|NCT02596152|Other|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
207584|NCT02596152|Other|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
207585|NCT02596139|Other|No Interventions|
207586|NCT02596126|Drug|Cardiovascular Polypill|"Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.~Participants will receive one of the following cardiovascular polypill:~(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).~or~(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg)."
207587|NCT02596126|Drug|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
207588|NCT02596100|Drug|Betrixaban|
207589|NCT02596087|Other|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
207590|NCT02596074|Drug|Omiganan (CLS001) topical gel|
207591|NCT02596074|Drug|Vehicle topical gel|
207592|NCT02596061|Behavioral|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
207593|NCT02596061|Other|Incentives|Patients receive incentives for completing smoking cessation activities.
207594|NCT02596048|Other|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
207595|NCT02596035|Drug|Nivolumab|
207596|NCT02596022|Drug|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
207597|NCT02596022|Drug|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
207598|NCT02596009|Device|Breezhaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
207599|NCT02596009|Device|Ellipta®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
207600|NCT02596009|Device|Handihaler®|No active drug or placebo were administered to patients during this study. Each patient were required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient was required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
207601|NCT02595996|Drug|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
207602|NCT02595983|Drug|Revusiran|500mg Revusiran by subcutaneous (sc) injection
207603|NCT02595970|Drug|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
207604|NCT02595944|Biological|Nivolumab|Given IV
207605|NCT02595931|Drug|ATR Kinase Inhibitor M6620|Given IV
207606|NCT02595931|Drug|Irinotecan|Given IV
207607|NCT02595931|Drug|Irinotecan Hydrochloride|Given IV
207608|NCT02595918|Procedure|Metastasectomy|Undergo metastasectomy
207609|NCT02595918|Procedure|Nephrectomy|Undergo nephrectomy
207610|NCT02595918|Biological|Nivolumab|Given IV
207611|NCT02595905|Drug|Cisplatin|Given IV
207612|NCT02595905|Other|Laboratory Biomarker Analysis|Correlative studies
207613|NCT02595905|Other|Placebo|Given PO
207614|NCT02595905|Drug|Veliparib|Given PO
207615|NCT02595892|Drug|ATR Kinase Inhibitor M6620|Given IV
207618|NCT02595879|Drug|Cisplatin|Given IV
207619|NCT02595879|Radiation|External Beam Radiation Therapy|Undergo pelvic EBRT
207620|NCT02595879|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
207621|NCT02595879|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
207622|NCT02595879|Radiation|Internal Radiation Therapy|Undergo LDR brachytherapy
207623|NCT02595879|Other|Laboratory Biomarker Analysis|Correlative studies
207624|NCT02595879|Other|Pharmacological Study|Correlative studies
207625|NCT02595879|Drug|Triapine|Given IV and PO
207626|NCT02595866|Other|Laboratory Biomarker Analysis|Correlative studies
207627|NCT02595866|Biological|Pembrolizumab|Given IV
207628|NCT02595853|Other|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
207629|NCT02595840|Drug|Afatinib|
207630|NCT02595840|Drug|Pemetrexed|
207631|NCT02595827|Other|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
207632|NCT02595801|Other|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
207633|NCT02595788|Other|Change from supine to prone position|Change from supine to prone position
207634|NCT02595775|Other|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
207635|NCT02595775|Other|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
207636|NCT02595775|Other|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
207637|NCT02595775|Other|A/F report alone|
207638|NCT02595749|Drug|Oxytocin|
207639|NCT02595749|Drug|Placebo|
207640|NCT02595736|Drug|Placebo (SC)|Administered SC
207641|NCT02595736|Drug|LY3200327 (SC)|Administered SC
207642|NCT02595736|Drug|LY3200327 (IV)|Administered IV
207643|NCT02595736|Drug|Placebo (IV)|Administered IV
207644|NCT02595723|Drug|Phenytoin 200 mg capsule|Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
207645|NCT02595723|Drug|Megestrol 800 mg liquid|Liquid megestrol 800 mg/was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
207646|NCT02595723|Drug|Phenytoin-matched Placebo capsule|Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
207647|NCT02595723|Drug|Megestrol-matched liquid Placebo|Megestrol-matched liquid placebo was initiated on Day 2 and administered at 09:00 for three consecutive days (Days 2 - 4).
207648|NCT02595710|Other|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
207649|NCT02595710|Other|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
207650|NCT02595710|Other|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
207651|NCT02595697|Behavioral|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
207652|NCT02595684|Drug|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
207653|NCT02595684|Drug|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
207654|NCT02595671|Other|Digital Super Coach|Receive Digital Super Coach during 12 weeks
207655|NCT02595671|Other|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
207656|NCT02595671|Other|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
207657|NCT02595671|Other|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
207658|NCT02595658|Dietary Supplement|Meal composition|
207659|NCT02595658|Drug|Rapid-Acting Insulin Dose|
207660|NCT02595645|Genetic|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
207661|NCT02595632|Other|No intervention|
207662|NCT02595619|Device|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
207663|NCT02595606|Drug|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
207664|NCT02595593|Device|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
207665|NCT02595580|Device|Glucopred|
207666|NCT02595567|Device|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
207667|NCT02595554|Radiation|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
207668|NCT02595554|Drug|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
207669|NCT02595554|Procedure|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
207670|NCT02595554|Drug|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
207719|NCT02595242|Drug|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
207671|NCT02595541|Drug|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
207672|NCT02595541|Drug|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
207673|NCT02595528|Drug|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
207674|NCT02595528|Drug|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
207675|NCT02595528|Drug|AGN-190584 vehicle|Vehicle to AGN-190584
207676|NCT02595528|Drug|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
207677|NCT02595528|Drug|AGN-199201 vehicle|Vehicle to AGN-199201
207678|NCT02595515|Other|Chiropractic treatment|Procedure: chiropractic treatment.
207679|NCT02595515|Other|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
207680|NCT02595502|Device|JJVC Marketed Contact Lens (Test)|
207681|NCT02595502|Device|Competitor Marketed Contact Lens (Control)|
207682|NCT02595489|Dietary Supplement|vitamin D3|Daily oral supplement provided by study investigators
207683|NCT02595476|Drug|Remifentanil|
207684|NCT02595476|Drug|propofol|
207685|NCT02595476|Device|TCI|
207686|NCT02595476|Procedure|Tetanic stimulation|
207687|NCT02595476|Device|Algiscan|Pupillometry
207688|NCT02595463|Drug|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
207689|NCT02595463|Drug|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
207690|NCT02595450|Drug|Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
207691|NCT02595437|Drug|Triferic|
207692|NCT02595424|Drug|Capecitabine|Given PO
207693|NCT02595424|Drug|Carboplatin|Given IV
207694|NCT02595424|Drug|Cisplatin|Given IV
207695|NCT02595424|Drug|Etoposide|Given IV
207696|NCT02595424|Other|Laboratory Biomarker Analysis|Correlative studies
207697|NCT02595424|Drug|Temozolomide|Given PO
207698|NCT02595398|Drug|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), will be administered as a single injection at 2 timepoints
207699|NCT02595398|Drug|Sham Procedure|Sham procedure will be administered at 2 timepoints
207700|NCT02595385|Device|Cell Salvage|Reinfusion of shed blood during the operation
207701|NCT02595385|Procedure|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
207702|NCT02595372|Drug|Omeprazole|
207703|NCT02595359|Drug|Moxifloxacin|Moxifloxacin intracameral
207704|NCT02595346|Drug|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
207705|NCT02595346|Drug|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.~glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.~oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
207706|NCT02595333|Drug|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
207707|NCT02595333|Drug|Group S1|sufentanil was administered for analgesia in primary cesarean section
207708|NCT02595333|Drug|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
207709|NCT02595333|Drug|Group S2|sufentanil was administered for analgesia in repeated cesarean section
207710|NCT02595320|Drug|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).~Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
207711|NCT02595307|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
207712|NCT02595294|Procedure|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
207713|NCT02595281|Other|Experimental arm|"Serum samples are collected:~at each neoadjuvant chemotherapy cycle~before surgery~at each adjuvant chemotherapy cycle~at each injection of bevacizumab as maintenance therapy~stop at the progression or after 24 months post chemotherapy"
207714|NCT02595268|Drug|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
207715|NCT02595268|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
207716|NCT02595255|Other|No intervention|No intervention
207717|NCT02595242|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
207718|NCT02595242|Drug|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
207720|NCT02595229|Procedure|Pronator quadratus repair|Suturing of the pronator quadratus muscle
207721|NCT02595216|Device|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
207722|NCT02595203|Drug|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
207723|NCT02595203|Drug|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
207724|NCT02595190|Procedure|sacral canal cyst microscopic tamponade|sacral canal cyst microscopic tamponade treatment
207725|NCT02595190|Drug|gabapentin + tramadol|dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
207726|NCT02595190|Device|resting state functional magnetic resonance imaging (rfMRI)|First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
207727|NCT02595177|Procedure|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
207728|NCT02595151|Device|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
207729|NCT02595138|Drug|Zoledronic acid|
207730|NCT02595125|Device|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
207731|NCT02595112|Other|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
207732|NCT02595099|Other|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
207733|NCT02595086|Procedure|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
207734|NCT02595086|Procedure|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
207735|NCT02595073|Drug|DSXS|Active treatment
207736|NCT02595073|Drug|Placebo|Placebo treatment
207737|NCT02595060|Drug|inhaled molgramostim (rhGM-CSF)|
207738|NCT02595060|Drug|inhaled placebo|formulated as the active substance without molgramostim
207739|NCT02595047|Procedure|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
207740|NCT02595034|Drug|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
207741|NCT02595034|Drug|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
207742|NCT02595034|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
207743|NCT02595021|Procedure|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
207744|NCT02595021|Procedure|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
207745|NCT02595008|Drug|DSXS|Active treatment
207746|NCT02594995|Drug|NBP|
207747|NCT02594982|Other|intervention bundle (sedation, pain, mobilization and sleep)|"Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night"
207748|NCT02594969|Other|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
207749|NCT02594956|Device|no nasogastric tube|
207750|NCT02594956|Device|nasogastric tube|
207751|NCT02594943|Device|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
207752|NCT02594943|Device|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
207753|NCT02594930|Procedure|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
207754|NCT02594917|Procedure|Right Heart Catheterization|Some participants (i.e., those that are willing and able) will undergo a Right Heart Catheterization to check Cardiopulmonary function.
207755|NCT02594917|Other|Blood draw|Test and control group will be asked to give 20 ml of blood samples
207756|NCT02594904|Drug|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
207757|NCT02594891|Device|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
207758|NCT02594891|Device|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
207759|NCT02594878|Drug|Pamidronatdinatrium|
207760|NCT02594878|Other|Natrium chloride 9mg/ml|
207761|NCT02594865|Dietary Supplement|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
207762|NCT02594865|Dietary Supplement|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
207763|NCT02594852|Device|+ laser|Use of laser in the treatment
207764|NCT02594839|Drug|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
207765|NCT02594839|Drug|Placebo|intravenous infusion of 400 mL saline
208967|NCT02586285|Drug|S-Adenosyl Methionine|500mg-1000mg,iv,qd
207766|NCT02594826|Behavioral|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
207767|NCT02594826|Behavioral|General health education control|General health and cancer education
207768|NCT02594813|Procedure|Biopsy or cold snare polypectomy|
207769|NCT02594800|Drug|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
207770|NCT02594787|Dietary Supplement|Phosphorus|
207771|NCT02594787|Dietary Supplement|Placebo|
207772|NCT02594774|Other|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
207773|NCT02594761|Biological|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
207774|NCT02594761|Biological|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
207775|NCT02594761|Biological|Herceptin US|Intravenous Infusion, 440 mg/vial
207776|NCT02594748|Behavioral|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
207777|NCT02594748|Behavioral|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
207778|NCT02594735|Drug|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight < 50 KG).
207779|NCT02594722|Device|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
207780|NCT02594722|Device|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
207781|NCT02594709|Radiation|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
207782|NCT02594696|Other|Proactive Psychiatry Consultation (PPC)|"The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.~The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.~The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks~The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).~Recommendations are documented in the medical record and communicated directly to the oncology team"
207783|NCT02594670|Other|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
207784|NCT02594670|Other|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
207785|NCT02594670|Other|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
207786|NCT02594657|Procedure|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
207787|NCT02594657|Procedure|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
207788|NCT02594644|Device|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 650 micrometers in length.
207789|NCT02594644|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
207790|NCT02594644|Radiation|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
207791|NCT02594631|Procedure|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
207792|NCT02594631|Procedure|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
207793|NCT02594605|Device|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
207794|NCT02594605|Device|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
207795|NCT02594592|Other|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
207796|NCT02594579|Drug|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
207797|NCT02594579|Drug|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
207798|NCT02594566|Drug|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
207799|NCT02594553|Behavioral|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
207800|NCT02594540|Device|Mechanical Peripheral Stimulation (GONDOLA)|
207801|NCT02594527|Other|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
207802|NCT02594501|Device|COBRA PzF|
207803|NCT02594501|Device|Drug Eluting Stent|
207804|NCT02594488|Device|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
207805|NCT02594475|Procedure|Endoscopic retrograde cholangiopancreatography|"Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.~Selective bile duct cannulation is performed using wire-guided cannulation.~In case of difficult cannulation, precut is performed using a needle-knife.~After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
207806|NCT02594462|Drug|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
207807|NCT02594449|Drug|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
207808|NCT02594436|Drug|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
207809|NCT02594423|Device|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
207810|NCT02594423|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
207811|NCT02594410|Device|stent|patients receiving renal artery stenting for renal artery atherosclerosis
207812|NCT02594410|Drug|Aspirine|100mg Qd
207813|NCT02594410|Drug|Clopidogrel|75mg Qd
207814|NCT02594410|Drug|Lercanidipine|10-20mg Qd
207815|NCT02594397|Other|acupoints combination 1|
207816|NCT02594397|Other|acupoints combination 2|
207817|NCT02594397|Other|sham acupoints combination|
207818|NCT02594384|Drug|LAM-002A|25 mg capsules or 50 mg capsules
207819|NCT02594384|Drug|Rituximab|375 mg/m2 by vein
207820|NCT02594384|Drug|Atezolizumab|1200 mg by vein
207821|NCT02594371|Drug|Oraxol|
207822|NCT02594371|Drug|IV paclitaxel|
207823|NCT02594358|Drug|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
207824|NCT02594345|Other|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
207825|NCT02594332|Drug|Mepolizumab|100 mg SC every 4 weeks for 13 injections
207826|NCT02594332|Drug|Placebo|
207827|NCT02594319|Behavioral|Monetary incentives|
207828|NCT02594319|Behavioral|Self monitoring|
207829|NCT02594306|Device|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
207830|NCT02594306|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
207831|NCT02594306|Procedure|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
207832|NCT02594306|Procedure|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
207833|NCT02594293|Drug|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
207834|NCT02594267|Drug|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)~CHOP : Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone"
207835|NCT02594254|Drug|C16G2 Gel|Antimicrobial peptide
207836|NCT02594254|Other|Placebo|Placebo
207837|NCT02594241|Drug|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
207838|NCT02594241|Drug|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
207839|NCT02594228|Behavioral|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
207840|NCT02594228|Behavioral|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
207841|NCT02594215|Drug|ARQ 092|ARQ 092 is small molecule that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a phase I study to determine a recommended dose for subsequent trials, which will determine the efficacy of ARQ 092 in Proteus syndrome.
207842|NCT02594189|Other|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
207843|NCT02594176|Device|FLEXISEQ®|applicable gel
207844|NCT02594176|Device|Placebo|applicable gel
207845|NCT02594163|Drug|Brentuximab Vedotin|
207846|NCT02594163|Drug|Rituximab|
207847|NCT02594163|Drug|Bendamustine|
207848|NCT02594150|Other|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
207849|NCT02594137|Procedure|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
207850|NCT02594124|Drug|nusinersen|Administered by intrathecal (IT) injection
207851|NCT02594111|Drug|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
207852|NCT02594098|Drug|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
207853|NCT02594098|Drug|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
207854|NCT02594085|Other|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
207855|NCT02594085|Other|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
207856|NCT02594085|Other|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
207857|NCT02594085|Other|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
207858|NCT02594085|Other|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
207859|NCT02594085|Other|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
207860|NCT02594072|Radiation|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
207861|NCT02594072|Radiation|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
207862|NCT02594072|Drug|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
207863|NCT02594059|Other|endothelial function|measure of reactive hyperemia-peripheral artery tone index
207864|NCT02594046|Other|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
207865|NCT02594033|Drug|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
207866|NCT02594020|Procedure|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
207867|NCT02594020|Procedure|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
207868|NCT02594020|Procedure|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
207869|NCT02594007|Device|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
207870|NCT02594007|Device|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
207871|NCT02594007|Device|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
207872|NCT02593994|Device|Onyx Drug Eluting Stent group|
207873|NCT02593981|Dietary Supplement|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
207874|NCT02593981|Dietary Supplement|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
207875|NCT02593968|Drug|Recombinant Human Interferon a-2b Gel|
207876|NCT02593968|Drug|Placebo|
207877|NCT02593955|Behavioral|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
207878|NCT02593955|Behavioral|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
207879|NCT02593942|Drug|Remifentanil|0.1-0.5 mcg/kg/min infusion
207880|NCT02593942|Drug|Propofol|75-200 mcg/kg/min infusion
207881|NCT02593929|Drug|ruxolitinib|
207882|NCT02593903|Drug|Septra|
207883|NCT02593890|Device|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
207884|NCT02593877|Device|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
207885|NCT02593864|Device|Variable-Stiffness Shoe|A load-modifying variable-stiffness shoe previously shown to reduce joint loading
207886|NCT02593851|Drug|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
207887|NCT02593851|Drug|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
207888|NCT02593838|Other|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
207889|NCT02593825|Behavioral|START-Play intervention|"The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill; the focus is not on a normal movement pattern. Parents and children learn to problem-solve motor challenges, and link small motor changes to cognitive skills."
207939|NCT02593487|Drug|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
207890|NCT02593825|Behavioral|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
207891|NCT02593812|Behavioral|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
207892|NCT02593799|Procedure|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
207893|NCT02593786|Drug|Nivolumab|
207894|NCT02593773|Drug|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after Week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
207895|NCT02593760|Other|Placebo|Placebo will be administered PO QD for up to 48 weeks.
207896|NCT02593760|Drug|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
207897|NCT02593760|Drug|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
207898|NCT02593747|Drug|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
207899|NCT02593747|Drug|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
207900|NCT02593734|Drug|olanzapine|oral antipsychotic drug therapy
207901|NCT02593734|Drug|risperidone|oral antipsychotic drug therapy
207902|NCT02593734|Drug|amitryptaline|oral antidepressant drug therapy
207903|NCT02593734|Drug|fluoxetine|oral drug therapy for depression
207904|NCT02593721|Procedure|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
207905|NCT02593721|Drug|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
207906|NCT02593708|Drug|Neratinib|
207907|NCT02593708|Drug|Paclitaxel|
207908|NCT02593708|Drug|Pertuzumab|
207909|NCT02593708|Drug|Trastuzumab|
207910|NCT02593695|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
207911|NCT02593695|Other|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
207912|NCT02593682|Drug|suvorexant|
207913|NCT02593682|Drug|placebo|
207914|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
207915|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
207916|NCT02593669|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
207917|NCT02593669|Drug|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
207918|NCT02593656|Behavioral|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
207919|NCT02593656|Behavioral|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
207920|NCT02593643|Drug|Ketamine|
207921|NCT02593643|Drug|Midazolam|
207922|NCT02593643|Other|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
207923|NCT02593630|Device|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
207924|NCT02593617|Other|Addiction Profile Index|
207925|NCT02593617|Other|Alcohol Use Disorders Identification Test|
207926|NCT02593617|Other|Barratt Impulsiveness Scale|
207927|NCT02593617|Other|Zuckerman Sensation Seeking Scale|
207928|NCT02593617|Other|Energy Drink Consumption Questionnaire|
207929|NCT02593565|Other|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
207930|NCT02593552|Device|DriveCam|Video event monitoring device
207931|NCT02593539|Drug|GSK2269557 DPI 500 mcg|Subjects will receive 2 inhalations of GSK2269557 500 mcg in DPI (total dose: 1000 mcg) to be taken every day before breakfast (with the exception of days when the subjects have a planned visit to the study clinic. On those days, they will be dosed at the clinic). The subject should hold their breath for 10 seconds before exhaling. Inhalations should be taken approximately 30 seconds apart.
207932|NCT02593526|Drug|Bumetanide|Diuretic
207933|NCT02593526|Other|Cool Dialysate|Cool dialysate (35°C)
207934|NCT02593513|Device|Daifert|
207935|NCT02593513|Procedure|Control Group|Control - Morphological Assessment
207936|NCT02593500|Drug|Budesonida Pulmictan® 200 µg|
207937|NCT02593500|Drug|Budesonide 200 µg|
207938|NCT02593487|Drug|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
208968|NCT02586272|Device|Daifert|
207940|NCT02593474|Drug|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
207941|NCT02593461|Device|Daifert|
207942|NCT02593461|Other|Control Group|
207943|NCT02593448|Procedure|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:~30 minutes after anaesthesia induction,~directly after the sternotomy,~during CPB - 20 minutes after aortic cross-clamping ,~40 minutes after aortic cross-clamping,~20 minutes after the release of the aortic cross-clamp,~45 minutes after weaning of CPB."
207944|NCT02593448|Procedure|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
207945|NCT02593448|Procedure|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
207946|NCT02593435|Genetic|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2."
207947|NCT02593422|Behavioral|Expressive Writing|Participants will be asked to write about their deepest thoughts and emotions about their experience with ovarian cancer
207948|NCT02593422|Behavioral|Fact Writing (Control)|Participants will be asked to write about the facts of their experience with ovarian cancer
207949|NCT02593409|Drug|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
207950|NCT02593396|Drug|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
207951|NCT02593396|Drug|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
207952|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
207953|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
207954|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
207955|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
207956|NCT02593383|Drug|Placebo|
207957|NCT02593370|Drug|Lidocaine-epinephrine added gadoterate meglumine|
207958|NCT02593357|Device|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
207959|NCT02593344|Device|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
207960|NCT02593331|Drug|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
207961|NCT02593331|Other|Placebo|Participants will receive a single dose of placebo on Day 1.
207962|NCT02593318|Drug|Oxaloacetate (OAA)|Pills to be taken orally in 500mg or 1000mg doses two times per day depending on the part of the study
207963|NCT02593305|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
207964|NCT02593305|Dietary Supplement|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
207965|NCT02593292|Behavioral|PROSPERO|"The intervention is carried out in 3 steps:~At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.~During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system~The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
207966|NCT02593292|Other|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
207967|NCT02593279|Genetic|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
208969|NCT02586272|Procedure|Control Group|
207968|NCT02593279|Genetic|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
207969|NCT02593266|Behavioral|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)~Module 1: Depression and family~Module 2: Psychoeducation about depression~Module 3:The child's perspective on their parent's depression~Module 4: Skills development~Module 5: Preparation for the family session~Module 6: Family session~Module 7: Revision and future planning~Follow-up"
207970|NCT02593253|Other|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
207971|NCT02593253|Other|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
207972|NCT02593240|Behavioral|The iDiet® with Food|Intensive iDiet group behavioral weight loss program delivered in-person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Ten participants per worksite per iDiet intervention arm will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
207973|NCT02593240|Behavioral|The iDiet® with Voucher|Intensive iDiet group behavioral weight loss program delivered in-person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Ten participants per worksite per iDiet intervention arm will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
207974|NCT02593240|Behavioral|Human Performance Institute©|Human Performance Institute© (HPI) training workshop: Is comprised of a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
207975|NCT02593227|Biological|Low dose FRα vaccine|165ug per peptide ID injection
207976|NCT02593227|Drug|Cyclophosphamide|IV infusion over 1 hour
207977|NCT02593227|Biological|High dose FRα vaccine|500ug per peptide ID injection
207978|NCT02593214|Device|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
207979|NCT02593201|Drug|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
207980|NCT02593201|Drug|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
207981|NCT02593188|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
207982|NCT02593175|Drug|Carboplatin|Given IV
207983|NCT02593175|Other|Laboratory Biomarker Analysis|Correlative studies
207984|NCT02593175|Drug|Paclitaxel|Given IV
207985|NCT02593175|Biological|Panitumumab|Given IV
207986|NCT02593162|Drug|Faldaprevir|
207987|NCT02593162|Drug|TD-6450|
207988|NCT02593162|Drug|Ribavirin|
207989|NCT02593149|Device|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
207990|NCT02593136|Dietary Supplement|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:~Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
207991|NCT02593136|Other|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
207992|NCT02593123|Drug|mycophenolate mofetil|Given PO, by mouth, orally or IV, intravenous medication administration.
207993|NCT02593123|Biological|Sargramostim|"GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.~Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.~Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF."
207994|NCT02593123|Biological|Filgrastim|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
207995|NCT02593110|Behavioral|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
208970|NCT02586259|Drug|budesonide MMX®|
207996|NCT02593110|Drug|Telmisartan|Participants randomized to the telmisartan arm of the study will take 40 mg of telmisartan daily. Participants will have their dose increased to up to 80 mg as tolerated.
207997|NCT02593110|Other|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
207998|NCT02593110|Drug|Placebo|
207999|NCT02593097|Drug|Metformin|Metformin 500mg twice daily
208000|NCT02593097|Drug|Matching Placebo|Matching Placebo twice daily
208001|NCT02593084|Behavioral|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
208002|NCT02593084|Behavioral|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
208003|NCT02593071|Biological|RSV-F Vaccine|
208004|NCT02593071|Biological|Phosphate Buffer Placebo|
208005|NCT02593058|Behavioral|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
208006|NCT02593058|Behavioral|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
208007|NCT02593045|Biological|IPH4102|
208008|NCT02593032|Device|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
208009|NCT02593019|Drug|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.~Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
208010|NCT02592993|Device|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
208011|NCT02592980|Genetic|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
208012|NCT02592980|Drug|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
208013|NCT02592967|Biological|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU] ) and at a higher dose in Cohort 1B (1x10^9 CFU)
208014|NCT02592967|Biological|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
208015|NCT02592954|Drug|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
208016|NCT02592954|Drug|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
208017|NCT02592941|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
208018|NCT02592928|Other|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
208019|NCT02592915|Drug|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
208020|NCT02592915|Other|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
208021|NCT02592902|Procedure|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
208022|NCT02592902|Procedure|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
208023|NCT02592889|Device|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
208024|NCT02592876|Drug|denintuzumab mafodotin|Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
208025|NCT02592876|Drug|rituximab|375 mg/m^2 by IV infusion, every 3 weeks for up to 3 cycles
208026|NCT02592876|Drug|ifosfamide|5000 mg/m^2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
208027|NCT02592876|Drug|carboplatin|AUC 5mg/mL x min by IV infusion, every 3 weeks for up to 3 cycles
208028|NCT02592876|Drug|etoposide|100 mg/m^2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
208029|NCT02592863|Drug|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
208030|NCT02592863|Drug|Placebo|Patients will take placebo 3 times per day for 12 weeks
208031|NCT02592850|Other|osteopathic manipulative treatment|"This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.~Duration: 45 minutes. Administered once a week for four weeks."
208032|NCT02592850|Other|sham|"In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.~Duration: 45 minutes. Administered once a week for four weeks."
208033|NCT02592837|Device|Flexible 19G EBUS-TBNA needle|
208034|NCT02592837|Device|21G EBUS-TBNA needle|
208035|NCT02592824|Drug|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
208036|NCT02592824|Drug|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
208037|NCT02592811|Procedure|ERCP|Common bile duct cannulation with a cannulation catheter
208038|NCT02592811|Procedure|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
208039|NCT02592811|Device|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
208040|NCT02592811|Procedure|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
208041|NCT02592798|Drug|Abatacept|
208042|NCT02592798|Other|Normal Saline|
208043|NCT02592798|Other|D5W|
208044|NCT02592785|Drug|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.~Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
208045|NCT02592772|Other|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
208046|NCT02592772|Other|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
208047|NCT02592772|Other|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
208048|NCT02592759|Device|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
208049|NCT02592746|Drug|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
208050|NCT02592746|Drug|Exemestane|Exemestane 25mg, orally once daily
208051|NCT02592746|Drug|Leuprolide Acetate|Leuprolide Acetate 3.75mg SC q 4weeks
208052|NCT02592746|Drug|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
208053|NCT02592733|Device|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
208054|NCT02592720|Drug|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
208055|NCT02592720|Device|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
208056|NCT02592720|Device|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
208057|NCT02592707|Drug|Satoreotide tetraxetan|Satoreotide tetraxetan will be administered in 3 cycles at intervals of 8 weeks (+ up to 2 additional optional cycles)
208058|NCT02592694|Drug|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
208059|NCT02592694|Device|thrombus aspiration|manual thrombus aspiration
208060|NCT02592681|Procedure|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
208061|NCT02592681|Procedure|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
208136|NCT02592278|Drug|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
208137|NCT02592278|Drug|Control Group|Twice a day brush with fluoride toothpaste.
208138|NCT02592252|Behavioral|Participatory gender training|10 sessions of participatory gender training
208139|NCT02592252|Other|Microfinance|Microfinance loan
208062|NCT02592681|Procedure|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
208063|NCT02592668|Device|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
208064|NCT02592655|Device|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
208065|NCT02592655|Device|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
208066|NCT02592655|Device|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
208067|NCT02592655|Device|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
208068|NCT02592655|Device|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
208069|NCT02592642|Behavioral|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
208070|NCT02592642|Behavioral|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
208071|NCT02592642|Device|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
208072|NCT02592642|Device|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine [NeuroTrac TENS from Verity Medical Ltd (U.K.)] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
208073|NCT02592642|Device|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
208074|NCT02592642|Device|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
208075|NCT02592629|Drug|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
208076|NCT02592629|Drug|ethyl chloride|topical spray
208077|NCT02592629|Drug|Kenalog|used with lidocaine in shoulder injection
208078|NCT02592616|Behavioral|CON|No exercise intervention.
208079|NCT02592616|Behavioral|CW|One hour of continuous walking on a treadmill.
208080|NCT02592616|Behavioral|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
208081|NCT02592603|Device|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
208104|NCT02592447|Other|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
208082|NCT02592590|Behavioral|Group A|"This condition receives three study components:~The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.~The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.~The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
208083|NCT02592590|Behavioral|Group B|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
208084|NCT02592590|Behavioral|Group C|"This condition receives two study components:~The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
208085|NCT02592590|Behavioral|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
208086|NCT02592577|Biological|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
208087|NCT02592564|Behavioral|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
208088|NCT02592551|Drug|MEDI4736|
208089|NCT02592551|Drug|Tremelimumab|
208090|NCT02592551|Other|Untreated arm (control)|
208091|NCT02592538|Device|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
208092|NCT02592538|Drug|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if <1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
208093|NCT02592538|Device|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
208094|NCT02592525|Behavioral|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
208095|NCT02592512|Other|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
208096|NCT02592512|Other|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
208097|NCT02592499|Device|HM III|
208098|NCT02592499|Other|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
208099|NCT02592486|Biological|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
208100|NCT02592486|Biological|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
208101|NCT02592473|Device|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
208102|NCT02592460|Other|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
208103|NCT02592460|Other|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
208135|NCT02592291|Device|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
208105|NCT02592447|Other|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
208106|NCT02592434|Drug|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet [BID] or solution [BID]):~5<7kg (2mg or 2mL); 7<10kg(2.5mg or 2. mL); 10 <15kg (3mg or 3mL); 15<25kg (3.5mg or 3.5mL); 25<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects <40 kg. Oral tablets (5 mg) are used for subjects >=40 kg."
208107|NCT02592434|Other|placebo|matching placebo tablet or solution for tofacitinib
208108|NCT02592421|Drug|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
208109|NCT02592421|Drug|Placebo|Placebo Comparator
208110|NCT02592408|Drug|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
208111|NCT02592408|Drug|SDPQ|single dose primaquine on day 2
208112|NCT02592408|Drug|14DPQ|14 day primaquine starting on day 2
208113|NCT02592408|Drug|14DPQ on Day 42|14 day primaquine starting on day 42
208114|NCT02592395|Drug|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:~Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
208115|NCT02592395|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
208116|NCT02592382|Dietary Supplement|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for two months
208117|NCT02592382|Other|Isotonic saline spray|saline nasal spray will be administered to this arm three times daily for two months
208118|NCT02592369|Device|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
208119|NCT02592356|Other|Strength and Balance Tests|"Participants have basic tests of their physical strength and balance. Participant's hand grip strength measured. Participant asked to rise from a chair without using their arms to push off, and they will complete a 6-minute walk test.~Tests performed at baseline, and at months 3, 6, and 12."
208120|NCT02592356|Procedure|Dual-Energy X-Ray Absorptiometry (DXA) Scan|DXA full body scan performed at baseline, and at months 3, 6, and 12.
208121|NCT02592356|Behavioral|Questionnaires|"Questionnaires completed about any pain or other symptoms participant may have had; about any gastrointestinal (GI) side effects they may be having before starting chemotherapy; about the amount of physical exercise and activity they get; and about their food intake over the last 24 hours.~Questionnaires completed at baseline, once a week during months 1, 2, and at months 3, 4, 5, 6, and 12."
208122|NCT02592356|Drug|Cabozantinib|After the baseline visit, participant starts receiving either Cabozantinib or Lenvatinib according to the treatment plan from their doctor.
208123|NCT02592356|Other|Body Measurements and Weight|Participant's weight, height, hip and waist circumference measurements done at baseline and repeated at every study visit
208124|NCT02592356|Drug|Lenvatinib|After the baseline visit, participant starts receiving either Cabozantinib or Lenvatinib according to the treatment plan from their doctor.
208125|NCT02592343|Biological|Lyophilized Fecal Microbiota Transplantation|
208126|NCT02592330|Procedure|Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
208127|NCT02592330|Biological|Cultivation of Limbal epithelial cells into a graft|A graft is manufactured for transplant
208128|NCT02592330|Procedure|CALEC Transplant|Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
208129|NCT02592330|Procedure|CLAU|Tissue is obtained from the healthy fellow eye (a limbal autograft) and immediately transplanted to recipient eye to provide a new source of epithelium for a diseased ocular surface after the removal of the recipient's scarred and diseased epithelium.
208130|NCT02592317|Drug|JNJ 56021927|JNJ 56021927 will be adminitered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
208131|NCT02592317|Drug|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administerd on Study Day 1 and 43.
208132|NCT02592317|Drug|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
208133|NCT02592317|Drug|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
208134|NCT02592304|Device|Dual energy computed tomography|one extra scanning with a dual energy ct.
208140|NCT02592239|Device|Functional brain MRI|Functional brain MRI before and after test meal ingestion
208141|NCT02592239|Dietary Supplement|A warm ham and cheese sandwich and a 200 ml fruit juice|
208142|NCT02592226|Procedure|Anesthesia: alveolar recruitment maneuver|
208143|NCT02592226|Procedure|Anesthesia: standardized|
208144|NCT02592213|Procedure|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
208145|NCT02592200|Dietary Supplement|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
208146|NCT02592200|Dietary Supplement|Placebo|Two doses per day for 28 days
208147|NCT02592187|Behavioral|ReMemory-MCI training|
208148|NCT02592187|Behavioral|Control intervention|
208149|NCT02592174|Other|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
208150|NCT02592174|Other|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
208151|NCT02592174|Radiation|cerebral images sub-study|Standard magnetic resonance imaging
208152|NCT02592161|Drug|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks~Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)~Three times a day, oral administration for 24weeks"
208153|NCT02592135|Other|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
208154|NCT02592122|Drug|Salbutamol Aerosol|
208155|NCT02592122|Drug|No drugs|
208156|NCT02592109|Behavioral|Enhanced Counseling using CFR based on Linear Programming|
208157|NCT02592096|Drug|0.1% Pazufloxacin Mesilate Ear Drops|
208158|NCT02592096|Drug|0.3% Pazufloxacin Mesilate Ear Drops|
208159|NCT02592096|Drug|0.5% Pazufloxacin Mesilate Ear Drops|
208160|NCT02592096|Drug|Pazufloxacin mesilate injection|
208161|NCT02592083|Drug|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
208162|NCT02592083|Drug|Palbociclib|
208163|NCT02592070|Behavioral|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
208164|NCT02592057|Drug|SOF|SOF tablets administered orally once daily based on approved prescribing information
208165|NCT02592044|Procedure|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
208166|NCT02592044|Procedure|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
208167|NCT02592044|Procedure|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
208168|NCT02592031|Drug|XM17|300 IU corresponds to an injection volume of 0.5 mL.
208169|NCT02592031|Drug|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
208170|NCT02592031|Drug|Zoladex®|3.6 mg
208171|NCT02592018|Drug|Secukinumab|Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
208172|NCT02592005|Other|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
208173|NCT02591992|Other|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
208174|NCT02591992|Other|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
208175|NCT02591953|Procedure|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
208176|NCT02591953|Procedure|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
208177|NCT02591953|Drug|Methylprednisolone|Corticosteroid used in injection (40 mg)
208178|NCT02591953|Drug|Lidocaine 1%|Anesthesic used in injection
208179|NCT02591940|Procedure|Surgery or Treatment by Heart Catheter|
208180|NCT02591927|Drug|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
208181|NCT02591927|Drug|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
208182|NCT02591914|Drug|Fovista™|Anti-PDGF-B pegylated aptamer
208183|NCT02591914|Drug|Lucentis®|Anti-VEGF
208184|NCT02591914|Drug|Avastin®|Anti-VEGF
208185|NCT02591914|Drug|Eylea®|Anti-VEGF
208186|NCT02591901|Drug|Uro vaxom|Prevention of recurrent lower urinary tract infections
208187|NCT02591901|Other|Placebo comparator|Placebo comparator
208188|NCT02591888|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
208189|NCT02591888|Drug|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
208190|NCT02591862|Drug|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
208191|NCT02591849|Dietary Supplement|Glucagon-like peptide-1 (GLP-1)|
208192|NCT02591849|Other|Isotonic saline|
208193|NCT02591849|Other|Hyperglycemic clamp|
208194|NCT02591836|Drug|Gemcabene|Gemcabene
208195|NCT02591836|Drug|Atorvastatin|Atorvastatin
208196|NCT02591836|Drug|Placebo|
208197|NCT02591810|Procedure|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
208198|NCT02591810|Procedure|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
208199|NCT02591810|Procedure|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
208200|NCT02591797|Procedure|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.~The application of anesthesia shall be in accordance with the following guidelines:~Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).~Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)~anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).~Syringe: carpule syringe-conventional harpoon with suction system."
208201|NCT02591784|Drug|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
208202|NCT02591784|Radiation|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
208203|NCT02591771|Drug|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
208204|NCT02591758|Device|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
208205|NCT02591758|Behavioral|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
208206|NCT02591758|Other|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
208207|NCT02591758|Other|Angina assessment with the angina diary, the SAQ and the SF-36|
208208|NCT02591758|Other|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
208209|NCT02591758|Other|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
208210|NCT02591745|Procedure|Fetal intervention|Type of fetal conditions requiring intervention and medications administered to fetuses undergoing varying types of fetal intervention will be documeted in this database.
208211|NCT02591719|Device|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
208212|NCT02591719|Device|MagPro magnetic stimulator (sham)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
208213|NCT02591719|Device|MagPro magnetic stimulator (LF rTMS)|"Most activated area from fNIRS findings: Contralesional homologs of Broca's area.~Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session"
208214|NCT02591706|Device|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
208215|NCT02591693|Behavioral|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
208216|NCT02591680|Other|Neuromuscular training|
208217|NCT02591680|Other|Muscle strengthening|
208218|NCT02591680|Device|Sensorimotor|
208219|NCT02591667|Procedure|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
208220|NCT02591667|Drug|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab~Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
208221|NCT02591667|Procedure|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
208222|NCT02591654|Drug|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
208252|NCT02591433|Other|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
208223|NCT02591654|Drug|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
208224|NCT02591641|Device|Anti-shear mattress overlay|A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
208225|NCT02591641|Other|Standard of Care|Standard ambulance stretcher mattress
208226|NCT02591628|Behavioral|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
208227|NCT02591615|Drug|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
208228|NCT02591615|Drug|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
208229|NCT02591615|Drug|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
208230|NCT02591615|Drug|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
208231|NCT02591602|Other|Teleradiology Service|Teleradiology Service at home or in nursing homes
208232|NCT02591589|Other|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 > 70 mmHg or oxygen saturation greater than or equal to 92%.
208233|NCT02591589|Other|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
208234|NCT02591563|Other|procedures|Nasopharyngeal swab, nasopharyngeal wash, tympanocentesis (if acute otitis media occurs), venipuncture
208235|NCT02591537|Device|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
208236|NCT02591524|Other|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
208237|NCT02591511|Device|smart phone and pad|Smart phone and pad is the mobile include the smart phone and pad, that can download the APP from internet.
208238|NCT02591511|Other|stroke-related health education manual|stroke-related health education manual is the manual mainly contained information regarding the prevention of stroke risk factors.
208239|NCT02591498|Behavioral|Computerized cognitive training|
208240|NCT02591485|Behavioral|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
208241|NCT02591472|Procedure|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208242|NCT02591472|Procedure|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
208243|NCT02591472|Other|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208244|NCT02591472|Other|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208245|NCT02591472|Other|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208246|NCT02591472|Other|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208247|NCT02591472|Other|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208248|NCT02591472|Other|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208249|NCT02591472|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208250|NCT02591472|Other|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
208251|NCT02591459|Other|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
208971|NCT02586246|Drug|CDP870|Self-injection
208253|NCT02591433|Other|Support Group Therapy|Undergo JeffQuit group therapy
208254|NCT02591433|Other|Quality-of-Life Assessment|Ancillary studies
208255|NCT02591420|Biological|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
208256|NCT02591420|Biological|Placebo for VRC01|Administered as an intravenous infusion over 30 to 60 minutes using a volumetric pump
208257|NCT02591420|Drug|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended, available first line once-daily oral combination therapy: currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
208258|NCT02591407|Procedure|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
208259|NCT02591407|Procedure|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
208260|NCT02591394|Behavioral|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
208261|NCT02591394|Behavioral|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.~After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.~Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
208262|NCT02591381|Procedure|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
208263|NCT02591368|Procedure|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
208264|NCT02591368|Procedure|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
208265|NCT02591368|Procedure|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
208266|NCT02591355|Device|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
208267|NCT02591355|Device|Saline solution injection|Placebo is a saline solution
208268|NCT02591329|Behavioral|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
208269|NCT02591329|Behavioral|Standard Care|
208270|NCT02591316|Other|no intervention|
208271|NCT02591303|Other|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
208272|NCT02591290|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses with 8-week interval)
208273|NCT02591277|Drug|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
208274|NCT02591264|Other|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
208275|NCT02591251|Drug|Povidone-iodine solution|
208276|NCT02591251|Drug|Normal saline solution|
208277|NCT02591238|Other|non-smoker oral placebo|Participants oral placebo last 2 weeks.
208278|NCT02591238|Drug|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
208279|NCT02591238|Other|smoker oral placebo|Participants oral placebo last 2 weeks.
208280|NCT02591238|Drug|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
208281|NCT02591225|Drug|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
208282|NCT02591225|Drug|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
208283|NCT02591212|Behavioral|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
208313|NCT02591004|Radiation|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
208314|NCT02590991|Other|Prebiotics|To study the long term effect of supplementation in early life
208315|NCT02590991|Other|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
208284|NCT02591212|Behavioral|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
208285|NCT02591199|Drug|URG101|
208286|NCT02591199|Drug|Placebo|
208287|NCT02591199|Drug|Lidocaine|
208288|NCT02591199|Drug|Heparin|
208289|NCT02591186|Procedure|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
208290|NCT02591173|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
208291|NCT02591173|Drug|Saline|Normal saline will be used as the placebo comparator.
208292|NCT02591160|Procedure|HCTZ cessation|Patients will stop taking their HCTZ for 3 months
208293|NCT02591147|Drug|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
208294|NCT02591147|Drug|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water (placebo) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
208295|NCT02591134|Other|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
208296|NCT02591134|Other|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
208297|NCT02591108|Device|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
208298|NCT02591108|Device|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
208299|NCT02591095|Drug|ABT-263|
208300|NCT02591082|Device|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
208301|NCT02591069|Device|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
208302|NCT02591056|Device|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
208303|NCT02591056|Device|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
208304|NCT02591043|Procedure|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
208305|NCT02591030|Drug|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:~Cisplatin 25 mg/m² over 1 hour at D1 and D8~Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
208306|NCT02591030|Drug|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:~Oxiplatin: 85 mg/m² (IP/120 minutes)~Irinotecan: 180 mg/m² (IV/90 minutes)~Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan~5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
208307|NCT02591017|Drug|Morphine|
208308|NCT02591017|Drug|Ketamine|
208309|NCT02591017|Drug|Placebo|
208310|NCT02591017|Drug|Chitosan|
208311|NCT02591004|Drug|Magesium sulphate|*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
208312|NCT02591004|Drug|Nifedipine|*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
208316|NCT02590978|Procedure|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
208317|NCT02590978|Procedure|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed once complete resolution of abdominal tenderness, oral feeding and trending down in pancreatic laboratory is achieved
208318|NCT02590965|Drug|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
208319|NCT02590965|Drug|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
208320|NCT02590952|Drug|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
208321|NCT02590939|Device|CEFALY Active|Active external trigeminal nerve stimulation
208322|NCT02590939|Device|CEFALY Placebo|Placebo external trigeminal nerve stimulation
208323|NCT02590926|Procedure|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
208324|NCT02590913|Dietary Supplement|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
208325|NCT02590913|Dietary Supplement|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
208326|NCT02590900|Drug|intravenous paracetamol (acetaminophen)|paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
208327|NCT02590887|Other|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (15, 28 and 42 days) drinking the beverage.
208328|NCT02590874|Drug|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
208329|NCT02590874|Drug|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
208330|NCT02590861|Procedure|Dental implant|All participants will receive the same intervention, this is a single group study.
208331|NCT02590848|Dietary Supplement|Walnut intake|Nutritional intervention: 30g walnut kernels per day
208332|NCT02590835|Procedure|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
208333|NCT02590835|Procedure|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
208334|NCT02590822|Dietary Supplement|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.~The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
208335|NCT02590822|Other|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.~Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
208336|NCT02590809|Drug|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
208337|NCT02590809|Drug|Placebo|Placebo will be given for 30 days
208338|NCT02590809|Other|Walk distance test|Walk distance test during 6 minutes
208339|NCT02590809|Other|Exercise echocardiography|
208340|NCT02590796|Other|No intervention given to participants|This is an observational study. Participants will receive no intervention.
208378|NCT02590497|Drug|Gadolinium|Undergo gadolinium-enhanced MRI
208379|NCT02590497|Other|Laboratory Biomarker Analysis|Tissue genetic analysis
208380|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
208381|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
208341|NCT02590783|Procedure|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
208342|NCT02590783|Procedure|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
208343|NCT02590770|Behavioral|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
208344|NCT02590770|Other|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
208345|NCT02590757|Device|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
208346|NCT02590757|Device|N-CPAP|Nasal-continuous positive airway pressure
208347|NCT02590744|Behavioral|eye patch|cover the sick eye with eye patch preoperatively for 3 hours
208348|NCT02590744|Behavioral|non-eye patch|do not cover the sick eye with eye patch preoperatively
208349|NCT02590718|Procedure|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
208350|NCT02590705|Drug|Lidocaine|surface anesthesia with lidocaine
208351|NCT02590692|Biological|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
208352|NCT02590679|Device|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
208353|NCT02590666|Procedure|Bipolar Polypectomy|Polyps resection with bipolar electrode
208354|NCT02590666|Procedure|Mechanical Polypectomy|Polyps resection with microscissors or graspers
208355|NCT02590666|Device|Bipolar electrode|Bipolar electrode used to performs polypectomy
208356|NCT02590666|Device|Microscissors or graspers|Mechanical instruments used to performs polypectomy
208357|NCT02590653|Drug|Atorvastatin|Lipid-lowering therapy
208358|NCT02590640|Device|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
208359|NCT02590640|Device|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
208360|NCT02590627|Drug|Artemether-lumefantrine|Artemether-lumefantrine
208361|NCT02590627|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
208362|NCT02590614|Dietary Supplement|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
208363|NCT02590614|Dietary Supplement|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
208364|NCT02590601|Drug|Bromocriptine|
208365|NCT02590601|Other|Guideline-driven medical therapy (GDMT)|
208366|NCT02590588|Drug|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
208367|NCT02590575|Device|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows~Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
208368|NCT02590562|Other|Routine clinical practice|
208369|NCT02590549|Procedure|Corneal Collagen Crosslinking|"Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.~Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.~After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,"
208370|NCT02590549|Device|Ufalink|UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
208371|NCT02590536|Drug|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.~This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
208372|NCT02590536|Drug|placebo|
208373|NCT02590523|Drug|Vancomycin|Intracameral vancomycin injection during cataract surgery
208374|NCT02590523|Drug|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
208375|NCT02590523|Drug|Placebo|Intracameral placebo injection with BSS during cataract surgery
208376|NCT02590510|Drug|methotrexate|The quantity of methotrexate is different in the two groups.
208377|NCT02590497|Procedure|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
208382|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo FLAIR sequence
208383|NCT02590497|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
208384|NCT02590484|Procedure|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
208385|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery|"A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
208386|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|"Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.~Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
208387|NCT02590458|Procedure|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
208388|NCT02590458|Behavioral|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
208389|NCT02590445|Device|deep brain stimulation system|
208390|NCT02590432|Drug|Linaclotide|Linaclotide capsules, orally, once daily.
208391|NCT02590419|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.~BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.~BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
208392|NCT02590406|Procedure|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
208393|NCT02590406|Procedure|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.~NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
208394|NCT02590393|Combination Product|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
208395|NCT02590380|Device|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
208396|NCT02590380|Device|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
208397|NCT02590367|Drug|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.~XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks."
208398|NCT02590367|Drug|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
208399|NCT02590367|Drug|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
208400|NCT02590354|Other|ART interruption|
208401|NCT02590315|Other|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
208402|NCT02590315|Device|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
208403|NCT02590315|Device|Conventional digital mammography.|Conventional digital mammography.
208404|NCT02590302|Other|Implementation Phase|"Core Components of the implementation intervention include:~Hospital and CMHA project commitment~Site champion teams (from hospital and CMHA)~Memorandum of Agreement between Hospital and CMHA~Pre-intervention site visits~Education sessions~Posters/reminders~Instructional videos (HEADS ED video)~Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
208405|NCT02590289|Drug|BBI-5000|BBI-5000 low dose, middle dose, or high doses
208406|NCT02590276|Behavioral|characterization|
208407|NCT02590263|Radiation|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
208408|NCT02590263|Drug|Temozolomide|Temozolomide will be administered per label.
208409|NCT02590263|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
208410|NCT02590250|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
208411|NCT02590237|Device|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
208412|NCT02590237|Device|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
208413|NCT02590224|Drug|Ferrous bis-glycinate|
208414|NCT02590224|Drug|Ferrous glycine sulphate|
208415|NCT02590211|Behavioral|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
208416|NCT02590198|Other|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
208417|NCT02590198|Other|PCT algorithm|care based on PCT algorithm
208418|NCT02590185|Drug|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:~A capsule of omeprazole ABBOTT® 10mg~10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)~1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)~A tablet of fexofenadine Zentiva® 120mg"
208419|NCT02590159|Device|BONGO NASAL EPAP|The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
208420|NCT02590146|Behavioral|Non-pharmacologic pain control adjuncts|
208421|NCT02590133|Drug|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
208422|NCT02590133|Drug|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
208423|NCT02590133|Drug|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
208424|NCT02590120|Dietary Supplement|Enteral nutrition|
208425|NCT02590107|Dietary Supplement|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
208426|NCT02590107|Dietary Supplement|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
208427|NCT02590107|Dietary Supplement|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
208428|NCT02590107|Other|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
208429|NCT02590094|Drug|Intravitreal bevacizumab or intravitreal ziv-aflibercept|Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
208430|NCT02590081|Drug|Dextrose 5%|
208431|NCT02590081|Drug|normal saline|
208432|NCT02590068|Drug|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
208433|NCT02590055|Drug|gemcitabine/docetaxel combination|
208434|NCT02590042|Biological|ADSC-SVF-002|"ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10^6 cells/g of liposuctioned (hydrated fat)"
208435|NCT02590029|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
208436|NCT02590029|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
208437|NCT02590029|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
208438|NCT02590016|Drug|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
208439|NCT02590003|Drug|Carboplatin|
208440|NCT02590003|Drug|Nab-paclitaxel|
208441|NCT02589990|Behavioral|Strength training|see arm description
208442|NCT02589977|Drug|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
208443|NCT02589964|Dietary Supplement|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
208444|NCT02589964|Other|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
208445|NCT02589951|Other|admission to non-psychiatric service|
208446|NCT02589938|Other|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
208447|NCT02589938|Other|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
208448|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
208449|NCT02589925|Device|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
208450|NCT02589925|Procedure|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
208451|NCT02589925|Procedure|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
208452|NCT02589925|Procedure|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
208453|NCT02589912|Device|Nucleus Profile ABI541 Auditory Brainstem Implant|
208454|NCT02589899|Other|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
208455|NCT02589886|Other|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
208456|NCT02589873|Behavioral|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
208457|NCT02589873|Behavioral|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
208458|NCT02589860|Other|Melphalan kinetic study|Concentration of Melphalan in plasma samples
208459|NCT02589860|Genetic|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
208460|NCT02589860|Genetic|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
208461|NCT02589847|Biological|RBX2660|suspension of intestinal microbes
208462|NCT02589834|Other|Quran group|
208463|NCT02589821|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
208464|NCT02589821|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
208465|NCT02589808|Device|Full TTE|Full transthoracic echocardiogram, with Doppler.
208466|NCT02589808|Device|GE Vscan|Handheld echo.
208467|NCT02589795|Biological|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
208468|NCT02589795|Biological|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
208469|NCT02589795|Device|Trigrid Delivery System - Intramuscular|Electroporation
208470|NCT02589795|Device|Trigrid Delivery System - Intradermal|Electroporation
208471|NCT02589782|Drug|Bedaquiline|
208472|NCT02589782|Drug|Pretomanid|
208473|NCT02589782|Drug|Moxifloxacin|
208474|NCT02589782|Drug|Linezolid|
208475|NCT02589782|Drug|Clofazimine|
208476|NCT02589782|Drug|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
208477|NCT02589769|Other|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
208478|NCT02589769|Other|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
208479|NCT02589756|Other|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
208480|NCT02589756|Other|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (~1400 kcal ~100 grams walnuts, ~50 grams hazelnuts and ~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
208481|NCT02589756|Other|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
208482|NCT02589743|Device|Sealant|Application of preventive agent
208483|NCT02589743|Device|Adhesive and Sealant|Application of preventive agent and technique for control moisture
208484|NCT02589730|Device|Welltang App|This App is a large platform of individualized diabetic management
208485|NCT02589717|Drug|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
208486|NCT02589691|Drug|Rocuronium|
208487|NCT02589691|Other|Sodium chloride 0.9%|
208488|NCT02589678|Biological|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
208489|NCT02589678|Biological|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
208490|NCT02589665|Drug|Mirikizumab|
208491|NCT02589665|Drug|Placebo|
208492|NCT02589652|Drug|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
208493|NCT02589652|Drug|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
208494|NCT02589652|Drug|Entecavir|ETV 0.5mg oral daily for 48 weeks
208495|NCT02589639|Drug|Empagliflozin|
208496|NCT02589639|Drug|Placebo|
208497|NCT02589639|Drug|Placebo|For blinding purposes
208498|NCT02589626|Drug|empagliflozin 10mg|
208499|NCT02589626|Drug|empagliflozin 25 mg|
208500|NCT02589626|Drug|Placebo|For blinding purposes
208501|NCT02589613|Dietary Supplement|tap water|300ml tap water via nasogastric tube
208502|NCT02589613|Dietary Supplement|Glucose|300ml tap water with 75g Glucose via nasogastric tube
208503|NCT02589613|Dietary Supplement|Fructose|300ml tap water with 25g Fructose via nasogastric tube
208504|NCT02589600|Drug|Zoledronic acid|Annual intravenous 5.0 mg
208505|NCT02589600|Dietary Supplement|vitamin D|800 IU daily
208506|NCT02589600|Dietary Supplement|calcium|approximately 1200 mg (dietary and supplement)
208507|NCT02589600|Other|Saline|Annual intravenous saline placebo
208508|NCT02589587|Procedure|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
208509|NCT02589587|Other|no intervention|lean control group
208510|NCT02589574|Other|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.~it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
208511|NCT02589561|Device|Remote fitting|remote fitting of hearing aids
208512|NCT02589561|Device|Face to face fitting|face to face fitting of hearing aids
208513|NCT02589522|Drug|ATR Kinase Inhibitor M6620|Given IV
208514|NCT02589522|Other|Laboratory Biomarker Analysis|Correlative studies
208515|NCT02589522|Other|Pharmacological Study|Correlative studies
208516|NCT02589522|Other|Quality-of-Life Assessment|Ancillary studies
208517|NCT02589522|Procedure|Therapeutic Conventional Surgery|Undergo surgery
208518|NCT02589522|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
208519|NCT02589509|Behavioral|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
208520|NCT02589509|Behavioral|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
208521|NCT02589496|Drug|pembrolizumab|200 mg every 3 weeks
208522|NCT02589483|Procedure|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
208523|NCT02589483|Device|Hemopatch|The rectal anastomosis reinforced with Hemopatch
208524|NCT02589470|Other|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
208525|NCT02589457|Drug|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
208526|NCT02589457|Drug|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
208527|NCT02589444|Dietary Supplement|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
208528|NCT02589444|Other|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
208529|NCT02589444|Other|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.~This will be done upon enrollment (baseline) and at 3 month follow-up."
208530|NCT02589444|Other|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
208531|NCT02589444|Procedure|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
208532|NCT02589418|Procedure|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
208533|NCT02589418|Procedure|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
208534|NCT02589418|Procedure|No Acupuncture|Control intervention: No needle insertion and manipulation
208535|NCT02589405|Drug|Benzoyl Peroxide|
208536|NCT02589405|Other|Dermotivin® Soft Liquid cleanser|
208537|NCT02589405|Other|Cetaphil® Dermacontrol Moisturizer SPF30|
208538|NCT02589392|Other|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
208539|NCT02589392|Other|Cetaphil® Restoraderm® body wash|
208540|NCT02589379|Procedure|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
208541|NCT02589366|Drug|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
208699|NCT02588157|Device|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
208542|NCT02589353|Drug|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
208543|NCT02589340|Drug|Buspirone|
208544|NCT02589340|Drug|Placebo|Sugar Pill
208545|NCT02589327|Other|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
208546|NCT02589314|Device|Mechanical periodontal therapy|
208547|NCT02589314|Procedure|nonsurgical periodontal therapy|
208548|NCT02589301|Biological|Pegfilgrastim|
208549|NCT02589288|Procedure|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
208550|NCT02589288|Procedure|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
208551|NCT02589275|Drug|TNX-102 SL Tablet 2.8 mg|TNX-102 SL 2.8 mg tablet taken daily at bedtime
208552|NCT02589262|Drug|AUT00206|
208553|NCT02589249|Dietary Supplement|AyuFlex|Active product
208554|NCT02589249|Dietary Supplement|Placebo|Placebo
208555|NCT02589236|Drug|Cavosonstat|GSNOR inhibitor
208556|NCT02589236|Drug|Placebo|Control sample with only capsule excipients and fillers
208557|NCT02589223|Other|Multisensory Stimulation|Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
208558|NCT02589223|Other|Control|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
208559|NCT02589210|Other|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
208560|NCT02589197|Device|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
208561|NCT02589197|Device|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
208562|NCT02589184|Other|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
208563|NCT02589184|Other|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
208564|NCT02589184|Other|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
208565|NCT02589171|Device|Neo Close Abdominal Closure|Neo Close Abdominal Closure
208566|NCT02589171|Device|Carter Thomason Device|Carter Thomason Device
208567|NCT02589158|Drug|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
208568|NCT02589158|Drug|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
208569|NCT02589145|Drug|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.~Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
208570|NCT02589145|Drug|Vorinostat|1000 mg by mouth on Days -9 to -2.
208571|NCT02589145|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
208572|NCT02589145|Drug|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
208573|NCT02589145|Drug|Melphalan|60 mg/m2 by vein on days -3 and -2.
208574|NCT02589145|Drug|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
208575|NCT02589145|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
208576|NCT02589145|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
208577|NCT02589145|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
208578|NCT02589145|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
208579|NCT02589145|Drug|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
208580|NCT02589145|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
208581|NCT02589145|Drug|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
208582|NCT02589132|Other|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
208583|NCT02589119|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
208584|NCT02589106|Device|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
208585|NCT02589093|Device|Stimulation|
208586|NCT02589080|Behavioral|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
208587|NCT02589067|Drug|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
208588|NCT02589067|Drug|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
208589|NCT02589054|Other|Monitoring|
208590|NCT02589041|Procedure|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.~A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
208591|NCT02589041|Drug|Ropivacaine 1%|
208592|NCT02589028|Dietary Supplement|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
208593|NCT02589028|Other|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
208594|NCT02589002|Other|Sucralose|
208595|NCT02588976|Device|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
208596|NCT02588963|Other|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
208597|NCT02588963|Other|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
208598|NCT02588963|Other|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
208599|NCT02588950|Drug|U-500R|Administered SC
208600|NCT02588937|Drug|EntecaBell ODT. 0.5mg|
208601|NCT02588937|Drug|Baraclude Tab. 0.5mg|
208602|NCT02588924|Other|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
208603|NCT02588924|Other|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
208604|NCT02588911|Procedure|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
208605|NCT02588911|Procedure|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
208606|NCT02588898|Device|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
208607|NCT02588885|Behavioral|Trauma-sensitive Care|"Psychological intervention~education~empowerment~desensitization~relaxation tools~Physical therapy intervention~techniques to address muscular tension~empowerment~comfort~encouragement of trauma-related coping skills"
208608|NCT02588872|Biological|Platelet-rich Plasma (PRP)|
208609|NCT02588872|Biological|Hyaluronic Acid|
208610|NCT02588846|Device|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
208611|NCT02588833|Drug|APL-2|Complement (C3) Inhibitor
208612|NCT02588820|Drug|Antiretroviral Therapy (Experimental)|"Initial ART until HLA-B5701 results became available (48 hours):~Tenofovir 245 mg once a day~Emtricitabine 200 mg once a day~Dolutegravir 50 mg once a day~Darunavir 800 mg once a day~Ritonavir 100 mg once a day~Maraviroc 150 mg twice a day~Three months continuation treatment (after HLA-B5701 confirmed as negative):~Dolutegravir 50 mg once a day.~Abacavir 600 mg once a day~Lamivudine 300 mg once a day~Darunavir 800 mg once a day~Ritonavir 100 mg once a day~Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~Nine months continuation treatment (till complete 12 months treatment):~Abacavir, 600mg once a day~Lamivudine, 300 mg once a day~Dolutegravir, 50 mg once a day"
208613|NCT02588807|Drug|Spirit1|Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
208614|NCT02588794|Device|CytoSorb 300 ml device (3804606CE01)|additional cytokine adsorber
208615|NCT02588781|Drug|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
208694|NCT02588183|Device|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
208695|NCT02588170|Drug|Surufatinib|Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
208616|NCT02588768|Device|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
208617|NCT02588755|Procedure|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
208618|NCT02588755|Procedure|TACE|TACE alone
208619|NCT02588742|Dietary Supplement|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
208620|NCT02588742|Dietary Supplement|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
208621|NCT02588729|Other|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
208622|NCT02588716|Drug|Terlipressin|Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.
208623|NCT02588716|Drug|normal saline|Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.
208624|NCT02588703|Behavioral|Cognitive Behavioral Therapy|Coping Skills Treatment
208625|NCT02588703|Behavioral|Usual Care|Existing DUI program group counseling
208626|NCT02588690|Procedure|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
208627|NCT02588690|Other|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol <190 mg/dL.~The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
208628|NCT02588690|Procedure|Blood pressure measurement|Blood pressure measurement
208629|NCT02588677|Drug|Masitinib (4.5)|4.5 mg/kg/day
208630|NCT02588677|Drug|Riluzole|
208631|NCT02588677|Drug|Placebo|
208632|NCT02588677|Drug|Masitinib (3.0)|3 mg/kg/day
208633|NCT02588664|Other|COMPASS Intervention|"A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.~Patient will receive a follow-up telephone call two days after having been discharged.~7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.~Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services."
208634|NCT02588651|Drug|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
208635|NCT02588625|Drug|BMS-986020|
208636|NCT02588625|Other|Placebo|
208637|NCT02588612|Genetic|NY-ESO-1ᶜ²⁵⁹T cell|NY-ESO-1ᶜ²⁵⁹ T cell is an autologous genetically modified T-cell product.
208638|NCT02588612|Drug|Cyclophosphamide|Cyclophosphamide will be used as a lymphodepleting chemotherapy.
208639|NCT02588612|Drug|Fludarabine|Fludarabine will be used as a lymphodepleting chemotherapy.
208640|NCT02588599|Device|Erchonia LUNULA|Active low level laser light therapy
208641|NCT02588586|Drug|3BNC117|3BNC117 infusions
208642|NCT02588586|Other|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
208643|NCT02588573|Device|etafilcon A (control)|contact lens
208644|NCT02588573|Device|somofilcon A (test)|contact lens
208645|NCT02588547|Drug|Granisetron|IV granisetron 1 mg before spinal anethesia
208646|NCT02588547|Drug|Granisetron|IV granisetron 0.7 mg before spinal anethesia
208647|NCT02588547|Drug|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
208648|NCT02588534|Device|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
208649|NCT02588534|Other|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
208650|NCT02588521|Drug|AL-794|
208651|NCT02588521|Other|Placebo/Vehicle|Suspension vehicle without active drug
208652|NCT02588508|Procedure|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
208653|NCT02588508|Procedure|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
208654|NCT02588495|Other|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
208655|NCT02588482|Device|high-density electroencephalography|Auditory stimulations during electroencephalography recording
208656|NCT02588482|Device|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
208696|NCT02588170|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
208697|NCT02588157|Device|Macintosh|Direct laryngoscopy
208698|NCT02588157|Device|Glidescope|Glidescope videolaryngoscope
208657|NCT02588469|Other|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
208658|NCT02588469|Other|Control group|Standard obesity care with physical activity program
208659|NCT02588456|Biological|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
208660|NCT02588443|Drug|RO70097890|
208661|NCT02588443|Drug|nab-paclitaxel|
208662|NCT02588443|Drug|gemcitabine|
208663|NCT02588417|Drug|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
208664|NCT02588417|Drug|Levobupivacaine|levobupivacaine 2.5 mg
208665|NCT02588404|Drug|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
208666|NCT02588391|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
208667|NCT02588391|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
208668|NCT02588391|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
208669|NCT02588378|Procedure|multi-modal cSLO imaging|
208670|NCT02588365|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
208671|NCT02588365|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
208672|NCT02588365|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
208673|NCT02588352|Dietary Supplement|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
208674|NCT02588339|Drug|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
208675|NCT02588339|Drug|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
208676|NCT02588339|Drug|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
208677|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
208678|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
208679|NCT02588313|Dietary Supplement|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
208680|NCT02588300|Procedure|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
208681|NCT02588287|Other|Blood draws for tenofovir PK, renal function|
208682|NCT02588274|Device|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
208683|NCT02588274|Device|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
208684|NCT02588261|Drug|naquotinib mesilate|Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.
208685|NCT02588261|Drug|Erlotinib|Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
208686|NCT02588261|Drug|Gefitinib|Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
208687|NCT02588248|Drug|Peppermint Oil|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640mg Placebo).
208688|NCT02588248|Other|Placebo|During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640mg Placebo).
208689|NCT02588235|Drug|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
208690|NCT02588235|Drug|Atorvastatin|atorvastatin (20 mg/day）
208691|NCT02588209|Behavioral|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
208692|NCT02588209|Behavioral|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
208693|NCT02588196|Drug|Dexamethasone acetate|
208700|NCT02588144|Procedure|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
208701|NCT02588144|Procedure|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
208702|NCT02588131|Drug|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
208703|NCT02588118|Drug|propofol|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
208704|NCT02588118|Drug|Cisatracurium|Propofol 2 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 1 min (t2). Patients will be monitored using bispectral index monitoring for propofol and Relaxometer mechanomyograph neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
208705|NCT02588105|Drug|AZD0156|All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
208706|NCT02588105|Drug|Olaparib|Module 1 combination with olaparib
208707|NCT02588105|Drug|irinotecan|Module 2 combination with irinotecan/FOLFIRI
208708|NCT02588105|Drug|Fluorouracil|Module 2 combination with irinotecan/FOLFIRI
208709|NCT02588105|Drug|Folinic Acid|Module 2 combination with irinotecan/FOLFIRI
208710|NCT02588092|Drug|ADCT-301|intravenous infusion
208711|NCT02588079|Behavioral|Internet-based cognitive behavioral therapy|
208712|NCT02588066|Procedure|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
208713|NCT02588040|Biological|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
208714|NCT02588027|Drug|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
208715|NCT02588027|Drug|Placebo|Pharmacy formulated placebo
208716|NCT02588014|Other|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
208717|NCT02588001|Drug|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
208718|NCT02587988|Drug|HCP1302|
208719|NCT02587988|Drug|HGP0904|
208720|NCT02587988|Drug|Placebo (for HCP1302)|
208721|NCT02587988|Drug|Placebo (for HGP0904)|
208722|NCT02587975|Drug|Evogliptin|10 mg
208723|NCT02587962|Drug|Birinapant|Birinapant IV on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2. In the expansion phase the assigned recommended phase two dose will be administered in all cohorts
208724|NCT02587962|Drug|Pembrolizumab|200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
208725|NCT02587936|Other|Collaborative Model of Primary care and Subspecialty care|Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
208726|NCT02587910|Dietary Supplement|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
208727|NCT02587910|Dietary Supplement|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
208728|NCT02587897|Other|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
208729|NCT02587897|Other|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
208730|NCT02587884|Procedure|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
208731|NCT02587871|Drug|Cytarabine|Given IV
208732|NCT02587871|Other|Laboratory Biomarker Analysis|Correlative studies
208733|NCT02587871|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
208734|NCT02587871|Biological|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
208735|NCT02587871|Biological|G-CSF mobilized peripheral blood cells|microtransplantation
208736|NCT02587845|Drug|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
208737|NCT02587845|Drug|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
208738|NCT02587832|Device|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
208739|NCT02587832|Device|NCPAP|Bubble CPAP System.
208740|NCT02587819|Drug|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.~Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
208741|NCT02587806|Biological|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
208742|NCT02587806|Other|Liberation therapy|
208743|NCT02587793|Other|not interventional study|
208744|NCT02587767|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
208745|NCT02587767|Device|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
208746|NCT02587754|Device|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
208747|NCT02587741|Drug|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
208748|NCT02587741|Drug|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
208749|NCT02587741|Drug|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
208750|NCT02587728|Procedure|Blood Draw|Samples to be obtained from all subjects will include at least 30 cc of whole blood. Blood specimens will be obtained specifically for the purposes of this study, and will be collected at intervals required for clinical purposes to minimize the need for additional blood draws of study participants.
208751|NCT02587715|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
208752|NCT02587715|Other|Liberation therapy|
208753|NCT02587702|Other|β-Palmitate Content|
208754|NCT02587702|Other|Placebo|
208755|NCT02587702|Other|β-Palmitate Content Naturely in Human Milk|
208756|NCT02587689|Biological|anti-MUC1 CAR T Cells|
208757|NCT02587676|Other|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
208758|NCT02587663|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
208759|NCT02587663|Procedure|Mammography|Undergo bilateral mammography
208760|NCT02587663|Procedure|Therapeutic Conventional Surgery|Undergo breast conserving surgery
208761|NCT02587663|Procedure|Ultrasonography|Undergo bilateral whole-breast ultrasound
208762|NCT02587663|Procedure|Ultrasonography|Undergo targeted breast ultrasound
208763|NCT02587663|Other|Gadolinium|Contrast agent used in MRI
208764|NCT02587650|Drug|Capmatinib|Given PO
208765|NCT02587650|Drug|Ceritinib|Given PO
208766|NCT02587650|Drug|Entrectinib|Given PO
208767|NCT02587650|Other|Laboratory Biomarker Analysis|Correlative studies
208768|NCT02587650|Drug|Regorafenib|Given PO
208769|NCT02587637|Device|Dorsal Root Ganglion Stimulation|
208770|NCT02587624|Procedure|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
208771|NCT02587611|Other|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
208772|NCT02587611|Other|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
208773|NCT02587598|Drug|INCB053914|"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.~INCB053914 tablets to be administered by mouth."
208972|NCT02586233|Drug|DS-1040b|DS-1040b for IV administration
208774|NCT02587598|Drug|INCB053914|Initial cohort dose of INCB053914 at the protocol-specified starting dose. INCB053914 tablets to be administered by mouth.
208775|NCT02587598|Drug|I-DAC (Intermediate dose cytarabine)|Cytarabine dose will be 1 g/m^2. Cytarabine will be administered as an intravenous (IV) infusion.
208776|NCT02587598|Drug|Azacitidine|Azacitidine dose will be 75 mg/m^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
208777|NCT02587598|Drug|Ruxolitinib|Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
208778|NCT02587585|Behavioral|Feedback against tailored target|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.
208779|NCT02587585|Behavioral|No feedback|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
208780|NCT02587572|Biological|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
208781|NCT02587559|Procedure|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
208782|NCT02587546|Procedure|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
208783|NCT02587546|Procedure|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
208784|NCT02587546|Procedure|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
208785|NCT02587533|Other|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
208786|NCT02587533|Other|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
208787|NCT02587533|Other|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
208788|NCT02587533|Other|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
208789|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 mL, Intramuscular
208790|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
208791|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
208792|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
208793|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
208794|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
208795|NCT02587507|Other|Orange juice|Individuals will consume the HFHC meal with 500mL of orange juice.
208796|NCT02587507|Other|Water|Individuals will consume the HFHC meal with 500mL of water.
208797|NCT02587507|Other|Water with glucose|Individuals will consume the HFHC meal with 500mL of water with glucose.
208798|NCT02587494|Procedure|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
208799|NCT02587468|Dietary Supplement|Juice Plus+(R)|before-after comparison of plasma phenolics
208800|NCT02587455|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
208801|NCT02587455|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
208802|NCT02587442|Drug|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
208803|NCT02587429|Behavioral|Patient education|
208804|NCT02587416|Drug|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
208805|NCT02587416|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
208806|NCT02587416|Drug|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
208807|NCT02587403|Device|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
208808|NCT02587403|Device|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
208809|NCT02587390|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
208810|NCT02587390|Drug|Simvastatin 80 mg|2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
208811|NCT02587377|Other|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
208812|NCT02587364|Drug|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
208813|NCT02587364|Drug|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
208814|NCT02587364|Drug|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
208815|NCT02587364|Drug|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
208816|NCT02587364|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
208817|NCT02587364|Drug|Placebo|Placebo once daily (QD)
208818|NCT02587351|Drug|Metoprolol succinate|Extended release Metoprolol succinate
208819|NCT02587351|Other|Placebo|Matching placebo
208820|NCT02587338|Device|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anadal, right cathodal
208973|NCT02586233|Drug|Placebo|Matching placebo for IV administration
208821|NCT02587338|Device|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
208822|NCT02587325|Drug|ABI-009, nab-rapamycin, albumin-bound rapamycin|ABI-009
208823|NCT02587312|Other|Very low nicotine content cigarettes|
208824|NCT02587312|Other|Standard nicotine content cigarettes|
208825|NCT02587286|Other|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
208826|NCT02587273|Drug|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
208827|NCT02587260|Drug|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
208828|NCT02587260|Drug|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
208829|NCT02587260|Drug|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
208830|NCT02587247|Drug|TF2 antibody/68Ga-IMP-288|
208831|NCT02587234|Device|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
208832|NCT02587221|Biological|MF59-adjuvanted Quadrivalent Influenza Vaccine|1 dose approximately 0.5 mL of aQIV
208833|NCT02587221|Biological|Non-Influenza Comparator (Boostrix)|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine (Boostrix)
208834|NCT02587208|Device|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
208835|NCT02587208|Procedure|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
208836|NCT02587195|Drug|Teriflunomide|
208837|NCT02587182|Device|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
208838|NCT02587169|Drug|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
208839|NCT02587156|Dietary Supplement|Meal serving at high dietary protein|Participants are habituated to a high level of dietary protein intake for 21 days.
208840|NCT02587156|Dietary Supplement|Meal serving at low dietary protein|Participants are habituated to a low level of dietary protein intake for 21 days.
208841|NCT02587156|Dietary Supplement|Meal serving|To investigate impact of habituated protein level
208842|NCT02587143|Drug|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
208843|NCT02587143|Drug|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
208844|NCT02587130|Drug|Ketamine|ketamine administered in bolus by subcutaneous injection
208845|NCT02587117|Drug|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
208846|NCT02587117|Drug|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
208847|NCT02587104|Other|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
208848|NCT02587091|Behavioral|Portable obstetric ultrasound|This intervention was advertised at the cluster level
208849|NCT02587078|Drug|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
208850|NCT02587078|Drug|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
208851|NCT02587065|Drug|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
208852|NCT02587052|Drug|Generic tacrolimus|Generic tacrolimus
208853|NCT02587052|Drug|Prograf|Prograf, the original tacrolimus
208854|NCT02587039|Procedure|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
208855|NCT02587039|Behavioral|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
208856|NCT02587026|Other|Blood sample collection|
208857|NCT02587026|Other|Tumor tissue sample collection|
208858|NCT02587013|Procedure|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
208859|NCT02587013|Procedure|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
208860|NCT02587000|Drug|Ulipristal acetate|
208861|NCT02587000|Drug|Placebo|
208862|NCT02586987|Drug|Selumetinib|Selumetinib oral
208863|NCT02586987|Drug|MEDI4736|MEDI4736 IV
208864|NCT02586987|Drug|Tremelimumab|Tremelimumab, IV
208865|NCT02586974|Device|Humigard|warmed and humidified CO2 insufflation
208866|NCT02586961|Drug|0.9% saline solution|"Placebo:~Nebulized 0.9% saline solution"
208867|NCT02586961|Drug|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
208868|NCT02586961|Drug|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
208869|NCT02586961|Drug|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
208870|NCT02586948|Device|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
208871|NCT02586935|Drug|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
208872|NCT02586935|Other|Placebo|Administered orally after dispersion in approximately 100 ml of water
208873|NCT02586922|Device|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
208874|NCT02586909|Drug|RVT-101 35 mg tablets|once daily, oral tablets
208875|NCT02586896|Behavioral|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
208876|NCT02586896|Behavioral|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
208877|NCT02586883|Other|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
208878|NCT02586870|Device|Intravascular Ultrasound|
208879|NCT02586857|Drug|ACP-196|
208880|NCT02586831|Drug|Anti-Thymocyte Globulin (ATG)|Concomitant Drug Administration
208881|NCT02586831|Drug|Placebo|Drug Administration
208882|NCT02586831|Drug|Pegylated GCSF|Concomitant Drug Administration
208883|NCT02586831|Drug|Interleukin 2|Concomitant Drug Administration
208884|NCT02586831|Drug|Etanercept|Concomitant Drug Administration
208885|NCT02586831|Drug|Exenatide|Concomitant Drug Administration
208886|NCT02586818|Procedure|SOC fingerstick|sample collection
208887|NCT02586818|Procedure|Venous blood draw|sample collection
208888|NCT02586805|Drug|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
208889|NCT02586805|Drug|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
208890|NCT02586805|Drug|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
208891|NCT02586805|Drug|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
208892|NCT02586792|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
208893|NCT02586779|Other|whatsApp|whatsApp application will be used for consultations.
208894|NCT02586779|Other|without whatsApp|whatsApp application will be not used for consultations.
208895|NCT02586766|Behavioral|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
208896|NCT02586753|Other|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
208927|NCT02586493|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
208965|NCT02586298|Other|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
208897|NCT02586753|Other|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).~Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.~Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
208898|NCT02586740|Procedure|Pulmonary artery rehabilitation|
208899|NCT02586727|Drug|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
208900|NCT02586714|Other|No intervention|Observation only
208901|NCT02586701|Other|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
208902|NCT02586688|Device|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
208903|NCT02586688|Device|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
208904|NCT02586688|Device|Open Label Active NeuroStar® TMS|Open label NeuroStar® coil.
208905|NCT02586675|Drug|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
208906|NCT02586675|Drug|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
208907|NCT02586675|Drug|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
208908|NCT02586649|Drug|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
208909|NCT02586649|Drug|Placebo|Placebo is a non-active inhalation capsule .
208910|NCT02586636|Drug|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
208911|NCT02586636|Drug|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
208912|NCT02586636|Drug|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
208913|NCT02586623|Drug|Droxidopa capsules|100, 200 or 300 mg
208914|NCT02586623|Drug|Placebo capsules|
208915|NCT02586610|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Days 1, 22 and 43
208916|NCT02586610|Drug|Capecitabine|Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
208917|NCT02586610|Radiation|Radiation Therapy|Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
208918|NCT02586597|Device|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.~PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.~PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.~PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
208919|NCT02586571|Behavioral|Breastfeeding|Breastfeeding at 5.5 months of age (exclusive or partial)
208920|NCT02586558|Other|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
208921|NCT02586558|Other|Reference group|Ready-to-feed infant formula to be fed ad libitum
208922|NCT02586545|Other|Shared care|
208923|NCT02586519|Device|SurroSense Rx System|"The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur."
208924|NCT02586506|Drug|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
208925|NCT02586506|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
208926|NCT02586493|Drug|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
208964|NCT02586311|Drug|Amlodipine 5mg|Once a day, 8 weeks
208966|NCT02586298|Other|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
208928|NCT02586480|Device|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
208929|NCT02586467|Behavioral|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
208930|NCT02586467|Behavioral|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
208931|NCT02586467|Behavioral|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
208932|NCT02586467|Behavioral|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
208933|NCT02586467|Behavioral|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
208934|NCT02586454|Procedure|Transmuscular quadratus lumborum block|
208935|NCT02586454|Drug|morphine|
208936|NCT02586454|Drug|ropivacaine|
208937|NCT02586441|Device|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
208938|NCT02586441|Drug|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
208939|NCT02586441|Drug|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
208940|NCT02586428|Other|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
208941|NCT02586415|Procedure|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
208942|NCT02586415|Device|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
208943|NCT02586415|Device|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
208944|NCT02586415|Device|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:~• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System [026, 032, 041] Penumbra System Separator Flex [026, 032, 041, 054] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 & ACE68"
208945|NCT02586415|Device|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
208946|NCT02586402|Drug|pegol-Sihematide|
208947|NCT02586402|Drug|Epoetin Alfa|
208948|NCT02586376|Device|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
208949|NCT02586376|Device|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
208950|NCT02586376|Device|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
208951|NCT02586376|Device|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
208952|NCT02586363|Drug|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
208953|NCT02586363|Drug|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
208954|NCT02586363|Drug|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
208955|NCT02586350|Drug|Anlotinib|
208956|NCT02586350|Drug|Placebo|Placebo p.o. qd
208957|NCT02586337|Drug|Anlotinib|Anlotinib p.o. qd
208958|NCT02586337|Drug|Placebo|Placebo p.o. qd
208959|NCT02586324|Biological|global medium|
208960|NCT02586324|Biological|SSM|
208961|NCT02586311|Drug|CKD-330 16/5mg|Once a day, 8 weeks
208962|NCT02586311|Drug|Amlodipine 5mg Placebo|Once a day, 8 weeks
208963|NCT02586311|Drug|CKD-330 16/5mg Placebo|Once a day, 8 weeks
208974|NCT02586207|Drug|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
208975|NCT02586207|Drug|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
208976|NCT02586207|Radiation|Radiation|70 Gy fractionated over 35 days
208977|NCT02586194|Drug|ASP015K|Oral
208978|NCT02586181|Dietary Supplement|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate~Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12~1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
208979|NCT02586181|Dietary Supplement|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
208980|NCT02586168|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
208981|NCT02586168|Drug|Placebo|Placebo
208982|NCT02586155|Drug|RVX000222|100 mg capsule
208983|NCT02586155|Drug|Placebo (for RVX000222)|Capsule manufactured to mimic RVX000222 100 mg capsule
208984|NCT02586155|Drug|atorvastatin|High-Intensity Statin
208985|NCT02586155|Drug|rosuvastatin|High-Intensity Statin
208986|NCT02586142|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
208987|NCT02586142|Other|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
208988|NCT02586129|Drug|YH14755|20/1500mg, QD
208989|NCT02586129|Drug|Metformin|1500mg, QD
208990|NCT02586129|Drug|Rosuvastatin|20mg, QD
208991|NCT02586116|Device|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
208992|NCT02586116|Device|C-Plus|C-Plus PEEK IBF Device with autograft
208993|NCT02586103|Device|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
208994|NCT02586090|Behavioral|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
208995|NCT02586090|Behavioral|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
208996|NCT02586077|Drug|Exparel|
208997|NCT02586064|Behavioral|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
208998|NCT02586064|Behavioral|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
208999|NCT02586051|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
209000|NCT02586051|Drug|Intravenous Immunoglobulin|High dose (2 grams per kilogram [g/kg]) IVIG (maximum 140 grams).
209001|NCT02586038|Drug|MLN9708|
209002|NCT02586038|Drug|Dexamethasone|
209003|NCT02586038|Drug|Cyclophosphamide|
209004|NCT02586038|Drug|Thalidomide|
209005|NCT02586025|Drug|FEC Chemotherapy|Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
209006|NCT02586025|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
209007|NCT02586025|Drug|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
209008|NCT02586025|Drug|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
209009|NCT02586025|Drug|Placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
209010|NCT02586025|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
209011|NCT02586012|Drug|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: [(weight in kg x desired FVIII increase of 100 IU/dL)/(2)].
209012|NCT02585999|Device|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
209013|NCT02585986|Dietary Supplement|Probiotic|daily intake of 1 capsule probiotic
209014|NCT02585986|Dietary Supplement|Placebo|daily intake of 1 capsule containing placebo
209015|NCT02585973|Drug|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
209016|NCT02585973|Drug|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
209017|NCT02585973|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
209018|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
209019|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Standard treatment
209020|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Intensified treatment
209021|NCT02585947|Drug|Tenofovir|Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
209022|NCT02585934|Drug|RVT-101|once daily, oral, 35 mg tablets
209023|NCT02585934|Drug|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
209024|NCT02585921|Behavioral|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
209025|NCT02585921|Behavioral|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
209026|NCT02585908|Biological|CIK|CIK cells will be used against tumor cells.
209027|NCT02585908|Biological|γδ T|γδ T cells will be used against tumor cells.
209028|NCT02585908|Biological|CIK and γδ T|CIK and γδ T cells will be used against tumor cells.
209029|NCT02585895|Biological|Evolocumab|Administered by subcutaneous injection once every 2 weeks
209030|NCT02585895|Procedure|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
209031|NCT02585882|Other|Fluoride table salt|
209032|NCT02585869|Drug|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
209033|NCT02585869|Drug|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
209034|NCT02585869|Drug|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
209035|NCT02585869|Drug|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
209036|NCT02585869|Drug|Placebo|Blinded capsule and tablets, once daily, 84 days
209037|NCT02585856|Device|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
209038|NCT02585856|Device|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
209039|NCT02585843|Drug|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
209040|NCT02585843|Drug|Spironolactone 25mg|25mg/day of spironolactone
209041|NCT02585817|Device|Remote CIED Management|Information Technology
209042|NCT02585804|Drug|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
209043|NCT02585791|Other|Propylene Glycol|inhaled Propylene Glycol (PG) by vaporing
209044|NCT02585791|Other|vegetable glycerin|inhaled vegetable glycerin (VG) by vaporing
209045|NCT02585791|Other|PG+VG|inhaled PG+VG by vaporing
209046|NCT02585778|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
209047|NCT02585778|Drug|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
209048|NCT02585778|Drug|Lipid-Modifying Therapy (LMT)|Statins at stable, maximally tolerated dose with or without other LMT as clinically indicated.
209049|NCT02585778|Drug|Antihyperglycemic Drug|Insulin (injectable or inhaled) alone or with other antihyperglycemic drugs as clinically indicated.
209050|NCT02585765|Drug|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
209051|NCT02585765|Drug|Placebo|8 weeks of daily placebo capsules.
209052|NCT02585752|Device|Noninvasive ventilation|Expiratory pressure modulation
209053|NCT02585739|Genetic|blood sample|
209054|NCT02585726|Device|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins for subjects in the treatment arm..
209055|NCT02585713|Drug|Apixaban|Given PO
209056|NCT02585713|Drug|Dalteparin|Given SC
209057|NCT02585713|Other|Questionnaire Administration|Ancillary studies
209058|NCT02585700|Biological|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen`s eggs, and inactivated with beta-propiolactone.
209059|NCT02585700|Other|Placebo|0.5 mL of phosphate buffered saline
209060|NCT02585687|Device|liver Perfusion MRI|
209061|NCT02585674|Drug|Insulin glargine (U300)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
209062|NCT02585674|Device|MyStar DoseCoach|Glucose meter
209063|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
209064|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
209065|NCT02585648|Device|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
209066|NCT02585648|Device|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
209195|NCT02584738|Drug|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
209067|NCT02585622|Biological|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
209068|NCT02585622|Other|Placebo|Volume total of fluid infused: 40 ml
209069|NCT02585596|Drug|YH23537 1000mg/day|YH23537 500mg 2 tab
209070|NCT02585596|Drug|YH23537 2000mg/day|YH23537 500mg 4 tab
209071|NCT02585596|Drug|YH23537 3000mg/day|YH23537 500mg 6 tab
209072|NCT02585596|Drug|placebo|YH23537 500mg tab placebo
209073|NCT02585583|Radiation|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
209074|NCT02585570|Drug|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
209075|NCT02585557|Other|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
209076|NCT02585544|Procedure|day-care surgery|day-care surgery
209077|NCT02585531|Drug|Hypertonic Saline 3%|"The treatment will be administered in the following order :~First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
209078|NCT02585531|Drug|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :~First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
209079|NCT02585505|Procedure|stem cells|stem cell will be injected
209080|NCT02585492|Other|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
209081|NCT02585492|Other|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
209082|NCT02585479|Drug|Pirarubicin|"Pirarubicin 30mg/m2 intravenously~Pirarubicin17mg/m2 are infused through the right and left hepatic arteries"
209083|NCT02585479|Drug|Oxaliplatin|"Oxaliplatin 100 mg/m2 intravenously~Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries"
209084|NCT02585479|Drug|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
209085|NCT02585479|Device|Gelfoam|Hepatic artery embolization with Gelfoam.
209086|NCT02585453|Device|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
209087|NCT02585453|Device|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
209088|NCT02585453|Device|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
209089|NCT02585440|Drug|CMX157|Oral tablet
209090|NCT02585440|Drug|placebo|Oral tablet
209091|NCT02585427|Dietary Supplement|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
209092|NCT02585401|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
209093|NCT02585388|Drug|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
209094|NCT02585388|Drug|Letrozole|Lestrozole at 2,5 mg every day , per oral
209095|NCT02585388|Drug|Anastrozole|Anastrozole at 1 mg every day, per oral
209096|NCT02585375|Drug|Preservative-free latanoprost 50µg/ml|
209097|NCT02585375|Drug|Preserved latanoprost 0.005%|
209098|NCT02585362|Behavioral|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
209099|NCT02585362|Behavioral|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
209100|NCT02585362|Dietary Supplement|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
209101|NCT02585336|Behavioral|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
209102|NCT02585323|Behavioral|Education session, Fitbit/FitViz, PT counselling|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
209103|NCT02585323|Behavioral|Same intervention with a 3 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
209104|NCT02585310|Other|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
209105|NCT02585297|Other|no intervention|
209106|NCT02585271|Device|Transanal decompression tube|22 Fr transanal decompression tube
209107|NCT02585271|Device|Stent|self-expandable colorectal nitinol alloys stent
209108|NCT02585258|Drug|Prednisolone|capsules 5 mg / day
209109|NCT02585258|Other|Placebo|capsules 1 / day
209110|NCT02585232|Behavioral|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
209142|NCT02585037|Other|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
209143|NCT02585037|Other|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
209111|NCT02585232|Behavioral|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
209112|NCT02585206|Behavioral|Personalization|"Phase I Factor~Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
209113|NCT02585206|Behavioral|Integration|"Phase I Factor~Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:~Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community~Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
209114|NCT02585206|Behavioral|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
209115|NCT02585206|Behavioral|Message Intensity|"Phase I Factor~Varying levels of text message intensity over a 12-week period."
209116|NCT02585206|Behavioral|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
209117|NCT02585193|Behavioral|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
209118|NCT02585180|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
209119|NCT02585180|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
209120|NCT02585167|Procedure|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
209121|NCT02585167|Device|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
209122|NCT02585154|Procedure|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
209123|NCT02585154|Procedure|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
209124|NCT02585154|Procedure|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
209125|NCT02585154|Device|STN-LFP and EEG recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
209126|NCT02585141|Device|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
209127|NCT02585141|Procedure|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
209128|NCT02585141|Drug|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
209129|NCT02585128|Other|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
209130|NCT02585128|Other|MMSE (Mini Mental State Examination)|
209131|NCT02585128|Other|Barthel index|
209132|NCT02585128|Other|HADS (Hospital Anxiety and Depression Scale)|
209133|NCT02585128|Other|MNA-SF (Mini Nutritional Assessment - Short Form)|
209134|NCT02585128|Device|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
209135|NCT02585128|Other|CIRS (Cumulative Illness Rating Scale)|
209136|NCT02585102|Other|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
209137|NCT02585102|Other|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
209138|NCT02585089|Other|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).~Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
209139|NCT02585089|Other|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
209140|NCT02585076|Other|Standard of care|As prescribed by treated physician
209141|NCT02585037|Other|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
209144|NCT02585024|Drug|Cytisine|
209148|NCT02584998|Other|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
209149|NCT02584998|Other|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
209150|NCT02584985|Procedure|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
209151|NCT02584985|Procedure|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
209152|NCT02584972|Other|no intervention required|no intervention required
209153|NCT02584959|Drug|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor [Human] Liquid administered Subcutaneously as specified on specified days
209154|NCT02584959|Drug|Placebo|Placebo
209155|NCT02584946|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
209156|NCT02584933|Drug|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
209157|NCT02584920|Drug|HLX01|
209158|NCT02584920|Drug|Rituximab|
209159|NCT02584907|Other|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
209160|NCT02584894|Device|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
209161|NCT02584894|Device|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
209162|NCT02584894|Behavioral|psychoneurological assessment|psychoneurological assessment
209163|NCT02584894|Device|conductivity meter|electrodermal conductance measure
209164|NCT02584894|Device|electrocardiogram|heart rate measure
209165|NCT02584881|Other|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
209166|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
209167|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
209168|NCT02584855|Drug|Ixekizumab|Administered SC
209169|NCT02584855|Drug|Placebo|Administered SC
209170|NCT02584829|Drug|Avelumab|Given IV
209171|NCT02584829|Other|Laboratory Biomarker Analysis|Correlative studies
209172|NCT02584829|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
209173|NCT02584829|Radiation|Radiation Therapy|Undergo radiation therapy
209174|NCT02584829|Biological|Recombinant Interferon Beta|Given via intra-tumor injection
209175|NCT02584816|Biological|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
209176|NCT02584816|Biological|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
209177|NCT02584816|Biological|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
209178|NCT02584816|Biological|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
209179|NCT02584803|Radiation|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.~Patient Acceptability of procedure~Patient Comfort:~Ease of exam for the examiner"
209180|NCT02584790|Device|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
209181|NCT02584777|Biological|Pacritinib|QD (Once a day)
209182|NCT02584764|Behavioral|Cognitive behavior therapy|
209183|NCT02584764|Behavioral|Internet support|
209184|NCT02584751|Drug|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
209185|NCT02584751|Device|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
209186|NCT02584751|Procedure|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
209187|NCT02584751|Procedure|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
209188|NCT02584751|Procedure|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
209189|NCT02584751|Procedure|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
209190|NCT02584751|Procedure|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
209191|NCT02584738|Drug|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
209192|NCT02584738|Drug|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.~will be continued with nebulized standard treatment every hour for 4 hours."
209193|NCT02584738|Drug|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
209194|NCT02584738|Drug|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
211012|NCT02572219|Dietary Supplement|Placebo|
209196|NCT02584725|Drug|Tranexamic Acid|Comparison of 3 different doses of the drug
209197|NCT02584712|Other|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
209198|NCT02584699|Radiation|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
209199|NCT02584686|Drug|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
209200|NCT02584686|Drug|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
209201|NCT02584673|Device|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
209202|NCT02584660|Drug|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
209203|NCT02584660|Drug|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
209204|NCT02584647|Drug|PLX3397|PLX3397 is a small molecule that potently and selectively inhibits macrophage colony-stimulating factor receptor (FMS), Kit, and FMS-like tyrosine kinase 3 (Flt3)‐internal tandem duplication (ITD) kinases, which regulate key components of the tumor microenvironment and oncogenic variants of these kinases that drive certain tumors.
209205|NCT02584647|Drug|Sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.~Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
209206|NCT02584634|Drug|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
209207|NCT02584634|Drug|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
209208|NCT02584634|Drug|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
209209|NCT02584621|Behavioral|Check Yourself App with Feedback|
209210|NCT02584608|Drug|ACTIMMUNE|
209211|NCT02584595|Device|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
209212|NCT02584582|Drug|Liraglutide|
209213|NCT02584582|Drug|Exenatide|
209214|NCT02584582|Procedure|Liquid meal test|
209215|NCT02584582|Other|No drug (Baseline day)|
209216|NCT02584569|Drug|TAK-915|TAK-915 oral suspension
209217|NCT02584556|Drug|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
209218|NCT02584556|Drug|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
209219|NCT02584543|Biological|HEV vaccine|
209220|NCT02584543|Biological|HBV vaccine|
209221|NCT02584530|Procedure|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
209222|NCT02584504|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
209223|NCT02584504|Drug|Placebo|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.
209224|NCT02584504|Drug|Atorvastatin|Atorvastatin 5 mg tablet orally.
209225|NCT02584504|Drug|Non-statin Lipid-Modifying Therapy|Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.
209226|NCT02584504|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
209227|NCT02584491|Behavioral|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
209228|NCT02584478|Drug|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
209229|NCT02584478|Drug|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
209230|NCT02584478|Drug|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
209231|NCT02584465|Drug|Tamoxifen|Tamoxifen: 40 mg/day
209232|NCT02584465|Drug|Regorafenib|Stivarga; 120mg/day
209233|NCT02584452|Drug|Mepivacaine|20cc of 2% mepivacaine <20 minutes prior to in room time.
209234|NCT02584452|Procedure|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
209235|NCT02584452|Drug|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
209236|NCT02584452|Procedure|adductor canal nerve block|ultrasound guided adductor canal nerve block
209237|NCT02584452|Drug|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
209238|NCT02584452|Drug|Propofol|Anesthesia induction will include a propofol bolus.
209239|NCT02584452|Drug|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
209240|NCT02584439|Drug|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
209241|NCT02584439|Drug|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
209242|NCT02584426|Device|Ultrasonic Distribution of Cefazolin|
209243|NCT02584413|Device|Magnetic resonance imaging|-Standard of care
209244|NCT02584413|Drug|Gadolinium contrast|-Standard of care
209245|NCT02584400|Drug|Injection with the hypoxia tracer [18F]HX4,|The [18F]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) [18F]HX4 via a bolus IV injection.
209246|NCT02584387|Behavioral|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
209247|NCT02584374|Other|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
209248|NCT02584361|Procedure|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
209249|NCT02584361|Procedure|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
209250|NCT02584348|Device|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
209251|NCT02584335|Drug|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
209252|NCT02584335|Drug|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.~The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).~Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
209253|NCT02584322|Other|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
209254|NCT02584309|Drug|Dexrazoxane|
209255|NCT02584309|Drug|Doxorubicin|
209256|NCT02584296|Behavioral|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, ~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
209257|NCT02584283|Procedure|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
209258|NCT02584283|Device|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
209259|NCT02584283|Procedure|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
209260|NCT02584283|Drug|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
209261|NCT02584270|Device|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis improves speech and swallowing function through reshaping the palatal contours in order to obtain contact of the tongue to the hard palate during function. It is intended to be fabricated after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.
209262|NCT02584270|Other|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
209263|NCT02584257|Other|methacholine chloride|
209264|NCT02584257|Drug|placebo ProAir HFA|
209265|NCT02584257|Drug|ProAir HFA|
209266|NCT02584257|Drug|Lupin albuterol HFA MDI|
209267|NCT02584257|Drug|placebo Lupin albuterol HFA MDI|
209268|NCT02584244|Drug|LUM015|
209269|NCT02584244|Device|LUM 2.6 Imaging Device|
209270|NCT02584231|Drug|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: >6 months and < 2years: 60µg; ≥2 years and <4 years: 120µg PO and ≥4 years and <8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
209271|NCT02584218|Procedure|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
209272|NCT02584218|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
209273|NCT02584205|Device|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
209274|NCT02584192|Behavioral|entailing an early home-based CR program|enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
209275|NCT02584192|Other|enter the usual care program|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
209276|NCT02584179|Device|Biparametric MRI before biopsy|All included men with suspicious lesions on bpMRI will have bpMRI targeted biopsies in addition to standard TRUS-bx.
209277|NCT02584166|Behavioral|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
209278|NCT02584153|Drug|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
209279|NCT02584153|Drug|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
209280|NCT02584140|Behavioral|Text Messaging|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
209281|NCT02584140|Behavioral|Adherence Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of <1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of <1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
209282|NCT02584140|Drug|Daily Oral PrEP|All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.
209283|NCT02584127|Behavioral|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
209284|NCT02584127|Behavioral|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
209285|NCT02584114|Behavioral|Peak app for memory training|
209286|NCT02584114|Behavioral|Non-memory training group|
209287|NCT02584101|Behavioral|ACT|ACT therapy administered in 3 sessions over a 4 week period
209288|NCT02584101|Behavioral|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
209289|NCT02584088|Other|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
209290|NCT02584075|Drug|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
209291|NCT02584075|Drug|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
209292|NCT02584062|Procedure|no-touch fluid-air exchange|
209293|NCT02584062|Procedure|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
209294|NCT02584049|Other|Osteopathy|3 sessions of osteopathy during 60 minutes each
209295|NCT02584049|Other|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
209296|NCT02584036|Biological|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
209297|NCT02584036|Behavioral|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
209298|NCT02584036|Behavioral|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
209299|NCT02584023|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
209300|NCT02584010|Other|Silicon-based aerosol|Apply twice a day over the postoperative scar
209301|NCT02584010|Other|Silicon-based gel|Apply twice a day over the postoperative scar
209302|NCT02583997|Procedure|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
209303|NCT02583997|Procedure|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
209304|NCT02583984|Procedure|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
209305|NCT02583984|Procedure|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
209306|NCT02583958|Device|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
209307|NCT02583958|Device|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
209308|NCT02583945|Procedure|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
209309|NCT02583932|Drug|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
209310|NCT02583932|Behavioral|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
209311|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
209312|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
209313|NCT02583919|Drug|Placebo|once weekly dosing for 26 weeks
209314|NCT02583906|Device|CPAP|Treatment with CPAP for six months in the CPAP arm.
209315|NCT02583893|Drug|Sirolimus|Given PO
209316|NCT02583893|Drug|Mitoxantrone|Given IV
209317|NCT02583893|Drug|Etoposide|Given IV
209318|NCT02583893|Drug|Cytarabine|Given IV
209319|NCT02583867|Behavioral|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
209320|NCT02583854|Device|RY-STOP hemostasis device|
209321|NCT02583854|Device|TR-Band, Terumo|
209322|NCT02583841|Procedure|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
209323|NCT02583828|Drug|Cyclophosphamide 50mg|
209324|NCT02583828|Drug|Letrozole 2.5 mg|
209325|NCT02583802|Drug|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
209326|NCT02583802|Drug|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
209327|NCT02583789|Drug|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
209328|NCT02583789|Drug|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
209329|NCT02583776|Device|Unblinded - CGM|Data from device will be readable and alarms on
209330|NCT02583776|Device|Blinded - CGM|Data from device will be blinded and alarms off
209331|NCT02583763|Other|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
209332|NCT02583763|Procedure|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
209333|NCT02583750|Behavioral|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
209334|NCT02583750|Behavioral|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
209335|NCT02583737|Procedure|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
209336|NCT02583737|Procedure|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
209337|NCT02583711|Device|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
209338|NCT02583698|Drug|Carvedilol|
209339|NCT02583698|Drug|Placebo|
209340|NCT02583685|Drug|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
209341|NCT02583685|Drug|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
209342|NCT02583685|Drug|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
209343|NCT02583685|Drug|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
209344|NCT02583685|Drug|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
209387|NCT02583386|Behavioral|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
209345|NCT02583685|Drug|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
209346|NCT02583685|Drug|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
209347|NCT02583685|Drug|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
209348|NCT02583672|Drug|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
209349|NCT02583633|Drug|Transdermal nitroglycerin|
209350|NCT02583633|Drug|nifedipine|
209351|NCT02583620|Genetic|blood sample|A blood test is realized on the subject
209352|NCT02583607|Device|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.~woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
209353|NCT02583594|Drug|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
209354|NCT02583594|Drug|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
209355|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
209356|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
209357|NCT02583594|Drug|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
209358|NCT02583594|Drug|Loratadine|Pharmaceutical form:tablet Route of administration: oral
209359|NCT02583594|Drug|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
209360|NCT02583594|Drug|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
209361|NCT02583581|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
209362|NCT02583581|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
209363|NCT02583568|Drug|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
209364|NCT02583555|Behavioral|Interview followed by frequent telephone support|Interview followed by telephone support
209365|NCT02583542|Drug|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
209366|NCT02583542|Drug|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
209367|NCT02583529|Device|Back Tibial Nerve Electrostimulation|The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
209368|NCT02583529|Device|Placebo Electrostimulation|The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
209369|NCT02583516|Drug|vemurafenib and cobimetinib|Comparison between different treatment regimens
209370|NCT02583503|Radiation|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
209371|NCT02583490|Device|spectrum 5000Q ECT device (RUL ECT)|
209372|NCT02583490|Device|spectrum 5000Q ECT device (RUL LAP ECT)|
209373|NCT02583477|Drug|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
209374|NCT02583477|Drug|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
209375|NCT02583464|Drug|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
209376|NCT02583451|Drug|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
209377|NCT02583451|Drug|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
209378|NCT02583451|Drug|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
209379|NCT02583451|Drug|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
209380|NCT02583451|Drug|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
209381|NCT02583451|Drug|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
209382|NCT02583438|Drug|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
209383|NCT02583425|Drug|DFN-11 Injection|
209384|NCT02583412|Biological|Bexsero®|Multicomponent meningococcal B vaccine
209385|NCT02583412|Biological|Havrix®|Hepatitis A vaccine
209386|NCT02583399|Drug|Ibuprofen|Ibuprofen, 10 mg/kg
211013|NCT02572206|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
209388|NCT02583386|Device|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
209389|NCT02583373|Drug|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
209390|NCT02583373|Drug|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
209391|NCT02583373|Drug|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
209392|NCT02583360|Other|Slower Flow Rate|Use of nipple that has a slower flow rate than used prior to testing. No change in formula prescription
209393|NCT02583360|Other|Thickened Formula|Use of a predetermined amount of cereal to thicken formula. Use of nipple preferred by patient
209394|NCT02583347|Device|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
209395|NCT02583334|Device|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
209396|NCT02583334|Device|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
209397|NCT02583321|Device|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
209398|NCT02583321|Device|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
209399|NCT02583308|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
209400|NCT02583308|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
209401|NCT02583295|Behavioral|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
209402|NCT02583295|Behavioral|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
209403|NCT02583282|Other|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
209404|NCT02583282|Other|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
209405|NCT02583269|Diagnostic Test|Laboratory Biomarker Analysis|Correlative studies
209406|NCT02583269|Drug|Muscadine Grape Skin Extract|Given PO
209407|NCT02583269|Procedure|Quality-of-Life Assessment|Ancillary studies
209408|NCT02583256|Biological|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
209409|NCT02583256|Biological|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
209410|NCT02583243|Behavioral|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
209411|NCT02583243|Drug|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
209412|NCT02583230|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
209413|NCT02583217|Drug|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
209414|NCT02583217|Drug|remifentanyl|
209415|NCT02583217|Drug|propofol|
209416|NCT02583217|Device|laryngeal mask|
209417|NCT02583204|Device|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
209499|NCT02582697|Drug|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
209500|NCT02582697|Drug|Filgrastim|"Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10^9/L, of a 21-day cycle for 4 cycles.~Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10^9/L, of a 14-day cycle for 4 cycles."
209501|NCT02582684|Drug|Dolutegravir|Participants were prescribed 50 mg of DTG orally daily
209502|NCT02582684|Drug|Lamivudine|Participants were prescribed 300 mg of 3TC orally daily.
209418|NCT02583204|Other|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
209419|NCT02583191|Drug|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
209420|NCT02583191|Drug|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.~Enoxaparin 1 mg/kg BW twice daily~Tinzaparin 175 I.E./kg BW once daily~Dalteparin 200 I.E./kg BW once daily"
209421|NCT02583178|Device|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
209422|NCT02583165|Biological|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
209423|NCT02583139|Behavioral|Designed Music Narratives|"Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.~The narrative and music reflect and support each other."
209424|NCT02583126|Behavioral|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
209425|NCT02583113|Device|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
209426|NCT02583100|Behavioral|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
209427|NCT02583100|Behavioral|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
209428|NCT02583087|Procedure|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
209429|NCT02583074|Procedure|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
209430|NCT02583074|Procedure|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
209431|NCT02583061|Other|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
209432|NCT02583048|Drug|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 22 weeks, for all study arms involving the use of this drug.
209433|NCT02583048|Drug|Delamanid|Delamanid will be administered with food as two 50 mg tablets (100 mg) by mouth twice a day for 24 weeks, for all study arms involving the use of this drug.
209434|NCT02583048|Drug|Dolutegravir|For HIV-positive participants only: dolutegravir will be administered at a dose of one 50 mg tablet once daily, to be used in combination with two NRTIs until study completion. (NRTIs will not be provided by the study.)
209435|NCT02583035|Other|Nurse telephone contact|Nurse will contact patient 3 days before consultation
209436|NCT02583022|Drug|PAC-14028 cream 1.0%|Topical application
209437|NCT02583022|Drug|PAC-14028 cream vehicle|Topical application
209438|NCT02583022|Drug|Elidel cream 1%|Topical application
209439|NCT02583009|Drug|PAC-14028 cream 0.1%|Topical application
209440|NCT02583009|Drug|PAC-14028 cream 0.3%|Topical application
209441|NCT02583009|Drug|PAC-14028 cream 1.0%|Topical application
209442|NCT02583009|Drug|PAC-14028 cream vehicle|Topical application
209443|NCT02582996|Drug|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
209444|NCT02582996|Drug|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
209445|NCT02582983|Drug|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
209446|NCT02582970|Drug|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
209447|NCT02582970|Drug|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
209448|NCT02582970|Drug|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
209449|NCT02582970|Drug|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
209450|NCT02582957|Other|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
209451|NCT02582944|Device|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
209452|NCT02582944|Device|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
209453|NCT02582944|Device|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
209454|NCT02582944|Procedure|Biopsy|
209455|NCT02582931|Device|MRI-guided SBRT|
209456|NCT02582931|Behavioral|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
209457|NCT02582931|Behavioral|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
209503|NCT02582671|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
209504|NCT02582671|Drug|Dasabuvir|Tablet
209505|NCT02582671|Drug|Ribavirin|Tablet
209458|NCT02582918|Behavioral|Outreach with patient education and patient navigation services|"Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~If results are normal, the patient is invited to repeat screening in 6 months.~If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~If CT/MRI is unremarkable, the patient is referred back for routine screening.~If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
209459|NCT02582905|Drug|Placebo|Inactive ingredient matching the active comparators in appearance.
209460|NCT02582905|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
209461|NCT02582905|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
209462|NCT02582892|Drug|Vit D|20 mg/day
209463|NCT02582866|Drug|Lacosamide|"Pharmaceutical Form: Oral tablets~Concentration: 50 mg~Route of Administration: Oral administration"
209464|NCT02582853|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
209465|NCT02582853|Procedure|Blood Sample|Blood sample
209466|NCT02582840|Drug|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
209467|NCT02582840|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
209468|NCT02582840|Drug|Placebo tablet|Placebo tablet. Oral dose
209469|NCT02582827|Drug|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
209470|NCT02582814|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
209471|NCT02582814|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
209472|NCT02582801|Drug|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
209473|NCT02582788|Other|Bathing Additive|
209474|NCT02582775|Drug|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
209475|NCT02582775|Drug|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
209476|NCT02582775|Drug|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
209477|NCT02582775|Radiation|Total Body Irradiation|See arm description for dosing.
209478|NCT02582775|Procedure|Bone marrow infusion|Bone marrow infusion on Day 0
209479|NCT02582775|Drug|Tacrolimus|Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors)
209480|NCT02582775|Drug|Mycophenolate Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
209481|NCT02582775|Biological|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
209482|NCT02582775|Drug|Busulfan|busulfan IV over 3 hours on days -3 and -2 for HLA-mismatched BM recipients only (Arms F and G)
209483|NCT02582762|Drug|Nail gel|apply nail gel on affected nails twice daily for 2 months
209484|NCT02582749|Drug|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
209485|NCT02582749|Drug|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
209486|NCT02582749|Radiation|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
209487|NCT02582736|Drug|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
209488|NCT02582736|Drug|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
209489|NCT02582736|Drug|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
209490|NCT02582736|Drug|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
209491|NCT02582723|Other|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
209492|NCT02582723|Other|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
209493|NCT02582723|Other|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
209494|NCT02582710|Dietary Supplement|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
209495|NCT02582710|Dietary Supplement|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
209496|NCT02582697|Drug|Bleomycin (active name: Bleomycin Sulfate)|"Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.~Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses."
209497|NCT02582697|Drug|Etoposide|"Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
209498|NCT02582697|Drug|Cisplatin|"Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.~Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
209563|NCT02582177|Drug|Baycuten N®|Apply on the affected area and around it twice a day
209506|NCT02582645|Procedure|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
209507|NCT02582645|Procedure|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
209508|NCT02582632|Drug|ombitasvir/paritaprevir/ritonavir|Tablet
209509|NCT02582632|Drug|dasabuvir|Tablet
209510|NCT02582619|Other|Focus groups, semistructured interviews and Delphi rounds|
209511|NCT02582606|Other|Regular meal pattern|a 14-day period of eating 6 meal per day
209512|NCT02582606|Other|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
209513|NCT02582593|Device|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
209514|NCT02582593|Device|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
209515|NCT02582580|Other|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
209516|NCT02582580|Device|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
209517|NCT02582580|Other|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
209518|NCT02582567|Other|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
209519|NCT02582554|Behavioral|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
209520|NCT02582541|Procedure|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
209521|NCT02582541|Procedure|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
209522|NCT02582528|Behavioral|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
209523|NCT02582528|Behavioral|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
209524|NCT02582515|Drug|D-cycloserine|
209525|NCT02582515|Drug|Placebo|
209526|NCT02582502|Other|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
209527|NCT02582489|Biological|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
209528|NCT02582489|Procedure|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
209564|NCT02582177|Drug|Canesten®|Apply on the affected area and around it twice a day
209529|NCT02582476|Drug|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
209530|NCT02582476|Drug|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
209531|NCT02582450|Other|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
209532|NCT02582437|Other|History for opioid use|
209533|NCT02582424|Other|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
209534|NCT02582424|Other|placebo|placebo
209535|NCT02582411|Device|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
209536|NCT02582411|Device|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.~calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
209537|NCT02582398|Other|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
209538|NCT02582398|Other|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
209539|NCT02582385|Other|in-situ cytokine expression|
209540|NCT02582372|Drug|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
209541|NCT02582372|Drug|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
209542|NCT02582359|Drug|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
209543|NCT02582359|Drug|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
209544|NCT02582359|Drug|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
209545|NCT02582346|Procedure|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
209546|NCT02582333|Other|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
209547|NCT02582320|Drug|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
209548|NCT02582307|Drug|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
209549|NCT02582307|Drug|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
209550|NCT02582294|Other|Questionnaire|
209551|NCT02582281|Device|intrauterine device TCu 380A|
209552|NCT02582268|Device|intrauterine device TCu 380A|
209553|NCT02582268|Radiation|Trans-abdominal sonography|
209554|NCT02582255|Biological|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.~One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
209555|NCT02582242|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
209556|NCT02582229|Device|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
209557|NCT02582216|Device|3D augmented reality|
209558|NCT02582203|Drug|Ceftaroline|
209559|NCT02582203|Drug|Vancomycin|
209560|NCT02582190|Drug|Colchicine group|antiarrhythmic therapy plus colchicine & antiarrhythmic therapy alone.
209561|NCT02582177|Drug|Candicort®|Apply on the affected area and around it twice a day
209562|NCT02582177|Drug|Nizoral®|Apply on the affected area and around it twice a day
209565|NCT02582164|Device|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
209566|NCT02582151|Device|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
209567|NCT02582138|Other|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .~The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:~a daily total energy intake of 25-30 kcal/kg body weight;~an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.~The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
209568|NCT02582138|Other|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
209569|NCT02582125|Drug|ONO-4538|
209570|NCT02582112|Other|Active Comparator: Warming group|Placebo Comparator: Control group
209571|NCT02582099|Drug|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
209572|NCT02582099|Drug|Normal saline nasal irrigation|Nasal wash with normal saline solution
209573|NCT02582086|Other|BOR15001L7|Active cream with 5% 15019L0
209574|NCT02582086|Other|Placebo|Placebo Cream with 0% 15019L0
209575|NCT02582073|Biological|Placebo (0.5ml)|
209576|NCT02582073|Biological|Placebo (1.0ml)|
209577|NCT02582073|Biological|Grass MATA MPL (0.5ml) 5100SU|
209578|NCT02582073|Biological|Grass MATA MPL (1.0ml) 10200SU|
209579|NCT02582073|Biological|Grass MATA MPL (1.0ml) 18200SU|
209580|NCT02582073|Biological|Grass MATA (0.5ml) 5100SU|
209581|NCT02582060|Other|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
209582|NCT02582047|Biological|Influenza vaccination with PPV23|GCflu and Pneumovax-23
209583|NCT02582047|Biological|Influenza vaccination with PCV13|GCflu and Prevenar-13
209584|NCT02582034|Radiation|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).~Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:~An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy~A dose at the treated healthy liver < 120 Gy in case of lobar treatment~Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve > 30%~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
209585|NCT02582034|Radiation|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:~An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)~A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
209586|NCT02582021|Procedure|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).~The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
209587|NCT02582021|Procedure|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
209588|NCT02582021|Procedure|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.~Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
209589|NCT02582021|Procedure|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
209590|NCT02582021|Procedure|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
209591|NCT02582021|Procedure|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.~Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
209592|NCT02582021|Procedure|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
209593|NCT02582008|Drug|Bupropion Hydrochloride|Given PO
209594|NCT02582008|Other|Laboratory Biomarker Analysis|Correlative studies
209595|NCT02582008|Drug|Nicotine Replacement|Given NRT
209596|NCT02582008|Other|Quality-of-Life Assessment|Ancillary studies
209597|NCT02582008|Other|Questionnaire Administration|Ancillary studies
209598|NCT02582008|Drug|Varenicline|Given PO
209599|NCT02581995|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
209600|NCT02581982|Other|Laboratory Biomarker Analysis|Correlative studies
209601|NCT02581982|Drug|Paclitaxel|Given IV
209602|NCT02581982|Biological|Pembrolizumab|Given IV
209603|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
209604|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
209605|NCT02581956|Behavioral|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
209606|NCT02581956|Behavioral|No walking exercise|no exercise
209607|NCT02581943|Drug|Carboplatin|Given IV
209608|NCT02581943|Other|Laboratory Biomarker Analysis|Correlative studies
209609|NCT02581943|Drug|Paclitaxel|Given IV
209610|NCT02581943|Biological|Pembrolizumab|Given IV
209611|NCT02581943|Other|Quality-of-Life Assessment|Ancillary studies
209612|NCT02581930|Drug|Ibrutinib|Given PO
209613|NCT02581930|Other|Laboratory Biomarker Analysis|Correlative studies
209614|NCT02581930|Other|Pharmacogenomic Study|Correlative studies
209615|NCT02581930|Other|Pharmacological Study|Correlative studies
209616|NCT02581917|Other|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
209617|NCT02581917|Other|Laboratory Biomarker Analysis|Undergo metabolic analysis
209618|NCT02581904|Device|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
209619|NCT02581904|Device|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
209620|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
209621|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
209622|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.5 MBq and increase in steps of 1.5 MBq, with a antibody-chelator conjugate dose of 2 or 10 mg.
209623|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection: Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. The dose for this expansion part of the study will be selected on the basis of all available information from the dose-escalation part and will not necessarily be the MTD.
209624|NCT02581865|Drug|NBI-98854|
209625|NCT02581865|Drug|Placebo|
209626|NCT02581852|Other|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
209627|NCT02581839|Drug|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
209628|NCT02581839|Device|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
209629|NCT02581839|Drug|Pre-Medication: Zofran|Zofran at 8mg orally. Given at the discretion of the treating physician
209630|NCT02581839|Drug|Pre-Medication: Decadron|decadron at 8mg orally. Given at the discretion of the treating physician
209631|NCT02581826|Drug|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
209632|NCT02581826|Drug|Placebo|No column specified.
209633|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
209634|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
209635|NCT02581800|Other|App group|
209636|NCT02581787|Biological|Fresolimumab|Given IV
209637|NCT02581787|Other|Pharmacological Study|Correlative studies
209638|NCT02581787|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
209639|NCT02581774|Other|normal delivery tracking|normal delivery tracking
209640|NCT02581761|Drug|CYTOTEC|synthetic prostaglandin E1
209641|NCT02581761|Other|Placebo|no active material
209642|NCT02581748|Drug|HLX02|
209643|NCT02581748|Drug|Herceptin|
209644|NCT02581735|Other|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
209645|NCT02581722|Device|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
209686|NCT02581423|Drug|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
209646|NCT02581709|Behavioral|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
209647|NCT02581696|Drug|Lafutidine|Lafutidine 10mg, 1 tablet, bid
209648|NCT02581696|Drug|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
209649|NCT02581683|Drug|Magnesium Sulfate|Given via adductor canal block
209650|NCT02581683|Drug|Ropivacaine|Given via adductor canal block
209651|NCT02581683|Other|Sham|Sham adductor canal block
209652|NCT02581670|Radiation|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
209653|NCT02581657|Drug|PE0139 Injection|PE0139 Injection
209654|NCT02581657|Drug|Placebo Injection|Placebo Injection
209655|NCT02581631|Biological|Nivolumab|
209656|NCT02581631|Drug|Brentuximab Vedotin|
209657|NCT02581618|Other|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
209658|NCT02581605|Device|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
209659|NCT02581592|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
209660|NCT02581579|Dietary Supplement|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
209661|NCT02581579|Other|Placebo|Placebo, 1 capsule per day during 14
209662|NCT02581566|Drug|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
209663|NCT02581566|Drug|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
209664|NCT02581566|Drug|Bupivacaine|Intrathecal Bupivacaine
209665|NCT02581553|Drug|lesinurad/allopurinol 200/300 FDC tablets|
209666|NCT02581553|Drug|lesinurad 200 mg|
209667|NCT02581553|Drug|allopurinol 300 mg|
209668|NCT02581553|Drug|lesinurad/allopurinol 200/200 FDC tablets|
209669|NCT02581553|Drug|allopurinol 200 mg|
209670|NCT02581527|Drug|Rifampicin|Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
209671|NCT02581527|Drug|Isoniazid|Isoniazid 75mg - all arms
209672|NCT02581527|Drug|Ethambutol|Ethambutol 275mg - all arms
209673|NCT02581527|Drug|Pyrazinamide|Pyrazinamide 400mg - all arms
209674|NCT02581514|Other|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
209675|NCT02581501|Drug|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
209676|NCT02581488|Biological|Santyl|
209677|NCT02581488|Other|Product containing silver|Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
209678|NCT02581475|Procedure|Extending withdrawal time in the proximal colon|
209679|NCT02581475|Procedure|Segmental examination twice of the proximal colon|
209680|NCT02581462|Drug|FLOT alone|"Pre-operative therapy:~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43"
209681|NCT02581462|Biological|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:~Herceptin 8/6 mg/kg, d1, d22, d43~Pertuzumab 840 mg, d1, d22, d43~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43~Surgery is recommended to be scheduled 4 weeks after d43.~Post-operative therapy (start 6 to 8 weeks after surgery):~Herceptin 8/6 mg/kg, d1, d22, d43~Pertuzumab 840 mg, d1, d22, d43~Docetaxel 50 mg/m², d1, d15, d29, d43~Oxaliplatin 85 mg/m², d1, d15, d29, d43~Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)~5-FU 2600 mg/m², d1, d15, d29, d43."
209682|NCT02581449|Dietary Supplement|omega-3|dietary supplement
209683|NCT02581449|Other|empty soft gelatin capsules|empty softgels of matched size, shape and color
209684|NCT02581436|Other|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
209685|NCT02581436|Other|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine >25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
209687|NCT02581410|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
209688|NCT02581397|Drug|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
209689|NCT02581397|Drug|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
209690|NCT02581397|Drug|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
209691|NCT02581384|Radiation|Stereotactic Body Radiotherapy (SBRT)|
209692|NCT02581371|Drug|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
209693|NCT02581371|Other|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
209694|NCT02581358|Other|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
209695|NCT02581345|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
209696|NCT02581345|Biological|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
209697|NCT02581332|Behavioral|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
209698|NCT02581319|Procedure|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
209699|NCT02581306|Other|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
209700|NCT02581293|Procedure|Group 1: Only visceral peritoneum will be closed|
209701|NCT02581293|Procedure|Group 2 : Only parietal peritoneum will be closed|
209702|NCT02581293|Procedure|Group 3 : Both of them will be closed|
209703|NCT02581293|Procedure|Group 4: None of them will be closed|
209704|NCT02581280|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
209705|NCT02581254|Device|Thin Wire Snare|
209706|NCT02581254|Device|Thick Wire Snare|
209707|NCT02581241|Device|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.~Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
209708|NCT02581228|Device|ML-PrediCare|
209709|NCT02581215|Drug|mFOLFIRINOX|"mFOLFIRINOX:~Oxaliplatin 85 mg/m2 over 2-4 hours~Irinotecan 165 mg/m2 over 90 minutes~5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
209710|NCT02581215|Drug|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
209711|NCT02581215|Other|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
209712|NCT02581202|Drug|lopinavir/ritonavir|tablet
209713|NCT02581202|Drug|lamivudine|tablet
209714|NCT02581189|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
209715|NCT02581189|Drug|Dasabuvir|Tablet
209716|NCT02581189|Drug|Ribavirin|Tablet
209717|NCT02581176|Drug|Apixaban|
209718|NCT02581163|Drug|Ombitasvir/paritaprevir/ritonavir|Co-formulated tablet
209719|NCT02581163|Drug|Dasabuvir|Tablet
209720|NCT02581163|Drug|Ribavirin|Tablet
209721|NCT02581150|Procedure|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
209722|NCT02581137|Other|Laboratory Biomarker Analysis|Correlative studies
209723|NCT02581137|Drug|Metformin Hydrochloride|Given PO
209724|NCT02581124|Drug|JTZ-951|
209725|NCT02581124|Drug|Lapatinib|
209726|NCT02581111|Drug|Naloxone|Naloxone 8-mg IV bolus
209727|NCT02581111|Drug|Normal saline|
209728|NCT02581098|Other|No interventions|No interventions
209729|NCT02581085|Drug|Tocotrienol (TCT)|TCT is a natural vitamin E supplement with a long history of safe dietary consumption in humans. The objective of the current trial is to validate the outcome observed in an earlier trial that oral TCT attenuates the rise in MELD score over time in patients with end stage liver disease/cirrhosis.
209730|NCT02581085|Other|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
209731|NCT02581072|Drug|SB204 4%|Applied topically once
209732|NCT02581072|Drug|SB204 8% or 12%|Applied once topically
209733|NCT02581072|Drug|Vehicle|Applied topically once
209734|NCT02581059|Drug|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
209735|NCT02581059|Dietary Supplement|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
209770|NCT02580734|Dietary Supplement|melatonin|Cross-over randomized clinical trials
211217|NCT02570581|Other|Jelly with Levothyroxine sodium salt|
209736|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
209737|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
209738|NCT02581046|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
209739|NCT02581033|Drug|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
209740|NCT02581007|Drug|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
209741|NCT02581007|Drug|Melphalan|
209742|NCT02581007|Drug|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
209743|NCT02581007|Procedure|peripheral blood stem cell transplant|
209744|NCT02580994|Drug|Pembrolizumab|IV infusion at the dose of 200 mg on day 1 every 3 weeks
209745|NCT02580994|Drug|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
209746|NCT02580981|Other|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
209747|NCT02580968|Device|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
209748|NCT02580968|Drug|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
209749|NCT02580955|Device|LEGFLOW DCB|
209750|NCT02580942|Device|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
209751|NCT02580942|Device|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
209752|NCT02580942|Drug|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
209753|NCT02580929|Radiation|radiotherapy|radiotherapy before surgery
209754|NCT02580916|Other|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires [Appendices C & D) at:~baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
209755|NCT02580903|Radiation|Radiology|Only a small subsample will require CT and right heart catherisation
209756|NCT02580890|Device|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
209757|NCT02580890|Device|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
209758|NCT02580877|Drug|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
209759|NCT02580877|Drug|500mg oral insulin crystals every other week|human insulin crystals in capsules
209760|NCT02580851|Other|diagnostic test - cardiac magnetic resonance imaging|
209761|NCT02580851|Other|diagnostic test - coronary angiography|
209762|NCT02580838|Drug|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
209763|NCT02580825|Behavioral|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
209764|NCT02580825|Behavioral|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
209765|NCT02580812|Other|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
209766|NCT02580786|Behavioral|Breastfeeding peer support|
209767|NCT02580773|Drug|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
209768|NCT02580773|Drug|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
209769|NCT02580747|Biological|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
209771|NCT02580721|Device|Dentsply Astra Tech Implant System EV|Dentsply Astra Tech Implant System EV will be placed
209772|NCT02580708|Drug|Rociletinib|
209773|NCT02580708|Drug|Trametinib|
209774|NCT02580695|Biological|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
209775|NCT02580695|Drug|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
209776|NCT02580682|Drug|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
209777|NCT02580682|Drug|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
209778|NCT02580682|Drug|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
209779|NCT02580669|Other|Neuropsychological assessment|A neuropsychological assessment is done
209780|NCT02580669|Other|Neurologic consultation|A neurologic consultation is done
209781|NCT02580669|Other|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
209782|NCT02580656|Behavioral|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
209783|NCT02580643|Biological|APS|intra-articular injection
209784|NCT02580630|Behavioral|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
209785|NCT02580630|Other|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
209786|NCT02580630|Drug|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
209787|NCT02580630|Drug|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
209788|NCT02580617|Biological|ALLO-ASC|Infusion for Crohn's disease
209789|NCT02580604|Drug|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
209790|NCT02580604|Drug|Placebo|Saline Infusion
209791|NCT02580591|Drug|Empagliflozin|
209792|NCT02580591|Drug|Placebo|For blinding purposes
209793|NCT02580578|Other|No Intervention|No intervention is administered in this study.
209794|NCT02580565|Other|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
209795|NCT02580552|Drug|Cobomarsen|
209796|NCT02580539|Biological|Group A|Peptide-stimulated T cells 2 x 10^7/m^2
209797|NCT02580539|Biological|Group B|Peptide-stimulated T cells per dose-escalation protocol
209798|NCT02580526|Procedure|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
209799|NCT02580526|Procedure|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.~When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
209800|NCT02580513|Behavioral|Circadian Misalignment|
209801|NCT02580500|Procedure|epidural catheter|epidural anaesthesia application for spinal catheter will be used
209802|NCT02580500|Procedure|spinal catheter|spinal anesthesia application for spinal catheter will be used
209803|NCT02580487|Procedure|appendicectomy|Appendix was removed either laparoscopically or open surgery
209804|NCT02580474|Drug|Daclatasvir plus Asunaprevir|
209805|NCT02580461|Behavioral|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
209806|NCT02580448|Drug|Seviteronel|Seviteronel given daily with evening meal in 28 day cycles
209807|NCT02580409|Behavioral|Exercise Intervention|Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.
209808|NCT02580396|Device|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
209809|NCT02580383|Procedure|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
209810|NCT02580370|Biological|Botulinum toxin type A|Topical botulinum toxin type A
209811|NCT02580370|Biological|Placebo comparator|Topical placebo comparator
209812|NCT02580357|Procedure|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
209813|NCT02580357|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
209814|NCT02580344|Drug|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
209815|NCT02580331|Drug|SRP and placebo|Placement of placebo gel into classII furcation defects after scaling and root planing
209816|NCT02580331|Drug|SRP and 1% metformin|Placement of 1% metformin gel into classII furcation defects after scaling and root planing
209817|NCT02580318|Device|breathalyzer|
209818|NCT02580305|Drug|SUVN-502|
209819|NCT02580305|Drug|Placebo|
209820|NCT02580279|Drug|EGCG|
209821|NCT02580279|Drug|placebo|
209822|NCT02580253|Drug|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
209823|NCT02580253|Drug|mFOLFOX6|Oxaliplatin,Fluorouracil
209824|NCT02580240|Drug|Hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
209825|NCT02580240|Drug|saline|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
209826|NCT02580227|Drug|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
209827|NCT02580227|Other|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
209828|NCT02580214|Dietary Supplement|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
209829|NCT02580201|Biological|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.~The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
209830|NCT02580188|Drug|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium as continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
209831|NCT02580175|Procedure|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
209832|NCT02580175|Procedure|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
209833|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
209834|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
209835|NCT02580162|Behavioral|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
209836|NCT02580149|Drug|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day~1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
209837|NCT02580149|Drug|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
209838|NCT02580123|Behavioral|Intervention taught by trained educators|
209839|NCT02580110|Other|Sucrose|
209840|NCT02580110|Other|Stevia glycosides|
209841|NCT02580110|Other|saccharin|
209842|NCT02580097|Other|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
209870|NCT02579889|Device|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
209982|NCT02579187|Radiation|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
209843|NCT02580084|Procedure|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
209844|NCT02580084|Procedure|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
209845|NCT02580071|Dietary Supplement|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)~patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
209846|NCT02580058|Biological|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
209847|NCT02580058|Drug|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
209848|NCT02580032|Other|No treatment given|No treatment given.
209849|NCT02580019|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
209850|NCT02580006|Drug|EPORON|single dose administration subcutaneously
209851|NCT02580006|Drug|EPREX|single dose administration subcutaneously
209852|NCT02579993|Procedure|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
209853|NCT02579993|Procedure|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
209854|NCT02579980|Procedure|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
209855|NCT02579980|Procedure|Surgery|Standard of care procedure for sarcoma patients
209856|NCT02579967|Drug|Immunosuppression Only Conditioning - Closed with amendment L|Pentostatin 4 mg/m2 /day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
209857|NCT02579967|Drug|Reduced Intensity Conditioning|pentostatin 4 mg/m(2)/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
209858|NCT02579967|Drug|Myeloablative Conditioning-Closed with amendment L|Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
209859|NCT02579967|Drug|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +180, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
209860|NCT02579967|Procedure|Allo BMT|Allogeneic blood or marrow transplantation
209861|NCT02579954|Behavioral|Rehabilitation|
209862|NCT02579941|Procedure|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
209863|NCT02579941|Procedure|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
209864|NCT02579928|Drug|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
209865|NCT02579928|Drug|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
209866|NCT02579915|Behavioral|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
209867|NCT02579915|Behavioral|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
209868|NCT02579902|Dietary Supplement|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
209869|NCT02579902|Dietary Supplement|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
210028|NCT02578888|Other|Palliative Therapy + idiographic|Ancillary studies
209871|NCT02579889|Device|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
209872|NCT02579876|Drug|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
209873|NCT02579876|Drug|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
209874|NCT02579863|Biological|Pembrolizumab|IV infusion
209875|NCT02579863|Drug|Lenalidomide|oral capsules
209876|NCT02579863|Drug|Dexamethasone|oral tablets
209877|NCT02579850|Drug|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
209878|NCT02579850|Drug|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
209879|NCT02579850|Procedure|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
209880|NCT02579850|Other|COPD assessment test|COPD assessment test (CAT) at visit 1
209881|NCT02579850|Procedure|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
209882|NCT02579850|Other|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
209883|NCT02579850|Other|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
209884|NCT02579837|Device|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
209885|NCT02579837|Device|Zeiss Cirrus|optical coherence tomographer (OCT)
209886|NCT02579824|Drug|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
209887|NCT02579811|Drug|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
209888|NCT02579798|Device|PEEP (positive end-expiratory pressure)|
209889|NCT02579785|Behavioral|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
209890|NCT02579772|Drug|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
209891|NCT02579772|Drug|Placebo|Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
209892|NCT02579759|Drug|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
209893|NCT02579759|Drug|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
209894|NCT02579759|Drug|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
209895|NCT02579746|Behavioral|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
209896|NCT02579746|Behavioral|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
209897|NCT02579733|Drug|Azathioprine|
209898|NCT02579733|Drug|Placebo|
209899|NCT02579707|Drug|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
209900|NCT02579694|Device|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
209901|NCT02579681|Drug|dimethyl fumarate|dimethyl fumarate administered as per the arm description
209902|NCT02579668|Other|Language Therapy|
209903|NCT02579655|Behavioral|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
209904|NCT02579655|Behavioral|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
209905|NCT02579642|Drug|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
209906|NCT02579642|Drug|Placebo|Normal saline administered with usual induction drugs for ECT
209907|NCT02579629|Drug|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
209908|NCT02579629|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
209949|NCT02579343|Drug|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
210029|NCT02578862|Drug|Propofol|
210030|NCT02578862|Drug|Sevoflurane|
209909|NCT02579629|Drug|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
209910|NCT02579629|Device|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
209911|NCT02579616|Drug|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
209912|NCT02579603|Drug|Nintedanib|Nintedanib 150mg bid
209913|NCT02579603|Drug|Pirfenidone|
209914|NCT02579590|Drug|Depot Medroxyprogesterone Acetate 150 mg|"the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month"
209915|NCT02579590|Drug|Implanon( 68 mg etonogestrel implant)|where they are using etonogestrel 68 mg implant (Implanon; Organon)
209916|NCT02579590|Drug|Cerazette pills (75 micrograms desogestrel)|where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
209917|NCT02579577|Other|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
209918|NCT02579577|Other|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
209919|NCT02579577|Other|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
209920|NCT02579564|Drug|Gemcitabine|
209921|NCT02579564|Drug|Vinorelbine|
209922|NCT02579564|Drug|Paclitaxel|
209923|NCT02579564|Drug|Pemetrexed|
209924|NCT02579564|Drug|Oncorine|
209925|NCT02579564|Drug|Endostar|
209926|NCT02579564|Drug|Cisplatin|
209927|NCT02579551|Procedure|Therapeutic Conventional Surgery|Undergo surgical excision
209928|NCT02579525|Other|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
209929|NCT02579525|Other|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
209930|NCT02579512|Other|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
209931|NCT02579499|Drug|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
209932|NCT02579499|Drug|targeted LDL-C goal statin|"Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)~Patients already received statin therapy~Baseline LDL-C <70mg: same intensity of statin therapy~Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C < 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C < 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)"
209933|NCT02579473|Drug|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
209934|NCT02579460|Other|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications. Endoscopy with biopsies will be performed in all patients on day 0, 7, and 14.
209935|NCT02579434|Drug|Midazolam I.V.|Midazolam I.V. 1mg/ml
209936|NCT02579421|Drug|Progesterone|generic progesterone
209937|NCT02579421|Drug|placebo|placebo
209938|NCT02579395|Behavioral|Collaborative implementation Intentions|With spouse/romantic partner
209939|NCT02579395|Behavioral|Individual implementation Intentions|Without spouse/romantic partner
209940|NCT02579395|Behavioral|Control|
209941|NCT02579382|Drug|TDF|300 mg tablets administered orally once daily
209942|NCT02579382|Drug|Vesatolimod|Tablets administered orally once a week (every 7 days) for 12 doses
209943|NCT02579382|Drug|Placebo|Placebo administered orally once a week (every 7 days) for 12 doses
209944|NCT02579369|Other|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
209945|NCT02579369|Device|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
209946|NCT02579356|Drug|Telmisartan|
209947|NCT02579356|Drug|Atorvastatin|
209948|NCT02579343|Device|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
211218|NCT02570581|Other|Jelly with Memantine|
209950|NCT02579330|Device|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
209951|NCT02579330|Other|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
209952|NCT02579317|Behavioral|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
209953|NCT02579317|Behavioral|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
209954|NCT02579304|Procedure|transbronchial lung cryobiopsy|bronchoscopic sampling
209955|NCT02579291|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
209956|NCT02579291|Other|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
209957|NCT02579278|Other|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
209958|NCT02579278|Other|Blood sample (mrEMVI negative patient)|
209959|NCT02579265|Drug|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal lipid dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the lipid dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Investigational or control drug will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~The lipid emulsions will be infused into a central or peripheral vein."
209960|NCT02579265|Drug|Intralipid® 20%|"Dose: The targeted maximal lipid dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the lipid dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Investigational or control drug will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~The lipid emulsions will be infused into a central or peripheral vein."
209961|NCT02579252|Biological|AADvac1|
209962|NCT02579252|Drug|Placebo|
209963|NCT02579239|Biological|ATYR1940|Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
209964|NCT02579239|Biological|Placebo|Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
209965|NCT02579226|Drug|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
209966|NCT02579213|Other|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
209967|NCT02579200|Device|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual ~50% Pimax values.
209968|NCT02579200|Device|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
209969|NCT02579187|Procedure|tooth extraction|The study tooth will be removed
209970|NCT02579187|Radiation|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
209971|NCT02579187|Drug|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
209972|NCT02579187|Other|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
209973|NCT02579187|Drug|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
209974|NCT02579187|Drug|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
209975|NCT02579187|Procedure|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
209976|NCT02579187|Drug|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
209977|NCT02579187|Drug|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
209978|NCT02579187|Procedure|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
209979|NCT02579187|Other|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
209980|NCT02579187|Procedure|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 & 4 weeks post extraction
209981|NCT02579187|Procedure|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
210097|NCT02578407|Other|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
209983|NCT02579187|Other|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
209984|NCT02579174|Device|Medacta GMK Sphere|
209985|NCT02579161|Drug|cephalosporins|Looking at the same drugs and doses the variable is the timeframe of the medication
209986|NCT02579161|Drug|aminoglycoside|
209987|NCT02579161|Drug|metronidazole|
209988|NCT02579161|Drug|Clindamycin|
209989|NCT02579161|Drug|aminoglycoside/ sulbactam|If allergies to above medicines
209990|NCT02579161|Drug|Fluoroquinolones|
209991|NCT02579148|Biological|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.`
209992|NCT02579148|Biological|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.`
209993|NCT02579135|Behavioral|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
209994|NCT02579135|Behavioral|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
209995|NCT02579109|Other|memory test|
209996|NCT02579096|Drug|Allopurinol|Patients will be titrated up to the dose that will lower to target uric acid levels.
209997|NCT02579096|Drug|Febuxostat|Febuxostat will be titrated up to the dose that will lower to target uric acid levels.
209998|NCT02579096|Drug|Placebo, vehicle control (Febuxostat-shaped)|Placebo in the shape of Febuxostat will be given with Allopurinol
209999|NCT02579096|Drug|Placebo, vehicle control (Allopurinol-shaped)|Placebo in the shape of Allopurinol will be given with Febuxostat
210000|NCT02579083|Drug|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
210001|NCT02579083|Drug|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
210002|NCT02579070|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
210003|NCT02579057|Drug|Furosemide Injection Solution (SCP-101)|
210004|NCT02579057|Drug|Furosemide Injection Solution, USP|
210005|NCT02579044|Drug|Everolimus and lonafarnib|
210006|NCT02579031|Device|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
210007|NCT02579031|Device|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
210008|NCT02579018|Behavioral|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
210009|NCT02579005|Biological|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
210010|NCT02579005|Biological|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
210011|NCT02578992|Procedure|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
210012|NCT02578992|Device|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
210013|NCT02578979|Device|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
210014|NCT02578979|Device|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
210015|NCT02578966|Behavioral|Motivational Interview|
210016|NCT02578966|Other|Traditional health education|
210017|NCT02578953|Drug|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
210018|NCT02578953|Drug|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
210019|NCT02578940|Drug|18F-Fluciclovine PET CT|Radioligand for PET CT scanning
210020|NCT02578927|Dietary Supplement|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
210021|NCT02578927|Dietary Supplement|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
210022|NCT02578927|Dietary Supplement|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
210023|NCT02578914|Drug|NS2 Ophthalmic Drops (0.5%)|
210024|NCT02578914|Drug|NS2 Ophthalmic Drops Vehicle (0.0%)|
210025|NCT02578901|Drug|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
210026|NCT02578901|Drug|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
210027|NCT02578888|Other|Palliative Therapy|Palliative Therapy
210031|NCT02578849|Drug|L-DOPA|Patients and healthy controls are recruited to participate in [11C]yohimbine scans before and after L-DOPA challenge.
210032|NCT02578836|Procedure|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
210033|NCT02578823|Device|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
210034|NCT02578823|Device|Arcticgel™|
210035|NCT02578823|Procedure|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
210036|NCT02578797|Drug|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
210037|NCT02578784|Device|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
210038|NCT02578784|Device|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
210039|NCT02578771|Drug|ZuraPrep with 70% IPA|Apply topically
210040|NCT02578771|Drug|ZuraPrep without 70% IPA|Apply topically. 0% IPA
210041|NCT02578771|Drug|ChloraPrep CHG/IPA Teal Tint|Apply topically
210042|NCT02578771|Other|Normal Saline|Apply topically
210043|NCT02578758|Behavioral|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
210044|NCT02578758|Behavioral|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
210045|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
210046|NCT02578745|Device|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
210047|NCT02578745|Other|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
210048|NCT02578732|Drug|FOLFOXA|"Schema:~1 cycle = 14 days **It will not be considered a deviation if a cycle or pre-cycle assessment must be adjusted to accommodate scheduling or holidays. Adjustment must be documented with reason to BrUOG**~Abraxane ®: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)~It is at the discretion of the treating physician to give Neulasta, 6 mg sq x 1 post treatment~Antiemetics will be administered as per standard institutional policy."
210049|NCT02578719|Drug|bupivacaine|marcaine %0.5 20 ml flacon
210050|NCT02578719|Drug|saline|%0.9 sodium chloride
210051|NCT02578706|Drug|Clopidogrel|Clopidogrel 75mg
210052|NCT02578706|Drug|Aspirin|81 mg
210053|NCT02578706|Drug|Placebo|
210054|NCT02578680|Biological|Pembrolizumab 200 mg|IV infusion
210055|NCT02578680|Drug|Cisplatin|IV infusion
210056|NCT02578680|Drug|Carboplatin|IV infusion
210057|NCT02578680|Drug|Pemetrexed|IV infusion
210058|NCT02578680|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
210059|NCT02578680|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
210060|NCT02578680|Drug|Dexamethasone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
210061|NCT02578680|Drug|Saline solution|IV infusion
210148|NCT02578017|Behavioral|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
210062|NCT02578667|Device|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
210063|NCT02578654|Other|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
210064|NCT02578641|Biological|autologous EBV specific Cytotoxic T cells|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
210065|NCT02578641|Drug|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
210066|NCT02578628|Other|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
210067|NCT02578615|Other|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
210068|NCT02578602|Drug|Gadoxetate Disodium|Given IV
210069|NCT02578602|Device|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
210070|NCT02578589|Procedure|Plica resection vs conservative treatment|Plica resection vs conservative treatment
210071|NCT02578550|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
210072|NCT02578550|Drug|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
210073|NCT02578550|Drug|Darunavir|A single tablet containing darunavir 800 mg will be administered.
210074|NCT02578550|Drug|Cobicistat|A single table containing cobistat 150 mg will be administered.
210075|NCT02578537|Drug|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
210076|NCT02578537|Drug|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
210077|NCT02578524|Other|Survey|
210078|NCT02578511|Drug|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
210079|NCT02578498|Dietary Supplement|High carbohydrate intake|Carbohydrate intake < 50 gram
210080|NCT02578498|Dietary Supplement|Low carbohydrate intake|Carbohydrate intake > 250 gram
210081|NCT02578485|Device|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
210082|NCT02578485|Device|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
210083|NCT02578485|Device|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
210084|NCT02578485|Device|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
210085|NCT02578485|Device|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
210086|NCT02578472|Drug|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
210087|NCT02578472|Drug|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
210088|NCT02578472|Drug|Placebo|Matching Placebo will be administered orally.
210089|NCT02578459|Device|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
210090|NCT02578459|Other|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
210091|NCT02578446|Device|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
210092|NCT02578446|Device|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
210093|NCT02578433|Behavioral|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
210094|NCT02578433|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
210095|NCT02578420|Other|open-label placebo|"Placebo Cream, openly described as Placebo"
210096|NCT02578420|Other|deceptive placebo|"Placebo Cream, described as Voltaren, containing Diclofenac"
210149|NCT02578004|Other|biochemical and molecular analysis|
210098|NCT02578394|Drug|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
210099|NCT02578394|Drug|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
210100|NCT02578381|Device|Boston Scientific Pressure Wire|St Jude Medical Pressure Wire
210101|NCT02578381|Device|Validation of Boston Scientific pressure wire|
210102|NCT02578368|Drug|5-Fluorouracil|2600 mg/m², d1 i.v., every 2 weeks
210103|NCT02578368|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
210104|NCT02578368|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
210105|NCT02578368|Drug|Docetaxel|50mg/m², d1, i.v., every 2 weeks
210106|NCT02578368|Drug|Trastuzumab|4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
210107|NCT02578368|Drug|sodium folinate|can be used to replace leucovorin (calcium folinate)
210108|NCT02578368|Procedure|Surgery|Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
210109|NCT02578342|Device|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
210110|NCT02578329|Behavioral|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
210111|NCT02578329|Behavioral|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
210112|NCT02578316|Drug|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.~Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
210113|NCT02578303|Other|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
210114|NCT02578290|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.~This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.~Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
210115|NCT02578277|Drug|CYP and transporter probe substrates|Cocktail of CYP (cytochrome P450) and transporter probe substrates
210116|NCT02578277|Drug|BMS-955176|BMS-955176
210117|NCT02578277|Drug|BMS-955176 plus CYP and transporter probe substrates|BMS-955176 plus the cocktail of CYP and transporter probe substrates
210118|NCT02578251|Drug|Paracetamol|
210119|NCT02578251|Drug|Pethidine|
210120|NCT02578225|Other|Non interventional study|
210121|NCT02578212|Other|Placebo|
210122|NCT02578199|Behavioral|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
210123|NCT02578186|Drug|Diphenhydramine Hydrochloride|30 mL at bedtime
210124|NCT02578186|Drug|Placebo|30 mL at bedtime
210125|NCT02578173|Device|AVERT PLUS|
210126|NCT02578160|Procedure|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
210127|NCT02578147|Behavioral|Mighty Girls|
210128|NCT02578147|Behavioral|Game Girls|
210129|NCT02578134|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
210130|NCT02578134|Other|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
210131|NCT02578121|Drug|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
210132|NCT02578121|Drug|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
210133|NCT02578121|Drug|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
210134|NCT02578108|Procedure|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
210135|NCT02578108|Procedure|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
210136|NCT02578095|Drug|VK5211|Capsule
210137|NCT02578095|Drug|Placebo|Capsule
210138|NCT02578082|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
210139|NCT02578069|Device|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
210140|NCT02578069|Device|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
210141|NCT02578056|Device|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
210142|NCT02578056|Procedure|Genital prolapse surgery|Surgical correction of genital prolapse
210143|NCT02578043|Drug|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
210144|NCT02578043|Drug|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
210145|NCT02578043|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
210146|NCT02578030|Drug|SHP465 12.5mg|
210147|NCT02578030|Drug|SHP465 25mg|
210150|NCT02577991|Drug|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
210151|NCT02577991|Drug|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
210152|NCT02577978|Device|Medacta GMK posterior stabilized prosthesis|
210153|NCT02577978|Device|Medacta GMK Sphere prosthesis|
210154|NCT02577965|Procedure|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
210155|NCT02577965|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
210156|NCT02577939|Behavioral|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
210157|NCT02577926|Drug|Ruxolitinib|Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
210158|NCT02577926|Drug|BAT|BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
210159|NCT02577900|Device|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
210160|NCT02577900|Device|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
210161|NCT02577900|Device|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
210162|NCT02577887|Device|Patients implanted with a St. Jude Medical pacemakers|
210163|NCT02577861|Procedure|Biopsy from donor eye|Corneal biopsy from undamaged limbus
210164|NCT02577861|Procedure|Implant of Holoclar|Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus
210165|NCT02577861|Procedure|Ophtalmologic examination|"The following assessments are performed:~Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia."
210166|NCT02577861|Procedure|Blood sample collection|Standard haematology, biochemistry and Infectious profile (Virology) are assessed
210167|NCT02577861|Procedure|Digital pictures|At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera
210168|NCT02577861|Procedure|ECG|A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.
210169|NCT02577861|Behavioral|Questionnaires|Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)
210170|NCT02577861|Procedure|Physical examination and vital signs|A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
210171|NCT02577848|Drug|GLP-1|GLP-1 were taken daily for 7 days
210172|NCT02577848|Drug|Placebo|Placebo were taken daily for 7 days
210173|NCT02577835|Device|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
210174|NCT02577822|Device|Taperloc standard length stem|
210175|NCT02577822|Device|Taperloc short length stem|
210176|NCT02577809|Drug|Morphine100|100mcg added to the spinal anaesthetic
210177|NCT02577809|Drug|Morphine50|50mcg added to the spinal anaesthetic
210178|NCT02577809|Drug|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
210179|NCT02577809|Drug|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
210180|NCT02577809|Drug|Indomethacin|100mg Indomethacin suppository
210181|NCT02577783|Drug|PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
210182|NCT02577783|Drug|PAD regimen: bortizomib, dexamethasone and doxorubicin|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
210183|NCT02577770|Device|acupuncture|therapeutic acupuncture treatment with actual needles
210184|NCT02577770|Dietary Supplement|200mg caffeine|8g coffee, po
210185|NCT02577770|Dietary Supplement|400mg caffeine|16g coffee, po
210186|NCT02577770|Dietary Supplement|Decaffeinated|decaffeinated coffee, po
210187|NCT02577757|Device|MRI|MRI
210188|NCT02577744|Other|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
210189|NCT02577744|Other|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
210190|NCT02577731|Other|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
210191|NCT02577731|Other|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
210192|NCT02577731|Other|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
210193|NCT02577718|Drug|Nitroglycerin-citrate-ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
211219|NCT02570581|Other|Jelly with Zopiclone|
210194|NCT02577705|Behavioral|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
210195|NCT02577705|Behavioral|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
210196|NCT02577705|Behavioral|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
210197|NCT02577692|Other|Oxygen|breathing oxygen
210198|NCT02577692|Other|Ambient|breathing ambient air
210199|NCT02577666|Behavioral|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
210200|NCT02577666|Behavioral|Housing Only|receives 3 months of project supported rental assistance
210201|NCT02577666|Behavioral|Treatment as Usual|receives services as normally offered within the community
210202|NCT02577653|Other|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
210203|NCT02577640|Dietary Supplement|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
210204|NCT02577627|Device|PrediCare|
210205|NCT02577614|Drug|FEIBA|Administration of FEIBA after cardiopulmonary bypass
210206|NCT02577614|Drug|Normal Saline|Administration of placebo after cardiopulmonary bypass
210207|NCT02577601|Drug|Ulipristal Acetate|
210208|NCT02577601|Drug|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
210209|NCT02577588|Biological|re-activated T cells|autologous reactivated T cells against p53
210210|NCT02577575|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
210211|NCT02577575|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
210212|NCT02577562|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
210213|NCT02577549|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
210214|NCT02577549|Behavioral|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
210215|NCT02577536|Other|No Interventions|No Interventions will be conducted under this study.
210216|NCT02577523|Drug|ND0612 (Levodopa/Carbidopa solution)|
210217|NCT02577510|Drug|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament [7]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic [7]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
210218|NCT02577510|Drug|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle [6]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
210219|NCT02577497|Drug|beclomethasone|
210220|NCT02577497|Drug|fluticasone|
210221|NCT02577484|Device|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.~Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.~The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
210222|NCT02577484|Device|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
210223|NCT02577458|Drug|CM082|CM082 tablets taken orally once a day on 28-day cycles
210224|NCT02577458|Drug|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
210225|NCT02577432|Drug|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
210226|NCT02577432|Drug|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
210227|NCT02577432|Drug|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
210228|NCT02577432|Drug|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
210229|NCT02577419|Other|Target Fortification|
210230|NCT02577419|Other|Higher Initial Concentration|
210231|NCT02577419|Other|Portagen Formula|
210232|NCT02577406|Drug|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
210233|NCT02577406|Other|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
210234|NCT02577406|Drug|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
210235|NCT02577406|Drug|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
210236|NCT02577406|Drug|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
210237|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
210238|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Patients begin medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
210239|NCT02577393|Drug|mLDG|mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
210240|NCT02577380|Behavioral|IPV/GBV HTC|Participants will be interviewed after receiving their services.
210241|NCT02577367|Drug|Levothyroxine|Administer Levothyroxine
210242|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Subject Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a Subject-appropriate level and subjects instructed to deliver stimulation in two 30-minute sessions per day.
210243|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and subjects instructed to deliver stimulation in two 30-minute sessions per day.
210244|NCT02577341|Drug|Nimotuzumab|Patients received five cycles of weekly nimotuzumab (200mg, IV) in combined with chemoradiotherapy.
210245|NCT02577341|Drug|docetaxel and cisplatin|Patients received five cycles of weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
210246|NCT02577341|Radiation|daily RT (65Gy in 25 fractions) to the chest|Patients received daily RT (65Gy in 25 fractions) to the chest
210247|NCT02577341|Drug|placebo|
210248|NCT02577315|Drug|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
210249|NCT02577315|Drug|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
210250|NCT02577315|Drug|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
210251|NCT02577315|Drug|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
210252|NCT02577302|Device|CAN-Stim - StimGuard Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the StimGuard CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will continue therapy and followed for a total of 12 months.
210253|NCT02577302|Device|SNS - InterStim® System|"Subjects randomized to SNS will have their Stage I device implanted and tested during a 2-week period. Stage I will have a tined, quadripolar lead placed in the S3 (preferred) or S4 (alternate) foramen in the standard fashion using fluoroscopic guidance and motor response. Motor responses can include a contraction of the levators (bellows response) with or without plantar flexion of the great toe. Subjects who are not demonstrating an appropriate motor response will not have the device implanted and will be exited from the study.Therapy will be delivered for a minimum of 8 hours per day for 2 weeks. Subjects who are considered a responder at the 2-week follow-up, will receive a full implant and followed for a total of 12 months."
210254|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
210255|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
210256|NCT02577276|Device|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
210257|NCT02577263|Other|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
211220|NCT02570581|Other|Jelly with Alprazolam|
210258|NCT02577250|Drug|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
210259|NCT02577237|Behavioral|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
210260|NCT02577237|Behavioral|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
210261|NCT02577237|Other|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
210262|NCT02577237|Other|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
210263|NCT02577224|Other|Patient-initiated treatment|Please see Intervention Arm
210264|NCT02577211|Dietary Supplement|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
210265|NCT02577211|Dietary Supplement|Normocaloric enteral nutrition|25 kcal/kg of body weight
210266|NCT02577198|Other|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
210267|NCT02577185|Drug|Botulinum Toxin Type A|
210268|NCT02577185|Drug|Sodium chloride 9 mg/ml|
210269|NCT02577172|Behavioral|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
210270|NCT02577172|Behavioral|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
210271|NCT02577159|Drug|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
210272|NCT02577146|Device|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
210273|NCT02577133|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
210274|NCT02577133|Dietary Supplement|Placebo|The placebo consisted of an identical bottle with distilled water
210275|NCT02577120|Device|Epiceram Skin Barrier Function|Epiceram is a non-sterile, viscous, lipid-rich emulsion
210276|NCT02577120|Biological|Vaseline Petroleum Jelly|A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
210277|NCT02577120|Biological|Ceramiseal|Topical serum designed to fortify delicate skin with essential lipids. The proprietary blend of naturally occurring lipids contained in Ceramiseal are designed to improve the barrier function of your skin's outer layer; thereby restoring critical moisture balance and improving physical appearance and function.
210278|NCT02577107|Drug|ranibizumab|
210279|NCT02577107|Drug|Conbercept|
210280|NCT02577094|Drug|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
210281|NCT02577094|Drug|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
210282|NCT02577094|Biological|allogeneic stem cell transplantation.|At Day 0
210283|NCT02577094|Drug|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
210284|NCT02577094|Biological|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
210285|NCT02577081|Other|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
210286|NCT02577068|Drug|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
210287|NCT02577068|Drug|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
210288|NCT02577055|Procedure|Poly-myomectomy|Surgical ablation of all fibroids
210289|NCT02577055|Procedure|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of >500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
210290|NCT02577042|Drug|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
210291|NCT02577042|Drug|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
210292|NCT02577042|Drug|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
210463|NCT02575989|Other|1: control group|Classic - current management of trauma patients by French medical teams
210293|NCT02577029|Drug|ARC-520|ARC-520 will be administered intravenously concomitantly with 0.9% normal saline using an infusion rate of 0.4 mL/min (24 mL/hour) for study treatment and 200 mL/hr for saline.
210294|NCT02577029|Drug|entecavir|0.5 mg once daily; oral
210295|NCT02577029|Biological|pegylated interferon alpha 2a|180 mcg; subcutaneous injection once weekly
210296|NCT02577029|Drug|tenofovir disoproxil|300 mg once daily; oral
210297|NCT02577029|Drug|antihistamine|All participants will be pre-treated with an oral antihistamine selected by the investigator from the list of approved antihistamines that is available in that country. Acceptable antihistamines are: diphenhydramine 50 mg p.o., chlorpheniramine 8 mg p.o., hydroxyzine 50 mg p.o., or cetirizine 10 mg p.o.
210298|NCT02577016|Drug|Sitagliptin|50 mg tablet administered orally
210299|NCT02577016|Drug|Placebo|Placebo to sitagliptin administered orally
210300|NCT02577016|Drug|Ipragliflozin|50 mg tablet administered orally as background medication
210301|NCT02577003|Drug|Ipragliflozin|50 mg tablet administered orally
210302|NCT02577003|Drug|Placebo|Placebo to ipragliflozin tablet administered orally
210303|NCT02577003|Drug|Sitagliptin|Background medication; 50 mg tablet administered orally
210304|NCT02576990|Biological|Pembrolizumab|IV infusion
210305|NCT02576977|Biological|Pembrolizumab|pembrolizumab 200 mg IV infusion
210306|NCT02576977|Drug|Pomalidomide|pomalidomide 4 mg capsules
210307|NCT02576977|Drug|Dexamethasone|dexamethasone 40 mg tablets
210308|NCT02576964|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
210309|NCT02576964|Drug|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
210310|NCT02576951|Drug|Galcanezumab|Administered SC
210311|NCT02576951|Drug|Placebo|Administered SC
210312|NCT02576938|Drug|Baricitinib|Administered orally
210313|NCT02576938|Drug|Placebo|Administered orally
210314|NCT02576938|Drug|Triamcinolone (Optional)|Administered topically
210315|NCT02576925|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
210316|NCT02576912|Drug|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
210317|NCT02576912|Drug|Active Pregnenolone|A dose given sublingually.
210318|NCT02576912|Drug|Placebo|A placebo dose given sublingually.
210319|NCT02576912|Drug|Placebo|Placebo dose given intravenously.
210320|NCT02576899|Behavioral|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
210321|NCT02576899|Behavioral|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
210322|NCT02576886|Device|Gamma Camera|All images acquired with the General Electric Discovery 530c
210323|NCT02576886|Procedure|Prone Imaging|
210324|NCT02576873|Other|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
210325|NCT02576860|Drug|CLS001 (Omiganan)|Topical gel
210326|NCT02576860|Drug|Vehicle|Vehicle gel
210327|NCT02576847|Drug|Omiganan|Topical gel
210328|NCT02576834|Behavioral|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
210329|NCT02576834|Other|Services as Usual|Services as usually provided in the community
210330|NCT02576821|Other|Neurological examinations|
210331|NCT02576821|Other|Neuropsychological examinations|
210332|NCT02576821|Other|Clinical examinations|
210333|NCT02576821|Radiation|MRI 3T|
210334|NCT02576821|Radiation|MRI 7T|
210335|NCT02576808|Drug|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
210336|NCT02576808|Drug|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
210337|NCT02576795|Genetic|BMN 270|
210338|NCT02576782|Drug|Perineural Dexamethasone and bupivacaine|
210339|NCT02576782|Drug|Systemic Dexamethasone plus perineural bupivacaine|
210340|NCT02576782|Drug|intravenous saline plus perineural bupivacaine|
210341|NCT02576769|Other|No intervention|
210342|NCT02576743|Device|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
210343|NCT02576730|Procedure|ORIF|surgery for foot and ankle fractures
210344|NCT02576717|Drug|RPC1063|
210345|NCT02576704|Device|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
210346|NCT02576691|Device|percutaneous coronary intervention|
210347|NCT02576678|Drug|Apremilast|
210348|NCT02576665|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
210349|NCT02576665|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
210350|NCT02576652|Other|Tetracycline|Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.
210351|NCT02576652|Other|Demeclocycline|Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.
210352|NCT02576652|Procedure|Total Hip Replacement|Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.
210353|NCT02576639|Drug|CNP520|
210354|NCT02576639|Drug|Placebo|Matching placebo to CNP520 was supplied in capsules.
210355|NCT02576626|Drug|indacaterol/glycopyrronium 110/50 Breezhaler®|
210356|NCT02576626|Device|Placebo by Breezhaler®|
210357|NCT02576626|Drug|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
210358|NCT02576626|Device|Placebo by nebulisation|
210359|NCT02576613|Other|MPP-S|> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
210360|NCT02576613|Other|TAU|standard medical treatment without structured psychotherapeutic intervention
210361|NCT02576600|Device|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
210362|NCT02576600|Other|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
210363|NCT02576600|Drug|Propofol|TCI
210364|NCT02576600|Drug|Remifentanil|TCI
210365|NCT02576587|Other|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI >=15) will be place on CPAP therapy.
210366|NCT02576574|Drug|Avelumab|Subjects will be administered with avelumab at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
210367|NCT02576574|Drug|Pemetrexed|Pemetrexed 500 mg per square meter (mg/m^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
210368|NCT02576574|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
210369|NCT02576574|Drug|Gemcitabine|Gemcitabine 1250 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
210370|NCT02576574|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
210371|NCT02576574|Drug|Carboplatin|Carboplatin AUC 5 mg/mL*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
210372|NCT02576574|Drug|Cisplatin|Cisplatin 75 mg/m^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
210373|NCT02576574|Drug|Carboplatin|Carboplatin AUC 6 mg/mL*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
210374|NCT02576574|Drug|Avelumab|Subjects will be administered with avelumab at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (IV) infusion once a week for 12 weeks and then once every 2 weeks until disease progression or unacceptable toxicities.
210375|NCT02576561|Biological|TVGV-1|Antigen + Adjuvant
210376|NCT02576561|Biological|GPI-0100|Adjuvant Alone
210377|NCT02576561|Biological|Placebo|Placebo
210378|NCT02576548|Biological|MEDI4276|MEDI4276 is an investigational product
210379|NCT02576535|Procedure|Fractionated stereotactic radiosurgery|
210380|NCT02576535|Device|Leskell gamma unit|FDA approved device
210381|NCT02576522|Radiation|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
210382|NCT02576509|Drug|Nivolumab|
210383|NCT02576509|Drug|Sorafenib|
210384|NCT02576496|Drug|EDO-S101|
210385|NCT02576483|Behavioral|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
210386|NCT02576470|Behavioral|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
210387|NCT02576470|Device|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
210388|NCT02576470|Behavioral|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
210389|NCT02576470|Behavioral|targeted dysphagia training maneuver|training swallowing maneuvers or compensatory techniques (referred to as targeted dysphagia training throughout this document) that might reduce their swallowing pathophysiology
210390|NCT02576470|Radiation|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing swallowing kinematics during the pharyngeal swallow.
210391|NCT02576470|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
210392|NCT02576470|Device|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
210393|NCT02576457|Biological|BMS-936559|
210394|NCT02576457|Other|Placebo|
210395|NCT02576444|Drug|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
210396|NCT02576444|Drug|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
210397|NCT02576444|Drug|AZD1775|The recommended dose will be available no earlier than March 2016.
210398|NCT02576444|Drug|AZD6738|Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
210399|NCT02576431|Drug|BAY2757556 (Larotrectinib, Vitrakvi)|Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles.
210400|NCT02576418|Other|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
210401|NCT02576392|Behavioral|Intervention|Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
210402|NCT02576366|Drug|Voriconazole|
210403|NCT02576366|Drug|Rifampin|
210404|NCT02576353|Drug|Fentanyl|Fentanyl Sublingual Spray (FSS)
210405|NCT02576353|Drug|Fentanyl Citrate|Fentanyl Citrate IV (FCIV)
210406|NCT02576340|Drug|otilonium bromide|otilonium bromide was administered before the procedure
210407|NCT02576327|Drug|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
210408|NCT02576327|Drug|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
210409|NCT02576327|Drug|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
210410|NCT02576314|Drug|sofosbuvir and daclatasvir|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
210411|NCT02576314|Drug|ledipasvir/sofosbuvir|"Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;"
210412|NCT02576301|Drug|Phase 1 - OXi4503|Determination of MTD of OXi4503
210413|NCT02576301|Drug|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
210414|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
210415|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
210416|NCT02576288|Drug|Sitagliptin|anti-inflammatory properties
210417|NCT02576288|Drug|Placebo|No anti-inflammatory properties
210418|NCT02576275|Drug|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
210419|NCT02576275|Drug|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
210420|NCT02576275|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
210421|NCT02576275|Drug|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
210422|NCT02576262|Procedure|TCT，HPV，colposcopic inspection|
210423|NCT02576249|Drug|Ropivacaine|4cc 0.5% ropivacaine
210424|NCT02576249|Drug|Normal saline|4cc of sterile normal saline (0.9%)
210425|NCT02576249|Drug|Methylprednisolone|1cc 40mg methylprednisolone
210426|NCT02576236|Other|Quadruple concomitant therapy treatment|"Quadruple concomitant therapy treatment:~high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days"
210427|NCT02576236|Other|Triple therapy guided by the result of the molecular resistance test|"Triple therapy guided by the result of the molecular resistance test:~If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.~If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
210428|NCT02576223|Drug|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
210429|NCT02576223|Drug|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
210430|NCT02576197|Dietary Supplement|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
210431|NCT02576197|Dietary Supplement|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
210432|NCT02576184|Device|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
210433|NCT02576184|Device|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
210464|NCT02575989|Other|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia~Continuous monitoring of body temperature~Ambulance warming (target : 30°C)~Patient warming with dedicated blanket~Infusion fluid warming (and temperature control)"
210465|NCT02575976|Behavioral|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
210434|NCT02576171|Behavioral|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
210435|NCT02576158|Procedure|TCT，HPV，colposcopic inspection|
210436|NCT02576145|Biological|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show >=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
210437|NCT02576145|Drug|Daclizumab|The fifth dose (1 milligram per kilogram [mg/kg]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
210438|NCT02576145|Biological|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
210439|NCT02576119|Drug|BMS-955176, Placebo (Part 1)|The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
210440|NCT02576119|Drug|BMS-955176, Moxifloxacin, Placebo (Part 2)|Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
210441|NCT02576106|Device|Cryoablation|
210442|NCT02576093|Drug|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
210443|NCT02576093|Drug|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
210444|NCT02576093|Drug|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
210445|NCT02576093|Drug|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
210446|NCT02576080|Drug|Imatinib|
210447|NCT02576080|Other|Surveillance|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
210448|NCT02576067|Drug|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
210449|NCT02576067|Drug|Placebo|
210450|NCT02576054|Biological|V501|Quadrivalent HPV [Type 6, 11, 16 and 18] L1 VLP vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
210451|NCT02576041|Drug|Bilastine|Bilastine tablets once a day for 7+3 days
210452|NCT02576041|Drug|Placebo|Placebo tablets once a day during 7+3 days run in period
210453|NCT02576028|Other|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
210454|NCT02576028|Other|standard active exercises|two sessions of 45 minutes of active exercises
210455|NCT02576015|Procedure|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
210456|NCT02576015|Procedure|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
210457|NCT02576015|Drug|lidocaine|
210458|NCT02576015|Device|ultrasound|
210459|NCT02576015|Device|insulated needle (Contiplex B Braun, Melsungen, Germany)|
210460|NCT02576015|Drug|ropivacaine|
210461|NCT02576015|Drug|saline|
210462|NCT02576002|Drug|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
210466|NCT02575976|Other|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
210467|NCT02575976|Other|wait list control|No cardiac rehabilitation.
210468|NCT02575963|Drug|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
210469|NCT02575963|Biological|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
210470|NCT02575963|Drug|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
210471|NCT02575963|Drug|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
210472|NCT02575950|Drug|LEO43204|
210473|NCT02575950|Drug|Placebo|
210474|NCT02575937|Behavioral|low glycemic diet|nutrition education-based low glycemic diet intervention
210475|NCT02575924|Drug|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
210476|NCT02575924|Drug|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
210477|NCT02575911|Device|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
210478|NCT02575911|Procedure|LASIK surgery|
210479|NCT02575898|Other|First Session|Creative Practice and Positive Re-enforcement
210480|NCT02575898|Other|Second Session|Disease Related
210481|NCT02575898|Behavioral|Third through Sixth Sessions|Life Review and Legacy
210482|NCT02575885|Other|Electronic Cigarette|Receive different type of ENDS product at each visit
210483|NCT02575885|Other|Electronic Cigarette|Receive BLU e-cigarette ENDS product
210484|NCT02575885|Other|Laboratory Biomarker Analysis|Correlative studies
210485|NCT02575885|Other|Pharmacological Study|Correlative studies
210486|NCT02575885|Other|Questionnaire Administration|Ancillary studies
210487|NCT02575872|Behavioral|Exercise Intervention|Participate in physical activity behavioral intervention
210488|NCT02575859|Drug|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
210489|NCT02575859|Procedure|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
210490|NCT02575846|Dietary Supplement|Enteral Intake - Human Milk|Comparing formula and human milk
210491|NCT02575846|Dietary Supplement|Enteral Intake - Formula|Comparing formula and human milk
210492|NCT02575833|Drug|Erenumab|A single dose of erenumab 140 mg infused over approximately 60 minutes.
210493|NCT02575833|Drug|Placebo|A single dose of a matching volume of placebo infused over approximately 60 minutes.
210494|NCT02575820|Procedure|Old red blood cells transfusion|Red blood cells (shelf life > 14 days) transfusion during the operation (total hip replacement arthroplasty)
210495|NCT02575820|Procedure|New red blood cells transfusion|Red blood cells (shelf life =< 14 days) transfusion during the operation (total hip replacement arthroplasty)
210496|NCT02575807|Biological|CRS-207|via IV infusion
210497|NCT02575807|Drug|Epacadostat|PO BID
210498|NCT02575807|Biological|Pembrolizumab|via IV infusion
210499|NCT02575794|Drug|Terameprocol|Given PO
210500|NCT02575794|Other|Pharmacological Study|Correlative studies
210501|NCT02575781|Drug|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
210502|NCT02575768|Other|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
210503|NCT02575755|Drug|Azithromycin plus piperaquine phosphate|
210504|NCT02575755|Drug|Sulfadoxine-pyrimethamine|
210505|NCT02575742|Device|3D-Transit system|
210506|NCT02575729|Drug|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
210507|NCT02575716|Device|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
210508|NCT02575703|Drug|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi [¹⁴C]-LY3023414
210509|NCT02575690|Dietary Supplement|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
210510|NCT02575690|Other|Placebo|Individuals receive a placebo daily, for 3 months.
210511|NCT02575677|Other|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
210512|NCT02575664|Drug|Buprenorphine|Buprenorphine 5 microg/h/7 days
210513|NCT02575664|Drug|Placebo|Placebo patch
210514|NCT02575651|Drug|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
210515|NCT02575638|Drug|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
210516|NCT02575625|Device|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
210517|NCT02575625|Biological|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
210518|NCT02575625|Device|MRI|Liver MRI
210668|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
210519|NCT02575612|Procedure|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (> 50 ultrasound guided minimal invasive biopsies per year, > 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
210520|NCT02575599|Behavioral|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
210521|NCT02575586|Device|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.~1 session in soleus muscle moving the needle up and down ten times."
210522|NCT02575586|Device|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.~1 session in soleus muscle moving the needle up and down ten times."
210523|NCT02575573|Other|Factors influencing resuscitation decisions of patients|
210524|NCT02575573|Other|Factors leading to not asking patients about resuscitation preference|
210525|NCT02575560|Other|history data|history data of PFS after 1st line or second line theray
210526|NCT02575547|Drug|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.~CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\three cycles during radiation therapy(RT).~Dietary supplement: enteral nutrition and parenteral nutrition"
210527|NCT02575534|Drug|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
210528|NCT02575521|Drug|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
210529|NCT02575521|Drug|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
210530|NCT02575508|Drug|Fluorouracil|Given IV
210531|NCT02575508|Drug|Irinotecan Hydrochloride|Given IV
210532|NCT02575508|Other|Laboratory Biomarker Analysis|Correlative studies
210533|NCT02575508|Drug|Oxaliplatin|Given IV
210534|NCT02575508|Drug|pan FGFR Kinase Inhibitor BGJ398|Given IV
210535|NCT02575508|Other|Pharmacological Study|Correlative studies
210536|NCT02575495|Drug|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
210537|NCT02575495|Drug|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
210538|NCT02575482|Drug|SUVN-D4010|
210539|NCT02575482|Drug|Placebo|
210540|NCT02575456|Biological|Ebola Vaccine|
210541|NCT02575456|Biological|Placebo|control
210542|NCT02575443|Drug|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
210543|NCT02575443|Drug|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
210544|NCT02575430|Other|No treatment: retrospective chart review|
210545|NCT02575417|Behavioral|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
210546|NCT02575404|Drug|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
210547|NCT02575404|Drug|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
210548|NCT02575391|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
210549|NCT02575378|Drug|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
210550|NCT02575378|Drug|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
210551|NCT02575365|Drug|0,5 mg Fingolimod|0.5 mg p.o fingolimod daily
210552|NCT02575339|Drug|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
210553|NCT02575339|Drug|MLN0128 (RP2D)|"Phase II Arm A:~MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
210554|NCT02575339|Drug|Sorafenib|"Phase II Arm B:~Sorafenib administered at 400mg PO BID daily"
210555|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
210556|NCT02575326|Behavioral|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
210557|NCT02575313|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
210558|NCT02575300|Drug|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
210559|NCT02575287|Device|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
210560|NCT02575287|Device|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
210561|NCT02575287|Device|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
210562|NCT02575274|Procedure|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
210563|NCT02575261|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
210564|NCT02575248|Drug|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
210565|NCT02575248|Drug|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
210566|NCT02575235|Drug|CPC|Two study groups take cetylpyridinium chloride of 1.5mg and 4.5mg daily for four weeks.
210567|NCT02575235|Drug|placebo|Control group takes the placebo for the same period.
210568|NCT02575222|Drug|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
210569|NCT02575209|Other|GENDER|
210570|NCT02575196|Device|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
210571|NCT02575183|Drug|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
210572|NCT02575183|Drug|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
210573|NCT02575183|Behavioral|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
210574|NCT02575170|Drug|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
210575|NCT02575170|Drug|Ringer's lactate solution|200 ml of Ringer's lactate solution
210576|NCT02575157|Other|No intervention|No intervention
210577|NCT02575144|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
210578|NCT02575144|Drug|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min
210579|NCT02575144|Drug|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
210580|NCT02575131|Other|whole wheat bread yeast basis|
210581|NCT02575131|Other|Oatmeal|
210582|NCT02575131|Other|Cheerios|
210583|NCT02575131|Other|whole wheat sourdough bread|
210584|NCT02575131|Other|standard breakfast|
210585|NCT02575118|Device|Restoration of dental caries with dental composite|
210586|NCT02575092|Drug|Enalapril Maleate Tablets(as the program-based antihypertension)|
210587|NCT02575092|Drug|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
210588|NCT02575092|Drug|Placebo|
210589|NCT02575079|Device|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
210590|NCT02575066|Radiation|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy / 18 x 2 Gy
210591|NCT02575066|Drug|pazopanib|pazopanib QD 800 mg
210592|NCT02575053|Procedure|assessment of a new latex protocol|"All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.~Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.~Removal of all materials containing latex from the resuscitation carts.~Further requirements in case of latex allergic patients:~Identification of patients with (suspected) latex allergy.~All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.~All latex containing materials should be removed from the room and latex free alternatives should be available.~All staff present in the room should use latex free synthetic gloves.~Operating tables and supports should be made of latex free material or should be covered with blankets.~The entire OR staff is thoroughly educated concerning the latex safe protocol."
210593|NCT02575040|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
210594|NCT02575027|Radiation|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
210595|NCT02575027|Other|Questionnaire Administration|Ancillary studies
210596|NCT02575027|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
210597|NCT02575014|Drug|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
210749|NCT02574039|Dietary Supplement|Oat bran|66g oat bran made up in 350ml skimmed milk
210750|NCT02574039|Dietary Supplement|refined grain|refined grain product and 350ml skimmed milk
210598|NCT02575001|Behavioral|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:~Child Attachment Interview (CAI)~General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy~Parenting Stress Index with the 19-item Life Stress Scale (PSI)~Achenbach System of Empirically Based Assessment (CBCL, YSR)~Holmes and Rahe Social readjustment rating scale~Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)~Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
210599|NCT02575001|Genetic|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
210600|NCT02575001|Procedure|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
210601|NCT02575001|Procedure|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
210602|NCT02574975|Drug|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
210603|NCT02574975|Drug|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
210604|NCT02574975|Drug|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
210605|NCT02574975|Device|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
210606|NCT02574975|Drug|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
210607|NCT02574962|Drug|H.P. Acthar® Gel|
210608|NCT02574949|Radiation|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
210609|NCT02574949|Radiation|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
210610|NCT02574949|Radiation|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
210611|NCT02574936|Procedure|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.~A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
210612|NCT02574923|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
210613|NCT02574910|Drug|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
210614|NCT02574897|Other|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
210615|NCT02574897|Other|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
210616|NCT02574884|Procedure|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
210617|NCT02574871|Other|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
210618|NCT02574858|Drug|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
210619|NCT02574845|Drug|Rosuvastatin|
210620|NCT02574845|Drug|Metformin HCl|
210621|NCT02574845|Drug|Furosemide|
210622|NCT02574832|Drug|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
210623|NCT02574819|Drug|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
210624|NCT02574819|Drug|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
210625|NCT02574806|Procedure|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
210626|NCT02574793|Device|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
210627|NCT02574780|Other|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
210628|NCT02574780|Other|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
210629|NCT02574767|Behavioral|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet & Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
210630|NCT02574767|Dietary Supplement|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
210631|NCT02574767|Behavioral|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet & PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
210751|NCT02574026|Behavioral|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
211221|NCT02570581|Other|Jelly with Oxazepam|
210632|NCT02574767|Dietary Supplement|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
210633|NCT02574754|Drug|warfarin|warfarin 10 mg PO x 1
210634|NCT02574741|Behavioral|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
210635|NCT02574741|Drug|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
210636|NCT02574741|Drug|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
210637|NCT02574728|Drug|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
210638|NCT02574728|Drug|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
210639|NCT02574728|Drug|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
210640|NCT02574728|Drug|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
210641|NCT02574715|Drug|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
210642|NCT02574702|Procedure|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
210643|NCT02574689|Behavioral|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
210644|NCT02574689|Behavioral|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
210645|NCT02574676|Other|non-interventional|
210646|NCT02574663|Drug|TGR-1202|TGR-1202 oral daily dose
210647|NCT02574663|Drug|nab-paclitaxel + gemcitabine|IV infusion
210648|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
210649|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
210650|NCT02574650|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
210651|NCT02574637|Drug|MEDI2070 High dose|MEDI2070 intravenous (IV)infusion wks 0 & 4 plus placebo SC injection wks 0 & 4, and then subcutaneous (SC) dose of MEDI2070 every 4 wks through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
210652|NCT02574637|Drug|MEDI2070 High-Med dose|MEDI2070 intravenous (IV) infusion wk 0 plus placebo SC injection wk 0, and then subcutaneous (SC) dose of MEDI2070 wk 4 plus placebo IV infusion wk 4, and then subcutaneous (SC) dose of MEDI2070 every 4 wks from wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
210653|NCT02574637|Drug|MEDI2070 Low-Med dose|Subcutaneous (SC) low-med dose of MEDI2070 wk 0 & wk 4 plus placebo intravenous (IV) infusion wk 0 & wk 4, then subcutaneous (SC) low-med dose of MEDI2070 every 4 wks wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
210654|NCT02574637|Drug|MEDI2070 Low dose|Subcutaneous (SC) low dose of MEDI2070 Wk 0 & Wk 4 plus intravenous (IV) Placebo dose Wk 0 & Wk 4, then subcutaneous (SC) low dose of MEDI2070 every 4 wks wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
210655|NCT02574637|Drug|Placebo|Placebo SC and IV infusion wks 0 & 4 and then SC dose of placebo every 4 weeks wk 8 through wk 24. then SC dose of MEDI2070 once every 4 weeks during Open Label period.
210656|NCT02574624|Procedure|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
210657|NCT02574611|Drug|Neostigmine|
210658|NCT02574611|Drug|Glycopyrrolate|
210659|NCT02574611|Other|Saline (Placebo)|
210660|NCT02574611|Device|High Resolution Colonic Manometry|
210661|NCT02574598|Drug|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
210662|NCT02574598|Drug|Docetaxel|Use on both arms as standard of care.
210663|NCT02574585|Biological|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
210664|NCT02574572|Biological|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
210665|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
210666|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
210667|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
210669|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
210670|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
210671|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
210672|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
210673|NCT02574559|Behavioral|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
210674|NCT02574546|Procedure|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
210675|NCT02574533|Biological|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
210676|NCT02574533|Drug|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
210677|NCT02574520|Drug|SABER®-Bupivacaine|
210678|NCT02574520|Drug|Bupivacaine HCl|
210679|NCT02574507|Behavioral|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
210680|NCT02574481|Device|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
210681|NCT02574481|Device|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
210682|NCT02574468|Drug|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
210683|NCT02574468|Procedure|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
210684|NCT02574455|Drug|Sacituzumab govitecan|Sacituzumab govitecan (10 mg/kg on Days 1 and 8 of 21-day cycles)
210685|NCT02574455|Drug|Eribulin|Eribulin (1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle) See section 6.5.1
210686|NCT02574455|Drug|Capecitabine|Capecitabine (1000-1250 mg/m2 orally twice daily on Days 1-14 of a 21-day cycle) See section 6.5.2
210687|NCT02574455|Drug|Gemcitabine|Gemcitabine (800-1200 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle). See section 6.5.3
210688|NCT02574455|Drug|Vinorelbine|Vinorelbine (25 mg/m2 IV on Day 1 weekly). See section 6.5.4 (Note: eligible patients with Grade 2 neuropathy should not be prescribed vinorelbine as TPC).
210689|NCT02574442|Device|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
210690|NCT02574429|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions & 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
210691|NCT02574416|Other|There is no intervention|The study is observational and there is no intervention
210692|NCT02574403|Drug|eculizumab|eculizumab discontinuation
210693|NCT02574377|Drug|A: myDC vaccination|
210694|NCT02574377|Drug|B: pDC vaccination|
210695|NCT02574377|Drug|C: combined myDC/pDC vaccination|
210696|NCT02574364|Radiation|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
210697|NCT02574364|Other|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
210698|NCT02574351|Biological|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
210699|NCT02574338|Device|Foley's Catheter|intracervical extraamniotic Foley's catheter
210700|NCT02574338|Drug|prostaglandin E1 analogue|intravaginal misoprostol
210701|NCT02574325|Drug|Placebo|Control
210702|NCT02574325|Drug|ARI-3037MO|Treatment
210703|NCT02574312|Device|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
210704|NCT02574312|Device|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
210705|NCT02574299|Other|E-learning|Management of auditory processing disorders with serious game (E-learning)
210706|NCT02574299|Device|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
210707|NCT02574286|Drug|Velaglucerase alfa|Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.
210708|NCT02574286|Dietary Supplement|Vitamin D|Participants will receive 800 IU vitamin D orally daily.
210709|NCT02574273|Behavioral|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
210752|NCT02574013|Device|Endoractor®|Endoscopic sponge for retraction of small intestine
210976|NCT02572505|Drug|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
210710|NCT02574273|Other|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
210711|NCT02574260|Biological|Talimogene Laherparepvec|Administered by intratumoral injection.
210712|NCT02574247|Procedure|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
210713|NCT02574234|Other|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
210714|NCT02574234|Other|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
210715|NCT02574234|Other|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
210716|NCT02574234|Other|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
210717|NCT02574234|Other|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
210718|NCT02574221|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
210719|NCT02574221|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
210720|NCT02574208|Procedure|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
210721|NCT02574208|Procedure|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
210722|NCT02574182|Radiation|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.~Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.~The GAITRite is a carpet for recording the walking operating parameters"
210723|NCT02574169|Other|alveolar recruitment maneuvers group 1|"Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
210724|NCT02574169|Other|alveolar recruitment maneuvers group 2|"Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
210725|NCT02574156|Drug|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
210726|NCT02574130|Drug|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
210727|NCT02574130|Drug|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
210728|NCT02574117|Procedure|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
210729|NCT02574104|Other|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
210730|NCT02574091|Drug|1% icotinib hydrochloride cream|Topical administration for twice daily
210731|NCT02574091|Drug|2% icotinib hydrochloride cream|Topical administration for twice daily.
210732|NCT02574091|Drug|Placebo|Topical administration for twice daily.
210733|NCT02574078|Drug|Nivolumab|
210734|NCT02574078|Drug|Bevacizumab|
210735|NCT02574078|Drug|Pemetrexed|
210736|NCT02574078|Other|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
210737|NCT02574078|Drug|nab-Paclitaxel|
210738|NCT02574078|Drug|Paclitaxel|
210739|NCT02574078|Drug|Docetaxel|
210740|NCT02574078|Drug|Gemcitabine|
210741|NCT02574078|Drug|Erlotinib|
210742|NCT02574078|Drug|Crizotinib|
210743|NCT02574078|Drug|Carboplatin|
210744|NCT02574065|Drug|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
210745|NCT02574065|Other|The placebo consists of an identical formulation without L. reuteri DSM 17938|
210746|NCT02574052|Behavioral|participants' food choices|just recorded the participants' food choices in the school cafeteria
210747|NCT02574052|Behavioral|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
210748|NCT02574052|Behavioral|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
210753|NCT02574000|Other|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
210754|NCT02574000|Other|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
210755|NCT02573987|Drug|Oxygen/nitrous oxide equimolar mix|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
210756|NCT02573987|Drug|Lidocaine|standard strategy by local injection anesthesia of lidocaine
210757|NCT02573974|Other|Samples|Blood samples, muscle biopsy and sample of hair
210758|NCT02573961|Device|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
210759|NCT02573961|Behavioral|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
210760|NCT02573961|Behavioral|low caloric diet|Tailored balanced low caloric diet
210761|NCT02573948|Other|no intervention is assessed|
210762|NCT02573935|Drug|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
210763|NCT02573935|Drug|Placebo|Placebo tablet twice daily for 63 days
210764|NCT02573935|Drug|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
210765|NCT02573922|Drug|oxycodone-naloxone|
210766|NCT02573922|Drug|Oxycodone|
210767|NCT02573909|Drug|Oxycodone intravenously|Oxycodone intravenously 0,1mg/kg
210768|NCT02573909|Drug|Oxycodone epidurally|Oxycodone 0,1 mg epidurally
210769|NCT02573896|Drug|Ch14.18|17.5 mg/m2/day of Ch.14.18 will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
210770|NCT02573896|Biological|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
210771|NCT02573896|Drug|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
210772|NCT02573883|Device|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
210773|NCT02573883|Drug|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
210774|NCT02573870|Drug|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
210775|NCT02573870|Drug|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
210776|NCT02573870|Drug|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
210777|NCT02573857|Drug|DSM265|Oral suspension from bulk powder
210778|NCT02573857|Drug|OZ439|Oral suspension from powder in a bottle
210779|NCT02573844|Drug|Proklama|
210780|NCT02573831|Drug|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
210781|NCT02573831|Drug|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
210782|NCT02573818|Device|SEDASYS System|propofol sedation with the SEDASYS System
210783|NCT02573805|Device|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
210784|NCT02573779|Other|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
210785|NCT02573766|Procedure|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
210786|NCT02573766|Procedure|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.~Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
210787|NCT02573766|Behavioral|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
210788|NCT02573766|Behavioral|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
210789|NCT02573753|Behavioral|Sleep restriction|
210790|NCT02573753|Dietary Supplement|Weight gain|
210791|NCT02573740|Drug|ABT-957|
210792|NCT02573740|Other|Placebo|
210793|NCT02573727|Drug|Nor adrenaline + albumin|
210794|NCT02573727|Drug|Terlipressin + albumin|
210795|NCT02573714|Drug|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
210796|NCT02573714|Drug|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
210797|NCT02573714|Other|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
210798|NCT02573714|Other|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
210799|NCT02573714|Other|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
210800|NCT02573701|Drug|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
210801|NCT02573701|Behavioral|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
210802|NCT02573701|Drug|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
210803|NCT02573688|Behavioral|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
210804|NCT02573662|Biological|Blood and Urine sampling|Blood and Urine Sampling
210805|NCT02573662|Radiation|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
210806|NCT02573662|Biological|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
210807|NCT02573649|Device|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
210808|NCT02573649|Device|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
210809|NCT02573610|Drug|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
210810|NCT02573610|Drug|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
210811|NCT02573597|Drug|Bupivacaine|Continuous or bolus administration
210812|NCT02573597|Drug|Sufentanil|Continuous or bolus administration
210813|NCT02573571|Other|Development of biomarkers|Blood sampling
210814|NCT02573558|Drug|Dexmedetomidine|
210815|NCT02573558|Drug|Propofol|
210816|NCT02573545|Device|Planning@IFE and Standard@IFE Software|
210817|NCT02573545|Device|MR Syngo (Numaris/4) software|
210818|NCT02573519|Radiation|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) [11C]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
210819|NCT02573519|Device|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:~A wireless electromagnetic capsule to be swallowed by the subject~A portable detector plate comprising four sensors worn in a belt around the waist~Specific software for visualizing and analyzing data"
210820|NCT02573519|Drug|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
210821|NCT02573519|Device|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
210867|NCT02573220|Biological|Cetuximab|Given IV
210868|NCT02573220|Drug|Fluorouracil|Given IV
210869|NCT02573220|Drug|Irinotecan Hydrochloride|Given IV
210870|NCT02573220|Drug|Leucovorin Calcium|Given IV
211222|NCT02570581|Other|Jelly with Donepezil|
210822|NCT02573506|Radiation|split-course radiotherapy|Patients are irradiation at a palliative dose at the initial course: 51Gy/17f to PTV-GTV. The disease is re-evaluated one month after the end of the initial course using CT. The patient who achieved a partial remission according to the RECIST criteria and had a recovery of lung function should get the additional boost. At the second course, the tumor is repositioned and scanned. The residual tumor was then treated with the second course of radiotherapy. A dose of 15-18 Gy/5-6f is delivered to the residue tumor.
210823|NCT02573506|Drug|Concurrent chemotherapy|Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.
210824|NCT02573493|Drug|nab-Paclitaxel|
210825|NCT02573493|Drug|Cisplatin|
210826|NCT02573493|Biological|Cetuximab|
210827|NCT02573493|Radiation|Intensity-Modulated Radiation Therapy|
210828|NCT02573480|Behavioral|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
210829|NCT02573467|Drug|Bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
210830|NCT02573467|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
210831|NCT02573454|Behavioral|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
210832|NCT02573441|Behavioral|Jump Math|Jump Math is a workbook based program aimed at improving math skills
210833|NCT02573441|Behavioral|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
210834|NCT02573441|Behavioral|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
210835|NCT02573415|Procedure|Uterus Transplant|transplant of a deceased donor uterus.
210836|NCT02573402|Device|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
210837|NCT02573402|Device|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
210838|NCT02573389|Device|Boston Scientific or Cook pancreatic duct stents|Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
210839|NCT02573376|Behavioral|Directly Observed Therapy|
210840|NCT02573376|Behavioral|Wirelessly Observed Therapy|
210841|NCT02573363|Drug|Cytarabine|Given per standard of care
210842|NCT02573363|Drug|Mitoxantrone Hydrochloride|Given per standard of care
210843|NCT02573363|Drug|Selinexor|Given PO
210844|NCT02573350|Drug|Delamanid|Delamanid was administered orally as 50-mg tablets.
210845|NCT02573337|Device|Emervel Classic Lidocaine|Treatment of wrinkles and folds
210846|NCT02573337|Device|Emervel Deep Lidocaine|Treatment of wrinkles and folds
210847|NCT02573324|Drug|Temozolomide|oral
210848|NCT02573324|Drug|ABT-414|intravenous infusion
210849|NCT02573324|Radiation|Radiation|
210850|NCT02573324|Drug|Placebo for ABT-414|intravenous infusion
210851|NCT02573311|Drug|tamsulosin hydrochloride|
210852|NCT02573298|Device|ice|local ice application for 30 minutes
210853|NCT02573298|Device|cold gas|local cold gas application for 2 minutes
210854|NCT02573285|Procedure|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
210855|NCT02573285|Procedure|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
210856|NCT02573272|Drug|eslicarbacepine|
210857|NCT02573259|Drug|PF-06801591|IV every 21 days (Part 1)
210858|NCT02573259|Drug|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
210859|NCT02573246|Behavioral|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
210860|NCT02573246|Device|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
210861|NCT02573246|Device|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
210862|NCT02573233|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
210863|NCT02573233|Drug|Dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
210864|NCT02573233|Drug|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
210865|NCT02573233|Drug|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
210866|NCT02573233|Drug|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
210871|NCT02573194|Dietary Supplement|Breakfasts varying in protein source content on appetite|In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
210872|NCT02573181|Biological|V114|V114 contains 2 µg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F, and 4 μg of serotype 6B; and 30 µg of CRM₁₉₇ and 125 µg of Aluminum Phosphate Adjuvant (APA) per 0.5 mL dose.
210873|NCT02573181|Biological|Prevnar 13™|Prevnar 13™ contains 2.2 μg of serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, and 23F, and 4.4 μg of serotype 6B; and 34 μg of CRM₁₉₇ and 125 μg of aluminum per 0.5mL dose.
210874|NCT02573168|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
210875|NCT02573168|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
210876|NCT02573168|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
210877|NCT02573155|Drug|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210878|NCT02573155|Drug|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210879|NCT02573155|Drug|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210880|NCT02573155|Drug|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210881|NCT02573155|Drug|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210882|NCT02573155|Drug|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210883|NCT02573155|Drug|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210884|NCT02573155|Drug|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
210885|NCT02573155|Drug|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
210886|NCT02573155|Drug|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
210887|NCT02573155|Drug|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
210888|NCT02573142|Behavioral|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
210889|NCT02573142|Behavioral|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
210890|NCT02573129|Other|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
210891|NCT02573129|Other|Red Meat Rich|Mediterranean diet rich in red meat
210892|NCT02573116|Procedure|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
210893|NCT02573090|Procedure|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
210894|NCT02573090|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
210895|NCT02573064|Drug|Colistin|
210896|NCT02573064|Drug|Tigecycline|
210897|NCT02573064|Drug|Vancomycin|
210898|NCT02573051|Drug|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
210899|NCT02573051|Drug|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
210900|NCT02573051|Other|placebo|
210901|NCT02573038|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
210902|NCT02573025|Drug|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
210975|NCT02572531|Dietary Supplement|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
211010|NCT02572232|Device|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
210903|NCT02573025|Drug|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
210904|NCT02573012|Drug|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
210905|NCT02573012|Drug|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
210906|NCT02573012|Biological|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
210907|NCT02572999|Procedure|Not applicable (observational design)|
210908|NCT02572986|Drug|Permethrin|
210909|NCT02572973|Other|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
210910|NCT02572960|Drug|Valsartan|2 weeks of Valsartan 80 mg per day
210911|NCT02572960|Drug|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
210912|NCT02572960|Dietary Supplement|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
210913|NCT02572960|Dietary Supplement|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
210914|NCT02572947|Drug|Dolutegravir|
210915|NCT02572921|Behavioral|Positive Psychotherapy|"The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:~positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life."
210916|NCT02572921|Behavioral|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
210917|NCT02572908|Other|Sourdough wheat bread|
210918|NCT02572908|Other|Regular yeast baked toast bread|
210919|NCT02572908|Other|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
210920|NCT02572895|Dietary Supplement|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
210921|NCT02572882|Dietary Supplement|p-inulin|12 week self-administered treatment phase
210922|NCT02572869|Other|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
210923|NCT02572869|Behavioral|questionnaires|"The participating patients will be asked to complete three questionnaires:~(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
210924|NCT02572856|Device|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 6 Professional CGM sensor at least 2.5 hours prior to surgery Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
210925|NCT02572843|Drug|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
210926|NCT02572830|Behavioral|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
210927|NCT02572830|Behavioral|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
210928|NCT02572817|Biological|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
210929|NCT02572817|Biological|Low-titer anti-influenza plasma|Human plasma (FFP or FP24, 225-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
211011|NCT02572219|Dietary Supplement|Nutraceutical compound|
210930|NCT02572804|Device|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
210931|NCT02572804|Device|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
210932|NCT02572791|Drug|Chlorhexidine|
210933|NCT02572791|Drug|Mupirocin|
210934|NCT02572791|Behavioral|Household cleaning|
210935|NCT02572778|Procedure|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
210936|NCT02572765|Other|PET/CT scan|PET/CT scan
210937|NCT02572752|Drug|Nintedanib|1 soft gelatine capsule, single dose, oral
210938|NCT02572752|Drug|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
210939|NCT02572752|Drug|Nintedanib|
210940|NCT02572739|Device|PICCO|measurements based on thermodilution
210941|NCT02572739|Device|NICCOMO|measurements based on impedance
210942|NCT02572726|Device|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
210943|NCT02572726|Device|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
210944|NCT02572713|Procedure|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
210945|NCT02572713|Procedure|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
210946|NCT02572713|Drug|DaTSCAN™|
210947|NCT02572700|Other|Pain and US assessment|All patients will have a baseline visit when treatment is initiated and a follow up visit after 4 months. At each time point, pain mechanisms will be clarified by clinical examination and questionnaires. Besides, ultrasonography of joints and entheses, AMPS test, blood samples, x-ray of hands and feet and interview/additional questionnaires will be applied
210948|NCT02572687|Drug|Ramucirumab|Administered IV
210949|NCT02572687|Drug|MEDI4736|Administered IV
210950|NCT02572674|Other|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
210951|NCT02572674|Genetic|Genetic sample|Blood samples
210952|NCT02572661|Radiation|radiation in Squamous Head and Neck Cancer|
210953|NCT02572648|Other|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes."
210954|NCT02572648|Other|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 & 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
210955|NCT02572635|Biological|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
210956|NCT02572635|Biological|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
210957|NCT02572622|Other|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
210958|NCT02572622|Other|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
210959|NCT02572622|Other|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
210960|NCT02572622|Other|exercise|special lumbar stabilization exercises were applied in advanced protocol.
210961|NCT02572609|Drug|Ambroxol hydrochloride soft pastille|
210962|NCT02572609|Drug|Mucosolvan ® adult syrup|
210963|NCT02572596|Drug|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
210964|NCT02572596|Drug|CTX|CTX 2.5/m2 for 2 days.
210965|NCT02572596|Drug|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
210966|NCT02572583|Drug|Liugan Shuangjie Heji|
210967|NCT02572583|Drug|Shufeng Jiedu Capsule|
210968|NCT02572583|Drug|Oseltamivir Phosphate Capsule|
210969|NCT02572570|Device|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Filtek Bulk Fill Posterior). Procedures will be done using local anesthesia and following ordinary restorative techniques.
210970|NCT02572570|Device|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Filtek Supreme Ultra). Procedures will be done using local anesthesia and following ordinary restorative techniques.
210971|NCT02572557|Device|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
210972|NCT02572557|Drug|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
210973|NCT02572544|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
210974|NCT02572531|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
210977|NCT02572492|Drug|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)~Subsequently all patients receive the conditioning regimen:~Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 > 2.0 m CD34+ stem cells/kg body weight on day 0"
210978|NCT02572492|Drug|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
210979|NCT02572492|Drug|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
210980|NCT02572466|Other|Hemodialysis|ESRD group received long-term hemodialysis
210981|NCT02572453|Drug|Onalespib|Given IV
210982|NCT02572440|Procedure|Sorin XTRA/Sorin Group,|
210983|NCT02572427|Other|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
210984|NCT02572427|Other|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
210985|NCT02572414|Behavioral|Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
210986|NCT02572414|Behavioral|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
210987|NCT02572401|Behavioral|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
210988|NCT02572401|Behavioral|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
210989|NCT02572388|Biological|R21|
210990|NCT02572388|Biological|Matrix-M1|
210991|NCT02572375|Drug|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
210992|NCT02572375|Drug|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
210993|NCT02572362|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
210994|NCT02572349|Drug|IW-1701|
210995|NCT02572349|Drug|Matching Placebo|
210996|NCT02572336|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
210997|NCT02572336|Drug|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
210998|NCT02572336|Drug|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
210999|NCT02572323|Drug|Tesamorelin|Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
211000|NCT02572310|Device|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
211001|NCT02572297|Other|video-EEG|Registration of seizures during video-EEG
211002|NCT02572284|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5 Gy of SBRT per day for 5 days, the second group will receive 6 Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
211003|NCT02572284|Procedure|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
211004|NCT02572284|Other|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
211005|NCT02572271|Procedure|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
211006|NCT02572271|Procedure|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
211007|NCT02572258|Other|Nutritional cookie|
211008|NCT02572245|Device|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
211009|NCT02572245|Device|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
211014|NCT02572206|Device|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
211015|NCT02572193|Procedure|POEM|To determine the feasibility of same-day discharge following a POEM procedure
211016|NCT02572180|Behavioral|EMG-based biofeedback training|
211017|NCT02572180|Behavioral|NIRS-based neurofeedback training|
211018|NCT02572167|Drug|brentuximab vedotin|1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
211019|NCT02572167|Drug|nivolumab|3 mg/kg by intravenous (IV) infusion for up to 4 cycles
211020|NCT02572154|Other|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
211021|NCT02572141|Drug|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
211022|NCT02572141|Drug|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
211023|NCT02572128|Other|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.~Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.~Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
211024|NCT02572115|Behavioral|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
211025|NCT02572115|Behavioral|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
211026|NCT02572102|Dietary Supplement|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
211027|NCT02572102|Dietary Supplement|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
211028|NCT02572102|Other|Placebo|Lime juice, water and cherry flavoring
211029|NCT02572089|Drug|Naloxone|
211030|NCT02572076|Device|Motus Cleansing System|
211031|NCT02572050|Procedure|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
211032|NCT02572024|Device|BAT|Baroreflex activation therapy device ON
211033|NCT02572024|Other|Placebo|Baroreflex activation therapy device OFF
211034|NCT02572011|Other|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
211035|NCT02571998|Drug|Omiganan (CLS001) Topical Gel|
211036|NCT02571998|Drug|Vehicle Topical Gel|
211037|NCT02571985|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation System|Zenith® Branch Endovascular Graft-Iliac Bifurcation (Branch Graft) with the ConnectSX™
211038|NCT02571972|Drug|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
211039|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
211040|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
211041|NCT02571946|Radiation|Proton beam therapy|
211042|NCT02571933|Other|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
211043|NCT02571933|Other|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
211044|NCT02571933|Other|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
211045|NCT02571907|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
211046|NCT02571907|Device|Atrium iCAST™|Implantation of Atrium iCAST
211047|NCT02571907|Device|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
211048|NCT02571894|Other|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
211049|NCT02571881|Procedure|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
211050|NCT02571881|Drug|Oxycodone|
211051|NCT02571881|Drug|oxycodone-naloxone|
211052|NCT02571868|Device|Optimization CRT-D|
211053|NCT02571855|Drug|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
211054|NCT02571855|Drug|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
211055|NCT02571855|Drug|Placebo|Placebo capsules matching the ACT-541468 formulations
211056|NCT02571842|Drug|Intravenous Rituximab|- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
211057|NCT02571842|Drug|ACEI/ARB and corticosteroids|"ACEI or ARB will be prescribed as high as tolerable dose.~Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
211058|NCT02571829|Drug|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
211059|NCT02571816|Drug|ASP2215|oral
211180|NCT02570919|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
211060|NCT02571803|Behavioral|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
211061|NCT02571803|Other|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
211062|NCT02571790|Behavioral|Relaxation optimized virtual reality|
211063|NCT02571790|Behavioral|Classical relaxation (without Virtual Reality)|
211064|NCT02571777|Drug|QVM149|
211065|NCT02571777|Drug|QVM149|
211066|NCT02571777|Drug|QMF149|
211067|NCT02571777|Drug|QMF149|
211068|NCT02571777|Drug|salmeterol/fluticasone|
211069|NCT02571764|Other|Nutritional Oats Cookie|
211070|NCT02571751|Device|UNIGEL Silicone Gel-Filled Breast Implant|
211071|NCT02571738|Biological|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
211072|NCT02571738|Other|Control|Standard of Care
211073|NCT02571725|Drug|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
211074|NCT02571725|Drug|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
211075|NCT02571712|Drug|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
211076|NCT02571699|Other|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
211077|NCT02571686|Device|Surveyor S4|
211078|NCT02571673|Behavioral|Assessments|Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
211079|NCT02571660|Drug|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
211080|NCT02571660|Drug|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
211081|NCT02571647|Other|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.~They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
211082|NCT02571634|Drug|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
211083|NCT02571621|Device|Combitube|Intubation with Combitube
211084|NCT02571608|Drug|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
211085|NCT02571608|Drug|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
211086|NCT02571595|Behavioral|Digital cognitive behavioural therapy for insomnia (dCBT-I)|dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
211087|NCT02571569|Drug|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
211088|NCT02571569|Drug|BAY1093884|Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
211089|NCT02571556|Drug|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
211090|NCT02571543|Drug|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
211091|NCT02571530|Drug|Intra-arterial Cerebral Infusion of Trastuzumab|
211092|NCT02571517|Drug|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
211093|NCT02571517|Other|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
211094|NCT02571504|Behavioral|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
211095|NCT02571491|Drug|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
211096|NCT02571491|Other|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
211097|NCT02571491|Drug|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
211098|NCT02571491|Drug|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
211099|NCT02571478|Behavioral|Marriage Checkup|The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strategies or resources for the couple to consider pursuing.
211100|NCT02571465|Other|Passive leg raising test and fluid challenge|
211101|NCT02571452|Behavioral|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
211102|NCT02571452|Behavioral|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
211103|NCT02571439|Procedure|Surgical TAP block|surgeon administered TAP block
211104|NCT02571439|Procedure|Conventional TAP block|Anesthesiologist administered TAP block
211105|NCT02571439|Drug|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
211106|NCT02571426|Drug|Sevoflurane|anesthetic agent
211107|NCT02571426|Drug|propofol|anesthetic agent
211108|NCT02571413|Other|score before teaching|score the check-point of correct INCS usage before teaching
211109|NCT02571413|Other|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
211110|NCT02571413|Other|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
211111|NCT02571400|Other|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics >90 days post-surgery
211112|NCT02571387|Behavioral|Mindfulness-based intervention|
211113|NCT02571387|Behavioral|Sham meditation|
211114|NCT02571374|Dietary Supplement|symbiotic group|this group received sachets of symbiotic
211115|NCT02571374|Dietary Supplement|placebo group|this group received placebo
211116|NCT02571361|Drug|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
211117|NCT02571361|Drug|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
211118|NCT02571361|Drug|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
211119|NCT02571361|Drug|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
211120|NCT02571361|Drug|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
211121|NCT02571348|Procedure|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
211122|NCT02571335|Behavioral|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.~Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.~Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.~Week 3 Same as week 2."
211123|NCT02571335|Behavioral|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
211124|NCT02571322|Device|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
211125|NCT02571322|Other|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
211126|NCT02571309|Device|Asthmatuner|Asthmatuner is an app for self-management of asthma.
211127|NCT02571296|Drug|micronized progesterone|Oral
211128|NCT02571296|Drug|Placebo|Oral
211129|NCT02571283|Drug|Cocktail|Administered as a single dose injection.
211130|NCT02571283|Drug|Exparel|Administered 20 minutes+ before additional medications.
211131|NCT02571283|Drug|Marcaine|Administered 20 minutes or more after Exparel is administered.
211132|NCT02571270|Other|Combined aerobic and resistance physical training program|
211133|NCT02571257|Drug|Gemcabene|1-300 mg tablet, QD, 56 days
211134|NCT02571257|Drug|Gemcabene|3-300 mg tablets, QD, 56 days
211135|NCT02571257|Drug|Placebo|
211136|NCT02571244|Behavioral|Motivational Interview plus text message|After discharge the experimental group has received extended care including a counseling session and text messages. The session provided basic information about smoking and successful quitting. The counselor has used motivational interview techniques to build coping skills with the goal of helping the participant build and implement a quit plan. The focus was to increase motivation to make quit attempt, including confidence building, medication use, and cessation planning. The session lasted approximately 30 minutes. Participants in the experimental arm were offered up to 30 text messages to help them to implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or those that had already quit have received 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages followed the self efficacy theory.
211137|NCT02571231|Device|HFV + and - VG|High frequency ventilation with and without volume guarantuee
211138|NCT02571218|Device|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
211181|NCT02570919|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
211139|NCT02571218|Device|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
211140|NCT02571205|Drug|Sustanon (testosterone)|Standard incremental regimen of Sustanon
211141|NCT02571192|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
211142|NCT02571192|Radiation|5.95 μCi RAD|
211143|NCT02571179|Drug|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
211144|NCT02571166|Biological|HSV529|Live, Replication-defective HSV-2 virus
211145|NCT02571166|Drug|Valacyclovir|500 mg orally, once daily for 4 weeks
211146|NCT02571153|Drug|Ketamine 0.4 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
211147|NCT02571153|Drug|Normal saline|Intravenous normal saline 0.9% 5 mL
211148|NCT02571153|Drug|Ketamine 0.2 mg/kg|Intravenous ketamine 0.2 mg/kg after induction of anesthesia
211149|NCT02571140|Drug|Teriparatide|subcutaneous standard injection
211150|NCT02571140|Drug|Oral PTH (1-34)|Different optimization of API
211151|NCT02571127|Drug|Hidra1|"Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.~Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.~Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient."
211152|NCT02571114|Dietary Supplement|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
211153|NCT02571114|Dietary Supplement|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
211154|NCT02571114|Dietary Supplement|Control 1|White bread (serving size = 25 g available carbohydrate)
211155|NCT02571114|Dietary Supplement|Control 2|White bread (serving size = 25 g available carbohydrate)
211156|NCT02571101|Drug|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
211157|NCT02571101|Drug|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
211158|NCT02571101|Drug|Condencia|Contains chlomipramine HCl 15mg.
211159|NCT02571101|Drug|CDFR0812-Placebo|Placebo tablet of CDFR0812.
211160|NCT02571101|Drug|Condencia-Placebo|Placebo tablet of Condencia
211161|NCT02571088|Other|Training Program|Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
211162|NCT02571075|Other|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
211163|NCT02571062|Drug|Fexinidazole|
211164|NCT02571049|Drug|DFN-11|Sumatriptan 3 mg versus 6 mg
211165|NCT02571036|Drug|DCC-2618|50 mg formulated tablets
211166|NCT02571036|Drug|DCC-2618|10 mg and 50 mg formulated tablets
211167|NCT02571023|Procedure|microscope surgery|
211168|NCT02571023|Procedure|neuroendoscope surgery|
211169|NCT02571010|Other|Standard Medical treatment|Standard treatment with drugs and usual rehabilitation
211170|NCT02571010|Device|Vibrotactile stimulation|Rehabilitation by vibrotactile stimulation at medical center
211171|NCT02571010|Device|Sham Stimulation with Vibradol device switched off|Sham Rehabilitation at medical center but with Vibradol device switched off
211172|NCT02570997|Drug|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
211173|NCT02570997|Drug|Placebo|Matching placebo administered.
211174|NCT02570984|Drug|Omalizumab|anti-ige injection
211175|NCT02570984|Drug|Placebo|placebo comparator arm, injection similar to active
211176|NCT02570971|Drug|Mannitol|
211177|NCT02570958|Drug|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
211178|NCT02570945|Procedure|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
211179|NCT02570932|Biological|Autologous Mesenchymal Bone Marrow Cell|"Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.~Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration"
211216|NCT02570581|Other|Jelly with Furosemide|
211182|NCT02570906|Device|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
211183|NCT02570893|Radiation|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
211184|NCT02570893|Radiation|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
211185|NCT02570893|Drug|Paclitaxel and carboplatin|
211186|NCT02570880|Other|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products — Determination of the glycaemic index (GI) and recommendation for food classification
211187|NCT02570854|Biological|CSJ137|Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
211188|NCT02570854|Drug|Placebo|Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
211189|NCT02570841|Drug|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
211190|NCT02570841|Drug|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
211191|NCT02570828|Device|Thermal Imaging|FLIR ONE attachment to an iPhone
211192|NCT02570815|Drug|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
211193|NCT02570802|Procedure|Ultrasonographic examination|
211194|NCT02570789|Drug|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
211195|NCT02570763|Device|Active tDCS stimulation|
211196|NCT02570763|Device|Sham tDCS stimulation|
211197|NCT02570750|Behavioral|QUESTIONNAIRE ON SMOKING HABITS|"Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).~Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points."
211198|NCT02570724|Drug|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
211199|NCT02570724|Biological|blood patch|
211200|NCT02570711|Drug|ACP-196|ACP-196 capsule
211201|NCT02570711|Drug|Nab-paclitaxel|Nab-paclitaxel infusion
211202|NCT02570711|Drug|Gemcitabine|Gemcitabine infusion
211203|NCT02570685|Behavioral|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
211204|NCT02570685|Behavioral|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
211205|NCT02570685|Behavioral|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
211206|NCT02570672|Drug|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
211207|NCT02570672|Drug|Placebo|Subjects will randomized to placebo will receive placebo
211208|NCT02570659|Behavioral|Information Video|A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
211209|NCT02570646|Behavioral|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
211210|NCT02570633|Other|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
211211|NCT02570633|Other|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
211212|NCT02570620|Device|Ultrasonography of the cervix|
211213|NCT02570607|Biological|BNP dosage|
211214|NCT02570594|Other|questionary|
211215|NCT02570581|Other|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.~The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.~The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.~Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
211223|NCT02570581|Other|Jelly with Clopidogrel|
211224|NCT02570581|Other|Jelly with Ramipril|
211225|NCT02570581|Other|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
211226|NCT02570581|Other|Plain jelly control|
211227|NCT02570581|Other|Apple compote Paracetamol|
211228|NCT02570581|Other|Apple compote Furosemide|
211229|NCT02570581|Other|Apple compote Levothyroxine sodium salt|
211230|NCT02570581|Other|Apple compote Memantine|
211231|NCT02570581|Other|Apple compote Zopiclone|
211232|NCT02570581|Other|Apple compote Alprazolam|
211233|NCT02570581|Other|Apple compote Oxazepam|
211234|NCT02570581|Other|Apple compote Donepezil|
211235|NCT02570581|Other|Apple compote Clopidogrel|
211236|NCT02570581|Other|Apple compote Ramipril|
211237|NCT02570581|Other|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
211238|NCT02570581|Other|Plain apple compote control|
211239|NCT02570568|Device|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
211240|NCT02570568|Device|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
211241|NCT02570568|Procedure|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
211242|NCT02570542|Procedure|leukapheresis|
211243|NCT02570542|Drug|Plerixafor|Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
211244|NCT02570542|Drug|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
211245|NCT02570542|Procedure|Autologous Stem Cell Transplantation|
211246|NCT02570529|Drug|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
211247|NCT02570529|Drug|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
211248|NCT02570516|Procedure|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
211249|NCT02570503|Drug|Ropivacaine|Ropivacaine (5mg/ml)-50ml
211250|NCT02570503|Drug|Ketorolac|ketorolac (30mg/ml)- 1 ml
211251|NCT02570503|Drug|Clonidine|clonidine (0.1mg/ml)- 0.8ml
211252|NCT02570503|Drug|Epinephrine|epinephrine (1mg/ml)-1ml
211253|NCT02570503|Drug|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
211254|NCT02570490|Drug|sodium fusidate|
211255|NCT02570490|Drug|linezolid|
211256|NCT02570477|Procedure|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
211257|NCT02570477|Drug|Vancomycin|125mg Vancomycin four times per day
211258|NCT02570464|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
211259|NCT02570464|Biological|Blood drawn|Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
211260|NCT02570451|Other|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
211261|NCT02570451|Other|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
211262|NCT02570451|Other|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
211263|NCT02570451|Other|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
211264|NCT02570451|Other|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
211265|NCT02570451|Other|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
211266|NCT02570451|Other|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
211267|NCT02570451|Other|Grip Strength|Measured using the JAMAR dynamometer
211268|NCT02570425|Device|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
211269|NCT02570425|Device|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
211270|NCT02570412|Drug|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
211271|NCT02570399|Radiation|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
211294|NCT02570243|Drug|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
211272|NCT02570386|Procedure|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
211273|NCT02570386|Procedure|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
211274|NCT02570373|Drug|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
211275|NCT02570360|Behavioral|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
211276|NCT02570360|Behavioral|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
211277|NCT02570347|Drug|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
211278|NCT02570347|Biological|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
211279|NCT02570334|Other|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
211280|NCT02570321|Procedure|Bacterial ulcer cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
211281|NCT02570321|Procedure|Bacterial ulcer control|For those bacterial ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for bacterial ulcers. This group will have their eyes irrigated with a balanced salt solution.
211282|NCT02570321|Procedure|Fungal ulcer cross-linking|"Prior to receiving cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis."
211283|NCT02570321|Procedure|Fungal ulcer control|"Prior to receiving sham cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.~For those fungal ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for fungal ulcers. This group will have their eyes irrigated with a balanced salt solution."
211284|NCT02570308|Drug|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific TCR fused to anti-CD3
211285|NCT02570295|Other|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
211286|NCT02570282|Drug|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
211287|NCT02570282|Drug|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
211288|NCT02570269|Procedure|AuraGain|Fiberoptic Intubation
211289|NCT02570269|Procedure|Slotted Guedeltubus|Fiberoptic Intubation
211290|NCT02570256|Behavioral|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
211291|NCT02570256|Behavioral|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
211292|NCT02570256|Behavioral|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
211293|NCT02570243|Drug|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
211296|NCT02570230|Drug|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
211297|NCT02570217|Device|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
211298|NCT02570217|Device|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
211299|NCT02570204|Behavioral|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
211300|NCT02570191|Drug|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
211301|NCT02570178|Other|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
211302|NCT02570165|Drug|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
211303|NCT02570165|Drug|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
211304|NCT02570165|Drug|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
211305|NCT02570152|Procedure|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever [body temperature ≥ 38°C/≥ 100.4°F] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
211306|NCT02570139|Device|Cavilon Advanced Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
211307|NCT02570139|Device|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
211308|NCT02570126|Biological|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
211309|NCT02570126|Biological|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
211310|NCT02570113|Device|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
211311|NCT02570100|Procedure|Biological collection|"Collection of blood samples and tumor specimens :~Biological collection before treatment :~1 tumor specimen (under echographic control)~4 blood collections~Biological collection during treatment :~1 tumor specimen after 3 cycles~4 blood collections after 3 and 6 cycles"
211312|NCT02570087|Procedure|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
211313|NCT02570074|Drug|Fosfomycin|Broad spectrum antibiotic
211314|NCT02570061|Behavioral|telephone|information given at the primary contact by phone, or at a scheduled later time
211315|NCT02570061|Behavioral|consultation face-to-face|information given at a scheduled consultation at the hospital
211316|NCT02570048|Device|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
211317|NCT02570035|Drug|Mirabegron|oral
211318|NCT02570022|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
211319|NCT02570022|Procedure|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
211320|NCT02570022|Drug|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
211321|NCT02570009|Behavioral|TEAMS (Talking about Eating, Activity, Mutual Support)|
211322|NCT02570009|Behavioral|Need Support Training|
211323|NCT02569996|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
211324|NCT02569983|Other|Observational cohort|No intervention - observational study
211325|NCT02569970|Drug|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
211326|NCT02569970|Drug|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.~At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
211327|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
211328|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
211329|NCT02569957|Drug|Acetylcysteine|Given IV and PO
211330|NCT02569944|Procedure|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.~No other procedure, drug or device was done/used in this patients."
211380|NCT02569619|Behavioral|Activity Intervention|
211331|NCT02569944|Procedure|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
211332|NCT02569931|Other|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
211333|NCT02569931|Other|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
211334|NCT02569931|Procedure|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
211335|NCT02569918|Device|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
211336|NCT02569905|Drug|parecoxib sodium|parecoxib sodium 40mg
211337|NCT02569905|Drug|flurbiprofen|flurbiprofen 50mg
211338|NCT02569905|Drug|saline|normal saline
211339|NCT02569892|Device|macular laser treatment|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
211340|NCT02569892|Device|sham macular laser treatment|Sham macular laser treatment with Pascal laser power setting of zero
211341|NCT02569879|Other|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
211342|NCT02569866|Drug|Cephalexin|Capsules containing cephalexin/500mg
211343|NCT02569866|Drug|Placebo|Capsules containing placebo/500mg
211344|NCT02569853|Drug|DFN-11|
211345|NCT02569853|Other|Placebo|
211346|NCT02569840|Dietary Supplement|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
211347|NCT02569827|Drug|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
211348|NCT02569827|Drug|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
211349|NCT02569827|Drug|Placebo|Placebo Q6H for 5 days
211350|NCT02569827|Drug|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
211351|NCT02569814|Drug|Fimasartan/Amlodipine/Rosuvastatin|
211352|NCT02569814|Drug|Fimasartan/Amlodipine|
211353|NCT02569814|Drug|Rosuvastatin|
211354|NCT02569801|Drug|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
211355|NCT02569801|Drug|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
211356|NCT02569788|Radiation|CIRT arm|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
211357|NCT02569775|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
211358|NCT02569762|Dietary Supplement|Sucralose-Aspartame|Sucralose or aspartame
211359|NCT02569762|Dietary Supplement|Aspartame-Sucralose|Aspartame or sucralose
211360|NCT02569749|Other|Berlin and Epworth questionaries|
211361|NCT02569749|Other|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
211362|NCT02569749|Other|Night polygraph / Polysomnography|
211363|NCT02569723|Drug|Carbon C 14 Oxaliplatin|Intravenous infusion
211364|NCT02569723|Drug|Oxaliplatin|Intravenous infusion
211365|NCT02569710|Drug|AL-335|AL-335 tablets will be administered in a dose range of 400 to 1200 mg once daily (QD).
211366|NCT02569710|Drug|Odalasvir (ODV)|ODV capsules will be administered in a dose range of 25 to 50 mg.
211367|NCT02569710|Drug|Simeprevir (SMV)|SMV tablets will be administered in a dose range of 75 to 150 mg QD or every other day (QOD).
211368|NCT02569697|Other|HEC Placebo gel|
211369|NCT02569697|Other|Placebo Intravaginal Ring|
211370|NCT02569697|Other|Placebo Vaginal Film|
211371|NCT02569697|Other|Placebo Vaginal Insert|
211372|NCT02569684|Dietary Supplement|Prebiotic fibers: oligofructose and inulin|
211373|NCT02569684|Dietary Supplement|Maltodextrin|
211374|NCT02569671|Device|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
211375|NCT02569671|Device|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
211376|NCT02569658|Drug|Tranexamic Acid|
211377|NCT02569658|Drug|Placebo|
211378|NCT02569645|Drug|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
211379|NCT02569632|Biological|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
211381|NCT02569619|Behavioral|Healthy Diet Intervention|
211382|NCT02569593|Dietary Supplement|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
211383|NCT02569580|Device|Topically|"use the No More medical device as anti lice treatment"
211384|NCT02569567|Procedure|Smart-Shear Wave(SSW) imaging|"All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.~The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.~Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
211385|NCT02569567|Procedure|Transient elastography(TE)|"Using the M probe in patients with BMI <30 kg/m2.~Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.~Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
211386|NCT02569554|Drug|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
211387|NCT02569554|Drug|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
211388|NCT02569541|Drug|sodium fusidate|
211389|NCT02569515|Drug|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
211390|NCT02569502|Drug|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
211391|NCT02569489|Drug|HBI-8000|
211392|NCT02569489|Drug|Trastuzumab|
211393|NCT02569489|Drug|Paclitaxel|
211394|NCT02569476|Drug|BGB-3111 and Obinutuzumab|
211395|NCT02569463|Drug|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
211396|NCT02569450|Behavioral|Surgical outcomes monitoring using Shewhart control chart|"Assistance by a local surgeon responsible for the implementation of intervention within his/her department~Quarterly team meeting to interpret variations in observed outcomes on the control charts~Restitution of surgical outcomes based on wall posters in operating room~Training sessions provided to local surgeon for appropriate control chart utilization"
211397|NCT02569437|Drug|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
211398|NCT02569437|Drug|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
211399|NCT02569437|Drug|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
211400|NCT02569437|Drug|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
211401|NCT02569437|Drug|sugar pill|placebo pill to match doxycycline
211402|NCT02569424|Behavioral|Patient's position|Supine or Trendelenburg strict -20°)
211403|NCT02569411|Other|Financial Incentive|money
211404|NCT02569398|Drug|Atabecestat, 5 mg|One atabecestat, 5 mg tablet orally once daily up to 54 months.
211405|NCT02569398|Drug|Atabecestat, 25 mg|One atabecestat, 25 mg tablet orally once daily up to 54 months.
211406|NCT02569398|Drug|Placebo|One matching placebo tablet orally once daily up to 54 months.
211407|NCT02569385|Other|Spontaneous breathing trial|
211408|NCT02569372|Biological|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
211409|NCT02569359|Dietary Supplement|shea nut oil extract|
211410|NCT02569359|Other|Placebo|
211411|NCT02569346|Drug|Triumeq|Single-dose Triumeq as a whole tablet
211412|NCT02569346|Drug|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
211413|NCT02569346|Drug|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
211414|NCT02569333|Other|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
211415|NCT02569320|Drug|Dexamethasone|Given PO
211416|NCT02569320|Drug|HDAC Inhibitor AR-42|Given PO
211417|NCT02569320|Other|Laboratory Biomarker Analysis|Correlative studies
211418|NCT02569320|Drug|Pomalidomide|Given PO
211419|NCT02569307|Drug|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
211420|NCT02569307|Drug|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
211421|NCT02569307|Drug|Placebo|Placebo added to TAU
211422|NCT02569307|Drug|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
211423|NCT02569294|Behavioral|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
211455|NCT02569034|Other|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
211490|NCT02568774|Other|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
211535|NCT02568423|Drug|Placebo - IV|Administered IV
211424|NCT02569294|Behavioral|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
211425|NCT02569294|Behavioral|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
211426|NCT02569281|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
211427|NCT02569281|Other|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
211428|NCT02569268|Other|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
211429|NCT02569255|Procedure|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
211430|NCT02569242|Drug|Nivolumab|
211431|NCT02569242|Drug|Docetaxel/Paclitaxel|
211432|NCT02569229|Other|Diagnostics for glucose tolerance with 3 different methods.|"A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).~An oral glucose tolerance test done within the 7 day period of CGMS.~Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS."
211433|NCT02569216|Device|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
211434|NCT02569203|Dietary Supplement|standard enteral nutrition|standard enteral nutrition
211435|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
211436|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
211437|NCT02569190|Device|Walkbot|Robot assisted gait training
211438|NCT02569151|Device|HBP & CBP measurement using systo 130 mmHg|
211439|NCT02569138|Device|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
211440|NCT02569138|Device|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
211441|NCT02569125|Drug|Everolimus|4.5 mg/m² daily
211442|NCT02569112|Device|multipolar RF, varipulse|Multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse).
211443|NCT02569112|Device|cryolipolysis|Cryolipolysis technology uses the sensitivity of fat cells to cold injury, causing them to freeze and undergo cellular apoptosis.
211444|NCT02569099|Other|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
211445|NCT02569086|Other|Blood draw|
211446|NCT02569073|Drug|Dronabinol|Dronabinol 5 mg, every other night, orally
211447|NCT02569073|Drug|Placebo|Placebo--no drug
211448|NCT02569060|Other|Testing and Monitoring of Blood Glucose Levels|Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
211449|NCT02569060|Other|Primary care coordination|Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
211450|NCT02569060|Other|Diabetes-appropriate food packages|Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
211451|NCT02569060|Behavioral|Diabetes self-management education|Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
211452|NCT02569047|Procedure|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
211453|NCT02569047|Procedure|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
211454|NCT02569034|Other|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
211584|NCT02568033|Drug|Carboplatin|
211456|NCT02569021|Device|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~Current best/optimized DBS setting (considered baseline)~DBS off for 30 minutes as a washout period~Biphasic pulse stimulation mode (assessment at 0.5hr)~Biphasic pulse stimulation mode (assessment at 1hr)~Biphasic pulse stimulation mode (assessment at 2hr)~Biphasic pulse stimulation mode (assessment at 3hr)"
211457|NCT02569021|Other|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
211458|NCT02569021|Other|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
211459|NCT02569021|Device|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
211460|NCT02569021|Device|Trigno wireless system|The Trigno system measure muscle contractions.
211461|NCT02569021|Other|GaitRite walking assessment.|GaitRite records a patients gait pattern.
211462|NCT02569008|Drug|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
211463|NCT02568995|Drug|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
211464|NCT02568982|Other|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
211465|NCT02568969|Device|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
211466|NCT02568943|Drug|Panobinostat|Panobinostat (PAN [LBH589]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
211467|NCT02568917|Procedure|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
211468|NCT02568917|Procedure|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
211469|NCT02568904|Other|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
211470|NCT02568904|Other|Glucose|oral Glucose tolerance test
211471|NCT02568904|Other|Fructose|oral fructose tolerance test
211472|NCT02568904|Other|vehicle|control (water)
211473|NCT02568891|Dietary Supplement|Probiotic|multispecies probiotic
211474|NCT02568891|Dietary Supplement|Placebo|matrix
211475|NCT02568878|Drug|Creatine monohydrate|
211476|NCT02568865|Other|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
211477|NCT02568865|Other|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
211478|NCT02568865|Other|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
211479|NCT02568865|Other|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
211480|NCT02568852|Procedure|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
211481|NCT02568852|Procedure|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
211482|NCT02568839|Drug|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
211483|NCT02568839|Drug|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
211484|NCT02568826|Drug|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
211485|NCT02568813|Behavioral|Multiscore Depression Inventory for Children scale|
211486|NCT02568800|Drug|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
211487|NCT02568800|Drug|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
211488|NCT02568787|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
211489|NCT02568787|Dietary Supplement|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
211585|NCT02568033|Drug|Cisplatin|
211491|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
211492|NCT02568761|Procedure|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
211493|NCT02568761|Other|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
211494|NCT02568748|Biological|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
211495|NCT02568748|Procedure|TACE|Trans-arterial chemoembolization
211496|NCT02568735|Drug|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
211497|NCT02568735|Drug|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
211498|NCT02568722|Other|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:~serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization."
211499|NCT02568722|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
211500|NCT02568709|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
211501|NCT02568709|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
211502|NCT02568683|Drug|Entospletinib|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
211503|NCT02568683|Drug|Vincristine|VCR administered intravenously
211504|NCT02568670|Other|clinical signs|to remove the peripheral venous catheter according clinical signs
211505|NCT02568657|Device|Celox group|
211506|NCT02568657|Device|Bakri Balloon|
211507|NCT02568644|Dietary Supplement|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerois).
211508|NCT02568644|Other|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
211509|NCT02568644|Drug|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
211510|NCT02568631|Other|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
211511|NCT02568631|Other|control video game|The patients will play 6 sessions of one hour with the control video game
211512|NCT02568618|Genetic|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
211513|NCT02568605|Dietary Supplement|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
211514|NCT02568605|Dietary Supplement|Placebo|Maltodextrin
211515|NCT02568605|Behavioral|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
211516|NCT02568592|Dietary Supplement|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
211517|NCT02568592|Dietary Supplement|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
211518|NCT02568592|Dietary Supplement|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
211519|NCT02568579|Procedure|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
211520|NCT02568566|Other|Laboratory Biomarker Analysis|Correlative studies
211521|NCT02568566|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
211522|NCT02568553|Biological|Blinatumomab|Given IV
211523|NCT02568553|Drug|Lenalidomide|Given PO
211524|NCT02568527|Device|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
211525|NCT02568514|Device|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
211526|NCT02568501|Behavioral|Daily feedback|Daily feedback on glucose levels from wireless glucometers
211527|NCT02568501|Behavioral|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
211528|NCT02568488|Drug|Metformin|850 mg orally twice daily for 6 months
211529|NCT02568475|Behavioral|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
211530|NCT02568462|Device|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
211531|NCT02568449|Drug|Nintedanib|Given PO
211532|NCT02568436|Radiation|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
211533|NCT02568423|Drug|Mirikizumab - IV|Administered IV
211534|NCT02568423|Drug|Mirikizumab - SC|Administered SC
211536|NCT02568423|Drug|Placebo - SC|Administered SC
211537|NCT02568410|Procedure|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
211538|NCT02568397|Drug|Lanabecestat|Administered orally
211539|NCT02568397|Drug|Dabigatran etexilate|Administered orally
211540|NCT02568384|Device|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
211541|NCT02568358|Other|Experimental Intervention: DNA-based testing of BAL fluid|DNA based testing needs 4.5 hours lab time in addition to standard testing
211542|NCT02568345|Drug|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.~In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
211543|NCT02568332|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
211544|NCT02568332|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
211545|NCT02568319|Drug|LIPO-202|
211546|NCT02568319|Drug|Placebo|
211547|NCT02568306|Drug|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose [SD] or multiple dose [MD] with daily dosing.
211548|NCT02568306|Drug|placebo|Administered subcutaneously (s.c., under the skin) single dose [SD]) or multiple dose [MD] with daily dosing.
211549|NCT02568293|Other|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
211550|NCT02568293|Other|Saline|Saline is used as a control.
211551|NCT02568280|Drug|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
211552|NCT02568280|Drug|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
211553|NCT02568267|Drug|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
211554|NCT02568254|Device|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
211555|NCT02568254|Device|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
211556|NCT02568254|Device|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
211557|NCT02568241|Other|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
211558|NCT02568228|Dietary Supplement|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
211559|NCT02568228|Other|Lean and fatty fish|The fish group will be open labeled.
211560|NCT02568228|Dietary Supplement|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
211561|NCT02568215|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
211562|NCT02568215|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
211563|NCT02568202|Other|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.~There will be no treatment."
211564|NCT02568189|Device|SonoSite Maxx Series Ultrasound System|Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
211565|NCT02568176|Drug|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
211566|NCT02568176|Drug|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
211567|NCT02568176|Drug|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
211568|NCT02568163|Other|Non surgical periodontal treatment|
211569|NCT02568150|Biological|Single group, open-label|
211570|NCT02568137|Behavioral|Smart-phone based technology|
211571|NCT02568124|Drug|Tranexamic Acid|
211572|NCT02568124|Drug|Placebo|
211573|NCT02568111|Drug|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
211574|NCT02568111|Drug|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
211575|NCT02568111|Drug|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
211576|NCT02568098|Drug|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
211577|NCT02568098|Drug|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
211578|NCT02568098|Drug|DHA-PQP|Regimen 6: DHA-PQP
211579|NCT02568085|Device|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
211580|NCT02568059|Drug|Sahastara remedy alcoholic extract|comparison of different dose of drug
211581|NCT02568046|Drug|Sym004|Sym004 is a 1:1 mixture of 2 monoclonal antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the epidermal growth factor receptor (EGFR).
211582|NCT02568046|Drug|FOLFIRI|The standard FOLFIRI regimen consists of Irinotecan (180 mg/m^2 IV, infused over 60-90 minutes) concurrently with Folinic Acid (400 mg/m^2 IV, infused over 120 minutes) followed by 5-FU (400 mg/m^2 IV bolus, then 2400 mg/m^2 infused over 46 hours).
211583|NCT02568033|Drug|Pemetrexed|
211588|NCT02568033|Radiation|stereotactic radiosurgery|
211589|NCT02568020|Drug|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
211590|NCT02568007|Drug|Cyproheptadine|
211591|NCT02567994|Drug|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
211592|NCT02567981|Dietary Supplement|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
211593|NCT02567981|Dietary Supplement|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
211594|NCT02567981|Dietary Supplement|Ferrous sulphate|"Ferrous sulfate drops children <12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).~Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
211595|NCT02567981|Dietary Supplement|Vitamin A|Vitamin A Capsules: children <12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
211596|NCT02567968|Drug|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
211597|NCT02567968|Drug|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
211598|NCT02567955|Biological|Immunogenicity two doses of Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
211599|NCT02567955|Biological|Immunogenicity Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
211600|NCT02567942|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation
211601|NCT02567942|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
211602|NCT02567929|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
211603|NCT02567929|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation.
211604|NCT02567916|Drug|Fresofol|
211605|NCT02567916|Drug|Propofol|
211606|NCT02567903|Device|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
211607|NCT02567903|Procedure|Knee arthroscopy|Knee arthroscopy
211608|NCT02567890|Behavioral|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
211609|NCT02567890|Behavioral|Expressive writing|Participants will be asked to reflect upon issues related to body image.
211610|NCT02567877|Procedure|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
211611|NCT02567877|Drug|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
211612|NCT02567864|Other|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
211613|NCT02567864|Other|control|participants maintain their daily activities.
211614|NCT02567851|Drug|Brentuximab Vedotin|Monoclonal antibody drug conjugate
211615|NCT02567838|Drug|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
211616|NCT02567838|Drug|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
211617|NCT02567825|Procedure|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used. Participants will be followed overtime for recurrences of AOM and treated with topical antimicrobials.
211618|NCT02567825|Procedure|Nonsurgical management|Participants will be followed overtime for recurrences of AOM and treated with systemic antimicrobials.
211619|NCT02567799|Drug|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
211620|NCT02567799|Drug|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
211621|NCT02567799|Drug|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg*min/mL will be administered by intravenous drip two times, 21 days apart."
211622|NCT02567799|Radiation|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 1.8-2.0 Gy per fraction, for 6-7 weeks.
211623|NCT02567786|Procedure|Surgery with CPB|
211624|NCT02567786|Other|Fresh Frozen Plasma|
211625|NCT02567786|Other|Plasmalyte|
211626|NCT02567773|Drug|GSK2881078|GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
211627|NCT02567773|Drug|Placebo|Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
211628|NCT02567773|Drug|Itraconazole|Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
211629|NCT02567760|Dietary Supplement|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
211630|NCT02567760|Other|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
211631|NCT02567747|Other|Data collection|Data will be collected retrospectively for cases identified through RIPS*/ DANE** from 2008 until 2014 and through PAI*** from 2009 until 2014. *Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. **Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. ***Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
211632|NCT02567734|Procedure|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
211633|NCT02567721|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
211634|NCT02567708|Drug|GSK2269557 DPI|GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
211635|NCT02567708|Drug|Placebo DPI|Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
211636|NCT02567695|Drug|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
211637|NCT02567682|Drug|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
211638|NCT02567669|Radiation|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
211639|NCT02567656|Drug|RP6530|Tablet starting at 200 mg
211640|NCT02567643|Radiation|Stereotactic Radiosurgery|
211641|NCT02567630|Behavioral|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
211642|NCT02567617|Dietary Supplement|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
211643|NCT02567617|Dietary Supplement|Placebo controlled|Starch capsules
211644|NCT02567604|Behavioral|Focus Groups|at least three focus groups lasting approximately one hour
211645|NCT02567591|Other|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
211646|NCT02567578|Drug|YH12852 0.1 mg|
211647|NCT02567578|Drug|YH12852 0.25 mg|
211648|NCT02567578|Drug|YH12852 0.5 mg|
211649|NCT02567578|Drug|Placebo|
211650|NCT02567565|Other|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
211651|NCT02567552|Drug|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
211652|NCT02567552|Drug|Intramuscular progesterone|intramuscular progesterone 50 mg/day
211653|NCT02567539|Radiation|IMRT with or without radiosensitive therapy|Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
211654|NCT02567539|Drug|Radiosensitive therapy|Radiosensitive therapy with Temozolomide
211655|NCT02567526|Behavioral|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
211656|NCT02567513|Behavioral|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
211657|NCT02567513|Behavioral|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
211658|NCT02567500|Behavioral|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with DSM-IV criteria:~MINI-Kids~Psychosis section of Kiddie-SADS"
211659|NCT02567500|Behavioral|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):~Evaluation at time 0 and 6 month after of:~The social cognitive marker (NEPSY II) : theory of mind and affect recognition~The emotional marker:~Differential emotion scale IV (DES IV): emotional individual stability~Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.~Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.~Evaluation of diagnosis with DSM-IV criteria:~MINI-Kids~Psychosis section of Kiddie-SADS"
211660|NCT02567487|Drug|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
211661|NCT02567474|Behavioral|5 A model|self management program based on 5A model
211662|NCT02567461|Drug|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
211663|NCT02567461|Drug|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
211664|NCT02567461|Drug|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
211665|NCT02567461|Drug|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
211666|NCT02567448|Other|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
211667|NCT02567435|Drug|Cyclophosphamide|Given IV and PO
211668|NCT02567435|Biological|Dactinomycin|Given IV
211669|NCT02567435|Drug|Irinotecan Hydrochloride|Given IV
211670|NCT02567435|Other|Laboratory Biomarker Analysis|Correlative studies
211671|NCT02567435|Other|Questionnaire Administration|Ancillary studies
211672|NCT02567435|Radiation|Radiation Therapy|Undergo RT
211673|NCT02567435|Drug|Temsirolimus|Given IV
211674|NCT02567435|Drug|Vincristine Sulfate|Given IV
211675|NCT02567435|Drug|Vinorelbine|Given IV
211676|NCT02567422|Drug|ATR Kinase Inhibitor M6620|Given IV
211677|NCT02567422|Drug|Cisplatin|Given IV
211678|NCT02567422|Other|Laboratory Biomarker Analysis|Correlative studies
211679|NCT02567422|Other|Pharmacological Study|Correlative studies
211680|NCT02567422|Radiation|Radiation Therapy|Undergo radiation therapy
211681|NCT02567409|Drug|ATR Kinase Inhibitor M6620|Given IV
211682|NCT02567409|Drug|Cisplatin|Given IV
211683|NCT02567409|Drug|Gemcitabine|Given IV
211684|NCT02567409|Drug|Gemcitabine Hydrochloride|Given IV
211685|NCT02567396|Other|Laboratory Biomarker Analysis|Correlative studies
211686|NCT02567396|Other|Pharmacological Study|Correlative studies
211687|NCT02567396|Drug|Talazoparib|Given PO
211688|NCT02567383|Radiation|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
211689|NCT02567383|Device|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
211690|NCT02567383|Drug|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
211691|NCT02567383|Drug|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
211692|NCT02567370|Drug|AMG 581|Active drug
211693|NCT02567370|Drug|Placebo|Placebo
211694|NCT02567357|Behavioral|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
211695|NCT02567357|Behavioral|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
211696|NCT02567344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
211697|NCT02567344|Device|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
211698|NCT02567331|Drug|Capecitabine|Participants will receive 1250 mg/m^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
211699|NCT02567318|Device|MRI-scan|Magnetic resonance imaging scan of the brain
211700|NCT02567305|Other|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
211701|NCT02567292|Other|Human Milk|Participants will receive an exclusive human milk diet comprised of mother's own milk (MOM, pasteurized donor human milk (DM) fortified with a donor-milk based fortifier (DMBF): Prolact+ for infants <37 weeks PMA and/or or weight <2,200g or PBCLN-002 for infants >37 weeks PMA and/or weight >2,200g)
211702|NCT02567279|Drug|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
211703|NCT02567279|Drug|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
211704|NCT02567266|Behavioral|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
211745|NCT02566928|Other|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
211746|NCT02566928|Behavioral|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
213871|NCT02551731|Drug|Cannabidiol Oral Solution|20 or 40 mg/kg/day BID
211705|NCT02567266|Behavioral|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
211706|NCT02567266|Behavioral|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
211707|NCT02567253|Procedure|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
211708|NCT02567253|Drug|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
211709|NCT02567253|Drug|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
211710|NCT02567253|Drug|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
211711|NCT02567253|Drug|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
211712|NCT02567240|Other|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
211713|NCT02567227|Other|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
211714|NCT02567227|Other|Active Control|Computer, multimedia and group based health education programs.
211715|NCT02567214|Drug|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
211716|NCT02567214|Drug|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
211717|NCT02567201|Other|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
211718|NCT02567201|Other|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
211719|NCT02567188|Other|MIRCERA|
211720|NCT02567175|Drug|Domperidone|
211721|NCT02567149|Drug|Cidofovir|Cidofovir
211722|NCT02567123|Behavioral|Experimental|
211723|NCT02567097|Behavioral|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
211724|NCT02567084|Device|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
211725|NCT02567071|Other|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
211726|NCT02567071|Other|clean swab|After planned C-section birth, newborns will suck on clean swab.
211727|NCT02567058|Device|Ultrasound exam|"Ultrasound exam with :~2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I~1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II~1 succession of 3 measures for group III"
211728|NCT02567058|Behavioral|IPAQ questionnaire|IPAQ questionnaire
211729|NCT02567045|Procedure|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
211730|NCT02567045|Procedure|colonoscopy with sedation|One-time Colonoscopy with sedation.
211731|NCT02567032|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
211732|NCT02567032|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
211733|NCT02567019|Other|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
211734|NCT02567006|Behavioral|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
211735|NCT02567006|Other|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
211736|NCT02566993|Drug|Lurbinectedin (PM01183)|
211737|NCT02566993|Drug|Doxorubicin (DOX)|
211738|NCT02566993|Drug|Cyclophosphamide (CTX)|
211739|NCT02566993|Drug|Vincristine (VCR)|
211740|NCT02566993|Drug|Topotecan|
211741|NCT02566967|Drug|tofacitinib|oral tofacitinib will be taken 2 times daily
211742|NCT02566954|Other|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.~3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
211743|NCT02566941|Device|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
211744|NCT02566928|Drug|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
211747|NCT02566915|Device|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
211748|NCT02566902|Device|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
211749|NCT02566902|Device|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
211750|NCT02566902|Drug|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
211751|NCT02566902|Procedure|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
211752|NCT02566902|Procedure|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
211753|NCT02566889|Drug|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
211754|NCT02566876|Drug|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
211755|NCT02566863|Drug|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
211756|NCT02566850|Device|Ekso|powered lower extremity exoskeleton
211757|NCT02566837|Procedure|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
211758|NCT02566837|Procedure|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
211759|NCT02566824|Behavioral|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
211760|NCT02566824|Behavioral|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
211761|NCT02566824|Other|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
211762|NCT02566824|Drug|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
211763|NCT02566811|Procedure|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
211764|NCT02566811|Procedure|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
211765|NCT02566798|Drug|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
211766|NCT02566798|Drug|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.~Blood samples and synovial fluid are performed on D0 and D7"
211799|NCT02566564|Drug|Lopain|intra-articular injection
211846|NCT02566226|Drug|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
211767|NCT02566785|Other|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
211768|NCT02566772|Drug|TAS3681|TAS3681 will be provided as 25 mg and 100 mg tablets to be administered orally for 28 day cycles, Number of cycles: approximately 6 or until discontinuation criteria is met.
211769|NCT02566759|Drug|TAK-831 Oral Suspension|TAK-831 oral suspension.
211770|NCT02566759|Drug|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
211771|NCT02566759|Drug|TAK-831 Tablet|TAK-831 tablet.
211772|NCT02566746|Device|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
211773|NCT02566746|Drug|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde At 12 months : implantation of the Chait Trapdoor caecostomie catheter
211774|NCT02566733|Drug|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
211775|NCT02566733|Drug|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
211776|NCT02566720|Drug|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
211777|NCT02566720|Procedure|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
211778|NCT02566707|Drug|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
211779|NCT02566707|Drug|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
211780|NCT02566707|Drug|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
211781|NCT02566694|Procedure|Implant|orthopaedic implant
211782|NCT02566681|Biological|MSC construct for Osteonecrosis|"30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.~The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures."
211783|NCT02566668|Other|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
211784|NCT02566655|Biological|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).~Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
211785|NCT02566642|Other|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
211786|NCT02566629|Other|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
211787|NCT02566616|Device|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
211788|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
211789|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
211790|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
211791|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
211792|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
211793|NCT02566590|Device|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
211794|NCT02566590|Dietary Supplement|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
211795|NCT02566590|Dietary Supplement|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
211796|NCT02566577|Biological|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
211797|NCT02566577|Biological|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
211798|NCT02566577|Device|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
211800|NCT02566551|Procedure|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
211801|NCT02566551|Device|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
211802|NCT02566551|Procedure|TURP|Bipolar transurethral resection of the prostate
211803|NCT02566551|Device|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
211804|NCT02566525|Device|CytoSorb|Cytosorb device use during cardiopulmonary bypass
211805|NCT02566512|Other|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
211806|NCT02566512|Other|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
211807|NCT02566499|Device|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
211808|NCT02566486|Device|Reciprocating system|Different root canal instrumentation systems
211809|NCT02566486|Device|Rotational system|Different root canal instrumentation systems
211810|NCT02566460|Other|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
211811|NCT02566447|Device|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
211812|NCT02566434|Dietary Supplement|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
211813|NCT02566421|Other|Laboratory Biomarker Analysis|Correlative studies
211814|NCT02566421|Other|Quality-of-Life Assessment|Ancillary studies
211815|NCT02566421|Other|Targeted Therapy|Receive treatment based on genomic sequencing
211816|NCT02566408|Other|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
211817|NCT02566408|Other|Survey Questions|Complete survey
211818|NCT02566395|Radiation|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
211819|NCT02566395|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
211820|NCT02566395|Biological|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
211821|NCT02566395|Biological|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
211822|NCT02566382|Procedure|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
211823|NCT02566369|Drug|CD5789 (trifarotene) 50μg/g cream|CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
211824|NCT02566369|Drug|Placebo cream|Placebo cream applied once daily for 12 weeks
211825|NCT02566356|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
211826|NCT02566356|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
211827|NCT02566330|Device|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
211828|NCT02566317|Device|Sit-Stand workstation|Installation of a sit-stand desk at work
211829|NCT02566317|Behavioral|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
211830|NCT02566304|Drug|Fludarabine|Given IV
211831|NCT02566304|Radiation|Total-Body Irradiation|Undergo TBI
211832|NCT02566304|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
211833|NCT02566304|Drug|Cyclophosphamide|Given IV
211834|NCT02566304|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
211835|NCT02566304|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
211836|NCT02566304|Drug|Tacrolimus|Given PO
211837|NCT02566304|Drug|Mycophenolate mofetil|Given IV
211838|NCT02566291|Device|Success|Success rate and time for insertion
211839|NCT02566278|Other|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
211840|NCT02566265|Biological|Fluzone High Dose Vaccine|
211841|NCT02566265|Biological|Standard of care/Placebo|
211842|NCT02566252|Drug|PUL-042 Inhalation Solution|PUL-042
211843|NCT02566252|Drug|Cromolyn Sodium|Pre-treatment
211844|NCT02566252|Drug|Albuterol sulfate|Pre-treatment
211845|NCT02566239|Other|Share activity data with care team|Share participant in-home activity data with retirement community care team.
211889|NCT02565888|Drug|Ritonavir|
211847|NCT02566226|Drug|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
211848|NCT02566213|Other|Parabolic flight|
211849|NCT02566213|Other|Motor skills measurements|"the kinematics measurements of the right hand with a motion analysis system;~the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;~the measurement of position of the moved object with an inductive position encoder."
211850|NCT02566187|Drug|Fimasartan/Atorvastatin Combination Tablet|
211851|NCT02566187|Drug|Fimasartan|
211852|NCT02566187|Drug|Atorvastatin|
211853|NCT02566135|Device|Tracheal Intubation using I-gel and ventilating bougie|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
211854|NCT02566135|Device|Tracheal Intubation using C-LMA and ventilating bougie|Following general anaesthesia C-LMA was inserted. After proper placement of C-LMA, ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
211855|NCT02566122|Other|measurements|
211856|NCT02566109|Diagnostic Test|Fast MRI|The fast MRI is a 10 minute MRI scan that will be used to determine if cardiovascular injury can be detected early while patients are receiving chemotherapy treatment.
211857|NCT02566096|Drug|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
211858|NCT02566083|Device|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
211859|NCT02566083|Device|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
211860|NCT02566070|Other|Continuous Gastric Feeding|
211861|NCT02566070|Other|Bolus Gastric Feeding|
211862|NCT02566057|Biological|PGx testing guided treatment (PGT)|Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
211863|NCT02566044|Other|Placebo|Placebo
211864|NCT02566044|Drug|QBW276|0.3 mg and 1.5 mg strengths
211865|NCT02566031|Drug|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
211866|NCT02566031|Drug|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
211867|NCT02566018|Procedure|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
211868|NCT02566018|Procedure|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
211869|NCT02566005|Device|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
211870|NCT02566005|Device|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
211871|NCT02565992|Biological|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
211872|NCT02565992|Drug|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
211873|NCT02565979|Dietary Supplement|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
211874|NCT02565979|Dietary Supplement|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
211875|NCT02565966|Other|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
211876|NCT02565953|Device|Paclitaxel-releasing PTA balloon catheter|
211877|NCT02565953|Device|PTA balloon catheter|
211878|NCT02565940|Other|biopsy|
211879|NCT02565927|Device|Traditional airway stent|process airway stenting
211880|NCT02565927|Drug|Iodine-125 seeds|process intraluminal brachytherapy
211881|NCT02565914|Drug|VX-661/ivacaftor|
211882|NCT02565914|Drug|ivacaftor|
211883|NCT02565901|Drug|Carboplatin|Given IV
211884|NCT02565901|Drug|Docetaxel|Given IV
211885|NCT02565901|Other|Laboratory Biomarker Analysis|Correlative studies
211886|NCT02565901|Drug|Sirolimus|Given PO
211887|NCT02565888|Drug|Daclatasvir|
211888|NCT02565888|Drug|Atazanavir|
211891|NCT02565875|Behavioral|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
211892|NCT02565875|Behavioral|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
211893|NCT02565875|Other|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
211894|NCT02565862|Drug|Daclatasvir|
211895|NCT02565862|Drug|Metformin|
211896|NCT02565836|Drug|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.~Check INR after infusion and may repeat dose if INR still elevated"
211897|NCT02565836|Drug|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.~Check INR after infusion and may repeat dose if INR still elevated."
211898|NCT02565823|Other|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
211899|NCT02565810|Drug|Adalimumab PFS and Pen|
211900|NCT02565797|Device|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
211901|NCT02565784|Device|Restylane|Facial tissue augmentation
211902|NCT02565784|Device|Perlane|Facial tissue augmentation
211903|NCT02565771|Other|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
211904|NCT02565758|Drug|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
211905|NCT02565745|Combination Product|Skin dressing|Pre-determined skin areas at risk for PUs (3 or more, depending on the prevaliing body position, prone, supine or Sims') will be covered. Dressings will be changed every 6-7 days unless found wet/contaminated
211906|NCT02565745|Other|Moisturizing cream|It will be applied twice a day to the same skin areas as the experimental group
211907|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
211908|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
211909|NCT02565732|Biological|Placebo comparator|Placebo, Dose C, Topical
211910|NCT02565719|Drug|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
211911|NCT02565719|Drug|Pegasys|immunotherapy
211912|NCT02565719|Drug|Viread|HBV RT polymerase inhibitor
211913|NCT02565719|Drug|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
211914|NCT02565706|Behavioral|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
211915|NCT02565706|Behavioral|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
211916|NCT02565693|Drug|Apixaban|
211917|NCT02565693|Drug|Aspirin|
211918|NCT02565693|Drug|Carbasalate calcium|
211919|NCT02565693|Drug|Clopidogrel|
211920|NCT02565693|Drug|Dipyridamole|
211921|NCT02565693|Other|No antithrombotic treatment|
211922|NCT02565680|Drug|placebo|Xyzall 5mg during 5 days + placebo 40mg during 4 days
211923|NCT02565680|Drug|prednisone|Xyzall 5mg during 5 days + prednisone 40mg during 4 days
211924|NCT02565667|Device|KOL|KOL staple was used for rectal anastomosis
211925|NCT02565667|Device|traditional staple|traditional staple was used for rectal anastomosis
211926|NCT02565641|Drug|Capecitabine|Capecitabine will be administered orally at 830 mg/m^2 BID (equivalent to a total daily dose of 1660 mg/m^2) as intermittent treatment (given days 1 to 21 q4w).
211927|NCT02565641|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
211928|NCT02565628|Drug|PF-06669571|1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
211929|NCT02565628|Drug|Placebo|Placebo
211930|NCT02565615|Other|No intervention|Because this is a non-interventional study, there is no intervention here.
211931|NCT02565602|Other|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
211932|NCT02565602|Other|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
211933|NCT02565602|Dietary Supplement|Vitamin D|One tablet daily (400IU per tablet)
211934|NCT02565576|Drug|Placebo|
211935|NCT02565576|Drug|CFZ533|
211936|NCT02565563|Other|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
211937|NCT02565563|Device|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
211938|NCT02565550|Dietary Supplement|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
211939|NCT02565537|Procedure|LASIK|WFG vs. WFO LASIK
211940|NCT02565524|Other|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
211941|NCT02565511|Biological|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
211942|NCT02565511|Other|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
211943|NCT02565511|Drug|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
211944|NCT02565511|Other|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
211945|NCT02565498|Radiation|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
211946|NCT02565498|Radiation|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
211947|NCT02565485|Drug|Lactated Ringer's|1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
211948|NCT02565472|Other|White grape juice|
211949|NCT02565472|Other|Apple juice|
211950|NCT02565459|Biological|Mesenchymal Stromal Cells|
211951|NCT02565446|Device|Magnetic Resolution Elastography|Correlation between histology and MRE with respect to liver fibrosis and inflammation.
211952|NCT02565446|Procedure|Bariatric surgery|Recruitment will be of patients who are scheduled to undergo bariatric surgery. During the time of surgery a liver biopsy will be taken clinically to identify liver disease. In addition, liver and fat tissue will be obtained for research purposes.
211953|NCT02565433|Other|questionnaire administration|Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
211954|NCT02565420|Other|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
211955|NCT02565420|Other|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
211956|NCT02565407|Behavioral|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
211957|NCT02565407|Behavioral|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
211958|NCT02565394|Other|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
211959|NCT02565381|Drug|Transdermal nicotine patch|"≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks~<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
211960|NCT02565381|Behavioral|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
211961|NCT02565381|Behavioral|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide <8ppm
211962|NCT02565381|Behavioral|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
211963|NCT02565368|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
211964|NCT02565368|Drug|CKD-395 0.5/1000mg|single oral administration
211965|NCT02565355|Other|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
211966|NCT02565355|Other|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
211967|NCT02565342|Procedure|Interscalene brachial plexus block|
211968|NCT02565316|Drug|Nepeta menthoides Boiss & Bohse freeze dried extract|
211969|NCT02565316|Drug|Sertraline|
211970|NCT02565303|Procedure|Intervertebral space|
211971|NCT02565303|Drug|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
211972|NCT02565290|Dietary Supplement|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
211973|NCT02565290|Dietary Supplement|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
211974|NCT02565277|Biological|Influenza Vaccine|
211975|NCT02565277|Drug|Placebo|
211976|NCT02565264|Other|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
212185|NCT02563808|Other|Standard Decision Aid|Females will receive standard decisions aid for early stage breast cancer.
211977|NCT02565251|Device|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
211978|NCT02565251|Device|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
211979|NCT02565251|Device|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
211980|NCT02565238|Device|BioMonitor 2|Implantation of BioMonitor 2
211981|NCT02565225|Behavioral|RheumaLive App use|
211982|NCT02565212|Drug|Montelukast,mometazon froat|
211983|NCT02565199|Device|rTMS over Premotor Cortex (Contralateral Hemisphere)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
211984|NCT02565199|Device|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
211985|NCT02565199|Device|rTMS (Control 1)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 400 milliseconds after the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
211986|NCT02565199|Device|rTMS (Control 2)|"Location of rTMS: somatosensory cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator"
211987|NCT02565199|Device|rTMS (Control 3)|"Location of rTMS: premotor cortex~Frequency of rTMS: 0.1 Hz~Time of rTMS: 50 milliseconds before the onset of movement-related EMG~Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
211988|NCT02565199|Other|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
211989|NCT02565186|Drug|lasmiditan|oral tablet
211990|NCT02565173|Drug|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
211991|NCT02565173|Drug|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
211992|NCT02565173|Drug|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
211993|NCT02565173|Drug|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
211994|NCT02565173|Drug|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
211995|NCT02565160|Procedure|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
211996|NCT02565160|Procedure|Joint irrigation washout|Procedural washout for treatment purposes
211997|NCT02565160|Procedure|Total Joint Arthroplasty|
211998|NCT02565160|Procedure|Revision Joint Arthroplasty|
211999|NCT02565147|Procedure|PPCI|PPCI for treatment of participants presenting with large STEMI.
212000|NCT02565147|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds thrombin in a bivalent and reversible fashion and directly inhibits it.
212001|NCT02565147|Drug|Heparin|Heparin is an anticoagulant.
212002|NCT02565134|Drug|PAC-14028 cream 0.1%|Topical application
212003|NCT02565134|Drug|PAC-14028 cream 0.3%|Topical application
212004|NCT02565134|Drug|PAC-14028 cream 1.0%|Topical application
212005|NCT02565134|Drug|PAC-14028 cream vehicle|Topical application
212006|NCT02565121|Drug|corticosteroids|
212007|NCT02565121|Behavioral|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
212008|NCT02565108|Drug|GWP42003-P 20 mg/kg/Day Dose|GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
212009|NCT02565108|Drug|Placebo|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
212010|NCT02565108|Drug|Clobazam|Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
212011|NCT02565095|Procedure|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
212012|NCT02565082|Other|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
212013|NCT02565082|Other|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
212014|NCT02565082|Other|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
212015|NCT02565082|Other|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
212016|NCT02565069|Device|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
212017|NCT02565056|Other|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
212018|NCT02565043|Device|RENASYS TOUCH Negative Pressure Wound Therapy System|RENASYS TOUCH NPWT System was administered to all participants.
212042|NCT02564796|Drug|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
212083|NCT02564445|Behavioral|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
212705|NCT02560194|Other|Fecal occult blood test|Test for hemoglobin in faeces
212019|NCT02565017|Behavioral|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
212020|NCT02564978|Drug|Minocycline|Adult participants will be instructed to take their prescribed IP orally two times a day, once in the morning and once in the evening, approximately 12 hours apart. The capsules will be dispensed to the participant in a tight, light-resistant container as defined in the USP in three- month supply aliquots. Starting at Month 9 and continuing at Month 12, a three-month supply will be dispensed to the participant during the study visit or mailed to the participant. Participants will be given an instruction sheet for taking the prescribed IP (Appendix 5). Starting at Month 15 participants will receive two bottles for a six-month supply. The IP should be stored between 15- 30 (Infinite)C (or 59-86 (Infinite)F). They should be protected from light, moisture, and excessive heat. Participants will be required to bring their bottles of IP to each appropriate visit for capsule counts for compliance monitoring.
212021|NCT02564965|Device|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
212022|NCT02564965|Device|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
212023|NCT02564952|Drug|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
212024|NCT02564952|Drug|Clobazam|Participants were taking CLB upon entry into the OLE phase of the trial. CLB was not an investigational medicinal product (IMP) for the OLE phase and was not administered by the Sponsor, but was administered at the physician's discretion, as required for each participant. CLB could be stopped, if clinically indicated, without impact on analysis.
212025|NCT02564939|Drug|ramelteon|double-blind RCT
212026|NCT02564939|Drug|Placebo|double-blind RCT
212027|NCT02564926|Drug|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
212028|NCT02564926|Drug|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
212029|NCT02564913|Other|clinical evaluation|
212030|NCT02564900|Drug|DS-8201a|
212031|NCT02564887|Device|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
212032|NCT02564874|Other|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
212033|NCT02564861|Drug|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
212034|NCT02564861|Drug|Placebo|Placebo matching DS-1971a suspension
212035|NCT02564848|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
212036|NCT02564835|Other|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
212037|NCT02564835|Other|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
212038|NCT02564822|Procedure|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
212039|NCT02564809|Behavioral|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
212040|NCT02564809|Behavioral|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
212041|NCT02564809|Behavioral|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
212082|NCT02564445|Behavioral|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
212043|NCT02564796|Other|Control|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
212044|NCT02564783|Other|No intervention|No intervention
212045|NCT02564744|Drug|Debio 1562|Safety run in: Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Part 2 and 3: Cohort A- Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle. Cohort B- Debio 1562 will be given at a total dose of 0.8 milligram per kilogram (mg/kg) IV over a 21-day cycle.
212046|NCT02564744|Drug|Rituximab|Rituximab will be given on the same day as Debio 1562, Q3W IV at a dose of 375 mg/m^2 on Day 1 of a 21-day cycle.
212047|NCT02564718|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venous thromboembolism (VTE) with 20 mg once daily.
212048|NCT02564705|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|
212049|NCT02564705|Procedure|Posterior Fusion|"Posterolateral Fusion (PLF)~Posterior Lumbar Interbody Fusion (PLIF)~Transforaminal Lumbar Interbody Fusion (TLIF)"
212050|NCT02564679|Procedure|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.~At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
212051|NCT02564679|Behavioral|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.~They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
212052|NCT02564666|Other|telephone counseling|regular telephone counseling for compliance and advese event
212053|NCT02564653|Behavioral|Technical Assistance, training and clinical reminders|Technical Assistance, training and clinical reminders (TTC)
212054|NCT02564653|Behavioral|TTC+Referral to Community Health Worker|TTC+ referral to a VHW for additional counseling and follow-up
212055|NCT02564640|Device|videolaryngoscope|patients intubated by using the videolaryngoscope
212056|NCT02564640|Device|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
212057|NCT02564627|Procedure|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
212058|NCT02564627|Procedure|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
212059|NCT02564627|Dietary Supplement|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
212060|NCT02564614|Drug|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
212061|NCT02564601|Behavioral|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
212062|NCT02564601|Behavioral|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
212063|NCT02564588|Drug|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
212064|NCT02564588|Drug|Placebo|Placebo once daily
212065|NCT02564575|Biological|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
212066|NCT02564562|Drug|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + [14C] PF-06463922
212067|NCT02564549|Procedure|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
212068|NCT02564549|Procedure|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
212069|NCT02564536|Drug|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
212070|NCT02564536|Drug|Decitabine|-From commercial stock
212071|NCT02564523|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)
212072|NCT02564523|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units)
212073|NCT02564523|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline
212074|NCT02564497|Biological|Process E Belatacept|
212075|NCT02564497|Biological|Process C Belatacept|
212076|NCT02564471|Drug|Chloroquine|FDA approve dosing schedule
212077|NCT02564471|Drug|Atovaquone and Proguanil|FDA approve dosing schedule
212078|NCT02564471|Drug|Doxycycline|FDA approve dosing schedule
212079|NCT02564471|Biological|Rabies Vaccine|FDA approve dosing schedule
212080|NCT02564458|Behavioral|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
212081|NCT02564445|Behavioral|Gamification|All participants will be entered with their teammate into a game that includes points and levels
212084|NCT02564445|Behavioral|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
212085|NCT02564419|Device|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
212086|NCT02564406|Device|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
212087|NCT02564380|Drug|Pembrolizumab|
212088|NCT02564380|Drug|Placebo|
212089|NCT02564367|Drug|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks"
212090|NCT02564354|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
212091|NCT02564341|Behavioral|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
212092|NCT02564341|Behavioral|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
212093|NCT02564341|Behavioral|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
212094|NCT02564328|Genetic|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
212095|NCT02564315|Drug|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
212096|NCT02564315|Behavioral|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
212097|NCT02564315|Behavioral|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
212098|NCT02564315|Behavioral|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
212099|NCT02564315|Behavioral|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
212100|NCT02564315|Behavioral|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
212101|NCT02564315|Behavioral|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
212174|NCT02563847|Dietary Supplement|75 g Glucose|
212175|NCT02563847|Dietary Supplement|300 mL tap water|
212176|NCT02563847|Other|50 mg 13C-sodium acetate|
212177|NCT02563834|Drug|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
212102|NCT02564315|Drug|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke >10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke <=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
212103|NCT02564302|Device|MUSE Headband|MUSE Headband will help patients with mindfulness.
212104|NCT02564276|Procedure|Sentinel lymph node biopsy|
212105|NCT02564263|Biological|pembrolizumab|IV infusion
212106|NCT02564263|Drug|paclitaxel|IV infusion
212107|NCT02564263|Drug|docetaxel|IV infusion
212108|NCT02564263|Drug|irinotecan|IV infusion
212109|NCT02564237|Biological|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
212110|NCT02564237|Biological|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
212111|NCT02564237|Biological|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
212112|NCT02564237|Biological|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
212113|NCT02564224|Procedure|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
212114|NCT02564224|Procedure|Conventional Wound Closure|Procedure: Conventional Wound Closure
212115|NCT02564224|Device|prolene|
212116|NCT02564211|Drug|Ipragliflozin|one 50 mg tablet QD
212117|NCT02564211|Drug|Sitagliptin|one 50 mg tablet QD
212118|NCT02564198|Drug|Ramucirumab|Administered IV
212119|NCT02564185|Other|Usual practice|
212120|NCT02564185|Other|Education program|
212121|NCT02564172|Device|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:~Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)~Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation~If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.~If test phase negative, the lead is removed.~Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.~(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
212122|NCT02564172|Other|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:~at effective dose, and minimal effective dose on the basis of adverse events and contraindications~as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.~Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.~Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated."
212123|NCT02564159|Other|Measure of quadriceps thickness with ultrasonography and albumin/prealbumin levels|"Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ;~Biospecimen collection: Blood samples (prealbumin levels, C-reactive protein, Interleukin-1, Interleukin-6, TNF-alpha and PATROL test™)collection of albumin and prealbumin levels"
212124|NCT02564146|Drug|nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
212125|NCT02564146|Drug|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:~3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Continouous treatment after randomization:~Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.~Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.~Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.~Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
212126|NCT02564133|Device|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
212127|NCT02564107|Drug|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
212128|NCT02564094|Drug|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
212129|NCT02564081|Other|Static Stretching lower limb|
212130|NCT02564081|Other|Static stretching Cervical|
212178|NCT02563834|Drug|Saline|Saline infusion for control
212179|NCT02563834|Drug|Insulin|Insulin infusion for insulin/glucose clamp procedure
212180|NCT02563821|Procedure|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
212181|NCT02563821|Drug|Levobupivacaine|
212182|NCT02563821|Drug|sufentanil|
212183|NCT02563821|Drug|clonidine|
212184|NCT02563821|Device|epidural catheter|
212131|NCT02564068|Drug|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. Ten subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
212132|NCT02564068|Drug|Placebo|Group B is a crossover study, where subjects will be randomized to receive either placebo or active drug on their first visit, and then the opposite intervention on their second visit.
212133|NCT02564055|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
212134|NCT02564055|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
212135|NCT02564055|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
212136|NCT02564042|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
212137|NCT02564042|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
212138|NCT02564042|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
212139|NCT02564029|Drug|PF-06372865|Single dose
212140|NCT02564029|Drug|Placebo|Placebo for PF-06372865 and placebo for lorazepam
212141|NCT02564029|Drug|Lorazepam|2 mg single oral dose
212142|NCT02564016|Drug|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
212143|NCT02564016|Other|Capped Epidural|epidural will be capped with no saline infusion.
212144|NCT02564003|Drug|Oxycodone|oxycodone 0,1 mg/kg iv
212145|NCT02563990|Procedure|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
212146|NCT02563990|Procedure|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
212147|NCT02563990|Drug|High Pressure Injection|Ropivacaine 0.2% injection at greater than 20 psi injection pressure
212148|NCT02563990|Drug|Low Pressure Injection|Ropivacaine 0.2% injection at less than 15 psi injection pressure
212149|NCT02563977|Device|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
212150|NCT02563951|Drug|GNS Spray 0.5mg|
212151|NCT02563951|Drug|GNS Spray 1.0mg|
212152|NCT02563951|Drug|GNS Spray 2.0mg|
212153|NCT02563951|Drug|Kytril 1mg (IV injection)|
212154|NCT02563951|Drug|Kytril 1mg (Tablet)|
212155|NCT02563938|Drug|AK001|Given parenterally.
212156|NCT02563938|Drug|Placebo|
212157|NCT02563925|Radiation|Brain radiotherapy or Stereotactic Radiosurgery|
212158|NCT02563925|Drug|Tremelimumab|
212159|NCT02563925|Drug|HER2 directed therapy|
212160|NCT02563925|Drug|Durvalumab|
212161|NCT02563912|Other|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
212162|NCT02563912|Other|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
212163|NCT02563899|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
212164|NCT02563899|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
212165|NCT02563886|Other|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
212166|NCT02563886|Other|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
212167|NCT02563873|Device|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
212168|NCT02563860|Drug|Lovastatin|dose escallating
212169|NCT02563847|Dietary Supplement|0.52 g L-Tryptophan|
212170|NCT02563847|Dietary Supplement|1.56 g L-Tryptophan|
212171|NCT02563847|Dietary Supplement|1.56 g L-Leucine|
212172|NCT02563847|Dietary Supplement|50 g Xylitol|
212173|NCT02563847|Dietary Supplement|75 g Erythritol|
212186|NCT02563808|Other|Post-surgical Regret Decision Aid|Females will receive anticipated regret-augmented version for early breast cancer.
212187|NCT02563795|Drug|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
212188|NCT02563795|Drug|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
212189|NCT02563782|Biological|Sub-retinal transplantation of MA09-hRPE cells|transplantation
212190|NCT02563782|Drug|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
212191|NCT02563782|Drug|Placebo tacrolimus and mycophenolate mofetil|placebo
212192|NCT02563782|Procedure|Sham Surgery|Sham surgery
212193|NCT02563769|Drug|Clavulanic acid|
212194|NCT02563769|Drug|Intravenous cocaine|
212195|NCT02563769|Drug|Placebo|
212196|NCT02563756|Procedure|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
212197|NCT02563756|Procedure|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
212198|NCT02563743|Behavioral|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
212199|NCT02563743|Behavioral|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
212200|NCT02563730|Procedure|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
212201|NCT02563717|Device|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
212202|NCT02563717|Device|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
212203|NCT02563704|Drug|Artesunate|
212204|NCT02563704|Drug|Quinine|
212205|NCT02563691|Radiation|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.~The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
212206|NCT02563678|Drug|Hyperbaric Oxygen|Hyperbaric oxygen therapy
212207|NCT02563678|Other|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
212208|NCT02563678|Other|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
212209|NCT02563613|Behavioral|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
212210|NCT02563613|Behavioral|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
212211|NCT02563613|Other|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
212212|NCT02563600|Behavioral|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
212213|NCT02563600|Behavioral|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
212214|NCT02563587|Other|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
212215|NCT02563587|Other|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
212216|NCT02563587|Drug|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
212217|NCT02563574|Behavioral|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
212218|NCT02563574|Other|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
212219|NCT02563574|Other|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
212220|NCT02563574|Other|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
212221|NCT02563561|Drug|Apaziquone|The first dose of either 4 mg/40 mL apaziquone or placebo will be administered by intravesical administration into the bladder at 60±30 minutes post TURBT (randomization date, Day 1) via an indwelling 100% Silicone Foley catheter. The second dose of either 4 mg/40 mL apaziquone or placebo will administered by intravesical administration via an indwelling catheter on Day 15 (±5 days).
212222|NCT02563561|Other|Placebo|Matching placebo containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol is supplied in identical appearing vials.
212223|NCT02563548|Drug|PEGPEM|PEGPH20
212224|NCT02563548|Drug|Pembrolizumab|Administered per schedule specified in the arm description.
212225|NCT02563535|Device|DEB|angioplasty with Litos drug eluting balloon
212226|NCT02563535|Device|PTA|angioplasty with conventional balloon
212227|NCT02563522|Genetic|VM202|gene therapy
212228|NCT02563522|Drug|Placebo|Standard of care plus placebo
212229|NCT02563509|Biological|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
212230|NCT02563496|Drug|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (150 mg) and fast-dispersing film coated tablet (50 mg)
212231|NCT02563496|Drug|Chloroquine|Subjects will receive chloroquine according to local/national treatment guidelines
212232|NCT02563483|Behavioral|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
212233|NCT02563457|Other|periodontal manual treatment|periodontal manual treatment
212234|NCT02563457|Other|no periodontal manual treatment|blood sampling
212235|NCT02563444|Device|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
212236|NCT02563431|Device|SYSTAM - SP-ED|"Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.~Daily passive mobilisation of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
212237|NCT02563431|Device|Ultrasling ER 15°Donjoy - 4P-ED|"Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.~A training of the patient and members of family on pathology, risk, use of material~Daily passive mobilization of the upper member by a therapist.~Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
212238|NCT02563418|Device|Eye-tracking|
212239|NCT02563405|Drug|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
212240|NCT02563405|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
212241|NCT02563392|Procedure|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
212242|NCT02563392|Procedure|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
212243|NCT02563366|Other|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
212244|NCT02563366|Other|Saline|Saline is the placebo of MSCs in this study.
212245|NCT02563353|Other|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,~1 minutes x 6 with 1 minute break between. 3 times a week."
212246|NCT02563353|Drug|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
212247|NCT02563340|Other|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
212248|NCT02563340|Other|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
212249|NCT02563327|Drug|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
212250|NCT02563327|Drug|Moxifloxacin|A fluoroquinolone
212251|NCT02563327|Drug|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
212252|NCT02563327|Drug|Isoniazid|An anti-tuberculosis agent
212253|NCT02563327|Drug|Pyrazinamide|An anti-tuberculosis agent
212254|NCT02563327|Drug|Ethambutol|An anti-tuberculosis agent
212255|NCT02563327|Dietary Supplement|Pyridoxine|An essential vitamin
212256|NCT02563314|Device|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
212257|NCT02563314|Device|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
212258|NCT02563301|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
212259|NCT02563288|Drug|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
212260|NCT02563288|Drug|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
212261|NCT02563275|Other|motion analysis system|
212262|NCT02563275|Other|parabolic flight|
212263|NCT02563262|Other|body angles measurements during weightlessness|
212264|NCT02563249|Other|Parabolic flight|
212265|NCT02563249|Other|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
212266|NCT02563236|Other|Parabolic flight|
212267|NCT02563223|Other|Parabolic flight|
212268|NCT02563223|Device|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
212269|NCT02563210|Other|airway resistance measurement|assessment of airway resistance
212270|NCT02563197|Device|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
212271|NCT02563184|Biological|Fluzone|
212272|NCT02563171|Other|non surgical periodontal treatment|"SRP under local anaesthesia, in a total of 2-3 clinical visits.~Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
212273|NCT02563171|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
212274|NCT02563158|Procedure|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
212275|NCT02563145|Behavioral|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
212276|NCT02563145|Behavioral|Treatment as usual|Psychoeducation, general counselling
212277|NCT02563132|Procedure|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
212278|NCT02563119|Procedure|Gastric Bypass or Sleeve gastrectomy|
212279|NCT02563106|Drug|SYN-004|
212280|NCT02563106|Drug|Placebo|
212706|NCT02560181|Radiation|HDR brachytherapy|Whole gland salvage
212281|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
212282|NCT02563093|Biological|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
212283|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
212284|NCT02563093|Biological|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
212285|NCT02563067|Drug|QAW039|QAW039 Dose 1 once daily
212286|NCT02563067|Drug|QAW039|QAW039 Dose 2 once daily
212287|NCT02563067|Drug|Placebo|Placebo once daily
212288|NCT02563054|Drug|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
212289|NCT02563054|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
212290|NCT02563054|Drug|Cisplatin|Participants will receive cisplastin, 80 mg/m^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
212291|NCT02563041|Drug|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
212292|NCT02563041|Drug|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
212293|NCT02563028|Device|SightSaver Visual Stimulator|Evoked response photic stimulator
212294|NCT02563015|Dietary Supplement|cholecalciferol|liquid drops
212295|NCT02563015|Dietary Supplement|Reference 400|liquid drops
212296|NCT02563002|Drug|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
212297|NCT02563002|Drug|FOLFIRI|Regimen consists of irinotecan 180 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-FU 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
212298|NCT02563002|Biological|pembrolizumab|
212299|NCT02563002|Biological|bevacizumab|
212300|NCT02563002|Biological|cetuximab|
212301|NCT02562989|Drug|[18F]MK-6240, ~185 MBq|IV dose of ~185 MBq [18F]MK-6240
212302|NCT02562989|Drug|[18F]MK-6240, ~160 MBq|IV dose of ~160 MBq [18F]MK-6240
212303|NCT02562976|Other|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
212304|NCT02562963|Biological|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment.
212305|NCT02562950|Drug|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
212306|NCT02562950|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
212307|NCT02562950|Drug|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
212308|NCT02562937|Behavioral|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
212309|NCT02562924|Device|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
212310|NCT02562924|Drug|Budesonide|Topical steroid
212311|NCT02562924|Drug|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
212312|NCT02562924|Drug|Prednisone|Post-operatively, 40 mg daily for 7 days
212313|NCT02562924|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
212314|NCT02562924|Drug|nasal saline spray|saline nasal mist every hour while awake
212315|NCT02562911|Procedure|Data collection|"Clinical examination~Complete pelvic ultrasound abdominal ultrasound~Bone age: X-ray~biological examination~Lung function assessed by the Maximum Volume Expired~Brasfield radiological score (if available)"
212316|NCT02562898|Drug|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
212317|NCT02562898|Drug|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
212318|NCT02562898|Drug|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
212319|NCT02562885|Device|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
212320|NCT02562872|Drug|DSM265|DSM265 400 mg single oral dose
212321|NCT02562872|Drug|Placebo|Placebo to match DSM265, single oral dose
212322|NCT02562872|Biological|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
212323|NCT02562872|Biological|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
212324|NCT02562859|Drug|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
212325|NCT02562859|Drug|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
212326|NCT02562846|Other|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
212327|NCT02562833|Device|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
212376|NCT02562508|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
213535|NCT02554240|Drug|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
212328|NCT02562833|Device|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
212329|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Ketamine
212330|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Normal Saline
212331|NCT02562807|Drug|TAS-303 18mg single-dose|
212332|NCT02562807|Drug|Placebo 18mg single-dose|
212333|NCT02562807|Drug|TAS-303 9mg single-dose|
212334|NCT02562807|Drug|Placebo 9mg single-dose|
212335|NCT02562794|Behavioral|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
212336|NCT02562781|Drug|Oxygen|Oxygen in sufficient quantity to maintain SpO2 > 98%
212337|NCT02562781|Other|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
212338|NCT02562768|Drug|LY3154207|Administered orally
212339|NCT02562768|Drug|Placebo|Administered orally
212340|NCT02562755|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
212341|NCT02562755|Drug|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.~Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.~Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
212342|NCT02562742|Drug|SOF|SOF 400 mg tablets administered orally once daily
212343|NCT02562742|Drug|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
212344|NCT02562729|Procedure|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
212345|NCT02562716|Drug|Fluorouracil|Given IV
212346|NCT02562716|Drug|Gemcitabine Hydrochloride|Given IV
212347|NCT02562716|Drug|Irinotecan Hydrochloride|Given IV
212348|NCT02562716|Drug|Oxaliplatin|Given IV
212349|NCT02562716|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
212350|NCT02562716|Procedure|Pancreatectomy|Undergo pancreatectomy
212351|NCT02562703|Device|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
212352|NCT02562690|Other|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
212353|NCT02562677|Device|Transcutaneous Trigeminal Nerve Stimulation|
212354|NCT02562664|Drug|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
212355|NCT02562664|Drug|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
212356|NCT02562664|Drug|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
212357|NCT02562651|Drug|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
212358|NCT02562651|Other|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
212359|NCT02562638|Other|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
212360|NCT02562625|Drug|Pembrolizumab|Powder solution for infusion
212361|NCT02562625|Radiation|Radiotherapy|24Gy
212362|NCT02562612|Drug|SM-88|Daily SM-88 in multiple ascending doses over 6 months
212363|NCT02562599|Drug|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
212364|NCT02562599|Radiation|Intensity-modulated radiotherapy (IMRT)|
212365|NCT02562586|Device|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
212366|NCT02562573|Drug|PBI4050|
212367|NCT02562560|Behavioral|Neuropsychological tests|
212368|NCT02562560|Device|Cerebral imaging (MRI, PET-FDG)|
212369|NCT02562547|Device|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
212370|NCT02562534|Device|MRI compatible ElectroCardioGraph|MRI with ECG control for personnes with healthy heart or heart diseases
212371|NCT02562521|Behavioral|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
212372|NCT02562521|Drug|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
212373|NCT02562521|Drug|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
212374|NCT02562521|Behavioral|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
212375|NCT02562508|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
212501|NCT02561728|Device|Hangar Helmet|Child will be fitted with the Hangar Helmet
212377|NCT02562495|Device|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
212378|NCT02562482|Biological|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
212379|NCT02562482|Other|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
212380|NCT02562469|Other|ACTIVATE|A home-based computerized brain training intervention for youth.
212381|NCT02562456|Procedure|ART using Fuji IX|Occlusal and occlusoproximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed under relative isolation. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked. For occlusoproximal restoration, an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
212382|NCT02562456|Procedure|Conventional Treatment|Occlusal and occlusoproximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Removal of unsupported enamel will be performed using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked. an adapted matrix strip with a wooden wedge will be used to assure appropriate contour.
212383|NCT02562443|Drug|rigosertib|Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).
212384|NCT02562443|Drug|Any approved or standard-of-care therapy|Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
212385|NCT02562443|Drug|best supportive care (BSC)|Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
212386|NCT02562443|Drug|best supportive care (BSC)|Patients will receive best supportive care (BSC).
212387|NCT02562430|Drug|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
212388|NCT02562430|Drug|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
212389|NCT02562417|Drug|Normal saline|
212390|NCT02562417|Drug|IV dexamethasone|
212391|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions)|
212392|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
212393|NCT02562378|Drug|Trastuzumab and non-pegylated liposomal doxorubicin|Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
212394|NCT02562365|Drug|Etoposide, Cyclophosphamide, Carboplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
212395|NCT02562352|Other|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
212396|NCT02562339|Behavioral|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
212397|NCT02562326|Drug|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
212398|NCT02562326|Drug|Humalog®|Injection immediately before the start of the individualised standard meal
212399|NCT02562313|Drug|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
212400|NCT02562313|Drug|Humalog®|Humalog® bolus infusion followed by test meal intake
212401|NCT02562300|Drug|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
212402|NCT02562300|Drug|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
212403|NCT02562287|Drug|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
212404|NCT02562287|Drug|Risperidone|Risperidone, in a flexible dosage
212405|NCT02562287|Drug|Olanzapine|Olanzapine, flexible dosage
212406|NCT02562287|Drug|Quetiapine|Quetiapine, flexible dosage
212407|NCT02562274|Dietary Supplement|Placebo|Subjects are received placebo treatments once daily for 8 weeks
212408|NCT02562274|Dietary Supplement|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
212409|NCT02562274|Dietary Supplement|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
212410|NCT02562248|Other|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
212411|NCT02562248|Other|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
212412|NCT02562235|Drug|Riociguat (Adempas, BAY63-2521)|The individual optimal (maintenance) dose is to be determined based on patients' monitoring of systolic blood pressure, well-being and clinical status.
212413|NCT02562222|Procedure|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212502|NCT02561728|Device|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
212414|NCT02562222|Procedure|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212415|NCT02562222|Procedure|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212416|NCT02562222|Procedure|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212417|NCT02562222|Procedure|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212418|NCT02562222|Procedure|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212419|NCT02562222|Procedure|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212420|NCT02562209|Dietary Supplement|PACER Diet|Pacer diet to be followed for 8 weeks
212421|NCT02562209|Other|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
212422|NCT02562196|Device|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
212423|NCT02562183|Drug|kallikrein|Using kallikrein
212424|NCT02562170|Device|TiLoop Bra|
212425|NCT02562170|Device|Protexa|
212426|NCT02562157|Device|NOTES gastroenteric anastomosis|
212427|NCT02562144|Drug|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
212428|NCT02562144|Drug|Placebo|Cutaneous placebo before intravenous cannulation.
212503|NCT02561715|Behavioral|Questionnaires|Pre and post deep brain surgery questionnaires
212504|NCT02561702|Other|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
212505|NCT02561702|Drug|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
212703|NCT02560207|Drug|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
212429|NCT02562118|Drug|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
212430|NCT02562105|Procedure|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
212431|NCT02562092|Behavioral|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
212432|NCT02562092|Behavioral|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
212433|NCT02562079|Biological|Blood samples|"biological features of the standard follow-up~2 more blood tube for the biological collection (serum and PBMC)"
212434|NCT02562079|Biological|Biopsy|Skin biopsies
212435|NCT02562066|Drug|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
212436|NCT02562066|Drug|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
212437|NCT02562053|Drug|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
212438|NCT02562053|Drug|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
212439|NCT02562053|Drug|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
212440|NCT02562053|Drug|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
212441|NCT02562040|Procedure|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
212442|NCT02562040|Behavioral|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
212443|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"30 quality of life questions for the participant to answer~The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)~The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
212444|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"13 quality of life questions for the participant to answer~The answers range from 1 (Not at All) to 4 (Very Much)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
212445|NCT02562027|Behavioral|Modified Medical Research Council|"Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
212446|NCT02562027|Behavioral|EQ-5D|"5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day~The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
212447|NCT02562027|Behavioral|Center for Epidemiological Studies Depression Scale|"20 quality of life questions for the participant to answer~Answers range from Rarely or none of the time to Most or all of the time~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
212448|NCT02562027|Behavioral|Medical Outcomes Study Social Support Survey|"19 quality of life questions for the participant to answer~Answers from from 1 (None of the time) to 5 (All of the time)~Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
212449|NCT02562014|Other|Glucose|75g glucose
212450|NCT02562014|Other|Inulin|75g glucose plus 24g inulin
212451|NCT02562014|Other|Resistant Starch|75g glucose plus 28.2g resistant starch
212452|NCT02562001|Device|Outpatient active group|active tDCS during 20 minutes before Lokomat training for outpatients
212453|NCT02562001|Device|Outpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for outpatients
212454|NCT02562001|Device|Inpatient active group|active tDCS during 20 minutes before Lokomat training for inpatients
212455|NCT02562001|Device|Inpatient placebo group|placebo tDCS during 20 minutes before Lokomat training for inpatients
212456|NCT02561988|Drug|Avapritinib|
212457|NCT02561975|Other|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.~With the expired air, some parameters will be assessed:~Alveolar volume (VA)~Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)~Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
212458|NCT02561962|Drug|AMG 224|AMG 224 will be given on Day 1 once every 3 weeks with dose ranging from 30 mg to 300 mg.
212620|NCT02560805|Drug|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
212459|NCT02561949|Behavioral|YRI|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
212460|NCT02561949|Other|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
212461|NCT02561936|Drug|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
212462|NCT02561936|Drug|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10*2.5 mg tablets.
212463|NCT02561936|Drug|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10*2.5 mg tablets.
212464|NCT02561936|Drug|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
212465|NCT02561936|Dietary Supplement|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter [mL]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) [189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins]).
212466|NCT02561923|Drug|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
212467|NCT02561923|Drug|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
212468|NCT02561923|Drug|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 [international units] IU/min) on Day 4.
212469|NCT02561923|Drug|Saline|Saline [Kcentra saline control or TXA saline control] on Day 4.
212470|NCT02561910|Device|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
212471|NCT02561897|Drug|Edoxaban|
212472|NCT02561897|Drug|Warfarin|
212473|NCT02561884|Drug|Olostar Tab.|
212474|NCT02561884|Drug|Co-administration of Olmetec and Crestor|
212475|NCT02561871|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 in Group 2.
212476|NCT02561871|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 85 in Group 2.
212477|NCT02561871|Drug|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
212478|NCT02561858|Other|acid load test|
212479|NCT02561845|Drug|rosuvastatin|5mg, 10mg, 20mg
212480|NCT02561832|Drug|Olaparib|tablets taken orally twice daily
212481|NCT02561832|Drug|Carboplatin|intravenous injections on day one of each cycle
212482|NCT02561832|Drug|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
212483|NCT02561832|Drug|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
212484|NCT02561806|Drug|Ixekizumab|Administered SC
212485|NCT02561806|Drug|Ustekinumab|Administered SC
212486|NCT02561806|Drug|Placebo|Administered SC
212487|NCT02561793|Drug|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
212488|NCT02561793|Drug|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
212489|NCT02561780|Behavioral|Curriculum|A mental health educational resource delivered in the classroom by trained educators
212490|NCT02561780|Behavioral|eLearning Follow-up|An online mental health education module that students access individually
212491|NCT02561767|Other|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
212492|NCT02561767|Other|Saline|Saline as placebo of MSCs
212493|NCT02561767|Drug|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
212494|NCT02561767|Drug|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
212495|NCT02561754|Dietary Supplement|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
212496|NCT02561754|Dietary Supplement|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
212497|NCT02561754|Behavioral|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
212498|NCT02561754|Behavioral|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
212499|NCT02561754|Other|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
212500|NCT02561741|Drug|COV155|COV155 tablets
212506|NCT02561689|Other|Fissure sealing|"Procedure:~The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation~Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years~The occlusal surface is sealed by the dentist or dental hygienist.~Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
212507|NCT02561676|Other|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
212508|NCT02561676|Other|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
212509|NCT02561663|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
212510|NCT02561663|Other|Placebo|
212511|NCT02561650|Drug|COV155|COV155 tablets
212512|NCT02561637|Behavioral|Case management|
212513|NCT02561637|Behavioral|Control group|
212514|NCT02561624|Behavioral|Behaviour change communication via text message|
212515|NCT02561611|Behavioral|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
212516|NCT02561585|Drug|LEO 124249|
212517|NCT02561585|Other|Vehicle|
212518|NCT02561572|Other|Acupuncture|Yintang point acupuncture
212519|NCT02561559|Radiation|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
212520|NCT02561546|Drug|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
212521|NCT02561546|Drug|Trans-catheter embolization|Trans-catheter embolization alone
212522|NCT02561533|Other|BRAF detection on fine needle aspiration biopsy (FNAB)|
212523|NCT02561520|Biological|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
212524|NCT02561520|Biological|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
212525|NCT02561507|Behavioral|Survey|
212526|NCT02561494|Drug|Nefopam|
212527|NCT02561494|Drug|Saline|
212528|NCT02561481|Drug|Sulforaphane|See under active arm description
212529|NCT02561481|Drug|Placebo|See under placebo arm description
212530|NCT02561468|Drug|Nefopam|
212531|NCT02561468|Drug|Saline|
212532|NCT02561455|Drug|gilteritinib|oral
212533|NCT02561442|Drug|ceftriaxone|
212534|NCT02561429|Procedure|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
212535|NCT02561416|Behavioral|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
212536|NCT02561416|Behavioral|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.~Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.~Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).~Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
212537|NCT02561416|Drug|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
212538|NCT02561403|Behavioral|EVO multitask video game|Participants will play a multitasking game for 4 weeks
212539|NCT02561403|Behavioral|EVO words video game|Participants will play a word puzzle game for 4 weeks
212540|NCT02561390|Procedure|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
212541|NCT02561390|Other|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
212542|NCT02561377|Behavioral|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
212543|NCT02561377|Behavioral|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
212544|NCT02561351|Other|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
212545|NCT02561338|Drug|HMS5552|50mgBID/75mgBID/75mgQD/100mgQD
212546|NCT02561338|Other|placebo|placebo BID/QD
212547|NCT02561325|Drug|Sodium Bicarbonate and Sodium chloride|
212548|NCT02561312|Other|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
212621|NCT02560805|Drug|Losartan|Subjects will receive Losartan 25 mg once a day orally up to 12 weeks
212549|NCT02561312|Other|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
212550|NCT02561299|Device|Peripheral Orbital Atherectomy System|Orbital Atherectomy
212551|NCT02561299|Device|014 Drug Coated Balloon|Drug Coated Balloon
212552|NCT02561286|Behavioral|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
212553|NCT02561286|Behavioral|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers—leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
212554|NCT02561273|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
212555|NCT02561273|Drug|Cyclophosphamide|Given IV
212556|NCT02561273|Drug|Doxorubicin Hydrochloride|Given IV
212557|NCT02561273|Drug|Etoposide|Given IV
212558|NCT02561273|Other|Laboratory Biomarker Analysis|Correlative studies
212559|NCT02561273|Drug|Lenalidomide|Given PO
212560|NCT02561273|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
212561|NCT02561273|Drug|Prednisone|Given PO
212562|NCT02561273|Drug|Vincristine Sulfate|Given IV
212563|NCT02561247|Device|Prismaflex HF20 CRRT Filter|
212564|NCT02561247|Device|Prismaflex® System 7.10 and 7.20|
212565|NCT02561234|Drug|Co-ArgI-PEG|Administered IV
212566|NCT02561221|Behavioral|Lifestyle Counseling|"Trained health coaches will deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
212567|NCT02561208|Other|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
212568|NCT02561195|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
212569|NCT02561195|Biological|Placebo|0.5 mL intramuscular injection
212570|NCT02561169|Drug|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
212571|NCT02561169|Other|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
212572|NCT02561156|Drug|TAK-653 Placebo|TAK-653 placebo-matching tablets.
212573|NCT02561156|Drug|TAK-653|TAK-653 tablets.
212574|NCT02561143|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
212575|NCT02561143|Dietary Supplement|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
212576|NCT02561143|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
212577|NCT02561143|Other|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
212578|NCT02561130|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
212579|NCT02561130|Drug|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
212580|NCT02561130|Drug|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
212581|NCT02561130|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
212582|NCT02561117|Drug|Metronidazole|Administration once daily
212583|NCT02561104|Procedure|Laser-assisted cataract surgery.|
212584|NCT02561104|Procedure|Traditional manual phacoemulsification|
212585|NCT02561091|Other|Placebo|
212586|NCT02561091|Drug|AM-111 0.4 mg/ml|
212587|NCT02561091|Drug|AM-111 0.8 mg/ml|
212588|NCT02561078|Drug|Human regular U-500 insulin (CSII)|Administered SC
212589|NCT02561078|Drug|Human regular U-500 insulin (MDI)|Administered SC
212622|NCT02560805|Drug|Atenolol|Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
212704|NCT02560194|Procedure|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
212590|NCT02561065|Behavioral|Lifestyle intervention|"Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday."
212591|NCT02561039|Drug|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
212592|NCT02561026|Biological|Frozen plasma|patients randomized to receive frozen plasma transfusions
212593|NCT02561013|Device|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.~The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
212594|NCT02561013|Device|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
212595|NCT02561000|Drug|PZ-128|
212596|NCT02561000|Drug|Placebo|
212597|NCT02560974|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
212598|NCT02560974|Drug|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m^2 on Day 1 of each 3-week cycle for 8 cycles.
212599|NCT02560961|Other|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
212600|NCT02560961|Other|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
212601|NCT02560948|Biological|Placebo solution|4 x 2 injections over 21 days
212602|NCT02560948|Biological|gpASIT+TM|4 x 2 injections over 21 days
212603|NCT02560935|Drug|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
212604|NCT02560935|Drug|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
212605|NCT02560922|Behavioral|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
212606|NCT02560909|Biological|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
212607|NCT02560909|Biological|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
212608|NCT02560870|Drug|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
212609|NCT02560870|Drug|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
212610|NCT02560857|Other|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
212611|NCT02560831|Behavioral|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
212612|NCT02560831|Behavioral|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
212613|NCT02560818|Other|collection of a blood sample and breast and ovarian tissue|a blood sample and a breast and ovarian tissue sample will be collected in healthy women during their surgery (breast or ovarian surgery according to selection group :A, B or C)
212614|NCT02560818|Other|use of a previous blood collection for patients|
212615|NCT02560805|Procedure|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
212616|NCT02560805|Behavioral|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
212617|NCT02560805|Procedure|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
212618|NCT02560805|Procedure|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (~0-1°C) up to the wrist for 1 minute.
212619|NCT02560805|Drug|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
213951|NCT02551172|Drug|HGP0816|Rosuvastatin
212623|NCT02560792|Behavioral|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
212624|NCT02560792|Behavioral|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
212625|NCT02560792|Behavioral|Control Condition|Participants receive no information about affective response
212626|NCT02560779|Drug|Carotuximab (TRC105)|Bi-weekly iv TRC105 (15 mg/kg) will be given with 400mg sorafenib twice daily in the phase 1B portion of the study. Weekly iv TRC105 (10 mg/kg) will be given with 400mg sorafenib twice daily in the phase 2 portion of the study.
212627|NCT02560779|Drug|Sorafenib|400 mg of sorafenib will be given twice daily.
212628|NCT02560766|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
212629|NCT02560766|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
212630|NCT02560766|Drug|Placebo|Placebo once daily
212631|NCT02560753|Drug|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
212632|NCT02560740|Dietary Supplement|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
212633|NCT02560740|Dietary Supplement|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
212634|NCT02560727|Device|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
212635|NCT02560727|Device|colonoscope|FMT via colonoscope is the most common approach.
212636|NCT02560714|Device|SImmetry Sacroiliac Fusion System|"SImmetry~The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
212637|NCT02560701|Other|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
212638|NCT02560688|Drug|DS-1040b|20 mg single 12-hour intravenous infusion
212639|NCT02560688|Drug|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
212640|NCT02560662|Behavioral|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:~• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.~Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
212641|NCT02560649|Drug|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
212642|NCT02560649|Drug|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
212643|NCT02560649|Drug|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
212644|NCT02560649|Drug|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
212645|NCT02560649|Drug|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
212646|NCT02560649|Drug|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
212647|NCT02560649|Drug|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
212648|NCT02560649|Drug|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
212649|NCT02560636|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
212650|NCT02560636|Radiation|Radiotherapy|Radiotherapy
212651|NCT02560623|Device|Sponge capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
212652|NCT02560610|Drug|OC000459|
212653|NCT02560610|Drug|Placebo|
212654|NCT02560597|Procedure|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.~In absence of effect, rTMS is given on 5 consecutive days at most."
212655|NCT02560584|Drug|Hexaminolevulinate hydrochloride|Instillation in bladder
212656|NCT02560584|Device|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
212657|NCT02560571|Device|ultrasound|
212658|NCT02560571|Other|blood test|
212659|NCT02560558|Drug|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
212660|NCT02560545|Drug|Cannabis oil|Cannabis oil 20% THC
212661|NCT02560532|Drug|Clazosentan|Concentrated solution for intravenous injection
212702|NCT02560220|Biological|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
212662|NCT02560519|Drug|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.~During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy.The volume replacement therapy is not determined but will be based on the clinical decision."
212663|NCT02560519|Drug|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.~During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 3200 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 3200 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not determined but will be based on the clinical decision."
212664|NCT02560506|Device|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
212665|NCT02560493|Behavioral|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
212666|NCT02560480|Device|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
212667|NCT02560467|Drug|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.~Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
212668|NCT02560454|Behavioral|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance`s"
212669|NCT02560454|Behavioral|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.~Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.~A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.~The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
212670|NCT02560441|Other|chemotherapy followed by radiotherapy|
212671|NCT02560441|Other|radiotherapy followed by chemotherapy|
212672|NCT02560441|Drug|IPGDP regimen chemotherapy|
212673|NCT02560428|Behavioral|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
212674|NCT02560415|Device|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
212675|NCT02560415|Behavioral|Comparator|Treatment as usual
212676|NCT02560389|Drug|Placebo|Sugar pill packaged to resemble levodopa
212677|NCT02560389|Drug|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
212678|NCT02560376|Drug|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
212679|NCT02560363|Drug|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
212680|NCT02560363|Drug|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
212681|NCT02560363|Drug|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
212682|NCT02560363|Drug|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
212683|NCT02560350|Other|no intervention|no intervention
212684|NCT02560337|Drug|Cabazitaxel|
212685|NCT02560337|Drug|Tocotrienol|
212686|NCT02560324|Drug|Ramelteon|
212687|NCT02560324|Drug|Placebo|
212688|NCT02560311|Other|observation|
212689|NCT02560298|Drug|Capecitabine|
212690|NCT02560298|Drug|Carboplatin|Given IV
212691|NCT02560298|Drug|Cisplatin|Given IV
212692|NCT02560298|Drug|Fluorouracil|Given IV
212693|NCT02560298|Other|Laboratory Biomarker Analysis|Correlative studies
212694|NCT02560298|Drug|Paclitaxel|Given IV
212695|NCT02560298|Other|Quality-of-Life Assessment|Ancillary studies
212696|NCT02560272|Biological|Minhai-HIB|0.5ml, intramuscular
212697|NCT02560272|Biological|Act-HIB®|0.5ml, intramuscular
212698|NCT02560259|Other|Physiotherapy|Physiotherapy
212699|NCT02560259|Other|Conservative treatment|Conservative treatment
212700|NCT02560233|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
212701|NCT02560233|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
212707|NCT02560168|Device|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
212708|NCT02560168|Device|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
212709|NCT02560168|Device|Transthoracic Echocardiography|
212710|NCT02560155|Drug|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
212711|NCT02560155|Drug|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
212712|NCT02560129|Other|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
212713|NCT02560103|Other|Transmeridian travel across multiple time zones|
212714|NCT02560090|Behavioral|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
212715|NCT02560090|Behavioral|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
212716|NCT02560090|Behavioral|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
212717|NCT02560077|Other|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
212718|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
212719|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
212720|NCT02560064|Procedure|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
212721|NCT02560051|Drug|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
212722|NCT02560051|Drug|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
212723|NCT02560051|Drug|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
212724|NCT02560051|Drug|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
212725|NCT02560051|Drug|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
212726|NCT02560038|Drug|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
212727|NCT02560038|Drug|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
212728|NCT02560038|Drug|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
212729|NCT02560025|Drug|Alisertib|
212730|NCT02560025|Drug|Cytarabine|
212731|NCT02560025|Drug|Idarubicin|
212732|NCT02560025|Drug|Daunorubicin|Can be used in place of idarubicin
212733|NCT02560012|Drug|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
212734|NCT02560012|Drug|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
212735|NCT02560012|Drug|Sorafenib|400 mg (2 tablets) orally twice daily without food
212736|NCT02560012|Drug|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
212737|NCT02560012|Drug|Everolimus|10 mg orally once daily with or without food
212738|NCT02560012|Drug|Axitinib|5 mg orally twice daily
212739|NCT02559999|Other|Painful tonic stimuli|
212740|NCT02559999|Other|non-painful stimuli|
212741|NCT02559986|Other|telephone interview|telephone interview about their care received during the first year of life and associated events
212742|NCT02559973|Drug|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
212743|NCT02559973|Drug|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
212744|NCT02559960|Drug|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
212745|NCT02559934|Drug|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
212746|NCT02559921|Biological|rhRIG（20 IU/kg）|
212747|NCT02559921|Biological|rhRIG（40 IU/kg）|
212748|NCT02559921|Biological|HRIG（20 IU/kg）|
212749|NCT02559921|Biological|rhRIG（20 IU/kg） and vaccine|
212750|NCT02559921|Biological|rhRIG（40 IU/kg） and vaccine|
212751|NCT02559921|Biological|HRIG（20 IU/kg） and vaccine|
212752|NCT02559921|Biological|placebo and vaccine|
213952|NCT02551172|Drug|Placebo of HCP1105|Soybean Oil
212753|NCT02559908|Device|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
212754|NCT02559895|Drug|ALD403|
212755|NCT02559895|Drug|Placebo|
212756|NCT02559869|Drug|[18F] GE-180|PET Tracer Ligand
212757|NCT02559856|Drug|Apixaban|
212758|NCT02559856|Drug|Rivaroxaban|
212759|NCT02559843|Dietary Supplement|pomegranate juice|
212760|NCT02559843|Behavioral|lifestyle modification|
212761|NCT02559830|Genetic|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10^6 transduced CD34+ cells/Kg (maximum 20x10^6) at bedside for infusion.
212762|NCT02559817|Drug|Linaclotide Dose A|
212763|NCT02559817|Drug|Linaclotide Dose B|
212764|NCT02559817|Drug|Linaclotide Dose C|
212765|NCT02559817|Drug|Linaclotide Approved Adult Dose|
212766|NCT02559817|Drug|Matching Placebo|
212767|NCT02559804|Other|survival and late effects|survival and late effects
212768|NCT02559791|Biological|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
212769|NCT02559791|Drug|Placebo|Matching placebo once monthly for 2 months
212770|NCT02559778|Drug|Ceritinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
212771|NCT02559778|Drug|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
212772|NCT02559778|Drug|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
212773|NCT02559778|Drug|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.
212774|NCT02559778|Drug|DFMO|DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.
212775|NCT02559752|Other|NIH Toolbox Cognitive Battery|"For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.~For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning."
212776|NCT02559726|Procedure|Echocardiography (TEE)|
212777|NCT02559726|Device|Magnetic resonance imaging (MRI) with gadolinium enhancement|
212778|NCT02559726|Device|Magnetic resonance imaging (MRI) without gadolinium enhancement|
212779|NCT02559726|Procedure|3D electrocardiographic mapping (ECM)|
212780|NCT02559713|Drug|Vedolizumab|Vedolizumab IV infusion
212781|NCT02559700|Behavioral|Brain training programme|An online package of brain training programmes
212782|NCT02559687|Biological|pembrolizumab|IV Q3W
212783|NCT02559674|Biological|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
212784|NCT02559674|Biological|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
212785|NCT02559674|Biological|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
212786|NCT02559661|Other|Training on a virtual simulator in eye surgery|
212787|NCT02559648|Drug|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
212788|NCT02559648|Drug|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.~The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
212789|NCT02559635|Procedure|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
212790|NCT02559635|Drug|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
212791|NCT02559622|Drug|Secukinumab|300 mg secukinumab
212792|NCT02559622|Other|Placebo|Placebo followed by 300 mg secukinumab
212793|NCT02559622|Other|Placebo|Placebo followed by 150 mg secukinumab
212794|NCT02559622|Drug|Secukinumab|150 mg secukinumab
212835|NCT02559440|Drug|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
212795|NCT02559609|Behavioral|contingency management for alcohol abstinence|Participants will earn chances to win prizes for each negative breath alcohol recording provided.
212796|NCT02559609|Behavioral|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
212797|NCT02559609|Behavioral|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
212798|NCT02559583|Other|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
212799|NCT02559583|Other|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
212800|NCT02559583|Other|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
212801|NCT02559570|Drug|Placebo|Participants received matching placebo LIN liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
212802|NCT02559570|Drug|LIN Dose A|Participants received LIN 9 or 18 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
212803|NCT02559570|Drug|LIN Dose B|Participants received LIN 18 or 36 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
212804|NCT02559570|Drug|LIN Dose C|Participants received LIN 36 or 72 ug liquid solution or solid capsules, orally, 30 minutes before evening meal, once daily for 4 weeks.
212805|NCT02559570|Drug|LIN 145 µg|Participants received LIN 145 µg, liquid solution or solid capsules, 30 minutes before evening meal, once daily for 4 weeks.
212806|NCT02559557|Other|Educational Intervention|Participate in focus groups
212807|NCT02559557|Other|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
212808|NCT02559557|Other|Quality-of-Life Assessment|Answer questionnaires
212809|NCT02559557|Other|Questionnaire Administration|Answer questionnaires
212810|NCT02559531|Device|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
212811|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
212812|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
212813|NCT02559518|Device|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
212814|NCT02559518|Device|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
212815|NCT02559518|Device|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
212816|NCT02559518|Device|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
212817|NCT02559518|Device|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
212818|NCT02559505|Biological|Seasonal IIV 0.25 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
212819|NCT02559505|Other|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
212820|NCT02559505|Biological|Seasonal IIV 0.5 mL dose|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
212821|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
212822|NCT02559492|Drug|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
212823|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
212824|NCT02559492|Drug|INCB050465|INCB050465 tablets will be administered orally once daily.
212825|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 18%-protein diet|
212826|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 35%-protein diet|
212827|NCT02559466|Device|Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Class IIa
212828|NCT02559466|Device|Positon Emission Tomography (PET) - Discovery 710®|Class IB
212829|NCT02559453|Procedure|Debridement|Removing dead tissue from infected wounds.
212830|NCT02559440|Drug|mometasone furoate|50μg, 1 puff in each nostril every evening
212831|NCT02559440|Drug|Placebo|1 puff in each nostril every evening
212832|NCT02559440|Drug|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
212833|NCT02559440|Drug|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
212834|NCT02559440|Drug|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
214930|NCT02544282|Drug|Sevoflurane|General Anesthesia
212836|NCT02559427|Other|3-week immediate SPA treatment|a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
212837|NCT02559427|Other|3-week late SPA treatment|a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
212838|NCT02559414|Drug|Aspirin|
212839|NCT02559414|Drug|Clopidogrel|
212840|NCT02559401|Other|MRI|
212841|NCT02559401|Other|Neurocognitive battery|
212842|NCT02559388|Drug|Montelukast|
212843|NCT02559388|Drug|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
212844|NCT02559375|Other|Survey|
212845|NCT02559362|Behavioral|Survey|
212846|NCT02559349|Other|Stool Collection|
212847|NCT02559336|Other|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
212848|NCT02559323|Other|Survey|
212849|NCT02559310|Drug|lefamulin|antibacterial agent
212850|NCT02559310|Drug|Moxifloxacin|antibacterial agent
212851|NCT02559310|Drug|Linezolid|antibacterial agent
212852|NCT02559297|Drug|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
212853|NCT02559297|Drug|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
212854|NCT02559284|Other|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.~Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.~The nasal washing procedure will be as follow:~Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting~Gentle blowing of the nose~Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
212855|NCT02559258|Drug|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
212856|NCT02559258|Drug|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
212857|NCT02559258|Drug|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
212858|NCT02559258|Drug|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
212859|NCT02559258|Drug|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
212860|NCT02559245|Other|Descurainia Sophia|
212861|NCT02559245|Other|Ficus carica|
212862|NCT02559232|Drug|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
212863|NCT02559219|Other|Questionniares|
212864|NCT02559206|Drug|Linaclotide|Oral, once daily
212865|NCT02559206|Drug|Matching Placebo|Oral, once daily
212866|NCT02559193|Other|Observational study, data collection only trial.|Data collection only trial design.
212867|NCT02559180|Drug|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
212868|NCT02559167|Drug|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
212869|NCT02559154|Drug|Bortezomib|
212870|NCT02559154|Drug|Dexamethasone|
212871|NCT02559154|Drug|Doxorubicin|
212872|NCT02559154|Drug|Cyclophosphamide|
212873|NCT02559154|Drug|Mitoxsnteone|
212874|NCT02559154|Drug|Thalidomide|
212875|NCT02559141|Drug|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
212876|NCT02559115|Radiation|68Ga-RM2 (RM2)|
212877|NCT02559115|Device|PET/CT Scan|
212878|NCT02559102|Drug|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
212879|NCT02559102|Drug|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
212880|NCT02559102|Procedure|Caudal anaesthesia|single shot caudal anaesthesia
212881|NCT02559102|Procedure|Inguinal hernia surgery|Infant inguinal hernia repair.
212882|NCT02559076|Behavioral|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
212883|NCT02559063|Behavioral|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
212884|NCT02559063|Behavioral|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
212885|NCT02559050|Other|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
212886|NCT02559037|Device|Acupuncture-moxibustion|"Acupuncture is puncture the needle into specific part of the body according to a certain angle, using specific means to cause the De-qi sensation, and maintain a certain amount of time.~Mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin, keeping the spot warm and making it reddened, but not burnt.The temperature maintained at 43 ± 1℃。"
212887|NCT02559037|Device|Placebo acupuncture-moxibustion|"Placebo acupuncture is puncture the needle into specific part of the body according to a certain angle, without using specific means to cause the De-qi sensation, and maintain a certain amount of time.~Placebo mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin (farther than the real moxibustion), keeping the temperature maintained at 37 ± 1℃。"
212888|NCT02559024|Drug|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
212889|NCT02558998|Other|Survey|
212890|NCT02558985|Procedure|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
212891|NCT02558972|Drug|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
212892|NCT02558972|Drug|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
212893|NCT02558972|Drug|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
212894|NCT02558972|Drug|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
212895|NCT02558959|Drug|Irinotecan|
212896|NCT02558959|Drug|Capecitabine|
212897|NCT02558946|Behavioral|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
212898|NCT02558946|Behavioral|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
212899|NCT02558933|Dietary Supplement|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
212900|NCT02558920|Other|Fructose-containing Sugars|An intervention in which calories from food sources of fructose-containing sugars are substituted, added, subtracted, or replaced ad libitum in the diet
212901|NCT02558907|Other|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
212902|NCT02558894|Drug|MEDI4736 monotherapy|MEDI4736 via IV infusion.
212903|NCT02558894|Drug|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
212904|NCT02558881|Procedure|Virtual colonoscopy|
212905|NCT02558881|Procedure|Colon capsule|
212906|NCT02558868|Drug|Irinotecan|
212907|NCT02558868|Drug|Oxaliplatin|
212908|NCT02558855|Other|Thrust Joint Manipulation of the Lumbar Spine|
212909|NCT02558855|Other|Non-thrust Joint Manipulation of the Lumbar Spine|
212910|NCT02558842|Other|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.~During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.~During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
212911|NCT02558829|Drug|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
212912|NCT02558829|Drug|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI > 30 kg/m2), intravenous injection, single dose
212913|NCT02558816|Drug|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients will receive the combination of Ibrutinib + GA101, as soon as the step A patients are recruited and if no toxicity observed the step B will be initiated, Step B : 24 new patients will receive the combination of Ibrutinib + GA101 + GDC-0199
212914|NCT02558803|Behavioral|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
212915|NCT02558790|Drug|L-Threonic Acid Magnesium Salt (L-TAMS)|
212916|NCT02558777|Other|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
212917|NCT02558764|Device|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
212918|NCT02558751|Biological|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
212919|NCT02558751|Biological|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
212920|NCT02558738|Device|ear spray|
212921|NCT02558725|Drug|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
212922|NCT02558712|Other|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
212923|NCT02558699|Procedure|physician's personal experience|physician's personal experience
212924|NCT02558699|Procedure|Virtual rotor mapping|Virtual rotor mapping
212925|NCT02558686|Other|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
212926|NCT02558686|Other|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
212927|NCT02558686|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
212928|NCT02558673|Other|TMAO dietary precursors|
212929|NCT02558673|Other|Control (or active comparator)|
212930|NCT02558660|Behavioral|Education|Educational intervention about an existing SNAP healthy food incentive program
212931|NCT02558660|Behavioral|voucher|$10 voucher to spend on produce at farmers markets
212932|NCT02558647|Behavioral|CBT for insomnia (CBT-I)|CBT-I is an online, fully automated, interactive, and tailored web-based program that incorporates the primary tenets of face-to-face CBT-I, including sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
212933|NCT02558647|Behavioral|Psycho-Education about Sleep (PE)|PE provides online information about insomnia symptoms; the impact, prevalence, and causes of insomnia; when to seek input from a doctor; and basic lifestyle, environmental, and behavioral strategies that may help to improve sleep.
212934|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation ON|
212935|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation OFF|
212936|NCT02558621|Device|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
212937|NCT02558608|Procedure|DIPL|dissection of the inferior pulmonary ligament
212938|NCT02558608|Procedure|WR|wedge resection of the lung bleb
212939|NCT02558608|Procedure|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
212940|NCT02558595|Dietary Supplement|Niacinamide|
212941|NCT02558595|Other|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
212942|NCT02558582|Behavioral|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
212943|NCT02558582|Behavioral|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.~Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
212944|NCT02558569|Drug|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
212945|NCT02558569|Other|NSS|Clear intravenous fluid looks alike local anesthetic.
212946|NCT02558556|Device|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
212947|NCT02558556|Other|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
212948|NCT02558543|Drug|Stromal Vascular fraction|
212949|NCT02558543|Drug|Ringer lactate|
212950|NCT02558530|Other|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
212951|NCT02558517|Drug|prednisone discontinuation|randomization
212952|NCT02558504|Procedure|Oesophagectomy|
212953|NCT02558504|Device|Radiofrequency ablation|
213034|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
214931|NCT02544282|Drug|Propofol|General Anesthesia
212954|NCT02558491|Device|Decision Support System|"The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment."
212955|NCT02558478|Genetic|blood sampling|
212956|NCT02558465|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
212957|NCT02558452|Drug|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
212958|NCT02558439|Drug|CNTX-4975|
212959|NCT02558439|Other|Placebo|
212960|NCT02558426|Procedure|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
212961|NCT02558413|Drug|BTA-C585 oral capsules|BTA-C585; Single ascending doses from 50 mg to 800 mg
212962|NCT02558413|Drug|BTA-C585 matching placebo|Single ascending doses to match 50 to 800 mg BTA-C585 capsules
212963|NCT02558400|Drug|PG324 Ophthalmic Solution 0.02%/0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
212964|NCT02558400|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
212965|NCT02558400|Drug|Latanoprost Ophthalmic Solution 0.005%|1 drop once daily (QD), in the evening (PM) in both eyes (OU)
212966|NCT02558387|Drug|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
212967|NCT02558374|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
212968|NCT02558374|Drug|Timolol Maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
212969|NCT02558374|Other|Placebo|1 drop QD, AM, OU
212970|NCT02558361|Drug|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. [30mg po BID after initial titration]
212971|NCT02558348|Drug|AL3818|Administered orally
212972|NCT02558322|Other|Primary medical care|All study participants receive primary care as usual in the respective region
212973|NCT02558296|Drug|Bexagliflozin|20 mg, tablet
212974|NCT02558296|Drug|Placebo|20 mg tablet to match active comparator
212975|NCT02558283|Device|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
212976|NCT02558283|Device|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
212977|NCT02558270|Drug|Dapagliflozin|
212978|NCT02558270|Drug|Placebo|
212979|NCT02558257|Behavioral|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
212980|NCT02558231|Drug|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
212981|NCT02558231|Drug|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
212982|NCT02558231|Drug|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
212983|NCT02558218|Drug|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
212984|NCT02558218|Drug|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
212985|NCT02558205|Radiation|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
212986|NCT02558205|Radiation|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
212987|NCT02558192|Dietary Supplement|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
212988|NCT02558192|Dietary Supplement|PLACEBO|1 vials q12 for 15 days
212989|NCT02558153|Device|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
212990|NCT02558153|Device|standard PTA|Percutaneous angioplasty performed with a standard balloon
212991|NCT02558140|Biological|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
212992|NCT02558140|Biological|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
212993|NCT02558127|Genetic|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
212994|NCT02558114|Drug|Ribavirin|
212995|NCT02558101|Behavioral|Control invitation materials|"In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~an invitation letter with a pre-scheduled appointment plus the same information booklet~a reminder re-invitation letter for those who miss their appointment without cancelling"
213126|NCT02557178|Device|COPD Activity Monitor|A custom activity monitor capable.
213127|NCT02557178|Behavioral|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
212996|NCT02558101|Behavioral|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
212997|NCT02558088|Drug|Salmeterol|
212998|NCT02558075|Behavioral|MoodLifters Sessions|This program consists of 15 different sessions with a different topic for each session. These sessions will occur once a week for 15 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
212999|NCT02558062|Other|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
213000|NCT02558049|Other|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
213001|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
213002|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
213003|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
213004|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
213005|NCT02558023|Drug|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1."
213006|NCT02558023|Drug|Nicardipine|"Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1"
213007|NCT02558010|Drug|Methadone|perioperative IV methadone to be given
213008|NCT02558010|Other|Normal Saline|control arm
213009|NCT02558010|Drug|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia pump.
213010|NCT02557997|Other|Blood tube bottom analyses|
213011|NCT02557984|Drug|Placebo|Placebo Pill
213012|NCT02557984|Drug|Amisulpride|400 mg Amisulpride
213013|NCT02557984|Drug|Naltrexone|50 mg Naltrexone
213014|NCT02557971|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
213015|NCT02557958|Drug|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
213016|NCT02557958|Drug|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
213017|NCT02557945|Drug|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
213018|NCT02557945|Drug|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
213019|NCT02557932|Drug|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
213020|NCT02557932|Drug|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
213021|NCT02557919|Other|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
213022|NCT02557919|Other|Usual Best Practice|.5 day training on tobacco control and emerging products.
213023|NCT02557906|Procedure|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
213024|NCT02557906|Procedure|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
213025|NCT02557906|Procedure|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
213026|NCT02557893|Behavioral|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
213027|NCT02557893|Other|Education|Bimonthly pregnancy education classes
213028|NCT02557893|Other|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
213029|NCT02557880|Behavioral|Sleep Application Diary|Tool used to document sleep hygiene.
213030|NCT02557880|Behavioral|Treatment As Usual|Sleep hygiene counseling
213031|NCT02557867|Drug|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
213032|NCT02557854|Drug|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
213033|NCT02557854|Device|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
213206|NCT02556697|Device|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
213035|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
213036|NCT02557841|Device|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
213037|NCT02557828|Procedure|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
213038|NCT02557815|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
213039|NCT02557802|Biological|Fluenz Tetra|Intranasal spray, 0.2 ml dose
213040|NCT02557802|Biological|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
213041|NCT02557789|Drug|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
213042|NCT02557776|Genetic|Germline genetic testing of BRCA1 and BRCA2|
213043|NCT02557763|Device|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
213044|NCT02557737|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
213045|NCT02557724|Procedure|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
213046|NCT02557724|Procedure|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
213047|NCT02557711|Device|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
213048|NCT02557698|Other|Balneum oil bath|
213049|NCT02557685|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
213050|NCT02557672|Drug|Prothrombin complex concentrate (Human)|PCC (Kcentra)
213051|NCT02557672|Biological|Fresh frozen plasma (FFP)|FFP
213052|NCT02557659|Device|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
213053|NCT02557646|Biological|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
213054|NCT02557646|Drug|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
213055|NCT02557633|Biological|Grass MATA MPL 10200|
213056|NCT02557633|Biological|Grass MATA MPL 18200|
213057|NCT02557633|Biological|Placebo|
213058|NCT02557620|Drug|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
213059|NCT02557620|Drug|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
213060|NCT02557607|Device|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
213061|NCT02557594|Drug|Viread 300mg|single dose administration after 10hr fasting
213062|NCT02557594|Drug|DA-2802 319mg|single dose administration after 10hr fasting
213063|NCT02557581|Other|No training|
213064|NCT02557581|Other|Endurance training|
213065|NCT02557581|Other|Resistance Training|
213066|NCT02557581|Drug|Terbutaline|
213067|NCT02557581|Drug|Clenbuterol|
213068|NCT02557581|Drug|Placebo|
213069|NCT02557568|Other|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
213070|NCT02557555|Other|educational information|patients will receive pamphlet on labor analgesia options.
213071|NCT02557542|Other|One Stop Vein Clinic|Same day diagnosis and treatment
213072|NCT02557542|Device|Radiofrequency ablation|Venous ablation
213073|NCT02557542|Device|Endovenous laser ablation|Venous ablation
213074|NCT02557542|Drug|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
213075|NCT02557529|Behavioral|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
213076|NCT02557529|Behavioral|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
213077|NCT02557529|Behavioral|Diet diary|Weekly diet diary during the 12-weeks intervention
213078|NCT02557516|Drug|monalizumab|"During phase 1b, patients receive IPH2201, IV, at the dose of 1, 2, 4 or 10 mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.~During phase 2a, patients receive IPH2201, IV, at the dose recommended upon completion of phase 1b portion, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of IPH2201 (from week 0 to week 6) occur every 2 weeks. From the 5th administration IPH2201 is administered every 4 weeks."
213079|NCT02557503|Drug|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
213250|NCT02556372|Drug|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation
213080|NCT02557490|Drug|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.~Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
213081|NCT02557477|Dietary Supplement|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
213082|NCT02557477|Dietary Supplement|Placebo|Three placebo capsules twice daily
213083|NCT02557464|Behavioral|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
213084|NCT02557464|Behavioral|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
213085|NCT02557451|Other|Surgery|
213086|NCT02557451|Other|Intravitreal injections of gas|
213087|NCT02557451|Procedure|injections of an antiangiogenic|
213088|NCT02557438|Procedure|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
213089|NCT02557438|Procedure|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
213090|NCT02557425|Other|No intervention in PROTECT|
213091|NCT02557412|Device|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
213092|NCT02557412|Behavioral|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
213093|NCT02557412|Other|Conventional treatment|Hygiene and diet recommendations on sleep
213094|NCT02557399|Drug|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
213095|NCT02557399|Drug|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
213096|NCT02557399|Drug|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
213097|NCT02557386|Drug|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
213098|NCT02557386|Drug|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
213099|NCT02557386|Drug|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
213100|NCT02557386|Drug|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
213101|NCT02557386|Drug|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
213102|NCT02557386|Drug|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
213103|NCT02557373|Dietary Supplement|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
213104|NCT02557373|Dietary Supplement|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
213105|NCT02557360|Dietary Supplement|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
213106|NCT02557347|Behavioral|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
213107|NCT02557334|Dietary Supplement|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
213108|NCT02557334|Dietary Supplement|High Dose Strawberry Powder|40 g freeze dried strawberry powder
213109|NCT02557334|Dietary Supplement|Placebo Powder|40 g color and taste matched placebo powder
213110|NCT02557321|Drug|PV-10|PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
213111|NCT02557321|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
213112|NCT02557269|Drug|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
213113|NCT02557269|Drug|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
213114|NCT02557269|Drug|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
213115|NCT02557269|Drug|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
213116|NCT02557269|Other|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
213117|NCT02557269|Drug|Bilastine 20 mg|1 tablet per os - as needed
213118|NCT02557269|Drug|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
213119|NCT02557217|Drug|NP202|Active
213120|NCT02557217|Other|Placebo|Placebo
213121|NCT02557204|Procedure|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
213122|NCT02557204|Procedure|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
213123|NCT02557204|Procedure|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
213124|NCT02557204|Procedure|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
213125|NCT02557191|Other|Observational study|
213128|NCT02557165|Procedure|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
213129|NCT02557152|Device|GentleWave System Treatment|
213130|NCT02557139|Drug|KD025 Tablet|
213131|NCT02557139|Drug|KD025 as drug in capsule|
213132|NCT02557126|Drug|URC102|
213133|NCT02557126|Drug|Placebo|
213134|NCT02557113|Procedure|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
213135|NCT02557113|Procedure|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
213136|NCT02557100|Drug|Abatacept|
213137|NCT02557100|Drug|Adalimumab|
213138|NCT02557100|Drug|Methotrexate|
213139|NCT02557087|Drug|Hyoscine|
213140|NCT02557087|Drug|Pethidine|
213141|NCT02557074|Drug|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
213142|NCT02557074|Drug|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
213143|NCT02557061|Procedure|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
213144|NCT02557061|Biological|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
213145|NCT02557035|Drug|Palonosetron|
213146|NCT02557035|Drug|Dexamethasone|
213147|NCT02557022|Other|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
213148|NCT02556996|Biological|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
213149|NCT02556996|Other|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10^11 heat-killed bacteria per dose)
213150|NCT02556983|Radiation|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
213151|NCT02556970|Procedure|Single port VATS|Performing video-assisted thorascopic surgery through a single port
213152|NCT02556970|Drug|Paracetamol|1g intraoperatively
213153|NCT02556970|Drug|Diclofenac|75mg intraoperatively
213154|NCT02556970|Device|Camera (5mm diameter 30 degree videothoracoscope)|
213155|NCT02556970|Device|Forceps grasper|
213156|NCT02556970|Drug|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
213157|NCT02556957|Behavioral|HealthScouts|
213158|NCT02556957|Other|Standard of Care|
213159|NCT02556944|Device|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
213160|NCT02556931|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
213161|NCT02556931|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
213162|NCT02556931|Radiation|Total body irradiation|Day -1: 200 cGy in a single fraction
213163|NCT02556931|Drug|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
213164|NCT02556931|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
213165|NCT02556918|Drug|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
213166|NCT02556918|Drug|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
213167|NCT02556918|Drug|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
213168|NCT02556918|Drug|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate >1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.~The total daily insulin dose will be adjusted as follow:~Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between >180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG >241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG <100 mg/dl: stop basal"
213169|NCT02556918|Drug|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG greater than 400 mg/dL; 7-9 units of insulin lispro"
213251|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
213170|NCT02556918|Drug|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin aspart~BG between 221-260 mg/dL; 3-5 units of insulin aspart~BG between 261-300 mg/dL; 4-6 units of insulin aspart~BG between 301-350 mg/dL; 5-7 units of insulin aspart~BG between 351-400 mg/dL; 6-8 units of insulin aspart~BG greater than 400 mg/dL; 7-9 units of insulin aspart"
213171|NCT02556905|Drug|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
213172|NCT02556905|Drug|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
213173|NCT02556892|Drug|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
213174|NCT02556879|Biological|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
213175|NCT02556879|Biological|Serum bank|Additional samples for serum bank at each visit if possible
213176|NCT02556879|Biological|DNA bank|Additional sample for DNA bank at inclusion visit if possible
213177|NCT02556879|Procedure|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
213178|NCT02556879|Procedure|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
213179|NCT02556866|Drug|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
213180|NCT02556866|Drug|Prednisone|
213181|NCT02556866|Drug|Placebo|
213182|NCT02556853|Device|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
213183|NCT02556853|Other|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
213184|NCT02556840|Other|insulin therapy|
213185|NCT02556827|Other|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
213186|NCT02556827|Device|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
213187|NCT02556827|Device|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
213188|NCT02556827|Device|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
213189|NCT02556814|Drug|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
213190|NCT02556814|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
213191|NCT02556814|Drug|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
213192|NCT02556801|Biological|SUBLIVAC FIX Phleum Prat.|sublingual daily administration
213193|NCT02556788|Drug|CD5789 (trifarotene) 50µg/g Cream|CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
213194|NCT02556788|Drug|Placebo Cream|Placebo cream applied once daily during 12 weeks.
213195|NCT02556775|Biological|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
213196|NCT02556775|Biological|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
213197|NCT02556762|Radiation|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
213198|NCT02556762|Radiation|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
213199|NCT02556762|Drug|PF|Chemotherapy: Cisplatin and 5fluorouracil
213200|NCT02556749|Dietary Supplement|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
213201|NCT02556749|Dietary Supplement|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
213202|NCT02556736|Drug|RST-001|RST-001 is a gene therapeutic delivered by intravitreal injection
213203|NCT02556723|Drug|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
213204|NCT02556710|Biological|AMPION™|4 mL Ampion Injection
213205|NCT02556710|Biological|Saline|4 mL Saline Injection
213536|NCT02554240|Drug|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
213207|NCT02556658|Device|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
213208|NCT02556658|Device|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
213209|NCT02556645|Other|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
213210|NCT02556645|Other|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
213211|NCT02556632|Drug|Curcumin-based Gel|Applied topically
213212|NCT02556632|Procedure|Dermatologic Complications Management|Apply HPR Plus topically
213213|NCT02556632|Other|Laboratory Biomarker Analysis|Correlative studies
213214|NCT02556632|Other|Placebo|Apply placebo gel topically
213215|NCT02556632|Other|Questionnaire Administration|Ancillary studies
213216|NCT02556619|Behavioral|Early Palliative Care/Symptom Control|"Establish palliative care goals~Determination of Medical Power of Attorney~Discuss/plan code status/advance directives~Document palliative care goals~Symptom Assessment and Control~Pain-treatment with opioid and non-opioid medications~Itching-H2 blockers, steroids~Nutrition-appetite stimulated with Megace, review low sodium diet~Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed~Nausea- treated with anti-emetics~Jaundice and Body Image- counselling regarding symptoms~End-of-Life Care~Discuss religious preferences~Assess for distress- ensure interaction with Cancer Resource Center~Hospice- charity Hospice options for select patients."
213217|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
213218|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
213219|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
213220|NCT02556606|Drug|Midazolam|single 40 min infusion of MID 0.03mg/Kg
213221|NCT02556593|Radiation|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
213222|NCT02556593|Radiation|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
213223|NCT02556593|Drug|erlotinib|erlotinib 150mg daily
213224|NCT02556580|Drug|Albumin 20%|Intervention: intravenious infusion Drug: albumin
213225|NCT02556567|Other|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
213226|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
213227|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
213228|NCT02556541|Procedure|IV puncture guided by ultrasound|
213229|NCT02556528|Behavioral|Health Coaching|
213230|NCT02556515|Procedure|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
213231|NCT02556515|Procedure|Total joint replacement|Total joint replacement
213232|NCT02556515|Device|Elektra prosthesis|Elektra prosthesis
213233|NCT02556502|Device|18F-Florbetaben PET|
213234|NCT02556476|Procedure|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
213235|NCT02556476|Procedure|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
213236|NCT02556476|Procedure|renal replacement therapy|the procedures used to treat acute kidney injury
213237|NCT02556476|Procedure|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
213238|NCT02556463|Drug|MEDI9197|Subjects will receive MEDI9197 (every 4 weeks) as monotherapy (or MEDI9197 every 8 weeks + durvalumab every 4 weeks)(PA6)
213239|NCT02556463|Biological|durvalumab|Subjects will receive durvalumab every 4 weeks
213240|NCT02556450|Drug|Spironolacton|Administration of Spironolacton 25 mg per day
213241|NCT02556437|Drug|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
213242|NCT02556437|Drug|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
213243|NCT02556424|Drug|Dexamethasone|Intravitreal implant at D0
213244|NCT02556424|Drug|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
213245|NCT02556411|Drug|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
213246|NCT02556411|Drug|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
213247|NCT02556398|Behavioral|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
213248|NCT02556385|Device|High frequency rTMS|Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
213249|NCT02556385|Device|Low frequency rTMS|Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
213252|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
213253|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
213254|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
213255|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
213256|NCT02556333|Drug|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
213257|NCT02556320|Drug|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
213258|NCT02556320|Biological|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
213259|NCT02556307|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
213260|NCT02556307|Drug|Ribavirin|Ribavirin according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
213261|NCT02556294|Behavioral|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
213262|NCT02556294|Behavioral|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
213263|NCT02556281|Biological|Blood sampling|Blood sampling is done for patient with colorectal cancer
213264|NCT02556268|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
213265|NCT02556268|Drug|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
213266|NCT02556268|Drug|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
213267|NCT02556268|Drug|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
213268|NCT02556268|Drug|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
213269|NCT02556268|Drug|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
213270|NCT02556255|Device|B-Laser™ Atherectomy Catheter|Laser atherectomy catheter based on 355 nm
213271|NCT02556242|Other|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
213272|NCT02556242|Other|Generalised Indoor residual spraying|IRS is carried out as normally practiced
213273|NCT02556229|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
213274|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg OD (once-daily)
213275|NCT02556203|Drug|Acetylsalicylic acid|75 - 100 mg OD (for first 90 days only in arm 1)
213276|NCT02556203|Drug|Clopidogrel|75 mg OD for first 90 days
213277|NCT02556177|Procedure|MRI|MRI scanning
213278|NCT02556164|Procedure|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
213279|NCT02556164|Other|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
213280|NCT02556151|Procedure|Repetitive lumbosacral magnetic stimulation (rTLSMS)|Patients randomized to Six sessions of weekly therapy with either 1 HZ or 5 Hz or 15 Hz magnetic stimulations of the lumbar and sacral regions.
213281|NCT02556138|Device|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
213282|NCT02556125|Device|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
213313|NCT02555852|Drug|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
213314|NCT02555852|Drug|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
213315|NCT02555852|Drug|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
213316|NCT02555852|Drug|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
213283|NCT02556112|Behavioral|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
213284|NCT02556112|Behavioral|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
213285|NCT02556112|Behavioral|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
213286|NCT02556099|Drug|Hydroxyurea|drug to be administered
213287|NCT02556086|Drug|Daclatasvir|
213288|NCT02556086|Drug|Sofosbuvir|
213289|NCT02556073|Other|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
213290|NCT02556073|Drug|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
213291|NCT02556060|Drug|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
213292|NCT02556060|Drug|Placebo|Same dosing schedule as study drug
213293|NCT02556047|Device|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N&S
213294|NCT02556034|Other|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
213295|NCT02556021|Drug|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
213296|NCT02556021|Drug|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
213297|NCT02556021|Drug|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
213298|NCT02556008|Drug|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
213299|NCT02555995|Device|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
213300|NCT02555982|Drug|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:~Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
213301|NCT02555982|Drug|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
213302|NCT02555943|Drug|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
213303|NCT02555943|Drug|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
213304|NCT02555943|Drug|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
213305|NCT02555943|Drug|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
213306|NCT02555943|Drug|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
213307|NCT02555930|Other|No Intervention|No intervention - observational only
213308|NCT02555917|Procedure|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
213309|NCT02555878|Drug|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
213310|NCT02555878|Drug|Placebo|Placebo tablet will be administered orally once daily for 180 days.
213311|NCT02555852|Drug|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
213312|NCT02555852|Drug|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
213317|NCT02555852|Drug|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
213318|NCT02555852|Drug|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
213319|NCT02555852|Drug|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
213320|NCT02555852|Drug|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
213321|NCT02555852|Drug|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
213322|NCT02555852|Drug|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
213323|NCT02555852|Drug|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
213324|NCT02555852|Drug|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
213325|NCT02555852|Drug|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
213326|NCT02555839|Drug|Pomalidomide|4mg capsules on Days 1 through 21 of a 28 day cycle
213327|NCT02555839|Drug|Dexamethasone|40mg by mouth on Days 1, 8, 15, 22 of a 28 day cycle
213328|NCT02555813|Drug|Abraxane|Abraxane By IV infusion on Days 1, 8, and 15 until progression or toxicity
213329|NCT02555813|Drug|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8 and 15 until disease progression or toxicity
213330|NCT02555800|Drug|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
213331|NCT02555800|Drug|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
213332|NCT02555800|Other|Placebo|Saline solution
213333|NCT02555787|Drug|Tacrolimus|oral
213334|NCT02555774|Behavioral|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
213335|NCT02555774|Behavioral|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
213336|NCT02555761|Drug|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
213337|NCT02555748|Drug|Pazopanib|
213338|NCT02555748|Drug|Sunitinib|
213339|NCT02555735|Drug|Standard of care chemotherapy|
213340|NCT02555722|Device|fanfilcon A (test)|silicone hydrogel lens
213341|NCT02555722|Device|enfilcon A (control)|silicone hydrogel lens
213342|NCT02555709|Drug|VTP-43742|VTP-43742 administered as an oral capsule once daily
213343|NCT02555709|Drug|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
213344|NCT02555709|Drug|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
213345|NCT02555696|Drug|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
213346|NCT02555683|Drug|QAW039|QAW039 Dose 1 once daily
213347|NCT02555683|Drug|QAW039|QAW039 Dose 2 once daily
213348|NCT02555683|Drug|Placebo|Placebo once daily
213349|NCT02555670|Other|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
213350|NCT02555657|Biological|pembrolizumab|
213351|NCT02555657|Drug|capecitabine|
213352|NCT02555657|Drug|eribulin|
213353|NCT02555657|Drug|gemcitabine|
213354|NCT02555657|Drug|vinorelbine|
213355|NCT02555644|Drug|Prexasertib|Administered IV
213356|NCT02555644|Drug|Cisplatin|Administered IV
213357|NCT02555644|Drug|Cetuximab|Administered IV
213358|NCT02555644|Radiation|Intensity Modulated Radiation Therapy|
213359|NCT02555631|Behavioral|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
213360|NCT02555618|Biological|TAK-850|TAK-850 subcutaneous injection
213361|NCT02555618|Biological|Influenza HA vaccine|Influenza HA vaccine subcutaneous injection
213362|NCT02555605|Drug|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg−1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg−1•h−1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg−1•h−1. In addition, propofol 0.5 mg.kg−1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
213363|NCT02555592|Procedure|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2~4 weeks after adjuvant chemotherapy.
214932|NCT02544282|Drug|Sufentanil|General Anesthesia
213364|NCT02555579|Behavioral|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
213365|NCT02555566|Procedure|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
213366|NCT02555566|Procedure|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
213367|NCT02555553|Behavioral|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
213368|NCT02555540|Biological|Boostrix|Randomised assignment
213369|NCT02555540|Biological|Placebo (Saline)|Randomised assignment
213370|NCT02555501|Other|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).~From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
213371|NCT02555501|Radiation|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
213372|NCT02555488|Device|diode laser|MB and diode
213373|NCT02555488|Device|diode laser|diode laser
213374|NCT02555488|Drug|Methylene blue|Methylene blue and diode laser was used
213375|NCT02555475|Other|community based hepatitis C care and treatment|
213376|NCT02555462|Device|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
213377|NCT02555449|Drug|[¹⁴C]-LY3202626|Administered as solution by mouth
213378|NCT02555423|Drug|Local anaesthetic - chirocaine|
213379|NCT02555410|Device|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
213380|NCT02555397|Biological|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
213381|NCT02555384|Other|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
213382|NCT02555384|Other|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
213383|NCT02555371|Biological|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
213384|NCT02555371|Drug|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
213385|NCT02555358|Drug|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
213386|NCT02555358|Drug|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
213387|NCT02555332|Other|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
213388|NCT02555319|Device|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
213389|NCT02555306|Drug|DE-122|DE-122 Injectable Solution
213390|NCT02555293|Drug|XIFAXAN® (Rifaximin)|
213391|NCT02555280|Device|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
213392|NCT02555280|Procedure|Decompression|Decompression alone
213393|NCT02555254|Procedure|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
213394|NCT02555254|Procedure|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
213395|NCT02555241|Behavioral|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
213396|NCT02555241|Behavioral|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
213397|NCT02555241|Behavioral|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
213398|NCT02555228|Drug|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
213399|NCT02555228|Other|Water|5mls of water is given at least 30 minutes before the gastroscopy.
213400|NCT02555215|Drug|dimethyl fumarate|administered orally
213401|NCT02555189|Drug|Enzalutamide|Given PO
213402|NCT02555189|Drug|Ribociclib|Given PO
213403|NCT02555176|Dietary Supplement|Dietary intervention|Follow a low-carbohydrate diet
213404|NCT02555163|Device|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
213405|NCT02555163|Device|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
213406|NCT02555150|Drug|PRC-063|Oral extended-release capsule
213407|NCT02555150|Drug|lisdexamfetamine dimesylate|Oral capsule
213408|NCT02555150|Drug|Placebo|Oral placebo capsule
213409|NCT02555137|Other|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
213410|NCT02555124|Drug|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
213411|NCT02555124|Drug|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
213412|NCT02555124|Drug|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
213413|NCT02555124|Drug|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
213414|NCT02555111|Drug|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
213415|NCT02555085|Biological|BIIB063|Single ascending IV dose
213416|NCT02555085|Other|Placebo|Single dose
213417|NCT02555072|Biological|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
213418|NCT02555059|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
213419|NCT02555046|Procedure|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
213420|NCT02555033|Other|Resistance training|traditional resistance training
213421|NCT02555033|Other|Instability resistance training|training under unstable conditions
213422|NCT02555020|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
213423|NCT02555020|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
213424|NCT02555020|Dietary Supplement|Allocated to MN NPO group,|Patients received NPO from MN.
213425|NCT02555007|Drug|Vinorelbine|
213426|NCT02554994|Other|Multifactorial intervention|"There are six components of intervention in this study.~For all participants:~Group exercise~Nutritional supplement(commercial liquid formula will be provided every day).~For selected participants:~Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.~At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).~Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
213427|NCT02554994|Other|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.~According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
213428|NCT02554981|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
213429|NCT02554968|Other|Questionnaires|
213430|NCT02554955|Drug|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
213431|NCT02554955|Drug|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
213432|NCT02554955|Drug|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
213433|NCT02554942|Drug|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
213434|NCT02554929|Behavioral|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
213435|NCT02554929|Behavioral|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
213436|NCT02554916|Behavioral|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
213437|NCT02554916|Behavioral|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
213438|NCT02554916|Other|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
213439|NCT02554916|Device|Dual-Belt Treadmill|
213440|NCT02554903|Drug|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
213441|NCT02554903|Drug|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
213442|NCT02554890|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
213443|NCT02554890|Drug|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
213444|NCT02554890|Drug|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
213445|NCT02554890|Drug|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
213446|NCT02554877|Drug|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
213447|NCT02554877|Drug|Placebo|oral tablet
213448|NCT02554864|Drug|lidocaine|Local anesthetic
213449|NCT02554864|Drug|ropivacaine|Local anesthetic
213528|NCT02554305|Device|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
213529|NCT02554292|Device|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
213450|NCT02554851|Drug|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
213451|NCT02554851|Other|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
213452|NCT02554838|Other|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
213453|NCT02554838|Other|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
213454|NCT02554838|Behavioral|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
213455|NCT02554825|Behavioral|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels—individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
213456|NCT02554825|Behavioral|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
213457|NCT02554812|Drug|Avelumab|Anti-PD-L1 antibody
213458|NCT02554812|Drug|Utomilumab|Anti-4-1BB antibody
213459|NCT02554812|Drug|PF-04518600|OX40 Agonist
213460|NCT02554812|Drug|PD 0360324|Anti-M-CSF
213461|NCT02554812|Drug|CMP-001|TLR9 agonist
213462|NCT02554799|Drug|MMV390048 formulation A|MMV390048 formulation A, tablet
213463|NCT02554799|Drug|MMV390048 formulation B|MMV390048 formulation B, tablet
213464|NCT02554786|Drug|QMF149|
213465|NCT02554786|Drug|QMF149|
213466|NCT02554786|Drug|MF 400|
213467|NCT02554786|Drug|MF 400|
213468|NCT02554786|Drug|salmeterol /fluticasone|
213469|NCT02554773|Drug|Fitusiran (SAR439774)|Pharmaceutical form: solution for injection Route of administration : subcutaneous (sc)
213470|NCT02554760|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
213471|NCT02554747|Device|Navigated laser|Aflibercept, Navilas®
213472|NCT02554747|Device|Conventional laser|Aflibercept, Pascal
213473|NCT02554734|Drug|levodopa, carbidopa, ODM-104|
213474|NCT02554734|Drug|levodopa, carbidopa, entacapone|
213475|NCT02554721|Drug|Cilostazol|
213476|NCT02554721|Drug|Acetylsalicylic acid|
213477|NCT02554721|Drug|Clopidogrel|
213478|NCT02554708|Device|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
213479|NCT02554695|Drug|placebo|subcutaneous saline injection
213480|NCT02554695|Drug|denosumab|single subcutaneous injection of denosumab 60 mg
213481|NCT02554682|Behavioral|Sexual Health|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, sexually transmitted disease (STD) prevention, and safe sex practices for teenager.
213482|NCT02554682|Behavioral|Alcohol Prevention|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
213483|NCT02554682|Behavioral|Teen Driving|Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
213484|NCT02554669|Behavioral|postprandial and postabsorptive physical activity on treadmill|
213485|NCT02554643|Other|Diet|Nutrition intervention, once a week during 12 weeks
213486|NCT02554643|Other|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
213487|NCT02554643|Other|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
213488|NCT02554630|Other|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
213489|NCT02554630|Other|Blood Collection|Blood collection will be performed on all groups.
213530|NCT02554279|Drug|menotropin|
213531|NCT02554279|Drug|recombinant FSH|
213532|NCT02554266|Device|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
213533|NCT02554253|Drug|Ketamine|Ketamine used for induction
213490|NCT02554578|Other|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.~Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.~Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).~mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
213491|NCT02554565|Procedure|Tumor biopsy|Tumor biopsy before treatment
213492|NCT02554565|Procedure|Blood sampling|Blood sample before, during and after treatment
213493|NCT02554552|Drug|YY1201 2ml|YY1201 2ml
213494|NCT02554552|Drug|Placebo 2ml|phosphate buffered saline 2ml
213495|NCT02554552|Drug|YY1201 3ml|YY1201 2ml
213496|NCT02554552|Drug|Placebo 3ml|phosphate buffered saline 3ml
213497|NCT02554539|Procedure|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
213498|NCT02554513|Device|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
213499|NCT02554513|Behavioral|SPT|A treatment hierarchy involving integral stimulation
213500|NCT02554500|Procedure|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
213501|NCT02554487|Device|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI > 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI < 5) following stroke serve as a control group
213502|NCT02554474|Behavioral|Education, Fitbit/FitViz, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
213503|NCT02554474|Behavioral|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
213504|NCT02554461|Other|advise for exercices given by team staff|"To respond to questions asked:~it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
213505|NCT02554448|Other|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
213506|NCT02554435|Device|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
213507|NCT02554435|Behavioral|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
213508|NCT02554435|Device|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
213509|NCT02554422|Device|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
213510|NCT02554409|Biological|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
213511|NCT02554396|Drug|PRX-100|ophthalmic solution
213512|NCT02554396|Drug|Placebo|saline ophthalmic solution
213513|NCT02554383|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
213514|NCT02554383|Drug|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
213515|NCT02554370|Behavioral|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
213516|NCT02554357|Drug|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
213517|NCT02554357|Drug|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
213518|NCT02554344|Drug|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
213519|NCT02554331|Radiation|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
213520|NCT02554331|Behavioral|neuropsychological evaluation|"Assessment of:~overall cognitive function~executive functions~visuospatial functions~Nonverbal memory~verbal memory~Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~Beck Depression Inventory"
213521|NCT02554331|Other|Gait recording with sensors|Gait recording with sensors
213522|NCT02554318|Drug|Rifampicin|
213523|NCT02554318|Drug|Isoniazid|
213524|NCT02554318|Drug|Pyrazinamide|
213525|NCT02554318|Drug|Ethambutol|
213526|NCT02554318|Dietary Supplement|Fermented soybean|
213527|NCT02554305|Device|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
213534|NCT02554253|Drug|Propofol|Propofol for induction
214933|NCT02544282|Drug|Atracurium|General Anesthesia
213537|NCT02554240|Drug|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
213538|NCT02554227|Other|Cytokine Profile and suPAR|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
213539|NCT02554214|Device|Glafkos drainage device|
213540|NCT02554201|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
213541|NCT02554201|Device|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
213542|NCT02554188|Biological|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine~Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old~Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
213543|NCT02554188|Other|Diet|A 5-day low calorie fasting-mimicking diet
213544|NCT02554175|Drug|Propofol|Propofol was administered to achieve target propofol Ce
213545|NCT02554162|Other|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
213546|NCT02554149|Radiation|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
213547|NCT02554136|Drug|HGP0918|
213548|NCT02554136|Drug|HGP0816|
213549|NCT02554136|Drug|HGP0918 + HGP0816|
213550|NCT02554123|Drug|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
213551|NCT02554123|Drug|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
213552|NCT02554110|Device|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
213553|NCT02554110|Device|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
213554|NCT02554097|Procedure|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
213555|NCT02554097|Procedure|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
213556|NCT02554097|Procedure|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
213557|NCT02554097|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
213558|NCT02554084|Other|Optical Coherence Tomography|Digital images of tear film
213559|NCT02554071|Other|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
213560|NCT02554058|Device|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
213561|NCT02554045|Drug|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
213562|NCT02554045|Drug|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
213563|NCT02554032|Procedure|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
213564|NCT02554032|Procedure|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
213565|NCT02554019|Biological|BT063|Repeated IV infusions over 12 weeks
213566|NCT02554019|Biological|Placebo|Repeated IV infusions over 12 weeks
213567|NCT02554006|Behavioral|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
213568|NCT02554006|Behavioral|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
213569|NCT02553993|Device|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
213570|NCT02553993|Device|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
213571|NCT02553993|Other|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
213613|NCT02553668|Drug|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
213572|NCT02553980|Behavioral|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
213573|NCT02553980|Other|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
213574|NCT02553967|Device|Functional MRI|Functional MRI
213575|NCT02553954|Procedure|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
213576|NCT02553941|Drug|Azacitidine|Given intravenous or subcutaneous
213577|NCT02553941|Drug|Ibrutinib|Given by mouth once daily
213578|NCT02553928|Drug|Memantine (once daily)|
213579|NCT02553928|Drug|Memantine (twice daily)|
213580|NCT02553915|Other|Placebo|Soybean oil placebo
213581|NCT02553915|Drug|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
213582|NCT02553915|Drug|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
213583|NCT02553915|Drug|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
213584|NCT02553902|Device|Sleep position trainer|
213585|NCT02553902|Device|Mandibular advancement device|
213586|NCT02553902|Device|Continuous positive airway pressure|
213587|NCT02553889|Drug|ISIS 416858|subcutaneous injection
213588|NCT02553889|Drug|Placebo|subcutaneous injection
213589|NCT02553863|Procedure|Acupuncture|Acupuncture for 30min [twice weekly for 8 weeks]
213590|NCT02553863|Procedure|Standard care|Standard care
213591|NCT02553837|Biological|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
213592|NCT02553824|Drug|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
213593|NCT02553824|Drug|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
213594|NCT02553811|Diagnostic Test|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
213595|NCT02553798|Drug|Glycopyrronium Topical Wipes|Glycopyrronium Topical Wipes
213596|NCT02553785|Device|Revivent TC|
213597|NCT02553772|Drug|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop (OM3 Tear) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
213598|NCT02553772|Drug|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
213599|NCT02553759|Other|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
213600|NCT02553746|Device|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
213601|NCT02553746|Procedure|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
213602|NCT02553733|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
213603|NCT02553733|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
213604|NCT02553720|Other|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
213605|NCT02553720|Other|conventional management|conventional management
213606|NCT02553707|Drug|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
213607|NCT02553694|Other|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
213608|NCT02553694|Other|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
213609|NCT02553694|Other|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
213610|NCT02553694|Other|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
213611|NCT02553681|Device|roflufocon D contact lenses|HPT treated rigid contact lenses
213612|NCT02553681|Device|RGP contact lenses made from roflufocon D|
213614|NCT02553668|Device|Facemask|
213615|NCT02553655|Procedure|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
213616|NCT02553655|Procedure|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
213617|NCT02553655|Procedure|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
213618|NCT02553642|Drug|Nivolumab|"Monotherapy Treatment~- Nivolumab 240 mg flat dose Dosed q 2 weeks for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit"
213619|NCT02553642|Drug|Nivolumab plus Ipilimumab|"Combination Treatment~Ipilimumab 3 mg/kg~Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses"
213620|NCT02553629|Drug|Rocuronium|
213621|NCT02553616|Behavioral|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
213622|NCT02553603|Drug|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
213623|NCT02553603|Drug|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
213624|NCT02553564|Other|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:~The participants's hospital course will be reviewed and their clinical recovery and stability assessed.~Determination of the participants's estimated dry weight (EDW).~The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.~Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.~Write new dialysis orders.~Dialysis Access- review access and determine any changes required in treatment"
213625|NCT02553551|Drug|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.~After discharge, no additional vitamin C pill was given."
213626|NCT02553551|Drug|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.~After discharge, no additional capsule was given."
213627|NCT02553538|Behavioral|Patient Navigation|Navigators utilized TopCare to track participants, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
213628|NCT02553525|Procedure|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
213629|NCT02553525|Procedure|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
213630|NCT02553512|Other|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
213631|NCT02553499|Biological|MK-1248|IV infusion
213632|NCT02553499|Biological|pembrolizumab|IV infusion
213633|NCT02553486|Other|quality of life evaluation|
213634|NCT02553473|Drug|Doxycycline|
213635|NCT02553473|Drug|Placebo|
213636|NCT02553460|Drug|ITMHA|Given intrathecally (IT).
213637|NCT02553460|Drug|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
213638|NCT02553460|Drug|Mitoxantrone|Given IV.
213639|NCT02553460|Drug|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
213640|NCT02553460|Drug|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
213641|NCT02553460|Drug|Bortezomib|Given IV.
213642|NCT02553460|Drug|Vorinostat|Taken PO or NG.
213643|NCT02553460|Drug|Cyclophosphamide|Given IV.
213644|NCT02553460|Drug|Mercaptopurine|Given PO or NG.
213645|NCT02553460|Drug|Methotrexate|Given IV.
213646|NCT02553460|Drug|Leucovorin Calcium|Leucovorin rescue PO or IV.
213647|NCT02553460|Drug|Cytarabine|Given IV.
213648|NCT02553460|Drug|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
213649|NCT02553460|Drug|Vincristine|Given IV.
213650|NCT02553447|Dietary Supplement|Cholecalciferol|Given PO
213651|NCT02553447|Other|Laboratory Biomarker Analysis|Optional correlative studies
213652|NCT02553434|Device|Pigtail catheter|Insertion of pigtail catheter
213653|NCT02553421|Device|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
213654|NCT02553408|Device|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
213655|NCT02553382|Dietary Supplement|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
213656|NCT02553382|Dietary Supplement|Positive Control|Oat bran blend and wheat bran capsules
213657|NCT02553369|Other|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
213658|NCT02553356|Drug|PT2385|
213659|NCT02553343|Biological|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
213660|NCT02553343|Biological|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
213661|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
213662|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
213663|NCT02553330|Drug|Placebo Cream|
213664|NCT02553330|Drug|Ruxolitinib Phosphate Cream|
213665|NCT02553317|Biological|Caplacizumab|"First day of treatment: 10 mg intravenous (i.v.) injection prior to plasma exchange (PE) followed by a 10 mg subcutaneous (s.c.) injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily 10 mg s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily 10 mg s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
213666|NCT02553317|Biological|Placebo|"First day of treatment: i.v. injection prior to PE followed by a s.c. injection (in the abdominal region) after completion of PE on that day.~Subsequent days of treatment during PE: daily s.c. injection (in the abdominal region) following PE.~Treatment after PE period: daily s.c. injections for 30 days. If the underlying immunological disease was not resolved, treatment could be extended for a maximum of 4 additional 1-week periods (i.e., 28 days) and was to be accompanied by optimization of immunosuppression."
213667|NCT02553291|Behavioral|SystemCHANGE|
213668|NCT02553291|Behavioral|Control|
213669|NCT02553278|Device|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
213670|NCT02553278|Device|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
213671|NCT02553265|Drug|Carbidopa Low Dose|
213672|NCT02553265|Other|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
213673|NCT02553265|Drug|Carbidopa High Dose|
213674|NCT02553252|Other|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
213675|NCT02553239|Device|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
213676|NCT02553226|Drug|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
213677|NCT02553226|Drug|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
213678|NCT02553213|Other|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
213679|NCT02553213|Other|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
213680|NCT02553213|Other|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
213681|NCT02553213|Other|easy digestible diet|
213682|NCT02553200|Device|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
213683|NCT02553200|Device|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
213684|NCT02553200|Device|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
213685|NCT02553187|Drug|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks)."
213686|NCT02553161|Drug|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
213687|NCT02553161|Behavioral|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
213688|NCT02553148|Other|Need for children's palliative care|Need for children's palliative care
213689|NCT02553135|Biological|Injection of AAV2-REP1 (10e11 vg)|Single Group: single arm study
213690|NCT02553122|Drug|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
213691|NCT02553122|Device|tourniquet|A tourniquet is applied to the thigh to stop/ decrease blood flow
213740|NCT02552706|Dietary Supplement|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
213692|NCT02553096|Device|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
213693|NCT02553083|Drug|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
213694|NCT02553083|Drug|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
213695|NCT02553083|Drug|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
213696|NCT02553083|Drug|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
213697|NCT02553083|Drug|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
213698|NCT02553083|Drug|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
213699|NCT02553070|Other|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
213700|NCT02553057|Device|mechanical ventilation|
213701|NCT02553044|Dietary Supplement|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
213702|NCT02553031|Device|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
213703|NCT02553018|Drug|Methotrexate|
213704|NCT02553005|Procedure|Acupuncture|
213705|NCT02552992|Behavioral|Yoga|
213706|NCT02552992|Behavioral|Self-Directed Mind-Body Program|
213707|NCT02552979|Other|atopic patch test|
213708|NCT02552966|Device|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
213709|NCT02552953|Drug|CYC065|
213710|NCT02552940|Drug|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
213711|NCT02552927|Device|Chest shield with aluminum foil (CALF)|
213712|NCT02552927|Device|SHIELD|
213713|NCT02552914|Device|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
213714|NCT02552901|Drug|0.1 mg/kg ICG Dose|least efficacious dose
213715|NCT02552901|Drug|0.5 mg/kg ICG dose|per package insert
213716|NCT02552888|Drug|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
213717|NCT02552888|Dietary Supplement|Isoquercetin|Isoquercetin 225 mg by mouth once per day
213718|NCT02552888|Other|placebos|placebos
213719|NCT02552875|Other|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
213720|NCT02552875|Other|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
213721|NCT02552862|Drug|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
213722|NCT02552862|Drug|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
213723|NCT02552849|Other|No intervention|
213724|NCT02552836|Behavioral|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
213725|NCT02552836|Behavioral|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
213726|NCT02552823|Other|Group1|
213727|NCT02552823|Other|Group2|
213728|NCT02552810|Device|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
213729|NCT02552810|Device|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
213730|NCT02552797|Behavioral|Shared Decision Making tool|
213731|NCT02552784|Behavioral|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
213732|NCT02552771|Procedure|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
213733|NCT02552771|Procedure|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
213734|NCT02552758|Biological|omega-3 fatty acid|omega-3 fatty acid
213735|NCT02552758|Biological|placebo|placebo
213736|NCT02552758|Device|positron emission tomography (PET)|
213737|NCT02552745|Drug|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
213738|NCT02552732|Device|NHF with Oxygen using myAIRVO™ 2|NHF will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
213739|NCT02552732|Device|NHF without Oxygen using myAIRVO™ 2|NHF will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C. Participants can also increase/decrease the flow rate (up to 30L/min or down to 20L/min).
213741|NCT02552706|Dietary Supplement|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
213742|NCT02552693|Other|Enhanced training, supervision and support|"The intervention includes the following activities:~Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
213743|NCT02552680|Other|Exercise|Physical Exercise
213744|NCT02552680|Other|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
213745|NCT02552680|Other|Brochure|Manual/brochure containing information about general health
213746|NCT02552667|Drug|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
213747|NCT02552667|Drug|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
213748|NCT02552654|Behavioral|Stress Film|Film scene with severe physical and sexual violence.
213749|NCT02552654|Drug|Hydrocortisone|10mg
213750|NCT02552654|Drug|Placebo|
213751|NCT02552641|Other|Food effect|
213752|NCT02552641|Drug|Esomeprazole|
213753|NCT02552641|Drug|Amoxicillin|
213754|NCT02552641|Drug|Clarythromycin|
213755|NCT02552628|Device|"Medtronic, Activa® PC on"|
213756|NCT02552628|Device|"Medtronic, Activa® PC off"|
213757|NCT02552615|Other|body awareness therapy|
213758|NCT02552615|Other|core stabilization exercises|
213759|NCT02552615|Other|traditional exercises|
213760|NCT02552602|Dietary Supplement|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
213761|NCT02552602|Dietary Supplement|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
213762|NCT02552602|Dietary Supplement|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
213763|NCT02552589|Other|Amine fluoride|toothpaste
213764|NCT02552589|Other|Placebo|toothpaste
213765|NCT02552576|Biological|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
213766|NCT02552563|Behavioral|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
213767|NCT02552550|Procedure|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
213768|NCT02552537|Drug|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
213769|NCT02552537|Drug|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
213770|NCT02552524|Device|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
213771|NCT02552524|Device|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
213772|NCT02552498|Procedure|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
213773|NCT02552485|Other|No intervention was applied, because it is an observational study|
213774|NCT02552459|Drug|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
213775|NCT02552459|Drug|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
213776|NCT02552459|Drug|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
213777|NCT02552459|Drug|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
213778|NCT02552433|Dietary Supplement|protein intake assessment and optimisation|
213779|NCT02552407|Device|Manual Aspiration Thrombectomy|Thrombus aspiration
213780|NCT02552394|Drug|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
213781|NCT02552381|Other|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
213782|NCT02552368|Device|IpsiHand Device|Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
213783|NCT02552355|Drug|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
213784|NCT02552355|Drug|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
213785|NCT02552355|Dietary Supplement|Carbohydrate Beverage|Supervised aerobic exercise 3 days per week followed by a carbohydrate drink
213786|NCT02552355|Dietary Supplement|Protein Beverage|Supervised aerobic exercise 3 days per week followed by a protein drink
213787|NCT02552342|Drug|methylprednisolone|
213788|NCT02552342|Drug|Normal saline|
213789|NCT02552329|Other|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
213790|NCT02552316|Device|NB-UVB Phototherapy|
213791|NCT02552303|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
213792|NCT02552303|Drug|Armodafinil|Active medication
213793|NCT02552303|Drug|Placebo|Placebo for Nuvigil (armodafinil)
213794|NCT02552290|Other|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
213795|NCT02552290|Other|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
213796|NCT02552290|Other|No intervention|Wait
213797|NCT02552277|Biological|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
213798|NCT02552277|Drug|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
213799|NCT02552264|Behavioral|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
213800|NCT02552251|Biological|Hormonal balance measurements|
213801|NCT02552251|Biological|metabolic balance measurements|
213802|NCT02552251|Biological|bone balance measurements|
213803|NCT02552251|Behavioral|quality of life assessment|
213804|NCT02552238|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent will be administered as 2 single 2-mL IV injections during rest and stress echocardiography
213805|NCT02552225|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
213806|NCT02552225|Other|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
213807|NCT02552212|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringe~Concentration: 200 mg / ml~Route of Administration: Subcutaneous injection"
213808|NCT02552212|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Prefilled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous injection"
213809|NCT02552199|Other|gravimetric|
213810|NCT02552186|Other|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
213811|NCT02552173|Radiation|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
213812|NCT02552147|Drug|Transdermal nicotine|
213813|NCT02552147|Other|Transdermal placebo|
213814|NCT02552134|Other|exercise training|
213815|NCT02552134|Other|recommendation to be active|
213816|NCT02552121|Drug|Tisotumab vedotin (HuMax-TF-ADC)|
213817|NCT02552108|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|
213818|NCT02552095|Device|Triathlon PKR|
213819|NCT02552082|Device|Scorpio NRG posterior stabilized (PS)|
213820|NCT02552069|Device|Tritanium® cup|
213821|NCT02552056|Other|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
213822|NCT02552043|Other|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
213823|NCT02552030|Device|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
213824|NCT02552030|Device|iPhone 4s|
213825|NCT02552017|Device|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
213826|NCT02552004|Device|pCLE|Histological examination by pCLE technique preceding the frozen section
213827|NCT02552004|Drug|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
213828|NCT02551991|Drug|nal-IRI|
213829|NCT02551991|Drug|5 fluorouracil|
213830|NCT02551991|Drug|Leucovorin|
213831|NCT02551991|Drug|Oxaliplatin|
213832|NCT02551978|Other|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
213833|NCT02551965|Other|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
213868|NCT02551757|Device|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
213834|NCT02551952|Device|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
213835|NCT02551939|Procedure|Autologous Fat Grafting|Autologous Fat Grafting
213836|NCT02551926|Behavioral|mobile text messages|
213837|NCT02551926|Behavioral|virtual community|
213838|NCT02551926|Behavioral|brochures|
213839|NCT02551926|Other|Usual care|
213840|NCT02551926|Device|mobile phone|
213841|NCT02551913|Behavioral|Control|the adolescents will not receive any specific intervention
213842|NCT02551913|Behavioral|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
213843|NCT02551900|Other|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
213844|NCT02551900|Other|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
213845|NCT02551900|Other|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
213846|NCT02551887|Behavioral|Automated Reminder|Automated reminder shown to provider
213847|NCT02551887|Behavioral|Automated Reminder Plus Script|Provider sees both reminder and script.
213848|NCT02551874|Drug|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
213849|NCT02551874|Drug|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
213850|NCT02551874|Drug|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
213851|NCT02551874|Drug|Metformin|Tablets, Oral, ≥ 1500mg/≤ 2500mg, Once daily, 24 weeks
213852|NCT02551861|Drug|Daclatasvir|
213853|NCT02551861|Drug|Sofosbuvir|
213854|NCT02551861|Drug|Ribavirin|
213855|NCT02551848|Drug|Botulinum toxin type A|
213856|NCT02551822|Device|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
213857|NCT02551809|Biological|UB-311|Intramuscular injection
213858|NCT02551809|Drug|Placebo|Intramuscular injection
213859|NCT02551796|Procedure|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
213860|NCT02551796|Procedure|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
213861|NCT02551796|Procedure|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
213862|NCT02551783|Procedure|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
213863|NCT02551783|Procedure|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
213864|NCT02551770|Procedure|Scaling and root planing|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
213865|NCT02551770|Procedure|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
213866|NCT02551770|Device|Emdogain application|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw
213867|NCT02551757|Device|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
213869|NCT02551744|Drug|histamine-2 receptor antagonist group|famotidine tab 40 mg qd for 6 months.
213870|NCT02551744|Drug|proton pump inhibitor group|pantoprazole tab 40 mg qd for 6 months.
213872|NCT02551718|Other|Chemosensitivity Assay|Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations
213873|NCT02551718|Other|Cytology Specimen Collection Procedure|Undergo blood or bone marrow collection
213874|NCT02551718|Genetic|Gene Expression Analysis|Analysis of leukemia cell genes to identify possible drug targets
213875|NCT02551718|Genetic|Genetic Variation Analysis|Analysis of leukemia cell genes to identify possible drug targets
213876|NCT02551718|Drug|In Vitro Sensitivity-Directed Chemotherapy|"Receive personalized chemotherapy with one or more of the following drugs:~Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin"
213877|NCT02551705|Other|functional Imaging|Brain responses associated with emotional memory will be investigated
213878|NCT02551692|Drug|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
213879|NCT02551692|Drug|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
213880|NCT02551692|Drug|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the VAR group, participants will wear a placebo patch while taking varenicline."
213881|NCT02551692|Drug|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.~In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
213882|NCT02551679|Biological|ACP-01|Injection into lower extremity
213883|NCT02551679|Biological|Placebo|Injection into lower extremity
213884|NCT02551666|Other|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
213885|NCT02551666|Other|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
213886|NCT02551653|Drug|[11C]-GSK2256098 500 MBq|[11C]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
213887|NCT02551640|Other|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:~Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.~Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.~Community: Users in later stages of change able to encourage and motivate one another through groups.~Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.~Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.~Social Support: Those using the FeatForward app will also have access to a Facebook group."
213888|NCT02551627|Dietary Supplement|Test Product|MMN fortified beverage powder.
213889|NCT02551627|Dietary Supplement|Control|Isocaloric beverage powder without micronutrient fortification.
213890|NCT02551614|Procedure|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
213891|NCT02551614|Procedure|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
213892|NCT02551614|Procedure|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
213893|NCT02551601|Other|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
213894|NCT02551588|Procedure|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
213895|NCT02551575|Drug|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
213896|NCT02551575|Drug|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
213897|NCT02551575|Drug|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
213898|NCT02551562|Other|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
213899|NCT02551562|Other|Placebo|Basic skin care regimen
213900|NCT02551549|Drug|CD101 IV|antifungal
213901|NCT02551549|Drug|Placebo|Normal saline
213902|NCT02551536|Drug|Montelukast|
213903|NCT02551536|Drug|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
213904|NCT02551536|Drug|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
213905|NCT02551523|Drug|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
213906|NCT02551523|Drug|Standard of care combinational antiretroviral therapy|
213907|NCT02551510|Procedure|Suture|Skin incision closure with standard subcuticular technique
213908|NCT02551510|Device|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n‐Butyl‐2‐Cyanoacrylate Monomer)
213909|NCT02551497|Drug|CNV1014802|
213910|NCT02551484|Device|Measurements using NIRS|
213911|NCT02551484|Device|TCPO2 measurements|
213912|NCT02551484|Other|2-minute walk test|
213913|NCT02551471|Other|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
213914|NCT02551471|Other|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
213915|NCT02551471|Other|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
213916|NCT02551458|Other|Systematic surgery|
213917|NCT02551458|Other|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
213918|NCT02551445|Behavioral|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
213919|NCT02551432|Drug|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
213920|NCT02551419|Dietary Supplement|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
213921|NCT02551419|Dietary Supplement|placebo|6 months' supplementation with the palcebodrink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
213922|NCT02551406|Device|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
213923|NCT02551393|Behavioral|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
213924|NCT02551380|Drug|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
213925|NCT02551380|Other|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
213926|NCT02551367|Drug|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
213927|NCT02551367|Drug|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
213928|NCT02551367|Drug|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
213929|NCT02551354|Device|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
213930|NCT02551341|Procedure|higher PEEP ventilation|
213931|NCT02551328|Drug|sevofluorane|Continuous infusion of sevofluorane
213932|NCT02551302|Device|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
213933|NCT02551302|Device|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:~CD HORIZON BalanC™ Medtronic"
213934|NCT02551289|Other|Gluten free diet|Patients will follow a gluten free diet
213935|NCT02551276|Drug|Salbutamol|
213936|NCT02551276|Drug|Placebo|
213937|NCT02551276|Other|Resistance training|
213938|NCT02551263|Drug|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
213939|NCT02551250|Device|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
213940|NCT02551250|Device|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
213941|NCT02551237|Radiation|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
213942|NCT02551237|Drug|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
213943|NCT02551237|Radiation|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
213944|NCT02551224|Other|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
213945|NCT02551211|Procedure|blood drawn|blood drawn
213946|NCT02551211|Procedure|surgical resection of cancer|
213947|NCT02551198|Drug|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)~: : PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
213948|NCT02551198|Drug|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]
213949|NCT02551185|Drug|ACY-241|
213950|NCT02551172|Drug|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
213953|NCT02551172|Drug|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
213954|NCT02551159|Biological|MEDI4736|Anti-PD-L1 antibody
213955|NCT02551159|Biological|Tremelimumab|Anti-CTLA-4 Antibody
213956|NCT02551159|Biological|MEDI4736+Tremelimumab|
213957|NCT02551159|Biological|Cetuximab|Monoclonal Antibody
213958|NCT02551159|Drug|5-fluorouracil (5FU)|Chemotherapy Agent
213959|NCT02551159|Drug|Cisplatin|Chemotherapy agent
213960|NCT02551159|Drug|Carboplatin|Chemotherapy Agent
213961|NCT02551146|Device|A Locator with retention elements|Insertion of GC Pilier locator abutments with retention elements
213962|NCT02551146|Device|B Locator without retention elements|Insertion of GC Pilier locator abutments without retention elements
213963|NCT02551133|Drug|dexamethasone|1 hour before surgery
213964|NCT02551107|Device|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
213965|NCT02551094|Drug|colchicine|0.5 mg tablet taken once a day
213966|NCT02551094|Drug|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
213967|NCT02551068|Other|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
213968|NCT02551068|Other|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
213969|NCT02551055|Drug|MLN1117|MLN1117 Tablets
213970|NCT02551055|Drug|TAK-659|TAK-659 Tablets
213971|NCT02551055|Drug|Alisertib|Alisertib Tablets
213972|NCT02551055|Drug|Paclitaxel|Paclitaxel intravenous infusion
213973|NCT02551055|Drug|Docetaxel|Docetaxel intravenous infusion
213974|NCT02551042|Drug|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
213975|NCT02551042|Drug|0.9% sodium chloride|IV infusion
213976|NCT02551029|Other|Capsaicin|
213977|NCT02551029|Other|Placebo|
213978|NCT02551003|Drug|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
213979|NCT02551003|Device|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
213980|NCT02550990|Behavioral|Cognitive training|
213981|NCT02550990|Behavioral|Aerobic exercise training|
213982|NCT02550990|Behavioral|Sequential combination of aerobic exercise and cognitive training|
213983|NCT02550977|Drug|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
213984|NCT02550964|Procedure|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
213985|NCT02550951|Procedure|lymphangiography|
213986|NCT02550938|Device|Invisalign|The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
213987|NCT02550925|Behavioral|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
213988|NCT02550925|Behavioral|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
213989|NCT02550912|Drug|Vitamin D3|vitamin D drops for paediatrics
213990|NCT02550912|Other|Placebo|glucose syrup with same taste and color to vitamin D3 drops
213991|NCT02550899|Procedure|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
213992|NCT02550899|Procedure|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
213993|NCT02550899|Procedure|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
213994|NCT02550886|Other|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
213995|NCT02550873|Biological|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
213996|NCT02550873|Other|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
213997|NCT02550860|Drug|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
213998|NCT02550860|Drug|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
213999|NCT02550847|Device|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
214000|NCT02550834|Other|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
214001|NCT02550795|Drug|Dexmedetomidine|administration of dexmedetomidine only
214002|NCT02550795|Drug|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
214003|NCT02550795|Drug|Control|administration of normal saline
214004|NCT02550782|Drug|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
214005|NCT02550782|Drug|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
214006|NCT02550769|Procedure|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
214007|NCT02550769|Procedure|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
214008|NCT02550756|Drug|CTNX-4975|
214009|NCT02550743|Drug|BYL719|
214010|NCT02550743|Drug|Capecitabine|
214011|NCT02550743|Radiation|Radiation|
214012|NCT02550730|Behavioral|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
214013|NCT02550730|Other|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
214014|NCT02550717|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
214015|NCT02550717|Drug|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
214016|NCT02550704|Procedure|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
214017|NCT02550691|Procedure|blood sampling|A blood sample will be taken on subject carrying specific genotype
214018|NCT02550678|Biological|ASN-002|ASN‐002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon‐gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
214019|NCT02550678|Drug|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
214020|NCT02550665|Drug|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
214021|NCT02550652|Drug|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
214022|NCT02550652|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
214023|NCT02550652|Other|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
214024|NCT02550652|Drug|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
214025|NCT02550652|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
214026|NCT02550639|Other|BIOMARKER- elispot test|ELISPOT TEST
214027|NCT02550613|Device|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
214028|NCT02550600|Procedure|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
214029|NCT02550600|Procedure|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
214030|NCT02550587|Behavioral|satisfaction|anesthesia satisfaction rates
214031|NCT02550574|Procedure|Wound Closure with 2-octylcyanoacrylate|
214032|NCT02550574|Procedure|Wound Closure with 5-0 Vicryl Sutures|
214033|NCT02550561|Device|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
214034|NCT02550548|Drug|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
214035|NCT02550548|Drug|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
214036|NCT02550548|Drug|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
214037|NCT02550535|Genetic|Autologous WT1 TCR transduced T cells|Gene therapy: Autologous WT1 TCR transduced T cells administered by intravenous infusion
214114|NCT02549976|Procedure|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
214038|NCT02550522|Device|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
214039|NCT02550509|Device|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
214040|NCT02550509|Device|elastography|elastography to patient with stoke
214041|NCT02550496|Device|Dermoscopy|
214042|NCT02550483|Other|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
214043|NCT02550483|Other|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
214044|NCT02550483|Other|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
214045|NCT02550470|Device|Carbon Dioxide Absorbents|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
214046|NCT02550470|Device|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
214047|NCT02550470|Drug|Sevoflurane|
214048|NCT02550457|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
214049|NCT02550457|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
214050|NCT02550457|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
214051|NCT02550444|Drug|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
214052|NCT02550444|Drug|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
214053|NCT02550444|Drug|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
214054|NCT02550418|Drug|Budesonide|
214055|NCT02550405|Behavioral|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
214056|NCT02550392|Behavioral|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
214057|NCT02550379|Behavioral|Intervention|Emotion Recognition Training
214058|NCT02550379|Other|Placebo|Placebo Training
214059|NCT02550366|Drug|MRI Contrast|MRI Contrast
214060|NCT02550353|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
214061|NCT02550353|Procedure|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
214062|NCT02550340|Other|acute alcohol intake|Smart phone based ECG recording
214063|NCT02550327|Drug|Nab-paclitaxel|125 mg/m2
214064|NCT02550327|Drug|Gemcitabine|1000 mg/m2
214065|NCT02550327|Drug|Cisplatin|25 mg/m2
214066|NCT02550327|Drug|Anakinra|100 mg
214067|NCT02550314|Drug|fiblast,gelatin sponge,fibrin glue|
214115|NCT02549963|Device|WATCHMAN Left Atrial Appendage Occlusion Device|
214116|NCT02549963|Drug|Rivaroxaban|
214117|NCT02549950|Procedure|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
214068|NCT02550301|Other|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
214069|NCT02550288|Drug|Ezetimibe 10 mg|
214070|NCT02550288|Drug|Atorvastatin 10 mg|
214071|NCT02550288|Drug|Placebo for Ezetimibe 10 mg tablet|
214072|NCT02550288|Drug|Placebo for Atorvastatin 10 mg capsule|
214073|NCT02550288|Behavioral|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
214074|NCT02550275|Behavioral|neuropsychological test|
214075|NCT02550275|Radiation|MRI|
214076|NCT02550262|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
214077|NCT02550262|Drug|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
214078|NCT02550262|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
214079|NCT02550249|Drug|Nivolumab|Intravenous administration of nivolumab
214080|NCT02550223|Procedure|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
214081|NCT02550210|Device|Breast Cancer Locator (BCL)|This locator is constructed pre-operatively, sterilized and provided to the surgeon at the time of the procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
214082|NCT02550197|Biological|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
214083|NCT02550197|Biological|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
214084|NCT02550184|Other|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
214085|NCT02550158|Procedure|Educational program EDU-MICI|
214086|NCT02550145|Drug|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
214087|NCT02550145|Other|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
214088|NCT02550132|Procedure|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
214089|NCT02550132|Device|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
214090|NCT02550119|Drug|Aprepitant|Given PO
214091|NCT02550119|Drug|Dexamethasone|Given PO or IV
214092|NCT02550119|Drug|Dolasetron Mesylate|Given PO or IV
214093|NCT02550119|Drug|Placebo|Given PO
214094|NCT02550106|Drug|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
214095|NCT02550093|Drug|Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.
214096|NCT02550093|Drug|Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.
214097|NCT02550080|Drug|Dapsone|For the HLA-B*1301 positive subjects, dapsone will not be administrated.
214098|NCT02550080|Genetic|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
214099|NCT02550067|Drug|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
214100|NCT02550067|Drug|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
214101|NCT02550067|Drug|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
214102|NCT02550054|Drug|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
214103|NCT02550054|Drug|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
214104|NCT02550041|Other|T specific response for diagnostic of aspergillus bronchitis|
214105|NCT02550028|Drug|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
214106|NCT02550028|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
214107|NCT02550015|Behavioral|High intensity interval training|Uphill treadmill walking
214108|NCT02550015|Behavioral|General information|Standard care
214109|NCT02550002|Drug|Aflibercept|Intravitreal injection
214110|NCT02549989|Drug|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
214111|NCT02549976|Procedure|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
214112|NCT02549976|Procedure|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
214113|NCT02549976|Procedure|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
214934|NCT02544282|Drug|Paracetamol|Pain Relief
214118|NCT02549950|Procedure|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
214119|NCT02549937|Drug|surufatinib|orally once daily (QD) in patients with advanced solid tumor.
214120|NCT02549924|Drug|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
214121|NCT02549924|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
214122|NCT02549911|Other|HIPEC,Chemotherapy AND surgery|"HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )~after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
214123|NCT02549898|Drug|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
214124|NCT02549898|Drug|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
214125|NCT02549898|Other|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
214126|NCT02549898|Other|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
214127|NCT02549885|Other|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
214128|NCT02549885|Other|Static stretching|Static stretching of neck muscles.
214129|NCT02549872|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
214130|NCT02549859|Device|DBS|"Patients will have a randomized double-blind prospective crossover study with usual medication on state under 3 different DBS stimulation frequency condition (60Hz vs 130Hz vs DBS off). Aspiration frequency on modified barium swallowing test and swallowing difficulty on questionnaire, FOG in stand-walk-sit test and questionnaire, and other axial and motor function will be assessed under each DBS condition. Changes in measurements between 60Hz and 130Hz at each visit and under 60Hz between two visits of 8 months apart on average will be analyzed, with swallowing function and FOG as primary, and the rest as secondary outcomes, correcting for potential carryover effect. Changes between other DBS conditions might also be explored in this 2-year study."
214131|NCT02549846|Drug|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
214132|NCT02549833|Biological|GBM6-AD and poly-ICLC before and after surgery|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
214133|NCT02549833|Biological|GBM6-AD and poly-ICLC after surgery only|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
214134|NCT02549820|Device|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO) in CDH with GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter
214135|NCT02549807|Device|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
214136|NCT02549794|Procedure|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
214137|NCT02549794|Procedure|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
214138|NCT02549794|Procedure|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
214139|NCT02549781|Other|Go-Nogo test|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
214140|NCT02549768|Drug|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
214141|NCT02549768|Drug|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
214142|NCT02549755|Drug|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).~There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
214143|NCT02549742|Procedure|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
214144|NCT02549742|Device|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
214145|NCT02549742|Drug|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
214146|NCT02549729|Behavioral|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
214147|NCT02549716|Drug|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
214148|NCT02549716|Drug|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
214608|NCT02546596|Device|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
214149|NCT02549716|Drug|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
214150|NCT02549716|Drug|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
214151|NCT02549690|Drug|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
214152|NCT02549690|Drug|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
214153|NCT02549677|Drug|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
214154|NCT02549677|Drug|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
214155|NCT02549677|Drug|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
214156|NCT02549651|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
214157|NCT02549651|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
214158|NCT02549651|Drug|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
214159|NCT02549638|Genetic|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
214160|NCT02549625|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
214161|NCT02549612|Device|Moniri Otovent|Please see arm description.
214162|NCT02549599|Behavioral|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
214163|NCT02549599|Behavioral|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
214164|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
214165|NCT02549586|Drug|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.~Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
214166|NCT02549573|Drug|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
214167|NCT02549573|Behavioral|Physical Therapy|All subjects will participate in a standardized PT intervention
214168|NCT02549560|Device|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
214169|NCT02549547|Behavioral|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:~Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes~Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes~Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
214170|NCT02549534|Procedure|Axon Reflexes|"*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:~Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33*C.~Heat Ramp: Increasing the heat in the heat probe to 42*C at approx. 0.1*C/10 sec.~Skin Heating: Heating the skin of the toe for 30 minutes 42*C.~Heat Ramp: Increasing the heat in the heat probe to 44*C at 0.1*C/10 sec..~Skin Heating: Heating the skin for an additional 5 minutes at 44*C.~The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
214171|NCT02549534|Procedure|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
214172|NCT02549534|Procedure|Self-Reported Signs & Symptoms of CIPN|Self-reported signs & symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
214173|NCT02549521|Dietary Supplement|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
214935|NCT02544282|Drug|Tramadol|Pain Relief
214174|NCT02549521|Dietary Supplement|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
214175|NCT02549508|Device|AutoCPAP with SensAwake On|The comfort feature 'SensAwake' will be turned on
214176|NCT02549508|Device|AutoCPAP with SensAwake Off|The comfort feature 'SensAwake' will be turned off
214177|NCT02549482|Other|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
214178|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
214179|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
214180|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
214181|NCT02549469|Drug|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
214182|NCT02549456|Procedure|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
214183|NCT02549456|Procedure|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
214184|NCT02549443|Dietary Supplement|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
214185|NCT02549430|Drug|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
214186|NCT02549430|Drug|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
214187|NCT02549430|Drug|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
214188|NCT02549430|Drug|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
214189|NCT02549430|Drug|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
214190|NCT02549417|Drug|KHK7580|Oral administration
214191|NCT02549404|Drug|KHK7580|Oral administration
214192|NCT02549391|Drug|KHK7580|Oral administration
214193|NCT02549391|Drug|KRN1493|Oral administration
214194|NCT02549378|Device|confocal microscopy|microvessel diameter measured by confocal microscopy
214195|NCT02549365|Drug|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
214196|NCT02549365|Procedure|Surveillance (nasal swabbing) during influenza season|
214197|NCT02549352|Drug|LEO43204 gel|
214198|NCT02549352|Drug|Vehicle gel|
214199|NCT02549339|Drug|LEO 43204 gel|
214200|NCT02549339|Drug|Vehicle gel|
214201|NCT02549326|Dietary Supplement|vitamin D|
214202|NCT02549326|Dietary Supplement|Placebo|
214203|NCT02549313|Procedure|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
214204|NCT02549300|Other|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
214205|NCT02549287|Behavioral|SafeCare|An evidence-based home visiting program
214206|NCT02549287|Behavioral|Supportive Case Management|Child welfare services as usual
214207|NCT02549274|Other|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
214208|NCT02549274|Other|physiotherapy|14 physiotherapy sessions (2 by week)
214209|NCT02549261|Drug|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
214210|NCT02549261|Drug|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
214211|NCT02549261|Drug|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.~the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
214212|NCT02549261|Radiation|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
214213|NCT02549248|Other|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
214214|NCT02549248|Other|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
214215|NCT02549248|Other|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
214216|NCT02549248|Other|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
214217|NCT02549248|Other|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
214218|NCT02549235|Other|Ultrasound|Routine 2D/3D ultrasound assessment
214219|NCT02549222|Other|Standard of Care|
214220|NCT02549209|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
214221|NCT02549209|Drug|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.~Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
214222|NCT02549209|Drug|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.~Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
214223|NCT02549196|Drug|Donepezil|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
214224|NCT02549196|Drug|Solifenacin|Donepezil dose increased at weekly intervals up to first intolerable dose (FID) or to maximum allowed dose (MAD) together with solifenacin.
214225|NCT02549183|Device|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
214226|NCT02549170|Biological|HYQVIA|Participants will receive subcutaneous (SC) HYQVIA/HyQvia which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).
214227|NCT02549170|Biological|0.25% albumin placebo solution with rHuPH20|Participants will receive placebo solution (0.25% human albumin in Lactated Ringer's solution) and rHuPH20.
214228|NCT02549170|Biological|IGIV|Participants will receive GAMMAGARD LIQUID/KIOVIG (all participants with the exception of those at US sites) or GAMUNEX®-C (participants at US sites only).
214229|NCT02549157|Procedure|Pelvic Floor Muscle Training|
214230|NCT02549144|Dietary Supplement|Low versus high fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day.
214231|NCT02549131|Procedure|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
214232|NCT02549118|Drug|Tenoxicam|
214233|NCT02549118|Drug|Pethidine|
214234|NCT02549105|Drug|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
214235|NCT02549105|Drug|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
214236|NCT02549092|Drug|ABT-SLV187|Dose levels will be individually optimized.
214237|NCT02549079|Other|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
214238|NCT02549066|Procedure|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
214239|NCT02549066|Drug|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.~Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) < 12 %."
214240|NCT02549053|Procedure|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
214241|NCT02549053|Procedure|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
214242|NCT02549040|Drug|Treatment A: MK-1439 100 mg film coated tablet|Single MK-1439 100 mg film coated tablet administered orally at the start of Period 2
214243|NCT02549040|Drug|Treatment B: MK-1439 150 mg tablet (40% drug loaded granule)|Single MK-1439 NF Type 1 dose (150 mg tablet [40% drug loaded granule]) administered orally at the start of Period 1
214244|NCT02549040|Drug|Treatment C: MK-1439 150 mg tablet (30% drug loaded granule)|Single MK-1439 NF Type 2 dose (150 mg tablet [30% drug loaded granule])administered orally at the start of Period 3
214245|NCT02549040|Drug|Treatment D: MK-1439 150 mg tablet (50% drug loaded granule)|Single MK-1439 NF Type 3 dose (150 mg tablet [50% drug loaded granule])administered orally at the start of Period 4
214246|NCT02549040|Drug|Treatment E: MK-1439 100 mg tablet (30% drug loaded granule)|Single MK-1439 NF Type 4 dose (100 mg tablet [30% drug loaded granule]) administered orally at the start of Period 5
214247|NCT02549027|Drug|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
214248|NCT02549027|Drug|MK-6096|Oral MK-6096 tablets (5 mg strength)
214249|NCT02549027|Drug|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
214250|NCT02549014|Drug|MK-1064|Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
214251|NCT02549014|Drug|Placebo|Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
214252|NCT02549001|Drug|P-3058 10%|
214253|NCT02549001|Drug|vehicle of P-3058 10%|
214254|NCT02549001|Drug|amorolfine 5%|
214255|NCT02548988|Other|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
214256|NCT02548975|Drug|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
214257|NCT02548975|Other|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
214258|NCT02548962|Drug|Ibrutinib|
214259|NCT02548962|Drug|Pomalidomide|
214260|NCT02548962|Drug|Dexamethasone|
214261|NCT02548962|Drug|Placebo|
214262|NCT02548936|Drug|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
214263|NCT02548923|Drug|Dexmedetomidine|comparison to propofol
214264|NCT02548910|Procedure|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
214265|NCT02548910|Device|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
214936|NCT02544282|Drug|Piritramide|Pain Relief
214266|NCT02548897|Device|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
214267|NCT02548897|Other|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
214268|NCT02548884|Procedure|Biliary cannulation|
214269|NCT02548871|Behavioral|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
214270|NCT02548858|Procedure|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
214271|NCT02548858|Procedure|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
214272|NCT02548832|Drug|Berberine|Berberine capsules, 500 mg 3 times daily with the first bite of each meal
214273|NCT02548832|Drug|Bezafibrate|Bezafibrate capsules, 200 mg 2 times daily with the first bite of each meal
214274|NCT02548832|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
214275|NCT02548832|Drug|Placebo|Placebo capsules, 200 mg 2 times daily with the first bite of each meal
214276|NCT02548819|Other|MRI|MR imaging of patients with implanted cardiac devices
214277|NCT02548806|Drug|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
214278|NCT02548806|Drug|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
214279|NCT02548806|Drug|Catapres 100μg|Catapres tablet 100μg, single dose
214280|NCT02548793|Other|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
214281|NCT02548793|Other|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
214282|NCT02548780|Device|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
214283|NCT02548780|Other|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
214284|NCT02548767|Other|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
214285|NCT02548767|Other|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
214286|NCT02548767|Other|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
214287|NCT02548767|Other|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
214288|NCT02548754|Device|Parasym device|
214289|NCT02548741|Drug|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy & David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
214290|NCT02548741|Drug|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
214291|NCT02548741|Other|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
214327|NCT02548468|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
214328|NCT02548468|Drug|Cyclophosphamide|Given IV
214937|NCT02544269|Procedure|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
214292|NCT02548741|Other|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
214293|NCT02548728|Drug|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
214294|NCT02548728|Drug|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
214295|NCT02548715|Drug|Levothyroxine|
214296|NCT02548715|Drug|Placebo|
214297|NCT02548702|Behavioral|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
214298|NCT02548676|Device|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
214299|NCT02548663|Other|Sport therapy|"Frequency: 60 min three times/week~20 min: aerobic training on bicycle ergometer.~20 min: strength training at 60% of maximal load.~20 min: proprioception and stretching exercises."
214300|NCT02548663|Other|Osteopathic treatment|Frequency: 60 min weekly
214301|NCT02548650|Drug|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
214302|NCT02548650|Drug|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
214303|NCT02548650|Drug|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
214304|NCT02548637|Procedure|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
214305|NCT02548624|Device|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.~The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
214306|NCT02548611|Drug|Prasugrel|see arm description
214307|NCT02548611|Drug|Clopidogrel|see arm description
214308|NCT02548598|Procedure|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
214309|NCT02548585|Drug|MEDI0382|MEDI0382 administered subcutaneously.
214310|NCT02548585|Drug|Placebo|Placebo administered subcutaneously.
214311|NCT02548572|Device|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
214312|NCT02548559|Drug|Cannabidiol|Cannabidiol; total daily dose of 30 mg.
214313|NCT02548546|Device|ECHO|Imaging
214314|NCT02548546|Device|ECG-gated MRA|Imaging
214315|NCT02548533|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
214316|NCT02548533|Drug|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
214317|NCT02548533|Drug|EMLA cream|Topical application 2 hours prior to the treatment.
214318|NCT02548520|Other|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
214319|NCT02548507|Other|observational study, no intervention|
214320|NCT02548494|Drug|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
214321|NCT02548494|Drug|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
214322|NCT02548494|Other|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
214323|NCT02548494|Other|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:~Administer 1-3 L during the first hour.~Administer 1 L during the second hour.~Administer 1 L during the following 2 hours~Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
214324|NCT02548481|Other|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
214325|NCT02548468|Drug|Fludarabine|Given IV
214326|NCT02548468|Radiation|Total-Body Irradiation|Undergo TBI
214329|NCT02548468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
214330|NCT02548468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
214331|NCT02548468|Drug|Mycophenolate mofetil|Given IV
214332|NCT02548468|Drug|Tacrolimus|Given IV
214333|NCT02548455|Device|Quartet 1457Q LV Lead|
214334|NCT02548416|Procedure|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.~As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI>25) in the intervention group.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
214335|NCT02548416|Procedure|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
214336|NCT02548403|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
214337|NCT02548403|Drug|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
214338|NCT02548390|Drug|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
214339|NCT02548377|Procedure|Remote ischemic preconditioning|
214340|NCT02548377|Procedure|Sham|
214341|NCT02548364|Drug|Calcifediol|calcifediol treatment
214342|NCT02548364|Drug|Placebo|placebo control group
214343|NCT02548351|Drug|Obeticholic Acid|
214344|NCT02548351|Drug|Placebo|
214345|NCT02548338|Procedure|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
214346|NCT02548325|Other|Not apply|None. Just registration epidemiology dates
214347|NCT02548312|Other|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
214348|NCT02548299|Other|Nutrition Education|Nutrition classes will be led by a registered dietician.
214349|NCT02548299|Other|Cooking Lecture|
214350|NCT02548299|Other|Cooking Demo|
214351|NCT02548299|Other|Hands-on Cooking|
214352|NCT02548299|Other|e-Coaching|
214353|NCT02548286|Drug|Candesartan 8mg|PO, 1day or 22day
214354|NCT02548286|Drug|Amlodipine 5mg|PO, 1day or 22day
214355|NCT02548286|Drug|CKD-330 8/5mg|PO, 1day or 22day
214356|NCT02548260|Device|Syndactyly without compression|three week relative immobilization by syndactyly
214357|NCT02548260|Device|Syndactyly with compression|three week relative immobilization by syndactyly and compression
214358|NCT02548260|Device|Rigid splint without compression|three week rigid immobilization by splint
214359|NCT02548260|Device|Rigid splint with compression|three week rigid immobilization by splint and compression
214360|NCT02548247|Dietary Supplement|Orafti® Inulin|Dietary fiber
214361|NCT02548247|Dietary Supplement|Placebo|Maltodextrin
214362|NCT02548234|Other|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
214363|NCT02548234|Other|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
214364|NCT02548221|Device|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
214365|NCT02548208|Device|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
214366|NCT02548208|Device|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
214367|NCT02548195|Drug|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
214368|NCT02548195|Drug|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
214397|NCT02548026|Behavioral|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
214398|NCT02548013|Other|outpatient management|patients if stable will be discharged to continue treatment at home
214399|NCT02548013|Other|Inpatient management|patients will continue there treatment in hospital till delivery
214532|NCT02547025|Drug|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
214369|NCT02548182|Device|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults [REF]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
214370|NCT02548182|Other|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
214371|NCT02548169|Biological|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:~Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)~FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation~Gemcitabine + nab-paclitaxel~The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .~The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.~Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
214372|NCT02548156|Other|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
214373|NCT02548156|Other|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
214374|NCT02548156|Other|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
214375|NCT02548156|Other|Orange Juice|Teeth will be rinsed with orange juice followed by rinsing with de-ionised water in test dentifrice and comparator dentifrice arms.
214376|NCT02548156|Other|De-ionised water|Teeth will be rinsed with de-ionised water followed by reference dentifrice and followed by rinsing with orange juice in test dentifrice and comparator dentifrice arms.
214377|NCT02548143|Biological|Coagulation Factor VIIa (Recombinant)|LR769
214378|NCT02548130|Other|MELD score|introduction of MELD score
214379|NCT02548117|Drug|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
214380|NCT02548104|Other|ACB|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with normal saline 15 ml
214381|NCT02548104|Other|ACB + iPACK|ultrasound-guided ACB with 0.25% Bupivicaine with 1:200,000 epinephrine 30 ml and ultrasound-guided genicular (IPACK) with 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
214382|NCT02548091|Other|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.~In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
214383|NCT02548091|Procedure|Non invasive ventilation|
214384|NCT02548091|Procedure|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
214385|NCT02548091|Procedure|Computed tomography (CT)|
214386|NCT02548078|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
214387|NCT02548078|Biological|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
214388|NCT02548065|Other|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
214389|NCT02548065|Other|Placebo|Bath with Thermal tap water
214390|NCT02548052|Drug|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
214391|NCT02548052|Drug|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
214392|NCT02548052|Drug|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
214393|NCT02548052|Drug|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
214394|NCT02548052|Drug|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
214395|NCT02548052|Drug|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
214396|NCT02548026|Behavioral|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
214400|NCT02548000|Other|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
214401|NCT02548000|Other|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
214402|NCT02547987|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
214403|NCT02547987|Drug|Carboplatin|Carboplatin AUC 6 intravenously on day 1 of each 21-day cycle. Number of Cycles: 6
214404|NCT02547974|Biological|Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214405|NCT02547974|Biological|Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214406|NCT02547974|Biological|Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214407|NCT02547974|Drug|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
214408|NCT02547961|Biological|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
214409|NCT02547948|Biological|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
214410|NCT02547935|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
214411|NCT02547935|Drug|Saxagliptin 2.5 mg|Tablets administered orally once daily for 24 weeks.
214412|NCT02547935|Drug|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
214413|NCT02547922|Biological|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
214414|NCT02547922|Drug|Placebo|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
214415|NCT02547909|Procedure|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.~At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
214416|NCT02547909|Device|Cellvizio|
214417|NCT02547909|Drug|fluorescein 10%|
214418|NCT02547896|Drug|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
214419|NCT02547896|Drug|Diclofenac|The patients will receive only diclofenac
214420|NCT02547883|Drug|Cessation of statin|The intervention evaluated is the cessation of statin
214421|NCT02547870|Drug|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
214422|NCT02547870|Drug|Rilpivirine Long-Acting Parenteral Formulation (RPV‐LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
214423|NCT02547870|Drug|Aged RPV‐LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
214424|NCT02547857|Other|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
214425|NCT02547844|Drug|efavirenz + emtricitabina + tenofovir|
214426|NCT02547844|Drug|rilpivirina + emtricitabina + tenofovir|
214427|NCT02547831|Other|Observational approach|Patients will be placed under wait and see approach without any specific treatment
214428|NCT02547818|Drug|ALZT-OP1a|1) Mast cell stabilizer, 2) Neuroinflammatory microglial modulator, 3) A-beta oligomerization inhibitor, and 4) anti-inflammatory
214429|NCT02547818|Drug|ALZT-OP1b|Anti-inflammatory
214430|NCT02547818|Other|Placebo ALZT-OP1a|Non-active capsules
214431|NCT02547818|Other|Placebo ALZT-OP1b|Non-active tablets
214432|NCT02547805|Drug|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
214433|NCT02547805|Drug|Placebo|Placebo 5 capsules PO TID with meals
214434|NCT02547792|Biological|VXA-BYW.10 (Low Dose) Oral Vaccine|Enteric coated tablet for oral delivery
214435|NCT02547792|Biological|VXA-BYW.10 (High Dose) Oral Vaccine|Enteric coated tablet for oral delivery
214436|NCT02547792|Other|Placebo Tablets|Enteric coated tablet for oral delivery
214437|NCT02547779|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
214438|NCT02547779|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
214439|NCT02547766|Drug|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
214440|NCT02547727|Biological|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
214441|NCT02547714|Drug|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
214442|NCT02547701|Drug|P-3058|
214443|NCT02547688|Device|Nasal High Flow|
214444|NCT02547675|Drug|Rociletinib|Rociletinib will be administered to patients orally
214445|NCT02547662|Drug|Dexamethasone|Given PO
214446|NCT02547662|Drug|Ixazomib Citrate|Given PO
214447|NCT02547662|Other|Laboratory Biomarker Analysis|Correlative studies
214448|NCT02547662|Drug|Pomalidomide|Given PO
214449|NCT02547649|Biological|V114-A|Formulation A of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-A uses a unique excipient to improve stability of the vaccine against physical stress).
214450|NCT02547649|Biological|V114-B|Formulation B of V114 contains 2 µg of pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, and 33F; 4 µg of serotype 6B; 32 µg of CRM197 protein carrier; and 125 µg of Aluminum Phosphate Adjuvant in each 0.5 mL dose (V114-B uses a unique excipient to improve stability of the vaccine against physical stress).
214451|NCT02547649|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
214452|NCT02547636|Other|Observational study|No intervention will be used in this study.
214453|NCT02547623|Drug|Dexamethasone|depot intracameral
214454|NCT02547623|Drug|Prednisolone|Prednisolone eye drops 1%
214455|NCT02547610|Device|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
214456|NCT02547597|Drug|Carvedilol|
214457|NCT02547597|Drug|Atenolol|
214458|NCT02547584|Procedure|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
214459|NCT02547571|Drug|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
214460|NCT02547571|Drug|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
214461|NCT02547571|Drug|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
214462|NCT02547571|Drug|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
214463|NCT02547571|Other|Clear liquid diet|
214464|NCT02547571|Other|Low residue diet|
214465|NCT02547571|Other|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
214466|NCT02547571|Other|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
214467|NCT02547558|Procedure|Arterial blood gases|Measured through radial arterial catheter
214468|NCT02547558|Procedure|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
214469|NCT02547558|Procedure|Vital signs|As measured in clinical practice
214470|NCT02547558|Procedure|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
214471|NCT02547558|Procedure|Spirometry|In a daily calibrated spirometer.
214472|NCT02547558|Drug|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
214473|NCT02547532|Other|collection of sputum|
214474|NCT02547519|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
214475|NCT02547519|Drug|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
214476|NCT02547493|Biological|pneumococcal polysaccharide vaccine|Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
214477|NCT02547493|Biological|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
214478|NCT02547493|Drug|Abatacept|Abatacept started on frst day
214479|NCT02547480|Device|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
214480|NCT02547467|Other|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
214481|NCT02547454|Drug|Methoxy polyethylene glycol-epoetin beta|
214482|NCT02547441|Drug|CLS001 (Omiganan)|Topical gel
214483|NCT02547441|Drug|Vehicle|Vehicle Gel
214484|NCT02547428|Drug|CTN SR|Participants will receive CTN SR tablets in a 100-mg dose strength, designed for twice-daily (BID) oral (PO) administration.
214485|NCT02547428|Drug|Placebo|Participants will receive CTN SR matching placebo tablets, orally twice daily, titrated in the same manner as CTN SR to protect the blind.
214531|NCT02547025|Drug|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
214486|NCT02547415|Other|questionnaires and psychological testing|"Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.~Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:~Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires~Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview."
214487|NCT02547402|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
214488|NCT02547402|Drug|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
214489|NCT02547402|Drug|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
214490|NCT02547389|Behavioral|Community support group|
214491|NCT02547389|Other|Printed material Supported|
214492|NCT02547363|Drug|LEO 43204 gel|
214493|NCT02547363|Drug|Vehicle gel|
214494|NCT02547350|Drug|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
214495|NCT02547324|Radiation|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
214496|NCT02547324|Radiation|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
214497|NCT02547311|Behavioral|Team Clinic|
214498|NCT02547298|Procedure|Hydrodistension|Patients who are already scheduled to have a gynecologic, urologic or uro-gynecologic procedure involving cystoscopy if consented will have hydrodistension performed
214499|NCT02547298|Device|Cystoscopy|
214500|NCT02547285|Other|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
214501|NCT02547272|Procedure|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
214502|NCT02547259|Procedure|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
214503|NCT02547259|Procedure|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
214504|NCT02547246|Device|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
214505|NCT02547246|Device|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
214506|NCT02547233|Drug|LEO 43204 gel|
214507|NCT02547233|Drug|Vehicle gel|
214508|NCT02547220|Biological|Cinryze®|Participants will receive 5000 Units of CINRYZE (50 millilitre [mL] of CINRYZE/ 50 mL of normal saline) on Day 1 and 2500 Units of CINRYZE (25 mL of CINRYZE/ 75 mL of normal saline) on Day 3, 5, 7, 9, 11, and 13 respectively.
214509|NCT02547220|Drug|Placebo|Participants will receive 7 doses of matched placebo over 13 days of treatment.
214510|NCT02547181|Behavioral|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
214511|NCT02547181|Behavioral|Splint|fibreglass splint
214512|NCT02547168|Device|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
214513|NCT02547155|Procedure|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
214514|NCT02547155|Procedure|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
214515|NCT02547142|Other|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
214516|NCT02547129|Device|Static Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
214517|NCT02547129|Device|Articulating Antibiotic Spacer Surgical Implant|Joint spacer for treatment of joint infection
214518|NCT02547116|Drug|Rifampin|Addition of Rifampin to standard anti-Staphylococcal treatment regimen
214519|NCT02547103|Other|Chlorhexidine gluconate-soaked cloths|
214520|NCT02547103|Other|Normal saline|
214521|NCT02547103|Other|mupirocin ointment|
214522|NCT02547090|Procedure|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
214523|NCT02547077|Procedure|Wound Closure with 2-octylcyanoacrylate|
214524|NCT02547077|Procedure|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
214525|NCT02547064|Procedure|Glidescope guided intubation|
214526|NCT02547064|Device|GlideScope®|
214527|NCT02547051|Other|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
214528|NCT02547038|Drug|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
214529|NCT02547038|Drug|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
214530|NCT02547025|Drug|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
214533|NCT02547012|Drug|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
214534|NCT02547012|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
214535|NCT02546999|Drug|botox|The agent will be given only once at point zero in the time scheme for the project.
214536|NCT02546999|Drug|placebo|The agent will be given only once at point zero in the time scheme for the project.
214537|NCT02546986|Drug|CC-486|CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
214538|NCT02546986|Drug|Pembrolizumab|Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
214539|NCT02546986|Drug|Placebo|Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
214540|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214541|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214542|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214543|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214544|NCT02546960|Biological|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the IDMC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
214545|NCT02546960|Drug|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
214546|NCT02546947|Other|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
214547|NCT02546934|Drug|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
214548|NCT02546934|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
214549|NCT02546921|Drug|MOv18 IgE|The allocated dose of MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for six weeks.
214550|NCT02546908|Other|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
214551|NCT02546895|Other|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.~Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
214552|NCT02546882|Biological|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
214553|NCT02546882|Drug|saline|1 ml saline was injected for 1 cm2 area.
214554|NCT02546869|Drug|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
214555|NCT02546869|Device|Prefilled Syringes|
214556|NCT02546856|Other|HF nurse up-titration|"Up-titration of Beta-Blocker (BB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 European Society of Cardiology (ESC) HF guidelines with cardiologist prescription and support"
214557|NCT02546856|Other|HF nurse up-titration|"Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support"
214558|NCT02546856|Other|HF nurse up-titration|"Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support"
214559|NCT02546856|Other|HF nurse up-titration|"Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support"
214560|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Beta-Blocker (BB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
214561|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
214562|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
214563|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
214564|NCT02546843|Drug|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
214565|NCT02546843|Drug|Cisatracurium|cisatracurium 0.15mg/kg intravenously
214566|NCT02546843|Drug|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
214567|NCT02546843|Drug|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
214568|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
214569|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
214570|NCT02546830|Device|FreeO2 v2.2 active|"Automatic adjustment of oxygen through the Free O2 device.~FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
214571|NCT02546830|Device|FreeO2 v2.2 with manual oxygenation|"Manual adjustment of oxygen without the assistance of the FreeO2 device.~Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
214572|NCT02546804|Procedure|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
214573|NCT02546804|Procedure|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
214574|NCT02546804|Procedure|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
214575|NCT02546791|Drug|Dasatinib|
214576|NCT02546778|Device|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
214577|NCT02546765|Drug|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
214578|NCT02546765|Drug|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
214579|NCT02546765|Drug|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
214580|NCT02546765|Drug|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
214581|NCT02546752|Other|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
214582|NCT02546739|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
214583|NCT02546726|Behavioral|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
214584|NCT02546726|Behavioral|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
214585|NCT02546713|Other|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
214586|NCT02546713|Other|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
214587|NCT02546700|Drug|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
214588|NCT02546700|Drug|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
214589|NCT02546687|Other|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
214590|NCT02546674|Drug|Nilotinib|Nilotinib will be prescribed by the investigator according to the patient's medical need.
214591|NCT02546661|Drug|AZD4547|AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
214592|NCT02546661|Drug|MEDI4736|MEDI4736
214593|NCT02546661|Drug|Olaparib|MEDI4736 (durvalumab) + Olaparib
214594|NCT02546661|Drug|AZD1775|MEDI4736 (durvalumab) + AZD1775
214595|NCT02546661|Drug|Vistusertib|MEDI4736 (durvalumab) + Vistusertib
214596|NCT02546661|Drug|AZD9150|MEDI4736 (durvalumab) + AZD9150
214597|NCT02546661|Drug|Selumetinib|MEDI4736 (durvalumab) + Selumetinib
214598|NCT02546648|Drug|Tranexamic Acid|
214599|NCT02546648|Drug|Tranexamic Acid Placebo|
214600|NCT02546648|Drug|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
214601|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
214602|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
214603|NCT02546622|Biological|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
214604|NCT02546622|Biological|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|Prophylaxis for prevention of bleeding, various regimens.
214605|NCT02546609|Drug|Leu-Met-Sil 0.5|NS-0200 low dose
214606|NCT02546609|Drug|Leu-Met-Sil 1.0|NS-200 high dose
214607|NCT02546609|Drug|Placebo|Placebo
214609|NCT02546583|Drug|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
214610|NCT02546583|Drug|IV Chlorothiazide|
214611|NCT02546570|Drug|Oxytocin|See arm/group descriptions for dosage amount and procedure.
214612|NCT02546570|Drug|Placebo|See arm/group descriptions for dosage amount and procedure.
214613|NCT02546557|Procedure|Coronary Artery Bypass Graft surgery|
214614|NCT02546544|Drug|Linsitinib|
214615|NCT02546531|Biological|Defactinib|
214616|NCT02546531|Biological|Pembrolizumab|
214617|NCT02546531|Drug|Gemcitabine|
214618|NCT02546518|Device|Moniri Otovent|Please see Arm Description.
214619|NCT02546518|Device|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
214620|NCT02546505|Other|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
214621|NCT02546505|Other|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
214622|NCT02546492|Drug|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
214623|NCT02546466|Procedure|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
214624|NCT02546466|Procedure|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
214625|NCT02546466|Behavioral|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
214626|NCT02546453|Biological|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
214627|NCT02546453|Biological|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
214628|NCT02546440|Drug|dimethylfumarate|dose escalation from 30 mg/d to 720 mg/d over 9 weeks following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until unacceptable side effects occur
214629|NCT02546427|Radiation|Helical TomoTherapy (HT)|
214630|NCT02546427|Radiation|CyberKnife SBRT|
214631|NCT02546427|Radiation|Permanent Prostate Implant (PPI)|
214632|NCT02546427|Radiation|HDR brachytherapy|
214633|NCT02546414|Other|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
214634|NCT02546401|Drug|Insulin Aspart|Injection of Insulin Aspart before or after meals
214635|NCT02546388|Drug|Indium-111 Pentreotide|
214636|NCT02546375|Drug|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
214637|NCT02546362|Device|Cefaly|
214638|NCT02546349|Drug|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
214639|NCT02546336|Device|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
214640|NCT02546323|Drug|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
214641|NCT02546323|Drug|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
214642|NCT02546310|Drug|HTL0009936|
214643|NCT02546310|Drug|HTL0009936 matching placebo|
214644|NCT02546297|Drug|Symbicort|drug are used for 12 months
214645|NCT02546297|Drug|Spiriva|drug are used for 12 months
214646|NCT02546284|Drug|lenzilumab|
214647|NCT02546271|Behavioral|GPS|
214648|NCT02546258|Device|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
214649|NCT02546245|Behavioral|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
214650|NCT02546245|Behavioral|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
214651|NCT02546232|Drug|Carboplatin|Chemotherapy
214652|NCT02546232|Drug|Paclitaxel|Chemotherapy
214653|NCT02546219|Other|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
214654|NCT02546206|Dietary Supplement|Probiotic Yoghurt|Probiotic yoghurt consumption
214655|NCT02546206|Dietary Supplement|Natural Yoghurt|Natural yoghurt consumption
214656|NCT02546193|Device|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
214657|NCT02546193|Drug|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
214658|NCT02546180|Other|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
214659|NCT02546180|Other|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
214660|NCT02546167|Biological|CART-BCMA|
214661|NCT02546154|Drug|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
214662|NCT02546141|Other|skimmed milk (UHT)|
214663|NCT02546141|Other|skimmed milk (pasteurized)|
214664|NCT02546141|Other|skimmed yoghurt|
214665|NCT02546141|Other|full-fat milk (UHT)|
214666|NCT02546141|Other|non-homogenized full-fat milk (pasteurized)|
214667|NCT02546141|Other|full-fat cheese (semi-matured)|
214668|NCT02546141|Other|whey protein|
214669|NCT02546141|Other|micellar casein|
214670|NCT02546128|Device|Extra-Corporeal Shockwave Therapy (ESWT)|The use of ESWT from a commercially available machine at approved settings already in routine clinical use
214671|NCT02546128|Other|structured rehabilitation programme|a structured and standardised rehabilitation programme specific to the tendon in question - already in routine clinical use
214672|NCT02546115|Device|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
214673|NCT02546115|Other|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
214674|NCT02546102|Biological|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
214675|NCT02546102|Biological|Placebo|
214676|NCT02546089|Other|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
214677|NCT02546089|Other|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
214678|NCT02546089|Other|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
214679|NCT02546076|Device|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
214680|NCT02546076|Device|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
214681|NCT02546063|Other|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
214682|NCT02546050|Drug|Metformin|
214683|NCT02546037|Device|FX100 dialyzer|comparison of dialyzers
214684|NCT02546037|Device|SOLACEA 21H|comparison of dialyzers
214685|NCT02546024|Drug|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
214686|NCT02546011|Other|Fetal Heart Rate Monitor|Standard of care, not part of research
214687|NCT02545998|Other|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
214688|NCT02545985|Device|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
214689|NCT02545972|Drug|tacrolimus extended release|daily dosing of tacrolimus
214690|NCT02545959|Drug|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
214691|NCT02545959|Drug|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
214692|NCT02545959|Drug|Rituximab IV|Blood infusion of rituximab (375mg/m2)
214693|NCT02545946|Device|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I&D
214694|NCT02545946|Other|traditional I&D with or without packing|abscess will be drained with a traditional I&D with or without packing (as deemed appropriate by ER doctor)
214695|NCT02545933|Drug|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
214696|NCT02545933|Drug|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
214697|NCT02545933|Drug|Aspirin|Aspirin will be administered at the dose of 81mg once daily
214698|NCT02545933|Drug|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
214699|NCT02545920|Other|no intervention|observational study
214700|NCT02545907|Drug|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
214701|NCT02545907|Drug|Thalidomide|50mg capsule.
214702|NCT02545907|Drug|Dexamethasone|2mg tablet.
214737|NCT02545712|Other|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
214738|NCT02545712|Other|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
214703|NCT02545894|Behavioral|Cognitive therapy|"The tasks are:~visually tracking a picture as it moves across the computer screen~pressing a button every time a picture is seen on the screen~pressing a button every time a specific picture is seen on the screen~Pressing a button every time a specific sound is heard~Matching objects to a picture~Matching gestures to objects~Matching two connected objects~Sorting objects by categories~Matching sounds to objects~Complete the category and odd on out with objects~Choosing target objects by pointing~Choosing objects to complete the category by pointing"
214704|NCT02545881|Other|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
214705|NCT02545868|Biological|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
214706|NCT02545868|Biological|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
214707|NCT02545868|Biological|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
214708|NCT02545868|Biological|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
214709|NCT02545868|Drug|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 600 mg, with the first dose given as two infusions of 300mg 14 days apart, according to the specifications described in the corresponding Group A and Group B arms.
214710|NCT02545868|Biological|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
214711|NCT02545855|Device|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
214712|NCT02545855|Device|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
214713|NCT02545842|Drug|INSULIN GLARGINE|"Pharmaceutical form: solution~Route of administration: subcutaneous"
214714|NCT02545829|Drug|HIP1302|Tenofovir 292mg
214715|NCT02545829|Drug|HGP1406|Tenofovir 300mg
214716|NCT02545816|Device|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
214717|NCT02545803|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
214718|NCT02545790|Procedure|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
214719|NCT02545790|Biological|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
214720|NCT02545777|Drug|diclofenac sodium enteric-coated|
214721|NCT02545777|Drug|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
214722|NCT02545777|Drug|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
214723|NCT02545777|Drug|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
214724|NCT02545764|Other|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
214725|NCT02545751|Radiation|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
214726|NCT02545751|Drug|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days until progression of other metastatic lesions. Tumor response is evaluated by assessing clinical and CT/MRI response for all the other measurable metastatic sites.
214727|NCT02545738|Drug|Liraglutide|active treatment
214728|NCT02545738|Drug|placebo|placebo
214729|NCT02545725|Other|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
214730|NCT02545712|Other|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
214731|NCT02545712|Other|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
214732|NCT02545712|Other|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
214733|NCT02545712|Other|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
214734|NCT02545712|Other|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
214735|NCT02545712|Other|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
214736|NCT02545712|Other|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
214739|NCT02545712|Other|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
214740|NCT02545699|Device|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
214741|NCT02545699|Device|Standard Colonoscopy|Standard Colonoscopy
214742|NCT02545686|Behavioral|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
214743|NCT02545686|Behavioral|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
214744|NCT02545686|Procedure|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
214745|NCT02545686|Procedure|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
214746|NCT02545673|Behavioral|Enhanced linkage to care|
214747|NCT02545673|Behavioral|Standard-of-care plus|
214748|NCT02545660|Other|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
214749|NCT02545660|Other|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
214750|NCT02545647|Device|BRYGB|65 patients undergo a banded RYGB
214751|NCT02545634|Dietary Supplement|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
214752|NCT02545634|Other|Placebo|
214753|NCT02545621|Other|RAGE TXNIP Inflammasome axis|
214754|NCT02545608|Device|Restylane Vital|
214755|NCT02545595|Drug|Sugammadex 1 mg/kg|
214756|NCT02545595|Drug|Sugammadex 2 mg/kg|
214757|NCT02545595|Drug|Sugammadex 4 mg/kg|
214758|NCT02545582|Device|VITARIA System|Implantable vagus nerve stimulator
214759|NCT02545569|Device|hearing aid (MD class IIa) - ITE, BTE, RIC|Hearing aid means any wearable instrument or device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing.
214760|NCT02545556|Procedure|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
214761|NCT02545543|Biological|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
214762|NCT02545543|Biological|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.~The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
214763|NCT02545530|Drug|transdermal clonidine|2.5mg/patch per week
214764|NCT02545517|Biological|Rabipur|Subjects in all the groups received Rabipur vaccine booster dose, administered intramuscularly in the deltoid region of the non-dominant arm
214765|NCT02545517|Procedure|Blood sampling|Blood samples were drawn from all subjects at day 1 and then at subsequent year intervals from extension study day 1 onwards.
214766|NCT02545504|Drug|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
214767|NCT02545504|Drug|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
214768|NCT02545504|Drug|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
214769|NCT02545504|Drug|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
214770|NCT02545504|Drug|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of Cycles 1 to 6
214771|NCT02545491|Behavioral|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
214772|NCT02545491|Behavioral|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
214773|NCT02545465|Drug|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
214774|NCT02545452|Drug|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
214775|NCT02545452|Drug|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
214776|NCT02545452|Drug|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
214777|NCT02545452|Drug|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
214778|NCT02545452|Other|Tampon|
214779|NCT02545439|Drug|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
214780|NCT02545426|Other|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
214781|NCT02545413|Drug|Probiotic VSL#3|
214782|NCT02545413|Drug|Placebo|
214783|NCT02545374|Other|Telemedicine|
214784|NCT02545374|Other|Control|
214820|NCT02545049|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
214821|NCT02545049|Drug|Placebo|Matching placebo to be taken orally, once daily.
214785|NCT02545361|Drug|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.~Planned doses for stage 1:~Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
214786|NCT02545348|Procedure|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
214787|NCT02545322|Radiation|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
214788|NCT02545296|Other|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
214789|NCT02545283|Drug|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m^2) intravenous (IV) infusion for 5 days of every treatment cycle.
214790|NCT02545283|Drug|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
214791|NCT02545283|Other|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
214792|NCT02545270|Procedure|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
214793|NCT02545270|Procedure|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
214794|NCT02545270|Procedure|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
214795|NCT02545257|Other|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
214796|NCT02545244|Dietary Supplement|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
214797|NCT02545244|Dietary Supplement|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
214798|NCT02545244|Drug|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
214799|NCT02545231|Drug|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
214800|NCT02545231|Drug|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
214801|NCT02545231|Drug|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
214802|NCT02545218|Procedure|Perineorraphy|Surgery for improperly healed perineal tear
214803|NCT02545218|Other|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
214804|NCT02545205|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).
214805|NCT02545205|Other|Conventional gait training|The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
214806|NCT02545192|Device|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
214807|NCT02545179|Other|web-based daily care training|12 week interactive web based caring training education
214808|NCT02545153|Drug|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
214809|NCT02545153|Drug|Control|No fibrin sealant applied
214810|NCT02545140|Other|No intervention|
214811|NCT02545127|Drug|merotocin|Merotocin nasal spray
214812|NCT02545127|Drug|placebo|The placebo nasal spray is identical with the active product except that it does not contain merotocin
214813|NCT02545114|Drug|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
214814|NCT02545088|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
214815|NCT02545088|Other|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
214816|NCT02545088|Other|2nd control group|The 2nd control group will not receive an intervention.
214817|NCT02545075|Drug|Ipilimumab|
214818|NCT02545075|Drug|Dacarbazine|
214819|NCT02545062|Other|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
214822|NCT02545036|Other|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
214823|NCT02545023|Other|Quality-of-Life Assessment|Complete an in-person one-on-one interview
214824|NCT02545023|Other|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
214825|NCT02545010|Drug|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
214826|NCT02545010|Radiation|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
214827|NCT02544997|Drug|Poziotinib|12mg P.O. for 2wks q21days
214828|NCT02544984|Drug|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
214829|NCT02544984|Drug|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
214830|NCT02544971|Behavioral|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
214831|NCT02544971|Other|Control|Treatment as usual
214832|NCT02544958|Device|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
214833|NCT02544945|Other|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
214834|NCT02544945|Other|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
214835|NCT02544932|Drug|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
214836|NCT02544932|Drug|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
214837|NCT02544932|Drug|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
214838|NCT02544919|Drug|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
214839|NCT02544906|Drug|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
214840|NCT02544906|Drug|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
214841|NCT02544893|Drug|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
214842|NCT02544893|Drug|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
214843|NCT02544893|Drug|serum physiologic|21 ml serum physiologic is applied paravertebral space
214844|NCT02544880|Drug|Tadalafil|"Tadalafil or placebo will be administered once daily orally (po) for 19 days in conjunction with the first vaccination course (pre-surgery). Thereafter, Tadalafil or placebo will be administered for 14 days in conjunction with each subsequent vaccination course (Courses 2, 3 and 4), except for the last vaccination at which no Tadalafil will be administered (Course 5).~The dose range of Tadalafil will be normalized to the patient's body weight, as follows:~Weight (lb) --> Daily oral dose of Tadalafil (mg)~≤ 140 lbs --> 10 mg~>140 lbs and ≤ 230 lbs --> 15 mg~>230 lbs --> 20 mg"
214845|NCT02544880|Biological|Anti-MUC1 Vaccine|"The Anti-MUC1 vaccine or placebo will be administered on Day 7 of Course 1, Day 10 of Courses 2, 3 and 4, and on Day 1 (of 1) of Course 5 (5-7 months after Course 4, day 10 and 11-13 months after Surgery).~The anti-MUC1 vaccine will be administered intramuscularly (IM) in the right upper limb of each patient."
214846|NCT02544880|Biological|Anti-Influenza Vaccine|"The Anti-Influenza vaccine (Flublok®) or placebo will be administered on Day 7 of Course 1, Day 10 of Courses 2, 3 and 4, and Day 1 (of 1) of Course 5 (5-7 months after Course 4, day 10 and 11-13 months after Surgery).~The anti-influenza vaccine will be administered intramuscularly (IM) in the left upper limb of each patient."
214847|NCT02544880|Other|Tadalafil Placebo|Placebo for Tadalafil.
214848|NCT02544880|Other|Vaccine Placebo|Placebo for Anti-MUC1 and Anti-Influenza vaccines.
214849|NCT02544880|Other|Standard of Care Treatment|Treatment according to prescribed standard of care regimen.
214850|NCT02544867|Behavioral|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
214919|NCT02544334|Other|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
214920|NCT02544334|Other|Saliva Collection|All participants will have a saliva collection.
214851|NCT02544854|Drug|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~First 15 minutes: 15 mg/kg/min~16 to 30 minutes: 13 mg/kg/min~31 to 60 minutes: 11 mg/kg/min~61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~5, 15 and 25 minutes of starting infusion,~1, 3, 5, 7, 9 and 12 minutes of bolus and,~5, 25, 60 and 120 minutes of infusion ended."
214852|NCT02544841|Behavioral|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
214853|NCT02544841|Behavioral|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
214854|NCT02544828|Drug|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
214855|NCT02544828|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
214856|NCT02544815|Drug|Digoxin|Digoxin 0.25 mg pills
214857|NCT02544815|Drug|Placebo|Placebo pills
214858|NCT02544802|Drug|Adipose-Derived Mesenchymal Stem Cells|
214859|NCT02544789|Drug|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
214860|NCT02544776|Drug|Clomifene citrate ( clomid 50 mg )|
214861|NCT02544776|Drug|Amlodipine|
214862|NCT02544763|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214863|NCT02544763|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214864|NCT02544750|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
214865|NCT02544737|Drug|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
214866|NCT02544724|Biological|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
214867|NCT02544711|Device|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
214868|NCT02544711|Procedure|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
214869|NCT02544698|Biological|One dose of PCV13a vaccine|
214870|NCT02544698|Biological|One dose of PCV13a vaccine|
214871|NCT02544698|Biological|three doses of PCV13a vaccine|
214872|NCT02544698|Biological|three doses of PCV13a vaccine|
214873|NCT02544685|Dietary Supplement|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration~Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
214874|NCT02544685|Dietary Supplement|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
214875|NCT02544685|Other|Placebo|Same dosage regimen as active drugs
214876|NCT02544672|Device|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
214877|NCT02544659|Drug|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
214878|NCT02544646|Other|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
214879|NCT02544633|Drug|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
214880|NCT02544620|Other|Does fulfil of discharge criteria on the day of the surgery|
214881|NCT02544620|Other|Does not fulfil of discharge criteria on the day of the surgery|
214882|NCT02544607|Drug|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
214883|NCT02544607|Other|Magnetic Resonance Imaging (MRI)|MRI technology will be used before and after ketamine for patients with depression
214884|NCT02544594|Device|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
214885|NCT02544581|Other|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
214886|NCT02544568|Other|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
214921|NCT02544321|Drug|Bromocriptine|
214922|NCT02544321|Other|Placebo|
214923|NCT02544308|Drug|Lenalidomide|Experimental Arm
214924|NCT02544308|Drug|Dexamethasone|Experimental Arm
214925|NCT02544308|Other|No further treatment|Comparator Arm
214926|NCT02544295|Behavioral|Clinical interview|
214927|NCT02544295|Behavioral|Virtual reality task|
214928|NCT02544282|Drug|Levobupivacaine|Pecs II Block
214887|NCT02544555|Procedure|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
214888|NCT02544555|Procedure|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
214889|NCT02544542|Device|Rectum cooling system|
214890|NCT02544542|Device|Hyper-hypothermia blanket|
214891|NCT02544529|Drug|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
214892|NCT02544529|Drug|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
214893|NCT02544516|Other|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
214894|NCT02544516|Other|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
214895|NCT02544503|Device|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at 1 month visit and 6 month visit.
214896|NCT02544503|Device|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain.Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at 1 month and 6 month visit.
214897|NCT02544503|Device|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain.Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at 1 month and 6 month visit.
214898|NCT02544503|Device|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at 1 month and 6 month visit.
214899|NCT02544477|Device|High-flow Nasal Cannula Oxygen (HFNCO)|
214900|NCT02544477|Device|Conventional oxygen treatment|
214901|NCT02544464|Drug|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
214902|NCT02544464|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
214903|NCT02544451|Drug|LUM/IVA|"Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age).~LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older)."
214904|NCT02544438|Drug|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients~0.5 gr/m2 (0.3 age>50) 3~1.5 gr/m2(0.8age>50) 3~3.0 gr/m2(1.5 age>50) 3~4.5 gr/m2(2.3 age>50) 6~4.5 gr/m2 (no age limit) 3 up to 6~6 gr/m2 (no age limit) 3 up to 6~Total number of patients: up to 24"
214905|NCT02544425|Drug|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
214906|NCT02544425|Drug|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
214907|NCT02544425|Drug|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
214908|NCT02544425|Drug|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
214909|NCT02544425|Drug|Busulfan|"Conditioning regimen for autologous stem cell transplantation:~Busulfan 3.2 mg/kg D -8, -7, -6"
214910|NCT02544425|Drug|Melphalan|"Conditioning regimen for autologous stem cell transplantation:~Melphalan 70 mg/m2 D -3, -2"
214911|NCT02544412|Behavioral|novel mindfulness-based well-being training|
214912|NCT02544399|Other|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
214913|NCT02544386|Procedure|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
214914|NCT02544373|Other|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
214915|NCT02544360|Behavioral|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
214916|NCT02544347|Other|gingival crevicular fluid|gingival crevicular fluid was collected
214917|NCT02544347|Other|non-surgical periodontal treatment|scaling and root planing were performed
214918|NCT02544334|Procedure|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
214929|NCT02544282|Drug|NaCl 0.9%|Placebo Pecs II block
214938|NCT02544269|Procedure|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
214939|NCT02544256|Procedure|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
214940|NCT02544243|Drug|Vinorelbine|
214941|NCT02544243|Drug|Gemcitabine|
214942|NCT02544243|Drug|Cisplatin|
214943|NCT02544217|Drug|KH176|
214944|NCT02544217|Drug|placebo|
214945|NCT02544204|Biological|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
214946|NCT02544204|Biological|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
214947|NCT02544191|Drug|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
214948|NCT02544178|Radiation|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
214949|NCT02544165|Dietary Supplement|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
214950|NCT02544165|Other|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
214951|NCT02544165|Other|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
214952|NCT02544152|Drug|Lubiprostone|8 mcg administered orally twice daily (BID)
214953|NCT02544152|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
214954|NCT02544139|Other|Chagas Detect Plus|
214955|NCT02544126|Device|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
214956|NCT02544126|Behavioral|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
214957|NCT02544113|Drug|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
214958|NCT02544113|Drug|Placebo|Normal transplant immunosupression
214959|NCT02544100|Other|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
214960|NCT02544087|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
214961|NCT02544087|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
214962|NCT02544087|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
214963|NCT02544074|Behavioral|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
214964|NCT02544061|Biological|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
214965|NCT02544061|Drug|Placebo|single subcutaneous dose
214966|NCT02544035|Other|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category;
214967|NCT02544035|Other|Play Partner|Each child will first play alone then play with parent.
214968|NCT02543983|Drug|Ketamine|non-competitive N-methyl-D-aspartate receptor antagonist
214969|NCT02543957|Procedure|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
214970|NCT02543944|Drug|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detox and transition to depot naltrexone.
214971|NCT02543944|Drug|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
214972|NCT02543944|Drug|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
214973|NCT02543944|Drug|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
214974|NCT02543944|Drug|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
214975|NCT02543944|Drug|Placebo|Microcrystalline cellulose
214976|NCT02543931|Drug|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
214977|NCT02543931|Drug|placebo|Placebo capsules containing inert ingredients
214978|NCT02543918|Drug|Ixekizumab|Administered by SQ injection
214979|NCT02543918|Drug|Boostrix®|Administered by IM injection
214980|NCT02543918|Drug|Pneumovax®23|Administered by IM injection
214981|NCT02543905|Procedure|Prostate MRI and Biopsy|All men will undergo a MRI and prostate biopsy
214982|NCT02543892|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
214983|NCT02543892|Biological|Placebo|Normal Saline
214984|NCT02543879|Drug|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
214985|NCT02543879|Drug|Azacitidine|Azacitidine will be administered per site's standard of care
214986|NCT02543866|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
214987|NCT02543853|Other|direct trocar entry|direct trocar entry to provide pneumoperitoneum
214988|NCT02543853|Other|veres needle entry|veres needle entry to provide pneumoperitoneum
214989|NCT02543840|Other|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
214990|NCT02543840|Other|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
214991|NCT02543827|Biological|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
214992|NCT02543827|Biological|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
214993|NCT02543801|Drug|Liposomal Bupivacaine|Periarticular injection
214994|NCT02543801|Drug|Ropivacaine|Periarticular injection
214995|NCT02543801|Drug|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
214996|NCT02543801|Drug|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
214997|NCT02543801|Drug|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
214998|NCT02543801|Drug|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
214999|NCT02543788|Procedure|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
215000|NCT02543775|Procedure|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
215001|NCT02543762|Procedure|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
215002|NCT02543749|Biological|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
215003|NCT02543736|Device|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
215004|NCT02543723|Behavioral|Nurse Coach Intervention|Participants randomized to the intervention 2 group will receive the MEMS, plus a tailored nurse coach component. Participants will receive a 60-minute session conducted by the nurse coach. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). MEMS feedback will be used to show Participants their own medication-taking behavior via the MEMS Report, to correct any misperceptions of actual adherence and to identify problem areas. The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
215005|NCT02543723|Behavioral|MEMs Intervention|Participants will be advised to only open their pill bottles when they take their medications. Participants will also be given a MEMS diary to record unscheduled cap openings, such as those to refill the bottle, so that those unscheduled events unrelated to adherence can be removed from analysis. Participants will meet with the nurse coach during their regularly scheduled monthly oncology visits where the MEMS data will be collected. During this monthly meeting, participants in the intervention 1 group will receive feedback of their medication-taking behavior via a MEMS report.
215006|NCT02543710|Procedure|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).~Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.~Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.~Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
215007|NCT02543710|Drug|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.~During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
215047|NCT02543424|Behavioral|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
215008|NCT02543697|Radiation|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
215009|NCT02543684|Other|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
215010|NCT02543684|Other|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
215011|NCT02543684|Other|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
215012|NCT02543684|Other|oral glucose load|glucose load providing 50g of carbohydrates
215013|NCT02543671|Other|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
215014|NCT02543671|Other|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
215015|NCT02543658|Drug|Neostigmine|Intramuscular injection of neostigmine
215016|NCT02543658|Drug|The traditional treatment|the traditional treatments according to associated guidelines
215017|NCT02543645|Drug|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg."
215018|NCT02543632|Device|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
215019|NCT02543619|Other|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
215020|NCT02543606|Drug|Esomelone|powder for injection/ infusion Esomeprazole 40mg
215021|NCT02543606|Drug|Nexium|powder for injection/ infusion Esomeprazole 40mg
215022|NCT02543593|Device|Active tDCS or Sham tDCS|tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
215023|NCT02543580|Other|transcutaneous electric acupoint stimulation|electrodes are attached o the skin and electric stimulation is given
215024|NCT02543580|Other|electrode attached but no stimulation|electrodes are attached o the skin but no stimulation is given
215025|NCT02543567|Biological|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
215026|NCT02543567|Biological|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
215027|NCT02543567|Biological|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
215028|NCT02543567|Biological|MVA‐BN‐Filo 1*10^8 Infectious Unit [Inf. U.]|MVA‐BN‐Filo‐ live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57
215029|NCT02543567|Biological|MVA‐BN‐Filo 5*10^7 Inf. U.|MVA‐BN‐Filo‐ live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
215030|NCT02543567|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
215031|NCT02543554|Procedure|lung protective ventilation|Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
215032|NCT02543541|Behavioral|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
215033|NCT02543541|Behavioral|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
215034|NCT02543528|Device|Investigational Lens 1|One fresh pair of Investigational Lens 1 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
215035|NCT02543528|Device|Investigational Lens 2|One fresh pair of Investigational Lens 2 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
215036|NCT02543528|Device|Investigational Lens 3|One fresh pair of Investigational Lens 3 contact lenses worn continuously in 6 nights/7 days wear cycles for 6 months of total wear.
215037|NCT02543528|Device|etafilcon A (Reusable)|One fresh pair of etafilcon A (Reusable) contact lenses worn continuously in 6nights/7 days wear cycles for 6 months of total wear.
215038|NCT02543528|Device|etafilcon A (1-Day)|2-week contact lens adaptation period wearing prior to randomization
215039|NCT02543515|Procedure|office hysteroscopy|diagnostic procedure
215040|NCT02543502|Procedure|periodontal treatment|treatment of periodontal cleaning
215041|NCT02543489|Device|Flex IM rod|
215042|NCT02543463|Device|Trident X3 Insert with Navigation system|
215043|NCT02543463|Device|Trident X3 Insert with conventional instrumentation|
215044|NCT02543450|Other|Cardiovascular and task-oriented training|
215045|NCT02543450|Other|Upper limb strength training program|
215046|NCT02543437|Device|Trident Acetabular X3 Insert|
215048|NCT02543411|Drug|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol"
215049|NCT02543411|Drug|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.~Sedation with fentanyl and propofol"
215050|NCT02543398|Procedure|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
215051|NCT02543385|Drug|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
215052|NCT02543372|Behavioral|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
215053|NCT02543372|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
215054|NCT02543359|Behavioral|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
215055|NCT02543359|Behavioral|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
215056|NCT02543359|Behavioral|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
215057|NCT02543346|Drug|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
215058|NCT02543346|Other|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
215059|NCT02543320|Other|LORETA Neurofeedback Training|Undergo LORETA neurofeedback training
215060|NCT02543320|Other|Questionnaire Administration|Ancillary studies
215061|NCT02543307|Procedure|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
215062|NCT02543294|Device|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
215063|NCT02543294|Device|Electrocardiogram|Electrocardiogram performed at baseline.
215064|NCT02543294|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
215065|NCT02543294|Behavioral|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
215066|NCT02543281|Device|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
215067|NCT02543281|Device|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
215068|NCT02543268|Biological|Ad26.ZEBOV‐Batch #1|Ad26.ZEBOV ‐ Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
215069|NCT02543268|Biological|Ad26.ZEBOV‐Batch #2|Ad26.ZEBOV ‐ Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
215070|NCT02543268|Biological|Ad26.ZEBOV‐Batch #3|Ad26.ZEBOV ‐ Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
215071|NCT02543268|Biological|MVA‐BN‐Filo|MVA‐BN‐Filo‐ live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57.
215072|NCT02543268|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
215073|NCT02543255|Drug|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
215074|NCT02543255|Drug|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
215075|NCT02543255|Drug|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 20 mg/m2 per cycle and 3 weeks between cycles.
215076|NCT02543242|Device|InToneTM (InControl Medical, LLC) - Medical Device|
215077|NCT02543229|Drug|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
215078|NCT02543229|Drug|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
215079|NCT02543216|Dietary Supplement|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
215080|NCT02543203|Biological|Essential Oil Mixture A|Topical Essential Oils mixture and aromatic method
215081|NCT02543203|Biological|Essential Oils Mixture B|Topical Essential Oils mixture and aromatic method
215082|NCT02543190|Behavioral|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
215083|NCT02543177|Procedure|coronary angiography|
215084|NCT02543177|Procedure|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
215085|NCT02543177|Procedure|prior kidney irrigation|
215086|NCT02543164|Other|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
215087|NCT02543164|Other|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :~Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
215088|NCT02543151|Procedure|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
215089|NCT02543138|Device|Trocar|Closed thoracostomy using the new trocar
215090|NCT02543125|Device|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
215091|NCT02543125|Device|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
215092|NCT02543099|Drug|policosanol|Patients will receive policosanol 20mg Qd
215093|NCT02543099|Drug|placebo|Patients will receive placebo 20mg Qd;
215094|NCT02543086|Drug|KAE609|Study drug
215095|NCT02543086|Drug|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
215096|NCT02543073|Biological|MSCs|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 weeks as one cycle treatment.
215097|NCT02543073|Drug|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
215098|NCT02543073|Drug|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
215099|NCT02543060|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
215100|NCT02543060|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
215101|NCT02543047|Device|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
215102|NCT02543034|Device|Betafoam Wound Dressing|Foam dressing including Betadine iodine
215103|NCT02543034|Device|Petrolatum Gauze|Gauze dressing
215104|NCT02543034|Device|Allevyn Wound Dressing|Foam dressing
215105|NCT02543021|Device|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
215106|NCT02543021|Procedure|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
215107|NCT02543008|Procedure|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
215108|NCT02543008|Procedure|Physical activity|Information already included in arm/group descriptions.
215109|NCT02543008|Procedure|Placebo|Information already included in arm/group descriptions.
215110|NCT02542995|Other|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
215111|NCT02542982|Device|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
215112|NCT02542969|Drug|Simvastatin|
215113|NCT02542969|Drug|Rosuvastatin|
215114|NCT02542969|Drug|MGL-3196|
215115|NCT02542956|Drug|Exparel|receive Exparel by injection
215116|NCT02542956|Drug|Marcaine|receive Marcaine in a pain pump
215117|NCT02542956|Drug|Marcaine|receive Marcaine by injection
215118|NCT02542943|Device|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
215119|NCT02542943|Device|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
215120|NCT02542943|Other|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
215121|NCT02542943|Drug|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
215122|NCT02542930|Radiation|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
215123|NCT02542930|Drug|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
215124|NCT02542917|Device|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
215125|NCT02542904|Procedure|mesenteric excision|
215126|NCT02542891|Other|Blended CBT|
215127|NCT02542891|Other|Treatment as Usual (TAU)|
215128|NCT02542878|Device|Foam roller|A bout of 60 seconds of myofascial release with foam roller
215129|NCT02542865|Dietary Supplement|Fortified malt based food|Fortified malt based food
215130|NCT02542852|Drug|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
215131|NCT02542839|Device|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
215132|NCT02542839|Device|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
215133|NCT02542839|Other|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
215424|NCT02540460|Drug|LCB01-0371 800mg|LCB01-0371 800mg
215134|NCT02542839|Other|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
215135|NCT02542839|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
215136|NCT02542839|Procedure|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
215137|NCT02542826|Other|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
215138|NCT02542813|Drug|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
215139|NCT02542813|Drug|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
215140|NCT02542813|Drug|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
215141|NCT02542813|Drug|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
215142|NCT02542813|Drug|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
215143|NCT02542813|Drug|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
215144|NCT02542800|Behavioral|Episodic memory task|
215145|NCT02542800|Device|fMRI|
215146|NCT02542787|Drug|VSN16R|Small molecule
215147|NCT02542787|Other|Placebo|dummy tablet
215148|NCT02542774|Other|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
215149|NCT02542761|Device|Fiberglass Composite foot|The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
215150|NCT02542761|Device|Carbon Fiber Composite Foot|All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
215151|NCT02542748|Drug|Norepinephrine|norepinephrine injection
215152|NCT02542748|Drug|Ephedrine|Ephedrine injection
215153|NCT02542722|Behavioral|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
215154|NCT02542722|Behavioral|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
215155|NCT02542709|Device|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
215156|NCT02542709|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
215157|NCT02542696|Drug|APL-130277|"Used to treat up to 5 OFF episodes per day"
215158|NCT02542683|Other|structured physical activity program|a structured modest physical activity program
215159|NCT02542670|Genetic|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
215160|NCT02542657|Drug|Clarithromycin|Given PO
215161|NCT02542657|Drug|Dexamethasone|Given PO
215162|NCT02542657|Drug|Ixazomib Citrate|Given PO
215163|NCT02542657|Drug|Pomalidomide|Given PO
215164|NCT02542644|Device|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.~A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
215165|NCT02542631|Device|Bolus Insulin Patch (Calibra Finesse)|
215166|NCT02542631|Device|Insulin Pen (Novo-Nordisk FlexPen®)|
215167|NCT02542618|Behavioral|Inquiry Based Stress Reduction (IBSR)|
215168|NCT02542618|Behavioral|Cognitive Behavioral Therapy (CBT)|
215169|NCT02542605|Drug|Erenumab|Administered once on day 1 of Part B of the study by intravenous infusion.
215170|NCT02542605|Drug|Placebo|Administered once on day 1 of Part B of the study by intravenous infusion.
215171|NCT02542605|Drug|PACAP-38 Challenge Agent|"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."
215172|NCT02542592|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
215173|NCT02542592|Drug|Isotonic Sodium Chloride|Placebo
215174|NCT02542579|Genetic|16S rRNA pyrosequencing analysis|Next generation sequencing analysis will be done for 16S rRNA V1,2 hypervariable regions at Biocore (Seoul, Korea).
215175|NCT02542566|Procedure|Physiotherapy rehabilitation|Physiotherapy rehabilitation
215176|NCT02542553|Procedure|Bilateral BAL|
215177|NCT02542540|Other|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
215178|NCT02542527|Procedure|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
215179|NCT02542514|Drug|Ibrutinib|p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
215180|NCT02542488|Other|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI >35 kg/m2? A: Are you >50 years old? N: Is your neck circumference >40cm? G: Is your gender male?"
215181|NCT02542488|Diagnostic Test|Overnight pulse oximetry|All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
215182|NCT02542488|Other|Epworth Sleepiness Scale|A questionnaire that rates how tired they are doing everyday tasks
215183|NCT02542475|Device|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (< 100x) than those used in ECT and rTMS.
215184|NCT02542462|Drug|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
215185|NCT02542462|Drug|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
215186|NCT02542462|Drug|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
215187|NCT02542462|Drug|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
215188|NCT02542449|Dietary Supplement|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
215189|NCT02542449|Dietary Supplement|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
215190|NCT02542436|Other|No intervention|No intervention administered in this study
215191|NCT02542423|Other|Endocan blood test samples|
215192|NCT02542410|Drug|Cabergoline|
215193|NCT02542410|Drug|Norethindrone acetate|
215194|NCT02542397|Genetic|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
215195|NCT02542384|Drug|CR845 IV 1 mcg/kg|"CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided."
215196|NCT02542384|Drug|CR845 IV 0.5 mcg/kg|"CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
215197|NCT02542384|Drug|Placebo IV|"Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.~Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.~Saline infusion (IV 0.45%) for fluid replenishment will be provided."
215198|NCT02542371|Other|Arterial Imaging|
215199|NCT02542345|Procedure|magnetic resonance imaging|
215200|NCT02542332|Other|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
215201|NCT02542319|Dietary Supplement|Mablet 360 mg|
215202|NCT02542319|Dietary Supplement|Placebo|
215203|NCT02542306|Drug|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
215204|NCT02542293|Biological|Durvalumab +Tremelimumab|
215205|NCT02542293|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
215206|NCT02542293|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
215207|NCT02542293|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
215208|NCT02542293|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
215209|NCT02542293|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
215210|NCT02542280|Procedure|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
215211|NCT02542280|Procedure|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
215212|NCT02542280|Drug|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
215213|NCT02542267|Device|Gore VIABAHN Endoprosthesis|
215214|NCT02542254|Drug|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
215215|NCT02542254|Drug|Ipratropium|40 micrograms ipratropium administered using a pMDI
215216|NCT02542254|Drug|RPL554|6 mg RPL554 administered using a nebuliser
215217|NCT02542254|Drug|Salbutamol matched placebo|Placebo pMDI
215218|NCT02542254|Drug|Ipratropium matched placebo|Placebo pMDI
215219|NCT02542254|Drug|RPL554 matched placebo|Nebulised placebo
215332|NCT02541344|Device|Placebo|"Placebo group will take 4 placebo tablets.~The placebo is designed to be identical to IQP-VV-102."
215220|NCT02542241|Drug|Sodium Chloride [3%]|Subjects in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc / hour rate, the medicine will be administered by a infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
215221|NCT02542241|Drug|Sodium Chloride [0.9%]|Subjects in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc / hour rate, the medicine will be administered by a infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
215222|NCT02542228|Other|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
215223|NCT02542215|Drug|Cobiprostone|
215224|NCT02542215|Drug|Placebo|matching placebo
215225|NCT02542202|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
215226|NCT02542176|Other|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
215227|NCT02542176|Other|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
215228|NCT02542150|Drug|acetate|acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
215229|NCT02542150|Drug|alcohol|"a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan."
215230|NCT02542137|Radiation|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
215231|NCT02542137|Drug|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
215232|NCT02542124|Biological|NM-IL-12 and TSEBT|The LD-TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
215233|NCT02542111|Drug|Bortezomib|Bortezomib IV
215234|NCT02542111|Drug|Gemcitabine|Gemcitabine IV
215235|NCT02542111|Drug|Dexamethasone|Dexamethasone IV
215236|NCT02542111|Drug|Cisplatin|Cisplatin IV
215237|NCT02542098|Drug|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
215238|NCT02542085|Procedure|Laparoscopic repair|operative method
215239|NCT02542085|Procedure|Hybrid repair|operative method
215240|NCT02542072|Device|comfilcon A|contact lens
215241|NCT02542072|Device|samfilcon A|contact lens
215242|NCT02542059|Radiation|68Ga-exendin PET/CT|68Ga-exendin PET/CT
215243|NCT02542046|Drug|Barium|Administration of barium oral contrast agent prior to CT scan
215244|NCT02542046|Drug|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
215245|NCT02542046|Drug|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
215246|NCT02542033|Other|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
215247|NCT02542033|Other|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
215248|NCT02542007|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
215249|NCT02542007|Device|sirolimus-eluting stent system|
215250|NCT02541994|Device|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
215251|NCT02541994|Device|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
215252|NCT02541968|Behavioral|Cognitive-behavioral therapy (face-to-face)|
215253|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy|With therapist support
215254|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy without therapist support|
215255|NCT02541955|Drug|Acthar|Injections will be self administered
215256|NCT02541942|Other|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
215257|NCT02541929|Dietary Supplement|Docosahexaenoic acid|
215333|NCT02541331|Biological|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
215334|NCT02541331|Biological|PLACEBO|Matched tablets without any active substance.
215425|NCT02540460|Drug|LCB01-0371 800mg BID|LCB01-0371 800mg BID
215258|NCT02541916|Other|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy & LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
215259|NCT02541903|Drug|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
215260|NCT02541890|Behavioral|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
215261|NCT02541877|Device|Down sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
215262|NCT02541877|Device|Standard sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
215263|NCT02541877|Device|Standard sizing valve in TAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
215264|NCT02541864|Drug|Bismuth quadruple therapy|pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
215265|NCT02541864|Drug|Hybrid therapy|(pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days) followed by (pantoprazole 40 mg bid for 7 days, amoxicillin 1 g bid for 7 days, clarithromycin 500 mg bid for 7 days, and metronidazole 500 mg bid for 7 days)
215266|NCT02541838|Other|Muscle power|
215267|NCT02541838|Other|balance perturbation|
215268|NCT02541838|Other|aerobic exercise|
215269|NCT02541825|Device|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
215270|NCT02541825|Device|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
215271|NCT02541812|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
215272|NCT02541799|Procedure|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
215273|NCT02541799|Procedure|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
215274|NCT02541786|Drug|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
215275|NCT02541786|Drug|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
215276|NCT02541773|Device|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
215277|NCT02541760|Drug|Monteleukast|4 ml monteleukast daily for one month
215278|NCT02541760|Drug|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
215279|NCT02541747|Behavioral|massage|massage
215280|NCT02541734|Drug|Gelofusine|Infusion of gelofusine
215281|NCT02541734|Radiation|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
215282|NCT02541734|Drug|Placebo|
215283|NCT02541721|Device|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
215284|NCT02541708|Drug|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
215285|NCT02541708|Drug|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
215286|NCT02541695|Biological|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.~At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
215287|NCT02541682|Other|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
215288|NCT02541669|Drug|TAK-491|TAK-491 tablets
215289|NCT02541669|Drug|TAK-491 placebo|TAK-491 placebo-matching tablets
215290|NCT02541656|Procedure|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
215335|NCT02541318|Behavioral|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
215291|NCT02541643|Drug|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.~A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:~H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent~H2 blocker: ranitidine (50mg IV) or equivalent~acetaminophen (650-1000mg PO)"
215292|NCT02541630|Behavioral|Big Mind|mindfulness based intervention
215293|NCT02541617|Procedure|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
215294|NCT02541617|Procedure|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
215295|NCT02541604|Drug|Atezolizumab|Atezolizumab will be administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
215296|NCT02541591|Other|Neuroprotective goal directed hemodynamic optimization|
215297|NCT02541591|Other|MAP > 65mmHg|MAP > 65mmHg
215298|NCT02541565|Drug|Cyclophosphamide|Given IV
215299|NCT02541565|Drug|Doxorubicin Hydrochloride|Given IV
215300|NCT02541565|Other|Laboratory Biomarker Analysis|Correlative studies
215301|NCT02541565|Biological|Pembrolizumab|Given IV
215302|NCT02541565|Drug|Prednisone|Given PO
215303|NCT02541565|Biological|Rituximab|Given IV
215304|NCT02541565|Drug|Vincristine Sulfate|Given IV
215305|NCT02541552|Drug|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
215306|NCT02541539|Dietary Supplement|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
215307|NCT02541539|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
215308|NCT02541526|Drug|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
215309|NCT02541526|Drug|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
215310|NCT02541513|Drug|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
215311|NCT02541500|Drug|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
215312|NCT02541487|Dietary Supplement|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
215313|NCT02541474|Other|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
215314|NCT02541461|Procedure|Laparoscopic gastrectomy|(1) Wedge resection, subtotal or total gastrectomy with or without lymph node dissection; (2) R0 resection; (3) Laparoscopic gastrectomy; (4) Gastroduodenal anastomosis or duodenal bypass, including Roux-en-Y or gastrojejunostomy
215315|NCT02541448|Device|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar & Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
215316|NCT02541422|Dietary Supplement|N Acetyl Cysteine|
215317|NCT02541422|Other|placebo|
215318|NCT02541409|Drug|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
215319|NCT02541409|Drug|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
215320|NCT02541409|Drug|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
215321|NCT02541396|Drug|Wafermine|35 or 70 mg ketamine in a sublingual wafer
215322|NCT02541396|Drug|Oxycodone|5 mg oxycodone capsule
215323|NCT02541396|Drug|Placebo|Placebo capsule or placebo wafer
215324|NCT02541383|Drug|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
215325|NCT02541383|Drug|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
215326|NCT02541383|Drug|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
215327|NCT02541370|Biological|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
215328|NCT02541357|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
215329|NCT02541357|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
215330|NCT02541344|Device|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
215331|NCT02541344|Device|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
215426|NCT02540460|Drug|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
215336|NCT02541305|Other|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
215337|NCT02541305|Other|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
215338|NCT02541292|Other|No intervention, observational|
215339|NCT02541279|Procedure|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
215340|NCT02541266|Other|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
215341|NCT02541253|Biological|GC3110A|A single 0.5mL dose intramuscular injection
215342|NCT02541253|Biological|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
215343|NCT02541240|Other|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
215344|NCT02541227|Drug|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
215345|NCT02541214|Device|Trial Nasal Mask|
215346|NCT02541201|Dietary Supplement|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
215347|NCT02541201|Dietary Supplement|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
215348|NCT02541188|Genetic|Genetic analysis|
215349|NCT02541162|Behavioral|Oral information and interviews|interviews about sexuality and self experience during the disease
215350|NCT02541149|Procedure|blood sample|
215351|NCT02541136|Behavioral|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, < 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.~The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
215352|NCT02541123|Other|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
215353|NCT02541097|Behavioral|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
215354|NCT02541084|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
215355|NCT02541071|Behavioral|Stress Film|
215356|NCT02541071|Drug|Yohimbine|
215357|NCT02541071|Drug|Clonidine|
215358|NCT02541071|Drug|placebo|
215359|NCT02541045|Drug|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
215360|NCT02541045|Other|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
215361|NCT02541032|Procedure|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
215362|NCT02541032|Procedure|Standard dental treatment|Supragingival mechanical scaling and polishing.
215363|NCT02541032|Drug|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
215364|NCT02541019|Drug|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
215365|NCT02541019|Drug|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
215366|NCT02541006|Drug|Tiotropium 18 mcg|tiotropium 18 mcg once a day
215367|NCT02540993|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
215368|NCT02540993|Drug|Placebo|Matching placebo to be taken orally, once daily.
215369|NCT02540967|Drug|Gadobutrol (Gadavist/Gadovist, BAY86-4875)|Gadovist dosage following summary of product characteristics
215370|NCT02540954|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
215371|NCT02540941|Other|non|
215372|NCT02540928|Drug|AMG 319 hydrate|
215373|NCT02540928|Drug|Placebo|
215374|NCT02540915|Other|Standard of Care - Registry|Standard of Care - Registry
215375|NCT02540902|Device|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
215376|NCT02540889|Behavioral|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
215377|NCT02540876|Drug|Ilorasertib|Given PO
215378|NCT02540876|Other|Laboratory Biomarker Analysis|Correlative studies
215379|NCT02540863|Other|myofascial release protocol and Rocabado exercise therapy|
215380|NCT02540863|Other|exercise therapy|
215381|NCT02540837|Drug|Bupivacaine|Obturator nerve block
215382|NCT02540837|Drug|Saline|Obturator nerve block with saline(placebo)
215383|NCT02540824|Drug|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
215384|NCT02540811|Device|dCELL® ACL Scaffold|
215422|NCT02540473|Behavioral|Manualized Therapy|Relational psychotherapy mothers
215423|NCT02540473|Behavioral|Control Group|one hour of free time to do with as they wish
215385|NCT02540785|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
215386|NCT02540785|Procedure|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
215387|NCT02540772|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
215388|NCT02540759|Dietary Supplement|Buglossoides oil|
215389|NCT02540759|Dietary Supplement|High Oleic Sunflower Oil|
215390|NCT02540746|Behavioral|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
215391|NCT02540746|Behavioral|Motivational Enhancement|Three week Motivational Enhancement group
215392|NCT02540746|Behavioral|Family Skills Training|12-week group-based family skills training using Family Connections model
215393|NCT02540720|Drug|Dexamethasone|
215394|NCT02540720|Drug|Gamma globulin|
215395|NCT02540720|Procedure|Hemoperfusion|
215396|NCT02540707|Drug|solifenacin|solifenacin 5 mg per day for 12 weeks
215397|NCT02540707|Drug|mirabegron|mirabegron 25 mg per day for 12 weeks
215398|NCT02540694|Device|Endosonography|
215399|NCT02540668|Drug|Lanabecestat|Administered orally
215400|NCT02540668|Drug|Warfarin|Administered orally
215401|NCT02540655|Biological|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
215402|NCT02540655|Procedure|Excipients|Patients will receive excipients through intravenous infusion
215403|NCT02540642|Dietary Supplement|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
215404|NCT02540629|Procedure|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
215405|NCT02540616|Device|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
215406|NCT02540603|Device|F&P Jupiter Full Face Mask|Investigative F&P Jupiter full face mask to be used for OSA therapy
215407|NCT02540590|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
215408|NCT02540590|Device|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
215409|NCT02540551|Procedure|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
215410|NCT02540538|Biological|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
215411|NCT02540538|Biological|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
215412|NCT02540525|Device|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
215413|NCT02540525|Device|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
215414|NCT02540512|Procedure|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
215415|NCT02540512|Device|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
215416|NCT02540512|Procedure|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
215417|NCT02540512|Drug|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
215418|NCT02540512|Drug|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
215419|NCT02540499|Radiation|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
215420|NCT02540486|Other|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
215421|NCT02540486|Other|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
215427|NCT02540460|Drug|Placebo|Placebo
215428|NCT02540447|Procedure|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
215429|NCT02540434|Device|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
215430|NCT02540434|Other|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
215431|NCT02540434|Drug|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
215432|NCT02540395|Drug|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
215433|NCT02540395|Drug|MMF (mycophenolate mofetil) (for Group B)|"MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.~From day 8 on, patients will not receive MMF."
215434|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group B)|"At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).~Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed."
215435|NCT02540395|Drug|Tacrolimus (for Group A)|"The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.~Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption."
215436|NCT02540395|Drug|Mycofenolate mofetil (MMF) (for Group A)|"Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.~Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).~The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation."
215437|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group A)|"At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).~Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day."
215438|NCT02540382|Device|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
215439|NCT02540382|Device|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.~The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.~The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.~It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
215440|NCT02540369|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
215441|NCT02540356|Biological|BAX69 Single-Route Arm|Intraperitoneal (IP) only
215442|NCT02540356|Biological|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
215443|NCT02540343|Other|questionnaires|fill out all questionnaires twice
215444|NCT02540330|Drug|Fulvestrant|
215445|NCT02540317|Behavioral|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
215446|NCT02540304|Behavioral|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
215447|NCT02540291|Drug|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
215580|NCT02539381|Procedure|Visual inattention assessment to bilateral stimuli|
215448|NCT02540278|Behavioral|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
215449|NCT02540265|Drug|N1539|
215450|NCT02540265|Drug|Intravenous Placebo|
215451|NCT02540252|Other|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
215452|NCT02540239|Drug|2L PEG|
215453|NCT02540239|Drug|2L PEG+simethicone|
215454|NCT02540226|Drug|Intravenous tranexamic acid|
215455|NCT02540226|Drug|Topical tranexamic acid|
215456|NCT02540226|Drug|Intravenous saline|
215457|NCT02540226|Drug|Topical saline|
215458|NCT02540213|Device|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
215459|NCT02540200|Device|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
215460|NCT02540200|Procedure|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
215461|NCT02540187|Other|blood specimen|
215462|NCT02540174|Procedure|integrated addiction treatment program|"At the inclusion, a 45 min interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I), the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million using the CO tester.~At 3, 6, and 12 months : a 20 min interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.~The first addiction consultation will be carried out directly in the cancer treatment unit and integrated to the overall cancer treatment program."
215463|NCT02540174|Procedure|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :~At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.~At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
215464|NCT02540161|Drug|Sym004|Sym004 was dosed at 18 mg/kg intravenously every two weeks. Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
215465|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
215466|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
215467|NCT02540135|Other|fluorescein|fluorescein and conventional neuro-navigation
215468|NCT02540135|Other|intraoperative MRI|conventional neuro-navigation and iMRI
215469|NCT02540122|Device|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
215470|NCT02540122|Device|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
215471|NCT02540122|Device|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
215472|NCT02540122|Device|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
215473|NCT02540109|Device|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
215474|NCT02540109|Device|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
215475|NCT02540096|Other|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
215476|NCT02540096|Other|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
215477|NCT02540083|Device|DBT and FFDM|Subjects underwent FFDM breast imaging followed by DBT breast imaging
215478|NCT02540070|Procedure|Periarticular|
215479|NCT02540070|Procedure|Motor free|
215480|NCT02540070|Procedure|Motor free with dex|
215481|NCT02540070|Drug|Ropivacaine|
215482|NCT02540070|Drug|epinephrine|
215483|NCT02540070|Drug|morphine|
215484|NCT02540070|Drug|Ketorolac|
215485|NCT02540070|Drug|Dexmedetomidine|
215486|NCT02540070|Drug|saline|
215487|NCT02540057|Procedure|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
215581|NCT02539381|Device|Digital tumbling E visual accuity assessment|
215488|NCT02540057|Procedure|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
215489|NCT02540044|Behavioral|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
215490|NCT02540044|Behavioral|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
215491|NCT02540031|Drug|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
215492|NCT02540031|Drug|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
215493|NCT02540018|Device|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.~Luminor35®-DEB PTA catheter is applied."
215494|NCT02540018|Device|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
215495|NCT02540005|Other|ROTEM analysis|
215496|NCT02539992|Device|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
215497|NCT02539992|Device|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
215498|NCT02539992|Device|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
215499|NCT02539979|Drug|Paracetamol|
215500|NCT02539979|Drug|Placebo - Normal Saline|Normal Saline 100cc
215501|NCT02539966|Device|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
215502|NCT02539953|Device|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
215503|NCT02539940|Device|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
215504|NCT02539914|Other|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
215505|NCT02539914|Other|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
215506|NCT02539901|Behavioral|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
215507|NCT02539901|Behavioral|Free hearing test categorization|Free hearing test categorization evaluation
215508|NCT02539901|Behavioral|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
215509|NCT02539901|Behavioral|psychomotor infancy development scale|
215510|NCT02539901|Behavioral|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
215511|NCT02539875|Behavioral|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
215512|NCT02539862|Other|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
215513|NCT02539862|Other|psychoeducation|the psychoeducation is delivered by a doctor
215514|NCT02539849|Dietary Supplement|FOS|
215515|NCT02539849|Drug|Adalimumab|
215516|NCT02539836|Dietary Supplement|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
215517|NCT02539836|Diagnostic Test|MRI in quantifying liver fat with MRS|To investigate the accuracy of MRI in quantifying liver fat with magnetic resonance spectroscopy (MRS) as a reference.
215518|NCT02539823|Drug|CBD 400 mg|Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
215519|NCT02539823|Drug|CBD 800 mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
215520|NCT02539823|Drug|Control (placebo)|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
215521|NCT02539810|Device|Renal artery Angioplasty plus stenting.|renal artery stenting
215522|NCT02539810|Drug|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is < 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
215523|NCT02539797|Device|tDCS|comparing anodal, cathodal, and sham tDCS
215524|NCT02539784|Device|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
215525|NCT02539771|Other|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
215582|NCT02539381|Device|Digital visual field assessment|
215583|NCT02539381|Device|Digital line crossing assessment|
215584|NCT02539381|Device|Digital shape cancellation assessment|
215526|NCT02539758|Other|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
215527|NCT02539758|Device|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
215528|NCT02539758|Device|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
215529|NCT02539745|Other|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
215530|NCT02539745|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
215531|NCT02539719|Drug|SC-003|
215532|NCT02539719|Drug|SC-003 in combination with ABBV-181|
215533|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
215534|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
215535|NCT02539693|Drug|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
215536|NCT02539693|Drug|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
215537|NCT02539693|Drug|Lidocaine|3 ml lidocaine 1% is injected at each block site
215538|NCT02539693|Procedure|Pilonidal sinus|Removal of pilonidal sinus
215539|NCT02539680|Procedure|endoscopy|duodenal biopsies
215540|NCT02539654|Drug|EXE844 Sterile Otic Suspension, 0.3%|
215541|NCT02539654|Procedure|Tympanostomy Tube Insertion|
215542|NCT02539641|Radiation|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
215543|NCT02539641|Other|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
215544|NCT02539628|Drug|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
215545|NCT02539615|Device|ForeCYTE Breast Aspirator|
215546|NCT02539602|Behavioral|The Need to Know students received the N2K curriculum as described previously|
215547|NCT02539589|Behavioral|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
215548|NCT02539589|Behavioral|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
215549|NCT02539576|Drug|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
215550|NCT02539563|Other|peanut shaped birthing ball|peanut ball will be utilized
215551|NCT02539550|Drug|Placebo|Placebo
215552|NCT02539550|Drug|PF-06266047|PF-06266047
215553|NCT02539537|Drug|Gemcitabine|
215554|NCT02539537|Drug|Folinic Acid|
215555|NCT02539537|Drug|5-Fluoro-uracil|
215556|NCT02539537|Drug|Oxaliplatin|
215557|NCT02539537|Drug|Irinotecan|
215558|NCT02539537|Drug|L-folinic|
215559|NCT02539524|Other|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
215560|NCT02539524|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
215561|NCT02539511|Drug|CI-581a|
215562|NCT02539511|Drug|CI-581b|
215563|NCT02539511|Behavioral|Motivational Enhancement Therapy (MET)|
215564|NCT02539498|Device|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
215565|NCT02539485|Other|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
215566|NCT02539472|Other|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
215567|NCT02539459|Drug|Everolimus|10 mg tablets
215568|NCT02539446|Behavioral|stable condition|
215569|NCT02539446|Behavioral|unstable condition|
215570|NCT02539446|Behavioral|attentional focus|
215571|NCT02539433|Procedure|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
215572|NCT02539420|Device|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
215573|NCT02539407|Other|Pharmacokinetics|
215574|NCT02539394|Drug|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
215575|NCT02539394|Other|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
215576|NCT02539381|Procedure|Formal Perimetry (Goldman or Octopus visual Field)|
215577|NCT02539381|Procedure|Albert's visual inattention test|
215578|NCT02539381|Procedure|Star cancellation visual inattention test|
215579|NCT02539381|Procedure|Visual field assessment to confrontation|
215585|NCT02539368|Drug|CT-P13|biosimilar infliximab
215586|NCT02539368|Drug|Remicade|infliximab
215587|NCT02539355|Other|Diet A|12-week diet
215588|NCT02539355|Other|Diet B|12-week Diet
215589|NCT02539342|Drug|Caphosol|"Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:~Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.~o Participants may increase the use to 6 times per day if you have symptoms of mucositis.~Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.~For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.~For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.~Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.~Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed"
215590|NCT02539342|Drug|Biotene|"• Use 5 to 10 mL of Biotene to swish and spit~o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab."
215591|NCT02539329|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
215592|NCT02539316|Drug|Smoflipid|
215593|NCT02539316|Drug|Médialipides|
215594|NCT02539303|Drug|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
215595|NCT02539290|Behavioral|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
215596|NCT02539290|Procedure|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
215597|NCT02539290|Procedure|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
215598|NCT02539290|Behavioral|Sexual intercourse|Sexual intercourse within 12 hours after intervention
215599|NCT02539277|Drug|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
215600|NCT02539277|Drug|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
215601|NCT02539277|Drug|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
215602|NCT02539277|Drug|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
215603|NCT02539264|Other|Smoking|Influence of smoking on parameters derived from overnight PSG
215604|NCT02539264|Other|Obesity|Influence of obesity on parameters derived from overnight PSG
215605|NCT02539264|Other|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
215606|NCT02539251|Behavioral|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
215607|NCT02539238|Other|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
215608|NCT02539225|Drug|Ramucirumab|Administered IV
215609|NCT02539225|Drug|Placebo|Administered IV
215610|NCT02539225|Drug|S-1|Administered PO
215611|NCT02539225|Drug|Oxaliplatin|Administered IV
215612|NCT02539225|Drug|Paclitaxel|Administered IV
215613|NCT02539212|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
215614|NCT02539212|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
215615|NCT02539199|Drug|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
215616|NCT02539199|Drug|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
215617|NCT02539186|Biological|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
215618|NCT02539186|Device|splint|
215619|NCT02539173|Other|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.~It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
215620|NCT02539160|Drug|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
215621|NCT02539147|Biological|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
215622|NCT02539134|Drug|TAK-935|TAK-935 oral solution
215623|NCT02539134|Drug|Placebo|TAK-935 placebo-matching oral solution
215624|NCT02539121|Device|Acupuncture|Acupuncture needles
215625|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
215626|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
215627|NCT02539095|Device|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
215628|NCT02539095|Device|Normal saline|"Supplementation of fluid and electrolytes (sodium or chlorine deficiency)~Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
215629|NCT02539082|Device|Regenseal|Regenseal, collagen, injection in the defect area
215630|NCT02539082|Drug|normal saline|placebo, normal saline, injection in the defect area
215631|NCT02539069|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
215632|NCT02539056|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
215633|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
215634|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
215635|NCT02539030|Procedure|Microfracture|simple microfracture
215636|NCT02539030|Device|CartiFill|add collagen when doing microfracture
215637|NCT02539017|Drug|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
215638|NCT02539017|Biological|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
215639|NCT02539004|Other|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
215640|NCT02538991|Device|Bulkamid|"Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.~Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation."
215641|NCT02538991|Device|Tension-free Vaginal Tape|TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
215642|NCT02538978|Biological|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.~Device: SurgWerks-CLI Kit~Device: VXP System"
215643|NCT02538978|Biological|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
215644|NCT02538965|Drug|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
215645|NCT02538952|Device|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
215646|NCT02538952|Other|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
215647|NCT02538939|Drug|Sodium thiosulfate|
215648|NCT02538926|Drug|Asparaginase|Given IM or IV
215649|NCT02538926|Drug|Cyclophosphamide|Given IV
215650|NCT02538926|Drug|Doxorubicin Hydrochloride|Given IV
215651|NCT02538926|Drug|Etoposide|Given IV
215652|NCT02538926|Drug|Imatinib Mesylate|Given PO
215653|NCT02538926|Other|Laboratory Biomarker Analysis|Correlative studies
215654|NCT02538926|Drug|Prednisone|Given PO
215655|NCT02538926|Biological|Rituximab|Given IV
215656|NCT02538926|Drug|Vincristine Sulfate|Given IV
215657|NCT02538913|Behavioral|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
215658|NCT02538913|Procedure|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
215693|NCT02538679|Drug|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
215659|NCT02538900|Behavioral|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
215660|NCT02538900|Other|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
215661|NCT02538887|Device|Radio Frequency Surgical Detection|
215662|NCT02538874|Drug|BMS-986171|
215663|NCT02538874|Other|Placebo|
215664|NCT02538861|Radiation|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
215665|NCT02538861|Radiation|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
215666|NCT02538861|Radiation|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
215667|NCT02538848|Drug|HTD4010|injectable solution
215668|NCT02538835|Behavioral|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
215669|NCT02538835|Behavioral|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel & Segal.
215670|NCT02538835|Behavioral|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
215671|NCT02538822|Device|dynamic imaging|In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
215672|NCT02538822|Device|mechanical testing|In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
215673|NCT02538809|Other|measurement of tumor mRNA concentration in urine|bed-side test of tumor mRNA concentration in urine
215674|NCT02538796|Other|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
215675|NCT02538796|Other|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
215676|NCT02538796|Other|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
215677|NCT02538796|Other|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.~The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.~The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
215678|NCT02538783|Behavioral|Escalating Lottery|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
215679|NCT02538770|Other|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
215680|NCT02538770|Other|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
215681|NCT02538744|Drug|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
215682|NCT02538744|Drug|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 [placebo], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
215683|NCT02538744|Drug|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
215684|NCT02538744|Drug|Placebo|
215685|NCT02538731|Procedure|dilation-assisted stone extraction|
215686|NCT02538731|Device|Spyglass Guided Laser Lithotrips|
215687|NCT02538718|Drug|MgSO4|
215688|NCT02538718|Drug|YTP(Ritodrine)|
215689|NCT02538705|Drug|Neovasculgen|
215690|NCT02538692|Drug|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
215691|NCT02538692|Drug|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
215692|NCT02538679|Other|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
216030|NCT02536248|Drug|Placebo|Placebo for 6 weeks
215694|NCT02538679|Drug|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
215695|NCT02538666|Biological|Nivolumab|
215696|NCT02538666|Biological|Ipilimumab|
215697|NCT02538666|Other|Placebo|
215698|NCT02538653|Other|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
215699|NCT02538653|Other|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
215700|NCT02538640|Other|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
215701|NCT02538640|Other|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
215702|NCT02538627|Drug|MM-151|MM-151
215703|NCT02538627|Drug|MM-121|MM-121
215704|NCT02538627|Drug|MM-141|MM-141
215705|NCT02538627|Drug|trametinib|trametininb
215706|NCT02538614|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
215707|NCT02538614|Drug|BI 836826|BI 836826 will be administered intravenously from Week 2 through Week 46.
215708|NCT02538601|Behavioral|CBT-A|"CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., I will lose control.); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking)."
215709|NCT02538601|Behavioral|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
215710|NCT02538588|Device|Nebulizer 1|
215711|NCT02538588|Device|Nebulizer 2|
215712|NCT02538575|Other|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
215713|NCT02538549|Behavioral|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
215714|NCT02538536|Drug|PBI4050|
215715|NCT02538510|Other|Laboratory Biomarker Analysis|Correlative studies
215716|NCT02538510|Biological|Pembrolizumab|Given IV
215717|NCT02538510|Drug|Vorinostat|Given PO or via PEG
215718|NCT02538497|Behavioral|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.~The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
215719|NCT02538497|Behavioral|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
215720|NCT02538484|Drug|Letrozole|Aromatase inhibitor
215721|NCT02538484|Dietary Supplement|Fish Oil|Omega-3 free fatty acid
215722|NCT02538471|Radiation|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
215723|NCT02538471|Drug|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
215724|NCT02538458|Drug|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
215725|NCT02538458|Drug|3 % hypertonic saline up to 24H|"Treatment by inhalation of 3 % hypertonic saline, up to 24H.~followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
215726|NCT02538445|Other|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
215727|NCT02538445|Other|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
215728|NCT02538445|Other|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
215729|NCT02538445|Other|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
215730|NCT02538432|Drug|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
215731|NCT02538432|Drug|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
215732|NCT02538419|Behavioral|CPAP + Peer Support|
215733|NCT02538419|Behavioral|CPAP + Individual Education|
215734|NCT02538406|Other|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
215735|NCT02538393|Drug|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state in Treatment A
215736|NCT02538393|Drug|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
215737|NCT02538380|Procedure|EUS-B-FNA followed by EUS-FNA for LAG analysis|
215738|NCT02538367|Drug|YH12852 IR 0.05mg|
215739|NCT02538367|Drug|YH12852 IR 0.1mg|
215740|NCT02538367|Drug|YH12852 IR 0.3mg|
215741|NCT02538367|Drug|YH12852 IR 0.5mg|
215742|NCT02538367|Drug|YH12852 IR 1mg|
215743|NCT02538367|Drug|YH12852 IR 2mg|
215744|NCT02538367|Drug|YH12852 IR 3mg|
215745|NCT02538367|Drug|YH12852 DR1 0.5mg|
215746|NCT02538367|Drug|YH12852 DR1 1mg|
215747|NCT02538367|Drug|YH12852 DR1 2mg|
215748|NCT02538367|Drug|YH12852 DR1 4mg|
215749|NCT02538367|Drug|YH12852 DR2 8mg|
215750|NCT02538367|Drug|Prucalopride 2mg|
215751|NCT02538367|Drug|Placebo|
215752|NCT02538354|Dietary Supplement|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
215753|NCT02538341|Biological|Herpes Zoster Vaccine|
215754|NCT02538341|Drug|Placebo|
215755|NCT02538328|Device|Harmonic scapel|different surgical devices used in the obesity surgery
215756|NCT02538328|Device|Ligasure|Bipolar vessel sealing system used in obesity surgery
215757|NCT02538315|Drug|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by [18F]FDOPA PET/CT imaging
215758|NCT02538302|Drug|Minirin|Minirin 5 to 10 mg daily for 6 months
215759|NCT02538302|Drug|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
215760|NCT02538289|Behavioral|Teaching talks|Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
215761|NCT02538263|Device|Volume-targeted noninvasive ventilation|
215762|NCT02538250|Dietary Supplement|Nutricomp Drink Plus|Oral nutritional supplementation
215763|NCT02538237|Drug|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
215764|NCT02538237|Drug|Ibuprofen 2% mouthwash|
215765|NCT02538224|Drug|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs"
215766|NCT02538224|Drug|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
215767|NCT02538211|Biological|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
215768|NCT02538198|Drug|Lenalidomide|
215769|NCT02538185|Device|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
215770|NCT02538185|Device|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
215771|NCT02538185|Device|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
215772|NCT02538185|Drug|Vaccin rabique Pasteur®|
215773|NCT02538185|Drug|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
215774|NCT02538172|Other|T-Track® CMV assay|
215775|NCT02538159|Device|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
215776|NCT02538159|Device|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
215777|NCT02538146|Dietary Supplement|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
215778|NCT02538133|Biological|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
215779|NCT02538120|Other|Microvascular assessment|Microvascular assessment
215780|NCT02538107|Drug|Methoxy-polyethyleneglycol epoetin beta|
215781|NCT02538094|Device|Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes or sham stimulation using Neuro-Conn Direct Current (DC) Stimulator Plus
215782|NCT02538081|Drug|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
215783|NCT02538081|Drug|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
215784|NCT02538068|Behavioral|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
215785|NCT02538068|Behavioral|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
215786|NCT02538055|Behavioral|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
215787|NCT02538055|Behavioral|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
215788|NCT02538042|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking <10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked <10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
215789|NCT02538042|Drug|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
215790|NCT02538042|Behavioral|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
215791|NCT02538042|Behavioral|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
215792|NCT02538029|Behavioral|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
215793|NCT02538029|Behavioral|Single Task Group|Performing motor or cognitive tasks alone.
215794|NCT02538016|Drug|Tolvaptan|
215795|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
215796|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
215797|NCT02537977|Biological|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
215798|NCT02537964|Other|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
215799|NCT02537951|Device|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
215800|NCT02537951|Device|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
215801|NCT02537951|Device|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
215802|NCT02537938|Drug|NGP 555|
215803|NCT02537925|Drug|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
215804|NCT02537925|Drug|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
215805|NCT02537925|Radiation|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68~74 Gy for primary tumor (2.0~2.3 Gy/f/day, 5 day/ week, /6~7 weeks), and 50~54 Gy for lymphatic positive area (1.8 ~ 2 Gy/f/day, 5 day/week, /5.0~5.5 weeks).
215806|NCT02537912|Dietary Supplement|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
215807|NCT02537912|Dietary Supplement|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
215808|NCT02537899|Drug|NeuroAiD|
215809|NCT02537886|Device|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
215810|NCT02537873|Drug|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
215811|NCT02537873|Drug|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
215812|NCT02537873|Drug|Placebo comparator|Dextrose in gelatin capsule
215813|NCT02537860|Other|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
215814|NCT02537860|Other|Placebo at T11 and L3|Two injections that contain saline are performed
215815|NCT02537860|Other|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
215816|NCT02537860|Procedure|Herniorrhaphy|Unilateral inguinal hernia repair
215817|NCT02537860|Drug|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
215818|NCT02537860|Drug|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
215819|NCT02537847|Drug|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
215820|NCT02537847|Drug|Ertapenem|Control group will be given ertapenem only for 10 days.
215821|NCT02537834|Drug|Tofogliflozin|
215822|NCT02537834|Drug|GLP-1 analogue|
215823|NCT02537795|Device|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
215824|NCT02537795|Procedure|anterior capsulotomy|
215825|NCT02537782|Device|Cardiac resynchronisation therapy|
215826|NCT02537782|Other|Echocardiography|
215827|NCT02537782|Other|Magnetic Resonance Imaging|
215828|NCT02537782|Other|Positron Emission Tomography|
215829|NCT02537769|Device|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
215830|NCT02537769|Procedure|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
215831|NCT02537756|Behavioral|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
215832|NCT02537730|Device|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
215833|NCT02537730|Device|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
215834|NCT02537730|Device|comfilcon A|contact lens
215835|NCT02537704|Behavioral|Group Lifestyle Balance Program|
215836|NCT02537691|Drug|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
215837|NCT02537691|Drug|LABA|LABA will be administered as per investigator discretion.
215838|NCT02537691|Drug|LTRA|LTRA will be administered as per investigator discretion.
215839|NCT02537691|Drug|LAMA|LAMA will be administered as per investigator discretion.
215840|NCT02537691|Drug|Theophylline|Theophylline will be administered as per investigator discretion.
215841|NCT02537691|Drug|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
215842|NCT02537678|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
215843|NCT02537678|Behavioral|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
215844|NCT02537665|Other|heating precondition|
215845|NCT02537652|Other|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
215846|NCT02537639|Device|Transesophageal echocardiography simulator|
215847|NCT02537626|Device|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
215848|NCT02537626|Device|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
215849|NCT02537613|Drug|Obinutuzumab|Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
215850|NCT02537613|Drug|Ibrutinib|Ibrutinib given once daily by mouth
215851|NCT02537600|Drug|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
215852|NCT02537587|Other|Control 1|67g of control bar
215853|NCT02537587|Other|Control 2|86g of control bar
215854|NCT02537587|Other|15/0|66g of experimental bar 15/0
215855|NCT02537587|Other|15/0LS|84g of experimental bar 15/0LS
215856|NCT02537587|Other|15/5|75g of experimental bar 15/5
215857|NCT02537587|Other|10/5|72g of experimental bar 10/5
215858|NCT02537587|Other|10/10|80g of experimental bar 10/10
215859|NCT02537574|Drug|NTX/BUP|Daily doses
215860|NCT02537574|Drug|NTX/PBO-B|Daily doses
215861|NCT02537574|Drug|PBO-N/PBO-B|Daily doses
215862|NCT02537561|Drug|Cisplatin|
215863|NCT02537561|Drug|Gemcitabine|
215864|NCT02537561|Drug|Talazoparib|
215865|NCT02537548|Other|Laboratory Biomarker Analysis|Correlative studies
215866|NCT02537548|Procedure|Retroperitoneal Lymph Node Dissection|Undergo RPLND
215867|NCT02537535|Other|survey|This is a cross-sectional study without specific intervention
215868|NCT02537522|Device|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
215869|NCT02537522|Device|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
215870|NCT02537509|Drug|Cholecalciferol|
215871|NCT02537509|Drug|Placebo of cholecalciferol|
215872|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
215873|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
215874|NCT02537483|Drug|IDP-120 Gel|Investigational Product: IDP-120 Gel
215875|NCT02537483|Drug|IDP-120 Component A|Comparator Product: IDP-120 Component A
215876|NCT02537483|Drug|IDP-120 Component B|Comparator Product: IDP-120 Component B
215877|NCT02537483|Drug|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
215878|NCT02537470|Drug|Biphasic Remogliflozin Etabonate|Experimental Drug
215879|NCT02537470|Other|Placebo|Placebo Comparator
215880|NCT02537457|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
215881|NCT02537457|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
215882|NCT02537444|Drug|Acalabrutinib|
215883|NCT02537444|Drug|acalabrutinib and pembrolizumab combination|
215884|NCT02537431|Biological|burosumab|solution for subcutaneous injection
215885|NCT02537418|Drug|durvalumab|
215886|NCT02537418|Drug|tremelimumab|
215887|NCT02537405|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
215888|NCT02537405|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
215889|NCT02537392|Dietary Supplement|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
215890|NCT02537392|Dietary Supplement|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
215891|NCT02537392|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid.
215892|NCT02537379|Drug|SOF|SOF 400 mg tablets administered orally once daily
215893|NCT02537379|Drug|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
215894|NCT02537366|Drug|Dexmedetomidine|
215895|NCT02537366|Drug|Placebo|
215896|NCT02537353|Device|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
215897|NCT02537353|Drug|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
215898|NCT02537353|Procedure|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
215899|NCT02537353|Drug|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
215900|NCT02537314|Drug|benzocaine|0.5% benzocaine solution in saline/hydrochloric acid administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
215901|NCT02537314|Other|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
215902|NCT02537301|Other|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
215903|NCT02537288|Drug|Fedovapagon|
215904|NCT02537288|Drug|Moxifloxacin|
215905|NCT02537288|Drug|Placebo (for fedovapagon)|
215906|NCT02537275|Device|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
215907|NCT02537275|Device|EyeLIKe Shine, Koryo Eyetech Co|clear lens
215908|NCT02537262|Dietary Supplement|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM~MN) the day before the surgery and 200ml three hours before the surgery.
215909|NCT02537262|Dietary Supplement|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
215910|NCT02537249|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
215911|NCT02537249|Drug|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
215912|NCT02537236|Dietary Supplement|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
215913|NCT02537236|Behavioral|TLC nutritional intervention|nutritional orientation.
215914|NCT02537236|Dietary Supplement|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
215915|NCT02537223|Drug|BYL719|
215916|NCT02537223|Drug|Cisplatin|
215917|NCT02537223|Radiation|Intensity modulated radiation therapy (IMRT)|
215918|NCT02537210|Drug|Mesalazine|Patients will be prescribed Asacol 2g daily for 12 months
215919|NCT02537210|Drug|Placebo oral capsule|Patients will be prescribed placebo 5 capsules daily for 12 months
215920|NCT02537197|Drug|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
215921|NCT02537184|Procedure|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
215922|NCT02537171|Drug|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
215923|NCT02537158|Drug|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
215924|NCT02537158|Procedure|TACE|TACE group patients will accept TACE therapy once at a month after resection.
215925|NCT02537132|Other|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
215926|NCT02537119|Procedure|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
215927|NCT02537119|Procedure|Massage therapy|Rubbing on hamstrings
215976|NCT02536755|Drug|eliglustat GZ385660|"Pharmaceutical form: capsule~Route of administration: oral"
216031|NCT02536235|Other|heat|activated heating pad to lower abdomen
215928|NCT02537106|Procedure|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
215929|NCT02537106|Procedure|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
215930|NCT02537093|Behavioral|Psychiatric Consultation|
215931|NCT02537080|Drug|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
215932|NCT02537080|Drug|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
215933|NCT02537067|Drug|CHONDRON|"Harvesting of ankle or knee cartilage~The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue."
215934|NCT02537054|Drug|Aflibercept|Intravitreal injection
215935|NCT02537041|Procedure|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
215936|NCT02537041|Procedure|MRI|
215937|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
215938|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
215939|NCT02537028|Drug|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
215940|NCT02537015|Drug|Bimatoprost|Bimatoprost Ocular Insert in each eye used continuously for 12 weeks, then replaced with a new Bimatoprost Ocular Insert in each eye used continuously for another 26 weeks.
215941|NCT02537002|Drug|PF-05230907|A single intravenous dose of 3 μg/kg
215942|NCT02537002|Drug|PF-05230907|A single intravenous dose of 5 μg/kg
215943|NCT02537002|Drug|Placebo|A single intravenous dose of matched placebo
215944|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
215945|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
215946|NCT02536976|Drug|mirabegron|
215947|NCT02536976|Drug|Placebo|
215948|NCT02536963|Device|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
215949|NCT02536963|Other|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
215950|NCT02536950|Device|Fixed set point|Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.
215951|NCT02536950|Device|Variable set point|Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
215952|NCT02536937|Drug|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
215953|NCT02536924|Behavioral|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
215954|NCT02536924|Behavioral|Treatment as usual.|The patient will receive treatment as usual.
215955|NCT02536911|Drug|eliglustat|"Pharmaceutical form: capsule~Route of administration: oral"
215956|NCT02536898|Other|Fracture Liaison Service|
215957|NCT02536898|Other|Current treatment|
215958|NCT02536885|Procedure|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
215959|NCT02536885|Procedure|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
215960|NCT02536872|Other|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
215961|NCT02536859|Drug|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
215962|NCT02536859|Drug|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
215963|NCT02536846|Drug|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
215964|NCT02536833|Drug|SM04690|
215965|NCT02536833|Drug|Placebo|
215966|NCT02536820|Behavioral|psychoneuroimmune therapy|
215967|NCT02536820|Drug|Conventional treatment|Actual diabetes treatment in each participant
215968|NCT02536807|Drug|Hyaluronan|HA gel injection
215969|NCT02536794|Biological|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
215970|NCT02536794|Other|Laboratory Biomarker Analysis|Correlative studies
215971|NCT02536794|Other|Pharmacological Study|Correlative studies
215972|NCT02536794|Biological|Tremelimumab|Given IV
215973|NCT02536781|Drug|Anthocyanin|Anti-inflammation gel
215974|NCT02536781|Drug|Placebo|Blank gel
215975|NCT02536768|Behavioral|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
216145|NCT02535403|Behavioral|ICBT|
215977|NCT02536742|Drug|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
215978|NCT02536742|Drug|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
215979|NCT02536729|Drug|Oral Sodium Phosphate - Normal preparation|
215980|NCT02536729|Drug|Oral sodium phosphate - Modified Preparation|
215981|NCT02536729|Drug|polyethylene glycol + Electrolytes|
215982|NCT02536716|Procedure|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
215983|NCT02536716|Procedure|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
215984|NCT02536703|Device|Lotus Valve System|Lotus Valve System
215985|NCT02536690|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
215986|NCT02536690|Drug|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
215987|NCT02536690|Drug|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
215988|NCT02536664|Drug|Rituximab|
215989|NCT02536651|Procedure|Ankle surgery|Plastic or orthopedic surgery of the ankle
215990|NCT02536638|Other|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
215991|NCT02536625|Other|prospective study|
215992|NCT02536612|Other|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
215993|NCT02536612|Other|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
215994|NCT02536586|Drug|LY3023414|LY3023414 administered orally.
215995|NCT02536573|Other|Radlink Surgical Positioning Software|
215996|NCT02536547|Device|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
215997|NCT02536534|Other|Correlation assessment|
215998|NCT02536508|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
215999|NCT02536508|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
216000|NCT02536508|Drug|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
216001|NCT02536495|Drug|Docetaxel|Given IV
216002|NCT02536495|Other|Laboratory Biomarker Analysis|Correlative studies
216003|NCT02536495|Other|Pharmacological Study|Correlative studies
216004|NCT02536495|Drug|Selinexor|Given PO
216005|NCT02536482|Dietary Supplement|Amix|Treat the children with cow`s milk allergy for 5 months.
216006|NCT02536469|Drug|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
216007|NCT02536430|Drug|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
216008|NCT02536430|Drug|Placebo|buccal infiltration of Normal Saline.
216009|NCT02536417|Drug|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
216010|NCT02536417|Drug|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
216011|NCT02536404|Drug|Etrasimod|
216012|NCT02536404|Drug|Placebo|
216013|NCT02536391|Drug|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
216014|NCT02536391|Drug|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
216015|NCT02536365|Behavioral|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
216016|NCT02536365|Behavioral|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
216017|NCT02536352|Drug|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
216018|NCT02536352|Dietary Supplement|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
216019|NCT02536339|Drug|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
216020|NCT02536339|Drug|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
216021|NCT02536326|Device|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
216022|NCT02536313|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
216023|NCT02536313|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
216024|NCT02536300|Drug|Idelalisib|Idelalisib tablet administered orally
216025|NCT02536287|Procedure|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
216026|NCT02536287|Procedure|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1*1 *1 mm,and placed into the subcutaneous of the forearm.
216027|NCT02536274|Device|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
216028|NCT02536274|Device|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
216029|NCT02536248|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
216032|NCT02536222|Other|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
216033|NCT02536209|Drug|MT-8554 low dose|
216034|NCT02536209|Drug|MT-8554 high dose|
216035|NCT02536209|Drug|Oxycodone hydrochloride|
216036|NCT02536209|Drug|Placebo|
216037|NCT02536196|Device|Embolic Protection Device|Embolic protection
216038|NCT02536196|Procedure|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
216039|NCT02536183|Device|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
216040|NCT02536183|Drug|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
216041|NCT02536170|Drug|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
216042|NCT02536170|Drug|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
216043|NCT02536170|Other|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
216044|NCT02536157|Device|Thermoplastic splinting|
216045|NCT02536144|Procedure|magnetic-controlled capsule endoscopy system|"A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.~The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.~While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.~The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
216046|NCT02536144|Procedure|Colonoscopy|"Bowel preparation should be well done before the examination.~A tube with illumination and camera system would insert into colon from anus.~From the pictures captured by the camera ,the doctor would see the mucous of the colon."
216047|NCT02536131|Other|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
216048|NCT02536118|Device|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
216049|NCT02536105|Drug|Methylphenidate HCl ER tablets 1|
216050|NCT02536105|Drug|Placebo|
216051|NCT02536105|Drug|Methylphenidate HCl ER tablets 2|
216052|NCT02536105|Drug|Methylphenidate HCl ER for suspension|
216053|NCT02536092|Device|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
216054|NCT02536079|Drug|NeuroAiD|
216055|NCT02536066|Behavioral|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
216056|NCT02536053|Procedure|Limb salvage|
216057|NCT02536040|Drug|38% diammine silver fluoride|treatment of cavity with study agent
216058|NCT02536040|Other|Water|Fluoride free, distilled water
216059|NCT02536027|Procedure|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
216060|NCT02536014|Drug|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
216061|NCT02536014|Drug|Saline|Saline infusion during the same time period
216062|NCT02536001|Device|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
216063|NCT02536001|Device|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
216064|NCT02535988|Radiation|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
216065|NCT02535988|Drug|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
216066|NCT02535975|Drug|Metformin|Tablets metformin 500 mg PO three times a day for 24 weeks
216067|NCT02535975|Drug|Placebo|Tablets placebo PO three times a day for 24 weeks
216068|NCT02535962|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
216069|NCT02535962|Other|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
216070|NCT02535949|Drug|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
216071|NCT02535949|Other|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
216072|NCT02535936|Procedure|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
216073|NCT02535923|Behavioral|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
216074|NCT02535923|Behavioral|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
216075|NCT02535910|Dietary Supplement|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
216076|NCT02535910|Dietary Supplement|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
216077|NCT02535910|Dietary Supplement|Control|Subjects are asked to consume a breakfast without vitamin D
216078|NCT02535897|Dietary Supplement|Flavoured water|
216079|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate|
216080|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate + protein|
216081|NCT02535884|Device|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
216082|NCT02535871|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
216083|NCT02535871|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
216084|NCT02535858|Device|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
216085|NCT02535858|Device|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
216086|NCT02535845|Behavioral|Project Voice|Project Voice tablet-based intervention plus informational video
216087|NCT02535845|Behavioral|HPV Informational Video|Informational video only
216088|NCT02535832|Drug|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
216089|NCT02535832|Drug|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
216090|NCT02535819|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
216091|NCT02535819|Procedure|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
216092|NCT02535806|Drug|Velcade|4 doses of study drug will be given.
216093|NCT02535806|Drug|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
216094|NCT02535806|Drug|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
216095|NCT02535806|Drug|Dexamethasone|Days 1-5 and 15-19
216096|NCT02535806|Drug|Mitoxantrone|Days 1 and 2
216097|NCT02535806|Drug|Vincristine|Days 1, 8, 15, 22
216098|NCT02535806|Drug|Pegaspargase|Days 3 and 17
216099|NCT02535793|Other|blood test (four dry tubes 7ml) and prick tests|
216100|NCT02535780|Procedure|Transcranial magnetic stimulation|TMS
216101|NCT02535780|Procedure|Transcranial direct current stimulation|tDCS
216102|NCT02535767|Drug|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
216103|NCT02535754|Behavioral|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
216104|NCT02535754|Behavioral|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
216105|NCT02535754|Behavioral|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
216106|NCT02535741|Device|Triathlon CR Total Knee System|Primary total knee replacement
216192|NCT02535143|Other|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
216107|NCT02535715|Drug|ORMD-0801 capsules- 2x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
216108|NCT02535715|Drug|ORMD-0801 capsules- 3x8mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
216109|NCT02535715|Drug|ORMD-0801 capsules- 1x16mg|Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
216110|NCT02535702|Other|MRI|used for the analysis of fMRI sequences
216111|NCT02535702|Other|Neurometer CPT/C|analyzation of subject response
216112|NCT02535689|Drug|Tofacitinib|Oral administration of tofacitinib, 5 mg
216113|NCT02535689|Drug|Placebo|
216114|NCT02535676|Device|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
216115|NCT02535663|Dietary Supplement|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
216116|NCT02535663|Dietary Supplement|Placebo|Same product without RG
216117|NCT02535650|Drug|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
216118|NCT02535637|Other|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
216119|NCT02535624|Procedure|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
216120|NCT02535624|Procedure|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
216121|NCT02535611|Drug|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
216122|NCT02535611|Drug|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
216123|NCT02535598|Behavioral|Normal presentation|All the material will be presented as plain text.
216124|NCT02535598|Behavioral|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
216125|NCT02535598|Behavioral|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
216126|NCT02535598|Behavioral|Enhanced support|Participants are offered daily support through the internet from trained therapists.
216127|NCT02535585|Device|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
216128|NCT02535585|Device|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
216129|NCT02535572|Device|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
216130|NCT02535572|Device|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
216131|NCT02535559|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
216132|NCT02535533|Drug|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
216133|NCT02535533|Drug|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
216134|NCT02535533|Drug|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
216135|NCT02535533|Drug|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 (4000 mcg SLM) given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
216136|NCT02535507|Drug|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
216137|NCT02535494|Other|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
216138|NCT02535481|Device|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
216139|NCT02535481|Procedure|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
216140|NCT02535455|Behavioral|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
216141|NCT02535429|Other|massage|
216142|NCT02535416|Drug|ARC-520|
216143|NCT02535416|Drug|cetirizine|
216144|NCT02535416|Drug|diphenhydramine|
216146|NCT02535390|Behavioral|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
216147|NCT02535390|Behavioral|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
216148|NCT02535377|Other|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
216149|NCT02535364|Biological|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants received, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.~Part B: Participants who were eligible for treatment in Part B received two IV doses of JCAR015 CAR T cells separated by 14 to 28 days. JCAR015 infusion was preceded by lymphodepleting chemotherapy with cyclophosphamide alone or cyclophosphamide + fludarabine."
216150|NCT02535351|Drug|sunitinib or pazopanib|First-line treatment
216151|NCT02535351|Procedure|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
216152|NCT02535338|Drug|Erlotinib Hydrochloride|Given PO
216153|NCT02535338|Other|Laboratory Biomarker Analysis|Correlative studies
216154|NCT02535338|Drug|Onalespib Lactate|Given IV
216155|NCT02535338|Other|Pharmacological Study|Correlative studies
216156|NCT02535325|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
216157|NCT02535325|Drug|Cisplatin|Given IV
216158|NCT02535325|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
216159|NCT02535325|Drug|Methoxyamine|Given PO
216160|NCT02535325|Drug|Methoxyamine Hydrochloride|Given PO
216161|NCT02535325|Drug|Pemetrexed|Given IV
216162|NCT02535325|Drug|Pemetrexed Disodium|Given IV
216163|NCT02535312|Drug|Cisplatin|Given IV
216164|NCT02535312|Drug|Methoxyamine|Given PO
216165|NCT02535312|Drug|Pemetrexed Disodium|Given IV
216166|NCT02535299|Drug|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
216167|NCT02535299|Drug|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
216168|NCT02535286|Drug|Umbralisib|A once daily oral agent
216169|NCT02535286|Biological|ublituximab|IV anti-CD20 monoclonal antibody
216170|NCT02535286|Biological|TG-1501|IV immunotherapy for cancer
216171|NCT02535273|Drug|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
216172|NCT02535273|Drug|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
216173|NCT02535273|Drug|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
216174|NCT02535273|Drug|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
216175|NCT02535273|Drug|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
216176|NCT02535273|Drug|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
216177|NCT02535247|Drug|MK-3475|
216178|NCT02535247|Drug|Copanlisib|
216179|NCT02535221|Drug|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
216180|NCT02535221|Drug|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
216181|NCT02535208|Other|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR < 0.73.
216182|NCT02535208|Other|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
216183|NCT02535195|Dietary Supplement|Ginger supplement|
216184|NCT02535195|Dietary Supplement|Placebo (starch)|
216185|NCT02535182|Other|Blood Draw|"Lab will draw one tube of blood to be stored in 8 mL BD Vacutainer CPT tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.~Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells."
216186|NCT02535169|Behavioral|Health Education and Coaching Strategy|Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
216187|NCT02535169|Behavioral|Dietary consult|A routine clinic-based dietary consult will be performed (approximately 1-hour).
216188|NCT02535156|Drug|Risperidone|1 mg Risperidone
216189|NCT02535156|Drug|Placebo|Lactose Placebo
216190|NCT02535143|Other|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
216191|NCT02535143|Drug|Taurine|250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
216240|NCT02534688|Drug|DMPA|
216193|NCT02535143|Dietary Supplement|Carbonated Apple Juice|250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
216194|NCT02535130|Device|Positive expiratory pressure|
216195|NCT02535130|Drug|amikacine nebulization|
216196|NCT02535117|Procedure|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
216197|NCT02535117|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
216198|NCT02535104|Drug|Ranpirnase|Topical application by subject
216199|NCT02535104|Drug|Vehicle|Vehicle control
216200|NCT02535091|Drug|YKP3089|see above
216201|NCT02535078|Drug|IMCgp100|soluble gp100-specific T cell receptor with anti-CD3 scFV
216202|NCT02535078|Drug|durvalumab|anti-PD-L1 monoclonal antibody
216203|NCT02535078|Drug|tremelimumab|anti-CTLA-4 monoclonal antibody
216204|NCT02535065|Device|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
216205|NCT02535052|Biological|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
216206|NCT02535039|Drug|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg * d for application to the third day after surgery
216207|NCT02535039|Other|Physiological saline|The same volume of physiological saline will be given in Placebo group
216208|NCT02535013|Device|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
216209|NCT02535000|Drug|Duloxetine|duloxetine 60 mg
216210|NCT02535000|Drug|Placebo|placebo
216211|NCT02534987|Other|iCPR2|clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
216212|NCT02534974|Device|NOSTEN|
216213|NCT02534961|Drug|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
216214|NCT02534948|Behavioral|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
216215|NCT02534935|Biological|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
216216|NCT02534935|Biological|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
216217|NCT02534922|Biological|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
216218|NCT02534909|Biological|LFG316|LFG316 will be administered to all patients enrolled in the study
216219|NCT02534896|Drug|Treatment I|Sunpharma1505 and Placebo
216220|NCT02534896|Drug|Treatment II|Sunpharma1505 and Placebo
216221|NCT02534896|Drug|Treatment III|Reference1505 and Placebo
216222|NCT02534883|Drug|Misoprostol|To be place vaginally
216223|NCT02534883|Drug|Placebo|To be placed vaginally
216224|NCT02534870|Drug|ABT-450/r/ABT-267|Tablet
216225|NCT02534870|Drug|ABT-333|Tablet
216226|NCT02534857|Procedure|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
216227|NCT02534844|Drug|VTS-270|Lumber intrathecal infusion of VTS-270 (dose to be selected after Part A)
216228|NCT02534844|Drug|Sham Procedure Control|No experimental drug administered to patients. All intrathecal administrations are simulated.
216229|NCT02534831|Procedure|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
216230|NCT02534818|Drug|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
216231|NCT02534818|Drug|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
216232|NCT02534792|Other|Revalvulation|
216233|NCT02534779|Other|Placebo Vaginal Insert|Placebo insert
216234|NCT02534753|Drug|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
216235|NCT02534740|Drug|tafamidis|relative bioavailability
216236|NCT02534740|Drug|tafamidis|fasted
216237|NCT02534740|Drug|tafamidis|fed
216238|NCT02534701|Device|ERIC® and SOFIA™|a self-expanding clot retrieval system
216239|NCT02534688|Drug|LNG-IUS|
216241|NCT02534662|Device|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
216242|NCT02534649|Procedure|Newly obtained biopsy and Blood samples collection|"For each patient:~Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
216243|NCT02534636|Drug|BMS-986165|
216244|NCT02534636|Drug|Interferon alpha-2a recombinant|
216245|NCT02534636|Drug|Famotidine|
216246|NCT02534636|Other|Placebo|
216247|NCT02534623|Procedure|Spinal anesthesia|
216248|NCT02534623|Procedure|General anesthesia|
216249|NCT02534623|Drug|bupivacaine|
216250|NCT02534623|Drug|fentanyl|
216251|NCT02534623|Drug|propofol|
216252|NCT02534623|Drug|sevoflurane|
216253|NCT02534610|Drug|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
216254|NCT02534610|Drug|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
216255|NCT02534597|Behavioral|Promotores Training|
216256|NCT02534597|Behavioral|Delayed Promotores training|
216257|NCT02534597|Behavioral|Caregiver training|
216258|NCT02534597|Behavioral|Delayed caregiver training|
216259|NCT02534597|Behavioral|Materials support|
216260|NCT02534597|Behavioral|Delayed materials support|
216261|NCT02534597|Behavioral|Technical assistance|
216262|NCT02534597|Behavioral|Delayed technical assistance|
216263|NCT02534571|Device|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 <=150g once
216264|NCT02534571|Device|Hemo-clipping|Hemo-clipping <=20 clips
216265|NCT02534571|Drug|Epinephrine|epinephrine injection endoscopically <20 mls
216266|NCT02534571|Device|thermo-coagulation|contact thermo-coagulation < = 4 pulses
216267|NCT02534558|Biological|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
216268|NCT02534545|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
216269|NCT02534545|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
216270|NCT02534532|Other|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
216271|NCT02534519|Other|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
216272|NCT02534506|Drug|Urelumab|
216273|NCT02534506|Drug|Nivolumab|
216274|NCT02534493|Device|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
216275|NCT02534480|Drug|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
216276|NCT02534467|Drug|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
216277|NCT02534454|Behavioral|Active Retraining|
216278|NCT02534454|Behavioral|Sham Retraining|
216279|NCT02534454|Device|Active transcranial direct current stimulation (TDCS)|
216280|NCT02534454|Device|Sham transcranial direct current stimulation (TDCS)|
216281|NCT02534454|Drug|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
216282|NCT02534441|Other|Skin patch test|
216283|NCT02534428|Other|wool clothing|superfine merino wool ensembles for baby wear
216284|NCT02534415|Drug|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
216285|NCT02534415|Drug|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
216286|NCT02534415|Drug|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
216287|NCT02534402|Drug|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
216288|NCT02534389|Dietary Supplement|omega-3 fish oil|2,4g of EPA + DHA
216289|NCT02534376|Drug|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
216290|NCT02534363|Drug|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
216291|NCT02534363|Drug|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
216292|NCT02534363|Drug|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
216364|NCT02533726|Other|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
216293|NCT02534363|Behavioral|Cognitive battery|Completed in the following standardized sequence: 1—the Rey Auditory Verbal Learning Test (RAVLT); 2—WAIS-III digit symbol subtest; 3—Grooved Pegboard Test; 4—The Zoo Map Test; 5—Tower of London Test (ToL); 6—Rey Complex Figure (RCF); 7—Trail Making Test (TMT); 8—WAIS-III digits forward and backward subtests; 9—WAIS-III letter-number sequencing subtest; 10—WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11—Stroop Test; 12—letter (FAS) and semantic (animal) fluency tests; 14—Eyes Task; 15—Continuous Performance Test (CPT).
216294|NCT02534350|Drug|Presatovir|Tablets administered orally or via nasogastric (NG) tube once daily
216295|NCT02534350|Drug|Placebo|Tablets administered orally or via NG tube once daily
216296|NCT02534337|Drug|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
216297|NCT02534337|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
216298|NCT02534324|Drug|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
216299|NCT02534311|Drug|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
216300|NCT02534298|Other|functional magnetic resonance imaging|functional magnetic resonance imaging
216301|NCT02534285|Device|hearing protection|Attenuation of hearing during surgery
216302|NCT02534272|Other|Stool sampling and sequencing of gut microbiota.|
216303|NCT02534259|Other|Force monitoring of external fixator struts|
216304|NCT02534246|Device|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) from single lesion.
216305|NCT02534246|Device|Ultrasound biopsy needle SharkCore|
216306|NCT02534233|Device|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
216307|NCT02534220|Device|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter & Gamble, Cincinnati, OH
216308|NCT02534220|Device|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter & Gamble, Cincinnati, OH
216309|NCT02534207|Drug|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
216310|NCT02534194|Other|Image acquisition|Images of baby's face (including ear) and feet
216311|NCT02534181|Drug|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
216312|NCT02534168|Device|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.~The device records sympathetic autonomous nervous system through its effect on skin.~The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
216313|NCT02534155|Device|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
216314|NCT02534155|Procedure|Mitral valve Surgery|Repair or replace mitral valve
216315|NCT02534129|Drug|Difinsa53|Difinsa53 cream is applied to one half of radiation field
216316|NCT02534129|Drug|Aquaphor|Aquaphor is applied to one half of radiation field
216317|NCT02534116|Procedure|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
216318|NCT02534116|Procedure|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
216319|NCT02534077|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
216320|NCT02534077|Drug|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
216321|NCT02534077|Drug|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
216322|NCT02534064|Dietary Supplement|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
216323|NCT02534064|Dietary Supplement|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
216324|NCT02534051|Other|Clinical Care Pathway|The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth & well-being, counselling about birth risks, and discussion of breastfeeding.
216325|NCT02534038|Drug|AVP-786|d6-DM/Q
216326|NCT02534038|Drug|Placebo|matching placebo
216327|NCT02534025|Procedure|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
216328|NCT02534012|Drug|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
216329|NCT02534012|Drug|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
216330|NCT02534012|Procedure|Major abdominal surgery|
216331|NCT02533999|Device|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
216332|NCT02533999|Device|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
216333|NCT02533986|Dietary Supplement|Berry peel drink|
216334|NCT02533986|Dietary Supplement|Control drink|
216335|NCT02533973|Drug|Xamiol® gel|
216336|NCT02533973|Drug|Daivonex® scalp solution|
216337|NCT02533960|Other|not applicable (observational study)|Observational study without study related intervention.
216338|NCT02533947|Behavioral|Exercise|The intervention consists of an individually tailored supervised exercise program with aerobic, strength and coordinative components.
216339|NCT02533947|Behavioral|Control|A waitlist control group will get the intervention after 7 month of treatment as usual.
216340|NCT02533934|Drug|Harvoni|Treatment of Hepatitis C with Harvoni
216341|NCT02533921|Other|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
216342|NCT02533921|Other|Standard of Care|Usual care defined as including both a PCP and neurologist
216343|NCT02533908|Drug|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
216344|NCT02533908|Drug|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
216345|NCT02533895|Biological|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
216346|NCT02533895|Other|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.~Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
216347|NCT02533882|Behavioral|Movement to Music|
216348|NCT02533882|Behavioral|Adapted Yoga|
216349|NCT02533869|Radiation|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
216350|NCT02533869|Procedure|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
216351|NCT02533856|Other|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
216352|NCT02533843|Procedure|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
216353|NCT02533830|Biological|sugarless gum|"One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
216354|NCT02533830|Other|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
216355|NCT02533817|Dietary Supplement|Dietary sugar|This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
216356|NCT02533791|Biological|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10^10vp/1ml per dose
216357|NCT02533791|Biological|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10^11vp/1ml per dose, with one dose to each arm at the same time
216358|NCT02533791|Biological|placebo|
216359|NCT02533778|Device|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
216360|NCT02533765|Drug|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
216361|NCT02533739|Behavioral|Cognitive and neuropsychological assesment|
216362|NCT02533726|Other|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
216363|NCT02533726|Other|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
216473|NCT02532855|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet
216365|NCT02533713|Device|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
216366|NCT02533700|Drug|CEOP/IVE/GDP chemotherapy regimen|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4"
216367|NCT02533700|Drug|CEOP chemotherapy regimen for 6 cycles|"CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2,PO,D1-D5 every 21 days for total 6 courses"
216368|NCT02533687|Procedure|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
216369|NCT02533687|Procedure|Bipolar TURP-2|Bipolar TURP
216370|NCT02533687|Procedure|Monopolar TURP|Monopolar TURP
216371|NCT02533674|Drug|Gemcitabine plus PM060184|
216372|NCT02533661|Other|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
216373|NCT02533648|Drug|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
216374|NCT02533648|Drug|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
216375|NCT02533635|Dietary Supplement|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
216376|NCT02533583|Device|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
216377|NCT02533570|Drug|Brentuximab vedotin|
216378|NCT02533570|Drug|Placebo|
216379|NCT02533557|Device|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.~1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
216380|NCT02533557|Drug|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
216381|NCT02533544|Drug|tenofovir disoproxil fumarate|
216382|NCT02533531|Device|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
216383|NCT02533518|Procedure|Rigid bronchoscopy with ultraviolet transmission|
216384|NCT02533518|Other|Biopsy|
216385|NCT02533505|Drug|Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
216386|NCT02533505|Drug|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
216387|NCT02533492|Device|vicryl|wound closure with vicryl suture
216388|NCT02533492|Device|Vicryl plus|wound closure with vicryl plus suture
216389|NCT02533479|Other|Caloric restriction|three alternate days weekly along 4 weeks.
216390|NCT02533466|Other|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
216391|NCT02533466|Other|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
216392|NCT02533453|Biological|Bydureon|exenatide once weekly
216393|NCT02533440|Procedure|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
216394|NCT02533440|Procedure|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
216395|NCT02533427|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857 (400/100/100 mg) FDC tablet administered orally once daily
216396|NCT02533427|Drug|GS-9857|GS-9857 100 mg tablet administered orally once daily
216397|NCT02533427|Drug|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
216398|NCT02533414|Device|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
216399|NCT02533414|Device|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
216400|NCT02533401|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
216401|NCT02533401|Drug|Fludarabine|Fludarabine will be administered IV at 25 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
216402|NCT02533401|Drug|Rituximab|Rituximab will be administered IV at 375 mg/m^2 on Day 1 of Cycle 1 and then at 500 mg/m^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
216438|NCT02533141|Drug|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
216439|NCT02533141|Other|Placebo|Placebo, once daily for 4 weeks
216440|NCT02533128|Drug|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 60 mmHg
216441|NCT02533128|Drug|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 75 mmHg
216403|NCT02533388|Device|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
216404|NCT02533388|Device|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
216405|NCT02533375|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
216406|NCT02533362|Drug|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
216407|NCT02533349|Drug|Motilitone|30mg, 1 tablet, 3 times a day
216408|NCT02533349|Drug|Pantoprazole|40mg, 1 tablet, 1time a day
216409|NCT02533349|Drug|Placebo|30mg, 1 tablet, 3 times a day
216410|NCT02533336|Drug|abamectin and fenpyroximate|
216411|NCT02533323|Drug|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
216412|NCT02533323|Drug|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
216413|NCT02533323|Drug|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
216414|NCT02533310|Other|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
216415|NCT02533310|Other|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
216416|NCT02533297|Other|Providing clinical skills conditions|
216417|NCT02533284|Drug|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
216418|NCT02533284|Drug|bupevecaine|US guided TAP using Bupevecaine 0.25 %
216419|NCT02533284|Drug|saline|US guided TAP using placebo (saline)
216420|NCT02533271|Radiation|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
216421|NCT02533271|Radiation|Long-term chemoradiotherapy|Standard chemoradiotherapy
216422|NCT02533245|Other|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
216423|NCT02533245|Other|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
216424|NCT02533245|Other|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
216425|NCT02533232|Drug|Minocycline|Minocycline 200mg per day
216426|NCT02533219|Drug|18 F-DOPA|Subjects will undergo PET imaging with [18F]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of [18F]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
216427|NCT02533206|Procedure|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
216428|NCT02533206|Procedure|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
216429|NCT02533193|Procedure|ERAS perioperative cares|"Patient's preoperative counseling & education before surgery~No Bowel preparation~Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery~Fluid restriction & Management by pulse contour analysis or transesophageal doppler~Early mobilization~Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)~Intravenous patient controlled analgesics (no opioids analgesics)~Postoperative Nausea Active Control~No nasogastric tube~No drain insertion~Patients will be discharged at POD#4 if there's no problem"
216430|NCT02533193|Procedure|Conventional perioperative cares|"No Patient's preoperative counseling & education before surgery~Bowel preparation~No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~Conventional Mobilization~Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~IV PCA~Postoperative Nausea Control if needed~No Thromboembolism prophylaxis~No or Low Content Oxygen therapy~Drainage tube insertion if needed"
216431|NCT02533180|Biological|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.~CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.~Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.~If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
216432|NCT02533167|Other|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
216433|NCT02533154|Drug|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
216434|NCT02533154|Drug|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
216435|NCT02533154|Other|Bacterial culture|bacterial cultures obtained with conjunctival swabs
216436|NCT02533141|Device|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
216437|NCT02533141|Device|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
216442|NCT02533115|Drug|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.~CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
216443|NCT02533102|Drug|E7050|100 mg tablet administered orally
216444|NCT02533089|Other|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
216445|NCT02533076|Other|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
216446|NCT02533076|Other|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.~In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
216447|NCT02533076|Device|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
216448|NCT02533076|Device|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
216449|NCT02533063|Device|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
216450|NCT02533050|Device|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
216451|NCT02533037|Other|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
216452|NCT02533037|Other|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
216453|NCT02533024|Other|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
216454|NCT02533011|Other|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
216455|NCT02532998|Drug|AZD9977 oral suspension|AZD9977 oral suspension, single dose
216456|NCT02532998|Drug|AZD9977 placebo oral suspension|oral suspension, single dose
216457|NCT02532998|Drug|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
216458|NCT02532998|Drug|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
216459|NCT02532985|Other|Negative Control|No added fiber beverage
216460|NCT02532985|Other|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
216461|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
216462|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
216463|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
216464|NCT02532972|Device|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
216465|NCT02532959|Device|Diagnostic Breath Analysis|Conduct exhaled breath samples
216466|NCT02532946|Behavioral|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
216467|NCT02532933|Device|DePuy Synthes Attune PS RP|
216468|NCT02532907|Procedure|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
216469|NCT02532894|Device|Electronic cigarette|Inhaling e-cigarette vapor
216470|NCT02532881|Other|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
216471|NCT02532881|Other|Treatment as usual|Treatment as usual
216472|NCT02532868|Drug|MK-0457|
216474|NCT02532855|Drug|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
216475|NCT02532855|Drug|Metformin|This medication is a standard-of-care medication and is administered in an open-label fashion. Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
216476|NCT02532855|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
216477|NCT02532855|Drug|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
216478|NCT02532855|Drug|Sulfonylurea|This medication is a standard-of-care medication and is administered in an open-label fashion. The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
216479|NCT02532829|Other|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
216480|NCT02532816|Dietary Supplement|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).~Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
216481|NCT02532803|Other|Novel Pelvic MRI scan assessment|A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
216482|NCT02532790|Drug|Prednisone|1.5mg/kg/d
216483|NCT02532790|Drug|ACEI|0.2-0.3mg/kg/d
216484|NCT02532777|Drug|Prednisone|
216485|NCT02532777|Drug|Cyclophosphamide(CTX)|
216486|NCT02532777|Drug|Mycophenolate mofetil(MMF)|
216487|NCT02532777|Drug|Leflunomide(LEF)|
216488|NCT02532777|Drug|Angiotensin-converting enzyme inhibitor(ACEI)|
216489|NCT02532777|Drug|Methylprednisolone|
216490|NCT02532764|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
216491|NCT02532764|Drug|Placebo|Normal Saline
216492|NCT02532738|Drug|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
216493|NCT02532738|Biological|MSC treatment 01|Injection of 3×10E6/kg of MSC
216494|NCT02532738|Biological|MSC treatment 02|Injection of 6×10E6/kg of MSC
216495|NCT02532738|Other|NS|Injection of NS
216496|NCT02532725|Procedure|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
216497|NCT02532725|Procedure|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
216498|NCT02532725|Procedure|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
216499|NCT02532725|Procedure|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
216500|NCT02532712|Drug|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
216501|NCT02532712|Drug|Placebo|Placebo with same shape and size
216502|NCT02532699|Dietary Supplement|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
216503|NCT02532699|Dietary Supplement|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
216504|NCT02532686|Drug|DAAOI-2|500-2000mg/d, oral, for 6 weeks
216505|NCT02532686|Drug|placebo|oral, for 6 weeks
216506|NCT02532660|Drug|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
216507|NCT02532660|Drug|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
216508|NCT02532660|Drug|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
216509|NCT02532660|Drug|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
216510|NCT02532647|Drug|Remimazolam|
216511|NCT02532647|Drug|Midazolam|
216512|NCT02532647|Drug|Placebo|
216513|NCT02532634|Drug|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
216545|NCT02532348|Other|Blood samples|Blood samples
216514|NCT02532634|Drug|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
216515|NCT02532621|Device|Venous InterGraft Connector|This is a pivotal multicenter, prospective, non-randomized adaptive design study. The planned study enrollment is 104 evaluable subjects who require AV graft placement for hemodialysis and who meet the entry criteria. The subjects will receive the VIG device and will have either a standard sutured arterial anastomosis or have received an AIG device for the arterial anastomosis (VIG-AIG subgroup). This number may be expanded following a planned interim analysis to up to 185 evaluable subjects for the primary study evaluation.
216516|NCT02532608|Other|Acute sleep deprivation|Participants will stay awake for 36 hours
216517|NCT02532595|Procedure|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
216518|NCT02532595|Procedure|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
216519|NCT02532569|Biological|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
216520|NCT02532556|Device|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
216521|NCT02532543|Biological|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
216522|NCT02532543|Biological|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
216523|NCT02532543|Biological|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
216524|NCT02532543|Biological|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
216525|NCT02532530|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
216526|NCT02532517|Device|CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System|
216527|NCT02532504|Other|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;~Five Areas vicious circle~Bad thought spotter~Amazing Bad thought Busting Programme (ABTPB)~Easy 4 Step plan~Things you do that mess you up/Confidence sheet~Happy List/ Things you do that boost how you feel sheet~Planner and Review sheets"
216528|NCT02532491|Drug|Aripiprazole|Initial dose: 10 mg.
216529|NCT02532491|Drug|Risperidone|Initial dose: 2 mg.
216530|NCT02532465|Device|Air-Q|
216531|NCT02532465|Device|i-gel|
216532|NCT02532452|Biological|Viral Specific CTL Infusion|"3rd party donor derived CTL's will be infused into immunocompromised patients who have evidence of viral infection or reactivation defined as any of the following:~Blood adenovirus PCR ≥ 1,000~Blood CMV PCR ≥ 500~Blood EBV PCR ≥ 9,000~Plasma BKV PCR >1,000~Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites.~Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven by biopsy or probable by an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation.~Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis."
216533|NCT02532439|Device|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
216534|NCT02532439|Device|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
216535|NCT02532426|Procedure|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
216536|NCT02532413|Drug|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
216537|NCT02532413|Drug|Entecavir|Entecavir can inhibit the replication of HBV.
216538|NCT02532400|Drug|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d*7 plus exemestane: 25mg, po, qd*24w, or anastrozole: 1mg, po, qd*24w
216539|NCT02532400|Drug|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w*6, Epirubicin 75mg/m2, d1, q3w*6 and Cyclophosphamide: 500mg/m2, d1, q3w*6
216540|NCT02532387|Other|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
216541|NCT02532374|Other|Nicorette® inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
216542|NCT02532374|Other|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
216543|NCT02532361|Device|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
216544|NCT02532361|Procedure|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
216546|NCT02532335|Drug|Obeticholic acid|active drug
216547|NCT02532335|Drug|Obeticholic acid placebo|matching placebo
216548|NCT02532322|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
216549|NCT02532322|Drug|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
216550|NCT02532309|Drug|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C>1.1mmol/L and <1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
216551|NCT02532309|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
216552|NCT02532296|Behavioral|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.~Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.~Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
216553|NCT02532296|Behavioral|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
216554|NCT02532283|Drug|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
216555|NCT02532283|Drug|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
216556|NCT02532283|Drug|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
216557|NCT02532270|Drug|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
216558|NCT02532257|Drug|Ibrutinib|Given PO
216559|NCT02532257|Other|Laboratory Biomarker Analysis|Correlative studies
216560|NCT02532257|Drug|Lenalidomide|Given PO
216561|NCT02532257|Biological|Rituximab|Given IV
216562|NCT02532244|Other|sample collection|collection of blood, saliva and buccal cells
216563|NCT02532231|Other|Laboratory Biomarker Analysis|Correlative studies
216564|NCT02532231|Biological|Nivolumab|Given IV
216565|NCT02532218|Drug|ARI-3037MO|Lipid lowering treatment Statins
216566|NCT02532192|Drug|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.~Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
216567|NCT02532192|Drug|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
216568|NCT02532192|Drug|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
216569|NCT02532192|Drug|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.~Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
216570|NCT02532192|Drug|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
216571|NCT02532192|Drug|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
216572|NCT02532192|Drug|Fluconazole|100 mg by mouth daily for 10 days.
216573|NCT02532179|Biological|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
216574|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
216575|NCT02532153|Drug|Ketamine Hydrochloride|Single open-label infusions
216576|NCT02532140|Drug|WCK 5107 250 mg to 2000 mg|
216577|NCT02532140|Drug|Cefepime 2000 mg|
216578|NCT02532140|Drug|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
216579|NCT02532140|Drug|Placebo|
216580|NCT02532127|Other|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
216581|NCT02532114|Drug|Enzalutamide|Given PO
216582|NCT02532114|Other|Laboratory Biomarker Analysis|Correlative studies
216583|NCT02532114|Drug|Niclosamide|Given PO
216584|NCT02532114|Other|Pharmacological Study|Correlative studies
216585|NCT02532101|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
216586|NCT02532088|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
216587|NCT02532088|Dietary Supplement|Placebo|Placebo
216588|NCT02532075|Other|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
216589|NCT02532075|Other|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
216590|NCT02532075|Other|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
216591|NCT02532075|Other|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
216592|NCT02532062|Dietary Supplement|Cholecalciferol|4,000 IU, oral, once a day for one year
216593|NCT02532062|Dietary Supplement|multivitamin|oral, once a day for one year
216594|NCT02532062|Dietary Supplement|Placebo|oral, once a day for one year
216595|NCT02532049|Biological|ChAd63 Pfs25-IMX313|
216596|NCT02532049|Biological|MVA Pfs25-IMX313|
216597|NCT02532036|Biological|Aerosol inhaled MVA85A|
216598|NCT02532036|Biological|Intramuscular MVA85A|
216599|NCT02532036|Biological|Intramuscular Saline placebo|
216600|NCT02532036|Biological|Aerosol inhaled Saline placebo|
216601|NCT02532023|Dietary Supplement|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
216602|NCT02532023|Dietary Supplement|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
216603|NCT02532023|Dietary Supplement|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
216604|NCT02532023|Dietary Supplement|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
216605|NCT02532010|Drug|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nanomolar (nM)and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit Janus kinase 1 (JAK1).
216606|NCT02532010|Drug|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
216607|NCT02532010|Drug|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
216608|NCT02531997|Behavioral|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
216609|NCT02531997|Behavioral|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
216610|NCT02531984|Drug|Azithromycin|
216611|NCT02531971|Drug|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
216612|NCT02531971|Drug|Duragesic®|TDDS dosage is 25 micrograms/hour
216613|NCT02531971|Drug|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour
216614|NCT02531958|Other|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
216615|NCT02531945|Device|Use of Biomod device|
216616|NCT02531932|Drug|Carboplatin|Carboplatin will be administered if ANC > 1.0 and platelets are >75k
216617|NCT02531932|Drug|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
216618|NCT02531919|Drug|Sodium Bicarbonate|Given PO
216619|NCT02531906|Drug|Gabapentin|Given PO
216620|NCT02531906|Drug|Methadone Hydrochloride|Given PO
216621|NCT02531906|Drug|Oxycodone Hydrochloride|Given PO
216622|NCT02531906|Other|Quality-of-Life Assessment|Ancillary studies
216623|NCT02531906|Other|Questionnaire Administration|Ancillary studies
216624|NCT02531880|Drug|Mangafodipir|A contrast agent previously approved for liver imaging with MRI, which contains manganese.
216625|NCT02531867|Biological|Asfotase Alfa|
216626|NCT02531854|Drug|ADXS11-001|
216627|NCT02531854|Drug|Pemetrexed|
216628|NCT02531841|Drug|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):~Rituximab 375 mg/m²/d i.v. (d0)~Dexamethasone 40 mg/d i.v. (d1-3)~Etoposide 100 mg/m²/d i.v. (d1-3)~Ifosfamide 1500 mg/m²/d i.v. (d1-3)~Carboplatin 300 mg/m² i.v. (d1)"
216629|NCT02531841|Drug|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:~Rituximab 375 mg/m²/d i.v. (d0,5)~Methotrexate 3.5 g/m² i.v. (d1)~Cytarabine 2 x 2 g/m²/d i.v. (d2-3)~Thiotepa 30 mg/m² i.v. (d4) Consolidation~High-dose chemotherapy (HDT-ASCT):~Carmustine* 400 mg/m² i.v. (d-6)~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)~* if carmustine is not available at the investigation site, busulfan can be administered instead:~Busulfan 3,2 mg/kg/d (d-8-(-7))~Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))~Autologous Stem Cell Transplantation (d0)"
216630|NCT02531828|Device|Application of dressings for surgical correction.|Dressing for surgical correction
216631|NCT02531828|Device|POLYSHAFT®|
216632|NCT02531815|Biological|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
216633|NCT02531815|Drug|Placebo|Placebo for PF-06741086, single dose
216634|NCT02531802|Biological|ETVAX|"Varying dosages of liquid ETVAX vaccine (Batch BX1003574). A full dose consisted of:~Hybrid protein between the B-subunit of the E. coli heat-labile enterotoxin and the B-subunit of the cholera toxin (LCTBA): 1 mg~E. coli ETEX 21 formalin inactivated: 1.3 mg colonization factor 1 (CFA/I)~E. coli ETEX 22 formalin inactivated: 6.4 mg coli surface antigen 3 (CS3)~E. coli ETEX 23 formalin inactivated: 1.1 mg coli surface antigen 5 (CS5)~E. coli ETEX 24 phenol inactivated: 0.5 mg coli surface antigen 6 (CS6)~The vaccine was given together with sodium bicarbonate effervescent granules (Recip), which was dissolved in water and mixed with the vaccine suspension prior to oral administration. The buffer was used to prevent degradation of LCTBA hybrid protein by the gastric acid."
216671|NCT02531529|Drug|dexmedetomedine|intraoperative infusion
216672|NCT02531529|Drug|Fentanyl|
216673|NCT02531516|Drug|Apalutamide|
216674|NCT02531516|Drug|Bicalutamide|
216675|NCT02531516|Drug|Bicalutamide Placebo|
216676|NCT02531516|Drug|Apalutamide Placebo|
216635|NCT02531802|Biological|dmLT|Varying dosages of dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
216636|NCT02531802|Other|Bicarbonate Buffer|Sodium bicarbonate buffer dissolved in 150 ml of potable water
216637|NCT02531789|Other|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
216638|NCT02531776|Device|Subcutaneous insertions of needles|"Various types of needles with different designs and mechanical properties.~Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson & Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).~Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.~Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.~No drugs are injected. Only the needle insertion is evaluated."
216639|NCT02531763|Behavioral|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
216640|NCT02531750|Other|Immobilization due to an Achilles tendon rupture|
216641|NCT02531737|Drug|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
216642|NCT02531737|Drug|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
216643|NCT02531724|Drug|Levosimendan|
216644|NCT02531724|Drug|Placebo|Sodium chloride
216645|NCT02531711|Other|Diet A|Experimental analgesic dietary intervention
216646|NCT02531711|Other|Diet B|Healthy comparator diet
216647|NCT02531698|Biological|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
216648|NCT02531698|Biological|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
216649|NCT02531698|Other|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
216650|NCT02531685|Other|Placebo|Placebo: 0.9% Sodium Chloride injection.
216651|NCT02531685|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose.
216652|NCT02531672|Drug|11C-choline|
216653|NCT02531672|Device|PET/CT Scan|
216654|NCT02531646|Radiation|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
216655|NCT02531633|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
216656|NCT02531633|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
216657|NCT02531633|Drug|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
216658|NCT02531633|Drug|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
216659|NCT02531620|Other|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
216660|NCT02531620|Other|Routine Care|Usual care for your disease process
216661|NCT02531607|Other|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
216662|NCT02531594|Behavioral|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
216663|NCT02531594|Behavioral|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
216664|NCT02531581|Drug|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output <500cc
216665|NCT02531581|Drug|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
216666|NCT02531568|Drug|Warfarin|
216667|NCT02531568|Drug|MT-3995|
216668|NCT02531555|Device|810 Nanometer Wavelenght GaAlAs Diode Laser|FDA approved 810 nanometer GaAlAs Diode Laser
216669|NCT02531555|Device|Gracey curettes|
216670|NCT02531542|Device|Echocardiography according to the READ method.|"Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
216677|NCT02531516|Drug|GnRH (agonist)|
216678|NCT02531516|Radiation|74-80 Grays (units of radiation)|
216679|NCT02531503|Other|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
216680|NCT02531490|Drug|Labetalol|
216681|NCT02531490|Drug|Nifedipine|
216682|NCT02531490|Drug|Methyldopa|
216683|NCT02531477|Drug|propofol|intracarotid propofol as an anesthetic agent
216684|NCT02531464|Other|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
216685|NCT02531451|Drug|Ibuprofen|
216686|NCT02531451|Drug|Acetylsalicylic acid|
216687|NCT02531438|Drug|Omadacycline|Injection for IV; Oral tablets
216688|NCT02531438|Drug|Moxifloxacin|IV solution; Oral tablets
216689|NCT02531425|Biological|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
216690|NCT02531412|Drug|Spironolactone|After a major surgery event a time 0, 24h and 48h
216691|NCT02531412|Drug|Placebo|After a major surgery event a time 0, 24h and 48h
216692|NCT02531399|Device|FDOCT|Measurement of retinal blood velocities
216693|NCT02531399|Device|LDV|Measurement of retinal blood velocities
216694|NCT02531399|Device|DVA|Measurement of retinal vessel diameters
216695|NCT02531399|Device|LSFG|Imaging of retinal blood flow
216696|NCT02531386|Device|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
216697|NCT02531373|Biological|V114 Medium Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
216698|NCT02531373|Biological|V114 High Dose|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
216699|NCT02531373|Biological|V114 Medium Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
216700|NCT02531373|Biological|V114 High Dose with Alternative Carrier Protein|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
216701|NCT02531373|Biological|Prevnar 13™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
216702|NCT02531360|Drug|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an [18F]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo [18F]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
216703|NCT02531347|Behavioral|Telemedical home blood pressure measurements|
216704|NCT02531347|Behavioral|Conventional blood pressure monitoring|
216705|NCT02531334|Dietary Supplement|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
216706|NCT02531321|Drug|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
216707|NCT02531308|Drug|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
216708|NCT02531308|Drug|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
216709|NCT02531308|Drug|Cyclophosphamide|Interferes with DNA replication
216710|NCT02531308|Drug|Doxorubicin|anthracycline antitumor antibiotic
216711|NCT02531308|Drug|Vincristine|Inhibits cell mitosis causing cell death.
216712|NCT02531308|Drug|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
216713|NCT02531308|Drug|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
216714|NCT02531295|Drug|Euphorbia kansui extract powder prepared as tea|1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
216715|NCT02531282|Behavioral|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
216716|NCT02531282|Behavioral|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
216717|NCT02531256|Device|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
216718|NCT02531243|Behavioral|CALMS|Family Therapy; Multi-user Biofeedback Videogames
216719|NCT02531230|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
216720|NCT02531217|Biological|ATYR1940|Biological: ATYR1940
216721|NCT02531204|Drug|ASP1585|oral
216722|NCT02531191|Drug|peficitinib|oral
216723|NCT02531178|Biological|ABBV-257|subcutaneous injection
216724|NCT02531178|Biological|Placebo|Placebo for ABBV-257
216725|NCT02531165|Drug|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
216770|NCT02530840|Behavioral|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
216726|NCT02531165|Drug|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
216727|NCT02531165|Drug|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
216728|NCT02531165|Drug|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
216729|NCT02531165|Drug|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
216730|NCT02531165|Procedure|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
216731|NCT02531152|Drug|Latanoprost|
216732|NCT02531152|Drug|SAR366234|
216733|NCT02531139|Other|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
216734|NCT02531139|Other|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
216735|NCT02531126|Drug|RPC1063|
216736|NCT02531113|Drug|RPC1063|
216737|NCT02531100|Device|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
216738|NCT02531100|Other|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
216739|NCT02531074|Behavioral|Mobile Application|
216740|NCT02531074|Behavioral|Food Journal|
216741|NCT02531074|Behavioral|Usual Care|
216742|NCT02531061|Device|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
216743|NCT02531048|Device|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
216744|NCT02531048|Device|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
216745|NCT02531048|Device|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
216746|NCT02531048|Device|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
216747|NCT02531035|Drug|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
216748|NCT02531035|Drug|Placebo|Placebo, once daily, before the first meal of the day
216749|NCT02531022|Behavioral|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
216750|NCT02531022|Behavioral|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
216751|NCT02530996|Drug|BH4|BH4 is between 5-20 mg/kg/day given to a total of 32 SSc patients (16 complicated, 16 uncomplicated)
216752|NCT02530996|Other|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
216753|NCT02530996|Drug|Placebo|This will be given to a total of total of 32 SSc patients (16 complicated, 16 uncomplicated)
216754|NCT02530983|Other|Mayo Clinic Conduit Report Card Questionnaires|Patients will be asked to complete the Mayo Clinic Conduit Report Card Questionnaires at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
216755|NCT02530957|Device|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
216756|NCT02530957|Device|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
216757|NCT02530931|Drug|Gadolinium|diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
216758|NCT02530918|Drug|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
216759|NCT02530918|Drug|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
216760|NCT02530905|Drug|SRP-4045|
216761|NCT02530905|Drug|Placebo|
216762|NCT02530892|Procedure|EmbryoHug|"An oocyte or embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the oocyte or embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the oocyte or embryo."
216763|NCT02530879|Drug|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
216764|NCT02530879|Behavioral|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
216765|NCT02530879|Other|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
216766|NCT02530866|Other|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
216767|NCT02530853|Other|Laser acupuncture|Laser acupuncture
216768|NCT02530840|Behavioral|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
216769|NCT02530840|Behavioral|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
216771|NCT02530827|Drug|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
216772|NCT02530814|Other|Blood Collection|Onetime blood collection.
216773|NCT02530801|Drug|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
216774|NCT02530801|Drug|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
216775|NCT02530788|Drug|Selenium Supplement (sodium selenite)|"On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
216776|NCT02530788|Drug|Placebo|"On the evening before operation the patient receives the first dosage of placebo orally as a pill.~After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
216777|NCT02530775|Procedure|instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
216778|NCT02530775|Procedure|non-instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
216779|NCT02530762|Other|Novel Fiber|novel fiber supplemented beverage provided in one serving
216780|NCT02530762|Other|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
216781|NCT02530762|Other|Negative Control|No added fiber beverage
216782|NCT02530736|Other|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
216783|NCT02530723|Other|power training|Resistance training machines with CAM devices will be used for training.
216784|NCT02530710|Drug|Q203|
216785|NCT02530710|Drug|Placebo|
216786|NCT02530697|Drug|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
216787|NCT02530697|Drug|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
216788|NCT02530697|Drug|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
216789|NCT02530684|Other|insole|Insoles available on the market without prescription
216790|NCT02530671|Device|Toothbrushing with manual toothbrush|
216791|NCT02530671|Device|Toothbrushing with power toothbrush|
216792|NCT02530658|Other|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, participants will meet with a genetic counselor and clinician, provide information for a family pedigree, undergo a physical and discuss germline testing options. Study introduction materials will be provided. Families interested in the G4K study will be referred to the study nurse or other G4K member and an Informed consent visit will be scheduled.
216793|NCT02530658|Other|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the research nurse or other study team member will consent the family and collect demographic and medical information. Participants will complete assessment questionnaires.
216794|NCT02530658|Other|Informed Consent Follow-Up Visit|Within 2-4 weeks following the Informed Consent Visit, or at the participant/family's convenience, a subset of participants (30-40) will participate in semi-structured interviews.
216795|NCT02530658|Other|Return of Results Conversation|Participants will complete the assessment questionnaires.
216796|NCT02530658|Other|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 32±8 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
216797|NCT02530658|Procedure|Blood Sample|For patients who have not previously provided a blood sample, a sample of blood will be obtained as a source of germline DNA.
216798|NCT02530658|Procedure|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
216799|NCT02530645|Behavioral|OnTrack|
216800|NCT02530645|Behavioral|Treatment as Usual|
216801|NCT02530645|Behavioral|Brief Motivational Interviewing|
216802|NCT02530632|Drug|Propofol|General anesthesia maintained with intravenous propofol infusion
216803|NCT02530632|Drug|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
216804|NCT02530632|Procedure|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
216805|NCT02530619|Drug|Alisertib|Given PO
216806|NCT02530619|Other|Laboratory Biomarker Analysis|Correlative studies
216807|NCT02530619|Other|Pharmacological Study|Correlative studies
216808|NCT02530606|Procedure|Photoacoustic Imaging|Undergo PAI
216809|NCT02530593|Behavioral|There is no intervention, only observation|
216810|NCT02530580|Drug|20 mg AZD7325|A single 20 mg oral dose of AZD7325
216811|NCT02530580|Drug|Placebo|A single oral dose
216812|NCT02530567|Procedure|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
216813|NCT02530554|Drug|CHG|Varied application times
216814|NCT02530541|Drug|CHG|Varied application times
216815|NCT02530528|Drug|CHG|Varied application times
216816|NCT02530515|Biological|Ex Vivo-activated Autologous Lymph Node Lymphocytes|Given IV
216817|NCT02530515|Other|Laboratory Biomarker Analysis|Correlative studies
216818|NCT02530502|Other|Laboratory Biomarker Analysis|Correlative studies
216819|NCT02530502|Biological|Pembrolizumab|Given IV
216820|NCT02530502|Radiation|Radiation Therapy|Undergo focal RT
216821|NCT02530502|Drug|Temozolomide|Given PO
216822|NCT02530489|Drug|Atezolizumab|Given IV
216823|NCT02530489|Other|Laboratory Biomarker Analysis|Correlative studies
216824|NCT02530489|Drug|Nab-paclitaxel|Given IV
216825|NCT02530476|Drug|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.~Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
216826|NCT02530476|Drug|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.~Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
216827|NCT02530463|Drug|Nivolumab|"Cohort 1: Nivolumab 3 mg/kg by vein every 2 weeks for 6 cycles. One cycle defined as 4 weeks.3 mg/kg by vein every 2 weeks.~Cohort 3: Nivolumab 3 mg/kg by vein on days 1 and 15 (i.e. 2 planned doses of Nivolumab)~Cohort 4: Nivolumab 3 mg/kg by vein on day 6 after 5 days of Azacitidine.~Cohort 6: Nivolumab 3 mg/kg by vein on day 6 and day 20 after 5 days of Azacitidine."
216828|NCT02530463|Drug|Ipilimumab|"Cohort 2, 3 , and 5: Ipilimumab 3 mg/kg by vein every 3 weeks.~Cohort 5: Ipilimumab 3 mg/kg by vein every 4 weeks.~Cohort 6: Ipilimumab 3 mg/kg by vein on day 6 following 5 days of Azacitidine."
216829|NCT02530463|Drug|5-azacitidine|Cohort 4,5, and 6: 75 mg/m2 by vein for 5 days every 4 weeks
216830|NCT02530450|Device|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
216831|NCT02530437|Drug|Carboplatin|Carboplatin AUC 2mg/ml/min given by vein on first radiation day of each week for 5 doses.
216832|NCT02530437|Radiation|External Beam Radiation Therapy|External beam radiation therapy at 1.8 Gy given on 28 consecutive weekdays.
216833|NCT02530437|Other|Laboratory Biomarker Analysis|Correlative studies
216834|NCT02530437|Drug|Paclitaxel|Paclitaxel 50 mg/m2/week given by vein on first radiation day of each week for 5 doses.
216835|NCT02530437|Drug|Taladegib|"Taladegib starting dose 400 mg daily for 38 days starting on first chemoradiation day.~In the event of unexpected toxicities (i.e. more than 1 dose-limiting toxicity [DLT] in the first 6 patients), we will study additional 6 patients but TALADEGIB 200 mg will be administered every day."
216836|NCT02530424|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
216837|NCT02530424|Drug|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
216838|NCT02530424|Drug|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
216839|NCT02530424|Drug|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
216840|NCT02530411|Drug|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
216841|NCT02530411|Drug|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
216842|NCT02530398|Drug|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
216843|NCT02530385|Other|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
216844|NCT02530385|Biological|FMT Capsules|Capsules will be generated as per FDA-approved procedures
216845|NCT02530372|Device|UriCap-F|non-invasive urine collection device for women
216846|NCT02530359|Drug|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
216847|NCT02530359|Drug|Placebo equivalent|Placebo equivalent per mouth
216848|NCT02530346|Drug|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
216849|NCT02530346|Drug|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
216850|NCT02530333|Other|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
216851|NCT02530320|Drug|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
216852|NCT02530307|Drug|HT-3951|
216853|NCT02530307|Drug|Placebo|
216854|NCT02530294|Drug|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
216855|NCT02530294|Other|Vehicle|Vehicle (placebo) topical wipes
216856|NCT02530281|Drug|glycopyrronium Topical Wipes|Topical wipes containing glycopyrronium
216857|NCT02530281|Other|Vehicle|Vehicle (placebo) topical wipes
216858|NCT02530255|Dietary Supplement|cycloastragenol|Oral telomerase activator - cycloastragenol.
216859|NCT02530255|Dietary Supplement|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
216860|NCT02530242|Device|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
216861|NCT02530242|Device|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
216862|NCT02530216|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
216863|NCT02530203|Device|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
216864|NCT02530203|Device|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
216865|NCT02530190|Device|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
216866|NCT02530190|Procedure|massage|20 minutes of massage to lower extremities
216867|NCT02530177|Other|Clinical Assessments|
216868|NCT02530177|Behavioral|Questionnaires|
216869|NCT02530177|Other|Saliva sample|(only once, preferably at baseline)
216870|NCT02530164|Device|Transcranial direct current stimulation (tDCS)|active/sham tDCS as adjunctive treatment with a SSRI
216871|NCT02530151|Drug|Morphine with clonidine|see arm description
216872|NCT02530151|Other|Normal saline|see arm description
216873|NCT02530138|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
216874|NCT02530138|Dietary Supplement|Placebo|2 placebo capsules per day for 28 weeks
216875|NCT02530125|Other|Laboratory Biomarker Analysis|Correlative studies
216876|NCT02530125|Biological|Pidilizumab|Given IV
216877|NCT02530112|Other|Survey|
216878|NCT02530099|Procedure|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
216879|NCT02530099|Procedure|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
216880|NCT02530086|Procedure|Nasogastric tube placement|Placement of a Nasogastric tube
216881|NCT02530086|Procedure|No Nasogastric tube use|No placement of a Nasogastric tube
216882|NCT02530073|Device|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH and observed/expected length head ratio <25% (O/E LHR).
216883|NCT02530060|Drug|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
216884|NCT02530047|Genetic|MSC-INFβ|"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10^5 MSC/kg once a week for 4 treatments."
216885|NCT02530047|Behavioral|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
216886|NCT02530034|Drug|Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4|Given IV
216887|NCT02530034|Other|Laboratory Biomarker Analysis|Correlative studies
216888|NCT02530034|Other|Pharmacological Study|Correlative studies
216889|NCT02530021|Other|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
216890|NCT02529995|Drug|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
216891|NCT02529995|Drug|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
216892|NCT02529982|Dietary Supplement|Curcumin|
216893|NCT02529982|Dietary Supplement|Placebo|
216894|NCT02529969|Dietary Supplement|curcumin|
216895|NCT02529969|Dietary Supplement|Placebo|
216896|NCT02529956|Drug|UCB4940|"Active Substance: UCB4940~Pharmaceutical Form: Solution for infusion~Concentration: 80 mg/ml~Route of Administration: Intravenous use"
216897|NCT02529956|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for infusion~Concentration: 0.9 % sodium chloride aqueous solution~Route of Administration: Intravenous use"
216898|NCT02529930|Biological|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
216899|NCT02529917|Dietary Supplement|Hemp powder|Hemp powder supplement
216900|NCT02529917|Dietary Supplement|Soy Powder|Soy powder supplement
216901|NCT02529904|Biological|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.~Adult participants will receive one dose of MF59-ATIV."
216970|NCT02529410|Procedure|Cardiac Resynchronisation Therapy|
216902|NCT02529891|Other|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
216903|NCT02529878|Drug|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
216904|NCT02529865|Biological|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
216905|NCT02529852|Drug|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.~Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
216906|NCT02529852|Drug|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
216907|NCT02529852|Drug|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
216908|NCT02529852|Drug|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
216909|NCT02529852|Drug|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
216910|NCT02529852|Drug|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
216911|NCT02529839|Procedure|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
216912|NCT02529839|Drug|Fludarabine|30mg/m2 on days -6 through -3
216913|NCT02529839|Drug|Cyclophosphamide|50mg/kg on days -5 through -4
216914|NCT02529839|Drug|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
216915|NCT02529826|Procedure|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
216916|NCT02529813|Drug|Cyclophosphamide|Given IV
216917|NCT02529813|Drug|Fludarabine Phosphate|Given IV
216918|NCT02529813|Other|Laboratory Biomarker Analysis|Correlative studies
216919|NCT02529813|Biological|Tisagenlecleucel|Given IV
216920|NCT02529800|Drug|HIP1402|Tamsulosin HCl 0.4mg
216921|NCT02529800|Drug|HGP0412|Tamsulosin HCl 0.2mg
216922|NCT02529787|Drug|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
216923|NCT02529787|Drug|Dexilant|1 capsule contains 60 mg Dexlansoprazole
216924|NCT02529774|Drug|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:~Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion~In combination with Systemic Chemotherapy CapeOX for 8 cycles:~Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14~Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:~Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1"
216925|NCT02529774|Drug|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:~Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14~Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:~Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1"
216926|NCT02529761|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
216927|NCT02529761|Procedure|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
216928|NCT02529748|Other|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
216929|NCT02529748|Other|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
216930|NCT02529748|Other|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
216931|NCT02529735|Other|efficiency study|Blood pressure values measured for comparative lower limb and arm
216932|NCT02529709|Other|High-Protein Condition|The participants will be fed a high-protein meal
216933|NCT02529709|Other|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
216934|NCT02529696|Device|Accelerometer|Measures patient movement
216935|NCT02529683|Drug|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
216936|NCT02529670|Procedure|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
216937|NCT02529670|Procedure|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
216938|NCT02529670|Procedure|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
216939|NCT02529657|Radiation|Low Level Laser Therapy|In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).
216940|NCT02529657|Procedure|Placebo|In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
217126|NCT02528227|Other|Bath Safety|Part of Health and Safety Curriculum
216941|NCT02529644|Behavioral|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
216942|NCT02529644|Behavioral|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
216943|NCT02529631|Drug|orlistat 60 mg|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."
216944|NCT02529631|Device|polyglucosamine|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.~Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."
216945|NCT02529618|Device|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
216946|NCT02529618|Device|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
216947|NCT02529618|Device|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
216948|NCT02529605|Dietary Supplement|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
216949|NCT02529605|Dietary Supplement|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
216950|NCT02529592|Biological|Endotoxin|
216951|NCT02529592|Biological|Placebo|
216952|NCT02529579|Other|iAPA-DC/CTL adoptive cellular immunotherapy|twice DC cell infusion and CTL cell infusion for 6 times
216953|NCT02529579|Drug|Gemcitabine|standard Gemcitabine therapy
216954|NCT02529553|Drug|LY3076226|Administered IV
216955|NCT02529540|Other|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
216956|NCT02529540|Other|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
216957|NCT02529540|Other|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
216958|NCT02529527|Behavioral|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
216959|NCT02529514|Drug|Baclofen|25 mg for 7 days at 10 pm every day
216960|NCT02529514|Drug|Placebo|Placebo for 7 days at 10 pm every day
216961|NCT02529488|Device|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
216962|NCT02529475|Drug|Gadoteric acid|Comparison with patients with Meniere's disease
216963|NCT02529462|Genetic|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
216964|NCT02529462|Drug|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
216965|NCT02529449|Drug|Placebo|Oral
216966|NCT02529449|Drug|ASP1941|Oral
216967|NCT02529423|Dietary Supplement|Multi‐nutrient supplement|"Omega 3 fatty acids~Folic acid~Calcium~Selenium~Vitamin D3"
216968|NCT02529423|Behavioral|Behavioral Activation|21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood‐related snacking) and helpful food‐related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.
216969|NCT02529423|Other|Placebo|Placebo pills identical in look and taste but including no active ingredients
216971|NCT02529397|Behavioral|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
216972|NCT02529397|Behavioral|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
216973|NCT02529384|Other|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
216974|NCT02529371|Device|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
216975|NCT02529358|Behavioral|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
216976|NCT02529358|Behavioral|Personalized text messages|Patients write their own messages
216977|NCT02529358|Behavioral|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
216978|NCT02529345|Device|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
216979|NCT02529332|Dietary Supplement|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
216980|NCT02529319|Procedure|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
216981|NCT02529319|Procedure|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
216982|NCT02529293|Drug|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
216983|NCT02529293|Drug|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
216984|NCT02529280|Behavioral|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
216985|NCT02529267|Other|Standard of care|
216986|NCT02529254|Behavioral|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
216987|NCT02529241|Drug|Group 1:LCB01-0371|"Period:LCB01-0371 Tablet 400 mg~Period: LCB01-0371 Tablet 400 mg"
216988|NCT02529241|Drug|Group 2:LCB01-0371|"Period:LCB01-0371 Tablet 800 mg~Period: LCB01-0371 Tablet 1200 mg"
216989|NCT02529228|Other|Meal (Eating) Frequency|Dividing meal intake into 2 or 6 meals with equal energy content
216990|NCT02529228|Other|Protein Composition|Consuming meals with higher or lower protein.
216991|NCT02529215|Behavioral|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
216992|NCT02529202|Drug|Dexmedetomidine|Dexmedetomidine infusion
216993|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
216994|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
216995|NCT02529176|Behavioral|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
216996|NCT02529163|Other|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:~Risperidone titrated to a max dose~Failure to Risperidone will lead to a second trial with either:~Quetiapine OR Aripiprazole~If subject refuses or if this trial does not work, then offer:~Ziprasidone or Loxapine~Failure of 2 anti-psychotic trials results in:~Clozapine trial~If subject refuses a Clozapine trial then:~Olanzapine offered~titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E~If compliance is an issue then a depot preparation:~Paliperidone~Risperidone~Flupentixol~Aripiprazole~Physicians will be prompted for non-pharmacological interventions"
216997|NCT02529163|Other|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):~metabolic monitoring~skin hygiene~pain management~nutritional counseling~family counselling~Financial/housing support~Group CBT (Cognitive Behavioral Therapy)~Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.~Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:~Risperidone~Aripiprazole~Quetiapine~Olanzapine~Paliperidone~Clozapine~Ziprasidone~Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
216998|NCT02529150|Behavioral|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
216999|NCT02529124|Dietary Supplement|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
217037|NCT02528851|Procedure|Extubation from endotracheal mechanical ventilation to CPAP|"Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation."
217080|NCT02528513|Drug|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
217000|NCT02529124|Dietary Supplement|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
217001|NCT02529124|Behavioral|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
217002|NCT02529111|Device|"Echonavigator software"|
217003|NCT02529098|Other|fMRI|functional magnetic resonance imaging
217004|NCT02529085|Other|blood samples|blood samples for the bank
217005|NCT02529072|Drug|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
217006|NCT02529072|Biological|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
217007|NCT02529059|Drug|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
217008|NCT02529046|Dietary Supplement|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
217009|NCT02529046|Behavioral|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
217010|NCT02529033|Device|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
217011|NCT02529020|Device|Mouthguard|Condition of wearing mouthguard
217012|NCT02529020|Device|No mouthguard|Condition without mouthguard
217013|NCT02529007|Device|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
217014|NCT02529007|Other|Standard colonoscopy|Standard colonoscopy without end-cuff
217015|NCT02528994|Dietary Supplement|L-serine|Participants will take dietary serine supplementation daily
217016|NCT02528981|Drug|Probiotic|Lactobacillus GR-1 and RC-14
217017|NCT02528981|Drug|Placebo|
217018|NCT02528968|Behavioral|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
217019|NCT02528955|Radiation|A: De-Intensification RT primary tumor region|"A:~Reduction of radiation dose in the primary tumor region to 56 Gy,~Elective Radiotherapy of both neck sides"
217020|NCT02528955|Radiation|B: De-Intensification RT contralateral lymph nodes|"B:~No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)~Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
217021|NCT02528955|Radiation|C. De-Intensification RT primary tumor region AND contralateral lymph nodes|"C:~Reduction of radiation dose in the primary tumor region to 56 Gy, AND~Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
217022|NCT02528942|Radiation|Radiation therapy|Radiation therapy will be given to study patients.
217023|NCT02528929|Dietary Supplement|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
217024|NCT02528903|Drug|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
217025|NCT02528903|Drug|Matching placebo|Single intravenous dose
217026|NCT02528890|Other|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
217027|NCT02528877|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
217028|NCT02528877|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoeitic stem cell transplant
217029|NCT02528877|Drug|Fludarabine Phosphate|Given IV
217030|NCT02528877|Other|Laboratory Biomarker Analysis|Correlative studies
217031|NCT02528877|Drug|Melphalan|Given IV
217032|NCT02528877|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo hematopoietic stem cell transplant
217033|NCT02528877|Other|Pharmacological Study|Correlative studies
217034|NCT02528877|Drug|Ruxolitinib Phosphate|Given PO
217035|NCT02528877|Drug|Sirolimus|Given PO
217036|NCT02528877|Drug|Tacrolimus|Given IV or PO
217124|NCT02528227|Other|Feeding Safety|Part of Health and Safety Curriculum
217125|NCT02528227|Other|Car Seat Safety|Part of Health and Safety Curriculum
217038|NCT02528825|Drug|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
217039|NCT02528812|Device|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
217040|NCT02528812|Other|Manual Massage|A massage therapist massaged the participant
217041|NCT02528799|Biological|Nexvax2|Nexvax2 intra-dermal injections twice weekly
217042|NCT02528799|Biological|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
217043|NCT02528786|Other|No Intervention|No study drug will be administered in this study.
217044|NCT02528760|Drug|Metaclopramide|23. Metoclopromide to be given 10mg iv 8 hourly
217045|NCT02528760|Drug|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
217046|NCT02528760|Other|Placebo|
217047|NCT02528721|Device|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
217048|NCT02528708|Drug|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
217049|NCT02528708|Drug|Placebo|0.9% saline solution
217050|NCT02528695|Radiation|18F-FDG PET/CT|18F-FDG PET/CT
217051|NCT02528695|Device|euglycemic clamp|euglycemic clamp
217052|NCT02528695|Device|hypoglycemic clamp|hypoglycemic clamp
217053|NCT02528682|Biological|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
217054|NCT02528669|Device|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
217055|NCT02528656|Device|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
217056|NCT02528656|Device|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
217057|NCT02528643|Drug|enzalutamide|Participants received 160 mg enzalutamide oral capsules (4 x 40 mg capsules) one daily.
217058|NCT02528643|Drug|placebo|Participants received placebo to match enzalutamide oral capsules once daily.
217059|NCT02528630|Other|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
217060|NCT02528630|Other|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
217061|NCT02528617|Drug|Velaglucerase alfa|Enzyme replacement therapy
217062|NCT02528604|Procedure|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
217063|NCT02528604|Procedure|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
217064|NCT02528604|Procedure|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
217065|NCT02528604|Device|Implantable loop recorder|
217066|NCT02528591|Device|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
217067|NCT02528578|Device|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
217068|NCT02528578|Other|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
217069|NCT02528565|Device|Adhesix Bioring|
217070|NCT02528552|Device|LH80 PRO|
217071|NCT02528552|Device|Sham Device|
217072|NCT02528539|Other|ITP|"The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.~Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points"
217073|NCT02528526|Drug|OXY111A|OXY111A intravenous infusion
217074|NCT02528513|Drug|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
217075|NCT02528513|Drug|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
217076|NCT02528513|Drug|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
217077|NCT02528513|Drug|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
217078|NCT02528513|Procedure|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
217079|NCT02528513|Procedure|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
217081|NCT02528500|Device|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
217082|NCT02528474|Device|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
217083|NCT02528474|Device|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
217084|NCT02528461|Drug|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
217085|NCT02528461|Procedure|Gastroscopy|
217086|NCT02528461|Procedure|Liver biopsy|
217087|NCT02528461|Procedure|Fibroscan|
217088|NCT02528461|Procedure|Liver vein catheterization|
217089|NCT02528461|Drug|Sofosbuvir|
217090|NCT02528448|Drug|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
217091|NCT02528448|Drug|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
217092|NCT02528422|Drug|Acyl-Ghrelin|
217093|NCT02528409|Drug|Vortioxetine|Medication currently approved for major depression.
217094|NCT02528409|Drug|Placebo|
217095|NCT02528396|Drug|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
217096|NCT02528396|Drug|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
217097|NCT02528383|Behavioral|Vagifem|"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:~Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.~Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.~Impact of treatment on quality of life"
217098|NCT02528370|Device|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
217099|NCT02528357|Drug|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to <=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
217100|NCT02528357|Drug|Pembrolizumab|Pembrolizumab as 100 mg/4 mL solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
217101|NCT02528344|Behavioral|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
217102|NCT02528331|Device|Transcranial magnetic stimulation|
217103|NCT02528331|Behavioral|Cognitive behavioral therapy|
217104|NCT02528318|Combination Product|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
217105|NCT02528318|Device|nCPAP alone|nCPAP therapy
217106|NCT02528305|Other|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&6, 8 sprints in sessions 7&8, 9 sprints in sessions 9&10 and 10 sprints in sessions 11&12.
217107|NCT02528292|Procedure|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
217108|NCT02528292|Drug|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
217109|NCT02528279|Drug|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:~Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
217110|NCT02528266|Device|Nerve Capping Device|
217111|NCT02528253|Biological|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
217112|NCT02528253|Biological|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
217113|NCT02528253|Biological|Tanezumab 5 mg SC|Tanezumab 5 mg SC
217114|NCT02528253|Biological|Tanezumab 10 mg SC|Tanezumab 10 mg SC
217115|NCT02528253|Biological|Tramadol PR oral|Tramadol PR oral
217116|NCT02528240|Procedure|EMS|
217117|NCT02528240|Device|+ occlusive membrane|
217118|NCT02528240|Device|conebeam CT|
217119|NCT02528227|Other|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
217120|NCT02528227|Other|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
217121|NCT02528227|Other|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
217122|NCT02528227|Other|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
217123|NCT02528227|Other|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
217127|NCT02528227|Other|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
217128|NCT02528227|Other|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
217129|NCT02528227|Other|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
217130|NCT02528214|Drug|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
217131|NCT02528214|Drug|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
217132|NCT02528214|Drug|Oral corticosteroid therapy (prednisone/prednisolone)|Oral administration.
217133|NCT02528214|Drug|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
217134|NCT02528214|Drug|Albuterol/Salbutamol|Oral inhalation as needed.
217135|NCT02528214|Drug|Levalbuterol/Levosalbutamol|Oral inhalation as needed.
217136|NCT02528201|Drug|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
217137|NCT02528201|Drug|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
217138|NCT02528201|Drug|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
217139|NCT02528188|Drug|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
217140|NCT02528188|Biological|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
217141|NCT02528188|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
217142|NCT02528175|Device|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
217143|NCT02528175|Radiation|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
217144|NCT02528175|Drug|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
217145|NCT02528162|Behavioral|education|Evaluation of education for GDM
217146|NCT02528149|Procedure|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
217147|NCT02528149|Other|blood sample|
217148|NCT02528136|Drug|Carbetocin|
217149|NCT02528136|Drug|Oxytocin|
217150|NCT02528123|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
217151|NCT02528123|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
217152|NCT02528123|Drug|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
217153|NCT02528123|Drug|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
217154|NCT02528123|Drug|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
217155|NCT02528110|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
217156|NCT02528110|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
217157|NCT02528110|Other|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
217158|NCT02528110|Other|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
217159|NCT02528097|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
217160|NCT02528097|Drug|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline)
217161|NCT02528084|Procedure|yoga|patients watch and follow an online yoga video.
217162|NCT02528084|Procedure|standard exercises|patients watch and follow an online standard exercises video.
217163|NCT02528071|Other|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
217164|NCT02528058|Procedure|Vitrectomy with internal limiting membrane peeling|
217165|NCT02528045|Procedure|Vitrectomy with scleral shortening|
217166|NCT02528032|Other|Echographic evaluation of heart function|Echocardiographic data collection and analysis, not fully exploited at present
217167|NCT02528019|Drug|DPP-4 inhibiotors|
217168|NCT02528019|Drug|SGLT2 inhibitors|
217169|NCT02528019|Drug|Glimepiride|
217170|NCT02528006|Device|Type 2 Thyroplasty using Titanium Bridges|
217171|NCT02527993|Drug|Glucobay (acarbose)|Se arm description
217172|NCT02527993|Drug|Januvia (sitagliptin)|Se arm description
217173|NCT02527993|Drug|Verapamil HEXAL (verapamil)|Se arm description
217174|NCT02527993|Drug|Victoza (liraglutide)|Se arm description
217175|NCT02527993|Drug|Signifor (pasireotide)|Se arm description
217176|NCT02527993|Device|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
217177|NCT02527993|Dietary Supplement|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
217220|NCT02527616|Device|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
217221|NCT02527603|Procedure|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
217376|NCT02526511|Procedure|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
217178|NCT02527980|Other|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
217179|NCT02527941|Drug|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
217180|NCT02527928|Other|None intervention|
217181|NCT02527915|Other|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
217182|NCT02527915|Other|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
217183|NCT02527902|Device|Holter|measure of ANS in IgAN patients
217184|NCT02527889|Other|Exercise training|8-week resistive exercise training
217185|NCT02527876|Behavioral|High Intensity Interval Training|High Intensity Interval Training
217186|NCT02527876|Behavioral|Moderate Intensity|Moderate Intensity Training
217187|NCT02527876|Behavioral|Delayed Control|Delayed Control
217188|NCT02527876|Device|FitBit Flex|Use to measure increase in Physical Activity
217189|NCT02527863|Drug|Tolvaptan|60 mg Tolvaptan pr day for 1 day
217190|NCT02527863|Drug|Placebo|1 tablet Unikalk pr day for 1 day
217191|NCT02527850|Device|B-cure laser|
217192|NCT02527837|Drug|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
217193|NCT02527837|Drug|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
217194|NCT02527824|Drug|Oxaliplatin, Irinotecan, S-1|"Treatment will be delivered every 2 weeks~Oxaliplatin 65 mg/m2 iv on day 1~Irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day on day1-7"
217195|NCT02527811|Drug|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
217196|NCT02527798|Drug|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
217197|NCT02527798|Drug|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
217198|NCT02527798|Drug|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
217199|NCT02527798|Other|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
217200|NCT02527785|Drug|Oxaliplatin, Irinotecan, S-1(OIS)|"Treatment will be delivered every 2 weeks~oxaliplatin 65 mg/m2 iv on day 1~irinotecan 135 mg/m2 iv on day 1~S-1 80 mg/m2/day po on day 1-7"
217201|NCT02527772|Drug|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
217202|NCT02527772|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
217203|NCT02527759|Behavioral|Survey|
217204|NCT02527746|Biological|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
217205|NCT02527746|Drug|EC regimen|Epirubicin 100 mg/m2 (in vein) and Cyclophosphamide 600 mg/m2 (in vein) on Day 1 of each cycle for 4 cycles.
217206|NCT02527733|Drug|Ranibizumab|
217207|NCT02527733|Drug|Ranibizumab and laser|
217208|NCT02527720|Behavioral|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at ~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
217209|NCT02527707|Drug|lonafarnib|antiviral farnesyltransferase inhibitor
217210|NCT02527707|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
217211|NCT02527694|Device|Flexible EMS stretcher cart|The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
217212|NCT02527694|Device|mechanical CPR|
217213|NCT02527681|Drug|ceftobiprole|single dose of ceftobiprole at 7.5 mg/kg body weight, given as a 4-hour constant-rate infusion of ceftobiprole medocaril
217214|NCT02527668|Dietary Supplement|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
217215|NCT02527668|Dietary Supplement|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
217216|NCT02527668|Other|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
217217|NCT02527655|Behavioral|Choice-Based Physical Activity and Active Transportation|
217218|NCT02527642|Other|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
217219|NCT02527629|Other|Decellularized human heart valves|Decellularized human aortic heart valves
217222|NCT02527603|Procedure|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
217223|NCT02527603|Drug|Anti-Inflammatory Agents, Non-Steroidal|"All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain."
217224|NCT02527590|Other|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
217225|NCT02527590|Other|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
217226|NCT02527590|Other|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
217227|NCT02527590|Other|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
217228|NCT02527590|Other|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
217229|NCT02527577|Drug|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
217230|NCT02527577|Drug|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
217231|NCT02527564|Drug|Suvorexant|
217232|NCT02527564|Drug|Placebo|
217233|NCT02527551|Other|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
217234|NCT02527538|Device|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
217235|NCT02527525|Behavioral|Stepped Care|
217236|NCT02527512|Drug|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
217237|NCT02527512|Other|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
217238|NCT02527499|Behavioral|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
217239|NCT02527499|Behavioral|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
217240|NCT02527499|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
217241|NCT02527473|Other|Dispatcher-Assisted Basic Life Support CPR Education|"The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.~The one hour training session is split into four parts:~Video self-instruction manikin practice (30 min), including a brief introduction to AED.~Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer~Debriefing (15 min): Questions, answers and reflection~Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone"
217242|NCT02527460|Drug|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
217243|NCT02527434|Biological|Tremelimumab monotherapy|IV infusion
217244|NCT02527434|Biological|MEDI4736 monotherapy|IV infusion
217245|NCT02527434|Biological|MEDI4736 + tremelimumab combination therapy|IV infusion
217246|NCT02527421|Drug|DFD01 Spray|DFD-01 (betamethasone dipropionate) Spray, 0.05%
217247|NCT02527395|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
217248|NCT02527395|Other|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
217249|NCT02527395|Other|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
217250|NCT02527382|Procedure|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
217251|NCT02527369|Device|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
217252|NCT02527356|Behavioral|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
217332|NCT02526836|Procedure|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
217253|NCT02527356|Behavioral|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
217254|NCT02527356|Behavioral|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
217255|NCT02527343|Drug|volanesorsen|
217256|NCT02527343|Drug|Placebo|
217257|NCT02527330|Other|MR T2* imaging|Cardiac magnetic resonance imaging with T2* imaging
217258|NCT02527317|Drug|Lipegfilgrastim|Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
217259|NCT02527304|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
217260|NCT02527304|Other|Quality-of-Life Assessment|Ancillary studies
217261|NCT02527304|Other|Questionnaire Administration|Ancillary studies
217262|NCT02527304|Radiation|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
217263|NCT02527291|Other|Blood test|Blood test for CMV PCR and IL28
217264|NCT02527278|Procedure|Laparoscopic tubal ligation|Female permanent birth control method performed via a surgical procedure
217265|NCT02527278|Procedure|Hysteroscopic sterilization|Female permanent birth control method performed via placement of a device
217266|NCT02527265|Drug|Afrezza|"Pharmaceutical form: powder~Route of administration: inhalation"
217267|NCT02527252|Other|Craniosacral therapy|
217268|NCT02527252|Other|Classic Massage|
217269|NCT02527239|Other|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
217270|NCT02527226|Behavioral|Facial exercises|A series of self-administered facial movements and expressions.
217271|NCT02527213|Drug|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
217272|NCT02527213|Drug|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
217273|NCT02527200|Drug|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
217274|NCT02527200|Drug|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
217275|NCT02527187|Biological|Betula verrucosa allergen extract|Four concentrations of Betula verrucosa allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
217276|NCT02527174|Drug|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
217277|NCT02527174|Drug|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
217278|NCT02527174|Drug|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
217279|NCT02527161|Device|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
217280|NCT02527148|Device|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
217281|NCT02527148|Device|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
217282|NCT02527148|Procedure|Total Knee Replacement|
217283|NCT02527148|Device|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including~Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;~Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;~Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
217284|NCT02527135|Behavioral|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
217285|NCT02527122|Diagnostic Test|Allergen extracts|
217286|NCT02527109|Drug|Nifedipine|
217287|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
217416|NCT02526199|Drug|Bupivacaine|Sciatic nerve block
217288|NCT02527096|Drug|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
217289|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
217290|NCT02527083|Drug|Propofol|
217291|NCT02527083|Drug|Sevoflurane|
217292|NCT02527083|Drug|Remifentanil|
217293|NCT02527083|Drug|Ketamine|
217294|NCT02527070|Device|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
217295|NCT02527070|Device|Quantum Warp10 (Red LED)|
217296|NCT02527070|Device|Omnilux new-U (Near Infrared LED)|
217297|NCT02527070|Other|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
217298|NCT02527057|Device|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
217299|NCT02527044|Procedure|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
217300|NCT02527031|Other|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
217301|NCT02527031|Other|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
217302|NCT02527018|Device|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
217303|NCT02527005|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
217304|NCT02527005|Drug|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
217305|NCT02526992|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
217306|NCT02526979|Drug|mirabegron|oral
217307|NCT02526966|Biological|blood sample|dosage of anti-hinge region antibodies
217308|NCT02526953|Drug|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
217309|NCT02526953|Drug|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
217310|NCT02526953|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
217311|NCT02526953|Drug|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
217312|NCT02526953|Drug|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
217313|NCT02526953|Radiation|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
217314|NCT02526940|Procedure|rectal biopsies|6 rectal biopsies
217315|NCT02526940|Other|Blood samples|Blood samples
217316|NCT02526927|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
217317|NCT02526927|Device|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
217318|NCT02526927|Other|Blood samples|
217319|NCT02526914|Drug|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
217320|NCT02526914|Drug|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
217321|NCT02526914|Drug|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
217322|NCT02526901|Other|No intervention|
217323|NCT02526888|Drug|ACT-541468|Oral capsule (25 mg) as single dose
217324|NCT02526888|Drug|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
217325|NCT02526875|Drug|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
217326|NCT02526862|Device|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
217327|NCT02526862|Device|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
217328|NCT02526862|Device|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
217329|NCT02526849|Drug|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
217330|NCT02526849|Behavioral|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
217331|NCT02526836|Procedure|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
217417|NCT02526199|Drug|Epinephrine|Adjuvant to perinerual block
217333|NCT02526823|Drug|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
217334|NCT02526823|Drug|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:~Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CDOPE:~PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~DBVD:~PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
217335|NCT02526810|Drug|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
217336|NCT02526810|Drug|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
217337|NCT02526784|Drug|degarelix|
217338|NCT02526771|Procedure|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
217339|NCT02526771|Procedure|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
217340|NCT02526758|Drug|beclomethasone|
217341|NCT02526758|Drug|formoterol|
217342|NCT02526758|Drug|budesonide|
217343|NCT02526745|Biological|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
217344|NCT02526745|Biological|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
217345|NCT02526745|Biological|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
217346|NCT02526745|Biological|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
217347|NCT02526745|Biological|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
217348|NCT02526745|Biological|placebo|
217349|NCT02526732|Other|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
217350|NCT02526719|Procedure|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
217351|NCT02526706|Other|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
217352|NCT02526693|Diagnostic Test|Pupillometer|The Konan RAPDx (relative afferent pupillary defect) (Konan Medical USA, Irvine, CA) pupillometer utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify pupillary response to light.
217353|NCT02526680|Device|OrCam|The OrCam low vision aid, camera attached to glasses, used by 27 glaucoma subjects for 1 month.
217354|NCT02526667|Drug|Chlorhexidine Gluconate|comparison with other CHG products
217355|NCT02526667|Other|Vehicle|Cloth with Excipients no CHG
217356|NCT02526667|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
217357|NCT02526654|Diagnostic Test|Heidelberg Edge Perimeter|HEP measures peripheral vision
217358|NCT02526654|Diagnostic Test|Octopus Visual Field|OVF measures peripheral vision
217359|NCT02526654|Diagnostic Test|Optical Coherence Tomography|OCT measures retinal nerve fiber layer thickness
217360|NCT02526641|Procedure|Functional Hepatic Nitrogen Clearance (FHNC)|
217361|NCT02526641|Procedure|Galactose Elimination Capacity (GEC)|
217362|NCT02526641|Procedure|Liver vein catheterization|
217363|NCT02526615|Drug|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
217364|NCT02526615|Drug|Metformin|Patients received either placebo, metformin or rosiglitazone
217365|NCT02526615|Drug|Placebo|Patients received either placebo, metformin or rosiglitazone
217366|NCT02526602|Procedure|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
217367|NCT02526602|Procedure|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
217368|NCT02526576|Biological|Stromal Vasular Fraction|The stromal vascular fraction obtained from adipose tissue will be added to the graft
217369|NCT02526576|Procedure|Biopsy|A subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
217370|NCT02526563|Procedure|ropivicaine|Blood draws to measure serum ropivicaine
217371|NCT02526550|Biological|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
217372|NCT02526550|Biological|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
217373|NCT02526524|Drug|Met DR|metformin delayed-release tablets
217374|NCT02526524|Drug|Met IR|metformin immediate-release tablets
217375|NCT02526524|Drug|Placebo|
217418|NCT02526199|Drug|Dexamethasone|Adjuvant to perinerual block
217377|NCT02526511|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
217378|NCT02526511|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
217379|NCT02526511|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
217380|NCT02526498|Radiation|Accelerated Partial Breast Irradiation|Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
217381|NCT02526498|Radiation|High-Dose Rate Brachytherapy|Undergo APBI using HDR brachytherapy
217382|NCT02526498|Other|Questionnaire Administration|Ancillary studies
217383|NCT02526485|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
217384|NCT02526472|Procedure|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
217385|NCT02526472|Procedure|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
217386|NCT02526459|Behavioral|Birth plan|Patient will receive a birth plan
217387|NCT02526446|Behavioral|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:~i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.~ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).~iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
217388|NCT02526446|Other|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
217389|NCT02526420|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
217390|NCT02526407|Behavioral|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
217391|NCT02526407|Behavioral|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
217392|NCT02526394|Biological|Meningococcal vaccine|Meningococcal vaccination
217393|NCT02526394|Drug|Pertussis containing vaccine|Pertussis containing vaccination
217394|NCT02526381|Drug|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
217395|NCT02526381|Drug|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
217396|NCT02526368|Drug|Pyruvate (13C)|Pyruvate injection followed by a magnetic resonance imaging (MRI) scan.
217397|NCT02526355|Behavioral|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
217398|NCT02526342|Device|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
217399|NCT02526329|Biological|donor regulatory T lymphocytes|Given IV
217400|NCT02526329|Other|laboratory biomarker analysis|Correlative studies
217401|NCT02526316|Biological|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
217402|NCT02526316|Biological|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
217403|NCT02526303|Drug|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
217404|NCT02526290|Device|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
217405|NCT02526277|Device|MMF07 Foot Massager|
217406|NCT02526277|Device|Heat Therapy|
217407|NCT02526264|Other|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
217408|NCT02526251|Other|observational|No intervention
217409|NCT02526238|Device|TMS and trunk rotation|TMS and trunk rotation
217410|NCT02526238|Device|Sham TMS and trunk rotation|Sham TMS and trunk rotation
217411|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection|5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
217412|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection simulation|5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
217413|NCT02526212|Behavioral|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
217414|NCT02526212|Behavioral|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
217415|NCT02526212|Drug|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
217471|NCT02525809|Device|Novae E®|
217419|NCT02526186|Device|Battlefield Auricular Acupuncture|
217420|NCT02526173|Procedure|RALP using full nerve sparing technique|RALP using full nerve sparing technique
217421|NCT02526173|Other|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
217422|NCT02526160|Biological|KRN23|solution for SC injection
217423|NCT02526160|Other|Placebo|saline solution for SC injection
217424|NCT02526147|Other|Cash|
217425|NCT02526147|Other|Voucher|
217426|NCT02526147|Other|Food|
217427|NCT02526134|Device|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
217428|NCT02526121|Procedure|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
217429|NCT02526121|Behavioral|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
217430|NCT02526108|Other|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
217431|NCT02526082|Other|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
217432|NCT02526069|Behavioral|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
217433|NCT02526056|Other|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
217434|NCT02526056|Other|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
217435|NCT02526043|Procedure|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
217436|NCT02526043|Procedure|Open hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
217437|NCT02526030|Drug|Aripiprazole|
217438|NCT02526030|Drug|Quetiapine|
217439|NCT02526030|Drug|Ziprasidone|
217440|NCT02526017|Biological|FPA008|
217441|NCT02526017|Biological|BMS-936558|
217442|NCT02526004|Drug|Ceftazidime|
217443|NCT02526004|Drug|Tobramycin|
217444|NCT02525991|Device|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
217445|NCT02525978|Behavioral|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
217446|NCT02525978|Other|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
217447|NCT02525965|Procedure|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
217448|NCT02525965|Procedure|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin <1cm
217449|NCT02525952|Procedure|Hepatectomy|Surgical removal of all lesions
217450|NCT02525952|Procedure|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
217451|NCT02525939|Drug|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
217452|NCT02525939|Drug|Placebo|matching placebo tablets
217453|NCT02525926|Procedure|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
217454|NCT02525926|Procedure|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
217455|NCT02525913|Device|RFA Applicator|
217456|NCT02525900|Procedure|Wound Infiltration|Wound Infiltration with 0.25% Bupivacine
217457|NCT02525900|Procedure|TAP Blocks|bilateral TAP block with 0.25% Bupivacaine
217458|NCT02525900|Procedure|TAP Catheters|bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine
217459|NCT02525887|Other|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
217460|NCT02525874|Drug|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
217461|NCT02525861|Biological|GLASSIA|60 mg/kg BW administered at a rate of 0.2 mL/kg/min
217462|NCT02525848|Drug|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
217463|NCT02525848|Drug|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
217464|NCT02525848|Drug|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
217465|NCT02525835|Dietary Supplement|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
217466|NCT02525835|Dietary Supplement|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
217467|NCT02525822|Drug|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
217468|NCT02525822|Drug|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
217469|NCT02525822|Drug|Vehicle Cream|Comparator Product: Vehicle Cream
217470|NCT02525822|Drug|Vehicle Lotion|Comparator Product: Vehicle Lotion
217474|NCT02525796|Drug|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
217475|NCT02525796|Drug|amiloride|amiloride, titrated up to a maximum of 10mg BID
217476|NCT02525796|Drug|Placebo|
217477|NCT02525796|Drug|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
217478|NCT02525770|Device|radiostereometric analysis (RSA)|
217479|NCT02525757|Drug|MPDL3280A|"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.~Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.~Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."
217480|NCT02525757|Drug|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
217481|NCT02525757|Drug|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
217482|NCT02525757|Radiation|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
217483|NCT02525744|Biological|LY900014|Administered SC
217484|NCT02525744|Biological|Insulin Lispro|Administered SC
217485|NCT02525718|Drug|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
217486|NCT02525718|Drug|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
217487|NCT02525705|Biological|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
217488|NCT02525692|Drug|ONC201|
217489|NCT02525679|Drug|BI 655130|
217490|NCT02525679|Drug|Placebo|
217491|NCT02525653|Drug|albumin-bound paclitaxel|
217492|NCT02525653|Drug|gemcitabine|
217493|NCT02525640|Device|Hearing Aid|Hearing aid comparison
217494|NCT02525627|Device|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
217495|NCT02525627|Device|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
217496|NCT02525627|Device|Symax stem|Orthopaedic implant
217497|NCT02525627|Device|Accolade TMZF stem|Orthopaedic implant
217498|NCT02525614|Device|Triathlon Standard Keel|Implantation of Knee Prosthesis
217499|NCT02525614|Device|Triathlon Short Keel|Implantation of Knee Prosthesis
217500|NCT02525601|Device|Triathlon CR cemented|Implantation of Knee Prosthesis
217501|NCT02525601|Device|Triathlon CR uncemented|Implantation of Knee Prosthesis
217502|NCT02525588|Device|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
217503|NCT02525575|Behavioral|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
217504|NCT02525562|Device|Triathlon Total Knee System with X3 insert|Total knee replacement
217505|NCT02525562|Device|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
217506|NCT02525562|Device|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
217507|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel|
217508|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel (Reference)|
217509|NCT02525549|Drug|Placebo gel|
217510|NCT02525536|Drug|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
217511|NCT02525536|Drug|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
217512|NCT02525536|Drug|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
217513|NCT02525523|Drug|Alicaforsen|
217514|NCT02525523|Drug|Placebo|
217515|NCT02525510|Other|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
217516|NCT02525510|Other|Pump Eligible - Hyporthermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.~Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
217517|NCT02525510|Other|Pump Eligible - Hyporthermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
217518|NCT02525510|Other|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.~Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
217519|NCT02525510|Other|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
217520|NCT02525497|Device|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
217521|NCT02525497|Device|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
217593|NCT02525003|Dietary Supplement|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
217522|NCT02525484|Drug|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
217523|NCT02525471|Drug|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 24 weeks.~In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
217524|NCT02525458|Device|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
217525|NCT02525458|Device|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
217526|NCT02525445|Procedure|acupuncture|acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
217527|NCT02525445|Procedure|sham acupuncture|"sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle [20]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no needle sensation occurred, and then lifted the needles up from the skin."
217528|NCT02525445|Procedure|positive communication|"During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension."
217529|NCT02525445|Procedure|neutral communication|"During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,"
217530|NCT02525432|Biological|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
217531|NCT02525432|Biological|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
217532|NCT02525419|Behavioral|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
217533|NCT02525419|Behavioral|HP-IF|High Protein, Intermittent Fast
217534|NCT02525419|Behavioral|HH|Heart Healthy
217535|NCT02525406|Other|All surgeries performed from Jan 01, 2010 to Dec 31, 2018|
217536|NCT02525393|Device|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
217537|NCT02525393|Device|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
217538|NCT02525393|Device|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
217539|NCT02525380|Procedure|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
217540|NCT02525367|Behavioral|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
217541|NCT02525367|Behavioral|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
217542|NCT02525341|Other|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
217543|NCT02525341|Other|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
217544|NCT02525341|Other|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
217545|NCT02525328|Other|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
217546|NCT02525315|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
217547|NCT02525302|Drug|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
217548|NCT02525289|Other|Bed Rotation Group|Patients received continuous lateral rotation by a mechanical device (Hill Rom Bed Rotation), consecutive cycles of to left and right side, plus supine position during 30 seconds for pause, in the first postoperative day until 48 hours. Additional breathing exercises.
217549|NCT02525289|Other|Orthostatic Group|Patients were seated on the bed 6 hours post extubation for two hours. After, sitting in the bed with their feet on the floor for two minutes; standing up and walking in the place for two minutes, in the first 24 hours and 48 hours postoperative. Additional breathing exercises.
217550|NCT02525276|Behavioral|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
217551|NCT02525276|Drug|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.~Including:~Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
217552|NCT02525263|Biological|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
217553|NCT02525250|Procedure|Realization of 3 Blood samples during study during treatment with lenalidomide|
217554|NCT02525237|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
217555|NCT02525237|Drug|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
217556|NCT02525224|Dietary Supplement|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
217557|NCT02525224|Radiation|Minimal Erythema Dose (MED)|1, 2, and 3 MED of solar simulated radiation on the right or left sun protected buttock conducted at baseline visit and week 8 visit
217558|NCT02525211|Drug|Ropivacaine|a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
217559|NCT02525211|Drug|physiological saline|a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
217560|NCT02525198|Dietary Supplement|fatty acid/flavonoid blend|see arm description
217561|NCT02525198|Dietary Supplement|Placebo|see arm description
217562|NCT02525185|Other|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
217563|NCT02525172|Drug|Rituximab|
217564|NCT02525172|Drug|intravenous immune globulin|
217565|NCT02525172|Drug|Bortezomib|
217566|NCT02525172|Drug|Methotrexate|
217567|NCT02525159|Dietary Supplement|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
217568|NCT02525159|Other|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
217569|NCT02525146|Other|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
217570|NCT02525133|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
217571|NCT02525133|Other|Placebo|Plain collagen implant (vehicle)
217572|NCT02525120|Device|Triojection|Triojection is system intended to deliver a specific amount of ozone to a herniated disc.
217573|NCT02525120|Procedure|Surgical discectomy|Patients will receive surgery to remove the herniated disc material.
217574|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients on Hydroxyurea
217575|NCT02525107|Dietary Supplement|Placebo|SCD patients on Hydroxyurea
217576|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients not on Hydroxyurea
217577|NCT02525107|Dietary Supplement|Placebo|SCD patients not on Hydroxyurea
217578|NCT02525094|Biological|MEDI9929|Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.
217579|NCT02525094|Biological|Placebo|Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.
217580|NCT02525081|Drug|Ramipril (ACE-inhibitor)|up to 10 mg
217581|NCT02525081|Drug|placebo|up to 10 mg
217582|NCT02525068|Drug|AZD5363|Until confirmed disease progression.
217583|NCT02525068|Drug|Enzalutamide|Until confirmed disease progression.
217584|NCT02525055|Biological|Infectious titre 1 (H3N2)|Infectious titre 1
217585|NCT02525055|Biological|Infectious titre 2 (H3N2)|Infectious titre 2
217586|NCT02525055|Biological|Infectious titre 3 (H3N2)|Infectious titre 3
217587|NCT02525055|Biological|Infectious titre 4 (H3N2)|Infectious titre 4
217588|NCT02525029|Drug|Pregnyl®|"ARM 1: High-Risk aGVHD~Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7:~If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.~If no response, the patient will be taken off study treatment~Doses for both arms:~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
217589|NCT02525029|Drug|Pregnyl®|"ARM 2a: Steroid Dependent aGVHD~Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7:~If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.~If no response, the patient will be taken off study treatment~Doses for both arms:~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
217590|NCT02525029|Drug|Pregnyl®|"ARM 2b: Steroid-Refractory aGVHD~Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 7 doses through day 14:~If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.~If no response, the patient will be taken off study treatment~Doses for both arms:~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
217591|NCT02525016|Biological|Blood sampling|
217594|NCT02525003|Dietary Supplement|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
217595|NCT02525003|Other|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
217596|NCT02524990|Behavioral|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
217597|NCT02524977|Behavioral|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
217598|NCT02524977|Behavioral|Educational Intervention Only|Educational conference series
217599|NCT02524964|Drug|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
217600|NCT02524964|Other|control|equivalent volume of sodium chloride solution
217601|NCT02524951|Drug|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
217602|NCT02524938|Dietary Supplement|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
217603|NCT02524938|Dietary Supplement|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
217604|NCT02524925|Procedure|fast track protocol|Evaluation of postoperative stress
217605|NCT02524899|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
217606|NCT02524899|Drug|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
217607|NCT02524899|Drug|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
217608|NCT02524886|Device|GPi DBS with Medtronic electorde and Activa PC pulsegenerator|The electric stimulation of 2 leads implanted in the Globus Pallidus internus
217609|NCT02524873|Device|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
217610|NCT02524860|Device|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
217611|NCT02524847|Drug|Methoxsalen with ECP|Combination product: Methoxsalen sterile solution in conjunction with extracorporeal photopheresis (ECP)
217612|NCT02524834|Procedure|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
217613|NCT02524834|Device|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
217614|NCT02524821|Device|Gelesis100|3 capsules each containing 0.75 mg
217615|NCT02524821|Drug|Metformin|1 tablet of 850 mg
217616|NCT02524795|Dietary Supplement|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
217617|NCT02524782|Biological|MEDI-4166|MEDI-4166 administered subcutaneously
217618|NCT02524782|Biological|Placebo|Placebo administered subcutaneously
217619|NCT02524769|Drug|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
217620|NCT02524756|Procedure|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
217621|NCT02524756|Procedure|laparoscopic radical hysterectomy (type III/C2).|
217622|NCT02524743|Drug|acetaminophen|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
217623|NCT02524743|Drug|Lidocaine|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated lidocaine (20 mg and 40 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
217669|NCT02524392|Other|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
217670|NCT02524379|Drug|Glyburide|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
217624|NCT02524743|Other|Placebo|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated 5 ml iv normal saline before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
217625|NCT02524730|Device|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
217626|NCT02524717|Drug|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
217627|NCT02524704|Device|CT scan|Applied only when part of the patient's standard care
217628|NCT02524691|Device|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
217629|NCT02524678|Drug|Placebo|
217630|NCT02524678|Drug|URC102|
217631|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
217632|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
217633|NCT02524665|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
217634|NCT02524665|Other|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
217635|NCT02524665|Other|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
217636|NCT02524665|Other|Skin Perfecting Lotion|Available over the counter.
217637|NCT02524652|Drug|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
217638|NCT02524639|Drug|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
217639|NCT02524626|Procedure|Sham stimulation|
217640|NCT02524626|Procedure|Vagus stimulation|
217641|NCT02524613|Other|Pelvis CT scan|
217642|NCT02524600|Device|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
217643|NCT02524600|Device|scintigraphic imaging|
217644|NCT02524587|Device|standard polyethylene acetabular irradiated at 3 Mrad|
217645|NCT02524587|Other|radio stereometric analysis (RSA) of the acetabular|
217646|NCT02524587|Device|acetabular polyethylene vitamys®|
217647|NCT02524574|Procedure|cardiac Rehabilitation|
217648|NCT02524574|Other|Tomography Positron Emission|
217649|NCT02524561|Drug|CEE pill|Conjugated equine estrogens 0.45 mg/day
217650|NCT02524561|Drug|Estradiol patch|Climara 50 mcg/day
217651|NCT02524561|Drug|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
217652|NCT02524561|Other|Placebo tablet|Placebo tablet
217653|NCT02524561|Other|Placebo patch|placebo patch
217654|NCT02524561|Other|Placebo progesterone|placebo progesterone
217655|NCT02524548|Other|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
217656|NCT02524535|Other|Therapeutic alliance|
217657|NCT02524522|Device|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
217658|NCT02524522|Device|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
217659|NCT02524483|Behavioral|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
217660|NCT02524483|Behavioral|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
217661|NCT02524470|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
217662|NCT02524470|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
217663|NCT02524457|Other|This is an observational study. There are no interventions|
217664|NCT02524444|Drug|Mefloquine|Tabs Mefloquine 250mg
217665|NCT02524444|Drug|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
217666|NCT02524431|Other|Collection of trabecular meshwork tissue during surgery|Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
217667|NCT02524418|Procedure|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
217668|NCT02524405|Other|Pittsburgh Compound B [11C]-PIB|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Pittsburgh Compound B [11C]-PIB, which is not yet approved for clinical use in Canada, will be performed in all subjects.
217671|NCT02524366|Device|Artificial Urinary Sphincter|
217672|NCT02524353|Other|cardiac surgery|Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
217673|NCT02524327|Other|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
217674|NCT02524327|Other|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
217675|NCT02524301|Drug|Positron Emission Tomography using [11C]diprenorphine|PET using [11C]diprenorphine
217676|NCT02524288|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
217677|NCT02524275|Drug|Capecitabine|Given PO
217678|NCT02524275|Drug|Docetaxel|Given IV
217679|NCT02524275|Other|Quality-of-Life Assessment|Ancillary studies
217680|NCT02524275|Other|Questionnaire Administration|Ancillary studies
217681|NCT02524262|Dietary Supplement|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
217682|NCT02524249|Drug|Caffeine|
217683|NCT02524249|Drug|Placebo (dextrose)|
217684|NCT02524236|Drug|Botox injection in the prostate|transrectal access of prostatic injection
217685|NCT02524223|Other|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
217686|NCT02524223|Other|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
217687|NCT02524223|Other|systematic HPV Status in newborns in case of pregnancy|
217688|NCT02524210|Drug|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
217689|NCT02524210|Drug|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
217690|NCT02524210|Drug|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
217691|NCT02524197|Drug|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
217692|NCT02524197|Drug|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
217693|NCT02524197|Drug|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
217694|NCT02524197|Drug|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
217695|NCT02524184|Drug|sildenafil|sildenafil 100 mg per day for 7 days.
217696|NCT02524184|Drug|placebo|an identical placebo per day for 7 days
217697|NCT02524171|Behavioral|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
217698|NCT02524158|Behavioral|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
217699|NCT02524145|Other|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
217700|NCT02524145|Drug|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
217701|NCT02524145|Drug|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
217702|NCT02524145|Drug|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
217703|NCT02524132|Behavioral|Physical Activity|
217704|NCT02524119|Drug|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
217705|NCT02524119|Procedure|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
217706|NCT02524106|Drug|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
217708|NCT02524093|Behavioral|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
217709|NCT02524093|Other|treatment as usual|
217710|NCT02524080|Procedure|Triage to optimal healthcare level|Triage to optimal healthcare level
217711|NCT02524067|Behavioral|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
217712|NCT02524054|Drug|Furosemide|80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
217713|NCT02524054|Drug|Aerosolized saline|8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
217714|NCT02524041|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
217715|NCT02524041|Other|blood specimen|blood specimen
217716|NCT02524015|Other|Novel physical therapy|
217717|NCT02524015|Other|Standard physical therapy|
217718|NCT02524002|Dietary Supplement|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
217719|NCT02524002|Dietary Supplement|Usual clear diet|Usual clear liquids
217720|NCT02523989|Other|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
217721|NCT02523976|Drug|Dasatinib|Second-generation tyrosine kinase inhibitor
217722|NCT02523976|Drug|prednisone|
217723|NCT02523976|Drug|cyclophosphamide|
217724|NCT02523976|Drug|daunorubicin|
217725|NCT02523976|Drug|vincristine|
217726|NCT02523976|Drug|cytarabine|
217727|NCT02523976|Drug|mercaptopurine|
217728|NCT02523976|Drug|methotrexate|
217729|NCT02523976|Drug|dexamethasone|
217730|NCT02523976|Drug|mitoxantrone|
217731|NCT02523976|Drug|etoposide|
217732|NCT02523976|Procedure|allogeneic hematopoietic stem cell transplantation|
217733|NCT02523976|Procedure|autologous hematopoietic stem cell transplantation|
217734|NCT02523963|Other|family work shop|"The family work shop has 5 courses, with 6 families in one course.~One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
217735|NCT02523950|Procedure|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.~Stage 2. DMEK is performed secondarily according to the corneal status of patients."
217736|NCT02523950|Procedure|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
217737|NCT02523950|Device|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
217738|NCT02523937|Other|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
217739|NCT02523924|Drug|18F-DCFPyL|18F-DCFPyL PET/CT
217740|NCT02523911|Drug|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
217741|NCT02523911|Drug|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
217742|NCT02523911|Drug|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
217743|NCT02523898|Drug|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
217744|NCT02523898|Drug|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
217745|NCT02523898|Drug|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
217746|NCT02523859|Drug|Propofol|Hypnotic drug used for anesthesia
217747|NCT02523859|Drug|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
217748|NCT02523846|Drug|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).~So, half of the total 24-hour morphine requirement will be infused over 24 hours.~e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
217873|NCT02522819|Device|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
217749|NCT02523846|Behavioral|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
217750|NCT02523833|Drug|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
217751|NCT02523820|Drug|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
217752|NCT02523820|Drug|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
217753|NCT02523794|Other|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
217754|NCT02523794|Other|Placebo|Purified Drinking Water
217755|NCT02523781|Other|information pamphlet|The intervention group receives the information pamphlet
217756|NCT02523768|Drug|ATG-F|
217757|NCT02523768|Drug|Simulect|
217758|NCT02523755|Drug|Epidural analgesia Ropivacaine|Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
217759|NCT02523755|Drug|Absence of epidural analgesia|Measurement of regional distribution as assessed by EIT before and after delivery
217760|NCT02523742|Device|IMRf|
217761|NCT02523742|Other|language task and a reference task (rest and Tamil)|
217762|NCT02523729|Dietary Supplement|Anke Malz|non-alcoholic malt drink
217763|NCT02523716|Other|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
217764|NCT02523716|Other|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
217765|NCT02523703|Biological|glutamate and aspartate|
217766|NCT02523690|Drug|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
217767|NCT02523690|Drug|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
217768|NCT02523664|Drug|Hydrocortisone|effects of hydrocortisone on memory while fMRI
217769|NCT02523664|Drug|Placebo|
217770|NCT02523651|Genetic|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
217771|NCT02523651|Other|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
217772|NCT02523638|Drug|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
217773|NCT02523625|Device|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
217774|NCT02523612|Procedure|Biopsy|
217775|NCT02523612|Procedure|Blood sample|
217776|NCT02523599|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
217777|NCT02523599|Other|Placebo|Plain collagen implant (vehicle)
217778|NCT02523586|Other|Oxygen administration|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
217779|NCT02523573|Procedure|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
217780|NCT02523560|Other|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
217781|NCT02523547|Drug|Cavir|0.5mg/day
217782|NCT02523547|Drug|Baraclude|0.5mg/day
217783|NCT02523534|Procedure|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
217784|NCT02523534|Procedure|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
217785|NCT02523521|Behavioral|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
217786|NCT02523508|Behavioral|Experimental group|Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
217787|NCT02523508|Other|Control group|Passive limb mobilization which did not involve the spine
217788|NCT02523469|Biological|ALT-803|
217789|NCT02523469|Biological|Nivolumab|
217790|NCT02523456|Behavioral|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
217791|NCT02523456|Behavioral|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
217792|NCT02523443|Other|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
217793|NCT02523443|Other|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
217794|NCT02523430|Procedure|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
217795|NCT02523417|Procedure|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
217796|NCT02523404|Procedure|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
217797|NCT02523391|Drug|TA-8995|Capsule
217798|NCT02523391|Drug|TA-8995|Tablet
217799|NCT02523378|Behavioral|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
217800|NCT02523378|Behavioral|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
217801|NCT02523365|Procedure|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
217802|NCT02523352|Procedure|Non-Invasive Ventilation|Progressive increase in airway pressure to open lungs atelectatic regions.
217803|NCT02523352|Procedure|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
217804|NCT02523326|Device|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
217805|NCT02523313|Drug|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
217806|NCT02523313|Drug|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
217807|NCT02523313|Drug|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
217808|NCT02523300|Procedure|TEVAR|The patients will be undertaken TEVAR
217809|NCT02523300|Drug|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
217810|NCT02523300|Drug|saline|The other 120 patients will be given saline as control group
217811|NCT02523287|Biological|Fluad|Randomized assignment
217812|NCT02523287|Biological|Saline|Randomized assignment
217813|NCT02523274|Drug|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
217814|NCT02523274|Drug|Placebo|Vegetable-based cellulose
217815|NCT02523274|Behavioral|Exercise|Multi-modal exercise regimen, 3 days/week
217816|NCT02523261|Procedure|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
217817|NCT02523261|Procedure|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
217818|NCT02523248|Procedure|tonsillectomy|Tonsillectomy with cold steel
217819|NCT02523248|Procedure|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
217820|NCT02523235|Drug|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
217821|NCT02523222|Dietary Supplement|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
217822|NCT02523209|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
217823|NCT02523209|Device|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( <15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
217824|NCT02523196|Device|HepQuant-SHUNT|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
217825|NCT02523196|Device|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
217826|NCT02523183|Drug|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
217827|NCT02523170|Device|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
217828|NCT02523157|Other|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
217829|NCT02523157|Other|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
217830|NCT02523144|Drug|Chloral Hydrate|70mg/kg chloral hydrate
217831|NCT02523144|Drug|Dexmedetomidine|2mcg/kg
217832|NCT02523144|Drug|Dexmedetomidine|3mcg/kg
217833|NCT02523144|Drug|Placebo|Flavored placebo syrup
217834|NCT02523131|Device|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:~Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.~An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
217835|NCT02523131|Device|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
217836|NCT02523105|Device|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).~EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
217837|NCT02523092|Drug|Acthar gel|Acthar gel given IM or SQ as per package insert
217838|NCT02523079|Behavioral|Cognitive Behavioral Group Therapy for Insomnia|
217839|NCT02523079|Behavioral|Cognitive Behavioral Self-help Therapy for Insomnia|
217840|NCT02523079|Behavioral|Sleep Hygiene Guidance|
217841|NCT02523066|Device|Magna Ease|This study is non-intervention
217842|NCT02523053|Procedure|Hepatectomy|Surgical removal of all lesions
217843|NCT02523053|Drug|5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
217844|NCT02523040|Drug|Lenalidomide|
217845|NCT02523027|Dietary Supplement|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
217846|NCT02523027|Dietary Supplement|Oral nutritional supplement|(List No- P968/Z0)
217847|NCT02523027|Other|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
217848|NCT02523014|Drug|vismodegib|Given PO
217849|NCT02523014|Drug|GSK2256098|Given PO
217850|NCT02522988|Behavioral|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
217851|NCT02522975|Drug|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
217852|NCT02522975|Drug|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.~Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
217853|NCT02522962|Behavioral|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
217854|NCT02522962|Behavioral|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
217855|NCT02522949|Device|ColdZyme® mouth spray|
217856|NCT02522949|Device|Placebo|
217857|NCT02522936|Drug|Biotene oral spray|Biotene oral spray will be provided to participants.
217858|NCT02522923|Other|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
217859|NCT02522923|Other|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
217860|NCT02522910|Drug|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
217861|NCT02522897|Drug|Ranibizumab|
217862|NCT02522897|Device|Laser|
217863|NCT02522884|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
217864|NCT02522871|Device|OCS™ Liver System|
217865|NCT02522871|Other|Control|
217866|NCT02522858|Drug|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.~During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
217867|NCT02522858|Drug|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
217868|NCT02522858|Drug|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
217869|NCT02522845|Device|Class II Compression Stockings (no specific device used)|This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
217870|NCT02522832|Other|Titre 1|Virus infection
217871|NCT02522832|Other|Titre 2|Virus infection
217872|NCT02522832|Other|Titre 3|Virus infection
217874|NCT02522806|Procedure|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
217875|NCT02522793|Other|No intervention; this is an observational study|
217876|NCT02522780|Drug|Mesalamine|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
217877|NCT02522780|Drug|Placebo|Pharmaceutical form: Granules in sachet; Route of administration: Oral use
217878|NCT02522767|Drug|Mesalamine|
217879|NCT02522767|Drug|Placebo|
217880|NCT02522754|Biological|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
217881|NCT02522754|Biological|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
217882|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
217883|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
217884|NCT02522741|Behavioral|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
217885|NCT02522728|Device|Triathlon CR|Implantation of Knee Prosthesis
217886|NCT02522728|Device|Triathlon PS|Implantation of Knee Prosthesis
217887|NCT02522715|Drug|Cabazitaxel|Given IV
217888|NCT02522715|Drug|Enzalutamide|Given PO
217889|NCT02522715|Other|Laboratory Biomarker Analysis|Correlative studies
217890|NCT02522715|Other|Pharmacological Study|Correlative studies
217891|NCT02522715|Drug|Prednisone|Given PO
217892|NCT02522702|Other|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
217893|NCT02522689|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
217894|NCT02522689|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
217895|NCT02522676|Procedure|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
217896|NCT02522676|Procedure|Endoscopic kidney stone surgery|Mini PCNL will be performed.
217897|NCT02522676|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
217898|NCT02522676|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
217899|NCT02522676|Procedure|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
217900|NCT02522676|Procedure|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
217901|NCT02522663|Other|24/7-telephone support|ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
217902|NCT02522650|Drug|Amiloride|5mg twice a day for 8 weeks
217903|NCT02522650|Drug|Triamterene|50mg twice a day for 8 weeks
217904|NCT02522637|Other|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.~At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each < 5 ).~The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
217905|NCT02522624|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
217906|NCT02522611|Drug|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
217907|NCT02522598|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
217908|NCT02522598|Drug|Placebo|water for injection
217909|NCT02522585|Other|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
217910|NCT02522572|Drug|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
217911|NCT02522572|Drug|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
217912|NCT02522572|Other|plasmapheresis|Plasmapheresis will be administered based on group assignment.
217913|NCT02522559|Other|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
217914|NCT02522546|Other|nasopharyngeal swab|nasopharyngeal swab
217915|NCT02522533|Other|Physical Therapy|6 weeks of an exercise program.
217916|NCT02522520|Behavioral|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
217917|NCT02522520|Behavioral|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
217918|NCT02522520|Device|Omron Walking Style pro. 20|
217919|NCT02522507|Behavioral|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
217920|NCT02522494|Behavioral|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
217921|NCT02522494|Behavioral|Video|An educational intervention delivered prior to patients' visits with primary care providers.
217922|NCT02522481|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent will be administered as 2 single 2-mL IV injections during rest and stress echocardiography
217923|NCT02522468|Procedure|Radioactive Seed Localization|
217924|NCT02522468|Procedure|Wire Localization|
217925|NCT02522455|Other|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
217926|NCT02522455|Other|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
217927|NCT02522442|Device|CPAP|Continuous positive airway pressure
217928|NCT02522442|Device|Auto BiLevel|Auto Bilevel positive airway pressure with Flex
217929|NCT02522429|Device|Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
217930|NCT02522416|Device|Central corneal thickness measurement|
217931|NCT02522403|Procedure|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
217932|NCT02522403|Device|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
217933|NCT02522390|Other|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.~The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
217934|NCT02522377|Drug|Ketamine|inter venous injections
217935|NCT02522377|Drug|Midazolam|inter venous injections
217936|NCT02522364|Device|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
217937|NCT02522364|Other|Standard|Clinical and intermittent electrocardiographic follow-up of patients
217938|NCT02522351|Other|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
217939|NCT02522351|Other|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
217940|NCT02522351|Other|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
217941|NCT02522351|Other|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
217942|NCT02522351|Other|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
217943|NCT02522351|Other|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
217944|NCT02522338|Drug|iohexol|10 ml de l'iohexol (300 mgI/ml)
217945|NCT02522325|Drug|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
217946|NCT02522325|Drug|Cocaine|Intranasal cocaine will be administered during experimental sessions.
217947|NCT02522325|Drug|Placebo|Placebo capsules will contain only cornstarch.
217948|NCT02522312|Other|No Intervention|No drug is administered in this study
217949|NCT02522299|Drug|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
217950|NCT02522299|Drug|Placebo|Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
217951|NCT02522299|Device|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
217952|NCT02522299|Device|ELLIPTA|It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
217953|NCT02522286|Behavioral|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
217954|NCT02522286|Behavioral|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.~2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.~3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
217955|NCT02522273|Device|EKF Diagnostics 'SensPoint' Lactate Meter|
217997|NCT02521961|Other|Questionnaire Administration|Ancillary studies
217998|NCT02521961|Procedure|Support Group Therapy|Attend support group sessions
218501|NCT02518555|Other|Laboratory Biomarker Analysis|Correlative studies
217956|NCT02522260|Other|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
217957|NCT02522260|Other|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
217958|NCT02522260|Other|Standard supportive care|Standard supportive care
217959|NCT02522247|Procedure|UPP|surgery with cold steel in general anesthesia
217960|NCT02522234|Biological|F-627 240 μg/kg|F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.
217961|NCT02522234|Biological|F-627 320 μg/kg|F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
217962|NCT02522221|Drug|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
217963|NCT02522221|Drug|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
217964|NCT02522208|Drug|BiDil XR|fixed combination capsule
217965|NCT02522208|Drug|BiDil Immediate Release (IR)|fixed combination tablet
217966|NCT02522182|Behavioral|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
217967|NCT02522182|Behavioral|Usual Treatment|Information related to intervention description have been already included in arm/group description
217968|NCT02522169|Drug|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A< 6month, group B < 6 month). Observation period is one year."
217969|NCT02522156|Behavioral|Looming Vulnerability Induction|guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.
217970|NCT02522156|Behavioral|Control|Neutral guided imagery scenarios making no reference to smoking.
217971|NCT02522143|Behavioral|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
217972|NCT02522143|Behavioral|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
217973|NCT02522130|Drug|Lidocaine|intracervical injection
217974|NCT02522130|Drug|oral misoprostol|oral treatment
217975|NCT02522130|Drug|naproxen|oral treatment
217976|NCT02522130|Other|placebo|oral treatment
217977|NCT02522117|Drug|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
217978|NCT02522117|Drug|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
217979|NCT02522104|Drug|Siklos|
217980|NCT02522091|Device|functional brain MRI|
217981|NCT02522091|Other|Neuropsychology tests|
217982|NCT02522078|Drug|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
217983|NCT02522078|Drug|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
217984|NCT02522052|Other|Blue mussel diet|5 meals a week containing blue mussels
217985|NCT02522052|Other|Meat/Control diet|5 meals a week containing meat
217986|NCT02522039|Drug|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
217987|NCT02522039|Drug|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
217988|NCT02522039|Drug|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
217989|NCT02522013|Drug|Aminophylline|
217990|NCT02522013|Drug|isotonic saline|
217991|NCT02521987|Procedure|8mm port|Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
217992|NCT02521987|Procedure|12mm port|Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
217993|NCT02521974|Biological|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
217994|NCT02521961|Other|Informational Intervention|Watch a Chair-robics DVD
217995|NCT02521961|Other|Informational Intervention|Receive community resource booklet
217996|NCT02521961|Other|Quality-of-Life Assessment|Ancillary studies
217999|NCT02521948|Device|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.
218000|NCT02521935|Device|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):~Appointment 1: Examination & diagnosis & initial impressions.~Appointment 2: Secondary impressions.~Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)~Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.~Appointment 5: Wax-trial denture try-in.~Appointment 6: Insertion and instructions for care of definitive prostheses.~Appointments 7-9 Post adjustments"
218001|NCT02521935|Device|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):~Appointment 1: Exam, diagnosis, & tray selection (begin impressions)~Appointment 2: Definitive impressions and Maxillomandibula relations~Appointment 3: Wax-trial arrangement~Appointment 4: Insertion and instructions for care of definitive prosthesis~Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
218002|NCT02521922|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
218003|NCT02521922|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
218004|NCT02521909|Device|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
218005|NCT02521909|Device|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
218006|NCT02521909|Device|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
218007|NCT02521896|Device|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
218008|NCT02521883|Device|Sooma tDCS|2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
218009|NCT02521883|Device|Sham tDCS|sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
218010|NCT02521870|Drug|SD-101(1)|SD-101 administered intratumorally at escalating doses (up to 11 doses)
218011|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses)
218012|NCT02521870|Drug|SD-101(2)|SD-101 administered intratumorally (up to 22 doses)
218013|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses)
218014|NCT02521870|Biological|SD-101(3)|4 weekly doses of SD-101 starting from Day 1 followed by 1 dose Q3W for 16 additional doses (up to 20 total doses).
218015|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses)
218016|NCT02521857|Drug|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
218017|NCT02521844|Drug|ETC-1922159|Oral administration
218018|NCT02521844|Drug|Pembrolizumab|IV administration
218019|NCT02521831|Drug|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
218020|NCT02521831|Drug|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
218021|NCT02521818|Other|Modified Atkins Diet|
218022|NCT02521818|Other|NIA Diet for Seniors|
218023|NCT02521805|Other|Animal protein|
218024|NCT02521805|Other|Vegetable protein|
218025|NCT02521805|Other|Dietary fiber (cereal food matrice)|
218026|NCT02521805|Other|Dietary fiber (meat food matrice)|
218027|NCT02521805|Other|Dietary fiber (vegetable food matrice)|
218028|NCT02521792|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
218029|NCT02521779|Other|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
218030|NCT02521779|Other|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
218031|NCT02521779|Other|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
218032|NCT02521779|Other|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
218033|NCT02521753|Drug|Metformin|Intervention also includes weight reduction diet and exercise therapy
218034|NCT02521753|Dietary Supplement|Magnesium|Intervention also includes weight reduction diet and exercise therapy
218035|NCT02521753|Dietary Supplement|PUFA|Intervention also includes weight reduction diet and exercise therapy
218502|NCT02518555|Other|Pharmacological Study|Correlative studies
218036|NCT02521740|Other|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
218037|NCT02521714|Drug|Lenalidomide|
218038|NCT02521701|Drug|NFL101|"Level 1: 100 µg~50 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.~Level 2: 200 µg~100 µg per injection (in each arm), two injections at day 1 and two injections at day 29~The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
218039|NCT02521688|Procedure|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
218040|NCT02521675|Behavioral|Usual algorithm|"The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :~Moderate activity 3 hours after lunch~Intense activity 3 hours after lunch~Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible"
218041|NCT02521675|Behavioral|Diabrasport algorithm|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey~The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:~Moderate activity 3 hours after lunch~Intense activity 3 hours after lunch~Moderate activity 90min after lunch These activities shall not exceed one hour"
218042|NCT02521675|Behavioral|Rest|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.~The patient goes home and he will not perform any physical activity during the week"
218043|NCT02521675|Device|Holter Glycemic Ipro2, Medtronic|
218044|NCT02521662|Drug|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
218045|NCT02521662|Device|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
218046|NCT02521662|Drug|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
218047|NCT02521662|Behavioral|Behavioural support|Withdrawal-oriented behavioural support
218048|NCT02521649|Drug|G17DT|
218049|NCT02521636|Other|Antibiotic therapy randomization|
218050|NCT02521636|Other|Serum PCT dosage|
218051|NCT02521623|Device|SurgiMend® Acellular Dermal Matrix|See arm description.
218052|NCT02521623|Device|Strattice™ Acellular Dermal Matrix|See arm description.
218053|NCT02521610|Drug|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
218054|NCT02521610|Drug|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
218055|NCT02521597|Device|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
218056|NCT02521597|Device|Traditional otoscope|Use of a regular otoscope
218057|NCT02521571|Behavioral|Resiliance Alliance|"The intervention is 6 months long & is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs & Supervisors/Managers separately.~Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
218058|NCT02521571|Behavioral|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
218059|NCT02521558|Behavioral|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
218060|NCT02521558|Behavioral|Control Group|"The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.~A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.~Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning."
218061|NCT02521545|Drug|BIIB061|Capsule
218062|NCT02521532|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
218063|NCT02521532|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
218064|NCT02521519|Other|Medial branch block in one side|MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
218065|NCT02521519|Other|paravertebral deep intramuscular (PDI) injection|injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
218066|NCT02521506|Device|Verio Pattern Alert® activated|
218067|NCT02521506|Device|Verio Pattern Alert® deactivated|
218068|NCT02521493|Drug|Asparaginase|Given IM or IV
218069|NCT02521493|Drug|Asparaginase Erwinia chrysanthemi|Given IM or IV
218070|NCT02521493|Drug|Cytarabine|Given IT and IV
218071|NCT02521493|Drug|Daunorubicin|Given IV
218072|NCT02521493|Drug|Daunorubicin Hydrochloride|Given IV
218073|NCT02521493|Drug|Etoposide|Given IV
218074|NCT02521493|Other|Laboratory Biomarker Analysis|Correlative studies
218075|NCT02521493|Drug|Mitoxantrone|Given IV
218076|NCT02521493|Drug|Mitoxantrone Hydrochloride|Given IV
218077|NCT02521493|Drug|Thioguanine|Given PO
218078|NCT02521480|Device|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
218079|NCT02521480|Device|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
218080|NCT02521467|Biological|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
218081|NCT02521467|Other|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
218082|NCT02521454|Behavioral|MBRT|
218083|NCT02521441|Biological|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
218084|NCT02521441|Biological|Filgrastim|Filgrastim at dose of 5 mcg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
218085|NCT02521428|Other|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
218086|NCT02521415|Drug|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
218087|NCT02521415|Drug|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
218088|NCT02521415|Drug|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
218089|NCT02521402|Biological|Biovance|decellularized, dehydrated human amniotic membrane
218090|NCT02521389|Drug|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
218091|NCT02521376|Drug|Entospletinib|Entospletinib 100 mg tablet administered orally
218092|NCT02521363|Device|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for ~24 hours.
218093|NCT02521363|Drug|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
218094|NCT02521337|Other|observation|observation
218095|NCT02521324|Device|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
218096|NCT02521311|Drug|Clemastine|12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
218097|NCT02521311|Drug|Placebo|Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
218098|NCT02521298|Other|Strength Training|
218099|NCT02521298|Procedure|Placebo|
218100|NCT02521298|Drug|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
218101|NCT02521298|Procedure|Dry Needling|
218102|NCT02521285|Drug|Aspirin|Given PO
218103|NCT02521285|Other|Laboratory Biomarker Analysis|Correlative studies
218104|NCT02521285|Other|Placebo|Given PO
218105|NCT02521285|Other|Questionnaire Administration|Ancillary studies
218106|NCT02521272|Other|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
218107|NCT02521272|Device|air pocket|Zero air pocket or one-liter air pocket in the snow.
218108|NCT02521259|Device|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
218109|NCT02521246|Drug|Candesartan + Chlorthalidone|
218110|NCT02521246|Drug|Candesartan + Chlorthalidone|
218111|NCT02521246|Drug|Losartan+hydrochlorothiazide|
218112|NCT02521233|Drug|Candesartan + Chlorthalidone (8mg+12,5mg)|
218113|NCT02521233|Drug|Candesartan + Chlorthalidone (8 mg + 25 mg)|
218114|NCT02521233|Drug|losartan+hydrochlorothiazide|
218115|NCT02521220|Dietary Supplement|L-citrulline|L-citrulline 2 times daily 3 gram (6g/day)
218116|NCT02521220|Dietary Supplement|Placebo|Maltodextrin 2 times daily 3 gram (6g/day)
218117|NCT02521207|Drug|Ibuprofen|
218118|NCT02521194|Behavioral|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
218119|NCT02521181|Drug|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
218120|NCT02521181|Drug|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
218121|NCT02521181|Drug|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
218122|NCT02521168|Drug|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
218123|NCT02521168|Drug|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
218124|NCT02521155|Behavioral|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:~i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
218125|NCT02521142|Other|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
218126|NCT02521142|Other|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
218127|NCT02521142|Other|Spectralis OCT and Topcon DRI OCT|The Spectralis OCT (Heidelberg Engineering) and the high definition Topcon DRI OCT (Topcon), will be used. Both are standard OCT devices for non-invasive imaging of retinal and choroidal structures.
218128|NCT02521142|Other|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
218129|NCT02521129|Device|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
218130|NCT02521116|Other|Dynamic Vessel Analyzer|
218131|NCT02521116|Other|Oxymap T1|
218132|NCT02521103|Device|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
218133|NCT02521090|Biological|EGFRBi-Armed Autologous T Cells|Given IT and IV
218134|NCT02521090|Other|Laboratory Biomarker Analysis|Correlative studies
218135|NCT02521077|Drug|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
218136|NCT02521077|Other|Normal Saline|Saline 0.9%
218137|NCT02521064|Dietary Supplement|Exclusive Enteral Nutrition (EEN)|Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
218138|NCT02521064|Drug|Prednisone|Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
218139|NCT02521051|Drug|Alectinib|
218140|NCT02521051|Drug|Bevacizumab|
218141|NCT02521038|Drug|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
218142|NCT02521025|Other|Intermittent feeding pattern|Intermittent feeding
218143|NCT02521025|Other|Continuous feeding pattern|Continuous feeding
218144|NCT02521012|Dietary Supplement|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
218145|NCT02521012|Dietary Supplement|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
218146|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
218147|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
218148|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
218149|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
218150|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
218151|NCT02520986|Device|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
218152|NCT02520986|Device|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
218153|NCT02520973|Other|Sputum sample|
218154|NCT02520947|Device|BIS|Bispectral index monitoring
218155|NCT02520947|Drug|Desflurane|volatile agent for maintenance of anesthesia
218156|NCT02520934|Drug|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
218157|NCT02520934|Drug|ERT|enzyme replacement therapy
218158|NCT02520921|Drug|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
218159|NCT02520921|Drug|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
218160|NCT02520908|Procedure|HSCT|Hematopoietic stem cell transplantation
218161|NCT02520908|Other|Standard Care|
218162|NCT02520895|Biological|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
218163|NCT02520882|Drug|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
218164|NCT02520882|Device|PET/CT|
218165|NCT02520869|Procedure|swim-up technique|swim-up technique used
218166|NCT02520869|Procedure|zeta test technique|zeta test technique used
218167|NCT02520856|Other|blood sample|
218168|NCT02520843|Drug|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
218169|NCT02520830|Dietary Supplement|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
218170|NCT02520830|Dietary Supplement|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
218171|NCT02520817|Dietary Supplement|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
218172|NCT02520817|Dietary Supplement|Lactulose|
218173|NCT02520804|Drug|sterofundin|sterofundin for shock patients in the first 72 hours
218174|NCT02520804|Drug|normal saline|Normal saline for shock patients in the first 72 hours
218175|NCT02520791|Biological|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
218176|NCT02520791|Other|Laboratory Biomarker Analysis|Correlative studies
218177|NCT02520791|Other|Pharmacological Study|Correlative studies
218178|NCT02520778|Drug|Navitoclax|Given PO
218179|NCT02520778|Drug|Osimertinib|Given PO
218180|NCT02520752|Drug|INC280|
218181|NCT02520752|Drug|Midazolam|
218182|NCT02520752|Drug|Caffeine|
218183|NCT02520739|Dietary Supplement|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
218184|NCT02520739|Dietary Supplement|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
218185|NCT02520739|Dietary Supplement|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
218186|NCT02520726|Drug|Sertraline|< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
218187|NCT02520726|Drug|Placebo oral capsule|Matched encapsulated placebo from 1-4 capsules daily
218188|NCT02520713|Genetic|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
218189|NCT02520700|Device|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
218190|NCT02520687|Dietary Supplement|Beetroot juice|200mls daily for seven days
218191|NCT02520687|Dietary Supplement|Nitrate-depleted beetroot juice|200mls daily for seven days
218192|NCT02520674|Other|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
218193|NCT02520661|Behavioral|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
218194|NCT02520648|Other|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
218195|NCT02520648|Other|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
218196|NCT02520648|Other|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
218197|NCT02520635|Drug|supra-early TEMODAL® chemotherapy|
218198|NCT02520635|Drug|standard TEMODAL® chemotherapy|
218199|NCT02520635|Radiation|Radiotherapy 60Gy|
218200|NCT02520622|Behavioral|Digital photographs loaded onto a mobile device|
218201|NCT02520622|Behavioral|Skin exam reminders|
218202|NCT02520622|Behavioral|Social support network|
218203|NCT02520596|Other|Bioavailability of Raspberry polyphenols|
218204|NCT02520583|Dietary Supplement|Lactic acid bacteria and bifidobacteria|
218205|NCT02520583|Other|Placebo|
218206|NCT02520570|Drug|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
218207|NCT02520557|Other|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
218208|NCT02520544|Device|Accolade stem|Total hip replacement
218209|NCT02520544|Device|Accolade II stem|Total hip replacement
218210|NCT02520544|Device|Trident/Tritanium cup|Total hip replacement
218211|NCT02520531|Device|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
218212|NCT02520531|Device|Scorpio NRG PS|Implantation of total knee prosthesis
218213|NCT02520518|Drug|Dapagliflozin|
218214|NCT02520518|Drug|Placebo|
218215|NCT02520518|Behavioral|Weight maintenance|
218216|NCT02520518|Behavioral|Ad libitum dietary intake|
218217|NCT02520518|Behavioral|Dietary restriction|
218218|NCT02520505|Drug|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
218219|NCT02520505|Behavioral|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
218220|NCT02520505|Procedure|Intrauterine Insemination|Intrauterine insemination will be performed ~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
218221|NCT02520492|Device|noninvasive method of ICP measurements (Elios)|
218222|NCT02520479|Drug|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
218223|NCT02520479|Radiation|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
218224|NCT02520479|Drug|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
218225|NCT02520466|Dietary Supplement|flavanol-rich drink vs flavanol-free drink|Patients will be randomized to either a flavanol-rich drink or a flavanol-free drink of similar volume, taste and calory and sugar content
218226|NCT02520453|Drug|Durvalumab|
218227|NCT02520453|Drug|Placebo|
218228|NCT02520440|Biological|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
218229|NCT02520440|Device|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
218230|NCT02520440|Biological|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
218231|NCT02520427|Drug|AMG 330|0.5-960 µg/day cIV infusion in cycles from 14 to 28 days
218232|NCT02520414|Device|Symphion® Bipolar Hysteroscopic Tissue Resection System|
218233|NCT02520401|Other|Probiotic - BioGaia|Use of a probiotic tablet
218234|NCT02520401|Other|Placebo|Use of a placebo tablet
218235|NCT02520388|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
218236|NCT02520388|Drug|Placebo|
218237|NCT02520375|Other|Prebiotic|
218238|NCT02520375|Other|Control|
218239|NCT02520362|Drug|denosumab|subcutaneous injection
218240|NCT02520362|Drug|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate [Fosamax®], risedronate [Actonel®], ibandronate [Boniva®/Bonviva®] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate [Reclast®/Aclasta®].
218241|NCT02520349|Device|MarkTen and e-Go e-cigarettes|
218242|NCT02520336|Behavioral|Reminder|
218243|NCT02520323|Other|Blood draw|
218244|NCT02520323|Procedure|Bronchoscopy|
218245|NCT02520323|Behavioral|Questionnaires|
218246|NCT02520310|Device|AVJ-514|Patients receiving AVJ-514 device
218247|NCT02520297|Drug|TRV130|Drug
218248|NCT02520284|Biological|Andecaliximab|Andecaliximab 150 mg administered via SC injection
218249|NCT02520284|Biological|Placebo|Placebo matched to andecaliximab administered via SC injection
218250|NCT02520271|Behavioral|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
218251|NCT02520271|Behavioral|Motivational Interview|"Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.~MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems."
218252|NCT02520258|Other|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
218253|NCT02520258|Other|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
218254|NCT02520245|Drug|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
218255|NCT02520232|Behavioral|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
218256|NCT02520232|Behavioral|Stretching and balance exercise program|Stretching and balance exercise program
218257|NCT02520219|Drug|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,>1h,d1; or DDP25 mg/m2,ivgtt,>1h,d1-3.
218258|NCT02520219|Biological|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.~Repeated every 21 days."
218259|NCT02520193|Procedure|Protocolized early mobilization in ICU|
218260|NCT02520180|Device|Firehawk™ stent system|MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
218261|NCT02520180|Device|Abbott Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
218262|NCT02520167|Behavioral|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
218263|NCT02520154|Drug|Carboplatin|Given IV
218264|NCT02520154|Other|Laboratory Biomarker Analysis|Correlative studies
218265|NCT02520154|Drug|Paclitaxel|Given IV
218266|NCT02520154|Biological|Pembrolizumab|Given IV
218267|NCT02520154|Other|Pharmacological Study|Correlative studies
218268|NCT02520141|Other|Laboratory Biomarker Analysis|Correlative studies
218269|NCT02520141|Biological|Ramucirumab|Given IV
218270|NCT02520128|Radiation|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
218271|NCT02520115|Drug|Dexamethasone|Given PO
218272|NCT02520115|Other|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
218273|NCT02520115|Drug|Valproic Acid|Given PO
218274|NCT02520102|Drug|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial~Route of administration: subcutaneous"
218275|NCT02520089|Procedure|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
218276|NCT02520089|Procedure|Platelet Rich Plasma plus bone autograft|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
218277|NCT02520076|Drug|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.~Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:~Pre-transplant Day -1~Post-transplant Day 3~Post-transplant Day 7~Post-transplant Day 14"
218278|NCT02520063|Drug|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
218279|NCT02520063|Drug|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
218280|NCT02520063|Drug|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
218281|NCT02520050|Behavioral|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
218282|NCT02520050|Behavioral|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
218283|NCT02520050|Behavioral|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
218284|NCT02520024|Behavioral|self-directed care|
218285|NCT02520011|Drug|Alvocidib|
218286|NCT02520011|Drug|Cytarabine|
218287|NCT02520011|Drug|Mitoxantrone|
218288|NCT02519998|Other|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
218289|NCT02519985|Device|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.~The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
218290|NCT02519972|Device|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
218291|NCT02519946|Other|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
218292|NCT02519933|Procedure|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
218293|NCT02519933|Procedure|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
218294|NCT02519920|Drug|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
218295|NCT02519920|Drug|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
218296|NCT02519920|Drug|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
218297|NCT02519920|Drug|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
218298|NCT02519894|Behavioral|Dietary Scanning Calculator|
218299|NCT02519881|Procedure|Microfracture|simple microfracture of ankle
218300|NCT02519881|Device|CartiFill|add collagen when doing microfracture
218301|NCT02519868|Device|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
218302|NCT02519868|Device|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
218303|NCT02519855|Biological|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
218304|NCT02519855|Biological|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
218305|NCT02519855|Biological|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
218306|NCT02519842|Drug|Fosaprepitant|
218307|NCT02519842|Drug|Placebo for fosaprepitant|
218308|NCT02519842|Drug|Ondansetron|
218309|NCT02519842|Drug|Dexamethasone|
218310|NCT02519842|Drug|5-HT3 antagonist|
218311|NCT02519829|Procedure|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
218312|NCT02519829|Procedure|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
218313|NCT02519829|Procedure|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
218314|NCT02519829|Procedure|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
218315|NCT02519816|Other|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
218316|NCT02519777|Drug|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
218317|NCT02519777|Drug|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
218318|NCT02519777|Drug|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
218319|NCT02519777|Drug|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
218320|NCT02519764|Other|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
218321|NCT02519764|Other|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
218322|NCT02519751|Dietary Supplement|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
218397|NCT02519192|Procedure|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
218323|NCT02519751|Dietary Supplement|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
218324|NCT02519738|Drug|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
218325|NCT02519738|Drug|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
218326|NCT02519738|Other|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
218327|NCT02519725|Other|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
218328|NCT02519712|Drug|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
218329|NCT02519712|Procedure|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
218330|NCT02519699|Drug|norepinephrine|Increase in mean arterial pressure using norepinephrine
218331|NCT02519673|Device|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
218332|NCT02519660|Drug|Lidocaine/Tetracaine patch|
218333|NCT02519660|Drug|Lidocaine/Prilocaine cream|
218334|NCT02519647|Device|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
218335|NCT02519647|Device|Tracheal intubation with S-guide|Tracheal intubation with S-guide
218336|NCT02519634|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
218337|NCT02519634|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
218338|NCT02519621|Device|NPWT PRO without irrigation|NPWT PRO without irrigation.
218339|NCT02519621|Device|NPWT PRO with irrigation|NPWT PRO with irrigation (saline)
218340|NCT02519621|Device|KCI Ulta|KCI Ulta NPWT without irrigation
218341|NCT02519608|Drug|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
218342|NCT02519608|Drug|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
218343|NCT02519608|Drug|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
218344|NCT02519595|Drug|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
218345|NCT02519595|Drug|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
218346|NCT02519595|Drug|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
218347|NCT02519582|Drug|Niclosamide|2 g per day orally
218348|NCT02519569|Other|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
218349|NCT02519556|Drug|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
218350|NCT02519556|Drug|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
218351|NCT02519543|Drug|Placebo|placebo to be given twice daily, once with breakfast and once with supper
218352|NCT02519543|Drug|Metformin|active experimental drug to be given twice a day, 500 mg with breakfast and 1,000 mg with supper.
218353|NCT02519530|Behavioral|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
218354|NCT02519517|Procedure|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
218355|NCT02519491|Other|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
218356|NCT02519491|Other|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
218357|NCT02519478|Behavioral|Helmetless Tackling Training (HuTT)|see previous sections
218398|NCT02519192|Procedure|ostomy bag|Non Vac Arm will receive ostomy bag applications.
218358|NCT02519465|Other|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 10l/min
218359|NCT02519465|Other|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 30l/min.
218360|NCT02519465|Other|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 50l/min.
218361|NCT02519452|Drug|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 and part 3 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
218362|NCT02519452|Drug|Recombinant Human Hyaluronidase [rHuPH20]) SC Administration|Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 and part 3 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
218363|NCT02519439|Drug|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
218364|NCT02519426|Procedure|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
218365|NCT02519413|Drug|dimethyl fumarate|delayed release capsules
218366|NCT02519400|Drug|Amitriptyline|Single oral dosing
218367|NCT02519387|Drug|Buprenorphine Transdermal Patch|
218368|NCT02519374|Drug|Placebo (including Maltodextrin)|
218369|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 1
218370|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 2
218371|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 3
218372|NCT02519348|Biological|Durvalumab + tremelimumab|Durvalumab will be administered by IV infusion in combination with tremelimumab.
218373|NCT02519348|Biological|Durvalumab|Durvalumab will be administered by IV infusion.
218374|NCT02519348|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
218375|NCT02519348|Biological|Durvalumab + Bevacizumab|Durvalumab will be administered by IV infusion in combination with bevacizumab
218376|NCT02519335|Drug|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
218377|NCT02519322|Biological|Ipilimumab|Given IV
218378|NCT02519322|Other|Laboratory Biomarker Analysis|Correlative studies
218379|NCT02519322|Biological|Nivolumab|Given IV
218380|NCT02519322|Biological|Relatlimab|Given IV
218381|NCT02519322|Procedure|Therapeutic Conventional Surgery|Undergo surgery
218382|NCT02519309|Other|Virta Program|
218383|NCT02519296|Behavioral|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
218384|NCT02519296|Behavioral|Observation|fMRI.
218385|NCT02519296|Device|fMRI|Functional Magnetic Resonance Imaging of the brain
218386|NCT02519283|Behavioral|GUIDED-HF|"Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge."
218387|NCT02519283|Behavioral|Standard of Care|"Those in the standard care arm will receive structured ED discharge assessment to include:~discharge instructions;~medication reconciliation~encourage follow-up."
218388|NCT02519270|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein.
218389|NCT02519257|Procedure|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
218390|NCT02519257|Procedure|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
218391|NCT02519244|Device|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
218392|NCT02519231|Drug|Naproxen|Naproxen 440mg 1x pid
218393|NCT02519231|Drug|Placebo|Placebo tablet 440mg 1x pid
218394|NCT02519218|Device|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
218395|NCT02519205|Other|Survey|
218396|NCT02519192|Device|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
218399|NCT02519192|Procedure|wet to dry dressings|Non Vac arm will receive wet to dry dressing changes.
218400|NCT02519179|Behavioral|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
218401|NCT02519179|Behavioral|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
218402|NCT02519166|Biological|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
218403|NCT02519153|Drug|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
218404|NCT02519140|Drug|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
218405|NCT02519127|Other|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
218406|NCT02519127|Other|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
218407|NCT02519114|Procedure|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
218408|NCT02519101|Device|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
218409|NCT02519075|Other|No intervention|Observational study
218410|NCT02519062|Other|No intervention|This is a retrospective study
218411|NCT02519049|Other|No intervention|This is an observational study
218412|NCT02519036|Drug|ISIS 443139 10 mg|ISIS 443139, 10 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218413|NCT02519036|Drug|ISIS 443139 30 mg|ISIS 443139, 30 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218414|NCT02519036|Drug|ISIS 443139 60 mg|ISIS 443139, 60 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218415|NCT02519036|Drug|ISIS 443139 90 mg|ISIS 443139, 90 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218416|NCT02519036|Drug|ISIS 443139 120 mg|ISIS 443139, 120 mg, was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218417|NCT02519036|Other|Placebo|Placebo was administered by intrathecal injection, on Study Days 1, 29, 57, and 85.
218418|NCT02519023|Drug|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
218419|NCT02519023|Drug|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
218420|NCT02519023|Device|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
218421|NCT02519023|Drug|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
218422|NCT02519023|Drug|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
218423|NCT02519023|Drug|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
218424|NCT02519023|Drug|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
218425|NCT02519010|Drug|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
218426|NCT02519010|Drug|Exforge|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
218427|NCT02518997|Other|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
218428|NCT02518971|Drug|Tamsulosin|0.4 mg daily
218429|NCT02518971|Drug|Placebo|one capsule daily
218430|NCT02518958|Drug|RRx-001|
218431|NCT02518958|Drug|Nivolumab|
218432|NCT02518945|Drug|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
218433|NCT02518945|Drug|Insulin|
218434|NCT02518945|Drug|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
218435|NCT02518945|Drug|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
218436|NCT02518932|Drug|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
218437|NCT02518932|Drug|placebo saline|
218438|NCT02518919|Other|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
218439|NCT02518919|Other|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
218440|NCT02518906|Behavioral|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.~Manual was published in 2013."
218441|NCT02518906|Behavioral|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
218442|NCT02518893|Other|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
218443|NCT02518893|Other|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
218444|NCT02518880|Other|Parabolic flight|
218445|NCT02518880|Other|plasma volume measurements|
218446|NCT02518867|Other|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
218447|NCT02518867|Other|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
218448|NCT02518867|Other|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
218449|NCT02518841|Device|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
218450|NCT02518841|Other|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
218451|NCT02518828|Other|High SpO2|SpO2 range ≥96%
218452|NCT02518828|Other|Low SpO2|SpO2 range 90-92%
218453|NCT02518815|Device|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
218454|NCT02518802|Drug|Gefitinib|Gefitinib 250mg per day for 2 years.
218455|NCT02518802|Drug|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
218456|NCT02518789|Drug|Low-dose Dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
218457|NCT02518789|Drug|High-dose dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
218458|NCT02518789|Drug|normal saline|Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
218459|NCT02518789|Drug|Etomidate|"After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.~-Does not offer any other drugs within 5 min after completion of etomidate."
218460|NCT02518789|Drug|midazolam，fentanyl，rocuronium|Anesthesia induction：Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg
218461|NCT02518789|Drug|propofol，remifentanil，cis atracurium|Anesthesia maintenance：Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg
218462|NCT02518776|Behavioral|Neuropsychological tests|Neuropsychological tests
218463|NCT02518763|Drug|Vitamin D3, 100 000 IU weekly, 4 times|
218464|NCT02518763|Biological|25 OH vitamin D serum concentration measurements|
218465|NCT02518750|Drug|Dexamethasone|Given orally (PO).
218466|NCT02518750|Drug|Panobinostat|Given PO.
218467|NCT02518750|Drug|Liposomal vincristine|For intravenous (IV) use only.
218468|NCT02518750|Drug|Mitoxantrone|Given IV.
218469|NCT02518750|Drug|Peg-asparaginase|"Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
218470|NCT02518750|Drug|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
218471|NCT02518750|Drug|Intrathecal Triples|Given IT as ITMHA.
218472|NCT02518750|Drug|High-dose methotrexate|Given intrathecally (IT) or IV.
218473|NCT02518750|Drug|6-Mercaptopurine|Given PO at consistent time each day.
218474|NCT02518750|Drug|High-dose cytarabine|Given IT or IV.
218475|NCT02518750|Drug|Nelarabine|Given IV
218476|NCT02518750|Drug|Cyclophosphamide|Given IV.
218477|NCT02518750|Drug|Etoposide|"Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
218478|NCT02518750|Drug|Clofarabine|"Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
218479|NCT02518737|Other|Meal Test|
218480|NCT02518724|Procedure|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
218481|NCT02518724|Procedure|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
218482|NCT02518711|Behavioral|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
218483|NCT02518698|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
218484|NCT02518685|Device|TransPyloric Shuttle|
218485|NCT02518685|Device|Sham procedure|
218486|NCT02518685|Behavioral|Lifestyle Counseling|The goal of lifestyle modification counseling is to promote adherence to a reduced calorie diet, increased physical activity and to recommend behavioral modification strategies.
218487|NCT02518672|Dietary Supplement|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
218488|NCT02518672|Dietary Supplement|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
218489|NCT02518659|Dietary Supplement|Inulin|This is the Intervention
218490|NCT02518633|Device|Continuous positive airway pressure devices|overnight use of CPAP device
218491|NCT02518620|Biological|ALX-0061|Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.
218492|NCT02518607|Drug|MGB-BP-3|Treatment of CDI
218493|NCT02518607|Other|Placebo|Placebo
218494|NCT02518594|Drug|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
218495|NCT02518594|Drug|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
218496|NCT02518594|Device|Arabin Pessary|Placement management from randomization to < 35 wks
218497|NCT02518581|Procedure|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
218498|NCT02518568|Drug|V0355|Oral administration (2 tablets)
218499|NCT02518555|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
218500|NCT02518555|Drug|Ibrutinib|Given PO
218503|NCT02518555|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
218504|NCT02518555|Other|Quality-of-Life Assessment|Ancillary studies
218505|NCT02518555|Biological|Trivalent Influenza Vaccine|Given IM
218506|NCT02518542|Procedure|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
218507|NCT02518542|Procedure|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
218508|NCT02518542|Procedure|Endoscopic intervention C|Endoscopic balloon dilatation
218509|NCT02518542|Procedure|Laparoscopic Surgery|Laparoscopic Heller myotomy
218510|NCT02518529|Biological|G17DT|
218511|NCT02518516|Drug|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed >120 days of the index date (i.e. no exposure within 120 days of the index date)."
218512|NCT02518516|Drug|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218513|NCT02518516|Drug|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218514|NCT02518516|Drug|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218515|NCT02518516|Drug|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218516|NCT02518516|Drug|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218517|NCT02518516|Drug|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218518|NCT02518516|Drug|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).~Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
218519|NCT02518503|Drug|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218520|NCT02518503|Drug|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218521|NCT02518503|Drug|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218522|NCT02518503|Drug|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218523|NCT02518503|Drug|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218524|NCT02518503|Drug|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218525|NCT02518503|Drug|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for <10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218526|NCT02518503|Drug|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218564|NCT02518191|Drug|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
218527|NCT02518503|Drug|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
218528|NCT02518477|Other|exercise|progressive resistance training
218529|NCT02518464|Drug|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
218530|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
218531|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
218532|NCT02518438|Drug|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
218533|NCT02518412|Other|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
218534|NCT02518412|Other|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
218535|NCT02518399|Other|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
218536|NCT02518399|Other|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
218537|NCT02518386|Other|No intervention|No intervention is planned
218538|NCT02518373|Biological|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
218539|NCT02518373|Drug|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
218540|NCT02518360|Other|Osteopathic|Body adjustment in three sessions (20 minutes/session).
218541|NCT02518360|Other|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
218542|NCT02518347|Dietary Supplement|FDS-Strawberry|Natural frozen and dried strawberries
218543|NCT02518347|Dietary Supplement|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
218544|NCT02518334|Other|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
218545|NCT02518321|Device|Technology-Assisted Toileting|
218546|NCT02518308|Behavioral|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
218547|NCT02518295|Other|Positive control|200ml milk containing 18g lactose
218548|NCT02518295|Other|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
218549|NCT02518295|Other|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
218550|NCT02518295|Other|Negative control|200 ml of UHT Lactose free milk
218551|NCT02518282|Other|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
218552|NCT02518282|Other|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
218553|NCT02518282|Other|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
218554|NCT02518269|Procedure|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
218555|NCT02518256|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
218556|NCT02518243|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~aromatherapy~music therapy~cognitive training in multimedia application offering cognitive games"
218557|NCT02518230|Device|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
218558|NCT02518230|Device|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
218559|NCT02518217|Behavioral|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
218560|NCT02518217|Behavioral|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
218561|NCT02518217|Behavioral|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
218562|NCT02518204|Other|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
218563|NCT02518204|Other|NP|"Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~HRB: Halstead-Reitan Battery~MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~WAIS-IV: Weschler Adult Intelligence Scale - IV"
218566|NCT02518178|Device|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
218567|NCT02518178|Device|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
218568|NCT02518165|Dietary Supplement|Proprietary spearmint extract|Water extracted spearmint extract
218569|NCT02518165|Other|Placebo|Microcrystalline Cellulose
218570|NCT02518152|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
218571|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
218572|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
218573|NCT02518139|Drug|TD-4208|Subjects receiving TD-4208 are blinded to one of two doses of 4208.
218574|NCT02518139|Drug|Tiotropium|There is not a placebo, there is an active comparator (Tiotropium) arm.
218575|NCT02518126|Other|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
218576|NCT02518113|Drug|LY3039478|Administered orally
218577|NCT02518113|Drug|Dexamethasone|Administered orally
218578|NCT02518113|Drug|Placebo|Administered orally
218579|NCT02518100|Device|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
218580|NCT02518100|Device|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
218581|NCT02518087|Device|oXiris®|"oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [oXiris® (Baxter Gambro)].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
218582|NCT02518074|Other|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
218583|NCT02518061|Other|No intervention|This is a retrospective study
218584|NCT02518048|Drug|LEO 90100 Aerosol foam|
218585|NCT02518048|Drug|Betesil® 2.25 mg|
218586|NCT02518035|Drug|Silicone Gel|Silicone gel will be applied twice per day in the experimental group
218587|NCT02518022|Drug|Insulin|Insulin for beer
218588|NCT02518009|Other|Genetic men treated with estrogen|Observational during estrogen treatment
218589|NCT02518009|Other|Genetic women treated with androgen|Observational during androgen treatment
218590|NCT02517996|Drug|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
218591|NCT02517996|Drug|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
218592|NCT02517983|Other|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
218593|NCT02517970|Behavioral|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
218594|NCT02517957|Drug|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
218595|NCT02517957|Drug|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
218596|NCT02517957|Drug|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
218597|NCT02517957|Drug|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
218598|NCT02517931|Procedure|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
218791|NCT02516709|Radiation|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
218792|NCT02516696|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
218599|NCT02517931|Procedure|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
218600|NCT02517918|Drug|Sirolimus combined with CP, MT and ZA|"Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).~Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established."
218601|NCT02517905|Drug|Bupivacaine liposome|Local administration
218602|NCT02517905|Drug|Placebo|Local administration
218603|NCT02517892|Procedure|Biopsy|
218604|NCT02517879|Other|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
218605|NCT02517879|Other|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
218606|NCT02517866|Drug|Azilsartan Medoxomil|Azilsartan medoxomil tablets
218607|NCT02517853|Device|Posterior tibial nerve stimulation|
218608|NCT02517853|Device|Sham posterior tibial nerve stimulation|
218609|NCT02517827|Device|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
218610|NCT02517827|Procedure|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
218611|NCT02517814|Dietary Supplement|Vitamin D|
218612|NCT02517801|Dietary Supplement|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
218613|NCT02517801|Dietary Supplement|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
218614|NCT02517788|Drug|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
218615|NCT02517788|Drug|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
218616|NCT02517788|Drug|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
218617|NCT02517775|Dietary Supplement|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
218618|NCT02517775|Dietary Supplement|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
218619|NCT02517775|Dietary Supplement|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
218620|NCT02517775|Dietary Supplement|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
218621|NCT02517775|Dietary Supplement|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
218622|NCT02517775|Dietary Supplement|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
218623|NCT02517762|Behavioral|Physical activity|
218624|NCT02517749|Device|Chest Drain Insertion and Talc Pleurodesis|
218625|NCT02517749|Device|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
218626|NCT02517736|Drug|Sorafenib at a dose of 800 mg / day|
218627|NCT02517723|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
218628|NCT02517723|Behavioral|Dialectical Behavior Therapy|"Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.~Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings."
218629|NCT02517723|Behavioral|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
218630|NCT02517723|Other|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
218631|NCT02517710|Procedure|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
218632|NCT02517697|Drug|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
218633|NCT02517697|Drug|Placebo|oral formulation of matching placebo three times daily for 12 weeks
218634|NCT02517684|Drug|Infliximab|
218635|NCT02517684|Drug|Prednisolone|
218636|NCT02517684|Other|Exclusive enteral nutrition|
218638|NCT02517671|Device|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
218639|NCT02517658|Other|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
218640|NCT02517658|Other|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
218641|NCT02517632|Behavioral|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
218642|NCT02517632|Behavioral|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
218643|NCT02517619|Drug|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
218644|NCT02517619|Drug|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
218645|NCT02517606|Other|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
218646|NCT02517606|Other|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
218647|NCT02517593|Genetic|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40%).
218648|NCT02517580|Dietary Supplement|Vitamin K2 (MK7)|
218649|NCT02517567|Device|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
218650|NCT02517567|Device|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
218651|NCT02517567|Device|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
218652|NCT02517554|Behavioral|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
218653|NCT02517554|Behavioral|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
218654|NCT02517554|Behavioral|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
218655|NCT02517541|Device|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
218656|NCT02517528|Drug|ABT-450/r/ABT-267|Tablet
218657|NCT02517528|Drug|ABT-333|Tablet
218658|NCT02517528|Drug|ribavirin|Tablet
218659|NCT02517515|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
218660|NCT02517515|Drug|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
218661|NCT02517502|Drug|DHA|4 capsules of 400 mg DHA daily
218662|NCT02517502|Drug|Placebo|Matched, blinded placebo
218663|NCT02517489|Drug|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
218664|NCT02517489|Drug|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
218665|NCT02517476|Dietary Supplement|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
218666|NCT02517463|Drug|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
218667|NCT02517450|Behavioral|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
218668|NCT02517450|Other|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
218669|NCT02517437|Drug|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
218793|NCT02516696|Drug|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
218801|NCT02516670|Other|Quality-of-Life Assessment|Ancillary studies
218670|NCT02517437|Drug|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
218671|NCT02517424|Drug|High THC/Low CBD Cannabis|Dried cannabis
218672|NCT02517424|Drug|High THC/High CBD Cannabis|Dried cannabis
218673|NCT02517424|Drug|Low THC/Low CBD Cannabis|Dried cannabis
218674|NCT02517411|Other|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
218675|NCT02517411|Other|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
218676|NCT02517398|Drug|MSB0011359C|Subjects will receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
218677|NCT02517385|Drug|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
218678|NCT02517372|Drug|CRD007|
218679|NCT02517359|Drug|RV6153 single dose|Safety and tolerability of single doses
218680|NCT02517359|Drug|RV6153 matching placebo single dose|Safety and tolerability of single doses
218681|NCT02517359|Drug|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
218682|NCT02517359|Drug|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
218683|NCT02517359|Drug|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
218684|NCT02517359|Drug|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
218685|NCT02517346|Other|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
218686|NCT02517346|Other|Telemonitoring|Follow up by telemonitoring system during 3 months
218687|NCT02517333|Other|EPIC Club|Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
218688|NCT02517320|Drug|MT-3995 Low|
218689|NCT02517320|Drug|MT-3995 Middle|
218690|NCT02517320|Drug|MT-3995 High|
218691|NCT02517320|Drug|Placebo|
218692|NCT02517307|Drug|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
218693|NCT02517307|Drug|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
218694|NCT02517307|Drug|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
218695|NCT02517294|Device|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
218696|NCT02517294|Device|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
218697|NCT02517281|Procedure|Biopsy|
218698|NCT02517268|Procedure|Pancreaticoduodenectomy|
218699|NCT02517255|Device|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
218700|NCT02517242|Device|Pens Device|
218701|NCT02517242|Device|Syringe|
218702|NCT02517242|Other|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
218703|NCT02517229|Other|Parabolic flight|
218704|NCT02517229|Other|balance control measurements|
218705|NCT02517229|Device|electromagnetic maneuverable postural platform|
218706|NCT02517216|Other|parabolic flight|
218707|NCT02517216|Device|MRI|
218708|NCT02517190|Other|Parabolic flight|
218709|NCT02517190|Other|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
218710|NCT02517190|Other|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
218711|NCT02517190|Other|cellular energy metabolism measurements|purines, lactate
218712|NCT02517177|Other|Parabolic flight|
218713|NCT02517177|Other|Cardiovascular parameters measurements|
218714|NCT02517164|Other|Measurement of serum 25-hydroxyvitamin D|
218715|NCT02517164|Other|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
218716|NCT02517151|Drug|Ferric carboxymaltose|
218717|NCT02517151|Drug|Placebo|
218718|NCT02517138|Other|Parabolic flight|
218719|NCT02517138|Other|Measurements of eye movements and perception|
218720|NCT02517125|Device|Transoral robotic-assisted surgery with Da Vinci Xi|
218721|NCT02517112|Other|Parabolic flight|
218722|NCT02517112|Other|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
218723|NCT02517112|Device|3D-BCG sensor|
218724|NCT02517099|Drug|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
218725|NCT02517099|Drug|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
218726|NCT02517099|Drug|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
218794|NCT02516696|Drug|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
218727|NCT02517086|Other|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
218728|NCT02517086|Other|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
218729|NCT02517086|Other|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
218730|NCT02517047|Device|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
218731|NCT02517034|Other|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
218732|NCT02517034|Other|Quality-of-Life Assessment|Ancillary studies
218733|NCT02517034|Other|Questionnaire Administration|Ancillary studies
218734|NCT02517034|Other|Survey Administration|Ancillary studies
218735|NCT02517021|Drug|Pro-netupitant/Palonosetron|
218736|NCT02517021|Drug|Netupitant/Palonosetron|
218737|NCT02517021|Drug|Dexamethasone|
218738|NCT02517008|Other|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
218739|NCT02516995|Device|Functional magnetic resonance imaging|
218740|NCT02516995|Device|Ultrasound|
218741|NCT02516982|Other|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
218742|NCT02516982|Other|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
218743|NCT02516982|Other|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
218744|NCT02516982|Other|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
218745|NCT02516969|Radiation|Stereotactic Body Radiotherapy|Radiation
218746|NCT02516956|Other|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
218747|NCT02516956|Other|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
218748|NCT02516956|Other|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
218749|NCT02516956|Other|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
218750|NCT02516956|Other|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
218751|NCT02516943|Other|Control|The patient's ABGs were test according to a 4 - hour routine
218752|NCT02516943|Other|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
218753|NCT02516930|Behavioral|crowdsourced video|video promoting condom use
218754|NCT02516930|Behavioral|social marketing video|
218755|NCT02516917|Behavioral|Attention Training Technique|
218756|NCT02516904|Drug|CD101 IV|antifungal
218757|NCT02516904|Drug|Placebo|normal saline
218758|NCT02516891|Device|Drug-Eluting Stents implantation in bifurcation lesions|
218795|NCT02516683|Other|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
218796|NCT02516670|Dietary Supplement|Ascorbic Acid|Given IV
218797|NCT02516670|Drug|Docetaxel|Given IV
218798|NCT02516670|Other|Laboratory Biomarker Analysis|Correlative studies
218799|NCT02516670|Other|Pharmacological Study|Correlative studies
218800|NCT02516670|Other|Placebo|Given IV
218759|NCT02516878|Procedure|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.~Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
218760|NCT02516865|Device|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
218761|NCT02516865|Device|Ankle weights|Worn during typical daily activities.
218762|NCT02516852|Other|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
218763|NCT02516839|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
218764|NCT02516839|Behavioral|Behavioral Weight Loss (BWL)|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
218765|NCT02516839|Behavioral|BWL + ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.
218766|NCT02516839|Behavioral|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
218767|NCT02516826|Drug|Rosuvastatin|
218768|NCT02516826|Drug|Olmesartan|
218769|NCT02516826|Drug|Combination|Rosuvastatin/Olmesartan(Combination)
218770|NCT02516826|Drug|Placebo of Rosuvastatin|
218771|NCT02516826|Drug|Placebo of Olmesartan|
218772|NCT02516826|Drug|Placebo of Rosuvastatin/Olmesartan(Combination)|
218773|NCT02516813|Drug|MSC2490484A|Phase Ia: Subjects will receive a starting dose of 100 milligram (mg) or 50 mg of MSC2490484A as Capsule or tablet orally once daily 1.5 hours prior each RT.
218774|NCT02516813|Radiation|Fractionated RT|Phase Ia: Subjects will receive fractionated palliative RT (3 Gray [Gy] * 10 in Arm A and 2 Gy * 33 to 35, 5 fractions per week [F/W]) in Arm B.
218775|NCT02516813|Drug|Cisplatin|Cisplatin will be given twice at a dose of 100 milligram per square meter (mg/m^2) or weekly at a dose of 40 (mg/m^2).
218776|NCT02516813|Drug|MSC2490484A|Phase Ib: Subjects will receive the assigned dose of MSC2490484A once daily orally.
218777|NCT02516813|Drug|MSC2490484A|Ancillary cPoP Study: Subjects will receive a single oral MSC2490484A capsule on Day 2, 1.5 hours before the start of RT.
218778|NCT02516813|Radiation|Fractionated RT|Phase Ib: Subjects will receive fractionated RT (2 Gy x 33, 5 F/W).
218779|NCT02516813|Radiation|Fractionated RT|Ancillary cPoP study: Subjects will receive a single high dose of RT (10-25 Gy) capsule on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2.
218780|NCT02516787|Other|Parabolic flight|
218781|NCT02516787|Other|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
218782|NCT02516787|Other|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
218783|NCT02516774|Drug|Adalimumab|
218784|NCT02516761|Other|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
218785|NCT02516761|Other|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
218786|NCT02516761|Other|Control group|With this group no intervention is done, but they are assessed like the other groups.
218787|NCT02516748|Behavioral|Feedback|Less experienced endoscopists in optical diagnosis will receive feedbacks about their own accuracy of optical diagnosis.
218788|NCT02516735|Device|I-scan with magnification|
218789|NCT02516735|Device|Standard endoscopy|
218790|NCT02516722|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.~Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
218802|NCT02516657|Drug|Liraglutide|Liraglutide 0.6 mg
218803|NCT02516644|Behavioral|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
218804|NCT02516644|Behavioral|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
218805|NCT02516631|Drug|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
218806|NCT02516631|Drug|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
218807|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
218808|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
218809|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
218810|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
218811|NCT02516618|Drug|Fasinumab|
218812|NCT02516618|Drug|Placebo|
218813|NCT02516605|Drug|Part 1: LJN452|LJN452 capsules administered once daily for 28 days
218814|NCT02516605|Drug|Part 1: Placebo|Matching placebo capsules administered once daily for 28 days
218815|NCT02516605|Drug|Part 2: LJN452 Dose level 1|LJN452 capsules administered once a day for 12 weeks
218816|NCT02516605|Drug|Part 2: Placebo|Matching placebo to LJN452 administered once a day for 12 weeks
218817|NCT02516605|Drug|Part 2: LJN452 Dose level 2|LJN452
218818|NCT02516592|Drug|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
218819|NCT02516592|Drug|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
218820|NCT02516579|Drug|Siklos|
218821|NCT02516566|Other|PEEP|Mechanical ventilation with PEEP 8 cmH2O
218822|NCT02516553|Drug|BI 894999|day 1 to day 21 in 3-week cycles
218823|NCT02516553|Drug|BI 894999|day 1 to day 14 followed by a week off in 3-week cycles in schedule B
218824|NCT02516553|Drug|BI 894999|one week on followed by one week off treatment, repeated every two weeks in 4-week cycles
218825|NCT02516540|Behavioral|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
218826|NCT02516527|Drug|Ipilimumab|
218827|NCT02516514|Procedure|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
218828|NCT02516501|Dietary Supplement|MyAmino|MyAmino is a supplement containing the eight essential amino acids. MyAmino has a theoretical net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
218829|NCT02516501|Dietary Supplement|betaquik|betaquik is a medium chain triglyceride (MCT) emulsion. One bottle is 225ml corresponding to 45g MCT fats.
218830|NCT02516501|Radiation|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
218831|NCT02516475|Dietary Supplement|zinc sulfate|1 zinc sulfate capsule for 15 weeks
218832|NCT02516475|Other|corn starch|1 corn starch capsule for 15 weeks
218833|NCT02516462|Device|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
218834|NCT02516462|Drug|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
218835|NCT02516449|Other|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
218836|NCT02516436|Drug|BEMA Buprenorphine NX|Buprenorphine with naloxone
218837|NCT02516436|Drug|Buprenorphine|Buprenorphine
218838|NCT02516423|Drug|ixazomib|oral
218839|NCT02516423|Drug|lenalidomide|oral
218840|NCT02516423|Drug|dexamethasone|oral
218841|NCT02516423|Drug|zoledronic acid|IV
218842|NCT02516410|Drug|VX-661 plus ivacaftor combination|
218843|NCT02516410|Drug|Ivacaftor|
218844|NCT02516410|Drug|Placebo (matched to VX-661 plus ivacaftor combination)|
218845|NCT02516410|Drug|Placebo (matched to ivacaftor)|
218846|NCT02516397|Dietary Supplement|Omnia|12weeks of treatment
218847|NCT02516397|Dietary Supplement|Placebo|12weeks of treatment
218848|NCT02516384|Biological|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (>18 year old) patients with active ulcerative colitis (UC).
218849|NCT02516371|Other|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
218850|NCT02516345|Device|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
218851|NCT02516345|Behavioral|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
218852|NCT02516332|Drug|Lexapro|
218853|NCT02516332|Drug|Placebo|
218854|NCT02516332|Behavioral|Supervised Aerboic Exercise|
218855|NCT02516319|Drug|ICG Dye|
218856|NCT02516306|Drug|EV06 Ophthalmic Solution|
218857|NCT02516306|Drug|Placebo Ophthalmic Solution|
218858|NCT02516293|Behavioral|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
219107|NCT02514629|Drug|Metformin + Testosterone Undecanoate|
218859|NCT02516280|Device|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
218860|NCT02516280|Device|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
218861|NCT02516267|Device|Multiplate ADP®|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG
218862|NCT02516254|Dietary Supplement|fortified bread|50 g of fortified bread + placebo daily
218863|NCT02516254|Dietary Supplement|supplement|vitamin D supplement+ plain bread
218864|NCT02516254|Dietary Supplement|placebo|plain bread+placebo
218865|NCT02516241|Drug|MEDI4736 (Durvalumab)|IV infusion
218866|NCT02516241|Drug|Tremelimumab|IV infusion
218867|NCT02516241|Drug|Cisplatin|IV infusion
218868|NCT02516241|Drug|Carboplatin|IV infusion
218869|NCT02516241|Drug|Gemcitabine|IV infusion
218870|NCT02516228|Device|GTEN 100|"Stimulation will be focused on the seizure generating cortex. All patients enrolled in the study will have a pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.~During this baseline period, two two-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone. Using the localization information, patients will be treated with the device for five concurrent days."
218871|NCT02516215|Other|No intervention|
218872|NCT02516202|Drug|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
218873|NCT02516202|Device|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
218874|NCT02516202|Other|Placebo tablet|Dispensed in visually identical bottle and tablet form to Vagifem.
218875|NCT02516202|Other|Placebo gel|Dispensed in visually identical tube and gel form to Replens.
218876|NCT02516189|Other|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.~Relaxation: 5 minutes of stretching."
218877|NCT02516176|Behavioral|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
218878|NCT02516163|Device|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
218879|NCT02516150|Drug|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
218880|NCT02516150|Drug|Glucagon|injection of 50 micrograms of glucagon
218881|NCT02516137|Procedure|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
218882|NCT02516137|Procedure|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
218883|NCT02516137|Procedure|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
218884|NCT02516137|Other|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
218885|NCT02516124|Procedure|Autologous HSCT|1st AHSCT
218886|NCT02516111|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
218887|NCT02516111|Biological|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
218888|NCT02516111|Drug|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
219263|NCT02513498|Other|Laboratory Biomarker Analysis|Correlative studies
218889|NCT02516111|Drug|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
218890|NCT02516098|Drug|hyoscine butylbromide|
218891|NCT02516085|Drug|Metformin|
218892|NCT02516085|Drug|L-Arginine|
218893|NCT02516072|Other|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
218894|NCT02516059|Drug|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
218895|NCT02516059|Drug|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
218896|NCT02516059|Drug|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
218897|NCT02516059|Device|epidural catheter|
218898|NCT02516046|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451. Some subjects may receive a second injection, if 6 months have passed since the first procedure.
218899|NCT02516020|Drug|Global|Embryos are cultured in single step culture from day 1 to day 5
218900|NCT02516020|Drug|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
218901|NCT02515994|Device|senofilcon C|Investigational contact lens
218902|NCT02515994|Device|comfilcon A|Marketed Monthly Replacement Lens (Control)
218903|NCT02515981|Behavioral|NH Medicaid Incentives Program|
218904|NCT02515968|Drug|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
218905|NCT02515968|Drug|Propofol|
218906|NCT02515955|Drug|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
218907|NCT02515955|Drug|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
218908|NCT02515955|Drug|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
218909|NCT02515955|Drug|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
218910|NCT02515955|Drug|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
218911|NCT02515942|Drug|CLG561|
218912|NCT02515942|Drug|LFG316|
218913|NCT02515942|Drug|Sham injection|Empty syringe (without a needle) placed against the eye
218914|NCT02515929|Dietary Supplement|Oligomeric Proanthocyanidins|
218915|NCT02515929|Dietary Supplement|Placebo|
218916|NCT02515916|Other|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
218917|NCT02515903|Procedure|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
218918|NCT02515903|Procedure|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
218919|NCT02515890|Drug|Dexmedetomidine|Subjects will receive this drug during a portion of the study
218920|NCT02515890|Drug|Midazolam|Subjects will receive this drug during a portion of the study
218921|NCT02515890|Device|Peripheral nerve stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the auditory experimental cues.
218922|NCT02515890|Drug|Ketamine|Subjects will receive this drug during a portion of the study
218923|NCT02515877|Radiation|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
218924|NCT02515877|Drug|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
218925|NCT02515877|Drug|Carboplatin|AUC= 2,5 (Calvert formula)
218926|NCT02515864|Drug|FYU-981|
218927|NCT02515864|Drug|Placebo|
218928|NCT02515864|Drug|Moxifloxacin|
218929|NCT02515864|Drug|Moxifloxacin Placebo|
218930|NCT02515851|Drug|Exparel|
218931|NCT02515851|Drug|Placebo|
218932|NCT02515838|Drug|Sevuparin|The Drug Product sevuparin solution for IV infusion
218933|NCT02515838|Other|Placebo|Placebo for IV infusion
218934|NCT02515825|Device|CADence System|Obtain CADence data under normal conditions of use for comparison of results with those of coronary angiogram
218935|NCT02515812|Drug|I-123-MIBG|
218936|NCT02515812|Device|CZT Camera (D-SPECT)|
218937|NCT02515812|Device|Anger Camera|
218938|NCT02515799|Drug|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
218939|NCT02515799|Other|Placebo|Inhaled Placebo
218940|NCT02515786|Other|oxygen humidification|humidification for oxygen delivered by nasal catheter
218941|NCT02515773|Drug|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
218942|NCT02515773|Behavioral|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
218943|NCT02515760|Procedure|Bone marrow aspiration from the iliac crest|
218944|NCT02515760|Device|Illinois bone marrow aspiration neddle|
218945|NCT02515747|Procedure|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
218946|NCT02515747|Procedure|coronary artery bypass grafting|elective surgical myocardial revascularisation
218947|NCT02515734|Drug|fluorouracil|
218948|NCT02515734|Drug|Leucovorin|
218949|NCT02515734|Drug|irinotecan|
218950|NCT02515734|Drug|oxaliplatin|
218951|NCT02515734|Biological|bevacizumab|
218952|NCT02515734|Biological|cetuximab|
219023|NCT02515175|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
218953|NCT02515721|Device|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
218954|NCT02515721|Device|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
218955|NCT02515708|Device|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
218956|NCT02515695|Drug|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
218957|NCT02515682|Dietary Supplement|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
218958|NCT02515682|Dietary Supplement|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
218959|NCT02515682|Dietary Supplement|Placebo|Participants will be give placebo for 24 weeks.
218960|NCT02515669|Drug|RO7239361|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
218961|NCT02515669|Drug|Placebo|Colorless to slightly yellow, clear to opalescent solution, essentially free of particulate matter packaged in a 1 cc glass syringe equipped with a safety syringe device.
218962|NCT02515656|Drug|POLYGYNAX®|
218963|NCT02515656|Drug|GYNODAKTARIN®|
218964|NCT02515656|Drug|Placebo|
218965|NCT02515643|Other|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:~Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.~Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.~Ambulatory blood pressure monitoring with overnight-automated ABPM monitor~Estimation of glomerular filtration rate by Iohexol method"
218966|NCT02515630|Drug|MMB|Momelotinib (MMB) tablet administered orally once daily
218967|NCT02515617|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
218968|NCT02515617|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.~In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
218969|NCT02515604|Drug|Misoprostol|
218970|NCT02515591|Other|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
218971|NCT02515578|Other|Enhanced practice transformation support|
218972|NCT02515578|Other|Standard practice transformation support|
218973|NCT02515565|Drug|cephalosporin with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
218974|NCT02515565|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
218975|NCT02515552|Behavioral|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
218976|NCT02515539|Device|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
218977|NCT02515526|Drug|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
218978|NCT02515526|Drug|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
218979|NCT02515513|Procedure|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
218980|NCT02515500|Behavioral|Gradual Cessation|
218981|NCT02515500|Behavioral|Gradual Cessation w/ Quitbit|
218982|NCT02515487|Other|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
218983|NCT02515474|Procedure|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
218984|NCT02515474|Procedure|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
218985|NCT02515461|Device|Low energy shockwave therapy|"Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.~Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).~Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG."
218986|NCT02515448|Drug|gentamicin|
218987|NCT02515435|Drug|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
218988|NCT02515422|Drug|Ketamine|Subcutaneous infiltration of ketamine
218989|NCT02515422|Drug|Bupivacaine|Subcutaneous infiltration of bupivacaine
218990|NCT02515422|Drug|Placebo (0.9% saline solution)|
218991|NCT02515409|Device|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
218992|NCT02515409|Device|CPAP|CPAP, as a first line treatment in OSAS.
218993|NCT02515396|Drug|MMI-0100|
218994|NCT02515396|Drug|Placebo|
218995|NCT02515383|Behavioral|MD Anderson Symptom Inventory (Adolescent Version)|"Part 1: Adolescent participants complete the MDASI (adolescent version).~Part 2: MDASI (adolescent version) administered twice, one day apart, to assess test-retest reliability. MDASI (adolescent version) then administered at 5 additional time points, each a week apart."
218996|NCT02515383|Behavioral|Interview|"Part 1: Participants are interviewed by study staff regarding the symptom questionnaire.~Part 2: First 20 participants are interviewed by study staff regarding the symptom questionnaire."
218997|NCT02515383|Behavioral|Questionnaires|"Part 1: Participants complete the EQ-5D and a single-item quality of life (QOL) questionnaire.~Part 2: Participants complete the EQ-5D and a single item quality of life question only after first MDASI (adolescent version) completion."
218998|NCT02515370|Other|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
218999|NCT02515357|Behavioral|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
219000|NCT02515357|Behavioral|Standard care|General written instructions regarding the adoption of a healthy lifestyle.
219001|NCT02515357|Behavioral|Mediterranean diet|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
219002|NCT02515344|Other|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
219003|NCT02515344|Other|Providing general information about CRC sreening|
219004|NCT02515331|Drug|LHW090|Capsule - oral dose
219005|NCT02515331|Drug|Placebo|Capsule - oral dose
219006|NCT02515318|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
219007|NCT02515318|Drug|Medical standard treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β‐lactamase inhibitor and fluoroquinolones."
219008|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel (combination)|
219009|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
219010|NCT02515305|Drug|Placebo gel (combination)|
219011|NCT02515279|Drug|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
219012|NCT02515279|Drug|Ribavirin|1000-1600 mg day orally for 48 weeks.
219013|NCT02515266|Other|nutrition: protein intake|additional protein fortification of human milk
219014|NCT02515253|Other|Bra prescription|
219015|NCT02515253|Other|Standard Care|
219016|NCT02515240|Biological|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
219017|NCT02515227|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
219018|NCT02515227|Drug|Pembrolizumab|Humanized monoclonal antibody (mAb) specific for PD-1.
219019|NCT02515201|Drug|Taurolidine|taurolidine in central catheter lumen
219020|NCT02515201|Drug|Heparin|heparin in central venous catheter lumen
219021|NCT02515188|Drug|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
219022|NCT02515188|Drug|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
219024|NCT02515175|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
219025|NCT02515175|Drug|Placebo|0.9% Normal Saline
219026|NCT02515162|Procedure|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
219027|NCT02515162|Procedure|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
219028|NCT02515149|Device|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
219029|NCT02515136|Behavioral|Stimulus-response|See summary
219030|NCT02515123|Device|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.~E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.~By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
219031|NCT02515123|Device|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
219032|NCT02515110|Radiation|External Beam Radiation Therapy|Undergo hypofractionated RNI
219033|NCT02515110|Other|Questionnaire Administration|Ancillary studies
219034|NCT02515110|Other|Laboratory Biomarker Analysis|Correlative studies
219035|NCT02515097|Drug|IDP-122 Lotion|Medicated lotion
219036|NCT02515097|Drug|IDP-122 Vehicle Lotion|Vehicle lotion with no active ingredient
219037|NCT02515084|Device|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
219038|NCT02515084|Device|MRI imaging|
219039|NCT02515071|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
219040|NCT02515071|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
219041|NCT02515058|Device|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
219042|NCT02515058|Device|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
219043|NCT02515045|Drug|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
219044|NCT02515045|Drug|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
219045|NCT02515045|Drug|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
219046|NCT02515045|Drug|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
219047|NCT02515032|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
219048|NCT02515032|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
219049|NCT02515019|Device|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
219050|NCT02515006|Other|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
219051|NCT02514980|Drug|Bupivacaine|Infraorbital nerve block using bupivacaine 0.25% on each side.
219052|NCT02514980|Drug|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
219053|NCT02514967|Drug|Blisibimod|Administered via subcutaneous injection once per week
219054|NCT02514967|Drug|Placebo|Administered via subcutaneous injection once per week
219055|NCT02514954|Drug|Biochaperone® Combo|Subcutaneous injection of an individualized dose
219056|NCT02514954|Drug|Humalog® Mix25|Subcutaneous injection of an individualized dose
219057|NCT02514941|Drug|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
219058|NCT02514941|Drug|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
219059|NCT02514941|Drug|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
219060|NCT02514941|Procedure|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
219061|NCT02514941|Procedure|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
219062|NCT02514941|Procedure|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
219063|NCT02514928|Procedure|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
219064|NCT02514928|Procedure|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
219065|NCT02514915|Radiation|Stereotactic Radiosurgery|Radiation therapy
219066|NCT02514902|Device|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
219067|NCT02514889|Behavioral|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
219068|NCT02514889|Behavioral|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.~Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits & vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
219069|NCT02514876|Device|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
219070|NCT02514850|Drug|Biochaperone Combo|Injection of BioChaperone Combo
219071|NCT02514850|Drug|Humalog Mix25|Injection of Humalog Mix25
219072|NCT02514850|Drug|Humalog|Injection of Humalog
219073|NCT02514850|Drug|Lantus|Injection of Lantus
219074|NCT02514850|Drug|Placebo|Injection of saline 0.9% solution
219075|NCT02514837|Device|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
219076|NCT02514824|Drug|MLN0128|Investigational mTOR kinase inhibitor
219077|NCT02514811|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
219078|NCT02514798|Other|Esophageal and gastric balloons|Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.
219079|NCT02514798|Other|Respiratory Inductance Plethysmography (RIP) system|Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
219080|NCT02514798|Other|Sentec transcutaneous monitoring system|The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.
219081|NCT02514798|Device|High-flow humidified nasal oxygen delivery system|
219082|NCT02514798|Device|CPAP (Positive Control)|
219083|NCT02514772|Biological|GP2013 - A Proposed biosimilar rituximab|
219084|NCT02514772|Biological|Originator rituximab - Rituxan ® or MabThera ®|
219085|NCT02514759|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
219086|NCT02514746|Biological|SA-14-14-2 live, attenuated JE vaccine|0.5 ml (single dose), Subcutaneous
219087|NCT02514720|Other|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
219088|NCT02514694|Drug|LEO32731|
219089|NCT02514694|Other|Placebo|
219090|NCT02514681|Drug|Trastuzumab|
219091|NCT02514681|Drug|Pertuzumab|
219092|NCT02514681|Drug|Docetaxel|
219093|NCT02514681|Drug|Paclitaxel|
219094|NCT02514681|Drug|Nab-paclitaxel|
219095|NCT02514681|Drug|Vinorelbine|
219096|NCT02514681|Drug|Eribulin|
219097|NCT02514681|Drug|Capecitabine|
219098|NCT02514681|Drug|Gemcitabine|
219099|NCT02514668|Drug|Isatuximab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
219100|NCT02514655|Device|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
219101|NCT02514655|Other|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
219102|NCT02514642|Drug|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
219103|NCT02514642|Drug|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
219104|NCT02514629|Drug|Placebo|
219105|NCT02514629|Drug|Metformin|
219106|NCT02514629|Drug|Testosterone Undecanoate|
219108|NCT02514616|Procedure|Laparoscopic IPG and lead implant procedure|EST placement
219109|NCT02514616|Device|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
219110|NCT02514616|Device|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
219111|NCT02514603|Drug|Prexasertib|Administered IV
219112|NCT02514590|Device|Freedom SCS System - High Frequency|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 10kHz therapy.
219113|NCT02514590|Device|Freedom SCS System - Low Frequency|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 therapy.
219114|NCT02514577|Drug|IDP-122 Lotion|lotion
219115|NCT02514577|Drug|IDP-122 Vehicle Lotion|lotion
219116|NCT02514564|Behavioral|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
219117|NCT02514551|Drug|Ramucirumab|Administered IV
219118|NCT02514551|Drug|Paclitaxel|Administered IV
219119|NCT02514538|Drug|Non- effervescent Paracetamol kern|1g
219120|NCT02514538|Drug|Effervescent paracetamol termalgin|1 g
219121|NCT02514525|Device|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
219122|NCT02514512|Device|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
219123|NCT02514499|Other|Questionnaires|
219124|NCT02514486|Behavioral|Questionnaire|
219125|NCT02514473|Drug|VX-809|
219126|NCT02514473|Drug|Placebo|
219127|NCT02514473|Drug|VX-770|
219128|NCT02514460|Device|plaque excision system|
219129|NCT02514460|Device|Stent|
219130|NCT02514447|Drug|Trilaciclib|
219131|NCT02514447|Drug|Placebos|
219132|NCT02514447|Drug|Topotecan|
219133|NCT02514434|Radiation|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
219134|NCT02514434|Radiation|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
219135|NCT02514421|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
219136|NCT02514421|Drug|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
219137|NCT02514421|Drug|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
219138|NCT02514408|Procedure|Catheter Management|Insertion of venous catheter under ultrasound guidance
219139|NCT02514408|Other|Cytology Specimen Collection Procedure|Collection of blood samples
219140|NCT02514408|Other|Laboratory Biomarker Analysis|Correlative studies
219141|NCT02514395|Other|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2[32] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
219142|NCT02514382|Drug|Bortezomib|Given SC or IV
219143|NCT02514382|Drug|Dexamethasone|Given PO, IV, or IM
219144|NCT02514382|Other|Laboratory Biomarker Analysis|Correlative studies
219145|NCT02514382|Other|Pharmacological Study|Correlative studies
219146|NCT02514382|Biological|Wild-type Reovirus|Given IV
219147|NCT02514356|Behavioral|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
219148|NCT02514356|Behavioral|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
219149|NCT02514343|Drug|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
219150|NCT02514343|Drug|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
219151|NCT02514330|Other|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
219152|NCT02514330|Other|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
219153|NCT02514317|Procedure|percutaneous treatment|
219154|NCT02514317|Device|Ultrasound|
219155|NCT02514291|Behavioral|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
219156|NCT02514278|Drug|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"oxaliplatin: 85 mg/m2~irinotecan: 180 mg/m²~folinic acid: 400 mg/m2~5FU: 2400 mg/m2"
219157|NCT02514278|Radiation|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
219264|NCT02513498|Other|Quality-of-Life Assessment|Ancillary studies
219158|NCT02514278|Procedure|Local excision in good responders|"If local excision:~Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)~Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
219159|NCT02514278|Procedure|Rectal excision in bad responders|
219160|NCT02514278|Drug|Capecitabine|1600 mg/m2 daily 5 days/7
219161|NCT02514252|Drug|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
219162|NCT02514252|Behavioral|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
219163|NCT02514252|Behavioral|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
219164|NCT02514252|Behavioral|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
219165|NCT02514239|Drug|BI 836909|
219166|NCT02514226|Procedure|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
219167|NCT02514226|Procedure|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
219168|NCT02514226|Procedure|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
219169|NCT02514226|Other|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
219170|NCT02514213|Biological|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
219171|NCT02514213|Biological|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
219172|NCT02514213|Biological|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
219173|NCT02514213|Biological|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
219174|NCT02514213|Device|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
219175|NCT02514200|Procedure|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
219176|NCT02514200|Procedure|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
219177|NCT02514200|Drug|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
219178|NCT02514200|Device|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
219179|NCT02514187|Drug|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
219180|NCT02514187|Drug|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.~All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
219181|NCT02514174|Drug|Afatinib|afatinib starting at 30 mg daily dose
219182|NCT02514161|Other|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
219183|NCT02514161|Other|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
219184|NCT02514148|Behavioral|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
219260|NCT02513524|Procedure|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
219185|NCT02514148|Other|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
219186|NCT02514148|Other|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
219187|NCT02514148|Other|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
219188|NCT02514135|Other|No intervention|
219189|NCT02514122|Drug|Ketamine|Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
219190|NCT02514122|Drug|Saline|Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
219191|NCT02514109|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
219192|NCT02514083|Drug|Ibrutinib|Ibrutinib
219193|NCT02514083|Drug|Fludarabine|Fludarabine
219194|NCT02514070|Drug|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
219195|NCT02514070|Drug|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
219196|NCT02514057|Other|Questionnaire|Form filling only
219197|NCT02514044|Drug|Dexedrine|10 mg immediate release of Dexedrine
219198|NCT02514044|Device|Active tDCS|1.5 mA tDCS anodal tDCS
219199|NCT02514044|Behavioral|Speech Therapy|60 min of speech therapy
219200|NCT02514044|Drug|Placebo|
219201|NCT02514044|Device|Sham tDCS|
219202|NCT02514031|Drug|ARQ-761|"Dose Level 1:~ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15~Dose Level 2:~ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15~Dose Level 3:~ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15~Expansion Dose Level:~ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
219203|NCT02514031|Drug|Gemcitabine|"Therapy after lead in Phase:~You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
219204|NCT02514031|Drug|nab-paclitaxel|"Therapy after lead in phase:~You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
219205|NCT02514018|Biological|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
219206|NCT02514005|Other|Manual therapy|- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
219207|NCT02514005|Device|Dry needling|"Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.~Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
219208|NCT02513992|Procedure|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
219209|NCT02513992|Drug|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
219210|NCT02513992|Device|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
219211|NCT02513992|Device|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
219212|NCT02513979|Drug|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
219213|NCT02513953|Procedure|Laparoscopic|Four Port Laparoscopic cystectomy
219214|NCT02513940|Drug|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
219215|NCT02513940|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
219216|NCT02513940|Drug|Placebo|Subjects will receive placebo transdermal gel and placebo (lactose) capsules
219217|NCT02513940|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
219218|NCT02513927|Drug|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
219219|NCT02513927|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
219220|NCT02513914|Device|Dural Venous Sinus Stenting|See Dural Venous Sinus Stenting arm.
219221|NCT02513914|Device|Cerebrospinal Fluid Shunting|See Cerebrospinal Fluid Shunting arm.
219222|NCT02513901|Drug|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
219223|NCT02513888|Dietary Supplement|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
219224|NCT02513888|Dietary Supplement|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
219225|NCT02513875|Dietary Supplement|vitamin D|60,000 IU per week for 8 weeks
219226|NCT02513875|Dietary Supplement|Placebo|placebo +diet and lifestyle
219261|NCT02513511|Procedure|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
219262|NCT02513498|Drug|Ixazomib Citrate|Given PO
219227|NCT02513862|Device|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
219228|NCT02513849|Drug|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
219229|NCT02513836|Other|Pre-education intervention|All study participants will be tested with a questionnaire (POEM; Patient Opioids Education Measurement) on their opioid knowledge during 1st visit at the pain clinic.
219230|NCT02513836|Other|Post-education intervention|All study participants will be educated on opioids via an education sheet, pamphlet and video from the Institute for Safe Medication Practices (ISMP) Canada. The questionnaire (POEM) will be tested again after this education on opioid knowledge on the same day.
219231|NCT02513823|Dietary Supplement|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
219232|NCT02513810|Device|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
219233|NCT02513810|Device|BioMatrix Flex with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
219234|NCT02513797|Device|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
219235|NCT02513797|Device|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
219236|NCT02513784|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
219237|NCT02513771|Drug|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
219238|NCT02513771|Drug|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
219239|NCT02513758|Other|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
219240|NCT02513745|Device|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
219241|NCT02513745|Device|Refractive Cataract Suite (Verion + ORA)|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
219242|NCT02513732|Device|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
219243|NCT02513719|Device|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
219244|NCT02513693|Drug|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
219245|NCT02513693|Drug|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
219246|NCT02513680|Device|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
219247|NCT02513680|Device|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
219248|NCT02513667|Drug|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
219249|NCT02513667|Radiation|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
219250|NCT02513654|Drug|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
219251|NCT02513641|Device|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of ~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
219252|NCT02513602|Procedure|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
219253|NCT02513589|Drug|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
219254|NCT02513576|Other|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
219255|NCT02513563|Drug|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
219256|NCT02513563|Drug|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
219257|NCT02513563|Drug|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
219258|NCT02513550|Drug|Ixekizumab|Administered SQ
219259|NCT02513550|Drug|Placebo|Administered SQ
219265|NCT02513498|Other|Questionnaire Administration|Ancillary studies
219266|NCT02513485|Drug|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 50 mg carbidopa. Sinemet will be administered orally at Visit 1 or Visit 2.
219267|NCT02513485|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 1 or Visit 2.
219268|NCT02513472|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
219269|NCT02513472|Drug|Pembrolizumab|Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent.
219270|NCT02513459|Drug|ABBV-066|dose regimen 2
219271|NCT02513459|Drug|ABBV-066|dose regimen 1
219272|NCT02513446|Drug|BI 1026706|Single dose of BI 1026706 on Day 1
219273|NCT02513446|Drug|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
219274|NCT02513433|Drug|Bupivacaine|Local anesthetic
219275|NCT02513433|Drug|Levobupivacaine|Local anesthetic
219276|NCT02513433|Drug|Ropivacaine|Local anesthetic
219277|NCT02513420|Behavioral|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
219278|NCT02513407|Behavioral|Behavioral Dietary Intervention|Attend healthy nutritional education session
219279|NCT02513407|Other|Educational Intervention|Attend EML educational session
219280|NCT02513407|Behavioral|Exercise Intervention|Attend exercise educational session
219281|NCT02513407|Behavioral|Exercise Intervention|Receive fitness tracker
219282|NCT02513407|Other|Laboratory Biomarker Analysis|Correlative studies
219283|NCT02513407|Other|Questionnaire Administration|Ancillary studies
219284|NCT02513394|Drug|Palbociclib|
219285|NCT02513394|Drug|Standard Adjuvant Endocrine Therapy|
219286|NCT02513381|Other|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
219287|NCT02513381|Other|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
219288|NCT02513368|Device|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
219289|NCT02513368|Procedure|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
219290|NCT02513355|Biological|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
219291|NCT02513355|Drug|Changchun marina|25mg/m2,d1 and d8,q21d×4
219292|NCT02513355|Drug|cisplatin|80mg/m2,d1, q21d×4
219293|NCT02513355|Drug|Taxol|135-175mg/m2,d1,q21d×4
219294|NCT02513355|Drug|parapl|AUC=5-6,d1,q21d×4
219295|NCT02513342|Biological|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
219296|NCT02513342|Drug|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
219297|NCT02513342|Drug|Cisplatin|d4，cisplatin，75（mg/m2），iv；
219298|NCT02513329|Drug|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
219299|NCT02513329|Drug|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
219300|NCT02513303|Drug|Sirolimus|Subjects in the treatment group will receive a single prophylactic dose of sirolimus delivered locally to the vessel wall at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery. Control group subjects will have surgery for creation of the AV fistula but will not receive the drug.
219301|NCT02513290|Drug|Bilastine|
219302|NCT02513290|Drug|Loratadine|
219303|NCT02513251|Other|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
219304|NCT02513238|Drug|Mesenchymal stem cell|Stemcells injected into submandibularis
219305|NCT02513238|Drug|Isotonic NaCl|
219306|NCT02513225|Behavioral|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
219307|NCT02513225|Other|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
219308|NCT02513212|Device|Potassium Oxalate|Professionally applied liquid
219309|NCT02513212|Drug|Stannous fluoride paste|SnF2 Paste
219310|NCT02513212|Device|Manual toothbrush|Marketed manual toothbrush
219311|NCT02513212|Device|Power toothbrush|Marketed power toothbrush
219312|NCT02513199|Radiation|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
219313|NCT02513199|Drug|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
219314|NCT02513186|Drug|lenalidomide|Pharmaceutical form: tablet Route of administration: oral
219315|NCT02513186|Drug|bortezomib|Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
219316|NCT02513186|Drug|cyclophosphamide|Pharmaceutical form: tablet Route of administration: oral
219317|NCT02513186|Drug|dexamethasone|Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
219318|NCT02513186|Drug|isatuximab SAR650984|Pharmaceutical form: solution for infusion Route of administration: intravenous
219319|NCT02513160|Drug|Beclomethasone Dipropionate 640|Beclomethasone Dipropionate 640 mcg BAI
219403|NCT02512575|Drug|Placebo oral suspension/ Placebo capsule|Matching placebo
219593|NCT02511145|Device|ablative fractional CO2 laser pretreatment|
219320|NCT02513160|Drug|Placebo|"Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug."
219321|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg BAI|Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
219322|NCT02513160|Drug|albuterol/salbutamol|Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
219323|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg MDI|Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
219324|NCT02513147|Drug|Dolutegravir|
219325|NCT02513147|Drug|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
219326|NCT02513147|Drug|2 NRTI|
219327|NCT02513147|Drug|2 NRTI|
219328|NCT02513121|Other|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
219329|NCT02513108|Procedure|same day discharge|same day discharge after PCI for stable CAD
219330|NCT02513095|Drug|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
219331|NCT02513082|Procedure|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
219332|NCT02513069|Drug|Nicotine gum|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
219333|NCT02513069|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
219334|NCT02513069|Behavioral|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
219335|NCT02513069|Drug|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
219336|NCT02513069|Drug|Nicotine lozenge|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
219337|NCT02513069|Device|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
219338|NCT02513069|Device|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
219339|NCT02513056|Other|MRI|MRI
219340|NCT02513043|Drug|medical abortion|medical abortion
219341|NCT02513030|Procedure|Defibrillation testing during ICD replacement|
219342|NCT02513017|Behavioral|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
219343|NCT02513004|Drug|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
219344|NCT02513004|Drug|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
219345|NCT02512991|Other|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
219346|NCT02512978|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
219347|NCT02512965|Radiation|20 Gy in 5 fractions|
219348|NCT02512965|Radiation|Conventional SBRT: 24 Gy in 2 fractions|
219349|NCT02512952|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
219350|NCT02512952|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
219351|NCT02512952|Procedure|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
219352|NCT02512939|Procedure|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
219353|NCT02512926|Drug|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
219354|NCT02512926|Drug|Cyclophosphamide|
219355|NCT02512926|Drug|Etoposide|
219404|NCT02512575|Drug|Prednisolone|Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
219405|NCT02512562|Drug|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
219406|NCT02512562|Drug|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
219591|NCT02511158|Procedure|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
219356|NCT02512913|Behavioral|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
219357|NCT02512900|Drug|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
219358|NCT02512887|Drug|Caudal Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
219359|NCT02512887|Drug|Dorsal Penile Block Anesthesia|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
219360|NCT02512874|Other|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
219361|NCT02512874|Device|Dynamometer|Grip Test
219362|NCT02512874|Radiation|DEXA|Body Composition Testing
219363|NCT02512874|Other|Gait Speed Test|15 foot walk test
219364|NCT02512874|Device|Activity Monitor|Measures energy expenditure and activity
219365|NCT02512874|Other|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
219366|NCT02512861|Drug|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs"
219367|NCT02512861|Drug|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:~Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients > 50 kgs"
219368|NCT02512835|Other|Community vital signs|We will present clinicians with information about their patients' communities
219369|NCT02512822|Procedure|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
219370|NCT02512809|Drug|Isoflurane|
219371|NCT02512809|Drug|Dexmedetomidine|
219372|NCT02512796|Drug|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
219373|NCT02512783|Drug|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
219374|NCT02512783|Drug|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
219375|NCT02512783|Drug|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
219376|NCT02512770|Procedure|endoscopic dilatation|
219377|NCT02512744|Procedure|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
219378|NCT02512744|Device|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
219379|NCT02512731|Device|Esophageal Doppler Monitor|Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
219380|NCT02512718|Drug|Omegaven|Comparison of FOLE vs. SOLE
219381|NCT02512718|Drug|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
219382|NCT02512705|Device|Pinel Restraints|
219383|NCT02512705|Behavioral|Seclusion Room|
219384|NCT02512692|Device|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
219385|NCT02512692|Drug|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
219386|NCT02512692|Drug|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
219387|NCT02512679|Drug|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
219388|NCT02512679|Drug|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
219389|NCT02512679|Drug|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
219390|NCT02512679|Drug|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
219391|NCT02512666|Device|AM4113-N5UT Dino-Lite|
219392|NCT02512653|Biological|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
219393|NCT02512640|Procedure|Volume-controlled ventilation|a tidal volume of 8 ml/kg
219394|NCT02512640|Procedure|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
219395|NCT02512627|Behavioral|Cognitive training|visuospatial, attention, memory, and executive abilities
219396|NCT02512627|Behavioral|Physical exercise|endurance, balance, and mobility
219397|NCT02512614|Other|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
219398|NCT02512601|Drug|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
219399|NCT02512601|Other|Compression therapy|"Compression:~With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.~With a bandage: 7-10 m long and 10 cm wide.~Both strategies (orthosis vs bandage) are equally applicable."
219400|NCT02512588|Drug|BTD-001|
219401|NCT02512588|Drug|Placebo|
219402|NCT02512575|Drug|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
219407|NCT02512562|Drug|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
219408|NCT02512549|Other|Pulmonary Rehabilitation|
219409|NCT02512536|Drug|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
219410|NCT02512523|Drug|Teneligliptin|
219411|NCT02512523|Drug|Sitagliptin|
219412|NCT02512510|Drug|TD-4208|
219413|NCT02512510|Drug|Placebo|
219414|NCT02512497|Drug|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.~Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
219415|NCT02512497|Drug|Busulfan|Part 1: First 2 doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic (PK) studies. An additional standard of care (SOC) option is now added for those with an HCT-CI >4 or deemed unfit by the investigator to receive full dose (AUC 5000 umol-min) Time-Sequential (TS) Busulfan. SOC busulfan is administered per OSU SCT SOP with a targeted AUC of 4000 umol-min/day for a total exposure of 16,000 umol-min +/- 12% u-Mol-min based upon PK studies. Busulfan 'test-dose' PK studies will be performed prior to administration of full dose of busulfan per SOC. Romidepsin and fludarabine will be administered in an identical fashion using the SOC busulfan as with the TS busulfan. TS busulfan method of busulfan administration will be the preferred method of conditioning therapy for patients enrolled.
219416|NCT02512497|Drug|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
219417|NCT02512497|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
219418|NCT02512497|Drug|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
219419|NCT02512484|Procedure|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
219420|NCT02512471|Drug|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
219421|NCT02512458|Drug|Cabazitaxel|
219422|NCT02512445|Behavioral|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
219423|NCT02512445|Behavioral|Supportive Care Therapy|Supportive therapy
219424|NCT02512432|Device|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
219425|NCT02512419|Behavioral|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
219426|NCT02512419|Behavioral|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
219427|NCT02512419|Device|Actigraph GT3X|
219428|NCT02512406|Other|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
219429|NCT02512406|Other|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
219430|NCT02512406|Other|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
219431|NCT02512406|Other|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
219432|NCT02512406|Other|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
219433|NCT02512406|Other|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
219434|NCT02512393|Device|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
219592|NCT02511145|Other|occlusive bandage|
219435|NCT02512393|Device|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
219436|NCT02512380|Drug|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
219437|NCT02512380|Drug|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
219438|NCT02512367|Other|Dental care education program|
219439|NCT02512367|Other|Surveillance|
219440|NCT02512354|Other|Sample of a fragment of fetal tissue|
219441|NCT02512354|Other|Blood samples|
219442|NCT02512341|Device|Computer Aided Auscultation (CAA)|
219443|NCT02512328|Device|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
219444|NCT02512315|Drug|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
219445|NCT02512315|Drug|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
219446|NCT02512315|Radiation|Concurrent chemoradiation (CRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
219447|NCT02512302|Drug|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
219448|NCT02512302|Drug|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
219449|NCT02512302|Drug|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
219450|NCT02512302|Drug|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
219451|NCT02512302|Drug|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
219452|NCT02512289|Device|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
219453|NCT02512276|Behavioral|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
219454|NCT02512263|Procedure|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
219455|NCT02512250|Other|Registry|
219456|NCT02512237|Drug|ARX788|ARX788, an antibody drug conjugate
219457|NCT02512224|Device|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
219458|NCT02512224|Device|Enteral nutrition|Participants are retrospectively selected with propensity score matching
219459|NCT02512198|Behavioral|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
219460|NCT02512172|Drug|Oral CC - 486|
219461|NCT02512172|Drug|Romidepsin|
219462|NCT02512172|Drug|MK - 3475|
219463|NCT02512159|Procedure|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
219464|NCT02512159|Procedure|Healing|"Were handled as follows:~Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.~healing of skin ulcers were performed every 24 hours.~the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
219465|NCT02512146|Procedure|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
219466|NCT02512133|Device|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
219467|NCT02512133|Procedure|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
219468|NCT02512120|Device|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
219589|NCT02511184|Drug|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
219469|NCT02512120|Device|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).~- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
219470|NCT02512107|Dietary Supplement|Juice Plus+|Dried fruit and vegetable juice capsule.
219471|NCT02512107|Other|Placebo|Placebo capsule
219472|NCT02512081|Other|No intervention applied|No intervention applied
219473|NCT02512068|Drug|Trelagliptin 25 mg|Trelagliptin 25 mg Tablets
219474|NCT02512068|Drug|Placebo|Placebo Tablets
219475|NCT02512055|Drug|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
219476|NCT02512042|Drug|Test-Brinzolamide 1% Ophthalmic suspension|
219477|NCT02512042|Drug|Reference-Brinzolamide 1% Ophthalmic suspension|
219478|NCT02512029|Drug|18F-AV-1451|
219479|NCT02512016|Other|Study Procedures|"Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)~Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.~Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.~Measures of strength and body habitus:~8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index~1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod~Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
219480|NCT02512003|Device|Fantom Scaffold|
219481|NCT02511990|Biological|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
219482|NCT02511990|Biological|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
219483|NCT02511990|Biological|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
219484|NCT02511977|Other|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
219485|NCT02511964|Behavioral|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
219486|NCT02511964|Behavioral|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
219487|NCT02511951|Procedure|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.~Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
219488|NCT02511938|Other|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
219489|NCT02511938|Other|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
219490|NCT02511925|Other|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
219491|NCT02511925|Other|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
219492|NCT02511925|Other|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
219493|NCT02511912|Procedure|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
219494|NCT02511899|Dietary Supplement|Mango fruit powder|Dietary supplement; Mango fruit powder
219495|NCT02511886|Drug|Arbaclofen Placarbil|Arbaclofen Placarbil
219496|NCT02511886|Drug|Placebo|Placebo matched tablets
219497|NCT02511873|Drug|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
219498|NCT02511873|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
219499|NCT02511860|Dietary Supplement|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
219500|NCT02511860|Dietary Supplement|Placebo|Methylcellulose (inert) tablet taken as placebo
219501|NCT02511847|Drug|Afatinib|"Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
219502|NCT02511834|Device|VEST External Support|
219503|NCT02511834|Procedure|Coronary Artery Bypass Surgery|
219504|NCT02511821|Other|Computer-Assisted Intervention|Complete online surveys
219505|NCT02511821|Device|Vivofit watch|Wear Vivofit watch
219506|NCT02511821|Other|Quality-of-Life Assessment|Ancillary studies
219507|NCT02511821|Other|Questionnaire Administration|Ancillary studies
219508|NCT02511808|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
219509|NCT02511808|Behavioral|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
219510|NCT02511808|Behavioral|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
219511|NCT02511795|Drug|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
219512|NCT02511795|Drug|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14."
219513|NCT02511782|Device|D-SQUAME Skin Sampling Discs|A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
219514|NCT02511769|Behavioral|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
219515|NCT02511769|Behavioral|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
219516|NCT02511756|Device|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
219517|NCT02511743|Other|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
219518|NCT02511730|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
219519|NCT02511730|Device|FFDM|FujiFilm Aspire Cristalle System
219520|NCT02511717|Other|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
219521|NCT02511717|Other|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
219522|NCT02511704|Drug|Nicotine|Multiple dose nicotine
219523|NCT02511704|Drug|Nicotine|Multiple dose nicotine
219524|NCT02511691|Drug|18F-PSS232|Diagnostic PET Tracer
219525|NCT02511678|Device|Cryoablation|The application of repeated freeze and thaw cycles to the identified tissues.
219526|NCT02511665|Drug|Metformin|Given metformin
219527|NCT02511665|Radiation|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
219528|NCT02511665|Drug|Placebo|Given placebo
219529|NCT02511652|Device|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
219530|NCT02511652|Device|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
219531|NCT02511652|Procedure|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
219532|NCT02511639|Drug|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
219533|NCT02511639|Drug|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
219534|NCT02511613|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
219535|NCT02511613|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
219536|NCT02511613|Drug|ranibizumab|ranibizumab intravitreal injection
219537|NCT02511600|Other|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
219538|NCT02511600|Other|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
219539|NCT02511600|Behavioral|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
219540|NCT02511587|Biological|FSME-Immune vaccination|booster vaccination with FSME-Immune
219541|NCT02511574|Drug|natural progesterone|
219542|NCT02511574|Device|cervical pessary|
219543|NCT02511561|Drug|OTO-201 (ciprofloxacin)|
219544|NCT02511548|Other|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
219545|NCT02511535|Biological|TBE booster vaccination|
219546|NCT02511522|Other|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
219547|NCT02511522|Radiation|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
219548|NCT02511509|Device|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
219549|NCT02511509|Device|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
219550|NCT02511483|Drug|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
219551|NCT02511483|Drug|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
219552|NCT02511483|Drug|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
219553|NCT02511483|Procedure|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
219554|NCT02511483|Other|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
219555|NCT02511483|Genetic|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
219556|NCT02511470|Other|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
219557|NCT02511470|Other|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
219558|NCT02511444|Other|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
219559|NCT02511431|Drug|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
219560|NCT02511431|Drug|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost Lonafarnib as they both use the same cytochrome P450 system. Will be administered at 100 mg daily.
219561|NCT02511431|Other|Placebo|Placebo
219562|NCT02511418|Drug|Simvastatin|
219563|NCT02511405|Drug|VB-111 + bevacizumab|"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
219564|NCT02511405|Drug|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
219565|NCT02511392|Procedure|rTMS-1Hz|
219566|NCT02511392|Procedure|rTMS-10 Hz|
219567|NCT02511392|Procedure|Sham rTMS|
219568|NCT02511379|Other|Propylene Glycol 0.6% eye drops|
219569|NCT02511366|Other|Ileal infusion of casein|Intraileal infusion of casein
219570|NCT02511366|Other|Ileal infusion of tap water|Intraileal infusion of tap water
219571|NCT02511353|Drug|ivermectin|
219572|NCT02511353|Drug|placebo|Placebo for ivermectin.
219573|NCT02511353|Drug|dihydroartemisinin-piperaquine|
219574|NCT02511340|Drug|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
219575|NCT02511327|Drug|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
219576|NCT02511314|Device|TENA Identifi|TENA Identifi
219577|NCT02511301|Device|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis. There are no interventions after the CBR™ is removed from the Study Subject.
219578|NCT02511275|Procedure|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
219579|NCT02511262|Device|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
219580|NCT02511236|Behavioral|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
219581|NCT02511236|Behavioral|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
219582|NCT02511236|Drug|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
219583|NCT02511223|Drug|OLAPARIB|Olaparib 300 MG twice a day per os given every day until disease progression or toxicity
219584|NCT02511210|Behavioral|regional anesthesia|preoperative anxiety
219585|NCT02511210|Behavioral|general anesthesia|preoperative anxiety
219586|NCT02511197|Drug|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
219587|NCT02511197|Device|PET/CT|
219588|NCT02511184|Drug|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
219590|NCT02511171|Other|Cranial osteopathic manipulative therapy|
219594|NCT02511145|Device|Microneedles pretreatment|
219595|NCT02511145|Drug|METVIXIA Cream|
219596|NCT02511132|Biological|Vigil|Vigil 1.0 x 10e7 cells/injection, intradermally on Day 15 and every 43 weeks thereafter.
219597|NCT02511132|Drug|Temozolomide|oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
219598|NCT02511132|Drug|Irinotecan|irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
219599|NCT02511106|Drug|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
219600|NCT02511106|Drug|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
219601|NCT02511093|Behavioral|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:~BP measurements;~an educational and counselling intervention on patient adherence;~an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
219602|NCT02511080|Device|Spot-On|use of active hot measures
219603|NCT02511067|Drug|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
219604|NCT02511067|Drug|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
219605|NCT02511054|Drug|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
219606|NCT02511054|Drug|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
219607|NCT02511054|Biological|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
219608|NCT02511041|Drug|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- <=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
219609|NCT02511041|Drug|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
219610|NCT02511028|Other|Ferumoxytol|510mg (17mL) IV
219611|NCT02510976|Drug|prucalopride|
219612|NCT02510976|Drug|placebo|
219613|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 24week of gestation
219614|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 28week of gestation
219615|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 32week of gestation
219616|NCT02510950|Biological|Personalized peptide vaccine|
219617|NCT02510950|Drug|Poly-ICLC|
219618|NCT02510950|Drug|Temozolomide|
219619|NCT02510937|Drug|CC-90001|
219620|NCT02510924|Device|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
219621|NCT02510911|Drug|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
219622|NCT02510911|Drug|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
219623|NCT02510911|Drug|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
219624|NCT02510911|Other|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .~On day 4 after surgery an abdominal X-ray will be performed to localize the markers.~Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
219625|NCT02510898|Behavioral|6-week Writing to Heal course|"During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.~Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways."
219697|NCT02510287|Drug|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
219626|NCT02510885|Device|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
219627|NCT02510872|Other|18F-FDG PET combined with CT with iodinated contrast injection|
219628|NCT02510872|Other|18F-FDG PET combined with CT without injection|
219629|NCT02510859|Other|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
219630|NCT02510846|Behavioral|Intensive educative management|5 hours a week
219631|NCT02510833|Behavioral|Exercises oriented, manual and monitoring by phone|Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
219632|NCT02510833|Behavioral|Exercises oriented, manual and without monitoring by phone|Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
219633|NCT02510820|Device|comfilcon A|soft contact lens
219634|NCT02510820|Device|Synergi|Multipurpose solution
219635|NCT02510820|Device|Biotrue|Multipurpose solution
219636|NCT02510820|Other|stenfilcon A|daily disposable contact lenses for washout period
219637|NCT02510807|Other|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
219638|NCT02510794|Drug|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations (Dose 1, 2 and 3).
219639|NCT02510781|Drug|Epirubicin|75mg/m2 d1 evry 21days
219640|NCT02510781|Drug|Docetaxel|75mg/m2 d1 evry 21days
219641|NCT02510781|Drug|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
219642|NCT02510781|Drug|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
219643|NCT02510768|Device|ELAPR002f|Intradermal implant
219644|NCT02510768|Device|ELAPR002g|Intradermal implant
219645|NCT02510768|Device|Saline|Intradermal implant
219646|NCT02510755|Other|MRI|
219647|NCT02510742|Device|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
219648|NCT02510742|Device|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
219649|NCT02510729|Device|Neurostimulation|
219650|NCT02510729|Device|Sham stimulation|
219651|NCT02510716|Behavioral|SGR|
219652|NCT02510716|Behavioral|Support message only|
219653|NCT02510703|Other|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
219654|NCT02510677|Other|myocardial perfusion scintigraphy|
219655|NCT02510664|Behavioral|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
219656|NCT02510651|Procedure|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
219657|NCT02510625|Procedure|Anatomic Glenoid Reconstruction|Distal tibia bone graft
219658|NCT02510625|Procedure|Arthroscopic bankart Repair|Arthroscopic bankart Repair
219659|NCT02510612|Drug|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
219660|NCT02510612|Drug|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
219661|NCT02510599|Drug|solithromycin|
219662|NCT02510586|Drug|Sevoflurane|administer 1.0 MAC (1.7~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
219663|NCT02510560|Drug|NTRA-2112|
219664|NCT02510560|Drug|Placebo|
219665|NCT02510547|Procedure|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
219666|NCT02510547|Procedure|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
219667|NCT02510534|Drug|Menopur 150 international units|Menopur 150 international units given x 1 dose
219668|NCT02510534|Drug|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
219669|NCT02510521|Device|acute muscle exercise by NMES|
219670|NCT02510521|Device|daily workout sequence with NMES in one week|
219671|NCT02510521|Other|rest situation|
219672|NCT02510508|Behavioral|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
219673|NCT02510508|Behavioral|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
219674|NCT02510508|Other|Non-intervention|Non-intervention
219698|NCT02510287|Drug|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
221000|NCT02500654|Device|Emdogain®|Surgery and Emdogain®
219675|NCT02510495|Procedure|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219676|NCT02510495|Procedure|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219677|NCT02510495|Procedure|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219678|NCT02510495|Procedure|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
219679|NCT02510482|Other|No intervention|
219680|NCT02510469|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
219681|NCT02510456|Device|Diffuse Optical Spectroscopy Imaging (DOSI)|Subjects will have up to seven DOSI scans at 7 different time points during the course of their chemotherapy. The time course of chemotherapy may vary between 39 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 7 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-45 minutes, although scans at infusion timepoint will take longer in total due to repeated or continuous measurements.
219682|NCT02510443|Device|ESS305 (Essure, BAY1454032)|Bilateral insert placement
219683|NCT02510430|Behavioral|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
219684|NCT02510430|Behavioral|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
219685|NCT02510430|Behavioral|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
219686|NCT02510417|Biological|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
219687|NCT02510404|Biological|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
219688|NCT02510391|Behavioral|PIPA|Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
219689|NCT02510378|Radiation|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.~After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
219690|NCT02510365|Biological|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
219691|NCT02510339|Other|Observation|Administration of two questionnairs during post operative visits.
219692|NCT02510313|Other|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
219693|NCT02510300|Drug|Sofosbuvir (SOF)|Exposure of interest for participants who received a SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
219694|NCT02510300|Drug|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a LDV/SOF-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
219695|NCT02510300|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|Exposure of interest for participants who received a SOF/VEL-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
219696|NCT02510300|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)|Exposure of interest for participants who received a SOF/VEL/VOX-based regimen in previous Gilead-sponsored chronic hepatitis C infection trials
219738|NCT02510040|Procedure|Botox Injection|Botulinum toxin injection
219699|NCT02510287|Drug|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
219700|NCT02510287|Drug|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
219701|NCT02510287|Drug|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
219702|NCT02510274|Drug|ASP3325|oral
219703|NCT02510261|Drug|Patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
219704|NCT02510248|Drug|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
219705|NCT02510248|Drug|Placebo|Placebo to match AL-704
219706|NCT02510235|Device|Lubricin|Lubricin 150 µg/ml eye drops
219707|NCT02510235|Device|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
219708|NCT02510222|Dietary Supplement|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
219709|NCT02510222|Other|Placebo|
219710|NCT02510209|Behavioral|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
219711|NCT02510196|Behavioral|reminder|
219712|NCT02510183|Device|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
219713|NCT02510183|Device|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
219714|NCT02510170|Other|no intervention|
219715|NCT02510157|Drug|Dexamethasone|active comparator
219716|NCT02510157|Drug|Normal Saline|placebo controlled intervention
219717|NCT02510157|Drug|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
219718|NCT02510144|Drug|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
219719|NCT02510144|Drug|Skin Prep Benzoyl Peroxide|
219720|NCT02510131|Behavioral|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
219721|NCT02510118|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
219722|NCT02510118|Drug|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks
219723|NCT02510118|Drug|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
219724|NCT02510118|Drug|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
219725|NCT02510105|Device|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
219726|NCT02510105|Device|CT scan|
219727|NCT02510105|Device|Servo-i|
219728|NCT02510105|Device|- Intubation|
219729|NCT02510105|Device|Ventilation ( with an ICU conventional ventilator)|
219730|NCT02510092|Device|Percutaneous coronary intervention with new generation fully resorbable scaffold|
219731|NCT02510079|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
219732|NCT02510066|Device|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
219733|NCT02510066|Device|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
219734|NCT02510053|Drug|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
219735|NCT02510040|Device|Prism|Ground-in or Fresnel prism
219736|NCT02510040|Other|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
219737|NCT02510040|Procedure|Eye Muscle Surgery|"Bilateral medial rectus muscle resection surgery~Single medial rectus muscle resection surgery~Recess lateral rectus muscle resection medial rectus muscle surgery~Bilateral lateral rectus muscle recession surgery~Single lateral rectus muscle recession surgery~Bilateral lateral rectus muscle resection surgery~Single lateral rectus muscle resection surgery~Recess medial rectus muscle resection lateral rectus muscle surgery~Bilateral medial rectus muscle recession surgery~Single medial rectus muscle recession surgery~Vertical rectus muscle recession surgery~Vertical rectus muscle mini-tenotomy (snip) surgery"
219739|NCT02510027|Other|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
219740|NCT02510014|Drug|SUBOXONE sublingual film|SUBOXONE (buprenorphine sublingual film) is used for induction therapy on Days -14 to -12. Participants then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to starting the Treatment Period.
219741|NCT02510014|Drug|RBP-6000|Injections administered subcutaneously every 28 days on alternate sides of participant's abdomen starting at 300 mg. Subsequent doses of RBP-6000 could be adjusted down to 100 mg with the possibility of adjusting back up to 300 mg based on the medical judgment of the investigator. De novo subjects receive up to 12 injections and roll-over subjects receive up to 6 injections.
219742|NCT02510001|Drug|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
219743|NCT02510001|Drug|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
219744|NCT02510001|Drug|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
219745|NCT02509988|Dietary Supplement|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
219746|NCT02509988|Dietary Supplement|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
219747|NCT02509975|Device|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
219748|NCT02509962|Dietary Supplement|Slow sodium tablets|6 g sodium chloride per day over 14 days
219749|NCT02509949|Drug|Dexmedetomidine|
219750|NCT02509949|Drug|Saline|
219751|NCT02509936|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
219752|NCT02509936|Dietary Supplement|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
219753|NCT02509923|Drug|Z-215 10mg|Z-215 10mg, capsules
219754|NCT02509923|Drug|Z-215 20mg|Z-215 20mg, capsules
219755|NCT02509923|Drug|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
219756|NCT02509923|Drug|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
219757|NCT02509897|Other|Hypoxic training|Hypoxic training 3 times per week four four weeks
219758|NCT02509897|Other|Normoxic training|Normoxic training 3 times per week four four weeks
219759|NCT02509871|Other|Body composition measurement|DXA, impedance
219760|NCT02509858|Drug|thyroxine|treatment with 50μg of thyroxine once daily for two months.
219761|NCT02509858|Drug|Placebo|treatment with 50μg of placebo, once daily, for two months.
219762|NCT02509858|Other|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
219763|NCT02509845|Drug|C16G2|Antimicrobial peptide
219764|NCT02509845|Other|Placebo|Placebo
219765|NCT02509832|Device|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
219766|NCT02509832|Device|PCI only|Standard of Care for PCI
219767|NCT02509819|Device|Heel Cushion Material Bulk (foam)|The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
219768|NCT02509806|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
219769|NCT02509793|Drug|Tetrabenazine|Xenazine, pill, dose to effect, three times a day, for 12 weeks
219770|NCT02509780|Other|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
219771|NCT02509767|Drug|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
219772|NCT02509754|Procedure|Atrial fibrillation catheter ablation|
219773|NCT02509754|Procedure|Rate control|Composite of optimal medical therapy and device implantation
219774|NCT02509741|Behavioral|Education|
219775|NCT02509741|Dietary Supplement|Food replacement|
219776|NCT02509741|Behavioral|IOT monitoring|
219777|NCT02509728|Dietary Supplement|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
219778|NCT02509728|Dietary Supplement|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
219779|NCT02509728|Dietary Supplement|standard nutrition|standard nutrition
219780|NCT02509715|Procedure|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
219781|NCT02509702|Behavioral|Connected to Care|10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment
219782|NCT02509689|Behavioral|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.~Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
219783|NCT02509676|Other|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
219784|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
219785|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
219786|NCT02509663|Device|Sinuplasty balloon|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
219787|NCT02509663|Device|Endoscope|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.~The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
219788|NCT02509637|Device|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
219789|NCT02509637|Other|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
219790|NCT02509637|Other|Control|
219791|NCT02509637|Other|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
219792|NCT02509637|Other|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
219793|NCT02509637|Other|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
219794|NCT02509637|Device|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
219795|NCT02509637|Other|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
219796|NCT02509624|Drug|GS-4997|GS-4997 6 mg tablet administered orally in a fed state
219797|NCT02509611|Other|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
219798|NCT02509598|Drug|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 15 minutes to 8 hours before surgery
219799|NCT02509598|Drug|Vital Blue Dye (optional)|A single dose 1-3 mL of vital blue dye (1%) administered intradermally at the start of or during surgery (optional, per institution's standard of care).
219800|NCT02509585|Drug|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
219801|NCT02509572|Behavioral|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
219802|NCT02509559|Drug|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
219803|NCT02509559|Drug|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
219804|NCT02509559|Device|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
219805|NCT02509559|Device|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
219806|NCT02509559|Device|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
219807|NCT02509559|Device|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
219808|NCT02509559|Device|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
219809|NCT02509559|Procedure|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
219810|NCT02509546|Other|Laboratory Biomarker Analysis|Correlative studies
219811|NCT02509546|Other|Pharmacological Study|Correlative studies
219812|NCT02509546|Drug|8-chloro-adenosine|Given IV
219813|NCT02509533|Device|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
219814|NCT02509533|Device|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
219815|NCT02509520|Dietary Supplement|MPR and High Protein Supplement (HPRO) and Neuromuscular Electric Stimulation (NMES)|The MPR provides strength and cardiopulmonary endurance training, which consist of exercises to promote function movements. Intensity is based on patient's hemodynamic responses and subjective report using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a moderately intense physiologic response. The NMES protocol requires self-adhesive surface electrodes be placed on quadriceps muscles and lower leg bilaterally, twice daily. This protocol is based on prior NMES protocols used to stimulate muscle protein synthesis in older diabetic patients, preserve muscle mass in intensive care patients and increase strength in older adults after knee replacement. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver ~15g of essential amino acids per serving, with a goal of 1.6 g/kg/day.
219816|NCT02509507|Drug|Talimogene Laherparepvec|Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with US/CT guidance. Part 1: initial dose of T-VEC is 10^6 PFU/mL up to 4mL in Cohorts 1 & 2, up to 8mL in Cohorts 3 & 4 of the Group A & Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10^6 PFU/mL to the 2nd dose at 10^7 or 10^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 & 4) for any individual lesion or for all lesions combined. Part 2: concentration of T-VEC (10^7 or 10^8 PFU/mL) to be administered will be determined on completion of combination treatment, in Part 1. T-VEC will be used at a max. volume of 4 mL (or up to 8mL if determined safe in monotherapy on opening Part 2). If 8ml safety is not established on opening Part 2, only newly enrolled subjects in Part 2 will receive up to a max. of 8mL if safety of administering 8mL in Part 1 is established
219817|NCT02509507|Drug|Pembrolizumab|Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
219818|NCT02509494|Biological|Ad26.ZEBOV|Ebola Zaire vaccine, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles.
219819|NCT02509494|Biological|MVA-BN-Filo|MVA‐BN‐Filo‐ is a non-replicating vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit (Inf. U.).
219820|NCT02509494|Biological|MenACWY|MenACWY is a WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
219821|NCT02509494|Biological|Placebo|0.9% saline for injection.
219822|NCT02509481|Drug|Ivermectin|
219823|NCT02509481|Drug|Albendazole|
219824|NCT02509468|Drug|Sirolimus|"each patient will be followed during a 12-month-period~each patient will start by an observational period and end being treated by sirolimus~at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
219825|NCT02509442|Procedure|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
219826|NCT02509429|Device|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
219827|NCT02509429|Device|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
219828|NCT02509403|Drug|Essential oils infused Perineal Hygiene wipe|Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
219829|NCT02509390|Procedure|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
219830|NCT02509377|Procedure|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
219831|NCT02509364|Other|No intervention|
219832|NCT02509351|Drug|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
219833|NCT02509351|Drug|placeboo|women will recive 2 identical tablets as placeboo
219834|NCT02509338|Device|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
219835|NCT02509325|Device|Parkinson's Kinetigraph|
219836|NCT02509312|Drug|Ketorolac|Patients in experimental arm will receive ketorolac at time of cord clamp and then for 3 more doses every 6 hours
219837|NCT02509312|Drug|Epidural Morphine|All patients, including those in both the experimental and control groups, in this study will receive epidural morphine prior to removal of epidural catheter as part of routine obstetric care for cesarean delivery.
219838|NCT02509312|Drug|Hydromorphone|Post-operatively all patients patients will have intravenous hydromorphone on an as needed basis to control their pain, as part of routine obstetric care for cesarean delivery.
219839|NCT02509299|Other|Physiotherapy program 1|the standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include daily resistance lower limbs exercises.
220501|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
219840|NCT02509299|Other|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included daily controlled breathing exercises and active mobilization.
219841|NCT02509299|Drug|Standard medical treatment|"The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β‐lactamase inhibitor and fluoroquinolones."
219842|NCT02509286|Drug|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
219843|NCT02509286|Drug|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
219844|NCT02509286|Drug|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
219845|NCT02509286|Drug|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
219846|NCT02509286|Drug|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
219847|NCT02509286|Drug|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
219848|NCT02509286|Radiation|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
219849|NCT02509273|Drug|Clonidine|
219850|NCT02509273|Drug|Midazolam|
219851|NCT02509260|Device|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
219852|NCT02509260|Other|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
219853|NCT02509247|Device|Telemonitoring|Wireless telemonitoring
219854|NCT02509234|Drug|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:~Trabectedin 1,1 - 1,5 mg/m²/day i.v.~Day 3-5 and 10-12:~Irinotecan 30- 90 mg/m²/day p.o. or i.v."
219855|NCT02509208|Device|SurgiClot haemostatic dressing|haemostatic dressing
219856|NCT02509195|Drug|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
219857|NCT02509182|Drug|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
219858|NCT02509182|Drug|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
219859|NCT02509169|Drug|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
219860|NCT02509169|Other|TAE|Trans-catheter embolization
219861|NCT02509156|Biological|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
219862|NCT02509156|Biological|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
219863|NCT02509143|Procedure|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).~An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
219864|NCT02509143|Device|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
219865|NCT02509143|Drug|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.~When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
219866|NCT02509117|Drug|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
219867|NCT02509117|Drug|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
219868|NCT02509117|Drug|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
219869|NCT02509117|Drug|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
219870|NCT02509117|Drug|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
219871|NCT02509117|Drug|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
219872|NCT02509104|Drug|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
219873|NCT02509104|Drug|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
220673|NCT02503137|Drug|Topical Vehicle solution|
219874|NCT02509091|Drug|Bronchoalveolar Lavage and Local Amikacin Injection|injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
219875|NCT02509078|Drug|Cisatracurium Besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisatracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
219876|NCT02509065|Device|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
219877|NCT02509065|Other|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
219878|NCT02509052|Other|Laboratory Biomarker Analysis|Correlative studies
219879|NCT02509052|Drug|Leflunomide|Given PO
219880|NCT02509052|Other|Pharmacological Study|Correlative studies
219881|NCT02509039|Drug|CC-122|5 continuous days out of 7 days per week intermittent dosing
219882|NCT02509026|Biological|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
219883|NCT02509000|Other|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
219884|NCT02508961|Behavioral|Exercise|web-based physio exercise programme
219885|NCT02508935|Drug|XARTEMIS XR|XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets
219886|NCT02508922|Dietary Supplement|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
219887|NCT02508922|Dietary Supplement|Placebo|Matching placebo drops will be taken daily for 20 weeks
219888|NCT02508909|Procedure|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
219889|NCT02508896|Biological|AFFITOPE® AT04A+adjuvant|subcutaneous injection
219890|NCT02508896|Biological|AFFITOPE® AT06A+adjuvant|subcutaneous injection
219891|NCT02508896|Biological|Adjuvant without active component|subcutaneous injection
219892|NCT02508870|Drug|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
219893|NCT02508870|Drug|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
219894|NCT02508857|Drug|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
219895|NCT02508857|Drug|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
219896|NCT02508857|Drug|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
219897|NCT02508844|Dietary Supplement|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
219898|NCT02508844|Dietary Supplement|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
219899|NCT02508831|Procedure|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
219900|NCT02508818|Other|Parabolic flight|
219901|NCT02508818|Other|Cardiovascular measurements|
219902|NCT02508805|Drug|Neuromultivit|
219903|NCT02508805|Drug|Voltaren|
219904|NCT02508805|Drug|Sirdalud|
219905|NCT02508792|Device|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
219906|NCT02508792|Device|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
219907|NCT02508779|Behavioral|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
219908|NCT02508779|Other|Routine Care|Participants will continue to receive care from their clinician.
219909|NCT02508766|Procedure|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
219910|NCT02508753|Drug|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
219911|NCT02508753|Drug|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
219912|NCT02508753|Drug|Moxifloxacin|400 mg tablet
219913|NCT02508753|Drug|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
219914|NCT02508740|Drug|bevenopran|Single oral dose
219915|NCT02508727|Other|MRI|
219916|NCT02508727|Other|3D cardiac ultrasound|
219917|NCT02508714|Device|Orsiro|stents will be implanted in case of significant coronary artery disease
219918|NCT02508714|Device|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
219919|NCT02508701|Behavioral|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
221001|NCT02500654|Device|Surgery alone|Surgery alone
219920|NCT02508688|Procedure|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
219921|NCT02508662|Other|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
219922|NCT02508649|Drug|selepressin|
219923|NCT02508649|Drug|placebo|
219924|NCT02508636|Drug|Enzalutamide|
219925|NCT02508636|Drug|Leuprolide|
219926|NCT02508623|Drug|Rifaximin|Rifaximin 550 mg tablet BID for 60 days
219927|NCT02508623|Drug|Placebo|Placebo 1 tablet BID for 60 days
219928|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
219929|NCT02508584|Biological|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
219930|NCT02508571|Other|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk (if the parents refuse, distilled water) via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. This training is provided once a day, 5 days a week. And it is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
219931|NCT02508571|Other|Oral sensorimotor stimulation (OSMS)|"The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier.~In combined DST and OSMS group, each intervention is provided once a day, 5 days a week. And it is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve."
219932|NCT02508571|Other|Routine NICU care|routine NICU care other than OSMS and DST
219933|NCT02508558|Other|motion perception and locomotor operation performance measurements|
219934|NCT02508558|Other|parabolic flight|
219935|NCT02508545|Other|perceived egocentric distance (PED) measurements|
219936|NCT02508545|Other|Parabolic flight|
219937|NCT02508532|Drug|Avapritinib|
219938|NCT02508519|Procedure|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
219939|NCT02508506|Drug|ALKS 5461|Single dose, given orally
219940|NCT02508493|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:~Digit Symbol Substitution Test (DSST)~Choice Reaction Time (CRT)~One-back working memory tool~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
219941|NCT02508493|Other|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:~Digit Symbol Substitution Test (DSST)~Trail Making Test B (TMT-B)~Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)~Variant of Choice Reaction Time (CRT)~Variant of the One-back working memory tool"
219942|NCT02508480|Behavioral|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.~In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
219943|NCT02508480|Behavioral|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
219944|NCT02508467|Drug|BLU-554|
219945|NCT02508441|Drug|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle~Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
219946|NCT02508428|Device|Total Hip Replacement (Marathon)|Comparison of Marathon and Enduron polyethylene
219947|NCT02508428|Device|Total Hip Replacement (Enduron)|
219948|NCT02508415|Other|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
219949|NCT02508402|Drug|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.~All the participants in both groups will randomly be assigned by computer list.~II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
219950|NCT02508402|Drug|Placebo|two milliliters of normal saline given to placebo group .
219951|NCT02508389|Drug|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
219952|NCT02508389|Drug|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
219953|NCT02508389|Drug|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
219954|NCT02508389|Radiation|Intensity-Modulated Radiation Therapy|Daily fractions of IMRT (2.0-2.2 Gy) to a total of 60-72 Gy over approximately 7 weeks
219955|NCT02508389|Drug|Cisplatin|"Administered 80-100 mg/m2 once every three weeks for 3 doses or 30-40 mg/m2 once weekly for 6-7 doses.~Substitution of other systemic agents due to related toxicities (i.e., carboplatin) would be evaluated to determine eligibility by the Medical Monitor"
219956|NCT02508376|Other|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
219957|NCT02508376|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
219958|NCT02508376|Biological|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
219959|NCT02508363|Behavioral|questionnaires|
219960|NCT02508350|Drug|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
219961|NCT02508350|Other|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
219962|NCT02508337|Drug|XG-102|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
219963|NCT02508337|Drug|Placebo|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
219964|NCT02508324|Biological|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
219965|NCT02508324|Biological|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 nucleated blood cells/kg
219966|NCT02508311|Drug|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
219967|NCT02508311|Drug|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
219968|NCT02508298|Procedure|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
219969|NCT02508298|Drug|Indocyanine Green Retention test|As decribed in arm descriptions
219970|NCT02508298|Device|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
219971|NCT02508298|Device|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
219972|NCT02508259|Drug|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
219973|NCT02508259|Drug|Saline|50 ml IV over 30 minutes
219974|NCT02508246|Drug|Cisplatin|Given IV
219975|NCT02508246|Drug|Docetaxel|Given IV
219976|NCT02508246|Other|Laboratory Biomarker Analysis|Correlative studies
219977|NCT02508246|Other|Pharmacological Study|Correlative studies
219978|NCT02508246|Procedure|Therapeutic Conventional Surgery|Undergo surgery
219979|NCT02508246|Drug|WEE1 Inhibitor AZD1775|Given PO
219980|NCT02508220|Drug|Syntocinon|Oxytocin nasal spray
219981|NCT02508220|Drug|Placebo|distilled water in nasal spray
219982|NCT02508207|Drug|Tezacaftor/Ivacaftor|Tezacaftor/Ivacaftor FDC
219983|NCT02508207|Drug|Ivacaftor|
219984|NCT02508207|Drug|Tezacaftor/Ivacaftor matching placebo|
219985|NCT02508207|Drug|Ivacaftor matching placebo|
219986|NCT02508194|Biological|MEDI7510|RSV soluble fusion protein (sF) antigen plus glucopyranosyl lipid A in stable emulsion (GLA-SE) adjuvant
219987|NCT02508194|Biological|IIV|Marketed Inactivated Influenza Vaccine
219988|NCT02508194|Other|Placebo|Sterile Saline
219989|NCT02508181|Device|I-gel|supraglottic airway device without cuff
219990|NCT02508181|Device|LMA Supreme|supraglottic airway device with cuff
219991|NCT02508168|Drug|Alogliptin|Alogliptin 12.5 mg tablets
219992|NCT02508168|Drug|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
219993|NCT02508168|Drug|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
219994|NCT02508155|Biological|MEDI7352 for IV infusion|MEDI7352 for IV infusion
219995|NCT02508155|Biological|Placebo for IV infusion|IV Placebo infusion
219996|NCT02508155|Biological|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
219997|NCT02508155|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
220178|NCT02506816|Drug|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
219998|NCT02508142|Drug|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)~Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
219999|NCT02508129|Behavioral|Brief Behavioral Treatment for Insomnia|BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
220000|NCT02508129|Behavioral|Sleep Healthy Using the Internet|"SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure."
220001|NCT02508129|Behavioral|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
220002|NCT02508116|Genetic|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 *2, *3, and *17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
220003|NCT02508103|Drug|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
220004|NCT02508103|Drug|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
220005|NCT02508077|Drug|Fluorouracil|Given IV
220006|NCT02508077|Drug|Irinotecan Hydrochloride|Given IV
220007|NCT02508077|Other|Laboratory Biomarker Analysis|Correlative studies
220008|NCT02508077|Drug|Leucovorin Calcium|Given PO
220009|NCT02508077|Biological|Panitumumab|Given IV
220010|NCT02508064|Drug|BMS-663068|BMS-663068
220011|NCT02508051|Behavioral|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
220012|NCT02508051|Behavioral|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
220013|NCT02508038|Procedure|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients with high-risk leukemia will receive myeloablative conditioning. All other patients will undergo a reduced-intensity conditioning with ATG, Fludarabine, Thiotepa and TBI followed by transplant with a KIR/KIR (Killer cell immunoglobulin-like recetptor) ligand mismatched haploidentical donor peripheral blood stem cell graft depleted of TCRab+ cells and CD19+ cells using the CliniMACS System. All other patientw will undergo a reduced-intensity conditioning regimen consisting of ATG, Fludarabine, Thiotep and Melphalan followed by haploidentical transplant.
220014|NCT02508038|Drug|Zoledronate|Given IV. Patients will receive five doses of Zoledronate (each 1.25 mg/m2 at a 28 day interval) following transplant.
220015|NCT02508025|Other|Functional Capacity Evaluation|Assessment of work related physical capacity
220016|NCT02508012|Other|Immuno monitoring|treatment optimization
220017|NCT02507999|Device|Flotrac|Flotrac guided intervention
220018|NCT02507986|Device|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
220019|NCT02507986|Device|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
220020|NCT02507973|Other|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
220021|NCT02507973|Other|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
220022|NCT02507960|Device|The Gamma Pod|Immobilization of breast during radiation.
220023|NCT02507960|Device|CT simulation|See arm description
220024|NCT02507934|Device|Lubricin|Lubricin 150 µg/ml eye drops
220025|NCT02507934|Device|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
220026|NCT02507895|Device|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
220027|NCT02507882|Biological|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
220179|NCT02506803|Drug|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
220028|NCT02507882|Biological|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.~The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).~cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
220029|NCT02507869|Behavioral|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
220030|NCT02507869|Behavioral|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
220031|NCT02507843|Drug|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
220032|NCT02507843|Drug|Placebo|Placebo will be administered in placebo group monthly for 6 months.
220033|NCT02507817|Other|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.~A small sample of the placenta will be examined in order to assess the level of ACTH protein"
220034|NCT02507804|Other|Patient diary PROMs|
220035|NCT02507804|Other|Counselling|
220036|NCT02507791|Other|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
220037|NCT02507778|Device|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
220038|NCT02507765|Other|Laboratory Biomarker Analysis|Correlative studies
220039|NCT02507765|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
220040|NCT02507765|Procedure|Transarterial Chemoembolization|Undergo TACE
220041|NCT02507739|Other|no possibility to walk during labor|
220042|NCT02507739|Other|possibility to walk during labor|
220043|NCT02507726|Device|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
220044|NCT02507700|Procedure|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
220045|NCT02507700|Drug|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
220046|NCT02507700|Device|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
220047|NCT02507700|Other|Plaster cover|Plaster cover will be used to control group for sham procedure
220048|NCT02507700|Drug|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
220049|NCT02507700|Other|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
220050|NCT02507687|Drug|Bimatoprost SR|Up to three Bimatoprost SR Dose A administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR Dose B administrations at Day 4 and Week 16 (Stage 2).
220051|NCT02507687|Drug|Sham Bimatoprost SR|Up to three Sham Bimatoprost SR administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Sham Bimatoprost SR administrations at Day 4 and Week 16 (Stage 2).
220052|NCT02507687|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
220053|NCT02507687|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
220054|NCT02507674|Device|ultrasound|
220055|NCT02507661|Drug|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
220056|NCT02507661|Drug|no-preservation of alveolar ridge - 2 months|
220057|NCT02507661|Drug|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
220058|NCT02507661|Drug|no-preservation of alveolar ridge - 4 months|
220059|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
220060|NCT02507661|Drug|no-preservation of alveolar ridge - 9 months|
220061|NCT02507648|Drug|Oseltamivir|1 tablet contains 75 mg oseltamivir
220062|NCT02507648|Drug|Tamiflu®|1 tablet contains 75 mg oseltamivir
220063|NCT02507635|Drug|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
220064|NCT02507635|Drug|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
220065|NCT02507622|Other|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
220066|NCT02507622|Other|Parabolic flight|
220067|NCT02507609|Other|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
220068|NCT02507609|Other|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
220069|NCT02507596|Biological|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
220070|NCT02507596|Procedure|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
220071|NCT02507583|Drug|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
220072|NCT02507570|Drug|Enzalutamide|used concomitantly
220073|NCT02507570|Radiation|Radium ra 223 dichloride|
220074|NCT02507544|Drug|TRX-818 capsules|
220075|NCT02507531|Device|NeXsys Embolization System|Woven metallic mesh placed in aneurysm fundus
220076|NCT02507518|Procedure|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
220077|NCT02507505|Procedure|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
220180|NCT02506790|Drug|metformin|
220078|NCT02507505|Procedure|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
220079|NCT02507492|Drug|RM-493|
220080|NCT02507479|Drug|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
220081|NCT02507466|Behavioral|exercise|Variable conditions of stepping practice
220082|NCT02507453|Other|parabolic flight|
220083|NCT02507453|Other|mass/weight perception estimation|estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
220084|NCT02507453|Device|ESA short-arm human centrifuge (SAHC)|
220085|NCT02507440|Drug|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
220086|NCT02507440|Drug|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
220087|NCT02507440|Drug|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
220088|NCT02507427|Device|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
220089|NCT02507414|Other|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
220090|NCT02507414|Other|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
220091|NCT02507414|Other|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.~End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
220092|NCT02507388|Drug|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
220093|NCT02507388|Drug|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
220094|NCT02507375|Drug|Erlotinib|Erlotinib will be administered as oral tablets.
220095|NCT02507375|Drug|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
220096|NCT02507362|Radiation|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
220097|NCT02507362|Radiation|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
220098|NCT02507362|Drug|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
220099|NCT02507362|Procedure|epithelial debridement|corneal epithelium will be removed by a cottons swab
220100|NCT02507349|Behavioral|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
220101|NCT02507349|Behavioral|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
220102|NCT02507336|Drug|Thalidomide|
220103|NCT02507336|Other|Clinical/Laboratory Evaluations|Annual Clinical/Laboratory evaluations will include Physical Exam, Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), Lactate dehydrogenase (LDH)
220104|NCT02507336|Other|Survival|Patient will be followed for survival by annual telephone contact or in-person visit.
220105|NCT02507323|Drug|ticagrelor|A platelet aggregation inhibitor
220106|NCT02507323|Drug|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
220107|NCT02507323|Drug|Placebo|placebo
220108|NCT02507310|Other|thermostat|ambient temperature as modified by thermostat
220109|NCT02507297|Device|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
220110|NCT02507284|Drug|SRX246|
220111|NCT02507284|Drug|Placebo|
220112|NCT02507271|Other|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
220113|NCT02507271|Other|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
220114|NCT02507258|Device|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
220115|NCT02507245|Drug|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
220116|NCT02507232|Device|NovoTTF-200A|12 cycles
220117|NCT02507232|Drug|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
220118|NCT02507219|Drug|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
220119|NCT02507206|Drug|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
220120|NCT02507206|Drug|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
220181|NCT02506790|Drug|Melatonin|
220182|NCT02506790|Drug|Toremifene|
220183|NCT02506777|Drug|metformin|
220184|NCT02506777|Drug|Fluoruracil|
220185|NCT02506777|Drug|Doxorubicin|
220121|NCT02507193|Procedure|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
220122|NCT02507193|Procedure|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
220123|NCT02507180|Other|LEFt clinical decision rule|"The LEFt rule~Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1~Clinical probability Unlikely: 0 or 1 point Likely: > 1 point"
220124|NCT02507167|Dietary Supplement|mixed meal|250 ml Fortimel compact (chocolate)
220125|NCT02507167|Drug|Rifampin|oral rifampin administration (600 mg EREMFAT®)
220126|NCT02507154|Drug|Cetuximab + NK cells|
220127|NCT02507141|Device|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
220128|NCT02507128|Drug|liraglutide|Liraglutide were taken 30 min before PCI.
220129|NCT02507128|Drug|placebo|Placebo were taken 30 min before PCI.
220130|NCT02507115|Behavioral|TMAP|Text messages for Alcohol Risk Reduction
220131|NCT02507115|Behavioral|Mojo Texts|Motivational texts not alcohol related
220132|NCT02507102|Device|Voyager|Non-invasive RFE therapy
220133|NCT02507089|Behavioral|Tailored sleep health education materials.|Tailored sleep health materials.
220134|NCT02507089|Behavioral|Generic sleep health education materials.|
220135|NCT02507076|Drug|isolated limb perfusion|Undergo ILP with melphalan
220136|NCT02507076|Drug|melphalan|Undergo ILP with melphalan
220137|NCT02507076|Procedure|quality-of-life assessment|Ancillary studies
220138|NCT02507063|Procedure|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
220139|NCT02507050|Drug|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
220140|NCT02507037|Dietary Supplement|gum+PEG|chew sugarless gum
220141|NCT02507037|Drug|polyethylene glycol|2L PEG
220142|NCT02507024|Other|Online questionnaire|
220143|NCT02507011|Drug|Carvedilol|Beta-adrenergic receptor blocker
220144|NCT02507011|Drug|Placebo|Placebo
220145|NCT02506998|Biological|DLE|Adjuvant treatment
220146|NCT02506998|Other|Second generation anti histamines + Nasal corticosteroids|Standard treatment
220147|NCT02506985|Drug|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
220148|NCT02506985|Drug|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
220149|NCT02506972|Other|Classic Quaker Quick Oats|Various doses of oats without or with sugar
220150|NCT02506972|Other|Cream of Rice Cereal|Various doses of cereal without sugar
220151|NCT02506959|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
220152|NCT02506959|Drug|Busulfan|Given IV
220153|NCT02506959|Drug|Gemcitabine Hydrochloride|Given IV
220154|NCT02506959|Other|Laboratory Biomarker Analysis|Correlative studies
220155|NCT02506959|Drug|Melphalan|Given IV
220156|NCT02506959|Drug|Panobinostat|Given PO
220157|NCT02506959|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
220158|NCT02506959|Other|Pharmacological Study|Correlative studies
220159|NCT02506933|Other|Laboratory Biomarker Analysis|Correlative studies
220160|NCT02506933|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
220161|NCT02506933|Other|Placebo|Given IM
220162|NCT02506920|Dietary Supplement|Six different types of fat in a meal in random order|Oral fat tolerance test
220163|NCT02506894|Drug|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
220164|NCT02506894|Other|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
220165|NCT02506881|Drug|Darbepoetin alfa|
220166|NCT02506868|Drug|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
220167|NCT02506855|Drug|Ropivacaine|
220168|NCT02506855|Other|Placebo|
220169|NCT02506855|Procedure|Transversus Abdominis Plane Block|
220170|NCT02506842|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
220171|NCT02506842|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
220172|NCT02506842|Drug|oxaliplatin|Patients receive oxaliplatin 85 mg/m^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
220173|NCT02506842|Drug|folinic acid|Patients receive folinic acid 200 mg/m^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
220174|NCT02506842|Drug|fluorouracil|Patients receive fluorouracil 2000 mg/m^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
220175|NCT02506829|Behavioral|Smoking cessation counseling (Quitline)|
220176|NCT02506829|Behavioral|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
220177|NCT02506829|Behavioral|Financial incentives|
220186|NCT02506777|Drug|Cyclophosphamide|
220187|NCT02506777|Drug|melatonin|
220188|NCT02506751|Drug|liothyronine|All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
220189|NCT02506738|Device|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
220190|NCT02506725|Other|prenatal care in groups|We will do prenatal care in groups using centering care pregnancy methodology
220191|NCT02506712|Device|SmartDrive assisting device|oxygen consumption
220192|NCT02506712|Device|Standard manuel wheelchair|oxygen consumption
220193|NCT02506699|Other|analgesic effect of rTMS|
220194|NCT02506686|Drug|Meropenem|Meropenem i.v.
220195|NCT02506673|Device|Zeiss, Cinema ProMED (audiovisual equipment)|
220196|NCT02506673|Drug|Midazolam|
220197|NCT02506673|Device|Skin Conductance Monitor|
220198|NCT02506660|Drug|Bupivacaine|
220199|NCT02506660|Drug|Perineural dexamethasone|Dexamethasone in nerve block
220200|NCT02506660|Drug|Intravenous dexamethasone|
220201|NCT02506660|Drug|Intravenous saline|
220202|NCT02506660|Drug|Perineural saline|Saline in nerve block
220203|NCT02506647|Drug|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan & Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
220204|NCT02506647|Drug|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan & Lee insulin glargine injection SC,
220205|NCT02506634|Drug|Esomeprazole MUPS, 20 mg|The treatment period would be 4 to 8 weeks according to the findings under upper endoscopy. For patients with esophagitis, this period would be 8 weeks(Esomeprazole MUPS, 20 mg bid); for patients with normal findings, this period would be 4 weeks(Esomeprazole MUPS, 20 mg bid).
220206|NCT02506621|Device|R test|
220207|NCT02506621|Device|Nuubo|
220208|NCT02506621|Device|TECHNOMED pocket ECG|
220209|NCT02506621|Device|ZIO xt patch|
220210|NCT02506621|Device|MoMe|
220211|NCT02506608|Procedure|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the sensorized prostheses. Afferent and efferent signals will be elaborated and integrated by the ODROID software.~The amputees will be able to control the prostheses movement and receive a sensory feedback from the prosthesis sensors.~The use of the prosthesis during different tasks will be considered the intervention."
220212|NCT02506595|Behavioral|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
220213|NCT02506582|Dietary Supplement|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
220214|NCT02506582|Dietary Supplement|placebo|40 g powdered rice flour
220215|NCT02506569|Device|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
220216|NCT02506569|Other|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
220217|NCT02506556|Drug|BYl719|"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days"
220218|NCT02506543|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
220219|NCT02506543|Behavioral|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
220220|NCT02506530|Procedure|intensive decongestive treatment|intensive decongestive treatment
220221|NCT02506530|Device|Cellu M6|Use of Cellu M6
220222|NCT02506517|Drug|Afatinib|
220223|NCT02506504|Device|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
220224|NCT02506504|Device|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
220225|NCT02506491|Other|Pilates exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
220226|NCT02506491|Other|Muscular exercise|2 sessions/week, 1 hour/session during 18 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
220227|NCT02506491|Other|Control Group|No exercise
220228|NCT02506478|Other|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
220229|NCT02506465|Device|iTIND|Temporary Implantable Nitinol Device (iTIND)
220230|NCT02506465|Procedure|Sham Arm|Foley catheter will be placed and immediately removed.
220231|NCT02506452|Other|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
220232|NCT02506452|Other|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
220233|NCT02506439|Dietary Supplement|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
220234|NCT02506439|Dietary Supplement|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
220235|NCT02506439|Dietary Supplement|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
220236|NCT02506426|Procedure|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
220237|NCT02506426|Procedure|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
220238|NCT02506413|Other|MamaToto Package|The MamaToto Package is an MNCH intervention that builds upon a prior successes in Uganda and will be adapted to meet the needs in Misungwi District in Tanzania. The intervention includes low-cost programming that builds upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers.
220239|NCT02506387|Device|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
220240|NCT02506348|Drug|Diclofenac|
220241|NCT02506348|Drug|Nepafenac|
220242|NCT02506335|Drug|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
220243|NCT02506322|Behavioral|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:~psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation~Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance~dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods~behavior changes, (social, problem solving) skill training, communication skills, crisis management"
220244|NCT02506322|Behavioral|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
220245|NCT02506309|Device|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
220246|NCT02506309|Device|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
220247|NCT02506296|Drug|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
220248|NCT02506296|Device|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
220249|NCT02506283|Device|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
220250|NCT02506270|Device|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
220251|NCT02506270|Device|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
220252|NCT02506257|Drug|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
220253|NCT02506257|Drug|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
220254|NCT02506257|Drug|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
220255|NCT02506257|Drug|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
220256|NCT02506244|Device|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
220257|NCT02506244|Device|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
220258|NCT02506231|Drug|Folinic acid|
220259|NCT02506231|Drug|Placebo|
220260|NCT02506218|Dietary Supplement|10 + 20 g protein consumption|whey isolate
220261|NCT02506218|Other|30 g protein breakfast|30 g mixed meal breakfast
220262|NCT02506218|Other|10 g protein breakfast|10 g mixed meal breakfast
220263|NCT02506205|Behavioral|Lee Silverman Voice Treatment (SVLT) LOUD|
220264|NCT02506192|Drug|Delayed-Release Prednisone|Delayed-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
220265|NCT02506192|Drug|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
220266|NCT02506166|Device|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
220267|NCT02506153|Biological|Ipilimumab|Given IV
220268|NCT02506153|Biological|Pembrolizumab|Given IV
220269|NCT02506153|Other|Quality-of-Life Assessment|Ancillary studies
220270|NCT02506153|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
220271|NCT02506140|Drug|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
220272|NCT02506140|Drug|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
220273|NCT02506127|Device|Neuronetics XPLOR system|
220274|NCT02506114|Biological|PROSTVAC V/F|PROSTVAC-V/F is a PSA (prostate-specific antigen)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
220275|NCT02506114|Drug|Ipilimumab|
220306|NCT02505854|Dietary Supplement|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
220276|NCT02506101|Device|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
220277|NCT02506088|Behavioral|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
220278|NCT02506075|Device|Transcranical direct current stimulator|approved by Conformity European as safe treatment device for stroke patients
220279|NCT02506075|Behavioral|Visual inattention training|
220280|NCT02506062|Device|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
220281|NCT02506049|Device|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
220282|NCT02506036|Other|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
220283|NCT02506023|Drug|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
220284|NCT02505997|Drug|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
220285|NCT02505997|Drug|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
220286|NCT02505984|Drug|Oxytocin|Study participants will be randomized to a placebo or drug group.
220287|NCT02505984|Drug|Placebo|Study participants will be randomized to a placebo or drug group.
220288|NCT02505971|Drug|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
220289|NCT02505971|Drug|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.~In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.~S/he will be monitored until Week 52."
220290|NCT02505958|Other|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing ~ 6000 Kcal/24 h.
220291|NCT02505958|Other|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (~333 calories each) totaling ~ 1,000 calories/24 hours.
220292|NCT02505945|Drug|Omeprazole|
220293|NCT02505945|Device|LINX Reflux Management System|
220294|NCT02505932|Procedure|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
220295|NCT02505932|Procedure|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
220296|NCT02505919|Device|AQUABEAM System|To utilizes proprietary heat-free high-pressure waterjet technology to resect and remove prostate tissue using the AQUABEAM system, which is a personalized image-guided tissue removal system.
220297|NCT02505919|Procedure|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
220298|NCT02505906|Radiation|Simultaneous Integrated Boost Technique|
220299|NCT02505893|Biological|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
220300|NCT02505893|Drug|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
220301|NCT02505893|Drug|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
220302|NCT02505893|Drug|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
220303|NCT02505880|Other|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
220304|NCT02505880|Drug|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
220305|NCT02505867|Device|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
220375|NCT02505269|Drug|Dacarbazine|
220376|NCT02505256|Other|No intervention|
220307|NCT02505854|Dietary Supplement|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
220308|NCT02505854|Dietary Supplement|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
220309|NCT02505841|Other|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
220310|NCT02505841|Drug|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
220311|NCT02505828|Procedure|Articular punction, salivary samples, blood sample|
220312|NCT02505815|Procedure|Surgery|
220313|NCT02505815|Procedure|Cortisol Level Measurement|
220314|NCT02505815|Procedure|Neurocognitive Testing|
220315|NCT02505802|Drug|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
220316|NCT02505789|Other|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
220317|NCT02505776|Drug|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
220318|NCT02505763|Procedure|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
220319|NCT02505750|Radiation|3D conformal EBRT|External Beam Radiation Therapy
220320|NCT02505750|Device|Contact X-ray brachytherapy 50 kV|
220321|NCT02505750|Drug|Capecitabine|
220322|NCT02505737|Behavioral|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
220323|NCT02505737|Other|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
220324|NCT02505724|Behavioral|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
220325|NCT02505724|Behavioral|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
220326|NCT02505711|Behavioral|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
220327|NCT02505672|Radiation|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
220328|NCT02505659|Behavioral|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
220329|NCT02505646|Other|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
220330|NCT02505633|Device|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.~1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
220331|NCT02505633|Drug|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
220332|NCT02505620|Procedure|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
220333|NCT02505620|Procedure|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
220334|NCT02505607|Other|Overactive Bladder Care Plan counseling|"Use of a printed Overactive Bladder Plan of Care information sheet."
220335|NCT02505581|Drug|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
220336|NCT02505581|Procedure|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
220337|NCT02505581|Drug|Cefuroxime 750mg oral|An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.
220338|NCT02505581|Drug|Metronidazole 250mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
220339|NCT02505581|Drug|Metronidazole 1,5gr Intravenous|An intravenous antibiotic pattern of cefuroxime 1g during anesthetic induction.
220340|NCT02505581|Drug|Cefuroxime 1g Intravenous|An intravenous antibiotic pattern of metronidazole 1,5gr during anesthetic induction.
220341|NCT02505568|Drug|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
220342|NCT02505555|Device|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
220499|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
220343|NCT02505542|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol~Pharmaceutical form: Prefilled syringe~Concentration: 200 mg / ml~Route of Administration: Subcutaneous injection"
220344|NCT02505542|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Prefilled syringe~Concentration: 0.9 % Saline~Route of Administration: Subcutaneous injection"
220345|NCT02505529|Other|Resistance Exercise Training|Behavioral interventions of resistance exercise
220346|NCT02505529|Other|Mental Imagery|Behavioral intervention of mental imagery
220347|NCT02505516|Other|metformin|
220348|NCT02505503|Device|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
220349|NCT02505503|Device|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
220350|NCT02505490|Other|Television|The purpose is to determine whether television impacts liking of food.
220351|NCT02505490|Other|No Television|The purpose is to determine whether the lack of television impacts liking of food.
220352|NCT02505477|Drug|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
220353|NCT02505477|Other|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
220354|NCT02505451|Drug|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
220355|NCT02505438|Behavioral|Exercise|
220356|NCT02505425|Behavioral|Behavioral Support|"ENABLE CHF-PC includes:~In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.~Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.~The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.~Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
220357|NCT02505425|Behavioral|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
220358|NCT02505399|Drug|ticagrelor|"Ticagrelor will be administered orally, according to the following scheme:~180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~90 mg the following morning (D Day before rotational atherectomy and angioplasty),~90 mg the following evening (D Day after rotational atherectomy and angioplasty),~90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
220359|NCT02505399|Drug|clopidogrel|"Clopidogrel will be administered orally, according to the following scheme:~300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),~75 mg the following morning (D Day before rotational atherectomy and angioplasty),~0 mg the following evening (D Day after rotational atherectomy and angioplasty),~75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
220360|NCT02505386|Drug|Ertapenem|
220361|NCT02505373|Behavioral|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.~Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.~Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.~Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.~Regular letters are sent to patients over a period of 2 years."
220362|NCT02505373|Behavioral|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
220363|NCT02505360|Other|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
220364|NCT02505347|Other|No splint|Can move arm as tolerated with no restrictions on mobility
220365|NCT02505347|Device|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
220366|NCT02505334|Drug|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
220367|NCT02505321|Other|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
220368|NCT02505321|Procedure|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
220369|NCT02505308|Other|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
220370|NCT02505295|Drug|Selenium|4 vials selenase stat and 2 vials daily for 5 days
220371|NCT02505295|Drug|normal saline|
220372|NCT02505282|Other|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
220373|NCT02505269|Drug|Brentuximab Vedotin|
220374|NCT02505269|Drug|Adriamycin|
220377|NCT02505230|Behavioral|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
220378|NCT02505204|Other|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
220379|NCT02505204|Other|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
220380|NCT02505191|Drug|St. John's wort prolonged-release tablet 500 mg|
220381|NCT02505191|Drug|St. John's wort film coated tablets 250 mg|
220382|NCT02505178|Other|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
220383|NCT02505165|Behavioral|IMPACT|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
220384|NCT02505165|Other|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
220385|NCT02505152|Procedure|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
220386|NCT02505139|Other|the number of circulating tumor cells|
220387|NCT02505126|Device|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
220388|NCT02505126|Device|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
220389|NCT02505113|Drug|Montelukast|Montelukast (10mg, q.d., p.o.)
220390|NCT02505100|Other|Touching relaxant|
220391|NCT02505100|Other|Hypnoses|
220392|NCT02505087|Drug|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.~Treatment periods are separated by a 2 month washout."
220393|NCT02505087|Drug|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
220394|NCT02505074|Procedure|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
220395|NCT02505061|Behavioral|Hospital-based Program|The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the child‟s natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team.
220396|NCT02505061|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child‟s natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase
220397|NCT02505048|Drug|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
220398|NCT02505035|Behavioral|Default ordering of palliative consult|
220399|NCT02505022|Drug|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
220400|NCT02505022|Behavioral|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
220401|NCT02505009|Drug|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
220402|NCT02505009|Drug|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
220403|NCT02505009|Drug|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
220404|NCT02504996|Drug|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
220405|NCT02504996|Drug|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
220406|NCT02504996|Drug|Placebo|Intravenous 100 ml normal saline
220407|NCT02504983|Drug|sorafenib|sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
220500|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
220408|NCT02504983|Procedure|TACE|Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
220409|NCT02504957|Procedure|Photodynamic therapy using polyhematoporphyrin|
220410|NCT02504944|Drug|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
220411|NCT02504931|Drug|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
220412|NCT02504931|Drug|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
220413|NCT02504892|Drug|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
220414|NCT02504866|Other|Excercise|Exercise training of different intensity
220415|NCT02504827|Drug|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
220416|NCT02504814|Device|Nasal Highflow (NHF)|changes in breathing physiology in NHF
220417|NCT02504801|Drug|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
220418|NCT02504788|Radiation|hippocampal-sparing WBRT|
220419|NCT02504775|Drug|Mejoral® 500 Tablets|500 mg tablet of paracetamol
220420|NCT02504775|Drug|Tylenol® Caplets|500 mg tablet of paracetamol
220421|NCT02504762|Procedure|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
220422|NCT02504762|Procedure|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
220423|NCT02504749|Procedure|general anasthesia,spinal anasthesia|"Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.~450-pregnant women with an indication for caesarean section were randomly allocated ."
220424|NCT02504723|Drug|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure >90 mm Hg.
220425|NCT02504723|Drug|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
220426|NCT02504710|Device|Kinematic Real Time Feedback|
220427|NCT02504710|Other|Traditional systems of manual therapy teaching|
220428|NCT02504697|Other|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
220429|NCT02504684|Device|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
220430|NCT02504684|Device|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
220431|NCT02504671|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
220432|NCT02504671|Drug|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
220433|NCT02504671|Drug|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
220434|NCT02504671|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
220435|NCT02504658|Behavioral|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
220436|NCT02504658|Behavioral|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
220437|NCT02504645|Drug|IPP-201101|
220438|NCT02504645|Drug|Placebo|
220439|NCT02504645|Other|Standard of Care|
220440|NCT02504632|Other|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.~The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.~Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
221129|NCT02499835|Biological|pTVG-HP Plasmid DNA Vaccine|Given ID
220441|NCT02504632|Other|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
220442|NCT02504619|Biological|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
220443|NCT02504606|Drug|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
220444|NCT02504606|Drug|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
220445|NCT02504593|Device|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
220446|NCT02504580|Drug|HTX-011|
220447|NCT02504580|Drug|Placebo|
220448|NCT02504580|Drug|HTX-002|
220449|NCT02504580|Drug|Bupivacaine Hydrochloride Injection|
220450|NCT02504580|Drug|HTX-011A|
220451|NCT02504580|Drug|HTX-011B|
220452|NCT02504580|Drug|HTX-009|
220453|NCT02504580|Drug|Marcaine|
220454|NCT02504567|Device|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
220455|NCT02504567|Device|RF ablation|Pulmonary vein isolation using the RF ablation catheter
220456|NCT02504554|Drug|oral Vancomycin|an antibiotic
220457|NCT02504554|Drug|MoviPrep|a bowel cleanse
220458|NCT02504554|Drug|Prilosec|a stomach acid suppressan
220459|NCT02504554|Biological|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
220460|NCT02504554|Biological|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
220461|NCT02504541|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment 50 mg or 75 mg or 100 mg based upon Testosterone levels
220462|NCT02504528|Other|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
220463|NCT02504515|Other|World Health Organization Quality of Life Bref Questionnaire|"The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.~The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials."
220464|NCT02504502|Other|enhanced genomic report|a patient-centered version of a genomic results report delivered to patient through the electronic record portal
220465|NCT02504489|Drug|Docetaxel + Plinabulin (DP)|Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
220466|NCT02504489|Drug|Docetaxel (D)|Docetaxel 75 mg/m2 IV
220467|NCT02504476|Drug|AMG 581|Active drug
220468|NCT02504476|Drug|Placebo|Placebo
220469|NCT02504476|Drug|Midazolam|Interaction
220470|NCT02504463|Drug|Samidorphan IV|Single IV administration
220471|NCT02504463|Drug|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
220472|NCT02504463|Drug|[14c]-Samidorphan oral|Single oral administration containing radiolabel
220473|NCT02504450|Drug|Adasuve|Inhaled medication to treat acute agitation in the emergency department
220474|NCT02504450|Drug|Alternative medications|Medication given to treat acute agitation in the emergency department
220475|NCT02504437|Biological|BMMSCs|
220476|NCT02504424|Device|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
220477|NCT02504411|Device|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
220478|NCT02504411|Device|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
220479|NCT02504398|Other|Fast injection speed by immunizer|
220480|NCT02504398|Other|Slow injection speed by immunizer|
220481|NCT02504385|Device|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
220482|NCT02504385|Other|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
220483|NCT02504372|Biological|pembrolizumab|
220484|NCT02504372|Other|Placebo|
220485|NCT02504359|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
220486|NCT02504359|Drug|Carmustine|Given BEAM chemotherapy
220487|NCT02504359|Drug|Cytarabine|Given BEAM chemotherapy
220488|NCT02504359|Drug|Etoposide|Given BEAM chemotherapy
220489|NCT02504359|Drug|Ixazomib Citrate|Given PO
220490|NCT02504359|Drug|Melphalan|Given BEAM chemotherapy
220491|NCT02504359|Drug|Methotrexate|Given IV
220492|NCT02504359|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
220493|NCT02504359|Other|Quality-of-Life Assessment|Ancillary studies
220494|NCT02504359|Drug|Tacrolimus|Given IV or PO
220495|NCT02504346|Drug|AZD9291|
220496|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
220497|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
220498|NCT02504333|Drug|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
221306|NCT02498613|Other|Laboratory Biomarker Analysis|Correlative studies
220502|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
220503|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
220504|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
220505|NCT02504307|Device|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
220506|NCT02504307|Device|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
220507|NCT02504294|Biological|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
220508|NCT02504294|Other|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
220509|NCT02504294|Drug|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
220510|NCT02504268|Drug|Abatacept|
220511|NCT02504268|Drug|Methotrexate|
220512|NCT02504268|Other|Abatacept Placebo|
220513|NCT02504268|Other|Methotrexate Placebo|
220514|NCT02504255|Biological|Biological samplings|Blood, urine and faecal sampling every 3 months
220515|NCT02504255|Other|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
220516|NCT02504242|Device|Inject BMP|
220517|NCT02504242|Procedure|Locally Harvested Bone|
220518|NCT02504229|Biological|autologous dendritic cells co-cultured with cytokine-induced killer cells|
220519|NCT02504229|Drug|Gimeracil and Oteracil Porassium Capsules|
220520|NCT02504229|Drug|Oxaliplatin|
220521|NCT02504216|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2.5 mg, twice daily, orally, tablet
220522|NCT02504216|Drug|Rivaroxaban-Placebo|matching placebo, twice daily, orally, tablet
220523|NCT02504203|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
220524|NCT02504177|Drug|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
220525|NCT02504177|Drug|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
220526|NCT02504164|Drug|midazolam 0.02mg/kg|
220527|NCT02504164|Drug|No premedication|No premedication before sedation for endoscopic submucosal dissection
220528|NCT02504151|Drug|Cannabidiol|
220529|NCT02504151|Drug|Placebo|
220530|NCT02504138|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
220531|NCT02504138|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
220532|NCT02504125|Drug|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
220533|NCT02504125|Drug|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
220534|NCT02504112|Other|there is no intervention|
220535|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
220536|NCT02504099|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
220537|NCT02504099|Drug|ribavirin|Tablet
220538|NCT02504086|Behavioral|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
220539|NCT02504073|Other|No intervention|No intervention
220540|NCT02504060|Drug|Starch Placebo|
220541|NCT02504060|Drug|N-acetyl-D-glucosamine|
220542|NCT02504047|Procedure|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 & 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
220543|NCT02504034|Procedure|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
220544|NCT02504034|Device|6-French sheath|
220545|NCT02504034|Device|22-gauge chiba needle|
220546|NCT02504034|Device|260-cm-long stiff shaft wire|
220547|NCT02504034|Device|Balloon catheter|
220548|NCT02504034|Device|Bare metal stent|
220549|NCT02504034|Device|Covered stent|
220550|NCT02504021|Behavioral|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
220551|NCT02504008|Drug|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
220552|NCT02504008|Drug|Placebo|Once weekly for 6 weeks
220553|NCT02503995|Behavioral|Physical Exercise Participation|
220719|NCT02502825|Device|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
220554|NCT02503982|Drug|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
220555|NCT02503969|Other|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
220556|NCT02503956|Device|Perforated Punctal plugs|Perforated punctal plugs
220557|NCT02503956|Procedure|Crawford tube insertion|
220558|NCT02503956|Device|Crawford lacrimal tube|
220559|NCT02503943|Drug|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
220560|NCT02503943|Drug|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
220561|NCT02503943|Drug|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
220562|NCT02503930|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
220563|NCT02503930|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
220564|NCT02503904|Procedure|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
220565|NCT02503904|Device|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
220566|NCT02503904|Drug|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
220567|NCT02503891|Device|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
220568|NCT02503878|Device|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
220569|NCT02503865|Drug|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
220570|NCT02503865|Dietary Supplement|"Analimentary detoxication"|Vegetable and salt diet
220571|NCT02503852|Device|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
220572|NCT02503852|Device|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
220573|NCT02503852|Procedure|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
220574|NCT02503852|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
220575|NCT02503839|Drug|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
220576|NCT02503839|Biological|H56:IC31|Therapeutic and prophylactic TB vaccine
220577|NCT02503826|Drug|Sufentanil|low dose
220578|NCT02503826|Drug|Sufentanil|moderate dose
220579|NCT02503826|Drug|Sufentanil|high dose
220580|NCT02503826|Drug|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
220581|NCT02503826|Drug|propofol|
220582|NCT02503826|Drug|cisatracurium|
220583|NCT02503813|Procedure|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
220584|NCT02503787|Device|Spinal Cord Stimulation (SCS)|SCS programming options
220585|NCT02503774|Biological|MEDI9447|Subjects will receive MEDI9447 until disease progression
220586|NCT02503774|Biological|MEDI9447 and MEDI4736|Subjects will receive MEDI9447 and MEDI4736 until disease progression
220587|NCT02503761|Drug|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
220588|NCT02503748|Other|Online tutorial|website informing about treatment options in localized prostate cancer
220589|NCT02503735|Drug|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
220590|NCT02503722|Other|Laboratory Biomarker Analysis|Correlative studies
220591|NCT02503722|Drug|Osimertinib|Given PO
220592|NCT02503722|Other|Pharmacological Study|Correlative studies
220593|NCT02503722|Drug|Sapanisertib|Given PO
220594|NCT02503709|Drug|CDK Inhibitor AT7519|Given IV
220595|NCT02503709|Other|Laboratory Biomarker Analysis|Correlative studies
220596|NCT02503709|Drug|Onalespib|Given IV
220597|NCT02503709|Other|Pharmacological Study|Correlative studies
220598|NCT02503696|Device|Stool Collection Kit|Stool Collection Kit.
220599|NCT02503683|Drug|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
220600|NCT02503683|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
220601|NCT02503670|Behavioral|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
220602|NCT02503670|Other|Control Group|Continue with standard care.
220603|NCT02503657|Drug|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
220604|NCT02503657|Drug|Placebo|Excipients of MN-001/tipelukast
220605|NCT02503644|Drug|IVA337|Capsules of 200mg IVA337
220606|NCT02503644|Drug|Placebo|Identical capsules without active substance
220607|NCT02503631|Device|Stool Sample Collection Kit|Stool sample collection kit
220608|NCT02503605|Drug|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
220609|NCT02503605|Drug|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
220806|NCT02502188|Drug|CC-90005|
220807|NCT02502188|Drug|Placebo|
220610|NCT02503592|Other|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
220611|NCT02503579|Behavioral|physical training|physical activity program, 30 minutes
220612|NCT02503566|Device|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
220613|NCT02503553|Behavioral|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
220614|NCT02503553|Behavioral|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
220615|NCT02503540|Drug|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
220616|NCT02503527|Other|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
220617|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
220618|NCT02503501|Drug|Insulin glulisine|
220619|NCT02503501|Drug|Placebo|Bacteriostatic 0.9% Sodium Chloride
220620|NCT02503488|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
220621|NCT02503488|Behavioral|Treatment as Usual|See arm description
220622|NCT02503475|Other|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:~(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
220623|NCT02503475|Behavioral|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
220624|NCT02503475|Device|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
220625|NCT02503462|Drug|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
220626|NCT02503462|Drug|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
220627|NCT02503462|Drug|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
220628|NCT02503423|Drug|ASTX660|described above
220629|NCT02503410|Behavioral|Usual care|Subjects receive standard physical therapy, including outpatient visits as prescribed by the treating clinician and home-based exercises based on recommendations by the physical therapist.
220630|NCT02503410|Behavioral|Interactive gaming|Subjects receive a combination of standard physical therapy in the clinic and home-based exercises that they perform using the Valedo system.
220631|NCT02503397|Device|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
220632|NCT02503371|Other|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
220633|NCT02503358|Other|Laboratory Biomarker Analysis|Correlative studies
220634|NCT02503358|Drug|Paclitaxel|Given IV
220635|NCT02503358|Other|Pharmacological Study|Correlative studies
220636|NCT02503358|Drug|Selumetinib|Given PO
220637|NCT02503345|Drug|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
220638|NCT02503345|Drug|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
220639|NCT02503345|Drug|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
220640|NCT02503345|Drug|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
220641|NCT02503332|Drug|APL-2|
220642|NCT02503332|Other|Sham Procedure|
220643|NCT02503319|Drug|Tranexamic Acid|"2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)~2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)"
220644|NCT02503319|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
220884|NCT02501603|Drug|afatinib|Afatinib 40mg daily oral administration
220645|NCT02503319|Drug|Oxytocin|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
220646|NCT02503306|Drug|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
220647|NCT02503306|Drug|placebo|Pharmaceutical form:tablets Route of administration: oral
220648|NCT02503293|Device|Chrono Super PID then Generic Syringe-Gammanorm|"Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• pump and then syringe~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
220649|NCT02503293|Device|Generic Syringe then Chrono Super PID-Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:~• syringe and then pump.~The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).~Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
220650|NCT02503280|Drug|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs.
220651|NCT02503280|Drug|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
220652|NCT02503280|Drug|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).
220653|NCT02503280|Device|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
220654|NCT02503267|Other|none intervention|
220655|NCT02503254|Other|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
220656|NCT02503254|Other|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
220657|NCT02503241|Procedure|PEEP INCREMENTAL|PEEP was progressively increased by steps of 2 cmH2O every 60 second until the end-expiratory transpulmonary pressure became positive between 0-2 cmH2O.
220658|NCT02503241|Procedure|PEEP DECREMENTAL|Lung recruitment maneuver (LRM) is a transitory and controlled increase in airway pressure to open collapsed alveoli. LRM is the first step of the PEEP DECREMENTAL method. After LRM, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified.
220659|NCT02503228|Other|Receiving MOPS-Preserved Cartilage|The Missouri Osteochondral Allograft Preservation System (MOPS) preserves donated cartilage tissue that is meant to be transplanted from the time it is obtained from the donor to the time it is transplanted into the recipient. The MOPS is a different media formulation from the standard media that is usually used to preserve the cartilage tissue.
220660|NCT02503215|Device|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
220661|NCT02503202|Biological|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
220662|NCT02503202|Biological|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
220663|NCT02503202|Biological|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
220664|NCT02503202|Biological|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
220665|NCT02503202|Biological|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
220666|NCT02503189|Drug|KCT-0809 ophthalmic solution|
220667|NCT02503189|Drug|Placebo|
220668|NCT02503176|Drug|KCT-0809 ophthalmic solution|
220669|NCT02503163|Drug|KCT-0809 ophthalmic solution|
220670|NCT02503150|Biological|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
220671|NCT02503150|Drug|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
220672|NCT02503137|Drug|Topical SM04554 solution|
220674|NCT02503124|Behavioral|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
220675|NCT02503124|Device|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
220676|NCT02503124|Other|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
220677|NCT02503124|Other|Informative meeting|A short sleep hygiene consultation.
220678|NCT02503124|Drug|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
220679|NCT02503111|Device|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
220680|NCT02503111|Other|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
220681|NCT02503098|Behavioral|Recovery Record adaptive smartphone application|
220682|NCT02503098|Behavioral|Recovery Record standard smartphone application|
220683|NCT02503085|Drug|Nurofen for Children®|
220684|NCT02503085|Drug|Algifor Dolo Junior®|
220685|NCT02503072|Behavioral|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
220686|NCT02503072|Behavioral|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
220687|NCT02503046|Other|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
220688|NCT02503046|Genetic|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
220689|NCT02503033|Drug|HMPL-523|Oral administration, once daily
220690|NCT02503020|Dietary Supplement|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
220691|NCT02503020|Dietary Supplement|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.~At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
220692|NCT02503007|Dietary Supplement|Placebo|
220693|NCT02503007|Dietary Supplement|HMB-FA|
220694|NCT02502994|Drug|GEN0101|
220695|NCT02502981|Drug|Spironolactone|25mg orally once a day for 40 weeks
220696|NCT02502981|Drug|Chlortalidone|25mg orally once a day for 40 weeks
220697|NCT02502968|Drug|Cytarabine|
220698|NCT02502968|Drug|BL-8040|
220699|NCT02502968|Drug|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
220700|NCT02502955|Procedure|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
220701|NCT02502942|Behavioral|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
220702|NCT02502942|Behavioral|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
220703|NCT02502929|Behavioral|Enhanced standard care|
220704|NCT02502929|Behavioral|Lifestyle|
220705|NCT02502929|Behavioral|Lifestyle Plus Medication Therapy Management|
220706|NCT02502903|Drug|BIV009|
220707|NCT02502903|Other|Placebo|
220708|NCT02502877|Drug|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
220709|NCT02502877|Drug|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
220710|NCT02502877|Drug|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
220711|NCT02502877|Device|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
220712|NCT02502864|Drug|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
220713|NCT02502864|Drug|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
220714|NCT02502864|Other|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
220715|NCT02502851|Device|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
220716|NCT02502851|Device|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
220717|NCT02502825|Other|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
220718|NCT02502825|Device|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
220720|NCT02502812|Drug|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
220721|NCT02502812|Drug|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
220722|NCT02502812|Drug|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
220723|NCT02502799|Behavioral|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
220724|NCT02502799|Behavioral|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
220725|NCT02502799|Drug|Methylphenidate|Adolescents will receive methylphenidate.
220726|NCT02502786|Biological|humanized anti-GD2 antibody|
220727|NCT02502786|Drug|GM-CSF|
220728|NCT02502773|Drug|Hydroxethyl starch|
220729|NCT02502760|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
220730|NCT02502760|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.~Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses"
220731|NCT02502760|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
220732|NCT02502747|Drug|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
220733|NCT02502747|Drug|optimal standard of care|Optimal standard of care
220734|NCT02502747|Procedure|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
220735|NCT02502734|Drug|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
220736|NCT02502734|Drug|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
220737|NCT02502734|Drug|Salbutamol|Salbutamol will be provided as a inhaler.
220738|NCT02502721|Drug|DWC20151|
220739|NCT02502721|Drug|DWC20152|
220740|NCT02502708|Drug|Indoximod|Indoximod will be administered orally twice daily.
220741|NCT02502708|Drug|Temozolomide|Temozolomide will be administered on days 1-5 of every 28 day cycle.
220742|NCT02502708|Radiation|Conformal Radiation|Conformal radiation will be administered on days 3-7 of induction cycle.
220743|NCT02502708|Drug|Cyclophosphamide|Cyclophosphamide will be administered orally daily.
220744|NCT02502708|Drug|Etoposide|Etoposide will be administered orally daily.
220745|NCT02502695|Other|VATS-associated best practices|
220746|NCT02502682|Drug|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
220747|NCT02502669|Drug|Finasteride 23.5 mg tablets|
220748|NCT02502669|Drug|Finasteride 33.5 mg tablets|
220749|NCT02502669|Drug|Placebo tablets|
220750|NCT02502643|Drug|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
220751|NCT02502643|Drug|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
220752|NCT02502630|Device|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
220753|NCT02502617|Dietary Supplement|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
220754|NCT02502604|Behavioral|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
220755|NCT02502591|Drug|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
220756|NCT02502578|Drug|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
220757|NCT02502565|Other|Uric acid level|
220758|NCT02502552|Other|blood specimen|blood specimen
220759|NCT02502539|Procedure|Controlled physical activity|
220760|NCT02502526|Device|Centurion® Vision System, 45° Balanced Tip|
220761|NCT02502526|Device|Centurion® Vision System, 45° MFK Tip|
220762|NCT02502526|Device|lnfiniti® Vision System, 45° MFK Tip|
220763|NCT02502526|Device|INTREPID® Ultra infusion sleeve|
220764|NCT02502526|Device|Ultra infusion sleeve|
220765|NCT02502513|Behavioral|Brief computerized intervention|"Computer game Tetris"
220766|NCT02502500|Drug|Celecoxib|
220767|NCT02502500|Drug|AKB-6548|
221307|NCT02498613|Drug|Olaparib|Given PO
220768|NCT02502487|Procedure|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
220769|NCT02502487|Drug|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
220770|NCT02502487|Drug|Tetracaine|1% Tetracaine gel instilled into urethra
220771|NCT02502474|Other|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
220772|NCT02502461|Procedure|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
220773|NCT02502448|Procedure|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
220774|NCT02502448|Drug|hydroxyethyl starch (HES 130/0.6)|
220775|NCT02502422|Device|Classic laryngeal mask airway|"measurement of head and neck~Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip~sternal notch), modified mallampati classification under sitting position, thyromental distance.~laryngeal mask airway insertion and measuring cuff pressure by pressure transducer~# 4.0 for female, #5.0 for male~initial cuff volume(air) : maximum volume recommended by the manufacturer~check pressure : if it exceed 60cmH20, we will remove air until 60cmH20~remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
220776|NCT02502409|Other|Standard care with blood and urine sample collection|
220777|NCT02502396|Other|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
220778|NCT02502383|Behavioral|ACTION PAC|Adolescents enrolled in ACTION PAC will meet with SBHC providers. SBHC providers will use Motivational Interviewing to motivate students to adopt strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI results discussion with providers. Overweight/Obese adolescents will meet with providers for 16 sessions over 2 years.
220779|NCT02502383|Behavioral|Comparison|Annual BMI results will not be discussed with participants in comparison schools; however, a letter containing BMI results and obesity prevention recommendations will be sent to parent/guardians.
220780|NCT02502370|Drug|observation alone|
220781|NCT02502370|Drug|LV5FU2|
220782|NCT02502370|Drug|FOLFOX|
220783|NCT02502357|Other|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:~Following this operation, [the participant] will feel very comfortable and [the participant] will heal very well.~Toward the end of the surgery, the study staff member will say 5 times:~The operation has gone very well. Following the operation, [the participant] will be hungry. [The participant] will be thirsty and urinate easily."
220784|NCT02502344|Behavioral|healthy lifestyle|food control and intensive exercise to lose weight
220785|NCT02502344|Drug|Metformin|use metformin to reduce insulin resistance
220786|NCT02502331|Biological|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
220787|NCT02502331|Biological|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
220788|NCT02502318|Procedure|Video-thoracoscopy|
220789|NCT02502318|Procedure|thoracotomy|
220790|NCT02502305|Behavioral|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
220791|NCT02502292|Behavioral|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.~The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
220792|NCT02502279|Device|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
220793|NCT02502279|Device|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
220794|NCT02502266|Drug|Cediranib|Given PO
220795|NCT02502266|Drug|Cediranib Maleate|Given PO
220796|NCT02502266|Drug|Olaparib|Given PO
220797|NCT02502266|Drug|Paclitaxel|Given IV
220798|NCT02502266|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
220799|NCT02502266|Other|Questionnaire Administration|Ancillary studies
220800|NCT02502266|Drug|Topotecan|Given IV
220801|NCT02502266|Drug|Topotecan Hydrochloride|Given IV
220802|NCT02502253|Drug|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract [GSE], and resveratrol) that contain abundant concentrations of polyphenols.
220803|NCT02502227|Behavioral|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
220804|NCT02502201|Other|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
220805|NCT02502201|Other|six-minute walk study outdoors|Performance of a six-minute walk test.
220808|NCT02502175|Drug|opium|Opium tincture (10mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
220809|NCT02502175|Drug|methadone|Methadone (5mg/ml), manufactured by Daroupakhsh.co, Tehran, Iran.
220810|NCT02502162|Drug|LDN|
220811|NCT02502162|Drug|Placebo|Sugar pill
220812|NCT02502149|Biological|rFVIIIFc|As per arm description
220813|NCT02502136|Procedure|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
220814|NCT02502136|Procedure|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
220815|NCT02502123|Other|No Intervention|No intervention was administered in this study.
220816|NCT02502110|Drug|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
220817|NCT02502097|Drug|Gefapixant first, then Placebo|
220818|NCT02502097|Other|Placebo first, then Gefapixant|
220819|NCT02502084|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
220820|NCT02502071|Drug|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
220821|NCT02502058|Device|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
220822|NCT02502045|Device|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
220823|NCT02502045|Device|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
220824|NCT02502032|Drug|Cisatracurium|Different groups received different pretreatments of cisatracurium.
220825|NCT02502019|Device|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
220826|NCT02502006|Drug|Celecoxib|
220827|NCT02502006|Drug|Naproxen|
220828|NCT02502006|Drug|Placebo|
220829|NCT02501980|Biological|Biomarker testing and Ultrasonography|
220830|NCT02501967|Other|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
220831|NCT02501954|Drug|Cisplatin|Given IV
220832|NCT02501954|Drug|Carboplatin|Given IV
220833|NCT02501954|Drug|Paclitaxel|Given IV
220834|NCT02501954|Radiation|Radiation Therapy|Undergo Radiation Therapy
220835|NCT02501941|Drug|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
220836|NCT02501928|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
220837|NCT02501928|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
220838|NCT02501928|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
220839|NCT02501928|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
220840|NCT02501915|Device|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
220841|NCT02501902|Drug|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
220842|NCT02501902|Drug|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
220843|NCT02501889|Behavioral|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
220844|NCT02501889|Behavioral|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
220845|NCT02501876|Other|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
220846|NCT02501863|Drug|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
220847|NCT02501863|Drug|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
220848|NCT02501850|Drug|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
220849|NCT02501850|Drug|metformin|Treatment with metformin and/or sulphonilurea
220850|NCT02501837|Drug|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
220851|NCT02501824|Other|anthroposophic therapeutic speech|anthroposophic therapeutic speech
220852|NCT02501811|Biological|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
220853|NCT02501811|Biological|c-kit+ cells|15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
220854|NCT02501811|Biological|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
220855|NCT02501798|Drug|Methylphenidate|Drug: Methylphenidate
220856|NCT02501798|Drug|Placebo|Drug: Placebo
220857|NCT02501785|Behavioral|Caregiver Reaction Assessment (CRA)|
220858|NCT02501785|Behavioral|The Caregiver Quality of Life - Cancer (CQOLC)|
220859|NCT02501772|Device|acupressure by ankle band|
220860|NCT02501759|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
220861|NCT02501759|Radiation|Gadodiamide|Given IV
220862|NCT02501759|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
220863|NCT02501759|Procedure|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
220864|NCT02501759|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
220865|NCT02501746|Other|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
220866|NCT02501746|Other|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
220867|NCT02501746|Other|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
220868|NCT02501733|Device|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.~To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
220869|NCT02501720|Procedure|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
220870|NCT02501720|Procedure|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
220871|NCT02501720|Procedure|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
220872|NCT02501694|Other|Auscultation|Electronic stethoscope
220873|NCT02501681|Other|priming solution during cardiovascular surgery|
220874|NCT02501655|Device|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
220875|NCT02501655|Device|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
220876|NCT02501642|Behavioral|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
220877|NCT02501642|Other|Treatment as usual|Treatment as usual
220878|NCT02501629|Drug|Reslizumab|Reslizumab 110 mg was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
220879|NCT02501629|Drug|Placebo|Placebo was administered by qualified study personnel as subcutaneous injections in the upper arm(s) once every 4 weeks for a total of 6 doses. Drug was supplied in pre-filled syringes.
220880|NCT02501629|Drug|Non-Oral Corticosteroid (non-OCS) Asthma Medication|Participants continue using their non-OCS background asthma medications without change during the study's treatment period.
220881|NCT02501629|Drug|Oral Corticosteroid (OCS)|After screening and prior to study start, the participant's OCS dose was adjusted to determine the minimal effective OCS requirement.
220882|NCT02501616|Drug|Metformin|
220883|NCT02501616|Drug|Dapagliflozin|
220885|NCT02501603|Drug|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
220886|NCT02501577|Device|SAD 1|Placement and fiberoptic control
220887|NCT02501577|Device|SAD 2|Placement and fiberoptic control
220888|NCT02501564|Drug|Naproxen Sodium Codeine|One tablet twice a day
220889|NCT02501564|Drug|Placebo|One tablet twice a day
220890|NCT02501551|Drug|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
220891|NCT02501538|Device|Transcutaneous O2 device|A portable device that delivers continuous diffusion of oxygen.
220892|NCT02501525|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
220893|NCT02501525|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
220894|NCT02501499|Other|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
220895|NCT02501486|Other|ACTH stimulation test|An ACTH stimulation test will be done
220896|NCT02501473|Drug|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
220897|NCT02501473|Drug|Pembrolizumab|PD-1 Inhibitor
220898|NCT02501460|Other|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
220899|NCT02501460|Other|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).~Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
220900|NCT02501460|Dietary Supplement|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
220901|NCT02501460|Other|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
220902|NCT02501447|Behavioral|Guided audio-visual relaxation|
220903|NCT02501434|Drug|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
220904|NCT02501421|Biological|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
220905|NCT02501421|Biological|Placebo|Buffer
220906|NCT02501408|Device|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
220907|NCT02501395|Other|No intervention, observational|
220908|NCT02501369|Behavioral|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
220909|NCT02501356|Dietary Supplement|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
220910|NCT02501356|Dietary Supplement|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
220911|NCT02501343|Drug|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
220912|NCT02501343|Drug|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
220913|NCT02501330|Drug|Bosutinib|The usual adult dosage of once 500 mg per day postprandial oral administration as bosutinib. The dosage may be adjusted according to the patient's condition, but can be increased to once 600 mg 1 day.
220914|NCT02501317|Behavioral|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
220915|NCT02501317|Behavioral|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
220916|NCT02501304|Device|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
220917|NCT02501291|Drug|Thalidomide|
220918|NCT02501278|Biological|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:~VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)~INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
220919|NCT02501278|Radiation|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.~Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.~Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
220920|NCT02501278|Drug|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
220921|NCT02501265|Behavioral|Varenicline Standard Protocol|"4 weeks pre-TQD: Start Placebo Varenicline~1 week prior to TQD: Switch to Active Varenicline~1 week prior to TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD"
220961|NCT02500940|Drug|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
220962|NCT02500940|Drug|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
220922|NCT02501265|Behavioral|Nicotine Patch Standard Protocol|"4 weeks pre-TQD: Start Placebo Nicotine Patch TQD: Start active Nicotine Patch~1 week prior to TQD: Start Placebo Bupropion Nicotine Patch + Placebo Bupropion to 12 weeks post TQD"
220923|NCT02501265|Drug|Varenicline Adaptive Protocol|"VARENICLINE RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES reduce cigs/day by > 50% 1 week pre-TQD: Start Placebo Bupropion Varenicline + Placebo Bupropion to 12 weeks post TQD~VARENICLINE NON-RESPONDER 4 weeks pre-TQD: Start Varenicline 2 weeks pre-TQD: DOES NOT reduce cigs/day by > 50%~1 week pre-TQD: Start active Bupropion Varenicline + Bupropion to 12 weeks post TQD"
220924|NCT02501265|Drug|Nicotine Adaptive Protocol|"NICOTINE PATCH RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES reduce cigs/day by > 50% 1 week pre-TQD: Start Placebo Bupropion Patch + Placebo Bupropion to 12 weeks post TQD~NICOTINE PATCH NON-RESPONDER 4 weeks pre-TQD: Start Patch 2 weeks pre-TQD: DOES NOT reduce cigs/day by > 50%~1 week pre-TQD: Start Bupropion Patch + Bupropion to 12 weeks post TQD"
220925|NCT02501252|Procedure|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
220926|NCT02501239|Behavioral|Accept Yourself!|
220927|NCT02501239|Behavioral|Weight Watchers|
220928|NCT02501226|Other|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
220929|NCT02501226|Behavioral|ENVIE psychoeducational program|The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.
220930|NCT02501213|Drug|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
220931|NCT02501200|Drug|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
220932|NCT02501200|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
220933|NCT02501187|Procedure|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
220934|NCT02501187|Procedure|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
220935|NCT02501187|Procedure|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
220936|NCT02501161|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
220937|NCT02501161|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
220938|NCT02501148|Device|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
220939|NCT02501135|Procedure|Femoral nerve block with ropivacaine or bupivacaine|
220940|NCT02501122|Other|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
220941|NCT02501109|Drug|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
220942|NCT02501096|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
220943|NCT02501096|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
220944|NCT02501083|Other|no intervention|The study will not include any intervention.
220945|NCT02501057|Behavioral|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
220946|NCT02501057|Behavioral|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
220947|NCT02501057|Behavioral|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
220948|NCT02501031|Dietary Supplement|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for approximately 50 days.
220949|NCT02501018|Biological|CLBS12|Intramuscular transfusion of CLBS12.
220950|NCT02501018|Drug|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
220951|NCT02501005|Procedure|VT ablation|Catheter ablation of ventricular tachycardia
220952|NCT02500992|Procedure|Transrectal sigmoidectomy|
220953|NCT02500979|Drug|Pramlintide acetate|Pramlintide acetate administered by a separate pump
220954|NCT02500979|Drug|Placebo|Placebo administered by separate pump
220955|NCT02500979|Drug|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
220956|NCT02500979|Drug|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
220957|NCT02500966|Device|DUDA device|Insertion DUDA device
220958|NCT02500966|Procedure|LEEP|Loop Electrosurgical Excision Procedure
220959|NCT02500953|Drug|ASP3325|
220960|NCT02500953|Drug|Placebo|
220999|NCT02500667|Drug|Rifampin|600 mg QD
220963|NCT02500940|Radiation|Radiation therapy|Intensity-Modulated Radiation Therapy
220964|NCT02500940|Drug|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
220965|NCT02500927|Drug|ASP8273 Capsules|oral
220966|NCT02500927|Drug|ASP8273 Capsules A|oral
220967|NCT02500914|Drug|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
220968|NCT02500901|Drug|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
220969|NCT02500901|Drug|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
220970|NCT02500888|Radiation|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
220971|NCT02500875|Device|PTNiA|
220972|NCT02500875|Device|PTNiB|
220973|NCT02500875|Device|PTN|
220974|NCT02500849|Genetic|SB-728mR-HSPC Infusion 3 days following busulfan conditioning|
220975|NCT02500836|Drug|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
220976|NCT02500836|Drug|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
220977|NCT02500836|Drug|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
220978|NCT02500810|Drug|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
220979|NCT02500797|Biological|Ipilimumab|Given IV
220980|NCT02500797|Other|Laboratory Biomarker Analysis|Correlative studies
220981|NCT02500797|Biological|Nivolumab|Given IV
220982|NCT02500797|Other|Quality-of-Life Assessment|Ancillary studies
220983|NCT02500784|Drug|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
220984|NCT02500784|Other|Formoterol B (placebo)|2mL, BID inhaler for 12 months
220985|NCT02500771|Behavioral|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
220986|NCT02500758|Procedure|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
220987|NCT02500758|Procedure|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
220988|NCT02500758|Procedure|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
220989|NCT02500732|Drug|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
220990|NCT02500732|Drug|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
220991|NCT02500719|Other|Fitted Q Learning Algorithm|A reinforcement learning algorithm, fitted Q learning, will be applied to fMRI and skin conductance response (SCR) data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory. The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
220992|NCT02500706|Drug|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
220993|NCT02500706|Drug|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
220994|NCT02500706|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted
220995|NCT02500693|Biological|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
220996|NCT02500680|Biological|MER4101|
220997|NCT02500680|Biological|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
220998|NCT02500667|Drug|N91115|200 mg BID
221002|NCT02500641|Drug|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration > 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
221003|NCT02500641|Drug|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
221004|NCT02500641|Drug|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
221005|NCT02500641|Drug|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
221006|NCT02500641|Drug|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
221007|NCT02500628|Drug|Metformin|500 mg orally after baseline testing of heart rate
221008|NCT02500615|Other|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
221009|NCT02500602|Drug|doxazosin|active medication
221010|NCT02500602|Drug|placebo|placebo pill
221011|NCT02500589|Behavioral|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
221012|NCT02500589|Other|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
221013|NCT02500576|Biological|Aldesleukin|Given IV or SC
221014|NCT02500576|Drug|Cyclophosphamide|Given IV
221015|NCT02500576|Drug|Fludarabine Phosphate|Given IVPB
221016|NCT02500576|Other|Laboratory Biomarker Analysis|Correlative studies
221017|NCT02500576|Biological|Pembrolizumab|Given IV
221018|NCT02500576|Other|Quality-of-Life Assessment|Ancillary studies
221019|NCT02500576|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Given IV
221020|NCT02500563|Other|Amino acid based infant formula|
221021|NCT02500563|Other|Extensively hydrolyzed casein infant formula|
221022|NCT02500563|Other|Mother's own breast milk|
221023|NCT02500550|Biological|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
221024|NCT02500550|Procedure|Haploidentical hematopoietic stem cell transplantation (HSCT)|CD34-selected HSCT from a haploidentical donor
221025|NCT02500537|Device|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
221026|NCT02500524|Drug|Cocamide diethanolamine|Topical lotion
221027|NCT02500524|Drug|Permethrin|Topical creme rinse
221028|NCT02500511|Biological|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
221029|NCT02500498|Drug|Nulojix|
221030|NCT02500485|Drug|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
221031|NCT02500472|Dietary Supplement|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
221032|NCT02500459|Drug|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
221033|NCT02500459|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
221034|NCT02500446|Drug|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
221035|NCT02500446|Other|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
221036|NCT02500433|Other|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
221037|NCT02500433|Other|Conventional therapy|
221180|NCT02499497|Drug|Placebo|The participants will receive pills containing no active drug.
221038|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).~Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
221039|NCT02500407|Drug|BTCT4465A (Mosunetuzumab) IV|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via IV infusion.
221040|NCT02500407|Drug|Atezolizumab|Participants assigned to an atezolizumab combination group will receive atezolizumab 1200 mg administered as an IV infusion in combination with BTCT4465A (Mosunetuzumab).
221041|NCT02500407|Drug|BTCT4465A (Mosunetuzumab) SC|Participants with B-cell NHL and CLL will receive BTCT4465A (Mosunetuzumab) via SC injection.
221042|NCT02500394|Procedure|Ionosteril|biomarker guided volume substitution with Ionosteril
221043|NCT02500381|Drug|SRP-4045|SRP-4045 solution for IV infusion
221044|NCT02500381|Drug|SRP-4053|SRP-4053 solution for IV infusion
221045|NCT02500381|Drug|Placebo|SRP-4045 or SRP-4053 placebo-matching solution for IV infusion
221046|NCT02500368|Device|silicone hydrogel lens (test)|contact lens
221047|NCT02500368|Device|enfilcon A lens (control)|contact lens
221048|NCT02500355|Procedure|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
221049|NCT02500355|Procedure|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
221050|NCT02500355|Procedure|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
221051|NCT02500355|Device|endoscope or an arthroscopic device|
221052|NCT02500342|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
221053|NCT02500342|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
221054|NCT02500329|Drug|Gemigliptin|Gemigliptin for 4 weeks
221055|NCT02500329|Drug|Acarbose|Acarbose for 4 weeks
221056|NCT02500316|Drug|MOD-4023|Once weekly injection of long acting r-hGH (MOD-4023) provided as a solution for injection containing 20 or 50 mg/mL MOD-4023 in a single patient use, multi-dose, disposable pre-filled pen (PEN).
221057|NCT02500277|Device|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
221058|NCT02500277|Device|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
221059|NCT02500264|Device|TENS|
221060|NCT02500251|Drug|belimumab|Belimumab will be administered per study protocol.
221061|NCT02500251|Drug|Bortezomib|Bortezomib will be administered per study protocol.
221062|NCT02500251|Drug|Rituximab|Rituximab will be administered per study protocol.
221063|NCT02500251|Drug|Plasmapheresis|Plasmapheresis will be administered per study protocol.
221064|NCT02500238|Other|Saliva sample|All participants will provide a saliva sample.
221065|NCT02500238|Other|Urine Sample|All participants will provide a urine sample.
221066|NCT02500238|Other|Toe nail clippings|All participants will provide toe nail clippings.
221067|NCT02500238|Other|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
221068|NCT02500225|Drug|Etomidate|0.2 mg/kg etomidate
221069|NCT02500225|Drug|Sevoflurane|8% Sevoflurane
221070|NCT02500212|Drug|ENVARSUS®|
221071|NCT02500212|Drug|ADVAGRAF®|
221072|NCT02500199|Drug|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
221073|NCT02500186|Drug|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
221074|NCT02500186|Other|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
221075|NCT02500173|Radiation|Radiation|Radiation therapy
221076|NCT02500160|Device|Patient specific instrumentation (MRI)|
221077|NCT02500160|Device|Patient specific instrumentation (CT)|
221078|NCT02500147|Drug|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
221079|NCT02500147|Drug|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
221080|NCT02500134|Other|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
221081|NCT02500121|Other|Placebo|Normal saline
221082|NCT02500121|Drug|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
221083|NCT02500108|Drug|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.~Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).~Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
221084|NCT02500095|Other|Fasting|72 hours of fasting
221085|NCT02500095|Drug|Saline|Concomitant saline during fasting
221086|NCT02500095|Drug|Pegvisomant|Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
221087|NCT02500082|Drug|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
221088|NCT02500069|Other|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
221089|NCT02500069|Other|Casein (in duodenum)|infusion of protein in duodenum
221090|NCT02500069|Other|Casein (in jejunum)|infusion of protein in jejunum
221091|NCT02500069|Other|Casein (in ileum)|infusion of protein in ileum
221092|NCT02500056|Device|Optilene LP mesh|Lichtenstein hernioplasty
221093|NCT02500056|Device|Ultrapro mesh|Lichtenstein hernioplasty
221094|NCT02500043|Drug|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
221095|NCT02500043|Drug|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
221096|NCT02500030|Procedure|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
221097|NCT02500030|Procedure|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
221098|NCT02500017|Dietary Supplement|Melatonin|5mg rapid release melatonin capsule
221099|NCT02500017|Other|Placebo|matching placebo capsule
221100|NCT02500004|Radiation|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
221101|NCT02500004|Radiation|DXA scanning|Body composition: DXA scanning, D2O and MRI.
221102|NCT02500004|Procedure|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
221103|NCT02500004|Procedure|Blood sampling|Systemic inflammatory profile: blood sampling.
221104|NCT02500004|Other|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
221105|NCT02500004|Device|Accelerometry|Physical activity level: accelerometry.
221106|NCT02500004|Other|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
221107|NCT02499991|Behavioral|memory|keep track of social events in diary for memory recall. Used by treatment group
221108|NCT02499978|Drug|Darunavir/Cobicistat|Fixed dose combination medication
221109|NCT02499978|Drug|Dolutegravir|single tablet medication
221110|NCT02499965|Drug|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
221111|NCT02499965|Drug|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
221112|NCT02499952|Drug|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
221113|NCT02499939|Behavioral|Standard Care|Education and home exercises
221114|NCT02499939|Other|Ultrasound Therapy|"Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.~(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)"
221115|NCT02499926|Dietary Supplement|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.~Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
221116|NCT02499913|Behavioral|breath alcohol monitoring|Daily breath alcohol monitoring
221117|NCT02499913|Behavioral|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
221118|NCT02499900|Drug|Copaxone®|Subcutaneous Injections
221119|NCT02499887|Drug|beclamethasone dipropionate|Inhaler
221120|NCT02499887|Drug|albuterol|Inhaler
221121|NCT02499887|Drug|Prednisone|Oral corticosteroid
221122|NCT02499874|Drug|Efavirenz|oral Efavirenz 400mg
221123|NCT02499874|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
221124|NCT02499874|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
221125|NCT02499874|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
221126|NCT02499861|Drug|Decitabine and Genistein|intravenous Decitabine with oral genistein
221127|NCT02499848|Drug|PRX302|Single prostate cancer lesion injected with PRX302.
221128|NCT02499835|Biological|Pembrolizumab|Given IV
221130|NCT02499822|Drug|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
221131|NCT02499822|Drug|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
221132|NCT02499809|Other|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
221133|NCT02499796|Device|Hygrovent Gold|
221134|NCT02499796|Device|Heated and moisture exchanger (HME)|
221135|NCT02499796|Device|Heated humidifier (HH)|
221136|NCT02499783|Biological|adalimumab|subcutaneous injections of adalimumab
221137|NCT02499783|Other|placebo|subcutaneous injections of placebo
221138|NCT02499770|Drug|Carboplatin|
221139|NCT02499770|Drug|Placebo|
221140|NCT02499770|Drug|Trilaciclib|
221141|NCT02499770|Drug|Etoposide|
221142|NCT02499757|Device|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
221143|NCT02499757|Device|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
221144|NCT02499757|Device|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
221145|NCT02499757|Device|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
221146|NCT02499744|Device|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
221147|NCT02499744|Device|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
221148|NCT02499731|Behavioral|Strong Hearts, Healthy Communities|"We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
221149|NCT02499731|Behavioral|Strong Hearts, Healthy Women|"The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.~Participants will learn and discuss techniques and strategies to improve personal health."
221150|NCT02499718|Device|BiPAP mode|Noninvasive ventilator
221151|NCT02499705|Dietary Supplement|Sucralose|2 packets
221152|NCT02499705|Dietary Supplement|Sucrose|equisweet to sucralose
221153|NCT02499705|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
221154|NCT02499692|Device|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
221155|NCT02499666|Procedure|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
221156|NCT02499666|Device|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
221157|NCT02499666|Drug|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
221158|NCT02499653|Behavioral|Psychological Intervention|
221159|NCT02499653|Behavioral|Videos|
221160|NCT02499640|Other|immersion cold water|immersion cold water at different temperatures and exposure times
221161|NCT02499627|Drug|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
221162|NCT02499627|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
221163|NCT02499614|Drug|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
221164|NCT02499601|Device|CORolla™ TAA device|
221165|NCT02499588|Device|Esteem Plus with ConvaTec Moldable Technology|
221166|NCT02499588|Device|Natura with ConvaTec Moldable Technology|
221167|NCT02499588|Device|Natura Accordion with ConvaTec Moldable Technology|
221168|NCT02499588|Device|Esteem synergy Plus with ConvaTec Moldable Technology|
221169|NCT02499575|Drug|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
221170|NCT02499575|Drug|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
221171|NCT02499562|Drug|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
221172|NCT02499562|Drug|Placebo|
221173|NCT02499562|Drug|Entecavir|
221174|NCT02499549|Drug|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
221175|NCT02499536|Device|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
221176|NCT02499523|Procedure|THR with conventional technique|THR with conventional technique.
221177|NCT02499523|Procedure|THR with Acetabular Cup Orientation Guides (ACOG)|THR with the ACOG System.
221178|NCT02499510|Device|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
221179|NCT02499497|Drug|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
221181|NCT02499484|Drug|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
221182|NCT02499484|Other|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
221183|NCT02499484|Other|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
221184|NCT02499471|Other|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
221185|NCT02499458|Other|None- observational study|
221186|NCT02499445|Drug|Remifentanil|administering remifentanil for anesthesia maintenance
221187|NCT02499445|Drug|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
221188|NCT02499445|Drug|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
221189|NCT02499445|Drug|propofol|administering propofol for anesthesia maintenance
221190|NCT02499445|Drug|sufentanil|administering sufentanil for anesthesia maintenance
221191|NCT02499432|Behavioral|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
221192|NCT02499406|Behavioral|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
221193|NCT02499393|Drug|Magnesium Sulfate|intravenous infusion of magnesium sulphate
221194|NCT02499380|Device|PneumRx Coil System|
221195|NCT02499367|Drug|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
221196|NCT02499367|Radiation|Radiation therapy|20 Gy to metastatic lesion
221197|NCT02499367|Drug|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
221198|NCT02499367|Drug|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
221199|NCT02499367|Drug|Cisplatin|40 mg/m2, weekly for 2 weeks
221200|NCT02499354|Drug|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
221201|NCT02499354|Drug|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
221202|NCT02499341|Drug|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
221203|NCT02499341|Drug|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
221204|NCT02499328|Drug|AZD9150|AZD9150
221205|NCT02499328|Drug|MEDI4736|MEDI4736
221206|NCT02499328|Drug|AZD5069|AZD5069
221207|NCT02499328|Drug|tremelimumab (treme)|tremelimumab
221208|NCT02499315|Drug|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
221209|NCT02499315|Drug|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
221210|NCT02499302|Behavioral|Mental training|
221211|NCT02499276|Device|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
221212|NCT02499250|Device|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
221213|NCT02499250|Drug|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
221214|NCT02499237|Drug|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
221215|NCT02499237|Drug|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
221216|NCT02499224|Drug|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.~Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
221217|NCT02499211|Other|Intervention stores|"In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.~Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.~Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them."
221218|NCT02499198|Drug|[D4]Nornicotine - Highest|Level equal to highest level of [D4]Nornicotine found in commercial tobacco based snuff
221219|NCT02499198|Other|[D4]Nornicotine - Mean|Level equal to mean level of [D4]Nornicotine found in commercial tobacco based snuff
221220|NCT02499198|Other|[D4]Nornicotine - Lowest|Level equal to lowest level of [D4]Nornicotine found in commercial tobacco based snuff
221221|NCT02499198|Other|[D4]Nornicotine - 50% Lowest|Level equal to 50% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
221222|NCT02499198|Other|[D4]Nornicotine - 10% Lowest|Level equal to 10% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
221223|NCT02499198|Other|[D4]Nornicotine - 5% Lowest|Level equal to 5% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
221224|NCT02499198|Other|13C6-NNN|0.5µg/g - below traditional levels found in moist snuff
221225|NCT02499198|Other|Herbal Snuff|A tobacco-free herbal snuff, such as Smokey Mountain or similar
221226|NCT02499185|Device|Nephro Check Test|Urine sample
221227|NCT02499185|Other|serum creatinine measurement|Blood sample
221228|NCT02499172|Biological|Shanchol|
221229|NCT02499159|Drug|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
221230|NCT02499159|Drug|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
221231|NCT02499146|Drug|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
221232|NCT02499146|Drug|Letrozole|2.5 mg , orally once daily (continuously)
221233|NCT02499133|Other|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
221234|NCT02499120|Drug|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
221235|NCT02499120|Drug|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
221236|NCT02499120|Drug|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.~Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
221237|NCT02499107|Dietary Supplement|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
221238|NCT02499107|Dietary Supplement|Pasta treatment|
221239|NCT02499107|Dietary Supplement|Boiled and mashed potato treatment|
221240|NCT02499107|Dietary Supplement|Baked french fries treatment|
221241|NCT02499107|Dietary Supplement|Fried french fries treatment|
221242|NCT02499094|Other|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
221243|NCT02499081|Drug|Ixazomib|
221244|NCT02499068|Device|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
221245|NCT02499055|Behavioral|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
221246|NCT02499042|Drug|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
221247|NCT02499029|Drug|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
221248|NCT02499029|Drug|Placebo|Identical looking placebo pills were administered each week.
221249|NCT02499016|Procedure|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
221250|NCT02499003|Drug|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
221251|NCT02498990|Behavioral|Low calorie diet followed by life style intervention|"Low calorie diet of 800 kcal/day for 7 weeks.~Life style intervention for the remaining study period"
221252|NCT02498977|Genetic|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
221253|NCT02498977|Drug|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
221254|NCT02498964|Other|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
221255|NCT02498951|Procedure|Cognitive Assessment|Ancillary studies
221256|NCT02498951|Biological|Obinutuzumab|Given IV
221257|NCT02498951|Other|Quality-of-Life Assessment|Ancillary studies
221258|NCT02498938|Genetic|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
221259|NCT02498925|Behavioral|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
221260|NCT02498912|Procedure|Production of Genetically-modified T cells|
221261|NCT02498912|Drug|Cyclophosphamide|
221262|NCT02498912|Device|IP Catheter Insertion|
221263|NCT02498912|Genetic|Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells|Patients who do not have sufficient CAR T cells for the assigned dose cohort will be treated in the cohort for which cells are available.
221264|NCT02498912|Drug|Fludarabine|fludarabine dose 25-30 mg/m2 x 3 days
221265|NCT02498899|Behavioral|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
221266|NCT02498899|Behavioral|Video|Participants watch a video lasting about 4 minutes.
221267|NCT02498886|Dietary Supplement|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
221268|NCT02498886|Dietary Supplement|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
221269|NCT02498873|Behavioral|Linear Periodization|Linear Intensity Periodization Running
221270|NCT02498873|Behavioral|Non Linear Periodization|Non Linear Periodization Running
221271|NCT02498860|Drug|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
221272|NCT02498860|Drug|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
221273|NCT02498847|Behavioral|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:~What is Osteoarthritis?~Information about treatments~Exercise~Sleep hygiene~Relaxation~Pleasant Activity Scheduling~Goal setting~Problem Solving~Pacing~Communication"
221274|NCT02498834|Behavioral|Educational Video and Question Prompt List|Educational Video and Question Prompt List
221275|NCT02498821|Device|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
221276|NCT02498821|Device|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
221277|NCT02498821|Procedure|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
221278|NCT02498795|Other|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
221279|NCT02498795|Other|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
221280|NCT02498795|Other|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
221281|NCT02498782|Drug|Fexinidazole|
221282|NCT02498782|Drug|Placebo|
221283|NCT02498769|Drug|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
221284|NCT02498769|Drug|Placebo|
221285|NCT02498756|Biological|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
221286|NCT02498756|Drug|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
221287|NCT02498743|Procedure|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
221288|NCT02498743|Behavioral|Watching Animated cartoons|
221289|NCT02498730|Behavioral|Interval Training|High Intensity Interval Training at 100% VO2Max
221290|NCT02498730|Behavioral|Continuous Training|Continuous Stimulous at 60% VO2Max
221291|NCT02498730|Behavioral|Control|Only Dependent Variables Measures
221292|NCT02498717|Device|GameReady|Cryotherapy and compression
221293|NCT02498717|Other|RICE|SOC ice and elevation
221294|NCT02498704|Procedure|Dry Needling|Trigger point dry needling to hamstring muscle group.
221295|NCT02498704|Other|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
221296|NCT02498691|Biological|Biological collection|Blood and saliva samples, placenta and cord blood collection
221297|NCT02498678|Procedure|Tetanus|tetanic electric stimulation
221298|NCT02498665|Drug|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.~MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.~MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
221299|NCT02498652|Drug|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).~Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
221300|NCT02498652|Drug|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
221301|NCT02498639|Procedure|percutaneous balloon aortic valvuloplasty|"Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.~The procedure terminates in case of:~Reduction of the mean aortic gradient ≥50%.~Aortic pressure drop during the inflations, indicative of valve orifice sealing.~Intraprocedural complication.~Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded."
221302|NCT02498626|Other|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
221303|NCT02498613|Other|18F-Fluoromisonidazole|Correlative studies
221304|NCT02498613|Drug|Cediranib|Given PO
221305|NCT02498613|Drug|Cediranib Maleate|Given PO
221308|NCT02498613|Procedure|Positron Emission Tomography|Correlative studies
221309|NCT02498600|Biological|Ipilimumab|Given IV
221310|NCT02498600|Biological|Nivolumab|Given IV
221311|NCT02498574|Device|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
221312|NCT02498574|Behavioral|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
221313|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
221314|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
221315|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
221316|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
221317|NCT02498548|Behavioral|Trained SCI Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control, members of this group will be trained at moderate gait speeds,
221318|NCT02498535|Drug|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
221319|NCT02498522|Drug|Metformin|83 patients will continue metformin until end of 1st trimester
221320|NCT02498509|Drug|CKD-342|treatment for 4 weeks after randomization
221321|NCT02498509|Drug|Mometasone furoate|treatment for 4 weeks after randomization
221322|NCT02498509|Drug|Levocabastine HCL|treatment for 4 weeks after randomization
221323|NCT02498496|Drug|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
221324|NCT02498496|Drug|Placebo|Administration of 100 mL of Normal Saline
221325|NCT02498483|Drug|Acetaminophen|Infants will receive 15 mg/kg of acetaminophen.
221326|NCT02498470|Procedure|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
221327|NCT02498457|Other|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
221328|NCT02498444|Drug|Treprostinil|Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
221329|NCT02498431|Procedure|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
221330|NCT02498431|Procedure|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
221331|NCT02498431|Device|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
221332|NCT02498418|Drug|Rifaximin 200mg Tablet|Generic rifaximin tablets
221333|NCT02498418|Drug|Xifaxan 200mg Tablet|Brand reference standard for comparison
221334|NCT02498418|Drug|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin
221335|NCT02498392|Drug|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
221336|NCT02498392|Other|Placebo|Matching Placebo will be administered orally.
221337|NCT02498379|Drug|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu[64]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
221338|NCT02498366|Other|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.~day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
221339|NCT02498353|Radiation|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
221340|NCT02498353|Radiation|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
221341|NCT02498353|Procedure|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
221342|NCT02498340|Dietary Supplement|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
221343|NCT02498327|Other|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
221344|NCT02498327|Other|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
221345|NCT02498314|Other|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
221346|NCT02498314|Other|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
221507|NCT02497157|Drug|Oxaliplatin (L-OHP)|
221347|NCT02498314|Other|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
221348|NCT02498301|Drug|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
221349|NCT02498301|Drug|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
221350|NCT02498288|Drug|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
221351|NCT02498288|Drug|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
221352|NCT02498288|Drug|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
221353|NCT02498262|Other|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
221354|NCT02498249|Device|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
221355|NCT02498249|Device|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
221356|NCT02498236|Drug|Intranasal Oxytocin|
221357|NCT02498223|Other|experiment protocol|"the subjects will undergo the following experiment protocol:~recruitment and medical examination day.~physiological evaluation day- the subjects will perform twice* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.~biomechanical valuation day- the subjects will perform twice* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.~once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
221358|NCT02498210|Other|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
221359|NCT02498197|Behavioral|Participatory Intervention|
221360|NCT02498197|Behavioral|Control|
221361|NCT02498184|Other|acupuncture|
221362|NCT02498171|Drug|Intrathecal morphine with fentanyl|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
221363|NCT02498171|Drug|Intrathecal morphine with bupivacaine|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
221364|NCT02498158|Device|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:~anatomical scan according to standard protocol~functional scan according to the standard protocol of rest-state fMRI.~scans of 10 healthy subjects will be taken from existing scans at the imaging department."
221365|NCT02498145|Other|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
221366|NCT02498145|Other|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
221367|NCT02498132|Other|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, & Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
221368|NCT02498132|Other|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
221369|NCT02498132|Other|Treatment as Usual|Individuals will be provided with one on one therapy sessions
221370|NCT02498106|Dietary Supplement|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins [B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene] and minerals [Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid [EPA] and docosahexaenic acid [DHA])
221371|NCT02498093|Behavioral|Maximal strength training|
221372|NCT02498093|Behavioral|conventional rehabilitation|
221373|NCT02498080|Procedure|DEB PTA|paclitaxel drug eluting balloon PTA
221374|NCT02498080|Procedure|Standard PTA|Standard PTA
221375|NCT02498067|Behavioral|rPlan dual protection waiting room app intervention|
221412|NCT02497872|Procedure|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
221376|NCT02498054|Behavioral|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
221377|NCT02498041|Procedure|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
221378|NCT02498041|Device|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
221379|NCT02498041|Device|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
221380|NCT02498041|Procedure|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
221381|NCT02498028|Procedure|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
221382|NCT02498028|Procedure|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
221383|NCT02498015|Drug|"3D regimen"|"The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis."
221384|NCT02498015|Drug|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis."
221385|NCT02498002|Device|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
221386|NCT02498002|Other|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
221387|NCT02498002|Other|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
221388|NCT02498002|Procedure|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
221389|NCT02498002|Procedure|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
221390|NCT02498002|Drug|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
221391|NCT02498002|Other|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
221392|NCT02498002|Radiation|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
221393|NCT02498002|Other|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
221394|NCT02498002|Other|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
221395|NCT02498002|Other|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
221396|NCT02498002|Other|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
221397|NCT02497989|Other|Inter-personal Communication (IPC)|RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
221398|NCT02497989|Other|Dedicated Service Outlets (DSO)|RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
221399|NCT02497976|Biological|Certolizumab pegol|400 mg
221400|NCT02497976|Drug|Placebo|Normal saline
221401|NCT02497963|Procedure|Foreskin Graft-Tubularized Incised Plate|TIP Urethroplasty with foreskin graft in primary hypospadias
221402|NCT02497963|Procedure|Tubularized Incised Plate|TIP Urethroplasty without foreskin graft in primary hypospadias
221403|NCT02497950|Device|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
221404|NCT02497937|Drug|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
221405|NCT02497937|Drug|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
221406|NCT02497924|Drug|GBT440|GBT440 capsules followed by single dose of [C14] GBT440 oral suspension
221407|NCT02497911|Procedure|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
221408|NCT02497911|Procedure|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
221409|NCT02497911|Drug|Ropivicaine|
221410|NCT02497911|Drug|Bupivicaine|
221411|NCT02497898|Biological|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
221413|NCT02497859|Behavioral|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
221414|NCT02497859|Behavioral|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
221415|NCT02497859|Behavioral|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
221416|NCT02497859|Behavioral|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
221417|NCT02497846|Device|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity [I]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
221418|NCT02497833|Dietary Supplement|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
221419|NCT02497833|Other|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
221420|NCT02497820|Drug|Aspirin|"Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place."
221421|NCT02497794|Other|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
221422|NCT02497781|Drug|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
221423|NCT02497781|Drug|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
221424|NCT02497768|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
221425|NCT02497755|Behavioral|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
221426|NCT02497755|Device|smartphone|
221427|NCT02497742|Other|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
221428|NCT02497729|Procedure|Written Checklist|Use of a written checklist pre and peri-intubation
221429|NCT02497729|Procedure|Head of Bed Up|Raising the patient's head of bed to 25 degrees
221430|NCT02497716|Drug|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
221431|NCT02497703|Device|Knee robot|
221432|NCT02497690|Behavioral|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
221433|NCT02497690|Behavioral|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
221434|NCT02497677|Behavioral|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
221435|NCT02497677|Behavioral|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
221436|NCT02497664|Other|Active Breathing Control|
221437|NCT02497651|Dietary Supplement|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
221438|NCT02497651|Other|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
221439|NCT02497638|Drug|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
221440|NCT02497638|Drug|Atorvastatin|Atorvastatin 20 mg once daily until progression.
221441|NCT02497638|Drug|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
221442|NCT02497638|Drug|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
221443|NCT02497625|Behavioral|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
221444|NCT02497625|Behavioral|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
221445|NCT02497625|Other|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
221446|NCT02497612|Drug|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
221447|NCT02497612|Drug|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
221448|NCT02497612|Other|Placebo|Capsules Placebo capsules are used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No patient will receive placebo only.
221449|NCT02497599|Drug|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
221450|NCT02497599|Radiation|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
221451|NCT02497599|Procedure|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
221452|NCT02497586|Radiation|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
221453|NCT02497573|Other|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
221454|NCT02497560|Dietary Supplement|proprietary formula|
221455|NCT02497547|Drug|Oxytocin|
221456|NCT02497547|Drug|Placebo|
221457|NCT02497508|Drug|nivolumab|
221458|NCT02497495|Other|immersion cold water|immersion cold water at different temperatures and exposure times
221459|NCT02497469|Drug|Vedolizumab|Vedolizumab infusion
221460|NCT02497469|Drug|Adalimumab placebo|Adalimumab placebo-matching injection
221461|NCT02497469|Drug|Adalimumab|Adalimumab injection
221462|NCT02497469|Drug|Vedolizumab placebo|Vedolizumab placebo-matching infusion
221463|NCT02497456|Behavioral|Follow-up counselling|
221464|NCT02497443|Biological|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
221465|NCT02497404|Drug|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible."
221466|NCT02497404|Drug|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
221467|NCT02497404|Drug|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
221468|NCT02497404|Drug|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.
221469|NCT02497404|Radiation|Total Body Irradiation|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
221470|NCT02497391|Drug|Evacetrapib|administered orally
221471|NCT02497378|Drug|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
221472|NCT02497378|Drug|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
221473|NCT02497378|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
221474|NCT02497365|Drug|Besifloxacin|
221475|NCT02497365|Drug|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
221476|NCT02497352|Dietary Supplement|flaxseed|
221477|NCT02497352|Behavioral|lifestyle modification|
221478|NCT02497339|Behavioral|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
221479|NCT02497326|Drug|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
221480|NCT02497326|Drug|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
221481|NCT02497326|Drug|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score >4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
221482|NCT02497313|Drug|Isotonic saline|
221483|NCT02497313|Drug|Metformin placebo|
221484|NCT02497313|Drug|Cholecystokinin|
221485|NCT02497313|Drug|Metformin|
221486|NCT02497300|Drug|Spironolactone|
221487|NCT02497300|Drug|Amiloride|
221488|NCT02497287|Drug|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 >= 65 years old will start at a dose of 28 mg in Week 5.
221489|NCT02497287|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
221490|NCT02497287|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants >= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
221491|NCT02497287|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
221492|NCT02497287|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants < 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants >= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
221493|NCT02497274|Other|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
221494|NCT02497261|Procedure|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
221495|NCT02497248|Procedure|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
221496|NCT02497235|Drug|TAK-935|TAK-935 oral solution.
221497|NCT02497235|Drug|[18F]MNI-792 (tracer)|[18F]MNI-792 injection.
221498|NCT02497222|Drug|RNS60|
221499|NCT02497222|Drug|Normal Saline|
221500|NCT02497196|Device|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
221501|NCT02497196|Device|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
221502|NCT02497196|Device|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
221503|NCT02497196|Device|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
221504|NCT02497183|Device|ultrasound|A repeat ultrasound exam following oral contrast material consumption
221505|NCT02497183|Other|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
221506|NCT02497170|Behavioral|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
221508|NCT02497157|Drug|Irinotecan hydrochloride hydrate (CPT-11)|
221509|NCT02497157|Drug|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
221510|NCT02497157|Drug|Levofolinate calcium (l-LV)|
221511|NCT02497157|Drug|Bevacizumab (Bmab)|
221512|NCT02497144|Other|NMES Group|Neuromuscular electrical stimulation
221513|NCT02497144|Other|Control Group|Breathing exercises
221514|NCT02497131|Drug|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
221515|NCT02497118|Drug|Endostatin|Endostatin,7.5mg/m^2,intravenous, d1-14;
221516|NCT02497118|Drug|Vinorelbine|vinorelbine,25mg/m^2,intravenous, d1, d8;
221517|NCT02497118|Drug|Cisplatin|Cisplatin，75mg/m^2 intravenous,divide into d1-3
221518|NCT02497105|Other|Ketogenic Diet|Dietary
221519|NCT02497092|Other|Technique of injection|
221520|NCT02497079|Device|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
221521|NCT02497079|Device|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
221522|NCT02497079|Device|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
221523|NCT02497066|Other|Neuropathic pain cream|Subjects will apply the cream to the painful area.
221524|NCT02497066|Other|Nociceptive pain cream|Subjects will apply the cream to the painful area.
221525|NCT02497066|Other|Mixed pain cream|Subjects will apply the cream to the painful area.
221526|NCT02497053|Drug|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
221527|NCT02497053|Drug|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
221528|NCT02497040|Drug|Levobupivacaine|local injection
221529|NCT02497040|Drug|Bupivacaine|local injection
221530|NCT02497040|Drug|placebo|local injection
221531|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
221532|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
221533|NCT02497014|Device|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
221534|NCT02497014|Device|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
221535|NCT02497001|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])
221536|NCT02497001|Drug|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
221537|NCT02497001|Drug|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
221538|NCT02497001|Drug|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
221539|NCT02496988|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
221540|NCT02496988|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
221541|NCT02496975|Drug|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
221542|NCT02496975|Other|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
221543|NCT02496962|Drug|Atorvastatin|atorvastatin were taken daily for 5 days
221544|NCT02496962|Drug|placebo|placebo were taken daily for 5 days
221545|NCT02496949|Drug|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
221546|NCT02496936|Other|SFA|High saturated fatty acid/SFA oil source
221547|NCT02496936|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
221548|NCT02496936|Other|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
221549|NCT02496936|Other|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
221550|NCT02496936|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
221551|NCT02496923|Device|High flow nasal oxygen therapy (Optiflow™)|
221552|NCT02496923|Device|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
221553|NCT02496910|Drug|YH22162|
221554|NCT02496910|Drug|Telmisartan/Amlodipine 80/5 mg (FDC)|
221555|NCT02496910|Drug|Chlorthalidone 25mg|
221556|NCT02496897|Biological|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
221557|NCT02496897|Other|Placebo|Placebo
221558|NCT02496897|Other|IC31® Adjuvant|IC31® Adjuvant
221559|NCT02496884|Drug|DS-5565|DS-5565 7.5 mg tablet for oral use
221560|NCT02496884|Drug|Placebo|Placebo tablet for oral use to match DS-5565 7.5 mg tablet
221561|NCT02496871|Behavioral|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
221562|NCT02496871|Behavioral|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
221563|NCT02496845|Drug|VL#FIA3-30|Vasoactive dual treatment (MH30-01 & IS045-01)
221564|NCT02496832|Drug|18F-Fluoroazomycin arabinoside|
221565|NCT02496819|Other|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
221566|NCT02496819|Other|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
221567|NCT02496819|Other|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
221568|NCT02496806|Dietary Supplement|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
221569|NCT02496793|Behavioral|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
221570|NCT02496780|Drug|novolog insulin|3x daily rapid-acting insulin
221571|NCT02496780|Drug|levemir insulin|basal insulin once a day
221572|NCT02496780|Drug|placebo|once or 3x daily
221573|NCT02496767|Drug|tirasemtiv|
221574|NCT02496767|Drug|Placebo tablets|
221575|NCT02496767|Drug|Riluzole 50 MG|
221576|NCT02496754|Drug|GnRH-a|In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
221577|NCT02496754|Drug|GnRH-a|In control group, patients use short term GnRH-a. Patients' serum or follicle fluid will be collected if needed.
221578|NCT02496741|Drug|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
221579|NCT02496728|Behavioral|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
221580|NCT02496728|Behavioral|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
221581|NCT02496728|Behavioral|Social Support|Participants may interact with each other through a private Facebook group.
221582|NCT02496728|Behavioral|Educational Materials|Educational materials regarding healthy behaviors.
221583|NCT02496715|Drug|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
221584|NCT02496715|Drug|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
221585|NCT02496715|Drug|Placebo|Placebo inhaler
221586|NCT02496702|Device|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
221587|NCT02496689|Biological|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
221588|NCT02496676|Dietary Supplement|Magnesium L-threonate|In Part I, patients within each cohort will be randomized into 2 arms. Each arm will receive 12 weeks of either oral magnesium L-threonate or placebo followed by crossover treatment for another 12 weeks. Patients in cohort 1 who experience >=0.5-log reduction in the number of EBV-infected B cells and patients in cohort 2 who experience greater than or equal to >=2-fold increase in NKG2D receptor expression on CDS T cells during oral magnesium treatment as compared to placebo will have completed the study. Patients who do not meet these respective criteria will undergo a 2-week washout and transition to Part II in which they will be hospitalized to receive 3 days of IV MgS04. These patients will then restart escalating doses of oral magnesium and continue for 24 weeks, at which point participation will be complete.
221589|NCT02496676|Other|Placebo|Participants will receive 12 weeks of placebo and 12 weeks of magnesium threonate. Will be dose escalated based on weight
221590|NCT02496663|Biological|Necitumumab|Given IV
221591|NCT02496663|Drug|Osimertinib|Given PO
221592|NCT02496650|Drug|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
222096|NCT02492867|Drug|Durvalumab|10 mg/kg during consolidation. Given IV
221593|NCT02496637|Behavioral|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
221594|NCT02496637|Behavioral|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
221595|NCT02496624|Other|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
221596|NCT02496611|Drug|Exenatide extended-release for injectable suspension (BYDUREON™)|
221597|NCT02496611|Dietary Supplement|Meal Replacement Therapy|A short-term meal replacement induction period designed to achieve >5% BMI reduction in 1, 2, or 3 months.
221598|NCT02496598|Procedure|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
221599|NCT02496598|Drug|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
221600|NCT02496585|Drug|Nintedanib|
221601|NCT02496585|Drug|Prednisone|
221602|NCT02496585|Other|Placebo|
221603|NCT02496572|Drug|Short course MDR-TB treatment regimen|"Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
221604|NCT02496559|Procedure|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
221605|NCT02496546|Drug|LEO 32731 cream|Applied for 3 weeks
221606|NCT02496546|Drug|LEO 32731 cream vehicle|Applied for 3 weeks
221607|NCT02496533|Procedure|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
221608|NCT02496520|Biological|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
221609|NCT02496520|Procedure|Surgery as needed by the patient´s tumor and stage|
221610|NCT02496520|Drug|Chemotherapy as needed by the patient´s tumor and stage|
221611|NCT02496520|Radiation|Radiation therapy as needed by the patient´s tumor and stage|
221612|NCT02496507|Other|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
221613|NCT02496494|Drug|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
221614|NCT02496481|Behavioral|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
221615|NCT02496481|Behavioral|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
221616|NCT02496455|Procedure|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
221617|NCT02496455|Drug|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
221618|NCT02496442|Device|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
221619|NCT02496429|Device|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
221620|NCT02496416|Behavioral|Aquatic Exercise Program|The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
221621|NCT02496416|Behavioral|Stretching Program|The stretching program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be conducted online via a secure video-conferencing website.
221622|NCT02496403|Behavioral|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
221623|NCT02496390|Biological|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
221624|NCT02496390|Biological|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
221625|NCT02496377|Drug|ferrous glycine sulfate Tardyferon|
221626|NCT02496377|Drug|Epoetin Alfa|
221627|NCT02496377|Drug|ferric carboxymaltose Ferinject|
221628|NCT02496364|Drug|Placebo (Topical)|Saline Solution 0,9% in situ, up to 100ml;
221629|NCT02496364|Drug|Placebo (Intravenous)|Saline Solution 0,9% in the vein, up to 500ml: 200ml as loading dose over 15 minutes followed by 1ml/Kg/hr throughout the surgery, in a maximum volume of 300ml
221630|NCT02496364|Drug|Tranexamic Acid (Topical)|30mg/ml of tranexamic acid in situ during surgery, up to 100ml
221631|NCT02496364|Drug|Tranexamic Acid (Intravenous)|5mg/ml of tranexamic acid in the vein, up to 500ml: 200ml (5mg/ml) as loading dose over 15 minutes followed by 1ml/Kg/hr (5mg/ml) throughout the surgery, in a maximum volume of 300ml.
221632|NCT02496351|Device|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
221633|NCT02496338|Other|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
221634|NCT02496325|Procedure|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
221635|NCT02496312|Behavioral|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
221636|NCT02496299|Drug|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
221637|NCT02496299|Drug|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
221638|NCT02496286|Drug|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
221639|NCT02496273|Biological|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
221640|NCT02496260|Procedure|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
221641|NCT02496260|Procedure|Biomarkers|"We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples."
221642|NCT02496247|Other|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
221643|NCT02496221|Drug|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
221644|NCT02496221|Drug|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
221645|NCT02496221|Drug|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
221646|NCT02496208|Drug|Cabozantinib|Given PO
221647|NCT02496208|Drug|Cabozantinib S-malate|Given PO
221648|NCT02496208|Biological|Ipilimumab|Given IV
221649|NCT02496208|Biological|Nivolumab|Given IV
221650|NCT02496182|Drug|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
221651|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
221652|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
221653|NCT02496169|Device|eucaLimus|Percutaneous Coronary Intervention (PCI)
221654|NCT02496156|Behavioral|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
221655|NCT02496156|Behavioral|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
221656|NCT02496143|Drug|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
221657|NCT02496143|Drug|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
221658|NCT02496117|Procedure|Electrical mapping, nerve stimulation checked renal denervation procedure|
221659|NCT02496117|Procedure|Electrial mapping, nerve stimulation guided renal denervation procedure|
221660|NCT02496104|Behavioral|Package n°1 of the APIB|
221661|NCT02496091|Device|ATLANTIS Abutment|
221662|NCT02496078|Drug|Daclatasvir|Daclatasvir tablet 60mg
221663|NCT02496078|Drug|Asunaprevir|Asunaprevir soft capsule 100 mg
221664|NCT02496065|Drug|BLZ-100|
221665|NCT02496052|Procedure|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
221666|NCT02496052|Device|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
221667|NCT02496052|Drug|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
221668|NCT02496039|Drug|NUEDEXTA®|NUEDEXTA® only
221669|NCT02496026|Device|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
221670|NCT02496026|Device|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
221671|NCT02496013|Drug|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
221672|NCT02496000|Drug|ORMD-0801|Oral Insulin
221673|NCT02496000|Drug|Placebo Comparator|Placebo
221674|NCT02495974|Drug|enzalutamide|oral
221675|NCT02495948|Device|Lotrafilcon B contact lenses|
221676|NCT02495948|Device|Samfilcon A contact lenses|
221677|NCT02495948|Device|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
221678|NCT02495948|Device|Saline solution|Used for rinsing contact lenses, as needed
221679|NCT02495935|Device|OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
221680|NCT02495935|Device|Sham-OkuStim®|Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
221681|NCT02495922|Drug|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
221682|NCT02495922|Drug|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
221683|NCT02495922|Drug|Bortezomib|all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
221684|NCT02495922|Drug|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).~8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).~20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).~12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
221685|NCT02495896|Drug|Cisplatin|Given IV
221686|NCT02495896|Drug|Docetaxel|Given IV
221687|NCT02495896|Drug|Gemcitabine Hydrochloride|Given IV
221688|NCT02495896|Other|Laboratory Biomarker Analysis|Correlative studies
221689|NCT02495896|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
221690|NCT02495896|Other|Pharmacological Study|Correlative studies
221691|NCT02495896|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
221692|NCT02495883|Other|Ethanol|50ml of 40% Ethanol
221693|NCT02495883|Drug|Propranolol|Beta blocker
221694|NCT02495870|Other|Pork|
221695|NCT02495857|Device|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
221696|NCT02495857|Device|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
221697|NCT02495857|Device|Placebo|0.9% sodium chloride, sterile
221698|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
221699|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
221700|NCT02495844|Drug|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
221701|NCT02495831|Drug|Diclofenac sodium|Diclofenac sodium 50 mg single dose
221702|NCT02495831|Drug|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
221703|NCT02495818|Procedure|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
221704|NCT02495818|Procedure|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
221705|NCT02495818|Other|Homemade exercises|Codman and Hughston exercises.
221897|NCT02494479|Drug|Placebo|Sugar pill designed to match Purisol tablet
221706|NCT02495805|Procedure|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
221707|NCT02495805|Procedure|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
221708|NCT02495792|Device|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
221709|NCT02495779|Drug|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
221710|NCT02495779|Behavioral|CBT-based counseling|Brief CBT-based counseling to promote adherence
221711|NCT02495766|Drug|XCEL-MC-ALPHA|Single infusion
221712|NCT02495766|Drug|Placebo|Single infusion
221713|NCT02495753|Procedure|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
221714|NCT02495753|Procedure|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
221715|NCT02495740|Behavioral|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
221716|NCT02495727|Behavioral|Step-reduction|Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
221717|NCT02495727|Behavioral|Pre-training|Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
221718|NCT02495727|Behavioral|Exercise snacking|Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
221719|NCT02495714|Behavioral|Active learning|Physical activity one hour a day as part of academic learning
221720|NCT02495714|Behavioral|Dietary councelling|Teaching children and parents about a healthy diet
221721|NCT02495701|Procedure|Hip arthroscopic surgery|Hip arthroscopic surgery
221722|NCT02495688|Procedure|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
221723|NCT02495688|Procedure|General anesthesia|Standard procedure.
221724|NCT02495675|Device|High flow nasal cannulas|Comparison of different flow levels
221725|NCT02495675|Device|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
221726|NCT02495662|Drug|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
221727|NCT02495662|Drug|Placebo|0.9% normal saline
221728|NCT02495649|Other|[18F]-DOPA|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
221729|NCT02495649|Device|PET-CT|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
221730|NCT02495636|Drug|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
221731|NCT02495636|Drug|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
221732|NCT02495623|Drug|SYN-010 21 mg|
221733|NCT02495623|Drug|SYN-010 42 mg|
221734|NCT02495623|Drug|Placebo|
221735|NCT02495610|Other|Gait analysis and MRI:|"Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.~MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
221736|NCT02495597|Other|no intervention - just observational|
221737|NCT02495584|Dietary Supplement|Fortified milk (10µg vitamin D3)|
221738|NCT02495584|Dietary Supplement|Unfortified milk (placebo)|
221739|NCT02495584|Dietary Supplement|10µg vitamin D3 supplement|
221740|NCT02495584|Dietary Supplement|Placebo supplement|
221741|NCT02495571|Other|Cough Assessment in ALS Patients|"Volitional Cough assessment by spirometer:~a) Peak Cough Espiratory Flow (PCEF)~Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)"
221742|NCT02495558|Other|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
221743|NCT02495545|Procedure|CSFD and elevation of MAP|Lumbar drain placement with CSFD with elevation of MAP
221744|NCT02495545|Procedure|Maintenance of MAP|Lumbar drain placement without CSFD and with maintenance of MAP
221745|NCT02495532|Other|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
221746|NCT02495532|Other|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution~(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
221747|NCT02495519|Drug|Imatinib|Imatinib 400 mg/day until disease progression
221748|NCT02495506|Other|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
221749|NCT02495506|Other|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery. Storage time for RCT platelet concentrates are up to 7 days.
221750|NCT02495493|Drug|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
221751|NCT02495480|Device|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
221752|NCT02495467|Drug|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
221753|NCT02495467|Drug|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
221754|NCT02495454|Drug|Ga101|
221755|NCT02495441|Other|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.~The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.~Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
221756|NCT02495428|Procedure|Kinesio Tape Method|
221757|NCT02495415|Drug|Fenretinide|Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
221758|NCT02495402|Behavioral|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
221759|NCT02495389|Drug|mirabegron|All study participants will be given mirabegron, 25 mg by mouth once a day for 12 weeks.
221760|NCT02495376|Behavioral|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
221761|NCT02495363|Procedure|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
221762|NCT02495363|Drug|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .~The concentration is determined by the upper dose limit to 2 mg / kg 11"
221763|NCT02495350|Other|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.~At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.~Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
221764|NCT02495337|Other|Tissue Collection|
221765|NCT02495324|Drug|Placebo|2 weeks of placebo PO daily
221766|NCT02495324|Drug|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
221767|NCT02495324|Drug|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
221768|NCT02495324|Drug|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
221769|NCT02495311|Procedure|myomectomy or adenomyomectomy|
221770|NCT02495298|Procedure|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
221771|NCT02495298|Procedure|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
221772|NCT02495285|Drug|Gelofusine 4%|
221773|NCT02495285|Drug|Gelaspan 4%|
221774|NCT02495272|Drug|Oxytocin|Oxytocin 10IU Administered intramuscularly.
221775|NCT02495259|Device|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
221776|NCT02495259|Device|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
221777|NCT02495259|Device|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
222009|NCT02493608|Device|scalpel|used to cut the abdominal wall.
221778|NCT02495259|Device|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
221779|NCT02495259|Device|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
221780|NCT02495246|Biological|ChAd3-EBO-Z|
221781|NCT02495246|Biological|Ad26.ZEBOV|
221782|NCT02495233|Drug|Gilteritinib|oral
221783|NCT02495233|Drug|Erlotinib|oral
221784|NCT02495220|Drug|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
221785|NCT02495220|Drug|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
221786|NCT02495207|Device|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
221787|NCT02495194|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
221788|NCT02495181|Drug|Intravitreal Aflibercept|
221789|NCT02495168|Drug|Generic Budesonide/Formoterol Fumarate Dihydrate|Oral inhalation, generic formulation of the brand-name product.
221790|NCT02495168|Drug|Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)|Oral inhalation, brand-name product.
221791|NCT02495168|Drug|Placebo|Oral inhalation, no active ingredient.
221792|NCT02495155|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
221793|NCT02495129|Drug|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
221794|NCT02495129|Drug|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
221795|NCT02495103|Drug|Vandetanib|PHASE I: Vandetanib PO daily at 300mg in combination with escalating doses of metformin.
221796|NCT02495103|Drug|Metformin|Phase I: Metformin starting dose 250mg PO daily in combination with Vandetanib
221797|NCT02495103|Drug|Vandetanib/Metformin|Phase II: Vandetanib and metformin PO daily at determined MTD.
221798|NCT02495090|Genetic|Exome sequencing|Plain DNA sequencing
221799|NCT02495077|Biological|Infliximab|A single dose, of 3mg/kg infusion
221800|NCT02495077|Drug|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
221801|NCT02495077|Drug|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
221802|NCT02495077|Drug|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
221803|NCT02495077|Biological|Thymoglobulin®|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
221804|NCT02495077|Drug|Acetaminophen|"30 to 60 minutes prior to the start of the infusion~Tylenol, 600 to 1000mg by mouth or~Suppository form"
221805|NCT02495077|Drug|Loratadine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
221806|NCT02495077|Biological|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
221807|NCT02495077|Drug|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
221808|NCT02495077|Drug|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion~Claritin (Loratadine) 10mg by mouth or~Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
221809|NCT02495064|Drug|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
221810|NCT02495051|Procedure|esophageal biopsies|
221811|NCT02495038|Drug|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
221812|NCT02495038|Drug|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
221813|NCT02495025|Behavioral|Telephone-based developmental screening and care coordination|
221814|NCT02495012|Drug|placebo|Freeze-dried powder without snake venom will be dissovled in saline
221815|NCT02495012|Drug|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
221816|NCT02494999|Biological|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
221817|NCT02494999|Biological|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
222010|NCT02493608|Device|Diathermy|Diathermy used to cut , coagulate the tissue
221818|NCT02494986|Drug|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or dispersible tablets for weight adjusted RPV dose, as applicable, in combination with an investigator selected background regimen consisting of 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs).
221819|NCT02494973|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
221820|NCT02494973|Drug|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
221821|NCT02494973|Drug|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
221822|NCT02494973|Drug|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
221823|NCT02494960|Behavioral|The brief smoking cessation AWARD model|"Ask whether or not the patient currently smokes~Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.~Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.~Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.~Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
221824|NCT02494960|Behavioral|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
221825|NCT02494947|Behavioral|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
221826|NCT02494947|Other|Usual care|
221827|NCT02494934|Behavioral|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
221828|NCT02494934|Behavioral|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
221829|NCT02494921|Drug|Docetaxel|
221830|NCT02494921|Drug|Ribociclib|
221831|NCT02494921|Drug|Prednisone|
221832|NCT02494921|Drug|Filgrastim|
221833|NCT02494908|Behavioral|Playing a computer game simulating a car race|Playing a computer game simulating a car race
221834|NCT02494895|Drug|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
221835|NCT02494895|Drug|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
221836|NCT02494882|Drug|Ruxolitinib|
221837|NCT02494882|Drug|Dasatinib|
221838|NCT02494882|Drug|Dexamethasone|
221839|NCT02494869|Behavioral|Nonlinear Aerobic Training|
221840|NCT02494869|Other|Height, Weight, BMI measure|
221841|NCT02494869|Other|Blood draw|
221842|NCT02494869|Other|Cardiopulmonary exercise test|
221843|NCT02494856|Drug|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
221844|NCT02494856|Drug|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
221845|NCT02494843|Other|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
221846|NCT02494843|Other|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
221847|NCT02494830|Drug|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
221848|NCT02494817|Behavioral|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
222480|NCT02489942|Drug|Jardiance|Empagliflozin
221849|NCT02494804|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
221850|NCT02494804|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
221851|NCT02494791|Behavioral|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
221852|NCT02494778|Drug|Pridopidine|45 mg BID
221853|NCT02494765|Device|I-gel TM|Airway management with I-gel
221854|NCT02494765|Device|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
221855|NCT02494752|Procedure|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
221856|NCT02494752|Procedure|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
221857|NCT02494739|Other|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
221858|NCT02494739|Other|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
221859|NCT02494726|Other|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
221860|NCT02494713|Drug|Degarelix|Subcutaneous injection, once/month for 4 months
221861|NCT02494713|Drug|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
221862|NCT02494713|Drug|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
221863|NCT02494713|Drug|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
221864|NCT02494713|Drug|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
221865|NCT02494700|Radiation|External Beam Radiation Therapy|Undergo orbital EBRT
221866|NCT02494700|Drug|Orbital Radiation|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy. If there is stable disease or progressive disease, an additional 20 Gy administered to involved site. If there are two consecutive evaluations with no change in disease burden then an additional 20 Gy administered. At one year if there is persistent disease, an additional 20 Gy administered to involved site.
221867|NCT02494687|Drug|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
221868|NCT02494687|Drug|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
221869|NCT02494687|Drug|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
221870|NCT02494674|Behavioral|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
221871|NCT02494661|Behavioral|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
221872|NCT02494661|Behavioral|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
221873|NCT02494648|Device|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
221874|NCT02494648|Other|Control|
221875|NCT02494635|Other|Laboratory Biomarker Analysis|Biomarker analysis
221876|NCT02494609|Drug|sotagliflozin|400 mg sotagliflozin
221877|NCT02494609|Drug|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
221878|NCT02494609|Drug|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
221879|NCT02494596|Drug|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
221880|NCT02494596|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
221881|NCT02494583|Biological|pembrolizumab|IV infusion
221882|NCT02494583|Drug|cisplatin|IV infusion
221883|NCT02494583|Drug|5-FU|IV infusion
221884|NCT02494583|Drug|capecitabine|oral tablet
221885|NCT02494570|Drug|ABI-009|
221886|NCT02494544|Device|Off the Shelf Total Knee Replacement|A knee replacement system by DePuy, Zimmer, Biomet, Smith & Nephew, or Stryker
221887|NCT02494544|Device|ConforMIS iTotal Knee Replacement|A knee replacement performed with patient specific implant and surgical jigs.
221888|NCT02494531|Radiation|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
221889|NCT02494531|Radiation|florbetapir F 18-PET|florbetapir F 18-PET performed within 2 months
221890|NCT02494518|Behavioral|Forced Exercise & Upper Extremity Repetitive Task Practice|
221891|NCT02494518|Behavioral|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
221892|NCT02494518|Behavioral|Stroke Education & Upper Extremity Repetitive Task Practice|
221893|NCT02494505|Drug|Mycophenolate Mofetil|2g/day per os
221894|NCT02494505|Drug|placebo|
221895|NCT02494492|Other|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
221896|NCT02494479|Drug|Prurisol|50mg tablet
221898|NCT02494466|Drug|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
221899|NCT02494453|Procedure|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
221900|NCT02494453|Procedure|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
221901|NCT02494427|Device|CAD/CAM manufactured fixed unitary dental prostheses|
221902|NCT02494427|Device|Conventionally manufactured unitary dental prostheses|
221903|NCT02494414|Other|Long-term follow-up|Vital and neurological follow-up
221904|NCT02494401|Other|Internet-based self-management program|
221905|NCT02494401|Other|Scleroderma book|
221906|NCT02494388|Procedure|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
221907|NCT02494375|Other|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
221908|NCT02494362|Other|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
221909|NCT02494349|Drug|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
221910|NCT02494349|Drug|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
221911|NCT02494336|Procedure|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
221912|NCT02494336|Procedure|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
221913|NCT02494336|Drug|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
221914|NCT02494323|Device|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
221915|NCT02494310|Device|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
221916|NCT02494284|Drug|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
221917|NCT02494284|Drug|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
221918|NCT02494258|Drug|CC-486|The subject will continue at the same dose, frequency and schedule used for the last dose of CC-486 given in the preceding CC-486 study. Subjects are allowed to rollover after the last cycle is finished and before the new cycle begins in the parent protocol. There is a 7 day window from End of Study on the parent protocol and when the participant will start Day 1 of the rollover study.
221919|NCT02494245|Other|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
221920|NCT02494219|Procedure|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
221921|NCT02494206|Drug|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
221922|NCT02494193|Other|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
221923|NCT02494193|Other|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
221924|NCT02494193|Other|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
221925|NCT02494193|Other|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
221926|NCT02494193|Other|Definitive restoration|Definite restoration will be performed using composite.
221927|NCT02494180|Drug|fentanyl|arm A receiving iv fentanyl
221928|NCT02494180|Drug|pethidine|arm B receiving iv pethidine
221929|NCT02494180|Drug|Diazepam|arm B receiving iv diazepam
221930|NCT02494180|Drug|Midazolam|arm A receiving iv midazolam
221931|NCT02494167|Biological|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 107 cells/m2; Dose Level Five: 1 x 108 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
221932|NCT02494154|Device|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
221933|NCT02494154|Device|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
221934|NCT02494141|Drug|Curcumin|Dietary Supplement
221935|NCT02494141|Other|Placebo|
221936|NCT02494128|Other|Education|Education in group leadership
221937|NCT02494115|Procedure|subcutaneous drainage|
221938|NCT02494102|Drug|Modafinil|Atypical Psychomotor stimulant
221939|NCT02494102|Drug|Placebo|
221940|NCT02494089|Other|distress analysis|
221941|NCT02494076|Drug|EzPAP|
221942|NCT02494076|Other|Standard Care|
221943|NCT02494063|Procedure|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
221944|NCT02494063|Procedure|At least unilateral systematic pelvic lymph node dissection|
221945|NCT02494050|Behavioral|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
221946|NCT02494050|Behavioral|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
221947|NCT02494050|Behavioral|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
221948|NCT02494024|Drug|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
221949|NCT02494024|Drug|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
221950|NCT02494011|Other|traditional exercise|mobilization stretching exercise
221951|NCT02494011|Other|Russian current stimulation|stimulation to wrist flexors for 15 minutes
221952|NCT02494011|Other|closed kinetic chain exercise|wall press exercise plyometric exercise
221953|NCT02493985|Other|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
221954|NCT02493985|Other|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
221955|NCT02493972|Procedure|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
221956|NCT02493972|Procedure|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
221957|NCT02493959|Biological|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
221958|NCT02493959|Biological|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
221959|NCT02493959|Biological|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
221960|NCT02493959|Biological|placebo|Infusion of saline for 2 hrs.
221961|NCT02493946|Biological|Botulinum toxin type A|
221962|NCT02493946|Drug|Placebo|
221963|NCT02493933|Drug|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
221964|NCT02493920|Other|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm).
221965|NCT02493920|Device|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
221966|NCT02493894|Drug|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
221967|NCT02493894|Drug|placebo|placebo each 8 hours for 24 hours
221968|NCT02493894|Drug|Cefazolin|cefazolin 1gram, every 6hours for 2 days
221969|NCT02493881|Device|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
222011|NCT02493582|Biological|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
221970|NCT02493868|Drug|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
221971|NCT02493868|Drug|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
221972|NCT02493868|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
221973|NCT02493868|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
221974|NCT02493868|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
221975|NCT02493868|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
221976|NCT02493855|Drug|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
221977|NCT02493855|Drug|Dasabuvir|Dasabuvir tablets
221978|NCT02493855|Drug|Ribavirin (RBV)|Ribavirin tablets
221979|NCT02493842|Device|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
221980|NCT02493829|Biological|AML Cell Vaccine|
221981|NCT02493816|Drug|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
221982|NCT02493803|Behavioral|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
221983|NCT02493790|Other|Cognitive and motor performances|
221984|NCT02493777|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
221985|NCT02493777|Drug|Placebo|
221986|NCT02493764|Drug|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
221987|NCT02493764|Drug|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
221988|NCT02493764|Drug|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
221989|NCT02493764|Drug|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
221990|NCT02493764|Drug|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
221991|NCT02493764|Drug|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
221992|NCT02493751|Drug|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
221993|NCT02493751|Drug|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
221994|NCT02493738|Drug|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
221995|NCT02493738|Drug|Sporanox 100mg|Sporanox 100mg single dose under fed condition
221996|NCT02493725|Drug|Eculizumab|
221997|NCT02493725|Drug|Placebo|
221998|NCT02493712|Drug|High dose|6 capsules of IBD98-M, twice a day
221999|NCT02493712|Drug|Low dose|4 capsules of IBD98-M
222000|NCT02493712|Drug|Placebo|Placebo
222001|NCT02493699|Other|physical exercise- based intervention (Karate techniques training)|
222002|NCT02493686|Other|n.a.|
222003|NCT02493673|Device|Continuous positive airway pressure device|(ResMed Spirit S8)
222004|NCT02493660|Device|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
222005|NCT02493660|Procedure|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
222006|NCT02493647|Behavioral|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
222007|NCT02493634|Procedure|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
222008|NCT02493634|Device|MRWire|
222012|NCT02493582|Drug|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
222013|NCT02493569|Procedure|The radical mastectomy of breast cancer|The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
222014|NCT02493556|Device|LLLT before muscle damage|
222015|NCT02493556|Device|Placebo LLLT before muscle damage|
222016|NCT02493556|Device|LLLT after muscle damage|
222017|NCT02493556|Device|Placebo LLLT after muscle damage|
222018|NCT02493543|Other|Blood collection|Blood collection from the subject's arm
222019|NCT02493530|Drug|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.~Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.~Expansion will commence after proper combination doses of both agents is established."
222020|NCT02493530|Drug|ruxolitinib|
222021|NCT02493517|Drug|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection (provided as a supersaturated solution of lanreotide acetate).
222022|NCT02493517|Drug|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection (provided as a sterile injectable lyophilisate of lanreotide acetate).
222023|NCT02493504|Drug|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
222024|NCT02493465|Drug|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
222025|NCT02493452|Drug|Plecanatide|
222026|NCT02493452|Drug|Placebo|
222027|NCT02493439|Behavioral|Best Possible Self|
222028|NCT02493439|Behavioral|Daily Activities|
222029|NCT02493426|Drug|Intranasal Oxytocin|
222030|NCT02493426|Drug|Placebo|
222031|NCT02493400|Other|No intervention in the follow up study.|
222032|NCT02493387|Other|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
222033|NCT02493387|Other|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
222034|NCT02493361|Drug|Pembrolizumab|
222035|NCT02493361|Drug|pIL-12|
222036|NCT02493348|Device|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) can be delivered through sound devices. In this study, the stimuli will be delivered with a portable consumer device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built-in mid to high-frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the gamma-frequency acoustic-driven rhythmic sensory stimulation, the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
222037|NCT02493335|Drug|Budesonide 0.5mg orodispersible tablet twice daily|
222038|NCT02493335|Drug|Budesonide 1mg orodispersible tablet twice daily|
222039|NCT02493335|Drug|Placebo orodispersible tablet twice daily|
222040|NCT02493322|Drug|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
222041|NCT02493322|Drug|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
222042|NCT02493322|Drug|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
222043|NCT02493309|Other|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
222044|NCT02493309|Other|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
222045|NCT02493296|Other|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
222046|NCT02493283|Drug|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
222047|NCT02493283|Drug|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
222048|NCT02493283|Biological|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
222049|NCT02493283|Biological|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
222093|NCT02492867|Drug|Paclitaxel|40 mg/m^2 IV concurrent with RT; 200 mg/m^2 during consolidation. Given IV
222094|NCT02492867|Device|FDG-PET|
222095|NCT02492867|Device|V/Q SPECT|
222050|NCT02493270|Behavioral|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
222051|NCT02493270|Procedure|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
222052|NCT02493257|Drug|Capsaicin|
222053|NCT02493257|Drug|Placebo|
222054|NCT02493244|Other|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
222055|NCT02493231|Drug|Nefopam|
222056|NCT02493231|Drug|Ketamine|
222057|NCT02493231|Drug|Saline|
222058|NCT02493218|Behavioral|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
222059|NCT02493218|Behavioral|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
222060|NCT02493192|Drug|pethidine and haloperidol injection|
222061|NCT02493192|Other|birth ball|
222062|NCT02493179|Drug|Serodase 5 mg|Serodase 5mg two tablets three times per day
222063|NCT02493179|Drug|Placebo|Placebo two tablets three times per day
222064|NCT02493166|Other|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
222065|NCT02493153|Procedure|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
222066|NCT02493140|Dietary Supplement|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
222067|NCT02493140|Dietary Supplement|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
222068|NCT02493127|Other|Standard PCS|Subject completes the standard version of the PCS Questionnaire
222069|NCT02493127|Other|Grip Strength|Research Assistant takes Grip Strength Measurements
222070|NCT02493127|Other|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
222071|NCT02493088|Other|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
222072|NCT02493075|Behavioral|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.~Usual ablation group:~Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
222073|NCT02493062|Device|Sonohysterogram|The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
222074|NCT02493049|Drug|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
222075|NCT02493036|Drug|SYN-010|
222076|NCT02493023|Device|navigated bronchoscopy|
222077|NCT02493010|Device|Arousal-based biofeedback system|
222078|NCT02492997|Device|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
222079|NCT02492997|Other|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
222080|NCT02492984|Drug|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
222081|NCT02492958|Biological|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
222082|NCT02492958|Biological|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
222083|NCT02492945|Drug|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
222084|NCT02492945|Drug|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
222085|NCT02492932|Device|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
222086|NCT02492919|Device|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
222087|NCT02492906|Other|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
222088|NCT02492906|Other|Healthy|Healthy and non-symptomatic volunteers.
222089|NCT02492893|Other|Hatha yoga|
222090|NCT02492880|Device|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
222091|NCT02492867|Radiation|Response-driven Adaptive Radiation Therapy|
222092|NCT02492867|Drug|Carboplatin|AUC 2 concurrent with RT; AUC 6 during consolidation. Given IV
222097|NCT02492854|Device|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
222098|NCT02492854|Other|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
222099|NCT02492841|Drug|Mineral trioxide aggregate|Mineral trioxide aggregate
222100|NCT02492841|Drug|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
222101|NCT02492841|Drug|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
222102|NCT02492802|Drug|posaconazole|collection plasma samples for measuring posaconazole drug concentration
222103|NCT02492789|Biological|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.~Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
222104|NCT02492776|Drug|Omeprazole|20 mg oral capsules administered once daily for 8 days
222105|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
222106|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
222107|NCT02492763|Drug|MK-8521|Dose strengths: 180 μg QD administered subcutaneously. A 2-step dose escalation regimen [60 μg, 120 μg] over the first 2 weeks is used to achieve the final dose up to 180 μg.); 300 μg QD administered subcutaneously (A 3-step dose escalation regimen [60 μg, 120 μg, 180 μg] over the first 3 weeks is used to achieve the final dose up to 300 μg.
222108|NCT02492763|Drug|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 μg QD administered subcutaneously; matching placebo for MK-8521 180 μg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 μg and 180 μg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.
222109|NCT02492763|Drug|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.
222110|NCT02492763|Drug|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
222111|NCT02492750|Biological|Anakinra|Given SC
222112|NCT02492750|Drug|Dexamethasone|Given PO
222113|NCT02492750|Other|Laboratory Biomarker Analysis|Correlative studies
222114|NCT02492750|Drug|Lenalidomide|Given PO
222115|NCT02492750|Other|Placebo|Given SC
222116|NCT02492737|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
222117|NCT02492711|Biological|Margetuximab|15 mg/kg via IV (intravenous) infusion over 120 minutes on day 1 of each 21 day cycle, until progression or unacceptable toxicity develops.
222118|NCT02492711|Biological|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion over 30-90 minutes on day 1 of each 21 day cycle, until progression or unacceptable toxicity develops.
222119|NCT02492711|Drug|Capecitabine|1000 mg/m2 BID for 14 days in a 21-day cycle
222120|NCT02492711|Drug|Eribulin|1.4 mg/m2 on days 1 and 8 of a 21-day cycle
222121|NCT02492711|Drug|Gemcitabine|1000 mg/m2 on days 1 and 8 of a 21-day cycle
222122|NCT02492711|Drug|Vinorelbine|25-30 mg/m2 on days 1 and 8 of a 21-day cycle
222123|NCT02492698|Dietary Supplement|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
222124|NCT02492698|Dietary Supplement|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
222125|NCT02492685|Device|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
222126|NCT02492659|Procedure|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
222127|NCT02492659|Procedure|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
222128|NCT02492646|Procedure|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
222129|NCT02492646|Procedure|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
222195|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
222196|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
222197|NCT02492152|Device|Study group|Dianatal
222130|NCT02492633|Behavioral|Control|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
222131|NCT02492633|Behavioral|Intervention|"At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:~A web-based smoking cessation intervention via Facebook~Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.~A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program."
222132|NCT02492620|Drug|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
222133|NCT02492607|Other|Standard treatment|"wide local excision only or wide local excision and radiotherapy or mastectomy.~+/- hormonal therapy"
222134|NCT02492607|Device|digital mammography|annual mammography
222135|NCT02492607|Radiation|radiotherapy|according local policy
222136|NCT02492594|Other|Peripheral blood sampling|"Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia:~at the start of neutropenic fever~after 24 hours~after 48 hours~before the start of antimycotic therapy, if pertinent~at the end of antimycotic therapy, if pertinent"
222137|NCT02492581|Drug|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
222138|NCT02492568|Drug|pembrolizumab|
222139|NCT02492568|Radiation|Stereotactic Body Radiation Therapy|
222140|NCT02492555|Other|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
222141|NCT02492555|Other|OD|A screening of FC and DA on demand (OD)
222142|NCT02492542|Device|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
222143|NCT02492529|Other|Neuropsychological tests|"Scales and tests to evaluate:~Global cognitive performance~Handedness~Memory functions performance~Gestural praxis functions performance~Lexical and semantic functions performance~Executive functions performance~Memory disorders~Way of life~Mood"
222144|NCT02492529|Device|A cranial MRI|
222145|NCT02492529|Other|Experimental procedure|
222146|NCT02492516|Biological|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
222147|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
222148|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
222149|NCT02492490|Other|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
222150|NCT02492490|Drug|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
222151|NCT02492477|Procedure|evaluation of PORT-A-CATH®|in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
222152|NCT02492477|Drug|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
222153|NCT02492477|Drug|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
222154|NCT02492464|Dietary Supplement|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
222155|NCT02492464|Dietary Supplement|Placebo|
222156|NCT02492451|Other|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
222157|NCT02492451|Drug|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
222158|NCT02492438|Biological|PPV23 vaccination or PCV13 vaccination|
222159|NCT02492412|Drug|HE 10|
222160|NCT02492412|Drug|Restasis|
222161|NCT02492399|Procedure|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
222198|NCT02492139|Device|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
222199|NCT02492139|Device|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
222730|NCT02488291|Drug|0.1% ropivacaine|0.1% ropivacaine
222162|NCT02492399|Procedure|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
222163|NCT02492386|Device|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
222164|NCT02492373|Drug|topical 0.05% Clobetasol propionate ointment|Apply only on the treated area twice a day as mentions
222165|NCT02492373|Device|Q switched Nd:YAG laser 532 nm|Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
222166|NCT02492360|Procedure|Blood sample collection|Six tubes of blood will be collected during one blood draw.
222167|NCT02492360|Behavioral|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
222168|NCT02492347|Procedure|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
222169|NCT02492334|Drug|Doxazosin|Doxazosin is a quinazoline compound that is a selective inhibitor of the alpha-1 subtype of alpha-adrenergic receptors. The chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate. The molecular formula for doxazosin is C23H25N5O5 • CH4O3S and the molecular weight is 547.6. Doxazosin is used clinically to treat hypertension and improve urination in men with benign prostatic hyperplasia.
222170|NCT02492334|Drug|Placebo|Placebo, or inactive pill.
222171|NCT02492321|Drug|EBI-005|
222172|NCT02492321|Drug|Placebo Comparator|
222173|NCT02492308|Procedure|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
222174|NCT02492308|Drug|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
222175|NCT02492295|Drug|Propofol|"Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge."
222176|NCT02492282|Device|Closed-Loop propofol and remifentanil system by Bispectral Index|
222177|NCT02492282|Device|Open-Loop propofol and remifentanil by Target Controlled Infusion|
222178|NCT02492282|Drug|propofol|
222179|NCT02492269|Drug|Dexmedetomidine|
222180|NCT02492269|Drug|Placebo|
222181|NCT02492256|Device|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
222182|NCT02492256|Device|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
222183|NCT02492256|Device|ILR implantation|Implantation the ECG loop recorder according to standard procedure
222184|NCT02492243|Device|PCI|
222185|NCT02492243|Device|ILR implantation|
222186|NCT02492230|Device|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
222187|NCT02492230|Drug|Warfarin|"Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.~All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0."
222188|NCT02492217|Drug|Adalimumab|
222189|NCT02492191|Device|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
222190|NCT02492178|Drug|Intrarectal artesunate|
222191|NCT02492178|Drug|Intravenous artesunate|
222192|NCT02492178|Drug|Intravenous quinine|
222193|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
222194|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
222200|NCT02492126|Other|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
222201|NCT02492113|Procedure|Positive end-expiratory pressure (PEEP)|"Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
222202|NCT02492113|Procedure|ZEEP|"After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged."
222203|NCT02492100|Behavioral|Multi-modality sexual dysfunction intervention|
222204|NCT02492087|Drug|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
222205|NCT02492087|Drug|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
222206|NCT02492074|Drug|Delta-9-tetrahydrocannabinol|oral administration of delta-9-tetrahydrocannabinol
222207|NCT02492074|Drug|Cannabidiol|oral administration of cannabidiol
222208|NCT02492074|Drug|Placebo|oral administration of placebo
222209|NCT02492061|Behavioral|Demand creation for couples' HCT|The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
222210|NCT02492048|Device|Cellutome Epidermal Harvesting System|Cellutome Epidermal Harvesting System
222211|NCT02492048|Procedure|Split Thickness Skin Graft|Split Thickness Skin Graft
222212|NCT02492035|Behavioral|Lifestyle intervention|
222213|NCT02492022|Dietary Supplement|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
222214|NCT02492022|Dietary Supplement|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
222215|NCT02492022|Other|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
222216|NCT02492009|Behavioral|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
222217|NCT02492009|Behavioral|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important.~At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
222218|NCT02491996|Behavioral|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
222219|NCT02491983|Drug|Palbociclib|
222220|NCT02491983|Drug|Fulvestrant|
222221|NCT02491983|Drug|Letrozole|
222222|NCT02491970|Drug|Fluticasone/Formoterol|
222223|NCT02491970|Drug|Fluticasone/Salmeterol|
222224|NCT02491957|Other|LOFT Therapy|"LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.~The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement."
222225|NCT02491944|Drug|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
222226|NCT02491944|Drug|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of [14C] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
222227|NCT02491931|Dietary Supplement|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
222228|NCT02491918|Procedure|cataract surgery|cataract surgery in children
222229|NCT02491918|Procedure|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
222230|NCT02491905|Drug|HL tablet|
222231|NCT02491905|Drug|Placebo|
222232|NCT02491892|Drug|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
222233|NCT02491879|Drug|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
222234|NCT02491879|Other|Placebo|Placebo gel with a 2 g local use
222235|NCT02491866|Other|to develop and validate a Computerized Adaptative Testing|"Elaboration of a pool of items, based on literature review and interview with patients.~Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.~Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.~Metrological validation of the CAT.~Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients."
222236|NCT02491853|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
222237|NCT02491840|Procedure|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
222336|NCT02491086|Behavioral|Smoking cessation counseling|Smoking cessation counseling
222923|NCT02487082|Other|Placebo|The duration depends on group assignment.
222238|NCT02491827|Other|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
222239|NCT02491814|Other|1% M.F. Milk|
222240|NCT02491814|Other|Yogurt Beverage|
222241|NCT02491814|Other|Soy Beverage|
222242|NCT02491814|Other|Almond Beverage|
222243|NCT02491814|Other|Water|
222244|NCT02491814|Other|Breakfast cereal|
222245|NCT02491801|Other|Dietary intervention|All arms are given to all participants, in a randomized order
222246|NCT02491788|Drug|Suvorexant|
222247|NCT02491788|Drug|Placebo|
222248|NCT02491762|Procedure|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
222249|NCT02491749|Procedure|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
222250|NCT02491736|Drug|Ketoprofen|2.5% ketoprofen gel
222251|NCT02491736|Other|Placebo|Placebo gel
222252|NCT02491723|Drug|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
222253|NCT02491710|Device|Training on low-cost box trainer|
222254|NCT02491710|Device|Training on standard box trainer|
222255|NCT02491697|Biological|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
222256|NCT02491697|Drug|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
222257|NCT02491684|Drug|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
222258|NCT02491684|Drug|Placebo|Placebo solution for once daily inhalation for 14 days
222259|NCT02491671|Device|Hemopatch|
222260|NCT02491671|Procedure|standard preventive measures|
222261|NCT02491658|Biological|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
222262|NCT02491645|Other|Sensory interventions|"Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.~Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.~Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.~Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.~Auditory stimulation : Sound familiarisation and music time will be done."
222263|NCT02491632|Drug|Dexamethasone|Given PO
222264|NCT02491632|Behavioral|Exercise Intervention|Complete a graded resistance exercise program and a walking regimen
222265|NCT02491632|Other|Laboratory Biomarker Analysis|Correlative studies
222266|NCT02491632|Other|Quality-of-Life Assessment|Ancillary studies
222267|NCT02491632|Other|Questionnaire Administration|Ancillary studies
222268|NCT02491619|Procedure|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
222269|NCT02491606|Drug|Tafenoquine|Tafenoquine 200mg and 400 mg
222270|NCT02491606|Other|Placebo|Placebo
222271|NCT02491593|Device|fecal occult blood test|
222272|NCT02491554|Device|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
222273|NCT02491554|Device|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
222274|NCT02491541|Biological|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.~1.0 ml experimental vaccine on day 0,3,7,14,28"
222275|NCT02491541|Biological|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.~1.0 ml comparator vaccine on day 0,3,7,14,28"
222276|NCT02491528|Biological|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
222277|NCT02491528|Biological|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
222278|NCT02491515|Drug|Denosumab|every 6 month injection
222279|NCT02491502|Device|Echopulse|HIFU Under ultrasound guidance
222280|NCT02491489|Other|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (~50 degrees abduction, slight horizontal adduction, external rotation).
222281|NCT02491476|Device|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
222282|NCT02491463|Biological|GSK3389245A_LD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
222283|NCT02491463|Biological|GSK3389245A_HD GROUP|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
222284|NCT02491463|Biological|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
222285|NCT02491463|Drug|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
222286|NCT02491450|Drug|Heterosofir|1 tablet contains 400 mg sofosbuvir
222287|NCT02491450|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
222288|NCT02491437|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
222289|NCT02491437|Drug|intravaginal progesterone gel 90 mg|
222377|NCT02490774|Drug|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
222290|NCT02491424|Device|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
222291|NCT02491411|Drug|Dexamethasone|Given PO
222292|NCT02491411|Drug|Enzalutamide|Given PO
222293|NCT02491411|Other|Laboratory Biomarker Analysis|Correlative studies
222294|NCT02491411|Other|Quality-of-Life Assessment|Ancillary studies
222295|NCT02491398|Drug|Bendamustine + Rituximab|
222296|NCT02491385|Procedure|thoracic epidural analgesia|In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
222297|NCT02491385|Drug|iv-PCA|iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
222298|NCT02491372|Behavioral|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
222299|NCT02491359|Drug|Carfilzomib|Given IV
222300|NCT02491359|Other|Laboratory Biomarker Analysis|Correlative studies
222301|NCT02491359|Other|Quality-of-Life Assessment|Ancillary studies
222302|NCT02491359|Other|Questionnaire Administration|Ancillary studies
222303|NCT02491346|Procedure|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
222304|NCT02491346|Procedure|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
222305|NCT02491333|Other|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
222306|NCT02491333|Other|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
222307|NCT02491333|Drug|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
222308|NCT02491333|Drug|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
222309|NCT02491320|Other|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
222310|NCT02491320|Drug|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
222311|NCT02491307|Other|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
222312|NCT02491294|Behavioral|School|students receive Cooking With Kids (CWK) - Colorado cooking & tasting lessons, SPARK active recess, and Cafeteria Connections
222313|NCT02491294|Behavioral|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
222314|NCT02491294|Behavioral|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
222315|NCT02491281|Drug|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
222316|NCT02491281|Drug|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
222317|NCT02491268|Drug|Cilostazol|
222318|NCT02491268|Drug|Placebo|
222319|NCT02491255|Device|Lotus Valve System|Device: Lotus Valve System
222320|NCT02491242|Other|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
222321|NCT02491229|Other|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
222322|NCT02491229|Other|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
222323|NCT02491216|Other|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
222324|NCT02491203|Other|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
222325|NCT02491190|Behavioral|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
222326|NCT02491177|Behavioral|cMM|Home visits from community mentor mothers
222327|NCT02491177|Behavioral|Text Messaging|Text messages received on mobile phone
222328|NCT02491164|Other|BAC TWO|BAC TWO administration
222329|NCT02491164|Device|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
222330|NCT02491138|Behavioral|Appearance-based intervention|
222331|NCT02491138|Other|Pamphlets|
222332|NCT02491125|Dietary Supplement|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
222333|NCT02491125|Dietary Supplement|Placebo|12 weeks daily intake of 15g of maltodextrin
222334|NCT02491099|Drug|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
222335|NCT02491086|Drug|Nicotine replacement therapy (NRT) sampling|1-week free NRT
222337|NCT02491073|Other|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
222338|NCT02491060|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
222339|NCT02491060|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
222340|NCT02491047|Device|BonyPid-1000|BonyPid-1000 implantation concomitantly to standard of care (SOC) treatment
222341|NCT02491047|Other|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
222342|NCT02491034|Behavioral|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
222343|NCT02491021|Other|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
222344|NCT02491008|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
222345|NCT02491008|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
222346|NCT02490995|Other|Movie|Besides the anesthesist explanations the children will have a movie explanation.
222347|NCT02490982|Drug|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
222348|NCT02490969|Procedure|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
222349|NCT02490956|Biological|Verorab® (PVRV; Purified Vero Cell Vaccine)|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular~Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
222350|NCT02490943|Other|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
222351|NCT02490943|Other|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
222352|NCT02490930|Drug|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
222353|NCT02490917|Device|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
222354|NCT02490917|Device|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
222355|NCT02490904|Drug|Eplerenone|Double-blinded Eplerenone administered for 4 days at 25mg every 12 hours
222356|NCT02490904|Drug|Placebo|Double-blinded Placebo administered for 4 days at 25mg every 12 hours
222357|NCT02490891|Device|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
222358|NCT02490878|Drug|bevacizumab|IV
222359|NCT02490878|Drug|corticosteroids|IV
222360|NCT02490878|Other|placebo|IV
222361|NCT02490865|Drug|RNS60|RNS60, 4 ml dose nebulized twice daily
222362|NCT02490865|Drug|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
222363|NCT02490852|Other|Investigational infant formula|fed ad libitum
222364|NCT02490852|Other|Active Comparator: Commercially available Infant formula|fed ad libitum
222365|NCT02490852|Other|Active Comparator: Human milk|fed ad libitum
222366|NCT02490839|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
222367|NCT02490839|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
222368|NCT02490826|Other|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~Auditory Bombardment;~Auditory and discrimination;~Letter-sound knowledge;~Phoneme identity and phoneme matching;~Blending;~Segmentation;~Rhyme;~Phoneme manipulation."
222369|NCT02490826|Other|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:~Auditory Bombardment;~Auditory and discrimination;~Letter-sound knowledge;~Phoneme identity and phoneme matching;~Blending;~Segmentation;~Rhyme;~Phoneme manipulation."
222370|NCT02490813|Dietary Supplement|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
222371|NCT02490813|Dietary Supplement|Placebo|Placebo will be starch with colorings
222372|NCT02490800|Drug|Oral daily administration of BAL101553|oral administration
222373|NCT02490787|Drug|Concizumab|Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
222374|NCT02490787|Drug|placebo|Administered subcutaneously (s.c., under the skin)
222375|NCT02490774|Drug|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
222376|NCT02490774|Drug|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
222378|NCT02490748|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
222379|NCT02490748|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
222380|NCT02490735|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
222381|NCT02490722|Other|Patient education|Four times two hours group based patient education
222382|NCT02490709|Procedure|Local excision|Local excision for rectal cancer with good response
222383|NCT02490696|Device|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
222384|NCT02490696|Device|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
222385|NCT02490683|Dietary Supplement|Luna Rich X|
222386|NCT02490683|Dietary Supplement|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
222387|NCT02490683|Dietary Supplement|Reliv Now|
222388|NCT02490670|Drug|Cephalexin|Administered orally
222389|NCT02490657|Drug|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.~Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
222390|NCT02490657|Drug|normal saline (Saline 0.9%)|
222391|NCT02490644|Procedure|Blood sampling|Blood sampling 5ml
222392|NCT02490631|Drug|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
222393|NCT02490618|Other|Probiotic tablet- Biogaia|
222394|NCT02490618|Other|Placebo tablet|
222395|NCT02490605|Procedure|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
222396|NCT02490605|Procedure|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
222397|NCT02490592|Other|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
222398|NCT02490592|Other|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
222399|NCT02490579|Behavioral|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
222400|NCT02490579|Behavioral|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
222401|NCT02490579|Behavioral|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
222402|NCT02490566|Other|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
222403|NCT02490553|Other|heteroevaluation scale by a nurse or doctor|
222404|NCT02490540|Drug|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
222405|NCT02490540|Drug|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
222406|NCT02490540|Drug|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
222407|NCT02490527|Dietary Supplement|Pure epicatechin capsules (50mg)|Epicatechin is a compound found naturally in dark chocolate.
222408|NCT02490527|Drug|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
222409|NCT02490527|Other|Placebo|A substance that has no therapeutic effect and will act as a control.
222410|NCT02490514|Other|No intervention|No intervention was administered in this study.
222411|NCT02490501|Procedure|SC0806 and rehabilitation|
222412|NCT02490501|Other|Rehabilitation only|
222413|NCT02490488|Drug|Masitinib|
222414|NCT02490488|Drug|Gemcitabine|
222415|NCT02490488|Drug|Placebo|
223589|NCT02482337|Procedure|POEM|POEM procedure in the OR
222416|NCT02490475|Drug|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
222417|NCT02490475|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
222418|NCT02490462|Other|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
222419|NCT02490462|Other|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
222420|NCT02490449|Drug|Dexlansoprazole MR|Administration of drug after or before diet
222421|NCT02490436|Drug|Cetuximab|Randomized cross-over between cetuximab and placebo
222422|NCT02490436|Drug|Placebo|Randomized cross-over between cetuximab and placebo
222423|NCT02490423|Other|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
222424|NCT02490410|Dietary Supplement|protein supplement|
222425|NCT02490397|Other|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
222426|NCT02490397|Other|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
222427|NCT02490384|Procedure|Physical exam indicated cerclage|Cervical cerclage
222428|NCT02490371|Device|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
222429|NCT02490371|Behavioral|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
222430|NCT02490345|Drug|gabapentin|gabapentin usage as adjunctive treatment for pain control
222431|NCT02490345|Drug|Placebo|Identical placebo
222432|NCT02490332|Device|Ventilation tube treatment|Tympanostomy
222433|NCT02490306|Device|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
222434|NCT02490293|Drug|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
222435|NCT02490293|Drug|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.~After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
222436|NCT02490280|Behavioral|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
222437|NCT02490267|Other|Quality of Life questionnaire|
222438|NCT02490254|Other|Surveillance card|
222439|NCT02490241|Drug|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
222440|NCT02490228|Procedure|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
222441|NCT02490202|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
222442|NCT02490202|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
222443|NCT02490189|Behavioral|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
222444|NCT02490189|Behavioral|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
222445|NCT02490176|Drug|liraglutide|Liraglutide were taken daily for 7 days
222446|NCT02490176|Drug|placebo|Placebo were taken daily for 7 days
222470|NCT02489994|Device|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
222471|NCT02489981|Drug|Spiriva|60 puffs
222472|NCT02489968|Drug|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
222473|NCT02489968|Drug|empagliflozin 10 mg|empagliflozin low dose once daily
222474|NCT02489968|Drug|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
222475|NCT02489968|Drug|empagliflozin 25 mg|empagliflozin high dose once daily
222447|NCT02490163|Device|Spectra Optia|"The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.~Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.~The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow."
222448|NCT02490150|Drug|Corifollitropin alfa|
222449|NCT02490137|Behavioral|Race Car Video Game|Repeatedly playing a race car video game
222450|NCT02490111|Drug|DWJ1319|
222451|NCT02490111|Drug|Placebo|
222452|NCT02490098|Other|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
222453|NCT02490098|Other|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
222454|NCT02490098|Other|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
222455|NCT02490098|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
222456|NCT02490098|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
222457|NCT02490098|Device|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
222458|NCT02490098|Device|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
222459|NCT02490085|Other|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
222460|NCT02490085|Other|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
222461|NCT02490085|Drug|Insulin|Subject's usual insulin analog will be used.
222462|NCT02490085|Device|Insulin pump Accu-Chek Combo|During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
222463|NCT02490085|Device|Dexcom G4 Platinum|In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
222464|NCT02490072|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
222465|NCT02490072|Drug|normal saline(Saline 0.9%)|
222466|NCT02490059|Other|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
222467|NCT02490046|Dietary Supplement|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
222468|NCT02490033|Device|Ablation Catheter|
222469|NCT02490020|Biological|mesenchymal stem cell|
222481|NCT02489929|Other|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
222482|NCT02489929|Drug|azacytidine|
222483|NCT02489916|Drug|CM4307|CM4307 300mg bid, each 4 week cycle
222484|NCT02489903|Drug|RRx-001|
222485|NCT02489903|Drug|Cisplatin|
222486|NCT02489903|Drug|Etoposide|
222487|NCT02489903|Drug|Carboplatin|
222488|NCT02489903|Drug|Irinotecan|
222489|NCT02489903|Drug|Vinorelbine|
222490|NCT02489903|Drug|Doxil|
222491|NCT02489903|Drug|Gemcitabine|
222492|NCT02489903|Drug|Taxane|
222493|NCT02489903|Drug|Paclitaxel|
222494|NCT02489903|Drug|Nab-Paclitaxel|
222495|NCT02489903|Drug|Pemetrexed|
222496|NCT02489890|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
222497|NCT02489864|Drug|Terlipressin|
222498|NCT02489851|Procedure|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
222499|NCT02489851|Procedure|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
222500|NCT02489825|Procedure|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
222501|NCT02489825|Procedure|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
222502|NCT02489812|Behavioral|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
222503|NCT02489799|Behavioral|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
222504|NCT02489799|Behavioral|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
222505|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except friday|
222506|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except thursday and friday|
222507|NCT02489786|Drug|patients take 0.125 mg of digoxin daily|
222508|NCT02489786|Drug|digoxin dose is calculated using Jusko-Koup method and given daily|
222509|NCT02489760|Biological|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
222510|NCT02489760|Biological|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
222511|NCT02489747|Dietary Supplement|WBE|wheat bran extract (3 g/day)
222512|NCT02489747|Dietary Supplement|Placebo|Placebo
222513|NCT02489734|Drug|sevoflurane|extubation when end-tidal concentration of sevoflurane < 0.5%
222514|NCT02489734|Drug|Sevoflurane|extubation when end-tidal concentration of sevoflurane >= 0.5%
222515|NCT02489721|Device|PICC and Midline|Peripherally inserted central venous catheter
222516|NCT02489708|Behavioral|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
222517|NCT02489695|Drug|axitinib|
222518|NCT02489682|Other|Long-form written Informed consent information|
222519|NCT02489682|Other|Short-form written Informed consent information|
222520|NCT02489682|Other|Video Informed consent information|
222521|NCT02489669|Device|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
222522|NCT02489656|Device|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
222523|NCT02489643|Procedure|Individualized practical training|
222524|NCT02489630|Drug|Ketamine|0.1mg/kg ketamine IV
222525|NCT02489630|Drug|Normal Saline|1ml/kg normal saline placebo
222526|NCT02489630|Drug|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
222527|NCT02489617|Other|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
222528|NCT02489604|Drug|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
222529|NCT02489604|Drug|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
222530|NCT02489591|Device|Oral appliance|Patients will bring their prescribed oral appliance.
222531|NCT02489591|Device|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
222532|NCT02489578|Other|other|retrospective cohort study
223590|NCT02482324|Drug|ALZT-OP1a|Mast cell stabilizer
222533|NCT02489565|Other|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
222534|NCT02489539|Device|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
222535|NCT02489526|Drug|VVZ-149 Injections|A novel analgesic drug candidate, VVZ-149 Injections shows dual antagonistic activity with moderate potency on glycine transporter type 2 (GlyT2, IC50=0.86 μM) and serotonin receptor 2A (5HT2A, IC50=1.3 μM), which are therapeutic targets for pain. GlyT2 inhibitors have been studied by many pharmaceutical companies as a well-known and promising analgesic candidate because of their role in inhibitory (glycine) modulation and regional specificity.
222536|NCT02489526|Drug|Placebo|Same formulation and appearance with VVZ-149 Injections
222537|NCT02489513|Drug|[14C]-AG-120|Labeled investigational drug
222538|NCT02489500|Drug|Bortezomib|"Conditioning Regimen:~Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
222539|NCT02489500|Drug|Melphalan|"Conditioning Regimen:~Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
222540|NCT02489500|Drug|Neupogen|granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days
222541|NCT02489500|Procedure|Stem Cell Collection|collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells
222542|NCT02489500|Procedure|Stem cell infusion|infusion of previously collected autologous stem cells
222543|NCT02489487|Drug|VM-1500|VM-1500 40 mg
222544|NCT02489487|Drug|Darunavir|Darunavir 600 mg
222545|NCT02489487|Drug|Ritonavir|Ritonavir 100 mg
222546|NCT02489487|Drug|Raltegravir|400 mg Raltegravir
222547|NCT02489461|Drug|VM-1500|VM-1500 up to 96 weeks
222548|NCT02489461|Drug|Efavirenz|Efavirenz up to 48 weeks
222549|NCT02489461|Drug|Antiretroviral therapy (ART)|Antiretroviral therapy up to 96 weeks
222550|NCT02489448|Drug|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
222551|NCT02489435|Drug|VM-1500|VM-1500
222552|NCT02489435|Drug|Placebo|Placebo
222553|NCT02489422|Other|Laboratory Biomarker Analysis|Correlative studies
222554|NCT02489422|Other|Questionnaire Administration|Ancillary studies
222555|NCT02489422|Other|Daily Survey Administration|Ancillary studies
222556|NCT02489422|Behavioral|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
222557|NCT02489422|Behavioral|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
222558|NCT02489422|Other|Actigraphy Assessment|Ancillary studies
222559|NCT02489409|Drug|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
222560|NCT02489409|Drug|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
222561|NCT02489409|Drug|Navelbine|40 mg/d, iv, d1, 8
222562|NCT02489409|Drug|Platinum|30 mg/m2, iv 3h, d1-3
222563|NCT02489409|Drug|Xeloda Tablets:|2 000 mg/m2, po, d1-14
222564|NCT02489396|Behavioral|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal & breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
222565|NCT02489396|Behavioral|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
222566|NCT02489396|Behavioral|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
222567|NCT02489396|Behavioral|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
223591|NCT02482324|Drug|ALZT-OP1b|anti-inflammatory
222568|NCT02489383|Other|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
222569|NCT02489383|Other|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
222570|NCT02489383|Behavioral|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
222571|NCT02489370|Device|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
222572|NCT02489357|Procedure|Cryosurgery|Undergo whole gland cryoablation
222573|NCT02489357|Drug|Degarelix|Given SC
222574|NCT02489357|Other|Laboratory Biomarker Analysis|Correlative studies
222575|NCT02489357|Biological|Pembrolizumab|Given IV
222576|NCT02489344|Drug|GZ/SAR402671|"Pharmaceutical form:capsule~Route of administration: oral"
222577|NCT02489318|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
222578|NCT02489318|Drug|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
222579|NCT02489318|Drug|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog [GnRHa] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
222580|NCT02489292|Biological|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
222581|NCT02489279|Behavioral|Sustained Attention Control (SAC) Method|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
222582|NCT02489279|Behavioral|Scrabble|Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
222583|NCT02489266|Biological|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
222584|NCT02489266|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
222585|NCT02489266|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
222586|NCT02489266|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
222587|NCT02489253|Other|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
222588|NCT02489240|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
222589|NCT02489240|Drug|placebo|2000 IU placebo tablets were taken daily for 6 days
222590|NCT02489227|Drug|CHS-1420|
222591|NCT02489227|Drug|Adalimumab|
222592|NCT02489214|Drug|donafenib tosilate tablets|200mg bid
222593|NCT02489201|Drug|donafenib tosilate tablets|200mg,bid
222594|NCT02489188|Procedure|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
222595|NCT02489188|Other|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
222596|NCT02489188|Procedure|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
222597|NCT02489175|Device|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
222598|NCT02489162|Device|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
222599|NCT02489162|Device|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
222600|NCT02489149|Other|Multi-sector interventions|"Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.~For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.~For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.~Helping families to have more knowledge about your citizen rights."
222601|NCT02489149|Other|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
222602|NCT02489136|Other|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
222603|NCT02489123|Drug|Enzalutamide|Given PO
222604|NCT02489123|Other|Laboratory Biomarker Analysis|Correlative studies
222605|NCT02489110|Behavioral|Webnovela|
222606|NCT02489110|Behavioral|Information|
222607|NCT02489097|Drug|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
222608|NCT02489097|Other|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
222609|NCT02489084|Other|Blood sampling|
222610|NCT02489071|Behavioral|Brain Training Program|
222611|NCT02489071|Behavioral|Brain Health Program|
222612|NCT02489045|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
222613|NCT02489032|Behavioral|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
222614|NCT02489032|Other|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
222615|NCT02489019|Drug|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
222616|NCT02489019|Drug|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
222617|NCT02489006|Drug|Olaparib|
222618|NCT02489006|Drug|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
222619|NCT02488993|Other|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
222620|NCT02488993|Other|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
222621|NCT02488993|Other|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
222622|NCT02488980|Drug|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
222623|NCT02488980|Drug|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
222624|NCT02488980|Drug|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
222625|NCT02488967|Drug|Carboplatin|Given IV
222626|NCT02488967|Drug|Cyclophosphamide|Given IV
222627|NCT02488967|Drug|Doxorubicin Hydrochloride|Given IV
222628|NCT02488967|Other|Laboratory Biomarker Analysis|Correlative studies
222629|NCT02488967|Drug|Paclitaxel|Given IV
222630|NCT02488954|Other|Probiotics in the form of cheese portion|
222631|NCT02488915|Device|EmboTrap® Revascularization Device|
222632|NCT02488902|Drug|Placebo|Placebo
222633|NCT02488902|Drug|Tafenoquine 25mg|Tafenoquine 25mg
222634|NCT02488902|Drug|Tafenoquine 50mg|Tafenoquine 50mg
222635|NCT02488902|Drug|Tafenoquine 100 mg|Tafenoquine 100 mg
222636|NCT02488902|Drug|Tafenoquine 200 mg|Tafenoquine 200 mg
222637|NCT02488902|Drug|Mefloquine 250 mg|Mefloquine 250 mg
222638|NCT02488889|Drug|Varenicline|
222639|NCT02488889|Drug|Placebo pill (for varenicline)|
222640|NCT02488889|Drug|Alcohol|
222641|NCT02488889|Drug|placebo beverage (for alcohol)|
222642|NCT02488863|Other|MRI Neuroimaging|MRI scans utilized to measure the structural and functional integrity of the brain.
222643|NCT02488863|Other|Quantitative Sensory Testing|Vibratory Detection Thresholds; Tactile Detection Thresholds; Thermal Detection Thresholds, Pain Thresholds, and Temporal Summation; Allodynia and Temporal Summation; Punctate Pain Testing and Temporal Summation; and Pressure Pain Thresholds.
222644|NCT02488863|Other|Questionnaires|The Modified Mini-Mental State Examination (3MS), the Montreal Cognitive Assessment (MoCA), the Center for Epidemiologic Studies Depression Scale (CES-D), the Geriatric Depression Scale (GDS), the Edinburg Handedness Inventory, the Ten-Item Personality Inventory (TIPI), the Pittsburgh Sleep Quality Index (PSQI), the state and trait versions of the State-Trait Anxiety Inventory (STAI), the state and trait versions of the Positive and Negative Affect Schedule (PANAS), pain questionnaires (the Graded Chronic Pain Scale (GCPS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Pain-Detect, the short-form McGill Pain Questionnaire (SF-MPQ-2), and the Coping Strategies Questionnaire-Revised (CSQ-R)), a standardized paper and pencil cognitive battery (Hopkins Verbal Learning Test (HVLT), Trail Making A&B, Boston Naming Test, Controlled Oral Word Association Test (COWAT), Stroop Interference Test, Ruff Figural Fluency Test, and Raven's Progressive Matrices Test).
222645|NCT02488863|Other|Physical and Cognitive Function Testing|Upper Limb Isometric Strength, Short Physical Performance Battery (SPPB), GAITRite Instrumented Walking, Galvanic Skin Response, Knee Extension Isokinetic Strength, the Pepper Assessment Tool for Disability (PAT-D), and an electronic NIH Toolbox Cognitive Battery.
222646|NCT02488850|Procedure|Surgery|
222647|NCT02488850|Radiation|SABR|
222648|NCT02488824|Procedure|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
222649|NCT02488798|Procedure|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
222650|NCT02488798|Procedure|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
222651|NCT02488798|Procedure|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
222652|NCT02488785|Behavioral|Virtual Diabetes Self-Care and Education Program|Participants will be able to have frequent contact in order to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
222731|NCT02488278|Device|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
222653|NCT02488785|Device|Fitbit|Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application.
222654|NCT02488785|Device|Smartphone|All virtual visits were performed via provided smartphone. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones
222655|NCT02488772|Device|Sleep mask|
222656|NCT02488772|Other|Standard of care|Standard of care as decided by treating emergency physician
222657|NCT02488772|Device|Ear Plugs|
222658|NCT02488759|Drug|Nivolumab|
222659|NCT02488759|Drug|Ipilimumab|
222660|NCT02488759|Drug|Relatlimab|
222661|NCT02488759|Drug|Daratumumab|
222662|NCT02488746|Device|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
222663|NCT02488733|Procedure|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
222664|NCT02488733|Drug|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)[50] and determined on an individual basis [52].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
222665|NCT02488707|Procedure|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
222666|NCT02488707|Procedure|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
222667|NCT02488694|Drug|Afatinib|40 mg/d
222668|NCT02488694|Drug|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
222669|NCT02488681|Device|Micra Pacemaker Implant|
222670|NCT02488668|Device|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
222671|NCT02488655|Device|Echopulse|HIFU Under ultrasound guidance
222672|NCT02488642|Drug|Isosorbide Dinitrate|
222673|NCT02488642|Drug|Misoprostol|
222674|NCT02488642|Drug|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
222675|NCT02488629|Drug|SCB01A|This study is a single arm, open-label, Phase II trial
222676|NCT02488616|Other|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.~Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
222677|NCT02488616|Other|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.~Participants will have been previously shown how to use the study insulin pump."
222678|NCT02488616|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
222679|NCT02488616|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
222680|NCT02488616|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
222681|NCT02488603|Behavioral|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
222682|NCT02488603|Drug|tamoxifen|
222683|NCT02488590|Drug|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
222684|NCT02488590|Drug|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
222685|NCT02488590|Drug|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
222686|NCT02488590|Drug|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
222687|NCT02488590|Drug|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
222688|NCT02488577|Procedure|Transanal minimally invasive total mesorectal excision|
222689|NCT02488577|Procedure|transanal minimally invasive locoregional resection|
222924|NCT02487069|Procedure|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
222690|NCT02488564|Drug|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
222691|NCT02488564|Drug|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
222692|NCT02488564|Drug|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
222693|NCT02488564|Drug|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
222694|NCT02488551|Device|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
222695|NCT02488551|Other|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
222696|NCT02488538|Drug|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
222697|NCT02488538|Drug|Fluoxetine|women will receive oral fluoxetine 20 mg daily
222698|NCT02488538|Drug|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
222699|NCT02488538|Drug|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
222700|NCT02488538|Procedure|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
222701|NCT02488525|Drug|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
222702|NCT02488512|Drug|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) [45-46], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
222703|NCT02488499|Behavioral|Coping Power|15 sessions of concurrent parent and child group treatment
222704|NCT02488499|Behavioral|Individualized Treatment|15 sessions of individualized child and parent treatment
222705|NCT02488486|Device|Automated postoperative sedation|
222706|NCT02488486|Drug|propofol|
222707|NCT02488486|Drug|remifentanil|
222708|NCT02488473|Drug|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
222709|NCT02488473|Drug|Ropivacaine|20 ml Ropivacaine 5mg/ml
222710|NCT02488473|Drug|Isotonic Saline|Placebo
222711|NCT02488460|Behavioral|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
222712|NCT02488434|Device|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
222713|NCT02488408|Drug|BGB324|
222714|NCT02488408|Drug|Cytarabine|Low dose cytarabine will be administered with BGB324 at a dose selected dose from Part A of the study
222715|NCT02488408|Drug|Decitabine|Decitabine will be administered with BGB324 at a dose selected dose from Part A of the study
222716|NCT02488395|Other|fMRI|The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
222717|NCT02488395|Other|Ophthalmologic evaluation|The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
222718|NCT02488395|Other|visual psychophysics test|This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
222719|NCT02488382|Drug|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
222720|NCT02488369|Device|PET / CT|
222721|NCT02488356|Dietary Supplement|Litramine|
222722|NCT02488343|Behavioral|Behavioral Intervention|Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
222723|NCT02488330|Drug|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
222724|NCT02488330|Drug|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
222725|NCT02488330|Drug|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
222726|NCT02488317|Other|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
222727|NCT02488304|Radiation|HRCT scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.~An upper airway (UA) scan will be taken on visit 2."
222728|NCT02488291|Drug|0.25 sufentanil|with different dosage
222729|NCT02488291|Drug|0.5µg/ml sufentanil|0.5µg/ml sufentanil
222732|NCT02488265|Other|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
222733|NCT02488265|Other|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
222734|NCT02488252|Drug|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction~B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction~C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis~D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb~E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
222735|NCT02488252|Drug|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
222736|NCT02488239|Device|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
222737|NCT02488226|Other|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
222738|NCT02488213|Other|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
222739|NCT02488213|Other|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
222740|NCT02488200|Other|No intervention|No intervention
222741|NCT02488187|Device|ABUS|Automated breast ultrasound
222742|NCT02488174|Other|PROOFcheck|
222743|NCT02488174|Other|Standard Care|
222744|NCT02488161|Other|No intervention|
222745|NCT02488148|Behavioral|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
222746|NCT02488148|Behavioral|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
222747|NCT02488135|Device|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
222748|NCT02488135|Procedure|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
222749|NCT02488122|Other|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
222750|NCT02488122|Other|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
222751|NCT02488109|Other|Higher Calorie Refeeding|
222752|NCT02488109|Other|Lower Calorie Refeeding|
222753|NCT02488096|Device|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
222754|NCT02488096|Device|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.~The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy ~ 1 week after the MRI."
222755|NCT02488083|Device|Ultrashape|circumference reduction
222756|NCT02488070|Procedure|Computed Tomography|Part of PET/CT scan
222757|NCT02488070|Drug|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
222758|NCT02488070|Procedure|Magnetic Resonance Imaging|Part of PET/MRI scan
222759|NCT02488070|Procedure|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
222760|NCT02488057|Drug|Liraglutide|Active comparator. See arm descriptions.
222761|NCT02488057|Behavioral|Weight loss|Active comparator. See arm descriptions.
222762|NCT02488044|Drug|AEB1102|modified human arginase I
222884|NCT02487290|Device|Aneufix ACP-T5|The ACP-T5 is injected via translumbar approach into the aneurysm sac near the entrance/exit of bloodvessel. ACP-T5 will cure and block the endoleak.
222885|NCT02487277|Drug|PEGPH20|
222763|NCT02488031|Behavioral|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.~The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
222764|NCT02488031|Behavioral|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
222765|NCT02488031|Behavioral|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
222766|NCT02488031|Behavioral|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
222767|NCT02488031|Behavioral|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
222768|NCT02488031|Behavioral|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
222769|NCT02488031|Behavioral|Brief Test of Attention|A cognitive test assessing focus and attention.
222770|NCT02488031|Behavioral|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
222771|NCT02488031|Behavioral|Hand Grip Dynamometer|This tests measures hand grip strength.
222772|NCT02488031|Behavioral|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
222773|NCT02488031|Behavioral|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
222774|NCT02488031|Behavioral|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
222775|NCT02488031|Behavioral|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
222776|NCT02488031|Behavioral|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
222777|NCT02488018|Biological|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.~25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
222778|NCT02488005|Device|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
222779|NCT02487992|Biological|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
222780|NCT02487979|Drug|Glembatumumab Vedotin|Given IV
222781|NCT02487979|Other|Laboratory Biomarker Analysis|Correlative studies
222782|NCT02487979|Other|Pharmacological Study|Correlative studies
222783|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
222784|NCT02487966|Behavioral|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
222785|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
222786|NCT02487966|Behavioral|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
222787|NCT02487953|Drug|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
222788|NCT02487953|Other|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
222789|NCT02487953|Other|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
222790|NCT02487953|Other|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
222886|NCT02487277|Drug|Gemcitabine|
222887|NCT02487277|Drug|Nab-paclitaxel|
222968|NCT02486809|Drug|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
222791|NCT02487940|Drug|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
222792|NCT02487940|Drug|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
222793|NCT02487927|Behavioral|weaning|T piece
222794|NCT02487914|Device|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
222795|NCT02487914|Drug|Lidocaine 10% was sprayed at the identified region|
222796|NCT02487914|Device|interferential current|
222797|NCT02487901|Device|ultrasonic osteotome|making gutter with ultrasonic osteotome
222798|NCT02487901|Device|drill|making gutter with drill
222799|NCT02487888|Other|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
222800|NCT02487888|Other|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
222801|NCT02487875|Other|rehabilitation|
222802|NCT02487862|Behavioral|Stress Reduction Protocol|Stress Reduction Protocol
222803|NCT02487849|Procedure|HIPEC|secondary cytoreductive operation
222804|NCT02487849|Drug|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
222805|NCT02487836|Device|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
222806|NCT02487823|Drug|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
222807|NCT02487810|Behavioral|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
222808|NCT02487810|Behavioral|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
222809|NCT02487797|Drug|Oxytocin|
222810|NCT02487797|Other|Sodium Chloride 0.9%|
222811|NCT02487784|Procedure|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
222812|NCT02487784|Procedure|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
222813|NCT02487771|Drug|DHA|600 mg DHA capsule
222814|NCT02487771|Drug|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
222815|NCT02487758|Procedure|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
222816|NCT02487745|Behavioral|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
222817|NCT02487745|Behavioral|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
222818|NCT02487732|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
222819|NCT02487732|Drug|Prasugrel|Prasugrel 10mg once daily for 5 weeks
222820|NCT02487719|Drug|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
222821|NCT02487706|Drug|Dolutegravir|Dolutegravir 50mg/day per 5 days
222822|NCT02487693|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
222823|NCT02487693|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
222824|NCT02487680|Dietary Supplement|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
222825|NCT02487680|Dietary Supplement|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
222826|NCT02487667|Device|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
222827|NCT02487654|Procedure|Pulmonary vein isolation|Catheter ablation within the left atrium that electrically disconnects these veins from the rest of the left atrium (pulmonary vein isolation)- Current standard of treatment.
222828|NCT02487654|Procedure|Ganglionic plexi ablation|Catheter ablation around the nerve supplying the heart and destroying the collection of these nerve endings(ganglionic plexi ablation).
222829|NCT02487628|Device|HQ® Matrix Soft Tissue Mesh|
222830|NCT02487628|Device|ULTRAPRO® Partially Absorbable Lightweight Mesh|
222831|NCT02487602|Device|Gelesis100|Gelesis100 capsules
222832|NCT02487602|Other|Placebo|Sucrose (sugar) capsules
222880|NCT02487329|Other|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
222881|NCT02487316|Drug|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
222882|NCT02487303|Drug|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
222833|NCT02487589|Other|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:~Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .~Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.~Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
222834|NCT02487576|Other|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
222835|NCT02487576|Other|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
222836|NCT02487563|Drug|Decitabine|Decitabine
222837|NCT02487563|Drug|rhTPO|rhTPO
222838|NCT02487563|Other|Conventional Treatment|immunoglobulin, glucocorticoid etc
222839|NCT02487550|Biological|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
222840|NCT02487550|Biological|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
222841|NCT02487537|Dietary Supplement|custom-made soft drink|
222842|NCT02487524|Other|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
222843|NCT02487524|Other|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
222844|NCT02487524|Other|QST|Quantitative sensory testing.
222845|NCT02487511|Other|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
222846|NCT02487498|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
222847|NCT02487498|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
222848|NCT02487498|Drug|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
222849|NCT02487498|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
222850|NCT02487485|Drug|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions—once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
222851|NCT02487485|Drug|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
222852|NCT02487485|Drug|Placebo|Placebo oral dose
222853|NCT02487472|Other|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
222854|NCT02487459|Biological|BPX-501|T cells transduced with CaspaCIDe suicide gene
222855|NCT02487459|Drug|AP1903|dimerizer drug administered to treat GVHD
222856|NCT02487446|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 single dose dry powder inhaler (SDDPI)
222857|NCT02487446|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
222858|NCT02487446|Drug|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
222859|NCT02487446|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
222860|NCT02487433|Drug|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
222861|NCT02487433|Drug|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
222862|NCT02487420|Behavioral|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
222863|NCT02487407|Drug|ODM-109|ODM-109 1 mg capsule for oral administration.
222864|NCT02487407|Drug|Placebo for ODM-109|Placebo capsule for oral administration.
222865|NCT02487394|Other|Asthma, Smokers and Non-Smokers|Comparing protein expressions between the two groups.
222866|NCT02487394|Other|COPD, Smokers and Non-Smokers|We will validate the prdictive value of the proteomic signatures for therapeutic responses.
222867|NCT02487381|Drug|delta-9-tetrahydrocannabinol|
222868|NCT02487381|Drug|Cannabidiol|
222869|NCT02487381|Drug|Placebo|
222870|NCT02487368|Device|Needle stimulation pad|
222871|NCT02487355|Drug|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
222872|NCT02487355|Drug|Magnesium Sulphate|Magnesium Sulphate 50 mg
222873|NCT02487355|Drug|Bupivacaine|1ml/kg of 0.25%of bupivacaine
222874|NCT02487355|Drug|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
222875|NCT02487342|Other|milk|small serving (217 mL) of british semi-skimmed milk
222876|NCT02487342|Other|orange fruit-juice|small serving (217 mL) of orange juice
222877|NCT02487329|Other|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
222878|NCT02487329|Other|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
222879|NCT02487329|Other|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
222883|NCT02487303|Drug|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
222922|NCT02487082|Drug|Melatonin and Donepezil|The duration depends on group assignment.
222888|NCT02487251|Behavioral|Meal Delivery|Participants receive a healthy, prepared family meal for consumption at home. Meals are received one per week for 8 weeks. Recipes for the meals are provided.
222889|NCT02487251|Behavioral|Ingredient Delivery|Participants receive ingredients to prepare a healthy, family meal for consumption at home. Meal ingredients are received one per week for 8 weeks. Recipes for the meals are provided.
222890|NCT02487251|Behavioral|Community Kitchen|Participants come to a Head Start site to prepare a family entree to take home, cook, and consume. Participants prepare their meals in small groups with an MSU Extension paraprofessional as a facilitator. The Community Kitchen is held once per week for 8 weeks.
222891|NCT02487251|Behavioral|Healthy Eating Classes|Participants attend a small-group class on healthy eating, nutrition and meal planning ideas. Recipes are provided. Classes are held once per week for 8 weeks.
222892|NCT02487251|Behavioral|Cooking Demonstrations|Participants meet in small groups and observe as an MSU paraprofessional demonstrates the preparation of a healthy family entree. Participants taste the recipe but do not take food home with them. Recipes are provided. Demonstrations are held once per week for 8 weeks.
222893|NCT02487251|Behavioral|Provision of Cookware|Participants receive a set of basic cookware and dishes to use in preparing healthy family meals at home. Recipes are provided. The cookware set is provided at the beginning of the typical 8 week intervention cycle.
222894|NCT02487251|Behavioral|Usual Head Start Exposure|Participants receive no supplemental information on family mealtimes beyond what is already addressed in Head Start programming.
222895|NCT02487238|Biological|Fecal Microbiota Enema|Active intervention.
222896|NCT02487238|Biological|Normal Saline Enema|Placebo comparator.
222897|NCT02487225|Drug|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cyclic adenosine monophosphate (cAMP), activates protein kinase A (PKA), inhibits Tumor Necrosis Factor (TNF) and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
222898|NCT02487225|Drug|Placebo|A harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
222899|NCT02487212|Drug|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
222900|NCT02487212|Drug|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
222901|NCT02487212|Device|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
222902|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
222903|NCT02487199|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
222904|NCT02487186|Drug|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
222905|NCT02487186|Procedure|Full-mouth debridment|"The patients will be treated by a single-session of periodontal debridement~during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de~Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed."
222906|NCT02487173|Device|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
222907|NCT02487173|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
222908|NCT02487173|Device|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
222909|NCT02487160|Device|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
222910|NCT02487160|Device|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
222911|NCT02487147|Other|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
222912|NCT02487147|Other|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
222913|NCT02487134|Device|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
222914|NCT02487134|Device|Control|Closure of the abdomen with conventional technique
222915|NCT02487121|Behavioral|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
222916|NCT02487121|Behavioral|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
222917|NCT02487108|Drug|Hydrocodone bitartrate|5.0 mg, 7.5 mg, 10 mg
222918|NCT02487108|Drug|Acetaminophen|325 mg
222919|NCT02487108|Drug|Placebo|Matching Placebo
222920|NCT02487095|Drug|Topotecan|Topotecan (incombination with M6620) administered by IV Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
222921|NCT02487095|Drug|VX-970 (M6620)|M6620 (in combination with Topotecan) administered by IV Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
222925|NCT02487069|Procedure|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
222926|NCT02487069|Procedure|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
222927|NCT02487069|Drug|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
222928|NCT02487069|Drug|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
222929|NCT02487069|Drug|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
222930|NCT02487069|Drug|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
222931|NCT02487043|Behavioral|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
222932|NCT02487030|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
222933|NCT02487030|Drug|RBV|Tablets administered orally in a divided daily dose based on weight (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
222934|NCT02487017|Procedure|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
222935|NCT02487017|Biological|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
222936|NCT02487004|Device|hemodialysis|
222937|NCT02486991|Procedure|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
222938|NCT02486991|Procedure|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
222939|NCT02486978|Other|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
222940|NCT02486978|Dietary Supplement|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
222941|NCT02486978|Dietary Supplement|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
222942|NCT02486965|Device|thermode (TSA-II model)|thermal stimulation with test thermode
222943|NCT02486965|Other|Adapted Physical Activity|
222944|NCT02486965|Other|Physical activity|
222945|NCT02486952|Drug|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
222946|NCT02486952|Drug|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
222947|NCT02486952|Drug|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
222948|NCT02486952|Drug|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
222949|NCT02486952|Drug|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
222950|NCT02486939|Drug|CHS-0214|Open label
222951|NCT02486926|Other|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
222952|NCT02486926|Drug|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
222953|NCT02486926|Drug|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
222954|NCT02486926|Drug|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
222955|NCT02486926|Drug|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
222956|NCT02486913|Other|Enhanced Health Check|National Health Service Health Check enhanced by risk report
222957|NCT02486900|Device|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
222958|NCT02486887|Device|telemonitoring of weight, pulse and blood pressure|
222959|NCT02486874|Device|PoreSkin|a human acellular dermal matrix
222960|NCT02486861|Other|optical coherence tomography|
222961|NCT02486848|Drug|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
222962|NCT02486848|Drug|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
222963|NCT02486835|Device|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
222964|NCT02486835|Device|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
222965|NCT02486822|Procedure|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
222966|NCT02486822|Drug|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
222967|NCT02486822|Procedure|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
223054|NCT02486211|Drug|Placebo|Placebo comparator
222969|NCT02486796|Biological|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
222970|NCT02486796|Drug|Coenzyme Q10|Preparation of coenzyme Q10
222971|NCT02486796|Drug|Melatonin|Preparation of melatonin
222972|NCT02486770|Biological|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
222973|NCT02486770|Biological|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
222974|NCT02486770|Biological|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
222975|NCT02486757|Drug|micronized progesterone|
222976|NCT02486757|Drug|transdermal estradiol|
222977|NCT02486744|Drug|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
222978|NCT02486718|Drug|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
222979|NCT02486718|Drug|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of up to four 21-day cycles.
222980|NCT02486718|Drug|Vinorelbine|Participants will receive vinorelbine 30 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
222981|NCT02486718|Drug|Docetaxel|Participants will receive docetaxel 75 mg/m^2 IV on Day 1 of each of the four 21-day cycles.
222982|NCT02486718|Drug|Gemcitabine|Participants will receive gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
222983|NCT02486718|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
222984|NCT02486705|Behavioral|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
222985|NCT02486705|Behavioral|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
222986|NCT02486692|Other|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and different treatments for PTSD.
222987|NCT02486679|Drug|Prostin (PGE2) tablets|
222988|NCT02486679|Device|Foley catheter|
222989|NCT02486666|Drug|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES WITH THROMBOSIS (FiXET)
222990|NCT02486653|Drug|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: tamsulosin 0.4mg in the evening~Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
222991|NCT02486653|Drug|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.~Outline of schedule:~Day 1-7: placebo in the evening~Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol~Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
222992|NCT02486640|Drug|Interferon beta-1b (Betaferon, BAY86-5046)|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.
222993|NCT02486640|Device|Betaconnect Autoinjector|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.
222994|NCT02486627|Drug|plazomicin|
222995|NCT02486627|Drug|meropenem|
222996|NCT02486627|Drug|levofloxacin (oral)|
222997|NCT02486614|Procedure|CRRT|citrate based continuous renal replacement therapy
222998|NCT02486601|Drug|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
222999|NCT02486601|Drug|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
223000|NCT02486588|Other|Messaging|See detailed study description for overview of the different messaging interventions in this study
223001|NCT02486588|Other|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
223002|NCT02486575|Other|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
223003|NCT02486575|Other|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
223004|NCT02486549|Procedure|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
223005|NCT02486549|Procedure|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
223006|NCT02486549|Drug|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
223007|NCT02486549|Device|Ultrasound|The Ultrasound will be used for brachial plexus visualization
223008|NCT02486536|Drug|polyethylene glycol|
223009|NCT02486536|Device|capsule endoscopy|
223055|NCT02486198|Drug|placebo|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
223107|NCT02485808|Other|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
223010|NCT02486523|Behavioral|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
223011|NCT02486523|Device|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
223012|NCT02486523|Behavioral|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
223013|NCT02486523|Behavioral|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
223014|NCT02486523|Procedure|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
223015|NCT02486510|Drug|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
223016|NCT02486497|Biological|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
223017|NCT02486484|Drug|ziv-aflibercept|zaltrap injection
223018|NCT02486471|Procedure|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
223019|NCT02486471|Other|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
223020|NCT02486458|Drug|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
223021|NCT02486458|Drug|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
223022|NCT02486445|Drug|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
223023|NCT02486432|Drug|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
223024|NCT02486419|Other|Outdoor weather|Seasonal changes in temperature
223025|NCT02486406|Drug|paritaprevir|
223026|NCT02486406|Drug|ombitasvir|
223027|NCT02486406|Drug|dasabuvir|
223028|NCT02486406|Drug|ribavirin|
223029|NCT02486406|Drug|ritonavir|
223030|NCT02486393|Procedure|Parotid surgery|Surgery of the parotid gland tumours
223031|NCT02486380|Device|Simplus/Eson|Released product Simplus and Eson masks
223032|NCT02486367|Drug|Clopidogrel|Standard ADP receptor blockade
223033|NCT02486367|Drug|Ticagrelor|High potency ADP receptor blockade
223034|NCT02486354|Drug|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
223035|NCT02486341|Drug|Insulin|Continuous glucose monitoring system over 120-hour period.
223036|NCT02486328|Drug|Midazolam|Dosage adjustment
223037|NCT02486328|Drug|Meperidine|Dosage adjustment
223038|NCT02486328|Drug|Remifentanil|Dosage adjustment
223039|NCT02486328|Drug|Propofol|Dosage adjustment
223040|NCT02486315|Device|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
223041|NCT02486302|Drug|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
223042|NCT02486289|Drug|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
223043|NCT02486289|Drug|Placebo|NBMI Placebo
223044|NCT02486276|Drug|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223045|NCT02486276|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223046|NCT02486276|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223047|NCT02486263|Other|Study|"Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)~Total fluid volume restriction (120-140 milliliters/kilogram/day)~Feeding duration over 30 minutes~Infant feeds with right side down~Infant is placed on back following feeds"
223048|NCT02486250|Other|Validation Study|
223049|NCT02486237|Other|None, observational study|None, it is an observational study
223050|NCT02486224|Dietary Supplement|Kona Deep|Subjects will receive Kona Deep post exercise
223051|NCT02486224|Dietary Supplement|Spring Water|Subjects will receive Spring Water post exercise
223052|NCT02486224|Dietary Supplement|Sports Drink|Subjects will receive Sports Drink post exercise
223053|NCT02486211|Drug|Amantadine|100mg BID for 7 days at 0600 and 1200
223056|NCT02486198|Drug|GM|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.~For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
223057|NCT02486198|Drug|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
223058|NCT02486185|Other|SCREENING TEST|"Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).~Muscle force will be measured using a hydraulic dynamometer~Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)"
223059|NCT02486172|Behavioral|Peer support program|Peer support program as an additional service to the routine clinical service
223060|NCT02486159|Drug|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
223061|NCT02486159|Procedure|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
223062|NCT02486133|Drug|Prezista|once daily
223063|NCT02486133|Drug|Norvir|once daily
223064|NCT02486133|Drug|Tivicay|once daily
223065|NCT02486133|Drug|Truvada|once daily
223066|NCT02486133|Drug|Kivexa|once daily
223067|NCT02486107|Procedure|surgical procedure|
223068|NCT02486081|Device|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
223069|NCT02486068|Device|ABSORB scaffold|
223070|NCT02486068|Device|Xience|
223071|NCT02486055|Drug|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
223072|NCT02486042|Drug|Omegaven|
223073|NCT02486016|Drug|Duragesic reference fentanyl TDS|25 µg/hour
223074|NCT02486016|Drug|Apotex generic fentanyl TDS|25 µg/hour
223075|NCT02486016|Drug|Mylan generic fentanyl TDS|25 µg/hour
223076|NCT02485990|Drug|Tremelimumab|
223077|NCT02485990|Drug|Olaparib|
223078|NCT02485977|Device|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
223079|NCT02485964|Other|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
223080|NCT02485951|Procedure|Central air injection|Air was injected inside the trephination site in the central injection group.
223081|NCT02485951|Procedure|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
223082|NCT02485938|Drug|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
223083|NCT02485925|Device|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
223084|NCT02485912|Biological|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
223085|NCT02485912|Biological|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
223086|NCT02485899|Biological|BMN 190|300 mg ICV infusion administered every other week for up to 240 weeks
223087|NCT02485899|Device|Intraventricular Access Device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
223088|NCT02485886|Drug|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
223089|NCT02485873|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
223090|NCT02485873|Drug|Vitamin K antagonists|As prescribed by treating physicians
223091|NCT02485860|Device|Melectis G|
223092|NCT02485847|Procedure|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
223093|NCT02485834|Procedure|FDG-PET|
223094|NCT02485834|Procedure|surgery|
223095|NCT02485834|Drug|5-FU|200 mg/m^2/day IV
223096|NCT02485834|Drug|capecitabine|oral 800 mg/m^2 BID
223097|NCT02485834|Drug|docetaxel|30 mg/m^2 IV
223098|NCT02485834|Drug|Irinotecan|50 mg/m^2 IV
223099|NCT02485834|Radiation|3D-CRT|
223100|NCT02485834|Radiation|IMRT|
223101|NCT02485821|Drug|Estradiol|
223102|NCT02485821|Drug|Placebo|
223103|NCT02485821|Drug|Misoprostol|
223104|NCT02485808|Other|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
223105|NCT02485808|Procedure|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
223106|NCT02485808|Other|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
226603|NCT02461173|Device|shepherd catheter|
223108|NCT02485795|Other|Observational|This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
223109|NCT02485782|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
223110|NCT02485782|Device|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
223111|NCT02485782|Device|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
223112|NCT02485769|Drug|PF-06650833|Suspension
223113|NCT02485769|Drug|Placebo|Suspension
223114|NCT02485769|Drug|PF-06650833|Tablet (Modified Release)
223115|NCT02485769|Drug|Placebo|Tablet (Modified Release)
223116|NCT02485756|Other|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
223117|NCT02485743|Other|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
223118|NCT02485743|Other|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
223119|NCT02485717|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
223120|NCT02485717|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
223121|NCT02485704|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
223122|NCT02485704|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
223123|NCT02485691|Drug|cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: intravenous
223124|NCT02485691|Drug|enzalutamide|Pharmaceutical form:capsule Route of administration: oral
223125|NCT02485691|Drug|abiraterone acetate|Pharmaceutical form:tablet Route of administration: oral
223126|NCT02485691|Drug|prednisone|Pharmaceutical form:tablet Route of administration: oral
223127|NCT02485678|Other|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
223128|NCT02485678|Other|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
223129|NCT02485678|Other|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
223130|NCT02485665|Device|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
223131|NCT02485652|Drug|HM61713|800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigator‟s opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
223132|NCT02485639|Biological|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants will receive vaccine IM on day 1.
223133|NCT02485626|Procedure|2D tissue doppler echocardiography|
223134|NCT02485613|Drug|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
223135|NCT02485587|Behavioral|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
223136|NCT02485587|Behavioral|Treatment as usual|counseling, psychoeducation
223137|NCT02485574|Procedure|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in left side of disc space and anterior bridging cages augmented with auto bone in rt side of disc space in transforaminal lumbar interbody arthrodesis.
223138|NCT02485561|Behavioral|Health communication intervention|This study will compare the effects of adding narratives that describe personal experiences with colon cancer screening to educational information alone to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
223139|NCT02485561|Behavioral|Education information|Educational materials such as those from the Centers for Disease Control and Prevention are used to present educational information to participants about colon cancer and screening tests.
223140|NCT02485548|Drug|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
223141|NCT02485548|Drug|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
223142|NCT02485548|Drug|Cisplatin|All patients will receive concurrent cisplatin.
223143|NCT02485548|Radiation|IMRT|All patients will receive IMRT
223144|NCT02485535|Other|Laboratory Biomarker Analysis|Correlative studies
223145|NCT02485535|Drug|Selinexor|Given PO
223146|NCT02485522|Other|No Intervention|No intervention
223147|NCT02485509|Drug|VM-1500/Placebo|VM-1500 or Placebo
223148|NCT02485496|Device|Endovascular abdominal repair|
223149|NCT02485470|Other|MPACT|Maintaining Physical Activity during Cancer Treatment
223150|NCT02485457|Procedure|Volume loading|Volume loading with Ringer Lactate
223151|NCT02485457|Drug|Ringer solution|
223152|NCT02485444|Drug|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
223153|NCT02485431|Drug|Deflazacort|
223154|NCT02485418|Drug|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 10 minutes, followed by an increase to 30 mcg/kg/min for 10 minutes and then by an increase to 40 mcg/kg/min for 40 minutes.
223155|NCT02485405|Other|Trier social stress test|Volunteers perform Trier social stress test
223156|NCT02485392|Device|Da Vinci Single Site Robot-Assisted Cholecystectomy|
223157|NCT02485392|Device|Single Incision Laparoscopic Cholecystectomy|
223158|NCT02485379|Procedure|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
223159|NCT02485366|Drug|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
223160|NCT02485366|Procedure|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
223161|NCT02485353|Drug|Vosaroxin and Cytarabine|
223162|NCT02485340|Drug|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223163|NCT02485340|Drug|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223164|NCT02485340|Drug|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
223165|NCT02485327|Drug|Technosphere Insulin SAR439065 Afrezza®|"Pharmaceutical form: dry powder~Route of administration: oral inhalation"
223166|NCT02485314|Other|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
223167|NCT02485301|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
223168|NCT02485301|Drug|Placebo|A single dose administrated intramuscular
223169|NCT02485262|Drug|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
223170|NCT02485249|Drug|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
223171|NCT02485236|Device|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
223172|NCT02485236|Device|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
223173|NCT02485210|Procedure|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
223174|NCT02485197|Other|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
223175|NCT02485184|Procedure|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
223176|NCT02485184|Drug|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
223177|NCT02485184|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
223178|NCT02485184|Drug|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
223179|NCT02485171|Device|SAFEWALKER|Medical device walking aids.
223180|NCT02485158|Drug|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
223181|NCT02485158|Drug|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
223182|NCT02485158|Drug|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
223183|NCT02485158|Drug|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
223184|NCT02485158|Drug|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
223185|NCT02485145|Drug|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
223186|NCT02485145|Drug|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
223187|NCT02485145|Drug|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
223188|NCT02485132|Other|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
223189|NCT02485119|Drug|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
223190|NCT02485106|Drug|Rifaximin|400mg three times per day for 28 days
223191|NCT02485106|Drug|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
223192|NCT02485093|Device|Septal ventricular pacing|Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
223193|NCT02485093|Device|VIP|Ventricular pacing must be less than 10%.
223194|NCT02485080|Drug|Simeprevir|
223195|NCT02485080|Drug|Sofosbuvir|
223196|NCT02485067|Drug|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
223197|NCT02485067|Drug|Placebo(For THVD-201)|
223198|NCT02485067|Drug|Detrusitol 2mg tablet|Tolterodine 2mg
223199|NCT02485067|Drug|Placebo(For Detrusitol 2mg tablet)|
223200|NCT02485054|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
223201|NCT02485041|Drug|Dapoxetine 30mg|Tablet, Orally administered
223202|NCT02485041|Drug|Mirodenafil 100mg|Table, Orally administered
223203|NCT02485028|Drug|Dapoxetine 30mg tablet|
223204|NCT02485028|Drug|Mirodenafil 50mg tablet|
223205|NCT02485015|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
223206|NCT02485015|Drug|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
223207|NCT02485002|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
223208|NCT02485002|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
223209|NCT02484989|Other|Surviellance card|
223210|NCT02484976|Behavioral|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
223211|NCT02484963|Drug|Zolpidem|
223212|NCT02484963|Drug|placebo|
223213|NCT02484950|Biological|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
223214|NCT02484950|Procedure|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
223215|NCT02484937|Other|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
223216|NCT02484937|Other|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
223217|NCT02484924|Drug|Ticagrelor|No intervention- purely observational
223218|NCT02484911|Drug|Olanzapine|5mg,twice a day orally on day 1 to day 4
223219|NCT02484911|Drug|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
223220|NCT02484911|Drug|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
223221|NCT02484911|Drug|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
223222|NCT02484885|Other|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
223223|NCT02484859|Drug|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the rate of infusion will be decreased to 0.05 µg/kg/min, and continued until the patient is extubated.
223224|NCT02484859|Drug|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via a perfusor. The infusion will be started just before the induction.
223319|NCT02484235|Other|HIIT|Group training with HIIT 3 times per week during 10 sessions
223225|NCT02484859|Drug|Metoprolol|0.1 mg/kg of metoprolol will be administered intravenously within 5 minutes following the administration of neuromuscular blocking agent.
223226|NCT02484846|Behavioral|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
223227|NCT02484833|Drug|Cetuximab|
223228|NCT02484833|Drug|FOLFIRI|
223229|NCT02484820|Device|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
223230|NCT02484807|Other|no intervention, only observation of different groups|
223231|NCT02484794|Behavioral|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
223232|NCT02484794|Behavioral|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
223233|NCT02484781|Other|Gait analysis on a trendmill|"Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining"
223234|NCT02484768|Drug|Iron isomaltoside 1000|Intravenous treatment
223235|NCT02484768|Drug|Sodium Chloride 0.9%|Intravenous treatment
223236|NCT02484755|Drug|Gefitinib|See Arm Description
223237|NCT02484742|Behavioral|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
223238|NCT02484729|Drug|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
223239|NCT02484729|Drug|Placebo, oral suspension|Matching placebo
223240|NCT02484729|Drug|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
223241|NCT02484716|Drug|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
223242|NCT02484716|Drug|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
223243|NCT02484703|Drug|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
223244|NCT02484703|Drug|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
223245|NCT02484690|Drug|Faricimab|Faricimab will be administered as per the regimen specified in individual arm.
223246|NCT02484690|Drug|Ranibizumab|Ranibizumab will be administered as per the regimen specified in individual arm.
223247|NCT02484677|Drug|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
223248|NCT02484677|Drug|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
223249|NCT02484677|Drug|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
223250|NCT02484664|Drug|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
223251|NCT02484651|Drug|Sugammadex|Reversal of deep neuromuscular block
223252|NCT02484651|Drug|Rocuronium|Maintenance of deep neuromuscular block
223253|NCT02484638|Drug|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
223254|NCT02484638|Drug|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
223255|NCT02484625|Other|Dietary treatment|Commercially available food products
223256|NCT02484612|Behavioral|acute exercise|
223257|NCT02484599|Behavioral|Computerized attention training (CAT)|Three sessions of active computerized attention training.
223258|NCT02484599|Behavioral|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
223259|NCT02484586|Device|Etafilcon A|Prototype lens material
223260|NCT02484586|Device|Etafilcon A|Control lens for presbyope group
223261|NCT02484586|Device|Nelfilcon A|Control lens for presbyope group
223262|NCT02484586|Device|Nesofilcon A|Control lens for presbyope group
223263|NCT02484586|Device|Nelfilcon A|Control lens for non-presbyope group
223264|NCT02484586|Device|Etafilcon A|Control lens for non-presbyope group
223265|NCT02484586|Device|Somofilcon A|Control lens for presbyope group
223266|NCT02484586|Device|58% Poly-HEMA|Control lens for presbyope group
223267|NCT02484586|Device|Omafilcon A|Control lens for non-presbyope group
223268|NCT02484573|Drug|Propanolol|
223269|NCT02484560|Drug|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
223270|NCT02484547|Drug|Aducanumab (BIIB037)|Low dose
223271|NCT02484547|Drug|Aducanumab (BIIB037)|High dose
223272|NCT02484547|Drug|Placebo|Placebo
223320|NCT02484235|Other|Strength|Group training with strength exercises 3 times per week during 10 sessions
223392|NCT02483689|Other|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
223273|NCT02484521|Device|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
223274|NCT02484521|Other|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.~Questionnaires what would be used are:~GAF- Global assessment of functioning~PANSS- Positive and negative syndrome scale~SANS- Scale for the Assessment of Negative Symptoms~The Calgary Depression Scale for schizophrenia~Demographic Questionnaire~Hamilton Anxiety scale"
223275|NCT02484508|Drug|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
223276|NCT02484508|Drug|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
223277|NCT02484495|Other|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.~Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
223278|NCT02484482|Drug|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
223279|NCT02484469|Device|The Virtual Human Project|Virtual Human educational videos about leprosy
223280|NCT02484456|Drug|AV 101 (4-Chlorokynurenine)|Glycine Receptor Antagonist
223281|NCT02484456|Other|Placebo|Placebo pill
223282|NCT02484443|Biological|Dinutuximab|Given IV
223283|NCT02484443|Other|Laboratory Biomarker Analysis|Correlative studies
223284|NCT02484443|Other|Pharmacological Study|Correlative studies
223285|NCT02484443|Biological|Sargramostim|Given SC
223286|NCT02484430|Other|Laboratory Biomarker Analysis|Correlative studies
223287|NCT02484430|Other|Pharmacological Study|Correlative studies
223288|NCT02484430|Drug|Sapanisertib|Given PO
223289|NCT02484417|Biological|RSV A2|Intranasal inoculation of healthy volunteers with 10^5 or 10^6.3 plaque forming units (PFU) of RSV A2.
223290|NCT02484404|Drug|Olaparib|"Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days.~MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID)~Ph II - MEDI4736 + Olaparib at RP2D"
223291|NCT02484404|Drug|Cediranib|"Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days.~MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily)~Ph II - MEDI4736 + Cediranib at RP2D"
223292|NCT02484404|Drug|MEDI4736|Ph I - MEDI4736 will be administered once every 2 weeks for 12 months.
223293|NCT02484391|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
223294|NCT02484391|Drug|Cytarabine|Given IV
223295|NCT02484391|Procedure|Hematopoietic Cell Transplantation|Undergo stem cell transplant
223296|NCT02484391|Drug|Mitoxantrone Hydrochloride|Given IV
223297|NCT02484378|Drug|CER-001|Engineered pre-beta HDL particle
223298|NCT02484378|Drug|Placebo|Normal saline
223299|NCT02484365|Other|No treatment|Attach adhesive probe on thumb or index finger
223300|NCT02484352|Drug|saline|different dosage of IV oxycodone was given before intubation
223301|NCT02484352|Drug|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
223302|NCT02484352|Drug|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
223303|NCT02484352|Drug|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
223304|NCT02484352|Drug|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
223305|NCT02484339|Drug|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
223306|NCT02484339|Other|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)->->conventional or high dose radiotherapy
223307|NCT02484326|Other|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
223308|NCT02484313|Other|dietary treatments|commercially available food products
223309|NCT02484300|Dietary Supplement|Melatonin|
223310|NCT02484300|Other|Placebo|
223311|NCT02484287|Device|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
223312|NCT02484287|Device|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
223313|NCT02484287|Device|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
223314|NCT02484274|Biological|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
223315|NCT02484261|Drug|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
223316|NCT02484261|Drug|Pravastatin|10 mg for age < 8 years, 20 mg for age 8-<13 years, 40 mg for ages >14 years
223317|NCT02484248|Drug|Ketotifen|Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
223318|NCT02484248|Drug|Placebo|The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.
223321|NCT02484222|Drug|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
223322|NCT02484209|Drug|Metformin|Metformin 1500 mg daily for 16 weeks
223323|NCT02484209|Drug|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
223324|NCT02484209|Drug|Metformin|metformin 1500 mg daily for 16 weeks
223325|NCT02484196|Behavioral|Questionnaires|Questionnaires
223326|NCT02484183|Device|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher & Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer & Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer & Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
223327|NCT02484170|Drug|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
223328|NCT02484170|Drug|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
223329|NCT02484157|Device|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
223330|NCT02484157|Device|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
223331|NCT02484144|Other|modern information|information by video for coronarography
223332|NCT02484144|Other|usual information|usual information for coronarography
223333|NCT02484131|Behavioral|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
223334|NCT02484131|Behavioral|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
223335|NCT02484118|Procedure|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
223336|NCT02484105|Behavioral|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
223337|NCT02484105|Behavioral|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
223338|NCT02484092|Biological|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
223339|NCT02484079|Procedure|Polypectomy|
223340|NCT02484066|Device|VBN|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
223341|NCT02484066|Device|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
223342|NCT02484066|Device|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
223343|NCT02484053|Drug|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
223344|NCT02484040|Radiation|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
223345|NCT02484040|Drug|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
223346|NCT02484027|Drug|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
223347|NCT02484014|Other|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
223348|NCT02484014|Other|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:~Awareness generation activities for all stakeholders in school~Wall-magazine~Speak-out box~Competitions~School Health Promotion Committee~School health policies~Peer groups of students of standard IX~Workshops and talks for all the students from standard IX, and for teachers~Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
223349|NCT02484001|Drug|ESL 800 mg|one (1) tablet of 800 mg (QD).
223350|NCT02484001|Drug|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
223351|NCT02484001|Drug|ESL 1600 mg|two (2) tablets of 800 mg (QD).
223352|NCT02484001|Drug|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
223353|NCT02483988|Device|NUsurface® Meniscus Implant|The NUsurface® Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network that supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
223354|NCT02483975|Drug|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
223355|NCT02483975|Drug|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
223356|NCT02483975|Drug|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
223357|NCT02483975|Drug|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
223358|NCT02483962|Other|Gelatine capsule|Gelatine capsules containing no active ingredients.
223359|NCT02483962|Other|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
223360|NCT02483949|Behavioral|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
223361|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
223362|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
223363|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
223364|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
223365|NCT02483923|Drug|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
223366|NCT02483923|Drug|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
223367|NCT02483910|Behavioral|Direct Instruction-Language for Learning (DI-LL)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
223368|NCT02483910|Behavioral|Treatment as Usual|Usual care including speech therapy in school, community or both
223369|NCT02483897|Drug|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
223370|NCT02483897|Drug|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
223371|NCT02483884|Drug|[68Ga]RM2|[68Ga]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
223372|NCT02483884|Procedure|PET/CT|Patients received [68Ga]RM2 undergo PET/CT 60 min p.i. for at least 20 min
223373|NCT02483871|Drug|Rosuvastatin|
223374|NCT02483858|Drug|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
223375|NCT02483845|Drug|Natalizumab|
223376|NCT02483832|Behavioral|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
223377|NCT02483806|Procedure|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0->5->10, 0->10->5, 5->10->0, 5->0->10, 10->5->0, 10->0->5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
223378|NCT02483793|Drug|Tamsulosin|
223379|NCT02483793|Drug|Oxybutynin|
223380|NCT02483780|Behavioral|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
223381|NCT02483767|Drug|goserelin|Gonadotropin-Releasing Hormone Agonist
223382|NCT02483767|Drug|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
223383|NCT02483741|Biological|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
223384|NCT02483728|Other|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
223385|NCT02483715|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
223386|NCT02483715|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
223387|NCT02483702|Other|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
223388|NCT02483702|Other|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
223389|NCT02483689|Drug|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
223390|NCT02483689|Other|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
223391|NCT02483689|Drug|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
223393|NCT02483676|Device|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
223394|NCT02483676|Behavioral|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
223395|NCT02483663|Device|Functional Magnetic Resonance Imaging|Measure brain activity.
223396|NCT02483663|Radiation|Dual Energy X-ray absorptiometry|Body composition measurements.
223397|NCT02483663|Other|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
223398|NCT02483663|Other|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
223399|NCT02483663|Other|Test Meals|Breakfast, a snack, and lunch provided during study visit.
223400|NCT02483663|Other|Computer Tests|Perform a series of computer tests to determine reaction time.
223401|NCT02483663|Procedure|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
223402|NCT02483637|Device|RejuvenAir|Device: RejuvenAir
223403|NCT02483624|Drug|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
223404|NCT02483624|Drug|Placebo|Placebo
223405|NCT02483611|Drug|Magnesium Sulfate|
223406|NCT02483611|Drug|Lidocaine|
223407|NCT02483611|Drug|Isotonic Solution|
223408|NCT02483611|Drug|Cisatracurium|
223409|NCT02483598|Drug|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
223410|NCT02483598|Drug|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
223411|NCT02483585|Drug|Erenumab|Administered once a month by subcutaneous injection
223412|NCT02483585|Drug|Placebo|Administered once a month by subcutaneous injection
223413|NCT02483572|Behavioral|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
223414|NCT02483559|Other|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (~470 nm) to be worn prior to desired sleep onset time.
223415|NCT02483559|Other|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
223416|NCT02483546|Device|Laerdal®|simulation- based educational intervention
223417|NCT02483546|Behavioral|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
223418|NCT02483546|Behavioral|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
223419|NCT02483533|Drug|LIPO-202|
223420|NCT02483533|Drug|Placebo|
223421|NCT02483520|Behavioral|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
223422|NCT02483507|Other|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
223423|NCT02483494|Other|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.~The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
223424|NCT02483481|Procedure|shear wave ultrasound elastography|
223425|NCT02483468|Behavioral|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
223426|NCT02483468|Device|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
223427|NCT02483468|Device|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
223428|NCT02483455|Drug|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
223429|NCT02483455|Drug|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
223471|NCT02483169|Device|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
223430|NCT02483429|Device|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
223431|NCT02483403|Other|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
223432|NCT02483403|Device|MRI|
223433|NCT02483390|Other|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
223434|NCT02483377|Other|Quality-of-Life Assessment|Ancillary studies
223435|NCT02483377|Other|Questionnaire Administration|Complete questionnaires
223436|NCT02483364|Other|HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)|A single application in the context of a single surgical intervention.
223437|NCT02483351|Other|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
223438|NCT02483351|Other|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of <=80g/L
223439|NCT02483338|Behavioral|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
223440|NCT02483325|Drug|Allogeneic transplant conditioning|Allogeneic transplant
223441|NCT02483312|Biological|IL-12|
223442|NCT02483299|Drug|Metformin|
223443|NCT02483299|Drug|Glucophage tablets and Victoza|
223444|NCT02483286|Behavioral|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly."
223445|NCT02483286|Behavioral|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
223446|NCT02483286|Behavioral|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
223447|NCT02483260|Drug|Ribavirin|"Loading dose, 33 mg/kg (maximum dose: 2.64 g)~Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)~Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
223448|NCT02483247|Drug|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
223449|NCT02483247|Drug|Capecitabine|Capecitabine 1000 mg/m^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
223450|NCT02483247|Drug|Doxorubicin|Doxorubicin 60 mg/m^2 body surface area is administered intravenously once every three weeks (21-days).
223451|NCT02483247|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
223452|NCT02483247|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
223453|NCT02483247|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
223454|NCT02483247|Drug|Sunitinib|Sunitinib 37.5 mg is administered once daily.
223455|NCT02483234|Drug|secukinumab|
223456|NCT02483221|Drug|Hydromorphone|Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
223457|NCT02483221|Drug|Morphine|Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
223458|NCT02483208|Drug|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
223459|NCT02483208|Drug|Advate|Advate infusion to analyze pharmacokinetics.
223460|NCT02483195|Drug|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
223461|NCT02483195|Drug|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
223462|NCT02483195|Drug|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
223463|NCT02483195|Other|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
223464|NCT02483182|Drug|ZEP-3 ointment 1.0%|
223465|NCT02483182|Drug|Acyclovir cream 5%|
223466|NCT02483169|Drug|cilostazol|Cilostazol 100mg bid
223467|NCT02483169|Drug|Probucol|Probucol 250mg bid
223468|NCT02483169|Drug|Aspirin|Aspirin 100mg qd
223469|NCT02483169|Drug|placebo of cilostazol|same shape and size of active cilostazol
223470|NCT02483169|Drug|Placebo of aspirin|same size and shape of active aspirin 100mg
223472|NCT02483156|Drug|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
223473|NCT02483156|Drug|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
223474|NCT02483156|Drug|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
223475|NCT02483143|Drug|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
223476|NCT02483143|Drug|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
223477|NCT02483143|Drug|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
223478|NCT02483130|Dietary Supplement|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
223479|NCT02483130|Other|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
223480|NCT02483117|Other|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
223481|NCT02483104|Drug|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
223482|NCT02483104|Drug|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
223483|NCT02483104|Drug|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
223484|NCT02483091|Behavioral|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.~After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.~The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
223485|NCT02483078|Drug|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
223486|NCT02483078|Drug|Placebo|
223487|NCT02483078|Drug|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
223488|NCT02483065|Other|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
223489|NCT02483052|Device|RejuvenAir|RejuvenAir
223490|NCT02483039|Behavioral|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
223491|NCT02483026|Dietary Supplement|Multi vitamin|Multi vitamin
223492|NCT02483026|Dietary Supplement|vitamin D|Vitamin D
223493|NCT02483013|Other|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
223494|NCT02483013|Other|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
223495|NCT02483000|Biological|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
223496|NCT02483000|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
223497|NCT02483000|Drug|Carmustine|Given IV
223498|NCT02483000|Drug|Clearing Agent|Given IV
223499|NCT02483000|Drug|Cytarabine|Given IV
223500|NCT02483000|Drug|Etoposide|Given IV
223501|NCT02483000|Radiation|Indium In 111-DOTA-Biotin|Given IV
223502|NCT02483000|Other|Laboratory Biomarker Analysis|Correlative studies
223503|NCT02483000|Drug|Melphalan|Given IV
223504|NCT02483000|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
223505|NCT02483000|Other|Pharmacological Study|Correlative studies
223506|NCT02483000|Radiation|Yttrium Y 90-DOTA-Biotin|Given IV
223507|NCT02482987|Device|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
223508|NCT02482987|Device|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
223509|NCT02482987|Procedure|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
223510|NCT02482987|Procedure|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
223511|NCT02482961|Drug|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
223512|NCT02482948|Device|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
223513|NCT02482948|Drug|Collagenase|Study agent to be applied daily to the wound.
223514|NCT02482935|Drug|Abemaciclib|Administered orally
223515|NCT02482922|Other|Exercise & Dietary Supplement|
223516|NCT02482909|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor
223517|NCT02482909|Procedure|Radiofrequency ablation|Percutaneous ablation using radiofrequency under the imaging guidance
223518|NCT02482883|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized [active stimulation vs non-active (placebo) stimulation], for an initial period of 10 days.
223519|NCT02482870|Device|Macintosh laryngoscope|Using a Macintosh laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
223520|NCT02482870|Device|King Vision video laryngoscope|Using a King Vision video laryngoscope, time to glottic view, best Cormack-Lehane grade, time to intubation, time to first ventilation has been recorded.
223521|NCT02482857|Drug|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
223522|NCT02482844|Other|pacemaker implantation|
223523|NCT02482844|Other|holter implantation|
223524|NCT02482831|Procedure|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
223525|NCT02482818|Drug|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
223526|NCT02482818|Drug|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
223527|NCT02482805|Behavioral|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
223528|NCT02482792|Other|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
223529|NCT02482792|Other|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
223530|NCT02482766|Drug|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
223531|NCT02482766|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
223532|NCT02482766|Device|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
223533|NCT02482753|Drug|Chidamide|30 mg, administered orally twice per week (BIW)
223534|NCT02482753|Drug|exemestane|25 mg, PO daily
223535|NCT02482753|Drug|placebo|Administered orally twice per week (BIW)
223536|NCT02482740|Drug|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
223537|NCT02482740|Drug|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
223538|NCT02482727|Device|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
223539|NCT02482714|Behavioral|Physical activity.|Have subject do moderate physical activity.
223540|NCT02482701|Device|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
223541|NCT02482688|Behavioral|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
223542|NCT02482675|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
223543|NCT02482675|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
223544|NCT02482675|Other|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
223545|NCT02482675|Other|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
223546|NCT02482662|Procedure|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
223547|NCT02482649|Behavioral|EAA/T|bi-weekly for 12weeks
223548|NCT02482649|Drug|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
223549|NCT02482649|Drug|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
223550|NCT02482636|Biological|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
223551|NCT02482636|Biological|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
223552|NCT02482636|Biological|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
223553|NCT02482636|Biological|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
223554|NCT02482636|Biological|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
223555|NCT02482636|Biological|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
223556|NCT02482623|Behavioral|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
223557|NCT02482610|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
223558|NCT02482610|Other|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
223559|NCT02482610|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
223560|NCT02482597|Device|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
223561|NCT02482584|Device|CPAP|CPAP intervention
223562|NCT02482584|Other|Control|Control
223563|NCT02482571|Device|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from ~21% (room air) to ~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic resonance spectroscopy (fMRS) while they are presented with visual stimuli.
223564|NCT02482558|Other|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
223565|NCT02482545|Dietary Supplement|Meal replacement|
223566|NCT02482532|Biological|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
223567|NCT02482519|Other|High calorie diet|High calorie diet for 10 days
223568|NCT02482519|Other|Fasting|10 day fast
223569|NCT02482506|Behavioral|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
223570|NCT02482506|Behavioral|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
223571|NCT02482493|Device|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
223572|NCT02482480|Other|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
223573|NCT02482480|Other|Control|Dietary and general recommendations
223574|NCT02482467|Other|Hormonal analysis, pelvic US|
223575|NCT02482454|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
223576|NCT02482454|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
223577|NCT02482441|Drug|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
223578|NCT02482441|Drug|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
223579|NCT02482428|Drug|Investigational Treatment|Applied twice daily for up to 12 weeks
223580|NCT02482428|Drug|Aldara|Applied 3 times a week for 16 weeks
223581|NCT02482415|Other|Psycho-educational|
223582|NCT02482402|Drug|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
223583|NCT02482402|Drug|Placebo|inhalation solution placebo
223584|NCT02482389|Radiation|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
223585|NCT02482376|Radiation|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
223586|NCT02482363|Radiation|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
223587|NCT02482363|Radiation|Sham Control|20 minutes of sham control exposure
223588|NCT02482350|Behavioral|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
223592|NCT02482324|Device|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
223593|NCT02482311|Drug|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."
223594|NCT02482298|Drug|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
223595|NCT02482298|Drug|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
223596|NCT02482272|Drug|Lamivudine|Lamivudine 100mg/day orally
223597|NCT02482272|Drug|Adefovir|Adefovir 10mg/day orally
223598|NCT02482272|Drug|Entecavir|Entecavir 1mg/day orally
223599|NCT02482233|Behavioral|ENDD (NJOY)|As described above.
223600|NCT02482233|Drug|NRT (NicoDerm CQ)|As described above.
223601|NCT02482233|Behavioral|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
223602|NCT02482233|Behavioral|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
223603|NCT02482233|Behavioral|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.~Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf"
223604|NCT02482220|Behavioral|Physical activity intervention|
223605|NCT02482207|Drug|Rosuvastatin|
223606|NCT02482207|Behavioral|Life style modification|
223607|NCT02482194|Biological|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
223608|NCT02482168|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
223609|NCT02482155|Drug|Ibuprofen|ibuprofen 400 mg single dose oral solution
223610|NCT02482142|Dietary Supplement|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
223611|NCT02482129|Drug|LME636 60 mg/mL ophthalmic solution|
223612|NCT02482129|Drug|Dexamethasone 0.1% ophthalmic solution|
223613|NCT02482129|Drug|LME636 Vehicle|Inactive ingredients used for masking purposes
223614|NCT02482116|Other|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
223615|NCT02482103|Procedure|Renal denervation|Catheter based renal nerve ablation
223616|NCT02482090|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
223617|NCT02482090|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
223618|NCT02482090|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
223619|NCT02482090|Drug|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
223620|NCT02482077|Drug|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
223621|NCT02482077|Drug|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
223622|NCT02482077|Drug|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
223623|NCT02482064|Other|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
223624|NCT02482038|Device|geko|neuromuscular electrostimulator
223625|NCT02482025|Other|SMMRT|Includes My HealtheVet registration and enrollment
223626|NCT02482012|Other|Survey|This was a survey
223627|NCT02481986|Behavioral|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
223628|NCT02481986|Behavioral|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
223629|NCT02481973|Other|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
223630|NCT02481960|Procedure|CM-BC2 Irinotecan drug-eluting bead|
223631|NCT02481947|Drug|BLI400 Laxative|Oral laxative
223632|NCT02481947|Drug|Lubiprostone|Oral laxative
223633|NCT02481934|Procedure|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
223634|NCT02481934|Drug|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
223635|NCT02481934|Drug|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
223636|NCT02481921|Behavioral|Group medical visits|Or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and medication management join to manage heart failure in addition to and in support of, the patient's regular physician visits.
223637|NCT02481908|Device|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
223638|NCT02481895|Behavioral|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
223639|NCT02481882|Device|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
223640|NCT02481882|Drug|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
223641|NCT02481869|Biological|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
223642|NCT02481869|Drug|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
223643|NCT02481856|Drug|SQ tree SLIT-tablet|
223644|NCT02481856|Drug|Placebo|
223645|NCT02481843|Other|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
223646|NCT02481830|Drug|Nivolumab|
223647|NCT02481830|Drug|Topotecan|
223648|NCT02481830|Drug|Amrubicin|
223649|NCT02481817|Procedure|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
223650|NCT02481817|Procedure|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
223651|NCT02481817|Procedure|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
223652|NCT02481804|Other|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.~Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
223653|NCT02481804|Other|Standard treatment|Standard treatment will be continued
223654|NCT02481791|Drug|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
223655|NCT02481791|Drug|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
223656|NCT02481791|Drug|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
223657|NCT02481778|Other|Blood sampling|
223658|NCT02481765|Device|High definition transcranial direct current stimulation|
223659|NCT02481752|Other|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
223660|NCT02481752|Other|SHAM Training|
223661|NCT02481739|Other|retrospective study|
223662|NCT02481726|Radiation|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
223663|NCT02481713|Behavioral|motivational interviewing|motivational interviewing
223664|NCT02481713|Behavioral|learning style interviews|interview and feedback about learning style
223665|NCT02481700|Procedure|Third molar removal|The surgical removal of third molars by local or general anaesthesia
223666|NCT02481687|Other|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
223667|NCT02481674|Drug|VX15/2503|VX15/2503 is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
223668|NCT02481674|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
223669|NCT02481661|Procedure|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
223670|NCT02481648|Other|Exercise|
223671|NCT02481635|Drug|Gemcitabine|
223672|NCT02481635|Drug|Nab-paclitaxel|
223673|NCT02481635|Radiation|Radiation Therapy|
223674|NCT02481635|Procedure|Surgical Resection|
223675|NCT02481609|Drug|N-acetyl cysteine (NAC)|
223676|NCT02481596|Behavioral|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
223677|NCT02481596|Behavioral|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
223986|NCT02479503|Procedure|Antibiotic prophylaxis in adult heart transplantation|
223678|NCT02481596|Behavioral|Helpline & A1c results|Participants complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
223679|NCT02481583|Drug|Levosulpiride|different formulations of levosulpiride
223680|NCT02481570|Other|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
223681|NCT02481557|Device|Oxalate Salt Solution|Applied by dentist
223682|NCT02481544|Behavioral|Gratitude Journaling Plus SOC|
223683|NCT02481544|Behavioral|Memorable Events Journaling Plus SOC|
223684|NCT02481531|Other|Previously marketed infant formula|
223685|NCT02481531|Other|Previously marketed formula using a similar protein|
223686|NCT02481518|Drug|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
223687|NCT02481518|Other|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
223688|NCT02481505|Drug|Chloroprocaine HCl 1%|Intrathecal Route
223689|NCT02481492|Device|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
223690|NCT02481492|Device|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
223691|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
223692|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
223693|NCT02481479|Drug|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
223694|NCT02481466|Behavioral|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
223695|NCT02481466|Behavioral|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
223696|NCT02481466|Behavioral|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
223697|NCT02481466|Behavioral|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.~Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
223698|NCT02481453|Drug|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
223699|NCT02481453|Drug|Placebo|Comparator: placebo
223700|NCT02481440|Biological|Umbilical Cord Mesenchymal Stem Cells|Intrathecal administration of UC-MSCs
223701|NCT02481427|Procedure|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
223759|NCT02481141|Drug|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
223760|NCT02481141|Drug|Placebo|
223702|NCT02481427|Procedure|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
223703|NCT02481414|Biological|Pepcan+Candin|
223704|NCT02481414|Biological|Candin|
223705|NCT02481401|Behavioral|Intensive Individual Intervention Program|
223706|NCT02481401|Behavioral|Peer-To-Peer Program Intervention|
223707|NCT02481388|Other|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
223708|NCT02481375|Dietary Supplement|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
223709|NCT02481375|Dietary Supplement|Iron|12-wk supplementation of iron
223710|NCT02481375|Dietary Supplement|Placebo|12-wk supplementation of placebo
223711|NCT02481362|Other|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
223712|NCT02481362|Other|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
223713|NCT02481349|Other|Best Practice|Undergo standard of care
223714|NCT02481349|Other|Informational Intervention|Receive DVD for home practice
223715|NCT02481349|Other|Quality-of-Life Assessment|Ancillary studies
223716|NCT02481349|Other|Questionnaire Administration|Ancillary studies
223717|NCT02481349|Other|Yoga|Complete couple-based Hatha yoga program
223718|NCT02481336|Other|Questionnaires|EORTC CIPN20 and EQ-5D-3L
223719|NCT02481336|Procedure|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
223720|NCT02481336|Genetic|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
223721|NCT02481323|Drug|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
223722|NCT02481323|Drug|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
223723|NCT02481310|Drug|Cyclophosphamide|Given IV
223724|NCT02481310|Drug|Cytarabine|Given IT or intraventricularly
223725|NCT02481310|Drug|Doxorubicin Hydrochloride|Given IV
223726|NCT02481310|Drug|Etoposide|Given IV
223727|NCT02481310|Drug|Ixazomib Citrate|Given PO
223728|NCT02481310|Other|Laboratory Biomarker Analysis|Correlative studies
223729|NCT02481310|Drug|Methotrexate|Given IT or intraventricularly
223730|NCT02481310|Drug|Prednisone|Given PO
223731|NCT02481310|Biological|Rituximab|Given IV
223732|NCT02481310|Drug|Therapeutic Hydrocortisone|Given IT or intraventricularly
223733|NCT02481310|Drug|Vincristine Sulfate|Given IV
223734|NCT02481297|Drug|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
223735|NCT02481297|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
223736|NCT02481284|Device|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
223737|NCT02481271|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week program, one introductory session and daily home practice"
223738|NCT02481271|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
223739|NCT02481258|Drug|Ataciguat (HMR1766)|
223740|NCT02481258|Other|Placebo Comparator: Matching Placebo|
223741|NCT02481245|Drug|Bezafibrate|30 patients with Bipolar I disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
223742|NCT02481232|Biological|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
223743|NCT02481219|Device|PillCam® COLON 2 procedure-CONTROL|
223744|NCT02481219|Drug|Senna tablets|
223745|NCT02481219|Drug|PEG|
223746|NCT02481219|Drug|Metoclopramide|
223747|NCT02481219|Drug|Erythromycin|
223748|NCT02481219|Drug|SUPREP oral sulfate solution|
223749|NCT02481219|Drug|Bisacodyl|
223750|NCT02481219|Drug|SUPREP oral sulfate solution with Gastrografin|
223751|NCT02481206|Device|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
223752|NCT02481193|Drug|Cisatracurium|Different doses of cisatracurium pretreatment
223753|NCT02481180|Drug|T0001|injection (SC) T0001 15mg weekly for 12 weeks
223754|NCT02481180|Drug|T0001|injection (SC) T0001 30mg weekly for 12 weeks
223755|NCT02481180|Drug|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
223756|NCT02481180|Drug|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
223757|NCT02481180|Drug|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
223758|NCT02481154|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
223761|NCT02481128|Procedure|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
223763|NCT02481076|Device|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
223764|NCT02481076|Other|Braun frame|The leg is elevated on a Braun frame
223765|NCT02481076|Device|compression bandage|application of flowtron hydroven boot and compression bandage
223766|NCT02481063|Other|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
223767|NCT02481063|Other|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
223768|NCT02481050|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
223769|NCT02481037|Other|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
223770|NCT02481037|Other|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
223771|NCT02481037|Other|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
223772|NCT02481011|Drug|antithrombotic drugs|
223773|NCT02480998|Biological|IL-YANG Flu Vaccine QIV 0.5mL|
223774|NCT02480998|Biological|IL-YANG Flu Vaccine TIV 0.5mL|
223775|NCT02480985|Other|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months~Thyroid-stimulating hormone, free T4 and T3~Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone~Adrenocorticotropic hormone stimulation test~Glucagon test (growth hormone deficit)~Risk factors evaluation of pituitary dysfunction~Demographic data~Daily data (clinical exam, secondary brain injuries)~Hormone levels on day 1, 3 and 7~Biomarkers on day 1, 3 and 7~Brain CT-Scan on day 1~Pituitary MRI on day 7~Outcome measures at 6 and 12 months~Neurological recovery (GOSe)~Independent functioning (FIM)~Quality of life (EQ-5D-5L)~Life satisfaction (LISAT-11)~Depression (PHQ-9)"
223776|NCT02480972|Procedure|magnetic resonance imaging|"multiparametric MRI as follows:~diffusion weighted imaging using multiple b-values~Fat quantification sequence~perfusion MRI using ECCM agent~MR elastography~------------------------------------~routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
223777|NCT02480959|Procedure|Surgical treatment for recurrent patellar instability|Either medial plication or MPFL reconstructuion surgery
223778|NCT02480946|Drug|MBS2320|As described in the arm descriptions
223779|NCT02480946|Drug|Placebo|As described in the arm descriptions
223780|NCT02480946|Drug|Methotrexate|Background therapy as described in the arm descriptions
223781|NCT02480933|Procedure|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
223782|NCT02480933|Other|Biopsy|Biopsy of BI-RADS 3 and superior lesions
223783|NCT02480907|Behavioral|Workshop Group|Workshop support group
223784|NCT02480907|Behavioral|Internet-based support group|Internet based support group with E-mail coaching
223785|NCT02480894|Drug|BMS-663068|BMS-663068
223786|NCT02480894|Drug|Maraviroc|Maraviroc
223787|NCT02480881|Drug|BMS-663068|Investigational product
223788|NCT02480881|Drug|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
223789|NCT02480881|Drug|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
223790|NCT02480868|Device|ARTEBONE|4,3 g Bone Void Filler
223791|NCT02480855|Other|Questionnaire and feedback|
223792|NCT02480842|Other|Alloplastic free ROM|
223793|NCT02480842|Other|Alloplastic limited ROM|
223794|NCT02480842|Other|Oncoplastic free ROM|
223795|NCT02480842|Other|Oncoplastic limited ROM|
223796|NCT02480816|Dietary Supplement|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
223797|NCT02480803|Drug|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
223798|NCT02480803|Device|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
223799|NCT02480777|Biological|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
223800|NCT02480764|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
223801|NCT02480764|Drug|Valsartan|Valsartan 80 mg capsules
223802|NCT02480764|Drug|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
223803|NCT02480764|Drug|Valsartan Placebo|Valsartan placebo-matching capsules
223804|NCT02480751|Drug|Beraprost|
223805|NCT02480751|Drug|Placebo|
223806|NCT02480738|Behavioral|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.~Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
223807|NCT02480725|Procedure|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
223808|NCT02480712|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
223809|NCT02480699|Biological|Recurring blood sample|
223857|NCT02480283|Procedure|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
224099|NCT02478580|Drug|Nuvigil|Patients will receive Nuvigil before the surgery
223810|NCT02480699|Other|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
223811|NCT02480686|Drug|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
223812|NCT02480673|Dietary Supplement|Chia|The subject will eat 25 gr of chia in 2 oatmeal cookies at day
223813|NCT02480673|Dietary Supplement|Oatmeal|The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.
223814|NCT02480673|Behavioral|Normocaloric diet|The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
223815|NCT02480660|Behavioral|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
223816|NCT02480647|Drug|Levonorgestrel|20μg/day.
223817|NCT02480647|Drug|Etonogestrel|20μg/day.
223818|NCT02480634|Drug|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
223819|NCT02480634|Radiation|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
223820|NCT02480621|Drug|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
223821|NCT02480608|Drug|Imatinib|
223822|NCT02480608|Drug|Hydroxyurea|
223823|NCT02480595|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
223824|NCT02480582|Other|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\kg
223825|NCT02480582|Other|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
223826|NCT02480569|Other|FFR Measurement|
223827|NCT02480556|Procedure|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction & cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
223828|NCT02480556|Procedure|Conservative separation of placenta|"Conservative separation of placenta:~in group B but following fetal extraction and cord clamping, the placenta will be left insitu & uterus is massaged awaiting spontaneous placental separation"
223829|NCT02480543|Drug|Misoprostol (cytotec)|
223830|NCT02480530|Behavioral|Individual Feedback|Patient gets feedback reports on adherence weekly.
223831|NCT02480530|Behavioral|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
223832|NCT02480517|Device|Ultrasound|
223833|NCT02480517|Device|Sham Ultrasound|
223834|NCT02480504|Other|dietary intervention intermittent energy restriction|Randomized clinical trial
223835|NCT02480504|Other|continuous energy restriction|
223836|NCT02480491|Other|measuring cell freeDNA|measuring cell free DNA using PCR
223837|NCT02480465|Drug|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
223838|NCT02480465|Drug|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
223839|NCT02480439|Drug|TAK-648 Tablet|Tak-648 tablet
223840|NCT02480439|Drug|TAK-648 Oral Solution|TAK-648 oral solution
223841|NCT02480426|Device|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
223842|NCT02480426|Drug|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
223843|NCT02480413|Other|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
223844|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
223845|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
223846|NCT02480387|Drug|Ledipasvir/Sofosbuvir FDC|
223847|NCT02480374|Biological|GEN-1|
223848|NCT02480361|Device|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
223849|NCT02480348|Device|Polymer-free DES (Drug Eluting Stent)|
223850|NCT02480335|Drug|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
223851|NCT02480322|Procedure|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
223852|NCT02480296|Drug|MYK-461|
223853|NCT02480296|Drug|Placebo|Placebo comparator
223854|NCT02480283|Procedure|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
223855|NCT02480283|Radiation|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
223856|NCT02480283|Procedure|Venipuncture|To collect blood cells and serum for analyses.
223921|NCT02479841|Other|Self management program|
223858|NCT02480257|Behavioral|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
223859|NCT02480244|Behavioral|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
223860|NCT02480244|Other|Control|Control arm receives no health-related behavioral intervention
223861|NCT02480231|Device|Retropubic Midurethral Sling|
223862|NCT02480218|Other|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
223863|NCT02480205|Device|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:~On conventional NIPPV device with the clinically prescribed settings (30 min)~With NeuroPAP and no change of Pmin (=peep) (60 min)~With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)~During CPAP delivered with NeuroPAP device (15 min)~Again with original NIPPV device and settings for 30 minutes"
223864|NCT02480192|Other|CBT for Menopausal Symptoms (CBT-Meno)|This 12-week CBT-based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
223865|NCT02480179|Device|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
223866|NCT02480166|Drug|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
223867|NCT02480166|Drug|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
223868|NCT02480153|Biological|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
223869|NCT02480153|Biological|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
223870|NCT02480140|Other|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
223871|NCT02480140|Other|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
223872|NCT02480140|Other|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
223873|NCT02480127|Procedure|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
223874|NCT02480114|Other|Educational Intervention|Undergo oral care and pain management education session
223875|NCT02480114|Drug|Gabapentin|Given PO
223876|NCT02480114|Other|Pain Therapy|Receive usual oral health care
223877|NCT02480114|Other|Quality-of-Life Assessment|Ancillary studies
223878|NCT02480114|Other|Questionnaire Administration|Ancillary studies
223879|NCT02480114|Drug|Oxycodone/Acetaminophen|Analgesia
223880|NCT02480114|Drug|Hydrocodone/Acetaminophen|Analgesia
223881|NCT02480114|Drug|Fentanyl|Transdermal Analgesia
223882|NCT02480114|Drug|Ibuprofen|NSAID Analgesia
223883|NCT02480114|Drug|Magic Mouthwash|Oral Solution to treat mucositis
223884|NCT02480101|Biological|H7N9 live influenza vaccine|H7N9 live influenza vaccine
223885|NCT02480101|Biological|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
223886|NCT02480088|Drug|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
223887|NCT02480088|Drug|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
223888|NCT02480075|Other|Observational|Observational Study only
223889|NCT02480062|Other|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
223890|NCT02480062|Other|Usual Care|Usual care at the community health centers
223891|NCT02480049|Drug|Asmakast|1 tablet contains 10 mg of montelukast
223892|NCT02480049|Drug|Singulair|1 tablet contains 10 mg of montelukast
223893|NCT02480036|Radiation|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
223894|NCT02480036|Device|Intrabeam®|
223895|NCT02480023|Radiation|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
223896|NCT02480010|Drug|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
223897|NCT02479997|Drug|Indocyanine green|"ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.~In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty."
223898|NCT02479997|Drug|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
223899|NCT02479984|Procedure|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.~Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
223900|NCT02479984|Device|Laparoscopic ultrasound|
223901|NCT02479971|Drug|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
223902|NCT02479971|Drug|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
223903|NCT02479958|Procedure|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
223904|NCT02479958|Procedure|Tooth drying|The tooth was dried with air jet.
223905|NCT02479958|Procedure|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
223906|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
223907|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
223908|NCT02479945|Other|Obtaining biospecimen|
223909|NCT02479932|Other|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
223910|NCT02479932|Other|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
223911|NCT02479919|Device|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
223912|NCT02479919|Device|Magstim® Sham TBS|Sham stimulation
223913|NCT02479906|Device|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
223914|NCT02479906|Device|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
223915|NCT02479893|Procedure|polypectomy|Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
223916|NCT02479880|Drug|Tenofovir DF|300 mg tablet administered orally once daily for up to 96 weeks
223917|NCT02479880|Radiation|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
223918|NCT02479867|Drug|Cefadroxil|1 tablet from test vs 1 tablet from reference
223919|NCT02479854|Drug|Asmakast|1 chewable tablet contains 5 mg montelukast
223920|NCT02479854|Drug|Singulair|1 chewable tablet contains 5 mg montelukast
223922|NCT02479828|Drug|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
223923|NCT02479828|Drug|Ropivacaine|
223924|NCT02479828|Device|ultrasound|
223925|NCT02479828|Drug|Placebo|
223926|NCT02479815|Dietary Supplement|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
223927|NCT02479802|Biological|Albumin|"27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:~three weeks of intensive treatment with two plasma exchanges per week~twenty-one weeks of maintenance treatment with one weekly plasma exchange"
223928|NCT02479789|Drug|Lidocaine|
223929|NCT02479789|Drug|Placebo|
223930|NCT02479776|Biological|stem cell injection|Injection of autologous bone marrow derived stem cells
223931|NCT02479763|Procedure|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
223932|NCT02479750|Device|ColdZyme® mouth spray|
223933|NCT02479750|Device|Placebo|
223934|NCT02479737|Device|Blood drainage post cardiac surgery using PleuraFlow System|
223935|NCT02479724|Device|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
223936|NCT02479711|Other|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
223937|NCT02479711|Other|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
223938|NCT02479698|Biological|Allogeneic BK-specific Cytotoxic T-lymphocytes|Given IV
223939|NCT02479698|Other|Laboratory Biomarker Analysis|Correlative studies
223940|NCT02479685|Procedure|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
223941|NCT02479672|Device|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
223942|NCT02479672|Procedure|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
223943|NCT02479672|Device|VividTrac®|
223944|NCT02479659|Other|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
223945|NCT02479659|Other|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
223946|NCT02479659|Other|Opt-out HIV testing for mothers and newborns|"Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:~If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.~If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner."
223947|NCT02479659|Other|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
223948|NCT02479659|Other|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
223949|NCT02479646|Biological|MYL-1401H|
223950|NCT02479646|Biological|EU-Neulasta|
223951|NCT02479646|Biological|US-Neulasta|
223982|NCT02479542|Device|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
224100|NCT02478580|Drug|Placebo|Placebo will be given before surgery
223952|NCT02479633|Other|Coronally advanced flap with connective tissue graft|"Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.~The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction."
223953|NCT02479620|Drug|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
223954|NCT02479607|Device|Smartphone or tablet|
223955|NCT02479594|Behavioral|competence-feedback|competence-feedback
223956|NCT02479594|Other|control|control group without competence-feedback
223957|NCT02479581|Procedure|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
223958|NCT02479581|Procedure|ERAS group|"No routine bowel preparation;~Normal eating 1 days before the operation;~No drinking 2h and solid food 6h before the operation;~Drink 10% glucose 250ml 3h before operation ;~Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
223959|NCT02479581|Procedure|ERAS group|Emphasize the preoperative psychological preparation for patients.
223960|NCT02479581|Procedure|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
223961|NCT02479581|Procedure|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
223962|NCT02479581|Procedure|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
223963|NCT02479581|Procedure|ERAS group|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction;~Goal-directed fluid management."
223964|NCT02479581|Procedure|ERAS group|"Infusion of Human Albumin Grifol®20% 50ml;~Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));~Shorten the Cardio-pulmonary Bypass line；~Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
223965|NCT02479581|Procedure|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
223966|NCT02479581|Procedure|ERAS group|Protective ventilation strategy：Low tidal volume about 6~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
223967|NCT02479581|Procedure|ERAS group|"Bilateral thoracic paravertebral block before induction of anesthesia;~Fast channel anesthesia:~Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1~0.4ug/kg·min, Propofol Injection 2~6mg/kg·h, Sevoflurane 0.5~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
223968|NCT02479581|Procedure|ERAS group|"Drink water after 6h, 200ml once, 2~3 times / day，~early ambulation，mobilization within 48 h,~Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；~Intravenous the lansoprazole 30mg q12h."
223969|NCT02479581|Procedure|Conventional control group|Routine preoperative psychological preparation for patients.
223970|NCT02479581|Procedure|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
223971|NCT02479581|Procedure|Conventional control group|"Routine bowel preparation;~Liquid food eating 2 days before the operation;"
223972|NCT02479581|Procedure|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
223973|NCT02479581|Procedure|Conventional control group|"Induction use Sufentanil 0.5~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2~0.6mg/kg,Midazolam0.05~0.1mg/kg ;~Maintain use Sufentanil 1~2ug/kg·h, Propofol 4~12mg/kg·h, Sevoflurane 1~3(minimal alveolar concentration)， Vecuronium 0.06~0.12mg/kg·h;"
223974|NCT02479581|Procedure|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
223975|NCT02479581|Procedure|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
223976|NCT02479581|Procedure|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
223977|NCT02479568|Dietary Supplement|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
223978|NCT02479568|Dietary Supplement|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
223979|NCT02479568|Dietary Supplement|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
223980|NCT02479555|Drug|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|"Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device."
223981|NCT02479542|Other|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
223983|NCT02479529|Drug|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
223984|NCT02479529|Drug|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
223985|NCT02479516|Behavioral|Community Health Assessment Program Philippines (CHAP-P)|
223987|NCT02479490|Drug|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.~A treatment cycle consists of 28 days."
223988|NCT02479477|Other|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
223989|NCT02479464|Genetic|Genotyping results|Genotyping results provided in Phase II
223990|NCT02479451|Drug|Theophylline|The study medication will be provided by Foundation Care.
223991|NCT02479438|Other|Diagnosed with GERD|Recording of patient outcomes
223992|NCT02479425|Procedure|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
223993|NCT02479412|Drug|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223994|NCT02479412|Drug|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223995|NCT02479412|Drug|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223996|NCT02479412|Drug|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
223997|NCT02479412|Drug|Salbutamol|Inhalation as needed
223998|NCT02479399|Drug|ipragliflozin|Tablets
223999|NCT02479386|Other|No intervention|No intervention was administered in this study.
224000|NCT02479373|Other|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
224001|NCT02479373|Other|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
224002|NCT02479373|Other|Biodex dynamometer|To study muscle strength
224003|NCT02479373|Other|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
224004|NCT02479373|Other|Quality of life questionnaires|
224005|NCT02479347|Drug|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
224006|NCT02479347|Drug|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
224007|NCT02479334|Other|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
224008|NCT02479334|Other|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
224009|NCT02479334|Other|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
224010|NCT02479334|Other|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
224011|NCT02479321|Other|PGDT based on noninvasive monitoring|"Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based PGDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.~In the intra and postoperative period (4 hours), hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. In case of instability a Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders."
224012|NCT02479321|Device|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index. We will also collect hourly diuresis and blood loss.
224013|NCT02479308|Drug|Moxifloxacin|Single administration
224014|NCT02479308|Drug|ALKS 5461|Daily administration for a total of 12 dosing days
224015|NCT02479308|Drug|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
224016|NCT02479295|Device|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
224017|NCT02479282|Procedure|natural cesarean section|
224018|NCT02479282|Procedure|traditional cesarean section|
224019|NCT02479269|Other|Aerobic exercise|Aerobic exercise for 8 weeks
224020|NCT02479256|Drug|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
224021|NCT02479256|Drug|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
224022|NCT02479256|Drug|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
224023|NCT02479256|Drug|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
224024|NCT02479230|Biological|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
224025|NCT02479230|Drug|gemcitabine hydrochloride|Given IV
224026|NCT02479217|Drug|Docetaxel|
224027|NCT02479217|Drug|Xeloda|
224028|NCT02479204|Drug|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
224029|NCT02479204|Drug|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
224030|NCT02479204|Drug|Placebo|ACT-33441-matching placebo
224031|NCT02479204|Drug|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
224032|NCT02479204|Drug|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
224033|NCT02479191|Device|Ovation Abdominal Stent Graft Platform|
224034|NCT02479178|Drug|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
224035|NCT02479165|Drug|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
224036|NCT02479165|Drug|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
224037|NCT02479152|Device|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
224038|NCT02479139|Biological|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
224039|NCT02479139|Biological|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
224040|NCT02479113|Procedure|Blood sampling|At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
224041|NCT02479100|Diagnostic Test|Contrast Enhanced Spectral Mammogram|Undergo a Contrast Enhanced Spectral Mammogram in additional to standard of care
224042|NCT02479087|Drug|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of > 1: 4.5.~The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.~The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
224043|NCT02479074|Drug|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
224044|NCT02479074|Drug|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
224045|NCT02479074|Drug|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
224046|NCT02479048|Dietary Supplement|Test meal 1|High fat meal (HF) with ½ avocado (~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
224047|NCT02479048|Dietary Supplement|Test meal 2|High fat meal (HF) with 1 avocado (~136g) matched for energy but not macronutrient content or type.
224048|NCT02479048|Dietary Supplement|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
224049|NCT02479035|Dietary Supplement|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
224050|NCT02479035|Dietary Supplement|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
224051|NCT02479035|Dietary Supplement|Control meal|0 g red raspberry
224052|NCT02479022|Drug|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
224053|NCT02479022|Drug|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
224054|NCT02479022|Drug|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
224055|NCT02479009|Device|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
224056|NCT02478996|Other|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
224057|NCT02478983|Device|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
224058|NCT02478983|Device|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
224059|NCT02478970|Device|Konan SP4000|current standard of care at Kellogg Eye Center
224060|NCT02478970|Device|NIDEK CEM-350|newly marketed device
224061|NCT02478957|Drug|PA101|40 mg PA101 administered via inhalation three times daily for 6 weeks
224062|NCT02478957|Drug|Placebo|matching placebo administered via inhalation three times daily for 6 weeks
224063|NCT02478944|Device|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
224064|NCT02478918|Other|Phone call|Automated phone call reminder
224065|NCT02478905|Other|Influenza|
224066|NCT02478892|Device|prophylactic endoscopic ultrasound|The patients will be followed up clinically with routine, prophylactic endoscopic ultrasound surveillance every 12 months for a duration of 5 years.
224067|NCT02478879|Drug|ZP-PTH|Patch applied daily for 30 minutes, 14 days
224068|NCT02478879|Drug|FORTEO|Subcutaneous injection administration daily for 14 days
224069|NCT02478866|Drug|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
224070|NCT02478853|Other|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
224071|NCT02478840|Drug|Lamazym|recombinant human alpha-mannosidase
224072|NCT02478827|Behavioral|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
224073|NCT02478814|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
224074|NCT02478801|Dietary Supplement|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
224075|NCT02478788|Drug|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
224076|NCT02478788|Drug|Placebo|Pills with no medication in it
224077|NCT02478775|Drug|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
224078|NCT02478775|Drug|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
224079|NCT02478762|Procedure|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
224080|NCT02478762|Procedure|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
224081|NCT02478749|Procedure|arm retraction|gently pulling through the ipsilateral arm to the knee
224082|NCT02478736|Other|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
224083|NCT02478723|Device|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
224084|NCT02478710|Drug|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
224085|NCT02478710|Drug|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
224086|NCT02478697|Behavioral|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
224087|NCT02478684|Other|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
224088|NCT02478684|Other|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
224089|NCT02478671|Device|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
224090|NCT02478658|Other|exercise training|high-intensity resistance training
224091|NCT02478645|Drug|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
224092|NCT02478645|Drug|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
224093|NCT02478645|Drug|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
224094|NCT02478632|Drug|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
224095|NCT02478619|Other|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.~They will also receive the routine physical therapy in the post operative period."
224096|NCT02478619|Other|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
224097|NCT02478606|Other|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
224098|NCT02478593|Behavioral|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
224101|NCT02478567|Other|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
224102|NCT02478567|Other|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
224103|NCT02478554|Other|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
224104|NCT02478541|Other|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
224105|NCT02478528|Device|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
224106|NCT02478528|Device|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
224107|NCT02478528|Other|control condition|No exposure of the subject to any light sources (control condition)
224108|NCT02478515|Drug|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
224109|NCT02478502|Drug|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
224110|NCT02478489|Drug|Oral naltrexone (PO-NTX)|oral naltrexone
224111|NCT02478489|Drug|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
224112|NCT02478463|Drug|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
224113|NCT02478463|Drug|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL [600 mg] total) IM given once on Day 1 of injection phase
224114|NCT02478450|Biological|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
224115|NCT02478437|Procedure|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
224116|NCT02478437|Procedure|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
224117|NCT02478424|Drug|Cannabidiol|"Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.~Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100."
224118|NCT02478424|Drug|cyclosporine|
224119|NCT02478424|Drug|Methotrexate|
224120|NCT02478411|Procedure|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
224121|NCT02478411|Procedure|Conventional physiotherapy|30 minutes of conventional physiotherapy
224122|NCT02478398|Biological|Short ragweed pollen allergen extract|One sublingual tablet containing 12 units of Amb a 1-U, once daily (QD) for up to 35 weeks.
224123|NCT02478398|Biological|Placebo|One placebo sublingual tablet, QD for up to 35 weeks.
224124|NCT02478398|Drug|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for severe allergic reactions. Epinephrine was only provided in countries/study sites where it was a regulatory requirement.
224125|NCT02478398|Drug|Albuterol/Salbutamol|Inhalation of albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed as asthma rescue medication for those participants with asthma
224126|NCT02478398|Drug|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rhinoconjunctivitis symptoms
224127|NCT02478398|Drug|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rhinoconjunctivitis symptoms
224128|NCT02478398|Drug|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rhinoconjunctivitis symptoms
224129|NCT02478385|Other|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
224130|NCT02478372|Drug|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
224131|NCT02478372|Drug|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
224132|NCT02478359|Behavioral|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention includes a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
224133|NCT02478346|Drug|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
224134|NCT02478333|Drug|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
226604|NCT02461160|Drug|TAK-915 suspension|TAK-915 oral suspension
224135|NCT02478333|Drug|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
224136|NCT02478333|Drug|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
224137|NCT02478333|Other|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
224138|NCT02478320|Drug|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
224139|NCT02478307|Other|Cognitive Therapy|
224140|NCT02478307|Other|Mindfulness Meditation|
224141|NCT02478307|Other|Mindfulness-Based Cognitive Therapy|
224142|NCT02478294|Procedure|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
224143|NCT02478294|Drug|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
224144|NCT02478281|Drug|Methylene Blue|
224145|NCT02478268|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
224146|NCT02478268|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
224147|NCT02478255|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
224148|NCT02478255|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
224149|NCT02478242|Drug|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
224150|NCT02478242|Drug|Normal saline|
224151|NCT02478229|Drug|Sofosbuvir (SOF) and Ledipasvir (LDV)|
224152|NCT02478216|Procedure|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
224153|NCT02478203|Device|Airtraq|videolaryngoscope for difficult airway
224154|NCT02478203|Device|Glidescope|videolaryngoscope for difficult airway
224155|NCT02478203|Device|direct laryngoscopy|gold standart for intubation
224156|NCT02478190|Other|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
224157|NCT02478190|Other|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
224158|NCT02478164|Drug|Ponatinib|
224159|NCT02478151|Device|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
224160|NCT02478138|Procedure|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
224161|NCT02478138|Drug|Indocyanine Green (ICG)|
224162|NCT02478138|Device|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
224163|NCT02478125|Drug|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
224164|NCT02478125|Drug|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
224165|NCT02478125|Drug|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
224166|NCT02478112|Device|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
224167|NCT02478099|Drug|MPDL3280A|Anti-PD-L1 antibody
224168|NCT02478086|Dietary Supplement|use amine acids parenteral 3.5g|"Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
224169|NCT02478086|Dietary Supplement|use amine acids parenteral 4g|"Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.~The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
224170|NCT02478060|Biological|Birch-SPIRE|
224171|NCT02478060|Biological|Placebo|
224172|NCT02478047|Drug|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
224173|NCT02478047|Other|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
224174|NCT02478047|Other|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
224175|NCT02478047|Other|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
224176|NCT02478034|Other|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
224177|NCT02478021|Other|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
224178|NCT02478008|Device|CardiAQ TMVI System (Transapical DS)|
224179|NCT02477995|Biological|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
224180|NCT02477995|Biological|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
224181|NCT02477969|Drug|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
224182|NCT02477969|Drug|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
224183|NCT02477969|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
224184|NCT02477969|Drug|Metformin|0.5mg,oral,tid.
224185|NCT02477956|Dietary Supplement|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
224186|NCT02477956|Dietary Supplement|vitamin D|
224187|NCT02477943|Device|BrainScope Ahead 200iD|The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and a balance/sway measurement. BrainScope Ahead 200iD device will be used to perform EEG.
224188|NCT02477943|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
224189|NCT02477930|Other|No interventions are done|No intervention is done. This is a registry study.
224190|NCT02477917|Biological|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
224191|NCT02477904|Other|Ketogenic Diet|Dietary
224192|NCT02477891|Drug|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
224193|NCT02477878|Biological|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
224194|NCT02477878|Drug|AP1903|AP1903 administered to treat GVHD
224195|NCT02477865|Drug|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
224196|NCT02477865|Drug|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
224197|NCT02477865|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
224198|NCT02477852|Drug|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
224199|NCT02477852|Drug|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
224200|NCT02477852|Drug|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
224201|NCT02477852|Drug|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
224202|NCT02477839|Drug|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
224203|NCT02477839|Other|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
224204|NCT02477826|Drug|Nivolumab|
224205|NCT02477826|Drug|Ipilimumab|
224206|NCT02477826|Drug|Carboplatin|
224207|NCT02477826|Drug|Cisplatin|
224208|NCT02477826|Drug|Gemcitabine|
224209|NCT02477826|Drug|Pemetrexed|
224210|NCT02477826|Drug|Paclitaxel|
224211|NCT02477813|Drug|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
224212|NCT02477800|Drug|Aducanumab (BIIB037)|Low dose
224213|NCT02477800|Drug|Aducanumab (BIIB037)|High dose
224214|NCT02477800|Drug|Placebo|Placebo
224302|NCT02477124|Device|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
226605|NCT02461160|Drug|Midazolam|Midazolam oral solution
224215|NCT02477787|Biological|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
224216|NCT02477774|Device|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
224217|NCT02477761|Dietary Supplement|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
224218|NCT02477748|Drug|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
224219|NCT02477748|Drug|Placebo|Tablet PO, taken once daily for 10 weeks.
224220|NCT02477735|Device|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
224221|NCT02477722|Other|EFP-NF|
224222|NCT02477722|Other|Sham|
224223|NCT02477709|Drug|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
224224|NCT02477696|Drug|ACP-196|
224225|NCT02477696|Drug|ibrutinib|
224226|NCT02477670|Drug|AVP-786|
224227|NCT02477670|Drug|Placebo|
224228|NCT02477657|Procedure|Paracentesis|Paracentesis
224229|NCT02477657|Device|Tunneled Intraperitoneal Drain (IPD)|Tunneled Intraperitoneal Drain (IPD)
224230|NCT02477657|Device|Peritoneal-Venous shunts (PVS)|Peritoneal-Venous shunts (PVS)
224231|NCT02477644|Drug|Olaparib|Tablets, per os, 300 mg twice daily;
224232|NCT02477644|Drug|Placebo|Tablets, per os, 300 mg twice daily.
224233|NCT02477631|Drug|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
224234|NCT02477618|Drug|SAGE-547|
224235|NCT02477618|Drug|Placebo|Placebo
224236|NCT02477605|Device|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
224237|NCT02477605|Device|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
224238|NCT02477605|Procedure|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
224239|NCT02477592|Procedure|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
224240|NCT02477592|Procedure|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
224241|NCT02477579|Device|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
224242|NCT02477566|Drug|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
224243|NCT02477566|Drug|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
224244|NCT02477553|Behavioral|DA - Quantitative|
224245|NCT02477553|Behavioral|DA - Verbal|
224246|NCT02477540|Drug|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip~Main ingredient: Autologous bone marrow-derived mesenchymal stem cells~Dosage: 50,000,000 cells/10ml, 2-time injection~Storage: An airtight container, 20~25℃~Injection Method: Intramuscular"
224247|NCT02477527|Drug|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
224248|NCT02477514|Drug|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
224249|NCT02477514|Drug|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
224250|NCT02477514|Drug|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
224251|NCT02477501|Drug|Norepinephrine|continuous infusion
224252|NCT02477501|Drug|Ephedrine|continuous infusion
224253|NCT02477488|Drug|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
224254|NCT02477462|Other|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
224255|NCT02477462|Other|Baseline visit|Blood draw and quality of life surveys
224256|NCT02477449|Drug|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
224257|NCT02477449|Drug|9% Saline (NS)|infusion for 24 hours
224258|NCT02477436|Drug|Avanafil|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.~Investigational products were administered prior to the sexual intercourse for total 8 weeks."
224259|NCT02477436|Drug|Placebo|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.~Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.~Placebos were administered prior to the sexual intercourse for total 8 weeks."
224448|NCT02476110|Dietary Supplement|Oral nutritive supplements|
224260|NCT02477423|Drug|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
224261|NCT02477423|Drug|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
224262|NCT02477423|Drug|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
224263|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
224264|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
224265|NCT02477410|Dietary Supplement|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
224266|NCT02477397|Drug|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
224267|NCT02477397|Drug|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
224268|NCT02477384|Procedure|8mm-TIPS|
224269|NCT02477384|Procedure|Endoscopic variceal ligation|
224270|NCT02477384|Drug|Propranolol|
224271|NCT02477384|Device|8mm ePTFE-covered stent|
224272|NCT02477371|Procedure|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values > 0,8 are deferred.
224273|NCT02477371|Procedure|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
224274|NCT02477358|Procedure|Platelet Rich Fibrin endodontic revascularization therapy|An in vivo model utilizing mature teeth previously treatment planned for extraction, treating in accordance to the procedure documented by Johns et al. (2013), reimplanting teeth and following for three to four months before extracting and performing histological analysis.
224275|NCT02477358|Biological|Platelet Rich Fibrin|Biological from patients own blood. No additives.
224276|NCT02477345|Drug|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to~1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
224277|NCT02477332|Biological|QGE031|
224278|NCT02477332|Biological|Omalizumab|
224279|NCT02477332|Other|Placebo|
224280|NCT02477319|Other|Observational|
224281|NCT02477306|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
224282|NCT02477306|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
224283|NCT02477293|Drug|Hyeonggaeyeongyo-tang|
224284|NCT02477280|Drug|Methylphenidate|Cross-over
224285|NCT02477280|Drug|Placebo|Medikinet
224286|NCT02477267|Drug|SL spray|
224287|NCT02477267|Drug|SL film|
224288|NCT02477254|Biological|Vaccination|A quadrivalent HPV vaccine
224289|NCT02477241|Procedure|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
224290|NCT02477241|Device|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
224291|NCT02477228|Procedure|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
224292|NCT02477228|Procedure|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
224293|NCT02477215|Drug|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
224294|NCT02477215|Drug|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
224295|NCT02477215|Drug|Bendamustine|80mg/m2 days 1,2
224296|NCT02477202|Device|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
224297|NCT02477189|Procedure|Silicone Block|
224298|NCT02477176|Other|Discectomy|Lumbar discectomy
224299|NCT02477150|Biological|Zostavax|Vaccination of a zoster vaccine (Zostavax)
224300|NCT02477150|Biological|placebo|placebo administration
224301|NCT02477137|Device|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
224303|NCT02477124|Other|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
224304|NCT02477111|Device|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
224305|NCT02477098|Drug|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
224306|NCT02477098|Drug|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
224307|NCT02477085|Other|all women with an induced labor|all women who have an induced labor
224308|NCT02477072|Procedure|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
224309|NCT02477072|Procedure|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
224310|NCT02477072|Procedure|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
224311|NCT02477072|Procedure|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
224312|NCT02477072|Drug|Heparin|Heparin doses will be administered according to the assigned group.
224313|NCT02477059|Drug|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
224314|NCT02477059|Drug|saline solution|La saline solution is administered by intravenous infusion.
224315|NCT02477046|Biological|tOPV|administered per protocol
224316|NCT02477046|Biological|bOPV|administered per protocol
224317|NCT02477046|Biological|IPV|administered per protocol
224318|NCT02477033|Dietary Supplement|Butyricicoccus pullicaecorum 25-3T|
224319|NCT02477033|Other|Maltodextrin|
224320|NCT02477020|Drug|TAK-063 20 mg|TAK-063 tablet.
224321|NCT02477020|Drug|Placebo|TAK-063 matching-placebo tablet.
224322|NCT02477007|Drug|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g).
224323|NCT02477007|Drug|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
224324|NCT02477007|Drug|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
224325|NCT02477007|Drug|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
224326|NCT02476994|Drug|Clinolipid|
224327|NCT02476994|Drug|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion
224328|NCT02476981|Drug|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
224329|NCT02476981|Drug|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
224330|NCT02476981|Drug|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
224331|NCT02476981|Drug|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
224332|NCT02476981|Drug|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
224333|NCT02476968|Drug|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
224334|NCT02476955|Drug|ARQ 092 + carboplatin + paclitaxel (Closed)|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
224335|NCT02476955|Drug|ARQ 092 + paclitaxel (Closed)|ARQ 092 will be administered orally at 200 mg twice a day (BID) weekly (Cohort 1P) of a 28-day cycle in combination with an intravenous (IV) infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
224336|NCT02476955|Drug|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 150 mg QD, 5 days on/9 days of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
224337|NCT02476942|Drug|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
224338|NCT02476942|Drug|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
224339|NCT02476929|Device|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
224483|NCT02475915|Drug|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
224340|NCT02476929|Device|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
224341|NCT02476916|Drug|AG-348|See arm for intervention description.
224342|NCT02476903|Drug|Monovisc|
224343|NCT02476890|Drug|Gefapixant 100 mg|Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2
224344|NCT02476890|Drug|Placebo|Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2
224345|NCT02476864|Drug|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
224346|NCT02476864|Drug|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
224347|NCT02476851|Device|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
224348|NCT02476851|Device|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
224349|NCT02476838|Procedure|Hand Transplantation|microvascular VCA transplant
224350|NCT02476825|Drug|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
224351|NCT02476825|Device|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
224352|NCT02476812|Behavioral|Positive Piggy Bank|Already noted.
224353|NCT02476799|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
224354|NCT02476799|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
224355|NCT02476799|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
224356|NCT02476799|Drug|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
224357|NCT02476786|Behavioral|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
224358|NCT02476786|Drug|Goserelin|
224359|NCT02476786|Drug|Anastrozole|
224360|NCT02476786|Drug|Exemestane|
224361|NCT02476786|Drug|Fulvestrant|
224362|NCT02476786|Drug|Tamoxifen|
224363|NCT02476786|Other|Archived tissue collection|
224364|NCT02476773|Biological|Na-GST-1/Alhydrogel plus GLA-AF|
224365|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel|
224366|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
224367|NCT02476773|Biological|Sterile Saline Placebo|
224368|NCT02476760|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224369|NCT02476760|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
224370|NCT02476760|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
224371|NCT02476760|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224372|NCT02476760|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224373|NCT02476760|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224374|NCT02476760|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
224375|NCT02476760|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
224376|NCT02476747|Other|EMR|performing EMR for patients with small polyp
224377|NCT02476747|Other|CSP|performing CSP for patients with small polyp
224378|NCT02476734|Biological|CART-19 autologous T-cells|
224379|NCT02476734|Radiation|FDG-PET/CT|
224380|NCT02476721|Other|detection of pulmonary embolism|
224381|NCT02476708|Dietary Supplement|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
224382|NCT02476708|Dietary Supplement|Placebo|oral placebo capsule
224383|NCT02476695|Device|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
224384|NCT02476695|Device|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
224385|NCT02476695|Device|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
224386|NCT02476682|Other|blood or stool samples will be collected|blood or stool samples will be collected
224387|NCT02476643|Other|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
224388|NCT02476630|Device|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
224389|NCT02476630|Other|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
224390|NCT02476617|Drug|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
224391|NCT02476617|Drug|dasabuvir|dasabuvir tablets
224392|NCT02476617|Drug|ribavirin|ribavirin tablets
224393|NCT02476604|Behavioral|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
224394|NCT02476591|Behavioral|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
224395|NCT02476578|Other|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
224396|NCT02476565|Device|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
224397|NCT02476565|Device|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
224398|NCT02476552|Drug|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
224399|NCT02476552|Drug|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of [14C]-niraparib)
224400|NCT02476552|Drug|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
224401|NCT02476539|Drug|Hemay022|
224402|NCT02476526|Drug|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
224403|NCT02476526|Drug|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
224404|NCT02476526|Drug|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
224405|NCT02476526|Procedure|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
224406|NCT02476500|Procedure|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
224407|NCT02476487|Procedure|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.~2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
224408|NCT02476474|Procedure|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
224409|NCT02476474|Procedure|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
224410|NCT02476461|Drug|xiapex|
224411|NCT02476461|Procedure|percutaneous needle fasciotomy|
224412|NCT02476448|Drug|Normal saline|Used to distend the bladder for cystoscopic evaluation
224413|NCT02476448|Drug|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
224414|NCT02476448|Drug|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
224415|NCT02476448|Drug|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
224416|NCT02476435|Device|Active rTMS|Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
224417|NCT02476435|Device|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
224418|NCT02476422|Drug|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
224419|NCT02476422|Drug|Ibuprofen|Single dose of ibuprofen 400 mg tablet
224420|NCT02476422|Drug|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
224421|NCT02476422|Drug|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
224422|NCT02476409|Drug|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
224423|NCT02476409|Other|Placebo|Placebo for tolvaptan
224449|NCT02476097|Drug|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
224450|NCT02476097|Other|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
224424|NCT02476396|Procedure|Carotid Endarterectomy|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).~This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.~In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).~Source: Mayo Clinic"
224425|NCT02476383|Procedure|spinal manipulative therapy|refer to arm descriptions
224426|NCT02476370|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises~1 week programm, one introductory session and daily home practice"
224427|NCT02476370|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery~1 single unit in the week before the surgery"
224428|NCT02476357|Device|Harmonic scalpel|
224429|NCT02476344|Other|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:~sack carrying exercise.~crawling exercise.~combined exercise: sack carrying, crawling and sprints.~heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
224430|NCT02476331|Behavioral|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
224431|NCT02476318|Device|ArterX Vascular Sealant|
224432|NCT02476305|Device|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
224433|NCT02476292|Other|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
224434|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
224435|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
224436|NCT02476266|Other|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
224437|NCT02476253|Drug|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
224438|NCT02476240|Behavioral|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
224439|NCT02476227|Procedure|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
224440|NCT02476214|Behavioral|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.~There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
224441|NCT02476201|Device|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
224442|NCT02476188|Procedure|Sample of Blood|
224443|NCT02476175|Drug|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
224444|NCT02476162|Device|iHealth Wireless Blood Pressure Monitor|"Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.~Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening."
224445|NCT02476149|Procedure|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
224446|NCT02476136|Drug|paroxetine, duloxetine, fluoxetine or venlafaxine|
224447|NCT02476123|Biological|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
224451|NCT02476097|Drug|Placebo|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
224452|NCT02476084|Other|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
224453|NCT02476084|Other|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
224454|NCT02476084|Other|Biological samples collection|Draw of research blood samples.
224455|NCT02476084|Other|Questionnaires|Administration of validated patients' questionnaires.
224456|NCT02476071|Other|Mass media|Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
224457|NCT02476071|Other|Stylish Man (SMEvent)|"Stylish Man Events: community mobilization via music, contests, testimonials from satisfied VMC adopters. Messages on how VMC, in conjunction with other HIV prevention, can make men feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages."
224458|NCT02476058|Drug|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
224459|NCT02476058|Drug|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
224460|NCT02476058|Drug|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
224461|NCT02476045|Drug|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
224462|NCT02476045|Drug|panitumumab|Maintenance treatment (ARM B)
224463|NCT02476045|Drug|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
224464|NCT02476032|Device|Prof applied oxalate|Crest Sensi-Stop strips (Procter & Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
224465|NCT02476032|Device|Self applied oxalate|Subjects will apply the strips (Procter & Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
224466|NCT02476032|Device|Prof applied placebo|Crest Sensi-Stop strips (Procter & Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
224467|NCT02476019|Drug|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
224468|NCT02476019|Drug|Placebo|Placebo administered subcutaneously
224469|NCT02476006|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
224470|NCT02476006|Drug|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
224471|NCT02475993|Other|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
224472|NCT02475980|Behavioral|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
224473|NCT02475967|Other|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
224474|NCT02475967|Other|Control group|The control group patients receive conventional cardiac care alone.
224475|NCT02475954|Behavioral|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via V2H.
224476|NCT02475954|Other|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable ADMs, established psychotherapy, clinical monitoring).
224477|NCT02475941|Other|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
224478|NCT02475941|Other|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).~The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
224479|NCT02475928|Dietary Supplement|zinc gluconate|Zinc supplementation plus nutritional education
224480|NCT02475928|Dietary Supplement|Placebo|
224481|NCT02475928|Behavioral|Nutritional education|
224482|NCT02475915|Drug|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
224484|NCT02475915|Drug|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
224485|NCT02475915|Drug|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
224486|NCT02475915|Drug|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
224487|NCT02475915|Drug|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
224488|NCT02475915|Drug|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
224489|NCT02475902|Behavioral|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
224490|NCT02475902|Behavioral|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
224491|NCT02475889|Procedure|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
224492|NCT02475889|Procedure|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
224493|NCT02475876|Drug|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:~Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;~Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose =12 mg/kg;~Cohort 3; No. Subjects = 5; Age >1-2 years; Dose =12 mg/kg.~Cohort 4; No. Subjects = 4; Age >2-6 years; Dose =12 mg/kg.~Cohort 5; No. Subjects = 4; Age >6-12 years; Dose =10 mg/kg.~Cohort 6; No. Subjects = 4; Age >12-16 years; Dose =10 mg/kg."
224494|NCT02475876|Drug|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:~Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.~Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose = 6 mg/kg.~Cohort 3; No. Subjects = 5; Age >1-2 years; Dose = 6 mg/kg.~Cohort 4; No. Subjects = 4; Age >2-6 years; Dose = 6 mg/kg.~Cohort 5; No. Subjects = 4; Age >6-12 years; Dose = 6 mg/kg.~Cohort 6; No. Subjects = 4; Age >12-16 years; Dose = 4 mg/kg."
224495|NCT02475863|Device|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
224496|NCT02475863|Other|Standard Practice|Warfarin dose adjustments according to standard unit protocol
224497|NCT02475850|Other|Evidence-based tailored fall prevention|
224498|NCT02475850|Other|Usual care|
224499|NCT02475837|Drug|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
224500|NCT02475837|Drug|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
224501|NCT02475824|Drug|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
224502|NCT02475824|Drug|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
224503|NCT02475824|Drug|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
224504|NCT02475824|Drug|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
224505|NCT02475811|Radiation|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
224506|NCT02475798|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
224507|NCT02475785|Device|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
224508|NCT02475785|Device|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
224509|NCT02475772|Drug|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
224510|NCT02475772|Procedure|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
224511|NCT02475759|Dietary Supplement|optimal caloric formula|nutritional intervention received two weeks before surgical intervention
224512|NCT02475759|Dietary Supplement|sub-optimal caloric formula|nutritional intervention received one weeks before surgical intervention
224513|NCT02475746|Drug|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
224514|NCT02475746|Drug|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
224515|NCT02475733|Drug|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
224516|NCT02475733|Drug|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
224517|NCT02475733|Drug|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
224559|NCT02475395|Device|TRAK device|Use of TRAK to attain sperm concentration measurement
224560|NCT02475382|Drug|Nivolumab|Specified dose on specified days
224561|NCT02475369|Drug|pancrelipase|
224562|NCT02475356|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|The treatment of Mirena should comply with the local product information.
225859|NCT02466256|Device|Autosert Injector|Motorised injection device for intraocular lens implantation
224518|NCT02475707|Biological|MultiTAA-specific T cells|"The 3 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
224519|NCT02475694|Other|No intervention|No treatment
224520|NCT02475681|Drug|Acalabrutinib|
224521|NCT02475681|Drug|Obinutuzumab|
224522|NCT02475681|Drug|Chlorambucil|
224523|NCT02475668|Device|Pulse oximeter|Hypoxia
224524|NCT02475655|Drug|Ruxolitinib|10 mg orally twice daily for 5 weeks
224525|NCT02475642|Other|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
224526|NCT02475642|Other|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
224527|NCT02475629|Biological|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
224528|NCT02475629|Drug|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
224529|NCT02475616|Drug|PCO371|
224530|NCT02475616|Drug|Placebo|
224531|NCT02475603|Procedure|Total knee arthroplasty|Total knee arthroplasty
224532|NCT02475590|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
224533|NCT02475590|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
224534|NCT02475577|Device|Peripherals with HealthInterlink technology|home remote monitoring
224535|NCT02475564|Drug|Placebo|40mg of starch
224536|NCT02475564|Drug|Resveratrol|40mg of resveratrol (powder)
224537|NCT02475551|Drug|IdeS|Intravenous infusion
224538|NCT02475538|Device|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.~Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
224539|NCT02475538|Device|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.~Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
224540|NCT02475525|Dietary Supplement|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
224541|NCT02475512|Other|Wash wipes (3M)|
224542|NCT02475512|Other|water and pH neutral soap|
224543|NCT02475499|Drug|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
224544|NCT02475499|Drug|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
224545|NCT02475499|Drug|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
224546|NCT02475499|Drug|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
224547|NCT02475499|Drug|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
224548|NCT02475499|Drug|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
224549|NCT02475499|Drug|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
224550|NCT02475486|Device|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
224551|NCT02475473|Other|Exercise Training|Chronic High-Intensity Resistance Training
224552|NCT02475460|Procedure|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
224553|NCT02475460|Device|HeartMate 3™|HM 3 LIS
224554|NCT02475447|Drug|Asimadoline|kappa-opioid receptor agonist
224555|NCT02475447|Drug|Placebo|placebo-matched control
224556|NCT02475434|Dietary Supplement|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
224557|NCT02475421|Biological|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
224558|NCT02475408|Device|Amplatzer vascular plug|
224659|NCT02474654|Drug|Normal Saline|30ml
224563|NCT02475343|Device|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
224564|NCT02475343|Device|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
224565|NCT02475343|Device|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
224566|NCT02475343|Device|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
224567|NCT02475343|Device|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
224568|NCT02475343|Device|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
224569|NCT02475330|Dietary Supplement|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
224570|NCT02475317|Drug|Placebo|Participants will receive placebo matched to maralixibat/volixibat orally for 7 days.
224571|NCT02475317|Drug|Maralixibat|Participants will receive maralixibat in 10 mg, 20 mg, 50 mg or 100 mg doses.
224572|NCT02475317|Drug|Volixibat|Participants will receive volixibat in 10 mg and 20 mg doses.
224573|NCT02475304|Drug|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
224574|NCT02475304|Drug|Placebo|
224575|NCT02475278|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
224576|NCT02475265|Drug|estradiol 0.045 mg/levonorgestrel 0.015mg|
224577|NCT02475252|Procedure|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
224578|NCT02475239|Behavioral|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
224579|NCT02475239|Behavioral|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
224580|NCT02475226|Other|type of the brain injury|epidural hematoma
224581|NCT02475226|Other|type of the brain injury|subdural hematoma
224582|NCT02475226|Other|type of the brain injury|subarachnoid hematoma
224583|NCT02475226|Other|type of the brain injury|intraparenchymal hematoma
224584|NCT02475226|Other|type of the brain injury|scull fracture
224585|NCT02475226|Other|type of the brain injury|brain contusion
224586|NCT02475213|Biological|Enoblituzumab|enoblituzumab is administered by IV infusion once per week for up to 51 doses.
224587|NCT02475213|Biological|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
224588|NCT02475213|Biological|MGA012|anti-PD-1 monoclonal antibody
224589|NCT02475200|Device|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
224590|NCT02475174|Other|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
224591|NCT02475174|Other|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
224592|NCT02475161|Drug|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
224593|NCT02475161|Drug|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
224594|NCT02475148|Drug|JNJ 54175446|
224595|NCT02475148|Drug|Placebo|
224596|NCT02475148|Other|High fat/high Calorie Breakfast|
224597|NCT02475135|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
224598|NCT02475135|Drug|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
224599|NCT02475135|Drug|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
224600|NCT02475135|Drug|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
224601|NCT02475135|Drug|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
224602|NCT02475135|Other|High-fat Breakfast|High-fat breakfast will be administered.
224603|NCT02475135|Other|Standardized Regular Breakfast|Standardized regular breakfast will administered.
224604|NCT02475122|Other|azygos blood flow measurements by MRI|
224605|NCT02475109|Drug|PAN-90806 Ophthalmic Solution|
224660|NCT02474654|Drug|Normal Saline|100 ml
224661|NCT02474654|Drug|Ropivicaine|100 ml
224662|NCT02474654|Drug|Epinephrine|600 mcg
224663|NCT02474654|Drug|Ketorolac|30 mg
224664|NCT02474654|Drug|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
224665|NCT02474641|Radiation|Standard Radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or~Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or~Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
224606|NCT02475096|Behavioral|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.~Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
224607|NCT02475083|Other|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
224608|NCT02475083|Other|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
224609|NCT02475070|Drug|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
224610|NCT02475070|Drug|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
224611|NCT02475057|Drug|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
224612|NCT02475057|Drug|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
224613|NCT02475057|Device|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
224614|NCT02475044|Behavioral|Cognitive-Behavioral Therapy|16 Sessions of CBT.
224615|NCT02475031|Device|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
224616|NCT02475031|Drug|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
224617|NCT02475018|Dietary Supplement|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
224618|NCT02475018|Dietary Supplement|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
224619|NCT02475005|Behavioral|pain self management app on smartphone|
224620|NCT02474992|Behavioral|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
224621|NCT02474979|Device|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
224622|NCT02474979|Other|Control|
224623|NCT02474966|Device|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
224624|NCT02474953|Dietary Supplement|Proprietary Curcumin Formulation|
224625|NCT02474953|Dietary Supplement|Unformulated Comparator Curcumin Product|
224626|NCT02474940|Behavioral|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
224627|NCT02474940|Behavioral|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
224666|NCT02474641|Radiation|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
224667|NCT02474628|Dietary Supplement|sodium bicarbonate|
224668|NCT02474628|Dietary Supplement|calcium carbonate|
224669|NCT02474615|Procedure|ENDODONTIC SURGERY|ENDODONTIC SURGERY
224707|NCT02474355|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
224708|NCT02474355|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
225890|NCT02466022|Drug|Fentanyl|Intrathecal Fentanyl 10ug
224628|NCT02474940|Behavioral|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
224629|NCT02474927|Drug|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
224630|NCT02474914|Drug|Octreotide|Octreotide will be given after PD
224631|NCT02474914|Drug|Placebo|Octreotide will NOT be given after PD
224632|NCT02474901|Biological|Quadrivalent Live Attenuated Influenza Vaccine|
224633|NCT02474888|Other|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
224634|NCT02474875|Other|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
224635|NCT02474862|Behavioral|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
224636|NCT02474862|Behavioral|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
224637|NCT02474849|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
224638|NCT02474836|Biological|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
224639|NCT02474836|Biological|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
224640|NCT02474836|Biological|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
224641|NCT02474823|Other|polysomnogram|all participants will undergo PSG for assessment of OSA
224642|NCT02474823|Other|home sleep test|all participants will undergo HST for assessment of OSA
224643|NCT02474823|Other|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
224644|NCT02474810|Drug|Alteplase|Alteplase for CVC dysfunction.
224645|NCT02474797|Device|Diaphragmatic ultrasonography|"Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.~Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = [(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100]. Diaphragmatic dysfunction is defined like a DTF < 20% (7)."
224646|NCT02474745|Procedure|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
224647|NCT02474745|Procedure|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:~After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible~Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:~After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
224648|NCT02474732|Device|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
224649|NCT02474719|Other|comparison of two regimens in peritoneal dialysis|Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
224650|NCT02474706|Drug|Cefoxitin|
224651|NCT02474706|Drug|imipenem|
224652|NCT02474680|Genetic|Pharmacogenetic testing|Psychotropic genotyping panel
224653|NCT02474667|Drug|BB3|
224654|NCT02474667|Other|Placebo|
224655|NCT02474654|Drug|Bupivicaine|15mg
224656|NCT02474654|Drug|Fentanyl|15mcg
224657|NCT02474654|Drug|Epimorphine|150mcg
224658|NCT02474654|Drug|Normal Saline|0.3 ml
224670|NCT02474602|Device|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
224671|NCT02474589|Drug|tecovirimat|Study is based on Animal Regulatory Rule
224672|NCT02474589|Other|Placebo|Does not apply
224673|NCT02474576|Procedure|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
224674|NCT02474563|Drug|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
224675|NCT02474563|Drug|Melphalan|Participants receiving Melphalan 9 mg/m^2 will be observed in this study.
224676|NCT02474563|Drug|Prednisone|Participants receiving Prednisone 60 mg/m^2 will be observed in this study.
224677|NCT02474537|Drug|INC280|Single 200 mg dose INC280
224678|NCT02474524|Behavioral|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
224679|NCT02474524|Behavioral|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
224680|NCT02474511|Other|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
224681|NCT02474498|Drug|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
224682|NCT02474498|Device|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
224683|NCT02474498|Procedure|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
224684|NCT02474485|Device|BVS Absorb implantation.|Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
224685|NCT02474485|Device|DEB Sequent Please inflation.|Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
224686|NCT02474485|Procedure|Control coronary angiography.|Control coronary angiography will be performed at 9 month follow-up.
224687|NCT02474485|Procedure|OCT visualization.|OCT visualization will be performed during index procedure and at 9 month follow-up.
224688|NCT02474485|Other|Clinical observation.|Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
224689|NCT02474459|Device|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
224690|NCT02474459|Other|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
224691|NCT02474446|Dietary Supplement|Vitamin D|150,000 IU of Vitamin D3 Oral solution
224692|NCT02474433|Drug|Misoprostol (Cytotec)|
224693|NCT02474420|Drug|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
224694|NCT02474420|Drug|Deferasirox|Deferasirox administered per standard of care by the treating physician
224695|NCT02474407|Drug|diazepam nasal spray|
224696|NCT02474407|Drug|diazepam rectal gel|
224697|NCT02474394|Device|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
224698|NCT02474394|Device|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
224699|NCT02474381|Biological|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
224700|NCT02474381|Device|Single PTA|Angioplasty of arteries below tibial plateau level only
224701|NCT02474368|Radiation|Intensity Modulated Radiation Therapy (IMRT)|
224702|NCT02474368|Drug|Cisplatin|
224703|NCT02474368|Radiation|Stereotactic Body Radiotherapy (SBRT)|
224704|NCT02474355|Procedure|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
224705|NCT02474355|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
224706|NCT02474355|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
225891|NCT02466022|Drug|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
224709|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~Low dose: 1x10e7 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
224710|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~Mid dose: 5x10e7 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
224711|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs~Injection dosage and volume of the study drugs:~High dose: 1x10e8 cells/3mL~Number of injections : only once during the study period~Device: Ultrasound~Injection technique: Injection into the lesion by investigator"
224712|NCT02474329|Other|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.ors) for every included patient. This assessment will last for 60 minutes, and it will be done once.
224713|NCT02474329|Device|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
224714|NCT02474316|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
224715|NCT02474316|Drug|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
224716|NCT02474303|Drug|Truvada|Demonstration Study
224717|NCT02474290|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
224718|NCT02474277|Other|30 sec chair stand test|diagnostic test for functional impairment
224719|NCT02474264|Other|Endothelial function assessment|reactive hyperemia index
224720|NCT02474264|Other|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
224721|NCT02474264|Other|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
224722|NCT02474251|Other|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
224723|NCT02474238|Device|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
224724|NCT02474238|Device|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
224725|NCT02474225|Drug|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
224726|NCT02474212|Drug|Enoxaparin|
224727|NCT02474199|Biological|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
224728|NCT02474199|Drug|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
224729|NCT02474199|Drug|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
224730|NCT02474199|Drug|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI‐based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
224731|NCT02474199|Procedure|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
224732|NCT02474186|Radiation|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
224733|NCT02474186|Drug|Xeloda|chemotherapy agent daily for two weeks
224734|NCT02474186|Drug|paclitaxel|chemotherapy agent weekly for two weeks
224735|NCT02474173|Other|Laboratory Biomarker Analysis|Correlative studies
224736|NCT02474173|Drug|Onalespib|Given IV
224737|NCT02474173|Drug|Onalespib Lactate|Given IV
224738|NCT02474173|Drug|Paclitaxel|Given IV
224739|NCT02474173|Other|Pharmacological Study|Correlative studies
224740|NCT02474160|Other|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
224741|NCT02474147|Other|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
224742|NCT02474147|Other|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
224743|NCT02474134|Drug|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
224744|NCT02474121|Device|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
225015|NCT02472314|Drug|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
224745|NCT02474108|Procedure|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
224746|NCT02474108|Device|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
224747|NCT02474095|Other|Quality-of-Life Assessment|Ancillary studies
224748|NCT02474095|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
224749|NCT02474082|Biological|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
224750|NCT02474082|Drug|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
224751|NCT02474069|Drug|Secukinumab|
224752|NCT02474043|Behavioral|Hep-Net Intervention|The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
224753|NCT02474043|Behavioral|Usual Care|Clients receive health education and risk reduction counseling from a trained prevention specialist.
224754|NCT02474017|Drug|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
224755|NCT02474017|Device|CRC749 inhaler|
224756|NCT02474004|Procedure|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis & knee scores 6 mo after the procedures
224757|NCT02473991|Radiation|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
224758|NCT02473978|Device|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
224759|NCT02473965|Drug|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C~Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
224760|NCT02473965|Drug|Placebo|
224761|NCT02473952|Drug|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
224762|NCT02473952|Drug|Placebo|
224763|NCT02473939|Drug|VR942 delivered via a Vectura Dry Powder Inhaler|
224764|NCT02473939|Drug|Placebo delivered via a Vectura Dry Powder Inhaler|
224765|NCT02473926|Behavioral|Physical Activity|Physical Activity Program Intervention
224766|NCT02473926|Behavioral|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
224767|NCT02473913|Drug|Milk Thistle|
224768|NCT02473913|Drug|Placebo|
224769|NCT02473900|Drug|HIP1403|Oseltamivir 75mg
224770|NCT02473900|Drug|HGP0919|Oseltamivir phosphate 75mg
224771|NCT02473887|Drug|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
224772|NCT02473874|Device|Skin Spect dermoscope|Skin imaging
224773|NCT02473874|Device|Spatially modulated quantitative|Skin imaging
224774|NCT02473861|Other|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
224775|NCT02473848|Drug|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
224776|NCT02473835|Other|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
224777|NCT02473835|Other|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
224778|NCT02473835|Other|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
224779|NCT02473809|Drug|Liraglutide|Once daily
224780|NCT02473809|Drug|Placebo|Once daily
224781|NCT02473796|Other|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight <2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term & weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
225047|NCT02472132|Device|POC US|Use of point of care ultrasound in insertion of CVC
224782|NCT02473783|Drug|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
224783|NCT02473783|Other|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
224784|NCT02473744|Other|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
224785|NCT02473731|Biological|KTN3379|
224786|NCT02473718|Other|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
224787|NCT02473718|Device|Ultrasound|
224788|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
224789|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate Placebo|1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
224790|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate|Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
224791|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate Placebo|Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
224792|NCT02473692|Other|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~Introduction to the series~Getting to know migraine~Making the most of your medical care~Partnering with your doctor~Best use of migraine medication~Keeping tabs on your migraine~Take home message (summary)"
224793|NCT02473653|Biological|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
224794|NCT02473640|Drug|SYN-004|
224795|NCT02473640|Drug|Esomeprazole|
224796|NCT02473640|Drug|Ceftriaxone|
224797|NCT02473627|Drug|DS-1971a|200mg tablet
224798|NCT02473627|Drug|midazolam hydrochloride|2.5mg oromucosal liquid
224799|NCT02473627|Drug|Omeprazole|20mg gastro-resistant capsule
224800|NCT02473627|Drug|Pioglitazone hydrochloride|15mg tablet
224801|NCT02473627|Drug|Buproprion|150mg Prolonged release tablet
224802|NCT02473627|Drug|Tolbutamide|500mg tablet
224803|NCT02473614|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
224804|NCT02473614|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
224805|NCT02473601|Drug|Mivacurium Chloride|"Anesthesia induction:~Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.~Anesthesia maintenance:~Two groups of sevoflurance 1%~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 ~ 60. PetCO2 was 30 ~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
224806|NCT02473588|Device|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
224807|NCT02473575|Dietary Supplement|caffeine gum|Gum is consumed 30 minutes before commencement of run
224808|NCT02473575|Dietary Supplement|placebo gum|Gum is consumed 30 minutes before commencement of run
224809|NCT02473562|Drug|Varenicline|Tablet 1 mg BID
224810|NCT02473562|Drug|Placebo (for varenicline)|Tablet 1 mg BID
224811|NCT02473549|Device|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
224812|NCT02473549|Device|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
224813|NCT02473549|Device|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
224814|NCT02473549|Device|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
224815|NCT02473536|Radiation|Stereotactic ablative radiation therapy|SABR
224816|NCT02473523|Other|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
224817|NCT02473523|Other|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
224818|NCT02473523|Device|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
224847|NCT02473341|Drug|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks~+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
224819|NCT02473523|Device|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
224820|NCT02473523|Other|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
224821|NCT02473523|Other|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
224822|NCT02473523|Other|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
224823|NCT02473523|Other|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
224824|NCT02473510|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
224825|NCT02473510|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
224826|NCT02473497|Drug|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
224827|NCT02473471|Device|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
224828|NCT02473458|Drug|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~Starch-filled capsules (as placebo)~450 mg whole licorice extract capsules~900 mg whole licorice extract capsules"
224829|NCT02473458|Drug|Placebo|
224830|NCT02473445|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
224831|NCT02473432|Procedure|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
224832|NCT02473432|Procedure|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
224833|NCT02473432|Procedure|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
224834|NCT02473419|Drug|Vayarin|
224835|NCT02473419|Drug|Placebo|
224836|NCT02473406|Drug|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
224837|NCT02473406|Drug|normal saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
224838|NCT02473393|Drug|OPS-2071 tablet|
224839|NCT02473380|Device|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
224840|NCT02473367|Drug|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
224841|NCT02473367|Drug|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
224842|NCT02473367|Drug|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
224843|NCT02473354|Drug|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air [21% Oxygen]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
224844|NCT02473354|Drug|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
224845|NCT02473354|Drug|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
224846|NCT02473341|Drug|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.~+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
224848|NCT02473328|Drug|Atazanavir 200 mg/r|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),~switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.~The administration will be done once a day orally for 48 weeks.~The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
224849|NCT02473315|Other|cryotherapy|"The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).~The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks)."
224850|NCT02473302|Other|ham|160g per day during 4 days
224851|NCT02473302|Other|ham + pomegranate extract|160g per day during 4 days
224852|NCT02473302|Other|ham + tocopherol|160g per day during 4 days
224853|NCT02473302|Other|rare sirloin steak|110g per day during 4 days
224854|NCT02473302|Other|marinated rare sirloin steak|110g per day during 4 days
224855|NCT02473302|Other|marinated cooked sirloin steak|110g per day during 4 days
224856|NCT02473289|Drug|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
224857|NCT02473289|Drug|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
224858|NCT02473276|Drug|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
224859|NCT02473276|Drug|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
224860|NCT02473263|Drug|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
224861|NCT02473263|Drug|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
224862|NCT02473263|Drug|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
224863|NCT02473263|Drug|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
224864|NCT02473250|Drug|Fluoxetine|Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
224865|NCT02473250|Drug|Citalopram|Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
224866|NCT02473237|Drug|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
224867|NCT02473237|Drug|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
224868|NCT02473224|Biological|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10^2 GEC or 1.2 x10^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, or 1.2 x 10^6 GEC, or 1.2 GEC x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
224869|NCT02473224|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
224870|NCT02473211|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
224871|NCT02473211|Drug|Daclatasvir|Daclatasvir 60mg tablet administered once daily
224872|NCT02473198|Drug|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
224873|NCT02473198|Drug|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
224874|NCT02473198|Drug|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
224875|NCT02473198|Drug|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
224876|NCT02473185|Drug|Methylphenidate|Cross-over
224877|NCT02473172|Device|Pressure Support ventilation|Assisted mechanical ventilation
224878|NCT02473172|Device|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
224879|NCT02473159|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
224880|NCT02473146|Drug|Gemtuzumab ozogamicin (GO)|
224881|NCT02473133|Radiation|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
224882|NCT02473133|Radiation|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
224883|NCT02473120|Biological|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
225007|NCT02472392|Drug|Cyclophosphamide|comparitor
225008|NCT02472379|Behavioral|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
224884|NCT02473107|Other|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
224885|NCT02473107|Other|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
224886|NCT02473094|Drug|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
224887|NCT02473094|Drug|Metformin|Metformin up to 2500mg/d
224888|NCT02473094|Radiation|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
224889|NCT02473094|Drug|Placebo|Placebo up to 2500mg/d
224890|NCT02473081|Behavioral|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
224891|NCT02473081|Other|Usual care|Usual care was given by their family physicians.
224892|NCT02473068|Device|CPAP|
224893|NCT02473055|Other|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
224894|NCT02473042|Procedure|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
224895|NCT02473042|Drug|Zofran|4 mg by vein for 1 dose.
224896|NCT02473042|Drug|Dexamethasone|10 mg by vein for 1 dose.
224897|NCT02473042|Drug|Phenergan|6.25 mg by vein for 1 dose.
224898|NCT02473042|Drug|Pepcid|10 mg by vein for 1 dose.
224899|NCT02473042|Behavioral|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
224900|NCT02473029|Radiation|Vascular tomodensitometry|
224901|NCT02473029|Other|Magnetic resonance angiography|
224902|NCT02473029|Other|Vascular ultrasonography|
224903|NCT02473029|Other|Retinal angiography|
224904|NCT02473029|Other|Retinal optical coherence tomography|
224905|NCT02473016|Drug|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode [ipsilateral nostril].
224906|NCT02473003|Behavioral|high intensity exercise|high intensity exercise 80-90%
224907|NCT02473003|Behavioral|low/medium intensity exercise|low/medium intensity exercise 40-50%
224908|NCT02473003|Behavioral|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
224909|NCT02472990|Other|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
224910|NCT02472977|Drug|Ulocuplumab|
224911|NCT02472977|Drug|Nivolumab|
224912|NCT02472964|Biological|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
224913|NCT02472964|Biological|MYL- 1401O|MYL-1401O 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
224914|NCT02472964|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
224915|NCT02472964|Drug|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
224916|NCT02472951|Other|Low carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 30% Protein 30% Fat 40%"
224917|NCT02472951|Other|Standard carbohydrate meals|"Meal macronutritional energy composition:~Carbohydrate 55% Protein 15% Fat 30%"
224918|NCT02472938|Drug|dimethyl fumarate|dimethyl fumarate 120 mg capsules
224919|NCT02472938|Other|Placebo|Placebo for BG00012
224920|NCT02472925|Behavioral|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
224921|NCT02472912|Biological|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
224922|NCT02472912|Biological|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
224923|NCT02472912|Biological|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
224924|NCT02472899|Other|Blood sample|Non-interventional study based on blood samples taken at a single study visit
224925|NCT02472886|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
224926|NCT02472886|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
224927|NCT02472873|Procedure|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
224928|NCT02472873|Procedure|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
224929|NCT02472873|Drug|Ethanol|
224930|NCT02472860|Behavioral|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
224931|NCT02472860|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition
224932|NCT02472847|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
224933|NCT02472847|Drug|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
225009|NCT02472379|Other|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
225010|NCT02472366|Drug|ILUVIEN|
224934|NCT02472834|Dietary Supplement|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing ~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
224935|NCT02472821|Behavioral|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
224936|NCT02472821|Behavioral|Internet-based educational booster|Visit to an educational Web site focused on hearing health
224937|NCT02472808|Other|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
224938|NCT02472808|Other|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
224939|NCT02472808|Other|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
224940|NCT02472808|Other|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
224941|NCT02472795|Drug|Placebo|Placebo matching ACT-334441 capsules or Experimental doses
224942|NCT02472795|Drug|ACT-334441|Selective Sphingosine 1-phosphate (S1P) modulator
224943|NCT02472782|Drug|Teriparatide|The study will include patients from pre‐defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
224944|NCT02472769|Drug|IBP-9414|
224945|NCT02472769|Drug|Placebo|Sterile water
224946|NCT02472756|Drug|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
224947|NCT02472756|Drug|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
224948|NCT02472743|Device|Custom-built phototherapy lamp|Described in the arm description
224949|NCT02472730|Device|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
224950|NCT02472717|Drug|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
224951|NCT02472717|Other|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
224952|NCT02472704|Dietary Supplement|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
224953|NCT02472704|Dietary Supplement|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
224954|NCT02472691|Drug|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
224955|NCT02472691|Drug|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
224956|NCT02472691|Biological|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10^6 CD3/kg (1st DLI), 1-5x10^6 CD3/kg (2nd DLI) and 5-15x10^6 CD3/kg (3rd DLI).
224957|NCT02472678|Other|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
224958|NCT02472678|Other|Standard care|The control group will receive standard care.
224959|NCT02472665|Drug|plasma-derived FVIII/VWF concentrate|1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered
224960|NCT02472652|Drug|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
224961|NCT02472639|Device|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
224962|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not use device
224963|NCT02472626|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
224964|NCT02472626|Drug|Cytarabine|Given IV
224965|NCT02472626|Drug|Daunorubicin Hydrochloride|Given IV
224966|NCT02472613|Device|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).~The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
224967|NCT02472613|Drug|placebo|Placebo was given for 12 consecutive weeks.
225011|NCT02472353|Drug|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
225012|NCT02472353|Drug|Doxorubicin|Standard of care treatment with doxorubicin
225013|NCT02472340|Procedure|Muscle Biopsy|Muscle Biopsy
225014|NCT02472327|Behavioral|Pre-operative support|
224968|NCT02472613|Device|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.~• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
224969|NCT02472613|Drug|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
224970|NCT02472600|Drug|Colistin|
224971|NCT02472600|Drug|Neomycin|
224972|NCT02472600|Drug|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
224973|NCT02472600|Drug|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
224974|NCT02472587|Other|Questionnaire|
224975|NCT02472574|Device|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
224976|NCT02472574|Drug|rt-PA|Up to 4 doses of 0.3~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
224977|NCT02472561|Other|Fitbit Physical Activity Monitor|Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
224978|NCT02472561|Other|mHealth Glucometer|Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
224979|NCT02472561|Other|mHealth Blood Pressure|Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
224980|NCT02472548|Biological|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
224981|NCT02472548|Biological|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
224982|NCT02472548|Other|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
224983|NCT02472535|Other|Run-In Period: Placebo|2 capsules, once a day for two weeks
224984|NCT02472535|Drug|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg capsule)"
224985|NCT02472535|Drug|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks~(MBX-8025 50 mg or 100 mg capsule)"
224986|NCT02472535|Drug|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks~(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
224987|NCT02472522|Drug|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
224988|NCT02472522|Other|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
224989|NCT02472509|Drug|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
224990|NCT02472483|Behavioral|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
224991|NCT02472483|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
224992|NCT02472470|Device|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
224993|NCT02472457|Other|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
224994|NCT02472457|Other|Free Diet|This diet contains no restrictions.
224995|NCT02472431|Other|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
224996|NCT02472431|Procedure|Liposuction|
224997|NCT02472431|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
224998|NCT02472418|Drug|DFN-15 Dose A (treatment A)|DFN-15 Dose A administered
224999|NCT02472418|Drug|DFN-15 Dose B (treatment B)|DFN-15 Dose B administered
225000|NCT02472418|Other|Placebo (treatment C)|Placebo administered
225001|NCT02472405|Device|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
225002|NCT02472405|Device|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
225003|NCT02472392|Drug|Rabbit anti-thymocyte globulin|Active treatment
225004|NCT02472392|Drug|Busulfan|comparitor
225005|NCT02472392|Drug|Melphalan|comparitor
225006|NCT02472392|Drug|Fludarabine|comparitor
225016|NCT02472314|Drug|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
225017|NCT02472301|Dietary Supplement|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
225018|NCT02472301|Dietary Supplement|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
225019|NCT02472301|Dietary Supplement|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
225020|NCT02472288|Device|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
225021|NCT02472288|Device|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
225022|NCT02472275|Drug|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
225023|NCT02472275|Other|Laboratory Biomarker Analysis|Correlative studies
225024|NCT02472275|Drug|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
225025|NCT02472275|Radiation|Radiation Therapy|Undergo radiation therapy
225026|NCT02472262|Dietary Supplement|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
225027|NCT02472262|Dietary Supplement|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
225028|NCT02472262|Dietary Supplement|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
225029|NCT02472249|Radiation|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
225030|NCT02472249|Drug|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds.
225031|NCT02472236|Drug|PEX168|200µg,injected subcutaneously,once a week.
225032|NCT02472236|Drug|Digoxin|0.5mg,oral,two times.
225033|NCT02472223|Drug|Betadine 5%|"One-time, in-office administration of Betadine 5%.~Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
225034|NCT02472223|Drug|Artificial Tears|Standard of care
225035|NCT02472210|Drug|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
225036|NCT02472197|Procedure|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
225037|NCT02472197|Procedure|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
225038|NCT02472184|Procedure|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
225039|NCT02472184|Procedure|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
225040|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
225041|NCT02472171|Dietary Supplement|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
225042|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
225043|NCT02472158|Device|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
225044|NCT02472158|Device|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
225045|NCT02472145|Drug|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/[m^2]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
225046|NCT02472145|Drug|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
225048|NCT02472119|Dietary Supplement|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
225049|NCT02472119|Dietary Supplement|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
225050|NCT02472119|Dietary Supplement|Gluten-free diet|gluten-free diet
225051|NCT02472106|Device|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
225052|NCT02472093|Other|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
225053|NCT02472093|Other|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
225054|NCT02472093|Other|Control group|The control group did brief educational sessions.
225055|NCT02472080|Drug|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
225056|NCT02472067|Behavioral|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
225057|NCT02472054|Drug|Alemtuzumab|
225058|NCT02472054|Drug|Methyl Prednisolone (MP)|
225059|NCT02472054|Drug|Cyclosporin A (CSA)|
225060|NCT02472041|Device|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
225061|NCT02472041|Device|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
225062|NCT02472028|Other|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
225063|NCT02472028|Other|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
225064|NCT02472015|Procedure|telemedicine|psycho-behavioural care by telemedicine
225065|NCT02472002|Biological|Mesenchymal cell therapy|"Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow~Registry Type: autologous~Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).~Route of administration: endomyocardial injection~Dose administered: 120-140 x106 MSC (mesenchymal stem cells)"
225066|NCT02471989|Dietary Supplement|Low-FODMAP diet|
225067|NCT02471989|Dietary Supplement|GERD diet|
225068|NCT02471976|Other|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
225069|NCT02471963|Drug|Empagliflozin|
225070|NCT02471963|Drug|Placebo|
225071|NCT02471950|Procedure|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
225072|NCT02471937|Biological|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :~mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
225073|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
225074|NCT02471911|Drug|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
225075|NCT02471911|Drug|Rituximab|IV Rituximab 375 mg/m2 on D1
225076|NCT02471911|Drug|Etoposide|IV Etoposide 100 mg/m2 on D1-3
225077|NCT02471911|Drug|Carboplatin|IV Carboplatin AUC 5 on D2
225078|NCT02471911|Drug|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
225079|NCT02471911|Drug|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
225080|NCT02471898|Drug|HTX-011|
225081|NCT02471898|Drug|Placebo|Saline
225113|NCT02471651|Drug|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
225082|NCT02471885|Procedure|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10^9/L; skip RIC if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
225083|NCT02471885|Other|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
225084|NCT02471872|Behavioral|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
225085|NCT02471872|Other|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
225086|NCT02471859|Drug|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
225087|NCT02471859|Drug|Placebo|Placebo at various doses, depending on the cohort and treatment period
225088|NCT02471846|Drug|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
225089|NCT02471846|Drug|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
225090|NCT02471833|Drug|Telmisartan 20mg|Subjects will be given 20 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 20mg for a duration of 8 months.
225091|NCT02471833|Drug|Telmisartan 40mg|Subjects will be given 40 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 40mg for a duration of 8 months.
225092|NCT02471833|Drug|Placebo|Subjects will be given placebo to be taken orally once a day before bedtime. Subjects will be on placebo for a duration of 8 months.
225093|NCT02471820|Drug|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
225094|NCT02471820|Drug|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
225095|NCT02471820|Drug|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
225096|NCT02471807|Device|Edwards FORMA Tricuspid Transcatheter Repair System|
225097|NCT02471794|Behavioral|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
225098|NCT02471781|Device|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
225099|NCT02471768|Procedure|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
225100|NCT02471755|Device|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
225101|NCT02471755|Device|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
225102|NCT02471742|Procedure|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
225103|NCT02471742|Procedure|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
225104|NCT02471729|Device|EnligHTN™ Renal Denervation System|The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
225105|NCT02471716|Biological|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks
225106|NCT02471703|Device|Total hip arthroplasty|Total hip arthroplasty
225107|NCT02471690|Drug|Oritavancin|IV - Single dose 1200 mg Oritavancin
225108|NCT02471690|Drug|Dextrose|D5W 5% in Water
225109|NCT02471677|Drug|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
225110|NCT02471677|Drug|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
225111|NCT02471664|Device|Mitral Loop Cerclage Annuloplasty|
225112|NCT02471651|Drug|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
226606|NCT02461160|Drug|Placebo|Placebo-matching TAK-915 suspension
225114|NCT02471638|Device|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
225115|NCT02471625|Device|ClearView Scanning|
225116|NCT02471599|Procedure|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
225117|NCT02471599|Other|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
225118|NCT02471586|Procedure|Coronary PCI guided by IVUS|Imaging type
225119|NCT02471586|Procedure|Coronary PCI guided by OCT|Imaging type
225120|NCT02471586|Procedure|Coronary PCI guided by Angiography|Imaging type
225121|NCT02471573|Procedure|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
225122|NCT02471573|Procedure|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
225123|NCT02471560|Drug|dimethyl fumarate|As per the prevailing local label.
225124|NCT02471560|Drug|injectable MS DMT|As described above.
225125|NCT02471547|Other|BWT with Mitomycin-C prior TURBT|"Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The Elmedical BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes"
225126|NCT02471534|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
225127|NCT02471521|Other|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
225128|NCT02471521|Drug|Rocuronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
225129|NCT02471508|Device|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
225130|NCT02471495|Device|Synergo® RITE + MMC|"Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.~MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection."
225131|NCT02471482|Other|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
225132|NCT02471469|Drug|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
225133|NCT02471456|Other|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
225134|NCT02471456|Other|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
225135|NCT02471443|Procedure|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
225136|NCT02471430|Drug|Panobinostat|Panobinostat will be administered orally.
225137|NCT02471430|Drug|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
225138|NCT02471417|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
225139|NCT02471417|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
225140|NCT02471404|Drug|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
225141|NCT02471404|Drug|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
225142|NCT02471404|Drug|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
225143|NCT02471404|Drug|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
225144|NCT02471404|Drug|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
225145|NCT02471404|Drug|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
225146|NCT02471391|Drug|ABT-199|
225147|NCT02471391|Drug|Ibrutinib|
225148|NCT02471339|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
225149|NCT02471326|Biological|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
225150|NCT02471313|Drug|[18F] FMISO|[18F] Fluromisonidazole, 1 h-(3-[18F]-fluro-2hydroxyl-propy10-2-nitro-imidazaole is an investigational positron emission tomography (PET) radiopharmaceutical for injection and used to visualize hypoxia imaging agent. Each patient will receive up to 10 mCi of [18F] FMISO PET imaging post TACE procedure.
225151|NCT02471274|Drug|sotagliflozin|single 400 mg dose
225152|NCT02471248|Device|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.~They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
225153|NCT02471248|Device|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.~They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
225154|NCT02471235|Behavioral|Physiotherapy|Pulmonary rehabilitation
225155|NCT02471222|Drug|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
225156|NCT02471222|Other|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
225157|NCT02471209|Drug|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
225158|NCT02471196|Drug|ORM-12741|ORM-12741 low dose twice a day
225159|NCT02471196|Drug|ORM-12741|ORM-12741 high dose twice a day
225160|NCT02471196|Drug|Placebo|Placebo twice a day
225161|NCT02471183|Drug|Selexipag|Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
225162|NCT02471157|Other|Observation|
225163|NCT02471144|Biological|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
225164|NCT02471144|Biological|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
225165|NCT02471144|Biological|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(<25 kg, 25- <50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
225166|NCT02471144|Biological|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
225167|NCT02471131|Device|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
225168|NCT02471118|Drug|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
225169|NCT02471118|Drug|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
225170|NCT02471105|Drug|Preserved Bimatoprost 0.01%|Eye drops solution Topical use Once in the evening 3 months
225171|NCT02471105|Drug|Tafluprost Unit Dose Preservative Free 15microgram/ml|Eye drops solution Topical use Once in the evening 3 months
225172|NCT02471092|Other|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
225173|NCT02471079|Radiation|Radiotherapy|
225174|NCT02471066|Device|rTMS|"Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham~Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
225175|NCT02471053|Other|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
225176|NCT02471040|Drug|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
225177|NCT02471040|Other|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
225178|NCT02471027|Procedure|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
225179|NCT02471014|Drug|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
225180|NCT02471014|Other|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
225181|NCT02471014|Other|Questionnaires|"All participants will answer the following questionnaires:~UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.~Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.~Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."
225182|NCT02471001|Biological|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
225183|NCT02470988|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|
225184|NCT02470988|Behavioral|CBASP Without DPI|
225185|NCT02470962|Other|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
225186|NCT02470949|Behavioral|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
225187|NCT02470949|Behavioral|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
225188|NCT02470936|Behavioral|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
225189|NCT02470923|Drug|Nicotine replacement therapy|
225190|NCT02470923|Behavioral|Intensive counseling|
225191|NCT02470923|Behavioral|Medical advice|
225192|NCT02470910|Device|Magnetic Resonance Imaging|
225193|NCT02470897|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
225194|NCT02470897|Radiation|SBRT|Undergo moderate dose SBRT with SIB
225195|NCT02470897|Radiation|SBRT|Undergo uniform dose SBRT
225196|NCT02470884|Device|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
225197|NCT02470871|Biological|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.~Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
225198|NCT02470871|Biological|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
225199|NCT02470858|Drug|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
225200|NCT02470858|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
225201|NCT02470858|Drug|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
225202|NCT02470845|Drug|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
225203|NCT02470845|Drug|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm*1cm round size.Each patch will be applied on one acupoint.
225204|NCT02470832|Drug|RG1662|
225205|NCT02470832|Drug|itraconazole|
225206|NCT02470819|Genetic|Genetic profiling|genetic profiling
225207|NCT02470806|Device|PICO|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
225208|NCT02470806|Device|tNPWT|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
225209|NCT02470793|Procedure|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
225210|NCT02470793|Procedure|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
225211|NCT02470780|Drug|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
225212|NCT02470780|Drug|Placebo|Placebo matching Rifaximin treatment.
225213|NCT02470767|Drug|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
225214|NCT02470754|Device|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
225215|NCT02470754|Device|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
225216|NCT02470741|Drug|Letrozole|
225217|NCT02470741|Other|Placebo|
225218|NCT02470728|Other|New Clinical Pathway|
225219|NCT02470715|Genetic|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
225220|NCT02470702|Drug|Oritavancin|
225221|NCT02470702|Drug|Placebo (D5W)|
225222|NCT02470689|Drug|Diacerin cream|Diacerin tablet solubule in ultraphil cream
225402|NCT02469415|Drug|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
225223|NCT02470676|Device|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
225224|NCT02470676|Drug|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
225225|NCT02470663|Dietary Supplement|DENSITYTM caplets (marketed as Amorphical)|supplementation
225226|NCT02470663|Dietary Supplement|Calcium carbonate 600 mg once daily|supplementation
225227|NCT02470650|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
225228|NCT02470650|Drug|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
225229|NCT02470650|Drug|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
225230|NCT02470650|Drug|Ritonavir|Ritonavir 100 mg recovered tablet once a day
225231|NCT02470650|Drug|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
225232|NCT02470650|Drug|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
225233|NCT02470637|Drug|SAR439065|"Pharmaceutical form:dry powder insulin~Route of administration: inhalation"
225234|NCT02470637|Drug|Insulin lispro|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
225235|NCT02470624|Other|treatment following current guideline|
225236|NCT02470611|Drug|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% sodium alendronate gel
225237|NCT02470611|Other|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% placebo gel
225238|NCT02470598|Other|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
225239|NCT02470585|Drug|Veliparib|Capsule
225240|NCT02470585|Drug|Paclitaxel|Intravenous infusion
225241|NCT02470585|Drug|Veliparib|Capsule
225242|NCT02470585|Drug|Carboplatin|Intravenous infusion
225243|NCT02470585|Other|Placebo|Capsule
225244|NCT02470572|Other|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
225245|NCT02470572|Other|Conventional light microscope|Conventional light microscope
225246|NCT02470559|Biological|Aldesleukin|Given SC
225247|NCT02470559|Biological|HER2Bi-Armed Activated T Cells|Given IV and IP
225248|NCT02470559|Other|Laboratory Biomarker Analysis|Correlative studies
225249|NCT02470559|Biological|Sargramostim|Given SC
225250|NCT02470546|Drug|Metformin|Metformin 1000mg twice a day
225251|NCT02470546|Drug|Placebo|Placebo 1000mg twice a day
225252|NCT02470533|Radiation|Radiation therapy|6 fractions of 8-9Gy
225253|NCT02470533|Device|chemoembolization|Up to 4 sessions
225254|NCT02470520|Procedure|CRRT|continuous renal replacement therapy
225255|NCT02470507|Other|AKI|development of immune dysregulation and rise in inflammatory markers and activation of immune cells
225256|NCT02470494|Device|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
225257|NCT02470481|Other|No Intervention|This is an obervational study
225258|NCT02470468|Biological|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
225259|NCT02470468|Biological|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
225260|NCT02470468|Other|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
225261|NCT02470455|Drug|Atorvastatin|Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
225262|NCT02470442|Drug|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
225263|NCT02470442|Drug|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
225264|NCT02470429|Device|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
225265|NCT02470429|Device|Hyabak 0.15% eye drops|Preservative-free
225266|NCT02470429|Drug|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
225267|NCT02470416|Device|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
225268|NCT02470403|Drug|LIK066|LIK066 25 mg tablets
225269|NCT02470403|Drug|Placebo|Matching placebo tablets
225270|NCT02470390|Drug|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
225271|NCT02470377|Device|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
225272|NCT02470338|Procedure|MBP plus arthroscopy (Group A)|
225273|NCT02470338|Procedure|MBP alone (Group B)|
225274|NCT02470325|Drug|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
225275|NCT02470325|Drug|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
225276|NCT02470312|Procedure|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
225277|NCT02470312|Device|MediGuide|
225278|NCT02470312|Procedure|EP|
225314|NCT02470013|Dietary Supplement|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
225403|NCT02469415|Drug|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
225404|NCT02469402|Dietary Supplement|Standard infant formula|
225279|NCT02470299|Drug|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds~Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:~Patients < 65 years of age: Daily dose of 30 mg for three doses.~Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
225280|NCT02470299|Other|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:~Patients < 65 years of age: Daily dose of 30 mg for three doses.~Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.~Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
225281|NCT02470286|Drug|SA001|
225282|NCT02470286|Drug|Placebo|
225283|NCT02470247|Other|Remote Ischemic Preconditioning (RIPC)|"RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.~RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
225284|NCT02470247|Other|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
225285|NCT02470234|Drug|Methylphenidate HCl ER Capsules|Methylphenidate Hydrochloride Extended-Release Capsules administered once daily in the morning
225286|NCT02470221|Other|Applying goal-directed fluid therapy by continuous hemodynamic monitoring system|Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
225287|NCT02470221|Other|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
225288|NCT02470195|Behavioral|workshop|workshop for procedural simulation for education in difficult airway situation
225289|NCT02470169|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
225290|NCT02470169|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
225291|NCT02470169|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
225292|NCT02470169|Device|shepherd catheter|
225293|NCT02470169|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
225294|NCT02470156|Behavioral|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
225295|NCT02470156|Behavioral|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
225296|NCT02470143|Behavioral|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
225297|NCT02470130|Behavioral|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
225298|NCT02470117|Drug|Alginate-based reflux suppressant|
225299|NCT02470117|Drug|magnesium-aluminium antacid gel|
225300|NCT02470104|Biological|Breastmilk|"A registered dietician will supervise milk provision.~If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
225301|NCT02470091|Biological|Denosumab|Given SC
225302|NCT02470091|Other|Laboratory Biomarker Analysis|Correlative studies
225303|NCT02470091|Other|Pharmacological Study|Correlative studies
225304|NCT02470078|Device|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
225305|NCT02470078|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
225306|NCT02470065|Drug|Afatinib|once daily afatinib at a dose of 40 mg for 8 weeks
225307|NCT02470065|Procedure|Immediate surgery|anatomical resection and systematic lymph node dissection
225308|NCT02470052|Device|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
225309|NCT02470039|Drug|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
225310|NCT02470039|Drug|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
225311|NCT02470039|Drug|placebo|Administered once daily
225312|NCT02470026|Drug|yohimbine|single low dose treatment
225313|NCT02470026|Drug|placebo|single control treatment
225315|NCT02470000|Device|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
225316|NCT02470000|Device|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
225317|NCT02470000|Other|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
225318|NCT02469987|Drug|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
225319|NCT02469987|Drug|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
225320|NCT02469987|Drug|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
225321|NCT02469974|Drug|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
225322|NCT02469974|Drug|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
225323|NCT02469974|Drug|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
225324|NCT02469961|Drug|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
225325|NCT02469961|Drug|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
225326|NCT02469961|Other|Interscalene block|Interscalene block is used for the main anesthetic for the case
225327|NCT02469948|Drug|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
225328|NCT02469935|Procedure|ultrasound|surgeon-performed ultrasound
225329|NCT02469922|Device|Positron emission tomography|
225330|NCT02469922|Radiation|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
225331|NCT02469909|Other|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
225332|NCT02469909|Other|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
225333|NCT02469909|Other|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
225334|NCT02469909|Procedure|immediate decannulation|the tracheostomy tube is removed at once
225335|NCT02469909|Procedure|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
225336|NCT02469896|Drug|Tocilizumab|IV Infusion
225337|NCT02469896|Other|Placebo|IV Infusion
225338|NCT02469883|Drug|Sinotecean|
225339|NCT02469870|Behavioral|Autism Parent Trainer (APT)|Experimental condition
225340|NCT02469870|Behavioral|self-paced ABC training online|Content comparison group.
225341|NCT02469857|Drug|AB103 0.5 mg/kg|
225342|NCT02469857|Other|NaCl 0.9%|
225343|NCT02469831|Drug|Rocuronium|
225344|NCT02469805|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
225345|NCT02469805|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
225346|NCT02469805|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
225347|NCT02469805|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
225348|NCT02469805|Device|Shepherd catheter|Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
225349|NCT02469792|Procedure|Liposuction|
225350|NCT02469792|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
225351|NCT02469792|Procedure|Arthroscopic surgery|
225352|NCT02469792|Other|Intraarticular administration of autologous ADRC|
225353|NCT02469779|Behavioral|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
225354|NCT02469779|Behavioral|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
225355|NCT02469779|Behavioral|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
225356|NCT02469779|Behavioral|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
225357|NCT02469766|Procedure|SWL|Patients in this arm will undergo SWL
225358|NCT02469766|Procedure|Semirigid URS|Patients in this arm will undergo semirigid URS
225359|NCT02469766|Procedure|Flexible URS|Patients in this arm will undergo Flexible URS
225360|NCT02469753|Drug|NSAIDs|continuous daily
225361|NCT02469753|Drug|NSAIDs|on demand
225362|NCT02469753|Drug|anti-TNF|
225363|NCT02469740|Drug|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
225364|NCT02469740|Drug|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
225365|NCT02469727|Behavioral|Fitbit|Participants will use the FitBit device to track their physical activity
225366|NCT02469727|Behavioral|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
225367|NCT02469714|Behavioral|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
225368|NCT02469701|Drug|nivolumab and ablation|
225369|NCT02469688|Drug|ASP4070|intramuscular or intradermal
225370|NCT02469688|Drug|Placebo|intramuscular or intradermal
225371|NCT02469675|Device|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
225372|NCT02469675|Device|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
225373|NCT02469675|Device|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
225374|NCT02469662|Device|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
225375|NCT02469623|Device|Dipole Density Mapping with AcQMap followed by ablation|
225376|NCT02469610|Other|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
225377|NCT02469597|Drug|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
225378|NCT02469597|Drug|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
225379|NCT02469584|Procedure|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
225380|NCT02469571|Dietary Supplement|Winclove 607|multispecies probiotic
225381|NCT02469571|Dietary Supplement|Placebo|Placebo
225382|NCT02469558|Dietary Supplement|Winclove 851 and 110|prebiotic and probiotic mixture
225383|NCT02469558|Dietary Supplement|Placebo|white powder without pro/probiotic
225384|NCT02469545|Drug|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
225385|NCT02469545|Drug|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
225386|NCT02469545|Drug|Escitalopram|5-20mg daily
225387|NCT02469545|Drug|Sertraline|50-100mg daily
225388|NCT02469532|Device|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
225389|NCT02469532|Device|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
225390|NCT02469519|Drug|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
225391|NCT02469519|Other|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
225392|NCT02469506|Device|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
225393|NCT02469493|Device|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
225394|NCT02469480|Drug|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
225395|NCT02469480|Drug|Ferro sanol|200 mg ferro sanol per day over 12 weeks
225396|NCT02469467|Dietary Supplement|VS-505|VS-505 is orally administered with meal for 8 weeks
225397|NCT02469454|Drug|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
225398|NCT02469454|Drug|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
225399|NCT02469428|Other|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
225400|NCT02469428|Other|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
225401|NCT02469415|Drug|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.~Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
225444|NCT02469155|Drug|Risperidone|
225405|NCT02469402|Dietary Supplement|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
225406|NCT02469389|Behavioral|Engaging in Community Roles and Experiences (ENCoRE)|"Engaging in Community Roles and Experiences (ENCoRE)~includes evidence-based psychosocial treatment~strategies to target the affective-motivational deficits,~negative expectancies, and behavioral skills deficits~that are central to the maintenance of negative~symptoms. Behavioral strategies include motivational~enhancement, psychoeducation, cognitive therapy, and~social skills tr"
225407|NCT02469389|Behavioral|Health & Wellness (H&W)|"Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related~concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.~Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing~Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions),~8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1sessi"
225408|NCT02469376|Drug|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
225409|NCT02469363|Device|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
225410|NCT02469363|Device|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
225411|NCT02469363|Device|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
225412|NCT02469363|Device|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
225413|NCT02469350|Other|Serious game|Rehabilitation with serious game
225414|NCT02469337|Drug|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
225415|NCT02469337|Dietary Supplement|Carbohydrate drinks|preoperative carbohydrate drinks
225416|NCT02469337|Behavioral|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
225417|NCT02469324|Behavioral|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
225418|NCT02469324|Behavioral|Compassionate Mind Training|see above
225419|NCT02469311|Other|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
225420|NCT02469311|Other|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
225421|NCT02469298|Drug|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
225422|NCT02469298|Drug|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
225423|NCT02469298|Drug|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
225424|NCT02469298|Drug|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
225425|NCT02469285|Dietary Supplement|Modified pork|Pork with modified fatty acid composition
225426|NCT02469285|Dietary Supplement|Pork|Pork with normal fat composition
225427|NCT02469285|Dietary Supplement|Pork and berries|Pork with normal fat composition and Finnish berries
225428|NCT02469272|Drug|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
225429|NCT02469259|Drug|Oxytocin|
225430|NCT02469259|Other|Placebo|
225431|NCT02469246|Drug|F/TAF|200/10 mg FDC tablet (with boosted 3rd ARV agents) or 200/25 mg FDC tablet (with unboosted 3rd ARV agents) administered orally once daily
225432|NCT02469246|Drug|ABC/3TC|600/300 mg FDC tablets administered orally once daily
225433|NCT02469246|Drug|ABC/3TC Placebo|Tablets administered orally once daily
225434|NCT02469246|Drug|F/TAF Placebo|Tablets administered orally once daily
225435|NCT02469246|Drug|3rd ARV agent|An allowed 3rd ARV agent of the participant's pre-existing regimen may include one of the following boosted ARV agents: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC; or, one of the following unboosted ARV agents: efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
225436|NCT02469233|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
225437|NCT02469220|Dietary Supplement|Low FODMAP|Blinded food supplements containing only items with a low content of FODMAPs
225438|NCT02469220|Dietary Supplement|Standardized FODMAP|Blinded food supplements containing FODMAPs
225439|NCT02469207|Other|Removal of tissue post-mortem|
225440|NCT02469194|Other|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
225441|NCT02469168|Device|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
225442|NCT02469168|Procedure|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
225443|NCT02469155|Drug|ITI-007|
225446|NCT02469142|Procedure|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
225447|NCT02469129|Drug|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of [18F]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.~For the Kinetic Studies, 10 mCi of [18F]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
225448|NCT02469116|Drug|Docetaxel|
225449|NCT02469116|Drug|Carboplatin|
225450|NCT02469116|Drug|Pegylated G-CSF|
225451|NCT02469103|Device|C2|C2 and colonoscopy will be performed one after another on the same day
225452|NCT02469103|Procedure|colonoscopy|
225453|NCT02469090|Drug|APL-130277|"Use to treat up to 5 OFF episodes per day"
225454|NCT02469090|Drug|Placebo|placebo
225455|NCT02469077|Behavioral|exercise|Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out.
225456|NCT02469077|Drug|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
225457|NCT02469077|Drug|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
225458|NCT02469077|Drug|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
225459|NCT02469064|Other|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
225460|NCT02469064|Other|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
225461|NCT02469051|Device|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
225462|NCT02469051|Device|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
225463|NCT02469051|Device|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
225464|NCT02469038|Device|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
225465|NCT02469038|Device|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
225466|NCT02469025|Other|Manual caudal traction mobilization in resting position|
225467|NCT02469025|Other|Manual caudal traction mobilization in end range position|
225468|NCT02469025|Other|Selftreatment|Each subject is advice to do some exercises at home
225469|NCT02469012|Drug|Combination #1|Sofosbuvir + Ribavirin
225470|NCT02469012|Drug|Combination #2|Sofosbuvir + Daclatasvir
225471|NCT02469012|Drug|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
225472|NCT02469012|Drug|Combination #4|Sofosbuvir + Ledipasvir
225473|NCT02469012|Drug|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
225474|NCT02468999|Drug|human insulin|
225475|NCT02468973|Behavioral|Life style counseling|Life style counseling for chronic patients by medical students
225476|NCT02468960|Device|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
225477|NCT02468960|Device|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
225478|NCT02468960|Device|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
225479|NCT02468960|Procedure|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
225480|NCT02468960|Other|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
225481|NCT02468934|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
225482|NCT02468921|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
225483|NCT02468908|Drug|Molgramostim|
225484|NCT02468908|Drug|Placebo|
225485|NCT02468882|Dietary Supplement|Watercress|100g of watercress daily during radiation therapy
225486|NCT02468869|Behavioral|"Communication skills training empathy skills"|
225487|NCT02468869|Behavioral|"Communication skills training information structuring skills"|
225488|NCT02468856|Drug|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
225489|NCT02468856|Drug|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
225490|NCT02468843|Device|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~Current best/optimized DBS setting (considered baseline)~DBS off for 30 minutes~Biphasic pulse stimulation mode (immediate assessment)~Biphasic pulse stimulation mode (assessment at 1h)~Biphasic pulse stimulation mode (assessment at 2h)"
225491|NCT02468843|Other|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
225492|NCT02468843|Other|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
225493|NCT02468830|Drug|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
225494|NCT02468817|Procedure|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
225495|NCT02468817|Procedure|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
225496|NCT02468804|Device|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
225497|NCT02468804|Device|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
225498|NCT02468791|Drug|Rituximab|
225499|NCT02468778|Device|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high-risk percutaneous coronary interventions (PCI) performed electively or urgently in hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is an acceptable therapeutic option. Use of the HeartMate PHP Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce peri-and post-procedural adverse events.
225500|NCT02468778|Device|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI.
225501|NCT02468765|Other|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
225502|NCT02468752|Drug|Oxygen|
225503|NCT02468752|Other|Air|
225504|NCT02468739|Drug|Ganglioside-monosialic acid|Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
225505|NCT02468739|Drug|placebo|Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
225506|NCT02468726|Device|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
225507|NCT02468726|Drug|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
225508|NCT02468713|Drug|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
225509|NCT02468713|Drug|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
225510|NCT02468700|Drug|Dexamethasone|
225511|NCT02468700|Other|Placebo Vehicle|
225512|NCT02468687|Drug|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
225513|NCT02468674|Drug|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose~Bimagrumab was administered as an intravenous infusion starting on Day 1 until week 25 in the core study. No intervention in the extension study."
225514|NCT02468674|Drug|Placebo|"Placebo~Placebo was administered as intravenous infusion from Day 1 to Week 25 in the core study. No intervention in the extension study."
225515|NCT02468661|Drug|INC280 single agent|
225516|NCT02468661|Drug|erlotinib|
225517|NCT02468648|Drug|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
225518|NCT02468648|Drug|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
225558|NCT02468323|Drug|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
225559|NCT02468323|Drug|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
225560|NCT02468310|Other|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
225519|NCT02468635|Other|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
225520|NCT02468635|Other|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
225521|NCT02468622|Other|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
225522|NCT02468609|Radiation|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
225523|NCT02468596|Other|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
225524|NCT02468596|Other|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
225525|NCT02468583|Drug|FX006 32 mg|Experimental
225526|NCT02468583|Drug|TCA IR 40 mg|Comparator
225527|NCT02468570|Other|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
225528|NCT02468557|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
225529|NCT02468557|Drug|Nab-paclitaxel|Nab-paclitaxel administered intravenously on Days 1, 8 and 15 of each 28 day cycle
225530|NCT02468557|Drug|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 mg/m^2 or racemic leucovorin 400 mg/m^2, oxaliplatin 85 mg/m^2, bolus 5-fluorouracil 400 mg/m^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m^2.
225531|NCT02468544|Other|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
225532|NCT02468531|Other|oxygen|50% oxygen inhalation
225533|NCT02468531|Drug|Xenon|50% Xenon inhalation
225534|NCT02468518|Drug|Vitamin E capsule|Capsules will be distributed to each participant free of cost
225535|NCT02468505|Behavioral|STEPS|time-limited behavioral counseling, online materials, training
225536|NCT02468492|Biological|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
225537|NCT02468492|Other|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
225538|NCT02468479|Other|No relevant intervention.|No relevant intervention.
225539|NCT02468466|Behavioral|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
225540|NCT02468466|Behavioral|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
225541|NCT02468453|Device|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
225542|NCT02468440|Other|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
225543|NCT02468427|Other|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
225544|NCT02468427|Other|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
225545|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
225546|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
225547|NCT02468401|Procedure|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
225548|NCT02468388|Other|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
225549|NCT02468388|Other|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
225550|NCT02468388|Other|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
225551|NCT02468375|Drug|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
225552|NCT02468362|Procedure|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
225553|NCT02468362|Procedure|open intersphincteric resection|
225554|NCT02468349|Other|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
225555|NCT02468336|Device|AngioDefender|
225556|NCT02468336|Device|Ultrasound|
225557|NCT02468323|Drug|Placebo|Patients will receive regular spinal anesthesia
225561|NCT02468297|Device|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.~Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
225562|NCT02468297|Drug|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
225563|NCT02468284|Drug|degarelix|
225564|NCT02468258|Procedure|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
225565|NCT02468245|Behavioral|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
225566|NCT02468245|Behavioral|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
225567|NCT02468232|Drug|LCZ696|LCZ696 50 mg, 100 mg, 200 mg film-coated tablets
225568|NCT02468232|Drug|Enalapril|Enalapril 2.5 mg, 5 mg, 10 mg film-coated tablets
225569|NCT02468232|Drug|Placebo to LCZ696|Placebo to match LCZ696 50 mg, 100 mg and 200 mg film-coated tablets
225570|NCT02468232|Drug|Placebo to Enalapril|Placebo to match enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets
225571|NCT02468219|Behavioral|cardiovascular rehabilitation program|"Phase I - respiratory muscle training and neuromuscular electrical stimulation 7x/week for 6 weeks.~Phase II - 8 weeks of supervised, structured, combined endurance and resistance training."
225572|NCT02468206|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
225573|NCT02468206|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
225574|NCT02468206|Drug|N-butyl-2-cyanoacrylate|
225575|NCT02468206|Drug|Lauromacrogol|
225576|NCT02468193|Drug|Osilodrostat|Osilodrostat will be prescribed by the investigator. Osirodrostat 1 mg, 5 mg, 10 mg in the form of film-coated tablets will be used for oral administration
225577|NCT02468180|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
225578|NCT02468180|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
225579|NCT02468180|Drug|N-butyl-2-cyanoacrylate|
225580|NCT02468180|Drug|Lauromacrogol|
225581|NCT02468167|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
225582|NCT02468167|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
225583|NCT02468167|Drug|N-butyl-2-cyanoacrylate|
225584|NCT02468167|Drug|Lauromacrogol|
225585|NCT02468154|Device|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
225586|NCT02468154|Other|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
225587|NCT02468141|Drug|SJDBT|Sipjeondaebo-tang
225588|NCT02468141|Drug|Placebo|Placebo
225589|NCT02468128|Drug|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
225590|NCT02468128|Drug|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
225591|NCT02468115|Drug|VIS410|Single fixed IV dose of VIS410
225592|NCT02468115|Drug|Placebo|Single IV dose of placebo
225593|NCT02468102|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban [od], tablets).~Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
225594|NCT02468102|Drug|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
225595|NCT02468089|Drug|Carbepenem|
225596|NCT02468089|Drug|Albumin|
225597|NCT02468089|Drug|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
225598|NCT02468076|Device|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
225599|NCT02468063|Drug|Low dose terlipressin|Terlipressin-2mg (low dose )
225600|NCT02468063|Drug|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
225601|NCT02468063|Drug|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
225602|NCT02468050|Behavioral|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
225687|NCT02467478|Drug|Linagliptin|5 mg tablet once daily for 12 weeks
225688|NCT02467478|Drug|Placebo|1 tablet daily for 12 weeks
225603|NCT02468050|Behavioral|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
225604|NCT02468037|Procedure|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
225605|NCT02468024|Procedure|Lung Surgery|Sublobar Lung Resection
225606|NCT02468024|Radiation|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
225607|NCT02468011|Other|vibration|vibration will be applied at 35 Hz
225608|NCT02467998|Device|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
225609|NCT02467985|Procedure|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
225610|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
225611|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
225612|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
225613|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
225614|NCT02467946|Drug|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
225615|NCT02467933|Other|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
225616|NCT02467933|Other|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
225617|NCT02467933|Other|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
225618|NCT02467920|Drug|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
225619|NCT02467920|Drug|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
225620|NCT02467907|Drug|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
225621|NCT02467907|Drug|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter*minute (mg/mL*min) on Day 1 every 3 weeks for at least 6 cycles
225622|NCT02467907|Drug|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m^2) on Day 1 every 3 weeks for at least 6 cycles
225623|NCT02467894|Other|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
225624|NCT02467881|Behavioral|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.~The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
225625|NCT02467881|Behavioral|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.~The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
225626|NCT02467881|Other|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
225627|NCT02467868|Biological|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
225628|NCT02467868|Biological|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
225629|NCT02467855|Other|No Intervention|No intervention was administered in this study.
225630|NCT02467842|Biological|NBP607-QIV(Quadrivalent)|0.5ml, intramuscular, a single dosing at Day 0
225631|NCT02467842|Biological|NBP607-Y(Trivalent)|0.5ml, intramuscular, a single dosing at Day 0
225632|NCT02467842|Biological|NBP607-V(Trivalent)|0.5ml, intramuscular, a single dosing at Day 0
225633|NCT02467829|Device|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
225734|NCT02467114|Other|Control without stimulation|
225634|NCT02467816|Behavioral|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
225635|NCT02467816|Behavioral|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
225636|NCT02467816|Behavioral|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
225637|NCT02467803|Other|Scapula mobilization|
225638|NCT02467803|Other|Shoulder ROM exercises|
225639|NCT02467790|Drug|PEX168|PEX 168: 200µg,Subcutaneous,one time.
225640|NCT02467777|Device|Bair Hugger|
225641|NCT02467777|Device|VitaHeat|
225642|NCT02467764|Other|Retrospective study|
225643|NCT02467738|Radiation|Brachytherapy|Undergo brachytherapy with Cesium-131
225644|NCT02467738|Drug|Cesium-131|Undergo brachytherapy with Cesium-131
225645|NCT02467738|Procedure|Conventional surgery|Undergo surgical resection
225646|NCT02467725|Other|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
225647|NCT02467686|Behavioral|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
225648|NCT02467686|Behavioral|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
225649|NCT02467686|Behavioral|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
225650|NCT02467686|Drug|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
225651|NCT02467686|Drug|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
225652|NCT02467686|Drug|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
225653|NCT02467673|Drug|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
225654|NCT02467673|Drug|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
225655|NCT02467660|Behavioral|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
225656|NCT02467660|Behavioral|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
225657|NCT02467647|Drug|Thalidomide|
225658|NCT02467647|Drug|HLJDT|
225659|NCT02467634|Biological|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
225660|NCT02467621|Drug|Pantoprazole|40 mg x 1 daily intravenously from ICU admission to ICU discharge
225661|NCT02467621|Other|Saline (0.9%)|10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
225662|NCT02467608|Drug|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
225663|NCT02467608|Drug|HRZE|the same as experimental group,without the excipient of HUEXC030 only
225664|NCT02467595|Drug|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
225665|NCT02467595|Drug|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
225666|NCT02467595|Drug|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
225667|NCT02467595|Drug|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
225668|NCT02467595|Drug|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
225669|NCT02467582|Drug|Aspirin|Aspirin 100 mg daily
225670|NCT02467582|Drug|Placebo|Placebo
225671|NCT02467569|Drug|Hemay020|
225672|NCT02467556|Drug|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
225673|NCT02467556|Behavioral|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
225674|NCT02467556|Other|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
225675|NCT02467543|Other|20% Ethanol|Unmedicated 20% Ethanol
225676|NCT02467543|Other|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
225677|NCT02467530|Other|AGE|
225678|NCT02467517|Drug|Ketamine|
225679|NCT02467517|Drug|Magnesium Sulfate|
225680|NCT02467517|Drug|placebo : sodium chloride|
225681|NCT02467504|Drug|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
225682|NCT02467504|Drug|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
225683|NCT02467504|Drug|MTX|Methotrexate (oral administration)
225684|NCT02467504|Drug|Folic Acid|Folic Acid (oral administration)
225685|NCT02467504|Drug|Loxoprofen|Loxoprofen (oral administration)
225686|NCT02467491|Device|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
225689|NCT02467465|Other|Physical therapy|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
225690|NCT02467465|Device|Dry needling|
225691|NCT02467452|Drug|BDP/FF/GB|
225692|NCT02467452|Drug|FlF/VI + Tiotropium|
225693|NCT02467439|Other|Notification cards|detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
225694|NCT02467426|Drug|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
225695|NCT02467413|Drug|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
225696|NCT02467413|Other|BAC Matched Vehicle|BAC Matched Vehicle
225697|NCT02467400|Drug|Atenolol|beta blocker
225698|NCT02467400|Drug|Nebivolol|beta blocker
225699|NCT02467400|Drug|Propranolol|beta blocker
225700|NCT02467400|Drug|placebo|placebo
225701|NCT02467387|Drug|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
225702|NCT02467387|Drug|Lactated Ringer's Solution|One time infusion 1.5mL/kg
225703|NCT02467374|Behavioral|Behavior Therapy|"BT for OCD focuses primarily on exposure with response prevention (ERP). ERP involves gradual exposure to anxiety-provoking situations (things or situations that frighten or disturb some people), and will help to prevent compulsions (repetitive behaviors)."
225704|NCT02467361|Drug|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
225705|NCT02467361|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
225706|NCT02467361|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
225707|NCT02467361|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
225708|NCT02467348|Drug|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
225709|NCT02467348|Drug|Ascitic fluid|
225710|NCT02467335|Drug|BMS-663068|BMS-663068
225711|NCT02467322|Drug|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
225712|NCT02467322|Drug|ascitic fluid|
225713|NCT02467296|Other|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
225714|NCT02467283|Genetic|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
225715|NCT02467270|Drug|Ponatinib 45 mg|45 mg tablet, taken orally once daily.
225716|NCT02467270|Drug|Ponatinib 30 mg|30 mg tablet, taken orally once daily.
225717|NCT02467270|Drug|Ponatinib 15 mg|15 mg tablet, taken orally once daily.
225718|NCT02467257|Dietary Supplement|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
225719|NCT02467244|Drug|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
225720|NCT02467218|Other|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
225721|NCT02467205|Other|pedometer supported walking and education|"A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.~The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support)."
225722|NCT02467192|Device|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
225723|NCT02467179|Device|Amigo™ Robotic Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to robotic catheter manipulation."
225724|NCT02467179|Device|Manual Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.~In this study, this group will be assigned to manual catheter manipulation."
225725|NCT02467166|Device|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
225726|NCT02467153|Other|RET|"RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.~The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.~Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months."
225727|NCT02467153|Dietary Supplement|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
225728|NCT02467153|Dietary Supplement|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
225729|NCT02467140|Device|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
225730|NCT02467140|Device|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
225731|NCT02467127|Dietary Supplement|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
225732|NCT02467114|Device|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
225733|NCT02467114|Device|Sham coil stimulation|Stimulation with a sham coil as a comparison
225735|NCT02467101|Other|Corticosteroid/Saline|"Corticosteroid/Saline~Two groups were defined: group A and group B.~Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head~Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.~Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.~Each patient will be injected on half-head."
225736|NCT02467088|Other|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
225737|NCT02467075|Drug|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
225738|NCT02467075|Drug|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
225739|NCT02467062|Device|MRI|MRI measurement to evualuate for 4D blood flow pattern
225740|NCT02467049|Device|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
225741|NCT02467049|Device|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
225742|NCT02467036|Behavioral|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
225743|NCT02467023|Device|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
225744|NCT02467023|Device|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
225745|NCT02467023|Procedure|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
225746|NCT02467023|Drug|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
225747|NCT02467023|Drug|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
225748|NCT02467023|Drug|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
225749|NCT02467023|Other|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
225750|NCT02467023|Device|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
225751|NCT02467010|Drug|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
225787|NCT02466776|Device|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean section.
225788|NCT02466776|Device|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean section.
225789|NCT02466763|Procedure|Cochlear implant surgery|Surgical placement of a cochlear implant device.
226607|NCT02461160|Drug|TAK-915 tablet|TAK-915 tablet
225752|NCT02467010|Drug|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
225753|NCT02467010|Drug|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
225754|NCT02466997|Drug|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
225755|NCT02466997|Drug|Placebo|
225756|NCT02466984|Drug|metoclopramide intravenous|Administration route
225757|NCT02466971|Drug|Cisplatin|Given IV
225758|NCT02466971|Radiation|External Beam Radiation Therapy|Undergo EBRT
225759|NCT02466971|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
225760|NCT02466971|Radiation|Internal Radiation Therapy|Undergo brachytherapy
225761|NCT02466971|Other|Laboratory Biomarker Analysis|Correlative studies
225762|NCT02466971|Radiation|Radiation Therapy|Undergo conventional RT
225763|NCT02466971|Drug|Triapine|Given IV
225764|NCT02466958|Drug|levomilnacipran|antidepressant
225765|NCT02466958|Drug|Placebo|an inactive drug
225766|NCT02466945|Device|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
225767|NCT02466932|Device|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
225768|NCT02466919|Drug|Pantoprazole|H. pylori eradication therapy
225769|NCT02466919|Drug|Amoxicillin|H. pylori eradication therapy
225770|NCT02466919|Drug|Metronidazole|H. pylori eradication therapy
225771|NCT02466919|Drug|Levofloxacin|H. pylori eradication therapy
225772|NCT02466919|Drug|Clarithromycin|H. pylori eradication therapy
225773|NCT02466906|Drug|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC>20.0X109/L.
225774|NCT02466906|Drug|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
225775|NCT02466893|Other|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
225776|NCT02466880|Device|Telemedicine|A diabetes self-management and education program delivered via telemedicine
225777|NCT02466880|Other|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
225778|NCT02466867|Drug|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
225779|NCT02466867|Drug|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
225780|NCT02466841|Procedure|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
225781|NCT02466828|Drug|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
225782|NCT02466815|Drug|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
225783|NCT02466815|Drug|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
225784|NCT02466815|Drug|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
225785|NCT02466802|Drug|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
225786|NCT02466802|Drug|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
225820|NCT02466516|Drug|SEL|SEL tablet administered orally once daily
225790|NCT02466750|Biological|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
225791|NCT02466737|Procedure|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
225792|NCT02466737|Procedure|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
225793|NCT02466724|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
225794|NCT02466711|Drug|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
225795|NCT02466711|Drug|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
225796|NCT02466698|Procedure|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
225797|NCT02466698|Drug|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
225798|NCT02466698|Drug|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
225799|NCT02466698|Drug|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
225800|NCT02466685|Drug|JNJ-18038683|JNJ-18038683 10-20 mg/day for 8 weeks
225801|NCT02466672|Other|none - observational only|
225802|NCT02466659|Device|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
225803|NCT02466646|Drug|Klorhex® Gel, rinse and sprey|nitial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Sprey 0,2% and Klorhex® rinse 0,2% for 3 weeks).
225804|NCT02466646|Procedure|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
225805|NCT02466646|Procedure|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
225806|NCT02466633|Other|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
225807|NCT02466607|Device|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
225808|NCT02466607|Device|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
225809|NCT02466607|Other|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
225810|NCT02466594|Device|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
225811|NCT02466581|Drug|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
225812|NCT02466581|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
225813|NCT02466581|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
225814|NCT02466581|Biological|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
225815|NCT02466568|Drug|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
225816|NCT02466568|Biological|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
225817|NCT02466555|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
225818|NCT02466542|Drug|Placebo group|Patients will receive regular general anesthesia
225819|NCT02466542|Drug|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
225821|NCT02466516|Biological|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
225822|NCT02466503|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
225823|NCT02466503|Drug|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
225824|NCT02466490|Drug|Fimasartan|Fimasartan tablets
225825|NCT02466490|Drug|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
225826|NCT02466477|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
225827|NCT02466477|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
225828|NCT02466477|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
225829|NCT02466464|Device|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
225830|NCT02466464|Device|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
225831|NCT02466451|Other|Questionnaires|"For not collaborative patients, under the age of 4 years:~Standardized questionnaire collecting anamnestic-clinical data~Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).~For collaborative patients, over the age of 4 years:~Standardized questionnaire collecting anamnestic-clinical data~Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )~Spirometry~6-minutes walk test (WT 6')~Prick tests~Children Quality of life questionnaire (KINDL questionnaire)~Psychological test (Raven Matrices)~Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
225832|NCT02466438|Drug|Piperacillin-tazobactam|"Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion~Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours~Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours~Acute Kidney injury : Dosing as prescribed by treating physician"
225833|NCT02466425|Drug|SHP465|12.5mg and 25mg capsules (one capsule daily)
225834|NCT02466425|Drug|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
225835|NCT02466412|Other|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
225836|NCT02466412|Other|mCC|Single use of subject's own menthol conventional cigarette (mCC)
225837|NCT02466399|Drug|POLAT-001|Subconjunctival injection
225838|NCT02466399|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
225839|NCT02466386|Drug|SPD489|SPD489 will be provided orally in 5, 10, 15, 20, and 30 milligram (mg) strength capsules once daily. Participants will be instructed to start with 5 mg of SPD489 and should be titrated in a step wise fashion until an optimal dose is reached with 10, 15, 20, and 30 mg dose.
225840|NCT02466373|Drug|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
225841|NCT02466360|Behavioral|Back Belief questionnaire|
225842|NCT02466360|Behavioral|QUEBEC scale|
225843|NCT02466360|Behavioral|Fear Avoidance beliefs questionnaire|
225844|NCT02466360|Behavioral|Visual analog scale|
225845|NCT02466360|Behavioral|individual interviews|
225846|NCT02466360|Behavioral|Focus groups|
225847|NCT02466347|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
225848|NCT02466347|Drug|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
225849|NCT02466334|Drug|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
225850|NCT02466334|Drug|Placebo|40 ml of normal saline over 20 mins
225851|NCT02466321|Procedure|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
225852|NCT02466308|Device|SAM Ultrasound Diathermy Device|
225853|NCT02466295|Other|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
225854|NCT02466295|Other|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
225855|NCT02466282|Device|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
225856|NCT02466282|Device|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
225857|NCT02466269|Procedure|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
225858|NCT02466256|Procedure|Intraocular lens implantation|Intraocular lens implantation
225860|NCT02466256|Device|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
225861|NCT02466256|Device|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
225862|NCT02466243|Drug|JBT-101|"Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84.~Part B: JBT-101 20 mg twice daily on Days 1 - 365 of the OLE."
225863|NCT02466243|Drug|Placebo|"Part A: Once daily on Days 1-28, then twice daily on Days 29-84.~Part B: Placebo twice daily on Days 1 - 365 of the OLE."
225864|NCT02466230|Device|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
225865|NCT02466217|Other|1: AID groups|Clinical and Biological investigations
225866|NCT02466217|Other|2: Control groups|Clinical and Biological investigations
225867|NCT02466204|Drug|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
225868|NCT02466204|Drug|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
225869|NCT02466191|Drug|Memantine|
225870|NCT02466191|Drug|Gabapentin|
225871|NCT02466178|Device|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
225872|NCT02466165|Behavioral|Physical exercise|
225873|NCT02466152|Drug|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram [mg/g]) and 1.0% (10 mg/g)
225874|NCT02466126|Behavioral|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
225875|NCT02466113|Other|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
225876|NCT02466113|Other|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and <12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
225877|NCT02466100|Behavioral|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
225878|NCT02466087|Drug|Mg Cl|Four supplements a day for 6 weeks.
225879|NCT02466074|Drug|Acetazolamide|see arm description
225880|NCT02466074|Drug|Placebo|Placebo arm
225881|NCT02466061|Behavioral|Telemedicine Weight Management plus Wi-Fi Scale (Arm A)|Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
225882|NCT02466061|Behavioral|Text for Diet (Text4Diet) Group (Arm B)|Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
225883|NCT02466061|Behavioral|Enhanced Usual Care Group (Arm C)|Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
225884|NCT02466048|Procedure|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
225885|NCT02466048|Device|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
225886|NCT02466035|Dietary Supplement|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
225887|NCT02466022|Drug|Dexmedetomidine|Bolus dose prior to spinal anesthetic
225888|NCT02466022|Drug|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
225889|NCT02466022|Drug|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
225892|NCT02466009|Drug|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
225893|NCT02465996|Device|pCLE examination|All FD patients received pCLE examination.
225894|NCT02465996|Drug|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
225895|NCT02465983|Biological|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
225896|NCT02465983|Drug|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
225897|NCT02465970|Device|STARSTIM|"Multifocal transcranial direct current stimulation.~CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~The stimulation is applied during a 60 min session"
225898|NCT02465970|Device|sham TDCS|
225899|NCT02465957|Biological|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
225900|NCT02465944|Drug|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
225901|NCT02465944|Drug|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
225902|NCT02465931|Other|Paper and Pencil Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacArthur Competence Assessment Tool (MacCAT) Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
225903|NCT02465931|Other|Digital Informed Consent Tool|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacArthur Competence Assessment Tool (MacCAT) /flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
225904|NCT02465918|Device|motor cortex stimulation (Change of Stimulation Timing)|
225905|NCT02465905|Other|raw milk|
225906|NCT02465905|Other|Heated milk|
225907|NCT02465892|Behavioral|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
225908|NCT02465879|Other|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
225909|NCT02465866|Drug|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
225910|NCT02465866|Drug|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
225911|NCT02465866|Drug|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
225912|NCT02465866|Drug|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
225913|NCT02465853|Drug|Hyaluronic Acid|Injection Hyaluronic Acid in the experimental group
225914|NCT02465853|Drug|Physiological saline solution|Injection 0.9% Physiological saline solution<1.0 ml
225915|NCT02465853|Other|physical therapy and occupational therapy|rehabilitation
225916|NCT02465840|Procedure|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
225917|NCT02465840|Procedure|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
225918|NCT02465840|Other|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
225919|NCT02465827|Drug|nerve block with ropivacaine|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
225920|NCT02465827|Drug|nerve block with ropivacaine and with saline|nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
225921|NCT02465827|Drug|nerve block with saline|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
225922|NCT02465814|Drug|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
225923|NCT02465814|Drug|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
225924|NCT02465814|Drug|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
225925|NCT02465814|Drug|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
225926|NCT02465814|Drug|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
225927|NCT02465814|Drug|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
225928|NCT02465814|Drug|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
225929|NCT02465801|Drug|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
225930|NCT02465801|Drug|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
225931|NCT02465801|Drug|GCSF|GCSF 5 mcg/kg/day
225932|NCT02465788|Device|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
226087|NCT02464969|Drug|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist.
225933|NCT02465775|Device|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
225934|NCT02465762|Device|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
225935|NCT02465749|Drug|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
225936|NCT02465749|Device|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
225937|NCT02465749|Drug|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
225938|NCT02465749|Drug|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
225939|NCT02465749|Drug|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
225940|NCT02465749|Drug|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
225941|NCT02465736|Drug|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
225942|NCT02465736|Drug|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
225943|NCT02465736|Radiation|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
225944|NCT02465736|Procedure|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
225945|NCT02465736|Drug|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
225946|NCT02465736|Drug|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
225947|NCT02465723|Device|MRI with IVIM DW-MRI|
225948|NCT02465723|Other|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
225949|NCT02465710|Procedure|Pelvic organ prolapse surgery without mesh|retrospective study
225950|NCT02465710|Procedure|Pelvic organ prolapse surgery with mesh|
225951|NCT02465697|Behavioral|Reappraisal Training|
225952|NCT02465684|Procedure|unicondylar knee arthroplasty|
225953|NCT02465658|Other|Medical records were reviewed.|retrospective study
225954|NCT02465645|Drug|Carvedilol|
225955|NCT02465645|Drug|Carvedilol + Simvastatin|
225956|NCT02465632|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
225957|NCT02465632|Drug|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
225958|NCT02465632|Drug|Placebo|
225959|NCT02465606|Drug|Lebrikizumab|
225960|NCT02465606|Drug|Topical corticosteroid (TCS) cream|
225961|NCT02465593|Drug|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
225962|NCT02465593|Drug|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
225963|NCT02465593|Drug|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
225964|NCT02465593|Procedure|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
225965|NCT02465593|Radiation|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
225966|NCT02465580|Drug|hrIL-2 active|active group: placebo group =1:1
225967|NCT02465580|Drug|hrIL-2 placebo|active group: placebo group =1:1
225968|NCT02465567|Drug|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
225969|NCT02465567|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
225970|NCT02465567|Drug|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
225971|NCT02465567|Drug|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
225972|NCT02465554|Procedure|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
225973|NCT02465541|Procedure|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
225974|NCT02465541|Other|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
225975|NCT02465541|Other|educational intervention|Undergo enhanced usual care
225976|NCT02465541|Other|quality-of-life assessment|Ancillary studies
225977|NCT02465541|Other|questionnaire administration|Ancillary studies
225978|NCT02465528|Drug|Ceritinib (LDK378)|Ceritinib was to be administered orally once daily at a dose of 750 mg (5 capsules of 150 mg) on a continuous dosing schedule. A complete treatment cycle was defined as 28 days of once daily continuous treatment with ceritinib.
225979|NCT02465515|Biological|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
225980|NCT02465515|Biological|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
225981|NCT02465515|Biological|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
225982|NCT02465502|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
225983|NCT02465489|Drug|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
225984|NCT02465489|Drug|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
225985|NCT02465476|Procedure|telemedicine|treatment pathway organized by telemedicine
225986|NCT02465463|Procedure|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
225987|NCT02465463|Device|flexible sigmoidoscopy|
226131|NCT02464670|Biological|INO-4212|INO-4212 delivered IM followed by Electroporation
225988|NCT02465450|Drug|JBT-101 (lenabasum)|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
225989|NCT02465450|Other|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
225990|NCT02465437|Drug|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
225991|NCT02465437|Drug|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
225992|NCT02465437|Drug|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
225993|NCT02465424|Other|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
225994|NCT02465411|Device|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
225995|NCT02465398|Procedure|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
225996|NCT02465385|Drug|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
225997|NCT02465372|Behavioral|CSPAP|Comprehensive School Physical Activity Program.
225998|NCT02465359|Drug|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
225999|NCT02465346|Device|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
226000|NCT02465346|Device|Control stroke management|Conventional stroke management
226001|NCT02465333|Procedure|Heel Fat Grafting|"Fat grafting is widely used by plastic surgeons and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested with a small liposuction cannula. The fat is then centrifuged, cleaned, and loaded into 1cc syringes and injected into the heel fat pad using specialized cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
226002|NCT02465333|Drug|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot."
226003|NCT02465320|Drug|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
226004|NCT02465320|Drug|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
226005|NCT02465307|Behavioral|Confusion Assessment Method|Confusion Assessment Method (CAM) score
226006|NCT02465307|Device|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
226007|NCT02465307|Device|Commercially available camera|As part of facial recognition video system
226008|NCT02465307|Device|Internet Pod (iPod)|Monitors noise levels in the room
226009|NCT02465307|Diagnostic Test|Cortisol Swab|Cortisol level collected through self administered salivary swab
226010|NCT02465294|Dietary Supplement|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
226011|NCT02465294|Behavioral|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
226012|NCT02465294|Other|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
226013|NCT02465294|Other|Blood Test|All subjects will have blood tests performed.
226014|NCT02465294|Dietary Supplement|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
226015|NCT02465281|Other|Device: 3T scanner with MRI-compatible robot|
226016|NCT02465268|Biological|pp65-shLAMP DC with GM-CSF|
226017|NCT02465268|Biological|unpulsed PBMC and saline|
226018|NCT02465268|Drug|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
226019|NCT02465268|Drug|Saline|
226020|NCT02465268|Biological|pp65-flLAMP DC with GM-CSF|
226021|NCT02465255|Drug|Ketorolac|
226022|NCT02465255|Drug|Tramadol|
226023|NCT02465255|Drug|Acetaminophen|
226024|NCT02465229|Procedure|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
226025|NCT02465216|Other|Placebo|Placebo
226026|NCT02465216|Biological|ID93 + GLA-SE|ID93 + GLA-SE
226027|NCT02465203|Drug|Previous treatment in DEB025 study|Follow-up after DEB025 active study
226028|NCT02465164|Device|Cook catheter|
226029|NCT02465164|Drug|Oxytocin|
226030|NCT02465151|Other|Protein-based beverage|protein-based beverage
226031|NCT02465138|Drug|Ketorolac|Intravenous ketorolac
226032|NCT02465138|Drug|Placebo|Intravenous saline
226033|NCT02465125|Biological|red blood cell transfusion|
226034|NCT02465112|Drug|In111-Pentetréotide|
226035|NCT02465112|Other|simple monitoring without active therapy|
226132|NCT02464670|Biological|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
226036|NCT02465099|Device|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
226037|NCT02465099|Device|Electrocautery Dissection (ED)|Electrocautery dissection will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) PSF
226038|NCT02465086|Other|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
226039|NCT02465073|Device|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
226040|NCT02465073|Device|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
226041|NCT02465073|Device|Standard of Care Group|Subjects will receive Standard of Care only.
226042|NCT02465060|Drug|Adavosertib|Given PO
226043|NCT02465060|Drug|Afatinib|Given PO
226044|NCT02465060|Drug|Afatinib Dimaleate|Given PO
226045|NCT02465060|Drug|Binimetinib|Given PO
226046|NCT02465060|Drug|Capivasertib|Given PO
226047|NCT02465060|Drug|Copanlisib|Given IV
226048|NCT02465060|Drug|Copanlisib Hydrochloride|Given IV
226049|NCT02465060|Drug|Crizotinib|Given PO
226050|NCT02465060|Other|Cytology Specimen Collection Procedure|Optional correlative studies
226051|NCT02465060|Drug|Dabrafenib|Given PO
226052|NCT02465060|Drug|Dabrafenib Mesylate|Given PO
226053|NCT02465060|Drug|Dasatinib|Given PO
226054|NCT02465060|Drug|Defactinib|Given PO
226055|NCT02465060|Drug|Defactinib Hydrochloride|Given PO
226056|NCT02465060|Drug|Erdafitinib|Given PO
226057|NCT02465060|Drug|FGFR Inhibitor AZD4547|Given PO
226058|NCT02465060|Drug|Ipatasertib|Given PO
226059|NCT02465060|Other|Laboratory Biomarker Analysis|Undergo molecular analysis
226060|NCT02465060|Drug|Larotrectinib|Given PO
226061|NCT02465060|Drug|Larotrectinib Sulfate|Given PO
226062|NCT02465060|Biological|Nivolumab|Given IV
226063|NCT02465060|Drug|Osimertinib|Given PO
226064|NCT02465060|Drug|Palbociclib|Given PO
226065|NCT02465060|Biological|Pertuzumab|Given IV
226066|NCT02465060|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
226067|NCT02465060|Drug|Sapanisertib|Given PO
226068|NCT02465060|Drug|Sunitinib Malate|Given PO
226069|NCT02465060|Drug|Taselisib|Given PO
226070|NCT02465060|Drug|Trametinib|Given PO
226071|NCT02465060|Biological|Trastuzumab|Given IV
226072|NCT02465060|Biological|Trastuzumab Emtansine|Given IV
226073|NCT02465060|Drug|Ulixertinib|Give PO
226074|NCT02465060|Drug|Vismodegib|Given PO
226075|NCT02465047|Other|Self-help booklet|See Arm/Group Description
226076|NCT02465034|Device|Transcranial Magnetic Stimulation (Magstim)|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 Hz) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
226077|NCT02465034|Device|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
226078|NCT02465034|Device|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1ms rectangular pulses at an intensity to evoke a 1mV response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
226079|NCT02465034|Device|Corticocortical Paired Associative Stimulation|Corticocortical Paired associative stimulation (ccPAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25Hz for 12 minutes. The interstimulus interval will range from 5-15ms depending on site of stimulation.Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This corticocortical paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
226080|NCT02465034|Device|Sham Paired Associative Stimulation|The sham paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25Hz for 12 minutes. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
226081|NCT02465021|Other|Dietary intervention|All arms are given to all participants, in a randomized order
226082|NCT02465008|Drug|Levobupivacaine|
226083|NCT02465008|Drug|Placebo|
226084|NCT02464995|Device|Bronchial thermoplasty with the Alair System|
226085|NCT02464982|Procedure|Tattoo|tattoo device with EC standards, and sterile single-use only needle
226086|NCT02464969|Drug|Apixaban|Tablet or Solution
226732|NCT02460289|Drug|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
226088|NCT02464943|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
226089|NCT02464917|Device|Device: simple facemask to administer supplemental oxygen|
226090|NCT02464904|Device|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
226091|NCT02464904|Other|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
226092|NCT02464891|Drug|CCX168|
226093|NCT02464878|Drug|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
226094|NCT02464878|Procedure|Islet Transplantation|
226095|NCT02464878|Drug|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
226096|NCT02464878|Drug|Basiliximab|Basiliximab will be used for subsequent transplants.
226097|NCT02464878|Drug|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
226098|NCT02464865|Drug|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
226099|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
226100|NCT02464865|Drug|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.~If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
226101|NCT02464852|Behavioral|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
226102|NCT02464852|Behavioral|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
226103|NCT02464852|Device|Sheffield Support Snood|
226104|NCT02464852|Device|sEMG|
226105|NCT02464826|Drug|Nailprotex|Nailprotex apply to the abnormal nail twice daily
226106|NCT02464813|Drug|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
226107|NCT02464813|Drug|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
226108|NCT02464813|Drug|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
226109|NCT02464800|Procedure|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
226110|NCT02464787|Dietary Supplement|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
226111|NCT02464774|Procedure|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
226112|NCT02464774|Procedure|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
226113|NCT02464774|Drug|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
226114|NCT02464774|Radiation|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
226115|NCT02464761|Drug|Visudyne|
226116|NCT02464748|Other|TiM telehealth arm|
226117|NCT02464735|Device|Polysomnography|
226118|NCT02464722|Drug|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
226119|NCT02464722|Drug|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
226120|NCT02464722|Drug|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
226121|NCT02464722|Drug|Propofol|Anesthesia was induced with propofol 2 mg kg-1
226122|NCT02464722|Drug|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
226123|NCT02464709|Drug|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
226124|NCT02464709|Drug|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
226125|NCT02464696|Other|Non-Invasive Positive Pressure Ventilation (NIPPV)|2 hours on NIPPV, alternating with < 2 hours off NIPPV, with continuous NIPPV at night or while sleeping with a minimum recommended time of 8 total hours of NIPPV/day.
226126|NCT02464696|Other|High Flow Nasal Cannula Oxygen Therapy|Participants maintained on high flow nasal cannula oxygen therapy.
226127|NCT02464683|Dietary Supplement|VitaminD|200 International Units (oral dose) daily of 60 days
226128|NCT02464670|Biological|INO-4201|INO-4201 delivered IM followed by Electroporation
226129|NCT02464670|Biological|INO-4202|INO-4202 delivered IM followed by Electroporation
226130|NCT02464670|Biological|INO-4201|INO-4201 delivered ID followed by Electroporation
226133|NCT02464670|Biological|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
226134|NCT02464657|Drug|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.~Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
226135|NCT02464657|Drug|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
226136|NCT02464657|Drug|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
226137|NCT02464657|Drug|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
226138|NCT02464657|Drug|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
226139|NCT02464644|Other|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
226140|NCT02464631|Drug|Sofosbuvir + Ribavirin 1|
226141|NCT02464631|Drug|Sofosbuvir + Ribavirin 2|
226142|NCT02464631|Drug|Sofosbuvir + Ribavirin 3|
226143|NCT02464618|Behavioral|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
226144|NCT02464605|Biological|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
226145|NCT02464592|Procedure|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
226146|NCT02464566|Behavioral|Intensive lifestyle intervention|
226147|NCT02464566|Other|Health Education|
226148|NCT02464553|Other|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
226149|NCT02464540|Procedure|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
226150|NCT02464540|Procedure|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
226151|NCT02464527|Behavioral|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
226152|NCT02464527|Other|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
226153|NCT02464514|Other|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
226154|NCT02464514|Other|High fat meal|58% fat, 17% protein, and 25% carbohydrate
226155|NCT02464501|Other|Paclitaxel administration using the OPC|
226156|NCT02464488|Other|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
226157|NCT02464475|Other|osteopathic manipulative treatment|
226158|NCT02464475|Other|sham osteopathic treatment|
226159|NCT02464462|Dietary Supplement|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
226160|NCT02464462|Other|Placebo|Rice powder pills
226161|NCT02464449|Behavioral|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
226162|NCT02464449|Behavioral|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
226163|NCT02464436|Drug|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
226164|NCT02464423|Behavioral|Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)|
226165|NCT02464410|Behavioral|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
226166|NCT02464410|Behavioral|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
226167|NCT02464410|Other|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
226168|NCT02464397|Device|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
226169|NCT02464384|Procedure|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
226170|NCT02464371|Other|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
226171|NCT02464358|Behavioral|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
226172|NCT02464358|Behavioral|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
226173|NCT02464345|Behavioral|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
226174|NCT02464345|Behavioral|CBT-E|CBT-E therapy
226175|NCT02464332|Drug|BLZ-100|"All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.~Three different imaging windows will be investigated during the study:~Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)~All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups."
226176|NCT02464319|Drug|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
226177|NCT02464319|Drug|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
226178|NCT02464306|Drug|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
226179|NCT02464293|Other|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
226180|NCT02464280|Other|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
226181|NCT02464280|Other|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
226182|NCT02464280|Other|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
226183|NCT02464254|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
226184|NCT02464254|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
226185|NCT02464241|Other|only examination|
226186|NCT02464228|Drug|Tipifarnib|oral
226187|NCT02464215|Procedure|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
226188|NCT02464215|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
226189|NCT02464202|Other|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
226190|NCT02464189|Other|Q-Kap|
226191|NCT02464176|Drug|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
226192|NCT02464176|Drug|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
226193|NCT02464176|Drug|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
226194|NCT02464176|Procedure|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
226195|NCT02464176|Drug|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
226196|NCT02464163|Biological|Panblok|Intramuscular injection
226197|NCT02464163|Biological|rHA adjuvant|Intramuscular injection
226198|NCT02464150|Dietary Supplement|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily.
226199|NCT02464137|Radiation|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
226200|NCT02464124|Drug|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
226201|NCT02464124|Drug|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
226202|NCT02464111|Other|Treatment 1: Control|No supplement provided.
226733|NCT02460276|Drug|Lenalidomide|
226203|NCT02464111|Dietary Supplement|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
226204|NCT02464111|Dietary Supplement|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
226205|NCT02464085|Other|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
226206|NCT02464072|Procedure|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
226207|NCT02464072|Procedure|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
226208|NCT02464072|Procedure|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
226209|NCT02464059|Drug|Vitamin D3|The design of the study to complete this aim will be in the format of a baseline and repeat bronchoscopy after oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
226210|NCT02464046|Drug|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
226211|NCT02464046|Drug|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
226212|NCT02464033|Drug|GAD-Alum|Recombinant Human Glutamic Acid Decarboxylase (rhGAD65)
226213|NCT02464033|Drug|Vitamin D|
226214|NCT02464033|Drug|Etanercept|
226215|NCT02464020|Drug|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
226216|NCT02464007|Biological|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
226217|NCT02463994|Drug|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
226218|NCT02463994|Radiation|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
226219|NCT02463981|Device|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
226220|NCT02463968|Procedure|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
226221|NCT02463968|Procedure|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
226222|NCT02463955|Device|flexible video endoscope|Thoracoscopy is done using flexible video endoscope
226223|NCT02463955|Device|video-rigid thoracoscope|Thoracoscopy is done using video-rigid thoracoscope
226224|NCT02463942|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
226225|NCT02463942|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
226226|NCT02463942|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
226227|NCT02463929|Drug|Diphenhydramine|Intravenous Injection
226228|NCT02463929|Drug|normal saline|Intravenous Injection
226229|NCT02463929|Drug|Ketamine|Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
226230|NCT02463929|Drug|Sevoflurane|Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
226231|NCT02463929|Drug|Bupivacaine|Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
226232|NCT02463916|Other|Exercise|8 week structured exercise programme
226233|NCT02463903|Behavioral|Coping Effectiveness Training (CET)|The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
226234|NCT02463890|Other|Training|
226235|NCT02463890|Other|Control|
226236|NCT02463877|Procedure|Minimally-Invasive Procedure|Laparoscopy
226237|NCT02463864|Other|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
226238|NCT02463864|Other|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
226239|NCT02463851|Device|PVAC GOLD multielectrode catheter|Cardiac ablation for Atrial Fibrillation
226240|NCT02463851|Device|Contact Force single-tip ablation catheter|
226241|NCT02463838|Other|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
226242|NCT02463825|Drug|Pimozide 2 mg per day|
226243|NCT02463825|Drug|Pimozide 4 mg per day|
226244|NCT02463825|Drug|Placebo (Lactose tablet)|
226245|NCT02463812|Drug|Intralipid|
226246|NCT02463812|Drug|Saline|
226734|NCT02460276|Drug|Ibrutinib|
226247|NCT02463799|Drug|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
226248|NCT02463799|Biological|Sipuleucel-T|3 infusions of sipuleucel-T alone
226249|NCT02463786|Other|No intervention|No intervention
226250|NCT02463773|Device|Ultrasound|Diaphragmatic excursion ultrasound assessment
226251|NCT02463760|Other|Medical imaging|
226252|NCT02463747|Drug|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
226253|NCT02463747|Drug|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
226254|NCT02463747|Drug|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
226255|NCT02463747|Drug|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
226256|NCT02463721|Other|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
226257|NCT02463708|Behavioral|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
226258|NCT02463695|Procedure|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
226259|NCT02463682|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
226260|NCT02463682|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:~DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
226261|NCT02463669|Device|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
226262|NCT02463643|Drug|Z-215 10mg|Z-215 10mg, capsules
226263|NCT02463643|Drug|Z-215 20mg|Z-215 20mg, capsules
226264|NCT02463643|Drug|Z-215 Placebo|Z-215 placebo-matching capsules
226265|NCT02463643|Drug|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
226266|NCT02463643|Drug|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
226267|NCT02463630|Procedure|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
226268|NCT02463617|Other|magnetic resonance imaging|
226269|NCT02463604|Procedure|Coronary Angiography|Coronary angiography is performed following usual site standards
226270|NCT02463591|Drug|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
226271|NCT02463565|Other|no intervention|
226272|NCT02463552|Drug|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
226273|NCT02463526|Other|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
226274|NCT02463526|Other|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
226275|NCT02463513|Dietary Supplement|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
226276|NCT02463513|Dietary Supplement|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
226735|NCT02460276|Drug|Rituximab|
226277|NCT02463513|Dietary Supplement|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
226278|NCT02463500|Other|DFU|Standard care.
226279|NCT02463487|Device|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
226280|NCT02463487|Device|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
226281|NCT02463474|Behavioral|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
226282|NCT02463461|Device|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
226283|NCT02463461|Device|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
226284|NCT02463461|Device|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
226285|NCT02463461|Device|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
226286|NCT02463461|Device|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
226287|NCT02463448|Biological|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the ample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
226288|NCT02463435|Behavioral|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
226289|NCT02463435|Other|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
226290|NCT02463435|Dietary Supplement|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
226291|NCT02463409|Drug|Theophylline|24 hour infusion of IV theophylline
226292|NCT02463396|Behavioral|MBCT for ADHD|
226293|NCT02463383|Drug|Ibuprofen Tab 400 MG|400mg ibuprofen is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
226294|NCT02463383|Drug|Placebo tab|A placebo tablet is provided and an alcohol challenge (0.4g/kg bw) is given 30min later
226295|NCT02463370|Other|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
226296|NCT02463370|Other|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
226297|NCT02463370|Other|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
226298|NCT02463370|Other|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
226299|NCT02463357|Dietary Supplement|Quercetin|
226300|NCT02463357|Drug|Nifedipine extended release|
226301|NCT02463357|Drug|Methazolamide|
226302|NCT02463357|Drug|Metformin|
226303|NCT02463357|Drug|Placebo|
226304|NCT02463357|Drug|Nitrite|
226305|NCT02463344|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
226306|NCT02463331|Drug|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
226307|NCT02463331|Drug|prednisone|Prednisone 5-15 mg/day until the end of the study
226308|NCT02463331|Drug|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
226309|NCT02463318|Drug|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
226310|NCT02463318|Other|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
226311|NCT02463305|Drug|Creatine monohydrate|
226312|NCT02463305|Other|Placebo|
226313|NCT02463292|Other|no intervention|no intervention
226314|NCT02463279|Device|Sinusys Dilation System|Dilation of frontal recess and/or sphenoid sinus ostia
226315|NCT02463266|Behavioral|SUSTAIN Monitoring and Care Management|Program participants are offered clinical services based on symptom severity and clinical need. Follow-up Monitoring consists of up to 4 brief, structured assessments following the baseline clinical assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor symptoms, adherence, side effects, and response to treatment. Care Management incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
226316|NCT02463227|Biological|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.~Administered over about 30 to 60 minutes using a volumetric pump."
226317|NCT02463214|Other|Engineered Room|"Touchless devices:~Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors~Copper products:~Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.~Titanium dioxide paint:~Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
226318|NCT02463201|Behavioral|Weight loss|
226368|NCT02462798|Other|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
226319|NCT02463188|Behavioral|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
226320|NCT02463175|Drug|Plasmalyte|Boluses of 5ml/kg of plasmalyte
226321|NCT02463175|Procedure|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
226322|NCT02463162|Other|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
226323|NCT02463149|Behavioral|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
226324|NCT02463136|Behavioral|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
226325|NCT02463136|Device|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).~Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
226326|NCT02463123|Device|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
226327|NCT02463110|Drug|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
226328|NCT02463110|Drug|No treatment|
226329|NCT02463110|Drug|Placebo|
226330|NCT02463097|Device|Insulin Pump|Closed Loop Algorithm
226331|NCT02463084|Other|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
226332|NCT02463084|Other|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
226333|NCT02463071|Drug|AZD0585|1g soft capsule
226334|NCT02463071|Drug|AZD0585 placebo|1g soft capsule
226335|NCT02463058|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
226336|NCT02463045|Drug|TOP1288|
226337|NCT02463032|Drug|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
226338|NCT02463019|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
226339|NCT02463006|Drug|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
226340|NCT02463006|Drug|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
226341|NCT02462993|Drug|Aloe Vera|Local drug delivery of aloe vera gel
226342|NCT02462967|Drug|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
226343|NCT02462967|Drug|Placebo|Placebo for GR-MD-02
226344|NCT02462954|Device|ContraGel|
226345|NCT02462954|Device|HEC Universal Placebo gel|
226346|NCT02462941|Drug|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
226347|NCT02462941|Procedure|Cardiac catheterization|(non-experimental) standard procedure
226348|NCT02462928|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
226349|NCT02462928|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
226350|NCT02462928|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
226351|NCT02462915|Device|i-gel|"a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.~gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration."
226352|NCT02462915|Device|endotracheal tube|traditional and regularly use in many surgeries for maintaining the airway.
226353|NCT02462915|Drug|lidocaine, propofol, fentanyl and cisatracurium|
226354|NCT02462902|Drug|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
226355|NCT02462902|Drug|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
226356|NCT02462889|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection
226357|NCT02462889|Drug|Placebo|Sham injection
226358|NCT02462876|Device|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
226359|NCT02462863|Dietary Supplement|Arginine and fish oil|Dietary supplements
226360|NCT02462850|Drug|CL-108|
226361|NCT02462837|Drug|Mirabegron|
226362|NCT02462837|Drug|Placebo|
226363|NCT02462824|Behavioral|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
226364|NCT02462811|Drug|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
226365|NCT02462811|Drug|Placebo|
226366|NCT02462811|Drug|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
226367|NCT02462798|Other|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
226369|NCT02462785|Behavioral|In-person Carbohydrate Counting Class|An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
226370|NCT02462785|Behavioral|Online Carbohydrate Counting Tutorial|A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
226371|NCT02462772|Drug|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
226372|NCT02462772|Drug|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
226373|NCT02462759|Drug|Nusinersen|Administered by intrathecal injection.
226374|NCT02462759|Procedure|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
226375|NCT02462746|Dietary Supplement|L-Cysteine|The trade name is New Root Herbal Inc.
226376|NCT02462733|Behavioral|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
226377|NCT02462733|Behavioral|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
226378|NCT02462720|Drug|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
226379|NCT02462720|Device|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
226380|NCT02462707|Drug|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
226381|NCT02462694|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
226382|NCT02462694|Behavioral|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
226383|NCT02462681|Drug|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
226384|NCT02462668|Procedure|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
226385|NCT02462668|Procedure|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
226386|NCT02462668|Procedure|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
226387|NCT02462655|Other|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
226388|NCT02462655|Other|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
226389|NCT02462642|Dietary Supplement|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
226390|NCT02462642|Other|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
226391|NCT02462642|Dietary Supplement|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
226392|NCT02462642|Other|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
226393|NCT02462629|Drug|BLZ-100|
226394|NCT02462616|Other|not intervention|This is a cross-sectional study, no intervention was performed.
226395|NCT02462603|Drug|EPI-589|EPI-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
226396|NCT02462590|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
226397|NCT02462590|Drug|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
226398|NCT02462577|Drug|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
226399|NCT02462551|Device|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
226525|NCT02461758|Biological|Standard dose Influenza vaccine (SDIV)|
226400|NCT02462538|Drug|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
226401|NCT02462538|Drug|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
226402|NCT02462525|Drug|ABBV-838|Varying doses of ABBV-838
226403|NCT02462525|Drug|Pomalidomide|Administered orally per the label.
226404|NCT02462525|Drug|Dexamethasone|Administered orally per the label.
226405|NCT02462499|Drug|Inspra (eplerenone)|
226406|NCT02462486|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
226407|NCT02462486|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
226408|NCT02462486|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
226409|NCT02462473|Drug|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
226410|NCT02462473|Drug|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
226411|NCT02462473|Drug|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
226412|NCT02462473|Drug|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
226413|NCT02462473|Drug|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
226414|NCT02462460|Device|MRI|
226415|NCT02462460|Behavioral|Optional Screening Questionnaire|
226416|NCT02462447|Drug|11C-sarcosine|Radiotracer injection for PET/CT scan
226417|NCT02462447|Drug|11C-choline|Radiotracer injection for PET/CT scan
226418|NCT02462434|Behavioral|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
226419|NCT02462421|Drug|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
226420|NCT02462408|Procedure|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
226421|NCT02462408|Procedure|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
226422|NCT02462395|Device|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.~A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.~Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
226423|NCT02462382|Procedure|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
226424|NCT02462382|Drug|Ropivacaine|
226425|NCT02462382|Drug|Saline|
226426|NCT02462369|Drug|Saxagliptin|
226427|NCT02462369|Drug|glimepiride|
226428|NCT02462356|Procedure|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
226429|NCT02462356|Procedure|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
226430|NCT02462343|Other|walk tests|
226431|NCT02462330|Drug|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
226432|NCT02462330|Drug|Placebo comparator|injections of human albumin
226433|NCT02462317|Drug|botulinum A toxin|botulinum toxin injection
226434|NCT02462317|Drug|Baclofen|baclofen oral tablet
226435|NCT02462317|Drug|Placebo toxin|placebo injection
226436|NCT02462317|Drug|placebo baclofen|placebo oral tablet
226437|NCT02462304|Procedure|End-Point-Management grid laser|
226438|NCT02462304|Drug|ranibizumab|
226439|NCT02462304|Drug|Bevacizumab|
226440|NCT02462291|Other|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
226441|NCT02462278|Device|TempuRing|
226442|NCT02462265|Drug|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) & Oshadi R (180mg TID) will be administrated;
226443|NCT02462265|Drug|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
226526|NCT02461758|Biological|High dose influenza vaccine (HDIV)|
226444|NCT02462252|Drug|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
226445|NCT02462252|Drug|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
226446|NCT02462252|Drug|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
226447|NCT02462252|Drug|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
226448|NCT02462239|Other|Whole-body FDG PET-CT|
226449|NCT02462226|Behavioral|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
226450|NCT02462226|Behavioral|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
226451|NCT02462213|Other|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
226452|NCT02462213|Other|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
226453|NCT02462200|Procedure|Breast-conserving surgery (BCS)|
226454|NCT02462200|Procedure|Cavity shave margins (CSM)|
226455|NCT02462200|Behavioral|BREAST-Q Questionnaire|
226456|NCT02462200|Device|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
226457|NCT02462200|Other|Indocyanine green|
226458|NCT02462200|Device|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
226459|NCT02462200|Procedure|Peripheral blood draw|-Time of surgery if coordinator is available
226460|NCT02462187|Drug|NVN1000 8% Gel|once and twice daily
226461|NCT02462187|Drug|NVN1000 16%|once daily
226462|NCT02462187|Drug|Vehicle|placebo comparator
226463|NCT02462187|Drug|NVN1000 24%|once daily
226464|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
226465|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
226466|NCT02462174|Drug|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
226467|NCT02462174|Drug|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
226468|NCT02462161|Drug|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
226469|NCT02462161|Drug|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
226470|NCT02462148|Drug|Dexamethasone|Used in nerve block mixture
226471|NCT02462148|Drug|Bupivacaine|Used in nerve block mixture
226472|NCT02462148|Drug|Epinephrine|Used in nerve block mixture
226473|NCT02462148|Procedure|Saphenous Peripheral Nerve Block|Peripheral nerve block.
226474|NCT02462135|Behavioral|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
226475|NCT02462135|Behavioral|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
226476|NCT02462122|Drug|IDP-118 Lotion|Lotion
226477|NCT02462122|Drug|IDP-118 Vehicle Lotion|Lotion
226478|NCT02462109|Drug|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.
226479|NCT02462096|Device|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
226480|NCT02462083|Drug|IDP-118 Lotion|Applied topically once daily
226481|NCT02462070|Drug|IDP-118 Lotion|Lotion
226482|NCT02462070|Drug|IDP-118 Vehicle Lotion|Lotion
226483|NCT02462057|Other|Email message regarding the HealthyFood benefit|
226484|NCT02462044|Drug|240 mg Iodine|
226485|NCT02462044|Drug|300 mg Iodine|
226486|NCT02462044|Drug|370 mg Iodine|
226487|NCT02462031|Drug|KD101|200mg, 400mg, 800mg, 1400mg
226488|NCT02462031|Drug|placebo|200mg, 400mg, 800mg
226527|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
226736|NCT02460263|Device|Tablo Hemodialysis System|
226489|NCT02462018|Device|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.~For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.~During the assessments each child will go through:~A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.~C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.~E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
226490|NCT02461992|Drug|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
226491|NCT02461979|Other|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
226492|NCT02461966|Other|Aflatoxin|Evaluation of Aflatoxin level
226493|NCT02461953|Device|hemoperfusion apparatus|
226494|NCT02461953|Device|low flux dialyzer|
226495|NCT02461953|Device|high flux dialyzer|
226496|NCT02461940|Behavioral|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
226497|NCT02461927|Drug|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
226498|NCT02461927|Drug|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
226499|NCT02461927|Drug|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
226500|NCT02461914|Drug|PEX168|200µg,injected subcutaneously,once a week.
226501|NCT02461914|Drug|Warfarin|5mg,oral,two times.
226502|NCT02461901|Other|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
226503|NCT02461901|Other|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
226504|NCT02461901|Other|Fecal sampling|Collection of fecal samples for C. difficile spores
226505|NCT02461888|Drug|Ixazomib|Chemotherapy
226506|NCT02461888|Drug|Cyclophosphamide|Chemotherapy
226507|NCT02461888|Drug|Dexamethasone|Chemotherapy
226508|NCT02461875|Drug|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
226509|NCT02461875|Drug|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
226510|NCT02461862|Behavioral|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
226511|NCT02461862|Procedure|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
226512|NCT02461862|Procedure|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
226513|NCT02461849|Drug|Imatinib|Imatinib 400mg qd daily
226514|NCT02461836|Drug|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
226515|NCT02461836|Radiation|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
226516|NCT02461823|Device|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
226517|NCT02461823|Device|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
226518|NCT02461810|Device|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
226519|NCT02461810|Procedure|Balloon Kyphoplasty|
226520|NCT02461797|Other|healthy controls|biopsy of nasal mucosa for healthy controls
226521|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
226522|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
226523|NCT02461784|Procedure|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.~Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
226524|NCT02461771|Drug|APL-2|On treatment day, subjects will be administered a single 100 μL IVT injection of APL-2 at the dose corresponding to their treatment assignment.
226528|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
226529|NCT02461732|Behavioral|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
226530|NCT02461732|Behavioral|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:~drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
226531|NCT02461719|Drug|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
226532|NCT02461719|Drug|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
226533|NCT02461706|Drug|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
226534|NCT02461706|Other|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
226535|NCT02461693|Drug|Caffeine|200mg delivered as pill; one-time dose
226536|NCT02461693|Drug|Placebo|Lactose-based pill; one-time dose
226537|NCT02461680|Procedure|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
226538|NCT02461680|Procedure|suture|
226539|NCT02461667|Drug|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
226540|NCT02461667|Drug|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
226541|NCT02461667|Drug|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
226542|NCT02461654|Other|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
226543|NCT02461641|Other|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
226544|NCT02461641|Other|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
226545|NCT02461641|Other|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
226546|NCT02461628|Behavioral|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
226547|NCT02461589|Drug|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen except subjects who received semaglutide flexible dosing.
226548|NCT02461589|Drug|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
226549|NCT02461589|Drug|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
226550|NCT02461576|Device|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
226551|NCT02461563|Drug|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
226552|NCT02461563|Drug|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
226553|NCT02461563|Drug|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
226554|NCT02461550|Device|Irreversible Electroporation Ablation|
226555|NCT02461537|Drug|HAM|High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)
226556|NCT02461537|Drug|LDAC and/or Mitoxantrone|Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
226557|NCT02461524|Device|Endurant Evo AAA Stent Graft System|
226558|NCT02461524|Procedure|Endovascular aneurysm repair (EVAR)|
226559|NCT02461511|Other|Therapeutic Education|participation in a therapeutic education program on diabetes
226560|NCT02461485|Other|Fermented milk product containing Probiotics|2 pots/day during 28 days
226561|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
226562|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
226563|NCT02461485|Other|Non fermented Milk Product|2 pots/day during 28 days
226564|NCT02461472|Other|not intervention|This is a cross-sectional study, no intervention was performed.
226565|NCT02461433|Device|Prevena|Prevena Incision Management system
226566|NCT02461433|Device|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
226567|NCT02461407|Drug|Anlotinib|Anlotinib p.o. qd
226568|NCT02461407|Drug|Placebo|Placebo p.o. qd
226569|NCT02461394|Device|Blood glucose monitoring systems for self-testing|
226570|NCT02461381|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
226571|NCT02461368|Drug|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226572|NCT02461368|Drug|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226573|NCT02461368|Drug|Glenohumeral lidocaine injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226574|NCT02461368|Drug|Glenohumeral lidocaine injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226575|NCT02461368|Drug|Glenohumeral normal saline injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226576|NCT02461368|Drug|Glenohumeral normal saline injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226577|NCT02461368|Drug|Glenohumeral Omnipaque injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226578|NCT02461368|Drug|Glenohumeral Omnipaque injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
226579|NCT02461355|Behavioral|Aphasia therapy|Aphasia therapy using a computerized scripting program
226580|NCT02461355|Device|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
226581|NCT02461355|Device|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
226582|NCT02461342|Other|not intervention|This is a cross-sectional study, no intervention was performed.
226583|NCT02461329|Drug|Gelofusine® B. Braun|Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
226584|NCT02461329|Drug|Ringerfundin ® B. Braun|Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
226585|NCT02461316|Other|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
226586|NCT02461303|Other|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
226587|NCT02461290|Radiation|Chemotherapy|
226588|NCT02461290|Drug|Rituximab|
226589|NCT02461277|Other|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
226590|NCT02461264|Drug|Single red blood packed cells Transfusion|
226591|NCT02461264|Drug|Two packed red blood cells Transfusion|
226592|NCT02461251|Device|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
226593|NCT02461238|Other|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
226594|NCT02461238|Other|Nutrition education|Nutrition education workshops taught by a dietician
226595|NCT02461212|Procedure|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
226596|NCT02461199|Biological|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
226597|NCT02461186|Drug|Arterolane maleate-piperaquine phosphate (Synriam)|
226598|NCT02461186|Drug|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
226599|NCT02461173|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
226600|NCT02461173|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
226601|NCT02461173|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
226602|NCT02461173|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
226608|NCT02461147|Procedure|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
226609|NCT02461134|Drug|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
226610|NCT02461121|Genetic|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
226611|NCT02461121|Genetic|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
226612|NCT02461121|Drug|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
226613|NCT02461121|Drug|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
226614|NCT02461121|Drug|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
226615|NCT02461121|Drug|fludarabine|30 mg/m2/d for 5days
226616|NCT02461121|Drug|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
226617|NCT02461121|Drug|cyclophosphamide|40 mg/kg/d for 2 days
226618|NCT02461108|Behavioral|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
226619|NCT02461108|Behavioral|Tax|Frame the price difference as a 10% tax on less nutritious food items.
226620|NCT02461108|Behavioral|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
226621|NCT02461095|Other|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
226622|NCT02461095|Other|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
226623|NCT02461082|Device|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
226624|NCT02461082|Other|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
226625|NCT02461069|Drug|Dimethyl fumarate|Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
226626|NCT02461056|Drug|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
226627|NCT02461056|Drug|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
226628|NCT02461043|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
226629|NCT02461043|Radiation|radiation|radiation
226630|NCT02461030|Drug|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
226631|NCT02461030|Drug|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
226632|NCT02461030|Procedure|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
226633|NCT02461017|Other|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
226634|NCT02461017|Other|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
226635|NCT02461004|Drug|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
226636|NCT02461004|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
226637|NCT02460991|Device|DEB-TACE|
226638|NCT02460991|Drug|Sorafenib|
226639|NCT02460978|Drug|Dapagliflozin|Tablets
226640|NCT02460978|Other|Placebo for dapagliflozin|Tablets
226641|NCT02460926|Procedure|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
226642|NCT02460913|Procedure|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
227158|NCT02457182|Other|Mindfulness-based Stress Reduction (MBSR)|
226643|NCT02460913|Drug|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
226644|NCT02460900|Drug|Varenicline|
226645|NCT02460900|Behavioral|Positively Smoke Free|
226646|NCT02460900|Drug|Placebo|
226647|NCT02460900|Behavioral|Standard of Care|
226648|NCT02460887|Drug|Gemcitabine|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
226649|NCT02460887|Drug|cisplatin|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
226650|NCT02460887|Drug|cisplatin|Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
226651|NCT02460887|Radiation|Intensity-modulated Radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
226652|NCT02460874|Drug|Glyburide|1.25mg, twice a day
226653|NCT02460874|Other|Placebo|1.25mg, twice a day
226654|NCT02460861|Procedure|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
226655|NCT02460861|Procedure|RPVE|Open Radical prostatovesiculectomy in Magdeburg
226656|NCT02460861|Procedure|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
226657|NCT02460861|Procedure|CE|Open cystectomy in Magdeburg/Gronau
226658|NCT02460861|Procedure|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
226659|NCT02460848|Other|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.~The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
226660|NCT02460848|Other|Outpatient therapeutic program and counseling|
226661|NCT02460835|Radiation|Adaptive Radiation Therapy|
226662|NCT02460822|Device|MyChemoCare iPad application|
226663|NCT02460809|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
226664|NCT02460796|Other|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
226665|NCT02460783|Dietary Supplement|Boost A|Supplement providing 530 Kcal/Bottle
226666|NCT02460783|Behavioral|Healthy Living Diet|Counseling and educational material on diet portion, consistency
226667|NCT02460770|Drug|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
226668|NCT02460757|Other|Laryngoscopy|Observation of glottic width in different arms
226669|NCT02460744|Radiation|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
226670|NCT02460731|Biological|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors] Solution for intravenous infusion
226671|NCT02460718|Behavioral|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
226672|NCT02460705|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
226673|NCT02460692|Drug|Placebos|Administration of vaporized cannabis plus either dronabinol or placebo pill
226674|NCT02460692|Drug|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
226675|NCT02460692|Drug|Vaporized Cannabis 3.7% THC/5.6% CBD|Administration of vaporized cannabis plus either dronabinol or placebo pill
226676|NCT02460679|Drug|EPI-589|An immediate release film-coated table at a 250 mg dosage strength.
226677|NCT02460666|Behavioral|Tai-Chi-Chih (TCC)|
226678|NCT02460666|Behavioral|Health Education and Wellness Classes (HEW)|
226679|NCT02460653|Device|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
226680|NCT02460640|Procedure|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
226681|NCT02460640|Procedure|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
226682|NCT02460640|Drug|Morphine|
226683|NCT02460640|Drug|Ropivacaine|
226684|NCT02460627|Drug|Lidocaine adhesive tape|700 mg for 12 hours
226685|NCT02460627|Other|Adhesive tape|For 12 hours
226686|NCT02460614|Procedure|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
226687|NCT02460614|Procedure|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
226688|NCT02460614|Other|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
226689|NCT02460601|Drug|Qizhiweitong granule|
226690|NCT02460588|Drug|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.~Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
226691|NCT02460588|Drug|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
226692|NCT02460588|Drug|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
226693|NCT02460575|Biological|Lactobacillus reuteri 17938|probiotic
226694|NCT02460575|Biological|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
226695|NCT02460562|Device|S-PRG filler|"Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.~The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567."
226696|NCT02460562|Device|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
226697|NCT02460549|Behavioral|therapeutic education program|
226698|NCT02460536|Behavioral|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
226699|NCT02460536|Behavioral|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
226700|NCT02460536|Behavioral|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
226701|NCT02460536|Behavioral|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
226702|NCT02460523|Procedure|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
226703|NCT02460523|Procedure|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
226704|NCT02460510|Drug|Mannitol|
226705|NCT02460510|Drug|3% hypertonic saline|
226706|NCT02460497|Drug|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
226707|NCT02460484|Biological|Autologous Cord Blood Infusion|Intravenous infusion
226708|NCT02460471|Radiation|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
226709|NCT02460445|Procedure|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
226710|NCT02460445|Drug|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
226711|NCT02460445|Drug|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
226712|NCT02460432|Device|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
226713|NCT02460432|Device|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
226714|NCT02460419|Drug|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
226715|NCT02460419|Other|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
226716|NCT02460406|Other|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching & walking so on).
226717|NCT02460406|Other|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
226718|NCT02460393|Drug|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people~Subcutaneous injection of different doses in healthy people"
226719|NCT02460393|Other|placebo|Subcutaneous injection of different doses for healthy people
226720|NCT02460380|Drug|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
226721|NCT02460380|Other|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
226722|NCT02460367|Drug|Docetaxel|
226723|NCT02460367|Biological|Tergenpumatucel-L|
226724|NCT02460367|Drug|Indoximod|
226725|NCT02460354|Drug|Metformin|Metformin 500 mg pill dispensed once orally
226726|NCT02460341|Drug|ondansetron|Ondansetron 8mg, 16mg, 24mg
226727|NCT02460341|Drug|placebo|placebo pill
226728|NCT02460315|Procedure|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
226729|NCT02460315|Procedure|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
226730|NCT02460302|Drug|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
226731|NCT02460302|Drug|Placebo|Placebo suppository inserted vaginally
226737|NCT02460250|Procedure|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
226738|NCT02460237|Procedure|Disease Screening|Complete HPV self-test
226739|NCT02460237|Other|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
226740|NCT02460237|Other|Informational Intervention|Receive standard instructions and information sheet
226741|NCT02460237|Other|Laboratory Biomarker Analysis|Correlative studies
226742|NCT02460237|Other|Survey Administration|Ancillary studies
226743|NCT02460224|Drug|LAG525|study drug 1
226744|NCT02460224|Drug|PDR001|study drug 2
226745|NCT02460211|Dietary Supplement|Vitamin D3|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
226746|NCT02460211|Dietary Supplement|Placebo|Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
226747|NCT02460198|Biological|Pembrolizumab|IV infusion
226748|NCT02460185|Behavioral|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
226749|NCT02460172|Device|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
226750|NCT02460172|Device|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision
226751|NCT02460159|Drug|EZ 10 mg/Atorva 20 mg FDC|
226752|NCT02460159|Drug|EZ 10 mg/Atorva 10 mg FDC|
226753|NCT02460146|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
226754|NCT02460146|Other|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
226755|NCT02460133|Drug|Paritaprevir|
226756|NCT02460133|Drug|Ritonavir|
226757|NCT02460133|Drug|Dasabuvir|
226758|NCT02460133|Drug|Ombitasvir|
226759|NCT02460133|Drug|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
226760|NCT02460120|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
226761|NCT02460107|Biological|Botulinum toxin type A|
226762|NCT02460107|Other|Normal saline|Placebo
226763|NCT02460094|Drug|BIIB092|See Arm Descriptions for dosing information.
226764|NCT02460094|Drug|Placebo|See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
226765|NCT02460081|Drug|PDA-002|
226766|NCT02460081|Drug|Placebo|
226767|NCT02460068|Drug|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
226768|NCT02460068|Drug|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
226769|NCT02460068|Drug|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
226770|NCT02460055|Device|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
226771|NCT02460055|Drug|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
226772|NCT02460055|Drug|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
226773|NCT02460055|Drug|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
226774|NCT02460055|Drug|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
226775|NCT02460055|Drug|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
226776|NCT02460042|Procedure|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
226777|NCT02460042|Device|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
226778|NCT02460029|Other|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
226779|NCT02460016|Drug|AK0529|AK0529 pellets for oral administration
226780|NCT02460003|Behavioral|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
226781|NCT02460003|Other|Home exercise program|Home exercise program
226782|NCT02459977|Drug|Basiliximab|Basiliximab induction therapy
226783|NCT02459977|Drug|No basiliximab|No basiliximab induction therapy
226784|NCT02459977|Procedure|Kidney transplantation|kidney transplantation
226785|NCT02459964|Drug|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
226786|NCT02459964|Drug|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
226787|NCT02459964|Behavioral|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
226788|NCT02459951|Other|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
227159|NCT02457182|Other|Usual medical therapy|
226789|NCT02459938|Drug|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
226790|NCT02459938|Drug|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
226791|NCT02459925|Behavioral|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
226792|NCT02459925|Behavioral|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
226793|NCT02459912|Procedure|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
226794|NCT02459912|Device|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
226795|NCT02459899|Drug|Placebo|Placebo, once daily, before the first meal of the day
226796|NCT02459899|Drug|Sotagliflozin|Sotagliflozin,once daily, before the first meal of the day
226797|NCT02459886|Drug|BIIB054|IV infusion
226798|NCT02459886|Drug|Placebo|IV infusion
226799|NCT02459873|Behavioral|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
226800|NCT02459860|Behavioral|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
226801|NCT02459860|Behavioral|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
226802|NCT02459847|Behavioral|Mindfulness Training|
226803|NCT02459847|Behavioral|Sonographic Biofeedback|
226804|NCT02459847|Other|Standard Care|
226805|NCT02459834|Other|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
226806|NCT02459834|Other|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
226807|NCT02459834|Other|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
226808|NCT02459821|Other|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
226809|NCT02459821|Other|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
226810|NCT02459795|Drug|Ingenol Mebutate (Perrigo)|
226811|NCT02459795|Drug|Ingenol Mebutate (Reference)|
226812|NCT02459795|Drug|Placebo gel|
226813|NCT02459782|Procedure|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
226814|NCT02459769|Behavioral|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
226815|NCT02459756|Other|Beverage: Spray dried blackcurrant powder dissolved in water|
226816|NCT02459756|Other|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
226817|NCT02459730|Procedure|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
226818|NCT02459730|Procedure|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
226819|NCT02459717|Other|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
226820|NCT02459717|Other|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
226821|NCT02459704|Procedure|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
226822|NCT02459704|Device|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
226850|NCT02459509|Drug|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
226948|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
226823|NCT02459691|Behavioral|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
226824|NCT02459691|Other|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
226825|NCT02459678|Behavioral|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
226826|NCT02459678|Other|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
226827|NCT02459665|Biological|Vaginal multiple lactobacilli-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
226828|NCT02459665|Drug|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
226829|NCT02459665|Biological|Vaginal Lcr35-containing probiotic for prevention of BV recurrence|Vaginal probiotic to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
226830|NCT02459652|Drug|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
226831|NCT02459652|Radiation|Radiation Therapy|Radiation therapy is delivered with >6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
226832|NCT02459639|Other|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:~A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.~Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
226833|NCT02459639|Other|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
226834|NCT02459626|Other|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
226835|NCT02459613|Other|99mTc-Annexin V-128 SPECT|
226836|NCT02459600|Other|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
226837|NCT02459587|Behavioral|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
226838|NCT02459574|Procedure|AVATAR-AF ablation|Experimental ablation protocol
226839|NCT02459574|Drug|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:~Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.~You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
226840|NCT02459574|Procedure|Conventional AF ablation|Conventional ablation procedure
226841|NCT02459561|Device|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
226842|NCT02459561|Other|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
226843|NCT02459548|Other|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
226844|NCT02459548|Other|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
226845|NCT02459535|Other|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
226846|NCT02459535|Other|oral stimulation saccharin|
226847|NCT02459535|Other|oral stimulation aspartame|
226848|NCT02459535|Other|oral stimulation sucralose|
226849|NCT02459522|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
227369|NCT02455739|Other|chewing gum|postoperative gum chewing to improve gastrointestinal function
226851|NCT02459496|Behavioral|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
226852|NCT02459483|Behavioral|Nurse phone call|
226853|NCT02459470|Procedure|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
226854|NCT02459457|Drug|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
226855|NCT02459457|Drug|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
226856|NCT02459457|Drug|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
226857|NCT02459457|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
226858|NCT02459444|Device|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
226859|NCT02459444|Other|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
226860|NCT02459431|Other|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
226861|NCT02459431|Other|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
226862|NCT02459418|Drug|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
226863|NCT02459418|Drug|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:~Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.~Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
226864|NCT02459405|Procedure|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
226865|NCT02459405|Device|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
226866|NCT02459392|Other|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:~Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.~Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
226867|NCT02459392|Drug|Hyaluronic Acid|
226868|NCT02459392|Drug|DepoMedrol|
226869|NCT02459379|Radiation|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
226870|NCT02459353|Drug|Dapagliflozin|
226871|NCT02459353|Drug|Placebo|
226872|NCT02459340|Other|therapeutic treatment (inpatient and outpatient setting)|
226873|NCT02459327|Behavioral|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
226874|NCT02459327|Behavioral|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
226875|NCT02459314|Dietary Supplement|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
226876|NCT02459314|Dietary Supplement|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
226877|NCT02459301|Drug|IPH2201|
226878|NCT02459288|Drug|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
226879|NCT02459288|Drug|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
226880|NCT02459275|Other|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day. A promotility agent will be started empirically concomitant with EN initiation. GRV will be checked every 4 hours and will be reinfused to the patient each time it is checked. GRV threshold is 500 ml. Once the patient shows tolerance of semi-elemental formula, the tube feeds will then be converted to standard polymeric formula. Daily, the patient will be reassessed for the need to continue promotility agents.
226881|NCT02459262|Biological|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
226882|NCT02459249|Other|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
226883|NCT02459249|Other|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
226884|NCT02459236|Drug|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
226885|NCT02459236|Drug|Placebo|
226886|NCT02459223|Dietary Supplement|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
226887|NCT02459223|Dietary Supplement|Khichadi|Khichadi.
226888|NCT02459210|Behavioral|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
226889|NCT02459210|Behavioral|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
226890|NCT02459197|Behavioral|Heat Pain Stimuli A|
226891|NCT02459197|Behavioral|Heat Pain Stimuli B|
226892|NCT02459197|Behavioral|Positive Video|
226893|NCT02459197|Behavioral|Neutral Video|
226894|NCT02459197|Drug|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
226895|NCT02459197|Drug|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
226896|NCT02459184|Other|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:~Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.~Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population~Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.~Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
226897|NCT02459171|Other|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
226898|NCT02459171|Other|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.~For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
226899|NCT02459171|Other|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
226900|NCT02459171|Other|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
226901|NCT02459158|Drug|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
226902|NCT02459158|Drug|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
226903|NCT02459145|Behavioral|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
226904|NCT02459132|Behavioral|High-intensity aerobic interval exercise|See arm/group description
226905|NCT02459119|Drug|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
226906|NCT02459093|Device|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
226907|NCT02459093|Device|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
226908|NCT02459080|Drug|TD-4208|
226909|NCT02459080|Drug|Placebo|
226910|NCT02459067|Biological|ImmuniCell®|Autologous γδ T Lymphocytes
226911|NCT02459054|Device|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
226912|NCT02459041|Other|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.~Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
226945|NCT02458755|Drug|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
226946|NCT02458742|Drug|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
226947|NCT02458742|Drug|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
226913|NCT02459028|Behavioral|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
226914|NCT02459028|Behavioral|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
226915|NCT02459015|Device|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
226916|NCT02459002|Behavioral|QOL Questionnaire|Participant outcomes assessed with survey
226917|NCT02459002|Behavioral|Caregiver Satisfaction Questionnaire|Caregiver satisfaction with quality of care assessed with surveys
226918|NCT02458989|Procedure|Scalpel|Use of a scalpel as a first incision during thyroid operation
226919|NCT02458989|Procedure|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
226920|NCT02458976|Device|PDL|
226921|NCT02458963|Procedure|IVF|Women will undergo one IVF cycle
226922|NCT02458963|Drug|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
226923|NCT02458937|Other|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
226924|NCT02458937|Other|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
226925|NCT02458937|Other|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
226926|NCT02458924|Biological|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
226927|NCT02458911|Device|Paclitaxel-eluting balloon|
226928|NCT02458898|Behavioral|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
226929|NCT02458872|Behavioral|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
226930|NCT02458859|Device|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
226931|NCT02458846|Other|Crowded HOTV Acuity Test|This is one of the most sensitive tests of acuity for vision screening of young children. The child is asked to recognize a letter (H,O,T,V) that is surrounded by bars to induce the crowding effects typical of amblyopia. Children were tested monocularly and was required to achieve at least 20/32 in each eye to pass. Children already wearing glasses were tested with their glasses on.
226932|NCT02458846|Other|Preschool Randot Stereoacuity Test|"This is a reliable screening test for stereo depth perception for young children. Children wear polarized stereoglasses and are asked to identify or match shapes that are hiding in the snow, which cannot be perceived if the child has abnormal binocular vision. Children were required to achieve at least 60 arcseconds of disparity to pass. Children already wearing glasses were tested with their glasses worn under the stereo glasses."
226933|NCT02458846|Device|Plusoptix Autorefractor|Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
226934|NCT02458846|Other|Comprehensive Eye Exam|Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near & far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
226935|NCT02458833|Behavioral|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
226936|NCT02458820|Procedure|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
226937|NCT02458794|Procedure|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
226938|NCT02458794|Device|LMA SupremeTM|
226939|NCT02458794|Device|Ambu-Aura GainTM|
226940|NCT02458781|Drug|Metronidazole|Metronidazole 500mg given twice daily for 14 days
226941|NCT02458781|Drug|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
226942|NCT02458781|Drug|Placebo|Placebo given twice daily for 14 days
226943|NCT02458768|Drug|IVF-M HP Inj.|
226944|NCT02458768|Drug|Menopur® Inj.|
227543|NCT02454387|Drug|ONO-4474 Part A2|Healthy volunteers
226949|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
226950|NCT02458729|Drug|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
226951|NCT02458729|Drug|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
226952|NCT02458729|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
226953|NCT02458716|Procedure|Robotic Assisted Radical Prostatectomy|Undergo RARP
226954|NCT02458716|Procedure|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
226955|NCT02458716|Other|Laboratory Biomarker Analysis|Correlative studies
226956|NCT02458716|Other|Quality-of-Life Assessment|Ancillary studies
226957|NCT02458716|Drug|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
226958|NCT02458703|Other|Cardiopulmonary exercise test|"Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis."
226959|NCT02458690|Behavioral|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
226960|NCT02458690|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
226961|NCT02458690|Drug|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. The depression clinical specialist (DCS) will work with the patient's primary care provider to develop a plan that follows the IMPACT algorithm. Primary care providers will manage prescriptions. To optimize eIMPACT for CVD risk reduction, we will restrict the list of antidepressants to SSRIs (except paroxetine) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
226962|NCT02458690|Other|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received.
226963|NCT02458677|Drug|PRX003|
226964|NCT02458677|Other|Placebo|
226965|NCT02458664|Genetic|Genetic analysis on tumor kept in tumor bank|
226966|NCT02458651|Other|No intervention|No intervention administered in this study
226967|NCT02458638|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
226968|NCT02458625|Dietary Supplement|Iron sucrose 500 mg|
226969|NCT02458625|Dietary Supplement|Iron bisglycinate 60 mg|
226970|NCT02458612|Other|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
226971|NCT02458612|Other|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
226972|NCT02458599|Dietary Supplement|Test product|Whey protein hydrolysate (20 g)
226973|NCT02458599|Dietary Supplement|Reference product 1|Iso-energetic carbohydrate (20 g)
226974|NCT02458599|Dietary Supplement|Reference product 2|Negligible energy placebo (20 g)
226975|NCT02458586|Dietary Supplement|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
226976|NCT02458573|Other|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
226977|NCT02458573|Other|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
226978|NCT02458560|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
226979|NCT02458547|Drug|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8~1.0
226980|NCT02458547|Drug|Propofol|Total intravenous anesthesia with propofol target controlled infusion
226981|NCT02458547|Drug|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
227370|NCT02455726|Dietary Supplement|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
226982|NCT02458534|Other|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
226983|NCT02458534|Other|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
226984|NCT02458534|Other|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
226985|NCT02458521|Device|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
226986|NCT02458521|Device|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
226987|NCT02458495|Behavioral|Diabetes MAP Intervention|
226988|NCT02458482|Device|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
226989|NCT02458482|Drug|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
226990|NCT02458469|Drug|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
226991|NCT02458469|Drug|Trazodone|100 mg dose before bed-time
226992|NCT02458469|Drug|Placebo|One placebo pill before bed-time
226993|NCT02458456|Other|Isometric resistance training|Isometric exercise using a hand dynamometer.
226994|NCT02458443|Other|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
226995|NCT02458417|Device|ReCell|A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
226996|NCT02458417|Device|Full surface CO2 laser 200 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
226997|NCT02458417|Device|Full surface CO2 laser 150 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
226998|NCT02458417|Device|Fractional CO2 laser 7.5 mJ, 20%|Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
226999|NCT02458391|Other|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
227000|NCT02458365|Behavioral|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
227001|NCT02458365|Behavioral|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
227002|NCT02458352|Device|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
227003|NCT02458352|Device|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
227004|NCT02458339|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
227005|NCT02458339|Drug|Methotrexate|4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
227006|NCT02458326|Other|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
227007|NCT02458326|Other|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
227008|NCT02458313|Drug|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
227009|NCT02458313|Other|Placebo|Placebo capsules b.i.d. for 12 weeks
227010|NCT02458300|Other|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
227119|NCT02457442|Drug|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
227011|NCT02458300|Other|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
227012|NCT02458300|Other|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
227013|NCT02458300|Other|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
227014|NCT02458300|Other|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
227015|NCT02458287|Biological|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
227016|NCT02458287|Biological|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
227017|NCT02458287|Biological|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
227018|NCT02458287|Biological|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
227019|NCT02458274|Other|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
227020|NCT02458248|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
227021|NCT02458235|Drug|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
227022|NCT02458235|Biological|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
227023|NCT02458222|Other|language game therapy|participants will take part in game therapy
227024|NCT02458222|Other|standard therapy|usual clinical care
227025|NCT02458209|Biological|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
227026|NCT02458209|Biological|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
227027|NCT02458209|Biological|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
227028|NCT02458196|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
227029|NCT02458196|Drug|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.~Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
227030|NCT02458183|Biological|DTaP-IPV combination vaccine|0.5-mL IM
227031|NCT02458183|Biological|DTaP vaccine and IPV vaccine|0.5-mL IM
227032|NCT02458157|Drug|Furosemide (Furix)|"Loading dose: 40 mg I.V.~Infusion rate 40 mg/h~Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
227033|NCT02458157|Other|Continuous renal replacement therapy (CRRT)|"Initiated in case of contraindications or inadequate effect of furosemide.~Fluid removal is started at 2 ml/kg/h~The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
227034|NCT02458157|Other|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:~Mottling beyond the edge of kneecaps~Hypotension (MAP < 50) resistant to inotropes and vasopressors~Plasma lactate ≥ 4 mmol/l~Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:~Fluid removal is paused~A crystalloid fluid bolus of 250-500 ml is given~Circulatory status is reevaluated within 30 minutes~Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour~Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
227035|NCT02458157|Other|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:~Hyperkalaemia (p-K+ > 6 mmol/l)~Severe metabolic acidosis attributable to AKI (pH < 7.25 and standard base excess < -10 mmol/l) resistant to IV bicarbonate infusion~Severe respiratory failure with PaO2/FiO2 < 13 kPa and bilateral infiltrates/oedema on the chest x-ray.~Progressive azotaemia and a blood urea nitrogen (BUN) > 25 mmol/l."
227036|NCT02458144|Procedure|Total hip arthroplasty|"The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.~The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed."
227037|NCT02458131|Behavioral|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
227038|NCT02458118|Drug|Secretin|Secretin 1 IU/kg over 3 min
227039|NCT02458105|Behavioral|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
227040|NCT02458105|Behavioral|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
227041|NCT02458092|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
227042|NCT02458092|Biological|Rabipur|Rabipur is a licensed rabies vaccine.
227043|NCT02458079|Drug|Pentoxiphylline|
227044|NCT02458079|Drug|Stool microbiota transplantation|
227045|NCT02458066|Other|IRS: bendiocarb|carbamate insecticide
227046|NCT02458066|Other|IRS: deltamethrin|Pyrethroid insecticide
227047|NCT02458053|Behavioral|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
227048|NCT02458053|Behavioral|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
227049|NCT02458053|Behavioral|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
227050|NCT02458053|Behavioral|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
227051|NCT02458053|Other|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
227052|NCT02458053|Behavioral|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
227053|NCT02458040|Drug|Drug selected in the study|
227054|NCT02458027|Dietary Supplement|Hemp Shake|Hemp Protein Shake
227055|NCT02458027|Dietary Supplement|Hemp Shake|Hemp Protein Shake
227056|NCT02458027|Dietary Supplement|Soybean Shake|Soybean Protein Shake
227057|NCT02458027|Dietary Supplement|Soybean Shake|Soybean Protein Shake
227058|NCT02458027|Dietary Supplement|Control|Non-Protein Shake
227059|NCT02458014|Biological|Blinatumomab|Given IV
227060|NCT02458014|Other|Laboratory Biomarker Analysis|Correlative studies
227061|NCT02458001|Behavioral|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.~Assessment Algorithm FSFI Interventions~Level 1:~Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.~Level 2:~A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.~Level 3:~16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
227062|NCT02457988|Device|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
227063|NCT02457975|Device|670nm PBM|Battery operated, hand-held, 10 cm2 Light Emitting Diode (LED) array designed to deliver 50 mW/cm2 of light for 90 seconds resulting in a light dose of 4.5 Joules/cm2
227064|NCT02457975|Drug|intravitreous VEGF-inhibitors|Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used for the treatment of diabetic macular edema causing vision impairment and have been shown to be beneficial and relatively safe. Study participants in the anti-VEGF group will be treated with intravitreous injections of one of these agents: afibercept (2.0 mg), bevacizumab (1.25 mg) or ranibizumab (0.5 mg) at appropriate intervals as determined by the treating ophthalmologist.
227065|NCT02457949|Other|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
227066|NCT02457949|Other|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
227067|NCT02457936|Behavioral|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
227068|NCT02457923|Other|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
227069|NCT02457910|Other|Biomarker Analysis|Correlative studies
227070|NCT02457910|Drug|Enzalutamide|Given PO
227071|NCT02457910|Other|Pharmacological Study|Correlative studies
227072|NCT02457910|Drug|Taselisib|Given PO
227073|NCT02457897|Drug|Liothyronine|Oral supplement given every 8 hours
227074|NCT02457884|Other|Temporal Group|Visual Processing Training
227075|NCT02457884|Other|Spatial Group|Spatial visual span training
227076|NCT02457884|Other|Combined Group|Visual processing speed and spatial visual span training
227077|NCT02457884|Other|Control Group|Leisure reading activities
227078|NCT02457871|Behavioral|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
227079|NCT02457858|Drug|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
227080|NCT02457845|Biological|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
227120|NCT02457442|Drug|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
227121|NCT02457442|Drug|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
227122|NCT02457442|Drug|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~SPR 1: Changing Propofol for skin incision."
227081|NCT02457832|Behavioral|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
227082|NCT02457832|Behavioral|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
227083|NCT02457819|Drug|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
227084|NCT02457806|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
227085|NCT02457806|Drug|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
227086|NCT02457793|Drug|Cobimetinib|Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
227087|NCT02457793|Drug|GDC-0994|GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
227088|NCT02457780|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
227089|NCT02457780|Behavioral|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
227090|NCT02457728|Device|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
227091|NCT02457702|Other|Orally administered labeled glycerol|Oral administration of labeled glycerol
227092|NCT02457689|Biological|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
227093|NCT02457689|Other|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
227094|NCT02457676|Behavioral|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
227095|NCT02457663|Procedure|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
227096|NCT02457650|Drug|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
227097|NCT02457650|Drug|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
227098|NCT02457650|Biological|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
227099|NCT02457637|Other|standard treatment|
227100|NCT02457624|Behavioral|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
227101|NCT02457611|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
227102|NCT02457598|Drug|Tirabrutinib|Capsules or tablets administered orally
227103|NCT02457598|Drug|Idelalisib|Tablets administered orally twice daily
227104|NCT02457598|Drug|Entospletinib|Tablets administered orally
227105|NCT02457598|Drug|Obinutuzumab|Administered intravenously
227106|NCT02457585|Drug|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
227107|NCT02457572|Procedure|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
227108|NCT02457572|Other|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
227109|NCT02457559|Drug|Tirabrutinib|Tablets or capsules administered orally
227110|NCT02457546|Biological|EVICEL Fibrin Sealant|
227111|NCT02457546|Device|Hydrogel sealant|
227112|NCT02457533|Behavioral|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
227113|NCT02457520|Drug|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
227114|NCT02457507|Dietary Supplement|Vitamin B12|2 tablets
227115|NCT02457507|Dietary Supplement|Placebo|2 tablets
227116|NCT02457481|Device|Embryo Culture medium|Two step sequential embryo culture medium system
227117|NCT02457468|Device|coflex|
227118|NCT02457442|Drug|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
227123|NCT02457442|Drug|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision."
227124|NCT02457429|Device|Experiemental diagnostic procedure: Dx-pH measurement system|"The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours."
227125|NCT02457429|Other|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
227126|NCT02457429|Other|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
227127|NCT02457416|Other|Peanut|Treatment with peanut in increasing doses until a maintenance dose
227128|NCT02457403|Device|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
227129|NCT02457403|Other|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
227130|NCT02457390|Procedure|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.~The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
227131|NCT02457377|Procedure|laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
227132|NCT02457351|Drug|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)~Part 1 & Part 2~Cycle 2 and subsequent 21-day cycles:~Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
227133|NCT02457351|Drug|Itraconazole (Sporanox)|Part 1 & Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
227134|NCT02457338|Dietary Supplement|Bifidobacterium|
227135|NCT02457325|Drug|Surgery with 2% articaine|During and after lower third molars surgeries, clinical efficacy of the local anesthetic articaine 2% in association with 1:200,000 adrenaline was study.
227136|NCT02457325|Drug|Surgery with 4% articaine|During and after lower third molars surgeries, clinical efficacy of the local anesthetic articaine 4% in association with 1:200,000 adrenaline was study.
227137|NCT02457312|Drug|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
227138|NCT02457312|Drug|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
227139|NCT02457299|Procedure|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
227140|NCT02457299|Procedure|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
227141|NCT02457286|Drug|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
227142|NCT02457286|Behavioral|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
227143|NCT02457286|Device|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
227144|NCT02457273|Drug|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
227145|NCT02457260|Drug|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
227146|NCT02457247|Drug|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
227147|NCT02457247|Drug|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
227148|NCT02457247|Drug|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
227149|NCT02457234|Behavioral|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
227150|NCT02457221|Drug|Tacrolimus capsules|oral
227151|NCT02457221|Drug|Cyclophosphamide injections|intravenous injection
227152|NCT02457221|Drug|Prednisone|oral
227153|NCT02457208|Drug|Isoniazid (H)|
227154|NCT02457208|Drug|Rifampicin (R)|
227155|NCT02457208|Drug|Pyrazinamide (Z)|
227156|NCT02457208|Drug|Ethambutol (E)|
227157|NCT02457195|Drug|granisetron|Application granisetron transdermal patch preoperatively
227160|NCT02457169|Behavioral|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
227161|NCT02457169|Behavioral|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
227162|NCT02457156|Procedure|Blumgart Anastomosis|"Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.~Pancreatic duct to jejunal mucosa sutures, inserted and tied.~Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
227163|NCT02457156|Procedure|Cattell-Warren Anastomosis|"Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.~Pancreatic duct to jejunal mucosa sutures, inserted and tied.~Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
227164|NCT02457156|Drug|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
227165|NCT02457143|Behavioral|Letter|
227166|NCT02457143|Behavioral|Phone call|
227167|NCT02457130|Drug|Ticagrelor|
227168|NCT02457130|Drug|Clopidogrel|
227169|NCT02457117|Radiation|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
227170|NCT02457104|Procedure|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
227171|NCT02457104|Behavioral|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
227172|NCT02457091|Behavioral|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
227173|NCT02457091|Behavioral|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
227174|NCT02457078|Dietary Supplement|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
227175|NCT02457078|Dietary Supplement|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
227176|NCT02457065|Behavioral|"Melanoma Survivor plaque"|The investigators give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin cancer prevention behaviors.
227177|NCT02457052|Device|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
227178|NCT02457039|Procedure|Dense cranial electroacupuncture stimulation|"DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.~Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz)."
227179|NCT02457039|Procedure|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).~Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered."
227180|NCT02457039|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
227181|NCT02457039|Drug|Cytoxan-containing chemotherapy regimens|"Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.~In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:~AC (x4) [Adriamycin + Cytoxan], TC (x4) [Taxotere + Cytoxan], AC-P (4+4) [Adriamycin + Cytoxan + Paclitaxel], TAC (x6) [Taxotere + Adriamycin + Cytoxan], or AC-PH (4+4) [Adriamycin + Cytoxan + Paclitaxel + Herceptin]."
227182|NCT02457026|Drug|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
227183|NCT02457026|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
227184|NCT02457026|Drug|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
227185|NCT02457013|Device|HFNC|Hygh flow nasal canula HFNC
227186|NCT02457013|Device|nCPAP|nasal nCPAP
227187|NCT02456987|Device|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
227188|NCT02456974|Procedure|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
227189|NCT02456974|Procedure|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
227491|NCT02454777|Other|Questionnaire Administration|Ancillary studies
227190|NCT02456974|Procedure|blood sampling in patients receiving vancomycin as part of routine clinical care.|
227191|NCT02456974|Procedure|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
227192|NCT02456974|Procedure|blood sampling in patients receiving meropenem as part of routine clinical care.|
227193|NCT02456974|Procedure|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
227194|NCT02456974|Procedure|blood sampling in patients receiving amikacin as part of routine clinical care.|
227195|NCT02456961|Procedure|iontophoresis of riboflavin|
227196|NCT02456961|Procedure|epithelium-off|
227197|NCT02456961|Procedure|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
227198|NCT02456961|Device|galvanizator, Potok-1|Device for providing iontophoresis procedure
227199|NCT02456961|Drug|Dextralink|Riboflavin 0,1% + Dextran T-500
227200|NCT02456961|Drug|Riboflavin 0,1%|
227201|NCT02456961|Device|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
227202|NCT02456948|Drug|Minocycline|6 weeks 200mg/day Minocycline add-on
227203|NCT02456948|Drug|Placebo|6 weeks Placebo add-on
227204|NCT02456935|Drug|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
227205|NCT02456935|Drug|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
227206|NCT02456922|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
227207|NCT02456909|Device|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
227208|NCT02456909|Device|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
227209|NCT02456909|Drug|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
227210|NCT02456896|Drug|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
227211|NCT02456883|Drug|gilteritinib|oral
227212|NCT02456883|Drug|14C-labeled gilteritinib|oral
227213|NCT02456870|Other|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
227214|NCT02456857|Biological|Bevacizumab|Given IV
227215|NCT02456857|Drug|Everolimus|Given PO
227216|NCT02456857|Other|Laboratory Biomarker Analysis|Correlative studies
227217|NCT02456857|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
227218|NCT02456844|Drug|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~BMS-986142: On Days 6 through 12."
227219|NCT02456844|Drug|Methotrexate, Leucovorin and BMS-986142|"Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~BMS-986142 on Days 6 through 10."
227220|NCT02456831|Other|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
227221|NCT02456831|Other|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
227222|NCT02456831|Other|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
227223|NCT02456831|Other|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
227224|NCT02456805|Other|Infant Formula 1|Feed ab libitum
227225|NCT02456805|Other|Infant Formula 2|Feed ab libitum
227226|NCT02456792|Procedure|IVF|Women will undergo one IVF cycle
227227|NCT02456792|Procedure|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
227228|NCT02456779|Other|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
227229|NCT02456779|Other|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
227230|NCT02456779|Other|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
227231|NCT02456766|Device|FibroTouch|
227232|NCT02456766|Procedure|Liver Biopsy|
227233|NCT02456753|Device|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
227234|NCT02456740|Drug|Erenumab|Administered by subcutaneous injection once a month
227235|NCT02456740|Drug|Placebo|Administered by subcutaneous injection once a month
227236|NCT02456727|Procedure|Group/Community Acupuncture|Acupuncture treatment in a group setting.
227237|NCT02456727|Procedure|Individual Acupuncture|Acupuncture treatment in an individual setting.
227238|NCT02456714|Drug|FOLFIRINOX|
227239|NCT02456701|Biological|KTN3379|IV every 2 weeks
227240|NCT02456701|Drug|vemurafenib|960 mg po bid
227241|NCT02456688|Drug|Imrecoxib|
227242|NCT02456675|Drug|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
227243|NCT02456675|Drug|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
227244|NCT02456675|Drug|itacitinib|The dose of itacitinib will be given orally once daily (QD).
227245|NCT02456662|Drug|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
227492|NCT02454764|Drug|Tenofovir + Interferon alpha 2b|
227246|NCT02456662|Drug|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
227247|NCT02456649|Device|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to < 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as < 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
227248|NCT02456636|Behavioral|Fee-for-Service Model|To be performed by participant's doctor or other healthcare professional in their doctor's office.
227249|NCT02456636|Behavioral|Patient Centered Medical Home|To be performed by a registered dietitian, a nurse or other healthcare professional.
227250|NCT02456636|Behavioral|Disease Management|To be preformed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling
227251|NCT02456623|Behavioral|Intervention|Home-based session targeting the parent
227252|NCT02456623|Behavioral|Attention Control|Attention condition with newsletters and support phone calls
227253|NCT02456610|Biological|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
227254|NCT02456597|Drug|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
227255|NCT02456597|Drug|Isotonic Saline|Isotonic saline injected through the novel Catheter
227256|NCT02456584|Drug|DMPA 150|injectable contraceptive
227257|NCT02456584|Drug|DMPA 300|injectable contraceptive
227258|NCT02456584|Drug|DMPA 104|injectable contraceptive
227259|NCT02456571|Device|CTC biomarker expression prevalence|
227260|NCT02456558|Drug|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
227261|NCT02456558|Drug|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
227262|NCT02456545|Other|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
227263|NCT02456545|Other|depressive syndrome|in- and outpatients with depressive syndrome
227264|NCT02456545|Other|ADHD|in- and outpatients with ADHD
227265|NCT02456532|Drug|placebo|
227266|NCT02456532|Drug|Zolpidem CR|
227267|NCT02456532|Drug|Eszopiclone|
227268|NCT02456519|Other|PaedQoR-15 questionnaire|Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
227269|NCT02456506|Radiation|Hyperfractionated IMRT|
227270|NCT02456506|Radiation|Conventional Fraction IMRT|
227271|NCT02456480|Drug|CLS001|topical gel
227272|NCT02456480|Drug|Vehicle|topical gel
227273|NCT02456454|Drug|Risperidone|Liquid risperidone
227274|NCT02456454|Drug|Valproic Acid|Liquid valproic acid
227275|NCT02456454|Drug|Placebo|
227276|NCT02456441|Other|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
227277|NCT02456441|Other|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
227278|NCT02456428|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
227279|NCT02456428|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
227280|NCT02456428|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
227281|NCT02456428|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
227282|NCT02456428|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
227283|NCT02456428|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
227284|NCT02456428|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
227285|NCT02456428|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
227286|NCT02456415|Device|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
227287|NCT02456402|Device|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
227288|NCT02456402|Device|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
227289|NCT02456389|Other|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
227290|NCT02456389|Other|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
227291|NCT02456389|Other|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
227292|NCT02456389|Other|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
227293|NCT02456389|Other|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
227294|NCT02456389|Other|Standard postoperative care|Routine postoperative care, as medically indicated
227295|NCT02456376|Procedure|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
227296|NCT02456376|Procedure|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
227297|NCT02456363|Biological|TNF alpha|Depending on patient need to use different TNF alpha
227298|NCT02456363|Drug|NSAIDs and sulfasalazine|randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
227299|NCT02456350|Drug|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
227300|NCT02456350|Drug|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
227301|NCT02456350|Biological|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
227302|NCT02456337|Device|Mucograft|Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
227303|NCT02456337|Device|Emdogain|Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
227304|NCT02456337|Procedure|Coronally Advanced flap|Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
227305|NCT02456324|Device|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
227306|NCT02456324|Device|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
227307|NCT02456311|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
227308|NCT02456298|Behavioral|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
227309|NCT02456298|Behavioral|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
227310|NCT02456285|Procedure|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
227311|NCT02456285|Procedure|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
227312|NCT02456285|Procedure|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
227313|NCT02456285|Procedure|No surgery|Patients who have no surgery.
227314|NCT02456272|Device|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
227315|NCT02456272|Procedure|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
227316|NCT02456259|Procedure|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
227317|NCT02456246|Procedure|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
227318|NCT02456233|Procedure|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
227319|NCT02456233|Procedure|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
227320|NCT02456220|Device|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
227321|NCT02456207|Drug|SCT400|
227322|NCT02456207|Drug|Rituximab|
227323|NCT02456194|Device|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
227324|NCT02456181|Behavioral|JumpMath|
227325|NCT02456155|Procedure|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
227326|NCT02456155|Procedure|placing nasal jejunal tube endoscopically|
227327|NCT02456142|Drug|caudal bupivacaine|
227328|NCT02456142|Drug|intravenous morphine|
227329|NCT02456129|Drug|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
227330|NCT02456129|Drug|[14C] Vilaprisan|an intravenous microtracer dose of [14C]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
227331|NCT02456129|Other|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
227332|NCT02456116|Device|acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
227333|NCT02456116|Device|sham acupuncture/PCA/NSAID|"standard program with defined points:~Ear acupuncture needles bitten once (day 0-5)~Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
227334|NCT02456116|Other|PCA/NSAID|standard boli of morphine by pressing a button of PCA
227335|NCT02456103|Drug|Ataluren|
227336|NCT02456077|Behavioral|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
227337|NCT02456064|Behavioral|Lifestyle counseling|"Group medical visits~Telephone medical consultations~Expert patient~Training workshops"
227338|NCT02456038|Drug|Asfotase Alfa (ALXN1215)|
227339|NCT02456025|Drug|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
227340|NCT02456012|Drug|oral esomeprazole 20 mg twice daily|for 36 weeks
227341|NCT02456012|Drug|oral esomeprazole 20 mg once daily|for 36 weeks
227342|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
227343|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
227344|NCT02455999|Drug|Placebo|Placebo eye drops administration for 10 consecutive days
227345|NCT02455986|Behavioral|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
227346|NCT02455973|Behavioral|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
227347|NCT02455973|Behavioral|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
227348|NCT02455960|Dietary Supplement|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
227349|NCT02455960|Dietary Supplement|Placebo|
227350|NCT02455947|Other|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
227351|NCT02455934|Dietary Supplement|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and <12 days apart.
227352|NCT02455921|Drug|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
227353|NCT02455921|Drug|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
227354|NCT02455908|Drug|Proleukin®|
227355|NCT02455895|Device|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
227356|NCT02455869|Drug|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
227357|NCT02455869|Drug|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
227358|NCT02455869|Drug|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
227359|NCT02455856|Drug|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6.
227360|NCT02455856|Drug|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
227361|NCT02455843|Other|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
227362|NCT02455830|Biological|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
227363|NCT02455804|Device|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
227364|NCT02455791|Procedure|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
227365|NCT02455778|Dietary Supplement|Cinnamon|
227366|NCT02455778|Dietary Supplement|Placebo|
227367|NCT02455765|Other|Rice and Amino Acid mixtures|Rice and amino acid mixture
227368|NCT02455752|Procedure|LE-TME|Retroperitoneal approach for total mesorectal excision
227371|NCT02455726|Dietary Supplement|Fructose|Oral fructose 10 g twice a day
227372|NCT02455726|Drug|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
227373|NCT02455726|Drug|Pregabalin|Pregabalin 25 mg at 8 pm
227374|NCT02455713|Device|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
227375|NCT02455700|Device|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
227376|NCT02455687|Drug|Intravenous magnesium sulfate|
227377|NCT02455687|Drug|Inhaled budesonide|
227378|NCT02455687|Drug|normal saline|
227379|NCT02455661|Device|TR Band (TM)|
227380|NCT02455661|Device|AngioSeal|
227381|NCT02455661|Device|StarClose|
227382|NCT02455648|Procedure|ESD/EMR plus Cell Sheet|"Patients receive ESD/EMR plus CellSheet:~Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR"
227383|NCT02455648|Procedure|ESD/EMR|"only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later"
227384|NCT02455635|Procedure|office hystroscopy|Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath & 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
227385|NCT02455622|Drug|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
227386|NCT02455609|Procedure|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
227387|NCT02455609|Drug|Dexmedetomidine|
227388|NCT02455609|Drug|ketamine|
227389|NCT02455609|Drug|Bupivacaine|
227390|NCT02455596|Drug|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
227391|NCT02455583|Behavioral|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
227392|NCT02455570|Other|No intervention|No intervention
227393|NCT02455557|Other|Laboratory Biomarker Analysis|Correlative studies
227394|NCT02455557|Drug|Montanide ISA 51 VG|Given SC
227395|NCT02455557|Biological|Sargramostim|Given SC
227396|NCT02455557|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
227397|NCT02455557|Drug|Temozolomide|Given PO or IV
227398|NCT02455518|Drug|Oxycodone/acetaminophen|
227399|NCT02455518|Drug|Hydrocodone/acetaminophen|
227400|NCT02455518|Drug|Codeine/acetaminophen|
227401|NCT02455518|Drug|Ibuprofen/acetaminophen|
227402|NCT02455505|Behavioral|background questionnaire|
227403|NCT02455505|Behavioral|bereavement risk screening tool|
227404|NCT02455492|Other|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
227405|NCT02455479|Biological|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
227406|NCT02455479|Biological|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
227407|NCT02455453|Drug|18F-FFNP|
227408|NCT02455453|Device|CTI/Siemens Biograph 40 PET/CT Scanner|"Will include (1) 18-FDG-PET/CT scan~Will include (2) 18F-FFNP-PET/CT scans"
227409|NCT02455453|Drug|Estradiol|
227410|NCT02455453|Drug|18F-FDG|
227411|NCT02455440|Drug|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
227412|NCT02455440|Drug|Placebo|
227413|NCT02455440|Drug|Propofol and sevoflurane|
227414|NCT02455427|Device|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
227415|NCT02455427|Other|Physical Therapy|Physical therapy will be administered for 60 minutes
227416|NCT02455427|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
227417|NCT02455401|Drug|High dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
227418|NCT02455401|Drug|Low dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
227419|NCT02455401|Drug|No remifentanil|Intervention: no remifentanil will be administrated
227420|NCT02455388|Dietary Supplement|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
227421|NCT02455388|Dietary Supplement|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
227422|NCT02455362|Drug|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
227423|NCT02455362|Drug|Placebo|
227424|NCT02455336|Drug|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
227425|NCT02455336|Other|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
227493|NCT02454764|Drug|Tenofovir disoproxil Fumarate|
227426|NCT02455323|Other|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
227427|NCT02455323|Other|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
227428|NCT02455323|Other|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
227429|NCT02455323|Other|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
227430|NCT02455310|Behavioral|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
227431|NCT02455297|Drug|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
227432|NCT02455284|Device|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
227433|NCT02455271|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
227434|NCT02455258|Other|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
227435|NCT02455258|Other|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
227436|NCT02455245|Drug|Carboplatin|
227437|NCT02455245|Drug|Vincristine|
227438|NCT02455232|Procedure|upper limb muscle block|
227439|NCT02455232|Drug|4cc of lidocaïne®|
227440|NCT02455219|Device|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
227441|NCT02455206|Behavioral|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
227442|NCT02455206|Behavioral|Usual care|
227443|NCT02455193|Behavioral|Exercise|
227444|NCT02455193|Behavioral|Diet|
227445|NCT02455180|Drug|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
227446|NCT02455167|Drug|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
227447|NCT02455167|Drug|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
227448|NCT02455167|Drug|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
227449|NCT02455154|Drug|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
227450|NCT02455154|Drug|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
227451|NCT02455154|Drug|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
227452|NCT02455141|Drug|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
227453|NCT02455141|Drug|Taxanes|Paclitaxel: 80mg/m2, d1, qw*12 or Docetaxel: 80-100mg/m2,d1,q3w*4
227454|NCT02455141|Drug|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w*4 Carboplatin AUC=2, d1,d8,d15, q4w*4 or Docetaxel: 75mg/m2,d1,q3w*4 plus Carboplatin AUC=5-6, d1, q3w*4
227455|NCT02455128|Other|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
227456|NCT02455115|Other|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
227457|NCT02455115|Drug|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
227458|NCT02455115|Drug|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
227459|NCT02455102|Other|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
227542|NCT02454387|Drug|Placebo Part A1|Healthy volunteers
227460|NCT02455089|Other|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
227461|NCT02455076|Drug|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
227462|NCT02455076|Drug|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.~FBG >180 mg/dL, no hypoglycemia; glargine increased by 4 IU.~FBG >140 mg/dL, no hypoglycemia; glargine increased by 2 IU.~FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.~FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.~FBG or RBG < 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.~FBG or RBG < 40 mg/dl, decrease dose of glargine by 30%."
227463|NCT02455076|Drug|Rapid-acting insulin analogs|"If the BG levels are >140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG> 400 mg/dL, the insulin will be 8,12 or 16 units."
227464|NCT02455050|Drug|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops [New Eye Drop Formula] in each eye.
227465|NCT02455050|Drug|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
227466|NCT02455050|Drug|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
227467|NCT02455037|Other|Neck Strengthening|Targeted neck strengthening exercises
227468|NCT02455011|Biological|REMD-477|
227469|NCT02454998|Other|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
227470|NCT02454972|Drug|lurbinectedin (PM01183)|
227471|NCT02454959|Device|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
227472|NCT02454959|Device|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
227473|NCT02454933|Drug|AZD9291|Once daily tablet 80 mg
227474|NCT02454933|Drug|MEDI4736|10mg/kg q2w (IV) infusion
227475|NCT02454907|Other|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
227476|NCT02454894|Drug|lidocaine|surface anesthesia with lidocaine
227477|NCT02454894|Procedure|postoperative management|lying without the pillow for half an hour after lumbar puncture
227478|NCT02454881|Drug|Dexmedetomidine|
227479|NCT02454881|Drug|Oxycodone|
227480|NCT02454868|Drug|Remifentanil|Remifentanil for intubation without neuromuscular blockade
227481|NCT02454855|Drug|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
227482|NCT02454855|Drug|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
227483|NCT02454842|Drug|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
227484|NCT02454829|Other|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
227485|NCT02454816|Device|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
227486|NCT02454816|Device|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
227487|NCT02454790|Radiation|Radiotherapy|
227488|NCT02454777|Behavioral|Exercise Intervention|Undergo HIT
227489|NCT02454777|Other|Laboratory Biomarker Analysis|Correlative studies
227490|NCT02454777|Other|Quality-of-Life Assessment|Ancillary studies
227494|NCT02454751|Drug|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
227495|NCT02454738|Radiation|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
227496|NCT02454725|Behavioral|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
227497|NCT02454725|Behavioral|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
227498|NCT02454712|Drug|PF614|PF614 is an oxycodone prodrug
227499|NCT02454712|Drug|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
227500|NCT02454712|Drug|Naltrexone Hydrochloride|Naltrexone HCl tablets, 50 mg, will be used to block high dose opioid effects in healthy volunteers
227501|NCT02454699|Drug|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
227502|NCT02454699|Other|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
227503|NCT02454660|Behavioral|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
227504|NCT02454647|Drug|Induction chemotherapy|
227505|NCT02454647|Radiation|Radiotherapy with concurrent chemotherapy|
227506|NCT02454647|Procedure|Salvage surgery|
227507|NCT02454634|Drug|IDH1 peptide vaccine|
227508|NCT02454621|Behavioral|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
227509|NCT02454608|Drug|Verapamil HCl|Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
227510|NCT02454608|Other|Placebo|Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
227511|NCT02454595|Behavioral|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
227512|NCT02454582|Device|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
227513|NCT02454556|Drug|FOLITIME®|
227514|NCT02454556|Drug|Gonal-F®|
227515|NCT02454543|Procedure|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
227516|NCT02454543|Drug|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.~The selection of best systemic therapy is up to the judgment of the treating urologist."
227517|NCT02454530|Biological|Nivestim®|
227518|NCT02454517|Behavioral|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
227519|NCT02454517|Behavioral|Exercise Intervention|Undergo DPP lifestyle intervention
227520|NCT02454517|Other|Informational Intervention|Receive oral and written guidelines and meet with dietician
227521|NCT02454517|Other|Laboratory Biomarker Analysis|Correlative studies
227522|NCT02454517|Other|Quality-of-Life Assessment|Ancillary studies
227523|NCT02454517|Other|Questionnaire Administration|Ancillary studies
227524|NCT02454504|Drug|sugammadex|
227525|NCT02454504|Drug|Neostigmine|
227526|NCT02454491|Drug|Heparin|intraradial administration of heparin 5000 ui
227527|NCT02454491|Drug|Verapamil|intraradial administration of verapamil 5 mg
227528|NCT02454478|Drug|Lenvatinib|
227529|NCT02454478|Drug|Everolimus|
227530|NCT02454465|Other|Acceptance and Commitment Therapy group|Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
227531|NCT02454452|Procedure|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
227532|NCT02454452|Procedure|Saphenous vein stripping|Saphenous vein stripping
227533|NCT02454452|Procedure|CHIVA|conservative hemodynamic treatment venous insufficiency
227534|NCT02454439|Other|CRT implantation|
227535|NCT02454426|Drug|Vortioxetine|open label treatment
227536|NCT02454413|Other|denture brushing with water and soap|denture brushing with water and soap
227537|NCT02454413|Other|ultrasonic denture cleaning|ultrasonic denture cleaning
227538|NCT02454413|Other|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
227539|NCT02454400|Other|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:~Active physiotherapy according to a treatment based classification:~Specific exercises and mobilization~Motor control exercises~Traction~Tailor-made general supervised exercise program~Behavioral approach to reduce fear avoidance and increase activity level.~Standardized information about:~the surgery~post-surgery rehabilitation~to stay active"
227540|NCT02454400|Other|Waiting-list|"Standardized information about:~the surgery~post-surgery rehabilitation~to stay active"
227541|NCT02454387|Drug|ONO-4474 Part A1|Healthy volunteers
227544|NCT02454387|Drug|Placebo Part A2|Healthy volunteers
227545|NCT02454387|Drug|ONO-4474 Part B|Healthy volunteers
227546|NCT02454387|Drug|Placebo Part B|Healthy volunteers
227547|NCT02454387|Drug|ONO-4474 Part C|Healthy volunteers
227548|NCT02454387|Drug|Placebo Part C|Healthy volunteers
227549|NCT02454387|Drug|ONO-4474 Part D|Healthy volunteers
227550|NCT02454387|Drug|Placebo Part D|Healthy volunteers
227551|NCT02454374|Procedure|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
227552|NCT02454374|Procedure|Routine Physiotherapy Care|Routine Physiotherapy Care
227553|NCT02454361|Drug|KBP-7072|KBP-7072
227554|NCT02454361|Drug|Placebo|Placebo
227555|NCT02454348|Drug|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
227556|NCT02454348|Drug|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
227557|NCT02454335|Procedure|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
227558|NCT02454322|Drug|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
227559|NCT02454309|Dietary Supplement|Cranberry concentrate|
227560|NCT02454309|Dietary Supplement|Placebo|
227561|NCT02454296|Drug|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
227562|NCT02454296|Drug|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
227563|NCT02454283|Drug|Vanoxerine HCl|
227564|NCT02454283|Drug|Placebo|
227565|NCT02454270|Drug|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 ‑day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28‑day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
227566|NCT02454270|Drug|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
227567|NCT02454244|Behavioral|ART with Mindfulness|"Introduction of ART with Mindfulness. Visualization of 100% recovery~Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~The ART. Breaking the negative thoughts related to the illness. Walking meditation~Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~Mindfulness and self-compassion. Kindly awareness meditation~The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~Return to regular life. Mindfulness practice"
227568|NCT02454244|Behavioral|Mindfulness Compassion|"Introduction.Definition of Compassion~Self-Esteemed and Compassion~Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~Love,affection and self-compassion.How participants connect with the suffering of others~Equanimity~Forgiveness~Interdependence. Gratitude.Affection to unknown people~Developing affection and empathy.Empathy and burn out~Review of the practices and meditations"
227569|NCT02454244|Behavioral|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
227570|NCT02454231|Biological|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
227571|NCT02454231|Biological|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
227572|NCT02454218|Device|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.~The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
227573|NCT02454205|Drug|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
227574|NCT02454205|Drug|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
227575|NCT02454205|Drug|Levofloxacin|750mg (<50kg) 1000mg (>50kg)
227576|NCT02454205|Drug|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
227577|NCT02454205|Drug|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
227578|NCT02454205|Drug|Ethionamide|15mg/kg (max 900mg)
227579|NCT02454205|Drug|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
227580|NCT02454205|Drug|Moxifloxacin|400mg po daily.
227581|NCT02454205|Drug|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
227582|NCT02454192|Behavioral|CHAMPS|
227583|NCT02454179|Drug|pembrolizumab|
227584|NCT02454179|Drug|Acalabrutinib|
227585|NCT02454166|Other|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
227586|NCT02454166|Other|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
227587|NCT02454153|Device|REMStar Postive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
227588|NCT02454153|Behavioral|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
227589|NCT02454140|Radiation|SBRT|Fixed five-fraction stereotactic radiotherapy
227590|NCT02454127|Behavioral|Atkins Diet|Dietary counseling for 1 year
227591|NCT02454127|Behavioral|Zone Diet|Dietary counseling for 1 year
227592|NCT02454127|Behavioral|Weight Watchers Diet|Dietary counseling for 1 year
227593|NCT02454127|Behavioral|Ornish Diet|Dietary counseling for 1 year
227594|NCT02454114|Other|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
227595|NCT02454114|Other|Standard Hospital Care|"No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.~SF-12 (physical and mental function) [performed twice in total] - at recruitment (day 0) and 6 weeks~CAP-SYM [performed 3 times in total] - at recruitment day 0 (twice including day minus 30) and 6 weeks~Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor."
227596|NCT02454101|Procedure|cord milking|milking of the cord 5 times toward the neonate
227597|NCT02454101|Procedure|delayed cord clamping|delay clamping of the cord for 120 seconds
227598|NCT02454088|Other|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
227599|NCT02454088|Device|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
227600|NCT02454075|Drug|YF476|Gastrin receptor antagonist
227601|NCT02454062|Drug|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
227602|NCT02454062|Drug|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
227603|NCT02454049|Dietary Supplement|beetroot juice|6mmol nitrate
227604|NCT02454049|Dietary Supplement|sodium nitrate|6mmol sodium nitrate
227605|NCT02454049|Dietary Supplement|water|plain water
227606|NCT02454036|Behavioral|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
227607|NCT02454023|Device|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
227608|NCT02454023|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
227609|NCT02454010|Biological|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
227610|NCT02453984|Other|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
227611|NCT02453971|Other|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
227612|NCT02453958|Device|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
227613|NCT02453945|Device|Adjustable Support Bra|A ClearPoint Medical support bra
227614|NCT02453932|Drug|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
227615|NCT02453932|Drug|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
227616|NCT02453932|Drug|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
227617|NCT02453906|Other|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
227618|NCT02453906|Other|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
227619|NCT02453906|Other|Control 2|stimulation at 5 control points
227620|NCT02453906|Other|Control 3|no stimulation at 5 control points
227621|NCT02453893|Drug|Iloperidone|
227622|NCT02453893|Drug|Risperidone|
227623|NCT02453880|Behavioral|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
227624|NCT02453867|Other|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels > 5ng/ml) Stop mycophenolate at month 6
227625|NCT02453867|Drug|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
227943|NCT02451865|Other|Laboratory Biomarker Analysis|Correlative studies
227626|NCT02453867|Drug|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
227627|NCT02453867|Drug|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
227628|NCT02453854|Behavioral|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
227629|NCT02453841|Drug|Oxymetazoline|
227630|NCT02453828|Procedure|Non-cardiac surgery|patients having non-cardiac surgery
227631|NCT02453815|Procedure|non-cardiac surgery|all surgical procedures except cardiac
227632|NCT02453815|Other|arterial catheter|arterial catheter
227633|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
227634|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
227635|NCT02453802|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
227636|NCT02453802|Drug|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
227637|NCT02453802|Drug|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
227638|NCT02453789|Drug|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
227639|NCT02453789|Drug|Placebo|
227640|NCT02453776|Drug|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
227641|NCT02453763|Device|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
227642|NCT02453763|Procedure|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
227643|NCT02453750|Drug|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls <10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls >10%, the previous step will be repeated.
227644|NCT02453750|Drug|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
227645|NCT02453737|Radiation|Brachytherapy APBI|
227646|NCT02453737|Radiation|3D-CRT (photon) APBI|
227647|NCT02453737|Radiation|Proton APBI|
227648|NCT02453724|Device|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
227649|NCT02453711|Drug|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
227650|NCT02453711|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
227651|NCT02453711|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
227652|NCT02453698|Drug|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, & Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
227653|NCT02453698|Other|Placebo|Lactose Placebo
227654|NCT02453685|Drug|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
227655|NCT02453685|Drug|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
227656|NCT02453685|Drug|insulin aspart|Injected s.c./subcutaneously once daily.
227657|NCT02453672|Biological|SB8|SB8, proposed bevacizumab biosimilar
227658|NCT02453672|Biological|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
227659|NCT02453672|Biological|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
227660|NCT02453659|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
227661|NCT02453659|Behavioral|Health Education (HE)|
227662|NCT02453659|Behavioral|Smoking Cessation counseling|
227663|NCT02453659|Drug|Transdermal Nicotine Patch|
227664|NCT02453646|Device|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
227715|NCT02453373|Drug|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
227716|NCT02453373|Procedure|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
227665|NCT02453633|Other|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.~tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.~No-show fee: Kr. 640.~Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
227666|NCT02453633|Other|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):~Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
227667|NCT02453620|Drug|Entinostat|Given PO
227668|NCT02453620|Biological|Ipilimumab|Given IV
227669|NCT02453620|Biological|Nivolumab|Given IV
227670|NCT02453620|Other|Pharmacogenomic Study|Correlative studies
227671|NCT02453620|Other|Pharmacological Study|Correlative studies
227672|NCT02453607|Drug|Infliximab|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
227673|NCT02453607|Drug|thiopurine|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
227674|NCT02453594|Biological|pembrolizumab|IV infusion
227675|NCT02453581|Drug|OZ439|OZ439 Powder for Oral Suspension
227676|NCT02453555|Drug|Linagliptin|
227677|NCT02453555|Drug|Empagliflozin placebo + linagliptin placebo low dose|Matching placebo empagliflozin + linagliptin
227678|NCT02453555|Drug|Empagliflozin + linagliptin low dose|tablet
227679|NCT02453555|Drug|Linagliptin placebo|Matching placebo linagliptin
227680|NCT02453555|Drug|Empagliflozin + linagliptin high dose|tablet
227681|NCT02453555|Drug|Empa + lina highdose placebo|
227682|NCT02453529|Drug|WCK 4873|Oral tablets
227683|NCT02453516|Procedure|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
227684|NCT02453516|Procedure|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
227685|NCT02453516|Drug|ropivacaine|Drug indicated for regional anesthesia
227686|NCT02453516|Drug|epinephrine|Drug indicated to prolong the action of regional anesthesia
227687|NCT02453516|Other|sterile saline|Neutral injection (no drug involved)
227688|NCT02453503|Drug|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
227689|NCT02453503|Drug|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
227690|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
227691|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
227692|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
227693|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
227694|NCT02453477|Genetic|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
227695|NCT02453464|Drug|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
227696|NCT02453464|Drug|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
227697|NCT02453464|Drug|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
227698|NCT02453464|Drug|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
227699|NCT02453451|Other|2D-/3D-TTE|recording of 3 cardiac cycles
227700|NCT02453451|Other|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
227701|NCT02453451|Other|Walking Test|for 6 minutes
227702|NCT02453451|Procedure|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
227703|NCT02453438|Other|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
227704|NCT02453425|Other|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
227705|NCT02453425|Other|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
227706|NCT02453425|Other|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
227707|NCT02453412|Device|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
227708|NCT02453399|Device|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
227709|NCT02453386|Drug|tozadenant|
227710|NCT02453386|Drug|placebo|
227711|NCT02453373|Device|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
227712|NCT02453373|Drug|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
227713|NCT02453373|Drug|tPA|tPA will be administered intravenously if indicated
227714|NCT02453373|Drug|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
227717|NCT02453360|Procedure|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
227718|NCT02453360|Drug|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
227719|NCT02453347|Device|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
227720|NCT02453334|Drug|Injectafer|
227721|NCT02453334|Other|Normal Saline|
227722|NCT02453321|Procedure|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
227723|NCT02453321|Procedure|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
227724|NCT02453321|Procedure|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
227725|NCT02453321|Drug|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
227726|NCT02453308|Drug|ACT|"Artemether-lumefantrine for 3 days~Dihydroartemisinin-piperaquine for 3 days.~Artesunate-mefloquine for 3 days"
227727|NCT02453308|Drug|TACT|"Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.~Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.~Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
227728|NCT02453295|Behavioral|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
227729|NCT02453282|Biological|MEDI4736 (Durvalumab)|
227730|NCT02453282|Biological|MEDI4736 (Durvalumab)+Tremelimumab|
227731|NCT02453282|Drug|Paclitaxel + Carboplatin|Chemotherapy Agents
227732|NCT02453282|Drug|Gemcitabine + Cisplatin|Chemotherapy Agents
227733|NCT02453282|Drug|Gemcitabine + Carboplatin|Chemotherapy Agents
227734|NCT02453282|Drug|Pemetrexed + Cisplatin|Chemotherapy Agents
227735|NCT02453282|Drug|Pemetrexed + Carboplatin|Chemotherapy Agents
227736|NCT02453282|Biological|Tremelimumab|
227737|NCT02453269|Behavioral|Transdisciplinary program|
227738|NCT02453256|Drug|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
227739|NCT02453256|Drug|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
227740|NCT02453243|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
227741|NCT02453243|Behavioral|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.~Sites will be trained on the Safety Planning Intervention and Lean."
227742|NCT02453230|Behavioral|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
227743|NCT02453217|Behavioral|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
227744|NCT02453217|Other|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
227745|NCT02453204|Behavioral|Sitting|
227746|NCT02453204|Behavioral|Standing|
227747|NCT02453204|Behavioral|Walking|
227748|NCT02453191|Drug|talimogene laherparepvec|talimogene laherparepvec
227749|NCT02453191|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
227750|NCT02453178|Behavioral|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
227883|NCT02452255|Drug|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
227751|NCT02453165|Procedure|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
227752|NCT02453165|Procedure|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
227753|NCT02453152|Other|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
227754|NCT02453152|Other|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
227755|NCT02453152|Other|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
227756|NCT02453152|Other|Peak cough flow|Subjects' strongest coughs will be measured.
227757|NCT02453152|Other|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
227758|NCT02453152|Other|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
227759|NCT02453152|Other|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
227760|NCT02453139|Behavioral|Exercise|6 month supervised and home based aerobic exercise intervention
227761|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
227762|NCT02453100|Behavioral|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
227763|NCT02453100|Behavioral|Education|Education on simple ways to manage incontinence
227764|NCT02453087|Drug|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
227765|NCT02453087|Drug|Rituximab|Participants will receive rituximab at a dose of 375 mg/m^2 of body surface area as intravenous infusion.
227766|NCT02453087|Drug|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
227767|NCT02453074|Other|Online survey - Follow up for Better Care|
227768|NCT02453061|Drug|Triheptanoin oil|Triheptanoin oil orally administered at 1g/kg/day
227769|NCT02453061|Drug|Placebo|Safflower oil orally administered at 1g/kg/day
227770|NCT02453048|Biological|BPZE1|Intranasal live, attenuated vaccine
227771|NCT02453048|Other|Placebo|Diluent
227772|NCT02453035|Device|PTCA - Desolve Scaffold|Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
227773|NCT02453022|Drug|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
227774|NCT02453022|Drug|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
227775|NCT02453022|Drug|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
227776|NCT02453009|Drug|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
227777|NCT02453009|Drug|Prednisone|Pharmaceutical form:tablet Route of administration: oral
227778|NCT02453009|Drug|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
227779|NCT02452996|Drug|GNbAC1|Single dose of IMP, IV infusion
227780|NCT02452983|Drug|Sertraline|
227781|NCT02452983|Procedure|Bone Marrow Aspirate/Biopsy|
227782|NCT02452970|Drug|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
227783|NCT02452970|Drug|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
227784|NCT02452944|Device|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
227785|NCT02452944|Device|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
227786|NCT02452931|Drug|Leuprolide Acetate 45 mg|Subcutaneous injection
227787|NCT02452918|Drug|Oritavancin|a single 1200 mg IV dose of Orbactiv (oritavancin)
227788|NCT02452905|Drug|Nitazoxanide|
227789|NCT02452905|Drug|Placebo (for Nitazoxanide)|
227790|NCT02452892|Device|LFMS|Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
227791|NCT02452879|Device|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
227792|NCT02452879|Device|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
227793|NCT02452879|Drug|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg / tablet
227794|NCT02452866|Drug|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
227940|NCT02451878|Behavioral|E-Couch|e-couch is an online CBT based intervention
227795|NCT02452853|Procedure|HR|"HR:~HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
227796|NCT02452853|Drug|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):~4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
227797|NCT02452840|Other|No Intervention|No Intervention
227798|NCT02452827|Other|Biomechanical parameters|
227799|NCT02452827|Other|MRI|MRI of cervical spine
227800|NCT02452801|Drug|ALKS 5461|Single dose, given orally
227801|NCT02452788|Other|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
227802|NCT02452775|Biological|OC-L|
227803|NCT02452775|Other|Montanide|
227804|NCT02452775|Other|poly-ICLC (Hiltonol),|
227805|NCT02452762|Drug|Vitamin D3|
227806|NCT02452762|Drug|Placebo|
227807|NCT02452749|Dietary Supplement|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
227808|NCT02452736|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
227809|NCT02452723|Biological|ISC-hpNSC|
227810|NCT02452710|Other|Placebo|Open-label placebo
227811|NCT02452697|Biological|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.~If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
227812|NCT02452697|Biological|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.~On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
227813|NCT02452684|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
227814|NCT02452658|Other|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
227815|NCT02452645|Behavioral|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
227816|NCT02452645|Behavioral|Comparison Group|Written materials, videos, books, and telephone counseling.
227817|NCT02452632|Drug|ASP1941|oral
227818|NCT02452632|Drug|Placebo|oral
227819|NCT02452619|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
227820|NCT02452606|Drug|Stalevo®|"Sleep disorders in Parkinson's disease~Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.~If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective."
227821|NCT02452593|Other|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
227822|NCT02452580|Other|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
227823|NCT02452567|Other|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose ~8-10% of their body weight through diet-intervention.
227824|NCT02452554|Other|Laboratory Biomarker Analysis|Correlative studies
227825|NCT02452554|Biological|Lorvotuzumab Mertansine|Given IV
227826|NCT02452554|Other|Pharmacological Study|Correlative studies
227827|NCT02452541|Other|Prognostic tests|"Brain CT-Scan on day 1, 3 and 7~Brain MRI on day 7~SomatoSensory Evoked Potentials on day 7~Electroencephalogram on day 7~Serum biomarkers on day 1, 3 and 7~Daily clinical exams"
227828|NCT02452528|Drug|ARC-520|
227829|NCT02452528|Drug|Placebo|
227830|NCT02452528|Drug|Entecavir|0.5 or 1.0 mg/day orally
227831|NCT02452528|Drug|Tenofovir|300 mg/day orally
227832|NCT02452528|Drug|diphenhydramine|50 mg orally as pretreatment antihistamine
227833|NCT02452515|Drug|BAY1142524|5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
227834|NCT02452515|Drug|BAY1142524|10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
227835|NCT02452515|Drug|BAY1142524|25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
227836|NCT02452515|Drug|BAY1142524|50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
227837|NCT02452515|Drug|Placebo|The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
227838|NCT02452502|Device|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
227941|NCT02451865|Drug|Binimetinib|Given PO
227839|NCT02452489|Device|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
227840|NCT02452489|Device|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
227841|NCT02452489|Device|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
227842|NCT02452476|Drug|CHF5633|Rescue treatment (if needed)
227843|NCT02452476|Drug|Poractant alfa|Rescue treatment (if needed)
227844|NCT02452463|Biological|Durvalumab|Given IV
227845|NCT02452463|Drug|Nintedanib|Given PO
227846|NCT02452463|Other|Placebo|Given PO
227847|NCT02452463|Procedure|Quality-of-Life Assessment|Ancillary studies
227848|NCT02452450|Drug|Ibuprofen Acid|
227849|NCT02452450|Drug|Ibuprofen Lysine|
227850|NCT02452450|Drug|Ibuprofen Sodium|
227851|NCT02452450|Drug|Ibuprofen Liquid Capsules|
227852|NCT02452450|Drug|Paracetamol|
227853|NCT02452437|Drug|Oxycodone|Controlled release oxycodone 40 mg twice daily
227854|NCT02452424|Drug|PLX3397|PLX3397 capsules, 200 mg
227855|NCT02452424|Biological|Pembrolizumab|Pembrolizumab, 200 mg, IV
227856|NCT02452411|Behavioral|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
227857|NCT02452398|Device|Venus Versa|"The Venus Versa system is a multi-application device intended to be used in aesthetic and cosmetic procedures.~The device consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated. The applicator that will be used for this study (HR 690) has a wavelength of 690 nm and has a spot size (treatment area) of 30 mm by 10 mm."
227858|NCT02452398|Other|IPL gel|water based gel used to protect the skin during light based treatments. Also used during ultrasound treatments.
227859|NCT02452385|Drug|CM082 tablet|CM082 tablets taken orally
227860|NCT02452372|Drug|givosiran (ALN-AS1)|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
227861|NCT02452372|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
227862|NCT02452359|Device|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
227863|NCT02452359|Other|IPL gel|water based gel used to protect the skin during light based treatments. Is also commonly used during ultrasound treatments.
227864|NCT02452346|Drug|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
227865|NCT02452333|Procedure|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
227866|NCT02452333|Procedure|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
227867|NCT02452333|Other|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
227868|NCT02452333|Other|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
227869|NCT02452320|Drug|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
227870|NCT02452320|Drug|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
227871|NCT02452307|Biological|Peptide vaccine|subcutaneous
227872|NCT02452307|Drug|Montanide ISA-51|subcutaneous
227873|NCT02452307|Drug|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
227874|NCT02452307|Drug|Imiquimod|epicutaneous
227875|NCT02452307|Drug|mRNA|subcutaneous
227876|NCT02452307|Drug|Protamin|subcutaneous
227877|NCT02452307|Procedure|local hyperthermia|
227878|NCT02452294|Drug|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
227879|NCT02452281|Drug|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
227880|NCT02452281|Drug|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
227881|NCT02452268|Drug|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
227882|NCT02452268|Drug|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
227884|NCT02452255|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
227885|NCT02452255|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
227886|NCT02452242|Drug|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
227887|NCT02452242|Other|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
227888|NCT02452229|Other|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
227889|NCT02452216|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
227890|NCT02452216|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
227891|NCT02452216|Procedure|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
227892|NCT02452203|Behavioral|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
227893|NCT02452190|Drug|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
227894|NCT02452190|Drug|Placebo|Matching Placebo
227895|NCT02452177|Drug|Vitamin D|
227896|NCT02452164|Other|Teaching|
227897|NCT02452164|Device|(CellScopeOTO)|
227898|NCT02452151|Drug|Infliximab-Biosimilar|
227899|NCT02452151|Drug|Infliximab-Innovator|
227900|NCT02452138|Other|Severe sepsis management|
227901|NCT02452125|Dietary Supplement|Nicotine gum|Nicotine chewing gum
227902|NCT02452112|Drug|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
227903|NCT02452112|Drug|Placebo|Placebo patch to be placed on the site of pain
227904|NCT02452099|Procedure|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
227905|NCT02452099|Procedure|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
227906|NCT02452099|Procedure|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
227907|NCT02452086|Device|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
227908|NCT02452086|Procedure|Placebo|LLLT with zero intensity
227909|NCT02452073|Other|Thyroid function tests|
227910|NCT02452060|Drug|Ketamine|0.4mg/kg infusion
227911|NCT02452060|Other|Placebo Comparator|0.4mg/kg infusion
227912|NCT02452047|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
227913|NCT02452047|Drug|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (~180 to 360 mg CMS), depending on renal function, once every 12 hours
227914|NCT02452047|Drug|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
227915|NCT02452047|Drug|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
227916|NCT02452034|Drug|Posaconazole IV solution|Posaconazole by IV solution twice on Day 1, then once daily on Days 2-10.
227917|NCT02452034|Drug|Posaconazole powder for oral suspension|Posaconazole once daily by PFS for a minimum of 10 days
227918|NCT02452008|Drug|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
227919|NCT02452008|Drug|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
227920|NCT02451995|Device|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
227921|NCT02451995|Device|Local activation Time Mapping AT Ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of local activation time mapping
227922|NCT02451982|Drug|Cyclophosphamide|200 mg/m2
227923|NCT02451982|Biological|GVAX pancreatic cancer|5x10^8 cells
227924|NCT02451982|Drug|Nivolumab|480 mg
227925|NCT02451982|Drug|Urelumab|8 mg
227926|NCT02451969|Biological|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
227927|NCT02451969|Biological|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
227928|NCT02451956|Drug|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
227929|NCT02451956|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
227930|NCT02451943|Drug|Olaratumab|Administered IV
227931|NCT02451943|Drug|Doxorubicin|Administered IV
227932|NCT02451943|Drug|Placebo|Administered IV
227933|NCT02451930|Drug|Necitumumab|Administered IV
227934|NCT02451930|Drug|Pembrolizumab|Administered IV
227935|NCT02451917|Drug|Glargine insulin|The initial insulin dose for those randomized to IGlar was 80% of the total daily NPH dose that was being discontinued. All of them had pre-prandial Regular insulin switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. After 24 weeks, basal insulins were switched; in other words, individuals on IGlar in the first period switched to INPH, and the doses of pre-meal insulin were sustained
227936|NCT02451917|Drug|NPH insulin|The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
227937|NCT02451904|Other|Observation|
227938|NCT02451891|Biological|MVA-EBO Z|
227939|NCT02451891|Biological|ChAd3-EBO Z|
227944|NCT02451852|Drug|AZD9291|AZD9291 80mg tablet once daily, open label
227945|NCT02451826|Drug|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
227946|NCT02451813|Procedure|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
227947|NCT02451800|Other|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
227948|NCT02451800|Other|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
227949|NCT02451800|Other|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
227950|NCT02451787|Dietary Supplement|Vitamin D|2400 units per day for 3 months
227951|NCT02451774|Drug|Pentoxifylline Plus Chemotherapy|Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
227952|NCT02451774|Drug|Placebo Plus Chemotherapy|Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
227953|NCT02451761|Biological|Blood sampling|
227954|NCT02451748|Other|Lab Work|Lab work to measure IL-7 and IL-7R
227955|NCT02451748|Drug|Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)|"Certolizumab pegol (CDP870, tradename Cimzia) or was provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg was given every 2 weeks. Treatment was performed through subcutaneous injection."
227956|NCT02451748|Drug|Certolizumab pegol (CDP870, tradename Cimzia)|"rtolizumab pegol (CDP870, tradename Cimzia) or was provided in prefilled syringes at the dose of 200mg.~Patients received 2x200mg at weeks 0, 2 and 4. Additionally a maintenance dose of 200mg was given every 2 weeks. Treatment was performed through subcutaneous injection."
227957|NCT02451735|Behavioral|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
227958|NCT02451735|Behavioral|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
227959|NCT02451722|Device|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
227960|NCT02451709|Device|Activated Smartinhaler or Smartturbo|Medication reminder alarms
227961|NCT02451709|Other|Feedback of adherence data|Review of adherence data with action planning
227962|NCT02451709|Device|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
227963|NCT02451696|Drug|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
227964|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
227965|NCT02451683|Other|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
227966|NCT02451683|Other|Training with some stimulation|motor task combined with real or sham stimulation
227967|NCT02451670|Behavioral|Prioritized Clinical Decision Support|After entry of blood pressure data at all primary care visits, relevant electronic health record data were automatically extracted, encrypted and processed through Web-based clinical algorithms that determined if the patient met intervention eligibility criteria. In intervention clinics, the rooming staff received a best practice alert and printed patient and primary care provider versions of the clinical decision support that identified evidence-based treatment options for any uncontrolled cardiovascular risk factors and prioritized treatment recommendations based on potential cardiovascular risk reduction. Cardiovascular risk factors addressed in study participants were control of lipids, blood pressure, weight, tobacco, glucose and appropriate aspirin use. In control clinics, rooming staff did not receive a best practice alert and patients and primary care providers did not receive and were not able to access the clinical decision support.
227968|NCT02451657|Other|No Intervention|No intervention was administered in this study
227969|NCT02451644|Device|pedometer|patient will cary pedometer
227970|NCT02451631|Other|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
228017|NCT02451267|Other|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
228018|NCT02451267|Other|physical therapy treatment|neck exercise strengthening program with neck massage
228019|NCT02451254|Procedure|circumferential ablation|circumferential ablation of the pulmonary veins
228020|NCT02451254|Device|SVT ablation|SVT ablation
227971|NCT02451631|Device|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
227972|NCT02451605|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
227973|NCT02451605|Procedure|Total knee replacement surgery.|Total knee replacement surgery.
227974|NCT02451579|Drug|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
227975|NCT02451579|Other|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
227976|NCT02451566|Device|Ovation Prime Abdominal Stent Graft System|
227977|NCT02451553|Drug|Afatinib Dimaleate|Given PO
227978|NCT02451553|Drug|Capecitabine|Given PO
227979|NCT02451553|Other|Laboratory Biomarker Analysis|Correlative studies
227980|NCT02451540|Radiation|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
227981|NCT02451540|Drug|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
227982|NCT02451540|Drug|Roflumilast|Roflumilast, once a day in the morning during 3 months
227983|NCT02451527|Drug|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
227984|NCT02451527|Drug|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
227985|NCT02451514|Biological|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and vaccine-naive Groups.
227986|NCT02451501|Device|AKITA|
227987|NCT02451488|Drug|GM-CSF|14 days in a dose of 125 µg/m^2
227988|NCT02451488|Other|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
227989|NCT02451475|Drug|Amitriptyline|Amitriptyline 25 mg/day
227990|NCT02451475|Drug|Venlafaxine|Venlafaxine 75 mg/day
227991|NCT02451475|Drug|Paroxetine|Paroxetine 25 mg/day
227992|NCT02451462|Drug|Zoledronic acid|
227993|NCT02451436|Behavioral|Sleep and Media Use Intervention|
227994|NCT02451436|Behavioral|Study Skills Control Group|
227995|NCT02451423|Drug|MPDL3280A Dose Level 1|1200 mg x 1 dose
227996|NCT02451423|Drug|MPDL3280A Dose Level 2|1200 mg every 3 weeks x 2 doses
227997|NCT02451423|Drug|MPDL3280A Dose Level 3|1200 mg evert 3 weeks x 3 doses
227998|NCT02451410|Other|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
227999|NCT02451384|Procedure|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
228000|NCT02451384|Procedure|no-touch surgery|
228001|NCT02451384|Procedure|laparoscopic surgery|
228002|NCT02451371|Device|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
228003|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative|0.25 mL, Intramuscular
228004|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative|0.5 mL, Intramuscular
228005|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative|0.5 mL, Intramuscular
228006|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine (2015 SH formulation), No Preservative|0.5 mL, Intramuscular
228007|NCT02451345|Behavioral|Personalized risk model+website+coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.~The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
228008|NCT02451332|Biological|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
228009|NCT02451319|Procedure|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
228010|NCT02451306|Drug|Quetiapine|See information in arm description.
228011|NCT02451306|Drug|Placebo|See information in arm description.
228012|NCT02451293|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|
228013|NCT02451293|Drug|Placebo|
228014|NCT02451280|Procedure|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
228015|NCT02451280|Procedure|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
228016|NCT02451280|Procedure|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
228021|NCT02451241|Other|acupuncture|electroacupuncture
228022|NCT02451228|Other|Serial blood collection|Serial blood collection from IV for pharmacokinetic and pharmacodynamic analysis. No drug, device, or biologic intervention. Opportunistic.
228023|NCT02451215|Device|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
228024|NCT02451202|Procedure|Deep Neuromuscular Blockade|"During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).~At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
228025|NCT02451202|Procedure|Moderate Neuromuscular Blockade|- During maintenance phase, if recovery at the presence of <10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
228026|NCT02451202|Drug|Sugammadex|
228027|NCT02451202|Drug|Rocuronium|
228028|NCT02451189|Dietary Supplement|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
228029|NCT02451189|Dietary Supplement|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
228030|NCT02451189|Dietary Supplement|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
228031|NCT02451176|Device|Davol Bard Soft Mesh synthetic|soft mesh synthetic
228032|NCT02451176|Device|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
228033|NCT02451163|Dietary Supplement|wheat polysaccharides|Consumed once daily for 12 weeks.
228034|NCT02451163|Dietary Supplement|maltodextrin|Consumed once daily for 12 weeks.
228035|NCT02451150|Drug|Azilsartan|Azilsartan tablets
228036|NCT02451137|Drug|Insulin glargine, 300 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
228037|NCT02451137|Drug|Insulin glargine, 100 U/ml|"Pharmaceutical form: solution~Route of administration: subcutaneous"
228038|NCT02451137|Drug|Insulin detemir|"Pharmaceutical form: solution~Route of administration: subcutaneous"
228039|NCT02451137|Drug|Background Therapy|Anti-diabetic drugs at investigator discretion and consistent with local labeling guidelines for use with insulin.
228040|NCT02451124|Device|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
228041|NCT02451124|Other|Questionnaire Administration|Ancillary studies
228042|NCT02451124|Other|Laboratory Biomarker Analysis|Correlative studies
228043|NCT02451124|Procedure|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
228044|NCT02451111|Drug|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
228045|NCT02451111|Drug|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
228046|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
228047|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
228048|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
228049|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
228050|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
228051|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
228052|NCT02451085|Behavioral|training with video therapy|training with video therapy
228053|NCT02451085|Behavioral|conventional exercise|training in conventional way
228054|NCT02451072|Drug|Placebo|Capsules containing mannitol looking identical to LSD per os
228055|NCT02451072|Drug|LSD|100µg per os, single dose
228056|NCT02451072|Drug|Ketanserin|40mg per os, single dose looking identical to LSD per os
228057|NCT02451059|Behavioral|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
228058|NCT02451059|Behavioral|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Study staff will conduct periodic booster sessions; study staff will also train new providers should there be staff turnover
228095|NCT02450747|Device|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
228096|NCT02450734|Procedure|Ultrasound-guided intermediate cervical plexus block|
228141|NCT02450409|Procedure|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
228142|NCT02450383|Drug|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
228059|NCT02451059|Behavioral|Patient Navigator|The peer patient navigator will offer guidance to families with accessing community resources. They will be available at least .5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. The navigator will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
228060|NCT02451033|Drug|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
228061|NCT02451033|Drug|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
228062|NCT02451033|Drug|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
228063|NCT02451020|Other|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
228064|NCT02451007|Drug|lurbinectedin (PM01183)|
228065|NCT02450994|Drug|Dexamethasone|
228066|NCT02450994|Drug|Placebo|
228067|NCT02450981|Drug|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
228068|NCT02450968|Drug|Dexamethasone|
228069|NCT02450968|Drug|Placebo|
228070|NCT02450955|Other|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
228071|NCT02450955|Other|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
228072|NCT02450942|Drug|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
228073|NCT02450903|Drug|LDK378|Oral LDK378 750mg once daily
228074|NCT02450890|Drug|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
228075|NCT02450890|Drug|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
228076|NCT02450877|Drug|Azacitidine|
228077|NCT02450877|Other|Control Arm|
228078|NCT02450864|Other|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
228079|NCT02450838|Biological|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
228080|NCT02450838|Biological|Alhydrogel™|Aluminum hydroxide gel adjuvant
228081|NCT02450838|Biological|Placebo|
228082|NCT02450825|Procedure|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
228083|NCT02450825|Procedure|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
228084|NCT02450825|Device|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
228085|NCT02450812|Drug|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
228086|NCT02450799|Device|Acrylic IOL|Acrylic IOL for long-term implantation in the cataract patient
228087|NCT02450799|Device|Silicone IOL|Silicone IOL for long-term implantation in the cataract patient
228088|NCT02450799|Device|PMMA IOL|Polymethylmethacrylate IOL for long-term implantation in the cataract patient
228089|NCT02450786|Drug|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
228090|NCT02450773|Drug|Furosemide|40 mg furosemide on postpartum day 1-6
228091|NCT02450773|Drug|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
228092|NCT02450773|Drug|Placebo #1|Placebo (for furosemide)
228093|NCT02450773|Drug|Placebo #2|Placebo (for KCl)
228094|NCT02450760|Other|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
228097|NCT02450721|Other|Biomarkers serum level measurement|"Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO."
228098|NCT02450708|Genetic|KIR genotyping|
228099|NCT02450708|Genetic|HLA genotyping|
228100|NCT02450695|Device|rTMS|
228101|NCT02450682|Drug|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
228102|NCT02450682|Drug|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
228103|NCT02450656|Drug|Afatinib|Tablet
228104|NCT02450656|Drug|Selumetinib|Capsule
228105|NCT02450656|Drug|Docetaxel|
228106|NCT02450643|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
228107|NCT02450643|Other|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
228108|NCT02450630|Behavioral|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated & severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
228109|NCT02450617|Behavioral|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
228110|NCT02450617|Behavioral|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
228111|NCT02450617|Behavioral|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
228112|NCT02450604|Genetic|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
228113|NCT02450591|Drug|Erlotinib|
228114|NCT02450591|Other|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
228115|NCT02450578|Drug|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
228116|NCT02450578|Drug|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
228117|NCT02450578|Biological|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
228118|NCT02450578|Drug|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
228119|NCT02450565|Other|Questionnaire|
228120|NCT02450552|Drug|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
228121|NCT02450552|Drug|Placebo|Matched placebo
228122|NCT02450539|Drug|Abemaciclib|Administered orally
228123|NCT02450539|Drug|Docetaxel|Administered IV
228124|NCT02450526|Biological|Botulinum toxin type A|
228125|NCT02450526|Biological|Botulinum toxin type A|
228126|NCT02450526|Drug|Placebo|50 Units
228127|NCT02450526|Drug|Placebo|20 Units
228128|NCT02450513|Drug|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
228129|NCT02450500|Behavioral|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
228130|NCT02450487|Drug|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
228131|NCT02450474|Device|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
228132|NCT02450474|Device|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
228133|NCT02450461|Other|no intervention|
228134|NCT02450448|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
228135|NCT02450448|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
228136|NCT02450435|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
228137|NCT02450435|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
228138|NCT02450422|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
228139|NCT02450422|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
228140|NCT02450409|Procedure|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
228262|NCT02449603|Drug|Exenatide|
228263|NCT02449603|Drug|Biphasic insulin Aspart 30|
228143|NCT02450383|Procedure|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
228144|NCT02450370|Behavioral|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
228145|NCT02450370|Behavioral|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
228146|NCT02450357|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
228147|NCT02450357|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
228148|NCT02450344|Behavioral|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
228149|NCT02450344|Behavioral|Passive health promotion|An electronic package of information related to alcohol
228150|NCT02450331|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg).
228151|NCT02450318|Other|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
228152|NCT02450292|Procedure|Bioabsorbable screw fixation|
228153|NCT02450279|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
228154|NCT02450279|Device|Vibrating-mesh nebulizer|
228155|NCT02450279|Device|Jet Nebulizer|
228156|NCT02450279|Other|Planar scintigraphy|
228157|NCT02450279|Other|Preoperative spirometry|
228158|NCT02450266|Device|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
228159|NCT02450266|Device|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
228160|NCT02450253|Drug|Tadalafil|single dose, 20 mg capsule p.o.
228161|NCT02450253|Drug|Placebo|single dose, matching capsule p.o.
228162|NCT02450253|Behavioral|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
228163|NCT02450253|Behavioral|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan & then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.~Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
228164|NCT02450253|Other|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
228165|NCT02450240|Behavioral|standardized diagnostic assessment|
228166|NCT02450240|Behavioral|self-report questionnaires|
228167|NCT02450240|Behavioral|behavioral tasks|
228168|NCT02450240|Other|physiological measurements|
228169|NCT02450240|Other|structural and functional magnetic resonance imaging and EEG|
228170|NCT02450240|Other|biomarker and microbiome assessments|
228171|NCT02450240|Other|blood to derive induced pluripotent stem cells|
228172|NCT02450240|Other|genetic and epigenetic assessments|
228173|NCT02450227|Dietary Supplement|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
228174|NCT02450227|Dietary Supplement|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
228175|NCT02450214|Drug|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
228176|NCT02450214|Drug|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
228177|NCT02450214|Drug|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
228178|NCT02450201|Drug|Pyruvate|
228179|NCT02450188|Drug|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.~Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
228180|NCT02450188|Behavioral|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.~On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.~CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
228181|NCT02450175|Drug|Everolimus|10 mg of Everolimus daily (by mouth)
228182|NCT02450175|Drug|Letrozole|2.5mg taken daily (by mouth)
228183|NCT02450162|Procedure|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
228184|NCT02450149|Drug|sorafenib|
228185|NCT02450136|Drug|pazopanib|
228186|NCT02450123|Drug|sunitinib|
228187|NCT02450110|Device|Spinal cord stimulation|
228188|NCT02450097|Other|Caloric restriction|
228189|NCT02450084|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
228190|NCT02450084|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
228191|NCT02450084|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
228192|NCT02450084|Drug|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
228193|NCT02450058|Drug|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
228194|NCT02450058|Drug|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
228195|NCT02450058|Drug|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
228196|NCT02450058|Drug|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
228197|NCT02450058|Drug|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
228198|NCT02450045|Procedure|Continuous femoral nerve block|
228199|NCT02450045|Drug|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
228200|NCT02450032|Biological|G17DT|
228201|NCT02450019|Procedure|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
228202|NCT02450019|Procedure|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
228203|NCT02449993|Device|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
228204|NCT02449980|Procedure|Primary Surgery Group|Patients will receive surgical intervention during the initial hospital admission, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
228205|NCT02449980|Procedure|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
228206|NCT02449967|Procedure|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
228207|NCT02449954|Drug|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
228208|NCT02449954|Drug|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
228209|NCT02449954|Drug|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
228210|NCT02449941|Drug|PPI (proton pump inhibitor)|"Pre ESD (endoscopic submucosal dissection)~Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori~Use of PPI for 2 months~Post ESD 1 (After 2 months)~Assess the distribution of helicobacter pylori after using PPI.~Stop of PPI~Post ESD 2 (After 4 months)~Assess the distribution of helicobacter pylori after stop of PPI."
228211|NCT02449928|Drug|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
228212|NCT02449928|Drug|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
228213|NCT02449915|Drug|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
228214|NCT02449915|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
228215|NCT02449902|Drug|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
228216|NCT02449902|Drug|placebo|1 placebo capsule inserted vaginally for 14 days.
228217|NCT02449889|Drug|highly purified human chorionic gonadotropin|
228218|NCT02449889|Drug|recombinant human chorionic gonadotropin|
228219|NCT02449876|Other|Neuroscience Education|"The following topics will be discussed in the education~Basic structure of the nervous system~Basic physiology of the nervous system~The function and importance of pain~Strategies to lessen the impact of pain~The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.~Session 2:~The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
228220|NCT02449863|Other|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
228221|NCT02449850|Other|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
228222|NCT02449850|Other|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
228223|NCT02449837|Other|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up clinic visit, but no more than every 3 months, up until 24 months after completion of radiation.
228224|NCT02449824|Other|magnetic resonance imaging|early MRI
228225|NCT02449811|Drug|Perindopril|
228226|NCT02449811|Drug|Olmesartan|
228227|NCT02449811|Drug|Amlodipine|
228228|NCT02449811|Drug|Hydrochlorothiazide|
228229|NCT02449798|Device|"AccuCath 2.25 BC Intravascular Catheter"|Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
228230|NCT02449785|Device|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
228231|NCT02449785|Device|CT measurements of lung morphological changes in cystic fibrosis|
228232|NCT02449772|Other|No intervention|No intervention
228364|NCT02448927|Device|Transcatheter Aortic Valve Implantation|
228233|NCT02449759|Behavioral|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
228234|NCT02449746|Biological|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
228235|NCT02449746|Biological|Intravenous immunoglobulin|"Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.~IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
228236|NCT02449733|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
228237|NCT02449733|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
228238|NCT02449733|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
228239|NCT02449733|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).~For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
228240|NCT02449733|Other|HIV Testing|Rapid HIV testing at multiple time points
228241|NCT02449733|Other|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
228242|NCT02449733|Procedure|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
228243|NCT02449733|Behavioral|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
228244|NCT02449720|Drug|Ropivacaine|Intraperitoneal instillation and infusion
228245|NCT02449720|Drug|0.9% Saline|Intraperitoneal instillation and infusion
228246|NCT02449707|Procedure|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
228247|NCT02449707|Device|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
228248|NCT02449707|Device|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
228249|NCT02449707|Device|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
228250|NCT02449707|Device|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
228251|NCT02449707|Procedure|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
228252|NCT02449707|Procedure|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
228253|NCT02449694|Device|OCS Liver|OCS Liver will be used to preserve the donor liver
228254|NCT02449681|Drug|TH-4000|
228255|NCT02449668|Device|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
228256|NCT02449668|Device|Sham Acupuncture|
228257|NCT02449655|Drug|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
228258|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
228259|NCT02449655|Drug|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
228260|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
228261|NCT02449616|Drug|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
228264|NCT02449590|Dietary Supplement|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
228265|NCT02449590|Dietary Supplement|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
228266|NCT02449577|Other|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
228267|NCT02449577|Other|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
228268|NCT02449577|Other|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
228269|NCT02449577|Other|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
228270|NCT02449577|Other|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
228271|NCT02449577|Other|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
228272|NCT02449577|Other|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
228273|NCT02449577|Other|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
228274|NCT02449577|Other|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
228275|NCT02449577|Other|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
228276|NCT02449577|Other|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
228277|NCT02449564|Drug|sirolimus|sirolimus 1mg daily
228278|NCT02449551|Drug|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
228279|NCT02449538|Drug|everolimus|everolimus 10 mg qd daily one cycle is 28days.
228280|NCT02449525|Procedure|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
228281|NCT02449486|Drug|Ropivacaine|
228282|NCT02449473|Biological|Tralokinumab|Subcutaneous Injection
228283|NCT02449473|Other|Placebo|Subcutaneous Injection
228284|NCT02449447|Behavioral|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
228285|NCT02449447|Other|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
228286|NCT02449421|Behavioral|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
228287|NCT02449421|Behavioral|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
228288|NCT02449408|Other|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
228289|NCT02449382|Procedure|continuous venovenous hemofiltration|If the serum sodium concentration >150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
228290|NCT02449382|Drug|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
228291|NCT02449369|Drug|Preop acetaminophen IV|
228292|NCT02449369|Drug|Preop orphenadrine IV|
228293|NCT02449369|Drug|Postop oral oxycodone & acetaminophen|
228294|NCT02449369|Drug|Postop hydromorphone IV|
228295|NCT02449369|Drug|Postop oral orphenadrine|
228296|NCT02449369|Drug|Postop oral oxycodone|
228297|NCT02449369|Drug|Postop acetaminophen IV|
228298|NCT02449369|Drug|Postop orphenadrine IV|
228299|NCT02449356|Device|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
228300|NCT02449343|Drug|Anlotinib|Anlotinib p.o. qd
228301|NCT02449343|Drug|Placebo|Placebo p.o. qd
228302|NCT02449330|Drug|Teneligliptin|
228303|NCT02449317|Other|Bioimpedance guided|"bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water~extracellular water/total body water < 0.36 : 4 ml/kg/hr~extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr~extracellular water/total body water > 0.4 : 1 ml/kg/hr"
228304|NCT02449317|Other|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
228305|NCT02449304|Device|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
228306|NCT02449291|Drug|APD421|
228307|NCT02449291|Drug|Placebo|
228308|NCT02449278|Radiation|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).~Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
228309|NCT02449278|Radiation|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).~Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
228310|NCT02449278|Drug|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
228311|NCT02449278|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
228312|NCT02449278|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy
228313|NCT02449278|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy
228362|NCT02448940|Dietary Supplement|lactose|2 capsule a day containing lactose
228363|NCT02448927|Device|balloon aortic valvuloplasty|
228314|NCT02449265|Radiation|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
228315|NCT02449265|Radiation|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.~The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15~18 fractions of 2 Gy 5 days per week for partial response (PR)."
228316|NCT02449265|Drug|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
228317|NCT02449265|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
228318|NCT02449265|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy.
228319|NCT02449265|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy.
228320|NCT02449252|Radiation|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.~Involved-site radiotherapy (ISRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
228321|NCT02449252|Radiation|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.~Involved-field RT (IFRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
228322|NCT02449252|Drug|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
228323|NCT02449252|Drug|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
228324|NCT02449252|Drug|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
228325|NCT02449252|Drug|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
228326|NCT02449239|Biological|Vicinium|Intravesical administration
228327|NCT02449200|Other|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
228328|NCT02449187|Drug|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
228329|NCT02449187|Drug|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.~In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
228330|NCT02449174|Biological|Frozen Microbiota|Frozen Microbiota will be delivered via enema route.
228331|NCT02449174|Biological|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
228332|NCT02449161|Drug|MPA|
228333|NCT02449161|Drug|placebo|
228334|NCT02449148|Other|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
228335|NCT02449135|Procedure|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
228336|NCT02449122|Procedure|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
228337|NCT02449109|Procedure|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
228338|NCT02449096|Device|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
228339|NCT02449096|Other|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
228340|NCT02449083|Procedure|MRI|MRI
228341|NCT02449083|Procedure|coronary angiography|coronary angiography
228342|NCT02449070|Drug|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
228343|NCT02449057|Other|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
228344|NCT02449044|Drug|Tolvaptan|Once Daily
228345|NCT02449031|Drug|TOBI Podhaler|
228346|NCT02449031|Drug|TOBI|tobramycin inhalation solution, USP
228347|NCT02449031|Drug|Bethkis|tobramycin inhalation solution
228348|NCT02449031|Drug|Cayston|aztreonam for inhalation solution
228349|NCT02449018|Drug|QBW251|QBW251 capsule(s) taken orally twice per day
228350|NCT02449018|Drug|Placebo|Matching placebo capsule(s) taken orally twice per day
228351|NCT02449005|Biological|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
228352|NCT02449005|Other|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
228353|NCT02449005|Procedure|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
228354|NCT02448992|Radiation|hippocampal-sparing WBRT|
228355|NCT02448979|Procedure|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
228356|NCT02448979|Procedure|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
228357|NCT02448966|Procedure|open esophagectomy|
228358|NCT02448966|Procedure|Minimally invasive esophagectomy|
228359|NCT02448953|Procedure|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
228360|NCT02448953|Procedure|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
228361|NCT02448940|Dietary Supplement|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
228365|NCT02448914|Drug|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
228366|NCT02448914|Drug|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
228367|NCT02448901|Drug|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
228368|NCT02448888|Other|Adapted exercise|2 months, 3 times/week
228369|NCT02448888|Other|General exercise recommendations|2 months, 3 times/week
228370|NCT02448875|Device|CyPass Micro-Stent|Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.
228371|NCT02448875|Device|Viscoelastic|Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
228372|NCT02448862|Device|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
228373|NCT02448849|Biological|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
228374|NCT02448849|Other|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
228375|NCT02448836|Device|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
228376|NCT02448836|Device|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
228377|NCT02448823|Other|Mass media and Stylish Events|"Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.~Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.~The Stylish Man Van (SMV) accompanies the SMLEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
228378|NCT02448823|Other|Mass Media|1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
228379|NCT02448810|Biological|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in~Administered weekly as part of a 4 week treatment cycle~Intravenous injection"
228380|NCT02448810|Biological|BAX69 + panitumumab|"Study Part 1: Safety Run-in~Administered weekly as part of a 4 week treatment cycle~Intravenous injection"
228381|NCT02448810|Biological|BAX69 + 5-FU/LV|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
228382|NCT02448810|Biological|BAX69 + panitumumab|"Study Part 2: Administered weekly as part of a 4 week treatment cycle~•Intravenous injection"
228383|NCT02448810|Drug|Standard of Care|"Investigator's choice~Dose according to drug label"
228384|NCT02448810|Biological|Standard of Care|"Investigator's choice~Dose according to drug label~Choice includes panitumumab in KRAS &NRAS wt group only"
228385|NCT02448797|Drug|Icotinib|125 mg three times daily (375 mg per day) orally for two years.
228386|NCT02448797|Drug|Chemotherapy|Vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m^2, day 1)/cisplatin (75 mg/m^2, day 1) for 4 cycles.
228387|NCT02448784|Drug|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
228388|NCT02448771|Drug|Palbociclib|
228389|NCT02448771|Drug|Bazedoxifene|
228390|NCT02448745|Device|Insecticide treated wall lining|Polypropylene non-woven fabric.
228391|NCT02448732|Drug|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
228392|NCT02448719|Drug|TAK-792 30 mg|TAK-792 30 mg was administered in the morning after a fast.
228393|NCT02448719|Drug|TAK-792 30 mg placebo|TAK-792 30 mg placebo was administered in the morning after a fast.
228394|NCT02448719|Drug|TAK-792 100 mg|TAK-792 100 mg was administered in the morning after a fast.
228395|NCT02448719|Drug|TAK-792 100 mg placebo|TAK-792 100 mg placebo was administered in the morning after a fast.
228396|NCT02448719|Drug|TAK-792 250 mg|TAK-792 250 mg was administered in the morning after a fast.
228397|NCT02448719|Drug|TAK-792 250 mg placebo|TAK-792 250 mg placebo was administered in the morning after a fast.
228398|NCT02448719|Drug|TAK-792 500 mg|TAK-792 500 mg was administered in the morning after a fast or after breakfast.
228399|NCT02448719|Drug|TAK-792 500 mg placebo|TAK-792 500 mg placebo was administered in the morning after a fast or after breakfast.
228400|NCT02448719|Drug|TAK-792 750 mg|TAK-792 750 mg was administered in the morning after a fast.
228401|NCT02448719|Drug|TAK-792 750 mg placebo|TAK-792 750 mg placebo was administered in the morning after a fast.
228402|NCT02448719|Drug|TAK-792 1250 mg|TAK-792 1250 mg was administered in the morning after a fast.
228403|NCT02448719|Drug|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo was administered in the morning after a fast.
228404|NCT02448706|Device|Hearing Aid Fitting A|
228405|NCT02448706|Device|Hearing Aid Fitting B|
228406|NCT02448693|Device|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
228407|NCT02448693|Device|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
228408|NCT02448680|Biological|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
228409|NCT02448667|Dietary Supplement|FAXE Kondi|Sucrose and glucose containing softdrink
228410|NCT02448667|Dietary Supplement|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
228411|NCT02448654|Drug|Tolcapone|Tolcapone will be compared to sugar pill
228412|NCT02448654|Drug|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
228413|NCT02448641|Biological|SB623 Implant (2.5M)|2.5 million SB623 cells
228414|NCT02448641|Biological|SB623 Implant (5.0M)|5 million SB623 cells
228415|NCT02448641|Procedure|Sham surgery|
228416|NCT02448628|Drug|CS-3150|
228417|NCT02448602|Other|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
228418|NCT02448602|Other|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
228419|NCT02448602|Other|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
228420|NCT02448589|Drug|TAS-119|
228421|NCT02448576|Radiation|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
228422|NCT02448563|Behavioral|Nutrition and physical activity education|Eight weekly in-person groups
228423|NCT02448550|Drug|Bivalirudin|
228424|NCT02448550|Drug|Unfractionated heparin|
228425|NCT02448537|Drug|PM01183|
228426|NCT02448537|Drug|Doxorubicin|
228427|NCT02448537|Drug|Gemcitabine|
228428|NCT02448524|Device|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
228429|NCT02448524|Device|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
228430|NCT02448511|Other|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
228431|NCT02448511|Device|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
228432|NCT02448511|Other|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
228433|NCT02448498|Behavioral|Exercise Intervention|
228434|NCT02448485|Procedure|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
228435|NCT02448472|Other|Observational study, none intervention|
228436|NCT02448459|Drug|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous)."
228437|NCT02448446|Drug|ranibizumab 0.3mg|intravitreally administered
228438|NCT02448433|Device|Phototherapy light-emitting glasses|"The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m^2) upon awakening and progressive shift to earlier wake-up times.~Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.~During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls."
228439|NCT02448420|Drug|Palbociclib|Oral dose 125 mg/d for 3 weeks, followed by one week off, in 4-week cycles.
228440|NCT02448420|Drug|Trastuzumab|Loading dose of 8mg/kg intravenous (iv) followed by 6 mg/kg once every 3 weeks; or subcutaneous trastuzumab 600mg every 3 weeks.
228441|NCT02448420|Drug|Endocrine therapy|Non-steroidal AIs (anastrozole, letrozole); steroidal AI (exemestane); Fulvestrant or Tamoxifen
228442|NCT02448420|Drug|Chemotherapy|Gemcitabine, vinorelbine, capecitabine, eribulin or a taxane
228443|NCT02448420|Drug|Antibody-Drug Conjugates|3.6 mg/kg iv every 3 weeks
228444|NCT02448407|Biological|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
228445|NCT02448407|Drug|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
228446|NCT02448394|Other|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
228776|NCT02446249|Biological|AAV2hAQP1|Infusion of gene therapy
228447|NCT02448381|Drug|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
228448|NCT02448381|Drug|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
228449|NCT02448368|Drug|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
228450|NCT02448368|Drug|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
228451|NCT02448368|Drug|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
228452|NCT02448368|Drug|RDEA3170, 10 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
228453|NCT02448368|Drug|RDEA3170, 2.5 mg|Fifteen subjects were randomized to 1 of 3 treatment sequences with single doses occurring on Days 1, 5, and 9.
228454|NCT02448355|Device|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
228455|NCT02448342|Device|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
228456|NCT02448329|Drug|AZD1775|AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1~3
228457|NCT02448329|Drug|paclitaxel|paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
228458|NCT02448316|Procedure|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.~A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).~Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
228459|NCT02448316|Drug|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
228460|NCT02448316|Drug|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
228461|NCT02448316|Behavioral|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
228462|NCT02448303|Drug|Pembrolizumab|
228463|NCT02448303|Drug|Acalabrutinib|
228464|NCT02448290|Drug|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
228465|NCT02448277|Device|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
228466|NCT02448277|Device|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
228467|NCT02448277|Device|Glidescope|the device is to assist the nasotracheal tube into trachea
228468|NCT02448264|Drug|BCX7353|
228469|NCT02448264|Drug|Placebo to match BCX7353|
228470|NCT02448251|Drug|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
228471|NCT02448238|Other|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
228472|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
228473|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FSPG PET/CT
228474|NCT02448225|Radiation|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
228475|NCT02448225|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
228476|NCT02448225|Other|Laboratory Biomarker Analysis|Correlative studies
228477|NCT02448225|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
228478|NCT02448225|Procedure|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
228479|NCT02448212|Drug|TS-121|Oral
228480|NCT02448212|Drug|[11C]TASP0410699|Intravenous radiotracer
228481|NCT02448212|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
228482|NCT02448199|Drug|Meloxicam and Glucosamine|Experimental
228483|NCT02448199|Drug|Meloxicam|Active Comparator
228484|NCT02448199|Drug|Glucosamine|Active Comparator
228485|NCT02448186|Behavioral|ESTEEM|10-session cognitive behavioral treatment
228486|NCT02448173|Biological|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
228487|NCT02448173|Procedure|Surgery|Surgical resection of Stage II colon cancer
228488|NCT02448160|Device|alfapump|Implantation of alfapump
228489|NCT02448160|Drug|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
228518|NCT02447939|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
228853|NCT02445599|Drug|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
228490|NCT02448147|Behavioral|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
228491|NCT02448147|Behavioral|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
228492|NCT02448134|Behavioral|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
228493|NCT02448121|Procedure|Autologous bone marrow stem cell graft|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
228494|NCT02448108|Behavioral|i-IPSRT|"internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT."
228495|NCT02448108|Other|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
228496|NCT02448095|Drug|Ponatinib|Observation of tolerability and safety profiles
228497|NCT02448082|Other|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
228498|NCT02448082|Other|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
228499|NCT02448069|Drug|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
228500|NCT02448043|Drug|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
228501|NCT02448043|Other|placebo: saline|Placebo drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
228502|NCT02448030|Other|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
228503|NCT02448030|Other|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
228504|NCT02448017|Device|The Herbst appliance|Orthodontic functional appliance
228505|NCT02448017|Device|Twin block appliance|Orthodontic functional appliance
228506|NCT02448004|Drug|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
228507|NCT02447991|Drug|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
228508|NCT02447991|Drug|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
228509|NCT02447978|Biological|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
228510|NCT02447978|Biological|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
228511|NCT02447978|Biological|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
228512|NCT02447965|Drug|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
228513|NCT02447965|Drug|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
228514|NCT02447952|Device|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
228515|NCT02447952|Device|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
228516|NCT02447952|Procedure|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
228517|NCT02447939|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
228649|NCT02446964|Drug|Fludarabine Phosphate|Given IV
228519|NCT02447926|Procedure|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.~On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.~During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.~Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
228520|NCT02447913|Behavioral|Voucher|"Introduction of vouchers will improve uptake of family method as well as child immunization.~Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method"
228521|NCT02447900|Device|BioXmark|
228522|NCT02447887|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
228523|NCT02447887|Drug|Pegylated IFN-alpha 2b|Weekly injection
228524|NCT02447874|Drug|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.~Loading dose: 200 mg/kg once~Continuous IV: 300 mg/kg/24 hours"
228525|NCT02447874|Drug|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 200 mg/kg once
228526|NCT02447874|Drug|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
228527|NCT02447848|Drug|sufentanil sublingual 30 mcg tablet|
228528|NCT02447835|Drug|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)[1,5]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
228529|NCT02447822|Drug|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
228530|NCT02447809|Drug|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)* 12 month.
228531|NCT02447809|Drug|acetylsalicylic acid (ASA)|
228532|NCT02447796|Drug|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
228533|NCT02447796|Drug|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
228534|NCT02447783|Dietary Supplement|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
228535|NCT02447783|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
228536|NCT02447770|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
228537|NCT02447757|Drug|remifentanil|Remifentanil analgesia during delivery
228538|NCT02447744|Behavioral|Mindfulness based stress reduction|The intervention will be an 8-week structured program about mindfulness based stress reduction that teaches skills of mindfulness meditation and mindful yoga.
228539|NCT02447731|Device|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
228540|NCT02447718|Biological|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
228541|NCT02447718|Biological|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
228542|NCT02447718|Biological|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
228543|NCT02447705|Drug|telbivudine|telbivudine replace Lamivudine
228544|NCT02447692|Other|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
228545|NCT02447692|Other|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
228546|NCT02447679|Drug|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
228547|NCT02447679|Drug|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
228548|NCT02447666|Drug|Azacitidine|
228549|NCT02447653|Device|G7 HA Acetabular Component|G7 HA Acetabular Component
228550|NCT02447653|Device|G7 PPS Acetabular Component|G7 PPS Acetabular Component
228551|NCT02447640|Drug|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
228552|NCT02447640|Radiation|[18F]FPEB|radiotracer used for PET scanning
228553|NCT02447614|Procedure|Adenotonsillectomy|Adenotonsillectomy
228650|NCT02446964|Other|Laboratory Biomarker Analysis|Correlative studies
228554|NCT02447614|Other|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
228555|NCT02447614|Other|no treatment|just regular follow-up
228556|NCT02447601|Drug|PEX168|200µg,injected subcutaneously,once a week.
228557|NCT02447601|Drug|Simvastatin|40mg,oral,two times
228558|NCT02447588|Other|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
228559|NCT02447588|Other|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
228560|NCT02447575|Device|Pre-Education Use of MDI|Subject will demonstrate use of MDI) with electronic flowmeter in place before short education process to demonstrate current use of MDI
228561|NCT02447562|Device|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
228562|NCT02447562|Other|Phone-based care group|
228563|NCT02447562|Other|Usual care group|
228564|NCT02447549|Radiation|WBRT|One RT plan with whole bladder treated to standard dose.
228565|NCT02447549|Radiation|SART|Three plans (small, medium & large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
228566|NCT02447549|Radiation|DART|Three plans (small, medium & large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
228567|NCT02447536|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
228568|NCT02447536|Biological|BCG-Russia-I (Serum Institute of India)|See above
228569|NCT02447523|Procedure|Elective abdominal surgery|
228570|NCT02447510|Procedure|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
228571|NCT02447510|Procedure|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
228572|NCT02447510|Procedure|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
228573|NCT02447497|Drug|3M CHG/IPA|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
228574|NCT02447497|Other|Normal Saline|0.9% sodium chloride applied with foam applicator
228575|NCT02447484|Behavioral|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education & Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
228576|NCT02447484|Behavioral|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
228577|NCT02447471|Device|Nexfin|Nexfin cuff placed on finger to measure blood pressure
228578|NCT02447458|Drug|MLN3126|MLN3126 tablets
228579|NCT02447458|Drug|MLN3126 Placebo|MLN3126 placebo-matching tablets
228580|NCT02447445|Procedure|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men < 27 kg and women <16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
228581|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
228582|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
228583|NCT02447432|Biological|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
228584|NCT02447419|Drug|Gefitinib|Gefitinib 250mg will be administered orally daily
228585|NCT02447406|Drug|AZD6094|
228586|NCT02447406|Drug|docetaxel|
228587|NCT02447393|Drug|levocetirizine|levocetirizine
228588|NCT02447393|Drug|cetirizine|cetiridine
228589|NCT02447393|Drug|placebo|placebo
228590|NCT02447380|Drug|AZD6094|AZD6094 600MG qd
228591|NCT02447380|Drug|Docetaxel|Docetaxel 60 mg/m2
228592|NCT02447367|Drug|JLP-1207(Fasted)|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
228593|NCT02447367|Drug|JLP-1207(Fed)|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
228594|NCT02447328|Drug|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
228595|NCT02447315|Drug|Pilocarpine|oral
228596|NCT02447315|Drug|Placebo|oral
228597|NCT02447302|Drug|Etrasimod|
228598|NCT02447302|Drug|Placebo|
228599|NCT02447289|Drug|Intranasal ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL administered into the nose with an atomizer; dose of 4.0 mg/kg, maximum 100.0 mg
228600|NCT02447289|Drug|Oral ketamine|Ketamine injectable solution in a concentration of 50.0 mg/mL via oral route; dose of 4.0 mg/kg maximum 100.0 mg
228601|NCT02447289|Drug|Intranasal midazolam|Midazolam injectable solution in a concentration of 5.0 mg/mL administered into the nose with an atomizer; dose of 0.2 mg/kg, maximum 5.0 mg
228602|NCT02447289|Drug|Oral midazolam|Midazolam oral solution in a concentration of 2.0 mg/mL via oral route; dose of 0.5 mg/kg, maximum 5.0 mg when associated with ketamine; dose of 1.0 mg/kg, maximum 20.0 mg when give as a solely agent
228603|NCT02447276|Drug|REGN475|
228604|NCT02447276|Drug|Placebo|
228651|NCT02446964|Drug|Mycophenolate Mofetil|Given PO or IV
228605|NCT02447263|Procedure|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
228606|NCT02447250|Drug|Varied albuterol dose response|Subjects will be evaluated in 3 sessions. The sessions will occur within a 7 day time span, beginning between 14 or more days from birth and at a corrected gestational age of 28w0d to 33w6d. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
228607|NCT02447237|Other|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
228608|NCT02447224|Drug|1 gm IV ertapenem at enrollment|
228609|NCT02447224|Drug|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
228610|NCT02447224|Procedure|Appendectomy|
228611|NCT02447211|Drug|Doxepin cream 5%|Patients use doxepin creamtwice daily for one weeks
228612|NCT02447211|Other|Placebo|Patients use cream without doxepin ingredient twice daily for one weeks
228613|NCT02447185|Drug|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.~All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
228614|NCT02447185|Drug|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.~During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.~All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
228615|NCT02447172|Drug|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
228616|NCT02447172|Other|Placebo|Matching placebo sponge
228617|NCT02447159|Behavioral|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
228618|NCT02447146|Other|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
228619|NCT02447146|Other|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
228620|NCT02447133|Device|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
228621|NCT02447120|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
228622|NCT02447107|Other|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
228623|NCT02447107|Other|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
228624|NCT02447094|Drug|Alteplase|Intravenous (i.v.) tPA per the standard of care
228625|NCT02447081|Device|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
228626|NCT02447068|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
228627|NCT02447068|Device|Luma Light|NBUVB light
228628|NCT02447068|Device|Occlusive Dressing|Off-the-shelf occlusive dressing
228629|NCT02447055|Biological|Tocilizumab|
228630|NCT02447055|Drug|Melphalan|
228631|NCT02447055|Drug|Fludarabine|
228632|NCT02447055|Drug|Cyclophosphamide|
228633|NCT02447055|Drug|Tacrolimus|
228634|NCT02447055|Drug|Mycophenolate mofetil|
228635|NCT02447055|Drug|Filgrastim|
228636|NCT02447042|Procedure|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
228637|NCT02447042|Device|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
228638|NCT02447029|Drug|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
228639|NCT02447029|Drug|standard lidocaine paracervical block|1% lidocaine paracervical injection
228640|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/rilpivirine|
228641|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/efavirenz|
228642|NCT02447003|Biological|Pembrolizumab|IV infusion
228643|NCT02446990|Drug|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
228644|NCT02446990|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
228645|NCT02446977|Drug|Vitamin B2 Streuli®|4ml IV
228646|NCT02446977|Other|Solution for injection|4ml IV
228647|NCT02446964|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
228648|NCT02446964|Drug|Cyclophosphamide|Given IV
228652|NCT02446964|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
228653|NCT02446964|Drug|Tacrolimus|Given IV and PO
228654|NCT02446964|Radiation|Total Marrow Irradiation|Undergo TMLI
228655|NCT02446938|Procedure|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
228656|NCT02446925|Device|Surefire® Infusion System|Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
228657|NCT02446925|Device|Standard End-hole catheter|Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
228658|NCT02446912|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
228659|NCT02446912|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
228660|NCT02446899|Biological|Anifrolumab|Intravenous infusion (IV)
228661|NCT02446899|Drug|Placebo|Intravenous infusion (IV)
228662|NCT02446886|Drug|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."
228663|NCT02446873|Other|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
228664|NCT02446860|Drug|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
228665|NCT02446847|Drug|3BNC117|3BNC117 infusions
228666|NCT02446847|Other|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
228667|NCT02446834|Behavioral|intensive lifestyle intervention|3 months low GI diet and exercise
228668|NCT02446834|Drug|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
228669|NCT02446834|Drug|Metformin|Use metformin 3 months to treat PCOS
228670|NCT02446834|Drug|Acarbose|Use acarbose 3 months to treat PCOS
228671|NCT02446821|Device|VeraCept|IUD placement of VeraCept
228672|NCT02446808|Device|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
228673|NCT02446795|Drug|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
228674|NCT02446795|Drug|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
228675|NCT02446795|Drug|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
228676|NCT02446782|Drug|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
228677|NCT02446782|Other|saline|100 mL normal saline 15-30 minutes before the start of the procedure
228678|NCT02446769|Device|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
228679|NCT02446756|Other|acupuncture|
228680|NCT02446756|Other|physiotherapy|
228681|NCT02446743|Biological|rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)|One dose of the vaccine administered intramuscularly in the deltoid area of the non-dominant arm.
228682|NCT02446730|Device|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
228683|NCT02446730|Drug|Prasugel|
228684|NCT02446730|Drug|Clopidogrel|
228685|NCT02446717|Drug|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
228686|NCT02446717|Drug|ribavirin (RBV)|Tablet
228687|NCT02446717|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
228688|NCT02446704|Drug|Olaparib|
228689|NCT02446704|Drug|Temozolomide|
228690|NCT02446691|Biological|MenACWY|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
228691|NCT02446678|Device|PillCam ESO2|Capsule endoscopy
228692|NCT02446665|Device|MR Elastography (MRE) and FibroScan|
228693|NCT02446652|Drug|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
228694|NCT02446652|Drug|Placebo|Placebo (orally) starting 1 week before the first day of the QT
228695|NCT02446652|Drug|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
228696|NCT02446652|Drug|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
228697|NCT02446639|Other|Blood collection|
228698|NCT02446626|Procedure|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
228699|NCT02446626|Procedure|Blood draw|Peripheral blood draws will be performed.
228700|NCT02446626|Device|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatchedfrom eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
228738|NCT02446444|Drug|Enzalutamide|
228739|NCT02446444|Drug|Conventional NSAA|
228701|NCT02446613|Other|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
228702|NCT02446600|Drug|Carboplatin|Given IV
228703|NCT02446600|Drug|Cediranib Maleate|Given PO
228704|NCT02446600|Drug|Gemcitabine|Given IV
228705|NCT02446600|Drug|Gemcitabine Hydrochloride|Given IV
228706|NCT02446600|Other|Laboratory Biomarker Analysis|Correlative studies
228707|NCT02446600|Drug|Olaparib|Given PO
228708|NCT02446600|Drug|Paclitaxel|Given IV
228709|NCT02446600|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
228710|NCT02446600|Other|Pharmacological Study|Correlative studies
228711|NCT02446600|Other|Quality-of-Life Assessment|Ancillary studies
228712|NCT02446587|Device|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
228713|NCT02446574|Drug|Paclitaxel|starting dose 20mg/m2 qw
228714|NCT02446574|Drug|Cisplatin|dose 25mg/m2 qw
228715|NCT02446574|Radiation|Radiation|60Gy/2Gy/30f
228716|NCT02446561|Drug|MRXXX|
228717|NCT02446561|Drug|MR1XXX|
228718|NCT02446561|Drug|MR2XXX|
228719|NCT02446561|Drug|MR3XXX|
228720|NCT02446548|Drug|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
228721|NCT02446548|Drug|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
228722|NCT02446548|Other|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
228723|NCT02446535|Other|achievement of the DW by means of the BIA DW (RE.S.T.)|
228724|NCT02446522|Procedure|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
228725|NCT02446522|Procedure|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
228726|NCT02446509|Behavioral|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
228727|NCT02446509|Behavioral|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
228728|NCT02446496|Drug|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
228729|NCT02446496|Drug|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
228730|NCT02446483|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
228731|NCT02446483|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
228732|NCT02446470|Procedure|Sinus Tarsi approach|A straight incision is made on the lateral side of the foot from the tip of the fibula to the base of the fourth metatarsal which centers the incision over the sinus tarsi. Then careful dissection is made through the subcutaneous tissues to prevent damage to the sural nerve, peroneal tendons, and extensor digitorum brevis (EDB). The origin of EDB is identified and the muscle is released distal enough to fully visualize the fracture and articular surface of the calcaneus. Following exposure of the fracture and articular surface of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
228733|NCT02446470|Procedure|Extensile Lateral approach|An L-shaped incision overlying the lateral wall of the calcaneus will be made, followed by sharp dissection of soft tissues in line with the skin incision down to the periosteum. Effort will be made to identify and protect the sural nerve, as it commonly crosses the surgical field with this approach. The soft tissue flap is retracted as a single unit as subperiosteal dissection is performed. Following exposure of the lateral wall of the calcaneus, open reduction and restoration of the articular surface of the calcaneus will be achieved followed by stable fracture fixation with plates and screws as dictated by the specific fracture pattern.
228734|NCT02446457|Other|Laboratory Biomarker Analysis|Correlative studies
228735|NCT02446457|Drug|Lenalidomide|Given PO
228736|NCT02446457|Biological|Pembrolizumab|Given IV
228737|NCT02446457|Biological|Rituximab|Given IV
228741|NCT02446444|Radiation|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
228742|NCT02446431|Drug|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
228743|NCT02446431|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
228744|NCT02446431|Drug|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
228745|NCT02446431|Drug|Temsirolimus|Temsirolimus [an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
228746|NCT02446418|Drug|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
228747|NCT02446418|Drug|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
228748|NCT02446418|Drug|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
228749|NCT02446418|Drug|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
228750|NCT02446418|Drug|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
228751|NCT02446418|Drug|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
228752|NCT02446405|Drug|Enzalutamide|
228753|NCT02446405|Drug|NSAA|
228754|NCT02446405|Drug|LHRHA or Surgical Castration|
228755|NCT02446392|Other|No intervention.|
228756|NCT02446379|Drug|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
228757|NCT02446379|Device|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
228758|NCT02446379|Device|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
228759|NCT02446366|Other|Laboratory Biomarker Analysis|Correlative studies
228760|NCT02446366|Other|Quality-of-Life Assessment|Ancillary studies
228761|NCT02446366|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
228762|NCT02446353|Drug|Apetrol ES / Megace|Sequences of administered drugs
228763|NCT02446340|Drug|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
228764|NCT02446340|Drug|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
228765|NCT02446327|Other|Blood sampling for biomarker assessment|
228766|NCT02446314|Dietary Supplement|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
228767|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
228768|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
228769|NCT02446314|Dietary Supplement|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
228770|NCT02446301|Drug|Bain®|Nalbuphine HCl 20mg, IM injection
228771|NCT02446301|Drug|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
228772|NCT02446288|Device|TMJ Next Generation|
228773|NCT02446288|Device|DSG Relaxer|
228774|NCT02446275|Other|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
228775|NCT02446275|Other|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
228777|NCT02446236|Drug|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
228778|NCT02446236|Drug|Ibrutinib|560 mg PO daily
228779|NCT02446236|Drug|Rituximab|375 mg/m2 IV Day 1
228780|NCT02446223|Drug|Inggenol Mebutate 0.015%|
228781|NCT02446210|Device|Magstim 200|Transcranial Magnetic Stimulation
228782|NCT02446210|Device|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
228783|NCT02446197|Other|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
228784|NCT02446184|Procedure|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
228785|NCT02446184|Procedure|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
228786|NCT02446171|Drug|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
228787|NCT02446171|Drug|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
228788|NCT02446171|Drug|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
228789|NCT02446171|Drug|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
228790|NCT02446158|Drug|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
228791|NCT02446145|Drug|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine~- concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes"
228792|NCT02446145|Drug|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine~- concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes"
228793|NCT02446132|Drug|AVP-786|
228794|NCT02446119|Device|EndoFLIP|Measurement of pyloric resistance and compliance
228795|NCT02446106|Dietary Supplement|Soup with MSG|0.5% MSG + 0.48% salt
228796|NCT02446106|Dietary Supplement|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
228797|NCT02446093|Biological|GMCI|Intratumoral cytotoxic immunotherapy using an adenoviral vector expressing HSV-tk followed by anti-herpetic prodrug valacyclovir
228798|NCT02446093|Drug|Chemotherapy|Standard of care chemotherapy given with radiation
228799|NCT02446093|Radiation|Radiation|
228800|NCT02446093|Procedure|Surgery|Pancreaticoduodenectomy (Whipple)
228801|NCT02446080|Dietary Supplement|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
228802|NCT02446080|Dietary Supplement|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
228803|NCT02446067|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
228804|NCT02446054|Dietary Supplement|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
228805|NCT02446041|Other|Non-Interventional Study|Non-Interventional Study
228806|NCT02446028|Drug|BIOD-531|
228807|NCT02446028|Drug|Humalog® Mix 75/25|
228808|NCT02446015|Drug|SYSTANE® ULTRA Lubricant Eye Drops|
228809|NCT02446002|Drug|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
228810|NCT02445989|Drug|NuvaRing|Provide NuvaRing to women seeking contraception
228811|NCT02445976|Drug|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
228812|NCT02445963|Biological|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
228813|NCT02445950|Behavioral|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
228814|NCT02445950|Behavioral|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
228854|NCT02445599|Drug|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
228855|NCT02445599|Drug|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
228856|NCT02445599|Drug|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
228815|NCT02445937|Behavioral|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
228816|NCT02445911|Drug|KQ-791|Capsules administered orally
228817|NCT02445911|Drug|Placebo|Capsules administered orally
228818|NCT02445898|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
228819|NCT02445898|Drug|Isotonic Sodium Chloride|Placebo
228820|NCT02445885|Procedure|PCI|Guideline directed Percutaneous Coronary Intervention
228821|NCT02445872|Drug|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
228822|NCT02445872|Drug|Palonosetron|
228823|NCT02445872|Drug|Dexamethasone|
228824|NCT02445859|Drug|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
228825|NCT02445846|Device|dual HIV/syphilis rapid diagnostics tests|
228826|NCT02445833|Behavioral|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
228827|NCT02445820|Drug|HES|2500 mL of balanced HES 130/0.4
228828|NCT02445820|Drug|Crystalloid|2500 mL of balanced crystalloid.
228829|NCT02445807|Drug|DFD06-Cream|Twice daily topical application for 14 days.
228830|NCT02445807|Drug|Vehicle Cream|Twice daily topical application for 14 days.
228831|NCT02445794|Drug|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
228832|NCT02445794|Drug|RT001 comparator|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
228833|NCT02445781|Device|Glucose clamp|Different levels of hypoglycemia
228834|NCT02445768|Other|Cognitive multisensory rehabilitation|
228835|NCT02445768|Device|3T scanner with MRI-compatible robot|
228836|NCT02445742|Drug|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
228837|NCT02445729|Other|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
228838|NCT02445729|Other|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
228839|NCT02445716|Drug|Testosterone|"It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.~Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.~Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit."
228840|NCT02445716|Drug|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
228841|NCT02445703|Biological|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
228842|NCT02445703|Biological|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
228843|NCT02445677|Device|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
228844|NCT02445677|Device|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
228845|NCT02445664|Behavioral|Educational video|Video: Information on osteoporosis and alendronate treatment.
228846|NCT02445651|Dietary Supplement|Intravenous and Oral n—acetyl cysteine|
228847|NCT02445638|Other|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
228848|NCT02445638|Other|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
228849|NCT02445625|Device|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
228850|NCT02445612|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
228851|NCT02445599|Drug|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
228852|NCT02445599|Drug|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
228979|NCT02444689|Behavioral|Standard of care education|
228857|NCT02445599|Drug|Metamizole-sodium|Additional rescue analgetic 2g intravenously
228858|NCT02445599|Drug|Tramadol|Additional rescue analgetic 100mg intravenously
228859|NCT02445586|Drug|Docetaxel|Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.
228860|NCT02445586|Drug|Pertuzumab|Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
228861|NCT02445586|Drug|Trastuzumab|Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
228862|NCT02445573|Other|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
228863|NCT02445573|Other|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
228864|NCT02445560|Dietary Supplement|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
228865|NCT02445560|Dietary Supplement|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
228866|NCT02445560|Dietary Supplement|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.~During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
228867|NCT02445560|Dietary Supplement|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.~During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
228868|NCT02445547|Other|UC-MSCs by peripheral intravenous infusion|
228869|NCT02445547|Drug|received hormone maintenance therapy|
228870|NCT02445534|Biological|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
228871|NCT02445508|Drug|Sevelamer|
228872|NCT02445508|Drug|Cholecystokinin|
228873|NCT02445508|Drug|Sevelamer placebo|
228874|NCT02445508|Drug|Isotonic saline|
228875|NCT02445495|Device|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
228876|NCT02445482|Procedure|Biopsy|archival tissue or fresh biospsy
228877|NCT02445469|Other|MRI exam of the brain|MRI exam of the brain
228878|NCT02445456|Drug|Sienna+ injection|Endoscopic injection of magnetic tracer
228879|NCT02445456|Other|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
228880|NCT02445456|Procedure|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
228881|NCT02445456|Device|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
228882|NCT02445443|Device|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
228883|NCT02445404|Drug|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
228884|NCT02445404|Drug|fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
228885|NCT02445391|Drug|Capecitabine|Given PO
228886|NCT02445391|Drug|Carboplatin|Given IV
228887|NCT02445391|Drug|Cisplatin|Given IV
228888|NCT02445391|Other|Laboratory Biomarker Analysis|Correlative studies
228889|NCT02445391|Procedure|Quality-of-Life Assessment|Ancillary studies
228890|NCT02445391|Other|Questionnaire Administration|Ancillary studies
228980|NCT02444676|Other|Stratification and outcomes|No necessary
228891|NCT02445378|Procedure|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
228892|NCT02445378|Other|Placebo|Undergo placebo intervention using rose water
228893|NCT02445378|Other|Questionnaire Administration|Ancillary studies
228894|NCT02445365|Device|AutoRIC device|
228895|NCT02445352|Drug|Rosuvastatin 5mg|
228896|NCT02445352|Drug|DP-R207 5/10mg|
228897|NCT02445352|Drug|Rosuvastatin 10mg|
228898|NCT02445352|Drug|DP-R207 10/10mg|
228899|NCT02445352|Drug|Rosuvastatin 20mg|
228900|NCT02445352|Drug|DP-R207 20/10mg|
228901|NCT02445352|Drug|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
228902|NCT02445352|Drug|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
228903|NCT02445352|Drug|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
228904|NCT02445339|Drug|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
228905|NCT02445326|Drug|Dexamethasone|
228906|NCT02445326|Other|Placebo Vehicle|
228907|NCT02445313|Device|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
228908|NCT02445300|Other|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
228909|NCT02445300|Other|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
228910|NCT02445287|Radiation|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
228911|NCT02445274|Procedure|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
228912|NCT02445261|Radiation|mobile phone|Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
228913|NCT02445248|Biological|CTL019|Single arm
228914|NCT02445235|Other|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
228915|NCT02445222|Genetic|Previously treated CART CD 19 patients|Lentiviral-based CD19 directed CART cell therapy
228916|NCT02445209|Other|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
228917|NCT02445209|Other|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
228918|NCT02445196|Behavioral|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
228919|NCT02445196|Device|Smartphone|All participants must have a smartphone, either apple or android.
228920|NCT02445183|Other|None, N/A|
228921|NCT02445170|Procedure|Amputation|Transmetatarsal or below-knee amputation
228922|NCT02445157|Other|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
228923|NCT02445131|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
228924|NCT02445131|Drug|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg~Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
228925|NCT02445131|Drug|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.~Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
228926|NCT02445118|Other|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
228927|NCT02445105|Behavioral|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
228928|NCT02445105|Behavioral|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
228976|NCT02444715|Behavioral|Standard care|Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
228977|NCT02444715|Behavioral|CAPSYS|In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
228929|NCT02445092|Other|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter~Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:~Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.~Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..~Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.~Labeling:~Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
228930|NCT02445079|Other|This is an observational study only|Observational study only
228931|NCT02445066|Dietary Supplement|Vitamin D3|
228932|NCT02445053|Drug|ivacaftor|
228933|NCT02445040|Device|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
228934|NCT02445027|Device|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
228935|NCT02445014|Device|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
228936|NCT02445001|Procedure|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
228937|NCT02444988|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
228938|NCT02444988|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
228939|NCT02444975|Dietary Supplement|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
228940|NCT02444975|Other|Coaching program|Coaching program to support increased water intake
228941|NCT02444975|Other|No intervention|No intervention
228942|NCT02444962|Device|HAVD-implant|hydroxy-apatite coated, acid etched implant for extra oral use to reconstruct craniofacial defects with an episthesis
228943|NCT02444949|Drug|endostar|
228944|NCT02444949|Radiation|intensity modulated radiation|
228945|NCT02444949|Drug|cisplatin|
228946|NCT02444936|Drug|ZOSTAVAX|Shingles vaccine
228947|NCT02444923|Device|Scleral rigid gas permeable contact lenses (SRGPcl) (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
228948|NCT02444923|Device|Corneal Rigid gas Permeable contact lenses (CRGPcl) (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
228949|NCT02444910|Drug|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
228950|NCT02444897|Drug|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.~Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
228951|NCT02444897|Drug|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
228952|NCT02444884|Drug|MLN8237|
228953|NCT02444858|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10^5/kg) ，once a day,a total of three times.
228954|NCT02444858|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
228955|NCT02444819|Drug|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
228956|NCT02444806|Other|Full polysomnography|Full sleep and respiratory monitoring with EEG
228957|NCT02444806|Other|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
228958|NCT02444793|Drug|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
228959|NCT02444793|Drug|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
228960|NCT02444780|Procedure|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
228961|NCT02444767|Drug|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
228962|NCT02444754|Other|Medical Chart Review|Obtain medical data
228963|NCT02444754|Other|Questionnaire Administration|Complete demographics questionnaires
228964|NCT02444754|Other|Survey Administration|Complete surveys
228965|NCT02444741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
228966|NCT02444741|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
228967|NCT02444741|Other|Laboratory Biomarker Analysis|Correlative studies
228968|NCT02444741|Biological|Pembrolizumab|Given IV
228969|NCT02444741|Radiation|Proton Beam Radiation Therapy|Undergo PBRT
228970|NCT02444741|Radiation|Radiation Therapy|Undergo low dose radiation therapy
228971|NCT02444741|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
228972|NCT02444728|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
228973|NCT02444728|Drug|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
228974|NCT02444728|Drug|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
228975|NCT02444728|Drug|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
228978|NCT02444689|Behavioral|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
228981|NCT02444663|Radiation|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
228982|NCT02444663|Radiation|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
228983|NCT02444663|Radiation|Device Valgus|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
228984|NCT02444663|Radiation|Device Varus|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
228985|NCT02444650|Device|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
228986|NCT02444650|Device|tonometer|
228987|NCT02444637|Drug|Rivastigmine|
228988|NCT02444611|Drug|BCG Vaccine|intradermal vaccination
228989|NCT02444611|Drug|Hepatitis B Vaccine|intramuscular vaccination
228990|NCT02444598|Device|Vaccum Assisted Closure device|Negative-pressure wound therapy
228991|NCT02444598|Procedure|Conventional wound dressings|Conventional wound dressings
228992|NCT02444585|Drug|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
228993|NCT02444572|Drug|Enoxaparin 4000 IU|
228994|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
228995|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Placebo|
228996|NCT02444546|Other|Laboratory Biomarker Analysis|Correlative studies
228997|NCT02444546|Biological|Sargramostim|Given SC
228998|NCT02444546|Biological|Wild-type Reovirus|Given IV
228999|NCT02444533|Drug|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
229000|NCT02444520|Behavioral|Integrated GP Care|"The overall aims of the intervention are to help the patient:~develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;~understand factors that may be maintaining the problem;~learn how to modify the behavioral and cognitive responses which may be maintaining the problem;~adopt a healthy sleep routine which can promote healthy living.~Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
229001|NCT02444507|Drug|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
229002|NCT02444507|Drug|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
229003|NCT02444481|Drug|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
229004|NCT02444468|Device|Flowtron ACS800|Flowtron ACS800 and bandage
229005|NCT02444468|Other|Bandage|Bandage only
229006|NCT02444455|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10^5/kg) once a day,a total of three times.
229007|NCT02444442|Device|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
229008|NCT02444442|Other|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
229009|NCT02444429|Drug|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.~An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.~The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
229010|NCT02444429|Other|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
229011|NCT02444429|Other|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
229012|NCT02444416|Procedure|blood sample|
229013|NCT02444403|Behavioral|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|"The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).~A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3)."
229014|NCT02444390|Procedure|Biopsy|biopsy of a metastasis
229015|NCT02444377|Behavioral|Interval training|
229016|NCT02444364|Drug|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
229017|NCT02444351|Drug|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
229018|NCT02444351|Other|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
229019|NCT02444338|Device|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
229020|NCT02444338|Other|standard of care|
229021|NCT02444325|Behavioral|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
229022|NCT02444312|Behavioral|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
229056|NCT02444039|Device|SL-D301|Slit Lamp
229057|NCT02444039|Device|DC-4|Digital Camera Attachment
229023|NCT02444312|Behavioral|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
229024|NCT02444299|Device|Shoulder hemi-arthroplasty|
229025|NCT02444273|Procedure|Exercise|Subjects will be given and individualized exercise program.
229026|NCT02444260|Drug|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
229027|NCT02444260|Drug|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
229028|NCT02444260|Drug|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
229029|NCT02444260|Drug|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
229030|NCT02444247|Other|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
229031|NCT02444247|Other|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
229032|NCT02444247|Other|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
229033|NCT02444247|Other|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
229034|NCT02444234|Drug|Tedizolid PO|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
229035|NCT02444234|Drug|Tedizolid IV|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
229036|NCT02444208|Behavioral|Active Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of cocaine cues.
229037|NCT02444208|Behavioral|Neutral Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of neutral cues.
229038|NCT02444195|Behavioral|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
229039|NCT02444182|Dietary Supplement|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
229040|NCT02444182|Dietary Supplement|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
229041|NCT02444169|Device|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
229042|NCT02444169|Drug|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
229043|NCT02444169|Device|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
229044|NCT02444169|Device|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
229045|NCT02444156|Other|Indoor rowing|
229046|NCT02444143|Drug|tacrolimus extended release|
229047|NCT02444130|Device|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
229048|NCT02444117|Other|functional rehabilitation of social communication|
229049|NCT02444091|Drug|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
229050|NCT02444078|Other|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
229051|NCT02444078|Other|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
229052|NCT02444065|Behavioral|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
229053|NCT02444065|Behavioral|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter & Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
229054|NCT02444052|Device|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
229055|NCT02444052|Device|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
229059|NCT02444026|Behavioral|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
229060|NCT02444013|Drug|Folic acid|
229061|NCT02444013|Drug|Placebo|
229062|NCT02444000|Drug|PCV chemotherapy alone|"PCV cycles are 6 weeks long~PCV chemotherapy is given as:~Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
229063|NCT02444000|Drug|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
229064|NCT02443987|Other|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
229065|NCT02443974|Device|Brace (Fisiotensor®)|
229066|NCT02443974|Device|Sleeve (Fisiotensor®)|
229067|NCT02443961|Biological|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
229068|NCT02443948|Other|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
229069|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 4 weeks
229070|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 24 weeks
229071|NCT02443922|Drug|Glimepiride|Glimepiride 2mg qam
229072|NCT02443922|Drug|Sitagliptin|Sitagliptin 100mg qam
229073|NCT02443922|Drug|Metformin|Metformin as prescribed
229074|NCT02443909|Procedure|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
229075|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
229076|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
229077|NCT02443909|Device|Holmium laser device|
229078|NCT02443896|Procedure|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
229079|NCT02443896|Procedure|No sealant of permanent molars|No sealant applied to permanent molars.
229080|NCT02443883|Drug|Ramucirumab|Administered IV
229081|NCT02443857|Device|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
229082|NCT02443857|Device|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
229083|NCT02443857|Device|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
229084|NCT02443857|Device|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
229085|NCT02443857|Device|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
229086|NCT02443857|Device|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
229087|NCT02443844|Procedure|Transurethral Resection|Endoscopic treatment of bladder cancer
229088|NCT02443844|Drug|Tamsulosin|Medical treatment for benign prostate hyperplasia
229089|NCT02443831|Procedure|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19 CAR T-cells
229090|NCT02443831|Drug|Lymphodepletion with fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19CAR T-cell infusion.
229091|NCT02443831|Drug|Lymphodepletion with cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19CAR T-cell infusion.
229092|NCT02443831|Biological|CD19 CAR T-cells|A single dose of 1 x 10^6/kg CD19CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
229093|NCT02443818|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
229094|NCT02443805|Biological|300 IR|300 IR tablet of HDM Allergen Extracts
229095|NCT02443805|Biological|Placebo|Placebo tablet
229096|NCT02443792|Procedure|Unicirc with tissue adhesive|As above
229097|NCT02443792|Procedure|Open Surgical|As above
229098|NCT02443766|Other|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
229099|NCT02443753|Device|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
229100|NCT02443740|Drug|PF-05251749|Single ascending doses of PF-05251749 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
229101|NCT02443740|Drug|PF-05251749|Single ascending doses of PF-05251749 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
229102|NCT02443740|Drug|PF-05251749|Single dose (Maximum Tolerated Dose) of PF-05251749 as extemporaneously prepared solution/suspension
229103|NCT02443727|Drug|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
229104|NCT02443727|Other|Placebo|Dosage and details described in arm.
229105|NCT02443714|Device|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
229106|NCT02443714|Device|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
229107|NCT02443701|Other|Exercise|Warmup program, maximum isometric strengthening, and jump training
229108|NCT02443701|Other|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
229109|NCT02443701|Other|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
229110|NCT02443688|Drug|CTX-4430|
229111|NCT02443688|Drug|Placebo|
229112|NCT02443662|Other|Catheterization|Routine catheterization during follow up.
229113|NCT02443649|Behavioral|Sleep hygiene program|Sleep hygiene program
229114|NCT02443649|Behavioral|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
229115|NCT02443623|Biological|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
229116|NCT02443597|Other|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
229117|NCT02443584|Other|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
229118|NCT02443571|Radiation|Fluciclovine (18F)|Not applicable. This is an observational study.
229119|NCT02443558|Other|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
229120|NCT02443558|Device|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
229121|NCT02443545|Drug|Deferiprone|
229122|NCT02443532|Behavioral|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
229123|NCT02443532|Behavioral|Individual education|Usual care (individual consultations as routinely performed)
229124|NCT02443519|Behavioral|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
229125|NCT02443506|Drug|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
229126|NCT02443506|Drug|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
229127|NCT02443493|Device|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
229128|NCT02443493|Device|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
229129|NCT02443493|Radiation|radiotherapy|
229130|NCT02443467|Other|No intervention|
229131|NCT02443454|Device|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
229132|NCT02443454|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
229133|NCT02443402|Drug|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) < 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
229134|NCT02443402|Drug|Placebo|One pill daily until discharge
229135|NCT02443402|Drug|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG > 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
229136|NCT02443402|Drug|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate >2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.~Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day~The basal insulin dose will be adjusted as follow:~If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change~If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day~If fasting and pre-dinner BG is > 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day~If fasting and pre-dinner BG is < 100 mg/dL in the absence of hypoglycemia: stop glargine"
229137|NCT02443402|Drug|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin lispro~BG between 221-260 mg/dL; 3-5 units of insulin lispro~BG between 261-300 mg/dL; 4-6 units of insulin lispro~BG between 301-350 mg/dL; 5-7 units of insulin lispro~BG between 351-400 mg/dL; 6-8 units of insulin lispro~BG > 400 mg/dL; 7-9 units of insulin lispro"
229138|NCT02443402|Drug|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.~For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:~BG between 181-220 mg/dL; 2-4 units of insulin aspart~BG between 221-260 mg/dL; 3-5 units of insulin aspart~BG between 261-300 mg/dL; 4-6 units of insulin aspart~BG between 301-350 mg/dL; 5-7 units of insulin aspart~BG between 351-400 mg/dL; 6-8 units of insulin aspart~BG > 400 mg/dL; 7-9 units of insulin aspart"
229139|NCT02443376|Device|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
229140|NCT02443376|Device|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:~Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
229141|NCT02443363|Other|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
229142|NCT02443363|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
229143|NCT02443337|Drug|LY3023414|Administered orally
229144|NCT02443337|Drug|Necitumumab|Administered IV
229145|NCT02443324|Drug|Ramucirumab|Administered IV
229146|NCT02443324|Drug|Pembrolizumab|Administered IV
229147|NCT02443311|Drug|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
229148|NCT02443311|Drug|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
229149|NCT02443298|Drug|placebo|Matching placebo for risankizumab
229150|NCT02443298|Drug|risankizumab|Monoclonal IgG antibody
229151|NCT02443285|Drug|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
229152|NCT02443285|Drug|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
229153|NCT02443272|Procedure|Vessel Loop Drainage|Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
229154|NCT02443272|Procedure|Incision and Drainage|Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
229155|NCT02443246|Drug|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
229156|NCT02443246|Drug|Placebo|
229157|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia in distal-proximal group"
229158|NCT02443220|Device|TEAS|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia in regional group"
229159|NCT02443220|Device|TEAS|"The device will be connected to Danzhong and Hegu but no stimulation to the acupoints 30 min before anesthesia"
229160|NCT02443194|Drug|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
229161|NCT02443194|Drug|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
229162|NCT02443181|Device|Activa PC+S|Implementation of closed loop DBS for essential tremor
229163|NCT02443168|Drug|AG-221|Part 1: oral solution containing 100 mg [14C]-AG-221
229164|NCT02443168|Radiation|14C AG-221|5 mL of 100 micrograms [14C] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
229165|NCT02443155|Drug|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
229166|NCT02443155|Drug|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
229167|NCT02443155|Drug|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
229168|NCT02443142|Drug|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
229169|NCT02443142|Drug|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
229170|NCT02443129|Device|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
229171|NCT02443116|Biological|NGM282|
229172|NCT02443116|Other|Placebo|
229173|NCT02443103|Drug|Guanabenz acetate|
229174|NCT02443090|Drug|fispemifene|
229175|NCT02443090|Other|Placebo|
229176|NCT02443077|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
229177|NCT02443077|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
229178|NCT02443077|Drug|Carmustine|Given IV
229179|NCT02443077|Drug|Cyclophosphamide|Given IV
229180|NCT02443077|Drug|Cytarabine|Given IV
229181|NCT02443077|Drug|Etoposide|Given IV
229182|NCT02443077|Drug|Ibrutinib|Given PO
229183|NCT02443077|Other|Laboratory Biomarker Analysis|Correlative studies
229184|NCT02443077|Drug|Melphalan|Given IV
229185|NCT02443077|Other|Pharmacogenomic Study|Correlative studies
229186|NCT02443077|Other|Placebo|Given PO
229224|NCT02442752|Drug|Dexlansoprazole|Dexlansoprazole capsules
229225|NCT02442739|Drug|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
229226|NCT02442739|Other|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
229187|NCT02443064|Drug|Vancomycin|"Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.~Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on."
229188|NCT02443051|Behavioral|Attention Bias Modification|Computer delivered modification in 80% of trials
229189|NCT02443038|Other|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.~The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
229190|NCT02443025|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
229191|NCT02443012|Drug|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
229192|NCT02443012|Procedure|Laser|Grid/Focal Laser Photocoagulation
229193|NCT02442999|Other|Screening for obstructive sleep apnea|
229194|NCT02442999|Device|CPAP - continuous positive airway pressure|
229195|NCT02442973|Procedure|Control group (CG): standard practice|Standard practice group
229196|NCT02442973|Procedure|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
229197|NCT02442973|Device|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
229198|NCT02442960|Drug|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
229199|NCT02442947|Other|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment [charcoal base], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
229200|NCT02442934|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
229201|NCT02442934|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
229202|NCT02442934|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.~The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.~The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
229203|NCT02442921|Drug|Colchicine|up to 2mg of Colchicine daily
229204|NCT02442921|Drug|Placebo|Daily placebo
229205|NCT02442908|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
229206|NCT02442908|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
229207|NCT02442869|Behavioral|Treatment as usual (TAU)|4-8 weeks of treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
229208|NCT02442869|Behavioral|CAMS short|4-8 weeks Collaborative Assessment and Management of Suicidality (CAMS) short course
229209|NCT02442869|Behavioral|CAMS long|4-16 weeks Collaborative Assessment and Management of Suicidality (CAMS) long course
229210|NCT02442869|Behavioral|Dialectical Behavioral Therapy (DBT) long|4-16 weeks of Dialectical Behavioral Therapy (DBT) long course
229211|NCT02442856|Device|Thigh Cuff|
229212|NCT02442843|Device|Active tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
229213|NCT02442843|Device|Sham tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
229214|NCT02442830|Device|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.~Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
229215|NCT02442817|Drug|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
229216|NCT02442804|Dietary Supplement|POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
229217|NCT02442804|Other|Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
229218|NCT02442791|Drug|Byetta (Lilly, Exenatide)|See description of Arms
229219|NCT02442791|Other|20% Human Albumin|See description of Arms
229220|NCT02442778|Drug|AVP-786|
229221|NCT02442778|Drug|Placebo|
229222|NCT02442765|Drug|AVP-786|
229223|NCT02442765|Drug|Placebo|
229227|NCT02442726|Device|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
229228|NCT02442713|Drug|fluvoxamine|fluvoxamine: 50-300mg/day
229229|NCT02442700|Drug|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
229230|NCT02442700|Drug|placebo|Treatment B = administration placebo for 12 weeks
229231|NCT02442687|Drug|JKB-121: 5 mg twice daily|
229232|NCT02442687|Drug|JKB-121: 10 mg twice daily|
229233|NCT02442687|Drug|Placebo|
229234|NCT02442674|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.~Dosage: Depending on age, weight and serum sodium response:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
229235|NCT02442674|Other|Placebo|Placebo tablet matching active drug
229236|NCT02442648|Drug|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
229237|NCT02442648|Drug|Rituximab|Rituximab will be administered for desensitization per study protocol.
229238|NCT02442635|Behavioral|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
229239|NCT02442622|Other|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
229240|NCT02442622|Device|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
229241|NCT02442609|Other|questionaire|questionaire before surgery
229242|NCT02442583|Other|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
229243|NCT02442570|Biological|recombinant human alpha B-crystallin|intravenous injections
229244|NCT02442570|Other|Placebo comparator|intravenous injection
229245|NCT02442557|Biological|recombinant human alpha B-crystallin|intravenous injection
229246|NCT02442557|Other|placebo comparator|intravenous injection
229247|NCT02442544|Dietary Supplement|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
229248|NCT02442544|Dietary Supplement|Placebo|maltodextrin 3.3g orally/day
229249|NCT02442531|Drug|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
229250|NCT02442518|Procedure|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
229251|NCT02442505|Device|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
229252|NCT02442492|Drug|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
229253|NCT02442492|Drug|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
229254|NCT02442479|Behavioral|resistance training|
229255|NCT02442466|Drug|Endothelin Receptor B inhibitor BQ788|
229256|NCT02442466|Drug|PBS|
229257|NCT02442453|Drug|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
229258|NCT02442453|Drug|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
229259|NCT02442440|Drug|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
229260|NCT02442427|Drug|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
229261|NCT02442427|Other|Placebo|An equal volume of 0.9% normal saline
229262|NCT02442414|Drug|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
229263|NCT02442401|Device|The negative pressure wound therapy|
229264|NCT02442388|Procedure|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
229265|NCT02442388|Procedure|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
229266|NCT02442388|Procedure|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
229267|NCT02442375|Radiation|standard dose prescription|"standard elective dose~no intermediate dose-level~visual interpretation of FDG-PET-scan"
229268|NCT02442375|Radiation|FDG‐PET guided gradient dose prescription|"de-escalation of elective dose~intermediate dose-level~standardized methods to evaluate FDG-PET-scan"
229269|NCT02442362|Drug|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
229270|NCT02442362|Drug|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area < 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
229271|NCT02442349|Drug|AZD9291|Once daily tablet 80 mg
229364|NCT02441686|Drug|Dexamethasone|
229272|NCT02442336|Behavioral|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
229273|NCT02442323|Behavioral|Walking Intervention|12-week walking program
229274|NCT02442310|Drug|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
229275|NCT02442310|Drug|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
229276|NCT02442297|Biological|HER2-specific T cells|"Dosing Schedule 1:~Cycle 1 A: 1x10^7 cells~Cycle 2 A: 1x10^7 cells~Cycle 3 A: 1x10^7 cells~Dosing Schedule 2:~Cycle 1 A: 1x10^7 cells~Cycle 2 B: 3x10^7 cells~Cycle 3 B: 3x10^7 cells~Dosing Schedule 3:~Cycle 1 A: 1x10^7 cells~Cycle 2 B: 3x10^7 cells~Cycle 3 C: 1x10^8 cells~Subsequent cycles*~*Additional cycles may be administered at ≤ the final cell dose reached in cycle 3, provided that the subject continues to meet eligibility criteria and does not have confirmed progressive disease."
229277|NCT02442284|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
229278|NCT02442284|Drug|Ribavirin|Tablet
229279|NCT02442271|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
229280|NCT02442271|Drug|ribavirin|Tablet
229281|NCT02442258|Drug|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
229282|NCT02442258|Drug|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
229283|NCT02442245|Dietary Supplement|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
229284|NCT02442245|Other|Placebo: Microcrystalline Cellulose|
229285|NCT02442245|Other|Control: No supplementation|
229286|NCT02442206|Drug|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
229287|NCT02442206|Drug|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
229288|NCT02442193|Other|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
229289|NCT02442180|Drug|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
229290|NCT02442180|Drug|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
229291|NCT02442180|Drug|placebo|equivalent to G-CSF doses
229292|NCT02442154|Procedure|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
229293|NCT02442128|Drug|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
229294|NCT02442128|Drug|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
229295|NCT02442115|Other|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
229296|NCT02442102|Behavioral|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
229297|NCT02442089|Behavioral|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
229298|NCT02442063|Drug|Radium Ra 223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
229299|NCT02442063|Drug|paclitaxel|90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
229300|NCT02442050|Other|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
229301|NCT02442050|Other|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
229302|NCT02442037|Biological|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10^6/kg) ,once every week，a total of three times.
229303|NCT02442037|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
229304|NCT02442024|Behavioral|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
229305|NCT02442024|Behavioral|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
229306|NCT02441998|Other|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
229307|NCT02441985|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
229308|NCT02441985|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
229309|NCT02441985|Other|Fahn-Tolosa-Marin Tremor Rating Scale (TRS)|All participants will receive a clinical assessment of tremor severity by using the TRS test.
229310|NCT02441985|Other|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
229311|NCT02441985|Other|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
229312|NCT02441985|Other|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
232570|NCT02418455|Drug|UX003|solution for intravenous infusion
229313|NCT02441985|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
229314|NCT02441972|Drug|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
229315|NCT02441959|Procedure|Lumbar discectomy Open|Open Discectomy
229316|NCT02441959|Procedure|Lumbar discectomy Endoscopic|Endoscopic Discectomy
229317|NCT02441946|Drug|Abemaciclib|Administered orally
229318|NCT02441946|Drug|Loperamide|Administered orally
229319|NCT02441946|Drug|Anastrozole|Administered orally
229320|NCT02441933|Drug|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.~Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles~Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
229321|NCT02441933|Drug|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.~Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles~Paclitaxel (80 mg/m2) IV weekly for 12 doses"
229322|NCT02441907|Drug|aflibercept|
229323|NCT02441894|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
229324|NCT02441894|Drug|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
229325|NCT02441894|Drug|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
229326|NCT02441894|Drug|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
229327|NCT02441894|Drug|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
229328|NCT02441894|Drug|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
229329|NCT02441894|Drug|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
229330|NCT02441881|Device|Venefit|Endovenous radiofrequency device
229331|NCT02441881|Device|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
229332|NCT02441881|Device|Endovenous Radiofrequency|Endovenous radiofrequency device
229333|NCT02441868|Behavioral|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
229334|NCT02441855|Device|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
229335|NCT02441842|Drug|atenolol|administered 60 minutes pre procedure
229336|NCT02441842|Drug|lisinopril|administered 60 minutes pre procedure
229337|NCT02441842|Other|glucose|administered 60 minutes pre procedure
229338|NCT02441829|Drug|Eleclazine|Eleclazine tablets administered orally in morning with food
229339|NCT02441816|Drug|Aflibercept|
229340|NCT02441816|Other|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
229341|NCT02441803|Drug|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
229342|NCT02441803|Drug|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
229343|NCT02441803|Drug|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.~Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
229344|NCT02441803|Radiation|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
229345|NCT02441803|Drug|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
229346|NCT02441803|Biological|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or >3.0 X 108 marrow mononuclear cells/kg if bone marrow.
229347|NCT02441803|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
229348|NCT02441803|Drug|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
229349|NCT02441803|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
229350|NCT02441803|Drug|Decitabine|20 mg/m2 by vein on Days 1 - 5.
229351|NCT02441803|Drug|Cytarabine|1 g/m2 by vein on Days 6 - 10.
229352|NCT02441803|Drug|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
229353|NCT02441790|Behavioral|Early Active Range of Motion|3-9 days
229354|NCT02441790|Behavioral|Standard Immobilization|21-27 days
229355|NCT02441777|Device|Polarization-Sensitive OFDI|OCT Imaging of the eye
229356|NCT02441751|Procedure|intra-operative blood loss|surgery in the urology and orthopedics
229357|NCT02441738|Procedure|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
229358|NCT02441738|Procedure|Catheter Ablation|The procedure will be performed following standard of care guidelines.
229359|NCT02441725|Other|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
229360|NCT02441712|Device|PENS|
229361|NCT02441699|Behavioral|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
229362|NCT02441686|Drug|Bortezomib|
229363|NCT02441686|Drug|Lenalidomide|
229365|NCT02441673|Drug|Nefopam|Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
229366|NCT02441673|Drug|Tramadol|Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
229367|NCT02441673|Drug|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
229368|NCT02441673|Drug|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
229369|NCT02441673|Drug|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
229370|NCT02441673|Drug|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
229371|NCT02441673|Drug|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
229372|NCT02441660|Drug|Capsaicin 8% Patch|Applied topically for 1 hour
229373|NCT02441660|Drug|Low Dose Capsaicin 0.04% gel|
229374|NCT02441647|Device|KL029 Intimate Lubricant Gel|
229375|NCT02441621|Other|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
229376|NCT02441621|Other|premedication|patients receive premedication with midazolam 7.5 mg p.o.
229377|NCT02441621|Other|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
229378|NCT02441621|Other|central venous catheter|a central venous catheter in the right or left internal jugular vein.
229379|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
229380|NCT02441621|Other|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
229381|NCT02441621|Other|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
229382|NCT02441608|Device|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
229383|NCT02441595|Behavioral|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
229384|NCT02441595|Behavioral|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
229385|NCT02441582|Other|Telemetry|
229386|NCT02441582|Other|Non-telemetry|
229387|NCT02441569|Behavioral|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
229388|NCT02441569|Behavioral|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
229389|NCT02441556|Device|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
229390|NCT02441556|Other|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
229391|NCT02441530|Dietary Supplement|Vitamin D|
229392|NCT02441530|Dietary Supplement|Vitamin E|
229393|NCT02441530|Drug|Ibuprofen|
229394|NCT02441517|Drug|Enzalutamide|Participants were administered four 40-mg capsules orally once daily and taken as close to the same time each day as possible and could be taken with or without food.
229395|NCT02441504|Other|Low intensity Exercise|aerobic exercise training using walking and running
229396|NCT02441491|Drug|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.~Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
229397|NCT02441478|Radiation|functional magnetic resonance imaging exam|
229398|NCT02441465|Drug|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
229399|NCT02441465|Drug|14C-Labeled Vemurafenib|IV infusion of 18.5 kilobecquerel (kBq) of 14C-labeled vemurafenib (3 milliliters [mL], which corresponds to a dose of 20 micrograms [mcg] of vemurafenib) on Day 21 (immediately after the morning oral dose of vemurafenib).
229400|NCT02441452|Other|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
229401|NCT02441439|Dietary Supplement|Iron sucrose 200 mg|I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes
229402|NCT02441439|Dietary Supplement|Iron sucrose 500 mg|I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
229403|NCT02441413|Radiation|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
229404|NCT02441400|Device|EndoStim LES Stimulation System|
230231|NCT02435186|Drug|Cisplatin|150 mg/m^2 cisplatin will be given intraperitoneally.
229405|NCT02441387|Drug|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
229406|NCT02441387|Other|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
229407|NCT02441387|Other|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
229408|NCT02441374|Device|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
229409|NCT02441374|Other|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
229410|NCT02441361|Other|Exercise training|Exercise training will comprise aerobic and strength exercises
229411|NCT02441348|Behavioral|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
229412|NCT02441322|Device|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
229413|NCT02441309|Drug|Mifamurtide|
229414|NCT02441309|Drug|Ifosfamide|
229415|NCT02441296|Other|Formula with lactose|
229416|NCT02441296|Other|Formula with maltodextrins|
229417|NCT02441283|Drug|ABT-530|Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.
229418|NCT02441283|Drug|ABT-493|Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.
229419|NCT02441270|Drug|Cyclophosphamide|
229420|NCT02441270|Radiation|Stereotactic body radiotherapy|
229421|NCT02441257|Procedure|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
229422|NCT02441257|Procedure|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
229423|NCT02441244|Drug|Visbiome|Visbiome probiotic
229424|NCT02441244|Other|Placebo|Placebo
229425|NCT02441231|Drug|Visbiome|Visbiome probiotic
229426|NCT02441231|Other|Placebo|Placebo
229427|NCT02441218|Drug|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
229428|NCT02441218|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
229429|NCT02441205|Behavioral|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
229430|NCT02441192|Other|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
229431|NCT02441192|Other|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
229432|NCT02441192|Other|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
229433|NCT02441179|Other|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
229434|NCT02441179|Other|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
229435|NCT02441179|Other|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
229436|NCT02441166|Procedure|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
229437|NCT02441153|Other|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
229438|NCT02441140|Procedure|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
229439|NCT02441140|Procedure|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
229440|NCT02441140|Procedure|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
229441|NCT02441140|Procedure|Blood collection|Intravenous blood collection will be drawn from an IV
229442|NCT02441140|Procedure|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
229443|NCT02441127|Device|diode laser group|the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
229444|NCT02441127|Procedure|scalpel control group|In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
229445|NCT02441114|Drug|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
229446|NCT02441101|Device|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
229447|NCT02441101|Device|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
229448|NCT02441088|Drug|90Y-DOTA-tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used in this a dosimetry-guided theranostics trial for both children and adults with neuroendocrine and other somatostatin receptor positive tumors. Each subject will receive three doses of 90Y-DOTATOC.
229449|NCT02441088|Radiation|Dosimetry-Guided Peptide Receptor Radiotherapy|90Y-DOTATOC delivers radiation to rumor cells that express somatostatin receptors.The dose of 90Y-DOTATOC administered in this dosimetry-guided theranostics trial will be determined by dosimetry that estimates the amount of radiation delivered to the kidneys during treatments one and two.
229450|NCT02441088|Drug|Aminosyn II|Aminosyn II is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
229451|NCT02441075|Other|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
229452|NCT02441062|Drug|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
229453|NCT02441049|Behavioral|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
229454|NCT02441036|Device|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
229455|NCT02441023|Behavioral|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.~Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
229456|NCT02441023|Behavioral|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
229457|NCT02441010|Device|meridian therapy instrument|The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
229458|NCT02441010|Other|health information push technology|The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
229459|NCT02441010|Device|monitoring device|The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
229460|NCT02440997|Other|aromatherapy|
229461|NCT02440997|Other|foot bath|
229462|NCT02440984|Procedure|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
229463|NCT02440971|Device|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
229464|NCT02440958|Drug|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
229465|NCT02440945|Device|Collection of blood|Blood test on blotting paper DBS (for the patients recruting)
229466|NCT02440932|Dietary Supplement|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
229467|NCT02440932|Other|Normal (control) diet|Breakfast, lunch and open buffet dinner
229468|NCT02440919|Other|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
229469|NCT02440919|Other|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
229470|NCT02440919|Other|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
229471|NCT02440919|Other|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
229472|NCT02440906|Behavioral|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
229473|NCT02440906|Behavioral|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
229474|NCT02440893|Diagnostic Test|Corus CAD (ASGES)|
229475|NCT02440880|Drug|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
229476|NCT02440880|Drug|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
229477|NCT02440880|Drug|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
229478|NCT02440880|Drug|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
229479|NCT02440880|Other|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
229480|NCT02440867|Device|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
229481|NCT02440867|Device|Sham TBS|Sham stimulation
229482|NCT02440841|Drug|fedovapagon|
229483|NCT02440841|Drug|Itraconazole|
229484|NCT02440841|Drug|rifampicin|
229485|NCT02440828|Drug|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
229486|NCT02440828|Drug|placebo|NaCl 0.9% inhalation 4 ml twice daily
229487|NCT02440815|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
229488|NCT02440802|Genetic|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
229489|NCT02440789|Drug|Sirolimus|
229490|NCT02440750|Procedure|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
229491|NCT02440750|Drug|Dienogest|21 days administration of dienogest 2 mg/die
229492|NCT02440750|Drug|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
229493|NCT02440737|Other|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
229494|NCT02440737|Other|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
229495|NCT02440737|Procedure|Psychosocial Assessment and Care|Undergo the NEST intervention
229496|NCT02440737|Other|Questionnaire Administration|Ancillary studies
229497|NCT02440724|Device|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
229498|NCT02440724|Device|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
229499|NCT02440711|Device|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
229500|NCT02440711|Device|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
229501|NCT02440698|Behavioral|Genetic test for personalized nutrition|
229502|NCT02440685|Drug|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
229503|NCT02440685|Drug|ASN002 RD|Recommended dose of ASN002 from Part A
229504|NCT02440672|Device|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
229505|NCT02440646|Radiation|Coronary computed tomography angiography|The coronary arteries will be visualized with the 128-slice CT scan Aquilion CX (Toshiba, Tokyo, Japan).
229506|NCT02440646|Radiation|Quantitative coronary angiography|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich, Germany).
229507|NCT02440633|Drug|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
229508|NCT02440607|Other|Electronic Cognitive Aid|
229509|NCT02440607|Other|Static Cognitive Aid|
229510|NCT02440594|Behavioral|Enhanced BHL Program Services|Patients or their caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard BHL Program.
229511|NCT02440594|Behavioral|Standard BHL Program Services|Patients or their caregivers receive a baseline clinical assessment as well as monitoring of symptoms and referral to community resources.
229512|NCT02440581|Drug|Alendronate|
229513|NCT02440581|Drug|Teriparatide|
229514|NCT02440581|Drug|Cinacalcet|
229515|NCT02440568|Drug|Omacetaxine|Omacetaxine (at assigned dose level) administered subcutaneously Q12 hours Days 1 to 7. Dose levels include: 0.625, 1.25, 2.0, 3.0, and 4.2 mg/m^2
229516|NCT02440568|Drug|Cytarabine|Cytarabine (100mg/m^2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
229517|NCT02440568|Drug|Idarubicin|Idarubicin (12 mg/m^2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
229518|NCT02440555|Other|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
229519|NCT02440542|Other|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
229520|NCT02440529|Behavioral|Intervention|Discussion
229521|NCT02440529|Behavioral|Verbal Group|Detailed Discussion
229522|NCT02440516|Other|Early treatment group|Physical- and occupational Therapy
229523|NCT02440516|Other|Late treatment group|Waiting list - then Physical- and occupational Therapy
229524|NCT02440490|Behavioral|Computerised cognitive training|
229525|NCT02440490|Behavioral|Video watching|
229526|NCT02440477|Other|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
229527|NCT02440464|Procedure|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
229528|NCT02440464|Drug|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
229529|NCT02440464|Drug|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
229530|NCT02440464|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
229531|NCT02440464|Drug|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
229532|NCT02440464|Drug|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
229533|NCT02440451|Device|Neurofeedback using BCI|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
229534|NCT02440438|Biological|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
229535|NCT02440425|Drug|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
229536|NCT02440425|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
229537|NCT02440412|Other|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
229538|NCT02440412|Other|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
229539|NCT02440399|Drug|Tramadol hydrochloride|Please see arm description
229540|NCT02440399|Drug|Morphine|Please see arm description
229541|NCT02440399|Drug|Paracetamol|
229542|NCT02440399|Drug|Diclofenac|
229543|NCT02440399|Drug|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
229544|NCT02440386|Behavioral|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:~Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and~send a text message to the study team to let us know they have started ART;~Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
229545|NCT02440360|Behavioral|PSH|Please see arm description.
229546|NCT02440360|Behavioral|Usual Care|Please see arm description.
229547|NCT02440347|Device|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
229548|NCT02440347|Device|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
229549|NCT02440334|Drug|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
229550|NCT02440321|Behavioral|Parent-child interactive program|
229551|NCT02440321|Other|written materials|
229552|NCT02440308|Drug|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl.~68Ga-DOTA-Bombesin is administered intravenously (IV)"
229553|NCT02440308|Procedure|Magnetic Resonance Imaging (MRI) scan|
229554|NCT02440308|Procedure|Positron Emission Tomography (PET) scan|
229555|NCT02440295|Procedure|Lower Extremity Amputation|
229678|NCT02439281|Drug|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
230232|NCT02435186|Drug|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
229556|NCT02440295|Device|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
229557|NCT02440295|Drug|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
229558|NCT02440256|Other|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
229559|NCT02440243|Drug|Purethal|prerseasonal course of SCIT - three years
229560|NCT02440243|Drug|Purethal -placebo|preseasonal course of SCIT - three years
229561|NCT02440230|Drug|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.~Patients will take anastrozole 1mg qd."
229562|NCT02440230|Drug|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
229563|NCT02440204|Procedure|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
229564|NCT02440204|Drug|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
229565|NCT02440204|Drug|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
229566|NCT02440191|Radiation|3DCRT|conventional radiotherapy
229567|NCT02440178|Drug|Micafungin|
229568|NCT02440165|Behavioral|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:~Information and advice;~Examples of energy and protein rich meals;~patients will be asked to register their nutritional intake for two days at home;~after a week, the nurse will call the patients to answer questions and to give advice.~This nutrition care plan will be tailored to the individual patient requirements.~Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
229569|NCT02440152|Device|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
229570|NCT02440139|Device|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
229571|NCT02440113|Device|Nellix|Nellix Implantation
229572|NCT02440100|Drug|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
229573|NCT02440100|Drug|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
229574|NCT02440100|Drug|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
229575|NCT02440087|Dietary Supplement|Refill Bypass|Dietary supplement
229576|NCT02440074|Other|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
229577|NCT02440061|Drug|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
229578|NCT02440061|Drug|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
229579|NCT02440061|Drug|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
229724|NCT02438904|Biological|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
229580|NCT02440048|Device|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
229581|NCT02440048|Device|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
229582|NCT02440035|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 in Group 3.
229583|NCT02440035|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 4.
229584|NCT02440035|Drug|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
229585|NCT02440022|Combination Product|Lutonix DCB|
229586|NCT02440022|Device|Standard Balloon Angioplasty Catheter|
229587|NCT02440022|Procedure|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
229588|NCT02440009|Drug|Itraconazole|Oral itraconazole 200 mg BD for 6 months
229589|NCT02440009|Drug|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
229590|NCT02439996|Drug|IVIG (1g/kg,once)|"Group C patients received IVIG 1g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
229591|NCT02439996|Drug|IVIG (1g/kg,twice)|"Group B patients received IVIG 1g/kg for 2 days continuously. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
229592|NCT02439996|Drug|IVIG (2g/kg.once)|"Group A patients received IVIG 2g/kg per day once. The IVIG was started on the fifth to tenth day of illness. In combination with IVIG, the patients were administered aspirin at a dose of 30 mg/kg per day; this dose was reduced to 3-5 mg/kg per day after the fever disappeared for 3 days and the CRP value was ≤8mg/L. Patients who were admitted before the fourth day of illness were treated only with aspirin. Each immunoglobulin was administered at a dose of 1 g/kg for 10h.~Patients who did not respond to initial IVIG therapy were given a second dose of IVIG 24-36 hours after the initial dose at 2g/kg. Patients who did not respond to second dose IVIG were given methylprednisolone 10mg/kg for 3 days or infliximab 5mg/kg once."
229593|NCT02439983|Dietary Supplement|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
229594|NCT02439983|Dietary Supplement|Placebo|2 capsules taken by mouth with morning and evening meals.
229595|NCT02439970|Drug|Brincidofovir|
229596|NCT02439970|Drug|Valganciclovir|
229597|NCT02439957|Drug|Brincidofovir|
229598|NCT02439957|Drug|Valganciclovir|
229599|NCT02439944|Drug|Nicotine patch|
229600|NCT02439944|Drug|Nicotine mouthspray|
229601|NCT02439931|Behavioral|Remote psychosocial intervention|
229602|NCT02439905|Drug|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
229603|NCT02439905|Drug|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
229604|NCT02439892|Behavioral|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
229636|NCT02439619|Other|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
229605|NCT02439892|Behavioral|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
229606|NCT02439879|Drug|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased >3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
229607|NCT02439866|Drug|placebo|gelatinous capsules filled with sugar as placebo
229608|NCT02439866|Drug|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
229609|NCT02439866|Drug|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
229610|NCT02439853|Behavioral|Monthly Check-in Session|Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
229611|NCT02439827|Behavioral|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
229612|NCT02439814|Drug|Pregnenolone|Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
229613|NCT02439814|Other|Placebo|Inactive comparator
229614|NCT02439801|Procedure|PEEP 0|0 cmH2O positive end expiratory pressure
229615|NCT02439801|Procedure|PEEP 5|5 cmH2O positive end expiratory pressure
229616|NCT02439801|Procedure|PEEP 8|8 cmH2O positive end expiratory pressure
229617|NCT02439788|Drug|cyclophosphamide|500 mg/m2/day x 2 days; for patients <12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
229618|NCT02439788|Drug|Fludarabine|30 mg/m2/day x 3 days; for patients <12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
229619|NCT02439788|Genetic|GINAKIT Cells|"Dose Level 1 = 3 x 10^6~Dose Level 2 = 1 x 10^7~Dose Level 3 = 3 x 10^7~Dose Level 4 = 1 x 10^8~After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
229620|NCT02439775|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
229621|NCT02439775|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
229622|NCT02439762|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
229623|NCT02439762|Behavioral|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
229624|NCT02439749|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
229625|NCT02439749|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
229626|NCT02439736|Other|Blood draw within 12 hours of head injury|
229627|NCT02439723|Drug|Regorafenib|
229628|NCT02439710|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
229629|NCT02439697|Other|Darbepoetin alfa|Conversion from Aranesp® to NESP®
229630|NCT02439671|Behavioral|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:~Social communication (e.g. listening, perspective taking)~Self-determination (e.g. problem-solving, self-advocacy)~Working with others (e.g. knowing your context, teamwork)~Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.~The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
229631|NCT02439658|Drug|Dofetilide and/or sotalol|This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
229632|NCT02439632|Drug|prulifloxacin|
229633|NCT02439632|Drug|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
229634|NCT02439632|Drug|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
229635|NCT02439632|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
229946|NCT02437253|Other|Placebo|Saline placebo
229637|NCT02439606|Device|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
229638|NCT02439606|Device|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
229639|NCT02439593|Other|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
229640|NCT02439593|Other|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
229641|NCT02439580|Dietary Supplement|Annona muricata extract|ethanol-soluble fraction of water extract
229642|NCT02439580|Dietary Supplement|Placebo|maltose
229643|NCT02439567|Device|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
229644|NCT02439541|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10^7)
229645|NCT02439528|Genetic|Genetic analysis|"One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.~The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis."
229646|NCT02439515|Device|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
229647|NCT02439515|Device|Balance|Balance control exercises with visual biofeedback
229648|NCT02439515|Other|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
229649|NCT02439502|Device|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
229650|NCT02439489|Drug|BKM120-CIS|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
229651|NCT02439489|Drug|BKM120-CARBO|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.~In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
229652|NCT02439463|Procedure|Below-knee amputation|Patients with traumatic below-knee amputation.
229653|NCT02439450|Biological|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
229654|NCT02439450|Drug|Nivolumab|Nivolumab 240mg IV q2weeks for 18 weeks or until disease progression or unacceptable toxicity. After the completion of 18 weeks of combination therapy, patients may receive either nivolumab dosing schedule listed in the current approved package insert (every 2 weeks or every 4 weeks) per Investigator discretion.
229655|NCT02439450|Drug|Pembrolizumab|The recommended dose of KEYTRUDA (pembrolizumab) is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
229656|NCT02439450|Drug|Pemetrexed|The recommended dose of ALIMTA (pemetrexed) when administered with carboplatin and pembrolizumab for the initial treatment of NSCLC in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m2 administered as an intravenous infusion over 10 minutes prior to carboplatin on Day 1 of each 21-day cycle for 4 cycles. Pembrolizumab should be administered prior to ALIMTA when given on the same day.
229657|NCT02439437|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
229658|NCT02439424|Device|Reactive ATP|"Reactive ATP turned to on"
229659|NCT02439411|Drug|Trametinib|
229660|NCT02439398|Biological|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
229661|NCT02439398|Other|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
229662|NCT02439385|Drug|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
229663|NCT02439385|Dietary Supplement|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
229664|NCT02439359|Drug|CF-301|Dose escalation
229665|NCT02439359|Drug|Placebo|
229666|NCT02439346|Drug|BAY1143269 tablet|BAY 1143269 5 mg or 25 mg tablet. Each treatment cycle will last 21 days.
229667|NCT02439333|Device|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
229668|NCT02439333|Device|nasal catheter or Venturi mask|Conventional oxygen therapy
229669|NCT02439320|Drug|Lasmiditan 100 mg|
229670|NCT02439320|Drug|Lasmiditan 200 mg|
229671|NCT02439320|Drug|Placebo (matches lasmiditan doses)|
229672|NCT02439307|Drug|Rifaximin|1200 mg of rifaximin for 2 weeks.
229673|NCT02439307|Drug|Placebo|Placebo for 2 weeks
229674|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|
229675|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|
229676|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|
229677|NCT02439294|Device|CPAP|
229679|NCT02439281|Drug|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
229680|NCT02439255|Other|Laboratory Biomarker Analysis|Correlative studies
229681|NCT02439255|Dietary Supplement|Phytochemical|Given BRB nectar PO
229682|NCT02439255|Other|Placebo|Given PO
229683|NCT02439255|Other|Screening Questionnaire Administration|Ancillary studies
229684|NCT02439242|Drug|fluid challenge of saline|250 ml of saline
229685|NCT02439216|Drug|Edasalonexent|
229686|NCT02439216|Drug|Placebo|
229687|NCT02439203|Drug|JM-010|
229688|NCT02439203|Drug|Placebo|
229689|NCT02439190|Drug|BMS-986120|
229690|NCT02439190|Drug|Aspirin|
229691|NCT02439190|Drug|Clopidogrel|
229692|NCT02439177|Device|Blood glucose monitoring system (Omnitest 3)|
229693|NCT02439177|Device|Blood glucose monitoring system (Omnitest 5)|
229694|NCT02439164|Drug|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
229695|NCT02439151|Device|New lung ventilation strategy|New ventilation strateg: pressure assist control mode; inspiratory pressure was lowered to keep Ppeak less than 25cmH2O; set the PEEP at such a level that expiratory transpulmonary pressure stays between 0 and 5 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
229696|NCT02439151|Device|Conventional ventilation strategy|Conventional ventilation strategy: pressure assist control mode; keep the Ppeak between 20 and 25 cmH2O; set PEEP between 10 and 15 cmH2O; respiratory rate of 10 breaths per minute; FiO2 less than 0.5.
229697|NCT02439138|Drug|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
229698|NCT02439125|Drug|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
229699|NCT02439125|Drug|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
229700|NCT02439125|Drug|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
229701|NCT02439125|Drug|Placebo|b.i.d. orally for 3 weeks
229702|NCT02439112|Other|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly >65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.~Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
229703|NCT02439086|Device|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
229704|NCT02439073|Behavioral|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
229705|NCT02439060|Other|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
229706|NCT02439047|Procedure|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery~A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum~- Adipose tissue samples : will be collected during surgery for breast reconstruction"
229707|NCT02439034|Drug|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
229708|NCT02439034|Drug|Ketoprofen|Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
229709|NCT02439021|Device|COBRA|
229710|NCT02439021|Device|LMA|
229711|NCT02439008|Procedure|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.~Before radiotherapy:~Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
229712|NCT02439008|Procedure|Blood samples collection during radiotherapy|"Sample T1: within 15 minutes after the administration of the first fraction,~Sample T2: within 15 minutes after the administration of the second fraction,~Sample T3: within 15 minutes after the administration of the third fraction"
229713|NCT02439008|Procedure|Blood samples collection after radiotherapy|"Sample T4: one week after the end of the radiotherapy,~Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
229714|NCT02439008|Radiation|Radiotherapy|
229715|NCT02438995|Drug|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
229716|NCT02438982|Drug|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
229717|NCT02438982|Drug|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3, it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
229718|NCT02438956|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
229719|NCT02438956|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
229720|NCT02438943|Other|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
229721|NCT02438943|Other|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
229722|NCT02438930|Behavioral|Motivational interviewing intervention during HIV testing|
229723|NCT02438930|Behavioral|Standard-of-care counseling during HIV testing|
233025|NCT02415140|Other|Rate of depression|
229725|NCT02438891|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
229726|NCT02438878|Behavioral|Baby Behavior|
229727|NCT02438865|Drug|Immediate instillation of intravesical chemotherapy-Epirubicin-|
229728|NCT02438865|Drug|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
229729|NCT02438852|Other|Placebo|Given IV
229730|NCT02438852|Other|Questionnaire Administration|Ancillary studies
229731|NCT02438852|Drug|Ropivacaine Hydrochloride|Given IV
229732|NCT02438826|Drug|Galcanezumab 300 mg|Administered SC
229733|NCT02438826|Drug|Placebo|Administered SC
229734|NCT02438813|Drug|Deoxycholic acid|Deoxycholic acid (ATX-101) injection as the treatment of SMF as per standard of care in clinical practice.
229735|NCT02438813|Procedure|Surgical Procedures|Surgical procedures for treatment of SMF as per standard of care in clinical practice.
229736|NCT02438813|Procedure|Laser Liposuction|Laser Liposuction for the treatment of SMF as per standard of care in clinical practice..
229737|NCT02438813|Device|Energy Devices|Energy Devices for the treatment of SMF as per standard of care in clinical practice.
229738|NCT02438813|Other|Other Treatments|Other treatments for SMF as per standard of care in clinical practice.
229739|NCT02438800|Behavioral|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
229740|NCT02438787|Drug|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
229741|NCT02438787|Drug|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
229742|NCT02438787|Drug|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
229743|NCT02438787|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
229744|NCT02438774|Behavioral|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
229745|NCT02438774|Behavioral|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
229746|NCT02438761|Drug|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections~The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
229747|NCT02438748|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
229748|NCT02438735|Procedure|laparoscopic endometrioma excision|
229749|NCT02438735|Other|Conservative follow up|
229750|NCT02438722|Drug|Afatinib Dimaleate|Given PO
229751|NCT02438722|Biological|Cetuximab|Given IV
229752|NCT02438722|Other|Laboratory Biomarker Analysis|Correlative studies
229753|NCT02438709|Drug|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
229754|NCT02438696|Drug|BI 1060469, iFF, Test|
229755|NCT02438696|Drug|BI 1060469, iFF, Test|
229756|NCT02438696|Drug|BI 1060469, TF1, Reference|
229757|NCT02438696|Drug|BI 1060469, TF2, Test|
229758|NCT02438696|Drug|BI 1060469, TF2, Test|
229759|NCT02438696|Drug|BI 1060469, iFF, Test|
229760|NCT02438696|Drug|BI 1060469, TF1, Reference|
229761|NCT02438696|Drug|BI 1060469, iFF, Test|
229762|NCT02438696|Drug|BI 1060469, iFF, Test|
229763|NCT02438696|Drug|BI 1060469, TF1, Reference|
229764|NCT02438696|Drug|BI 1060469, TF2, Test|
229765|NCT02438696|Drug|BI 1060469, TF1, Reference|
229766|NCT02438696|Drug|BI 1060469, TF1, Reference|
229767|NCT02438696|Drug|BI 1060469, TF2, Test|
229768|NCT02438696|Drug|BI 1060469, TF2, Test|
229769|NCT02438696|Drug|BI 1060469, iFF, Test|
229770|NCT02438696|Drug|BI 1060469, TF2, Test|
229771|NCT02438696|Drug|BI 1060469, TF1, Reference|
229772|NCT02438683|Drug|BI 409306|medium dose, single dose, oral administration
229773|NCT02438683|Drug|BI 409306|low dose, single dose, oral administration
229774|NCT02438683|Drug|Placebo|single dose, oral administration
229775|NCT02438670|Device|PID control algorithm|
229776|NCT02438670|Device|MPC control algorithm|
229777|NCT02438657|Procedure|median nerve block|
229778|NCT02438618|Procedure|Surgery for Ponto bone anchored hearing aids|
229779|NCT02438605|Device|Nellix|
229780|NCT02438579|Other|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
229781|NCT02438566|Drug|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
230018|NCT02436798|Drug|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
229782|NCT02438566|Drug|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
229783|NCT02438553|Device|OSTNS Neurostimulator|Non-invasive transcutaneous neurostimulation.
229784|NCT02438553|Device|Placebo OSTNS Neurostimulator|Placebo non-invasive transcutaneous neurostimulation
229785|NCT02438540|Drug|metformin|metformin tablet 500 mg
229786|NCT02438540|Other|acupuncture|Electro body acupuncture and auricular acupuncture
229787|NCT02438527|Behavioral|Chart for CPR guidance|
229788|NCT02438514|Other|Biological Sample Collection|"Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.~Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.~Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits"
229789|NCT02438501|Radiation|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
229790|NCT02438501|Radiation|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
229791|NCT02438475|Device|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
229792|NCT02438475|Other|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
229793|NCT02438462|Other|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
229794|NCT02438449|Procedure|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
229795|NCT02438436|Dietary Supplement|simo decoction|
229796|NCT02438436|Other|gum chewing|
229797|NCT02438423|Biological|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
229798|NCT02438423|Other|Placebo|
229799|NCT02438397|Drug|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
229800|NCT02438397|Drug|metformin|500 mg tid by Merck
229801|NCT02438397|Drug|Acarbose|100mg tid by Bayer
229802|NCT02438384|Behavioral|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
229803|NCT02438384|Behavioral|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
229804|NCT02438371|Drug|Nifedipine|Nifedipine will be given for the treatment of preterm labor
229805|NCT02438371|Drug|Indomethacin|Nifedipine and indomethacin will be give for the treatment of pretermlabor
229806|NCT02438358|Drug|LUM015|
229807|NCT02438358|Device|LUM 2.6 Imaging Device|
229808|NCT02438345|Biological|PRO 140|Humanized monoclonal antibody to CCr5
229809|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
229810|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
229811|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
229812|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
229813|NCT02438319|Other|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
229814|NCT02438319|Other|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
229815|NCT02438306|Biological|Autologous cell therapy|Autologous cell therapy delivered into the heart muscle using the CardiAMP Cell Therapy System. The CardiAMP Cell Therapy System consists of the CardiAMP Cell Separator, a cardiac delivery catheter, and flexible tip guide catheter.
229816|NCT02438306|Other|Sham|An introducer guidewire is placed into the heart and left ventriculography is performed just like it is in the Experimental Arm but no autologous cell therapy is delivered.
229817|NCT02438293|Other|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
229818|NCT02438280|Device|AcceleDent, Vibrational Device|20 minutes of vibration each day
229819|NCT02438241|Procedure|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
229820|NCT02438241|Procedure|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
229821|NCT02438241|Procedure|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
229822|NCT02438228|Other|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
229823|NCT02438215|Drug|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
229824|NCT02438202|Device|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
229825|NCT02438189|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
229826|NCT02438176|Procedure|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
229827|NCT02438176|Procedure|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
229828|NCT02438163|Device|Theta Burst Stimulation|"During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.~During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session."
229829|NCT02438150|Behavioral|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
229830|NCT02438150|Behavioral|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
229831|NCT02438137|Drug|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
229832|NCT02438137|Drug|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
229833|NCT02438124|Behavioral|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
229834|NCT02438111|Genetic|metagenome|metagenome
229835|NCT02438098|Drug|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
229836|NCT02438085|Other|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
229837|NCT02438072|Drug|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
229838|NCT02438059|Behavioral|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
229839|NCT02438046|Procedure|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
229840|NCT02438033|Device|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
229841|NCT02438020|Drug|Metformin|One tablet of 500 mg will be ingested before the main meal
229842|NCT02438020|Other|Placebo|A placebo tablet will be ingested daily before main meal.
229843|NCT02438007|Drug|Galeterone|2550 mg galeterone tablets once daily PO
229844|NCT02438007|Drug|Enzalutamide|160 mg enzalutamide capsules once daily PO
229845|NCT02437994|Behavioral|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
229846|NCT02437981|Drug|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
229847|NCT02437968|Behavioral|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
229848|NCT02437955|Other|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
229849|NCT02437955|Other|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
229850|NCT02437955|Other|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
229851|NCT02437955|Other|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
230072|NCT02436421|Other|Best Practice Alert based in the Electronic Medical Record|
229852|NCT02437942|Other|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
229853|NCT02437929|Procedure|Mobilization|
229854|NCT02437929|Procedure|Positioning|
229855|NCT02437929|Procedure|Personal Hygiene Care|
229856|NCT02437929|Procedure|Bladder catheterization|
229857|NCT02437929|Procedure|Wound care|
229858|NCT02437929|Procedure|Subcutaneous drugs administration|
229859|NCT02437916|Drug|AMG 228|AMG 228 will be administered intravenously
229860|NCT02437903|Device|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
229861|NCT02437890|Biological|ALX-0061|
229862|NCT02437890|Biological|Placebo|
229863|NCT02437864|Device|Supplemental oxygen via nasal cannula|
229864|NCT02437851|Procedure|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
229865|NCT02437838|Other|No Intervention|No Intervention
229866|NCT02437825|Drug|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
229867|NCT02437825|Other|placebo|placebo ( saline) act as comperator in this study.
229868|NCT02437812|Drug|Metformin|Metformin with standard chemotherapy
229869|NCT02437812|Drug|Paclitaxel|Standard chemotherapy
229870|NCT02437812|Drug|Carboplatin|Standard chemotherapy
229871|NCT02437799|Other|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
229872|NCT02437786|Drug|GRAZAX|GRAZAX
229873|NCT02437773|Behavioral|Cognitive Behavioral Therapy - Adolescents|"A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
229874|NCT02437773|Behavioral|Stress Management Therapy - Adolescents|An active control therapy with minimal effects on OCD symptoms.
229875|NCT02437773|Behavioral|Optional CBT - Adolescents|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
229876|NCT02437773|Behavioral|Cognitive Behavioral Therapy - Adults|"A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
229877|NCT02437773|Behavioral|Stress Management Therapy - Adults|An active control therapy with minimal effects on OCD symptoms.
229878|NCT02437773|Behavioral|Optional CBT - Adults|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
229879|NCT02437773|Other|fMRI only - Healthy Control Adults|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.
229880|NCT02437773|Other|fMRI only - Healthy Control Adolescents|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
229881|NCT02437760|Other|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:~at time of diagnosis~every 3 month during treatment~stop at the progression or after 12 months"
229882|NCT02437747|Drug|SRP + Aloe|Scaling and root planing along with aloe vera application was done
229883|NCT02437747|Procedure|SRP|Scaling and root planing was done
229884|NCT02437734|Procedure|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
229885|NCT02437721|Other|infant formula containing folic acid|
229886|NCT02437721|Other|infant formula containing MTHF|
229887|NCT02437708|Procedure|REP with L-PRF|
229888|NCT02437708|Procedure|REP|
229889|NCT02437708|Biological|stem and progenitor cells|
229890|NCT02437669|Drug|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
229891|NCT02437656|Drug|Metformin|"J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day"
229892|NCT02437643|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
229893|NCT02437643|Dietary Supplement|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
229894|NCT02437643|Behavioral|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
229895|NCT02437630|Procedure|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
229896|NCT02437630|Procedure|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
229897|NCT02437630|Other|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
230073|NCT02436408|Drug|Vismodegib|
229898|NCT02437630|Procedure|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
229899|NCT02437630|Procedure|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
229900|NCT02437630|Other|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
229901|NCT02437617|Procedure|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
229902|NCT02437604|Drug|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
229903|NCT02437604|Drug|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
229904|NCT02437604|Drug|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
229905|NCT02437604|Drug|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
229906|NCT02437591|Drug|fidaxomicin|oral
229907|NCT02437565|Other|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
229908|NCT02437565|Other|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
229909|NCT02437552|Device|ergometer cycle exercise|
229910|NCT02437552|Other|routine physiotherapy|routine physiotherapy
229911|NCT02437539|Drug|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
229912|NCT02437539|Device|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
229913|NCT02437526|Other|Analytic treatment interruption|
229914|NCT02437513|Device|NewBreez|Intralaryngeal prosthesis to protect the airways
229915|NCT02437500|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
229916|NCT02437487|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
229917|NCT02437487|Drug|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
229918|NCT02437474|Behavioral|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
229919|NCT02437474|Behavioral|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
229920|NCT02437474|Behavioral|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
229921|NCT02437461|Drug|Triamcinolone hexacetonide|intraarticular knee injection
229922|NCT02437448|Other|No intervention|
229923|NCT02437435|Other|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.~Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.~Hand therapist will keep in touch at all times on the suprapubic region of the patient."
229924|NCT02437422|Biological|SANGUINATE|Single two-hour infusion of SANGUINATE
229925|NCT02437409|Device|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
229926|NCT02437383|Drug|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
229927|NCT02437383|Drug|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
229928|NCT02437370|Drug|Pembrolizumab|Given IV
229929|NCT02437370|Drug|Docetaxel|Given IV
229930|NCT02437370|Drug|Gemcitabine Hydrochloride|Given IV
229931|NCT02437357|Other|Metacognitive Training|8 group sessions á 60 min
229932|NCT02437357|Other|Positivity Training|8 group sessions á 60 min
229933|NCT02437344|Drug|CI-581aa|92 minute infusion of CI-581aa
229934|NCT02437344|Drug|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
229935|NCT02437318|Drug|Fulvestrant|
229936|NCT02437318|Drug|Alpelisib|
229937|NCT02437318|Drug|Alpelisib placebo|
229938|NCT02437305|Behavioral|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
229939|NCT02437305|Behavioral|ABCDEs of Melanoma|Conventional melanoma educational intervention.
229940|NCT02437292|Other|Ischemic compression with stretching|
229941|NCT02437279|Procedure|Surgery of the tumor|
229942|NCT02437279|Drug|Infusion with ipilimumab 3 mg/kg q3wks|
229943|NCT02437279|Drug|Infusion with nivolumab 1 mg/kg q3wks|
229944|NCT02437266|Other|Scapular mobilization|
229945|NCT02437253|Drug|Adalimumab|Subjects will be treated with adalimumab (20 mg [weight 15-<30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
229947|NCT02437240|Behavioral|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
229948|NCT02437240|Behavioral|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
229949|NCT02437227|Drug|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
229950|NCT02437214|Other|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
229951|NCT02437201|Behavioral|Liberty Program|
229952|NCT02437188|Behavioral|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
229953|NCT02437175|Dietary Supplement|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
229954|NCT02437175|Dietary Supplement|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
229955|NCT02437162|Drug|Placebo|Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
229956|NCT02437162|Drug|Ustekinumab 45 mg|Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
229957|NCT02437162|Drug|Ustekinumab 90 mg|Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
229958|NCT02437162|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Groups 1, 2 and 3.
229959|NCT02437149|Behavioral|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
229960|NCT02437149|Behavioral|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
229961|NCT02437149|Behavioral|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
229962|NCT02437136|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACs)
229963|NCT02437136|Drug|pembrolizumab|A selective humanized monoclonal antibody (mAb)
229964|NCT02437123|Behavioral|The Cedar Project mHealth intervention|
229965|NCT02437110|Drug|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
229966|NCT02437110|Drug|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100 mg twice daily.
229967|NCT02437110|Drug|dolutegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 50 mg once daily.
229968|NCT02437110|Drug|Tenofovir alafenamide (TAF)|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 25 mg once daily.
229969|NCT02437097|Other|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
229970|NCT02437097|Other|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
229971|NCT02437097|Other|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
230118|NCT02436018|Device|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
230119|NCT02435992|Drug|RPC1063|
229972|NCT02437097|Other|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
229973|NCT02437084|Drug|Atorvastatin|study subjects divided into 2 groups as described earlier and both receiving atorvastatin 40 mg for 8 weeks.
229974|NCT02437071|Drug|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
229975|NCT02437071|Radiation|Radiotherapy|
229976|NCT02437071|Procedure|Radiofrequency ablation|
229977|NCT02437058|Other|preidictive model|
229978|NCT02437045|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
229979|NCT02437045|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
229980|NCT02437032|Drug|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
229981|NCT02437032|Drug|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
229982|NCT02437032|Drug|hMG|Controlled ovarian stimulation with 150-300 UI hMG
229983|NCT02437019|Drug|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
229984|NCT02437006|Other|exercise|cycle ergometry
229985|NCT02436993|Drug|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
229986|NCT02436993|Drug|Paclitaxel|80 mg/m^2 IV over 1-3 hours weekly for 12 doses
229987|NCT02436993|Drug|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
229988|NCT02436993|Drug|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
229989|NCT02436993|Drug|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
229990|NCT02436980|Drug|Tramadol|GROUP T
229991|NCT02436980|Drug|Midazolam|GROUP M
229992|NCT02436967|Other|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
229993|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 8 mmHg|
229994|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 12 mmHg|
229995|NCT02436941|Radiation|Proton or Photon|
229996|NCT02436928|Biological|AT-501 High Dose vaccine|Comparison of each dose of vaccine
229997|NCT02436928|Biological|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
229998|NCT02436928|Biological|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
229999|NCT02436928|Biological|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
230000|NCT02436915|Other|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
230001|NCT02436915|Other|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
230002|NCT02436902|Procedure|TACE|
230003|NCT02436902|Drug|Sorafenib|
230004|NCT02436902|Drug|TACE plus sorafenib|
230005|NCT02436902|Procedure|transarterial chemotherapy plus embolization|
230006|NCT02436889|Drug|Mirabegron|
230007|NCT02436889|Drug|Tolterodine Tartrate|
230008|NCT02436876|Drug|MBN-101|MBN-101 is a locally administered, anti-infective drug product
230009|NCT02436876|Other|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
230010|NCT02436863|Procedure|Surgical performance|Two different surgical performances
230011|NCT02436850|Procedure|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
230012|NCT02436837|Other|sessions with virtual reality|sessions with virtual reality to improve the balance
230013|NCT02436824|Drug|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
230014|NCT02436824|Other|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
230015|NCT02436811|Behavioral|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
230016|NCT02436811|Behavioral|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
230017|NCT02436811|Behavioral|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
230120|NCT02435992|Drug|Placebo|
230019|NCT02436785|Other|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
230020|NCT02436785|Other|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
230021|NCT02436759|Drug|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
230022|NCT02436759|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
230023|NCT02436733|Procedure|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
230024|NCT02436733|Drug|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
230025|NCT02436707|Drug|Ibrutinib|
230026|NCT02436707|Drug|Rituximab|
230027|NCT02436707|Drug|Gemcitabine|
230028|NCT02436707|Drug|Dexamethasone|
230029|NCT02436707|Drug|Cisplatin|
230030|NCT02436707|Drug|Mesna|
230031|NCT02436707|Drug|Cyclophosphamide|
230032|NCT02436707|Drug|Etoposide|
230033|NCT02436707|Drug|G-CSF|
230034|NCT02436694|Drug|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
230035|NCT02436694|Drug|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
230036|NCT02436681|Device|MIROMESH|
230037|NCT02436668|Drug|Ibrutinib|
230038|NCT02436668|Drug|Gemcitabine|
230039|NCT02436668|Drug|Nab-paclitaxel|
230040|NCT02436655|Procedure|surgical aortic valve replacement|open heart aortic valve replacement
230041|NCT02436642|Device|AVERT Plus System|
230042|NCT02436629|Dietary Supplement|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
230043|NCT02436629|Dietary Supplement|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
230044|NCT02436616|Device|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).~If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
230045|NCT02436603|Behavioral|Nutrition/Mind-Body Coaching|Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
230046|NCT02436590|Device|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
230047|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
230048|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
230049|NCT02436577|Drug|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
230050|NCT02436564|Genetic|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
230051|NCT02436551|Other|Observation|
230052|NCT02436538|Other|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
230053|NCT02436525|Device|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
230054|NCT02436525|Device|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
230055|NCT02436525|Device|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
230056|NCT02436512|Drug|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:~(Dose 1): 5 ppm inhaled nitric oxide for 15 minutes~(Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
230057|NCT02436499|Drug|Botulinum Toxin-A|
230058|NCT02436486|Drug|Placebo|Capsules, orally, single dose
230059|NCT02436486|Drug|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
230060|NCT02436486|Drug|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
230061|NCT02436486|Drug|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
230062|NCT02436473|Drug|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
230063|NCT02436473|Other|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
230064|NCT02436473|Drug|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
230065|NCT02436473|Drug|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
230066|NCT02436460|Biological|AbGn-168H|Humanized monoclonal antibody
230067|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
230068|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
230069|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
230070|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
230071|NCT02436434|Device|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
230074|NCT02436395|Procedure|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
230075|NCT02436395|Procedure|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
230076|NCT02436382|Other|change in temperature|increase in ambient room temperature
230077|NCT02436369|Dietary Supplement|low fat yogurt enriched with flaxseed|daily intake of low fat yogurt enriched with flaxseed for 8 weeks
230078|NCT02436369|Dietary Supplement|low fat yogurt|daily intake of low fat yogurt for 8 weeks
230079|NCT02436356|Device|Osteoprobe-RPI|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
230080|NCT02436356|Radiation|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
230081|NCT02436356|Radiation|MRI|Determines bound water and pore water of bone.
230082|NCT02436343|Other|echocardiogram|"At each echocardiographic evaluation, the investigator will obtain the following parameters:~Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume"
230083|NCT02436330|Behavioral|Exergaming|"6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc."
230084|NCT02436330|Behavioral|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
230085|NCT02436317|Device|Point Of Care Ultrasound|Examination with an ultrasound machine
230086|NCT02436304|Drug|EXE844 Sterile Otic Suspension, 0.3%|
230087|NCT02436304|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
230088|NCT02436291|Device|CURE-EX device|Treatment with CURE-EX device twice daily for 24-30 weeks.
230089|NCT02436278|Other|4MGS|Usual walking speed measured over 4 metres
230090|NCT02436265|Drug|Dexamethasone|IV dexamethasone
230091|NCT02436265|Drug|Ropivacaine|Ropivacaine only
230092|NCT02436252|Drug|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
230093|NCT02436239|Drug|Vilazodone|Vilazodone tablets, once daily, oral administration
230094|NCT02436226|Drug|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
230095|NCT02436226|Drug|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
230096|NCT02436213|Other|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
230097|NCT02436213|Procedure|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
230098|NCT02436200|Device|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
230099|NCT02436174|Device|novel device|novel device being used to measure shivering
230100|NCT02436161|Behavioral|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
230101|NCT02436148|Other|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
230102|NCT02436135|Drug|Idelalisib|Idelalisib tablets administered orally for 24 weeks
230103|NCT02436135|Drug|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
230104|NCT02436109|Device|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
230105|NCT02436096|Drug|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
230106|NCT02436096|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
230107|NCT02436083|Drug|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
230108|NCT02436070|Behavioral|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
230109|NCT02436070|Behavioral|General text messages|Subjects received text messages generalized to children with asthma
230110|NCT02436057|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|
230111|NCT02436044|Procedure|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
230112|NCT02436044|Drug|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
230113|NCT02436044|Drug|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
230114|NCT02436044|Drug|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
230115|NCT02436031|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
230116|NCT02436031|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
230117|NCT02436018|Device|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
230121|NCT02435979|Other|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
230122|NCT02435979|Other|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
230123|NCT02435966|Device|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
230124|NCT02435966|Device|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
230125|NCT02435966|Other|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
230126|NCT02435953|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
230127|NCT02435953|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
230128|NCT02435927|Drug|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
230129|NCT02435927|Drug|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
230130|NCT02435914|Drug|AGN-223575 ophthalmic solution|AGN-223575 ophthalmic solution once or twice daily
230131|NCT02435914|Drug|AGN-223575 vehicle ophthalmic solution|Vehicle to AGN22375 ophthalmic solution once or twice daily.
230132|NCT02435901|Drug|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
230133|NCT02435901|Drug|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
230134|NCT02435901|Drug|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
230135|NCT02435901|Drug|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
230136|NCT02435901|Drug|Mycophenolate mofetil|Immunosuppresant to prevent graft vs host disease is given on Day -1.
230137|NCT02435901|Drug|Tacrolimus|Immunosuppresant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
230138|NCT02435901|Biological|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
230139|NCT02435875|Other|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
230140|NCT02435862|Drug|1.0mg Luminate®|
230141|NCT02435862|Drug|2.0mg Luminate®|
230142|NCT02435862|Drug|3.0mg Luminate®|
230143|NCT02435862|Other|Balanced Salt Solution for intravitreal injection in 0.10cc|
230144|NCT02435849|Biological|Single dose of CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
230145|NCT02435836|Drug|Aripiprazole|
230146|NCT02435823|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
230147|NCT02435797|Drug|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
230148|NCT02435797|Drug|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
230149|NCT02435784|Other|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
230150|NCT02435784|Other|Treatment as usual|Patients will attend a psychiatric consultation as usual.
230151|NCT02435771|Drug|Ergocalciferols|Treatment 1- 400,000 IU
230152|NCT02435771|Drug|Ergocalciferols|Treatment 2- 800,000 IU
230153|NCT02435758|Procedure|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
230154|NCT02435732|Drug|Placebo saline solution|saline solution
230155|NCT02435732|Drug|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
230156|NCT02435732|Drug|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
230157|NCT02435706|Procedure|Flapless immediate implant placement|Experimental group: No elevation of flap prior to immediate implant placement
230158|NCT02435706|Procedure|Flap assisted immediate implant placement|Control group: Flap will be elevated prior to immediate implant placement
230159|NCT02435706|Device|Implant and temporary crown|Both groups receive this intervention
230160|NCT02435693|Other|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
230161|NCT02435693|Other|Without PHARMACEUTICAL CARE programe|
230162|NCT02435680|Drug|MCS110|taken by I.V
230163|NCT02435680|Drug|carboplatin|taken by I.V
230164|NCT02435680|Drug|gemcitabine|taken by I.V
230165|NCT02435667|Other|Resistance Exercise Training|"Aerobic Exercise~a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.~Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.~a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises~Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
230166|NCT02435667|Radiation|DEXA bone scan|A DEXA scan that provides bone density measures.
230167|NCT02435667|Other|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
230168|NCT02435667|Other|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
230169|NCT02435667|Other|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
230170|NCT02435667|Other|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
230171|NCT02435654|Drug|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
230172|NCT02435641|Other|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
230173|NCT02435628|Other|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
230174|NCT02435615|Device|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
230175|NCT02435602|Procedure|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
230176|NCT02435602|Procedure|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions >= 5 mm diameter Pathologic examination of all biopsy tissue specimens
230177|NCT02435589|Other|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
230178|NCT02435589|Other|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
230179|NCT02435576|Radiation|Radiotherapy (primary or postoperative)|
230180|NCT02435563|Drug|ticagrelor 180 mg administrated alone|
230181|NCT02435563|Drug|Ticagrelor adjusted dose + ritonavir 100mg|
230182|NCT02435550|Genetic|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
230183|NCT02435537|Drug|Dexmedetomidine (Precedex)|intrathecal administration
230184|NCT02435537|Drug|Bupivacaine|intrathecal 10 mg bupivacaine
230185|NCT02435537|Drug|Morphine|intrathecal 0.5mg morphine
230186|NCT02435524|Behavioral|A&T infant and young child feeding intervention|"Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:~Increase mother's knowledge about optimal breastfeeding and its benefits~Increase mother's self-efficacy related to breastfeeding~Improve mother's perceptions about social norms relating to breastfeeding~Community mobilisation activities to:~- Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers~Enhanced training of government health workers in infant and young child feeding to:~Improve their ability to support mothers and provide timely information about infant feeding"
230187|NCT02435511|Other|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
230188|NCT02435498|Other|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
230189|NCT02435498|Other|Video|The online video will contain the same information within the website.
230190|NCT02435498|Other|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
230191|NCT02435485|Device|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
230192|NCT02435485|Other|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
230193|NCT02435472|Behavioral|Exercise|This open-label, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.
230194|NCT02435459|Procedure|No lining|No lining material placed under amalgam dental restorations
230195|NCT02435459|Procedure|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
230196|NCT02435459|Procedure|RMGI cement|placement of lining material under amalgam dental restorations
230197|NCT02435459|Procedure|Resin Bonding Agent|placement of lining material under amalgam dental restorations
230198|NCT02435446|Device|Cone-beam computed tomography|Cone-beam computed tomography
230199|NCT02435433|Drug|Ramucirumab|Administered IV
230200|NCT02435433|Drug|Placebo|Administered IV
230201|NCT02435420|Device|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
230202|NCT02435407|Behavioral|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
230203|NCT02435407|Other|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
230204|NCT02435394|Behavioral|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
230205|NCT02435394|Behavioral|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
230206|NCT02435394|Behavioral|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
230207|NCT02435381|Drug|Carisbamate|600mg Orally on days 2-4
230208|NCT02435381|Drug|Placebo|Placebo treatment only
230209|NCT02435368|Drug|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
230210|NCT02435355|Behavioral|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
230211|NCT02435342|Drug|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
230212|NCT02435342|Drug|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
230213|NCT02435329|Other|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
230214|NCT02435316|Other|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
230215|NCT02435316|Other|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
230216|NCT02435303|Drug|Sildenafil|
230217|NCT02435303|Drug|Placebo|
230218|NCT02435290|Behavioral|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.~the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient.~."
230219|NCT02435277|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
230220|NCT02435277|Drug|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
230221|NCT02435277|Drug|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
230222|NCT02435277|Drug|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
230223|NCT02435264|Other|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
230224|NCT02435251|Device|dual energy X-ray absorptiometry|
230225|NCT02435225|Behavioral|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
230226|NCT02435212|Drug|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use.
230227|NCT02435212|Drug|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use
230228|NCT02435199|Drug|EMA401 600mg|
230229|NCT02435199|Drug|Placebo|
230230|NCT02435186|Drug|p53 gene|p53 gene will be given intraperitoneally.
230233|NCT02435173|Drug|CDZ173|Part I 10, 30 and 70 mg bid Part II 70 mg bid and matching placebo
230234|NCT02435160|Biological|Fecal Microbiota Transplantation|
230235|NCT02435147|Drug|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
230236|NCT02435134|Other|no intervention|
230237|NCT02435121|Drug|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
230238|NCT02435108|Drug|crizotinib|crizotinib 250mg bid daily
230239|NCT02435095|Drug|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
230240|NCT02435095|Drug|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.~All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
230241|NCT02435069|Drug|Dose Response - NS and USP Glycerin - First Intervention|This trial used a repeated measures, single subjects alternating treatments A-B-C-Bʹ-Cʹ-B1ʹ withdrawal design in which all subjects were tested under all conditions and each subject acted as his or her own control. The subjects were randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A served as the control and was obtained pre-operatively. The B-C arm evaluated dose-response relationship and was used to identify the minimum dosing volume and frequency of ACE administration of NS and USP Glycerin necessary to promote fecal continence. When the optimal dose as identified, the child continued on that dose for 2 weeks to insure treatment stability and effectiveness.
230242|NCT02435069|Drug|Effectiveness - NS and USP Glycerin - Second Intervention|To prevent statistical bias from subject loss due to treatment failure, each child was randomized to a second treatment sequence once they have achieved continence with minimal side effects on optimal dosing The second phase Bʹ-Cʹ-B1ʹ of the study compared the two regimens at optimal dose and administration frequency. This phase was used to confirm the effectiveness of NS and USP Glycerin at optimal dosing on continence and assess side effects.
230243|NCT02435056|Other|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:~Minimum Data Set for supporting the diagnosis~Electronic Diary with associated alerting system for monitoring the patient during the follow-up period~Second opinion system for improving the management"
230244|NCT02435043|Other|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
230245|NCT02435043|Other|standard management after stroke|standard management after stroke is individualised.
230246|NCT02435004|Device|Spinal Modulation Axium™|"The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).~If during the trial treatment the pain will decrease significantly (> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket."
230247|NCT02434991|Device|Barostat|"During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.~A urine pregnancy test for females of childbearing years.~Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.~At this point healthy controls have completed the study.~Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.~Patients will be contacted to complete a phone survey 3 & 6 months and 2 & 4 years after treatment."
230248|NCT02434978|Device|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
230249|NCT02434978|Drug|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
230250|NCT02434978|Other|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
230251|NCT02434965|Drug|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
230252|NCT02434965|Drug|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
230253|NCT02434952|Drug|Dihydroartemisinin piperaquine (DHA PP)|
230254|NCT02434952|Drug|Primaquine|
230404|NCT02433548|Procedure|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
230255|NCT02434939|Drug|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
230256|NCT02434939|Drug|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
230257|NCT02434913|Device|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
230258|NCT02434887|Device|KL029 Intimate Lubricant Gel|
230259|NCT02434874|Device|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
230260|NCT02434861|Drug|Rolapitant|
230261|NCT02434861|Drug|Digoxin|P-gp substrate
230262|NCT02434861|Drug|Sulfasalazine|BCRP substrate
230263|NCT02434861|Drug|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
230264|NCT02434848|Drug|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
230265|NCT02434848|Drug|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK~Route of Administration, dose regimen:~Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.~Prescription and administration:~The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.~Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).~The shelf life is 3 years."
230266|NCT02434835|Drug|[14C]KWA-0711|
230267|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
230268|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
230269|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
230270|NCT02434809|Procedure|Bronchoscopic Implantation|Calypso transponders
230271|NCT02434809|Device|Cone-Beam CT-Guided|
230272|NCT02434809|Radiation|stereotactic body radiation treatments|
230273|NCT02434796|Behavioral|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
230274|NCT02434796|Behavioral|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
230275|NCT02434770|Biological|TiantanBio bOPV lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
230276|NCT02434770|Biological|TiantanBio bOPV lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
230277|NCT02434770|Biological|Bivalent Type 1 & 3 Oral Poliomyelitis Vaccine (BioFarma)|Each dose of tOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 and 105.8 infective units per dose, respectively
230278|NCT02434757|Drug|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
230279|NCT02434744|Drug|KD026|Dosed in combination
230280|NCT02434744|Drug|Placebo|Dosed in combination
230281|NCT02434744|Drug|Metformin|Drug prescribed by each subject's prescribing physician
230282|NCT02434731|Device|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
230283|NCT02434718|Drug|Aducanumab|As described in the treatment arm
230284|NCT02434718|Drug|Placebo|IV administration of 0.9% sodium chloride
230285|NCT02434705|Other|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
230286|NCT02434692|Device|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after cataract surgery on day 0 (V01)
230287|NCT02434666|Drug|CPC-201|
230288|NCT02434653|Other|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
230405|NCT02433548|Procedure|Sham injection|subcutaneous of 5 cc of normal saline
230289|NCT02434653|Other|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
230290|NCT02434640|Drug|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
230291|NCT02434640|Drug|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
230292|NCT02434640|Drug|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
230293|NCT02434627|Drug|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
230294|NCT02434614|Drug|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
230295|NCT02434614|Radiation|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
230296|NCT02434614|Drug|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
230297|NCT02434601|Procedure|Treatment of Dentin Surface|"Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.~Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.~Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
230298|NCT02434601|Procedure|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
230299|NCT02434601|Procedure|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
230300|NCT02434588|Device|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
230301|NCT02434562|Other|Serum (with or without urine) samples|
230302|NCT02434549|Drug|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
230303|NCT02434549|Drug|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
230304|NCT02434523|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
230305|NCT02434523|Other|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
230306|NCT02434497|Drug|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
230307|NCT02434471|Device|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.~Respiratory-triggered T1w DISCO LAVA precontrast~Respiratory-triggered T1w DISCO LAVA in the portal venous phase~Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
230308|NCT02434432|Behavioral|music therapy selected by mothers|mothers' choice of music
230309|NCT02434432|Behavioral|Music therapy recorded lullaby|recorded lullaby
230310|NCT02434419|Device|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
230311|NCT02434419|Other|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
230312|NCT02434406|Behavioral|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
230313|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
230314|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
230315|NCT02434367|Behavioral|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
230316|NCT02434354|Drug|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
230317|NCT02434328|Drug|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection administered as a 6 mg/50 µL dose
230318|NCT02434328|Drug|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection administered as a 2 mg/50 µL dose
230319|NCT02434315|Device|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
230406|NCT02433535|Drug|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
230320|NCT02434315|Device|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
230321|NCT02434315|Device|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
230322|NCT02434289|Dietary Supplement|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
230323|NCT02434289|Other|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
230324|NCT02434276|Biological|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
230325|NCT02434276|Biological|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
230326|NCT02434263|Device|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
230327|NCT02434250|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
230328|NCT02434224|Procedure|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
230329|NCT02434211|Other|Questionnaire and focus group|
230330|NCT02434172|Other|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
230331|NCT02434159|Other|Heart scan|
230332|NCT02434146|Drug|Topical Phenylephrine Solution|Given topically via spray
230333|NCT02434133|Procedure|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
230334|NCT02434107|Procedure|Completion Lymphadenectomy|
230335|NCT02434107|Procedure|Clinical Monitoring (Palpation and node ultrasound)|
230336|NCT02434094|Behavioral|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
230337|NCT02434081|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
230338|NCT02434068|Other|CT|followup
230339|NCT02434055|Device|AVERT PLUS|
230340|NCT02434042|Dietary Supplement|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
230341|NCT02434042|Other|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
230342|NCT02434029|Drug|Budesonide 1mg orodispersible tablet twice daily|
230343|NCT02434029|Drug|Placebo orodispersible tablet twice daily|
230344|NCT02433977|Dietary Supplement|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 3 g/day
230345|NCT02433977|Drug|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
230346|NCT02433977|Drug|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
230347|NCT02433964|Other|Grupo LED|
230348|NCT02433964|Other|Placebo|ledterapia off + price
230349|NCT02433951|Other|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
230350|NCT02433938|Procedure|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
230351|NCT02433938|Procedure|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
230352|NCT02433925|Dietary Supplement|Resveratrol|
230353|NCT02433925|Dietary Supplement|Placebo|
230354|NCT02433912|Procedure|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
230355|NCT02433912|Procedure|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
230356|NCT02433912|Drug|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
230357|NCT02433912|Drug|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
230358|NCT02433899|Procedure|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
230359|NCT02433899|Procedure|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
230360|NCT02433899|Drug|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
230361|NCT02433899|Drug|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
230362|NCT02433899|Drug|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
230363|NCT02433886|Procedure|Gamma Ventral Capsulotomy|
230364|NCT02433873|Dietary Supplement|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
230407|NCT02433535|Other|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
233124|NCT02414503|Device|OptiNose Breath Powered Bi|
230365|NCT02433860|Behavioral|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately > 36 weeks gestation or at delivery."
230366|NCT02433847|Drug|Mosapride|
230367|NCT02433834|Drug|Glycopyrronium MDI|GP MDI
230368|NCT02433834|Drug|Serevent Diskus 50 μg|
230369|NCT02433834|Drug|Placebo|
230370|NCT02433821|Other|Pilates|
230371|NCT02433808|Drug|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
230372|NCT02433808|Other|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
230373|NCT02433795|Drug|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
230374|NCT02433782|Other|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
230375|NCT02433769|Device|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
230376|NCT02433769|Device|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
230377|NCT02433756|Device|CRTD|
230378|NCT02433743|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
230379|NCT02433730|Drug|Testosterone|intramuscular injection
230380|NCT02433730|Drug|placebo|intramuscular injection
230381|NCT02433717|Drug|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
230382|NCT02433704|Device|New Intraosseous|Intraosseous administration of prophylactic antibiotics
230383|NCT02433704|Drug|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
230384|NCT02433691|Other|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
230385|NCT02433691|Other|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
230386|NCT02433691|Other|stretching and toning|anaerobic stretching and toning followed by memory training.
230387|NCT02433678|Drug|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
230388|NCT02433678|Drug|Placebo|
230389|NCT02433665|Drug|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
230390|NCT02433665|Device|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
230391|NCT02433652|Biological|Recombinant live attenuated trivalent dengue vaccine|Contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10^3.0 PFU of each component.
230392|NCT02433652|Biological|Placebo|
230393|NCT02433652|Biological|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10^3 PFU
230394|NCT02433639|Drug|TH-302 monotherapy|TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
230395|NCT02433626|Drug|COTI2|COTI-2 is a third generation thiosemicarbazone.
230396|NCT02433626|Drug|Cisplatin|Cisplatin is approved to treat a range of solid tumors and lymphomas.
230397|NCT02433600|Other|Cow's milk-based infant formula|
230398|NCT02433600|Other|Cow milk-based infant formula with enriched protein fractions|
230399|NCT02433587|Drug|Aspirin|Patients will take Aspirin 81 mg
230400|NCT02433587|Drug|Clopidogrel|Patients will take Clopidogrel 75 mg
230401|NCT02433574|Radiation|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.~The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
230402|NCT02433561|Procedure|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
230403|NCT02433561|Procedure|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
230408|NCT02433522|Drug|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
230409|NCT02433522|Drug|Placebo|
230410|NCT02433509|Other|HUCB monocyte cells|"The cord blood need to be infusion within less than 10 days after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.~20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
230411|NCT02433496|Other|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.~The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
230412|NCT02433483|Drug|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
230413|NCT02433483|Drug|Intrathecal Triples|given IT.
230414|NCT02433483|Biological|HPC-A|Given IV.
230415|NCT02433470|Device|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
230416|NCT02433457|Drug|CC-292|
230417|NCT02433457|Drug|Oral Omeprazole (OMP)|
230418|NCT02433444|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
230419|NCT02433431|Behavioral|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
230420|NCT02433431|Behavioral|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
230421|NCT02433431|Behavioral|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
230422|NCT02433418|Procedure|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
230423|NCT02433418|Drug|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
230424|NCT02433405|Biological|Fetuin-A|Acute phase protein
230425|NCT02433405|Biological|Serum Amyloid A|Acute phase protein
230426|NCT02433392|Procedure|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
230427|NCT02433379|Device|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
230428|NCT02433353|Drug|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
230429|NCT02433353|Behavioral|EMDR|psychotherapy
230430|NCT02433353|Drug|Placebo|Look-alike venlafaxine XR tablets containing no active drug
230431|NCT02433340|Drug|ABT-122|
230432|NCT02433327|Other|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
230433|NCT02433327|Other|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
230434|NCT02433314|Drug|SAGE-547|
230435|NCT02433288|Other|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
230436|NCT02433288|Other|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
230437|NCT02433262|Other|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
230438|NCT02433262|Other|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
230439|NCT02433249|Behavioral|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
230440|NCT02433249|Behavioral|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
230441|NCT02433249|Behavioral|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
230442|NCT02433236|Drug|Fostamatinib Disodium tablet 100 mg|
230443|NCT02433236|Drug|Fostamatinib Disodium tablet 150 mg|
230444|NCT02433210|Device|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
230445|NCT02433210|Device|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
230446|NCT02433210|Device|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
230447|NCT02433197|Device|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.~In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
230448|NCT02433184|Drug|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
230449|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
230450|NCT02433184|Drug|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
230451|NCT02433184|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
230452|NCT02433184|Drug|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
230453|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
230454|NCT02433171|Procedure|Standard of Care FDG-PET Imaging|[11C]Methionine [11]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. [11C]PBR28 [12]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
230455|NCT02433158|Drug|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses. Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg. Subjects 6 to 11 years of age or subject who weighs 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
230456|NCT02433132|Other|Nasal brushing|The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
230457|NCT02433119|Drug|OROSARTAN® 5/160mg|
230458|NCT02433119|Drug|CODIOVAN® 160/12.5mg|
230459|NCT02433106|Other|GAA 15|Neuromuscular injury prevention training
230460|NCT02433106|Other|Control|Usual training
230461|NCT02433093|Drug|Basimglurant|Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
230462|NCT02433093|Drug|Placebo|Participants will receive 22 days of once-daily oral matching placebo capsules.
230463|NCT02433080|Behavioral|Shape-Up following cancer treatment|"The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention."
230464|NCT02433067|Other|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
230465|NCT02433067|Other|Control Group|standard oncologic care
230466|NCT02433054|Device|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
230467|NCT02433041|Drug|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
230468|NCT02433041|Drug|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
230469|NCT02433041|Drug|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
230470|NCT02433041|Drug|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
230471|NCT02433015|Other|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
230472|NCT02433015|Other|Tobacco Cigarette|Smoke own brand of cigarette as previously
230473|NCT02432989|Behavioral|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
230474|NCT02432976|Drug|Exenatide|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.~The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .~The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
230475|NCT02432976|Drug|Insulin|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.~The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.~The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
230476|NCT02432963|Other|Laboratory Biomarker Analysis|Correlative studies
230477|NCT02432963|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
230478|NCT02432963|Biological|Pembrolizumab|Given IV
230479|NCT02432950|Dietary Supplement|Dietary Intervention|Participate in the PNP
230480|NCT02432950|Other|Educational Intervention|Participate in the PNP
230481|NCT02432950|Other|Laboratory Biomarker Analysis|Correlative studies
230482|NCT02432950|Other|Quality-of-Life Assessment|Ancillary studies
230483|NCT02432937|Drug|Corever|Corever
230484|NCT02432924|Behavioral|Instant + Multidimensional Physical Activity Feedback|
230485|NCT02432911|Drug|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
230486|NCT02432911|Drug|low dose cytarabine|cytarabine 20mg bid for 10 days.
230487|NCT02432898|Device|3D OCT-1|Spectral Domain OCT Device
230488|NCT02432898|Device|3D OCT-2000|Spectral Domain OCT Device
230489|NCT02432898|Device|DRI OCT-1|Swept Source OCT Device
230490|NCT02432898|Device|NW-300|Fundus Camera
230491|NCT02432898|Device|CT-1P|Tonometry
230492|NCT02432898|Device|TRK-2P|Tonometry, Corneal Topography
230493|NCT02432898|Device|SP-1P|Specular Microscopy
230494|NCT02432898|Device|SL-D701|Slit Lamp Imaging
230495|NCT02432898|Device|MC-4S|Visual Acuity Testing
230496|NCT02432885|Drug|Enalapril|up to 20mg bid
230497|NCT02432872|Drug|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
230498|NCT02432872|Drug|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
230499|NCT02432859|Procedure|Electrical Stimulation|Direct current with sensory intensity for one hour
230500|NCT02432859|Procedure|Placebo|Direct current with zero intensity for one hour
230501|NCT02432846|Biological|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, pro-inflammatory dendritic cells.
230502|NCT02432846|Drug|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
230503|NCT02432833|Drug|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
230504|NCT02432833|Drug|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
230505|NCT02432833|Drug|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
230506|NCT02432807|Drug|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
230507|NCT02432807|Drug|Placebo|Placebo
230508|NCT02432794|Procedure|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
230509|NCT02432781|Dietary Supplement|Carbohydrate-rich drink|
230510|NCT02432781|Dietary Supplement|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
230511|NCT02432768|Drug|Triheptanoin|Anaplerotic dietary oil
230512|NCT02432768|Other|Placebo oil|Safflower oil
230513|NCT02432755|Behavioral|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
230514|NCT02432755|Behavioral|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
230515|NCT02432755|Behavioral|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
230516|NCT02432742|Device|Restylane Perlane|Intradermal injection
230517|NCT02432742|Device|Restylane|Intradermal injection
230518|NCT02432716|Drug|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
230519|NCT02432716|Drug|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
230520|NCT02432703|Drug|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
230521|NCT02432703|Drug|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
230522|NCT02432690|Drug|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
230523|NCT02432677|Drug|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
230524|NCT02432677|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
230525|NCT02432677|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
230526|NCT02432677|Drug|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
230527|NCT02432664|Drug|ODM-108 Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
230528|NCT02432664|Drug|Placebo Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
230529|NCT02432664|Drug|ODM-108-Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
230530|NCT02432664|Drug|Placebo Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
230531|NCT02432664|Drug|ODM-108 Part III|Oral capsules 1 - 4 times daily for 7 to 10 days
230532|NCT02432664|Drug|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
230533|NCT02432651|Drug|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
230534|NCT02432651|Drug|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
230535|NCT02432651|Drug|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
230536|NCT02432651|Drug|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
230537|NCT02432612|Drug|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
230538|NCT02432599|Radiation|F18-choline PET examination|F18-choline PET examination will be performed before surgery
230539|NCT02432586|Behavioral|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
230540|NCT02432573|Behavioral|Delayed rounds|
230541|NCT02432560|Drug|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
230542|NCT02432560|Drug|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
230543|NCT02432547|Drug|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
230544|NCT02432547|Procedure|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
230545|NCT02432534|Drug|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
230546|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
230547|NCT02432521|Other|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
230548|NCT02432508|Device|Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (50mW, 655nm)
230549|NCT02432508|Device|Sham Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
230550|NCT02432495|Other|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
233635|NCT02410863|Drug|Trametinib|2 mg daily
230551|NCT02432495|Other|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
230552|NCT02432482|Behavioral|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
230553|NCT02432482|Behavioral|Standard care|Brief advice to quit (<5 minutes) Self-help brochure Offer of nicotine patches
230554|NCT02432469|Behavioral|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
230555|NCT02432456|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
230556|NCT02432456|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
230557|NCT02432456|Procedure|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
230558|NCT02432456|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
230559|NCT02432456|Drug|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
230560|NCT02432456|Drug|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
230561|NCT02432456|Drug|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
230562|NCT02432456|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
230563|NCT02432443|Behavioral|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, & Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice & McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
230564|NCT02432443|Other|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
230565|NCT02432430|Behavioral|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
230566|NCT02432430|Behavioral|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
230567|NCT02432417|Drug|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
230568|NCT02432404|Drug|NuvaRing|
230569|NCT02432391|Behavioral|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
230570|NCT02432378|Biological|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
230571|NCT02432378|Biological|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
230572|NCT02432365|Drug|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
230573|NCT02432365|Drug|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
230574|NCT02432365|Procedure|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
230575|NCT02432352|Behavioral|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
230833|NCT02430480|Drug|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
230576|NCT02432339|Drug|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
230577|NCT02432339|Drug|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
230578|NCT02432326|Drug|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
230579|NCT02432326|Drug|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
230580|NCT02432313|Drug|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
230581|NCT02432300|Behavioral|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
230582|NCT02432287|Drug|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
230583|NCT02432287|Drug|Placebo|there is no other name we used for the placebo
230584|NCT02432274|Drug|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
230585|NCT02432274|Drug|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
230586|NCT02432274|Drug|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
230587|NCT02432274|Drug|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose).
230588|NCT02432274|Drug|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
230589|NCT02432274|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
230590|NCT02432274|Drug|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
230591|NCT02432274|Drug|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
230592|NCT02432274|Drug|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
230593|NCT02432261|Drug|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
230594|NCT02432261|Drug|Testosterone only gel|Testosterone only gel
230595|NCT02432248|Drug|Dehydroepiandrosterone|75mg/day, PO for 90 days
230596|NCT02432248|Other|placebo(medical starch)|75mg/day, PO for 90 days
230597|NCT02432235|Drug|ADCT-301|intravenous infusion
230598|NCT02432222|Behavioral|Visual Arts Training|Visual arts training
230599|NCT02432222|Behavioral|Music Training|Music training
230600|NCT02432209|Other|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
230601|NCT02432209|Drug|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
230602|NCT02432209|Other|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
230603|NCT02432196|Device|Harpoon Medical Device|It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
230604|NCT02432170|Device|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
230605|NCT02432157|Drug|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
230606|NCT02432157|Drug|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
230607|NCT02432144|Drug|UX003|solution for intravenous (IV) infusion
230608|NCT02432118|Procedure|Lumpectomy|Undergo lumpectomy
230609|NCT02432118|Other|Questionnaire Administration|Ancillary studies
230610|NCT02432118|Procedure|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
230611|NCT02432105|Drug|EXE844 Sterile Otic Suspension, 0.3%|
230612|NCT02432105|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
230613|NCT02432066|Drug|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
230614|NCT02432066|Drug|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
230615|NCT02432053|Drug|Advagraf|
230616|NCT02432040|Drug|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
230617|NCT02432040|Drug|Placebo|Placebo tablets, made to look like the interventional drug
230618|NCT02432027|Drug|C-82 Topical Gel, Placebo|placebo
230619|NCT02432027|Drug|C-82 Topical Gel, 1%|active
230620|NCT02432027|Drug|Daivonex cream|comparator
230621|NCT02432027|Drug|Diprosis gel|comparator
230622|NCT02432014|Behavioral|PMTO-PTC Group clinic-based|
230623|NCT02432014|Behavioral|PMTO Individual home-based|
230624|NCT02432014|Behavioral|PMTO Individual clinic-based|
230625|NCT02432014|Behavioral|Services as Usual|
230626|NCT02432001|Procedure|Image-Guided Biopsies|
230627|NCT02431988|Procedure|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
230834|NCT02430480|Drug|Enzalutamide|160mg orally, daily for 24 weeks
230628|NCT02431988|Drug|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
230629|NCT02431988|Drug|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
230630|NCT02431988|Biological|CAR19 T-Cells|"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.~Three dose cohorts are planned:~Dose Level 1: 2x105 CAR19 T-cells/kg~Dose Level 2: 1x106 CAR19 T-cells/kg~Dose Level 3: 5x106 CAR19 T-cells/kg"
230631|NCT02431975|Drug|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.~The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
230632|NCT02431975|Drug|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.~ZDV will be dosed as per standard guideline and routine practices."
230633|NCT02431975|Drug|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.~3TC will be dosed as per standard guideline and routine practices."
230634|NCT02431975|Drug|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.~LPV/r will be dosed as per standard guideline and routine practices."
230635|NCT02431962|Procedure|Computed Tomography|Low dose chest CT screening annually x 3
230636|NCT02431962|Behavioral|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
230637|NCT02431962|Behavioral|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
230638|NCT02431949|Other|Admission to BCPP|There is no intervention associated with this study.
230639|NCT02431936|Drug|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
230640|NCT02431936|Drug|Placebo|Sugar pill made to look identical to Prazosin intervention.
230641|NCT02431910|Other|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
230642|NCT02431910|Other|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
230643|NCT02431897|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
230644|NCT02431897|Drug|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for >5 weeks before surgery, then 2x/week for 1 year after surgery.
230645|NCT02431884|Procedure|collect body fluids/tissues & med history|collect tissues/fluids & history
230646|NCT02431858|Device|E-Catheter (Pajunk)|
230647|NCT02431858|Device|Sonolong Catheter (Pajunk)|
230648|NCT02431845|Drug|SSRIs|usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40~80 mg dose equivalents
230649|NCT02431832|Drug|Augmentin tab|
230650|NCT02431819|Device|contention socks|Patients wear contention socks during 15 days.
230651|NCT02431806|Drug|Placebo|
230652|NCT02431806|Drug|Levomilnacipran ER|
230653|NCT02431806|Drug|Fluoxetine|
230654|NCT02431793|Behavioral|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.
230655|NCT02431793|Behavioral|SMS Text Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
230656|NCT02431780|Device|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
230657|NCT02431767|Biological|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
230658|NCT02431767|Biological|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
230659|NCT02431767|Biological|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
230660|NCT02431754|Drug|Tadalafil|Administered orally
230661|NCT02431754|Drug|Placebo|Administered orally
230662|NCT02431754|Drug|Alpha1 Blocker|Administered orally
230663|NCT02431741|Device|Mepilex Transfer Ag|
230664|NCT02431728|Dietary Supplement|Melatonin|5 mg capsule p.o. at bedtime daily
230665|NCT02431728|Dietary Supplement|Matched Placebo|5 mg capsule p.o. at bedtime daily
230666|NCT02431715|Drug|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.~The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.~The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.~Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.~Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
230667|NCT02431702|Drug|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
230668|NCT02431702|Drug|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
230669|NCT02431702|Drug|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
230670|NCT02431702|Drug|Oral Paliperidone ER|Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
230671|NCT02431702|Drug|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
230672|NCT02431702|Drug|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
230673|NCT02431702|Drug|Oral Risperidone|Risperidone tablets 1-6 mg per day will be administered orally.
230674|NCT02431702|Drug|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
230675|NCT02431702|Drug|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
230676|NCT02431689|Procedure|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
230677|NCT02431676|Drug|Metformin|Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
230678|NCT02431676|Behavioral|Coach Directed Behavioral Weight Loss|Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
230679|NCT02431676|Behavioral|Self-control weight loss|
230680|NCT02431663|Drug|Ketamine|Intravenous administration in continuous
230681|NCT02431650|Drug|OZ439|
230682|NCT02431650|Drug|Primaquine|
230683|NCT02431637|Biological|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
230684|NCT02431637|Drug|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
230685|NCT02431624|Drug|BTDS|
230686|NCT02431611|Behavioral|Biomarker feedback (phone based smoking cessation counseling)|Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
230687|NCT02431611|Behavioral|Control condition (phone based smoking cessation counseling)|phone-based behavioral smoking cessation counseling
230688|NCT02431598|Drug|gadoxetate disodium|
230689|NCT02431598|Drug|gadoterate dimeglumine|
230690|NCT02431598|Drug|Saline|
230691|NCT02431585|Dietary Supplement|gluten|
230692|NCT02431585|Dietary Supplement|placebo|
230693|NCT02431572|Other|PBR PET|
230694|NCT02431572|Biological|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
230695|NCT02431572|Radiation|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
230696|NCT02431559|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes.
230697|NCT02431559|Drug|Pegylated Liposomal Doxorubicin|PLD was administered as an IV infusion in accordance with local prescribing information.
230698|NCT02431559|Drug|Motolimod|Motolimod was administered as an SC injection. Within 30 minutes prior to each dose of motolimod, subjects were administered 650-1000 mg acetaminophen by mouth to help mitigate potential adverse events (AEs) commonly associated with the administration of motolimod (e.g., fever, myalgia). On days with concurrent motolimod and durvalumab dosing, motolimod administration occurred 30-60 minutes after the end of the durvalumab infusion. After completion of Phase 1, a protocol amendment was implemented to remove motolimod dosing from the study.
230699|NCT02431546|Behavioral|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.~A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
230700|NCT02431533|Dietary Supplement|PX0612|PX0612 is a probiotic contained in a veggie capsule.
230701|NCT02431533|Dietary Supplement|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
230702|NCT02431520|Procedure|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
230703|NCT02431520|Procedure|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
230704|NCT02431507|Device|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
230705|NCT02431494|Device|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
230835|NCT02430480|Procedure|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
230706|NCT02431494|Device|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
230707|NCT02431494|Device|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
230708|NCT02431481|Drug|LEE011|400 mg
230709|NCT02431468|Drug|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
230710|NCT02431468|Other|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
230711|NCT02431455|Device|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
230712|NCT02431455|Device|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
230713|NCT02431442|Drug|RM-493|
230714|NCT02431442|Drug|Placebo|
230715|NCT02431429|Drug|Miltefosine|
230716|NCT02431416|Drug|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
230717|NCT02431416|Drug|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
230718|NCT02431403|Drug|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
230719|NCT02431390|Device|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
230720|NCT02431390|Behavioral|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
230721|NCT02431377|Other|S-26 Gold|A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
230722|NCT02431364|Drug|Verdinexor|
230723|NCT02431364|Other|Placebo|
230724|NCT02431351|Drug|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
230725|NCT02431338|Procedure|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
230726|NCT02431325|Drug|Teduglutide|
230727|NCT02431325|Drug|Placebo|
230728|NCT02431312|Biological|INO-1800|INO-1800 delivered by EP
230729|NCT02431312|Biological|INO-9112|INO-9112 delivered by EP
230730|NCT02431312|Drug|Nucleos(t)ide Analogue Treatment|Continued treatment with nucleos(t)ide analogue
230731|NCT02431286|Drug|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
230732|NCT02431286|Drug|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
230733|NCT02431286|Drug|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
230734|NCT02431273|Drug|TDF IVR|
230735|NCT02431273|Drug|TDF-FTC IVR|
230736|NCT02431273|Drug|TDF-FTC-MVC IVR|
230737|NCT02431260|Drug|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
230738|NCT02431247|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
230739|NCT02431247|Drug|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
230740|NCT02431247|Drug|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
230741|NCT02431247|Drug|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
230742|NCT02431247|Drug|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
230743|NCT02431247|Drug|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
230744|NCT02431234|Other|serum RANKL|
230745|NCT02431221|Drug|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
230746|NCT02431221|Drug|Placebo|
230747|NCT02431208|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
230776|NCT02430948|Other|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
230885|NCT02430090|Drug|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
230748|NCT02431208|Drug|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
230749|NCT02431208|Drug|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
230750|NCT02431208|Drug|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
230751|NCT02431208|Drug|Dexamethasone|Participants will receive either 20mg or 40mg of dexamethasone PO every 7 days from Day 1 of each cycle.
230752|NCT02431182|Behavioral|Memory Training Workshop|"Presentation of the workshop: Objectives and Methodology~Explanation of the different types of memory and its implication in normal life~Strategies for gathering and codification of the information~Strategies for selection and storage the information~Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory~Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences~Strategies for recuperation according to the individual profile. Improving self-esteem~Strategies for recuperation Social skills.~Personal and social skills~New contexts and opportunities~Evaluation of the workshop"
230753|NCT02431156|Other|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.~VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
230754|NCT02431143|Drug|Miltefosine|
230755|NCT02431130|Other|low-fidelity instructor driven simulation training|
230756|NCT02431104|Device|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
230757|NCT02431091|Other|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
230758|NCT02431078|Procedure|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
230759|NCT02431065|Procedure|Rectus sheath block|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
230760|NCT02431065|Drug|Ropivacaine|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
230761|NCT02431065|Other|Normal saline|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:~Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.~Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.~Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
230762|NCT02431052|Drug|Olumacostat Glasaretil|
230763|NCT02431052|Other|Vehicle|
230764|NCT02431039|Device|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
230765|NCT02431039|Device|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
230766|NCT02431026|Device|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
230767|NCT02431013|Drug|Simvastatin|Simvastatin 40 mg on Day 1 & Day 8.
230768|NCT02431013|Drug|Pravastatin|Pravastatin 20 mg on Day 1 & Day 8.
230769|NCT02431013|Drug|Cilostazol|Cilostazol 100 mg twice a day for 6 days & on Day 8 with statin.
230770|NCT02431000|Procedure|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
230771|NCT02430987|Diagnostic Test|Female sexual function index questionnaire|will be applied questionnaire about sexuality and give diagnoses of metabolic syndrome
230772|NCT02430974|Drug|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
230773|NCT02430948|Other|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
230774|NCT02430948|Other|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
230775|NCT02430948|Other|Standard support|Screening recommendations presented in standard format
230777|NCT02430935|Behavioral|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
230778|NCT02430935|Behavioral|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
230779|NCT02430922|Device|iVolution nitinol stent|
230780|NCT02430909|Biological|Bimekizumab|"Pharmaceutical form: Solution for infusion~Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose~Route of administration: iv infustion"
230781|NCT02430909|Biological|Certolizumab Pegol|"Pharmaceutical form: Prefilled syringes~Concentration: 200 mg/ml~Route of administration: Subcutaneous injection"
230782|NCT02430909|Other|Placebo|"Pharmaceutical form: Solution for infusion~Concentration: 0.9% saline~Route of administration: Intravenous infusion"
230783|NCT02430896|Drug|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
230784|NCT02430896|Drug|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
230785|NCT02430883|Procedure|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
230786|NCT02430870|Drug|TAK-648|TAK-648 solution
230787|NCT02430870|Drug|Placebo|TAK-648 placebo-matching solution
230788|NCT02430857|Other|OMT|Manuel osteopathic treatment of the spine
230789|NCT02430831|Dietary Supplement|Nidina|
230790|NCT02430831|Dietary Supplement|Placebo|
230791|NCT02430818|Drug|ketamine|
230792|NCT02430818|Drug|morphine|
230793|NCT02430805|Other|dna extraction and genotyping|blood and urine sample
230794|NCT02430792|Behavioral|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
230795|NCT02430779|Procedure|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
230796|NCT02430779|Device|NanoKnife|
230797|NCT02430766|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
230798|NCT02430766|Device|NanoKnife|
230799|NCT02430753|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
230800|NCT02430753|Device|NanoKnife|
230801|NCT02430740|Drug|recFSH|
230802|NCT02430714|Drug|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
230803|NCT02430701|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
230804|NCT02430701|Device|NanoKnife|
230805|NCT02430688|Procedure|Irreversible electroporation (IRE)|
230806|NCT02430688|Device|NanoKnife|
230807|NCT02430675|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
230808|NCT02430675|Device|NanoKnife|
230809|NCT02430662|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
230810|NCT02430662|Device|NanoKnife|
230811|NCT02430649|Procedure|Irreversible electroporation (IRE)|
230812|NCT02430649|Device|NanoKnife|
230813|NCT02430636|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
230814|NCT02430636|Device|NanoKnife|
230815|NCT02430623|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
230816|NCT02430623|Device|NanoKnife|
230817|NCT02430610|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
230818|NCT02430610|Device|NanoKnife|
230819|NCT02430597|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
230820|NCT02430597|Device|NanoKnife|
230821|NCT02430584|Other|Observational - no intervention|
230822|NCT02430558|Biological|OD-PHOENIX|dellelularized, freeze-dried, irradiated osteochondral allograft
230823|NCT02430545|Drug|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
230824|NCT02430545|Drug|Rifampin|Subjects receive rifampin 600 mg oral dose daily [Day -6 to day 4]
230825|NCT02430532|Drug|dimethyl fumarate|capsule
230826|NCT02430532|Other|Placebo|matched placebo capsule
230827|NCT02430519|Procedure|Furcation treatment with PRF|PRF Placed into the furcation after flap elevation and debridement
230828|NCT02430519|Procedure|Furcation Treatment with Allograft and GTR|Allograft and GTR placed into furcation after flap elevation and debridement
230829|NCT02430519|Device|allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)|
230830|NCT02430519|Device|autologous platelet-rich fibrin|
230831|NCT02430506|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
230832|NCT02430506|Biological|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
230836|NCT02430467|Behavioral|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
230837|NCT02430467|Behavioral|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
230838|NCT02430454|Behavioral|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
230839|NCT02430428|Device|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
230840|NCT02430415|Device|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
230841|NCT02430415|Device|traditional lightwand intubation|traditional lightwand intubation
230842|NCT02430402|Other|Rehabilitation in warm climate|
230843|NCT02430389|Drug|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
230844|NCT02430389|Drug|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
230845|NCT02430363|Drug|MK - 3475|Administered Intravenously
230846|NCT02430363|Biological|Suppressor of the PI3K/Akt pathways|Capsules orally with food
230847|NCT02430350|Drug|Compound Edaravone Injection|
230848|NCT02430350|Drug|Edaravone Injection|
230849|NCT02430337|Behavioral|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
230850|NCT02430337|Behavioral|SafeCare|SafeCare, an evidence-based home visiting program
230851|NCT02430324|Other|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
230852|NCT02430311|Drug|Olaparib|Tablet-150mg, Oral
230853|NCT02430311|Drug|Paclitaxel|Injection
230854|NCT02430311|Drug|Olaparib|Tablet-100mg, Oral
230855|NCT02430298|Drug|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
230856|NCT02430298|Drug|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
230857|NCT02430285|Procedure|Endoscopic Ultrasound|Endoscopic Ultrasound
230858|NCT02430285|Device|Olympus 180 series echoendoscope|
230859|NCT02430272|Drug|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
230860|NCT02430259|Drug|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
230861|NCT02430246|Dietary Supplement|Urex Plus|Probiotic
230862|NCT02430246|Other|Placebo|capsule without active ingredient
230863|NCT02430246|Dietary Supplement|Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14|
230864|NCT02430233|Drug|micronized progesterone 400 mg (Utrogestan)|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
230865|NCT02430207|Procedure|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
230866|NCT02430207|Procedure|temporary pacing subclavian vein|
230867|NCT02430194|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
230868|NCT02430194|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
230869|NCT02430194|Drug|PEG IFN-a|immunomodulator
230870|NCT02430181|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
230871|NCT02430181|Drug|PEG IFN-a|immunomodulator
230872|NCT02430181|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
230873|NCT02430168|Procedure|Percutaneous nephrolithotomy|
230874|NCT02430168|Procedure|Retrograde intrarenal surgery|
230875|NCT02430155|Device|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
230876|NCT02430155|Device|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
230877|NCT02430142|Other|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
230878|NCT02430129|Procedure|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
230879|NCT02430129|Procedure|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
230880|NCT02430129|Device|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
230881|NCT02430129|Device|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
230882|NCT02430116|Procedure|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
230883|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
230884|NCT02430090|Drug|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
233636|NCT02410850|Device|Oral Appliance|Mandibular Advancement Splints
230886|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
230887|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
230888|NCT02430077|Drug|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
230889|NCT02430077|Drug|Placebo|Identical to Obeticholic Acid - placebo drug
230890|NCT02430064|Other|Low PAMP diet|
230891|NCT02430051|Behavioral|Sensory Adapted Dental Environment|The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
230892|NCT02430012|Behavioral|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
230893|NCT02429999|Drug|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
230894|NCT02429999|Drug|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
230895|NCT02429986|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
230896|NCT02429973|Drug|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
230897|NCT02429960|Device|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
230898|NCT02429960|Device|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
230899|NCT02429960|Device|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
230900|NCT02429960|Drug|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
230901|NCT02429934|Drug|abatacept|125mg injected subcutaneously weekly for 16 weeks
230902|NCT02429934|Drug|Placebo|
230903|NCT02429921|Dietary Supplement|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
230904|NCT02429921|Dietary Supplement|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
230905|NCT02429908|Device|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
230906|NCT02429895|Drug|ABT-122|Injection
230907|NCT02429882|Drug|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
230908|NCT02429882|Drug|Placebo|Placebo will be administered subcutaneously
230909|NCT02429869|Drug|everolimus|
230910|NCT02429856|Device|SCORPIO™|subjects randomized at surgery to receive 1 of the 2 specified implants
230911|NCT02429843|Drug|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
230912|NCT02429830|Device|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
230913|NCT02429817|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
230914|NCT02429817|Device|Aeroneb Solo|
230915|NCT02429817|Device|Jet Nebulizer|
230916|NCT02429817|Other|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
230917|NCT02429817|Other|Spirometry|FEV1, FVC assessment
230918|NCT02429804|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
230919|NCT02429804|Drug|Fludeoxyglucose F-18|Given IV
230920|NCT02429804|Drug|Fluorine F 18 Sodium Fluoride|Given IV
230921|NCT02429804|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
230922|NCT02429804|Procedure|Positron Emission Tomography|Undergo PET/MRI
230923|NCT02429791|Drug|DTG 50 mg|Participants will take one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet will contain 52.62 mg dolutegravir sodium salt, which is equivalent to 50 mg dolutegravir free acid.
230924|NCT02429791|Drug|RPV 25 mg|Participants will take one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet will contain 27.5 mg of rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.
230925|NCT02429791|Drug|CAR|CAR will include following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
230926|NCT02429778|Behavioral|Diaphragmatic Breathing|Deep or diaphragmatic breathing is taught prior to relaxation.
230927|NCT02429778|Behavioral|Progressive Muscle Relaxation|Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
230928|NCT02429765|Drug|ACL/FOR|
230929|NCT02429765|Drug|Placebo|
230930|NCT02429752|Other|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
230931|NCT02429739|Behavioral|Working memory Training|"The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.~Other name: Cogmed RoboMemo"
230932|NCT02429726|Drug|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
230933|NCT02429726|Drug|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
230934|NCT02429726|Drug|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
230935|NCT02429713|Procedure|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
230936|NCT02429713|Procedure|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
230937|NCT02429700|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
230938|NCT02429700|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
230939|NCT02429700|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
230940|NCT02429700|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
230941|NCT02429700|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
230942|NCT02429687|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
230943|NCT02429687|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 4-6 courses in the absence of disease progression or unacceptable toxicity.
230944|NCT02429687|Drug|Bleomycin|Bleomycin 30000IU IM per day for 3 days every 3 weeks for 3-4 cycles.
230945|NCT02429687|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles.
230946|NCT02429687|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3-4 cycles in the absence of disease progression or unacceptable toxicity.
230947|NCT02429674|Behavioral|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
230948|NCT02429661|Behavioral|Peer support groups|
230949|NCT02429648|Procedure|DCC first then PVI|DCC performed prior to PVI
230950|NCT02429648|Procedure|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
230951|NCT02429635|Behavioral|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.~Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.~Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
230952|NCT02429622|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage once respectively
230953|NCT02429622|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
230954|NCT02429622|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
230955|NCT02429622|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
230956|NCT02429609|Device|Moorfields Acuity Chart|
230957|NCT02429596|Drug|Experimental|Switch from brand to generic
230958|NCT02429583|Drug|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
230959|NCT02429570|Drug|Meclofenamate|
230960|NCT02429557|Other|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
230961|NCT02429557|Other|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
230962|NCT02429557|Drug|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
230963|NCT02429557|Drug|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
230964|NCT02429544|Behavioral|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
230965|NCT02429544|Behavioral|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
230966|NCT02429544|Device|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
230967|NCT02429544|Other|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
230968|NCT02429544|Behavioral|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
230969|NCT02429531|Biological|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
230970|NCT02429531|Biological|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
230971|NCT02429518|Drug|Miltefosine|
230972|NCT02429505|Drug|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
230973|NCT02429492|Device|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
230974|NCT02429479|Behavioral|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
230975|NCT02429479|Behavioral|Standard advance care planning|This is a online simple living will form.
230976|NCT02429466|Drug|Guadecitabine (SGI-110)|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
230977|NCT02429453|Drug|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
230978|NCT02429453|Biological|Fresh Frozen Plasma|A pooled collection of plasma from donors
230979|NCT02429440|Biological|peptide vaccine|subcutaneous
230980|NCT02429440|Drug|Granulocyte Macrophage Colony Stimulating Factor|intradermal
230981|NCT02429440|Drug|Montanide ISA-51|subcutaneous
230982|NCT02429427|Drug|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
230983|NCT02429427|Other|Placebo|Two capsules once daily with food
230984|NCT02429414|Device|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
230985|NCT02429414|Procedure|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
230986|NCT02429414|Device|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
230987|NCT02429401|Behavioral|Non-adapted brief motivational interview|1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
230988|NCT02429401|Behavioral|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
230989|NCT02429388|Drug|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
230990|NCT02429375|Drug|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
230991|NCT02429349|Procedure|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
230992|NCT02429323|Drug|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
230993|NCT02429310|Device|Revitive IX|This is a neuromuscular electrical stimulation device
230994|NCT02429297|Other|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
230995|NCT02429297|Other|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
230996|NCT02429271|Drug|Ticagrelor|
230997|NCT02429271|Drug|Clopidogrel|
230998|NCT02429271|Procedure|Percutaneous Coronary Intervention (PCI)|
230999|NCT02429271|Procedure|Coronary Angiography|
231000|NCT02429258|Drug|Farxiga|Farxiga 10mg/day
231001|NCT02429258|Drug|Placebo|Placebo
231002|NCT02429258|Drug|Metformin|Metformin background therapy >/= 1500mg/day
231003|NCT02429258|Drug|Insulin|Insulin >/= 30 units
231004|NCT02429245|Other|Retrospective study|
231005|NCT02429232|Drug|Pioglitazone|Pioglitazone 30mg/tablet once daily
231006|NCT02429232|Drug|Linagliptin|Linagliptin 5mg/tablet once daily
231007|NCT02429219|Drug|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
231008|NCT02429219|Procedure|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
231009|NCT02429219|Procedure|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
231010|NCT02429206|Other|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
231011|NCT02429206|Other|standard moisturizing cream (Glaxal Base)|
231012|NCT02429193|Drug|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
231013|NCT02429193|Drug|Enzalutamide|Enzalutamide (160 mg/day p.o.)
231049|NCT02428868|Drug|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
231050|NCT02428868|Drug|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
231051|NCT02428868|Other|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
231014|NCT02429180|Other|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.~Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals~Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.~Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme~Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
231015|NCT02429154|Other|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
231016|NCT02429154|Other|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
231017|NCT02429141|Procedure|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
231018|NCT02429141|Procedure|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
231019|NCT02429128|Other|14 weeks exercise training|
231020|NCT02429115|Other|Mentoring|Six months of peer-mentoring.
231021|NCT02429102|Drug|MT-8554|
231022|NCT02429102|Drug|Placebo|
231023|NCT02429089|Drug|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.~In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
231024|NCT02429076|Drug|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
231025|NCT02429076|Drug|Placebo|normal saline
231026|NCT02429076|Drug|Sevoflurane|Inhaled anesthetic
231027|NCT02429076|Drug|Propofol|IV anesthetic
231028|NCT02429063|Other|Bright White Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
231029|NCT02429063|Other|Dim Red Light|The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
231030|NCT02429050|Drug|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
231031|NCT02429050|Drug|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
231032|NCT02429037|Drug|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10^12 viral particles (VP) in a 21-days cycle.
231033|NCT02429037|Radiation|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
231034|NCT02429037|Drug|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
231035|NCT02429024|Device|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
231036|NCT02429024|Device|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
231037|NCT02428998|Dietary Supplement|Korean Red Ginseng|
231038|NCT02428998|Dietary Supplement|Placebo|
231039|NCT02428985|Drug|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
231040|NCT02428972|Drug|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
231041|NCT02428972|Drug|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
231042|NCT02428959|Drug|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
231043|NCT02428946|Drug|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
231044|NCT02428933|Drug|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
231045|NCT02428920|Behavioral|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
231046|NCT02428907|Behavioral|simulation training|teamtraining of endoscopy staff
231047|NCT02428894|Device|LVAD|
231048|NCT02428881|Drug|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
231052|NCT02428855|Drug|Dasatinib|
231053|NCT02428842|Procedure|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
231054|NCT02428842|Procedure|Blood sampling|Blood sampling will be performed before and after treatment.
231055|NCT02428829|Procedure|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
231056|NCT02428829|Procedure|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
231057|NCT02428816|Other|MRI acquisition|MRI acquisitions
231058|NCT02428816|Behavioral|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
231059|NCT02428803|Other|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
231060|NCT02428777|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
231061|NCT02428777|Drug|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
231062|NCT02428777|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
231063|NCT02428764|Drug|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
231064|NCT02428764|Drug|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
231065|NCT02428764|Drug|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
231066|NCT02428764|Procedure|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
231067|NCT02428751|Drug|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
231068|NCT02428751|Drug|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
231069|NCT02428751|Drug|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
231070|NCT02428751|Drug|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
231071|NCT02428751|Drug|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
231072|NCT02428751|Drug|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
231073|NCT02428725|Other|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
231074|NCT02428712|Drug|PLX8394|(Formulation 1 or Formulation 2)
231075|NCT02428699|Other|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
231076|NCT02428699|Other|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
231077|NCT02428686|Drug|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
231078|NCT02428673|Other|Assisted Standing Treatment Program|
231079|NCT02428660|Genetic|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
231080|NCT02428660|Other|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
231081|NCT02428660|Other|MTM|Medication Therapy Management
231082|NCT02428647|Dietary Supplement|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
231083|NCT02428647|Dietary Supplement|preventive zinc supplement|7 mg zinc daily as dispersible tablet
231084|NCT02428647|Dietary Supplement|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
231085|NCT02428647|Dietary Supplement|preventive placebo supplement|dispersible daily placebo tablet
231086|NCT02428647|Dietary Supplement|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
231087|NCT02428647|Dietary Supplement|placebo powder|placebo powder
231088|NCT02428634|Behavioral|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
231089|NCT02428634|Behavioral|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
231090|NCT02428621|Device|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
231091|NCT02428621|Device|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.~The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
231092|NCT02428608|Biological|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
231124|NCT02428361|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
231125|NCT02428348|Other|Interview about prototype EEG-cap|
231126|NCT02428322|Dietary Supplement|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
231093|NCT02428595|Device|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
231094|NCT02428582|Device|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
231095|NCT02428582|Device|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
231096|NCT02428569|Behavioral|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
231097|NCT02428556|Other|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
231098|NCT02428556|Other|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
231099|NCT02428556|Other|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
231100|NCT02428556|Other|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
231101|NCT02428556|Other|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
231102|NCT02428543|Drug|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
231103|NCT02428530|Other|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
231104|NCT02428517|Procedure|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
231105|NCT02428517|Procedure|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
231106|NCT02428517|Procedure|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
231107|NCT02428517|Procedure|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
231108|NCT02428491|Biological|Hexaxim®|DTaP-IPV-Hep B-PRP-T combined vaccine, 0.5 mL, Intramuscular
231109|NCT02428478|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
231110|NCT02428478|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
231111|NCT02428465|Behavioral|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
231112|NCT02428452|Behavioral|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
231113|NCT02428439|Drug|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
231114|NCT02428426|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
231115|NCT02428413|Device|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
231116|NCT02428413|Device|Standard oxygen mask|Provide supplemental oxygen
231117|NCT02428400|Biological|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
231118|NCT02428400|Biological|Placebo|Placebo: adenovirus reference material (ARM) buffer
231119|NCT02428387|Behavioral|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
231120|NCT02428374|Drug|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
231121|NCT02428374|Drug|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
231122|NCT02428374|Drug|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
231123|NCT02428374|Drug|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
231222|NCT02427672|Device|Sham transcranial direct current stimulation|
231127|NCT02428322|Dietary Supplement|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
231128|NCT02428309|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
231129|NCT02428296|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
231130|NCT02428283|Drug|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
231131|NCT02428283|Drug|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
231132|NCT02428283|Drug|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
231133|NCT02428270|Drug|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
231134|NCT02428270|Drug|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
231135|NCT02428257|Procedure|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
231136|NCT02428257|Drug|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
231137|NCT02428257|Drug|isobaric bupivacaine|0.5% isobaric bupivacaine
231138|NCT02428257|Drug|ephedrine|
231139|NCT02428244|Behavioral|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
231140|NCT02428244|Behavioral|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.~In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
231141|NCT02428231|Drug|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
231142|NCT02428218|Drug|dimethyl fumarate|enteric-coated microtablets
231143|NCT02428218|Drug|Placebo|enteric-coated microtablets
231144|NCT02428205|Drug|Propranolol|Participant will receive Propranolol prior to each EIBI session
231145|NCT02428205|Drug|Placebo|Participant will receive placebo prior to each EIBI session
231146|NCT02428192|Biological|Ipilimumab|Given IV
231147|NCT02428192|Other|Laboratory Biomarker Analysis|Correlative studies
231148|NCT02428192|Biological|Nivolumab|Given IV
231149|NCT02428179|Procedure|StOP? - Control group|Control group - Surgical procedure without Study Intervention
231150|NCT02428179|Procedure|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
231151|NCT02428153|Other|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
231152|NCT02428140|Device|Medtronic Reveal LINQ|
231153|NCT02428140|Device|Sorin Spiderflash-t|
231154|NCT02428127|Dietary Supplement|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
231155|NCT02428127|Dietary Supplement|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
231156|NCT02428127|Other|Water|lukewarm water
231157|NCT02428101|Genetic|polymorphism analysis|
231158|NCT02428088|Drug|Dasotraline|Dasotraline 2 mg once daily
231159|NCT02428088|Drug|Dasotraline|Dasotraline 4 mg once daily
231160|NCT02428088|Drug|Placebo Comparator|Placebo once daily
231161|NCT02428075|Behavioral|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
231162|NCT02428062|Procedure|Hemodynamic target|"The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:~vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)~intravenous fluids~patient's positioning~reduction of depth of anesthesia"
231163|NCT02428062|Drug|Phenylephrine|Phenylephrine 0.1-0.2 mg intravenous bolus
231164|NCT02428062|Drug|Intravenous fluids|A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
231165|NCT02428062|Procedure|Patient's positioning|The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
231166|NCT02428062|Procedure|Reduction of depth of anesthesia|The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
231167|NCT02428062|Drug|Ephedrine|Ephedrine 5-25 mg intravenous bolus
231168|NCT02428062|Drug|Epinephrine|Epinephrine 5-10 mcg intravenous bolus
231169|NCT02428062|Drug|Norepinephrine|Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
231170|NCT02428062|Drug|Dopamine|Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
231171|NCT02428049|Radiation|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
231172|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^6 TCID50/mL.
231173|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^7 TCID50/mL.
231174|NCT02428010|Device|TMVR Implant|Implantation of the Twelve TMVR System
231223|NCT02427659|Behavioral|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
231603|NCT02424981|Device|Threshold inspiratory muscle training|Inspiratory muscle training
231175|NCT02427997|Behavioral|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
231176|NCT02427997|Behavioral|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
231177|NCT02427984|Other|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
231178|NCT02427984|Other|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of range of noise"
231179|NCT02427984|Other|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.~Determination of local/systemic reaction"
231180|NCT02427958|Drug|Leuprorelin|Suspension for injection.
231181|NCT02427945|Behavioral|Provision of information on safe water|A promoter from Evidence Action will visit the household and provide information on safe water.
231182|NCT02427945|Behavioral|Provision of information on safe water and child nutrition|A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
231183|NCT02427932|Drug|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
231184|NCT02427932|Drug|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
231185|NCT02427932|Drug|Gentamicin|Prescribed to non-pregnant participants
231186|NCT02427919|Drug|G-CSF|Comparison of the effect of G-CSF use
231187|NCT02427893|Drug|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
231188|NCT02427893|Drug|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
231189|NCT02427880|Drug|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
231190|NCT02427880|Drug|Furosemide and Hydrochlorothiazide Followed by Furosemide|
231191|NCT02427867|Other|Remote ischemic preconditioning|
231192|NCT02427867|Other|no ischemic preconditioning|
231193|NCT02427854|Behavioral|Education by animated training video|Training performed by watching an animated educational video.
231194|NCT02427854|Procedure|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
231195|NCT02427841|Drug|Fluorouracil|Given IV
231196|NCT02427841|Drug|Gemcitabine Hydrochloride|Given IV
231197|NCT02427841|Radiation|Image Guided Radiation Therapy|Undergo IG-IMRT
231198|NCT02427841|Radiation|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
231199|NCT02427841|Other|Laboratory Biomarker Analysis|Correlative studies
231200|NCT02427841|Drug|Nab-paclitaxel|Given IV
231201|NCT02427841|Procedure|Therapeutic Conventional Surgery|Undergo surgery
231202|NCT02427828|Device|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
231203|NCT02427802|Drug|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
231204|NCT02427802|Other|Placebo|Matching collagen sponge
231205|NCT02427789|Other|Physical Exercise|physical exercise
231206|NCT02427776|Biological|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
231207|NCT02427763|Device|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
231208|NCT02427763|Other|collect saliva|the patient spit during 30 seconds in a small bottle
231209|NCT02427763|Other|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
231210|NCT02427763|Other|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
231211|NCT02427750|Biological|Aggripal®|TIV
231212|NCT02427737|Behavioral|Comfort Talk® Training|Personnel of MRI units is trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This entails 16 hrs classroom work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
231213|NCT02427724|Drug|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
231214|NCT02427724|Drug|lidocaine 7%/tetracaine 7% topical anesthetic|
231215|NCT02427724|Drug|placebo vehicle|
231216|NCT02427724|Device|Q-switched 532nm Laser|
231217|NCT02427711|Device|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
231218|NCT02427698|Procedure|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
231219|NCT02427698|Procedure|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
231220|NCT02427685|Device|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
231221|NCT02427672|Device|Transcranial direct current stimulation|
231224|NCT02427659|Behavioral|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
231225|NCT02427659|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
231226|NCT02427646|Drug|BoNT-A|A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
231227|NCT02427633|Other|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
231228|NCT02427633|Other|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
231229|NCT02427620|Drug|Cyclophosphamide|Given IV
231230|NCT02427620|Drug|Cytarabine|Given IV
231231|NCT02427620|Drug|Dexamethasone|Given PO or IV
231232|NCT02427620|Drug|Doxorubicin|Given IV
231233|NCT02427620|Drug|Doxorubicin Hydrochloride|Given IV
231234|NCT02427620|Drug|Ibrutinib|Given PO
231235|NCT02427620|Other|Laboratory Biomarker Analysis|Correlative studies
231236|NCT02427620|Drug|Methotrexate|Given IV
231237|NCT02427620|Biological|Rituximab|Given IV
231238|NCT02427620|Drug|Vincristine|Given IV
231239|NCT02427620|Drug|Vincristine Sulfate|Given IV
231240|NCT02427607|Drug|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
231241|NCT02427594|Drug|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
231242|NCT02427594|Other|Controlled diet|Diet without sodium bicarbonate supplementation
231243|NCT02427581|Biological|Personalized synthetic long peptide vaccine (Poly ICLC)|
231244|NCT02427581|Drug|Poly ICLC|
231245|NCT02427568|Drug|MDMA|Subjects undergo two day-long experimental sessions of psychotherapy
231246|NCT02427568|Drug|Placebo|Subjects undergo two day-long experimental sessions of psychotherapy
231247|NCT02427555|Other|Barley kernel bread|3 days intervention with barley kernel bread
231248|NCT02427555|Other|white wheat bread|3 days intervention with white wheat bread
231249|NCT02427542|Other|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
231250|NCT02427542|Other|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
231251|NCT02427529|Drug|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
231252|NCT02427529|Drug|Placebo|
231253|NCT02427529|Other|Low calorie diet|
231254|NCT02427503|Procedure|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
231255|NCT02427490|Behavioral|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
231256|NCT02427490|Other|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
231257|NCT02427477|Device|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
231258|NCT02427477|Device|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
231259|NCT02427464|Biological|VM202|gene therapy
231260|NCT02427464|Other|placebo|
231261|NCT02427451|Drug|Bcl-2 Inhibitor GDC-0199|Given PO
231262|NCT02427451|Biological|Obinutuzumab|Given IV
231263|NCT02427451|Drug|Ibrutinib|Given PO
231264|NCT02427451|Other|Pharmacological Study|Correlative studies
231265|NCT02427451|Other|Laboratory Biomarker Analysis|Correlative studies
231266|NCT02427451|Other|Quality-of-Life Assessment|Ancillary studies
231267|NCT02427438|Other|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
231268|NCT02427438|Other|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
231269|NCT02427425|Device|TENS|
231270|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
231271|NCT02427412|Drug|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
231272|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
231273|NCT02427399|Other|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
231274|NCT02427399|Other|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
231275|NCT02427399|Other|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
231276|NCT02427399|Other|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
231277|NCT02427386|Drug|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
231278|NCT02427386|Drug|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
231279|NCT02427373|Dietary Supplement|fish oil ethyl ester|
231280|NCT02427373|Dietary Supplement|fish oil triglyceride|
231281|NCT02427373|Dietary Supplement|krill oil|
231282|NCT02427347|Other|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
231283|NCT02427347|Other|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
231284|NCT02427334|Drug|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
231285|NCT02427334|Drug|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
231286|NCT02427334|Drug|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
231287|NCT02427321|Device|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
231288|NCT02427308|Drug|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
231289|NCT02427295|Drug|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:~Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.~Frequency: every 4 weeks.~Route of administration: IM injection."
231290|NCT02427282|Device|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
231291|NCT02427282|Device|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
231292|NCT02427269|Other|Specimen Collection|"1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.~Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),~Two biopsies from normal squamous epithelium, and~One biopsy from each area of esophageal nodularity seen during the procedure~Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.~Up to 4 cytology brushes during the procedure."
231293|NCT02427256|Device|Device: Topcon Specular Microscope SP-1P|Device: Topcon Specular Microscope SP-1P
231294|NCT02427243|Drug|Crenezumab|
231295|NCT02427243|Drug|Crenezumab|
231296|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
231297|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.~At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.~Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
231298|NCT02427230|Drug|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
231299|NCT02427217|Biological|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
231300|NCT02427191|Other|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
231301|NCT02427191|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
231302|NCT02427178|Biological|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
231303|NCT02427165|Drug|RPL554|A dual PDE3 and PDE4 inhibitor
231304|NCT02427165|Drug|Salbutamol|a beta-2 receptor agonist
231305|NCT02427165|Drug|Placebo|RPL554 placebo containing no active ingredients
231306|NCT02427139|Device|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
231452|NCT02426112|Drug|Placebo|
231453|NCT02426099|Drug|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
231307|NCT02427126|Drug|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
231308|NCT02427126|Drug|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
231309|NCT02427113|Other|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
231310|NCT02427113|Other|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
231311|NCT02427100|Behavioral|Diet/Physical Activity|Diet/Physical Activity Intervention
231312|NCT02427087|Behavioral|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
231313|NCT02427087|Behavioral|Healthy Diet|Diet group (21) Recommendation for healthy diet.
231314|NCT02427074|Procedure|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
231315|NCT02427074|Procedure|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
231316|NCT02427061|Behavioral|Intervention Program (Manhood 2.0)|
231317|NCT02427061|Behavioral|Control Program (Job Skills Training)|
231318|NCT02427048|Behavioral|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
231319|NCT02427035|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
231320|NCT02427035|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
231321|NCT02427022|Other|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
231322|NCT02427009|Other|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
231323|NCT02427009|Procedure|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
231324|NCT02426996|Procedure|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
231325|NCT02426983|Device|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).~Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
231326|NCT02426983|Drug|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
231327|NCT02426957|Behavioral|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
231328|NCT02426944|Drug|NOAC|Medical arm, patients will be treated by NOAC.
231329|NCT02426944|Device|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
231330|NCT02426931|Device|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
231331|NCT02426931|Device|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
231332|NCT02426918|Drug|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
231333|NCT02426918|Drug|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
231334|NCT02426918|Drug|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
231335|NCT02426918|Drug|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
231336|NCT02426918|Drug|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
231337|NCT02426918|Drug|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
231338|NCT02426905|Drug|trientine dihydrochloride|A retrospective review of patients' medical records
231339|NCT02426892|Biological|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
231340|NCT02426892|Drug|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
231341|NCT02426879|Procedure|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
231342|NCT02426866|Drug|Efavirenz|
231343|NCT02426853|Behavioral|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
231344|NCT02426853|Other|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
231345|NCT02426853|Behavioral|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
231346|NCT02426840|Dietary Supplement|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
231347|NCT02426840|Dietary Supplement|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
231348|NCT02426827|Device|Spinal Cord Stimulation|
231349|NCT02426814|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
231350|NCT02426814|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
231351|NCT02426801|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
231352|NCT02426801|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
231353|NCT02426788|Behavioral|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to improve quality of life. The approach is transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
231354|NCT02426775|Drug|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
231355|NCT02426762|Procedure|Laparoscopic surgery|"Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:~4-5 trocar-produced incisions (5/10mm, minor incision)~1 sample-retrieval incision (4-5cm, small incision)"
231356|NCT02426762|Device|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
231357|NCT02426749|Device|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
231358|NCT02426749|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
231359|NCT02426736|Drug|Dexamethasone|
231360|NCT02426736|Drug|Bupivacaine|
231361|NCT02426736|Procedure|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
231362|NCT02426723|Drug|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
231363|NCT02426723|Drug|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
231364|NCT02426710|Device|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
231365|NCT02426697|Drug|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
231366|NCT02426697|Drug|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
231367|NCT02426684|Drug|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
231368|NCT02426671|Device|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
231369|NCT02426658|Other|Laboratory Biomarker Analysis|Correlative studies
231370|NCT02426658|Drug|Pemetrexed Disodium|Given IV
231371|NCT02426658|Other|Quality-of-Life Assessment|QOL studies
231372|NCT02426632|Drug|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
231373|NCT02426632|Drug|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
231374|NCT02426632|Drug|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
231375|NCT02426632|Drug|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
231376|NCT02426632|Drug|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
231377|NCT02426632|Drug|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
231378|NCT02426632|Drug|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
231379|NCT02426632|Drug|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
231380|NCT02426632|Drug|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
231381|NCT02426632|Drug|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
231382|NCT02426632|Drug|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
231383|NCT02426632|Drug|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
231384|NCT02426619|Device|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
231385|NCT02426619|Device|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
231386|NCT02426606|Other|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~white rice or white rice combined with 1 of 3 different lentil varieties or~white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
231387|NCT02426593|Device|IMED-4|Non-invasive novel lung hydration status sensor.
231388|NCT02426580|Behavioral|wechat|The wechat model of dietary education every 1 month by cellphone
231389|NCT02426567|Other|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
231390|NCT02426567|Other|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
231391|NCT02426554|Dietary Supplement|DDU-supplement|DDU: Vitamin D, DHA, Uridine
231392|NCT02426554|Dietary Supplement|Placebo supplement|
231393|NCT02426541|Drug|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
231394|NCT02426541|Drug|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
231395|NCT02426528|Other|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
231396|NCT02426515|Device|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
231397|NCT02426502|Drug|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
231398|NCT02426502|Drug|conversion of non-immunosuppressant drugs to once daily|"Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."
231399|NCT02426502|Drug|Conversion to once daily MPA|"Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~Patients taking azathioprine will be maintained on the same dose.~Patients will be maintained on the same prednisone dose."
231400|NCT02426489|Device|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
231401|NCT02426476|Behavioral|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
231402|NCT02426476|Behavioral|sham HRVB training|passive relaxation
231403|NCT02426463|Drug|propofol|
231404|NCT02426463|Drug|oxycodone|
233637|NCT02410837|Procedure|Electromagnetic Navigation Bronchoscopy|
231405|NCT02426450|Procedure|RFA|"RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
231406|NCT02426450|Drug|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
231407|NCT02426450|Drug|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
231408|NCT02426437|Other|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
231409|NCT02426437|Other|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
231410|NCT02426424|Device|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
231411|NCT02426424|Device|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
231412|NCT02426411|Drug|EMA401 200 mg|
231413|NCT02426411|Drug|EMA401 600 mg|
231414|NCT02426411|Drug|Placebo|
231415|NCT02426385|Device|FineVision Toric|Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
231416|NCT02426372|Biological|QBECO SSI|QBECO Site Specific Immunomodulators
231417|NCT02426359|Drug|Q301 Cream|
231418|NCT02426359|Drug|Placebo|
231419|NCT02426346|Behavioral|Behavioral weight control|Prescription of diet & physical activity and behavioral strategies for weight control
231420|NCT02426346|Behavioral|Group-based physical activity|Teens exercise for 60 minutes with their group
231421|NCT02426346|Behavioral|Group-based incentives|Adolescents earn reinforcements within group
231422|NCT02426346|Behavioral|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
231423|NCT02426333|Other|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
231424|NCT02426320|Other|Sedation Interruption Protocol|
231425|NCT02426320|Other|Standard Sedation Protocol|
231426|NCT02426307|Procedure|TAVR|TAVR: Transcatheter Aortic Valve Replacement
231427|NCT02426307|Procedure|SAVR|SAVR: surgical Aortic Valve Replacement
231428|NCT02426294|Drug|Pioglitazone|
231429|NCT02426294|Drug|Glimepiride|
231430|NCT02426281|Drug|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
231431|NCT02426281|Drug|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
231432|NCT02426255|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
231433|NCT02426242|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
231434|NCT02426229|Drug|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
231435|NCT02426203|Procedure|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
231436|NCT02426190|Other|Anti-gravity treadmill|The intervention is to ask study participants to ambulate using an anti-gravity treadmill that integrates patented, NASA Differential Air Pressure (DAP) technology -- a precise air calibration system -- to uniformly reduce gravitational load and body weight during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
231437|NCT02426190|Other|PENS - neuro-muscular stimulation|The intervention is to ask study participants to warm up using Patterned Electrical Neuromuscular Stimulation (PENS) - that closely replicates the body's normal muscle and nerve firing patterns -- on his/her surgical leg in conjunction with a recumbent bike or a Nu-step bike during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
231438|NCT02426190|Other|Anti-gravity treadmill & PENS - neuro-muscular stimulation|The intervention is to ask study participants to ambulate using an anti-gravity treadmill in conjunction with use of Patterned Electrical Neuromuscular Stimulation (PENS) during the warm-up phase of an outpatient physical therapy following a single total knee replacement.
231439|NCT02426190|Other|Recumbent or Nu-step bike|This is the active comparator of the trial that participants are asked to use either a recumbent or Nu-step bike normally seen in an outpatient physical therapy clinic to warm-up during a physical therapy session following a single total knee replacement.
231440|NCT02426177|Drug|Labetalol|anti-hypertensive agents
231441|NCT02426177|Drug|Nifedipine|calcium channel blocker ,for lowering blood pressure
231442|NCT02426164|Drug|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
231443|NCT02426164|Drug|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
231444|NCT02426151|Drug|BEPO-A|BEPO-A (Bioreactor manufacturing process)
231445|NCT02426151|Drug|REPO-A|REPO-A (Roller bottle manufacturing process)
231446|NCT02426138|Other|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
231447|NCT02426138|Other|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure for 12 weeks
231448|NCT02426125|Drug|Ramucirumab|Administered IV
231449|NCT02426125|Drug|Docetaxel|Administered IV
231450|NCT02426125|Drug|Placebo|Administered IV
231451|NCT02426112|Drug|Azithromycin|
231454|NCT02426099|Other|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
231455|NCT02426086|Drug|Imetelstat 9.4 milligram/kilogram (mg/kg)|Participants will receive imetelstat intravenously as 9.4 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end.
231456|NCT02426086|Drug|Imetelstat 4.7 mg/kg|Participants will receive imetelstat intravenously as 4.7 mg/kg every 3 weeks or at an escalated dose of 9.4 mg/kg based on investigator's discretion. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end.
231457|NCT02426060|Drug|Imrecoxib|
231458|NCT02426060|Drug|Warfarin|
231459|NCT02426047|Dietary Supplement|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
231460|NCT02426034|Drug|Apatinib|Apatinib Mesylate Tablets 850 mg qd p.o. The observation period is 28 days
231461|NCT02426021|Drug|MLN1202|Subcutaneous administration of MLN1202
231462|NCT02426021|Drug|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
231463|NCT02426008|Other|Growth Factors and Cytokine adding to embryo culture media|
231464|NCT02426008|Other|No Intervention|Nothing to Add
231465|NCT02425995|Procedure|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
231466|NCT02425982|Procedure|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
231467|NCT02425982|Procedure|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
231468|NCT02425969|Procedure|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
231469|NCT02425969|Drug|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
231470|NCT02425956|Device|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
231471|NCT02425943|Device|injectable poly-L-lactic acid Sculptra Aesthetic|
231472|NCT02425930|Procedure|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
231473|NCT02425930|Drug|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
231474|NCT02425917|Device|geko|neuromuscular electrostimulator
231475|NCT02425917|Device|IPC-Calf|IPC used on calf with or without geko
231476|NCT02425904|Drug|Clofarabine|Evaluation of response to clofarabine
231477|NCT02425891|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
231478|NCT02425891|Drug|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel will be administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
231479|NCT02425891|Drug|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
231480|NCT02425878|Drug|Ulipristal Acetate|
231481|NCT02425878|Drug|Placebo|
231482|NCT02425865|Drug|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
231483|NCT02425852|Drug|Azathioprine|Azathioprine alone versus Azathioprine and IFX
231484|NCT02425852|Drug|Infliximab|
231485|NCT02425852|Drug|Prednisolone|
231486|NCT02425852|Drug|Hydrocortisone|
231487|NCT02425839|Device|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
231488|NCT02425839|Device|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
231489|NCT02425826|Drug|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
231490|NCT02425826|Drug|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
231491|NCT02425826|Drug|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
231492|NCT02425813|Drug|Budesonide|Given PO
231493|NCT02425813|Drug|Methylprednisolone Sodium Succinate|Given IA and IV
231494|NCT02425800|Other|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
231495|NCT02425800|Other|Laboratory Biomarker Analysis|Correlative studies
231535|NCT02425514|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
231496|NCT02425787|Behavioral|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be conducted by the study PI or designee. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.~In order to ensure that the interviewer does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
231497|NCT02425787|Behavioral|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:~With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews &/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.~With Hematology/Oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
231498|NCT02425774|Procedure|Vagus stimulation|
231499|NCT02425774|Procedure|Sham stimulation|
231500|NCT02425774|Drug|Prucalopride|
231501|NCT02425774|Drug|Placebo|
231502|NCT02425761|Procedure|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
231503|NCT02425748|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
231504|NCT02425748|Biological|γδ T Cell|γδ T cells will be used against non small lung tumor.
231505|NCT02425748|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
231506|NCT02425735|Biological|DC-CIK cells|DC-CIK cells will be used against tumor cells.
231507|NCT02425735|Biological|γδ T cells|γδ T cells will be used against breast tumor.
231508|NCT02425735|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
231509|NCT02425722|Drug|ASP0456|oral
231510|NCT02425722|Drug|Placebo|oral
231511|NCT02425709|Drug|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
231512|NCT02425709|Drug|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
231513|NCT02425709|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
231514|NCT02425683|Drug|Regorafenib|120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
231515|NCT02425670|Other|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
231516|NCT02425657|Behavioral|Training of junior doctors|Training program
231517|NCT02425644|Drug|ponesimod|film-coated tablet with 20 mg ponesimod, administered orally once daily in the morning
231518|NCT02425644|Drug|teriflunomide|film-coated tablet with 14 mg teriflunomide, administered orally once daily in the morning
231519|NCT02425631|Device|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
231520|NCT02425605|Radiation|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
231521|NCT02425605|Drug|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
231522|NCT02425579|Drug|Inhaled Carbon Monoxide at 100ppm (4 participants)|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
231523|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
231524|NCT02425579|Drug|Inhaled Carbon Monoxide at 200ppm (4 participants)|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
231525|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)|Inhaled Medical Air for up to 90 minutes daily for 5 days
231526|NCT02425566|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
231527|NCT02425566|Drug|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
231528|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
231529|NCT02425553|Other|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
231530|NCT02425553|Other|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
231531|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
231532|NCT02425540|Device|Pelvic MRI|
231533|NCT02425527|Behavioral|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
231534|NCT02425527|Behavioral|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
231604|NCT02424968|Biological|Anti-Thymocyte Globulin|Given per standard institutional practice
231536|NCT02425514|Device|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
231537|NCT02425501|Drug|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
231538|NCT02425488|Behavioral|Nursing therapeutics education|"Educational intervention will focus on~Appropriate lifestyles~Early recognition of signs/prodromal symptoms of HF~Early recognition of signs of inflammation of the ICD-pocket~Good management of the device~1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
231539|NCT02425475|Device|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
231540|NCT02425462|Drug|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
231541|NCT02425449|Drug|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
231542|NCT02425436|Drug|Ginkgo Biloba Extract|
231543|NCT02425436|Other|Placebo|
231544|NCT02425423|Dietary Supplement|New thickened formula|
231545|NCT02425410|Other|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
231546|NCT02425410|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
231547|NCT02425397|Genetic|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
231548|NCT02425397|Genetic|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
231549|NCT02425384|Behavioral|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
231550|NCT02425384|Behavioral|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
231551|NCT02425384|Other|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
231552|NCT02425371|Other|Screening and treatment of comorbidities|Screening and treatment of comorbidities
231553|NCT02425371|Other|Placebo Comparator|No screening of comorbidities
231554|NCT02425358|Other|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
231555|NCT02425358|Other|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
231556|NCT02425358|Other|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
231557|NCT02425358|Other|PCI only|The saline was intracoronary infusion with the use of microtubular.
231558|NCT02425345|Behavioral|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.The intervention is conducted primarily by mail with website support and resources available.
231559|NCT02425332|Device|Lokomat gait trainer|
231560|NCT02425306|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
231561|NCT02425306|Drug|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
231562|NCT02425306|Drug|polyICLC|polyICLC, local adjuvant
231563|NCT02425306|Drug|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
231564|NCT02425293|Behavioral|asthma patient education|
231565|NCT02425280|Behavioral|Narrative Exposure Therapy|
231566|NCT02425280|Behavioral|Treatment as Usual|
231600|NCT02425020|Dietary Supplement|Carbohydrate|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
231601|NCT02425007|Device|Incentive spirometry|
231602|NCT02424994|Other|No intervention|
231605|NCT02424968|Drug|Cyclosporine|Given PO
231567|NCT02425267|Other|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
231568|NCT02425254|Drug|Intravenous paracetamol|1000mg intravenous solution for infusion
231569|NCT02425254|Drug|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
231570|NCT02425241|Biological|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
231571|NCT02425241|Biological|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10^10 vp at week 12.
231572|NCT02425241|Biological|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10^8 pfu at week 20
231573|NCT02425241|Drug|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
231574|NCT02425241|Other|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
231575|NCT02425228|Device|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
231576|NCT02425202|Drug|Ketamine|Post-operative continuous infusion until 0600 the next day
231577|NCT02425202|Other|Saline infusion|Post-operative continuous infusion until 0600 the next day
231578|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline"
231579|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
231580|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
231581|NCT02425163|Device|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
231582|NCT02425163|Procedure|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
231583|NCT02425150|Procedure|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
231584|NCT02425150|Procedure|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
231585|NCT02425137|Drug|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
231586|NCT02425124|Behavioral|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
231587|NCT02425111|Drug|Vedolizumab|Vedolizumab intravenous injection
231588|NCT02425098|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
231589|NCT02425098|Biological|Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)|High-dose TDV subcutaneous injection
231590|NCT02425085|Procedure|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
231591|NCT02425085|Procedure|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
231592|NCT02425072|Device|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
231593|NCT02425059|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
231594|NCT02425059|Device|NanoKnife|
231595|NCT02425046|Behavioral|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
231596|NCT02425046|Behavioral|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
231597|NCT02425033|Procedure|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
231598|NCT02425020|Dietary Supplement|Meat Protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
231599|NCT02425020|Dietary Supplement|Whey protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
231606|NCT02424968|Drug|Mycophenolate Mofetil|Given PO
231607|NCT02424968|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic HSCT
231608|NCT02424968|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
231609|NCT02424968|Biological|Therapeutic Allogeneic Lymphocytes|Receive CD8+ memory T-cells via IV
231610|NCT02424968|Radiation|Total Nodal Irradiation|Undergo TLI
231611|NCT02424955|Drug|perflutren lipid microspheres|
231612|NCT02424955|Diagnostic Test|3D ultrasound|
231613|NCT02424942|Drug|placebo|"Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular"
231614|NCT02424942|Drug|GZ389988|"Pharmaceutical form:suspension for injection~Route of administration: intraarticular"
231615|NCT02424929|Procedure|Sedation|Propofol anesthesia administered during entire surgery.
231616|NCT02424929|Procedure|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
231617|NCT02424916|Biological|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
231618|NCT02424890|Other|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
231619|NCT02424877|Procedure|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
231620|NCT02424864|Other|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
231621|NCT02424851|Drug|Bortezomib|"1.3 mg/m2 subcutaneously* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).~*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
231622|NCT02424851|Drug|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
231623|NCT02424851|Drug|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
231624|NCT02424851|Drug|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
231625|NCT02424838|Procedure|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
231626|NCT02424838|Device|22 gauge needle|
231627|NCT02424838|Device|25 gauge needle|
231628|NCT02424825|Behavioral|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
231629|NCT02424812|Behavioral|Lifebuoy School of Five Handwashing Intervention|
231630|NCT02424799|Drug|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
231631|NCT02424799|Drug|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
231632|NCT02424799|Drug|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
231633|NCT02424786|Other|STOPP/START criteria|Evaluation of medication lists
231634|NCT02424773|Device|High Flow Nasal Canula (HFNC)|
231635|NCT02424773|Device|Venturi mask|
231636|NCT02424773|Drug|Oxygen|
231637|NCT02424760|Device|Shoulder hemi-arthroplasty|
231638|NCT02424747|Other|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
231639|NCT02424734|Drug|Ceftaroline Fosamil|Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).
231640|NCT02424734|Drug|Ampicillin|Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.
231641|NCT02424734|Drug|Aminoglycoside|Optional, will be given as per local standard of care.
231642|NCT02424708|Drug|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
231643|NCT02424708|Drug|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
231644|NCT02424708|Drug|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
231645|NCT02424695|Drug|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:~600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
231646|NCT02424695|Drug|Placebo|
231647|NCT02424682|Other|No intervention|No intervention administered in this study
231648|NCT02424669|Other|ALS Functional rating Scale-revised (ALS FRS-R)|
231649|NCT02424669|Other|slow vital capacity|
231650|NCT02424669|Other|Blood sample|
231651|NCT02424669|Other|Cerebrospinal Fluid (CSF) sample|
231652|NCT02424656|Procedure|MRI|EEG-functional MRI, structural MRI, diffusion MRI
231653|NCT02424656|Procedure|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
231654|NCT02424656|Procedure|FDG-PET|
231655|NCT02424656|Other|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
231656|NCT02424643|Behavioral|Monetary Incentive|$20 Amazon.com gift card
231692|NCT02424396|Drug|Placebo|
231657|NCT02424643|Behavioral|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
231658|NCT02424643|Behavioral|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
231659|NCT02424630|Device|Ultrasound-guided ISB|ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
231660|NCT02424630|Device|Arthroscopy-guided SSNB|At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
231661|NCT02424630|Drug|Placebo|
231662|NCT02424630|Drug|Ropivacaine|All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
231663|NCT02424617|Drug|erlotinib|erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
231664|NCT02424617|Drug|BGB324|Study investigational product.
231665|NCT02424591|Drug|Ketamine|Infusion at a rate of 10 mcg/kg/min
231666|NCT02424591|Other|Placebo|Placebo IV
231667|NCT02424578|Drug|Diclofenac Capsules low dose|
231668|NCT02424578|Drug|Diclofenac Capsules high dose|
231669|NCT02424565|Drug|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
231670|NCT02424565|Other|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
231671|NCT02424552|Drug|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
231672|NCT02424552|Drug|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
231673|NCT02424539|Drug|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
231674|NCT02424539|Other|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
231675|NCT02424526|Other|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
231676|NCT02424526|Device|Treadmill|
231677|NCT02424513|Radiation|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
231678|NCT02424500|Device|d-Nav|Insulin dosage is adjusted as required
231679|NCT02424500|Device|Blood Glucose Monitoring System|Insulin dosage is adjusted as required
231680|NCT02424487|Procedure|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
231681|NCT02424474|Device|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
231682|NCT02424474|Biological|Regular serum screening|
231683|NCT02424461|Drug|Ceftriaxone|1 injection 1 g per day for 2 days
231684|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
231685|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
231686|NCT02424461|Drug|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
231687|NCT02424448|Procedure|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
231688|NCT02424435|Drug|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
231689|NCT02424409|Behavioral|2: Intervention|"The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.~A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter~A written action plan with formalized recommendations for the patient~A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.~The ED doctor at discharge will explain all these documents orally~Recommendations for an early contact with the general practitioner;~Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
231690|NCT02424409|Behavioral|1: Control|patients without discharge protocol
231691|NCT02424396|Drug|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
231693|NCT02424383|Device|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.~The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
231694|NCT02424370|Procedure|TAVR|Percutaneous aortic valve replacement
231695|NCT02424357|Drug|5%povidone iodine ophthalmic solution|one drop of 5% povidone iodine instilled into the conjunctival fornix.
231696|NCT02424357|Drug|routine post-operative ophthalmic ointment|patient received a routine antibiotic/steroid ointment to operated eye at surgery completion
231697|NCT02424344|Drug|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
231698|NCT02424344|Drug|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
231699|NCT02424331|Other|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
231700|NCT02424331|Other|Quiet Breathing|
231701|NCT02424318|Drug|Topiramate|topiramate 25mg twice 1 week -> topiramate 50mg twice 7 weeks
231702|NCT02424305|Drug|LEO 43204 gel 0.018%|
231703|NCT02424305|Drug|LEO 43204 gel 0.1%|
231704|NCT02424305|Drug|LEO 43204 gel 0.037%|
231705|NCT02424292|Other|Physical activity|Physical activity in a personalised program.
231706|NCT02424279|Procedure|Splanchnicectomy|
231707|NCT02424266|Device|None invasive imaging of the tear film (AdOM)|White light tomography imaging
231708|NCT02424253|Drug|ZPL-3893787|ZPL-3893787
231709|NCT02424253|Drug|Placebo|Matched Placebo
231710|NCT02424240|Other|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 & IGFBP-3 combination
231711|NCT02424214|Other|Artificial Oocyte activation|
231712|NCT02424214|Drug|Ca Ionophore|
231713|NCT02424214|Drug|Strontium Chloride|
231714|NCT02424201|Drug|Misoprostol|experimental
231715|NCT02424201|Drug|vitamin c|control
231716|NCT02424188|Other|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
231717|NCT02424175|Biological|Fecal Microbiota Transplantation|
231718|NCT02424162|Device|+2.75 diopters multifocal intraocular lens|
231719|NCT02424162|Device|+3.25 diopters multifocal intraocular lens|
231720|NCT02424149|Drug|Phenazopyridine|
231721|NCT02424136|Other|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
231722|NCT02424136|Other|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
231723|NCT02424136|Other|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures (Not required for those age less than 6 years).
231724|NCT02424136|Other|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures (Not required for those age less than 6 years).
231725|NCT02424136|Other|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
231726|NCT02424136|Other|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
231727|NCT02424136|Other|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
231728|NCT02424110|Procedure|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
231729|NCT02424110|Procedure|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
231730|NCT02424110|Device|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
231731|NCT02424110|Device|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
231732|NCT02424097|Drug|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste & MI Varnish- in-office:~varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)~- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
231733|NCT02424097|Drug|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:~Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
231734|NCT02424084|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
231735|NCT02424071|Drug|Melatonin|
231736|NCT02424071|Drug|placebo|
231737|NCT02424058|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
231738|NCT02424058|Behavioral|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
231739|NCT02424045|Drug|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
231740|NCT02424032|Behavioral|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
233638|NCT02410824|Device|stenfilcon A toric lens|toric contact lens
231741|NCT02424032|Behavioral|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
231742|NCT02424019|Drug|ILUVIEN 0.19 MG|
231743|NCT02424006|Device|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
231744|NCT02424006|Device|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
231745|NCT02423993|Behavioral|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
231746|NCT02423993|Device|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
231747|NCT02423993|Device|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
231748|NCT02423993|Procedure|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
231749|NCT02423993|Procedure|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
231750|NCT02423993|Procedure|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
231751|NCT02423993|Procedure|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
231752|NCT02423980|Drug|Glucagon|
231753|NCT02423967|Biological|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
231754|NCT02423967|Biological|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
231755|NCT02423954|Drug|Temsirolimus|
231756|NCT02423954|Drug|Irinotecan|
231757|NCT02423954|Drug|Irinotecan + capecitabine|
231758|NCT02423954|Drug|nivolumab|
231759|NCT02423941|Procedure|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
231760|NCT02423941|Procedure|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
231761|NCT02423928|Biological|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
231762|NCT02423928|Drug|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
231763|NCT02423928|Drug|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
231764|NCT02423915|Drug|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
231765|NCT02423915|Drug|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
231766|NCT02423915|Drug|Cyclophosphamide|50 mg/kg by vein on Day -8.
231767|NCT02423915|Radiation|Total Body Radiation|2 Gy delivered on Day -4.
231768|NCT02423915|Procedure|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^6/kg Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Fucosylated T-reg cells on Day -1."
231769|NCT02423915|Procedure|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
231770|NCT02423915|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
231771|NCT02423915|Drug|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
231772|NCT02423915|Procedure|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
232571|NCT02418429|Other|waxy maize starch|pancake test meal with waxy maize starch only
231773|NCT02423915|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
231774|NCT02423915|Procedure|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1.~Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1."
231775|NCT02423902|Biological|Ad-RTS-hIL-12|Approximately 1.0x10^12 viral particles (vp) per injection
231776|NCT02423902|Drug|Veledimex|7 oral doses of veledimex
231777|NCT02423889|Radiation|Radiotherapy|
231778|NCT02423876|Drug|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:~0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate~3 mL/hr RN bolus, to be used as needed based on pain ratings~3 mL/30 minutes patient bolus, which is available on patient demand."
231779|NCT02423876|Other|Intraoperative Complication Management and Prevention|Undergo ERP
231780|NCT02423876|Procedure|Pain Therapy|Undergo ERP
231781|NCT02423863|Biological|Hiltonol|"Wk 1 Days 1, 3 and 5: Poly-ICLC (Hiltonol®) 1 mg (0. 5 ml) IntraTumoral (priming treatment course). Weeks 2-25 Poly-ICLC (Hiltonol®) 1 mg (0.5 ml) IM twice a week with a 48-72 hour interval between the two injections, AND either:~No additional immunotherapy OR~ONLY ONE of the Anti-PD1 or anti-PDL-1 regimens will be administered, per manufacturer's dosing and clinical oncologist's discretion as follows: (Not to be Administered on the same day as Poly-ICLC [Hiltonol®]) Either Nivolumab, OR Pembrolizumab, OR Atezolizumab, OR Cemiplimab, OR Durvalumab"
231782|NCT02423850|Device|3D Wound Assessment Monitor (WAM) camera|Three-dimensional wound measurement (2D area, 3D area, perimeter, volume) using 3D-WAM camera
231783|NCT02423837|Drug|Rituximab, bendamustine|
231784|NCT02423824|Biological|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
231785|NCT02423811|Dietary Supplement|Fursultiamine|Use of Fursultiamine in addition to CCRT
231786|NCT02423798|Device|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
231787|NCT02423772|Behavioral|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
231788|NCT02423759|Drug|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
231789|NCT02423759|Drug|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
231790|NCT02423759|Drug|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
231791|NCT02423746|Behavioral|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.~Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
231792|NCT02423746|Behavioral|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.~Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
231793|NCT02423733|Other|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
231794|NCT02423720|Behavioral|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
231795|NCT02423707|Drug|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
231796|NCT02423707|Drug|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
231797|NCT02423694|Device|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5~1.0 mA"
231798|NCT02423694|Drug|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
231799|NCT02423681|Device|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
231800|NCT02423681|Device|Without ThermoSmart|ThermoSmart is switched off
233292|NCT02413255|Drug|TAK-020 Placebo|TAK-020 placebo-matching oral solution
231801|NCT02423668|Procedure|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
231802|NCT02423668|Procedure|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
231803|NCT02423668|Procedure|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
231804|NCT02423655|Other|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
231805|NCT02423655|Other|Algorithm for routine dialysis intervention|"Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.~Or patients have indications below: 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment"
231806|NCT02423642|Procedure|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation~Filter : AQUAMAX™ (Edwards Lifesciences)"
231807|NCT02423642|Procedure|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
231808|NCT02423629|Device|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
231809|NCT02423616|Other|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
231810|NCT02423603|Drug|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
231811|NCT02423603|Drug|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
231812|NCT02423603|Drug|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
231813|NCT02423590|Drug|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
231814|NCT02423590|Drug|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
231815|NCT02423590|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
231816|NCT02423577|Drug|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
231817|NCT02423577|Drug|Placebo|Placebo dry powder administered by nasal inhalation
231818|NCT02423564|Dietary Supplement|Digesta Lac|
231819|NCT02423564|Other|Placebo|
231820|NCT02423551|Other|MRE|MRE consumption
231821|NCT02423538|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
231822|NCT02423538|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
231823|NCT02423525|Drug|Afatinib|
231824|NCT02423486|Device|Electromagnetic stimulation therapy (BIOCON-2000)|
231825|NCT02423486|Device|Electromagnetic stimulation therapy with biofeedback|
231826|NCT02423473|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
231827|NCT02423473|Procedure|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
231828|NCT02423460|Other|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
231829|NCT02423447|Device|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
231830|NCT02423447|Device|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
231831|NCT02423434|Other|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.~In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
231832|NCT02423421|Other|Faecal microbiota transplantation|Human Stool.
231833|NCT02423408|Drug|TNX-201|TNX-201 capsule
231834|NCT02423408|Drug|Placebo|Placebo capsule
231835|NCT02423395|Drug|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
231836|NCT02423395|Drug|Placebo|calcium in muscle cramps in cirrhotic patients
231837|NCT02423382|Procedure|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
231838|NCT02423369|Procedure|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
231839|NCT02423369|Other|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
231840|NCT02423369|Other|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
231841|NCT02423356|Procedure|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
231842|NCT02423343|Drug|Galunisertib|Administered orally
231843|NCT02423343|Drug|Nivolumab|Administered IV
231844|NCT02423330|Device|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
231845|NCT02423317|Device|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
231846|NCT02423317|Device|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
231847|NCT02423304|Genetic|blood samples collected from all patients|blood samples collected from brachial pluxes
231848|NCT02423291|Drug|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
231849|NCT02423278|Procedure|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.~All lymph nodes around stomach (station 1&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
231850|NCT02423278|Procedure|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.~Lymph nodes around stomach (station 1&2 LNs) and para-aortic lymph nodes must be removed during the operation."
231851|NCT02423278|Drug|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:~S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
231852|NCT02423265|Drug|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
231853|NCT02423265|Drug|Placebo|Matching placebo: up-titration after 1 week
231854|NCT02423252|Behavioral|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
231855|NCT02423252|Other|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
231856|NCT02423239|Drug|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
231857|NCT02423239|Drug|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
231858|NCT02423239|Drug|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
231859|NCT02423239|Drug|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
231860|NCT02423226|Procedure|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
231861|NCT02423226|Drug|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
231862|NCT02423200|Drug|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
231863|NCT02423187|Other|No Intervention|
231864|NCT02423174|Procedure|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
231865|NCT02423174|Device|FMwand Surgical System|
231866|NCT02423148|Drug|Indocyanine green (ICG)|
231867|NCT02423148|Device|FluoSCOPE|
231868|NCT02423135|Biological|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
231869|NCT02423122|Drug|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
231870|NCT02423109|Device|fanfilcon A|contact lens
231871|NCT02423109|Device|enfilcon A|contact lens
231872|NCT02423096|Drug|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
231873|NCT02423083|Drug|Guanabenz|
231874|NCT02423057|Drug|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
231875|NCT02423018|Drug|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
231876|NCT02423018|Drug|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
231877|NCT02423005|Device|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
231878|NCT02423005|Device|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
231879|NCT02422979|Drug|RM-1929|Dose-escalation, fixed low fluency light application study to determine the drug dose that can be safely given to saturate the epidermal growth factor receptor (EGFR) at the tumor
231880|NCT02422979|Device|Photoimmunotherapy|Light dose-escalation, fixed drug dosing infusion study to determine the optimal light application, in combination with the Part I drug dose, needed to achieve clinical response with an acceptable safety profile.
231881|NCT02422966|Drug|Paracetamol|
231882|NCT02422966|Drug|Ibuprofen|
231883|NCT02422953|Dietary Supplement|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of Wheat Soya Blend (WSB) will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
231884|NCT02422953|Dietary Supplement|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
231885|NCT02422953|Dietary Supplement|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of Micronutrient Powders (MNP) in alternate days
231886|NCT02422953|Behavioral|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
231887|NCT02422940|Drug|dalfampridine-ER 7.5 mg|
231888|NCT02422940|Drug|dalfampridine-ER 10 mg|
231889|NCT02422927|Dietary Supplement|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
231890|NCT02422927|Other|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
231891|NCT02422927|Other|Placebo|placebo
231892|NCT02422914|Behavioral|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
231893|NCT02422914|Behavioral|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.~The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
231894|NCT02422914|Behavioral|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
231895|NCT02422901|Drug|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
231896|NCT02422888|Drug|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
231897|NCT02422888|Drug|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
231898|NCT02422862|Other|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
231899|NCT02422849|Other|hospital specialist|
231900|NCT02422849|Other|General Practitioner|
231901|NCT02422836|Other|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
231902|NCT02422823|Drug|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
231903|NCT02422823|Drug|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
231904|NCT02422823|Drug|Epinephrine|
231905|NCT02422797|Drug|DTG 50 mg|Participants will take one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet will contain 52.62 mg dolutegravir sodium salt, which is equivalent to 50 mg dolutegravir free acid.
231906|NCT02422797|Drug|RPV 25 mg|Participants will take one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet will contain 27.5 mg of rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.
231907|NCT02422797|Drug|CAR|CAR will include following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
231908|NCT02422784|Dietary Supplement|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
231909|NCT02422784|Dietary Supplement|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
231910|NCT02422784|Dietary Supplement|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
231911|NCT02422771|Other|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
231912|NCT02422758|Device|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative & Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
231913|NCT02422758|Other|Passive Prewarming|
231914|NCT02422745|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 600 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
231915|NCT02422745|Dietary Supplement|Multivitamin|Multivitamin
231916|NCT02422745|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
231917|NCT02422745|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
231918|NCT02422732|Other|Neuropsychological assessments|"IQ (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
231919|NCT02422732|Radiation|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
231920|NCT02422732|Genetic|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
231921|NCT02422719|Drug|Radotinib|Radotinib 400mg bid
231922|NCT02422706|Drug|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
231923|NCT02422706|Drug|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
231924|NCT02422706|Drug|Omeprazole|Omeprazole 20 twice daily
231925|NCT02422706|Drug|Clarithromycin|KLacid twice daily
231926|NCT02422706|Drug|Levofloxacin|Tavanic. Tavacin
231927|NCT02422706|Drug|Doxicycline|Vibramycin 100 mg twice daily
231928|NCT02422693|Other|Aquatic Exercises|Exercises performed in the water.
231929|NCT02422693|Other|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
231930|NCT02422680|Procedure|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
231931|NCT02422667|Other|Patient Registry|Orthopedic Data Registry
231932|NCT02422654|Drug|eliglustat|"Pharmaceutical form:liquid formulation~Route of administration: oral without ingestion"
231933|NCT02422641|Drug|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
231934|NCT02422615|Drug|Ribociclib|Riblociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle)
231935|NCT02422615|Drug|fulvestrant|Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
231936|NCT02422615|Drug|Ribociclib placebo|Riblociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle)
231937|NCT02422602|Drug|Xarelto|Taking conventional charge
231938|NCT02422602|Other|Experimental: Personalized information intervention|
231939|NCT02422589|Drug|ceritinib|
231940|NCT02422589|Drug|warfarin|
231941|NCT02422589|Drug|midazolam|
231942|NCT02422576|Other|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
231943|NCT02422576|Other|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
231944|NCT02422576|Other|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
231945|NCT02422576|Other|Thicken Up clear: TUC|
231946|NCT02422563|Procedure|hysterectomy|radical hysterectomy
231947|NCT02422563|Radiation|Radiation|
231948|NCT02422563|Drug|Cisplatin|
231949|NCT02422563|Drug|Paclitaxel|
231950|NCT02422563|Drug|Carboplatin|
231951|NCT02422563|Drug|Ifosfamide|
231952|NCT02422550|Device|MRI|Participants enrolled on this protocol may undergo multiple MRI examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
231953|NCT02422537|Dietary Supplement|Unmodified wheat bran|
231954|NCT02422537|Dietary Supplement|Wheat bran with reduced particle size|
231955|NCT02422537|Dietary Supplement|Destarched pericarp-enriched wheat bran|
231956|NCT02422537|Dietary Supplement|No wheat bran fraction|
231957|NCT02422524|Drug|PA-824|PA-824 is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg PA-824 on day 1.
231989|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
231958|NCT02422511|Genetic|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
231959|NCT02422511|Other|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
231960|NCT02422498|Radiation|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
231961|NCT02422498|Drug|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
231962|NCT02422498|Procedure|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
231963|NCT02422485|Drug|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
231964|NCT02422472|Device|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
231965|NCT02422459|Behavioral|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
231966|NCT02422446|Drug|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
231967|NCT02422433|Device|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
231968|NCT02422420|Behavioral|Financial Incentives|Use of financial incentives to promote health behaviors.
231969|NCT02422407|Procedure|Biopsy|Salivary Gland
231970|NCT02422394|Drug|Eltrombopag|
231971|NCT02422381|Drug|MK-3475|Investigational drug.
231972|NCT02422381|Drug|Gemcitabine|Standard care drug.
231973|NCT02422368|Drug|Methylprednisolone + ASTED|"ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
231974|NCT02422368|Drug|Methylprednisolone +Placebo|"Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
231975|NCT02422355|Device|FNS|Surgical intervention using the FNS
231976|NCT02422342|Device|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).~The data from the oximeter will be sent by Bluetooth to the mobile application"
231977|NCT02422329|Behavioral|Questionnaires|Participants complete questionnaires at baseline and after intervention.
231978|NCT02422329|Behavioral|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
231979|NCT02422329|Behavioral|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
231980|NCT02422316|Other|Non-contrast Cardiac CT scan|
231981|NCT02422303|Drug|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
231982|NCT02422290|Drug|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
231983|NCT02422277|Device|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.~-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
231984|NCT02422277|Drug|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
231985|NCT02422264|Biological|Infanrix hexa|• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
231986|NCT02422264|Drug|Prevnar13|• All subjects will receive Infanrix hexa co-administered with Prevenar13* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. *In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
231987|NCT02422251|Device|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
231988|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
231990|NCT02422225|Device|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients~tDCS intervention]~Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany~Stimulation site <Experimental group>~Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit~Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex~Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit <Control group> Sham stimulation"
231991|NCT02422225|Device|Sham Eldith DC-STIMULATOR|
231992|NCT02422212|Other|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
231993|NCT02422199|Drug|pyrotinib|
231994|NCT02422199|Drug|Lapatinib|
231995|NCT02422199|Drug|capecitabine|
231996|NCT02422186|Drug|Esketamine|All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
231997|NCT02422186|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
231998|NCT02422186|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
231999|NCT02422186|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
232000|NCT02422186|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
232001|NCT02422186|Drug|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
232002|NCT02422173|Device|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
232003|NCT02422173|Device|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
232004|NCT02422173|Device|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
232005|NCT02422173|Device|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
232006|NCT02422160|Other|No interventions are planned|No interventions are planned
232007|NCT02422147|Procedure|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
232008|NCT02422134|Other|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
232009|NCT02422121|Drug|RNS60|
232010|NCT02422121|Drug|Placebo|
232011|NCT02422108|Drug|Denosumab|
232012|NCT02422095|Procedure|EUS of pancreatic cyst lesion|All pancreatic cyst lesions evaluated by EUS will be documented in this registry. Information collected will include patient demographics, pancreatic cyst or fluid collection characteristics, tests undertaken on cyst contents and follow-up data.
232013|NCT02422082|Dietary Supplement|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
232014|NCT02422082|Dietary Supplement|Placebo|Dietary supplementation with placebo twice daily for 12 months
232015|NCT02422056|Drug|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
232016|NCT02422056|Drug|Saline|Infusion of saline in the same rate used for the intervention group
232017|NCT02422043|Other|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
232018|NCT02422030|Drug|Lipitor Tab. 40mg|
232019|NCT02422030|Drug|Trilipix 135mg|
232020|NCT02422017|Drug|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest
232021|NCT02422017|Other|Local care treatment|Local care treatment with dressing compression in accordance with standards applied every other day
232022|NCT02422004|Other|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
232023|NCT02422004|Other|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
232024|NCT02421991|Behavioral|Telephone Delivered Intervention|
232025|NCT02421965|Behavioral|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
232026|NCT02421965|Behavioral|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
232027|NCT02421939|Drug|gilteritinib|tablet, oral
232028|NCT02421939|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
232029|NCT02421939|Drug|Azacitidine|SC or IV injection
232030|NCT02421939|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
232031|NCT02421939|Drug|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
232032|NCT02421926|Drug|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
232033|NCT02421913|Drug|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
232034|NCT02421900|Other|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
232035|NCT02421887|Drug|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
232036|NCT02421887|Other|Placebo|Placebo
232037|NCT02421874|Behavioral|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
232038|NCT02421874|Behavioral|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
232039|NCT02421861|Behavioral|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
232040|NCT02421861|Other|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C&L service; (2) referral to psychiatry C&L service; or (3) pharmacologic management.
232041|NCT02421835|Dietary Supplement|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
232042|NCT02421835|Dietary Supplement|Placebo|700 mg Maltodextrin per day
232043|NCT02421822|Other|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
232044|NCT02421770|Other|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
232045|NCT02421770|Other|placebo|
232046|NCT02421757|Device|Fischell Transcutaneous Magnetic Stimulation Pain Treatment Device|Transcutaneous Magnetic Stimulation
232047|NCT02421757|Device|Placebo|The placebo Transcutaneous device
232048|NCT02421744|Behavioral|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
232049|NCT02421744|Behavioral|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
232050|NCT02421731|Device|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
232086|NCT02421458|Radiation|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
232051|NCT02421731|Other|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
232052|NCT02421718|Radiation|Radiotherapy|
232053|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
232054|NCT02421692|Other|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
232055|NCT02421679|Drug|TNX-102 SL|TNX-102 Sublingual tablets
232056|NCT02421666|Behavioral|PNMI|eligible patients will receive patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care. Bilingually trained patient navigators will be recruited from our existing patient navigator training network and receive intensive training on HBV prevention, diagnosis and treatment management. The PN-led plus mobile phone text messaging intervention will offer three education sessions and serve as a liaison with respective clinics. The phone-based, text messaging will be designed by and for HBV patients who will craft appropriate reminders for follow up appointments or treatment, educational and motivational messages
232057|NCT02421653|Dietary Supplement|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
232058|NCT02421653|Dietary Supplement|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
232059|NCT02421653|Dietary Supplement|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
232060|NCT02421653|Dietary Supplement|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
232061|NCT02421653|Dietary Supplement|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
232062|NCT02421653|Dietary Supplement|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
232063|NCT02421640|Drug|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
232064|NCT02421640|Drug|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
232065|NCT02421627|Device|moxibustion|Mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin, keeping the spot warm and making it reddened, but not burnt.The temperature maintained at 43 ± 1℃。
232066|NCT02421627|Device|Placebo moxibustion|Placebo mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin (farther than the real moxibustion), keeping the temperature maintained at 37 ± 1℃。
232067|NCT02421614|Other|high-protein low-carbohydrate diet with high olive oil|
232068|NCT02421614|Other|high-protein low-carbohydrate diet with high sunflower oil|
232069|NCT02421601|Drug|Condoliase|1.25 U, intradiscal injection, one time
232070|NCT02421588|Drug|Lurbinectedin (PM01183)|
232071|NCT02421588|Drug|Pegylated liposomal doxorubicin (PLD)|
232072|NCT02421588|Drug|Topotecan|
232073|NCT02421575|Drug|Hydroxychloroquine|Given PO
232074|NCT02421575|Other|Laboratory Biomarker Analysis|Correlative studies
232075|NCT02421562|Procedure|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
232076|NCT02421549|Device|Unpaired remote monitoring transmitter|
232077|NCT02421536|Other|Vibrogent Smartphone Application|
232078|NCT02421523|Procedure|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of ~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
232079|NCT02421523|Procedure|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of ~30% of the subject's MVC. Subjects will be asked to perform ~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (~50% MVC). Similarly, if no damage has occurred at ~50% MVC, four more subjects exercise at ~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
232080|NCT02421523|Procedure|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
232081|NCT02421510|Drug|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
232082|NCT02421510|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
232083|NCT02421510|Drug|Placebo|Placebo, once daily, before the first meal of the day
232084|NCT02421484|Biological|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
232085|NCT02421471|Drug|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
232153|NCT02421003|Procedure|heart surgery|
232087|NCT02421458|Radiation|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
232088|NCT02421432|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
232089|NCT02421419|Drug|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
232090|NCT02421419|Drug|Xylocaine|a local anesthetic agent
232091|NCT02421419|Drug|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
232092|NCT02421406|Behavioral|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
232093|NCT02421406|Behavioral|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
232094|NCT02421393|Other|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
232095|NCT02421380|Drug|Hyperpolarized Pyruvate|
232096|NCT02421367|Biological|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
232097|NCT02421354|Other|Laboratory Biomarker Analysis|Correlative studies
232098|NCT02421354|Biological|Nivolumab|Given IV
232099|NCT02421354|Other|Quality-of-Life Assessment|Ancillary studies
232100|NCT02421341|Drug|Fentanyl|During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
232101|NCT02421341|Procedure|Catheters|A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
232102|NCT02421341|Other|Exercise|You will be asked to exercise, ride a stationary bike, at maximal exertion.
232103|NCT02421341|Radiation|DEXA|During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
232104|NCT02421341|Other|Pulmonary Function Tests|During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
232105|NCT02421341|Other|Blood Draw|You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
232106|NCT02421341|Other|Chemosensitivity Test|Using a bag you breath in and out your own air.
232107|NCT02421341|Drug|Placebo|
232108|NCT02421328|Device|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
232109|NCT02421328|Device|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
232110|NCT02421315|Behavioral|Exposure & Response Prevention (EX/RP) and when indicated medication treatment|Cognitive Behavioral Therapy (CBT) for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
232111|NCT02421302|Dietary Supplement|RUTF|This is ready-to-use-therapeutic-food
232112|NCT02421289|Drug|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
232113|NCT02421289|Drug|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
232114|NCT02421289|Other|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
232115|NCT02421276|Other|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
232116|NCT02421263|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
232117|NCT02421250|Device|Radical-7 Noninvasive Hgb Monitor|
232118|NCT02421237|Behavioral|Narrative Enhancement and Cognitive Therapy|
232119|NCT02421237|Behavioral|Supportive Group Therapy|
232120|NCT02421224|Behavioral|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
232154|NCT02420990|Behavioral|Medication Integration Protocol (MIP)|
232155|NCT02420990|Behavioral|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
232334|NCT02419846|Other|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
232121|NCT02421224|Behavioral|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
232122|NCT02421224|Behavioral|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
232123|NCT02421224|Behavioral|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
232124|NCT02421224|Behavioral|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
232125|NCT02421224|Behavioral|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
232126|NCT02421211|Drug|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
232127|NCT02421211|Drug|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
232128|NCT02421211|Drug|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
232129|NCT02421198|Behavioral|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
232130|NCT02421185|Drug|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.~Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
232131|NCT02421172|Biological|CJM112|CJM112 Fully human IgG1 monoclonal antibody
232132|NCT02421172|Drug|Placebo|
232133|NCT02421159|Behavioral|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
232134|NCT02421159|Behavioral|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
232135|NCT02421146|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
232136|NCT02421146|Device|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
232137|NCT02421133|Other|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.~The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.~During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
232138|NCT02421133|Other|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician…) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
232139|NCT02421120|Drug|Ceftolozane/Tazobactam|1 hour intravenous infusion
232140|NCT02421107|Other|Glysure CGM|
232141|NCT02421107|Other|iStat intermittent testing|
232142|NCT02421094|Drug|GR-MD-02|GM-MD-02 active
232143|NCT02421094|Drug|Placebo|Placebo
232144|NCT02421081|Procedure|vessel microsurgery|That is a surgery ro repair artery laceration.
232145|NCT02421081|Procedure|tendon repair|That is a surgery ro repair tendon cut.
232146|NCT02421081|Procedure|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
232147|NCT02421055|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
232148|NCT02421055|Procedure|Laparoscopic Sleeve Gastrectomy|
232149|NCT02421042|Drug|Lenvatinib|5- or 10-mg single oral dose of E7080, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
232150|NCT02421029|Drug|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
232151|NCT02421016|Device|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
232152|NCT02421016|Device|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
232156|NCT02420977|Drug|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT~Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
232157|NCT02420964|Other|video instruction|Patient Directed Video Instruction
232158|NCT02420964|Other|Nurse instruction|Nurse directed instruction
232159|NCT02420951|Drug|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
232160|NCT02420951|Other|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
232161|NCT02420938|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
232162|NCT02420938|Drug|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
232163|NCT02420925|Procedure|Celiac Plexus Block|Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
232164|NCT02420912|Drug|Ibrutinib|Given PO
232165|NCT02420912|Other|Laboratory Biomarker Analysis|Correlative studies
232166|NCT02420912|Biological|Nivolumab|Given IV
232167|NCT02420899|Drug|rosuvastatin|10mg/d or 20mg/d,po
232168|NCT02420886|Other|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
232169|NCT02420873|Drug|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
232170|NCT02420860|Biological|Elotuzumab|Given IV
232171|NCT02420860|Drug|Lenalidomide|Given PO
232172|NCT02420860|Other|Questionnaire Administration|Ancillary studies
232173|NCT02420847|Drug|Ixazomib|"Phase I Starting Dose of Ixazomib: 4.0 mg by mouth on Day 1 of every 14-day cycle.~Phase II Starting Dose of Ixazomib: MTD from Phase I."
232174|NCT02420847|Drug|Gemcitabine|"Phase I Starting Dose of Gemcitabine: 10 mg/m2/min by vein on Day 1 of each 14 day cycle.~Phase II Starting Dose of Gemcitabine: MTD from Phase I."
232175|NCT02420847|Drug|Doxorubicin|"Phase I Starting Dose of Doxorubicin: 33 mg/m2 by vein on Day 1 of each 14 day cycle.~Phase II Starting Dose of Doxorubicin: MTD from Phase I."
232176|NCT02420834|Other|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
232177|NCT02420834|Other|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
232178|NCT02420834|Other|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
232179|NCT02420834|Other|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
232180|NCT02420821|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle.
232181|NCT02420821|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle.
232182|NCT02420821|Drug|Sunitinib|Sunitinib will be administered at a dose of 50 mg once daily, orally via capsule, on Day 1 through Day 28 of each 42-day cycle.
232183|NCT02420795|Drug|Akt/ERK Inhibitor ONC201|Given PO
232184|NCT02420795|Other|Laboratory Biomarker Analysis|Correlative studies
232185|NCT02420795|Other|Pharmacological Study|Correlative studies
232186|NCT02420782|Drug|ASP6282|oral
232187|NCT02420782|Drug|Itraconazole|oral
232188|NCT02420782|Drug|Pilocarpine|oral
232189|NCT02420782|Drug|Placebo|oral
232190|NCT02420782|Drug|Midazolam|oral
232191|NCT02420756|Device|PET Scan|
232192|NCT02420743|Procedure|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
232193|NCT02420743|Procedure|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
232194|NCT02420730|Drug|AGN-232411|AGN-232411 topical ophthalmic solution
232195|NCT02420730|Drug|AGN-232411 Vehicle|Vehicle for AGN-232411 topical ophthalmic solution.
232196|NCT02420717|Drug|Cyclophosphamide|Given IV
232197|NCT02420717|Drug|Cytarabine|Given IV
232198|NCT02420717|Drug|Dasatinib|Given PO
232199|NCT02420717|Drug|Dexamethasone|Given PO or IV
232200|NCT02420717|Drug|Doxorubicin Hydrochloride|Given IV
232201|NCT02420717|Other|Laboratory Biomarker Analysis|Correlative studies
232202|NCT02420717|Drug|Leucovorin Calcium|Given IV or PO
232203|NCT02420717|Drug|Mercaptopurine|Given PO
232204|NCT02420717|Drug|Methotrexate|Given IV and PO
232205|NCT02420717|Drug|Prednisone|Given PO
232206|NCT02420717|Biological|Rituximab|Given IV
232207|NCT02420717|Drug|Ruxolitinib Phosphate|Given PO
232208|NCT02420717|Drug|Vincristine Sulfate|Given IV
232209|NCT02420704|Procedure|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
232210|NCT02420691|Drug|LEE011|600 mg by mouth daily on Days 1 - 21 of a 28 day cycle.
232211|NCT02420665|Drug|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
232212|NCT02420665|Device|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
232213|NCT02420665|Behavioral|Phone Call|Study staff follow up with participant by phone one month after procedure.
232214|NCT02420665|Procedure|Colposcopy|Colposcopy performed after visual inspection of cervix.
232215|NCT02420665|Drug|Acetic Acid|3 - 5% added to cervix before visual inspection.
232216|NCT02420652|Drug|Aspirin|Given PO
232217|NCT02420652|Other|Laboratory Biomarker Analysis|Correlative studies
232218|NCT02420652|Drug|Metformin Hydrochloride|Given PO
232219|NCT02420652|Other|Placebo|Given metformin hydrochloride placebo PO
232220|NCT02420652|Other|Placebo|Given aspirin placebo PO
232221|NCT02420639|Device|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
232222|NCT02420613|Other|Laboratory Biomarker Analysis|Correlative studies
232223|NCT02420613|Radiation|Radiation Therapy|Undergo radiation therapy
232224|NCT02420613|Drug|Temsirolimus|Given IV
232225|NCT02420613|Drug|Vorinostat|Given PO
232226|NCT02420587|Drug|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
232227|NCT02420587|Behavioral|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
232228|NCT02420574|Drug|albendazole BENDEX|randomized clinical trial with 2 parallel arms
232229|NCT02420574|Drug|albendazole OVIS|
232230|NCT02420561|Behavioral|Motivational Interviewing|"One in-person motivational interviewing session intervention that lasts for 45-minutes~Additional two 15-minute telephone booster sessions post in-person 45 minute sessions"
232231|NCT02420561|Behavioral|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
232232|NCT02420548|Behavioral|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
232233|NCT02420548|Behavioral|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
232234|NCT02420535|Behavioral|Immediately Receive Tool|
232235|NCT02420535|Behavioral|One Month Delay|
232236|NCT02420522|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
232237|NCT02420522|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
232238|NCT02420509|Drug|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
232239|NCT02420496|Drug|Enteral fish oil|
232240|NCT02420496|Drug|Ursodeoxycholic Acid|
232241|NCT02420496|Drug|Placebo|
232242|NCT02420483|Other|Cardiopulmonary resuscitation chest compressions|
232243|NCT02420457|Procedure|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
232244|NCT02420457|Drug|Epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
232245|NCT02420444|Biological|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
232246|NCT02420444|Biological|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
232247|NCT02420444|Biological|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
232248|NCT02420431|Behavioral|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
232249|NCT02420431|Behavioral|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
232250|NCT02420418|Dietary Supplement|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
232251|NCT02420418|Other|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
232252|NCT02420405|Procedure|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
232253|NCT02420405|Procedure|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
232254|NCT02420392|Drug|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
232255|NCT02420379|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
232256|NCT02420353|Drug|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
232257|NCT02420353|Drug|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
232258|NCT02420340|Behavioral|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
232259|NCT02420327|Drug|Placebo patch & placebo capsule|On this test day, cognition is assessed after administration of a placebo patch and a placebo capsule.
232260|NCT02420327|Drug|Placebo patch & galantamine capsule|On this test day, cognition is assessed after administration of a placebo patch and a galantamine capsule (4 mg p.o.).
232261|NCT02420327|Drug|Nicotine patch & placebo capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a placebo capsule.
232262|NCT02420327|Drug|Nicotine patch and galantamine capsule|On this test day, cognition is assessed after administration of a nicotine patch (7 mg/24 hrs) and a galantamine capsule (4 mg p.o.).
232263|NCT02420314|Drug|Paclitaxel|"Administered intravenously (IV)~Prescribed at 200 mg/m2 (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
232264|NCT02420314|Drug|Carboplatin|"Administered intravenously (IV)~Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~Given once every 21 days (i.e., one cycle)~Up to 4 cycles are administered depending on disease response"
232265|NCT02420314|Drug|Ascorbic Acid|"Administered intravenously (IV)~75g per infusion~Two infusions per week~1 cycle is 3 weeks~given up to 4 cycles~may be given while chemotherapy if delayed due to low counts"
232266|NCT02420301|Other|Tuina exercises|
232267|NCT02420301|Other|Placebo Tuina exercises|
232268|NCT02420288|Behavioral|Exercise Group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
232269|NCT02420275|Other|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
232270|NCT02420275|Device|"Luminette,Lucimed Belgium"|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
232271|NCT02420262|Drug|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
232272|NCT02420262|Drug|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
232273|NCT02420262|Drug|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
232274|NCT02420249|Behavioral|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong [in Chinese]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
232275|NCT02420236|Behavioral|High-intensity resistance training|
232276|NCT02420236|Behavioral|General physical activity|
232277|NCT02420236|Behavioral|Multidisciplinary rehabilitation program|
232278|NCT02420223|Drug|Propranolol|
232279|NCT02420210|Drug|Bendamustine Hydrochloride|Given IV
232280|NCT02420210|Biological|Obinutuzumab|Given IV
232281|NCT02420210|Drug|Dexamethasone|Given PO
232282|NCT02420210|Other|Quality-of-Life Assessment|Ancillary studies
232283|NCT02420210|Other|Laboratory Biomarker Analysis|Correlative studies
232284|NCT02420197|Behavioral|High-intensity resistance training|
232285|NCT02420197|Behavioral|General physical activity|
232286|NCT02420197|Behavioral|Multidisciplinary rehabilitation program|
232287|NCT02420184|Device|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
232288|NCT02420184|Other|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
232289|NCT02420171|Other|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
232290|NCT02420158|Device|Trans-cutaneous vagal nerve electrical stimulation|
232291|NCT02420145|Behavioral|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
232292|NCT02420132|Other|Ranibizumab|Ranibizumab administered as part of standard-of-care
232293|NCT02420119|Other|non interventional|
232294|NCT02420106|Procedure|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
232295|NCT02420093|Device|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
232296|NCT02420080|Drug|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
232297|NCT02420054|Behavioral|Intermittent fasting|Eating every other day for at total of 20 days.
232298|NCT02420054|Other|Time control|Time control period with no change in eating habits.
232299|NCT02420041|Procedure|Active comparator: Fluoroscopic Guided SIJ injection|"Needle entry point is in the lower one-third of the SIJ~Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry~Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ~1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake~Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine~Patient observed in recovery bay for 20 minutes and then discharged home"
232331|NCT02419846|Other|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
232332|NCT02419846|Procedure|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
232333|NCT02419846|Other|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
233444|NCT02412241|Procedure|Technical measure|Undergo standard CT scan
232300|NCT02420041|Procedure|Ultrasound Guided Sacroiliac Joint Injection|"Sterile preparation (with chlorhexidine) and drape~Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer~3 mL of 1% lidocaine is injected subcutaneously at site of needle entry~Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).~After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.~Patient observed in recovery bay for 20 minutes and then discharged home"
232301|NCT02420041|Device|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
232302|NCT02420041|Device|SonoSite S-nerve|
232303|NCT02420041|Device|iohexol|
232304|NCT02420041|Drug|triamcinolone/lidocaine|
232305|NCT02420028|Device|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
232306|NCT02420028|Device|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
232307|NCT02420015|Drug|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
232308|NCT02420015|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
232309|NCT02420015|Behavioral|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
232310|NCT02420015|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
232311|NCT02420015|Behavioral|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
232312|NCT02420015|Behavioral|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
232313|NCT02420002|Drug|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
232314|NCT02420002|Other|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
232315|NCT02420002|Procedure|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
232316|NCT02419976|Other|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.~Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
232317|NCT02419976|Device|Aeonose|
232318|NCT02419963|Procedure|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
232319|NCT02419963|Other|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
232320|NCT02419963|Other|Stool Sample|Stool sample to evaluate microbiome fingerprint.
232321|NCT02419950|Device|Fixation of mesh in TEP|An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
232322|NCT02419937|Drug|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
232323|NCT02419937|Drug|Placebo|Saline injection
232324|NCT02419924|Device|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
232325|NCT02419911|Procedure|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
232326|NCT02419911|Device|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
232327|NCT02419911|Device|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
232328|NCT02419872|Drug|Marketed antagonists|Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
232329|NCT02419859|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
232330|NCT02419859|Drug|Insulin, Asp(B28)-|a fast-acting analog of human insulin
232335|NCT02419846|Other|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
232336|NCT02419846|Other|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
232337|NCT02419833|Procedure|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
232338|NCT02419833|Procedure|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
232339|NCT02419833|Device|Coronary artery stenting|Implantation of coronary stents
232340|NCT02419820|Drug|APD791|Temanogrel
232341|NCT02419820|Drug|Clopidogrel|Clopidogrel
232342|NCT02419820|Drug|Aspirin|Aspirin
232343|NCT02419820|Drug|Placebo for APD791|Placebo for APD791
232344|NCT02419807|Drug|Indocyanine Green Solution|Given subdermally
232345|NCT02419807|Radiation|Technetium Tc-99m Sulfur Colloid|Given via injection
232346|NCT02419807|Procedure|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
232347|NCT02419807|Procedure|Axillary Lymph Node Biopsy|Undergo biopsy
232348|NCT02419794|Procedure|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
232349|NCT02419781|Procedure|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
232350|NCT02419781|Procedure|No endovascular therapy|
232351|NCT02419768|Other|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
232352|NCT02419755|Drug|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
232353|NCT02419755|Drug|Vorinostat|Vorinostat should be taken orally (PO) with food.
232354|NCT02419755|Drug|Mitoxantrone|Given by intravenous (IV) injection.
232355|NCT02419755|Drug|Cytarabine|Given by intravenous (IV) injection.
232356|NCT02419755|Drug|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
232357|NCT02419755|Drug|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
232358|NCT02419755|Drug|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
232359|NCT02419755|Drug|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
232360|NCT02419755|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
232361|NCT02419755|Drug|Mercaptopurine|Given orally (PO).
232362|NCT02419755|Drug|Doxorubicin|Given intravenously (IV).
232363|NCT02419742|Drug|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams*milliliter/minute [mg*mL/min]) multiplied by (Glomerular Filtration Rate [GFR] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
232364|NCT02419742|Drug|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
232365|NCT02419742|Drug|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
232366|NCT02419742|Drug|Doxorubicin|Participants will receive Doxorubicin 60 mg/m^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
232367|NCT02419742|Drug|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
232368|NCT02419742|Drug|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
232369|NCT02419729|Device|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
232370|NCT02419729|Drug|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
232371|NCT02419729|Drug|Placebo of Estrogen|Placebo of topical estrogen cream.
232372|NCT02419729|Device|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
232373|NCT02419716|Device|Cologuard|Prescription of Cologuard for at-home stool collection
232374|NCT02419703|Device|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
232457|NCT02419261|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
232458|NCT02419261|Procedure|Arthroscopic surgical repair of the anterior cruciate ligament|
232459|NCT02419235|Other|20% ethanol|Unmedicated 20% ethanol.
232375|NCT02419690|Behavioral|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
232376|NCT02419677|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
232377|NCT02419677|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
232378|NCT02419664|Procedure|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
232379|NCT02419651|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
232380|NCT02419651|Drug|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
232381|NCT02419651|Drug|Placebo|Women will receive a placebo 1 hour before the procedure
232382|NCT02419638|Drug|Rebif (IFN β-1a subcutaneous three times per week)|
232383|NCT02419638|Drug|Tecifdera (dimethyl fumarate)|
232384|NCT02419625|Behavioral|questionnaires|questionnaires , serum samples will be used
232385|NCT02419612|Drug|Saxagliptin|
232386|NCT02419612|Drug|Dapagliflozin|
232387|NCT02419612|Drug|Glimepiride|
232388|NCT02419612|Other|Placebo|
232389|NCT02419599|Other|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
232390|NCT02419599|Other|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
232391|NCT02419586|Other|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
232392|NCT02419573|Device|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
232393|NCT02419573|Device|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
232394|NCT02419560|Drug|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
232395|NCT02419547|Drug|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
232396|NCT02419547|Drug|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
232397|NCT02419547|Drug|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
232398|NCT02419547|Drug|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
232399|NCT02419534|Drug|Polyethylene glycol|Laxative to treat constipation
232400|NCT02419534|Drug|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
232401|NCT02419521|Device|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
232402|NCT02419508|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
232403|NCT02419508|Drug|Brinz/brim vehicle|Inactive ingredients used as a placebo for masking purposes
232404|NCT02419508|Drug|Prostaglandin analogue|
232405|NCT02419495|Drug|Capecitabine|Given PO
232406|NCT02419495|Drug|Carboplatin|Given IV
232407|NCT02419495|Drug|Cyclophosphamide|Given IV
232408|NCT02419495|Drug|Doxorubicin Hydrochloride|Given IV
232409|NCT02419495|Drug|Eribulin Mesylate|Given IV
232410|NCT02419495|Drug|Fluorouracil|Given IV
232411|NCT02419495|Drug|Irinotecan Hydrochloride|Given IV
232412|NCT02419495|Other|Laboratory Biomarker Analysis|Correlative studies
232413|NCT02419495|Drug|Leucovorin Calcium|Given IV
232414|NCT02419495|Biological|Nivolumab|Given IV
232415|NCT02419495|Drug|Olaparib|Given PO
232416|NCT02419495|Drug|Oxaliplatin|Given IV
232417|NCT02419495|Drug|Paclitaxel|Given IV
232418|NCT02419495|Biological|Pembrolizumab|Given IV
232419|NCT02419495|Drug|Pemetrexed Disodium|Given IV
232420|NCT02419495|Drug|Selinexor|Given PO
232421|NCT02419495|Drug|Topotecan Hydrochloride|Given IV
232422|NCT02419482|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
232423|NCT02419482|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
232424|NCT02419469|Drug|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.~Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.~Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
232425|NCT02419469|Drug|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
232460|NCT02419235|Other|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
232497|NCT02418988|Drug|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
233445|NCT02412241|Procedure|Technical measure|Undergo standard ultrasound
232426|NCT02419469|Drug|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.~Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.~Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.~Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.~Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.~Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
232427|NCT02419469|Drug|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
232428|NCT02419469|Drug|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.~Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.~Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.~Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.~Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
232429|NCT02419469|Drug|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.~Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.~Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
232430|NCT02419469|Drug|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.~Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
232431|NCT02419469|Drug|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
232432|NCT02419469|Drug|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
232433|NCT02419469|Drug|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
232434|NCT02419469|Drug|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
232435|NCT02419469|Drug|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.~Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
232436|NCT02419469|Drug|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
232437|NCT02419456|Drug|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
232438|NCT02419456|Drug|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
232439|NCT02419443|Drug|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
232440|NCT02419443|Drug|Placebo|Control group
232441|NCT02419430|Behavioral|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
232442|NCT02419430|Behavioral|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:~Joys of Life~Count your blessings~Think differenc, feel better~Exercising --> Happier~+ Exercising --> Sleep~Pre-Sleep routine~Eat that frog~Mindful Meditation"
232443|NCT02419430|Behavioral|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
232444|NCT02419417|Drug|BMS-986158|Specified dose on specified days
232445|NCT02419417|Biological|Nivolumab|Specified dose on specified days
232446|NCT02419391|Biological|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
232447|NCT02419391|Other|Placebo|Tris Buffered Saline, sterile
232448|NCT02419378|Drug|Alemtuzumab|
232449|NCT02419352|Drug|Sugammadex|
232450|NCT02419352|Drug|Neostigmine/atropine|
232451|NCT02419339|Procedure|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
232452|NCT02419326|Behavioral|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
232453|NCT02419313|Drug|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
232454|NCT02419313|Drug|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
232455|NCT02419300|Device|ultrasoungraphy|pelvic ultrasonography and Doppler
232456|NCT02419287|Drug|crizotinib|
232496|NCT02419001|Drug|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
232461|NCT02419222|Behavioral|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
232462|NCT02419209|Other|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
232463|NCT02419196|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
232464|NCT02419183|Other|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
232465|NCT02419183|Other|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
232466|NCT02419170|Procedure|Standard of care surgery|
232467|NCT02419170|Procedure|Apheresis|
232468|NCT02419170|Drug|Cyclophosphamide|
232469|NCT02419170|Biological|Personalized mature dendritic cell vaccine|
232470|NCT02419157|Drug|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
232471|NCT02419157|Drug|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
232472|NCT02419157|Device|Clearfil SE Bond|
232473|NCT02419157|Device|Xeno V|
232474|NCT02419144|Behavioral|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
232475|NCT02419131|Behavioral|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
232476|NCT02419131|Behavioral|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
232477|NCT02419131|Behavioral|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
232478|NCT02419118|Drug|Daratumumab|Treatment of myeloma patients with Daratumumab
232479|NCT02419118|Drug|Lenalidomide|Treatment of myeloma patients
232480|NCT02419118|Drug|Dexamethasone|Treatment of myeloma patients
232481|NCT02419105|Drug|Testosterone|transdermal gel, 75 mg daily
232482|NCT02419105|Drug|Colecalciferol|drink solution, 24000 IU once per month
232483|NCT02419105|Drug|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
232484|NCT02419105|Drug|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
232485|NCT02419053|Other|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
232486|NCT02419040|Procedure|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
232487|NCT02419040|Procedure|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
232488|NCT02419040|Procedure|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
232489|NCT02419027|Dietary Supplement|GI Flora|
232490|NCT02419027|Dietary Supplement|Placebo|
232491|NCT02419014|Device|Active CES Device Alpha-Stim®|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
232492|NCT02419014|Device|Sham Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
232493|NCT02419001|Drug|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
232494|NCT02419001|Drug|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
232495|NCT02419001|Drug|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
232498|NCT02418988|Drug|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
232499|NCT02418975|Other|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
232500|NCT02418975|Other|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
232501|NCT02418962|Biological|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
232502|NCT02418962|Other|Normal Saline|0.9% Sodium chloride solution for injection
232503|NCT02418949|Drug|Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
232504|NCT02418949|Drug|Placebo for Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.~Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
232505|NCT02418949|Other|Active Movement Practice (AMP)|Participants will alternate between active training with a custom video game and a robot active-assistive Voice and EMG-Driven Actuated (VAEDA) glove during active training occupational therapy.
232506|NCT02418949|Other|Passive Cyclical Stretching|Participants will wear the actuated device/glove for the duration of the training sessions (2 20-min stints followed by 10 min of rest) during which time the actuated glove will cyclically stretch the joints of the digits in the hand between flexion and extension while remaining passive/relaxed.
232507|NCT02418936|Device|gene diagnostic kit|
232508|NCT02418923|Other|Procedure: Blood specimen collection|Blood specimen collection
232509|NCT02418884|Drug|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
232510|NCT02418871|Device|FluidVisionTM AIOL with an improved injector|
232511|NCT02418858|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
232512|NCT02418845|Drug|SYM-1219|
232513|NCT02418845|Drug|Placebo|
232514|NCT02418832|Procedure|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
232515|NCT02418819|Drug|PF-06412562 3mg BID|PF-06412562
232516|NCT02418819|Drug|PF-06412562 9mg BID|PF-06412562
232517|NCT02418819|Drug|PF-06412562 45mg BID|PF-06412562
232518|NCT02418819|Other|Placebo|Placebo
232519|NCT02418806|Behavioral|Psychotherapy groups|
232520|NCT02418806|Behavioral|Self-help groups|
232521|NCT02418793|Drug|MOD-5014|Long Acting Factor VIIa
232522|NCT02418780|Other|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
232523|NCT02418767|Drug|MOD-4023|
232524|NCT02418767|Drug|Placebo|
232525|NCT02418754|Drug|REGN2176-3|
232526|NCT02418754|Drug|Intravitreal Aflibercept Injection (IAI)|
232527|NCT02418741|Other|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
232528|NCT02418728|Other|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
232529|NCT02418715|Other|Water Aerobics Training|
232530|NCT02418702|Drug|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
232531|NCT02418702|Other|placebo|20 patients will randomly be assigned a placebo
232532|NCT02418689|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
232533|NCT02418676|Drug|Gel with HPβCD-I complex|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
232534|NCT02418676|Drug|Gel with insulin|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
232535|NCT02418676|Drug|Control gel|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.~The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
232536|NCT02418663|Drug|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
232537|NCT02418650|Drug|ODM-201 300 mg tablet|
232538|NCT02418650|Drug|intravenous14C-ODM-201|
232539|NCT02418650|Drug|300 mg 14C-ODM-201 oral solution|
232540|NCT02418637|Other|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
232541|NCT02418624|Drug|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
232542|NCT02418598|Genetic|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10^11 vg/subject.
232543|NCT02418598|Genetic|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10^11 vg/subject.
232544|NCT02418585|Drug|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
232545|NCT02418585|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
232546|NCT02418585|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
232547|NCT02418585|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
232548|NCT02418585|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
232549|NCT02418585|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
232550|NCT02418572|Drug|Testosterone gel|"Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)"
232551|NCT02418572|Drug|Placebo gel|"Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.~The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.~Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG"
232552|NCT02418559|Drug|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
232553|NCT02418559|Drug|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2*300 mg) tablet orally once on Day 1 under fasted conditions.
232554|NCT02418559|Drug|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4*300 mg) tablet orally once on Day 1 under fasted conditions.
232555|NCT02418559|Drug|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
232556|NCT02418546|Behavioral|In-Person Nutritional Counseling by a Registered Dietitian|
232557|NCT02418546|Behavioral|Nutritional counseling using an e-Health Application|
232558|NCT02418533|Drug|menotropin|Menopur is used for controlled ovarian stimulation (COH)
232559|NCT02418533|Drug|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
232560|NCT02418520|Device|Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
232561|NCT02418507|Dietary Supplement|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
232562|NCT02418507|Other|Placebo|The placebo is administered to randomized healthy participants
232563|NCT02418494|Other|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
232564|NCT02418494|Other|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
232565|NCT02418481|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
232566|NCT02418481|Biological|γδ T Cell|γδ T cells will be used against breast tumor.
232567|NCT02418481|Biological|Combination|γδ T/DC-CIK cells will be used against breast tumor.
232568|NCT02418468|Drug|Indacaterol|Indacaterol 150µg capsules for inhalation daily
232569|NCT02418468|Drug|Placebo|Matching placebo indacaterol capsules for inhalation daily
232572|NCT02418429|Other|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
232573|NCT02418429|Other|Resistant Starch|pancake test meal with resistant starch only
232574|NCT02418429|Other|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
232575|NCT02418416|Other|Oocyte double chemical activation|Oocyte double chemical activation
232576|NCT02418403|Behavioral|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
232577|NCT02418403|Behavioral|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
232578|NCT02418390|Procedure|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
232579|NCT02418364|Other|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
232580|NCT02418364|Other|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
232581|NCT02418338|Other|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
232582|NCT02418325|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
232583|NCT02418325|Other|Liberation therapy|
232584|NCT02418312|Drug|histamine-2 receptor antagonist|famotidine 40 mg qd plus thienopyridine
232585|NCT02418312|Drug|Placebo|placebo plus thienopyridine
232586|NCT02418299|Device|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
232587|NCT02418286|Other|expose to any drugs or procedures based on traditional Korean medicine theory|There are no specific interventions associated with this registry as it is purely observational study of medical utilization.
232588|NCT02418273|Drug|denosumab|These subjects will receive two doses of denosumab.
232589|NCT02418260|Procedure|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
232590|NCT02418260|Procedure|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
232591|NCT02418260|Procedure|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
232592|NCT02418247|Drug|I131|
232593|NCT02418247|Drug|I123|
232594|NCT02418234|Other|mutation detection|
232595|NCT02418234|Other|ARMS and ddPCR|
232596|NCT02418234|Genetic|ctDNA analysis|
232597|NCT02418221|Dietary Supplement|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
232598|NCT02418221|Procedure|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure & pulse
232599|NCT02418208|Diagnostic Test|Performint EEG tests and BNA analysis|
232600|NCT02418195|Drug|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
232601|NCT02418182|Drug|Acetaminophen|Acetaminophen total dose of 1000mg
232602|NCT02418182|Drug|placebo|subjects randomized to this group will be given placebo tablets
232603|NCT02418156|Device|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair.
232604|NCT02418143|Device|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
232605|NCT02418130|Drug|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
232606|NCT02418130|Drug|Placebo|
232607|NCT02418117|Other|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
232608|NCT02418104|Drug|CHS-1701|
232609|NCT02418104|Drug|Pegfilgrastim (Neulasta)|
232610|NCT02418091|Behavioral|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
232611|NCT02418078|Procedure|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
232612|NCT02418065|Other|training on ergonomic bicycle|
232613|NCT02418065|Drug|Testosterone|
232614|NCT02418065|Drug|Oral nutritional supplementation|
232615|NCT02418065|Drug|n3 polyunsaturated fatty acid|
232616|NCT02418052|Procedure|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
232689|NCT02417428|Other|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
232617|NCT02418039|Dietary Supplement|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
232618|NCT02418039|Dietary Supplement|Normal protein|A normal protein diet will be administrated in patients with MHE.
232619|NCT02418026|Other|hypnosis|Conversational hypnotic induction and therapeutic suggestions
232620|NCT02418013|Other|Fresh cord blood(experimental group A)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
232621|NCT02418013|Other|Frozen cord blood(experimental group B)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
232622|NCT02418013|Other|Frozen plasma(experimental group C)|"Cord blood is administered through intravenous at CHA clinical trail institute.~Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
232623|NCT02418013|Other|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed."
232624|NCT02418000|Drug|E6201|Single Group Assignment
232625|NCT02417987|Other|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
232626|NCT02417987|Drug|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
232627|NCT02417987|Biological|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
232628|NCT02417974|Biological|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
232629|NCT02417961|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
232630|NCT02417948|Other|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
232631|NCT02417948|Other|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
232632|NCT02417935|Drug|Duloxetine|Administered orally
232633|NCT02417935|Drug|Pregabalin|Administered orally
232634|NCT02417935|Drug|Placebo|Administered orally
232635|NCT02417922|Other|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
232636|NCT02417922|Other|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
232637|NCT02417909|Other|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
232638|NCT02417896|Drug|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
232639|NCT02417883|Drug|Furosemide|Evaluate urinary excretion rate fo furosemide
232640|NCT02417870|Biological|aldesleukin|
232641|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
232642|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
232643|NCT02417844|Drug|tamsulosin (Astellas)|
232644|NCT02417844|Drug|Tamsulosin HCL|
232645|NCT02417831|Drug|tamsulosin capsules|
232646|NCT02417831|Drug|tamsulosin HCl|
232647|NCT02417818|Device|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
232648|NCT02417818|Device|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
232649|NCT02417805|Procedure|Intervention: Remote Ischemic Preconditioning|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
232650|NCT02417779|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
232651|NCT02417779|Device|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
232652|NCT02417753|Drug|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
232653|NCT02417701|Other|Laboratory Biomarker Analysis|Correlative studies
232654|NCT02417701|Other|Pharmacological Study|Correlative studies
232655|NCT02417701|Drug|Sapanisertib|Given PO
232656|NCT02417688|Device|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
232657|NCT02417675|Other|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.~Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
232688|NCT02417428|Dietary Supplement|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
232658|NCT02417675|Other|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
232659|NCT02417675|Other|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
232660|NCT02417662|Radiation|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
232661|NCT02417662|Other|Non-investigational platinum-based doublet chemotherapy|There is no intervention in the control group, patients will receive standard chemotherapy alone.
232662|NCT02417649|Biological|Placebo|"The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~Three months of rest, according to the indications, will be allowed.~A second cycle (the same as point 1.) will be performed~A second three month rest (according to point 2.) will be provided."
232663|NCT02417649|Biological|Ismigen|"The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.~Three months of rest, according to the indications, will be allowed.~A second cycle (the same as point 1.) will be performed~A second three month rest (according to point 2.) will be provided."
232664|NCT02417636|Other|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
232665|NCT02417623|Behavioral|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
232666|NCT02417610|Device|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
232667|NCT02417610|Device|Hyaluronic acid - HA - Ialart|Hyaluronic acid
232668|NCT02417597|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
232669|NCT02417584|Device|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
232670|NCT02417571|Device|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A&D Company, Tokyo, Japan)
232671|NCT02417558|Behavioral|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
232672|NCT02417558|Behavioral|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
232673|NCT02417532|Device|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
232674|NCT02417519|Other|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
232675|NCT02417519|Other|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
232676|NCT02417519|Other|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
232677|NCT02417506|Other|E-OA-07 (Lanconone)|
232678|NCT02417506|Drug|Ibuprofen|
232679|NCT02417493|Behavioral|Simulation of epinephrine self-injection|
232680|NCT02417480|Behavioral|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
232681|NCT02417480|Behavioral|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
232682|NCT02417467|Other|Nicotine E-Cigarette|
232683|NCT02417467|Other|Non-Nicotine E-Cigarette|
232684|NCT02417467|Behavioral|Counseling|
232685|NCT02417454|Dietary Supplement|ProbioStick|"One sachet daily, without or without meals (3 x 10^9 CFU per sachet)~(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
232686|NCT02417454|Other|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
232687|NCT02417441|Device|Eeva|Embryos of subjects randomized in this group were assessed using Eeva System and morphological grading to identify optimal embryos for transfer.
232756|NCT02416973|Device|Provant|
232690|NCT02417428|Behavioral|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
232691|NCT02417428|Other|without exercise|No exercise program will be assigned to participants.
232692|NCT02417415|Other|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at ~44ºC continuously for 2 hr.
232693|NCT02417415|Other|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
232694|NCT02417402|Other|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
232695|NCT02417402|Other|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
232696|NCT02417389|Drug|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
232697|NCT02417389|Drug|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
232698|NCT02417376|Device|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
232699|NCT02417376|Device|Gracey curettes|set of 7 instruments number #1-14
232700|NCT02417350|Other|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
232701|NCT02417350|Other|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
232702|NCT02417337|Procedure|Root Canal Treatment|A standardized endodontic procedures performed.
232703|NCT02417337|Drug|Paracetamol|
232704|NCT02417337|Drug|Ibuprofen|
232705|NCT02417337|Drug|Mefenamic acid|
232706|NCT02417337|Drug|Diclofenac|
232707|NCT02417311|Other|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
232708|NCT02417298|Drug|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
232709|NCT02417298|Drug|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
232710|NCT02417285|Drug|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
232711|NCT02417285|Drug|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
232712|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
232713|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
232714|NCT02417246|Drug|brand name metoprolol ER|This medication will be taken for 7 to 28 days
232715|NCT02417246|Drug|Generic A|This medication will be taken for 7 days
232716|NCT02417246|Drug|Generic B|This medication will be taken for 7 days
232717|NCT02417233|Behavioral|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
232718|NCT02417233|Behavioral|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
232719|NCT02417220|Behavioral|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
232720|NCT02417220|Other|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
232721|NCT02417207|Drug|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
232722|NCT02417207|Drug|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
232723|NCT02417181|Other|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
232724|NCT02417155|Behavioral|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
232725|NCT02417155|Behavioral|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
232726|NCT02417142|Drug|Exenatide|Exenatide (plus existing treatment) 2mg/week for 24 weeks.
232727|NCT02417142|Drug|Placebo|Placebo (plus existing treatment) for 24 weeks.
232728|NCT02417129|Drug|Rituximab|BI 695500 375 mg/M2
232729|NCT02417129|Drug|BI 695500|BI 695500 375 mg/M2
232730|NCT02417116|Other|Tear supplement|Application as required to improve comfort
232731|NCT02417116|Other|Tear supplement 2|Application as required to improve comfort
232732|NCT02417116|Dietary Supplement|Omega 3 nutrition supplement|Taken each day
232733|NCT02417116|Device|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
232734|NCT02417116|Other|Saline|Application as required to improve comfort
232735|NCT02417103|Drug|GLP-1 (Liraglutide)|GLP-1 Analogon
232736|NCT02417103|Drug|Placebo|Placebo
232737|NCT02417090|Drug|Insulin|Pregnant women who used insulin to treat gestational diabetes
232738|NCT02417090|Drug|Metformin|Pregnant women who used metformin to treat gestational diabetes
232739|NCT02417077|Other|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
232740|NCT02417064|Drug|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
232741|NCT02417064|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
232742|NCT02417064|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
232743|NCT02417064|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
232744|NCT02417064|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
232745|NCT02417064|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
232746|NCT02417051|Behavioral|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
232747|NCT02417038|Device|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
232748|NCT02417025|Behavioral|PE|Prolonged Exposure
232749|NCT02417012|Behavioral|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
232750|NCT02417012|Behavioral|Standard care|Standard individual diabetes support
232751|NCT02416999|Drug|Ultra-low dose Bevacizumab|
232752|NCT02416999|Drug|Temozolomide|
232753|NCT02416986|Behavioral|6 hour smoking abstinence|
232754|NCT02416986|Behavioral|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
232755|NCT02416986|Behavioral|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
232757|NCT02416960|Other|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
232758|NCT02416960|Other|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
232759|NCT02416947|Dietary Supplement|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
232760|NCT02416947|Dietary Supplement|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
232761|NCT02416947|Dietary Supplement|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
232762|NCT02416934|Drug|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
232763|NCT02416934|Drug|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
232764|NCT02416921|Behavioral|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
232765|NCT02416921|Behavioral|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
232766|NCT02416908|Drug|Selinexor|
232767|NCT02416908|Drug|Cladribine|
232768|NCT02416908|Drug|G-CSF|
232769|NCT02416908|Drug|Cytarabine|
232770|NCT02416908|Procedure|Bone marrow biopsy|
232771|NCT02416895|Other|In vivo immunity model|A measure of in vivo immune function.
232772|NCT02416882|Other|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
232773|NCT02416882|Other|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
232774|NCT02416882|Other|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
232775|NCT02416869|Procedure|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
232776|NCT02416869|Procedure|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
232777|NCT02416869|Drug|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
232778|NCT02416869|Drug|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
232779|NCT02416869|Procedure|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
232780|NCT02416869|Procedure|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
232781|NCT02416843|Other|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
232782|NCT02416817|Other|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
232783|NCT02416817|Other|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
232784|NCT02416804|Drug|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -> 10 μg/hr -> 15 (5+10) μg/hr -> 20 μg/hr
232785|NCT02416804|Drug|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -> 200 mg/d -> 250 mg/d -> 300 mg/d
232786|NCT02416791|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
232787|NCT02416791|Device|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
232788|NCT02416791|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
232789|NCT02416791|Other|Physical Therapy|Physical therapy will be administered for 40 minutes.
232790|NCT02416791|Other|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
232791|NCT02416778|Drug|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
232792|NCT02416765|Other|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
232793|NCT02416765|Drug|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
232794|NCT02416765|Drug|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
232795|NCT02416765|Other|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
232796|NCT02416752|Drug|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
232797|NCT02416752|Drug|choice of intra-operative opioids were left to the discretion of anesthesiologist|
233639|NCT02410824|Device|etafilcon A toric lens|toric contact lens
232798|NCT02416739|Drug|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
232799|NCT02416726|Device|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
232800|NCT02416713|Device|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
232801|NCT02416713|Other|Education Only|No active intervention, educational materials will be provided
232802|NCT02416700|Procedure|immediate implant surgery|Surgery of dental implants in one side of the mouth.
232803|NCT02416700|Device|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
232804|NCT02416687|Device|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
232805|NCT02416674|Procedure|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
232806|NCT02416674|Drug|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
232807|NCT02416648|Behavioral|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.~Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
232808|NCT02416635|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
232809|NCT02416635|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
232810|NCT02416622|Biological|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
232811|NCT02416609|Radiation|LDR|LDR will be delivered on days 1 and 2, 8 and 9 of each of four GemOx cycles
232812|NCT02416609|Drug|Gem|Gemcitabine (1.000 mg/sqm in a 30-minute infusion) will be administered on day 1-8 of each 21-day cycle, concurrent with LDR (for four cycles). Further two cycles of additional GemOx without LDR can be administered after SBRT
232813|NCT02416609|Drug|Ox|Oxaliplatin (130 mg/sqm in a 2-hour infusion) will be administered on day 1 of each 21-day cycle, concurrent with LDR (for four cycles). Further two cycles of additional GemOx without LDR can be administered after SBRT
232814|NCT02416609|Radiation|SBRT|SBRT will be administered after the fourth GemOx cycle, if no progression; three fractions will be administered
232815|NCT02416596|Procedure|Hysteroscopy|"Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection."
232816|NCT02416596|Device|Hysteroscope|"The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
232817|NCT02416583|Drug|Oxytocin|
232818|NCT02416583|Drug|Dinoprostone|
232819|NCT02416583|Procedure|Membrane sweeping|
232820|NCT02416570|Drug|Clarithromycin|
232821|NCT02416570|Drug|Placebo|
232822|NCT02416557|Procedure|PEEP|application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
232823|NCT02416544|Other|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
232824|NCT02416531|Drug|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
232825|NCT02416531|Radiation|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
232826|NCT02416531|Radiation|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
232827|NCT02416505|Behavioral|Verbal+Anatomic Model|
232828|NCT02416505|Behavioral|Verbal+Video|
232829|NCT02416492|Biological|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
232830|NCT02416492|Procedure|Sham Control|Sham Surgery (Partial burr hole only)
232831|NCT02416479|Behavioral|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
232832|NCT02416479|Behavioral|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
232833|NCT02416466|Biological|anti-CEA CAR-T cells|Gene modified patient T cells.
232834|NCT02416466|Device|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
232835|NCT02416453|Biological|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
232836|NCT02416453|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
232837|NCT02416453|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
232838|NCT02416440|Other|blood sample|blood sample
232839|NCT02416427|Drug|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
232840|NCT02416414|Device|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
232841|NCT02416414|Device|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
232842|NCT02416401|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
232843|NCT02416401|Other|Commercially available computerized training|
232844|NCT02416388|Drug|Idarubicin|"Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
232845|NCT02416388|Drug|Daunorubicin|"Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
232846|NCT02416388|Drug|HD Cytarabine|"Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
232847|NCT02416388|Drug|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
232848|NCT02416388|Drug|Methotrexate|"GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
232849|NCT02416388|Drug|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :~720 mg BID from D0 to D+28 for HLA-identical siblings~720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
232850|NCT02416388|Drug|vosaroxin|"Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4"
232851|NCT02416388|Drug|ID cytarabine|"Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group"
232852|NCT02416362|Other|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
232853|NCT02416362|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
232854|NCT02416349|Other|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.~Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
232855|NCT02416349|Other|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
232856|NCT02416336|Device|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.~In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
232857|NCT02416323|Other|AIM HI Training|
232858|NCT02416310|Device|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
232859|NCT02416297|Procedure|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
232860|NCT02416284|Other|NFBDG|"Intervention consists of:~Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)"
232861|NCT02416271|Drug|Teriparatide|Administered SC
232862|NCT02416271|Drug|Alendronate|Administered orally
232863|NCT02416271|Dietary Supplement|Calcium|Administered orally
232864|NCT02416271|Dietary Supplement|Vitamin D|Administered orally
232865|NCT02416271|Drug|Placebo-Oral|Administered orally
232866|NCT02416271|Drug|Placebo-SC|Administered SC
232867|NCT02416258|Drug|LP0113 aerosol spray|
232868|NCT02416258|Drug|Aerosol spray vehicle|
232869|NCT02416258|Drug|LEO 90100 aerosol foam|
232870|NCT02416258|Drug|Betamethasone dipropionate aerosol spray|
232871|NCT02416258|Drug|Calcipotriol aerosol spray|
232872|NCT02416258|Drug|Daivobet® gel|
232873|NCT02416245|Dietary Supplement|Beverage powder fortified with micronutrients and Bacopa monnieri extract|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
233012|NCT02415257|Drug|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
233013|NCT02415244|Procedure|TEE|Spinal cord segments will be imaged using the TEE
233014|NCT02415231|Behavioral|humor|
232874|NCT02416245|Other|Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
232875|NCT02416232|Drug|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
232876|NCT02416232|Drug|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
232877|NCT02416219|Procedure|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
232878|NCT02416219|Device|Ultrasound|
232879|NCT02416206|Drug|BeEAM|BeEAM
232880|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
232881|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
232882|NCT02416180|Device|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
232883|NCT02416180|Device|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
232884|NCT02416180|Device|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
232885|NCT02416167|Drug|FYU-981|
232886|NCT02416167|Drug|Placebo|
232887|NCT02416154|Procedure|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
232888|NCT02416141|Drug|fast release oro dispersible tramadol 50 mg|idem arm 1
232889|NCT02416128|Drug|Euphrasia|1 drop in the treated eye QID X 10 days
232890|NCT02416128|Drug|Prednisolone acetate|1 drop in the treated eye QID X 10 days
232891|NCT02416115|Drug|Ramosetron|Ramosetron was given iv.
232892|NCT02416115|Drug|Naloxone|Naloxone added to PCA was given iv.
232893|NCT02416115|Drug|saline|Saline was given iv.
232894|NCT02416115|Drug|Morphine|Morphine in the PCA was given iv.
232895|NCT02416102|Drug|Losartan 50 mg|50 mg QD for 4 weeks
232896|NCT02416102|Drug|losartan 100 mg|50 mg BID for 4 weeks
232897|NCT02416089|Device|Tampostat|
232898|NCT02416089|Device|Condom catheter tamponade|
232899|NCT02416076|Device|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
232900|NCT02416076|Device|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
232901|NCT02416063|Drug|Caudal Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Drug: Caudal dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline~sevoflurane Induction and maintenance of anesthesia"
232902|NCT02416063|Drug|Intravenous dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg.~Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml~sevoflurane Induction and maintenance of anesthesia"
232903|NCT02416063|Drug|Placebo|"Drug:Caudal bupivacaine 0.25% 1ml/kg~Intravenous: Normal saline 10 ml~sevoflurane Induction and maintenance of anesthesia"
232904|NCT02416050|Procedure|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
232905|NCT02416037|Device|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
232906|NCT02416037|Device|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
232907|NCT02416024|Device|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
232908|NCT02416011|Behavioral|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
232909|NCT02416011|Behavioral|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
232910|NCT02415998|Procedure|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
232911|NCT02415985|Drug|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
232912|NCT02415985|Drug|Rifabutin|
232913|NCT02415972|Other|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
232914|NCT02415959|Drug|Creon IR|
232915|NCT02415959|Drug|Creon® (DR/GR)|
232916|NCT02415946|Procedure|Sinus floor augmentation (lateral)|
232917|NCT02415946|Procedure|Sinus floor augmentation (transcrestal)|
232918|NCT02415933|Behavioral|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:~Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;~Provision of seed grants to assist in business start-ups through microfinance loans;~One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;~Trainings on financial planning and household livelihoods."
232919|NCT02415933|Behavioral|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).~Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
232920|NCT02415920|Drug|Oxytocin|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
232921|NCT02415920|Drug|Placebo|Participants will be randomly assigned to intra-nasally administer either oxytocin or a placebo on their first visit and then they will receive the other spray during their second visit.
232922|NCT02415907|Drug|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 ([ethyl-1-14C]-idalopirdine) in one capsule for oral administration, single dose
232923|NCT02415907|Drug|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 ([benzyl-7-14C]-idalopirdine) in one capsule for oral administration, single dose
232924|NCT02415881|Drug|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
232925|NCT02415881|Device|da Vinci Firefly|Da Vinci surgical robot with build-in fluorescence imaging option (Firefly technology)
232926|NCT02415881|Device|IMAGE1 + ICG Hopkins telescope and/or VITOM|IMAGE1 + ICG Hopkins telescope and/or VITOM -- Fluorescence camera allowing for imaging of IRDye800. Camera is suitable for open and laparoscopic surgery.
232927|NCT02415855|Drug|Dabigatran|
232928|NCT02415842|Other|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
232929|NCT02415829|Drug|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
232930|NCT02415816|Procedure|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
232931|NCT02415803|Drug|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
232932|NCT02415803|Drug|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
232933|NCT02415803|Drug|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
232934|NCT02415790|Drug|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
232935|NCT02415790|Drug|E2027 matching placebo|E2027 matching placebo capsule will be administered.
232936|NCT02415777|Drug|Ursodeoxycholic acid, thiamine, riboflavin|
232937|NCT02415764|Behavioral|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).~While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
232938|NCT02415751|Behavioral|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
232939|NCT02415738|Procedure|Prone positioning|
232940|NCT02415725|Drug|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
232941|NCT02415712|Drug|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
232942|NCT02415699|Drug|Fluorouracil|
232943|NCT02415699|Drug|Oxaliplatin|
232944|NCT02415699|Drug|Leucovorin|
232945|NCT02415699|Biological|DC-CIK|
232946|NCT02415673|Device|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
232947|NCT02415660|Procedure|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
232948|NCT02415660|Procedure|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
233015|NCT02415218|Biological|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
233016|NCT02415192|Drug|Levacalm|
233017|NCT02415192|Drug|Valsartan/amlodipine|
232949|NCT02415660|Behavioral|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
232950|NCT02415660|Behavioral|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
232951|NCT02415660|Procedure|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
232952|NCT02415660|Device|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
232953|NCT02415634|Other|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include~Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)~Part 2: A rehabilitation goal setting care plan~Part 3: A patient communication forum~Part 4: Useful supports and contact information~Part 5: Tailored exercise programme~The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.~The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
232954|NCT02415634|Other|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
232955|NCT02415621|Drug|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
232956|NCT02415608|Drug|Ibrutinib|Given orally in 28-day cycles
232957|NCT02415595|Drug|BMS-955176|HIV Maturation Inhibitor
232958|NCT02415595|Drug|EFV|EFV
232959|NCT02415595|Drug|TDF/FTC|TDF/FTC
232960|NCT02415582|Other|Aerobic exercise|Aerobic exercise on treadmill
232961|NCT02415582|Other|Combined exercises|Combined resistance and aerobic exercise
232962|NCT02415582|Other|Control|45 minutes resting sitting
232963|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
232964|NCT02415569|Drug|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
232965|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
232966|NCT02415556|Drug|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
232967|NCT02415556|Drug|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
232968|NCT02415543|Procedure|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
232969|NCT02415543|Procedure|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
232970|NCT02415530|Behavioral|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3~6 months
232971|NCT02415530|Other|No intervention|No intervention
232972|NCT02415517|Behavioral|Cognitive training|"Cognitive training on computer. Six sessions with different tasks: Tiere merken & Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)"
232973|NCT02415517|Behavioral|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
232974|NCT02415504|Behavioral|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
232975|NCT02415504|Behavioral|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
233018|NCT02415179|Drug|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
233019|NCT02415179|Drug|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
233020|NCT02415166|Biological|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
233021|NCT02415166|Other|NaCl-saline placebo|placebo
233022|NCT02415153|Other|Laboratory Biomarker Analysis|Optional correlative studies
233023|NCT02415153|Other|Pharmacological Study|Correlative studies
233024|NCT02415153|Drug|Pomalidomide|Given PO
232976|NCT02415491|Other|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.~Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.~Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
232977|NCT02415478|Other|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.~Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
232978|NCT02415465|Procedure|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
232979|NCT02415465|Procedure|General|General Intraoperative Anesthesia
232980|NCT02415465|Procedure|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
232981|NCT02415465|Procedure|Spinal|Spinal Intraoperative Anesthesia
232982|NCT02415452|Procedure|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
232983|NCT02415439|Drug|VBP15|
232984|NCT02415439|Drug|Placebo|
232985|NCT02415426|Behavioral|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek & Steffen Moritz, http://clinical-neuropsychology.de/metacognitive_training_for_depression.html).
232986|NCT02415413|Drug|carfilzomib|
232987|NCT02415413|Drug|Lenalidomide|
232988|NCT02415413|Drug|Dexamethasone|
232989|NCT02415413|Drug|Melphalan|
232990|NCT02415400|Drug|Apixaban|
232991|NCT02415400|Drug|vitamin K antagonist|
232992|NCT02415400|Drug|Acetylsalicylic acid|
232993|NCT02415400|Other|Acetylsalicylic acid placebo|
232994|NCT02415387|Biological|typhoid vaccine|Given IM
232995|NCT02415387|Other|Placebo|Given IM
232996|NCT02415374|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
232997|NCT02415361|Other|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
232998|NCT02415348|Device|Fibroscan|
232999|NCT02415335|Drug|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
233000|NCT02415335|Drug|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
233001|NCT02415322|Other|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
233002|NCT02415309|Dietary Supplement|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
233003|NCT02415309|Dietary Supplement|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
233004|NCT02415309|Other|Placebo|40 patients will randomly receive a placebo/sugar pill
233005|NCT02415296|Other|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
233006|NCT02415296|Other|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
233007|NCT02415296|Other|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
233008|NCT02415283|Device|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
233009|NCT02415270|Other|Reduced Nicotine Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
233010|NCT02415270|Other|Reduced ROS/RNS|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
233011|NCT02415270|Other|Control|Human topography data will show if smokers change the way they smoke due to being in a research study. Select biosamples of participants will be used to analyze how biomarkers differ among groups
233026|NCT02415127|Drug|Interferon γ-1b|The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By Week 13, all participants are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related adverse events (AEs).
233027|NCT02415127|Drug|Placebo|The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
233028|NCT02415114|Dietary Supplement|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
233029|NCT02415101|Procedure|Resective surgery|
233030|NCT02415088|Procedure|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
233031|NCT02415088|Procedure|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
233032|NCT02415075|Behavioral|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
233033|NCT02415062|Drug|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
233034|NCT02415049|Other|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
233035|NCT02415049|Other|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
233036|NCT02415036|Device|Delcath Hepatic Delivery System|
233037|NCT02415036|Drug|Melphalan|
233038|NCT02415023|Drug|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
233039|NCT02415010|Device|Enterprise 2 Vascular Reconstruction Device|
233040|NCT02414997|Procedure|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
233041|NCT02414997|Procedure|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
233042|NCT02414984|Biological|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
233043|NCT02414971|Other|There is no intervention|There is no intervention
233044|NCT02414958|Drug|Empagliflozin|
233045|NCT02414958|Drug|Empagliflozin|
233046|NCT02414958|Drug|Placebo|
233047|NCT02414945|Drug|Cyclophosphamide|
233048|NCT02414945|Drug|Fludarabine|
233049|NCT02414945|Biological|Autologous tumor infiltrating lymphocytes (TILs)|
233050|NCT02414945|Biological|Interleukin-2|
233051|NCT02414932|Drug|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
233052|NCT02414932|Drug|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
233053|NCT02414919|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
233054|NCT02414919|Drug|ParaGard|Copper T380A
233055|NCT02414919|Drug|Implanon/Nexplanon|Etonorgestrel contraceptive implant
233056|NCT02414906|Other|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
233057|NCT02414893|Procedure|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
233058|NCT02414880|Drug|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
233059|NCT02414880|Drug|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
233060|NCT02414880|Drug|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
233061|NCT02414854|Drug|Dupilumab|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
233062|NCT02414854|Drug|Placebo|Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
233063|NCT02414854|Drug|Inhaled corticosteroid (ICS) therapy|Oral inhalation, stable dose (medium or high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy)
233064|NCT02414854|Drug|Albuterol/Salbutamol|Oral inhalation as needed
233065|NCT02414854|Drug|Levalbuterol/Levosalbutamol|Oral inhalation as needed
233066|NCT02414841|Drug|Vonapanitase|
233067|NCT02414841|Drug|Placebo|
233068|NCT02414828|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.
233069|NCT02414828|Biological|AERAS-402 3 x 10^8 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
233070|NCT02414828|Biological|AERAS-402 3 x 10^9 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
233071|NCT02414828|Biological|AERAS-402 3 x 10^10 vp|AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
233072|NCT02414815|Device|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
233073|NCT02414802|Device|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
233074|NCT02414802|Procedure|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
233075|NCT02414802|Drug|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
233076|NCT02414802|Drug|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
233077|NCT02414789|Procedure|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
233078|NCT02414776|Drug|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
233079|NCT02414763|Behavioral|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
233080|NCT02414750|Drug|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
233081|NCT02414750|Device|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
233082|NCT02414750|Procedure|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
233083|NCT02414750|Procedure|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
233084|NCT02414737|Drug|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
233085|NCT02414724|Drug|Gemcitabine Hydrochloride|Given IV
233086|NCT02414724|Other|Laboratory Biomarker Analysis|Correlative studies
233087|NCT02414724|Other|Pharmacological Study|Correlative studies
233088|NCT02414724|Drug|Ribociclib|Given PO
233089|NCT02414711|Other|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (<1.75)
233090|NCT02414711|Other|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
233091|NCT02414698|Procedure|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
233092|NCT02414698|Drug|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
233093|NCT02414685|Drug|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
233094|NCT02414685|Drug|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
233095|NCT02414685|Drug|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
233096|NCT02414672|Behavioral|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
233097|NCT02414659|Procedure|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
233098|NCT02414620|Device|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
233099|NCT02414607|Biological|Elderberry Juice|
233100|NCT02414607|Other|Placebo|
233101|NCT02414594|Drug|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
233102|NCT02414594|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
233103|NCT02414581|Drug|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
233104|NCT02414581|Drug|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
233105|NCT02414581|Drug|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
233106|NCT02414568|Drug|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
233107|NCT02414568|Drug|Prednisone|Prednisone 40 mg/m² PO
233108|NCT02414568|Drug|Vinblastine|Vinblastine 6 mg/m² IV
233109|NCT02414568|Drug|Doxorubicin|Doxorubicin 40 mg/m² IV
233110|NCT02414555|Drug|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
233111|NCT02414555|Drug|fluid bolus|
233112|NCT02414555|Device|oesophagus doppler (CardioQ)|
233113|NCT02414555|Drug|Normal Saline|
233114|NCT02414555|Device|arterial cannulation|
233115|NCT02414555|Device|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
233116|NCT02414555|Drug|Elo-Mel Isoton (balanced acetat-based infusate)|
233117|NCT02414542|Device|MINIMA stem|
233118|NCT02414529|Drug|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
233119|NCT02414529|Drug|Placebo|
233120|NCT02414516|Drug|OBP-801|OBP-801 will be administered IV
233121|NCT02414503|Drug|8IU intranasal oxytocin|
233122|NCT02414503|Drug|24IU intranasal oxytocin|
233123|NCT02414503|Drug|Placebo|
233125|NCT02414490|Drug|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
233126|NCT02414477|Drug|Deuterated NNN|Smokeless tobacco study product
233127|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.~In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
233128|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
233129|NCT02414464|Other|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.~Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
233130|NCT02414451|Drug|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
233131|NCT02414451|Drug|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:~Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
233132|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
233133|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
233134|NCT02414425|Procedure|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
233135|NCT02414425|Procedure|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
233136|NCT02414425|Drug|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
233137|NCT02414412|Dietary Supplement|Ulmus macrocarpa water extract|
233138|NCT02414399|Drug|Azithromycin|oral administration of Azithromycin
233139|NCT02414399|Drug|Placebo|5 days of taste/appearance/bottle-matched inactive substance
233140|NCT02414386|Other|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
233141|NCT02414373|Drug|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
233142|NCT02414373|Drug|Bupivacaine|local anesthetics, which will epidurally administered
233143|NCT02414373|Device|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
233144|NCT02414373|Device|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
233145|NCT02414360|Other|Shortened Format|Shortened format of a systematic review
233146|NCT02414360|Other|Full Length|Full length systematic review
233147|NCT02414347|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
233148|NCT02414334|Radiation|Stereotactic Ablative Radiotherapy (SABR)|
233149|NCT02414308|Drug|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
233150|NCT02414295|Drug|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
233151|NCT02414282|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
233152|NCT02414269|Genetic|iCasp9M28z T cell infusions|Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI. Patients who do not have enough cells to match the current dose cohort will be treated in the cohort in which they have cells available
233153|NCT02414269|Drug|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2)
233154|NCT02414269|Drug|pembrolizumab|Pembrolizumab will be given as 200 mg flat dose infusion intravenously.
233155|NCT02414256|Other|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
233156|NCT02414243|Other|New Amino Acid formula|Ordesa's Amino-Acid based Infant Formula
233157|NCT02414243|Other|Commercially available Amino Acid Formula|Commercially available Amino Acid Formula
233158|NCT02414230|Drug|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
233159|NCT02414217|Behavioral|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
233160|NCT02414217|Behavioral|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
233161|NCT02414204|Drug|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
233162|NCT02414204|Other|Placebo|Placebo will be over encapsulated to identical to drug comparison
233163|NCT02414191|Behavioral|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
233164|NCT02414191|Behavioral|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
233165|NCT02414178|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
233166|NCT02414165|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
233167|NCT02414165|Drug|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
233168|NCT02414165|Drug|Lomustine|
233169|NCT02414165|Drug|Temozolomide|
233170|NCT02414165|Biological|Bevacizumab|
233171|NCT02414152|Drug|anakinra|100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
233172|NCT02414139|Drug|INC280 (capmatinib)|
233173|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
233174|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
233175|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours~st period: Spontaneous breathing for 10 minutes~nd period: CPAP for 10 minutes~rd period: Spontaneous breathing for 10 minutes to check the return to baseline.~After each period, the following parameters will be recorded during 5 minutes:~oesogastric pressures~air flow~gas exchange~right and left cardiac function~Patients > 6 years old will assess their dyspnea on a visual analogue scale"
233176|NCT02414126|Device|CPAP|
233177|NCT02414100|Other|Laboratory Biomarker Analysis|Correlative studies
233178|NCT02414100|Other|Cytology Specimen Collection Procedure|Correlative studies
233179|NCT02414087|Device|ICB Medical insoles|"Study group:~Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.~Control group:~Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
233180|NCT02414074|Behavioral|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
233181|NCT02414074|Behavioral|Parent Education|Everyday Parenting is a parent training curriculum.
233182|NCT02414061|Dietary Supplement|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
233183|NCT02414061|Other|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
233184|NCT02414048|Drug|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
233185|NCT02414009|Drug|Capecitabine|
233186|NCT02414009|Drug|Temozolomide|
233187|NCT02414009|Drug|Irinotecan|
233188|NCT02414009|Drug|Fluorouracil|
233189|NCT02414009|Drug|Leucovorin|
233190|NCT02413996|Device|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
233191|NCT02413996|Behavioral|Functional activities|Stairs, walking
233192|NCT02413996|Other|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
233193|NCT02413996|Other|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
233240|NCT02413632|Other|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
233194|NCT02413983|Procedure|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
233195|NCT02413983|Procedure|hepatectomy midline incision|
233196|NCT02413983|Procedure|hepatectomy transverse incision|
233197|NCT02413970|Device|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
233198|NCT02413957|Other|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
233199|NCT02413957|Other|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
233200|NCT02413944|Procedure|ACTH stimulation test|ACTH stimulation test
233201|NCT02413931|Other|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
233202|NCT02413918|Drug|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
233203|NCT02413905|Biological|Stool samples|Stool samples
233204|NCT02413879|Device|CleanCision|Wound protection during colorectal surgery.
233205|NCT02413866|Behavioral|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
233206|NCT02413866|Behavioral|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
233207|NCT02413853|Drug|CBP/beta-catenin Antagonist PRI-724|Given IV
233208|NCT02413853|Biological|Bevacizumab|Given IV
233209|NCT02413853|Drug|Leucovorin Calcium|Given IV
233210|NCT02413853|Drug|Oxaliplatin|Given IV
233211|NCT02413853|Drug|Fluorouracil|Given IV
233212|NCT02413853|Other|Laboratory Biomarker Analysis|Correlative studies
233213|NCT02413840|Behavioral|Baduanjin qigong|
233214|NCT02413827|Drug|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
233215|NCT02413827|Drug|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.~Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
233216|NCT02413814|Behavioral|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
233217|NCT02413814|Behavioral|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
233218|NCT02413788|Other|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
233219|NCT02413788|Other|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
233220|NCT02413788|Device|treadmill|
233221|NCT02413762|Other|No intervention|No intervention
233222|NCT02413736|Drug|Imatinib|Imatinib 400 mg/day
233223|NCT02413723|Device|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
233224|NCT02413723|Device|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
233225|NCT02413710|Other|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
233226|NCT02413710|Behavioral|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
233227|NCT02413697|Device|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
233228|NCT02413697|Device|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
233229|NCT02413684|Behavioral|Patient engagement toolkit|"Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care"
233230|NCT02413671|Dietary Supplement|Lupin Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
233231|NCT02413671|Dietary Supplement|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
233232|NCT02413671|Other|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
233233|NCT02413658|Drug|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
233234|NCT02413658|Drug|Sugar solution|
233235|NCT02413645|Biological|TriMix_100|100 μg of TriMix in
233236|NCT02413645|Biological|TriMix_300|300 μg of TriMix in
233237|NCT02413645|Biological|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
233238|NCT02413645|Biological|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
233239|NCT02413645|Biological|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
233241|NCT02413632|Other|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
233242|NCT02413619|Procedure|Vitrectomy|Vitrectomy
233243|NCT02413619|Procedure|Cataract surgery|Cataract surgery
233244|NCT02413619|Procedure|Combined surgery|Combined vitrectomy and cataract surgery at the same time
233245|NCT02413606|Other|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
233246|NCT02413593|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
233247|NCT02413593|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
233248|NCT02413580|Biological|IGIV-C|an IV dose of 2 g/kg of IGIV-C will be administered as 2 doses of 1 g/kg on two consecutive days
233249|NCT02413567|Device|DMR Procedure (Fractyl)|Endoscopic procedure
233250|NCT02413554|Drug|Rivastigmine patch|acetylcholine esterase inhibitor
233251|NCT02413541|Procedure|Polymyxin-B Hemoperfusion|Endotoxin removal
233252|NCT02413541|Procedure|Standard treatment|
233253|NCT02413528|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
233254|NCT02413528|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
233255|NCT02413515|Drug|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
233256|NCT02413502|Biological|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10^8 CFUs.
233257|NCT02413489|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
233258|NCT02413476|Procedure|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
233259|NCT02413476|Procedure|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
233260|NCT02413463|Procedure|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
233261|NCT02413463|Procedure|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
233262|NCT02413437|Other|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided.
233263|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided.
233264|NCT02413437|Device|Ultrasound|
233265|NCT02413424|Dietary Supplement|Sucralose|60 ml of 2mM sucralose
233266|NCT02413424|Other|Water|60 ml of water
233267|NCT02413424|Dietary Supplement|glucose load|
233268|NCT02413411|Behavioral|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
233269|NCT02413411|Behavioral|an educational program (an NIH-developed booklet)|
233270|NCT02413398|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
233271|NCT02413398|Drug|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
233272|NCT02413385|Behavioral|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
233273|NCT02413372|Drug|BMS-986036|
233274|NCT02413372|Drug|BMS-986036|
233275|NCT02413372|Drug|Placebo|
233276|NCT02413346|Drug|Sarecycline|Administered based on participant's body weight.
233277|NCT02413333|Device|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
233278|NCT02413333|Device|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
233279|NCT02413333|Device|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
233280|NCT02413320|Drug|Paclitaxel|
233281|NCT02413320|Drug|Carboplatin|
233282|NCT02413320|Drug|Doxorubicin|
233283|NCT02413320|Drug|Cyclophosphamide|
233284|NCT02413320|Drug|Docetaxel|
233285|NCT02413307|Other|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
233286|NCT02413294|Device|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
233287|NCT02413281|Drug|ALKS 5461|Sublingual tablets, single administration
233288|NCT02413281|Drug|Buprenorphine|Sublingual tablets, single administration
233289|NCT02413281|Drug|Placebo|Sublingual tablets, single administration
233290|NCT02413268|Drug|Nitroglycerin|
233291|NCT02413255|Drug|TAK-020|TAK-020 oral solution
233293|NCT02413242|Other|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
233294|NCT02413229|Drug|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
233295|NCT02413229|Drug|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
233296|NCT02413216|Behavioral|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
233297|NCT02413216|Other|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
233298|NCT02413203|Drug|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
233299|NCT02413203|Drug|Placebo|Blood and urine collections before and 3 hours after placebo administration.
233300|NCT02413177|Behavioral|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
233301|NCT02413177|Behavioral|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
233302|NCT02413164|Other|A multimodal physiotherapy programme|"Intervention: individualised Multimodal Physiotherapy Programme of therapeutic exercises with education healthy-style-of-life based.~Groupal sessions two times per week during 12 weeks. Each session 60 minutes: 10 minutes of warm up, 20 minutes of strength and muscular endurance, 20 minuts of aerobic training, 10 minutes of cold-down.~Intensity aerobic training: The training heart rate will be calculated according to recommendations of the American College of Sport Medicine (ACSM), it must oscillate between 55/65% and 90% of the HRmax. Initial four weeks: moderate intensity (55-69% HRmax); Following weeks according to each response, to higher level of training (70-89% HRmax). Strength training: individualised working with the principal muscular groups. 3 sessions using a weight which can repeat the exercise 10-15 times, increasing to a weight at which they can repeat the exercise 8-12 times."
233303|NCT02413151|Behavioral|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
233304|NCT02413151|Device|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
233305|NCT02413138|Drug|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
233306|NCT02413125|Device|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
233307|NCT02413125|Drug|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
233308|NCT02413112|Behavioral|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week."
233309|NCT02413099|Drug|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
233310|NCT02413086|Procedure|Early-stage amputation|Individuals with DFU were given early-stage amputation.
233311|NCT02413086|Procedure|Amputation|Individuals with DFU were given amputation.
233312|NCT02413086|Other|External herbs chitosan|Wound was given external herbs chitosan after amputation.
233313|NCT02413086|Other|Traditional gauze|Wound was given traditional gauze after amputation.
233314|NCT02413073|Procedure|Whole Body Vibration|We wil use vibration in patients with kidney disease
233315|NCT02413060|Other|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
233316|NCT02413060|Behavioral|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
233317|NCT02413047|Drug|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
233318|NCT02413047|Drug|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
233319|NCT02413047|Drug|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
233320|NCT02413034|Drug|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
233321|NCT02413034|Other|Control group|no antibiotic prophylaxis
233322|NCT02413021|Drug|Cytarabine|20 mg/m^2 , SC, two times a day for 10 days every 30 days for 1 cycle
233323|NCT02413021|Drug|Deferasirox|20 mg/kg ,oral, per day
233324|NCT02413008|Drug|estriol|0.005% estriol vaginal gel
233325|NCT02413008|Drug|Placebo|placebo vaginal gel
233326|NCT02412995|Other|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233327|NCT02412995|Other|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233328|NCT02412995|Other|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233329|NCT02412995|Other|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233330|NCT02412995|Other|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233331|NCT02412995|Other|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
233332|NCT02412982|Drug|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
233333|NCT02412982|Drug|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
233334|NCT02412969|Procedure|Lumbar Epidural|control group will receive lumbar puncture epidural
233335|NCT02412969|Procedure|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
233336|NCT02412956|Behavioral|SmokefreeMOM Text|
233337|NCT02412943|Other|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
233338|NCT02412930|Procedure|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.~After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
233339|NCT02412930|Drug|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
233340|NCT02412930|Drug|Bupivacaine|
233341|NCT02412930|Device|Ultrasound|
233342|NCT02412917|Drug|FV-100|antiviral nucleoside analog
233343|NCT02412917|Drug|valacyclovir|antiviral nucleoside analog
233344|NCT02412904|Drug|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
233765|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 1|
233345|NCT02412904|Drug|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
233346|NCT02412891|Device|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
233347|NCT02412891|Device|Sham UroShield device|
233348|NCT02412878|Drug|Carfilzomib|Carfilzomib was administered as an IV infusion
233349|NCT02412878|Drug|Dexamethasone|Commercially available dexamethasone was obtained by the investigational site.
233350|NCT02412865|Behavioral|Quit4Baby|
233351|NCT02412865|Behavioral|Text4Baby|
233352|NCT02412852|Drug|Sodium nitrite|Sustained release formulation of sodium nitrite
233353|NCT02412852|Drug|Placebo|Placebo tablets
233354|NCT02412826|Device|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
233355|NCT02412813|Device|LEGION OXINIUM|Investigational Group
233356|NCT02412813|Device|LEGION Cobalt Chrome|Control Group
233357|NCT02412787|Drug|Idursulfase-IT|Participants will receive 10 mg of idursulfase-IT intrathecally via IDDD or LP once every 28 days. Participants who are younger than 3 years of age will receive an adjusted dose of 7.5 mg (>8 months to 30 months of age) and 10 mg (>30 months to 3 years of age).
233358|NCT02412787|Drug|Elaprase|Participants will receive intravenous (IV) Elaprase infusions at a minimum of 48 hours after IT administration of idursulfase-IT.
233359|NCT02412774|Behavioral|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
233360|NCT02412774|Behavioral|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
233361|NCT02412761|Drug|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
233362|NCT02412761|Drug|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
233363|NCT02412761|Drug|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
233364|NCT02412748|Behavioral|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
233365|NCT02412748|Behavioral|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
233366|NCT02412735|Drug|rexlemestrocel-L|"rexlemestrocel-L alone: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells - Intervention will be injected into the painful intervertebral disc"
233367|NCT02412735|Drug|rexlemestrocel-L + HA|"rexlemestrocel-L + HA: 2.0mL 6 million rexlemestrocel-L cells with 1% HA - Intervention will be injected into the painful intervertebral disc"
233368|NCT02412735|Drug|Placebo|saline control: 2.0 mL saline solution
233369|NCT02412722|Drug|Milled MLN0128 API|Capsules containing milled MLN0128 active pharmaceutical ingredient (API)
233370|NCT02412722|Drug|Unmilled MLN0128 API|Capsules containing unmilled MLN0128 active pharmaceutical ingredient (API)
233371|NCT02412722|Drug|Paclitaxel|Paclitaxel
233372|NCT02412709|Device|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
233373|NCT02412696|Device|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
233374|NCT02412696|Other|Nasal Dilator Strips|Nasal dilator strips
233375|NCT02412683|Other|oxaliplatin|
233376|NCT02412670|Drug|Methotrexate|Given IV
233377|NCT02412670|Drug|Vinblastine|Given IV
233378|NCT02412670|Drug|Doxorubicin Hydrochloride|Given IV
233379|NCT02412670|Drug|Cisplatin|Given IV
233380|NCT02412670|Drug|Gemcitabine Hydrochloride|Given IV
233381|NCT02412670|Drug|Carboplatin|Given IV
233382|NCT02412670|Procedure|Therapeutic Conventional Surgery|Undergo nephroureterectomy and lymph node dissection
233383|NCT02412670|Other|Laboratory Biomarker Analysis|Correlative studies
233384|NCT02412657|Drug|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
233385|NCT02412657|Drug|Normal Saline|
233386|NCT02412644|Drug|apremilast|
233387|NCT02412631|Drug|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
233388|NCT02412631|Drug|Varenicline|Chantix is an FDA approved medication for smoking cessation
233389|NCT02412631|Drug|Placebo|Placebo for lorcaserin
233390|NCT02412618|Drug|Mifepristone|Progesterone antagonist
233391|NCT02412618|Drug|Misoprostol|Prostaglandin E1
233392|NCT02412618|Dietary Supplement|Placebo|Tasteless, odorless, sugar based pill
233393|NCT02412605|Procedure|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.~Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
233394|NCT02412579|Other|None - Standard of Care|
233446|NCT02412228|Drug|Ixazomib|"Cycle 1:~Ixazomib: 4mg/day 1, 8, 15~Cycles 2-6:~Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,~Maintenance:~Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
233493|NCT02411942|Drug|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
233395|NCT02412566|Drug|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
233396|NCT02412553|Other|Specific carbohydrate diet|
233397|NCT02412553|Other|Elemental diet|
233398|NCT02412540|Behavioral|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
233399|NCT02412527|Other|Patch III heart rate sensor|
233400|NCT02412514|Biological|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
233401|NCT02412514|Biological|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
233402|NCT02412514|Biological|IPV|IPV administered at 6 weeks of age
233403|NCT02412501|Device|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
233404|NCT02412488|Other|Out of cathlab insertion|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
233405|NCT02412475|Drug|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
233406|NCT02412475|Drug|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
233407|NCT02412475|Drug|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
233408|NCT02412475|Drug|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
233409|NCT02412475|Drug|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
233410|NCT02412475|Drug|Cytarabine|"Patient Age (years) IT Cytarabine Dose > 1 30 mg~2 and < 3 50 mg~3 and ≤ 18 70 mg > 18 100 mg~given IT on day 0 or -1"
233411|NCT02412475|Drug|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
233412|NCT02412462|Drug|AB-16B5|
233413|NCT02412449|Drug|AKB-6548 tablet, reference formulation given in the fasted state|
233414|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fasted state.|
233415|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fed state|
233416|NCT02412436|Drug|Depot medroxyprogesterone acetate|Depot medroxyprogesterone acetate intramuscular injection
233417|NCT02412423|Drug|post-transplantation cyclophosphamide|
233418|NCT02412410|Behavioral|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
233419|NCT02412397|Procedure|Total Shoulder Arthroplasty|
233420|NCT02412384|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
233421|NCT02412384|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
233422|NCT02412371|Drug|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week/cycle.
233423|NCT02412371|Other|Placebo for Veliparib|Oral capsule of varying doses
233424|NCT02412371|Drug|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week/cycle.
233425|NCT02412371|Drug|Veliparib|Oral capsule of varying doses
233426|NCT02412371|Radiation|Radiotherapy|Radiation treatment administered on Day 1 through Day 5 of each week for approximately 30-34 visits.
233427|NCT02412358|Device|toothbrush|
233428|NCT02412345|Procedure|Extracorporeal shockwave therapy|
233429|NCT02412345|Procedure|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
233430|NCT02412345|Other|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
233431|NCT02412332|Procedure|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
233432|NCT02412332|Procedure|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
233433|NCT02412319|Drug|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
233434|NCT02412319|Other|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
233435|NCT02412306|Drug|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
233436|NCT02412293|Behavioral|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
233437|NCT02412293|Other|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
233438|NCT02412293|Behavioral|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
233439|NCT02412280|Other|retrospecive observational|
233440|NCT02412267|Drug|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
233441|NCT02412254|Other|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
233442|NCT02412254|Other|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
233443|NCT02412241|Other|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
233447|NCT02412228|Drug|Cyclophosphamide|"Cycle 1:~Cyclophosphamide: 50 mg/day continuous daily~Cycles 2-6:~Cyclophosphamide: 50 mg/day continuous daily"
233448|NCT02412228|Drug|Dexamethasone|"Cycle 1:~Dexamethasone: 20 mg/day 1, 8, 15~Cycles 2-6:~Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18"
233449|NCT02412215|Procedure|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
233450|NCT02412215|Device|NanoFlex toric Intraocular Lens|
233451|NCT02412202|Other|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
233452|NCT02412189|Procedure|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
233453|NCT02412189|Drug|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
233454|NCT02412176|Procedure|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
233455|NCT02412176|Procedure|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
233456|NCT02412163|Device|Ellipse IM HTO Nail|
233457|NCT02412150|Drug|Desflurane|Anesthesia is maintained with desflurane
233458|NCT02412150|Drug|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
233459|NCT02412150|Procedure|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
233460|NCT02412150|Other|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.~And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
233461|NCT02412150|Behavioral|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. [Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)]
233462|NCT02412150|Behavioral|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.~Awake Patient anxious and agitated or restless or both!~Patient cooperative, oriented and tranquil!~Patient responds to commands only!~Asleep A brisk response to a light glabellar tap or loud auditory stimulus!~A sluggish response to a light glabellar tap or loud auditory stimulus!~No response to a light glabellar tap or loud auditory stimulus"
233463|NCT02412150|Other|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.~And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
233464|NCT02412150|Behavioral|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
233465|NCT02412150|Other|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
233466|NCT02412150|Other|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
233467|NCT02412150|Other|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
233468|NCT02412150|Drug|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
233469|NCT02412150|Drug|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
233470|NCT02412137|Other|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
233471|NCT02412124|Procedure|Supportive Care|Complete W2W mentoring program
233472|NCT02412124|Other|Quality-of-Life Assessment|Complete the FACT-G
233473|NCT02412124|Other|Questionnaire Administration|Complete the W2W Patient Survey
233474|NCT02412111|Drug|Ivacaftor|
233475|NCT02412111|Drug|Tezacaftor/Ivacaftor|
233476|NCT02412098|Drug|Eleclazine|Eleclazine tablets administered orally
233477|NCT02412085|Drug|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~body weight < 80kg: 50 mg every 4 weeks~body weight ≥ 80 kg: 100 mg every 4 weeks"
233478|NCT02412059|Drug|Prednisolone acetate|
233479|NCT02412046|Procedure|Muscle biopsy|
233480|NCT02412033|Drug|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
233481|NCT02412033|Drug|Placebo|This group will receive placebo
233482|NCT02412020|Drug|PA101|
233483|NCT02412020|Drug|Placebo|
233484|NCT02412007|Other|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to~Standing up from squatting position to catch an object of interest.~Squatting from standing position to pick an object of interest.~Walking to reach an object of interest.~Climbing up steps to get an object of interest.~Climbing down steps to keep the above object of interest.~Cycling~Kicking a football~Dancing"
233485|NCT02411994|Drug|Pyronaridine-artesunate|
233486|NCT02411994|Drug|Artemether-lumefantrine combination|
233487|NCT02411981|Other|Autogenic drainage|
233488|NCT02411968|Other|111In-Girentuximab DOTA SPECT|
233489|NCT02411955|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
233490|NCT02411955|Drug|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
233491|NCT02411955|Drug|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
233492|NCT02411942|Drug|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
233494|NCT02411942|Drug|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
233495|NCT02411929|Drug|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
233496|NCT02411929|Drug|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
233497|NCT02411929|Drug|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
233498|NCT02411916|Biological|misoprostol|rectal insertion
233499|NCT02411903|Drug|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
233500|NCT02411903|Drug|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
233501|NCT02411890|Procedure|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
233502|NCT02411890|Procedure|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
233503|NCT02411890|Procedure|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
233504|NCT02411890|Procedure|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
233505|NCT02411877|Procedure|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
233506|NCT02411877|Procedure|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
233507|NCT02411877|Device|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
233508|NCT02411877|Device|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
233509|NCT02411864|Other|different low b-values distribution|
233510|NCT02411851|Drug|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
233511|NCT02411851|Other|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
233512|NCT02411838|Other|Calorie restriction|"Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.~Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI <28 will follow a regimen of fasting for two days per week while patients with BMI>28 will follow a regimen of fasting for three days per week."
233513|NCT02411825|Drug|SAR425899|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
233514|NCT02411825|Drug|placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
233515|NCT02411825|Drug|metformin|"Pharmaceutical form: tablet~Route of administration: oral"
233516|NCT02411812|Device|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
233517|NCT02411812|Device|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
233518|NCT02411812|Device|Twin-Block appliance|Group treated with Twin-Block appliance
233519|NCT02411786|Biological|pTVG-AR|Given ID
233520|NCT02411786|Biological|gm-csf|Given ID
233521|NCT02411773|Drug|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum HCO3 > 30).
233522|NCT02411773|Drug|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session
233523|NCT02411773|Other|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
233524|NCT02411773|Other|Stretching|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
233525|NCT02411760|Procedure|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
233526|NCT02411747|Behavioral|Testing|
233527|NCT02411747|Behavioral|Directed self-regulated simulation training|
233528|NCT02411734|Behavioral|Rehabilitation|Rehabilitation after hospitalization
233557|NCT02411500|Drug|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
233558|NCT02411448|Drug|Ramucirumab|Administered IV.
233559|NCT02411448|Drug|Placebo|Administered IV.
233560|NCT02411448|Drug|Erlotinib|Administered orally.
233561|NCT02411448|Drug|Gefitinib|Administered orally.
233529|NCT02411721|Behavioral|Animal Assisted Intervention|"Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.~The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.~Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
233530|NCT02411708|Drug|SANGUINATE|Single two-hour infusion of SANGUINATE
233531|NCT02411708|Drug|Placebo|Single two-hour infusion of placebo
233532|NCT02411695|Drug|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
233533|NCT02411682|Other|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
233534|NCT02411682|Other|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
233535|NCT02411669|Other|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.~They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
233536|NCT02411656|Other|Laboratory Biomarker Analysis|Correlative studies
233537|NCT02411656|Biological|Pembrolizumab|Given IV
233538|NCT02411643|Drug|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
233539|NCT02411630|Drug|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.~The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
233540|NCT02411617|Device|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
233541|NCT02411604|Drug|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
233542|NCT02411591|Drug|Necitumumab|Administered IV.
233543|NCT02411591|Drug|Abemaciclib|Administered orally.
233544|NCT02411578|Drug|G-Pen Mini™ (glucagon injection)|"1st BG check, 1st treatment~BG is 50-69 mg/dl, treatment is 150 µg of glucagon~BG is 40-49 mg/dl, treatment is 300 µg of glucagon~15 min later, 2nd BG check, 2nd treatment~BG is 60-69 mg/dl, no treatment~BG is 50-59 mg/dl, treatment is 150 µg of glucagon~BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~BG is >=70, no treatment~BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(150 µg of glucagon per syringe)"
233545|NCT02411578|Other|Glucose Tablets|"1st BG check, 1st treatment~BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates~BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates~15 min later, 2nd BG check, 2nd treatment~BG is 60-69 mg/dl, no treatment~BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates~BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~30 minutes later, 3rd BG check, 3rd treatment~BG is >=70, no treatment~BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon~(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)"
233546|NCT02411565|Drug|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
233547|NCT02411565|Drug|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
233548|NCT02411565|Other|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
233549|NCT02411565|Other|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
233550|NCT02411552|Behavioral|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
233551|NCT02411539|Biological|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
233552|NCT02411539|Biological|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
233553|NCT02411526|Drug|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
233554|NCT02411526|Drug|Risperdal Consta|Risperdal Consta administered as a IM injection
233555|NCT02411526|Drug|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
233556|NCT02411513|Device|CEFALY|
233562|NCT02411448|Drug|Osimertinib|Administered orally.
233563|NCT02411435|Drug|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
233564|NCT02411435|Drug|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
233565|NCT02411422|Device|Conventional endotracheal tube|Conventional endotracheal tube
233566|NCT02411422|Device|Reinforced endotracheal tube|Reinforced endotracheal tube
233567|NCT02411409|Behavioral|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
233568|NCT02411383|Device|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
233569|NCT02411370|Behavioral|phonetic tests|
233570|NCT02411357|Behavioral|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
233571|NCT02411357|Behavioral|WHO contraception protocol|World Health Organization's contraception protocol
233572|NCT02411357|Behavioral|Incentives|Financial incentives contingent on follow-up visit attendance
233573|NCT02411344|Drug|Pertuzumab|"Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles~Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle~Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
233574|NCT02411331|Drug|Ethanol 40% + Enoxaparine 400UI/ml|
233575|NCT02411331|Drug|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
233576|NCT02411318|Other|Exercise|Subjects will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
233577|NCT02411318|Drug|ProLab 200mg caffeine capsule|Subjects will swallow one ProLab caffeine 200mg tablet.
233578|NCT02411318|Other|Ethanol ingestion|Subjects will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
233579|NCT02411292|Drug|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
233580|NCT02411279|Other|Equiped group with telemedicine systems|
233581|NCT02411266|Other|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
233582|NCT02411253|Drug|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
233583|NCT02411253|Drug|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
233584|NCT02411240|Device|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
233585|NCT02411227|Behavioral|VR Driving|Baseline: Tactical A3 scenario, composite score Post-Assessment: Tactical A4 scenario composite score
233586|NCT02411214|Other|survey|questionnaire survey sent by regular mail for 3 groups
233587|NCT02411201|Drug|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
233588|NCT02411188|Behavioral|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
233589|NCT02411175|Other|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
233590|NCT02411175|Drug|20% ethanol|
233591|NCT02411162|Drug|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm^2 of skin.
233592|NCT02411162|Drug|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
233593|NCT02411149|Drug|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
233594|NCT02411149|Drug|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
233595|NCT02411149|Drug|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
233596|NCT02411136|Drug|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
233597|NCT02411136|Drug|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
233598|NCT02411123|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
233599|NCT02411110|Combination Product|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
233600|NCT02411110|Combination Product|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
233634|NCT02410863|Drug|Dabrafenib|150 mg twice daily
233601|NCT02411097|Procedure|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
233602|NCT02411084|Biological|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
233603|NCT02411084|Biological|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
233604|NCT02411058|Behavioral|Uninformed|Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
233605|NCT02411058|Behavioral|Informed|Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
233606|NCT02411045|Behavioral|Take and send a selfie|Direction to take and send a selfie.
233607|NCT02411045|Behavioral|Workout gears|Direction to wear workout gears.
233608|NCT02411045|Behavioral|Exercise|Direction to complete a 30 minute workout.
233609|NCT02411032|Behavioral|Reminder|Customer gets mailing that reminds them to take their medication.
233610|NCT02411032|Behavioral|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
233611|NCT02411032|Behavioral|Fresh start framing|The fresh start event will be highlighted in the mailings.
233612|NCT02411019|Biological|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
233613|NCT02411006|Behavioral|Prediction mailing|Ask people to predict their upcoming medication adherence
233614|NCT02411006|Behavioral|Commitment mailing|Ask people to commit to their upcoming medication adherence
233615|NCT02411006|Behavioral|Reminder|Remind people to take their medicine
233616|NCT02411006|Behavioral|Anonymity|Keep patient predictions and commitment anonymous
233617|NCT02411006|Behavioral|Identification|Ask patients to report their predictions and commitments
233618|NCT02410993|Procedure|CABG surgery|
233619|NCT02410980|Drug|Tretinoin cream 0.1%|Assessment of the skin change
233620|NCT02410967|Behavioral|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
233621|NCT02410967|Behavioral|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
233622|NCT02410954|Device|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
233623|NCT02410941|Behavioral|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
233624|NCT02410928|Device|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
233625|NCT02410928|Device|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
233626|NCT02410928|Device|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
233627|NCT02410915|Device|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
233628|NCT02410915|Other|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
233629|NCT02410902|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
233630|NCT02410902|Drug|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
233631|NCT02410889|Other|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
233632|NCT02410876|Procedure|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
233633|NCT02410876|Procedure|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
233640|NCT02410811|Other|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
233641|NCT02410798|Device|TransLoc electrode|Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
233642|NCT02410785|Device|Polyglucosamine|ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
233643|NCT02410785|Other|Placebo|Placebo tablet
233644|NCT02410772|Drug|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
233645|NCT02410772|Drug|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
233646|NCT02410772|Drug|control|standard six-month treatment
233647|NCT02410759|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
233648|NCT02410759|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
233649|NCT02410746|Other|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
233650|NCT02410746|Other|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
233651|NCT02410746|Other|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
233652|NCT02410733|Biological|Lipo-MERIT|vaccination
233653|NCT02410720|Other|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
233654|NCT02410720|Other|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
233655|NCT02410720|Other|Explanation of paper and application instructions|The research fellow will explain instructions to patients
233656|NCT02410720|Other|Picoprep solution|
233657|NCT02410707|Drug|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
233658|NCT02410707|Drug|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
233659|NCT02410707|Drug|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
233660|NCT02410694|Drug|Ixazomib|
233661|NCT02410694|Drug|Thalidomide|
233662|NCT02410694|Drug|Dexamethasone|
233663|NCT02410681|Device|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.~3 recordings after the baseline visit~3 recordings 6 weeks after the baseline visit~3 recordings one year after the baseline visit"
233664|NCT02410681|Radiation|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
233665|NCT02410681|Other|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:~At the baseline visit~Three months after the baseline visit~One year after the baseline visit"
233666|NCT02410668|Dietary Supplement|flaxseed|
233667|NCT02410668|Dietary Supplement|Placebo|
233668|NCT02410668|Behavioral|Exercise recommendation|
233669|NCT02410655|Drug|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
233670|NCT02410655|Drug|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
233671|NCT02410642|Procedure|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
233672|NCT02410629|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
233673|NCT02410629|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
233674|NCT02410616|Behavioral|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
233675|NCT02410616|Behavioral|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
233676|NCT02410590|Drug|Rocuronium|
233677|NCT02410590|Drug|Sugammadex|
233678|NCT02410590|Drug|Cisatracurium|
233679|NCT02410590|Drug|Neostigmine/Atropine|
233680|NCT02410590|Drug|Succinylcholine|
233728|NCT02410356|Drug|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
233766|NCT02410083|Drug|Clopirin 2|
233681|NCT02410577|Drug|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
233682|NCT02410577|Device|PET/CT Scan|
233683|NCT02410577|Device|MRI|
233684|NCT02410577|Other|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
233685|NCT02410564|Behavioral|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
233686|NCT02410564|Behavioral|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
233687|NCT02410551|Drug|Pacritinib|200 mg by mouth twice a day for 60 days.
233688|NCT02410551|Drug|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
233689|NCT02410551|Behavioral|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
233690|NCT02410551|Behavioral|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
233691|NCT02410551|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
233692|NCT02410551|Drug|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
233693|NCT02410538|Other|"list of FAQ"|
233694|NCT02410525|Drug|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug [11C]PF-06427878 on Day 1 of all 3 Periods
233695|NCT02410525|Drug|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
233696|NCT02410525|Drug|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
233697|NCT02410512|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
233698|NCT02410512|Drug|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
233699|NCT02410499|Drug|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
233700|NCT02410499|Drug|MLN1202|MLN1202 solution for SC injection
233701|NCT02410473|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
233702|NCT02410473|Other|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
233703|NCT02410460|Drug|clonidine|
233704|NCT02410460|Drug|glycopyrrolate|
233705|NCT02410460|Drug|propofol|
233706|NCT02410460|Drug|ketamine|
233707|NCT02410460|Drug|marcaine|
233708|NCT02410460|Drug|scopolamine|
233709|NCT02410460|Drug|midazolam|
233710|NCT02410460|Device|ondansetron|
233711|NCT02410460|Drug|metoclopramide|
233712|NCT02410460|Drug|glycopyrrolate|
233713|NCT02410460|Drug|lidocaine|
233714|NCT02410460|Drug|famotidine|
233715|NCT02410460|Drug|desflurane|
233716|NCT02410460|Drug|sevoflurane|
233717|NCT02410447|Device|Defocused shock wave therapy (DUOLITH® SD1)|
233718|NCT02410434|Other|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
233719|NCT02410421|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
233720|NCT02410408|Device|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
233721|NCT02410408|Other|information package|Information on PSC and RCA
233722|NCT02410395|Procedure|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
233723|NCT02410395|Procedure|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
233724|NCT02410382|Drug|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
233725|NCT02410382|Drug|Placebo|oral placebo
233726|NCT02410369|Drug|S-588410|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
233727|NCT02410369|Drug|Placebo|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
233729|NCT02410356|Drug|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
233730|NCT02410343|Drug|TV-1106|A starting dose of 5.0 mg was expected to be appropriate for most patients because the daily recommended starting dose of recombinant human growth hormone (rhGH) treatments (e.g. somatropin) is 0.2 mg/day, and the conversion factor was 28. Dosage could be titrated by an unblinded central reader on weeks 4, 8, 12 and 16 until the participant's insulin-like growth factor 1 (IGF-1) standard deviation score (SDS) was within the range of -0.5 to +1.5.
233731|NCT02410343|Drug|Placebo|Placebo treatment was administered in a blinded fashion and titrated on weeks 4, 8, 12 and 16 to mimic the active treatment.
233732|NCT02410330|Procedure|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
233733|NCT02410330|Procedure|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
233734|NCT02410317|Drug|Ropivacaine|
233735|NCT02410317|Drug|Morphine|
233736|NCT02410304|Device|Xrays|Clinical evaluation
233737|NCT02410304|Device|Ultrasound (B mode )|
233738|NCT02410304|Device|Ultrasound (D mode)|
233739|NCT02410291|Other|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
233740|NCT02410278|Drug|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
233741|NCT02410278|Drug|montelukast|As described in the treatment arm
233742|NCT02410278|Drug|Placebo|Matched placebo
233743|NCT02410265|Behavioral|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
233744|NCT02410265|Behavioral|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
233745|NCT02410252|Device|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature. Participants are asked to use this device for two weeks.
233746|NCT02410239|Biological|Mesenchymal Stem Cells|
233747|NCT02410226|Procedure|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
233748|NCT02410226|Radiation|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
233749|NCT02410226|Radiation|Sham ultrasound procedure|Applying the ultrasound probe on the patient`s back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
233750|NCT02410213|Drug|Ferric Carboxymaltose (FCM)|
233751|NCT02410200|Drug|dimethyl fumarate|
233752|NCT02410187|Radiation|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
233753|NCT02410187|Drug|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.~Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
233754|NCT02410187|Radiation|palliative RT|fraction size of RT = < 3 Gy
233755|NCT02410174|Radiation|Stereotactic Body Radiotherapy (SBRT)|
233756|NCT02410161|Dietary Supplement|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
233757|NCT02410148|Device|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
233758|NCT02410135|Drug|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
233759|NCT02410109|Behavioral|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
233760|NCT02410096|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
233761|NCT02410096|Other|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
233762|NCT02410096|Dietary Supplement|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
233763|NCT02410096|Dietary Supplement|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
233764|NCT02410083|Drug|Clopirin 1|
233767|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 2|
233768|NCT02410070|Procedure|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
233769|NCT02410057|Dietary Supplement|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula
233770|NCT02410057|Dietary Supplement|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
233771|NCT02410057|Dietary Supplement|Standard infant formula|Standard infant formula
233772|NCT02410031|Drug|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
233773|NCT02410018|Device|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
233774|NCT02410005|Dietary Supplement|Calcitriol|
233775|NCT02410005|Drug|Losartan|
233776|NCT02409992|Behavioral|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
233777|NCT02409992|Behavioral|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
233778|NCT02409979|Other|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
233779|NCT02409979|Other|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
233780|NCT02409979|Other|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
233781|NCT02409966|Procedure|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
233782|NCT02409966|Procedure|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.~Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
233783|NCT02409953|Other|Lying in a bath during 2 hours|
233784|NCT02409953|Other|Lying in a bed during 2 hours|
233785|NCT02409940|Biological|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
233786|NCT02409927|Dietary Supplement|MCT oil 10g|10 g of pure MCT oil mixed with skim milk in a standardized breakfast
233787|NCT02409927|Dietary Supplement|MCT homogenate 10g|10g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
233788|NCT02409927|Dietary Supplement|Control|vehicule (skim milk) with a standardized breakfast
233789|NCT02409927|Dietary Supplement|MCT oil 20g|20g of pure MCT oil mixed with skim milk in a standardized breakfast
233790|NCT02409927|Dietary Supplement|MCT homogenate 20g|20g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
233791|NCT02409927|Dietary Supplement|MCT oil 30g|30g of 100% pure MCT oil mixed with skim milk in a standardized breakfast
233792|NCT02409927|Dietary Supplement|MCT homogenate 30g|30g provided by 10% MCT homogenate mixed with skim milk in a standardized breakfast
233793|NCT02409901|Behavioral|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
233794|NCT02409888|Behavioral|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
233795|NCT02409888|Behavioral|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
233796|NCT02409888|Other|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
233797|NCT02409888|Other|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
233798|NCT02409862|Drug|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
233799|NCT02409862|Drug|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
233800|NCT02409849|Drug|Octreotide lar|
233801|NCT02409836|Drug|Marketed Dentifrice|Marketed Dentifrice
233802|NCT02409836|Drug|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
233803|NCT02409836|Drug|Marketed Flavored Dentifrice|Bubble Gum Flavored
233804|NCT02409823|Drug|Atypical Antipsychotics|any atypical antipsychotic
233805|NCT02409810|Drug|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
233806|NCT02409797|Other|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2‐week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
233807|NCT02409784|Dietary Supplement|Pre-KD|Before starting 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
233808|NCT02409784|Dietary Supplement|Post-KD|After 4 days of 4:1 (lipids:protein/carbohydrates) ketogenic diet
233809|NCT02409771|Device|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
233810|NCT02409758|Behavioral|Voice therapy|Voice therapy applied during 6 weeks.
233811|NCT02409745|Procedure|endometrial scratch|local injury to the endometrium by Pipelle
233812|NCT02409732|Drug|aminolevulinic acid hydrochloride|
233813|NCT02409732|Procedure|Photodynamic therapy with blue light|
233814|NCT02409719|Other|Schedule|Illustrative daily planner to point the day that the exercise was performed
233815|NCT02409693|Procedure|Myringotomy with tube insertion|
233816|NCT02409680|Drug|Low dose aspirin|Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
233817|NCT02409680|Drug|Placebo|Placebo
233818|NCT02409667|Biological|Secukinumab|Secukinumab for s.c. injection was supplied in single boxes each containing 2 pre-filled syringes (PFS) of 150 mg secukinumab in a 1 mL liquid formulation. Each 300 mg dose was administered as 2 PFS injections of 150 mg secukinumab.
233819|NCT02409654|Other|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
233820|NCT02409654|Other|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
233821|NCT02409641|Drug|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
233822|NCT02409628|Device|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
233823|NCT02409615|Other|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
233824|NCT02409615|Other|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
233825|NCT02409602|Other|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
233826|NCT02409589|Device|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
233827|NCT02409589|Procedure|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
233828|NCT02409576|Biological|Expanded , Activated NK cells|"Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
233829|NCT02409563|Drug|Budesonide nasal spray (100 mcg bid)|
233830|NCT02409563|Drug|Budesonide nasal spray (50 mcg bid|
233831|NCT02409550|Other|CARATKids Questionnaire|
233832|NCT02409537|Dietary Supplement|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
233833|NCT02409537|Dietary Supplement|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
233834|NCT02409537|Other|placebo|the individuals were given placebo for 1 month
233835|NCT02409524|Biological|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
233836|NCT02409524|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
233837|NCT02409524|Biological|CRCL|Autologous tumor-derived chaperone protein mixture
233838|NCT02409511|Other|non intervention|
233839|NCT02409498|Drug|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
233840|NCT02409498|Drug|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
233841|NCT02409485|Behavioral|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
233842|NCT02409472|Other|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
233843|NCT02409459|Drug|Injectafer|
233844|NCT02409459|Drug|Placebo|Normal saline solution
233845|NCT02409446|Dietary Supplement|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
233846|NCT02409433|Drug|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.~The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
233847|NCT02409433|Drug|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
233848|NCT02409420|Behavioral|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
233849|NCT02409407|Drug|Misoprostol , Prostaglandins E1 analogue|
233850|NCT02409394|Drug|Hetrombopag Olamine|
233851|NCT02409381|Drug|Motore|250 mg
233852|NCT02409381|Drug|Alivium|600 mg
233853|NCT02409368|Drug|Nivolumab|
233854|NCT02409355|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
233855|NCT02409355|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
233856|NCT02409355|Drug|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
233857|NCT02409355|Drug|Gemcitabine|Gemcitabine will be administered at 1000 mg/m^2 (when coadministered with carboplatin) or 1250 mg/m^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
233858|NCT02409342|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
233859|NCT02409342|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
233860|NCT02409342|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m^2) every 21 days for 4 or 6 cycles as per local standard of care.
233861|NCT02409342|Drug|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m^2 (in combination with cisplatin) or 1000 mg/m^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
233862|NCT02409342|Drug|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
233863|NCT02409329|Behavioral|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
233864|NCT02409329|Behavioral|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
233865|NCT02409329|Behavioral|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
233866|NCT02409316|Drug|[18F]FES|[18F]FES PET/CT scan
233867|NCT02409303|Behavioral|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
233868|NCT02409290|Drug|Regimen A locally-used WHO-approved MDR-TB regimen (2011 guideline)|Drug: Locally-used WHO-approved MDR-TB regimen
233869|NCT02409290|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
233870|NCT02409290|Drug|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-sopropyliminophenazine.
233871|NCT02409290|Drug|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
233872|NCT02409290|Drug|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
233873|NCT02409290|Drug|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
233874|NCT02409290|Drug|Prothionamide|Prothionamide has a bacteriostatic action.
233875|NCT02409290|Drug|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
233876|NCT02409290|Drug|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
233877|NCT02409290|Drug|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
233878|NCT02409277|Other|Experimental: Standard vs Intensive e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
234085|NCT02407652|Behavioral|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
234086|NCT02407639|Other|CO2|gas
233879|NCT02409264|Other|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
233880|NCT02409251|Behavioral|Education and feedback|
233881|NCT02409238|Drug|Metformin|Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
233882|NCT02409238|Behavioral|Intensive Lifestyle Intervention|"The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.~This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises."
233883|NCT02409238|Behavioral|Standard LIfestyle Recommendation|The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
233884|NCT02409225|Device|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
233885|NCT02409225|Device|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
233886|NCT02409212|Behavioral|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
233887|NCT02409212|Behavioral|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
233888|NCT02409199|Drug|Docetaxel|
233889|NCT02409199|Drug|apatinib|
233890|NCT02409186|Drug|Nimotuzumab|400mg/w，d1, week 1-7
233891|NCT02409186|Radiation|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
233892|NCT02409186|Drug|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
233893|NCT02409186|Drug|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
233894|NCT02409186|Other|placebo|400mg/w，d1, week 1-7
233895|NCT02409173|Device|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
233896|NCT02409173|Procedure|Bariatric Surgery|Standard Roux-en-Y gastric bypass
233897|NCT02409160|Procedure|Standard Roux-en-Y gastric bypass|
233898|NCT02409147|Procedure|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
233899|NCT02409121|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
233900|NCT02409108|Device|Exatherm-TBH system|One treatment of Total Body Hyperthermia
233901|NCT02409095|Biological|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
233902|NCT02409095|Device|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
233903|NCT02409095|Other|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
233904|NCT02409069|Device|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
233905|NCT02409069|Device|Sham stimulation (Nemos®, Cerbomed GmbH)|
233906|NCT02409056|Behavioral|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
233907|NCT02409056|Behavioral|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
233908|NCT02409043|Other|Blood draw|Blood drawn for comparison with other groups
233909|NCT02409043|Other|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
233910|NCT02409017|Procedure|Insulin drip|
233911|NCT02409004|Drug|Ataluren|Powder for oral suspension (supplied in sachets) 1X 125 mg + 1 x 250 mg + 1000 mg (total of 1375 mg)
233912|NCT02409004|Drug|Rifampin|Capsule 2x3oo mg Oral
233913|NCT02408991|Drug|Neupogen|Neupogen is given as an injection in your skin every three days for a total of 5 doses.
233914|NCT02408991|Device|Art-Assist Device|The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
233915|NCT02408978|Drug|OXP005|
233916|NCT02408978|Drug|Naproxen|
233917|NCT02408965|Drug|Methergine|0.2 mg of methylergonovine maleate
233918|NCT02408965|Other|placebo|saline placebo to maintain blinding
233919|NCT02408952|Behavioral|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
233920|NCT02408952|Behavioral|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
233921|NCT02408939|Drug|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
233922|NCT02408926|Biological|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
233923|NCT02408926|Biological|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
233924|NCT02408926|Biological|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
233925|NCT02408926|Biological|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
233926|NCT02408913|Biological|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
233927|NCT02408913|Biological|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
233928|NCT02408887|Procedure|Total Thyroidectomy (TT)|Total removal of thyroid
233929|NCT02408887|Procedure|Prophylactic central neck lymph node dissection(pCND)|Lymph node dissection
233930|NCT02408861|Biological|Ipilimumab|Given IV
233931|NCT02408861|Biological|Nivolumab|Given IV
233932|NCT02408848|Other|Observational|This is an observational study. There is no intervention.
233933|NCT02408835|Device|PICO™|Negative pressure wound therapy device for closed surgical wounds.
233934|NCT02408822|Device|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
233935|NCT02408822|Device|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
233936|NCT02408809|Behavioral|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
233937|NCT02408809|Behavioral|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
233938|NCT02408796|Drug|OTO-201|
233939|NCT02408770|Drug|ulipristal acetate|selective progesterone receptor modulator
233940|NCT02408757|Procedure|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
233941|NCT02408744|Drug|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
233942|NCT02408731|Drug|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
233943|NCT02408718|Behavioral|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
233944|NCT02408705|Drug|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
233945|NCT02408705|Drug|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
233946|NCT02408705|Drug|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
233947|NCT02408692|Drug|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of <25 kg/m2 will have completed study participation.
233948|NCT02408692|Drug|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
233949|NCT02408679|Procedure|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
233950|NCT02408679|Other|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
233951|NCT02408666|Other|Interview|
233952|NCT02408653|Device|EEG|
233953|NCT02408640|Behavioral|Cannabishjalpen.se|
233954|NCT02408627|Device|EEG|
233955|NCT02408614|Other|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
233956|NCT02408614|Other|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
233957|NCT02408614|Other|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
233958|NCT02408614|Device|Treadmill|
233959|NCT02408601|Other|Helioseal - F|"Helioseal -F ( Resin based sealant)~isolate the tooth surface~etch the fissure anatomy with 37% phosphoric acid for 20 seconds~wash the tooth surface and dry it. No salivary contamination is accepeted~using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.~light cure the sealant~check for high points and the occlusion"
234087|NCT02407639|Other|air|air
234088|NCT02407626|Drug|Propofol|Total intravenous anesthesia is a clinical standard procedure
234089|NCT02407626|Drug|Sevoflurane|Volatile anesthesia is a clinical standard procedure
233960|NCT02408601|Other|ART sealant|"Fuji IX extra strength~isolate the tooth surface~condition the fissure anatomy using a GC conditioner for 10 seconds~wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.~dry the tooth surface~mix the GIC according to the standard powder: liquid ratio~place the mix onto the fissures using a plastic spatula~apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)~apply pressure for 10-15 sec and withdraw the finger in a sideways motion~scrap out the excess material~check for the high points and the occlusion~apply petroleum jelly onto the GIC mix~advice patient not to eat or drink for 30 minutes."
233961|NCT02408588|Other|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
233962|NCT02408575|Device|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
233963|NCT02408575|Device|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3~No notched filtering"
233964|NCT02408562|Other|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
233965|NCT02408562|Other|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
233966|NCT02408549|Drug|Lacosamide Tablet|"Active substance: Lacosamide~Pharmaceutical form: Tablet~Concentration: 50 mg and 100 mg~Route of Administration: oral administration"
233967|NCT02408549|Drug|Lasosamide Oral Solution|"Active substance: Lacosamide~Pharmaceutical form: Oral solution~Concentration: 10 mg/ml~Route of Administration: Oral administration"
233968|NCT02408523|Drug|Lacosamide Tablet|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
233969|NCT02408523|Drug|Lasosamide Oral Solution|"Active Substance: Lacosamide~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
233970|NCT02408523|Other|Placebo Tablet|"Active Substance: Placebo~Pharmaceutical Form: Film-coated Tablet~Concentration: 50 mg~Route of Administration: Oral use"
233971|NCT02408523|Other|Placebo Oral Solution|"Active Substance: Placebo~Pharmaceutical Form: Oral Solution~Concentration: 10 mg/ml~Route of Administration: Oral use"
233972|NCT02408484|Biological|Octafibrin|Plasma-derived Fibrinogen concentrate
233973|NCT02408471|Device|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
233974|NCT02408458|Device|MIROMESH®|
233975|NCT02408445|Drug|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
233976|NCT02408432|Biological|Mesenchymal Stem Cell Transplantation|Undergo mesenchymal stem cell infusion Drug: Standard of Care for Heart Failure Both groups will also receive standard of care drugs for heart failure. The study doctor will tell you which drugs you are taking, their risks, and when you should take them.
233977|NCT02408432|Drug|Standard of Care for Heart Failure|Both groups will also receive standard of care drugs for heart failure. The study doctor will tell you which drugs you are taking, their risks, and when you should take them.
233978|NCT02408419|Drug|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
233979|NCT02408419|Drug|Saline|Saline is injected as a placebo
233980|NCT02408406|Other|Communication Intervention|Use PatientCareAnywhere system
233981|NCT02408406|Other|Educational Intervention|Use PatientCareAnywhere system
233982|NCT02408406|Other|Internet-Based Intervention|Use PatientCareAnywhere system
233983|NCT02408406|Other|Quality-of-Life Assessment|Ancillary studies
233984|NCT02408406|Other|Questionnaire Administration|Ancillary studies
233985|NCT02408393|Drug|Saline|
233986|NCT02408393|Drug|Ropivacaine|
233987|NCT02408367|Behavioral|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
233988|NCT02408367|Behavioral|Relaxation|30
233989|NCT02408354|Drug|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.~Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
233990|NCT02408354|Drug|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
233991|NCT02408328|Drug|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
233992|NCT02408328|Device|Home monitor|Use of home monitor until 44 weeks postmenstrual age
233993|NCT02408328|Other|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
233994|NCT02408315|Drug|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
233995|NCT02408302|Drug|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
233996|NCT02408289|Dietary Supplement|Lo-Flav|low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
233997|NCT02408289|Dietary Supplement|Hi-Flav|High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
233998|NCT02408289|Dietary Supplement|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
233999|NCT02408289|Dietary Supplement|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
234280|NCT02406261|Drug|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
234000|NCT02408276|Other|dGEMERIC MRI technique|"Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.~All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant."
234001|NCT02408263|Procedure|Total Hip Replacement (THR) and Total Knee Replacement (TKR)|Total Hip Replacement is a surgical procedure where the cartilage and bone of the hip joint is replaced with artificial materials. Total Knee Replacement involves replacement of all three compartments of the knee the medial, the lateral and patellofemoral compartment.
234002|NCT02408250|Procedure|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
234003|NCT02408237|Device|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
234004|NCT02408237|Device|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
234005|NCT02408237|Device|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
234006|NCT02408237|Device|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
234007|NCT02408198|Behavioral|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
234008|NCT02408185|Drug|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
234009|NCT02408185|Drug|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
234010|NCT02408172|Drug|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
234011|NCT02408172|Drug|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
234012|NCT02408159|Drug|Varicella Zoster Vaccine|
234013|NCT02408159|Drug|Placebo|
234014|NCT02408146|Procedure|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
234015|NCT02408146|Drug|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
234016|NCT02408146|Procedure|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
234017|NCT02408146|Drug|fentanyl citrate+ ondansetron hydrochloride + normal saline|
234018|NCT02408146|Drug|celecoxib|
234019|NCT02408133|Other|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
234020|NCT02408120|Drug|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.~Daily insulin dose will be adjusted as follow:~If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
234021|NCT02408120|Drug|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.~Daily insulin dose will be adjusted as follow:~If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change~If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day~If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day~If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day~If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
234022|NCT02408120|Drug|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.~For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:~BG >141-180 mg/dL; 2-4 units of insulin aspart~BG between 181-220 mg/dL; 3-6 units of insulin aspart~BG between 221-260 mg/dL; 4-8 units of insulin aspart~BG between 261-300 mg/dL; 5-10 units of insulin aspart~BG between 301-350 mg/dL; 6-12 units of insulin aspart~BG between 351-400 mg/dL; 7-14 units of insulin aspart~BG > 400 mg/dL; 8-16 units of insulin aspart~For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:~BG between 261-300 mg/dL; 5-10 units of insulin aspart~BG between 301-350 mg/dL; 6-12 units of insulin aspart~BG between 351-400 mg/dL; 7-14 units of insulin aspart~BG > 400 mg/dL; 8-16 units of insulin aspart"
234023|NCT02408107|Behavioral|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
234024|NCT02408081|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
234025|NCT02408068|Drug|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
234026|NCT02408068|Drug|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
234027|NCT02408068|Drug|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
234028|NCT02408068|Drug|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
234029|NCT02408055|Drug|TA-8995|
234030|NCT02408042|Drug|Pembrolizumab|
234031|NCT02408042|Drug|Etoposide|
234032|NCT02408042|Drug|Ifosfamide|
234033|NCT02408042|Drug|Mesna|
234034|NCT02408042|Drug|Carboplatin|
234035|NCT02408042|Drug|Brentuximab vedotin|
234036|NCT02408042|Drug|Rituximab|
234037|NCT02408029|Other|Observational study - no intervention|
234038|NCT02408016|Biological|Aldesleukin|Given SC
234039|NCT02408016|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
234040|NCT02408016|Drug|Cyclophosphamide|Given IV
234041|NCT02408016|Other|Laboratory Biomarker Analysis|Correlative studies
234042|NCT02408016|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
234043|NCT02408003|Drug|Levosimendan|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
234044|NCT02408003|Drug|Milrinone|"Data is collected at baseline as two controls.~Three physiological interventions follows, and data is collected after each:~Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.~Raising cardiac preload by increasing central venous pressure through leg elevation.~Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.~Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
234045|NCT02407990|Biological|BGB-A317|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme. In the schedule exploration part, patients will be assigned to doses and dose schedules. In the fix dose exploration, patients will be assigned to dose group(s) not to exceed the MTD.~In the dose expansion part, patients will be assigned to different groups based on their tumor type."
234046|NCT02407990|Biological|BGB-A317|Patients will be assigned to different groups based on their tumor types
234047|NCT02407977|Other|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
234090|NCT02407613|Device|Philips Sonalleve MR-HIFU Breast Tumor Therapy System|Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
234091|NCT02407600|Drug|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
234092|NCT02407600|Drug|Placebo|
234539|NCT02404454|Procedure|Hysteroscopic metroplasty|
234048|NCT02407951|Behavioral|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians."
234049|NCT02407951|Behavioral|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians."
234050|NCT02407938|Other|Rice meal|
234051|NCT02407925|Behavioral|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
234052|NCT02407912|Drug|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
234053|NCT02407899|Drug|Saxagliptin|Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.
234054|NCT02407899|Drug|Vitamin D3|Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.
234055|NCT02407899|Drug|Insulin|For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
234056|NCT02407899|Drug|Metformin|Take Metformin tablet 1.5g p.o. per day for 104 weeks (adjust the dose between 1-1.7g per day according to subject's specific situation) before or after randomization.
234057|NCT02407873|Other|Non|
234058|NCT02407860|Other|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
234059|NCT02407860|Other|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
234060|NCT02407847|Other|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
234061|NCT02407834|Other|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
234062|NCT02407834|Other|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
234063|NCT02407834|Other|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
234064|NCT02407834|Other|S4|Immersion in Saline solution for 20 minutes, during 7 days.
234065|NCT02407821|Drug|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
234066|NCT02407821|Drug|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
234067|NCT02407808|Drug|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
234068|NCT02407808|Drug|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
234069|NCT02407795|Radiation|conventional radiotherapy|1x8Gy
234070|NCT02407795|Radiation|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
234071|NCT02407782|Drug|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
234072|NCT02407782|Drug|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
234073|NCT02407769|Dietary Supplement|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
234074|NCT02407756|Drug|Dupilumab|
234075|NCT02407743|Behavioral|Surgical patients' clinical progression|Study the dynamic nature of pain
234076|NCT02407743|Genetic|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
234077|NCT02407704|Drug|Venlafaxine XR|
234078|NCT02407704|Other|Aerobic Exercise|
234079|NCT02407704|Drug|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
234080|NCT02407691|Other|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
234081|NCT02407691|Other|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
234082|NCT02407678|Genetic|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
234083|NCT02407665|Behavioral|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
234084|NCT02407652|Behavioral|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
234720|NCT02403271|Drug|Durvalumab|Anti PDL-1
234093|NCT02407587|Device|cochlear implants|"PET scans for the mature patients with unilateral cochlear implants and preserved hearing~4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
234094|NCT02407574|Device|External Pacing Box|Atrial pacing using an external pacing box
234095|NCT02407548|Dietary Supplement|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
234096|NCT02407548|Dietary Supplement|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
234097|NCT02407548|Dietary Supplement|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
234098|NCT02407535|Device|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
234099|NCT02407522|Dietary Supplement|Black rice|They asked to keep their normal life style during intervention
234100|NCT02407522|Other|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
234101|NCT02407509|Drug|RO5126766|
234102|NCT02407509|Drug|Everolimus|
234103|NCT02407496|Other|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
234104|NCT02407483|Device|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
234105|NCT02407483|Device|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
234106|NCT02407470|Drug|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
234107|NCT02407470|Procedure|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
234108|NCT02407470|Procedure|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
234109|NCT02407457|Device|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
234110|NCT02407457|Device|FDA Approved EVAR AAA Graft Systems|
234111|NCT02407444|Other|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
234112|NCT02407444|Other|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.~In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.~Overall treatment session will last 50 minutes."
234113|NCT02407418|Other|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
234114|NCT02407418|Other|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
234115|NCT02407405|Drug|Selumetinib|orally 50 mg/dose, every 12 hours every day continuously (1 cycle = 28 days)
234116|NCT02407392|Drug|Acetic Acid|During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
234117|NCT02407392|Procedure|Non targeted quadrantic biopsies|During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
234118|NCT02407379|Procedure|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
234119|NCT02407379|Procedure|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
234120|NCT02407366|Drug|Icotinib|Icotinib (125 mg ,Three times daily)
234121|NCT02407366|Drug|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
234122|NCT02407366|Drug|Carboplatin|Carboplatin (AUC，5) every 21 days
234123|NCT02407366|Radiation|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
234124|NCT02407353|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
234125|NCT02407353|Drug|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
234126|NCT02407340|Drug|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
234127|NCT02407340|Drug|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
234128|NCT02407314|Procedure|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
234129|NCT02407314|Device|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
234161|NCT02407119|Drug|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
234130|NCT02407314|Other|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
234131|NCT02407314|Other|Six minute walk distance|Assessment of the walking distance in 6 minutes.
234132|NCT02407314|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
234133|NCT02407314|Drug|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
234134|NCT02407301|Other|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
234135|NCT02407301|Other|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
234136|NCT02407301|Other|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
234137|NCT02407301|Other|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
234138|NCT02407301|Other|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
234139|NCT02407288|Device|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
234140|NCT02407288|Device|Sham tDCS|
234141|NCT02407275|Other|Biological sample|
234142|NCT02407262|Dietary Supplement|Black seed oil|
234143|NCT02407262|Other|Placebo|vegetable oil
234144|NCT02407236|Drug|Placebo IV|Placebo will be administered as intravenous infusion.
234145|NCT02407236|Drug|Placebo SC|Placebo will be administered Subcutaneously.
234146|NCT02407236|Drug|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
234147|NCT02407236|Drug|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
234148|NCT02407223|Drug|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
234149|NCT02407223|Drug|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
234150|NCT02407223|Drug|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
234151|NCT02407210|Drug|azilsartan|
234152|NCT02407210|Drug|Olmesartan medoxomil|
234153|NCT02407184|Other|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
234154|NCT02407171|Drug|MK-3475|200 mg every 2 weeks by IV infusion
234155|NCT02407171|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
234156|NCT02407158|Device|SonarMed Airwave Device|Measure the concordance of chest x-ray and the Airwave device for measuring the change of position of an endotracheal tube.
234157|NCT02407145|Other|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
234158|NCT02407132|Behavioral|Adapted DSME|Participants assigned to this arm received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
234159|NCT02407132|Behavioral|Standard DSME|Active Comparator: Standard DSME Participants assigned to this arm received standard diabetes self-management education classes offered at community locations, taught by Certified Diabetes Educators (CDEs) in a group/classroom setting.
234160|NCT02407119|Drug|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
234279|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
234162|NCT02407106|Dietary Supplement|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
234163|NCT02407093|Behavioral|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
234164|NCT02407093|Behavioral|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
234165|NCT02407080|Drug|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
234166|NCT02407080|Drug|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
234167|NCT02407067|Device|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
234168|NCT02407067|Device|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.~Personal Communication System"
234169|NCT02407054|Drug|LY3023414|Administered orally
234170|NCT02407054|Drug|Enzalutamide|Administered orally
234171|NCT02407054|Drug|Placebo|Administered orally
234172|NCT02407041|Drug|GR-MD-02|IV infusion
234173|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
234174|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
234175|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
234176|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
234177|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
234178|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
234179|NCT02407028|Drug|Normobaric Hyperoxia (NBH)|100% FiO2 for 4.5 hours twice a day for five days or until patient following commands or brain dead
234180|NCT02407028|Other|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
234181|NCT02407015|Other|Nintendo 3DS gameplay|
234182|NCT02406989|Drug|MS-553|Study Drug
234183|NCT02406989|Drug|Placebo|Matching placebo to MS-553
234184|NCT02406976|Other|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.~Furthermore the similar treatment to G3."
234185|NCT02406976|Behavioral|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.~Furthermore the similar treatment to G3."
234186|NCT02406976|Other|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
234187|NCT02406963|Other|Digital Photograph|A digital photograph sent by the family of the surgical site
234188|NCT02406963|Other|Telephone Call|Standard telephone call with the nurse practitioner
234189|NCT02406950|Drug|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
234190|NCT02406937|Dietary Supplement|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
234191|NCT02406937|Dietary Supplement|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
234192|NCT02406937|Dietary Supplement|Breast Feeding|Oral intake of breast milk
234193|NCT02406924|Procedure|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
234194|NCT02406924|Radiation|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
234195|NCT02406924|Other|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
234196|NCT02406924|Other|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
234197|NCT02406911|Drug|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
234198|NCT02406898|Device|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
234800|NCT02402660|Drug|Placebo|Daily, oral administration for 24 months
234199|NCT02406885|Drug|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
234200|NCT02406872|Drug|Remimazolam Tosilate|IV pumping for anesthesia
234201|NCT02406872|Drug|Propofol|IV bolus for anesthesia
234202|NCT02406859|Behavioral|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
234203|NCT02406859|Behavioral|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
234204|NCT02406846|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
234205|NCT02406846|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
234206|NCT02406833|Drug|TGF-β2 antisense oligonucleotide|intravitreal injection
234207|NCT02406833|Procedure|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
234208|NCT02406820|Device|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
234209|NCT02406807|Other|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
234210|NCT02406807|Other|Sham Spinal lumbar manipulation|Sham manipulation
234211|NCT02406794|Drug|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
234212|NCT02406781|Drug|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
234213|NCT02406781|Drug|Combination of MK3475 with Metronomic CP and G100|"Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
234214|NCT02406755|Other|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
234215|NCT02406755|Other|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
234216|NCT02406755|Other|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
234217|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
234218|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 2 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
234219|NCT02406742|Drug|Ibrutinib|
234220|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 9 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
234221|NCT02406742|Drug|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
234222|NCT02406729|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
234223|NCT02406729|Other|Placebo|Route:subcutaneous
234224|NCT02406716|Other|Biospecimen retention|
234225|NCT02406703|Drug|Chloroprocaine|
234226|NCT02406703|Drug|Mepivacaine|
234227|NCT02406690|Other|Estradiol Valerate, Progesterone in Oil, Leuprolide|Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
234228|NCT02406677|Other|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
234229|NCT02406664|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
234230|NCT02406651|Drug|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
234231|NCT02406651|Drug|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
234232|NCT02406638|Other|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
234233|NCT02406625|Behavioral|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
234234|NCT02406612|Device|X-Seal 6F Vascular Closure Device|
234235|NCT02406599|Device|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
234236|NCT02406599|Other|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
234237|NCT02406586|Drug|Salsalate|Salsalate 750 mg
234238|NCT02406586|Drug|Carvedilol|Carvedilol 3.125 mg
234239|NCT02406586|Drug|Placebo|One tablet
234240|NCT02406586|Drug|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
234241|NCT02406573|Device|Crest® Sensi-Stop™ Strips|
234242|NCT02406560|Drug|tafamidis|fasted
234243|NCT02406560|Drug|tafamidis|high fat meal
234244|NCT02406560|Drug|tafamidis|
234245|NCT02406547|Device|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
234246|NCT02406547|Device|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
234247|NCT02406534|Behavioral|HRQoL surveys|
234248|NCT02406521|Drug|Pazopanib|
234249|NCT02406521|Drug|Sorafenib|
234250|NCT02406521|Drug|Radium-223|
234251|NCT02406508|Device|Melphalan/HDS|
234252|NCT02406508|Drug|Sorafenib|
234253|NCT02406495|Device|filcon IV 1|contact lens
234254|NCT02406495|Device|ocufilcon D|contact lens
234255|NCT02406482|Behavioral|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
234256|NCT02406482|Behavioral|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
234257|NCT02406469|Dietary Supplement|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
234258|NCT02406456|Other|Neurofeedback|
234259|NCT02406443|Drug|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
234260|NCT02406443|Other|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
234261|NCT02406430|Procedure|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
234262|NCT02406417|Device|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
234263|NCT02406417|Device|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
234264|NCT02406404|Behavioral|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
234265|NCT02406365|Device|Diagnostic imaging aid for one-visit management of cervical lesions|
234266|NCT02406352|Device|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change."
234267|NCT02406339|Device|NMES|Neuromuscular Electrical Stimulation
234268|NCT02406339|Device|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
234269|NCT02406313|Other|CTS|Standardized Thermal Cure
234270|NCT02406313|Other|ETP|Patient Therapeutic Education
234271|NCT02406300|Procedure|Subarachnoid Anesthesia|
234272|NCT02406300|Procedure|PNB/GA|
234273|NCT02406300|Drug|ropivacaine|
234274|NCT02406300|Drug|sevoflurane or desflurane|
234275|NCT02406300|Drug|bupivacaine or levobupivacaine|
234276|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
234277|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
234278|NCT02406274|Other|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated & or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) & record their findings. They will then interpret the CESM & record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding & will either be called negative & followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
234281|NCT02406261|Drug|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
234282|NCT02406261|Drug|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
234283|NCT02406261|Drug|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
234284|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
234285|NCT02406248|Drug|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
234286|NCT02406222|Drug|Pomalidomide|Chemotherapy
234287|NCT02406222|Drug|Dexamethasone|Chemotherapy
234288|NCT02406222|Drug|Cyclophosphamide|Chemotherapy
234289|NCT02406209|Drug|NS2|NS2 ophthalmic drops (0.5%)
234290|NCT02406209|Drug|Prednisolone acetate ophthalmic suspension (1%)|
234291|NCT02406183|Radiation|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
234292|NCT02406183|Drug|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
234293|NCT02406170|Drug|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
234294|NCT02406170|Drug|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
234295|NCT02406157|Device|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
234296|NCT02406157|Device|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
234297|NCT02406144|Drug|MLN9708|
234298|NCT02406144|Drug|Lenalidomide|
234299|NCT02406144|Drug|Dexamethasone|
234300|NCT02406131|Other|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
234301|NCT02406118|Procedure|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
234302|NCT02406105|Radiation|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
234303|NCT02406105|Drug|CyberKnife|
234304|NCT02406092|Drug|Rituximab|Rituximab SC 1400 mg
234305|NCT02406092|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
234306|NCT02406092|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice.
234307|NCT02406092|Drug|Vincristine|Vincristine will be administered as per standard local practice.
234308|NCT02406092|Drug|Prednisone|Prednisone will be administered as per standard local practice.
234309|NCT02406092|Drug|Fludarabine|Fludarabine will be administered as per standard local practice.
234310|NCT02406079|Procedure|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
234311|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
234312|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
234313|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
234314|NCT02406066|Drug|Placebo|Each cohort will have 2 subjects receiving placebo
234315|NCT02406053|Genetic|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
234316|NCT02406040|Other|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
234317|NCT02406027|Drug|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2*5 mg), orally, once daily.
234318|NCT02406027|Drug|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
234319|NCT02406027|Drug|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
234320|NCT02406027|Drug|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
234321|NCT02406014|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
234322|NCT02406014|Drug|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
234323|NCT02406001|Device|Tigran PTG|Open Flap Debridement
234324|NCT02406001|Procedure|Surgical intervention|Open Flap Debridement
234325|NCT02405988|Drug|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
234326|NCT02405988|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
234327|NCT02405975|Other|SCRIPT|An online tool designed to train doctors in all areas of prescribing
234412|NCT02405390|Procedure|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
235026|NCT02401087|Procedure|Anaesthesiological procedure|
234328|NCT02405962|Behavioral|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). The goal of ACT is to enhance the psychological flexibility of the parents, enabling them to (1) become aware of their thoughts and feelings regarding their child's asthma and its management, (2) accept and adapt flexibly to challenging situations, and (3) take actions to achieve valued goals in childhood asthma management.
234329|NCT02405962|Behavioral|Control|One session of educational talk about pediatric asthma care, as the usual care. To ensure the equivalency of the assigned sessions between groups, after attending the talk in the first week, the parents in the Control group will receive three telephone calls, starting from the second week on a weekly basis. This arrangement can also minimize the interference of the usual care naturalistically available in the study setting.
234330|NCT02405949|Genetic|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
234331|NCT02405936|Procedure|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
234332|NCT02405923|Other|HRF|The subject will take the formula for a period of 12 months.
234333|NCT02405923|Other|eHF|The subject will take the formula for a period of 12 months.
234334|NCT02405910|Drug|Nab-paclitaxel|
234335|NCT02405910|Drug|Gemcitabine|
234336|NCT02405897|Device|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
234337|NCT02405897|Device|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
234338|NCT02405884|Other|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
234339|NCT02405858|Drug|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
234340|NCT02405858|Drug|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
234341|NCT02405845|Radiation|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
234342|NCT02405832|Dietary Supplement|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
234343|NCT02405832|Dietary Supplement|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
234344|NCT02405819|Other|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
234345|NCT02405819|Other|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
234346|NCT02405806|Dietary Supplement|low carbohydrate food|low carbohydrate food
234347|NCT02405806|Dietary Supplement|standard food|standard food
234348|NCT02405793|Drug|Meloxicam Test Capsules|
234349|NCT02405793|Drug|Meloxicam Test Capsules|
234350|NCT02405793|Drug|Meloxicam Tablets|
234351|NCT02405780|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
234352|NCT02405780|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
234353|NCT02405767|Other|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
234354|NCT02405754|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
234355|NCT02405741|Device|Hyperbaric chamber treatment|
234356|NCT02405728|Device|Centrally inserted central catheters (CICCs)|Randomization between two well established clinical routine vascular access devices
234357|NCT02405728|Device|Peripherally inserted central catheters (PICCs)|Randomization between two well established clinical routine vascular access devices
234358|NCT02405715|Drug|Oxytocin|
234359|NCT02405702|Other|restrospective study|
234360|NCT02405689|Drug|Remifentanil|
234361|NCT02405689|Drug|Dexmedetomidine|
234362|NCT02405689|Drug|Sevoflurane|
234363|NCT02405676|Drug|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
234364|NCT02405676|Drug|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
234365|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 60mg/m2, D3~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1;
234366|NCT02405676|Drug|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
234367|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 100mg/m2, D3~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
234368|NCT02405676|Drug|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
234369|NCT02405663|Procedure|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
234370|NCT02405663|Procedure|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
234371|NCT02405637|Drug|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
234372|NCT02405637|Drug|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
234373|NCT02405624|Procedure|continuous positive airway pressure|CPAP training for muscle strength
234374|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
234375|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
234376|NCT02405611|Behavioral|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
234377|NCT02405598|Drug|Salbutamol|"Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)~VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)"
234378|NCT02405585|Drug|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
234379|NCT02405585|Biological|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
234380|NCT02405585|Radiation|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
234381|NCT02405585|Drug|Gemcitabine|"Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection."
234382|NCT02405572|Other|infant formula|infant formulas
234383|NCT02405559|Drug|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
234384|NCT02405546|Other|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
234385|NCT02405546|Other|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
234386|NCT02405533|Dietary Supplement|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
234387|NCT02405533|Other|Placebo|Placebo supplementation x 12 months
234388|NCT02405520|Biological|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
234389|NCT02405520|Biological|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
234390|NCT02405520|Biological|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
234391|NCT02405520|Biological|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
234392|NCT02405507|Dietary Supplement|wheat bread with wheat germ|
234393|NCT02405507|Dietary Supplement|wheat bread without wheat germ|
234394|NCT02405494|Dietary Supplement|Beverage 1|
234395|NCT02405494|Dietary Supplement|Beverage 2|
234396|NCT02405494|Dietary Supplement|Beverage 3|
234397|NCT02405494|Dietary Supplement|Beverage 4|
234398|NCT02405494|Dietary Supplement|Beverage 5|
234399|NCT02405494|Dietary Supplement|Beverage 6|
234400|NCT02405494|Dietary Supplement|Beverage 7|
234401|NCT02405494|Dietary Supplement|Beverage 8|
234402|NCT02405494|Dietary Supplement|Beverage 9|
234403|NCT02405481|Behavioral|SEPA III|
234404|NCT02405455|Procedure|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
234405|NCT02405455|Device|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
234406|NCT02405442|Drug|Andecaliximab|Andecaliximab administered via subcutaneous (SC) injection
234407|NCT02405442|Drug|Placebo|Placebo to match andecaliximab administered via SC injection
234408|NCT02405416|Procedure|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
234409|NCT02405416|Procedure|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
234410|NCT02405416|Procedure|Portal triad clamping|Portal triad are clamped in hepatectomy.
234411|NCT02405403|Drug|[18F]DPA-714 PET|[18F]DPA-714 Positron Emission Tomography
235097|NCT02400476|Drug|Neratinib|
234413|NCT02405390|Procedure|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
234414|NCT02405390|Device|Storz C-Mac® laryngoscope|
234415|NCT02405377|Procedure|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
234416|NCT02405377|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
234417|NCT02405377|Drug|0.9% sodium chloride ﬂuid administration|
234418|NCT02405377|Device|5-French catheter|
234419|NCT02405364|Drug|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
234420|NCT02405351|Behavioral|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
234421|NCT02405338|Biological|WT1/PRAME vaccination|
234422|NCT02405325|Behavioral|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
234423|NCT02405312|Behavioral|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
234424|NCT02405299|Other|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
234425|NCT02405286|Other|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
234426|NCT02405273|Procedure|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
234427|NCT02405273|Procedure|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
234428|NCT02405260|Drug|TTP399 400 mg|once daily
234429|NCT02405260|Drug|TTP399 800 mg|once daily
234430|NCT02405260|Drug|Sitagliptin 100 mg|once daily
234431|NCT02405260|Drug|Placebo|once daily
234432|NCT02405247|Other|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
234433|NCT02405234|Device|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
234434|NCT02405234|Device|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
234435|NCT02405221|Biological|TA-CIN (arm)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
234436|NCT02405221|Biological|TA-CIN (thigh)|TA-CIN vaccine 100µg IM in the arm at Week 1, 5, and 9.
234437|NCT02405208|Device|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
234438|NCT02405195|Procedure|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
234439|NCT02405182|Other|Magnetic Resonance Imaging|
234440|NCT02405169|Device|4 vs 6 implant treatment in the maxilla|
234441|NCT02405156|Drug|Letrozole|
234442|NCT02405156|Drug|Placebo|
234443|NCT02405156|Drug|Misoprostol|
234444|NCT02405143|Device|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
234445|NCT02405143|Device|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
234446|NCT02405130|Other|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
234447|NCT02405130|Other|no intracoronary epinephrine|patients will receive standard therapy only
234491|NCT02404779|Drug|cisatracurium besilate|
234492|NCT02404766|Other|C0-C1 dorsal glide manual mobilization|
234493|NCT02404766|Other|C7-T1 ventral cranial glide manual mobilization|
234448|NCT02405117|Behavioral|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
234449|NCT02405104|Drug|chlorzoxazone|ATC-code: M03BB03
234450|NCT02405104|Drug|Placebo|Placebo
234451|NCT02405104|Procedure|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
234452|NCT02405104|Procedure|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
234453|NCT02405091|Drug|NBI-98854|
234454|NCT02405078|Drug|Chemotherapy|Given standard salvage chemotherapy
234455|NCT02405078|Procedure|Computed Tomography|Undergo FDG-PET/CT scan
234456|NCT02405078|Drug|Fludeoxyglucose F-18|Undergo FDG-PET/CT scan
234457|NCT02405078|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT scan
234458|NCT02405065|Drug|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
234459|NCT02405052|Other|No intervention|Validation of the Panic Screening Score
234460|NCT02405039|Drug|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
234461|NCT02405039|Drug|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
234462|NCT02405013|Drug|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
234463|NCT02405013|Drug|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
234464|NCT02405013|Drug|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
234465|NCT02405013|Drug|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
234466|NCT02405000|Other|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
234467|NCT02404987|Other|Nutritional Supplement|
234468|NCT02404974|Behavioral|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
234469|NCT02404961|Other|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
234470|NCT02404948|Other|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
234471|NCT02404935|Drug|Cetuximab|
234472|NCT02404935|Drug|FOLFIRI and cetuximab|
234473|NCT02404922|Drug|CTP-730|
234474|NCT02404922|Drug|Placebo for CTP-730|
234475|NCT02404909|Other|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
234476|NCT02404896|Drug|Metreleptin|Metreleptin open-label treatment
234477|NCT02404883|Other|Online Decision-Aid Tool|
234478|NCT02404870|Drug|Placebo|Placebo
234479|NCT02404870|Drug|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
234480|NCT02404857|Device|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
234481|NCT02404844|Drug|BKM120|daily oral
234482|NCT02404844|Drug|Tamoxifen|daily oral
234483|NCT02404831|Other|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
234484|NCT02404831|Other|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
234485|NCT02404818|Procedure|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
234486|NCT02404818|Procedure|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
234487|NCT02404805|Drug|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
234488|NCT02404805|Drug|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
234489|NCT02404792|Other|High-intensity cardiovascular and resistance exercise|
234490|NCT02404792|Other|Moderate-intensity cardiovascular and resistance exercise|
234494|NCT02404753|Drug|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
234495|NCT02404753|Procedure|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
234496|NCT02404753|Procedure|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
234497|NCT02404753|Drug|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
234498|NCT02404740|Device|Pulse oximetry|Pulse oximetry
234499|NCT02404727|Procedure|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
234500|NCT02404727|Device|Avantage® Cup|
234501|NCT02404714|Device|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
234502|NCT02404701|Dietary Supplement|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234503|NCT02404701|Dietary Supplement|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234504|NCT02404701|Dietary Supplement|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234505|NCT02404701|Dietary Supplement|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234506|NCT02404701|Dietary Supplement|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234507|NCT02404701|Dietary Supplement|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234508|NCT02404701|Dietary Supplement|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234535|NCT02404493|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
234536|NCT02404493|Drug|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
234537|NCT02404480|Drug|PTC596|PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted
234538|NCT02404467|Device|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
234509|NCT02404701|Dietary Supplement|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
234510|NCT02404688|Drug|Active delta-9-THC|"Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes."
234511|NCT02404688|Drug|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
234512|NCT02404688|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
234513|NCT02404688|Drug|Placebo|Control: no alcohol, administered for a total of 80 minutes.
234514|NCT02404675|Drug|icotinib|
234515|NCT02404662|Other|Supportive text messages intervention|"The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot."
234516|NCT02404662|Other|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
234517|NCT02404649|Device|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
234518|NCT02404649|Device|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
234519|NCT02404636|Other|Interview|Brief structured interview
234520|NCT02404623|Dietary Supplement|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
234521|NCT02404610|Procedure|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
234522|NCT02404610|Procedure|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
234523|NCT02404610|Drug|propofol|
234524|NCT02404597|Device|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure <100 or mean arterial pressure <65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.~The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
234525|NCT02404584|Genetic|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
234526|NCT02404584|Biological|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.*~*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
234527|NCT02404571|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
234528|NCT02404558|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
234529|NCT02404558|Drug|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
234530|NCT02404545|Device|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
234531|NCT02404532|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
234532|NCT02404519|Dietary Supplement|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
234533|NCT02404519|Dietary Supplement|Placebo|1 tablet without MK-7 taken orally every day during 1 year
234534|NCT02404506|Drug|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
234540|NCT02404454|Device|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
234541|NCT02404454|Procedure|Office second look hysteroscopy|Second-look hysteroscopy after three months
234542|NCT02404441|Biological|PDR001|anti-PD1 antibody
234543|NCT02404428|Dietary Supplement|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
234544|NCT02404428|Dietary Supplement|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
234545|NCT02404402|Other|LED|Low Level Light Therapy
234546|NCT02404402|Other|sham LED|Inactive (sham) LED treatment
234547|NCT02404389|Drug|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
234548|NCT02404389|Drug|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
234549|NCT02404376|Drug|Exenatide|Intravenous administration of Exenatide
234550|NCT02404376|Other|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
234551|NCT02404376|Drug|Placebo|Intrevenous administration of Placebo
234552|NCT02404363|Drug|Clopidogrel|"Clopidogrel tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --> clopidogrel 150 mg/d x 7days then 75mg/d"
234553|NCT02404363|Drug|Placebo|"Placebo tablets 75 mg for six months:~In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --> placebo 150 mg/d x 7days then 75mg/d"
234554|NCT02404350|Biological|Secukinumab|Anti IL-17a monoclonal antibody
234555|NCT02404337|Drug|Betaine|
234556|NCT02404324|Other|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
234557|NCT02404311|Biological|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
234558|NCT02404311|Biological|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
234559|NCT02404311|Biological|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
234560|NCT02404311|Biological|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
234561|NCT02404298|Drug|IVIg|
234562|NCT02404285|Drug|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
234563|NCT02404285|Drug|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
234564|NCT02404272|Other|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.~The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.~Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
234565|NCT02404259|Drug|TDF (Tenofovir)|
234566|NCT02404259|Drug|Efavirenz|
234567|NCT02404259|Drug|lopinavir/ritonavir, atazanavir/ritonavir|
234568|NCT02404246|Behavioral|Peer support program|
234569|NCT02404233|Drug|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
234570|NCT02404233|Drug|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
234571|NCT02404220|Drug|Entospletinib|Entospletinib tablet(s) administered orally
234572|NCT02404220|Drug|VCR|Vincristine (VCR) administered intravenously
234573|NCT02404220|Drug|Dexamethasone|Dexamethasone tablet(s) administered orally
234574|NCT02404220|Drug|CNS Prophylaxis|CNS prophylaxis per institutional standard
234575|NCT02404207|Other|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
234576|NCT02404207|Other|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
234577|NCT02404207|Other|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
234578|NCT02404207|Other|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
234619|NCT02403882|Behavioral|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
234667|NCT02403674|Drug|ATRIPLA™|One ATRIPLA™ tablet taken q.d. by mouth
234579|NCT02404194|Behavioral|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
234580|NCT02404194|Behavioral|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
234581|NCT02404168|Drug|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
234582|NCT02404168|Drug|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
234583|NCT02404155|Drug|Clozapine|
234584|NCT02404142|Drug|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
234585|NCT02404142|Drug|saline isotonic solution|
234586|NCT02404129|Other|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
234587|NCT02404116|Other|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
234588|NCT02404116|Other|Wait List|Individuals are on a waiting list
234589|NCT02404103|Drug|Flunisolide HFA|
234590|NCT02404090|Radiation|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
234591|NCT02404077|Drug|Clonidine|
234592|NCT02404064|Drug|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
234593|NCT02404064|Drug|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
234594|NCT02404064|Drug|Placebo|No perioperative antibiotics
234595|NCT02404051|Drug|Everolimus|10 mg daily tablets
234596|NCT02404051|Drug|Exemestane|25 mg daily tablets
234597|NCT02404051|Drug|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
234598|NCT02404038|Drug|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
234599|NCT02404038|Device|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
234600|NCT02404038|Drug|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert"
234601|NCT02404025|Drug|Eltrombopag|Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
234602|NCT02404025|Drug|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
234603|NCT02404025|Drug|CsA|CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.
234604|NCT02404012|Dietary Supplement|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
234605|NCT02403999|Other|Test shampoo|Participants used Oilatum Soothe & Protect Shampoo at home in place of their usual wash product at least twice weekly for a two week period.
234606|NCT02403999|Other|Test bath foam|Participants used Oilatum Soothe & Protect Bath Foam at home in place of their usual wash product at least twice weekly for a two week period.
234607|NCT02403999|Other|Test head to toe wash|Participants used Oilatum Soothe & Protect Head to Toe Wash at home in place of their usual wash product at least twice weekly for a two week period.
234608|NCT02403986|Device|Restylane Vital Skinboosters Lidocaine|
234609|NCT02403973|Other|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
234610|NCT02403960|Dietary Supplement|probiotic|the patients used probiotic tablets in addition to scaling and root planning
234611|NCT02403960|Dietary Supplement|placebo|the patients used placebo tablets in addition to scaling and root planning
234612|NCT02403947|Drug|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
234613|NCT02403947|Drug|Suspension media|injection suspension media
234614|NCT02403934|Device|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
234615|NCT02403908|Device|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery <2 mm proximal from both ostia of right and left pulmonary arteries.
234616|NCT02403895|Drug|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
234617|NCT02403895|Drug|paclitaxel|Taxane
234618|NCT02403882|Behavioral|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
234620|NCT02403882|Behavioral|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
234621|NCT02403882|Behavioral|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
234622|NCT02403882|Behavioral|Default Option|In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
234623|NCT02403856|Drug|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
234624|NCT02403856|Drug|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
234625|NCT02403856|Procedure|Ultrasound-guided Needling and Lavage|
234626|NCT02403843|Device|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
234627|NCT02403830|Drug|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
234628|NCT02403830|Other|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
234629|NCT02403830|Drug|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
234630|NCT02403830|Drug|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
234631|NCT02403817|Behavioral|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
234632|NCT02403817|Behavioral|Eye Motor Training|Gameplay will be controlled by the player's eye movements (via an eye tracking device)
234633|NCT02403817|Behavioral|Hand Motor Training|Gameplay will be controlled by the player's hand movements (via a joystick).
234634|NCT02403804|Dietary Supplement|Phosphatidylcholine|Phosphatidylcholine 3600 mg qam and 2700 mg qpm
234635|NCT02403804|Dietary Supplement|Betaine (588 mg qam and 412 mg qpm)|Betaine anhydrous 588 mg qam and 412 mg qpm
234636|NCT02403804|Dietary Supplement|Betaine (1000 mg BID)|Betaine anhydrous 1000 mg BID
234637|NCT02403791|Device|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
234638|NCT02403791|Device|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
234639|NCT02403778|Drug|VESANOID|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).
234640|NCT02403778|Drug|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
234641|NCT02403752|Behavioral|Paired PLIE Program|Integrative exercise as described above
234642|NCT02403739|Other|No Intervention|No Intervention
234643|NCT02403726|Procedure|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
234644|NCT02403726|Procedure|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
234645|NCT02403713|Drug|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
234646|NCT02403713|Drug|Formoterol|Formoterol
234647|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
234648|NCT02403713|Drug|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
234649|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
234650|NCT02403700|Device|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
234651|NCT02403687|Drug|baclofen 2%|compound topical cream
234652|NCT02403687|Drug|Bupivacaine hydrochloride 1%|compound topical cream
234653|NCT02403687|Drug|Cyclobenzaprine hydrochloride 2%|compound topical cream
234654|NCT02403687|Drug|Diclofenac Sodium 3%|compound topical cream
234655|NCT02403687|Drug|Flurbiprofen 10%|compound topical cream
234656|NCT02403687|Drug|Gabapentin 6%|compound topical cream
234657|NCT02403687|Drug|Ketamine 10%|compound topical cream
234658|NCT02403687|Drug|Lidocaine 2%|compound topical cream
234659|NCT02403687|Drug|Prilocaine 2.5%|compound topical cream
234660|NCT02403687|Drug|Meloxicam 0.09%|compound topical cream
234661|NCT02403687|Drug|Sumatriptan 5%|compound topical cream
234662|NCT02403687|Drug|Tizanidine 0.1%|compound topical cream
234663|NCT02403687|Drug|Topiramate 2.5%|compound topical cream
234664|NCT02403687|Drug|Capsaicin, USP 0.0375%|compound topical cream
234665|NCT02403687|Drug|Menthol, NF 5.00 %|compound topical cream
234666|NCT02403674|Drug|MK-1439A|One MK-1439A tablet taken q.d. by mouth.
235098|NCT02400476|Drug|Loperamide|
234668|NCT02403674|Drug|Placebo|Placebo tablets matched to ATRIPLA® or MK-1439A.
234669|NCT02403661|Procedure|Post surgical electrical stimulation|Post surgical electrical stimulation immediately after surgical nerve repair
234670|NCT02403648|Drug|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
234671|NCT02403648|Drug|Lilly Glucagon|
234672|NCT02403648|Drug|Novo Glucagon|
234673|NCT02403635|Drug|Midazolam|
234674|NCT02403635|Drug|ASP2151|
234675|NCT02403622|Drug|Fecal Microbiota Preparations|Frozen processed human fecal material for treating recurrent clostridium difficile infections.
234676|NCT02403609|Other|BPT, Computerized Assessment|
234677|NCT02403596|Drug|Exacyl®|
234678|NCT02403596|Other|Placebo of Exacyl®|
234679|NCT02403583|Behavioral|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
234680|NCT02403570|Other|Brain MRI|
234681|NCT02403557|Behavioral|Waitlist|Weekly check up.
234682|NCT02403557|Behavioral|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
234683|NCT02403544|Radiation|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
234684|NCT02403544|Drug|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
234685|NCT02403544|Drug|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
234686|NCT02403531|Drug|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
234687|NCT02403531|Drug|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
234688|NCT02403531|Radiation|Radiotherapy|definitive radiotherapy
234689|NCT02403518|Device|Freedom Spinal Cord Stimulator System|
234690|NCT02403505|Drug|ABIRATERONE - Group 1|ZYTIGA - ABIRATERONE ACETATE TABLET plus DELTASONE - PREDNISONE TABLET plus XTANDI - ENZALUTAMIDE CAPSULE
234691|NCT02403505|Drug|ABIRATERONE - Group 2|ZYTIGA - ABIRATERONE ACETATE TABLET plus DELTASONE - PREDNISONE TABLET plus XTANDI - NILANDRON - NILUTAMIDE TABLET
234692|NCT02403492|Device|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
234693|NCT02403492|Device|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
234694|NCT02403492|Device|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
234695|NCT02403479|Drug|Silver Colloid|Topical silver colloid will be administered for 6 weeks. This will either occur before topical saline nasal spray. Participants are randomized as to the order of sprays. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
234696|NCT02403479|Other|Saline|Topical saline will be administered for 6 weeks. This will occur before the topical silver colloidal nasal spray. Participants are randomized as to the order of sprays.
234697|NCT02403466|Behavioral|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
234698|NCT02403453|Device|Rhine Cervical Disc|RHINE Cervical Disc
234699|NCT02403440|Drug|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
234700|NCT02403427|Device|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.~Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
234701|NCT02403414|Device|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
234702|NCT02403401|Drug|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
234703|NCT02403388|Other|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
234704|NCT02403375|Device|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
234705|NCT02403362|Drug|EPO-018B|
234706|NCT02403349|Drug|Fimasartan|
234707|NCT02403349|Drug|Valsartan|
234708|NCT02403349|Drug|Atenolol|
234709|NCT02403336|Other|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
234710|NCT02403336|Behavioral|Behavioral group intervention|Intervention on patients (educational workshop).
234711|NCT02403336|Other|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
234712|NCT02403323|Drug|Etrolizumab|105 mg etrolizumab subcutaneous administration once every 4 weeks
234713|NCT02403310|Drug|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.~Dose Level 2: 80 mg twice weekly.~Dose Level 1 (starting dose): 60 mg twice weekly.~Dose Level -1: 40 mg twice weekly.~Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.~Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
234714|NCT02403310|Drug|Daunorubicin|"Induction: Daunorubicin 60 mg/m^2/day (days 1-3).~Consolidation: Daunorubicin 45 mg/m^2/day (days 1-2)."
234715|NCT02403310|Drug|Cytarabine|"Induction: Cytarabine 100 mg/m^2/day (days 1-7).~Consolidation: Cytarabine 100 mg/m^2/day (continuous infusion on days 1-5)."
234716|NCT02403297|Device|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
234717|NCT02403284|Drug|Liraglutide|Subcutaneous injection by patient
234718|NCT02403284|Drug|Sugar Pill|Subcutaneous injection daily
234719|NCT02403271|Drug|Ibrutinib|BTK Inhibitor
234721|NCT02403258|Other|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
234722|NCT02403258|Behavioral|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
234723|NCT02403245|Other|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
234724|NCT02403232|Procedure|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.~The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.~The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.~Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
234725|NCT02403232|Device|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
234726|NCT02403232|Device|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
234727|NCT02403219|Drug|Botulinum toxin type A injection|Injection of botulinum toxin type A
234728|NCT02403219|Other|Saline solution injection|Injection of saline solution
234729|NCT02403206|Device|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
234730|NCT02403206|Procedure|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
234731|NCT02403193|Drug|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
234732|NCT02403193|Drug|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
234733|NCT02403193|Drug|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
234734|NCT02403193|Drug|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
234735|NCT02403193|Drug|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
234736|NCT02403193|Drug|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
234737|NCT02403193|Drug|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
234738|NCT02403193|Drug|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
234739|NCT02403193|Drug|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
234740|NCT02403180|Device|DACP MF|Nelfilcon A multifocal contact lenses
234741|NCT02403180|Device|PROCLEAR 1D MF|Omafilcon A multifocal contact lenses
234742|NCT02403154|Procedure|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
234743|NCT02403154|Procedure|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
234744|NCT02403141|Other|Questionnaire|
234745|NCT02403128|Drug|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
234746|NCT02403115|Other|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
234747|NCT02403089|Other|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
234748|NCT02403089|Other|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
234749|NCT02403063|Drug|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
234750|NCT02403063|Drug|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
234751|NCT02403063|Drug|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
234752|NCT02403050|Device|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
234753|NCT02403037|Device|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
234754|NCT02403037|Device|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
234755|NCT02403037|Drug|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
234756|NCT02403024|Behavioral|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
234797|NCT02402686|Drug|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
234757|NCT02403024|Behavioral|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
234758|NCT02403011|Other|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
234759|NCT02403011|Other|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
234760|NCT02402998|Drug|Eltrombopag|Eltrombopag 50 mg/daily.
234761|NCT02402985|Other|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
234762|NCT02402985|Other|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
234763|NCT02402972|Drug|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
234764|NCT02402972|Drug|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
234765|NCT02402959|Other|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
234766|NCT02402946|Behavioral|Biofeedback|
234767|NCT02402946|Drug|Placebo|
234768|NCT02402933|Drug|Nasal Glucagon|3 mg nasal glucagon powder
234769|NCT02402920|Drug|Carboplatin|Given IV
234770|NCT02402920|Drug|Cisplatin|Given IV
234771|NCT02402920|Drug|Etoposide|Given IV
234772|NCT02402920|Other|Laboratory Biomarker Analysis|Correlative studies
234773|NCT02402920|Biological|Pembrolizumab|Given IV
234774|NCT02402920|Procedure|Radiation Therapy|Undergo radiation therapy
234775|NCT02402907|Device|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
234776|NCT02402907|Device|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
234777|NCT02402894|Other|no intervention|
234778|NCT02402881|Behavioral|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
234779|NCT02402868|Drug|Ketamine and saline|Ketamine intravenous and intranasal
234780|NCT02402855|Other|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
234781|NCT02402855|Other|Interview with a sociologist|For a sub-group of 40 womens
234782|NCT02402855|Other|No intervention|
234783|NCT02402842|Drug|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
234784|NCT02402829|Procedure|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
234785|NCT02402816|Device|MultiPoint Pacing ON|MultiPoint Pacing ON
234786|NCT02402816|Device|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
234787|NCT02402803|Other|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
234788|NCT02402764|Drug|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m^2).
234789|NCT02402751|Procedure|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
234790|NCT02402751|Device|MRI|
234791|NCT02402738|Behavioral|Interpersonal and Social Rhythm Therapy|
234792|NCT02402738|Behavioral|Enhanced Treatment as Usual|
234793|NCT02402725|Drug|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
234794|NCT02402712|Drug|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
234795|NCT02402712|Drug|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
234796|NCT02402712|Drug|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
234798|NCT02402673|Other|Temporary activity modification and graded exercises|
234799|NCT02402660|Drug|ALK-001|Daily, oral administration for 24 months
234801|NCT02402647|Behavioral|CREST|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.~Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
234802|NCT02402647|Behavioral|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
234803|NCT02402634|Other|Mechanical ventilatory lung care|
234804|NCT02402621|Drug|fentanyl|fentanyl with antiemetic drug
234805|NCT02402608|Dietary Supplement|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
234806|NCT02402608|Dietary Supplement|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
234807|NCT02402595|Drug|AVP-923|
234808|NCT02402595|Drug|AVP-786|
234809|NCT02402595|Drug|Itraconazole|
234810|NCT02402582|Other|Family-centered empowerment model|FCEM and Control groups had similar inpatient care. Patients in the intervention group received care employing the FCEM in four stages. Stage 1: Awareness and cognition. During 3-5 group sessions they were evaluated for their insight into their perceived illness severity and perceived sensitivity, or the degree to which they felt threatened by their illness. Stage 2: Expectations. 3-5 sessions. Stage 3: Acceptance. Assessed using an educational participation method in group discussion. Stage 4: Formative summative evaluations. The formative evaluation encourages patients to internalize their locus of control by seeing his/her self-empowerment (increasing self-responsibility about their health). Summative evaluations were performed to evaluate the influence of the intervention on HRQoL dimensions, perceived stress and anxiety -- assessed at baseline and at 3 months post-intervention. Empowerment was measured at baseline and at 10 days post-intervention by deploying FCEM questionnaires.
234811|NCT02402582|Other|Control|FCEM and Control groups had similar inpatient care. Upon discharge the Control group underwent routine care and follow-up.
234812|NCT02402569|Device|32 channels Deep Brain Stimulator|
234813|NCT02402556|Behavioral|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
234814|NCT02402543|Drug|Gabapentin|
234815|NCT02402543|Drug|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
234816|NCT02402543|Drug|Acetaminophen|
234817|NCT02402543|Drug|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
234818|NCT02402543|Drug|Placebo|
234819|NCT02402530|Drug|Placebo|Matching placebo administered as intravenous infusion.
234820|NCT02402530|Drug|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
234821|NCT02402517|Other|Control|Non pulse extruded snack
234822|NCT02402517|Other|Small particle size pea flour|Pulse extruded snack
234823|NCT02402517|Other|Large particle size pea flour|Pulse extruded snack
234824|NCT02402517|Other|Lentil flour|Pulse extruded snack
234825|NCT02402517|Other|Navy bean flour|Pulse extruded snack
234826|NCT02402517|Other|Pinto bean flour|Pulse extruded snack
234827|NCT02402504|Other|Control|Non pulse extruded snack
234828|NCT02402504|Other|Small particle size pea flour|Pulse extruded snack
234829|NCT02402504|Other|Large particle size pea flour|Pulse extruded snack
234830|NCT02402504|Other|Lentil flour|Pulse extruded snack
234831|NCT02402504|Other|Navy bean flour|Pulse extruded snack
234832|NCT02402504|Other|Pinto bean flour|Pulse extruded snack
234833|NCT02402491|Drug|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
234834|NCT02402491|Drug|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
234835|NCT02402491|Drug|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
234836|NCT02402465|Drug|Placebo|Patients will be treated by placebo
234837|NCT02402465|Drug|Fluticasone propionate|Patients will receive fluticasone nasal spray
234838|NCT02402465|Drug|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
234839|NCT02402465|Procedure|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
234840|NCT02402452|Drug|GS-9857|GS-9857 100 mg tablet administered orally
234841|NCT02402439|Drug|Islet cells|Transplantation of islets into the gastrointestinal submucosa
234842|NCT02402439|Procedure|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
234843|NCT02402413|Procedure|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
234844|NCT02402413|Procedure|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
234845|NCT02402413|Device|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
234846|NCT02402400|Drug|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
234847|NCT02402387|Procedure|Neutral head position|
234848|NCT02402387|Procedure|Flexed head position|
234849|NCT02402387|Procedure|Extended head position|
234850|NCT02402387|Procedure|Rotated head position|
234851|NCT02402387|Device|Air-Q SP Airway|
234852|NCT02402374|Device|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
234853|NCT02402374|Device|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
234854|NCT02402348|Drug|Metformin|
234855|NCT02402322|Behavioral|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
234856|NCT02402322|Behavioral|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
234857|NCT02402309|Drug|Active topical NS2 1% dermatologic cream|
234858|NCT02402309|Drug|Vehicle placebo 0.0% NS2 dermatologic cream|
234859|NCT02402296|Drug|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
234860|NCT02402296|Other|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
234861|NCT02402283|Drug|Metronidazole benzoate oral granules|Single oral dose of 400 mg
234862|NCT02402283|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
234863|NCT02402270|Drug|NuLYTELY® (PEG 3350)|
234864|NCT02402270|Drug|ECP-019|
234865|NCT02402270|Drug|MoviPrep® (PEG 3350)|
234866|NCT02402257|Behavioral|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
234867|NCT02402244|Other|Cytology Specimen Collection Procedure|Undergo cytology specimen collection
234868|NCT02402244|Other|Medical Chart Review|Undergo medical data review
234869|NCT02402231|Drug|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
234870|NCT02402218|Other|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
234871|NCT02402218|Other|Usual care plus incentives|Participants are given incentives after completing treatment goals.
234872|NCT02402218|Other|Usual Care|Participants receive standard of care in the clinic from their health care team.
234873|NCT02402205|Behavioral|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
234874|NCT02402192|Drug|Corifollitropin alfa|
234875|NCT02402179|Other|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
234876|NCT02402166|Drug|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
234877|NCT02402153|Device|Hyposafe device|Subcutaneous EEG recorder for EEG measurements
234878|NCT02402140|Other|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
234879|NCT02402127|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
234880|NCT02402127|Device|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
234881|NCT02402127|Device|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
234882|NCT02402114|Drug|Hydrocortisone|120 mg Hydrocortisone given orally one time.
234883|NCT02402101|Device|Procedure: active tDCS|Intensity 2 mA during 20 minutes
234884|NCT02402101|Device|Procedure: sham tDCS|sham condition as delivered by the stimulator
234885|NCT02402088|Behavioral|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
234886|NCT02402088|Behavioral|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
234887|NCT02402088|Behavioral|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
234888|NCT02402062|Drug|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
234889|NCT02402049|Drug|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
234890|NCT02402049|Drug|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
234891|NCT02402049|Drug|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
235308|NCT02398890|Other|routine care|routine care
234892|NCT02402049|Drug|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
234893|NCT02402049|Drug|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
234894|NCT02402049|Drug|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
234895|NCT02402049|Drug|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
234896|NCT02402049|Drug|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
234897|NCT02402049|Drug|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
234898|NCT02402049|Drug|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
234899|NCT02402049|Drug|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
234900|NCT02402049|Drug|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
234901|NCT02402036|Drug|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
234902|NCT02402023|Behavioral|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
234903|NCT02402023|Behavioral|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
234904|NCT02402010|Behavioral|Adjunctive Yoga|
234905|NCT02402010|Behavioral|Enhanced Treatment as Usual|
234906|NCT02401997|Behavioral|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
234907|NCT02401984|Other|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
234908|NCT02401971|Drug|Thalidomide|Given orally
234909|NCT02401971|Drug|CPT-11|Given Ivgtt
234910|NCT02401958|Other|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
234911|NCT02401945|Drug|DE-120|
234912|NCT02401945|Drug|Aflibercept|
234913|NCT02401932|Other|Hemophagocytosis|Best supportive care and immunosuppressive treatments
234914|NCT02401919|Behavioral|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
234915|NCT02401906|Other|MRI|
234916|NCT02401893|Biological|Influenza Vaccine|Everyone immunized as recommended by current guidelines
234917|NCT02401880|Drug|Linagliptin|22 subjects will receive Linagliptin for 30 days
234918|NCT02401880|Other|Placebo|22 subjects will receive Placebo for 30 days
234919|NCT02401880|Drug|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
234920|NCT02401841|Drug|Two different types of drug for resolution of neuro-muscular blockade|
234921|NCT02401828|Drug|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
234922|NCT02401815|Drug|PLX9486|PLX9486 tablets, 50mg
234923|NCT02401815|Drug|PLX3397|PLX3397 capsules, 200mg
234924|NCT02401815|Drug|Sunitinib|
234925|NCT02401802|Dietary Supplement|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
234926|NCT02401802|Dietary Supplement|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
234927|NCT02401789|Device|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
234928|NCT02401776|Dietary Supplement|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
234929|NCT02401776|Dietary Supplement|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
234930|NCT02401776|Dietary Supplement|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
234931|NCT02401776|Dietary Supplement|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
234932|NCT02401750|Drug|Oxycodone Naltrexone (a)|
234933|NCT02401750|Drug|Oxycodone Naltrexone (b)|
234934|NCT02401750|Drug|Placebo|Matches both experimental drugs
234935|NCT02401737|Drug|NVR 3-778|
234936|NCT02401737|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
234937|NCT02401737|Drug|Pegasys|
234938|NCT02401724|Other|Transcranial direct current stimulation|
234939|NCT02401724|Other|Action Training|
234940|NCT02401711|Behavioral|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
234941|NCT02401711|Behavioral|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
234942|NCT02401711|Behavioral|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
235309|NCT02398877|Other|stress|
234943|NCT02401698|Other|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
234944|NCT02401685|Other|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
234945|NCT02401685|Procedure|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
234946|NCT02401672|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
234947|NCT02401659|Device|CareLinK|
234948|NCT02401646|Dietary Supplement|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
234949|NCT02401646|Dietary Supplement|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
234950|NCT02401633|Procedure|CO-CPR|CPR provided by bystander with chest-compressions only
234951|NCT02401633|Procedure|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
234952|NCT02401607|Other|Karasek questionnaire|
234953|NCT02401594|Drug|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
234954|NCT02401594|Drug|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
234955|NCT02401581|Other|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
234956|NCT02401568|Device|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
234957|NCT02401568|Procedure|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
234958|NCT02401555|Device|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
234959|NCT02401542|Drug|Vofatamab|
234960|NCT02401542|Drug|Docetaxel|
234961|NCT02401542|Drug|Placebo|
234962|NCT02401529|Drug|IV dexamethasone|0.15 mg/kg
234963|NCT02401529|Drug|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
234964|NCT02401529|Drug|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
234965|NCT02401529|Drug|IV saline|IV saline
234966|NCT02401516|Device|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
234967|NCT02401503|Drug|Bendamustine|Debulking: Cycles 1-2, d1 & 2: 70mg/m² i.v.
234968|NCT02401503|Drug|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
234969|NCT02401503|Drug|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
234970|NCT02401490|Drug|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
234971|NCT02401490|Drug|Placebo|
234972|NCT02401477|Drug|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
234973|NCT02401464|Drug|TAK-536 Tablet|TAK-536 10 mg tablet
234974|NCT02401464|Drug|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
234975|NCT02401464|Drug|TAK-536 Ganule Formulation|TAK-536 granule formulation
234976|NCT02401451|Device|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
234977|NCT02401438|Other|5D ultrasound|
234978|NCT02401438|Other|2D ultrasound|
234979|NCT02401425|Drug|Letrozole|
234980|NCT02401425|Drug|Misoprostol|
234981|NCT02401425|Other|Placebo|
234982|NCT02401412|Device|Test Ostomy Barrier|
234983|NCT02401412|Device|Control Ostomy Barrier|
234984|NCT02401399|Dietary Supplement|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
234985|NCT02401399|Dietary Supplement|High protein formula|The patients receive high protein formula during 15 days before surgery
234986|NCT02401399|Dietary Supplement|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
235099|NCT02400476|Drug|Colestipol|2 g twice daily with or without food for one 28 day cycle
235100|NCT02400476|Drug|Budesonide|9 mg extended release tablets once daily with or without food for 28 days
235101|NCT02400463|Drug|Ruxolitinib|
235310|NCT02398864|Procedure|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
234987|NCT02401386|Behavioral|The Eight Brocades|Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
234988|NCT02401373|Biological|Ad5-EBOV|intramuscular injection
234989|NCT02401360|Drug|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
234990|NCT02401360|Drug|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
234991|NCT02401347|Drug|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
234992|NCT02401334|Device|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
234993|NCT02401321|Behavioral|Telephone-Based Intervention|Complete Taking Care of Her program
234994|NCT02401321|Other|Caregiver-Assisted Training|Complete Taking Care of Her program
234995|NCT02401321|Other|Questionnaire Administration|Ancillary studies
234996|NCT02401321|Other|Quality-of-Life Assessment|Ancillary studies
234997|NCT02401308|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
234998|NCT02401295|Drug|ATRA|
234999|NCT02401295|Drug|Celecoxib|
235000|NCT02401295|Drug|Itraconazole|
235001|NCT02401282|Behavioral|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
235002|NCT02401282|Behavioral|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
235003|NCT02401269|Drug|Aspirin|
235004|NCT02401269|Drug|Placebo|
235005|NCT02401256|Drug|Efavirenz|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
235006|NCT02401256|Drug|Bupropion|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
235007|NCT02401256|Drug|Rosuvastatin|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
235008|NCT02401256|Drug|Montelukast|"The study has 4 phases:~Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).~Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.~Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).~Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
235009|NCT02401243|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen~Route of administration: subcutaneous"
235010|NCT02401230|Drug|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
235011|NCT02401230|Device|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
235012|NCT02401217|Other|Phase 1- Arm 1 Infant Formula|Powder infant formula
235013|NCT02401217|Other|Phase 2- Arm 2 Infant Formula|Powder infant formula
235014|NCT02401217|Other|Phase 2- Arm 3 Infant Formula|Powder infant formula
235015|NCT02401204|Other|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.~A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.~If participant is intubated/ventilated, a throat swab will be collected."
235016|NCT02401191|Drug|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
235017|NCT02401165|Other|Blood test|blood test
235018|NCT02401152|Other|Sports drink 1|Sports drink with a specific source of CHO.
235019|NCT02401152|Other|Sports drink 2|Sports drink with a specific source of CHO
235020|NCT02401152|Other|Placebo|iso-caloric sports drink with maltodextrin as CHO source
235021|NCT02401139|Drug|Ketamine|
235022|NCT02401139|Drug|Placebo|
235023|NCT02401126|Dietary Supplement|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
235024|NCT02401126|Dietary Supplement|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
235025|NCT02401113|Dietary Supplement|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
235027|NCT02401074|Biological|Segmental Bronchoprovocation with Allergen (SBP-Ag)|Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
235028|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 (3, 6,12, 18, or 24) microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
235029|NCT02401048|Drug|Ibrutinib|
235030|NCT02401048|Drug|MEDI4736|
235031|NCT02401035|Drug|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
235032|NCT02401022|Drug|AZD8529|comparison of different dosages of drug
235033|NCT02400983|Device|Pacemaker, ICD|
235034|NCT02400970|Other|malignant cells|
235035|NCT02400957|Other|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
235036|NCT02400957|Other|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
235037|NCT02400944|Behavioral|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
235038|NCT02400944|Other|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
235039|NCT02400931|Procedure|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
235040|NCT02400931|Procedure|no mask ventilation|
235041|NCT02400931|Drug|Rocuronium|
235042|NCT02400918|Other|The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)|An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
235043|NCT02400905|Device|BioMimics 3D Stent System|Femoropopliteal stenting
235044|NCT02400892|Other|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
235045|NCT02400879|Drug|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
235046|NCT02400879|Drug|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
235047|NCT02400866|Drug|Olanzapine|
235048|NCT02400853|Device|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
235049|NCT02400853|Procedure|Cord blood analysis|Cord blood will be collected during deliverance and analysed
235050|NCT02400840|Procedure|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
235051|NCT02400840|Drug|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
235052|NCT02400827|Other|malignant cells|
235053|NCT02400814|Drug|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
235054|NCT02400814|Radiation|Stereotactic Body Radiation Therapy|Undergo SAR
235055|NCT02400801|Drug|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
235056|NCT02400801|Drug|ethinylestradiol + dienogest|oral oestroprogestogen
235057|NCT02400788|Drug|Resminostat|
235058|NCT02400788|Drug|Sorafenib|
235059|NCT02400775|Drug|Azilsartan|Azilsartan tablets
235060|NCT02400749|Drug|Apremilast|"Apremilast tablets will be provided to sites in blister cards.~Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
235061|NCT02400749|Drug|Placebo|Placebo tablets will be provided to sites in blister cards.
235062|NCT02400736|Behavioral|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) Competitive Employment: The IPS intervention assists participants to enter into competitive jobs; 2) Eligibility Based on Client Choice, i.e. zero exclusion; 3) Integration of IPS and Treatment Team, i.e. the PACT; 5) Personalized Benefits Counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) Rapid Job Search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) Systematic Job Development: IPS specialists build an employer network based on Veterans' interests; 8) Time-Unlimited and Individualized Support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
235102|NCT02400450|Dietary Supplement|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
235423|NCT02398045|Other|Computerised CBT for OCD|Computerised CBT for OCD
235063|NCT02400736|Other|Usual Care/Transitional Work Program (TWP)|Transitional Work Program (TWP) involves 1) Time-limited Set-Aside Employment: short-term transitional work experiences in a brokered or set-aside work setting; 2) Eligibility Criteria: no strict entrance criteria other than general medical clearance; 3) Limited Integration of TWP and Clinical Services: not integrated within PACT; 4) Less Patient-Centered: TWP jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) Personalized Benefits Counseling: TWP specialists help Veterans obtain information about their VA, Social Security, Medicaid, and government entitlements; 6) Job Search: The TWP specialists provide variable and limited guidance for competitive job search; 7) Limited Job Development: TWP specialists do not engage in community based job development for a specific Veteran; 8) Time Limited Support: The TWP specialist does not provide long-term follow-up after the first job is obtained.
235064|NCT02400723|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
235065|NCT02400723|Behavioral|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
235066|NCT02400723|Other|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
235067|NCT02400710|Behavioral|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
235068|NCT02400710|Behavioral|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
235069|NCT02400697|Other|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
235070|NCT02400684|Biological|blood samples|Evolution of AMH before and after deep endometriosis surgery
235071|NCT02400671|Behavioral|SMS messaging|
235072|NCT02400658|Device|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
235073|NCT02400645|Procedure|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
235074|NCT02400645|Procedure|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
235075|NCT02400645|Drug|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
235076|NCT02400645|Drug|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
235077|NCT02400645|Drug|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
235078|NCT02400632|Device|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
235079|NCT02400619|Device|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
235080|NCT02400619|Drug|Botulinum Toxin Type A|Botulinum toxin type A Botox
235081|NCT02400606|Other|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
235082|NCT02400606|Other|Solving VP cases|See above
235083|NCT02400593|Behavioral|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
235084|NCT02400580|Drug|IV acetaminophen|The patients in the treatment arm will receive 1000mg of IV acetaminophen.
235085|NCT02400580|Drug|placebo|The patients in the placebo arm will receive normal saline.
235086|NCT02400567|Drug|Fluorouracile|
235087|NCT02400567|Drug|Epirubicin|
235088|NCT02400567|Drug|Cyclophosphamide|
235089|NCT02400567|Drug|Letrozole|
235090|NCT02400567|Drug|Palbociclib|
235091|NCT02400554|Behavioral|Yappalli|"Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, & women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership & personal change goals on the main outcome.~Month 2: Overnight Culture Camp to strengthen group cohesion & synthesize goals.~Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal & leadership goals & experience on the Trail.~Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD & obesity prevention. Includes: digital storytelling training to create a story related to ATOD & obesity prevention & an individual MI booster session to revise their personal & community leadership goals.~Month 12: Share digital stories & community event experiences & undergo a ceremony to transition to health leaders within their communities."
235092|NCT02400541|Behavioral|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
235093|NCT02400541|Other|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
235094|NCT02400528|Behavioral|quality of life questionnaires|
235095|NCT02400515|Other|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
235096|NCT02400502|Behavioral|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
235103|NCT02400450|Dietary Supplement|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
235104|NCT02400437|Drug|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
235105|NCT02400437|Drug|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
235106|NCT02400437|Drug|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
235107|NCT02400424|Radiation|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
235108|NCT02400411|Other|Wheat bread|
235109|NCT02400411|Other|margarine|
235110|NCT02400411|Other|ham|
235111|NCT02400411|Other|soup|
235112|NCT02400411|Other|rye bread|
235113|NCT02400398|Other|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Peptamen (medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
235114|NCT02400385|Drug|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
235115|NCT02400385|Drug|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
235116|NCT02400372|Device|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
235117|NCT02400359|Drug|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
235118|NCT02400359|Drug|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
235119|NCT02400346|Drug|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.~Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
235120|NCT02400346|Drug|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
235121|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
235122|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
235123|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
235124|NCT02400333|Drug|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
235125|NCT02400320|Drug|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
235126|NCT02400320|Drug|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
235127|NCT02400320|Other|Saline|Saline
235128|NCT02400307|Drug|Bictegravir|75 mg tablet administered orally
235129|NCT02400294|Other|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
235130|NCT02400281|Drug|Crenolanib besylate|
235131|NCT02400281|Drug|Idarubicin|
235132|NCT02400281|Drug|Cytarabine|
235133|NCT02400281|Drug|Azacytidine|
235134|NCT02400281|Drug|Mitoxantrone|
235135|NCT02400281|Drug|Etoposide|
235136|NCT02400281|Drug|Fludarabine|
235137|NCT02400281|Drug|G-CSF|
235138|NCT02400268|Other|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
235139|NCT02400268|Other|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
235140|NCT02400255|Drug|Crenolanib besylate|
235141|NCT02400242|Drug|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
235142|NCT02400242|Drug|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
235143|NCT02400242|Drug|Dexamethasone|40 mg qd on days 1, 8, 15, 22
235144|NCT02400229|Procedure|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
235145|NCT02400229|Procedure|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
235146|NCT02400203|Other|Control|
235147|NCT02400203|Other|Hemp foods|
235148|NCT02400190|Other|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
235149|NCT02400177|Behavioral|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
235150|NCT02400164|Device|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
235151|NCT02400151|Drug|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
235152|NCT02400151|Drug|Placebo|Patients randomized to this group will receive placebo for 90 days.
235153|NCT02400151|Other|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
235154|NCT02400151|Other|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
235301|NCT02398968|Dietary Supplement|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
235302|NCT02398955|Device|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
235155|NCT02400138|Other|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
235156|NCT02400138|Other|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
235157|NCT02400112|Drug|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
235158|NCT02400099|Dietary Supplement|High-protein low calorie diet|
235159|NCT02400099|Dietary Supplement|Control low calorie diet|
235160|NCT02400099|Other|Anthropometrical measurements|
235161|NCT02400099|Other|Body composition|
235162|NCT02400099|Other|8-h metabolic profile|
235163|NCT02400099|Other|Liver biopsy|
235164|NCT02400073|Device|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
235165|NCT02400060|Behavioral|Telephone-Based Intervention|Receive text messaging
235166|NCT02400060|Other|Survey Administration|Ancillary studies
235167|NCT02400060|Other|Laboratory Biomarker Analysis|Correlative studies
235168|NCT02400047|Drug|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
235169|NCT02400047|Drug|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
235170|NCT02400047|Drug|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
235171|NCT02400034|Other|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
235172|NCT02400021|Drug|Prometrium|
235173|NCT02400008|Procedure|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
235174|NCT02399995|Behavioral|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:~Baseline sociodemographic and clinical variable data sheet (RSA)~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:~EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS~Post surgical follow up disease status and treatment assessment questionnaire~At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
235175|NCT02399982|Other|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
235176|NCT02399982|Other|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
235177|NCT02399969|Other|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
235178|NCT02399956|Other|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
235179|NCT02399943|Drug|Trametinib|
235180|NCT02399943|Drug|Panitumumab|
235181|NCT02399930|Other|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.~Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.~If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
235182|NCT02399917|Drug|Azacitidine|Given SC or IV
235183|NCT02399917|Biological|Lirilumab|Given IV
235184|NCT02399904|Other|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
235185|NCT02399891|Other|Quality Assurance Implementation|
235186|NCT02399891|Other|Standard of Care|
235187|NCT02399878|Drug|Inspiratory oxygen|
235303|NCT02398929|Drug|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
235304|NCT02398929|Drug|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
235188|NCT02399865|Other|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.~Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
235189|NCT02399852|Drug|Lomitapide|
235190|NCT02399839|Drug|lomitapide|As prescribed by Physician.
235191|NCT02399826|Device|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
235192|NCT02399826|Procedure|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
235193|NCT02399813|Drug|ADXS11-001|
235194|NCT02399800|Procedure|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
235195|NCT02399800|Procedure|No Celiac Block|EUS but no celiac block performed
235196|NCT02399800|Drug|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
235197|NCT02399787|Other|blastocyst biopsy|Performed on day 5
235198|NCT02399774|Device|Leboride|"Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~Control group: participants will not receive any device for breastfeeding pain control~Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
235199|NCT02399735|Biological|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
235200|NCT02399735|Biological|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
235201|NCT02399735|Biological|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
235202|NCT02399722|Device|WICVAC|combined wound therapy
235203|NCT02399722|Device|VAC mono therapy|mono therapy
235204|NCT02399709|Drug|simvastatin|
235205|NCT02399709|Drug|Placebo|
235206|NCT02399696|Behavioral|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
235207|NCT02399696|Behavioral|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
235208|NCT02399683|Biological|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
235209|NCT02399657|Drug|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
235210|NCT02399644|Behavioral|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
235211|NCT02399644|Other|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
235212|NCT02399631|Other|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
235213|NCT02399618|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
235214|NCT02399605|Other|Stimulation|Subcutaneous abdominal electrical stimulation
235215|NCT02399592|Drug|Bevacizumab|10 mg/kg q3w
235216|NCT02399592|Drug|Tocotrinol|300 mg tid
235217|NCT02399579|Other|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
235218|NCT02399566|Drug|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
235219|NCT02399553|Other|Soccer boot intervention|
235220|NCT02399540|Device|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
235221|NCT02399540|Device|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
235222|NCT02399540|Device|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
235223|NCT02399540|Device|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
235224|NCT02399514|Other|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
235225|NCT02399501|Procedure|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
235305|NCT02398916|Behavioral|Music listening|
235226|NCT02399501|Device|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
235227|NCT02399501|Device|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
235228|NCT02399501|Device|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
235229|NCT02399488|Device|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
235230|NCT02399475|Drug|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
235231|NCT02399475|Drug|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
235232|NCT02399475|Drug|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
235233|NCT02399462|Drug|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC twice weekly* Weeks 1 and 2~H.P. Acthar Gel 80 units SC twice weekly* Weeks 3 through 24~H.P. Acthar Gel 80 units SC once weekly* Weeks 25 through 26~H.P. Acthar Gel 40 units SC once weekly* Weeks 27 through 28~*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
235234|NCT02399449|Drug|sodium ferric gluconate (brand)|brand product
235235|NCT02399449|Drug|sodium ferric gluconate (generic)|generic product
235236|NCT02399436|Behavioral|School-Based Healthy Snacking Campaign|"The school-based healthy snacking campaign includes the following activities:~Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;~The installation of new filtered water fountains outfitted with water-filling stations;~The distribution of re-usable water bottles to students at participating schools; and~A social marketing campaign to support adoption of the healthy snacks and water consumption by students."
235237|NCT02399436|Behavioral|Community Cooking Classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
235238|NCT02399423|Behavioral|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
235239|NCT02399423|Behavioral|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
235240|NCT02399410|Drug|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
235241|NCT02399410|Procedure|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
235242|NCT02399410|Drug|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
235243|NCT02399397|Procedure|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
235244|NCT02399397|Procedure|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
235245|NCT02399397|Procedure|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
235246|NCT02399397|Drug|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
235247|NCT02399397|Procedure|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
235248|NCT02399371|Biological|Pembrolizumab|Given IV
235249|NCT02399371|Other|Laboratory Biomarker Analysis|Correlative studies
235250|NCT02399371|Other|Pharmacogenomic Study|Correlative studies
235251|NCT02399345|Drug|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
235252|NCT02399345|Drug|sofosbuvir (SOF)|tablet
235253|NCT02399345|Drug|ribavirin (RBV)|tablet
235254|NCT02399332|Other|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
235255|NCT02399319|Procedure|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
235256|NCT02399319|Procedure|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
235257|NCT02399306|Drug|Enteral nutrition|Patients in the Trial Group received concurrent chemoradiotherapy and standardized, whole-course enteral nutrition management.
235258|NCT02399306|Radiation|radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f."
235306|NCT02398903|Other|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
235307|NCT02398903|Other|DXA and impedancemetry|Body composition by DXA and impedancemetry
235259|NCT02399293|Behavioral|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
235260|NCT02399293|Behavioral|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.~Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
235261|NCT02399280|Behavioral|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
235262|NCT02399280|Behavioral|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
235263|NCT02399267|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
235264|NCT02399267|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
235265|NCT02399267|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =< 8 cm H2O with PEEP =< 5 cm H2O.
235266|NCT02399267|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
235267|NCT02399241|Device|Bluetooth enabled nebuliser device (I-neb)|
235268|NCT02399228|Drug|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
235269|NCT02399215|Other|Laboratory Biomarker Analysis|Correlative studies
235270|NCT02399215|Drug|Nintedanib|Given PO
235271|NCT02399215|Other|Pharmacological Study|Correlative studies
235272|NCT02399215|Other|Quality-of-Life Assessment|Ancillary studies
235273|NCT02399202|Drug|osilodrostat|
235274|NCT02399189|Drug|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
235275|NCT02399176|Behavioral|Yoga|Subjects assume 10 physical postures for 30 seconds each
235276|NCT02399163|Drug|Fluoride free toothpaste|Brushing with fluoride free toothpaste
235277|NCT02399163|Drug|Fluoride toothpaste|Brushing with fluoride containing toothpaste
235278|NCT02399163|Drug|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
235279|NCT02399150|Other|No intervention as observational study|
235280|NCT02399137|Drug|MM-141|
235281|NCT02399137|Drug|Placebo|
235282|NCT02399137|Drug|Gemcitabine|
235283|NCT02399137|Drug|Nab-Paclitaxel|
235284|NCT02399124|Device|PROSENSE™|single arm, open label, PROSENSE™ treatment
235285|NCT02399111|Device|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
235286|NCT02399098|Behavioral|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
235287|NCT02399085|Drug|MOR00208|12 mg/kg
235288|NCT02399085|Drug|Lenalidomide|25 mg
235289|NCT02399072|Other|No intervention|No intervention administered in this study
235290|NCT02399059|Procedure|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
235291|NCT02399059|Procedure|Normal saline lavage|Peritoneal irrigation with normal saline
235292|NCT02399046|Device|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
235293|NCT02399046|Device|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
235294|NCT02399033|Drug|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
235295|NCT02399020|Behavioral|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
235296|NCT02399007|Device|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
235297|NCT02399007|Device|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
235298|NCT02398994|Drug|Intravenous Methylprednisolone|
235299|NCT02398994|Drug|Intravenous Immunoglobulin|
235300|NCT02398981|Other|Clinical decision support tool|
235311|NCT02398851|Behavioral|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
235312|NCT02398851|Behavioral|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
235313|NCT02398838|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
235314|NCT02398838|Drug|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
235315|NCT02398825|Drug|Ponatinib|Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to > 1%. Dose adjustments for toxicity are detailed in the protocol.
235316|NCT02398812|Other|Medication assessment and treatment plan based on it|"Intervention~Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.~Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
235317|NCT02398799|Behavioral|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.~Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
235318|NCT02398786|Other|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
235319|NCT02398773|Procedure|Computed Tomography|Undergo PET/CT
235320|NCT02398773|Drug|F-18 16 Alpha-Fluoroestradiol|Given IV
235321|NCT02398773|Other|Laboratory Biomarker Analysis|Correlative studies
235322|NCT02398773|Procedure|Positron Emission Tomography|Undergo PET/CT
235323|NCT02398760|Other|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
235324|NCT02398747|Drug|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
235325|NCT02398734|Device|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
235326|NCT02398721|Other|Fine Needle Aspiration Cytology|
235327|NCT02398708|Other|Questionnaires|Both groups will have questionnaires collected and compared.
235328|NCT02398708|Other|Blood Sample|Both groups will have a blood sample collected and compared.
235329|NCT02398708|Other|Stool Sample|Both groups will have a stool sample collected and compared.
235330|NCT02398708|Other|Clinical data|Both groups will have clinical data collected and compared.
235331|NCT02398695|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
235332|NCT02398682|Other|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:~1) Rapidly establish a credible diagnosis of the cause of AKI including:~Improved assessment of volume status~Standardised use of urine dipstick .~Appropriate sepsis investigations.~Urgent ultrasound with suspected obstruction."
235333|NCT02398682|Other|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
235334|NCT02398682|Other|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
235335|NCT02398682|Other|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
235336|NCT02398682|Other|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
235337|NCT02398682|Other|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
235338|NCT02398669|Drug|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
235339|NCT02398656|Drug|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
235340|NCT02398656|Drug|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
235341|NCT02398643|Other|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
235342|NCT02398643|Other|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
235343|NCT02398630|Radiation|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
235344|NCT02398630|Other|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
235345|NCT02398630|Other|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
235346|NCT02398630|Other|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
235347|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
235348|NCT02398604|Drug|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
235349|NCT02398604|Drug|Placebo|Placebo
235350|NCT02398591|Drug|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
235351|NCT02398591|Drug|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
235352|NCT02398578|Device|Amphora OAB Device|Cystoscopic procedure to treat OAB
235353|NCT02398565|Other|No intervention|
235354|NCT02398552|Drug|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
235355|NCT02398539|Drug|Silver Nitrate|Silver Nitrate Sticks
235356|NCT02398539|Drug|Triamcinolone|0.5% cream
235357|NCT02398526|Drug|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
235358|NCT02398513|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
235359|NCT02398500|Biological|LMG324|IVT injection
235360|NCT02398500|Biological|Ranibizumab 0.5 mg|IVT injection
235361|NCT02398500|Biological|Sham|Fake injection used for masking purposes
235362|NCT02398487|Device|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
235363|NCT02398487|Device|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
235364|NCT02398474|Drug|TFP block ropivacaine|
235365|NCT02398474|Drug|ropivacaine infiltration of the iliac crest bone|
235366|NCT02398461|Drug|rHIgM22|Administered via IV infusion
235367|NCT02398461|Drug|Placebo|
235368|NCT02398448|Drug|Zyloprim® 300 mg|
235369|NCT02398448|Drug|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
235370|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
235371|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 3|
235372|NCT02398435|Biological|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
235373|NCT02398422|Behavioral|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.~The non-filtered music intervention will consist of the same music as the filtered-music intervention."
235374|NCT02398409|Behavioral|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
235375|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
235376|NCT02398396|Biological|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
235377|NCT02398383|Other|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
235378|NCT02398383|Other|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
235379|NCT02398383|Other|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
235380|NCT02398370|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
235381|NCT02398357|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
235424|NCT02398032|Device|CPAP nasal|During the night
235382|NCT02398344|Device|tDCS active|Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
235383|NCT02398344|Device|tDCS Sham|Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
235384|NCT02398331|Other|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:~Educational footage~Clinical neurological examination with educational aim~Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
235385|NCT02398318|Device|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
235386|NCT02398318|Device|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
235387|NCT02398305|Device|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
235388|NCT02398305|Device|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
235389|NCT02398292|Other|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
235390|NCT02398292|Other|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
235391|NCT02398279|Dietary Supplement|L-Arginine|Experimental supplement
235392|NCT02398279|Other|Placebo|Placebo capsules in the same color and shape with the experimental supplement
235393|NCT02398266|Drug|Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)|Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
235394|NCT02398253|Behavioral|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
235395|NCT02398253|Behavioral|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
235396|NCT02398240|Drug|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
235397|NCT02398240|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
235398|NCT02398240|Drug|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
235399|NCT02398240|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
235400|NCT02398227|Behavioral|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
235401|NCT02398227|Behavioral|PCT|Present Centered Therapy for PTSD
235402|NCT02398214|Behavioral|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to < 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
235403|NCT02398201|Drug|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
235404|NCT02398188|Drug|LIPO-202|
235405|NCT02398188|Drug|Placebo|
235406|NCT02398175|Other|reanimation/intubation|
235407|NCT02398162|Procedure|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
235408|NCT02398162|Procedure|Single Blood Collection|On the enrollment day
235409|NCT02398136|Drug|Ketamine|
235410|NCT02398136|Drug|Midazolam|
235411|NCT02398123|Other|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
235412|NCT02398123|Other|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
235413|NCT02398123|Drug|Bupivacaine|
235414|NCT02398110|Procedure|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
235415|NCT02398110|Procedure|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
235416|NCT02398097|Biological|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
235417|NCT02398097|Biological|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
235418|NCT02398097|Biological|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
235419|NCT02398084|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
235420|NCT02398071|Device|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
235421|NCT02398058|Drug|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
235422|NCT02398058|Drug|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
235425|NCT02398032|Device|sham CPAP nasal|During the night
235426|NCT02398019|Device|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [OXIRIS® (Baxter Gambro)].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
235427|NCT02398006|Other|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
235428|NCT02398006|Other|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
235429|NCT02397993|Procedure|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
235430|NCT02397993|Procedure|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
235431|NCT02397993|Procedure|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
235432|NCT02397980|Behavioral|Behavioral intervention|"What the dementia is~How to deal with behavioral problems in patients with dementia~How to manage caregiver's stress~How to care dementic patients as well as caregivers themselves"
235433|NCT02397967|Other|Neuropsychological assessments|"Neuropsychological assessments:~Intelligence Quotient (WISC-IV)~Reading tests (reading accuracy, reading speed, reading comprehension and strategy):~Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
235434|NCT02397954|Drug|Zimura|Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
235435|NCT02397941|Other|Ultrasound|ultrasound measures
235436|NCT02397928|Device|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
235437|NCT02397928|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
235438|NCT02397928|Drug|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
235439|NCT02397915|Drug|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
235440|NCT02397915|Drug|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
235441|NCT02397902|Dietary Supplement|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
235442|NCT02397902|Dietary Supplement|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
235443|NCT02397889|Drug|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
235444|NCT02397889|Drug|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
235445|NCT02397876|Other|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
235446|NCT02397863|Drug|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
235447|NCT02397850|Behavioral|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
235448|NCT02397850|Behavioral|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
235449|NCT02397837|Drug|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
235450|NCT02397837|Drug|Placebo|placebo match study drug
235451|NCT02397824|Other|Salivary and blood samples|
235452|NCT02397811|Dietary Supplement|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
235453|NCT02397811|Dietary Supplement|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
235454|NCT02397811|Dietary Supplement|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
235455|NCT02397811|Dietary Supplement|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
235456|NCT02397811|Dietary Supplement|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
235457|NCT02397811|Dietary Supplement|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
235458|NCT02397798|Behavioral|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
235459|NCT02397798|Behavioral|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
235460|NCT02397785|Device|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
235461|NCT02397785|Device|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
235462|NCT02397772|Drug|albendazole|Single dose of albendazole (400 mg)
235463|NCT02397759|Other|Blood draw and cerebrospinal fluid draw|
235464|NCT02397746|Device|total hip arthroplasty implant|
235465|NCT02397733|Radiation|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
235466|NCT02397733|Radiation|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
235467|NCT02397720|Drug|Azacitidine|Given SC or IV
235468|NCT02397720|Biological|Ipilimumab|
235469|NCT02397720|Other|Laboratory Biomarker Analysis|Correlative studies
235470|NCT02397720|Biological|Nivolumab|Given IV
235471|NCT02397707|Drug|GS-9857|GS-9857 100 mg tablet administered orally
235472|NCT02397694|Drug|BIC|75 mg tablet administered orally once daily
235473|NCT02397694|Drug|F/TAF|200/25 mg FDC tablet administered orally once daily
235474|NCT02397694|Drug|DTG|50 mg tablet administered orally once daily
235475|NCT02397694|Drug|BIC Placebo|Tablet administered orally once daily
235476|NCT02397694|Drug|DTG Placebo|Tablet administered orally once daily
235477|NCT02397694|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily
235478|NCT02397681|Other|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
235479|NCT02397668|Device|CorMatrix Cor TRICUSPID ECM Valve|CorMatrix Cor TRICUSPID ECM Valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.
235480|NCT02397642|Procedure|IVF/ICSI|
235481|NCT02397642|Drug|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
235482|NCT02397629|Other|This study has no intervention|
235483|NCT02397616|Other|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
235484|NCT02397603|Drug|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
235485|NCT02397603|Drug|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
235486|NCT02397590|Drug|Fimasartan|
235487|NCT02397590|Drug|Atorvastatin|
235488|NCT02397577|Other|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
235489|NCT02397564|Device|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
235490|NCT02397551|Procedure|IVF/ICSI|
235491|NCT02397551|Drug|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
235492|NCT02397538|Drug|Fimasartan|
235493|NCT02397538|Drug|Amlodipine|
235494|NCT02397538|Drug|Rosuvastatin|
235495|NCT02397525|Drug|LIPO-202|
235496|NCT02397512|Drug|application of lactulose|Subjects will ingest 50g of lactulose once
235497|NCT02397512|Other|application of sucrose|Subjects will ingest 50g of sucrose once
235498|NCT02397499|Drug|LIPO-202|
235499|NCT02397499|Drug|Placebo|
235500|NCT02397486|Drug|Pentoxifylline|
235501|NCT02397486|Drug|Vitamin E|
235502|NCT02397486|Drug|Cisplatin|
235503|NCT02397486|Radiation|Radiation therapy|
235504|NCT02397473|Drug|Galcanezumab|Administered SC
235505|NCT02397473|Drug|Placebo|Administered SC
235506|NCT02397460|Drug|Gefapixant|
235507|NCT02397460|Drug|Placebo (for gefapixant)|
235508|NCT02397447|Drug|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
235509|NCT02397447|Drug|Placebo|Placebo: 2000 mg per day for three months
235510|NCT02397434|Radiation|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
235511|NCT02397421|Drug|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
235512|NCT02397421|Drug|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
235513|NCT02397408|Drug|Choline PET/MR|
235514|NCT02397395|Drug|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
235515|NCT02397395|Drug|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
235516|NCT02397382|Drug|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8.
235517|NCT02397382|Drug|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
235518|NCT02397382|Drug|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
235519|NCT02397382|Drug|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
235520|NCT02397382|Drug|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
235521|NCT02397382|Drug|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
235522|NCT02397369|Other|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
235562|NCT02397122|Biological|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
235563|NCT02397122|Procedure|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
235523|NCT02397369|Behavioral|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
235524|NCT02397369|Behavioral|Tobacco users:Behavioural therapy Only|"Focus Group discussion:~This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.~Individual tobacco cessation counseling sessions:~Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
235525|NCT02397369|Other|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
235526|NCT02397356|Drug|Ketamine first AB|Nebulised ketamine 1mg/kg
235527|NCT02397356|Drug|Placebo first BA|Nebulised saline 1-2ml
235528|NCT02397343|Drug|Hyperbaric oxygen|
235529|NCT02397330|Drug|bupivacaine|
235530|NCT02397330|Device|ultrasound|ultrasound guided nerve blocks
235531|NCT02397330|Drug|morphine|
235532|NCT02397317|Radiation|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
235533|NCT02397304|Other|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
235534|NCT02397291|Drug|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
235535|NCT02397291|Drug|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
235536|NCT02397291|Drug|Placebo|placebo
235537|NCT02397278|Drug|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
235538|NCT02397265|Device|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
235539|NCT02397265|Device|Standard opened loop pump|Using a standard opened loop pump
235540|NCT02397265|Device|Insulin closed loop|Using a closed loop
235541|NCT02397252|Device|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
235542|NCT02397252|Device|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
235543|NCT02397252|Procedure|Physician-collected sampling|Routine colposcopy sample collected by a physician.
235544|NCT02397226|Procedure|Radiofrequency ablation|
235545|NCT02397226|Procedure|High ligation/stripping|
235546|NCT02397226|Device|Radiofrequency ablation catheter|
235547|NCT02397226|Procedure|Tumescent anesthesia|
235548|NCT02397226|Procedure|General anesthesia|
235549|NCT02397226|Device|Vein stripping catheter|
235550|NCT02397213|Drug|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
235551|NCT02397213|Drug|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
235552|NCT02397200|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
235553|NCT02397200|Dietary Supplement|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
235554|NCT02397187|Behavioral|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
235555|NCT02397174|Other|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
235556|NCT02397174|Other|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
235557|NCT02397161|Other|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
235558|NCT02397161|Other|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
235559|NCT02397161|Other|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
235560|NCT02397148|Radiation|Computed Tomography|imagery with ionizing radiation
235561|NCT02397148|Radiation|Cone Beam Computed Tomography|imagery with ionizing radiation
235601|NCT02396836|Other|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
235564|NCT02397122|Procedure|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
235565|NCT02397096|Drug|MK-1439A|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
235566|NCT02397096|Drug|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
235567|NCT02397096|Drug|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
235568|NCT02397096|Drug|Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
235569|NCT02397096|Drug|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
235570|NCT02397083|Drug|Everolimus|Given PO
235571|NCT02397083|Other|Laboratory Biomarker Analysis|Correlative studies
235572|NCT02397083|Device|Levonorgestrel-Releasing Intrauterine System|Placed in the uterus
235573|NCT02397070|Procedure|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
235574|NCT02397070|Device|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
235575|NCT02397057|Drug|Injectafer|
235576|NCT02397057|Other|Placebo|
235577|NCT02397044|Procedure|Implant surgery|Compare surgical protocols
235578|NCT02397031|Behavioral|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
235579|NCT02397031|Behavioral|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
235580|NCT02397018|Biological|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
235581|NCT02397005|Drug|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
235582|NCT02397005|Drug|Placebo matching ZL-2102|
235583|NCT02396992|Other|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
235584|NCT02396979|Drug|Methadone|
235585|NCT02396979|Behavioral|Holistic Health Recovery Program|
235586|NCT02396953|Drug|Lanreotide PRF|
235587|NCT02396940|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
235588|NCT02396940|Device|2D HD laparoscopy|Placebo
235589|NCT02396927|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
235590|NCT02396927|Device|2D HD laparoscopy|Placebo
235591|NCT02396901|Other|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
235592|NCT02396888|Drug|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
235593|NCT02396888|Drug|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
235594|NCT02396875|Procedure|Blood sampling and exercise protocol pre and post CRT implant|
235595|NCT02396875|Procedure|Peripheral blood sampling|
235596|NCT02396875|Procedure|Central blood sampling pre and post CRT implant|
235597|NCT02396875|Procedure|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
235598|NCT02396862|Drug|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
235599|NCT02396849|Device|CPAP|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
235600|NCT02396849|Device|CPAP Sham|Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
235894|NCT02394535|Drug|Nab-paclitaxel|Given IV
235602|NCT02396836|Other|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
235603|NCT02396823|Behavioral|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
235604|NCT02396810|Other|intra-operative MRI|Intra-operative magnetic resonance imaging under general anesthesia
235605|NCT02396810|Procedure|Transsphenoidal resection of pituitary macroadenoma|Routine transsphenoidal resection of pituitary macro adenomas
235606|NCT02396797|Behavioral|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
235607|NCT02396797|Behavioral|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
235608|NCT02396771|Procedure|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
235609|NCT02396771|Procedure|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
235610|NCT02396758|Device|Ekosonic® Endovascular Device ultrasonic infusion catheter|r-tPA will be administered via EKOS.
235611|NCT02396758|Biological|Recombinant tissue plasminogen activator|Recombinant tissue plasminogen activator will be administered as per the dose and schedule specified in the arm.
235612|NCT02396745|Device|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of BE lesion.~ECM PLACEMENT:~Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
235613|NCT02396732|Drug|Aspirin|Daily dose is 81 mg oral tablet
235614|NCT02396732|Drug|Enoxaparin|Daily dose is by subcutaneous injection and weight based at the discretion of the treating clinician.
235615|NCT02396719|Device|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
235616|NCT02396706|Drug|Ivy Leaves Cough Liquid|
235617|NCT02396706|Drug|Placebo|
235618|NCT02396693|Device|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) < 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) < 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
235619|NCT02396693|Device|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
235620|NCT02396693|Device|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
235621|NCT02396667|Other|5D ultrasound|
235622|NCT02396654|Other|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
235623|NCT02396641|Other|Best Supportive Care Checklist|
235624|NCT02396628|Drug|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
235625|NCT02396628|Drug|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
235626|NCT02396615|Dietary Supplement|SATIN pineapple|Active juice with added fibre and ginseng
235627|NCT02396615|Dietary Supplement|SATIN pineapple control|Control products without active ingredients
235628|NCT02396602|Behavioral|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
235629|NCT02396589|Behavioral|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
235630|NCT02396589|Behavioral|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
235787|NCT02395367|Radiation|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
235631|NCT02396576|Behavioral|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
235632|NCT02396563|Procedure|epidural analgesia|
235633|NCT02396563|Drug|Ropivacaine|
235634|NCT02396550|Behavioral|Positive Expectations|Give positive expectation of the treatment efficacy to patients
235635|NCT02396550|Procedure|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
235636|NCT02396537|Drug|Lidocaine|Administered intranasally prior to Midazolam administration.
235637|NCT02396537|Drug|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
235638|NCT02396537|Drug|0.9% Saline|Administered intranasally prior to Midazolam administration.
235639|NCT02396524|Behavioral|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
235640|NCT02396511|Biological|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
235641|NCT02396511|Biological|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
235642|NCT02396498|Drug|HIPEC|Using cisplatin in HIPEC plus oral S-1
235643|NCT02396485|Other|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
235644|NCT02396472|Behavioral|Order by time and topic|
235645|NCT02396472|Behavioral|Order by information relevance|
235646|NCT02396472|Behavioral|Order by social relationship|
235647|NCT02396472|Behavioral|Order by help giving|
235648|NCT02396472|Behavioral|Order by self-disclosure|
235649|NCT02396459|Drug|Triac|Triac, following a dose-escalation scheme
235650|NCT02396446|Other|Abdominal acoustic measurement|
235651|NCT02396433|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle.
235652|NCT02396433|Drug|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
235653|NCT02396433|Drug|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
235654|NCT02396420|Device|Embosphere Microspheres|
235655|NCT02396407|Behavioral|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.~Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.~Handwashing: Handwashing stations including soapy water bottles and detergent soap.~Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children < 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
235656|NCT02396394|Behavioral|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
235657|NCT02396381|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
235658|NCT02396381|Other|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
235659|NCT02396368|Drug|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
235660|NCT02396368|Radiation|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
235661|NCT02396355|Device|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
235662|NCT02396355|Device|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
235663|NCT02396355|Device|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
235664|NCT02396342|Genetic|AAV5-hFIX|AAV5hFIX gene therapy
235665|NCT02396329|Drug|Chlorhexidine|
235666|NCT02396329|Drug|Povidone-Iodine|
235895|NCT02394535|Other|Questionnaire Administration|Ancillary studies
235896|NCT02394535|Radiation|Radiation Therapy|Undergo radiation therapy
235667|NCT02396316|Drug|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
235668|NCT02396316|Drug|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
235669|NCT02396303|Drug|Carbetocin|
235670|NCT02396290|Procedure|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
235671|NCT02396290|Procedure|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
235672|NCT02396277|Procedure|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
235673|NCT02396264|Other|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
235674|NCT02396264|Other|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
235675|NCT02396251|Device|HA experimental|
235676|NCT02396251|Device|HA comparator|
235677|NCT02396238|Device|Celution Device|ADRCs prepared using the investigational Celution Device
235678|NCT02396238|Other|Placebo|Placebo
235679|NCT02396225|Drug|Voriconazole|
235680|NCT02396212|Biological|Canakinumab|canakinumab was provided as a 150 mg/1 mL solution for subcutaneous injection and administered at 4mg/kg every 4 weeks.
235681|NCT02396199|Device|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
235682|NCT02396186|Device|PTCA Balloon Angioplasty|
235683|NCT02396173|Other|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
235684|NCT02396160|Dietary Supplement|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
235685|NCT02396160|Other|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
235686|NCT02396147|Drug|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
235687|NCT02396147|Drug|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
235688|NCT02396147|Drug|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
235689|NCT02396134|Biological|CMVpp65-A*0201 peptide vaccine|Given SC
235690|NCT02396134|Other|Placebo|Given SC
235691|NCT02396134|Other|Laboratory Biomarker Analysis|Correlative studies
235692|NCT02396121|Dietary Supplement|Oral nutritional supplement : Renutryl® Booster|
235693|NCT02396108|Drug|Paclitaxel + Carboplatin + ASLAN001|"Phase I~IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle~PO ASLAN001 daily continuously (starting dose 500mg BID)~Phase II~•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks~Followed by:~IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles~IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles~PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
235694|NCT02396082|Behavioral|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
235695|NCT02396082|Other|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
235696|NCT02396069|Drug|JPI-289|PARP-1 inhibitor
235697|NCT02396069|Drug|Placebo|Placebo
235698|NCT02396056|Other|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
235699|NCT02396056|Other|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
235700|NCT02396043|Drug|induction|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22"
235701|NCT02396043|Drug|induction|Cyclophosphamide: 1000 mg/m2 iv on days 29, 57,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41, 45-48, 52-55,Mercaptopurine: 60 mg/m2 po on days 29-56
235702|NCT02396043|Drug|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
235703|NCT02396043|Drug|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
235704|NCT02396043|Drug|reinduction|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8"
235705|NCT02396043|Drug|reinduction|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
235706|NCT02396043|Drug|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
235707|NCT02396030|Drug|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
235708|NCT02396030|Drug|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
235709|NCT02396017|Device|Capsule endoscopy|Endoscopic device
235710|NCT02396017|Drug|Polyethylene Glycol|Bowel purgative
235711|NCT02396004|Device|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
235712|NCT02395991|Drug|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
235713|NCT02395991|Other|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.~precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
235714|NCT02395978|Drug|PDC-1421 Capsule|
235715|NCT02395978|Drug|placebo|
235716|NCT02395952|Drug|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
235717|NCT02395952|Device|Acuvue Oasys Bandage Contact Lens|
235718|NCT02395952|Device|Ambiodisk|
235719|NCT02395952|Device|Prokera|
235720|NCT02395939|Procedure|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
235721|NCT02395939|Procedure|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
235722|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
235723|NCT02395926|Drug|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
235724|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
235725|NCT02395913|Drug|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
235726|NCT02395913|Drug|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
235727|NCT02395913|Drug|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
235728|NCT02395913|Drug|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
235729|NCT02395900|Dietary Supplement|Flaxseed|
235730|NCT02395900|Other|control|
235731|NCT02395874|Procedure|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
235732|NCT02395861|Other|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
235733|NCT02395848|Drug|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
235734|NCT02395822|Biological|IL-15|"Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if < 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total"
235735|NCT02395809|Procedure|lateral internal sphincterotomy|
235736|NCT02395809|Procedure|TENS|
235737|NCT02395796|Procedure|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
235738|NCT02395783|Drug|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
235739|NCT02395783|Drug|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
235740|NCT02395783|Other|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
235788|NCT02395367|Drug|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
235741|NCT02395770|Other|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.~Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.~Stretching & Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.~Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
235742|NCT02395757|Device|MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|
235743|NCT02395744|Other|Paclitaxel administration using the OPC|
235744|NCT02395731|Behavioral|MIND at Home-Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
235745|NCT02395718|Other|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
235746|NCT02395718|Other|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
235747|NCT02395705|Drug|cisplatin and paclitaxel|"Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles."
235748|NCT02395692|Other|Treatment|Correlative studies
235749|NCT02395692|Drug|Methoxyamine|Given PO
235750|NCT02395692|Drug|Temozolomide|Given PO
235751|NCT02395679|Biological|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
235752|NCT02395666|Drug|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
235753|NCT02395653|Drug|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
235754|NCT02395640|Drug|Epirubicin|50mg/m2 ivgtt d1
235755|NCT02395640|Drug|Oxaliplatin|
235756|NCT02395640|Drug|Capecitabine|1000mg/m2 po d1-14
235757|NCT02395627|Drug|Tamoxifen|
235758|NCT02395627|Drug|Vorinostat|
235759|NCT02395627|Drug|pembrolizumab|
235760|NCT02395614|Drug|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
235761|NCT02395614|Drug|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.~80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
235762|NCT02395601|Drug|CPI-1205|Small molecule inhibitor of the enzyme EZH2
235763|NCT02395588|Other|Guideline based care|Patient education using guideline based teaching guides
235764|NCT02395549|Drug|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
235765|NCT02395549|Drug|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
235766|NCT02395549|Drug|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
235767|NCT02395549|Drug|Vehicle Control Gel|
235768|NCT02395536|Other|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
235769|NCT02395536|Other|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
235770|NCT02395523|Radiation|Proton Beam Therapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan~Clinical target volume (CTV) = GTV + internal target volume~Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week~Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
235771|NCT02395510|Drug|Vortioxetine|Vortioxetine 5-20mg
235772|NCT02395497|Procedure|Penile Transplant|
235773|NCT02395497|Biological|Monoclonal Antibody (Humanized Anti-CD52)|
235774|NCT02395497|Drug|Tacrolimus|
235775|NCT02395471|Device|Cytosponge™ Cell Collection Device|Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
235776|NCT02395458|Drug|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
235777|NCT02395458|Drug|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
235778|NCT02395445|Device|orotracheal intubation|
235779|NCT02395432|Device|orotracheal intubation|
235780|NCT02395419|Device|Orotracheal intubation with Totaltrack|
235781|NCT02395419|Device|Orotracheal intubation with Airtraq|
235782|NCT02395406|Device|Orotracheal intubation with Totaltrack|
235783|NCT02395406|Device|Orotracheal intubation with Airtraq|
235784|NCT02395393|Device|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
235785|NCT02395380|Other|C-reactive protein dosage|
235786|NCT02395367|Procedure|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
235789|NCT02395354|Device|Placing a self-expanding metallic stent|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center~Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion~Clips can be placed at the distal end of the prosthesis according to the endoscopist.~Prosthesis removal time in 4 weeks."
235790|NCT02395354|Device|A balloon dilatation|"Income on short stay unit (SSU) post-procedure~Light sedation by the endoscopist vs anesthetist by center.~Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion~Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion~It shall be deemed failure to expansion if required> 2 expansions."
235791|NCT02395328|Behavioral|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
235792|NCT02395315|Device|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
235793|NCT02395315|Device|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
235794|NCT02395302|Device|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
235795|NCT02395289|Behavioral|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
235796|NCT02395289|Behavioral|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
235797|NCT02395276|Device|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
235798|NCT02395263|Drug|Yuxintine|
235799|NCT02395250|Biological|anti-GPC3 CAR T|
235800|NCT02395237|Drug|: Amaryl® M IR 2/1000|
235801|NCT02395224|Other|cancer treatment and follow-up according to current regional and national guidelines|
235802|NCT02395211|Behavioral|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.~The intervention will last 30 minute a day x 4 weeks"
235803|NCT02395211|Device|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
235804|NCT02395185|Other|Milk bottle administration|Patients are given a bottle of milk during the casting process.
235805|NCT02395185|Other|Water bottle administration|Patients are given a bottle of water during the casting process.
235806|NCT02395185|Other|Sucrose bottle administration|Patients are given a bottle of sucrose during the casting process.
235807|NCT02395172|Drug|Avelumab|Participants received 10 milligram per kilogram (mg/kg) of avelumab as a 1-hour intravenous infusion once every 2 weeks until confirmed disease progression.
235808|NCT02395172|Drug|Docetaxel|Participants received 75 mg per square meter (m^2) (per label) of docetaxel by intravenous infusion once every 3 weeks until confirmed disease progression.
235809|NCT02395159|Device|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.~The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
235810|NCT02395159|Other|sterile plaster dressings|standard wound management method of sterile plaster dressings
235811|NCT02395146|Procedure|Monitoring|intraoperative EBSLN monitoring
235812|NCT02395133|Drug|Dupilumab|Subcutaneous injection of Dupilumab 300 mg alternatively with placebo (matched to Dupilumab) was administered.
235813|NCT02395133|Drug|Placebo|Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
235814|NCT02395120|Behavioral|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
235815|NCT02395120|Behavioral|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
235816|NCT02395120|Behavioral|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
235817|NCT02395120|Behavioral|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
235818|NCT02395120|Behavioral|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
235893|NCT02394535|Other|Laboratory Biomarker Analysis|Correlative studies
235819|NCT02395094|Behavioral|Child Life|"Child Life preparation in surgical daycare can include:~role-play using dolls and medical equipment (either toy doctor kits or true medical materials)~the use of books/storyboards that show pictures of operating room and daycare routines~teaching & rehearsing coping and relaxation skills such as deep breathing and guided imagery~age-appropriate explanation of what to expect throughout the day in SDCU"
235820|NCT02395081|Dietary Supplement|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
235821|NCT02395081|Dietary Supplement|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
235822|NCT02395081|Dietary Supplement|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
235823|NCT02395068|Drug|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
235824|NCT02395068|Drug|irinotecan|"Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.~Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h"
235825|NCT02395055|Drug|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
235826|NCT02395055|Drug|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
235827|NCT02395042|Drug|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
235828|NCT02395042|Drug|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
235829|NCT02395029|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
235830|NCT02395016|Drug|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
235831|NCT02395016|Drug|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
235832|NCT02395016|Other|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
235833|NCT02395003|Other|Palmitate Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
235834|NCT02394990|Behavioral|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
235835|NCT02394990|Behavioral|ABI|
235836|NCT02394977|Device|Compression with Feedback|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel™ (CFA; INOTECH, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. The device does not require an electrical power supply."
235837|NCT02394977|Other|Standard chest compression|CPR in accordance with published international guidelines using standard manual chest compression.
235838|NCT02394964|Other|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
235839|NCT02394951|Drug|Pregabalin|Anticonvulsant
235840|NCT02394951|Drug|Placebo|Identical, matching inactive substance
235841|NCT02394938|Other|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
235842|NCT02394925|Device|Multifocal Test Contact lens|Used in a daily wear modality
235843|NCT02394912|Device|vena cava filter implantation (LUMIFI with Crux VCF System)|
235844|NCT02394899|Behavioral|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
235845|NCT02394899|Other|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
235846|NCT02394886|Biological|ALLO-ASC-DFU|
235847|NCT02394873|Biological|ALLO-ASC-DFU|Dressing for second-degree burn wound.
235848|NCT02394860|Other|echo Doppler lower limbs|
235849|NCT02394847|Drug|propofol|
235850|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
235851|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
235852|NCT02394821|Drug|Polihexanide 2%|
235853|NCT02394821|Drug|Metronidazole 0.8%|
235854|NCT02394808|Device|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
235855|NCT02394808|Device|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
235856|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
235857|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
235858|NCT02394782|Device|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
235859|NCT02394782|Device|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
235860|NCT02394769|Drug|Aspirin|
235861|NCT02394769|Drug|Placebo for Aspirin|
235862|NCT02394756|Device|Marketed Soft Contact lens|Replacement schedule every 2 weeks
235863|NCT02394756|Device|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
235864|NCT02394756|Device|Biofinity®|Replacement schedule every 4 weeks
235865|NCT02394743|Radiation|18FDG-PET|
235866|NCT02394730|Drug|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
235867|NCT02394730|Drug|Placebo|Sugar pill taken orally once daily for 12 weeks
235868|NCT02394717|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
235869|NCT02394704|Other|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while ruminating. Stimuli will consist of non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders) or vibratory stimulation with a vibroacoustic element placed on the back near the shoulders. Up to four sessions will be approximately 45 minutes, over the course of two weeks."
235870|NCT02394691|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
235871|NCT02394678|Device|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
235872|NCT02394665|Radiation|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
235873|NCT02394665|Drug|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:~Concurrent during Radiation Therapy: 75 mg/m^2 orally for 6 weeks;~Post-radiation, adjuvant therapy: 150 mg/m^2 - 200 mg/m^2 orally daily on days 1 - 5 of each cycle."
235874|NCT02394665|Behavioral|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
235875|NCT02394665|Radiation|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:~HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
235876|NCT02394665|Radiation|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
235877|NCT02394665|Device|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
235878|NCT02394652|Drug|Metformin|
235879|NCT02394652|Drug|Cisplatin|
235880|NCT02394652|Drug|FAZA|
235881|NCT02394639|Other|video-EEG monitoring|
235882|NCT02394626|Procedure|Surgery followed by adjuvant second-line therapy|"Surgery:~Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.~Adjuvant second-line therapy:~Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
235883|NCT02394626|Procedure|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
235884|NCT02394613|Drug|ANX776|Single intravenous injection
235885|NCT02394600|Drug|Grastek®|one tablet daily for four months
235886|NCT02394600|Drug|Placebo|one tablet daily for four months
235887|NCT02394587|Behavioral|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
235888|NCT02394574|Other|Clean Cookstove|Ethanol
235889|NCT02394574|Other|Traditional Cookstove|Firewood / Kerosene
235890|NCT02394561|Biological|Secukinumab|Secukinumab was supplied as 150 mg solution in pre-filled syringe for subcutaneous injection
235891|NCT02394548|Radiation|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
235892|NCT02394535|Drug|Capecitabine|Given PO
235897|NCT02394522|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
235898|NCT02394522|Device|Active Ingredient|Transfluthrin (Active ingredient)
235899|NCT02394522|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
235900|NCT02394509|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
235901|NCT02394496|Drug|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
235902|NCT02394496|Drug|Lapatinib|1500mg (TBD) O.S. qd
235903|NCT02394496|Drug|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
235904|NCT02394496|Drug|Placebo Lapatinib|1500mg (TBD) O.S. qd
235905|NCT02394483|Drug|F901318 safety|Safety assessments
235906|NCT02394483|Drug|F901318 tolerability|Tolerability assessments
235907|NCT02394483|Drug|F901318 pharmacokinetics|Pharmacokinetic assessments
235908|NCT02394483|Other|Placebo safety|Safety assessments
235909|NCT02394483|Other|Placebo tolerability|Placebo tolerability
235910|NCT02394483|Other|Placebo pharmacokinetics|Plaacebo pharmacokinetics
235911|NCT02394470|Other|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
235912|NCT02394470|Other|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
235913|NCT02394470|Other|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
235914|NCT02394457|Drug|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
235915|NCT02394457|Procedure|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
235916|NCT02394444|Other|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
235917|NCT02394431|Other|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
235918|NCT02394431|Other|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
235919|NCT02394431|Other|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
235920|NCT02394418|Drug|Sevoflurane|Treatment of delirium by inhaled sevoflurane
235921|NCT02394418|Drug|Propofol|Treatment of delirium by propofol i.v. infusion
235922|NCT02394418|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
235923|NCT02394379|Device|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
235924|NCT02394366|Other|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
235925|NCT02394366|Other|OHS base only|Olive and beeswax salve base
235926|NCT02394353|Device|Transient hepatic elastography|
235927|NCT02394340|Drug|Omeprazole 40 mg|Oral capsule to be taken as per the instructions regarding proper dosing technique.
235928|NCT02394340|Drug|Luliconazole Cream 1%|Topical cream to be applied as per the instructions regarding proper study drug application technique.
235929|NCT02394327|Device|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
235930|NCT02394327|Device|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
235931|NCT02394314|Drug|MEDI0382|MEDI0382 administered subcutaneously
235932|NCT02394314|Drug|Placebo|Placebo administered subcutaneously
235933|NCT02394288|Procedure|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
235934|NCT02394275|Biological|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
235935|NCT02394262|Radiation|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
235936|NCT02394262|Other|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
235937|NCT02394249|Behavioral|Physical activity regime|Information already included in arm descriptions
235938|NCT02394236|Other|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
235939|NCT02394223|Procedure|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
235940|NCT02394197|Drug|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
235941|NCT02394197|Drug|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
235942|NCT02394184|Procedure|transcatheter aortic valve replacement|
235943|NCT02394171|Behavioral|Group Cohesion|See description in arm/group above
235944|NCT02394158|Drug|Metformin|
235945|NCT02394158|Drug|placebo|
235946|NCT02394145|Drug|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
235998|NCT02393807|Drug|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
235947|NCT02394145|Drug|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
235948|NCT02394132|Drug|Imiquimod|
235949|NCT02394132|Radiation|Radiotherapy|
235950|NCT02394119|Drug|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
235951|NCT02394119|Drug|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
235952|NCT02394106|Drug|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
235953|NCT02394106|Other|Placebo|Normal saline, 1000 ml, administered once
235954|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
235955|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
235956|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
235957|NCT02394080|Device|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
235958|NCT02394067|Other|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
235959|NCT02394054|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
235960|NCT02394054|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
235961|NCT02394041|Device|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
235962|NCT02394041|Device|Sham acupuncture|Sham acupuncture with sham needles
235963|NCT02394028|Drug|Etrolizumab|Etrolizumab will be administered as per regimen specified in individual arms.
235964|NCT02394028|Drug|Placebo|Etrolizumab-matching placebo will be administered as per regimen specified in individual arms.
235965|NCT02394015|Drug|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
235966|NCT02394002|Drug|Propofol|
235967|NCT02393989|Procedure|posterior restoration|restorations for caries effected teeth
235968|NCT02393976|Dietary Supplement|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
235969|NCT02393976|Dietary Supplement|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
235970|NCT02393963|Drug|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
235971|NCT02393963|Other|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
235972|NCT02393950|Drug|ODM-106|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
235973|NCT02393950|Drug|Placebo|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
235974|NCT02393937|Drug|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
235975|NCT02393937|Drug|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
235976|NCT02393937|Drug|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
235977|NCT02393924|Other|No intervention|
235978|NCT02393911|Dietary Supplement|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
235979|NCT02393898|Drug|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
235980|NCT02393898|Drug|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
235981|NCT02393898|Drug|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
235982|NCT02393885|Device|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
235983|NCT02393872|Behavioral|Feel4Diabetes-intervention|Community-based intervention.
235984|NCT02393859|Drug|Blinatumomab|The patient will receive one cycle of blinatumomab, which includes 4 weeks of CIVI of blinatumomab.
235985|NCT02393859|Drug|Conventional Consolidation Chemotherapy|The patient will receive one block of standard consolidation chemotherapy.
235986|NCT02393846|Drug|Ketoprofen gel|Topical ketoprofen as used in gel form.
235987|NCT02393846|Drug|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
235988|NCT02393833|Drug|Cyclophosphamide|
235989|NCT02393833|Drug|Doxorubicin hydrochloride|
235990|NCT02393833|Drug|Epirubicin hydrochloride|
235991|NCT02393833|Drug|Fluorouracil|
235992|NCT02393833|Drug|Methotrexate|
235993|NCT02393833|Procedure|Adjuvant therapy|
235994|NCT02393833|Drug|Docetaxel|
235995|NCT02393833|Drug|Paclitaxel|
235996|NCT02393820|Drug|pazopanib|treatment will be given until progression or unacceptable toxicity .
235997|NCT02393807|Drug|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
235999|NCT02393794|Drug|Romidepsin|Histone deacetylase inhibitor
236000|NCT02393794|Drug|Cisplatin|Platinum compound
236001|NCT02393794|Drug|Nivolumab|Monoclonal antibody, checkpoint inhibitor
236002|NCT02393755|Drug|Capecitabine|Given PO
236003|NCT02393755|Other|Laboratory Biomarker Analysis|Correlative studies
236004|NCT02393755|Drug|Nintedanib|Given PO
236005|NCT02393755|Other|Pharmacological Study|Correlative studies
236006|NCT02393742|Drug|Sodium nitrite|
236007|NCT02393742|Drug|Placebo|
236008|NCT02393729|Behavioral|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:~Intellectual ability~Laterality~Reading Skills~Motor skills~Oral Language~Attention~Child's behaviour"
236009|NCT02393729|Other|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes~Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.~Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
236010|NCT02393716|Device|Endurant Evo AAA Stent Graft System|
236011|NCT02393716|Procedure|Endovascular aneurysm repair (EVAR)|
236012|NCT02393690|Radiation|Iodine I-131|Given PO
236013|NCT02393690|Other|Placebo|Given PO
236014|NCT02393690|Drug|Selumetinib|Given PO
236015|NCT02393677|Drug|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
236016|NCT02393677|Drug|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
236017|NCT02393664|Drug|propofol, bupivacaine|Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
236018|NCT02393664|Drug|sevoflurane, rocuronium|Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
236019|NCT02393651|Device|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
236020|NCT02393638|Other|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
236021|NCT02393638|Other|Lecture|Lecture
236022|NCT02393625|Drug|Ceritinib (LDK378)|
236023|NCT02393625|Drug|Nivolumab|
236024|NCT02393612|Drug|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
236025|NCT02393612|Drug|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
236026|NCT02393599|Drug|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
236027|NCT02393599|Drug|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
236028|NCT02393599|Drug|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
236029|NCT02393586|Drug|Faropenem|Single oral dose
236030|NCT02393586|Drug|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
236031|NCT02393586|Drug|Rifampicin|Single oral dose
236032|NCT02393573|Drug|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
236033|NCT02393573|Drug|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
236034|NCT02393560|Procedure|DECT scan|
236035|NCT02393547|Drug|Varenicline|All subjects receive Varenicline
236036|NCT02393547|Drug|Lorcaserin|All subjects receive Lorcaserin
236037|NCT02393534|Other|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
236038|NCT02393521|Device|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
236039|NCT02393508|Other|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
236040|NCT02393508|Other|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
236041|NCT02393495|Device|intrauterine device TCu 380A|
236042|NCT02393482|Drug|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
236043|NCT02393482|Drug|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
236044|NCT02393482|Drug|Add back therapy 1 (tibolone)|tibolone 5 mg/die
236045|NCT02393482|Drug|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
236046|NCT02393469|Other|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
236047|NCT02393469|Other|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
236048|NCT02393456|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
236049|NCT02393456|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
236050|NCT02393443|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
236051|NCT02393443|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
236052|NCT02393430|Drug|Rebamipide|Rebamipide is a
236053|NCT02393430|Behavioral|optimization of life style|
236054|NCT02393417|Biological|CANDIN|Candida albicans Skin Test Antigen for Cellular Hypersensitivity
236055|NCT02393417|Other|Placebo|0.9% Sodium Chloride Injection USP (non-preserved)
236056|NCT02393404|Other|PT-FMT|Physiotherapeutic functional movement-power training
236057|NCT02393404|Other|FMT alone|Physiotherapeutic power training
236058|NCT02393391|Device|Neuroelectrics STARSTIM|
236059|NCT02393378|Drug|Namilumab|Namilumab injection
236060|NCT02393378|Drug|Adalimumab|Adalimumab SC injection
236061|NCT02393378|Drug|Methotrexate|Methotrexate tablet
236062|NCT02393378|Drug|Folic Acid|Folic Acid Tablet
236063|NCT02393365|Other|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
236064|NCT02393365|Procedure|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.~In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
236065|NCT02393352|Other|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
236066|NCT02393352|Other|Electrical Stimulation Therapy|
236067|NCT02393339|Drug|paracetamol|Pre-operative administration of Paracetamol syrup
236068|NCT02393339|Drug|placebo|Pre-operative administration of placebo syrup
236069|NCT02393326|Procedure|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
236070|NCT02393326|Procedure|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
236071|NCT02393313|Procedure|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
236072|NCT02393313|Device|Rayner T-flex Toric IOLs|
236073|NCT02393300|Drug|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
236074|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
236075|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
236076|NCT02393287|Other|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
236077|NCT02393274|Device|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
236078|NCT02393261|Other|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
236079|NCT02393261|Other|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
236080|NCT02393248|Drug|Pemigatinib|
236081|NCT02393248|Drug|Gemcitabine + Cisplatin|
236082|NCT02393248|Drug|Pembrolizumab|
236083|NCT02393248|Drug|Docetaxel|
236084|NCT02393248|Drug|Trastuzumab|
236085|NCT02393248|Drug|INCMGA00012|
236086|NCT02393235|Other|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
236087|NCT02393222|Other|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
236088|NCT02393209|Drug|Docetaxel|Docetaxel intravenous infusion
236089|NCT02393209|Drug|TAK-117|TAK-117 Tablets
236090|NCT02393196|Drug|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
236091|NCT02393196|Drug|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
236092|NCT02393183|Drug|ASTED|A tablet of ASTED will be taken twice a day
236093|NCT02393183|Dietary Supplement|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
236094|NCT02393183|Other|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
236095|NCT02393170|Other|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.~They will be requested to play 60 minutes a day for 5 weeks."
236096|NCT02393170|Other|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
236097|NCT02393157|Drug|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
236098|NCT02393157|Drug|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
236099|NCT02393157|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
236100|NCT02393157|Drug|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
236101|NCT02393157|Drug|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
236102|NCT02393144|Device|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
236103|NCT02393144|Device|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
236104|NCT02393144|Other|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
236105|NCT02393144|Drug|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
236106|NCT02393144|Drug|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
236107|NCT02393144|Drug|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
236108|NCT02393144|Drug|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
236109|NCT02393131|Radiation|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
236110|NCT02393131|Radiation|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
236111|NCT02393118|Device|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
236112|NCT02393092|Behavioral|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
236113|NCT02393092|Behavioral|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
236114|NCT02393092|Behavioral|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
236115|NCT02393079|Device|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
236116|NCT02393079|Device|Sham|A SHAM identical helmet will be used in the control group.
236117|NCT02393066|Drug|Propofol|Sedation
236118|NCT02393066|Drug|Dexmedetomidine|Sedation
236119|NCT02393053|Procedure|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
236120|NCT02393053|Procedure|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
236121|NCT02393040|Other|PRP/Saline|"PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head."
236122|NCT02393027|Drug|[18F] LBT-999 PET|
236123|NCT02393014|Procedure|Simple physical exercises|"The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.~The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.~The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
236124|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
236125|NCT02393001|Other|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
236126|NCT02393001|Other|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
236127|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
236128|NCT02392988|Other|acupuncture treatment|acupuncture treatment
236129|NCT02392988|Other|Placebo Comparator|Placebo Comparator
236130|NCT02392975|Procedure|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
236207|NCT02392442|Biological|Endotoxin|4 ng/kg in final volume of 2 ml
236131|NCT02392975|Procedure|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
236132|NCT02392962|Procedure|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
236133|NCT02392962|Procedure|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
236134|NCT02392949|Behavioral|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
236135|NCT02392949|Other|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
236136|NCT02392936|Procedure|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
236137|NCT02392910|Drug|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
236138|NCT02392910|Drug|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
236139|NCT02392897|Behavioral|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
236140|NCT02392897|Behavioral|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
236141|NCT02392884|Behavioral|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
236142|NCT02392871|Radiation|Palliative radiotherapy|
236143|NCT02392871|Drug|Dabrafenib and trametinib (combination)|Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
236144|NCT02392858|Other|influenza cohort|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
236145|NCT02392845|Drug|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
236146|NCT02392832|Biological|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.~Starts from 2016, fourteen sites in each of the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
236147|NCT02392819|Dietary Supplement|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
236148|NCT02392819|Dietary Supplement|Placebo|
236149|NCT02392806|Device|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus Bubbler at time of extubation
236150|NCT02392806|Device|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to B&B Bubbler at time of extubation
236151|NCT02392793|Drug|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
236152|NCT02392793|Drug|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
236153|NCT02392793|Drug|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
236154|NCT02392793|Drug|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless peg-filgrastim is given.
236155|NCT02392793|Drug|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless filgrastim is given.
236156|NCT02392780|Drug|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
236157|NCT02392780|Drug|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
236158|NCT02392780|Drug|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
236159|NCT02392767|Dietary Supplement|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
236160|NCT02392767|Dietary Supplement|Placebo|corn starch
236161|NCT02392754|Device|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
236162|NCT02392741|Other|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
236208|NCT02392429|Drug|Chemotherapy|Given anthracycline IV
236209|NCT02392429|Procedure|Computed Tomography|Undergo FLT PET/CT
236210|NCT02392429|Drug|Cytarabine|Given IV
236163|NCT02392728|Behavioral|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
236164|NCT02392728|Behavioral|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
236165|NCT02392715|Device|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training~15 minutes, 3x/weeks, 36 sessions~Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
236166|NCT02392715|Device|Sham Inspiratory muscle training|"with Threshold by respironics~15 minutes, 3x/weeks, 36 sessions~Intensity: 5 centimeters of water (cmH20)"
236167|NCT02392702|Drug|C-10355|
236168|NCT02392702|Drug|C-10358|
236169|NCT02392702|Drug|Kalydeco|
236170|NCT02392689|Other|Procalcitonin|Procalcitonin guided antibiotic therapy
236171|NCT02392676|Drug|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
236172|NCT02392676|Drug|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
236173|NCT02392663|Other|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
236174|NCT02392663|Other|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
236175|NCT02392663|Other|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
236176|NCT02392637|Drug|Abraxane (Nab-Paclitaxel)|100 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
236177|NCT02392637|Drug|Cisplatin|25 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
236178|NCT02392637|Drug|Gemcitabine|800 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
236179|NCT02392637|Behavioral|Phone Calls|Participant receives phone call from study staff 30 days after last dose of study drugs, and every 12 weeks thereafter.
236180|NCT02392624|Drug|Omalizumab|Omalizumab 300 mg administered SC Q4W.
236181|NCT02392624|Drug|Placebo|Placebo matched to omalizumab administered SC Q4W.
236182|NCT02392611|Drug|GS-5829|Tablet administered orally
236183|NCT02392611|Drug|Exemestane|Tablets administered orally once daily
236184|NCT02392611|Drug|Fulvestrant|Administered intramuscularly every 28 days
236185|NCT02392585|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
236186|NCT02392585|Procedure|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
236187|NCT02392572|Drug|ONC201|"Phase I Starting dose of ONC201: 125 mg by mouth once every 3 weeks.~Phase II Starting dose of ONC201: MTD from Phase I."
236188|NCT02392572|Drug|Cytarabine|20 mg subcutaneous twice daily for 10 days.
236189|NCT02392559|Drug|Evolocumab|Dose of subcutaneous Evolocumab every 4 weeks
236190|NCT02392559|Drug|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
236191|NCT02392546|Drug|elobixibat|
236192|NCT02392546|Drug|placebo|
236193|NCT02392533|Other|Education|Education
236194|NCT02392520|Drug|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
236195|NCT02392520|Drug|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
236196|NCT02392507|Drug|Necitumumab|Administered IV
236197|NCT02392507|Drug|Nab-Paclitaxel|Administered IV
236198|NCT02392507|Drug|Carboplatin|Administered IV
236199|NCT02392494|Drug|MK-1075|MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.
236200|NCT02392481|Procedure|Biofluid sampling|
236201|NCT02392468|Drug|BI 409306 matching placebo|placebo
236202|NCT02392468|Drug|BI 409306 matching placebo|placebo
236203|NCT02392468|Drug|BI 409306|low dose
236204|NCT02392468|Drug|BI 409306|high dose
236205|NCT02392455|Drug|treatment|Docetaxel plus nintedanib until progression or intolerability
236206|NCT02392442|Other|Saline|180 of normal saline instilled in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total)
236211|NCT02392429|Other|Fluorothymidine F-18|Undergo FLT PET/CT
236212|NCT02392429|Other|Laboratory Biomarker Analysis|Correlative studies
236213|NCT02392429|Procedure|Positron Emission Tomography|Undergo FLT PET/CT
236214|NCT02392403|Device|Nucleus CI532 cochlear implant|
236215|NCT02392390|Procedure|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
236216|NCT02392390|Drug|Metvixia cream|
236217|NCT02392377|Drug|Paclitaxel|Given IV or IVPB
236218|NCT02392377|Drug|Carboplatin|Given IV or IVPB
236219|NCT02392377|Drug|Oxaliplatin|Given IV
236220|NCT02392377|Drug|Leucovorin Calcium|Given IV
236221|NCT02392377|Drug|Fluorouracil|Given IV
236222|NCT02392377|Radiation|Radiation Therapy|Undergo radiation therapy
236223|NCT02392377|Procedure|Therapeutic Conventional Surgery|Undergo esophagectomy
236224|NCT02392377|Other|Laboratory Biomarker Analysis|Correlative studies
236225|NCT02392364|Drug|Intravitreal Aflibercept Injection|
236226|NCT02392351|Device|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
236227|NCT02392351|Device|Renal Angiography|Percutaneous renal angiography
236228|NCT02392338|Procedure|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
236229|NCT02392325|Biological|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10^3.0 plaque-forming units (PFU)
236230|NCT02392325|Biological|Placebo|Administered subcutaneously in 0.5 mL
236231|NCT02392325|Biological|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10^3.0 PFU
236232|NCT02392312|Drug|ATF-Fresenius S|intravenous
236233|NCT02392286|Drug|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
236234|NCT02392273|Drug|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
236235|NCT02392260|Device|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
236236|NCT02392247|Device|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
236237|NCT02392234|Drug|VX-661/Ivacaftor|Fixed dose combination tablet, oral use
236238|NCT02392234|Drug|Ivacaftor|Tablet, oral use
236239|NCT02392234|Drug|Placebo matched to VX-661/ ivacaftor|Fixed dose combination tablet, oral use
236240|NCT02392234|Drug|Placebo matched to Ivacaftor|Tablet, oral use
236241|NCT02392208|Drug|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
236242|NCT02392208|Procedure|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
236243|NCT02392195|Other|Non-interventional|Observational
236244|NCT02392182|Other|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
236245|NCT02392169|Drug|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
236246|NCT02392156|Biological|rFVIIIFc|As described in the treatment arm
236247|NCT02392156|Biological|rFIXFc|As described in the treatment arm
236248|NCT02392156|Drug|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
236249|NCT02392156|Drug|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
236250|NCT02392143|Other|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test [18]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
236251|NCT02392143|Other|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
236252|NCT02392143|Other|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
236253|NCT02392130|Drug|Clobetasol propionate 0.05% ointment|
236254|NCT02392130|Drug|LEO 130852A gel 1%|
236255|NCT02392130|Drug|LEO 130852A placebo gel|
236256|NCT02392117|Drug|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
236257|NCT02392104|Drug|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
236258|NCT02392078|Device|NeuroBlate System|
236259|NCT02392052|Behavioral|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
236260|NCT02392052|Behavioral|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
236261|NCT02392039|Drug|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
236262|NCT02392039|Drug|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
236263|NCT02392039|Other|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.~Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
236264|NCT02392039|Behavioral|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
236265|NCT02392026|Drug|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
236266|NCT02392013|Other|Home Modification|Removal of home barriers or hazards.
236267|NCT02392000|Device|WatchPAT sleep monitor|Self-management of insomnia using a mobile sleep device
236268|NCT02392000|Behavioral|CBT-i Coach mobile app|Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
236269|NCT02391987|Device|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.~Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
236270|NCT02391974|Device|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.~Touch-up treatment provided at 3 and 6 weeks."
236271|NCT02391961|Drug|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
236272|NCT02391961|Drug|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
236273|NCT02391935|Drug|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
236274|NCT02391935|Drug|Placebo|Cryomedium
236275|NCT02391935|Device|Sham injection|skin penetration of the needle without injection of liquid
236276|NCT02391922|Behavioral|First aid course|
236277|NCT02391922|Behavioral|First aid instructions by mobile phone|
236278|NCT02391909|Biological|Vivotif|
236279|NCT02391896|Device|Dual energy and tomosynthesis xray|
236280|NCT02391883|Drug|Clopidogrel|
236281|NCT02391870|Behavioral|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
236282|NCT02391857|Procedure|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
236283|NCT02391844|Drug|Oxycodone|Oxycodone with Acetaminophen Extended Release
236284|NCT02391831|Other|Strength, function and activity measurements|
236285|NCT02391831|Other|Muscle MRI|
236286|NCT02391831|Other|Electrophysiology measurements|
236287|NCT02391831|Other|Blood sampling for biomarker analysis|
236288|NCT02391805|Drug|Entecavir|Entecavir will be administered as per local labeling.
236289|NCT02391805|Drug|Placebo|Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
236290|NCT02391805|Drug|RO6864018|Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
236291|NCT02391805|Drug|Tenofovir|Tenofovir will be administered as per local labeling.
236292|NCT02391779|Dietary Supplement|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
236293|NCT02391779|Behavioral|Walking training|30-60 minutes walking training, 5 days/week.
236294|NCT02391779|Behavioral|Flexibility training|5 days/week; e.g. stretching training at home
236295|NCT02391779|Dietary Supplement|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
236296|NCT02391779|Behavioral|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
236297|NCT02391766|Behavioral|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours~topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
236298|NCT02391766|Behavioral|usual care|
236299|NCT02391753|Device|Transperineal 3D Ultrasound|Imaging was performed with women in lithotomy position with empty bladder. The probe was covered with a sterile film and placed on the perineum in the sagittal plane. The field of view angle was set to a maximum of 70° in the sagittal plane and the volume acquisition angle to 85° in the axial plane. Analysis of stored volumes was conducted offline by another experienced investigator blinded to clinical and delivery data.
236300|NCT02391740|Other|Questionnaire|
236301|NCT02391727|Biological|SYN004|subjects who have received effective treatment for their cancers are eligible
236419|NCT02390869|Drug|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
236302|NCT02391714|Procedure|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
236303|NCT02391714|Drug|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
236304|NCT02391714|Drug|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
236305|NCT02391714|Other|Oxygen|100% oxygen via nasal mask.
236306|NCT02391714|Other|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
236307|NCT02391701|Behavioral|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
236308|NCT02391688|Drug|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
236309|NCT02391688|Drug|Bupropion|
236310|NCT02391688|Drug|Fexofenadine|
236311|NCT02391662|Drug|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 & 15 in a 28 days cycle
236312|NCT02391662|Drug|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
236313|NCT02391649|Behavioral|bibliotherapy program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the [psychosocial] effects of the illness; and Module 5:Dealing with [physical and mental health] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
236314|NCT02391649|Behavioral|Psycho-education program|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
236315|NCT02391636|Drug|Carbetocin|at delivery of anterior shoulder
236316|NCT02391636|Drug|Oxytocin|at delivery of anterior shoulder
236317|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
236318|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
236319|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
236320|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
236321|NCT02391610|Other|No intervention|
236322|NCT02391584|Device|XprESS|Balloon dilation of the Eustachian tube
236323|NCT02391584|Other|Control|Continued medical management
236324|NCT02391571|Drug|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
236325|NCT02391571|Drug|Oxycodone|Oxycodone to be taken with stable dose of Methadone
236326|NCT02391571|Drug|Placebo|2 day placebo run in prior to test and active drug phase of study
236327|NCT02391545|Drug|Duvelisib|PI3K Inhibitor
236328|NCT02391545|Drug|Rituximab|monoclonal antibody
236329|NCT02391545|Drug|Obinutuzumab|monoclonal antibody
236330|NCT02391532|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
236331|NCT02391532|Dietary Supplement|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
236332|NCT02391519|Procedure|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
236333|NCT02391506|Device|Cartiva|Cartiva Synthetic Cartilage Implant
236334|NCT02391493|Device|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
236335|NCT02391480|Drug|ABBV-075|ABBV-075 Oral tablets
236336|NCT02391480|Drug|Venetoclax|Venetoclax tablets, film-coated
236337|NCT02391454|Device|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
236338|NCT02391454|Other|Usual care|
236339|NCT02391428|Procedure|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
236340|NCT02391428|Dietary Supplement|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
236341|NCT02391415|Biological|VPM1002|Tuberculosis vaccine
236342|NCT02391415|Biological|BCG|commercially available live vaccine BCG
236343|NCT02391415|Biological|VPM1002(Hyg+)|Tuberculosis vaccine
236414|NCT02390895|Procedure|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
236344|NCT02391402|Behavioral|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
236345|NCT02391402|Behavioral|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
236346|NCT02391389|Procedure|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
236347|NCT02391376|Other|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
236348|NCT02391376|Other|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
236349|NCT02391376|Other|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
236350|NCT02391363|Behavioral|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
236351|NCT02391363|Behavioral|Information and referral|Resource counseling and follow-up for mental health and basic needs
236352|NCT02391350|Behavioral|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
236353|NCT02391350|Procedure|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
236354|NCT02391337|Drug|Bisoprolol|Drug intervention
236355|NCT02391337|Drug|Digoxin|Drug intervention
236356|NCT02391324|Procedure|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
236357|NCT02391324|Procedure|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
236358|NCT02391324|Procedure|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
236359|NCT02391311|Device|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
236360|NCT02391298|Behavioral|Mindfulness Meditation|
236361|NCT02391285|Device|dynamometer (Auckland vaginal elastometer)|"The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.~I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.~II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.~III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings."
236362|NCT02391272|Drug|rhTPO|
236363|NCT02391259|Drug|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
236364|NCT02391259|Drug|Placebo|contains no active drug
236365|NCT02391246|Other|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
236366|NCT02391233|Behavioral|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
236367|NCT02391233|Behavioral|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
236368|NCT02391220|Other|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
236369|NCT02391220|Other|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
236370|NCT02391207|Procedure|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
236371|NCT02391194|Drug|AVB-620|
236415|NCT02390895|Procedure|Postnatal Myelomeningocele Repair Surgery|repair of myleomeningocele after birth
236416|NCT02390882|Drug|Placebo|Placebo
236417|NCT02390882|Drug|HGP0412 capsule|Tamsulon high dose
236372|NCT02391181|Drug|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
236373|NCT02391181|Drug|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
236374|NCT02391155|Procedure|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
236375|NCT02391155|Procedure|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
236376|NCT02391142|Drug|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
236377|NCT02391129|Procedure|Operation for Periprosthetic fractures of the hip with stem loosening|
236378|NCT02391116|Drug|Copanlisib (Aliqopa, BAY80-6946)|Participants assigned to receive copanlisib intravenous (IV) infusion at a dose of 60 mg as single agent on Days 1, 8, and 15 of 28-day treatment cycle. Copanlisib treatment was to be continued until disease progression (PD), unacceptable toxicity, or until another criterion was met for withdrawal from the study treatment
236379|NCT02391103|Device|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
236380|NCT02391103|Device|sham-stimulation|no electricity applied
236381|NCT02391090|Device|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
236382|NCT02391090|Device|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
236383|NCT02391090|Procedure|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
236384|NCT02391090|Other|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
236385|NCT02391090|Procedure|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
236386|NCT02391090|Procedure|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
236387|NCT02391090|Procedure|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
236388|NCT02391077|Other|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
236389|NCT02391077|Other|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
236390|NCT02391077|Other|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
236391|NCT02391064|Behavioral|Cognitive evaluation|"Questionnaires for assessment of confounding factors~Cognitive evaluation~Walking tests and 9 Hole Peg Test"
236392|NCT02391064|Behavioral|Expanded Disability Status Scale (EDSS) score|- EDSS score
236393|NCT02391051|Radiation|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
236394|NCT02391038|Drug|MLN0264|MLN0264 IV.
236395|NCT02391025|Drug|Gallium-68 citrate PET|Injection of Gallium-68 citrate followed by PET imaging
236396|NCT02391025|Procedure|Positron Emission Tomography (PET)|
236397|NCT02391012|Biological|Fecal microbial l transplantation|infusion of preparation of fecal preparation from a healthy donor to a colitis patient
236398|NCT02390999|Procedure|48 hours of therapeutic hypothermia|
236399|NCT02390986|Drug|LON002|Extension study to provide continuing access to LON002 medication.
236400|NCT02390973|Procedure|Sleeve Gastrectomy|
236401|NCT02390973|Procedure|Roux-en-Y Gastric Bypass|
236402|NCT02390973|Procedure|Biliopancreatic Diversion with Duodenal Switch|
236403|NCT02390973|Other|Medical management|
236404|NCT02390960|Drug|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
236405|NCT02390960|Drug|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
236406|NCT02390960|Device|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
236407|NCT02390947|Drug|Famitinib|25 mg p.o. qd
236408|NCT02390947|Drug|Placebo|25 mg p.o. qd
236409|NCT02390934|Radiation|Radium 223|
236410|NCT02390921|Drug|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
236411|NCT02390921|Drug|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
236412|NCT02390908|Behavioral|immediate PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
236413|NCT02390908|Behavioral|wait-list PLUS intervention|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
236418|NCT02390882|Drug|HIP1402 capsule|Tamsulon high dose
236420|NCT02390869|Drug|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
236421|NCT02390856|Device|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
236422|NCT02390856|Device|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
236423|NCT02390843|Drug|Simvastatin|The starting dose of simvastatin will be 140 mg/m^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m^2/dose BID, 225 mg/m^2/dose BID, and 290 mg/m^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
236424|NCT02390843|Drug|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
236425|NCT02390843|Drug|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
236426|NCT02390843|Drug|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm^3
236427|NCT02390830|Other|Falls Prevention|
236428|NCT02390830|Other|Reduction of limitations at body function and activity levels|
236429|NCT02390817|Drug|Sugammadex|Administration of Sugammadex
236430|NCT02390817|Drug|Neostigmine|Administration of Neostigmine
236431|NCT02390804|Device|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
236432|NCT02390804|Device|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
236433|NCT02390791|Other|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
236434|NCT02390791|Other|treatment as usual standard portal|Standard version of myADHDportal.com web software
236435|NCT02390778|Behavioral|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
236436|NCT02390778|Behavioral|leisure activity (film showing)|
236437|NCT02390752|Drug|PLX3397|Take oral drug daily for a 28 day cycle
236438|NCT02390739|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
236439|NCT02390739|Drug|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
236440|NCT02390739|Drug|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
236441|NCT02390739|Biological|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
236442|NCT02390726|Biological|Fecal Microbiota Transplant|
236443|NCT02390726|Biological|Placebo|
236444|NCT02390713|Device|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.~Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
236445|NCT02390700|Biological|Golimumab Intravenous|This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
236446|NCT02390687|Drug|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
236447|NCT02390687|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
236448|NCT02390674|Drug|Ciclosporin|Comparison between ciclosporin and placebo
236449|NCT02390674|Drug|Saline|
236450|NCT02390661|Device|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
236451|NCT02390648|Drug|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
236452|NCT02390648|Drug|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
236453|NCT02390635|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
236454|NCT02390635|Procedure|Diffusion Weighted Imaging|Undergo whole body PET/MRI
236455|NCT02390635|Radiation|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
236456|NCT02390635|Drug|Gadolinium|Given IV
236457|NCT02390635|Procedure|Magnetic Resonance Imaging|Undergo whole body PET/MRI
236458|NCT02390635|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT and whole body PET/MRI
236459|NCT02390635|Procedure|Three-Dimensional Spoiled Gradient MRI|Undergo whole body PET/MRI
236460|NCT02390622|Other|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
236461|NCT02390609|Drug|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
236462|NCT02390609|Drug|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
236463|NCT02390609|Drug|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
236464|NCT02390609|Drug|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
236465|NCT02390609|Drug|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
236466|NCT02390609|Drug|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
236467|NCT02390596|Drug|Anakinra|The dose of Anakinra will be 2mg/kg (patients <10kg and/or <8 months: 4mg/kg). If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra 4mg/kg (patients <10kg and/or <8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients <10kg and/or <8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
236468|NCT02390583|Behavioral|CBT treatment of internet dependence|CBT treatment of internet dependence
236469|NCT02390583|Behavioral|CBT treatment of sleep disorders|CBT treatment of sleep disorders
236470|NCT02390570|Other|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
236471|NCT02390557|Other|Survey|PDQS survey reports only
236472|NCT02390557|Other|YESHealth|Arm 3: YESHealth and PDQS survey reports to providers
236473|NCT02390544|Drug|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
236474|NCT02390531|Drug|Bevacizumab|Varying dosages in 10µl
236475|NCT02390518|Radiation|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.~Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy~Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
236476|NCT02390505|Drug|Vitamin C|
236477|NCT02390505|Drug|Placebo|
236478|NCT02390492|Drug|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous [14C]-ipatasertib on Day 1 of study
236479|NCT02390492|Drug|Period 2 treatment|200-mg/100-mcCi oral [14C]-ipatasertib on Day 15 of study
236480|NCT02390479|Other|non surgical periodontal treatment|"SRP under local anaesthesia, in a total of four clinical visits~Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
236481|NCT02390466|Biological|VAC-3S|Administered via intra-muscular injection in the arm
236482|NCT02390453|Behavioral|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
236483|NCT02390453|Behavioral|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
236484|NCT02390453|Behavioral|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
236485|NCT02390453|Behavioral|Control|Control modules provide social contact for group discussion and instruction in health self-management and successful aging.
236486|NCT02390440|Drug|EXPAREL|
236487|NCT02390427|Drug|Taselisib|
236488|NCT02390427|Drug|Trastuzumab emtansine|
236489|NCT02390427|Drug|Pertuzumab|
236490|NCT02390427|Drug|Trastuzumab|
236491|NCT02390427|Drug|Paclitaxel|
236492|NCT02390401|Device|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
236493|NCT02390401|Device|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
236494|NCT02390388|Procedure|pudendal nerve block|nerve stimulator-guided Pudendal block
236495|NCT02390388|Procedure|caudal block|caudal block
236496|NCT02390375|Drug|DW-0929|5/10mg
236497|NCT02390375|Drug|DW-0929|10/10mg
236498|NCT02390375|Drug|DW-0929|20/10mg
236499|NCT02390375|Drug|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
236500|NCT02390375|Drug|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
236501|NCT02390375|Drug|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
236502|NCT02390362|Drug|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
236503|NCT02390362|Drug|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
236504|NCT02390349|Other|Placebo|
236505|NCT02390349|Dietary Supplement|Curamin|
236506|NCT02390349|Dietary Supplement|CuraMed|
236507|NCT02390336|Other|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
236508|NCT02390336|Other|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
236509|NCT02390323|Procedure|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
236510|NCT02390323|Device|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
236511|NCT02390310|Device|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
236512|NCT02390310|Drug|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
236513|NCT02390310|Drug|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
236514|NCT02390297|Genetic|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
236515|NCT02390284|Drug|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
236516|NCT02390284|Drug|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
236517|NCT02390284|Drug|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
236518|NCT02390284|Drug|Timolol|Lower intraocular pressure by decreasing production of fluid
236519|NCT02390284|Drug|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
236520|NCT02390284|Drug|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
236521|NCT02390284|Drug|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
236522|NCT02390284|Drug|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
236523|NCT02390271|Other|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
236524|NCT02390258|Drug|10mg XEN-D0103|
236525|NCT02390258|Drug|Placebo|
236526|NCT02390258|Drug|30mg XEN-D0103|
236527|NCT02390258|Drug|60mg XEN-D0103|
236528|NCT02390258|Drug|120mg XEN-D0103|
236529|NCT02390258|Drug|200mg XEN-D0103|
236530|NCT02390258|Drug|150mg XEN-D0103|
236531|NCT02390245|Other|Use of patient navigation and social worker|This arm will include phoning patients to schedule appointments; confirming appointments by mailings, emails and/or text messaging; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and scheduling trained medical interpreters.
236532|NCT02390232|Biological|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
236533|NCT02390232|Biological|collection of stools|collection of stools
236534|NCT02390232|Biological|blood sample|collection of blood sample
236535|NCT02390219|Drug|Lumacaftor|
236536|NCT02390219|Drug|Ivacaftor|
236537|NCT02390193|Procedure|Hemodialysis|"Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.~The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.~The patients who required a change in medication for medical reasons were subsequently excluded from the study."
236538|NCT02390180|Other|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
236539|NCT02390167|Device|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
236540|NCT02390154|Drug|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of [14C] roniciclib solution
236541|NCT02390154|Drug|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
236542|NCT02390141|Drug|ZP4207|
236543|NCT02390141|Drug|Placebo|
236544|NCT02390128|Other|observational only|
236545|NCT02390115|Other|Elastic tape application in shoulder|
236546|NCT02390102|Drug|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
236547|NCT02390102|Drug|Placebo|Saline solution 0.9%
236548|NCT02390089|Drug|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
236549|NCT02390089|Other|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
236550|NCT02390089|Radiation|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
236551|NCT02390089|Device|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
236552|NCT02390076|Device|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
236553|NCT02390076|Other|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
236554|NCT02390076|Device|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
236555|NCT02390076|Device|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
236556|NCT02390063|Biological|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
236557|NCT02390063|Biological|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
236558|NCT02390063|Drug|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
236559|NCT02390050|Drug|Bexagliflozin tablets|Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
236560|NCT02390050|Drug|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
236561|NCT02390024|Device|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:~Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
236562|NCT02390011|Procedure|MRI|
236563|NCT02389998|Other|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
236564|NCT02389998|Drug|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
236565|NCT02389985|Drug|CRLX101|
236566|NCT02389985|Drug|Paclitaxel|
236567|NCT02389972|Drug|Dasatinib|
236568|NCT02389959|Drug|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
236569|NCT02389959|Drug|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
236570|NCT02389946|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
236571|NCT02389946|Device|Xience DES|
236572|NCT02389933|Drug|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
236573|NCT02389920|Drug|Nilotinib|
236574|NCT02389894|Device|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
236575|NCT02389894|Device|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
236576|NCT02389881|Drug|TAK-058|TAK-058 Solution
236577|NCT02389881|Drug|TAK-058 Placebo|TAK-058 placebo-matching solution
236578|NCT02389868|Drug|Lovastatin|
236579|NCT02389855|Procedure|NeuroBlate® System Therapy|
236580|NCT02389842|Drug|Palbociclib + Taselisib / Pictilisib|
236581|NCT02389829|Drug|Hydromorphone|
236582|NCT02389829|Drug|Prochlorperazine|
236583|NCT02389829|Drug|Diphenhydramine|
236584|NCT02389816|Drug|Placebo|Placebo tablets
236585|NCT02389816|Drug|Vortioxetine|Vortioxetine tablets
236586|NCT02389803|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
236587|NCT02389803|Dietary Supplement|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
236588|NCT02389790|Drug|MT-1303|
236589|NCT02389777|Biological|ST266 immediate|ST266 will be applied immediately to the UV light burn wound topically by spray twice per day
236590|NCT02389777|Biological|ST266 delayed|ST266 will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
236591|NCT02389764|Drug|BIBF 1120|Initial dose is 200 mg twice daily orally for a 28 day cycle.
236592|NCT02389764|Behavioral|Phone Call|Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
236593|NCT02389751|Drug|Carboplatin|Given IV
236594|NCT02389751|Drug|Ganetespib|Given IV
236595|NCT02389751|Drug|Paclitaxel|Given IV
236596|NCT02389751|Radiation|Radiation Therapy|Undergo radiation therapy
236597|NCT02389738|Drug|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
236598|NCT02389738|Drug|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
236599|NCT02389738|Device|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
236600|NCT02389725|Device|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
236601|NCT02389725|Device|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
236602|NCT02389712|Drug|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
236603|NCT02389712|Drug|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed > 40mg.
236604|NCT02389699|Radiation|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
236605|NCT02389699|Radiation|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
236606|NCT02389686|Device|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
236607|NCT02389673|Device|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
236608|NCT02389660|Behavioral|Blended Cognitive Behavioural Therapy (CBT)|
236609|NCT02389660|Behavioral|Treatment as usual|
236610|NCT02389621|Drug|Lusutrombopag|Tablets for oral administration
236611|NCT02389621|Drug|Placebo|Tablets for oral administration
236612|NCT02389608|Device|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
236613|NCT02389608|Device|Functional electrical stimulation (FES)|
236614|NCT02389608|Device|Sham stimulation|
236615|NCT02389595|Other|HIV positive subjects|This group will provide a blood sample.
236616|NCT02389595|Other|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
236617|NCT02389582|Drug|Dabigatran|Use for 5 days
236618|NCT02389582|Drug|Enoxaparin|Use for 5 days
236619|NCT02389569|Procedure|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
236620|NCT02389569|Procedure|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
236621|NCT02389543|Drug|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
236622|NCT02389543|Drug|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
236623|NCT02389543|Drug|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.~For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
236624|NCT02389530|Drug|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
236625|NCT02389517|Drug|Ixazomib Citrate|Given PO
236626|NCT02389517|Drug|Lenalidomide|Given PO
236627|NCT02389517|Drug|Dexamethasone|Given PO
236628|NCT02389504|Other|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
236629|NCT02389504|Other|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
236630|NCT02389491|Dietary Supplement|normal density formula (Necocate)|In control group,there are 32 infants
236631|NCT02389491|Dietary Supplement|high density formula(Infatrini)|In intervention group,there are 32 infants
236632|NCT02389478|Procedure|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
236633|NCT02389478|Procedure|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
236634|NCT02389465|Drug|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
236635|NCT02389465|Drug|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
236636|NCT02389452|Drug|Synvisc-One|intraarticular injection
236637|NCT02389439|Drug|Pyronaridine-artesunate|
236638|NCT02389426|Device|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
236639|NCT02389426|Device|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
236640|NCT02389426|Device|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls."
236641|NCT02389426|Device|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis."
236642|NCT02389413|Drug|PQ912 oral|
236643|NCT02389413|Other|Placebo|
236644|NCT02389400|Drug|methotrexate|Single Group Assignment
236645|NCT02389387|Other|Intensive Intervention|I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
236646|NCT02389374|Drug|chloroquine|standard dose
236647|NCT02389374|Drug|Artemether-lumefantrine combination|standard dose
236648|NCT02389374|Drug|Primaquine|single dose
236649|NCT02389374|Drug|Primaquine|14 days
236650|NCT02389361|Drug|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
236651|NCT02389361|Drug|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
236652|NCT02389348|Drug|DSM265|Single oral doses of DSM265
236653|NCT02389348|Drug|OZ439|Single oral doses of OZ439
236654|NCT02389322|Biological|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
236655|NCT02389322|Biological|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
236656|NCT02389322|Biological|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
236657|NCT02389322|Biological|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
236658|NCT02389309|Drug|Cyclophosphamide|Given PO
236659|NCT02389309|Drug|Dasatinib|Given PO
236660|NCT02389309|Other|Laboratory Biomarker Analysis|Correlative studies
236661|NCT02389309|Drug|Temsirolimus|Given IV
236662|NCT02389296|Other|Questionnaire|Questionnaires will be distributed to nursing staff
236663|NCT02389257|Device|MINIMAG / MEG|
236664|NCT02389257|Device|MINIMAG / ECG|
236665|NCT02389244|Drug|Regorafenib|For adults patients and children with BSA ≥ 1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥ 1.30 and ≤ 1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
236666|NCT02389244|Drug|Placebo|For adults patients and children with BSA ≥ 1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥ 1.30 and ≤ 1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
236667|NCT02389231|Drug|Interleukine-2|"Four courses of IL2 ( [Proleukin, Novartis]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
236668|NCT02389218|Device|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
236669|NCT02389218|Drug|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
236670|NCT02389205|Other|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
236671|NCT02389192|Drug|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
236672|NCT02389179|Drug|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
236673|NCT02389166|Device|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
236827|NCT02388126|Device|Transrectal ultrasound|Bk Medical Pro Focus Ultraview 2202 system
236674|NCT02389166|Device|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
236675|NCT02389153|Behavioral|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
236676|NCT02389140|Other|Trigger point release|Trigger point therapy
236677|NCT02389140|Other|Ultrasound|sham ultrasound
236678|NCT02389127|Device|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
236679|NCT02389114|Other|Soy Protein|Soy protein is commonly consumed in Asian diet.
236680|NCT02389114|Other|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
236681|NCT02389101|Other|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
236682|NCT02389088|Drug|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
236683|NCT02389075|Procedure|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
236684|NCT02389075|Procedure|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
236685|NCT02389062|Other|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
236686|NCT02389036|Drug|SDD Oral Paste|A six-hourly topical application of 0.5g paste, containing colistin 10mg, tobramycin 10mg and nystatin 125,000 IU, to the buccal mucosa and oropharynx
236687|NCT02389036|Drug|SDD Gastric Suspension|2. A six-hourly administration of 10 mL of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 10 ^6 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
236688|NCT02389036|Drug|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
236689|NCT02389023|Other|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
236690|NCT02389023|Other|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
236691|NCT02389010|Biological|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
236692|NCT02389010|Other|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
236693|NCT02388997|Drug|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
236694|NCT02388997|Biological|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
236695|NCT02388984|Drug|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
236696|NCT02388984|Drug|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
236697|NCT02388971|Drug|MLN1202|MLN1202 solution
236698|NCT02388971|Drug|Placebo|MLN1202 placebo-matching solution
236699|NCT02388945|Other|APD|PDGO APD machines used in the PD patients for 8 weeks
236700|NCT02388945|Other|CAPD|CAPD used in the PD Patients for 8 weeks
236701|NCT02388932|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
236702|NCT02388932|Device|Positron Emission Tomography|Undergo PET/CT
236703|NCT02388932|Device|Computed Tomography|Undergo PET/CT
236704|NCT02388932|Other|Quality-of-Life Assessment|Ancillary studies
236705|NCT02388919|Drug|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
236706|NCT02388919|Drug|Placebo|Basic dosage, take once when limosis in the morning.
236707|NCT02388906|Drug|Ipilimumab|
236708|NCT02388906|Drug|Nivolumab|
236709|NCT02388906|Other|Placebo matching Ipilimumab|
236710|NCT02388906|Other|Placebo matching Nivolumab|
236711|NCT02388880|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
236828|NCT02388113|Behavioral|accumulated exercise|
236829|NCT02388113|Behavioral|traditional exercise|
236712|NCT02388867|Procedure|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
236713|NCT02388867|Procedure|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
236714|NCT02388854|Genetic|SNPs analysis with Sanger sequencing|Research of frequency of SNPs (WNT4, VEZT, FSHB and SIRT1 genes) in Sardinian women affected by endometriosis and controls
236715|NCT02388841|Radiation|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
236716|NCT02388828|Biological|lentiviral-based CART meso therapy|
236717|NCT02388815|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.~During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
236718|NCT02388802|Procedure|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
236719|NCT02388802|Procedure|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
236720|NCT02388802|Procedure|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
236721|NCT02388802|Drug|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
236722|NCT02388802|Procedure|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
236723|NCT02388802|Procedure|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
236724|NCT02388789|Other|active movement|same as arm description
236725|NCT02388776|Device|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
236726|NCT02388763|Device|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
236727|NCT02388763|Device|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
236728|NCT02388750|Drug|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
236729|NCT02388750|Radiation|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
236730|NCT02388737|Drug|Vonoprazan|Vonoprazan tablets
236731|NCT02388737|Drug|Lansoprazole|Lansoprazole capsules or tablets
236732|NCT02388737|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
236733|NCT02388737|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
236734|NCT02388724|Drug|Vonoprazan|Vonoprazan tablets
236735|NCT02388724|Drug|Lansoprazole|Lansoprazole capsules
236736|NCT02388724|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
236737|NCT02388724|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
236738|NCT02388711|Other|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
236739|NCT02388698|Procedure|Cervical swab|"Cervical Swab at baseline.~HPV testing at recurrence, if applicable."
236740|NCT02388698|Radiation|PET-CT|PET-CT will be completed 3 month post chemoradiation.
236741|NCT02388698|Biological|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
236742|NCT02388685|Other|Exercise|Home exercise therapy
236743|NCT02388672|Dietary Supplement|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
236744|NCT02388672|Dietary Supplement|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
236745|NCT02388672|Dietary Supplement|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
236746|NCT02388672|Dietary Supplement|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
236747|NCT02388659|Device|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
236748|NCT02388646|Other|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
236749|NCT02388646|Device|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
236750|NCT02388646|Other|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
236751|NCT02388633|Procedure|Plasmapharesis|Clinically-indicated LDL apheresis
236752|NCT02388620|Drug|LEE011|400 mg
236753|NCT02388607|Other|measurements|performance measurements
236754|NCT02388594|Drug|ZFN Modified CD4+ T Cells|
236755|NCT02388594|Drug|Cyclophosphamide|
236756|NCT02388581|Drug|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
236757|NCT02388568|Drug|Lorcaserin|Lorcaserin plus Lifestyle Modification
236758|NCT02388568|Drug|Placebo|Placebo plus Lifestyle Modification
236759|NCT02388555|Procedure|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
236760|NCT02388542|Behavioral|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
236761|NCT02388529|Drug|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
236762|NCT02388529|Drug|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
236763|NCT02388529|Drug|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
236764|NCT02388529|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
236765|NCT02388516|Dietary Supplement|Vitamin D3|
236766|NCT02388516|Dietary Supplement|Placebo|
236767|NCT02388503|Dietary Supplement|no added fruit extract|
236768|NCT02388503|Dietary Supplement|fruit extract|
236769|NCT02388503|Dietary Supplement|fruit extract|
236770|NCT02388503|Dietary Supplement|fruit extract|
236771|NCT02388503|Dietary Supplement|fruit extract|
236772|NCT02388490|Drug|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
236773|NCT02388477|Drug|Doxycycline|antibiotic used to treat infection
236774|NCT02388477|Drug|sugar pill|placebo with no pharmacologic effect
236775|NCT02388464|Drug|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
236776|NCT02388464|Drug|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
236777|NCT02388464|Drug|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
236778|NCT02388464|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
236779|NCT02388451|Device|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
236780|NCT02388438|Device|Bongener|
236781|NCT02388399|Procedure|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex> cap thickness, spotty calcification)
236782|NCT02388399|Procedure|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
236783|NCT02388386|Device|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
236784|NCT02388373|Drug|Fluticasone 250/formoterol 10|
236785|NCT02388373|Drug|Fluticasone 250/salmeterol 25|
236786|NCT02388373|Drug|Fluticasone 125/formoterol 5|
236787|NCT02388360|Drug|topical prostaglandin analogs|
236788|NCT02388347|Drug|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
236789|NCT02388347|Biological|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
236790|NCT02388347|Biological|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
236791|NCT02388347|Biological|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
236792|NCT02388347|Biological|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
236793|NCT02388334|Other|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).~The development of this standardized tool will also :~identify the specific support needs of the caregivers~study the links between the quality of care as perceived by the professionals, patients and caregivers~identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
236794|NCT02388321|Drug|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
236795|NCT02388321|Drug|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
236796|NCT02388308|Device|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
236797|NCT02388295|Drug|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
236798|NCT02388295|Drug|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
236799|NCT02388282|Device|diaphragm ecography|recording of diaphragm ecography
236800|NCT02388269|Device|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
236830|NCT02388100|Procedure|Capillary HbA1c collection|
236831|NCT02388087|Device|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
236957|NCT02387112|Device|Early VAD implantation|Implantation of a left ventricular assist device
236801|NCT02388256|Device|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
236802|NCT02388256|Other|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
236803|NCT02388243|Behavioral|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
236804|NCT02388243|Behavioral|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
236805|NCT02388243|Behavioral|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
236806|NCT02388243|Behavioral|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
236807|NCT02388230|Device|Ultrasound imaging|
236808|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
236809|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
236810|NCT02388191|Drug|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
236811|NCT02388191|Other|Placebo tablet|
236812|NCT02388178|Drug|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
236813|NCT02388178|Drug|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
236814|NCT02388178|Drug|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
236815|NCT02388165|Biological|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
236816|NCT02388165|Other|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
236817|NCT02388152|Drug|Lu AF20513, low dose|
236818|NCT02388152|Drug|Lu AF20513, medium dose|
236819|NCT02388152|Drug|Lu AF20513, high dose|
236820|NCT02388152|Drug|Lu AF20513, double high dose|
236821|NCT02388139|Procedure|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
236822|NCT02388139|Procedure|coronarography|
236823|NCT02388139|Procedure|coronary angioplasty|
236824|NCT02388139|Procedure|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
236825|NCT02388139|Procedure|body composition monitoring|using Fresenius device
236826|NCT02388126|Device|3T multiparametric MRI|Magnetom Verio 3T, Erlangen, Germany
236832|NCT02388087|Procedure|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
236833|NCT02388074|Device|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
236834|NCT02388061|Drug|Tenecteplase|
236835|NCT02388061|Drug|Tissue Plasminogen Activator|
236836|NCT02388048|Drug|Ibrutinib + ofatumumab|
236837|NCT02388035|Drug|Cefotaxime|
236838|NCT02388022|Device|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
236839|NCT02388009|Biological|Flexyn2a|Intramuscular doses of 0.5 mL
236840|NCT02388009|Biological|Placebo|Intramuscular doses of 0.5 mL
236841|NCT02388009|Biological|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
236842|NCT02387996|Drug|Nivolumab|
236843|NCT02387983|Drug|Posaconazole|Posaconazole 300 mg solid oral tablet
236844|NCT02387970|Procedure|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
236845|NCT02387970|Procedure|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
236846|NCT02387970|Device|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
236847|NCT02387970|Device|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
236848|NCT02387957|Drug|Fovista®|
236849|NCT02387957|Drug|bevacizumab|
236850|NCT02387957|Drug|ranibizumab|
236851|NCT02387957|Drug|aflibercept|
236852|NCT02387931|Dietary Supplement|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
236853|NCT02387931|Dietary Supplement|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
236854|NCT02387931|Other|Placebo|Placebo capsule, 2 taken daily
236855|NCT02387918|Drug|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
236856|NCT02387918|Device|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
236857|NCT02387905|Procedure|Management of Therapy Complications|Undergo vertebral body cement augmentation
236858|NCT02387905|Other|Quality-of-Life Assessment|Ancillary studies
236859|NCT02387905|Other|Questionnaire Administration|Ancillary studies
236860|NCT02387905|Radiation|Stereotactic Radiosurgery|Undergo standard stereotactic spinal radiosurgery
236861|NCT02387892|Dietary Supplement|Cheese & yogurt + Vitamin D|cheese & yogurt with added 420 IU cholecalciferol
236862|NCT02387892|Dietary Supplement|Cheese & yogurt|Cheese & yogurt without added vitamin D
236863|NCT02387866|Drug|AG-221|
236864|NCT02387853|Drug|LEO 90100|
236865|NCT02387840|Device|Magnetic Resonance Imaging|Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
236866|NCT02387840|Device|Magnetic Resonance Fingerprinting|Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
236867|NCT02387827|Behavioral|Diet+ short term versus long -term physical activity|
236868|NCT02387814|Drug|Abemaciclib|Administered Orally
236869|NCT02387801|Drug|Ixekizumab|Administered SC
236870|NCT02387788|Drug|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
236871|NCT02387775|Device|Esophageal temperature control|"Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit."
236872|NCT02387762|Drug|acalabrutinib|
236873|NCT02387762|Drug|Placebo|
236874|NCT02387749|Genetic|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
236875|NCT02387736|Behavioral|Dialectical Behaviour Therapy-6 months|Modification of behaviours achieved with reframing thoughts and impulses
236876|NCT02387736|Behavioral|Dialectical Behaviour Therapy-12 months|Modification of behaviours achieved with reframing thoughts and impulses
236877|NCT02387723|Biological|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
236878|NCT02387710|Drug|Tiagabine|GABA reuptake inhibitor
236879|NCT02387710|Drug|Placebo|Placebo comparator
236880|NCT02387697|Device|Edwards Sapien XT Valve|The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
236881|NCT02387671|Behavioral|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
236882|NCT02387671|Behavioral|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
236883|NCT02387671|Behavioral|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
236884|NCT02387671|Behavioral|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue & dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
236885|NCT02387658|Procedure|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
236886|NCT02387645|Procedure|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
236887|NCT02387619|Drug|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
236888|NCT02387619|Drug|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
236889|NCT02387619|Drug|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
236890|NCT02387606|Drug|Placebo|Participants will receive placebo once daily.
236891|NCT02387606|Drug|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
236892|NCT02387593|Device|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
236893|NCT02387580|Drug|OZ439 + TPGS|
236894|NCT02387580|Drug|OZ439 Prototype 1|
236895|NCT02387580|Drug|OZ439 Prototype 3|
236896|NCT02387580|Drug|PQP|
236897|NCT02387567|Drug|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
236898|NCT02387567|Drug|Sham Lidocaine|Sham injection, without lidocaine.
236899|NCT02387567|Other|Standard treatment|Standard treatment only, without lidocaine or sham injection.
236900|NCT02387554|Drug|HGP0904|
236901|NCT02387554|Drug|HGP0608|
236902|NCT02387554|Drug|HGP1405|
236903|NCT02387528|Behavioral|1- Mindfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and illness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
236904|NCT02387528|Behavioral|2- Relaxation Intervention|Eight meetings where the participants will practice relaxation techniques.
236905|NCT02387528|Other|3- Wait List Control Group|No intervention
236906|NCT02387515|Other|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
236907|NCT02387502|Device|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
236908|NCT02387502|Device|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
236909|NCT02387502|Device|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
236910|NCT02387489|Behavioral|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
236911|NCT02387489|Behavioral|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
236912|NCT02387476|Device|FRESCA mask first night|FRESCA nasal mask first night
236913|NCT02387476|Device|CPAP Mask first night|CPAP Nasal Mask first night
236914|NCT02387450|Drug|Sildenafil|100 mg per day
236915|NCT02387450|Drug|Placebo|Placebo with same presentation as the active drug
236916|NCT02387437|Behavioral|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
236917|NCT02387437|Behavioral|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
236918|NCT02387437|Behavioral|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
236954|NCT02387125|Biological|CMB305|
236955|NCT02387125|Biological|G100|
236919|NCT02387424|Behavioral|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
236920|NCT02387424|Behavioral|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
236921|NCT02387411|Other|High-intensity interval exercise training|High-intensity interval exercise training [4 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)]
236922|NCT02387411|Other|Combined exercise training|High intensity [2 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
236923|NCT02387398|Procedure|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
236924|NCT02387385|Device|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
236925|NCT02387372|Drug|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:~Participants with CLCR > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours~Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours~Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
236926|NCT02387372|Drug|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
236927|NCT02387359|Drug|Plecanatide|
236928|NCT02387359|Drug|Placebo|
236929|NCT02387346|Device|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
236930|NCT02387346|Device|Magstim Rapid 2 Sham Stimulation|
236931|NCT02387333|Procedure|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin."
236932|NCT02387333|Procedure|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
236933|NCT02387320|Other|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
236934|NCT02387307|Drug|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
236935|NCT02387294|Biological|ntervention: Vaccination with Fluval AB Novo.|vaccination
236936|NCT02387268|Device|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
236937|NCT02387255|Device|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
236938|NCT02387242|Drug|Rifampicin|Single oral dose of rifampicin
236939|NCT02387229|Drug|Rivaroxaban|15 mg
236940|NCT02387229|Other|standard of care|
236941|NCT02387216|Drug|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
236942|NCT02387216|Drug|Docetaxel|approved chemotherapy treatment for NSCLC
236943|NCT02387203|Drug|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
236944|NCT02387190|Other|Telenursing monitoring|"The telenursing program protocol is based on:~Contact the patient by telephone, weekly;~Distribution and explanation of the educational booklet;~Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support."
236945|NCT02387177|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
236946|NCT02387177|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
236947|NCT02387164|Drug|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
236948|NCT02387164|Drug|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
236949|NCT02387151|Drug|mesenchymal stromal cells|2 doses of 1-2x10^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
236950|NCT02387138|Drug|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.~The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
236951|NCT02387138|Drug|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
236952|NCT02387138|Drug|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
236953|NCT02387138|Other|G-csf|G-csf : d8 to d13 systematically
236958|NCT02387099|Drug|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
236959|NCT02387099|Drug|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.~All patients will be treated within the approved indication of everolimus in combination with exemestane.~Patients will be randomized in a 1:1 ratio"
236960|NCT02387099|Drug|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
236961|NCT02387099|Drug|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
236962|NCT02387086|Drug|Thalidomide|
236963|NCT02387086|Drug|placebo|
236964|NCT02387086|Drug|Gefitinib|
236965|NCT02387086|Drug|Aspirin|
236966|NCT02387073|Other|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
236967|NCT02387060|Drug|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
236968|NCT02387060|Drug|Fentanyl|Intrathecal administration of fentanyl 25 mcg
236969|NCT02387034|Behavioral|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
236970|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
236971|NCT02387021|Procedure|Continuous femoral nerve block|
236972|NCT02387021|Procedure|Continuous adductor canal block|
236973|NCT02387021|Procedure|infragluteal Sciatic nerve block|
236974|NCT02387021|Drug|Ropivacaine 0.2%|
236975|NCT02387021|Drug|Saline|
236976|NCT02387008|Device|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
236977|NCT02387008|Device|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
236978|NCT02387008|Device|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
236979|NCT02386995|Device|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
236980|NCT02386995|Device|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
236981|NCT02386982|Drug|HMS5552|
236982|NCT02386969|Device|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
236983|NCT02386969|Device|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
236984|NCT02386956|Other|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
236985|NCT02386956|Other|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
236986|NCT02386956|Other|Control|10 minutes with the patient lying on a machine off of magnetotherapy
236987|NCT02386943|Drug|Sitagliptin|100mg po once.
236988|NCT02386943|Drug|Saxagliptin|5mg po once.
236989|NCT02386943|Drug|Blank control|No medication is taken.
236990|NCT02386930|Behavioral|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
236991|NCT02386917|Procedure|Gastric bypass|Weight loss surgery
236992|NCT02386917|Behavioral|Very low calorie diet|Non-surgical weight loss procedure
236993|NCT02386904|Drug|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
236994|NCT02386891|Other|Thermal Environment|
236995|NCT02386878|Behavioral|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
237028|NCT02386644|Other|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
237029|NCT02386631|Device|Custom Made Orthotic|Provides longitudinal arch support
237070|NCT02386293|Drug|Irbesartan|Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
237071|NCT02386293|Other|Placebo|Sugar pill made to look identical to irbesartan intervention.
236996|NCT02386878|Behavioral|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
236997|NCT02386852|Drug|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
236998|NCT02386852|Drug|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
236999|NCT02386852|Drug|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
237000|NCT02386826|Drug|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:~Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)~Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
237001|NCT02386826|Biological|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
237002|NCT02386800|Drug|Ruxolitinib|tablets
237003|NCT02386800|Drug|Panobinostat|capsules
237004|NCT02386787|Device|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
237005|NCT02386774|Device|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
237006|NCT02386774|Device|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM~anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)~Fluorescein 0,5%, Rose Bengal , Infracyanine"
237007|NCT02386774|Procedure|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
237008|NCT02386761|Drug|Single Ascending Dose (SAD)|
237009|NCT02386761|Drug|Multiple Ascending Dose (MAD)|
237010|NCT02386748|Dietary Supplement|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
237011|NCT02386748|Dietary Supplement|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
237012|NCT02386748|Other|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
237013|NCT02386735|Drug|Placebo|Three days prednisone 40mg, two days placebo
237014|NCT02386735|Drug|Prednisone|Five days prednisone 40mg.
237015|NCT02386722|Device|Smartinhaler/POEMS with audio reminders and additional support calls|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
237016|NCT02386709|Device|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
237017|NCT02386696|Other|Ultrasound|Lung ultrasound examination on healthy volunteers
237018|NCT02386683|Other|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
237019|NCT02386670|Other|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. per session.~CR sessions will follow the tDCS session and last 2 hours in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks."
237020|NCT02386670|Other|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).~tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes.~CR sessions will follow the tDCS session and last 2 hours in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels."
237021|NCT02386657|Other|Satisfaction|Satisfaction questionnaire to be filled in
237022|NCT02386657|Other|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
237023|NCT02386657|Other|Pain management|Validated pain scale questionnaire to be filled in
237024|NCT02386644|Other|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
237025|NCT02386644|Device|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
237026|NCT02386644|Device|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
237027|NCT02386644|Other|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
237030|NCT02386618|Procedure|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN < 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN > 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN > 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
237031|NCT02386605|Behavioral|Motivational Interviewing and Cognitive Behavioral Therapy|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
237032|NCT02386605|Behavioral|Relaxation Skills|Relaxation and mindfulness skills training group for comparison condition for negative symptoms of schizophrenia
237033|NCT02386592|Drug|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
237034|NCT02386592|Behavioral|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
237035|NCT02386592|Behavioral|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
237036|NCT02386592|Other|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
237037|NCT02386579|Procedure|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
237038|NCT02386566|Drug|natalizumab|As described in the treatment arm
237039|NCT02386553|Drug|Nusinersen|Solution for intrathecal injection
237040|NCT02386540|Behavioral|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
237041|NCT02386501|Drug|ADXS31-164|
237042|NCT02386488|Drug|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
237043|NCT02386488|Drug|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
237044|NCT02386488|Drug|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
237045|NCT02386488|Drug|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
237046|NCT02386475|Other|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
237047|NCT02386475|Drug|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
237048|NCT02386475|Drug|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
237049|NCT02386462|Drug|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
237050|NCT02386462|Drug|Propofol|
237051|NCT02386449|Drug|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
237052|NCT02386449|Drug|mannitol|
237053|NCT02386449|Drug|Bisacodyl|
237054|NCT02386436|Drug|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
237055|NCT02386436|Drug|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume [w/v] Sodium Chloride) administered as single dose s.c.
237056|NCT02386423|Device|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
237057|NCT02386410|Behavioral|Group parent training for anxious parents|
237058|NCT02386410|Behavioral|Internet delivered parent training for anxious parents|
237059|NCT02386397|Drug|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
237060|NCT02386397|Drug|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
237061|NCT02386371|Procedure|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
237062|NCT02386371|Radiation|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
237063|NCT02386358|Drug|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
237064|NCT02386358|Drug|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
237065|NCT02386332|Procedure|transplantation|
237066|NCT02386319|Drug|Melatonin|Gelatin capsules
237067|NCT02386319|Drug|Placebo|Placebo capsules
237072|NCT02386280|Behavioral|Motivational Interviewing for Change of Parenting Styles|
237073|NCT02386280|Behavioral|Psicoeducation|
237074|NCT02386267|Drug|L-leucine|L-leucine pills per os for 6 months
237075|NCT02386241|Other|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
237076|NCT02386228|Genetic|collection of CSF and blood|collection of CSF and blood
237077|NCT02386215|Behavioral|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:~One standard OraQuick ADVANCE I/II test kit~Written pre-test information including test instructions in written and pictorial form~A phone number that participants can call to obtain additional information~Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
237078|NCT02386202|Other|No intervention|No interventions
237079|NCT02386189|Behavioral|Patient Care Coordination Training|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
237080|NCT02386163|Biological|MSC from synovial membrane and infrapatellar Fat Pad|
237081|NCT02386150|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
237082|NCT02386137|Device|Contrast-enhancement ultrasound with Sonovue|
237083|NCT02386124|Other|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
237084|NCT02386111|Drug|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.~Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.~The Study was terminated prior to initiation of Phase II.~All patients will receive sunitinib at a dose of 50 mg."
237085|NCT02386098|Drug|BMS-955176|HIV Maturation Inhibitor
237086|NCT02386098|Drug|Atazanavir (ATV)|Atazanavir
237087|NCT02386098|Drug|Ritonavir (RTV)|Ritonavir
237088|NCT02386098|Drug|Dolutegravir (DTG)|Dolutegravir
237089|NCT02386098|Drug|Tenofovir (TDF)|Tenofovir
237090|NCT02386085|Procedure|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study. All participants would have received the same intervention (OMT) if they had not enrolled in the study.
237091|NCT02386072|Drug|mirabegron|oral
237092|NCT02386072|Drug|antimuscarinic medication|oral
237093|NCT02386059|Drug|PLACEBO|received normal saline, intravenously
237094|NCT02386059|Drug|Dexamethasone|4 mg, intravenously, at the start of surgery
237095|NCT02386059|Drug|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
237096|NCT02386059|Drug|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
237097|NCT02386046|Other|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
237098|NCT02386033|Drug|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
237099|NCT02386033|Drug|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
237100|NCT02386020|Drug|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
237101|NCT02386020|Drug|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
237102|NCT02386007|Drug|DW-3101_150mg|
237103|NCT02386007|Drug|DW-3101_300mg|
237104|NCT02386007|Drug|DW-3101_600mg|
237105|NCT02386007|Drug|Placebo|
237106|NCT02385994|Device|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
237107|NCT02385981|Device|Stivax|
237108|NCT02385955|Procedure|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
237109|NCT02385942|Device|Smart phone|"measure the Live assessed wound size and the transmitted Smart phone-based wound size~determine dressing materials using Smart phone-based tele-consultation"
237110|NCT02385929|Behavioral|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.~iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
237111|NCT02385916|Other|EstroSense®/MD|A natural product already approved by Health Canada
237112|NCT02385916|Other|Placebo|Placebo
237113|NCT02385903|Other|Flammacerium|
237114|NCT02385903|Other|Standard dressing procedure|
237115|NCT02385890|Other|Control|Non pulse ingredient bagel
237116|NCT02385890|Other|Pea flour|Pulse ingredient bagel
237117|NCT02385890|Other|Pea fibre|Pulse ingredient bagel
237118|NCT02385890|Other|Pea protein|Pulse ingredient bagel
237119|NCT02385890|Other|Pea flour + pea protein|Pulse ingredient bagel
237120|NCT02385890|Other|Pea fibre + pea protein|Pulse ingredient bagel
237121|NCT02385877|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
237122|NCT02385877|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
237123|NCT02385851|Drug|CHS-1701|
237125|NCT02385838|Behavioral|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
237126|NCT02385838|Behavioral|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
237127|NCT02385838|Behavioral|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
237128|NCT02385838|Behavioral|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
237129|NCT02385825|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
237130|NCT02385812|Procedure|Low-dose computed tomography Annual scan x3|Annual scan x3
237131|NCT02385812|Procedure|Low-dose computed tomography Baseline scan only|Baseline scan only
237132|NCT02385799|Drug|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
237133|NCT02385799|Drug|Sertraline|Active medication
237134|NCT02385786|Behavioral|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
237135|NCT02385773|Dietary Supplement|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
237136|NCT02385773|Dietary Supplement|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
237137|NCT02385760|Drug|CTX-4430|
237138|NCT02385760|Drug|Placebo|
237139|NCT02385747|Procedure|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
237140|NCT02385734|Other|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
237141|NCT02385734|Procedure|Coronally Advanced Flap|Periodontal plastic surgery technique
237142|NCT02385708|Drug|2% Chlorohexidine Gluconate Standard of Care|Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.
237143|NCT02385708|Drug|2% Chlorohexidine Gluconate Chin to Toe|Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
237144|NCT02385695|Procedure|Posterior Dynamic Stabilization|
237145|NCT02385695|Procedure|Internal Fixation and Fusion|
237146|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
237147|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
237148|NCT02385669|Drug|Ipilimumab|Checkpoint blockade inhibitor
237149|NCT02385669|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
237150|NCT02385656|Drug|Modafinil|200mg of modafinil daily for 4 weeks
237151|NCT02385643|Behavioral|SmartPhone Support System|
237152|NCT02385630|Other|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
237153|NCT02385617|Drug|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
237154|NCT02385617|Drug|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
237155|NCT02385591|Behavioral|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
237156|NCT02385591|Behavioral|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
237157|NCT02385578|Other|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
237158|NCT02385565|Other|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
237159|NCT02385565|Other|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
237160|NCT02385552|Behavioral|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
237161|NCT02385539|Drug|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
237162|NCT02385526|Device|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
237163|NCT02385513|Biological|10-valent pneumococcal conjugate vaccine|
237164|NCT02385500|Drug|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
237165|NCT02385500|Drug|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.~For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.~The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
237166|NCT02385474|Drug|12% SDF|12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
237167|NCT02385474|Drug|38% SDF|38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
237168|NCT02385461|Drug|Low Molecular Weight Heparins (LMWHs)|
237169|NCT02385448|Drug|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
237170|NCT02385448|Drug|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
237171|NCT02385435|Drug|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
237172|NCT02385435|Drug|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
237173|NCT02385435|Drug|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
237174|NCT02385422|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
237175|NCT02385422|Drug|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
237176|NCT02385396|Dietary Supplement|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
237177|NCT02385383|Drug|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
237178|NCT02385383|Other|Standard Care|Standard Care in a historical control cohort
237179|NCT02385370|Drug|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
237180|NCT02385370|Drug|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
237181|NCT02385357|Dietary Supplement|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
237182|NCT02385344|Device|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
237183|NCT02385318|Drug|Ingenol Mebutate (Perrigo)|
237184|NCT02385318|Drug|Ingenol Mebutate (Reference)|
237185|NCT02385318|Drug|Placebo gel|
237186|NCT02385305|Device|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
237187|NCT02385292|Device|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
237188|NCT02385279|Device|MiStent|Percutaneous Coronary Intervention
237189|NCT02385279|Device|XIENCE EES|Percutaneous Coronary Intervention
237190|NCT02385266|Drug|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
237191|NCT02385266|Drug|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
237192|NCT02385253|Behavioral|Educational training program|"The educational training program (intervention) consists of four sequential phases:~Knowledge Acquisition~Skills Assessment~Deliberate Practice~Clinical Proficiency"
237193|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
237194|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Reference)|
237195|NCT02385240|Drug|Placebo gel|
237196|NCT02385227|Other|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
237197|NCT02385227|Other|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
237198|NCT02385227|Other|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
237199|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
237200|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
237201|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
237202|NCT02385227|Other|Nicotine product cessation C|Nicotine cessation
237203|NCT02385214|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
237204|NCT02385214|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
237205|NCT02385201|Device|Senza|Spinal Cord Stimulation
237206|NCT02385188|Drug|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
237207|NCT02385188|Drug|paracetamol|
237208|NCT02385188|Drug|lidocaine in Vaseline ointment|
237209|NCT02385175|Other|Different objective clinical tests of Eustachian tube function|
237210|NCT02385175|Other|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
237211|NCT02385149|Other|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
237212|NCT02385149|Other|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
237213|NCT02385136|Drug|Temozolomide|
237310|NCT02384499|Drug|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
237214|NCT02385123|Biological|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
237215|NCT02385110|Drug|Alemtuzumab|"Group 1 and 2 Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.~Group 1 Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
237216|NCT02385110|Drug|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.~Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
237217|NCT02385110|Drug|Dexamethasone|"Induction Phase: 10 mg/m2 for 1 week followed by Dexamethasone 5 mg/m2 for 2 weeks followed by Dexamethasone 2.5 mg/m2 for 2 weeks followed by Dexamethasone 1.25 mg/m2 for 2 weeks.~Maintenance Phase: 1.25 mg/m2 by mouth three times a week for 16 weeks."
237218|NCT02385110|Drug|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
237219|NCT02385110|Behavioral|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
237220|NCT02385110|Drug|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
237221|NCT02385097|Drug|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
237222|NCT02385097|Drug|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
237223|NCT02385084|Drug|LY2409021|Administered orally
237224|NCT02385071|Drug|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
237225|NCT02385071|Drug|Treatment B|Treatment B (3*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
237226|NCT02385071|Drug|Treatment C|Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions).
237227|NCT02385071|Drug|Treatment D|*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions.
237228|NCT02385071|Drug|Treatment E|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
237229|NCT02385071|Drug|Treatment F|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
237230|NCT02385058|Drug|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
237231|NCT02385058|Drug|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
237232|NCT02385058|Drug|Placebo|Placebo tablet orally once starting on Day 21.
237233|NCT02385045|Device|i-scan|i-scan function is located on the head of the Pentax endoscopes
237234|NCT02385045|Device|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
237235|NCT02385032|Drug|Ursodiol|
237236|NCT02385032|Drug|URSO Forte|
237237|NCT02385019|Biological|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:~- Negative selection of CD8 and CD19 cells~- Positive selection of CD25 cells"
237238|NCT02385006|Biological|Blood sample|
237239|NCT02384993|Behavioral|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
237240|NCT02384980|Device|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
237241|NCT02384967|Drug|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
237242|NCT02384954|Biological|Rituximab|Intravenous infusion; Patients will receive a 4-week induction cycle consisting of Rituximab given on Day 1, 8, 15, 22. Eligible patients will receive a consolidation treatment consisting of Rituximab given on Day 78, 134, 190, 246.
237243|NCT02384954|Biological|ALT-803|Intravenous infusion for cohort 1, 2 and 3; subcutaneous injection for cohort 4, 5, 6 and 7; Patients will receive a 4-week induction cycle consisting of ALT-803 given on Day 2, 8, 15, 22 for patients in cohort 1, 2, 3, 4 and Day 1, 8, 15 and 22 for patients in cohort 5, 6, 7. Eligible patients will receive a consolidation treatment consisting of ALT-803 given on Day 78, 134, 190, 246.
237244|NCT02384941|Drug|Placebo|Placebo once daily, before first meal of the day.
237245|NCT02384941|Drug|Sotagliflozin|Sotagliflozin once daily, before first meal of the day.
237246|NCT02384928|Procedure|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
237247|NCT02384928|Device|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
237311|NCT02384486|Behavioral|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
237248|NCT02384928|Drug|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
237249|NCT02384928|Procedure|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
237250|NCT02384928|Behavioral|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
237251|NCT02384915|Drug|prilocaine|
237252|NCT02384915|Drug|mepivacaine|
237253|NCT02384915|Procedure|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
237254|NCT02384915|Procedure|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
237255|NCT02384915|Device|Sonoplex, Pajunk|
237256|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
237257|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
237258|NCT02384902|Other|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
237259|NCT02384889|Drug|Difluoromethylornithine|Active Therapy with DFMO
237260|NCT02384889|Drug|Placebo|Placebo Comparitor
237261|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
237262|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
237263|NCT02384850|Drug|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
237264|NCT02384850|Drug|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
237265|NCT02384850|Drug|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
237266|NCT02384850|Drug|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
237267|NCT02384837|Device|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
237268|NCT02384824|Procedure|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
237269|NCT02384811|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.~The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
237270|NCT02384798|Other|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
237271|NCT02384798|Other|interval training|interval training
237272|NCT02384785|Device|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
237273|NCT02384772|Other|Survey|
237274|NCT02384759|Drug|aflibercept|
237275|NCT02384759|Drug|LV5FU2|
237276|NCT02384746|Drug|Fulvestrant|500 mg intramuscular every 28 days
237277|NCT02384746|Drug|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
237278|NCT02384733|Radiation|Loco-regional RT|
237279|NCT02384720|Other|Age: 20-40years|
237280|NCT02384720|Other|Age: 41-64years|
237281|NCT02384720|Other|Age: ≥65years|
237282|NCT02384707|Other|allegic food|"Reintroduction procedure for small doses :~Administration of the first dose~Clinical monitoring for 45 minutes~Administration of the second dose"
237283|NCT02384707|Other|Placebo|
237284|NCT02384694|Other|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
237285|NCT02384681|Other|Exposure to auditory fatigue|12-hour auditory exposure
237286|NCT02384668|Dietary Supplement|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
237287|NCT02384668|Dietary Supplement|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
237288|NCT02384655|Drug|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
237312|NCT02384486|Other|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
237313|NCT02384473|Procedure|Real-Time CEUS|Undergo real-time CEUS
237289|NCT02384642|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
237290|NCT02384642|Behavioral|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
237291|NCT02384629|Device|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
237292|NCT02384629|Device|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
237293|NCT02384629|Device|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
237294|NCT02384629|Device|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
237295|NCT02384616|Other|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
237296|NCT02384603|Other|Global postural reeducation|
237297|NCT02384603|Other|Segmental muscle stretching exercises|
237298|NCT02384603|Other|Cognitive behavioral therapy|
237299|NCT02384590|Behavioral|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
237300|NCT02384577|Drug|Budesonide, Formoterol Fumarate Dihydrate|
237301|NCT02384564|Device|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
237302|NCT02384564|Device|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
237303|NCT02384551|Other|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
237304|NCT02384538|Biological|ABT-981|ABT-981 administered by subcutaneous injection
237305|NCT02384538|Biological|Placebo for ABT-981|Placebo for ABT-981 administered by subcutaneous injection
237306|NCT02384525|Procedure|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
237307|NCT02384525|Procedure|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
237308|NCT02384512|Drug|Azilect®|AZILECT® 1mg Tablets
237309|NCT02384499|Biological|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
237314|NCT02384473|Procedure|SWE|Undergo SWE
237315|NCT02384473|Drug|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
237316|NCT02384473|Device|Philips Shear Wave Elastography|Type of equipment used for SWE
237317|NCT02384460|Drug|SD-101-6.0 cream|applied topically once a day for 90 days
237318|NCT02384460|Drug|Placebo (SD-101-0.0) cream|applied topically once a day for 90 days
237319|NCT02384434|Device|Low Level Laser Therapy|Red Light Therapy
237320|NCT02384421|Device|Adaptive DBS (Activa PC+S Neurostimulator)|
237321|NCT02384421|Device|Continuous DBS (Activa PC+S Neurostimulator)|
237322|NCT02384408|Procedure|Endometrial Biopsy|Histological assessment
237323|NCT02384408|Device|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
237324|NCT02384408|Procedure|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
237325|NCT02384395|Drug|DTG/3TC/ABC FDC|DTG/3TC/ABC FDC as initial therapy for AHI
237326|NCT02384382|Drug|Enzalutamide|
237327|NCT02384369|Drug|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
237328|NCT02384343|Drug|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
237329|NCT02384343|Drug|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
237330|NCT02384317|Drug|CCX168|BID for 84 days
237331|NCT02384304|Behavioral|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
237332|NCT02384304|Behavioral|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
237333|NCT02384304|Behavioral|Self help|A self help program consisting of 8 modules
237334|NCT02384291|Device|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
237335|NCT02384291|Device|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
237336|NCT02384278|Behavioral|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
237337|NCT02384265|Behavioral|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
237338|NCT02384252|Other|functional tissu atrial analysis|
237339|NCT02384239|Drug|Palbociclib|
237340|NCT02384200|Drug|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
237341|NCT02384200|Drug|ampicillin|IV (2 g)
237342|NCT02384200|Drug|gentamicin|IV (5 mg/kg)
237343|NCT02384200|Drug|vancomycin|IV (1 g)
237344|NCT02384200|Drug|ceftriaxone|IV (2 g)
237345|NCT02384187|Drug|Gabapentin as premedication|Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
237346|NCT02384187|Drug|placebo|Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
237347|NCT02384174|Dietary Supplement|Resistant starch|
237348|NCT02384174|Dietary Supplement|Dietary fibre (arabinogalactan, gum guar, pectin)|
237349|NCT02384161|Other|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
237350|NCT02384148|Other|Circadian rhythm measurement|
237351|NCT02384148|Procedure|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
237352|NCT02384135|Other|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
237353|NCT02384122|Drug|Octreotide|Two injections of 20 mg will be given monthly.
237354|NCT02384109|Behavioral|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
237355|NCT02384109|Other|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
237356|NCT02384096|Device|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
237357|NCT02384096|Device|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
237358|NCT02384083|Drug|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
237359|NCT02384070|Procedure|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
237360|NCT02384070|Drug|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
237361|NCT02384070|Drug|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
237362|NCT02384070|Drug|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
237363|NCT02384057|Other|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
237364|NCT02384057|Other|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
237365|NCT02384044|Device|Crest® Sensi-Stop™ Strips|
237366|NCT02384044|Device|Colgate® Sensitivity Relief Pen|
237367|NCT02384031|Device|Traumatic needle|Lumbar puncture is performed with a traumatic needle
237368|NCT02384031|Device|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
237369|NCT02384018|Biological|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
237370|NCT02384005|Other|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
237371|NCT02383992|Drug|3% H2O2 solution|
237372|NCT02383992|Drug|0.9% normal saline|
237373|NCT02383979|Device|Sham (Comparator) Plasma Ball|"will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
237374|NCT02383979|Device|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
237375|NCT02383966|Drug|Cetuximab|Participants received Cetuximab as an intravenous infusion at an initial dose of 400 milligrams per square meter (mg/m^2) on Day 1 and a subsequent dose of 250 mg/m^2 on Day 8 and Day 15 of each 21-day treatment cycle.
237376|NCT02383966|Drug|Cisplatin/Carboplatin|Cisplatin or Carboplatin (at an equivalent dose in case of intolerability of cisplatin) was administered at a dose of 75 mg/m^2 as an intravenous infusion on Day 1 of each 21-day treatment cycle.
237377|NCT02383966|Drug|5-fluorouracil|Participants received 5-fluorouracil (FU) at a dose of 750 mg/m^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle.
237378|NCT02383940|Drug|Sotagliflozin|Sotagliflozin 400 mg, once daily before the first meal of the day
237379|NCT02383940|Drug|Placebo|Placebo, once daily before the first meal of the day
237380|NCT02383927|Drug|Tipifarnib|FTase inhibitor
237381|NCT02383901|Drug|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
237382|NCT02383888|Drug|BI 425809|
237383|NCT02383888|Drug|BI 425809|
237384|NCT02383888|Drug|Placebo|
237385|NCT02383888|Drug|BI 425809|
237386|NCT02383875|Behavioral|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
237387|NCT02383862|Other|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
237388|NCT02383823|Drug|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
237389|NCT02383823|Other|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
237390|NCT02383810|Drug|Elsiglutide|
237391|NCT02383810|Drug|Placebo|
237392|NCT02383797|Biological|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
237393|NCT02383784|Dietary Supplement|Low GI index diet|Low glycemic index diet
237394|NCT02383784|Dietary Supplement|High GI diet|High glycemic index diet
237395|NCT02383771|Drug|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
237396|NCT02383771|Drug|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
237397|NCT02383771|Drug|Control|No Anti-platelet Therapy
237398|NCT02383771|Drug|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
237399|NCT02383758|Drug|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
237400|NCT02383758|Drug|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
238642|NCT02374567|Drug|Amitriptyline oxide|
237401|NCT02383758|Drug|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
237402|NCT02383745|Other|Acute EEG with fast EEG electrode|
237403|NCT02383732|Behavioral|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention & Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
237404|NCT02383732|Behavioral|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
237405|NCT02383732|Behavioral|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
237406|NCT02383719|Device|Oro-nasal Mask|
237407|NCT02383706|Device|ApneaLink Air|Overnight, home polysomnography device
237408|NCT02383706|Behavioral|Berlin Quesionnaire|OSA screening questionnaire
237409|NCT02383706|Behavioral|Epworth Sleepiness Scale|OSA screening questionnaire
237410|NCT02383706|Behavioral|STOP-BANG questionnaire|OSA screening questionnaire
237411|NCT02383706|Other|Physical exam|Physical exam of neck, mouth and upper airway
237412|NCT02383693|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
237413|NCT02383680|Biological|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
237414|NCT02383667|Device|Electrocardiogram holter|
237415|NCT02383654|Procedure|Autologous Adipose-Tissue Derived Stem Cells|"Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells~Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.~Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
237416|NCT02383615|Procedure|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
237417|NCT02383589|Drug|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
237418|NCT02383589|Drug|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
237419|NCT02383589|Drug|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
237420|NCT02383589|Drug|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
237421|NCT02383576|Other|No Intervention|No intervention administered in this study.
237422|NCT02383563|Drug|metformin extended release|
237423|NCT02383550|Other|Observational Cognitive assessments|Observational
237424|NCT02383537|Other|Diabetes|the trial is observational with no intervention
237425|NCT02383524|Procedure|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
237426|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
237427|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
237428|NCT02383511|Drug|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
237429|NCT02383498|Other|GI-6301 Placebo|GI-6301 Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of GI-6301 placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
237430|NCT02383498|Biological|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
237431|NCT02383498|Radiation|Radiotherapy|Standard of care
237432|NCT02383498|Device|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
237433|NCT02383485|Behavioral|Exercise|Heart rate monitors worn by each child at each session
237434|NCT02383485|Behavioral|After-school program|Supervised recreational program with token economy
237435|NCT02383472|Device|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
237436|NCT02383472|Device|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
237437|NCT02383446|Device|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
237438|NCT02383433|Drug|Regorafenib|Given PO
237439|NCT02383433|Drug|Gemcitabine Hydrochloride|Given IV
237440|NCT02383420|Radiation|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
237441|NCT02383407|Device|Medtronic Deep Brain Stimulation|
237442|NCT02383394|Other|follow up antenatal care|ultrasound follow up of pregnancy
237443|NCT02383381|Procedure|lateral rectus recession|typical surgery for correcting intermittent exotropia
237444|NCT02383368|Drug|ASP4132|oral
237445|NCT02383355|Drug|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
237446|NCT02383355|Drug|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
237447|NCT02383329|Dietary Supplement|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
237448|NCT02383316|Other|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
237449|NCT02383303|Behavioral|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
237450|NCT02383290|Other|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
237451|NCT02383277|Other|Stretching|Stretching of the rib cage muscles
237452|NCT02383277|Other|Control|Rest without stretching (sham)
237453|NCT02383277|Other|Exercise|Constant load exercise on a bike
237454|NCT02383251|Drug|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
237455|NCT02383251|Drug|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
237456|NCT02383238|Drug|Dapagliflozin|10 mg, oral for 6 weeks
237457|NCT02383238|Drug|Placebo|oral for 6 weeks
237458|NCT02383225|Behavioral|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
237459|NCT02383225|Behavioral|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
237460|NCT02383225|Behavioral|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
237461|NCT02383212|Drug|Cemiplimab|
237462|NCT02383212|Radiation|Hypofractionated radiotherapy|
237463|NCT02383212|Drug|Cyclophosphamide|
237464|NCT02383212|Drug|Docetaxel|
237465|NCT02383212|Drug|Carboplatin|
237466|NCT02383212|Drug|GM-CSF|
237467|NCT02383212|Drug|Paclitaxel|
237468|NCT02383212|Drug|Pemetrexed|
237469|NCT02383186|Procedure|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
237470|NCT02383186|Procedure|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
237471|NCT02383173|Other|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
237544|NCT02382575|Drug|Tacrolimus|Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
238080|NCT02378415|Drug|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
237472|NCT02383173|Other|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
237473|NCT02383160|Device|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
237474|NCT02383160|Device|Sham device|Placebo device with no active therapy
237475|NCT02383147|Device|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
237476|NCT02383147|Device|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
237477|NCT02383121|Drug|Midodrine|Not appliciable
237478|NCT02383108|Drug|DTG +DRV/r|NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
237479|NCT02383108|Drug|SOC|Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
237480|NCT02383095|Behavioral|Art therapy|
237481|NCT02383095|Behavioral|metacognitive therapy|
237482|NCT02383069|Other|Intervention Group|Aerobic training
237483|NCT02383069|Other|Control Group|Chest physiotherapy: Flutter and muscle stretching
237484|NCT02383056|Device|Omnilux|Photomodulation irradiated with a 633 +/- 3 mm light source for 20 minutes (105 mW/cm, 126 J/cm)
237485|NCT02383056|Device|Omnilux Sham|Sham light instead of phototherapy from the same light device
237486|NCT02383043|Drug|Cocaine|
237487|NCT02383043|Drug|Sustained Release d-Amphetamine|
237488|NCT02383030|Drug|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
237489|NCT02383017|Dietary Supplement|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
237490|NCT02383017|Dietary Supplement|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
237491|NCT02383004|Other|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
237492|NCT02382991|Device|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
237493|NCT02382991|Device|NMPK-3C60|1 month with NMPK - 3 months with 3C60
237494|NCT02382978|Other|nurse-provided well child visit|
237495|NCT02382965|Device|transcranial focused ultrasound|
237496|NCT02382952|Device|Differential Dissector|
237497|NCT02382952|Other|Standard Dissection Method|
237498|NCT02382939|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
237499|NCT02382939|Drug|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
237500|NCT02382926|Other|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
237501|NCT02382913|Biological|aP booster|"Acellular pertussis vaccine:~Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
237502|NCT02382913|Biological|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
237503|NCT02382913|Biological|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.~Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
237504|NCT02382900|Biological|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
237505|NCT02382887|Procedure|tracheal intubation|tracheal intubation with the Airtraq
237506|NCT02382887|Device|Airtraq|
237507|NCT02382887|Device|fiberscope|
237508|NCT02382874|Biological|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
237509|NCT02382861|Device|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
237510|NCT02382861|Device|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
238081|NCT02378415|Drug|Placebo|Normal Saline Infusion
238643|NCT02374567|Drug|Fluoxetine|
238644|NCT02374567|Drug|Citalopram|
237511|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
237512|NCT02382848|Drug|Placebo|Prazosin-matched placebo pill
237513|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
237514|NCT02382848|Drug|Placebo|Prazosin-matched placebo pill
237515|NCT02382822|Other|No intervention.|
237516|NCT02382809|Drug|DC071|Mouthwash, twice daily
237517|NCT02382809|Drug|Placebo|Mouthwash, twice daily
237518|NCT02382796|Drug|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
237519|NCT02382783|Other|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...~The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
237520|NCT02382770|Procedure|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
237521|NCT02382757|Drug|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
237522|NCT02382744|Device|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
237523|NCT02382744|Device|Ultrasound guidance + nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
237524|NCT02382731|Behavioral|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
237525|NCT02382731|Behavioral|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
237526|NCT02382718|Biological|FAST fish mCyp c 1|Subcutaneous immunotherapy
237527|NCT02382718|Biological|Placebo|Subcutaneous immunotherapy
237528|NCT02382679|Dietary Supplement|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
237529|NCT02382679|Dietary Supplement|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
237530|NCT02382666|Drug|Rolapitant|
237531|NCT02382653|Drug|oral perixicam|Oral adminstration of buccal perixicam
237532|NCT02382640|Drug|Febuxostat XR|Febuxostat extended-release (XR) capsules
237533|NCT02382640|Drug|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
237534|NCT02382614|Device|Spiration Valve System|
237535|NCT02382601|Radiation|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
237536|NCT02382601|Radiation|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
237537|NCT02382601|Procedure|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
237538|NCT02382601|Behavioral|Neurological Function Assessment|Neurological development tests called a Bayley exam and Pediatric Stroke Outcome Measure (PSOM) will be performed.
237539|NCT02382601|Procedure|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
237540|NCT02382601|Procedure|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
237541|NCT02382588|Drug|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
237542|NCT02382588|Drug|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
237543|NCT02382575|Drug|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
238645|NCT02374567|Drug|Paroxetine|
237545|NCT02382562|Behavioral|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
237546|NCT02382549|Drug|dabrafenib|Braf inhibitor
237547|NCT02382549|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
237548|NCT02382549|Drug|Trametinib|MEK1 AND MEK2 inhibitor
237549|NCT02382536|Device|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
237550|NCT02382536|Device|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
237551|NCT02382523|Drug|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.~If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.~If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
237552|NCT02382510|Drug|TRN-157|
237553|NCT02382510|Other|Placebo|
237554|NCT02382510|Drug|Tiotropium|
237555|NCT02382497|Device|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
237556|NCT02382497|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
237557|NCT02382497|Device|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
237558|NCT02382497|Device|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
237559|NCT02382484|Device|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
237560|NCT02382471|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
237561|NCT02382471|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
237562|NCT02382458|Behavioral|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
237563|NCT02382458|Behavioral|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
237564|NCT02382445|Device|Anesthesia depth monitor|
237565|NCT02382445|Device|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
237566|NCT02382445|Drug|propofol and sevoflurane|
237567|NCT02382432|Drug|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
237568|NCT02382432|Drug|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
237569|NCT02382419|Drug|carrageenan-containing gel|Applied vaginally
237570|NCT02382419|Other|Placebo|Applied vaginally
237571|NCT02382419|Other|Laboratory Biomarker Analysis|Correlative studies
237572|NCT02382419|Other|Questionnaire Administration|Ancillary studies
237573|NCT02382406|Drug|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
237574|NCT02382406|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
237575|NCT02382406|Drug|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
237576|NCT02382406|Drug|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
237577|NCT02382393|Other|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
237578|NCT02382393|Other|Computerized Assessment|a validated, computerized cognitive assessment tool
237617|NCT02382055|Behavioral|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
237579|NCT02382380|Drug|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
237580|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
237581|NCT02382367|Other|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
237582|NCT02382354|Drug|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
237583|NCT02382354|Device|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
237584|NCT02382354|Device|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
237585|NCT02382354|Drug|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
237586|NCT02382341|Device|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
237587|NCT02382328|Drug|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
237588|NCT02382328|Drug|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
237589|NCT02382315|Behavioral|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
237590|NCT02382302|Device|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
237591|NCT02382289|Procedure|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
237592|NCT02382276|Drug|Nalmefene hydrochloride|
237593|NCT02382263|Drug|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
237594|NCT02382263|Drug|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
237595|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
237596|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
237597|NCT02382250|Behavioral|Survey|Survey will be given to all participants
237598|NCT02382237|Device|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
237599|NCT02382224|Behavioral|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
237600|NCT02382224|Behavioral|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
237601|NCT02382198|Drug|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
237602|NCT02382198|Drug|Placebo|
237603|NCT02382185|Other|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
237604|NCT02382185|Drug|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
237605|NCT02382185|Device|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
237606|NCT02382172|Behavioral|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
237607|NCT02382172|Other|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
237608|NCT02382146|Drug|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
237609|NCT02382146|Drug|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
237610|NCT02382133|Device|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
237611|NCT02382107|Other|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
237612|NCT02382094|Drug|Bicalutamide|
237613|NCT02382081|Procedure|Patient-initiated shared care|
237614|NCT02382068|Drug|Dexamethasone|Given via intratympanic injection
237615|NCT02382068|Other|Placebo|Given via intratympanic injection
237616|NCT02382068|Drug|Cisplatin|"Standard of care treatment with the following treatment course criteria:~Dose: > 50 mg/m2~Frequency: q3 -q4 weeks~Cycles: 7 maximum"
238387|NCT02376036|Biological|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
237618|NCT02382055|Behavioral|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
237619|NCT02382055|Behavioral|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
237620|NCT02382042|Behavioral|Intensive Referral Intervention|
237621|NCT02382029|Drug|Clonazepam|Active medical treatment for burning mouth syndrome
237622|NCT02382029|Other|acupuncture|Traditional chinese acupuncture
237623|NCT02382016|Drug|Macitentan|Macitentan film-coated tablet 10 mg once daily.
237624|NCT02382016|Other|Placebo|Matching placebo tablet once daily.
237625|NCT02382003|Behavioral|Positive Cognitive Bias Modification - Interpretation|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.
237626|NCT02382003|Behavioral|50/50 Cognitive Bias Modification - Interpretation|This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.
237627|NCT02382003|Behavioral|Anxious Imagery Prime|We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.
237628|NCT02382003|Behavioral|Neutral Imagery Prime|At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
237629|NCT02381990|Procedure|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|"Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic cryoprobes/devices are employed to freeze and all circuled or noted cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins"
237630|NCT02381977|Other|No intervention|
237631|NCT02381964|Dietary Supplement|Supradyn® (1RDA+CoQ10)|
237632|NCT02381964|Dietary Supplement|Supradyn® (3RDA)|
237633|NCT02381964|Dietary Supplement|Placebo|
237634|NCT02381951|Device|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
237635|NCT02381938|Behavioral|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
237636|NCT02381938|Other|Healthy Finances|6-month intervention to educate and improve financial health
237637|NCT02381912|Other|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
237638|NCT02381899|Drug|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
237639|NCT02381886|Drug|IDH305|
237640|NCT02381860|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
237641|NCT02381860|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
237642|NCT02381847|Procedure|intraperitoneal chemoperfusion|HIPEC with cisplatin at the time of D2 radical surgery
237643|NCT02381834|Procedure|Bladder stimulation technique|
237644|NCT02381821|Other|3 D ultrasound and Doppler examination|Endometrial thickness was measured in the longitudinal plane at the widest anteroposterior diameter with a trans-vaginal 2D ultrasound, and then 3D mode was then activated with power Doppler setting for this study standardized using a frequency at 4-9 MHZ pulse repetition frequency at 0.5KHz gain at-3.0 and wall motion filter at 1. The sub-endometrial region was considered to be within 3 mm of the originally defined myometrial-endometrial contour. The endometrial volume (EV) and 3D power Doppler indices below the endometrium were measured using the automated VOCAL™ for the 3D power Doppler histogram analysis
237645|NCT02381821|Drug|GnRH agonist|All women received daily subcutaneous 0.1 mg triptorelin injection started from day 21) of the cycle preceding stimulation. Downregulation of the pituitary gonadotropins was confirmed after 12 days , gonadotropin (Gn) induction was started using Human menopausal gonadotropins for ovarian stimulation. The starting dose was 225 to 300 IU . Ultrasound Folliculometry was done every other day . When two or more follicles reached a minimum mean diameter of 18 mm, triggering of ovulation trigger was done using Human chorionic gonadotropin (hCG) 10,000 IU and ovum pick up was scheduled 36 hours later
237646|NCT02381795|Drug|Nasal Carbon Dioxide|
237647|NCT02381769|Dietary Supplement|Soybean based lipid emulsion|
237648|NCT02381756|Device|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
237649|NCT02381743|Behavioral|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
237650|NCT02381743|Behavioral|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
237651|NCT02381730|Drug|Intravitreal aflibercept|Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
237652|NCT02381717|Other|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
237653|NCT02381717|Drug|bupivacaine|
237654|NCT02381717|Drug|morphine|
237655|NCT02381691|Other|maternal breast milk odor|
237656|NCT02381691|Other|no odor|
238646|NCT02374567|Drug|Sertraline|
237657|NCT02381678|Device|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
237658|NCT02381665|Device|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
237659|NCT02381665|Device|Flexstim IF faked|Patient enrolled will receive a sham device.
237660|NCT02381652|Device|Cingal®|Injection into the knee
237661|NCT02381639|Behavioral|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
237662|NCT02381626|Device|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
237663|NCT02381626|Behavioral|questionnaires|
237664|NCT02381626|Other|Log-book|PM and biological measurements
237665|NCT02381626|Other|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
237666|NCT02381613|Other|Baked beef|A meal based on baked beef
237667|NCT02381613|Other|Baked herring|A meal based on baked herring
237668|NCT02381613|Other|Pickled herring|A meal based on pickled herring
237669|NCT02381600|Drug|Vitamin D|"Experimental :~Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.~Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.~At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
237670|NCT02381587|Other|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
237671|NCT02381561|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
237672|NCT02381561|Other|Laboratory Biomarker Analysis|Correlative studies
237673|NCT02381561|Other|Pharmacological Study|Correlative studies
237674|NCT02381561|Drug|Ropidoxuridine|Given PO
237675|NCT02381548|Drug|Adavosertib|Given PO
237676|NCT02381548|Drug|Belinostat|Given IV
237677|NCT02381548|Other|Laboratory Biomarker Analysis|Correlative studies
237678|NCT02381548|Other|Pharmacological Study|Correlative studies
237679|NCT02381535|Drug|Cisplatin|Given IV
237680|NCT02381535|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
237681|NCT02381535|Other|Laboratory Biomarker Analysis|Correlative studies
237682|NCT02381535|Drug|Onalespib|Given IV
237683|NCT02381535|Other|Pharmacological Study|Correlative studies
237684|NCT02381522|Other|Remote Ischemic Pre-conditioning|
237685|NCT02381522|Other|Sham RIPC|
237686|NCT02381509|Device|IVC Filter|
237687|NCT02381496|Drug|ACT-453859 1 mg|Capsule
237688|NCT02381496|Drug|ACT-453859 3 mg|Capsule
237689|NCT02381496|Drug|ACT-453859 10 mg|Capsule
237690|NCT02381496|Drug|ACT-453859 30mg|Capsule
237691|NCT02381496|Drug|ACT-453859 100 mg|Capsule
237692|NCT02381496|Drug|ACT-453859 300 mg|Capsule
237693|NCT02381496|Drug|ACT-453859 800 mg|Capsule
237694|NCT02381496|Other|Placebo|Matching ACT-453859 placebo capsule
237695|NCT02381496|Drug|Setipiprant 500 mg|Capsule
237696|NCT02381496|Drug|Setipiprant 1000 mg|Capsule
237697|NCT02381483|Other|Cold exposure|
237698|NCT02381470|Drug|Faropenem|Faropenem 600mg
237699|NCT02381470|Drug|Amoxicillin/clavulanic acid|Amoxicillin 500mg/ clavulanic acid 125mg
237700|NCT02381470|Drug|Cefadroxil|Cefadroxil 1g
237701|NCT02381470|Drug|Rifampicin|Rifampicin 10mg/kg
237702|NCT02381431|Device|FLIR ONE|
237703|NCT02381418|Biological|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
237704|NCT02381405|Dietary Supplement|Enterade beverage|
237705|NCT02381392|Device|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
237706|NCT02381379|Drug|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
237707|NCT02381366|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:~Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
237708|NCT02381353|Drug|Bupivacaine|Intraoperative orbital injection of local pain medication
237709|NCT02381340|Device|ACE stapling procedure|Endoscopic trans-oral gastroplication
237710|NCT02381327|Device|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
237711|NCT02381314|Biological|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
237712|NCT02381301|Biological|Venous blood sampling prior to CCTA.|
237713|NCT02381288|Drug|TAK-448|TAK-448 solution for subcutaneous injection
237714|NCT02381288|Drug|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
237715|NCT02381275|Drug|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
238647|NCT02374567|Drug|Fluvoxamine|
237716|NCT02381262|Behavioral|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
237717|NCT02381249|Drug|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
237718|NCT02381249|Drug|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
237719|NCT02381236|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
237720|NCT02381210|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
237721|NCT02381197|Device|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
237722|NCT02381184|Drug|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
237723|NCT02381184|Procedure|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
237724|NCT02381171|Device|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
237725|NCT02381171|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
237726|NCT02381171|Device|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
237727|NCT02381171|Device|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
237728|NCT02381158|Drug|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
237729|NCT02381145|Dietary Supplement|EGCG+RSV-supplementation|Teavigo (~300mg/d) Resveratrol (~80mg/d)
237730|NCT02381145|Dietary Supplement|Placebo|
237731|NCT02381132|Drug|Norco 7.5mg/325|
237732|NCT02381132|Drug|MNK155|
237733|NCT02381119|Behavioral|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).~This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
237734|NCT02381119|Behavioral|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
237735|NCT02381093|Other|Modified BLS course|BLS using CI
237736|NCT02381093|Other|Standard BLS Course|Usual BLS teaching
237737|NCT02381080|Drug|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
237738|NCT02381080|Drug|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
237739|NCT02381080|Drug|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
237740|NCT02381067|Other|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
237741|NCT02381028|Other|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
237742|NCT02381028|Other|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
237743|NCT02381015|Genetic|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
237744|NCT02381015|Genetic|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
237745|NCT02381015|Behavioral|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
237746|NCT02381015|Behavioral|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
237747|NCT02381002|Other|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
237748|NCT02380989|Device|Ayurveda|Ayurveda combinations in the form of gel and patches were applied on acute pain site.
237749|NCT02380989|Device|Placebo|
237750|NCT02380976|Drug|combination drug: DW330SR, DW1030|
237751|NCT02380976|Drug|DW340|
237752|NCT02380963|Dietary Supplement|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.~Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.~Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
237867|NCT02380001|Drug|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
237868|NCT02380001|Drug|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
237753|NCT02380963|Behavioral|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.~Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.~Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.~Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
237754|NCT02380950|Behavioral|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
237755|NCT02380937|Procedure|ablation for typical atrial flutter|ablation for typical atrial flutter
237756|NCT02380937|Device|Vision Ablation Catheter|
237757|NCT02380924|Drug|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
237758|NCT02380924|Drug|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
237759|NCT02380911|Other|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.~In addition, 2 intervention support tools are used at the intervention clinics:~A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.~On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
237760|NCT02380898|Drug|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
237761|NCT02380898|Drug|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
237762|NCT02380885|Behavioral|SCIT|psychosocial group intervention
237763|NCT02380885|Behavioral|TAFT|psychosocial group intervention
237764|NCT02380872|Procedure|Connective tissue graft|gingival recession treated with connective tissue graft
237765|NCT02380872|Procedure|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
237766|NCT02380859|Behavioral|Prism adaptation|Prism adaptation is one type of sensorimotor adaptation. Prism adaptation described any adaptation to a prismatic shift in vision (i.e. any magnitude or direction of shift). In this study we are using adaptation to upward-shifting prisms, which induces a downward sensorimotor after-effect.
237767|NCT02380846|Other|White rice|Control - white rice
237768|NCT02380846|Other|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
237769|NCT02380846|Other|Rice with fish|Treatment 2 - steamed white rice with steamed fish
237770|NCT02380846|Other|Rice with egg white|Treatment 3 - steamed white rice with egg white
237771|NCT02380846|Other|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
237772|NCT02380833|Behavioral|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
237773|NCT02380833|Behavioral|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
237774|NCT02380833|Behavioral|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
237775|NCT02380833|Behavioral|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
237776|NCT02380820|Device|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
237777|NCT02380820|Device|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
237778|NCT02380807|Device|Dry Needling|"Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots."
237779|NCT02380807|Other|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
237780|NCT02380794|Drug|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.~Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
237781|NCT02380794|Drug|Placebo|
237782|NCT02380781|Behavioral|Information in the form of a video|see intervention description
237783|NCT02380768|Device|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
237784|NCT02380768|Device|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
237785|NCT02380755|Drug|Clomiphene Citrate|50 mg orally daily during 12 weeks
237786|NCT02380755|Drug|Placebo|1 pill orally daily during 12 weeks
238648|NCT02374567|Drug|Escitalopram|
237787|NCT02380742|Drug|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
237788|NCT02380742|Drug|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
237789|NCT02380729|Genetic|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
237790|NCT02380729|Genetic|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
237791|NCT02380703|Behavioral|Aggression Prevention Training (APT)|
237792|NCT02380703|Other|Enhanced Usual Primary Care (EU-PC)|
237793|NCT02380690|Behavioral|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
237794|NCT02380677|Drug|CRLX301|
237795|NCT02380664|Device|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
237796|NCT02380664|Behavioral|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
237797|NCT02380651|Procedure|Limb salvage|Local or free flaps
237798|NCT02380638|Device|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
237799|NCT02380625|Drug|Azithromycin|Adults (>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to <18 yrs): 30mg/kg (oral suspension) daily for 5 days
237800|NCT02380625|Drug|Sunitinib and Erlotinib|Sunitinib - Adults (>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to <18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to <20kg): 3.5 mg/kg daily for 7 days; Children (>20kg to <30kg): 3.0 mg/kg daily for 7 days; Children (>30kg to < 18 yrs): 25 mg/kg daily for 7 days
237801|NCT02380625|Drug|Atorvastatin and Irbesartan|Atorvastatin - Adults (>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to <18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to <18 yrs): 1 x 75mg tablet daily until discharge.
237802|NCT02380625|Other|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
237803|NCT02380612|Device|ReCell Treatment|
237804|NCT02380612|Procedure|Skin Graft|
237805|NCT02380599|Other|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
237806|NCT02380599|Other|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
237807|NCT02380599|Other|Sham Ultrasound|Sham ultrasound to T3-5 region
237808|NCT02380586|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
237809|NCT02380573|Drug|Methylene Blue|
237810|NCT02380573|Drug|FD&C Blue # 2|
237811|NCT02380573|Drug|Phenazopyridine hydrochloride|
237812|NCT02380560|Device|Ultrasonographic examination|"An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:~a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.~(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker."
237813|NCT02380547|Other|Sonographic diaphragmatic measurements|
237814|NCT02380534|Procedure|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
237815|NCT02380521|Drug|Exenatide once weekly (BYDUREON™)|"Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.~Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.~Subjects will follow a fixed dose of 2 mg"
237816|NCT02380508|Drug|BCG SSI|Intradermal injection
237817|NCT02380508|Other|No vaccination|
237818|NCT02380508|Drug|BCG Sii|intradermal injection
237819|NCT02380495|Other|Data Collection|
237820|NCT02380482|Other|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
237821|NCT02380482|Other|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
237977|NCT02379182|Behavioral|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
237822|NCT02380469|Behavioral|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
237823|NCT02380443|Biological|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
237824|NCT02380443|Procedure|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
237825|NCT02380430|Other|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
237826|NCT02380417|Procedure|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
237827|NCT02380417|Drug|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
237828|NCT02380417|Device|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
237829|NCT02380404|Procedure|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
237830|NCT02380365|Device|Electrocardiography|"Duration of intervention per patient/subject:~5 min, observation 6 months"
237831|NCT02380352|Drug|Amoxicillin|
237832|NCT02380352|Drug|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
237833|NCT02380339|Behavioral|Psych-Educational session and virtual reality|Psych-Educational session and virtual reality
237834|NCT02380339|Behavioral|Psych-Educational and BF sessions|Psych-Educational and BF sessions
237835|NCT02380326|Procedure|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
237836|NCT02380313|Drug|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
237837|NCT02380313|Drug|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
237838|NCT02380313|Drug|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
237839|NCT02380313|Drug|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
237840|NCT02380287|Drug|humanized monoclonal antibody against human IL-17|
237841|NCT02380261|Other|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
237842|NCT02380248|Other|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
237843|NCT02380235|Biological|PEG-somatropin|0.20mg/kg/w
237844|NCT02380235|Biological|PEG-somatropin|0.12mg/kg/w
237845|NCT02380222|Other|Interview|Single interview lasting approximately one hour
237846|NCT02380209|Other|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
237847|NCT02380183|Device|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
237848|NCT02380157|Drug|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
237849|NCT02380157|Drug|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
237850|NCT02380144|Other|Fresh orange fruit and pasteurized fruit juice|
237851|NCT02380131|Drug|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
237852|NCT02380131|Drug|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
237853|NCT02380118|Drug|Olanzapine|Intramuscular injection
237854|NCT02380118|Drug|Haloperidol|Intramuscular injection
237855|NCT02380118|Drug|Midazolam|Intramuscular injection
237856|NCT02380105|Behavioral|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
237857|NCT02380105|Device|Interocclusal Appliances|Patients were treated using interocclusal appliances
237858|NCT02380092|Device|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
237859|NCT02380079|Drug|SCD-101|Administered as gelatin capsules
237860|NCT02380066|Drug|Anyu Peibo|
237861|NCT02380053|Drug|Bisoprolol|2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
237862|NCT02380053|Drug|Celiprolol|2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
237863|NCT02380040|Device|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
237864|NCT02380027|Device|MRI|This will be a multi-parametric MRI of the prostate
237865|NCT02380027|Procedure|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
237866|NCT02380027|Procedure|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
238649|NCT02374567|Drug|Tranylcypromine|
237869|NCT02379988|Radiation|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
237870|NCT02379975|Procedure|Non-surgical Periodontal Therapy|
237871|NCT02379962|Other|no intervention|
237872|NCT02379949|Behavioral|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
237873|NCT02379949|Behavioral|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
237874|NCT02379936|Device|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.~Point of care method"
237875|NCT02379936|Procedure|Traditional evaluation|Traditional way of evaluation
237876|NCT02379936|Device|iPhone 4S|
237877|NCT02379923|Device|Crossing of Coronary Artery CTO|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.~Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE.~Other Name: ASAHI Corsair Microcatheter, ASAHI PTCA Guide Wires"
237878|NCT02379910|Drug|AM1030-CREAM or placebo|
237879|NCT02379897|Other|Diet|
237880|NCT02379871|Other|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
237881|NCT02379871|Other|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
237882|NCT02379858|Drug|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
237883|NCT02379858|Drug|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
237884|NCT02379845|Device|NBTXR3|One intratumor implantation by injection
237885|NCT02379845|Device|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
237886|NCT02379819|Device|Nucleus Hybrid L24 Implant|
237887|NCT02379806|Drug|Enoxaparin|
237888|NCT02379806|Drug|Placebo|
237889|NCT02379793|Drug|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
237890|NCT02379780|Procedure|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71*50 mm 22G*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
237891|NCT02379780|Procedure|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71*50 mm 22 G* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.~we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
237892|NCT02379767|Device|Electroconvulsive therapy|
237893|NCT02379767|Other|Positron emission tomography of the brain using [11C]harmine|
237894|NCT02379767|Other|Structural magnetic resonance imaging|
237895|NCT02379754|Drug|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
237896|NCT02379741|Biological|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
237897|NCT02379728|Device|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time she spends in this position via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist or thorax. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back of the user when she lies on her back, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back."
237898|NCT02379728|Device|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
238010|NCT02378935|Drug|VOX|100 mg tablet(s) administered orally once daily with food
238011|NCT02378935|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
238650|NCT02374567|Drug|Moclobemide|
238651|NCT02374567|Drug|Mianserin|
237899|NCT02379728|Device|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
237900|NCT02379715|Drug|Remifentanil|
237901|NCT02379715|Drug|Desflurane|
237902|NCT02379702|Other|Metabolic Syndrome|This study will provide important information on the social and economic dimensions of metabolic syndrome
237903|NCT02379689|Drug|Injectable placental tissue extract called BioDGenesis (Active Product)|
237904|NCT02379689|Drug|Placebo|
237905|NCT02379676|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
237906|NCT02379676|Drug|Clopidogrel|Clopidogrel 75mg once daily for 30 days
237907|NCT02379663|Drug|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
237908|NCT02379663|Drug|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
237909|NCT02379663|Other|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
237910|NCT02379650|Drug|Hydroxychloroquine (HCQ)|
237911|NCT02379650|Drug|Placebo|
237912|NCT02379637|Drug|N-acetylcysteine|
237913|NCT02379637|Drug|Placebo|
237914|NCT02379624|Drug|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
237915|NCT02379611|Procedure|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
237916|NCT02379598|Dietary Supplement|Aminoacid based formula|Formula based on aminoacid
237917|NCT02379598|Dietary Supplement|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
237918|NCT02379585|Drug|Doxorubicin|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
237919|NCT02379585|Drug|cyclophosphamide|doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
237920|NCT02379585|Drug|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
237921|NCT02379585|Drug|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
237922|NCT02379585|Drug|Trastuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
237923|NCT02379585|Drug|Pertuzumab|docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
237924|NCT02379572|Device|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
237925|NCT02379572|Drug|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
237926|NCT02379559|Behavioral|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
237927|NCT02379559|Behavioral|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
237928|NCT02379546|Drug|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
237929|NCT02379546|Device|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
237930|NCT02379533|Other|Aerobic exercise|
237931|NCT02379520|Genetic|HPV Specific T Cells|"Dose escalation study with 5 dose levels: DL1-1×10^7 cells/m2, DL2-3×10^7 cells/m2, and DL3-1×10^8 cells/m2, DL4- 2 to 3×10^8 cells/m2, DL5- 0.8 to 1×10^9 cells/m2~Group A -HPVST cells Group B -lymphodepletion & nivolumab & HPVST cells.~First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2, DL3, DL4, and DL5.~Group A will be treated at DL3, DL4, and DL5 only if there is excessive toxicity in cohorts treated with lymphodepletion.~HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0.~If patients have clinical benefit (as determined by symptoms, physical exam or radiological studies) & no significant toxicities, they may get up to 5 repeat infusions (for max total of 6 infusions) of HPVSTs at or below the same dose level."
237932|NCT02379520|Drug|Cytoxan|500mg/m^2/day x 3 days (on days -4, -3 and -2)
237933|NCT02379520|Drug|Fludarabine|30mg/m^2/day x 3 days (on days -4, -3, and -2)
237934|NCT02379520|Biological|Nivolumab|240mg every 2 weeks (+/- 3 days) starting on day -1
237935|NCT02379507|Other|DEC033 Study Product|Apply twice daily
237936|NCT02379481|Dietary Supplement|NS 550mg|
237937|NCT02379481|Dietary Supplement|NS 1100mg|
237938|NCT02379481|Dietary Supplement|placebo|
237939|NCT02379468|Drug|Pedyphar Ointment|
237940|NCT02379468|Drug|Panthenol|Ointment
237941|NCT02379455|Other|Comprehensive drug review|1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
237942|NCT02379442|Biological|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
237943|NCT02379416|Drug|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
237944|NCT02379390|Drug|Cabazitaxel XRP6258|
237945|NCT02379390|Drug|Ezalutamide|
237946|NCT02379390|Drug|Abiraterone acetate|
237947|NCT02379390|Drug|Prednisone|
237948|NCT02379377|Radiation|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET scan
237949|NCT02379377|Radiation|Carbon-11 Acetate|Undergo 11C-acetate PET scan
237950|NCT02379377|Device|Positron Emission Tomography|Undergo 18F-FSPG PET
237951|NCT02379377|Procedure|Positron Emission Tomography|Undergo 11C-acetate PET
237952|NCT02379377|Other|Laboratory Biomarker Analysis|Correlative studies
237953|NCT02379364|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
237954|NCT02379351|Device|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
237955|NCT02379338|Drug|[18F]Fluortriopride|All subjects will receive a [18F]Fluortriopride PET/CT scan
237956|NCT02379325|Behavioral|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
237957|NCT02379325|Behavioral|pamphlets material|Given pamphlets material on smoking and complication
237958|NCT02379312|Dietary Supplement|Very low energy aerated beverage|
237959|NCT02379312|Dietary Supplement|Normal energy aerated beverage 1|
237960|NCT02379312|Dietary Supplement|Normal energy aerated beverage 2|
237961|NCT02379312|Dietary Supplement|Normal energy aerated beverage 3|
237962|NCT02379299|Device|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
237963|NCT02379299|Device|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
237964|NCT02379286|Other|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
237965|NCT02379273|Device|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
237966|NCT02379260|Other|Interview with a sociologist|
237967|NCT02379247|Drug|BYL719|Oral PI3K inhibitor
237968|NCT02379247|Drug|Nab-paclitaxel|IV taxane
237969|NCT02379234|Other|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
237970|NCT02379221|Drug|Injectable|20% benzocaine gel, 2% lidocaine, 1:100k epinephrine nerve block injection
237971|NCT02379221|Drug|Topical|4% Topicaine gel
237972|NCT02379195|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
237973|NCT02379195|Drug|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
237974|NCT02379195|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
237975|NCT02379195|Drug|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
237976|NCT02379195|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
238078|NCT02378441|Drug|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
237978|NCT02379182|Device|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
237979|NCT02379182|Device|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
237980|NCT02379169|Dietary Supplement|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
237981|NCT02379169|Dietary Supplement|Placebo|Triglycerides of medium chain fatty acids
237982|NCT02379156|Drug|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
237983|NCT02379156|Other|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
237984|NCT02379143|Other|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
237985|NCT02379130|Behavioral|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
237986|NCT02379130|Behavioral|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
237987|NCT02379104|Device|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
237988|NCT02379091|Drug|Namilumab|Namilumab subcutaneous injection
237989|NCT02379091|Drug|Placebo|Namilumab placebo-matching subcutaneous injection
237990|NCT02379091|Drug|Methotrexate|Methotrexate tablets
237991|NCT02379091|Drug|Folic/folinic acid|Folic/folinic acid tablets
237992|NCT02379078|Other|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
237993|NCT02379078|Other|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
237994|NCT02379078|Other|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
237995|NCT02379065|Device|The Aerogen Aeroneb Solo©|
237996|NCT02379065|Device|Phillips Respironic© mask|
237997|NCT02379052|Drug|Dupilumab|
237998|NCT02379052|Drug|Placebo|
237999|NCT02379026|Dietary Supplement|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
238000|NCT02379026|Behavioral|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
238001|NCT02379026|Dietary Supplement|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
238002|NCT02379013|Procedure|Volunteer with MRI|functional MRI
238003|NCT02379000|Drug|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
238004|NCT02379000|Procedure|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
238005|NCT02378974|Biological|Cordstem-ST|
238006|NCT02378974|Biological|Placebo|
238007|NCT02378961|Drug|VOX|100 mg tablet(s) administered orally once daily with food
238008|NCT02378961|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
238009|NCT02378948|Dietary Supplement|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
238079|NCT02378428|Drug|MIBG|
238012|NCT02378935|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
238013|NCT02378922|Biological|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
238014|NCT02378922|Other|Laboratory Biomarker Analysis|Correlative studies
238015|NCT02378922|Other|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
238016|NCT02378909|Device|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
238017|NCT02378896|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
238018|NCT02378896|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
238019|NCT02378883|Device|Apollo™ Onyx™ Delivery Micro Catheter|
238020|NCT02378870|Drug|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
238021|NCT02378870|Drug|Placebo|
238022|NCT02378844|Device|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
238023|NCT02378844|Device|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
238024|NCT02378818|Behavioral|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
238025|NCT02378805|Drug|ACE-inhibitor|observational study!
238026|NCT02378805|Drug|AT1-inhibitor|observational study!
238027|NCT02378805|Drug|HMG-Coenzyme inhibitor (statin)|observational study!
238028|NCT02378805|Drug|Spironolactone|observational study!
238029|NCT02378805|Drug|Paricalcitol|observational study!
238030|NCT02378792|Device|Vagus Nerve Stimulation|Vagus Nerve Stimulator
238031|NCT02378779|Other|Questionary SF12 and PEDT|12 questions are asking to the patients 5 questions are asking to the patients
238032|NCT02378779|Other|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
238033|NCT02378779|Other|Humour|Use the humour to approach the subject of premature ejaculation
238034|NCT02378779|Other|Take the drama out|Take the drama out to approach the subject of premature ejaculation
238035|NCT02378779|Other|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
238036|NCT02378779|Other|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
238037|NCT02378779|Other|Help to verbalize|Help for the patient to speak about premature ejaculation
238038|NCT02378766|Behavioral|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).~TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
238039|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
238040|NCT02378753|Biological|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
238041|NCT02378740|Drug|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
238042|NCT02378740|Drug|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
238043|NCT02378727|Device|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
238044|NCT02378727|Device|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
238045|NCT02378714|Drug|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
238046|NCT02378714|Behavioral|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.~Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
238047|NCT02378714|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
238048|NCT02378701|Behavioral|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
238049|NCT02378701|Behavioral|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
238050|NCT02378688|Drug|MT-1303|
238051|NCT02378688|Drug|Placebo|
238052|NCT02378675|Other|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
238053|NCT02378662|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
238054|NCT02378649|Drug|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
238055|NCT02378649|Drug|Placebo|Placebo comparator concomitant with best practice usual care
238056|NCT02378636|Device|600S|Monofocal Aspheric Intraocular Lens (IOL)
238057|NCT02378623|Drug|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
238058|NCT02378623|Drug|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
238059|NCT02378610|Other|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
238060|NCT02378597|Behavioral|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
238061|NCT02378584|Other|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
238062|NCT02378571|Behavioral|Medication adherence telemonitoring|The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
238063|NCT02378558|Device|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
238064|NCT02378545|Drug|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.~On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
238065|NCT02378532|Drug|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level. Based on the results of the DSMB an additional leven of 300mg was added.
238066|NCT02378532|Radiation|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
238067|NCT02378532|Drug|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
238068|NCT02378519|Behavioral|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
238069|NCT02378519|Behavioral|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
238070|NCT02378506|Biological|etanercept|50mg subcutaneous, once weekly, 24 weeks
238071|NCT02378493|Biological|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
238072|NCT02378480|Drug|Omadacycline|Injection for IV dosing; Tablets for oral dosing
238073|NCT02378480|Drug|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
238074|NCT02378467|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
238075|NCT02378467|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
238076|NCT02378454|Device|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
238077|NCT02378441|Drug|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
238652|NCT02374567|Drug|Trazodone|
238653|NCT02374567|Drug|Mirtazapine|
238082|NCT02378402|Other|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
238083|NCT02378389|Drug|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
238084|NCT02378376|Dietary Supplement|Arabinoxylan oligosaccharides|
238085|NCT02378376|Dietary Supplement|Dietary fiber enriched bran|
238086|NCT02378363|Other|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
238087|NCT02378350|Device|Hemodialysis treatment (no specific device is defined)|
238088|NCT02378350|Drug|Peritoneal Dialysis treatment (no specific drug is defined)|
238089|NCT02378337|Other|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
238090|NCT02378324|Other|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
238091|NCT02378298|Drug|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
238092|NCT02378298|Drug|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
238093|NCT02378298|Drug|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
238094|NCT02378285|Device|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
238095|NCT02378285|Other|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
238096|NCT02378272|Other|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
238097|NCT02378259|Procedure|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
238098|NCT02378259|Procedure|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
238099|NCT02378246|Dietary Supplement|Iodine|We use multivitamin tablets one with 150 microgram iodine for Active comparator and one without iodine as placebo
238100|NCT02378246|Dietary Supplement|Placebo|multivitamin tablets without iodine
238101|NCT02378233|Dietary Supplement|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
238102|NCT02378233|Dietary Supplement|Placebo|Patients are given a non-iodine containing multivitamin tablet
238103|NCT02378220|Genetic|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
238104|NCT02378207|Biological|H4:IC31|H4 contains Mtb antigens Ag85B and TB10.4
238105|NCT02378207|Biological|H56:IC31|H56 contains Mtb antigens ESAT-6, and Rv2660c
238106|NCT02378207|Biological|BCG|
238107|NCT02378207|Biological|Control Sodium Chloride 0.9%|
238108|NCT02378194|Drug|Placebo|24 weeks, once daily oral administration
238109|NCT02378194|Drug|HD-003 (800mg/day)|24 weeks, once daily oral administration
238110|NCT02378194|Drug|HD-003 (1600mg/day)|24 weeks, once daily oral administration
238111|NCT02378181|Behavioral|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
238112|NCT02378181|Behavioral|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
238113|NCT02378168|Other|no intervention; retrospective study|
238114|NCT02378155|Device|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
238115|NCT02378142|Drug|Pazopanib|
238116|NCT02378129|Drug|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
238117|NCT02378129|Drug|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
238118|NCT02378116|Procedure|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
238119|NCT02378077|Procedure|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
238120|NCT02378077|Procedure|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
238121|NCT02378077|Dietary Supplement|Fish Oil Supplement|Fish Oil supplementation for three months.
238122|NCT02378064|Drug|6-month treatment|
238123|NCT02378051|Behavioral|Staying Strong with Schools Intervention|"On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.~Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
238124|NCT02378051|Other|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
238125|NCT02378038|Drug|PNT2258|
238126|NCT02378025|Behavioral|Yoga Group|A 10-week yoga course designed to treat pain.
238127|NCT02378025|Behavioral|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
238128|NCT02378012|Other|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
238129|NCT02378012|Other|Computer-Assisted Intervention|Receive iPad and instruction manuals.
238130|NCT02378012|Other|Questionnaire Administration|Ancillary studies
238131|NCT02377999|Drug|Picato|
238132|NCT02377986|Behavioral|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
238133|NCT02377986|Behavioral|In-Home Decluttering|In-home decluttering practice
238134|NCT02377960|Behavioral|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
238135|NCT02377960|Behavioral|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
238136|NCT02377960|Behavioral|Usual care|Usual care
238137|NCT02377934|Radiation|Cardiac Magnetic Resonance Imaging (MRI)|
238138|NCT02377921|Drug|aceneuramic acid extended-release (Ace-ER)|tablets for oral use
238139|NCT02377921|Drug|Placebo|tablets for oral use
238140|NCT02377908|Other|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
238141|NCT02377895|Drug|Nasapaque Nasal Solution|
238142|NCT02377895|Drug|Placebo Saline Nasal Solution|
238143|NCT02377869|Other|No intervantion|
238144|NCT02377856|Drug|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
238145|NCT02377843|Behavioral|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making~Practice using the communication strategy via role play~Discussion on applying the communication strategy to medical practice"
238146|NCT02377843|Behavioral|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:~Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine~Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines~Practice using the communication strategy via role play~Discussion on applying the communication strategy to medical practice"
238147|NCT02377830|Device|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
238148|NCT02377830|Other|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
238149|NCT02377817|Device|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.~The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
238388|NCT02376023|Other|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
238389|NCT02376010|Drug|rivaroxaban|
238150|NCT02377817|Device|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
238151|NCT02377804|Other|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
238152|NCT02377804|Other|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
238153|NCT02377804|Device|stainless steel needles (0.3mm x 50mm)|
238154|NCT02377791|Genetic|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5*1/*1 vs CYP3A5*1/*3 or CYP3A5*3/*3
238155|NCT02377778|Drug|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
238156|NCT02377778|Drug|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
238157|NCT02377765|Device|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
238158|NCT02377765|Procedure|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
238159|NCT02377752|Biological|Olaratumab|Administered IV
238160|NCT02377752|Drug|Doxorubicin|Administered IV
238161|NCT02377739|Other|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
238162|NCT02377726|Behavioral|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
238163|NCT02377726|Behavioral|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
238164|NCT02377726|Behavioral|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
238165|NCT02377713|Drug|KHK6640|Single ascending dose administration
238166|NCT02377713|Drug|Placebo|Single ascending dose administration
238167|NCT02377700|Device|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
238168|NCT02377687|Other|observational study|
238169|NCT02377674|Device|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
238170|NCT02377661|Drug|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of < 140/90 mmHg is not reached at the respective follow-up
238171|NCT02377648|Device|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS <70%) associated with concomitant signs or symptoms of myocardial ischemia.
238172|NCT02377635|Dietary Supplement|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
238173|NCT02377635|Dietary Supplement|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
238174|NCT02377622|Device|THERANOVA 400 dialyzer prototype AA|
238175|NCT02377622|Device|THERANOVA 400 dialyzer prototype BB|
238176|NCT02377622|Device|FX CorDiax 80 Dialyzer|
238177|NCT02377622|Device|FX CorDiax 800 Dialyzer|
238178|NCT02377609|Drug|Tacrolimus|oral
238179|NCT02377570|Device|THERANOVA 400 dialyzer prototype AA|Hemodialysis
238180|NCT02377570|Device|THERANOVA 400 dialyzer prototype BB|Hemodialysis
238181|NCT02377570|Device|THERNOVA 400 dialyzer prototype CC|Hemodialysis
238182|NCT02377570|Device|FX CorDiax 80 dialyzer|Hemodialysis
238183|NCT02377557|Drug|Topical Steroids|
238184|NCT02377544|Dietary Supplement|Probiotic|
238185|NCT02377544|Other|Placebo|
238186|NCT02377531|Other|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
238390|NCT02376010|Drug|Warfarin|
238391|NCT02375997|Other|Palliative care|Early nutrition intervention and psychological intervention
238187|NCT02377531|Other|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
238188|NCT02377518|Radiation|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
238189|NCT02377505|Device|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
238190|NCT02377505|Device|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
238191|NCT02377492|Drug|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
238192|NCT02377479|Drug|Clomiphene|Taken for controlled ovarian hyperstimulation.
238193|NCT02377479|Drug|Letrozole|Taken for controlled ovarian hyperstimulation
238194|NCT02377466|Drug|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
238195|NCT02377466|Drug|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
238196|NCT02377427|Drug|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
238197|NCT02377414|Drug|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
238198|NCT02377414|Drug|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
238199|NCT02377401|Drug|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
238200|NCT02377388|Drug|sitagliptin OR saxagliptin|sitagliptin OR saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
238201|NCT02377388|Drug|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
238202|NCT02377375|Procedure|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
238203|NCT02377375|Procedure|Standard technique|Medtronic DBS lead 3391-28cm
238204|NCT02377362|Drug|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
238205|NCT02377362|Drug|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
238206|NCT02377362|Drug|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
238207|NCT02377362|Drug|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
238208|NCT02377362|Drug|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
238209|NCT02377362|Drug|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
238210|NCT02377349|Biological|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
238211|NCT02377349|Drug|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
238212|NCT02377336|Drug|GS-6615|GS-6615 tablets administered orally
238213|NCT02377336|Drug|Placebo|Placebo to match GS-6615 tablets administered orally
238214|NCT02377323|Other|MACFIMS|Cognitive evaluation of 50 participants
238215|NCT02377323|Other|MSQoL-54|Quality of life questionnaires
238216|NCT02377297|Procedure|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
238217|NCT02377297|Procedure|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
238218|NCT02377297|Procedure|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
238219|NCT02377284|Other|Photograph|Add a photograph to a chef card.
238220|NCT02377271|Drug|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
238221|NCT02377271|Drug|placebo|treatment by bosentan or placebo is randomized
238222|NCT02377258|Other|Non Interventional|
238223|NCT02377232|Behavioral|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
238224|NCT02377232|Behavioral|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
238225|NCT02377219|Other|hormonal and blood analysis|
238226|NCT02377206|Other|ADAS-Cog evaluation|[18F]DPA-714 PET imaging
238227|NCT02377193|Drug|Simulect|"Simulect IV 40 mg/day D0 and D4~and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
238228|NCT02377193|Drug|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
238229|NCT02377180|Procedure|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
238230|NCT02377180|Procedure|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.~Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
238231|NCT02377180|Procedure|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
238654|NCT02374567|Drug|Bupropion|
238232|NCT02377167|Procedure|Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
238233|NCT02377154|Device|Slit lamp|Examination of cornea
238234|NCT02377154|Device|Autorefractor|Measurement of refraction
238235|NCT02377154|Device|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
238236|NCT02377154|Device|Pentacam HR|Measurement of white-to-white distance; Keratometry
238237|NCT02377154|Device|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
238238|NCT02377154|Device|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
238239|NCT02377141|Procedure|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
238240|NCT02377141|Procedure|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
238241|NCT02377128|Procedure|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
238242|NCT02377128|Procedure|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
238243|NCT02377115|Other|Tablet computer application|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
238244|NCT02377102|Procedure|Physical Therapy|12 weeks of supervised physical therapy.
238245|NCT02377089|Device|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
238246|NCT02377089|Device|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
238247|NCT02377076|Dietary Supplement|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
238248|NCT02377076|Dietary Supplement|Control|Control (Whey protein, vitamin D, sugar and salt)
238249|NCT02377063|Dietary Supplement|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
238250|NCT02377050|Other|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
238251|NCT02377037|Other|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
238252|NCT02377024|Dietary Supplement|TF 600mg|
238253|NCT02377024|Dietary Supplement|TF 1200mg|
238254|NCT02377024|Dietary Supplement|placebo|
238255|NCT02377011|Behavioral|Problem solving cognitive behaviour therapy (PS CBT)|
238256|NCT02376998|Device|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:~The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.~After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
238257|NCT02376985|Procedure|Oral management|
238258|NCT02376985|Drug|Everolimus|
238259|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
238260|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
238261|NCT02376972|Drug|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
238262|NCT02376972|Drug|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
238263|NCT02376959|Behavioral|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.~The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
238264|NCT02376946|Device|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
238265|NCT02376946|Device|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
238266|NCT02376933|Procedure|Vertebroplasty|Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
238267|NCT02376933|Radiation|Radiotherapy|Radiotherapy of metastatic lesions to the spine.
238268|NCT02376907|Procedure|Biliary drainage|EUS-BD or ERCP
238269|NCT02376881|Drug|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
238270|NCT02376881|Other|placebo|100 ml normal saline in 2 hr for 3 successive days
238271|NCT02376868|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
238272|NCT02376868|Device|iVue|OCT machines used for diagnostic purposes
238273|NCT02376855|Other|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
238274|NCT02376842|Behavioral|Severe sepsis early warning best practice alert|
238275|NCT02376842|Behavioral|Standard care|
238276|NCT02376829|Device|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
238277|NCT02376816|Biological|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
238278|NCT02376803|Drug|Warfarin|Morning vs Evening administration
238279|NCT02376790|Drug|Etanercept|Etanercept was administered by subcutaneous injection once a week
238280|NCT02376790|Drug|Methotrexate|Methotrexate capsules taken orally once a week. Dosing was initiated at 10 mg weekly and titrated up to a final dose of 20 mg weekly over a 4-week period.
238281|NCT02376790|Drug|Placebo to Etanercept|Placebo to etanercept was administered by subcutaneous injection once a week.
238282|NCT02376790|Drug|Placebo to Methotrexate|Placebo to methotrexate capsules taken orally once a week.
238283|NCT02376777|Other|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
238284|NCT02376764|Procedure|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
238285|NCT02376751|Drug|sebelipase alfa|
238286|NCT02376725|Procedure|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
238287|NCT02376725|Procedure|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
238288|NCT02376699|Drug|Intravenous (IV) SEA-CD40|Given intravenously; schedule is cohort-specific.
238289|NCT02376699|Drug|Pembrolizumab|Given intravenously; schedule is cohort-specific.
238290|NCT02376699|Drug|Subcutaneous (SC) SEA-CD40|Given subcutaneously on Day 1 every 3 weeks
238291|NCT02376699|Drug|Gemcitabine|1000 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
238292|NCT02376699|Drug|Nab-paclitaxel|125 mg/m^2 given intravenously on Day 1, 8, and 15 of each 28-day cycle
238293|NCT02376686|Other|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
238294|NCT02376673|Other|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
238295|NCT02376673|Other|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
238296|NCT02376660|Other|Oats|
238297|NCT02376647|Other|Driving pressure limited ventilation|"Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.~Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment."
238298|NCT02376647|Other|Conventional ventilation|Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
238299|NCT02376634|Behavioral|Hypnosis|Patients will be taught self-hypnosis.
238300|NCT02376621|Dietary Supplement|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
238301|NCT02376621|Dietary Supplement|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
238302|NCT02376621|Dietary Supplement|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
238303|NCT02376621|Dietary Supplement|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
238304|NCT02376621|Dietary Supplement|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
238549|NCT02374749|Behavioral|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
238305|NCT02376608|Dietary Supplement|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
238306|NCT02376608|Dietary Supplement|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
238307|NCT02376608|Dietary Supplement|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
238308|NCT02376608|Dietary Supplement|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
238309|NCT02376595|Drug|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
238310|NCT02376582|Biological|DNA|DNA co-administered with protein at month 0, 1 and 6
238311|NCT02376582|Biological|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
238312|NCT02376543|Device|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
238313|NCT02376543|Device|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
238314|NCT02376530|Behavioral|Nutrient profiling|Nutrient profiling system will be present during shopping session.
238315|NCT02376530|Behavioral|Price Changes|Price changes will be present during shopping session.
238316|NCT02376517|Behavioral|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
238317|NCT02376504|Behavioral|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
238318|NCT02376491|Device|Transcranial magnetic stimulation|
238319|NCT02376478|Drug|TNF-alpha inhibitors|therapy for at least 6 months
238320|NCT02376478|Drug|Alternative/no medication|therapy for at least 6 months or no therapy
238321|NCT02376478|Other|Alternative/no medication|phototherapy for at least 6 months
238322|NCT02376478|Drug|Purine/folic acid analogues|therapy for at least 6 months
238323|NCT02376465|Drug|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
238324|NCT02376465|Drug|PEG based bowel preparation|Oral bowel preparation for colonoscopy
238325|NCT02376452|Drug|Raltitrexed|2mg/m2 iv gtt, d1
238326|NCT02376452|Drug|Irinotecan|180 mg/m2 iv gtt, d1
238327|NCT02376452|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
238328|NCT02376452|Drug|Leucovorin|400mg/m2 iv gtt,d1
238329|NCT02376439|Other|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
238330|NCT02376426|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.
238331|NCT02376426|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.
238332|NCT02376426|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
238333|NCT02376413|Procedure|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
238334|NCT02376413|Drug|Chemotherapy or endocrine therapy or Trastuzumab therapy|
238335|NCT02376413|Radiation|Radiation therapy|
238336|NCT02376400|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29 or 57.
238337|NCT02376400|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29 or 57.
238338|NCT02376400|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
238339|NCT02376374|Other|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
238340|NCT02376361|Device|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).~Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines~Recirculation, access flow will be performed according to HD03 Manual.~Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
238341|NCT02376348|Behavioral|A targeted demand creation Activities|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
238392|NCT02375984|Biological|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
238393|NCT02375971|Drug|Ranibizumab|Administered as an intravitreal injection
238342|NCT02376335|Biological|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
238343|NCT02376335|Other|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
238344|NCT02376322|Radiation|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
238345|NCT02376309|Behavioral|Inactivity|Inactivity
238346|NCT02376309|Drug|ND|1 nandrolone decanoate injection
238347|NCT02376309|Dietary Supplement|Leu|Leucine supplements
238348|NCT02376296|Drug|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
238349|NCT02376296|Other|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
238350|NCT02376283|Drug|Prasugrel|
238351|NCT02376283|Drug|Clopidogrel|
238352|NCT02376283|Drug|ticagrelor|
238353|NCT02376270|Dietary Supplement|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
238354|NCT02376270|Dietary Supplement|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
238355|NCT02376257|Drug|250 mg DCS|Drug
238356|NCT02376257|Drug|100 mg Modafinil|Drug
238357|NCT02376257|Drug|Placebo|Drug
238358|NCT02376244|Other|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
238359|NCT02376244|Other|Standard care|Standard care cardiac rehabilitation according to current guidelines
238360|NCT02376231|Device|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
238361|NCT02376218|Drug|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
238362|NCT02376205|Drug|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
238363|NCT02376205|Drug|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
238364|NCT02376192|Device|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
238365|NCT02376192|Drug|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
238366|NCT02376192|Device|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
238367|NCT02376192|Drug|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
238368|NCT02376192|Drug|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
238369|NCT02376179|Device|Cuffed ETT|
238370|NCT02376166|Drug|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade > 1 toxicities)
238371|NCT02376153|Device|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
238372|NCT02376153|Device|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
238373|NCT02376127|Procedure|Dynamic contrast enhancement MRI|
238374|NCT02376114|Drug|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
238375|NCT02376114|Drug|Placebo to Ginkgo biloba|
238376|NCT02376101|Procedure|Surgery less than 60 minutes|
238377|NCT02376088|Drug|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
238378|NCT02376075|Drug|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
238379|NCT02376075|Drug|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
238380|NCT02376062|Other|Bundled Intervention|"The authors have designed continuing medical education curriculum to improve clinical capacity and competency about mental health for Nepali Primary Care Providers. Specifically:~On-site care coordinator and off-site psychiatric supervisors based in Nepal's capital, Kathmandu~Weekly case conferences~Surveys of clinicians and clinical supervisors in accordance with CME curriculum"
238381|NCT02376049|Drug|Pimecrolimus cream|
238382|NCT02376049|Drug|Betamethasone dipropionate cream|
238383|NCT02376049|Drug|Clobetasol propionate cream|
238384|NCT02376049|Drug|Glaxal Base cream vehicle|
238385|NCT02376036|Drug|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
238386|NCT02376036|Drug|Placebo|Placebo comparator.
238394|NCT02375971|Procedure|Laser therapy|Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
238395|NCT02375958|Drug|PCA062|
238396|NCT02375945|Device|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
238397|NCT02375945|Device|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
238398|NCT02375932|Behavioral|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
238399|NCT02375932|Behavioral|Usual Care Control|Patients continue to receive usual care from their primary care provider
238400|NCT02375919|Other|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
238401|NCT02375893|Other|No intervention|Collecting blood and feces samples
238402|NCT02375893|Other|Healthy subject|Collecting blood and feces samples
238403|NCT02375880|Drug|DKN-01|Administration by intravenous (IV) infusion.
238404|NCT02375880|Drug|gemcitabine|Administered by IV infusion.
238405|NCT02375880|Drug|cisplatin|Administered by IV infusion
238406|NCT02375867|Drug|prednisolone|Oral administration of 1 mg/Kg/day
238407|NCT02375867|Drug|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
238408|NCT02375854|Other|Observation|
238409|NCT02375841|Behavioral|psychometric tests, questionnaires and neurocognitive assessments|
238410|NCT02375828|Drug|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
238411|NCT02375815|Other|Statin Choice Implementation|
238412|NCT02375802|Biological|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
238413|NCT02375802|Drug|Adipose-derived stromal cells|
238414|NCT02375789|Device|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.~The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
238415|NCT02375789|Device|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
238416|NCT02375776|Other|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
238417|NCT02375763|Other|Software instruction|
238418|NCT02375750|Device|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
238419|NCT02375750|Other|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
238420|NCT02375737|Behavioral|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
238421|NCT02375724|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
238422|NCT02375724|Drug|Placebo|Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
238423|NCT02375711|Biological|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
238424|NCT02375698|Biological|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
238425|NCT02375698|Biological|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
238426|NCT02375685|Biological|Gevokizumab|
238427|NCT02375672|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
238428|NCT02375672|Drug|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)~Oxaliplatin 85 mg/m^2 IV with~Leucovorin 400 mg/m^2 IV followed by~5FU 400 mg/m^2 bolus and then 2400 mg/m^2 via continuous infusion"
238429|NCT02375646|Drug|Warfarin|
238430|NCT02375646|Drug|LMW Heparin|
238431|NCT02375633|Drug|DW-330SR2|
238432|NCT02375633|Drug|Pelubiprofen|
238433|NCT02375620|Biological|PEG-somatropin|
238434|NCT02375607|Device|Algometer|Algometer performed patients
238435|NCT02375594|Other|Exercise in park equipment|
238436|NCT02375581|Drug|Icotinib|125mg, Po, TID during RT
238437|NCT02375581|Radiation|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
238438|NCT02375568|Other|103024-F|mesenchymal stem cell isolation
238439|NCT02375555|Drug|Lenalidomide|
238440|NCT02375555|Drug|Elotuzumab|
238441|NCT02375555|Drug|Bortezomib|
238442|NCT02375555|Drug|Dexamethasone|
238443|NCT02375555|Procedure|Stem Cell Mobilization|
238550|NCT02374749|Behavioral|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
238655|NCT02374567|Drug|Venlafaxine|
238656|NCT02374567|Drug|Reboxetine|
238444|NCT02375529|Procedure|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
238445|NCT02375529|Procedure|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.~Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
238446|NCT02375516|Behavioral|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
238447|NCT02375503|Dietary Supplement|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
238448|NCT02375503|Dietary Supplement|Placebo|
238449|NCT02375490|Behavioral|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal, interpersonal, organizational, community and physical environment and political levels. These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
238450|NCT02375477|Other|Educational Intervention|Given educational presentation
238451|NCT02375464|Drug|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
238452|NCT02375451|Other|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
238453|NCT02375425|Other|no intervention|no intervention-specimen collection study only
238454|NCT02375412|Procedure|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
238455|NCT02375386|Procedure|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
238456|NCT02375386|Procedure|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
238457|NCT02375386|Procedure|fMRI|Both groups will receive an fMRI.
238458|NCT02375386|Behavioral|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
238459|NCT02375386|Other|Questionnaires|Both groups will receive Questionnaires
238460|NCT02375386|Behavioral|Physical Impairment|Both groups will receive testing on physical impairment.
238461|NCT02375373|Other|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.~Fecal samples collected monthly."
238462|NCT02375360|Other|Oral immunotherapy|
238463|NCT02375347|Other|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.~Stool Samples collected at Day 1, Day 9, and Day 14."
238464|NCT02375334|Other|Medical Chart Review|Medical chart review by the Cancer Center ORIS and EPIC based systems
238465|NCT02375321|Behavioral|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
238466|NCT02375308|Behavioral|HDT|20 sessions, individual psychotherapy
238467|NCT02375308|Behavioral|ACDT|20 sessions, individual psychotherapy
238468|NCT02375295|Drug|ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin|Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
238504|NCT02375100|Procedure|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
238629|NCT02374567|Drug|Zaleplon|
238630|NCT02374567|Drug|Melatonin|
238631|NCT02374567|Drug|Clomethiazole|
238632|NCT02374567|Drug|Diphenhydramine|
238633|NCT02374567|Drug|Promethazine|
238634|NCT02374567|Drug|Imipramine|
238469|NCT02375282|Procedure|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
238470|NCT02375269|Device|RIPC with a tourniquet|
238471|NCT02375256|Biological|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
238472|NCT02375256|Biological|Placebo|Identical buffer solution in which AERAS-402 is formulated.
238473|NCT02375256|Biological|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
238474|NCT02375243|Drug|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
238475|NCT02375230|Procedure|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
238476|NCT02375230|Procedure|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
238477|NCT02375217|Drug|Sugammadex|half dose
238478|NCT02375217|Drug|Sugammadex|full dose
238479|NCT02375217|Drug|Neostigmine|IV = 50mcg/kg
238480|NCT02375217|Drug|glycopyrrolate|
238481|NCT02375204|Drug|paclitaxel|IV
238482|NCT02375204|Drug|ifosfamide|IV
238483|NCT02375204|Drug|cisplatin|IV
238484|NCT02375204|Drug|pegylated G-CSF|IV
238485|NCT02375204|Drug|G-CSF|IV
238486|NCT02375204|Drug|carboplatin|IV
238487|NCT02375204|Drug|etoposide phosphate|IV
238488|NCT02375204|Procedure|stem cell reinfusion|surgical procedure
238489|NCT02375191|Drug|fentanyl|
238490|NCT02375191|Drug|dexmedetomidine|
238491|NCT02375191|Drug|Ropivacaine|
238492|NCT02375178|Drug|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
238493|NCT02375178|Drug|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
238494|NCT02375178|Drug|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
238495|NCT02375165|Procedure|phlebotomy|phlebotomy for collection of plasma and serum, ~30 cc
238496|NCT02375165|Other|Measurement of skin thickness by caliper|For each subject, at each assessment, 3 measurements will be obtained: the dorsum of the hand (or foot); the midpoint of the volar aspect of the forearm (or medial aspect of the calf); and the midpoint of the medial aspect of the upper arm (or thigh). At the initial evaluation, a dermatographic pencil is used to mark the site of each measurement. Once the locations were determined, the exact distance of each location is measured from the wrist or lateral malleolus. These locations are then reutilized when serial measurements are obtained. The calipers are calibrated prior to each use.
238497|NCT02375165|Other|Limb volume quantitation by circumferential measurements|"Limb volume will be measured through serial quantitation of the limb circumference at 4-cm intervals along its long axis. The procedure is performed with gauged tape to ensure a uniform stretching force.~Using these measurements, the volume of the limb is calculated with the truncated cone approximation."
238498|NCT02375152|Procedure|Anterior Capsulotomy|
238499|NCT02375139|Drug|DA-1229_01|complex single administration
238500|NCT02375139|Drug|E+M|co-administration of 2 drugs
238501|NCT02375126|Procedure|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
238502|NCT02375113|Dietary Supplement|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.~Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
238503|NCT02375100|Procedure|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
238548|NCT02374788|Behavioral|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
238505|NCT02375100|Procedure|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
238506|NCT02375100|Drug|Bupivacaine %0.5 (hyperbaric)|
238507|NCT02375100|Drug|Bupivacaine %0.25 (isobaric)|
238508|NCT02375100|Device|25G Quincke needle|
238509|NCT02375100|Device|Echogenic Needle with 30° bevel|
238510|NCT02375100|Drug|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
238511|NCT02375100|Drug|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
238512|NCT02375074|Behavioral|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
238513|NCT02375074|Behavioral|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
238514|NCT02375061|Behavioral|e-BPS|
238515|NCT02375061|Behavioral|Daily Activities|
238516|NCT02375048|Radiation|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
238517|NCT02375048|Radiation|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
238518|NCT02375035|Device|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
238519|NCT02375022|Drug|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
238520|NCT02375009|Procedure|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
238521|NCT02374983|Other|Gamma knife radiosurgery re-planning with convolution algorithm|"The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.~Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms."
238522|NCT02374970|Other|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
238523|NCT02374970|Other|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
238524|NCT02374957|Drug|Cilostazol|100 mg twice daily for 90 days
238525|NCT02374944|Procedure|Hardware removal|
238526|NCT02374931|Drug|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
238527|NCT02374931|Procedure|Positron Emission Tomography|Undergo 18F-FES PET/CT
238528|NCT02374931|Procedure|Computed Tomography|Undergo 18F-FES PET/CT
238529|NCT02374931|Other|Laboratory Biomarker Analysis|Correlative studies
238530|NCT02374918|Device|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
238531|NCT02374918|Device|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
238532|NCT02374918|Device|HC wavelength-1 bright light|30 minutes of light exposure
238533|NCT02374918|Device|HC wavelength-2 bright light|30 minutes of light exposure
238534|NCT02374905|Device|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
238535|NCT02374905|Behavioral|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
238536|NCT02374892|Behavioral|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
238537|NCT02374879|Device|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
238538|NCT02374866|Other|closer monitoring|
238539|NCT02374853|Drug|Vancomycin|Topical prophylactic antibiotic
238540|NCT02374853|Other|No Vancomycin|Placebo: Sterile water. No Vancomycin.
238541|NCT02374827|Procedure|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
238542|NCT02374827|Procedure|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
238543|NCT02374814|Drug|Rabies vaccine|Compare dose schedule and route of administration
238544|NCT02374814|Drug|Placebo|Placebo
238545|NCT02374801|Device|"SonR automatic optimization feature turned ON (AV+VV)."|
238546|NCT02374788|Behavioral|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
238547|NCT02374788|Behavioral|Group meetings|Participants receive 12 group meetings over two years' time.
238635|NCT02374567|Drug|Clomipramine|
238551|NCT02374736|Drug|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).~Privigen will be provided in vials containing 10 g IgG in 100 mL."
238552|NCT02374723|Device|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
238553|NCT02374723|Device|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
238554|NCT02374710|Procedure|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
238555|NCT02374710|Procedure|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
238556|NCT02374697|Device|During tele-expertise|
238557|NCT02374684|Drug|Methosulide|"Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
238558|NCT02374684|Drug|Placebo|Placebo to match with experimental groups
238559|NCT02374671|Device|VisAbility Micro Insert|The VisAbility Micro Insert (Model SGP-046) is an injection molded curved scleral implant molded from PMMA (polymethylmethacrylate), a material with an extensive history of long-term implantation in the human eye, including intraocular lenses (IOLs). Four (4) VisAbility Micro Insert segments are placed in a single presbyopic eye to improve near vision.
238560|NCT02374658|Behavioral|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
238561|NCT02374645|Drug|Volitinib|600mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
238562|NCT02374645|Drug|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
238563|NCT02374645|Drug|Volitinib|800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
238564|NCT02374632|Other|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
238565|NCT02374632|Other|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
238566|NCT02374632|Other|Sham feeding|
238567|NCT02374619|Dietary Supplement|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement [Resoferon Ferrous Sulfate 125 (37) mg]
238568|NCT02374619|Dietary Supplement|Placebo|
238569|NCT02374593|Drug|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
238570|NCT02374593|Device|Ultrasound|
238571|NCT02374567|Drug|Phenobarbital|
238572|NCT02374567|Drug|Phenytoin|
238573|NCT02374567|Drug|Carbamazepine|
238574|NCT02374567|Drug|Oxcarbazepine|
238575|NCT02374567|Drug|Valproic Acid|
238576|NCT02374567|Drug|Lamotrigine|
238577|NCT02374567|Drug|Topiramate|
238578|NCT02374567|Drug|Gabapentin|
238579|NCT02374567|Drug|Levetiracetam|
238580|NCT02374567|Drug|Pregabalin|
238581|NCT02374567|Drug|Lacosamide|
238582|NCT02374567|Drug|Clonazepam|
238583|NCT02374567|Drug|Biperiden|
238584|NCT02374567|Drug|Levomepromazine|
238585|NCT02374567|Drug|Fluphenazine|
238586|NCT02374567|Drug|Perphenazine|
238587|NCT02374567|Drug|Perazine|
238588|NCT02374567|Drug|Thioridazine|
238589|NCT02374567|Drug|Haloperidol|
238590|NCT02374567|Drug|Melperone|
238591|NCT02374567|Drug|Pipamperone|
238592|NCT02374567|Drug|Bromperidol|
238593|NCT02374567|Drug|Benperidol|
238594|NCT02374567|Drug|Sertindole|
238595|NCT02374567|Drug|Ziprasidone|
238596|NCT02374567|Drug|Flupentixol|
238597|NCT02374567|Drug|Chlorprothixene|
238598|NCT02374567|Drug|Zuclopenthixol|
238599|NCT02374567|Drug|Fluspirilene|
238600|NCT02374567|Drug|Pimozide|
238601|NCT02374567|Drug|Clozapine|
238602|NCT02374567|Drug|Olanzapine|
238603|NCT02374567|Drug|Quetiapine|
238604|NCT02374567|Drug|Sulpiride|
238605|NCT02374567|Drug|Tiapride|
238606|NCT02374567|Drug|Amisulpride|
238607|NCT02374567|Drug|Prothipendyl|
238608|NCT02374567|Drug|Risperidone|
238609|NCT02374567|Drug|Aripiprazole|
238610|NCT02374567|Drug|Paliperidone|
238611|NCT02374567|Drug|Diazepam|
238612|NCT02374567|Drug|Oxazepam|
238613|NCT02374567|Drug|Lorazepam|
238614|NCT02374567|Drug|Bromazepam|
238615|NCT02374567|Drug|Clobazam|
238616|NCT02374567|Drug|Alprazolam|
238617|NCT02374567|Drug|Hydroxyzine|
238618|NCT02374567|Drug|Buspirone|
238619|NCT02374567|Drug|Chloral Hydrate|
238620|NCT02374567|Drug|Flurazepam|
238621|NCT02374567|Drug|Nitrazepam|
238622|NCT02374567|Drug|Triazolam|
238623|NCT02374567|Drug|Lormetazepam|
238624|NCT02374567|Drug|Temazepam|
238625|NCT02374567|Drug|Midazolam|
238626|NCT02374567|Drug|Brotizolam|
238627|NCT02374567|Drug|Zopiclone|
238628|NCT02374567|Drug|Zolpidem|
238668|NCT02374554|Device|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
238669|NCT02374554|Device|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
238670|NCT02374541|Behavioral|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
238671|NCT02374528|Procedure|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
238672|NCT02374528|Procedure|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
238673|NCT02374515|Device|EndoCuff-assisted colonoscopy|Adenoma detection rate
238674|NCT02374515|Device|Standard Colonoscopy|
238675|NCT02374502|Behavioral|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
238676|NCT02374489|Drug|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
238677|NCT02374476|Device|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
238678|NCT02374463|Behavioral|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
238679|NCT02374463|Behavioral|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
238680|NCT02374450|Procedure|Lumbar puncture|For all enrolled children, hospitalised and suspected of a neurological AESI or meningitis, where a cerebrospinal fluid (CSF) sample has been taken as part of routine practice, part of the CSF sample will be stored for this study (minimum 500 µL).
238681|NCT02374450|Procedure|Venous blood sample|Approximately 5 mL of whole blood will be collected from all enrolled children, hospitalised and suspected of having an AESI or meningitis, and the serum will be stored.
238682|NCT02374437|Drug|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
238683|NCT02374437|Drug|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
238684|NCT02374424|Drug|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~Dexamethasone 40 mg day 1-4 of every cycles~Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
238685|NCT02374398|Drug|Tranexamic Acid|see arm/group descriptions
238686|NCT02374398|Device|Aquamantys System|see arm/group descriptions
238687|NCT02374398|Other|Control|Standard Electro-cautery and Saline
238688|NCT02374385|Biological|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
238689|NCT02374385|Other|Placebo|Normal saline
238690|NCT02374372|Device|conventional hemodialysis|
238691|NCT02374372|Device|hemodiafiltration On-line|
238692|NCT02374359|Other|follow-up|
238693|NCT02374333|Biological|huCART19|
238694|NCT02374320|Drug|liposomal bupivacaine|injected as an axillary block
238695|NCT02374307|Other|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
238696|NCT02374294|Device|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
238697|NCT02374281|Drug|Glucose sucking|
238698|NCT02374281|Drug|Water sucking|
238699|NCT02374281|Other|No sucking|
238700|NCT02374268|Behavioral|Exercise program alone|
238701|NCT02374268|Dietary Supplement|Combined exercise program and nutrition supplement|
238702|NCT02374268|Other|Waitlist control group|
238703|NCT02374255|Behavioral|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
238704|NCT02374242|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD‐1 (programmed death‐1 or programmed cell death‐1/PCD‐1) with immunopotentiation activity.
238705|NCT02374242|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4). CTLA‐4 is a negative regulator of T‐cell activation. Ipilimumab binds to CTLA‐4 and blocks the interaction of CTLA‐4 with its ligands, CD80/CD86. Blockade of CTLA‐4 has been shown to augment T‐cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T‐cell mediated anti‐tumour immune responses.
238706|NCT02374229|Procedure|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
238707|NCT02374229|Procedure|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
238708|NCT02374216|Procedure|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
238709|NCT02374203|Dietary Supplement|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
238710|NCT02374190|Other|Standard Hospital Care|Retrospective, observational analysis will be used to examine the relationship between pre‐admission patient characteristics (as available), acute clinical management and patient outcomes. Standard hospital care is here defined as interventional (e.g., primary angioplasty) and pharmaceutical (e.g., warfarin, beta-blockers) care provided to patients during index hospitalization for MI.
238711|NCT02374164|Drug|Febuxostat XR|Febuxostat XR capsules
238712|NCT02374151|Device|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
238713|NCT02374138|Behavioral|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
238714|NCT02374138|Other|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
238715|NCT02374125|Device|Diacutaneous Fibrolysis|Applied only around teres major muscle.
238716|NCT02374125|Other|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
238717|NCT02374125|Other|Protocolized physiotherapy|Exercises, TENS and cryotherapy
238718|NCT02374112|Dietary Supplement|Creatine|Creatine supplementation
238719|NCT02374112|Other|Placebo|Placebo supplementation
238720|NCT02374099|Drug|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
238721|NCT02374099|Drug|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
238722|NCT02374086|Behavioral|Exercise training|
238723|NCT02374073|Other|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
238724|NCT02374073|Other|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
238725|NCT02374060|Drug|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
238726|NCT02374060|Drug|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
238727|NCT02374060|Drug|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
238728|NCT02374047|Drug|CAT-2054|
238729|NCT02374047|Drug|Placebo|
238730|NCT02374047|Drug|CAT-2054-C|
238731|NCT02374047|Drug|Atorvastatin|
238732|NCT02374034|Other|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
238733|NCT02374021|Drug|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
238734|NCT02374021|Drug|Sulfasalazine|1 gm bid
238735|NCT02374021|Drug|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
238736|NCT02374021|Drug|Etanercept|50 mg SC weekly
238737|NCT02374021|Drug|Adalimumab|40 mg SQ every other week
238738|NCT02374008|Drug|Ropivacaine|
238739|NCT02373995|Biological|LAB4|Additional treatment with the specific LAB4 probiotic preparation
238740|NCT02373956|Device|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
238741|NCT02373956|Procedure|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
238742|NCT02373943|Other|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
238821|NCT02373423|Other|Advocacy|See above for description
239221|NCT02370589|Biological|Matrix-M Adjuvant|
238743|NCT02373943|Other|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
238744|NCT02373943|Other|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
238745|NCT02373930|Drug|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
238746|NCT02373930|Drug|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
238747|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
238748|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
238749|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
238750|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
238751|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
238752|NCT02373904|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
238753|NCT02373891|Drug|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
238754|NCT02373891|Drug|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
238755|NCT02373878|Behavioral|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
238756|NCT02373878|Behavioral|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
238757|NCT02373865|Drug|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
238758|NCT02373865|Drug|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
238759|NCT02373865|Drug|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
238760|NCT02373865|Drug|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
238761|NCT02373852|Device|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
238762|NCT02373839|Other|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
238763|NCT02373813|Drug|etanercept pre-filled syringe sq injection|etanercept for injection in pre-filled syringes
238764|NCT02373813|Drug|Oral methotrexate|methotrexate capsules
238765|NCT02373813|Drug|Placebo for etanercept sq injection|etanercept placebo for injection in pre-filled syringes
238766|NCT02373813|Drug|Placebo for methotrexate|methotrexate placebo capsules
238767|NCT02373800|Device|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
238768|NCT02373787|Device|creos xenoprotect|Implant placement with simultaneous bone augmentation
238769|NCT02373787|Device|Bio-Gide|resorbable collagen membrane
238770|NCT02373774|Device|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
238771|NCT02373761|Device|Stryker Triathlon Tritanium primary knee|
238772|NCT02373748|Device|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
238773|NCT02373735|Other|crystalloid|Group A (SVV <10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
238774|NCT02373735|Other|colloid|Group A (SVV <10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is > 20%
238775|NCT02373735|Other|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is < 10%
238776|NCT02373735|Other|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is < 10%
238777|NCT02373722|Procedure|Mohs Surgery|Undergo Mohs surgery
238778|NCT02373722|Other|Internet-Based Intervention|Watch website application based educational video
238779|NCT02373722|Behavioral|Telephone-Based Intervention|Receive text messages
238780|NCT02373722|Other|Educational Intervention|Watch website application based educational video
238781|NCT02373722|Behavioral|Exercise Intervention|Use Fitbit
238782|NCT02373722|Other|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
238783|NCT02373722|Other|Questionnaire Administration|Ancillary studies
238784|NCT02373722|Other|Survey Administration|Ancillary studies
238785|NCT02373683|Device|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
238786|NCT02373670|Behavioral|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
238787|NCT02373670|Behavioral|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
238788|NCT02373657|Behavioral|instruction in soap-making and hygiene education|
239268|NCT02370264|Other|Medical Chart Review|Ancillary studies
238789|NCT02373644|Other|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
238790|NCT02373644|Other|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
238791|NCT02373631|Other|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
238792|NCT02373631|Other|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
238793|NCT02373618|Other|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
238794|NCT02373618|Other|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
238795|NCT02373605|Other|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
238796|NCT02373605|Other|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
238797|NCT02373592|Behavioral|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.~During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.~Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
238798|NCT02373592|Device|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
238799|NCT02373579|Drug|Omega-3 Fatty Acids|"study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .~Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
238800|NCT02373579|Drug|Methotrexate|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
238801|NCT02373566|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
238802|NCT02373553|Other|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
238803|NCT02373553|Other|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
238804|NCT02373540|Device|Algovita Spinal Cord Stimulation system|
238805|NCT02373527|Other|No Fasting prior to catheterization|No restriction for oral intake
238806|NCT02373514|Drug|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
238807|NCT02373514|Drug|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
238808|NCT02373501|Procedure|Intra-abdominal repair|Intra abdominal repair of uterine incision
238809|NCT02373501|Procedure|Extra-abdominal repair|Extra abdominal repair of uterine incision
238810|NCT02373488|Other|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
238811|NCT02373488|Other|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
238812|NCT02373488|Other|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
238813|NCT02373475|Other|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
238814|NCT02373475|Other|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
238815|NCT02373462|Drug|Olmesartan|
238816|NCT02373462|Drug|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
238817|NCT02373449|Other|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
238818|NCT02373449|Drug|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
238819|NCT02373436|Other|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.~The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.~The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:~The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.~The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.~The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
238820|NCT02373436|Other|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
238822|NCT02373410|Procedure|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
238823|NCT02373410|Procedure|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
238824|NCT02373410|Procedure|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
238825|NCT02373410|Procedure|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
238826|NCT02373410|Drug|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
238827|NCT02373410|Drug|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
238828|NCT02373410|Drug|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
238829|NCT02373410|Drug|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
238830|NCT02373397|Device|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
238831|NCT02373397|Device|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
238832|NCT02373384|Drug|Oral alkalinization (Potassium citrate, Allopurinol)|"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy~Potassium citrate 20 mEq three times daily~Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:~Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."
238833|NCT02373384|Behavioral|Life style modification|"Eligible patients, who fulfilled the study criteria, will be also instructed for;~Adequate fluid intake in order to maintain urine volume between 2-3 L per day."
238834|NCT02373384|Dietary Supplement|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
238835|NCT02373371|Drug|Metvix®|
238836|NCT02373371|Procedure|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
238837|NCT02373371|Procedure|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
238838|NCT02373358|Behavioral|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
238839|NCT02373332|Other|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
238840|NCT02373319|Behavioral|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
238841|NCT02373319|Behavioral|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
238842|NCT02373319|Behavioral|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
238843|NCT02373319|Behavioral|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
238844|NCT02373306|Procedure|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
238845|NCT02373280|Drug|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
238846|NCT02373280|Drug|7 day tailored PPI triple therapy (clarithromycin-containing triple therapy)|the participants received PPI based triple therapy[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)]
238847|NCT02373280|Drug|7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|moxifloxacin triple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)].
238848|NCT02373280|Drug|7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)|bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
238849|NCT02373267|Biological|Technozyme|determination of ADAMTS13 activity
238850|NCT02373254|Drug|Ibuprofen|Ibuprofen 400 mg and 800 mg
238851|NCT02373254|Drug|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
238852|NCT02373241|Drug|Losartan|Standard dosing
238853|NCT02373241|Drug|Losartan|Experimental dosing
238854|NCT02373228|Other|Audio signal processing (applied offline before playback)|
238855|NCT02373215|Drug|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
238856|NCT02373202|Drug|Sarilumab|Pharmaceutical form:solution
238857|NCT02373202|Drug|Sulfasalazine|Pharmaceutical form: Tablet Route of administration: Oral
238858|NCT02373202|Drug|Leflunomide|Pharmaceutical form: Tablet Route of administration: Oral
238859|NCT02373202|Drug|Bucillamine|Pharmaceutical form: Tablet Route of administration: Oral
238860|NCT02373202|Drug|Tacrolimus|Pharmaceutical form: Capsule Route of administration: Oral
238861|NCT02373202|Drug|Mizoribine|Pharmaceutical form: Tablet Route of administration: Oral
238862|NCT02373189|Device|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
238863|NCT02373176|Drug|[14C]PRC 4016 (Icosabutate)|Single oral dose
238864|NCT02373163|Drug|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
238865|NCT02373163|Drug|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
238866|NCT02373163|Drug|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
238867|NCT02373150|Drug|Imeglimin|
238868|NCT02373150|Drug|Placebo|
238869|NCT02373137|Procedure|DSAEK|
238870|NCT02373137|Procedure|DMEK|
238871|NCT02373137|Device|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
238872|NCT02373137|Drug|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
238873|NCT02373137|Drug|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
238874|NCT02373137|Drug|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
238875|NCT02373137|Drug|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
238876|NCT02373137|Device|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
238877|NCT02373124|Drug|infusion of NMDA antagonist|52 minute infusion
238878|NCT02373111|Dietary Supplement|Isoflavone|
238879|NCT02373111|Dietary Supplement|Astaxanthin|
238880|NCT02373111|Dietary Supplement|Placebo|
238881|NCT02373098|Drug|Fingolimod 0.5 mg|66 relapsing remitting MS (RRMS) patients were recruited. Patients who met all inclusion and none of the exclusion criteria were treated by Fingolimod 0.5 mg.
238882|NCT02373085|Other|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
238883|NCT02373072|Drug|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
238884|NCT02373072|Drug|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
238885|NCT02373072|Drug|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
238886|NCT02373059|Other|Diabetes Issue Cards Decision Aids|
238887|NCT02373059|Other|Usual Pharmaceutical Care|
238888|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
238889|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
238890|NCT02373033|Other|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
238891|NCT02373033|Other|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
238892|NCT02373033|Other|Apple juice|Received apple juice containing no folate or folic acid.
238893|NCT02373020|Other|colonoscopic biopsies|
238894|NCT02373007|Procedure|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
238895|NCT02372994|Other|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
238896|NCT02372981|Device|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
238897|NCT02372968|Other|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.~Plasma and urine metabolites will be measured using metabolomics"
239312|NCT02369939|Procedure|Hyperthermia|6x deep regional hyperthermia
238898|NCT02372955|Drug|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
238899|NCT02372955|Drug|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
238900|NCT02372942|Drug|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
238901|NCT02372942|Drug|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
238902|NCT02372929|Procedure|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
238903|NCT02372916|Drug|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
238904|NCT02372903|Drug|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
238905|NCT02372877|Device|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
238906|NCT02372864|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
238907|NCT02372851|Device|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
238908|NCT02372838|Procedure|Microvascular fibula bone transfer|Reconstructive surgery with a microvascular bone flap
238909|NCT02372825|Procedure|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
238910|NCT02372812|Drug|dexamethasone|12 mg of dexamethasone
238911|NCT02372812|Drug|Placebo|
238912|NCT02372799|Drug|Vilazodone|
238913|NCT02372799|Drug|Placebo|
238914|NCT02372799|Drug|Fluoxetine|
238915|NCT02372786|Drug|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
238916|NCT02372786|Drug|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
238917|NCT02372786|Device|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
238918|NCT02372786|Device|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
238919|NCT02372760|Device|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
238920|NCT02372760|Other|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
238921|NCT02372760|Drug|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
238922|NCT02372747|Procedure|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
238923|NCT02372747|Procedure|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
238924|NCT02372734|Other|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
238925|NCT02372708|Drug|dinitrophenyl(DNP)|
238926|NCT02372708|Radiation|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
238927|NCT02372695|Drug|Paricalcitol|
238928|NCT02372682|Device|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
238929|NCT02372669|Device|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
238930|NCT02372669|Procedure|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
238931|NCT02372656|Drug|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
238932|NCT02372656|Drug|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
238933|NCT02372656|Drug|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
239014|NCT02372123|Other|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
238934|NCT02372643|Other|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
238935|NCT02372630|Drug|Linagliptin|
238936|NCT02372630|Drug|Placebo|
238937|NCT02372617|Procedure|periacetabular osteotomy|
238938|NCT02372604|Drug|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|"Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)~the evening : placebo capsule~Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)~the evening : 10 mg of levocetirizine (capsule))"
238939|NCT02372604|Drug|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|"Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)~the evening : 10 mg of levocetirizine(tablet)~Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)~the evening : placebo tablet"
238940|NCT02372591|Drug|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
238941|NCT02372591|Drug|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
238942|NCT02372591|Drug|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
238943|NCT02372578|Drug|ASP3662|oral
238944|NCT02372578|Drug|pregabalin|oral
238945|NCT02372578|Drug|ASP3662 placebo|oral
238946|NCT02372578|Drug|pregabalin placebo|oral
238947|NCT02372565|Behavioral|Facebook and text Message|Culturally-relevant physical activity promotion program
238948|NCT02372565|Behavioral|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
238949|NCT02372552|Device|CROMA|Microwave coagulation of small blood vessels
238950|NCT02372539|Other|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
238951|NCT02372539|Other|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
238952|NCT02372526|Other|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
238953|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
238954|NCT02372526|Other|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
238955|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
238956|NCT02372500|Dietary Supplement|Chewing gum|Sugar free chewing gum
238957|NCT02372487|Drug|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
238958|NCT02372487|Dietary Supplement|fluid therapy|2 liters of fluid per day
238959|NCT02372474|Biological|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
238960|NCT02372461|Drug|Placebo|This is an non inferiority trial, the intervention is a placebo
238961|NCT02372461|Drug|Amoxicillin|Amoxicillin Liquid
238962|NCT02372448|Other|ALK analysis on CTCs detected by ISET|
238963|NCT02372435|Procedure|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
238964|NCT02372422|Other|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
238965|NCT02372422|Other|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
238966|NCT02372409|Device|MRI-guided laser ablation|
238967|NCT02372409|Drug|Doxorubicin|
238968|NCT02372409|Drug|Etoposide|
238969|NCT02372409|Device|Dynamic contrast-enhanced (DCE) MRI|
238970|NCT02372409|Device|Dynamic susceptibility contrast (DSC) MRI|
238971|NCT02372396|Behavioral|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
238972|NCT02372396|Behavioral|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
238973|NCT02372383|Drug|Ethambutol|Anti-mycobacterial oral drug
238974|NCT02372383|Drug|Rifampin|Anti-mycobacterial oral drug
238975|NCT02372383|Drug|Azithromycin|Anti-mycobacterial oral drug
238976|NCT02372383|Drug|Pancrelipase|Pancreatic enzyme replacement therapy
238977|NCT02372370|Procedure|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
238978|NCT02372370|Procedure|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
238979|NCT02372370|Procedure|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
238980|NCT02372370|Procedure|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
238981|NCT02372370|Procedure|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
238982|NCT02372370|Drug|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
238983|NCT02372370|Other|Untreated Control|Untreated control. No interventions.
238984|NCT02372357|Drug|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
238985|NCT02372357|Procedure|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
238986|NCT02372344|Drug|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
238987|NCT02372331|Other|ERAS perioperative management|"Preop Counseling~Preop biliary drainage (X) when Serum Total bilirubin < 14.62mg/dl and cholangitis (-)~Preop enteral nutrition~Oral bowel preparation (mechanical bowel preparation ) (X)~Preop fasting < 6 hours~Prevention of postoperative nausea and vomiting (PONV) (O)~Nasogastric intubation (X)~Near-zero fluid balance~Somatostatin analogues (X)~Postop routine artificial nutrition (X), soft diet at POD #2~Audit~Other items are same as conventional"
238988|NCT02372318|Drug|Nalmefene|18mg of Nalmefen will be administered orally
238989|NCT02372318|Drug|Placebo|Placebo tablet
238990|NCT02372305|Biological|FlexHD|Patients will be randomized to receive FlexHD.
238991|NCT02372305|Biological|Alloderm|Patient will be randomized to receive Alloderm.
238992|NCT02372292|Drug|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
238993|NCT02372279|Other|Embryo observation|In EO group, conventional observations will be made.
238994|NCT02372266|Other|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
238995|NCT02372266|Other|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
238996|NCT02372253|Drug|Verapamil|
238997|NCT02372253|Drug|Placebo|
238998|NCT02372240|Drug|VLX1570 and dexamethasone|
238999|NCT02372227|Drug|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
239000|NCT02372214|Procedure|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
239001|NCT02372201|Other|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
239002|NCT02372188|Other|water|Control
239003|NCT02372188|Dietary Supplement|caffeine|
239004|NCT02372188|Dietary Supplement|caffein + homoeriodictyol sodium salt|
239005|NCT02372188|Dietary Supplement|homoeriodictyol sodium salt|
239006|NCT02372175|Biological|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
239007|NCT02372162|Other|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
239008|NCT02372162|Other|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
239009|NCT02372149|Drug|10% intravenous immunoglobulin (IVIg)|
239010|NCT02372149|Drug|0.9% sodium chloride|
239011|NCT02372136|Dietary Supplement|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.~In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.~In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
239012|NCT02372136|Dietary Supplement|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
239013|NCT02372123|Other|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
240010|NCT02364752|Procedure|Loop Diuretic Withdrawal/Salt Load|
239015|NCT02372110|Drug|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
239016|NCT02372110|Drug|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
239017|NCT02372097|Drug|SYR-472|SYR-472 25mg, 50mg
239018|NCT02372084|Drug|osilodrostat|
239019|NCT02372071|Device|BiliCare|Two measurements with the BiliCare device
239020|NCT02372058|Device|BiliCare|"Three non invasive measurements of TcB:~Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
239021|NCT02372032|Procedure|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
239022|NCT02372032|Procedure|ozone therapy|percutaneous intradiscal ozone injection
239023|NCT02372019|Behavioral|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 20 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
239024|NCT02372019|Behavioral|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
239025|NCT02372019|Behavioral|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
239026|NCT02372006|Drug|afatinib|
239027|NCT02371993|Dietary Supplement|Choline|
239028|NCT02371993|Other|Placebo|
239029|NCT02371980|Drug|Vortioxetine|Vortioxetine capsules
239030|NCT02371980|Drug|Placebo|Vortioxetine placebo-matching capsules
239031|NCT02371967|Drug|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
239032|NCT02371954|Behavioral|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
239033|NCT02371954|Other|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
239034|NCT02371941|Drug|oral cromolyn sodium|Oral cromolyn sodium
239035|NCT02371941|Drug|Placebo|Saline
239036|NCT02371928|Other|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.~Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.~Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.~Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.~Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
239037|NCT02371928|Other|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.~All exercises are performed three times a week with 2 sets of 10 repetitions."
239038|NCT02371915|Other|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
239039|NCT02371902|Device|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
239040|NCT02371902|Device|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
239041|NCT02371889|Drug|Topiramate|Max therapeutic dose of 200mg/day
239042|NCT02371889|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
239043|NCT02371889|Drug|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
239085|NCT02371590|Drug|Obinutuzumab|Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
240011|NCT02364739|Other|Written information|Brochure
239044|NCT02371876|Device|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
239045|NCT02371850|Drug|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
239046|NCT02371837|Other|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
239047|NCT02371824|Other|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
239048|NCT02371811|Device|uterine manipulator (v care)|
239049|NCT02371798|Drug|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
239050|NCT02371785|Device|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
239051|NCT02371772|Other|Training|Patients were trained to monitor INR and dose warfarin
239052|NCT02371759|Drug|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
239053|NCT02371759|Drug|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
239054|NCT02371759|Drug|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
239055|NCT02371759|Drug|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
239056|NCT02371746|Drug|ENV515-3 Travoprost XR|
239057|NCT02371746|Drug|ENV515-1 Travoprost XR|
239058|NCT02371746|Drug|ENV515-3-2 Travoprost XR|
239059|NCT02371733|Other|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
239060|NCT02371733|Other|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week."
239061|NCT02371720|Behavioral|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
239062|NCT02371707|Drug|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
239063|NCT02371707|Drug|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
239064|NCT02371694|Other|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.~All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
239065|NCT02371681|Drug|Treatment|Different Drug combinations
239066|NCT02371681|Radiation|PET/CT Scan|PET/CT Scans
239067|NCT02371681|Procedure|Sample Collection|Sample Collection
239068|NCT02371668|Biological|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
239069|NCT02371668|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
239070|NCT02371655|Procedure|Diet|A low-fibre diet for three days before the examination
239071|NCT02371655|Drug|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
239072|NCT02371655|Drug|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
239073|NCT02371655|Procedure|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
239074|NCT02371629|Drug|NVA237|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
239075|NCT02371629|Drug|Placebo|Placebo to NVA237
239076|NCT02371629|Drug|Salbutamol|All patients received salbutamol (100 μg) as only rescue medication
239077|NCT02371616|Device|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
239078|NCT02371616|Other|Sodium fluoride|1426 ppm fluoride as sodium fluoride
239079|NCT02371616|Other|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
239080|NCT02371603|Drug|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
239081|NCT02371603|Drug|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
239082|NCT02371603|Drug|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
239083|NCT02371603|Drug|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
239084|NCT02371590|Drug|Lenalidomide|"Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.~The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject."
239429|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
239086|NCT02371577|Drug|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
239087|NCT02371564|Device|High flow humidified oxygen|
239088|NCT02371564|Device|Standard flow humidified oxygen|
239089|NCT02371551|Other|Blood/urine sampling|Routine chemistry profile
239090|NCT02371551|Other|Conventional routine CT examination|Standard diagnostic examination
239091|NCT02371551|Other|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
239092|NCT02371551|Other|Functional MRI|Study-specific diagnostic examination
239093|NCT02371538|Biological|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
239094|NCT02371525|Behavioral|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
239095|NCT02371512|Device|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
239096|NCT02371512|Procedure|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
239097|NCT02371499|Dietary Supplement|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
239098|NCT02371499|Dietary Supplement|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
239099|NCT02371486|Procedure|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
239100|NCT02371486|Procedure|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
239101|NCT02371486|Procedure|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.~The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
239102|NCT02371486|Procedure|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
239103|NCT02371473|Drug|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
239104|NCT02371473|Drug|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
239105|NCT02371460|Dietary Supplement|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
239106|NCT02371460|Dietary Supplement|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
239107|NCT02371447|Drug|VPM1002BC|"Phase 1:~Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)~Phase 2:~Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
239108|NCT02371434|Biological|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 106, 1 x 106, and 3 x 106 cells/kg body weight in cohorts of three patients each.
239109|NCT02371421|Drug|Allopurinol|
239110|NCT02371408|Drug|ravidasvir hydrochloride|200 mg
239111|NCT02371408|Drug|sofosbuvir|400 mg
239112|NCT02371408|Drug|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
239113|NCT02371395|Other|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
239114|NCT02371382|Device|Arthroplasty hip|Hip replacement
239115|NCT02371369|Drug|Pexidartinib|Each capsule contains 200 mg of pexidartinib for oral administration
239116|NCT02371369|Drug|Placebo|Placebo capsule matching pexidartinib capsule for oral administration
239117|NCT02371343|Dietary Supplement|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
239118|NCT02371343|Dietary Supplement|Sunflower Oil|
239119|NCT02371317|Behavioral|Mindfulness-Based Stress Reduction|Patients are randomized to an intervention
239120|NCT02371317|Behavioral|Stress Management Education|Patients are randomized to an intervention
239121|NCT02371317|Other|American Heart Association Recommended Self-Care|All Patients receive AHA Recommended Self-Care
239122|NCT02371304|Radiation|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
239123|NCT02371304|Procedure|Additional TME surgery|
239124|NCT02371304|Drug|capecitabine|
239125|NCT02371291|Behavioral|Memory Flexibility Training|As in experimental arm description.
239126|NCT02371291|Behavioral|Psychoeducation|As in experimental arm description.
239127|NCT02371278|Dietary Supplement|Leucine|5 g leucine with sucrose and maltodextrin
239128|NCT02371278|Dietary Supplement|Placebo|5 g glycine with sucrose and maltodextrin
239170|NCT02370901|Behavioral|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
239222|NCT02370576|Other|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.~rating scale application"
239129|NCT02371265|Other|Adherence and retention package|"Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:~Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;~Adherence and retention package: 1) Creation of Adherence Committees at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision."
239130|NCT02371252|Drug|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
239131|NCT02371239|Behavioral|Physical activity intervention|
239132|NCT02371226|Drug|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
239133|NCT02371213|Other|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
239134|NCT02371200|Device|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
239135|NCT02371187|Drug|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
239136|NCT02371187|Drug|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
239137|NCT02371161|Drug|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:~R-DHAP~Rituximab 375 mg/m2, e.v. day 1~Desamethasone 40 mg days 1-4~cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)~Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)~R-ICE~Rituximab 375 mg/m2, e.v. day 1~Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)~Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)~Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)~Conditioning BEAM or FEAM"
239138|NCT02371148|Drug|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22* Rituximab: 375 mg/sqm i.v. day 1** Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles *In case of toxicity is omitted~**In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
239139|NCT02371135|Genetic|colonic biopsies|
239140|NCT02371135|Genetic|questionnaires|
239141|NCT02371122|Device|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
239142|NCT02371122|Device|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
239143|NCT02371122|Device|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
239144|NCT02371122|Device|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
239145|NCT02371109|Other|selftaken versus clinically taken swabs|
239146|NCT02371096|Drug|MabThera (rituximab)|
239147|NCT02371096|Drug|RGB-03|
239148|NCT02371083|Other|Extended timing of pessary care|
239149|NCT02371031|Drug|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
239150|NCT02371031|Device|PET/MRI|
239151|NCT02371031|Procedure|Surgical resection (standard of care)|
239152|NCT02371018|Dietary Supplement|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
239153|NCT02371005|Radiation|Cone Beam Computed Tomography (CBCT)|
239154|NCT02370992|Radiation|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
239155|NCT02370979|Biological|Blood samples|
239156|NCT02370966|Dietary Supplement|Berry powder|Berry and gingivitis trial
239157|NCT02370953|Device|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
239158|NCT02370953|Procedure|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
239159|NCT02370940|Other|High phytate intake|
239160|NCT02370940|Other|Low phytate intake|
239161|NCT02370927|Other|Control|Non pulse extruded cereal
239162|NCT02370927|Other|Pea protein|Pulse extruded cereal
239163|NCT02370927|Other|Pea Starch|Pulse extruded cereal
239164|NCT02370927|Other|Pea fibre + pea starch|Pulse extruded cereal
239165|NCT02370927|Other|Pea protein + pea starch|Pulse extruded cereal
239166|NCT02370927|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
239167|NCT02370914|Device|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
239168|NCT02370914|Behavioral|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
239169|NCT02370901|Device|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
239171|NCT02370888|Drug|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
239172|NCT02370875|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
239173|NCT02370875|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
239174|NCT02370862|Drug|Neostigmine and Glycopyrrolate|
239175|NCT02370849|Drug|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
239176|NCT02370849|Drug|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
239177|NCT02370849|Drug|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
239178|NCT02370836|Other|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
239179|NCT02370823|Procedure|Regenexx SD|stem cell treatment
239180|NCT02370810|Behavioral|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
239181|NCT02370797|Radiation|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
239182|NCT02370784|Drug|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
239183|NCT02370784|Drug|Placebo|oral drug of similar appearance to atorvastatin
239184|NCT02370771|Procedure|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
239185|NCT02370771|Device|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
239186|NCT02370758|Drug|Valganciclovir or Ganciclovir|
239187|NCT02370745|Drug|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
239188|NCT02370745|Drug|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
239189|NCT02370745|Dietary Supplement|Oral amino acids|Oral amino acids containing 15 g of amino acids
239190|NCT02370745|Drug|GIP|This will be co infused with GLP-1 and intravenous amino acids
239191|NCT02370745|Drug|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
239192|NCT02370732|Other|Alcohol|A weight based dose of alcohol will be administered during each study day.
239193|NCT02370719|Behavioral|Mobile application for diabetes self-management|
239194|NCT02370706|Drug|PIM447|pan-pim inhibitor
239195|NCT02370706|Drug|Ruxolitinib|JAK1/JAK2 inhibitor
239196|NCT02370706|Drug|LEE011|CDK4/6 inhibitor
239197|NCT02370693|Drug|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
239198|NCT02370693|Drug|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
239199|NCT02370693|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
239200|NCT02370680|Drug|Aspirin|steady-state run-in prior to Durlaza treatment
239201|NCT02370680|Drug|Durlaza™|comparison of different numbers of capsules
239202|NCT02370667|Other|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
239203|NCT02370667|Other|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
239204|NCT02370667|Other|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
239205|NCT02370654|Behavioral|Tai chi|
239206|NCT02370654|Behavioral|Conventional exercise|
239207|NCT02370641|Dietary Supplement|PomX|1000 mg POMx daily for 4 weeks
239208|NCT02370628|Procedure|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.~In our trial, vertebroplasty shall be performed in two steps:~Step 1: facet block~Step 2: cement infusion~Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
239209|NCT02370628|Procedure|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.~All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
239210|NCT02370615|Drug|TAK-272|TAK-272 tablet.
239211|NCT02370615|Drug|Digoxin|Digoxin tablet.
239212|NCT02370615|Drug|Itraconazole|Itraconazole oral solution
239213|NCT02370615|Drug|Midazolam|Midazolam syrup.
239214|NCT02370602|Drug|TAK-063|TAK-063 tablets
239215|NCT02370602|Drug|[^11C]T-773|[^11C]T-773 IV solution
239216|NCT02370589|Biological|Base Dose EBOV GP Vaccine|
239217|NCT02370589|Biological|2x Base Dose EBOV GP Vaccine|
239218|NCT02370589|Biological|4x Base Dose EBOV GP Vaccine|
239219|NCT02370589|Biological|8x Base Dose EBOV GP Vaccine|
239220|NCT02370589|Biological|Placebo|
239223|NCT02370563|Drug|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
239224|NCT02370550|Drug|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
239225|NCT02370550|Drug|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
239226|NCT02370550|Drug|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
239227|NCT02370550|Drug|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
239228|NCT02370537|Drug|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
239229|NCT02370537|Drug|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
239230|NCT02370524|Drug|[18F]T807|All enrolled subjects will undergo an [18F]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
239231|NCT02370511|Device|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
239232|NCT02370498|Biological|pembroliziumab|200 mg administered as IV infusion on Day 1 of each 21-day cycle.
239233|NCT02370498|Drug|paclitaxel|80 mg/m^2 administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle.
239234|NCT02370485|Drug|LY2801653|Administered orally
239235|NCT02370472|Other|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
239236|NCT02370459|Other|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
239237|NCT02370459|Other|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
239238|NCT02370446|Other|personalized medication log|
239239|NCT02370446|Other|standard of care|
239240|NCT02370446|Behavioral|questionnaires|
239241|NCT02370446|Behavioral|Cognitive Interview|
239242|NCT02370433|Drug|Intravenous Neostigmine and Glycopyrrolate|
239243|NCT02370433|Drug|Transdermal Neostigmine and Glycopyrrolate|
239244|NCT02370420|Biological|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
239245|NCT02370420|Behavioral|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
239246|NCT02370407|Device|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
239247|NCT02370407|Device|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
239248|NCT02370394|Behavioral|ROSE Program|The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
239249|NCT02370368|Device|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
239250|NCT02370355|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
239251|NCT02370355|Other|Laboratory Biomarker Analysis|Correlative studies
239252|NCT02370342|Procedure|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
239253|NCT02370342|Procedure|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
239254|NCT02370342|Procedure|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
239255|NCT02370342|Device|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
239256|NCT02370329|Other|Laboratory Biomarker Analysis|Correlative studies
239257|NCT02370329|Biological|PEG-Proline-Interferon Alfa-2b|Given SC
239258|NCT02370329|Other|Quality-of-Life Assessment|Ancillary studies
239259|NCT02370316|Behavioral|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
239260|NCT02370316|Behavioral|Clinical Structured Treatment|structured case management and symptom-targeted medication
239261|NCT02370290|Other|Medical Chart Review|Clinical and imaging information collected
239262|NCT02370290|Other|Informational Intervention|Clinical and imaging data collected
239263|NCT02370277|Other|Cytology Specimen Collection Procedure|Undergo collection of stool samples
239264|NCT02370277|Other|Laboratory Biomarker Analysis|Correlative studies
239265|NCT02370277|Other|Questionnaire Administration|Ancillary studies
239266|NCT02370264|Procedure|Quality-of-Life Assessment|Ancillary studies
239267|NCT02370264|Other|Questionnaire Administration|Ancillary studies
239269|NCT02370251|Drug|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB <2 mg/dL) occurs.
239270|NCT02370238|Drug|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
239271|NCT02370238|Drug|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
239272|NCT02370238|Drug|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
239273|NCT02370225|Other|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
239274|NCT02370212|Dietary Supplement|Creatine|
239275|NCT02370212|Dietary Supplement|Placebo|
239276|NCT02370212|Other|High intensity interval training|
239277|NCT02370199|Device|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
239278|NCT02370199|Drug|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
239279|NCT02370173|Device|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
239280|NCT02370173|Device|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
239281|NCT02370160|Biological|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
239282|NCT02370147|Behavioral|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
239283|NCT02370147|Behavioral|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
239284|NCT02370134|Device|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
239285|NCT02370134|Device|sham glove|
239286|NCT02370121|Drug|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
239287|NCT02370121|Drug|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
239288|NCT02370108|Device|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
239289|NCT02370095|Drug|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
239290|NCT02370095|Drug|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
239291|NCT02370082|Device|Localization of breast lesion|localization of breast lesion for removal
239292|NCT02370069|Biological|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
239293|NCT02370056|Diagnostic Test|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
239294|NCT02370056|Diagnostic Test|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
239295|NCT02370043|Drug|KQ-791|Capsules administered orally while fasting, in up to 3 periods
239296|NCT02370043|Drug|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
239297|NCT02370043|Drug|Placebo|Capsules, administered orally, in 1 period
239298|NCT02370030|Dietary Supplement|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
239299|NCT02370017|Biological|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
239300|NCT02370004|Procedure|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.~During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
239301|NCT02369991|Procedure|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
239302|NCT02369978|Drug|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
239303|NCT02369978|Drug|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
239304|NCT02369978|Drug|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
239305|NCT02369965|Drug|albuvirtide|albuvirtide 320mg administered intravenously once a week
239306|NCT02369965|Drug|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
239307|NCT02369965|Drug|tenofovir|tenofovir 300mg administered orally once daily
239308|NCT02369965|Drug|lamivudine|lamivudine 300mg administered orally once daily
239309|NCT02369939|Radiation|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
239310|NCT02369939|Drug|Mitomycin C|MMC w1, w5
239311|NCT02369939|Drug|5-Fluorouracil|5-FU w1, w5
239313|NCT02369926|Procedure|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
239314|NCT02369926|Procedure|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
239315|NCT02369913|Other|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
239316|NCT02369900|Drug|Esmolol|
239317|NCT02369900|Other|Saline|
239318|NCT02369874|Drug|MEDI4736|MEDI4736 Monotherapy
239319|NCT02369874|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
239320|NCT02369874|Drug|Standard of Care|Standard of Care
239321|NCT02369861|Drug|ST266|Topical ocular application 4 times per day
239322|NCT02369861|Drug|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
239323|NCT02369848|Device|Shockwave Lithoplasty System|
239324|NCT02369835|Drug|Dakin's solution|Apply modified Dakin's solution (0.005 to 0.01%) topically
239325|NCT02369835|Other|Placebo|Applied topically
239326|NCT02369822|Dietary Supplement|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
239327|NCT02369809|Drug|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
239328|NCT02369796|Drug|TAK-448|TAK-448 solution for subcutaneous injection
239329|NCT02369783|Other|Questionnaire and interview|The aim is to detect social fragility.
239330|NCT02369770|Device|stretching and active movement training|A portable rehabilitation robot will be used to strongly or gently move the impaired ankle joint back and forth. Then subjects will be asked to use muscles to move the ankle with or without the robotic guidance depending on which group the subjects are in.
239331|NCT02369757|Behavioral|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
239332|NCT02369744|Drug|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
239333|NCT02369744|Drug|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
239334|NCT02369731|Drug|Translarna|
239335|NCT02369718|Other|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
239336|NCT02369718|Other|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR*2 coding strategies*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
239337|NCT02369692|Device|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
239338|NCT02369679|Device|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
239339|NCT02369679|Device|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.~After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
239340|NCT02369666|Dietary Supplement|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
239341|NCT02369666|Dietary Supplement|Placebo|Contains MCT oil.
239342|NCT02369653|Drug|Apixaban|
239343|NCT02369653|Other|No systemic anticoagulant prophylaxis|
239344|NCT02369640|Procedure|Error-management training vs error-avoidance training. Defined by training instructions.|". Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.~Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!"
239345|NCT02369627|Device|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
239392|NCT02369276|Other|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
239393|NCT02369250|Drug|Rosuvastatin|Rosuvastatin, is a statin group of drug.
239394|NCT02369250|Biological|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
239346|NCT02369627|Device|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
239347|NCT02369627|Other|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
239348|NCT02369614|Other|Active Comparator: 1 Hz rTMS|1 Hz rTMS
239349|NCT02369614|Other|Active Comparator: 10 Hz rTMS|10 Hz rTMS
239350|NCT02369614|Other|Sham Comparator:|Sham rTMS
239351|NCT02369601|Other|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
239352|NCT02369588|Other|Food portion size|
239353|NCT02369575|Other|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
239354|NCT02369562|Procedure|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
239355|NCT02369549|Drug|Micro-particle Curcumin|as described in Arm
239356|NCT02369549|Drug|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
239357|NCT02369536|Dietary Supplement|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
239358|NCT02369536|Dietary Supplement|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
239359|NCT02369523|Drug|Exparel|Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
239360|NCT02369523|Drug|Ropivacaine cocktail (PIC)|400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
239361|NCT02369523|Drug|Bupivacaine|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.~Sciatic nerve block - 0.125% bupivacaine"
239362|NCT02369510|Drug|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
239363|NCT02369510|Drug|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
239364|NCT02369510|Drug|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
239365|NCT02369497|Device|HRA|Humeral head resurfacing with the HRA device
239366|NCT02369484|Drug|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
239367|NCT02369471|Drug|GWP42006|
239368|NCT02369471|Drug|Placebo|
239369|NCT02369458|Drug|Mitomycin-C|
239370|NCT02369458|Drug|Pegfilgrastim|
239371|NCT02369445|Behavioral|Moisture Pager Intervention for Toilet Training|
239372|NCT02369445|Behavioral|Standard of Care|
239373|NCT02369432|Drug|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
239374|NCT02369419|Other|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as <14/17 points using the ONCODAGE score
239375|NCT02369406|Drug|Nevirapine|
239376|NCT02369406|Drug|Kaletra|
239377|NCT02369406|Drug|Lamivudine|
239378|NCT02369406|Drug|Zidovudine|
239379|NCT02369393|Behavioral|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
239380|NCT02369393|Behavioral|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
239381|NCT02369380|Device|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
239382|NCT02369354|Behavioral|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
239383|NCT02369354|Other|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
239384|NCT02369341|Biological|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
239385|NCT02369328|Device|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
239386|NCT02369315|Behavioral|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
239387|NCT02369315|Behavioral|Control (Invited entry 2013)|Entry to music program offered in September 2013
239388|NCT02369302|Drug|DWC20141|Tablet
239389|NCT02369302|Drug|DWC20142|Tablet
239390|NCT02369302|Drug|DWC20141, DWC20142|Tablet
239391|NCT02369289|Other|bone mineral density test|
239428|NCT02368912|Drug|ASP1707 single dose fed|Oral, healthy young male
239395|NCT02369211|Drug|Acetaminophen (Ofirmev)|The patient was administered IV Ofirmev during anesthesia and then 3 more IV doses (1g each) every 6 hours up to 24 hrs.
239396|NCT02369211|Other|Placebo|The patient was administered IV Placebo during anesthesia and then 3 more doses of IV Placebo every 6 hours up to 24 hrs.
239397|NCT02369198|Drug|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected."
239398|NCT02369172|Drug|Bupropion|
239399|NCT02369172|Drug|ASP2151|
239400|NCT02369159|Drug|Peramivir|
239401|NCT02369159|Drug|Oseltamivir|
239402|NCT02369146|Drug|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
239403|NCT02369133|Drug|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
239404|NCT02369133|Drug|Placebo|
239405|NCT02369120|Other|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
239406|NCT02369120|Other|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
239407|NCT02369107|Other|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
239408|NCT02369107|Other|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
239409|NCT02369094|Other|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
239410|NCT02369081|Drug|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
239411|NCT02369081|Drug|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
239412|NCT02369081|Drug|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
239413|NCT02369081|Drug|Placebo|Placebo treatment for 12 weeks.
239414|NCT02369068|Drug|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
239415|NCT02369068|Drug|Kenalog|Intravaginal pelvic floor injection one series
239416|NCT02369042|Device|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
239417|NCT02369029|Drug|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
239418|NCT02369016|Drug|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
239419|NCT02369003|Procedure|Autologous Peripheral Nerve Graft|Implantation of Autologous Peripheral Nerve Graft into the substantia nigra, basal forebrain, putamen, and/or STN of participants with PD undergoing deep brain stimulation (DBS) surgery.
239420|NCT02368977|Device|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
239421|NCT02368964|Drug|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
239422|NCT02368964|Drug|high dose hCG 500 mcg|Treatment for triggering
239423|NCT02368951|Drug|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
239424|NCT02368925|Device|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
239425|NCT02368912|Drug|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
239426|NCT02368912|Drug|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
239427|NCT02368912|Drug|ASP1707 single dose fasted|Oral, healthy young male
239430|NCT02368912|Drug|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
239431|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
239432|NCT02368912|Drug|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
239433|NCT02368912|Drug|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
239434|NCT02368912|Drug|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
239435|NCT02368899|Other|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
239436|NCT02368899|Other|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
239437|NCT02368886|Drug|Clobetasol Propionate|Given topically
239438|NCT02368886|Other|Pharmacological Study|Correlative studies
239439|NCT02368886|Other|Quality-of-Life Assessment|Ancillary studies
239440|NCT02368886|Drug|Regorafenib|Given PO
239441|NCT02368873|Procedure|Application of IPOM mesh|
239442|NCT02368860|Drug|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
239443|NCT02368847|Device|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
239444|NCT02368847|Device|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
239445|NCT02368834|Behavioral|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
239446|NCT02368808|Behavioral|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
239447|NCT02368795|Device|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
239448|NCT02368795|Drug|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
239449|NCT02368795|Drug|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
239450|NCT02368795|Drug|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
239451|NCT02368769|Device|During Tele-expertise|
239452|NCT02368743|Drug|mesalazine|
239453|NCT02368730|Drug|desmopressin|
239454|NCT02368717|Drug|Mesalazine Enema|
239455|NCT02368717|Drug|Placebo Enema|
239456|NCT02368704|Other|No intervention|
239457|NCT02368691|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
239458|NCT02368678|Procedure|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
239459|NCT02368678|Procedure|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.~Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.~Oral hygiene instructions were given to all participants."
239460|NCT02368665|Drug|Amlodipine 5mg|- Daily oral administration for 8 weeks
239461|NCT02368665|Drug|Amlodipine 5mg, Candesartan cilexetil 16mg|- Daily oral administration Amlodipine 5mg for 8 weeks
239462|NCT02368665|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
239463|NCT02368652|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
239464|NCT02368652|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
239465|NCT02368639|Device|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher & Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
239466|NCT02368626|Device|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
239467|NCT02368613|Drug|DW-3102|
239468|NCT02368600|Behavioral|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
239469|NCT02368587|Biological|WJMSCs Vs. placebo|WJMSCs Vs. placebo
239470|NCT02368587|Biological|Placebo|WJMSCs Vs. placebo
239471|NCT02368574|Procedure|Class II hysterectomy|Class II hysterectomy
239472|NCT02368561|Drug|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
239473|NCT02368548|Other|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
239474|NCT02368548|Other|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
239475|NCT02368535|Other|Survey|25-item questionnaire on pereception of interdisciplinary rounds
239476|NCT02368509|Other|Perform sensory tests|
239477|NCT02368496|Device|HR-pQCT|
239478|NCT02368483|Other|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
239479|NCT02368470|Drug|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
239480|NCT02368470|Drug|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
239481|NCT02368457|Drug|Pentoxifylline and Tocopherol|pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
239482|NCT02368444|Behavioral|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
239483|NCT02368431|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
239484|NCT02368431|Drug|Placebo|Placebo
239485|NCT02368418|Procedure|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
239486|NCT02368418|Procedure|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
239487|NCT02368405|Behavioral|Control|Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
239488|NCT02368405|Behavioral|Eat Smart, Live Better|Intervention participants will participate in a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
239489|NCT02368392|Other|Exposure for cardiac arrests|There is no particular intervention. This study merely observes the occurrence of cardiac arrests
239490|NCT02368379|Other|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
239491|NCT02368379|Other|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
239492|NCT02368366|Behavioral|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
239493|NCT02368366|Behavioral|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
239494|NCT02368366|Behavioral|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
239495|NCT02368353|Other|Cognitive behavioral therapy|
239496|NCT02368353|Other|Supportive therapy|
239497|NCT02368340|Other|Pulmonary function test|Pulmonary function testing performed
239498|NCT02368340|Other|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
239499|NCT02368340|Other|Sample collection|Blood and urine sample collections
239500|NCT02368327|Biological|Fluad|
239501|NCT02368327|Biological|Fendrix|
239502|NCT02368327|Biological|Placebo|
239503|NCT02368314|Drug|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
239504|NCT02368301|Drug|Elotuzumab in combination with Lenalidomide and Dexamethasone|
239505|NCT02368288|Drug|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
239506|NCT02368262|Other|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart"
239507|NCT02368262|Procedure|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
239508|NCT02368249|Drug|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
239509|NCT02368249|Drug|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
239510|NCT02368236|Behavioral|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
239511|NCT02368223|Device|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
239512|NCT02368210|Drug|122-0551 Foam|Topical Foam
239513|NCT02368210|Drug|Vehicle Foam|Topical Foam
239514|NCT02368197|Drug|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
239515|NCT02368197|Device|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
239516|NCT02368171|Other|measure exhaled carbon monoxide and nitric oxide|
239517|NCT02368158|Other|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
239518|NCT02368132|Behavioral|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
239519|NCT02368132|Behavioral|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
239520|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
239521|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
239522|NCT02368119|Biological|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
239523|NCT02368119|Other|Placebo|IM injection injection of Phosphate Buffered Saline
239524|NCT02368106|Radiation|Radiation Therapy|targeted radiation treatment
239525|NCT02368093|Drug|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
239526|NCT02368080|Device|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
239527|NCT02368067|Procedure|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
239528|NCT02368067|Procedure|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
239529|NCT02368054|Drug|Bupivacaine|Infiltration anesthesia
239530|NCT02368054|Drug|Adrenaline|Infiltration anesthesia
239531|NCT02368041|Device|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology Inc. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
239532|NCT02368028|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
239533|NCT02368015|Other|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
239534|NCT02368015|Drug|cefazolin|
239535|NCT02368002|Behavioral|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
239536|NCT02368002|Behavioral|Meal replacements|"Participants continue with behavioral weight loss therapy, but this is augmented with meal replacements (MR). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. MRs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. MRs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
239537|NCT02368002|Behavioral|Enhanced behavioral weight loss therapy|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
239538|NCT02367989|Dietary Supplement|0g barley β-glucan no fibre|Food containing no barley β-glucan and no additional fibre
239539|NCT02367989|Dietary Supplement|2g barley β-glucan|Food containing low amounts of barley β-glucan
239540|NCT02367989|Dietary Supplement|4g barley β-glucan|Food containing medium amounts of barley β-glucan
239541|NCT02367989|Dietary Supplement|6g barley β-glucan|Food containing high amounts of barley β-glucan
239542|NCT02367989|Dietary Supplement|0g barley β-glucan with fibre|Food containing no barley β-glucan, but matches fibre content in β-glucan treatments
239543|NCT02367976|Drug|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
239544|NCT02367963|Behavioral|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
239545|NCT02367963|Behavioral|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
239546|NCT02367950|Behavioral|Exercise|10 exercise sessions with a personal trainer
239547|NCT02367937|Drug|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
239548|NCT02367924|Drug|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
239549|NCT02367911|Drug|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
239550|NCT02367911|Drug|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
239551|NCT02367898|Other|Lumosity Cognitive Training|adaptive online cognitive training
239552|NCT02367898|Other|Crossword Puzzles|timed online crossword puzzles
239553|NCT02367885|Drug|TAK-850 0.5 mL injection|TAK-850 injection
239554|NCT02367885|Drug|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
239555|NCT02367872|Drug|TAK-272|TAK-272 tablet
239556|NCT02367859|Drug|Dabrafenib|Given PO
239557|NCT02367859|Other|Laboratory Biomarker Analysis|Correlative studies
239558|NCT02367859|Drug|Trametinib|Given PO
239559|NCT02367846|Drug|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
239560|NCT02367846|Drug|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
239561|NCT02367833|Drug|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
239562|NCT02367833|Drug|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
239563|NCT02367833|Drug|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
239564|NCT02367820|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
239565|NCT02367807|Drug|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
239566|NCT02367794|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
239567|NCT02367794|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
239568|NCT02367794|Drug|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
240201|NCT02363283|Other|Pharmacological Study|Correlative studies
239569|NCT02367794|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.
239570|NCT02367781|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab will be administered to participants who are randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
239571|NCT02367781|Drug|Carboplatin|Carboplatin will be administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
239572|NCT02367781|Drug|Nab-Paclitaxel|Nab-paclitaxel will be administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
239573|NCT02367781|Drug|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
239574|NCT02367755|Drug|Propofol|Propofol use during therapeutic hypothermia
239575|NCT02367755|Drug|Lorazepam|Lorazepam use during therapeutic hypothermia
239576|NCT02367742|Behavioral|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
239577|NCT02367742|Behavioral|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:~Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.~Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
239578|NCT02367729|Device|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
239579|NCT02367729|Device|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
239580|NCT02367716|Device|CRT|Quartet™ left heart leads or any newer St. Jude Medical quadripolar CRT systems including CRT-P systems that CFDA might approve in the future
239581|NCT02367703|Procedure|laparoscopic hysterectomy|
239582|NCT02367690|Drug|Selinexor|Topical gel
239583|NCT02367690|Other|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
239584|NCT02367690|Other|Vehicle Gel|Topical vehicle gel with no active ingredients.
239585|NCT02367677|Other|Method comparison|
239586|NCT02367664|Biological|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
239587|NCT02367664|Biological|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
239588|NCT02367664|Biological|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
239589|NCT02367651|Drug|Pazopanib 800 mg|Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
239590|NCT02367651|Drug|Placebo|Tablets matching the 200 mg and 400 mg pazopanib tablets
239591|NCT02367638|Biological|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
239592|NCT02367638|Biological|VARIVAX|VARIVAX is administered by subcutaneous injection
239593|NCT02367625|Device|CryoPop|The new CryoPop device will be compared to standard cryotherapy
239594|NCT02367625|Device|MedGyn MGC 200|Standard cryotherapy
239595|NCT02367612|Dietary Supplement|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
239596|NCT02367612|Dietary Supplement|Placebo|Maltodextrin
239597|NCT02367599|Drug|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
239598|NCT02367573|Procedure|2D laparoscopic TAPP inguinal hernia repair|
239599|NCT02367573|Procedure|3D laparoscopic TAPP inguinal hernia repair|
239600|NCT02367560|Procedure|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
239601|NCT02367560|Procedure|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
239602|NCT02367560|Drug|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
239603|NCT02367560|Device|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
239604|NCT02367547|Drug|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
239605|NCT02367547|Drug|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
239606|NCT02367547|Drug|Methylaminolevulinate cream|In the study we use Metvix.
239607|NCT02367534|Procedure|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
239677|NCT02367001|Other|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
240202|NCT02363270|Procedure|Ketamine|IV Push or or IV Drip
239608|NCT02367521|Combination Product|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.~Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
239609|NCT02367521|Device|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
239610|NCT02367508|Behavioral|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
239611|NCT02367495|Device|PCB|PCB with Citrate-based excipient
239612|NCT02367456|Drug|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
239613|NCT02367456|Drug|Azacitidine|75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
239614|NCT02367443|Radiation|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
239615|NCT02367430|Behavioral|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
239616|NCT02367430|Behavioral|Buried in Treasures Workshop|
239617|NCT02367404|Drug|Duloxetine|Duloxetine 60mg OD for 3 months
239618|NCT02367404|Behavioral|Pelvic Floor Muscle Training|PMFT weekly for 3 months
239619|NCT02367391|Behavioral|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
239620|NCT02367391|Behavioral|Control|Usual Care. All participants receive the active medication, Varenicline.
239621|NCT02367365|Other|No Intervention|No intervention
239622|NCT02367365|Other|No Intervention|No intervention
239623|NCT02367352|Drug|Alisertib|Alisertib tablets
239624|NCT02367352|Drug|Paclitaxel|Paclitaxel intravenous solution
239625|NCT02367339|Other|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
239626|NCT02367326|Other|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
239627|NCT02367313|Drug|Vapendavir|Vapendavir 264 mg twice daily
239628|NCT02367313|Drug|Vapendavir|Vapendavir 528 mg twice daily
239629|NCT02367313|Drug|Placebo|Placebo twice daily
239630|NCT02367300|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
239631|NCT02367274|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
239632|NCT02367261|Device|SPI implant|SPI implant - the original spiral implant
239633|NCT02367248|Drug|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
239634|NCT02367248|Drug|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
239635|NCT02367248|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
239636|NCT02367235|Procedure|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
239637|NCT02367235|Procedure|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
239638|NCT02367222|Other|Exposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
239639|NCT02367222|Other|Unexposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
239640|NCT02367196|Drug|CC-90002|
239641|NCT02367196|Drug|Rituximab|
239642|NCT02367183|Drug|GED-0301|
239643|NCT02367183|Drug|Placebo|
239644|NCT02367170|Procedure|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
239645|NCT02367170|Drug|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
239678|NCT02367001|Other|Revised invitation signed by the attending physician|signature typed or typed + handwritten
239646|NCT02367170|Procedure|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
239647|NCT02367170|Device|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
239648|NCT02367170|Device|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
239649|NCT02367170|Procedure|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
239650|NCT02367170|Other|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
239651|NCT02367157|Procedure|Kenzo Kase Method|
239652|NCT02367157|Device|Kinesio Taping|
239653|NCT02367131|Drug|Jardiance|Empagliflozin
239654|NCT02367118|Drug|Prednisone|
239655|NCT02367118|Drug|Placebo|
239656|NCT02367105|Drug|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
239657|NCT02367105|Other|Lifestyle Therapy|Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week
239658|NCT02367105|Drug|Placebo|Placebo gel for testosterone
239659|NCT02367092|Behavioral|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
239660|NCT02367079|Device|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
239661|NCT02367066|Drug|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
239662|NCT02367066|Other|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
239663|NCT02367053|Drug|ZP4207|
239664|NCT02367053|Drug|Glucagon|
239665|NCT02367040|Drug|Copanlisib (BAY 80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
239666|NCT02367040|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
239667|NCT02367040|Drug|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
239668|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
239669|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
239670|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
239671|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
239672|NCT02367014|Drug|MTP-131|MTP-131 (low dose) administered as single day intravenous infusion over 2 hours for 5 days
239673|NCT02367014|Drug|MTP-131|MTP-131 (intermediate dose) administered as single day intravenous infusion over 2 hours for 5 days
239674|NCT02367014|Drug|MTP-131|MTP-131 (high dose) administered as single day intravenous infusion over 2 hours for 5 days
239675|NCT02367014|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
239676|NCT02367001|Other|Normal invitation|No modification and signed by the coordinating doctor as usual
239890|NCT02365571|Drug|Placebo|Administered orally
239679|NCT02366988|Device|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
239680|NCT02366988|Procedure|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
239681|NCT02366975|Drug|Testosterone gel 2%|testosterone gel 2% (50mg/die).
239682|NCT02366975|Other|Placebo|placebo gel
239683|NCT02366962|Biological|ASP7374|subcutaneous
239684|NCT02366949|Drug|BAY 1217389|"BAY 1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY 1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY 1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 > (or equal to) a relative bioavailability assessment of BAY 1217389 liquid capsule formulation compared to BAY 1217389 oral solution will be performed."
239685|NCT02366949|Drug|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY 1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY 1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
239686|NCT02366936|Device|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
239687|NCT02366923|Device|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
239688|NCT02366923|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
239689|NCT02366910|Device|omafilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
239690|NCT02366910|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
239691|NCT02366897|Device|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
239692|NCT02366884|Drug|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
239693|NCT02366884|Drug|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
239694|NCT02366884|Drug|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
239695|NCT02366871|Drug|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
239696|NCT02366871|Drug|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
239697|NCT02366858|Procedure|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
239698|NCT02366858|Procedure|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
239699|NCT02366845|Biological|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
239700|NCT02366845|Diagnostic Test|Pre-Transfusion International Normalized Ratio (INR)|INR result prior to Fresh Frozen Plasma (FFP) transfusion determined by clinical lab testing performed within 6 hours to 1 day before transfusion start time.
239701|NCT02366845|Diagnostic Test|Post-Transfusion International Normalized Ratio (INR)|INR result after Fresh Frozen Plasma (FFP) transfusion completed, determined by clinical lab testing performed within 1 hour after transfusion completed.
239702|NCT02366832|Procedure|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
239703|NCT02366832|Device|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
239704|NCT02366819|Drug|Oxaliplatin|Given IV
239705|NCT02366819|Drug|Leucovorin Calcium|Given IV
239706|NCT02366819|Drug|Irinotecan Hydrochloride|Given IV
239707|NCT02366819|Drug|Fluorouracil|Given IV
239708|NCT02366819|Procedure|Conventional Surgery|Undergo surgery
239709|NCT02366793|Other|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
239710|NCT02366793|Other|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
239711|NCT02366780|Procedure|Pump|Breast milk expression using manually or using an electric pump
239712|NCT02366767|Device|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
239713|NCT02366767|Device|Control|Threshold suspend
239714|NCT02366754|Device|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
239715|NCT02366754|Device|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
239716|NCT02366741|Radiation|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
239717|NCT02366728|Biological|Unpulsed DCs|Patients in Group I will receive 1 x 10^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
239718|NCT02366728|Biological|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
239719|NCT02366728|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
239720|NCT02366728|Biological|111In-labeled DCs|111In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
239721|NCT02366728|Drug|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
239722|NCT02366728|Drug|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
239723|NCT02366728|Drug|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
239724|NCT02366715|Device|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. [3] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.~Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
239725|NCT02366702|Device|Lower Limb Powered Knee-Ankle Prosthesis|
239726|NCT02366689|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
239727|NCT02366689|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
239728|NCT02366689|Drug|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
239729|NCT02366689|Drug|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
239730|NCT02366689|Drug|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
239731|NCT02366676|Drug|hyaluronic acid and chondroitin sulphate|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd~5th month:once a month)
239732|NCT02366663|Radiation|90-Yttrium Ibritumomab tiuxetan|0.4 mCi/kg given IV
239733|NCT02366663|Drug|Carmustine|Given IV
239734|NCT02366663|Drug|Etoposide|Given IV
239735|NCT02366663|Drug|Cytarabine|Given IV
239736|NCT02366663|Drug|Melphalan|Given IV
239737|NCT02366663|Procedure|Autologous Hematopoietic Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplantation (ASCT)
239738|NCT02366663|Biological|Rituximab|Given IV
239739|NCT02366637|Drug|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
239740|NCT02366637|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
239741|NCT02366611|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
239742|NCT02366598|Other|Hemp shake|Hemp protein shake
239743|NCT02366598|Other|Soybean shake|Soybean protein shake
239744|NCT02366598|Other|Control|Non-protein shake
239745|NCT02366585|Drug|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
239746|NCT02366572|Other|Control|Non pulse extruded cereal
239747|NCT02366572|Other|Pea protein|Pulse extruded cereal
239748|NCT02366572|Other|Pea starch|Pulse extruded cereal
239749|NCT02366572|Other|Pea fibre + pea starch|Pulse extruded cereal
239750|NCT02366572|Other|Pea protein + pea starch|Pulse extruded cereal
239751|NCT02366572|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
239752|NCT02366559|Device|Hyfrecator|
239753|NCT02366559|Device|532 nm Q-switched Nd:YAG laser|
239754|NCT02366546|Drug|TBI-1301|TBI-1301(5*10^8 or 5*10^9) is administered.
239755|NCT02366546|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
240006|NCT02364791|Device|standard techniques used to achieve air leak control|
239756|NCT02366546|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
239757|NCT02366520|Device|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
239758|NCT02366494|Drug|Bicalutamide|ANDROGEN BLOCKADE
239759|NCT02366494|Drug|Leuprolide|ANDROGEN BLOCKADE
239760|NCT02366494|Drug|Goserelin|ANDROGEN BLOCKADE
239761|NCT02366494|Drug|Triptorelin|ANDROGEN BLOCKADE
239762|NCT02366494|Drug|Docetaxel|Chemo hormonal therapy
239763|NCT02366481|Dietary Supplement|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
239764|NCT02366481|Dietary Supplement|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
239765|NCT02366481|Dietary Supplement|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
239766|NCT02366468|Drug|ranibizumab 0.5 mg|intravitreal injection
239767|NCT02366455|Procedure|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
239768|NCT02366455|Procedure|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
239769|NCT02366442|Other|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
239770|NCT02366429|Behavioral|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
239771|NCT02366429|Other|TAU|Treatment as usual provided at antenatal clinics and other health care instances
239772|NCT02366416|Behavioral|Exercise training|Physical activity
239773|NCT02366403|Behavioral|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
239774|NCT02366403|Behavioral|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
239775|NCT02366390|Behavioral|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
239776|NCT02366377|Drug|SHR3824|
239777|NCT02366377|Drug|Placebo|
239778|NCT02366377|Drug|Metformin|
239779|NCT02366364|Drug|Placebo|Single oral administration of placebo consumption on Day 1
239780|NCT02366364|Drug|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
239781|NCT02366364|Drug|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
239782|NCT02366364|Drug|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
239783|NCT02366351|Drug|SHR3824|Once daily, 12 weeks
239784|NCT02366351|Drug|Placebo|Once daily, 12 weeks
239785|NCT02366325|Drug|EPO-018B|
239786|NCT02366312|Drug|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
239787|NCT02366299|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
239788|NCT02366299|Drug|Propofol|Treatment of delirium by Propofol i.v. infusion
239789|NCT02366273|Other|PASI and HOMA index|
239790|NCT02366247|Drug|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
239791|NCT02366247|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
239792|NCT02366247|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
239793|NCT02366221|Other|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
239794|NCT02366221|Other|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
239795|NCT02366208|Drug|PEG-Tα1|1.6 mg/ml, once a week, taken subcutaneously
239796|NCT02366208|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
239797|NCT02366208|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
239798|NCT02366195|Drug|Talimogene Laherparepvec|The initial dose of talimogene laherparepvec is up to 4.0 mL of 10^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10^8 PFU/mL.
239799|NCT02366169|Device|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
239800|NCT02366156|Dietary Supplement|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
239801|NCT02366156|Dietary Supplement|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
239802|NCT02366156|Dietary Supplement|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
239803|NCT02366143|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
240007|NCT02364791|Device|Hemopatch|
239804|NCT02366143|Drug|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
239805|NCT02366143|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
239806|NCT02366143|Drug|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 200 milligrams per square meter (mg/m^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
239807|NCT02366130|Drug|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
239808|NCT02366130|Drug|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
239809|NCT02366130|Drug|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
239810|NCT02366117|Behavioral|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
239811|NCT02366091|Drug|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
239812|NCT02366091|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
239813|NCT02366091|Drug|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
239814|NCT02366078|Behavioral|SMART|Paced breathing meditation with cognitive training
239815|NCT02366065|Drug|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
239816|NCT02366052|Behavioral|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
239817|NCT02366052|Dietary Supplement|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
239818|NCT02366052|Other|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
239819|NCT02366026|Biological|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
239820|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
239821|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
239822|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
239823|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
239824|NCT02366000|Other|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
239825|NCT02365987|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
239826|NCT02365987|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
239827|NCT02365974|Device|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
239828|NCT02365974|Device|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
239829|NCT02365961|Drug|ropivicaine|
239830|NCT02365961|Drug|clonidine|
239831|NCT02365961|Drug|Epinephrine|
239832|NCT02365961|Drug|Noropin|
239833|NCT02365948|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/mL~Route of Administration: Subcutaneous injection"
239834|NCT02365948|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Prefilled syringes~Concentration: 0.9 % Saline~Route of Administration: Subcutaneous injection"
239835|NCT02365935|Procedure|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
239836|NCT02365935|Procedure|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
239837|NCT02365935|Drug|Cisplatin|
239838|NCT02365935|Drug|Paclitaxel|
239839|NCT02365909|Drug|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
239840|NCT02365909|Drug|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
239841|NCT02365896|Procedure|TLDG or LADG|
239842|NCT02365883|Device|Photoacoustic Imaging System|manufactured by Endra
239843|NCT02365870|Drug|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
239844|NCT02365870|Drug|placebo|Participants will receive a placebo transdermal patch to be worn daily
239845|NCT02365857|Drug|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine & Bupivacaine.
239846|NCT02365857|Drug|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
239847|NCT02365831|Other|Observation of treatment management|Group/cohort
239848|NCT02365818|Biological|CG0070|
240193|NCT02363335|Drug|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin
239849|NCT02365805|Drug|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
239850|NCT02365805|Drug|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
239851|NCT02365805|Drug|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
239852|NCT02365792|Procedure|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
239853|NCT02365779|Procedure|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
239854|NCT02365779|Device|endomicroscopy Cellvizio® system|
239855|NCT02365766|Drug|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
239856|NCT02365766|Drug|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
239857|NCT02365766|Drug|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
239858|NCT02365766|Procedure|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
239859|NCT02365753|Device|SofPulse|Pulsed Electomagnetic Field Therapy Device placed over incision and turned on and kept in place with tape.
239860|NCT02365740|Other|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
239861|NCT02365740|Other|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
239862|NCT02365740|Other|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
239863|NCT02365740|Drug|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
239864|NCT02365740|Drug|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
239865|NCT02365727|Drug|Liposomal bupivacaine|
239866|NCT02365727|Drug|Ropivacaine|
239867|NCT02365727|Drug|Epinephrine|
239868|NCT02365727|Drug|Clonidine|
239869|NCT02365727|Drug|Saline|
239870|NCT02365714|Radiation|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
239871|NCT02365701|Drug|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
239872|NCT02365701|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
239873|NCT02365688|Procedure|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
239874|NCT02365675|Device|Cotton gauze with petrolatum|
239875|NCT02365675|Device|Cellulose acetate with petrolatum|
239876|NCT02365675|Device|Nanocrystalline silver (Acticoat)|
239877|NCT02365675|Device|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
239878|NCT02365662|Drug|ABBV-221|ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
239879|NCT02365649|Drug|ABT-494|Oral Dosing
239880|NCT02365649|Drug|Placebo|Oral Dosing
239881|NCT02365636|Drug|TV-45070|TV-45070 is an ointment applied topically twice daily to area of pain.
239882|NCT02365636|Drug|Placebo|The matching placebo ointment contained only the excipients of the active treatment; also applied topically twice daily to area of pain.
239883|NCT02365623|Drug|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
239884|NCT02365623|Drug|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS], para-aminosalicylic acid [PAS], amikacin [AMK], levofloxacin [LVFX] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
239885|NCT02365610|Drug|GWP42006|
239886|NCT02365610|Drug|Placebo Control|
239887|NCT02365597|Drug|Erdafitinib|8 mg orally once daily for 28 days on a 28 day cycle.
239888|NCT02365584|Drug|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
239889|NCT02365571|Drug|LY3154207|Administered orally
239891|NCT02365571|Drug|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
239892|NCT02365558|Drug|Evacetrapib|Administered orally
239893|NCT02365558|Drug|Omeprazole|Administered orally
239894|NCT02365532|Drug|GS-6615|GS-6615 tablets administered orally
239895|NCT02365532|Drug|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
239896|NCT02365532|Drug|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
239897|NCT02365532|Drug|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
239898|NCT02365519|Biological|LME636 ophthalmic solution|
239899|NCT02365519|Biological|LME636 Vehicle|Inactive ingredients used as a placebo comparator
239900|NCT02365506|Drug|Eleclazine|Eleclazine tablets administered orally
239901|NCT02365506|Drug|Placebo|Placebo to match eleclazine tablets administered orally
239902|NCT02365493|Drug|Beta-Lactam|
239903|NCT02365480|Drug|Berberine Chloride|Given PO
239904|NCT02365480|Other|Laboratory Biomarker Analysis|Correlative studies
239905|NCT02365480|Other|Placebo|Given PO
239906|NCT02365467|Device|Valiant Mona LSA Thoracic Stent Graft System|
239907|NCT02365454|Device|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.~This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
239908|NCT02365441|Drug|Regorafenib|
239909|NCT02365441|Drug|imatinib|
239910|NCT02365428|Behavioral|Physical activity text messages|
239911|NCT02365415|Drug|Sirolimus|8 weeks oral sirolimus, following drug levels
239912|NCT02365402|Drug|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
239913|NCT02365389|Drug|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
239914|NCT02365389|Drug|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
239915|NCT02365363|Other|Control|Non pulse ingredient bagel
239916|NCT02365363|Other|Pea flour|Pulse ingredient bagel
239917|NCT02365363|Other|Pea fibre|Pulse ingredient bagel
239918|NCT02365363|Other|Pea flour and pea fibre|Pulse ingredient bagel
239919|NCT02365363|Other|Pea flour and pea protein|Pulse ingredient bagel
239920|NCT02365363|Other|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
239921|NCT02365350|Procedure|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
239922|NCT02365350|Procedure|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
239923|NCT02365324|Behavioral|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
239924|NCT02365324|Behavioral|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
239925|NCT02365311|Procedure|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
239926|NCT02365298|Device|etafilcon A|etafilcon A soft contact lens
239927|NCT02365298|Device|nelfilcon A|nelfilcon A
239928|NCT02365285|Drug|Galantamine|16 mg po prior to the infusion of intralipid
239929|NCT02365285|Drug|Placebo Oral Capsule|Placebo oral capsule prior to the infusion of intralipid/heparin
239930|NCT02365285|Drug|Intralipid|Intralipid 20% will be infused at 0.8 mL/m2/min for 4h after oral placebo or Galantamine
239931|NCT02365285|Drug|Heparin|heparin bolus of 1000 U will be followed by 200 U/h infusion for 4h after oral placebo or Galantamine
239932|NCT02365272|Drug|Amikacin|Amikacin administered in a single dose for critical care patients
239933|NCT02365259|Device|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
239934|NCT02365246|Device|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
239935|NCT02365233|Drug|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
239936|NCT02365233|Drug|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
239937|NCT02365233|Drug|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
239938|NCT02365220|Behavioral|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
239939|NCT02365220|Behavioral|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
239940|NCT02365220|Behavioral|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
239941|NCT02365220|Behavioral|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
239942|NCT02365207|Drug|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
239943|NCT02365194|Behavioral|Prehabilitation|information included in arm description
239944|NCT02365194|Behavioral|Standard counseling|information included in arm description
239945|NCT02365181|Procedure|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
239946|NCT02365181|Procedure|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
239947|NCT02365181|Drug|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
239948|NCT02365168|Other|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
239949|NCT02365168|Other|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
239950|NCT02365168|Other|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
239951|NCT02365168|Other|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
239952|NCT02365155|Other|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
239953|NCT02365155|Other|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
239954|NCT02365155|Other|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
239955|NCT02365155|Other|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
239956|NCT02365155|Other|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
239957|NCT02365155|Other|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
239958|NCT02365142|Biological|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
239959|NCT02365142|Biological|Platelet Rich plasma (PRGF)|3 injections of PRGF
239960|NCT02365129|Other|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
239961|NCT02365116|Behavioral|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
239962|NCT02365116|Behavioral|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
239963|NCT02365103|Other|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
239964|NCT02365103|Other|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
239965|NCT02365103|Other|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
239966|NCT02365103|Other|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
239967|NCT02365090|Other|patching|covering the sound eye with a patch to force use of the amblyopic eye
239968|NCT02365090|Other|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
239969|NCT02365064|Device|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
239970|NCT02365051|Behavioral|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
240008|NCT02364765|Drug|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
240009|NCT02364752|Procedure|Blood Draw|
239971|NCT02365038|Other|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
239972|NCT02365038|Other|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
239973|NCT02365025|Other|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
239974|NCT02365012|Drug|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
239975|NCT02364999|Drug|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
239976|NCT02364999|Drug|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
239977|NCT02364999|Drug|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
239978|NCT02364999|Drug|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
239979|NCT02364986|Drug|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
239980|NCT02364986|Drug|Avonex|Avonex 30µg (day 1 and 8) i.m.
239981|NCT02364973|Other|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
239982|NCT02364947|Drug|Nalmefene hydrochloride|As-needed; tablets, orally
239983|NCT02364947|Drug|Placebo|As-needed; tablets, orally
239984|NCT02364934|Drug|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
239985|NCT02364934|Drug|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
239986|NCT02364921|Device|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.~Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
239987|NCT02364921|Device|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
239988|NCT02364908|Other|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
239989|NCT02364895|Other|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
239990|NCT02364895|Other|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
239991|NCT02364895|Other|Males Group 2: New letter with neutral gender content|Unisex letter
239992|NCT02364895|Other|Males Group 3: New letter with male-specific content|New letter tailored for men
239993|NCT02364895|Other|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
239994|NCT02364895|Other|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
239995|NCT02364895|Other|Females Group 2: New letter with neutral gender content|Unisex letter
239996|NCT02364882|Drug|Sildenafil|
239997|NCT02364869|Dietary Supplement|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
239998|NCT02364869|Dietary Supplement|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
239999|NCT02364856|Device|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.~ANI is calculated from heart rate recording."
240000|NCT02364843|Dietary Supplement|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
240001|NCT02364830|Drug|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
240002|NCT02364830|Other|Placebo|One Placebo Capsule/Day for 4 Weeks
240003|NCT02364830|Drug|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
240004|NCT02364817|Behavioral|cognitive and psychiatric assessment|"Administered at baseline:~Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)~hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)~psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)~cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)~impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)~alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.~administered at week 12: ASRS"
240005|NCT02364804|Drug|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
240012|NCT02364739|Other|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
240013|NCT02364726|Procedure|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
240014|NCT02364726|Behavioral|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
240015|NCT02364726|Behavioral|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
240016|NCT02364713|Drug|Gemcitabine Hydrochloride|Given IV
240017|NCT02364713|Other|Laboratory Biomarker Analysis|Correlative studies
240018|NCT02364713|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
240019|NCT02364713|Drug|Paclitaxel|Given IV
240020|NCT02364713|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
240021|NCT02364713|Other|Quality-of-Life Assessment|Ancillary studies
240022|NCT02364713|Drug|Topotecan Hydrochloride|Given IV
240023|NCT02364700|Device|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~warm up-passive stretch of hand in flexion and extension (5 minutes);~setting the EMG threshold parameters for the device;~active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~active practice of closing then hand (UFO Catcher game; 10 min)~open and closing the hand (Ball and Basket game; 10 min)~open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~cool down-passive stretch of hand in flexion and extension (5 minutes)"
240024|NCT02364687|Radiation|Computed tomography late enhancement imaging|
240025|NCT02364674|Radiation|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1."
240026|NCT02364661|Behavioral|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
240027|NCT02364648|Dietary Supplement|MitoQ|Mitochondria targeted antioxidant
240028|NCT02364648|Dietary Supplement|Placebo|Placebo
240029|NCT02364635|Drug|icosabutate|Single dose at each dose levet
240030|NCT02364622|Device|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
240031|NCT02364622|Device|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
240032|NCT02364622|Device|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
240033|NCT02364609|Drug|Afatinib Dimaleate|Given PO
240034|NCT02364609|Biological|Pembrolizumab|Given IV
240035|NCT02364596|Biological|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
240036|NCT02364596|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
240037|NCT02364583|Drug|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
240038|NCT02364570|Other|Glucose (100g)|Ingestion of glucose (100g)
240039|NCT02364570|Other|Glucose (75g)|Ingestion of glucose (75g)
240040|NCT02364570|Other|Whole Eggs|Ingestion of 1.5 whole eggs
240041|NCT02364570|Other|Egg Whites|Ingestion of 7 egg whites
240042|NCT02364570|Other|Egg Yolks|Ingestion of 2 egg yolks
240043|NCT02364557|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
240044|NCT02364557|Procedure|Therapeutic Conventional Surgery|Undergo surgery
240045|NCT02364557|Other|Laboratory Biomarker Analysis|Correlative studies
240046|NCT02364544|Behavioral|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
240047|NCT02364544|Behavioral|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
240048|NCT02364544|Behavioral|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
240049|NCT02364544|Behavioral|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
240050|NCT02364544|Other|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
240086|NCT02364219|Other|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
240194|NCT02363335|Drug|Sitagliptin|
240051|NCT02364531|Other|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
240052|NCT02364518|Procedure|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
240053|NCT02364505|Behavioral|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
240054|NCT02364505|Behavioral|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
240055|NCT02364492|Drug|MAG-TN3 + AS15|
240056|NCT02364479|Drug|etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
240057|NCT02364479|Drug|etanercept (half dose)|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
240058|NCT02364479|Drug|placebo|
240059|NCT02364453|Drug|PACAP38|Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
240060|NCT02364440|Device|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
240061|NCT02364427|Device|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
240062|NCT02364414|Device|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
240063|NCT02364401|Device|Ablation|Catheter ablation for atrial fibrillation
240064|NCT02364388|Device|Imagio Scan|The Imagio breast imaging system is indicated for use by a qualified and trained healthcare provider for opto-acoustic (OA) evaluation of breasts in women who are referred for a diagnostic breast ultrasound work-up due to a suspicious mass (including both palpable and non-palpable) or an imaging finding such as mammographic mass, architectural distortion, asymmetry or suspicious calcifications.
240065|NCT02364362|Drug|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m^2
240066|NCT02364362|Drug|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m^2
240067|NCT02364362|Drug|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m^2
240068|NCT02364349|Drug|Bee Venom (BV)|Raw Bee Venom
240069|NCT02364349|Drug|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
240070|NCT02364336|Drug|Peginterferon alfa-2a|
240071|NCT02364323|Behavioral|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
240072|NCT02364323|Other|Normal usual care|General education on diabetes and diabetic complications
240073|NCT02364310|Device|Baroreceptor stimulation with Barostim Neo TM|
240074|NCT02364297|Device|Early TIPS|TIPS (first 5 days)
240075|NCT02364271|Biological|point-of-care test for H-FABP|Patients were tested with an H-FABP point-of-care test according to the instructions of the manufacturer. It is a rapid chromatographic immunoassay designed for quantitative determination of H-FABP in blood samples using a reader QuickSens®Ω100 (8sens.biognostic GmbH, Germany). This test has a limit of detection of 2 µg/L, a 99th percentile cut-off value of 7 µg/L, and a coefficient of variation of less than 10% at 5 µg/L. The test requires a 120 µL blood sample and the result was interpreted at 15 minutes after sample application. The test was invalid if no control line is visible. In such a case, the measurement was repeated immediately. The research assistant performed the H-FABP point-of-care tests, was blinded to the CACS results and TIMI scores.
240076|NCT02364271|Radiation|Coronary CT Angiography|Patients underwent CACS on a 64-slice multidetector CT scanner. Images were acquired during a single breath hold, using prospective ECG gating with imaging triggered at 70% of the R-R interval (collimation 16x2.5 mm, voltage 120 KeV, current 150 mAs). The computer software automatically defined the presence of calcified lesions as those greater than 130 Hounsfield units. A radiologist blinded to the H-FABP results and TIMI scores then calculated the CACS by selecting only calcified lesions specifically located within the coronary arteries, along with a description of whether the scan result is normal (CACS = 0), or shows minimal (1 to 10), mild (11 to 100), moderate (101 to 400), or severe (>400) calcification.
240077|NCT02364271|Other|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
240078|NCT02364271|Biological|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
240079|NCT02364271|Other|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
240080|NCT02364258|Drug|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
240081|NCT02364258|Drug|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
240082|NCT02364245|Device|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
240083|NCT02364245|Other|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
240084|NCT02364245|Other|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
240085|NCT02364232|Behavioral|bilateral training with and without mirror feedback|
240087|NCT02364219|Device|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
240091|NCT02364193|Device|MRI|"Cardiac MRI for LVEF and segmentation.~Phase-contrast MRI for CO in aorta and each pulmonary vein.~DCE-MRI for bolus kinetic parameter analysis."
240092|NCT02364193|Drug|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
240093|NCT02364193|Device|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).~Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.~Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
240094|NCT02364193|Device|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
240095|NCT02364180|Diagnostic Test|Electromyography (EMG)|
240096|NCT02364167|Drug|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
240097|NCT02364167|Device|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
240098|NCT02364167|Other|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
240099|NCT02364154|Other|Control group-Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
240100|NCT02364154|Other|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
240101|NCT02364141|Other|Trunk restraint therapy|"Reaching training with trunk restraint by a harness that limited the trunk movements.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks."
240102|NCT02364141|Other|Trunk unrestraint therapy|"Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.~Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks"
240103|NCT02364128|Behavioral|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
240104|NCT02364115|Radiation|Stereotactic Body Radiotherapy|
240105|NCT02364089|Procedure|Laparoscopic surgical removal of the adrenal tumor|
240106|NCT02364089|Drug|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~step 4: Add-on of Indapamide LP 1.5 mg~step 5: Add-on of Spironolactone 25 mg~step 6: Add-on of Bisoprolol 10 mg~step 7: Add-on of Prazosine LP 5mg/day."
240107|NCT02364076|Drug|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
240108|NCT02364076|Drug|Epacadostat|100mg taken by mouth twice daily
240109|NCT02364063|Other|urotherapy with or without pharmacotherapy|Individualized
240110|NCT02364037|Behavioral|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
240111|NCT02364037|Behavioral|Contraceptive Education Session|Prior to Phase 2, health care providers at the recruitment sites will undergo a contraceptive education session with a focus on evidence-based provision of contraception including LARC (IUDs and implant) and same-day insertion.
240112|NCT02364037|Device|Cost Support for IUDs and implants|Women in Phase 2 of the study who desire an IUD or implant can receive one through the study at no cost if they do not have insurance coverage. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
240113|NCT02363998|Drug|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
240114|NCT02363985|Dietary Supplement|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
240115|NCT02363972|Device|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
240116|NCT02363959|Drug|Hyperbaric Oxygen Therapy|2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
240117|NCT02363959|Procedure|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
240118|NCT02363946|Drug|ARC-AAT Injection|RNA interference-based, liver-targeted therapeutic
240119|NCT02363946|Other|Placebo|0.9 % normal saline
240120|NCT02363946|Drug|Diphenhydramine|Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
240121|NCT02363933|Drug|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
240122|NCT02363920|Device|HOF|the addition of high oxygen flow to patients breathing spontaneously
240123|NCT02363920|Device|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
240124|NCT02363855|Drug|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
240125|NCT02363842|Device|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
240126|NCT02363842|Other|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
240127|NCT02363829|Drug|Nelfinavir|
240128|NCT02363829|Biological|Cisplatin|
240129|NCT02363803|Drug|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
240130|NCT02363803|Drug|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
240131|NCT02363790|Procedure|LVHR PFC|Information included in arm description
240132|NCT02363790|Procedure|Bridging LVHR|Information included in arm description
240133|NCT02363777|Procedure|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
240134|NCT02363777|Procedure|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
240135|NCT02363764|Procedure|Nasal swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
240136|NCT02363764|Procedure|Cough swab|"Will be obtained by the physiotherapist in:~Expectorating CF patients~Non-expectorating CF patients~Bronchoscopy CF patients"
240137|NCT02363764|Procedure|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:~- Expectorating CF patients"
240138|NCT02363764|Procedure|Induced sputum|"Will be obtained by the physiotherapist in:~Non-expectorating CF patients~Bronchoscopy CF patients"
240139|NCT02363764|Procedure|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:~- Bronchoscopy CF patients"
240140|NCT02363764|Other|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients >6 years of age
240141|NCT02363751|Drug|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinium salt+bevacizumab).~In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
240142|NCT02363738|Drug|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
240143|NCT02363738|Other|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
240144|NCT02363725|Drug|Colchimax®|
240145|NCT02363725|Drug|Conventional treatment|
240146|NCT02363712|Device|APOS shoe|"It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls."
240147|NCT02363712|Device|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
240148|NCT02363699|Drug|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
240149|NCT02363699|Drug|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
240150|NCT02363686|Procedure|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
240151|NCT02363686|Procedure|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
240152|NCT02363673|Other|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
240153|NCT02363660|Biological|GINI|
240195|NCT02363335|Drug|Roflumilast|
240196|NCT02363322|Drug|B/Current Standard of Care Plus ZMapp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
240197|NCT02363322|Other|A/Current Standard of Care Alone|Optimized standard of care for Ebola virus infection
240198|NCT02363296|Device|TMS|Paired associative stimulation and single pulse TMS
240199|NCT02363283|Drug|Glembatumumab Vedotin|Given IV
240200|NCT02363283|Other|Laboratory Biomarker Analysis|Correlative studies
240154|NCT02363647|Other|Tumor Genomic Analysis|"Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process."
240155|NCT02363634|Dietary Supplement|magnesium threonate|nutritional product
240156|NCT02363621|Drug|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
240157|NCT02363621|Drug|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
240158|NCT02363608|Other|standard post surgery care|
240159|NCT02363608|Behavioral|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
240160|NCT02363608|Behavioral|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
240161|NCT02363582|Other|formula|An infant formula contains prebiotics and lactoferrin
240162|NCT02363556|Procedure|Misoprostol administered vaginally|
240163|NCT02363556|Procedure|Misoprostol administered buccally|
240164|NCT02363556|Procedure|Misoprostol administered vaginally with Dilapan|
240165|NCT02363556|Procedure|Misoprostol administered buccally with Dilapan|
240166|NCT02363543|Device|Hyalomatrix|
240167|NCT02363543|Device|Integra|
240168|NCT02363530|Device|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
240169|NCT02363530|Device|BSS|Balanced Salt Solution including normal saline and glucose
240170|NCT02363517|Drug|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
240171|NCT02363504|Other|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
240172|NCT02363491|Drug|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
240173|NCT02363478|Drug|buspirone|buspirone 10 mg X2 for 4 weeks
240174|NCT02363465|Other|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.~The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
240175|NCT02363452|Drug|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
240176|NCT02363439|Drug|IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly|IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
240177|NCT02363426|Device|INVOcell Culture Device|INVOcell is a vaginal culture device
240178|NCT02363426|Device|IVF Incubation|IVF Incubator
240179|NCT02363413|Other|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
240180|NCT02363413|Other|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
240181|NCT02363400|Drug|MEP|Adjuvant Chemotherapy
240182|NCT02363387|Behavioral|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
240183|NCT02363387|Behavioral|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
240184|NCT02363374|Drug|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
240185|NCT02363374|Radiation|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
240186|NCT02363374|Radiation|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
240187|NCT02363374|Drug|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
240188|NCT02363374|Procedure|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
240189|NCT02363361|Drug|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
240190|NCT02363348|Dietary Supplement|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
240191|NCT02363348|Other|Placebo|calcined magnesia
240203|NCT02363218|Radiation|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
240204|NCT02363205|Behavioral|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
240205|NCT02363192|Behavioral|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
240206|NCT02363179|Behavioral|Live preferential music|Live preferential music will be performed for patients in the emergency department.
240207|NCT02363166|Other|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
240208|NCT02363153|Other|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.~Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
240209|NCT02363140|Other|Will undergo a single MRI assessment with intravenous dye|
240210|NCT02363140|Other|pre and post surgery MRI scan|
240211|NCT02363127|Drug|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
240212|NCT02363127|Drug|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
240213|NCT02363088|Other|Neutral text message reminder|"Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
240214|NCT02363088|Other|Messenger text message reminder|"<GP NAME>: Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
240215|NCT02363088|Other|Social Norms A reminder|"Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
240216|NCT02363088|Other|Social Norms B reminder|"Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
240217|NCT02363088|Other|Framed Gain text reminder|"Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
240218|NCT02363088|Other|Framed Loss text reminder|"Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
240219|NCT02363075|Drug|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
240220|NCT02363075|Drug|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
240221|NCT02363049|Procedure|Colectomy|
240222|NCT02363049|Drug|Chemotherapy|
240223|NCT02363023|Procedure|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
240224|NCT02363010|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
240225|NCT02363010|Behavioral|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
240226|NCT02363010|Behavioral|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
240227|NCT02362997|Drug|Pembrolizumab|Anti-PD-1 monoclonal antibody
240228|NCT02362984|Drug|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
240229|NCT02362984|Drug|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
240230|NCT02362958|Drug|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
240231|NCT02362945|Drug|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
240232|NCT02362932|Other|Sanitation|Shared sanitation
240233|NCT02362906|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
240234|NCT02362906|Drug|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
240235|NCT02362906|Drug|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
240236|NCT02362906|Drug|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
240237|NCT02362906|Drug|second generation cephalosporin|
240238|NCT02362906|Drug|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
240239|NCT02362906|Drug|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
240274|NCT02362594|Biological|pembrolizumab|Pembrolizumab 200 mg administered intravenously (IV) on Day 1 of each 21-day cycle
240240|NCT02362893|Other|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
240241|NCT02362880|Radiation|Florbetaben|single dose of Florbetaben followed by PET scan
240242|NCT02362867|Device|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
240243|NCT02362854|Procedure|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
240244|NCT02362854|Device|DL application in peri-implantitis|Diode laser application in the diseased implants.
240245|NCT02362815|Other|Apple juice|Intervention consists in allowing drinks during labour
240246|NCT02362802|Device|Implantable Cardioverter Defibrillator|
240247|NCT02362789|Biological|Secukinumab|150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)
240248|NCT02362789|Biological|Placebo|Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
240249|NCT02362776|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
240250|NCT02362763|Procedure|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
240251|NCT02362750|Other|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
240252|NCT02362750|Other|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
240253|NCT02362750|Other|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
240254|NCT02362750|Other|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
240255|NCT02362750|Other|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
240256|NCT02362750|Other|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
240257|NCT02362750|Other|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
240258|NCT02362737|Behavioral|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be ~16 weekly meetings of ~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
240259|NCT02362711|Drug|NPC-16 Standard Dosing Regimen Group|
240260|NCT02362711|Drug|NPC-16 Continuous Dosing Regimen Group|
240261|NCT02362711|Drug|Placebo Group|
240262|NCT02362698|Other|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.~HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
240263|NCT02362698|Other|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
240264|NCT02362685|Device|functional test|subjects perform a metabolic exercise testing
240265|NCT02362685|Genetic|matching genotype with phenotype|
240266|NCT02362672|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-400 mg twice daily (BID)
240267|NCT02362672|Drug|Placebo to match NKTR-181 BID tablets|Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
240268|NCT02362646|Biological|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
240269|NCT02362646|Drug|Control Solution|
240270|NCT02362633|Device|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
240271|NCT02362633|Device|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
240272|NCT02362607|Behavioral|Integrated Diabetes Management Protocol|
240273|NCT02362607|Behavioral|Standard Diabetes Management Protocol|
240275|NCT02362594|Drug|placebo|Normal saline solution administered IV on Day 1 of each 21-day cycle
240276|NCT02362581|Other|prophylaxis treatment, on demand treatment|
240277|NCT02362568|Procedure|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
240278|NCT02362555|Other|no intervention was used in this observational study|
240279|NCT02362542|Device|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
240280|NCT02362529|Drug|Minocycline|50 mg and 100 mg capsule, oral administration
240281|NCT02362529|Drug|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
240282|NCT02362529|Drug|Celecoxib|100 mg and 200 mg capsules, oral administration.
240283|NCT02362516|Drug|BI 425809|
240284|NCT02362503|Drug|BMS-663068|BMS-663068
240285|NCT02362503|Other|Placebo|Placebo
240286|NCT02362490|Drug|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
240287|NCT02362477|Behavioral|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
240288|NCT02362477|Behavioral|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
240289|NCT02362464|Biological|ME TARP vaccine|Dose of 20 x 10^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally every 3 weeks at weeks 3, 6, 9, 12, 15 and 24.
240290|NCT02362451|Biological|Autologus elutriated monocyte placebo vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
240291|NCT02362451|Biological|ME TARP vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
240292|NCT02362438|Drug|Intrathecal Delivery of scAAV9/JeT-GAN|Intrathecal transfer of scAAV9/JeT-GAN, with escalating doses at 3.5x10^13 vg, 3.3 x higher dose of 1.2 x10^14 vg, and the 5x higher dose of 1.8 x10^14 vg.
240293|NCT02362425|Drug|N-acetylcysteine|
240294|NCT02362425|Drug|Placebo|
240295|NCT02362412|Drug|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
240296|NCT02362399|Drug|sildenafil citrate|single oral dose of 50 mg
240297|NCT02362399|Other|placebo|single oral dose of placebo tablet
240298|NCT02362386|Device|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
240299|NCT02362373|Drug|levonorgestrel IUS|placement of levonorgestrel intrauterine system
240300|NCT02362360|Device|Coloplast Test Product|A new 2-piece ostomy appliance developed by Coloplast A/S
240301|NCT02362360|Device|Comparator (Hollister)|Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
240302|NCT02362347|Device|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
240303|NCT02362347|Other|exercise|exercise
240304|NCT02362321|Drug|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
240305|NCT02362321|Other|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
240306|NCT02362308|Other|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
240307|NCT02362308|Drug|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
240308|NCT02362295|Other|qualitative interview|some patient are interviewed.
240309|NCT02362282|Behavioral|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
240310|NCT02362282|Behavioral|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
240311|NCT02362282|Behavioral|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
240312|NCT02362269|Dietary Supplement|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
240313|NCT02362256|Drug|Naltrexone|
240314|NCT02362256|Drug|Clonidine|
240315|NCT02362256|Drug|Lorazepam|
240355|NCT02361905|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
240356|NCT02361892|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
240402|NCT02361619|Drug|Clarithromycin|perpetrator
240316|NCT02362243|Other|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
240317|NCT02362243|Other|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
240318|NCT02362230|Drug|Icotinib|Icotinib 125 mg BID
240319|NCT02362217|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
240320|NCT02362217|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
240321|NCT02362217|Biological|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
240322|NCT02362217|Biological|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
240323|NCT02362204|Behavioral|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
240324|NCT02362191|Device|Alternating current stimulator|The stimulator used in this study was developed by the Frohlich lab and has been reviewed by the biomedical engineering department. The stimulator has multiple safety features and is considered to be non-significant risk.
240325|NCT02362178|Procedure|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time>40 mm and/or platelets (PLTs 10 units/Kg) for MA<30 mm
240326|NCT02362178|Procedure|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR>1.8 and/or PLTS (10 units/Kg) If PLTs count < 50000/μl
240327|NCT02362165|Drug|Cyclophosphamide|500mg/d,once-weekly,per oral.
240328|NCT02362165|Drug|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
240329|NCT02362165|Drug|Dexamethasone|40mg/d,once-weekly,per oral
240330|NCT02362165|Drug|Doxorubicin|9mg/㎡,d1-4
240331|NCT02362152|Drug|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
240332|NCT02362152|Drug|5-fluorouracil|Topical field treatment as prescribed by dermatologist
240333|NCT02362152|Drug|Imiquimod|Topical field treatment as prescribed by dermatologist
240334|NCT02362152|Drug|Diclofenac|Topical field treatment as prescribed by dermatologist
240335|NCT02362139|Drug|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
240336|NCT02362126|Device|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
240337|NCT02362113|Other|GI/GL|GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
240338|NCT02362100|Other|Non operative|non operative treatment
240339|NCT02362100|Procedure|locking plate surgical fixation|
240340|NCT02362087|Other|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
240341|NCT02362061|Radiation|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
240342|NCT02362048|Drug|ACP-196|
240343|NCT02362048|Drug|ACP-196 in combination with pembrolizumab|
240344|NCT02362035|Drug|Acalabrutinib|oral
240345|NCT02362035|Drug|Pembrolizumab|intravenous
240346|NCT02362022|Drug|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
240347|NCT02361983|Device|DLT versus bronchial blockers|Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
240348|NCT02361957|Dietary Supplement|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
240349|NCT02361957|Dietary Supplement|Placebo|Placebo
240350|NCT02361944|Drug|Oxygen|
240351|NCT02361931|Drug|A hydrogel containing erythropoietin|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. RMD-G1 applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
240352|NCT02361931|Drug|Hydrogel (as a part of SOC)|Standard of wound care, which includes initial debridement, wound cleansing, pressure relief, and infection control. Hydrogel applied daily onto a clean wound at 0.25g per sq.cm. of wound surface. After its application, the wound is covered with a dressing in order to prevent leakage of the gel and contamination of the wound area.
240353|NCT02361918|Procedure|Colon surgery|
240354|NCT02361905|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
240400|NCT02361619|Drug|Midazolam|probe
240401|NCT02361619|Drug|Dabigatran|probe
240357|NCT02361879|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
240358|NCT02361879|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
240359|NCT02361866|Biological|GC1107|0.5 ml, Intramuscular, single dose(day0)
240360|NCT02361866|Biological|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
240361|NCT02361853|Other|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
240362|NCT02361853|Other|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
240363|NCT02361853|Other|Exposure: abundance of Immature monocytes counts in blood samples|
240364|NCT02361853|Other|Exposure: abundance of Immature neutrophils counts in blood samples|
240365|NCT02361827|Procedure|Embryo transfer|For patients in each group, they will have embryo transferred 3 or 5 days after oocyte retrieval.
240366|NCT02361814|Procedure|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
240367|NCT02361801|Drug|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
240368|NCT02361801|Drug|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output < 2 mL/Kg/h despite adequate fluid replacement.
240369|NCT02361775|Device|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
240370|NCT02361775|Device|opioid iv pca|opioid pca consisting of hydromorphone
240371|NCT02361775|Drug|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
240372|NCT02361775|Device|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
240373|NCT02361762|Behavioral|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.~Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.~A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
240374|NCT02361749|Drug|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
240375|NCT02361749|Procedure|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
240376|NCT02361736|Drug|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
240377|NCT02361736|Drug|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
240378|NCT02361723|Drug|BGB-290|
240379|NCT02361723|Drug|BGB-290|
240380|NCT02361723|Drug|BGB-290|
240381|NCT02361723|Drug|BGB-290|
240382|NCT02361723|Drug|BGB-290|
240383|NCT02361710|Procedure|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
240384|NCT02361697|Other|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
240385|NCT02361684|Behavioral|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
240386|NCT02361684|Other|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
240387|NCT02361671|Other|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
240388|NCT02361658|Other|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
240389|NCT02361658|Other|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
240390|NCT02361658|Other|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
240391|NCT02361645|Drug|Ketorolac 0.5% eyedrops|
240392|NCT02361645|Drug|Indomethacin 0.5% eyedrops|
240393|NCT02361645|Drug|Bromfenac 0.09% eyedrops|
240394|NCT02361645|Drug|Nepafenac 0.1% eyedrops|
240395|NCT02361632|Dietary Supplement|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
240396|NCT02361619|Drug|Caffeine|probe
240397|NCT02361619|Drug|Diclofenac|probe
240398|NCT02361619|Drug|Esomeprazole|probe
240399|NCT02361619|Drug|Metoprolol|probe
240403|NCT02361606|Behavioral|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
240404|NCT02361593|Procedure|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
240405|NCT02361593|Procedure|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
240406|NCT02361580|Other|Diary|Subject keeps diary of recovery
240407|NCT02361567|Drug|Tramacet|Pain medication commonly used post-operatively
240408|NCT02361567|Drug|Percocet|Pain medication commonly used post-operatively
240409|NCT02361554|Device|Medtronic Activa Deep Brain Stimulation System|
240410|NCT02361541|Procedure|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
240411|NCT02361528|Drug|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
240412|NCT02361528|Drug|Placebo|placebo subcutaneously, for 5 days
240413|NCT02361515|Radiation|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
240414|NCT02361515|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
240415|NCT02361502|Drug|mirabegron|
240416|NCT02361502|Drug|placebo|
240417|NCT02361489|Device|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
240418|NCT02361476|Drug|Clonidine|Injection - during surgery
240419|NCT02361476|Drug|Placebo|Injection - during surgery
240420|NCT02361463|Device|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
240421|NCT02361463|Device|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
240422|NCT02361450|Device|Retrograde Colonic Irrigation|
240423|NCT02361450|Other|Usual Care|
240424|NCT02361437|Dietary Supplement|Vasculera|Vasculera 630 mg b.i.d.
240425|NCT02361424|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
240426|NCT02361424|Drug|placebo|
240427|NCT02361398|Other|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
240428|NCT02361385|Other|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
240429|NCT02361372|Other|Placebo|Placebo daily for 6 months
240430|NCT02361372|Other|CaCO3|CaCO3 daily for 6 months
240431|NCT02361372|Other|Kefir|Kefir daily for 6 months
240432|NCT02361359|Other|Psychological questionnaires|
240433|NCT02361346|Drug|MT-3724 Phase 1|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 28 day initial cycle and then 21 week repeat cycles for up to 5 total cycles.
240434|NCT02361346|Drug|MT-3724 Phase 2|Intravenous dosing on M-W-F x 2 weeks; MT-3724 infusion over 1 hour on each dosing day over 21 day cycle up to 6 cycles and then can be continued for 6 additional cycles.
240435|NCT02361333|Behavioral|Teaching Intervention|Patients will be taught how to install and use a remote monitor
240436|NCT02361320|Procedure|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
240437|NCT02361320|Behavioral|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
240438|NCT02361307|Procedure|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
240439|NCT02361307|Procedure|Conventional ADL training|The control group receive the conventional ADL training programme
240440|NCT02361294|Other|Blood samples|
240441|NCT02361268|Behavioral|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
240442|NCT02361268|Behavioral|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
240443|NCT02361255|Other|no intervention|
240444|NCT02361242|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
240445|NCT02361216|Drug|Ingenol Mebutate|
240446|NCT02361216|Other|Vehicle|Vehicle gel
240447|NCT02361203|Behavioral|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
240448|NCT02361190|Drug|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
240449|NCT02361190|Drug|Placebo|Administration of 1ml aqueous saline spray
240450|NCT02361177|Drug|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
240451|NCT02361151|Behavioral|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
240452|NCT02361151|Behavioral|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
240453|NCT02361138|Drug|SHR3824|
240454|NCT02361138|Drug|Placebo|
240455|NCT02361125|Drug|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
240494|NCT02360787|Behavioral|Almonds (15% kcal/day)|
240722|NCT02359149|Procedure|intravitreal injections given by a nurse|
240456|NCT02361125|Behavioral|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
240457|NCT02361112|Drug|pyrotinib combined with capecitabine|
240458|NCT02361099|Other|Monitoring by SENTINEL application|Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
240459|NCT02361086|Drug|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
240460|NCT02361060|Drug|Neostigmine|40mcg/kg
240461|NCT02361060|Drug|Sugammadex|4mg/kg
240462|NCT02361060|Drug|Atropine|10 mcg/kg
240463|NCT02361047|Behavioral|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
240464|NCT02361034|Drug|GRC 27864|
240465|NCT02361034|Drug|Placebo|
240466|NCT02361021|Other|- Weaning from mechanical ventilation|
240467|NCT02361008|Device|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
240468|NCT02361008|Procedure|Surgery repair with CBP|Traditional surgery repair under the CBP.
240469|NCT02360995|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
240470|NCT02360995|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
240471|NCT02360995|Drug|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
240472|NCT02360995|Drug|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
240473|NCT02360995|Drug|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
240474|NCT02360982|Behavioral|propofol and esmeron(rokuronyum)|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
240475|NCT02360982|Behavioral|marcaine and fentanyl|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
240476|NCT02360969|Other|Examination of the eye|"Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.~During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.~Pictures of the eye will be performed under general anesthesia.~Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:~Deep anesthesia: BIS <50 Deep anesthesia and muscle relaxation: BIS <50 and TOF 0/4"
240477|NCT02360956|Drug|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
240478|NCT02360956|Drug|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
240479|NCT02360943|Other|4 blood samples|PK and / or PD measurements during hospitalization
240480|NCT02360917|Other|Emerging from the Haze|A 6 week psycho-educational class
240481|NCT02360904|Other|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
240482|NCT02360891|Other|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
240483|NCT02360878|Device|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
240484|NCT02360865|Other|Exercise|
240485|NCT02360852|Drug|A4250|A4250 once daily
240486|NCT02360839|Device|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
240487|NCT02360826|Drug|Pravastatin|
240488|NCT02360826|Drug|Simvastatin|
240489|NCT02360813|Behavioral|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
240490|NCT02360813|Other|Treatment as usual|Keep getting usual care.
240491|NCT02360800|Procedure|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
240492|NCT02360800|Procedure|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
240493|NCT02360787|Behavioral|Energy restriction|
240495|NCT02360774|Drug|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
240496|NCT02360774|Drug|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
240497|NCT02360761|Procedure|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
240498|NCT02360761|Procedure|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
240499|NCT02360748|Dietary Supplement|Plant based high protein food items|Patients will add high protein plant based food items to their diet
240500|NCT02360735|Other|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
240501|NCT02360735|Other|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
240502|NCT02360722|Other|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
240503|NCT02360722|Other|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
240504|NCT02360709|Device|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
240505|NCT02360683|Other|patients with Parkinson's disease|
240506|NCT02360670|Other|control imaging|
240507|NCT02360670|Other|additional multimodal imaging|
240508|NCT02360657|Drug|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2*5 mg tablet) orally once daily for 4 weeks.
240509|NCT02360657|Drug|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
240510|NCT02360657|Drug|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
240511|NCT02360644|Dietary Supplement|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
240512|NCT02360631|Drug|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
240513|NCT02360631|Drug|Placebo|Health education counseling will be provided to all participants.
240514|NCT02360618|Drug|Metformin|See Group Description
240515|NCT02360618|Drug|Simvastatin|See Group Description
240516|NCT02360605|Behavioral|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
240517|NCT02360605|Behavioral|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
240518|NCT02360605|Behavioral|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
240519|NCT02360592|Drug|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
240520|NCT02360592|Drug|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
240521|NCT02360592|Drug|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
240522|NCT02360592|Drug|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
240523|NCT02360579|Biological|Lifileucel|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
240592|NCT02359994|Device|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot or the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
240723|NCT02359149|Procedure|intravitreal injections given by a physician|
240524|NCT02360566|Behavioral|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
240525|NCT02360553|Behavioral|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
240526|NCT02360553|Behavioral|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
240527|NCT02360540|Other|Gestalt estimation|
240528|NCT02360514|Drug|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
240529|NCT02360501|Drug|Docetaxel|75mg/㎡,d1
240530|NCT02360501|Drug|Cisplatin|25mg/㎡,d1-3
240531|NCT02360501|Drug|Capecitabine|2000mg/㎡,d1-14
240532|NCT02360488|Device|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
240533|NCT02360488|Behavioral|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
240534|NCT02360475|Biological|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
240535|NCT02360475|Biological|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
240536|NCT02360475|Biological|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
240537|NCT02360475|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
240538|NCT02360462|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
240539|NCT02360462|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
240540|NCT02360449|Behavioral|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
240541|NCT02360423|Device|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
240542|NCT02360423|Device|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
240543|NCT02360410|Behavioral|Check Yourself App with Feedback|
240544|NCT02360397|Drug|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
240545|NCT02360384|Drug|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
240546|NCT02360384|Dietary Supplement|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
240547|NCT02360371|Drug|Within-subject assessment of double-blind study drug|Participants will receive a double-blinded study drug as part of their daily sessions and will provide feedback regarding the effects of the drug on various measures. Though the study drug is FDA approved, it is being used here for a non-FDA approved purpose (though the FDA has provided permission to use the drug in this study).
240548|NCT02360358|Drug|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
240549|NCT02360358|Other|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
240550|NCT02360345|Drug|ONX-0801|
240551|NCT02360332|Behavioral|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
240552|NCT02360319|Drug|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
240553|NCT02360319|Drug|aripiprazole long acting injectable formulation|
240554|NCT02360306|Procedure|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
240673|NCT02359344|Drug|CNV1014802|
240555|NCT02360293|Behavioral|Stay Strong w/coaching|Pts randomly placed in the Stay Strong w/coaching group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
240556|NCT02360293|Behavioral|Stay Strong|Pts randomly placed in the Stay Strong arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
240557|NCT02360280|Drug|ketamine|sedative
240558|NCT02360280|Drug|midazolam|sedative
240559|NCT02360254|Drug|Insulin degludec|Once daily injection of insulin degludec
240560|NCT02360241|Device|Robot|Use of the robot to locate the fictional needle
240561|NCT02360228|Device|tACS (alpha)|
240562|NCT02360228|Device|tDCS|
240563|NCT02360215|Other|Cognitive Assessment|Ancillary studies
240564|NCT02360215|Radiation|Intensity-Modulated Radiation Therapy|Undergo HA-WBRT using IMRT
240565|NCT02360215|Drug|Memantine Hydrochloride|Given PO
240566|NCT02360215|Other|Quality-of-Life Assessment|Ancillary studies
240567|NCT02360215|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
240568|NCT02360215|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT using IMRT
240569|NCT02360202|Procedure|Impedance analysis|"Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.~impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle"
240570|NCT02360202|Drug|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
240571|NCT02360176|Procedure|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
240572|NCT02360176|Procedure|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
240573|NCT02360163|Procedure|Traditional Landmark Technique (TLT)|
240574|NCT02360163|Device|ultrasound guided peripheral intravenous access (USGPIVA)|
240575|NCT02360150|Radiation|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
240576|NCT02360124|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
240577|NCT02360124|Other|Water as placebo|topical application of water as a placebo in the control arm
240578|NCT02360124|Other|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
240579|NCT02360111|Drug|Cyclophosphamide|
240580|NCT02360098|Other|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
240581|NCT02360059|Drug|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
240582|NCT02360059|Other|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
240583|NCT02360059|Behavioral|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
240584|NCT02360059|Other|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
240585|NCT02360046|Drug|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
240586|NCT02360046|Drug|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
240587|NCT02360033|Behavioral|Systemic Therapy for Social Anxiety Disorder|
240588|NCT02360033|Behavioral|Cognitive Behavioral Therapy for Social Anxiety Disorder|
240589|NCT02360020|Device|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
240590|NCT02360007|Drug|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:~Buprenorphine (BUP)~Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~HIV+Hepatitis Education delivered via iPad"
240591|NCT02359994|Device|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot or the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
240674|NCT02359344|Drug|Placebo|
240724|NCT02359149|Procedure|Intravitreal injections|
240593|NCT02359981|Behavioral|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
240594|NCT02359981|Behavioral|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
240595|NCT02359981|Device|Smartphone|An Android Smartphone with operating system version higher than 2.2
240596|NCT02359968|Drug|FOLFOX|radiochemotherapy before surgery
240597|NCT02359968|Drug|CarboP-pacliT|radiochemotherapy before surgery
240598|NCT02359955|Device|zero degree teeth|zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
240599|NCT02359955|Device|anatomic teeth|when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
240600|NCT02359942|Drug|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
240601|NCT02359929|Biological|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
240602|NCT02359916|Other|Time delays on delivery of less healthy snacks|
240603|NCT02359916|Other|25%/$0.25 discount on healthy snacks|
240604|NCT02359916|Other|25%/$0.25 tax on less healthy snacks|
240605|NCT02359903|Drug|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
240606|NCT02359903|Drug|Infliximab (Remicade)|
240607|NCT02359890|Device|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
240608|NCT02359877|Drug|BCD-054|
240609|NCT02359877|Drug|Rebif|
240610|NCT02359877|Drug|Avonex|
240611|NCT02359864|Radiation|5 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
240612|NCT02359864|Radiation|10 daily fractions of 2 Gy|Whole Brain Irradiation to treat Alzheimer's Disease
240613|NCT02359851|Biological|Pembrolizumab|Given IV
240614|NCT02359851|Other|Laboratory Biomarker Analysis|Correlative studies
240615|NCT02359838|Other|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
240616|NCT02359838|Other|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
240617|NCT02359825|Drug|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
240618|NCT02359799|Device|IntelliStretch|The impaired ankle of the participants are trained 3 times a week for 6 weeks in the lab or at home. The participants use the portable robotic device to stretch the ankle and increase range of motion (ROM). Then subjects use their gained ROM immediately in the active movement training to play video games and improve motor control.
240619|NCT02359760|Procedure|Piezocision|Flapless corticotomies
240620|NCT02359747|Genetic|Polymerase Chain Reaction and Whole Genome Amplification|
240621|NCT02359734|Other|Smart pump safety Intervention bundle for improving IV medication administration process with smart pump|Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
240622|NCT02359721|Drug|tablet clarithromycin 500 mg (Clarino-500) orally|orally
240623|NCT02359708|Procedure|Surgical hand disinfection.|Bacterial recolonization
240624|NCT02359695|Drug|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
240625|NCT02359682|Other|No intervention|No Intervention
240626|NCT02359669|Behavioral|StimuLearn Intervention|"StimuLearn apps~Cognitive questionnaires"
240627|NCT02359669|Behavioral|Without StimuLearn intervention|Cognitive Questionnaires
240628|NCT02359656|Procedure|surgical treatment|C1-C1 arthrodesis
240629|NCT02359656|Other|non operative treatment for odontoid non unions|specific non operative treatment protocol
240630|NCT02359643|Drug|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:~Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).~Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
240631|NCT02359630|Device|EasyTube|Insertion for ventilation
240632|NCT02359630|Device|Endotracheal tube|Insertion for ventilation
240633|NCT02359617|Drug|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
240634|NCT02359617|Device|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
240635|NCT02359604|Drug|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.~The medication used (esomeprazole) in this trial is approved by the FDA"
240636|NCT02359604|Procedure|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
240637|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
240638|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
240639|NCT02359591|Other|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
240640|NCT02359578|Drug|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
240641|NCT02359565|Procedure|Diffusion Tensor Imaging|Correlative studies
240642|NCT02359565|Procedure|Diffusion Weighted Imaging|Correlative studies
240643|NCT02359565|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
240644|NCT02359565|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
240645|NCT02359565|Other|Laboratory Biomarker Analysis|Correlative studies
240646|NCT02359565|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative studies
240647|NCT02359565|Biological|Pembrolizumab|Given IV
240648|NCT02359565|Procedure|Perfusion Magnetic Resonance Imaging|Correlative studies
240649|NCT02359552|Drug|Rasagiline|
240650|NCT02359552|Drug|Placebo|
240651|NCT02359539|Procedure|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
240652|NCT02359526|Drug|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
240653|NCT02359513|Drug|Antidepressants|bulimic patients are treated during 3 months
240654|NCT02359513|Drug|Positron Emission Tomography (PET)|PET scan using [18F]MPPF is performed before and after (3 months)antidepressant treatment
240655|NCT02359500|Drug|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
240656|NCT02359487|Behavioral|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
240657|NCT02359487|Behavioral|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
240658|NCT02359474|Drug|Trabectedin|
240659|NCT02359474|Genetic|DNA double-strand breaks|"The rationale for combining Tr and RHT is based on immune mechanisms induced by local heating of which are independent of the anti-tumor effects of Tr. Recent results demonstrate that an acute inflammation at the site of the heated tumor area and danger signals are responsible for immune reactions against tumor and metastases (Frey 2012). Abscopal effects after local radiation of tumors with response of distant metastases are induced by similar mechanisms like heat stress (Formenti 2013, Golden 2015). The long-term results for soft-tissue sarcoma are consistent with abscopal effects induced by RHT in a randomized trial compared to chemotherapy alone (Issels 2018)."
240660|NCT02359461|Device|Combination pulsatile Stendo3|
240661|NCT02359448|Drug|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
240662|NCT02359435|Drug|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
240663|NCT02359435|Drug|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
240664|NCT02359422|Behavioral|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
240665|NCT02359409|Device|goggle balloon|Colonoscopy will be performed using the water immersion technique.
240666|NCT02359409|Other|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
240667|NCT02359396|Drug|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
240668|NCT02359383|Other|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
240669|NCT02359370|Drug|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
240670|NCT02359370|Drug|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
240671|NCT02359357|Drug|FDL169|
240672|NCT02359357|Drug|Placebo|
240675|NCT02359331|Procedure|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.~All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
240676|NCT02359331|Drug|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy~Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
240677|NCT02359331|Drug|Metronidazole|
240678|NCT02359331|Drug|Tetracycline|
240679|NCT02359331|Drug|tripotassium dicitrate bismuthate|
240680|NCT02359331|Drug|7 days tailored therapy Proton Pump Inhibitor|
240681|NCT02359331|Drug|Moxifloxacin|
240682|NCT02359331|Drug|Amoxicillin|
240683|NCT02359318|Procedure|Resin infiltration|Resin infiltration is done according to manufactures´ instructions after de-bonding of old brackets and prior bonding of new brackets.
240684|NCT02359318|Procedure|Bonding and debonding of brackets.|Brackets (Gemini metal brackets (3M Unitek) are bonded and de-bonded by one clinician (Roberto Vogel) and using the same bonding and de-bonding techniques and materials for all patients. All brackets were finally de-bonded at the end of the treatment, with silicon impressions taken before adhesive removal.
240685|NCT02359305|Drug|Acetaminophen|Acetaminophen given by IV
240686|NCT02359305|Drug|Acetaminophen|Acetaminophen suppository given rectally
240687|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI|
240688|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI|
240689|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
240690|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
240691|NCT02359292|Drug|Placebo pMDI|
240692|NCT02359279|Device|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
240693|NCT02359266|Dietary Supplement|Vitamin D|Given to patients with existing vitamin D deficiency
240694|NCT02359253|Other|Passive stretching|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot within preset ranges of motion.
240695|NCT02359253|Other|Passive movement|Prior to active training, subjects will be passively move their arm or hand by IntelliArm or the hand robot only within ranges that produce no to very minimal forces.
240696|NCT02359253|Other|IntelliArm|During the active training, subjects will be asked to actively move their arm while supported with IntelliArm robot to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
240697|NCT02359253|Other|Hand robot|During the active training, subjects will be asked to actively open and close their hand with the hand robot on while participating in task oriented occupational therapy focused on grasp and release tasks. The hand robot may provide resistance or assistance.
240698|NCT02359240|Procedure|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
240699|NCT02359240|Procedure|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
240700|NCT02359227|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
240701|NCT02359214|Dietary Supplement|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
240702|NCT02359214|Other|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
240703|NCT02359201|Drug|V0018|Oromucosal - Single dose
240704|NCT02359201|Drug|Placebo|Oromucosal - Single dose
240705|NCT02359188|Device|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
240706|NCT02359175|Drug|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
240707|NCT02359175|Drug|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
240708|NCT02359175|Drug|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
240709|NCT02359175|Drug|Oral Paracetamol|Paracetamol to be given orally
240710|NCT02359175|Drug|Oral NSAID|NSAID to be given orally
240711|NCT02359175|Drug|Oral opioids|Opioids to be given orally
240712|NCT02359175|Drug|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
240713|NCT02359162|Drug|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
240714|NCT02359162|Drug|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
240715|NCT02359162|Drug|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
240716|NCT02359162|Drug|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
240717|NCT02359162|Drug|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
240718|NCT02359162|Drug|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
240719|NCT02359162|Drug|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
240720|NCT02359162|Drug|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
240721|NCT02359162|Radiation|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
240725|NCT02359149|Drug|Anti-VEGF agents|
240726|NCT02359136|Procedure|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
240727|NCT02359136|Procedure|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
240728|NCT02359136|Procedure|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
240729|NCT02359123|Other|Cannabics capsules|Cannabis extract in an oil formulation
240730|NCT02359110|Drug|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
240731|NCT02359110|Other|Placebo|Patient will receive placebo tab less than 1 hour before surgery
240732|NCT02359097|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC or DCE-CBV mapping
240733|NCT02359097|Drug|Ferumoxytol|Given IV
240734|NCT02359097|Drug|Gadoteridol|Given IV
240735|NCT02359097|Procedure|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
240736|NCT02359084|Behavioral|Family Navigation|
240737|NCT02359084|Behavioral|Conventional Care Management|
240738|NCT02359071|Other|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
240739|NCT02359058|Drug|Ramucirumab|Administered IV
240740|NCT02359058|Drug|Capecitabine|Administered orally
240741|NCT02359058|Drug|Cisplatin|Administered IV
240742|NCT02359058|Drug|S-1|Administered orally
240743|NCT02359058|Drug|Oxaliplatin|Administered IV
240744|NCT02359045|Drug|D1400147|Treatment A
240745|NCT02359045|Drug|D14000136|Treatment B
240746|NCT02359045|Drug|D14000137|Treatment C
240747|NCT02359045|Drug|Epanova®|Treatment D
240748|NCT02359032|Drug|ASP6858|Oral tablets
240749|NCT02359032|Drug|Placebo|Oral tablets
240750|NCT02359019|Biological|Pembrolizumab|Given IV
240751|NCT02359019|Other|Laboratory Biomarker Analysis|Correlative studies
240752|NCT02359006|Drug|Minocycline|Minocycline will be compared with placebo
240753|NCT02359006|Drug|Placebo|Placebo will be compared with minocycline
240754|NCT02358993|Drug|methenamine hippurate|A urinary antiseptic used for prevention of UTI
240755|NCT02358993|Drug|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
240756|NCT02358980|Device|KIDNEY therapy|
240757|NCT02358967|Dietary Supplement|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
240758|NCT02358967|Dietary Supplement|Placebo|2 x 150 mg capsules
240759|NCT02358954|Procedure|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
240760|NCT02358954|Procedure|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
240761|NCT02358954|Procedure|3D Turntable|
240762|NCT02358954|Procedure|Vection stimulation|
240763|NCT02358941|Behavioral|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
240764|NCT02358941|Behavioral|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
240765|NCT02358928|Other|Diet Intervention|
240766|NCT02358915|Device|FastStart neuromuscular electrical stimulator|
240767|NCT02358902|Device|tDCS|tDCS - DC stimulator, Neurocom, Germany
240768|NCT02358902|Procedure|active intervention of aerobic exercise|different types of aerobic exercise
240769|NCT02358902|Device|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
240770|NCT02358902|Procedure|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
240771|NCT02358889|Biological|hI-con1|Intravitreal injection of hI-con1 0.3 mg
240772|NCT02358889|Biological|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
240773|NCT02358889|Other|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
240774|NCT02358863|Drug|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
240775|NCT02358863|Drug|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
240776|NCT02358863|Drug|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
240777|NCT02358863|Drug|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
240778|NCT02358863|Drug|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
240779|NCT02358863|Drug|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
240780|NCT02358863|Drug|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
240781|NCT02358863|Drug|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
240782|NCT02358850|Drug|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
240783|NCT02358850|Drug|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
240784|NCT02358850|Drug|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
240785|NCT02358850|Drug|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
240786|NCT02358824|Drug|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily~(1arm:2period and 4period, 2arm:1period and 3period)"
240787|NCT02358824|Drug|Telmisartan|"- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)~(1arm:1period and 3period, 2arm: 2period and 4period)"
240788|NCT02358824|Drug|S-amlodipine|"- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)~(1arm:1period and 3period, 2arm: 2period and 4period)"
240789|NCT02358811|Device|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.~Before any examination, the manipulator will check the absence of contraindication to MRI.~During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.~Throughout the examination, a physician will always be present."
240790|NCT02358811|Behavioral|Cognitive assessment|"This cognitive assessment will include the following executive tests :~test of Stroop~left Trail Making Test A and B~verbal fluence test~test of memory of figures direct and inverse in order~completion of matrices~Paced Auditory Serial Addition Test (PASAT)"
240791|NCT02358798|Other|3 years-assessment of respiratory function|
240792|NCT02358785|Device|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
240793|NCT02358772|Other|thrombolysis in a pre-hospital setting (STEMO concept)|
240794|NCT02358759|Procedure|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
240795|NCT02358746|Other|combined endo/epicardial approach|
240796|NCT02358746|Other|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
240797|NCT02358733|Procedure|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
240798|NCT02358733|Procedure|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
240799|NCT02358720|Radiation|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
240800|NCT02358720|Radiation|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
240801|NCT02358707|Other|Ibuprofen phonophoresis|
240802|NCT02358694|Dietary Supplement|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
240803|NCT02358694|Other|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
240804|NCT02358681|Drug|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
240805|NCT02358681|Drug|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
240806|NCT02358681|Drug|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
240807|NCT02358681|Drug|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
240808|NCT02358668|Drug|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
240809|NCT02358668|Drug|BTI320 matching placebo|Placebo
240810|NCT02358655|Other|Retrospective review of OAC prescription|
240811|NCT02358655|Other|Prescription of OAC in ED|
240812|NCT02358655|Other|Community AF clinic|
240813|NCT02358642|Drug|Angiotensin converting enzyme inhibitor (Lisinopril)|
240814|NCT02358642|Drug|Placebo|
240815|NCT02358629|Device|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
240816|NCT02358590|Behavioral|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
240817|NCT02358590|Behavioral|Standard care|The treating physician will advice participants to take vitamin D
240818|NCT02358577|Device|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
240819|NCT02358577|Other|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
240820|NCT02358564|Procedure|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
240821|NCT02358564|Procedure|Upper Endoscopy|
240822|NCT02358564|Procedure|Rectal Barostat and Infusion of Fats|Feeding tube will be placed, as well as a small balloon in the rectum.
240823|NCT02358551|Device|Placement of electrode lead through axillary vein puncture|
240824|NCT02358551|Device|Placement of electrode lead through subclavian vein puncture|
240825|NCT02358538|Drug|Ganaxolone|oral suspension or capsules
240826|NCT02358525|Behavioral|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
240827|NCT02358512|Other|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
240828|NCT02358499|Drug|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
240829|NCT02358486|Device|Acupuncture|"Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 ~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
240830|NCT02358486|Device|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
240831|NCT02358473|Biological|mogamulizumab|Mogamulizumab will be administered by IV infusion.
240832|NCT02358473|Drug|Docetaxel|Docetaxel will be administered by IV infusion.
240833|NCT02358460|Device|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
240834|NCT02358447|Procedure|TKR|non-navigated versus computer-navigated total knee replacement
240835|NCT02358434|Radiation|Observational use of fluoroscopy|
240836|NCT02358408|Device|Blood glucose monitoring systems for self-testing|
240837|NCT02358395|Drug|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
240838|NCT02358395|Drug|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
240839|NCT02358382|Drug|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
240840|NCT02358369|Drug|Bimatoprost|Bimatoprost sustained release
240841|NCT02358369|Drug|Timolol|BID drops OU, 0.5% ophthalmic solution
240842|NCT02358356|Drug|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
240843|NCT02358356|Drug|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
240844|NCT02358356|Drug|Temozolomide|temozolomide 75mg/m2 b.i.d.
240845|NCT02358343|Behavioral|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
240846|NCT02358343|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
240847|NCT02358343|Drug|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
240848|NCT02358330|Other|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
240849|NCT02358317|Behavioral|Video Game Motor Training|
240850|NCT02358317|Behavioral|Sedentary Video Game Training|
240851|NCT02358304|Drug|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
240852|NCT02358304|Drug|Placebo|
240853|NCT02358291|Procedure|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
240854|NCT02358291|Procedure|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
240855|NCT02358291|Procedure|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
240856|NCT02358265|Drug|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
240857|NCT02358265|Drug|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
240858|NCT02358265|Drug|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
240859|NCT02358265|Drug|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
240860|NCT02358239|Procedure|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
240861|NCT02358226|Behavioral|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
240862|NCT02358226|Behavioral|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Silulo or Zenzele programs based in Khayelitsha for a period of 6 months. These programs offer practical and market-related training in computer skills, woodwork, or welding. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
240863|NCT02358213|Procedure|Ultrasound|Ultrasound examinations are done 5 times
240864|NCT02358200|Drug|BMN-673|
240865|NCT02358200|Drug|Carboplatin|
240866|NCT02358200|Drug|Paclitaxel|
240867|NCT02358187|Biological|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
240868|NCT02358174|Procedure|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.~All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
240869|NCT02358174|Other|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
240870|NCT02358174|Other|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
240871|NCT02358161|Drug|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
240872|NCT02358135|Other|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
240873|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
240874|NCT02358122|Other|Wholegrain rye|A variety of cereal foods providing >100g/day wholegrain from rye
240875|NCT02358122|Other|Wholegrain wheat|A variety of cereal foods providing >100g/day wholegrain from wheat
240876|NCT02358122|Other|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
240877|NCT02358109|Behavioral|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
240878|NCT02358096|Drug|ASP8232|oral capsule
240879|NCT02358096|Drug|Placebo|oral capsule
240880|NCT02358083|Behavioral|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
240881|NCT02358057|Drug|Dexmedetomidine|
240882|NCT02358057|Drug|Alfentanil|
240883|NCT02358044|Drug|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
240884|NCT02358044|Biological|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
240885|NCT02358044|Drug|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
240886|NCT02358044|Drug|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
240887|NCT02358031|Biological|Pembrolizumab|
240888|NCT02358031|Drug|Cisplatin|
240889|NCT02358031|Drug|Carboplatin|
240890|NCT02358031|Drug|5-FU|
240891|NCT02358031|Biological|Cetuximab|
240932|NCT02357706|Device|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
240933|NCT02357693|Drug|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
241145|NCT02355821|Drug|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
240892|NCT02358018|Drug|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately ~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
240893|NCT02358005|Procedure|Extracorporeal shock wave therapy 60mj|
240894|NCT02358005|Procedure|Extracorporeal shock wave therapy 120mj|
240895|NCT02358005|Procedure|non extracorporeal shock wave therapy|
240896|NCT02357992|Radiation|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
240897|NCT02357979|Device|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
240898|NCT02357979|Other|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
240899|NCT02357966|Biological|514G3|True Human Monoclonal Antibody
240900|NCT02357966|Drug|Placebo|Buffered saline solution
240901|NCT02357966|Drug|Standard IV antibiotic therapy|standard antibiotic therapy will be determined by the attending physician and will be guided by the results of cultures with sensitivities.
240902|NCT02357953|Other|Measurement of cardiac index|
240903|NCT02357940|Drug|Experimental Product|1% Colloidal Oatmeal Balm
240904|NCT02357927|Behavioral|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
240905|NCT02357927|Behavioral|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
240906|NCT02357901|Drug|SUBOXONE|SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
240907|NCT02357901|Drug|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
240908|NCT02357901|Drug|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
240909|NCT02357888|Drug|V0018|Oromucosal - Single dose
240910|NCT02357888|Drug|Placebo|Oromucosal - Single dose
240911|NCT02357862|Procedure|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
240912|NCT02357849|Drug|Aripiprazole|see arm description
240913|NCT02357849|Drug|Fluoxetine|see arm description
240914|NCT02357836|Drug|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
240915|NCT02357823|Other|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
240916|NCT02357823|Other|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
240917|NCT02357810|Drug|Pazopanib Hydrochloride|Given PO
240918|NCT02357810|Drug|Oral Topotecan Hydrochloride|Given PO
240919|NCT02357810|Other|Laboratory Biomarker Analysis|Correlative studies
240920|NCT02357797|Drug|Vortioxetine|
240921|NCT02357797|Other|Placebo|
240922|NCT02357784|Device|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
240923|NCT02357771|Drug|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
240924|NCT02357771|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
240925|NCT02357758|Drug|Antibiotic Prophylaxis|
240926|NCT02357745|Procedure|Non surgical periodontal therapy|scaling and root planing
240927|NCT02357732|Drug|Nivolumab|
240928|NCT02357732|Drug|Trametinib|
240929|NCT02357732|Drug|Dabrafenib|
240930|NCT02357719|Device|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
240931|NCT02357706|Device|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
241136|NCT02355899|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
240934|NCT02357680|Other|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.~The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
240935|NCT02357654|Drug|GnRH|single shot of GnRH agonist
240936|NCT02357654|Drug|placebo|placebo
240937|NCT02357641|Other|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
240938|NCT02357628|Device|Wound treatment with RO-NPT|
240939|NCT02357628|Device|Wound Irrigation|
240940|NCT02357615|Drug|nifedipine CR tablets (Xin Ran)|
240941|NCT02357615|Drug|Adalat|
240942|NCT02357602|Drug|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
240943|NCT02357589|Procedure|2D laparoscopic cholecystectomy|
240944|NCT02357589|Procedure|3D laparoscopic cholecystectomy|
240945|NCT02357576|Drug|Intralipid 20% I.V. Fat Emulsion|
240946|NCT02357563|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
240947|NCT02357563|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
240948|NCT02357550|Drug|ketone|3-OHB is infused intravenously.
240949|NCT02357550|Drug|placebo|Saline infusion.
240950|NCT02357537|Behavioral|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
240951|NCT02357524|Drug|Oritavancin|
240952|NCT02357511|Device|Study Monitor used|
240953|NCT02357498|Procedure|transsphenoidal surgery|
240954|NCT02357485|Biological|ADSC|Single injection of ADSC
240955|NCT02357472|Drug|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
240956|NCT02357459|Drug|FX006|Single 5 mL IA injection
240957|NCT02357459|Drug|Placebo|Single 5 mL IA injection
240958|NCT02357459|Drug|TCA IR 40|Single 1 mL IA injection
240959|NCT02357433|Device|High Doses CPFA|
240960|NCT02357420|Drug|Relamorelin|Double blind relamorelin was given subcutaneously BID for 12 weeks.
240961|NCT02357420|Drug|Placebo|Placebo given subcutaneously for 12 weeks.
240962|NCT02357407|Drug|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
240963|NCT02357407|Drug|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
240964|NCT02357394|Device|Arabin Pessary|Arabin pessary is a ring manufactured from medical grade silicone. It comes in 13 different sizes. Participants will be fitted to the appropriate size by the study team.
240965|NCT02357381|Device|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
240966|NCT02357368|Drug|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
240967|NCT02357368|Device|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
240968|NCT02357368|Device|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
240969|NCT02357368|Device|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
240970|NCT02357355|Device|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
240971|NCT02357342|Drug|Sirolimus|intravitreal injection
240972|NCT02357342|Drug|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
240973|NCT02357303|Drug|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
240974|NCT02357303|Drug|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
240975|NCT02357303|Other|Placebo|100mL of water
240976|NCT02357290|Drug|Open-label Treatment with N-Acetylcysteine|
240977|NCT02357277|Drug|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
240978|NCT02357277|Other|Placebo Inhaler|inhaled placebo
240979|NCT02357264|Device|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
240980|NCT02357251|Other|Enhanced recovery protocol|
240981|NCT02357225|Drug|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
240982|NCT02357212|Procedure|coronary angiography|invasive procedure performed to determine coronary anatomy
240983|NCT02357212|Procedure|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
240984|NCT02357199|Other|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
240985|NCT02357173|Other|electronic cigarette|
240986|NCT02357173|Other|cigarette group|
240987|NCT02357160|Behavioral|Artwork|Prints by local artists that are hung on the walls of patient rooms.
240988|NCT02357147|Drug|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
240989|NCT02357147|Drug|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.~Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
240990|NCT02357147|Drug|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
240991|NCT02357147|Drug|Cisplatin|Combination Phase - Cisplatin 75 mg/m2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
240992|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow oxygen
240993|NCT02357134|Procedure|Oxygen Therapy|Receive high-flow air
240994|NCT02357134|Other|Quality-of-Life Assessment|Ancillary studies
240995|NCT02357134|Other|Questionnaire Administration|Ancillary studies
240996|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow oxygen
240997|NCT02357134|Procedure|Respiratory Therapy|Receive low-flow air
240998|NCT02357121|Device|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
240999|NCT02357108|Other|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
241000|NCT02357108|Behavioral|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
241001|NCT02357095|Procedure|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
241002|NCT02357082|Radiation|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
241003|NCT02357069|Drug|Enbrel|Etanercept
241004|NCT02357069|Drug|LBEC0101|Etanercept
241005|NCT02357056|Other|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
241006|NCT02357056|Other|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
241007|NCT02357056|Other|Virtual Reality|daVinci Surgical Skills simulation
241008|NCT02357043|Device|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
241009|NCT02357043|Device|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
241010|NCT02357030|Drug|Methyl-P plus GWI Nutrient Formula|"Week 1:~One tablet of Methyl-P (5mg) twice daily~Four tablets of GWI Nutrient Formula twice daily~Week 2 to Week 12 :~Two tablets of Methyl-P (10mg) twice daily~Four tablets of GWI Nutrient Formula twice daily"
241011|NCT02357017|Dietary Supplement|NaCl tablets|
241012|NCT02357004|Drug|Carvedilol|CR 40 mg daily in addition to normal BP medications
241013|NCT02357004|Drug|Chlorthalidone|12.5 mg daily in addition to normal BP medications
241014|NCT02356991|Drug|Famitinib|
241015|NCT02356991|Drug|Placebo|
241016|NCT02356978|Device|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
241017|NCT02356978|Device|DRAP|
241018|NCT02356965|Drug|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
241019|NCT02356965|Drug|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
241020|NCT02356952|Behavioral|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
241021|NCT02356952|Behavioral|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
241022|NCT02356952|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
241023|NCT02356939|Device|intraductal removable stent custom-made segment (2 cm)|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.~In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.~In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 5th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
241024|NCT02356939|Procedure|stent extraction by ERCP|stent extraction by endoscopic retrograde cholangio-pancreatography
241025|NCT02356913|Drug|Nicotine gum|
241026|NCT02356900|Procedure|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
241027|NCT02356900|Procedure|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
241028|NCT02356900|Drug|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
241029|NCT02356887|Other|IJV Flow in the sitting position|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions. The volunteers will be scanned initially in the sitting position at rest followed by the 2 conditions mimicking venous occlusion, one with internal jugular compression using neck collar and Valsalva maneuver.. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
241030|NCT02356874|Behavioral|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
241137|NCT02355886|Drug|Gabapentin|Given PO
241138|NCT02355886|Other|Placebo|Given PO
241031|NCT02356861|Device|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.~18 LED pods are in the helmet. Each LED pod:~Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2~20 NIR diodes, 830 nm and 4 red diodes, 633 nm.~1 J/cm2 = 30.4 sec"
241032|NCT02356848|Behavioral|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
241033|NCT02356848|Behavioral|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
241034|NCT02356835|Device|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
241035|NCT02356835|Device|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
241036|NCT02356822|Other|Patient registry|Oncology data registry
241037|NCT02356809|Drug|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
241038|NCT02356796|Other|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.~The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
241039|NCT02356796|Other|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
241040|NCT02356783|Device|Pedometer|Wireless pedometer
241041|NCT02356770|Device|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
241042|NCT02356770|Procedure|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
241043|NCT02356757|Behavioral|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
241044|NCT02356757|Behavioral|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
241045|NCT02356744|Other|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
241046|NCT02356718|Behavioral|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
241047|NCT02356718|Behavioral|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
241048|NCT02356705|Drug|Midazolam|midazolam 0.2 mg/kg given intranasally
241049|NCT02356705|Drug|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
241050|NCT02356705|Drug|saline placebo|intranasal saline given as placebo
241051|NCT02356692|Device|enfilcon A|Daily disposable contact lens worn in a daily wear, daily disposable mode
241052|NCT02356692|Device|senofilcon A|Daily disposable contact lens worn in a daily wear, daily disposable mode
241053|NCT02356679|Drug|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
241054|NCT02356679|Drug|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
241055|NCT02356653|Device|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
241056|NCT02356640|Procedure|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
241139|NCT02355886|Other|Questionnaire Administration|Ancillary studies
241140|NCT02355873|Device|AN69ST hemofilter|
241141|NCT02355873|Device|AN69 hemofilter|
241057|NCT02356640|Procedure|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson &Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
241058|NCT02356640|Device|Olympus UM 2000|
241059|NCT02356640|Device|B-D Quincke Type Point|
241060|NCT02356640|Drug|Levobupivacaine|
241061|NCT02356627|Other|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
241062|NCT02356588|Drug|Sufentanil Tablet 30 mcg|
241063|NCT02356588|Drug|Placebo Tablet|
241064|NCT02356575|Other|Acupuncture|
241065|NCT02356575|Other|Cognitive Behavior Therapy|
241066|NCT02356562|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|tablet, ombitasvir coformulated with paritaprevir and ritonavir; tablet, dasabuvir
241067|NCT02356562|Drug|Sofosbuvir|tablet
241068|NCT02356562|Drug|Ribavirin|tablet
241069|NCT02356549|Behavioral|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
241070|NCT02356549|Behavioral|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
241071|NCT02356549|Behavioral|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
241072|NCT02356536|Device|Agilitas|WCD trial
241073|NCT02356510|Procedure|Primary PCI|
241074|NCT02356471|Device|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
241075|NCT02356471|Other|Questionnaire Administration|Ancillary studies
241076|NCT02356471|Other|Quality-of-Life Assessment|Ancillary studies
241077|NCT02356458|Drug|Ibrutinib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg"
241078|NCT02356458|Drug|bortezomib|"Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11"
241079|NCT02356445|Other|Cytotoxic drug|Observe patients versus treatment type
241080|NCT02356419|Drug|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
241081|NCT02356406|Radiation|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.~It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
241082|NCT02356380|Other|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.~Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
241083|NCT02356367|Other|telemonitoring|
241084|NCT02356354|Procedure|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
241085|NCT02356341|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
241086|NCT02356328|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
241087|NCT02356315|Other|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
241088|NCT02356302|Device|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|Contains 182 mg vicriviroc (MK-4176).
241089|NCT02356302|Device|MK-2048 IVR|Contains 30 mg MK-2048.
241090|NCT02356302|Device|MK-2048A IVR|Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
241091|NCT02356302|Device|Placebo IVR|
241092|NCT02356289|Drug|Placebo|
241093|NCT02356289|Drug|MYK-461|
241094|NCT02356276|Procedure|D2 lymphadenectomy|
241095|NCT02356276|Procedure|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
241096|NCT02356276|Drug|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.~SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40 mg/m^2 bid, po, day 1-14 (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
241097|NCT02356237|Other|No episiotomy|Avoidance of episiotomy
241098|NCT02356224|Drug|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
241099|NCT02356224|Drug|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
241142|NCT02355860|Behavioral|assessment|assessment
241143|NCT02355847|Other|Lectures|Lectures
241144|NCT02355834|Other|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
241192|NCT02355470|Behavioral|GIFTSS|Universal education and brief counseling regarding sexual violence
241100|NCT02356211|Other|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIATRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
241101|NCT02356211|Other|Falls e-consult|Electronic medical record review for falls assessment (Falls e-consult) was also available to primary care physicians during the time of the study. Recommendations were made based on information available in the EMR, but without the benefit of a history and physical targeted at falls assessment.
241102|NCT02356198|Drug|EXPAREL|transversus abdominis plane injection
241103|NCT02356198|Drug|Intrathecal hydromorphone|Intrathecal opioid administration
241104|NCT02356159|Biological|Rituximab|Rituximab: 375 mg/m2 IV, day 1 for patients with CD20-positive disease
241105|NCT02356159|Drug|Conditioning Chemotherapy|Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3
241106|NCT02356159|Drug|TMS|Tacrolimus: 0.02 mg/kg , start day 3. Continue IV or PO. Taper will begin at day +60 if no acute GVHD then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.
241107|NCT02356159|Drug|FLAG|Fludarabine:25 mg/m2 per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m2 IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy
241108|NCT02356159|Drug|EPOCH-F|Fludarabine:25 mg/m2 per day IV infusion over 30 minutes, daily on days 1-4. Etoposide :50 mg/m2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin:10 mg/m2/day CIV, days 1-4. Vincristine: 0.4 mg/m2 per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide: 750 mg/m2 IV infusion over 30 minutes on day 5 Prednisone:60 mg/m2 per day PO daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV.
241109|NCT02356159|Procedure|Hematopoietic Stem Cell Transplant|Hematopoietic stem cell transplant
241110|NCT02356159|Drug|Palifermin|Escalating doses of palifermin given during transplant phase
241111|NCT02356146|Drug|Tacrolimus C12|
241112|NCT02356120|Other|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
241113|NCT02356107|Drug|5-hydroxytryptophan and Creatine monohydrate|
241114|NCT02356094|Procedure|Pentacam|Corneal topography using Scheimpflug Pentacam examination
241115|NCT02356081|Other|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
241116|NCT02356068|Other|ROTEM analysis|3 blood samples for ROTEM analysis
241117|NCT02356055|Behavioral|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
241118|NCT02356042|Other|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
241119|NCT02356016|Behavioral|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
241120|NCT02356016|Behavioral|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
241121|NCT02356016|Other|control (dietary counseling)|Monthly dietary counseling only
241122|NCT02356003|Device|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
241123|NCT02355990|Procedure|Minimally Invasive Micro Sclerostomy|Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
241124|NCT02355977|Drug|minocycline|Periocline dental ointment
241125|NCT02355977|Procedure|surface and root planning|surface and root planning
241126|NCT02355964|Behavioral|Exercise|Aerobe exercise 3 times a week in 8 weeks
241127|NCT02355964|Behavioral|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
241128|NCT02355951|Other|blood draw|
241129|NCT02355938|Drug|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
241130|NCT02355938|Drug|Placebo|1 dose of placebo every 6 hours x 2 doses
241131|NCT02355938|Drug|Vancomycin|Vancomycin 125 mg every 6 hours
241132|NCT02355925|Drug|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
241133|NCT02355925|Drug|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
241134|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
241135|NCT02355912|Device|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
241146|NCT02355821|Drug|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
241147|NCT02355808|Behavioral|Tailored Leaflet|
241148|NCT02355808|Behavioral|GP visit|
241149|NCT02355795|Behavioral|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
241150|NCT02355795|Behavioral|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
241151|NCT02355795|Behavioral|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
241152|NCT02355782|Biological|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
241153|NCT02355756|Drug|Maxadilan|
241154|NCT02355756|Drug|Placebo|
241155|NCT02355743|Drug|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
241156|NCT02355730|Procedure|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
241157|NCT02355717|Other|Observational Study|
241158|NCT02355704|Drug|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
241159|NCT02355704|Drug|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
241160|NCT02355691|Device|PREVENA|The device is a sealed negative pressure wound therapy tool. The device will be placed on the skin during surgery and left in place until their followup at 7 days.
241161|NCT02355678|Drug|dexamethasone|IV 0.5 mg/kg
241162|NCT02355678|Drug|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
241163|NCT02355678|Drug|General anesthesia|"Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).~Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%."
241164|NCT02355678|Procedure|Tonsillectomy|Mono-polar electrocautery or cold dissection
241165|NCT02355678|Procedure|gastric content suction|By orogastric tube
241166|NCT02355678|Drug|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
241167|NCT02355678|Drug|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
241168|NCT02355678|Drug|Paracetamol Suppository|If Visual Analogue Scale was less than 4
241169|NCT02355665|Drug|Nicotine Spray|Nicotine Spray
241170|NCT02355665|Drug|Placebo|Placebo to match nicotine spray
241171|NCT02355652|Device|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
241172|NCT02355652|Device|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
241173|NCT02355639|Drug|Clobetasol propionate 0.05 % ointment|
241174|NCT02355639|Drug|Betamethasone dipropionate 0.064 % ointment|
241175|NCT02355639|Drug|Petrolatum ointment|
241176|NCT02355613|Radiation|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
241177|NCT02355613|Radiation|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
241178|NCT02355600|Other|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
241179|NCT02355561|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
241180|NCT02355561|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
241181|NCT02355561|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
241182|NCT02355548|Other|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
241183|NCT02355535|Drug|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
241184|NCT02355522|Drug|Intrauterine lidocaine|
241185|NCT02355522|Drug|Lidocaine gel|
241186|NCT02355522|Drug|KY jelly|
241187|NCT02355522|Drug|Intrauterine normal saline|
241188|NCT02355509|Drug|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.~The treatment for three months"
241189|NCT02355509|Drug|Placebo|Placebo pills are given instead of acarbose in this group
241190|NCT02355496|Other|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
241191|NCT02355483|Device|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
242387|NCT02346786|Dietary Supplement|tap water|
241193|NCT02355470|Behavioral|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
241194|NCT02355444|Dietary Supplement|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
241195|NCT02355444|Dietary Supplement|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
241196|NCT02355431|Drug|Itacitinib|tablets to be administered by mouth once daily at dose selected from safety run-in phase
241197|NCT02355431|Drug|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
241198|NCT02355431|Drug|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
241199|NCT02355418|Procedure|Mitral valve repair|Standard mitral valve repair surgery
241200|NCT02355405|Device|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
241201|NCT02355405|Radiation|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
241202|NCT02355392|Other|Telemedical home blood pressure measurements|
241203|NCT02355379|Drug|LV5FU2 or capectitabine|
241204|NCT02355379|Drug|FOLFOX4 or XELOX|
241205|NCT02355379|Other|Observation|
241206|NCT02355379|Drug|LV5FU2 or capecitabine|
241207|NCT02355366|Behavioral|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
241208|NCT02355366|Behavioral|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
241209|NCT02355353|Other|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
241210|NCT02355340|Other|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
241211|NCT02355340|Other|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
241212|NCT02355327|Device|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
241213|NCT02355327|Behavioral|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
241214|NCT02355314|Other|Doppler-based renal|Doppler-based renal : day 0 and day 3
241215|NCT02355314|Biological|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
241216|NCT02355301|Procedure|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
241217|NCT02355288|Procedure|Minimally Invasive Coronary Bypass|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
241218|NCT02355288|Procedure|Percutenous Coronary Intervention|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
241219|NCT02355275|Procedure|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
241220|NCT02355262|Other|Informational Intervention|Receive CATCH-UP intervention
241221|NCT02355249|Procedure|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
241222|NCT02355249|Procedure|OE|Patients will be treated with traditional three incisions esophagectomy.
241223|NCT02355236|Drug|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
241224|NCT02355236|Drug|Celecoxib 200mg|Capsule, o.d.
241225|NCT02355236|Drug|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
241226|NCT02355236|Drug|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
241227|NCT02355223|Other|FAST|See information in arm description
241228|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1|packet containing 10^9 cells of Bifidobacteria adolescentis BD1
241229|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10^9 cells of Bifidobacteria animalis subsp. lactis BB-12
241230|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
241231|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
241232|NCT02355210|Dietary Supplement|galactooligosaccharide|5 g galactooligosaccharide
241233|NCT02355210|Dietary Supplement|Placebo|lactose powder, 5 grams
241234|NCT02355197|Drug|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
241235|NCT02355184|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
241236|NCT02355158|Drug|clonidine hydrochloride topical gel, 0.1%|
241237|NCT02355132|Other|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
241238|NCT02355119|Drug|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
241239|NCT02355119|Drug|Gemcitabine|
241240|NCT02355106|Device|PolarStart System|Atrial flutter Ablation
241241|NCT02355093|Procedure|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
241242|NCT02355093|Procedure|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
241243|NCT02355093|Drug|ropivacaine|
241244|NCT02355080|Behavioral|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
241245|NCT02355080|Behavioral|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
241246|NCT02355067|Behavioral|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
241247|NCT02355067|Behavioral|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
241248|NCT02355054|Drug|C-11 Choline PET Imaging|Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
241249|NCT02355041|Behavioral|Meal Replacement-based Weight Loss Diet|
241250|NCT02355041|Behavioral|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
241251|NCT02355028|Drug|LHA510 ophthalmic suspension|
241252|NCT02355028|Drug|LHA510 vehicle|Inactive ingredients used as a placebo comparator
241253|NCT02355028|Drug|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
241254|NCT02355002|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects. See attached Rossi et. al. 2009 as a reference to safety guidelines for TMS.
241255|NCT02354989|Device|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
241256|NCT02354989|Device|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
241257|NCT02354976|Drug|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
241258|NCT02354976|Drug|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
241259|NCT02354976|Drug|Fenofibrate 200mg|200mg capsule administered once daily
241260|NCT02354976|Drug|Placebo|Placebo matching to fenofibrate 200mg
241261|NCT02354963|Procedure|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
241262|NCT02354950|Drug|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
241263|NCT02354937|Drug|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
241264|NCT02354924|Device|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
241265|NCT02354924|Device|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
241266|NCT02354911|Biological|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (~10 million cells/injection).
241267|NCT02354911|Other|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
241268|NCT02354898|Drug|BBI503|
241269|NCT02354898|Drug|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
241270|NCT02354885|Drug|Tranexamic Acid|Coagulation Management / Efficiency
241271|NCT02354872|Drug|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
241302|NCT02354664|Other|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
242980|NCT02342782|Biological|Yttrium Y 90 Basiliximab|Given IV
241272|NCT02354872|Behavioral|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
241273|NCT02354872|Behavioral|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
241274|NCT02354872|Behavioral|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
241275|NCT02354872|Other|No Treatment|No Treatment
241276|NCT02354859|Drug|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
241277|NCT02354859|Drug|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
241278|NCT02354833|Drug|Phenylephrine|
241279|NCT02354833|Drug|Norepinephrine|
241280|NCT02354820|Other|Evidence Based Constipation Reminders|
241281|NCT02354807|Drug|Mirabegron|One-time dose of 100mg of Mirabegron
241282|NCT02354807|Other|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
241283|NCT02354794|Dietary Supplement|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
241284|NCT02354794|Dietary Supplement|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
241285|NCT02354781|Biological|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
241286|NCT02354768|Drug|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
241287|NCT02354768|Drug|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
241288|NCT02354755|Device|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
241289|NCT02354742|Other|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
241290|NCT02354742|Other|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
241291|NCT02354729|Other|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
241292|NCT02354716|Device|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions & function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- & post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, & what characteristics determine & predict refractory & recurrent strictures.
241293|NCT02354703|Drug|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
241294|NCT02354703|Drug|Placebo|Placebo + BBCET counseling
241295|NCT02354690|Drug|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
241296|NCT02354690|Drug|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
241297|NCT02354690|Drug|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.~On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
241298|NCT02354690|Drug|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
241299|NCT02354677|Other|In vitro experiments on bronchial epithelial cells|
241300|NCT02354664|Other|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
241301|NCT02354664|Other|Spirometry|Upright forced vital capacity (FVC)
241303|NCT02354664|Other|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
241304|NCT02354664|Other|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
241305|NCT02354664|Other|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
241306|NCT02354651|Other|Pulmonary function testing|Measure the breathing muscles ability to move gases in and out
241307|NCT02354651|Other|Resting breathing pattern|Record resting ventilatory flow and timing
241308|NCT02354651|Other|Respiratory muscle endurance test|Subjects will maintain breathing rate with loaded breaths
241309|NCT02354651|Other|Phrenic nerve stimulation|
241310|NCT02354651|Other|Maximal inspiratory pressure|Measure the maximal airflow on inhalation
241311|NCT02354651|Other|Forced expiratory testing|Measure the maximal airflow and volume of gas that can be exhaled with the subject breathing or coughing forcefully
241312|NCT02354651|Other|EMG|Evaluate electrical activity of diaphragm via pacer
241313|NCT02354638|Behavioral|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
241314|NCT02354638|Drug|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
241315|NCT02354625|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
241316|NCT02354612|Drug|TRC105|
241317|NCT02354612|Drug|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
241318|NCT02354612|Drug|Axitinib|companion therapy selection depends on companion therapy used in the parent study
241319|NCT02354612|Drug|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
241320|NCT02354612|Drug|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
241321|NCT02354599|Drug|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
241322|NCT02354599|Drug|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
241323|NCT02354599|Drug|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
241324|NCT02354586|Drug|Niraparib|
241325|NCT02354573|Drug|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
241326|NCT02354560|Drug|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
241327|NCT02354547|Genetic|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
241328|NCT02354547|Drug|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
241329|NCT02354547|Drug|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
241330|NCT02354534|Drug|Artesunate Suppositories|
241331|NCT02354521|Other|NO INTERVENTIONS|
241332|NCT02354508|Drug|Pasireotide LAR|Pasireotide 40 mg and 60 mg.
241333|NCT02354495|Dietary Supplement|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
241334|NCT02354482|Behavioral|Patient Communication and Care Management|"Received the following Transitional Care strategies:~Helpful Health Care Contact OR Symptom Management~Post-discharge Care Consultation~Patient Goal/Preference Assessment~Plain Language Communication in Hospital~Plain Language Communication at Home~Transition Summary for Patients and Family Caregivers"
241335|NCT02354482|Behavioral|Home-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~Transition Team~Home visits~Plain Language Communication at Home~Promote Trust at Home~Referral to Community Services~Follow-up Appointment"
241336|NCT02354482|Behavioral|Hospital-Based Trust, Plain Language, and Coordination|"Received the following Transitional Care Strategies:~Post-discharge care consultation~Identify High-Risk Patients and Intervene~Medication Reconciliation~Plain Language Communication in Hospital~Promote Trust in the Hospital~Transition Summary for Patients and Family Caregivers"
241337|NCT02354482|Behavioral|Patient/Caregiver Assessment and Provider Information Exchange|"Received the following Transitional Care Strategies:~Patient Goal/Preference Assessment~Identify High-Risk Patients and Intervene~Timely Exchange of Critical Patient Information among Providers~Patient/Family Caregiver Transitional Care Needs Assessment"
241338|NCT02354482|Behavioral|Assessment and Teach Back|"Received the following Transitional Care Strategies:~Post-discharge care consultation~Language Assessment~Teach Back for Information and Skills"
242981|NCT02342782|Drug|Carmustine|Given IV
241339|NCT02354482|Other|Standard of Care (Reference)|No specific Transitional Care Strategy
241340|NCT02354443|Biological|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
241341|NCT02354430|Behavioral|Water-exercise|"An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.~One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice~Unsupervised water-exercises (The six AquaMama exercises)~Motivating weekly emails during the 12 week training period.~Brush up sessions is held once every month for guidance in performing the exercises."
241342|NCT02354417|Biological|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
241343|NCT02354404|Biological|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
241344|NCT02354404|Biological|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
241345|NCT02354404|Biological|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
241346|NCT02354391|Drug|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
241347|NCT02354391|Drug|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
241348|NCT02354391|Procedure|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
241349|NCT02354378|Drug|Dexmedetomidine|
241350|NCT02354378|Other|Memory Test|
241351|NCT02354365|Device|Transpulmonary Pressure measurement|Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
241352|NCT02354352|Drug|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
241353|NCT02354352|Drug|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
241354|NCT02354339|Dietary Supplement|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
241355|NCT02354339|Other|Placebo|Intervention will be administered 30 minutes before meals
241356|NCT02354326|Radiation|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
241357|NCT02354326|Radiation|computed tomography|Undergo CT without VNC
241358|NCT02354313|Drug|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).~Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
241359|NCT02354300|Device|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
241360|NCT02354287|Procedure|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
241361|NCT02354274|Radiation|Escalated: Inhomogene dose plan|
241362|NCT02354274|Radiation|Standard: Homogene dose plan|
241363|NCT02354261|Drug|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
241364|NCT02354248|Procedure|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
241365|NCT02354235|Drug|Teneligliptin|
241366|NCT02354235|Drug|Canagliflozin|
241367|NCT02354235|Drug|Placebo|
241368|NCT02354222|Drug|Canagliflozin|
241369|NCT02354222|Drug|Teneligliptin|
241370|NCT02354222|Drug|Placebo|
241371|NCT02354196|Procedure|CCTA|CT of heart to assess coronary disease
241372|NCT02354183|Behavioral|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
241373|NCT02354170|Drug|Mifepristone|
241374|NCT02354170|Drug|Placebo|
241375|NCT02354157|Other|no intervention|no intervention
241403|NCT02353962|Other|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
241376|NCT02354144|Other|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
241377|NCT02354144|Other|Control gel|A gel not containing carrageenan
241378|NCT02354131|Drug|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
241379|NCT02354131|Drug|Bevacizumab|
241380|NCT02354118|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
241381|NCT02354118|Other|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
241382|NCT02354092|Procedure|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
241383|NCT02354092|Procedure|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
241384|NCT02354092|Procedure|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
241385|NCT02354092|Procedure|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference~Drugs:~Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.~Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
241386|NCT02354092|Behavioral|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
241387|NCT02354092|Drug|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
241388|NCT02354079|Genetic|hypobetalipoproteinemia genetic and genotypic screening|
241389|NCT02354066|Device|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
241390|NCT02354066|Device|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
241391|NCT02354066|Device|Retail Shoe|Brake response time measurement before surgery (control run)
241392|NCT02354053|Drug|Switch to Triumeq|
241393|NCT02354053|Behavioral|Adherence support + current ART|
241394|NCT02354040|Behavioral|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
241395|NCT02354027|Drug|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.~Drug: SHR3824 + Metformin"
241396|NCT02354014|Drug|Bedaquiline (TMC207)|TMC207 oral tablet adult formulation (containing 100 mg TMC207 per tablet) administered as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive an age appropriate oral tablet formulation containing 20mg TMC207. Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. In Cohort 3, dose of TMC207 6 mg/kg qd for the first 2 weeks, followed by TMC207 4 mg/kg tiw with intakes at least 2 days (48 hours) apart for 22 weeks will be administered. In cohort 4 the dose will depend upon the review of safety and pharmacokinetic data from Cohort 1 and 2 by internal safety monitoring group.
241397|NCT02354014|Drug|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
241398|NCT02354001|Drug|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
241399|NCT02354001|Drug|Placebo|1 capsule daily for 12 week trial - lactose
241400|NCT02353988|Drug|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade >= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
241401|NCT02353988|Other|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.~The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.~Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
241402|NCT02353975|Drug|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
241404|NCT02353949|Drug|Flutemetamol (Vizamyl)|PET-MR Scan using the radiotracer Flutemetamol (Vizamyl) for diagnostic purpose
241938|NCT02350114|Procedure|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
242982|NCT02342782|Drug|Etoposide|Given IV
241405|NCT02353936|Drug|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH & Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).~Route of administration: Orally (Take by swallowing) Dosage: Once daily"
241406|NCT02353923|Dietary Supplement|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
241407|NCT02353910|Procedure|Ultrasound|
241408|NCT02353871|Biological|Botulinum toxin type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
241409|NCT02353871|Drug|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
241410|NCT02353858|Other|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
241411|NCT02353858|Radiation|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
241412|NCT02353858|Drug|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
241413|NCT02353832|Device|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
241414|NCT02353819|Radiation|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
241415|NCT02353806|Drug|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
241416|NCT02353793|Device|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
241417|NCT02353793|Device|Cotton wool blanket|Using cotton wool blanket for patient warming
241418|NCT02353780|Drug|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
241419|NCT02353780|Drug|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
241420|NCT02353780|Drug|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
241421|NCT02353767|Procedure|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
241422|NCT02353754|Drug|Intrathecal morphine injection|0.2 mg
241423|NCT02353754|Drug|EXPAREL|266 mg
241424|NCT02353741|Drug|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
241425|NCT02353741|Radiation|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
241426|NCT02353728|Drug|Nilotinib|
241427|NCT02353715|Drug|Enzalutamide|
241428|NCT02353715|Drug|Abiraterone acetate|
241429|NCT02353715|Drug|Sipuleucel-T|
241430|NCT02353702|Procedure|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
241431|NCT02353702|Drug|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.~20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
241432|NCT02353702|Device|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
241433|NCT02353702|Drug|Infusion of placebo during 48 hours|
241434|NCT02353702|Drug|NaCl|
241435|NCT02353689|Dietary Supplement|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
241436|NCT02353689|Dietary Supplement|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
241437|NCT02353689|Dietary Supplement|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
241438|NCT02353676|Drug|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
241439|NCT02353676|Other|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
241440|NCT02353663|Other|Echocardiography|Echocardiography examination
241441|NCT02353650|Dietary Supplement|Q10|
241442|NCT02353650|Dietary Supplement|placebo|
241443|NCT02353637|Dietary Supplement|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
241444|NCT02353624|Behavioral|Cycling|Cycling distance of 2880 km in 14 days
241445|NCT02353611|Other|6% hydrogen peroxide|
241446|NCT02353611|Other|35% hydrogen peroxide|conventional peroxide whitening compound acted like control
241447|NCT02353598|Drug|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
241448|NCT02353598|Drug|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
241630|NCT02352350|Other|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
242020|NCT02349451|Biological|adalimumab|
241449|NCT02353598|Drug|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
241450|NCT02353598|Drug|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
241451|NCT02353572|Drug|Melphalan|Given IV
241452|NCT02353572|Drug|Bortezomib|Given IV
241453|NCT02353572|Drug|Dexamethasone|Given IV
241454|NCT02353572|Procedure|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
241455|NCT02353559|Behavioral|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
241456|NCT02353546|Behavioral|CALM|
241457|NCT02353533|Device|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
241458|NCT02353533|Device|EMR|Standard endoscopic mucosal resection using a resection snare
241459|NCT02353520|Other|motricity index strength assessment|
241460|NCT02353507|Device|Opticell Ag+|
241461|NCT02353507|Device|Aquacel Ag+|
241462|NCT02353494|Drug|Dihydroartemisinin-Piperaquine|Treatment according to national guidelines with follow up.
241463|NCT02353481|Other|Heart Failure Management|
241464|NCT02353468|Drug|Bortezomib|Given IV
241465|NCT02353468|Drug|Lenalidomide|Given PO
241466|NCT02353468|Drug|Dexamethasone|Given PO or IV
241467|NCT02353455|Procedure|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
241468|NCT02353442|Other|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
241469|NCT02353442|Other|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
241470|NCT02353442|Other|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
241471|NCT02353442|Other|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
241472|NCT02353442|Other|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
241473|NCT02353442|Other|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
241474|NCT02353429|Drug|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
241475|NCT02353416|Behavioral|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
241476|NCT02353416|Other|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
241477|NCT02353403|Other|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
241478|NCT02353403|Other|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
241479|NCT02353390|Other|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
241480|NCT02353364|Other|PGS|Embryos screened by the validated NGS technology CNV-Seq
241481|NCT02353351|Device|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
241482|NCT02353338|Procedure|Surgical intervention|Surgical management of radial fracture
241483|NCT02353338|Procedure|Conservative management|Immobilized/cast for 6 weeks
241484|NCT02353338|Device|cast|
241485|NCT02353325|Dietary Supplement|non-encapsulated FeSO4|
241486|NCT02353325|Dietary Supplement|encapsulated FeSO4, before cooking|
241487|NCT02353325|Dietary Supplement|encapsulated FeSO4, after cooking|
241488|NCT02353325|Dietary Supplement|non-encapsulated FeSO4 + ascorbic acid|
241489|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, before cooking|
241490|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, after cooking|
241491|NCT02353312|Drug|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
241492|NCT02353299|Drug|Silenor 6 mg|Silenor 6 mg single nighttime dose.
241493|NCT02353299|Drug|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
241494|NCT02353299|Drug|Placebo|placebo single nighttime dose-1.5 hours
241495|NCT02353299|Drug|Placebo|placebo single nighttime dose-4 hours
241496|NCT02353286|Device|Endoscopic insertion of biodegradable biliary stent|Endoscopic insertion of biodegradable biliary stent
241497|NCT02353273|Drug|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
241498|NCT02353260|Device|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
241499|NCT02353260|Drug|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
241500|NCT02353247|Drug|Norethindrone acetate|
241501|NCT02353234|Other|Bread|In each arm subjects consume bread
241502|NCT02353208|Other|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
241503|NCT02353208|Other|Placebo|Participants will not be asked to chew bacon bits
242021|NCT02349451|Biological|ABT-122|
241504|NCT02353195|Other|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
241505|NCT02353182|Drug|Dexmedetomidine|Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1-1.5 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
241506|NCT02353182|Drug|Remifentanil|Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
241507|NCT02353182|Drug|Bupivacaine|Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
241508|NCT02353182|Drug|Ropivacaine|Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
241509|NCT02353169|Drug|Dexmedetomidine|
241510|NCT02353169|Drug|Saline|
241511|NCT02353156|Other|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
241512|NCT02353156|Other|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
241513|NCT02353143|Drug|MEN1112|Intravenous infusion of MEN1112 pro/Kg body weight dose on days 1, 8, 15 of a 21-day cycle. Two induction cycles followed by a 3 week End of induction period. Post-induction/Maintenance Visits every 4 weeks with or without maintenance treatment administration, whilst clinical benefit is maintained as per Investigator's judgement. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).
241514|NCT02353130|Drug|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
241515|NCT02353117|Behavioral|Congenital Syphilis Intervention Group|
241516|NCT02353104|Dietary Supplement|Onion-Pumpkin Extract|
241517|NCT02353091|Device|Personal FM system|
241518|NCT02353078|Drug|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
241519|NCT02353078|Procedure|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
241520|NCT02353078|Device|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
241521|NCT02353065|Procedure|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
241522|NCT02353065|Radiation|Bedside x-ray|Portable x-ray of fracture post-reduction
241523|NCT02353052|Other|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
241524|NCT02353039|Drug|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
241525|NCT02353039|Drug|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
241526|NCT02353039|Drug|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
241527|NCT02353039|Drug|Placebo|Administer placebo t.i.d for 2 weeks
241528|NCT02353026|Drug|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
241529|NCT02353013|Dietary Supplement|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
241530|NCT02353013|Dietary Supplement|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
241531|NCT02353000|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
241532|NCT02353000|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
241533|NCT02352987|Drug|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
241534|NCT02352987|Drug|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
241535|NCT02352974|Drug|GAD-Alum|
241536|NCT02352974|Drug|Vitamin D|
241537|NCT02352961|Other|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
241538|NCT02352948|Drug|MEDI4736 (durvalumab)|MEDI4736 (durvalumab) treatment by intravenous infusion
241539|NCT02352948|Drug|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
241540|NCT02352948|Drug|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
241541|NCT02352948|Drug|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
241542|NCT02352948|Drug|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)|MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
241543|NCT02352948|Drug|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
241544|NCT02352935|Device|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
241545|NCT02352922|Drug|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
241546|NCT02352922|Drug|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
242022|NCT02349438|Device|senofilcon A|A soft spherical contact lens
241547|NCT02352909|Other|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
241548|NCT02352909|Other|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
241549|NCT02352909|Other|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
241550|NCT02352896|Drug|EPI-743|EPI-743 is a quinone oxidation product of alpha tocotrienol
241551|NCT02352883|Procedure|Magnetic Resonance Imaging|Undergo MRI
241552|NCT02352883|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy
241553|NCT02352883|Procedure|Therapeutic Surgical Procedure|Undergo wide local excision
241554|NCT02352883|Radiation|Radiation Therapy|Undergo radiation therapy
241555|NCT02352883|Drug|Endocrine Therapy|Undergo endocrine therapy
241556|NCT02352883|Other|Quality-of-Life Assessment|Ancillary studies
241557|NCT02352883|Other|Laboratory Biomarker Analysis|Correlative studies
241558|NCT02352883|Other|Cytology Specimen Collection Procedure|Correlative studies
241559|NCT02352870|Behavioral|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
241560|NCT02352870|Behavioral|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
241561|NCT02352857|Other|Sugar|100g of sponge cakes made with 24g of dextrose.
241562|NCT02352857|Other|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
241563|NCT02352844|Drug|Everolimus|
241564|NCT02352831|Drug|Tosedostat|
241565|NCT02352831|Drug|Capecitabine|
241566|NCT02352831|Procedure|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
241567|NCT02352818|Other|no study intervention|
241568|NCT02352805|Device|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
241569|NCT02352792|Radiation|radiochemotherapy with 70 Gy|
241570|NCT02352792|Radiation|radiochemotherapy with 77 Gy|
241571|NCT02352779|Dietary Supplement|Omega-3 Fatty Acid|Given PO
241572|NCT02352779|Other|Placebo|Given PO
241573|NCT02352779|Other|Questionnaire Administration|Ancillary studies
241574|NCT02352779|Other|Laboratory Biomarker Analysis|Correlative studies
241575|NCT02352753|Drug|Denosumab|All subjects will receive denosumab 1 mg/kg (up to a maximum of 60 mg) given subcutaneously every 6 months for 36 months.
241576|NCT02352740|Dietary Supplement|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
241577|NCT02352740|Dietary Supplement|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
241578|NCT02352714|Drug|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
241579|NCT02352714|Drug|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
241580|NCT02352701|Drug|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
241581|NCT02352701|Drug|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
241582|NCT02352701|Drug|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
241583|NCT02352688|Procedure|Enhanced Colorectal Geriatric Care|
241584|NCT02352675|Other|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
241585|NCT02352662|Other|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
241586|NCT02352649|Drug|Neovasculgen|
241587|NCT02352636|Other|magnetotherapy|The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
241588|NCT02352636|Device|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
241589|NCT02352636|Other|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
241590|NCT02352623|Radiation|DXA scan|DXA scan
241591|NCT02352623|Procedure|Clinical examination|Clinical examination
241592|NCT02352610|Procedure|LRTI|
241593|NCT02352610|Device|Biotenodesis Screw|
241594|NCT02352597|Drug|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
241595|NCT02352597|Drug|estradiol valerate|2mg from cycle day 7 to day 11
241596|NCT02352597|Drug|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
241597|NCT02352584|Biological|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
241598|NCT02352584|Biological|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
241599|NCT02352584|Biological|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
241631|NCT02352350|Other|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
241632|NCT02352337|Drug|FOLFIRINOX|Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
241633|NCT02352337|Drug|LV5FU2|Perfusion: Folinic Acid,5FU Bolus,5FU continue
241634|NCT02352337|Drug|FOLFIRI.3|Perfusion :Irinotecan,Acide folinique ,5FU continue
241600|NCT02352571|Biological|GC1118|"For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.~For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.~For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.~Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease."
241601|NCT02352558|Drug|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
241602|NCT02352558|Drug|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
241603|NCT02352558|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
241604|NCT02352558|Drug|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
241605|NCT02352558|Drug|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
241606|NCT02352545|Drug|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
241607|NCT02352532|Other|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
241608|NCT02352532|Other|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
241609|NCT02352519|Procedure|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
241610|NCT02352519|Procedure|Local Infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
241611|NCT02352506|Other|Blood draw for measurement of MIF|Observational study, no intervention
241612|NCT02352493|Drug|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
241613|NCT02352493|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
241614|NCT02352480|Device|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
241615|NCT02352467|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
241616|NCT02352454|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
241617|NCT02352441|Other|Implementation Intentions(II)|"Implementation Intention training will include:~Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
241618|NCT02352428|Other|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
241619|NCT02352402|Drug|Ticagrelor|
241620|NCT02352402|Drug|Placebo|
241621|NCT02352389|Other|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
241622|NCT02352389|Other|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
241623|NCT02352389|Other|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
241624|NCT02352389|Other|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
241625|NCT02352389|Other|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
241626|NCT02352376|Other|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
241627|NCT02352376|Other|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
241628|NCT02352363|Drug|CVT-301|
241629|NCT02352363|Other|Observational cohort|
241635|NCT02352337|Drug|Gemcitabine|Gemcitabine perfusion
241636|NCT02352324|Other|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
241637|NCT02352311|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
241638|NCT02352311|Drug|AVODART|Dutasteride 0.5 mg
241639|NCT02352311|Drug|CIALIS|Tadalafil 5 mg
241640|NCT02352298|Device|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
241641|NCT02352298|Device|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
241642|NCT02352285|Drug|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
241643|NCT02352285|Drug|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
241644|NCT02352272|Other|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
241645|NCT02352259|Procedure|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
241646|NCT02352259|Device|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
241647|NCT02352259|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
241648|NCT02352246|Procedure|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
241649|NCT02352246|Procedure|Physical activity programs high intensity intermittent exercise (HIIE)|
241650|NCT02352233|Procedure|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
241651|NCT02352207|Other|identification of a pulmonary malformation in the fetus|
241652|NCT02352194|Other|Rehabilitation|Physiotherapy and physical activity
241653|NCT02352181|Procedure|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if fibrinogen <1gram per liter~Platelet concentrate :~if platelets <50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.~if platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :~if prothrombin<40% before transfusion at anhepatic phase or in case of bleeding.~if prothrombin<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.~Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
241654|NCT02352181|Procedure|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM <8 mm~Platelet concentrate :~If MCF EXTEM <40mm or A10<35 mm and MCF or A10 FIBTEM >8mm.~If platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding.~2 Fresh frozen plasma if CT EXTEM >100s.~Bolus Tranexamic acid 1g and 3g every 24 hours :~if fibrinolysis in EXTEM~Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes >15%.~Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).~Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
241655|NCT02352168|Drug|Budesonide nasal spray|64mcg/1putt, 1 putt/nostril,b.i.d
241656|NCT02352168|Drug|Placebo|1 putt/nostril,b.i.d
241657|NCT02352155|Procedure|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
241658|NCT02352155|Other|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
241659|NCT02352142|Other|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
241660|NCT02352142|Behavioral|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
241661|NCT02352129|Other|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
241662|NCT02352116|Other|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
241663|NCT02352116|Other|Standard of care management|Current standard of care at a major U.S. teaching hospital.
241664|NCT02352103|Procedure|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
241665|NCT02352103|Procedure|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
242023|NCT02349438|Device|lotrafilcon B|
241666|NCT02352103|Device|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
241667|NCT02352090|Drug|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
241668|NCT02352090|Drug|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
241669|NCT02352090|Drug|Dienogest|One tablet orally for 9 weeks, continuous use
241670|NCT02352077|Biological|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
241671|NCT02352064|Procedure|PET (18-FDG)|Every patient will have a PET
241672|NCT02352051|Drug|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
241673|NCT02352051|Drug|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
241674|NCT02352038|Device|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
241675|NCT02352038|Other|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
241676|NCT02352025|Drug|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
241677|NCT02352012|Other|Autologous blood|Autologous blood was perfused to the target pulmonary segment
241678|NCT02352012|Device|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
241679|NCT02351999|Device|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
241680|NCT02351986|Procedure|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
241681|NCT02351986|Other|ice pack|
241682|NCT02351973|Drug|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
241683|NCT02351973|Drug|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
241684|NCT02351973|Drug|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg & + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.~In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.~In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
241685|NCT02351960|Drug|Dexlansoprazole|Dexlansoprazole capsules
241686|NCT02351947|Other|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
241687|NCT02351934|Drug|Furosemide|
241688|NCT02351934|Drug|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
241689|NCT02351934|Drug|Gabapentin|Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
241690|NCT02351921|Device|Transcranial magnetic stimulation|Intermittent theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. ITBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (~1 hour) in neural activity in the brain. The delivery of cTBS requires ~ 40 seconds in total.
241691|NCT02351908|Drug|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
241692|NCT02351908|Drug|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
241693|NCT02351908|Drug|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
241694|NCT02351895|Other|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
241695|NCT02351882|Drug|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
241696|NCT02351882|Drug|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
241697|NCT02351869|Drug|Nitrous Oxide|
241698|NCT02351869|Drug|Midazolam|
241699|NCT02351856|Drug|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
241700|NCT02351843|Device|MECTA Spectrum 5000Q|
241701|NCT02351830|Other|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
242024|NCT02349425|Drug|Gefapixant|
241702|NCT02351830|Procedure|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
241703|NCT02351817|Device|Test A|Ostomy appliance
241704|NCT02351817|Device|Test B|Ostomy appliance
241705|NCT02351817|Device|Baseline|Ostomy appliance
241706|NCT02351804|Drug|Ropivacaine + dexamethasone|Adductor canal block, single bolus
241707|NCT02351804|Drug|Ropivacaine + placebo|Adductor canal block, single bolus
241708|NCT02351791|Other|Patch 1, Center|
241709|NCT02351791|Other|Patch 1, Leakage pocket|
241710|NCT02351791|Other|Patch 1, Adhesive|
241711|NCT02351791|Other|Patch 2, Center|
241712|NCT02351791|Other|Patch 2, Leakage pocket|
241713|NCT02351791|Other|Patch 2, Adhesive|
241714|NCT02351791|Other|Patch 3, Center|
241715|NCT02351791|Other|Patch 3, Leakage pocket|
241716|NCT02351791|Other|Patch 3, Adhesive|
241717|NCT02351791|Other|Patch 4, Center|
241718|NCT02351791|Other|Patch 4, Leakage pocket|
241719|NCT02351791|Other|Patch 4, Adhesive|
241720|NCT02351791|Other|Patch 5, Center|
241721|NCT02351791|Other|Patch 5, Leakage pocket|
241722|NCT02351791|Other|Patch 5, Adhesive|
241723|NCT02351791|Other|Patch 6, Center|
241724|NCT02351791|Other|Patch 6, Leakage pocket|
241725|NCT02351791|Other|Patch 6, Adhesive|
241726|NCT02351765|Drug|Acelarin|First-in-class nucleotide analogue
241727|NCT02351765|Drug|Cisplatin|Platinum-compound chemotherapy drug
241728|NCT02351752|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR>60)
241729|NCT02351739|Drug|pembrolizumab|
241730|NCT02351739|Drug|ACP-196 in combination with pembrolizumab|
241731|NCT02351726|Device|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
241732|NCT02351713|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
241733|NCT02351700|Drug|IV Caldolor (IV Ibuprofen)|Compare addition of IV Caldolor (IV ibuprofen) intraoperatively and postoperatively against IV ibuprofen placebo added intraoperatively and postoperatively.
241734|NCT02351700|Drug|IV Ibuprofen placebo|Compare addition of IV ibuprofen placebo intraoperatively and postoperatively against IV Caldolor (IV ibuprofen) added intraoperatively and postoperatively.
241735|NCT02351687|Dietary Supplement|Lipid Nutrient Supplement|
241736|NCT02351687|Drug|Sulfadoxine-pyrimethamine|
241737|NCT02351687|Drug|Albendazole|
241738|NCT02351687|Drug|Zinc|
241739|NCT02351687|Other|Insecticide-treated bednet|
241740|NCT02351661|Other|There was no intervention|observational study, no intervention
241741|NCT02351648|Other|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge~Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge~Intervention after discharge:~Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
241742|NCT02351648|Other|Control|Patients receive usual standard of care from the internal medicine team
241743|NCT02351635|Other|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
241744|NCT02351622|Drug|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
241745|NCT02351622|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
241746|NCT02351622|Drug|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
241747|NCT02351609|Behavioral|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.~Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
241748|NCT02351609|Other|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
241749|NCT02351596|Other|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.~Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
241750|NCT02351596|Other|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
242025|NCT02349425|Drug|Placebo (for gefapixant)|
241751|NCT02351583|Device|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
241752|NCT02351583|Device|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
241753|NCT02351544|Drug|Botulinum Toxin Type A|
241754|NCT02351544|Procedure|Surgery|
241755|NCT02351544|Other|Daily headache diary|
241756|NCT02351544|Other|Migraine Disability Assessment Test (MIDAS)|
241757|NCT02351544|Other|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
241758|NCT02351544|Other|Migraine-Specific Quality of Life Questionnaire (MSQ)|
241759|NCT02351531|Dietary Supplement|Extensively Hydrolyzed formula|
241760|NCT02351518|Other|No intervention|There will be no interventions in this study
241761|NCT02351505|Drug|Selinexor|Given PO
241762|NCT02351505|Other|Laboratory Biomarker Analysis|Correlative studies
241763|NCT02351505|Other|Pharmacological Study|Correlative studies
241764|NCT02351492|Procedure|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
241765|NCT02351492|Procedure|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
241766|NCT02351492|Device|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
241767|NCT02351492|Device|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
241768|NCT02351479|Behavioral|Hula|
241769|NCT02351466|Other|Observational|
241770|NCT02351440|Drug|duloxetine|patients will be randomized to receive either duloxetine or placebo
241771|NCT02351440|Drug|placebo|placebo
241772|NCT02351427|Drug|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
241773|NCT02351427|Drug|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
241774|NCT02351414|Device|Total Knee Arthroplasty (EVOLUTION®)|
241775|NCT02351401|Behavioral|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
241776|NCT02351388|Device|Transcranial Direct Current Stimulation|
241777|NCT02351388|Other|Sham Stimulation|
241778|NCT02351375|Other|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
241779|NCT02351375|Device|IntelliCap® system|
241780|NCT02351362|Behavioral|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
241781|NCT02351349|Other|multidisciplinary intervention|multidisciplinary intervention
241782|NCT02351336|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)~- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )~- CL measurement using 2D ultrasound ( in cm)"
241783|NCT02351323|Drug|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
241784|NCT02351323|Behavioral|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
241785|NCT02351310|Drug|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
241786|NCT02351310|Genetic|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
241787|NCT02351297|Dietary Supplement|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
241788|NCT02351297|Dietary Supplement|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
241789|NCT02351297|Dietary Supplement|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
241790|NCT02351284|Other|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
241791|NCT02351271|Device|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
241792|NCT02351271|Device|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
241793|NCT02351258|Device|70% Isopropyl alcohol embedded caps|Protective cap on central lines
241794|NCT02351258|Other|Usual Care|"This involves the Best Practice Central Line Maintenance Care Bundle which includes;~Daily assessment whether central line is needed~Central line Site Care~Central line Hub/Cap/Tubing Care"
241795|NCT02351245|Other|observation|
241796|NCT02351232|Drug|Liraglutide|
241797|NCT02351232|Drug|Placebo|
241798|NCT02351219|Drug|FOLFOXIRI|
241799|NCT02351206|Radiation|x-ray, MRI|
241800|NCT02351193|Other|transvaginal Ultrasound|
241801|NCT02351180|Drug|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
241802|NCT02351180|Drug|Placebo|Placebo will serve as a control treatment
241803|NCT02351167|Drug|Combination NRT (Nicotine patch, Nicotine lozenge)|
241804|NCT02351167|Drug|Varenicline|
241805|NCT02351167|Drug|Placebo|
241806|NCT02351167|Behavioral|Intensive smoking counseling|
241807|NCT02351154|Other|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
241900|NCT02350439|Drug|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
241808|NCT02351141|Other|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
241809|NCT02351128|Drug|Lanreotide|
241810|NCT02351115|Drug|Staccato® Alprazolam, 0.5 mg|
241811|NCT02351115|Drug|Staccato® Alprazolam, 1 mg|
241812|NCT02351115|Drug|Staccato® Alprazolam, 2 mg|
241813|NCT02351115|Drug|Staccato® Placebo (a)|
241814|NCT02351115|Drug|Staccato® Placebo (b)|
241815|NCT02351102|Drug|Valacyclovir|
241816|NCT02351102|Drug|Placebo|
241817|NCT02351089|Dietary Supplement|Capsules placebo|Capsules
241818|NCT02351089|Dietary Supplement|Capsules probiotic powder and corn starch|
241819|NCT02351063|Drug|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
241820|NCT02351050|Device|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
241821|NCT02351050|Other|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
241822|NCT02351037|Drug|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
241823|NCT02351037|Drug|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
241824|NCT02351037|Drug|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
241825|NCT02351024|Drug|OXP005|
241826|NCT02351024|Drug|Naprosyn®|
241827|NCT02351011|Biological|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
241828|NCT02351011|Biological|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
241829|NCT02351011|Biological|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
241830|NCT02350998|Drug|OTO-201|
241831|NCT02350985|Drug|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
241832|NCT02350985|Drug|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
241833|NCT02350972|Biological|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
241834|NCT02350959|Drug|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
241835|NCT02350959|Drug|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
241836|NCT02350946|Drug|Oxytocin|
241837|NCT02350946|Drug|Placebo|
241838|NCT02350933|Procedure|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
241839|NCT02350920|Behavioral|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
241840|NCT02350894|Behavioral|Graded and behavevial theraphy|Graded and behavevial theraphy
241841|NCT02350881|Device|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
241842|NCT02350868|Drug|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
241843|NCT02350855|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
241844|NCT02350855|Other|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
241845|NCT02350855|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
241846|NCT02350842|Device|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
241847|NCT02350842|Device|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
241848|NCT02350829|Other|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
241849|NCT02350816|Drug|HGT-1410|HGT-1410 administered according to Patient Group assignment.
241850|NCT02350803|Device|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
241851|NCT02350790|Procedure|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
241852|NCT02350790|Procedure|Robotic excision|Robotic excision of endometriosis
241901|NCT02350426|Other|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
242026|NCT02349412|Other|Early palliative care|
242983|NCT02342782|Drug|Cytarabine|Given IV
241853|NCT02350777|Procedure|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
241854|NCT02350777|Device|CliniMACS Cell Selection System|
241855|NCT02350764|Drug|nivolumab|
241856|NCT02350764|Drug|pilimumab|
241857|NCT02350751|Drug|MEDI8852|
241858|NCT02350751|Drug|Placebo|
241859|NCT02350738|Other|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
241860|NCT02350738|Other|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
241861|NCT02350738|Other|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
241862|NCT02350725|Drug|Furosemide injection solution for subcutaneous administration (80 mg)|
241863|NCT02350725|Drug|Oral Furosemide tablets (80 mg)|
241864|NCT02350712|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
241865|NCT02350712|Drug|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
241866|NCT02350712|Drug|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
241867|NCT02350712|Drug|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
241868|NCT02350699|Device|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
241869|NCT02350686|Drug|capecitabine|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
241870|NCT02350686|Drug|oxaliplatin|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
241871|NCT02350673|Drug|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
241872|NCT02350673|Drug|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
241873|NCT02350660|Dietary Supplement|cow's milk|daily consumption of cow's milk
241874|NCT02350660|Dietary Supplement|peanut powder|peanut oral immunotherapy
241875|NCT02350647|Device|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
241876|NCT02350647|Device|Suture anchor Twinfix Ultra HA|
241877|NCT02350634|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
241878|NCT02350621|Procedure|ACDF|
241879|NCT02350621|Procedure|minimal invasive Posterior Cervical Foraminotomy|
241880|NCT02350608|Device|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
241881|NCT02350595|Other|Lean fish|
241882|NCT02350595|Other|Fatty fish|
241883|NCT02350582|Device|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
241884|NCT02350569|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
241885|NCT02350556|Other|Dynamic Avoidance Task|
241886|NCT02350556|Procedure|physical therapy|
241887|NCT02350556|Device|3D motion on optoelectronic device|
241888|NCT02350543|Drug|Aspirin|
241889|NCT02350530|Drug|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
241890|NCT02350530|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
241891|NCT02350517|Drug|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
241892|NCT02350504|Behavioral|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
241893|NCT02350491|Other|Collection of biological samples|collection of biologic samples ( blood and urine) befor and after woman pregnacy
241894|NCT02350478|Drug|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
241895|NCT02350478|Drug|Placebo|The subject will receive placebo orally once daily for 12 weeks.
241896|NCT02350465|Behavioral|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
241897|NCT02350465|Behavioral|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
241898|NCT02350452|Procedure|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
241899|NCT02350452|Procedure|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
241902|NCT02350426|Other|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
241903|NCT02350426|Other|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
241904|NCT02350413|Other|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
241905|NCT02350400|Device|DEBIRI|DEBIRI TACE
241906|NCT02350387|Procedure|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
241907|NCT02350387|Procedure|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
241908|NCT02350374|Other|carbohydrate counting|"patients must fill their logbook with the following data:~cho amount at breakfast, lunch, snack and dinner~insulin amount at breakfast, lunch, snack and dinner"
241909|NCT02350361|Drug|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
241910|NCT02350361|Drug|Placebo|Placebo
241911|NCT02350335|Drug|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
241912|NCT02350322|Other|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
241913|NCT02350322|Other|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
241914|NCT02350322|Dietary Supplement|Supplement|Omega-3 capsules three times a week for 12 weeks
241915|NCT02350309|Drug|E2006 5 mg|E2006 5 mg tablet
241916|NCT02350309|Drug|E2006 10 mg|E2006 10 mg tablet
241917|NCT02350309|Drug|E2006-matched placebo|E2006-matched placebo tablet
241918|NCT02350309|Drug|Flurazepam 30 mg|Flurazepam 30 mg capsule
241919|NCT02350296|Drug|KSL 40 mg|Ketoprofen lysine salt oral immediate release tablets 40 mg
241920|NCT02350296|Drug|OKi® 80 mg|Ketoprofen lysine salt granules for oral solution 40 mg (half of a bipartite sachet)
241921|NCT02350283|Device|Interventional treatment with Solitaire|Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
241922|NCT02350270|Other|gait and cognitive testing|
241923|NCT02350257|Behavioral|Internet-based CBT|12 weeks of internet-based CBT
241924|NCT02350244|Behavioral|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
241925|NCT02350231|Drug|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
241926|NCT02350231|Drug|Tonics group|Those patients will receive only tonics
241927|NCT02350218|Drug|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
241928|NCT02350205|Biological|Self assembled skin substitute (SASS)|Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.
241929|NCT02350205|Procedure|Split-thickness autograft|Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.
241930|NCT02350192|Behavioral|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
241931|NCT02350179|Drug|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.~The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.~Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.~The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
241932|NCT02350179|Drug|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
241933|NCT02350166|Procedure|laparoscopic surgery|laparoscopic-assisted small-incision surgery
241934|NCT02350140|Other|Text messaging from beginning|"Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time."
241935|NCT02350140|Other|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
241936|NCT02350127|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLI is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
241937|NCT02350127|Behavioral|Usual Care Control|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the adult day center, which include a combination of daily physical, mental and social activities.
241939|NCT02350101|Device|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
241940|NCT02350088|Drug|probiotics|probiotics
241941|NCT02350088|Drug|placebo|placebo
241942|NCT02350075|Procedure|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
241943|NCT02350075|Device|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
241944|NCT02350036|Other|ultrasound monitoring|Uterine artery Doppler assessment
241945|NCT02350023|Drug|Topical latanoprost 0.005%|Local application of the drug on affected skin/scalp
241946|NCT02350023|Drug|Topical betamethasone 0.05%|Local application of the drug on affected skin/scalp
241947|NCT02350010|Device|CT Angiography|"CTA Scan with the specified sequences below:~120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.~Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
241948|NCT02349997|Other|no interventions|This is an observational study and no intervention applied.
241949|NCT02349971|Device|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
241950|NCT02349958|Device|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
241951|NCT02349958|Device|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
241952|NCT02349958|Device|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
241953|NCT02349958|Device|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
241954|NCT02349945|Drug|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.~Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage > 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
241955|NCT02349932|Other|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
241956|NCT02349919|Drug|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
241957|NCT02349919|Drug|Placebo|Placebo twice daily for 4 weeks
241958|NCT02349906|Drug|Treosulfan|
241959|NCT02349906|Drug|Busilvex|
241960|NCT02349893|Device|RFA treatment|RFA treatment using CelonProSleep plus system
241961|NCT02349880|Behavioral|shared decision making training|
241962|NCT02349867|Drug|Gemcitabine|Given IV
241963|NCT02349867|Drug|Sorafenib|Given PO
241964|NCT02349867|Drug|Vorinostat|Given PO
241965|NCT02349867|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
241966|NCT02349867|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
241967|NCT02349867|Other|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
241968|NCT02349867|Other|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
241969|NCT02349854|Procedure|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm & 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
241970|NCT02349841|Drug|Meropenem|To administer 2g daily 8 hourly for 14 days
241971|NCT02349841|Drug|Faropenem|To adminster 600mg 8 hourly daily for 14 days
241972|NCT02349841|Drug|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
241973|NCT02349841|Drug|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
241974|NCT02349828|Drug|Acyclovir|
241975|NCT02349815|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
241976|NCT02349802|Drug|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
241977|NCT02349802|Drug|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
241978|NCT02349776|Other|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.~Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
241979|NCT02349763|Drug|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
241980|NCT02349763|Drug|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
241981|NCT02349750|Procedure|endometrial scratch injury|ESI using No.8 neonatal feeding tube
241982|NCT02349737|Other|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
241983|NCT02349724|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
241984|NCT02349711|Dietary Supplement|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
241985|NCT02349711|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
241986|NCT02349698|Biological|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
241987|NCT02349685|Procedure|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute [amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC > 1.0 μ g / ml; metronidazole (MET), MIC > 8 μ g / ml; tetracycline (TC), MIC > 4 μ g / ml; and moxifloxacin (MOX), MIC > 1 μ g / ml).
241988|NCT02349685|Drug|14 day PBMT group|Rescue therapy using 14 day PBMT regimen [Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d]
241989|NCT02349685|Drug|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
241990|NCT02349672|Procedure|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
241991|NCT02349659|Device|Implantation with the commercially available Axium neurostimulator|
241992|NCT02349646|Device|Implantation with the commercially available Axium neurostimulator|
241993|NCT02349633|Drug|PF-06747775|
241994|NCT02349633|Drug|Palbociclib|
241995|NCT02349633|Drug|Avelumab|
241996|NCT02349620|Biological|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
241997|NCT02349607|Drug|PF-05089771 300mg|PF-05089771 300 mg
241998|NCT02349607|Drug|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
241999|NCT02349607|Drug|Placebo|Placeco
242000|NCT02349607|Drug|pregabalin 300 mg|pregabalin 300 mg
242001|NCT02349607|Drug|ibuprofen 600 mg|ibuprofen 600 mg
242002|NCT02349594|Drug|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
242003|NCT02349594|Drug|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
242004|NCT02349581|Procedure|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
242005|NCT02349581|Drug|Bupivacaine|
242006|NCT02349568|Procedure|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
242007|NCT02349568|Procedure|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
242008|NCT02349555|Dietary Supplement|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
242009|NCT02349542|Drug|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
242010|NCT02349529|Behavioral|Psychosocial Intervention Group|6 group sessions
242011|NCT02349529|Other|Waiting list control|Treatment as usual
242012|NCT02349516|Drug|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
242013|NCT02349503|Drug|NBI-77860|
242014|NCT02349503|Drug|NBI-77860|
242015|NCT02349503|Drug|NBI-77860|
242016|NCT02349490|Device|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
242017|NCT02349477|Drug|Gabapentin|gaba potentiating medication
242018|NCT02349477|Drug|Placebo|a pill that looks exactly like the active medication but does not contain medication
242019|NCT02349464|Other|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
242027|NCT02349399|Drug|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
242028|NCT02349386|Drug|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
242029|NCT02349386|Drug|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
242030|NCT02349373|Behavioral|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
242031|NCT02349373|Behavioral|16 week training period|Receipt of a weekly running schedule through an online training diary.
242032|NCT02349360|Biological|L. johnsonii N6.2|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks
242033|NCT02349360|Biological|Placebo|Encapsulated starch placebo administered for 8 weeks
242034|NCT02349347|Drug|Melphalan|
242035|NCT02349347|Drug|Lenograstim|
242036|NCT02349334|Device|Percutaneous Tibial Nerve Stimulation|
242037|NCT02349321|Behavioral|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
242038|NCT02349321|Behavioral|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
242039|NCT02349308|Device|CentrosFLO Long Term Hemodialysis Catheter|
242040|NCT02349295|Drug|Placebo|Administered SC
242041|NCT02349295|Drug|Ixekizumab 80 mg Q4W|Administered SC
242042|NCT02349295|Drug|Ixekizumab 80 mg Q2W|Administered SC
242043|NCT02349282|Dietary Supplement|Calcifediol 10ug/day|
242044|NCT02349282|Dietary Supplement|Vitamin D3 20ug/day|
242045|NCT02349282|Dietary Supplement|Placebo|
242046|NCT02349243|Drug|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
242047|NCT02349243|Drug|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
242048|NCT02349230|Other|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
242049|NCT02349217|Behavioral|Mindfulness-Based Relationship Enhancement (MBRE)|Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
242050|NCT02349217|Behavioral|Self-Help Materials|Participants and partner receive self-help materials.
242051|NCT02349217|Behavioral|Pain Assessment|Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
242052|NCT02349217|Behavioral|Questionnaires|Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
242053|NCT02349217|Behavioral|Neurocognitive Tests|Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
242054|NCT02349217|Procedure|Cortisol Tests|Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
242055|NCT02349217|Behavioral|Interviews|Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
242056|NCT02349204|Behavioral|Music - Mozart's sonata for 2 pianos in D-440|
242057|NCT02349191|Procedure|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
242058|NCT02349178|Drug|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
242059|NCT02349178|Drug|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
242060|NCT02349178|Drug|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
242061|NCT02349165|Procedure|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
242062|NCT02349165|Drug|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
242063|NCT02349165|Drug|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
242064|NCT02349152|Drug|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
242065|NCT02349152|Drug|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
242066|NCT02349139|Drug|ASN001: Escalating dose Part A|Androgen inhibitor
242067|NCT02349126|Drug|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
242068|NCT02349113|Drug|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
242069|NCT02349100|Device|Nellix Endoprosthesis|Implantation of Nellix
242070|NCT02349087|Device|Acute EEG with fast applicable EEG electrode|
242071|NCT02349074|Procedure|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
242072|NCT02349061|Drug|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
242073|NCT02349061|Drug|Placebo Infusion|Placebo intravenously at Week 0.
242074|NCT02349061|Drug|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
242075|NCT02349061|Drug|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
242984|NCT02342782|Drug|Melphalan|Given IV
242076|NCT02349061|Other|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
242077|NCT02349048|Drug|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
242078|NCT02349048|Drug|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
242079|NCT02349048|Drug|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
242080|NCT02349035|Device|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
242081|NCT02349035|Procedure|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
242082|NCT02349022|Radiation|[89Zr]Df-IAB2M|
242083|NCT02349009|Drug|C-82 Topical Gel, 1%|active
242084|NCT02349009|Drug|C-82 Topical Gel, Placebo|placebo
242085|NCT02348996|Other|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
242086|NCT02348996|Other|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
242087|NCT02348983|Behavioral|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
242088|NCT02348970|Device|ONIRIS®|sleeping test
242089|NCT02348970|Device|TALI|sleeping test
242090|NCT02348944|Other|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
242091|NCT02348931|Device|Use of customized nasal brace (Nasella) for nose deformities|
242092|NCT02348931|Procedure|corrective surgery|
242093|NCT02348918|Drug|Luminate 1.0mg|
242094|NCT02348918|Drug|Luminate 2.0mg|
242095|NCT02348918|Drug|Luminate 3.0mg|
242096|NCT02348918|Drug|Avastin|
242097|NCT02348918|Drug|Luminate 0.5mg|
242098|NCT02348905|Drug|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
242099|NCT02348905|Drug|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
242100|NCT02348892|Other|Coordinator|Patients in complex situation taken care by coordinator
242101|NCT02348892|Other|Classic plan|Patients in complex situation taken care by classic plan
242102|NCT02348879|Drug|AMG 403|AMG 403 is for treatment of subjects with chronic pain
242103|NCT02348879|Drug|Placebo|contains no active drug
242104|NCT02348866|Other|method of laundering and donning scrubs|
242105|NCT02348853|Behavioral|Healthy Weight for Living (HWL)|
242106|NCT02348853|Behavioral|Current Best Practice (CBP)|
242107|NCT02348840|Device|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
242108|NCT02348827|Behavioral|Family psychoeducation|
242109|NCT02348827|Behavioral|Social support group|
242110|NCT02348801|Behavioral|Weight loss and Exercise|"Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.~Exercise sessions of ~90 min duration 15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and, after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months."
242111|NCT02348801|Behavioral|Healthy lifestyle|Diabetes support and education
242112|NCT02348788|Drug|Artemether-lumefantrine + Primaquine|
242113|NCT02348788|Drug|Chloroquine + Primaquine|
242114|NCT02348775|Dietary Supplement|Cysteine (as n-acetylcysteine) and glycine|HIV patients will be studied before and after receiving cysteine and glycine
242115|NCT02348762|Dietary Supplement|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
242116|NCT02348749|Radiation|18F-MFBG (meta-fluoro benzylguanidine)|Adult patients: about 8-12 mCi of 18F-MFBG will be administered intravenously. Pediatric patients: 12 mCi/1.7m2 IV (up to a maximum of 12mCi).
242117|NCT02348749|Device|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
242985|NCT02342782|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
242118|NCT02348749|Other|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
242119|NCT02348736|Device|Time for tracheal intubation|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
242120|NCT02348723|Drug|Warfarin|Patients receiving Warfarin to keep International Normalized Ratio (INR)between 2.0 - 3.0
242121|NCT02348723|Drug|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg twice daily dosing (BID)
242122|NCT02348710|Behavioral|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
242123|NCT02348710|Behavioral|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
242124|NCT02348697|Biological|NOVOCART 3D|Autologous Chondrocyte Implantation
242125|NCT02348684|Radiation|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
242126|NCT02348671|Other|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
242127|NCT02348658|Drug|TAK-536TCH|TAK-536TCH tablets
242128|NCT02348645|Procedure|Spinal fusion|
242129|NCT02348645|Procedure|Spinal decompression|
242130|NCT02348632|Drug|JZP-110|
242131|NCT02348619|Drug|JZP-110|
242132|NCT02348606|Drug|JZP-110|
242133|NCT02348606|Drug|Placebo oral tablet|
242134|NCT02348593|Drug|JZP-110|
242135|NCT02348593|Drug|Placebo oral tablet|
242136|NCT02348580|Behavioral|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
242137|NCT02348567|Other|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
242138|NCT02348567|Other|announced hospital surveys|
242139|NCT02348554|Behavioral|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
242140|NCT02348554|Behavioral|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
242141|NCT02348541|Device|CollaGUARD|
242142|NCT02348528|Drug|Lenalidomide|
242143|NCT02348528|Drug|Dexamethasone|
242144|NCT02348515|Procedure|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
242145|NCT02348515|Procedure|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
242146|NCT02348515|Procedure|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
242147|NCT02348515|Procedure|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
242148|NCT02348515|Procedure|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
242149|NCT02348489|Drug|SGI-110 (guadecitabine)|Investigational Medicinal Product
242150|NCT02348489|Drug|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
242151|NCT02348476|Other|No Intervention|No study drug is administered in this study.
242152|NCT02348463|Drug|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
242153|NCT02348450|Drug|Irinotecan|40mg
242154|NCT02348450|Drug|Etoposide|5ml：0.1g
242155|NCT02348450|Drug|Cisplatin|6ml：30mg
242156|NCT02348437|Procedure|Repair|An on-going suture technique with minimum four stitches.
242157|NCT02348437|Procedure|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
242158|NCT02348424|Drug|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
242159|NCT02348411|Device|ExAblate|
242160|NCT02348398|Drug|Pazopanib|600 mg by mouth daily in a 28 day cycle.
242161|NCT02348398|Drug|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
242162|NCT02348398|Behavioral|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
242163|NCT02348385|Drug|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
242164|NCT02348372|Drug|GSK1278863A Placebo|Matching size, shape and color
242165|NCT02348372|Drug|GSK1278863A|A round, biconvex, white film coated tablet
242166|NCT02348359|Drug|X-82|
242167|NCT02348359|Drug|Anti-VEGF|
242168|NCT02348359|Drug|Placebo|
242256|NCT02347761|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
242169|NCT02348346|Other|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
242170|NCT02348333|Drug|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
242171|NCT02348333|Drug|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
242172|NCT02348320|Biological|Personalized polyepitope DNA vaccine|
242173|NCT02348307|Drug|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
242174|NCT02348307|Drug|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
242175|NCT02348294|Other|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
242176|NCT02348281|Drug|Bicalutamide|150mg, po, qd, d1-28
242177|NCT02348268|Other|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
242178|NCT02348268|Other|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
242179|NCT02348268|Device|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
242180|NCT02348255|Procedure|Electric Field Therapy|Undergo NovoTTF-100A
242181|NCT02348255|Biological|Bevacizumab|Given IV
242182|NCT02348255|Drug|Carmustine|Given IV
242183|NCT02348255|Other|Quality-of-Life Assessment|Ancillary studies
242184|NCT02348242|Device|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
242185|NCT02348242|Device|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
242186|NCT02348242|Device|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
242187|NCT02348229|Procedure|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
242188|NCT02348229|Procedure|ERAS protocols|No bowel preparation
242189|NCT02348229|Procedure|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
242190|NCT02348229|Procedure|ERAS protocols|Vasoactive drugs used if need be
242191|NCT02348229|Procedure|ERAS protocols|Temperature management
242192|NCT02348229|Procedure|ERAS protocols|Intra-abdominal drains not to be used
242193|NCT02348229|Procedure|ERAS protocols|Intraperitoneal Ropivicaine infusion
242194|NCT02348229|Procedure|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.~Oral non‐opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
242195|NCT02348229|Procedure|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
242196|NCT02348229|Procedure|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
242197|NCT02348229|Procedure|ERAS protocols|On the5-6th postoperative day Check discharge criteria
242198|NCT02348229|Procedure|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
242199|NCT02348229|Procedure|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
242200|NCT02348229|Procedure|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
242201|NCT02348229|Procedure|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
242202|NCT02348229|Procedure|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
242203|NCT02348229|Procedure|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.~Drains removed"
242204|NCT02348216|Biological|Axicabtagene Ciloleucel|A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10^6 anti-CD19 CAR T cells/kg.
242205|NCT02348216|Drug|Fludarabine|Administered according to package insert
242206|NCT02348216|Drug|Cyclophosphamide|Administered according to package insert
242207|NCT02348203|Drug|Aspirin|Given PO
242208|NCT02348203|Other|Laboratory Biomarker Analysis|Correlative studies
242209|NCT02348203|Other|Placebo|Given aspirin placebo PO
242210|NCT02348203|Other|Placebo|Given zileuton placebo PO
242211|NCT02348203|Drug|Zileuton|Given PO
242212|NCT02348190|Other|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.~Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
242213|NCT02348177|Drug|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
242214|NCT02348177|Drug|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
242215|NCT02348164|Other|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
242216|NCT02348164|Other|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
242217|NCT02348151|Other|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
242218|NCT02348151|Other|Corridor|The volunteers will perform the shuttle walk test on the corridor
242219|NCT02348138|Other|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
242220|NCT02348125|Drug|Mitochondrial Cocktail|
242221|NCT02348112|Device|Altis Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
242222|NCT02348112|Device|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
242223|NCT02348099|Other|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
242224|NCT02348073|Drug|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.~At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
242225|NCT02348073|Drug|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
242226|NCT02348047|Device|Hamilton T1|
242227|NCT02348034|Device|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
242228|NCT02348021|Procedure|Percutaneous coronary intervention (PCI)|
242229|NCT02348021|Drug|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
242230|NCT02348008|Drug|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
242231|NCT02348008|Drug|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
242232|NCT02348008|Drug|MK-3475|Arm B: Phase II Treatment: 200mg IV
242233|NCT02348008|Drug|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 5mg or 10mg as established in the Phase 1b dose escalation cohort study.
242234|NCT02347995|Other|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
242235|NCT02347995|Other|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
242236|NCT02347969|Dietary Supplement|X34|Dietary supplement named X34
242237|NCT02347956|Procedure|Reduced port robotic distal gastrectomy|
242238|NCT02347930|Other|kidney ultrasound|kidney ultrasound
242239|NCT02347917|Drug|BBI608|480 mg orally twice daily (960 mg total daily dose)
242240|NCT02347917|Drug|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
242241|NCT02347917|Drug|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
242242|NCT02347904|Drug|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
242243|NCT02347891|Drug|Belimumab|Randomized phase: Week 0 - Week 36
242244|NCT02347891|Drug|Placebo|Randomized phase: Week 0 - Week 36
242245|NCT02347878|Drug|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
242246|NCT02347865|Drug|AMG 162 - Prolia|500 patients
242247|NCT02347865|Drug|AMG 162 - Prolia|250 patients, one year later
242248|NCT02347852|Drug|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
242249|NCT02347839|Procedure|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
242250|NCT02347813|Drug|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
242251|NCT02347787|Behavioral|IMPaCT|"The IMPaCT intervention has three stages:~Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.~Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.~Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
242252|NCT02347787|Other|Usual care|
242253|NCT02347774|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer
242254|NCT02347774|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
242255|NCT02347774|Drug|Placebo eFlow (CS) nebulizer|Placebo BID eFlow (R) Closed System (CS) nebulizer
242257|NCT02347761|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
242258|NCT02347761|Drug|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
242259|NCT02347748|Behavioral|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
242260|NCT02347748|Behavioral|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
242261|NCT02347748|Behavioral|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.~Patients will be read a comfort talk script before extubation"
242262|NCT02347735|Other|No interventions, only data collection|Only data is collected from the subjects in both groups.
242263|NCT02347709|Procedure|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
242264|NCT02347709|Other|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
242265|NCT02347709|Other|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
242266|NCT02347709|Other|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
242267|NCT02347696|Behavioral|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
242268|NCT02347696|Behavioral|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
242269|NCT02347696|Behavioral|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity:~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1."
242270|NCT02347696|Behavioral|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:~Frequency: 3 times/week Duration: 60 minutes~Intensity (for Endurance activity):~weeks 1-4: 14.2 kcal*kg-1*week-1;~weeks 5-8: 18.9 kcal*kg-1*week-1;~weeks 9-12: 23.6 kcal*kg-1*week-1.~Resistance activity:~Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);~Progression: increase of 1-2.5 kg*week-1~Training of all muscle groups in the same session"
242271|NCT02347696|Behavioral|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
242272|NCT02347696|Behavioral|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
242273|NCT02347670|Behavioral|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
242274|NCT02347670|Behavioral|Office-Based Usual Care|"Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital."
242275|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination|FDC tablet, oral use
242276|NCT02347657|Drug|Ivacaftor|Tablet, oral use
242277|NCT02347657|Drug|VX-661 Plus Ivacaftor Combination Placebo|FDC tablet, oral use
242278|NCT02347657|Drug|Ivacaftor placebo|Tablet, oral use
242279|NCT02347644|Behavioral|Brief Motivational Interview|"Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:~No perception of any alcohol consumption problem~Realization of alcohol consumption problem with no corresponding action"
242280|NCT02347631|Device|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1|Soft contact lens - Daily wear disposable to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over project where both lenses will be worn by participant over the course of the study. The order of randomization will differ for each participant. There is a washout period in between earch contact lens wearing schedule.
242281|NCT02347631|Device|Acuvue TruEye|
242282|NCT02347618|Radiation|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
242283|NCT02347605|Drug|Nicotine lozenge 4 mg|
242284|NCT02347605|Drug|Placebo lozenge|
242285|NCT02347592|Device|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
242286|NCT02347592|Device|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
242287|NCT02347566|Behavioral|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
242986|NCT02342782|Other|Laboratory Biomarker Analysis|Correlative studies
242288|NCT02347566|Other|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
242289|NCT02347553|Other|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
242290|NCT02347527|Behavioral|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
242291|NCT02347527|Behavioral|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
242292|NCT02347514|Behavioral|Diabetes group visit|
242293|NCT02347501|Drug|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
242294|NCT02347488|Device|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
242295|NCT02347488|Procedure|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
242296|NCT02347475|Other|Observational Study|Ultrasound and NIRS
242297|NCT02347462|Device|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
242298|NCT02347462|Other|Standard care|Standard care according to the hospital severe asthma protocol
242299|NCT02347449|Other|Questionnaires, Oncotype Dx Assay|"Physician pre-assay questionnaire~Patient pre-assay questionnaire~Oncotype DX® Assay~Physician post- assay questionnaire~Patient post-assay questionnaire"
242300|NCT02347436|Procedure|24-hr ambulatory blood pressure measurement|
242301|NCT02347423|Biological|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
242302|NCT02347423|Biological|IPV Vaccine SSI|
242303|NCT02347410|Device|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
242304|NCT02347397|Device|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head & SL-TWIN Stem
242305|NCT02347397|Device|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head & SL-PLUS Stem
242306|NCT02347384|Device|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
242307|NCT02347384|Device|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem
242308|NCT02347358|Device|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
242309|NCT02347358|Drug|IV r-tPA|intravenous recombinant human tissue plasminogen activator
242310|NCT02347345|Drug|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks
242311|NCT02347332|Drug|Vinflunine|
242312|NCT02347332|Drug|Methotrexate|
242313|NCT02347319|Drug|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
242314|NCT02347319|Drug|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
242315|NCT02347319|Drug|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
242316|NCT02347306|Other|Telephone interview|
242317|NCT02347293|Other|High levels of indigestible carbohydrates|
242318|NCT02347293|Other|Low levels of indigestible carbohydrates|
242319|NCT02347280|Procedure|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
242320|NCT02347280|Procedure|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
242321|NCT02347267|Behavioral|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
242322|NCT02347267|Behavioral|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
242323|NCT02347254|Device|Transcranial ExAblate|Transcranial ExAblate MRgFUS
242324|NCT02347241|Other|Educational intervention|Educational Debriefings and High frequency training and team reflection
242325|NCT02347228|Drug|OB318 capsule|Oral qd, at least 30 minutes before breakfast
242326|NCT02347215|Other|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
242327|NCT02347215|Procedure|Stress imaging|Stress imaging
242328|NCT02347202|Other|Online counseling via Zoom teleconferencing|
242329|NCT02347202|Other|Telephone support as needed|
242330|NCT02347189|Device|Melody Transcatheter Pulmonary Valve PB1016|
242331|NCT02347176|Other|Placebo|Subcutaneous injection with placebo
242332|NCT02347176|Biological|Tralokinumab Dose 1|Subcutaneous injection with tralokinumab
242333|NCT02347176|Biological|Tralokinumab Dose 2|Subcutaneous injection with tralokinumab
242334|NCT02347176|Biological|Tralokinumab Dose 3|Subcutaneous injection with tralokinumab
242335|NCT02347163|Drug|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
242336|NCT02347137|Other|step-reduction|reduce daily physical activity to less than 1500 steps per day
242385|NCT02346799|Behavioral|Partner Assignment|"Participants will be required to have same workout window as partners."
242337|NCT02347137|Other|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
242338|NCT02347124|Behavioral|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
242339|NCT02347124|Behavioral|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
242340|NCT02347111|Drug|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
242341|NCT02347111|Drug|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
242342|NCT02347098|Device|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
242343|NCT02347098|Drug|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
242344|NCT02347085|Drug|GFF MDI (PT003)|
242345|NCT02347085|Drug|Placebo MDI|
242346|NCT02347072|Drug|GFF MDI (PT003)|
242347|NCT02347072|Drug|Placebo MDI|
242348|NCT02347072|Drug|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
242349|NCT02347059|Drug|L-dopa|Antiparkinsonian medication
242350|NCT02347059|Drug|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
242351|NCT02347046|Drug|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
242352|NCT02347033|Drug|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.~We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
242353|NCT02347033|Behavioral|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.~Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
242354|NCT02347020|Behavioral|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
242355|NCT02347020|Behavioral|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
242356|NCT02347020|Behavioral|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
242357|NCT02347020|Behavioral|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
242386|NCT02346786|Dietary Supplement|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
242358|NCT02347007|Dietary Supplement|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
242359|NCT02347007|Dietary Supplement|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
242360|NCT02346994|Dietary Supplement|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
242361|NCT02346994|Dietary Supplement|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
242362|NCT02346981|Behavioral|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
242363|NCT02346968|Other|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
242364|NCT02346955|Biological|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
242365|NCT02346955|Biological|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
242366|NCT02346929|Other|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
242367|NCT02346916|Drug|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
242368|NCT02346903|Drug|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
242369|NCT02346890|Drug|AZD1722|
242370|NCT02346890|Drug|Renvela|
242371|NCT02346877|Behavioral|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
242372|NCT02346864|Behavioral|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
242373|NCT02346864|Behavioral|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
242374|NCT02346851|Procedure|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
242375|NCT02346838|Dietary Supplement|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
242376|NCT02346838|Dietary Supplement|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
242377|NCT02346825|Behavioral|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
242378|NCT02346825|Behavioral|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
242379|NCT02346825|Behavioral|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
242380|NCT02346812|Other|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
242381|NCT02346812|Other|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
242382|NCT02346799|Behavioral|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
242383|NCT02346799|Behavioral|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
242384|NCT02346799|Behavioral|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
242388|NCT02346773|Dietary Supplement|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
242389|NCT02346773|Other|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
242390|NCT02346760|Drug|UB-621|100 mg/ml, subcutaneous injection
242391|NCT02346747|Biological|Vigil|bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
242392|NCT02346747|Biological|Placebo|"freeze media."
242393|NCT02346734|Device|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
242394|NCT02346721|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
242395|NCT02346708|Device|Real TMS|real treatment
242396|NCT02346708|Device|Sham TMS|placebo treatment
242397|NCT02346682|Drug|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
242398|NCT02346669|Procedure|gastroscopy|as detailed in arm description
242399|NCT02346669|Drug|Fecal Microbiota Transplantation|as detailed in arm description
242400|NCT02346669|Other|high fat low fiber diet|as detailed in arm description
242401|NCT02346669|Other|sham diet|as detailed in arm description
242402|NCT02346669|Other|low fat high fiber diet|as detailed in arm description
242403|NCT02346656|Device|Implantation with the commercially available Axium neurostimulator|
242404|NCT02346643|Device|Implantation with the commercially available Axium Neurostimulator|
242405|NCT02346630|Drug|Placebo|Placebo capsules daily for 3 weeks.
242406|NCT02346630|Drug|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
242407|NCT02346630|Device|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
242408|NCT02346617|Biological|IFN-γ positive selected T-cells|
242409|NCT02346591|Behavioral|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
242410|NCT02346591|Behavioral|Online stress management information|Online educational information about stress management
242411|NCT02346578|Drug|Enzalutamide|
242412|NCT02346578|Drug|Flutamide|
242413|NCT02346565|Procedure|Exercise ECG|
242414|NCT02346565|Procedure|Stress Echocardiography|
242415|NCT02346552|Device|AutoLap|
242416|NCT02346539|Drug|Nicotine polacrilex|Single Acute dose
242417|NCT02346526|Procedure|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
242418|NCT02346526|Procedure|CT scan and bone scan|Standard CT and bone scans will be carried out prior to treatment, week 9, and week 25.
242419|NCT02346526|Procedure|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
242420|NCT02346526|Drug|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
242421|NCT02346513|Device|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
242422|NCT02346513|Device|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
242423|NCT02346500|Device|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
242424|NCT02346487|Drug|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day~Between 6 and 9.9kg: 3 capsules twice a day~Between 10 and 13.9kg: 4 capsules twice a day~Between 14 and 19.9kg: 5 capsules twice a day~Between 20 and 24.9kg: 6 capsules twice a day~Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:~Between 3 and 5.9kg: 1 tablet twice a day~Between 6 and 9.9kg: 1.5 tablets twice a day~Between 10 and 13.9kg: 2 tablets twice a day~Between 14 and 19.9kg: 2.5 tablets twice a day~Between 20 and 24.9kg: 3 tablets twice a day"
242425|NCT02346461|Drug|ManNAc|At doses of 3 g and 6 g twice daily for a total dose of 6 and 12 g per day.
242426|NCT02346461|Drug|ManNAc|At doses of 6 g twice daily (12 g per day).
242427|NCT02346448|Procedure|endoscopic sphincterotomy|sphincterotomy during ERCP
242428|NCT02346448|Procedure|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
242429|NCT02346448|Procedure|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
242430|NCT02346422|Genetic|MYDICAR Phase 1|Single dose of MYDICAR
242431|NCT02346422|Genetic|MYDICAR Phase 2|Single dose of MYDICAR
242432|NCT02346422|Genetic|Placebo Phase 2 only|Single dose of placebo
242433|NCT02346409|Device|tACS of the cerebellum|tACS of the cerebellum
242434|NCT02346396|Device|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
242435|NCT02346383|Device|preset program|Change to different present program using epidural and peripheral lead to cover pain
242436|NCT02346370|Drug|PEGylated recombinant human hyaluronidase PH20|
242437|NCT02346370|Drug|Docetaxel|
242584|NCT02345395|Procedure|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
242438|NCT02346357|Procedure|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% [local anesthetic]) 30 minutes prior to induction of anesthesia.
242439|NCT02346357|Drug|Ropivacaine|
242440|NCT02346357|Drug|Placebo Saline|
242441|NCT02346331|Other|WHO algorithm of fluid boluses guided by physical examination|
242442|NCT02346331|Other|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
242443|NCT02346331|Other|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
242444|NCT02346331|Other|Oxygen delivery|
242445|NCT02346331|Other|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
242446|NCT02346331|Other|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
242447|NCT02346318|Drug|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
242448|NCT02346305|Device|Non-invasive ventilation|Home NIV installation
242449|NCT02346279|Other|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
242450|NCT02346266|Other|SMART Education|
242451|NCT02346253|Radiation|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
242452|NCT02346253|Drug|Bicalutamide|Given PO
242453|NCT02346253|Drug|Leuprolide Acetate|Given IM or SC
242454|NCT02346253|Drug|Goserelin Acetate|Given SC
242455|NCT02346253|Drug|Triptorelin Pamoate|Given IM
242456|NCT02346253|Drug|Degarelix|Given SC
242457|NCT02346253|Other|Laboratory Biomarker Analysis|Correlative studies
242458|NCT02346253|Other|Quality-of-Life Assessment|Ancillary studies
242459|NCT02346240|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/ mL~Route of Administration: Subcutaneous use"
242460|NCT02346240|Biological|Etanercept|"Active Substance: Etanercept~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 50 mg / mL~Route of Administration: Subcutaneous use"
242461|NCT02346240|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
242462|NCT02346227|Drug|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
242463|NCT02346227|Drug|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
242464|NCT02346201|Drug|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
242465|NCT02346201|Drug|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
242466|NCT02346188|Dietary Supplement|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
242467|NCT02346188|Dietary Supplement|Zinc oxide|Tablet formulated from 30 mg zinc oxide
242468|NCT02346188|Dietary Supplement|Placebo|
242469|NCT02346175|Drug|SHR3824|
242470|NCT02346175|Drug|Placebo|
242471|NCT02346162|Behavioral|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI </=25, and when pregnant, weight gain within IOM guidelines.
242472|NCT02346162|Other|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
242473|NCT02346149|Other|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
242474|NCT02346136|Behavioral|Tai Chi training|
242475|NCT02346136|Behavioral|Educational Control|
242476|NCT02346123|Genetic|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
242477|NCT02346110|Drug|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
242478|NCT02346110|Drug|Dexamethasone|4 mg
242479|NCT02346110|Other|Sodium chloride|1 mL of sodium chloride solution as placebo
242480|NCT02346097|Device|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
242481|NCT02346084|Drug|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.~Each treatment regimen will be followed by a washout period of 14 to 21 days.~Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
242482|NCT02346071|Behavioral|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
242589|NCT02345356|Other|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
242590|NCT02345343|Drug|Apixaban|
242987|NCT02342782|Other|Pharmacological Study|Correlative studies
242483|NCT02346071|Other|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.~The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
242484|NCT02346058|Drug|Esarin Gel|
242485|NCT02346045|Procedure|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed~After femoral puncture guiding catheter is engaged in renal artery~Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery~4-5 ablations are applied in each renal artery.~In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
242486|NCT02346032|Drug|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
242487|NCT02346019|Procedure|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
242488|NCT02346006|Behavioral|More physical activity.|Subjects receiving more physical activity in school.
242489|NCT02345993|Drug|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
242490|NCT02345980|Drug|Sildenafil|
242491|NCT02345980|Drug|Placebo|
242492|NCT02345967|Device|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
242493|NCT02345954|Procedure|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
242494|NCT02345954|Procedure|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
242495|NCT02345941|Other|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
242496|NCT02345941|Other|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
242497|NCT02345928|Drug|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
242498|NCT02345928|Drug|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
242499|NCT02345928|Drug|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
242500|NCT02345928|Drug|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
242501|NCT02345915|Other|Blood sample|
242502|NCT02345915|Other|Electrocardiogram|
242503|NCT02345902|Drug|Haloperidol|haloperidol 1.25 mg P.O q.d
242504|NCT02345902|Other|Placebo|placebo 1.25 mg P.O q.d
242505|NCT02345902|Other|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
242506|NCT02345889|Device|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
242507|NCT02345889|Device|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
242508|NCT02345889|Device|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
242509|NCT02345889|Device|Standard Colonoscopy|Current standard of care colonoscopy
242510|NCT02345876|Other|no intervention|
242511|NCT02345863|Drug|Bendamustine|"Debulking:~2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
242512|NCT02345863|Drug|GA101|"Induction~GA101 iv infusion:~Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~GA101: Cycle 1-8 Day 1 1000 mg"
242513|NCT02345863|Drug|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.~Cycle 2-6: Day 1 420 mg daily~Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.~Ibrutinib: Cycle 1-8 420 mg daily"
242514|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
242515|NCT02345850|Procedure|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
242591|NCT02345330|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
243038|NCT02342405|Other|30% oxygen|
242516|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
242517|NCT02345850|Drug|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
242518|NCT02345850|Drug|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
242519|NCT02345850|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
242520|NCT02345837|Device|endometrial sampling|injury to the endometrium
242521|NCT02345837|Drug|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
242522|NCT02345824|Drug|Ribociclib|CDK4/6 INHIBITOR
242523|NCT02345798|Procedure|Standard Follow-Up Care|Undergo usual care
242524|NCT02345798|Other|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
242525|NCT02345798|Other|Educational Intervention|Undergo video-assisted intervention
242526|NCT02345798|Other|Quality-of-Life Assessment|Undergo quality of life assessment
242527|NCT02345798|Other|Questionnaire Administration|Undergo questionnaire administration
242528|NCT02345785|Other|urologic surgery and caudal block|
242529|NCT02345772|Drug|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
242530|NCT02345772|Drug|Docetaxel|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
242531|NCT02345772|Drug|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
242532|NCT02345772|Drug|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
242533|NCT02345746|Drug|Oxaliplatin|infusion over 12 hours via HAI
242534|NCT02345746|Drug|Folinic Acid|as a 2-hour infusion via HAI on day 2
242535|NCT02345746|Drug|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
242536|NCT02345733|Other|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
242537|NCT02345733|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
242538|NCT02345720|Device|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
242539|NCT02345707|Drug|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
242540|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
242541|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
242542|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
242543|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
242544|NCT02345694|Device|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
242545|NCT02345694|Device|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
242546|NCT02345681|Drug|Furosemide|
242585|NCT02345382|Drug|Atuveciclib, BAY1143572|The starting dose was 20 mg BAY 1143572 once daily from Cycle 1 Day 1. Each cycle was defined as a period of 28 days. Dosing cycles continued until evidence of progression, unacceptable toxicity, consent withdrawal, or withdrawal from the study at the discretion of the investigator.
242586|NCT02345369|Device|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
242587|NCT02345369|Device|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
242588|NCT02345356|Genetic|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
243111|NCT02341898|Other|Training and structured support for nominated key nurses|
242547|NCT02345668|Behavioral|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
242548|NCT02345668|Drug|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
242549|NCT02345668|Behavioral|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
242550|NCT02345655|Procedure|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
242551|NCT02345655|Other|no test|normal procedure decided by the general practitioner
242552|NCT02345642|Device|ActiveCare+SFT Supine|
242553|NCT02345642|Device|VenaFlow Elite Supine|
242554|NCT02345642|Device|ActiveCare+SFT Standing|
242555|NCT02345642|Device|VenaFlow Elite Standing|
242556|NCT02345629|Procedure|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
242557|NCT02345629|Behavioral|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
242558|NCT02345629|Procedure|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
242559|NCT02345629|Procedure|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
242560|NCT02345616|Drug|Nitric oxide|
242561|NCT02345603|Procedure|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
242562|NCT02345590|Drug|Eplerenone|25mg of eplerenone
242563|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
242564|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
242565|NCT02345564|Device|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
242566|NCT02345551|Behavioral|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
242567|NCT02345525|Behavioral|mCIMT|"This intervention is based on 3 main aspects:~intensive training of functional tasks with the affected arm (massed practice)~constraint of the un-affected hand through a mitt~shaping techniques designed to transfer gains to the real world activities~The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
242568|NCT02345525|Behavioral|hCIMT|"This intervention is based on 3 main aspects:~intensive training of functional tasks with the affected arm (massed practice)~constraint of the un-affected hand through a mitt~shaping techniques designed to transfer gains to the real world activities~In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.~In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
242569|NCT02345512|Device|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
242570|NCT02345499|Procedure|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
242571|NCT02345499|Procedure|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
242572|NCT02345486|Other|0.9% sodium chloride|
242573|NCT02345486|Other|Physiologically balanced fluid|
242574|NCT02345473|Genetic|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
242575|NCT02345460|Drug|Irinotecan Hydrochloride|Given IV
242576|NCT02345460|Drug|Oxaliplatin|Given IV
242577|NCT02345460|Drug|Leucovorin Calcium|Given IV
242578|NCT02345460|Drug|Fluorouracil|Given IV
242579|NCT02345460|Other|Laboratory Biomarker Analysis|Correlative studies
242580|NCT02345447|Drug|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
242581|NCT02345447|Drug|Placebo|Aqueous ethanol solution non-distinguishable from verum
242582|NCT02345434|Other|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
242583|NCT02345408|Drug|CCX872-B|Tablets (oral administration)
242592|NCT02345330|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
242593|NCT02345304|Drug|Omeprazole|
242594|NCT02345304|Drug|Warfarin|
242595|NCT02345304|Drug|BI 1181181|
242596|NCT02345304|Drug|Midazolam|
242597|NCT02345304|Drug|Omeprazole|
242598|NCT02345304|Drug|BI 1181181|
242599|NCT02345304|Drug|Midazolam|
242600|NCT02345304|Drug|Midazolam|
242601|NCT02345304|Drug|Warfarin|
242602|NCT02345304|Drug|BI 1181181|
242603|NCT02345304|Drug|Digoxin|
242604|NCT02345304|Drug|Digoxin|
242605|NCT02345291|Drug|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
242606|NCT02345291|Drug|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
242607|NCT02345278|Drug|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
242608|NCT02345278|Other|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
242609|NCT02345265|Drug|Cediranib Maleate|Given PO
242610|NCT02345265|Drug|Olaparib|Given PO
242611|NCT02345265|Other|Questionnaire Administration|Ancillary studies
242612|NCT02345252|Drug|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
242613|NCT02345252|Drug|FTC/RPV/TDF Placebo|Tablets administered orally once daily
242614|NCT02345252|Drug|FTC/RPV/TDF|200/25/300 mg FDC tablets administered orally once daily
242615|NCT02345252|Drug|FTC/RPV/TAF Placebo|Tablets administered orally once daily
242616|NCT02345239|Drug|Pantoprazole|proton pump inhibitor
242617|NCT02345226|Drug|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
242618|NCT02345226|Drug|EFV/FTC/TDF Placebo|Tablets administered orally once daily
242619|NCT02345226|Drug|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
242620|NCT02345226|Drug|FTC/RPV/TAF Placebo|Tablets administered orally once daily
242621|NCT02345213|Drug|E2020|E2020 tablets will be orally administered once daily after breakfast
242622|NCT02345213|Drug|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
242623|NCT02345200|Procedure|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
242624|NCT02345200|Procedure|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
242625|NCT02345187|Dietary Supplement|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
242626|NCT02345187|Dietary Supplement|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
242627|NCT02345174|Drug|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
242628|NCT02345174|Drug|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
242629|NCT02345161|Drug|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
242630|NCT02345161|Drug|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
242631|NCT02345161|Drug|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
242632|NCT02345161|Drug|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
242633|NCT02345161|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
242634|NCT02345148|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
242635|NCT02345135|Procedure|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
242636|NCT02345135|Procedure|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
242637|NCT02345135|Behavioral|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
242686|NCT02344784|Device|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
242638|NCT02345122|Behavioral|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
242639|NCT02345122|Other|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
242640|NCT02345109|Device|Transtek DUT|"Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT."
242641|NCT02345109|Device|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
242642|NCT02345096|Dietary Supplement|Saccharomyces cerevisiae|
242643|NCT02345096|Dietary Supplement|Placebo|
242644|NCT02345070|Drug|SAR156597|Pharmaceutical form:solution Route of administration: subcutaneous
242645|NCT02345070|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
242646|NCT02345057|Drug|CS-3150|
242647|NCT02345057|Drug|placebo|
242648|NCT02345044|Drug|CS-3150|
242649|NCT02345044|Drug|placebo|
242650|NCT02345044|Drug|eplerenone|
242651|NCT02345031|Drug|AUT00063|600 mg, orally, once a day, for 4 weeks
242652|NCT02345031|Drug|Placebo|orally, once a day, for 4 weeks
242653|NCT02345018|Procedure|Mechano-chemical ablation|Treatment with mechano-chemical ablation
242654|NCT02345005|Device|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
242655|NCT02344992|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
242656|NCT02344992|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
242657|NCT02344940|Drug|Toremifene|patients will take toremifene 60 mg qd.
242658|NCT02344940|Drug|Tamoxifen|patients will take tamoxifen 10 mg bid.
242659|NCT02344927|Other|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
242660|NCT02344927|Other|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
242661|NCT02344914|Device|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.~Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
242662|NCT02344888|Drug|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
242663|NCT02344888|Drug|Clomiphene citrate and folic acid|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
242664|NCT02344875|Drug|FYU-981, (Oral single dosing)|
242665|NCT02344862|Drug|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
242666|NCT02344862|Drug|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
242667|NCT02344862|Drug|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
242668|NCT02344862|Drug|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
242669|NCT02344849|Drug|mesenchymal stem cell|Patients will receive single injection of Cellgram-ED( 30,000,000 mesenchymal stem cell) intracavernously.
242670|NCT02344836|Behavioral|Podcast + mobile diet app|Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
242671|NCT02344836|Behavioral|Podcast + theory-based mobile diet app|Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
242672|NCT02344823|Drug|Vardenafil|per oral intake of 10mg Vardenafil once daily
242673|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
242674|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
242675|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
242676|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
242677|NCT02344823|Drug|Placebo intake once daily|
242678|NCT02344810|Drug|c-Met inhibitor AMG 337|Given PO
242679|NCT02344810|Other|placebo|Given PO
242680|NCT02344810|Drug|oxaliplatin|Given IV
242681|NCT02344810|Drug|leucovorin calcium|Given IV
242682|NCT02344810|Drug|fluorouracil|Given IV
242683|NCT02344810|Other|pharmacological study|Correlative studies
242684|NCT02344810|Other|laboratory biomarker analysis|Correlative studies
242685|NCT02344797|Procedure|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures >185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
242687|NCT02344784|Drug|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
242688|NCT02344771|Procedure|Elective colon cancer surgery|
242689|NCT02344758|Device|Non-invasive lateral flow test for monitoring gluten intake|
242690|NCT02344758|Behavioral|gluten-free diet (GFD)|
242691|NCT02344758|Behavioral|gluten-containing diet|
242692|NCT02344745|Other|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
242693|NCT02344745|Other|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
242694|NCT02344732|Drug|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
242695|NCT02344732|Drug|Homatropine 2% eye drops thrice daily|
242696|NCT02344732|Drug|Oxygen gas|
242697|NCT02344719|Drug|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
242698|NCT02344719|Procedure|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
242699|NCT02344719|Procedure|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
242700|NCT02344719|Drug|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
242701|NCT02344706|Device|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
242702|NCT02344680|Drug|Anti-HIV Agents|
242703|NCT02344667|Radiation|Stereotactic Body Radiotherapy|
242704|NCT02344654|Drug|Indocyanine green|
242705|NCT02344654|Device|Near-infrared illumination|To see the fluorescence from indocyanine green
242706|NCT02344654|Drug|Urografin|
242707|NCT02344654|Radiation|X-ray|
242708|NCT02344641|Drug|Exenatide|
242709|NCT02344628|Drug|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
242710|NCT02344615|Procedure|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
242711|NCT02344615|Procedure|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
242712|NCT02344602|Drug|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
242713|NCT02344589|Drug|Lidocaine|used for the active blocks
242714|NCT02344589|Drug|Saline|used for the placebo-block
242715|NCT02344576|Behavioral|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
242716|NCT02344563|Drug|Meropem|
242717|NCT02344563|Drug|Mepem|
242718|NCT02344550|Drug|Everolimus(afinitor)|Everolimus 10mg p.o. daily
242719|NCT02344550|Drug|Letrozole|Letrozole 2.5 mg p.o. daily
242720|NCT02344550|Drug|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
242721|NCT02344537|Behavioral|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
242722|NCT02344524|Device|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
242723|NCT02344511|Drug|Dalbavancin|Drug
242724|NCT02344511|Drug|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
242725|NCT02344498|Drug|Tenofovir disoproxil|
242726|NCT02344485|Procedure|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
242727|NCT02344472|Drug|pertuzumab|HER2 targeted Therapy
242728|NCT02344472|Drug|Trastuzumab|HER2 targeted Therapy
242729|NCT02344472|Drug|Capecitabine|Chemotherapy
242730|NCT02344472|Drug|Paclitaxel|Chemotherapy
242731|NCT02344472|Drug|Vinorelbine|Chemotherapy
242732|NCT02344472|Drug|Docetaxel|Chemotherapy
242733|NCT02344472|Drug|Exemestane|endocrine therapy
242734|NCT02344472|Drug|Letrozole|endocrine therapy
242735|NCT02344472|Drug|Anastrozole|endocrine therapy
242736|NCT02344472|Drug|Fulvestrant|endocrine therapy
242737|NCT02344472|Drug|Ribociclib|CDK 4/6 inhibitor
242738|NCT02344472|Drug|nab-Paclitaxel|chemotherapy
242739|NCT02344472|Drug|eribulin|chemotherapy
242740|NCT02344472|Drug|leuprorelin|endocrine therapy
242741|NCT02344472|Drug|goserelin|endocrine therapy
242742|NCT02344459|Device|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
242743|NCT02344446|Other|Skilled Therapy|Active physical therapy treatment
242744|NCT02344433|Behavioral|VICKY|Relational agent/virtual counselor
242745|NCT02344433|Behavioral|MFHP|US Surgeon General's family history tool
242780|NCT02344238|Other|ID Capsule|Capsule containing ingestible sensor
242781|NCT02344238|Dietary Supplement|Riboflavin|50mg
242746|NCT02344420|Procedure|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.~Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
242747|NCT02344420|Behavioral|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
242748|NCT02344420|Procedure|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
242749|NCT02344420|Behavioral|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
242750|NCT02344407|Biological|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
242751|NCT02344407|Biological|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
242752|NCT02344407|Biological|Placebo|
242753|NCT02344394|Device|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
242754|NCT02344394|Device|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
242755|NCT02344394|Device|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
242756|NCT02344381|Dietary Supplement|Sucrose|
242757|NCT02344381|Dietary Supplement|Glucose|
242758|NCT02344368|Other|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
242759|NCT02344368|Other|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
242760|NCT02344355|Drug|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
242761|NCT02344355|Radiation|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
242762|NCT02344355|Drug|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
242763|NCT02344342|Device|Telemonitoring|The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.
242764|NCT02344342|Other|Flexible Diuretic Regimen|Patients will have a prescribed diuretic regimen specified by specific weight ranges.
242765|NCT02344329|Device|Topical wound dressing|Topical Wound Dressing
242766|NCT02344329|Biological|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
242767|NCT02344329|Other|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
242768|NCT02344316|Drug|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
242769|NCT02344316|Other|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
242770|NCT02344303|Drug|TRV130|
242771|NCT02344303|Drug|Moxifloxacin|
242772|NCT02344303|Drug|Placebo|
242773|NCT02344290|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
242774|NCT02344290|Drug|Placebo|One tablet taken once daily, orally with or without food
242775|NCT02344277|Device|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.~Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
242776|NCT02344264|Drug|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
242777|NCT02344264|Drug|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
242778|NCT02344251|Device|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
242779|NCT02344251|Device|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
242782|NCT02344238|Behavioral|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
242783|NCT02344225|Drug|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
242784|NCT02344225|Drug|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
242785|NCT02344225|Drug|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
242786|NCT02344212|Behavioral|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
242787|NCT02344186|Drug|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
242788|NCT02344160|Other|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
242789|NCT02344134|Biological|NBP607|0.5 mL, intramuscular, a single dose
242790|NCT02344134|Biological|Agrippal S1|0.5 mL, intramuscular, a single dose
242791|NCT02344121|Radiation|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
242792|NCT02344108|Device|Inspire® Upper Airway Simulation System (Model 3028 IPG )|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
242793|NCT02344095|Drug|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
242794|NCT02344095|Drug|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
242795|NCT02344095|Device|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.~- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
242796|NCT02344082|Other|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
242797|NCT02344069|Drug|Fibrinogen|Human fibrinogen concentrate as a injection
242798|NCT02344069|Drug|Placebo|Saline 0.9% as a injection
242799|NCT02344056|Other|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
242800|NCT02344056|Other|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
242801|NCT02344043|Device|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
242802|NCT02344030|Device|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
242803|NCT02344030|Device|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
242804|NCT02344017|Drug|ODM-204|co-administered with prednisone, orally daily
242805|NCT02344017|Drug|Prednisone|ODM-204 is co-administered with oral prednisone
242806|NCT02344004|Drug|LAI (Liposomal Amikacin for Inhalation) 590 mg|LAI 590 mg QD, administered by inhaling drug product that had been aerosolized in an eFlow nebulizer over approximately 14 minutes.
242807|NCT02343991|Device|Transcranial ExABlate|MR Guided Focused Ultrasound
242808|NCT02343978|Drug|KWA-0711|
242809|NCT02343965|Other|Touch-massage|
242810|NCT02343952|Drug|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
242811|NCT02343939|Drug|Entospletinib|Tablet(s) administered orally every 12 hours
242812|NCT02343939|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 for up to two 14-day induction cycles
242813|NCT02343939|Drug|Cytarabine|100 mg/m^2 administered intravenously daily on Days 1 to 7 for up to two 14-day cycles
242814|NCT02343939|Drug|Decitabine|20 mg/m^2 administered intravenously
242815|NCT02343939|Drug|Azacitidine|75 mg/m^2 administered intravenously or subcutaneously
242816|NCT02343926|Drug|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet~Route of administration: oral"
242817|NCT02343926|Drug|vildagliptin|"Pharmaceutical form:tablet~Route of administration: oral"
242818|NCT02343926|Drug|metformin|"Pharmaceutical form:tablet~Route of administration: oral"
242819|NCT02343913|Device|PAC checklist|
242820|NCT02343887|Other|neuropsychological tests|
242821|NCT02343887|Other|STAI-Y scale for anxiety|
242822|NCT02343887|Other|Beck scale for depression|
242823|NCT02343887|Other|without intervention|
242824|NCT02343874|Other|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
242825|NCT02343861|Behavioral|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
242826|NCT02343861|Behavioral|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
242827|NCT02343848|Device|smart bracelet.|Physical activity will be evaluated using smart bracelet.
242828|NCT02343835|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
242865|NCT02343536|Drug|Oral Azacitidine|
242829|NCT02343822|Other|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
242830|NCT02343822|Other|Saline Injection|"Saline~-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
242831|NCT02343809|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
242832|NCT02343809|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
242833|NCT02343809|Other|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
242834|NCT02343796|Other|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
242835|NCT02343796|Device|everStick|GC, Belgium
242836|NCT02343783|Other|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
242837|NCT02343770|Other|blood sample for identifying biomarkers|
242838|NCT02343757|Device|PET/MRI|
242839|NCT02343744|Drug|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
242840|NCT02343731|Other|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
242841|NCT02343718|Drug|Vinblastine|
242842|NCT02343718|Drug|Temsirolimus|
242843|NCT02343705|Device|Latella Knee Implant System|
242844|NCT02343692|Procedure|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
242845|NCT02343679|Drug|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
242846|NCT02343666|Biological|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
242847|NCT02343666|Drug|Carmustine|Given IV
242848|NCT02343666|Biological|Filgrastim|Given SC
242849|NCT02343666|Other|Laboratory Biomarker Analysis|Correlative studies
242850|NCT02343666|Drug|O6-Benzylguanine|Given IV
242851|NCT02343666|Drug|Plerixafor|Given SC
242852|NCT02343653|Behavioral|Nutrition and strength training|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.~The intervention group will receive supervised training."
242853|NCT02343653|Behavioral|Nutrition|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:~Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered."
242854|NCT02343627|Drug|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
242855|NCT02343627|Drug|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
242856|NCT02343614|Drug|Celecoxib|
242857|NCT02343601|Device|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
242858|NCT02343588|Behavioral|The Health Lifestyles Interventions|"Creating supportive school and family environment, whole intervention periods;~Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;~Instruct and promote school physical education, whole intervention periods;~The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor"
242859|NCT02343575|Drug|Valproic Acid|"1.~Start:~VPA PO/NGT 500 mg BID~2.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS~3.~If need to increase in 24 or more hours:~VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS~4.If need to increase in 24 or more hours:~VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS"
242860|NCT02343575|Drug|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
242861|NCT02343575|Drug|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
242862|NCT02343562|Dietary Supplement|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
242863|NCT02343562|Dietary Supplement|Placebo|Multivitamin off-the-counter.
242864|NCT02343549|Device|bevacizumab, NovoTTF100A, temozolomide|
242870|NCT02343510|Other|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
242871|NCT02343497|Dietary Supplement|Astaxanthin|
242872|NCT02343497|Dietary Supplement|Placebo|
242873|NCT02343484|Drug|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
242874|NCT02343484|Drug|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
242875|NCT02343471|Dietary Supplement|20 g whey protein|
242876|NCT02343458|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
242877|NCT02343458|Drug|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
242878|NCT02343458|Drug|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
242879|NCT02343458|Drug|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
242880|NCT02343445|Drug|P-1037|P-1037 is a novel ENaC inhibitor
242881|NCT02343445|Drug|Hypertonic Saline|4.2% saline solution
242882|NCT02343445|Drug|Saline|0.17% saline solution
242883|NCT02343432|Drug|Triamcinolone|Triamcinolone
242884|NCT02343432|Drug|Epidural Volume|Epidural Volume
242885|NCT02343432|Drug|Bupivacaine|Bupivacaine
242886|NCT02343419|Other|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.~In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
242887|NCT02343406|Drug|Lomustine|Lomustine will be administered orally.
242888|NCT02343406|Drug|ABT-414|ABT-414 will be administered by intravenous infusion over approximately 30-40 minutes.
242889|NCT02343406|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally.
242890|NCT02343393|Drug|Hydralazine|
242891|NCT02343393|Drug|Isosorbide Dinitrate|
242892|NCT02343380|Other|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
242893|NCT02343367|Behavioral|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
242894|NCT02343367|Other|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
242895|NCT02343367|Behavioral|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
242896|NCT02343367|Behavioral|Text messages|regularly scheduled cell phone text messages for 12 months
242897|NCT02343367|Behavioral|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
242898|NCT02343367|Behavioral|Newsletters|12 monthly newsletters mailed to participant homes
242899|NCT02343354|Behavioral|Nutrition/physical activity intervention|Please see arm description
242900|NCT02343341|Behavioral|Preschool Health Promotion Education Program|
242901|NCT02343328|Biological|Fecal Microbiota Transplant|
242902|NCT02343328|Biological|Placebo|
242903|NCT02343315|Device|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.~Equipment- TENS (CEFAR Basic TENS Machine)~Electrodes- Four channel electrode to cover the site of pain~Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.~Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.~Frequency- 5 Hertz~Duration- 30 minutes"
242904|NCT02343315|Other|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.~Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
242947|NCT02343029|Other|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
242905|NCT02343315|Other|UHEP|"All the participants will receive the following treatments:~Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.~Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.~Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
242906|NCT02343302|Device|Jackson-Pratt Drain|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
242907|NCT02343302|Device|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
242908|NCT02343289|Drug|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
242909|NCT02343289|Drug|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
242910|NCT02343276|Drug|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
242911|NCT02343276|Other|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
242912|NCT02343263|Drug|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
242913|NCT02343263|Biological|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
242914|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
242915|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
242916|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
242917|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
242918|NCT02343237|Procedure|Osteopathic treatment|osteopathic sessions of 20 minutes
242919|NCT02343237|Procedure|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
242920|NCT02343224|Drug|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
242921|NCT02343211|Drug|Immunoglobulin|
242922|NCT02343198|Device|Custom-built research muscle stimulator|Muscle stimulator
242923|NCT02343185|Other|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
242924|NCT02343185|Other|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
242925|NCT02343172|Drug|HDM201|
242926|NCT02343172|Drug|LEE011|
242927|NCT02343159|Drug|dimethyl fumarate|120 mg and 240 mg delayed release capsules
242928|NCT02343159|Device|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
242929|NCT02343159|Behavioral|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
242930|NCT02343146|Behavioral|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
242931|NCT02343133|Biological|HemaMax|
242932|NCT02343133|Drug|Placebo|
242933|NCT02343120|Drug|BGB-3111|"In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.~In the safety, schedule and efficacy expansion part, patients will be assigned to different cohorts based on histology type."
242934|NCT02343107|Behavioral|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
242935|NCT02343094|Drug|PBA 7,5g/d|Treatment for 14 days with PBA
242936|NCT02343094|Drug|PBA 15g/d|Treatment for 14 days with PBA
242937|NCT02343081|Drug|Temozolomide|
242938|NCT02343081|Drug|Temozolomide|
242939|NCT02343055|Other|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
242940|NCT02343042|Drug|Selinexor|Tablets
242941|NCT02343042|Drug|Dexamethasone|Oral tablets in a multi-dose vial.
242942|NCT02343042|Drug|Lenalidomide|25 mg Oral capsule
242943|NCT02343042|Drug|Pomalidomide|4 mg oral tablets
242944|NCT02343042|Drug|Bortezomib|3.5 mg for injection supplied as lyophilized powder in single-use viles for subcutaneous injection.
242945|NCT02343042|Drug|Daratumumab|16 mg/kg Intravenous
242946|NCT02343042|Drug|Carfilzomib|56 mg/m2 Intravenous
242948|NCT02343029|Other|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
243112|NCT02341898|Other|Facultative train-the-trainer module for key nurses|
242949|NCT02343016|Device|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
242950|NCT02343003|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
242951|NCT02343003|Drug|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
242952|NCT02342990|Other|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
242953|NCT02342990|Other|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
242954|NCT02342977|Drug|Placebo|Patients will randomly receive placebo
242955|NCT02342977|Drug|Lacosamide|Patients will randomly receive lacosamide
242956|NCT02342964|Other|Measure of hepatic elasticity|"Measure of hepatic elasticity by four non-invasive methods:~Fibroscan, Fibrotest, SWE, MRE."
242957|NCT02342951|Other|Lung clearance index determination|Lung clearance index determination
242958|NCT02342938|Procedure|MEG or fMRI And INtracranial EEG|
242959|NCT02342938|Procedure|fMRI|
242960|NCT02342925|Other|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
242961|NCT02342925|Drug|RG1662|Oral administration twice daily
242962|NCT02342925|Drug|metformin|Single 850 mg dose of metformin
242963|NCT02342912|Behavioral|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
242964|NCT02342899|Device|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
242965|NCT02342899|Device|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
242966|NCT02342886|Drug|Moxifloxacin|Oral
242967|NCT02342886|Drug|PA-824|Oral
242968|NCT02342886|Drug|Pyrazinamide|Oral
242969|NCT02342886|Drug|HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)|Oral
242970|NCT02342886|Drug|HR (rifampicin plus isoniazid combination tablets)|Oral
242971|NCT02342873|Procedure|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
242972|NCT02342873|Procedure|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
242973|NCT02342860|Other|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:~Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;~Software: operations and maintenance (O&M) training for teachers, hygiene training, and basic hygiene package."
242974|NCT02342847|Other|N/A (non-interventional study)|
242975|NCT02342834|Dietary Supplement|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
242976|NCT02342808|Behavioral|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
242977|NCT02342808|Behavioral|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
242978|NCT02342795|Other|e-cigarette|
242979|NCT02342795|Other|cigarette substitute|
242988|NCT02342769|Drug|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
242989|NCT02342756|Device|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
242990|NCT02342743|Device|CEFALY|
242991|NCT02342730|Behavioral|Weight Loss Specialist|Referred to a weight loss specialist
242992|NCT02342730|Other|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
242993|NCT02342730|Other|Medical Chart Review|Chart reviews are performed
242994|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
242995|NCT02342717|Drug|Itraconazole|multiple doses of Itraconazole capsules
242996|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
242997|NCT02342704|Drug|natalizumab|Administered as specified in the treatment arm
242998|NCT02342704|Drug|fingolimod|Administered as specified in the treatment arm
242999|NCT02342691|Drug|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
243000|NCT02342691|Drug|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
243001|NCT02342678|Behavioral|Yoga Therapy|
243002|NCT02342678|Behavioral|Physical Conditioning|
243003|NCT02342665|Drug|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
243004|NCT02342652|Drug|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
243005|NCT02342652|Drug|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
243006|NCT02342639|Drug|Rifaximin|550mg pills
243007|NCT02342639|Drug|Placebo|Placebo pill
243008|NCT02342626|Behavioral|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
243009|NCT02342613|Biological|Activated PTCy-MILs|The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
243010|NCT02342600|Drug|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
243011|NCT02342600|Drug|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
243012|NCT02342587|Drug|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
243013|NCT02342574|Drug|F901318|Administration of active compound
243014|NCT02342574|Drug|Placebo|Administration of placebo
243015|NCT02342561|Device|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
243016|NCT02342548|Drug|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
243017|NCT02342535|Behavioral|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
243018|NCT02342522|Device|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total.
243019|NCT02342522|Device|Control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
243020|NCT02342509|Drug|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
243021|NCT02342509|Drug|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
243022|NCT02342509|Drug|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
243023|NCT02342496|Dietary Supplement|Placebo|Powder
243024|NCT02342496|Dietary Supplement|Active, only probiotics|Powder
243025|NCT02342496|Dietary Supplement|Active, blend of berries and probiotics|Powder
243026|NCT02342483|Dietary Supplement|MSM|
243027|NCT02342470|Drug|Placebo|Drug : Placebo
243028|NCT02342470|Drug|PMK-S005 1|Drug : PMK-S005 1 (50mg)
243029|NCT02342470|Drug|PMK-S005 2|Drug : PMK-S005 2 (100mg)
243030|NCT02342470|Drug|PMK-S005 3|Drug : PMK-S005 3 (150mg)
243031|NCT02342457|Device|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
243032|NCT02342444|Drug|Enoxaparin Sodium Injection 30 mg BID|
243033|NCT02342444|Drug|Enoxaparin Sodium Injection 40 mg QD|
243034|NCT02342431|Device|Forced air warming compressible|Warming with a compressible forced air mattress
243035|NCT02342431|Device|Forced air non-compressible|Warming with a non-compressible forced air mattress
243036|NCT02342418|Drug|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
243037|NCT02342405|Other|80% oxygen|
243039|NCT02342392|Drug|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
243040|NCT02342379|Drug|Bevacizumab|10mg/kg
243041|NCT02342379|Drug|TH-302|670mg/m2
243042|NCT02342366|Drug|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
243043|NCT02342366|Drug|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
243044|NCT02342353|Drug|Pacritinib|
243045|NCT02342353|Drug|Erlotinib|
243046|NCT02342340|Other|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
243047|NCT02342340|Other|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
243048|NCT02342340|Other|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
243049|NCT02342340|Other|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
243050|NCT02342340|Other|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
243051|NCT02342340|Other|White Rice|One time consumption of 3/4 cup of cooked white rice.
243052|NCT02342327|Other|switch to non-menthol cigarettes prior to cessation attempt|
243053|NCT02342327|Other|continue smoking menthol cigarettes prior to cessation attempt|
243054|NCT02342314|Drug|LY3143753 (Part A)|Administered via SC injection
243055|NCT02342314|Drug|LY3185643 (Part B)|Administered via SC injection
243056|NCT02342314|Drug|Placebo (Part A and Part B)|Administered via SC injection
243057|NCT02342314|Drug|rGlucagon (Part B)|Administered via SC injection
243058|NCT02342301|Behavioral|Standing Desk|Participants will be provided with a standing desk for 3 months
243059|NCT02342301|Behavioral|Traditional Desk|Participants will use a traditional seated desk for 3 months
243060|NCT02342288|Procedure|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
243061|NCT02342288|Procedure|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
243062|NCT02342275|Drug|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
243063|NCT02342275|Drug|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
243064|NCT02342262|Dietary Supplement|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
243065|NCT02342262|Other|Placebo|similar appearance as the probiotic product, but without bacteria
243066|NCT02342249|Drug|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
243067|NCT02342249|Drug|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2*300 mg tablets) will be administered over 5-6 days.
243068|NCT02342249|Drug|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
243069|NCT02342249|Drug|Placebo|Subjects will receive matching placebo of Oseltamivir
243070|NCT02342236|Device|cemented or cementless type of hip prothesis|
243071|NCT02342223|Device|Voluma|
243072|NCT02342210|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
243073|NCT02342197|Drug|Decapeptyl|half the dose of Gn agonist
243074|NCT02342184|Drug|GB-0998|
243075|NCT02342171|Other|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
243076|NCT02342158|Procedure|biopsy or surgical sampling|
243077|NCT02342158|Other|blood sampling|
243078|NCT02342145|Drug|Basiliximab,|Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
243079|NCT02342145|Drug|cyclosporine A|Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
243080|NCT02342145|Drug|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
243081|NCT02342145|Drug|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
243113|NCT02341898|Other|Printed study material|
243114|NCT02341898|Other|Supportive material (poster, mugs etc.)|
243115|NCT02341872|Other|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
243116|NCT02341872|Other|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
243117|NCT02341859|Device|stenfilcon A|contact lens
243118|NCT02341859|Device|delefilcon A|contact lens
243082|NCT02342132|Device|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
243083|NCT02342132|Device|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
243084|NCT02342132|Device|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
243085|NCT02342119|Other|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
243086|NCT02342119|Other|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
243087|NCT02342093|Drug|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
243088|NCT02342093|Drug|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
243089|NCT02342080|Other|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
243090|NCT02342080|Device|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
243091|NCT02342067|Drug|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
243092|NCT02342067|Drug|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
243093|NCT02342054|Radiation|MRI-TRUS fusion guided Single Frac HDR|
243094|NCT02342041|Drug|SUVN-G3031|
243095|NCT02342041|Drug|Placebo|
243096|NCT02342028|Biological|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
243097|NCT02342015|Drug|Atorvastatin|Atorvastatina 40mg/day for three months
243098|NCT02342002|Drug|Mifepristone|Mifepristone for treatment of missed abortion
243099|NCT02342002|Drug|Misoprostol|Misoprostol for treatment of missed abortion
243100|NCT02341989|Drug|Bleomycin Etoposide and Cisplatin|
243101|NCT02341989|Drug|Carboplatin|
243102|NCT02341976|Other|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
243103|NCT02341963|Drug|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
243104|NCT02341950|Behavioral|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
243105|NCT02341937|Other|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
243106|NCT02341924|Other|Portfolio of functional foods|
243107|NCT02341924|Other|Control foods|
243108|NCT02341911|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
243109|NCT02341911|Drug|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
243110|NCT02341898|Other|Educational programme for all nurses|
243119|NCT02341859|Device|narafilcon A|contact lens
243120|NCT02341846|Other|Qualitative interviews|
243121|NCT02341833|Drug|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
243122|NCT02341807|Biological|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
243123|NCT02341794|Drug|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
243124|NCT02341768|Device|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
243125|NCT02341742|Device|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
243126|NCT02341729|Drug|ticagrelor|crushed tablets and non-crushed tablets
243127|NCT02341716|Procedure|WA|Walk advice with Nordic Poles and best medical treatment
243128|NCT02341716|Procedure|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
243129|NCT02341716|Procedure|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
243130|NCT02341703|Drug|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
243131|NCT02341703|Drug|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
243132|NCT02341703|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
243133|NCT02341703|Other|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
243134|NCT02341690|Other|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.~IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
243135|NCT02341690|Other|control|Standard care at the promotion centre in the municipality
243136|NCT02341677|Procedure|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
243137|NCT02341651|Other|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
243138|NCT02341638|Drug|BMS-986141|
243139|NCT02341638|Drug|Placebo|
243140|NCT02341638|Drug|Aspirin|
243141|NCT02341638|Drug|Itraconazole|
243142|NCT02341625|Drug|BMS-986148|
243143|NCT02341625|Biological|Nivolumab|
243144|NCT02341612|Other|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
243145|NCT02341612|Other|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
243146|NCT02341612|Other|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
243147|NCT02341612|Other|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
243148|NCT02341612|Other|passive recovery|The control group was exposed to treatment after the EIMD protocol.
243149|NCT02341599|Drug|MK-6183|MK-6183 (CB-238,614) is supplied as lyophilized powder 500 mg vial and mixed into solution for 100 mL intravenous (IV) administration over 1 hour.
243150|NCT02341586|Other|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
243151|NCT02341586|Dietary Supplement|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
243152|NCT02341586|Other|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
243153|NCT02341573|Drug|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
243154|NCT02341573|Drug|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
243155|NCT02341560|Drug|QPI-1007 Injection - 1.5 mg|
243156|NCT02341560|Drug|QPI-1007 Injection - 3.0 mg|
243157|NCT02341560|Other|Sham Injection Procedure|Sham Procedure
243158|NCT02341547|Drug|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
243159|NCT02341534|Device|BioMonitor|Patients will be implanted with the BioMonitor + standard of care
243160|NCT02341521|Drug|OC000459|Taken orally for 8 days
243161|NCT02341508|Biological|0.5 mg/kg Lpathomab|
243162|NCT02341508|Biological|1.0 mg/kg Lpathomab|
243163|NCT02341508|Biological|3.0 mg/kg Lpathomab|
243164|NCT02341508|Biological|10 mg/kg Lpathomab|
243165|NCT02341508|Biological|20 mg/kg Lpathomab|
243166|NCT02341508|Other|Saline solution for intravenous infusion|
243167|NCT02341495|Drug|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
243572|NCT02338531|Procedure|Breast cancer surgery|
243168|NCT02341495|Drug|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
243169|NCT02341495|Drug|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
243170|NCT02341482|Drug|PF-04958242|PF-04958242 will be provided in a capsule. subjects will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.
243171|NCT02341482|Drug|Itraconazole|Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17).
243172|NCT02341469|Other|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:~REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.~The training of nurses on IMCI and REC.~A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.~A supervision system conducted implemented by district managers to provide support and guidance to health centres.~A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
243173|NCT02341456|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
243174|NCT02341456|Drug|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
243175|NCT02341456|Drug|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
243176|NCT02341443|Procedure|Implants|"Experimental arm: Rigid~Surgical treatment using arch bars and according to the following fixation:~Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).~Active comparator: Non-rigid~Surgical treatment using arch bars and according to the following fixation:~Non-rigid fixation on both fracture sides.~Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate."
243177|NCT02341430|Device|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
243178|NCT02341417|Drug|Cinacalcet|Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
243179|NCT02341404|Drug|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
243180|NCT02341391|Biological|TissueGene-C(Low dose)|3.0 x 10^6 cells
243181|NCT02341391|Biological|TissueGene-C(Medium dose)|1.0 x 10^7 cells
243182|NCT02341391|Biological|TissueGene-C(High dose)|3.0 x 10^7 cells
243183|NCT02341378|Biological|TissueGene-C(Low dose)|TissueGene-C at 6.0x10^6 cells
243184|NCT02341378|Biological|TissueGene-C(High dose)|TissueGene-C at 1.8x10^7 cells
243185|NCT02341365|Other|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
243186|NCT02341352|Drug|fluoride varnish|Sodium fluoride 50mg/ml
243187|NCT02341352|Biological|Immunoglobulin Yolk|anti—Streptococcus mutans IgY
243188|NCT02341352|Dietary Supplement|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
243189|NCT02341339|Procedure|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
243190|NCT02341300|Device|Cast Iron Pot|Cast iron pot
243191|NCT02341300|Device|Alumnium Pot|Aluminum Skillet
243192|NCT02341287|Device|Warming hydrogel device|Patients will wear a warming hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
243193|NCT02341287|Device|Non thermal hydrogel device|Patients will wear a hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
243194|NCT02341274|Drug|Tacrolimus|Bioequivalence study
243195|NCT02341261|Behavioral|Standard Care Counseling|
243196|NCT02341261|Behavioral|Supervised Exercise and Counseling|
243197|NCT02341248|Other|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
243198|NCT02341235|Behavioral|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
243199|NCT02341235|Behavioral|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
243200|NCT02341222|Device|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
243235|NCT02340962|Drug|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.~Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
243201|NCT02341222|Device|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
243202|NCT02341209|Drug|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
243203|NCT02341196|Procedure|CEA|Patients in both groups received an intra-operative angiography
243204|NCT02341183|Device|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
243205|NCT02341183|Device|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
243206|NCT02341170|Radiation|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
243207|NCT02341144|Procedure|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
243208|NCT02341144|Procedure|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
243209|NCT02341144|Drug|Ropivacaine|
243210|NCT02341131|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
243211|NCT02341131|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
243212|NCT02341118|Genetic|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
243213|NCT02341105|Procedure|Catheter ablation|Pulmonary vein isolation by catheter ablation
243214|NCT02341105|Drug|Amiodarone|antiarrhythmic therapy using Amiodarone
243215|NCT02341092|Behavioral|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
243216|NCT02341079|Drug|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
243217|NCT02341079|Drug|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
243218|NCT02341066|Device|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
243219|NCT02341053|Other|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
243220|NCT02341027|Device|Jadelle|within 5 days of delivery and before discharge from hospital
243221|NCT02341027|Device|Jadelle|6-8 weeks (42-56 days) postpartum
243222|NCT02341014|Drug|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient regardless of dose level must be 20mg/m2 . All subsequent doses of carfilzomib will be based on the patient's dose level.
243223|NCT02341014|Drug|Romidepsin|
243224|NCT02341014|Drug|Lenalidomide|
243225|NCT02341001|Other|Daily text message of support|
243226|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
243227|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
243228|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
243229|NCT02340975|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
243230|NCT02340975|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
243231|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab
243232|NCT02340975|Biological|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab
243233|NCT02340962|Drug|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
243234|NCT02340962|Drug|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
243236|NCT02340949|Drug|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
243237|NCT02340949|Drug|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
243238|NCT02340949|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
243239|NCT02340949|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
243240|NCT02340936|Drug|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
243241|NCT02340936|Drug|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
243242|NCT02340936|Drug|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
243243|NCT02340936|Drug|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
243244|NCT02340910|Procedure|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
243245|NCT02340910|Procedure|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.~Interventions will occur for a total of 20 sessions over 4 consecutive weeks ."
243246|NCT02340884|Behavioral|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
243247|NCT02340871|Genetic|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
243248|NCT02340858|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
243249|NCT02340845|Biological|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
243250|NCT02340819|Drug|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
243251|NCT02340806|Device|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
243252|NCT02340793|Dietary Supplement|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of >15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
243253|NCT02340780|Drug|Buparlisib|
243254|NCT02340767|Device|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
243255|NCT02340767|Device|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
243256|NCT02340754|Behavioral|Mindfulness-based Stress Reduction|
243257|NCT02340754|Behavioral|MS Education Control|
243258|NCT02340741|Procedure|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
243259|NCT02340741|Procedure|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
243260|NCT02340741|Procedure|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
243261|NCT02340728|Device|ERCP with SEMS plus radiofrequency ablation|
243262|NCT02340728|Device|ERCP with SEMS alone (standard of care)|
243263|NCT02340702|Other|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of <0.7.
243264|NCT02340689|Other|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
243265|NCT02340676|Procedure|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
243266|NCT02340676|Drug|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
243267|NCT02340663|Device|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
243268|NCT02340663|Device|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
243269|NCT02340650|Device|Standard High Resolution Microendoscope and/or Line-Scanning Confocal High Resolution Microendoscope|
243381|NCT02339805|Other|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
243270|NCT02340637|Behavioral|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
243271|NCT02340637|Behavioral|TAU|Treatment as usual
243272|NCT02340624|Behavioral|Referral to SmokeFreeMoms, Quitline or Brief intervention|"SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.~The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.~Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
243273|NCT02340611|Drug|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
243274|NCT02340611|Drug|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
243275|NCT02340598|Other|cold vest|The lowering of body temperature increases basal metabolic rate
243276|NCT02340585|Device|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
243277|NCT02340572|Drug|PRS-080#022-DP|hepcidin antagonist
243278|NCT02340572|Drug|PRS-080-Placebo#001|Placebo treatment
243279|NCT02340559|Behavioral|Meta-cognitive Training|
243280|NCT02340559|Behavioral|Psychoeducational group|
243281|NCT02340546|Device|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
243282|NCT02340533|Procedure|hysteroscopic endo-myometrial biopsy|
243283|NCT02340533|Device|ultrasound|two dimensional trans-vaginal ultrasonography
243284|NCT02340520|Drug|Theophylline|Oral
243285|NCT02340520|Drug|Roflumilast|Oral
243286|NCT02340507|Other|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
243287|NCT02340507|Other|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
243288|NCT02340494|Behavioral|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
243289|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
243290|NCT02340481|Drug|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
243291|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
243292|NCT02340481|Drug|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
243293|NCT02340468|Device|diffuse optical spectroscopy|diffuse optical spectroscopy
243294|NCT02340455|Drug|Pregabalin_male|Pregabalin 150mg bid 1day Men
243295|NCT02340455|Drug|Pregabalin_female|Pregabalin 150mg bid 1day Women
243296|NCT02340455|Drug|Placebo_Men|Placebo durg
243297|NCT02340455|Drug|Placebo_Women|Placebo_Women
243298|NCT02340442|Other|Obstetrical care parameters|
243299|NCT02340442|Other|DVA measurements|
243300|NCT02340442|Other|Fundus photographs|
243301|NCT02340429|Device|DE500 Digital Video Otoscope|
243302|NCT02340416|Device|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
243303|NCT02340403|Procedure|NMR Spectroscopy|
243304|NCT02340390|Device|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
243305|NCT02340390|Device|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
243306|NCT02340377|Device|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
243307|NCT02340364|Behavioral|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
243308|NCT02340364|Behavioral|Self-care Education|208 patients randomized to self-care education alone.
243382|NCT02339805|Device|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
243383|NCT02339792|Other|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
243992|NCT02335294|Drug|Morphine|Rescue: Ibuprofen, oxycodone
243309|NCT02340351|Device|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
243310|NCT02340351|Procedure|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
243311|NCT02340338|Biological|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.~Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of < 20 to > 40 or a 4-fold increase in TSST-1 Ab titer .~Patients 3 µg or more will be randomized."
243312|NCT02340325|Drug|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
243313|NCT02340325|Drug|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
243314|NCT02340312|Procedure|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
243315|NCT02340312|Other|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
243316|NCT02340299|Device|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
243317|NCT02340299|Device|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
243318|NCT02340273|Device|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
243319|NCT02340273|Device|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
243320|NCT02340260|Behavioral|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
243321|NCT02340260|Behavioral|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
243322|NCT02340247|Other|Water|
243323|NCT02340247|Drug|Ursodeoxycholic Acid|
243324|NCT02340247|Drug|Chenodeoxycholic Acid|
243325|NCT02340234|Drug|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
243326|NCT02340234|Drug|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
243327|NCT02340234|Drug|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
243328|NCT02340221|Drug|Taselisib|Taselisib 4 mg was administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
243329|NCT02340221|Drug|Placebo|Placebo matching to taselisib was administered as per the schedule specified in the respective arm.
243330|NCT02340221|Drug|Fulvestrant|Fulvestrant 500 mg was administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
243331|NCT02340208|Drug|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
243332|NCT02340195|Drug|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
243333|NCT02340182|Drug|Vancomycin|250mg 3dd2
243334|NCT02340182|Drug|Ciprofloxacin|500mg 2dd1
243335|NCT02340182|Drug|Metronidazole|500mg 3dd1
243336|NCT02340169|Drug|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
243337|NCT02340156|Genetic|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
243338|NCT02340156|Drug|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
243339|NCT02340143|Other|Control|Marketed partially hydrolyzed cow's milk protein infant formula
243340|NCT02340143|Other|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
243341|NCT02340130|Biological|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
243342|NCT02340130|Biological|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
243993|NCT02335294|Drug|Placebo|Rescue: Ibuprofen, oxycodone
243343|NCT02340117|Genetic|SGT-53|The starting dose of SGT-53 in week 1 will be 2.4 mg DNA/infusion. If the combination therapy of SGT-53 and gemcitabine/nab-paclitaxel is tolerated, starting in week 2, the dose of SGT-53 will be escalated to 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 1.2 mg DNA/infusion (dose level -1) or 0.6 mg DNA/infusion (dose level -2) in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
243344|NCT02340117|Drug|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 75 or 100 mg/m² when appropriate.
243345|NCT02340117|Drug|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 750 mg/m² when appropriate.
243346|NCT02340104|Drug|Baricitinib|4 milligrams (mg) administered orally
243347|NCT02340104|Drug|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
243348|NCT02340091|Device|HA IDF plus|
243349|NCT02340091|Device|HA IDF|
243350|NCT02340078|Device|HA IDF II plus|
243351|NCT02340078|Device|HA IDF II|
243352|NCT02340065|Procedure|standard colonoscopy|examination of the colon with a conventional colonoscope
243353|NCT02340065|Procedure|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
243354|NCT02340052|Drug|Pain treatment|Registration af actual analgesic treatment and outcomes
243355|NCT02340039|Dietary Supplement|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
243356|NCT02340026|Other|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
243357|NCT02340026|Other|Conventional Therapy|"No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child"
243358|NCT02340013|Drug|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
243359|NCT02340000|Drug|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
243360|NCT02340000|Drug|high dose amoxicillin/clavulanate|Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
243361|NCT02339974|Device|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava|
243362|NCT02339961|Radiation|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
243363|NCT02339948|Radiation|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
243364|NCT02339935|Behavioral|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
243365|NCT02339935|Other|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
243366|NCT02339922|Drug|Ixazomib Citrate|Given PO
243367|NCT02339922|Other|Laboratory Biomarker Analysis|Correlative studies
243368|NCT02339922|Biological|Rituximab|Given IV
243369|NCT02339909|Behavioral|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
243370|NCT02339909|Behavioral|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
243371|NCT02339909|Behavioral|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
243372|NCT02339896|Biological|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
243373|NCT02339870|Other|Psychosocial Support for Caregiver|Complete expressive disclosure writing
243374|NCT02339870|Other|Psychosocial Support for Caregiver|Complete benefit finding writing
243375|NCT02339870|Other|Questionnaire Administration|Ancillary studies
243376|NCT02339870|Other|Sham Intervention|Complete writing on an emotionally neutral topic
243377|NCT02339857|Procedure|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
243378|NCT02339844|Drug|Aripiprazole|6 weeks of individual doses of aripiprazole
243379|NCT02339831|Device|CAMOPED|Camoped given after surgery
243380|NCT02339831|Device|CPM passive motion device|passive motion device given after surgery
243384|NCT02339779|Procedure|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.~Typically three separate procedures are needed for a complete breast reconstruction:~First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.~Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.~Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
243385|NCT02339779|Procedure|breast implant|"Implant-based reconstruction typically will occur as follows:~During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.~The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.~When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.~(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
243386|NCT02339766|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
243387|NCT02339766|Procedure|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
243388|NCT02339766|Drug|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
243389|NCT02339766|Drug|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
243390|NCT02339753|Drug|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
243391|NCT02339740|Drug|Arsenic Trioxide|Given IV
243392|NCT02339740|Drug|Cytarabine|Given IV
243393|NCT02339740|Drug|Dexamethasone|Given PO or IV
243394|NCT02339740|Drug|Idarubicin|Given IV
243395|NCT02339740|Other|Laboratory Biomarker Analysis|Correlative studies
243396|NCT02339740|Drug|Mitoxantrone Hydrochloride|Given IV
243397|NCT02339740|Other|Quality-of-Life Assessment|Ancillary studies
243398|NCT02339740|Other|Questionnaire Administration|Ancillary studies
243399|NCT02339740|Drug|Tretinoin|Given PO
243400|NCT02339727|Dietary Supplement|Preterm infants formula|The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
243401|NCT02339714|Other|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).~Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
243402|NCT02339714|Drug|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
243403|NCT02339701|Radiation|IMRT|
243404|NCT02339701|Radiation|SBRT|
243405|NCT02339688|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
243406|NCT02339675|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
243407|NCT02339662|Drug|Gabapentin|muscles pain treatment
243408|NCT02339662|Drug|Amitriptyline|muscles pain treatment
243409|NCT02339649|Procedure|Blood Sample|Blood Sample
243410|NCT02339649|Behavioral|Neurocognitive Assessment|Neurocognitive Assessment
243411|NCT02339649|Other|Resting State EEG|10-20 Minutes of Resting State EEG
243412|NCT02339649|Procedure|Lumbar Puncture|Lumbar Puncture
243413|NCT02339649|Other|MRI|60 Minutes MRI
243414|NCT02339636|Other|PDUS examination|
243415|NCT02339623|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound~- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound~- CL measurement using 2D ultrasound"
243416|NCT02339610|Device|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
243417|NCT02339597|Procedure|Automatic Positive Airway Pressure (APAP) initiation|
243418|NCT02339584|Drug|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
243419|NCT02339584|Drug|Brinzolamide 10 mg/mL eye drops, suspension|
243420|NCT02339584|Drug|Brimonidine 2 mg/mL eye drops, solution|
243421|NCT02339584|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
243422|NCT02339571|Biological|Ipilimumab|Given IV
243423|NCT02339571|Biological|Nivolumab|Given IV
243424|NCT02339571|Biological|Sargramostim|Given SC
243425|NCT02339558|Other|Laboratory Biomarker Analysis|Correlative studies
243426|NCT02339558|Biological|Nivolumab|Given IV
243427|NCT02339545|Device|Coronary Orbital Atherectomy plus Stenting|
243428|NCT02339532|Drug|FEC100|"3 cycles of FEC 100 administered IV q3w~5-Fluorouracil (5-FU) 500 mg/m2~Epirubicin 100 mg/m2~Cyclophosphamide 500 mg/m2"
243429|NCT02339532|Drug|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m2 IV escalading at 100 mg/m2 IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m2 IV
243430|NCT02339532|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
243431|NCT02339532|Drug|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
243432|NCT02339532|Drug|Carboplatin|CARBOPLATIN AUC 6 IV q3w
243433|NCT02339519|Device|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
243535|NCT02338739|Behavioral|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
243434|NCT02339519|Device|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
243435|NCT02339519|Device|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
243436|NCT02339506|Drug|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
243437|NCT02339506|Drug|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
243438|NCT02339493|Other|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
243439|NCT02339480|Other|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
243440|NCT02339467|Other|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
243441|NCT02339467|Other|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
243442|NCT02339454|Device|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
243443|NCT02339454|Device|Placebo group|Placebo Applicator
243444|NCT02339441|Drug|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
243445|NCT02339441|Drug|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
243446|NCT02339441|Drug|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
243447|NCT02339428|Drug|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
243448|NCT02339428|Drug|Placebo|Inactive pill manufactured to mimic diclofenac tablet
243449|NCT02339415|Drug|Edoxaban 30mg daily|
243450|NCT02339415|Drug|Matching placebo|
243451|NCT02339389|Other|Labor analgesia|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
243452|NCT02339376|Device|Low-frequency repetitive transcranial magnetic stimulation|
243453|NCT02339376|Device|High-frequency repetitive transcranial magnetic stimulation|
243454|NCT02339376|Device|Sham repetitive transcranial magnetic stimulation|
243455|NCT02339363|Behavioral|Sitting Meditation|4 weeks Sitting Meditation
243456|NCT02339363|Behavioral|Hatha yoga|4 weeks of Hatha yoga
243457|NCT02339350|Drug|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
243458|NCT02339350|Drug|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
243459|NCT02339337|Other|Abbreviation of treatment duration|
243460|NCT02339324|Drug|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
243461|NCT02339311|Other|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
243462|NCT02339298|Other|music application|music is applied during anaesthesia using headphones
243463|NCT02339298|Other|only headphones|music is not applied, only headphones are placed
243464|NCT02339298|Drug|a caudal block|
243465|NCT02339285|Device|tACS (alpha)|
243466|NCT02339285|Device|tACS (gamma)|
243467|NCT02339272|Other|non interventional|
243468|NCT02339259|Other|Observation|
243469|NCT02339246|Drug|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
243470|NCT02339246|Drug|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
243471|NCT02339233|Device|Standing and Stepping with spinal cord Epidural Stimulation|Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
243994|NCT02335281|Procedure|FMT|Standardized FMT once
243472|NCT02339220|Behavioral|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
243473|NCT02339220|Behavioral|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
243474|NCT02339220|Behavioral|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
243475|NCT02339220|Behavioral|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
243476|NCT02339207|Drug|AL-335 matching placebo|=
243477|NCT02339207|Drug|AL-335|
243478|NCT02339194|Procedure|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
243479|NCT02339168|Drug|Enzalutamide|Given PO
243480|NCT02339168|Drug|Metformin Hydrochloride|Given PO
243481|NCT02339155|Biological|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
243482|NCT02339155|Biological|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
243483|NCT02339155|Drug|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
243484|NCT02339142|Radiation|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
243485|NCT02339142|Drug|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
243486|NCT02339129|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
243487|NCT02339129|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
243488|NCT02339116|Drug|fluoruracil|
243489|NCT02339116|Drug|Oxaliplatin|
243490|NCT02339116|Drug|Irinotecan|
243491|NCT02339116|Drug|Bevacizumab|
243492|NCT02339103|Other|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
243493|NCT02339103|Other|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
243494|NCT02339090|Drug|somavaratan|long acting growth hormone therapy
243495|NCT02339090|Drug|Daily rhGH|daily growth hormone therapy
243496|NCT02339064|Drug|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
243497|NCT02339051|Behavioral|Jumping on one leg|
243498|NCT02339038|Drug|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
243499|NCT02338999|Radiation|PET/CT|The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.
243500|NCT02338999|Drug|Pioglitazone|Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.
243501|NCT02338973|Drug|Interferon gamma-1b|
243502|NCT02338960|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
243503|NCT02338960|Drug|Placebo|Placebo
243504|NCT02338947|Procedure|Off-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions, an absorbable hemostat will be used in the sternal bone marrow. An automatic autotransfusion system will be used to recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time >200s. The proximal anastomosis will be performed according to our guidelines. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
243536|NCT02338739|Behavioral|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
243608|NCT02338245|Drug|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
243505|NCT02338947|Procedure|On-pump coronary-artery bypass grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time >480 s. Heparin will be neutralized with 1:1 protamine sulfate. The automatic autotransfusion system will be used just in massive blood loss to recovery the red blood cells. Surgical techniques will be performed according to our guidelines.
243506|NCT02338934|Drug|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
243507|NCT02338921|Drug|Sitagliptin|"100mg qd per oral during 24months~compared with other treatment groups"
243508|NCT02338921|Drug|Dapagliflozin|"10mg qd per oral during 24months~compared with other treatment groups"
243509|NCT02338921|Drug|Lobeglitazone|"0.5mg qd per oral during 24months~compared with other treatment groups"
243510|NCT02338921|Drug|Glimepirde|
243511|NCT02338921|Drug|Metformin|
243512|NCT02338908|Other|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
243513|NCT02338908|Other|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
243514|NCT02338895|Device|Ultrasound|Ultrasound of inferior vena cava and kidneys
243515|NCT02338882|Device|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
243516|NCT02338882|Device|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
243517|NCT02338869|Behavioral|Dialogue-based psychosocial rehabilitation|
243518|NCT02338856|Drug|MB12066 200mg|100mg bid (multiple dose, day 8)
243519|NCT02338856|Drug|Placebo|100mg bid (multiple dose, day 8)
243520|NCT02338843|Drug|LJPC-501|Treatment arm
243521|NCT02338843|Drug|Placebo|PBO
243522|NCT02338830|Drug|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
243523|NCT02338817|Device|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
243524|NCT02338804|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
243525|NCT02338804|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
243526|NCT02338791|Device|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
243527|NCT02338778|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
243528|NCT02338778|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
243529|NCT02338765|Behavioral|mHealth Physical Activity|
243530|NCT02338765|Behavioral|Buddy-partnered exercise|
243531|NCT02338752|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
243532|NCT02338752|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
243533|NCT02338739|Behavioral|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
243534|NCT02338739|Behavioral|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
243537|NCT02338739|Behavioral|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
243538|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
243539|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
243540|NCT02338739|Behavioral|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
243541|NCT02338739|Behavioral|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
243542|NCT02338739|Behavioral|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
243543|NCT02338739|Behavioral|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
243544|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
243545|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
243546|NCT02338739|Behavioral|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
243547|NCT02338739|Behavioral|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
243548|NCT02338726|Other|Gynecological examination|Comparison of questionnaires and gynecological examination
243549|NCT02338713|Drug|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
243550|NCT02338713|Drug|Noncarbonated Water|Noncarbonated water 200 mL
243551|NCT02338700|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
243552|NCT02338700|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
243553|NCT02338687|Dietary Supplement|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
243554|NCT02338687|Behavioral|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
243555|NCT02338674|Drug|Tenofovir and telbivudine|tenofovir and telbivudine administered at least 48 weeks
243556|NCT02338674|Drug|Tenofovir|tenofovir administered at least 48 weeks
243557|NCT02338661|Device|SBG hip stem|
243558|NCT02338648|Drug|SUN-131 1.5% TDS|Active transdermal patch
243559|NCT02338648|Drug|Placebo TDS|Placebo transdermal patch for blinding
243560|NCT02338635|Drug|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
243561|NCT02338622|Drug|olaparib|olaparib BD
243562|NCT02338622|Drug|AZD5363|AZD5363 BD
243563|NCT02338609|Drug|Everolimus|Blood sample and Tanner Stage assessment
243564|NCT02338609|Drug|Envirolimus drug class as prescribed by Physician|At the discretion of the investigator, patients may be treated with commercially available everolimus, as per local product information/ standard of care.
243565|NCT02338596|Procedure|Total hip replacement|"Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.~Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.~The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups."
243566|NCT02338583|Device|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
243567|NCT02338570|Drug|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
243568|NCT02338557|Device|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
243569|NCT02338557|Device|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
243570|NCT02338544|Drug|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
243573|NCT02338518|Drug|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.~Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
243574|NCT02338518|Drug|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
243575|NCT02338518|Drug|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
243576|NCT02338518|Drug|S-1|80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
243577|NCT02338505|Device|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.~Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
243578|NCT02338492|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
243579|NCT02338466|Drug|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
243580|NCT02338466|Drug|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.~The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
243581|NCT02338453|Behavioral|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
243582|NCT02338453|Behavioral|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
243583|NCT02338440|Drug|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
243584|NCT02338427|Other|Immunohistochemistry|
243585|NCT02338427|Other|Proteomic analysis|
243586|NCT02338414|Drug|Romiplostim|Subcutaneous Romiplostim (weekly injection) -> if titrated with maintaining PLT count between 50-200 x 10^9/L -> Subcutaneous Romiplostim (biweekly injection)
243587|NCT02338401|Dietary Supplement|Omega-3 Complete|Fish Oil Capsules
243588|NCT02338401|Dietary Supplement|Placebo Pill|Olive Oil Capsules
243589|NCT02338388|Procedure|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
243590|NCT02338375|Biological|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
243591|NCT02338362|Drug|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
243592|NCT02338362|Drug|Saline placebo inhaler|saline metered dose inhaler
243593|NCT02338349|Drug|Elacestrant|
243594|NCT02338336|Drug|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
243595|NCT02338336|Drug|Placebo|Matching placebo liquid for topic administration.
243596|NCT02338323|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
243597|NCT02338323|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
243598|NCT02338310|Drug|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
243599|NCT02338297|Procedure|TACE|Transarterial chemoembolisation (TACE)
243600|NCT02338297|Drug|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
243601|NCT02338297|Drug|PVA|Occlude arterioportal shunts(APS) with PVA
243602|NCT02338284|Other|ultrasound of globe|"A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.~A value > 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
243603|NCT02338271|Other|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
243604|NCT02338258|Device|Anti-rotational plate|
243605|NCT02338258|Device|Exchanged Intramedullary nailing|
243606|NCT02338245|Drug|ASLAN001|ASLAN001 400mg BID
243607|NCT02338245|Drug|Lapatinib|Lapatinib 1250mg QD
243609|NCT02338232|Drug|Telmisartan|
243610|NCT02338219|Other|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
243611|NCT02338219|Other|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
243612|NCT02338206|Drug|Growth hormone|
243613|NCT02338193|Drug|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
243614|NCT02338193|Drug|DAPA|10 mg dapagliflozin QD for 20-24 weeks
243615|NCT02338193|Drug|MET XR|1000 mg Metformin XR BID for 20-24 weeks
243616|NCT02338180|Other|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
243617|NCT02338180|Other|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
243618|NCT02338167|Procedure|Blood sampling|A blood sample will be taken during a routine blood draw
243619|NCT02338141|Device|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
243620|NCT02338141|Device|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
243621|NCT02338115|Drug|Paclitaxel 80mg/m2 weekly x 12 weeks|
243622|NCT02338102|Other|Saline mixture|premeasured salt packets mixed with distilled water
243623|NCT02338089|Drug|Oxytocin|Oxytocin, 100 micromolar solution
243624|NCT02338076|Drug|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)~1 well will be empty and the other well will contain petrolatum~Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch~1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
243625|NCT02338063|Behavioral|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
243626|NCT02338063|Behavioral|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
243627|NCT02338050|Biological|Moxetumomab Pasudotox|
243628|NCT02338037|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
243629|NCT02338037|Procedure|Biopsy|Undergo biopsy
243630|NCT02338037|Drug|Eribulin Mesylate|Given IV
243631|NCT02338037|Procedure|Microdialysis|Undergo intracerebral microdialysis
243632|NCT02338037|Other|Pharmacological Study|Correlative studies
243633|NCT02338024|Behavioral|Modified Antiretroviral Treatment Access Study intervention|
243634|NCT02338011|Drug|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
243635|NCT02338011|Radiation|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
243636|NCT02337998|Other|load carriage|
243637|NCT02337985|Drug|Prednisone|Given PO
243638|NCT02337985|Biological|Rituximab|Given IV
243639|NCT02337985|Drug|Etoposide|Given IV
243640|NCT02337985|Drug|Doxorubicin Hydrochloride|Given IV
243641|NCT02337985|Drug|Vincristine Sulfate|Given IV
243642|NCT02337985|Drug|Cyclophosphamide|Given IV
243643|NCT02337985|Biological|Filgrastim|Given SC
243644|NCT02337985|Biological|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
243645|NCT02337972|Drug|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
243646|NCT02337959|Radiation|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
243647|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
243648|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
243649|NCT02337933|Drug|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
243650|NCT02337933|Drug|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
243651|NCT02337907|Drug|Placebo|for blinding purposes
243652|NCT02337907|Drug|Placebo|
243653|NCT02337907|Drug|BI 409306|
243654|NCT02337907|Drug|Donepezil|
243655|NCT02337894|Dietary Supplement|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
243656|NCT02337894|Dietary Supplement|Placebo|Flavored drink without essential amino acids plus arginine.
243657|NCT02337881|Drug|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
243658|NCT02337881|Drug|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
243659|NCT02337868|Biological|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
243660|NCT02337868|Other|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
243661|NCT02337855|Other|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
243662|NCT02337855|Biological|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
243663|NCT02337855|Biological|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
243664|NCT02337842|Biological|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units.
243665|NCT02337842|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
243666|NCT02337829|Drug|acalabrutinib|Patients undergo lymph node biopsies
243667|NCT02337829|Drug|acalabrutinib|Patients undergo bone marrow biopsies
243668|NCT02337816|Procedure|laparoscopic surgery, obtainment of biological samples|
243669|NCT02337803|Behavioral|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
243670|NCT02337803|Behavioral|Usual Care|Will continue daily physical activity and complete surveys online
243671|NCT02337764|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
243672|NCT02337751|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
243673|NCT02337738|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
243674|NCT02337738|Drug|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
243675|NCT02337738|Drug|Placebo|Placebo Tablets
243676|NCT02337725|Drug|TVP-1012|TVP-1012 1mg Tablets
243677|NCT02337725|Drug|Placebo|Placebo tablets
243678|NCT02337712|Radiation|q.d. RT|65 Gy in 26 fractions
243679|NCT02337712|Radiation|b.i.d.RT|45 Gy in 30 fractions
243680|NCT02337712|Drug|etoposide and cisplatin|etoposide and cisplatin concurrent with radiotherapy
243681|NCT02337699|Device|Implantation with the commercially available Axium neurostimulator|
243682|NCT02337699|Procedure|QST Testing|
243683|NCT02337686|Other|Laboratory Biomarker Analysis|Correlative studies
243684|NCT02337686|Biological|Pembrolizumab|Given IV
243685|NCT02337686|Other|Pharmacological Study|Correlative studies
243686|NCT02337686|Procedure|Therapeutic Conventional Surgery|Undergo surgery
243687|NCT02337660|Procedure|Liver biopsy|One ultrasound guided liver biopsy
243688|NCT02337660|Other|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
243689|NCT02337647|Other|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
243690|NCT02337634|Drug|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
243691|NCT02337634|Drug|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
243692|NCT02337621|Other|No intervention|
243693|NCT02337608|Drug|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
243694|NCT02337608|Drug|Placebo|placebo daily dosing in the morning daily for 12 weeks
243695|NCT02337595|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
243696|NCT02337582|Other|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
243697|NCT02337582|Other|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
243698|NCT02337569|Drug|NPC-02|
243699|NCT02337569|Drug|Placebos|
243700|NCT02337556|Other|Peptamen Bariatric|Commercially available enteral diet
243701|NCT02337556|Other|Replete|Commercially available enteral diet
243702|NCT02337543|Drug|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
243703|NCT02337543|Drug|Placebo|Placebo
243704|NCT02337530|Drug|Selumetinib|
243705|NCT02337530|Drug|Pemetrexed|
243706|NCT02337530|Drug|Cisplatin|
243707|NCT02337530|Drug|Carboplatin|
243708|NCT02337517|Other|Laboratory Biomarker Analysis|Correlative studies
243709|NCT02337517|Drug|Vismodegib|Given PO
243710|NCT02337504|Other|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
243711|NCT02337491|Drug|Pembrolizumab|
243712|NCT02337491|Drug|Bevacizumab|
243713|NCT02337478|Drug|Vincristine Sulfate Liposome|Given via injection
243714|NCT02337478|Other|Laboratory Biomarker Analysis|Correlative studies
243715|NCT02337465|Device|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
243802|NCT02336815|Drug|Dexamethasone|20 mg will be given with each dose of Selinexor.
243716|NCT02337465|Radiation|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
243717|NCT02337452|Behavioral|Family History Questionnaire|Participants complete a family history questionnaire online or hardcopy, which should take about 20 minutes to complete.
243718|NCT02337452|Behavioral|Web-Based Family Outreach Registry|Participants taught how to use the Web-Based Family Outreach Registry. They will be given a secure log-in username and password for the web site.
243719|NCT02337439|Behavioral|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
243720|NCT02337439|Behavioral|Active Control Training|Commercially available educational software
243721|NCT02337426|Drug|Dimethyl Fumarate|Given PO
243722|NCT02337426|Drug|Temozolomide|Given PO
243723|NCT02337426|Radiation|Radiation Therapy|Undergo radiation therapy
243724|NCT02337413|Drug|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
243725|NCT02337413|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
243726|NCT02337413|Behavioral|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
243727|NCT02337400|Behavioral|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
243728|NCT02337400|Behavioral|15 minute counseling interview|
243729|NCT02337387|Biological|Blosozumab|Administered SC
243730|NCT02337387|Other|Placebo|Administered SC
243731|NCT02337374|Device|Midurethral sling mesh|
243732|NCT02337361|Behavioral|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:~1) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
243733|NCT02337348|Other|Optical coherence tomography|Preintervention imaging
243734|NCT02337348|Radiation|Coronary angiography|Conventional coronary intervention
243735|NCT02337322|Drug|Dolutegravir|
243736|NCT02337322|Drug|Darunavir/r|
243737|NCT02337309|Drug|SF1126|SF1126 in IV form with be given to patients on this study.
243738|NCT02337296|Behavioral|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.~All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
243739|NCT02337283|Drug|BI 425809|Tablets
243740|NCT02337283|Drug|Placebo|Tablets
243741|NCT02337270|Biological|Ad5Ag85A|Aerosol administration of Ad5Ag85A
243742|NCT02337257|Drug|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
243743|NCT02337257|Drug|Placebo|subjects will receive placebo one pill per day for 16 weeks
243744|NCT02337244|Device|Zimmer Persona Total Knee System|No Intervention
243745|NCT02337231|Dietary Supplement|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
243746|NCT02337218|Device|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
243747|NCT02337205|Drug|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
243748|NCT02337192|Drug|Curcumin|
243749|NCT02337192|Device|LED|
243750|NCT02337192|Drug|Surfactant|
243751|NCT02337192|Drug|DMSO + water|
243752|NCT02337192|Drug|Chlorhexidine gluconate|
243753|NCT02337179|Procedure|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
243754|NCT02337166|Device|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
243755|NCT02337166|Procedure|Periodontal flap surgery|
243756|NCT02337140|Device|Pacemaker SORIN Group KORA DR|
243757|NCT02337140|Procedure|transcatheter aortic valve implantation (TAVI)|
243758|NCT02337127|Drug|Lamivudine|Lamivudine, 100mg/day, per os
243759|NCT02337114|Behavioral|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
243760|NCT02337114|Behavioral|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
243761|NCT02337101|Other|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
243799|NCT02336841|Other|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
243800|NCT02336841|Other|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
243801|NCT02336815|Drug|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
243762|NCT02337101|Behavioral|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.~The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.~Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
243763|NCT02337088|Procedure|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
243764|NCT02337088|Procedure|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
243765|NCT02337075|Behavioral|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
243766|NCT02337075|Device|Activity Mentor|
243767|NCT02337062|Drug|APD421|
243768|NCT02337062|Drug|Placebo|
243769|NCT02337036|Other|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
243770|NCT02337036|Other|Pharmacogenetic|Pharmacogenetic study
243771|NCT02337036|Drug|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
243772|NCT02337023|Radiation|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
243773|NCT02337010|Device|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
243774|NCT02337010|Device|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
243775|NCT02337010|Drug|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
243776|NCT02337010|Drug|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
243777|NCT02336997|Procedure|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
243778|NCT02336997|Procedure|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1*10e6 cells/cm2.
243779|NCT02336997|Procedure|PLACEBO|Saline will be injected into expanded skin.
243780|NCT02336984|Biological|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
243781|NCT02336984|Drug|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
243782|NCT02336984|Drug|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
243783|NCT02336971|Behavioral|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
243784|NCT02336971|Behavioral|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
243785|NCT02336958|Drug|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
243786|NCT02336958|Drug|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
243787|NCT02336958|Drug|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
243788|NCT02336958|Drug|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
243789|NCT02336945|Device|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
243790|NCT02336919|Behavioral|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
243791|NCT02336906|Drug|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
243792|NCT02336906|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
243793|NCT02336906|Behavioral|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
243794|NCT02336893|Behavioral|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
243795|NCT02336880|Behavioral|Internet-delivered cognitive behavioural therapy|
243796|NCT02336867|Device|Closure clip (OTSC® Proctology)|
243797|NCT02336854|Drug|Tacrobell tab. 2mg|
243798|NCT02336854|Drug|Prograf cap. 2mg|
243803|NCT02336802|Behavioral|Avoidance experiment|Participants complete an avoidance task
243804|NCT02336789|Other|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
243805|NCT02336789|Other|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
243806|NCT02336776|Other|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
243807|NCT02336763|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
243808|NCT02336763|Other|Laboratory Biomarker Analysis|Correlative studies
243809|NCT02336750|Drug|Aprepitant|125mg D1, 80mg D2-3
243810|NCT02336750|Drug|Mirtazapine|15mg D2-4
243811|NCT02336737|Device|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
243812|NCT02336737|Drug|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
243813|NCT02336737|Drug|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
243814|NCT02336724|Drug|Famitinib|
243815|NCT02336711|Radiation|dose escalation|molecular imaging based radiotherapy dose escalation
243816|NCT02336698|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
243817|NCT02336698|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
243818|NCT02336698|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
243819|NCT02336685|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
243820|NCT02336685|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
243821|NCT02336685|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
243822|NCT02336685|Drug|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
243823|NCT02336672|Device|Cryothermal ablation|Procedures are performed with patients sedated by anaesthesiologists. Device setting and application time are set and recorded on a computer, that analyzes the changes of the tissue's properties. The setting of the maximal application time is based on the results of our previously described ex-vivo and in-vivo studies and is adjusted to the tumour's size, thus ensuring a reduction of procedure-related complications. Application of Power Doppler makes the procedure safer. The HybridTherm probe is guided under real-time EUS into the tumour, and the success of its placement is an index of the treatment's feasibility. The system analyzes the effects on the tissue and EUS records the changes of the tissue, the growing edema around the treated area, and the tissue devitalization.
243824|NCT02336659|Drug|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
243825|NCT02336659|Drug|sitagliptin|DPP-4 Inhibition
243826|NCT02336659|Other|Placebo|Saline
243827|NCT02336646|Drug|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
243828|NCT02336646|Drug|Normal saline|
243829|NCT02336633|Dietary Supplement|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
243830|NCT02336633|Other|Placebo|
243831|NCT02336620|Drug|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
243832|NCT02336620|Drug|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
243833|NCT02336607|Drug|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
243834|NCT02336607|Drug|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
243835|NCT02336607|Drug|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
243989|NCT02335307|Other|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
243836|NCT02336607|Drug|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.~If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
243837|NCT02336594|Drug|RDEA3170 10 mg|
243838|NCT02336594|Drug|RDEA3170 2.5 mg|
243839|NCT02336581|Behavioral|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
243840|NCT02336581|Behavioral|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
243841|NCT02336568|Drug|Oxytoine|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
243842|NCT02336568|Drug|PLACEBO|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
243843|NCT02336555|Drug|MK-8291|MK-8291 10 mg tablet orally, once daily, on days 1,2 and 28; and twice daily, on days 3 to 27
243844|NCT02336555|Drug|Placebo|Placebo for MK-8291 tablet orally, once daily on days 1,2, and 28; and twice daily, on days 3 to 27
243845|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
243846|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
243847|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
243848|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
243849|NCT02336529|Drug|Bupivacaine|
243850|NCT02336529|Drug|NaCl|
243851|NCT02336516|Drug|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
243852|NCT02336516|Drug|Placebo (glucose solution 10%)|
243853|NCT02336503|Drug|BBI-4000 Low Concentration|BBI-4000 Low Dose
243854|NCT02336503|Drug|BBI-4000 Middle Concentration|BBI-4000 Middle Dose
243855|NCT02336503|Drug|BBI-4000 High Concentration|BBI-4000 High Dose
243856|NCT02336503|Drug|Placebo|Vehicle
243857|NCT02336490|Other|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
243858|NCT02336477|Drug|Mexiletine|"Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~Patients will receive gradual dose of the treatment as it would be done in clinical practice.~Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~The duration of each treatment period is 18 days minimum (maximum 22 days)."
243859|NCT02336477|Drug|placebo|
243860|NCT02336451|Drug|LDK378|LDK378 (ceritinib) 750 mg once daily, orally administered
243861|NCT02336438|Dietary Supplement|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
243862|NCT02336425|Drug|QGE031|QGE031 120 mg per 1 mL liquid in vial
243863|NCT02336425|Drug|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
243864|NCT02336412|Other|SMS reminder|Daily SMS medication reminder
243865|NCT02336386|Drug|CDD|Chemotherapy
243866|NCT02336386|Drug|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
243867|NCT02336373|Drug|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
243868|NCT02336360|Drug|18F-AV-1451|370 megabecquerel (MBq) (10 millicurie [mCi]) administered in a separate Avid-sponsored study. No drug will be administered in this study.
243869|NCT02336347|Drug|AVP-786|
243870|NCT02336347|Drug|AVP-923|
243871|NCT02336334|Device|Positioning measurement|Logging of posturing informations
243872|NCT02336334|Device|Patient feedback|Evaluation of patients questionary
243873|NCT02336334|Procedure|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
243874|NCT02336334|Device|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
243875|NCT02336321|Device|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
243876|NCT02336308|Drug|Ketamine|
243877|NCT02336308|Drug|Placebo, Normal Saline|
243878|NCT02336295|Other|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
243879|NCT02336282|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level < 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
243911|NCT02336048|Drug|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
243990|NCT02335307|Other|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
243880|NCT02336282|Device|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
243881|NCT02336282|Other|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.~The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.~The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
243882|NCT02336282|Other|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
243883|NCT02336256|Procedure|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
243884|NCT02336243|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
243885|NCT02336243|Dietary Supplement|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
243886|NCT02336230|Drug|remestemcel-L|Subjects will be treated with intravenous (IV) remestemcel-L at a dose of 2 x 10e6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart and no more than 5 days apart for any infusion.
243887|NCT02336217|Other|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
243888|NCT02336217|Other|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
243889|NCT02336191|Procedure|living donor liver transplantation|living donor liver transplantation
243890|NCT02336178|Drug|Benefix|"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.~The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."
243891|NCT02336165|Drug|Durvalumab|Durvalumab is administered as an IV infusion over 60 ± 5 minutes Q2W.
243892|NCT02336165|Radiation|Standard radiotherapy|Focal radiotherapy is administered at 2 Gy given daily 5 days per week for a total of 60 Gy over 30 fractions per local institutional guidelines or local prescribing information. On days when radiotherapy and durvalumab overlap, radiotherapy is administered first followed by durvalumab.
243893|NCT02336165|Biological|Bevacizumab|Bevacizumab is administered as an IV infusion (per local prescribing information) Q2W. When durvalumab and bevacizumab are administered together (i.e., Cohorts B2, B3, and C), durvalumab is administered first followed by a 1-hour observation period, after which, bevacizumab is infused.
243894|NCT02336152|Device|Anaesthesia, Teles Pro, Body suit|
243895|NCT02336139|Drug|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
243896|NCT02336126|Behavioral|Biopsychological intervention|
243897|NCT02336113|Behavioral|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge, as well as written drug information to the next level of care
243898|NCT02336100|Device|Endoscopy (FICE and pCLE)|FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
243899|NCT02336087|Drug|Gemcitabine Hydrochloride|Given IV
243900|NCT02336087|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
243901|NCT02336087|Drug|Metformin Hydrochloride|Given PO
243902|NCT02336087|Dietary Supplement|Therapeutic Dietary Intervention|Given PO
243903|NCT02336087|Other|Laboratory Biomarker Analysis|Correlative studies
243904|NCT02336087|Other|Quality-of-Life Assessment|Ancillary studies
243905|NCT02336074|Drug|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
243906|NCT02336074|Drug|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
243907|NCT02336074|Drug|Vorinostat|"Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).~Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
243908|NCT02336074|Biological|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
243909|NCT02336074|Biological|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
243910|NCT02336061|Behavioral|Evaluation of gender differences on the psychosocial and economic impact.|
243983|NCT02335359|Drug|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
243912|NCT02336048|Drug|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
243913|NCT02336048|Drug|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
243914|NCT02336048|Other|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
243915|NCT02336048|Drug|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
243916|NCT02336035|Procedure|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
243917|NCT02336022|Device|Respiratory Motion Inc|
243918|NCT02336009|Device|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
243919|NCT02335996|Biological|Blood samples for measuring adiponectin, leptin and omentin plasma|
243920|NCT02335996|Device|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
243921|NCT02335983|Drug|Carfilzomib|
243922|NCT02335983|Drug|Lenalidomide|
243923|NCT02335983|Drug|Dexamethasone|
243924|NCT02335970|Other|Training group|"After 1 week~Chest expansions~Static thoracic extension in prone~Lateral flexion of the spine in standing~Bilateral shoulder flexion~Shoulder external rotation of shoulders~Rotation of the thoracic spine in sitting~Static back extensor strength in prone~After 1 month~Thoracic extension, rotation and flexion abduction~Hand in neck and in back~Bilateral active flexion abduction~Strength training of leg muscles~Static back extensor strength~After 2 months~Strength training of legs and back muscles~Push-ups against a wall~Thoracic extension in sitting and standing~Thoracic rotation in lying~Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
243925|NCT02335957|Radiation|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
243926|NCT02335944|Drug|INC280|cMET inhibitor
243927|NCT02335944|Drug|EGF816|EGFR-TKI
243928|NCT02335918|Drug|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.~Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.~Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
243929|NCT02335905|Drug|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
243930|NCT02335879|Biological|Gonal-F|
243931|NCT02335866|Procedure|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
243932|NCT02335866|Procedure|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
243933|NCT02335840|Other|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
243934|NCT02335840|Other|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
243935|NCT02335840|Other|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
243936|NCT02335840|Other|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
243937|NCT02335827|Procedure|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
243938|NCT02335814|Drug|FLX925|
243939|NCT02335788|Device|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
243940|NCT02335749|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
243941|NCT02335736|Drug|Gonadotropins releasing hormone antagonist|
243942|NCT02335723|Device|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.~Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
243943|NCT02335723|Device|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
243944|NCT02335710|Device|Journey II BCS TKA|
243984|NCT02335359|Drug|tranexamic acid undiluted (continous infusion)|
243985|NCT02335359|Drug|Placebo|Saline
243986|NCT02335346|Drug|Duloxetine|Administered orally
243987|NCT02335333|Other|No treatment|
243988|NCT02335307|Genetic|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
243991|NCT02335294|Drug|TRV130|Rescue: Ibuprofen, oxycodone
243945|NCT02335697|Behavioral|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
243946|NCT02335697|Other|No intervention|
243947|NCT02335684|Other|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
243948|NCT02335684|Other|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
243949|NCT02335671|Procedure|Intra-operative Magnetic Resonance Imaging (MRI)|
243950|NCT02335671|Other|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
243951|NCT02335658|Drug|DSP-5423P|40-80mg/day
243952|NCT02335645|Other|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.~The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.~Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.~At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
243953|NCT02335632|Drug|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
243954|NCT02335632|Drug|Placebo|For probiotics
243955|NCT02335619|Behavioral|Early palliative care|
243956|NCT02335593|Dietary Supplement|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
243957|NCT02335593|Other|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
243958|NCT02335593|Drug|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
243959|NCT02335593|Drug|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
243960|NCT02335580|Drug|Somatostatin and its analogs|Somatostatin and/or octreotide will be intravenously infused.
243961|NCT02335580|Procedure|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|Endoscopic sclerotherapy, endoscopic variceal ligation, and/or endoscopic tissue glue injection will be performed based on the endoscopists' choice.
243962|NCT02335567|Other|there is no intervention|
243963|NCT02335554|Behavioral|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
243964|NCT02335554|Behavioral|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
243965|NCT02335528|Behavioral|SimCoach|
243966|NCT02335515|Device|Soctec|Gastroretentive Drug Delivery System
243967|NCT02335502|Device|Implantation with the commercially available Axium neurostimulator|
243968|NCT02335489|Device|Implantation with the commercially available Axium neurostimulator|
243969|NCT02335450|Behavioral|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
243970|NCT02335450|Device|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
243971|NCT02335424|Biological|pembrolizumab|IV infusion
243972|NCT02335411|Biological|pembrolizumab|IV infusion
243973|NCT02335411|Drug|cisplatin|IV infusion
243974|NCT02335411|Drug|5-FU|IV infusion
243975|NCT02335411|Drug|capecitabine|oral tablets
243976|NCT02335398|Drug|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
243977|NCT02335385|Procedure|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
243978|NCT02335385|Procedure|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
243979|NCT02335372|Procedure|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
243980|NCT02335372|Drug|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
243981|NCT02335372|Drug|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
243982|NCT02335372|Procedure|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
243995|NCT02335281|Drug|Mesalazine|2g Po perday
243996|NCT02335268|Drug|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
243997|NCT02335255|Drug|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
243998|NCT02335255|Drug|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
243999|NCT02335255|Drug|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
244000|NCT02335242|Drug|Sildenafil 20 mg tablets|
244001|NCT02335242|Other|Placebo tablets (resembling Revatio)|
244002|NCT02335229|Device|Axium DRG Neurostimulator|Implantation with Axium DRG Neurostimulator
244003|NCT02335216|Device|Implantation with the commercially available Axium neurostimulator|
244004|NCT02335203|Drug|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
244005|NCT02335203|Other|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
244006|NCT02335190|Procedure|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
244007|NCT02335190|Procedure|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
244008|NCT02335190|Drug|Lidocaine|
244009|NCT02335177|Behavioral|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
244010|NCT02335164|Biological|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
244011|NCT02335164|Biological|Advax1|Delta inulin adjuvant formulation 1
244012|NCT02335164|Biological|Advax2|Delta inulin adjuvant formulation 2
244013|NCT02335151|Drug|Desflurane|Apply desflurane as anesthetic
244014|NCT02335138|Behavioral|Couples HIV Testing and Counseling (CHTC, CVCT)|Male couples randomized to the experimental group (Couples HIV Testing and Counseling, CHTC/CVCT) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
244015|NCT02335138|Behavioral|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
244016|NCT02335125|Behavioral|Motivational Interviewing|
244017|NCT02335125|Behavioral|Cognitive Behavioral Therapy Elements|
244018|NCT02335125|Drug|Psychotropic Drugs|
244019|NCT02335125|Other|Care Management|
244020|NCT02335112|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
244021|NCT02335112|Device|NanoKnife|
244022|NCT02335099|Drug|ticagrelor|ticagrelor 90 mg twice a day for 6 months
244023|NCT02335099|Drug|Placebo|1 pill twice a day for 6 months
244024|NCT02335073|Other|Venous blood|
244025|NCT02335060|Drug|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
244026|NCT02335060|Drug|N-acetylcysteine|A pill given orally.
244027|NCT02335060|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
244028|NCT02335060|Drug|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
244029|NCT02335047|Other|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
244030|NCT02335034|Behavioral|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
244031|NCT02335034|Behavioral|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.~At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
244032|NCT02335021|Dietary Supplement|Sucralose|2 packets per 12 fl oz
244033|NCT02335021|Dietary Supplement|Sucrose|equisweet to sucralose
244034|NCT02335021|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
244035|NCT02335021|Dietary Supplement|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
244036|NCT02335008|Dietary Supplement|Sucralose|2 packets per 12 fl oz
244037|NCT02335008|Dietary Supplement|Sucrose|equisweet to sucralose
244038|NCT02334982|Drug|TAK-137|TAK-137 tablets
244039|NCT02334982|Drug|Placebo|TAK-137 placebo-matching tablets
244040|NCT02334969|Drug|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
244041|NCT02334969|Drug|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
244042|NCT02334956|Other|Brain MRI|
244043|NCT02334943|Biological|Blood test|Blood test
244044|NCT02334930|Other|Biopsy|
244045|NCT02334917|Procedure|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
244046|NCT02334904|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
244047|NCT02334904|Drug|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
244048|NCT02334891|Other|Standard|Standard management
244049|NCT02334878|Biological|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
244050|NCT02334878|Procedure|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra & through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted & the remaining tape cut off at the level of the skin.
244051|NCT02334865|Biological|Incomplete Freund's Adjuvant|Given SC
244052|NCT02334865|Other|Laboratory Biomarker Analysis|Correlative studies
244053|NCT02334865|Drug|Lenalidomide|Given PO
244054|NCT02334865|Biological|Sargramostim|Given SC
244055|NCT02334865|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
244056|NCT02334839|Other|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
244057|NCT02334826|Procedure|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
244058|NCT02334826|Procedure|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
244059|NCT02334813|Drug|Prednisone|Continuous daily therapy
244060|NCT02334813|Drug|Dexamethasone|4-day pulses every 3 weeks
244061|NCT02334800|Drug|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
244062|NCT02334787|Drug|0.3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
244063|NCT02334787|Drug|1% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
244064|NCT02334787|Drug|3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
244065|NCT02334787|Drug|Placebo Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
244066|NCT02334774|Procedure|Swallowing and Oral Care Program|An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
244067|NCT02334748|Drug|canakinumab|canakinumab
244068|NCT02334735|Biological|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)~10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 10^6 cells)"
244069|NCT02334735|Biological|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
244070|NCT02334735|Biological|Poly-ICLC|1.4 mg
244071|NCT02334722|Drug|Levetiracetam extended release|
244072|NCT02334709|Radiation|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
244120|NCT02334319|Procedure|Therapeutic Conventional Surgery|Undergo surgery
244121|NCT02334319|Other|Laboratory Biomarker Analysis|Correlative studies
244073|NCT02334683|Device|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
244074|NCT02334683|Device|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
244075|NCT02334670|Drug|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
244076|NCT02334657|Other|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
244077|NCT02334644|Dietary Supplement|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
244078|NCT02334644|Dietary Supplement|Placebo|2 sachets/day x 12 weeks
244079|NCT02334631|Drug|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
244080|NCT02334631|Drug|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
244081|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.~Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
244082|NCT02334605|Device|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
244083|NCT02334605|Device|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
244084|NCT02334592|Radiation|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
244085|NCT02334579|Radiation|CyberKnife Stereotactic Radiosurgery|Five treatments given over about one week.
244086|NCT02334566|Behavioral|NET TX|Intervention procedures are a behavioral intervention (NET & KIDNET) with 8-12 sessions administered on a weekly basis.
244087|NCT02334553|Drug|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
244088|NCT02334553|Drug|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
244089|NCT02334540|Dietary Supplement|purses|food intake
244090|NCT02334540|Dietary Supplement|a calorie/protein matched smoothie|
244091|NCT02334527|Drug|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
244092|NCT02334501|Drug|Lansoprazole|
244093|NCT02334501|Drug|Neratinib|
244094|NCT02334488|Drug|Everolimus|Active Comparator
244095|NCT02334488|Drug|Tacrolimus|Active Comparator
244096|NCT02334488|Drug|Mycophenolate sodium|Experimental Arm
244097|NCT02334475|Biological|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
244098|NCT02334475|Biological|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
244099|NCT02334462|Biological|Pfs230D1M-EPA/Alhydrogel|
244100|NCT02334462|Biological|Pfs25M-EPA/Alhydrogel|
244101|NCT02334462|Drug|TWINRIX|
244102|NCT02334462|Drug|Menactra|
244103|NCT02334449|Drug|LML134|LML134 will be administered first as single doses and then as multiple doses
244104|NCT02334449|Drug|Placebo|All study cohorts (except food effect cohort) are placebo controlled
244105|NCT02334436|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
244106|NCT02334436|Other|0.9% sterile, unpreserved saline|Placebo Comparator Arm
244107|NCT02334423|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
244108|NCT02334423|Other|0.9% sterile, unpreserved saline|Placebo
244109|NCT02334410|Device|Whole body vibration (WBV)|Side-alternating WBV
244110|NCT02334397|Behavioral|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
244111|NCT02334384|Biological|Antimicrobial TheraGauze|"In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.~In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess."
244112|NCT02334371|Radiation|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
244113|NCT02334358|Device|YVOIRE Classic s|
244114|NCT02334345|Drug|Evoskin|Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
244115|NCT02334345|Drug|Trixiera|Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
244116|NCT02334332|Other|Educational Intervention|Receive educational brochure
244117|NCT02334332|Procedure|Standard Follow-Up Care|Receive standard post-operative care
244118|NCT02334332|Procedure|Quality-of-Life Assessment|Ancillary studies
244119|NCT02334319|Drug|Ganetespib|Given IV
244122|NCT02334306|Biological|AMG 557/MEDI5872|Participants will receive a fixed SC dose of 210 mg MEDI5872 (AMG 557/MEDI5872) QW for 3 weeks (Days 1 to 15) and then Q2W for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, all participants from double-blind period will receive a fixed SC dose of 210 mg MEDI5872 from Day 99 to Day 183 (QW from Days 99 to 113 for participants from Placebo arm and on Days 99 and 113 for participants from MEDI5872 210 mg arm; and Q2W from Days 127 to 183 for participants from both arms).
244123|NCT02334306|Other|Placebo|The SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85) in double-blind period of the study. In open-label period, an additional dose of blinded placebo will be administered on Day 106 for participants who will receive MEDI5872 210mg in double-blinded period.
244124|NCT02334293|Drug|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
244125|NCT02334280|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
244126|NCT02334267|Device|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
244127|NCT02334267|Device|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
244128|NCT02334254|Drug|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
244129|NCT02334254|Drug|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
244130|NCT02334241|Device|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
244131|NCT02334241|Device|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
244132|NCT02334228|Behavioral|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
244133|NCT02334228|Behavioral|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
244134|NCT02334215|Drug|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
244135|NCT02334215|Behavioral|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
244136|NCT02334215|Behavioral|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
244137|NCT02334202|Behavioral|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
244138|NCT02334202|Other|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
244139|NCT02334189|Behavioral|Letter|Patients receive an information letter following an avoidable visit to the Emergency Department.
244140|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
244141|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
244142|NCT02334176|Drug|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
244143|NCT02334163|Drug|Nitazoxanide|500 mg nitazoxanide tablets twice daily
244144|NCT02334163|Drug|Oral lactulose|Oral lactulose (65%)
244145|NCT02334163|Drug|Metronidazole|250 mg metronidazole tablets every 8 hours
244146|NCT02334163|Drug|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
245474|NCT02324192|Other|Ultrasonography|imaging findings
244147|NCT02334150|Drug|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
244148|NCT02334137|Behavioral|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
244149|NCT02334137|Behavioral|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
244150|NCT02334137|Behavioral|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
244151|NCT02334124|Other|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
244152|NCT02334124|Other|Ward|Admission to a hospital based ward
244153|NCT02334124|Drug|ceftriaxone|50mg/kg once daily
244154|NCT02334124|Drug|flucloxacillin|50mg/kg 6 hourly
244155|NCT02334111|Behavioral|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
244156|NCT02334098|Dietary Supplement|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.~1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
244157|NCT02334098|Dietary Supplement|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
244158|NCT02334072|Device|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
244159|NCT02334072|Device|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
244160|NCT02334072|Device|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
244161|NCT02334072|Device|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
244162|NCT02334072|Device|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
244163|NCT02334059|Drug|Ketamine|Ketamine infusion plus placebo infusion of normal saline
244164|NCT02334059|Drug|Ketamine plus magnesium|Ketamine plus magnesium infusion
244165|NCT02334059|Other|Placebo|2 placebo infusions
244166|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
244167|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
244168|NCT02334046|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
244169|NCT02334033|Other|other|
244170|NCT02334020|Other|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
244171|NCT02334007|Drug|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
244172|NCT02334007|Other|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
244173|NCT02333994|Device|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
244174|NCT02333994|Other|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
244212|NCT02333695|Device|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
244213|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
244214|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
244175|NCT02333981|Device|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
244176|NCT02333968|Behavioral|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
244177|NCT02333955|Drug|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
244178|NCT02333942|Device|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
244179|NCT02333929|Device|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
244180|NCT02333916|Other|overfeeding + exercise pre-training|
244181|NCT02333916|Behavioral|fitness training|
244182|NCT02333916|Other|overfeeding + exercise post-training|
244183|NCT02333903|Other|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.~Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
244184|NCT02333890|Drug|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
244185|NCT02333890|Drug|Placebo|
244186|NCT02333877|Other|Skinlink|suture using Skinlink
244187|NCT02333877|Other|Nylon|conventional suture using nylon
244188|NCT02333864|Device|POGO® BGMS|SMBG
244189|NCT02333851|Drug|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
244190|NCT02333851|Drug|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
244191|NCT02333838|Drug|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)
244192|NCT02333838|Drug|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
244193|NCT02333838|Drug|IV Busulfan|(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)
244194|NCT02333838|Drug|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
244195|NCT02333825|Procedure|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
244196|NCT02333825|Other|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
244197|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
244198|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
244199|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
244200|NCT02333799|Drug|Bedaquiline|100mg tablets
244201|NCT02333799|Drug|PA-824|200mg tablets
244202|NCT02333799|Drug|Linezolid|Scored 600mg tablets
244203|NCT02333786|Other|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
244204|NCT02333786|Other|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
244205|NCT02333773|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
244206|NCT02333760|Genetic|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
244207|NCT02333747|Device|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
244208|NCT02333734|Other|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces ~ 90% of the maximum heart rate. The time spent per session is expected to last ~ 25 minutes.
244209|NCT02333721|Procedure|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
244210|NCT02333721|Procedure|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
244211|NCT02333708|Other|Blood sample|
244215|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
244216|NCT02333682|Dietary Supplement|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
244217|NCT02333669|Other|no intervention|no intervention
244218|NCT02333656|Other|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
244219|NCT02333643|Drug|CLS003|
244220|NCT02333643|Drug|Furosemide|
244221|NCT02333643|Drug|Digoxin|
244222|NCT02333643|Drug|Vehicle topical|
244223|NCT02333630|Other|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
244224|NCT02333630|Other|Asthma education|A website with links to written asthma education and videos
244225|NCT02333617|Other|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point [No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
244226|NCT02333617|Other|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
244227|NCT02333617|Other|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
244228|NCT02333617|Other|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
244229|NCT02333591|Drug|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
244230|NCT02333591|Drug|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
244231|NCT02333591|Drug|Saline|Infused intravenously for 2,5 hours.
244232|NCT02333578|Procedure|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
244233|NCT02333565|Drug|Everolimus|
244234|NCT02333565|Drug|Octreotide|
244235|NCT02333539|Behavioral|Adherence behaviors and recommendations for improvement.|
244236|NCT02333539|Behavioral|Adherence behavior that needs improvement is targeted|
244237|NCT02333513|Drug|Lomustine/Vincristine/Procarbazine|
244238|NCT02333500|Other|olfactory workshop|olfactory workshop
244239|NCT02333500|Other|other workshop|other workshop: discussion group, dance and body Expression
244240|NCT02333500|Other|No intervention|control group
244241|NCT02333487|Drug|Lu AF35700|5 mg tablets for oral administration once daily, up to 21 days. Dose will be established based on receptor occupancy, safety, tolerability and PK data from previous cohorts. Starting at 10 mg/day and not more than 20 mg/ day
244242|NCT02333474|Biological|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
244243|NCT02333474|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
244244|NCT02333461|Dietary Supplement|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
244245|NCT02333461|Dietary Supplement|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
244246|NCT02333461|Dietary Supplement|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
244247|NCT02333461|Dietary Supplement|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
244248|NCT02333461|Dietary Supplement|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
244249|NCT02333448|Biological|Blood sample taken on the day the treatment is initiated|
244250|NCT02333448|Biological|Blood sample taken on day 3 after initiation of treatment|
244251|NCT02333448|Biological|Blood sample taken on day 5 after initiation of|
244252|NCT02333448|Biological|Blood sample taken on day 7 after initiation of treatment|
244253|NCT02333448|Biological|Blood sample taken on day 10 after initiation of treatment|
244254|NCT02333435|Dietary Supplement|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
244255|NCT02333435|Dietary Supplement|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
244256|NCT02333422|Other|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
244257|NCT02333409|Procedure|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
244258|NCT02333396|Other|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
244259|NCT02333396|Other|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
244260|NCT02333383|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
244261|NCT02333370|Drug|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
244262|NCT02333370|Drug|Letrozole|25mg
244263|NCT02333370|Drug|Tamoxifen|20 mg
244264|NCT02333370|Drug|Fulvestrant|500 mg
244265|NCT02333370|Drug|goserelin|
244266|NCT02333357|Behavioral|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
244267|NCT02333357|Behavioral|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
244268|NCT02333344|Drug|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
244269|NCT02333331|Drug|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
244270|NCT02333331|Other|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
244271|NCT02333318|Drug|VVZ-149 injection|Colorless, transparent liquid in water for injection
244272|NCT02333318|Other|Placebo|water for injection
244273|NCT02333305|Dietary Supplement|CoQ10|• 2 dosages according to patient weight: Weight < 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
244274|NCT02333305|Other|Sanomit Placebo|• according to patient weight: Weight < 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
244275|NCT02333292|Drug|Telaprevir|Initiation of a regimen containing TVR
244276|NCT02333292|Drug|Boceprevir|Initiation of a regimen containing BOC
244277|NCT02333292|Drug|Sofosbuvir|Initiation of a regimen containing SOF
244278|NCT02333292|Drug|Simeprevir|Initiation of a regimen containing SMV
244279|NCT02333292|Drug|Daclatasvir|Initiation of a regimen containing DCV
244280|NCT02333292|Drug|Ledipasvir|Initiation of a regimen containing LDV
244281|NCT02333292|Drug|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
244282|NCT02333292|Drug|Dasabuvir|Initiation of a regimen containing DBV
244283|NCT02333292|Drug|Velpatasvir|Initiation of a regimen containing VPV
244284|NCT02333292|Drug|Elbasvir|Initiation of a regimen containing EBV
244285|NCT02333292|Drug|Grazoprevir|Initiation of a regimen containing GZR
244286|NCT02333266|Other|Candidemia|
244287|NCT02333253|Drug|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach >12 mm
244288|NCT02333240|Other|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
244289|NCT02333227|Dietary Supplement|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
244290|NCT02333214|Other|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
244338|NCT02332915|Behavioral|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
244424|NCT02332278|Procedure|Late feeding|Fluid diet 12 hours after cesarean section
244291|NCT02333214|Other|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
244292|NCT02333188|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
244293|NCT02333188|Drug|Leucovorin Calcium|Given IV
244294|NCT02333188|Drug|Irinotecan Hydrochloride|Given IV
244295|NCT02333188|Drug|Fluorouracil|Given IV
244296|NCT02333188|Other|Laboratory Biomarker Analysis|Correlative studies
244297|NCT02333175|Other|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
244298|NCT02333162|Drug|Fludarabine Phosphate|Given IV
244299|NCT02333162|Drug|Melphalan|Given IV
244300|NCT02333162|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMTMI
244301|NCT02333162|Radiation|Total Marrow Irradiation|Undergo IMTMI
244302|NCT02333162|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
244303|NCT02333162|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
244304|NCT02333162|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
244305|NCT02333162|Drug|Tacrolimus|Given IV or PO
244306|NCT02333162|Drug|Mycophenolate Mofetil|Given IV or PO
244307|NCT02333162|Other|Laboratory Biomarker Analysis|Correlative studies
244308|NCT02333149|Dietary Supplement|Melatonin|"Children <40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.~Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
244309|NCT02333149|Drug|Placebo|Placebo frequency and volume are identical to the experimental arm
244310|NCT02333136|Device|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
244311|NCT02333123|Drug|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
244312|NCT02333123|Drug|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
244313|NCT02333110|Radiation|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
244314|NCT02333084|Dietary Supplement|PRN Joint Health Formula|
244315|NCT02333084|Dietary Supplement|placebo|
244316|NCT02333084|Dietary Supplement|PRN Flex Omega Benefits® combination|
244317|NCT02333071|Drug|bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
244318|NCT02333071|Other|Placebo|Placebo
244319|NCT02333058|Drug|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA:~One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
244320|NCT02333045|Drug|Truvada qd|Truvada 1 tablet PO daily for 7 days
244321|NCT02333045|Drug|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
244322|NCT02333032|Other|Inclined treadmill training|
244323|NCT02333019|Behavioral|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
244324|NCT02333019|Behavioral|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
244325|NCT02333006|Other|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
244326|NCT02332993|Dietary Supplement|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
244327|NCT02332980|Drug|Ibrutinib|Given PO
244328|NCT02332980|Drug|Idelalisib|Given PO
244329|NCT02332980|Other|Laboratory Biomarker Analysis|Correlative studies
244330|NCT02332980|Biological|Pembrolizumab|Given IV
244331|NCT02332967|Other|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
244332|NCT02332967|Other|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
244333|NCT02332967|Other|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
244334|NCT02332954|Drug|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
244335|NCT02332941|Drug|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
244336|NCT02332928|Drug|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
244337|NCT02332928|Drug|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
244731|NCT02330029|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
244339|NCT02332902|Drug|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
244340|NCT02332889|Biological|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be > 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
244341|NCT02332889|Drug|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
244342|NCT02332876|Behavioral|Exercise|
244343|NCT02332876|Behavioral|Control|
244344|NCT02332863|Device|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:~total length of procedure~how many markers are successfully deployed~technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
244345|NCT02332863|Device|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:~total length of procedure~how many markers are successfully deployed~technical success~Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
244346|NCT02332850|Drug|SAR650984|
244347|NCT02332850|Drug|Carfilzomib|
244348|NCT02332837|Behavioral|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
244349|NCT02332837|Behavioral|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
244350|NCT02332837|Behavioral|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
244351|NCT02332824|Drug|TAK-272|TAK-272 tablets
244352|NCT02332824|Drug|TAK-272 Placebo|TAK-272 placebo-matching tablets
244353|NCT02332824|Drug|Candesartan cilexetil|Candesartan cilexetil tablets
244354|NCT02332824|Drug|Candesartan cilexetil Placebo|Candesartan cilexetil placebo-matching tablets
244355|NCT02332811|Drug|sevelamer carbonate 800mg|"Pharmaceutical form:tablet~Route of administration: oral"
244356|NCT02332811|Drug|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder~Route of administration: oral"
244357|NCT02332798|Drug|PF-04958242|Oral capsule, 0.20 mg, twice a day dosing for 14 days
244358|NCT02332798|Drug|Placebo|Oral capsule, placebo, twice a day dosing for 14 days
244359|NCT02332798|Drug|PF-04958242|Oral capsule, 0.35 mg, twice a day dosing for 14 days
244360|NCT02332798|Drug|Placebo|Oral capsule, placebo, twice a day dosing for 14 days
244361|NCT02332785|Other|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
244362|NCT02332772|Other|Data Collection|Data collected from endoscopy procedures.
244363|NCT02332759|Device|Materna Medical|
244364|NCT02332733|Biological|TV003|10^3 plaque forming units (PFU) of rDEN1 delta 30, 10^3 PFU of rDEN2/4 delta 30(ME), 10^3 PFU of rDEN3 delta 30/31-7164, and 10^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
244365|NCT02332733|Biological|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
244366|NCT02332720|Drug|Grazoprevir|Part A: one grazoprevir 100 mg tablet taken q.d. by mouth.
244367|NCT02332720|Drug|Uprifosbuvir|Part A: two or three uprifosbuvir 150 mg (300 or 450 mg total daily dose) tablets taken q.d. by mouth.
244368|NCT02332720|Drug|Elbasvir|Part A: one elbasvir 50 mg tablet taken q.d. by mouth.
244369|NCT02332720|Drug|Ruzasvir|Part A: six ruzasvir 10 mg (60 mg total daily dose) capsules taken q.d. by mouth.
244370|NCT02332720|Drug|MK-3682B|Part B and Part C: two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg, taken q.d. by mouth.
244371|NCT02332720|Drug|Ribavirin (RBV)|Part B and Part C: RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
244372|NCT02332707|Drug|Grazoprevir|One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.
244373|NCT02332707|Drug|Uprifosbuvir|Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.
244374|NCT02332707|Drug|Elbasvir|One EBR 50 mg tablet (Part A), taken q.d. by mouth.
244375|NCT02332707|Drug|Ruzasvir|Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.
244376|NCT02332707|Drug|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
244377|NCT02332707|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.
244378|NCT02332694|Device|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
244379|NCT02332668|Biological|Pembrolizumab|IV infusion
244380|NCT02332655|Drug|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.~The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
244381|NCT02332642|Other|Immuno-monitoring|
244382|NCT02332629|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
244383|NCT02332629|Drug|Isotonic Sodium Chloride|Placebo
244384|NCT02332616|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
244385|NCT02332616|Drug|Isotonic Sodium Chloride|Placebo
244386|NCT02332603|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
244387|NCT02332603|Drug|Isotonic Sodium Chloride|Placebo
244388|NCT02332590|Drug|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
244389|NCT02332590|Drug|Adalimumab|Pharmaceutical form:solution for injection in pre-filled syringe; Route of administration: SC
244390|NCT02332590|Drug|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
244391|NCT02332590|Drug|Placebo (for adalimumab)|Pharmaceutical form:solution for injection in pre-filled syringe; Route of administration: SC
244392|NCT02332577|Drug|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
244393|NCT02332577|Drug|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
244394|NCT02332577|Drug|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
244395|NCT02332577|Drug|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
244396|NCT02332564|Other|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
244397|NCT02332551|Device|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
244398|NCT02332538|Procedure|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
244399|NCT02332538|Procedure|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
244400|NCT02332538|Procedure|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
244401|NCT02332525|Device|Oral Vibrational Stimulation|"Oral application of vibratory stimulus~: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
244402|NCT02332512|Drug|Apatinib|
244403|NCT02332512|Drug|Placebo|
244404|NCT02332499|Drug|Anlotinib|Anlotinib p.o. qd
244405|NCT02332499|Drug|Placebo|Placebo p.o. qd
244406|NCT02332486|Drug|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
244407|NCT02332473|Drug|Ypeginterferon alfa-2b|
244408|NCT02332473|Drug|Granulocyte-macrophage colony stimulating factor|
244409|NCT02332447|Drug|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
244410|NCT02332447|Drug|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.~The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
244411|NCT02332434|Other|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
244412|NCT02332421|Device|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
244413|NCT02332408|Radiation|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
244414|NCT02332408|Radiation|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
244415|NCT02332369|Device|Capsular Tension Ring|
244416|NCT02332356|Drug|azathioprine or adalimumab and infliximab|
244417|NCT02332343|Other|No intervention - Natural history study|
244418|NCT02332330|Device|VEST|
244419|NCT02332317|Behavioral|Palliative rehabilitation|12-week individually customized, specialized palliative rehabilitation program
244420|NCT02332304|Procedure|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
244421|NCT02332291|Drug|Escitalopram|Escitalopram 10-20mg daily
244422|NCT02332291|Drug|Bupropion XL|Bupropion XL 150-450mg daily
244423|NCT02332278|Procedure|Early feeding|Fluid diet four hours after cesarean section
244425|NCT02332265|Other|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed & implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, & Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission & partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices & sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings & Loans Groups, 3) building capacity of local governance structures & 4) integrating HIV education & gender empowerment into programs through training & education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
244426|NCT02332252|Device|Scalpel|Skin incision performed with a scalpel during cesarean section.
244427|NCT02332252|Device|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
244428|NCT02332252|Procedure|Skin incision|
244429|NCT02332239|Behavioral|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~Eight-week longitudinal tailored text-message program"
244430|NCT02332239|Behavioral|Control (EUC)|"In-ED brief session, discussing home safety & nutrition~Eight-week longitudinal home safety & nutrition text-message program"
244431|NCT02332226|Behavioral|Representational approach|Representational approach to patient education
244432|NCT02332213|Procedure|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
244433|NCT02332213|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
244434|NCT02332213|Procedure|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
244435|NCT02332213|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
244436|NCT02332213|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
244437|NCT02332213|Procedure|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
244438|NCT02332200|Other|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
244439|NCT02332187|Device|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
244440|NCT02332187|Device|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
244441|NCT02332174|Drug|rufinamide|comparison of different doses, sex and medication conditions
244442|NCT02332161|Other|surveys, evaluative tests for leg function|See outcome measures
244443|NCT02332148|Drug|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
244444|NCT02332148|Drug|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
244445|NCT02332135|Procedure|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
244446|NCT02332135|Drug|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
244447|NCT02332122|Procedure|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is >= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
244448|NCT02332122|Procedure|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of >= 3mm is a positive result.
244449|NCT02332122|Other|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
244450|NCT02332109|Device|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
244451|NCT02332096|Device|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
244452|NCT02332083|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
244453|NCT02332083|Device|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
244454|NCT02332083|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
244455|NCT02332083|Device|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
244456|NCT02332070|Procedure|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
244457|NCT02332057|Drug|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
244458|NCT02332057|Drug|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
244459|NCT02332044|Drug|Erdos|capsule, 300mg
244460|NCT02332044|Drug|Talion|tablet, 10mg
244461|NCT02332044|Drug|Erdos, Talion|capsule 300mg and tablet 10mg
244462|NCT02332031|Drug|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
244463|NCT02332031|Drug|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
244464|NCT02332018|Radiation|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
244465|NCT02332005|Drug|diepalrestat choline|aldose reductase inhibitor
244466|NCT02332005|Drug|Placebo|Placebo
244467|NCT02331992|Behavioral|Adherence program|Participants will receive supportive messages while enrolled in the program.
244468|NCT02331979|Device|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
244469|NCT02331940|Drug|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
244470|NCT02331940|Device|Handihaler|Inhalation via the HandiHaler once daily
244471|NCT02331940|Device|Respimat|Inhalation via the Respimat once daily
244472|NCT02331927|Biological|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
244473|NCT02331914|Procedure|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
244474|NCT02331914|Procedure|Tumor biopsy|Tumor biopsy after disease progression
244475|NCT02331888|Device|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
244476|NCT02331875|Drug|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
244477|NCT02331875|Procedure|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
244478|NCT02331875|Radiation|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
244479|NCT02331862|Drug|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
244480|NCT02331849|Device|High resolution manometry (HRM)|High resolution manometry of the esophagus
244481|NCT02331836|Device|Arc Endocuff (AEC 110, 120, 130, 140)|
244482|NCT02331836|Device|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
244483|NCT02331836|Device|Standard colonoscope|
244484|NCT02331823|Drug|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
244485|NCT02331823|Drug|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
244486|NCT02331810|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
244487|NCT02331810|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
244488|NCT02331797|Device|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
244489|NCT02331797|Device|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
244732|NCT02330029|Drug|Radix curcumae|Radix curcumae (~10g)
244733|NCT02330029|Drug|Fingered citron|Fingered citron (~10g)
244490|NCT02331784|Behavioral|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
244491|NCT02331784|Behavioral|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
244492|NCT02331771|Drug|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
244493|NCT02331771|Drug|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
244494|NCT02331758|Behavioral|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
244495|NCT02331745|Drug|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
244496|NCT02331745|Drug|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
244497|NCT02331732|Behavioral|Virtually Observed Treatment|
244498|NCT02331732|Other|Directly Observed Treatment|
244499|NCT02331706|Drug|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
244500|NCT02331693|Biological|anti-EGFR CAR T|
244501|NCT02331680|Drug|OPC-41061|
244502|NCT02331680|Drug|OPC-41061|
244503|NCT02331680|Drug|Placebo|
244504|NCT02331667|Other|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
244505|NCT02331667|Other|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
244506|NCT02331654|Other|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
244507|NCT02331654|Other|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
244508|NCT02331641|Procedure|Hepatectomy|Removal of a part of the liver
244509|NCT02331628|Device|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:~Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\52 from baseline until and including week 14\52, one dose every two weeks ± 3 days), administered by the principal investigator.~Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.~The energy flux density (EFD) will be 'high level'~All participants will be supplied with headphones to reduce the noise level emitted by the machine."
244510|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
244511|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
244512|NCT02331615|Device|SHAM|no meaningful stimulation will be given
244513|NCT02331602|Drug|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
244514|NCT02331602|Drug|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
244515|NCT02331589|Drug|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
244516|NCT02331589|Drug|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
244517|NCT02331576|Drug|rocaine|
244518|NCT02331576|Drug|Fentanyl|
244519|NCT02331563|Drug|Dexmedetomidine|ultrasound guided transvers abdominis plane block
244520|NCT02331563|Drug|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
244521|NCT02331550|Procedure|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
244522|NCT02331550|Procedure|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
244523|NCT02331537|Behavioral|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
244524|NCT02331524|Behavioral|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
244525|NCT02331524|Other|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
244526|NCT02331511|Drug|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
244527|NCT02331511|Drug|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
244528|NCT02331511|Drug|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
244529|NCT02331498|Drug|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
244530|NCT02331485|Device|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
244531|NCT02331459|Other|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
244532|NCT02331459|Other|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
244533|NCT02331446|Behavioral|Physical exercise intervention|
244534|NCT02331433|Drug|APN1125|APN1125 orally at ascending doses
244535|NCT02331433|Drug|Placebo|Matching Placebo
244536|NCT02331420|Procedure|Gastric bypass|A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.
244537|NCT02331420|Behavioral|Medical therapy|"Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);~Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;~Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;~Programs for diet and lifestyle modification, including reduced overall energy and fat intake (<30% total fat, <10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);~low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids)."
244538|NCT02331407|Device|Robotic arm therapy|Training with the ReoGo device
244539|NCT02331394|Dietary Supplement|Chinese herbs formula: Shu Yu Wan|The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
244540|NCT02331381|Device|Magnetic resonance imaging|
244541|NCT02331368|Procedure|Autologous Stem Cell Transplant|
244542|NCT02331368|Drug|Melphalan|140-200 mg/m^2
244543|NCT02331368|Drug|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
244544|NCT02331368|Drug|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
244545|NCT02331342|Device|NICOM cardiac output measurement|
244546|NCT02331342|Device|Innocor cardiac output measurement|
244547|NCT02331329|Device|NICOM cardiac output measurement|
244548|NCT02331329|Device|Cardiac MRT cardiac output measurement|
244549|NCT02331316|Other|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified~Intervention-B: Daily extra water assigned at any time during 24 hour period"
244550|NCT02331303|Other|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
244551|NCT02331277|Drug|BI 655064|subcutaneous injection
244552|NCT02331277|Drug|Placebo|Placebo
244553|NCT02331264|Other|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
244554|NCT02331251|Drug|Pembrolizumab|
244555|NCT02331251|Drug|Gemcitabine|
244556|NCT02331251|Drug|Docetaxel|
244557|NCT02331251|Drug|Nab-paclitaxel|
244558|NCT02331251|Drug|Vinorelbine|
244559|NCT02331251|Drug|Irinotecan|
244560|NCT02331251|Drug|Liposomal Doxorubicin|
244561|NCT02331238|Behavioral|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
244562|NCT02331225|Other|No intervention given|There is no intervention for this study
244563|NCT02331212|Other|Cytology Specimen Collection Procedure|Correlative studies
244564|NCT02331212|Other|Laboratory Biomarker Analysis|Correlative studies
244565|NCT02331199|Device|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
244566|NCT02331199|Device|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
244567|NCT02331186|Procedure|bariatric surgery|bariatric surgery for obese women
244734|NCT02330029|Drug|Tuckahoe|Tuckahoe (15g)
244735|NCT02330029|Drug|Placebo|Placebo is blindly given to patients.
244568|NCT02331173|Drug|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:~Topical dorzolamide 2% three times per day~Topical brinzolamide 1% three times per day"
244569|NCT02331160|Behavioral|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
244570|NCT02331147|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment
244571|NCT02331147|Other|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
244572|NCT02331134|Drug|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
244573|NCT02331121|Behavioral|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
244574|NCT02331121|Behavioral|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
244575|NCT02331108|Drug|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
244576|NCT02331095|Drug|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
244577|NCT02331095|Drug|Warfarin|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
244578|NCT02331082|Other|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
244579|NCT02331082|Other|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
244580|NCT02331082|Device|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
244581|NCT02331082|Device|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
244582|NCT02331082|Behavioral|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
244583|NCT02331082|Other|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
244584|NCT02331069|Drug|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
244585|NCT02331069|Other|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
244586|NCT02331056|Other|fluid loading|"Fluid loading at defined period~500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
244587|NCT02331056|Procedure|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
244588|NCT02331056|Procedure|thoracotomy|the patient group for scheduled open pulmonary lobectomy
244589|NCT02331043|Dietary Supplement|Plant stanol ester|
244590|NCT02331043|Dietary Supplement|Placebo|
244591|NCT02331030|Procedure|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
244592|NCT02331030|Procedure|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
244593|NCT02331030|Procedure|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
244594|NCT02331030|Drug|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
244595|NCT02331030|Drug|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
244736|NCT02330016|Device|Voluma XC|Voluma XC
244596|NCT02331017|Behavioral|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
244597|NCT02331004|Other|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
244598|NCT02331004|Other|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
244599|NCT02330991|Drug|Temozolomide|
244600|NCT02330978|Procedure|Intravitreal transplantation of mesenchymal stem cell|
244601|NCT02330978|Biological|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
244602|NCT02330965|Procedure|Blood Draw|Blood draws (65 mLs [~4 tablespoons] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
244603|NCT02330965|Procedure|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
244604|NCT02330952|Drug|Prednisone|40mg/day per os for 5 days
244605|NCT02330952|Drug|Placebo|40mg/day per os for 5 days
244606|NCT02330939|Other|Low fat- Low glycemic index meal|
244607|NCT02330939|Other|MUFA- Low glycemic index meal|
244608|NCT02330939|Other|SAFA- Low glycemic index meal|
244609|NCT02330939|Other|Low fat- High glycemic index meal|
244610|NCT02330939|Other|MUFA- High glycemic index meal|
244611|NCT02330939|Other|SAFA- High glycemic index meal|
244612|NCT02330926|Other|standard care|
244613|NCT02330926|Other|nutritional supplements and advice|
244614|NCT02330926|Other|home-based self-assisted exercise program|
244615|NCT02330926|Drug|Ibuprofen|
244616|NCT02330913|Procedure|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
244617|NCT02330900|Other|Study group|Exposure to cell phone interference of the ICD
244618|NCT02330887|Other|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
244619|NCT02330887|Other|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
244620|NCT02330861|Device|combowire and IVUS|
244621|NCT02330848|Dietary Supplement|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
244622|NCT02330848|Dietary Supplement|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
244623|NCT02330835|Behavioral|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
244624|NCT02330835|Behavioral|School bus driver training videos|Basic bus driving safety videos
244625|NCT02330822|Drug|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
244626|NCT02330809|Other|Daily extra water intake|Amount of extra daily water intake to consume
244627|NCT02330809|Other|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
244628|NCT02330796|Drug|Bucillamine|Bucillamine Tablets
244629|NCT02330796|Drug|Colchicine|
244630|NCT02330783|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
244631|NCT02330783|Drug|Sorafenib|400mg twice daily by oral of each 4-week cycle
244632|NCT02330770|Drug|GnRHa and HCG|Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM
244633|NCT02330770|Drug|GnRHa then HCG (single low-dose)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
244634|NCT02330770|Drug|GnRHa then HCG (multiple low-doses)|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
244635|NCT02330757|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
244636|NCT02330757|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
245114|NCT02327052|Other|No intervention was performed.|No intervention was performed.
244637|NCT02330744|Behavioral|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
244638|NCT02330744|Behavioral|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
244639|NCT02330731|Procedure|injection sclerotherapy for gastric varices|The intravariceal technique of injection
244640|NCT02330718|Other|No intervention|
244641|NCT02330705|Drug|HCG|Women will be given HCG before IUI
244642|NCT02330692|Other|No intervention|
244643|NCT02330679|Drug|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
244644|NCT02330679|Drug|Placebo|
244645|NCT02330666|Behavioral|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
244646|NCT02330653|Biological|Fecal Microbiota Transplant|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standards by OpenBiome. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
244647|NCT02330653|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
244648|NCT02330640|Drug|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
244649|NCT02330640|Drug|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
244650|NCT02330640|Drug|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
244651|NCT02330627|Behavioral|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
244652|NCT02330614|Other|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
244653|NCT02330614|Other|Nothing - control group|Only NEO-FFI test , data used as control
244654|NCT02330601|Procedure|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
244655|NCT02330588|Behavioral|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
244656|NCT02330588|Behavioral|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.~*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
244657|NCT02330588|Behavioral|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
244658|NCT02330575|Behavioral|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
244659|NCT02330575|Behavioral|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
244660|NCT02330562|Drug|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2.~Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.~The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
244661|NCT02330562|Drug|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
244662|NCT02330549|Drug|Cenicriviroc 150 mg|Cenicriviroc (CVC) 150 mg, administered orally once daily and taken every morning with food.
244663|NCT02330549|Drug|Placebo|Placebo-matching CVC administered orally once daily and taken every morning with food.
244664|NCT02330536|Device|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or sixteen L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
244665|NCT02330523|Device|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
244666|NCT02330523|Device|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
244667|NCT02330497|Procedure|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
244668|NCT02330484|Behavioral|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
244669|NCT02330484|Behavioral|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
244670|NCT02330471|Procedure|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
244671|NCT02330471|Procedure|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
244672|NCT02330458|Procedure|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall >3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
244673|NCT02330445|Drug|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
244674|NCT02330432|Biological|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
244675|NCT02330432|Other|Best standard care|Antibiotics as early as possible; Norepinephrine > vasopressin > epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
244676|NCT02330419|Drug|Placebo|
244677|NCT02330419|Drug|Naltrexone|
244678|NCT02330406|Drug|Anagliptin|Suiny 100 mg
244679|NCT02330406|Drug|Sitagliptin|Januvia 50 mg Glactiv 50 mg
244680|NCT02330380|Drug|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
244681|NCT02330380|Drug|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
244682|NCT02330380|Drug|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
244683|NCT02330380|Drug|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
244684|NCT02330380|Drug|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
244685|NCT02330380|Other|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
244686|NCT02330380|Other|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
244687|NCT02330367|Drug|AC0010|"Stage 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Stage 2: AC0010 will be administered twice-daily at RP2D."
244688|NCT02330354|Behavioral|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
244689|NCT02330341|Dietary Supplement|Artemisia dracunculus|
244690|NCT02330341|Other|Placebo|
244691|NCT02330328|Other|No Telemetry Monitoring|
244692|NCT02330328|Device|Telemetry Monitoring|
244693|NCT02330315|Device|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
244694|NCT02330315|Device|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
244695|NCT02330302|Drug|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
244696|NCT02330302|Drug|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
244697|NCT02330289|Behavioral|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
244698|NCT02330276|Drug|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
244699|NCT02330263|Dietary Supplement|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
245475|NCT02324166|Drug|Cefazolin|cephalosporin antibiotic
244700|NCT02330250|Other|Pharmaceutical Care|"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.~The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."
244701|NCT02330250|Other|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
244702|NCT02330237|Drug|natural gels|whole fruits and vegetables
244703|NCT02330237|Drug|Placebo|
244704|NCT02330224|Other|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:~Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients~Motivational conversation by nurses and nurse practitioners for high risk patients at baseline~Telephone based follow-up for all patients by nurses"
244705|NCT02330185|Device|ultrasonography|spinal anesthesia guided with ultrasonography
244706|NCT02330172|Other|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.~During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
244707|NCT02330159|Procedure|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
244708|NCT02330146|Drug|RCT-01|
244709|NCT02330146|Drug|Placebo|
244710|NCT02330133|Behavioral|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
244711|NCT02330133|Behavioral|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
244712|NCT02330120|Drug|propofol|
244713|NCT02330120|Drug|dexmedetomidine|
244714|NCT02330107|Other|MAT & LAT|"For MAT, the magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
244715|NCT02330094|Drug|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
244716|NCT02330094|Drug|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications."
244717|NCT02330081|Device|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:~radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.~radio-labeled platelets derived from subject's untreated fresh whole blood."
244718|NCT02330068|Drug|citalopram|Cases
244719|NCT02330055|Procedure|Forty-five degrees elevated upper body position|
244720|NCT02330055|Procedure|non-elevated upper body position|
244721|NCT02330055|Device|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
244722|NCT02330055|Other|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.~The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
244723|NCT02330055|Other|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.~The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
244724|NCT02330055|Other|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.~The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
244725|NCT02330055|Other|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
244726|NCT02330029|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
244727|NCT02330029|Device|Atractylodes|Atractylodes (~10-15g)
244728|NCT02330029|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
244729|NCT02330029|Device|Tangerine Peel|Tangerine Peel (~10g)
244730|NCT02330029|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
244737|NCT02330003|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
244738|NCT02330003|Biological|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
244739|NCT02329990|Dietary Supplement|phosphorus|phosphorus supplement
244740|NCT02329977|Other|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
244741|NCT02329964|Drug|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
244742|NCT02329964|Drug|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
244743|NCT02329951|Procedure|Facet intervention|Diagnostic block of the nerves innervation the lumbar facet joint. If this block is positive (greater or equal to 50% relief), the participant will proceed to radiofrequency nerve ablation when the pain returns
244744|NCT02329951|Procedure|Sacroiliac joint injection|Injection of steroid and local anesthetic into SI joint
244745|NCT02329951|Procedure|Epidural steroid injection|Transforaminal or interlaminar injection of steroid epidurally
244746|NCT02329938|Procedure|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
244747|NCT02329938|Procedure|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
244748|NCT02329925|Device|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
244749|NCT02329912|Device|SmartPill|Application of the SmartPill at the end of surgery
244750|NCT02329899|Other|Second step of investigations|"Second step according to results of the first step:~exploration of coagulation factors;~factor XIII and fibrinolysis investigations;~investigation of platelet function;~investigation of thrombocytopenia."
244751|NCT02329873|Behavioral|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
244752|NCT02329860|Drug|Apatinib|
244753|NCT02329860|Drug|Placebo|
244754|NCT02329847|Drug|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
244755|NCT02329847|Drug|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
244756|NCT02329834|Drug|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
244757|NCT02329834|Drug|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
244758|NCT02329821|Other|hartmann solution|hartmann solution infusion in patients for hepatic resection
244759|NCT02329808|Procedure|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
244760|NCT02329795|Radiation|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
244761|NCT02329795|Drug|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
244762|NCT02329782|Behavioral|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
244763|NCT02329769|Drug|PRO044 SC 6 mg/kg|
244764|NCT02329769|Drug|PRO044 IV 6 mg/kg|
244765|NCT02329769|Drug|PRO044 IV 9 mg/kg|
244766|NCT02329756|Drug|Tranexamic Acid (TXA)|1g Tranexamic Acid (TXA) will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
244767|NCT02329756|Drug|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia~Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.~The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
244768|NCT02329743|Drug|RX-10045|topical therapy
244769|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
244770|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
244771|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
244798|NCT02329561|Drug|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
245115|NCT02327039|Drug|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
245116|NCT02327039|Drug|Placebo|Tables of Dapagliflozin placebo
244772|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
244773|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
244774|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
244775|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
244776|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
244777|NCT02329717|Drug|PBI 05204|PBI 05204 daily dosing
244778|NCT02329704|Procedure|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).~Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
244779|NCT02329704|Procedure|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.~Grading using A and B scale scored by (WHO 2010) references."
244780|NCT02329704|Procedure|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
244781|NCT02329704|Procedure|24 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
244782|NCT02329704|Procedure|48 H half life|"percentage of active motile to non motile sperms.~Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
244783|NCT02329704|Procedure|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).~By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
244784|NCT02329704|Biological|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
244785|NCT02329678|Procedure|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
244786|NCT02329665|Device|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
244787|NCT02329652|Device|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
244788|NCT02329639|Genetic|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
244789|NCT02329626|Device|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography.~This intervention is required for the observational needs of the study."
244790|NCT02329613|Other|Standard evening meals.|Patients will receive usual evening meals.
244791|NCT02329613|Other|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
244792|NCT02329600|Drug|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
244793|NCT02329600|Drug|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
244794|NCT02329587|Other|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
244795|NCT02329587|Other|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
244796|NCT02329561|Drug|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
244797|NCT02329561|Behavioral|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
244799|NCT02329548|Other|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
244800|NCT02329535|Drug|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
244801|NCT02329522|Device|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).~USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
244802|NCT02329522|Device|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
244803|NCT02329509|Procedure|two stage palate surgical repair|two stage palate surgical repair with a hard palate closure at 3 to 4 years old
244804|NCT02329509|Procedure|One stage Palate Surgical repair|One stage palate repair at the age of 9 to 24 months old
244805|NCT02329496|Device|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
244806|NCT02329470|Procedure|Withdrawal of CPAP treatment|Withdrawal of CPAP treatment
244807|NCT02329457|Biological|Zostavax|varicella zoster vaccine
244808|NCT02329457|Biological|Normal Saline|normal saline placebo vaccine
244809|NCT02329444|Procedure|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
244810|NCT02329444|Procedure|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
244811|NCT02329431|Behavioral|activation curriculum|psychosocial activation curriculum
244812|NCT02329431|Behavioral|support group|parent directed support group
244813|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
244814|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
244815|NCT02329405|Drug|Rifampicin|
244816|NCT02329405|Drug|Placebo|
244817|NCT02329379|Drug|Levothyroxine|
244818|NCT02329366|Other|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
244819|NCT02329353|Drug|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
244820|NCT02329340|Behavioral|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
244821|NCT02329340|Behavioral|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
244822|NCT02329327|Biological|Andexanet|
244823|NCT02329301|Drug|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
244824|NCT02329301|Drug|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
244825|NCT02329288|Drug|Triamcinolone Acetonide|
244826|NCT02329288|Drug|placebo|
244827|NCT02329275|Procedure|Testicular biopsy|
244828|NCT02329262|Behavioral|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
244829|NCT02329262|Behavioral|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
244830|NCT02329249|Behavioral|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
244831|NCT02329249|Other|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
244832|NCT02329223|Biological|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
244833|NCT02329223|Other|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
244834|NCT02329197|Drug|Human Chorionic Gonadotropin (HCG)|intrauterine injection of HCG prior to embryo transfer in an IVF cycle
244835|NCT02329184|Drug|MYK-461|
244836|NCT02329171|Drug|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
244837|NCT02329171|Procedure|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
244838|NCT02329158|Drug|6% hydroxyethyl starch|
244839|NCT02329145|Procedure|renal denervation|
244933|NCT02328469|Drug|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
244840|NCT02329132|Drug|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
244841|NCT02329119|Other|electrophysiological recordings|
244842|NCT02329106|Device|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
244843|NCT02329093|Procedure|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
244844|NCT02329080|Drug|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
244845|NCT02329080|Drug|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
244846|NCT02329080|Drug|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
244847|NCT02329080|Drug|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
244848|NCT02329080|Drug|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
244849|NCT02329080|Drug|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
244850|NCT02329080|Drug|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
244851|NCT02329080|Drug|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
244852|NCT02329080|Radiation|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
244853|NCT02329067|Other|walnuts|consumption of 43 g walnuts per day
244854|NCT02329054|Drug|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.~Group C: daily dosages will be adapted to their body weight."
244855|NCT02329041|Device|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
244856|NCT02329041|Device|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
244857|NCT02329028|Device|Prehospital mini-EEG|Observational
244858|NCT02329015|Behavioral|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
244859|NCT02329015|Behavioral|Physical Education Class|Standard physical education
244860|NCT02329002|Device|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
244861|NCT02328989|Device|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
244862|NCT02328976|Other|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
244863|NCT02328963|Drug|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
244864|NCT02328963|Drug|mycophenolic acid|"Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
244865|NCT02328950|Drug|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
244866|NCT02328937|Device|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
244867|NCT02328937|Device|lotrafilcon B|
244868|NCT02328937|Device|comfilcon A|
244869|NCT02328924|Other|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
244870|NCT02328911|Device|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
244871|NCT02328911|Device|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
244872|NCT02328898|Device|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
244873|NCT02328898|Device|Resolute Integrity stent|
244874|NCT02328885|Other|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
244970|NCT02328118|Drug|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
244875|NCT02328872|Device|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
244876|NCT02328872|Device|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
244877|NCT02328859|Other|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
244878|NCT02328859|Other|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
244879|NCT02328833|Other|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
244880|NCT02328820|Other|Percutaneous coronary intervention (PCI)|For lesions with both FFR<=0.8 and CFR<2.0
244881|NCT02328820|Other|Optimal medical therapy (OMT)|For lesions with FFR>0.8 or CFR>=2.0 or both
244882|NCT02328807|Procedure|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
244883|NCT02328794|Behavioral|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
244884|NCT02328794|Behavioral|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
244885|NCT02328794|Behavioral|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
244886|NCT02328794|Behavioral|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
244887|NCT02328794|Behavioral|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
244888|NCT02328781|Device|Drug-eluting stent|
244889|NCT02328768|Drug|Omegaven|
244890|NCT02328755|Drug|peg-IFN-α|
244891|NCT02328755|Procedure|Hematopoietic Cell Transplant (HCT)|
244892|NCT02328755|Drug|Calcineurin Inhibitor|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
244893|NCT02328755|Drug|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
244894|NCT02328742|Biological|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.~This intervention is required for the observational needs of this study."
244895|NCT02328742|Other|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.~This intervention is required for the observational needs of this study."
244896|NCT02328742|Biological|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.~This intervention is required for the observational needs of this study."
244897|NCT02328742|Biological|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.~This intervention is required for the observational needs of this study."
244898|NCT02328729|Procedure|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
244899|NCT02328729|Procedure|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
244900|NCT02328729|Procedure|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
244901|NCT02328729|Procedure|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
244902|NCT02328729|Procedure|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
244903|NCT02328729|Procedure|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
244904|NCT02328716|Procedure|Cytoreduction|Cytoreduction
244905|NCT02328716|Drug|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
244906|NCT02328703|Other|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
244907|NCT02328690|Other|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz [Hz]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
244908|NCT02328664|Procedure|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
244971|NCT02328105|Drug|Carboplatin|Dosing: AUC = 6; on Day 1
244909|NCT02328651|Drug|Ribavirin plus Xiao'er jiebiao oral liquid|"For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.~For moderate (Phase II) patients:~recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg,iv, Bid~tid）"
244910|NCT02328651|Drug|Ribavirin|"For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.~For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg, iv, Bid~tid）"
244911|NCT02328638|Behavioral|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
244912|NCT02328638|Behavioral|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
244913|NCT02328612|Other|Intravenous infusion of cells|"The treatment administration will be infused intravenously to the subjects after randomization:~An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."
244914|NCT02328599|Procedure|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
244915|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
244916|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
244917|NCT02328586|Other|Group Acupuncture|
244918|NCT02328573|Behavioral|Communal singing|
244919|NCT02328547|Drug|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
244920|NCT02328547|Drug|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
244921|NCT02328534|Behavioral|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
244922|NCT02328534|Procedure|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.~Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
244923|NCT02328534|Procedure|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.~The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
244924|NCT02328521|Drug|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
244925|NCT02328521|Drug|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
244926|NCT02328508|Device|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
244927|NCT02328495|Drug|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
244928|NCT02328495|Other|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
244929|NCT02328482|Drug|Tehalose 30gr|Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
244930|NCT02328469|Drug|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
244931|NCT02328469|Drug|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
244932|NCT02328469|Other|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
244934|NCT02328456|Other|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
244935|NCT02328443|Drug|Midazolam|
244936|NCT02328443|Drug|itraconazole|
244937|NCT02328443|Drug|rifampicin|
244938|NCT02328430|Device|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
244939|NCT02328417|Other|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
244940|NCT02328404|Drug|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
244941|NCT02328404|Drug|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
244942|NCT02328378|Procedure|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
244943|NCT02328365|Other|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
244944|NCT02328352|Procedure|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
244945|NCT02328352|Procedure|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
244946|NCT02328352|Procedure|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
244947|NCT02328352|Procedure|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
244948|NCT02328339|Other|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
244949|NCT02328339|Other|Placebo|Placebo matched to tea with respect to taste and appearance
244950|NCT02328326|Other|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
244951|NCT02328326|Other|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
244952|NCT02328313|Behavioral|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
244953|NCT02328300|Drug|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
244954|NCT02328287|Drug|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
244955|NCT02328274|Procedure|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
244956|NCT02328261|Drug|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
244957|NCT02328248|Procedure|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
244958|NCT02328235|Other|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
244959|NCT02328222|Drug|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
244960|NCT02328209|Drug|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
244961|NCT02328196|Behavioral|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
244962|NCT02328183|Drug|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
244963|NCT02328170|Other|EUROIMMUN Allergy|Immunoblot assay
244964|NCT02328170|Other|ImmunoCap|Fluoroallergosorbent test
244965|NCT02328157|Device|Vitrectomy with cataract surgery and toric IOL|
244966|NCT02328157|Device|Vitrectomy with cataract surgery and common IOL|
244967|NCT02328144|Drug|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
244968|NCT02328144|Drug|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
244969|NCT02328118|Drug|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
244972|NCT02328105|Drug|Abraxane|100 mg/m^2; Days 1, 8, 15
244973|NCT02328092|Device|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
244974|NCT02328079|Drug|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: First group (prednisolone 60 mg /day IM /IV), second group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
244975|NCT02328066|Device|NBI used by trained endoscopists|Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
244976|NCT02328053|Procedure|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
244977|NCT02328053|Drug|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
244978|NCT02328040|Drug|Placebo and Insulin monotherapy via CL|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL)
244979|NCT02328040|Drug|Sitagliptin and insulin/novolog via CL|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
244980|NCT02328027|Drug|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
244981|NCT02328014|Drug|Acalabrutinib|Oral
244982|NCT02328014|Drug|ACP-319|Oral
244983|NCT02328001|Behavioral|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
244984|NCT02327988|Other|Cryotherapy|
244985|NCT02327988|Device|Laser therapy|
244986|NCT02327975|Other|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).~During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
244987|NCT02327975|Other|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
244988|NCT02327975|Other|Control group|No received intervention.
244989|NCT02327949|Device|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
244990|NCT02327949|Device|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
244991|NCT02327936|Drug|Fesoterodine|Administer medication to patients with overactive bladder
244992|NCT02327936|Drug|Oxybutynin XL|Administer medication to patients with overactive bladder
244993|NCT02327923|Drug|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
244994|NCT02327923|Drug|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
244995|NCT02327923|Drug|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
244996|NCT02327923|Drug|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
244997|NCT02327923|Drug|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
244998|NCT02327923|Drug|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
244999|NCT02327923|Drug|Vecuronium|Inj Vecuronium 0.1mg/kg will be given at induction and for maintenance.
245000|NCT02327923|Drug|Atropine|Inj Atropine 0.4 mg IV will be given for bradycardia (HR < 50/min)
245001|NCT02327923|Drug|Ephedrine|
245002|NCT02327923|Drug|Morphine|
245003|NCT02327923|Drug|Ketorolac|
245004|NCT02327923|Drug|Ondansetron|
245005|NCT02327923|Drug|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
245006|NCT02327923|Drug|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
245007|NCT02327923|Drug|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
245008|NCT02327923|Drug|Glycopyrrolate|10 mcg/kg with neostigmine
245009|NCT02327910|Other|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
245010|NCT02327910|Other|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
245011|NCT02327871|Device|Esophageal cooling device (and usual standard procedure)|Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
245056|NCT02327416|Drug|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
245162|NCT02326688|Other|Kinematic analysis of trunk compensation|
245012|NCT02327858|Other|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
245013|NCT02327832|Procedure|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
245014|NCT02327832|Drug|bone marrow-derived mesenchymal stem cells|
245015|NCT02327819|Dietary Supplement|Branched-chain amoni acids (BCAA)|
245016|NCT02327819|Dietary Supplement|non-BCAA protein supplement|
245017|NCT02327806|Device|pulsed electromagnetic field therapy|
245018|NCT02327793|Drug|Nitroglycerin|
245019|NCT02327793|Drug|Labetalol|
245020|NCT02327780|Other|FODMAP diet|
245021|NCT02327767|Device|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
245022|NCT02327754|Drug|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
245023|NCT02327754|Drug|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
245024|NCT02327741|Drug|plavix|taking plavix more than 12 months
245025|NCT02327741|Drug|plavix|taking plavix less than 12 months
245026|NCT02327728|Procedure|Botulinum toxin A injection (5 sites: 12.5U)|
245027|NCT02327728|Procedure|Botulinum toxin A injection (4 sites: 10U)|
245028|NCT02327728|Drug|Botulinum toxin A 12.5U|
245029|NCT02327728|Drug|Botulinum toxin A 10U|
245030|NCT02327715|Drug|Emtricitabine|emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
245031|NCT02327702|Drug|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
245032|NCT02327689|Drug|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
245033|NCT02327676|Drug|Emtricitabine|emtricitabine were given to each patients for 48 weeks
245034|NCT02327663|Drug|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
245035|NCT02327650|Procedure|The examinations for bones in joints of OA and RA patients|
245036|NCT02327637|Behavioral|Moderate Activity|Ambulation 150 feet, two times per day
245037|NCT02327624|Drug|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
245038|NCT02327624|Drug|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
245039|NCT02327624|Drug|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
245040|NCT02327611|Drug|Custodiol|
245041|NCT02327611|Drug|Enriched Ringer's lactate solution|
245042|NCT02327585|Behavioral|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
245043|NCT02327559|Behavioral|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
245044|NCT02327559|Behavioral|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
245045|NCT02327546|Drug|AKB-6548|
245046|NCT02327546|Drug|Ferrous Sulfate|
245047|NCT02327520|Other|Colitis with CDI treatment|All patients will be treated with standard treatment
245048|NCT02327507|Behavioral|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
245049|NCT02327494|Drug|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
245050|NCT02327481|Procedure|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
245051|NCT02327481|Procedure|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
245052|NCT02327455|Procedure|Stress Dobutamine Echocardiographic using 4DE System|Subjects will undergo their clinically indicated stress dobutamine echocardiographic studies using our standard clinical graded dobutamine stress imaging protcol, employing the iE33 4DE system.
245053|NCT02327442|Radiation|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
245054|NCT02327429|Behavioral|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
245055|NCT02327416|Drug|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
245057|NCT02327416|Drug|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
245058|NCT02327403|Drug|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
245059|NCT02327390|Procedure|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
245060|NCT02327390|Biological|X-ACT|Administered as an IV infusion
245061|NCT02327377|Behavioral|Online Cognitive Behavior Therapy|
245062|NCT02327377|Behavioral|Online Education|
245063|NCT02327351|Other|Biological: TCR alfa beta T cell depletion|
245064|NCT02327338|Device|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
245065|NCT02327338|Drug|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
245066|NCT02327325|Behavioral|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
245067|NCT02327325|Behavioral|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
245068|NCT02327312|Device|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
245069|NCT02327312|Procedure|Laser|Laser Trabeculoplasty
245070|NCT02327312|Device|Laser Trabeculoplasty|
245071|NCT02327299|Dietary Supplement|Bouillon fortified with FePP|
245072|NCT02327299|Dietary Supplement|Bouillon fortified with FePP + Stabilizer|
245073|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4|
245074|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4 + Stabilizer|
245075|NCT02327286|Behavioral|Promote and support healthy behaviors|"Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.~Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.~Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.~A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
245076|NCT02327273|Drug|BMS-963272|
245077|NCT02327273|Drug|Placebo|
245078|NCT02327260|Behavioral|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
245079|NCT02327260|Behavioral|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
245080|NCT02327247|Drug|Felodipine|Extended Release Tablets, 10mg
245081|NCT02327247|Drug|PLENDIL®|Extended Release Tablets, 10mg
245082|NCT02327234|Drug|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
245083|NCT02327234|Drug|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
245084|NCT02327221|Drug|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
245085|NCT02327221|Drug|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
245086|NCT02327208|Dietary Supplement|Control|
245087|NCT02327208|Dietary Supplement|Protein|
245088|NCT02327208|Dietary Supplement|Carbohydrate|
245089|NCT02327195|Drug|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
245090|NCT02327195|Drug|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
245091|NCT02327182|Drug|MT-4666|
245092|NCT02327169|Drug|MLN2480|MLN2480.
245093|NCT02327169|Drug|MLN0128|MLN0128.
245094|NCT02327169|Drug|Alisertib|Alisertib.
245095|NCT02327169|Drug|Paclitaxel|Paclitaxel.
245096|NCT02327169|Drug|Cetuximab|Cetuximab.
245097|NCT02327169|Drug|Irinotecan|Irinotecan.
245098|NCT02327156|Drug|dexmedetomidine|adding dexmedetomidine to the local anesthetic
245099|NCT02327143|Drug|LY2835219|Administered orally
245100|NCT02327143|Drug|¹³C₈-LY2835219|Administered IV
245101|NCT02327130|Device|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
245102|NCT02327117|Drug|Tranexamic Acid|
245103|NCT02327117|Drug|Normal saline|
245104|NCT02327104|Behavioral|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
245105|NCT02327104|Other|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
245106|NCT02327091|Drug|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
245107|NCT02327078|Drug|Nivolumab (Phase 1)|specified dose and dosing schedule
245108|NCT02327078|Drug|Epacadostat (Phase 1)|oral twice daily continuous at the protocol-defined dose
245109|NCT02327078|Drug|Chemotherapy (Phase 1)|Specified dose on specified days
245110|NCT02327078|Drug|Nivolumab (Phase 2)|specified dose and dosing schedule
245111|NCT02327078|Drug|Epacadostat (Phase 2)|oral twice daily continuous at the protocol-defined dose
245112|NCT02327065|Device|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
245113|NCT02327065|Device|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
245476|NCT02324166|Drug|Lidocaine|local anesthetic
245117|NCT02327026|Procedure|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
245118|NCT02327026|Procedure|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
245119|NCT02327013|Drug|vortioxetine 10 mg tablet|Oral tablets, once daily
245120|NCT02327013|Drug|vortioxetine 20 mg tablet|Oral tablets, once daily
245121|NCT02327013|Other|Placebo tablet|Oral tablets, once daily
245122|NCT02327000|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
245123|NCT02327000|Drug|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
245124|NCT02326987|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
245125|NCT02326987|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
245126|NCT02326974|Drug|T-DM1|Participants will receive Trastuzumab emtansine (T-DM1) by IV every 3 weeks for 6 doses; for a total of 18 weeks of treatment.
245127|NCT02326974|Drug|Pertuzumab|Participants will receive a loading dose of pertuzumab by IV on Cycle 1 Day 1 followed by maintenance dose of pertuzumab by IV every 3 weeks for a total of 6 doses; for a total of 18 weeks of treatment.
245128|NCT02326974|Procedure|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
245129|NCT02326961|Device|Celution Device|ADRCs Prepared using the Celution Device
245130|NCT02326961|Other|Placebo|Inactive Placebo
245131|NCT02326935|Biological|Autologous adipose derived mesenchymal cells|Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
245132|NCT02326922|Device|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
245133|NCT02326909|Device|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
245134|NCT02326909|Device|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
245135|NCT02326883|Behavioral|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
245136|NCT02326883|Behavioral|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
245137|NCT02326883|Behavioral|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
245138|NCT02326870|Device|AutoLap|
245139|NCT02326844|Drug|BMN 673 (talazoparib)|1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
245140|NCT02326818|Procedure|US guidance|US guidance during injection of their stable, effective BoNT regimen
245141|NCT02326818|Procedure|E-stim Guidance|Electrophysiologic guidance via electrical stimulation during injection of their stable, effective BoNT regimen
245142|NCT02326805|Other|Laboratory Biomarker Analysis|Correlative studies
245143|NCT02326805|Other|Placebo|Given SC
245144|NCT02326805|Biological|Rilimogene Galvacirepvec|Given SC
245145|NCT02326792|Other|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
245146|NCT02326779|Drug|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
245147|NCT02326766|Dietary Supplement|KRG|5g Korea red ginseng (KRG)
245148|NCT02326766|Dietary Supplement|Placebo|5g placebo
245149|NCT02326753|Device|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
245150|NCT02326753|Device|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
245151|NCT02326753|Device|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
245152|NCT02326740|Drug|gevokizumab|
245153|NCT02326740|Drug|Placebo|
245154|NCT02326740|Drug|gevokizumab open-label|
245155|NCT02326727|Drug|Ropivacaine|Epidural analgesia
245156|NCT02326727|Drug|Fentanyl|General Anesthesia
245157|NCT02326727|Drug|Propofol|General Anesthesia
245158|NCT02326727|Drug|Isoflurane|General Anesthesia
245159|NCT02326727|Drug|Nitrous Oxide|General Anesthesia
245160|NCT02326714|Other|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
245161|NCT02326714|Other|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
245163|NCT02326675|Other|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
245164|NCT02326675|Other|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
245165|NCT02326662|Biological|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
245166|NCT02326649|Device|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
245167|NCT02326636|Biological|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
245168|NCT02326623|Other|distraction|distraction using an iPad with a selection of child-appropriate games
245169|NCT02326623|Other|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
245170|NCT02326610|Drug|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
245171|NCT02326597|Other|Decision Aid Tool|The tool is a web based decision aid that provides information about the risks and benefits associated with sickle cell disease therapies. Participants will be provided a unique access ID and password to access the information.
245172|NCT02326597|Other|Standard Practice|Standard of care teaching and discussion regarding treatment options given by patient's healthcare provider.
245173|NCT02326584|Drug|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
245174|NCT02326584|Drug|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
245175|NCT02326584|Drug|Daunorubicin|60 mg/m2/day Days 1-3
245176|NCT02326584|Drug|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
245177|NCT02326558|Procedure|laparoscopic microwave ablation-assisted enucleation|
245178|NCT02326558|Procedure|conventional laparoscopic partial nephrectomy|
245179|NCT02326545|Behavioral|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
245180|NCT02326545|Behavioral|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
245181|NCT02326532|Other|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
245182|NCT02326532|Other|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
245183|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
245184|NCT02326506|Device|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
245185|NCT02326493|Device|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
245186|NCT02326480|Other|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
245187|NCT02326467|Drug|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
245188|NCT02326454|Drug|talaporfin sodium|1 mg/kg
245189|NCT02326454|Drug|Saline|
245190|NCT02326454|Device|Drug Activator 100 J/cm|Light Dose: 100 J/cm
245191|NCT02326454|Device|Drug Activator 200 J/cm|Light Dose: 200 J/cm
245192|NCT02326441|Drug|KX2-361|
245193|NCT02326428|Device|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, pREset, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
245194|NCT02326428|Drug|Intravenous thrombolysis by alteplase (Actilyse) (optional)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
245195|NCT02326415|Other|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
245196|NCT02326415|Other|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
245197|NCT02326402|Device|TandemHeart System|Percutaneous insertion of TandemHeart System
245198|NCT02326389|Behavioral|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
245199|NCT02326389|Behavioral|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
245200|NCT02326376|Drug|anakinra (Kineret)|
245201|NCT02326363|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
245249|NCT02325999|Procedure|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
245250|NCT02325986|Drug|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
245202|NCT02326363|Behavioral|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
245203|NCT02326350|Drug|Aspirin 75mg|Active treatment
245204|NCT02326350|Drug|Lactose powder|Placebo
245205|NCT02326337|Device|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
245206|NCT02326337|Device|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
245207|NCT02326311|Drug|imatinib|Tyrosin kinase inhibitor
245208|NCT02326311|Drug|nilotinib|Tyrosin kinase inhibitor
245209|NCT02326311|Drug|dasatinib|Tyrosin kinase inhibitor
245210|NCT02326298|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
245211|NCT02326298|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
245212|NCT02326285|Drug|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
245213|NCT02326285|Drug|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
245214|NCT02326285|Drug|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
245215|NCT02326285|Procedure|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
245216|NCT02326272|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
245217|NCT02326272|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 0.9 % saline~Route of Administration: Subcutaneous use"
245218|NCT02326259|Other|Initiation of treatment of diabetes|Treatment of diabetes according to the standard of care.
245219|NCT02326246|Other|multi-parametic MRI|
245220|NCT02326233|Biological|Pen of SB5|
245221|NCT02326233|Biological|PFS of SB5|
245222|NCT02326220|Drug|Alirocumab|
245223|NCT02326220|Drug|Placebo|
245224|NCT02326207|Device|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
245225|NCT02326194|Biological|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
245226|NCT02326194|Biological|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
245227|NCT02326194|Biological|placebo (one dose)|placebo, one doses
245228|NCT02326194|Biological|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
245229|NCT02326181|Device|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
245230|NCT02326181|Device|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
245231|NCT02326168|Drug|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
245232|NCT02326142|Drug|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
245233|NCT02326142|Drug|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
245234|NCT02326116|Other|Trachael Preparation Education|
245235|NCT02326103|Drug|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
245236|NCT02326103|Drug|Placebo|
245237|NCT02326090|Drug|cis-UCA ophthalmic solution 1.0%|
245238|NCT02326090|Drug|cis-UCA ophthalmic solution 2.5%|
245239|NCT02326090|Drug|Placebo ophthalmic solution|
245240|NCT02326077|Other|Ultrasound|Monitoring of the mechanism of labor
245241|NCT02326077|Other|Acceptability of ultrasound monitoring of labor|Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
245242|NCT02326077|Other|Patients' experience regarding intrapartum ultrasound|The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
245243|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
245244|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
245245|NCT02326038|Drug|Methylphenidate|single oral administration of 20 mg tablet
245246|NCT02326025|Drug|Olaratumab|Administered IV
245247|NCT02326025|Drug|Doxorubicin|Administered IV
245248|NCT02326012|Behavioral|Emotion Regulation Individual Therapy for Adolescents|
245359|NCT02325063|Drug|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
245251|NCT02325986|Drug|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
245252|NCT02325986|Radiation|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
245253|NCT02325973|Device|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
245254|NCT02325960|Drug|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
245255|NCT02325960|Drug|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
245256|NCT02325947|Device|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
245257|NCT02325947|Device|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
245258|NCT02325934|Drug|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
245259|NCT02325934|Drug|Stribild, crushed|Crushed Stribild tablet
245260|NCT02325921|Device|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences (including diffusion tensor imaging), but without contrast enhancement.
245261|NCT02325895|Other|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
245262|NCT02325882|Drug|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
245263|NCT02325882|Drug|Fentanyl 1|conventional fentanyl-based epidural PCA
245264|NCT02325882|Drug|Fentanyl 2|conventional fentanyl based intravenous PCA
245265|NCT02325869|Device|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
245266|NCT02325856|Device|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
245267|NCT02325856|Behavioral|Clinical judgement|
245268|NCT02325843|Other|human bone marrow MSC|The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.
245269|NCT02325830|Device|CARILLON Mitral Contour System|Percutaneous mitral valve repair
245270|NCT02325817|Device|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
245271|NCT02325817|Device|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
245272|NCT02325804|Behavioral|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
245273|NCT02325791|Drug|Suptavumab 30 mg/kg|Participants received single dose of suptavumab 30 milligram per kilogram (mg/kg) intramuscularly (IM) on Day 1.
245274|NCT02325791|Drug|Placebo Matched to Suptavumab|Participants received 2 IM doses of placebo matched to suptavumab: the first dose on Day 1 and the second dose on Day 57.
245275|NCT02325791|Drug|Suptavumab 30 mg/kg- 1 Dose|Participants received single dose of suptavumab 30 mg/kg IM on Day 1 and single dose of placebo matched to suptavumab on Day 57.
245276|NCT02325791|Drug|Suptavumab 30 mg/kg - 2 Doses|Participants received 2 doses of suptavumab 30 mg/kg IM: the first dose on Day 1 and the second dose on Day 57.
245277|NCT02325778|Procedure|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
245278|NCT02325752|Other|Intervention|"A multidisciplinary team delivered the transitional care program.~Our transitional care program focused on four key areas:~Post discharge surveillance of the patient to ensure adherence to care plans.~Coordination of follow-up visits with specialist care providers.~Patent education and care giver training.~Activation of community and social services.~Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
245279|NCT02325739|Drug|FGF401|FGF401 is a FGFR4 inhibitor.
245280|NCT02325739|Biological|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
245281|NCT02325726|Procedure|Renal Resistive Index compared with NephroCheckTM|
245282|NCT02325713|Drug|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
245283|NCT02325713|Drug|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
245284|NCT02325713|Drug|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
245285|NCT02325713|Drug|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
245286|NCT02325713|Drug|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
245287|NCT02325713|Drug|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
245288|NCT02325700|Procedure|Aortic repair|Aortic bypass
245360|NCT02325063|Drug|Corticoid injection|Patients will be treated with an injection of Corticoids.
245361|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
245362|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp).
245512|NCT02323880|Other|Pharmacological Study|Correlative studies
245289|NCT02325687|Procedure|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
245290|NCT02325661|Other|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
245291|NCT02325648|Drug|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
245292|NCT02325635|Other|Educational Training|Intervention/Training offered to endoscopists only.
245293|NCT02325596|Genetic|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
245294|NCT02325583|Drug|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
245295|NCT02325583|Drug|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
245296|NCT02325570|Device|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
245297|NCT02325570|Procedure|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
245298|NCT02325557|Drug|ADXS31-142|starting at 1x10^9 cfu IV
245299|NCT02325557|Drug|ADXS31-142 + Pembrolizumab (MK-3475)|starting at dose from Part A + 200mg of Pembrolizumab
245300|NCT02325544|Behavioral|Cognitive Behavioral Therapy|"12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.~Standardised medical as described in other intervention."
245301|NCT02325544|Behavioral|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
245302|NCT02325531|Other|ALL|"The ALL Initiative ('ALL') is a population-level management program developed at Kaiser Permanente (KP). It seeks to decrease cardiovascular disease (CVD) morbidity and mortality in patients with diabetes by improving rates of prescribing for guideline-concordant cardioprotective medications.~For SPREAD-NET, we propose to compare the effectiveness of 3 support strategies for optimizing the sustainable implementation of the evidence-based ALL intervention. To do so, we will randomize 30 CHCs to receive 1 of 3 implementation support strategies: Low support (toolkit only), Medium (toolkit, staff training), High (toolkit, training, on-site facilitation). Using a mixed methods approach, we will assess how effectively each strategy supports sustainable implementation of ALL at the practice- and patient-levels, and we will identify clinic characteristics associated with success at each level of support. We will also conduct a cost analysis to compare costs per patient in each study arm."
245303|NCT02325518|Drug|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
245304|NCT02325518|Drug|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
245305|NCT02325518|Drug|Subject's habitual PGA monotherapy|
245306|NCT02325492|Drug|Aramchol|
245307|NCT02325492|Drug|Placebo|
245308|NCT02325492|Device|Ultrasound|
245309|NCT02325479|Drug|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
245310|NCT02325479|Drug|tissue culture media|intrauterine administration after oocyte pickup as placebo
245311|NCT02325466|Drug|Aspirin|Aspirin 81mg
245312|NCT02325466|Drug|Ticagrelor|ticagrelor 90 mg
245313|NCT02325466|Drug|Aspirin Placebo|
245314|NCT02325466|Drug|Ticagrelor Placebo|
245315|NCT02325453|Procedure|Robotic Surgery|Surgical procedure performed with a robotic system.
245316|NCT02325453|Procedure|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
245317|NCT02325453|Procedure|Open Surgery|Traditional approach for gastric cancer.
245318|NCT02325440|Drug|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
245319|NCT02325440|Drug|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
245320|NCT02325427|Device|tDCS|tDCS could deliver either real or sham stimulation.
245321|NCT02325414|Drug|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
245322|NCT02325414|Drug|Placebo|Placebo infusion to match zoledronic acid
245323|NCT02325401|Drug|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
245324|NCT02325401|Drug|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
245325|NCT02325401|Radiation|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
245363|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
245364|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 1*10^11 viral particles (vp).
245365|NCT02325050|Other|Placebo|One 0.5 mL IM injection of 0.9% saline.
245513|NCT02323880|Drug|Selinexor|Given PO
245326|NCT02325388|Device|ForeSite PT™ system|"XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts."
245327|NCT02325375|Procedure|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
245328|NCT02325362|Drug|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
245329|NCT02325362|Drug|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
245330|NCT02325349|Drug|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
245331|NCT02325336|Device|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.~In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
245332|NCT02325310|Biological|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
245333|NCT02325297|Other|Letter of condolence|
245334|NCT02325284|Device|Pressure Algometer Testing|
245335|NCT02325271|Other|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
245336|NCT02325258|Other|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
245337|NCT02325245|Drug|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
245338|NCT02325245|Drug|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
245339|NCT02325232|Device|Capsule endoscopy, double balloon enteroscopy sequential use|Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
245340|NCT02325219|Drug|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
245341|NCT02325219|Drug|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
245342|NCT02325219|Drug|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
245343|NCT02325219|Drug|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
245344|NCT02325206|Drug|dapagliflozin|one administration in the morning
245345|NCT02325206|Drug|Placebo|one administration in the morning
245346|NCT02325193|Device|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
245347|NCT02325180|Drug|Dihydroartemisinin-Piperaquine|
245348|NCT02325180|Drug|Artemether-lumefantrine|
245349|NCT02325167|Behavioral|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
245350|NCT02325167|Behavioral|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
245351|NCT02325154|Device|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
245352|NCT02325141|Procedure|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
245353|NCT02325128|Behavioral|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
245354|NCT02325102|Other|No intervention|As this is an observational study, no intervention was conducted.
245355|NCT02325089|Device|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
245356|NCT02325089|Device|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
245357|NCT02325076|Device|Spirodoc|A device to detect the physical condition of the lungs
245358|NCT02325063|Drug|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
245366|NCT02325037|Drug|GLPG1837 single ascending doses|Single dose, oral suspension
245367|NCT02325037|Drug|Placebo single dose|Single dose, oral suspension matching placebo
245368|NCT02325037|Drug|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
245369|NCT02325037|Drug|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
245370|NCT02325024|Drug|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
245371|NCT02325011|Drug|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
245372|NCT02325011|Drug|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.~Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
245373|NCT02324998|Drug|Olaparib|PARP Inhibitor
245374|NCT02324998|Drug|Degarelix|Gonadotrophin releasing hormone blocker
245375|NCT02324985|Drug|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
245376|NCT02324985|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
245377|NCT02324972|Drug|AQX-1125|Synthetic SHIP1 activator
245378|NCT02324972|Drug|Placebo|
245379|NCT02324959|Device|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
245380|NCT02324959|Device|Acupuncture|"The affected meridian group is treated by needling on Baihui (GV20|DU20) and Shenting (GV24|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices)."
245381|NCT02324946|Other|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
245382|NCT02324933|Drug|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
245383|NCT02324920|Device|DDD-CLS|
245384|NCT02324920|Device|ODO|
245385|NCT02324907|Device|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
245386|NCT02324894|Procedure|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
245387|NCT02324881|Behavioral|Telephone-Based Intervention|Use PSMA
245388|NCT02324881|Other|Questionnaire Administration|Ancillary studies
245389|NCT02324868|Device|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
245390|NCT02324868|Device|Conventional IV catheter protection|No Shower patch will be provided during study period
245391|NCT02324855|Other|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
245392|NCT02324842|Drug|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
245393|NCT02324842|Drug|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
245394|NCT02324816|Device|The Zeltiq System|CoolSculpting treatment.
245395|NCT02324803|Drug|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
245396|NCT02324790|Device|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
245397|NCT02324777|Drug|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
245398|NCT02324777|Device|Volcano® Medic Vapourizer|"Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).~The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique."
245399|NCT02324764|Device|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
245400|NCT02324764|Device|standard 6- French radial sheath|
245401|NCT02324751|Biological|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
245402|NCT02324751|Biological|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
245444|NCT02324400|Device|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
245472|NCT02324218|Other|Data collection|Data extraction from CPRD database of UK.
245473|NCT02324205|Device|DBT and FFDM|Subjects underwent breast imaging using each device: DBT and FFDM.
245403|NCT02324751|Biological|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
245404|NCT02324738|Drug|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
245405|NCT02324738|Other|Wash-out period|
245406|NCT02324738|Drug|Mefloquine|2 tablets of Mefloquine single dose
245407|NCT02324725|Drug|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
245408|NCT02324712|Device|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
245409|NCT02324712|Device|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
245410|NCT02324699|Drug|Prednisone|
245411|NCT02324699|Drug|Placebo|
245412|NCT02324699|Drug|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
245413|NCT02324686|Drug|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
245414|NCT02324673|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
245415|NCT02324660|Other|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
245416|NCT02324634|Device|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
245417|NCT02324621|Drug|Oral ONC201|Given PO
245418|NCT02324621|Other|pharmacological study|Correlative studies
245419|NCT02324621|Other|laboratory biomarker analysis|Correlative studies
245420|NCT02324608|Biological|cetuximab|Given IV
245421|NCT02324608|Other|laboratory biomarker analysis|Correlative studies
245422|NCT02324595|Procedure|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
245423|NCT02324582|Drug|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembroluzimab.
245424|NCT02324569|Drug|SYR-472|SYR-472 tablets
245425|NCT02324569|Drug|Placebo|Placebo tablets
245426|NCT02324543|Drug|Gemcitabine|IV over 40 minutes; Days 4 and 11 of a 21 day cycle
245427|NCT02324543|Drug|Taxotere|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
245428|NCT02324543|Drug|Xeloda|orally, twice daily; Days 1 through 14 of a 21 day cycle
245429|NCT02324543|Drug|Cisplatin|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
245430|NCT02324543|Drug|Irinotecan|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
245431|NCT02324530|Device|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
245432|NCT02324504|Device|C3 Wave ECG-based PICC Tip Confirmation System|The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will be connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
245433|NCT02324491|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
245434|NCT02324491|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
245435|NCT02324478|Procedure|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
245436|NCT02324465|Device|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
245437|NCT02324465|Device|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
245438|NCT02324452|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
245439|NCT02324439|Drug|Omega Nutrition cold-milled flaxseeds|Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
245440|NCT02324426|Drug|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
245441|NCT02324413|Drug|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
245442|NCT02324413|Drug|Placebo|
245443|NCT02324400|Device|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
245445|NCT02324387|Procedure|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
245446|NCT02324387|Drug|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
245447|NCT02324374|Device|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
245448|NCT02324374|Device|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
245449|NCT02324361|Device|Physical Activity Monitor|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
245450|NCT02324361|Behavioral|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
245451|NCT02324348|Procedure|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
245452|NCT02324348|Procedure|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
245453|NCT02324335|Drug|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
245454|NCT02324335|Other|Placebo|
245455|NCT02324322|Device|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
245456|NCT02324322|Other|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.~To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
245457|NCT02324322|Other|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
245458|NCT02324309|Drug|BIOD-531|
245459|NCT02324309|Drug|Humalog Mix 75/25|
245460|NCT02324309|Drug|Humulin R U-500|
245461|NCT02324309|Drug|BIOD-531|
245462|NCT02324296|Drug|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
245463|NCT02324283|Drug|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.~Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
245464|NCT02324283|Drug|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
245465|NCT02324270|Drug|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
245466|NCT02324270|Other|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
245467|NCT02324257|Drug|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
245468|NCT02324257|Drug|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
245469|NCT02324257|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
245470|NCT02324231|Other|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
245471|NCT02324231|Other|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
245477|NCT02324153|Drug|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
245478|NCT02324153|Drug|Microcrystalline Cellulose|Placebo Comparator
245479|NCT02324153|Drug|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
245480|NCT02324140|Other|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
245481|NCT02324127|Device|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
245482|NCT02324114|Device|Hsp90|Detect plasma Hsp90α concentration
245483|NCT02324101|Device|Hsp90|Detect plasma Hsp90α concentration
245484|NCT02324088|Drug|Docetaxel|
245485|NCT02324088|Drug|Cyclophosphamide|
245486|NCT02324088|Drug|Epirubicin|
245487|NCT02324075|Behavioral|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
245488|NCT02324062|Other|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
245489|NCT02324062|Other|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
245490|NCT02324049|Drug|SBC-103|
245491|NCT02324036|Device|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
245492|NCT02324036|Behavioral|Coached Care|Community health worker provides participation training to patient
245493|NCT02324023|Device|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
245494|NCT02324010|Drug|Sitagliptin|100mg mane for 2 days
245495|NCT02324010|Drug|Placebo|Inactive drug (Placebo)
245496|NCT02323984|Other|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
245497|NCT02323971|Drug|Ticagrelor|
245498|NCT02323958|Other|acupoint stimulation|stimulation is given at acupoints
245499|NCT02323958|Other|non-acupoint stimulation|stimulation is given at acupoints
245500|NCT02323958|Other|electrode attached|electrodes are attached to skin
245501|NCT02323958|Device|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
245502|NCT02323945|Other|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FiO2) = 0.10±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
245503|NCT02323945|Other|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
245504|NCT02323945|Other|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
245505|NCT02323932|Behavioral|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
245506|NCT02323919|Behavioral|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
245507|NCT02323919|Behavioral|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
245508|NCT02323919|Behavioral|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
245509|NCT02323906|Drug|CC-122|Investigational new drug
245510|NCT02323906|Drug|Sorafenib|Kinase inhibitor
245511|NCT02323893|Drug|[18F]F-AraG|
245514|NCT02323867|Device|Alpha Beta T cell depletion|
245515|NCT02323854|Device|Ablation|Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated and the antenna will be removed.
245516|NCT02323854|Procedure|Surgical Resection|The planned surgical resection of the lung tumor will be conducted as scheduled post ablation procedure.
245517|NCT02323841|Procedure|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
245518|NCT02323828|Dietary Supplement|High RS cookies|High RS cookies ingestion in healthy young adults
245519|NCT02323828|Dietary Supplement|Placebo|Placebo cookies ingestion in healthy young adults
245520|NCT02323815|Dietary Supplement|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
245521|NCT02323815|Behavioral|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
245522|NCT02323802|Behavioral|educational group intervention|
245523|NCT02323802|Behavioral|prescriptive diet|
245524|NCT02323789|Drug|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
245525|NCT02323776|Other|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
245526|NCT02323763|Other|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
245527|NCT02323737|Drug|Irinotecan and cisplatin|
245528|NCT02323737|Drug|Etoposide and cisplatin|
245529|NCT02323724|Genetic|BRAF V600E mutation by pyrosequencing technique|
245530|NCT02323711|Device|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
245531|NCT02323698|Drug|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 30min after consumption to approximately coincide with peak plasma concentrations.Throughout the 30min wait time and experimentation, blood pressure and heart rate will be monitored.
245532|NCT02323698|Other|AIH|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.10±0.02 (hypoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
245533|NCT02323698|Other|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 30min after consumption to mimic the caffeine drug protocol. Throughout experimentation, blood oxygenation, blood pressure and heart rate will be monitored.
245534|NCT02323698|Other|SHAM|This is a placebo counterpart to breathing intermittent low oxygen. Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2 (fraction of inspired oxygen) = 0.21±0.02 (normoxia). Throughout experimentation, blood pressure and heart rate will be monitored.
245535|NCT02323685|Biological|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
245536|NCT02323659|Drug|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
245537|NCT02323659|Drug|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
245538|NCT02323646|Drug|Placebo|Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
245539|NCT02323646|Drug|Telapristone Acetate|Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
245540|NCT02323633|Device|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
245541|NCT02323633|Device|Sham|No transcranial Pulsed Current Stimulation (tPCS)
245542|NCT02323620|Procedure|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
245543|NCT02323607|Drug|Pacritinib|Given PO
245544|NCT02323607|Drug|Cytarabine|Given IV
245545|NCT02323607|Drug|Daunorubicin Hydrochloride|Given IV
245546|NCT02323607|Drug|Decitabine|Given IV
245547|NCT02323607|Other|Laboratory Biomarker Analysis|Correlative studies
245548|NCT02323607|Other|Pharmacological Study|Correlative studies
245549|NCT02323594|Drug|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
245550|NCT02323594|Drug|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
245551|NCT02323594|Drug|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
245552|NCT02323594|Drug|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
245589|NCT02323295|Procedure|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
245590|NCT02323282|Drug|ropivacaine|
245591|NCT02323269|Drug|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
245671|NCT02322632|Drug|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
245553|NCT02323581|Device|Endovascular treatment of Thoracoabdominal Aortic Aneurysm|"A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.~This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm."
245554|NCT02323568|Other|Gynecological consultation|
245555|NCT02323555|Other|Paramedic telephone consultation|
245556|NCT02323542|Other|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
245557|NCT02323529|Drug|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
245558|NCT02323516|Drug|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
245559|NCT02323516|Drug|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
245560|NCT02323503|Device|CRT-D device replacement|
245561|NCT02323490|Procedure|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
245562|NCT02323490|Procedure|without microfractures|standard procedure meniscal repair without augmentation.
245563|NCT02323477|Biological|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
245564|NCT02323464|Procedure|Open surgery for colorectal cancer|
245565|NCT02323464|Procedure|Laparoscopic or robotic surgery|
245566|NCT02323451|Device|Medical Chitosan|intra-articular injection
245567|NCT02323451|Drug|Sodium Hyaluronate Injection|intra-articular injection
245568|NCT02323438|Other|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
245569|NCT02323438|Other|Electronic Cigarette #1|Electronic cigarette
245570|NCT02323438|Other|Electronic Cigarette #2|Electronic cigarette
245571|NCT02323438|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
245572|NCT02323425|Device|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
245573|NCT02323412|Drug|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
245574|NCT02323412|Drug|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
245575|NCT02323399|Drug|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level]; each initial treatment group will have two PK sampling schedules.
245576|NCT02323386|Device|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.~The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
245577|NCT02323373|Drug|Tranexamic Acid - topical|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
245578|NCT02323373|Drug|Placebo|100 ml of saline solution administered with anesthesia during 10 minutes
245579|NCT02323373|Drug|Tranexamic Acid - intravenous|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
245580|NCT02323360|Radiation|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
245581|NCT02323360|Procedure|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
245582|NCT02323347|Other|Progesterone|Progesterone level
245583|NCT02323334|Drug|LY3202626|administered orally
245584|NCT02323334|Drug|Placebo (Part A, B, C)|administered orally
245585|NCT02323334|Drug|Itraconazole|administered orally
245586|NCT02323321|Device|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
245587|NCT02323308|Other|blood sampling|
245588|NCT02323295|Radiation|Radiation|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
245592|NCT02323256|Other|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
245593|NCT02323256|Other|Speech-ABR|
245594|NCT02323256|Other|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
245595|NCT02323256|Other|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
245596|NCT02323243|Device|"Allium  Bulbar Urethral Stent  (BUS) system"|
245597|NCT02323230|Biological|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
245598|NCT02323230|Drug|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
245599|NCT02323217|Radiation|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
245600|NCT02323217|Drug|Idazoxan|Idazoxan block of [11C]BU99008
245601|NCT02323217|Drug|Isocarboxazid|Isocarboxazid block of [11C]BU99008
245602|NCT02323204|Behavioral|Link for Injured Kids|Psychological First Aid
245603|NCT02323204|Other|So you've been in an accident|Educational materials
245604|NCT02323191|Drug|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
245605|NCT02323191|Drug|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
245606|NCT02323178|Drug|eltrombopag|initial dose of 50 mg once daily, then the dose can be sequentially increased every 2 weeks up to a maximum dose of 300mg/day
245607|NCT02323165|Other|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
245608|NCT02323152|Behavioral|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
245609|NCT02323152|Other|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
245610|NCT02323139|Drug|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
245611|NCT02323126|Drug|EGF816|
245612|NCT02323126|Drug|INC280|
245613|NCT02323126|Drug|Nivolumab|
245614|NCT02323113|Drug|TAK-659|TAK-659 tablets.
245615|NCT02323100|Drug|Ravicti low dose|8 am, 4pm and midnight
245616|NCT02323100|Drug|Ravicti high dose|8 am, 4pm and midnight
245617|NCT02323100|Drug|Placebo|8 am, 4pm and midnight
245618|NCT02323087|Device|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
245619|NCT02323087|Device|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
245620|NCT02323074|Procedure|Brain Computer Interface|
245621|NCT02323061|Procedure|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
245622|NCT02323048|Drug|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
245623|NCT02323048|Drug|placebo|Placebo (sugar pill)
245624|NCT02323035|Device|Headgear|Investigative Headgear with CPAP Mask.
245625|NCT02323022|Drug|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
245626|NCT02323022|Drug|High-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
245627|NCT02323022|Drug|Intermediate-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 10mg/msq/d (d1-3)
245628|NCT02323009|Device|Esophageal Balloon|Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
245629|NCT02323009|Other|Cstat|PEEP was adjusted to achieve the best CStat in this group of patients
245630|NCT02322996|Other|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
245631|NCT02322983|Behavioral|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
245668|NCT02322671|Drug|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
245632|NCT02322970|Device|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
245633|NCT02322957|Drug|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
245634|NCT02322944|Behavioral|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
245635|NCT02322944|Behavioral|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
245636|NCT02322931|Procedure|Intra-operative C-arm CT imaging|"Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.~Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.~One Cine loop C-arm scan in the sagittal plane while retracting the probe.~One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
245637|NCT02322918|Genetic|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
245638|NCT02322905|Behavioral|Emotion Regulation Therapy|8 sessions of ERT
245639|NCT02322892|Drug|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
245640|NCT02322892|Drug|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
245641|NCT02322879|Drug|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
245642|NCT02322879|Other|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
245643|NCT02322879|Drug|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
245644|NCT02322866|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day.
245645|NCT02322866|Drug|Placebo|Placebo-matching sarecycline tablets, taken orally at the same time each day.
245646|NCT02322853|Drug|Tamoxifen|hormonotherapy
245647|NCT02322853|Drug|Ralimetinib (LY2228820 dimesylate)|
245648|NCT02322814|Drug|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
245649|NCT02322814|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
245650|NCT02322814|Drug|Placebo|Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
245651|NCT02322814|Drug|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
245652|NCT02322814|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
245653|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M2
245654|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M3
245655|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
245656|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
245657|NCT02322775|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
245658|NCT02322775|Biological|Placebo|Placebo administered subcutaneously every 4 weeks
245659|NCT02322749|Drug|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
245660|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
245661|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
245662|NCT02322710|Device|Urgotul: Low-adherent dressing|
245663|NCT02322710|Device|TulleGras M.S.: Vaseline gauze|
245664|NCT02322697|Drug|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
245665|NCT02322684|Device|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
245666|NCT02322671|Drug|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
245667|NCT02322671|Drug|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
245669|NCT02322658|Drug|Eszopiclone Tablets 3 mg|
245670|NCT02322645|Drug|Eszopiclone Tablets 3 mg|
245672|NCT02322619|Drug|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
245673|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
245674|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
245675|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
245676|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
245677|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
245678|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
245679|NCT02322593|Drug|TAS-118 plus Oxaliplatin|
245680|NCT02322593|Drug|S-1 plus Cisplatin|
245681|NCT02322580|Drug|etanercept|
245682|NCT02322567|Other|medical records|review of medical records
245683|NCT02322554|Biological|Cellular and tissue based products|Procedure: Application of device or biological to wounds
245684|NCT02322541|Other|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
245685|NCT02322528|Drug|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
245686|NCT02322515|Other|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
245687|NCT02322515|Other|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
245688|NCT02322502|Drug|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
245689|NCT02322502|Drug|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
245690|NCT02322502|Drug|propofol|intravenous injection to maintain anaesthesia
245691|NCT02322489|Device|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
245692|NCT02322489|Device|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
245693|NCT02322476|Other|No intervention will be performed|No intervention will be performed
245694|NCT02322463|Drug|Arab children|Treatment with Oxycodone
245695|NCT02322450|Drug|QGC001|
245696|NCT02322450|Drug|Placebo|
245697|NCT02322437|Other|Home treatment|Patients are treated at home whenever possible and appropriate
245698|NCT02322437|Other|Treatment As Usual|Patients are treated at a mental hospital
245699|NCT02322424|Procedure|pancreaticoduodenectomy|
245700|NCT02322411|Device|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
245701|NCT02322411|Behavioral|Compensatory approaches|
245702|NCT02322398|Drug|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
245703|NCT02322398|Drug|hMG|150-300 IU/d hMG
245704|NCT02322372|Drug|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
245705|NCT02322372|Drug|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
245706|NCT02322346|Other|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
245707|NCT02322346|Drug|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
245708|NCT02322346|Drug|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.~During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
245709|NCT02322333|Drug|MLD10|
245710|NCT02322333|Drug|Placebo|
245711|NCT02322320|Drug|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
245792|NCT02321631|Dietary Supplement|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
245793|NCT02321618|Behavioral|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
245794|NCT02321618|Behavioral|BP educational materials|Exposure to hypertension educational materials
245712|NCT02322307|Other|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.~Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
245713|NCT02322307|Other|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
245714|NCT02322294|Dietary Supplement|Glucodia™|
245715|NCT02322294|Other|Placebo|
245716|NCT02322281|Drug|Rociletinib|
245717|NCT02322281|Drug|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
245718|NCT02322268|Dietary Supplement|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
245719|NCT02322242|Drug|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
245720|NCT02322242|Drug|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
245721|NCT02322229|Drug|Ocriplasmin 0.125 mg in a 0.1 mL volume|
245722|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
245723|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
245724|NCT02322216|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
245725|NCT02322203|Dietary Supplement|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
245726|NCT02322190|Procedure|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment
245727|NCT02322190|Drug|Methoxsalen|Used in conjuction with photopheresis procedure
245728|NCT02322138|Other|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
245729|NCT02322138|Other|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
245730|NCT02322138|Other|Reference Group|Breast fed ad libitum
245731|NCT02322125|Device|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
245732|NCT02322112|Other|Microcrystalline Cellulose Supplementation|Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
245733|NCT02322112|Other|Acacia Gum Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
245734|NCT02322112|Other|Resistant Starch Type 4 Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
245735|NCT02322099|Drug|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
245736|NCT02322099|Drug|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
245737|NCT02322099|Dietary Supplement|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
245738|NCT02322099|Drug|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
245739|NCT02322086|Drug|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
245740|NCT02322073|Procedure|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
245741|NCT02322060|Procedure|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
245742|NCT02322060|Procedure|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
245743|NCT02322060|Procedure|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
245744|NCT02322047|Drug|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 15-49: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
245745|NCT02322047|Drug|Naltrexone|Naltrexone Dosing Days 1-49: 50mg @ 9PM
245746|NCT02322047|Drug|(Praz)Placebo|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 15-49: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
245747|NCT02322047|Drug|(Nal)Placebo|Placebo Dosing Days 1-49: 50mg @ 9PM
245842|NCT02321267|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
245748|NCT02322034|Other|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
245749|NCT02322021|Drug|Elenbecestat (E2609)|In the double-blind portion of the study, each participant will receive two tablets, which when combined will make up the required dose of elenbecestat (E2609) or placebo, to be administered orally once per day (QD) with food. During the OLE Phase, participants will receive a single tablet of elenbecestat (E2609).
245750|NCT02322021|Drug|Placebo|In the double-blind portion of the study, each participant will receive two tablets, which when combined will make up the required dose of elenbecestat (E2609) or placebo, to be administered orally QD with food.
245751|NCT02322008|Biological|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
245752|NCT02321982|Other|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
245753|NCT02321969|Dietary Supplement|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate [EGCG]).
245754|NCT02321956|Diagnostic Test|Ultrasound|Using ultrasound to determine the size of endotracheal tube
245755|NCT02321930|Drug|tofacitinib 5mg po bid|
245756|NCT02321917|Device|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
245757|NCT02321904|Procedure|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
245758|NCT02321904|Procedure|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
245759|NCT02321904|Procedure|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
245760|NCT02321904|Procedure|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
245761|NCT02321904|Procedure|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
245762|NCT02321891|Device|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
245763|NCT02321878|Drug|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.~No treatment given."
245764|NCT02321865|Drug|NPC-02|
245765|NCT02321852|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
245766|NCT02321852|Drug|Placebo|Once daily oral administration of placebo mannitol for 7 days
245767|NCT02321839|Drug|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
245768|NCT02321826|Behavioral|Music|Participants choice among 4 genres of music matched on music characteristics
245769|NCT02321826|Behavioral|Audiobook|Participants choice among 4 types of audiobooks
245770|NCT02321813|Behavioral|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
245771|NCT02321813|Other|placebo control|Quality of life measurement
245772|NCT02321800|Drug|S-649266|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function and body weight)
245773|NCT02321800|Drug|Imipenem/cilastatin|1000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function and body weight)
245774|NCT02321787|Procedure|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
245775|NCT02321761|Drug|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
245776|NCT02321748|Drug|Montelukast|
245777|NCT02321748|Drug|ASP2151|
245778|NCT02321735|Behavioral|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
245779|NCT02321709|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
245780|NCT02321709|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
245781|NCT02321696|Device|Acupuncture|
245782|NCT02321696|Other|Physiotherapy and eccentric exercise|
245783|NCT02321696|Other|Watchful waiting and eccentric exercise|
245784|NCT02321696|Other|eccentric exercise|
245785|NCT02321683|Device|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
245786|NCT02321670|Procedure|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
245787|NCT02321670|Procedure|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
245788|NCT02321657|Other|iPad app containing art, music and games|An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
245789|NCT02321657|Other|Toys, books and games|Games, books and toys used to distract
245790|NCT02321644|Drug|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
245791|NCT02321631|Dietary Supplement|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
245795|NCT02321605|Behavioral|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.~They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
245796|NCT02321605|Behavioral|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
245797|NCT02321592|Drug|AFM13|
245798|NCT02321579|Dietary Supplement|vitamin B-6|50 mg/d
245799|NCT02321579|Dietary Supplement|Glutathione|500 mg/d
245800|NCT02321579|Dietary Supplement|Dextrins|50 mg/d
245801|NCT02321566|Device|Epidural Motor Cortex Stimulation|
245802|NCT02321553|Other|Brown rice|brown rice cake
245803|NCT02321553|Other|White rice|white rice cake
245804|NCT02321540|Drug|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.~Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
245805|NCT02321527|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
245806|NCT02321527|Device|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
245807|NCT02321527|Procedure|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
245808|NCT02321527|Behavioral|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
245809|NCT02321514|Device|Tendyne Mitral Valve System|Transcatheter mitral valve replacement
245810|NCT02321501|Drug|Ceritinib|Given PO
245811|NCT02321501|Drug|Everolimus|Given PO
245812|NCT02321501|Other|Laboratory Biomarker Analysis|Correlative studies
245813|NCT02321501|Other|Pharmacological Study|Correlative studies
245814|NCT02321475|Drug|EGb761®|
245815|NCT02321462|Drug|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
245816|NCT02321462|Drug|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
245817|NCT02321436|Biological|Botulinum toxin type A|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
245818|NCT02321436|Drug|Placebo|Placebo administered intramuscularly in the targeted upper limb.
245819|NCT02321410|Other|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
245820|NCT02321410|Other|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
245821|NCT02321397|Drug|Oxycodone|
245822|NCT02321397|Drug|Naloxone|Prolonged Release Tablets
245823|NCT02321384|Drug|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
245824|NCT02321384|Drug|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
245825|NCT02321384|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
245826|NCT02321384|Drug|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
245827|NCT02321371|Drug|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
245828|NCT02321371|Drug|Lactulose|Continuation of Lactulose therapy for further 48 hours.
245829|NCT02321358|Behavioral|Two-time implementation intention|Will be given intervention and booster at six weeks
245830|NCT02321358|Behavioral|One-time implementation intention|Will only be given the intervention once
245831|NCT02321358|Behavioral|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
245832|NCT02321358|Behavioral|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
245833|NCT02321345|Other|Palliative Care Support|Palliative care meetings Quality of Life Assessments
245834|NCT02321332|Procedure|bilateral simultaneous endoscopic thoracic symapthectomy|Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
245835|NCT02321332|Procedure|unilateral sequential endoscopic thoracic symapthectomy.|Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
245836|NCT02321319|Drug|Hydromorphone HCl ER Tablets|Hydromorphone hydrochloride (HCl) extended release tablet
245837|NCT02321306|Drug|LUM001|LUM001 administered orally once each day.
245838|NCT02321293|Dietary Supplement|CurcuVIVA™|80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
245839|NCT02321293|Drug|Tyrosine Kinase Inhibitor gefitinib (Iressa)|250 mg PO daily until progression
245840|NCT02321293|Drug|Tyrosine Kinase Inhibitor erlotinib (Tarceva)|150 mg PO daily until progression
245841|NCT02321280|Drug|Denosumab|Single dose subcutaneous administration
245843|NCT02321254|Device|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
245844|NCT02321254|Behavioral|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
245845|NCT02321241|Drug|Aflibercept (EYLEA, BAY-86-5321)|"st year: 3 monthly injections followed by 1 injection every two months~nd year and following: injection according the visual and anatomical results observed the 1st year"
245846|NCT02321228|Procedure|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
245847|NCT02321228|Procedure|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
245848|NCT02321215|Other|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
245849|NCT02321202|Drug|Omega-3 Fatty Acid-Based Parenteral Nutrition|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid [FA] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
245850|NCT02321202|Drug|Structolipid|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
245851|NCT02321189|Drug|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
245852|NCT02321189|Drug|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
245853|NCT02321176|Drug|trans-resveratrol|"patients received 100mg Longevinex everyday,total of three days~1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient"
245854|NCT02321163|Device|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
245855|NCT02321163|Device|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
245856|NCT02321163|Device|NMES no stimulation|Placebo, electrode pad on, no stimulation
245857|NCT02321150|Procedure|Cautery|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~Conjunctiva undermined at the recipient site.~Relaxing incisions placed at the corners of the recipient site.~Graft is slid into place~Graft / host interface is gently dried with a Qtip~Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.~Power setting: 25.~Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.~Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off~Cautery is applied at the 4 apices of the graft then in between these points."
245858|NCT02321150|Procedure|Sutures|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.~Conjunctiva undermined at the recipient site.~Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
245859|NCT02321137|Procedure|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
245860|NCT02321137|Procedure|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
245861|NCT02321124|Other|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
245862|NCT02321124|Behavioral|life style advice|We will apply life style advice for four weeks.
245863|NCT02321111|Drug|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
245864|NCT02321111|Drug|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
245865|NCT02321098|Drug|Loceryl NL + Cosmetic varnish|Loceryl NL + Cosmetic varnish once/week for 12 weeks
245866|NCT02321098|Drug|Loceryl NL 12 weeks|Loceryl NL once/week for 12 weeks
245867|NCT02321098|Drug|Loceryl NL 15 months|Loceryl once/week for additional 15 months
245868|NCT02321085|Procedure|Sinus Rhythm control|
245869|NCT02321085|Procedure|Pulse Rate control|
245870|NCT02321072|Drug|Oxygen|
245871|NCT02321059|Device|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
245872|NCT02321033|Dietary Supplement|soft drinks|soft drinks with palatinose and maltodextrin
245873|NCT02321020|Procedure|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
245874|NCT02321020|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
245875|NCT02320981|Diagnostic Test|Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance|
245876|NCT02320968|Other|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
245877|NCT02320955|Procedure|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
245878|NCT02320942|Other|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
245879|NCT02320929|Procedure|Intraoperative flexor tendon sheath irrigation|
245880|NCT02320929|Procedure|Postoperative flexor tendon sheath irrigation|
245881|NCT02320916|Procedure|23Gauge|Arterial puncture will be made using a 23Gauge needle
245882|NCT02320916|Procedure|25Gauge|Arterial puncture will be made using a 25Gauge needle
245883|NCT02320903|Device|VillageWhere App|
245884|NCT02320890|Device|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
245885|NCT02320890|Device|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
245886|NCT02320877|Device|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
245887|NCT02320864|Procedure|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
245888|NCT02320851|Behavioral|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
245889|NCT02320851|Behavioral|Self-help group (SHG)|(see description of corresponding study arm)
245890|NCT02320838|Device|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
245891|NCT02320838|Device|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
245892|NCT02320838|Device|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
245893|NCT02320825|Radiation|single-fraction SRS|
245894|NCT02320825|Radiation|high-dose hypofractionated SRS|
245895|NCT02320825|Behavioral|Quality of Life Measures|
245896|NCT02320812|Biological|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
245897|NCT02320799|Behavioral|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
245898|NCT02320799|Behavioral|treatment as usual|Clinic psychosocial treatment as usual
245899|NCT02320786|Behavioral|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
245900|NCT02320773|Drug|Betmiga®|Oral
245901|NCT02320760|Behavioral|Physical activity on prescription|
245902|NCT02320747|Other|Tai Chi|
245903|NCT02320734|Drug|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
245904|NCT02320721|Drug|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
245905|NCT02320721|Drug|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
245906|NCT02320721|Drug|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
245907|NCT02320708|Drug|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
245908|NCT02320708|Drug|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
245909|NCT02320708|Drug|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
245910|NCT02320708|Drug|Placebo|2 placebo caplets for acetaminophen taken orally one time
245911|NCT02320708|Drug|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
245912|NCT02320708|Drug|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
245913|NCT02320695|Drug|Saline|
245914|NCT02320695|Drug|Isopropyl Alcohol|
245915|NCT02320695|Drug|Pain Relieving Cream|
245916|NCT02320695|Drug|Antibiotic/Pain Relieving Ointment|
245917|NCT02320695|Drug|Original Ointment|
245918|NCT02320695|Drug|Pain Relief Ointment|
245919|NCT02320682|Device|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
245920|NCT02320669|Drug|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
245921|NCT02320669|Drug|Placebo|Bolus of Placebo followed by infusion for 48 hours
245922|NCT02320656|Other|Blood sampling|Longitudinal (3 stages of the disease)
245923|NCT02320656|Other|Bone marrow aspirate|Longitudinal (3 stages of the disease)
245924|NCT02320656|Other|Skin biopsy|Single biopsy (optional)
245925|NCT02320656|Other|Buccal swab|Single sampling.
245926|NCT02320643|Device|Seratom® PA mesh|Partially absorbable mesh
245927|NCT02320630|Drug|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
245928|NCT02320630|Drug|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
245929|NCT02320630|Drug|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
245930|NCT02320617|Procedure|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
245931|NCT02320604|Drug|Administration of study drug|i.v. administration of Ambisome in two different dossages
245932|NCT02320591|Other|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
245933|NCT02320591|Other|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
245934|NCT02320591|Other|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
245935|NCT02320578|Procedure|3D Laparoscopy|3D Laparoscopy approach
245936|NCT02320578|Procedure|Standard Laparoscopy|Standard laparoscopy approach
245937|NCT02320565|Procedure|3D Laparoscopy|3D Laparoscopy approach
245938|NCT02320565|Procedure|Standard Laparoscopy|Standard laparoscopy approach
245939|NCT02320552|Other|No intervention|no intervention
245940|NCT02320526|Behavioral|Control|
245941|NCT02320526|Behavioral|Continuous walking|
245942|NCT02320526|Behavioral|Interval walking|
245943|NCT02320513|Other|Wearing activty monitoring device (Fitbit Flex)|
245944|NCT02320513|Device|Fitbit Flex|
245945|NCT02320500|Behavioral|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
245946|NCT02320500|Other|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
245947|NCT02320487|Drug|Bendamustine|Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2‐6.
245948|NCT02320487|Drug|Obinutuzumab|Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2‐6.
245949|NCT02320474|Drug|Aflibercept|
245950|NCT02320448|Drug|PIPAC|
245951|NCT02320435|Drug|Pertuzumab|Pertuzumab single agent or in combination with other anti-cancer therapies, at the same dose and schedule at which it was given at the end of the Parent study
245952|NCT02320422|Behavioral|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
245953|NCT02320409|Drug|Sufatinib|250mg Sufatinib ,single dose,oral
245954|NCT02320396|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
245955|NCT02320396|Drug|Placebo|Placebo tablets
245956|NCT02320383|Biological|GA101 (Obinutuzumab)|"Induction~Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d~Cycle 2 - 6: d1 - 1000 mg i.v., q28d~Maintenance~GA101 iv 1000 mg (flat dose): every 84 days"
245957|NCT02320383|Drug|Bendamustine|"Induction~Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d~Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
245958|NCT02320370|Device|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
245959|NCT02320357|Drug|Treatment by clopidogrel|Peripheral blood will be obtained during the study
245960|NCT02320344|Behavioral|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
245961|NCT02320331|Behavioral|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
245962|NCT02320318|Drug|Ibodutant 10 mg|Oral tablet, once daily.
245963|NCT02320318|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
245964|NCT02320305|Biological|MART-1 Antigen|Given IM
245965|NCT02320305|Drug|TLR4 Agonist GLA-SE|Given IM
245966|NCT02320305|Other|Laboratory Biomarker Analysis|Correlative studies
245967|NCT02320292|Other|Laboratory Biomarker Analysis|Correlative studies
245968|NCT02320292|Other|Quality-of-Life Assessment|Ancillary studies
245969|NCT02320292|Biological|Rituximab|Given IV
245970|NCT02320292|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
245971|NCT02320279|Device|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
245972|NCT02320253|Behavioral|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
245973|NCT02320253|Behavioral|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
245974|NCT02320253|Behavioral|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
245975|NCT02320240|Drug|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245976|NCT02320240|Drug|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245977|NCT02320240|Drug|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245978|NCT02320240|Drug|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245979|NCT02320240|Drug|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245980|NCT02320240|Drug|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245981|NCT02320240|Drug|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245982|NCT02320240|Drug|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245983|NCT02320240|Drug|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
245984|NCT02320227|Device|Miami w/o frag Personal lubricant|
245985|NCT02320214|Device|Miami w/ frag Personal lubricant|
245986|NCT02320201|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
245987|NCT02320188|Other|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
245988|NCT02320188|Other|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
245989|NCT02320175|Behavioral|Communication Bundle|Communication bundle to improve patient and family experience and patient safety
245990|NCT02320162|Behavioral|Experiential learning oral health education|
245991|NCT02320149|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day,
245992|NCT02320149|Drug|Placebo|Placebo-matching sarecycline tablets taken orally at the same time each day.
245993|NCT02320136|Behavioral|cognitive testing|patients perform simple tasks like watching a video or memorizing items
245994|NCT02320123|Behavioral|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
245995|NCT02320097|Other|Foot pressure measurement|"Description of the foot pressure measurement:~The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.~The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
245996|NCT02320084|Drug|Nitisinone|Nitisinone according to prescription
245997|NCT02320071|Other|Examination of abdominal wall strength changes over time|
245998|NCT02320058|Drug|Ipilimumab|
245999|NCT02320058|Drug|Nivolumab|
246000|NCT02320045|Drug|ITCA 650 (Exenatide in osmotic mini pump)|
246001|NCT02320032|Drug|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
246002|NCT02320019|Drug|Placebo|Placebo matching YH14618
246003|NCT02320019|Drug|YH14618|
246004|NCT02320006|Other|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
246005|NCT02319993|Drug|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
246006|NCT02319993|Drug|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
246007|NCT02319993|Drug|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
246008|NCT02319980|Procedure|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
246009|NCT02319967|Behavioral|CAPE|Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers
246010|NCT02319967|Behavioral|CHW home visits|Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
246011|NCT02319954|Procedure|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
246012|NCT02319941|Drug|ticagrelor|
246013|NCT02319941|Drug|clopidogrel|
246014|NCT02319928|Procedure|Colonoscopy|
246015|NCT02319915|Drug|Tranexamic Acid|
246016|NCT02319915|Drug|Adrenalin|
246017|NCT02319902|Device|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
246018|NCT02319902|Device|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
246019|NCT02319889|Radiation|Stereotactic Body Radiotherapy|Undergo SBRT
246020|NCT02319889|Drug|Carboplatin|Given IV
246021|NCT02319889|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
246022|NCT02319863|Procedure|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
246023|NCT02319863|Procedure|hepatectomy (rapid ligating)|
246024|NCT02319850|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
246025|NCT02319837|Drug|Enzalutamide|
246026|NCT02319837|Drug|Placebo|Sugar pill to mimic enzalutamide
246027|NCT02319837|Drug|Leuprolide|
246028|NCT02319824|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
246029|NCT02319824|Other|Laboratory Biomarker Analysis|Correlative studies
246030|NCT02319824|Radiation|Palliative Radiation Therapy|Undergo palliative radiation therapy
246031|NCT02319811|Procedure|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
246032|NCT02319798|Other|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
246033|NCT02319798|Other|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
246034|NCT02319785|Behavioral|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
246035|NCT02319785|Behavioral|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
246036|NCT02319785|Behavioral|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
246037|NCT02319785|Behavioral|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
246038|NCT02319785|Behavioral|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
246039|NCT02319785|Behavioral|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
246040|NCT02319772|Drug|BCX4430|
246041|NCT02319772|Drug|Placebo|
246042|NCT02319759|Drug|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
246043|NCT02319759|Drug|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
246044|NCT02319759|Drug|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
246045|NCT02319746|Behavioral|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
246046|NCT02319746|Behavioral|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
246047|NCT02319733|Device|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
246048|NCT02319720|Biological|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
246049|NCT02319720|Biological|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
246050|NCT02319720|Procedure|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
246134|NCT02319122|Other|High Intensity Interval Training|See arm description
246135|NCT02319122|Other|Progressive Resistance Training|See arm description
246471|NCT02316470|Biological|Placebo|phosphate buffered saline (PBS) solution
246051|NCT02319707|Drug|Oxytocin|"The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
246052|NCT02319707|Drug|Oxytocin in 100 ml NaCl 0.9%|"The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
246053|NCT02319681|Behavioral|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
246054|NCT02319681|Behavioral|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
246055|NCT02319668|Drug|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
246056|NCT02319668|Drug|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
246057|NCT02319655|Procedure|Air tamponade|Air tamponade
246058|NCT02319655|Procedure|Balanced salt solution filling|BSS filling
246059|NCT02319642|Drug|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
246060|NCT02319629|Drug|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
246061|NCT02319629|Drug|Placebo|
246062|NCT02319616|Drug|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
246063|NCT02319616|Drug|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
246064|NCT02319603|Drug|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
246065|NCT02319603|Drug|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
246066|NCT02319577|Drug|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
246067|NCT02319577|Drug|Gefitinib|EGFR tyrosine kinase inhibitor
246068|NCT02319564|Drug|Beclomethasone|
246069|NCT02319564|Drug|Beclomethasone and Salbutamol|
246070|NCT02319564|Drug|Placebo|
246071|NCT02319564|Device|Aerochamber Max®|
246072|NCT02319538|Procedure|Total thyroidectomy performed|Surgery combined with standard thyroxine treatment
246073|NCT02319525|Other|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
246074|NCT02319525|Other|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology [ACR]) regarding lupus and its treatments, that explained risks and benefits of various treatments
246075|NCT02319512|Other|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
246076|NCT02319512|Other|Glucose|12ml glucose solution (13,6g) per day
246077|NCT02319499|Dietary Supplement|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
246078|NCT02319499|Dietary Supplement|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
246079|NCT02319499|Dietary Supplement|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
246080|NCT02319499|Other|Placebo|Placebo group received no minerals/vitamin
246081|NCT02319486|Drug|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
246082|NCT02319486|Drug|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
246083|NCT02319473|Other|JAC Registry|patients who received acute reperfusion therapy
246084|NCT02319460|Biological|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
246085|NCT02319460|Biological|Plasma|
246086|NCT02319447|Behavioral|Additional education|"Our Intervention includes a 60-90 minute educational seminar, entitled Destination: Transplant, featuring live speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about Chronic Kidney Disease (CKD), transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar."
246087|NCT02319434|Device|Ostom-i Alert Sensor|Sensor on ostomy bag.
246136|NCT02319096|Other|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
246137|NCT02319083|Procedure|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
246088|NCT02319421|Other|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
246089|NCT02319408|Radiation|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
246090|NCT02319395|Genetic|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
246091|NCT02319382|Radiation|PET with the tracer 18F-DPA-714|
246092|NCT02319382|Radiation|PET with the tracer 11C-PE2I|
246093|NCT02319382|Other|MRI|Magnetic field
246094|NCT02319369|Drug|Milademetan|Milademetan will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg milademetan
246095|NCT02319369|Drug|AZA|AZA will be administered at 75 mg/m^2 subcutaneously or intravenously
246096|NCT02319356|Dietary Supplement|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
246097|NCT02319356|Dietary Supplement|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
246098|NCT02319343|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
246099|NCT02319343|Drug|Isotonic Sodium Chloride|Placebo
246100|NCT02319330|Behavioral|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
246101|NCT02319330|Behavioral|Treatment as Usual|Routine HIV clinic-based counseling
246102|NCT02319317|Behavioral|Risky driving prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
246103|NCT02319317|Behavioral|Control group general health promotion|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
246104|NCT02319304|Drug|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
246105|NCT02319304|Radiation|Low dose fractionated radiation therapy (LDFRT)|see arm description
246106|NCT02319291|Device|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
246107|NCT02319278|Drug|Ferumoxytol|Infusion following between paired MRI scans
246108|NCT02319265|Drug|Melatonin|Oral liquid
246109|NCT02319252|Device|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
246110|NCT02319252|Device|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
246111|NCT02319239|Radiation|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
246112|NCT02319239|Radiation|hypofractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
246113|NCT02319239|Radiation|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
246114|NCT02319226|Other|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
246115|NCT02319213|Other|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
246116|NCT02319213|Other|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
246117|NCT02319213|Other|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
246118|NCT02319200|Drug|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)~Metformin daily during 36 months"
246119|NCT02319200|Drug|placebo tablet|4 tablets per day for 36 months
246120|NCT02319187|Drug|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
246121|NCT02319187|Drug|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
246122|NCT02319187|Drug|irinotecan|irinotecan 160mg/m2 d1, every 14 days
246123|NCT02319174|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
246124|NCT02319161|Drug|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
246125|NCT02319148|Drug|itraconazole|itraconazole dosed at 200 mg
246126|NCT02319148|Drug|diltiazem|diltiazem dosed at 240 mg
246127|NCT02319148|Drug|SR verapamil|SR verapamil dosed at 240 mg
246128|NCT02319148|Drug|PF-00489791|PF-00489791 20 mg single dose administration
246129|NCT02319135|Drug|Azacitadine|
246130|NCT02319135|Drug|Fludarabine|
246131|NCT02319135|Drug|Cytarabine|
246132|NCT02319135|Drug|Lenograstim|
246133|NCT02319135|Drug|Filgastrim|
246138|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
246139|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
246140|NCT02319057|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
246141|NCT02319057|Drug|ORM-12741 IR|Immediate release formulation of ORM-12741
246142|NCT02319057|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
246143|NCT02319044|Drug|MEDI4736|MEDI4736 monotherapy
246144|NCT02319044|Drug|Tremelimumab|Tremelimumab monotherapy
246145|NCT02319044|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
246146|NCT02319031|Drug|Daclatasvir|
246147|NCT02319031|Drug|Sofosbuvir|
246148|NCT02319031|Drug|Ribavirin|
246149|NCT02319018|Drug|Alisertib|Given PO
246150|NCT02319018|Drug|Fluorouracil|Given IV
246151|NCT02319018|Other|Laboratory Biomarker Analysis|Correlative studies
246152|NCT02319018|Drug|Leucovorin Calcium|Given IV
246153|NCT02319018|Drug|Oxaliplatin|Given IV
246154|NCT02319005|Drug|Revusiran (ALN-TTRSC)|
246155|NCT02319005|Drug|Sterile Normal Saline (0.9% NaCl)|
246156|NCT02318992|Biological|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
246157|NCT02318979|Device|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
246158|NCT02318979|Device|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
246159|NCT02318979|Device|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
246160|NCT02318966|Dietary Supplement|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
246161|NCT02318953|Device|Mobile app follow-up care|The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
246162|NCT02318953|Other|Conventional, in-person follow-up care|This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
246163|NCT02318940|Device|central venous catheter|installation of Central venous catheter ultrasound guided
246164|NCT02318940|Device|central venous catheter|installation of Central venous catheter landmark guided
246165|NCT02318927|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
246166|NCT02318914|Drug|gevokizumab|
246167|NCT02318901|Drug|Pembrolizumab|
246168|NCT02318901|Drug|Trastuzumab|
246169|NCT02318901|Drug|ado-trastuzumab emtansine|
246170|NCT02318901|Drug|Cetuximab|
246171|NCT02318888|Procedure|Surgery|
246172|NCT02318888|Drug|Icodextrin|
246173|NCT02318875|Dietary Supplement|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
246174|NCT02318875|Other|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
246175|NCT02318862|Procedure|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
246176|NCT02318849|Behavioral|Web intervention|interactive website using social media and gamification
246177|NCT02318836|Drug|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
246178|NCT02318823|Other|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
246179|NCT02318823|Other|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
246180|NCT02318810|Drug|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
246181|NCT02318810|Drug|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
246182|NCT02318810|Drug|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
246183|NCT02318810|Drug|Placebo|Patients receive saline
246184|NCT02318797|Behavioral|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
246185|NCT02318797|Behavioral|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
246186|NCT02318784|Drug|Carfilzomib|
246187|NCT02318771|Radiation|Radiation Therapy (RT)|Undergo RT
246188|NCT02318771|Drug|MK-3475|Given IV
246189|NCT02318758|Drug|UT-15C|sustained release oral treprostinil
246190|NCT02318758|Other|ethanol|Absolut 100 vodka
246191|NCT02318745|Behavioral|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
246192|NCT02318745|Behavioral|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
246193|NCT02318732|Behavioral|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
246194|NCT02318719|Drug|Placebo|Placebo
246195|NCT02318719|Drug|DS-5565|
246196|NCT02318706|Drug|DS-5565|
246197|NCT02318706|Drug|placebo|
246198|NCT02318693|Drug|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
246199|NCT02318693|Drug|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
246200|NCT02318680|Other|Review of follow home visits after discharge from Nykøbing Falster Hospital|The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
246201|NCT02318667|Biological|Golimumab|Golimumab 50mg/0.5 mL in a single-use, ready-to-use autoinjector. Golimumab is a fully human anti-TNF (tumor necrosis factor) alpha monoclonal antibody that will be administered SC.
246202|NCT02318654|Other|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
246203|NCT02318654|Drug|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
246204|NCT02318641|Device|oximetry|Retinal oximetry will be performed with Oxymap.
246205|NCT02318628|Device|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.~CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
246206|NCT02318615|Procedure|Immediate Axillary Plasty|Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
246207|NCT02318602|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
246208|NCT02318576|Other|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
246209|NCT02318563|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
246210|NCT02318563|Drug|Placebo Solution|A matching oral solution containing no cannabidiol
246211|NCT02318550|Other|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:~Normal operating mode~SAR ≤ 2.0 W/kg per patient."
246212|NCT02318537|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
246213|NCT02318537|Drug|Placebo Solution|A matching oral solution containing no cannabidiol.
246214|NCT02318511|Procedure|Knee injection|Injection into knee for the treatment of Osteoarthritis
246215|NCT02318511|Device|ReNu amniotic allograft|
246216|NCT02318511|Device|placebo saline|
246217|NCT02318511|Device|Hyaluronic Acid|
246218|NCT02318498|Procedure|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
246219|NCT02318485|Biological|Limbal epithelial stem cell graft|
246220|NCT02318472|Device|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
246221|NCT02318472|Device|Plaster cast|Lower limb plaster cast
246222|NCT02318459|Other|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
246223|NCT02318459|Other|Traditionnal group rehabilitation|Traditionnal group rehabilitation, 3 times a week, 1 hour duration
246224|NCT02318446|Drug|Folic Acid|Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
246225|NCT02318446|Drug|Saccharine|Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
246226|NCT02318433|Drug|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
246227|NCT02318433|Drug|Saline|
246228|NCT02318420|Other|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
246229|NCT02318407|Drug|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
246230|NCT02318407|Drug|Placebo|contains no active drug
246231|NCT02318394|Biological|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
246232|NCT02318381|Procedure|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
246233|NCT02318368|Drug|Ficlatuzumab|
246234|NCT02318368|Drug|Erlotinib|
246235|NCT02318368|Drug|placebo|
246236|NCT02318355|Other|normal saline|Crystalloid intravenous solution
246237|NCT02318355|Other|lactated ringers|Crystalloid intravenous solution
246238|NCT02318342|Drug|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
246239|NCT02318329|Drug|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
246240|NCT02318316|Other|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
246241|NCT02318303|Drug|GSP 301-1 NS (QD)|GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
246242|NCT02318303|Drug|GSP 301-2 NS (BID)|GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
246243|NCT02318303|Drug|GSP 301 Placebo NS|GSP 301 placebo NS administered as 2 sprays/nostril
246244|NCT02318303|Drug|Olopatadine HCl-1 NS (QD)|Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
246245|NCT02318303|Drug|Olopatadine HCl-2 NS (BID)|Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
246246|NCT02318303|Drug|Mometasone Furoate-1 NS (QD)|Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
246247|NCT02318303|Drug|Mometasone Furoate-2 NS (BID)|Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
246248|NCT02318290|Drug|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
246249|NCT02318277|Drug|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
246250|NCT02318277|Drug|INCB024360|INCB024360: Oral daily dosing
246251|NCT02318264|Device|Kinesio Tape|Elastic tape placed over the skin
246252|NCT02318251|Other|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
246253|NCT02318251|Other|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
246254|NCT02318238|Other|6 minutes walking test|
246255|NCT02318238|Other|6 minutes step test|
246256|NCT02318238|Other|4 meters gait speed|
246257|NCT02318225|Drug|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
246258|NCT02318225|Drug|Placebo|"Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.~Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
246259|NCT02318212|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
246260|NCT02318199|Procedure|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
246261|NCT02318173|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix
246262|NCT02318160|Other|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
246263|NCT02318147|Procedure|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
246264|NCT02318147|Drug|The traditional treatment|the traditional treatments according to associated guidelines
246265|NCT02318134|Procedure|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
246266|NCT02318134|Drug|The traditional treatment|the traditional treatments according to associated guidelines
246267|NCT02318121|Procedure|Amniotomy first|rupture of membranes to augment labor
246268|NCT02318121|Procedure|Oxytocin first|Administration of oxytocin to augment labor
246269|NCT02318121|Procedure|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
246270|NCT02318121|Drug|Oxytocin|
246271|NCT02318108|Other|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
246272|NCT02318108|Other|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
246273|NCT02318095|Drug|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
246274|NCT02318095|Radiation|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
246275|NCT02318095|Other|Sugical resection|Surgical resection of the pancreas post radiation therapy
246276|NCT02318095|Drug|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
246277|NCT02318082|Drug|Interleukin-2|
246278|NCT02318069|Biological|FSME-immune|0.5 ml im as scheduled in the 5 arms
246279|NCT02318056|Other|Aquacel® Ag Burn Glove|burn dressing
246280|NCT02318056|Other|Mepilex® Transfer Ag|burn dressing
246281|NCT02318056|Drug|antibiotic|antibiotic burn dressing
246282|NCT02318043|Drug|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
246283|NCT02318017|Drug|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
246284|NCT02318017|Drug|Placebo|
246285|NCT02318004|Other|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
246286|NCT02317991|Drug|nab-paclitaxel|nab-paclitaxel 125 mg/m^2 IV
246287|NCT02317991|Biological|ramucirumab|Ramucirumab 8 mg/kg IV
246288|NCT02317978|Procedure|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
246289|NCT02317965|Other|Maternal Blood Draw|Maternal Blood Draw
246290|NCT02317952|Other|Experimental Extensively Hydrolyzed Formula|
246291|NCT02317952|Other|Active Comparator Formula|
246292|NCT02317939|Other|instruction|online instruction tutorials at followup visits
246293|NCT02317939|Other|standard baseline instruction|self-guidance at followup visits
246294|NCT02317926|Drug|Levothyroxine|
246295|NCT02317926|Drug|Levothyroxine Plus Liothyronine|
246296|NCT02317926|Drug|Desiccated Thyroid Extract|
246297|NCT02317900|Biological|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10^3 plaque forming units (PFUs) of each component (10^3.3 PFUs/mL of rDEN1∆30, 10^4.3 PFU/mL of rDEN2/4∆30(ME), 10^3.3 PFU/mL of rDEN3∆30/31-7164 and 10^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
246298|NCT02317900|Biological|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
246299|NCT02317900|Biological|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
246300|NCT02317887|Biological|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
246301|NCT02317874|Drug|Carboplatin|Given IV
246302|NCT02317874|Drug|Paclitaxel|Given IV
246303|NCT02317874|Other|Pharmacokinetic Study|Correlative studies
246304|NCT02317874|Drug|Talazoparib|Given PO
246305|NCT02317874|Drug|Talazoparib Tosylate|Given PO
246306|NCT02317861|Drug|RDEA3170|Oral Treatment
246307|NCT02317861|Drug|Febuxostat|Oral Treatment
246308|NCT02317861|Drug|Benzbromarone|Oral Treatment
246309|NCT02317848|Other|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
246310|NCT02317835|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
246311|NCT02317809|Drug|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
246312|NCT02317809|Drug|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
246313|NCT02317796|Drug|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
246314|NCT02317783|Drug|FDG-PET, [18F]Flutemetamol|
246315|NCT02317770|Drug|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
246316|NCT02317770|Drug|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
246317|NCT02317744|Drug|Naltrexone and bupropion combination|
246318|NCT02317744|Other|Pill Placebo|
246319|NCT02317731|Other|Straw|Bowel preparation ingestion with a straw
246320|NCT02317718|Other|monitor reproductive outcome|
246321|NCT02317705|Drug|OTL38|
246322|NCT02317692|Behavioral|Parent training|
246323|NCT02317679|Drug|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
246324|NCT02317679|Device|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
246416|NCT02316964|Biological|aldesleukin|Given SC
246325|NCT02317666|Procedure|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
246326|NCT02317640|Drug|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
246327|NCT02317640|Other|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
246328|NCT02317640|Device|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
246329|NCT02317627|Drug|KD025|
246330|NCT02317614|Behavioral|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
246331|NCT02317601|Drug|methylprednisolone sodium succinate|Single dose Intravenous
246332|NCT02317601|Drug|placebo saline|
246333|NCT02317588|Dietary Supplement|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
246334|NCT02317588|Dietary Supplement|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
246335|NCT02317575|Biological|LY900014|Administered SC
246336|NCT02317575|Biological|Insulin Lispro|Administered SC
246337|NCT02317562|Drug|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
246338|NCT02317549|Drug|LB1148|
246339|NCT02317549|Drug|Placebo|
246340|NCT02317536|Dietary Supplement|Carnipure Product 1|
246341|NCT02317536|Dietary Supplement|Carnipure Product 2|
246342|NCT02317536|Other|Placebo|Placebo
246343|NCT02317523|Behavioral|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
246344|NCT02317523|Behavioral|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
246345|NCT02317510|Procedure|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
246346|NCT02317510|Procedure|general anesthesia|General anesthesia for laparoscopic cholecystectomy
246347|NCT02317497|Other|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
246348|NCT02317497|Drug|Vasopressors to maintain normal blood pressure values, if needed|
246349|NCT02317497|Drug|Osmotherapeutics to lowr intracranial pressure, if needed|
246350|NCT02317497|Procedure|Endovascular stroke care to treat brain vessel occlusions, if needed|
246351|NCT02317497|Procedure|Decompressive neurosurgery, if needed|
246352|NCT02317484|Drug|Ipragliflozin (SGLT2 inhibitor)|
246353|NCT02317471|Biological|autologous gp96 vaccination|"Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.~gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion."
246354|NCT02317471|Drug|Oxaliplatin+S-1|"Treatment will be start at the 5th week after the surgery.~S-1: 40~60mg bid，d1~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles."
246355|NCT02317458|Biological|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
246356|NCT02317458|Biological|Sham comparator|One arm with standard of care undergoing a sham procedure
246357|NCT02317432|Behavioral|Comparison of a combined CBT + exercise intervention and enhanced usual care|
246358|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
246359|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
246360|NCT02317419|Drug|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
246361|NCT02317419|Drug|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
246362|NCT02317406|Drug|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
246363|NCT02317406|Drug|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
246364|NCT02317393|Other|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
246417|NCT02316964|Other|laboratory biomarker analysis|Correlative studies
246365|NCT02317393|Other|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
246366|NCT02317341|Drug|Ketamine|Single intravenous dose
246367|NCT02317341|Drug|Placebo (saline)|Given intravenously over 40 minutes
246368|NCT02317341|Drug|Ketamine|Single intravenous dose given over 40 minutes
246369|NCT02317341|Drug|Midazolam|Given intravenously over 40 minutes
246370|NCT02317341|Drug|Midazolam(placebo)|Given intravenously over 40 minutes
246371|NCT02317302|Device|FDG-PET/MR|
246372|NCT02317302|Device|FDG-PET/CT|
246373|NCT02317289|Device|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
246374|NCT02317276|Drug|Triamcinolone 0.1%|Topical ointment
246375|NCT02317263|Drug|testosterone|
246376|NCT02317263|Drug|placebo gel|
246377|NCT02317250|Procedure|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
246378|NCT02317250|Procedure|FDG-PET|[F-18] FDG-PET brain scans are administered once to all arms.
246379|NCT02317237|Procedure|Local anesthesia|Conscious sedation
246380|NCT02317224|Procedure|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
246381|NCT02317224|Procedure|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
246382|NCT02317224|Procedure|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
246383|NCT02317211|Dietary Supplement|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
246384|NCT02317211|Dietary Supplement|placebo|starch
246385|NCT02317198|Drug|Clopidogrel|
246386|NCT02317198|Drug|Ticagrelor or Prasugrel|
246387|NCT02317185|Device|genex bone graft with bone graft|
246388|NCT02317185|Other|autogenous bone graft|
246389|NCT02317172|Other|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
246390|NCT02317159|Drug|Imatinib|400mg imatinib qd PO
246391|NCT02317146|Drug|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
246392|NCT02317133|Biological|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
246393|NCT02317133|Biological|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
246394|NCT02317120|Genetic|NGS BRCA 1 and BRCA 2 full sequencing|
246395|NCT02317120|Genetic|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
246396|NCT02317094|Other|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
246397|NCT02317094|Drug|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
246398|NCT02317081|Device|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
246399|NCT02317068|Device|HBR|
246400|NCT02317068|Device|DD|
246401|NCT02317055|Other|imaging|
246402|NCT02317042|Device|Juno|'Juno' is the ventilator unit. It will have a flow generator which will deliver air pressure to the participant during sleep. It will have a water tub for humidification, and a single tube circuit which will be connected to a vented face mask. It will have the ventilator programs: Spontaneous Timed (ST) mode, Intelligent Volume Assured Pressure Support (iVAPS) and Automatic Expiratory Positive Airway Pressure (AutoEPAP) iVAPS programed into the software. It is also compatible with <4 L/min oxygen therapy. It is for people who weight at least 13 kg (when in ST mode), or at least 30 kg (when in iVAPS or AutoEPAP iVAPS modes).
246403|NCT02317029|Device|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
246404|NCT02317029|Procedure|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
246405|NCT02317029|Device|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
246406|NCT02317029|Procedure|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
246407|NCT02317016|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
246408|NCT02317016|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
246409|NCT02317016|Drug|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
246410|NCT02317016|Procedure|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
246411|NCT02317016|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
246412|NCT02317003|Behavioral|Intervention PPIL|
246413|NCT02317003|Behavioral|Control OR|
246414|NCT02316964|Drug|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
246415|NCT02316964|Biological|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
246418|NCT02316951|Device|single-arm study group|Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
246419|NCT02316925|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning
246420|NCT02316925|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning
246421|NCT02316912|Drug|ATX2417|Randomised double blind parallel group ascending dose assessment
246422|NCT02316912|Drug|Placebo|Randomised double blind parallel group ascending dose assessment
246423|NCT02316899|Drug|ASP0456|Oral administration once daily
246424|NCT02316899|Drug|Placebo|Oral administration once daily
246425|NCT02316886|Device|Coronary intervention|Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment
246426|NCT02316886|Drug|Optimal Medical treatment|
246427|NCT02316873|Behavioral|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
246428|NCT02316873|Behavioral|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
246429|NCT02316860|Other|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
246430|NCT02316847|Drug|diazepam nasal spray|
246431|NCT02316834|Other|Laboratory Biomarker Analysis|Correlative studies
246432|NCT02316834|Drug|BMN 673|"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."
246433|NCT02316821|Drug|RTA 402|
246434|NCT02316821|Drug|Placebo|
246435|NCT02316808|Dietary Supplement|Plant stanol ester|Smoothie that contains plant stanol ester
246436|NCT02316808|Dietary Supplement|placebo|Smoothie that contains placebo
246437|NCT02316795|Procedure|Sentinel lymph node biopsy|
246438|NCT02316795|Device|Goggle-based device with light-emitting diodes (LED)|
246439|NCT02316795|Drug|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
246440|NCT02316782|Device|Blinded IVUS assessment|Only the angiogram is used for stent placement
246441|NCT02316782|Device|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
246442|NCT02316769|Procedure|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
246443|NCT02316769|Procedure|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
246444|NCT02316756|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
246445|NCT02316756|Drug|Placebo|Placebo which will be given as oral suspension
246446|NCT02316743|Drug|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
246447|NCT02316730|Drug|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
246448|NCT02316730|Drug|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
246449|NCT02316717|Biological|IMM-124E|IMM-124E
246450|NCT02316717|Other|Placebo|Matched placebo
246451|NCT02316704|Device|THA with G7 PPS coted acetabular component|
246452|NCT02316704|Device|THA with G7 OsseoTi coted acetabular component|
246453|NCT02316678|Other|No intervention|There is no intervention
246454|NCT02316665|Device|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
246455|NCT02316665|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
246456|NCT02316652|Procedure|Scaling and root planing|Mechanical instrumentation
246457|NCT02316652|Procedure|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
246458|NCT02316639|Other|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
246459|NCT02316626|Drug|Subcutaneous progesterone|25 mg daily for 14 days
246460|NCT02316626|Drug|Vaginal progesterone|90 mg daily for 14 days
246461|NCT02316613|Drug|Rituximab|
246462|NCT02316600|Device|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
246463|NCT02316574|Behavioral|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
246464|NCT02316561|Radiation|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
246465|NCT02316548|Radiation|Intensity-Modulated Radiation Therapy|Postoperative adjuvant IMRT radiotherapy 50.4 Gy in 28 fractions. In patients not getting postoperative adjuvant chemotherapy the radiation treatment must begin within 140 days after cystectomy. For patients getting adjuvant chemotherapy radiation treatment must start within 49 days of completing chemotherapy.
246466|NCT02316535|Drug|Capecitabine|adjuvant chemotherapy;
246467|NCT02316509|Drug|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
246468|NCT02316496|Drug|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
246469|NCT02316496|Drug|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
246470|NCT02316470|Biological|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
246472|NCT02316457|Biological|IVAC_W_bre1_uID|vaccination
246473|NCT02316457|Biological|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
246474|NCT02316444|Biological|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol
246475|NCT02316418|Device|Hairstetics™ anchoring system|"Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.~Hair extensions will be attached to the fibers four weeks after the implantation."
246476|NCT02316405|Other|Arm and Leg Cycling Exercise for Walking after Stroke|
246477|NCT02316392|Drug|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
246478|NCT02316379|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
246479|NCT02316379|Device|MRI|
246480|NCT02316366|Device|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
246481|NCT02316353|Biological|C1-esterase inhibitor|
246482|NCT02316340|Drug|Vorinostat|400mg by mouth daily
246483|NCT02316340|Drug|Hydroxychloroquine|600mg by mouth daily
246484|NCT02316340|Drug|Regorafenib|160 mg by mouth daily
246485|NCT02316327|Drug|gemcitabine, cisplatin and bevacizumab|Therapeutic
246486|NCT02316314|Procedure|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
246487|NCT02316314|Procedure|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
246488|NCT02316314|Procedure|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
246489|NCT02316314|Procedure|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
246490|NCT02316301|Drug|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
246491|NCT02316301|Drug|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
246492|NCT02316288|Behavioral|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
246493|NCT02316288|Behavioral|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
246494|NCT02316275|Other|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
246495|NCT02316275|Other|Standard post-operative activity restriction|
246496|NCT02316262|Procedure|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves—after excision of end-neuromas—are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
246497|NCT02316249|Drug|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
246498|NCT02316249|Other|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
246499|NCT02316236|Drug|dexmedetomidine|an alpha-2 receptor agonist
246500|NCT02316236|Other|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
246501|NCT02316236|Other|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
246534|NCT02315911|Procedure|APP|surgical removal of adenoids and tonsils and suturing of palatal pillars
246535|NCT02315898|Drug|Treatment-inhaled tPA|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment. The tPA regimen will consist of 5mg every six hours for a total of 72 hours.
246536|NCT02315885|Other|Alcohol administration|
246537|NCT02315872|Drug|ACTH|ACTH injections twice weekly for 28 weeks.
246538|NCT02315872|Drug|Placebo|Placebo injections twice weekly for 28 weeks.
246502|NCT02316223|Behavioral|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
246503|NCT02316210|Device|electrical stimulation|
246504|NCT02316197|Drug|MSC2490484A|Initial starting dose at 100 mg (oral administration), once daily, subsequent doses and treatment regimens will be determined by the SMC (once or twice daily). MSC2490484A will be administered in continuous 21-day cycles in dose escalation or dose expansion cohorts, as long as they do not experience unacceptable toxicity or disease progression.
246505|NCT02316184|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
246506|NCT02316184|Behavioral|Brief Advice|
246507|NCT02316171|Biological|CVA21|CAVATAK is a purified preparation of CVA21
246508|NCT02316171|Drug|Mitomycin C|Chemotherapy
246509|NCT02316158|Other|Web-based support|Comparison between the efficacy between webb-based support and informational support
246510|NCT02316145|Behavioral|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
246511|NCT02316132|Drug|Stress|Corticotropin-Releasing Hormone
246512|NCT02316132|Drug|Control|Saline 0.9%
246513|NCT02316106|Drug|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle, and every 8 weeks after Cycle 20, in case treatment will be extended as per investigator discretion, if there is a positive benefit/risk ratio, absence of Grade greater than or equal to (>=) 3 treatment related toxicity, and at least stable disease has been achieved. Treatment cycles are 8 weeks in length.
246514|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20, and every 8 weeks after Cycle 20, in case treatment will be extended as per investigator discretion, if there is a positive benefit/risk ratio, absence of Grade >=3 treatment related toxicity, and at least stable disease has been achieved. Treatment cycles are 8 weeks in length.
246515|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
246516|NCT02316093|Other|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
246517|NCT02316080|Other|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
246518|NCT02316080|Other|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
246519|NCT02316067|Other|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
246520|NCT02316054|Device|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
246521|NCT02316041|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
246522|NCT02316041|Device|ReLEx® (SMILE)|
246523|NCT02316028|Drug|Decitabine|"administration of decitabine by hepatic arterial infusion~Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.~Proposed dose levels:~10 mg/m2 per course~15 mg/m2 per course~20 mg/m2 per course"
246524|NCT02316015|Dietary Supplement|Infatrini® or Infatrini Peptisorb®|
246525|NCT02316002|Drug|Pembrolizumab|
246526|NCT02315989|Radiation|proton therapy|proton therapy
246527|NCT02315976|Drug|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
246528|NCT02315963|Other|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
246529|NCT02315950|Other|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
246530|NCT02315937|Procedure|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
246531|NCT02315924|Other|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
246532|NCT02315924|Other|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
246533|NCT02315911|Procedure|ATE|surgical removal of adenoids and tonsils
246539|NCT02315833|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
246540|NCT02315833|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
246541|NCT02315820|Procedure|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
246542|NCT02315807|Device|transcranial direct current stimulation|
246543|NCT02315794|Device|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
246544|NCT02315794|Device|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
246545|NCT02315781|Device|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
246546|NCT02315781|Device|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
246547|NCT02315768|Drug|GA101|
246548|NCT02315768|Drug|ibrutinib|
246549|NCT02315742|Behavioral|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
246550|NCT02315716|Procedure|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
246551|NCT02315716|Drug|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
246552|NCT02315703|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
246553|NCT02315703|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
246554|NCT02315703|Biological|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
246555|NCT02315703|Biological|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
246556|NCT02315703|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
246557|NCT02315690|Drug|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
246558|NCT02315690|Procedure|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
246559|NCT02315677|Device|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
246560|NCT02315677|Device|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
246561|NCT02315664|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
246562|NCT02315664|Behavioral|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
246563|NCT02315651|Dietary Supplement|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
246564|NCT02315651|Dietary Supplement|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
246565|NCT02315625|Drug|Sunitinib|37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity
246566|NCT02315625|Drug|Everolimus|10 mg daily will continue until progression or unacceptable treatment-related toxicity
246567|NCT02315612|Biological|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
246568|NCT02315573|Procedure|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
246569|NCT02315560|Device|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
246570|NCT02315547|Drug|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
246650|NCT02314988|Drug|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~The placebo solution will be 100 mL of sterile normal saline."
246651|NCT02314975|Device|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
246571|NCT02315534|Drug|BBI608|"In arm A, BBI608 will be administered at the RP2D twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
246572|NCT02315534|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m^2.
246573|NCT02315521|Procedure|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.~Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
246574|NCT02315508|Drug|AUT00063|800 mg orally, once a day, for 4 weeks
246575|NCT02315508|Drug|Placebo|orally, once a day, for 4 weeks
246576|NCT02315495|Drug|Saxagliptin|
246577|NCT02315495|Drug|Acarbose|
246578|NCT02315482|Procedure|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
246579|NCT02315469|Other|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
246580|NCT02315469|Other|Questionnaire Administration|Ancillary studies
246581|NCT02315456|Procedure|capsulorhexis|
246582|NCT02315443|Drug|NA-1|
246583|NCT02315443|Drug|Placebo|
246584|NCT02315430|Drug|Cabozantinib S-malate|Given PO
246585|NCT02315430|Other|Laboratory Biomarker Analysis|Optional correlative studies
246586|NCT02315417|Drug|gevokizumab|
246587|NCT02315417|Drug|Placebo|
246588|NCT02315417|Drug|gevokizumab open-label|
246589|NCT02315404|Procedure|CAP|CAP fitted to the end of the endoscope
246590|NCT02315391|Dietary Supplement|isolated whey protein|isolated whey protein
246591|NCT02315391|Dietary Supplement|micellar whey protein|micellar whey protein
246592|NCT02315391|Dietary Supplement|glycine|glycine
246593|NCT02315391|Dietary Supplement|citrulline|citrulline
246594|NCT02315378|Behavioral|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
246595|NCT02315378|Behavioral|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
246596|NCT02315352|Drug|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
246597|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
246598|NCT02315352|Drug|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
246599|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
246600|NCT02315352|Drug|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
246601|NCT02315326|Drug|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
246602|NCT02315326|Drug|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
246603|NCT02315326|Drug|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
246604|NCT02315300|Device|medilog® DARWIN FD12|
246605|NCT02315300|Device|Continuous Glucose Monitoring|
246606|NCT02315287|Drug|Pioglitazone|Comparison of two different thiazolidinediones
246607|NCT02315287|Drug|Lobeglitazone|Comparison of two different thiazolidinediones
246608|NCT02315274|Other|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
246649|NCT02314988|Drug|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.~TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
246957|NCT02312557|Drug|Enzalutamide|Given PO
246609|NCT02315261|Procedure|Elective Thoracic and Abdominal Surgery Patients|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection in Elective Thoracic and Abdominal Surgery Patients only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
246610|NCT02315248|Radiation|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
246611|NCT02315235|Biological|Normal saline|Normal saline is injected in one leg of patient.
246612|NCT02315235|Biological|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.~The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
246613|NCT02315222|Dietary Supplement|Regenium|
246614|NCT02315222|Dietary Supplement|Placebo|
246615|NCT02315222|Procedure|Full Mouth Disinfection|
246616|NCT02315209|Device|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
246617|NCT02315196|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
246618|NCT02315196|Drug|epirubicin hydrochloride|Given IV
246619|NCT02315196|Drug|carboplatin|Given IV
246620|NCT02315196|Procedure|therapeutic conventional surgery|Undergo definitive surgery
246621|NCT02315196|Drug|paclitaxel|Given IV
246622|NCT02315196|Other|laboratory biomarker analysis|Correlative studies
246623|NCT02315196|Other|quality-of-life assessment|Ancillary studies
246624|NCT02315183|Other|This is an observational Study|THis study has no intervention
246625|NCT02315170|Device|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
246626|NCT02315170|Device|standard lid speculum|standard wire lid speculum
246627|NCT02315157|Drug|Bendamustine|Given IV
246628|NCT02315144|Drug|TV48108|TV48108 15, 60, 120 μg
246629|NCT02315144|Drug|Placebo|Placebo Comparator
246630|NCT02315131|Drug|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
246631|NCT02315131|Drug|Placebo|Placebo Comparator
246632|NCT02315118|Drug|T-cell therapy + Rituximab + IL-2|"T cells collection~T cells expansion and modification in the laboratory~T cells infusion back to the patients"
246633|NCT02315105|Procedure|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
246634|NCT02315092|Device|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
246635|NCT02315079|Other|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
246636|NCT02315079|Other|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
246637|NCT02315066|Drug|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
246638|NCT02315066|Drug|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be randomized to receive treatment with PF-04518600 at various doses administered intravenously
246639|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
246640|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (ocular melanoma, cutaneous/acral melanoma or non-small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
246641|NCT02315053|Other|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
246642|NCT02315040|Device|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
246643|NCT02315040|Other|Standard Intrauterine Insemination|standard intrauterine insemination procedure
246644|NCT02315027|Biological|autologous mesenchymal stem cells|"There will be three treatment groups of up to 8 patients each. Groups 1 will receive a single dose of cells. Groups 2 and 3 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~Group 1: single intrathecal dose of 1 x 107 cells.~Group 2: one intrathecal dose of 5 x 107 cells followed one month (+/- 4 days) later by a second intrathecal dose of 5 x 107 cells.~Group 3: one intrathecal dose of 1 x 108 cells followed one month (+/- 4 days) later by a second intrathecal dose of 1 x 108 cells."
246645|NCT02315014|Other|whey protein|whey protein.
246646|NCT02315014|Other|placebo|placebo.
246647|NCT02315001|Drug|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
246648|NCT02315001|Other|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
246652|NCT02314975|Device|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
246653|NCT02314975|Other|Fixed appliance only|Fixed appliance treatment only
246654|NCT02314949|Procedure|intestinal transplantation|
246655|NCT02314936|Dietary Supplement|Litesse powder containing 12 g polydextrose|12 g polydextrose
246656|NCT02314936|Dietary Supplement|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
246657|NCT02314936|Dietary Supplement|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
246658|NCT02314936|Dietary Supplement|Placebo|12 g Maltodextrin
246659|NCT02314923|Biological|BPSC-1001 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^3, 3x10^4, 3x10^5, 3x10^6, 9x10^6, 2x10^7, or 1x10^8 pfu.
246660|NCT02314923|Other|Placebo|0.9% Saline
246661|NCT02314910|Other|Sample histology|
246662|NCT02314897|Device|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
246663|NCT02314897|Device|RV pacing|Conventional right ventricular pacing.
246664|NCT02314884|Drug|Cafusertib Hydrochloride|
246665|NCT02314871|Other|Epidural analgesia|see Arm/group description
246666|NCT02314871|Drug|Piritramide|see Arm/group description
246667|NCT02314871|Drug|Morphine|see Arm/group description
246668|NCT02314858|Behavioral|Brief Personalized Video (BPV)|The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
246669|NCT02314858|Behavioral|Non-Personalized Video (NPV)|The NPV group will see a stock video of someone with OSA.
246670|NCT02314858|Behavioral|Treatment as Usual (TAU)|The TAU group will not watch a video.
246671|NCT02314845|Other|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
246672|NCT02314845|Other|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
246673|NCT02314832|Procedure|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
246674|NCT02314832|Procedure|femoral nerve block|ultrasound guided femoral nerve block
246675|NCT02314819|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
246676|NCT02314819|Drug|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
246677|NCT02314806|Drug|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
246678|NCT02314806|Drug|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
246679|NCT02314806|Drug|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
246680|NCT02314793|Drug|ASP2205|oral
246681|NCT02314793|Drug|Placebo|oral
246682|NCT02314780|Drug|heme arginate 1mg/kg|
246683|NCT02314780|Drug|heme arginate 3mg/kg|
246684|NCT02314780|Drug|placebo|
246685|NCT02314767|Behavioral|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
246686|NCT02314767|Behavioral|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
246687|NCT02314754|Drug|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
246688|NCT02314741|Procedure|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually ~6cm long & averages 8-10cm. After the myotomy is performed the scope is withdrawn & inserted into the lumen to inspect the mucosa, ensure mucosal integrity & confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, & is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
246689|NCT02314728|Drug|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
246690|NCT02314728|Drug|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
246691|NCT02314702|Device|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
246692|NCT02314689|Drug|Intravenous (IV) citrulline|
246693|NCT02314676|Biological|PEG-somatropin|
246694|NCT02314663|Device|"COMBINED STRATEGY"|"Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up)."
246695|NCT02314650|Other|acupoint stimulation|stimulation was given at acupoints
246696|NCT02314650|Other|non-acupoint stimulation|stimulation was given at non-acupoints
246697|NCT02314650|Other|electrodes attached|electrode were attached to skin
246698|NCT02314637|Drug|Teneligliptin|Teneligliptin for 52 weeks
246699|NCT02314637|Drug|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
246700|NCT02314624|Behavioral|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
246701|NCT02314624|Behavioral|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
246702|NCT02314611|Device|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
246703|NCT02314598|Other|No treatment|
246704|NCT02314585|Other|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
246705|NCT02314585|Other|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
246706|NCT02314572|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
246707|NCT02314559|Drug|Manual titration of propofol|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
246708|NCT02314559|Drug|Target controlled infusion of propofol|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
246709|NCT02314546|Drug|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:~Group 1 - Placebo - Control patients will receive intranasal saline.~Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.~Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
246710|NCT02314546|Drug|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
246711|NCT02314546|Drug|saline placebo|Placebo - Control patients will receive intranasal saline.
246712|NCT02314533|Drug|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
246713|NCT02314520|Device|peripherally inserted central catheter|Any complication associated with central access
246714|NCT02314520|Device|centrally inserted central catheter|Central access not associated with any complication
246715|NCT02314507|Other|Gua sha|A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
246716|NCT02314507|Other|Hot pack|A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
246717|NCT02314494|Behavioral|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
246718|NCT02314481|Drug|MPDL3280A|Intravenous (IV) infusion
246719|NCT02314481|Drug|Vemurafenib|Film coated tablet
246720|NCT02314481|Drug|Alectinib|capsule
246721|NCT02314481|Drug|Trastuzumab emtansine|Powder for concentrate for solution for infusion
246722|NCT02314468|Procedure|Negative pressure wound therapy|NPWT changed twice a week.
246723|NCT02314468|Procedure|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
246724|NCT02314455|Other|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
246725|NCT02314442|Drug|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
246726|NCT02314442|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
246727|NCT02314429|Device|Vaginal ring releasing lactic acid (racemic mixture)|
246728|NCT02314416|Biological|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix`. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
246729|NCT02314403|Drug|Belatacept|A selective T-cell (lymphocyte) costimulation blocker
246730|NCT02314403|Drug|ATG|A T-Cell Depleting Agent
246731|NCT02314403|Drug|Rituximab|B-Cell Depleting Agent
246732|NCT02314403|Radiation|Total Body Irradiation|
246733|NCT02314403|Radiation|Thymic Irradiation|
246734|NCT02314403|Procedure|Combined Bone Marrow/Kidney Transplantation|
246735|NCT02314390|Behavioral|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
246736|NCT02314390|Behavioral|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
246737|NCT02314377|Drug|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
246738|NCT02314364|Radiation|SBRT with protons or photons|
246739|NCT02314351|Drug|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
246740|NCT02314351|Drug|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
246741|NCT02314351|Drug|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
246742|NCT02314338|Other|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
246958|NCT02312557|Other|Laboratory Biomarker Analysis|Correlative studies
246743|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
246744|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
246745|NCT02314312|Drug|Everolimus + low dose cyclosporin A + prednisolone|
246746|NCT02314312|Drug|Standard immunosupressive regimen|
246747|NCT02314299|Drug|MTP-131|
246748|NCT02314286|Drug|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
246749|NCT02314286|Drug|Placebo|
246750|NCT02314273|Drug|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
246751|NCT02314260|Other|bishop score calculation|Assessment of bishop score by vaginal examination
246752|NCT02314260|Other|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
246753|NCT02314260|Other|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
246754|NCT02314260|Procedure|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
246755|NCT02314247|Drug|Selinexor|"20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment."
246756|NCT02314234|Drug|sugammadex (Bridion)|single dose of sugammadex at skin incision
246757|NCT02314221|Device|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
246758|NCT02314208|Drug|Xenbilox|
246759|NCT02314208|Dietary Supplement|Resveratrol|
246760|NCT02314208|Drug|Tahor|
246761|NCT02314195|Drug|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
246762|NCT02314195|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
246763|NCT02314195|Other|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
246764|NCT02314182|Procedure|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection~Within 3 weeks after randomization~Immunonutrition given 7 days prior to PT resection~Mechanical bowel preparation performed before surgery according to the local practices~Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)~Step 2: postoperative CT-scan~Must be performed within 4 weeks after surgery~CT-scan/MRI with the same criteria as pre-treatment evaluation~Step 3: Chemotherapy +/- target therapy~Within 4 weeks after the surgery~Chemotherapy administered according to the usual scheme for the chosen protocol~All validated and/or registered perioperative rectal cancer treatments authorized~The duration of one treatment cycle depending on the type of treatment administered~Radiotherapy is allowed after randomization if indicated"
246765|NCT02314182|Drug|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.~If complications occur, emergency surgery can be performed according to the local practices of each investigator center.~Radiotherapy is allowed after randomization if indicated (MDOC)."
246766|NCT02314169|Biological|Ipilimumab|Given IV
246767|NCT02314169|Other|Laboratory Biomarker Analysis|Correlative studies
246768|NCT02314169|Biological|Nivolumab|Given IV
246769|NCT02314156|Drug|Telapristone Acetate|Given transdermally
246770|NCT02314156|Other|Placebo|Given PO
246771|NCT02314156|Drug|Telapristone Acetate|Given PO
246772|NCT02314156|Other|Placebo|Given transdermally
246773|NCT02314156|Other|Laboratory Biomarker Analysis|Correlative studies
246774|NCT02314156|Other|Questionnaire Administration|Ancillary studies
246775|NCT02314143|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
246776|NCT02314143|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
246777|NCT02314130|Dietary Supplement|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
246778|NCT02314117|Drug|Ramucirumab|Administered IV
246779|NCT02314117|Drug|Capecitabine|Administered orally
246780|NCT02314117|Drug|Cisplatin|Administered IV
246781|NCT02314117|Drug|Placebo|Administered IV
246782|NCT02314117|Drug|Fluorouracil|Administered IV
246783|NCT02314104|Drug|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
246784|NCT02314091|Procedure|onlay mesh hernioplasty|
246785|NCT02314065|Behavioral|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
246786|NCT02314065|Behavioral|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
246787|NCT02314052|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.125mg/kg/dose~Number of cycles: until progression or unacceptable toxicity develops.~PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.~PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
246788|NCT02314026|Device|Suspected NASH BreathID test with 13C-Octanoate|Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
246789|NCT02314026|Device|Suspected NASH Breath test with 13C Methacetin|Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
246790|NCT02314013|Drug|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
246791|NCT02314000|Device|Precision or Precision Spectra Spinal Cord Stimulator System|
246792|NCT02313974|Procedure|Renal Biopsy|
246793|NCT02313961|Other|Remote ischaemic conditioning|Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
246794|NCT02313935|Other|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
246795|NCT02313935|Other|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
246796|NCT02313935|Other|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
246797|NCT02313935|Other|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
246798|NCT02313922|Drug|etanercept combined with methotrexate or etanercept combined with placebo|
246799|NCT02313909|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
246800|NCT02313909|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|100 mg, once daily, orally, tablet
246801|NCT02313909|Other|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
246802|NCT02313909|Other|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
246803|NCT02313896|Behavioral|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
246804|NCT02313883|Drug|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
246805|NCT02313870|Drug|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
246806|NCT02313870|Drug|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
246807|NCT02313857|Biological|Viralym-C|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 35 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
246808|NCT02313844|Biological|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
246809|NCT02313831|Other|Interval training|Patients of this group will be submitted to an interval training program
246810|NCT02313818|Behavioral|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
246811|NCT02313805|Other|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
246812|NCT02313792|Drug|Palifermin|
246813|NCT02313779|Behavioral|Lovingkindness Meditation (LKM)|Compassionate behavior training (REVISE)
246814|NCT02313779|Behavioral|Mindfulness Meditation|
246815|NCT02313766|Other|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
246816|NCT02313766|Other|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
246817|NCT02313753|Behavioral|CLASP|
246818|NCT02313753|Behavioral|SAFE|
246819|NCT02313740|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
246820|NCT02313727|Drug|Pamidronate|intravenous infusion of pamidronate 60 mg
246821|NCT02313727|Other|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
246822|NCT02313714|Device|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
246823|NCT02313714|Device|Sham|very low electric muscular stimulation
246824|NCT02313701|Other|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
246825|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
246826|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
246827|NCT02313675|Drug|Acetaminophen|
246828|NCT02313675|Drug|Ketorolac Tromethamine|
246829|NCT02313675|Drug|Saline|
246830|NCT02313662|Device|NBI and PDD|
246831|NCT02313623|Procedure|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
246832|NCT02313610|Drug|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
246833|NCT02313610|Drug|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
246834|NCT02313597|Procedure|VAAFT|Video assisted Anal fistula Treatment is minimal invasive method of treatment of complex and high anal fistulas.
246835|NCT02313584|Drug|dabigatran|
246836|NCT02313584|Drug|placebo|
246837|NCT02313558|Drug|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
246838|NCT02313558|Drug|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
246839|NCT02313545|Drug|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%"
246840|NCT02313519|Dietary Supplement|Probiotics|Probiotics are prepared in capsule form
246841|NCT02313519|Dietary Supplement|Placebo|Glucose powder
246842|NCT02313506|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
246843|NCT02313506|Behavioral|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
246844|NCT02313493|Behavioral|Baby Triple P|
246845|NCT02313480|Other|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
246846|NCT02313467|Drug|Topical application of 1.5% Butenyl ALA|
246847|NCT02313467|Drug|Topical application of sham control|
246848|NCT02313441|Other|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
246849|NCT02313428|Device|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
246850|NCT02313415|Procedure|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
246851|NCT02313402|Device|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
246852|NCT02313389|Drug|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
246853|NCT02313376|Biological|GAP3KO|GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
246854|NCT02313363|Device|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
246855|NCT02313350|Device|Chemonucleolysis with Discogel|
246856|NCT02313350|Procedure|open discectomy|
246857|NCT02313337|Other|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
246858|NCT02313337|Other|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
246859|NCT02313337|Other|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
246860|NCT02313337|Other|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
246861|NCT02313337|Drug|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
246862|NCT02313337|Procedure|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
246863|NCT02313337|Drug|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
246864|NCT02313324|Device|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
246865|NCT02313324|Device|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
246866|NCT02313311|Other|time-lapse imaging|Embryos are observed using time-lapse imaging (Primo Vision®). It is an incubator with a compact, sealed, and digitally inverted camera unit which can automatically acquire images.The system can record the actual developmental stage of the embryos, all the recorded images can be saved to be analyzed later using a special software program.
246867|NCT02313298|Radiation|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
246868|NCT02313272|Radiation|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
246869|NCT02313272|Drug|Pembrolizumab|"Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.~Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase."
246870|NCT02313272|Drug|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a > 10% change in weight.
246871|NCT02313259|Other|Speed discrimination test|"The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.~The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm."
246872|NCT02313259|Behavioral|Driving simulation|"25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.~Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).~A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes)."
246873|NCT02313246|Behavioral|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
246874|NCT02313233|Dietary Supplement|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
246875|NCT02313233|Dietary Supplement|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
246876|NCT02313220|Drug|Dapagliflozin|Oral use
246877|NCT02313220|Drug|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
246878|NCT02313220|Drug|Placebo|Oral and Subcutaneous use.
246879|NCT02313207|Dietary Supplement|FODMAP|patients will undergo a specific FODMAP diet for a period of 2 weeks.
246880|NCT02313194|Device|Epidural Stimulation|Determine if epidural stimulation can improve motor function
246881|NCT02313181|Other|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
246882|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
246883|NCT02313168|Other|observation, inspection|
246884|NCT02313155|Drug|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
246885|NCT02313155|Drug|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
246886|NCT02313142|Behavioral|Leg exercises|
246887|NCT02313116|Device|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
246888|NCT02313103|Drug|lofexidine HCl|400 micrograms
246889|NCT02313090|Other|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
246890|NCT02313077|Biological|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose [TCID50]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
246891|NCT02313077|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
246892|NCT02313077|Other|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
246893|NCT02313064|Drug|CXA-10|Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
246894|NCT02313064|Drug|CXA-10 placebo|
246895|NCT02313051|Drug|Everolimus|mTOR inhibitor
246896|NCT02313051|Drug|Goserelin|
246897|NCT02313051|Drug|Letrozole|
246898|NCT02313025|Other|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.~Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
246899|NCT02313025|Other|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
246900|NCT02313012|Drug|CC-90003|CC-90003 PO once daily
246901|NCT02312999|Drug|Plasmalyte|
246902|NCT02312999|Drug|Volulyte|
246903|NCT02312986|Biological|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
246904|NCT02312973|Drug|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
246905|NCT02312973|Drug|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
246906|NCT02312960|Other|Data Collection|No study treatment will be provided in this long term follow up study.
246907|NCT02312947|Device|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
246908|NCT02312947|Device|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
246909|NCT02312934|Drug|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
246910|NCT02312934|Other|Placebo Transdermal Patch|
246911|NCT02312921|Other|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
246912|NCT02312908|Drug|Clonazepam|For experimental treatment of RBD
246913|NCT02312908|Drug|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
246914|NCT02312895|Other|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
246915|NCT02312895|Other|Dry needling|Dry needling involves inserting a dry, mono-filament needle through the skin and into an area of symptomatic soft tissue. The two-inch needles will be placed segmentally and into the lower extremities following peripheral nerve patterning by the treating physical therapist. Following initial penetration into the skin over the tender area, the therapist carefully advances the needle into the tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the tender area identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the tissue for up to 5 minutes, removed, and appropriately disposed of.
246916|NCT02312895|Other|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 1x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
246917|NCT02312882|Drug|Tofacitinib|Tofacitinib 5 mg tablet taken by mouth twice a day.
246918|NCT02312869|Other|No intervention|not applicable, observational study
246919|NCT02312856|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
246920|NCT02312843|Behavioral|Exercise/Aerobic|
246921|NCT02312843|Behavioral|Exercise/Stretching|
246922|NCT02312817|Other|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:~Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.~Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
246923|NCT02312817|Other|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:~Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.~Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.~Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
246924|NCT02312804|Drug|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
246925|NCT02312804|Drug|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
246926|NCT02312804|Drug|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
246927|NCT02312778|Other|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
246928|NCT02312765|Behavioral|AirCare App|Tablet software to encourage adherence and support
246929|NCT02312752|Device|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
246930|NCT02312739|Procedure|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
246931|NCT02312739|Drug|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
246932|NCT02312739|Drug|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
246933|NCT02312739|Drug|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
246934|NCT02312739|Other|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
246935|NCT02312739|Other|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
246936|NCT02312726|Procedure|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
246937|NCT02312713|Behavioral|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
246938|NCT02312713|Behavioral|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
246939|NCT02312700|Behavioral|Interactive empowerment tool|
246940|NCT02312687|Biological|KRN23|KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
246941|NCT02312674|Dietary Supplement|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
246942|NCT02312661|Drug|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
246943|NCT02312661|Drug|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
246944|NCT02312661|Drug|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
246945|NCT02312648|Other|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
246946|NCT02312648|Other|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
246947|NCT02312635|Drug|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
246948|NCT02312635|Behavioral|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
246949|NCT02312622|Drug|Pegylated Irinotecan|Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
246950|NCT02312609|Drug|Minocycline hydrochloride|extended release tablets 135 mg
246951|NCT02312596|Device|PRP Concepts Fibrin Bio-Matrix|Application of PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
246952|NCT02312596|Other|Usual and Customary Practice|Usual and customary care for non-healing wounds
246953|NCT02312583|Behavioral|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
246954|NCT02312583|Behavioral|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.~Participants will complete the modules of a structured online programme for depression"
246955|NCT02312570|Device|PRP Concepts Fibrin Bio-Matrix|Administration of PRP Concepts Fibrin Bio-Matrix to wound in addition to usual and customary care
246956|NCT02312570|Other|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
247154|NCT02310997|Drug|Fludarabine|
246959|NCT02312557|Biological|Pembrolizumab|Given IV
246960|NCT02312544|Drug|OTX-TP|OTX-TP and placebo drops
246961|NCT02312544|Drug|Timolol|Timolol drops and placebo punctum plug
246962|NCT02312531|Drug|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
246963|NCT02312518|Device|PRP Concepts Fibrin Bio-Matrix|PRP Concepts Fibrin Bio-Matrix in addition to usual and customary practice
246964|NCT02312518|Other|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
246965|NCT02312505|Device|COPFX|cardiac Output by semi-invasive pulse contour analysis
246966|NCT02312492|Other|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
246967|NCT02312492|Other|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
246968|NCT02312492|Other|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
246969|NCT02312479|Device|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
246970|NCT02312453|Procedure|Posterior approach|We adopted the technique as described by Hebbard et al.
246971|NCT02312440|Drug|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
246972|NCT02312440|Drug|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
246973|NCT02312440|Drug|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.~60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
246974|NCT02312427|Drug|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
246975|NCT02312427|Drug|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
246976|NCT02312427|Drug|Suspending DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes may be suspended or continued. During the treatment for heart failure, drugs including DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be suspended and serum BNP before and after the suspension of DPP-4 inhibitor will be measured.
246977|NCT02312414|Drug|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
246978|NCT02312401|Device|multi-parametric MRI(MP-MRI)|
246979|NCT02312401|Device|dynamic contrast-enhanced MRI (DCE)|
246980|NCT02312401|Procedure|biopsy|
246981|NCT02312388|Other|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
246982|NCT02312388|Other|Thin-wall needle technique|using 18 - 21 G introducer needle
246983|NCT02312375|Drug|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
246984|NCT02312375|Drug|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
246985|NCT02312362|Procedure|Combined sclerotomy ab interno and phaco|
246986|NCT02312362|Procedure|Phacoemulsification with IOL implantation|
247328|NCT02309515|Other|Laboratory Biomarker Analysis|Correlative studies
246987|NCT02312336|Other|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
246988|NCT02312336|Other|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).~The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
246989|NCT02312323|Device|Definitive 65 HPT contact lenses|
246990|NCT02312323|Device|Definitive 65 contact lenses|
246991|NCT02312310|Dietary Supplement|Cocoa Flavanol|12 weeks administration of cocoa flavanol
246992|NCT02312297|Drug|Minocycline hydrochloride|extended release tablets 135 mg
246993|NCT02312271|Other|enteral formula|standard tube feeding formulas
246994|NCT02312258|Drug|Ixazomib|Ixazomib Capsules.
246995|NCT02312258|Drug|Placebo|Ixazomib placebo-matching capsules.
246996|NCT02312245|Biological|Bevacizumab|Given IV
246997|NCT02312245|Drug|Gemcitabine Hydrochloride|Given IV
246998|NCT02312245|Drug|Paclitaxel|Given IV
246999|NCT02312245|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
247000|NCT02312245|Drug|Topotecan Hydrochloride|Given IV
247001|NCT02312232|Drug|levodopa, carbidopa, ODM-104|
247002|NCT02312219|Drug|Folic Acid|1 mg folic acid once daily
247003|NCT02312219|Drug|Placebo|placebo once weekly
247004|NCT02312219|Drug|Low Dose Methotrexate|An anti-inflammatory drug
247005|NCT02312206|Drug|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
247006|NCT02312206|Other|Placebo|Placebo
247007|NCT02312180|Biological|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
247008|NCT02312167|Device|confocal laser endomicroscopy|probe-based and needle-based confocal laser endomicroscopy
247009|NCT02312154|Device|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
247010|NCT02312128|Other|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
247011|NCT02312128|Radiation|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
247012|NCT02312128|Other|Grip Strength|Grip strength measurement
247013|NCT02312128|Other|VAS Score|Measurement pain according to the visual analogue scale (VAS)
247014|NCT02312128|Other|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
247015|NCT02312115|Drug|Furosemide|Diuretic
247016|NCT02312115|Drug|Placebo|Saline
247017|NCT02312102|Drug|Lenalidomide|Chemotherapy
247018|NCT02312102|Drug|Velcade|Chemotherapy
247019|NCT02312089|Drug|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
247020|NCT02312076|Drug|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
247021|NCT02312063|Drug|Sitagliptin|
247022|NCT02312063|Drug|Glimepiride|
247023|NCT02312050|Drug|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
247024|NCT02312050|Drug|Placebo|
247025|NCT02312037|Biological|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:~Mylotarg <=9 mg/m2 as a single agent on Day 1 & 14 of a 28-day cycle for a total of two cycles~Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen~Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
247026|NCT02312024|Device|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
247027|NCT02312011|Drug|IONIS-DMPKRx|Drug
247028|NCT02312011|Drug|Placebo|Placebo
247029|NCT02311998|Drug|Bosutinib|Given PO
247030|NCT02311998|Biological|Inotuzumab Ozogamicin|Given IV
247031|NCT02311998|Other|Laboratory Biomarker Analysis|Correlative studies
247032|NCT02311985|Other|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR >1.5 or PTT >50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen <150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
247033|NCT02311985|Other|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex <80 sec. and A10ex >40 mm, then no blood transfusion is performed; when CTex >80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex <40 mm or A10fib >10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex <40 mm or A10fib <10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
247034|NCT02311985|Other|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR >5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
247035|NCT02311972|Device|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
247036|NCT02311972|Device|Standard of care feeding tube|
247037|NCT02311959|Procedure|Nipple sparing mastectomy|"Standardized surgical procedure by :~Nipple sparing mastectomy with nipple core histopathology.~Immediate breast reconstruction (flap and/or implant).~+/- lymph node evaluation (sentinel node procedure or axillary dissection)."
247329|NCT02309515|Drug|Lenalidomide|Given PO
247038|NCT02311946|Drug|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
247039|NCT02311946|Drug|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
247040|NCT02311933|Other|Laboratory Biomarker Analysis|Correlative studies
247041|NCT02311933|Other|Pharmacological Study|Correlative studies
247042|NCT02311933|Drug|Tamoxifen Citrate|Given PO
247043|NCT02311933|Drug|Z-Endoxifen Hydrochloride|Given PO
247044|NCT02311920|Biological|Ipilimumab|Given IV
247045|NCT02311920|Other|Laboratory Biomarker Analysis|Correlative studies
247046|NCT02311920|Biological|Nivolumab|Given IV
247047|NCT02311920|Drug|Temozolomide|Given PO
247048|NCT02311907|Drug|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
247049|NCT02311907|Drug|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
247050|NCT02311907|Other|Laboratory Biomarker Analysis|Correlative studies
247051|NCT02311907|Drug|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
247052|NCT02311907|Other|Placebo|Given IV
247053|NCT02311907|Other|Quality-of-Life Assessment|Ancillary studies
247054|NCT02311894|Drug|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus [+]/minus [-]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
247055|NCT02311881|Drug|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
247056|NCT02311881|Drug|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
247057|NCT02311881|Drug|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
247058|NCT02311868|Dietary Supplement|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
247059|NCT02311868|Dietary Supplement|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
247060|NCT02311855|Biological|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:~Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)~At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
247061|NCT02311829|Other|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
247062|NCT02311803|Procedure|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
247063|NCT02311803|Procedure|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
247064|NCT02311790|Dietary Supplement|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
247065|NCT02311790|Dietary Supplement|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
247066|NCT02311777|Drug|Pregabalin|Pregabalin will be given orally during preoperative period
247067|NCT02311777|Drug|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
247068|NCT02311777|Drug|Placebo|Placebo will be given orally during preoperative period
247069|NCT02311764|Drug|Carboplatin|Carboplatin will be administered weekly
247070|NCT02311751|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
247071|NCT02311738|Other|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
247072|NCT02311725|Behavioral|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
247073|NCT02311725|Behavioral|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
247074|NCT02311712|Device|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
247155|NCT02310971|Biological|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
247156|NCT02310958|Procedure|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
247370|NCT02309177|Drug|Gemcitabine|
247075|NCT02311699|Behavioral|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two‐hour session per group of participants.
247076|NCT02311686|Dietary Supplement|10 g ethanol|Alcohol single oral dose
247077|NCT02311686|Dietary Supplement|20 g ethanol|Alcohol single oral dose
247078|NCT02311686|Dietary Supplement|40 g ethanol|Alcohol single oral dose
247079|NCT02311686|Dietary Supplement|60 g ethanol|Alcohol single oral dose
247080|NCT02311686|Dietary Supplement|80 g ethanol|Alcohol single oral dose
247081|NCT02311673|Drug|RM-493|subcutaneous injection
247082|NCT02311673|Drug|Placebo|subcutaneous injection
247083|NCT02311660|Device|Vagus Nerve Stimulation Device|Cyberonics VNS System
247084|NCT02311634|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
247085|NCT02311634|Device|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
247086|NCT02311621|Biological|Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
247087|NCT02311621|Biological|Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
247088|NCT02311621|Biological|Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (long spacer 2nd generation T cells)
247089|NCT02311608|Drug|Terlipressin|administered as a first-line medicine or as salvage
247090|NCT02311608|Drug|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
247091|NCT02311608|Drug|High Dose Somatostatin/Octreotide|administered as salvage
247092|NCT02311595|Procedure|reduced port laparoscopic distal gastrectomy|
247093|NCT02311582|Biological|MK-3475|
247094|NCT02311582|Device|MRI-guided laser ablation|
247095|NCT02311582|Procedure|Surgical resection/debulking|"Optional~Standard of care"
247096|NCT02311582|Procedure|Biopsy|"If no surgical resection/debulking~Phase II patients only"
247097|NCT02311582|Procedure|Blood draw for research purposes|"Phase II patients only~Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, 36, and at the end of treatment"
247098|NCT02311582|Procedure|Cervical lymph node fine needle aspiration|"Optional~Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure"
247099|NCT02311569|Drug|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
247100|NCT02311556|Device|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
247101|NCT02311543|Drug|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
247102|NCT02311530|Drug|Felodipine|Extended Release Tablets, 10mg
247103|NCT02311530|Drug|Felodipine (Plendil®)|
247104|NCT02311517|Drug|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
247105|NCT02311517|Drug|Normal Saline|
247106|NCT02311504|Device|OCT examination|
247107|NCT02311491|Device|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
247108|NCT02311478|Device|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
247109|NCT02311465|Other|Palliative Care|"Components of the palliative care service intervention are expected to include:~Establishment of a palliative care plan~Care coordination by palliative care team~Informational, patient friendly materials supporting Palliative Care~Communication by palliative care team to all providers and teams involved in patient's care~Systematic collection of information, including identification of surrogate or health care proxy and advance care planning~Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
247110|NCT02311452|Device|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
247157|NCT02310945|Other|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
247327|NCT02309528|Other|Educational computerized digital stories|computerized digital stories made by American Indians
247111|NCT02311439|Drug|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.~In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.~Radiotherapy :~A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
247112|NCT02311426|Other|Observational study|
247113|NCT02311413|Drug|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
247114|NCT02311413|Drug|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
247115|NCT02311374|Other|Brain connectivity and physiology|fMRI to measure ADC during wake and sleep states
247116|NCT02311361|Biological|Durvalumab|10 mg/kg, mg IV, every two weeks, or 1500 mg, IV, every four weeks.
247117|NCT02311361|Biological|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
247118|NCT02311361|Radiation|Sterostatic body radiation therapy (SBRT)|8Gy x 1; 5Gy x 5
247119|NCT02311309|Other|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration >8 g/dL.
247120|NCT02311309|Other|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration < 8 g/dL.
247121|NCT02311231|Drug|bivalirudin|Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
247122|NCT02311231|Drug|Heparin|Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
247123|NCT02311218|Dietary Supplement|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
247124|NCT02311218|Dietary Supplement|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
247125|NCT02311205|Procedure|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
247126|NCT02311205|Drug|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
247127|NCT02311192|Device|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
247128|NCT02311179|Device|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
247129|NCT02311179|Device|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
247130|NCT02311153|Device|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
247131|NCT02311153|Device|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
247132|NCT02311140|Other|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
247133|NCT02311127|Device|SecurAcath|Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC
247134|NCT02311127|Device|StatLock|Device secures PICC however, device has to be changed weekly
247135|NCT02311114|Other|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
247136|NCT02311114|Other|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
247137|NCT02311114|Other|Survey|Surveys with participants will be conducted using validated survey tools.
247138|NCT02311101|Drug|Mitomycin C|Given intravesically
247139|NCT02311088|Drug|Caffeine|
247140|NCT02311088|Drug|Placebo|
247141|NCT02311075|Biological|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
247142|NCT02311062|Other|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
247143|NCT02311062|Other|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
247144|NCT02311062|Other|Control|Only soccer training
247145|NCT02311049|Radiation|Hypofractionation|
247146|NCT02311036|Other|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
247147|NCT02311023|Other|Intermittent fasting|
247148|NCT02311010|Drug|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
247149|NCT02310997|Other|Umbilical Cord Blood Transplant|
247150|NCT02310997|Drug|Cyclophosphamide|
247151|NCT02310997|Radiation|Total body irradiation|
247152|NCT02310997|Drug|Busulfan|
247153|NCT02310997|Drug|Melphalan|
247158|NCT02310932|Behavioral|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
247159|NCT02310919|Drug|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
247160|NCT02310919|Drug|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
247161|NCT02310906|Drug|Placebo|SRP-4053 placebo-matching solution for IV infusion
247162|NCT02310906|Drug|SRP-4053|SRP-4053 solution for IV infusion
247163|NCT02310893|Behavioral|Combined Contingency Management and Peer Navigation|
247164|NCT02310893|Behavioral|Contingency Management|
247165|NCT02310893|Behavioral|Peer Navigation|
247166|NCT02310867|Drug|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
247167|NCT02310867|Procedure|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
247168|NCT02310854|Procedure|ACL Repair|augmented suture of acute ACL rupture (<3 weeks after injury)
247169|NCT02310854|Procedure|ACL reconstruction|reconstruction hamstring autograft
247170|NCT02310841|Device|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
247171|NCT02310828|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
247172|NCT02310828|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
247173|NCT02310815|Device|ReSure Sealant|
247174|NCT02310802|Drug|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
247175|NCT02310802|Drug|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
247176|NCT02310802|Drug|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
247177|NCT02310802|Drug|Placebo|Placebo dispersible tablets for single oral administration
247178|NCT02310789|Drug|Ivacaftor|150mg administered orally twice daily.
247179|NCT02310789|Drug|β-Adrenergic cocktail|Administered subcutaneously to induce sweating. Cocktail composed of atropine (280µM), isoproterenol (160µM), and aminophylline (20 mM).
247180|NCT02310789|Drug|Pilocarpine Nitrate 5%|Administered subcutaneously using Macroduct sweat stimulator device.
247181|NCT02310789|Device|Macroduct sweat stimulator|
247182|NCT02310776|Device|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
247183|NCT02310776|Device|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
247184|NCT02310763|Biological|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
247185|NCT02310763|Drug|Placebo|
247186|NCT02310750|Drug|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
247187|NCT02310750|Other|Placebo|Matching placebo given during the single ascending and multiple dose periods
247188|NCT02310750|Drug|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
247189|NCT02310737|Procedure|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
247190|NCT02310737|Procedure|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
247191|NCT02310724|Other|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
247192|NCT02310711|Other|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.~Other concomitant standard of care treatment • Radiation therapy to the whole breast~o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
247193|NCT02310698|Device|contrast enhanced digital mammography (CEDM)|
247194|NCT02310698|Device|whole breast screening ultrasound (WBUS)|
247195|NCT02310685|Other|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
247196|NCT02310672|Drug|Macitentan|All patients take open-label macitentan 10mg o.d.
247197|NCT02310659|Other|No intervention|No intervention
247198|NCT02310646|Drug|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
247199|NCT02310646|Drug|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
247200|NCT02310633|Behavioral|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
247201|NCT02310633|Behavioral|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
247249|NCT02310204|Other|standard psoriasis care alone|
247202|NCT02310633|Behavioral|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
247203|NCT02310620|Behavioral|Cognitive training|regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
247204|NCT02310607|Other|Not an interventional study|Not an interventional study
247205|NCT02310594|Other|cytology specimen collection procedure|Undergo blood sample collection
247206|NCT02310594|Other|laboratory biomarker analysis|Correlative studies
247207|NCT02310581|Drug|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
247208|NCT02310581|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
247209|NCT02310568|Drug|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
247210|NCT02310555|Procedure|Gastric bypass|
247211|NCT02310555|Procedure|Modified gastric bypass.|
247212|NCT02310555|Procedure|Slevee Gastrectomy|
247213|NCT02310542|Device|MARS albumin dialysis system|
247214|NCT02310542|Device|SPAD albumin dialysis system|
247215|NCT02310529|Behavioral|Interpersonal Psychotherapy|"Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.~Intervention will be delivered by trained clinical psychologists."
247216|NCT02310516|Device|preoperative adequate explanations about awake surgery|
247217|NCT02310516|Other|no preoperative explanation|
247218|NCT02310503|Procedure|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
247219|NCT02310490|Device|DermaVeil right with left side Sculptra left side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
247220|NCT02310490|Device|DermaVeil left with left side Sculptra right side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
247221|NCT02310477|Drug|regorafenib|regorafenib for all groups
247222|NCT02310464|Drug|OBI-833/OBI-821|
247223|NCT02310451|Biological|blood test|blood test to J0-M3-M6-M12
247224|NCT02310438|Other|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
247225|NCT02310425|Drug|S. boulardii|50 mg/kg twice daily
247226|NCT02310425|Drug|Placebo|he control group (group C) did not receive S. boulardii (nor other probiotics)
247227|NCT02310412|Biological|INTERCEPT treated platelets|
247228|NCT02310399|Device|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
247229|NCT02310386|Device|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
247230|NCT02310373|Other|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
247231|NCT02310360|Radiation|Fallypride|
247232|NCT02310347|Drug|dronabinol|
247233|NCT02310347|Drug|Placebo|
247234|NCT02310334|Other|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
247235|NCT02310334|Other|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
247236|NCT02310321|Drug|gilteritinib|Once-daily oral administration on 14 consecutive days in every cycle in each period.
247237|NCT02310321|Drug|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m^2 idarubicin on 3 consecutive days.
247238|NCT02310321|Drug|Cytarabine|"Induction period: Once-daily intravenous injection of 100 mg/m^2 cytarabine on 7 consecutive days.~Consolidation period: Twice-daily intravenous injection of 1.5 g/m^2 cytarabine on Days 1, 3, and 5."
247239|NCT02310308|Dietary Supplement|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
247240|NCT02310295|Device|Laser|focal macular laser therapy
247241|NCT02310295|Drug|Bevacizumab|Intravitreal injection of Bevacizumab
247242|NCT02310295|Drug|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
247243|NCT02310282|Device|Telemedicine|In-hospital telemedicine
247244|NCT02310269|Drug|SOM230|
247245|NCT02310256|Other|Five plus exercise training|calf raise exercise
247246|NCT02310243|Drug|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
247247|NCT02310230|Device|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
247248|NCT02310204|Behavioral|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
247250|NCT02310191|Procedure|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
247251|NCT02310178|Procedure|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
247252|NCT02310165|Procedure|Z-tract Insertion Technique|
247253|NCT02310165|Procedure|Coaxial Insertion Technique|
247254|NCT02310152|Behavioral|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
247255|NCT02310152|Behavioral|CBT|Cognitive Behavioral Therapy
247256|NCT02310139|Procedure|Colonoscopy|
247257|NCT02310126|Device|etafilcon A (multi-focal)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
247258|NCT02310126|Device|etafilcon A (sphere)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
247259|NCT02310113|Other|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
247260|NCT02310100|Device|TactiCath Quartz treatment|
247261|NCT02310087|Dietary Supplement|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
247262|NCT02310087|Other|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
247263|NCT02310074|Drug|Pulsatile Gonadotropin Releasing Hormone|
247264|NCT02310074|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
247265|NCT02310074|Drug|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
247266|NCT02310061|Procedure|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
247267|NCT02310061|Other|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
247268|NCT02310048|Drug|MT-1303-FormA|
247269|NCT02310048|Drug|MT-1303-FormB|
247270|NCT02310022|Drug|Drug Omega 3|4 g (4 capsules) once a day, administered with food
247271|NCT02310022|Drug|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
247272|NCT02310009|Drug|Anakinra (AN)|
247273|NCT02310009|Behavioral|Exercise (EX)|
247274|NCT02310009|Behavioral|Control (CON)|
247275|NCT02309996|Behavioral|Supervisor Training Program|
247276|NCT02309983|Other|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
247277|NCT02309983|Other|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
247278|NCT02309970|Drug|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
247279|NCT02309970|Drug|alteplase|subject in this group will receive intravenous tPA
247280|NCT02309970|Procedure|endovascular|
247281|NCT02309957|Device|BioMatrix CRD|
247282|NCT02309944|Procedure|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if >2 cm deep, followed by staple or suture closure of the skin.
247283|NCT02309944|Device|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
247284|NCT02309931|Procedure|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
247285|NCT02309931|Procedure|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
247286|NCT02309918|Drug|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
247287|NCT02309905|Device|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
247288|NCT02309892|Drug|L-DOS47|A treatment cycle will be 21 days, with patients receiving L DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
247289|NCT02309879|Drug|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
247290|NCT02309879|Drug|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
247291|NCT02309879|Drug|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
247326|NCT02309541|Device|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
247292|NCT02309879|Drug|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
247293|NCT02309866|Genetic|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
247294|NCT02309853|Other|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.~Visual or tactile scanning in the personal space~Visual or tactile scanning and trunk rotation in the peripersonal space~Visual scanning and trunk rotation in the extrapersonal space"
247295|NCT02309853|Other|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
247296|NCT02309840|Behavioral|choice architecture|"Place vegetables at the beginning of the lunch line.~Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.~Promote fruits and vegetables with prominently displayed signage and images.~Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
247297|NCT02309840|Other|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
247298|NCT02309827|Drug|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
247299|NCT02309814|Device|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
247300|NCT02309801|Dietary Supplement|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
247301|NCT02309801|Dietary Supplement|Alcohol|Alcohol single oral dose
247302|NCT02309775|Other|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
247303|NCT02309762|Drug|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
247304|NCT02309762|Drug|Placebo|Solution containing no active ingredients
247305|NCT02309749|Other|CAP|
247306|NCT02309736|Device|ReSure Sealant|
247307|NCT02309723|Device|Beta amyloid imaging|
247308|NCT02309710|Device|ShangRing|ShangRing administered to males seeking medical male circumcision
247309|NCT02309671|Drug|FE 999049|
247310|NCT02309671|Drug|follitropin beta|
247311|NCT02309658|Drug|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
247312|NCT02309658|Drug|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
247313|NCT02309658|Radiation|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
247314|NCT02309645|Biological|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
247315|NCT02309645|Other|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
247316|NCT02309632|Other|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
247317|NCT02309632|Other|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
247318|NCT02309619|Procedure|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
247319|NCT02309606|Other|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
247320|NCT02309593|Device|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
247321|NCT02309580|Drug|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
247322|NCT02309567|Other|Blood Collection|
247323|NCT02309554|Other|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
247324|NCT02309554|Other|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
247325|NCT02309554|Other|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
247330|NCT02309515|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
247331|NCT02309502|Device|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session~Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%~Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
247332|NCT02309502|Device|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
247333|NCT02309489|Behavioral|Partner involvement|Partner is involved in maternity care
247334|NCT02309476|Device|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
247335|NCT02309476|Device|PASCAL Laser, Green Laser 1|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
247336|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
247337|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
247338|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
247339|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
247340|NCT02309463|Drug|Endothelin receptor antagonist therapy|
247341|NCT02309450|Drug|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
247342|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
247343|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
247344|NCT02309424|Dietary Supplement|Vinegar|0,50mmol vinegar (6% acetic acid)
247345|NCT02309424|Other|Placebo|50 ml water
247346|NCT02309411|Drug|Rivaroxaban (Xarelto, BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
247347|NCT02309385|Drug|8% Dexamethasone Sodium Phosphate - Visulex|
247348|NCT02309385|Drug|15% Dexamethasone Sodium Phosphate - Visulex|
247349|NCT02309385|Drug|Prednisolone Acetate (1%) Eye Drops|
247350|NCT02309372|Behavioral|Beating the Blues|Computerized depression treatment intervention
247351|NCT02309359|Biological|ALX-0061|
247352|NCT02309359|Other|Placebo|
247353|NCT02309359|Drug|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
247354|NCT02309346|Drug|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
247355|NCT02309320|Biological|ALX-0171|
247356|NCT02309320|Other|Placebo|
247357|NCT02309307|Device|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
247358|NCT02309294|Device|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
247359|NCT02309294|Device|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
247360|NCT02309294|Device|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
247361|NCT02309294|Device|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
247362|NCT02309294|Device|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
247363|NCT02309281|Drug|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
247364|NCT02309255|Other|no intervention|
247365|NCT02309242|Behavioral|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
247366|NCT02309216|Other|Whol-Body MRI scan|
247367|NCT02309203|Device|FRED|Flow Re-Direction Endoluminal Device
247368|NCT02309177|Drug|nab-Paclitaxel|
247369|NCT02309177|Drug|Nivolumab|
247372|NCT02309164|Procedure|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
247373|NCT02309164|Behavioral|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
247374|NCT02309151|Procedure|Immediate coronary angiography|Immediate coronary angiography for out of hospital cardiac arrest patients with no signs of ST elevation on their first ECG after ROSC
247375|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
247376|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
247377|NCT02309125|Procedure|immediate progressive loading using gingival formers|"Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.~The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm)."
247378|NCT02309125|Procedure|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
247379|NCT02309112|Other|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
247380|NCT02309099|Device|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
247381|NCT02309086|Biological|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
247382|NCT02309060|Behavioral|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
247383|NCT02309034|Behavioral|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
247384|NCT02309034|Behavioral|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
247385|NCT02309034|Other|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
247386|NCT02309021|Other|Sport|
247387|NCT02309021|Other|Non-sport activities|
247388|NCT02309008|Drug|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
247389|NCT02309008|Other|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
247390|NCT02308995|Procedure|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
247391|NCT02308995|Procedure|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
247392|NCT02308995|Device|V-Loc (Covidien, Mansfield, MA)|
247393|NCT02308995|Device|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
247394|NCT02308982|Drug|Immunoglobulins, Intravenous (Privigen)|
247395|NCT02308982|Drug|Placebo|
247396|NCT02308969|Drug|LSD|100ug per os, single dose
247397|NCT02308969|Drug|Placebo|Capsules containing mannitol looking identical to LSD
247398|NCT02308956|Behavioral|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
247399|NCT02308956|Behavioral|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
247400|NCT02308930|Dietary Supplement|Vitamins + DHA supplement (Vitamins A,D, E and algal oil)|
247401|NCT02308930|Dietary Supplement|Vitamins supplement (Vitamins A,D, E and corn oil)|
247402|NCT02308904|Other|Blood Draw/Semen Exam|"Females:~1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.~Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.~Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
247403|NCT02308904|Other|Retrospective data/Chart Review/Relevant Clinical Results|"1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2* MRI. 4. Ferritin levels.~NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.~1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.~1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).~Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
247434|NCT02308618|Other|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
247515|NCT02308059|Other|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
247516|NCT02308046|Drug|Terconazole|
247404|NCT02308904|Other|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.~MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
247405|NCT02308891|Drug|lactated Ringer's solution (vigorous hydration arm)|"Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
247406|NCT02308891|Drug|lactated Ringer's solution (standard hydration arm)|- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
247407|NCT02308891|Device|endoscopic retrograde cholangiopancreatography (ERCP)|endoscopic retrograde cholangiopancreatography
247408|NCT02308878|Behavioral|Mobile health cognitive stimulation|
247409|NCT02308865|Other|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
247410|NCT02308852|Device|tDCS|
247411|NCT02308839|Device|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
247412|NCT02308826|Behavioral|Turtle Program|
247413|NCT02308826|Behavioral|Cool Little Kids|
247414|NCT02308813|Other|Braking and functionality|
247415|NCT02308800|Device|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
247416|NCT02308800|Device|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
247417|NCT02308787|Device|Spectra Optia Apheresis System|Platelet Depletion
247418|NCT02308761|Drug|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
247419|NCT02308748|Drug|Dofetilide|"8 am: Placebo~12 pm (noon): 250 µg~5:30 pm: 250 µg"
247420|NCT02308748|Drug|Mexiletine|"8 am: weight x 4 mg/kg~12 pm (noon): Same as at 8 am~5:30 pm: Same as at 8 am"
247421|NCT02308748|Drug|Lidocaine|"9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
247422|NCT02308748|Drug|Moxifloxacin|"9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
247423|NCT02308748|Drug|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
247424|NCT02308748|Drug|Placebo|Placebo (#2 Gelcap or IV saline)
247425|NCT02308735|Other|N/A - No intervention|
247426|NCT02308722|Radiation|5-fraction stereotactic body radiation therapy|"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.~Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.~Level -1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)~Level 1:~Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)~Level 2:~Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)~Level 3:~Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)"
247427|NCT02308709|Radiation|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
247428|NCT02308696|Behavioral|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
247429|NCT02308696|Behavioral|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
247430|NCT02308683|Dietary Supplement|Moringa oleifera|12 weeks supplementation
247431|NCT02308644|Drug|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
247432|NCT02308631|Procedure|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
247433|NCT02308618|Other|Traditional Immobilization|"After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed~The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises"
247517|NCT02308046|Drug|Placebo|
247518|NCT02308033|Drug|Metronidazole|
247519|NCT02308033|Drug|Gel vehicle|
247435|NCT02308605|Device|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
247436|NCT02308592|Behavioral|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:~Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;~(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and~A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
247437|NCT02308592|Behavioral|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).~Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
247438|NCT02308566|Procedure|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
247439|NCT02308566|Procedure|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
247440|NCT02308553|Drug|Nintedanib|Nintedanib (150 mg or 200 mg BID)
247441|NCT02308553|Drug|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
247442|NCT02308553|Drug|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
247443|NCT02308540|Biological|SIILPCV10|10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate [alum]) and preservative (thiomersal).
247444|NCT02308540|Biological|Pneumovax 23|23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
247445|NCT02308540|Biological|Prevenar 13|13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
247446|NCT02308527|Drug|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
247447|NCT02308527|Drug|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
247448|NCT02308527|Drug|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
247449|NCT02308527|Drug|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
247450|NCT02308527|Drug|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
247451|NCT02308527|Drug|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
247452|NCT02308527|Drug|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
247453|NCT02308514|Device|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
247454|NCT02308514|Other|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
247455|NCT02308501|Drug|Lastacaft ®|
247456|NCT02308501|Drug|Tears Naturale ®|
247457|NCT02308488|Drug|Radiation|Whole breast/chest wall, level 1- III (includes Cohort A) and SCV nodes IMRT at 2.7 Gy x 15 fractions. The treatment will consist of 15 fractions, with one fraction daily for five days a week, for 3 consecutive weeks.
247458|NCT02308475|Device|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
247459|NCT02308462|Behavioral|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).~The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid & Plass, 2011)."
247460|NCT02308449|Drug|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
247461|NCT02308449|Drug|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
247462|NCT02308436|Device|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries & acidic challenges
247463|NCT02308423|Radiation|XR of shoulder|Radiologic examination: Axial view, Axillary view and Anterior posterior view- to evaluate the level of osteoarthritis by Kellgren Lawrence score and Samilson score.
247464|NCT02308410|Procedure|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
247465|NCT02308397|Other|Normal gluten containing bread|Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
247466|NCT02308397|Other|Bread with reduced gliadins content|Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
247467|NCT02308397|Other|Bread with reduced ATIs content|Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
247468|NCT02308397|Other|Bread with reduced overall protein content|Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
247469|NCT02308384|Behavioral|Intervention|CME, Start-package and status mail
247514|NCT02308059|Other|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
247470|NCT02308371|Device|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
247471|NCT02308345|Other|Pre-chemotherapy visit summary Video|
247472|NCT02308332|Drug|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
247473|NCT02308319|Drug|Tenofovir disoproxil fumarate|300mg q.d. per oral
247474|NCT02308293|Behavioral|High intensity exercise|3x30 seconds 'all out' sprints
247475|NCT02308293|Behavioral|Lay down comfortably|rest
247476|NCT02308280|Drug|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
247477|NCT02308267|Other|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
247478|NCT02308267|Other|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
247479|NCT02308267|Procedure|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
247480|NCT02308254|Drug|Lixisenatide|Abdominal administration
247481|NCT02308254|Drug|Placebo|Abdominal administration
247482|NCT02308241|Drug|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
247483|NCT02308228|Behavioral|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
247484|NCT02308228|Drug|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
247485|NCT02308202|Drug|doxazosin|
247486|NCT02308202|Drug|Perindopril|
247487|NCT02308202|Drug|Placebo|
247488|NCT02308189|Behavioral|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
247489|NCT02308189|Behavioral|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
247490|NCT02308176|Behavioral|APP + health advice|health advice and reinforcement to it
247491|NCT02308176|Behavioral|health advice|health advice
247492|NCT02308163|Drug|peficitinib|oral
247493|NCT02308163|Drug|Placebo|oral
247494|NCT02308163|Biological|Etanercept|subcutaneous injection
247495|NCT02308150|Device|transcatheter aortic valve replacement|
247496|NCT02308137|Drug|Domperidone|Simon-2-stage design for domperidone futility
247497|NCT02308124|Drug|Midodrine|
247498|NCT02308124|Drug|Pyridostigmine Bromide|
247499|NCT02308124|Drug|Midodrine + pyridostigmine|
247500|NCT02308111|Drug|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as Child-Pugh Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of patients).~Cirrhotic and classified as Child-Pugh Class B and C: 5 mg tablet of OCA once weekly for at least 3 months, subsequently titrating up to a maximum dose and frequency of 10 mg OCA twice weekly based on tolerability and biochemical response for the duration of the study."
247501|NCT02308111|Drug|Placebo|One tablet daily (or a lower frequency depending on Child Pugh score) for the remainder of the study
247502|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
247503|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
247504|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
247505|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
247506|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
247507|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
247508|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
247509|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
247510|NCT02308085|Other|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.~Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
247511|NCT02308072|Drug|Olaparib|50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
247512|NCT02308072|Drug|Cisplatin|35 mg/m^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m^2)
247513|NCT02308072|Radiation|IMRT|2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
247520|NCT02308020|Drug|Abemaciclib|Administered orally
247521|NCT02308007|Drug|Terconazole|
247523|NCT02308007|Drug|Terconazole/metronidazole|
247524|NCT02307994|Drug|75IU uFSH|
247525|NCT02307981|Other|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
247526|NCT02307968|Other|insulin injection site|insulin injected site between inner thigh and out thigh
247527|NCT02307955|Device|firefly|
247528|NCT02307955|Other|Standard of care|
247529|NCT02307942|Procedure|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
247530|NCT02307916|Drug|FGF-2|The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
247531|NCT02307916|Other|Placebo|Placebo comparator using a sterile saline solution.
247532|NCT02307864|Drug|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
247533|NCT02307864|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
247534|NCT02307864|Drug|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
247535|NCT02307864|Drug|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
247536|NCT02307851|Biological|Quadrivalent VLP Vaccine|
247537|NCT02307851|Biological|Comparator TIV|
247538|NCT02307838|Other|Assessments arm|Protocol required assessments not provided in standard of care
247539|NCT02307825|Drug|Azithromycin|The drug will be taken three times a week for four months.
247540|NCT02307825|Drug|Placebo|The placebo will be taken three times a week for four months.
247541|NCT02307812|Drug|Ramucirumab|Administered intravenously (IV)
247542|NCT02307812|Drug|Paclitaxel|Administered IV
247543|NCT02307773|Drug|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
247544|NCT02307760|Other|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
247545|NCT02307760|Other|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
247546|NCT02307747|Other|blood samples|Blood samples will be collected every 4 hours during 24 h
247547|NCT02307734|Behavioral|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
247548|NCT02307734|Behavioral|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
247549|NCT02307721|Drug|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
247550|NCT02307721|Drug|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
247551|NCT02307721|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
247552|NCT02307721|Device|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
247553|NCT02307708|Device|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).~The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.~During the walk we will have:~In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).~In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
247554|NCT02307708|Other|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
247555|NCT02307695|Drug|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
247556|NCT02307695|Drug|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
247557|NCT02307682|Drug|Brolucizumab ophthalmic solution|Ophthalmic solution for IVT injection
247558|NCT02307682|Drug|Aflibercept ophthalmic solution|Ophthalmic solution for IVT injection
247559|NCT02307669|Behavioral|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
247589|NCT02307474|Radiation|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
247653|NCT02307097|Procedure|Cognitive-Behavioural Bibliotherapy|
247560|NCT02307669|Behavioral|Usual Care|"The core features of the usual care group are:~The patient's inhaler technique will be checked using a checklist, at each visit. If there are errors these will be corrected using teach-to-goal principals.~Adherence will be discussed and barriers to adherence addressed, using motivational interview techniques.~Written action plans for managing asthma, based on changes in PEF and symptoms will be given.~In follow up, medication changes in response to the above will be directed by these, as suggested by Guidelines."
247561|NCT02307656|Drug|Atazanavir|
247562|NCT02307656|Drug|Cobicistat|
247563|NCT02307656|Drug|Active Pharmaceutical Ingredient|
247564|NCT02307643|Drug|MT-1303 Low dose|
247565|NCT02307643|Drug|MT-1303 High dose|
247566|NCT02307630|Biological|124I-Humanized 3F8|
247567|NCT02307604|Genetic|Tumour markers testing|
247568|NCT02307591|Drug|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
247569|NCT02307591|Drug|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .~During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).~Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.~Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.~Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).~Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:~Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)~Children < 29 kg: 5 mg/kg 3 times a day"
247570|NCT02307578|Drug|Perampanel|Perampanel will be available in 2-milligrams (mg), 4-mg and 8-mg tablets and as 0.5 milligram per milliliter (mg/mL) oral suspension. Participants will start this EAP with the dose that they were receiving at the end of their participation in Study 332, Study 311, or EAP 401. Doses of perampanel can be adjusted based on clinical judgment.
247571|NCT02307565|Drug|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
247572|NCT02307565|Drug|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
247573|NCT02307552|Device|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
247574|NCT02307539|Procedure|Psychosocial Assessment and Care|Undergo PCPI
247575|NCT02307539|Other|Palliative Therapy|Undergo PCPI
247576|NCT02307539|Other|Quality-of-Life Assessment|Undergo QOL assessment
247577|NCT02307539|Other|Questionnaire Administration|Undergo questionnaire administration
247578|NCT02307526|Drug|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
247579|NCT02307526|Device|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
247580|NCT02307513|Drug|Apremilast|Patients randomized to this arm will receive 30 mg apremilast tablets twice daily by mouth for 64 weeks.
247581|NCT02307513|Drug|Placebo|Patients randomized to this arm received placebo tablets twice daily by mouth for the first twelve weeks. Upon completion of the Week 12 visit, participants were switched to 30 mg apremilast tablets twice daily by mouth and continued the assigned dose for the 52-week active treatment phase.
247582|NCT02307500|Drug|Regorafenib|oral therapy
247583|NCT02307487|Drug|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
247584|NCT02307487|Drug|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
247585|NCT02307487|Drug|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
247586|NCT02307487|Drug|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
247587|NCT02307487|Drug|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
247588|NCT02307487|Drug|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
247590|NCT02307474|Drug|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
247591|NCT02307461|Drug|IPI-145 (duvelisib)|High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
247592|NCT02307461|Drug|IPI-145|Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose
247593|NCT02307461|Drug|IPI-145|High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
247594|NCT02307448|Procedure|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
247595|NCT02307448|Procedure|Standard of Care|Patients will receive weekly standard of care.
247596|NCT02307435|Biological|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
247597|NCT02307422|Genetic|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
247598|NCT02307409|Other|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
247599|NCT02307396|Drug|Olanzapine|
247600|NCT02307396|Drug|Amisulpride|
247601|NCT02307396|Drug|Risperidone|
247602|NCT02307396|Drug|Haloperidol|
247603|NCT02307396|Drug|Quetiapine|
247604|NCT02307396|Drug|Perphenazine|
247605|NCT02307396|Drug|Sulpiride|
247606|NCT02307396|Drug|bromperidol|
247607|NCT02307396|Drug|Zuclopenthixol|
247608|NCT02307396|Drug|Thioridazine|
247609|NCT02307396|Drug|Paliperidone|
247610|NCT02307396|Drug|Ziprasidone|
247611|NCT02307396|Drug|Benperidol|
247612|NCT02307396|Drug|Fluspirilene|
247613|NCT02307396|Drug|Pimozide|
247614|NCT02307396|Drug|Perazine|
247615|NCT02307396|Drug|Fluphenazine|
247616|NCT02307396|Drug|Flupentixole|
247617|NCT02307396|Drug|Sertindole|
247618|NCT02307383|Drug|Lactitol|
247619|NCT02307383|Drug|Lactobacillus|
247620|NCT02307370|Device|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
247621|NCT02307357|Behavioral|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
247622|NCT02307344|Dietary Supplement|Nigella Sativa|
247623|NCT02307344|Dietary Supplement|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
247624|NCT02307331|Device|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
247625|NCT02307331|Device|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
247626|NCT02307331|Device|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
247627|NCT02307331|Device|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
247628|NCT02307331|Device|Sirius stem|A polished tapered stem
247629|NCT02307318|Device|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
247630|NCT02307305|Drug|Duloxetine|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)~Phase II (titration): POD#1~6 (30mg for another 6 days)~Phase III (maintenance): POD#7~13(60mg for 7 days)~Phase IV (tapering-1): POD#14~20 (30mg for 7 days)~Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)"
247631|NCT02307305|Drug|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
247632|NCT02307292|Device|POLARIS Peripheral Vascular Self Expanding Stent System|
247633|NCT02307279|Device|Gelesis100|
247634|NCT02307279|Device|placebo|
247635|NCT02307266|Behavioral|Standard of care + supplementary education|
247636|NCT02307266|Behavioral|Standard of care + additional visits|
247637|NCT02307266|Behavioral|Standard of care|
247638|NCT02307253|Device|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
247639|NCT02307240|Drug|CUDC-907|CUDC-907 oral with meals.
247640|NCT02307227|Drug|Trastuzumab|
247641|NCT02307227|Drug|Paclitaxel|
247642|NCT02307227|Drug|Epirubicin|
247643|NCT02307227|Drug|Docetaxel|
247644|NCT02307214|Other|BaroReflex Sensitivity, endothelial function measurement|no other
247645|NCT02307201|Drug|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
247646|NCT02307188|Device|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
247647|NCT02307162|Drug|RPL554|Phosphodiesterase 3 and 4 Inhibitor
247648|NCT02307162|Drug|Placebo|Dummy solution
247649|NCT02307149|Biological|CAVATAK|CAVATAK is a preparation of CVA21
247650|NCT02307149|Drug|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
247651|NCT02307123|Procedure|Intubation|HEMS physician prehospital intubation
247652|NCT02307110|Other|cross-sectional observation|cross-sectional opthalmic examination
247654|NCT02307097|Procedure|Cognitive-Behavioural Therapy|
247655|NCT02307097|Other|WAIT|
247656|NCT02307084|Procedure|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
247657|NCT02307071|Device|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
247658|NCT02307058|Radiation|LEAD RT|LEAD RT: Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over ~8 weeks. The multiparametric-MRI (MP-MRI) defined gross tumor volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SVs, usually 7-10 mm and/or <= 50%, whichever is less), the CTV1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full IMRT dose of 76 Gy, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
247659|NCT02307058|Radiation|HEIGHT RT|HEIGHT RT: Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 38 fractions over ~7.5 weeks. The MRI defined GTV will receive a higher dose per day than the clinical tumor volume (CTV) by dose painting. The GTV will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles CTV1 will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full IMRT dose of 76 Gy, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
247660|NCT02307058|Behavioral|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) will be administered pretreatment, at the end of treatment and at each follow-up visit.
247661|NCT02307058|Behavioral|Memorial Anxiety Scale for Prostate Cancer patients|Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Quality of Life questionnaire - Recommended after enrollment and prior to fiducial marker placement, as well as during the last week of treatment, and post-RT at 3 mo, 9 mo and then yearly to 5.25 years.
247662|NCT02307058|Behavioral|Expanded Prostate Cancer Index Composite-Short Form 12|Expanded Prostate Cancer Index Composite-Short Form 12 (EPIC SF-12) Quality of Life questionnaire - Recommended after enrollment and prior to fiducial marker placement, as well as during the last week of treatment, and post-RT at 3 mo, 9 mo and then yearly to 5.25 years.
247663|NCT02307045|Drug|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
247664|NCT02307045|Drug|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
247665|NCT02307019|Other|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
247666|NCT02307019|Other|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
247667|NCT02307006|Drug|Ceftaroline|Surgical prophylaxis
247668|NCT02307006|Drug|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
247669|NCT02306993|Other|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
247670|NCT02306993|Other|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
247671|NCT02306993|Other|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
247672|NCT02306980|Other|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
247673|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected.
247674|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected
247675|NCT02306954|Biological|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
247676|NCT02306954|Radiation|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
247677|NCT02306941|Behavioral|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
247678|NCT02306928|Other|Blood draw|
247679|NCT02306915|Drug|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
247680|NCT02306902|Drug|fenofibrate|130mg, Capsules
247681|NCT02306902|Drug|ANTARA® (fenofibrate)|130mg, Capsules
247682|NCT02306889|Drug|Fenofibrate|130mg Capsules
247683|NCT02306889|Drug|ANTARA® (fenofibrate)|130mg Capsules
247684|NCT02306876|Drug|PF-06412562 3mg BID|PF-06412562
247685|NCT02306876|Drug|PF-06412562 15mg BID|PF-06412562
247686|NCT02306876|Other|Placebo|Placebo
247687|NCT02306863|Device|vibrating chair|vibration provided via physioacoustic method
247688|NCT02306863|Device|sham treatment|simulated whole-body vibration
247689|NCT02306850|Drug|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
247690|NCT02306837|Drug|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
247691|NCT02306811|Drug|Vatelizumab|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
247692|NCT02306798|Drug|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
247693|NCT02306785|Drug|TP05 Coating D|One radio-labelled tablet given to subjects
247694|NCT02306785|Drug|TP05 Coating E|One radio-labelled tablet given to subjects
247695|NCT02306785|Drug|TP05 Coating H|One radio-labelled tablet given to subjects
247696|NCT02306772|Drug|TP05 Coating A|One radio-labelled tablet given to subjects
247697|NCT02306772|Drug|TP05 Coating B|One radio-labelled tablet given to subjects
247698|NCT02306759|Drug|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
247699|NCT02306759|Drug|Placebo|Normal saline 50ml, administered over 15 minutes
247700|NCT02306746|Dietary Supplement|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
247701|NCT02306746|Dietary Supplement|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
247702|NCT02306733|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
247703|NCT02306733|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
247704|NCT02306707|Procedure|Endoscopic Mucosal Resection|
247705|NCT02306694|Drug|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
247706|NCT02306681|Other|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
247707|NCT02306629|Biological|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
247708|NCT02306629|Biological|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
247709|NCT02306603|Procedure|Endoscopic Mucosal Resection|
247710|NCT02306590|Dietary Supplement|Calogen|
247711|NCT02306590|Dietary Supplement|Placebo|
247712|NCT02306577|Drug|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
247713|NCT02306564|Drug|Cabergoline|given to patients at high risk for OHSS
247714|NCT02306551|Other|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
247715|NCT02306525|Procedure|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
247716|NCT02306512|Procedure|H&E|Sample will be stained with H&E according to standard procedures
247717|NCT02306512|Procedure|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
247718|NCT02306512|Procedure|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
247719|NCT02306512|Procedure|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
247720|NCT02306499|Procedure|ICSI|Intracytoplasmic Sperm Injection
247721|NCT02306486|Other|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
247722|NCT02306473|Drug|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
247723|NCT02306447|Device|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.~rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.~For stimulation we use MagPro X100 (Medtronic, Denmark)."
247724|NCT02306434|Behavioral|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
247725|NCT02306434|Other|Standard care-counselling|Standard care (Counselling by midwives)
247726|NCT02306421|Procedure|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
247727|NCT02306421|Procedure|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
247728|NCT02306421|Procedure|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
247729|NCT02306421|Procedure|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
247730|NCT02306421|Procedure|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
247731|NCT02306395|Procedure|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
247732|NCT02306382|Procedure|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
247733|NCT02306382|Device|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
247734|NCT02306369|Behavioral|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
247735|NCT02306356|Behavioral|Internet-delivered Cognitive Behavior Therapy|
247736|NCT02306343|Device|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
247737|NCT02306330|Device|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
247738|NCT02306330|Other|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
247739|NCT02306317|Other|Standard procedure|FiO2 manually controlled by nursing
247740|NCT02306317|Other|Experimental procedure|FiO2 manually controlled by parents, after training.
247741|NCT02306304|Other|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
247742|NCT02306291|Drug|GMI-1271|E-selectin antagonist
247743|NCT02306291|Drug|Mitoxantrone|induction chemotherapy
247744|NCT02306291|Drug|Etoposide|induction chemotherapy
247745|NCT02306291|Drug|Cytarabine|induction chemotherapy
247746|NCT02306291|Drug|Idarubicin|induction chemotherapy
247747|NCT02306278|Drug|gabapentin|gabapentin capsules 0.3g
247748|NCT02306278|Drug|vitamin capsules|vitamin B
247749|NCT02306265|Device|FFDM|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
247750|NCT02306265|Device|DBT|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
247751|NCT02306252|Other|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
247752|NCT02306239|Drug|Terlipressin|
247753|NCT02306239|Drug|Norepinephrine|
247754|NCT02306213|Drug|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
247755|NCT02306213|Other|standard volume therapy|
247756|NCT02306187|Drug|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
247757|NCT02306174|Behavioral|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|
247758|NCT02306161|Drug|Cyclophosphamide|Given IV
247759|NCT02306161|Drug|Doxorubicin|Given IV
247760|NCT02306161|Drug|Doxorubicin Hydrochloride|Given IV
247761|NCT02306161|Drug|Etoposide|Given IV
247762|NCT02306161|Drug|Etoposide Phosphate|Given IV
247763|NCT02306161|Radiation|External Beam Radiation Therapy|Undergo EBRT
247764|NCT02306161|Biological|Ganitumab|Given IV
247765|NCT02306161|Drug|Ifosfamide|Given IV
247766|NCT02306161|Radiation|Stereotactic Radiosurgery|Undergo SBRT
247767|NCT02306161|Procedure|Therapeutic Surgical Procedure|Undergo surgery
247768|NCT02306161|Drug|Vincristine|Given IV
247769|NCT02306161|Drug|Vincristine Sulfate|Given IV
247770|NCT02306148|Other|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
247771|NCT02306135|Other|n/a- this is an observational study|
247772|NCT02306122|Behavioral|Pharmacist calls patient unless physician cancels call|
247773|NCT02306122|Behavioral|Patient nonadherence information sent to physician|
247774|NCT02306122|Behavioral|Pharmacist calls patient if physician requests call|
247775|NCT02306122|Behavioral|Patient HMO/PPO status revealed to physician|
247776|NCT02306109|Procedure|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
247777|NCT02306109|Procedure|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
247778|NCT02306083|Drug|Placebo three times a day|
247779|NCT02306083|Drug|glucosamine sulfate 1500 mg three times a day|
247780|NCT02306070|Drug|Metformin|metformin treatment + standard of care dietary and exercise advice
247781|NCT02306070|Drug|No metformin treatment|no metformin treatment + standard of care dietary and exercise advice
247782|NCT02306057|Procedure|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
247783|NCT02306057|Procedure|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
247784|NCT02306057|Procedure|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
247785|NCT02306057|Procedure|TCPC|Surgical procedure Total CavoPulmonary Connection
247786|NCT02306031|Drug|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
247787|NCT02306031|Drug|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
247788|NCT02306018|Device|EV1000™/volumeView™|
247789|NCT02305992|Procedure|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
247790|NCT02305992|Procedure|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
247791|NCT02305992|Procedure|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
247792|NCT02305979|Drug|Loratadine|
247793|NCT02305966|Procedure|surgery|All patients will receive a Delta XTEND reverse shoulder implant
247794|NCT02305966|Device|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
247795|NCT02305940|Drug|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
247796|NCT02305940|Drug|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
247797|NCT02305927|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
247798|NCT02305927|Other|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
247799|NCT02305901|Drug|repaglinide|single dose on day 1 of visits 2 and 3
247800|NCT02305901|Drug|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
247801|NCT02305901|Drug|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
247802|NCT02305888|Drug|LEO 43204|Treatment of actinic keratosis
247803|NCT02305875|Other|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
247804|NCT02305862|Drug|Rosuvastatin 5mg|drug intervention
247805|NCT02305862|Drug|Rosuvastatin 20mg|drug intervention
247806|NCT02305849|Drug|Peficitinib|Oral tablet
247807|NCT02305849|Drug|Placebo|Oral tablet
247808|NCT02305849|Drug|Methotrexate|Oral tablet/capsule
247809|NCT02305836|Procedure|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
247810|NCT02305836|Drug|donepezil|cholinesterase inhibitors (ChE-Is)
247811|NCT02305823|Drug|Aripiprazole|
247812|NCT02305823|Drug|Quetiapine|
247813|NCT02305823|Drug|Ziprasidone|
247814|NCT02305810|Drug|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
247815|NCT02305797|Drug|Extended-release lorazepam|Extended-release lorazepam capsules
247816|NCT02305797|Drug|Placebo|Placebo capsules
247817|NCT02305771|Device|Electroencephalography|
247818|NCT02305771|Device|MRI|
247819|NCT02305758|Drug|Veliparib|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
247820|NCT02305758|Drug|Placebo|200 mg oral dose beginning 2 days prior to the start of FOLFIRI and continuing twice a day (BID) for a total of 7 consecutive days
247821|NCT02305758|Drug|Modified FOLFIRI|Irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and saline bolus (up to 15-minute infusion) on Day 1 of each 14-day cycle
247822|NCT02305758|Drug|FOLFIRI|Irinotecan 180 mg/m^2 (90-minute infusion ± 30 minutes); leucovorin 400 mg/m^2 (90-minute infusion ± 30 minutes); and fluorouracil bolus 400 mg/m^2 (up to 15-minute infusion) on Day 1 of each 14-day cycle
247823|NCT02305758|Drug|Bevacizumab|At the discretion of the Investigator, 5 mg/kg may be administered intravenously immediately preceding FOLFIRI dosing
247824|NCT02305758|Drug|Fluorouracil infusion|2400 mg/m^2 (46-hour continuous infusion ± 4 hours) starting on Day 1 of each 14-day cycle
247825|NCT02305745|Other|Observational|
247826|NCT02305732|Biological|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
247827|NCT02305706|Procedure|starting position in colonoscopy|
247828|NCT02305693|Drug|Letrozole|
247829|NCT02305693|Procedure|Laparoscopic ovarian drilling|
247830|NCT02305667|Device|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
247831|NCT02305667|Device|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
247832|NCT02305667|Device|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
247833|NCT02305667|Device|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
247834|NCT02305654|Procedure|ILND - Inguinal Lymph Node Dissection|Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.
247835|NCT02305654|Drug|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
247836|NCT02305654|Drug|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
247837|NCT02305654|Drug|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
247838|NCT02305654|Radiation|Intensity modulated radiation treatment (IMRT)|Treatment with very high energy X-rays (radiotherapy).
247839|NCT02305654|Procedure|Prophylactic PLND - pelvic lymph node dissection|Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.
247840|NCT02305615|Other|Bevacizumab|Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.
247841|NCT02305615|Combination Product|Chemotherapy|Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil [5-FU] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
247842|NCT02305602|Biological|VentriGel|VentriGel will be injected via MyoStar catheter after NOGA mapping
247843|NCT02305589|Drug|Sugammadex|Muscle relax reversing agent
247844|NCT02305563|Drug|BMS-936564|
247845|NCT02305563|Drug|Cytarabine|
247846|NCT02305550|Device|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
247847|NCT02305537|Behavioral|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
247848|NCT02305524|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
247849|NCT02305524|Device|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
247850|NCT02305511|Device|Peripheral venous catheterization|Cannulation using standard method
247851|NCT02305511|Device|Jamshidi|intraosseous access using the Jamshidi device
247852|NCT02305511|Device|BIG|intraosseous access using the BIG device
247853|NCT02305511|Device|Cook|intraosseous access using the Cook device
247854|NCT02305511|Device|EZIO|intraosseous access using the EZIO device
247855|NCT02305498|Other|Vigorous yoga practice|
247856|NCT02305498|Other|Restorative (gentle) yoga practice|
247857|NCT02305485|Device|NeoVas BCS|Subjects receiving NeoVas BCS
247858|NCT02305485|Device|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
247859|NCT02305472|Device|NeoVas BCS|Subjects receiving NeoVas BCS
247942|NCT02304822|Drug|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
248508|NCT02300636|Other|Training|Standard ACL rehabilitation
247860|NCT02305459|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
247861|NCT02305459|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
247862|NCT02305446|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
247863|NCT02305433|Other|Home-based physiotherapy (physical exercise)|Each physiotherapy (physical exercise) session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
247864|NCT02305420|Device|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/ BlastGen media)
247865|NCT02305420|Device|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
247866|NCT02305407|Procedure|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
247867|NCT02305407|Other|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
247868|NCT02305394|Drug|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
247869|NCT02305394|Drug|propofol and normal saline|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.
247870|NCT02305381|Drug|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
247871|NCT02305381|Drug|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
247872|NCT02305368|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
247873|NCT02305355|Drug|Omega-3-acids ethylesters 90 4g|
247874|NCT02305355|Drug|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
247875|NCT02305329|Drug|BIA 9-1067|
247876|NCT02305316|Drug|BIA 9-1067 non-micronized|
247877|NCT02305316|Drug|BIA 9-1067 micronized|
247878|NCT02305303|Procedure|Diary|A diary written prospectively during the ICU stay by the staff and relatives
247879|NCT02305290|Procedure|Endoscopic Mucosal Resection|
247880|NCT02305277|Drug|BIA 9-1067 (clinical micronized, CM)|
247881|NCT02305277|Drug|BIA 9-1067 (to-be-marketed, TBM)|
247882|NCT02305264|Drug|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
247883|NCT02305251|Other|Survey|Standard Gamble Survey
247884|NCT02305238|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
247885|NCT02305225|Behavioral|Sleep Deprivation|
247886|NCT02305212|Behavioral|Cogmed|
247887|NCT02305199|Drug|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
247888|NCT02305199|Drug|Normal saline|Fluid containing Sodium chloride 9 g/L
247889|NCT02305186|Drug|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
247890|NCT02305186|Radiation|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
247891|NCT02305173|Drug|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
247892|NCT02305173|Drug|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
247893|NCT02305160|Drug|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
247894|NCT02305160|Drug|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
247895|NCT02305147|Other|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
247896|NCT02305134|Drug|Tipepidine Hibenzate|
247897|NCT02305134|Drug|Placebo|
247898|NCT02305121|Device|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
247899|NCT02305108|Other|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.~Specific points of fascial tissue will be treated with a deep friction to improve elasticity.~The number of point treated will be refered to a specific evaluation for each patient.~Fascial manipulation provide 3 session treatment (one treatment for week)."
248006|NCT02304302|Drug|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic dose escalation protocol)
247900|NCT02305108|Other|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.~After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
247901|NCT02305095|Drug|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
247902|NCT02305082|Other|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
247903|NCT02305069|Drug|Pioglitazone|Described elsewhere
247904|NCT02305069|Drug|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
247905|NCT02305069|Drug|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
247906|NCT02305069|Drug|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
247907|NCT02305069|Drug|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
247908|NCT02305069|Other|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
247909|NCT02305069|Other|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
247910|NCT02305056|Drug|C13 N15 Valine|C13 N15 Valine administration
247911|NCT02305043|Other|non-interventional|non-interventional
247912|NCT02305030|Drug|BIA 9-1067|
247913|NCT02305030|Drug|Warfarin|
247914|NCT02305017|Drug|BIA 9-1067|BIA 9-1067 50 mg
247915|NCT02305017|Drug|Paracetamol|Paracetamol 1g
247916|NCT02304991|Drug|Liquid Peanut Extract|5000mcg/ml peanut protein
247917|NCT02304991|Drug|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
247918|NCT02304978|Biological|Group CRC|blood samples
247919|NCT02304978|Biological|Group control|Blood samples
247920|NCT02304965|Behavioral|Daily physical activity|A combination of walking (> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
247921|NCT02304952|Procedure|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
247922|NCT02304952|Other|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
247923|NCT02304952|Device|Arthrocare Topaz MicroDebrider|
247924|NCT02304939|Procedure|changeover|
247925|NCT02304939|Device|use of automatic infusion pump|
247926|NCT02304939|Behavioral|datas collection|
247927|NCT02304926|Drug|Simvastatin|simvastatin (40 mg/day) for 4 weeks
247928|NCT02304926|Drug|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
247929|NCT02304926|Drug|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
247930|NCT02304913|Other|Hypoglossal acupuncture|
247931|NCT02304913|Other|Sham acupuncture|
247932|NCT02304913|Behavioral|Dietary recommendations|
247933|NCT02304900|Other|white implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant~nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
247934|NCT02304900|Other|yellow implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant~nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
247935|NCT02304887|Drug|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
247936|NCT02304874|Other|Phlebotomy|
247937|NCT02304861|Procedure|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
247938|NCT02304861|Procedure|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
247939|NCT02304848|Other|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
247940|NCT02304822|Drug|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
247941|NCT02304822|Drug|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
248007|NCT02304289|Drug|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
247943|NCT02304809|Drug|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
247944|NCT02304796|Behavioral|Unified Cognitive-Behavioral Therapy|"20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention."
247945|NCT02304796|Behavioral|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
247946|NCT02304783|Drug|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
247947|NCT02304783|Drug|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
247948|NCT02304770|Drug|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
247949|NCT02304757|Drug|99Tc-MDP|99Tc-MDP, H20000218
247950|NCT02304757|Drug|fosamax|H20080172
247951|NCT02304757|Drug|Caltrate|Calcium 600 mg and vitamine D3 125iu.
247952|NCT02304744|Other|Observational study, no intervention.|Observational study, no intervention.
247953|NCT02304731|Other|Physical Exercise|Incremental running
247954|NCT02304718|Behavioral|Stationary bike|
247955|NCT02304705|Drug|Sildenafil|20 mg three times daily by mouth for 90 days
247956|NCT02304705|Drug|Placebo|One capsule three times daily by mouth for 90 days
247957|NCT02304692|Device|Bone anchored hearing aid|
247958|NCT02304679|Other|Pre-inclusion questionnaires|"(Month -2)~During this visit, the investigator will:~Validate the patient's inclusion and exclusion criteria;~Obtain informed consent from the patient;~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~Prescribe 1 month of PDE5i treatment.~The next visit will be scheduled"
247959|NCT02304679|Drug|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
247960|NCT02304679|Other|PDE5i follow-up questionnaires|"(Month -1)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).~The next visit will be scheduled"
247961|NCT02304679|Other|Inclusion questionnaires|"(Day 0)~During this visit the investigator will:~Verify inclusion and exclusion criteria, and proceed with final inclusion~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~Randomize the patient at the end of the visit~The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
247962|NCT02304679|Device|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
247963|NCT02304679|Device|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
247964|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 1|"(Month 2)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
247965|NCT02304679|Other|Follow-up questionnaires 3 months after Wave 1|"(Month 4)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
247966|NCT02304679|Device|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
247967|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 2|"(Month 6)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
247968|NCT02304679|Other|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
248549|NCT02300298|Drug|Docetaxel|Docetaxel
247969|NCT02304679|Other|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)~During this visit the investigator will:~Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
247970|NCT02304666|Procedure|Colonoscopy for biopsies samples|
247971|NCT02304653|Other|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
247972|NCT02304627|Drug|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
247973|NCT02304614|Other|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
247974|NCT02304614|Other|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
247975|NCT02304614|Other|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
247976|NCT02304614|Other|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
247977|NCT02304588|Biological|Mesenchymal stem cells|10-20 x 10^6 cells/20mL
247978|NCT02304575|Other|Questionnaires|"Questionnaires:~For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.~For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory."
247979|NCT02304575|Other|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
247980|NCT02304562|Biological|UCB Mesenchymal Stem Cells treatment|reduce skin injury
247981|NCT02304536|Drug|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
247982|NCT02304536|Procedure|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
247983|NCT02304523|Drug|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
247984|NCT02304523|Drug|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
247985|NCT02304523|Drug|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
247986|NCT02304497|Other|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
247987|NCT02304484|Biological|Evolocumab|Administered by subcutaneous injection once a month
247988|NCT02304458|Biological|Ipilimumab|Given IV
247989|NCT02304458|Other|Laboratory Biomarker Analysis|Correlative studies
247990|NCT02304458|Biological|Nivolumab|Given IV
247991|NCT02304458|Other|Pharmacological Study|Correlative studies
247992|NCT02304445|Procedure|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
247993|NCT02304445|Radiation|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
247994|NCT02304432|Drug|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
247995|NCT02304432|Drug|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
247996|NCT02304432|Drug|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
247997|NCT02304419|Drug|Galunisertib|Administered orally.
247998|NCT02304393|Drug|Atezolizumab|Atezolizumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
247999|NCT02304393|Drug|Selicrelumab|Selicrelumab will be administered as per the dosage regimen mentioned in respective arm descriptions.
248000|NCT02304367|Biological|KRN23|Solution for SC injection
248001|NCT02304354|Drug|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
248002|NCT02304328|Other|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
248003|NCT02304315|Biological|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
248004|NCT02304315|Biological|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
248005|NCT02304302|Drug|Memantine|Encapsulated Namenda 10 mg bid (after four week dose escalation protocol)
248008|NCT02304276|Radiation|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
248009|NCT02304276|Radiation|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
248010|NCT02304263|Drug|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
248011|NCT02304250|Drug|Dexamethasone|dexamethasone 1ml (5mg)
248012|NCT02304250|Drug|saline|saline 1ml
248013|NCT02304237|Drug|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
248014|NCT02304237|Drug|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
248015|NCT02304224|Other|eye masks|eye masks from 21:00 to 6:00 each night during admission
248016|NCT02304211|Drug|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
248017|NCT02304198|Drug|Udenafil|Udenafil 50mg tablet
248018|NCT02304185|Biological|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
248019|NCT02304185|Biological|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
248020|NCT02304185|Biological|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
248021|NCT02304185|Biological|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
248022|NCT02304185|Drug|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
248023|NCT02304172|Device|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
248024|NCT02304172|Device|Harmonic (Group B)|hemostatic device utilized intraoperatively
248025|NCT02304159|Drug|daclatasvir|
248026|NCT02304159|Drug|Sofosbuvir, Sovaldi|
248027|NCT02304159|Drug|Ribavirin|
248028|NCT02304133|Other|Education|
248029|NCT02304120|Other|Proprioceptive postural training|
248030|NCT02304120|Other|Treadmill training|
248031|NCT02304120|Other|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
248032|NCT02304107|Drug|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
248033|NCT02304107|Drug|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
248034|NCT02304094|Drug|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine
248035|NCT02304094|Other|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
248036|NCT02304081|Drug|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
248037|NCT02304081|Drug|Placebo for Saxagliptin|
248038|NCT02304068|Other|Home monitoring|
248039|NCT02304068|Other|Hospital assessment|
248040|NCT02304055|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
248041|NCT02304055|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
248042|NCT02304042|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
248043|NCT02304042|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
248044|NCT02304029|Device|MRI|
248045|NCT02304016|Behavioral|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
248046|NCT02304003|Other|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
248047|NCT02304003|Other|Standard Care|Standard follow up in primary care.
248048|NCT02303990|Drug|Pembrolizumab|
248049|NCT02303990|Radiation|Radiotherapy|
248050|NCT02303977|Drug|Abraxane|
248051|NCT02303977|Drug|Gemcitabine|
248052|NCT02303964|Biological|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
248053|NCT02303964|Drug|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
248054|NCT02303951|Drug|Vemurafenib|Run-In: Day 1-21 960 mg bid orally, Day 22-28 720 mg bid orally Triple-Treatment (week 5 ongoing): 720 mg bid orally
248055|NCT02303951|Drug|Cobimetinib|Run-In: Day 1-21 60 mg od orally Triple-Treatment (week 5 ongoing): 60 mg od 21/7 orally (3 weeks on drug, 1 week off)
248056|NCT02303951|Drug|Atezolizumab|Triple-Treatment (week 5 ongoing): 840 mg Q2W i.v
248057|NCT02303938|Behavioral|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
248058|NCT02303925|Device|NESTER COILS|
248059|NCT02303912|Drug|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
248060|NCT02303899|Drug|Gemcitabine|infusion drug
248061|NCT02303899|Drug|Imatinib mesylate|oral drug
248062|NCT02303886|Drug|Methylene blue|In NaCL0.9% 100 ml
248063|NCT02303886|Drug|Methylene blue|in NaCl 0.9% 100 ml
248064|NCT02303873|Drug|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp & Dohme．LTD.).
248065|NCT02303860|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
248066|NCT02303860|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
248067|NCT02303860|Drug|ORM-12741 IR|Immediately release formulation of ORM-12741
248068|NCT02303847|Drug|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
248069|NCT02303834|Device|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
248070|NCT02303821|Drug|Carfilzomib|
248071|NCT02303821|Drug|Dexamethasone|
248072|NCT02303821|Drug|Mitoxantrone|
248073|NCT02303821|Drug|PEG-asparaginase|
248074|NCT02303821|Drug|Vincristine|
248075|NCT02303821|Drug|Intrathecal (IT) Methotrexate|
248076|NCT02303821|Drug|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
248077|NCT02303821|Drug|6-Mercaptopurine|
248078|NCT02303821|Drug|Cyclophosphamide|
248079|NCT02303821|Drug|Cytarabine|
248080|NCT02303821|Drug|Daunorubicin|
248081|NCT02303808|Device|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
248082|NCT02303795|Drug|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
248083|NCT02303795|Drug|Warfarin|"Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.~Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day."
248084|NCT02303782|Drug|OTX015|
248085|NCT02303782|Drug|Vidaza (azacitidine)|
248086|NCT02303769|Drug|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
248087|NCT02303769|Drug|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
248088|NCT02303756|Device|Pillcam® COLON Capsule|colonoscopy
248089|NCT02303743|Device|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
248090|NCT02303743|Device|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
248091|NCT02303730|Drug|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose<2.9 mmol/l or < 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
248092|NCT02303730|Drug|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c <8% use 0.1 -0.2 U/kg per day;HbA1c >8% use 0.2 -0.3 U/kg per day).~Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):~fasting blood glucose(FBG) > 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.~If hypoglycemia, reduce insulin glargine by:~blood glucose <70mg/dl（3.9mmol/l）: 10%-20%; blood glucose <40mg/dl（2.2mmol/l）: 20%-40%."
248093|NCT02303717|Device|Percutaneous coronary intervention|Percutaneous coronary stent implantation
248094|NCT02303717|Drug|Dual antiplatelet therapy|Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
248095|NCT02303704|Procedure|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
248096|NCT02303704|Procedure|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
248097|NCT02303691|Behavioral|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
248098|NCT02303691|Behavioral|Neutral Training|A control version of computerized attention training.
248099|NCT02303678|Drug|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
248100|NCT02303665|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
248101|NCT02303665|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
248102|NCT02303652|Procedure|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
248103|NCT02303652|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
248104|NCT02303639|Procedure|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
248105|NCT02303639|Drug|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
248106|NCT02303626|Drug|BCX4161|
248107|NCT02303626|Drug|Placebo|
248108|NCT02303613|Other|Mapping|Mapping of current triage situation regarding 30 days mortality
248109|NCT02303600|Drug|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
248110|NCT02303600|Other|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
248111|NCT02303587|Drug|methylprednisolone|
248112|NCT02303574|Drug|AZD7986, oral solution, 1 to 50 mg/mL|Starting dose in single ascending dose part: 5 mg
248113|NCT02303574|Drug|Placebo, oral solution|Matching placebo
248114|NCT02303561|Behavioral|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
248115|NCT02303561|Behavioral|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
248116|NCT02303548|Drug|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
248117|NCT02303548|Drug|Normal saline|Placebo
248118|NCT02303535|Procedure|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
248119|NCT02303535|Procedure|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
248120|NCT02303522|Other|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
248121|NCT02303509|Drug|UCB5857 Part 1|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 1 mg, 5 mg, 10 mg or 15 mg~Route of administration: Oral"
248122|NCT02303509|Drug|UCB5857 Part 2|"Active substance: UCB5857~Pharmaceutical form: Capsule~Concentration: 5 mg, 8 mg, 15 mg~Route of administration: Oral"
248123|NCT02303509|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Capsule~Concentration: Avicel PH 102, 50 mg~Route of administration: Oral"
248124|NCT02303496|Biological|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
248125|NCT02303496|Biological|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
248126|NCT02303483|Dietary Supplement|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
248127|NCT02303483|Dietary Supplement|Placebo|
248128|NCT02303470|Behavioral|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
248129|NCT02303470|Behavioral|Moderate Exercise|
248130|NCT02303457|Procedure|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
248131|NCT02303457|Procedure|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
248132|NCT02303444|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
248133|NCT02303444|Drug|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
248134|NCT02303431|Drug|Edoxaban low dose|Edoxaban low dose
248135|NCT02303431|Drug|Edoxaban high dose|Edoxaban high dose
248136|NCT02303418|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
248137|NCT02303418|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
248138|NCT02303405|Drug|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
248139|NCT02303405|Drug|Pioglitazone|Anti-hyperglycemic agent
248140|NCT02303392|Drug|Selinexor|Given PO
248141|NCT02303392|Drug|Ibrutinib|Given PO
248142|NCT02303392|Other|Pharmacological Study|Correlative studies
248143|NCT02303392|Other|Laboratory Biomarker Analysis|Correlative studies
248144|NCT02303379|Other|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
248145|NCT02303379|Other|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
248146|NCT02303379|Other|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
248147|NCT02303366|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
248148|NCT02303366|Drug|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
248149|NCT02303340|Radiation|Dual Energy X-ray Absorptiometry|
248150|NCT02303327|Radiation|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
248151|NCT02303327|Radiation|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
248152|NCT02303327|Drug|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
248153|NCT02303314|Drug|Trigonella Foenum-graecum Seed Extract|
248154|NCT02303314|Drug|Drug: Placebo|
248155|NCT02303301|Dietary Supplement|Probiotics|Cultures from the oropharynx
248156|NCT02303301|Dietary Supplement|Placebo|Cultures from the oropharynx
248272|NCT02302352|Other|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
248157|NCT02303288|Device|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
248158|NCT02303275|Behavioral|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)~The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:~Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
248159|NCT02303275|Behavioral|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
248160|NCT02303262|Drug|Mocetinostat|Mocetinostat is taken orally at 70 mg/dose, 3 days per week, during cycle 1. Dose is increased to 90 mg starting at cycle 2.
248161|NCT02303262|Drug|Gemcitabine|Gemcitabine is administered via intravenous infusion at 1,000 mg/m2 at a rate of approximately 10 mg/m2/minute, on days 5 and 12 of every cycle.
248162|NCT02303249|Other|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
248163|NCT02303223|Drug|Propofol|
248164|NCT02303210|Device|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
248165|NCT02303210|Device|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
248166|NCT02303197|Drug|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
248167|NCT02303184|Drug|suprachoroidal CLS-TA|suprachoroidal injection of CLS-TA
248168|NCT02303184|Drug|suprachoroidal sham|suprachoroidal sham procedure
248169|NCT02303184|Drug|IVT aflibercept|2 mg intravitreal injection of aflibercept
248170|NCT02303171|Drug|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
248171|NCT02303171|Drug|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
248172|NCT02303132|Other|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
248173|NCT02303119|Drug|Rituximab IV|intra-venous, 375 mg/m²
248174|NCT02303119|Drug|Rituximab SC|sub-cutaneous, 1400 mg
248175|NCT02303106|Drug|Lamotrigine|
248176|NCT02303093|Biological|Octagam IVIG 5% or 10%|Octagam IVIG 5% or 10%
248177|NCT02303093|Biological|Panzyga|Panzyga
248178|NCT02303080|Other|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
248179|NCT02303080|Other|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
248180|NCT02303080|Other|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
248181|NCT02303080|Other|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
248182|NCT02303054|Procedure|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
248183|NCT02303041|Drug|Buparlisib|Administered orally at starting dose of 80 mg/day
248184|NCT02303041|Drug|Sonidegib|Administered orally at starting dose of 200 mg/day
248185|NCT02303028|Drug|Topotecan and Pazopanib|Dose escalation of low-dose metronomic Topotecan with a fixed dose of Pazopanib
248186|NCT02303002|Biological|Botulinum Toxin Type A|Intramuscular injection (IM)
248187|NCT02303002|Biological|Active Comparator botulinum toxin|IM injection
248188|NCT02303002|Biological|Placebo Comparator|IM injection
248189|NCT02302989|Drug|Ranibizumab 0.5mg|
248190|NCT02302976|Drug|cocaine hydrochloride|
248191|NCT02302976|Drug|exenatide|
248192|NCT02302976|Drug|placebo|
248193|NCT02302963|Device|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
248194|NCT02302963|Device|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
248195|NCT02302950|Drug|raltegravir|HIV therapy component
248196|NCT02302937|Procedure|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
248197|NCT02302937|Procedure|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
248198|NCT02302911|Behavioral|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
248199|NCT02302911|Behavioral|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
248200|NCT02302911|Other|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
248201|NCT02302898|Behavioral|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
248202|NCT02302898|Other|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
248203|NCT02302898|Other|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
248204|NCT02302885|Other|Blood collection|Blood Collection
248205|NCT02302872|Device|ARTO System|
248206|NCT02302859|Drug|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
248207|NCT02302859|Behavioral|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
248208|NCT02302859|Other|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
248209|NCT02302859|Behavioral|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.~Participants also have access to additional counseling content on the smart phone, which can be used at any time."
248210|NCT02302859|Other|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
248211|NCT02302859|Device|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.~Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
248212|NCT02302846|Drug|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
248213|NCT02302833|Drug|Cabozantinib S-malate|Given PO
248214|NCT02302833|Other|Laboratory Biomarker Analysis|Correlative studies
248215|NCT02302833|Other|Questionnaire Administration|Ancillary studies
248216|NCT02302820|Other|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
248217|NCT02302807|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
248218|NCT02302807|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
248219|NCT02302807|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
248220|NCT02302807|Drug|Vinflunine|Vinflunine 320 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
248221|NCT02302794|Procedure|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
248222|NCT02302794|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
248223|NCT02302781|Other|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
248224|NCT02302768|Dietary Supplement|Selenomethionine|
248225|NCT02302768|Other|Placebo|
248226|NCT02302755|Drug|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
248227|NCT02302729|Dietary Supplement|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
248228|NCT02302729|Behavioral|Responsive feeding|"Strategy~Mother ensures that feeding area is set up with infant and mother able to see one another.~Mother mirrors the infant's facial expressions to attract the infant's attention.~Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
248229|NCT02302729|Dietary Supplement|Placebo|Riboflavin Vitamin B2
248230|NCT02302716|Drug|LY2963016|Administered SC
248231|NCT02302716|Drug|LANTUS®|Administered SC
248232|NCT02302716|Drug|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
248233|NCT02302703|Other|low FODMAP diet vs Gluten free diet|
248234|NCT02302690|Biological|Blood sample for immunology|
248235|NCT02302664|Procedure|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
248269|NCT02302378|Procedure|Taylor's approach (paramedian approach at L5-S1 interspace)|Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
248270|NCT02302365|Device|Spectra Optia® Apheresis System|White Blood Cell Depletion
248271|NCT02302352|Other|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
248273|NCT02302339|Drug|glembatumumab vedotin|
248236|NCT02302664|Procedure|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
248237|NCT02302651|Device|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
248238|NCT02302638|Other|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
248239|NCT02302625|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
248240|NCT02302612|Behavioral|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
248241|NCT02302612|Other|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
248242|NCT02302599|Biological|Umbilical cord mesenchymal stem cells|Infusion treatment
248243|NCT02302599|Biological|Controlled suspension liquid|Infusion treatment
248244|NCT02302586|Drug|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
248245|NCT02302586|Drug|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
248246|NCT02302573|Drug|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
248247|NCT02302547|Drug|triple therapy|Dosage treatment and usual prescription
248248|NCT02302547|Drug|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
248249|NCT02302534|Device|MRI|MRI
248250|NCT02302521|Device|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
248251|NCT02302508|Drug|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
248252|NCT02302495|Drug|Carfilzomib|"DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
248253|NCT02302482|Other|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
248254|NCT02302469|Drug|Revlimid|Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
248255|NCT02302456|Drug|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
248256|NCT02302456|Drug|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
248257|NCT02302443|Biological|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
248258|NCT02302443|Biological|Active comparator|Single dose subcutaneous administration of active comparator
248259|NCT02302430|Drug|Oxytocin|20 International Units Intranasal Oxytocin
248260|NCT02302430|Other|Placebo comparator|Saline nasal spray
248261|NCT02302417|Procedure|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
248262|NCT02302417|Other|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
248263|NCT02302404|Drug|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
248264|NCT02302404|Drug|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
248265|NCT02302404|Drug|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
248266|NCT02302404|Drug|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
248267|NCT02302391|Other|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
248268|NCT02302378|Procedure|Lumbar paramedian approach at L3-L4 interspace|Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)
248274|NCT02302339|Drug|glembatumumab vedotin and varlilumab|
248275|NCT02302339|Drug|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
248276|NCT02302339|Drug|glembatumumab vedotin and CDX-301|
248277|NCT02302326|Drug|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
248278|NCT02302326|Dietary Supplement|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
248279|NCT02302313|Device|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
248280|NCT02302300|Device|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
248281|NCT02302287|Dietary Supplement|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
248282|NCT02302287|Other|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
248283|NCT02302287|Other|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
248284|NCT02302274|Drug|flecainide iv|infusion over 10 min
248285|NCT02302248|Behavioral|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
248286|NCT02302248|Behavioral|Expressive writing intervention|3 week access to a web-based expressive writing platform.
248287|NCT02302235|Other|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction.
248288|NCT02302235|Other|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
248289|NCT02302222|Device|Customizable Dressing with ActiV.A.C. Therapy Unit|
248290|NCT02302222|Device|Standard of Care Dressing|
248291|NCT02302209|Drug|Oxytocin|
248292|NCT02302209|Other|Placebo Comparator|
248293|NCT02302196|Procedure|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
248294|NCT02302196|Other|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
248295|NCT02302183|Device|FreeO2 v2.0 automatic adjustment|
248296|NCT02302183|Device|FreeO2 v2.0 data collecting|
248297|NCT02302170|Biological|H. pylori vaccine|
248298|NCT02302170|Biological|placebo|
248299|NCT02302157|Biological|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
248300|NCT02302144|Behavioral|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
248301|NCT02302131|Other|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
248302|NCT02302118|Procedure|Esophagogastrectomy|Esophagogastrectomy
248303|NCT02302105|Radiation|IGRT|Image Guided RT to the prostate
248304|NCT02302092|Drug|Flomoxef|Flomoxef intravenous infusion
248305|NCT02302092|Drug|Cefepime|Cefepime intravenous infusion
248306|NCT02302079|Drug|ASP8232|oral capsule
248307|NCT02302079|Drug|ranibizumab|intravitreal (IVT) injection
248308|NCT02302079|Drug|Placebo|oral capsule
248309|NCT02302079|Other|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
248310|NCT02302066|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
248311|NCT02302066|Drug|TDV Placebo|Takeda's tetravalent dengue placebo-matching vaccine
248312|NCT02302053|Dietary Supplement|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
248313|NCT02302053|Dietary Supplement|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
248314|NCT02302040|Behavioral|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
248315|NCT02302040|Behavioral|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
248316|NCT02302027|Device|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 * 67 * 36 cm
248379|NCT02301494|Drug|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
248317|NCT02302014|Other|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
248318|NCT02302001|Device|Silicone Implant|
248319|NCT02301988|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
248320|NCT02301988|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion QW for 3 cycles.
248321|NCT02301988|Drug|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
248322|NCT02301975|Drug|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
248323|NCT02301975|Drug|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
248324|NCT02301975|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
248325|NCT02301975|Drug|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
248326|NCT02301975|Drug|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
248327|NCT02301962|Drug|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
248328|NCT02301949|Drug|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
248329|NCT02301949|Other|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
248330|NCT02301936|Drug|LDV/SOF|90/400 mg fixed dose combination (FDC) tablet administered orally once daily
248331|NCT02301910|Drug|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
248332|NCT02301910|Drug|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)~55 to <60 30 mg 6 ml~60 to <70 35 mg 7 ml~70 to <80 40 mg 8 ml"
248333|NCT02301897|Drug|Telapristone Acetate|Telapristone acetate, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
248334|NCT02301897|Drug|Placebo|Matching placebo, orally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
248335|NCT02301884|Biological|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
248336|NCT02301871|Device|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
248337|NCT02301871|Procedure|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
248338|NCT02301871|Procedure|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
248339|NCT02301858|Genetic|Genome analysis of tissue samples.|Genome analysis of tissue samples.
248340|NCT02301845|Drug|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
248341|NCT02301819|Device|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
248342|NCT02301819|Other|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
248343|NCT02301806|Other|dieting|
248344|NCT02301806|Drug|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
248345|NCT02301806|Drug|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
248346|NCT02301793|Behavioral|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
248347|NCT02301793|Behavioral|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
248348|NCT02301780|Drug|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
248349|NCT02301780|Drug|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days."
248350|NCT02301754|Biological|INVAC-1|intradermal injection combined with electroporation
248351|NCT02301741|Behavioral|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
248352|NCT02301728|Other|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
248353|NCT02301715|Drug|Oxytocin|OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
248354|NCT02301715|Drug|Placebo|The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
248355|NCT02301702|Biological|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
248356|NCT02301702|Biological|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
248357|NCT02301676|Behavioral|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
248358|NCT02301676|Drug|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
248359|NCT02301676|Drug|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
248360|NCT02301676|Device|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
248361|NCT02301663|Other|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
248362|NCT02301663|Other|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
248363|NCT02301663|Other|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
248364|NCT02301650|Drug|Lamivudine|mothers use Lamivudine in late pregnancy
248365|NCT02301650|Drug|Telbivudine|mothers use Telbivudine in late pregnancy
248366|NCT02301650|Drug|Tenofovir|mothers use Tenofovir in late pregnancy
248367|NCT02301637|Device|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
248368|NCT02301624|Biological|Eculizumab|Open-Label eculizumab 1200mg IV every 2 weeks
248369|NCT02301611|Drug|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
248370|NCT02301611|Drug|Placebo|
248371|NCT02301598|Procedure|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
248372|NCT02301585|Procedure|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
248373|NCT02301585|Procedure|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
248374|NCT02301559|Behavioral|Pilates exercises|Pilates exercises with emphasis on pelvic region
248375|NCT02301546|Behavioral|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
248376|NCT02301533|Behavioral|Shikamana Intervention|See arm description
248377|NCT02301533|Behavioral|Standard Care|See arm description
248378|NCT02301507|Behavioral|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
248380|NCT02301494|Drug|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
248381|NCT02301481|Radiation|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
248382|NCT02301481|Drug|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
248383|NCT02301481|Procedure|Surgery|Surgery, preferred D2 lymphadenectomy
248384|NCT02301481|Drug|SOX|SOX (S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
248385|NCT02301468|Other|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
248386|NCT02301468|Other|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
248387|NCT02301455|Behavioral|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
248388|NCT02301442|Behavioral|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
248389|NCT02301442|Behavioral|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic & strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers & exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
248390|NCT02301429|Device|Model 20105|implant and follow-up of study device
248391|NCT02301416|Drug|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
248392|NCT02301416|Other|low calorie diet|The low-calorie diet will be individually tailored based on initial resting metabolic rate measurement and co-morbid conditions.
248393|NCT02301403|Drug|Nicotine patch|8 weeks of nicotine patch
248394|NCT02301403|Behavioral|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
248395|NCT02301403|Drug|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
248396|NCT02301403|Drug|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
248397|NCT02301403|Behavioral|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
248398|NCT02301403|Behavioral|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
248399|NCT02301403|Behavioral|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
248400|NCT02301390|Drug|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
248401|NCT02301390|Device|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
248402|NCT02301377|Device|Spiro PD personal spirometer|
248403|NCT02301364|Drug|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
248404|NCT02301351|Other|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
248405|NCT02301351|Other|Text Warning Label|All packs provided will include standard text warning labels
248406|NCT02301338|Other|Usual care|
248407|NCT02301338|Other|Phone Calls|
248408|NCT02301325|Behavioral|Smoking research cigarettes with or without NRT|
248409|NCT02301312|Device|POSS-PCU vascular graft|New vascular access graft
248410|NCT02301299|Behavioral|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
248411|NCT02301286|Drug|Acetylsalicylic acid|
248412|NCT02301286|Drug|Placebo Acetylsalicylic acid|
248413|NCT02301273|Other|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
248502|NCT02300662|Device|Cycle Ergometer|Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
248628|NCT02299869|Device|Verde (Competitor-control)|contact lens
248414|NCT02301273|Other|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
248415|NCT02301260|Behavioral|Speed of Processing Training (SPT)|
248416|NCT02301260|Behavioral|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
248417|NCT02301247|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
248418|NCT02301247|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
248419|NCT02301234|Drug|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
248420|NCT02301234|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
248421|NCT02301234|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
248422|NCT02301234|Drug|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
248423|NCT02301234|Drug|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
248424|NCT02301221|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
248425|NCT02301221|Drug|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
248426|NCT02301208|Drug|Nedaplatin|Nedaplatin combine with IMRT
248427|NCT02301208|Drug|Cisplatin|Cisplatin combine with IMRT
248428|NCT02301195|Other|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
248429|NCT02301195|Other|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
248430|NCT02301182|Device|ADM X3-MoP Cup|
248431|NCT02301182|Device|CoC Cup|
248432|NCT02301169|Behavioral|Heat pain stimuli A|
248433|NCT02301169|Behavioral|Video A|
248434|NCT02301169|Drug|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
248435|NCT02301169|Behavioral|Heat pain stimuli B|
248436|NCT02301169|Behavioral|Video B|
248437|NCT02301169|Drug|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
248438|NCT02301156|Drug|Ublituximab|Ublituximab IV infusion
248439|NCT02301156|Drug|ibrutinib|Ibrutinib oral daily dose
248440|NCT02301143|Drug|nab-Paclitaxel|
248441|NCT02301143|Drug|Gemcitabine|
248442|NCT02301143|Drug|Chemoradiation|
248443|NCT02301143|Drug|Capecitabine|
248444|NCT02301143|Procedure|Surgery|Surgical intervention
248445|NCT02301130|Biological|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
248446|NCT02301130|Biological|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
248447|NCT02301130|Biological|tremelimumab|Tremelimumab will be administered intravenously (IV).
248448|NCT02301117|Drug|TAS-102|
248449|NCT02301104|Drug|TAS-102|
248450|NCT02301091|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
248451|NCT02301091|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
248452|NCT02301091|Drug|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
248453|NCT02301078|Procedure|Percutaneous Needle Aponeurotomy|single procedure (day 0)
248454|NCT02301078|Drug|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
248455|NCT02301052|Drug|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
248456|NCT02301052|Drug|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
248457|NCT02301052|Drug|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
248458|NCT02301039|Drug|Pembrolizumab|
248459|NCT02301026|Drug|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
248460|NCT02301013|Procedure|Urinary incontience surgery|Surgery for stress or mixed urinary incontience
248461|NCT02301013|Drug|300 cc saline|
248462|NCT02301000|Biological|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
248463|NCT02301000|Drug|Metronidazole|Peroral metronidazole 400 mg t.i.d. for ten days
248464|NCT02300987|Drug|LEE011|
248465|NCT02300987|Drug|LEE011 Placebo|
248466|NCT02300961|Behavioral|Cognitive rehabilitation program|
248503|NCT02300662|Other|Conventional physiotherapy|Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
248504|NCT02300649|Drug|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
248505|NCT02300649|Drug|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
248506|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
248467|NCT02300948|Drug|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
248468|NCT02300948|Drug|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
248469|NCT02300935|Drug|trametinib|
248470|NCT02300935|Drug|nab-paclitaxel|
248471|NCT02300922|Drug|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
248472|NCT02300922|Drug|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
248473|NCT02300922|Drug|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
248474|NCT02300909|Procedure|Lumbar Decompression Surgery|Lumbar Decompression Surgery
248475|NCT02300909|Procedure|Microdiscectomy Surgery|Microdiscectomy Surgery
248476|NCT02300909|Other|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
248477|NCT02300896|Other|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
248478|NCT02300870|Drug|Optison|Echocardiogram with IV contrast
248479|NCT02300857|Behavioral|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
248480|NCT02300857|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
248481|NCT02300857|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
248482|NCT02300844|Drug|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.~Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
248483|NCT02300844|Drug|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
248484|NCT02300831|Other|Data Collection|Non interventional prospective data collection
248485|NCT02300818|Device|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
248486|NCT02300818|Drug|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
248487|NCT02300792|Dietary Supplement|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
248488|NCT02300792|Dietary Supplement|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
248489|NCT02300779|Dietary Supplement|Low-residue diet|"Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted."
248490|NCT02300779|Dietary Supplement|Usual care|"Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.~Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.~Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made."
248491|NCT02300753|Drug|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
248492|NCT02300740|Dietary Supplement|Nicotinamide riboside|NIAGEN, ChromaDex
248493|NCT02300727|Drug|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
248494|NCT02300727|Drug|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.~The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
248495|NCT02300727|Drug|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
248496|NCT02300714|Procedure|oblique view approach|
248497|NCT02300701|Drug|Xolair|According to manufacturer's instructions
248498|NCT02300701|Drug|Placebo|Placebo
248499|NCT02300688|Drug|Treatment A|administration of 1 time administration of the test drug (Treatment A)
248500|NCT02300688|Drug|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
248501|NCT02300675|Behavioral|therapeutic education program|
248507|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
248509|NCT02300623|Drug|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
248510|NCT02300623|Drug|Antiretroviral therapy alone|Standard antiretroviral therapy
248511|NCT02300610|Drug|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
248512|NCT02300610|Drug|Cisplatin|Cisplatin at 70 mg/m^2 IV on day 1, repeated every 21 days for total of 6 cycles.
248513|NCT02300610|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
248514|NCT02300597|Other|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
248515|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
248516|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
248517|NCT02300584|Other|iPad|a tablet computer with an internet connection
248518|NCT02300558|Drug|Eleclazine|Tablets administered orally
248519|NCT02300558|Drug|Eleclazine placebo|Tablets administered orally
248520|NCT02300545|Drug|Pazopanib|
248521|NCT02300532|Other|No intervention|
248522|NCT02300519|Other|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
248523|NCT02300506|Other|No intervention|
248524|NCT02300493|Behavioral|Experimental|Asked to weigh themselves
248525|NCT02300480|Procedure|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
248526|NCT02300480|Procedure|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
248527|NCT02300467|Drug|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
248528|NCT02300454|Device|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
248529|NCT02300454|Device|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
248530|NCT02300441|Other|ECG, blood pressure and oximetry|
248531|NCT02300428|Dietary Supplement|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
248532|NCT02300415|Biological|blood sample|Dosage of presepsine
248533|NCT02300389|Radiation|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
248534|NCT02300389|Radiation|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
248535|NCT02300376|Drug|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
248536|NCT02300363|Drug|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
248537|NCT02300363|Drug|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
248538|NCT02300363|Drug|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
248539|NCT02300350|Drug|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
248540|NCT02300350|Drug|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
248541|NCT02300350|Drug|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
248542|NCT02300337|Device|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
248543|NCT02300324|Dietary Supplement|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
248544|NCT02300324|Dietary Supplement|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
248545|NCT02300324|Dietary Supplement|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
248546|NCT02300311|Drug|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
248547|NCT02300311|Drug|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
248548|NCT02300298|Drug|Nintedanib|Nintedanib
248550|NCT02300285|Device|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
248551|NCT02300272|Device|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
248552|NCT02300272|Device|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
248553|NCT02300259|Drug|LY2623091|Administered orally
248554|NCT02300259|Drug|Itraconazole|Administered orally
248555|NCT02300259|Drug|Simvastatin|Administered orally
248556|NCT02300259|Drug|Tadalafil|Administered orally
248557|NCT02300259|Drug|Diltiazem|Administered orally
248558|NCT02300246|Procedure|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
248559|NCT02300233|Drug|volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks
248560|NCT02300233|Drug|Placebo|Placebo administered subcutaneously once-weekly for 26 weeks
248561|NCT02300220|Drug|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
248562|NCT02300220|Drug|Placebo|One capsule, twice daily for 1 week
248563|NCT02300207|Device|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
248564|NCT02300194|Drug|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
248565|NCT02300194|Drug|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
248566|NCT02300181|Dietary Supplement|Placebo|
248567|NCT02300181|Dietary Supplement|Bacillus subtilis var natto DC-15|
248568|NCT02300168|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
248569|NCT02300155|Drug|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
248570|NCT02300155|Drug|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
248571|NCT02300142|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
248572|NCT02300142|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
248573|NCT02300142|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
248574|NCT02300142|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
248575|NCT02300142|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
248576|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
248577|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.~1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
248578|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:~1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
248579|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:~1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.~500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.~Period 2:~1g of Placebo on full face once daily 7 days per week for 2 weeks.~1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
248580|NCT02300103|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
248629|NCT02299869|Device|Green (CVI-test)|contact lens
248581|NCT02300103|Drug|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
248582|NCT02300090|Device|Test Group|Patients receive a mobile phone with the Me & My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
248583|NCT02300090|Other|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
248584|NCT02300077|Drug|methadone|Escalating dose of methadone up to .3mg/kg.
248585|NCT02300077|Drug|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
248586|NCT02300064|Other|Knee-extensor exercise test|Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
248587|NCT02300064|Other|Exercise test with restricting/releasing blood flow|10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
248588|NCT02300064|Other|Exercise test with variable oxygen concentration and MRI|Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
248589|NCT02300064|Other|Exercise test with oral antioxidant or placebo cocktail|Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
248590|NCT02300051|Behavioral|STPGP and RPGT|
248591|NCT02300051|Drug|TAU|
248592|NCT02300038|Drug|Lidocaine (Xylocaine)|perineuromally administration of 1 ml lidocaine
248593|NCT02300038|Dietary Supplement|NaCl|perineuromally administration of NaCL
248594|NCT02300025|Drug|cobimetinib|single oral 10-mg dose of cobimetinib
248595|NCT02300012|Procedure|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
248596|NCT02299999|Drug|AZD2014|Target: m-TOR
248597|NCT02299999|Drug|AZD4547|Target: EGFR
248598|NCT02299999|Drug|AZD5363|Target: AKT
248599|NCT02299999|Drug|AZD8931|Target: HER2, EGFR
248600|NCT02299999|Drug|Selumetinib|Target: MEK
248601|NCT02299999|Drug|Vandetanib|Target: VEGF, EGFR
248602|NCT02299999|Drug|Bicalutamide|target: Androgen receptor
248603|NCT02299999|Drug|Olaparib|Target: PARP
248604|NCT02299999|Drug|Anthracyclines|DNA intercalation
248605|NCT02299999|Drug|Taxanes|Target: mitotic tubulin and microtubules
248606|NCT02299999|Drug|cyclophosphamide|Alkylating agents
248607|NCT02299999|Drug|DNA intercalators|DNA intercalators
248608|NCT02299999|Drug|Methotrexate|DNA intercalators
248609|NCT02299999|Drug|vinca alkaloids|Target: mitotic tubulin and microtubules
248610|NCT02299999|Drug|Platinum based chemotherapies|Platinum based chemotherapies
248611|NCT02299999|Drug|Bevacizumab|Target: VEGF
248612|NCT02299999|Drug|Mitomycin C|Alkylating agents
248613|NCT02299999|Drug|Eribulin|Microtubule modulator
248614|NCT02299999|Drug|MEDI4736|Target: PD-L1
248615|NCT02299986|Other|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
248616|NCT02299973|Procedure|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
248617|NCT02299973|Procedure|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
248618|NCT02299960|Device|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
248619|NCT02299960|Device|NICOM|Non-invasive measurement of cardiac output
248620|NCT02299947|Drug|Haemocomplettan P|
248621|NCT02299947|Drug|Placebo|
248622|NCT02299934|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
248623|NCT02299934|Diagnostic Test|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
248624|NCT02299921|Other|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
248625|NCT02299908|Drug|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
248626|NCT02299908|Drug|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
248627|NCT02299882|Drug|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
248630|NCT02299869|Device|Cinza (Competitor-control)|contact lens
248631|NCT02299869|Device|Grey (CVI-test)|contact lens
248632|NCT02299869|Device|Esmeralda (Competitor-control)|contact lens
248633|NCT02299869|Device|Jade (CVI-test)|contact lens
248634|NCT02299869|Device|Azul (Competitor-control)|contact lens
248635|NCT02299869|Device|Blue (CVI-test)|contact lens
248636|NCT02299856|Other|Cardiac magnetic resonance scan|
248637|NCT02299843|Procedure|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
248638|NCT02299843|Procedure|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
248639|NCT02299830|Procedure|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
248640|NCT02299830|Procedure|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
248641|NCT02299830|Procedure|stent placement|use stent placement to open the airway compressed by out neoplasm
248642|NCT02299830|Procedure|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
248643|NCT02299817|Drug|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.~Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.~Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
248644|NCT02299817|Drug|Placebo|Placebo
248645|NCT02299804|Drug|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
248646|NCT02299804|Drug|Placebo|No active ingredient
248647|NCT02299791|Other|ALL|"This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~EHR tools to expedite identification~a. EHR automated point-of-care alerts (Best Practice Alerts)~EHR tools to expedite prescribing~EHR order sets~EHR text shortcuts for notation~patient education materials (handout, poster)~EHR-based outreach support tools a. EHR registries"
248648|NCT02299791|Other|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
248649|NCT02299778|Dietary Supplement|13C6-p-aminobenzoic acid|
248650|NCT02299765|Drug|Gefitinib|patients in arm A will be given gefitinib as target therapy
248651|NCT02299765|Drug|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
248652|NCT02299765|Drug|carboplatin|patients in arm A will be given carboplatin chemotherapy
248653|NCT02299752|Procedure|single-gloving system|single-gloving system was used during Catheterization
248654|NCT02299752|Procedure|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
248655|NCT02299739|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
248656|NCT02299739|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
248657|NCT02299739|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
248658|NCT02299739|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
248659|NCT02299739|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
248660|NCT02299726|Drug|Spironolactone|
248661|NCT02299726|Other|Placebo|Matching placebo
248662|NCT02299713|Device|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
248663|NCT02299700|Other|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
248664|NCT02299687|Drug|Omeprazole|
248665|NCT02299674|Other|Level overground ambulation|
248666|NCT02299661|Drug|DS-1093a|DS-1093a, single oral doses up to 50 mg
248667|NCT02299648|Other|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
248668|NCT02299635|Drug|PF-03084014|Tablet, 10 mg, twice a day.
248669|NCT02299635|Drug|PF-03084014|Tablet, 50 mg, twice a day
248670|NCT02299635|Drug|PF-03084014|Tablet, 100 mg, twice a day
248671|NCT02299622|Genetic|Genetic test|Next-generation sequencing (AmpliSeq) & fusion analysis
248672|NCT02299609|Other|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
248673|NCT02299596|Other|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
248674|NCT02299583|Other|Preventive intervention trauma-informed early intervention|Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
248675|NCT02299570|Biological|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
248676|NCT02299570|Other|Placebo|A suspension of saline and cryoprotectant
248677|NCT02299557|Drug|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
248678|NCT02299557|Drug|Placebo gel|Placebo gel applied intra-anally once daily
248679|NCT02299544|Device|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
248680|NCT02299531|Other|Varying meal energy density and portion size|
248681|NCT02299518|Drug|mitoxantrone hydrochloride|Given IV
248682|NCT02299518|Drug|etoposide|Given IV and PO
248683|NCT02299518|Drug|cytarabine|Given IV
248684|NCT02299518|Drug|selinexor|Given PO
248685|NCT02299518|Other|laboratory biomarker analysis|Correlative studies
248686|NCT02299518|Other|pharmacological study|Correlative studies
248687|NCT02299505|Drug|ceritinib|
248688|NCT02299492|Other|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
248689|NCT02299479|Device|Dexcom G4 Platinum CGM|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
248690|NCT02299479|Device|Activity monitor|Participants will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
248691|NCT02299453|Behavioral|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
248692|NCT02299440|Other|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
248693|NCT02299440|Drug|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
248694|NCT02299440|Drug|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
248695|NCT02299440|Other|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
248696|NCT02299440|Drug|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
248697|NCT02299440|Drug|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
248698|NCT02299427|Behavioral|dog safety|use of dog safety website at home for about 2 weeks
248699|NCT02299427|Behavioral|transportation safety|use of transportation safety website at home for about 2 weeks
248700|NCT02299414|Drug|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
248701|NCT02299414|Other|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains <160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
248702|NCT02299401|Drug|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
248703|NCT02299401|Device|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
248704|NCT02299388|Drug|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
248705|NCT02299375|Drug|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
248748|NCT02298998|Other|Control|Patients randomized into the control group will follow the American Urologic Association (AUA) surveillance guidelines using cystoscopy ever 3 months for the first two years, and then every 6 months for 2 years.
248749|NCT02298985|Drug|Curcumin|3 g/day (3 capsules/day) for 6 months
248706|NCT02299375|Drug|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
248707|NCT02299375|Drug|Salbutamol MDI|Salbutamol MDI will be provided as a rescue medication.
248708|NCT02299349|Drug|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
248709|NCT02299349|Drug|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
248710|NCT02299336|Drug|Aflibercept|pro re nata (PRN)
248711|NCT02299336|Procedure|Focal Laser|Focal laser administered based on pre-specified criteria
248712|NCT02299323|Device|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
248713|NCT02299310|Drug|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
248714|NCT02299310|Drug|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
248715|NCT02299297|Drug|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
248716|NCT02299284|Other|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
248717|NCT02299271|Drug|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
248718|NCT02299271|Drug|Saline|Saline as a one-time, 60 milliliter injection.
248719|NCT02299258|Device|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
248720|NCT02299258|Device|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
248721|NCT02299245|Drug|rosuvastatin|different dose of rosuvastatin treatment
248722|NCT02299232|Drug|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
248723|NCT02299219|Behavioral|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
248724|NCT02299219|Behavioral|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
248725|NCT02299206|Drug|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
248726|NCT02299206|Drug|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
248727|NCT02299193|Behavioral|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
248728|NCT02299193|Behavioral|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
248729|NCT02299180|Behavioral|ACP|
248730|NCT02299167|Drug|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
248731|NCT02299154|Behavioral|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
248732|NCT02299141|Drug|Nintedanib|
248733|NCT02299128|Other|Physical Therapy Treatment|
248734|NCT02299115|Drug|Prednisolone|Corticosteroid
248735|NCT02299115|Drug|Vigabatrin|Antiepileptic
248736|NCT02299102|Device|Jamshidi Manual Standard Device|Jamshidi Manual Standard Device
248737|NCT02299102|Device|OnControl Powered Ported Device|OnControl Powered Ported Device
248738|NCT02299089|Drug|octreotide FluidCrystal® injection depot|
248739|NCT02299076|Behavioral|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
248740|NCT02299076|Other|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
248741|NCT02299063|Drug|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
248742|NCT02299063|Drug|0.9% NaCl|
248743|NCT02299050|Drug|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
248744|NCT02299024|Behavioral|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
248745|NCT02299011|Device|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
248746|NCT02299011|Drug|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
248747|NCT02298998|Other|Intervention|Patients randomized into the intervention group will follow the European Urologic Association (EAU) surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
248750|NCT02298985|Drug|placebo|3 g/day (3 capsules/day) for 6 months
248751|NCT02298972|Behavioral|Nurse support and selfmanagement intervention|
248752|NCT02298959|Biological|Pembrolizumab|Given IV
248753|NCT02298959|Biological|Ziv-Aflibercept|Given IV
248754|NCT02298946|Drug|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
248755|NCT02298946|Radiation|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day. Dose Level 2: 8Gy x 3 days
248756|NCT02298946|Drug|Cyclophosphamide|200mg/m(2) IV on day 0.
248757|NCT02298933|Drug|Eculizumab|300 mg single-use vials
248758|NCT02298920|Drug|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
248759|NCT02298868|Drug|Baclofen|
248760|NCT02298855|Behavioral|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
248761|NCT02298842|Device|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
248762|NCT02298842|Device|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
248763|NCT02298829|Drug|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
248764|NCT02298803|Device|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
248765|NCT02298790|Behavioral|Meal schedule|
248766|NCT02298777|Procedure|- Skin biopsy - Urine sample - Blood sample|
248767|NCT02298764|Other|Standard back pain treatment|Standard back pain treatment
248768|NCT02298764|Other|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
248769|NCT02298751|Behavioral|Cue Exposure Treatment|
248770|NCT02298725|Other|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
248771|NCT02298725|Other|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
248772|NCT02298660|Drug|BOTOX|"BOTOX® Total dose OR units/kg (per patient): 200U Number of cycles:1 cycle~200 units of BOTOX will be injected per procedure. BOTOX will be diluted in 15mL saline to 20U/mL. BOTOX injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."
248773|NCT02298621|Other|pomegranate juice|Randomized clinical trial or RCT
248774|NCT02298621|Other|placebo|Randomized clinical trial or RCT
248775|NCT02298608|Device|Nano Knife|Percutaneous, CT guided, ablation of renal mass
248776|NCT02298595|Drug|cisplatin|75 mg/m2 IV day 1 of each cycle
248777|NCT02298595|Drug|Cetuximab|XXXX day 1, 8, and 15 of each cycle
248778|NCT02298595|Drug|BYL719|200, 250, 300, or 350 mg/day by mouth every day
248779|NCT02298582|Drug|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
248780|NCT02298569|Behavioral|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.~Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
248781|NCT02298543|Other|coronary spasm|
248782|NCT02298530|Other|Combination of caffeine and theanine|Beverage containing caffeine and theanine
248783|NCT02298530|Other|Caffeine|Beverage containing caffeine
248784|NCT02298517|Procedure|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
248785|NCT02298517|Procedure|inspiratory load equipment|Threshold and Power breathe
248786|NCT02298504|Drug|Mineral Trioxide Aggregate|Vital pulp therapy
248787|NCT02298504|Drug|Biodentin|Vital pulp therapy
248788|NCT02298504|Device|Vitrebond|Vital pulp therapy
248789|NCT02298491|Drug|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
248790|NCT02298478|Behavioral|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.~NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
248791|NCT02298465|Procedure|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
248792|NCT02298465|Procedure|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
248793|NCT02298465|Device|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
248794|NCT02298452|Device|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
248795|NCT02298426|Behavioral|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
248796|NCT02298426|Behavioral|General Management|We provide general information about health. Information is provided through telephones and materials.
248797|NCT02298426|Other|Placebo|We use placebo to replace the health product.
248798|NCT02298426|Dietary Supplement|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
248799|NCT02298413|Device|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
248800|NCT02298400|Device|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
248801|NCT02298400|Device|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
248802|NCT02298400|Device|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
248803|NCT02298387|Drug|OMP-305B83|intravenous (in the vein) infusions
248804|NCT02298374|Other|Homecare reablement|
248805|NCT02298374|Other|usual care|
248806|NCT02298361|Other|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
248807|NCT02298348|Drug|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
248808|NCT02298348|Drug|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
248809|NCT02298348|Drug|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
248810|NCT02298335|Drug|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
248811|NCT02298322|Device|CoolSculpting System|
248812|NCT02298309|Other|Test-and-Treat TB|
248813|NCT02298283|Drug|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
248814|NCT02298283|Drug|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
248815|NCT02298283|Drug|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
248816|NCT02298283|Drug|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
248817|NCT02298283|Drug|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
248818|NCT02298283|Drug|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
248819|NCT02298283|Drug|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
248820|NCT02298283|Drug|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
248821|NCT02298283|Drug|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
248822|NCT02298283|Radiation|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
248823|NCT02298270|Behavioral|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
248824|NCT02298257|Drug|brentuximab vedotin|given IV
248825|NCT02298257|Drug|Doxorubicin Hydrochloride|Given IV
248826|NCT02298257|Drug|Vinblastine|Given IV
248827|NCT02298257|Drug|Dacarbazine|Given IV
248828|NCT02298244|Procedure|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
248829|NCT02298244|Procedure|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.~8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
248830|NCT02298231|Other|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
248831|NCT02298231|Other|Mystic Isle Balance Intervention|Balance therapy using virtual reality
248832|NCT02298231|Other|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
248833|NCT02298218|Drug|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
248834|NCT02298205|Other|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
248835|NCT02298205|Other|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
248836|NCT02298192|Drug|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
248837|NCT02298179|Biological|RSV F subunit 45 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248838|NCT02298179|Biological|RSV F subunit 45 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248839|NCT02298179|Biological|RSV F subunit 45 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248840|NCT02298179|Biological|RSV F subunit 90 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248841|NCT02298179|Biological|RSV F subunit 90 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248842|NCT02298179|Biological|RSV F subunit 90 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248843|NCT02298179|Biological|RSV F subunit 135 μg No adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248844|NCT02298179|Biological|RSV F subunit 135 μg Aluminum hydroxide adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248845|NCT02298179|Biological|RSV F subunit 135 μg MF59 adjuvant|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248846|NCT02298179|Drug|Placebo|2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
248847|NCT02298166|Drug|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:~Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients > 60 years of age and/or previous allogeneic HCT) d 1-3~Cytarabine 1000 mg/m² IV (500 mg/m² for patients > 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6~Consolidation therapy:~Younger adult patients (18 to 60 yrs):~Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).~Older patients (> 60 yrs) and or previous allogeneic HCT:~Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
248848|NCT02298166|Drug|Placebo|"Induction therapy:~Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with placebo will be given at the same dose tolerated during induction therapy."
248881|NCT02297893|Behavioral|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
248882|NCT02297893|Behavioral|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
248883|NCT02297880|Other|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
248849|NCT02298166|Drug|Crenolanib|"Induction therapy:~Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.~Consolidation therapy:~Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.~Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
248850|NCT02298166|Other|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.~Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
248851|NCT02298153|Drug|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
248852|NCT02298153|Drug|epacadostat|epacadostat: Oral daily dosing
248853|NCT02298140|Other|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
248854|NCT02298127|Other|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
248855|NCT02298114|Device|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
248856|NCT02298114|Other|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
248857|NCT02298101|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
248858|NCT02298101|Device|Aeroneb Solo Adapter|Nebulizer
248859|NCT02298101|Device|Opti-Mist Plus Nebulizer|Standard jet nebulizer
248860|NCT02298101|Other|Planar scintigraphy|Imaging technique to investigate whole lung deposition
248861|NCT02298101|Other|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
248862|NCT02298101|Other|Spirometry|FEV1, FVC assessment
248863|NCT02298088|Drug|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
248864|NCT02298088|Drug|Clopidogrel|"300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.~For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
248865|NCT02298075|Drug|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
248866|NCT02298075|Drug|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
248867|NCT02298062|Drug|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
248868|NCT02298062|Drug|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
248869|NCT02298049|Other|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
248870|NCT02298049|Device|MRI|
248871|NCT02298036|Behavioral|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
248872|NCT02298023|Biological|allogenic adipose stem cell treatment|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
248873|NCT02298010|Drug|Capecitabine, oxaliplatin|
248874|NCT02297997|Drug|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
248875|NCT02297997|Drug|Placebo|Control group takes the placebo for the same period.
248876|NCT02297945|Drug|metyrapone|Single arm study
248877|NCT02297932|Behavioral|Strength training|Participants will engage in a home-based strength training program.
248878|NCT02297932|Behavioral|Stretching|Participants will engage in a home-based stretching training program
248879|NCT02297919|Behavioral|Effectiveness of Internet Based Obesity Control Programme|
248880|NCT02297906|Drug|Ketorolac|Non-steroidal anti-inflammatory drug
248884|NCT02297880|Other|Still water|Still water (no flavour)
248885|NCT02297867|Drug|ADSCs|autologous ADSCs
248886|NCT02297854|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
248887|NCT02297841|Device|Experimental: Novel lubricant Miami Fragrance|
248888|NCT02297841|Device|Experimental: Novel lubricant Miami no Fragrance|
248889|NCT02297841|Device|KY Liquid lubricant|
248890|NCT02297841|Device|Astroglide Gel lubricant|
248891|NCT02297828|Device|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
248892|NCT02297828|Device|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
248893|NCT02297815|Drug|Broad-spectrum antibiotics|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cefadroxil, cephalexin
248894|NCT02297815|Drug|Narrow-spectrum antibiotics|Amoxicillin, Penicillin
248895|NCT02297802|Drug|PD-0325901|
248896|NCT02297789|Device|Investigative Full Face Mask with Headgear|
248897|NCT02297763|Drug|quetiapine|"patient body weight <50kg : quetiapine 12.5mg patient body weight >=50kg : quetiapine 25mg~quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.~The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
248898|NCT02297763|Drug|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
248899|NCT02297750|Procedure|double-wire technique in patients undergoing ERCP with biliary cannulation|
248900|NCT02297750|Procedure|single-wire technique in patients undergoing ERCP with biliary cannulation|
248901|NCT02297737|Behavioral|Tai Chi|
248902|NCT02297737|Other|Health Education|
248903|NCT02297724|Other|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
248904|NCT02297711|Procedure|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
248905|NCT02297711|Procedure|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
248906|NCT02297698|Biological|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
248907|NCT02297698|Drug|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
248908|NCT02297698|Drug|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
248909|NCT02297685|Device|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
248910|NCT02297685|Device|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
248911|NCT02297685|Device|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
248912|NCT02297672|Radiation|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
248913|NCT02297672|Device|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
248914|NCT02297672|Device|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
248915|NCT02297659|Procedure|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
248916|NCT02297659|Device|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
248917|NCT02297646|Behavioral|Endurance Training|
248918|NCT02297620|Drug|Suglat®|oral
248919|NCT02297607|Dietary Supplement|Tube Feeding|
248920|NCT02297594|Drug|AK0529|AK0529 capsule for oral administration
248921|NCT02297594|Drug|Placebo|Sugar placebo capsule for oral administration
248922|NCT02297568|Drug|Calciferol|Comparison 25OHD levels between calciferol and placebo
248923|NCT02297568|Drug|placebo|
248924|NCT02297555|Device|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
248925|NCT02297542|Biological|Flu Vaccine|
248926|NCT02297529|Drug|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
248927|NCT02297516|Drug|Azzalure or Dysport|Glabellar lines
248928|NCT02297516|Device|Restylane or Emervel filler|Facial tissue augmentation
248929|NCT02297516|Device|Restylane Skinbooster|Facial skin rejuvenation
248930|NCT02297503|Drug|Azzalure|Glabellar lines
248931|NCT02297503|Device|Restylane/Emervel filler|Facial tissue augmentation
248932|NCT02297503|Device|Restylane Skinbooster|Facial skin rejuvenation
248933|NCT02297490|Drug|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
248934|NCT02297490|Biological|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
248935|NCT02297477|Drug|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
248936|NCT02297477|Drug|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
248937|NCT02297464|Other|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
248938|NCT02297464|Other|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
248939|NCT02297451|Procedure|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
248940|NCT02297438|Drug|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
248941|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
248942|NCT02297438|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
248943|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
248944|NCT02297425|Drug|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
248945|NCT02297412|Drug|Minocycline Hydrochloride|Given PO
248946|NCT02297412|Other|Placebo|Given PO
248947|NCT02297412|Other|Quality-of-Life Assessment|Ancillary studies
248948|NCT02297412|Other|Questionnaire Administration|Ancillary studies
248949|NCT02297399|Drug|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
248950|NCT02297399|Drug|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.~Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
248951|NCT02297386|Drug|[18F] DIHYDRO-TESTOSTERONE|
248952|NCT02297386|Device|PET scan|
248953|NCT02297386|Device|MRI|
248954|NCT02297386|Other|Blood draw|
248955|NCT02297360|Dietary Supplement|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
248956|NCT02297360|Other|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
248957|NCT02297334|Device|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
248958|NCT02297321|Device|Describe patch|Application of Describe patch over tattoo for approximately 5 minutes during Q-switched laser treatment
248959|NCT02297295|Other|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
248960|NCT02297282|Behavioral|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
248961|NCT02297269|Device|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
248962|NCT02297269|Device|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
248963|NCT02297256|Procedure|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
248964|NCT02297256|Procedure|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
248965|NCT02297243|Device|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
248966|NCT02297230|Radiation|Radiation Therapy (RT)|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
248967|NCT02297230|Drug|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
248968|NCT02297230|Drug|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
248969|NCT02297230|Drug|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
248970|NCT02297217|Drug|Carboplatin and Taxol (paclitaxel)|Patients will receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1. Preparation and administration of chemotherapy will be according to local site standard of care.
248971|NCT02297217|Radiation|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks (or reduced to 25 Gy/10 fractions if acute toxicity parameters are met during the run-in) and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on Days 1 and 8. Treatment will be planned, prescribed and delivered using standard 3D radiotherapy planning techniques to encompass the primary tumor and surrounding clinical target volume. Patients are seen for 2 weekly Treatment Visits during concurrent chemo-radiation then every 28 days until the End of Study Visit, approximately 6 months after Treatment Visit 1.
248972|NCT02297204|Procedure|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
248973|NCT02297204|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
248974|NCT02297191|Procedure|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.~Ultrasound images will be saved using the nomenclature TLIP Anatomy~Photos will only include surface anatomy of the low-to-mid back.~Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
248975|NCT02297191|Drug|Ropivicaine|
248976|NCT02297178|Procedure|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
248977|NCT02297178|Procedure|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
248978|NCT02297165|Behavioral|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).~For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
248979|NCT02297152|Device|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
248980|NCT02297139|Drug|Dasatinib|
249007|NCT02296931|Drug|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
249008|NCT02296918|Drug|acalabrutinib|100 mg twice daily continuous
249009|NCT02296918|Drug|Obinutuzumab|Cycle 2 Day 1, 100 mg IV will be administered. Then on Cycle 2 Day 2, 900 mg administered. On Cycle 2 Days 8 and 15, 1000 mg IV will be administered. On Cycles 3-7, 1000 mg on Day 1 of each cycle will be administered.
248981|NCT02297126|Other|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
248982|NCT02297113|Device|Macintosh blade|conventional endotracheal intubation
248983|NCT02297113|Device|C-MAC videolaryngoscope|
248984|NCT02297100|Drug|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
248985|NCT02297100|Procedure|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
248986|NCT02297100|Procedure|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
248987|NCT02297087|Genetic|Standard of care based on target(s) identified via GWS.|
248988|NCT02297074|Other|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
248989|NCT02297074|Other|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
248990|NCT02297074|Other|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
248991|NCT02297074|Other|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
248992|NCT02297074|Other|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.~After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
248993|NCT02297074|Other|Glucose|50 g of glucose were administered as a reference
248994|NCT02297061|Biological|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
248995|NCT02297048|Dietary Supplement|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
248996|NCT02297035|Behavioral|Behavioural testing|
248997|NCT02297035|Other|Brain imaging|MRI, PET
248998|NCT02297035|Genetic|Genetic screening|APOE, Progranulin
248999|NCT02297022|Device|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
249000|NCT02297009|Procedure|Buccal swab|Buccal swabs will be taken from the volunteers
249001|NCT02296996|Drug|Dabrafenib + Trametinib|
249002|NCT02296983|Biological|VSV-ZEBOV|VSV-ZEBOV
249003|NCT02296970|Procedure|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
249004|NCT02296957|Procedure|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
249005|NCT02296944|Other|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
249006|NCT02296931|Other|Saline|Standard IV Saline Fluids
249010|NCT02296918|Drug|Venetoclax|20 mg daily for 1 week, 50 mg daily for 1 week, 100 mg daily for 1 week, 200 mg daily for 1 week, then 400 mg daily for duration of treatment.
249011|NCT02296918|Drug|Rituximab|Rituximab will be given at a starting dose of 375 mg/m2 on Day 1 of Cycle 2, followed by 375 mg/m2 every week for 3 doses and then every 4 weeks for 5 doses for a total of 9 infusions
249012|NCT02296905|Drug|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
249013|NCT02296905|Drug|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
249014|NCT02296892|Drug|Remimazolam|For induction and maintenance of sedation
249015|NCT02296892|Drug|Placebo|Inactive control arm
249016|NCT02296892|Drug|Midazolam|For induction and maintenance of sedation
249017|NCT02296879|Genetic|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
249018|NCT02296853|Drug|TAF|Tenofovir alafenamide (TAF) 25 mg tablet administered orally
249019|NCT02296840|Drug|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
249020|NCT02296840|Drug|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
249021|NCT02296814|Drug|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
249022|NCT02296814|Drug|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
249023|NCT02296801|Drug|Letrozole|
249024|NCT02296801|Drug|palbociclib|
249025|NCT02296788|Behavioral|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
249026|NCT02296775|Biological|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
249027|NCT02296775|Biological|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
249028|NCT02296775|Biological|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
249029|NCT02296762|Drug|Sirolimus|Sirolimus tablets 2 mg
249030|NCT02296749|Drug|Sirolimus|Sirolimus tablets 2 mg
249031|NCT02296736|Radiation|Computerised tomography (CT) scan|Retrospective review of CT scans
249032|NCT02296723|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
249033|NCT02296710|Procedure|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
249034|NCT02296697|Device|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
249035|NCT02296697|Device|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
249036|NCT02296697|Other|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
249037|NCT02296684|Biological|MK-3475 (neoadjuvant)|
249038|NCT02296684|Procedure|Surgery|Standard of care
249039|NCT02296684|Radiation|Intensity modulated radiation therapy|Recommended, standard of care
249040|NCT02296684|Radiation|Image-guided radiation therapy|Recommended, standard of care
249041|NCT02296684|Drug|Cisplatin|Standard of care
249042|NCT02296684|Biological|MK-3475 (adjuvant)|
249043|NCT02296684|Procedure|Peripheral blood|-Baseline, time of surgery (between day 14-24 inclusive), 3 months post surgery, 6 months post surgery, 9 months post surgery, 12 months post surgery
249044|NCT02296671|Drug|Pemetrexed|
249045|NCT02296671|Drug|Oxaliplatin|
249046|NCT02296671|Drug|Leucovorin|
249047|NCT02296671|Drug|Fluorouracil|
249048|NCT02296671|Genetic|Germline genotyping analyses for TSER|
249049|NCT02296658|Radiation|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
249050|NCT02296658|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
249051|NCT02296645|Drug|ZuraPrep|Apply topically.
249052|NCT02296645|Drug|ChloraPrep|Apply topically.
249053|NCT02296632|Behavioral|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
249054|NCT02296619|Procedure|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
249055|NCT02296619|Procedure|Control|A sham band-aid will be applied to the abdomen of subjects
249056|NCT02296593|Device|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
249057|NCT02296580|Device|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
249058|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
249059|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
249060|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
249061|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
249319|NCT02294721|Device|TrueCPR|feedback device -2
249062|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
249063|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
249064|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
249065|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
249066|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
249067|NCT02296567|Other|Control Group|Control group Subjects will no previous anti-VEGF treatment
249068|NCT02296554|Procedure|SLAP Repair|SLAP repair for SLAP tear
249069|NCT02296554|Procedure|Biceps Tenodesis|Biceps tenodesis for SLAP tear
249070|NCT02296541|Biological|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249071|NCT02296541|Biological|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249072|NCT02296541|Biological|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249073|NCT02296541|Biological|MVA-CMDR|1×10^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249074|NCT02296541|Biological|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249075|NCT02296541|Biological|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249076|NCT02296541|Biological|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249077|NCT02296541|Biological|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
249078|NCT02296528|Device|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
249079|NCT02296515|Procedure|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
249080|NCT02296502|Other|DSM|Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
249081|NCT02296489|Device|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
249082|NCT02296476|Drug|MK-8628|Administered orally in a fasted state once daily.
249083|NCT02296463|Biological|RSV F Vaccine with adjuvant (0.5mL injection)|
249084|NCT02296463|Biological|RSV F Vaccine (0.5mL injection)|
249085|NCT02296463|Biological|Hepatitis A Vaccine (0.5mL injection)|
249086|NCT02296463|Biological|Placebo (0.5mL injection)|
249087|NCT02296450|Behavioral|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY-written, CDLQI (Children's DLQI; Cartoon version) - for patients under the age of 18 ONLY - cartoon version, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale)
249088|NCT02296437|Other|Transcranial direct current stimulation combined with cognitive training|
249089|NCT02296424|Drug|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
249090|NCT02296411|Drug|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
249091|NCT02296411|Drug|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
249092|NCT02296398|Drug|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
249093|NCT02296385|Dietary Supplement|Triple Strength Fish Oil|Triple Strength Fish Oil
249094|NCT02296372|Device|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.~In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
249095|NCT02296359|Biological|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
249096|NCT02296346|Drug|SoluMedrol|Infusion of drug subcutaneously, once a month.
249097|NCT02296346|Device|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
249098|NCT02296333|Drug|ondansetron|8 mg intravenous in the skin closure
249099|NCT02296333|Drug|isotonic|8 mg intravenous in the skin closure
249100|NCT02296320|Drug|MEDI4893|Participants will receive a single IV dose of MEDI4893 2000 or 5000 mg on Day 1 of the study.
249101|NCT02296320|Other|Placebo|Participants will receive a single IV dose of placebo matched to MEDI4893 on Day 1 of the study.
249102|NCT02296307|Other|Blood test: CA-125 biomarker|"CA-125 biomarker blood test at visit 1, day 1.~CA-125 biomarker blood test at visit 2, week 6."
249103|NCT02296307|Other|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
249104|NCT02296307|Other|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
249105|NCT02296294|Drug|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
249106|NCT02296294|Device|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
249107|NCT02296281|Drug|Pirfenidone|
249108|NCT02296268|Behavioral|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
249109|NCT02296255|Biological|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
249110|NCT02296242|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
249111|NCT02296229|Radiation|stereotactic body radiation therapy|Undergo SBRT
249112|NCT02296229|Other|quality-of-life assessment|Ancillary studies
249113|NCT02296229|Other|laboratory biomarker analysis|Correlative studies
249114|NCT02296229|Drug|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
249115|NCT02296216|Device|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
249116|NCT02296203|Drug|cetuximab|
249117|NCT02296203|Drug|irinotecan|
249118|NCT02296190|Drug|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
249119|NCT02296190|Drug|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
249120|NCT02296177|Behavioral|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
249121|NCT02296164|Drug|Valchlor|Valchlor gel 0.016%
249122|NCT02296151|Other|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
249123|NCT02296151|Other|iliotibial band stretches|Iliotibial band stretches
249124|NCT02296138|Drug|olodaterol|fixed dose combination
249125|NCT02296138|Drug|tiotropium|fixed dose combination
249126|NCT02296138|Drug|tiotropium|
249127|NCT02296125|Drug|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
249128|NCT02296125|Drug|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
249129|NCT02296125|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
249130|NCT02296125|Drug|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
249131|NCT02296125|Drug|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
249132|NCT02296125|Drug|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
249133|NCT02296112|Drug|trametinib|Given PO
249134|NCT02296112|Other|laboratory biomarker analysis|Correlative studies
249135|NCT02296112|Other|pharmacological study|Correlative studies
249136|NCT02296099|Drug|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
249137|NCT02296099|Drug|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
249138|NCT02296073|Drug|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
249139|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
249140|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
249141|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
249142|NCT02296073|Drug|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
249143|NCT02296073|Other|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
249144|NCT02296060|Procedure|6 minutes walking test|
249145|NCT02296047|Drug|Placebo|physiological saline
249146|NCT02296047|Drug|ipratropium bromide|80 µg inhalation once
249147|NCT02296047|Drug|salbutamol|400 µg inhalation once
249148|NCT02296021|Drug|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
249149|NCT02296021|Drug|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
249150|NCT02296021|Drug|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
249151|NCT02296021|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
249152|NCT02296021|Drug|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
249153|NCT02296008|Device|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.~3D picture of pressures of anorectal will be recorded."
249154|NCT02295995|Behavioral|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Approximately 50 Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
249155|NCT02295982|Procedure|Hand assisted laparoscopic nephrectomy|patients with renal cancer will undergo hans assisted laparoscopic nephrectomy
249156|NCT02295969|Drug|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
249157|NCT02295956|Behavioral|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
249158|NCT02295956|Other|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
249159|NCT02295956|Other|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
249160|NCT02295956|Behavioral|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
249161|NCT02295956|Other|Booklet|Exercise instructional booklet given to all participants describing all exercises.
249162|NCT02295943|Other|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
249163|NCT02295930|Other|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
249164|NCT02295930|Other|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:~CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by~IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm IV over 2-h, day 1 followed by~5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.~Surgical revaluation will be performed after the induction phase (8 cycles).~Patients deemed unsuitable for surgery will received maintenance treatment as follows:~•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
249165|NCT02295917|Device|Transvaginal sonography|Transvaginal sonography
249166|NCT02295891|Device|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
249167|NCT02295878|Dietary Supplement|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
249168|NCT02295878|Dietary Supplement|Placebo|
249169|NCT02295865|Drug|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
249170|NCT02295865|Drug|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
249171|NCT02295865|Drug|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
249172|NCT02295865|Drug|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
249173|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
249174|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID DIET|2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
249175|NCT02295839|Behavioral|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
249176|NCT02295826|Drug|Dabigatran|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
249177|NCT02295826|Drug|Acetylsalicylic acid|participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
249178|NCT02295813|Biological|FBF001|
249179|NCT02295813|Drug|Placebo|
249180|NCT02295800|Other|Standard of care|
249181|NCT02295800|Other|Semi-structured interviews|
249182|NCT02295787|Drug|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
249183|NCT02295787|Drug|Placebo|
249184|NCT02295774|Procedure|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
249185|NCT02295774|Drug|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
249186|NCT02295761|Behavioral|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
249187|NCT02295761|Behavioral|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
249188|NCT02295748|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
249189|NCT02295735|Device|Mepilex® Border Sacrum and Mepilex® Border Heel|
249190|NCT02295722|Drug|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
249191|NCT02295722|Drug|Melphalan|200 mg/m2
249192|NCT02295722|Other|ASCT|Day 0 - Stem cell infusion
249193|NCT02295709|Procedure|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
249194|NCT02295709|Procedure|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.~Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
249195|NCT02295709|Drug|Dexamethasone|One of the most efficient steroids
249196|NCT02295709|Device|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
249197|NCT02295709|Radiation|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
249198|NCT02295696|Behavioral|EMMA|Consultations using dialogue tools
249199|NCT02295683|Device|Renal Denervation|
249200|NCT02295670|Device|Vividtrac|video-laryngoscopy
249201|NCT02295670|Device|MIL|direct-laryngoscopy
249202|NCT02295657|Device|standard double-lumen tube|intubation using standard double-lumen tube
249203|NCT02295657|Device|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
249204|NCT02295644|Device|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
249205|NCT02295631|Device|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
249206|NCT02295631|Device|ETView VivaSight SL|ETI with ETView VivaSight SL
249207|NCT02295618|Device|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
249208|NCT02295618|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
249209|NCT02295605|Other|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
249210|NCT02295605|Other|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
249211|NCT02295592|Procedure|TSTstarr+|"TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
249212|NCT02295592|Procedure|PPH|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
249213|NCT02295579|Other|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
249214|NCT02295566|Drug|Nitric Oxide|Not required
249215|NCT02295566|Drug|Control|Not required
249216|NCT02295553|Drug|Ketamine|
249217|NCT02295553|Drug|Propofol|
249218|NCT02295540|Radiation|hypofractionated radiation therapy|Undergo hypofractionated IMRT
249219|NCT02295540|Radiation|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
249220|NCT02295540|Procedure|therapeutic conventional surgery|Undergo surgery
249221|NCT02295540|Other|laboratory biomarker analysis|Correlative studies
249269|NCT02295072|Behavioral|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
249270|NCT02295059|Dietary Supplement|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
249271|NCT02295046|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
249272|NCT02295033|Radiation|Boost irradiation|
249273|NCT02295020|Drug|Standard treatment only|Standard treatment such as NSAIDs and injections
249222|NCT02295527|Other|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
249223|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
249224|NCT02295514|Biological|PTP1B dosage|PTP1B sampled and dosed during sepsis
249225|NCT02295501|Biological|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
249226|NCT02295488|Procedure|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
249227|NCT02295488|Biological|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
249228|NCT02295475|Drug|Apixaban|
249229|NCT02295475|Drug|Warfarin|
249230|NCT02295462|Other|Person-centered Care|Medication Review + Person-centered Care
249231|NCT02295462|Other|Optimised Treatment|Medication Review only
249232|NCT02295449|Device|biopsy sample performed after the SonoVue® injection|
249233|NCT02295436|Drug|minodronic acid|comparison of different doses, ages and medication conditions
249234|NCT02295410|Behavioral|CPT|
249235|NCT02295397|Other|food|food provocation, skin testing, blood sampling
249236|NCT02295384|Other|Retrospective Audit|Retrospective Audit
249237|NCT02295345|Other|Cognitive Behavioural Therapy for Insomnia|
249238|NCT02295332|Drug|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
249239|NCT02295332|Drug|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
249240|NCT02295319|Other|Individual discharge|"See previous description in Arms"
249241|NCT02295306|Device|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
249242|NCT02295293|Drug|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
249243|NCT02295293|Drug|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
249244|NCT02295280|Drug|Metoclopramide|IV
249245|NCT02295280|Drug|Diphenhydramine|iv
249246|NCT02295280|Drug|Codeine|PO
249247|NCT02295267|Other|walnut allergy provocation|double blind placebo controlled food challenge
249248|NCT02295254|Other|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
249249|NCT02295241|Other|No intervention|This is an observational trial, no interventions are being used.
249250|NCT02295228|Other|No intervention|There are no interventions. This is an observational trial.
249251|NCT02295215|Other|Exercise|Exercise Training for 4 months
249252|NCT02295202|Device|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
249253|NCT02295202|Device|Nasal strips|
249254|NCT02295189|Drug|Ketorolac Tromethamine|anti-inflammatory injection
249255|NCT02295189|Drug|Triamcinolone Acetonide|corticosteroid injection
249256|NCT02295176|Dietary Supplement|Armolipid Plus|
249257|NCT02295176|Dietary Supplement|Placebo|
249258|NCT02295163|Procedure|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
249259|NCT02295163|Procedure|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
249260|NCT02295150|Drug|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
249261|NCT02295137|Procedure|Using pre-procedural CTA to guide advanced EVAR procedure|
249262|NCT02295124|Drug|Oxycodone|Patients will receive oxycodone 10mg (5mg if > 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
249263|NCT02295124|Drug|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if > 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
249264|NCT02295111|Device|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
249265|NCT02295111|Behavioral|TCM health consult|Traditional Chinese Medicine Health Consult without needling
249266|NCT02295111|Other|Usual Care|Standard NHS care
249267|NCT02295098|Other|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
249268|NCT02295098|Other|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
249274|NCT02295020|Device|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
249275|NCT02295007|Behavioral|text message|
249276|NCT02294994|Drug|tirofiban|
249277|NCT02294981|Device|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
249278|NCT02294968|Other|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
249279|NCT02294955|Device|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
249280|NCT02294955|Drug|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
249281|NCT02294955|Drug|Sotalol|Dosage orally 80-160 mg twice daily
249282|NCT02294955|Drug|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
249283|NCT02294955|Drug|Propafenone|Dosage orally 300 mg twice daily
249284|NCT02294955|Drug|Disopyramide|Dosage orally 250-375 mg twice Daily
249285|NCT02294955|Drug|Dronedarone|Dosage orally 400 mg twice daily
249286|NCT02294942|Drug|RANCAD|Extended-Release RANCAD
249287|NCT02294929|Procedure|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
249288|NCT02294916|Device|AWS|Video-laryngoscopy 1
249289|NCT02294916|Device|Intubrite|Video-laryngoscopy 2
249290|NCT02294916|Device|AirTraq|Optical-laryngoscopy
249291|NCT02294916|Device|MIL|Direct-laryngoscopy
249292|NCT02294903|Procedure|Coiled Bipolar Radiofrequency Ablation|Radiofrequency ablation by use of bipolar electrodes
249293|NCT02294890|Procedure|Total knee arthroplasty|
249294|NCT02294877|Drug|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
249295|NCT02294864|Device|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
249296|NCT02294864|Procedure|Physical Therapy|
249297|NCT02294851|Drug|BMS-986168|
249298|NCT02294851|Drug|BMS-986168 Placebo|
249299|NCT02294838|Device|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
249300|NCT02294838|Other|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
249301|NCT02294838|Other|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
249302|NCT02294825|Procedure|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
249303|NCT02294812|Behavioral|Cognitive training|"Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training."
249304|NCT02294799|Procedure|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization. 3 times a week during 4 weeks.
249305|NCT02294786|Drug|Lapatinib|Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
249306|NCT02294786|Drug|Capecitabine|Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
249307|NCT02294786|Drug|Octreotide|Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability
249308|NCT02294773|Procedure|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
249309|NCT02294773|Drug|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
249310|NCT02294773|Drug|Letrozole|Patient is to take letrozole during cycle days 3-7.
249311|NCT02294760|Device|Subsensory|The stimulation is set to 90% of the sensory threshold.
249312|NCT02294760|Device|OFF|The stimulation is turned OFF.
249313|NCT02294747|Device|Sliding Hip Screw with Trochanteric Stabilization Plate|
249314|NCT02294747|Device|Sliding Hip Screw without Trochanteric Stabilization Plate|
249315|NCT02294734|Drug|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
249316|NCT02294734|Drug|Placebo|Dry powder for inhalation via DISKUS 'device'
249317|NCT02294721|Device|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
249318|NCT02294721|Device|The CPREazy|feedback device-1
249320|NCT02294721|Device|The CPR PRO APP|feedback device -3
249321|NCT02294721|Device|The CardioPump|feedback device- 4
249322|NCT02294708|Behavioral|postoperative postures|two postoperative postures: supine and temporal-lateral
249323|NCT02294682|Drug|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
249324|NCT02294669|Device|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
249325|NCT02294656|Drug|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
249326|NCT02294656|Drug|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
249327|NCT02294643|Drug|Sarpogrelate|
249328|NCT02294643|Drug|Aspirin|
249329|NCT02294643|Drug|Clopidogrel|
249330|NCT02294643|Drug|Placebo (for Sarpogrelate)|
249331|NCT02294630|Drug|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
249332|NCT02294617|Other|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
249333|NCT02294617|Other|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
249334|NCT02294604|Device|ethyl alcochol, chlorhexidine and moisturizers|
249335|NCT02294604|Device|chlorhexidine|
249336|NCT02294604|Device|povidone-iodine|
249337|NCT02294591|Drug|N-acetylcysteine|Add-on treatment of NAC
249338|NCT02294591|Drug|Placebo|Add-on treatment of placebo
249339|NCT02294565|Drug|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
249340|NCT02294565|Drug|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
249341|NCT02294552|Drug|Cyclophosphamide|
249342|NCT02294552|Drug|Busulfan|
249343|NCT02294552|Drug|Fludarabine monophosphate|
249344|NCT02294552|Drug|Tacrolimus|
249345|NCT02294552|Drug|Mycophenolate mofetil|
249346|NCT02294552|Procedure|Allogeneic hematopoietic stem cell transplantation|
249347|NCT02294539|Drug|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
249348|NCT02294539|Drug|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
249349|NCT02294539|Drug|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
249350|NCT02294539|Drug|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
249351|NCT02294526|Other|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
249352|NCT02294513|Device|Standard audiologic rehabilitation (incl. HI)|The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
249353|NCT02294474|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
249354|NCT02294474|Drug|Humalog|Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
249355|NCT02294474|Drug|insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
249356|NCT02294461|Drug|Enzalutamide|Oral
249357|NCT02294461|Drug|Placebo|Oral
249358|NCT02294448|Drug|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
249359|NCT02294435|Device|Visceral Manifold and Thoracic Bifurcation|Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
249360|NCT02294435|Device|Unitary Manifold|Unitary Manifold Endovascular stent graft system
249361|NCT02294422|Device|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
249362|NCT02294422|Device|LOR|
249363|NCT02294422|Device|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
249393|NCT02294240|Other|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
249394|NCT02294227|Biological|Secukinumab|Secukinumab 150 mg (1 mL liquid formulation) in pre-filled syringes were supplied by Novartis. Each secukinumab 300 mg dose was given as two sc injections of secukinumab 150 mg.
249395|NCT02294227|Other|Placebo|Placebo to secukinumab was also available in 1.0 mL liquid formulation in prefilled syringe to match the active drug.
249396|NCT02294214|Device|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
249397|NCT02294214|Device|Active ingredient|Transfluthrin (Active ingredient)
249448|NCT02293876|Device|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
249364|NCT02294409|Behavioral|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
249365|NCT02294409|Behavioral|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
249366|NCT02294396|Drug|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
249367|NCT02294396|Drug|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 2 tablets)
249368|NCT02294396|Drug|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (could be increased to 1 tablet twice daily after breakfast and after dinner)
249369|NCT02294396|Drug|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (could be increased to 2 tablets twice daily after breakfast and after dinner)
249370|NCT02294396|Drug|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (could not be increased)
249371|NCT02294357|Drug|Carfilzomib|
249372|NCT02294357|Drug|Dexamethasone|If the patient was receiving steroids at the equivalent of > 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
249373|NCT02294357|Drug|Prednisone|f the patient was receiving prednisone, at the equivalent of > 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
249374|NCT02294357|Drug|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of > 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
249375|NCT02294357|Drug|Lenalidomide|given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
249376|NCT02294357|Drug|Pomalidomide|administered PO at 4mg daily on days 1-21 of a 28 day cycle
249377|NCT02294344|Other|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
249378|NCT02294344|Drug|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.~After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).~The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count ＜3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count ＜3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
249379|NCT02294318|Behavioral|HealthCall+Motivational Interviewing|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
249380|NCT02294318|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
249381|NCT02294305|Drug|Vortioxetine|
249382|NCT02294305|Drug|Placebo|
249383|NCT02294292|Drug|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
249384|NCT02294292|Drug|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.~If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
249385|NCT02294292|Procedure|Endoscopic Variceal Ligation|
249386|NCT02294279|Drug|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
249387|NCT02294266|Drug|Mephedrone and alcohol|"Single oral dose mephedrone~Single oral dose alcohol"
249388|NCT02294266|Drug|Mephedrone|Single oral dose mephedrone
249389|NCT02294266|Drug|Alcohol|Single oral dose alcohol
249390|NCT02294266|Drug|Placebo|Single oral dose placebo
249391|NCT02294253|Drug|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
249392|NCT02294240|Dietary Supplement|Energy dense biscuits|Energy dense biscuits will be provided
249398|NCT02294214|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
249399|NCT02294201|Device|Spatial Repellent product with active ingredient|Spatial Repellent product
249400|NCT02294201|Device|Active ingredient|Transfluthrin (Active ingredient)
249401|NCT02294201|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
249402|NCT02294188|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
249403|NCT02294188|Device|Active ingredient|Transfluthrin (Active ingredient)
249404|NCT02294188|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
249405|NCT02294175|Device|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
249406|NCT02294175|Procedure|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
249407|NCT02294162|Drug|Ketamine i.v|
249408|NCT02294149|Drug|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
249409|NCT02294149|Drug|placebo|
249410|NCT02294136|Behavioral|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
249411|NCT02294136|Behavioral|Educational Control|Attention Control
249412|NCT02294123|Other|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
249413|NCT02294110|Other|spinal anesthesia|non diabetes mellitus
249414|NCT02294097|Procedure|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
249415|NCT02294084|Drug|Sitagliptin|Each subject in this arm will receive Sitagliptin (100mg/day) for a duration of 12 weeks.
249416|NCT02294084|Drug|placebo|Each subject will receive a placebo (once a day) for 12 weeks.
249417|NCT02294071|Drug|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
249418|NCT02294071|Drug|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
249419|NCT02294058|Drug|RPC1063|
249420|NCT02294058|Drug|Beta interferon|
249421|NCT02294032|Drug|Immunosuppressive Agents|standard of care for patients post-transplant
249422|NCT02294019|Drug|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
249423|NCT02294006|Drug|Everolimus plus Octreotide LAR plus Metformin|
249424|NCT02293993|Drug|SGI-110|
249425|NCT02293980|Drug|PART 1: PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment for this patient population.
249426|NCT02293980|Drug|PART 2: PT2385 Tablets in combination with nivolumab|PT2385 inhibits HIF-2α and in combination with nivolumab is a novel approach to treatment for this patient population.
249427|NCT02293980|Drug|PART 3: PT2385 Tablets in combination with cabozantinib|PT2385 inhibits HIF-2α an upstream regulator of VEGF activation. In combination with the VEGF inhibitor cabozantinib tablets, this is a novel approach to treatment for this patient population.
249428|NCT02293967|Drug|MT-1303|
249429|NCT02293954|Procedure|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
249430|NCT02293954|Procedure|positron emission tomography|Undergo PET
249431|NCT02293954|Other|laboratory biomarker analysis|Correlative studies
249432|NCT02293954|Other|pharmacological study|Correlative studies
249433|NCT02293954|Drug|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
249434|NCT02293941|Drug|JKB-122|Participants were randomized to receive JKB-122 5mg/15mg/35mg/placebo for 12 weeks
249435|NCT02293941|Drug|Placebo|Participants were randomized to receive JKB-122 5mg/15mg/35mg/placebo for 12 weeks
249436|NCT02293928|Procedure|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
249437|NCT02293915|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
249438|NCT02293915|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
249439|NCT02293902|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
249440|NCT02293902|Other|Placebo (for sarilumab)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
249441|NCT02293902|Drug|Methotrexate|Dispensed according to local practice.
249442|NCT02293902|Drug|Folic acid|Dispensed according to local practice.
249443|NCT02293889|Dietary Supplement|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (>50nmol/L) by 3 months.
249444|NCT02293889|Behavioral|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
249445|NCT02293889|Other|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
249446|NCT02293876|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
249447|NCT02293876|Device|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
249449|NCT02293863|Drug|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
249450|NCT02293863|Drug|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
249451|NCT02293863|Drug|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
249452|NCT02293850|Biological|OBP-301|A range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
249453|NCT02293837|Drug|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
249454|NCT02293837|Drug|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
249455|NCT02293824|Drug|Caffeine|Given per standard of care.
249456|NCT02293811|Other|Analysis|"An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.~We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.~Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating)."
249457|NCT02293798|Device|silk surgical scaffold|surgical implant
249458|NCT02293785|Drug|Oxycodone-Naloxone|
249459|NCT02293772|Other|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
249460|NCT02293772|Other|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
249461|NCT02293772|Other|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
249462|NCT02293759|Procedure|HoLEP|Holmium laser enucleation of the prsotate
249463|NCT02293759|Procedure|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
249464|NCT02293746|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
249465|NCT02293720|Device|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
249466|NCT02293707|Biological|GX301|"GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.~Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).~Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG."
249467|NCT02293694|Drug|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
249468|NCT02293681|Drug|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
249469|NCT02293681|Drug|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
249470|NCT02293681|Drug|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
249471|NCT02293668|Drug|FSH 225IU and hMG 225IU|
249472|NCT02293668|Drug|FSH 150IU and hMG 150IU|
249473|NCT02293668|Drug|Letrozole 5mg and hMG 150IU|
249474|NCT02293655|Drug|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
249475|NCT02293629|Drug|BMS-986147|
249476|NCT02293629|Drug|Placebo matching BMS-986147|
249477|NCT02293616|Dietary Supplement|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
249478|NCT02293616|Dietary Supplement|Placebo|
249479|NCT02293603|Biological|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
249480|NCT02293590|Drug|Certolizumab Pegol|
249481|NCT02293577|Device|continuous glucose monitor|In this study all subjects will wear a continuous glucose monitor for 5 days.
249482|NCT02293564|Drug|gevokizumab|Solution for subcutaneous injection
249483|NCT02293551|Drug|Lispro|Administered SC
249484|NCT02293538|Drug|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
249485|NCT02293538|Drug|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
249486|NCT02293538|Device|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
249487|NCT02293525|Device|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
249488|NCT02293525|Drug|Ropivacaine|
249489|NCT02293525|Drug|Saline|
249490|NCT02293525|Drug|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
249491|NCT02293525|Drug|Oxycodone|10mg every 4-6 hours
249492|NCT02293512|Behavioral|Coping Effectiveness Training|A CET psychoeducational intervention is provided to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
249493|NCT02293512|Behavioral|Cognitive-behavioral therapy|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
249575|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Once Daily|
249494|NCT02293512|Behavioral|Acceptance and Commitment Therapy|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
249495|NCT02293499|Behavioral|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma [LTAA],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
249496|NCT02293486|Dietary Supplement|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
249497|NCT02293473|Device|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
249498|NCT02293473|Device|BIS-Bispectral Index Monitor|Depth of anaesthesia
249499|NCT02293473|Device|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
249500|NCT02293473|Other|Standard of care|Using standard of care
249501|NCT02293460|Drug|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days."
249502|NCT02293447|Drug|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
249503|NCT02293447|Drug|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
249504|NCT02293421|Other|Obstructive sleep apnea|
249505|NCT02293395|Drug|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
249506|NCT02293395|Drug|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
249507|NCT02293395|Drug|Clopidogrel|Clopidogrel 75 mg once daily orally.
249508|NCT02293395|Drug|Ticagrelor|Ticagrelor 90 mg twice daily orally.
249509|NCT02293369|Procedure|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
249510|NCT02293369|Procedure|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
249511|NCT02293356|Drug|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
249512|NCT02293343|Other|blood profile|
249513|NCT02293330|Drug|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
249514|NCT02293330|Drug|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
249515|NCT02293317|Biological|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
249516|NCT02293317|Drug|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
249517|NCT02293317|Other|Saline|Placebo
249518|NCT02293304|Other|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
249519|NCT02293304|Other|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
249520|NCT02293291|Dietary Supplement|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.~To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
249521|NCT02293278|Behavioral|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
249522|NCT02293265|Drug|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
249523|NCT02293252|Device|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
249524|NCT02293239|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
249525|NCT02293226|Device|CoopDech|Video-laryngoscopy 1
249526|NCT02293226|Device|CoPilot|video-laryngoscopy 2
249527|NCT02293226|Device|Intubrite|Video-laryngoscopy 3
249528|NCT02293226|Device|Vividtrack|video-laryngoscopy 4
249529|NCT02293213|Behavioral|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
249530|NCT02293213|Behavioral|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
249531|NCT02293213|Behavioral|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
249532|NCT02293213|Behavioral|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
249533|NCT02293213|Behavioral|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
249534|NCT02293213|Behavioral|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
249535|NCT02293200|Device|Standard BLS|basic life support without any feedback device
249536|NCT02293200|Device|TrueCPR|CPR with feedback device
249537|NCT02293187|Dietary Supplement|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level <70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
249538|NCT02293187|Other|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
249539|NCT02293174|Device|Topcon TRC-NW400|Retinal Fundus Camera
249540|NCT02293174|Device|TRC-NW8|Retinal Fundus Camera
249541|NCT02293174|Device|TRC-NW400|Retinal Fundus Camera
249542|NCT02293174|Device|Canon-CR2|Retinal Fundus Camera
249543|NCT02293174|Device|Zeiss Visucam PRO|Retinal Fundus Camera
249544|NCT02293161|Drug|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
249545|NCT02293161|Drug|Placebo|It is Sodium Chloride Intravenous Infusion
249546|NCT02293148|Drug|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
249547|NCT02293148|Drug|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
249548|NCT02293148|Drug|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
249549|NCT02293148|Drug|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
249550|NCT02293148|Drug|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
249551|NCT02293135|Device|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
249552|NCT02293135|Device|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
249553|NCT02293122|Other|Observational|Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F&A Specular Microscope.
249554|NCT02293109|Drug|carfilzomib|Given IV
249555|NCT02293109|Drug|cyclophosphamide|Given IV
249556|NCT02293109|Drug|vincristine sulfate|Given IV
249557|NCT02293109|Drug|doxorubicin hydrochloride|Given IV
249558|NCT02293109|Drug|dexamethasone|Given PO
249559|NCT02293109|Drug|methotrexate|Given IV
249560|NCT02293109|Drug|cytarabine|Given IV
249561|NCT02293109|Drug|leucovorin calcium|Given IV or PO
249562|NCT02293109|Drug|methylprednisolone|Given IV
249563|NCT02293109|Biological|rituximab|
249564|NCT02293109|Other|laboratory biomarker analysis|Correlative studies
249565|NCT02293096|Drug|metoprolol succinate|
249566|NCT02293096|Genetic|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
249567|NCT02293096|Procedure|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
249568|NCT02293083|Drug|trigger point injection|
249569|NCT02293070|Other|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
249570|NCT02293070|Procedure|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
249571|NCT02293057|Behavioral|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 60 minutes long and include required and optional activities.
249572|NCT02293057|Behavioral|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
249573|NCT02293044|Device|Crest® Sensi-Stop™ Strips|
249574|NCT02293031|Device|"Gene-activated matrix Nucleostim"|"Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®."
249576|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Twice Daily|
249577|NCT02293018|Drug|1.5% (w/w) MTC896 Gel Once Daily|
249578|NCT02293005|Drug|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
249579|NCT02292992|Device|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
249580|NCT02292979|Drug|Doxorubicin|25mg/m2
249581|NCT02292979|Drug|Bleomycin|10mg/m2
249582|NCT02292979|Drug|Vinblastine|6mg/m2
249583|NCT02292979|Drug|Dacarbazine|375mg/m2
249584|NCT02292979|Drug|Brentuximab Vedotin|1.2 mg/kg
249585|NCT02292966|Drug|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
249586|NCT02292953|Other|Serum Prolactin levels|blood samples will be drawn from patients undergoing ICSI to analyse serum prolactin levels
249587|NCT02292927|Behavioral|Post-intervention arm = Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
249588|NCT02292914|Procedure|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
249589|NCT02292914|Procedure|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
249590|NCT02292901|Device|Macintosh laryngoscope|
249591|NCT02292901|Device|McGrath Mac videolaryngoscope|
249592|NCT02292888|Other|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
249593|NCT02292862|Procedure|Lymph node and blood sampling|"By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.~Blood (1ml) is taken from mother and infant."
249594|NCT02292849|Behavioral|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
249595|NCT02292849|Other|Standard Mental Health Referral|Standard mental health referral to a community agency
249596|NCT02292836|Other|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
249597|NCT02292823|Device|MGuard™ Prime Embolic Protection Stent System|
249598|NCT02292810|Device|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
249599|NCT02292810|Device|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
249600|NCT02292797|Other|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
249601|NCT02292784|Drug|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
249602|NCT02292784|Drug|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
249603|NCT02292784|Drug|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
249604|NCT02292771|Drug|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
249605|NCT02292771|Drug|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
249606|NCT02292771|Drug|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
249607|NCT02292771|Drug|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
249608|NCT02292758|Biological|Bevacizumab|Given IV
249609|NCT02292758|Biological|Cetuximab|Given IV
249610|NCT02292758|Drug|Irinotecan|Given IV
249611|NCT02292758|Other|Laboratory Biomarker Analysis|Correlative studies
249612|NCT02292758|Other|Placebo|Given IV
249613|NCT02292745|Radiation|stereotactic radiotherapy|
249614|NCT02292732|Drug|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter [mm]) to be taken orally and once daily
249615|NCT02292732|Drug|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
249616|NCT02292732|Drug|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
249617|NCT02292732|Drug|Placebo|Each green tablet will contain only inert ingredients: D&C yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
249618|NCT02292719|Drug|OBV/PTV/r|Tablet
249620|NCT02292719|Drug|Ribavirin (RBV)|Tablet
249621|NCT02292706|Drug|Sofosbuvir|Exposure of interest for participants who received a sofosbuvir-based regimen in a previous Gilead study for chronic hepatitis C virus infection.
249622|NCT02292693|Device|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
249623|NCT02292693|Device|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
249624|NCT02292693|Device|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
249625|NCT02292667|Procedure|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
249626|NCT02292667|Drug|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
249627|NCT02292667|Drug|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
249628|NCT02292654|Drug|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
249629|NCT02292641|Procedure|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
249630|NCT02292628|Drug|Infusion of mesenchymal stem cells from adipose tissue|
249631|NCT02292628|Other|Infusion of placebo|
249632|NCT02292615|Other|Medical Imaging|
249633|NCT02292602|Behavioral|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
249634|NCT02292589|Device|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
249635|NCT02292589|Device|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
249636|NCT02292589|Device|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
249637|NCT02292576|Other|Cocoa Pure|Cocoa Pure.
249638|NCT02292576|Other|Placebo|Placebo.
249639|NCT02292563|Procedure|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
249640|NCT02292563|Procedure|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
249641|NCT02292550|Drug|Ribociclib|CDK 4/6 inhibitor
249642|NCT02292550|Drug|Ceritinib|ALK inhibitor
249643|NCT02292537|Drug|Nusinersen|Administered by intrathecal (IT) lumbar puncture (LP) injection
249644|NCT02292537|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
249645|NCT02292524|Other|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
249646|NCT02292511|Behavioral|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
249647|NCT02292498|Device|FLIR ONE|
249648|NCT02292485|Behavioral|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
249649|NCT02292472|Drug|Botulinum Toxin Type A|Inject intramuscularly once in visit 2
249650|NCT02292472|Drug|Placebos|Inject intramuscularly once in visit 2
249651|NCT02292459|Drug|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
249652|NCT02292459|Drug|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
249653|NCT02292446|Drug|Ruxolitinib|supplied as 5 mg, 10 mg and 20 mg tablets to be taken orally
249654|NCT02292433|Drug|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
249655|NCT02292433|Drug|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
249656|NCT02292433|Drug|Placebo|tablets, breakfast plus lunch, 7 days
249657|NCT02292407|Device|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
249658|NCT02292394|Behavioral|Multicomponent Cognitive Behavioral Telephone Intervention|
249659|NCT02292394|Behavioral|Telephone Intervention Pleasant Activities|
249660|NCT02292381|Other|Isometric exercise|
249708|NCT02292082|Device|8 MHz. Chiba needle, 22 G / 4 inches|
249709|NCT02292069|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
249756|NCT02291640|Device|MIL|direct laryngoscopy
249661|NCT02292368|Behavioral|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
249662|NCT02292368|Procedure|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
249663|NCT02292368|Procedure|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
249664|NCT02292355|Other|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
249665|NCT02292342|Dietary Supplement|Water|Control
249666|NCT02292342|Dietary Supplement|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
249667|NCT02292342|Dietary Supplement|Epicatechin 0.5 mg/kg|EC 0.5
249668|NCT02292342|Dietary Supplement|Epicatechin 1.0 mg/kg|EC 1.0
249669|NCT02292329|Dietary Supplement|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
249670|NCT02292329|Dietary Supplement|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
249671|NCT02292316|Behavioral|gait and cognitive assessments|several tests are given in each domain
249672|NCT02292316|Biological|blood sample|routine analyses in rheumatology such blood count and 25OH-D
249673|NCT02292316|Other|osteodensitometry|Looking for osteoporosis
249674|NCT02292303|Dietary Supplement|zinc-enriched yeast|
249675|NCT02292303|Dietary Supplement|Zinc references|
249676|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
249677|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
249678|NCT02292290|Drug|Sulfonylurea or Pioglitazone|Addition to Metformin
249679|NCT02292290|Drug|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
249680|NCT02292277|Drug|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
249681|NCT02292251|Behavioral|Device-assisted therapy|
249682|NCT02292251|Behavioral|Therapy-based occupational therapy|
249683|NCT02292238|Drug|Benfotiamine|"To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).~To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
249684|NCT02292225|Drug|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
249685|NCT02292225|Drug|Obinutuzumab|1000mg/40mL single-use vials
249686|NCT02292212|Device|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
249687|NCT02292199|Device|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
249688|NCT02292199|Device|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
249689|NCT02292199|Device|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
249690|NCT02292186|Drug|Revusiran (ALN-TTRSC)|
249691|NCT02292173|Drug|Trametinib|"Dose Escalation:~Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
249692|NCT02292173|Drug|Sorafenib|"Dose Escalation:~Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.~Dose Expansion:~Maximum Tolerated Dose (MTD)"
249693|NCT02292134|Device|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
249694|NCT02292121|Procedure|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
249695|NCT02292121|Other|a solution of mannitol and lactitol|
249696|NCT02292108|Behavioral|dietetic counselling|
249697|NCT02292108|Behavioral|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
249698|NCT02292095|Procedure|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
249699|NCT02292095|Procedure|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
249700|NCT02292082|Drug|Bupivacaine|
249701|NCT02292082|Drug|Morphine|
249702|NCT02292082|Drug|Methylprednisolone|
249703|NCT02292082|Drug|Cefazolin|
249704|NCT02292082|Drug|Normal saline|
249705|NCT02292082|Drug|Midazolam|
249706|NCT02292082|Drug|Propofol|
249710|NCT02292056|Behavioral|1-on-1 counseling|"Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method~Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.~Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.~10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.~Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.~Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
249711|NCT02292043|Drug|HTEA|HTEA
249712|NCT02292030|Drug|HTEA|usually high thoracic epidural anesthesia
249713|NCT02292017|Device|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
249714|NCT02292004|Device|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
249715|NCT02292004|Procedure|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
249716|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
249717|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
249718|NCT02291978|Device|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
249719|NCT02291952|Behavioral|Meal schedule|
249720|NCT02291939|Procedure|Parotidectomy|Surgical Intervention with the FMwand Surgical System
249721|NCT02291926|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
249722|NCT02291913|Drug|Everolimus|
249723|NCT02291913|Drug|Exemestane|Anti-estrogen therapy
249724|NCT02291913|Drug|Tamoxifen|Anti-estrogen therapy
249725|NCT02291913|Drug|Fulvestrant|Anti-estrogen therapy
249726|NCT02291913|Drug|Anastrozole|Anti-estrogen therapy
249727|NCT02291913|Drug|Letrozole|Anti-estrogen therapy
249728|NCT02291913|Drug|Toremifine|Anti-estrogen therapy
249729|NCT02291900|Procedure|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
249730|NCT02291887|Drug|Ranibizumab|Intravitreal injection of Ranibizumab
249731|NCT02291887|Drug|Aflibercept|Intravitreal injection of Aflibercept
249732|NCT02291874|Drug|Ipragliflozin|oral
249733|NCT02291861|Drug|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
249734|NCT02291861|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks. Tablets were swallowed whole with water and taken with food.
249735|NCT02291848|Biological|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 5 x 10^6 cells/m2 and Day 14: 5 x 10^6 cells/m2~Dose Level Two:~Day 0: 1 x 10^7 cells/m2 and Day 14: 1 x 10^7 cells/m2~Dose Level Three:~Day 0 2 x 10^7 cells/m2 and Day 14 2 x 10^7 cells/m2~If patients without measurable disease remain in complete remission or those patients with measurable active disease at the time of infusion have stable disease or a partial response at their 8 week or subsequent evaluations, they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product) than their second infusion."
249736|NCT02291822|Drug|Gadobenate Dimeglumine|gadolinium contrast agent
249737|NCT02291809|Biological|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
249738|NCT02291796|Drug|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
249739|NCT02291783|Drug|HTL0009936|Single dose
249740|NCT02291783|Drug|HTL0009936 placebo|Placebo single dose
249741|NCT02291770|Biological|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
249742|NCT02291757|Dietary Supplement|NEM brand eggshell membrane|NEM 500 mg, once daily, p.o.
249743|NCT02291757|Dietary Supplement|Placebo|Placebo, 500 mg, once daily, p.o.
249744|NCT02291744|Procedure|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
249745|NCT02291744|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
249746|NCT02291731|Drug|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
249747|NCT02291718|Drug|Isovue|iodine contrast
249748|NCT02291705|Procedure|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
249749|NCT02291705|Drug|Tramadol|tramadol 1 mg/kg iv
249750|NCT02291692|Procedure|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
249751|NCT02291679|Drug|Linaclotide|
249752|NCT02291679|Drug|Matching Placebo|
249753|NCT02291666|Drug|CRCHUM-MT cocktail|
249754|NCT02291653|Device|McGrath|video-laryngoscopy
249755|NCT02291653|Device|MIL|direct-laryngoscopy
249757|NCT02291640|Device|CoPilot|video laryngoscopy
249758|NCT02291627|Device|MAC|direct laryngoscopy
249759|NCT02291627|Device|Coopdech|Video laryngoscopy
249760|NCT02291627|Device|AirTraq|optical laryngoscopy
249761|NCT02291614|Drug|AMG 211|200-12,800 µg/day cIV infusion in cycles from 7 to 28 days
249762|NCT02291601|Drug|Chlorhexidine Gluconate|comparison with other CHG products
249763|NCT02291601|Other|Vehicle|Cloth with Excipients no CHG
249764|NCT02291601|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
249765|NCT02291588|Drug|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
249766|NCT02291588|Drug|Placebo|contains no active drug
249767|NCT02291575|Other|Training|(please see Arm Description)
249768|NCT02291575|Other|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
249769|NCT02291562|Drug|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
249770|NCT02291562|Drug|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
249771|NCT02291562|Drug|placebo|placebo (capsule, once) oral intake
249772|NCT02291549|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
249773|NCT02291549|Drug|Mometasone furoate nasal spray|Mometasone furoate nasal spray (200mcg) once daily
249774|NCT02291549|Procedure|Sham|In-office bilateral sham procedure, consisting of advancement of a delivery system with the S8 Sinus Implant into the ethmoid sinuses followed by removal without deployment.
249775|NCT02291536|Drug|tetrahydrocannabinol|
249776|NCT02291536|Drug|cannabidiol|
249777|NCT02291536|Other|placebo|
249778|NCT02291523|Biological|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
249779|NCT02291510|Drug|Met DR|metformin delayed-release tablets
249780|NCT02291510|Drug|Met XR|metformin extended-release tablets
249781|NCT02291510|Drug|Met IR|metformin immediate-release tablets
249782|NCT02291484|Device|Cardiac CT scan|CT-guided management
249783|NCT02291471|Drug|T0001，10mg|
249784|NCT02291471|Drug|T0001，20mg|
249785|NCT02291471|Drug|T0001，35mg|
249786|NCT02291471|Drug|T0001，50mg|
249787|NCT02291471|Drug|T0001，65mg|
249788|NCT02291471|Drug|T0001，75mg|
249789|NCT02291458|Drug|L-arginine|9 gram L-arginine / day for 6 weeks
249790|NCT02291458|Drug|Placebo|9 gram placebo / day for 6 weeks
249791|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
249792|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
249793|NCT02291432|Biological|autologous muscle-derived cells (AMDC)|Cell treatment
249794|NCT02291419|Drug|ticagrelor|ticagrelor 90 mg bid
249795|NCT02291419|Drug|aspirin|aspirin 81 mg daily
249796|NCT02291406|Procedure|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
249797|NCT02291406|Procedure|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
249798|NCT02291393|Device|80 lead ECG|
249799|NCT02291380|Drug|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
249800|NCT02291380|Drug|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
249801|NCT02291367|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
249802|NCT02291367|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
249803|NCT02291354|Drug|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
249804|NCT02291354|Other|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
249805|NCT02291354|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
249806|NCT02291341|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
249807|NCT02291341|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
249808|NCT02291328|Other|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
249809|NCT02291328|Other|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
249810|NCT02291302|Other|integrated pest management|integrated pest management and environmental strategy
249811|NCT02291302|Other|air purifier|air purifiers
249812|NCT02291302|Other|No intervention (control)|no integrated pest management and sham air purifier
249813|NCT02291289|Drug|Cetuximab|500 mg/m^2 via IV infusion on Day 1 of every 2-week cycle
249814|NCT02291289|Drug|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
249973|NCT02290158|Other|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
249815|NCT02291289|Drug|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 1600-2400 mg/m^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
249816|NCT02291289|Drug|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
249817|NCT02291289|Drug|Vemurafenib|960 mg vermurafenib BID by mouth
249818|NCT02291289|Drug|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
249819|NCT02291289|Drug|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
249820|NCT02291289|Drug|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
249821|NCT02291289|Drug|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
249822|NCT02291289|Drug|5-FU/LV|1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.
249823|NCT02291263|Biological|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
249824|NCT02291263|Biological|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
249825|NCT02291263|Biological|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
249826|NCT02291250|Dietary Supplement|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
249827|NCT02291250|Dietary Supplement|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
249828|NCT02291250|Dietary Supplement|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
249829|NCT02291250|Dietary Supplement|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.~The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.~The equivalent carbohydrate load will be standardised across the groups"
249830|NCT02291237|Drug|Eleclazine|Tablet (s) administered orally once daily
249831|NCT02291237|Drug|Placebo|Placebo to match eleclazine administered orally once daily
249832|NCT02291224|Behavioral|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
249833|NCT02291224|Behavioral|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
249834|NCT02291224|Behavioral|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
249835|NCT02291211|Drug|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
249836|NCT02291198|Device|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
249837|NCT02291172|Behavioral|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
249838|NCT02291159|Device|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
250217|NCT02288403|Behavioral|Continuous training|
249839|NCT02291159|Device|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
249840|NCT02291146|Behavioral|LA Sprouts intervention|see arm 1 description
249841|NCT02291133|Procedure|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
249842|NCT02291133|Device|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes, after liver mobilization."
249843|NCT02291133|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
249844|NCT02291120|Procedure|Pulpotomy|
249845|NCT02291107|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
249846|NCT02291107|Other|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
249847|NCT02291094|Drug|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
249848|NCT02291094|Drug|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
249849|NCT02291081|Other|Comprehensive non invasive cardiovascular examination|"Comprehensive non invasive cardiovascular examination~Anamnesis with the participants~File recherche,Physical examination~Documentation of the cardiovascular and antiretroviral medical therapy~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~Exercise Montreal Cognitive Assessment test~Exercise the Grooved Pegboard test~Blood collection~Questionnaire to quality of life and health economics"
249850|NCT02291068|Behavioral|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
249851|NCT02291055|Drug|ADXS11-001|
249852|NCT02291055|Drug|Medi4736|
249853|NCT02291042|Drug|B+O Suppository|
249854|NCT02291029|Drug|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
249855|NCT02291029|Drug|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
249856|NCT02291029|Drug|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
249857|NCT02291029|Drug|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
249858|NCT02291029|Drug|CFZ533 active -Cohort 3|multiple doses of CFZ533 s.c. injection
249859|NCT02291029|Drug|CFZ533 active - Cohort 3|Single dose of CFZ533 i.v. infusion and multiple doses of CFZ533 s.c. injection
249860|NCT02291016|Drug|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
249861|NCT02291016|Other|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
249862|NCT02290990|Behavioral|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
249863|NCT02290977|Radiation|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
249864|NCT02290964|Procedure|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
249865|NCT02290951|Drug|REGN1979 multiple dose levels|
249866|NCT02290938|Behavioral|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
249867|NCT02290938|Other|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
249868|NCT02290925|Drug|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (containing Salacia reticulata extract) as a snack. This herb has been used by traditional physicians to control blood sugar.
249869|NCT02290925|Dietary Supplement|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
249903|NCT02290639|Behavioral|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
249870|NCT02290912|Behavioral|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
249871|NCT02290886|Other|Intravenous administration of placebo|
249872|NCT02290886|Drug|Intravenous administration of 1 million of MSC|
249873|NCT02290886|Drug|Intravenous administration of 2 million of MSC|
249874|NCT02290886|Drug|Intravenous administration of 4 million of MSC|
249875|NCT02290873|Drug|Remimazolam|For induction and maintenance of sedation
249876|NCT02290873|Drug|Midazolam|For induction of maintenance and sedation
249877|NCT02290873|Drug|Placebo|For induction and maintenance of sedation
249878|NCT02290860|Procedure|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
249879|NCT02290847|Behavioral|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, & Chard, 2008; Resick & Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
249880|NCT02290834|Other|Cognitive, functional and subjective assessments|Cognitive and functional assessments
249881|NCT02290834|Device|MRI|Magnetic Resonance Imaging (MRI) Scan
249882|NCT02290834|Radiation|PET Scan|Positron Emission Tomography (PET) Scan
249883|NCT02290821|Drug|placebo|
249884|NCT02290821|Drug|Placebos|
249885|NCT02290808|Behavioral|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
249886|NCT02290795|Other|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
249887|NCT02290782|Radiation|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.~To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
249888|NCT02290769|Device|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
249889|NCT02290769|Device|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
249890|NCT02290756|Behavioral|Parenting Program|The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
249891|NCT02290756|Behavioral|Low cost evidence based toolkit|"The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:~Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials~Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information"
249892|NCT02290743|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
249893|NCT02290730|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
249894|NCT02290717|Device|Fractional CO2 laser|
249895|NCT02290717|Other|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
249896|NCT02290717|Drug|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
249897|NCT02290691|Biological|Influenza Vaccine|Influenza Vaccine
249898|NCT02290678|Behavioral|Adventure-based Programming|
249899|NCT02290665|Other|Thermosensitive gel rectal formulation|
249900|NCT02290665|Other|Saline enema|
249901|NCT02290652|Other|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.~Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.~Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
249902|NCT02290652|Other|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.~Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).~Maximum retrospective collection of data 12 months."
249931|NCT02290418|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
250107|NCT02289261|Drug|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
249904|NCT02290639|Behavioral|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
249905|NCT02290626|Drug|Elmental diet|elemental diet is administered using PEG.
249906|NCT02290626|Drug|Semi-solid diet|Semi-solid diet is administered using PEG.
249907|NCT02290613|Drug|Ambrisentan|"Titration:~As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.~Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.~Maximum dose allowed: not to exceed 10 mg/die.~Administration:~Ambrisentan and placebo will be administered orally with or without food intake."
249908|NCT02290613|Drug|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
249909|NCT02290600|Device|Continuous Glucose Monitor|CGM sensor calibration individualization
249910|NCT02290587|Other|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :~Questionnaire for depression and anxiety~Evaluation of executive functions~Evaluation of attention, information processing speed, verbal memory and working memory~Theory of mind evaluation~Clinical Evaluation~MRI Evaluation :~morphological MRI~functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
249911|NCT02290587|Device|MRI|
249912|NCT02290574|Radiation|Hyperthermia with concurrent chemo-radiation therapy|
249913|NCT02290561|Procedure|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
249914|NCT02290561|Device|MRI|
249915|NCT02290561|Device|high intensity focused ultrasound (HIFU)|
249916|NCT02290548|Device|high flow nasal cannula|High flow nasal cannula used in postextubation patients
249917|NCT02290535|Procedure|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
249918|NCT02290535|Procedure|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
249919|NCT02290522|Procedure|Tumor biopsy|Biopsy of lesion for molecular characterization
249920|NCT02290509|Biological|Flublok Quadrivalent|Intramuscular injection of study vaccine
249921|NCT02290509|Biological|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
249922|NCT02290496|Behavioral|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
249923|NCT02290496|Behavioral|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
249924|NCT02290470|Drug|Olanzapine|"Drug: Olanzapine 10 mg oral~Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.~Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
249925|NCT02290470|Drug|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
249926|NCT02290457|Behavioral|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
249927|NCT02290444|Drug|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
249928|NCT02290431|Drug|LBH589 (panobinostat)|Panobinostat (PAN) capsules were supplied at dose strengths of 10 mg and 15 mg. and dosed at 20mg during treatment phase 1 (21 days) and treatment phase 2 (42 days)
249929|NCT02290431|Drug|bortezomib|Bortezomib (BTZ) s.c: 1.3 mg/m2 was administered during both treatment phase 1 (21 days) & treatment phase 2 (42 days).
249930|NCT02290431|Drug|dexamethasone|Dexamethasone (Dex): 20mg tablets taken during both treatment phase 1 (21 days & treatment phase 2 (42 days)
250110|NCT02289248|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
249932|NCT02290418|Procedure|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
249933|NCT02290405|Behavioral|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
249934|NCT02290379|Drug|TNX-201 35 mg|Drug: TNX-201 35 mg
249935|NCT02290379|Drug|TNX-201 70 mg|Drug: TNX-201 70 mg
249936|NCT02290379|Drug|TNX-201 140 mg|Drug: TNX-201 140 mg
249937|NCT02290379|Drug|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
249938|NCT02290379|Drug|Placebo|Drug: Placebo
249939|NCT02290366|Radiation|Focal prostate brachytherapy with Cesium-131|
249940|NCT02290353|Device|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer [2]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.~During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
249941|NCT02290340|Drug|Placebo|Participants will receive placebo intramuscularly.
249942|NCT02290340|Drug|MEDI8897 10 mg|Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
249943|NCT02290340|Drug|MEDI8897 25 mg|Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
249944|NCT02290340|Drug|MEDI8897 50 mg|Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
249945|NCT02290327|Drug|Pantoprazole|Proton pump inhibitor
249946|NCT02290327|Drug|Placebo|50 ml of 0.9% normal saline
249947|NCT02290314|Procedure|minimally invasive MID-line Lumbar Fusion (MIDLF)|
249948|NCT02290314|Procedure|Posterior lumbar interbody fusion (PLIF)|
249949|NCT02290301|Drug|gemigliptin|
249950|NCT02290288|Procedure|vaginal surgery|
249951|NCT02290288|Procedure|laparoscopic surgery|
249952|NCT02290275|Dietary Supplement|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
249953|NCT02290275|Other|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
249954|NCT02290275|Dietary Supplement|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
249955|NCT02290262|Other|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.~The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
249956|NCT02290249|Device|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
249957|NCT02290249|Device|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
249958|NCT02290236|Device|Pulseoximetry|Peripheral saturation will be recorded continuously
249959|NCT02290223|Behavioral|Behavioral Based Treatment Model|Behavioral based treatment consists of four 90 minute group sessions, one meeting per week. The sessions addressed: empowering patients to take an active role in pain management and overall health; pain management lifestyle practices; use of health information technology resources for active self-care; education on neurobiology of pain and opioids; and improving communication with providers.
249960|NCT02290210|Drug|URC102 0.25mg|
249961|NCT02290210|Drug|URC102 0.5mg|
249962|NCT02290210|Drug|URC102 1.0mg|
249963|NCT02290210|Drug|URC102 2.0mg|
249964|NCT02290210|Drug|placebo|
249965|NCT02290197|Procedure|Surgery|Surgical reconstruction of all injured ligaments.
249966|NCT02290197|Device|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
249967|NCT02290197|Device|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
249968|NCT02290184|Behavioral|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
249969|NCT02290184|Behavioral|Active Control|This is a 3-month active control using a pedometer only without any education related to wt loss, physical activity, health eating, or tracking healthy behaviors
249970|NCT02290171|Behavioral|Activity groups|Children attend to activity groups weekly during the intervention periode.
249971|NCT02290171|Behavioral|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
249972|NCT02290171|Behavioral|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
249974|NCT02290145|Drug|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
249975|NCT02290145|Procedure|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
249976|NCT02290145|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
249977|NCT02290132|Drug|Rabbit Anti－human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
249978|NCT02290119|Device|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofermoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
249979|NCT02290119|Procedure|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
249980|NCT02290106|Drug|pitavastatin|
249981|NCT02290106|Other|PLACEBO|
249982|NCT02290093|Drug|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
249983|NCT02290093|Drug|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
249984|NCT02290093|Drug|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
249985|NCT02290080|Drug|Oxygen|see arm description
249986|NCT02290067|Device|Blood glucose monitoring system (Omnitest 3)|
249987|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5)|
249988|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5D)|
249989|NCT02290054|Procedure|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
249990|NCT02290054|Procedure|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
249991|NCT02290054|Procedure|Intra-venous anesthesia|
249992|NCT02290041|Drug|Infusion of MSC|Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).
249993|NCT02290041|Drug|Infusion of placebo|Infusion of placebo (weeks 0-4-8-20)
249994|NCT02290028|Device|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
249995|NCT02290015|Other|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
249996|NCT02290002|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
249997|NCT02290002|Other|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
249998|NCT02289989|Drug|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
249999|NCT02289989|Drug|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
250000|NCT02289976|Procedure|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
250001|NCT02289963|Drug|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
250002|NCT02289963|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
250003|NCT02289963|Drug|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
250004|NCT02289950|Drug|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
250005|NCT02289950|Drug|Placebo|Placebo will be administered intravenously (IV) weekly
250006|NCT02289937|Drug|Ropivacaine|
250007|NCT02289937|Drug|Placebo|
250008|NCT02289937|Device|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
250009|NCT02289924|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
250010|NCT02289911|Other|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
250011|NCT02289898|Drug|Demcizumab|administered intravenously
250012|NCT02289898|Drug|Abraxane®|administered intravenously
250013|NCT02289898|Drug|gemcitabine|administered intravenously
250014|NCT02289898|Drug|Placebo|
250015|NCT02289885|Device|SonoScape|Ultrasonography device
250016|NCT02289872|Device|Macintosh Laryngoscope|Direct-Laryngoscopy
250017|NCT02289872|Device|TruView PCD Video laryngoscope|Video-Laryngoscopy
250018|NCT02289859|Procedure|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
250019|NCT02289859|Procedure|Wound Closure without Undermining|One side of the wound will remain un-undermined.
250020|NCT02289846|Drug|IW-9179|
250021|NCT02289846|Drug|Matching Placebo|
250022|NCT02289833|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously (IV) at a dose of 3.6 mg/kg on Day 1 of every 21-day cycle until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the sponsor, whichever occurs first.
250023|NCT02289820|Biological|MEDI7510|RSV sF antigen plus adjuvant
250024|NCT02289820|Biological|IIV|Marketed Inactivated Influenza Vaccine
250025|NCT02289807|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
250026|NCT02289807|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
250027|NCT02289794|Biological|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
250028|NCT02289794|Biological|Placebo|Single dose, intramuscular injection (0.5 mL)
250029|NCT02289781|Device|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
250030|NCT02289768|Drug|5-fluorouracil/salicylic acid|
250031|NCT02289768|Drug|Vehicle|
250032|NCT02289755|Drug|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
250033|NCT02289742|Device|Nelfilcon A multifocal contact lenses|
250034|NCT02289742|Device|Nelfilcon A toric contact lenses|
250035|NCT02289742|Device|Nelfilcon A sphere contact lenses|
250036|NCT02289716|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
250037|NCT02289716|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
250038|NCT02289716|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
250039|NCT02289703|Drug|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
250040|NCT02289690|Drug|Veliparib|Varying doses administered on Days -2 to 5 in a 21-day cycle
250041|NCT02289690|Drug|Carboplatin|Administered on Day 1 via intravenous infusion in a 21-day cycle
250042|NCT02289690|Drug|Etoposide|Administered on Days 1 to 3 via intravenous infusion in a 21-day cycle
250043|NCT02289677|Device|ATMOS Scope|Video-laryngoscopy 1
250044|NCT02289677|Device|COOPDECH|Video-laryngoscopy-1
250045|NCT02289677|Device|AirTraq|Optical-laryngoscopy
250046|NCT02289664|Device|MAC|Direct-Laryngoscopy
250047|NCT02289664|Device|Coopdech|Video-Laryngoscopy -1
250048|NCT02289664|Device|CoPilot|Video-Laryngoscopy -2
250049|NCT02289664|Device|Intubrite|Video-Laryngoscopy -3
250050|NCT02289651|Device|Venner|Video-laryngoscopy
250051|NCT02289651|Device|Miller|Direct-Laryngoscopy
250052|NCT02289638|Device|Intubrite|Video-Laryngoscopy
250053|NCT02289638|Device|MIL|Direct-Laryngoscopy
250054|NCT02289625|Other|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
250055|NCT02289612|Other|Yellow Mustard Gum Fibre|
250056|NCT02289612|Other|Soluble Flaxseed Gum Fibre|
250057|NCT02289612|Other|Fenugreek Gum Fibre|
250058|NCT02289599|Drug|E2307|
250059|NCT02289599|Drug|E2307 Matching Placebo|
250060|NCT02289586|Procedure|invasive ventilation|
250061|NCT02289586|Procedure|interventional bronchoscopy|
250062|NCT02289586|Device|noninvasive ventilation|
250063|NCT02289586|Drug|sedation(dezocine and midazolam)|
250064|NCT02289586|Drug|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
250065|NCT02289573|Device|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
250066|NCT02289560|Device|Transcranial ExAblate|Transcranial ExAblate
250067|NCT02289547|Drug|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
250068|NCT02289521|Device|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.~Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).~Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
250069|NCT02289508|Device|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
250108|NCT02289261|Drug|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
250109|NCT02289248|Drug|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
250070|NCT02289508|Device|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
250071|NCT02289495|Drug|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
250072|NCT02289495|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
250073|NCT02289495|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
250074|NCT02289482|Drug|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
250075|NCT02289482|Drug|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
250076|NCT02289482|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
250077|NCT02289482|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
250078|NCT02289469|Other|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
250079|NCT02289456|Drug|nab-Paclitaxel|
250080|NCT02289456|Drug|Carboplatin|
250081|NCT02289443|Other|complete denture|Comparison of different procedures
250082|NCT02289430|Drug|Crestor+Ezetrol|rosuvastatin+ezetimibe
250083|NCT02289430|Drug|Ezetrol|ezetimibe
250084|NCT02289430|Drug|Crestor|rosuvastatin
250085|NCT02289417|Drug|Apremilast|
250086|NCT02289417|Drug|Placebo|
250087|NCT02289404|Drug|NVP-1203|Oral
250088|NCT02289404|Drug|NVP-1203|Oral
250089|NCT02289391|Drug|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
250090|NCT02289391|Drug|Anesthesia maintenance|"Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3~8mg/(kg•h).~Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30~40 mmHg and bispectral index (BIS) to 45~60."
250091|NCT02289391|Drug|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
250092|NCT02289378|Drug|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
250093|NCT02289365|Drug|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
250094|NCT02289365|Drug|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
250095|NCT02289365|Drug|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
250096|NCT02289352|Drug|Brimonidine|
250097|NCT02289352|Drug|placebo|
250098|NCT02289339|Device|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
250099|NCT02289313|Behavioral|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
250100|NCT02289300|Drug|DCB-BO1202|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
250101|NCT02289300|Drug|Placebo|"The assignment will be as follows:~Placebo: 4 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
250102|NCT02289300|Drug|DCB-BO1202+Placebo|"The assignment will be as follows:~(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)~DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.~Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
250103|NCT02289287|Behavioral|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
250104|NCT02289287|Behavioral|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
250105|NCT02289274|Drug|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
250106|NCT02289274|Drug|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
250111|NCT02289235|Drug|Ginger|Ginger powder capsule 500 mg daily for 3 months
250112|NCT02289235|Drug|Placebo|Placebo powder 1 capsule daily for 3 months
250113|NCT02289222|Drug|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
250114|NCT02289222|Drug|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
250115|NCT02289222|Drug|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
250116|NCT02289209|Radiation|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
250117|NCT02289209|Drug|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
250118|NCT02289196|Drug|Vx-006: 0,5mg|
250119|NCT02289196|Drug|Vx-006: 1mg|
250120|NCT02289196|Drug|Vx-006: 5mg|
250121|NCT02289196|Drug|Vx-006: 10mg|
250122|NCT02289183|Procedure|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
250123|NCT02289183|Procedure|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
250124|NCT02289170|Device|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
250125|NCT02289170|Device|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
250126|NCT02289157|Device|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
250127|NCT02289144|Drug|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
250128|NCT02289131|Procedure|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
250129|NCT02289118|Drug|[18F]-T807 imaging tracer|Tau Imaging tracer
250130|NCT02289105|Behavioral|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
250131|NCT02289092|Behavioral|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
250132|NCT02289079|Drug|Bupivacaine|
250133|NCT02289079|Drug|liposomal bupivacaine|
250134|NCT02289040|Procedure|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
250135|NCT02289027|Biological|cAd3-EBOZ vaccine|
250136|NCT02289027|Biological|Placebo (for cAd3-EBOZ vaccine)|Diluent
250137|NCT02289014|Other|online stress Management program|Active treatment group
250138|NCT02289001|Behavioral|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
250139|NCT02288988|Procedure|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
250140|NCT02288975|Device|CytoSorb 300ml device (3804606CE01)|
250141|NCT02288962|Drug|cabergoline|
250142|NCT02288949|Other|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
250143|NCT02288936|Drug|Enzalutamide|Enzalutamide 160 mg/day
250144|NCT02288923|Procedure|Femoral nerve block|"Supine position~If using peripheral nerve stimulator for localisation of the femoral nerve:~50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine~If using ultrasound for localisation of the femoral nerve:~High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
250145|NCT02288923|Procedure|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:~40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
250146|NCT02288923|Procedure|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
250147|NCT02288923|Procedure|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
250148|NCT02288923|Drug|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
250149|NCT02288923|Drug|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
250150|NCT02288923|Drug|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight >70kg 2 hourly.
250151|NCT02288923|Drug|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
250152|NCT02288923|Drug|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
250153|NCT02288897|Drug|PV-10 (10% rose bengal disodium)|
250154|NCT02288897|Drug|Dacarbazine, temozolomide or talimogene laherparepvec|
250155|NCT02288884|Device|Acticoat PostOp|
250156|NCT02288884|Device|OpSite PostOp|
250157|NCT02288871|Radiation|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).~In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
250158|NCT02288858|Dietary Supplement|Viviscal Oral Supplement Tablets|Tablet (512 mg)
250159|NCT02288845|Drug|ITI-007|
250160|NCT02288832|Other|-self-collected vaginal samples|
250161|NCT02288832|Drug|zithromax|
250162|NCT02288832|Other|usual practices|
250163|NCT02288819|Device|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
250164|NCT02288819|Drug|Loop diuretic downtitration|"The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.~In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.~In case of a total daily maintenance dose >40 mg furosemide OR >1 mg bumetanide OR >20 mg torsemide, the loop diuretic dose is halved."
250165|NCT02288793|Other|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
250166|NCT02288767|Device|Conventional arterial blood pressure monitoring|
250167|NCT02288767|Device|Stroke volume variation monitoring with arterial blood pressure monitoring|
250168|NCT02288754|Diagnostic Test|Blood test|No intervention except to collect blood for diagnostic test development
250169|NCT02288741|Drug|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
250170|NCT02288741|Drug|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
250171|NCT02288741|Drug|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
250172|NCT02288741|Procedure|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 * 10E6/kg
250173|NCT02288741|Drug|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
250174|NCT02288741|Procedure|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2*10E6 CD34-cell/kg per transplantation)
250175|NCT02288728|Procedure|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.~(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
250176|NCT02288728|Procedure|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).~(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
250177|NCT02288715|Other|no interventions|
250178|NCT02288702|Device|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
250179|NCT02288689|Device|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
250180|NCT02288663|Other|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
250181|NCT02288663|Biological|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
250182|NCT02288663|Biological|albumin or blood in urine|dipstick analysis for albumin or blood in urine
250183|NCT02288663|Device|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
250184|NCT02288663|Device|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
250185|NCT02288663|Biological|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
250186|NCT02288650|Other|early refeeding|
250187|NCT02288650|Other|refeeding only in the recovery room (usual practice).|
250188|NCT02288637|Other|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
250189|NCT02288637|Other|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
250190|NCT02288637|Other|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
250191|NCT02288624|Dietary Supplement|Processed orange juice|3 different formulation of edible orange drinks
250192|NCT02288611|Dietary Supplement|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
250193|NCT02288611|Dietary Supplement|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
250194|NCT02288598|Device|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
250195|NCT02288598|Behavioral|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
250196|NCT02288585|Dietary Supplement|Plant sterols|Plant sterols
250197|NCT02288585|Dietary Supplement|Placebo product|Placebo product
250198|NCT02288572|Dietary Supplement|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
250199|NCT02288572|Dietary Supplement|Placebo|Taking dietary supplement on a daily basis for 3 months.
250200|NCT02288559|Other|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
250201|NCT02288559|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
250202|NCT02288533|Device|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
250203|NCT02288507|Drug|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
250204|NCT02288507|Radiation|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
250205|NCT02288494|Other|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia < 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
250206|NCT02288481|Drug|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
250207|NCT02288481|Other|Placebo|Placebo Suspension
250208|NCT02288468|Device|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
250209|NCT02288455|Device|GTU Artificial Urinary Sphincter|A totally implantable Artificial Urinary Sphincter (AUS) for the treatment of male Stress Urinary Incontinence (SUI)
250210|NCT02288442|Other|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
250211|NCT02288429|Drug|colistimethate sodium|
250212|NCT02288416|Other|educational intervention|Undergo video-based intervention
250213|NCT02288416|Other|questionnaire administration|Ancillary studies
250214|NCT02288416|Other|quality-of-life assessment|Ancillary studies
250215|NCT02288416|Other|Best Practice|
250216|NCT02288403|Behavioral|Aerobic interval training|
250218|NCT02288390|Procedure|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
250219|NCT02288377|Drug|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
250220|NCT02288377|Drug|Placebo|
250221|NCT02288364|Drug|1% Lidocaine|
250222|NCT02288364|Drug|1% Lidocaine plus sodium bicarbonate|
250223|NCT02288351|Other|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
250224|NCT02288351|Other|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
250225|NCT02288351|Other|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
250226|NCT02288351|Other|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
250227|NCT02288351|Other|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
250228|NCT02288351|Device|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
250229|NCT02288338|Drug|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
250230|NCT02288338|Drug|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250231|NCT02288338|Drug|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250232|NCT02288338|Drug|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250233|NCT02288338|Drug|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250234|NCT02288338|Drug|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
250235|NCT02288338|Drug|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250236|NCT02288338|Drug|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
250237|NCT02288338|Drug|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250238|NCT02288338|Drug|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
250239|NCT02288338|Drug|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250240|NCT02288338|Drug|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250241|NCT02288338|Drug|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250242|NCT02288338|Drug|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
250243|NCT02288338|Drug|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250244|NCT02288338|Drug|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250245|NCT02288338|Drug|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
250246|NCT02288338|Drug|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
250247|NCT02288325|Drug|Levomilnacipran ER|Levomilnacipran ER taken orally at 40, 80 or 120 mg once daily.
250248|NCT02288325|Drug|Placebo|Dose-matched placebo taken orally once daily.
250249|NCT02288312|Drug|BIA 2-093|
250250|NCT02288299|Device|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
250251|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
250252|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
250253|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
250254|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
250255|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
250256|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
250257|NCT02288273|Drug|Bydureon|Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
250258|NCT02288273|Drug|Placebo|Placebo
250259|NCT02288247|Drug|Enzalutamide|Oral
250260|NCT02288247|Drug|Docetaxel|intravenous infusion
250261|NCT02288247|Drug|Prednisolone|Oral
250262|NCT02288247|Drug|Placebo|Oral
250396|NCT02287324|Procedure|Manual Contact|
250263|NCT02288234|Drug|Vibativ|This is an observational study for patients who were already prescribed Vibativ.
250264|NCT02288221|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :~aromatherapy~music therapy~cognitive training in multimedia application offering cognitive games"
250265|NCT02288221|Other|Patient's answer without non pharmacological therapeutic|No installation at patient's home
250266|NCT02288208|Drug|Antiviral Therapy (tenofovir or entecavir)|
250267|NCT02288208|Drug|Birinapant|
250268|NCT02288208|Drug|Placebo (for birinapant)|
250269|NCT02288195|Drug|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
250270|NCT02288195|Drug|capecitabine|"825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.~1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B."
250271|NCT02288195|Radiation|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
250272|NCT02288182|Device|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
250273|NCT02288182|Device|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
250274|NCT02288169|Behavioral|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
250275|NCT02288169|Behavioral|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
250276|NCT02288156|Drug|Capsaicin|via nasal spray
250277|NCT02288156|Drug|placebo|via nasal spray
250278|NCT02288143|Drug|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:~Oral clomiphene citrate: 100 mg/day until the day of the triggering.~Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.~The triggering will be performed using urinary hCG (5,000 IU subcutaneous).~1-2 days after the identification of one follicle ≥ 17 mm~0-1 days after the identification of one follicle ≥ 19 mm."
250279|NCT02288130|Drug|GnRHa|
250280|NCT02288130|Drug|Ulipristal|
250281|NCT02288104|Device|needle based confocal endomicroscopy|real time imaging of living tissue at microscopic scale, through a needle.
250282|NCT02288091|Drug|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
250283|NCT02288078|Other|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
250284|NCT02288078|Other|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
250285|NCT02288078|Other|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
250286|NCT02288078|Other|Clinical findings|"Blood and lymphatic system disorders: febrile neutropenia~Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting~General disorders and administration site conditions: fatigue and malaise~Immune system disorders: allergic reaction~Metabolism and nutrition disorders: anorexia~Nervous system disorders: dysgeusia and peripheral sensory neuropathy~Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)~Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome~Vascular disorders: hypertension~Symptomatic pancreatitis"
250287|NCT02288078|Other|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
250288|NCT02288078|Other|Coagulation and fibrinolysis system|international normalized ratio (INR)
250289|NCT02288078|Other|Urinalysis|Proteinuria (qualitative)
250290|NCT02288078|Other|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
250291|NCT02288078|Other|Adverse event|CTCAE ver.4.0
250292|NCT02288078|Other|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
250293|NCT02288078|Other|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
250294|NCT02288078|Other|Brain MRI|If any symptom of brain metastasis is suspected
250295|NCT02288078|Drug|Dexamethasone|Capsule filled with dexamethasone and lactose
250296|NCT02288078|Drug|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
250297|NCT02288078|Drug|Placebo|Capsule filled with lactose
250298|NCT02288078|Drug|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
250299|NCT02288065|Drug|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
250300|NCT02288052|Behavioral|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
250301|NCT02288052|Behavioral|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
250302|NCT02288039|Other|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
250303|NCT02288013|Procedure|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
250304|NCT02288000|Drug|Memantine|Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
250305|NCT02288000|Drug|Placebo|the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
250306|NCT02287987|Procedure|Clamp Robotic partial nephrectomy|Renal artery clamping during partial nephrectomy
250307|NCT02287987|Procedure|Clampless Robotic partial nephrectomy|Robotic partial nephrectomy without renal artery clamping
250308|NCT02287974|Drug|Stem cell infusion|Unique stem cell infusion of the randomized group
250309|NCT02287961|Procedure|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
250310|NCT02287961|Procedure|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
250311|NCT02287961|Procedure|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
250312|NCT02287961|Procedure|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
250313|NCT02287948|Device|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.~1) Instrumental evaluations~All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:~Open eyes, monopodalic balance for 20 seconds~Closed eyes, monopodalic balance for 20 seconds~Open eyes, balance on both feet for 60 seconds~Closed eyes, balance on both feet for 60 seconds~During trials subjects can leave arms in the most comfortable position they prefere~Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
250314|NCT02287935|Procedure|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
250315|NCT02287935|Procedure|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
250316|NCT02287922|Biological|ALX-0061|
250317|NCT02287922|Biological|Placebo|
250318|NCT02287922|Biological|Tocilizumab|
250319|NCT02287909|Drug|Clopidogrel|Swiching from ticagrelor to clopidogrel
250320|NCT02287909|Drug|Ticagrelor|Continue treatment with ticagrelor
250321|NCT02287896|Drug|ROLEDUMAB|See Arm description
250322|NCT02287883|Other|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
250323|NCT02287870|Drug|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
250324|NCT02287870|Drug|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
250325|NCT02287857|Drug|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
250326|NCT02287857|Drug|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
250327|NCT02287844|Other|XOS|5 g of XOS everyday for 4 weeks.
250328|NCT02287844|Other|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
250329|NCT02287844|Other|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
250330|NCT02287831|Biological|umbilical cord mesenchymal stem cells|patients were divided into 3 dose treatment groups (6.29 × 107,9.43 × 107 and 14.15 × 107 cells/m2). After 4 and 8 weeks, patients were injected the same number of cells.
250331|NCT02287818|Drug|Placebo|Placebo twice daily from Day 1 to Week 12
250332|NCT02287818|Drug|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
250333|NCT02287818|Drug|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration <6 mg/dL
250334|NCT02287805|Other|qualitative survey|
250335|NCT02287805|Other|quantitative survey|
250336|NCT02287792|Procedure|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
250337|NCT02287779|Drug|SHP626|
250338|NCT02287779|Drug|Placebo|
250339|NCT02287753|Other|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
250340|NCT02287740|Behavioral|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
250341|NCT02287740|Behavioral|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
250342|NCT02287740|Behavioral|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
250343|NCT02287727|Other|Laboratory Biomarker Analysis|Correlative studies
250344|NCT02287727|Drug|Regorafenib|Given PO
250345|NCT02287714|Procedure|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
250346|NCT02287714|Procedure|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
250347|NCT02287701|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
250581|NCT02285816|Biological|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
250348|NCT02287688|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
250349|NCT02287675|Drug|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
250350|NCT02287675|Drug|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
250351|NCT02287662|Other|Vancouver 3M Clinical Pathway|
250352|NCT02287649|Other|blood sample|
250353|NCT02287636|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
250354|NCT02287636|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
250355|NCT02287636|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
250356|NCT02287636|Procedure|positron emission tomography|Undergo PET/MRI
250357|NCT02287636|Procedure|magnetic resonance imaging|Undergo PET/MRI
250358|NCT02287623|Drug|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
250359|NCT02287623|Drug|bupivacaine|patients will receive a tap with bupivacaine
250360|NCT02287610|Drug|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
250361|NCT02287584|Drug|DSP-5423P 40mg|
250362|NCT02287584|Drug|DSP-5423P 80mg|
250363|NCT02287584|Drug|DSP-5423P Placebo|
250364|NCT02287571|Device|Derotation splint|This group is the actual intervention group.
250365|NCT02287571|Device|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
250366|NCT02287558|Drug|Pomalidomide|
250367|NCT02287545|Procedure|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
250368|NCT02287532|Device|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
250369|NCT02287519|Behavioral|Group Session|
250370|NCT02287519|Behavioral|Telephone Coaching Session|
250371|NCT02287519|Behavioral|Webinar|
250372|NCT02287506|Other|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
250373|NCT02287493|Other|Pharmacokinetic Analysis|
250374|NCT02287480|Biological|VSV-ZEBOV|See arm/group descriptions.
250375|NCT02287467|Biological|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
250376|NCT02287467|Biological|Placebo for IVIG|Administered IV as 500 mL of normal saline
250377|NCT02287454|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
250378|NCT02287441|Other|Tomato|Tomato Products (tomato)
250379|NCT02287441|Other|Raw|Vegetables Prepared Raw (raw).
250380|NCT02287428|Radiation|Radiation Therapy|Standard radiotherapy (approximately 60 Gy over 6 weeks)
250381|NCT02287428|Biological|Personalized NeoAntigen Vaccine|NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
250382|NCT02287428|Drug|Pembrolizumab|Pembrolizumab will be administered every 3 weeks at a flat dose of 200 mg intravenously. Pembrolizumab should be administered as a 30 minute IV infusion (Pembrolizumab treatment cycle intervals may be increased due to toxicity per protocol).
250383|NCT02287415|Drug|BIA 2-093|
250384|NCT02287415|Drug|Warfarin|
250385|NCT02287402|Drug|AO-128|AO-128 tablet
250386|NCT02287389|Device|balloon dilation|
250387|NCT02287389|Procedure|cryotherapy|
250388|NCT02287389|Procedure|spiculiform electrosurgery|
250389|NCT02287389|Drug|mitomycin C|
250390|NCT02287376|Drug|Diclofenac Potassium for Oral Solution|NSAID
250391|NCT02287363|Other|No intervention involved|No interventions will be involved since it is an observational study
250392|NCT02287350|Drug|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
250393|NCT02287337|Procedure|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
250394|NCT02287337|Procedure|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
250395|NCT02287324|Procedure|Manipulation|
250397|NCT02287311|Biological|MABEL CTLs|"Dose escalation:~DL1:2x10^7 cells/m2+2x10^7 cells/m2~DL2:2x10^7cells/m2+5x10^7 cells/m2~DL3:5x10^7 cells/m2+1x10^8 cells/m2~*Doses are based on total CD3+cells/m2~Patients with active disease that have apparent clinical benefit at the 8 wk post 1st infusion (6 wks after 2nd infusion) or subsequent evaluations may receive up to 6 additional doses of CTLs at intervals at least 6 wks apart, each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) before additional infusions. Patients cannot receive additional doses until the initial safety profile is completed at 6 wks following the second infusion."
250398|NCT02287311|Drug|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
250399|NCT02287311|Drug|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.~3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
250400|NCT02287298|Procedure|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
250401|NCT02287285|Drug|Exendin9|Dosed at 600 pmol/kg/min for 210 minutes.
250402|NCT02287272|Drug|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
250403|NCT02287272|Drug|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
250404|NCT02287259|Drug|olanzapine|
250405|NCT02287259|Drug|lithium|
250406|NCT02287246|Drug|Extended-Release liposomal bupivacaine (Exparel)|20mL
250407|NCT02287246|Drug|Normal saline|20mL
250408|NCT02287233|Drug|Venetoclax|Venetoclax will be taken orally once daily on Days 1 through 28 of each cycle. This is a dose escalation study, therefore the dose of venetoclax will change.
250409|NCT02287233|Drug|Cytarabine|Cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
250410|NCT02287220|Device|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
250411|NCT02287207|Device|transcranial direct current stimulation (tDCS)|
250412|NCT02287194|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
250413|NCT02287181|Drug|Remifentanil|short acting opiate
250414|NCT02287181|Drug|Propofol|hypnotic drug
250415|NCT02287181|Other|Bispectral index|electroencephalograph
250416|NCT02287168|Procedure|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
250417|NCT02287168|Procedure|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
250418|NCT02287168|Procedure|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
250419|NCT02287155|Behavioral|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
250420|NCT02287142|Procedure|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
250421|NCT02287129|Drug|Oxaliplatin|130 mg/m2
250422|NCT02287129|Drug|Epirubicin|50 mg/m2
250423|NCT02287129|Drug|Capecitabine|625 mg/m2
250424|NCT02287129|Drug|5-FU|200 mg/m2
250425|NCT02287129|Drug|Carboplatin|2 mg/ml min
250426|NCT02287129|Drug|Paclitaxel|50 mg/m2
250427|NCT02287129|Radiation|radiation|total dosage 41,4 Gy
250428|NCT02287129|Procedure|Biopsy|translational analysis
250429|NCT02287116|Device|Easy Flow system and INCA® nasal cannulae set|
250430|NCT02287103|Other|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
250431|NCT02287103|Other|Eating Breakfast|YesB: will eat all three meals
250432|NCT02287090|Other|Observational Cohort|
250433|NCT02287077|Procedure|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
250434|NCT02287064|Drug|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.~There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
250435|NCT02287038|Drug|Atomoxetine 80 MG|Subjects will be randomized and assigned by the study investigator into crossover group 1 (Atomoxetine 80mg at Phase I, then placebo at Phase II) or group 2 (placebo at Phase I, then Atomoxetine at Phase II) with both placebo and medication administered through pharmacy. There was a 1-week interval between the two phases.
250436|NCT02287025|Drug|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
250437|NCT02287025|Other|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
250438|NCT02287025|Other|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
250582|NCT02285803|Device|transcranial direct current stimulation (tDCS)|
250583|NCT02285790|Device|Reflectance confocal microscopy|
250439|NCT02287012|Other|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
250440|NCT02286999|Drug|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
250441|NCT02286999|Drug|Placebo|
250442|NCT02286986|Drug|Cannabidiol|
250443|NCT02286973|Drug|Tranexamic Acid|
250444|NCT02286960|Drug|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
250445|NCT02286960|Dietary Supplement|Lactose Pills|4 day course 2 x 20mg per da
250446|NCT02286947|Drug|Eteplirsen|Eteplirsen solution for IV infusion
250447|NCT02286934|Drug|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd~Day 4 to 8 : Carvedilol 25 mg qd~Day 9 to 11 : Carvedilol 12.5 mg qd"
250448|NCT02286934|Other|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
250449|NCT02286921|Drug|Testosterone cypionate|Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
250450|NCT02286921|Drug|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
250451|NCT02286921|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
250452|NCT02286895|Biological|pentavalent rotavirus vaccine (PRV)|Each two-ml dose contains 5 live human-bovine reassortant rotaviruses with a minimum of 2.0 - 2.8 x 106 infectious units (IU) per reassortant, depending on the serotype, and not greater than 116 x 106 IU per aggregate dose. Each vaccine dose contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq contains no preservatives. RotaTeq is a pale yellow clear liquid that may have a pink tint. This vaccine was administered orally.
250453|NCT02286895|Biological|measles vaccine (MV)|A lyophilized vaccine in a pack containing one vial plus one ampoule of sterile water for injection. After reconstitution, each 0.5 ml/dose of MV contains active substances not less than 1000 units of 50% cell culture infectious doses (CCID50) of MV. Measles Vaccine Live Attenuated virus is propagated on Human Diploid Cells. This MV is currently part of the local EPI program in Mali. This vaccine was administered subcutaneously to the right deltoid.
250454|NCT02286895|Biological|yellow fever vaccine (YFV)|A freeze-dried live attenuated yellow fever virus of the 17D strain for injection. After reconstitution, one dose (0.5 ml) contains active substances not less than 1000 units of 50% lethal doses (LD50) of yellow fever virus. This YFV is currently part of the local EPI program in Mali. This vaccine was administered intramuscularly to the left deltoid.
250455|NCT02286895|Biological|meningitis conjugate vaccine (PsA-TT-5μg)|A meningococcal A vaccine, with meningococcal A polysaccharide (PsA) conjugated to the carrier protein, tetanus toxoid (TT). After reconstitution, one dose (0.5 ml) contains 5μg meningococcal A polysaccharide and 5-16 μg tetanus toxoid as a carrier protein. PsA-TT-5μg was considered experimental at the initiation of this study, but received approval from the WHO for infants on 30 December 2014. For all participants enrolled January 1st, 2015 or later, PsA-TT-5μg was not included in Group A or Group B, due to its December 2014 expiration date. This vaccine was administered intramuscularly to the right thigh.
250456|NCT02286882|Drug|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
250457|NCT02286869|Procedure|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
250458|NCT02286856|Behavioral|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
250459|NCT02286843|Radiation|89Zr-trastuzumab|
250460|NCT02286843|Device|PET/CT scan|
250461|NCT02286843|Radiation|89Zr-pertuzumab|
250462|NCT02286830|Drug|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
250463|NCT02286817|Drug|NFC-1|Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
250464|NCT02286804|Device|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
250465|NCT02286791|Behavioral|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
250584|NCT02285790|Procedure|Punch biopsy|
250585|NCT02285790|Procedure|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
250716|NCT02284802|Procedure|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
250466|NCT02286791|Behavioral|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.~Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
250467|NCT02286778|Dietary Supplement|Acetogenins|Acetogenins BID for 12 months
250468|NCT02286778|Dietary Supplement|Placebo|
250469|NCT02286765|Device|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
250470|NCT02286752|Drug|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
250471|NCT02286752|Drug|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
250472|NCT02286739|Device|"TKA with Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA 510K clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
250473|NCT02286739|Procedure|"TKA without Verasense"|TKA will be performed manually without the use of Verasense
250474|NCT02286726|Other|Laboratory Biomarker Analysis|Correlative studies
250475|NCT02286726|Drug|Liposome-encapsulated Daunorubicin-Cytarabine|Given IV
250476|NCT02286713|Behavioral|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
250477|NCT02286713|Behavioral|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
250478|NCT02286713|Behavioral|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
250479|NCT02286700|Drug|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
250480|NCT02286700|Other|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
250481|NCT02286687|Other|Laboratory Biomarker Analysis|Correlative studies
250482|NCT02286687|Other|Pharmacological Study|Correlative studies
250483|NCT02286687|Drug|Talazoparib|Given PO
250484|NCT02286674|Other|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
250485|NCT02286661|Procedure|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
250486|NCT02286661|Procedure|Casting (short arm)|
250487|NCT02286648|Drug|Formocresol|pulpotomy with formocresol
250488|NCT02286648|Drug|Mineral Trioxide Aggregate|pulpotomy with MTA
250489|NCT02286635|Drug|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
250490|NCT02286635|Drug|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
250491|NCT02286622|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
250492|NCT02286609|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
250493|NCT02286596|Device|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
250494|NCT02286596|Device|dextran sulfate adsorption|Lipid apheresis for 3 hours
250495|NCT02286583|Device|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
250496|NCT02286570|Device|Glidescope|videolaryngoscope used for endotracheal intubation
250497|NCT02286570|Device|Airtraq|videolaryngoscope used for endotracheal intubation
250498|NCT02286570|Device|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
250499|NCT02286557|Drug|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
250500|NCT02286557|Drug|Placebo|
250586|NCT02285777|Biological|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
250501|NCT02286544|Biological|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
250502|NCT02286544|Drug|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.~Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
250503|NCT02286544|Drug|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
250504|NCT02286531|Drug|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
250505|NCT02286518|Drug|TAK-114 10 mg capsule|
250506|NCT02286518|Drug|TAK-114 matched placebo|
250507|NCT02286505|Device|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
250508|NCT02286505|Other|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
250509|NCT02286492|Drug|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
250510|NCT02286479|Procedure|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
250511|NCT02286479|Procedure|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
250512|NCT02286466|Behavioral|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
250513|NCT02286466|Behavioral|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
250514|NCT02286453|Drug|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
250515|NCT02286453|Drug|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
250516|NCT02286440|Other|AssureRx GeneSight genotyping results|
250517|NCT02286440|Other|Treatment as usual|
250518|NCT02286427|Device|Amniotic Membrane|
250519|NCT02286414|Drug|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants : dabigatran, rivaroxaban, apixaban
250520|NCT02286414|Drug|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
250521|NCT02286388|Procedure|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.~Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.~Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.~The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
250522|NCT02286388|Procedure|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:~Idem partial excavation arm.~In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
250587|NCT02285777|Biological|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
250588|NCT02285764|Other|Nutritional Supplement|Modified carbohydrate
250589|NCT02285764|Other|Standard of Care|As determined by the study site
250590|NCT02285751|Drug|acetylsalicylic acid|
250591|NCT02285751|Drug|clopidogrel|
250523|NCT02286388|Device|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.~The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
250524|NCT02286388|Device|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
250525|NCT02286375|Behavioral|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
250526|NCT02286349|Device|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
250527|NCT02286349|Device|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
250528|NCT02286336|Other|brachial plexus block|brachial plexus block with ropivacaine 40ml
250529|NCT02286323|Device|Bonfils|Bonfils Intubation Fiberoscope
250530|NCT02286323|Device|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
250531|NCT02286310|Other|Kinetic Chain Exercises|Exercises include kinetic chain segments.
250532|NCT02286310|Other|Traditional Exercises|Stretching, strengthening exercises.
250533|NCT02286297|Device|McGRATH® MAC|video-laryngoscopy-1
250534|NCT02286297|Device|AirTraq|video-laryngoscopy-2
250535|NCT02286297|Device|GlideScope|video-laryngoscopy-3
250536|NCT02286297|Device|Miller|Direct laryngoscopy
250537|NCT02286284|Device|Apheresis for extracorporal removal of sFlt-1|
250538|NCT02286258|Drug|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
250539|NCT02286258|Drug|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
250540|NCT02286245|Other|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
250541|NCT02286245|Other|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
250542|NCT02286232|Behavioral|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
250543|NCT02286232|Behavioral|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
250544|NCT02286219|Drug|FS102|Experimental
250545|NCT02286206|Drug|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
250546|NCT02286193|Behavioral|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
250547|NCT02286167|Other|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
250548|NCT02286154|Drug|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
250549|NCT02286115|Behavioral|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
250550|NCT02286102|Device|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
250551|NCT02286102|Device|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
250552|NCT02286089|Biological|OpRegen|Targeted dose of 50,000 - 200,000 cells will be delivered into the subretinal space
250553|NCT02286063|Drug|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).~Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
250554|NCT02286050|Other|CF Nursing Program|
250592|NCT02285751|Drug|prasugrel|
250593|NCT02285751|Drug|ticagrelor|
250594|NCT02285738|Drug|Aspirin|81mg/day for 4 weeks
250595|NCT02285738|Drug|Simvastatin|Daily dose of Simvastatin for 4 weeks
250596|NCT02285738|Other|Observation|participants will be observed for thrombotic evens for 4 weeks
250555|NCT02286011|Biological|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.~For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
250556|NCT02286011|Other|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
250557|NCT02285998|Biological|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
250558|NCT02285998|Biological|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
250559|NCT02285985|Drug|Saxagliptin|Tablets: 5 mg
250560|NCT02285985|Drug|Placebo|Tablets: 5mg
250561|NCT02285972|Drug|saline|before the anesthesia induction, 2mL saline iv injection
250562|NCT02285972|Drug|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
250563|NCT02285972|Drug|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
250564|NCT02285959|Drug|Bevacizumab|
250565|NCT02285946|Procedure|major spine surgery|
250566|NCT02285933|Other|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
250567|NCT02285933|Other|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
250568|NCT02285920|Drug|Spironolactone|The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
250569|NCT02285907|Other|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
250570|NCT02285907|Other|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
250571|NCT02285907|Other|Serving Size Matched BEEF|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
250572|NCT02285907|Other|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
250573|NCT02285894|Other|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
250574|NCT02285881|Behavioral|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
250575|NCT02285855|Drug|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
250576|NCT02285855|Other|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
250577|NCT02285855|Radiation|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
250578|NCT02285842|Device|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
250579|NCT02285829|Drug|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
250580|NCT02285816|Biological|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
250597|NCT02285725|Procedure|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
250598|NCT02285725|Biological|Injections of BMAC + PRP + HA|All patients will receive up to 12 post-operative intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA (Supartz)
250599|NCT02285712|Device|Vascular ultrasound system|
250600|NCT02285699|Drug|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
250601|NCT02285673|Biological|Umbilical Cord Mesenchymal Stem Cell|
250602|NCT02285660|Procedure|4D PET-CT Scan|
250603|NCT02285660|Other|No intervention|
250604|NCT02285647|Drug|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
250605|NCT02285647|Drug|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
250606|NCT02285634|Drug|Oxymetazoline 0.05%|sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
250607|NCT02285634|Drug|Phenylephrine 0.25%|sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
250608|NCT02285634|Drug|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
250609|NCT02285634|Drug|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
250610|NCT02285621|Other|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
250611|NCT02285608|Other|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
250612|NCT02285595|Device|Sonendo GentleWave™ System|
250613|NCT02285582|Other|Registry study|No intervention.
250614|NCT02285556|Behavioral|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
250615|NCT02285556|Behavioral|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
250616|NCT02285556|Radiation|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
250617|NCT02285556|Radiation|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
250618|NCT02285543|Drug|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.~Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
250619|NCT02285543|Procedure|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
250620|NCT02285543|Radiation|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
250621|NCT02285530|Drug|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle.
250622|NCT02285530|Procedure|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
250623|NCT02285530|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
250624|NCT02285517|Procedure|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
250625|NCT02285517|Procedure|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
250626|NCT02285504|Drug|SAGE-547|Intravenous
250627|NCT02285491|Drug|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
250628|NCT02285491|Drug|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
250629|NCT02285465|Drug|ASP3700|Oral
250630|NCT02285465|Drug|Placebo|Oral
250631|NCT02285452|Drug|Zingiberis Rhizoma plv.|
250632|NCT02285452|Drug|Sinapis nigrea semen|
250633|NCT02285452|Drug|Placebo|
250634|NCT02285439|Drug|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
250635|NCT02285426|Device|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.~When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality [visual scale adapted from Herth 2009 and Zaric 2013] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
250636|NCT02285413|Biological|DC vaccination|DC vaccination without cisplatinum
250637|NCT02285413|Biological|DC vaccination with cisplatinum|DC vaccination with cisplatinum
250638|NCT02285400|Procedure|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
250639|NCT02285387|Procedure|Rhythm control|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation~Cardioversion after 1 month~Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)~If AF recur, RFCA"
250640|NCT02285387|Procedure|Rate control|"No AAD, just anticoagulation~HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)~Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
250641|NCT02285374|Drug|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
250642|NCT02285361|Drug|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
250643|NCT02285361|Drug|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
250644|NCT02285361|Drug|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
250645|NCT02285348|Procedure|Lumbar puncture|Lumbar puncture is done according to general practice
250646|NCT02285335|Dietary Supplement|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
250647|NCT02285309|Procedure|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
250648|NCT02285296|Other|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
250649|NCT02285283|Drug|Itraconazole|
250650|NCT02285283|Drug|Placebo|
250651|NCT02285270|Device|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
250652|NCT02285244|Drug|sotrastaurin acetate|Given PO
250653|NCT02285244|Other|pharmacological study|Correlative studies
250654|NCT02285244|Other|laboratory biomarker analysis|Correlative studies
250655|NCT02285231|Dietary Supplement|Arginyl-fructose|
250656|NCT02285231|Dietary Supplement|Placebo|
250657|NCT02285218|Other|serum blood sampling|
250658|NCT02285205|Drug|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
250659|NCT02285192|Radiation|18F-Fluorodeoxyglucose (18F-FDG)|
250660|NCT02285192|Device|PET/CT imaging|
250661|NCT02285192|Device|PET/MRI imaging|
250662|NCT02285179|Drug|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
250663|NCT02285179|Drug|Tamoxifen|daily dose of 20 mg
250664|NCT02285166|Drug|Omega-3-acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
250665|NCT02285166|Drug|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
250666|NCT02285153|Drug|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
250667|NCT02285153|Drug|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
250668|NCT02285140|Drug|Cefazolin|administration as outlined
250669|NCT02285140|Drug|Vancomycin|administration as outlined
250670|NCT02285127|Procedure|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
250671|NCT02285114|Drug|F/TAF|F/TAF tablets administered orally once daily
250672|NCT02285114|Drug|3rd ARV agent|A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), efavirenz (EFV), nevirapine (NVP), raltegravir (RAL), or dolutegravir (DTG). Cohort 2, Group 1 will receive only boosted PIs (ATV, LPV or DRV).
250673|NCT02285101|Biological|PEG-BCT-100|
250674|NCT02285088|Drug|GBT440|GBT440 will be administered as oral capsules
250675|NCT02285088|Drug|Placebo|Matching placebo will be administered as oral capsules
250715|NCT02284815|Dietary Supplement|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
250676|NCT02285075|Drug|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T > MIC of 8 and 16 mg/L).
250677|NCT02285062|Drug|lenalidomide|
250678|NCT02285062|Drug|Placebo|
250679|NCT02285062|Drug|Rituximab|
250680|NCT02285062|Drug|Cyclophosphamide|
250681|NCT02285062|Drug|Doxorubicin|
250682|NCT02285062|Drug|prednisone|
250683|NCT02285062|Drug|vincristine|
250684|NCT02285049|Other|Urticaria Control Test|"The patients get the 1st UAS28 form and four-week appointment to follow up.~Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)~Then patients fill the 1st UCT and DLQI questionnaire by themselves.~The patients get the 2nd UAS28 form and four-week appointment to follow up.~At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
250685|NCT02285036|Biological|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
250686|NCT02285036|Biological|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
250687|NCT02285023|Other|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.~At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.~At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
250688|NCT02285010|Drug|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
250689|NCT02285010|Drug|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
250690|NCT02284997|Device|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
250691|NCT02284984|Drug|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
250692|NCT02284971|Biological|CDX1127|
250693|NCT02284971|Radiation|SBRT|
250694|NCT02284958|Behavioral|Standard|Back care advice
250695|NCT02284958|Behavioral|Walking|Back care advice, individualized 12 week pedometer-driven walking program
250696|NCT02284945|Procedure|Open fixation|
250697|NCT02284945|Procedure|Keyhole surgery|
250698|NCT02284932|Other|No specific intervention for this study|No specific intervention for this study
250699|NCT02284919|Drug|[18F]ISO-1|[18F]ISO-1 PET/CT scan
250700|NCT02284906|Drug|Pioglitazone|Pioglitazone tablets
250701|NCT02284906|Drug|Placebo|Pioglitazone placebo-matching tablets
250702|NCT02284893|Drug|Saxagliptin|administered orally once daily
250703|NCT02284893|Drug|Dapagliflozin|administered orally once daily
250704|NCT02284893|Drug|Sitagliptin|administered orally once daily
250705|NCT02284893|Drug|Placebo matching with Saxagliptin|administered orally once daily
250706|NCT02284893|Drug|Placebo matching with Dapagliflozin|administered orally once daily
250707|NCT02284893|Drug|Placebo matching with Sitagliptin|administered orally once daily
250708|NCT02284880|Drug|BIA 2-093|MF - Marketed formulation
250709|NCT02284880|Drug|BIA 2-093|TBM - to-be-marketed
250710|NCT02284867|Other|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
250711|NCT02284854|Drug|BIA 2-093|
250712|NCT02284854|Drug|Carbamazepine|
250713|NCT02284841|Device|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
250714|NCT02284828|Drug|BIA 2-093|
250717|NCT02284789|Other|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
250718|NCT02284776|Behavioral|Therapeutic education|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
250719|NCT02284763|Other|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
250720|NCT02284750|Procedure|Percutaneous coronary intervention|
250721|NCT02284737|Procedure|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
250722|NCT02284737|Procedure|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
250723|NCT02284737|Drug|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
250724|NCT02284724|Procedure|Dry Needling|
250725|NCT02284724|Procedure|Sham Needling|
250726|NCT02284711|Device|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
250727|NCT02284711|Device|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
250728|NCT02284698|Other|Health Education|Heath education will be given through awareness creation & pamphlet distribution
250729|NCT02284685|Behavioral|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
250730|NCT02284672|Drug|Dexmedetomidine|
250731|NCT02284672|Drug|Normal saline|
250732|NCT02284659|Device|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
250733|NCT02284659|Device|FES- Sham|
250734|NCT02284646|Other|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
250735|NCT02284620|Procedure|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
250736|NCT02284620|Procedure|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
250737|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
250738|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
250739|NCT02284607|Drug|Placebo|Matching placebo to MHAA4549A administration
250740|NCT02284594|Behavioral|text message|series of text messages regarding influenza vaccination
250741|NCT02284568|Drug|Placebo|Placebo
250742|NCT02284568|Drug|Laquinimod|Laquinimod capsules in 0.5 mg and 0.6 mg strengths
250743|NCT02284568|Drug|Placebo|Placebo capsules
250744|NCT02284555|Drug|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
250745|NCT02284542|Procedure|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
250746|NCT02284542|Procedure|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.~(Falowski et al., 2011)."
250747|NCT02284529|Drug|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
250748|NCT02284516|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
250749|NCT02284516|Drug|Placebo|Placebo to match active treatment, BID for 84 days
250750|NCT02284503|Drug|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
250751|NCT02284490|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
250752|NCT02284477|Other|non- PVC containing packing materials|Beverage which was stored in glass bottle for 24 hours in 4 ℃.
250753|NCT02284477|Other|PVC containing packing materials|Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
250754|NCT02284464|Drug|Prednisone withdrawal|Withdrawal of steroids
250755|NCT02284464|Drug|Prednisone continuation|Continuation of steroids
250756|NCT02284451|Other|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
250757|NCT02284438|Device|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
250758|NCT02284425|Drug|REGN1193|
250759|NCT02284425|Drug|Placebo|
250760|NCT02284412|Drug|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
250761|NCT02284412|Drug|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
250762|NCT02284412|Drug|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
250763|NCT02284399|Other|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
250764|NCT02284386|Drug|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
250765|NCT02284386|Drug|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
250766|NCT02284373|Other|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
250767|NCT02284373|Other|Routine wound care for venous ulcers and lymphedema|wound care /dressings
250768|NCT02284373|Device|Flexitouch pneumonic compression|pneumonic compression only
250769|NCT02284360|Drug|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.~Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.~From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.~On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
250770|NCT02284347|Device|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
250771|NCT02284334|Other|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
250772|NCT02284308|Other|Blood withdrawal|An extra withdrawal of blood, during a routine blood withdrawal. This is an optional inverventions for patients.
250773|NCT02284295|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
250774|NCT02284295|Other|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
250775|NCT02284282|Drug|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
250776|NCT02284282|Drug|subcutaneum injection lidocaine|placebo injection
250777|NCT02284269|Drug|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
250778|NCT02284256|Drug|Fibrocaps|
250779|NCT02284256|Drug|TachoSil|
250780|NCT02284243|Drug|Intranasal Dexmedetomidine|
250781|NCT02284243|Drug|Intranasal Placebo|
250782|NCT02284230|Drug|Liraglutide|
250783|NCT02284230|Drug|Placebo|
250784|NCT02284217|Device|EVD|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
250785|NCT02284204|Drug|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
250786|NCT02284204|Drug|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
250787|NCT02284191|Radiation|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
250788|NCT02284178|Other|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
250789|NCT02284178|Other|Usual Care|Oral suction with suction swab every 4 hours
250790|NCT02284165|Other|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
250791|NCT02284152|Behavioral|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
250792|NCT02284139|Drug|Arm EGF ointment 1ppm|EGF Ointment 1ppm evenly apply to skin lesion every 12 hr/ day
250793|NCT02284139|Drug|Arm EGF ointment 20 ppm|EGF Ointment 20 evenly apply to skin lesion every 12 hr/ day
250794|NCT02284139|Drug|Arm Placebos|EGF Ointment 0ppm evenly apply to skin lesion every 12 hr/ day
250795|NCT02284126|Drug|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
250796|NCT02284113|Device|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
250797|NCT02284113|Device|iovera° Sham|iovera° device used for sham treatment
250798|NCT02284100|Behavioral|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.~The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
250799|NCT02284087|Device|PAS|
250895|NCT02283398|Other|without RIPC|the cuff will be placed around the left arm without being inflated
251029|NCT02282488|Other|Low protein formula|
250800|NCT02284074|Other|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
250801|NCT02284061|Other|physical activities adapted to children|
250802|NCT02284048|Drug|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
250803|NCT02284035|Drug|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
250804|NCT02284035|Drug|EFV/TDF/FTC|standard combination therapy
250805|NCT02284035|Drug|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
250806|NCT02284035|Drug|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
250807|NCT02284035|Drug|EFV plus ABC/3TC or RPV/TDF/FTC|
250808|NCT02284035|Drug|ATV/r plus ABC/3TC|
250809|NCT02284035|Drug|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
250810|NCT02284035|Drug|RAL plus ABC/3TC|
250811|NCT02284035|Drug|Other ART regimens|
250812|NCT02284022|Device|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
250813|NCT02284009|Biological|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
250814|NCT02284009|Biological|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
250815|NCT02284009|Biological|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
250816|NCT02283996|Other|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.~Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:~http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
250817|NCT02283996|Drug|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
250818|NCT02283983|Other|mittens and booties|
250819|NCT02283983|Other|cooling helmet|
250820|NCT02283957|Drug|CNTX-4975|
250821|NCT02283957|Other|Placebo|
250822|NCT02283944|Device|TMS|Pulsed non-invasive brain stimulation using electromagnets
250823|NCT02283931|Device|TTE / NICOM|
250824|NCT02283905|Drug|amphotericin-B|continuously infused
250825|NCT02283905|Drug|voriconazole|intravenously or orally administered
250826|NCT02283892|Other|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
250827|NCT02283892|Other|Conventional evaluation|Physician evaluation without the use of checklists
250828|NCT02283879|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
250829|NCT02283866|Drug|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
250830|NCT02283866|Drug|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
250831|NCT02283853|Drug|dimethyl fumarate|administered orally
250832|NCT02283853|Drug|Interferon β-1a|administered by intramuscular injection
250833|NCT02283840|Drug|BIA 2-093|
250834|NCT02283827|Drug|BIA 2-093|
250835|NCT02283827|Drug|Phenytoin|
250836|NCT02283814|Drug|BIA 2-093|
250837|NCT02283814|Drug|Topamax|
250838|NCT02283801|Drug|Eslicarbazepine acetate|
250839|NCT02283801|Drug|Lamotrigine|
250840|NCT02283788|Drug|BIA 2-093|
250841|NCT02283788|Drug|Moxifloxacin|
250842|NCT02283788|Drug|Placebo|
250843|NCT02283775|Drug|Isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
250844|NCT02283775|Drug|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
250845|NCT02283775|Drug|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
250846|NCT02283762|Drug|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5 mg very 2 weeks until highest possible dose of 2.5 mg TID
250847|NCT02283762|Drug|Placebo|Sham-titration
250848|NCT02283749|Biological|Xofigo|This is a radio-isotope
250849|NCT02283736|Other|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
250850|NCT02283736|Other|Talc powder|Tablet containing talc powder
250851|NCT02283736|Procedure|Periodontal treatment|Scaling and root planning
250852|NCT02283723|Other|Health TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
250853|NCT02283723|Other|Usual care|While waiting for the Health TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
250854|NCT02283710|Drug|Pentoxifylline|Pentoxifylline 600 mg BD
250855|NCT02283710|Behavioral|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
251025|NCT02282514|Drug|Methylprednisolone|Steroid
251030|NCT02282488|Other|High protein formula|
250856|NCT02283697|Behavioral|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the DASH diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
250857|NCT02283697|Other|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
250858|NCT02283684|Procedure|Greenlight laser PVP|Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
250859|NCT02283684|Procedure|Bipolar TUVP|Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
250860|NCT02283671|Biological|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
250861|NCT02283658|Drug|Everolimus|Given PO
250862|NCT02283658|Other|Laboratory Biomarker Analysis|Correlative studies
250863|NCT02283658|Drug|Letrozole|Given PO
250864|NCT02283645|Drug|3 % minoxidil lotion|
250865|NCT02283645|Drug|Placebo|
250866|NCT02283632|Procedure|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
250867|NCT02283619|Other|None - no intervention, observational study|No intervention, observational study
250868|NCT02283606|Device|Accuvix SnonAce UGEO|vaginal ultrasonography
250869|NCT02283593|Behavioral|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
250870|NCT02283580|Other|Single limb|"Low load, high-repetitive resistance training.~single limb at a time (e.g., one arm or one leg)~elastic bands~8 weeks~3 times/week,~each session 60 minutes~seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~maximal number of repetitions (RM) * 3 sets in each exercise."
250871|NCT02283580|Other|Two limb|"Low load, high-repetitive resistance training.~two limbs at a time (e.g., both arms or both legs)~elastic bands~8 weeks~3 times/week,~each session 60 minutes~seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension~maximal number of repetitions (RM) * 3 sets in each exercise."
250872|NCT02283554|Procedure|open flap debridement (OFD)|
250873|NCT02283554|Other|Platelet rich fibrin (PRF)|
250874|NCT02283554|Drug|Metformin|
250875|NCT02283541|Behavioral|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
250876|NCT02283528|Device|Stryker Hybrid|Place Hybrid arch bars
250877|NCT02283528|Device|Erich|Control group is Erich arch bars
250878|NCT02283515|Drug|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
250879|NCT02283502|Device|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
250880|NCT02283489|Drug|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).~Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
250881|NCT02283489|Drug|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
250882|NCT02283489|Drug|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
250883|NCT02283476|Drug|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
250884|NCT02283476|Drug|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
250885|NCT02283476|Drug|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
250886|NCT02283476|Drug|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
250887|NCT02283463|Device|Intrauterine device (IUD) insertion|
250888|NCT02283463|Procedure|Endometrial biopsy|
250889|NCT02283450|Drug|Qiliqiangxin Capsule|
250890|NCT02283437|Behavioral|Problem-solving Based Bibliotherapy Program|The PSBPF will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
250891|NCT02283437|Behavioral|Psychoeducation Group Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) psychoeducation programs for schizophrenia.
250892|NCT02283424|Drug|Icotinib|compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
250893|NCT02283424|Drug|chemotherapy (Carboplatin and Docetaxel)|as control group,compared with Icotinib
250894|NCT02283411|Device|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
250896|NCT02283398|Procedure|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
250897|NCT02283385|Behavioral|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
250898|NCT02283372|Drug|nab-Paclitaxel|
250899|NCT02283372|Drug|Gemcitabine|
250900|NCT02283372|Radiation|Intensity modulated radiation|
250901|NCT02283359|Drug|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
250902|NCT02283359|Drug|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
250903|NCT02283346|Radiation|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).~+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
250904|NCT02283333|Behavioral|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
250905|NCT02283333|Behavioral|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
250906|NCT02283320|Drug|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
250907|NCT02283307|Other|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
250908|NCT02283307|Other|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
250909|NCT02283294|Drug|Apixaban|
250910|NCT02283294|Drug|Warfarin|
250911|NCT02283281|Drug|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
250912|NCT02283281|Drug|Acetaminophen|50 ml intravenous vial
250913|NCT02283281|Drug|Midazolam|2 ml prefilled syringe
250914|NCT02283281|Drug|Dummy oromucosal spray|Oromucosal spray containing only alcohol vehicle without the active compound (i.e.: without nabiximols)
250915|NCT02283268|Biological|Recombinant von Willebrand Factor (rVWF)|rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
250916|NCT02283255|Other|Physical Activity|Physical Activity, Exercise training: aerobic and respiratory exercise with POWERbreathe device
250917|NCT02283242|Drug|Galantamine|Oral use for 12 weeks
250918|NCT02283242|Drug|Placebo (for galantamine)|Oral use for 12 weeks
250919|NCT02283229|Behavioral|Newborns with preventive caring advices|Advices to prevent head molding
250920|NCT02283229|Other|Newborns with normal caring advices|Normal handling
250921|NCT02283216|Device|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
250922|NCT02283216|Device|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
250923|NCT02283216|Device|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
250924|NCT02283203|Drug|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
250925|NCT02283203|Drug|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
250926|NCT02283190|Drug|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
250927|NCT02283177|Drug|crenolanib|
250928|NCT02283177|Drug|cytarabine|
250929|NCT02283177|Drug|daunorubicin|
250930|NCT02283177|Drug|idarubicin|
250931|NCT02283164|Behavioral|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
250932|NCT02283151|Dietary Supplement|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
250933|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
250934|NCT02283112|Other|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
250935|NCT02283099|Biological|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10^6 pfu, 2x10^7 pfu or 3x10^5)
250936|NCT02283086|Behavioral|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
250937|NCT02283060|Drug|Stribild|To be administered orally, once daily with food.
250938|NCT02283060|Drug|Atripla|To be administered orally, once daily at bedtime on an empty stomach
250939|NCT02283047|Behavioral|DIET|Lifestyle intervention through hypocaloric diet
251031|NCT02282462|Other|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
250940|NCT02283047|Behavioral|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
250941|NCT02283047|Behavioral|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
250942|NCT02283047|Behavioral|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
250943|NCT02283034|Device|The CPRmeter|Feedback device - 1
250944|NCT02283034|Device|The PocketCPR|Feedback device - 2
250945|NCT02283034|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
250946|NCT02283034|Device|The CPREazy|Feedback device - 3
250947|NCT02283034|Device|The CPR PRO APP|Feedback device - 4
250948|NCT02283034|Device|The CardioPump|Feedback devices - 5
250949|NCT02283034|Device|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
250950|NCT02283021|Other|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
250951|NCT02283008|Behavioral|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
250952|NCT02282969|Behavioral|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
250953|NCT02282969|Behavioral|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
250954|NCT02282956|Drug|Ropivacaine 0,75%|Ropivacaine injection
250955|NCT02282956|Procedure|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
250956|NCT02282956|Drug|morphine and droperidol|i.v PCA
250957|NCT02282943|Device|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
250958|NCT02282943|Device|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
250959|NCT02282930|Drug|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
250960|NCT02282917|Drug|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
250961|NCT02282904|Drug|Sirolimus|"For pediatric patients: Begin sirolimus 1 mg/m2 PO q4h for 3 doses, then 1 mg/m2 once a day (QD). For adult patients, begin sirolimus 5 mg PO q4h for 3 doses, then 5 mg once a day (QD).~Doses may be adjusted to maintain trough levels between 8-14 ng/ml. Recipients will take sirolimus from Day +5 to at least Day 100 (minimum)."
250962|NCT02282904|Biological|Donor peripheral blood stem cells.|Infuse donor graft.
250963|NCT02282904|Drug|Cyclophosphamide post transplant|50 mg/kg/d IV infused over 90 minutes. Day +3 and +4
250964|NCT02282904|Radiation|Total body 200cGy|Day -1
250965|NCT02282904|Drug|Cyclophosphamide|14.5 mg/kg IV over one hour Day -6 and -5
250966|NCT02282904|Drug|Fludarabine|30 mg/m2 over 30 minutes Day -6 through Day -2
250967|NCT02282904|Drug|Busulfan|Busulfan 3.2 mg/kg IV once daily over 2-3 hours Day -4,-3,-2
250968|NCT02282891|Drug|Propofol|Induction of general anesthesia using propofol 2mg/kg
250969|NCT02282891|Drug|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
250970|NCT02282878|Dietary Supplement|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
250971|NCT02282852|Device|Wireless Capsule Endoscopy|
250972|NCT02282852|Device|Magnetically steerable capsule endoscopy|
250973|NCT02282839|Dietary Supplement|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
250974|NCT02282839|Dietary Supplement|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
250975|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
250976|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: intravenous
250977|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
250978|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
250979|NCT02282826|Drug|acyclovir|Pharmaceutical form:tablet Route of administration: oral
250980|NCT02282813|Drug|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
250981|NCT02282813|Drug|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
250982|NCT02282813|Drug|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
250983|NCT02282813|Drug|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
250984|NCT02282800|Genetic|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
250985|NCT02282787|Drug|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
251026|NCT02282514|Drug|G-CSF|Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
251027|NCT02282514|Drug|Rituxan|A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders
251028|NCT02282501|Other|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
250986|NCT02282774|Drug|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
250987|NCT02282774|Drug|Sham subtenon block|
250988|NCT02282761|Drug|ITI-007|
250989|NCT02282761|Drug|Placebo|
250990|NCT02282748|Other|No intervention|
250991|NCT02282722|Other|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
250992|NCT02282722|Other|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
250993|NCT02282709|Drug|Daclatasvir|60 mg once daily
250994|NCT02282709|Drug|asunaprevir|100 mg BID
250995|NCT02282696|Other|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
250996|NCT02282683|Drug|prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
250997|NCT02282670|Drug|DA-5204|
250998|NCT02282670|Drug|Stillen tab.|
250999|NCT02282657|Device|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).~Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.~Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.~Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
251000|NCT02282657|Other|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
251001|NCT02282657|Device|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
251002|NCT02282657|Other|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
251003|NCT02282657|Other|Respiratory Rate|RR will be kept what it was at baseline
251004|NCT02282657|Other|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
251005|NCT02282657|Other|Ventilation will be adapted|If PaCO2> 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
251006|NCT02282657|Other|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
251007|NCT02282644|Biological|Bone marrow sampling|
251008|NCT02282631|Behavioral|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
251009|NCT02282618|Device|Cardiac Sympathetic Blockade|
251010|NCT02282605|Drug|XF-73 nasal gel|
251011|NCT02282605|Drug|Placebo nasal gel|
251012|NCT02282605|Other|Chlorhexidine gluconate 2% topical cloths|
251013|NCT02282592|Other|Observation about the presence of metabolic syndrome|
251014|NCT02282579|Drug|Pazopanib|Non interventional study
251015|NCT02282566|Other|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
251016|NCT02282553|Device|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
251017|NCT02282553|Device|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
251018|NCT02282540|Procedure|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
251019|NCT02282527|Biological|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
251020|NCT02282527|Biological|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
251021|NCT02282514|Biological|Autologous Hematopoietic Stem Cells|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
251022|NCT02282514|Drug|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
251023|NCT02282514|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
251024|NCT02282514|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
251032|NCT02282462|Other|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
251033|NCT02282462|Other|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
251034|NCT02282462|Other|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
251035|NCT02282462|Other|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
251036|NCT02282462|Other|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
251037|NCT02282449|Device|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
251038|NCT02282449|Device|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
251039|NCT02282436|Other|No specific intervention for this study|No specific intervention for this study
251040|NCT02282423|Behavioral|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
251041|NCT02282423|Procedure|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
251042|NCT02282423|Procedure|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
251043|NCT02282423|Procedure|VO2max.|VO2max.
251044|NCT02282423|Behavioral|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
251045|NCT02282423|Procedure|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
251046|NCT02282410|Drug|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
251047|NCT02282397|Device|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
251048|NCT02282384|Drug|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
251049|NCT02282384|Other|Placebo|
251050|NCT02282371|Drug|Cetuximab|
251051|NCT02282371|Drug|BYL719|
251052|NCT02282371|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
251053|NCT02282358|Drug|Mocetinostat|
251054|NCT02282345|Other|Laboratory Biomarker Analysis|Correlative studies
251055|NCT02282345|Drug|Talazoparib|Given PO
251056|NCT02282332|Drug|Ticagrelor|
251057|NCT02282319|Drug|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
251058|NCT02282319|Other|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
251059|NCT02282319|Drug|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
251060|NCT02282306|Behavioral|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
251061|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|
251062|NCT02282293|Drug|Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)|
251063|NCT02282280|Drug|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
251064|NCT02282267|Drug|Gefitinib|Iressa 250mg oral daily
251065|NCT02282254|Other|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
251066|NCT02282241|Drug|Melatonin|
251067|NCT02282241|Other|Placebo|
251068|NCT02282228|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
251069|NCT02282215|Biological|CLT-008|Single intravenous infusion
251070|NCT02282215|Biological|G-CSF|Daily subcutaneous injections
251145|NCT02281565|Behavioral|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
251146|NCT02281552|Drug|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
251071|NCT02282202|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.~There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
251072|NCT02282189|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
251073|NCT02282176|Drug|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
251074|NCT02282176|Drug|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
251075|NCT02282163|Drug|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
251076|NCT02282150|Drug|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
251077|NCT02282150|Drug|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
251078|NCT02282137|Drug|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
251079|NCT02282124|Behavioral|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
251080|NCT02282124|Behavioral|Usual Care, containing one session|Session takes place within the first three months after transplantation
251081|NCT02282111|Device|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|Using a linear EUS with color and pulsed Doppler to scan the area for vessels, the lesion was then sampled with a 22-gauge beveled needle (using the slow capillary suction and fanning techniques with 5 to 15 to-and-fro movements with each pass). A total of 4 passes were performed and after that, the procedure terminated.
251082|NCT02282111|Device|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Using a conventional needle-knife sphincterotome connected to an electrosurgical unit, and under direct endoscopic vision, a 6-12mm linear incision was made from the periphery of the lesion to its highest convexity zone. A conventional biopsy forceps was then deeply introduced through the hole, and 2 bites were obtained per pass. A total of 4 passes were performed by passing the biopsy forceps through the incision on each occasion. The mucosal incision was then closed with endoclips whenever possible.
251083|NCT02282098|Drug|Colchicine|Colchicine 0.6mg twice daily
251084|NCT02282098|Drug|Placebo|Placebo Colchicine
251085|NCT02282085|Drug|Aripiprazole Once-Monthly|
251086|NCT02282085|Drug|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
251087|NCT02282072|Device|Deep brain stimulation：PINS Stimulation System|
251088|NCT02282059|Drug|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
251089|NCT02282033|Device|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
251090|NCT02282020|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
251091|NCT02282020|Drug|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
251092|NCT02282007|Behavioral|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
251093|NCT02281994|Device|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
251094|NCT02281981|Dietary Supplement|Curcumin|333mg CurcuWin OAHTCUR002-2014
251095|NCT02281981|Dietary Supplement|Placebo|OAHTCUR005-2014
251096|NCT02281968|Drug|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
251097|NCT02281968|Drug|Placebo|
251098|NCT02281955|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
251099|NCT02281955|Drug|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
251147|NCT02281552|Drug|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
251148|NCT02281539|Device|Neuromotus|
251100|NCT02281955|Procedure|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
251101|NCT02281942|Behavioral|Yoga|
251102|NCT02281942|Behavioral|Education|
251103|NCT02281929|Drug|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
251104|NCT02281929|Drug|Placebo|Placebo in three daily doses during 30 days
251105|NCT02281929|Drug|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
251106|NCT02281916|Drug|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
251107|NCT02281903|Device|The TrueCPR feedback device|feedback devices
251108|NCT02281903|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
251109|NCT02281890|Other|Proven sepsis|Exposure is proven sepsis
251110|NCT02281877|Procedure|Neuromuscular electrical stimulation (NMES)|5x/week, 2x/day, for 45 minutes/session
251111|NCT02281877|Behavioral|Standard Rehabilitation Protocol|Standard physical therapy after TKA
251112|NCT02281864|Behavioral|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
251113|NCT02281864|Other|Control Group: Quitline|Referral to the Quitline
251114|NCT02281838|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
251115|NCT02281812|Procedure|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
251116|NCT02281799|Drug|Azathioprine|"Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa."
251117|NCT02281786|Drug|Placebo|Matching placebo to RO6926496
251118|NCT02281786|Drug|RO6926496|single, ascending dose, intravenous administration
251119|NCT02281773|Drug|BI 409306 100 mg QD|
251120|NCT02281773|Drug|BI 498306 50 mg QD|
251121|NCT02281773|Drug|Placebo|
251122|NCT02281773|Drug|BI 498306 25 mg QD|
251123|NCT02281773|Drug|BI 409306 10 mg QD|
251124|NCT02281760|Drug|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
251125|NCT02281760|Drug|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
251126|NCT02281721|Device|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
251127|NCT02281708|Drug|vinorelbine plus cisplatin|"Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days~vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks"
251128|NCT02281695|Other|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
251129|NCT02281682|Drug|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
251130|NCT02281682|Drug|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
251131|NCT02281682|Drug|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
251132|NCT02281682|Procedure|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
251133|NCT02281669|Drug|Pentostam|Intralesional injection of Pentostam
251134|NCT02281656|Procedure|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
251135|NCT02281656|Procedure|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
251136|NCT02281643|Drug|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
251137|NCT02281630|Drug|KWA-0711|
251138|NCT02281630|Drug|Placebo|
251139|NCT02281617|Behavioral|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
251140|NCT02281591|Drug|BIA 2-093|Tablets containing 900 mg
251141|NCT02281591|Drug|S-licarbazepine|capsules containing 225 mg
251142|NCT02281591|Drug|R-licarbazepine|capsules containing 225 mg
251143|NCT02281578|Behavioral|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
251144|NCT02281578|Behavioral|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
251149|NCT02281526|Drug|BIA 2-093|
251150|NCT02281513|Other|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
251151|NCT02281513|Other|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
251152|NCT02281513|Other|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
251153|NCT02281500|Biological|Human Plasma-Derived Fibrinogen Concentrate|A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20 mg/ml of active substance fibrinogen when reconstituted.
251154|NCT02281487|Procedure|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
251155|NCT02281487|Procedure|Hysterectomy|standard hysterectomy
251156|NCT02281487|Device|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
251157|NCT02281474|Drug|Nilotinib|
251158|NCT02281461|Device|Male circumcision using a non-surgical device|Male Circumcision
251159|NCT02281448|Drug|BIA 2-093|
251160|NCT02281448|Drug|Contraceptives, Oral, Combined|
251161|NCT02281435|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
251162|NCT02281422|Drug|BIA 2-093|
251163|NCT02281409|Biological|Mogamulizumab (KW-0761)|
251164|NCT02281396|Biological|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
251165|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
251166|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
251167|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
251168|NCT02281383|Biological|Bacillus Calmette-Guérin (BCG)|
251169|NCT02281370|Drug|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
251170|NCT02281370|Drug|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
251171|NCT02281357|Biological|Tralokinumab|Tralokinumab dose
251172|NCT02281357|Other|Placebo|Placebo dose
251173|NCT02281344|Drug|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
251174|NCT02281344|Drug|MMV390048 x mg|Supplied as a powder to be prepared as a suspension for oral use
251175|NCT02281344|Drug|MMV390048 y mg|Supplied as a powder to be prepared as a suspension for oral use
251176|NCT02281331|Dietary Supplement|Supplement|supplement/placebo plus exercise training
251177|NCT02281318|Biological|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
251178|NCT02281318|Drug|Placebo|Sterile 0.9% sodium chloride solution
251179|NCT02281318|Drug|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
251180|NCT02281305|Drug|Colchicine|
251181|NCT02281292|Biological|LKA651 ophthalmic solution|
251182|NCT02281292|Biological|Ranibizumab ophthalmic solution|
251183|NCT02281292|Biological|Sham injection|Mock injection administered as an empty hub without needle
251184|NCT02281279|Biological|rituximab|Given IV
251185|NCT02281279|Drug|lenalidomide|Given PO
251186|NCT02281279|Drug|romidepsin|Given IV
251187|NCT02281279|Other|laboratory biomarker analysis|Correlative studies
251188|NCT02281266|Procedure|curative resection|
251189|NCT02281266|Drug|thymalfasin|1.6mg twice a week, 12 months
251190|NCT02281266|Drug|nucleoside analog (suggest to use entecavir)|
251191|NCT02281253|Dietary Supplement|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.~Patients were recommended to consume the bread twice per day with main meals."
251192|NCT02281253|Dietary Supplement|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
251193|NCT02281240|Drug|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
251194|NCT02281227|Procedure|skin compression|skin compression with an indicator for determination of needle entry point
251195|NCT02281214|Other|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
251196|NCT02281201|Biological|BE1116 (Prothrombin Complex Concentrate)|
251197|NCT02281175|Behavioral|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
251428|NCT02279641|Drug|allopurinol 300 mg|
251198|NCT02281175|Behavioral|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
251199|NCT02281162|Other|Blood Draw|Blood Draw
251200|NCT02281136|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
251201|NCT02281136|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
251202|NCT02281123|Other|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
251203|NCT02281110|Device|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
251204|NCT02281097|Other|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
251205|NCT02281097|Other|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
251206|NCT02281084|Drug|CC-486 (ORAL AZACITIDINE)|200 mg CC-486 (Oral Azacitidine) will be given for the first 21 days of each 28-day treatment cycle
251207|NCT02281071|Procedure|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
251208|NCT02281058|Drug|Abatacept|self-injected subcutaneous biologic medication
251209|NCT02281045|Device|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
251210|NCT02281045|Device|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
251211|NCT02281032|Other|interRAI PC|"PREPARATORY PHASE~Step 0: Introductory information~Step 1: Training on the interRAI PC and the BelRAI webapplication~Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization~IMPLEMENTATION PHASE~Step 3: Identification of residents with palliative care needs, based on the surprise question~Step 4: Informed consent signature requirements~Step 5: Login to the BelRAI webapplication~Step 6: Definitions of roles and functions~Step 7: Completion of the interRAI PC~Step 8: Interpretation of results~Step 9: Use of results"
251212|NCT02281019|Procedure|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
251213|NCT02281019|Device|SpyGlass DVS and SpyGlass Digital Simple (DS)|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
251214|NCT02281006|Drug|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
251215|NCT02280993|Drug|DHAP|DHAP
251216|NCT02280993|Drug|Brentuximab Vedotin|Brentuximab Vedotin
251217|NCT02280993|Other|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
251218|NCT02280980|Other|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
251219|NCT02280967|Behavioral|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
251220|NCT02280954|Drug|Indocyanine Green (ICG)|
251221|NCT02280941|Other|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
251222|NCT02280928|Other|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
251223|NCT02280928|Other|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
251224|NCT02280928|Other|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
251225|NCT02280915|Other|Savoury food product|
251226|NCT02280902|Biological|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
251227|NCT02280876|Drug|1 - Andrographis paniculata p/st extract|"Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile."
251228|NCT02280876|Drug|2 - Excipients|"Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile"
251229|NCT02280863|Device|Medtronic Hybrid Closed-loop System - Android Platform|A continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm using an Android controller.
251230|NCT02280863|Device|Medtronic Hybrid Closed-loop Integrated System|A fully integrated continuous glucose sensor and insulin delivery system designed for continuous closed-loop control with the PID-IFB (proportional-integral-derivative insulin feed-back) algorithm
251231|NCT02280850|Drug|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
251232|NCT02280850|Drug|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
251233|NCT02280850|Drug|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.~The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
251234|NCT02280837|Other|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
251235|NCT02280824|Procedure|CA-TAVR|Transcaval acesss for transcatheter aortic valve replacement in patients with no good options for aortic access
251236|NCT02280824|Device|Amplatzer Duct Occluder|
251237|NCT02280811|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m^2/day for 5 days.
251238|NCT02280811|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
251239|NCT02280811|Biological|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
251240|NCT02280811|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
251241|NCT02280798|Procedure|Endometrial Biopsy|4 endometrial biopsy
251242|NCT02280785|Drug|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
251243|NCT02280772|Dietary Supplement|Glucomannan|
251244|NCT02280772|Dietary Supplement|Maltodextrin|
251245|NCT02280759|Drug|Gelatin Tannate|
251246|NCT02280759|Drug|Placebo|Placebo consists of an identical formulation, except active substance
251247|NCT02280746|Other|Gluten challenge|Intervention will be continued for at least 6 months
251248|NCT02280733|Other|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
251249|NCT02280720|Procedure|Stenting using Optimax™|
251250|NCT02280720|Procedure|Stenting using PROMUS Element™ Plus|
251251|NCT02280707|Other|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
251252|NCT02280694|Drug|Capecitabine|
251253|NCT02280694|Drug|Cyclophosphamide|
251254|NCT02280694|Drug|Methotrexate|
251255|NCT02280694|Drug|Celecoxib|
251256|NCT02280681|Other|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
251257|NCT02280668|Other|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
251258|NCT02280668|Other|the eccentric muscle damage exercise|
251259|NCT02280655|Biological|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
251260|NCT02280655|Biological|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
251261|NCT02280642|Biological|Both 2nd and 3rd doses on time|
251262|NCT02280642|Biological|2nd dose late and 3rd dose on time|
251263|NCT02280642|Biological|2nd dose on time and 3rd dose late|
251264|NCT02280642|Biological|Both doses late|
251265|NCT02280629|Drug|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
251266|NCT02280629|Drug|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
251267|NCT02280629|Drug|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
251268|NCT02280616|Drug|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
251269|NCT02280616|Drug|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
251270|NCT02280616|Drug|high dose budesonide suspension|placebo tablet twice daily AND 5ml [0.4mg budesonide/ml] suspension twice daily
251271|NCT02280616|Drug|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
251272|NCT02280603|Drug|DA-4001C|1ml by topical application twice a day
251273|NCT02280603|Drug|5% minoxidil|1ml by topical application twice a day
251274|NCT02280590|Drug|Rosuvastatin(Cresnon®)|10mg
251275|NCT02280590|Drug|Rosuvastatin(Crestor®)|10mg
251276|NCT02280564|Behavioral|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
251277|NCT02280538|Device|Intra-Articular Hyaluronic Acid|
251278|NCT02280538|Device|Placebo|
251279|NCT02280525|Drug|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
251280|NCT02280525|Drug|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
251281|NCT02280525|Drug|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
251899|NCT02276196|Drug|Lixisenatide|GLP-1 receptor agonist
251282|NCT02280525|Drug|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
251283|NCT02280525|Procedure|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
251284|NCT02280525|Drug|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
251285|NCT02280512|Device|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
251286|NCT02280499|Device|standard PROMOS prosthesis|
251287|NCT02280486|Drug|Saxagliptin|5 mg/d
251288|NCT02280486|Drug|Glimepiride|1mg/d, up titrated 1mg if FPG ＞6.1 mmol/L (110mg/dL) till 6 mg
251289|NCT02280473|Drug|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
251290|NCT02280473|Drug|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
251291|NCT02280447|Biological|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
251292|NCT02280447|Biological|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
251293|NCT02280447|Biological|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
251294|NCT02280447|Biological|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
251295|NCT02280434|Drug|CBP-307|
251296|NCT02280434|Drug|Placebo|
251297|NCT02280421|Drug|ASP2151 400mg + 100mg ciclosporin|
251298|NCT02280421|Drug|ASP2151 1200mg + 100mg ciclosporin|
251299|NCT02280408|Other|Placebo|Normal saline placebo.
251300|NCT02280408|Biological|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
251301|NCT02280395|Drug|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
251302|NCT02280395|Drug|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
251303|NCT02280382|Device|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
251304|NCT02280369|Device|Automated abdominal binder|Inflatable abdominal binder
251305|NCT02280356|Radiation|external beam radiation therapy|
251306|NCT02280356|Radiation|brachytherapy|
251307|NCT02280356|Behavioral|questionnaires|
251308|NCT02280343|Other|evaluated lung function|lung function tests
251309|NCT02280330|Dietary Supplement|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
251310|NCT02280330|Other|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
251311|NCT02280317|Drug|VAL201|VAL201-001 Sub-cutaneous injection.
251312|NCT02280304|Behavioral|Inner Resources for Veterans (IRV)|Meditation therapy which utilizes mindfulness, techniques that encourage non-judgmental attention to oneself in the present moment
251313|NCT02280304|Behavioral|PTSD and mTBI education|Participants will learn about symptoms and triggers of PTSD and mTBI
251314|NCT02280291|Procedure|GA/sedation with a Single Shot, peripheral nerve block|A single shot peripheral nerve block will be used as the primary mode of pain control intraoperatively with adjunct pain medications prescribed for the patient to take as needed
251315|NCT02280291|Procedure|GA/sedation with continuous, peripheral nerve block|A continuous peripheral nerve block delivered by the OnQ infusion system will be given in the post-operative period and removed within 48 hours of surgery. Adjunct pain medications will be prescribed for the patient to take as needed
251316|NCT02280291|Drug|lidocaine|
251317|NCT02280291|Drug|Propofol|
251318|NCT02280291|Drug|Fentanyl|
251319|NCT02280291|Drug|epinephrine,|
251320|NCT02280291|Drug|bupivacaine|
251321|NCT02280291|Device|OnQ infusion system|
251322|NCT02280278|Procedure|Radical surgery|
251323|NCT02280278|Drug|Adjuvant chemotherapy|
251324|NCT02280278|Biological|Cytokine-induced killer cell immunotherapy|
251325|NCT02280265|Drug|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
251326|NCT02280252|Drug|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
251327|NCT02280252|Radiation|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
251328|NCT02280239|Drug|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
251329|NCT02280239|Drug|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
251330|NCT02280226|Device|magnetic resonance imaging (MRI)|
251331|NCT02280213|Device|MIL|Direct laryngoscopy 1
251332|NCT02280213|Device|MAC|Direct laryngoscopy 2
251333|NCT02280213|Device|WIS|Direct laryngoscopy 3
251334|NCT02280213|Device|PHIL|Direct laryngoscopy 4
251335|NCT02280200|Device|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
251900|NCT02276196|Drug|Insulin glulisine|Insulin analogue
251336|NCT02280187|Procedure|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
251337|NCT02280174|Drug|linagliptin|linagliptin 5 mg/d for12 weeks
251338|NCT02280161|Other|cytology specimen collection procedure|Correlative studies
251339|NCT02280148|Procedure|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
251340|NCT02280148|Device|Driving Simulator|
251341|NCT02280148|Drug|Propofol|2mg / kg
251342|NCT02280135|Biological|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.~After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
251343|NCT02280135|Other|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.~After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
251344|NCT02280122|Other|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
251345|NCT02280109|Drug|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
251346|NCT02280109|Drug|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
251347|NCT02280096|Drug|4-aminopyridine|Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
251348|NCT02280096|Drug|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
251349|NCT02280083|Drug|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
251350|NCT02280083|Drug|placebo|placebo
251351|NCT02280070|Other|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
251352|NCT02280070|Other|Medical history and physical examination|medical history and physical examination
251353|NCT02280070|Other|BW and height|Body weight (kg) and height (cm)
251354|NCT02280070|Other|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
251355|NCT02280070|Other|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft & Gault method using serum creatinine (mg/dL), age and body weight (kg).
251356|NCT02280070|Other|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
251357|NCT02280070|Radiation|Contrasting CT|Computed tomography
251358|NCT02280070|Other|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
251359|NCT02280070|Other|HBs antigen and HCV antibody|check for exclusion criteria
251360|NCT02280070|Other|Endoscopy|Endoscopy for lower digestive tract
251361|NCT02280070|Other|HBs antibody and HBc antibody|Check according to hepatitis B guideline
251362|NCT02280070|Drug|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
251363|NCT02280070|Drug|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
251364|NCT02280070|Drug|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
251365|NCT02280070|Drug|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
251366|NCT02280070|Drug|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
251367|NCT02280057|Drug|Metformin|Metformin 1500 mg (=2 pills) per day in six months
251368|NCT02280057|Drug|Placebo|2 pills per day in six months; pills look like metformin pills
251369|NCT02280044|Biological|Rifaximin intervention|Rifaximin administered then Challenge with C jejuni
251370|NCT02280044|Biological|Placebo intervention|Placebo administered then Challenge with C jejuni
251371|NCT02280031|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
251372|NCT02280031|Drug|Placebo|Capsule containing placebo pill with lactose
251373|NCT02280018|Drug|JNJ-49122944, 5 milligram (mg)|Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
251374|NCT02280018|Drug|Placebo|Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
251375|NCT02280005|Device|WAK Treatment|Hemodialysis with WAK device.
251376|NCT02279992|Drug|Vardenafil|
251377|NCT02279992|Drug|Carboplatin|
251901|NCT02276183|Dietary Supplement|Nutrition intervention, test formula|
251378|NCT02279979|Device|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
251379|NCT02279966|Drug|Vortioxetine 10 mg|
251380|NCT02279966|Drug|Paroxetine 20 mg|
251381|NCT02279966|Drug|Placebo|
251382|NCT02279953|Drug|Vortioxetine 10-20 mg|
251383|NCT02279953|Drug|Placebo|
251384|NCT02279953|Drug|SSRI|escitalopram, citalopram or sertraline
251385|NCT02279927|Device|Ureteroscopy|Ureteroscopy with laser stone fragmentation
251386|NCT02279914|Drug|Misoprostol 400 mcg 3 hours prior to procedure|
251387|NCT02279914|Drug|Misoprostol 600 mcg 90 minutes prior to procedure|
251388|NCT02279901|Behavioral|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:~OSA program~CPAP program~Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
251389|NCT02279901|Behavioral|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.~Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
251390|NCT02279888|Device|CardioMEMS HF System|Pulmonary artery pressure sensor
251391|NCT02279875|Drug|Linezolid|
251392|NCT02279875|Drug|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
251393|NCT02279862|Drug|Ipilimumab|
251394|NCT02279849|Other|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
251395|NCT02279849|Other|Pricing|The pricing incentives were used to help promote sales of healthier food items.
251396|NCT02279849|Other|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
251397|NCT02279836|Device|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
251398|NCT02279823|Drug|CB-03-01 solution|Investigational drug solution
251399|NCT02279823|Drug|Minoxidil Solution 5%|FDA approved marketed product
251400|NCT02279823|Drug|Placebo solution|Vehicle solution
251401|NCT02279810|Behavioral|survey|Survey
251402|NCT02279797|Behavioral|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
251403|NCT02279784|Device|Freeway PTA|angioplasty with Freeway drug-eluting balloon
251404|NCT02279784|Device|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
251405|NCT02279771|Procedure|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
251406|NCT02279771|Procedure|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
251407|NCT02279771|Device|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
251408|NCT02279758|Drug|Metformin|
251409|NCT02279745|Drug|Ralinepag|Active
251410|NCT02279732|Biological|Paclitaxel|
251411|NCT02279732|Biological|Carboplatin|
251412|NCT02279732|Biological|Ipilimumab|
251413|NCT02279732|Other|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
251414|NCT02279719|Drug|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
251415|NCT02279719|Drug|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
251416|NCT02279719|Drug|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
251417|NCT02279706|Other|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
251418|NCT02279693|Other|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
251419|NCT02279693|Other|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
251420|NCT02279693|Radiation|IGRT Associated With IMRT|
251421|NCT02279680|Device|Electroencephalography|
251422|NCT02279680|Behavioral|Neuropsychological assesments|
251423|NCT02279667|Drug|BIA 2-093|oral suspension 50 mg/mL
251424|NCT02279667|Drug|BIA 2-093|200 mg tablet
251425|NCT02279667|Drug|BIA 2-093|800 mg tablet
251426|NCT02279654|Drug|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
251427|NCT02279641|Drug|RDEA3170 10 mg|
251429|NCT02279628|Drug|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
251430|NCT02279628|Drug|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
251431|NCT02279615|Drug|Mirabegron|50mg of mirabegron per day will be given.
251432|NCT02279615|Drug|Tamsulosin|0.4mg of flomax per day.
251433|NCT02279602|Drug|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
251434|NCT02279589|Biological|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
251435|NCT02279589|Biological|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
251436|NCT02279589|Biological|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).~One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
251437|NCT02279576|Drug|Pazopanib|Pazopanib 800mg/day continuously administered.
251438|NCT02279576|Drug|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
251439|NCT02279563|Drug|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.~During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
251440|NCT02279563|Drug|Dymista™ Nasal Spray|
251441|NCT02279563|Drug|Placebo|
251442|NCT02279537|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
251443|NCT02279524|Drug|Aramchol|"Subjects will be administered Aramchol as follows:~One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.~One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.~Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).~Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
251444|NCT02279511|Drug|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
251445|NCT02279511|Drug|PLACEBO|Infusion of 500 mL of saline solution. (IV)
251446|NCT02279498|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
251447|NCT02279498|Drug|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
251448|NCT02279485|Drug|Perampanel|
251449|NCT02279472|Procedure|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
251450|NCT02279446|Other|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
251451|NCT02279433|Drug|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
251452|NCT02279420|Device|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
251453|NCT02279407|Drug|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
251454|NCT02279407|Drug|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
251455|NCT02279407|Drug|Dapagliflozin|10 mg administered as 10 mg tablet
251456|NCT02279407|Drug|Placebo|Placebo matching to dapagliflozin 10 mg
251457|NCT02279394|Drug|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
251458|NCT02279394|Drug|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
251459|NCT02279394|Drug|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
251460|NCT02279381|Drug|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
251461|NCT02279381|Other|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
251462|NCT02279381|Other|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
251463|NCT02279368|Behavioral|Family Counselling and safeguarding|
251464|NCT02279342|Drug|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
251498|NCT02279095|Drug|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
251499|NCT02279082|Drug|DFN-02|Active Experimental Drug
251500|NCT02279069|Device|4-roll canne|
251465|NCT02279329|Other|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
251466|NCT02279316|Drug|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
251467|NCT02279316|Other|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
251468|NCT02279316|Other|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
251469|NCT02279303|Behavioral|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
251470|NCT02279303|Behavioral|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
251471|NCT02279290|Behavioral|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
251472|NCT02279290|Behavioral|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
251473|NCT02279277|Behavioral|Supervised physical therapy program prior to total knee replacement surgery|
251474|NCT02279264|Device|RightSpot Infant pH Indicator|pH indicator
251475|NCT02279251|Behavioral|VÅG|Low-intensity CBT intervention
251476|NCT02279251|Behavioral|CHILLED|Evidence based CBT intervention
251477|NCT02279238|Procedure|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest [Washout time] in between the two test.~6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.~3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.~The data of [HR, SPO2, PSG RPE scale, Distance walked, BP] the participants are collected before, during and after the completion of each lap [according to American Thoracic Society [ATS] protocol]."
251478|NCT02279225|Radiation|Group Phototherapy|
251479|NCT02279225|Radiation|Phototherapy + Physical activity|
251480|NCT02279225|Other|Physical activity|
251481|NCT02279225|Other|Placebo|
251482|NCT02279186|Drug|Tranexamic Acid|Intravenous Injection
251483|NCT02279173|Drug|Romiplostim|Romiplostim subcutaneous weekly injection
251484|NCT02279160|Drug|APD811|
251485|NCT02279160|Drug|Placebo|
251486|NCT02279147|Drug|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
251487|NCT02279134|Radiation|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Prophylactic polyethylene glycol recombinant human G-CSF is administered 48 hours after chemotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
251488|NCT02279134|Radiation|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
251489|NCT02279134|Drug|Paclitaxel|135-150mg/m2 (D1 and D29)
251490|NCT02279134|Drug|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
251491|NCT02279121|Device|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
251492|NCT02279121|Drug|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
251493|NCT02279108|Drug|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
251494|NCT02279108|Drug|isotope|One injection, 20 MBq techntium99, intradermal use
251495|NCT02279095|Drug|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
251496|NCT02279095|Drug|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
251497|NCT02279095|Drug|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
251607|NCT02278263|Drug|Tranexamic Acid|Given intravenously or topically
251501|NCT02279056|Behavioral|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
251502|NCT02279056|Behavioral|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
251503|NCT02279043|Behavioral|Interaction with users of IUC and non-IUC users|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
251504|NCT02279043|Behavioral|Interaction with non-IUC users only|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions."
251505|NCT02279030|Other|MIBG nuclear scan|To have scan to help define pathways for PVC ablations.
251506|NCT02279017|Behavioral|mHealth Texting for Weight Loss|
251507|NCT02278991|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
251508|NCT02278978|Drug|BIBF1120|BIBF1120 200 mg two times per day orally
251509|NCT02278965|Drug|Metformin|Metformin 850mg, oral, twice a day for 12 months
251510|NCT02278965|Drug|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
251511|NCT02278939|Behavioral|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
251512|NCT02278926|Other|Ultrasound|Ultrasound measurements
251513|NCT02278926|Other|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
251514|NCT02278913|Drug|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
251515|NCT02278913|Drug|Human Insulin|NPH twice a day + Regular insulin before meals
251516|NCT02278900|Other|Communication aids|Question Prompt list Audiofile
251517|NCT02278887|Procedure|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
251518|NCT02278887|Drug|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
251519|NCT02278887|Drug|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
251520|NCT02278887|Drug|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
251521|NCT02278887|Drug|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
251522|NCT02278861|Drug|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
251523|NCT02278861|Drug|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
251524|NCT02278861|Drug|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
251525|NCT02278848|Other|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
251526|NCT02278835|Other|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
251527|NCT02278835|Device|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
251528|NCT02278835|Device|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
251529|NCT02278835|Device|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
251530|NCT02278822|Other|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
251531|NCT02278822|Other|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
251532|NCT02278809|Behavioral|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)~After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
251533|NCT02278796|Drug|BeEAM|Chemotherapy regimen consisting of bendamustine intravenously on days −7 and −6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
251534|NCT02278796|Drug|BEAM|Chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
251535|NCT02278783|Drug|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
251608|NCT02278263|Drug|Normal saline (0.9% NaCl)|Administered in all 3 groups
251609|NCT02278250|Drug|M4344|Dose escalation of M4344 administered as a single agent.
251536|NCT02278757|Other|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
251537|NCT02278757|Other|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
251538|NCT02278744|Radiation|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 18 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
251539|NCT02278744|Device|MRI and/or CT|
251540|NCT02278731|Other|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
251541|NCT02278718|Drug|NexoBrid|NexoBrid is an enzymatic debriding agent for Eschar Removal.
251542|NCT02278718|Procedure|Standard of Care|Surgical or Non-Surgical methods for Eschar Removal
251543|NCT02278705|Other|Attention to BMI|Evidence (using electronic health record data) denoting provider attention to about high BMI.
251544|NCT02278705|Other|Attention to high-BMI-related Medical Risk|Evidence (using electronic health record data) denoting provider attention to high-BMI-related medical risk, including from high blood pressure/hypertension, cholesterol/dyslipidemia, blood sugar/diabetes, liver enzymes/fatty liver, and low vitamin D/vitamin-D deficiency.
251545|NCT02278705|Other|No attention to high BMI or high-BMI-related medical risk|Lack of evidence (using electronic health record data) denoting provider attention to high BMI or high-BMI-related medical risk.
251546|NCT02278692|Dietary Supplement|Vitamin K|Oral vitamin K
251547|NCT02278692|Other|Placebo|Oral placebo tablet
251548|NCT02278679|Procedure|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
251549|NCT02278666|Procedure|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
251550|NCT02278666|Device|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
251551|NCT02278666|Device|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
251552|NCT02278653|Other|Questionnaires for the evaluation of Quality of Life|"European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score~Short Form (36) health survey~EORTC CR38~Vaizey score~Low Anterior Resection Syndrome (LARS) score~International Index of Erectile Function for men~International Prostate Symptom Score for men~Female Sexual Function Index for women"
251553|NCT02278653|Other|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
251554|NCT02278640|Device|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
251555|NCT02278627|Other|manual lymphatic drainage|
251556|NCT02278614|Drug|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
251557|NCT02278614|Drug|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
251558|NCT02278601|Device|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
251559|NCT02278601|Drug|Ropivacaine|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
251560|NCT02278601|Drug|Fentanyl|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
251561|NCT02278588|Drug|Rasagiline|
251562|NCT02278575|Drug|Atenativ|intravenous transfusion
251563|NCT02278562|Drug|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
251564|NCT02278562|Drug|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
251565|NCT02278562|Other|placebo|placebo capsules and injection
251566|NCT02278523|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
252222|NCT02273557|Drug|Asasantin ER (new formulation III - medium)|
251567|NCT02278510|Drug|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
251568|NCT02278510|Drug|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
251569|NCT02278510|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
251570|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
251571|NCT02278484|Device|XprESS device and PathAssist confirmation tools|
251572|NCT02278471|Drug|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
251573|NCT02278458|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
251574|NCT02278458|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
251575|NCT02278445|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
251576|NCT02278445|Device|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
251577|NCT02278419|Drug|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
251578|NCT02278419|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
251579|NCT02278406|Other|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
251580|NCT02278393|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
251581|NCT02278393|Other|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
251582|NCT02278380|Other|Low GI Standard Breakfast|Low GI Standard Breakfast
251583|NCT02278380|Other|Medium GI Standard Breakfast|Medium GI Standard Breakfast
251584|NCT02278380|Other|Enfamama A+|Nutritional pregnant milk supplement
251585|NCT02278380|Other|Glucerna Triple Care|Nutritional product for diabetics
251586|NCT02278380|Other|Dumex Precima|Pregnant and lactation women milk powder
251587|NCT02278380|Other|Diasip|Nutritional drinks for diabetics
251588|NCT02278380|Other|Test product|Test product not patented yet
251589|NCT02278367|Drug|18F-AV-1451|370 megabecquerel (MBq) (10 millicurie [mCi])
251590|NCT02278354|Drug|18F-AV-1451|
251591|NCT02278341|Drug|roxadustat|Oral Tablet
251592|NCT02278341|Drug|epoetin alfa|Subcutaneous (SC) or Intravenous (IV) Injection
251593|NCT02278341|Drug|darbepoetin alfa|Subcutaneous or Intravenous Injection
251594|NCT02278328|Drug|STX209 (15mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (15mg) intervention is the low dose"
251595|NCT02278328|Drug|placebo|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The placebo intervention is the non-active placebo control dose
251596|NCT02278328|Drug|STX209 (30mg)|"A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate. The STX209 (30mg) intervention is the high dose"
251597|NCT02278315|Drug|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
251598|NCT02278315|Drug|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
251599|NCT02278315|Drug|I-131-CLR1404|Multiple IV dose of I-131-CLR1404, increased/decreased by cohort
251600|NCT02278302|Drug|Aggrenox®|
251601|NCT02278302|Drug|Placebo|
251602|NCT02278302|Other|Ethanol|
251603|NCT02278289|Device|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
251604|NCT02278289|Procedure|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
251605|NCT02278276|Drug|sodium polysulthionate|Bioavailable composition of α-sulfur
251606|NCT02278276|Drug|Placebo|400 mg capsules containing placebo
251610|NCT02278250|Drug|Carboplatin|Carboplatin will be administered in combination with escalated dose of M4344.
251611|NCT02278237|Behavioral|VME Group|Received inhaler education through VME (virtual education module)
251612|NCT02278224|Behavioral|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
251613|NCT02278224|Behavioral|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
251614|NCT02278198|Drug|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
251615|NCT02278185|Drug|Enzalutamide|Given PO
251616|NCT02278185|Drug|leuprolide acetate|Given SC or IM
251617|NCT02278185|Drug|goserelin acetate|Given SC or IM
251618|NCT02278185|Drug|histrelin acetate|Given SC or IM
251619|NCT02278185|Drug|triptorelin|Given SC or IM
251620|NCT02278185|Drug|degarelix|Given SC or IM
251621|NCT02278172|Dietary Supplement|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
251622|NCT02278172|Dietary Supplement|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
251623|NCT02278159|Procedure|Peritoneal dialysis|
251624|NCT02278159|Procedure|Home hemodialysis|
251625|NCT02278146|Device|ParaPatch|A device for the treatment of urinary incontinence
251626|NCT02278133|Drug|WNT974|
251627|NCT02278133|Drug|LGX818|
251628|NCT02278133|Biological|Cetuximab|
251629|NCT02278120|Drug|LEE011|LEE011 600 mg daily oral
251630|NCT02278120|Drug|Tamoxifen|tamoxifen 20 mg daily oral
251631|NCT02278120|Drug|Letrozole|letrozole 2.5 mg daily oral
251632|NCT02278120|Drug|Anastrozole|anastrozole 1 mg daily oral
251633|NCT02278120|Drug|Goserelin|Goserelin 3.6 mg subcutaneous injection
251634|NCT02278120|Drug|LEE011 Placebo|LEE011 placebo 600 mg daily oral
251635|NCT02278107|Device|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
251636|NCT02278107|Device|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
251637|NCT02278094|Device|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
251638|NCT02278094|Device|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
251639|NCT02278094|Procedure|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
251640|NCT02278094|Device|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
251641|NCT02278081|Drug|lansoprazole|the lansoprazole will be taken orally.
251642|NCT02278081|Drug|placebo|the lansoprazole placebo will be taken orally.
251643|NCT02278068|Device|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
251644|NCT02278055|Drug|Radium-223|
251645|NCT02278042|Other|Beverage Consumption|
251646|NCT02278003|Other|memory test|
251647|NCT02278003|Drug|Propofol|
251648|NCT02277990|Device|TYRX™ Absorbable Antibacterial Envelope|
251649|NCT02277977|Other|Contrast enhanced ultrasound|Contrat enhanced ultrasound during septic shock
251650|NCT02277951|Device|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
251651|NCT02277951|Device|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
251652|NCT02277951|Device|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
251653|NCT02277951|Device|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
251654|NCT02277938|Drug|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
251655|NCT02277925|Other|Polytetrafluoroethylene|Suture used to attach mesh during sacral colpopexy surgery
251656|NCT02277925|Other|Polydioxanone|Suture used to attach mesh during sacral colpopexy surgery
251657|NCT02277912|Device|navigated rTMS of motor cortex|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
251658|NCT02277912|Device|navigated rTMS of somatosensory cortex 2|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
251659|NCT02277912|Device|SHAM rTMS with SHAM block|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
251660|NCT02277899|Other|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
251661|NCT02277899|Other|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
251662|NCT02277899|Other|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
251663|NCT02277899|Other|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
251664|NCT02277899|Other|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
251665|NCT02277886|Drug|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
251666|NCT02277886|Drug|esomeprazole|40mg/tablet, one tablet once before breakfast
251667|NCT02277873|Behavioral|pregnancy|Observational study in order to establish relationship between moon and births
251668|NCT02277860|Behavioral|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
251669|NCT02277847|Drug|Idarubicin(8mg/m2) and cytosine arabinoside|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
251670|NCT02277847|Drug|Idarubicin(10mg/m2), cytosine arabinoside|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
251671|NCT02277821|Device|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
251672|NCT02277808|Drug|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
251673|NCT02277808|Device|Respirgard II|
251674|NCT02277808|Device|Isoneb®|
251675|NCT02277795|Device|AccuCirc|Circumcision with the use of the AccuCirc device.
251676|NCT02277782|Drug|Hydromorphone|
251677|NCT02277782|Drug|Hyperbaric bupivacaine|
251678|NCT02277782|Drug|Fentanyl|
251679|NCT02277769|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
251680|NCT02277769|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
251681|NCT02277756|Device|thermode|thermal stimulation with test thermode
251682|NCT02277743|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
251683|NCT02277743|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms
251684|NCT02277730|Device|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
251685|NCT02277730|Drug|phenylephrine|
251686|NCT02277730|Drug|ephedrine|
251687|NCT02277730|Device|manual vasopressor delivery|
251688|NCT02277717|Drug|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
251689|NCT02277704|Drug|TNX-102 SL|
251690|NCT02277704|Drug|Placebo|
251691|NCT02277691|Drug|TAK-536TCH tablet|TAK-536TCH tablets
251692|NCT02277691|Drug|TAK-536CCB tablet|TAK-536CCB tablets
251693|NCT02277691|Drug|HCTZ 12.5 mg tablet|HCTZ tablets
251694|NCT02277678|Drug|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
251695|NCT02277678|Drug|Opioid administration morphine|
251696|NCT02277665|Behavioral|CUD Treatment|
251697|NCT02277665|Behavioral|Tobacco Treatment|
251698|NCT02277652|Device|The Miller Laryngoscope|Direct laryngoscopy
251699|NCT02277652|Device|The Bonfils intubation fibrescope|Optical laryngoscopy
251700|NCT02277652|Device|The GlideScope Ranger|Videolaryngoscopy
251701|NCT02277652|Device|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
251702|NCT02277639|Device|CliniMACs device|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
251703|NCT02277626|Device|Electro Flo 5000|Airway clearance device
251704|NCT02277626|Device|Incourage Vest System|Airway Clearance Device
251705|NCT02277613|Biological|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
251706|NCT02277613|Other|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
251707|NCT02277600|Drug|BMS-663068|BMS-663068
251708|NCT02277600|Drug|Darunavir|Darunavir
251709|NCT02277600|Drug|Cobicistat|Cobicistat
251710|NCT02277587|Drug|Plenadren|Oral Tablets: 20-25-30 mg
251711|NCT02277587|Drug|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
251712|NCT02277574|Biological|AMP-110|2, 5, or 10 mg/kg
251713|NCT02277574|Other|Placebo|Placebo
251714|NCT02277561|Procedure|diffusion tensor imaging|Undergo VB-DTI
251715|NCT02277561|Radiation|whole-brain radiation therapy|Undergo WBRT
251716|NCT02277561|Radiation|stereotactic radiosurgery|Undergo SRS
251717|NCT02277561|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
251718|NCT02277561|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
251719|NCT02277548|Drug|Lyrica 300 mg|Lyrica 300 mg per day
251720|NCT02277548|Drug|Placebo|
251721|NCT02277535|Other|Feedback/Reminder email.|
252223|NCT02273557|Drug|Asasantin ER (new formulation II - high)|
251722|NCT02277522|Biological|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
251723|NCT02277509|Behavioral|Chinese DPP|"The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~."
251724|NCT02277509|Behavioral|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
251725|NCT02277496|Behavioral|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
251726|NCT02277483|Drug|LAIS®|10 X 1,000 / twice a week
251727|NCT02277457|Radiation|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
251728|NCT02277457|Drug|Erlotinib|150 mg once daily
251729|NCT02277457|Drug|Crizotinib|250 mg twice daily
251730|NCT02277444|Drug|Golimumab|Golimumab 80 mg/m^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244.
251731|NCT02277444|Drug|Methotrexate|Methotrexate BSA-based dose (10 to 30 mg/m^2 per week for participants with BSA <1.67 m^2, or minimum of 15 mg/week for participants with BSA >=1.67 m^2) weekly at least through Week 28.
251732|NCT02277431|Dietary Supplement|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:~Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])~Bifidobacterium bifidum Malyoth super strain (40 billion CFU)~Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
251733|NCT02277431|Dietary Supplement|placebo|
251734|NCT02277418|Device|VAVL|Videolaryngoscope
251735|NCT02277418|Device|MIL|Direct laryngoscopy
251736|NCT02277405|Device|Shikani Optical Stylet|Optical intubation
251737|NCT02277405|Device|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
251738|NCT02277392|Biological|Vaccine--‐primed, CD3/CD28--‐costimulated autologous peripheral blood T--‐cells|
251739|NCT02277392|Biological|SB--‐485232 (Human recombinant Interleukin--‐18)|
251740|NCT02277366|Procedure|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
251741|NCT02277353|Other|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
251742|NCT02277340|Procedure|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
251743|NCT02277327|Behavioral|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
251744|NCT02277327|Behavioral|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
251745|NCT02277314|Procedure|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
251746|NCT02277301|Behavioral|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
251747|NCT02277288|Other|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
251748|NCT02277275|Dietary Supplement|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
251749|NCT02277275|Dietary Supplement|Placebo|Placebo will be provided to the other two arms for six months
251750|NCT02277262|Device|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
251751|NCT02277262|Procedure|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
251769|NCT02277119|Device|Maestro|OCT machines used for diagnostic purposes
251770|NCT02277119|Device|iVue|OCT machines used for diagnostic purposes
251752|NCT02277249|Drug|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
251753|NCT02277249|Drug|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
251754|NCT02277236|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
251755|NCT02277236|Radiation|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
251756|NCT02277223|Dietary Supplement|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
251757|NCT02277223|Drug|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.~Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
251758|NCT02277210|Other|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
251759|NCT02277197|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
251760|NCT02277197|Drug|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.~Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
251761|NCT02277184|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.~Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.~Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)"
251762|NCT02277184|Drug|Cisplatin|"Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.~Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.~Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes."
251763|NCT02277184|Radiation|Intensity Modulated Radiotherapy (IMRT)|"Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.~Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).~The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue."
251764|NCT02277171|Device|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
251765|NCT02277158|Drug|Chemoradiotherapy|S-1 CCRT
251766|NCT02277145|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
251767|NCT02277132|Drug|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
251768|NCT02277132|Drug|Placebo|Placebo tablets three times daily orally from randomization until delivery
251774|NCT02277067|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
251775|NCT02277067|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
251776|NCT02277054|Device|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
251777|NCT02277041|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
251778|NCT02277041|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
251779|NCT02277028|Behavioral|priming and task specific training|This task specific training protocol has been used in several clinical trials.
251780|NCT02277015|Device|Miller Laryngoscope|Direct Laryngoscopy
251781|NCT02277015|Device|The Berci-Kaplan DCI|Videolaryngoscope-1
251782|NCT02277015|Device|The AirTraq|Videolaryngoscope-2
251783|NCT02277015|Device|GlideScope GVL|Videolaryngoscope-3
251784|NCT02277015|Device|The Pentax AWS|Videolaryngoscope-4
251785|NCT02277002|Device|Cabin Air Filtration|
251786|NCT02277002|Other|Placebo|No Cabin Air Filtration
251787|NCT02276989|Drug|acetazolamide|"On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.~On Day 1, pregabalin PK measures will be collected.~On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.~On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On the mornings of Days 7-8 subjects will receive their PGB dose only."
251788|NCT02276989|Drug|Quinine|"On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.~On Day 11, PK testing of QUIN and PGB will be repeated.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.~On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week."
251789|NCT02276989|Drug|Riboflavin|"All subjects will receive riboflavin on the following days of the study:~On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.~On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected."
251790|NCT02276963|Drug|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
251791|NCT02276950|Procedure|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
251792|NCT02276950|Procedure|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
251793|NCT02276937|Drug|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
251794|NCT02276924|Device|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
251795|NCT02276911|Drug|Ibuprofen|
251796|NCT02276911|Other|normal saline|
251797|NCT02276898|Drug|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
251798|NCT02276898|Drug|Isotonic Saline 0.9% (Placebo)|
251799|NCT02276885|Radiation|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
251800|NCT02276885|Radiation|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
251801|NCT02276872|Drug|oral treprostinil|
251802|NCT02276859|Drug|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
251803|NCT02276859|Drug|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
251804|NCT02276859|Drug|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
251805|NCT02276846|Device|Paclitaxel-Eluting Balloon|
251806|NCT02276833|Other|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
251807|NCT02276820|Biological|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
251808|NCT02276807|Behavioral|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
251809|NCT02276807|Other|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
251810|NCT02276794|Other|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
251993|NCT02275507|Device|Masimo Rainbow Sensor|Non-Invasive Hemoglobin Measurement
251811|NCT02276794|Other|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
251812|NCT02276768|Drug|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
251813|NCT02276768|Drug|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
251814|NCT02276768|Drug|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
251815|NCT02276768|Drug|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
251816|NCT02276768|Other|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
251817|NCT02276755|Dietary Supplement|Cholecalciferol (vitamin D3)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
251818|NCT02276755|Other|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
251819|NCT02276742|Behavioral|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
251820|NCT02276742|Other|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
251821|NCT02276729|Other|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
251822|NCT02276716|Drug|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
251823|NCT02276703|Device|Skin Conductance Monitor|monitors skin conductance values
251824|NCT02276690|Biological|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
251825|NCT02276690|Biological|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.~Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
251826|NCT02276677|Drug|Oxytocin|Single dose, intranasal
251827|NCT02276677|Drug|Placebo|Single dose, intranasal
251828|NCT02276664|Behavioral|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
251829|NCT02276664|Behavioral|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
251830|NCT02276638|Device|Specular Microscope Nidek CEM-530|Nidek CEM-530
251831|NCT02276638|Device|Specular Microscope Konan CELLCHEK XL|Konan CELLCHEK XL
251832|NCT02276625|Biological|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
251833|NCT02276612|Drug|E/C/F/TAF|150/150/200/10 mg fixed-dose combination (FDC) tablet administered orally once daily with food
251834|NCT02276599|Procedure|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
251835|NCT02276586|Procedure|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
251836|NCT02276586|Procedure|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
251837|NCT02276573|Biological|buccal cavity sample|
251838|NCT02276560|Drug|Neoadjuvant Cisplatin, nab-paclitaxel|Cisplatin (75mg/m2) D1, nab-paclitaxel 125 mg/m2) D1, 8, 15; repeat each 28 D cycle x 2 then surgery
251839|NCT02276560|Drug|Adjuvant Cisplatin,nab-paclitaxel|Cisplatin 75mg/m2 D1,nab-paclitaxel 125mg/m2 D1, 8, 15, repeat each 28D cycle x 2
251840|NCT02276560|Drug|Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine|Cisplatin 75mg/m2 D1 + pemetrexed 500mg/m2 D1 or Gemcitabine 1000 mg/m2 D1, 8 (if SqCC) repeat each 21 D Cycle x 4
251841|NCT02276547|Device|Mitral valve replacement|Transcatheter mitral valve replacement
251842|NCT02276534|Behavioral|SENSE Theatre|A peer-mediated, theatre-based intervention.
251843|NCT02276534|Behavioral|Delayed Intervention|
251844|NCT02276521|Biological|Cervarix®|All groups will received one dose of Cervarix® vaccine
251845|NCT02276508|Drug|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
251846|NCT02276495|Other|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
251847|NCT02276495|Drug|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
251848|NCT02276495|Drug|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:~Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
251849|NCT02276482|Drug|Tedizolid Phophate|Tedizolid Phophate 200 mg, IV and/or oral for 6 days
252224|NCT02273557|Drug|Asasantin ER (present commercial formulation)|
251850|NCT02276482|Drug|Antibiotic comparator|Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
251851|NCT02276482|Drug|Aztreonam|In countries and/or sites where aztreonam is available, adjunctive aztreonam (IV) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with gram-negative aerobic pathogens.
251852|NCT02276482|Drug|Metronidazole|Metronidazole (IV or oral) may be initiated on Day 1 or during the first 3 days of treatment if the participant is determined or suspected to have an infection with anaerobic pathogens.
251853|NCT02276469|Behavioral|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
251854|NCT02276456|Behavioral|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
251855|NCT02276443|Drug|Chemotherapy|Undergo standard chemotherapy
251856|NCT02276443|Other|Laboratory Biomarker Analysis|Correlative studies
251857|NCT02276443|Procedure|Lymph Node Biopsy|Undergo baseline lymph node evaluation
251858|NCT02276443|Procedure|Ultrasonography|Undergo standard ultrasound
251859|NCT02276430|Other|Vena punction|Once 90 ml
251860|NCT02276417|Other|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
251861|NCT02276417|Other|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
251862|NCT02276417|Other|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
251863|NCT02276417|Other|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
251864|NCT02276417|Other|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
251865|NCT02276417|Other|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
251866|NCT02276417|Other|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
251867|NCT02276404|Behavioral|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
251868|NCT02276404|Other|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
251869|NCT02276391|Drug|Telmisartan/HCTZ combination|
251870|NCT02276391|Drug|Telmisartan|
251871|NCT02276378|Drug|Telmisartan low|
251872|NCT02276378|Drug|Telmisartan high|
251873|NCT02276378|Drug|Hydrochlorothiazide (HCTZ)|
251874|NCT02276378|Other|Japanese meal|
251875|NCT02276365|Drug|BI 10773|
251876|NCT02276365|Drug|Pioglitazone|
251877|NCT02276352|Drug|Treatment 1|
251878|NCT02276352|Drug|Treatment 2|
251879|NCT02276352|Drug|Treatment 3|
251880|NCT02276339|Other|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
251881|NCT02276326|Dietary Supplement|VSL#3 sachets|4 sachets a day for 4 months
251882|NCT02276313|Device|Passeo-18 Lux|Endovascular Therapy
251883|NCT02276300|Drug|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
251884|NCT02276300|Drug|Sargramostim|Sargramostim is part of Her2 vaccination
251885|NCT02276300|Drug|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
251886|NCT02276300|Drug|Imiquimod|Imiquimod is part of Her2 vaccination
251887|NCT02276274|Drug|SYR-322-MET|Oral administration of SYR-322-MET
251888|NCT02276261|Procedure|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
251889|NCT02276261|Procedure|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
251890|NCT02276248|Radiation|Intensity-modulated radiation therapy|total dose: 50 to 56 grays per fraction: 2 grays
251891|NCT02276248|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
251892|NCT02276235|Device|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
251893|NCT02276235|Device|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.~Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
251894|NCT02276222|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
251895|NCT02276222|Drug|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
251896|NCT02276209|Drug|Dasotraline|Dasotraline 4 mg once daily
251897|NCT02276209|Drug|Dasotraline|Dasotraline 6 mg once daily
251898|NCT02276209|Other|Placebo|Placebo once daily
251902|NCT02276183|Behavioral|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
251903|NCT02276144|Other|Liver ultrasound|For evaluate whether fatty liver is exist or not
251904|NCT02276131|Device|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
251905|NCT02276118|Device|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
251906|NCT02276118|Device|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
251907|NCT02276105|Other|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
251908|NCT02276092|Other|antimicrobial stewardship|A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
251909|NCT02276079|Behavioral|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 − 0.7 × age).
251910|NCT02276079|Behavioral|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
251911|NCT02276066|Other|Iohexol|Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
251912|NCT02276066|Other|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.
251913|NCT02276066|Other|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.
251914|NCT02276040|Drug|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
251915|NCT02276027|Drug|BYL719|BYL719 will be dosed as 350 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take BYL719 exactly as prescribed.
251916|NCT02276027|Drug|INC280|INC280 will be dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to takeINC280 exactly as prescribed.
251917|NCT02276027|Drug|LDK378|LDK378 will be dosed as 750 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take LDK378 exactly as prescribed.
251918|NCT02276027|Drug|MEK162|MEK162 will be dosed as 45 mg twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take MEK162 exactly as prescribed.
251919|NCT02276014|Dietary Supplement|Beta-carotene|
251920|NCT02276001|Drug|K-877|
251921|NCT02276001|Drug|Cyclosporine|
251922|NCT02275988|Drug|K-877|
251923|NCT02275988|Drug|Clarithromycin|
251924|NCT02275975|Drug|K-877|
251925|NCT02275975|Drug|Fluconazole|
251926|NCT02275962|Drug|K-877|
251927|NCT02275962|Drug|Rifampin|
251928|NCT02275949|Device|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
251929|NCT02275949|Device|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
251930|NCT02275949|Device|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
251931|NCT02275949|Device|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
251932|NCT02275949|Device|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
251933|NCT02275936|Drug|N91115|S Nitrosoglutathione Reductase Inhibitor
251934|NCT02275923|Device|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
251935|NCT02275910|Drug|E7090|
251936|NCT02275897|Procedure|Slow Speed of spinal injection|Speed of injection over 60 seconds
251937|NCT02275897|Procedure|Fast Speed of spinal injection|Speed of injection over 15 seconds
251938|NCT02275884|Dietary Supplement|Dark chocolate (85% cocoa)|
251939|NCT02275884|Dietary Supplement|White chocolate (0% cocoa)|
251940|NCT02275871|Other|MRI|High risk screening MRI will be performed as part of the patient's routine care.
252225|NCT02273544|Drug|Asasantin ER (new formulation - low)|
251941|NCT02275871|Other|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
251942|NCT02275858|Device|Stiffening wire|Stiffening wire
251943|NCT02275858|Device|Placebo wire|Placebo wire
251944|NCT02275845|Drug|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
251945|NCT02275845|Other|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
251946|NCT02275832|Drug|3 % Minoxidil lotion|
251947|NCT02275832|Drug|Placebo|
251948|NCT02275806|Drug|Irinotecan|
251949|NCT02275806|Drug|Cisplatin|
251950|NCT02275780|Drug|Doravirine|Doravirine 100 mg tablet administered p.o., q.d.
251951|NCT02275780|Drug|Darunavir|Darunavir 800 mg tablet administered p.o., q.d.
251952|NCT02275780|Drug|Ritonavir|Ritonavir 100 mg tablet administered p.o., q.d.
251953|NCT02275780|Drug|TRUVADA™ or EPZICOM™/KIVEXA™|The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, p.o., q.d., or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine, p.o., q.d.
251954|NCT02275767|Device|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
251955|NCT02275767|Device|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
251956|NCT02275767|Device|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
251957|NCT02275754|Behavioral|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
251958|NCT02275754|Behavioral|PN Only|Participants will be navigated by PN on request
251959|NCT02275741|Biological|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
251960|NCT02275728|Other|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
251961|NCT02275728|Other|Eletromyography Biofeedback|
251962|NCT02275715|Behavioral|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
251963|NCT02275702|Drug|Dexamethasone IV|It will be administered at the induction of the anesthesia
251964|NCT02275702|Drug|Saline solution|
251965|NCT02275689|Procedure|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
251966|NCT02275689|Procedure|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
251967|NCT02275676|Other|bioelectrical impedance analysis|
251968|NCT02275676|Other|indirect calorimetry|
251969|NCT02275663|Drug|Azacytidine|
251970|NCT02275663|Drug|Fludarabine|
251971|NCT02275663|Drug|Cytarabine|
251972|NCT02275663|Drug|Filgrastim|G-CSF
251973|NCT02275650|Radiation|nbUVB|2 SED nbUVB exposure will be given every other week
251974|NCT02275637|Device|implantable cardioverter defibrillator|
251975|NCT02275611|Drug|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
251976|NCT02275611|Drug|Intranasal Placebo Spray|Intranasal Placebo Spray
251977|NCT02275598|Drug|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
251978|NCT02275598|Drug|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
251979|NCT02275585|Other|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
251980|NCT02275572|Procedure|Pharmacist Intervention|
251981|NCT02275559|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
251982|NCT02275559|Behavioral|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
251983|NCT02275546|Drug|Placebo vaginal ring|Drug-free placebo vaginal ring
251984|NCT02275546|Device|Single-use, non-sterile applicator|Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
251985|NCT02275533|Other|Clinical Observation|Undergo standard of care clinical observation
251986|NCT02275533|Other|Laboratory Biomarker Analysis|Correlative studies
251987|NCT02275533|Biological|Nivolumab|Given IV
251988|NCT02275520|Device|NIO Adult device|IO access-1
251989|NCT02275520|Device|Bone Iniection Gun|IO access-2
251990|NCT02275520|Device|EZ-IO|IO access-3
251991|NCT02275520|Device|Jamshidi Intraosseous Needle|IO access-4
251992|NCT02275520|Device|Cook Intraosseous Needle|IO access-5
251994|NCT02275494|Procedure|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
251995|NCT02275481|Drug|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
251996|NCT02275481|Drug|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
251997|NCT02275468|Drug|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
251998|NCT02275455|Behavioral|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
251999|NCT02275442|Other|EPICES scale|
252000|NCT02275429|Procedure|Blood test|blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
252001|NCT02275416|Drug|Ipilimumab|
252002|NCT02275416|Biological|UV1 vaccine|
252003|NCT02275416|Biological|GM-CSF|
252004|NCT02275403|Procedure|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
252005|NCT02275403|Other|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
252006|NCT02275390|Behavioral|Nurse-led Psycho-education|The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).
252007|NCT02275390|Behavioral|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
252008|NCT02275377|Other|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
252009|NCT02275377|Other|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
252010|NCT02275364|Device|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
252011|NCT02275364|Device|Placebo strip|Placebo strip
252012|NCT02275364|Other|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
252013|NCT02275351|Drug|SM04554|Topical solution, applied once a day
252014|NCT02275351|Drug|Vehicle|Topical solution, applied once a day
252015|NCT02275338|Drug|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
252016|NCT02275325|Other|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
252017|NCT02275299|Drug|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
252018|NCT02275299|Drug|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
252019|NCT02275299|Drug|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
252020|NCT02275286|Drug|Trabectedin|Escalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks. Cohort A: unlimited cycles Cohort B: 3 cycles
252021|NCT02275286|Radiation|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction) Cohort B: 45Gy in 25 fractions (1.8Gy/fraction)
252022|NCT02275260|Device|Cerebral Diffusion-Weighted Magnetic Resonance Imaging|Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
252023|NCT02275260|Device|Transesophageal Echocardiography|Patients undergo a Transesophageal Echocardiography prior to the ablation itself
252024|NCT02275260|Other|Paperbased neurocognitive testing|To assess the impact of PVI on the patient's neurocognitive status
252025|NCT02275247|Drug|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
252026|NCT02275234|Other|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
252027|NCT02275208|Procedure|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
252028|NCT02275182|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
252226|NCT02273544|Drug|Asasantin ER (new formulation - medium)|
252029|NCT02275182|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
252030|NCT02275169|Drug|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
252031|NCT02275169|Other|Placebo|Placebo ampoules administered three times a week for three months
252032|NCT02275156|Biological|Evolocumab|Administered by subcutaneous injection
252033|NCT02275143|Radiation|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
252034|NCT02275130|Procedure|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
252035|NCT02275130|Device|Radiesse Voice (Calcium Hydroxyapatite)|
252036|NCT02275117|Biological|ALD403|
252037|NCT02275117|Biological|Placebo|
252038|NCT02275104|Device|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
252039|NCT02275104|Device|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
252040|NCT02275104|Device|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
252041|NCT02275104|Device|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
252042|NCT02275104|Procedure|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
252043|NCT02275078|Behavioral|COPD self-management using an action plan|"Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription."
252044|NCT02275078|Device|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
252045|NCT02275078|Other|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
252046|NCT02275065|Drug|GS-9883|GS-9883 tablet(s) administered orally once daily
252047|NCT02275065|Drug|GS-9883 Placebo|Placebo to match GS-9883 administered orally once daily
252048|NCT02275052|Drug|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
252049|NCT02275052|Drug|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
252050|NCT02275052|Drug|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
252051|NCT02275039|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
252052|NCT02275039|Drug|gemcitabine hydrochloride|Given IV
252053|NCT02275039|Other|laboratory biomarker analysis|Correlative studies
252054|NCT02275026|Procedure|Functional magnetic resonance imaging|Diffusion tensor imaging
252055|NCT02275013|Drug|Levosimendan|
252056|NCT02275000|Other|5 Day Physiotherapy Programme|The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.
252057|NCT02275000|Other|Physiotherapy|Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
252058|NCT02274987|Other|Specialized tumor board recommendation|A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
252059|NCT02274987|Radiation|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
252060|NCT02274974|Drug|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
252061|NCT02274974|Drug|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
252062|NCT02274961|Drug|S-pantoprazole 10mg|
252063|NCT02274961|Drug|Placebo|
252064|NCT02274948|Drug|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
252065|NCT02274948|Drug|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
252066|NCT02274935|Other|Exercise|Balance and gait exercise twice a week for an hour
252067|NCT02274909|Other|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
252068|NCT02274896|Device|PD Catheter group|PD catheter
252069|NCT02274883|Dietary Supplement|Enriched Protein Fractions|Enriched protein fractions
252070|NCT02274883|Dietary Supplement|Protein Fractions|Protein fractions
252071|NCT02274870|Drug|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
252072|NCT02274870|Drug|Bupivacaine HCl|Administered via CFNB
252073|NCT02274857|Procedure|Standard PVI Ablation|Standard PVI procedure without FIRMap.
252074|NCT02274857|Procedure|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
252075|NCT02274844|Behavioral|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
252076|NCT02274831|Other|Email Reminder of need to follow up with primary physician|
252077|NCT02274818|Behavioral|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:~No more than 80 hours of work per week (when averaged over 4 weeks)~1 day off in 7 (when averaged over 4 weeks)~In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
252078|NCT02274805|Procedure|Adults presenting for surgery in the neck area|
252079|NCT02274792|Drug|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
252080|NCT02274779|Drug|ELIGARD|"Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.~Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical."
252081|NCT02274766|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
252082|NCT02274766|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
252083|NCT02274740|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
252084|NCT02274740|Drug|metformin|Pharmaceutical form:tablet Route of administration: oral
252085|NCT02274714|Other|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
252086|NCT02274701|Other|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
252087|NCT02274688|Behavioral|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
252088|NCT02274675|Device|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
252089|NCT02274675|Other|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
252090|NCT02274662|Biological|Thymus Transplantation|"Subjects receive thymus transplantation. Subjects may receive pre and/or post-transplantation immunosuppression.~Potential thymus recipient subjects are screened for eligibility. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue is transplanted into the subject's quadriceps. Two to three months post-transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, skin biopsy conducted. Subjects undergo laboratory testing for approximately one year post-transplantation. At year 2 post-transplantation, subjects are contacted for data collection."
252091|NCT02274662|Procedure|Blood Draw|Biological Parent of Thymus Recipients may be asked to participate in the study and undergo phlebotomy to allow for testing of T cell identity in the thymus recipient subjects. If blood is not obtainable, then a buccal swab may be done.
252092|NCT02274662|Drug|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
252093|NCT02274649|Behavioral|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
252094|NCT02274649|Behavioral|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
252095|NCT02274636|Dietary Supplement|Xylitol|A comparison between discs and gel
252096|NCT02274623|Drug|CTAP101 Capsules|escalating doses
252097|NCT02274610|Drug|Docetaxel-PNP|Docetaxel Polymeric Nanoparticle Formulation
252098|NCT02274610|Drug|Taxotere|Docetaxel
252099|NCT02274597|Device|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
252100|NCT02274584|Genetic|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
252227|NCT02273544|Drug|Asasantin ER (new formulation - high)|
252101|NCT02274571|Drug|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
252102|NCT02274571|Other|Placebo|non active
252103|NCT02274558|Drug|NBI-98854|NBI-98854 40 mg capsules
252104|NCT02274558|Drug|Placebo|NBI-98854 placebo capsules
252105|NCT02274545|Biological|H7N9 Anhui 2013/AA ca|10^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
252106|NCT02274545|Biological|Inactivated subvirion H7N9 vaccine|30 mcg
252107|NCT02274532|Device|SoftHand|Biomechanical, ADL, and functional testing.
252108|NCT02274519|Other|Tai Chi|Arm 1
252109|NCT02274519|Other|Education|Arm 2
252110|NCT02274506|Drug|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
252111|NCT02274506|Drug|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
252112|NCT02274506|Procedure|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
252113|NCT02274493|Device|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
252114|NCT02274493|Procedure|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
252115|NCT02274493|Procedure|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
252116|NCT02274493|Behavioral|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
252117|NCT02274480|Device|cardiac MRI with DWI|
252118|NCT02274467|Device|Trans-catheter electric stimulation test|
252119|NCT02274454|Drug|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
252120|NCT02274454|Drug|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
252121|NCT02274428|Drug|pneumostem|human umbilical cord blood derived mesenchymal stem cells
252122|NCT02274415|Biological|Vaccination with the combined vaccine (Prevenar13 ®)|
252123|NCT02274415|Biological|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
252124|NCT02274402|Biological|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
252125|NCT02274389|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
252126|NCT02274363|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque‐type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
252127|NCT02274350|Radiation|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
252128|NCT02274337|Drug|AC0010|patients take avitinib orally once per day at different dose
252129|NCT02274324|Dietary Supplement|different diets|3 different diets: A\B\C
252130|NCT02274311|Drug|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
252131|NCT02274298|Behavioral|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
252132|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
252133|NCT02274285|Biological|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
252134|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
252135|NCT02274272|Other|ADR-1|two ADR-1 capsules, once daily, QD
252136|NCT02274272|Other|GMNL-263|two GMNL-263 capsules, once daily, QD
252137|NCT02274272|Other|placebo|two placebo capsules, once daily, QD
252138|NCT02274259|Drug|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
252139|NCT02274259|Drug|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
252140|NCT02274246|Drug|gadobutrol|Gadobutrol administration in healthy volunteers
252141|NCT02274233|Drug|SP-420|
252142|NCT02274220|Dietary Supplement|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
252143|NCT02274220|Dietary Supplement|Standard advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 3 mL every three hours for 24 hours. Bolus feeds then up-titrated by 1 mL/kg every-other feed (Q 6 hours) for 24 hours. Bolus feeds then up-titrated by 1mL/kg every feed for to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will reach target feeds by 60-63 hours after protocol initiation.
252144|NCT02274207|Device|NPWT application|NPWT mode is cyclic mode : -125~-50 mmHg
252145|NCT02274194|Device|Nasal CPAP|use of nasal mask to titrate CPAP during a manual full night: if nasal mask is the best interface during titration compared with oronasal mask - patients will go 30-day period of treatment
252146|NCT02274194|Device|Oronasal CPAP|use of oronasal mask to titrate CPAP during a manual full night: if oronasal mask is the best interface during titration compared with nasal mask - patients will go 30-day period of treatment
252147|NCT02274181|Drug|Androxal|
252148|NCT02274168|Procedure|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
252228|NCT02273544|Drug|Asasantin ER - commercial formulation|
252149|NCT02274168|Procedure|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
252150|NCT02274155|Drug|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
252151|NCT02274155|Procedure|Surgical Resection|Surgical Resection of Tumor
252152|NCT02274142|Procedure|ART with powder-liquid material|restoration with powder liquid glass ionomer cement
252153|NCT02274142|Procedure|ART with Encapsulated material|restoration with encapsulated ionomer cement
252154|NCT02274142|Device|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
252155|NCT02274142|Device|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
252156|NCT02274129|Device|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
252157|NCT02274116|Other|SHAM - Intermittent Room Air - room air mixture|Participants will breathe intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.21±0.02 (normoxia). Participants will receive treatment 5 times per week for 2 weeks.
252158|NCT02274116|Other|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breathe intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of fraction of inspired oxygen (FIO2)=0.10±0.02 (hypoxia). Participants will receive treatment 5 times per week for 2 weeks.
252159|NCT02274103|Behavioral|BFST|Family-based skills training.
252160|NCT02274090|Drug|Placebo gel|Placebo gel consist of drug without the active component.
252161|NCT02274090|Drug|1% Metformin gel|Metformin gel consist of active component.
252162|NCT02274077|Drug|EXPAREL|
252163|NCT02274077|Drug|Normal Saline|
252164|NCT02274064|Behavioral|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
252165|NCT02274051|Dietary Supplement|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
252166|NCT02274038|Drug|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
252167|NCT02274038|Drug|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
252168|NCT02274038|Drug|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
252169|NCT02274012|Drug|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
252170|NCT02274012|Drug|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
252171|NCT02273999|Device|RecoveryRx™|Appliance of the device after surgery
252172|NCT02273986|Drug|Digoxin|
252173|NCT02273986|Drug|K-877|
252174|NCT02273973|Drug|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
252175|NCT02273973|Other|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
252176|NCT02273973|Drug|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
252177|NCT02273960|Drug|BMS-986004 75 mg IV|BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
252178|NCT02273960|Drug|BMS-986004 225 mg IV|BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
252179|NCT02273960|Drug|BMS-986004 675 mg IV|BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
252180|NCT02273960|Drug|BMS-986004 1500 mg IV|BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
252181|NCT02273947|Drug|BMS-955176|Single dose by mouth for each treatment specified
252182|NCT02273934|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
252183|NCT02273934|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
252184|NCT02273921|Other|EEG recording|EEG is recorded once for each participant
252185|NCT02273908|Other|No intervention|The study is observational
252186|NCT02273895|Drug|Scopolamine|0.3 mg/mL, intravenously, once
252187|NCT02273843|Drug|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
252188|NCT02273843|Drug|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
252189|NCT02273830|Drug|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
252220|NCT02273570|Drug|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
252190|NCT02273817|Drug|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.~During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:~Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.~Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
252191|NCT02273804|Drug|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
252192|NCT02273804|Drug|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
252193|NCT02273791|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
252194|NCT02273791|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
252195|NCT02273778|Procedure|MRI Scan|
252196|NCT02273778|Procedure|PET-CT Scan|
252197|NCT02273778|Other|No intervention|
252198|NCT02273765|Drug|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :~Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
252199|NCT02273765|Drug|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:~Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)~OR:~• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food~In countries where TDF/3TC FDC is not available, the following separate drugs will be used:~Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)~Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)~Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
252200|NCT02273752|Drug|Everolimus|Given PO
252201|NCT02273739|Drug|AG-221|AG-221 administered orally on every day of 28 day cycles until disease progression or unacceptable toxicities. Multiple doses.
252202|NCT02273726|Drug|Epoetin Alfa|Epoetin alfa will be dosed intravenously three times a week.
252203|NCT02273726|Drug|FG-4592|Roxadustat will be dosed orally three times a week.
252204|NCT02273713|Drug|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
252205|NCT02273700|Drug|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
252206|NCT02273687|Device|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.~The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
252207|NCT02273674|Device|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
252208|NCT02273674|Device|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
252209|NCT02273661|Drug|Liposomal amphotericin B (Ambisome®)|An aerosol of Liposomal Amphotericin B (Ambisome®) at 25 mg x 1/ week will be administered during 6 months
252210|NCT02273661|Drug|placebo|An aerosol of isotonic saline x 1/ week will be administered during 6 months
252211|NCT02273648|Device|Drug Eluting Stent (DES)|Percutaneous Coronary Intervention
252212|NCT02273635|Drug|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
252213|NCT02273635|Drug|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
252214|NCT02273622|Dietary Supplement|hydroxytyrosol|Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.
252215|NCT02273622|Dietary Supplement|placebo|
252216|NCT02273609|Drug|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor."
252217|NCT02273596|Drug|WTX101|Dosage Form: 15 mg Tablets
252218|NCT02273583|Drug|continuous oral cyclophosphamide and methotrexate|
252219|NCT02273570|Drug|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
252221|NCT02273557|Drug|Asasantin ER (new formulation I - low)|
252229|NCT02273531|Drug|Asasantin ER, new formulation|
252230|NCT02273531|Drug|Asasantin ER, present commercial formulation|
252231|NCT02273518|Drug|Asasantin ER, new formulation I|
252232|NCT02273518|Drug|Asasantin ER, new formulation II|
252233|NCT02273518|Drug|Asasantin ER, present commercial formulation|
252234|NCT02273505|Drug|Asasantin (ER)|
252235|NCT02273505|Drug|Persantin|
252236|NCT02273505|Drug|Acetyl salicylic acid (ASA)|
252237|NCT02273492|Drug|Asasantin ER|
252238|NCT02273492|Other|Standardized breakfast|
252239|NCT02273479|Drug|Asasantin®|Asasantin® extended release (RAD-SP)
252240|NCT02273479|Drug|Placebo|
252241|NCT02273466|Drug|Desipramine tablet|
252242|NCT02273466|Drug|Crobenetine infusion|
252243|NCT02273466|Drug|Placebo infusion|
252244|NCT02273453|Drug|Songha® Night|
252245|NCT02273453|Drug|Oxazepam|
252246|NCT02273453|Drug|Placebo|
252247|NCT02273440|Drug|BIIL 284 BS|
252248|NCT02273440|Drug|Theophylline|
252249|NCT02273440|Drug|Placebo|
252250|NCT02273427|Drug|BIIL 284 BS|
252251|NCT02273427|Other|high fat meal|
252252|NCT02273427|Other|low fat meal|
252253|NCT02273414|Drug|BIIL 284 BS - rising dose|
252254|NCT02273414|Drug|Placebo|
252255|NCT02273401|Drug|BI 11054 CL|
252256|NCT02273401|Drug|Placebo|
252257|NCT02273388|Drug|BI 6727|
252258|NCT02273375|Drug|MEDI4736|
252259|NCT02273375|Drug|Placebo|
252260|NCT02273362|Drug|Erlotinib|Given PO
252261|NCT02273362|Drug|Erlotinib Hydrochloride|Given PO
252262|NCT02273362|Other|Laboratory Biomarker Analysis|Correlative studies
252263|NCT02273362|Other|Quality-of-Life Assessment|Ancillary studies
252264|NCT02273349|Device|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
252265|NCT02273336|Other|cytology specimen collection procedure|Undergo tissue and blood sample collection
252266|NCT02273336|Other|laboratory biomarker analysis|Correlative studies
252267|NCT02273323|Other|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
252268|NCT02273323|Other|Placebo|Placebo: tea flavour, colouring and sugar
252269|NCT02273310|Behavioral|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
252270|NCT02273297|Other|Maternal factors|
252271|NCT02273284|Device|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
252272|NCT02273271|Other|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
252273|NCT02273258|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
252274|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
252275|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
252276|NCT02273245|Radiation|Thoracic aortogram CT|With and without contrast dye
252277|NCT02273232|Other|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
252278|NCT02273232|Other|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
252279|NCT02273232|Other|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
252280|NCT02273219|Drug|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
252281|NCT02273219|Drug|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
252282|NCT02273206|Behavioral|Preventive Care Management for Depression|
252283|NCT02273206|Behavioral|Preventive Care Management for Cancer Screening|
252284|NCT02273180|Drug|SAR342434|SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by deep subcutaneous (SC) injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2-hour post prandial plasma glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
252285|NCT02273180|Drug|Humalog|Humalog 100 U/mL (dose range of 1 unit to 60 units) self-administered by deep SC injection, immediately (within 5-10 minutes) before meal intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycaemia.
252286|NCT02273180|Drug|Insulin glargine HOE901|Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
252287|NCT02273167|Drug|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
252288|NCT02273167|Drug|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.~After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
252289|NCT02273167|Drug|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
252505|NCT02271633|Dietary Supplement|Beetroot juice|
252290|NCT02273154|Drug|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
252291|NCT02273154|Drug|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
252292|NCT02273141|Drug|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
252293|NCT02273141|Drug|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
252294|NCT02273128|Genetic|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
252295|NCT02273115|Drug|Oxytocin|
252296|NCT02273115|Device|Transcervical Foley catheter|
252297|NCT02273102|Drug|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
252298|NCT02273102|Drug|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
252299|NCT02273089|Device|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
252300|NCT02273076|Device|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
252301|NCT02273063|Device|Transcranial Magnetic Stimulation (TMS)|Up to 40 sessions of TMS delivered with the first 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper schedule over 3 weeks. Treatment is adjunct to ongoing stable pharmacotherapy.
252302|NCT02273050|Drug|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
252303|NCT02273050|Drug|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
252304|NCT02273050|Drug|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
252305|NCT02273050|Drug|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
252306|NCT02273037|Device|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
252307|NCT02273037|Procedure|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
252308|NCT02273024|Behavioral|Exercise|
252309|NCT02273011|Procedure|caesarean section|elective caesarean section under regional anesthesia
252310|NCT02272998|Drug|ponatinib hydrochloride|Given PO
252311|NCT02272998|Other|laboratory biomarker analysis|Correlative studies
252312|NCT02272985|Other|[15O]H2O PET-CT scan|All participants will undergo 3 [15O]H2O PET-CT scans during the hemodialysis study session
252313|NCT02272985|Other|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
252314|NCT02272972|Other|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
252315|NCT02272959|Behavioral|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
252316|NCT02272959|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
252317|NCT02272946|Drug|Canakinumab|150mg Canakinumab received subcutaneously
252318|NCT02272946|Drug|Placebo|150mg Placebo received subcutaneously
252319|NCT02272933|Device|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
252320|NCT02272933|Device|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
252321|NCT02272920|Procedure|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
252322|NCT02272907|Other|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
252323|NCT02272894|Procedure|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
252324|NCT02272881|Procedure|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
252325|NCT02272881|Procedure|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
252326|NCT02272868|Biological|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
252327|NCT02272868|Drug|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
252328|NCT02272868|Drug|rifaximin+omeprazole+miralax|
252506|NCT02271633|Dietary Supplement|Spinach|
252507|NCT02271633|Dietary Supplement|Rocket salad|
252329|NCT02272855|Biological|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
252330|NCT02272842|Dietary Supplement|Vitamin B12|Vitamin B12 in a multivitamin paste.
252331|NCT02272829|Behavioral|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
252332|NCT02272829|Other|Health Education|
252333|NCT02272816|Drug|Carboplatin AUC-10|Carboplatin AUC-10 according to the Calvert formula [10 x (glomerular filtration rate (ml/min) + 25)]mg given in 5% glucose over 1 hour every 21 days for 3 or 4 cycles.
252334|NCT02272803|Drug|Lenalidomide|
252335|NCT02272803|Drug|Dexamethasone|
252336|NCT02272803|Biological|Elotuzumab (BMS-901608)|
252337|NCT02272790|Drug|Adavosertib|Adavosertib will be taken as oral capsules with water, approx. 2 hours before or 2 hours after food.
252338|NCT02272790|Drug|Paclitaxel|"Paclitaxel will be administered as a 1-hour IV infusion (± 10 minutes) at a dose of 80 mg/m2 according to institutional standards on Days 1, 8, and 15 of each 28 Day cycle.~Patients should be pre-medicated with corticosteroids, diphenhydramine and/or H2 antagonists according to institutional standards."
252339|NCT02272790|Drug|Carboplatin|Carboplatin, at a dose calculated to produce an AUC of 5 will be administered by intravenous infusion according to institutional standards on Day 1 of each 21 Day cycle. The carboplatin dose will be calculated using the Calvert Formula based on the patient's glomerular filtration rate (GFR) which is estimated by using the creatinine clearance.
252340|NCT02272790|Drug|Gemcitabine|Gemcitabine 800 mg/m² will be administered IV on Days 1, 8, and 15 of each 28-Day cycle.
252341|NCT02272790|Drug|PLD|PLD (pegylated liposomal doxorubicin) 40 mg/m² IV will be given on Day 1 of each 28-Day cycle.
252342|NCT02272777|Drug|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
252343|NCT02272777|Drug|Nilotinib|Nilotinib 300mg BID or 400mg QD
252344|NCT02272764|Drug|Itraconazole|Administered orally in a crossover design
252345|NCT02272764|Drug|ALKS 5461|Administered sublingually in a crossover design
252346|NCT02272751|Behavioral|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
252347|NCT02272751|Behavioral|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
252348|NCT02272738|Drug|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
252349|NCT02272738|Drug|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
252350|NCT02272725|Drug|Ibuprofen|Ibuprofen
252351|NCT02272725|Drug|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
252352|NCT02272712|Behavioral|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
252353|NCT02272699|Drug|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
252354|NCT02272699|Drug|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
252355|NCT02272699|Drug|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
252356|NCT02272699|Radiation|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
252357|NCT02272699|Procedure|Surgery|Esophagectomy
252358|NCT02272686|Drug|Ibrutinib|560 mg by mouth daily.
252359|NCT02272673|Dietary Supplement|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
252360|NCT02272660|Drug|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
252361|NCT02272660|Drug|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
252362|NCT02272647|Drug|IM Saline Placebo (0.25 ml)|
252363|NCT02272647|Drug|IM Estradiol valerate (2.5 mg)|
252364|NCT02272647|Drug|IM Saline Placebo (0.5 ml)|
252365|NCT02272647|Drug|IM Estradiol valerate (5.0 mg)|
252366|NCT02272647|Drug|Oral Micronized Progesterone|
252367|NCT02272647|Drug|Oral Placebo|
252368|NCT02272647|Drug|Ghrelin (0.3 ug/kg)|
252369|NCT02272647|Drug|Medroxyprogesterone - Acetate|
252370|NCT02272647|Drug|Oral Placebo|(in lieu of Medroxyprogesterone)
252371|NCT02272634|Drug|YPL-001 low dose|twice daily [BID]
252372|NCT02272634|Drug|YPL-001 high dose|twice daily [BID]
252373|NCT02272634|Drug|placebo|twice daily [BID]
252374|NCT02272621|Procedure|Minimally invasive aortic valve replacement|
252375|NCT02272621|Procedure|Full sternotomy aortic valve replacement|
252376|NCT02272608|Other|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
252377|NCT02272595|Other|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
252378|NCT02272595|Other|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
252379|NCT02272582|Device|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
252380|NCT02272582|Other|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
252381|NCT02272569|Device|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotic medications.
252382|NCT02272556|Other|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
252383|NCT02272556|Other|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
252384|NCT02272543|Dietary Supplement|Fish surimi peptide|
252385|NCT02272517|Drug|Vortioxetine 10-20 mg|
252386|NCT02272517|Drug|Escitalopram 10-20 mg|
252387|NCT02272491|Device|ZrO2 (Straumann CARES)|"Straumann CARES Variobase Abutment RN~Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
252388|NCT02272491|Device|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
252389|NCT02272478|Drug|Arm A Mylotarg plus DA Versus CPX-351|Patients not known to have adverse risk cytogenetics will enter a randomisation comparing DA with Mylotarg (GO) delivered at 3mg/m2 on day 1 of chemotherapy, with CPX-351 on days 1, 3 and 5.
252390|NCT02272478|Drug|Arm B Vosaroxin and Decitabine|If a patient is known to have adverse risk Cytogenetics at diagnosis they will enter a registration to receive up to 5 courses of Vosaroxin and Decitabine.
252391|NCT02272478|Drug|Arm D Small molecule or Not|The randomisation to AC220 or not will take place immediately before course 2 of treatment for patients who have received DA induction +/- Mylotarg, irrespective of residual disease status. Patients allocated to receive AC220 will be randomised in a 1:1 fashion to AC220 or no small molecule with a 1:1 randomisation in patients drawing AC220 between short and long therapy.
252392|NCT02272478|Drug|Arm C DA V FLAG-Ida V DAC|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1:1 fashion between DA, FLAG-Ida (or mini FLAG-Ida if 70 years or older) and DAC.
252393|NCT02272478|Drug|Arm E CPX-351 (200 V 300)|If a patient is not in CR or CRi after course 1 or is MRD +ve/unknown by flow cytometry they will be eligible to be randomised in a 1:1 fashion between CPX given on days 1, 3 and 5 (3 doses) and CPX given on days 1 and 3 (2 doses).
252394|NCT02272478|Drug|Arm F DA V IDAC|Following recovery from course 2, patients in the MRD-ve arm will be randomised between a further 5-day cycle of DA or a cycle of intermediate dose cytarabine (IDAC) as the third chemotherapy course.
252395|NCT02272465|Other|No intervention|Observational study
252396|NCT02272452|Device|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
252397|NCT02272426|Behavioral|CARET|Combined Aerobic and Resistance Exercise Training
252398|NCT02272426|Behavioral|CTI|Cognitive Training Intervention
252399|NCT02272426|Behavioral|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
252400|NCT02272426|Behavioral|Sham CTI|Sham Cognitive Training Intervention
252401|NCT02272413|Drug|BI 695502|
252402|NCT02272413|Drug|Avastin|
252403|NCT02272400|Other|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
252404|NCT02272387|Dietary Supplement|Vitamin D3 (Cholecalciferol)|
252405|NCT02272387|Other|Placebo|
252406|NCT02272374|Procedure|AVF creation|
252407|NCT02272374|Procedure|TCC placement|
252408|NCT02272374|Procedure|AVG creation|
252409|NCT02272361|Other|laparoscopic sacrocolpopexy|
252410|NCT02272361|Other|vaginal mesh surgery|
252411|NCT02272348|Other|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
252412|NCT02272348|Other|Usual diabetes management.|
252413|NCT02272335|Behavioral|Group Sessions|"10 weekly sessions:~CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.~CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
252414|NCT02272322|Device|cystocele repair with biomesh soft prolaps and endofast reliant|
252415|NCT02272309|Procedure|EEG and EP measurement|
252416|NCT02272296|Device|jet injector|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
252417|NCT02272296|Device|Conventional pen (NovoPen IV)|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
252418|NCT02272283|Device|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
252503|NCT02271646|Drug|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
252419|NCT02272270|Drug|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
252420|NCT02272257|Behavioral|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
252421|NCT02272257|Behavioral|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
252422|NCT02272244|Behavioral|Decision Support & Navigation|
252423|NCT02272244|Behavioral|Standard|
252424|NCT02272218|Procedure|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
252425|NCT02272205|Other|Retrospective analysis of records|
252426|NCT02272192|Behavioral|Play-based|The Early Start Denver Model (ESDM) is a comprehensive behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures used to deliver this content. The teaching format focuses on natural activities involving play or daily routines, though structure is added for children who need more structure to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches. Discrete Trial Teaching is not used in this group.
252427|NCT02272192|Behavioral|Discrete Trial Teaching|Discrete trial training (DTT) is a one-to-one instructional approach used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
252428|NCT02272179|Behavioral|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, Brite); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
252429|NCT02272179|Behavioral|Brite|Brite is a HIPAA-compliant mobile application designed to provide the participants with emotion regulation and distress tolerance skills, social support, and convenient access to safety plan resources via the patients' phone.
252430|NCT02272179|Behavioral|Treatment as Usual|Participants received usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which included a paper safety plan.
252431|NCT02272166|Drug|propofol|
252432|NCT02272166|Drug|Sevoflurane|
252433|NCT02272153|Other|Egg refined grain|
252434|NCT02272153|Other|Egg Whole Grain|
252435|NCT02272153|Other|Cereal Refined grain|
252436|NCT02272127|Drug|icotinib|
252437|NCT02272101|Dietary Supplement|Vitamin D versus placebo|Cross-over design
252438|NCT02272088|Behavioral|physical activity-moderate|cross -over of moderate and intense physical activity
252439|NCT02272088|Behavioral|Intense physical activity|cross -over of moderate and intense physical activity
252440|NCT02272075|Device|Mobile OCT M3 scope|
252441|NCT02272062|Other|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
252442|NCT02272049|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
252443|NCT02272036|Procedure|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
252444|NCT02272036|Device|mobile phone|SMS received by mobile phone
252445|NCT02272023|Behavioral|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
252446|NCT02272023|Behavioral|Single session of Motivational Interviewing|
252447|NCT02272010|Other|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
252448|NCT02272010|Other|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
252449|NCT02271997|Drug|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
252450|NCT02271997|Drug|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
252451|NCT02271997|Drug|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
252452|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each intervention period.
252453|NCT02271984|Drug|Cysticide|Subjects will receive a single oral dose of current PZQ formulation (Cysticide®) at 40 mg/kg with water, under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
252454|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 10 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
252455|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 30 mg/kg dispersed in water under fed condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
252456|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg dispersed in water in fasted condition in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
252457|NCT02271984|Drug|MSC2499550A|Subjects will receive a single oral dose of MSC2499550A formulation at 20 mg/kg directly disintegrated in the mouth without water under fed conditions in one of the intervention periods. There will be a wash-out period of at least 7 days between each of the intervention period.
252458|NCT02271971|Dietary Supplement|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
252459|NCT02271971|Dietary Supplement|Placebo|A daily placebo capsule during 6 weeks.
252460|NCT02271958|Drug|Mifepristone|
252461|NCT02271958|Drug|PLACEBO|
252462|NCT02271945|Drug|MEDI-551 12 mg/kg|Participants will receive intravenous (IV) infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and Day 1 of Cycle 2 through Cycle 13
252463|NCT02271945|Drug|MEDI0680 2.5 mg/kg|Participants will receive IV infusion of MEDI0680 2.5 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
252464|NCT02271945|Drug|MEDI0680 10 mg/kg|Participants will receive IV infusion of MEDI0680 10 mg/kg on Days 2 and 15 of Cycle 1 and Days 1 and 15 of Cycle 2 through Cycle 13.
252465|NCT02271932|Other|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
252466|NCT02271919|Drug|Nicotine Lozenge|Given PO
252467|NCT02271919|Drug|Nicotine Patch|Given via patch
252468|NCT02271919|Other|Placebo|Given PO or via patch
252469|NCT02271919|Other|Tobacco Cessation Counseling|Receive behavioral smoking cessation counseling
252470|NCT02271919|Drug|Varenicline|Given PO
252471|NCT02271906|Drug|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
252472|NCT02271893|Drug|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
252473|NCT02271880|Other|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
252474|NCT02271880|Other|STAR|Adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
252475|NCT02271867|Procedure|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
252476|NCT02271854|Drug|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
252477|NCT02271854|Drug|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
252478|NCT02271841|Device|PVI|Pleth Variability Index
252479|NCT02271828|Procedure|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
252480|NCT02271815|Other|Oral Hygiene|Oral Hygiene
252481|NCT02271802|Dietary Supplement|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
252482|NCT02271802|Dietary Supplement|NaCl|
252483|NCT02271789|Other|problematic tooth|problematic tooth
252484|NCT02271776|Dietary Supplement|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
252485|NCT02271776|Dietary Supplement|maltodextrin|
252486|NCT02271763|Other|ultrasound|subjects' neck will be scanned using ultrasound
252487|NCT02271750|Procedure|lumbar puncture|for spinal fluid
252488|NCT02271737|Behavioral|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
252489|NCT02271724|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
252490|NCT02271724|Procedure|Blood sample|Blood sample
252491|NCT02271711|Other|Laboratory Biomarker Analysis|Correlative studies
252492|NCT02271711|Biological|Natural Killer Cell Therapy|Given autologous ex-vivo expanded NK cells IV
252493|NCT02271698|Drug|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
252494|NCT02271698|Other|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
252495|NCT02271685|Other|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
252496|NCT02271685|Other|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
252497|NCT02271685|Other|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
252498|NCT02271685|Other|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
252499|NCT02271672|Device|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
252500|NCT02271672|Device|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
252501|NCT02271659|Radiation|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
252502|NCT02271659|Radiation|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
252504|NCT02271633|Dietary Supplement|Sodium nitrate|
252508|NCT02271620|Procedure|nasal allergen provocation test|nasal allergen provocation test
252509|NCT02271607|Device|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
252510|NCT02271594|Behavioral|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
252511|NCT02271568|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
252512|NCT02271568|Other|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
252513|NCT02271555|Drug|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
252514|NCT02271555|Drug|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
252515|NCT02271555|Drug|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
252516|NCT02271542|Drug|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
252517|NCT02271529|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
252518|NCT02271516|Radiation|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
252519|NCT02271503|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
252520|NCT02271503|Drug|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
252521|NCT02271503|Drug|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
252522|NCT02271503|Drug|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
252523|NCT02271503|Drug|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
252524|NCT02271490|Other|Acrosome Reaction induction|
252525|NCT02271490|Other|capacitation in incubation medium prior to ICSI|
252526|NCT02271477|Device|Ultrasound-guided volemic repletion|After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
252527|NCT02271464|Drug|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
252528|NCT02271464|Drug|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~IRINOTECAN 165 mg/sqm IV over 1-h, day 1~OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),~CAPECITABINE 500 mg/tid orally, continuously,~CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
252529|NCT02271451|Device|Q collar|collar worn around neck
252530|NCT02271438|Drug|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6*140 mg capsules) of ibrutinib in Treatment B.
252531|NCT02271438|Drug|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
252532|NCT02271438|Drug|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
252533|NCT02271438|Drug|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
252534|NCT02271425|Drug|Evacetrapib Tablet|Oral administration
252535|NCT02271425|Drug|Evacetrapib Intravenous|Intravenous administration
252536|NCT02271412|Drug|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
252537|NCT02271412|Drug|Placebo|Placebo
252538|NCT02271399|Drug|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
252539|NCT02271399|Drug|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
252540|NCT02271386|Behavioral|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.~3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
252624|NCT02270749|Drug|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
252541|NCT02271373|Behavioral|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
252542|NCT02271360|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
252543|NCT02271360|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
252544|NCT02271347|Drug|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
252545|NCT02271334|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
252546|NCT02271334|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
252547|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
252548|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
252549|NCT02271321|Other|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
252550|NCT02271308|Behavioral|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
252551|NCT02271295|Drug|Enoxaparine|Enoxaparine 4000UI/day during 24 months
252552|NCT02271282|Drug|Toremifene|
252553|NCT02271282|Drug|Placebo|
252554|NCT02271282|Drug|GHRH/Ghrelin combined Injection|
252555|NCT02271269|Behavioral|Value Pricing Subsidies|"Usual care for glaucoma~Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.~Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
252556|NCT02271256|Device|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining with the application of 3-point pressure system, d) axial rotation or coupled motion by using uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
252557|NCT02271230|Drug|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
252558|NCT02271230|Dietary Supplement|Fish oil (EPA/DHA) alone|1 g/d fish oil
252559|NCT02271230|Drug|Vitamin D alone|2000 IU vitamin D
252560|NCT02271230|Other|Placebo|Vitamin D placebo and fish oil placebo
252561|NCT02271217|Drug|Placebo|
252562|NCT02271217|Drug|dalfampridine-ER 7.5mg|
252563|NCT02271217|Drug|dalfampridine-ER 10mg|
252564|NCT02271204|Drug|Ibandronic acid|As prescribed by physician
252565|NCT02271191|Drug|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
252566|NCT02271178|Other|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
252567|NCT02271178|Other|Conventional therapy|Usual therapy
252568|NCT02271165|Drug|Immunoglobulin (Hizentra)|
252569|NCT02271152|Procedure|FAST mapping and ablation|
252570|NCT02271152|Procedure|PVI|
252571|NCT02271139|Drug|Alectinib|Alectinib 600 mg administered orally with food.
252572|NCT02271126|Device|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
252573|NCT02271126|Device|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
252574|NCT02271126|Drug|Heparin|Anticoagulation provided to patients in ECMO
252575|NCT02271113|Drug|GMI-1271|
252576|NCT02271113|Drug|Placebo|
252577|NCT02271113|Drug|Enoxaparin Sodium (Lovenox®)|
252578|NCT02271100|Device|ultrasound guidance|use of ultrasound for entry position estimation
252579|NCT02271100|Device|palpation guidance|use of palpation for position estimation
252580|NCT02271074|Other|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
252581|NCT02271074|Behavioral|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
252582|NCT02271074|Other|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
252625|NCT02270736|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
252626|NCT02270736|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
252627|NCT02270723|Drug|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
252583|NCT02271061|Device|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
252584|NCT02271061|Device|Control tape|Apply tape in same technique without tension.
252585|NCT02271048|Device|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
252586|NCT02271035|Drug|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
252587|NCT02271035|Drug|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
252588|NCT02271022|Other|Non-Interventional Study|Non-Interventional Study
252589|NCT02271009|Drug|AllerT|Ultrafast immunotherapy
252590|NCT02271009|Drug|Placebo|placebo control
252591|NCT02270996|Other|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
252592|NCT02270983|Drug|Linaclotide 145 micrograms|
252593|NCT02270983|Drug|Linaclotide 290 micrograms|
252594|NCT02270983|Drug|Placebo|Matching placebo
252595|NCT02270970|Biological|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
252596|NCT02270957|Biological|Abatacept|
252597|NCT02270957|Other|Placebo|
252598|NCT02270944|Biological|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
252599|NCT02270944|Biological|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
252600|NCT02270931|Device|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
252601|NCT02270918|Drug|Kcentra|IV infusion
252602|NCT02270918|Drug|Apixaban|
252603|NCT02270918|Drug|Placebo|
252604|NCT02270905|Device|dCELL® Meniscus|decellularised porcine xenograft
252605|NCT02270892|Device|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
252606|NCT02270879|Procedure|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
252607|NCT02270866|Device|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
252608|NCT02270853|Device|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
252609|NCT02270840|Device|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
252610|NCT02270827|Drug|Aminophylline|intravenous medication
252611|NCT02270827|Drug|Hydrocortisone|Intravenous medication
252612|NCT02270814|Drug|nab-paclitaxel|
252613|NCT02270814|Drug|Cisplatin|
252614|NCT02270814|Drug|Carboplatin|
252615|NCT02270814|Biological|Cetuximab|
252616|NCT02270801|Drug|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
252617|NCT02270788|Drug|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
252618|NCT02270788|Drug|Sorafenib|"Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
252619|NCT02270788|Drug|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
252620|NCT02270762|Other|Rest in bed|
252621|NCT02270762|Other|Passive verticalization|
252622|NCT02270762|Other|Rest in bed|
252623|NCT02270749|Drug|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
252628|NCT02270723|Drug|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
252629|NCT02270697|Device|Array|Applications of oligonucleotide array in diagnosis.
252630|NCT02270684|Device|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
252631|NCT02270671|Behavioral|ABMT|Attention Bias Modification Training
252632|NCT02270671|Other|Placebo|Placebo Training
252633|NCT02270658|Device|CPAP|
252634|NCT02270645|Device|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
252635|NCT02270632|Drug|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
252636|NCT02270632|Drug|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
252637|NCT02270632|Drug|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
252638|NCT02270619|Biological|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
252639|NCT02270619|Behavioral|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
252640|NCT02270619|Other|Placebo|0.9% saline as IV bolus
252641|NCT02270619|Other|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
252642|NCT02270606|Radiation|intensity-modulated radiation therapy|Undergo IMRT
252643|NCT02270606|Drug|fluorouracil|Given IV
252644|NCT02270606|Drug|oxaliplatin|Given IV
252645|NCT02270606|Drug|leucovorin calcium|Given IV
252646|NCT02270606|Procedure|therapeutic conventional surgery|Undergo total mesorectal excision
252647|NCT02270580|Behavioral|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
252648|NCT02270580|Behavioral|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
252649|NCT02270567|Device|NETest|Non-invasive blood test
252650|NCT02270554|Device|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
252651|NCT02270541|Other|Telemedicine|In-ambulance telemedicine
252652|NCT02270528|Behavioral|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (~5 minutes)
252653|NCT02270528|Behavioral|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
252654|NCT02270515|Other|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
252655|NCT02270502|Device|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
252656|NCT02270502|Other|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
252657|NCT02270502|Other|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
252658|NCT02270489|Biological|AFFITOPE® PD01A + Adjuvant|s.c. injection
252659|NCT02270489|Biological|AFFITOPE® PD03A + Adjuvant|s.c. injection
252660|NCT02270489|Biological|Adjuvant without active component|s.c. injection
252661|NCT02270463|Drug|SL-401|
252662|NCT02270450|Procedure|therapeutic conventional surgery|Undergo abdominal surgery
252663|NCT02270450|Procedure|gastrointestinal complications management/prevention|Undergo non-surgical management
252664|NCT02270450|Other|quality-of-life assessment|Ancillary studies
252665|NCT02270437|Drug|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
252666|NCT02270424|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
252667|NCT02270424|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
252668|NCT02270424|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
252669|NCT02270424|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
252670|NCT02270424|Drug|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
252671|NCT02270424|Drug|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
252742|NCT02269800|Drug|Benzalkonium chloride solution|Tid, 7 days
252672|NCT02270424|Drug|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
252673|NCT02270398|Behavioral|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
252674|NCT02270398|Behavioral|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
252675|NCT02270398|Behavioral|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
252676|NCT02270385|Behavioral|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
252677|NCT02270385|Behavioral|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
252678|NCT02270372|Biological|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.~Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
252679|NCT02270359|Device|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
252680|NCT02270359|Procedure|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
252681|NCT02270359|Drug|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
252682|NCT02270346|Device|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
252683|NCT02270346|Device|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
252684|NCT02270333|Device|Inspiratory muscle training|"Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).~The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.~The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
252685|NCT02270333|Device|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).~The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
252686|NCT02270320|Behavioral|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
252687|NCT02270307|Drug|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
252688|NCT02270307|Biological|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
252689|NCT02270294|Other|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
252690|NCT02270294|Other|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
252691|NCT02270281|Drug|Dexmedetomidine 0.7 Mcg/kg/h|CIF 0.7mcg/kg/h
252692|NCT02270268|Dietary Supplement|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
252693|NCT02270268|Dietary Supplement|maltodextrin|
252694|NCT02270255|Procedure|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
252695|NCT02270255|Drug|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
252696|NCT02270255|Procedure|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
252697|NCT02270255|Drug|1% Xylocaine|5ml of 1% Xylocaine
252698|NCT02270242|Drug|Aspirin|
252699|NCT02270242|Drug|Placebo|
252700|NCT02270242|Drug|ticagrelor|
252701|NCT02270216|Procedure|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
252736|NCT02269839|Device|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
252743|NCT02269800|Drug|Normal saline|Tid, 7 days
252785|NCT02269566|Drug|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
252702|NCT02270216|Procedure|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.~Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
252703|NCT02270203|Radiation|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
252704|NCT02270190|Device|Percutaneous Tibial Nerve Stimulation (PTNS)|
252705|NCT02270177|Other|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
252706|NCT02270164|Dietary Supplement|Artichoke Leaf Extract|Capsule
252707|NCT02270164|Other|Placebo|Capsule
252708|NCT02270151|Device|MyDiagnostick|Diagnostick strategy with MyDiagnostick
252709|NCT02270138|Behavioral|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
252710|NCT02270125|Procedure|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
252711|NCT02270112|Device|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
252712|NCT02270073|Behavioral|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
252713|NCT02270060|Other|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
252714|NCT02270060|Other|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
252715|NCT02270047|Dietary Supplement|Orange nectar|Orange nectar
252716|NCT02270047|Dietary Supplement|Orange Nectar with fibre|
252717|NCT02270034|Drug|Crizotinib|Crizotinib is added to Stupp method
252718|NCT02270021|Other|Provider Mobile Application (ProvAPP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
252719|NCT02270021|Other|ProvAPP + Patient Educational Tool (Tab)|"Patient Educational Tool (Tab): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.~ProvAPP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
252720|NCT02270008|Other|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
252721|NCT02269995|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
252722|NCT02269982|Device|AR-v7 assays|
252723|NCT02269969|Drug|Tobramycin|
252724|NCT02269956|Behavioral|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
252725|NCT02269943|Drug|CC-486|
252726|NCT02269930|Drug|peginterferon beta-1a|Administered as subcutaneous injection
252727|NCT02269930|Drug|Rebif|Administered as subcutaneous injection
252728|NCT02269917|Drug|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
252729|NCT02269917|Drug|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) as per current treatment regimen.
252730|NCT02269917|Drug|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
252731|NCT02269904|Drug|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
252732|NCT02269904|Drug|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
252733|NCT02269891|Dietary Supplement|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
252734|NCT02269891|Other|Placebo|
252735|NCT02269852|Biological|trivalent seasonal influenza vaccine|"Infants: 0.25 ml/ dose;~Adults: 0.5 ml/ dose;~Seniors: 0.5 ml/ dose;"
252737|NCT02269826|Device|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
252738|NCT02269826|Device|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
252744|NCT02269787|Behavioral|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
252745|NCT02269774|Procedure|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
252746|NCT02269761|Device|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
252747|NCT02269748|Procedure|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
252748|NCT02269748|Procedure|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
252749|NCT02269748|Drug|Analgesic Therapy|Ibuprofen 600 mg TID
252750|NCT02269735|Drug|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
252751|NCT02269735|Biological|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
252752|NCT02269735|Drug|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
252753|NCT02269735|Biological|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
252754|NCT02269735|Drug|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
252755|NCT02269722|Device|Vascular compression device- RADAR TM-Short clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
252756|NCT02269722|Device|Vascular compression device RADAR TM-Long clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
252757|NCT02269709|Device|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI). This is a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
252758|NCT02269696|Drug|Metoprolol|Intraoperative metoprolol infusion.
252759|NCT02269696|Drug|Normal saline|Equal of volume compared to metoprolol.
252760|NCT02269683|Procedure|Robot-assisted distal pancreatectomy|
252761|NCT02269683|Procedure|Laparoscopic distal pancreatectomy|
252762|NCT02269670|Drug|everolimus|Given PO
252763|NCT02269670|Drug|anastrozole|Given PO
252764|NCT02269670|Drug|letrozole|Given PO
252765|NCT02269670|Drug|tamoxifen citrate|Given PO
252766|NCT02269670|Drug|fulvestrant|Given IM or PO
252767|NCT02269670|Drug|megestrol acetate|Given PO
252768|NCT02269657|Device|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
252769|NCT02269644|Drug|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
252770|NCT02269644|Drug|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
252771|NCT02269644|Drug|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
252772|NCT02269644|Drug|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
252773|NCT02269631|Behavioral|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
252774|NCT02269631|Behavioral|Control diet group|no legumes in lunch or dinner meals
252775|NCT02269631|Device|Smartpill|to assess how long food takes to pass through the digestive system
252776|NCT02269631|Other|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
252777|NCT02269618|Other|Home-based telehealth program|"Home-based telehealth program~Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.~Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms~Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor~Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need~Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises."
252778|NCT02269618|Other|Home-based rehabilitation|"Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer~Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)~Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient."
252779|NCT02269618|Other|Usual care|Usual care All patients will be followed also in usual care manner by their GPs.
252780|NCT02269605|Other|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
252781|NCT02269605|Drug|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
252782|NCT02269605|Drug|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
252783|NCT02269579|Drug|CPX-351|
252784|NCT02269566|Drug|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
252786|NCT02269553|Device|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
252787|NCT02269553|Device|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
252788|NCT02269540|Drug|Sertraline|selective serotonin reuptake inhibitor
252789|NCT02269540|Drug|Citalopram|selective serotonin reuptake inhibitor
252790|NCT02269540|Drug|N-acetylcysteine (NAC)|natural health product
252791|NCT02269540|Drug|Existing depression medication treatment|Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
252792|NCT02269527|Other|Live music|Providing 1-hour live music 5 days/ week.
252793|NCT02269514|Other|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
252794|NCT02269514|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
252795|NCT02269514|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
252796|NCT02269514|Other|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
252797|NCT02269514|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
252798|NCT02269501|Other|Exercise treatment|
252799|NCT02269488|Drug|MEDI3250|MEDI3250
252800|NCT02269475|Drug|MEDI3250|MEDI3250
252801|NCT02269475|Drug|Placebo|Placebo
252802|NCT02269462|Drug|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
252803|NCT02269462|Drug|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
252804|NCT02269449|Device|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
252805|NCT02269449|Device|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
252806|NCT02269449|Procedure|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
252807|NCT02269449|Procedure|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
252808|NCT02269436|Drug|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
252809|NCT02269423|Biological|V920|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
252810|NCT02269423|Other|Placebo|Normal saline placebo.
252811|NCT02269410|Dietary Supplement|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252812|NCT02269410|Dietary Supplement|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252813|NCT02269410|Dietary Supplement|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252814|NCT02269410|Dietary Supplement|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
252815|NCT02269384|Procedure|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
252816|NCT02269384|Behavioral|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
252817|NCT02269384|Behavioral|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
252818|NCT02269384|Procedure|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
252819|NCT02269371|Other|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
252820|NCT02269371|Other|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
252821|NCT02269358|Drug|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
252822|NCT02269345|Other|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
252823|NCT02269345|Other|Standard Treatment|Standard Treatment alone.
252824|NCT02269332|Other|Screening Colonoscopy|we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
252825|NCT02269319|Drug|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
252826|NCT02269319|Drug|Linezolid|Oral linezolid 600mg given twice a day for 10 days
252827|NCT02269306|Drug|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
252828|NCT02269293|Drug|Paclitaxel|
252829|NCT02269293|Drug|Carboplatin|
252830|NCT02269293|Drug|Selinexor|
252831|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
252832|NCT02269280|Drug|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
252833|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
252834|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
252835|NCT02269267|Other|Stopping their TKI|Patients with CML patients who are on imatinib, dasatinib, nilotinib, or bosutinib and have had deep molecular response is defined as BCR-ABL < 0.01%, (> MR4 i.e. > 4 log reduction) by PCR for at least 2 years will stop their TKI. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
252836|NCT02269254|Device|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
252837|NCT02269254|Device|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
252838|NCT02269241|Drug|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
252839|NCT02269228|Drug|Asasantin ER|
252840|NCT02269228|Drug|Placebo|
252841|NCT02269215|Drug|BIII 890 CL|
252842|NCT02269215|Drug|Placebo|
252843|NCT02269202|Drug|Midazolam, tablet|
252844|NCT02269202|Drug|Crobenetine, i.v. infusion|
252845|NCT02269202|Drug|Placebo|
252846|NCT02269189|Drug|BIIL 284 BS, high dose|
252847|NCT02269189|Drug|BIIL 284 BS, low dose|
252848|NCT02269189|Drug|Placebo|
252849|NCT02269176|Drug|Low dose of telmisartan|
252850|NCT02269176|Drug|High dose of telmisartan|
252851|NCT02269176|Drug|Low dose of losartan|
252852|NCT02269176|Drug|High dose of losartan|
252853|NCT02269163|Biological|CP|Commercially available IGIV
252854|NCT02269163|Biological|IMP|Liquid formulation of Prometic IGIV 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
252855|NCT02269150|Biological|fecal microbiota transplantation (FMT)|
252856|NCT02269150|Other|No fecal microbiota transplantation (FMT), routine management|
252857|NCT02269124|Device|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
252858|NCT02269111|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
252859|NCT02269111|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
252860|NCT02269111|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
252861|NCT02269111|Procedure|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
252862|NCT02269098|Other|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
252863|NCT02269085|Drug|Ibrutinib|"Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I."
252864|NCT02269085|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I."
252865|NCT02269085|Behavioral|Phone Calls|Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
252866|NCT02269072|Drug|Testosterone|Testosterone cream applied daily for two weeks
252867|NCT02269072|Drug|Nesiritide|Administered IV once during the study
252868|NCT02269072|Drug|Leuprolide|Administered twice during the study by injection
252869|NCT02269072|Drug|Anastrozole|Daily pill for 8 weeks
252870|NCT02269072|Drug|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
252871|NCT02269059|Drug|MK-7680|MK-7680 10 mg and 100 mg capsules
252872|NCT02269046|Other|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
252873|NCT02269046|Drug|Simvastatin|10mg/d,p.o,12 weeks.
252874|NCT02269046|Other|Therapeutic Lifestyle Change|"Reduced intakes of saturated fats (<7% of total calories) and cholesterol (<200 mg per day)~Therapeutic options for enhancing LDL lowering~Weight reduction~Increased physical activity"
252875|NCT02269033|Behavioral|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
252876|NCT02269033|Behavioral|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
252877|NCT02269020|Procedure|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
252878|NCT02269007|Biological|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
252879|NCT02268994|Drug|ferric citrate|1 g ferric citrate containing approximately 210 mg of ferric iron
252880|NCT02268994|Drug|Placebo|Matching placebo
252881|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
252882|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
252883|NCT02268981|Device|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
252884|NCT02268968|Drug|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
252885|NCT02268955|Drug|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
252886|NCT02268955|Drug|Saline|Saline will be administered to the placebo group
252887|NCT02268942|Device|HeartWare HVAD|Implant of HeartWare HVAD via thoracotomy implant technique
252888|NCT02268942|Procedure|Thoracotomy|Thoracotomy implant technique
252889|NCT02268929|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
252890|NCT02268929|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
252891|NCT02268916|Behavioral|Counseling|OT led counseling
252892|NCT02268916|Behavioral|Usual education|At the end of the study, will receive OT-led counseling
252893|NCT02268903|Drug|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
252894|NCT02268903|Drug|Placebo|Placebo in one single direct intra venous injection
252895|NCT02268890|Drug|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
252896|NCT02268877|Other|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
252897|NCT02268877|Device|Ultrasound|An ultrasound will be performed by a radiology department technician
252898|NCT02268864|Drug|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
252899|NCT02268864|Drug|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
252900|NCT02268851|Drug|TGR-1202|Capsules taken whole daily with water and with food
252901|NCT02268851|Drug|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
252902|NCT02268838|Drug|E6007|
252903|NCT02268838|Drug|E6007 matching placebo|
252904|NCT02268825|Drug|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose"
252905|NCT02268786|Other|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
252906|NCT02268773|Drug|Asasantin®|
252907|NCT02268773|Drug|Acetylsalicylic acid low dose|
252908|NCT02268773|Drug|Acetylsalicylic acid high dose|
252909|NCT02268760|Drug|BILN 2061 ZW single rising doses|
252910|NCT02268760|Drug|Placebo|
252911|NCT02268760|Drug|BILN 2061 ZW fixed dose|
252912|NCT02268760|Other|Standardized breakfast|
252913|NCT02268747|Drug|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).~If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
252914|NCT02268721|Device|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
252915|NCT02268708|Procedure|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
252916|NCT02268695|Drug|Cisplatin|
252917|NCT02268695|Drug|5-Fluorouracile|
252918|NCT02268695|Drug|Docetaxel|
252919|NCT02268695|Drug|Cetuximab|
252920|NCT02268695|Drug|granulocyte colony-stimulating factor (G-CSF)|
252921|NCT02268682|Other|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
252922|NCT02268682|Other|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
252923|NCT02268669|Other|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
252924|NCT02268656|Drug|propofol|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
252925|NCT02268643|Other|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
252970|NCT02268188|Behavioral|exercise intervention|Use FitBit to log daily steps as part of Harvesting Health program
252971|NCT02268188|Other|questionnaire administration|Ancillary studies
252972|NCT02268188|Other|laboratory biomarker analysis|Correlative studies
252973|NCT02268188|Other|quality-of-life assessment|Ancillary studies
252974|NCT02268175|Drug|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
252926|NCT02268617|Other|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
252927|NCT02268604|Drug|BIIB 722 CL|
252928|NCT02268604|Drug|Placebo|
252929|NCT02268591|Device|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
252930|NCT02268578|Device|Transcranial Direct Current Stimulation|2mA tDCS
252931|NCT02268578|Procedure|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
252932|NCT02268565|Drug|Aspirin|81mg aspirin daily at bedtime over a 2 week period
252933|NCT02268565|Drug|Placebo|pill that looks like aspirin without the effects of aspirin
252934|NCT02268552|Drug|branaplam|
252935|NCT02268539|Procedure|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
252936|NCT02268526|Biological|CSJ148|CSJ148 IV q 4weeks
252937|NCT02268526|Drug|Placebo|Placebo IV q 4weeks
252938|NCT02268500|Biological|Influenza vaccine|Influenza vaccine
252939|NCT02268487|Drug|Sertraline|Treatment
252940|NCT02268474|Device|Excel V 532nm (KTP) Laser or 595nm Pulse Dye Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization.
252941|NCT02268461|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
252942|NCT02268461|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
252943|NCT02268448|Drug|Clonidine|
252944|NCT02268448|Drug|Naltrexone|
252945|NCT02268435|Drug|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
252946|NCT02268422|Drug|Buprenorphine|7 day patch
252947|NCT02268409|Drug|ACE-536|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
252948|NCT02268396|Drug|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
252949|NCT02268383|Drug|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection
252950|NCT02268370|Drug|Dasatinib|
252951|NCT02268357|Drug|Propranolol|Oral propranolol capsules
252952|NCT02268344|Device|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
252953|NCT02268331|Other|Active Surveillance|
252954|NCT02268331|Other|Passive Surveillance|
252955|NCT02268318|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
252956|NCT02268318|Other|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
252957|NCT02268305|Drug|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
252958|NCT02268305|Other|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
252959|NCT02268292|Behavioral|bicycle exercise|All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
252960|NCT02268279|Drug|solithromycin|
252961|NCT02268266|Device|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
252962|NCT02268253|Drug|SL-401|
252963|NCT02268240|Behavioral|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
252964|NCT02268214|Drug|Dapagliflozin|Tablets
252965|NCT02268214|Drug|Placebo for dapagliflozin|Tablets
252966|NCT02268201|Drug|Advagraf|oral
252967|NCT02268201|Drug|Prograf|oral
252968|NCT02268188|Other|education|Attend classes as part of Harvesting Health program
252969|NCT02268188|Other|nutrition intervention|Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
252975|NCT02268175|Drug|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
252976|NCT02268175|Drug|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
252977|NCT02268175|Drug|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
252978|NCT02268162|Procedure|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
252979|NCT02268149|Drug|BIIL 284 BS|
252980|NCT02268149|Drug|Prednisone|
252981|NCT02268149|Drug|Placebo|
252982|NCT02268136|Drug|BIII 890 CL|
252983|NCT02268136|Drug|Placebo|
252984|NCT02268110|Other|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
252985|NCT02268110|Other|Abdominal binding|Wearing an abdominal binder for 12 weeks
252986|NCT02268097|Procedure|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
252987|NCT02268097|Procedure|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
252988|NCT02268084|Device|EEG,ECG-guided Transcranial Magnetic Stimulation|A coil delivers a pulsed magnetic field to the cortex of the brain
252989|NCT02268084|Device|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
252990|NCT02268071|Drug|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values <135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
252991|NCT02268058|Drug|Acetaminophen|routine administration of medication for a 72 hour period
252992|NCT02268058|Drug|Ibuprofen|routine administration of medication for a 72 hour period
252993|NCT02268045|Biological|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
252994|NCT02268045|Biological|Mabthera|Mabthera will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
252995|NCT02268032|Drug|DHEA|DHEA 2.2 g in vaginal ring
252996|NCT02268032|Drug|Another Androgenic Agent (VRaA)|Testosterone 35 mg in vaginal ring
252997|NCT02268032|Drug|Fixed combination of 2 androgenic agents (VR2A)|DHEA 1.5 g/testosterone 25 mg fixed combination in vaginal ring
252998|NCT02268019|Procedure|tourniquet application|
252999|NCT02268019|Drug|epinephrine injection|
253000|NCT02268006|Radiation|IMRT-SIB|
253001|NCT02268006|Drug|Capecitabine|
253002|NCT02268006|Procedure|Surgery|
253003|NCT02267993|Drug|recombinant human thrombopoietin|Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of < 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
253004|NCT02267980|Drug|Sevoflurane|Inhalation anesthetic agent
253005|NCT02267980|Drug|Ketamine|Intravenous anesthetic agent
253006|NCT02267980|Drug|Saline|Isotonic solution for placebo group
253007|NCT02267967|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
253008|NCT02267954|Other|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
253009|NCT02267941|Other|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
253010|NCT02267928|Other|Check Symptoms|"Symptoms are Checked"
253011|NCT02267928|Other|Uncheck Symptoms|"Symptoms are Un-checked"
253012|NCT02267928|Other|Experienced|Focus of instructions is on symptoms the participant has experienced
253013|NCT02267928|Other|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
253014|NCT02267915|Drug|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
253015|NCT02267902|Drug|DA-1229|
253016|NCT02267889|Procedure|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
253017|NCT02267889|Device|D-SPECT dedicated cardiac nuclear camera|
253018|NCT02267876|Device|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
253019|NCT02267876|Procedure|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
253020|NCT02267863|Drug|APTO-253|APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.
253021|NCT02267850|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
253022|NCT02267850|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
253023|NCT02267850|Device|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
253024|NCT02267837|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
253025|NCT02267824|Device|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
253174|NCT02266771|Device|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
253026|NCT02267824|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
253027|NCT02267811|Other|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
253028|NCT02267811|Device|OrthoPulse™|Participants carry out daily OrthoPulse™ treatments at home.
253029|NCT02267798|Other|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.~The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
253030|NCT02267798|Device|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.~Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
253031|NCT02267785|Other|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
253032|NCT02267785|Other|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
253033|NCT02267785|Other|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
253034|NCT02267772|Drug|IV Acetaminophen|IV Acetaminophen
253035|NCT02267772|Drug|IV Morphine|IV Morphine
253036|NCT02267759|Device|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
253037|NCT02267759|Device|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
253038|NCT02267746|Drug|Tazarotene (Fabior™)|
253039|NCT02267746|Drug|Tazarotene (Actavis)|
253040|NCT02267746|Drug|Vehicle foam|
253041|NCT02267733|Drug|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
253042|NCT02267720|Procedure|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
253043|NCT02267720|Procedure|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
253044|NCT02267707|Drug|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
253045|NCT02267707|Drug|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
253046|NCT02267694|Drug|Freeze-dried black raspberry powder|
253047|NCT02267681|Drug|Fentanyl|Intravenous fentanyl for sedation/analgesia
253048|NCT02267681|Drug|Alfentanil|Intravenous alfentanyl for sedation/analgesia
253049|NCT02267681|Drug|Propofol|Intravenous propofol for sedation
253050|NCT02267668|Behavioral|STEP|Physical therapists guide participants through novel set of assigned exercises
253051|NCT02267668|Behavioral|Control|Participants self-guide through standard exercises
253052|NCT02267655|Drug|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
253053|NCT02267655|Drug|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
253054|NCT02267655|Drug|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
253055|NCT02267642|Biological|AbGn-168H|monoclonal antibody
253056|NCT02267629|Drug|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
253057|NCT02267616|Device|Etonogestrel Implant|Subdermal arm implant
253058|NCT02267603|Other|Laboratory Biomarker Analysis|Ancillary studies
253059|NCT02267603|Biological|Pembrolizumab|Given IV
253060|NCT02267577|Device|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
253061|NCT02267577|Device|GE Dinamap ProCare Automatic Blood Pressure Monitor|This commercially available gold standard blood pressure monitor will be used as a control to assess the accuracy of the Sphygmo device.
253062|NCT02267564|Procedure|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
253063|NCT02267564|Procedure|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
253064|NCT02267551|Other|Mimic dv-Trainer|
253065|NCT02267551|Other|daVinci Skills Simulator|
253066|NCT02267538|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
253067|NCT02267538|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.~Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.~At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation after surgery."
253068|NCT02267525|Drug|Velusetrag|
253069|NCT02267525|Drug|Placebo|
253070|NCT02267512|Drug|ATG-F|Intravenous (IV)
253071|NCT02267499|Other|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
253072|NCT02267486|Other|Standard therapy of Alzheimer Dementia (AD)|
253073|NCT02267486|Other|Observation|
253074|NCT02267460|Biological|AA4500|
253075|NCT02267460|Device|ErecAid® Esteem® Manual Vacuum Therapy System|
253076|NCT02267460|Procedure|Investigator Modeling|
253077|NCT02267434|Biological|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
253078|NCT02267434|Biological|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
253079|NCT02267434|Biological|Adjuvant without active component|s.c. injection
253080|NCT02267421|Behavioral|Home based Aerobic exercise training|
253081|NCT02267408|Other|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
253082|NCT02267408|Other|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
253083|NCT02267395|Other|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
253084|NCT02267395|Other|(2) scapular dyskinesis test|Test to determine scapular control
253085|NCT02267395|Other|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
253086|NCT02267382|Drug|VT-1161|
253087|NCT02267382|Drug|Placebo|
253088|NCT02267369|Behavioral|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
253089|NCT02267369|Behavioral|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
253090|NCT02267369|Behavioral|Basic fitness program|Participants can register workshops online and track program participation.
253091|NCT02267356|Drug|VT-1161|
253092|NCT02267356|Drug|Placebo|
253093|NCT02267343|Drug|ONO-4538|
253094|NCT02267343|Drug|Placebo|
253095|NCT02267330|Procedure|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
253096|NCT02267317|Drug|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
253097|NCT02267317|Other|D5W|5% Dextrose Water = Vehicle
253098|NCT02267304|Drug|50 mL of sodium chloride (0,9%)|
253099|NCT02267304|Drug|Morphine 0,05mg/kg|
253100|NCT02267304|Drug|Naloxone 10mg|
253101|NCT02267291|Other|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
253102|NCT02267278|Drug|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
253103|NCT02267278|Drug|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
253104|NCT02267278|Behavioral|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
253105|NCT02267265|Other|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
253106|NCT02267265|Other|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
253107|NCT02267252|Other|Antibody-sperm binding|
253175|NCT02266758|Other|GDM Screening Methods|
253176|NCT02266745|Drug|PT-112 Injection|
253177|NCT02266732|Device|Stimuplex HNS 12|
253108|NCT02267239|Drug|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (I-EO).
253109|NCT02267239|Drug|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
253110|NCT02267239|Drug|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (M-EO).
253111|NCT02267239|Drug|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
253112|NCT02267239|Procedure|professional oral cleaning|scaling and polishing teeth of the volunteers
253113|NCT02267239|Procedure|Plaster cast|Taking a plaster cast of the volunteers' mouth
253114|NCT02267239|Device|IDODS|Specific intraoral device which carries six glass disks
253115|NCT02267226|Drug|Octafibrin|
253116|NCT02267213|Drug|Lipotecan|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.
253117|NCT02267187|Procedure|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
253118|NCT02267187|Drug|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
253119|NCT02267187|Device|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
253120|NCT02267187|Other|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
253121|NCT02267174|Behavioral|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
253122|NCT02267161|Other|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
253123|NCT02267135|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
253124|NCT02267135|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
253125|NCT02267122|Procedure|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
253126|NCT02267122|Procedure|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
253127|NCT02267109|Biological|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
253128|NCT02267109|Biological|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
253129|NCT02267096|Behavioral|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
253130|NCT02267096|Behavioral|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
253131|NCT02267083|Drug|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
253132|NCT02267070|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
253133|NCT02267070|Behavioral|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
253134|NCT02267070|Behavioral|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
253135|NCT02267070|Behavioral|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
253136|NCT02267057|Drug|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
253137|NCT02267057|Drug|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
253138|NCT02267057|Drug|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
253139|NCT02267057|Drug|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
253140|NCT02267044|Drug|Ropivacaine|The drug used for the interscalene blocks
253141|NCT02267031|Procedure|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).~Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
253142|NCT02267018|Device|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
253143|NCT02267005|Dietary Supplement|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
253144|NCT02267005|Dietary Supplement|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
253145|NCT02266992|Biological|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
253146|NCT02266966|Drug|F2695|
253147|NCT02266966|Drug|Placebo|
253148|NCT02266953|Behavioral|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
253149|NCT02266953|Behavioral|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
253150|NCT02266940|Drug|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
253151|NCT02266940|Drug|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
253152|NCT02266927|Drug|Flovent HFA|
253153|NCT02266927|Drug|OPTINOSE™ FLUTICASONE|
253154|NCT02266914|Device|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
253155|NCT02266901|Procedure|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
253156|NCT02266888|Biological|Rituximab (Rituxan®)|2 Doses: 375 mg/m^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/‐2 days).
253157|NCT02266888|Biological|Placebo|Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/‐2 days).
253158|NCT02266875|Drug|hypertonic saline|
253159|NCT02266875|Drug|standard saline|
253160|NCT02266862|Radiation|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
253161|NCT02266849|Drug|Loperamide|12 mg Loperamide each day for three days
253162|NCT02266849|Drug|Placebo|6 tablets daily for three days
253163|NCT02266836|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non‐damaged pathways of the central nervous system.
253164|NCT02266823|Behavioral|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
253165|NCT02266810|Device|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
253166|NCT02266810|Procedure|Sinus Surgery alone|Sinus surgery only, without implant placement
253167|NCT02266810|Device|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
253168|NCT02266797|Drug|Dexamethasone|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
253169|NCT02266797|Other|Saline|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
253170|NCT02266784|Behavioral|Contingency Management (CM)|
253171|NCT02266784|Drug|Transdermal nicotine skin patches (i.e. Habitrol)|
253172|NCT02266784|Other|Supportive Counseling|
253173|NCT02266771|Device|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
253178|NCT02266719|Device|Fenestrated CMD|"The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft.~In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used.~Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms."
253179|NCT02266719|Device|Type I - III TAAA|"Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms. Devices will be implanted in patients with type I-III thoracic abdominal aneurysms.~The branches in this study will be constructed as internal/external cuffs, axially oriented and caudally or cranially directed, as necessary . Branch position will be determined by the anatomic location of the target vessels using a consistent craniocaudal and circumferential cuff position."
253180|NCT02266706|Drug|Ceftolozane/Tazobactam 1000/500 mg|A fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
253181|NCT02266706|Drug|Ceftolozane/Tazobactam 30/15 mg/kg|A FDC of 30 mg/kg of ceftolozane and 15 mg/kg of tazobactam as a 60 minute infusion.
253182|NCT02266706|Drug|Ceftolozane/Tazobactam 20/10 mg/kg|A FDC of 20 mg/kg of ceftolozane and 10 mg/kg of tazobactam as a 60 minute infusion.
253183|NCT02266706|Drug|Ceftolozane/Tazobactam 18/9 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
253184|NCT02266706|Drug|Ceftolozane/Tazobactam 12/6 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
253185|NCT02266693|Behavioral|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
253186|NCT02266680|Behavioral|Yoga Treatment Group|The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
253187|NCT02266667|Device|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
253188|NCT02266667|Device|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
253189|NCT02266654|Other|IV fluids|Normal Saline 0.9%
253190|NCT02266654|Other|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
253191|NCT02266641|Behavioral|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
253192|NCT02266641|Dietary Supplement|multivitamin supplement|
253193|NCT02266628|Biological|RSV-F Vaccine|
253194|NCT02266628|Biological|Saline Placebo|
253195|NCT02266615|Genetic|Biobanking of biomaterial for future genetic research.|
253196|NCT02266602|Radiation|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
253197|NCT02266589|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
253198|NCT02266576|Behavioral|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the Indian Health Center is the Group Lifestyle Balance DPP, which has previously been tailored for the urban American Indian/Alaskan Natives (AIAN). The Standard DPP consists of 16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator. The intervention will occur over the course of 20 weeks.
253199|NCT02266576|Behavioral|Enhanced DPP|The Enhanced Diabetes Prevention Program (DPP) will include all components of the Standard DPP [16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator] delivered by the Indian Health Center and additional components to address psychosocial issues. The Enhanced DPP components include 4 visits with a mental health counselor, active referrals to mental health services, and traditional healing workshops, such as the use of talking circles to address specific psychosocial issues that are a result of historical trauma, stress, and grief. The intervention will occur over the course of 20 weeks.
253200|NCT02266563|Drug|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
253201|NCT02266563|Drug|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
253202|NCT02266550|Drug|[14C] BILL 284 BS|
253203|NCT02266537|Drug|Tamsulosin|
253204|NCT02266537|Drug|Alfuzosin|
253205|NCT02266537|Drug|Doxazosin|
253206|NCT02266537|Drug|Placebo|
253207|NCT02266524|Drug|Tamsulosin hydrochloride, very low dose|
253208|NCT02266524|Drug|Tamsulosin hydrochloride, low dose|
253209|NCT02266524|Drug|Tamsulosin hydrochloride, medium dose|
253210|NCT02266524|Drug|Tamsulosin hydrochloride, high dose|
253211|NCT02266511|Drug|Flomax®, Norman II facility|
253212|NCT02266511|Drug|Flomax®, Nishine facility|
253213|NCT02266498|Drug|BIBB 515 BS|
253214|NCT02266498|Other|Standard breakfast (40 g fat)|
253215|NCT02266485|Drug|BIBB 515 BS|
253216|NCT02266485|Drug|Pravastatin|
253217|NCT02266485|Drug|Placebo|
253218|NCT02266472|Drug|metformin|single dose of metformin given as tablets
253219|NCT02266472|Drug|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
253220|NCT02266472|Drug|empagliflozin|single dose of empagliflozin given as tablet
253221|NCT02266459|Device|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is < 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
253222|NCT02266446|Behavioral|Attention & Interpretation Modification|
253223|NCT02266433|Drug|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study~Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
253224|NCT02266433|Drug|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.~In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
253225|NCT02266420|Procedure|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
253226|NCT02266407|Procedure|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
253227|NCT02266394|Drug|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
253228|NCT02266394|Procedure|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
253229|NCT02266381|Procedure|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
253230|NCT02266381|Procedure|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
253231|NCT02266381|Procedure|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
253232|NCT02266368|Device|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
253233|NCT02266355|Drug|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
253234|NCT02266342|Device|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
253235|NCT02266329|Drug|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
253236|NCT02266329|Drug|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
253237|NCT02266316|Device|Air warming mask|Mask that warms air at the mouth
253238|NCT02266303|Other|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
253239|NCT02266290|Procedure|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
253240|NCT02266290|Device|Sport tex® kinesiotape|
253241|NCT02266290|Device|Pretape Cramer®|
253242|NCT02266277|Other|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
253243|NCT02266277|Other|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
253244|NCT02266277|Other|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
253245|NCT02266277|Other|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
253246|NCT02266264|Drug|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
253247|NCT02266238|Device|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
253248|NCT02266238|Device|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
253249|NCT02266238|Procedure|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
253250|NCT02266225|Other|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
253251|NCT02266212|Procedure|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
253252|NCT02266186|Behavioral|Traditional Cognitive behavioural therapy|Therapist supported live therapy
253253|NCT02266186|Behavioral|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
253254|NCT02266173|Drug|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
253255|NCT02266160|Drug|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
253256|NCT02266160|Other|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
253257|NCT02266147|Drug|SD-101|
253258|NCT02266147|Radiation|Radiation therapy|
253259|NCT02266134|Behavioral|Tailored Implementation of Measurement Based Care|measurement based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire, the implementation of measurement based care will be tailored based on clinic specific barriers and facilitators
253260|NCT02266134|Behavioral|Standard Implementation of Measurement Based Care|measurement based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9), the implementation of measurement based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session
253261|NCT02266121|Device|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
253262|NCT02266108|Behavioral|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
253263|NCT02266095|Device|Oval-8 Splint|Splinting with Oval-8
253264|NCT02266095|Device|Tee Pee Splint|Splinting with Tee Pee
253265|NCT02266095|Device|Forearm Based Splint|Splinting with Forearm based
253266|NCT02266082|Other|No intervention|There is no intervention in this study.
253267|NCT02266069|Other|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
253268|NCT02266056|Drug|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
253269|NCT02266056|Drug|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
253270|NCT02266043|Device|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.~This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
253271|NCT02266030|Drug|Cilostazol|Pletaal as an active drug
253272|NCT02266030|Drug|Aspirin|Aspirin as an active comparator
253273|NCT02266017|Behavioral|Pain Coping Skills Training|
253274|NCT02266004|Device|Transcranial Direct Current Stimulation (tDCS)|anodal Transcranial Direct Current Stimulation (tDCS will be applied for 20 minutes at 2mA with IOMED Phoresor.
253275|NCT02266004|Other|locomotor training|An individualized training exercise for patients with Parkinson's disease.
253276|NCT02266004|Other|sham-tDCS|this is sham Transcranial Direct Current Stimulation (tDCS)
253277|NCT02265991|Procedure|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
253278|NCT02265978|Device|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
253279|NCT02265965|Drug|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
253280|NCT02265952|Drug|REGN1500|
253281|NCT02265939|Drug|NPO-13|
253282|NCT02265926|Device|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
253283|NCT02265913|Drug|Acyclovir 5 percent (Perrigo)|
253284|NCT02265913|Drug|Acyclovir 5 percent (Reference)|
253285|NCT02265913|Drug|Placebo cream|
253286|NCT02265900|Other|Exercise|One type of exercise
253287|NCT02265900|Other|Exercise|A different type of exercise
253288|NCT02265887|Other|standard of care|No intervention, this a patient registry and is purely an observational study
253289|NCT02265874|Drug|Habitrol|Patch used daily for 28 weeks
253290|NCT02265874|Drug|Placebo to Habitrol|
253291|NCT02265861|Drug|HCG|
253292|NCT02265848|Other|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
253293|NCT02265848|Other|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
253294|NCT02265835|Other|no intervention|no intervention
253295|NCT02265822|Drug|melatonin in children premedication|
253296|NCT02265822|Drug|midazolam in children premedication|
253297|NCT02265809|Drug|Aldesleukin|
253298|NCT02265796|Drug|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
253299|NCT02265796|Drug|Sugar pill|"500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
253334|NCT02265666|Other|standard breakfast|
253335|NCT02265653|Drug|BIIL 284 BS tablet C|
253300|NCT02265783|Device|Nellcor USB Pulse Oximeter Monitor Interface Cable|Volunteers are subjected to certain simulated, sensor removal conditions known to represent challenges to the sensor-off feature. Such conditions include exposing the sensor to an ambient light source, sensor slipping off the finger with the light emitter and detector facing each other or a sensor slipping off under a blanket.
253301|NCT02265770|Drug|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
253302|NCT02265770|Drug|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
253303|NCT02265770|Drug|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.~Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
253304|NCT02265770|Radiation|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
253305|NCT02265770|Drug|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
253306|NCT02265770|Drug|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
253307|NCT02265770|Radiation|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.~In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
253308|NCT02265757|Behavioral|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.~Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
253309|NCT02265757|Behavioral|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
253310|NCT02265757|Behavioral|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
253311|NCT02265757|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
253312|NCT02265757|Behavioral|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
253313|NCT02265744|Drug|BMS-931699|
253314|NCT02265744|Drug|Placebo matching BMS-931699|
253315|NCT02265731|Drug|azacitadine|75 mg/m2 by IV infusion or subcutaneous dosing
253316|NCT02265731|Drug|venetoclax|Step-up doses of venetoclax to the designated cohort dose
253317|NCT02265731|Drug|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
253318|NCT02265731|Drug|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
253319|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
253320|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
253321|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
253322|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
253323|NCT02265705|Drug|Baricitinib|Administered orally
253324|NCT02265705|Drug|Placebo|Administered orally
253325|NCT02265679|Drug|BIIL 284 BS, low dose, pediatric patients|
253326|NCT02265679|Drug|BIIL 284 BS, medium dose, pediatric patients|
253327|NCT02265679|Drug|BIIL 284 BS, high dose, pediatric patients|
253328|NCT02265679|Drug|BIIL 284 BS, low dose, adult patients|
253329|NCT02265679|Drug|BIIL 284 BS, medium dose, adult patients|
253330|NCT02265679|Drug|BIIL 284 BS, high dose, adult patients|
253331|NCT02265679|Drug|Placebo|
253332|NCT02265666|Drug|BIIL 284 BS Tablet FF|
253333|NCT02265666|Drug|BIIL 284 BS tablet C|
253336|NCT02265653|Drug|BIIL 284 BS tablet D|
253337|NCT02265653|Drug|BIIL 284 BS WIF tablet|
253338|NCT02265640|Drug|BIIL 284 BS boli|
253339|NCT02265640|Drug|BIIL 284 BS tablet C|
253340|NCT02265640|Other|standard breakfast|
253341|NCT02265627|Drug|BIIL 284 BS|
253342|NCT02265614|Genetic|PGS|
253343|NCT02265601|Other|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
253344|NCT02265601|Other|standard care|paper/pencil living will form
253345|NCT02265588|Behavioral|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
253346|NCT02265575|Drug|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
253347|NCT02265562|Drug|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
253348|NCT02265562|Drug|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
253349|NCT02265536|Drug|LY3022855|Administered IV
253350|NCT02265523|Other|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
253351|NCT02265510|Drug|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
253352|NCT02265510|Drug|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
253353|NCT02265510|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
253354|NCT02265510|Drug|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
253355|NCT02265510|Drug|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
253356|NCT02265510|Drug|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
253357|NCT02265510|Drug|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
253358|NCT02265510|Drug|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
253359|NCT02265510|Drug|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
253360|NCT02265510|Drug|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
253361|NCT02265510|Drug|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
253362|NCT02265510|Drug|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
253363|NCT02265484|Drug|Lactulose+Rifaximin +Bromocriptine|
253364|NCT02265458|Behavioral|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
253365|NCT02265445|Drug|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
253366|NCT02265445|Drug|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
253367|NCT02265432|Behavioral|General physical activity educational materials|
253368|NCT02265432|Device|Wearable activity tracking devices (fitbit)|
253369|NCT02265432|Other|online map|
253370|NCT02265432|Other|Personalized text messages|
253371|NCT02265419|Device|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
253372|NCT02265406|Drug|Anti-Infective Agents|
253373|NCT02265406|Drug|Placebo|
253374|NCT02265393|Drug|OTO-104|
253375|NCT02265393|Drug|Placebo|
253376|NCT02265380|Device|Placement of IV catheter|
253377|NCT02265367|Drug|Levomilnacipran|
253378|NCT02265367|Drug|Placebo|
253379|NCT02265354|Behavioral|Collective-Intelligence computer tailored health communication|
253380|NCT02265354|Behavioral|Rule-based computer tailored health communication|
253381|NCT02265341|Other|Laboratory Biomarker Analysis|Correlative studies
253382|NCT02265341|Drug|Ponatinib Hydrochloride|Given PO
253383|NCT02265341|Other|Quality-of-Life Assessment|Ancillary studies
253384|NCT02265328|Dietary Supplement|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
253385|NCT02265328|Dietary Supplement|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
253386|NCT02265328|Other|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. (If Lilli score > 0.45 after 7 days, then prednisolone would be stopped)
253387|NCT02265315|Other|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
253388|NCT02265315|Behavioral|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
253389|NCT02265302|Drug|BIIL 284 oral solution|
253390|NCT02265302|Drug|BIIL 284 wetability improved formulation (WIF) tablets|
253391|NCT02265302|Drug|Placebo|
253392|NCT02265289|Drug|Lefradafiban|
253393|NCT02265289|Drug|Clopidogrel|
253394|NCT02265276|Drug|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
253395|NCT02265276|Drug|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
253396|NCT02265250|Other|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
253397|NCT02265250|Other|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
253398|NCT02265250|Other|Laboratory blood test|Cardiovascular biomarkers
253399|NCT02265237|Drug|ombitasvir/paritaprevir/ritonavir|tablets
253402|NCT02265211|Behavioral|Self-Help App|
253403|NCT02265172|Procedure|Physiotherapy screening|Physiotherapy screening.
253404|NCT02265172|Procedure|Standard practice|Orthopaedic surgeon assessment
253405|NCT02265159|Procedure|Focal Therapy Using High Intensity Focused Ultrasound|
253406|NCT02265120|Behavioral|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
253407|NCT02265107|Other|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
253408|NCT02265094|Other|Electroencephalography|EEG recordings during memory tests
253409|NCT02265094|Behavioral|Neuropsychological assessment|patterns of eye gaze during cognitive tests
253410|NCT02265081|Procedure|ultrasound|pelvic floor ultrasound
253411|NCT02265081|Procedure|uroflow-meter|uroflow meter: measurement of passed urine volume
253412|NCT02265068|Drug|Ticagrelor|Treatment of ACS patients with Ticagrelor
253413|NCT02265055|Procedure|transfer early cleavage embryos|transfer early cleavage embryos
253414|NCT02265055|Procedure|transfer non early cleavage embryo|
253415|NCT02265042|Device|Stimulette|electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
253416|NCT02265029|Other|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
253417|NCT02265029|Other|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
253418|NCT02264990|Drug|Paclitaxel|Intravenous infusion
253419|NCT02264990|Drug|Pemetrexed|Intravenous infusion
253420|NCT02264990|Drug|Carboplatin|Intravenous infusion
253421|NCT02264990|Drug|Cisplatin|Intravenous infection
253422|NCT02264990|Drug|Veliparib|Oral Capsule
253423|NCT02264977|Device|Branched TAG® Device|
253424|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
253425|NCT02264964|Procedure|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
253426|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
253427|NCT02264964|Procedure|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
253428|NCT02264951|Dietary Supplement|Tributyrin|a triglyceride containing three C4-acids
253429|NCT02264951|Dietary Supplement|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
253430|NCT02264951|Dietary Supplement|Olive oil|a triglyceride containing mostly three oleic acids
253431|NCT02264951|Dietary Supplement|Carrot|mainly water and glucose
253432|NCT02264938|Dietary Supplement|Antioxidant|Oral supplemmentation with antioxidants
253433|NCT02264925|Device|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
253434|NCT02264912|Drug|antiplatelet drugs - P2Y12 antagonists|
253435|NCT02264899|Other|in Memento-VASCOD|"Pulse wave velocity assessment~Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences~Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement~Neuropsychological testing and behaviorial and mood scales~Urinary albumin excretion measurement"
253436|NCT02264886|Radiation|MRI-guided stereotactive body radiation therapy|
253437|NCT02264873|Drug|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
253438|NCT02264860|Dietary Supplement|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
253439|NCT02264847|Drug|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
253440|NCT02264847|Drug|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
253441|NCT02264834|Drug|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
253442|NCT02264834|Drug|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
253443|NCT02264834|Procedure|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
253444|NCT02264821|Drug|ropivacaine infiltration|wound infiltration
253445|NCT02264821|Drug|intrathecal morphine|100 µg added to the spinal anaesthesia
253446|NCT02264821|Drug|placebo|placebo in spinal anaesthesia and in wound infiltration
253447|NCT02264808|Other|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
253448|NCT02264795|Drug|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
253449|NCT02264795|Drug|Placebo|0.9% Sodium Chloride Solution
253450|NCT02264782|Other|Computer-Assisted Intervention|Complete PreView
253451|NCT02264782|Other|Computer-Assisted Intervention|Watch an educational video
253452|NCT02264782|Other|Questionnaire Administration|Ancillary studies
253453|NCT02264769|Drug|Carbetocin|
253454|NCT02264756|Other|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
253455|NCT02264743|Drug|Femoston Conti|Ultra-low-dose oral E2/D [Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg] oral Femoston Conti 0.5mg Estradiol&Dydrogesterone vs Oestradiol&Norethisterone acetate
253456|NCT02264743|Drug|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
253457|NCT02264730|Drug|ClotFoam|Patient has not received blood products between screenings
253458|NCT02264717|Procedure|SPECT|Patients are randomized to either SPECT or Cardiac MRI
253459|NCT02264717|Procedure|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
253460|NCT02264704|Other|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
253461|NCT02264704|Other|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
253462|NCT02264678|Drug|Administration of AZD6738 in combination with carboplatin|An oral formulation of AZD6738 will be used. In Module 1 Part A, patients will receive a single dose of AZD6738 on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive AZD6738 and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
253463|NCT02264678|Drug|Administration of AZD6738|An oral formulation of AZD6738 will be used. In Module 2 Part A1, patients will receive a single dose of AZD6738 on Day 1, followed by 4 to 6 days washout, before multiple dosing.
253464|NCT02264678|Drug|Administration of AZD6738 in combination with olaparib|An oral formulations of AZD6738 and olaparib will be used. In Module 2 Part A2, patients will receive a single dose of AZD6738 followed by 4 to 6 days washout, before multiple dosing with AZD6738 and olaparib. In Module 2 Part B, patients will receive AZD6738 and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2.
253465|NCT02264678|Drug|Administation of AZD6738 in combination with MEDI4736|An oral formulation of AZD6738 will be used. MEDI4736 is given via IV infusion. In Module 3 Part A patients will receive and initial single dose of AZD6738 on Day 1, followed by multiple dosing in combination with MEDI4736. In Module 3 Part B expansion cohorts will receive AZD6738 at the dose, frequency and schedule recommended from Module 3 Part A, in combination with MEDI4736.
253466|NCT02264665|Drug|sunitinib|sunitinib 37.5mg/d orally
253467|NCT02264665|Drug|everolimus|everolimus 10mg/d orally
253468|NCT02264665|Drug|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
253469|NCT02264652|Device|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
253470|NCT02264639|Drug|APL-2|Complement (C3) Inhibitor
253471|NCT02264626|Drug|Remifentanil|infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
253472|NCT02264613|Drug|ALRN-6924|ALRN-6924 will be administered as an IV infusion
253473|NCT02264587|Drug|Mosapride|Mosapride 5mg by mouth ,3 times one day for 1 4days.
253474|NCT02264587|Drug|domperidone|Domperidone 10mg by mouth ,3 times one day for 1 4days.
253475|NCT02264574|Drug|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
253476|NCT02264574|Drug|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
253477|NCT02264574|Drug|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
253478|NCT02264561|Other|Food|Active group
253479|NCT02264561|Other|Food|Control group
253480|NCT02264548|Radiation|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
253481|NCT02264535|Drug|0.1mg/ml Ginkgolides Meglumine Injection|
253482|NCT02264535|Drug|1mg/ml Ginkgolides Meglumine Injection|
253483|NCT02264535|Drug|5mg/ml Ginkgolides Meglumine Injection|
253484|NCT02264522|Other|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
253485|NCT02264522|Other|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
253486|NCT02264522|Other|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
253487|NCT02264522|Other|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
253488|NCT02264509|Procedure|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
253489|NCT02264496|Behavioral|Exercise|
253490|NCT02264470|Other|Not relevant|Not relevant
253491|NCT02264457|Device|T-flex Aspheric Toric IOL|
253492|NCT02264457|Device|AT TORBI toric IOL|
253493|NCT02264444|Other|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
253494|NCT02264418|Drug|ODM 203|ODM 203
253495|NCT02264418|Drug|ODM 203|ODM 203
253496|NCT02264392|Procedure|Ultrasound Guided Incision and Drainage|Ultrasound guidance of the abscess drainage
253497|NCT02264392|Procedure|Blind Incision and Drainage|Incision and drainage of abscess guided by physical exam alone
253498|NCT02264379|Radiation|normal fractionated irradiation|25*2 Gy (once a day, 5 days a week)
253499|NCT02264379|Radiation|hypo fractionated irradiation|3*10 Gy (once a day, 2-3 days a week)
253546|NCT02264106|Drug|Lefradafiban double chamber sachet|
253500|NCT02264366|Behavioral|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
253501|NCT02264353|Drug|Donepezil|Donepezil 10mg before sleep
253502|NCT02264353|Drug|placebo|One piece of placebo before sleep
253503|NCT02264340|Behavioral|Relaxation technique Autogenic Training|Autogenic Training
253504|NCT02264340|Behavioral|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
253505|NCT02264327|Behavioral|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
253506|NCT02264327|Behavioral|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
253507|NCT02264327|Behavioral|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
253508|NCT02264314|Behavioral|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
253509|NCT02264314|Other|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
253510|NCT02264301|Drug|Puerarin injection 400 mg|
253511|NCT02264301|Drug|Qingkailing injection 40 ml|
253512|NCT02264288|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
253513|NCT02264288|Biological|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
253514|NCT02264288|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
253515|NCT02264288|Other|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
253516|NCT02264275|Behavioral|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
253517|NCT02264262|Other|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
253518|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy split dose prep|"Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep~split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)"
253519|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
253520|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
253521|NCT02264236|Biological|P10s-PADRE vaccine|"P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Chemotherapy Subcutaneous injection at weeks 2, 3, 5, and 6. 3-Week Interval Immunotherapy Subcutaneous injection at weeks 2, 3, and 4. 2-Week Interval Immunotherapy Subcutaneous injection at weeks 3, 4, and 5."
253522|NCT02264223|Dietary Supplement|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
253523|NCT02264223|Dietary Supplement|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
253524|NCT02264210|Drug|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
253525|NCT02264197|Drug|BIBX 245 CL - fed|
253526|NCT02264197|Drug|BIBX 245 CL- fasted|
253527|NCT02264184|Drug|Tamsulosin|
253528|NCT02264184|Drug|Paroxetine|
253529|NCT02264171|Drug|Tamsulosin HCl|
253530|NCT02264171|Drug|Ketoconazole|
253531|NCT02264158|Drug|Telmisartan high|
253532|NCT02264158|Drug|Telmisartan low|
253533|NCT02264158|Drug|Lacidipine high|
253534|NCT02264158|Drug|Lacidipine low|
253535|NCT02264158|Drug|Placebo|
253536|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - low|
253537|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - medium|
253538|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - high|
253539|NCT02264145|Drug|Ethanolic Solution From Respimat®|
253540|NCT02264132|Drug|Pramipexole ER tablet|
253541|NCT02264132|Drug|Pramipexole IR tablet|
253542|NCT02264119|Drug|Lefradafiban tablet|
253543|NCT02264119|Drug|Pantoprazole tablet|
253544|NCT02264119|Device|Lefradafiban double chamber sachet|
253545|NCT02264106|Drug|Lefradafiban tablet|
253547|NCT02264106|Drug|Pantoprazole|
253554|NCT02264054|Drug|[14C]talsaclidine, oral|
253555|NCT02264054|Drug|[14C]talsaclidine, iv|
253556|NCT02264041|Drug|Cilobradine, low dose|
253557|NCT02264041|Drug|Cilobradine, high dose|
253558|NCT02264041|Drug|Itraconazole|
253559|NCT02264028|Drug|[14C]-DK-AH 269 CL, solution for infusion|
253560|NCT02264028|Drug|[14C]-DK-AH 269 CL, drinking solution|
253561|NCT02264015|Drug|Cilobradine, low, film-coated tablets|
253562|NCT02264015|Drug|Cilobradine, high, film-coated tablets|
253563|NCT02264015|Drug|Placebo, film-coated tablets|
253564|NCT02264015|Drug|Moxifloxacin, film-coated tablets|
253565|NCT02264002|Drug|Cilobradine low dose 1|
253566|NCT02264002|Drug|Cilobradine low dose 2|
253567|NCT02264002|Drug|Cilobradine medium dose|
253568|NCT02264002|Drug|Cilobradine high dose 1|
253569|NCT02264002|Drug|Cilobradine high dose 2|
253570|NCT02264002|Drug|Metoprolol succinate tablets|
253571|NCT02264002|Drug|Placebo|
253572|NCT02263989|Drug|Telmisartan film coated tablet|
253573|NCT02263989|Drug|Telmisartan conventional tablet|
253574|NCT02263976|Drug|BEA 2180 BR|
253575|NCT02263976|Drug|Placebo|
253576|NCT02263976|Device|Respimat® A 4|
253577|NCT02263976|Drug|Methacholine Chloride|methacholine challenge test
253578|NCT02263976|Drug|Spiriva|
253579|NCT02263963|Drug|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
253580|NCT02263963|Procedure|TAP Block|no intervention will be done to this arm.
253581|NCT02263950|Drug|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
253582|NCT02263937|Procedure|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
253583|NCT02263937|Procedure|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
253584|NCT02263924|Dietary Supplement|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
253585|NCT02263924|Dietary Supplement|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
253586|NCT02263911|Drug|Baricitinib|Administered orally
253587|NCT02263898|Drug|Raf kinase inhibitor LGX818|Given PO
253588|NCT02263898|Drug|binimetinib|Given PO
253589|NCT02263898|Other|laboratory biomarker analysis|Correlative studies
253590|NCT02263885|Device|ExAblate Transcranial System|Transcranial MRgFUS
253591|NCT02263872|Drug|Minocycline|Minocycline 200mg perday
253592|NCT02263859|Device|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
253593|NCT02263833|Drug|Mircera|Participants received Mircera according to individualized physician-prescribed regimen.
253594|NCT02263807|Procedure|MPFL Group|MPFL reconstruction or standard treatment followed by physiotherapy
253595|NCT02263807|Procedure|Control|Arthroscopy followed by active rehabilitation
253596|NCT02263794|Procedure|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
253597|NCT02263794|Procedure|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
253598|NCT02263781|Procedure|Blood draw|Blood draw
253599|NCT02263781|Procedure|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
253600|NCT02263768|Procedure|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
253601|NCT02263742|Behavioral|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
253602|NCT02263742|Behavioral|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
253603|NCT02263729|Drug|Losartan|
253604|NCT02263729|Drug|placebo|
253605|NCT02263703|Biological|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
253606|NCT02263690|Procedure|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
253607|NCT02263690|Procedure|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
253608|NCT02263690|Procedure|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
253609|NCT02263677|Drug|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
253644|NCT02263352|Drug|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
253610|NCT02263651|Procedure|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.~Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.~The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
253611|NCT02263651|Procedure|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.~The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
253612|NCT02263638|Drug|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
253613|NCT02263586|Behavioral|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
253614|NCT02263573|Other|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.~Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.~Session 2 Session 17: increase in the burden of BASE (5 BASE * 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC * 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).~Session 18 = Session 1."
253615|NCT02263573|Other|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
253616|NCT02263560|Behavioral|Kinematic measurements|
253617|NCT02263547|Drug|teriflunomide|
253618|NCT02263547|Drug|Colestipol|
253619|NCT02263534|Procedure|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
253620|NCT02263534|Procedure|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
253621|NCT02263521|Other|No intervention employed. Study is based on a cross-sectional observational design.|
253622|NCT02263508|Drug|talimogene laherparepvec|Phase 1b: talimogene laherparepvec will be administered by intralesional injection at Day 1, Week -5; then every 2 weeks starting at Day 1, Week -2; Phase 3, Arm 1 talimogene laherparepvec will be administered by intralesional injection at Day 1 Week 0, 3, 5, 7 then every 3 weeks starting at Day 1 Week 9.
253623|NCT02263508|Drug|pembrolizumab (MK-3475)|Phase 1b: pembrolizumab will be administered intravenously every 2 weeks starting at Day 1 Week 0; Phase 3, Arm 1 and Arm 2 pembrolizumab will be administered intravenously on Day 1 Week 0, then every 3 weeks starting at Day 1 Week 3.
253624|NCT02263508|Drug|placebo|Phase 3, Arm 2 placebo will be administered by intralesional injection at Day 1 Week 0, 3, 5, 7 then every 3 weeks starting at Day 1 Week 9.
253625|NCT02263495|Drug|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
253626|NCT02263495|Drug|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
253627|NCT02263495|Drug|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
253628|NCT02263482|Other|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
253629|NCT02263482|Other|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
253630|NCT02263482|Other|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
253631|NCT02263469|Biological|Replenine®-VF (High Purity Factor IX)|
253632|NCT02263456|Biological|Replenine®-VF (High Purity Factor IX)|
253633|NCT02263443|Procedure|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
253634|NCT02263443|Procedure|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
253635|NCT02263443|Procedure|No enema|Patients NPO groups will NPO and no bowel preparation.
253636|NCT02263430|Device|Deep Brain Stimulation|
253637|NCT02263417|Device|Deep Brain Stimulation (DBS) of Gpi|
253638|NCT02263417|Device|Deep Brain Stimulation (DBS) of STN|
253639|NCT02263404|Device|Deep Brain Stimulation|DBS Implant Stimulation
253640|NCT02263391|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
253641|NCT02263391|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
253642|NCT02263378|Drug|ellagic acid + annona muricata|pills
253643|NCT02263365|Drug|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
253725|NCT02262754|Drug|Naproxen|500 mg BID for 4 weeks
253645|NCT02263352|Device|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
253646|NCT02263339|Behavioral|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
253647|NCT02263339|Behavioral|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
253648|NCT02263339|Behavioral|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
253649|NCT02263326|Drug|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
253650|NCT02263326|Drug|lamivudine|300 mg tablet by mouth once daily for 48 weeks
253651|NCT02263326|Drug|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
253652|NCT02263313|Other|EGO-COMBO group|Assess the safety and effectiveness of Combo stent
253653|NCT02263287|Other|LeSCoD scale|LeSCoD is a clinical scale
253654|NCT02263274|Device|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
253655|NCT02263261|Other|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
253656|NCT02263248|Drug|venlafaxine|slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
253657|NCT02263248|Drug|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
253658|NCT02263248|Drug|placebo|patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
253659|NCT02263235|Biological|administration of stable isotope-labelled leucine-|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
253660|NCT02263235|Other|collection of CSF, blood, urine, saliva|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
253661|NCT02263222|Drug|MDT-10013|
253662|NCT02263209|Device|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
253663|NCT02263209|Device|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
253664|NCT02263196|Other|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
253665|NCT02263196|Other|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
253666|NCT02263183|Dietary Supplement|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
253667|NCT02263183|Dietary Supplement|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
253668|NCT02263170|Other|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
253669|NCT02263170|Other|US (ultra sound)|Assessment of the sphincter morphology
253670|NCT02263170|Other|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
253671|NCT02263170|Other|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
253672|NCT02263144|Procedure|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
253673|NCT02263131|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
253674|NCT02263131|Biological|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
253675|NCT02263118|Other|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
253676|NCT02263118|Device|Feature phone|Participants were given a feature phone.
253677|NCT02263118|Other|Virtual communities|Exposure to virtual community communication via SMS
253678|NCT02263118|Other|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
253679|NCT02263105|Drug|CDDP|
253680|NCT02263105|Drug|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
253722|NCT02262767|Drug|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
253724|NCT02262754|Drug|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
253681|NCT02263092|Behavioral|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
253682|NCT02263092|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
253683|NCT02263092|Behavioral|Rest|15 or 30 minutes seat without move the legs
253684|NCT02263079|Drug|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
253685|NCT02263079|Drug|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
253686|NCT02263079|Drug|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m^2) BSA.
253687|NCT02263066|Biological|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
253688|NCT02263053|Procedure|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
253689|NCT02263053|Procedure|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
253690|NCT02263040|Biological|Fluzone High-Dose|Influenza vaccine
253691|NCT02263040|Biological|Fluzone (standard dose)|Influenza vaccine
253692|NCT02263027|Biological|Vaccine|Licensed trivalent inactivated influenza vaccine
253693|NCT02263014|Behavioral|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
253694|NCT02263001|Other|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
253695|NCT02263001|Other|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
253696|NCT02262988|Procedure|Autologous cells and total knee arthroplasty|
253697|NCT02262988|Procedure|Standard total knee arthroplasty surgery|
253698|NCT02262962|Other|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
253699|NCT02262949|Device|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
253700|NCT02262936|Drug|Desmopressin|
253701|NCT02262936|Drug|Fesoterodine|
253702|NCT02262923|Drug|metoclopramide|
253703|NCT02262910|Biological|ES414|ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
253704|NCT02262897|Drug|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
253705|NCT02262884|Device|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
253706|NCT02262884|Device|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
253707|NCT02262871|Device|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
253708|NCT02262871|Device|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
253709|NCT02262858|Drug|Telmisartan and HCTZ|
253710|NCT02262858|Drug|Telmisartan|
253711|NCT02262858|Drug|HCTZ|
253712|NCT02262845|Device|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
253713|NCT02262832|Drug|Metreleptin|administered subcutaneously 1-2 times/day.
253714|NCT02262819|Drug|S. aureus|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
253715|NCT02262806|Drug|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
253716|NCT02262793|Drug|telmisartan|
253717|NCT02262793|Drug|ASA/ER-DP|
253718|NCT02262780|Drug|Low dose of telmisartan|
253719|NCT02262780|Drug|High dose of telmisartan|
253720|NCT02262780|Drug|HCTZ|
253721|NCT02262767|Drug|PF-06649751|Experimental Pfizer compound.
253723|NCT02262754|Drug|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
253792|NCT02262325|Drug|etoposide|Given IV
253726|NCT02262741|Biological|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
253727|NCT02262741|Biological|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
253728|NCT02262728|Drug|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
253729|NCT02262728|Drug|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
253730|NCT02262728|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
253731|NCT02262715|Drug|VX-787|Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
253732|NCT02262715|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
253733|NCT02262715|Other|Placebo|Participants will receive placebo matching to VX-787 either two times a day or or once a day.
253734|NCT02262702|Drug|Paracetamol 665 mg|Paracetamol 665 mg tablet
253735|NCT02262702|Drug|Paracetamol 500 mg|Paracetamol 500 mg tablet
253736|NCT02262689|Drug|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
253737|NCT02262689|Drug|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
253738|NCT02262676|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
253739|NCT02262663|Drug|Vilaprisan (BAY1002670)|
253740|NCT02262650|Drug|Telmisartan|
253741|NCT02262650|Drug|Clopidogrel|
253742|NCT02262637|Drug|Micardis®|
253743|NCT02262637|Drug|MicardisPlus®|
253744|NCT02262624|Drug|Telmisartan|
253745|NCT02262624|Drug|Hydrochlorthiazide (HCTZ)|
253746|NCT02262624|Drug|Telmisartan/HCTZ fixed combination|
253747|NCT02262611|Drug|Micardis®|
253748|NCT02262611|Drug|MicardisPlus®|
253749|NCT02262598|Drug|Telmisartan|
253750|NCT02262598|Drug|Hydrochlorthiazide (HCTZ)|
253751|NCT02262598|Drug|Telmisartan/HCTZ fixed dose|
253752|NCT02262585|Drug|BIBR 277 tablet|
253753|NCT02262585|Drug|BIBR 277 capsule|
253754|NCT02262572|Drug|Telmisartan /HCTZ - compression tablet (DC)|
253755|NCT02262572|Drug|Telmisartan /HCTZ - dry granulation tablet (DG)|
253756|NCT02262572|Drug|Telmisartan /HCTZ - present commercial formulation|
253757|NCT02262559|Drug|BIBR 277 tablet|
253758|NCT02262559|Drug|BIBR 277 capsule|
253759|NCT02262546|Drug|Pramipexole extended-release (ER) tablets|
253760|NCT02262546|Drug|Pramipexole immediate-release (IR) tablets|
253761|NCT02262546|Drug|Moxifloxacin|
253762|NCT02262546|Drug|Pramipexole Placebo|
253763|NCT02262546|Drug|Moxifloxacin Placebo|
253764|NCT02262533|Drug|Apixaban|
253765|NCT02262533|Drug|Atenolol|
253766|NCT02262520|Drug|Apixaban|
253767|NCT02262520|Drug|Digoxin|
253768|NCT02262507|Device|Q Collar|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins
253769|NCT02262494|Procedure|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
253770|NCT02262494|Procedure|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
253771|NCT02262494|Procedure|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
253772|NCT02262481|Drug|dydrogesterone|
253773|NCT02262481|Drug|placebo|
253774|NCT02262468|Radiation|x ray|
253775|NCT02262455|Drug|STM 434|STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
253776|NCT02262455|Drug|Liposomal doxorubicin|Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
253777|NCT02262442|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
253778|NCT02262442|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
253779|NCT02262429|Other|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
253780|NCT02262429|Other|ONS Standard Feeding|Standard of care
253781|NCT02262416|Drug|leuprolide|normal saline
253782|NCT02262403|Other|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
253783|NCT02262390|Procedure|Partner Notification Reminders|"For all 3 arms, the following will be done:~All participants will have an antenatal clinic visit every 4 weeks until delivery.~All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
253784|NCT02262377|Behavioral|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
253785|NCT02262364|Biological|APS|See above
253786|NCT02262351|Other|30 Second Pulse Check|To detect atrial fibrillation
253787|NCT02262351|Device|Watch BP Home A|Blood pressure device that detects atrial fibrillation
253788|NCT02262351|Device|HeartCheck Hand-held ECG device|To detect atrial fibrillation
253789|NCT02262338|Drug|AGT-182|Recombinant HIRMAb-IDS
253790|NCT02262325|Radiation|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
253791|NCT02262325|Drug|cisplatin|Given IV
253793|NCT02262325|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
253794|NCT02262325|Other|laboratory biomarker analysis|Correlative studies
253795|NCT02262312|Other|Transient elastography|All patients will have a transient elastography performed as a measure of liver stiffness.
253796|NCT02262299|Drug|Pirfenidone|Receive tablets with pirfenidone
253797|NCT02262299|Drug|Placebo|Recieve tablets with placebo
253798|NCT02262273|Other|Data Collection|Colleciton of data from medical records only
253799|NCT02262260|Drug|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
253800|NCT02262260|Drug|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
253801|NCT02262234|Other|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
253802|NCT02262234|Other|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
253803|NCT02262221|Other|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
253804|NCT02262208|Other|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.~Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
253805|NCT02262208|Other|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
253806|NCT02262208|Device|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
253807|NCT02262195|Other|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
253808|NCT02262182|Other|KP group|
253809|NCT02262182|Other|KM group|
253810|NCT02262169|Drug|Omeprazole|2 Omeprazole capsules 20 mg, once daily
253811|NCT02262169|Drug|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
253812|NCT02262169|Drug|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
253813|NCT02262169|Drug|Placebo capsule of Omeprazole|2 placebo capsules of Omeprazole, once daily
253814|NCT02262156|Other|Cognitive behavioral therapy|"The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.~The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention"
253815|NCT02262156|Drug|SSRI|"Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned."
253816|NCT02262143|Drug|Rosuvastatin|Rosuvastatin 10 mg, qd, po
253817|NCT02262143|Drug|Fenofibrate|Fenofibrate 160mg, qd, po
253818|NCT02262130|Drug|Omalizumab|
253819|NCT02262117|Other|standard care|No specific medical care
253820|NCT02262117|Drug|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
253821|NCT02262104|Behavioral|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
253822|NCT02262104|Behavioral|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
253823|NCT02262091|Dietary Supplement|Food fibers|
253824|NCT02262091|Dietary Supplement|Maltodextrin|
253825|NCT02262091|Biological|Influenza vaccine (incl. criterion)|
253826|NCT02262078|Drug|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
253827|NCT02262078|Other|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
253828|NCT02262052|Other|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
253829|NCT02262039|Device|Valveless recirculating insufflation (VTI)|10 mmHg target pressure
253830|NCT02262039|Device|Conventional pressure|15 mmHg target pressure
253831|NCT02262026|Drug|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
253832|NCT02262026|Drug|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
253833|NCT02262026|Drug|Placebo|Placebo
253834|NCT02262013|Behavioral|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
253835|NCT02262013|Behavioral|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
253836|NCT02262000|Radiation|Image Guided Stereotatic Ablative Radiotherapy|
253837|NCT02261987|Other|Autogenic drainage (AD)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
253838|NCT02261987|Other|Resistive inspiratory manoeuvre (RIM)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
253839|NCT02261987|Other|Resistive inspiratory manoeuvre+autogenic drainage|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
253840|NCT02261974|Device|Active Treatment Viveve|Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus
253841|NCT02261974|Device|Sham Treatment Viveve|Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus
253842|NCT02261961|Biological|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
253843|NCT02261961|Other|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
253844|NCT02261961|Other|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
253845|NCT02261961|Other|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
253846|NCT02261961|Dietary Supplement|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
253847|NCT02261961|Dietary Supplement|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
253848|NCT02261948|Drug|Levosimendan|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
253849|NCT02261948|Drug|Placebo|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
253850|NCT02261935|Other|Existing home care nursing practice|"Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done."
253851|NCT02261935|Other|Practice support tool intervention|"The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.~The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.~Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs."
253852|NCT02261922|Drug|ticagrelor|
253853|NCT02261922|Drug|prasugrel|
253854|NCT02261896|Drug|Placebo|Evaluate usefullness of antibiotic prophylaxis
253855|NCT02261896|Drug|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
253856|NCT02261883|Drug|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
253857|NCT02261883|Drug|Placebo|matching placebo
253858|NCT02261870|Device|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
253859|NCT02261857|Device|Personalized continuous positive airway pressure (CPAP) mask|Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
253860|NCT02261844|Dietary Supplement|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
253861|NCT02261844|Drug|Placebo|Placebo 1 pill daily X 10 days
253862|NCT02261831|Other|obese patients|collection of blood sampling and biopsies
253863|NCT02261831|Other|diabetic patients|collection of blood sampling and biopsies
253864|NCT02261831|Other|patients free of obesity and diabetes|collection of blood sampling and biopsies
253865|NCT02261831|Other|patients free type 2 diabetes|collection of blood sampling and biopsies
253866|NCT02261818|Behavioral|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
253867|NCT02261805|Drug|Ganetespib|
253868|NCT02261805|Drug|Doxorubicin|
253869|NCT02261792|Procedure|24 hours Trendelenburg position|Trendelenburg position
253870|NCT02261792|Procedure|24 hours bed rest|24 hours bed rest after EBP
253871|NCT02261792|Procedure|EBP|Autologous Epidural Blood Patch
253872|NCT02261779|Drug|Tranylcypromine|
253873|NCT02261779|Drug|Tretinoin|
253874|NCT02261766|Device|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
253875|NCT02261753|Dietary Supplement|Classical ketogenic diet|A high fat low carbohydrate, low protein diet.
253876|NCT02261740|Behavioral|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).~Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
253877|NCT02261727|Drug|Theophylline|Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
253878|NCT02261727|Drug|Prednisone|Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
253879|NCT02261727|Drug|Placebo (for prednisone)|"Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily"
253880|NCT02261727|Drug|Placebo (for Theophylline)|One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
253881|NCT02261714|Biological|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
253882|NCT02261714|Biological|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.~TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.~Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
253883|NCT02261701|Other|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
253884|NCT02261701|Other|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
253885|NCT02261688|Dietary Supplement|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
253886|NCT02261688|Dietary Supplement|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
253887|NCT02261688|Dietary Supplement|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
253888|NCT02261675|Drug|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
253889|NCT02261662|Drug|Ribavirin|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.~It will be used along with Topical steroids; Betamethasone"
253890|NCT02261662|Drug|Betamethasone|Topical Steroids alone will be used; Betamethasone
253891|NCT02261649|Device|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
253892|NCT02261649|Procedure|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
253893|NCT02261649|Device|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
253894|NCT02261649|Other|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
253895|NCT02261636|Drug|mesalazine|
253896|NCT02261623|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
253897|NCT02261623|Device|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
253898|NCT02261623|Device|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
253899|NCT02261610|Procedure|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
253900|NCT02261597|Behavioral|Cold Pressor Test|Repeated immersion of hand in ice-cold water
253901|NCT02261584|Device|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
253902|NCT02261584|Device|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
253903|NCT02261571|Other|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.~The moxibustion will be removed when the patient feel hotness and require remove them"
253904|NCT02261558|Other|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
253905|NCT02261558|Other|Clinical Vocal Improvisation|* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
253906|NCT02261545|Dietary Supplement|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
253907|NCT02261545|Dietary Supplement|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
253908|NCT02261532|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
253909|NCT02261519|Drug|NaBen®|500 mg twice daily (1000 mg total)
253910|NCT02261519|Other|Placebo|0 mg twice daily (0 mg total)
253911|NCT02261506|Other|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
253912|NCT02261506|Other|14 days of adequate antibiotic treatment durations|
253913|NCT02261493|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
253914|NCT02261493|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
253915|NCT02261480|Other|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
253916|NCT02261480|Other|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
253917|NCT02261467|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
253918|NCT02261467|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
253919|NCT02261454|Other|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
253920|NCT02261441|Other|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
253921|NCT02261428|Device|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
253922|NCT02261428|Device|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
253923|NCT02261415|Drug|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
253924|NCT02261415|Drug|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
253925|NCT02261402|Other|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
253926|NCT02261389|Other|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
253927|NCT02261376|Drug|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
253928|NCT02261350|Dietary Supplement|Food fortification|
253929|NCT02261350|Dietary Supplement|Oral Nutritional Supplements|
253930|NCT02261311|Other|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
253931|NCT02261298|Drug|ONO-4538|
253932|NCT02261285|Drug|ONO-4538|
253933|NCT02261272|Behavioral|CBT for insomnia SHUTi|SHUTi
253934|NCT02261272|Behavioral|passive patient education/sleep hygiene|
253935|NCT02261259|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
253936|NCT02261246|Procedure|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
253937|NCT02261233|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
253938|NCT02261220|Biological|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
253939|NCT02261220|Biological|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
253940|NCT02261207|Drug|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
253941|NCT02261194|Behavioral|Self-Care Tools|
254000|NCT02260882|Biological|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
254032|NCT02260674|Drug|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
254033|NCT02260674|Drug|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
253942|NCT02261181|Device|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
253943|NCT02261168|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
253944|NCT02261155|Procedure|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
253945|NCT02261142|Device|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
253946|NCT02261129|Drug|Telmisartan film-coated tablet|
253947|NCT02261129|Drug|Telmisartan uncoated tablet|
253948|NCT02261116|Drug|Telmisartan|
253949|NCT02261116|Drug|Candesartan|
253950|NCT02261116|Drug|Placebo|
253951|NCT02261103|Drug|Pramipexole ER tablets|
253952|NCT02261103|Drug|Pramipexole IR tablets|
253953|NCT02261103|Drug|Placebo matching Pramipexole ER tablets|
253954|NCT02261103|Drug|Placebo matching Pramipexole IR tablets|
253955|NCT02261103|Other|Standard high-fat breakfast|
253956|NCT02261090|Drug|Formulation B: Pramipexole Slow release (SR) tablet|
253957|NCT02261090|Drug|Formulation C: Pramipexole Slow release tablet|
253958|NCT02261090|Drug|Formulation D: Pramipexole Slow release tablet|
253959|NCT02261090|Drug|Formulation E: Pramipexole Slow release tablet|
253960|NCT02261090|Drug|Formulation F: Pramipexole Slow release tablet|
253961|NCT02261090|Drug|Formulation G: Pramipexole Slow release tablet|
253962|NCT02261090|Drug|Formulation H: Pramipexole Slow release tablet|
253963|NCT02261090|Drug|Pramipexole immediate release (IR) tablets|
253964|NCT02261077|Drug|Hyoscine butylbromide|
253965|NCT02261077|Drug|Placebo|
253966|NCT02261064|Drug|Telmisartan/Amlodipine low dose|
253967|NCT02261064|Drug|Telmisartan/Amlodipine high dose|
253968|NCT02261064|Other|Japanese meal|
253969|NCT02261051|Other|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
253970|NCT02261038|Other|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
253971|NCT02261025|Drug|acetylsalicylic acid|75-100mg,per day
253972|NCT02260986|Drug|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
253973|NCT02260986|Drug|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
253974|NCT02260986|Other|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
253975|NCT02260973|Dietary Supplement|Omega-3 (Triglyceride form)|
253976|NCT02260960|Dietary Supplement|Omega-3 (Triglyceride form)|
253977|NCT02260947|Drug|PF-06273340|PF-06273340 50 mg
253978|NCT02260947|Drug|PF-06273340|PF-06273340 400 mg
253979|NCT02260947|Drug|Pregabalin|Pregabalin 300 mg
253980|NCT02260947|Drug|Ibuprofen|Ibuprofen 600 mg
253981|NCT02260947|Drug|Placebo|Matching Placebo
253982|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
253983|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
253984|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
253985|NCT02260934|Drug|Methylprednisolone|"Week 0 and Week 2:~Solumedrol (100 mg) IV"
253986|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
253987|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
253988|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
253989|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
253990|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~Continue prednisone 10 mg/day to week 96"
253991|NCT02260934|Drug|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
253992|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
253993|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
253994|NCT02260934|Biological|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
253995|NCT02260921|Device|iovera°|
253996|NCT02260921|Device|Sham Comparator|
253997|NCT02260908|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
253998|NCT02260908|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
253999|NCT02260895|Dietary Supplement|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
254072|NCT02260388|Drug|Nortriptyline|
254001|NCT02260869|Procedure|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
254002|NCT02260869|Device|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
254003|NCT02260856|Device|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
254004|NCT02260856|Procedure|Percutaneous Drill Epiphysiodesis|
254005|NCT02260856|Procedure|Percutaneous Screw Epiphysiodesis|
254006|NCT02260843|Other|Generic Fitness|Participants in this groups will receive three fitness lessons in a weeks while each session last for 1 hour for 12 weeks
254007|NCT02260843|Other|Tai Chi Intervention|Subjects in this groups will receive three tai chi lessons in a weeks while each session last for 1 hour for 12 weeks
254008|NCT02260830|Drug|Lu AF11167|
254009|NCT02260817|Drug|11C-choline Injection|"Choline C11 Injection for PET/CT Imaging Protocol:~15 - millicuries (mCi) 11C-choline IV Injection~PET images skull base to mid thigh with 3 min per bed position~Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~Fusion of PET and CT images~Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~No IV contrast~High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~Fusion of coronal and PET images"
254010|NCT02260804|Biological|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
254011|NCT02260804|Biological|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
254012|NCT02260791|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
254013|NCT02260791|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
254014|NCT02260778|Behavioral|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
254015|NCT02260765|Device|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
254016|NCT02260752|Procedure|hysterectomy|surgical removal of the uterus
254017|NCT02260752|Procedure|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
254018|NCT02260752|Procedure|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
254019|NCT02260752|Drug|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
254020|NCT02260752|Procedure|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
254021|NCT02260752|Procedure|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
254022|NCT02260752|Procedure|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
254023|NCT02260739|Other|Blood samples|
254024|NCT02260726|Procedure|Magnetic resonance imaging|
254025|NCT02260726|Procedure|Ultrasound|
254026|NCT02260713|Biological|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
254027|NCT02260700|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
254028|NCT02260700|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
254029|NCT02260700|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
254030|NCT02260687|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
254031|NCT02260674|Drug|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
254073|NCT02260388|Drug|Duloxetine|
254034|NCT02260661|Drug|AZD8835|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
254035|NCT02260661|Drug|AZD8835|AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
254036|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
254037|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
254038|NCT02260648|Drug|Evacetrapib|Administered orally
254039|NCT02260648|Drug|Ezetimibe|Administered orally
254040|NCT02260648|Drug|Atorvastatin|Administered orally
254041|NCT02260648|Drug|Placebo|Administered orally
254042|NCT02260635|Drug|Evacetrapib|Administered orally
254043|NCT02260635|Drug|Placebo|Administered orally
254044|NCT02260622|Drug|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
254045|NCT02260622|Drug|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
254046|NCT02260609|Other|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.~Patients will be treated for up to 16 weeks.~Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
254047|NCT02260583|Device|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
254048|NCT02260570|Drug|Tolcapone|COMT Inhibitor
254049|NCT02260570|Drug|Placebo|A pill that contains no active ingredient
254050|NCT02260557|Drug|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
254051|NCT02260557|Drug|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
254052|NCT02260544|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
254053|NCT02260531|Drug|Cabozantinib|One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
254054|NCT02260531|Drug|Trastuzumab|For HER2-Positive participants only. Administered by IV on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
254055|NCT02260518|Behavioral|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
254056|NCT02260518|Behavioral|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
254057|NCT02260505|Drug|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
254058|NCT02260492|Drug|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
254059|NCT02260492|Drug|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
254060|NCT02260492|Drug|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
254061|NCT02260479|Procedure|Preheated|Skin disinfection solution is preheated in a warming cupboard
254062|NCT02260466|Other|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
254063|NCT02260453|Other|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
254064|NCT02260453|Other|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
254065|NCT02260440|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
254066|NCT02260440|Drug|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
254067|NCT02260427|Device|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
254068|NCT02260427|Device|Insertion of the air-Q sp|
254069|NCT02260414|Drug|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
254070|NCT02260414|Other|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
254071|NCT02260401|Other|Individualized report|Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
254076|NCT02260375|Biological|Mesenchymal Stromal Cells|
254077|NCT02260349|Drug|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
254078|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 1g|
254079|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 5g|
254080|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 10g|
254081|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 15g|
254082|NCT02260336|Drug|Celecoxib Capsule 400 mg daily|
254083|NCT02260323|Other|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
254084|NCT02260323|Other|patient-tailored DMARDs|patient use tailored disease-modifying antirheumatic drugs
254085|NCT02260310|Other|Weizhong and Huantiao|
254086|NCT02260310|Other|A-shi point|
254087|NCT02260297|Device|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
254088|NCT02260284|Other|Yaotong points acupuncture|Patients receive the treatments of Yaotong points penetration
254089|NCT02260284|Other|the usual care|participants received no study-related care-just the care, if any, that they and their physicians chose: mostly massage and physical therapy visits and continued use of medications (mostly nonsteroidal anti-inflammatory drugs (NSAIDS))
254090|NCT02260284|Other|standardized acupuncture|Patients were given to the standardized acupuncture groups. This prescription included six acupuncture points that are commonly applied for the treatment of CLBP (Bladder 23-bilateral, Bladder 40-bilateral, and Kidney 3-bilateral) on the low back and lower leg.
254091|NCT02260271|Other|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
254092|NCT02260258|Drug|Rocuronium|Neuromuscular Blockade
254093|NCT02260258|Drug|Normal Saline|Normal Saline
254094|NCT02260245|Behavioral|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
254095|NCT02260232|Other|exercise training|
254096|NCT02260219|Procedure|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
254097|NCT02260206|Drug|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
254098|NCT02260193|Drug|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
254099|NCT02260193|Drug|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
254100|NCT02260193|Drug|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
254101|NCT02260180|Drug|A-101|Topical Solution
254102|NCT02260167|Other|A mix of natural treatments and medications|
254103|NCT02260154|Drug|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
254104|NCT02260141|Dietary Supplement|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
254105|NCT02260128|Other|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
254106|NCT02260115|Device|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
254107|NCT02260115|Procedure|Surgical Control|Surgery only
254108|NCT02260102|Drug|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations [no change due to enrollment in the study]).
254109|NCT02260089|Drug|Low dose of telmisartan|
254110|NCT02260089|Drug|High dose of telmisartan|
254111|NCT02260089|Drug|Placebo|
254112|NCT02260076|Drug|PEG 400|
254113|NCT02260076|Drug|Placebo|
254114|NCT02260063|Drug|Epinastine syrup|
254115|NCT02260063|Drug|Epinastine tablets|
254116|NCT02260050|Drug|WAL 801 CL dry syrup new formulation|
254117|NCT02260050|Drug|WAL 801 CL dry syrup conventional formulation|
254118|NCT02260037|Drug|Epinastine nasal|
254119|NCT02260037|Drug|Placebo|
254120|NCT02260024|Other|High fat, high caloric meal|
254121|NCT02260024|Drug|Pramipexole IR tablets|
254122|NCT02260024|Drug|Pramipexole SR C|
254123|NCT02260024|Drug|Pramipexole SR C2|
254124|NCT02260024|Drug|Pramipexole SR C2A|
254125|NCT02260024|Drug|Pramipexole SR C2B|
254126|NCT02260011|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
254127|NCT02260011|Drug|Atrovent® CFC inhalation aerosol|
254128|NCT02260011|Drug|Placebo|
254129|NCT02259998|Drug|Persantin® new formulation|
254130|NCT02259998|Drug|Persantin® commercial formulation|
254131|NCT02259985|Drug|Itasetron tablet|
254132|NCT02259985|Drug|Itasetron infusion|
254133|NCT02259985|Other|high fat breakfast|
254134|NCT02259972|Drug|BI 113823 solution|
254135|NCT02259972|Drug|BI 113823 tablet|
254136|NCT02259972|Drug|Placebo|
254137|NCT02259972|Other|High fat, high calorie breakfast|only for dose group 5
254138|NCT02259959|Drug|Single rising doses of BI 1744 CL, solution for oral inhalation|
254139|NCT02259959|Drug|Tiotropium, fixed dose, solution for oral inhalation|
254140|NCT02259959|Drug|Placebo|
254141|NCT02259946|Drug|BI 1744 CL|
254142|NCT02259946|Drug|Placebo|
254143|NCT02259946|Drug|Tiotropium bromide|
254144|NCT02259933|Drug|KUC 7483 CL|
254145|NCT02259933|Drug|Placebo|
254146|NCT02259920|Drug|KUC 7483 CL, immediate release tablet|
254147|NCT02259920|Drug|KUC 7483 CL, particulate formulation|
254148|NCT02259920|Drug|KUC 7483 CL, solution formulation|
254149|NCT02259920|Device|Enterion™ capsule|
254150|NCT02259907|Drug|KUC 7483 CL|
254151|NCT02259907|Drug|Placebo|
254152|NCT02259907|Other|High fat meal|
254153|NCT02259894|Drug|BIRT 2584 XX|
254154|NCT02259894|Drug|Placebo|
254155|NCT02259881|Drug|Low dose of BIBT 986 CL, per i.v. infusion|
254156|NCT02259881|Drug|Medium dose of BIBT 986 CL, per i.v. infusion|
254157|NCT02259881|Drug|High dose of BIBT 986 CL, per i.v. infusion|
254158|NCT02259881|Drug|Placebo|
254159|NCT02259881|Drug|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
254160|NCT02259868|Drug|BILR 355 BS /1B, current low dose formulation|
254161|NCT02259868|Drug|BILR 355 BS /1B, current high dose formulation|
254162|NCT02259868|Drug|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
254163|NCT02259868|Drug|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
254164|NCT02259868|Drug|BILR 355 BS - Suspension low dose|
254165|NCT02259868|Drug|BILR 355 BS - Suspension high dose|
254166|NCT02259868|Drug|Ritonavir|
254167|NCT02259855|Drug|Tipranavir|
254168|NCT02259855|Drug|Ritonavir|
254169|NCT02259855|Drug|Pegylated interferon|
254170|NCT02259855|Drug|Ribavirin|
254171|NCT02259842|Drug|BI 34021 FU2 solution|
254172|NCT02259842|Drug|BI 34021 FU2 tablet|dose group 4 only
254173|NCT02259842|Drug|Placebo|
254174|NCT02259842|Other|High fat, high calorie breakfast|only for dose groups 3 and 5
254175|NCT02259829|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
254176|NCT02259829|Drug|Telmisartan|
254177|NCT02259829|Drug|Amlodipine|
254178|NCT02259816|Drug|Telmisartan|
254179|NCT02259816|Drug|Amlodipine|
254180|NCT02259803|Drug|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
254181|NCT02259803|Drug|Telmisartan|
254182|NCT02259803|Drug|Amlodipine|
254183|NCT02259790|Drug|Telmisartan/amlodipine fixed-dose combination tablet|
254184|NCT02259790|Drug|Telmisartan|
254185|NCT02259790|Drug|Amlodipine|
254186|NCT02259777|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
254187|NCT02259777|Other|high fat, high caloric meal|
254188|NCT02259764|Drug|KUC 7483 CL - single rising dose|
254189|NCT02259764|Drug|Placebo|
254190|NCT02259764|Other|standardized high fat meal|
254191|NCT02259751|Drug|KUC 7483 CL|
254192|NCT02259751|Drug|Placebo|
254193|NCT02259738|Drug|Human Urinary Kallidinogenase|
254194|NCT02259738|Drug|Shuxuening injection|
254195|NCT02259725|Drug|regorafenib|Given PO
254196|NCT02259725|Other|laboratory biomarker analysis|Correlative studies
254197|NCT02259712|Other|Hipopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
254198|NCT02259712|Behavioral|Therapeutic education.|"The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.~In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant."
254199|NCT02259712|Other|Pelviperineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
254200|NCT02259712|Other|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
254201|NCT02259699|Other|Decision Aid|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
254202|NCT02259686|Drug|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
254203|NCT02259686|Drug|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
254204|NCT02259686|Drug|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
254205|NCT02259686|Drug|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
254206|NCT02259686|Drug|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
254207|NCT02259673|Other|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
254208|NCT02259673|Other|fun exercise|"Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)"
254245|NCT02259361|Drug|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
254246|NCT02259361|Drug|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
254209|NCT02259660|Device|Respiratory muscle strength training|Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
254210|NCT02259660|Device|Sham respiratory muscle strength training|The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
254211|NCT02259647|Drug|Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
254212|NCT02259647|Drug|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo|Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
254213|NCT02259634|Behavioral|Patient Navigation|Motivational Interviewing
254214|NCT02259621|Drug|Nivolumab|Anti-PD-1 Therapy
254215|NCT02259608|Biological|BCG vaccine SSI|BCG vaccination
254216|NCT02259595|Drug|HPN-07|500-1,500 mg oral capsules administered in a single dose
254217|NCT02259595|Drug|NAC|1,200mg NAC administered via oral capsule in single dose
254218|NCT02259595|Drug|Placebo|placebo oral capsule
254219|NCT02259582|Drug|Pemetrexed|
254220|NCT02259582|Drug|Carboplatin|
254221|NCT02259582|Drug|demcizumab|
254222|NCT02259569|Other|Pressure-controlled ventilation|
254223|NCT02259569|Other|Volume-controlled ventilation|
254224|NCT02259556|Biological|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
254225|NCT02259543|Other|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
254226|NCT02259530|Behavioral|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
254227|NCT02259517|Drug|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
254228|NCT02259517|Drug|Lisdexamfetamine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
254229|NCT02259504|Other|PHASE 1- HyperSoft® 3D and HyperSoft® Helical Coils|Framing with HyperSoft® 3D or any FDA-approved bare platinum coil. Must fill and finish the the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils.
254230|NCT02259504|Other|PHASE 2 - HydroSoft® 3D and HydroSoft® Helical Coils|Framing with HydroFrame® or HydroSoft® 3D coils. Must fill the aneurysm with HydroFrame®, HydroSoft® (3D and/or Helical), and/or HydroFill® Coils and finish with HydroSoft® (3D and/or Helical) Coils.
254231|NCT02259491|Drug|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
254232|NCT02259465|Behavioral|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
254233|NCT02259465|Dietary Supplement|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
254234|NCT02259465|Dietary Supplement|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
254235|NCT02259452|Procedure|SPECT Lung Perfusion Scan|
254236|NCT02259452|Procedure|SPECT Heart Perfusion Scan|
254237|NCT02259452|Procedure|Pulmonary Function Tests|
254238|NCT02259426|Drug|Dihydroartemisinin-piperaquine combination (Artekin)|
254239|NCT02259426|Drug|Primaquine|Single-dose 0.25mg/kg
254240|NCT02259413|Behavioral|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks.
254241|NCT02259400|Device|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)< 0.3.
254242|NCT02259400|Device|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 < 0.3.
254243|NCT02259374|Procedure|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
254244|NCT02259374|Procedure|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
254247|NCT02259348|Drug|Cyclophosphamide|Given intravenously (IV)
254248|NCT02259348|Drug|Fludarabine|Given IV
254249|NCT02259348|Biological|G-CSF|Given IV or subcutaneously (SQ)
254250|NCT02259348|Biological|Interleukin-2|Given SQ
254251|NCT02259348|Drug|Melphalan|Given IV
254252|NCT02259348|Drug|Thiotepa|Given IV
254253|NCT02259348|Drug|Rituximab|Given IV
254254|NCT02259348|Biological|Natural killer cell therapy|Given IV
254255|NCT02259348|Biological|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
254256|NCT02259348|Biological|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
254257|NCT02259335|Device|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
254258|NCT02259322|Behavioral|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
254259|NCT02259322|Behavioral|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
254260|NCT02259322|Behavioral|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
254261|NCT02259309|Drug|Misoprostol - buccal|buccal administration
254262|NCT02259309|Drug|Misoprostol - vaginal|vaginal administration
254263|NCT02259296|Procedure|Lower eGFR for AVF construction|Lower eGFR patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
254264|NCT02259296|Procedure|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
254265|NCT02259283|Device|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
254266|NCT02259270|Other|Record review|Record review. No intervention with patient or physician. No effect on outcome.
254267|NCT02259270|Other|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
254268|NCT02259244|Behavioral|Weight reduction program|
254269|NCT02259231|Drug|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
254270|NCT02259231|Drug|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
254271|NCT02259231|Drug|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
254272|NCT02259231|Drug|Omaveloxolone Capsules (10 mg/capsule)|Capsules containing 10 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
254273|NCT02259231|Drug|Omaveloxolone Capsules (50 mg/capsule)|Capsules containing 50 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
254274|NCT02259218|Other|laboratory biomarker analysis|Correlative studies
254275|NCT02259205|Other|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
254276|NCT02259205|Other|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
254277|NCT02259192|Device|MED-EL Maestro Cochlear Implant|cochlear implant
254278|NCT02259179|Drug|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
254279|NCT02259179|Drug|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
254280|NCT02259166|Other|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
254281|NCT02259153|Behavioral|Changes in cholesterol metabolism|
254282|NCT02259153|Other|Lean red meat diet|
254283|NCT02259153|Other|Fat red meat diet|
254284|NCT02259140|Procedure|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
254285|NCT02259140|Procedure|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
254286|NCT02259127|Drug|DTG|
254287|NCT02259114|Drug|MK-8628|MK-8628 10, 20 and/or 40 mg oral capsules
254288|NCT02259101|Behavioral|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
254289|NCT02259101|Behavioral|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
254290|NCT02259088|Drug|Ranibizumab (RFB002)|Ranibizumab 0.5 mg/0.05 mL for intravitreal injection
254291|NCT02259088|Procedure|Laser|Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines
254292|NCT02259088|Drug|Sham injection|Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle
254293|NCT02259088|Procedure|Sham laser|Imitation of an active laser
254294|NCT02259075|Drug|Botulinum Toxin Type A|
254295|NCT02259062|Other|Music with brief mindfulness intervention|Music listening with mindfulness therapy
254296|NCT02259062|Other|Music listening alone|
254297|NCT02259062|Other|Audiobook listening|
254298|NCT02259049|Dietary Supplement|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
254299|NCT02259049|Dietary Supplement|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
254653|NCT02256709|Drug|BIBP 5371 CL tablet|single rising daily doses
254300|NCT02259036|Other|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
254301|NCT02259023|Other|Liquid: Sugar sweetened beverage consumption|Sugar sweetened beverage consumption
254302|NCT02259023|Other|Solid: Grain based desserts and candy consumption|Grain based desserts and candy consumption
254303|NCT02259010|Drug|Alisertib|Alisertib tablets
254304|NCT02259010|Drug|Itraconazole|Itraconazole oral solution
254305|NCT02258984|Device|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
254306|NCT02258971|Drug|BEA 2180 BR oral|Oral solution
254307|NCT02258971|Drug|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
254308|NCT02258919|Procedure|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:~All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.~Best medical treatment:~Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
254309|NCT02258919|Procedure|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
254310|NCT02258906|Drug|ulinastatin|
254311|NCT02258906|Drug|normal saline|
254312|NCT02258893|Other|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
254313|NCT02258893|Other|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
254314|NCT02258893|Other|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
254315|NCT02258880|Drug|SUN13837|
254316|NCT02258880|Drug|placebo|
254317|NCT02258867|Drug|Placebo|Solution for subcutaneous injection
254318|NCT02258867|Drug|Gevokizumab|Solution for subcutaneous injection
254319|NCT02258854|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
254320|NCT02258841|Behavioral|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
254321|NCT02258841|Behavioral|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
254322|NCT02258841|Behavioral|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
254323|NCT02258841|Behavioral|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
254324|NCT02258841|Behavioral|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
254325|NCT02258828|Drug|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
254326|NCT02258815|Drug|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
254327|NCT02258802|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
254328|NCT02258789|Other|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
254329|NCT02258776|Dietary Supplement|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
254330|NCT02258776|Dietary Supplement|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
254331|NCT02258776|Dietary Supplement|Placebo|Placebo will be taken 1/day for 12 weeks.
254332|NCT02258763|Drug|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
254333|NCT02258763|Drug|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
254411|NCT02258230|Device|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
254334|NCT02258750|Dietary Supplement|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
254335|NCT02258750|Other|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
254336|NCT02258737|Behavioral|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
254337|NCT02258737|Behavioral|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
254338|NCT02258711|Device|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
254339|NCT02258698|Procedure|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
254340|NCT02258672|Other|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
254341|NCT02258659|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
254342|NCT02258659|Drug|carboplatin|Given IV
254343|NCT02258659|Radiation|radiation therapy|Undergo radiation therapy
254344|NCT02258659|Drug|paclitaxel|Given IV
254345|NCT02258659|Drug|fluorouracil|Given IV
254346|NCT02258659|Drug|hydroxyurea|Given PO
254347|NCT02258659|Drug|cisplatin|Given IV
254348|NCT02258659|Other|laboratory biomarker analysis|Correlative studies
254349|NCT02258659|Procedure|quality-of-life assessment|Ancillary studies
254350|NCT02258646|Behavioral|Exercise training at home|
254351|NCT02258646|Behavioral|Telemonitoring and education/self-management|
254352|NCT02258633|Other|Interactive interview and tailored family centered seatbelt safety intervention|
254353|NCT02258620|Drug|dinitrate isosorbide|dinitrate isosorbide (cedocard*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard*) 5 mg by intra arterial direct in the sheat
254354|NCT02258620|Drug|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
254355|NCT02258607|Drug|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
254356|NCT02258607|Drug|Trametinib|Trametinib tablet administered orally once daily
254357|NCT02258594|Other|Web-Based Patient Centered Toolkit (PCTK)|"The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread."
254358|NCT02258594|Behavioral|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
254359|NCT02258581|Drug|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
254360|NCT02258581|Drug|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
254361|NCT02258581|Drug|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
254362|NCT02258568|Behavioral|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
254363|NCT02258555|Drug|GS-9901|GS-9901 tablets administered orally
254364|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
254365|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
254366|NCT02258529|Drug|Idelalisib|150 tablets administered orally twice daily
254367|NCT02258529|Biological|Rituximab|375 mg/m^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
254368|NCT02258516|Behavioral|CHIME 3-M|behavioral intervention for self-management in heart failure
254369|NCT02258516|Behavioral|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
254370|NCT02258503|Other|pain in elderly patients|
254412|NCT02258217|Drug|Acthar|Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
254413|NCT02258204|Drug|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
254414|NCT02258204|Drug|Placebo|
254415|NCT02258191|Device|telemonitoring|
254416|NCT02258191|Device|sham telemonitoring|
254417|NCT02258178|Biological|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
254654|NCT02256709|Drug|BIBP 5371 CL solution|
254655|NCT02256709|Other|High fat, high caloric breakfast|
254371|NCT02258490|Biological|G-CSF mobilized CD34+ selected cells for transplantation|"Mobilization of Donor: Following screening and enrollment after informed consent, the donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using the standard National Marrow Donor Program (NMDP) guidelines.~CD34+ selection with CliniMACS device: CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs). If the donor's plasma is not available, CliniMACS buffer will be used.~The Day of CD34+ cell infusion: Immediately after the release tests have been performed and the product passes the release criteria, the patient will receive the final product. No conditioning regimen will be administered prior to cell infusion."
254372|NCT02258477|Dietary Supplement|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
254373|NCT02258477|Dietary Supplement|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
254374|NCT02258477|Dietary Supplement|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
254375|NCT02258477|Dietary Supplement|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
254376|NCT02258464|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update)
254377|NCT02258464|Drug|Placebo (saline)|Up to 6 cycles of saline injection
254378|NCT02258464|Other|Background hormonal therapy|Prescribed by PI and is provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
254379|NCT02258451|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update)
254380|NCT02258451|Drug|Placebo (saline)|Up to 6 cycles of saline injection
254381|NCT02258451|Drug|Exemestane|25 mg once daily with or without food Dosage and administration of exemestane must be in compliance with the local labels in each of the participating countries and in line with standard practice guidelines.
254382|NCT02258451|Drug|Everolimus|10 mg tablet once daily after a meal Dosage and administration of everolimus must be in compliance with the local labels in each of the participating countries and in line with standard practice guidelines.
254383|NCT02258438|Behavioral|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
254384|NCT02258438|Behavioral|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
254385|NCT02258438|Behavioral|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
254386|NCT02258425|Behavioral|FEM-CARE|
254387|NCT02258425|Behavioral|Health Promotion|
254388|NCT02258412|Drug|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
254389|NCT02258412|Drug|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
254390|NCT02258399|Behavioral|Exercise|Moderate intensity exercise
254391|NCT02258399|Dietary Supplement|Breakfast|Breakfast consumption
254392|NCT02258373|Device|CGM+BGM|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter
254393|NCT02258373|Device|CGM Only|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
254394|NCT02258360|Other|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
254395|NCT02258347|Device|Echopulse|
254396|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
254397|NCT02258334|Biological|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
254398|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
254399|NCT02258334|Biological|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
254400|NCT02258321|Drug|PPI-668 tablet|
254401|NCT02258321|Drug|PPI-668 capsule|
254402|NCT02258308|Behavioral|CHW intervention|Home education and support for asthma self management
254403|NCT02258295|Drug|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
254404|NCT02258295|Drug|Saline|Saline
254405|NCT02258282|Drug|Etanercept|
254406|NCT02258282|Drug|Control|
254407|NCT02258269|Other|SQ|
254408|NCT02258269|Other|Control|
254409|NCT02258256|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
254410|NCT02258230|Device|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
254418|NCT02258165|Device|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
254419|NCT02258152|Drug|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
254420|NCT02258152|Drug|Placebo|Placebo QD
254421|NCT02258126|Other|Multidisciplinary intervention program|"Exercise group:~The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
254422|NCT02258113|Device|Ocusweep|A novel reaction-time based visual field device.
254423|NCT02258100|Other|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
254424|NCT02258087|Radiation|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
254425|NCT02258087|Radiation|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
254426|NCT02258074|Drug|Nicotinamide|
254427|NCT02258074|Drug|Lanthanum Carbonate|
254428|NCT02258074|Drug|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
254429|NCT02258074|Drug|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
254430|NCT02258061|Procedure|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
254431|NCT02258061|Procedure|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
254432|NCT02258035|Other|Blood draw|Sampling of 100-150 ml of blood
254433|NCT02258009|Drug|Ranibizumab|0.5 mg intravitreal injections
254434|NCT02258009|Drug|Aflibercept|2 mg intravitreal injections
254435|NCT02257996|Behavioral|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
254436|NCT02257983|Drug|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
254437|NCT02257983|Drug|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
254438|NCT02257970|Drug|Ketoprofen|
254439|NCT02257970|Drug|Placebo|Placebo to match ketoprofen.
254440|NCT02257957|Drug|PRP injection|
254441|NCT02257957|Drug|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
254442|NCT02257944|Behavioral|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
254443|NCT02257944|Other|Treatment as Usual|treatment as usual
254444|NCT02257918|Drug|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
254445|NCT02257918|Drug|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
254446|NCT02257853|Other|Stress reduction intervention|Gentle chair yoga and breath work
254447|NCT02257827|Radiation|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.~The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
254448|NCT02257814|Behavioral|Incredible Years Teacher Training|
254449|NCT02257814|Behavioral|Preschool PATHS|
254450|NCT02257814|Behavioral|Tools of the Mind|
254451|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
254452|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
254453|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
254454|NCT02257788|Biological|PRO 140|Humanized monoclonal antibody to CCR5
254455|NCT02257775|Genetic|n/a - observational|
254456|NCT02257762|Dietary Supplement|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
254457|NCT02257762|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
254458|NCT02257762|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet.
254459|NCT02257749|Other|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
254460|NCT02257749|Other|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
254637|NCT02256761|Drug|Placebo|
254461|NCT02257736|Drug|Apalutamide|Participants will receive 240 milligram (mg) tablet of apalutamide once daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
254462|NCT02257736|Drug|Abiraterone acetate|Participants will receive 1000 mg (four 250 mg tablets) of abiraterone acetate (AA) once daily on an empty stomach until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
254463|NCT02257736|Drug|Prednisone|Participants will receive 5 mg tablet prednisone twice daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
254464|NCT02257736|Drug|Placebo|Participants will receive matching placebo to apalutamide once daily until study drug discontinuation.
254465|NCT02257723|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
254466|NCT02257723|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
254467|NCT02257723|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
254468|NCT02257723|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
254469|NCT02257723|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
254470|NCT02257710|Device|Orsiro|
254471|NCT02257697|Drug|Mizoribine (MZR)|
254472|NCT02257697|Drug|Cyclophosphamide (CTX)|
254473|NCT02257684|Drug|pegcrisantaspase|
254474|NCT02257671|Drug|Oral contraceptive|Neovletta
254475|NCT02257658|Drug|Doxycycyline|
254476|NCT02257658|Behavioral|Incentive|
254477|NCT02257632|Drug|Ranibizumab 0.5 mg|Administered as an intravitreal injection
254478|NCT02257632|Drug|Aflibercept 2 mg|Administered as an intravitreal injection
254479|NCT02257619|Drug|Itacitinib|Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.
254480|NCT02257619|Drug|docetaxel|Administered as an intravenous infusion in the clinic at 75 mg/m^2 Q3W for Part 1 of the study.
254481|NCT02257606|Other|I-TRAVLE training|
254482|NCT02257593|Other|Dietary protein|"Persons were fed~Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
254483|NCT02257580|Drug|E-Aminocaproic acid|E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
254484|NCT02257567|Drug|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
254485|NCT02257567|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
254486|NCT02257567|Drug|Polatuzumab vedotin (Liquid)|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
254487|NCT02257567|Drug|Rituximab|Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
254488|NCT02257567|Drug|Polatuzumab vedotin (Lyophilized)|Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
254489|NCT02257554|Behavioral|education|Discussion of surgical expectations with patients
254490|NCT02257541|Drug|BGJ398|
254491|NCT02257541|Drug|Imatinib Mesylate|
254492|NCT02257528|Other|Laboratory Biomarker Analysis|Correlative studies
254493|NCT02257528|Biological|Nivolumab|Given IV
254494|NCT02257502|Drug|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
254495|NCT02257489|Drug|ACE-083|recombinant fusion protein
254496|NCT02257476|Drug|Carfilzomib|Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
254497|NCT02257476|Drug|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
254498|NCT02257463|Drug|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
254499|NCT02257463|Other|peripheral muscles exercise training|
254500|NCT02257463|Device|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
254501|NCT02257437|Dietary Supplement|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
254502|NCT02257437|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
254503|NCT02257437|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
254504|NCT02257437|Dietary Supplement|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
254505|NCT02257424|Drug|Trametinib 2 mg daily|
254506|NCT02257424|Drug|hydroxychloroquine (HCQ)|hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
254507|NCT02257424|Drug|dabrafenib 150 mg orally twice a day|
254508|NCT02257411|Device|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
254509|NCT02257398|Drug|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
254510|NCT02257398|Drug|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
254511|NCT02257398|Drug|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
254512|NCT02257398|Drug|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
254513|NCT02257385|Drug|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
254514|NCT02257385|Drug|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
254515|NCT02257385|Drug|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
254516|NCT02257385|Drug|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
254517|NCT02257385|Drug|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
254518|NCT02257385|Drug|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
254519|NCT02257385|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
254520|NCT02257372|Drug|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
254521|NCT02257372|Drug|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
254522|NCT02257372|Drug|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
254523|NCT02257372|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
254524|NCT02257359|Drug|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
254525|NCT02257346|Drug|Lidocaine|Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
254526|NCT02257346|Drug|Normal Saline|Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
254527|NCT02257320|Device|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
254638|NCT02256761|Drug|BIRT 2584 XX - single dose|
254639|NCT02256761|Other|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
254640|NCT02256748|Drug|BIRT 2584 XX|
254528|NCT02257307|Procedure|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
254529|NCT02257294|Drug|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
254530|NCT02257294|Other|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
254531|NCT02257281|Device|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
254532|NCT02257281|Device|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
254533|NCT02257268|Behavioral|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
254534|NCT02257255|Procedure|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
254535|NCT02257255|Procedure|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
254536|NCT02257242|Drug|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
254537|NCT02257242|Drug|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
254538|NCT02257242|Drug|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
254539|NCT02257229|Procedure|Surgical|Surgery only
254540|NCT02257229|Procedure|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
254541|NCT02257229|Procedure|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
254542|NCT02257216|Other|Vayarin®|Medical Food
254543|NCT02257216|Other|Placebo|Cellulose
254544|NCT02257203|Behavioral|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
254545|NCT02257203|Behavioral|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
254546|NCT02257190|Behavioral|Control|One hour of rest.
254547|NCT02257190|Behavioral|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
254548|NCT02257190|Behavioral|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
254549|NCT02257177|Drug|Inhaled TD139|DPI Galectin-3 inhibitor
254550|NCT02257177|Drug|Placebo|DPI placebo
254551|NCT02257164|Procedure|Femoral nerve block|2 mg/ml
254552|NCT02257164|Procedure|obturator nerve block|
254553|NCT02257164|Procedure|intraarticular injection|
254554|NCT02257151|Drug|BMS-986142|
254555|NCT02257151|Drug|Placebo|
254556|NCT02257138|Drug|Decitabine|Given IV
254557|NCT02257138|Other|Laboratory Biomarker Analysis|Correlative studies
254558|NCT02257138|Drug|Ruxolitinib Phosphate|Given PO
254559|NCT02257125|Behavioral|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
254560|NCT02257125|Behavioral|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
254561|NCT02257112|Device|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
254562|NCT02257073|Behavioral|Cognitive-behavioral treatment|
254563|NCT02257073|Behavioral|Waiting List|
254564|NCT02257060|Procedure|Endocardial Ablation|
254565|NCT02257047|Dietary Supplement|Tea|
254566|NCT02257047|Dietary Supplement|RYR|red yeast rice
254567|NCT02257034|Other|Taichi|
254568|NCT02257034|Other|Dance|
254569|NCT02257021|Drug|BILR 355 BS|
254570|NCT02257021|Drug|Tipranavir|
254571|NCT02257021|Drug|Low dose of ritonavir|
254572|NCT02257021|Drug|High dose of ritonavir|
254573|NCT02257008|Drug|BILR 355 BS|
254574|NCT02257008|Other|Grapefruit juice|
254575|NCT02257008|Drug|Nelfinavir|
254576|NCT02257008|Drug|Atazanavir|
254577|NCT02257008|Drug|Ritonavir|
254578|NCT02256995|Device|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
254579|NCT02256982|Drug|Gemcitabine|
254580|NCT02256982|Drug|Cisplatin|
254581|NCT02256982|Procedure|Surgery|Surgical Resection and Lymphadenectomy
254582|NCT02256982|Radiation|Radiation|Radiation Therapy
254583|NCT02256969|Drug|Blephamide|
254584|NCT02256969|Drug|GenTeal PM Night-Time|
254641|NCT02256748|Drug|Midazolam|
254642|NCT02256735|Drug|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
254643|NCT02256735|Drug|Treatment B|
254644|NCT02256735|Drug|Treatment C|
254645|NCT02256735|Drug|Treatment D|
254646|NCT02256735|Drug|Placebo|
254647|NCT02256735|Drug|Moxifloxacin|
254585|NCT02256969|Procedure|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
254586|NCT02256969|Procedure|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
254587|NCT02256956|Drug|Amitriptyline|25 mg / day for 10 days
254588|NCT02256956|Drug|Tolterodine|Placebo 1 mg / day for 10 days
254589|NCT02256943|Drug|Amitriptyline|100 mg single dose
254590|NCT02256943|Drug|Tolterodine|Placebo 1 mg single dose
254591|NCT02256930|Drug|M518101|
254592|NCT02256930|Drug|M518101 Vehicle|
254593|NCT02256930|Other|Sodium lauryl sulfate|
254594|NCT02256930|Other|Saline|
254595|NCT02256917|Biological|Human cl rhFVIII|
254596|NCT02256904|Procedure|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
254597|NCT02256904|Procedure|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
254598|NCT02256891|Device|PRFM|
254599|NCT02256891|Procedure|Double Row|
254600|NCT02256878|Drug|BIRT 2584 XX|
254601|NCT02256878|Drug|Amitriptyline|
254602|NCT02256865|Drug|Ketoconazole|Ketoconazole is taken 4 times a day
254603|NCT02256865|Drug|Hydrocortisone|Hydrocortisone is taken 3 times a day
254604|NCT02256865|Drug|Testosterone|Testosterone gel is applied once a day
254605|NCT02256865|Drug|Placebo for ketoconazole|Placebo for ketoconazole
254606|NCT02256865|Drug|Placebo for hydrocortisone|Placebo for hydrocortisone
254607|NCT02256865|Drug|Placebo for testosterone|Placebo for testosterone
254608|NCT02256852|Biological|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
254609|NCT02256839|Device|CST_001|
254610|NCT02256826|Drug|BILR 355 BS|
254611|NCT02256826|Drug|Ritonavir (RTV)|NORVIR®
254612|NCT02256826|Drug|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
254613|NCT02256813|Drug|BIRT 2584 XX|
254614|NCT02256813|Drug|Warfarin sodium|
254615|NCT02256813|Drug|Omeprazole|
254616|NCT02256813|Drug|Dextromethorphan hydrobromide|
254617|NCT02256813|Drug|Caffeine|
254618|NCT02256813|Drug|Midazolam hydrochloride|
254619|NCT02256813|Drug|Vitamin K1|
254620|NCT02256800|Genetic|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
254621|NCT02256800|Genetic|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
254622|NCT02256800|Genetic|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.~After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
254623|NCT02256800|Genetic|UGT1A1 non-genotyping|"The investigators will use the regimen as following:~Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
254624|NCT02256800|Drug|bevacizumab (Avastin)|
254625|NCT02256800|Drug|irinotecan|
254626|NCT02256800|Drug|Leucovorin|
254627|NCT02256800|Drug|5-FU|
254628|NCT02256787|Drug|BILB 1941 ZW - single rising dose part|
254629|NCT02256787|Drug|Placebo|
254630|NCT02256787|Drug|BILB 1941 ZW - solution|
254631|NCT02256787|Drug|BILB 1941 ZW - tablet|
254632|NCT02256787|Other|standardized breakfast|
254633|NCT02256774|Drug|BILR 355 BS|
254634|NCT02256774|Drug|Combivir®|
254635|NCT02256774|Drug|Ritonavir|
254636|NCT02256761|Drug|BIRT 2584 XX - multiple escalating dose|
254657|NCT02256709|Drug|BIBP 5371 CL tablet high dose|
254658|NCT02256709|Drug|Placebo drinking solution|
254659|NCT02256709|Drug|BIBP 5371 CL tablet low dose|
254660|NCT02256696|Drug|PA-824|200 mg QD
254661|NCT02256696|Drug|Rifampin|600 mg QD
254662|NCT02256696|Drug|Rifabutin|300 mg QD
254663|NCT02256696|Drug|Pyrazinamide|25mg/kg QD
254664|NCT02256696|Drug|Ethambutol|15mg/kg QD
254665|NCT02256696|Drug|Isoniazid|300 mg QD
254666|NCT02256683|Drug|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
254667|NCT02256683|Drug|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
254668|NCT02256670|Behavioral|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
254669|NCT02256657|Behavioral|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
254670|NCT02256631|Biological|VRC01|Administered by subcutaneous injection in the thigh
254671|NCT02256631|Biological|VRC01LS|Administered by subcutaneous injection in the thigh
254672|NCT02256631|Biological|VRC07-523LS|Administered by subcutaneous injection in the thigh
254673|NCT02256618|Other|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
254674|NCT02256605|Dietary Supplement|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D [259OH)D] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
254675|NCT02256592|Drug|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
254676|NCT02256566|Behavioral|emotional memory training exercise|
254677|NCT02256566|Behavioral|memory training exercise|
254678|NCT02256553|Biological|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
254679|NCT02256553|Biological|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
254680|NCT02256553|Drug|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
254681|NCT02256540|Drug|Climara|
254682|NCT02256540|Drug|Placebo patch|Placebo patch designed to match active Climara patches.
254683|NCT02256540|Dietary Supplement|Resveratrol|
254684|NCT02256540|Dietary Supplement|Placebo|Placebo tablets designed to match active resveratrol tablets.
254685|NCT02256527|Other|Observational|compare data
254686|NCT02256514|Biological|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
254687|NCT02256501|Biological|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
254688|NCT02256488|Biological|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
254689|NCT02256488|Biological|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
254690|NCT02256488|Biological|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
254691|NCT02256488|Biological|TIVf|Single IM administration dose of 0.5 mL of TIVf
254692|NCT02256475|Drug|NBI-98854|
254693|NCT02256462|Drug|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (> 40kg 160/80/40 mg every 2 weeks or < 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
254694|NCT02256436|Biological|pembrolizumab|IV infusion
254695|NCT02256436|Drug|paclitaxel|IV infusion
254696|NCT02256436|Drug|vinflunine|IV infusion
254697|NCT02256436|Drug|docetaxel|IV infusion
254698|NCT02256423|Drug|REFERENCE 1: Nurofen® 200 mg tablet|
254699|NCT02256423|Drug|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
254700|NCT02256423|Drug|ibuprofen 200 mg soft gel capsule|
254701|NCT02256410|Device|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
254702|NCT02256410|Other|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
254703|NCT02256397|Other|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
254704|NCT02256397|Other|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:~If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller~5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
254705|NCT02256384|Device|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
254706|NCT02256371|Behavioral|Hypnosis sessions|1 session per week during 8 weeks
254707|NCT02256371|Behavioral|Relaxation group|1 relaxation session per week during 8 weeks
254708|NCT02256358|Drug|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
254709|NCT02256358|Drug|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
254710|NCT02256345|Drug|KNO3|Active Comparator
254711|NCT02256345|Drug|KCl|Placebo Comparator
254712|NCT02256332|Dietary Supplement|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
254713|NCT02256332|Dietary Supplement|High dose plant based ingredient|Reference food with high dose of plant based ingredient
254714|NCT02256332|Dietary Supplement|Reference food format|Reference food without plant-based ingredient
254715|NCT02256319|Drug|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
254716|NCT02256319|Drug|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
254717|NCT02256306|Other|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
254718|NCT02256293|Behavioral|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
254719|NCT02256280|Drug|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~If Post tetanic count = 1-15: 4 mg/kg~If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
254720|NCT02256280|Drug|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.~Administration will be according to the neuromuscular blockade:~If Post tetanic count = 1-15: 0.07 mg/kg~If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
254721|NCT02256267|Drug|LY2835219|Administered orally
254722|NCT02256267|Drug|Rifampin|Administered orally
254723|NCT02256254|Drug|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
254724|NCT02256254|Drug|Placebo|2 placebo capsules every evening for 14 days
254725|NCT02256228|Drug|Ropivacaine|Active Group
254726|NCT02256228|Drug|Saline|Placebo Comparator
254727|NCT02256215|Drug|Vitamin D|
254728|NCT02256202|Other|Interview|Monitoring interviews to show medical and economic advantages of given therapy
254729|NCT02256189|Drug|Sitagliptin|Sitagliptin 100 mg daily
254730|NCT02256189|Drug|Placebo|Placebo one tablet daily
254731|NCT02256150|Drug|Mizoribine (MZR)|
254732|NCT02256150|Drug|Cyclophosphamide (CTX)|
254733|NCT02256124|Drug|Lamotrigine|
254734|NCT02256124|Drug|Placebo|
254735|NCT02256111|Drug|Enzalutamide|
254736|NCT02256111|Drug|Androgen deprivation therapy|
254737|NCT02256111|Behavioral|Supervised exercise training|
254738|NCT02256098|Device|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
254739|NCT02256098|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
254740|NCT02256085|Device|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
254741|NCT02256085|Device|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
254742|NCT02256085|Device|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
254743|NCT02256072|Other|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
254789|NCT02255760|Drug|MEDI3902 - Dose 4|Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
254790|NCT02255760|Other|Placebo|Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
254791|NCT02255747|Drug|Lactulose|
254744|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
254745|NCT02256059|Procedure|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
254746|NCT02256046|Device|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
254747|NCT02256033|Drug|Istradefylline|One 40 mg-tablet administered on Day 1
254748|NCT02256020|Other|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
254749|NCT02256020|Other|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
254750|NCT02256007|Other|Paper and Pencil Assessments|Videogame Assessments
254751|NCT02255994|Device|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
254752|NCT02255994|Procedure|No mesh.|Patients in this arm had subvesical plication without reinforcement.
254753|NCT02255981|Other|Traditional Chinese Medicine (TCM) Acupuncture|Treatment consist in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.
254754|NCT02255968|Drug|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
254755|NCT02255968|Drug|Placebo|Matching placebo capsules. All interventions are given as multiple doses
254756|NCT02255955|Drug|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
254757|NCT02255955|Drug|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
254758|NCT02255955|Drug|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
254759|NCT02255942|Other|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
254760|NCT02255942|Other|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
254761|NCT02255942|Other|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
254762|NCT02255942|Other|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
254763|NCT02255929|Radiation|Gamma Knife Radiosurgery|
254764|NCT02255916|Other|Music|live sound-bed music intervention
254765|NCT02255903|Other|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
254766|NCT02255877|Device|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
254767|NCT02255877|Device|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
254768|NCT02255864|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
254769|NCT02255851|Device|SENTINEL (Cerebral Protection System)|
254770|NCT02255838|Device|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
254771|NCT02255838|Device|Bronchoscope disposable (aScope 4)|Bronchoscopy and alveolar lavage
254772|NCT02255825|Genetic|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
254773|NCT02255825|Procedure|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
254774|NCT02255825|Other|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
254775|NCT02255812|Dietary Supplement|Single intragastric instillation of 200 mL tap water via nasogastric tube|
254776|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
254777|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
254778|NCT02255812|Dietary Supplement|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
254779|NCT02255812|Dietary Supplement|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
254780|NCT02255812|Dietary Supplement|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
254781|NCT02255799|Drug|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
254782|NCT02255799|Drug|Placebo|Placebo capsule once daily for 70 days.
254783|NCT02255786|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
254784|NCT02255773|Behavioral|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
254785|NCT02255773|Behavioral|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
254786|NCT02255760|Drug|MEDI3902 - Dose 1|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
254787|NCT02255760|Drug|MEDI3902 - Dose 2|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
254788|NCT02255760|Drug|MEDI3902 - Dose 3|Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
254792|NCT02255734|Drug|Acyclovir|
254793|NCT02255721|Behavioral|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
254794|NCT02255721|Behavioral|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
254795|NCT02255708|Other|Proprioceptive Neuromuscular Facilitation - PNF|
254796|NCT02255695|Other|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
254797|NCT02255682|Drug|Simvastatin|
254798|NCT02255682|Dietary Supplement|Q10|
254799|NCT02255669|Device|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
254800|NCT02255669|Device|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
254801|NCT02255656|Drug|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
254802|NCT02255643|Device|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
254803|NCT02255630|Other|Cycling Exercise|
254804|NCT02255617|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
254805|NCT02255604|Drug|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
254806|NCT02255604|Drug|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
254807|NCT02255604|Drug|0.1 ml Isoton saline|4 injection into a lymphnode
254808|NCT02255591|Drug|Lidocaine-adrenaline added gadolinium.|
254809|NCT02255578|Device|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
254810|NCT02255578|Drug|clomiphene citrate treatment|
254811|NCT02255565|Drug|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
254812|NCT02255565|Drug|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
254813|NCT02255565|Drug|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
254814|NCT02255552|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
254815|NCT02255526|Device|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
254816|NCT02255513|Drug|HLD200|methylphenidate hydrochloride (MPH) Capsules
254817|NCT02255513|Drug|Placebo|
254818|NCT02255500|Drug|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
254819|NCT02255500|Drug|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
254820|NCT02255487|Device|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.~Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
254821|NCT02255487|Other|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) only surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
254822|NCT02255474|Device|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
254823|NCT02255474|Device|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
254824|NCT02255474|Device|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
254825|NCT02255461|Drug|palbociclib isethionate|Given PO
254826|NCT02255461|Other|pharmacological study|Correlative studies
254827|NCT02255461|Other|laboratory biomarker analysis|Correlative studies
254828|NCT02255448|Device|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
254829|NCT02255435|Drug|Omaveloxolone Capsules, 2.5 mg|
254830|NCT02255435|Drug|Omaveloxolone Capsules, 5 mg|
254831|NCT02255435|Drug|Omaveloxolone Capsules, 10 mg|
254832|NCT02255435|Drug|Placebo|
254833|NCT02255435|Drug|Omaveloxolone Capsules, 20 mg|
254834|NCT02255435|Drug|Omaveloxolone Capsules, 40 mg|
254835|NCT02255435|Drug|Omaveloxolone Capsules, 80 mg|
254836|NCT02255435|Drug|Omaveloxolone Capsules, 160 mg|
254837|NCT02255435|Drug|Omaveloxolone Capsules, 300 mg|
254838|NCT02255435|Drug|Omaveloxolone Capsules, 150 mg|
254839|NCT02255422|Drug|Omaveloxolone capsules, 2.5 mg|
254840|NCT02255422|Drug|omaveloxolone capsules, 5 mg|
254841|NCT02255422|Drug|omaveloxolone capsules, 10 mg|
254842|NCT02255422|Drug|Placebo capsules|
254843|NCT02255422|Drug|omaveloxolone capsules, 20 mg|
254844|NCT02255422|Drug|omaveloxolone capsules, TBD mg|
254845|NCT02255422|Drug|omaveloxolone capsules, 40 mg|
254846|NCT02255422|Drug|omaveloxolone capsules, 80 mg|
254847|NCT02255422|Drug|omaveloxolone capsules, 160 mg|
254848|NCT02255409|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
254849|NCT02255409|Biological|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
254850|NCT02255396|Other|ESTRADIOL|
254851|NCT02255383|Device|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
254852|NCT02255370|Drug|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
254853|NCT02255357|Drug|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
254854|NCT02255357|Drug|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
254855|NCT02255318|Device|Taurolock|
254856|NCT02255318|Drug|Placebo|
254857|NCT02255305|Biological|FMT|Patients in the FMT group will receive ~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.
254858|NCT02255305|Drug|Antimicrobials|Patients randomized to the control group will receive antimicrobials targeting C. difficile.
254859|NCT02255292|Drug|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study
254860|NCT02255279|Biological|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
254861|NCT02255279|Biological|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
254862|NCT02255266|Drug|liraglutide|No treatment given.
254863|NCT02255253|Drug|Telmisartan|capsule,40mg per day,2 months
254864|NCT02255253|Drug|Hydrochlorothiazide|tablet, 25mg per day, 2 months
254865|NCT02255240|Behavioral|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
254866|NCT02255227|Biological|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
254867|NCT02255227|Biological|Pneumo 23|one dose
254868|NCT02255201|Dietary Supplement|Master Performance Blend Dose 1|Caffeine content: 200 mg
254869|NCT02255201|Dietary Supplement|Master Performance Blend Dose 2|Caffeine content: 400 mg
254870|NCT02255201|Dietary Supplement|Performance Energy Blend|Caffeine content: 175 mg
254871|NCT02255201|Dietary Supplement|Energy Blend|Caffeine content: 200 mg
254872|NCT02255201|Dietary Supplement|Placebo|Caffeine content: 0 mg
254873|NCT02255188|Procedure|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
254874|NCT02255175|Drug|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
254875|NCT02255175|Drug|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
254876|NCT02255162|Drug|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
254877|NCT02255162|Genetic|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
254878|NCT02255162|Drug|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
254879|NCT02255149|Device|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
254880|NCT02255136|Other|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
254881|NCT02255136|Other|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
254882|NCT02255110|Drug|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
254883|NCT02255110|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
254884|NCT02255097|Biological|pembrolizumab|
255086|NCT02253927|Drug|BILR 355 - D3|
255087|NCT02253927|Drug|BILR 355 - D4|
255088|NCT02253927|Drug|Ritonavir|
254885|NCT02255084|Behavioral|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.~Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
254886|NCT02255084|Behavioral|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.~When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
254887|NCT02255071|Device|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
254888|NCT02255071|Device|Sham wristband|A wristband over wrist but no acupressure for seven days.
254889|NCT02255058|Other|No intervention|The study is a Prospective observational cohort study
254890|NCT02255045|Drug|Meloxicam|1 Meloxicam Vaginal Ring (MVR) for 4-6 days
254891|NCT02255045|Drug|Diclofenac Potassium|1 tablet 50 mg diclofenac every 12 hours for 4-6 days
254892|NCT02255045|Drug|Placebo Oral|1 placebo tablet every 12 hours for 4-6 days
254893|NCT02255045|Drug|Placebo Vaginal|1 placebo vaginal ring for 4-6 days
254894|NCT02255032|Drug|4 mg CLS-TA|4 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
254895|NCT02255032|Drug|0.8 mg CLS-TA|0.8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
254896|NCT02255006|Device|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
254897|NCT02255006|Device|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods."
254898|NCT02255006|Drug|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
254899|NCT02255006|Drug|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
254900|NCT02254993|Drug|C16G2|antimicrobial peptide
254901|NCT02254980|Device|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
254902|NCT02254980|Device|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
254903|NCT02254967|Drug|Fidaxomicin|oral tablets administered in an extended pulsed regimen
254904|NCT02254967|Drug|Vancomycin|oral capsule
254905|NCT02254954|Drug|Macitentan in combination with RT and TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
254906|NCT02254941|Drug|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
254907|NCT02254941|Biological|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
254908|NCT02254928|Drug|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
254909|NCT02254915|Device|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
254910|NCT02254915|Drug|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
254911|NCT02254902|Behavioral|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
254912|NCT02254889|Drug|proton pump inhibitor|). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
254913|NCT02254876|Other|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
254914|NCT02254876|Other|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.~In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
254915|NCT02254863|Biological|DUOC-01|Intrathecal administration of DUOC-01
255089|NCT02253927|Other|high fat breakfast|
255090|NCT02253914|Drug|BILR 355 BS, solution|
254916|NCT02254850|Procedure|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
254917|NCT02254850|Drug|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
254918|NCT02254850|Drug|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
254919|NCT02254850|Drug|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
254920|NCT02254850|Drug|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
254921|NCT02254837|Device|Zilver PTX Drug-Eluting Stent|
254922|NCT02254824|Drug|Xuezhikang|Xuezhikang
254923|NCT02254824|Drug|Atorvastatin|Atorvastatin
254924|NCT02254824|Behavioral|Lifestyle modification|Lifestyle modification
254925|NCT02254811|Biological|Fecal Microbiota Transplant|transfer of healthy human gut bacteria to restore the microbiome
254926|NCT02254798|Other|no intervention|this is a non interventional study
254927|NCT02254785|Drug|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
254928|NCT02254785|Drug|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
254929|NCT02254785|Drug|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
254930|NCT02254772|Biological|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
254931|NCT02254772|Drug|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
254932|NCT02254772|Radiation|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
254933|NCT02254759|Drug|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
254934|NCT02254759|Drug|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
254935|NCT02254759|Drug|RO5186582|RO5186582 120 mg film-coated release tablet.
254936|NCT02254746|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
254937|NCT02254733|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
254938|NCT02254733|Other|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
254939|NCT02254720|Drug|BEA 2180 BR solution for infusion|
254940|NCT02254720|Drug|Placebo|Intravenous infusion
254941|NCT02254720|Drug|BEA 2180 BR solution for inhalation|
254942|NCT02254720|Device|Respimat®|
254943|NCT02254707|Drug|BILB 1941 ZW|
254944|NCT02254707|Drug|Placebo|
254945|NCT02254694|Other|high heeled shoes|see detailed study description
254946|NCT02254681|Drug|Gemcitabine|
254947|NCT02254681|Drug|Cisplatin|
254948|NCT02254681|Radiation|low dose radiotherapy|Whole liver and portal lymph node basin low dose radiotherapy
254949|NCT02254668|Other|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
254950|NCT02254668|Other|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
254951|NCT02254655|Drug|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
254952|NCT02254655|Drug|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
254953|NCT02254642|Procedure|Ischemic preconditioning during aortic clamping|
254954|NCT02254642|Procedure|Procedure/Surgery: usual surgery|
254955|NCT02254629|Drug|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
254956|NCT02254629|Drug|Laxative Polyethylene Glycol|laxative：2000 ml.
254957|NCT02254616|Behavioral|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
254958|NCT02254616|Behavioral|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
254959|NCT02254616|Behavioral|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
254960|NCT02254616|Behavioral|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
254961|NCT02254603|Device|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
254962|NCT02254603|Behavioral|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
254963|NCT02254590|Procedure|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
254964|NCT02254577|Drug|Endometrin® plus Progesterone in Oil (PIO)|
254965|NCT02254577|Drug|Progesterone in Oil (PIO) Only|
254966|NCT02254551|Drug|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.~Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.~Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
254967|NCT02254551|Drug|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
254968|NCT02254538|Drug|BILR 355 BS|
254969|NCT02254538|Drug|PEG 400|
254970|NCT02254525|Drug|Intravenous ibuprofen|"Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
254971|NCT02254525|Drug|Saline solution|"Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.~All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
254972|NCT02254486|Drug|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
254973|NCT02254486|Drug|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
254974|NCT02254473|Other|Wedge Insert|
254975|NCT02254473|Other|Flat Insert|
254976|NCT02254460|Dietary Supplement|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
254977|NCT02254460|Other|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
254978|NCT02254447|Drug|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
254979|NCT02254447|Drug|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
254980|NCT02254447|Drug|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
254981|NCT02254434|Drug|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
254982|NCT02254421|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
254983|NCT02254421|Drug|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
254984|NCT02254408|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
254985|NCT02254408|Drug|Placebo|Tablets administered orally or via nasogastric tube
254986|NCT02254395|Device|Deep Brain Stimulation|
254987|NCT02254382|Device|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
254988|NCT02254369|Drug|GC021109|
254989|NCT02254369|Other|Placebo|
254990|NCT02254356|Device|Zilver Flex Bare Metal Stent|
254991|NCT02254343|Device|proximal robot-assisted therapy|
254992|NCT02254343|Device|distal robot-assisted therapy|
254993|NCT02254343|Behavioral|individualized intensive therapy|
254994|NCT02254317|Dietary Supplement|0 mg placebo|Not containing GSE (Placebo)
254995|NCT02254317|Dietary Supplement|300 mg GSE|300 mg GSE
254996|NCT02254317|Dietary Supplement|600 mg GSE|Containing 600 mg of GSE
254997|NCT02254317|Dietary Supplement|900 mg GSE|Containing 900 mg of GSE
254998|NCT02254304|Drug|Rebif|Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.
254999|NCT02254291|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
255091|NCT02253914|Drug|BILR 355 BS, tablet|
255092|NCT02253914|Drug|Ritonavir|
255093|NCT02253914|Drug|Placebo|
255000|NCT02254291|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
255001|NCT02254291|Drug|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
255002|NCT02254278|Drug|Cisplatin|Given IV
255003|NCT02254278|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
255004|NCT02254278|Other|Laboratory Biomarker Analysis|Correlative studies
255005|NCT02254278|Other|Quality-of-Life Assessment|Ancillary studies
255006|NCT02254265|Drug|OTX-101 0.05%|OTX-101 0.05% Ophthalmic Solution
255007|NCT02254265|Drug|OTX-101 0.09%|OTX-101 0.09% Ophthalmic Solution
255008|NCT02254265|Drug|Vehicle|Vehicle of OTX-101 Ophthalmic Solution
255009|NCT02254252|Drug|Nicorandil|nicorandil (10mg tablets, two times a day)
255010|NCT02254252|Drug|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
255011|NCT02254239|Drug|Brentuximab Vedotin|Given IV
255012|NCT02254239|Drug|Everolimus|Given PO
255013|NCT02254239|Other|Laboratory Biomarker Analysis|Correlative studies
255014|NCT02254239|Other|Pharmacological Study|Correlative studies
255015|NCT02254226|Drug|Salmeterol Diskus low|
255016|NCT02254226|Drug|Salmeterol Diskus high|
255017|NCT02254226|Drug|Salmeterol MDI low|
255018|NCT02254226|Drug|Salmeterol MDI high|
255019|NCT02254213|Other|EEG recording|A short EEG recording is performed 10 times over the span of three months.
255020|NCT02254200|Other|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
255021|NCT02254200|Other|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of ~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
255022|NCT02254187|Drug|Salmeterol capsule - low|
255023|NCT02254187|Drug|Salmeterol capsule - high|
255024|NCT02254187|Drug|Salmeterol via Serevent® Diskus®|
255025|NCT02254174|Drug|Tiotropium/Salmeterol|Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
255026|NCT02254174|Drug|Serevent® Diskus®|
255027|NCT02254174|Drug|Spiriva®|
255028|NCT02254161|Drug|Matching placebo|Tablet
255029|NCT02254161|Drug|BI 1181181 healthy elderly|Tablet
255030|NCT02254161|Drug|BI 1181181 Healthy young|Tablet
255031|NCT02254148|Drug|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
255032|NCT02254148|Drug|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
255033|NCT02254148|Drug|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
255034|NCT02254148|Drug|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
255035|NCT02254148|Drug|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
255036|NCT02254148|Drug|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
255037|NCT02254148|Drug|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
255038|NCT02254135|Drug|BEA 2180 BR - rising dose|
255039|NCT02254135|Drug|Placebo|
255040|NCT02254122|Drug|BEA 2180 BR|
255041|NCT02254122|Drug|Placebo|
255042|NCT02254122|Device|Respimat®|
255043|NCT02254109|Drug|BEA 2180 BR - rising dose|
255044|NCT02254109|Drug|Placebo|
255045|NCT02254096|Drug|BIRT 1696 BS|
255046|NCT02254096|Drug|Placebo|
255047|NCT02254096|Other|Grapefruit juice (GFJ)|
255048|NCT02254096|Other|High fat meal (HFM)|
255049|NCT02254083|Drug|BIBT 986 BS - low|
255050|NCT02254083|Drug|BIBT 986 BS - high|
255051|NCT02254083|Drug|Placebo|
255052|NCT02254070|Drug|BIBT 986 BS|
255053|NCT02254057|Drug|BIBT 986 BS - single rising dose|
255054|NCT02254057|Drug|Placebo|
255055|NCT02254044|Drug|bivatuzumab mertansine|
255056|NCT02254031|Drug|bivatuzumab mertansine|
255057|NCT02254018|Drug|bivatuzumab mertansine|
255058|NCT02254005|Drug|bivatuzumab mertansine|
255059|NCT02253992|Biological|Urelumab|
255060|NCT02253992|Biological|Nivolumab|
255061|NCT02253979|Device|Standard double lumen tube|Endotracheal left side double lumen tube
255062|NCT02253979|Device|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
255063|NCT02253966|Drug|Methylprednisoloneacetate|
255064|NCT02253966|Drug|Lidocaine|
255065|NCT02253966|Other|sodium chloride|
255066|NCT02253953|Drug|BILR 355 BS, D1|
255067|NCT02253953|Drug|BILR 355 BS, D2|
255068|NCT02253953|Drug|BILR 355 BS, D3|
255069|NCT02253953|Drug|BILR 355 BS, D4|
255070|NCT02253953|Drug|BILR 355 BS, D5|
255071|NCT02253953|Drug|BILR 355 BS, D6|
255072|NCT02253953|Drug|BILR 355 BS, D7|
255073|NCT02253953|Drug|BILR 355 BS, D8|
255074|NCT02253953|Drug|BILR 355 BS, D10|
255075|NCT02253953|Drug|Placebo|
255076|NCT02253953|Other|high-fat breakfast|
255077|NCT02253953|Drug|Ritonavir|
255078|NCT02253940|Drug|BILR 355 - Treatment A (current tablet formulation)|
255079|NCT02253940|Drug|BILR 355 - Treatment B (new tablet formulation)|
255080|NCT02253940|Drug|BILR 355 - Treatment C (new capsule formulation)|
255081|NCT02253940|Drug|BILR 355 - Treatment D (current tablet formulation)|
255082|NCT02253940|Drug|BILR 355 - Treatment E (new capsule formulation)|
255083|NCT02253940|Drug|Ritonavir|
255084|NCT02253927|Drug|BILR 355 - D1|
255085|NCT02253927|Drug|BILR 355 - D2|
255097|NCT02253888|Drug|TPV - Room condition|
255098|NCT02253888|Drug|TPV - Refrigerated conditions|
255099|NCT02253888|Drug|Ritonavir (RTV)|
255100|NCT02253875|Drug|Tipranavir (TPV)|
255101|NCT02253875|Drug|Ritonavir|
255102|NCT02253875|Drug|Omeprazole|
255103|NCT02253862|Drug|Tadalafil|administered days 1, 8 and 16
255104|NCT02253862|Drug|Tipranavir|administered days 8-18
255105|NCT02253862|Drug|Ritonavir|administered days 8-18
255106|NCT02253849|Drug|Carbamazepine|
255107|NCT02253849|Drug|Tipranavir|
255108|NCT02253849|Drug|Ritonavir|
255109|NCT02253836|Drug|Tipranavir|TPV
255110|NCT02253836|Drug|Ritonavir|RTV
255111|NCT02253836|Drug|Atazanavir|TAZ
255112|NCT02253823|Drug|EFV|
255113|NCT02253823|Drug|TPV/RTV - low dose|
255114|NCT02253823|Drug|TPV/RTV - high dose|
255115|NCT02253810|Drug|Tranexamic Acid|
255116|NCT02253810|Drug|Placebo|
255117|NCT02253797|Drug|14C-Tipranavir|
255118|NCT02253797|Drug|Tipranavir|
255119|NCT02253797|Drug|Ritonavir|
255120|NCT02253784|Drug|Dexamethasone|
255121|NCT02253784|Drug|Bupivacaine|
255122|NCT02253771|Device|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
255123|NCT02253758|Drug|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
255124|NCT02253745|Drug|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
255125|NCT02253745|Drug|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
255126|NCT02253732|Behavioral|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength & aerobic exercises
255127|NCT02253719|Procedure|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
255128|NCT02253706|Device|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
255129|NCT02253706|Device|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
255130|NCT02253680|Procedure|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
255131|NCT02253667|Device|HFONC|
255132|NCT02253667|Device|Conventional oxygen therapy|
255133|NCT02253654|Drug|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
255134|NCT02253641|Behavioral|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
255135|NCT02253641|Behavioral|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
255136|NCT02253628|Other|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255137|NCT02253628|Other|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255138|NCT02253628|Other|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255139|NCT02253628|Other|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
255140|NCT02253615|Other|Machines exercises|Resistance training in pneumatic machines.
255141|NCT02253615|Other|Elastic exercises|Resistance training with elastic tubes.
255142|NCT02253602|Drug|Ferumoxytol|maximum rate of administration 1 ml/sec
255143|NCT02253589|Behavioral|modified ASSIST-linked Brief Intervention|Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
255144|NCT02253576|Other|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
255145|NCT02253576|Other|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
255146|NCT02253563|Behavioral|Resistance Training|
255147|NCT02253563|Behavioral|Balance Training|
255148|NCT02253550|Drug|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
255149|NCT02253550|Drug|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
255150|NCT02253537|Device|CST001|
255151|NCT02253524|Drug|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
255152|NCT02253524|Drug|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
255153|NCT02253511|Drug|Cidan capsule|
255154|NCT02253498|Device|deep brain stimulation (DBS)|
255155|NCT02253485|Drug|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.~in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
255156|NCT02253472|Device|Deep Brain Stimulation|
255157|NCT02253459|Drug|UTD1 Injection plus capecitabine|
255159|NCT02253446|Drug|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
255160|NCT02253446|Drug|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
255161|NCT02253433|Other|Enhanced Clinic Care|The intervention includes a standard clinical appointment including spirometry, as well as collection of self-report information from detailed health and exposure questionnaires, asthma education, assessment for allergies, and a customized asthma self-management plan developed using motivational interviewing.
255162|NCT02253433|Other|Enhanced Clinic Care + Home Intervention|The home-based component includes environmental exposure assessment (observed and measured) and a multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
255163|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose TBD (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose TBD (based on part 1 data)~Part 1 & Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
255164|NCT02253420|Drug|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
255165|NCT02253420|Drug|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
255166|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
255167|NCT02253407|Biological|MMR vaccine|
255168|NCT02253394|Drug|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
255169|NCT02253394|Drug|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
255170|NCT02253381|Procedure|Right|Right lateral decubitus position during spinal anesthesia
255171|NCT02253381|Procedure|Left|Left lateral decubitus position during spinal anesthesia
255172|NCT02253368|Other|sleep|
255173|NCT02253355|Device|Deep Brain Stimulation|
255174|NCT02253342|Drug|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
255175|NCT02253329|Procedure|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
255176|NCT02253329|Procedure|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
255177|NCT02253316|Biological|Ixazomib|
255178|NCT02253316|Drug|Lenalidomide|
255179|NCT02253316|Drug|Dexamethasone|
255180|NCT02253303|Other|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
255181|NCT02253277|Drug|Nilotinib|Nilotinib was supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib was not dosed by weight or body surface area. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take nilotinib exactly as prescribed.
255182|NCT02253277|Drug|Ruxolitinib|Ruxolitinib was supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels were in German and complied with the legal requirements of Germany. They included storage conditions for the drug but no information about the patient. The investigator emphasized compliance and instructed the patient to take ruxolitinib exactly as prescribed.
255183|NCT02253264|Drug|Rituximab|
255184|NCT02253251|Genetic|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
255185|NCT02253238|Behavioral|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
255186|NCT02253238|Behavioral|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
255187|NCT02253238|Other|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
255188|NCT02253238|Behavioral|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.~Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
255189|NCT02253238|Behavioral|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
255190|NCT02253225|Other|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
255191|NCT02253212|Device|SonoCloud|SonoCloud : dose escalation
255192|NCT02253212|Drug|Carboplatin|Carboplatin : min 6 cycles - individual dose determination according to renal function and AUC
255193|NCT02253199|Drug|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.~The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
255194|NCT02253186|Device|Auto-Adjustable MOBIDERM Armsleeve|
255195|NCT02253173|Drug|Estradiol|
255196|NCT02253173|Drug|Placebo|
255197|NCT02253160|Device|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
255198|NCT02253160|Device|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
255310|NCT02252354|Drug|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
255199|NCT02253160|Drug|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
255200|NCT02253147|Device|TEOSYAL® RHA Ultra Deep|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27Gauge ½ disposable sterile needles."
255201|NCT02253121|Drug|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
255202|NCT02253121|Drug|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
255203|NCT02253108|Device|Everolimus eluting bioresorbable polymer stent|
255204|NCT02253108|Device|Biolimus eluting bioresorbable polymer stent|
255205|NCT02253095|Drug|Albendazole|
255206|NCT02253095|Dietary Supplement|Zinc|
255207|NCT02253095|Dietary Supplement|Multiple Micronutrient Supplement|
255208|NCT02253095|Drug|Placebo|
255209|NCT02253082|Drug|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
255210|NCT02253082|Biological|Fresh frozen plasma|Standard FFP from the Blood Bank
255211|NCT02253069|Device|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
255212|NCT02253069|Device|Applying Placebo to tie-over dressings|Placebo control
255213|NCT02253056|Other|Fasting / Caloric Restriction|
255214|NCT02253056|Other|Healthy Diet|
255215|NCT02253043|Device|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
255216|NCT02253030|Device|Optical Coherence Tomography|
255217|NCT02253017|Other|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
255218|NCT02253004|Drug|Cilostazol|Single oral administration of active or placebo one week apart
255219|NCT02253004|Drug|Placebo|
255220|NCT02252991|Other|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
255221|NCT02252978|Drug|ciprofloxacin|Given PO
255222|NCT02252978|Other|placebo|Given PO
255223|NCT02252978|Other|quality-of-life assessment|Ancillary studies
255224|NCT02252978|Other|laboratory biomarker analysis|Correlative studies
255225|NCT02252965|Drug|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
255226|NCT02252965|Drug|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
255227|NCT02252952|Other|Beverage Consumption|
255228|NCT02252939|Radiation|X-Ray|X-ray as part of standard care
255229|NCT02252926|Drug|Bupivacaine|25 mg bupivacaine lozenge
255230|NCT02252926|Drug|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
255231|NCT02252913|Drug|Volitinib|oral administration
255232|NCT02252913|Drug|Docetaxel|intravenous injection
255233|NCT02252900|Other|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
255234|NCT02252887|Drug|Gemcitabine|
255235|NCT02252887|Drug|Trastuzumab|
255236|NCT02252887|Drug|Pertuzumab|
255237|NCT02252874|Behavioral|Slow-paced action video game|20 hours slow-paced action video games
255238|NCT02252874|Behavioral|Fast-paced action video game|20 hours fast-paced action video games
255239|NCT02252874|Behavioral|Control|20 hours leisure activities
255240|NCT02252861|Other|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
255241|NCT02252835|Drug|Arhalofenate|800 mg once daily orally for four weeks
255242|NCT02252835|Drug|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
255243|NCT02252835|Drug|Arhalofenate|600 mg once daily orally for four weeks
255244|NCT02252835|Drug|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
255245|NCT02252835|Drug|Colchicine|0.6 mg daily
255246|NCT02252822|Behavioral|Overcoming Bulimia Online Programme|
255247|NCT02252809|Drug|adalimumab|
255248|NCT02252809|Drug|methylprednisolone|
255249|NCT02252796|Radiation|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
255250|NCT02252796|Drug|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
255251|NCT02252796|Drug|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
255252|NCT02252796|Radiation|Image-guided IMRT|Given during chemo-radiation phase
255311|NCT02252354|Drug|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
255312|NCT02252354|Drug|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
255253|NCT02252783|Drug|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
255254|NCT02252770|Dietary Supplement|Nitric oxide supplement|Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
255255|NCT02252770|Dietary Supplement|Placebo|Placebo will not contain nitric oxide supplement.
255256|NCT02252757|Device|CoVa|
255257|NCT02252744|Other|No intervention|
255258|NCT02252731|Drug|Warfarin|Oral
255259|NCT02252731|Drug|FG-4592|Oral
255260|NCT02252718|Other|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
255261|NCT02252692|Drug|Enalapril|oral administration
255262|NCT02252666|Device|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
255263|NCT02252640|Biological|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
255264|NCT02252640|Biological|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
255265|NCT02252640|Biological|ChAd63 ME-TRAP (5 x 10^10 vp)|
255266|NCT02252640|Biological|MVA ME-TRAP (2 x 10^8 pfu)|
255267|NCT02252627|Drug|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
255268|NCT02252627|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
255269|NCT02252627|Other|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
255270|NCT02252627|Drug|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
255271|NCT02252614|Drug|naproxen sodium codein|Pain intensity, contramal consumption
255272|NCT02252614|Drug|paracetamol codein|Pain intensity, contramal consumption
255273|NCT02252614|Drug|Placebo|Pain intensity, contramal consumption
255274|NCT02252601|Other|HFDT test|
255275|NCT02252601|Other|Pure tone Audiogram|
255276|NCT02252588|Drug|Chlorhexidine|Oral Rinse
255277|NCT02252588|Other|Placebo|Oral Rinse
255278|NCT02252575|Device|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
255279|NCT02252562|Device|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
255280|NCT02252549|Device|SPIES+WLI assisted TURB|
255281|NCT02252549|Device|WLI assisted TURB|
255282|NCT02252536|Drug|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
255283|NCT02252536|Drug|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
255284|NCT02252523|Drug|Dexmedetomidine|
255285|NCT02252510|Other|HALOSPERM|
255286|NCT02252497|Drug|Active comparator : Tranexamic Acid (Exacyl)|"1g Exacyl Intra Venous, just before surgery~Then infusion of 1g of Exacyl over eight hours ."
255287|NCT02252497|Drug|Placebo comparator : physiologic serum|"1g Intra Venous just before surgery~Then infusion of 1g of physiologic serum over eight hours"
255288|NCT02252484|Other|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
255289|NCT02252484|Other|Standard of Care|Standard of Care for this patient population.
255290|NCT02252471|Behavioral|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
255291|NCT02252458|Drug|Fentanyl|
255292|NCT02252445|Drug|Propofol|Propofol will be administered.
255293|NCT02252445|Drug|Sevoflurane|Sevoflurane will be administered.
255294|NCT02252432|Drug|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
255295|NCT02252432|Drug|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
255296|NCT02252432|Drug|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
255297|NCT02252419|Drug|Dexamethasone|Dexamethasone will be administered.
255298|NCT02252419|Drug|Paracetamol|Paracetamol will be administered.
255299|NCT02252406|Drug|Ranolazine|Ranolazine 500 mg from baseline to week 3
255300|NCT02252406|Drug|Placebo|Matching placebo tablets daily for 24 weeks.
255301|NCT02252406|Drug|Ranolazine|Ranolazine 1000mg daily at week 3 until weeks 24.
255302|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with IUD
255303|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with EUD
255304|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with IUD
255305|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with EUD
255306|NCT02252393|Other|quality-of-life assessment|Ancillary studies
255307|NCT02252380|Device|Transcranial ExAblate System|MR Guided Focused Ultrasound
255308|NCT02252367|Drug|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
255309|NCT02252367|Other|Placebo|Placebo tablet once daily for 12 weeks.
255496|NCT02251184|Drug|Aggrenox|
255313|NCT02252341|Dietary Supplement|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
255314|NCT02252328|Drug|Simvastatin|Simvastatin 80mg once daily
255315|NCT02252328|Drug|Placebo|Placebo tablets once daily
255316|NCT02252315|Other|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
255317|NCT02252315|Other|Verbal education module|A structured in-person education module about mild traumatic brain injury.
255318|NCT02252302|Other|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
255319|NCT02252302|Other|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 55% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
255320|NCT02252302|Drug|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
255321|NCT02252302|Drug|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
255322|NCT02252302|Other|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
255323|NCT02252302|Other|Filtered air|Participants will be breathing filtered air
255324|NCT02252276|Procedure|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
255325|NCT02252276|Procedure|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
255326|NCT02252263|Drug|Elotuzumab|
255327|NCT02252263|Drug|Lirilumab|
255328|NCT02252263|Drug|Urelumab|
255329|NCT02252250|Procedure|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
255330|NCT02252250|Procedure|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
255331|NCT02252237|Biological|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at two following visits. Buccal cell collection swab
255332|NCT02252211|Drug|DS-8895a 1 mg/kg|Patients received infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 1 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 1 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
255333|NCT02252211|Drug|DS-8895a 3 mg/kg|Patients received infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 3 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 3 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
255334|NCT02252211|Drug|DS-8895a 10 mg/kg|Patients were to receive infusions with ^89Zr-Df-DS-8895a at a dose of 0.2 mg/kg on Day 1, DS-8895a at a dose of 10 mg/kg on Days 8 and 22, and ^89Zr-Df-DS-8895a at a dose of 10 mg/kg on Day 36. Patients who responded or had stable disease per RECIST version 1.1 at the Day 50 restaging may have continued to receive biweekly treatment with DS-8895a until disease progression.
255335|NCT02252198|Other|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
255336|NCT02252185|Device|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson & Johnson Medical Suzhou Ltd.
255337|NCT02252185|Device|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
255338|NCT02252172|Drug|Daratumumab|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
255339|NCT02252172|Drug|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
255340|NCT02252172|Drug|Dexamethasone|Dexamethasone 40 mg orally or intravenously once in a week.
255341|NCT02252146|Drug|IMO-8400|MO-8400 given subcutaneously twice weekly
255342|NCT02252133|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear
255343|NCT02252133|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear
255344|NCT02252120|Device|Supreme|
255345|NCT02252120|Device|Laryngeal Tube|
255346|NCT02252107|Drug|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
255347|NCT02252094|Device|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
255348|NCT02252094|Other|Ultra-protective ventilation|Ventilation with </= 3ml/kg predicted body weight
255349|NCT02252094|Other|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
255497|NCT02251184|Drug|Dipyridamole|
255350|NCT02252081|Drug|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
255351|NCT02252081|Drug|Placebo|placebo pill(s) orally per day for 16 weeks
255352|NCT02252068|Behavioral|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
255353|NCT02252068|Behavioral|IDC|Individual Drug Counseling manual that has demonstrated efficacy for the treatment of drug dependence.
255354|NCT02252055|Biological|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.~Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
255355|NCT02252042|Biological|pembrolizumab|
255356|NCT02252042|Drug|methotrexate|
255357|NCT02252042|Drug|docetaxel|
255358|NCT02252042|Biological|cetuximab|
255359|NCT02252016|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
255360|NCT02252016|Drug|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
255361|NCT02252003|Other|Pain scales testing|
255362|NCT02251990|Drug|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
255363|NCT02251990|Drug|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
255364|NCT02251977|Drug|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
255365|NCT02251977|Drug|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
255366|NCT02251977|Drug|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
255367|NCT02251964|Drug|Rituximab|2 times 1000mg dose at 14 days interval treatment
255368|NCT02251964|Radiation|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
255369|NCT02251951|Drug|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
255370|NCT02251938|Drug|DE-109|Medium Dose of DE-109
255371|NCT02251925|Biological|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
255372|NCT02251925|Drug|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
255373|NCT02251925|Drug|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
255374|NCT02251925|Drug|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
255375|NCT02251912|Drug|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
255376|NCT02251912|Drug|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
255377|NCT02251899|Behavioral|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
255378|NCT02251886|Other|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
255379|NCT02251886|Other|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
255380|NCT02251873|Drug|TPV + RTV (low dose)|
255381|NCT02251873|Drug|TPV + RTV (high dose)|
255382|NCT02251873|Drug|ddl|
255383|NCT02251847|Drug|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
255384|NCT02251834|Behavioral|Community Health Worker (CHW)|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
255385|NCT02251834|Other|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
255386|NCT02251821|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
255387|NCT02251821|Drug|Busulfan|Given IV
255388|NCT02251821|Drug|Cyclophosphamide|Given IV
255389|NCT02251821|Drug|Fludarabine Phosphate|Given IV
255390|NCT02251821|Other|Laboratory Biomarker Analysis|Correlative studies
255391|NCT02251821|Drug|Melphalan|Given IV
255392|NCT02251821|Drug|Methotrexate|Given IV
255393|NCT02251821|Drug|Mycophenolate Mofetil|Given IV or PO
255394|NCT02251821|Drug|Ruxolitinib|Given PO
255395|NCT02251821|Drug|Tacrolimus|Given IV or PO
255396|NCT02251821|Radiation|Total-Body Irradiation|Undergo TBI
255397|NCT02251821|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
255398|NCT02251795|Drug|Tipranavir|
255399|NCT02251795|Drug|Ritonavir|
255400|NCT02251795|Drug|Darunavir|
255401|NCT02251795|Drug|Aspirin|single dose on day 2
255402|NCT02251782|Device|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
255403|NCT02251782|Device|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
255404|NCT02251769|Drug|Tipranavir|
255405|NCT02251769|Drug|Ritonavir|
255406|NCT02251769|Drug|Clarithromycin|
255407|NCT02251769|Other|High-Fat Test Meal|
255408|NCT02251756|Device|Actinica, 0.8 mg/cm2, 1 application|
255409|NCT02251756|Device|Actinica, 0.8 mg/cm2, 2 applications|
255410|NCT02251756|Device|Actinica, 2 mg/cm2, 1 application|
255411|NCT02251756|Device|Actinica, 2 mg/cm2, 2 applications|
255412|NCT02251743|Device|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:~The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)~Average voltage of theta waves~Average voltage of beta~Average ratio of theta to beta power (TBR)"
255413|NCT02251730|Behavioral|Smoking cessation|Refer for smoking cessation
255414|NCT02251717|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
255415|NCT02251704|Procedure|Blood sampling|Capillary blood samples collected for determination of parasite prevalence at the time of survey.
255416|NCT02251704|Procedure|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
255417|NCT02251691|Drug|Advagraf|Compare the drug compliance between once daily or twice daily regimen
255418|NCT02251691|Drug|Prograf|Compare the drug compliance between once daily or twice daily regimen
255419|NCT02251678|Dietary Supplement|Elimune Capsules|2 capsules BID for 28 days
255420|NCT02251665|Other|No intervention|a single-center prospective observational study
255421|NCT02251652|Drug|Ingenol Mebutate|Ingenol mebutate 0.05% gel
255422|NCT02251652|Procedure|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
255423|NCT02251639|Behavioral|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
255424|NCT02251639|Device|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
255425|NCT02251639|Procedure|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
255426|NCT02251626|Dietary Supplement|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
255427|NCT02251626|Dietary Supplement|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
255428|NCT02251613|Drug|Olopatadine HCl ophthalmic solution, 0.1%|
255429|NCT02251613|Drug|Epinastine HCl ophthalmic solution, 0.05%|
255430|NCT02251600|Drug|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
255431|NCT02251587|Other|Standard Weight Management Program|Standard Diet program based on diet and exercise.
255432|NCT02251587|Other|Sensible Weigh Program|Weight loss program designed for low income women.
255433|NCT02251574|Other|Low Calorie Diet|Weight management program designed around a low calorie diet.
255434|NCT02251574|Other|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
255435|NCT02251574|Other|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
255436|NCT02251561|Device|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
255437|NCT02251561|Device|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
255438|NCT02251561|Device|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
255439|NCT02251548|Drug|Ibrutinib|Oral BTK inhibitor
255440|NCT02251548|Drug|Fludarabine|IV purine analogue chemotherapy agent
255441|NCT02251548|Drug|Cyclophosphamide|IV alkylator chemotherapy agent
255442|NCT02251548|Drug|Rituximab|IV anti-CD20 monoclonal antibody
255443|NCT02251535|Device|ATTUNE® Knee System|
255444|NCT02251535|Device|PFC® SIGMA® Knee System|
255445|NCT02251522|Device|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
255498|NCT02251184|Drug|Aspirin|
255499|NCT02251184|Drug|Lansoprazole|
255446|NCT02251522|Device|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
255447|NCT02251509|Drug|Carvedilol|
255448|NCT02251509|Drug|Metoprolol tartrate|
255449|NCT02251496|Other|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
255450|NCT02251496|Other|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
255451|NCT02251483|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|
255452|NCT02251483|Other|Placebo|
255453|NCT02251470|Other|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
255454|NCT02251470|Other|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
255455|NCT02251457|Drug|Ranolazine|Ranexa is FDA approved for chronic angina
255456|NCT02251444|Procedure|outpatient rehabilitation program|
255457|NCT02251444|Procedure|physical therapy|
255458|NCT02251431|Drug|BYDUREON|Exenatide-extended release, Cohorts A and B
255459|NCT02251431|Drug|Placebo|Cohort A only
255460|NCT02251418|Device|Extracorporeal shockwave therapy|
255461|NCT02251405|Behavioral|One bag, stainless container|
255462|NCT02251392|Other|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
255463|NCT02251392|Other|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
255464|NCT02251392|Drug|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
255465|NCT02251379|Drug|Flovent Diskus|Inhaled corticosteroids
255466|NCT02251379|Other|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
255467|NCT02251379|Drug|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
255468|NCT02251366|Procedure|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
255469|NCT02251353|Procedure|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
255470|NCT02251353|Drug|systemic treatment|Systemic therapy
255471|NCT02251340|Behavioral|Eczema Care Plan|
255472|NCT02251327|Device|Investigational Xpert DST test|One investigational test performed directly on the same sputum specimen.
255473|NCT02251301|Dietary Supplement|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
255474|NCT02251301|Behavioral|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
255475|NCT02251301|Other|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
255476|NCT02251301|Dietary Supplement|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
255477|NCT02251288|Biological|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
255478|NCT02251288|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
255479|NCT02251288|Drug|MF59 adjuvant|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
255480|NCT02251275|Drug|Tolvaptan|Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
255481|NCT02251262|Device|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
255482|NCT02251249|Drug|Paracetamol concentration time curve from 0 to 120 min|It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
255483|NCT02251236|Drug|Stribild|To be administered orally, once daily with food.
255484|NCT02251236|Drug|Genvoya|To be administered orally, once daily with food.
255485|NCT02251223|Drug|Tipranavir low dose|
255486|NCT02251223|Drug|Tipranavir medium dose|
255487|NCT02251223|Drug|Tipranavir high dose|
255488|NCT02251223|Drug|Ritonavir low dose|
255489|NCT02251223|Drug|Ritonavir high dose|
255490|NCT02251210|Drug|BIIL 284 BS low dose|
255491|NCT02251210|Drug|BIIL 284 BS medium dose|
255492|NCT02251210|Drug|BIIL 284 BS high dose|
255493|NCT02251210|Drug|Placebo|
255494|NCT02251197|Drug|BIII 890 CL|
255495|NCT02251197|Drug|Placebo|
255503|NCT02251158|Drug|Tipranavir oral solution|
255504|NCT02251158|Drug|Tipranavir capsules|
255505|NCT02251158|Drug|Ritonavir oral solution|
255506|NCT02251158|Drug|Ritonavir soft gel capsules|
255507|NCT02251158|Other|High fat breakfast|
255508|NCT02251145|Drug|Tipranavir low dose|
255509|NCT02251145|Drug|Tipranavir high dose|
255510|NCT02251145|Drug|Ritonavir low dose|
255511|NCT02251145|Drug|Ritonavir high dose|
255512|NCT02251145|Drug|Tenofovir disoproxil fumarate|
255513|NCT02251132|Drug|TPV low 1|
255514|NCT02251132|Drug|TPV low 2|
255515|NCT02251132|Drug|TPV medium|
255516|NCT02251132|Drug|TPV high 1|
255517|NCT02251132|Drug|TPV high 2|
255518|NCT02251132|Drug|RTV low|
255519|NCT02251132|Drug|Ritonavir high|
255520|NCT02251132|Drug|Radiolabelled erythromycin|
255521|NCT02251119|Drug|Tipranavir|
255522|NCT02251119|Drug|Ritonavir|
255523|NCT02251119|Drug|Loperamide|
255524|NCT02251106|Device|Lumbar corset (Quickdraw, Aspen Medical Products)|The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
255525|NCT02251093|Drug|Lcr Regenerans|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
255526|NCT02251093|Drug|Placebo|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
255527|NCT02251067|Drug|VPI-2690B low dose|Comparison of different doses of study drug
255528|NCT02251067|Drug|VPI-2690B medium dose|Comparison of different doses of study drug
255529|NCT02251067|Drug|Placebo to match VPI-2690B|
255530|NCT02251067|Drug|VPI-2690B high dose|Comparison of different doses of study drug
255531|NCT02251054|Other|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
255532|NCT02251054|Other|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
255533|NCT02251041|Drug|Antithrombin-III|
255534|NCT02251041|Drug|Infliximab|
255535|NCT02251041|Drug|Apotransferrin|
255536|NCT02251041|Drug|Human recombinant erythropoietin|
255537|NCT02251041|Drug|C1-Inhibitor|
255538|NCT02251041|Drug|Glutathione|
255539|NCT02251041|Drug|Alfa-tocopherol|
255540|NCT02251041|Drug|Melatonin|
255541|NCT02251041|Drug|Epoprostenol|
255542|NCT02251041|Drug|Sodium chloride solution|
255543|NCT02251028|Behavioral|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
255544|NCT02251015|Procedure|occlusal plate|"In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.~The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day."
255545|NCT02251015|Procedure|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
255546|NCT02250976|Drug|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
255547|NCT02250976|Drug|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
255548|NCT02250976|Drug|Livaro tab. 2mg|Pitavastatin Ca 2mg
255549|NCT02250950|Behavioral|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
255550|NCT02250950|Behavioral|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
255551|NCT02250937|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
255552|NCT02250937|Drug|Busulfan|Given IV
255553|NCT02250937|Drug|Cladribine|Given IV
255554|NCT02250937|Drug|Fludarabine Phosphate|Given IV
255555|NCT02250937|Other|Laboratory Biomarker Analysis|Correlative studies
255556|NCT02250937|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
255557|NCT02250937|Other|Pharmacological Study|Correlative studies
255558|NCT02250937|Drug|Venetoclax|Given PO
255559|NCT02250924|Dietary Supplement|Caffeine|
255560|NCT02250924|Other|Gum|Chewing gum
255561|NCT02250924|Behavioral|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
255562|NCT02250911|Other|webcasts|
255563|NCT02250911|Behavioral|Assessments|
255564|NCT02250911|Other|Usual care|
255622|NCT02250456|Procedure|Echo doppler|vascular ultrasound explorations
255623|NCT02250443|Drug|BYM338 (Bimagrumab)|
255624|NCT02250430|Drug|SB204|Applied topically twice a day on days 1, 2 and 3 to left and right cheeks
255565|NCT02250898|Other|Myofascial Massage Therapy|Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
255566|NCT02250898|Other|Global Relaxation Massage|Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
255567|NCT02250885|Drug|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
255568|NCT02250872|Drug|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
255569|NCT02250872|Drug|Placebo|100mg in 2 divided doses plus cisplatin
255570|NCT02250872|Drug|Cisplatin|All patients will receive intravenous cisplatin
255571|NCT02250859|Drug|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
255572|NCT02250846|Drug|EGFR-TKI|egfr-TKI treatment
255573|NCT02250833|Drug|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
255574|NCT02250833|Drug|Telmisartan|- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
255575|NCT02250833|Drug|S-amlodipine|- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
255576|NCT02250820|Drug|Dexmedetomidine|Nasal administration
255577|NCT02250820|Drug|Pentobarbital|Oral administration
255578|NCT02250820|Other|Oral Placebo|Oral placebo will be cherry syrup
255579|NCT02250820|Other|Nasal Placebo|Nasal placebo will be nasally atomized saline
255580|NCT02250807|Drug|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
255581|NCT02250807|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
255582|NCT02250794|Drug|metformin and sitagliptin|metformin 750 mg PO twice daily
255583|NCT02250794|Drug|insulin glargine and insulin lispro|insulin glargine given once daily
255584|NCT02250794|Drug|metformin and sitagliptin|sitagliptin 100 mg PO once daily
255585|NCT02250794|Drug|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
255586|NCT02250781|Drug|Oral ONC201|Given PO
255587|NCT02250768|Biological|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
255588|NCT02250755|Other|MRI T1 T2 sequences|MRI
255589|NCT02250742|Other|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
255590|NCT02250729|Other|intradermal pholcodine allergy test in cases|
255591|NCT02250729|Other|Blood sampling|
255592|NCT02250716|Procedure|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
255593|NCT02250703|Drug|Midazolam|oral midazolam 0.5mg/kg upto maximum dose of 15mg
255594|NCT02250703|Drug|Dexmedetomidine|intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
255595|NCT02250690|Device|experimental group - tDCS|
255596|NCT02250690|Device|Control group (tDCS sham)|
255597|NCT02250664|Other|Very low nicotine content cigarettes|Very low nicotine content cigarettes
255598|NCT02250651|Drug|Bimatoprost sustained-release|Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
255599|NCT02250651|Other|Sham|Sham administered on Day 1, Week 16, and Week 32, as per protocol.
255600|NCT02250651|Drug|Timolol|Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
255601|NCT02250651|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
255602|NCT02250638|Other|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
255603|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose A|
255604|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose B|
255605|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose C|
255606|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose D|
255607|NCT02250612|Drug|1 drop of timolol maleate|0.5 %
255608|NCT02250599|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
255609|NCT02250599|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
255610|NCT02250599|Drug|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
255611|NCT02250586|Behavioral|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
255612|NCT02250573|Biological|Replenine®-VF (High Purity Factor IX)|
255613|NCT02250560|Biological|Replenine®-VF (High Purity Factor IX)|
255614|NCT02250534|Other|Very low nicotine content cigarettes|
255615|NCT02250521|Device|McGrath MAC enhanced direct laryngoscope|"The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct laryngoscopy with an inline video camera for an enhanced view.~All 100 patients will be intubated using the McGRATH® MAC video laryngoscope, either through direct or indirect vision laryngoscopy. The LCD monitor of the McGRATH™ MAC was initially covered; if the anesthesiologist visualized a modified C-L grade 1-3 view, the patient was intubated utilizing this direct view. If the anesthesiologist observed a modified C-L grade 4 view during their initial direct view, the patient was intubated using the indirect method. If intubation via direct laryngoscopy was unsuccessful on the first attempt, the patient was intubated using the indirect view. If both methods of laryngoscopy were unsuccessful, the rescue intubation technique was performed at the discretion of the anesthesiologist."
255616|NCT02250508|Biological|Optivate® (Human Coagulation Factor VIII)|
255617|NCT02250508|Biological|Haemate P® (Human Coagulation Factor VIII)|
255618|NCT02250495|Device|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
255619|NCT02250482|Biological|Optivate® (Human Coagulation Factor VIII)|
255620|NCT02250469|Device|Treatment with the Axium SCS system|
255621|NCT02250469|Device|Treatment with the Medtronic SCS System|
255625|NCT02250417|Other|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
255626|NCT02250404|Other|cytology specimen collection procedure|Correlative studies
255627|NCT02250404|Other|laboratory biomarker analysis|Correlative studies
255628|NCT02250391|Drug|NPB-06|5 days continuous-infusion
255629|NCT02250391|Drug|Placebo|5 days continuous-infusion
255630|NCT02250378|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
255631|NCT02250378|Procedure|therapeutic conventional surgery|Undergo wedge resection
255632|NCT02250378|Other|laboratory biomarker analysis|Correlative studies
255633|NCT02250378|Other|quality-of-life assessment|Ancillary studies
255634|NCT02250365|Other|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
255635|NCT02250365|Other|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
255636|NCT02250352|Other|cytology specimen collection procedure|Correlative studies
255637|NCT02250339|Other|LAKU family program|Multi-systemic and multicomponent family-based intervention program
255638|NCT02250339|Other|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
255639|NCT02250339|Other|Family therapy|Treatment as usual (TAU)
255640|NCT02250326|Drug|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
255641|NCT02250326|Drug|CC-486|Oral CC-486
255642|NCT02250326|Drug|Duravalumab|
255643|NCT02250300|Drug|MLN9708|
255644|NCT02250274|Biological|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
255645|NCT02250274|Biological|IIV|"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.~[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.]"
255646|NCT02250261|Behavioral|KÄPY|
255647|NCT02250248|Biological|AttraX Putty|
255648|NCT02250248|Other|Iliac Crest Bone Graft (ICBG)|
255649|NCT02250235|Other|Health risk information|
255650|NCT02250222|Drug|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex [β-cyclodextrin] sulfobutylether sodium, NF)
255651|NCT02250222|Drug|Placebo (Captisol ®)|betadex [β-cyclodextrin] sulfobutylether sodium, NF
255652|NCT02250209|Drug|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14~16 cycles.
255653|NCT02250209|Drug|Capecitabine|"Capecitabine 800~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.~Number of cycles: 8 cycles."
255654|NCT02250209|Drug|Oxaliplatin|"Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles."
255655|NCT02250196|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
255656|NCT02250196|Drug|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
255657|NCT02250183|Device|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
255658|NCT02250183|Device|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
255659|NCT02250170|Drug|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
255660|NCT02250157|Drug|Oratecan|
255661|NCT02250144|Device|Foot orthoses|
255662|NCT02250131|Procedure|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery > 280 mL/min/m2
255663|NCT02250118|Drug|Bevacizumab|Intrapleural Bevacizumab
255664|NCT02250105|Drug|ARI-3037MO|Lipid lowering
255665|NCT02250105|Drug|Placebo|Inactive
255666|NCT02250092|Device|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
255667|NCT02250092|Device|Placebo Comparator|
255668|NCT02250079|Device|polyethylene plastic bag|Inborn neonates with both a gestational age >29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
255708|NCT02249741|Drug|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
255709|NCT02249728|Drug|IV PBT2 microtracer and oral PBT2 single dose|
255710|NCT02249728|Drug|oral 14C-PBT2|
255711|NCT02249715|Device|Brainsway Multiway deep TMS device (two channels)|
255712|NCT02249702|Drug|gemcitabine + docetaxel|
255713|NCT02249702|Drug|trabectedin|
255714|NCT02249689|Other|Definitive 65|
255715|NCT02249689|Other|Definitive 74|
255669|NCT02250079|Device|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
255670|NCT02250066|Other|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
255671|NCT02250053|Other|Exercise|
255672|NCT02250040|Other|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
255673|NCT02250040|Other|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
255674|NCT02250027|Drug|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
255675|NCT02250027|Drug|Placebo|2 capsules at once, 3 times a day, for 7 days
255676|NCT02250014|Procedure|cryotherapy|Undergo cryotherapy
255677|NCT02250014|Biological|sargramostim|Given subcutaneously
255678|NCT02249988|Drug|ABX203 therapeutic Hepatitis B vaccine treatment arm|
255679|NCT02249975|Device|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.~Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.~Evaluations include, but are not limited to the following:~Device malfunctions~Adverse events~Patient Pain~Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
255680|NCT02249949|Drug|efatutazone|Given PO
255681|NCT02249936|Drug|AZD1722|
255682|NCT02249936|Drug|Omeprazole|
255683|NCT02249910|Drug|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
255684|NCT02249910|Drug|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
255685|NCT02249910|Drug|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
255686|NCT02249910|Drug|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
255687|NCT02249897|Drug|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
255688|NCT02249884|Drug|Urea Dose A|Urea cream for topical use.
255689|NCT02249884|Drug|Urea Dose B|Urea cream for topical use.
255690|NCT02249884|Drug|Urea Dose C|Urea cream for topical use.
255691|NCT02249884|Drug|Chamomile Dose A|Chamomile gel for topical use.
255692|NCT02249884|Drug|Chamomile Dose B|Chamomile gel for topical use.
255693|NCT02249884|Drug|Chamomile Dose C|Chamomile gel for topical use.
255694|NCT02249871|Drug|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
255695|NCT02249871|Drug|Omeprazole|Will be given daily with oral semaglutide.
255696|NCT02249858|Procedure|Cranial Vault Hold|
255697|NCT02249858|Procedure|Cervical HVLA|
255698|NCT02249832|Device|seated robot-assisted ankle therapy|The MIT anklebot provides over one thousand total dorsi/plantar flexion and inversion/eversion robot-assisted movements of the ankle while in a seated position.
255699|NCT02249819|Device|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
255700|NCT02249806|Other|PH target therapy according to physician|Patients receiving PH target therapy
255701|NCT02249780|Procedure|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
255702|NCT02249780|Procedure|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
255703|NCT02249780|Procedure|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
255704|NCT02249780|Drug|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
255705|NCT02249767|Drug|Tretinoin|Treatment of acne once daily in evening
255706|NCT02249754|Behavioral|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
255707|NCT02249754|Behavioral|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
255716|NCT02249676|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
255717|NCT02249663|Drug|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
255718|NCT02249663|Drug|Dymista™|137/50 mcg Nasal Spray
255719|NCT02249663|Other|Placebo|Nasal spray with no pharmaceutically active content
255720|NCT02249650|Drug|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
255721|NCT02249637|Procedure|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
255722|NCT02249611|Device|Mobile physical activity promotion tool|"Mobile activity sensor~Smartphone with APP~Interactional webpage of internet~Evidence based health information~Individualized reminding messages according to the data from activity recording system~Personal counseling from professional personnel"
255723|NCT02249611|Other|Standard care|Counseling on lifestyles with health education material
255724|NCT02249598|Biological|lactamica|
255725|NCT02249598|Biological|Placebo|
255726|NCT02249585|Device|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
255727|NCT02249585|Device|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
255728|NCT02249585|Drug|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
255729|NCT02249585|Drug|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
255730|NCT02249572|Radiation|gamma knife radiosurgery|Leksell Perfection model gamma knife.
255731|NCT02249546|Drug|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
255732|NCT02249546|Drug|PPI-amoxicillin-clarithromycin|Triple therapy
255733|NCT02249533|Other|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
255734|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
255735|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
255736|NCT02249520|Other|MR imaging on the Siemens Vida 3T MR scanner|Participants will undergo MR imaging to test the technical aspects of the MR protocol on the Vida MR scanner
255737|NCT02249507|Other|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
255738|NCT02249494|Other|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
255739|NCT02249494|Other|nutritional counseling|Performing routine nutritional counseling in their clinical practice
255740|NCT02249494|Device|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
255741|NCT02249481|Procedure|Adductor Canal catheter delivering 0.0625% L- Bupivacaine|Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
255742|NCT02249481|Procedure|Femoral nerve catheter delivering 0.0625% L- Bupivacaine|Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
255743|NCT02249455|Device|Acapella|Treatment time for 20 min twice daily
255744|NCT02249455|Other|ELTGOL|ELTGOL technique 20 min twice daily
255745|NCT02249455|Other|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
255746|NCT02249442|Drug|Tipranavir (TPV)|
255747|NCT02249442|Drug|Ritonavir (r)|
255748|NCT02249429|Drug|bimiralisib|60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
255749|NCT02249416|Drug|Tipranavir (TPV) low|
255750|NCT02249416|Drug|Ritonavir (RTV) low|Norvir®
255751|NCT02249416|Drug|Tipranavir (TPV) high|Retrovir®
255752|NCT02249416|Drug|Ritonavir (RTV) high|
255753|NCT02249416|Drug|Zidovudine|
255754|NCT02249403|Drug|Talsaclidine 6 mg|
255755|NCT02249403|Drug|Talsaclidine 12 mg|
255756|NCT02249403|Drug|Talsaclidine 24 mg|
255757|NCT02249403|Drug|Talsaclidine 36 mg|
255758|NCT02249403|Drug|Placebo|
255759|NCT02249377|Other|Platelets-Rich-Plasma|Platelet-Rich Plasma
255760|NCT02249377|Drug|Corticosteroid|Corticosteroid
255761|NCT02249364|Procedure|Control|Routine practice
255762|NCT02249364|Procedure|Hypnosis|Hypnosis session before induction of anesthesia
255763|NCT02249364|Drug|propofol|Closed-loop administration of propofol for anesthesia induction
255764|NCT02249351|Drug|Talsaclidine|
255765|NCT02249351|Drug|Placebo|
255766|NCT02249338|Drug|BIIL 284 BS|
255767|NCT02249338|Drug|Placebo|
255768|NCT02249325|Dietary Supplement|Probiotic dietary supplement|Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
255769|NCT02249312|Drug|BIIL 284 BS|
255770|NCT02249312|Drug|Placebo|
255771|NCT02249299|Drug|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
255772|NCT02249299|Drug|Placebo|
255773|NCT02249286|Behavioral|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
255774|NCT02249286|Other|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
255775|NCT02249273|Other|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
255776|NCT02249260|Behavioral|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
255777|NCT02249247|Drug|Low dose of BIIL 284 BS tablets|
255778|NCT02249247|Drug|Medium dose of BIIL 284 BS tablets|
255779|NCT02249247|Drug|High dose of BIIL 284 BS tablets|
255780|NCT02249247|Drug|Placebo|
255781|NCT02249234|Drug|Botox|
255782|NCT02249234|Drug|Placebo|
255783|NCT02249221|Biological|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
255784|NCT02249221|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
255785|NCT02249208|Device|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
255786|NCT02249208|Device|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
255787|NCT02249208|Device|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
255788|NCT02249182|Drug|LDV/SOF|LDV/SOF FDC administered orally once daily
255789|NCT02249182|Drug|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
255790|NCT02249156|Behavioral|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
255791|NCT02249143|Device|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
255792|NCT02249130|Drug|Tipranavir (TPV)|
255793|NCT02249130|Drug|Ritonavir (RTV)|
255794|NCT02249130|Drug|Delavirdine (DLV)|
255795|NCT02249130|Drug|Zidovudine (ZDV)|
255796|NCT02249130|Drug|Lamivudine (3TC)|
255797|NCT02249130|Drug|Stavudine (d4T)|
255798|NCT02249117|Drug|BIWH 3|
255799|NCT02249117|Drug|Placebo|
255800|NCT02249104|Drug|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
255801|NCT02249104|Other|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
255802|NCT02249091|Drug|Selinexor|Patients receive Selinexor 40 mg/m2 twice weekly orally
255803|NCT02249091|Drug|Idarubcin|infusion, iv, 10 mg/m2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
255804|NCT02249091|Drug|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m2, iv,
255805|NCT02249078|Drug|E6011|E6011 solution for injection
255806|NCT02249078|Drug|Placebo|Placebo 2-mL vial solution for injection
255807|NCT02249065|Drug|Brimonidine|
255808|NCT02249052|Drug|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
255809|NCT02249052|Drug|placebo|Placebo
255810|NCT02249039|Drug|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
255811|NCT02249026|Drug|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
255894|NCT02248428|Drug|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
255895|NCT02248428|Drug|Cyclophosphamide|300mg/m^2 intravenously daily on day 1-3,repeated every 28 days
255896|NCT02248428|Drug|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
255812|NCT02249026|Drug|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
255813|NCT02249013|Procedure|Cytoreductive Surgery (CRS)|CRS has been performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
255814|NCT02249013|Procedure|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC was planed to be performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) [the first 10 patients] or CDDP plus Doxorubicin (15mg/L) [the last 10 patients] for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) has been circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
255815|NCT02249013|Drug|Neoadjuvant Chemotherapy (NACT)|Systemic chemotherapy has included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
255816|NCT02249013|Drug|Adjuvant Chemotherapy|Systemic chemotherapy has included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.
255817|NCT02249013|Procedure|Fast-track recovery strategy|A comprehensive fast-track program was planned to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
255818|NCT02249000|Device|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
255819|NCT02248987|Other|patients treated with antipsychotics|
255820|NCT02248974|Other|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.~This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
255821|NCT02248961|Drug|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).~If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).~When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
255822|NCT02248961|Drug|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg
255823|NCT02248948|Dietary Supplement|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
255824|NCT02248948|Dietary Supplement|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
255825|NCT02248922|Drug|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
255826|NCT02248896|Drug|Telmisartan|
255827|NCT02248896|Drug|Other angiotensin-receptor blockers (ARBs)|
255828|NCT02248896|Drug|Angiotensin-converting enzyme inhibitors (ACEIs)|
255829|NCT02248896|Drug|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
255830|NCT02248883|Drug|TPV low|
255831|NCT02248883|Drug|Placebo|
255832|NCT02248883|Drug|Moxifloxacin|
255833|NCT02248883|Drug|TPV high|
255834|NCT02248883|Drug|RTV|
255835|NCT02248870|Drug|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
255836|NCT02248870|Drug|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
255837|NCT02248857|Other|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
255838|NCT02248857|Other|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
255839|NCT02248844|Biological|Botulinum Toxin Type A|Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
255840|NCT02248831|Device|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
255841|NCT02248818|Drug|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
255842|NCT02248818|Drug|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
255843|NCT02248805|Drug|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
255844|NCT02248792|Drug|Methotrexate|
255845|NCT02248766|Device|somofilcon A|somofilcon A lens
255846|NCT02248753|Drug|Pharmacological cardioversion - Flecainide|
255847|NCT02248753|Procedure|Electrical cardioversion|
255848|NCT02248753|Drug|Metoprolol|
255849|NCT02248753|Drug|Verapamil|
255850|NCT02248753|Drug|Digoxin|
255851|NCT02248753|Drug|Pharmacological cardioversion - Amiodarone|
255897|NCT02248415|Other|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
255852|NCT02248740|Procedure|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
255853|NCT02248727|Device|somofilcon A|somofilcon A lens
255854|NCT02248714|Dietary Supplement|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
255855|NCT02248701|Drug|testosterone enanthate, finasteride|Subjects receive testosterone (125 mg/week) by intramuscular injection and finasteride (5 mg/day) orally
255856|NCT02248701|Drug|placebo|Subjects receive weekly placebo injection and placebo pill daily
255857|NCT02248688|Device|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
255858|NCT02248688|Procedure|Left Gastric Artery Embolization|
255859|NCT02248675|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
255860|NCT02248675|Other|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
255861|NCT02248649|Behavioral|Structured physical activity|Walking instruction and encouragement
255862|NCT02248649|Behavioral|Health education|Provision of general information about a variety of health topics
255863|NCT02248636|Drug|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
255864|NCT02248636|Drug|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
255865|NCT02248610|Other|Non-interventional study|
255866|NCT02248597|Drug|fludarabine phosphate|Given IV
255867|NCT02248597|Drug|busulfan|Given IV
255868|NCT02248597|Drug|cyclophosphamide|Given IV
255869|NCT02248597|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
255870|NCT02248597|Drug|tacrolimus|
255871|NCT02248597|Drug|mycophenolate mofetil|
255872|NCT02248584|Dietary Supplement|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
255873|NCT02248571|Drug|Bevacizumab|administered as combined therapy with Capecitabine
255874|NCT02248571|Drug|Capecitabine|administered as combined therapy with Bevacizumab
255875|NCT02248571|Drug|Everolimus|administered as combined therapy with Exemestane
255876|NCT02248571|Drug|Exemestane|administered as combined therapy with Everolimus
255877|NCT02248571|Other|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
255878|NCT02248558|Behavioral|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
255879|NCT02248558|Behavioral|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
255880|NCT02248532|Biological|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes >1.9 mV, and linear shortening <6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
255881|NCT02248519|Procedure|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
255882|NCT02248519|Procedure|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
255883|NCT02248506|Other|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
255884|NCT02248493|Drug|Paracetamol|
255885|NCT02248493|Drug|Placebo (for paracetamol)|
255886|NCT02248493|Drug|Ketoprofen|
255887|NCT02248493|Drug|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
255888|NCT02248493|Drug|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
255889|NCT02248480|Drug|Duloxetine|Administered orally
255890|NCT02248480|Drug|Placebo|Administered orally
255891|NCT02248454|Drug|Lispro|Increasing insulin doses
255892|NCT02248441|Other|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
255893|NCT02248428|Drug|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
256174|NCT02246257|Other|Losartan|BT > 140/90 mmHg treated with 50 mg OD
255898|NCT02248415|Other|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
255899|NCT02248415|Other|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
255900|NCT02248415|Other|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
255901|NCT02248415|Other|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
255902|NCT02248415|Other|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
255903|NCT02248402|Biological|Vax-DC/MM|
255904|NCT02248389|Device|Sonatherm 600i ablation system|HIFU ablation of tumor.
255905|NCT02248376|Drug|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
255906|NCT02248363|Other|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
255907|NCT02248350|Behavioral|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
255908|NCT02248350|Behavioral|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
255909|NCT02248337|Drug|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
255910|NCT02248298|Drug|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
255911|NCT02248298|Drug|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
255912|NCT02248298|Drug|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
255913|NCT02248285|Device|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
255914|NCT02248272|Other|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
255915|NCT02248272|Other|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
255916|NCT02248259|Drug|BI 409306|Oral single dose of BI 409306
255917|NCT02248259|Drug|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
255918|NCT02248259|Drug|BI 409306|Oral single dose
255919|NCT02248246|Device|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:~Inferior mesenteric artery (IMA)~Inferior mesenteric vein (IMV) (if identified)"
255920|NCT02248233|Drug|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
255921|NCT02248233|Drug|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
255922|NCT02248220|Drug|Pramipexole|
255923|NCT02248207|Drug|Pramipexole|
255924|NCT02248194|Device|Tactile electrosurgical ablation probe|
255925|NCT02248194|Device|Hysteroscopic endometrial ablation|
255926|NCT02248181|Drug|Pramipexole|
255927|NCT02248168|Drug|Pramipexole|
255928|NCT02248155|Drug|Pramipexole|
255929|NCT02248142|Drug|Pramipexole|
255930|NCT02248129|Drug|Telmisartan and hydrochlorothiazide|
255931|NCT02248116|Drug|Talsaclidine|
255932|NCT02248103|Procedure|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
255933|NCT02248103|Biological|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
255934|NCT02248090|Drug|AZD9496|AZD9496
255935|NCT02248090|Drug|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
255936|NCT02248077|Device|AutoloGel|
255937|NCT02248077|Other|Usual and Customary Care (UCC)|
255938|NCT02248064|Device|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
255939|NCT02248051|Drug|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
255940|NCT02248038|Procedure|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
255941|NCT02248038|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
255942|NCT02248025|Other|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
255943|NCT02248012|Drug|Everolimus , temozolomide|
255944|NCT02247986|Drug|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
255945|NCT02247973|Biological|mesenchymal stem cells|Intravenous administration of up to 1~2x10^6 MSCs per kg,for 2 times,d0 and d14
255946|NCT02247973|Biological|mesenchymal stem cells|bone marrow derived mesenchymal stem cells from related donors.
255947|NCT02247960|Drug|Ciprofloxacin|
255948|NCT02247921|Other|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
255949|NCT02247908|Other|Surgeon General's Warning|"Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:~SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.~SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.~SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.~SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide."
255950|NCT02247908|Other|Graphic Warning|"Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:~Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.~Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.~Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.~Text: WARNING: Smoking can kill you. Image: Woman dying from cancer."
255951|NCT02247895|Device|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
255952|NCT02247895|Device|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
255953|NCT02247882|Other|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.~The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
255954|NCT02247882|Other|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
255955|NCT02247869|Drug|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~Doxorubicin 25 mg/m2 i.v. day 1 and 8~Bleomycin 10 mg/m2 i.v. day 1 and 8~Vinblastine 6 mg/m2 i.v. day 1 and 8~Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
256837|NCT02241148|Drug|Acetaminophen 500mg|500 mg, tablets every 8 hours
255956|NCT02247856|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
255957|NCT02247856|Device|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
255958|NCT02247856|Device|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
255959|NCT02247843|Biological|βAS3-FB vector transduced peripheral blood CD34+ cells|CD34+ from the peripheral blood of patients with sickle cell disease (SCD) are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
255960|NCT02247830|Other|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
255961|NCT02247830|Drug|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
255962|NCT02247817|Device|Hybrid CRT-D/P implantation|
255963|NCT02247804|Drug|Bimatoprost sustained-release|Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
255964|NCT02247804|Other|Sham|Sham administered on Day 1, Week 16, and Week 32, as per protocol.
255965|NCT02247804|Drug|Timolol|Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
255966|NCT02247804|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
255967|NCT02247791|Procedure|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
255968|NCT02247791|Procedure|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
255969|NCT02247778|Procedure|conventional plate osteosynthesis|Standard incision
255970|NCT02247778|Procedure|mini-incision-type osteosynthesis|Mini-incision
255971|NCT02247765|Device|Arterial line|Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601
255972|NCT02247765|Device|Motion|The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
255973|NCT02247752|Other|inactive carrier|"Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.~Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology."
255974|NCT02247739|Biological|Recombinant human C1 inhibitor|
255975|NCT02247739|Other|Placebo|
255976|NCT02247726|Drug|Saline Placebo (0.5mL injection)|
255977|NCT02247726|Drug|RSV F vaccine (0.5mL injection)|
255978|NCT02247687|Drug|Protease inhibitor|"Modification in the antiretroviral treatment~•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling."
255979|NCT02247687|Drug|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
255980|NCT02247687|Other|Counseling arm|No change of antiretroviral treatment but only counseling
255981|NCT02247674|Procedure|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
255982|NCT02247648|Drug|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
255983|NCT02247648|Drug|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
255984|NCT02247635|Behavioral|Healthy lifestyle and adherence|"Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care"
255985|NCT02247609|Genetic|Anti-CD19 CAR T cells|Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
255986|NCT02247596|Drug|Resveratrol|1g tds 2 weeks
255987|NCT02247596|Drug|Placebo|Sugar pill 1g tds for 2 weeks
255988|NCT02247570|Procedure|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
255989|NCT02247557|Drug|Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
255990|NCT02247557|Drug|BOTOX 200U in normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
255991|NCT02247557|Drug|Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
255992|NCT02247544|Drug|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
255993|NCT02247531|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally.
255994|NCT02247531|Other|Sham Comparator|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
255995|NCT02247518|Drug|Cialis Tab. 5mg|
255996|NCT02247518|Drug|Harnal-D Cap. 0.2mg|
255997|NCT02247505|Drug|Harnal-D Cap. 0.2mg|
255998|NCT02247505|Drug|Cialis Tab. 5mg|
255999|NCT02247479|Drug|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
256000|NCT02247479|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
256001|NCT02247466|Drug|Rocuronium and Sugammadex|
256002|NCT02247453|Other|screening|"All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.~Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT."
256003|NCT02247440|Drug|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
256004|NCT02247427|Device|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
256005|NCT02247414|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
256006|NCT02247414|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
256007|NCT02247414|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
256008|NCT02247414|Drug|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
256009|NCT02247401|Drug|2 DAA|ABT-450/r/ABT-267 tablets
256010|NCT02247401|Drug|RBV|Ribavirin tablets
256011|NCT02247388|Behavioral|Computerized Alcohol Screening|iPad based automated alcohol screening
256012|NCT02247388|Behavioral|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
256013|NCT02247375|Drug|Low dose of BIIL 284 BS tablets|
256014|NCT02247375|Drug|High dose of BIIL 284 BS tablets|
256015|NCT02247375|Drug|Placebo|
256016|NCT02247362|Biological|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
256017|NCT02247362|Other|Placebo|Vaccine Diluent
256018|NCT02247349|Biological|BMS-986012 (anti-fucosyl-GM1)|
256019|NCT02247349|Biological|Nivolumab|
256020|NCT02247336|Behavioral|MeTree|Participants will enter their family health history information into MeTree, patients and providers will receive a decision support document and pedigree
256021|NCT02247323|Other|Risk of malignancy index|Calculation of RMI before sugery.
256022|NCT02247310|Drug|Interferon beta-1b (Betaferon®, BAY 86-5046)|Patients will be treated with Betaferon
256023|NCT02247310|Device|BETACONNECT|Auto-injector device to support the injection of Betaferon
256024|NCT02247297|Procedure|Blood collection|Diagnostic blood collection
256025|NCT02247284|Device|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
256026|NCT02247271|Behavioral|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
256027|NCT02247258|Drug|Azathioprine|See arm/group descriptions
256028|NCT02247258|Drug|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
256029|NCT02247258|Procedure|Ileocolonoscopy|See arm/group descriptions
256030|NCT02247258|Procedure|Small bowel follow trough|See arm/group descriptions
256031|NCT02247245|Drug|Ivabradine|Ivabradine 7.5mg
256032|NCT02247245|Other|Atrial fibrillation|Pacemaker base rate alteration
256033|NCT02247232|Drug|Z-100|
256034|NCT02247232|Drug|Placebo|
256035|NCT02247219|Behavioral|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
256036|NCT02247206|Behavioral|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
256037|NCT02247193|Drug|Botulinum Toxin Type A|Injection of toxin at the time of surgery at cleft lip repair site
256038|NCT02247193|Drug|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair.
256039|NCT02247180|Behavioral|cognitive rehabilitation|
256040|NCT02247180|Behavioral|standardized cognitive training|
256041|NCT02247167|Procedure|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
256042|NCT02247154|Biological|Vigam® (Human Normal Immunoglobulin)|
256043|NCT02247141|Biological|Subgam® (Human Normal Immunoglobulin Solution)|
256044|NCT02247128|Drug|Aspirin + clopidogrel|
256045|NCT02247128|Drug|Aspirin monotherapy|
256046|NCT02247128|Drug|OAC + clopicogrel|
256047|NCT02247128|Drug|OAC monotherapy|
256048|NCT02247102|Dietary Supplement|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
256049|NCT02247102|Dietary Supplement|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.~Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
256050|NCT02247089|Other|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
256051|NCT02247089|Other|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
256052|NCT02247076|Behavioral|Grazing|
256053|NCT02247076|Behavioral|Time-restricted feeding (early eating)|
256054|NCT02247063|Device|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1 that involves sending a weak electrical current into your brain.
256055|NCT02247050|Behavioral|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
256056|NCT02247037|Other|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
256057|NCT02247011|Other|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
256058|NCT02247011|Radiation|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
256059|NCT02247011|Radiation|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
256060|NCT02247011|Other|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
256061|NCT02246998|Drug|STB|150/150/200/300 mg fixed dose combination (FDC) tablet administered orally once daily with food
256062|NCT02246998|Drug|TVD|200/300 mg FDC tablet administered orally once daily with food
256063|NCT02246998|Drug|ATR|600/200/300 mg FDC tablet administered orally once daily on an empty stomach at bedtime
256064|NCT02246998|Drug|RTV|100 mg tablet administered orally once daily with food
256065|NCT02246998|Drug|ATV|300 mg capsule administered orally once daily with food
256066|NCT02246998|Drug|ABC/3TC|600/300 mg FDC tablet administered orally once daily with food
256067|NCT02246998|Drug|Iohexol|1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
256068|NCT02246985|Dietary Supplement|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
256069|NCT02246985|Dietary Supplement|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
256070|NCT02246985|Dietary Supplement|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
256071|NCT02246985|Dietary Supplement|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
256072|NCT02246972|Behavioral|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
256073|NCT02246959|Behavioral|Process Incentive|Daily sweepstake conditional on daily medication adherence
256074|NCT02246959|Behavioral|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
256075|NCT02246946|Device|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
256076|NCT02246946|Other|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
256077|NCT02246946|Procedure|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
256078|NCT02246933|Other|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
256079|NCT02246933|Other|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
256080|NCT02246920|Drug|Fluticasone propionate|50 mcg/actuation Nasal Spray
256081|NCT02246920|Drug|Flonase®|50 mcg/actuation Nasal Spray
256082|NCT02246920|Drug|Placebo|Inactive Nasal Spray
256170|NCT02246296|Dietary Supplement|Modified F75 Milk|This is the experimental group
256171|NCT02246270|Drug|Intravesical Heparin|Heparin bladder instillation
256172|NCT02246270|Other|Placebo|Intravesical saline
256083|NCT02246907|Other|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
256084|NCT02246894|Biological|Optivate® (Human Coagulation Factor VIII)|
256085|NCT02246881|Biological|Optivate® (Human Coagulation Factor VIII)|
256086|NCT02246868|Biological|Optivate® (Human Coagulation Factor VIII)|
256087|NCT02246855|Biological|Gammaplex® (Human Normal Immunoglobulin)|
256088|NCT02246842|Biological|D-Gam® (human anti-D immunoglobulin)|
256089|NCT02246842|Biological|Rhophylac® (human anti-D immunoglobulin)|
256090|NCT02246829|Procedure|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
256091|NCT02246816|Drug|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
256092|NCT02246803|Procedure|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
256093|NCT02246803|Procedure|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
256094|NCT02246790|Procedure|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
256095|NCT02246790|Procedure|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
256096|NCT02246777|Device|Ex-PRESS® Glaucoma Filtration Device, Model P50PL|
256097|NCT02246764|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
256098|NCT02246764|Drug|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
256099|NCT02246764|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
256100|NCT02246764|Other|Placebo|1 drop QD, AM, OU
256101|NCT02246751|Device|Targeted Training for trunk control|Orthotics Research and Locomotor Research Unit (ORLAU) standers will be custom fit to help the child train at the segmental level of the trunk where they begin to lose control of posture. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body. The researchers evaluate children every 8 weeks and adjust the stander to lower levels of support as the child gains control.
256102|NCT02246738|Other|Blood Collection|
256103|NCT02246725|Other|Contact with palliative care unit.|
256104|NCT02246712|Drug|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
256105|NCT02246712|Other|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.~CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
256106|NCT02246712|Other|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.~The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.~The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
256107|NCT02246712|Genetic|CYP2B6 genotype|The single nucleotide polymorphism 516G>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
256108|NCT02246699|Device|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
256109|NCT02246699|Other|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
256110|NCT02246686|Drug|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
256111|NCT02246686|Drug|Placebo|Application over 12 weeks 20 drops three time daily
256112|NCT02246673|Drug|RDEA3170 15 mg|
256113|NCT02246673|Drug|RDEA3170 10 mg|
256114|NCT02246673|Drug|RDEA3170 2.5|
256115|NCT02246673|Drug|RDEA3170 5 mg|
256116|NCT02246673|Drug|Febuxostat 40 mg|
256117|NCT02246673|Drug|Febuxostat 80 mg|
256118|NCT02246660|Drug|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.~OR~The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
256119|NCT02246660|Drug|Placebo|Placebo will be taken orally for 6 months.
256120|NCT02246647|Diagnostic Test|Permeability measurement|Saccharide excretion was compared between IBS-C and healthy volunteers
256121|NCT02246647|Procedure|Esophagogastroduodenoscopy|Duodenal biopsies were collected from IBS-C and healthy volunteers
256122|NCT02246647|Procedure|Flexible sigmoidoscopy|Colonic biopsies were collected from IBS-C and healthy volunteers
256123|NCT02246634|Other|Diffusion Weighted MRI scan|Non-contrast diffusion weighted MRI scan of the liver
256124|NCT02246621|Drug|Abemaciclib|Administered orally
256125|NCT02246621|Drug|Anastrozole|Administered orally
256126|NCT02246621|Drug|Letrozole|Administered orally
256127|NCT02246621|Drug|Placebo|Administered orally
256173|NCT02246257|Other|Simvastatin|LDL > 2.5 is treated with 40 mg
256128|NCT02246608|Device|NPWT Standard of Care plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
256129|NCT02246608|Device|Routine NPWT Standard of Care|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
256130|NCT02246595|Biological|CaCP29|
256131|NCT02246595|Biological|Placebo|
256132|NCT02246582|Device|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen & arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
256133|NCT02246582|Device|Guardian Mobile App|
256134|NCT02246582|Device|640G Insulin Pump|
256135|NCT02246556|Device|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
256136|NCT02246556|Other|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
256137|NCT02246556|Device|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
256138|NCT02246543|Dietary Supplement|Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
256139|NCT02246543|Dietary Supplement|HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
256140|NCT02246543|Dietary Supplement|LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
256141|NCT02246543|Dietary Supplement|HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
256142|NCT02246543|Dietary Supplement|LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
256143|NCT02246530|Procedure|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.~PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
256144|NCT02246530|Drug|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
256145|NCT02246517|Drug|N2O|
256146|NCT02246517|Drug|Oxygen|
256147|NCT02246504|Device|HIFU treatment|
256148|NCT02246491|Other|A-T iPS cell line|Reprogramming A-T patients iPS cell line
256149|NCT02246491|Other|Carrier patients iPS cell line|Reprogramming iPS cell line from carrier patients
256150|NCT02246478|Drug|TAS-205|"Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
256151|NCT02246478|Drug|Placebo|"Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
256152|NCT02246465|Drug|RXI-109|
256153|NCT02246439|Drug|RHB-102|RHB-102, Bimodal Release Ondansetron Tablets
256154|NCT02246439|Drug|Placebo Oral Tablet|Placebo
256155|NCT02246426|Other|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
256156|NCT02246426|Other|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
256157|NCT02246413|Behavioral|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
256158|NCT02246400|Behavioral|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
256159|NCT02246387|Procedure|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
256160|NCT02246374|Device|ExAblate Transcranial System|ExAblate Transcranial System subthalamotomy for symptoms of Parkinson's Disease
256161|NCT02246361|Procedure|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
256162|NCT02246348|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
256163|NCT02246335|Device|Cemented total hip arthroplasty|
256164|NCT02246335|Device|Cemented hemiarthroplasty|
256165|NCT02246322|Device|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
256166|NCT02246322|Device|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
256167|NCT02246309|Device|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
256168|NCT02246309|Device|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
256169|NCT02246296|Dietary Supplement|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
256175|NCT02246257|Other|Losartan|DM BT > 130/80 mmHg treated with 50 mg OD
256176|NCT02246257|Other|Losartan|Microalbuminuria (urinary albumin creatinin ratio > 30 mg) treated with 100 mg OD
256177|NCT02246257|Other|Metformin|HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
256178|NCT02246257|Other|Outpatient rheumatology department|(4 times yearly)
256179|NCT02246257|Other|Refered to general practice|
256180|NCT02246244|Drug|Escitalopram|
256181|NCT02246244|Other|Placebo|
256182|NCT02246231|Device|MR imaging|
256183|NCT02246218|Drug|RAVICTI|
256184|NCT02246205|Procedure|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
256185|NCT02246192|Procedure|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
256186|NCT02246192|Procedure|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
256187|NCT02246179|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
256188|NCT02246179|Drug|AHES|Topical application at test region 1 and 3 under occlusion for 10 minutes
256189|NCT02246179|Drug|EMLA cream|Topical application at test region 2 and 4 under occlusion for 10 minutes
256190|NCT02246166|Drug|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
256191|NCT02246166|Other|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
256192|NCT02246153|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
256193|NCT02246153|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience."
256194|NCT02246140|Other|Cerebral MRI and MRA|
256195|NCT02246127|Drug|Drug: Everolimus|10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
256196|NCT02246127|Drug|STZ-5FU|"0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).~Number of Cycles: until progression or unacceptable toxicity develops."
256197|NCT02246114|Device|piCO+ Smokerlyzer® monitor|
256198|NCT02246114|Other|Text messages|
256199|NCT02246088|Procedure|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.~The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
256200|NCT02246088|Procedure|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
256201|NCT02246075|Drug|EVP-6124|
256202|NCT02246062|Behavioral|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
256203|NCT02246062|Behavioral|smartphone|the child received smartphone application immediately before entering the operating room
256204|NCT02246049|Biological|Bevacizumab|Given IV
256205|NCT02246049|Drug|5-fluorouracil|Given IV
256206|NCT02246049|Drug|Irinotecan hydrochloride|Given IV
256207|NCT02246049|Drug|Leucovorin calcium|Given IV
256208|NCT02246049|Drug|Oxaliplatin|Given IV
256209|NCT02246036|Device|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
256210|NCT02246023|Device|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
256211|NCT02246023|Device|Oxygen saturation|Continuous measurement of oxygen saturation;
256212|NCT02246023|Device|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
256213|NCT02246023|Device|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
256214|NCT02246023|Device|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
256215|NCT02246010|Dietary Supplement|Lactose- free milk|Lactose- free milk
256216|NCT02245997|Radiation|External beam radiotherapy|
256217|NCT02245997|Radiation|proton beam RT|
256218|NCT02245984|Other|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
256219|NCT02245984|Other|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
256220|NCT02245971|Procedure|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
256884|NCT02240823|Other|adipose derived stem cells|
256221|NCT02245971|Procedure|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
256222|NCT02245958|Other|No Intervention|No treatment (intervention) was administered.
256223|NCT02245945|Drug|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
256224|NCT02245945|Drug|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
256225|NCT02245932|Dietary Supplement|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
256226|NCT02245932|Dietary Supplement|Placebo|4 weeks of placebo supplementation (two doses per day)
256227|NCT02245919|Other|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
256228|NCT02245906|Dietary Supplement|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
256229|NCT02245906|Dietary Supplement|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
256230|NCT02245906|Dietary Supplement|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
256231|NCT02245893|Procedure|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
256232|NCT02245880|Device|Glidescope|videolaryngoscope
256233|NCT02245880|Device|ILMA|handling of the device till the optimal ventilation achieved
256234|NCT02245867|Drug|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
256235|NCT02245854|Device|Exacto™|Cold snare polypectomy
256236|NCT02245841|Drug|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
256237|NCT02245828|Drug|QCC374|Single and multiple ascending doses of QCC374
256238|NCT02245828|Drug|Placebo|Placebo comparator
256239|NCT02245815|Dietary Supplement|use probiotics Boucardii|group A will be administered the lactobacillus boucardii probiotic (1x109 colonies forming units (UFC) per day for 3 weeks). The diagnosis of NEC will be made using the Bell criteria by the attending physician. Gastric tolerance will be measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) will be measured at the beginning and at the end of treatment.
256240|NCT02245815|Dietary Supplement|use probiotics Multi-species|Group B will be administered multi-species probiotic (1x109 colonies forming units (UFC) per day for 3 weeks). The diagnosis of NEC will be made using the Bell criteria by the attending physician. Gastric tolerance will be measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) will be measured at the beginning and at the end of treatment.
256241|NCT02245789|Procedure|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
256242|NCT02245789|Drug|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
256243|NCT02245776|Biological|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
256244|NCT02245763|Device|Leaflet Clip|
256245|NCT02245750|Device|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
256246|NCT02245737|Drug|Lanabecestat|Administered orally
256247|NCT02245737|Drug|Placebo|Administered orally
256248|NCT02245724|Biological|Stem Cell|Autologous bone marrow mononuclear cell transplantation
256249|NCT02245711|Biological|Stem Cell|
256250|NCT02245698|Biological|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
256251|NCT02245672|Drug|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
256252|NCT02245672|Drug|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
256253|NCT02245672|Drug|Placebo|Placebo administered via the CRC749 and Diskus devices
256254|NCT02245659|Device|CPAP|Continuous Positive Airway Pressure
256255|NCT02245659|Other|Nasal dilator strip|Nasal dilator strip to be worn nightly
256256|NCT02245620|Drug|MTP-131 (Bendavia™)|MTP-131 (Bendavia™; 0.25 mg/kg/hour) administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
256257|NCT02245620|Drug|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
256258|NCT02245607|Behavioral|Compensatory Cognitive Training|
256259|NCT02245607|Behavioral|Recreational Therapy|
256260|NCT02245581|Procedure|SVV-guided fluid management|
256261|NCT02245581|Procedure|CVP-guided fluid management|
256480|NCT02243839|Procedure|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
256262|NCT02245568|Drug|TRx0237|All subjects will initially be given 200 mg/day of TRx0237 (one 100-mg tablet in the morning and one 100-mg tablet in the evening). Thereafter, dosing is flexible (100 mg/day to 300 mg/day).
256263|NCT02245555|Drug|Tamsulosin|
256264|NCT02245542|Drug|ALNA®OCAS®|
256265|NCT02245529|Drug|Tamsulosin|
256266|NCT02245516|Drug|KPI-121 0.25% Ophthalmic Suspension|KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
256267|NCT02245516|Drug|KPI-121 1.0% Ophthalmic Suspension|KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
256268|NCT02245503|Drug|Tamsulosin|
256269|NCT02245490|Drug|Tamsulosin HCl controlled release capsules|
256270|NCT02245490|Drug|Matching placebo capsule|
256271|NCT02245477|Device|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
256272|NCT02245477|Other|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
256273|NCT02245464|Drug|Telmisartan|
256274|NCT02245451|Drug|Tipranavir|
256275|NCT02245451|Drug|Ritonavir|
256276|NCT02245451|Drug|Methadone|
256277|NCT02245438|Drug|Tipranavir low dose|
256278|NCT02245438|Drug|Tipranavir high dose|
256279|NCT02245438|Drug|Ritonavir low dose|
256280|NCT02245438|Drug|Ritonavir high dose|
256281|NCT02245438|Drug|Norethindrone-Ethinyl Estradiol|
256282|NCT02245425|Other|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
256283|NCT02245425|Other|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
256284|NCT02245412|Biological|ALXN1007 10 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
256285|NCT02245412|Biological|ALXN1007 20 mg/kg once weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
256286|NCT02245412|Biological|ALXN1007 20 mg/kg twice weekly|ALXN1007 is a recombinant humanized monoclonal antibody that binds to complement component C5a and its metabolite C5a desArg.
256287|NCT02245399|Behavioral|A canola oil enriched mediterranean diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
256288|NCT02245399|Behavioral|A high wheat fiber diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
256289|NCT02245386|Radiation|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
256290|NCT02245373|Drug|Antidepressants|
256291|NCT02245373|Other|Active Monitoring|
256292|NCT02245360|Drug|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
256293|NCT02245360|Drug|placebo|placebo tablet given once daily over 60 days
256294|NCT02245334|Drug|Povidone-Iodine|1 pill per biopsy
256295|NCT02245321|Dietary Supplement|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
256296|NCT02245321|Dietary Supplement|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
256297|NCT02245321|Other|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
256298|NCT02245321|Other|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
256299|NCT02245321|Dietary Supplement|Placebo|Receive pills to take daily that contain 0 mg iron.
256300|NCT02245308|Drug|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
256301|NCT02245308|Behavioral|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
256302|NCT02245308|Behavioral|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
256481|NCT02243826|Drug|50:50 mixture of nitrous oxide/oxygen|
256838|NCT02241148|Device|Kinesio taping|Taping will be changed every week.
256303|NCT02245308|Drug|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
256304|NCT02245308|Drug|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
256305|NCT02245295|Procedure|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
256306|NCT02245295|Procedure|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
256307|NCT02245269|Drug|Tipranavir|
256308|NCT02245269|Drug|Ritonavir|
256309|NCT02245269|Drug|Atorvastatin|
256310|NCT02245269|Drug|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
256311|NCT02245256|Drug|Precedex|infusion of 0.1mcg/kg/hr of precedex
256312|NCT02245256|Drug|placebo control|placebo
256313|NCT02245243|Drug|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
256314|NCT02245230|Drug|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
256315|NCT02245230|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
256316|NCT02245230|Drug|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
256317|NCT02245217|Device|PET/CT scan to assess treatment efficacy|
256318|NCT02245204|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
256319|NCT02245191|Drug|Ephedrine|5mg after Spinal Anesthesia
256320|NCT02245191|Drug|Phenylephrine|100mcg after Spinal Anesthesia
256321|NCT02245191|Drug|Metaraminol|200mcg Metaraminol after Spinal Anesthesia
256322|NCT02245178|Procedure|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
256323|NCT02245178|Other|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
256324|NCT02245165|Biological|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
256325|NCT02245165|Biological|saline|
256326|NCT02245152|Dietary Supplement|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
256327|NCT02245152|Behavioral|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).~Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
256328|NCT02245152|Behavioral|National policy well-baby visits|
256329|NCT02245126|Drug|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
256330|NCT02245126|Drug|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
256331|NCT02245113|Other|diets|Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
256332|NCT02245100|Other|Cytology specimen|Correlative studies
256333|NCT02245100|Other|Laboratory biomarker analysis|Correlative studies
256334|NCT02245087|Drug|Atorvastatin|20 mg of atorvastatin daily
256335|NCT02245074|Other|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
256336|NCT02245061|Other|paired pulses cortical electrical stimulation|
256337|NCT02245048|Other|Carotid Intima-Media Thickness (CIMT)|
256338|NCT02245022|Drug|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
256339|NCT02245022|Drug|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
256340|NCT02245009|Procedure|Cardioversion|
256341|NCT02244996|Dietary Supplement|Lycium Barbarum|Traditional Chinese Herbs
256342|NCT02244996|Dietary Supplement|Placebo|Placebo
256343|NCT02244983|Other|Patients History|History taking and drawing of a blood sample
256344|NCT02244970|Other|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
256345|NCT02244970|Other|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
256572|NCT02243202|Drug|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
256346|NCT02244957|Device|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations <88% while on stable bi-level settings.
256347|NCT02244957|Drug|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
256348|NCT02244944|Drug|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
256349|NCT02244931|Device|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
256350|NCT02244931|Device|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
256351|NCT02244931|Device|Standard manual Wheelchair|Standard manual Wheelchair
256352|NCT02244918|Drug|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
256353|NCT02244918|Behavioral|Smoking Cessation Counseling|
256354|NCT02244905|Behavioral|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
256355|NCT02244905|Other|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
256356|NCT02244879|Dietary Supplement|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
256357|NCT02244866|Drug|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
256358|NCT02244866|Drug|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
256359|NCT02244840|Device|Electronic bidet|commercial electronic bidet
256360|NCT02244840|Device|Sitz bath|Conventional sitz bath
256361|NCT02244827|Drug|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
256362|NCT02244814|Behavioral|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
256363|NCT02244814|Behavioral|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
256364|NCT02244801|Drug|darTreg infusion|"The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.~Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects."
256365|NCT02244788|Device|SR™ PIP|
256366|NCT02244775|Device|SR™MCP|
256367|NCT02244762|Drug|20 mg HC-ER|1-72 hours
256368|NCT02244762|Drug|20 mg HC-ER|1-72 hours
256369|NCT02244762|Drug|20 mg HC-ER|1-72 hours
256370|NCT02244749|Other|skin specimen|skin specimen
256371|NCT02244723|Other|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
256372|NCT02244710|Drug|Ticagrelor vs Clopidogrel|
256373|NCT02244671|Procedure|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
256374|NCT02244671|Drug|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
256375|NCT02244671|Device|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
256376|NCT02244658|Drug|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
256377|NCT02244645|Behavioral|passive modality|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
256378|NCT02244645|Behavioral|Yoga treatment|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
256379|NCT02244632|Drug|Modufolin|IV injection every second week for 8 weeks.
256380|NCT02244632|Drug|Fluorouracil|IV injection every second week for 8 weeks.
256381|NCT02244632|Drug|Oxaliplatin|IV infusion every second week for 8 weeks.
256382|NCT02244632|Drug|Irinotecan|IV infusion every second week for 8 weeks.
256383|NCT02244632|Drug|Bevacizumab|IV infusion every second week for 8 weeks.
256384|NCT02244619|Drug|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
256385|NCT02244619|Drug|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
256386|NCT02244606|Drug|SCY-078|
256387|NCT02244606|Drug|Fluconazole|
256388|NCT02244606|Drug|Micafungin|
257132|NCT02238977|Drug|Bupropion|Antidepressant
256389|NCT02244593|Other|FAST MRI and mammography screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
256390|NCT02244580|Device|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
256391|NCT02244567|Drug|Metformin 850 mg twice daily for 3 months|This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
256392|NCT02244567|Procedure|Serum uc-oc|Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
256393|NCT02244567|Other|drug|This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
256394|NCT02244554|Device|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
256395|NCT02244541|Drug|ANAVEX2-73 Oral|
256396|NCT02244541|Drug|ANAVEX2-73 Intravenous|
256397|NCT02244541|Drug|ANAVEX2-73 Oral|30 mg hard gelatin capsule
256398|NCT02244541|Drug|ANAVEX2-73 Oral|50 mg hard gelatin capsule
256399|NCT02244528|Drug|Sildenafil|
256400|NCT02244515|Drug|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
256401|NCT02244502|Device|NovoTTF-100L(O)|Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
256402|NCT02244502|Drug|Paclitaxel|Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
256403|NCT02244489|Drug|Momelotinib (MMB)|Momelotinib (MMB) tablet(s) administered orally once or twice daily
256404|NCT02244489|Drug|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
256405|NCT02244489|Drug|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
256406|NCT02244463|Drug|MLN0128|This is a non-randomized phase II study to investigate efficacy of MLN0128 in metastatic anaplastic thyroid cancer cases.
256407|NCT02244450|Biological|SCID screening|
256408|NCT02244437|Drug|Ibuprofen|
256409|NCT02244437|Drug|Acetaminophen|
256410|NCT02244424|Behavioral|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
256411|NCT02244411|Behavioral|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
256412|NCT02244411|Behavioral|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
256413|NCT02244411|Behavioral|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
256414|NCT02244411|Other|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
256415|NCT02244398|Other|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
256416|NCT02244398|Other|FP services|VHTs in the control arm only provide family planning services
256417|NCT02244385|Other|no intervention|
256418|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 0.76 g|
256419|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.15 g|
256420|NCT02244372|Dietary Supplement|Placebo|
256421|NCT02244359|Behavioral|Training|
256422|NCT02244359|Behavioral|Usual care|
256423|NCT02244346|Drug|Secotex®|
256424|NCT02244333|Drug|ALNA®|
256425|NCT02244320|Drug|Tamsulosin|
256426|NCT02244307|Drug|alpha-adrenergic blocker|
256427|NCT02244294|Drug|FLOMAX® capsules|
256428|NCT02244294|Drug|Placebo capsules|
256429|NCT02244281|Drug|tamsulosin hydrochloride|
256430|NCT02244281|Drug|Placebo|
256431|NCT02244268|Drug|ALNA®|
256432|NCT02244255|Drug|FLOMAX® capsules|
256433|NCT02244255|Drug|Ascending doses of HYTRIN® capsules|
256434|NCT02244242|Drug|Tamsulosin hydrochloride|
256435|NCT02244229|Drug|Tamsulosin|
256436|NCT02244229|Drug|Finasteride|
256437|NCT02244229|Drug|Placebo|
256438|NCT02244216|Drug|Berotec® N 100 µg Metered-dose Inhaler|
256439|NCT02244203|Drug|BI 60732|
256440|NCT02244203|Drug|Placebo|
256441|NCT02244190|Drug|Tipranavir|New oral solution (back up) formulation
256442|NCT02244190|Drug|Tipranavir|
256443|NCT02244190|Drug|Ritonavir|
256444|NCT02244164|Drug|Incretinomimetics|
256445|NCT02244164|Drug|DPP-4 inhibitors|
256446|NCT02244151|Drug|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
256447|NCT02244151|Drug|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
256448|NCT02244138|Behavioral|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
256449|NCT02244125|Drug|PCD|"STUDY TREATMENT PHASE: All patients~4x 28 days cycles of PCD~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]~[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle]~CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:~Arm A:~Melphalan 200mg/m2 followed by Autologous Transplantation~2x 28 days cycles of PCD, three months post transplantation~Arm B:~5x 28 days cycles of PCD~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]~[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle]~MAINTENANCE PHASE: All patients~- Until progression/relapse or discontinuation for any other reason~[Pomalidomide: 4mg/day oral route on 21 days per cycle]~[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle]"
256450|NCT02244125|Procedure|Autologous transplantation (ASCT)|"Arm A:~•Melphalan 200mg/m2 followed by Autologous Transplantation"
256451|NCT02244112|Drug|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
256452|NCT02244112|Drug|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
256453|NCT02244099|Other|Controlled Substance|Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
256454|NCT02244086|Drug|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
256455|NCT02244073|Drug|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
256456|NCT02244060|Other|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
256457|NCT02244047|Drug|Bifidobacterium breve|
256458|NCT02244047|Drug|Placebo (for Bifidobacterium breve)|
256459|NCT02244021|Drug|BRENTUXIMAB VEDOTIN|"Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment~Growth factors may be used at the discretion of investigators but are not routinely advised.~Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT."
256460|NCT02244008|Other|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
256461|NCT02244008|Other|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
256462|NCT02243995|Other|Physical training|
256463|NCT02243995|Behavioral|Physical training|
256464|NCT02243982|Other|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
256465|NCT02243969|Dietary Supplement|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
256466|NCT02243969|Dietary Supplement|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
256467|NCT02243956|Other|Flavanol rich food product|polyphenol rich test product
256468|NCT02243943|Drug|Sugammadex|
256469|NCT02243943|Drug|Neostigmine|
256470|NCT02243930|Device|Disposable distal attachment|
256471|NCT02243917|Drug|CB-5083|
256472|NCT02243891|Procedure|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
256473|NCT02243891|Procedure|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
256474|NCT02243878|Radiation|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
256475|NCT02243878|Drug|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
256476|NCT02243865|Device|Chordate System S200 + CT100 (active treatment)|
256477|NCT02243865|Device|Chordate System S200 + CT100 (placebo treatment)|
256478|NCT02243852|Drug|Growth Hormone Replacement Therapy|An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
256479|NCT02243839|Drug|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
257776|NCT02234141|Drug|Selonsertib|Tablets administered orally once daily
256482|NCT02243813|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
256483|NCT02243800|Other|cholecalciferol versus placebo|
256484|NCT02243787|Drug|COVA322|
256485|NCT02243787|Other|Placebo|
256486|NCT02243774|Behavioral|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
256487|NCT02243774|Behavioral|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
256488|NCT02243774|Behavioral|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
256489|NCT02243774|Behavioral|Core letter signed by SG + enhanced implementation prompt|"The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated."
256490|NCT02243761|Other|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
256491|NCT02243748|Other|Palliative Therapy|Receive individualized palliative care
256492|NCT02243748|Other|quality-of-life assessment|Ancillary studies
256493|NCT02243748|Other|questionnaire administration|Ancillary studies
256494|NCT02243735|Drug|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
256495|NCT02243735|Drug|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
256496|NCT02243709|Drug|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
256497|NCT02243683|Drug|AX-024.HCl|
256498|NCT02243683|Other|Placebo|
256499|NCT02243670|Device|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
256500|NCT02243657|Drug|ASP3652|oral
256501|NCT02243657|Drug|Placebo|oral
256502|NCT02243644|Drug|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
256503|NCT02243644|Drug|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
256504|NCT02243631|Drug|Probenecid|Treatment
256505|NCT02243618|Drug|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
256506|NCT02243618|Drug|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
256507|NCT02243605|Drug|Cabozantinib S-malate|Given PO
256508|NCT02243605|Other|Laboratory Biomarker Analysis|Correlative studies
256509|NCT02243592|Other|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
256510|NCT02243579|Other|Laboratory Biomarker Analysis|Correlative studies
256511|NCT02243579|Biological|Pembrolizumab|Given IV
256512|NCT02243566|Drug|MicardisPlus®|
256513|NCT02243553|Drug|Tipranavir capsule|
256514|NCT02243553|Drug|Tipranavir solution|
256515|NCT02243553|Drug|Ritonavir capsule|
256516|NCT02243553|Drug|Caffeine|
256517|NCT02243553|Drug|Warfarin sodium|
256518|NCT02243553|Drug|Vitamin K|
256519|NCT02243553|Drug|Omeprazole|
256520|NCT02243553|Drug|Dextromethorphan hydrobromide|
256521|NCT02243553|Drug|Midazolam injection|
256522|NCT02243553|Drug|Midazolam oral solution|
256523|NCT02243553|Drug|Digoxin tablet|
256524|NCT02243553|Drug|Digoxin injection|
256525|NCT02243527|Other|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
256526|NCT02243527|Other|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
256527|NCT02243501|Behavioral|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
256528|NCT02243488|Device|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
256573|NCT02243202|Drug|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
258019|NCT02232152|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
256529|NCT02243462|Device|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
256530|NCT02243462|Other|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
256531|NCT02243449|Procedure|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
256532|NCT02243449|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
256533|NCT02243436|Drug|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
256534|NCT02243436|Drug|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
256535|NCT02243436|Drug|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
256536|NCT02243436|Drug|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
256537|NCT02243436|Drug|Ara C|Intravenous use, 2g/m2, day 5
256538|NCT02243423|Procedure|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.~A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
256539|NCT02243423|Procedure|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.~A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
256540|NCT02243384|Procedure|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
256541|NCT02243384|Procedure|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
256542|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6
256543|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 1 of Cycles 3-6
256544|NCT02243371|Drug|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6
256545|NCT02243371|Biological|GVAX|5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2
256546|NCT02243371|Drug|CY|200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2
256547|NCT02243358|Drug|Folfox6|
256548|NCT02243358|Drug|Gemcitabine|
256549|NCT02243358|Radiation|Radiation Therapy|
256550|NCT02243358|Procedure|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
256551|NCT02243332|Device|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
256552|NCT02243319|Drug|HGP1201|
256553|NCT02243319|Drug|HGP0904|
256554|NCT02243319|Drug|HGP0904 and HGP1201 co-administraion|
256555|NCT02243306|Drug|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
256556|NCT02243293|Drug|ABT-493|Tablet
256557|NCT02243293|Drug|ABT-530|Tablet
256558|NCT02243293|Drug|ribavirin (RBV)|Tablet
256559|NCT02243293|Drug|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
256560|NCT02243280|Drug|ABT-493|Tablet
256561|NCT02243280|Drug|ABT-530|Tablet
256562|NCT02243267|Other|sample collection|
256563|NCT02243254|Drug|high dose remifentanil|high dose remifentanil
256564|NCT02243254|Drug|Ibuprofen|intravenous ibuprofen
256565|NCT02243254|Drug|low dose remifentanil|low dose remifentanil
256566|NCT02243241|Drug|HYD|Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg [(1) 40 mg tablet + (1) 120 mg tablet] (day 15) extended-release tablets administered orally every 24 hours.
256567|NCT02243241|Drug|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
256568|NCT02243241|Drug|Placebo for HYD|Placebo to match HYD tablets administered orally every 24 hours.
256569|NCT02243241|Drug|Placebo for moxifloxacin|Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
256570|NCT02243228|Drug|GM-CSF|
256571|NCT02243215|Other|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
256574|NCT02243202|Drug|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
256575|NCT02243202|Drug|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
256576|NCT02243189|Drug|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
256577|NCT02243189|Drug|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
256578|NCT02243189|Drug|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
256579|NCT02243176|Drug|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
256580|NCT02243176|Drug|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
256581|NCT02243163|Behavioral|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
256582|NCT02243150|Drug|G1T28-1 (CDK 4/6 Inhibitor)|
256583|NCT02243150|Drug|Placebo|
256584|NCT02243137|Drug|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
256585|NCT02243137|Drug|prasugrel|Administration: one loading dose (60mg)
256586|NCT02243137|Drug|lysine acetylsalicylate|Administration: one dose (450mg iv)
256587|NCT02243124|Drug|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
256588|NCT02243124|Drug|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
256589|NCT02243111|Radiation|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
256590|NCT02243098|Drug|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
256591|NCT02243098|Drug|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
256592|NCT02243098|Drug|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
256593|NCT02243072|Behavioral|Fit Families plus Standard Medical Care|Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
256594|NCT02243059|Drug|Gadofosveset trisodium (Ablavar™ )|
256595|NCT02243059|Device|MRI|
256596|NCT02243046|Drug|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
256597|NCT02243046|Drug|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
256598|NCT02243046|Drug|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
256599|NCT02243033|Device|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
256600|NCT02243020|Device|Vagus Nerve Stimulation (VNS)|
256601|NCT02243007|Drug|FOLFIRINOX|
256602|NCT02243007|Drug|Gemcitabine/nab-Paclitaxel|
256603|NCT02243007|Radiation|Radiation therapy|
256604|NCT02243007|Drug|Capecitabine|
256605|NCT02242994|Device|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
256606|NCT02242994|Device|Experimental App|Participant receives experimental app to test speed and error rate of communication.
256607|NCT02242981|Drug|LY2623091|Administered orally
256608|NCT02242955|Drug|Diazepam|40 mg per day.
256609|NCT02242942|Drug|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
256610|NCT02242942|Drug|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
256611|NCT02242942|Drug|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
256612|NCT02242929|Drug|Imiquimod 5% cream with prior curettage|
256613|NCT02242929|Procedure|Standard surgical excision|
256614|NCT02242916|Radiation|Photon therapy versus proton therapy|
256615|NCT02242916|Radiation|Photon therapy versus C-ion therapy|
256616|NCT02242903|Drug|LY3079514|Administered SC
256617|NCT02242903|Drug|LY3079514|Administered IV
256618|NCT02242903|Drug|Placebo|Administered SC
256619|NCT02242903|Drug|Placebo|Administered IV
256620|NCT02242890|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
256621|NCT02242877|Drug|Telmisartan|
256622|NCT02242877|Drug|Telmisartan combined with hydrochlorothiazide|
256623|NCT02242864|Drug|Micardis®|
256624|NCT02242864|Drug|MicardisPlus®|
256625|NCT02242851|Drug|Telmisartan|
256626|NCT02242838|Drug|Telmisartan|
256627|NCT02242825|Drug|Micardis®|
256628|NCT02242825|Drug|MicardisPlus®|
256629|NCT02242812|Drug|Telmisartan|
256630|NCT02242812|Drug|Metoprolol succinate|
256631|NCT02242812|Drug|Placebo|
256632|NCT02242799|Drug|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
256633|NCT02242799|Drug|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
256634|NCT02242799|Drug|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
256635|NCT02242786|Radiation|External beam radiation therapy|
256636|NCT02242773|Device|Multi-Parametric MRI|Multi-Parametric MRI
256637|NCT02242773|Device|MRI-Guided Biopsy|MRI-Guided Biopsy
256638|NCT02242773|Behavioral|Expanded Prostate Cancer Index Composite SF12 Questionnaire|Quality of Life Questionnaire administered to subjects at intervals defined by study protocol.
256639|NCT02242773|Behavioral|Memory Anxiety Scale for Prostate Cancer patients|Quality of Life Questionnaire administered to subjects at intervals defined by study protocol.
256640|NCT02242773|Behavioral|Food Frequency Questionnaire|Quality of Life Questionnaire administered at baseline
256641|NCT02242760|Drug|SB204 2%|Applied topically twice daily
256642|NCT02242760|Drug|SB204 4%|Applied topically daily
256643|NCT02242760|Drug|Vehicle Gel|Applied topically twice and once daily
256644|NCT02242747|Drug|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
256645|NCT02242747|Drug|5% 5-FU|two applications a day for four weeks in a pre-determined area
256646|NCT02242734|Drug|20 mg HC-ER|1-72 hours
256647|NCT02242734|Drug|20 mg HC-ER|1-72 hours
256648|NCT02242734|Drug|20 mg HC-ER|1-72 hours
256649|NCT02242708|Behavioral|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
256650|NCT02242695|Drug|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
256651|NCT02242695|Drug|Canesten vaginal tablets|one vaginal tablet for 7 days
256652|NCT02242682|Other|Child passenger safety video|
256653|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
256654|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
256655|NCT02242643|Biological|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
256656|NCT02242643|Biological|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
256657|NCT02242630|Drug|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
256658|NCT02242630|Drug|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
256659|NCT02242630|Drug|Triamcinolone, 20 mg|Compared with methylprednisolone
256660|NCT02242630|Drug|Triamcinolone, 40 mg|Compared with methylprednisolone
256661|NCT02242617|Device|Positive Airway Pressure (PAP)|Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
256662|NCT02242617|Device|Mandibular Advancement Splints (MAS)|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
256663|NCT02242604|Other|Multidimensional Geriatric Assessment (MGA)|"The MGA contains the following tests:~Barthel Katz Index (activity of daily living, ADL)~Mini Mental State Test (MMST)~DemTec (dementia detection test)~Clock Test~Geriatric Depression Scale (GDS)~Tinetti Test~TUG (timed up-and-go Test)~Esslinger Transfer Scale (ETS)~Handgrip Test~Mini Nutritional Assessment (MNA)"
256664|NCT02242591|Drug|Ropivacaine 7,5 mg/ml|
256665|NCT02242591|Drug|Saline|
256666|NCT02242578|Device|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
256667|NCT02242578|Device|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
256668|NCT02242565|Device|ShangRing|ShangRing device for male circumcision
256669|NCT02242539|Behavioral|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
256670|NCT02242539|Behavioral|Community-based monitoring|"Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day."
256671|NCT02242526|Device|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
256672|NCT02242526|Device|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
256747|NCT02242006|Other|serial serum sampling for quantification of drug concentration|
256748|NCT02241980|Other|Patient survey|
256673|NCT02242513|Device|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
256674|NCT02242513|Drug|Xylocaine|
256675|NCT02242500|Procedure|Coronally Advanced Flap|
256676|NCT02242500|Device|Mucograft|
256677|NCT02242487|Drug|CVT-301|
256678|NCT02242474|Drug|Anti-TNF suspended perioperatively|
256679|NCT02242474|Drug|Anti-TNFα continued perioperatively|
256680|NCT02242461|Drug|Rhodiola placebo capsules|Corn starch
256681|NCT02242461|Drug|Rhodiola Crenulata|Rhodiola Crenulata
256682|NCT02242435|Biological|Ampion <5 kDa ultrafiltrate of 5% human serum albumin|4 mL intra-articular injection of Ampion
256683|NCT02242435|Biological|Placebo|Saline
256684|NCT02242409|Drug|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
256685|NCT02242396|Drug|Telmisartan|
256686|NCT02242396|Drug|Telmisartan hydrochlorothiazide|
256687|NCT02242383|Drug|Telmisartan|
256688|NCT02242383|Drug|Telmisartan in combination with hydrochlorothiazide|
256689|NCT02242370|Drug|Low dose of telmisartan|
256690|NCT02242370|Drug|High dose of telmisartan|
256691|NCT02242357|Drug|Micardis®|
256692|NCT02242357|Drug|Micardis® Plus|
256693|NCT02242344|Drug|Telmisartan|
256694|NCT02242344|Drug|Placebo|
256695|NCT02242331|Drug|Micardis®|
256696|NCT02242318|Drug|Telmisartan|
256697|NCT02242318|Drug|Valsartan|
256698|NCT02242318|Drug|Placebo|
256699|NCT02242305|Drug|Hyoscine Butylbromide - Tablet|
256700|NCT02242305|Drug|Hyoscine Butylbromide - Capsule|
256701|NCT02242305|Drug|Placebo|
256702|NCT02242292|Drug|Hyoscine butylbromide|
256703|NCT02242292|Drug|Placebo|
256704|NCT02242279|Drug|BEA 2180 BR|
256705|NCT02242279|Drug|Tiotropium|
256706|NCT02242279|Drug|Placebo|
256707|NCT02242266|Drug|Tiotropium low dose|inhalation powder, hard PE capsule
256708|NCT02242266|Drug|Tiotropium medium dose|inhalation powder, hard PE capsule
256709|NCT02242266|Drug|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
256710|NCT02242266|Drug|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
256711|NCT02242266|Drug|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
256712|NCT02242253|Drug|Tiotropium|administered via HandiHaler®
256713|NCT02242253|Drug|Salmeterol|administered via metered dose inhaler (MDI)
256714|NCT02242253|Drug|Placebo-MDI|
256715|NCT02242253|Drug|Placebo HandiHaler®|
256716|NCT02242240|Drug|Formoterol twice daily|
256717|NCT02242240|Drug|Formoterol once daily|
256718|NCT02242240|Drug|Tiotropium once daily|
256719|NCT02242240|Drug|Placebo|
256720|NCT02242227|Drug|Salmeterol xinafoate|
256721|NCT02242227|Drug|Serevent® Diskus®|
256722|NCT02242227|Drug|Placebo (HandiHaler®)|
256723|NCT02242227|Drug|Placebo (Diskus®)|
256724|NCT02242214|Drug|Misoprostol|
256725|NCT02242201|Drug|PNB Bupivacaine|Infusion
256726|NCT02242201|Drug|PAI Ropivacaine|Injection
256727|NCT02242201|Drug|PAI liposomal bupivacaine|Injection
256728|NCT02242201|Drug|Epinephrine|Injection, weight-based dosage of 100 mcg - 300 mcg
256729|NCT02242201|Drug|Ketorolac|Injection, 30 mg
256730|NCT02242188|Drug|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.~The intervention will last from 4 months to 9 months of age."
256731|NCT02242188|Dietary Supplement|Placebo|Maltodextrin (packed in identical sachets as active products)
256732|NCT02242175|Device|Glucose breath test (hydrogen breath test)|Glucose breath test (hydrogen breath test) is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
256733|NCT02242162|Procedure|phrenic nerves magnetic stimulations|
256734|NCT02242149|Drug|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
256735|NCT02242149|Drug|Placebo|Sugar pill manufactured to mimic Diacerein
256736|NCT02242136|Behavioral|FORNET|
256737|NCT02242110|Behavioral|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
256738|NCT02242097|Drug|ibrutinib|Given PO
256739|NCT02242097|Other|laboratory biomarker analysis|Correlative studies
256740|NCT02242084|Drug|Intravenuse Alteplase|
256741|NCT02242071|Biological|Stem Cell|intrathecal autologous bone marrow mononuclear cell transplantation
256742|NCT02242058|Other|Quantitative sensory testing|
256743|NCT02242045|Drug|Idelalisib|Tablet (s) administered orally twice daily
256744|NCT02242032|Drug|P-321 Ophthalmic Solution|
256745|NCT02242032|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
256746|NCT02242019|Device|Erchonia LUNULA|The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
256750|NCT02241967|Device|Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current delivered by electrodes attached to the scalp.
256751|NCT02241954|Device|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
256752|NCT02241941|Drug|Daptomycin|
256753|NCT02241928|Biological|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
256754|NCT02241915|Procedure|Open Colorectal Surgery|
256755|NCT02241915|Procedure|Laparoscopic Surgery|
256756|NCT02241889|Device|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
256757|NCT02241889|Device|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
256758|NCT02241876|Drug|N-acetylcysteine|
256759|NCT02241863|Behavioral|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
256760|NCT02241863|Behavioral|Routine counseling|
256761|NCT02241850|Other|High intensity training|9 weeks of supervised high intensity training
256762|NCT02241824|Device|In-elastic lumbar brace|
256763|NCT02241824|Device|Elastic abdominal binder|
256764|NCT02241811|Drug|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
256765|NCT02241811|Drug|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
256766|NCT02241798|Other|oxygen|O2 by nasal prongs
256767|NCT02241785|Drug|natalizumab|Administered as specified in the treatment arm
256768|NCT02241772|Drug|TA-8995|
256769|NCT02241772|Drug|Placebo|
256770|NCT02241759|Drug|TA-8995|
256771|NCT02241759|Drug|Moxifloxacin|
256772|NCT02241759|Drug|Placebo|
256773|NCT02241746|Other|no intervention|
256774|NCT02241733|Behavioral|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
256775|NCT02241733|Behavioral|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
256776|NCT02241720|Drug|regorafenib|
256777|NCT02241694|Other|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
256778|NCT02241681|Dietary Supplement|Peptamen 1.5|Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
256779|NCT02241668|Procedure|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
256780|NCT02241668|Drug|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
256781|NCT02241655|Device|a pragmatic EEG-guided anesthetic protocol|
256782|NCT02241642|Device|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
256783|NCT02241629|Drug|placebo|placebo of levo phencynonate hydrochloride
256784|NCT02241629|Drug|levo phencynonate hydrochloride|levo phencynonate hydrochloride
256785|NCT02241616|Drug|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
256786|NCT02241603|Behavioral|Weight loss|Obese Veterans will undergo dietary education for weight loss or weight maintenance
256787|NCT02241590|Drug|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
256788|NCT02241590|Drug|Entecavir + Fuzheng Huayu Tablet|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
256789|NCT02241577|Procedure|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
256790|NCT02241577|Procedure|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
256791|NCT02241564|Other|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
256792|NCT02241564|Drug|Switch from calcineurin inhibitor to an mTOR inhibitor|
256793|NCT02241551|Drug|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
256794|NCT02241551|Drug|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
256795|NCT02241538|Device|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
256796|NCT02241538|Device|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
256797|NCT02241538|Device|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
256839|NCT02241135|Biological|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
256840|NCT02241122|Procedure|prostate biopsy|
256798|NCT02241538|Device|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
256799|NCT02241512|Drug|Ibuprofen|
256800|NCT02241512|Drug|placebo|
256801|NCT02241499|Radiation|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
256802|NCT02241499|Drug|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
256803|NCT02241486|Drug|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
256804|NCT02241473|Other|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single‐blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
256805|NCT02241460|Drug|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
256806|NCT02241460|Drug|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
256807|NCT02241447|Other|Early Information|Nurse based at echo facility will inform referring physician within one week that their Patient was diagnosed with severe aortic Stenosis. outcomes and Treatment decision will be documented.
256808|NCT02241434|Biological|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
256809|NCT02241421|Drug|Amoxicillin|
256810|NCT02241421|Drug|Vancomycin|
256811|NCT02241395|Biological|Intrathecal autologous bone marrow mononuclear cell transplantation|
256812|NCT02241382|Device|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
256813|NCT02241382|Device|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
256814|NCT02241369|Biological|INO-3106, INO-9012|
256815|NCT02241356|Device|bifocals|bifocal glasses with an addition of 2.5 Dioptres
256816|NCT02241356|Device|single vision glasses|single vision glasses
256817|NCT02241343|Device|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
256818|NCT02241330|Dietary Supplement|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
256819|NCT02241330|Dietary Supplement|Fortification|Wheat flour is fortified before testmeal preparation
256820|NCT02241330|Dietary Supplement|Control|wheat flour is used as control comparator.
256821|NCT02241291|Procedure|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
256822|NCT02241278|Drug|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
256823|NCT02241252|Device|iPhone ECG|Please see detailed description for additional information.
256824|NCT02241226|Behavioral|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
256825|NCT02241213|Device|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
256826|NCT02241213|Device|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
256827|NCT02241200|Drug|DA3880|
256828|NCT02241200|Drug|Aranesp|
256829|NCT02241187|Drug|PEGPH20|
256830|NCT02241187|Drug|Cetuximab|
256831|NCT02241187|Device|DW & DCE-MRI|
256832|NCT02241187|Other|blood draws|Blood samples will be drawn at various time points.
256833|NCT02241174|Drug|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
256834|NCT02241161|Other|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
256835|NCT02241161|Other|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
256836|NCT02241161|Other|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
256841|NCT02241109|Other|no intervention|progression monitoring by echocardiography
256842|NCT02241096|Drug|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
256843|NCT02241083|Drug|Dopamine|
256844|NCT02241083|Drug|Norepinephrine|
256845|NCT02241083|Other|no medication|
256846|NCT02241070|Behavioral|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
256847|NCT02241057|Device|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
256848|NCT02241057|Other|Temperature Probe|
256849|NCT02241044|Device|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
256850|NCT02241044|Device|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
256851|NCT02241031|Biological|MPs|MPs are generated from cord blood using a combination of cytokines.
256852|NCT02241031|Drug|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
256853|NCT02241018|Drug|CD25 monoclonal antibody|
256854|NCT02241018|Drug|calcineurin inhibitors|
256855|NCT02241018|Biological|MSCs|
256856|NCT02241005|Other|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
256857|NCT02241005|Other|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
256858|NCT02240992|Biological|PBSC|
256859|NCT02240992|Biological|MSCs|
256860|NCT02240979|Device|cardiac MRI|cardiac MRI
256861|NCT02240953|Drug|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
256862|NCT02240953|Drug|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
256863|NCT02240953|Drug|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
256864|NCT02240953|Drug|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
256865|NCT02240940|Device|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
256866|NCT02240927|Drug|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
256867|NCT02240927|Drug|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
256868|NCT02240927|Drug|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
256869|NCT02240927|Drug|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
256870|NCT02240901|Device|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
256871|NCT02240901|Device|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
256872|NCT02240888|Biological|0,5 mg Prevenar i.m.|
256873|NCT02240888|Biological|0,5 mg seasonal influenza vaccine i.m.|
256874|NCT02240875|Biological|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
256875|NCT02240875|Biological|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
256876|NCT02240875|Biological|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
256877|NCT02240875|Biological|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
256878|NCT02240875|Biological|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
256879|NCT02240875|Biological|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
256880|NCT02240862|Device|Carotid Artery Stent|Placement of a stent within the carotid artery
256881|NCT02240849|Device|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
256882|NCT02240849|Device|Placebo general pillow|
256883|NCT02240836|Other|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
256885|NCT02240810|Device|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
256886|NCT02240797|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
256887|NCT02240771|Procedure|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
256888|NCT02240771|Drug|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count & Platelet count would be monitored every 15 days"
256889|NCT02240758|Procedure|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
256890|NCT02240745|Other|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
256891|NCT02240719|Drug|everolimus|Given PO
256892|NCT02240719|Drug|bendamustine hydrochloride|Given IV
256893|NCT02240706|Procedure|Best Supportive Care|At Discretion of the Investigator (Transfusions)
256894|NCT02240706|Drug|BI 836858|Monotherapy with BI 836858
256895|NCT02240693|Drug|BI 409306|
256896|NCT02240693|Drug|Placebo|
256897|NCT02240693|Drug|BI 409306|
256898|NCT02240693|Drug|Placebo|
256899|NCT02240693|Drug|Placebo|
256900|NCT02240693|Drug|BI 409306|
256901|NCT02240693|Drug|BI 409306|
256902|NCT02240693|Drug|Placebo|
256903|NCT02240693|Drug|Placebo|
256904|NCT02240680|Drug|placebo|placebo matching linagliptin 5 mg
256905|NCT02240680|Drug|linagliptin|5 mg once a day
256906|NCT02240667|Drug|Dabigatran etexilate|150 mg or 110 mg capsules twice daily
256907|NCT02240667|Drug|Vitamin K antagonists|International Normalized Ratio (INR) 2-3
256908|NCT02240641|Drug|Lacidipine|
256909|NCT02240641|Drug|Diuretics|
256910|NCT02240641|Drug|antihypertensive drugs|
256911|NCT02240641|Drug|alpha blockers|
256912|NCT02240641|Drug|Angiotensin-Converting Enzyme Inhibitors|
256913|NCT02240641|Drug|beta blockers|
256914|NCT02240628|Device|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
256915|NCT02240628|Drug|Saline|Patients in arm 2 will receive Saline with the Propofol.
256916|NCT02240628|Drug|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
256917|NCT02240615|Device|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
256918|NCT02240602|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
256919|NCT02240602|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
256920|NCT02240602|Drug|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
256921|NCT02240589|Drug|Memantine|Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
256922|NCT02240589|Drug|Placebo|Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
256923|NCT02240563|Procedure|Low-level laser therapy|
256924|NCT02240563|Procedure|Non laser ordinary red light|
256925|NCT02240550|Device|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
256926|NCT02240550|Device|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
256927|NCT02240537|Drug|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
256928|NCT02240537|Drug|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
256929|NCT02240537|Drug|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.~Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
256930|NCT02240524|Procedure|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
256931|NCT02240524|Procedure|Systemic chemotherapy|
256932|NCT02240524|Procedure|HIPEC|
256933|NCT02240511|Dietary Supplement|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
256934|NCT02240511|Other|Resistance Exercise|
256935|NCT02240498|Drug|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
256936|NCT02240498|Drug|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
256937|NCT02240498|Device|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
256938|NCT02240498|Device|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
256939|NCT02240498|Device|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
256940|NCT02240498|Device|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
256941|NCT02240498|Device|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
256942|NCT02240498|Device|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
256943|NCT02240498|Device|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
256944|NCT02240485|Behavioral|Couple therapy|"The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors imcompatibles with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
256945|NCT02240485|Behavioral|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
256946|NCT02240472|Procedure|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
256947|NCT02240459|Drug|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
256948|NCT02240459|Drug|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
256949|NCT02240459|Drug|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
256950|NCT02240459|Drug|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
256951|NCT02240446|Device|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
256952|NCT02240446|Device|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
256953|NCT02240433|Drug|LY2157299|LY2157299 administered orally
256954|NCT02240433|Drug|Sorafenib|Sorafenib administered orally
256955|NCT02240420|Behavioral|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
256956|NCT02240407|Genetic|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose selected for this study is a fixed dose of 4.6 x 10^13 vg per TA muscle (range of 7.64 x 10^11 vg/gm to 4.6 x 10^11 vg/gm based on TA weight).
256957|NCT02240407|Drug|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until four months after second injection.
256958|NCT02240407|Other|saline|Same volume as rAAV9-DES-hGAA injection will be used.
256959|NCT02240407|Drug|Rituxan|Patients will receive Rituxan (dose: 750 mg/m^2 twice) 21 and 7 day prior first AAV9 injection, with a Rituxan dose 375 mg/m^2 on the day of the injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 375 mg/m^2.
256960|NCT02240407|Drug|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
256961|NCT02240407|Drug|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
256962|NCT02240407|Drug|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
256963|NCT02240407|Drug|LMX 4 Topical Cream|Topical anesthesia cream will be used prior to gene therapy/saline injection.
256964|NCT02240381|Procedure|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
256965|NCT02240381|Procedure|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
256966|NCT02240381|Other|laboratory biomarker analysis|Correlative studies
256967|NCT02240355|Drug|RO6885247|oral solution
256968|NCT02240355|Drug|placebo|oral solution
256969|NCT02240342|Drug|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
258020|NCT02232152|Drug|fluorouracil|Given IV
256970|NCT02240329|Behavioral|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
256971|NCT02240329|Behavioral|Respiratory measures|We will collect measures of cough airflow and breathing strength.
256972|NCT02240329|Drug|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
256973|NCT02240303|Procedure|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
256974|NCT02240303|Procedure|Physical Performance|Participants in both groups will have a Physical Performance test.
256975|NCT02240303|Procedure|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
256976|NCT02240303|Procedure|Blood Sample|Participants in both groups will have blood samples taken.
256977|NCT02240290|Drug|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
256978|NCT02240290|Drug|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
256979|NCT02240264|Dietary Supplement|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
256980|NCT02240264|Dietary Supplement|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
256981|NCT02240251|Other|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
256982|NCT02240238|Drug|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
256983|NCT02240238|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
256984|NCT02240212|Drug|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
256985|NCT02240212|Drug|Paclitaxel|Paclitaxel sourced locally will be administered IV
256986|NCT02240199|Drug|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
256987|NCT02240199|Drug|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
256988|NCT02240199|Drug|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
256989|NCT02240199|Drug|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
256990|NCT02240186|Device|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
256991|NCT02240186|Device|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
256992|NCT02240173|Dietary Supplement|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
256993|NCT02240173|Drug|Haloperidol|Conventional drug normally used for psychotic problems
256994|NCT02240160|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
256995|NCT02240147|Behavioral|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
256996|NCT02240134|Behavioral|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
256997|NCT02240134|Device|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
256998|NCT02240134|Device|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
256999|NCT02240121|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
257000|NCT02240121|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
257001|NCT02240108|Drug|Rifaximin EIR|Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
257002|NCT02240108|Drug|Placebo|Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
257003|NCT02240095|Behavioral|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
257004|NCT02240095|Behavioral|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
257005|NCT02240095|Behavioral|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
257006|NCT02240082|Behavioral|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
257007|NCT02240069|Behavioral|Education (Tx1)|Education on best burn practices
257008|NCT02240069|Device|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove"
257009|NCT02240069|Device|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
257010|NCT02240043|Other|growth hormone secretion|The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
257011|NCT02240030|Drug|CVT-301 Low Dose|
257012|NCT02240030|Drug|CVT-301 High Dose|
257013|NCT02240030|Other|Placebo|
257014|NCT02240017|Drug|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
257015|NCT02240017|Drug|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
257016|NCT02240017|Drug|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
257017|NCT02240004|Device|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
257018|NCT02239991|Procedure|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
257019|NCT02239978|Behavioral|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
257020|NCT02239952|Drug|Sunitinib|50 mg once daily, oral use for 14 days
257021|NCT02239952|Drug|vandetanib|300 mg, once daily, oral use for 14 days
257022|NCT02239952|Drug|Erlotinib|150 mg, once daily, oral use for 14 days
257023|NCT02239939|Behavioral|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
257024|NCT02239939|Behavioral|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
257025|NCT02239926|Drug|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
257026|NCT02239926|Drug|Placebo|
257027|NCT02239913|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
257028|NCT02239913|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
257029|NCT02239913|Drug|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
257030|NCT02239913|Drug|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
257031|NCT02239900|Drug|Ipilimumab|"Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.~Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.~Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4"
257032|NCT02239900|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.~Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.~Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1."
257033|NCT02239887|Device|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
257034|NCT02239874|Dietary Supplement|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
257035|NCT02239874|Dietary Supplement|Fish oil and vitamin D placebo|840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
257036|NCT02239874|Dietary Supplement|Vitamin D placebo and fish oil placebo|placebo
257037|NCT02239874|Dietary Supplement|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
257058|NCT02239718|Procedure|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
257059|NCT02239692|Drug|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
257060|NCT02239679|Drug|Aminolevulinic Acid|20% ALA applied to face for one hour prior to 10 J/cm2 blue light
257038|NCT02239861|Biological|TAA-Specific CTLs|"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
257039|NCT02239835|Drug|Tipranavir (TPV) low dose|
257040|NCT02239835|Drug|Tipranavir (TPV) high dose|
257041|NCT02239835|Drug|Ritonavir low dose|
257042|NCT02239835|Drug|Ritonavir high dose|
257043|NCT02239835|Drug|Saquinavir|
257044|NCT02239822|Procedure|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks."
257045|NCT02239822|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
257046|NCT02239809|Procedure|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
257047|NCT02239809|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.~After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.~Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.~The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
257048|NCT02239796|Device|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.~Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
257049|NCT02239796|Device|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
257050|NCT02239783|Device|total hip arthroplasty implant|
257051|NCT02239770|Drug|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
257052|NCT02239770|Drug|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
257053|NCT02239757|Procedure|Left radial approach|Primary PCI performed through left radial approach.
257054|NCT02239757|Procedure|Right radial approach|Primary PCI performed through right radial approach.
257055|NCT02239744|Behavioral|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
257056|NCT02239731|Drug|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
257057|NCT02239718|Procedure|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
257061|NCT02239679|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light
257062|NCT02239679|Device|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
257063|NCT02239679|Procedure|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
257064|NCT02239666|Other|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
257065|NCT02239653|Behavioral|Physician communication|
257066|NCT02239627|Drug|Epidural steroid|
257067|NCT02239627|Drug|Clonidine|
257068|NCT02239614|Biological|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
257069|NCT02239614|Biological|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
257070|NCT02239601|Other|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program was provided and continued throughout chemotherapy treatment
257071|NCT02239588|Other|Oral consumption|"Daily oral consumption for 12 weeks:~Placebo;~Pure Canterbury;~Other infant formula milk powder:~Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)~Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)~Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)~Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)~Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)~Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
257072|NCT02239562|Drug|sPIF|
257073|NCT02239562|Drug|Placebo|
257074|NCT02239549|Device|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
257075|NCT02239549|Device|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
257076|NCT02239536|Procedure|hot snare polypectomy|hot snare polypectomy using electrosurgical snare with application of electrocautery for eligible polyps
257077|NCT02239536|Procedure|hot snare polypectomy after saline injection|hot snare polypectomy after saline injection using electrosurgical snare with application of electrocautery for eligible polyps
257078|NCT02239523|Procedure|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
257079|NCT02239523|Procedure|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
257080|NCT02239510|Drug|Senna|1 capsule (50 mg) Senna daily for 12 weeks
257081|NCT02239510|Drug|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
257082|NCT02239497|Procedure|Femoral block by ultrasound and neurostimulation|
257083|NCT02239497|Drug|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
257084|NCT02239484|Drug|Tadalafil|
257085|NCT02239484|Drug|Tamsulosin|
257086|NCT02239484|Drug|Tadalafil + Tamsulosin|
257087|NCT02239458|Drug|Saxagliptin|
257088|NCT02239445|Drug|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
257089|NCT02239445|Drug|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
257090|NCT02239445|Drug|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
257091|NCT02239419|Procedure|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
257092|NCT02239419|Procedure|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
257093|NCT02239393|Biological|Mesenchymal Stem Cells|"Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.~Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product)."
257094|NCT02239380|Drug|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to < 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.~Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
257095|NCT02239367|Behavioral|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
257096|NCT02239354|Device|VC-01™ Combination Product|Biologic and Device
257097|NCT02239341|Other|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
257098|NCT02239341|Other|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
257099|NCT02239315|Other|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
257100|NCT02239289|Other|Biofeedback|Idem as described in the arm section (above)
257101|NCT02239276|Drug|Stiripentol|The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
257102|NCT02239250|Device|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
257103|NCT02239237|Drug|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
257104|NCT02239224|Biological|Placebo|Patients will enter the double-blind treatment period and will receive 30-minute IV infusions of Placebo according to their random treatment assignment.
257105|NCT02239224|Biological|ATYR1940|Patients will enter the double-blind treatment period and will receive 30-minute IV infusions of ATYR1940 according to their random treatment assignment.
257106|NCT02239211|Drug|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
257107|NCT02239198|Other|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
257108|NCT02239185|Procedure|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
257109|NCT02239185|Procedure|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
257110|NCT02239172|Biological|PA83-FhCMB|
257111|NCT02239159|Other|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
257112|NCT02239146|Drug|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
257113|NCT02239146|Drug|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
257114|NCT02239133|Device|ProVATE vaginal pessary|
257115|NCT02239120|Drug|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
257116|NCT02239120|Drug|placebo to ASA|placebo to comparator drug
257117|NCT02239120|Drug|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
257118|NCT02239120|Drug|placebo to dabigatran etexilate|placebo
257119|NCT02239120|Drug|ASA 100 mg|active comparator drug
257120|NCT02239120|Drug|dabigatran etexilate|active drug
257121|NCT02239107|Drug|N-Acetyl cysteine|
257122|NCT02239107|Procedure|laparoscopic ovarian drilling|
257123|NCT02239094|Drug|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
257124|NCT02239081|Drug|CTP-730|
257125|NCT02239081|Drug|Placebo for CTP-730|
257126|NCT02239042|Procedure|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
257127|NCT02239029|Drug|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
257128|NCT02239029|Drug|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
257129|NCT02239003|Drug|DAOIB|
257130|NCT02239003|Drug|Placebo|
257131|NCT02238977|Drug|Fluoxetine|Antidepressant
257133|NCT02238964|Device|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
257134|NCT02238964|Procedure|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
257135|NCT02238951|Other|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
257136|NCT02238951|Other|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
257137|NCT02238938|Procedure|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
257138|NCT02238938|Procedure|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.~After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
257139|NCT02238925|Drug|CPX-351|
257140|NCT02238912|Drug|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
257141|NCT02238886|Dietary Supplement|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
257142|NCT02238873|Drug|Pegfilgrastim|
257143|NCT02238860|Drug|Entacavir|Entacavir-0.5 mg ,OD,for
257144|NCT02238860|Drug|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
257145|NCT02238847|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
257146|NCT02238834|Drug|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
257147|NCT02238834|Drug|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
257148|NCT02238834|Drug|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
257149|NCT02238834|Drug|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
257150|NCT02238808|Drug|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
257151|NCT02238782|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
257152|NCT02238782|Other|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of [14C] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
257153|NCT02238769|Device|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
257154|NCT02238756|Biological|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
257155|NCT02238756|Biological|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
257156|NCT02238756|Biological|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
257157|NCT02238730|Device|Ultrabrief Right Unilateral|The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
257158|NCT02238730|Device|Brief Pulse Bitemporal|The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
257159|NCT02238717|Drug|PF-06372865 (65mg)|single oral dose (65 mg)
257160|NCT02238717|Drug|PF-06372865 (15mg)|single oral dose (15mg)
257161|NCT02238717|Drug|Pregabalin|single oral dose (300mg)
257162|NCT02238717|Drug|Placebo|matching oral placebo
257163|NCT02238704|Dietary Supplement|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
257164|NCT02238704|Dietary Supplement|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
257165|NCT02238691|Procedure|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.~15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
257166|NCT02238665|Device|Endomicroscopy|
257167|NCT02238652|Behavioral|Communication|A preparation process before the patient become incapable of participating in life prolonging decisions
257168|NCT02238652|Behavioral|Systematic Pain Assessment and Treatment|Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
257169|NCT02238652|Behavioral|Medication Review|An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
257170|NCT02238652|Behavioral|Occupational therapy|Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
257171|NCT02238652|Behavioral|Safety|Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
257219|NCT02238327|Procedure|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
257220|NCT02238327|Procedure|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
257172|NCT02238639|Procedure|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.~If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
257173|NCT02238626|Drug|Placebo (for MN-166)|
257174|NCT02238626|Drug|MN-166|
257175|NCT02238626|Drug|riluzole|Patient is given 50 mg riluzole twice daily.
257176|NCT02238613|Device|radioactive stent|radioactive stent carrying seed iodine 125
257177|NCT02238613|Device|plastic stent|common plastic stent without carrying seed iodine 125
257178|NCT02238587|Other|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
257179|NCT02238587|Dietary Supplement|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
257180|NCT02238574|Procedure|surgery|excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity
257181|NCT02238574|Other|follow up|Intensified outpatient follow up (16 visits in 5 years)
257182|NCT02238548|Biological|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
257183|NCT02238548|Other|Raw milk|
257184|NCT02238535|Drug|Ventavis|
257185|NCT02238535|Drug|Warfarin|
257186|NCT02238522|Drug|ZEN003365|
257187|NCT02238509|Drug|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
257188|NCT02238509|Drug|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
257189|NCT02238496|Procedure|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
257190|NCT02238496|Drug|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
257191|NCT02238496|Drug|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
257192|NCT02238483|Drug|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
257193|NCT02238483|Drug|Placebo|Inhaled placebo solution
257194|NCT02238470|Drug|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
257195|NCT02238457|Drug|Low dose losartan|25 mg losartan bid for 10 weeks
257196|NCT02238457|Drug|High dose losartan|50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
257197|NCT02238444|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
257198|NCT02238444|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
257199|NCT02238444|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
257200|NCT02238444|Drug|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
257201|NCT02238431|Drug|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
257202|NCT02238431|Drug|OCP|to schedule the start of the artificial cycle
257203|NCT02238431|Other|Natural|to use the normal menstrual period to schedule treatment start
257204|NCT02238418|Drug|Cholecalciferol vial (100 000 UI)|"VISIT 1:~Patient > 60 kg and initial 25OHD serum concentration < 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration < 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient < 20 kg and initial 25OHD serum concentration < 75 nmol/L: prescription of 1 single vial~A local lab will performed urinary dosage of calciuria and creatininuria:~at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial~at days 0, 2 and 4 after other intakes (when applicable)~VISIT 2:~25OHD serum concentration will then be dosed at month 2 after visit 1"
257205|NCT02238405|Other|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
257206|NCT02238392|Procedure|Adenosine test|Testing dormant conduction after PVI
257207|NCT02238392|Procedure|Termination of AF|Testing AF iducibility and ermination of
257208|NCT02238379|Drug|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
257209|NCT02238379|Other|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
257210|NCT02238366|Drug|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
257211|NCT02238353|Drug|azelastine + fluticasone|
257212|NCT02238353|Drug|Placebo|
257213|NCT02238340|Drug|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
257214|NCT02238340|Drug|Extended- release Oxycodone|
257215|NCT02238340|Drug|ketoprofen|
257216|NCT02238340|Drug|dipirone|
257217|NCT02238340|Drug|dexametasone|
257218|NCT02238340|Drug|Morphine IV (rescue)|
257276|NCT02237937|Drug|Sertraline|
257277|NCT02237937|Drug|Citalopram|
257221|NCT02238327|Procedure|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
257222|NCT02238327|Procedure|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to <88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
257223|NCT02238327|Radiation|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
257224|NCT02238327|Procedure|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
257225|NCT02238327|Procedure|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
257226|NCT02238314|Drug|Tipranavir low dose|
257227|NCT02238314|Drug|Tipranavir high dose|
257228|NCT02238314|Drug|Ritonavir|
257229|NCT02238314|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
257230|NCT02238314|Drug|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
257231|NCT02238301|Other|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
257232|NCT02238301|Other|Bold + ASL sequence|"A first sequence BOLD+ASL will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.~Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
257233|NCT02238288|Drug|Aminocaproic acid|Crushed tablet in the dental socket
257234|NCT02238288|Other|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
257235|NCT02238288|Drug|lidocaine and epinephrine|2%
257236|NCT02238288|Drug|Paracetamol|750 mg
257237|NCT02238275|Drug|Micardis® plus|
257238|NCT02238262|Drug|Telmisartan|
257239|NCT02238249|Drug|Alesion®|Dry Syrup
257240|NCT02238236|Drug|Alesion®|Dry Syrup
257241|NCT02238223|Drug|Alesion®|
257242|NCT02238210|Drug|Atrovent®|
257243|NCT02238197|Drug|Atrovent® Inhalation Solution|
257244|NCT02238184|Drug|Atrovent®|
257245|NCT02238184|Drug|Ventilat®|
257246|NCT02238171|Drug|Atrovent® inhalets|
257247|NCT02238158|Drug|Atrovent® inhalets|
257248|NCT02238145|Drug|Atrovent® Inhaletten|
257249|NCT02238132|Drug|ATROVENT® inhalets|
257250|NCT02238119|Drug|Tiotropium + formoterol combination|
257251|NCT02238119|Drug|Tiotropium|
257252|NCT02238119|Drug|Formoterol|
257253|NCT02238106|Drug|Salmeterol medium dose|
257254|NCT02238106|Drug|Salmeterol low dose|
257255|NCT02238106|Drug|Salmeterol high dose|
257256|NCT02238106|Drug|Serevent® Diskus®|
257257|NCT02238106|Drug|Placebo HandiHaler®|
257258|NCT02238106|Drug|Placebo Diskus®|
257259|NCT02238080|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
257260|NCT02238067|Drug|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
257261|NCT02238067|Other|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
257262|NCT02238041|Device|GlucoClear System|
257263|NCT02238028|Behavioral|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
257264|NCT02238015|Procedure|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
257265|NCT02238002|Procedure|cataract surgery|The patients of both groups underwent cataract surgery
257266|NCT02237989|Drug|paracetamol|1500 mg
257267|NCT02237989|Drug|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
257268|NCT02237976|Behavioral|Self-hypnosis|
257269|NCT02237976|Behavioral|Routine practice|
257270|NCT02237963|Procedure|Posterolateral thoracotomy|
257271|NCT02237963|Procedure|Axillary thoracotomy|
257272|NCT02237950|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
257273|NCT02237950|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
257274|NCT02237950|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
257275|NCT02237937|Drug|Paroxetine|
257284|NCT02237924|Drug|endostar|Endostar 7.5mg / m2, 2 cycles of intravenous infusion for ten days,and 2 cycles of maintenance therapy after radiotherapy
257285|NCT02237924|Drug|DDP|DDP:80mg/m2 for 2-3 cycles
257286|NCT02237924|Radiation|IMRT|IMRT:70-74Gy for 2-3 cycles
257287|NCT02237911|Other|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
257288|NCT02237911|Other|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
257289|NCT02237898|Behavioral|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application & Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
257290|NCT02237898|Behavioral|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the Sensodrone™ CO sensor.
257291|NCT02237898|Device|Sensordrone™ carbon-monoxide sensor|
257292|NCT02237898|Device|MoMba Live Long Smartphone application|
257293|NCT02237885|Device|NeuroSky MindWave Mobile|
257294|NCT02237859|Drug|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
257295|NCT02237859|Dietary Supplement|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
257296|NCT02237846|Biological|Human umbilical cord tissue-derived mesenchymal stem cells|
257297|NCT02237820|Drug|Dexamethasone|6 mg/day of Oral Dexamethasone
257298|NCT02237820|Drug|Prednisone|40 mg/day of Oral Prednisone
257299|NCT02237807|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
257300|NCT02237807|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
257301|NCT02237781|Drug|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
257302|NCT02237768|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
257303|NCT02237768|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
257304|NCT02237755|Drug|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
257305|NCT02237755|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
257306|NCT02237742|Drug|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
257307|NCT02237729|Biological|PF-06410293|PF-06410293 will be administered as a single 40 mg, subcutaneous dose
257308|NCT02237729|Biological|Adalimumab-US|Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
257309|NCT02237729|Biological|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
257310|NCT02237703|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
257311|NCT02237690|Drug|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
257312|NCT02237677|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
257313|NCT02237664|Procedure|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
257314|NCT02237664|Procedure|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
257315|NCT02237651|Device|topical anesthesia multi-use device|
257316|NCT02237651|Device|topical anesthesia Intranasal Mucosal Atomization|
257317|NCT02237638|Biological|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
257318|NCT02237612|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
257319|NCT02237612|Other|laboratory biomarker analysis|Correlative studies
257320|NCT02237586|Biological|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
257321|NCT02237573|Other|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:~a detailed report of the consultation (motive, case history, clinical examination, conclusion)~written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
257322|NCT02237573|Other|Control|"Other:~Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
257323|NCT02237560|Behavioral|Cybercycle-Game|Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
258021|NCT02232152|Other|pharmacological study|Correlative studies
257324|NCT02237560|Behavioral|Cybercyle-Tour|Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
257325|NCT02237560|Behavioral|Game Only|While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
257326|NCT02237547|Biological|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
257327|NCT02237534|Drug|Lanthanum carbonate|
257328|NCT02237534|Drug|Calcium Carbonate|
257329|NCT02237521|Other|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
257330|NCT02237521|Other|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
257331|NCT02237508|Drug|Z7200|
257332|NCT02237508|Drug|Symbicort Turbohaler|
257333|NCT02237508|Drug|Z7200 with charcoal|
257334|NCT02237508|Drug|Symbicort Turbohaler with charcoal|
257335|NCT02237508|Drug|Symbicort Turbohaler replicate|
257336|NCT02237495|Drug|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
257337|NCT02237495|Drug|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
257338|NCT02237482|Device|Trilogy cup|
257339|NCT02237482|Device|Trabecular metal cup (TM)|
257340|NCT02237482|Device|ZCA cup|
257341|NCT02237469|Radiation|Prone and supine simulation|Treatment planning in the two positions.
257342|NCT02237456|Procedure|Comparison of OCT scans|
257343|NCT02237456|Procedure|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
257344|NCT02237443|Drug|Rocuronium|Administration of a NMBD
257345|NCT02237443|Drug|Vecuronium Bromide|Administration of a NMBD
257346|NCT02237443|Drug|Succinylcholine|Administration of a NMBD
257347|NCT02237430|Device|MynxGrip|Closure device for femoral artery access closure
257348|NCT02237430|Other|Manual compression|Conventional manual compression
257349|NCT02237417|Drug|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
257350|NCT02237417|Drug|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
257351|NCT02237417|Other|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
257352|NCT02237404|Device|Telemedicine System|Telemedicine System is used in remote monitoring group
257353|NCT02237391|Other|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
257354|NCT02237391|Other|Treatment as Usual (TAU)|Control group
257355|NCT02237378|Radiation|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
257356|NCT02237365|Drug|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
257357|NCT02237365|Drug|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
257358|NCT02237365|Drug|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
257359|NCT02237339|Drug|Allopurinol|Uric acid lowering medication.
257360|NCT02237339|Drug|Placebo|
257361|NCT02237326|Procedure|Visual Inspection with Acetic Acid|Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
257362|NCT02237326|Procedure|Visual Inspection with Lugol's Iodine|Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
257363|NCT02237313|Behavioral|psychological support and therapeutic education program|
257364|NCT02237300|Behavioral|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
257365|NCT02237300|Behavioral|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
257366|NCT02237287|Other|wound dressing with VAC and sNAG without antiaggregation|
257367|NCT02237287|Procedure|wound dressing with VAC|
257368|NCT02237287|Drug|wound dressing with VAC and sNAG under Antiaggregation|
257369|NCT02237274|Other|High altitude exposition|High altitude exposition
257370|NCT02237261|Drug|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:~Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4~Cycle 2-9 (d1-28) - Consolidation:~Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
257371|NCT02237235|Drug|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks"
257372|NCT02237235|Drug|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
257373|NCT02237222|Other|Gait rehabilitation|
257374|NCT02237209|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
257375|NCT02237209|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
257376|NCT02237196|Biological|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
257377|NCT02237196|Biological|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
257378|NCT02237196|Biological|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
257379|NCT02237196|Biological|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
257380|NCT02237183|Drug|Iloprost|Given via inhalation
257381|NCT02237183|Other|Placebo|Given via inhalation
257382|NCT02237183|Other|Quality-of-Life Assessment|Ancillary studies
257383|NCT02237183|Other|Questionnaire Administration|Ancillary studies
257384|NCT02237157|Drug|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
257385|NCT02237144|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
257386|NCT02237144|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
257387|NCT02237144|Other|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
257388|NCT02237144|Behavioral|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
257389|NCT02237131|Drug|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
257390|NCT02237131|Drug|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
257391|NCT02237118|Device|Mepitel One|
257392|NCT02237118|Device|UrgoTul|
257393|NCT02237105|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
257394|NCT02237092|Procedure|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
257395|NCT02237079|Drug|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
257396|NCT02237079|Drug|Placebo Oral Tablet|Daily placebo tablet
257397|NCT02237066|Device|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
257398|NCT02237066|Device|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
257399|NCT02237053|Drug|Glucagon|
257400|NCT02237053|Drug|Octreotide|
257401|NCT02237053|Behavioral|Placebo|
257402|NCT02237053|Drug|Insulin|
257403|NCT02237040|Procedure|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
257404|NCT02237027|Biological|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
257405|NCT02237027|Biological|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
257406|NCT02237001|Device|Suture-based meniscal repair|Suture-based meniscal repair
257407|NCT02236988|Drug|Apremilast|
257408|NCT02236975|Device|BuMA Supreme Biodegradable drug coating coronary stent system|
257409|NCT02236975|Device|Resolute Integrity durable polymer stent system|
257410|NCT02236962|Drug|Placebo|
257411|NCT02236962|Drug|Ephedrine, pioglitazone|
257412|NCT02236949|Behavioral|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
257413|NCT02236936|Dietary Supplement|Standard care of parenteral nutrition|Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
257548|NCT02236000|Drug|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
257414|NCT02236936|Dietary Supplement|Parenteral over night nutrition|Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.
257415|NCT02236936|Biological|Cetuximab|"Weekly during radiotherapy; not given if cisplatin is given during radiotherapy~Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)"
257416|NCT02236936|Drug|Cisplatin|Cisplatin total dose of >200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
257417|NCT02236936|Radiation|Radiotherapy|70 Gy / 5 fractions per week, over 7 weeks
257418|NCT02236910|Other|Lu-DOTA-TATE|
257419|NCT02236897|Other|PET Scanning|
257420|NCT02236884|Procedure|no-scar transanal total mesorectal excision(TME)|
257421|NCT02236871|Behavioral|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
257422|NCT02236871|Behavioral|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
257423|NCT02236858|Device|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
257424|NCT02236858|Device|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
257425|NCT02236845|Device|Lacrima Medical Device and sham comparator|
257426|NCT02236832|Device|transcranial magnetic stimulation|
257427|NCT02236832|Other|MRI imaging|
257428|NCT02236832|Other|EEG recording|
257429|NCT02236832|Behavioral|Neuropsychological examination|
257430|NCT02236806|Drug|Bisoprolol|5 mg daily
257431|NCT02236806|Drug|Ramipril|5 mg daily
257432|NCT02236806|Drug|Placebo|1 capsule daily
257433|NCT02236793|Drug|BioChaperone PDGF-BB|
257434|NCT02236793|Other|Standard of Care|
257435|NCT02236767|Device|Neurostar Transcranial Magnetic Stimulation Therapy System|Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
257436|NCT02236754|Drug|18F-FP-DTBZ|The drug, no carrier added [18F]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce [18F]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 mCi of [18F]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
257437|NCT02236754|Radiation|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
257438|NCT02236741|Drug|Mirapexin® (Sifrol®)|
257439|NCT02236728|Drug|Pramipexole|
257440|NCT02236715|Drug|Atrovent®|
257441|NCT02236702|Other|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
257442|NCT02236689|Procedure|Non operative|no surgical intervention
257443|NCT02236689|Procedure|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
257444|NCT02236676|Behavioral|Nap after rehearsal trials|
257445|NCT02236663|Behavioral|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
257446|NCT02236663|Behavioral|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.~Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.~Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
257447|NCT02236650|Behavioral|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
257448|NCT02236650|Other|Treatment as Usual|Treatment as Usual for 4 weeks
257449|NCT02236624|Behavioral|Aerobic exercise|
257450|NCT02236611|Drug|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
257451|NCT02236611|Drug|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
257452|NCT02236598|Drug|K+ supplement|
257453|NCT02236598|Drug|Placebo|
257454|NCT02236585|Procedure|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
257455|NCT02236585|Procedure|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
258022|NCT02232152|Other|laboratory biomarker analysis|Correlative studies
257456|NCT02236572|Drug|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:~Anastrozole 1 mg~Letrozole 2.5 mg~Exemestane 25 mg"
257457|NCT02236559|Device|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.~FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
257458|NCT02236559|Device|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%.
257459|NCT02236546|Diagnostic Test|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
257460|NCT02236546|Other|Molecular assays on biopsied tissue|Correlative studies
257461|NCT02236546|Device|positron emission tomography|Undergo FDG-PET/CT
257462|NCT02236546|Device|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
257463|NCT02236533|Dietary Supplement|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
257464|NCT02236520|Drug|Spironolactone|
257465|NCT02236520|Drug|Chlorthalidone|
257466|NCT02236520|Dietary Supplement|Diet|
257467|NCT02236520|Drug|Placebo|
257468|NCT02236507|Device|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
257469|NCT02236494|Behavioral|Brief Negotiated Interview|As per arm
257470|NCT02236494|Behavioral|General Health Information|As per arm (this is the active comparator)
257471|NCT02236481|Drug|Anakinra|
257472|NCT02236481|Drug|TNF alpha inhibitors|
257473|NCT02236468|Other|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
257474|NCT02236468|Behavioral|WASH/malaria behavior change|WASH/malaria behavior change communication
257475|NCT02236468|Dietary Supplement|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
257476|NCT02236468|Other|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
257477|NCT02236455|Behavioral|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
257478|NCT02236455|Behavioral|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
257479|NCT02236455|Behavioral|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
257480|NCT02236455|Behavioral|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
257481|NCT02236442|Other|Recommendation to use global headache treatment protocol|"The global treatment protocol is :~Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor~Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.~Provide a sound-proof helmet to the patient.~Provide a light-blocking google to the patient.~If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.~If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :~Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.~Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.~Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.~Other etiology : Treatment left at the discretion of the physician in charge of the patient."
257482|NCT02236429|Biological|vaginal flora transplant|
257483|NCT02236416|Behavioral|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
257484|NCT02236416|Behavioral|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
257485|NCT02236403|Drug|Ivermectin 0.1% Metronidazole 1%|
257486|NCT02236390|Behavioral|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
257487|NCT02236390|Behavioral|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
257488|NCT02236377|Behavioral|Exposure, Relaxation, and Rescripting Therapy|Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
257489|NCT02236364|Device|Contour, Bayer Healthcare, LLC|Blood glucose measurement
257490|NCT02236351|Device|Pinched Patch|
257588|NCT02235701|Drug|aldoxorubicin|administered 350 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
257589|NCT02235701|Drug|ifosfamide|
257491|NCT02236338|Procedure|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
257492|NCT02236338|Device|ClosureFAST radiofrequency catheter|
257493|NCT02236338|Device|EVLT 980nm diode laser system|
257494|NCT02236325|Behavioral|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
257495|NCT02236325|Behavioral|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
257496|NCT02236312|Drug|Botulinum Toxin Type A|
257497|NCT02236312|Drug|Placebo|
257498|NCT02236299|Procedure|Right Coronary Artery Percutaneous Coronary Intervention|
257499|NCT02236299|Other|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
257500|NCT02236299|Other|GLP-1 Infusion|30 minute infusion GLP-1
257501|NCT02236286|Behavioral|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
257502|NCT02236273|Behavioral|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
257503|NCT02236273|Behavioral|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
257504|NCT02236260|Procedure|Electroacupuncture|Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.
257505|NCT02236260|Drug|Local Anesthesia (lidocaine hydrochloride)|All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
257506|NCT02236247|Drug|ivabradine|5 mg oral twice daily
257507|NCT02236247|Drug|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
257508|NCT02236234|Biological|HPV vaccine|HPV vaccine
257509|NCT02236195|Drug|Mocetinostat|
257510|NCT02236182|Drug|Ipratropium Bromide low dose|
257511|NCT02236182|Drug|Placebo|
257512|NCT02236182|Drug|Ipratropium Bromide high dose|
257513|NCT02236169|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
257514|NCT02236169|Drug|Atrovent CFC inhalation aerosol|
257515|NCT02236156|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
257516|NCT02236156|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
257517|NCT02236156|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
257518|NCT02236130|Procedure|Regional block|Single shot peripheral nerve block
257519|NCT02236130|Procedure|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
257520|NCT02236130|Drug|Local Anesthetic Ropivacaine|0.5% Ropivacaine
257521|NCT02236130|Drug|Opioids Morphine|Morphine
257522|NCT02236130|Drug|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
257523|NCT02236117|Other|Aerobic Training|Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week−1; intensity, >80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
257524|NCT02236104|Device|Plethysmography opto electronic|
257525|NCT02236104|Procedure|respiratory parameters|
257526|NCT02236078|Drug|Capreomycin|See arm Description
257527|NCT02236078|Drug|High dose isoniazid|See arm description
257528|NCT02236078|Drug|Rifampicin|see arm description
257529|NCT02236078|Drug|Rifabutin|see arm description
257530|NCT02236078|Drug|Moxifloxacin|see arm description
257531|NCT02236065|Procedure|Umbilical cord blood therapy|
257532|NCT02236065|Biological|Filgrastim|
257533|NCT02236052|Biological|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
257534|NCT02236052|Biological|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
257535|NCT02236052|Biological|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
257536|NCT02236052|Biological|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
257537|NCT02236052|Biological|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
257538|NCT02236052|Biological|Placebo|A single dose of placebo
257539|NCT02236039|Procedure|Bronchoscopy|Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
257540|NCT02236026|Drug|Supratherapuetic dose of Nestorone|
257541|NCT02236026|Drug|Placebo|
257542|NCT02236026|Drug|Moxifloxacin|
257543|NCT02236013|Drug|Gilteritinib|Oral
257544|NCT02236013|Drug|Idarubicin|lyophilized powder administered intravenously
257545|NCT02236013|Drug|Cytarabine|solution administered intravenously
257546|NCT02236013|Drug|Daunorubicin|solution administered intravenously
257547|NCT02236000|Drug|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
257549|NCT02235987|Drug|octreotide|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
257550|NCT02235987|Drug|DG3173|Eligible patients are to receive 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
257551|NCT02235974|Behavioral|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
257552|NCT02235974|Behavioral|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
257553|NCT02235974|Behavioral|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
257554|NCT02235974|Behavioral|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
257555|NCT02235961|Drug|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
257556|NCT02235961|Drug|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
257557|NCT02235961|Drug|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
257558|NCT02235948|Drug|folic acid supplementation|0.8mg folic acid/day
257559|NCT02235922|Other|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
257560|NCT02235922|Other|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
257561|NCT02235909|Drug|Azilsartan Medoxomil|
257562|NCT02235909|Drug|Losartan|
257563|NCT02235909|Drug|Placebo for Azilsartan Medoxomil|
257564|NCT02235909|Drug|Placebo for Losartan|
257565|NCT02235896|Behavioral|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
257566|NCT02235870|Device|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
257567|NCT02235870|Device|Sham Device|Sham Intragastric Balloon
257568|NCT02235870|Behavioral|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
257569|NCT02235857|Device|LIPOSORBER® LA-15 System|LIPOSORBER® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
257570|NCT02235844|Biological|Umbilical Cord Mesenchymal Stem Cells|
257571|NCT02235831|Device|Nelfilcon A MF contact lenses (DACP MF)|Multifocal contact lenses in Low, Medium, High Add
257572|NCT02235831|Device|Nelfilcon A single vision contact lenses (DACP)|
257573|NCT02235818|Device|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
257574|NCT02235818|Device|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
257575|NCT02235805|Dietary Supplement|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
257576|NCT02235805|Dietary Supplement|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
257577|NCT02235792|Device|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
257578|NCT02235779|Other|Transbronchial lung cryobiopsy|
257579|NCT02235766|Other|Echocardiographic assessment|
257580|NCT02235753|Behavioral|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
257581|NCT02235753|Behavioral|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
257582|NCT02235740|Drug|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
257583|NCT02235740|Drug|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
257584|NCT02235727|Drug|GBR 900|
257585|NCT02235727|Drug|Placebo|
257586|NCT02235701|Drug|aldoxorubicin|administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
257587|NCT02235701|Drug|aldoxorubicin|administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
257590|NCT02235688|Drug|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
257591|NCT02235688|Drug|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
257592|NCT02235688|Drug|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
257593|NCT02235688|Drug|gemcitabine|
257594|NCT02235675|Device|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
257595|NCT02235662|Drug|TFV IVR|
257596|NCT02235662|Drug|TFV/LNG IVR|
257597|NCT02235662|Other|Placebo IVR|
257598|NCT02235649|Behavioral|Social Cognition therapy ( Psychological Therapy)|
257599|NCT02235623|Procedure|Single-stage Fowler-Stephens orchidopexy (FSO)|
257600|NCT02235623|Procedure|Two-stage Fowler-Stephens orchidopexy (FSO)|
257601|NCT02235610|Procedure|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.~Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
257602|NCT02235584|Drug|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
257603|NCT02235571|Behavioral|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
257604|NCT02235558|Drug|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
257605|NCT02235545|Device|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
257606|NCT02235532|Other|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
257607|NCT02235532|Other|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
257608|NCT02235519|Drug|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
257609|NCT02235519|Drug|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
257610|NCT02235506|Procedure|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
257611|NCT02235506|Procedure|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
257612|NCT02235506|Device|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
257613|NCT02235506|Device|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
257614|NCT02235493|Biological|Retrospective Case Only|
257615|NCT02235480|Drug|Experimental Tazarotene Gel|
257616|NCT02235480|Drug|Placebo|
257617|NCT02235467|Behavioral|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
257618|NCT02235454|Device|SDOCT-GMPE software|Noninvasive imaging of the optic nerve in patients with existing glaucoma
257619|NCT02235441|Other|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
257620|NCT02235428|Drug|Ipratropium bromide|
257621|NCT02235428|Drug|Placebo|
257622|NCT02235428|Drug|Salbutamol|
257623|NCT02235415|Drug|Motens® (lacidipine)|
257624|NCT02235402|Drug|Lacidipine|
257625|NCT02235402|Drug|Bendrofluazide|
257626|NCT02235402|Drug|Placebo|
257627|NCT02235389|Drug|Alteplase (Actilyse)|
257628|NCT02235389|Drug|Standard therapy|
257629|NCT02235376|Other|weaning trial of mechanical ventilation|
257630|NCT02235363|Procedure|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
257631|NCT02235350|Other|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
257670|NCT02235038|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
257632|NCT02235350|Other|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
257633|NCT02235337|Drug|Riboflavin 400mg daily|
257634|NCT02235324|Biological|ziv-aflibercept|Given IV
257635|NCT02235324|Drug|leucovorin calcium|Given IV
257636|NCT02235324|Drug|fluorouracil|Given IV
257637|NCT02235324|Other|laboratory biomarker analysis|Correlative studies
257638|NCT02235311|Drug|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
257639|NCT02235298|Drug|Dapagliflozin|Dapaglifozin causes a rapid and significant reduction of epicardial fat in type 2 diabetic patients
257640|NCT02235298|Drug|Metformin|
257641|NCT02235285|Procedure|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
257642|NCT02235272|Drug|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
257643|NCT02235272|Drug|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
257644|NCT02235259|Drug|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
257645|NCT02235259|Drug|Placebo|
257646|NCT02235246|Drug|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
257647|NCT02235246|Drug|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
257648|NCT02235233|Drug|Technetium Tc 99M Mebrofenin|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
257649|NCT02235220|Other|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.~A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
257650|NCT02235207|Behavioral|Neuromuscular exercise|"Fustra20 Neck & Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~improve movement control in different posture and movements of the neck and back~improve flexibility with active functional movements~improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
257651|NCT02235194|Dietary Supplement|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
257652|NCT02235194|Dietary Supplement|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
257653|NCT02235181|Device|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
257654|NCT02235168|Procedure|six minute walking test|
257655|NCT02235142|Other|Blood sample|
257656|NCT02235129|Other|breath-holding|
257657|NCT02235116|Other|Survey|
257658|NCT02235103|Other|Sperm Chromatin Dispersion Test|
257659|NCT02235090|Other|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
257660|NCT02235077|Drug|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.~Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
257661|NCT02235077|Drug|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.~Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
257662|NCT02235064|Drug|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
257663|NCT02235064|Drug|Placebo|Capsule containing cellulose powder of same color as experimental arm
257664|NCT02235051|Behavioral|exercise intervention|Undergo Curves exercise program
257665|NCT02235051|Other|laboratory biomarker analysis|Correlative studies
257666|NCT02235051|Other|questionnaire administration|Ancillary studies
257667|NCT02235051|Other|quality-of-life assessment|Ancillary studies
257668|NCT02235038|Behavioral|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
257669|NCT02235038|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
257671|NCT02235025|Other|Cardio-pulmonary exercise testing|
257672|NCT02235012|Drug|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :~Initial rapid infusion of 0,23 mg/kg~Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
257673|NCT02235012|Drug|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :~Initial rapid infusion of 0,23 mg/kg~Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min~Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
257674|NCT02234999|Drug|CC-122|3mg [14C]-CC-122 will be administered as a single dose
257675|NCT02234986|Drug|ENMD-2076|250 mg oral dose, QD for 28 day cycles
257676|NCT02234973|Behavioral|Quality Improvement|Community and Clinical Teams engaged in implementing Quality Improvement initiatives to improve diabetes prevention and management within their First Nations community and clinic.
257677|NCT02234960|Drug|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
257678|NCT02234947|Procedure|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
257679|NCT02234934|Biological|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.~The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then frozen, and an aliquot tested and characterized for quality. If the cell product passes release criteria, it is thawed at bedside and infused into the patient after the patient has received myelo-ablative conditioning. The cell/product dose will consist of at least 3 x 10^6 cells per kg of body weight transduced ex vivo with 1 x 10^8 IG/mL of lentiviral vector to achieve > 0.3 integrated copies per cell."
257680|NCT02234921|Drug|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
257681|NCT02234921|Biological|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
257682|NCT02234921|Biological|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
257683|NCT02234921|Drug|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
257684|NCT02234908|Behavioral|Contacts|Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.
257685|NCT02234908|Behavioral|Index|Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
257686|NCT02234895|Device|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
257687|NCT02234895|Device|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
257688|NCT02234882|Drug|Rosuvastatin|
257689|NCT02234882|Drug|BMS-663068|
257690|NCT02234869|Drug|Interferon Beta|Subcutaneous injection
257691|NCT02234869|Drug|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
257692|NCT02234856|Procedure|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
257693|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
257694|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
257695|NCT02234843|Drug|Standard of Care|"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.~dose : as per standard of care"
257696|NCT02234830|Device|Exoseal closure device|Closure device for femoral artery access closure
257697|NCT02234830|Device|Angioseal closure device|Closure device for femoral artery access closure
257698|NCT02234804|Device|Xience Prime Stent|
257699|NCT02234804|Device|Medtronic Resolute Integrity stent|
257700|NCT02234804|Procedure|Angiography|
257701|NCT02234804|Procedure|OCT|
257702|NCT02234778|Device|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
257703|NCT02234765|Other|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
257704|NCT02234765|Other|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
257705|NCT02234752|Drug|Galantamine ER|
257706|NCT02234752|Drug|Memantine XR|
257707|NCT02234739|Drug|Voriconazole|2-week long intravenous instillation of voriconazole
258534|NCT02228395|Drug|Placebo|Oral capsule, single placebo dose
257708|NCT02234726|Behavioral|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.~Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
257709|NCT02234713|Behavioral|Motivational Interview|
257710|NCT02234713|Other|Video Attention Control|
257711|NCT02234687|Drug|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
257712|NCT02234687|Drug|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
257713|NCT02234687|Drug|Placebo|Placebo, one dose, one time
257714|NCT02234674|Other|Current intensive CDP|"Standard Intensive CDP including~manual lymph drainage,~pressotherapy and~bandaging"
257715|NCT02234674|Other|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
257716|NCT02234661|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
257717|NCT02234648|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
257718|NCT02234648|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
257719|NCT02234635|Other|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
257720|NCT02234622|Behavioral|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
257721|NCT02234622|Behavioral|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity physical activity with didactics about wellness topics.
257722|NCT02234609|Device|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
257723|NCT02234596|Drug|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
257724|NCT02234583|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
257725|NCT02234570|Drug|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
257726|NCT02234570|Other|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
257727|NCT02234557|Behavioral|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.~Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).~Practice will consist of warm up, followed by practice of selected pieces of the form.~Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
257728|NCT02234544|Drug|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
257729|NCT02234544|Drug|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
257730|NCT02234544|Other|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
257731|NCT02234531|Device|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
257773|NCT02234167|Behavioral|Risk behaviour and infectious diseases|through counselling, testing vaccination
257774|NCT02234154|Device|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
257775|NCT02234141|Drug|Placebo|Tablet administered orally once daily
257732|NCT02234531|Device|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
257733|NCT02234518|Other|High quantity fiber|The intervention type is food product
257734|NCT02234518|Other|Low quantity fiber|The intervention type is food product
257735|NCT02234518|Other|Placebo|
257736|NCT02234505|Procedure|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
257737|NCT02234492|Drug|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
257738|NCT02234479|Biological|Hydrophor (Group A)|"Rehydrates dry, chapped or chafed skin~May be used alone as a skin lubricant or protectant"
257739|NCT02234479|Biological|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:~Maintain a balanced environment for healing.~Aids in reducing dermatitis.~Reduce affected area pH.2-3"
257740|NCT02234466|Drug|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
257741|NCT02234466|Drug|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
257742|NCT02234466|Other|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
257743|NCT02234453|Device|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
257744|NCT02234440|Drug|Metformin|
257745|NCT02234440|Drug|Insulin|
257746|NCT02234427|Drug|Aspirin|2-week aspirin therapy (81mg/day)
257747|NCT02234401|Device|Bi level pressure support|
257748|NCT02234401|Other|Standard Care|
257749|NCT02234388|Other|Observation|There are no interventions associated with this registry as it is purely observational.
257750|NCT02234375|Drug|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
257751|NCT02234362|Drug|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
257752|NCT02234349|Procedure|pancreas kidney transplantation|
257753|NCT02234349|Procedure|kidney transplantation|
257754|NCT02234336|Procedure|Noncontrast echocardiography|
257755|NCT02234336|Procedure|Contrast Echocardiography|
257756|NCT02234336|Procedure|Cardiac magnetic resonance imaging|
257757|NCT02234323|Biological|rFVIIIFc|Administered as specified in the treatment arm
257758|NCT02234310|Biological|rFIXFc|Adjustments to the dose and interval of rFIXFc can be made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There is an option to start study dosing as episodic treatment (on-demand).
257759|NCT02234297|Drug|BLZ-100|
257760|NCT02234284|Behavioral|Health Coaching|Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers.
257761|NCT02234271|Other|Mobile Health Application|Mobile Health application for contraception information
257762|NCT02234271|Other|Health Educator Counseling|Counseling via health educator
257763|NCT02234258|Behavioral|Cognitive behavioral social skills|
257764|NCT02234258|Behavioral|Psychoeducation|
257765|NCT02234245|Device|Telemedicine System|Telemedicine System is used in remote monitoring group
257766|NCT02234232|Behavioral|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
257767|NCT02234219|Drug|Probiotics|
257768|NCT02234206|Drug|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration~Preparation from approved sastric book as per drugs & cosmetic act 1940"
257769|NCT02234193|Device|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
257770|NCT02234193|Procedure|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
257771|NCT02234180|Other|Placebo|Given PO
257772|NCT02234180|Drug|Regorafenib|Given PO
257777|NCT02234128|Device|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
257778|NCT02234115|Drug|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
257779|NCT02234102|Device|Endoscopically guided laser ablation HeartLight system|
257780|NCT02234089|Drug|Degarelix|According to medical practice
257781|NCT02234089|Drug|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
257782|NCT02234076|Behavioral|VRET|
257783|NCT02234076|Behavioral|TAU|Treatment as usual offered by the participating mental health care organisations
257784|NCT02234063|Other|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
257785|NCT02234050|Drug|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
257786|NCT02234050|Other|Local standard of care|Left to the discretion of the investigator
257787|NCT02234037|Drug|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
257788|NCT02234037|Behavioral|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise > 10 minutes of muscle strengthening, > 10 minutes of aerobic exercise (treadmill walking or cycling), > 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
257789|NCT02234024|Dietary Supplement|Supplementation of dairy-derived concentrated gangliosides.|
257790|NCT02234011|Drug|Ketamine|
257791|NCT02234011|Drug|Placebo|
257792|NCT02233998|Other|Mouth Rinse 1|
257793|NCT02233998|Other|Mouth Rinse 2|
257794|NCT02233998|Other|Mouth Rinse 3|
257795|NCT02233985|Drug|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
257796|NCT02233985|Drug|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
257797|NCT02233972|Drug|Midazolam|
257798|NCT02233972|Drug|Ginkgolides Meglumine Injection|
257799|NCT02233972|Drug|placebo|
257800|NCT02233946|Behavioral|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
257801|NCT02233933|Other|Hemospray|hemospray is used after argon coagulation to stop bleeding
257802|NCT02233920|Drug|Ventilat® - metered dose inhaler|
257803|NCT02233907|Drug|Ventilat® - metered dose inhaler|
257804|NCT02233894|Drug|Atrovent® - inhalets|
257805|NCT02233881|Drug|Atrovent® - inhalets|
257806|NCT02233868|Other|connectivity|Magnetic resonance imaging (MRI) scans will be done to assess brain structure, functional reactivity and functional connectivity.
257807|NCT02233868|Other|neuroinflammation|The use of [11C] PBR28 will allow us to assess for the first time in vivo if there is neuroinflammation in the brain of alcoholics. It will also allow us to assess if it recovers with alcohol detoxification.
257808|NCT02233868|Drug|neurofunction|To assess regional brain glucose metabolism.
257809|NCT02233842|Behavioral|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
257810|NCT02233829|Drug|Methylphenidate|IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of [11C]raclopride.
257811|NCT02233829|Drug|C-11 Raclopride|The radiotracer [11C] raclopride is used for imaging dopamine receptors and dopamine release.
257812|NCT02233816|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
257813|NCT02233816|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
257814|NCT02233816|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
257815|NCT02233816|Biological|Placebo|A single dose of placebo
257816|NCT02233803|Drug|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
257817|NCT02233803|Drug|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
257818|NCT02233803|Drug|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
257819|NCT02233803|Drug|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
257820|NCT02233790|Drug|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
257821|NCT02233790|Drug|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
257822|NCT02233777|Drug|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
257823|NCT02233777|Drug|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
257824|NCT02233764|Other|FeZnPM|Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
257825|NCT02233764|Other|CtrlPM|Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
257826|NCT02233751|Combination Product|Testosterone enanthate auto-injector|Randomization then administration of combination product study medication according to group assignment
257827|NCT02233738|Behavioral|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
257828|NCT02233738|Behavioral|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
257829|NCT02233725|Device|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
257830|NCT02233712|Biological|G17DT|
257831|NCT02233699|Drug|XEN-D0501|
257832|NCT02233699|Drug|Placebo|
257833|NCT02233686|Drug|XEN-D0501|
257834|NCT02233686|Drug|Placebo|
257835|NCT02233673|Behavioral|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
257836|NCT02233660|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
257837|NCT02233660|Procedure|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
257838|NCT02233647|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
257839|NCT02233647|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
257840|NCT02233634|Drug|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
257841|NCT02233634|Other|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
257842|NCT02233634|Other|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
257843|NCT02233621|Other|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with [18F]FES before coelioscopy
257844|NCT02233608|Behavioral|Advanced Pelvic Floor Muscle Exercise (APFX)|
257845|NCT02233595|Radiation|Chemoradiation|
257846|NCT02233582|Drug|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
257847|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
257848|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
257849|NCT02233569|Device|Ventralight ST implant|
257850|NCT02233569|Device|ETHICON PHYSIOMESH®|
257851|NCT02233556|Drug|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:~Mismatch negativity(MMN)~P50"
257852|NCT02233543|Drug|QVA149|Delivered once daily via single-dose dry powder inhaler
257853|NCT02233543|Drug|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
257854|NCT02233530|Behavioral|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
257855|NCT02233517|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
257856|NCT02233517|Behavioral|Present Centered Therapy|"Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning."
257857|NCT02233504|Drug|Exjade® (deferasirox, ICL670)|
257858|NCT02233491|Behavioral|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
257859|NCT02233491|Other|Control|No additional support other than lifestyle advice by clinician
257860|NCT02233478|Dietary Supplement|Pomegranate Juice|Pomegranate Juice alone
257861|NCT02233478|Dietary Supplement|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
257862|NCT02233478|Dietary Supplement|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
257863|NCT02233465|Procedure|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
257864|NCT02233452|Drug|Methadone|The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
257865|NCT02233452|Drug|Ketamine|The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.
257866|NCT02233452|Drug|Methadone plus Ketamine|the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
257867|NCT02233439|Dietary Supplement|Herbal galactagogue|
257868|NCT02233439|Dietary Supplement|Placebo|
257869|NCT02233413|Device|Active LLLT helmet application|LED helmet applied with light activated
257870|NCT02233413|Device|Non-active LLLT helmet application|LED helmet applied without light activated
257871|NCT02233400|Drug|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
257872|NCT02233387|Other|injection with [18F] HX4 and PET imaging|"A standard clinical [18F]FDG PET-CT will be performed for the radiotherapy planning.~After a minimum time interval of 24 hours, baseline [18F]HX4 PET scans will be performed:~Based on the phase I trial1 444 MBq (12 mCi) [18F]HX4 is administrated via a bolus IV injection.~The first image acquisition is started together with the administration of [18F]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i"
257873|NCT02233374|Other|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
257874|NCT02233374|Other|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
257875|NCT02233361|Behavioral|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
257876|NCT02233322|Dietary Supplement|Iron|All subjects will receive iron supplementation based on iron levels in the blood
257877|NCT02233309|Other|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
257878|NCT02233296|Drug|Lasmiditan|2 discrete doses separated by 6 days.
257879|NCT02233283|Other|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
257880|NCT02233283|Other|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
257881|NCT02233283|Other|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
257882|NCT02233283|Other|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
257883|NCT02233257|Drug|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
257884|NCT02233244|Drug|CTX-4430|
257885|NCT02233244|Drug|Midazolam|
257886|NCT02233231|Drug|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
257887|NCT02233231|Drug|Placebo|
257888|NCT02233218|Drug|Telmisartan|
257889|NCT02233218|Drug|Amlodipine|
257890|NCT02233218|Drug|Rosuvastatin|
257891|NCT02233205|Device|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
257892|NCT02233205|Drug|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
257893|NCT02233179|Device|Removable cast walker|Offloading device that can be removed by patients.
257894|NCT02233179|Device|Irremovable cast walker|Offloading device that cannot be removed by patients.
257895|NCT02233153|Other|Elder-Friendly Surgical Unit|
257896|NCT02233140|Device|Extra-corporeal pulsed-activated therapy or shockwave therapy|
257897|NCT02233114|Other|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
257898|NCT02233114|Other|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
257899|NCT02233101|Drug|Oral Tranexamic Acid|patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
257900|NCT02233101|Drug|Intravenous Tranexamic Acid|Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
257901|NCT02233088|Behavioral|ELM Group|"ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity."
257902|NCT02233088|Other|ELM Classes|ELM classes will be administered through Rush Generations program and focus on health education.
257903|NCT02233088|Other|ELM Individual|ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
257904|NCT02233075|Drug|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
257905|NCT02233062|Dietary Supplement|Exclusive Enteral Nutrition Therapy|
257906|NCT02233049|Drug|Erlotinib|
257907|NCT02233049|Drug|Everolimus|
257908|NCT02233049|Drug|Dasatinib|
257909|NCT02233023|Drug|Pramipexole|
257910|NCT02233023|Drug|Bromocriptine and other dopamine agonists|
257911|NCT02233010|Other|The level of NGAL after pre op,post op 4hr, post op 12hr|
257912|NCT02232997|Other|Long Hydration|The hydration with sodium chloride was set 12 hours before the procedure (before contrast exposure during coronary angiography), continued for the duration of the procedure, and for 12 hours post-procedure at the speed of 1ml/kg/hr (0.5ml/kg/hr for patients with congestive heart failure, New York Heart Association class III or LVEF<35%). For patients who weighed more than 80 kg, the bolus and infusion rate were limited to those calculated for patients weighing 80 kg.
257913|NCT02232997|Other|Short Hydration|The hydration with sodium chloride was set 1 hour before the procedure (before contrast exposure during coronary angiography), continued for the duration of the procedure, and for 4 hours post-procedure at the speed of 3ml/kg/hr (1.5ml/kg/hr for patients with congestive heart failure, New York Heart Association class III or LVEF<35%). For patients who weighed more than 80 kg, the bolus and infusion rate were limited to those calculated for patients weighing 80 kg.
257914|NCT02232971|Drug|Glucagon|Glucagon is given in three different doses according to three research days.
257915|NCT02232971|Other|Isotonic saline solution|Placebo
257916|NCT02232958|Other|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
257917|NCT02232945|Drug|placebo of oseltamivir phosphate|
257918|NCT02232945|Drug|oseltamivir phosphate|
257919|NCT02232945|Drug|Banlangen (Radix Isatidis) granules|
257920|NCT02232945|Drug|placebo of Banlangen(Radix Isatidis) granules|
257921|NCT02232932|Procedure|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
257922|NCT02232932|Procedure|RESECTION|Intent-to-treat R0 liver resection
257923|NCT02232919|Device|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
257924|NCT02232906|Drug|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation >20%)
257925|NCT02232893|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.
257926|NCT02232893|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.
257927|NCT02232880|Drug|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
257928|NCT02232880|Drug|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
257929|NCT02232867|Behavioral|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
257977|NCT02232451|Device|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
257978|NCT02232451|Device|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
258614|NCT02227784|Drug|Evacetrapib|Administered orally
257930|NCT02232854|Behavioral|Depression training/supervision program|"The intervention will be composed of:~Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.~After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.~Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.~Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
257931|NCT02232841|Device|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
257932|NCT02232841|Device|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
257933|NCT02232828|Procedure|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
257934|NCT02232828|Procedure|Stepwise removal|"Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.~If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described."
257935|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
257936|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
257937|NCT02232789|Drug|Mephedrone|Single oral dose mephedrone
257938|NCT02232789|Drug|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
257939|NCT02232789|Drug|Placebo|Single oal dose placebo
257940|NCT02232776|Drug|Losartan|Dose of Losartan : 0.7mg/kg once daily.
257941|NCT02232763|Drug|Losartan|12 weeks of losartan or placebo with crossover to the other
257942|NCT02232763|Drug|Placebo|12 weeks of losartan or placebo with crossover to the other
257943|NCT02232737|Other|Very low nicotine content cigarettes|
257944|NCT02232724|Device|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
257945|NCT02232698|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
257946|NCT02232698|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
257947|NCT02232685|Device|18F-Choline PET/CT|18F-Choline PET/CT
257948|NCT02232672|Device|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
257949|NCT02232659|Device|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
257950|NCT02232646|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
257951|NCT02232633|Drug|BBI503|
257952|NCT02232620|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
257953|NCT02232607|Drug|Lacidipine, low dose|
257954|NCT02232607|Drug|Lacidipine, medium dose|
257955|NCT02232607|Drug|Lacidipine, high dose|
257956|NCT02232607|Drug|Placebo|
257957|NCT02232594|Drug|Berodual®|
257958|NCT02232581|Drug|Alovudine - low|
257959|NCT02232581|Drug|Alovudine - medium|
257960|NCT02232581|Drug|Alovudine - high|
257961|NCT02232581|Drug|Placebo|
257962|NCT02232568|Behavioral|Feedback|
257963|NCT02232555|Drug|Duloxetine|
257964|NCT02232555|Drug|Placebo|
257965|NCT02232542|Drug|Duloxetine - low dose|
257966|NCT02232542|Drug|Duloxetine - high dose|
257967|NCT02232542|Drug|Placebo|
257968|NCT02232529|Drug|MIN-101|
257969|NCT02232529|Drug|Placebo|
257970|NCT02232516|Drug|romidepsin|Given IV
257971|NCT02232516|Drug|lenalidomide|Given PO
257972|NCT02232516|Other|laboratory biomarker analysis|Correlative studies
257973|NCT02232503|Genetic|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
257974|NCT02232490|Biological|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
257975|NCT02232490|Biological|Placebo|
257976|NCT02232477|Drug|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
257979|NCT02232438|Behavioral|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
257980|NCT02232425|Drug|IX-01|
257981|NCT02232425|Drug|Placebo|
257982|NCT02232399|Drug|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
257983|NCT02232399|Drug|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
257984|NCT02232386|Drug|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
257985|NCT02232386|Drug|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
257986|NCT02232373|Behavioral|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
257987|NCT02232373|Dietary Supplement|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
257988|NCT02232373|Dietary Supplement|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
257989|NCT02232360|Drug|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
257990|NCT02232360|Drug|Rosuvastatin alone|Rosuvastatin 10mg per day
257991|NCT02232347|Drug|Ketamine|
257992|NCT02232347|Drug|Sufentanil|
257993|NCT02232334|Other|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
257994|NCT02232321|Other|PsA MDA|
257995|NCT02232308|Drug|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
257996|NCT02232308|Drug|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
257997|NCT02232308|Drug|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
257998|NCT02232295|Device|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
257999|NCT02232295|Device|Mirror Box|A resource used for many pain and disability states of the hands and feet.
258000|NCT02232282|Device|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
258001|NCT02232282|Device|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
258002|NCT02232269|Other|Black Coffee|
258003|NCT02232269|Other|Grapefruit Juice|
258004|NCT02232269|Other|Water|
258005|NCT02232269|Drug|Felodipine|
258006|NCT02232256|Drug|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
258007|NCT02232243|Drug|Hydroxychloroquine, 200mg twice dailiy|Hydroxychloroquine, 200mg twice daily (400mg/day total) was given to subjects for up to 14 days prior to surgery.
258008|NCT02232243|Drug|Hydroxychloroquine, 400mg twice daily|Hydroxychloroquine, 400mg twice daily (800mg/day total) was given to subjects for up to 14 days prior to surgery.
258009|NCT02232230|Drug|Provenge|
258010|NCT02232217|Behavioral|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
258011|NCT02232217|Other|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
258012|NCT02232204|Behavioral|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
258013|NCT02232191|Biological|Pneumovax-23|
258014|NCT02232178|Drug|2 100mg Xaracoll implants|
258015|NCT02232178|Drug|3 100mg Xaracoll implants|
258016|NCT02232178|Drug|150mg Bupivacaine HCl injection|
258017|NCT02232165|Other|Hypotension avoidance|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP >= 65 mmHg is not inferior to induced hypertension.
258018|NCT02232165|Other|Induced hypertension|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
258023|NCT02232139|Drug|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
258024|NCT02232126|Other|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
258025|NCT02232113|Drug|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
258026|NCT02232100|Behavioral|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
258027|NCT02232100|Behavioral|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
258028|NCT02232087|Drug|salmeterol (as salmeterol xinafoate)|2, 6, and 12 inhalations
258029|NCT02232087|Drug|fluticasone propionate|2, 6, and 12 inhalations
258030|NCT02232074|Other|Patient navigation enhanced with legal support|
258031|NCT02232061|Drug|Fingolimod|
258032|NCT02232048|Other|Transthoracic Echocardiogram|
258033|NCT02232035|Drug|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
258034|NCT02232022|Device|Reveal LINQ Insertable Cardiac Monitor|
258035|NCT02232009|Device|3.0 T Neonatal MRI Scanner|Eligible subjects will undergo neonatal MRI scanning procedures.
258036|NCT02231983|Genetic|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
258037|NCT02231970|Procedure|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
258038|NCT02231957|Other|educational text message reminders|
258039|NCT02231957|Other|conventional text message reminders|
258040|NCT02231944|Biological|Replenine®-VF (High Purity Factor IX)|
258041|NCT02231931|Drug|Digoxin|single dose, fasted
258042|NCT02231931|Drug|Rosuvastatin|single dose, fasted
258043|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
258044|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
258045|NCT02231931|Drug|Metformin hydrochloride|single dose, fasted
258046|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
258047|NCT02231931|Drug|Furosemide|single dose, fasted
258048|NCT02231918|Drug|MIRAPEX® - low|
258049|NCT02231918|Drug|MIRAPEX® - medium|
258050|NCT02231918|Drug|MIRAPEX® - high|
258051|NCT02231905|Drug|BI-Sifrol®|
258052|NCT02231892|Device|TMS|HAC coil (real rTMS or sham rTMS)
258053|NCT02231879|Drug|Plerixafor|Twice daily low dose injection for 14 months.
258054|NCT02231879|Drug|G-CSF|Twice daily low dose injection for 14 months.
258055|NCT02231866|Biological|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
258056|NCT02231866|Biological|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
258057|NCT02231853|Biological|MVST|MVST Infusion
258058|NCT02231853|Biological|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.~Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
258059|NCT02231827|Other|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
258060|NCT02231814|Dietary Supplement|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
258061|NCT02231814|Other|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
258062|NCT02231801|Behavioral|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
258063|NCT02231788|Drug|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
258064|NCT02231788|Drug|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
258065|NCT02231775|Drug|Dabrafenib|Given PO
258066|NCT02231775|Other|Laboratory Biomarker Analysis|Correlative studies
258067|NCT02231775|Procedure|Therapeutic Conventional Surgery|Undergo surgery
258068|NCT02231775|Drug|Trametinib|Given PO
258069|NCT02231762|Drug|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
258070|NCT02231762|Drug|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
258071|NCT02231749|Biological|Nivolumab|
258072|NCT02231749|Biological|Ipilimumab|
258073|NCT02231749|Drug|Sunitinib|
258074|NCT02231723|Drug|BBI608|Administered continuously twice daily with doses separated by 12 hours
258075|NCT02231723|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
258076|NCT02231723|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
258077|NCT02231723|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
258078|NCT02231723|Drug|Leucovorin|Arm C, D: Leucovorin 400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
258079|NCT02231723|Drug|Irinotecan|Arm B: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
258080|NCT02231723|Drug|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m^2 I.V. bolus followed by 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
258081|NCT02231723|Drug|MM-398|MM-398 70 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
258082|NCT02231710|Biological|BPX-501 and AP1903|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by AP1903 infusion on day 7
258083|NCT02231697|Other|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
258084|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
258085|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
258086|NCT02231671|Drug|ALS-008176|
258087|NCT02231671|Drug|ALS-008112|
258088|NCT02231658|Drug|Liraglutide|
258089|NCT02231658|Drug|Lixisenatide|
258090|NCT02231645|Device|STN DBS|The DBS device is turned on and off by the physician.
258091|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
258092|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
258093|NCT02231619|Behavioral|Baseline verbal instruction on LSUPT|
258094|NCT02231606|Other|Free Glasses|Provide free glasses
258095|NCT02231606|Other|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
258096|NCT02231606|Other|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
258097|NCT02231593|Other|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
258098|NCT02231580|Drug|BN82451B|BN82451B capsule
258099|NCT02231580|Drug|Placebo|Placebo capsule
258100|NCT02231567|Other|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
258101|NCT02231567|Other|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
258102|NCT02231554|Other|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
258103|NCT02231554|Other|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
258104|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
258105|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is turned off.
258106|NCT02231528|Device|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
258107|NCT02231528|Device|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
258108|NCT02231515|Device|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
258109|NCT02231515|Device|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
258110|NCT02231502|Other|Vegetable-based convenience food|
258111|NCT02231502|Other|Vegetable meal|
258112|NCT02231489|Drug|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
258113|NCT02231489|Drug|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
258114|NCT02231489|Drug|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
258115|NCT02231463|Other|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
258116|NCT02231463|Other|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
258117|NCT02231463|Other|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
258118|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
258119|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
258120|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
258121|NCT02231450|Drug|Lu AE58054 encapsulated film-coated tablets|
258122|NCT02231437|Drug|Berodual®|
258123|NCT02231424|Drug|Drug: Berodual®|
258124|NCT02231411|Procedure|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
258125|NCT02231411|Procedure|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
258126|NCT02231411|Procedure|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
258127|NCT02231385|Drug|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.~Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
258128|NCT02231372|Drug|Berodual® Respimat® solution for inhalation|
258129|NCT02231359|Drug|Berodual® Respimat® solution for inhalation|
258130|NCT02231346|Drug|Berodual® Respimat® - inhaler|
258131|NCT02231333|Drug|S-adenosylmethionine (SAMe)|
258132|NCT02231333|Drug|pentoxiphylline (PTX)|
258133|NCT02231320|Drug|Berodual® Respimat® - inhaler|
258134|NCT02231307|Drug|SUBLIVAC FIX Birch|
258135|NCT02231294|Drug|Sifrol®|
258136|NCT02231281|Drug|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
258137|NCT02231281|Procedure|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
258138|NCT02231268|Drug|Gladem|
258139|NCT02231255|Drug|Sifrol®|
258140|NCT02231242|Biological|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.~Intrathecal Autologous Bone Marrow TNC"
258141|NCT02231229|Other|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
258142|NCT02231229|Drug|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
258143|NCT02231216|Procedure|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
258144|NCT02231216|Procedure|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
258145|NCT02231216|Procedure|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
258146|NCT02231203|Drug|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
258147|NCT02231203|Drug|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
258148|NCT02231190|Drug|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
258149|NCT02231190|Drug|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
258150|NCT02231177|Drug|BI 1744 CL|
258151|NCT02231177|Drug|BI 1744 CL/Tiotropium FDC|
258152|NCT02231177|Drug|Tiotropium|
258153|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
258154|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
258155|NCT02231164|Drug|placebo|oral placebo
258156|NCT02231164|Drug|nintedanib|oral experimental therapy
258157|NCT02231151|Behavioral|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
258158|NCT02231138|Drug|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
258159|NCT02231125|Drug|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
258160|NCT02231125|Drug|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
258161|NCT02231112|Radiation|Whole breast RT on prone position|
258162|NCT02231099|Procedure|Prolift + M|prolapse surgery with mesh
258163|NCT02231099|Procedure|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
258164|NCT02231086|Procedure|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
258165|NCT02231086|Drug|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
258166|NCT02231086|Procedure|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
258167|NCT02231073|Behavioral|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
258168|NCT02231047|Dietary Supplement|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
258169|NCT02231047|Other|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
258170|NCT02231021|Drug|alogliptin|alogliptin 25 mg add-on background medication metformin
258171|NCT02231021|Drug|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
258172|NCT02231021|Drug|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
258173|NCT02231008|Drug|tasimelteon|
258174|NCT02230995|Drug|metformin|single dose of metformin given as tablets
258175|NCT02230995|Drug|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
258176|NCT02230995|Drug|empagliflozin|single dose of empagliflozin given as tablet
258177|NCT02230982|Drug|nintedanib|soft gelatin capsule
258178|NCT02230969|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
258179|NCT02230956|Biological|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
258180|NCT02230956|Drug|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
258181|NCT02230930|Drug|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
258182|NCT02230930|Device|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
258183|NCT02230930|Drug|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
258184|NCT02230930|Drug|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
258185|NCT02230917|Drug|Sotatercept|
258186|NCT02230917|Drug|Placebo|
258187|NCT02230904|Drug|Rotigotine (Test product PR 2.3.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
258188|NCT02230904|Drug|Rotigotine (Reference product PR 2.1.1)|"Pharmaceutical form: Transdermal patch~Concentration: 8 mg/24 hours~Route of administration: Transdermal"
258189|NCT02230891|Drug|Carvedilol|Carvedilol is a non selective beta blocker
258190|NCT02230891|Drug|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
258191|NCT02230878|Drug|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
258192|NCT02230878|Drug|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
258193|NCT02230878|Drug|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
258194|NCT02230878|Drug|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
258195|NCT02230878|Drug|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
258196|NCT02230839|Behavioral|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
258197|NCT02230839|Behavioral|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (<30% of calories from fat) diet will be used as part of the weight loss intervention.
258198|NCT02230800|Drug|Tocovid SupraBio plus pentoxifylline|
258199|NCT02230800|Drug|Matching placebos|
258200|NCT02230787|Device|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
258201|NCT02230787|Device|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
258202|NCT02230761|Drug|XOPH5 Ointment|
258203|NCT02230761|Drug|Placebo|
258204|NCT02230735|Drug|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
258205|NCT02230735|Drug|Normal Saline|(placebo for bupivacaine)
258206|NCT02230722|Behavioral|Motivational Interviewing|
258207|NCT02230722|Behavioral|Attention Control|
258208|NCT02230709|Other|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
258209|NCT02230709|Other|"TENS and dry needling"|Application of TENS current after dry needling technique
258210|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
258211|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
258212|NCT02230696|Drug|Placebo nasal spray|
258213|NCT02230683|Drug|IDN-6556|25 mg BID
258214|NCT02230670|Drug|IDN-6556|25 mg BID
258215|NCT02230670|Drug|Placebo|
258216|NCT02230657|Procedure|Same day discharge|
258217|NCT02230657|Procedure|Next day discharge|
258218|NCT02230644|Other|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
258219|NCT02230644|Other|Other distraction|Such as newspaper, magazine or the news on television
258220|NCT02230631|Other|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
258221|NCT02230618|Drug|insulin degludec/insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
258222|NCT02230605|Other|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
258223|NCT02230605|Other|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
258224|NCT02230605|Other|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
258225|NCT02230605|Other|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
258226|NCT02230605|Other|Short Form 36 Health Survey|To be completed at the Screening Visit
258227|NCT02230605|Other|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
258228|NCT02230605|Other|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 7:30AM ± 1.5 hrs and 6:30PM ± 1.5 hrs. (or until hospital discharge)
258229|NCT02230605|Other|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:30PM ± 1.5 hrs (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
258230|NCT02230579|Drug|MMV390048 5mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
258231|NCT02230579|Drug|MMV390048 20mg|"Supplied as powder in bottle formulation for reconstitution pre-dose."
258232|NCT02230579|Drug|MMV390048 40mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
258233|NCT02230579|Drug|MMV390048 80mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
258234|NCT02230579|Drug|MMV390048 120mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
258235|NCT02230579|Drug|Placebo to match MMV390048|"Supplied as powder in bottle formulation for reconstitution pre-dose"
258236|NCT02230566|Drug|UX003|UX003 is a sterile concentrate formulation of rhGUS for intravenous infusion
258237|NCT02230566|Other|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
258238|NCT02230553|Drug|Lapatinib|
258239|NCT02230553|Drug|trametinib|
258240|NCT02230540|Device|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
258241|NCT02230540|Device|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
258242|NCT02230540|Device|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
258243|NCT02230527|Drug|Ticagrelor|90mg twice a day by mouth
258244|NCT02230527|Drug|Clopidogrel|75mg once a day by mouth
258245|NCT02230514|Drug|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
258246|NCT02230514|Other|autologous iliac crest|Autologous iliac crest in association with surgery
258247|NCT02230514|Procedure|Surgery|Standard surgery for non-union fractures
258248|NCT02230501|Dietary Supplement|stringent diet regimen|
258249|NCT02230501|Dietary Supplement|moderate diet regimen|
258250|NCT02230488|Other|Intensive Diabetes Case Management|"A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE~--------------------------------------------------------------------------------"
258251|NCT02230462|Other|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
258252|NCT02230436|Other|Early drain removal|Removing drain(s) on postoperative day 3
258253|NCT02230436|Other|Late drain removal|Removing drain(s) on postoperative day 4 or later
258254|NCT02230423|Procedure|Nasal surgery|
258255|NCT02230410|Device|CryoBalloon Focal Ablation|
258256|NCT02230397|Other|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
258257|NCT02230397|Other|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
258258|NCT02230384|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
258259|NCT02230384|Drug|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
258260|NCT02230371|Drug|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
258261|NCT02230371|Drug|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
258262|NCT02230358|Procedure|Regional anesthesia|Regional anesthesia
258263|NCT02230358|Procedure|General anesthesia|General anesthesia
258264|NCT02230358|Device|Transcranial Doppler ultrasonography|6x for 4 hours
258265|NCT02230358|Procedure|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
258266|NCT02230358|Procedure|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
258267|NCT02230358|Procedure|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
258268|NCT02230358|Behavioral|Neurological Control|perioperative, 2-3 days, as done in clinical routine
258269|NCT02230358|Behavioral|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
258270|NCT02230358|Device|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
258271|NCT02230345|Dietary Supplement|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
258272|NCT02230345|Dietary Supplement|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
258273|NCT02230332|Drug|Alendronate|
258274|NCT02230332|Drug|Placebo|
258275|NCT02230319|Other|Cryotherapy|
258276|NCT02230319|Drug|Paclitaxel|
258277|NCT02230306|Drug|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
258278|NCT02230306|Drug|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
258279|NCT02230293|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
258280|NCT02230293|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
258281|NCT02230280|Other|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
258282|NCT02230267|Other|High intensity exercise and balance training|
258283|NCT02230267|Other|Usual care arm exercise|
258284|NCT02230254|Device|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
258285|NCT02230228|Drug|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
258286|NCT02230215|Device|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
258287|NCT02230202|Other|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
258288|NCT02230202|Other|single blood draw|single blood draw of approximately 45 mL.
258289|NCT02230189|Biological|Segmental airway allergen challenge|
258290|NCT02230176|Drug|Sunitinib|
258291|NCT02230176|Drug|177Lu-DOTA0-Tyr3-Octreotate|
258292|NCT02230163|Biological|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
258293|NCT02230150|Behavioral|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
258294|NCT02230137|Behavioral|Text message arm|Text message sent before each injection of insulin
258295|NCT02230124|Device|MRE|
258296|NCT02230111|Behavioral|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
258297|NCT02230111|Behavioral|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
258298|NCT02230098|Other|Remote Ischemic Conditioning|
258299|NCT02230085|Other|Administration of the questionnaire and monitoring of CPAP adherence|
258300|NCT02230072|Device|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
258301|NCT02230059|Other|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
258302|NCT02230046|Drug|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
258303|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
258304|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
258305|NCT02230033|Drug|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
258306|NCT02230033|Drug|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
258307|NCT02230033|Drug|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
258308|NCT02230020|Device|Nasal High Flow|
258309|NCT02230007|Drug|MEOPA|3 sessions of reeducation using MEOPA
258310|NCT02229994|Other|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.~From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).~From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
258311|NCT02229981|Drug|ABC294640|
258312|NCT02229968|Drug|Amicar (ε-aminocaproic acid)|
258313|NCT02229968|Drug|normal saline|
258314|NCT02229955|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
258315|NCT02229942|Drug|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).~Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
258316|NCT02229942|Drug|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
258317|NCT02229929|Drug|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
258318|NCT02229929|Drug|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
258319|NCT02229929|Drug|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
258320|NCT02229929|Drug|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
258321|NCT02229929|Drug|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
258322|NCT02229929|Drug|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
258323|NCT02229903|Device|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
258324|NCT02229903|Device|Sham Treatment|29 treatments over 6 weeks.
258325|NCT02229890|Drug|alteplase|
258326|NCT02229877|Drug|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
258327|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
258328|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
258329|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
258330|NCT02229864|Device|Coronary artery stenting: Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm"
258331|NCT02229851|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
258332|NCT02229851|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
258333|NCT02229851|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
258334|NCT02229838|Drug|BIBB 1464 MS tablet|
258335|NCT02229838|Drug|BIBB 1464 MS solution|
258336|NCT02229838|Drug|BIBB 1464 MS placebo|
258337|NCT02229838|Other|Standard dinner|
258338|NCT02229825|Drug|Duloxetine high|
258339|NCT02229825|Drug|Duloxetine low|
258340|NCT02229812|Drug|alteplase|
258341|NCT02229799|Drug|Actilyse|
258342|NCT02229786|Drug|Buscopan® plus|
258343|NCT02229786|Drug|Buscopan®|
258344|NCT02229786|Drug|Paracetamol|
258345|NCT02229786|Drug|Placebo|
258346|NCT02229773|Drug|BIBB 1464 MS low dose|
258347|NCT02229773|Drug|Placebo|
258348|NCT02229773|Drug|Pravastatin|
258349|NCT02229773|Drug|BIBB 1464 MS medium dose|
258350|NCT02229773|Drug|BIBB 1464 MS high dose|
258351|NCT02229760|Drug|Tipranavir capsules|
258352|NCT02229760|Drug|Ritonavir capsules|
258353|NCT02229747|Drug|Meloxicam|
258354|NCT02229747|Drug|Diclofenac|
258355|NCT02229747|Drug|Nimesulide|
258356|NCT02229734|Radiation|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
258357|NCT02229734|Drug|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
258358|NCT02229721|Drug|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
258359|NCT02229721|Drug|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
258360|NCT02229708|Behavioral|Healthy Lifestyle Group|
258361|NCT02229682|Radiation|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
258362|NCT02229669|Procedure|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
258363|NCT02229669|Procedure|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
258364|NCT02229656|Radiation|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
258365|NCT02229656|Drug|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
258366|NCT02229630|Radiation|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
258367|NCT02229617|Drug|Subcutaneous testosterone|
258368|NCT02229604|Other|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
258369|NCT02229604|Drug|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
258370|NCT02229578|Drug|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
258371|NCT02229578|Drug|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
258372|NCT02229565|Device|Biopsy or prostatectomy|
258373|NCT02229539|Drug|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
258374|NCT02229539|Drug|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
258375|NCT02229539|Other|Placebo|2.5 mL placebo and 2.5 mL water administered orally
258376|NCT02229526|Dietary Supplement|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
258377|NCT02229526|Dietary Supplement|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
258378|NCT02229526|Dietary Supplement|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
258379|NCT02229526|Dietary Supplement|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
258380|NCT02229513|Procedure|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
258381|NCT02229500|Dietary Supplement|Inulin|
258382|NCT02229500|Dietary Supplement|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
258383|NCT02229500|Dietary Supplement|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
258384|NCT02229487|Other|Oral glucose tolerance|
258385|NCT02229474|Behavioral|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
258386|NCT02229461|Drug|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
258387|NCT02229461|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
258427|NCT02229097|Drug|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
258388|NCT02229422|Drug|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:~On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.~On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.~On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.~On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.~All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:~•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
258389|NCT02229409|Behavioral|Walkadoo|Walkadoo is a MeYou Health, LLC product.
258390|NCT02229396|Drug|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
258391|NCT02229396|Drug|Exentide|2 mg
258392|NCT02229396|Drug|Dapagliflozin|10 mg once daily Dapagliflozin
258393|NCT02229383|Drug|Exenatide|2 mg weekly suspension injection
258394|NCT02229383|Drug|Exenatide matching placebo|Once weekly Placebo injection
258395|NCT02229357|Biological|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
258396|NCT02229344|Other|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
258397|NCT02229331|Other|Gait analysis|
258398|NCT02229318|Dietary Supplement|FruitiVits|Daily administration of FruitiVits dietary supplement
258399|NCT02229305|Behavioral|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
258400|NCT02229305|Behavioral|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita & Weisz, 2010).
258401|NCT02229292|Drug|Tranexamic Acid|"Active group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
258402|NCT02229292|Drug|Saline|"Placebo group:~Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
258403|NCT02229279|Device|Teleconsulting|
258404|NCT02229266|Biological|NK cells|
258405|NCT02229266|Drug|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
258406|NCT02229253|Drug|degarelix|
258407|NCT02229240|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
258408|NCT02229240|Drug|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
258409|NCT02229227|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
258410|NCT02229227|Drug|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
258411|NCT02229214|Drug|Qsymia|
258412|NCT02229214|Drug|Placebo|
258413|NCT02229201|Drug|Propofol|4-6 mg/kg/h during anaesthesia
258414|NCT02229201|Drug|Sevoflurane|0.8 MAC
258415|NCT02229188|Behavioral|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
258416|NCT02229188|Behavioral|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
258417|NCT02229188|Behavioral|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
258418|NCT02229175|Drug|bevacizumab|intravitreal injections of antibodies inhibiting vascular endothelial growth factor
258419|NCT02229175|Device|PASCAL Endpoint Management (EpM) laser treatment|This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
258420|NCT02229149|Drug|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.~Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.~For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
258421|NCT02229149|Drug|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
258422|NCT02229149|Drug|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:~Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR~Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR~Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR~Docetaxel 75 mg/m2 IV every 3 weeks; OR~Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
258423|NCT02229136|Drug|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
258424|NCT02229136|Drug|Prednisolone|Prednisolone oral solution 15 mg/5 ml
258425|NCT02229123|Drug|Intravenous Levetiracetam|Open-study. If seizure lasting more than 3 minutes on EEG recording or brief repeated seizures (more or equal to 2 seizures lasting more than 20 seconds on a 1 hour-interval), the loading-dose of LEV allocated to patient is infused followed by the 8 maintenance dose.
258426|NCT02229110|Other|Signal|Automatic signal in the electronic medical record
258428|NCT02229097|Drug|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
258429|NCT02229084|Biological|Chemovax|Timing of the vaccination relative to chemotherapy
258430|NCT02229071|Drug|Donafenib(200mg)|Donafenib 200mg,bid,po
258431|NCT02229071|Drug|Donafenib(300mg)|Donafenib 300mg,bid,po
258432|NCT02229058|Drug|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
258433|NCT02229058|Drug|S-1|40mg QD D1-D14,every 3 weeks,for BSA<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA>1.5m2,until disease progress or intolerable toxicity.
258434|NCT02229045|Drug|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
258435|NCT02229045|Drug|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
258436|NCT02229019|Behavioral|Volunteer mealtime assistance|
258437|NCT02229006|Radiation|18F-NaF PET-CT|
258438|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
258439|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
258440|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
258441|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
258442|NCT02228967|Behavioral|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
258443|NCT02228954|Procedure|Molecular imaging|
258444|NCT02228928|Drug|CAPNP, 50 ug/cm2 capsaicin patch|
258445|NCT02228928|Drug|CAPNP, 100 ug/cm2 capsaicin patch|
258446|NCT02228928|Drug|0.075% capsaicin cream|
258447|NCT02228928|Other|Placebo patch|
258448|NCT02228902|Drug|Ferrous fumarate|one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
258449|NCT02228902|Drug|Ferrous gluconate|One group receives ferrous fumarate and one group receives ferrous fumarate.
258450|NCT02228889|Procedure|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
258451|NCT02228889|Other|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
258452|NCT02228889|Other|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
258453|NCT02228889|Other|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
258454|NCT02228889|Other|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
258455|NCT02228889|Other|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
258456|NCT02228889|Other|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
258457|NCT02228889|Other|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
258458|NCT02228889|Other|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
258459|NCT02228889|Other|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
258460|NCT02228889|Other|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
258461|NCT02228889|Other|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
258462|NCT02228889|Other|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
258463|NCT02228889|Other|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
258464|NCT02228889|Other|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
258465|NCT02228889|Other|Assess overall complications at 30 days postoperatively|
258466|NCT02228889|Other|Assess overall complications at 1 year postoperatively|
258467|NCT02228889|Procedure|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
258468|NCT02228889|Device|Strattice|Strattice mesh
258469|NCT02228889|Device|XenMatrix|Xenmatrix mesh
258470|NCT02228863|Other|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
258471|NCT02228863|Other|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
258472|NCT02228863|Other|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
258473|NCT02228863|Other|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
258474|NCT02228850|Drug|Alprostadil|
258475|NCT02228850|Other|Placebo|
258476|NCT02228837|Dietary Supplement|Pear|
258477|NCT02228837|Dietary Supplement|Placebo|
258478|NCT02228824|Drug|Very low nicotine content cigarettes|0.07 mg nicotine delivery
258479|NCT02228824|Drug|Normal nicotine content cigarettes|0.8 mg nicotine delivery
258480|NCT02228811|Drug|DCC-2701 tablet|
258481|NCT02228785|Biological|G17DT|
258482|NCT02228772|Drug|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
258483|NCT02228772|Drug|Vincristine|Standard chemotherapy dosage and duration
258484|NCT02228772|Drug|Cytarabine|Standard chemotherapy dosage and duration
258485|NCT02228772|Drug|Doxorubicin|Standard chemotherapy dosage and duration
258486|NCT02228772|Drug|Mercaptopurine|Standard chemotherapy dosage and duration
258487|NCT02228772|Drug|Cyclophosphamide|Standard chemotherapy dosage and duration
258488|NCT02228772|Drug|Methotrexate|Standard chemotherapy dosage and duration
258489|NCT02228759|Procedure|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
258490|NCT02228746|Dietary Supplement|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
258491|NCT02228733|Drug|KBP-5074|Comparisons of different doses of study drug
258492|NCT02228720|Device|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
258493|NCT02228707|Drug|BIIB061|Participants receive BIIB061
258494|NCT02228707|Other|Placebo|Matched placebo
258495|NCT02228681|Drug|Everolimus|10mg daily by mouth
258496|NCT02228681|Drug|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
258497|NCT02228681|Drug|Letrozole|2.5mg twice a day by mouth
258498|NCT02228681|Drug|Medroxyprogesterone Acetate|200 mg daily by mouth
258499|NCT02228655|Drug|FMX-8|
258500|NCT02228629|Device|CrocsRx Medical Silver cloud clogs|
258501|NCT02228616|Drug|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
258502|NCT02228616|Drug|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
258503|NCT02228616|Drug|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
258504|NCT02228603|Behavioral|high-intensity exercise training|
258505|NCT02228603|Behavioral|web-based follow-up program|
258506|NCT02228603|Behavioral|usual care|
258507|NCT02228590|Drug|APL-130277|Apomorphine Hydrochloride, Sublingual Thin Film
258508|NCT02228564|Procedure|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
258509|NCT02228564|Device|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
258510|NCT02228551|Other|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
258511|NCT02228538|Device|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system & off-the-shelf standard knee implant system from various manufacturers
258512|NCT02228525|Drug|selinexor (KPT-330)|
258513|NCT02228512|Drug|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
258514|NCT02228512|Drug|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
258515|NCT02228512|Drug|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
258516|NCT02228512|Drug|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
258517|NCT02228512|Drug|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
258518|NCT02228512|Drug|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
258519|NCT02228512|Drug|Cyclophosphamide|Part B: 750 mg/m2 Day 5
258520|NCT02228499|Other|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
258521|NCT02228486|Device|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
258522|NCT02228486|Behavioral|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
258523|NCT02228473|Drug|Glycopyrrolate|Glycopyrrolate will be administered.
258524|NCT02228473|Drug|Atropine|Atropine will be administered.
258525|NCT02228460|Drug|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
258526|NCT02228447|Behavioral|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
258527|NCT02228434|Behavioral|Monitoring and Tailored prescription|
258528|NCT02228434|Behavioral|Happy 10 program|
258529|NCT02228434|Behavioral|Specified nutrition education|
258530|NCT02228434|Behavioral|General Health Education|
258531|NCT02228408|Drug|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.~Target Dose:~Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day~Allowable Dosage Forms:~ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day~Dose Titration:~ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
258532|NCT02228408|Drug|Placebo|Placebo titration will mimic titration of active study arm
258533|NCT02228395|Drug|PF-04958242|Oral capsule, single dose, 0.35 mg, 0.55 mg, 0.75 mg
258535|NCT02228382|Drug|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
258536|NCT02228369|Drug|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
258537|NCT02228369|Drug|AZD9291|AZD9291 160mg once daily
258538|NCT02228356|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
258539|NCT02228343|Other|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
258540|NCT02228330|Procedure|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
258541|NCT02228317|Device|Telemedicine consultation|Telemedicine consultation done by telephone or video
258542|NCT02228304|Drug|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
258543|NCT02228304|Drug|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
258544|NCT02228291|Dietary Supplement|Capsule containing citrus flavonoid|
258545|NCT02228291|Dietary Supplement|Placebo|
258546|NCT02228278|Behavioral|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.~Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
258547|NCT02228278|Other|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.~Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
258548|NCT02228265|Other|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
258549|NCT02228265|Drug|Enzalutamide|Given PO
258550|NCT02228265|Other|Laboratory Biomarker Analysis|Correlative studies
258551|NCT02228252|Other|Whey protein|
258552|NCT02228252|Other|Casein|
258553|NCT02228252|Other|Gluten protein|
258554|NCT02228239|Drug|Esketamine|Esketamine 84 milligram (mg) [3*1 of spray in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
258555|NCT02228239|Drug|Mirtazapine|Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
258556|NCT02228239|Drug|Placebo (Matched to Esketamine)|Placebo [3*1 in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
258557|NCT02228239|Drug|Placebo (Matched to Mirtazapine)|Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
258558|NCT02228213|Biological|MIS416|Intravenous administration weekly for 52 weeks
258559|NCT02228213|Drug|Saline|Intravenous administration weekly for 52 weeks
258560|NCT02228200|Behavioral|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
258561|NCT02228200|Behavioral|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
258562|NCT02228187|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
258563|NCT02228174|Device|Intrauterine Ultrasound-Guided Radiofreq. Ablation System|The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, including those associated with heavy menstrual bleeding(HMB).
258564|NCT02228161|Behavioral|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
258565|NCT02228148|Device|NFS|Cochlear Nucleus Fitting Software
258566|NCT02228148|Device|CSS|Cochlear Nucleus Custom SoundTM Suite
258567|NCT02228135|Drug|Dexamethasone|
258568|NCT02228122|Device|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
258569|NCT02228109|Device|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
258570|NCT02228109|Device|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
258571|NCT02228109|Device|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
258572|NCT02228096|Biological|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg).
258573|NCT02228083|Drug|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
258574|NCT02228070|Device|strabismus video goggles|
258575|NCT02228044|Behavioral|Prevention program|
258576|NCT02228031|Drug|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
258577|NCT02228031|Other|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
258578|NCT02228018|Device|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
258579|NCT02228005|Drug|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
258580|NCT02227992|Biological|EVARREST™ Sealant Matrix|EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
258581|NCT02227992|Device|SURGICEL®|SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
258582|NCT02227979|Behavioral|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
258583|NCT02227979|Behavioral|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
258584|NCT02227966|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
258585|NCT02227966|Device|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
258586|NCT02227953|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
258587|NCT02227953|Device|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
258588|NCT02227940|Drug|Ceritinib|Given PO
258589|NCT02227940|Drug|Cisplatin|Given IV
258590|NCT02227940|Drug|Gemcitabine Hydrochloride|Given IV
258591|NCT02227940|Other|Laboratory Biomarker Analysis|Correlative studies
258592|NCT02227940|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
258593|NCT02227940|Other|Pharmacological Study|Correlative studies
258594|NCT02227927|Drug|Domperidone|10-30mg oral dose, four times daily.
258595|NCT02227914|Drug|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
258596|NCT02227914|Drug|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
258597|NCT02227901|Drug|Tipifarnib|Given PO
258598|NCT02227901|Radiation|External Beam Radiation Therapy|Undergo EBRT
258599|NCT02227901|Drug|Temozolomide|Given PO
258600|NCT02227901|Other|Laboratory Biomarker Analysis|Correlative studies
258601|NCT02227888|Drug|N91115|S nitrosoglutathione reductase inhibitor
258602|NCT02227875|Drug|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
258603|NCT02227875|Drug|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
258604|NCT02227862|Drug|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
258605|NCT02227862|Drug|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
258606|NCT02227849|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 52 weeks
258607|NCT02227849|Drug|GLP-1 analogue|
258608|NCT02227836|Device|Allergy Patch Testing|
258609|NCT02227823|Drug|Pyridostigmine Bromide|
258610|NCT02227810|Other|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
258611|NCT02227810|Other|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
258612|NCT02227810|Other|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
258613|NCT02227797|Drug|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
258615|NCT02227784|Drug|Atorvastatin|Administered orally
258616|NCT02227784|Drug|Ezetimibe|Administered orally
258617|NCT02227784|Drug|Placebo|Administered orally
258618|NCT02227771|Device|Percutaneous coronary intervention|
258619|NCT02227745|Drug|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
258620|NCT02227745|Drug|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
258621|NCT02227732|Device|New Indwelling Pleural Catheter|Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
258622|NCT02227719|Device|CTI|CTI is the titanium mesh
258623|NCT02227719|Device|Collagen membrane|
258624|NCT02227706|Biological|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
258625|NCT02227706|Device|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
258626|NCT02227693|Drug|avatrombopag|E5501 (avatrombopag) 20-mg tablets
258627|NCT02227693|Drug|Placebo|Placebo matching 20-mg tablets
258628|NCT02227680|Other|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
258629|NCT02227680|Other|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
258630|NCT02227667|Drug|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
258631|NCT02227654|Procedure|Abnormal Ovarian Ultrasound|Ultrasound
258632|NCT02227641|Biological|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
258633|NCT02227628|Dietary Supplement|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
258634|NCT02227628|Dietary Supplement|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
258635|NCT02227615|Dietary Supplement|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
258636|NCT02227615|Dietary Supplement|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
258637|NCT02227602|Drug|Mango polyphenolics|Frozen mango pack will be provided (200~400g per day).
258638|NCT02227589|Behavioral|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
258639|NCT02227589|Behavioral|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
258640|NCT02227589|Other|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
258641|NCT02227576|Drug|Romiplostim|
258642|NCT02227563|Device|Active tDCS|repetitive daily tDCS sessions for a period of one week
258643|NCT02227563|Device|control|
258644|NCT02227550|Drug|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
258645|NCT02227550|Drug|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine >= 1.5 mg/dl (133mM), <= 60 kg body weight or age >= 80 years.
258646|NCT02227537|Device|Providence Nighttime Bracing System|Providence Nighttime Bracing System
258647|NCT02227537|Device|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
258648|NCT02227524|Other|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
258649|NCT02227524|Device|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
258650|NCT02227524|Device|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
258651|NCT02227524|Device|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
258652|NCT02227511|Dietary Supplement|Fruits|Randomization to extra fruit or nuts as snacks
258653|NCT02227511|Dietary Supplement|Nuts|
258654|NCT02227498|Device|Effect of Argus II on Functional Vision|To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
258655|NCT02227485|Drug|Punica granatum Pleniflora (Golnaar) mouth rinse|"All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks."
258656|NCT02227485|Drug|Chlorhexidine (0.2%)|All the patient in control group use 10 ml of chlorhexidine (0.2%) for 2 minutes every night for 2 weeks.
258657|NCT02227485|Procedure|Tooth bleaching|Tooth bleaching for both groups one time after using mouth rinses.
258658|NCT02227472|Other|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
258659|NCT02227472|Other|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
258660|NCT02227459|Drug|ND-L02-s0201 Injection|
258661|NCT02227446|Drug|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
258662|NCT02227433|Drug|Brentuximab Vedotin|
258663|NCT02227420|Drug|Anakinra|Anakinra 100mg s.c. x 5
258664|NCT02227407|Device|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
258665|NCT02227394|Drug|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).~At visit 2 or 3 (cross-over design)"
258666|NCT02227394|Drug|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
258667|NCT02227394|Drug|Placebo of Test product|"Single dose of 2 puffs~Z7200 inhalation powder placebo is filled in size 3 hydroxypropyl methylcellulose (HPMC) capsules.~At visit 2 or 3 (cross-over)~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
258668|NCT02227394|Drug|Placebo of Reference Drug|"Single dose of 2 puffs~Symbicort placebo does not contain any drug substances, (Budesonide and Formoterol fumarate), or excipients (Lactose monohydrate).~At visit 2 or 3 (cross-over)~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
258669|NCT02227394|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose.
258670|NCT02227368|Drug|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
258671|NCT02227368|Drug|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
258672|NCT02227342|Biological|Fecal Microbiota Transplant|serial FMT
258673|NCT02227329|Drug|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
258674|NCT02227329|Drug|Heparin Lock|3 mL of 100 U/ml heparin
258675|NCT02227329|Drug|Normal Saline|
258676|NCT02227316|Drug|IV Ibuprofen|Uterine fibroid embolization
258677|NCT02227316|Drug|IV Acetaminophen|Uterine fibroid embolization
258678|NCT02227316|Drug|Intravenous placebo/Intravenous placebo|Uterine fibroid embolization
258679|NCT02227303|Behavioral|lifestyle modification instructional and motivational sessions|
258680|NCT02227290|Drug|Naftin Cream|
258681|NCT02227290|Drug|Placebo Cream|
258682|NCT02227277|Drug|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL > 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
258683|NCT02227264|Drug|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
258684|NCT02227264|Procedure|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
258685|NCT02227251|Drug|Selinexor|Fixed milligram dose of 60 mg selinexor orally twice weekly.
258686|NCT02227238|Drug|DTG|DTG is supplied as 50 mg tablets
258687|NCT02227238|Drug|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
258688|NCT02227238|Drug|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
258689|NCT02227212|Drug|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
258690|NCT02227199|Drug|Brentuximab Vedotin|Given IV
258691|NCT02227199|Drug|Carboplatin|Given IV
258692|NCT02227199|Drug|Etoposide|Given IV
258693|NCT02227199|Drug|Ifosfamide|Given IV
258694|NCT02227199|Other|Laboratory Biomarker Analysis|Correlative studies
258695|NCT02227186|Other|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
258696|NCT02227173|Drug|BMS-986020|
258697|NCT02227173|Drug|Montelukast|
258698|NCT02227173|Drug|Flurbiprofen|
258699|NCT02227173|Drug|Digoxin|
258700|NCT02227160|Behavioral|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
258701|NCT02227160|Behavioral|Outpatient counseling and support groups|Usual mental health care
258702|NCT02227147|Drug|rhNGF 20µg/ml|
258703|NCT02227147|Other|Placebo|Formulation containing antioxidant
258704|NCT02227134|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
258797|NCT02226406|Other|A: Chair - Leg Cycle ergometer|
258705|NCT02227121|Device|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
258706|NCT02227108|Drug|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
258707|NCT02227095|Behavioral|Exercise|Heart rate monitors worn by each child at each session
258708|NCT02227095|Behavioral|After-school program|Supervised recreational program with token economy
258709|NCT02227082|Radiation|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
258710|NCT02227082|Drug|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
258711|NCT02227069|Drug|M518101|
258712|NCT02227069|Drug|M518101 Vehicle|
258713|NCT02227069|Other|sodium lauryl sulfate|
258714|NCT02227069|Other|saline|
258715|NCT02227056|Drug|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
258716|NCT02227030|Drug|BIIB 722 CL solution|
258717|NCT02227030|Drug|BIIB 722 CL tablet|
258718|NCT02227030|Drug|Placebo solution|
258719|NCT02227030|Drug|Placebo tablet|
258720|NCT02227017|Drug|TPV capsule|
258721|NCT02227017|Drug|TPV solution|
258722|NCT02227017|Drug|RTV capsule|
258723|NCT02227017|Drug|RTV solution|
258724|NCT02227017|Other|standard meal|
258725|NCT02227004|Diagnostic Test|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
258726|NCT02226991|Drug|Tipranavir|
258727|NCT02226991|Drug|Ritonavir|
258728|NCT02226991|Drug|Efavirenz|
258729|NCT02226978|Drug|Tipranavir|
258730|NCT02226978|Drug|Ritonavir|
258731|NCT02226978|Drug|Valaciclovir|
258732|NCT02226965|Drug|PNT2258|
258733|NCT02226952|Drug|BILN 2061 W, low dose|
258734|NCT02226952|Drug|BILN 2061 W, medium dose|
258735|NCT02226952|Drug|BILN 2061 W, high dose|
258736|NCT02226952|Drug|Placebo|
258737|NCT02226939|Drug|BILN 2061 ZW|
258738|NCT02226939|Drug|Placebo|
258739|NCT02226926|Drug|Aggrenox|
258740|NCT02226926|Drug|Persantin Retard|
258741|NCT02226926|Drug|Acetylsalicylic acid|
258742|NCT02226913|Drug|2% lidocaine with 1:80,000 epinephrine|2% lidocaine with 1:80,000 epinephrine
258743|NCT02226913|Drug|sodium bicarbonate|8.4% sodium bicarbonate
258744|NCT02226913|Drug|placebo|sterile distilled water (Samen Pharmaceutical Co, Iran)
258745|NCT02226900|Procedure|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
258746|NCT02226900|Procedure|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
258747|NCT02226887|Procedure|MESH|"Pre-operative :~It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~Surgical technique:~Peristomal incision with electrocautery~Release the handle of ileum~Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~We add the mesh between the edges of the defect during fascia closure.~The skin is sutured purse string style.~Post-Op~Hospital discharge after verification of normal digestive transit."
258748|NCT02226887|Procedure|NO MESH|"Pre-operative :~It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .~Surgical technique:~Peristomal incision with electrocautery~Release the handle of ileum~Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).~Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.~The skin is sutured purse string style.~Post-Op~- Hospital discharge after verification of normal digestive transit"
258749|NCT02226887|Radiation|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
258750|NCT02226887|Radiation|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
258751|NCT02226887|Other|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
258752|NCT02226861|Device|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
258753|NCT02226861|Biological|ULD IL-2|sterile, white to off-white, preservative-free, lyophilized powder suitable for IV infusion upon reconstitution and dilution
258754|NCT02226848|Drug|Erythropoeitin|
258755|NCT02226809|Device|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
258756|NCT02226796|Device|transcranial direct current stimulation Prime Condition|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
258757|NCT02226796|Other|Non-Prime Condition|
258758|NCT02226796|Behavioral|Traditional behavioral treatment|
258759|NCT02226783|Drug|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
258798|NCT02226406|Other|B: Chair - Arm Cycle ergometer|
258760|NCT02226783|Drug|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
258761|NCT02226783|Drug|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
258762|NCT02226770|Device|Implantable Cardioverter Defibrillator (ICD)|
258763|NCT02226757|Drug|Paclitaxel-trastzumab|"Trastuzumab~Dose:~First dose: 4 mg/kg IV~Subsequent doses: 2 mg/kg every week IV.~The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.~Paclitaxel~- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
258764|NCT02226744|Behavioral|Focused Breathing|
258765|NCT02226731|Device|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
258766|NCT02226731|Device|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
258767|NCT02226718|Other|Administration of questionnaire|
258768|NCT02226705|Procedure|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
258769|NCT02226679|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
258770|NCT02226666|Drug|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
258771|NCT02226666|Drug|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
258772|NCT02226653|Drug|Evacetrapib|Administered orally
258773|NCT02226614|Device|University of Edinburgh head cooling device|head cooling
258774|NCT02226601|Drug|Aprepitant|3 days perioperative Aprepitant once a day
258775|NCT02226601|Drug|Placebo|3 days perioperative Placebot once a day
258776|NCT02226588|Drug|Misoprostol|
258777|NCT02226575|Behavioral|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
258778|NCT02226562|Drug|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
258779|NCT02226562|Drug|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
258780|NCT02226549|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
258781|NCT02226549|Drug|VDV|VDV 80 mg tablet administered orally once daily
258782|NCT02226549|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
258783|NCT02226536|Behavioral|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
258784|NCT02226510|Drug|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
258785|NCT02226510|Drug|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
258786|NCT02226497|Device|Health Telemonitoring|Use home telemonitoring device
258787|NCT02226497|Other|Quality-of-Life Assessment|Ancillary studies
258788|NCT02226497|Other|Questionnaire Administration|Ancillary studies
258789|NCT02226497|Procedure|Supportive Care|Receive standard outpatient supportive care
258790|NCT02226484|Drug|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
258791|NCT02226458|Drug|EPI-743|
258792|NCT02226445|Other|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.~ADHD medication:~First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.~When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.~If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.~If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
258793|NCT02226432|Procedure|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.~Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.~Comparision of both groups will be statistified"
258794|NCT02226432|Device|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
258795|NCT02226432|Other|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
258796|NCT02226419|Dietary Supplement|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
258800|NCT02226393|Behavioral|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
258801|NCT02226393|Behavioral|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
258802|NCT02226380|Drug|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
258803|NCT02226367|Drug|prazosin hydrochloride|study drug arm prazosin
258804|NCT02226367|Drug|placebo|study drug arm placebo
258805|NCT02226354|Dietary Supplement|Ahiflower oil|9.73 ml per day for 28 days
258806|NCT02226354|Dietary Supplement|Flaxseed oil|9.73ml per day for 28 days
258807|NCT02226341|Drug|CellCept|"For both arms:~CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
258808|NCT02226341|Drug|ACTHar gel|Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
258809|NCT02226341|Drug|ACTHar gel|Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
258810|NCT02226328|Drug|Propofol sedation|
258811|NCT02226328|Drug|Midazolam and Fentanyl sedation|
258812|NCT02226289|Drug|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
258813|NCT02226276|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
258814|NCT02226276|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
258815|NCT02226276|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
258816|NCT02226276|Biological|trastuzumab|Given IV
258817|NCT02226276|Radiation|copper Cu 64-DOTA-trastuzumab|Given IV
258818|NCT02226276|Procedure|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
258819|NCT02226276|Biological|ado-trastuzumab emtansine|Given IV
258820|NCT02226276|Other|laboratory biomarker analysis|Correlative studies
258821|NCT02226263|Dietary Supplement|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 [CFU] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
258822|NCT02226250|Dietary Supplement|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
258823|NCT02226237|Procedure|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
258824|NCT02226237|Procedure|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
258825|NCT02226211|Device|Air-Q intubation laryngeal airway|"The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using removal stylet ."
258826|NCT02226211|Device|Ambu-Aura i laryngeal mask|"The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (> 100kg).~After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.~After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.~After successful intubation, the device will be removed according to the manufactures guides using another ETT."
258827|NCT02226198|Drug|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
258828|NCT02226198|Drug|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
258829|NCT02226185|Drug|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 2-3 years
258830|NCT02226185|Drug|placebo|supplement of placebo two times per day for 2-3 years
258831|NCT02226172|Drug|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
258832|NCT02226172|Drug|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
258833|NCT02226159|Drug|Lidocaine|
258834|NCT02226159|Drug|Lidocaine with Dexamethasone|
258835|NCT02226146|Biological|Bertilimumab|
258836|NCT02226133|Device|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
259021|NCT02224729|Drug|Bortezomib|Given SC
258837|NCT02226120|Drug|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
258838|NCT02226107|Behavioral|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
258839|NCT02226107|Behavioral|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
258840|NCT02226094|Device|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
258841|NCT02226094|Device|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
258842|NCT02226094|Device|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
258843|NCT02226094|Device|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
258844|NCT02226068|Drug|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
258845|NCT02226068|Other|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
258846|NCT02226055|Device|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).~We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
258847|NCT02226042|Behavioral|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
258848|NCT02226029|Other|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability~Lipid emulsion 1: acid stable, particle size 0.6 µm~Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm~13C-markers will be mixed with emulsions"
258849|NCT02226016|Device|FG-5000A|a measuring device for the assessment of levator muscle strength
258850|NCT02226003|Drug|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
258851|NCT02226003|Drug|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
258852|NCT02226003|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
258853|NCT02226003|Drug|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
258854|NCT02226003|Drug|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
258855|NCT02225990|Other|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
258856|NCT02225990|Other|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
258857|NCT02225990|Other|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
258858|NCT02225990|Other|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
258859|NCT02225977|Drug|Gilenya|
258860|NCT02225951|Dietary Supplement|Nutritional product|
258861|NCT02225951|Other|Standard breakfast according to ADA recommendations|
258862|NCT02225925|Radiation|Brachytherapy|
258863|NCT02225912|Other|PrevinC|
258864|NCT02225912|Drug|placebo|
258865|NCT02225886|Drug|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
258866|NCT02225873|Other|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
258867|NCT02225873|Other|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
258868|NCT02225860|Behavioral|Diet and water adjustment|The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
258869|NCT02225847|Other|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
258870|NCT02225847|Procedure|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
258871|NCT02225847|Behavioral|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
258872|NCT02225834|Drug|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
258873|NCT02225821|Drug|Cephalozin|1000 mg Cephalozin
258874|NCT02225821|Other|Sodium chloride|10 cc of NaCl 0.9%
258875|NCT02225808|Behavioral|CBT for anxiety in autism|
258876|NCT02225795|Other|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:~Day Treatment~6 r-ATG 2 mg/kg~5 r-ATG3 2 mg/kg~4 r-ATG3 2 mg/kg~3 Cyclophosphamide with Mesna~2 Cyclophosphamide with Mesna~1 REST 0 PBSC infusion~3 Cyclophosphamide with Mesna~4 Cyclophosphamide with Mesna~6 Start GCSF"
258877|NCT02225782|Drug|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
258878|NCT02225769|Other|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
258879|NCT02225769|Other|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
258880|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
258881|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
258882|NCT02225756|Drug|Placebo|Oral administration for a short time of placebo
258883|NCT02225743|Other|Observation Of Temperature|Participants temperature will be recorded perioperatively.
258884|NCT02225717|Procedure|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
258885|NCT02225704|Drug|Radium-223 and enzalutamide|
258886|NCT02225691|Device|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
258887|NCT02225665|Genetic|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
258888|NCT02225665|Genetic|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
258889|NCT02225665|Drug|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
258890|NCT02225652|Drug|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
258891|NCT02225639|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
258892|NCT02225639|Drug|Placebo|Oral placebo capsule
258893|NCT02225639|Drug|PRC-063 35 mg|Oral 35 mg capsule - active
258894|NCT02225639|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
258895|NCT02225639|Drug|PRC-063 55 mg|Oral 55 mg capsule - active
258896|NCT02225639|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
258897|NCT02225639|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
258898|NCT02225639|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
258899|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
258900|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
258901|NCT02225626|Drug|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
258902|NCT02225613|Other|Usual protocol|
258903|NCT02225613|Other|Spa protocol|
258904|NCT02225600|Drug|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
258905|NCT02225600|Drug|Placebo|Intranasal Placebo
258906|NCT02225600|Drug|24 IU intranasal Oxytocin|
259022|NCT02224729|Drug|Dexamethasone|Given PO
259023|NCT02224703|Drug|GWP42003-P|
259024|NCT02224703|Drug|Placebo Control|
258907|NCT02225587|Biological|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
258908|NCT02225587|Biological|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
258909|NCT02225587|Biological|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
258910|NCT02225574|Drug|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
258911|NCT02225574|Drug|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.~Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.~Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
258912|NCT02225574|Behavioral|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
258913|NCT02225561|Procedure|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.~As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:~Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.~The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.~Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
258914|NCT02225561|Procedure|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
258915|NCT02225548|Drug|Selegiline|
258916|NCT02225548|Drug|Tadalafil|
258917|NCT02225535|Other|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
258918|NCT02225535|Other|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
258919|NCT02225535|Other|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
258920|NCT02225522|Other|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
258921|NCT02225509|Procedure|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
258922|NCT02225496|Procedure|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
258923|NCT02225496|Procedure|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
258924|NCT02225496|Behavioral|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
258925|NCT02225470|Drug|E7389 (Eribulin Mesylate)|
258926|NCT02225470|Drug|Vinorelbine injection|
258927|NCT02225457|Other|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
258928|NCT02225457|Dietary Supplement|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
258929|NCT02225457|Dietary Supplement|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
258930|NCT02225444|Other|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
258931|NCT02225431|Drug|sodium chloride infusion|
258932|NCT02225418|Drug|Ropivacaine|
258933|NCT02225418|Drug|saline|
258934|NCT02225405|Drug|Cisplatin|Given IV
258935|NCT02225405|Drug|Docetaxel|Given IV
258936|NCT02225405|Other|Laboratory Biomarker Analysis|Correlative studies
258937|NCT02225405|Drug|Nintedanib|Given PO
259134|NCT02224040|Drug|ceftriaxone and azithromycin|
258938|NCT02225392|Procedure|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
258939|NCT02225392|Device|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
258940|NCT02225379|Device|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
258941|NCT02225366|Biological|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
258942|NCT02225366|Other|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
258943|NCT02225353|Drug|Progesterone Cervical Pessary 6.3 g|Progesterone Cervical Pessary low dose
258944|NCT02225353|Drug|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
258945|NCT02225353|Drug|Progesterone Cervical Pessary 7.7 g|Progesterone Cervical Pessary high dose
258946|NCT02225327|Biological|Fluad alone|Fluad
258947|NCT02225327|Biological|Fluad and PPV23 on the different arms|Fluad and Prodiax
258948|NCT02225327|Biological|Fluad and PPV23 on the same arm|Fluad and Prodiax
258949|NCT02225327|Biological|PPV23 alone|Prodiax
258950|NCT02225314|Behavioral|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
258951|NCT02225314|Behavioral|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
258952|NCT02225314|Behavioral|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
258953|NCT02225301|Other|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention that takes 1.5-2 hours to complete.
258954|NCT02225288|Drug|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
258955|NCT02225275|Drug|Lenalidomide|Given PO
258956|NCT02225275|Biological|Obinutuzumab|Given IV
258957|NCT02225262|Radiation|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
258958|NCT02225236|Behavioral|Classroom Intervention|
258959|NCT02225223|Device|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
258960|NCT02225223|Device|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
258961|NCT02225210|Drug|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
258962|NCT02225210|Drug|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
258963|NCT02225210|Drug|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
258964|NCT02225197|Radiation|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
258965|NCT02225132|Drug|Hydroxyurea|"The precise mechanism by which hydroxyurea produces its cytotoxic and cytoreductive effects is not known. However, various studies support the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein.~The mechanisms by which DROXIA produces its beneficial effects in patients with sickle cell anemia (SCA) are uncertain. Known pharmacologic effects of DROXIA that may contribute to its beneficial effects include increasing hemoglobin F levels in RBCs, decreasing neutrophils, increasing the water content of RBCs, increasing deformability of sickled cells, and altering the adhesion of RBCs to endothelium."
258966|NCT02225106|Drug|Methylphenidate|Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
258967|NCT02225093|Drug|Caffeine|Oral
258968|NCT02225093|Drug|Dextromethorphan|Oral /.L
258969|NCT02225093|Drug|Enzalutamide|Oral
258970|NCT02225093|Drug|Enzalutamide Placebo to Match (PTM)|Oral
258971|NCT02225067|Drug|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
258972|NCT02225054|Drug|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
258973|NCT02225054|Drug|Ropivacaine|15 ml 0.5%
258974|NCT02225054|Drug|Normal Saline|1 mL 0.9%
258975|NCT02225028|Behavioral|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
258976|NCT02225015|Behavioral|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
258977|NCT02225002|Drug|CP-870,893|
258978|NCT02224989|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
258979|NCT02224976|Behavioral|Intensified Training|Volunteers will increase exercise training by 30% from baseline
258980|NCT02224963|Behavioral|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
259135|NCT02224040|Drug|azithromycin|
258981|NCT02224963|Behavioral|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
258982|NCT02224950|Device|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
258983|NCT02224950|Other|Non-medicated Emollient plus Cotton Sleeve|
258984|NCT02224950|Other|Placebo Sleeve|
258985|NCT02224937|Drug|Melatonin|
258986|NCT02224937|Drug|Placebo|
258987|NCT02224924|Other|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
258988|NCT02224924|Device|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
258989|NCT02224911|Device|Laser Interstitial Thermal Therapy|
258990|NCT02224898|Behavioral|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
258991|NCT02224885|Device|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
258992|NCT02224872|Procedure|Bone marrow transplant|Day 0
258993|NCT02224872|Drug|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
258994|NCT02224872|Drug|Fludarabine|30 mg/M2 IV on days -6 to -2
258995|NCT02224872|Drug|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
258996|NCT02224872|Radiation|TBI|200 cGy on day -1
258997|NCT02224872|Drug|Mesna|40 mg/kg IV on days 3, 4
258998|NCT02224872|Drug|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
258999|NCT02224872|Drug|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
259000|NCT02224859|Device|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.~The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
259001|NCT02224859|Other|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
259002|NCT02224846|Drug|Tadalafil|Administered orally
259003|NCT02224833|Behavioral|Pharmacist intervention|"Systematic review of treatments:~Identification of reasons for PPI.~Determination of recommended pharmacotherapeutic alternatives.~Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.~After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
259004|NCT02224820|Biological|IdeS|Doses are administered in ascending doses
259005|NCT02224807|Behavioral|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
259006|NCT02224807|Behavioral|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
259007|NCT02224794|Device|Ovation® Abdominal Stent Graft Platform|
259008|NCT02224781|Drug|Dabrafenib|Given PO
259009|NCT02224781|Drug|Dabrafenib Mesylate|Given PO
259010|NCT02224781|Biological|Ipilimumab|Given IV
259011|NCT02224781|Biological|Nivolumab|Given IV
259012|NCT02224781|Other|Quality-of-Life Assessment|Ancillary studies
259013|NCT02224781|Drug|Trametinib|Given PO
259014|NCT02224781|Drug|Trametinib Dimethyl Sulfoxide|Given PO
259015|NCT02224768|Drug|Ipilimumab|
259016|NCT02224755|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
259017|NCT02224755|Device|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
259018|NCT02224742|Device|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
259019|NCT02224742|Other|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.~Components of usual wound care include:~Formal assessment of ulcer and surrounding skin~Provision of any necessary off-loading~Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)~Appropriate dressing products~Appropriate antibiotic therapy~Nutrition and self care~Optimal glycaemic control~Revascularisation if deemed clinically necessary~Continued close observation"
259020|NCT02224729|Drug|Bendamustine hydrochloride|Given IV
259025|NCT02224690|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
259026|NCT02224690|Drug|Placebo|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
259027|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 5mg QD
259028|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD
259029|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
259030|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 25 mg QD
259031|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.
259032|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
259033|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.
259034|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
259035|NCT02224638|Device|TheraHoney HD|Honey
259036|NCT02224638|Device|SkinTegrity|Hydrogel
259037|NCT02224625|Drug|2% CHG Cloth solution|Investigational CHG
259038|NCT02224625|Device|Vehicle Cloth|Excipients from CHG cloth only
259039|NCT02224625|Drug|Active Comparator|Active comparator
259040|NCT02224625|Other|Saline|Negative control
259041|NCT02224625|Other|SLS|Provides a slight irritation for a positive control
259042|NCT02224612|Device|Medline Pediatric Face Masks|Medline Face Masks, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
259043|NCT02224612|Device|KC Childs Mask|KC Childs Mask, which are single use disposable masks were evaluated on children. The mask was worn for 2-3 minutes for EtCO2 and respiration assessments and physical fit assessment.
259044|NCT02224599|Biological|TAPA-pulsed DC vaccine|Subjects will given the vaccine which contains 1 x 10^7 TAPA-pulsed dendritic cells and is administered ID. A total of three (3) cycles therapy will be administered weekly.
259045|NCT02224599|Drug|Cyclophosphamide Pill|Subjects will be given low-dose cyclophosphamide by mouth for 5 days starting 5 to 7 days prior to the vaccine cycle.
259046|NCT02224599|Drug|Imiquimod Topical Cream|Topical Imiquimod Cream will be applied after vaccination.
259047|NCT02224586|Device|light treatment|clinical routine treatment according to the doctor's advice
259048|NCT02224573|Drug|GWP42003-P|
259049|NCT02224560|Drug|GWP42003-P|GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 10 or 20 mg/kg/day.
259050|NCT02224560|Drug|Placebo control|Placebo was presented as an oral solution containing 0 mg/mL CBD in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
259051|NCT02224547|Radiation|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
259052|NCT02224534|Drug|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
259053|NCT02224534|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
259054|NCT02224521|Drug|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
259055|NCT02224521|Drug|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
259056|NCT02224521|Drug|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
259057|NCT02224521|Drug|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
259058|NCT02224521|Drug|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
259059|NCT02224521|Drug|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
259060|NCT02224495|Behavioral|Structured exercise training|
259061|NCT02224482|Behavioral|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
259062|NCT02224469|Device|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
259063|NCT02224456|Drug|Tenofovir disoproxil fumarate|"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."
259064|NCT02224443|Drug|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
259065|NCT02224443|Drug|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
259066|NCT02224443|Drug|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
259067|NCT02224443|Drug|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4~5μg.kg-1 fentanyl,1.0~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
259068|NCT02224443|Drug|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05~0.1mg.kg-1.h-1cisatracurium besylate,4~8mg.kg-1.h-1propofol,0.1~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%~1.0%
259069|NCT02224417|Behavioral|Diabetes Educational Program (DEP)|"Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.~The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic."
259070|NCT02224417|Behavioral|DEP + Process Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:~SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.~SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.~SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit."
259071|NCT02224417|Behavioral|DEP + Outcome Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.~SGD 2 weekly if one glucose readings falls within the normal range,~SGD 7 weekly if two glucose readings fall within the normal range,~SGD 14 weekly if all three glucose readings fall within the normal range."
259072|NCT02224404|Device|Fast Gelling Dressing (Exufiber)|
259073|NCT02224391|Behavioral|Computer-Assisted Smoking Cessation Intervention|Receive ABM training via a smartphone
259074|NCT02224391|Other|Laboratory Biomarker Analysis|Correlative studies
259075|NCT02224391|Drug|Nicotine Patch|Given via transdermal patch
259076|NCT02224391|Other|Questionnaire Administration|Ancillary studies
259077|NCT02224391|Other|Sham Intervention|Undergo sham training
259078|NCT02224378|Procedure|peep induced CVP|
259079|NCT02224378|Procedure|passive leg raising(PLR)|
259080|NCT02224365|Dietary Supplement|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
259081|NCT02224365|Dietary Supplement|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
259082|NCT02224352|Device|Functional neuromuscular electrical stimulation|
259083|NCT02224313|Drug|oral estradiol 1.0 mg|one tablet of oral estradiol 1.0 mg once a day for 28 days
259084|NCT02224313|Drug|oral progesterone 100 mg|one tablet of oral progesterone 100 mg once a day for 14 days
259085|NCT02224300|Behavioral|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
259086|NCT02224287|Procedure|Technologist control of fluoroscopy|Technologist control of fluoroscopy
259087|NCT02224287|Procedure|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
259088|NCT02224274|Drug|Clopidogrel|
259089|NCT02224274|Drug|Ticagrelor|
259090|NCT02224261|Other|Physical Therapy protocol|Physical therapy protocol includes manual lymph-drainage technique in axilla, and proximal ipsilateral arm, specific thumb manual lymph-drainage on the taut cords to make them gradually more flexible, in conjunction with progressive active and action-assisted arm exercises
259091|NCT02224261|Other|Control|Control protocol includes same progressive active and action-assisted arm exercises than the experimental group.
259092|NCT02224248|Behavioral|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
259093|NCT02224248|Behavioral|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
259094|NCT02224235|Drug|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
259095|NCT02224235|Device|Resolute Integrity DES|Resolute Integrity DES
259096|NCT02224235|Device|COBRA PzF|
259097|NCT02224235|Drug|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
259098|NCT02224209|Device|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:~Method of stage-1 angioplasty~The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;~Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.~Method of stage-2:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;~After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
259099|NCT02224209|Device|a balloon, stent|"Routine stenting procedure:~The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);~Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;~After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
259131|NCT02224053|Drug|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
259132|NCT02224053|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
259133|NCT02224040|Drug|ceftriaxone|
259100|NCT02224196|Other|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
259101|NCT02224196|Other|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
259102|NCT02224183|Behavioral|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
259103|NCT02224183|Behavioral|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
259104|NCT02224170|Drug|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
259105|NCT02224170|Drug|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
259106|NCT02224157|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
259107|NCT02224157|Drug|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
259108|NCT02224144|Drug|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
259109|NCT02224144|Drug|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
259110|NCT02224144|Drug|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
259111|NCT02224131|Drug|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
259112|NCT02224131|Drug|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
259113|NCT02224118|Drug|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
259114|NCT02224118|Drug|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
259115|NCT02224118|Drug|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
259116|NCT02224118|Drug|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
259117|NCT02224118|Drug|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
259118|NCT02224105|Drug|BI 653048 BS|
259119|NCT02224105|Drug|Prednisolone low|
259120|NCT02224105|Drug|Prednisolone high|
259121|NCT02224105|Drug|Placebo|
259122|NCT02224105|Drug|sodium chloride infusion|
259123|NCT02224105|Drug|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
259124|NCT02224092|Dietary Supplement|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
259125|NCT02224079|Drug|BIIB 722 CL|
259126|NCT02224079|Drug|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
259127|NCT02224066|Drug|Ticagrelor 90 mg twice per day during three months following TAVI|
259128|NCT02224066|Drug|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
259129|NCT02224053|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
259130|NCT02224053|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
259275|NCT02222961|Drug|Placebo|
259136|NCT02224040|Drug|azithromycin and cefixime|
259137|NCT02224027|Device|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
259138|NCT02224027|Device|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
259139|NCT02224027|Device|i-gel|In i-gel group, i-gel is inserted by novices.
259140|NCT02224014|Drug|Lendormin D tablets|
259141|NCT02224001|Procedure|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts~The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
259142|NCT02223988|Procedure|subglottic secretion removal|
259143|NCT02223962|Behavioral|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
259144|NCT02223949|Device|Cook double balloon catheter|
259145|NCT02223949|Drug|PGE1 tablet|
259146|NCT02223936|Other|group exposed|Assessment by Brunet Lezine scale
259147|NCT02223936|Other|Control|Not exposed group
259148|NCT02223923|Drug|AZD6738|
259149|NCT02223923|Radiation|Palliative radiotherapy|
259150|NCT02223910|Procedure|Neurofeedback training of functional connectivity|
259151|NCT02223897|Drug|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
259152|NCT02223897|Drug|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
259153|NCT02223884|Drug|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
259154|NCT02223884|Drug|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
259155|NCT02223871|Drug|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
259156|NCT02223871|Other|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
259157|NCT02223871|Drug|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
259158|NCT02223871|Drug|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
259159|NCT02223858|Behavioral|Positive Activities (PA) Program|6-week program of at-home activities (1 per week) that have been shown to increase positivity. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
259160|NCT02223858|Behavioral|Attention Control (AC) Program|6-week program of at-home activities (1 per week) based on affectively neutral activities from control conditions in studies of positive activities interventions. Activities were delivered via activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist oriented participants to the booklets and reviewed the first activity at the end of an in-person baseline visit. Booklets contained all instructions patients needed to complete the full program. Interventionists also provided support via weekly calls in which they assessed completion of the previous week's activity, reviewed instructions for the next activity, and helped participants trouble-shoot anticipated barriers.
259161|NCT02223845|Other|Music|Self-selected music played via headphones
259162|NCT02223832|Drug|ACT-128800|
259163|NCT02223819|Drug|Crizotinib|"An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.~Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."
259164|NCT02223806|Behavioral|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
259165|NCT02223806|Behavioral|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
259166|NCT02223793|Behavioral|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
259167|NCT02223793|Behavioral|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
259168|NCT02223793|Behavioral|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
259169|NCT02223780|Other|early palliative care|the patients will benefit from an early palliative care consultation
259170|NCT02223767|Device|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
259171|NCT02223767|Device|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
259172|NCT02223754|Device|lotrafilcon B|Soft contact lens to be worn as daily wear, monthly replacement modality.
259173|NCT02223754|Device|etafilcon A|Soft contact lens to be worn as daily wear, daily disposable modality.
259174|NCT02223741|Other|Korean medical treatment|acupuncture and herbal drugs
259175|NCT02223728|Behavioral|Lifestyle|
259176|NCT02223728|Behavioral|Health Education|
259177|NCT02223715|Other|CDI Pts|
259178|NCT02223702|Drug|Amoxicillin|500 mg, 3 times per day for 7 days
259179|NCT02223702|Drug|Metronidazole|500 mg, 3 times per day, for 7 days
259180|NCT02223702|Drug|Moxifloxacin|400 mg, once in a day for 7 days.
259181|NCT02223689|Procedure|Skin Affix|
259182|NCT02223676|Procedure|Clinical pharmacists conduct medication history|pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
259183|NCT02223650|Device|Overminus treatment|2.50D overminus spectacles
259184|NCT02223650|Device|Non-overminus treatment|spectacles without overminus or no spectacles
259185|NCT02223637|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
259186|NCT02223624|Other|walking and light weights|
259187|NCT02223624|Other|eccentric aerobic exercise|
259188|NCT02223624|Other|concentric aerobic exercise|
259189|NCT02223611|Drug|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)＜1.25 m2 40mg twice a day, 1.25 m2≤BSA＜1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
259190|NCT02223611|Drug|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
259191|NCT02223598|Drug|CB-5083|
259192|NCT02223598|Drug|Dexamethasone|
259193|NCT02223585|Other|Animal-based protein diet|
259194|NCT02223585|Other|Vegan-based protein diet|
259195|NCT02223572|Radiation|hip Xray|
259196|NCT02223533|Device|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
259197|NCT02223533|Drug|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
259198|NCT02223520|Drug|Mupirocin and Chlorhexidine|
259199|NCT02223520|Drug|Placebo ointment and placebo cloths|
259200|NCT02223507|Drug|BIIR 561 CL|
259201|NCT02223507|Drug|Placebo|
259202|NCT02223494|Drug|Terbogrel|
259203|NCT02223481|Drug|Terbogrel low dose|
259204|NCT02223481|Drug|Terbogrel high dose|
259205|NCT02223481|Drug|Placebo|
259206|NCT02223455|Other|Hand Hygiene Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
259207|NCT02223429|Drug|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
259208|NCT02223429|Drug|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
259209|NCT02223429|Drug|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
259210|NCT02223416|Drug|RGB-10|
259211|NCT02223416|Drug|Teriparatide|
259212|NCT02223403|Dietary Supplement|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
259213|NCT02223403|Dietary Supplement|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
259214|NCT02223390|Behavioral|Improving AIDS Care after Trauma (ImpACT)|
259215|NCT02223377|Drug|Morphine|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
259216|NCT02223377|Drug|Hydromorphone|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
259217|NCT02223364|Drug|Peripheral nerve blocks with Bupivacaine|Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
259218|NCT02223364|Drug|Intra articular injection with Ropivacaine|Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
259219|NCT02223364|Drug|Intra articular injection with liposomal bupivacaine|Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
259220|NCT02223351|Drug|ASP2151|
259221|NCT02223351|Drug|ritonavir|
259276|NCT02222948|Drug|Vatelizumab|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
259277|NCT02222948|Drug|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
259222|NCT02223338|Drug|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
259223|NCT02223338|Drug|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
259224|NCT02223312|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
259225|NCT02223299|Dietary Supplement|L-tyrosine|6g/d daily for 30 days
259226|NCT02223299|Dietary Supplement|L-Tryptophan|2g/d daily for 30 days
259227|NCT02223299|Drug|deplin|15mg daily for 30 days
259228|NCT02223299|Other|Placebo A|a sugar-pill that looks like a real medication
259229|NCT02223299|Other|Placebo B|a sugar-pill that looks like a real medication
259230|NCT02223286|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
259231|NCT02223273|Behavioral|Multifaceted Strategy|"Simulation Based Team Training~Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions~Reminders -~Check lists - decision support algorithm~Distribution of educational materials: guidelines and recommendations for best practices"
259232|NCT02223260|Drug|dabigatran|Experimental dose chosen based on age and weight
259233|NCT02223247|Drug|TVB-2640|
259234|NCT02223234|Behavioral|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
259235|NCT02223234|Behavioral|Control|Monthly emails on child health
259236|NCT02223234|Behavioral|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
259237|NCT02223221|Procedure|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
259238|NCT02223221|Genetic|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
259239|NCT02223221|Other|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
259240|NCT02223208|Drug|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8~Dose modification according to toxicity:~14mg/ms day +1 and +8~10mg/ms day +1 and +8~8mg/ms day +1 and +8~CHOEP-21~Doxorubicin 50 mg/ms iv day +1,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,~Cyclophosphamide 750 mg/ms iv day +1,~Etoposide 100mg/ms iv from day +1 to +3~Prednisone100 mg orally from days +1 to +5~PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
259241|NCT02223208|Drug|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles~Romidepsin dose according to phase I iv day +1 and +8~Doxorubicin 50 mg/ms iv day +1,~Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,~Cyclophosphamide 750 mg/ms iv day +1,~Etoposide 100mg/ms iv from day +1 to +3~Prednisone100 mg orally from days +1 to +5~PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
259242|NCT02223182|Biological|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
259243|NCT02223182|Biological|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
259244|NCT02223182|Biological|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
259245|NCT02223182|Biological|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
259246|NCT02223169|Dietary Supplement|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
259247|NCT02223130|Behavioral|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
259248|NCT02223117|Biological|Thrombosomes|Freeze-dried platelets
259249|NCT02223117|Biological|Placebo|
259250|NCT02223104|Device|Flexima Active|
259251|NCT02223104|Device|Sensura|
259252|NCT02223091|Behavioral|Consultation by a trained physician|
259253|NCT02223091|Behavioral|Consultation by an untrained physician|
259254|NCT02223078|Biological|G17DT|
259255|NCT02223078|Biological|Placebo Comparator|
259256|NCT02223065|Drug|Saxagliptin|
259257|NCT02223065|Drug|Dapagliflozin|
259258|NCT02223052|Drug|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
259259|NCT02223052|Drug|Vidaza|75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
259260|NCT02223039|Biological|AbGn-168H|AbGn-168H monoclonal antibody
259261|NCT02223039|Biological|Placebo|Placebo of AbGn-168H
259262|NCT02223026|Drug|Linagliptin/metformin FDC|
259263|NCT02223026|Other|high-fat, high caloric meal|
259264|NCT02223013|Drug|BIBV 308 SE solution|
259265|NCT02223013|Drug|BIBV 308 SE capsule L|
259266|NCT02223013|Drug|BIBV 308 SE capsule S|
259267|NCT02223000|Drug|BIBV 308 SE solution|
259268|NCT02223000|Drug|BIBV 308 SE capsule 1|
259269|NCT02223000|Drug|BIBV 308 SE capsule 2|
259270|NCT02222987|Drug|Terbogrel|
259271|NCT02222987|Drug|Clopidogrel|
259272|NCT02222974|Drug|BIIR 561 CL|
259273|NCT02222974|Drug|Placebo|
259274|NCT02222961|Drug|BIIR 561 CL|
259278|NCT02222935|Behavioral|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
259279|NCT02222935|Behavioral|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
259280|NCT02222922|Drug|PF-06647020 Q3W|"Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
259281|NCT02222922|Drug|fluconazole|combination drug used for drug-drug interaction sub-study
259282|NCT02222922|Drug|PF-06647020 Q2W|"Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.~Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1."
259283|NCT02222922|Drug|PF-06647020 combined with Avelumab|Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
259284|NCT02222909|Other|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
259285|NCT02222896|Drug|Chlorhexidine Gluconate|comparison with other CHG products
259286|NCT02222896|Other|Vehicle|Cloth with Excipients no CHG
259287|NCT02222896|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
259288|NCT02222883|Genetic|Testing of BRCA status regarding germline and somatic mutation|
259289|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
259290|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2014-2015 formulation)
259291|NCT02222844|Other|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
259292|NCT02222831|Procedure|Day 0 denudation and time lapse culture on IVF-oocytes.|
259293|NCT02222818|Device|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
259294|NCT02222818|Device|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
259295|NCT02222805|Procedure|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
259296|NCT02222805|Procedure|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
259297|NCT02222766|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
259298|NCT02222766|Behavioral|Control|Minimal attention control- 9 weekly mailed information on general child development
259299|NCT02222740|Drug|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
259300|NCT02222740|Drug|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
259301|NCT02222727|Drug|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
259302|NCT02222714|Biological|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
259303|NCT02222714|Drug|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
259304|NCT02222688|Drug|cirmtuzumab|
259305|NCT02222675|Procedure|Sonography assisted breast surgery|
259306|NCT02222675|Procedure|Conventional breast surgery|
259307|NCT02222662|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
259308|NCT02222662|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
259309|NCT02222649|Dietary Supplement|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
259310|NCT02222649|Dietary Supplement|Placebo|Capsules of starch, no therapeutic action
259311|NCT02222636|Drug|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
259312|NCT02222636|Drug|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
259313|NCT02222636|Drug|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
259314|NCT02222636|Drug|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
259315|NCT02222636|Drug|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
259316|NCT02222623|Drug|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
259317|NCT02222623|Drug|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
259318|NCT02222610|Drug|0.5 mg ranibizumab|
259397|NCT02221999|Drug|Paclitaxel|
259319|NCT02222610|Procedure|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
259320|NCT02222597|Device|infrascanner|
259321|NCT02222571|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
259322|NCT02222571|Behavioral|Supervision for Safety|group-based safety intervention for parents
259323|NCT02222558|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
259324|NCT02222545|Biological|OMS721|
259325|NCT02222532|Drug|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
259326|NCT02222532|Drug|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
259327|NCT02222519|Drug|Rocuronium|Rocuronium 0.6mg/kg iv single dose
259328|NCT02222506|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
259329|NCT02222493|Biological|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
259330|NCT02222493|Biological|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
259331|NCT02222480|Drug|Fimasartan|
259332|NCT02222480|Drug|Hydrochlorothiazide|
259333|NCT02222480|Drug|Placebo|
259334|NCT02222467|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
259335|NCT02222454|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
259336|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
259337|NCT02222441|Drug|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
259338|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
259339|NCT02222441|Drug|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
259340|NCT02222428|Drug|BI 1744 CL/BI 54903 XX FDC|
259341|NCT02222428|Drug|BI 54903 XX|
259342|NCT02222428|Drug|BI 1744 CL|
259343|NCT02222415|Dietary Supplement|Exercise + Protein drink|
259344|NCT02222402|Behavioral|INTRA-DIALYTIC EXERCISE TRAINING|
259345|NCT02222389|Behavioral|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.~Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
259346|NCT02222389|Behavioral|CM for drugs|"Escalating reinforcement for drug abstinence.~Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
259347|NCT02222389|Behavioral|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.~Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
259348|NCT02222389|Behavioral|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
259349|NCT02222376|Drug|Pirfenidone|Twice a day topical application
259350|NCT02222376|Procedure|Debridement|Weekly ulcer debridement
259351|NCT02222363|Drug|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
259352|NCT02222350|Drug|10mg DS-8500a tablet|
259353|NCT02222350|Drug|75mg DS-8500a tablet|
259354|NCT02222350|Drug|placebo|
259355|NCT02222337|Behavioral|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
259356|NCT02222324|Drug|Placebo|8 placebo tablets matching E2609
259357|NCT02222324|Drug|E2609|E2609 will be administered as 8 tablets
259358|NCT02222324|Drug|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
259359|NCT02222311|Other|Blood Samples|
259398|NCT02221999|Drug|Cisplatin|
259399|NCT02221999|Drug|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
259400|NCT02221999|Drug|Letrozole|
259401|NCT02221986|Behavioral|Interdisciplinary rehabilitation|
259360|NCT02222298|Procedure|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
259361|NCT02222298|Procedure|Bascom Cleft lift procedure|
259362|NCT02222285|Other|Medical Food : Vayarin_005|
259363|NCT02222285|Other|Placebo|
259364|NCT02222259|Procedure|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
259365|NCT02222246|Drug|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
259366|NCT02222246|Drug|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
259367|NCT02222246|Drug|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
259368|NCT02222246|Drug|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
259369|NCT02222233|Drug|BI 671800 HEA delayed release (enteric coated) tablet|
259370|NCT02222233|Drug|BI 671800 HEA solution|
259371|NCT02222233|Drug|BI 671800 HEA particulate|
259372|NCT02222220|Drug|Metoclopramide|30 mg/day during 4 weeks
259373|NCT02222220|Drug|placebo|
259374|NCT02222207|Drug|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
259375|NCT02222207|Procedure|Sham IVT|Sham injections
259376|NCT02222207|Drug|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
259377|NCT02222207|Drug|Placebo|Placebo eye drops
259378|NCT02222181|Other|Pharmacotherapy Management|"assessment of patient characteristics as alcoholic, smoker, food, drugs~Pharmacotherapy follow-up~to evaluated medication adherence~Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention."
259379|NCT02222168|Drug|BI 409306|medium dose, oral administration
259380|NCT02222168|Drug|BI 409306|medium dose, oral administration
259381|NCT02222168|Drug|BI 409306|medium dose, oral administration
259382|NCT02222155|Drug|CCX168 low dose plus standard of care|
259383|NCT02222155|Drug|CCX168 high dose plus standard of care|
259384|NCT02222155|Other|Placebo BID plus standard of care|
259385|NCT02222142|Drug|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
259386|NCT02222129|Drug|Bupivacaine|
259387|NCT02222129|Drug|liposomal bupivacaine|
259388|NCT02222116|Device|MGuard Prime|
259389|NCT02222116|Device|Control BMS DES|
259390|NCT02222064|Behavioral|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
259391|NCT02222051|Behavioral|Tai Chi|traditional chinese martial art meditative movement technique
259392|NCT02222051|Behavioral|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
259393|NCT02222038|Other|skin biopsy|
259394|NCT02222025|Other|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
259395|NCT02222012|Device|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
259396|NCT02222012|Device|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
259402|NCT02221973|Dietary Supplement|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
259403|NCT02221960|Biological|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
259404|NCT02221960|Biological|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
259405|NCT02221947|Drug|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
259406|NCT02221947|Drug|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
259407|NCT02221934|Device|Altius|Electrical signal
259408|NCT02221921|Device|MicroPort's Transcatheter Aortic Valve and Delivery System|
259409|NCT02221908|Device|Mespere Venus 1000 CVP System|
259410|NCT02221895|Other|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
259411|NCT02221895|Other|Postpartum follow up 6-8wk after delivery|control arm
259412|NCT02221882|Drug|LY3164530|Administered IV.
259413|NCT02221869|Drug|Xyrem|
259414|NCT02221856|Procedure|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
259415|NCT02221856|Procedure|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
259416|NCT02221830|Drug|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
259417|NCT02221830|Drug|Placebo|This intervention utilizes a Placebo Camparator
259418|NCT02221817|Procedure|Trochanter bursa injections|
259419|NCT02221817|Device|Ultrasound|
259420|NCT02221804|Behavioral|14 days of voluntary step count reduction to no more than 1500 steps/day.|
259421|NCT02221791|Dietary Supplement|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
259422|NCT02221791|Dietary Supplement|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
259423|NCT02221791|Dietary Supplement|Placebo|Participants will consume 70g white chocolate + placebo capsules
259424|NCT02221778|Radiation|SBRT|"SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:~Prescription dose(Gy) / (MLD) (Gy)~50 / 13~45 / 15~40 / 15~35 / 15.5~30 / 16~27.5 / 17~If the dose constraints cannot be met, prescription will be according to the level immediately bellow.~Treatment will be delivered in 5 fractions in consecutive working days"
259425|NCT02221765|Drug|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
259426|NCT02221765|Drug|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
259427|NCT02221752|Dietary Supplement|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
259428|NCT02221752|Dietary Supplement|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
259429|NCT02221739|Drug|Ipilimumab|
259430|NCT02221739|Radiation|Radiotherapy (IMRT or 3-D CRT)|
259431|NCT02221726|Drug|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
259432|NCT02221726|Drug|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 44 cm^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
259433|NCT02221700|Procedure|Massage Therapy|Undergo massage therapy
259434|NCT02221700|Other|Quality-of-Life Assessment|Ancillary studies
259435|NCT02221700|Other|Questionnaire Administration|Ancillary studies
259436|NCT02221687|Dietary Supplement|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
259437|NCT02221687|Dietary Supplement|Control formula|Standard milk formula without pre and probiotic
259438|NCT02221674|Drug|Tapentadol|
259439|NCT02221648|Drug|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
259440|NCT02221648|Drug|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
259441|NCT02221635|Procedure|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
259442|NCT02221635|Drug|Risperidone|Risperidone (2-4 mg) was took orally.
259443|NCT02221622|Drug|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
259444|NCT02221622|Drug|Placebo injection (intravenous solution)|Placebo intravenous infusion
259445|NCT02221609|Other|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
259488|NCT02221375|Drug|Ciclesonide|
259489|NCT02221349|Device|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
259446|NCT02221609|Other|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
259447|NCT02221596|Dietary Supplement|vitamin D|50,000IU/wk of vitamin D3
259448|NCT02221596|Other|aerobic training|7 days of treadmill training during the 13th week of study
259449|NCT02221583|Drug|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
259450|NCT02221583|Drug|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
259451|NCT02221583|Drug|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
259452|NCT02221570|Drug|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
259453|NCT02221557|Device|easy-graft (beta-Tricalcium Phosphate)|
259454|NCT02221544|Device|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.~The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
259455|NCT02221544|Device|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
259456|NCT02221544|Device|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
259457|NCT02221544|Device|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
259458|NCT02221531|Drug|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
259459|NCT02221531|Drug|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
259460|NCT02221518|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
259461|NCT02221505|Drug|LOP628|
259462|NCT02221492|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
259463|NCT02221492|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
259464|NCT02221479|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
259465|NCT02221479|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
259466|NCT02221453|Drug|Triamcinolone Acetonide|
259467|NCT02221440|Device|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
259468|NCT02221427|Other|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
259469|NCT02221427|Other|Static labour progression curve (F)|
259470|NCT02221414|Drug|Linagliptin/Metformin FDC|
259471|NCT02221414|Drug|Linagliptin|
259472|NCT02221414|Drug|Metformin|
259473|NCT02221401|Drug|Linagliptin/Metformin FDC|
259474|NCT02221401|Drug|Linagliptin|
259475|NCT02221401|Drug|Metformin|
259476|NCT02221388|Drug|BI 671800 HEA, 200 mg tablets|
259477|NCT02221388|Drug|BI 671800 HEA EC, 200 mg tablets|
259478|NCT02221388|Drug|BI 671800 HEA, 50 mg tablets|
259479|NCT02221388|Drug|BI 671800 ED, 100 mg capsules|
259480|NCT02221388|Other|Standard meal|
259481|NCT02221375|Drug|BHT low|
259482|NCT02221375|Drug|BHT medium|
259483|NCT02221375|Drug|BHT high|
259484|NCT02221375|Drug|BI 54903 XX low|
259485|NCT02221375|Drug|BI 54903 XX medium 1|
259486|NCT02221375|Drug|BI 54903 XX medium 2|
259487|NCT02221375|Drug|BI 54903 XX high|
259490|NCT02221349|Drug|Sodium fluoride paste|Toothpaste used by subject
259491|NCT02221349|Drug|Stannous fluoride paste|Toothpaste used by subject
259492|NCT02221336|Device|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
259493|NCT02221336|Device|Non-MONARCA II system|Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
259494|NCT02221323|Drug|Insulin LISPRO|
259495|NCT02221310|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m^2/dose given IV over 2 hours once during conditioning
259496|NCT02221297|Dietary Supplement|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
259497|NCT02221284|Drug|Alogliptin|Alogliptin tablets
259498|NCT02221271|Drug|NPB-01|
259499|NCT02221258|Biological|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
259500|NCT02221245|Procedure|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
259501|NCT02221232|Drug|Chloraprep|Apply topically.
259502|NCT02221232|Drug|ZuraPrep|Apply topically.
259503|NCT02221232|Drug|ZuraPrep Vehicle|Apply topically.
259504|NCT02221219|Drug|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
259505|NCT02221219|Procedure|delay in umbilical cord clamp at birth|provision of a ~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
259506|NCT02221219|Drug|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
259507|NCT02221219|Procedure|immediate cord clamp at birth|no delay in umbilical cord clamp; <10sec (recorded in delivery note)
259508|NCT02221206|Device|Mini-Screw implant|Mini-screw implants (VectorTASTM8*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
259509|NCT02221193|Other|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
259510|NCT02221180|Drug|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
259511|NCT02221180|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
259512|NCT02221180|Drug|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
259513|NCT02221167|Other|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
259514|NCT02221154|Dietary Supplement|Inofolic®|
259515|NCT02221154|Other|Gonadotropins; Folic Acid|standard ovarian stimulation
259516|NCT02221115|Device|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
259517|NCT02221102|Drug|Aspirin|non-steroidal anti-inflammatory drugs
259518|NCT02221102|Drug|edoxaban|orally active direct factor Xa inhibitor
259519|NCT02221102|Drug|placebo|
259520|NCT02221089|Drug|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
259521|NCT02221089|Dietary Supplement|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
259522|NCT02221089|Other|Placebo|Placebo capsules identical in appearance to Retaron capsules
259523|NCT02221076|Device|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
259524|NCT02221063|Other|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
259525|NCT02221063|Other|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
259526|NCT02221063|Other|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
259527|NCT02221037|Drug|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
259528|NCT02221037|Drug|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
259529|NCT02221024|Procedure|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
259530|NCT02221024|Drug|Normal saline|
259531|NCT02221024|Device|MicroClave ICU Medica|
259750|NCT02219412|Drug|ticagrelor|90 mg bid for 2 weeks
259532|NCT02221011|Device|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.~Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
259533|NCT02220998|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
259534|NCT02220998|Drug|SOF|SOF 400 mg tablet administered orally once daily
259535|NCT02220998|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
259536|NCT02220985|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
259537|NCT02220985|Drug|Cyclophosphamide|Given IV
259538|NCT02220985|Drug|Fludarabine Phosphate|Given IV
259539|NCT02220985|Other|Laboratory Biomarker Analysis|Correlative studies
259540|NCT02220985|Drug|Methotrexate|Given IV
259541|NCT02220985|Drug|Mycophenolate Mofetil|Given IV and PO
259542|NCT02220985|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
259543|NCT02220985|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
259544|NCT02220985|Drug|Tacrolimus|Given IV or PO
259545|NCT02220985|Drug|Thiotepa|Given IV
259546|NCT02220985|Radiation|Total-Body Irradiation|Undergo TBI
259547|NCT02220972|Drug|Perampanel|
259548|NCT02220972|Drug|Placebo|
259549|NCT02220959|Other|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
259550|NCT02220946|Device|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
259551|NCT02220933|Drug|MD1003 100mg capsule|
259552|NCT02220933|Drug|Placebo|
259553|NCT02220920|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
259554|NCT02220920|Drug|Placebo|The patients will receive Placebo orally for 16 weeks
259555|NCT02220920|Drug|Insulin|
259556|NCT02220907|Drug|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
259557|NCT02220894|Biological|pembrolizumab|
259558|NCT02220894|Drug|carboplatin|
259559|NCT02220894|Drug|paclitaxel|
259560|NCT02220894|Drug|pemetrexed|
259561|NCT02220881|Device|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
259562|NCT02220881|Other|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
259563|NCT02220868|Drug|Sofosbuvir, Ribavirin, and Stribild|
259564|NCT02220855|Drug|BKM120|
259565|NCT02220842|Drug|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
259566|NCT02220842|Drug|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
259567|NCT02220842|Drug|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
259568|NCT02220829|Drug|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
259569|NCT02220829|Drug|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
259570|NCT02220816|Behavioral|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
259571|NCT02220816|Behavioral|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
259572|NCT02220803|Drug|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
259573|NCT02220803|Device|nasal Continuous Positive Airway Pressure (nCPAP)|
259574|NCT02220777|Drug|ASP8477|oral
259575|NCT02220777|Drug|omeprazole|oral
259576|NCT02220777|Drug|Placebo|oral
259577|NCT02220764|Device|Teeth abutment|
259578|NCT02220764|Device|Implant abutments|
259579|NCT02220751|Drug|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.~Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
259751|NCT02219412|Drug|Aspirin|100mg Qd for 2 weeks.
259752|NCT02219399|Dietary Supplement|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
260077|NCT02217228|Device|Sebacia microparticles and laser|
259580|NCT02220751|Procedure|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
259581|NCT02220738|Drug|ABT-957|ABT-957 administered twice-daily for 7 days
259582|NCT02220738|Other|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
259583|NCT02220725|Biological|Andexanet|
259584|NCT02220725|Other|Placebo|
259585|NCT02220712|Drug|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
259586|NCT02220686|Behavioral|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
259587|NCT02220673|Drug|BHT 0.1%|
259588|NCT02220673|Drug|BHT 0.5%|
259589|NCT02220673|Drug|Placebo for RMT-B|
259590|NCT02220673|Drug|Placebo for HFA-MDI|
259591|NCT02220660|Drug|BI 1744 CL|
259592|NCT02220660|Drug|BI 54903 XX|
259593|NCT02220660|Drug|BI 1744 CL + BI 54903 XX FDC|
259594|NCT02220660|Drug|Placebo|
259595|NCT02220647|Drug|Linagliptin/Metformin FDC|
259596|NCT02220647|Drug|Linagliptin|
259597|NCT02220647|Drug|Metformin|
259598|NCT02220634|Drug|Regadenoson|Injection for intravenous administration
259599|NCT02220621|Device|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
259600|NCT02220621|Device|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
259601|NCT02220608|Biological|Bortezomib|
259602|NCT02220608|Drug|G-CSF|
259603|NCT02220595|Procedure|Carotid endarterectomy vs. carotid stenting|
259604|NCT02220582|Other|MRI|Magnetic Resonance Imaging
259605|NCT02220556|Procedure|Blood sampling|
259606|NCT02220543|Other|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
259607|NCT02220543|Other|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
259608|NCT02220530|Drug|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
259609|NCT02220517|Device|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
259610|NCT02220517|Device|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
259611|NCT02220504|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
259612|NCT02220504|Other|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
259613|NCT02220491|Radiation|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
259614|NCT02220491|Radiation|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
259615|NCT02220478|Device|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
259616|NCT02220465|Behavioral|PA+ Smoking Cessation (LMPA)|
259617|NCT02220465|Behavioral|Standard Care Smoking Counseling (SCC)|
259618|NCT02220452|Other|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
259619|NCT02220452|Other|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
259620|NCT02220426|Drug|Xenon|Inhalation of hyperpolarized xenon gas
259621|NCT02220400|Drug|Ketamine|
259622|NCT02220387|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
259623|NCT02220387|Other|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
259624|NCT02220374|Other|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
259625|NCT02220361|Drug|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
259626|NCT02220361|Drug|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
259627|NCT02220361|Drug|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.~The infusion was completed in 30 minutes"
259628|NCT02220348|Drug|linaclotide|
259753|NCT02219399|Dietary Supplement|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
259754|NCT02219399|Dietary Supplement|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
260078|NCT02217228|Device|Vehicle suspension and laser|
259629|NCT02220335|Procedure|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
259630|NCT02220335|Drug|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
259631|NCT02220309|Drug|Pramipexole Oral Tablet|Pramipexole is an oral Dopamine agonist.
259632|NCT02220296|Drug|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
259633|NCT02220296|Drug|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
259634|NCT02220296|Drug|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
259635|NCT02220296|Drug|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
259636|NCT02220270|Device|ASD and PDA closure|
259637|NCT02220244|Drug|MD1003 100mg capsule|
259638|NCT02220231|Procedure|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
259639|NCT02220218|Drug|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
259640|NCT02220218|Drug|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
259641|NCT02220218|Drug|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
259642|NCT02220205|Other|PelvicSim|
259643|NCT02220205|Device|Manufacturer model|
259644|NCT02220192|Procedure|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
259645|NCT02220179|Behavioral|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
259646|NCT02220166|Dietary Supplement|Triticum monococcum|
259647|NCT02220153|Biological|UCB7665 Intravenous 1|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
259648|NCT02220153|Biological|UCB7665 Intravenous 2|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
259649|NCT02220153|Biological|UCB7665 Intravenous 3|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
259650|NCT02220153|Biological|UCB7665 Intravenous 4|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
259651|NCT02220153|Biological|UCB7665 Intravenous 5|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: intravenous infusion"
259652|NCT02220153|Biological|UCB7665 Subcutaneous 1|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: subcutaneous infusion"
259653|NCT02220153|Biological|UCB7665 Subcutaneous 2|"Active substance: UCB7665~Pharmaceutical form: solution~Concentration: 140 mg/mL~Route of Administration: subcutaneous infusion"
259654|NCT02220153|Biological|Intravenous Placebo|"Active substance: Placebo~Pharmaceutical form: solution~Concentration: 0.9 % saline~Route of Administration: intravenous infusion"
259655|NCT02220153|Biological|Subcutaneous Placebo|"Active substance: Placebo~Pharmaceutical form: solution~Concentration: 0.9 % saline~Route of Administration: subcutaneous infusion"
259656|NCT02220140|Behavioral|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
259657|NCT02220127|Radiation|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
259658|NCT02220127|Radiation|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
259659|NCT02220114|Drug|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.~second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.~Dose and treatment regimen should be maintained as in first treatment phase.~- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
259660|NCT02220088|Procedure|TAI of FOLFOX|Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
259661|NCT02220088|Drug|Sorafenib|Accept sorafenib.
259662|NCT02220062|Procedure|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5~10cc ethanol would be performed as bilateral injections at the celiac trunk.
259663|NCT02220062|Procedure|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
259664|NCT02220049|Drug|Bortezomib|
259788|NCT02219152|Drug|tranexamic acid|
259789|NCT02219152|Drug|saline|
259665|NCT02220036|Dietary Supplement|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
259666|NCT02220023|Drug|INOmax Inhalation|
259667|NCT02220010|Device|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
259668|NCT02219997|Device|Clear clip-on glasses|Clip-on glasses with no blue light filtering properties used as a placebo
259669|NCT02219997|Device|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
259670|NCT02219997|Device|ACRYSOF® IQ IOL|AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
259671|NCT02219997|Device|Clear IOL|Clear IOL, previously implanted
259672|NCT02219984|Drug|Anticoagulants|
259673|NCT02219971|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
259674|NCT02219945|Other|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
259675|NCT02219932|Drug|fampridine|
259676|NCT02219932|Drug|Placebo|Matched placebo
259677|NCT02219919|Other|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
259678|NCT02219919|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
259679|NCT02219906|Dietary Supplement|Resveratrol|1000mg tid
259680|NCT02219906|Dietary Supplement|Placebo|1000mg tid placebo
259681|NCT02219893|Drug|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
259682|NCT02219880|Dietary Supplement|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
259683|NCT02219880|Dietary Supplement|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
259684|NCT02219867|Drug|Ketamine|Drug (including placebo)
259685|NCT02219854|Procedure|Laparoscopic gastrectomy|
259686|NCT02219854|Procedure|Open gastrectomy|
259687|NCT02219841|Procedure|radiofrequency catheter ablation|
259688|NCT02219828|Drug|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
259689|NCT02219828|Drug|Placebo|Placebo
259690|NCT02219815|Behavioral|Prehab Intervention|Pre-operative, structured exercise intervention.
259691|NCT02219802|Procedure|Treatment according arm|
259692|NCT02219789|Drug|Alisertib|Given PO
259693|NCT02219789|Drug|Fulvestrant|Given IM
259694|NCT02219789|Other|Laboratory Biomarker Analysis|Correlative studies
259695|NCT02219776|Drug|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
259696|NCT02219776|Other|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
259697|NCT02219750|Drug|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
259698|NCT02219737|Drug|Carboplatin|Given IVPB
259699|NCT02219737|Drug|Etoposide|Given IVPB
259700|NCT02219737|Drug|Ibrutinib|Given PO
259701|NCT02219737|Drug|Ifosfamide|Given IV
259702|NCT02219737|Other|Laboratory Biomarker Analysis|Correlative studies
259703|NCT02219737|Other|Pharmacological Study|Correlative studies
259704|NCT02219737|Biological|Rituximab|Given IV
259705|NCT02219724|Drug|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
259706|NCT02219711|Drug|MGCD516|MGCD516 capsules will be taken with water.
259707|NCT02219698|Drug|Ibuprofen|
259708|NCT02219698|Drug|Paracetamol|
259709|NCT02219685|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
259710|NCT02219685|Drug|Placebo|Tablet administered orally once daily
259711|NCT02219672|Drug|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.~Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
259712|NCT02219672|Drug|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
259713|NCT02219659|Drug|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
259714|NCT02219659|Drug|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
259715|NCT02219659|Drug|Fentanyl Push First|Fentanyl 25 mcg intravenous push (IVP) every 5 min up to 4 doses hourly as needed to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
259716|NCT02219646|Drug|Vardenafil|Vardenafil 10 mg twice daily for six months
259717|NCT02219646|Drug|Placebo|Placebo two tablets daily for 6 months
259718|NCT02219633|Drug|LEO 39652 cream|Applied for 21 days
259719|NCT02219620|Behavioral|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
259720|NCT02219620|Behavioral|Social Control|social conversational group facilitated by care counselor
259721|NCT02219594|Device|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
259722|NCT02219581|Drug|Dexamethasone 10 mg|Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
259723|NCT02219581|Drug|Dexamethasone 20 mg|Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
259724|NCT02219581|Drug|Standard multimodal pain management regimen|"The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:~Preoperative:~Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)~Intraoperative:~Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)~Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. (15 mg if older patient or CrCl low)~Postoperative~Tylenol: 1000mg po q 8hr (scheduled)~Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid~IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain~Morphine PCA: only for failure of the above~MS Contin: Use as backup prn pain"
259725|NCT02219581|Drug|Placebo|Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
259726|NCT02219568|Procedure|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
259727|NCT02219568|Device|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
259728|NCT02219555|Drug|NaCl and lidocaine placebo/salt water|1ml of 0.9% NaCl and 2 ml of 1% lidocaine placebo/salt water injection at the time of enrollment into the study. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
259729|NCT02219555|Drug|triamcinolone acetonide, lidocaine|a mixture of one ml of triamcinolone acetonide, 240 mg/ml, and 2 ml of 1% lidocaine, active medication injection. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
259730|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
259731|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
259732|NCT02219529|Device|MCE|
259733|NCT02219529|Device|Standard gastroscopy|
259734|NCT02219516|Drug|RDEA3170|
259735|NCT02219503|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
259736|NCT02219503|Drug|Dasabuvir|Tablet
259737|NCT02219490|Drug|ABT-333|tablet
259738|NCT02219490|Drug|ABT-450/r/ABT-267|tablet
259739|NCT02219490|Drug|Ribavirin (RBV)|tablet
259740|NCT02219477|Drug|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
259741|NCT02219477|Drug|dasabuvir|tablet
259742|NCT02219477|Drug|ribavirin|tablet
259743|NCT02219464|Device|Nasopharyngeal catheter|
259744|NCT02219464|Device|Nasal Cannula|
259745|NCT02219464|Procedure|Oxygen Supplementation|Initially set at 3 liters/minute
259746|NCT02219464|Procedure|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
259747|NCT02219451|Other|exercise training|exercise training
259748|NCT02219438|Drug|ropivacaine|
259749|NCT02219425|Procedure|endometrial biopsy|
259755|NCT02219386|Other|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
259756|NCT02219386|Other|group 2. Passive analitical stretch (performed in both groups)|
259757|NCT02219373|Drug|Gabapentin|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit <30% pain reduction, the patient will crossover to the other medication option in the protocol.
259758|NCT02219373|Drug|Oxcarbazepine|Patients will be randomized to receive either Gabapentin or Oxcarbazepine. The assignment of the medications will be randomized and blinded to both the study investigators and the patient. If patients exhibit >30% pain reduction on receiving the medication evaluated after 4 weeks, then they may continue to receive either the same medication or placebo. If patients exhibit <30% pain reduction, the patient will crossover to the other medication option in the protocol.
259759|NCT02219373|Other|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
259760|NCT02219347|Drug|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
259761|NCT02219334|Device|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
259762|NCT02219321|Drug|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
259763|NCT02219321|Drug|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
259764|NCT02219308|Procedure|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.~IUD placement then proceeds"
259765|NCT02219308|Procedure|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride~Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blanching, indentation, or pain.~IUD placement then proceeds"
259766|NCT02219295|Dietary Supplement|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
259767|NCT02219295|Dietary Supplement|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
259768|NCT02219295|Dietary Supplement|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
259769|NCT02219295|Other|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
259770|NCT02219282|Other|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
259771|NCT02219256|Drug|TAK-079|TAK-079 solution
259772|NCT02219256|Drug|Placebo to TAK-079|Placebo to TAK-079 solution
259773|NCT02219243|Behavioral|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
259774|NCT02219243|Behavioral|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
259775|NCT02219230|Device|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
259776|NCT02219230|Device|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
259777|NCT02219230|Device|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
259778|NCT02219217|Drug|Dolutegravir, Elvitegravir and Cobicistat|
259779|NCT02219204|Procedure|Acupuncture|
259780|NCT02219204|Other|Herbal treatment|
259781|NCT02219191|Drug|puerarin tablet 50 mg|
259782|NCT02219191|Drug|Atorvastatin tablet 20 mg|Approval No.: H19990258
259783|NCT02219178|Drug|lenalidomide|25mg days 1 - 14 of 21 day schedule
259784|NCT02219178|Drug|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
259785|NCT02219178|Drug|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
259786|NCT02219165|Drug|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
259787|NCT02219165|Drug|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
259790|NCT02219139|Device|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
259791|NCT02219126|Other|Dietary intervention|
259792|NCT02219113|Procedure|Arthroscopic surgery|
259793|NCT02219113|Procedure|Liposuction|
259794|NCT02219113|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
259795|NCT02219113|Other|Intraarticular administration of autologous ADRC|
259796|NCT02219100|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
259797|NCT02219087|Drug|Liposomal bupivacaine|
259798|NCT02219087|Drug|Standard of Care|Pre-operative adductor canal nerve block (20mL of 0.5% ropivacaine). Intra-operative popliteal nerve block from the surgeon: 20mL 0.2% ropivacaine and a peri-articular injection of 10mg morphine, 30mg ketorolac and 40mg methylprednisolone.
259799|NCT02219074|Device|Sebacia microparticle and laser treatment|
259800|NCT02219074|Device|Vehicle and laser treatment|
259801|NCT02219048|Drug|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
259802|NCT02219048|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
259803|NCT02219022|Other|Control group|
259804|NCT02219022|Other|Experimental group|
259805|NCT02219009|Device|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
259806|NCT02218996|Other|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
259807|NCT02218983|Device|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
259808|NCT02218983|Other|Usual care|
259809|NCT02218970|Behavioral|strength training|
259810|NCT02218970|Behavioral|no training (control)|
259811|NCT02218957|Procedure|Extended Pouch RYGB|
259812|NCT02218957|Procedure|Standard RYGB|
259813|NCT02218944|Behavioral|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
259814|NCT02218931|Behavioral|Targeted ESTEEM diet|"The key components of the diet are:~High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)~The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
259815|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
259816|NCT02218918|Behavioral|Ground walk training|3 times a week and 6 weeks
259817|NCT02218918|Behavioral|Supervised Treadmill Walk training|3 times a week and 6 weeks
259818|NCT02218905|Behavioral|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
259819|NCT02218879|Drug|Tecfidera|Oral Tecfidera 240 mg bid
259820|NCT02218840|Other|Smoking topography|Evaluation of cigar smoking topography
259821|NCT02218827|Drug|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
259822|NCT02218814|Procedure|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.~Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
259823|NCT02218814|Procedure|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.~Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
259824|NCT02218801|Other|Evaluation of treatment for liver metastasis|
259825|NCT02218775|Drug|LY2456302|Mood and Anxiety Disorders
259826|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
259827|NCT02218762|Drug|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
259828|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
259829|NCT02218762|Drug|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
259830|NCT02218749|Other|Initially triaged to physiotherapist|
259831|NCT02218749|Other|Initially triaged to physician|
259832|NCT02218736|Drug|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
259833|NCT02218736|Drug|placebo|oral dosing of 10 mg placebo daily for 8 weeks
259834|NCT02218723|Drug|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
259835|NCT02218723|Drug|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
259836|NCT02218697|Biological|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
259837|NCT02218697|Biological|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
259838|NCT02218697|Biological|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
259839|NCT02218684|Drug|Telmisartan|
259840|NCT02218684|Drug|Lacidipine|
259841|NCT02218684|Drug|Placebo|
259842|NCT02218671|Drug|WE 941 OD tablets|
259843|NCT02218658|Drug|WE941 OD tablets|
259844|NCT02218658|Drug|Brotizolam|
259845|NCT02218645|Drug|WE 941 OD tablets|
259846|NCT02218645|Drug|Brotizolam|
259847|NCT02218632|Other|lactose-free diet|standard diet
259848|NCT02218632|Dietary Supplement|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
259849|NCT02218619|Drug|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
259850|NCT02218619|Drug|Sugar Pill (placebo)|Placebo
259851|NCT02218606|Drug|Abiraterone acetate 1000 mg po daily|
259852|NCT02218606|Drug|Cabazitaxel 25 mg/m2 IV|
259853|NCT02218606|Drug|prednisone 5 mg po BID|
259854|NCT02218593|Device|WREX orthosis|Upper extremity exoskleton used to assist movement
259855|NCT02218580|Other|Massage therapy|
259856|NCT02218580|Other|Standard care|
259857|NCT02218567|Behavioral|questionnaire qualilty of life|
259858|NCT02218567|Behavioral|psychological interview|
259859|NCT02218567|Behavioral|psychological tests|
259860|NCT02218567|Other|Motor evaluation|
259861|NCT02218567|Behavioral|Behavioral evaluation|
259862|NCT02218567|Behavioral|cognitive tests|
259863|NCT02218554|Genetic|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
259864|NCT02218541|Device|abutment margin 0.5 mm subgingival|
259865|NCT02218541|Device|abutment margin 1.5 mm subgingival|
259866|NCT02218528|Dietary Supplement|Plant-based ingredient|
259867|NCT02218528|Dietary Supplement|No Plant-based ingredient|
259868|NCT02218515|Procedure|Open Flap Debridement|Open Flap Debridement (Control Group)
259869|NCT02218515|Biological|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
259870|NCT02218515|Biological|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
259871|NCT02218502|Other|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
259872|NCT02218502|Other|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
259873|NCT02218502|Other|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
259874|NCT02218502|Other|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
259875|NCT02218489|Drug|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
259876|NCT02218489|Drug|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
259877|NCT02218476|Drug|CoQ10|
259878|NCT02218476|Drug|Placebo|
259879|NCT02218463|Drug|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
259880|NCT02218463|Drug|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
259881|NCT02218437|Drug|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
259882|NCT02218424|Drug|Magnesium|
259883|NCT02218424|Drug|Normal saline|
259884|NCT02218411|Other|Exercise training|Exercises routine based on the Otago exercise programme
259885|NCT02218398|Drug|Albuterol|
259886|NCT02218385|Device|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
259887|NCT02218372|Drug|Fidaxomicin oral suspension|Participants from birth to < 6 years of age received weight based doses of fidaxomicin oral suspension (32 mg/kg/day with a maximum dose of 400 mg/day divided in 2 doses) 2 times daily for 10 days.
259888|NCT02218372|Drug|Fidaxomicin tablets|Participants aged ≥ 6 years to < 18 years of age received a 200 mg fidaxomicin tablet 2 times daily for 10 days.
259889|NCT02218372|Drug|Vancomycin oral liquid|Participants from birth to < 6 years of age received weight based doses of vancomycin oral liquid (40 mg/kg/day with a maximum dose of 500 mg/day divided in 4 doses) 4 times daily for 10 days.
259890|NCT02218372|Drug|Vancomycin capsules|Participants aged ≥ 6 years to < 18 years of age received a 125 mg vancomycin capsule 4 times daily for 10 days.
259891|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
259931|NCT02218099|Drug|ASP8232|Oral
259892|NCT02218359|Drug|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
259893|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
259894|NCT02218346|Drug|AG221|AG221 in fed and fasted conditions
259895|NCT02218333|Dietary Supplement|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
259896|NCT02218333|Dietary Supplement|Placebo|
259897|NCT02218320|Drug|Raltegravir|
259898|NCT02218320|Drug|Dolutegravir|
259899|NCT02218320|Procedure|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
259900|NCT02218307|Drug|Mupirocin|
259901|NCT02218307|Drug|Placebo|
259902|NCT02218294|Drug|BCX4161|
259903|NCT02218281|Behavioral|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
259904|NCT02218281|Behavioral|NCI's QuitSTART app|NCI's smoking cessation app
259905|NCT02218281|Behavioral|Written smoking cessation materials only|Receipt of written smoking cessation materials
259906|NCT02218268|Drug|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
259907|NCT02218268|Drug|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
259908|NCT02218255|Device|Eeva™ results|
259909|NCT02218242|Device|Intraoperative ultrasound|Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
259910|NCT02218229|Device|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
259911|NCT02218216|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
259912|NCT02218203|Drug|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject, relative to each subject's MTD)
259913|NCT02218203|Drug|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
259914|NCT02218203|Drug|Placebo (Dextromethorphan)|0mg Dextromethorphan
259915|NCT02218203|Drug|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
259916|NCT02218190|Drug|Alvimopan|
259917|NCT02218190|Drug|Placebo|
259918|NCT02218177|Drug|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
259919|NCT02218177|Drug|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
259920|NCT02218177|Procedure|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
259921|NCT02218164|Drug|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
259922|NCT02218164|Drug|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
259923|NCT02218164|Drug|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
259924|NCT02218151|Other|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
259925|NCT02218151|Other|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
259926|NCT02218138|Behavioral|Learning 2 BREATHE|Mindfulness-based group program
259927|NCT02218138|Behavioral|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
259928|NCT02218125|Biological|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
259929|NCT02218125|Biological|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
259930|NCT02218112|Procedure|bariatric surgery (gastric bypass)|
259933|NCT02218086|Device|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
259934|NCT02218086|Device|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
259935|NCT02218086|Device|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
259936|NCT02218086|Device|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
259937|NCT02218086|Device|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
259938|NCT02218086|Device|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
259939|NCT02218086|Device|Slackline vs. standing-on-1-leg vs. control|beginners have to train 9 times ~15minutes within y few weeks.
259940|NCT02218073|Drug|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
259941|NCT02218073|Drug|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
259942|NCT02218073|Drug|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
259943|NCT02218060|Procedure|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
259944|NCT02218060|Procedure|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
259945|NCT02218047|Drug|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
259946|NCT02218047|Drug|Best available therapy (BAT)|Best available therapy as selected by the investigator
259947|NCT02218034|Drug|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
259948|NCT02218034|Drug|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
259949|NCT02218034|Drug|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
259950|NCT02218034|Drug|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
259951|NCT02218021|Drug|Samidorphan|
259952|NCT02218021|Drug|Placebo|
259953|NCT02218021|Drug|Oxycodone|
259954|NCT02218008|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
259955|NCT02218008|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
259956|NCT02217995|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams & Teasdale, 2002)."
259957|NCT02217982|Drug|Simethicone|
259958|NCT02217982|Drug|Loperamide|
259959|NCT02217982|Other|Peanut Butter|
259960|NCT02217969|Behavioral|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
259961|NCT02217956|Drug|Cisplatin|
259962|NCT02217956|Drug|Bevacizumab|
259963|NCT02217943|Procedure|Roux-en-Y gastric bypass|
259964|NCT02217943|Procedure|Sleeve gastrectomy|
259965|NCT02217930|Drug|WCK 2349|
259966|NCT02217930|Drug|Placebo|
259967|NCT02217930|Drug|Moxifloxacin|
259968|NCT02217917|Drug|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
259969|NCT02217917|Drug|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
259970|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
259971|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
259972|NCT02217917|Drug|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
259973|NCT02217904|Drug|1 mg islatravir|Single oral dose of 1 mg islatravir administered following ≥8 hour fast
259974|NCT02217904|Drug|2 mg islatravir|Single oral dose of 2 mg islatravir administered following ≥8 hour fast
259975|NCT02217904|Drug|10 mg islatravir|Single oral dose of 10 mg islatravir administered following ≥8 hour fast
259976|NCT02217904|Drug|30 mg islatravir|Single oral dose of 30 mg islatravir administered following ≥8 hour fast
259977|NCT02217904|Drug|0.5 mg islatravir|Single oral dose of 0.5 mg islatravir administered following ≥8 hour fast
259978|NCT02217904|Drug|0.25 mg islatravir|Single oral dose of 0.25 mg islatravir administered following ≥8 hour fast
260029|NCT02217605|Dietary Supplement|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
260030|NCT02217579|Dietary Supplement|Protein|A food containing 5 grams/serving of supplemental protein.
260031|NCT02217579|Dietary Supplement|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
259979|NCT02217891|Behavioral|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, & qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits & harms of tumor genomic profiling; 2) interest in & perceived benefits & harms of incidental findings arising from tumor genomic profiling; 3) anticipated process & needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, & those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; & 6) implications of & concerns about incidental findings for family.
259980|NCT02217878|Drug|Morphine|IV bolus injection
259981|NCT02217878|Drug|Placebo|IV bolus injection
259982|NCT02217878|Drug|Ticagrelor|180 mg loading dose
259983|NCT02217865|Behavioral|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
259984|NCT02217865|Behavioral|Questionnaire|Questionnaire completion asking general health and demographic questions.
259985|NCT02217865|Behavioral|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
259986|NCT02217865|Behavioral|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
259987|NCT02217852|Drug|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
259988|NCT02217852|Drug|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
259989|NCT02217852|Drug|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
259990|NCT02217852|Drug|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
259991|NCT02217839|Drug|DG3173|
259992|NCT02217839|Drug|DG3173+Octreotide|
259993|NCT02217839|Drug|Octreotide|
259994|NCT02217839|Drug|DG3173 Placebo|
259995|NCT02217839|Drug|DG3173 Placebo+Octreotide Placebo|
259996|NCT02217839|Drug|Octreotide+DG3173 Placebo|
259997|NCT02217826|Drug|DG3173|
259998|NCT02217826|Drug|Saline|
259999|NCT02217826|Drug|Octreotide|
260000|NCT02217813|Drug|Tafamidis|20 mg of current commercial formulation
260001|NCT02217813|Drug|Tafamidis|20 mg of new formulation
260002|NCT02217800|Drug|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
260003|NCT02217800|Drug|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
260004|NCT02217800|Drug|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
260005|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
260006|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
260007|NCT02217774|Device|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
260008|NCT02217748|Other|Survey questionnaire|
260009|NCT02217735|Behavioral|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
260010|NCT02217722|Other|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
260011|NCT02217722|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
260012|NCT02217709|Drug|phenelzine sulfate|Given by mouth
260013|NCT02217709|Other|laboratory biomarker analysis|Correlative studies
260014|NCT02217709|Other|questionnaire administration|Ancillary studies
260015|NCT02217696|Other|Computerized reading training|
260016|NCT02217683|Drug|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
260017|NCT02217670|Drug|Metformin 1000 mg granules|
260018|NCT02217670|Drug|Metformin 1000 mg film-coated tablets|
260019|NCT02217657|Device|Thermocool Smart Touch Catheter|Physician informed to contact force
260020|NCT02217644|Drug|BI 653048 H3PO4 solution|
260021|NCT02217644|Drug|BI 653048 H3PO4 low dose capsule|
260022|NCT02217644|Drug|BI 653048 H3PO4 high dose capsule|
260023|NCT02217644|Drug|Placebo|
260024|NCT02217631|Drug|BI 653048 BS H3PO4|
260025|NCT02217631|Drug|Prednisolone low dose|
260026|NCT02217631|Drug|Prednisolone high dose|
260032|NCT02217579|Dietary Supplement|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
260033|NCT02217579|Dietary Supplement|Control|An isocaloric food not containing the test protein and fiber.
260034|NCT02217566|Drug|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
260035|NCT02217566|Drug|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
260036|NCT02217566|Drug|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
260037|NCT02217553|Drug|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
260038|NCT02217540|Other|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
260039|NCT02217540|Other|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
260040|NCT02217527|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
260041|NCT02217527|Drug|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
260042|NCT02217514|Drug|Midazolam|
260043|NCT02217514|Drug|BI 44370 low dose|
260044|NCT02217514|Drug|BI 44370 medium dose|
260045|NCT02217514|Drug|BI 44370 high dose|
260046|NCT02217501|Drug|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
260047|NCT02217501|Drug|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
260048|NCT02217488|Drug|DG3173|
260049|NCT02217488|Drug|Placebo|
260050|NCT02217475|Drug|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food.
260051|NCT02217475|Drug|Placebo|Placebo administered orally once daily and taken every morning with food.
260052|NCT02217449|Other|Prediction of histology|
260053|NCT02217436|Device|iPad|iPad with age-appropriate applications, videos, and music
260054|NCT02217436|Other|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
260055|NCT02217423|Other|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
260056|NCT02217423|Other|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
260057|NCT02217410|Biological|CFZ533|
260058|NCT02217410|Drug|Tacrolimus (Tac)|
260059|NCT02217410|Drug|Mycophenolate mofetil (MMF)|
260060|NCT02217410|Drug|Corticosteroids (CS)|
260061|NCT02217410|Biological|anti-IL2 Induction|
260062|NCT02217397|Device|OA, CPAP, combination therapy|
260063|NCT02217371|Other|Neuropsychological tests|"The tests are :~Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT~These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
260064|NCT02217358|Device|NBI endoscopy|"see in detail description of the study part of the protocol"
260065|NCT02217345|Drug|Growth hormone|
260066|NCT02217345|Drug|Placebo|
260067|NCT02217332|Drug|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
260068|NCT02217319|Drug|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
260069|NCT02217319|Drug|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
260070|NCT02217293|Device|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
260071|NCT02217280|Drug|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
260072|NCT02217267|Drug|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
260073|NCT02217267|Drug|Placebo|
260074|NCT02217254|Procedure|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
260075|NCT02217254|Device|Cryoballoon catheter ablation|
260079|NCT02217228|Device|Sebacia microparticles without laser|
260080|NCT02217215|Device|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
260081|NCT02217202|Device|Aquacel Ag dressing|Participants will have their knee arthroplasty wound dressed using the Aquacel Ag dressing instead of the standard Aquacel dressing.
260082|NCT02217189|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
260083|NCT02217163|Drug|Carfilzomib, Cyclophosphamide, Dexamethasone|Carfilzomib is administered over 30 minutes as an infusion. For cycle 1 only, Carfilzomib is administered at 20mg/m2 IV on days 1 and 2, followed by escalation to 56mg/m2 on days 8,9,15 and 16 on a 28 day cycle. Patients who tolerate 56mg/m2 dose are kept at this dose for the subsequent cycles on Days 1,2,8,9,15,16 on a 28 day cycle. Dose and schedule modifications for intolerable side effects are detailed in the protocol. Additionally Cyclophosphamide is given a fixed dose of 500mg once per week orally, along with dexamethasone is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib.
260084|NCT02217124|Other|dried apples|120 calories
260085|NCT02217124|Other|muffin|120 calories
260086|NCT02217111|Behavioral|Adventures in Voice: Pediatric Voice Therapy|
260087|NCT02217098|Procedure|GIC Restorations|Restorations using Glass Ionomer Cement
260088|NCT02217098|Procedure|Carbomer Restorations|Restorations using Glass Carbomer
260089|NCT02217098|Procedure|Compomer Restorations|Restorations using Compomer
260090|NCT02217072|Behavioral|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
260091|NCT02217072|Behavioral|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
260092|NCT02217046|Procedure|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
260093|NCT02217033|Other|'R' (Electro-kinetically altered beverage)|
260094|NCT02217033|Other|Placebo (water)|
260095|NCT02217020|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
260096|NCT02217007|Drug|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
260097|NCT02216994|Drug|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
260098|NCT02216994|Behavioral|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
260099|NCT02216994|Drug|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
260100|NCT02216981|Behavioral|Cognitive Behavioural Therapy (CBT)|
260101|NCT02216968|Behavioral|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
260102|NCT02216942|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
260103|NCT02216942|Drug|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
260104|NCT02216916|Drug|HM781-36B|
260105|NCT02216890|Drug|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
260106|NCT02216877|Drug|Mablet 360 mg|
260107|NCT02216877|Drug|Placebo|
260108|NCT02216864|Procedure|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
260109|NCT02216851|Device|Restylane Perlane|Intradermal injection
260110|NCT02216838|Drug|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
260111|NCT02216838|Other|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
260112|NCT02216825|Dietary Supplement|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
260113|NCT02216825|Dietary Supplement|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
260114|NCT02216812|Drug|500 mg vitamin c, 1 pill per day for 6 weeks|
260115|NCT02216812|Drug|1 placebo pill for 6 weeks|
260116|NCT02216799|Drug|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
260117|NCT02216799|Drug|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
260118|NCT02216786|Drug|AZD2014|Oral tablet
260119|NCT02216786|Drug|Everolimus|Oral tablet
260120|NCT02216786|Drug|Fulvestrant|Im injection
260121|NCT02216773|Procedure|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
260122|NCT02216773|Procedure|Portal vein embolization (PVE)|
260123|NCT02216760|Device|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
260124|NCT02216760|Device|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
260125|NCT02216747|Drug|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
260126|NCT02216747|Drug|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
260127|NCT02216747|Drug|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
260128|NCT02216734|Behavioral|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
260129|NCT02216708|Other|Rapid dehydration|
260130|NCT02216708|Other|Slow rehydration|
260131|NCT02216669|Drug|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
260132|NCT02216656|Drug|Placebo|Oral administration
260133|NCT02216656|Drug|KHK7580 low dose|Oral administration
260134|NCT02216656|Drug|KHK7580 middle dose|Oral administration
260135|NCT02216656|Drug|KHK7580 high dose|Oral administration
260136|NCT02216656|Drug|KRN1493|Oral administration
260137|NCT02216643|Procedure|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire and/or thromboaspiration with Penumbra System versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
260138|NCT02216643|Device|Stentriever Solitaire or Penumbra System|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
260139|NCT02216630|Drug|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
260140|NCT02216617|Drug|Taxotere, Cisplatin, Afatinib|
260141|NCT02216604|Behavioral|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
260142|NCT02216591|Device|Active Cognitive Training (ACT)|
260143|NCT02216591|Device|Control (CON)|
260144|NCT02216578|Drug|cabozantinib|Oral
260145|NCT02216565|Other|Hospitalization in specialized neuro-vascular unit|
260146|NCT02216565|Drug|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
260147|NCT02216565|Other|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
260148|NCT02216565|Procedure|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
260149|NCT02216552|Dietary Supplement|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
260150|NCT02216552|Dietary Supplement|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
260366|NCT02215005|Drug|Telmisartan|
260151|NCT02216539|Behavioral|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
260152|NCT02216539|Procedure|Lung transplantation|
260153|NCT02216539|Other|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
260154|NCT02216526|Other|Cetaphil® Restoraderm|
260155|NCT02216526|Other|Excipial|
260156|NCT02216513|Drug|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
260157|NCT02216513|Drug|placebo|normal saline IV for 4 hours for 5 consecutive days
260158|NCT02216500|Dietary Supplement|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
260159|NCT02216487|Drug|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
260160|NCT02216474|Other|Transcranial direct current stimulation|
260161|NCT02216461|Drug|Low dose of BIBW 2948 BS for oral inhalation|
260162|NCT02216461|Drug|Medium dose of BIBW 2948 BS for oral inhalation|
260163|NCT02216461|Drug|High dose of BIBW 2948 BS for oral inhalation|
260164|NCT02216461|Drug|Placebo|
260165|NCT02216448|Other|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
260166|NCT02216448|Other|OR Training|Training on diagnostic knee arthroscopy in the OR
260167|NCT02216422|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
260168|NCT02216422|Drug|Dasabuvir|Tablet
260169|NCT02216422|Drug|Ribavirin (RBV)|Tablet
260170|NCT02216409|Drug|Hu5F9-G4|
260171|NCT02216383|Drug|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
260172|NCT02216383|Drug|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
260173|NCT02216383|Drug|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
260174|NCT02216357|Drug|Ifetroban, Oral Capsule|
260175|NCT02216357|Drug|Placebo, Oral Capsule|
260176|NCT02216331|Drug|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
260177|NCT02216331|Drug|rifapentine|
260178|NCT02216331|Drug|rifampicin|
260179|NCT02216318|Other|blue light|
260180|NCT02216305|Procedure|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorroidal base with absorbable suture
260181|NCT02216305|Procedure|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorroid. Other procedures will not be associated.
260182|NCT02216292|Other|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
260183|NCT02216292|Other|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
260184|NCT02216279|Drug|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
260185|NCT02216266|Drug|Physostigmine|
260186|NCT02216266|Other|Sodium Chloride solution|
260187|NCT02216253|Drug|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
260188|NCT02216253|Other|Placebo|Placebo tablet twice a day 7 days before and after surgery
260189|NCT02216240|Other|Paramedic|
260190|NCT02216240|Other|Standard care|
260191|NCT02216227|Drug|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
260192|NCT02216227|Drug|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
260193|NCT02216227|Drug|Cefazolin|All patients will receive Cefazolin during surgery
260194|NCT02216227|Drug|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
260195|NCT02216227|Drug|Nasal Povidone Iodine|The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
260196|NCT02216214|Drug|Mirabegron|oral tablet
260197|NCT02216214|Drug|Placebo|oral tablet
260198|NCT02216188|Biological|AFFITOPE® PD01A|s.c. injection
260199|NCT02216188|Other|Control|Untreated control group
260200|NCT02216175|Other|SLIT to cow's milk|Sublingual immunotherapy
260201|NCT02216175|Other|Low dose OIT|Oral Immunotherapy (low dose)
260202|NCT02216175|Other|Conventional OIT to cow's milk|Oral Immunotherapy
260203|NCT02216162|Other|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.~A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
260204|NCT02216162|Other|No intervention|Usual clinical follow-up
260205|NCT02216149|Drug|S-1|S-1 25 mg/m2/day BID d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
260206|NCT02216149|Drug|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14, oxaliplatin injection 130 mg/m2 D1 every 3 weeks
260207|NCT02216149|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 D1 every 3 weeks
260208|NCT02216123|Drug|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
260209|NCT02216123|Drug|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
260210|NCT02216123|Drug|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:~tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,~tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
260211|NCT02216123|Drug|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
260212|NCT02216123|Drug|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
260213|NCT02216110|Procedure|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
260214|NCT02216097|Drug|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
260215|NCT02216097|Drug|Placebo|Matching placebo tablet taken once daily for 7 days.
260216|NCT02216084|Drug|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.~Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
260217|NCT02216071|Drug|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
260218|NCT02216071|Drug|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
260219|NCT02216058|Device|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
260220|NCT02216045|Drug|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
260221|NCT02216045|Drug|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
260222|NCT02216032|Other|TMW Curriculum|
260223|NCT02216032|Other|Nutrition Curriculum|
260224|NCT02216019|Other|Whole blood|preoparatoire whole blood and postoperative whole blood
260225|NCT02216006|Procedure|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.~Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
260226|NCT02216006|Procedure|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.~Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.~Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
260227|NCT02215993|Drug|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
260228|NCT02215993|Drug|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
260229|NCT02215980|Drug|Lenalidomide|
260230|NCT02215980|Drug|Dexamethasone|
260231|NCT02215967|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
260232|NCT02215967|Drug|Fludarabine|30 mg/m^2 intravenous (IV) over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
260367|NCT02215005|Drug|Ramipril|
260233|NCT02215967|Biological|Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells|0.3x10^6- 15.0x10^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
260234|NCT02215954|Drug|FE 999169|FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
260235|NCT02215954|Drug|Niflec|Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
260236|NCT02215941|Drug|TV-45070|TV-45070 8% ointment
260237|NCT02215941|Drug|Placebo|Placebo
260238|NCT02215928|Genetic|mutation analysis|Correlative studies
260239|NCT02215928|Other|cytology specimen collection procedure|Correlative studies
260240|NCT02215928|Other|laboratory biomarker analysis|Correlative studies
260241|NCT02215915|Procedure|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
260242|NCT02215915|Procedure|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
260243|NCT02215915|Procedure|DES implantation|
260244|NCT02215902|Device|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
260245|NCT02215889|Procedure|Liver transplantation|
260246|NCT02215876|Drug|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
260247|NCT02215876|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
260248|NCT02215876|Drug|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
260249|NCT02215863|Biological|Fluad and Prevenar13|
260250|NCT02215863|Biological|Fluad|
260251|NCT02215863|Biological|Prevenar13|
260252|NCT02215850|Drug|SLC-0111|
260253|NCT02215837|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
260254|NCT02215837|Biological|Ag-D-CIK|8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
260255|NCT02215824|Drug|BIWH 3|
260256|NCT02215824|Drug|Placebo|
260257|NCT02215811|Biological|Mesenchymal stromal cells|
260258|NCT02215798|Drug|Cymbalta|
260259|NCT02215785|Other|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
260260|NCT02215772|Drug|BI 44370 BS|
260261|NCT02215759|Drug|BI 44370 TA|
260262|NCT02215759|Drug|Placebo|
260263|NCT02215746|Drug|BI 44370 powder for oral solution|
260264|NCT02215746|Drug|BI 44370 tablet|
260265|NCT02215746|Other|high fat breakfast|
260266|NCT02215733|Drug|ARB|other than telmisartan
260267|NCT02215733|Drug|ACEI|
260268|NCT02215733|Drug|Beta-blockers|
260269|NCT02215733|Drug|Diuretics|
260270|NCT02215733|Drug|Telmisartan|
260271|NCT02215720|Drug|Cetuximab|
260272|NCT02215720|Drug|Temsirolimus|
260273|NCT02215707|Biological|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
260274|NCT02215694|Dietary Supplement|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
260275|NCT02215694|Dietary Supplement|placebo|2g of powder daily without probiotics
260276|NCT02215681|Device|acupuncture|
260277|NCT02215668|Procedure|Physical exercise|Exercise muscle stretching and body warming.
260278|NCT02215655|Behavioral|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
260279|NCT02215629|Drug|VS-4718|
260280|NCT02215616|Drug|Laquinimod|Laquinimod capsules will be administered as per the dose and schedule specified in the respective arms.
260281|NCT02215616|Drug|Placebo|Matching laquinimod placebo will be administered as per the schedule specified in the respective arms.
260282|NCT02215603|Behavioral|Breaking prolonged sitting with physical activity|
260283|NCT02215590|Device|Re-Step|"Research Group:~Each session begins with a warm-up exercise, muscle-stretching and strengthening exercises: duration 10 minutes.~Afterwards, walking exercises with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.~At the end of the session 5 min of cool down exercises~20 training sessions of 60 minutes, two/three a week."
260284|NCT02215577|Procedure|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
260285|NCT02215577|Procedure|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
260286|NCT02215538|Drug|OROS methylphenidate|
260287|NCT02215538|Drug|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
260288|NCT02215525|Device|UVA|device uses UVA
260289|NCT02215525|Dietary Supplement|Herbal|Herbal tablets, 1000 mg every 6 hours daily for 6 months
260290|NCT02215512|Drug|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
260291|NCT02215499|Drug|Placebo|
260292|NCT02215499|Drug|Sodium Oxybate|
260293|NCT02215499|Drug|JZP-386|
260294|NCT02215486|Other|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
260295|NCT02215486|Other|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
260296|NCT02215473|Drug|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
260297|NCT02215473|Procedure|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
260298|NCT02215460|Procedure|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260299|NCT02215460|Procedure|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260300|NCT02215460|Drug|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260301|NCT02215460|Drug|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260302|NCT02215460|Drug|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260303|NCT02215460|Drug|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260304|NCT02215460|Drug|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260305|NCT02215460|Drug|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260306|NCT02215460|Drug|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260307|NCT02215460|Drug|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
260308|NCT02215447|Drug|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
260309|NCT02215447|Drug|Carboplatin|
260310|NCT02215434|Drug|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
260311|NCT02215434|Drug|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
260312|NCT02215421|Behavioral|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
260313|NCT02215408|Behavioral|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS followed each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
260314|NCT02215395|Drug|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
260315|NCT02215382|Drug|sugammadex|sugammadex 2 mg/kg
260316|NCT02215382|Drug|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
260317|NCT02215369|Device|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
260318|NCT02215356|Drug|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
260319|NCT02215356|Drug|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
260320|NCT02215343|Dietary Supplement|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R&D Centre Europe).
260321|NCT02215343|Dietary Supplement|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
260322|NCT02215330|Drug|Eplerenone|
260323|NCT02215330|Drug|Maltodextrin|
260324|NCT02215304|Dietary Supplement|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
260325|NCT02215304|Dietary Supplement|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
260326|NCT02215304|Dietary Supplement|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
260327|NCT02215304|Dietary Supplement|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
260328|NCT02215278|Dietary Supplement|10 x 55 g/ bean per arm|
260329|NCT02215265|Drug|Cisplatin|Chemotherapy
260330|NCT02215265|Radiation|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
260331|NCT02215252|Drug|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
260332|NCT02215252|Drug|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
260333|NCT02215252|Drug|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
260334|NCT02215252|Drug|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
260335|NCT02215239|Behavioral|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
260336|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D
260337|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
260338|NCT02215200|Drug|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
260339|NCT02215200|Drug|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
260340|NCT02215200|Drug|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
260341|NCT02215200|Drug|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
260342|NCT02215187|Behavioral|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
260343|NCT02215187|Behavioral|Attention Control|Social contact control (health education/no skill training)
260344|NCT02215174|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
260345|NCT02215161|Drug|Selinexor|Given PO
260346|NCT02215148|Drug|Tolvaptan|
260347|NCT02215135|Drug|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
260348|NCT02215122|Drug|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
260349|NCT02215122|Drug|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
260350|NCT02215122|Drug|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
260351|NCT02215096|Drug|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
260352|NCT02215096|Drug|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
260353|NCT02215083|Dietary Supplement|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
260354|NCT02215070|Drug|Pasireotide + Chemo|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Chemotherapy (Busulfan) will be given 4 days before stem cell transplant.
260355|NCT02215070|Drug|Pasireotide + Total Body Irradiation|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Total Body Irradiation (TBI) will be given 4 days before stem cell transplant.
260356|NCT02215057|Drug|topical anesthesia|topical anesthetic drops and Group 2
260357|NCT02215057|Drug|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
260358|NCT02215044|Drug|BI 2536, intravenous|
260359|NCT02215044|Drug|Gemcitabine, intravenous|
260360|NCT02215031|Drug|BI 44370|
260361|NCT02215031|Drug|Placebo|
260362|NCT02215018|Drug|BI 44370 TA solution|
260363|NCT02215018|Drug|BI 44370 TA tablet|
260364|NCT02215018|Drug|Placebo solution|
260365|NCT02215018|Drug|Placebo tablet|
260368|NCT02214992|Drug|Telmisartan/Ramipril|Fixed dose combination tablet
260369|NCT02214992|Drug|Telmisartan|
260370|NCT02214992|Drug|Ramipril capsule|
260371|NCT02214992|Drug|Ramipril tablet|
260372|NCT02214979|Drug|Telmisartan/Ramipril|fixed dose combination tablet
260373|NCT02214979|Drug|Telmisartan|
260374|NCT02214979|Drug|Ramipril capsule|
260375|NCT02214979|Drug|Ramipril tablet|
260376|NCT02214966|Drug|Telmisartan/Ramipril, fixed dose combination tablet|
260377|NCT02214966|Other|high fat, high caloric meal|
260378|NCT02214953|Drug|BI 11634 ER formulation A|
260379|NCT02214953|Drug|BI 11634 ER formulation B|
260380|NCT02214953|Drug|BI 11634 ER formulation M|
260381|NCT02214953|Drug|BI 11634 ER formulation C|
260382|NCT02214953|Drug|BI 11634 IR tablet|
260383|NCT02214940|Drug|BI 11634|
260384|NCT02214940|Drug|Placebo|
260385|NCT02214927|Drug|BI 11634 tablet|
260386|NCT02214927|Drug|BI 11634 drinking solution|
260387|NCT02214914|Drug|BI 11634 drinking solution|
260388|NCT02214914|Drug|BI 11634 tablet|
260389|NCT02214914|Drug|Placebo|
260390|NCT02214901|Drug|BIBW 2948 BS for oral inhalation|
260391|NCT02214901|Drug|Placebo|
260392|NCT02214888|Drug|BIRB 796 BS, low dose|
260393|NCT02214888|Drug|BIRB 796 BS, high dose|
260394|NCT02214888|Drug|Placebo|
260395|NCT02214875|Other|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
260396|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
260397|NCT02214862|Drug|[F18]-FDDNP|radiopharmaceutical tracer
260398|NCT02214849|Behavioral|LATCH Intervention|
260399|NCT02214836|Device|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
260400|NCT02214823|Device|FES-Cycling|
260401|NCT02214823|Other|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
260402|NCT02214810|Drug|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
260403|NCT02214797|Device|Etafilcon A, Lotrafilcon B , Senofilcon A|
260404|NCT02214784|Device|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
260405|NCT02214784|Device|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
260406|NCT02214771|Drug|Fidaxomicin|oral
260407|NCT02214771|Drug|Treatment for CDI other than fidaxomicin Type|Oral
260408|NCT02214758|Other|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
260409|NCT02214745|Other|Questionnaire|Questionnaire developed for this purpose by the investigators
260410|NCT02214732|Behavioral|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
260411|NCT02214719|Behavioral|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
260412|NCT02214706|Drug|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
260413|NCT02214706|Other|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
260414|NCT02214706|Device|Pulsed Dye Laser|
260415|NCT02214693|Drug|DA-1229|
260578|NCT02213497|Radiation|18F-FDG (Fluorodeoxyglucose) PET|
260579|NCT02213497|Drug|Carboplatin|
260580|NCT02213497|Drug|Paclitaxel|
260416|NCT02214680|Drug|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
260417|NCT02214680|Drug|Timolol|0.5% eye drop
260418|NCT02214667|Behavioral|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
260419|NCT02214667|Behavioral|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
260420|NCT02214667|Behavioral|Jail and community-based behavioral health services|Existing behavioral health service programs
260421|NCT02214641|Behavioral|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
260422|NCT02214641|Behavioral|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
260423|NCT02214628|Drug|Fovista® (anti-PDGF BB) plus anti-VEGF|
260424|NCT02214615|Drug|Carbamazepine|"Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.~Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days."
260425|NCT02214615|Drug|Placebo|
260426|NCT02214602|Drug|Epirubicin|"Experimental: Study group(Epirubicin)~in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
260427|NCT02214589|Other|Oral glucose, facilitated tucking, NNS|
260428|NCT02214589|Other|Oral glucose and NNS|
260429|NCT02214589|Other|Facilitated tucking and NNS|
260430|NCT02214563|Dietary Supplement|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
260431|NCT02214563|Dietary Supplement|Olive oil|
260432|NCT02214550|Drug|microgestin 1/20|"Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat~Continuous OC use - Pills containing hormones will be taken every day for 1 year"
260433|NCT02214537|Other|MACS|
260434|NCT02214524|Device|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
260435|NCT02214511|Behavioral|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
260436|NCT02214511|Behavioral|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
260437|NCT02214498|Drug|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
260438|NCT02214498|Drug|Placebo|
260439|NCT02214485|Behavioral|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
260440|NCT02214485|Behavioral|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
260441|NCT02214472|Behavioral|Biofeedback|
260442|NCT02214472|Drug|Placebo|
260443|NCT02214459|Behavioral|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
260444|NCT02214433|Drug|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
260445|NCT02214433|Drug|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
260446|NCT02214433|Drug|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
260447|NCT02214433|Drug|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
260448|NCT02214433|Drug|Debio 1450 Capsule|Debio 1450 40 mg capsules
260449|NCT02214433|Drug|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
260450|NCT02214433|Drug|Pantoprazole|Pantoprazole 40 mg orally
260451|NCT02214420|Drug|Simeprevir|
260452|NCT02214420|Drug|Sofosbuvir|
260453|NCT02214420|Drug|Ribavirin|
260618|NCT02213172|Dietary Supplement|Bifidobacterium longum R0175|
260619|NCT02213172|Dietary Supplement|Lactobacillus paracasei HA-196|
260454|NCT02214407|Drug|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
260455|NCT02214407|Drug|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.~Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
260456|NCT02214394|Other|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
260457|NCT02214394|Device|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
260458|NCT02214381|Drug|Myocet|
260459|NCT02214381|Drug|Cyclophosphamide|
260460|NCT02214381|Drug|Paclitaxel|
260461|NCT02214368|Other|Early application of NIV|"Device:BiPAP Vision.~NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
260462|NCT02214368|Device|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
260463|NCT02214368|Drug|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).~NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).~In the conventional treatment group: No intervention."
260464|NCT02214368|Other|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2> 0.5 or breathing at least 10 L/min oxygen.
260465|NCT02214342|Other|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
260466|NCT02214329|Device|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
260467|NCT02214329|Other|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
260468|NCT02214316|Other|Hypertonic Saline|
260469|NCT02214290|Drug|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
260470|NCT02214290|Drug|Placebo|A 750 gram placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
260471|NCT02214290|Dietary Supplement|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
260472|NCT02214277|Device|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
260473|NCT02214277|Device|TAVR|
260474|NCT02214264|Behavioral|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
260475|NCT02214264|Behavioral|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
260476|NCT02214264|Behavioral|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
260477|NCT02214264|Behavioral|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
260478|NCT02214251|Device|PK-16CH EXG system|
260479|NCT02214238|Device|PAP device|
260480|NCT02214225|Biological|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
260481|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
260482|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
260483|NCT02214212|Device|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
260484|NCT02214212|Device|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
260485|NCT02214199|Other|Manipulative Therapy Techniques|
260486|NCT02214199|Other|Home Exercises|
260487|NCT02214186|Other|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
260488|NCT02214173|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
260489|NCT02214173|Dietary Supplement|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
260490|NCT02214160|Drug|UX007|Administered orally (PO) with food or by gastronomy tube, at the target dose range of 25-35% of total calories.
260491|NCT02214147|Drug|Alisertib|Alisertib will be supplied as enteric coated tablets.
260492|NCT02214134|Genetic|Tumour markers testing|
260493|NCT02214121|Drug|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
260494|NCT02214121|Drug|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
260495|NCT02214108|Other|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
260496|NCT02214095|Drug|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
260497|NCT02214095|Drug|lactose capsules|
260498|NCT02214082|Other|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
260499|NCT02214069|Device|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
260500|NCT02214056|Other|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
260501|NCT02214056|Procedure|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
260502|NCT02214030|Device|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
260503|NCT02214017|Device|A videotelephone, TandBerg E20,|
260504|NCT02214017|Behavioral|Behavioral motivation|Optimization of medical care in diabetes
260505|NCT02214004|Drug|Trastuzumab|"- Eight times IV administration of trastuzumab per 3 weeks~Trastuzumab 8mg/kg on Day 1 of Cycle 1~Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
260506|NCT02214004|Drug|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
260507|NCT02213991|Device|Intraoperative radiotherapy using Intrabeam®|"Operation day~Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.~Purse string suture pulles up tissues and wraps up the applicator.~Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.~After IORT, applicator was out of the operative field, and usual wound closure will be done.~Postoperative period~Chemotherapy WBRT (46 Gy) for 4~5 weeks~Endocrine therapy or target therapy"
260508|NCT02213965|Device|Peripheral IV catheter|Intravenous access according to Instructions For Use
260509|NCT02213952|Drug|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
260510|NCT02213952|Other|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
260511|NCT02213926|Drug|ACP-196 (acalabrutinib)|
260512|NCT02213913|Drug|lenalidomide|Given PO
260513|NCT02213913|Drug|etoposide|Given IV
260514|NCT02213913|Drug|prednisone|Given PO
260515|NCT02213913|Drug|vincristine sulfate|Given IV
260516|NCT02213913|Drug|doxorubicin hydrochloride|Given IV
260517|NCT02213913|Drug|cyclophosphamide|Given IV
260518|NCT02213913|Biological|rituximab|Given IV
260519|NCT02213913|Other|quality-of-life assessment|Ancillary studies
260520|NCT02213913|Other|laboratory biomarker analysis|Correlative studies
260521|NCT02213900|Drug|Haloperidol|0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
260522|NCT02213900|Drug|Placebo|
260523|NCT02213887|Drug|Pantoprazole|40 mg PO QAM
260524|NCT02213887|Drug|Pantoprazole|0 mg PO QAM
260525|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
260526|NCT02213861|Drug|SHAPE|topical gel
260527|NCT02213848|Drug|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
260528|NCT02213848|Drug|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
260529|NCT02213835|Other|Specific Carbohydrate diet (SCD)|
260576|NCT02213510|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
260620|NCT02213172|Other|Placebo|
260530|NCT02213822|Other|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
260531|NCT02213809|Behavioral|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
260532|NCT02213809|Behavioral|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
260533|NCT02213796|Drug|Meropenem|
260534|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
260535|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
260536|NCT02213757|Drug|Premarin vaginal estrogen cream|
260537|NCT02213757|Drug|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
260538|NCT02213744|Drug|MM-302|
260539|NCT02213744|Drug|Gemcitabine|
260540|NCT02213744|Drug|Capecitabine|
260541|NCT02213744|Drug|Vinorelbine|
260542|NCT02213744|Drug|Trastuzumab|
260543|NCT02213731|Other|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
260544|NCT02213718|Drug|Desflurane|desflurane (7%-8% end-tidal concentration)
260545|NCT02213718|Drug|propofol|propofol (TCI:3.5-4.0μg/min)
260546|NCT02213718|Drug|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
260547|NCT02213705|Biological|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
260548|NCT02213679|Dietary Supplement|Guanidinoacetic acid|Dietary supplement
260549|NCT02213679|Other|Placebo|Placebo
260550|NCT02213666|Device|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
260551|NCT02213653|Drug|ARM A : IV iron + epoietin zeta|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously~Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
260552|NCT02213653|Drug|ARM B: IV iron + epoietin zeta sequence|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7~carboxymaltose ferric (Ferinject ®) at week 1~Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).~Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
260553|NCT02213653|Drug|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
260554|NCT02213640|Device|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
260555|NCT02213640|Device|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
260556|NCT02213627|Drug|Corifollitropin alfa|
260557|NCT02213627|Drug|Recombinant FSH|
260558|NCT02213627|Drug|HP-hMG|
260559|NCT02213614|Dietary Supplement|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
260560|NCT02213614|Dietary Supplement|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
260561|NCT02213614|Other|natural spring water|A group will drink natural spring water for 4 months
260562|NCT02213601|Behavioral|Yoga|
260563|NCT02213588|Dietary Supplement|AOX blend|Antioxidant supplement
260564|NCT02213588|Dietary Supplement|Placebo|
260565|NCT02213575|Drug|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
260566|NCT02213562|Dietary Supplement|200 mg of chrysanthemum flower oil|
260567|NCT02213562|Dietary Supplement|300 mg of chrysanthemum flower oil|
260568|NCT02213562|Dietary Supplement|400 mg of chrysanthemum flower oil|
260569|NCT02213549|Dietary Supplement|Placebo|
260570|NCT02213549|Dietary Supplement|Ume paste and ginger powder|
260571|NCT02213536|Radiation|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
260572|NCT02213523|Dietary Supplement|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
260573|NCT02213523|Dietary Supplement|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
260574|NCT02213523|Dietary Supplement|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
260575|NCT02213523|Dietary Supplement|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
260577|NCT02213510|Device|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
260581|NCT02213458|Behavioral|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
260582|NCT02213432|Biological|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
260583|NCT02213419|Drug|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.~The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
260584|NCT02213406|Dietary Supplement|yogurt|Subjects will receive yogurt with varying fat concentrations
260585|NCT02213393|Dietary Supplement|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
260586|NCT02213393|Dietary Supplement|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
260587|NCT02213380|Procedure|method of anesthesia|"Method of anesthesia includes: general anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA"
260588|NCT02213367|Drug|Bilastine|20mg (8 weeks)
260589|NCT02213367|Drug|Bilastine|40mg
260590|NCT02213367|Drug|Bilastin|80mg
260591|NCT02213354|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
260592|NCT02213354|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
260593|NCT02213341|Procedure|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
260594|NCT02213341|Procedure|Blood draw|
260595|NCT02213328|Drug|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
260596|NCT02213315|Drug|100mg Mavrilimumab|100mg Mavrilimumab
260597|NCT02213315|Drug|150mg mavrilimumab|150mg mavrilmumab
260598|NCT02213315|Other|Placebo|Placebo
260599|NCT02213302|Drug|placebo administration|
260600|NCT02213302|Drug|midazolam intravenous administration|
260601|NCT02213289|Drug|Trastuzumab|HER2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line) + Trastuzumab
260602|NCT02213289|Drug|ABT-806|EGFR Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ ABT-806
260603|NCT02213289|Drug|TBD2|FGFR2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ TBD2
260604|NCT02213289|Drug|Ramucirumab|VEGFR2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ Ramucirumab
260605|NCT02213289|Drug|Nivolumab|MSI-H Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ Nivolumab
260606|NCT02213276|Other|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
260607|NCT02213276|Other|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
260608|NCT02213263|Biological|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
260609|NCT02213263|Biological|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
260610|NCT02213250|Drug|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
260611|NCT02213224|Drug|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
260612|NCT02213224|Drug|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
260613|NCT02213224|Drug|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
260614|NCT02213211|Drug|Artemether lumefantrine|
260615|NCT02213198|Behavioral|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
260616|NCT02213198|Behavioral|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
260617|NCT02213185|Other|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
260621|NCT02213159|Drug|Dexmedetomidine|
260623|NCT02213146|Drug|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
260624|NCT02213146|Drug|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
260625|NCT02213146|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
260626|NCT02213133|Drug|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly.
260627|NCT02213107|Drug|Enzalutamide and Dutasteride|Enzalutamide by mouth daily. Dutasteride by mouth daily.
260628|NCT02213094|Drug|Nicotinamide 500 mg|Nicotinamide 500 mg taken by mouth each morning
260629|NCT02213094|Drug|Nicotinamide 1000 mg|Nicotinamide 1000 mg taken by mouth each morning
260630|NCT02213081|Drug|Ulipristal|Patients will take 15mg every other day, or every 4 days per week.
260631|NCT02213068|Drug|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
260632|NCT02213068|Drug|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
260633|NCT02213068|Drug|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
260634|NCT02213055|Drug|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
260635|NCT02213055|Drug|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
260636|NCT02213042|Drug|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm are to receive 1000 mg per day of Lapatinib, so will be instructed to take 4 x 250 mg tablets per day. Lapatinib should be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
260637|NCT02213042|Biological|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab will be administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab will be administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab can be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg)
260638|NCT02213029|Drug|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
260639|NCT02213029|Drug|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
260640|NCT02213029|Drug|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
260641|NCT02213029|Drug|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson & Johnson
260642|NCT02213016|Device|Transcranial Magnetic Stimulation|
260643|NCT02213016|Device|Sham Transcranial Magnetic Stimulation|
260644|NCT02213003|Biological|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
260645|NCT02212990|Other|Acetaminophen Arm|Blinded Therapy
260646|NCT02212990|Other|Placebo Arm|Blinded Therapy
260647|NCT02212990|Other|Ibuprofen Arm|Open Label Therapy
260648|NCT02212977|Device|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
260649|NCT02212977|Procedure|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
260650|NCT02212951|Drug|BIOD-531|
260651|NCT02212951|Drug|Humalog Mix 75/25|
260652|NCT02212951|Drug|Humulin R U-500|
260653|NCT02212938|Drug|BI 14332 CL|
260654|NCT02212938|Other|high fat breakfast|
260655|NCT02212925|Drug|BI 14332 CL|
260656|NCT02212925|Drug|Placebo|
260657|NCT02212912|Behavioral|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.~The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
260658|NCT02212912|Behavioral|no intervention|No intervention indicated that the physicians among control hospital provide routine
260659|NCT02212886|Drug|GA Depot 80 mg|Recruitment completed
260660|NCT02212886|Drug|GA Depot 40 mg|Recruitment completed
260661|NCT02212873|Other|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
260739|NCT02212301|Device|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
260662|NCT02212860|Radiation|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (single dose, 21 Gy) followed by lumpectomy for stage I and IIA early stage breast carcinoma
260663|NCT02212847|Other|vestibular stimulation|
260664|NCT02212821|Drug|Erythromycin|
260665|NCT02212821|Drug|Placebo|physiological saline
260666|NCT02212808|Other|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
260667|NCT02212808|Other|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
260668|NCT02212795|Drug|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
260669|NCT02212795|Drug|Levofloxacin 250mg|Levofloxacin 250mg single dose
260670|NCT02212795|Drug|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
260671|NCT02212782|Drug|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
260672|NCT02212782|Drug|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
260673|NCT02212769|Drug|Losartan 50mg|Losartan 50mg once daily for 7 days
260674|NCT02212769|Drug|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
260675|NCT02212756|Drug|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
260676|NCT02212756|Drug|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
260677|NCT02212730|Drug|Pembrolizumab Pre-Resection|Up to 3 doses of 200 mg, administered by IV, every 3 weeks
260678|NCT02212730|Procedure|Surgical Resection|Standard of care surgical resection of RCC tumor
260679|NCT02212730|Drug|Pembrolizumab Post-Resection|Up to 17 doses of 200 mg, administered by IV, every 3 weeks
260680|NCT02212717|Procedure|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
260681|NCT02212717|Procedure|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
260682|NCT02212704|Other|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
260683|NCT02212704|Other|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
260684|NCT02212704|Other|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
260685|NCT02212678|Drug|N-acetylcysteine capsule|N-acetylcysteine capsule
260686|NCT02212665|Behavioral|High intense interval training|
260687|NCT02212665|Behavioral|Increased daily activity detected by the pedometer|
260688|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+HIIT|
260689|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+group intervention|
260690|NCT02212652|Dietary Supplement|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
260691|NCT02212652|Other|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
260692|NCT02212652|Other|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
260693|NCT02212639|Drug|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
260694|NCT02212626|Device|Rotarex S|
260695|NCT02212613|Drug|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
260696|NCT02212600|Other|Observational|observational cohort of proximal humerus fractures
260697|NCT02212587|Drug|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
260698|NCT02212574|Drug|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
260699|NCT02212574|Drug|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
260700|NCT02212574|Drug|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
260701|NCT02212574|Drug|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
260702|NCT02212574|Drug|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
260740|NCT02212288|Other|Blood sample|Blood samples are for metabolic and genetic and biological investigation
260782|NCT02211937|Other|high fat breakfast|
260703|NCT02212574|Drug|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
260704|NCT02212561|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
260705|NCT02212561|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
260706|NCT02212561|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
260707|NCT02212561|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
260708|NCT02212548|Device|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
260709|NCT02212535|Drug|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
260710|NCT02212522|Other|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
260711|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
260712|NCT02212522|Other|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
260713|NCT02212522|Other|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
260714|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
260715|NCT02212483|Other|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
260716|NCT02212483|Other|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
260717|NCT02212483|Other|Final home visit|"Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices."
260718|NCT02212470|Device|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
260719|NCT02212470|Device|Nitinol stenting|Nitinol stent deployment
260720|NCT02212457|Biological|Bexsero|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
260721|NCT02212457|Other|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
260722|NCT02212457|Biological|Havrix|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
260723|NCT02212457|Biological|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
260724|NCT02212444|Device|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
260725|NCT02212444|Device|Off -the-shelf triplanar orthoses|
260726|NCT02212431|Drug|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
260727|NCT02212418|Other|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
260728|NCT02212405|Device|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
260729|NCT02212405|Other|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
260730|NCT02212392|Drug|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
260731|NCT02212379|Drug|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.~Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
260732|NCT02212366|Device|Active TDCS|Active Stimulation
260733|NCT02212366|Device|Sham TDCS|Sham Stimulation
260734|NCT02212353|Other|Observational study, not interventional|
260735|NCT02212340|Drug|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
260736|NCT02212340|Drug|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
260737|NCT02212314|Behavioral|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
260738|NCT02212301|Device|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
260741|NCT02212288|Other|Urine sample|Urine sample for biological investigation
260742|NCT02212275|Drug|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
260743|NCT02212249|Biological|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
260744|NCT02212236|Other|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
260745|NCT02212223|Dietary Supplement|Vitamin D3|
260746|NCT02212210|Drug|Methylprednisolone|
260747|NCT02212210|Drug|Normal saline|
260748|NCT02212197|Drug|leuprolide acetate FluidCrystal® injection depot|
260749|NCT02212197|Drug|leuprolide acetate|
260750|NCT02212184|Other|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
260751|NCT02212184|Other|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
260752|NCT02212171|Other|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.~Administrative staff:~Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.~Nursing staff:~They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.~GP:~They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
260753|NCT02212158|Behavioral|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
260754|NCT02212132|Other|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
260755|NCT02212119|Drug|Botulinum Toxin|
260756|NCT02212119|Drug|Saline|
260757|NCT02212106|Biological|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
260758|NCT02212106|Biological|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
260759|NCT02212080|Drug|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
260760|NCT02212080|Drug|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
260761|NCT02212067|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
260762|NCT02212067|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
260763|NCT02212054|Behavioral|conservative|anal dilatation; colonic lavage; oral probiotic
260764|NCT02212054|Procedure|operative|one stage pull through radical colectomy
260765|NCT02212041|Other|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
260766|NCT02212028|Drug|prasugrel|the effects of whole tablets versus crushed tablets will be compared
260767|NCT02212015|Drug|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
260768|NCT02212002|Drug|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
260769|NCT02211989|Drug|BI 14332 CL|
260770|NCT02211989|Drug|Placebo|
260771|NCT02211976|Drug|Bisacodyl|
260772|NCT02211976|Drug|Simeticone|
260773|NCT02211963|Drug|BI 44847|
260774|NCT02211963|Drug|Placebo|
260775|NCT02211950|Drug|BI 44847|
260776|NCT02211950|Drug|Acarbose|
260777|NCT02211950|Other|Japanese diet|
260778|NCT02211937|Drug|BI 44847 solution, low dose|
260779|NCT02211937|Drug|BI 44847 suspension, high dose|
260780|NCT02211937|Drug|BI 44847 tablet, low dose|
260781|NCT02211937|Drug|BI 44847 tablet, high dose|
260788|NCT02211885|Drug|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
260789|NCT02211872|Drug|BI 2536 BS, intravenous|
260790|NCT02211859|Drug|BI 2536|
260791|NCT02211846|Drug|Mirabegron|oral
260792|NCT02211833|Drug|BI 2536|
260793|NCT02211833|Drug|Pemetrexed|
260794|NCT02211794|Other|data collection|
260795|NCT02211768|Procedure|MRI, FDG-PET/CT scans|Standard of care to be obtained as part of the study
260796|NCT02211768|Drug|[18F]-FLT-PET/CT scans|FLT PET to be performed as a research imaging study as it is not considered standard imaging in NF1
260797|NCT02211755|Drug|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
260798|NCT02211742|Drug|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
260799|NCT02211729|Drug|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
260800|NCT02211729|Drug|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin|Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
260801|NCT02211716|Device|BeGraft Peripheral Stent Graft System|
260802|NCT02211690|Drug|dolutegravir 50 mg (one tablet daily)|
260803|NCT02211690|Drug|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
260804|NCT02211664|Device|Passeo-18 balloon|
260805|NCT02211664|Device|Passeo-18 Lux drug releasing balloon|
260806|NCT02211664|Device|Pulsar-18 stent|
260807|NCT02211638|Drug|Candesartan Cilexetil|Candesartan Cilexetil tablet
260808|NCT02211625|Drug|Open-label TRV734 125 mg|125 mg
260809|NCT02211625|Drug|TRV734 blinded|blinded, multiple ascending dose
260810|NCT02211625|Drug|Oxycodone IR 10 mg|
260811|NCT02211625|Drug|Placebo|TRV734-matched and oxycodone placebo
260812|NCT02211612|Dietary Supplement|PUFA-group|
260813|NCT02211612|Dietary Supplement|SFA-group|
260814|NCT02211599|Other|15% protein|Meal to provide 15%en from protein.
260815|NCT02211599|Other|30% protein|Meal to provide 30%en from protein.
260816|NCT02211599|Other|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
260817|NCT02211573|Other|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
260818|NCT02211560|Other|Phosphatidylserine|
260819|NCT02211560|Other|Placebo|
260820|NCT02211547|Device|Epic 10 Diode Laser by Biolase Inc.|
260821|NCT02211547|Other|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
260822|NCT02211534|Device|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
260823|NCT02211534|Device|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
260824|NCT02211521|Biological|PRP|3ml of PRP
260825|NCT02211521|Drug|Hyaluronic acid|3ml hyaluronic acid
260826|NCT02211508|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
260827|NCT02211495|Device|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
260828|NCT02211495|Other|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
260829|NCT02211482|Drug|dolutegravir, lamivudine|single arm
260830|NCT02211469|Drug|BMS-986104|
260831|NCT02211469|Drug|Placebo|
260832|NCT02211456|Procedure|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
260833|NCT02211443|Biological|Recombinant full human Anti-EGFR Monoclonal Antibody|
260834|NCT02211430|Behavioral|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
260835|NCT02211430|Behavioral|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
260836|NCT02211417|Drug|DS107G|
260837|NCT02211417|Drug|Placebo|
260838|NCT02211391|Other|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
260839|NCT02211391|Other|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
260840|NCT02211378|Other|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
260841|NCT02211378|Other|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
260842|NCT02211352|Drug|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
260843|NCT02211352|Drug|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
260844|NCT02211339|Behavioral|Peer facilitator training|Peer facilitation of a project-based activity without staff present
260845|NCT02211339|Other|Usual care|Staff-led social activity
260846|NCT02211326|Behavioral|Genotype-guided dosing algorithm for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.The overall follow-up period is 12 weeks.
260847|NCT02211326|Behavioral|Standard initiation dose for warfarin|Intervention：initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.The overall follow-up period is 12 weeks.
260848|NCT02211313|Device|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
260849|NCT02211300|Device|The OptiScanner|treatment of blood glucose per standard of care
260850|NCT02211300|Device|YSI 2300 STAT Plus™|
260851|NCT02211287|Other|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q&A form and can help answer frequent family questions.
260852|NCT02211287|Other|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
260853|NCT02211274|Other|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
260854|NCT02211261|Biological|PF-06293620|subcutaneous, single dose 0.3 mg/kg
260855|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
260856|NCT02211261|Biological|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
260857|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
260858|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 3 mg/kg
260859|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
260860|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 6 mg/kg
260861|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
260862|NCT02211261|Biological|PF-06293620|Intravenous infusion single dose 1 mg/kg
260863|NCT02211261|Biological|Placebo|Intravenous infusion normal saline single dose
260864|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
260865|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
260866|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
260867|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
260868|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
260869|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
260870|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
260871|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
260872|NCT02211248|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
260873|NCT02211248|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
260874|NCT02211222|Drug|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
260875|NCT02211209|Drug|volanesorsen|
260876|NCT02211209|Drug|Placebo|
260877|NCT02211196|Behavioral|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
260878|NCT02211196|Other|survey administration|Ancillary studies
260879|NCT02211196|Other|questionnaire administration|Ancillary studies
260880|NCT02211183|Procedure|Best Repair of torn Rotator Cuff|
260881|NCT02211183|Device|InSpace™ system|
260882|NCT02211170|Drug|BIBR 796 BS, low dose|
260883|NCT02211170|Drug|BIBR 796 BS, high dose|
260885|NCT02211170|Drug|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
260886|NCT02211157|Drug|BIBR 796 BS|
260887|NCT02211157|Drug|Placebo|
260888|NCT02211157|Other|high fat breakfast|
260889|NCT02211144|Drug|BIBR 796 BS|
260890|NCT02211144|Drug|Placebo|
260891|NCT02211131|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
260892|NCT02211131|Procedure|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
260893|NCT02211118|Drug|Intranasal dexemdetomidine (IN-DEX)|
260894|NCT02211092|Behavioral|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
260895|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
260896|NCT02211079|Drug|JNJ-54861911|JNJ-54861911, 50 mg (2*25 mg tablets) orally once daily from Day 2 to Day 9.
260897|NCT02211079|Drug|Caffeine|Single oral dose of caffeine 100 mg (2*50 mg tablets), on Day 1, 2, and 9.
260898|NCT02211079|Drug|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
260899|NCT02211079|Drug|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
260900|NCT02211066|Drug|Clopidogrel|
260901|NCT02211066|Drug|Ticagrelor|
260902|NCT02211053|Drug|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
260903|NCT02211053|Drug|placebo|
260904|NCT02211040|Behavioral|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.~Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.~In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.~Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.~In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
260905|NCT02211027|Biological|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.~Patients will have vaccinations administered at 4 different sites as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
260906|NCT02211014|Drug|acalabrutinib|
260907|NCT02211001|Other|Pilates Group|The exercises were applied once a week during eight weeks.
260908|NCT02211001|Other|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
260909|NCT02211001|Other|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
260910|NCT02210988|Other|acupuncture|
260911|NCT02210988|Device|acupuncture|experimental
260912|NCT02210988|Device|Acupuncture|
260913|NCT02210975|Device|LES-Stimulation Device|
260914|NCT02210962|Dietary Supplement|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
260915|NCT02210962|Dietary Supplement|olive oil|Yellow capsules containing olive oil (placebo)
260916|NCT02210949|Drug|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
260917|NCT02210936|Other|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.~We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
260918|NCT02210910|Device|InSpace™ system over repair|
260919|NCT02210910|Procedure|Best Repair of torn Rotator Cuff|
260920|NCT02210884|Dietary Supplement|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
260921|NCT02210871|Drug|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
260922|NCT02210858|Other|Laboratory Biomarker Analysis|Correlative studies
260923|NCT02210858|Drug|Tipifarnib|Given PO
260924|NCT02210845|Behavioral|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
260925|NCT02210845|Behavioral|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
260926|NCT02210845|Other|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
260927|NCT02210832|Behavioral|Best practices|
260928|NCT02210832|Behavioral|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
260929|NCT02210819|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
260977|NCT02210520|Device|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
260930|NCT02210819|Drug|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
260931|NCT02210806|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
260932|NCT02210806|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
260933|NCT02210806|Other|Placebo DPI|Placebo, 1 inhalation
260934|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
260935|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
260936|NCT02210793|Procedure|transepithelial PRK|
260937|NCT02210793|Procedure|LASIK|
260938|NCT02210780|Drug|Dupilumab|Administered via subcutaneous injection.
260939|NCT02210780|Drug|placebo|An inactive substance containing no medicine administered via subcutaneous injection
260940|NCT02210767|Other|Walnut Diet|2 oz. walnuts/day (2-3% of total calories from ALA)
260941|NCT02210767|Other|Walnut Control Diet|2-3% ALA but no walnuts provided
260942|NCT02210767|Other|Low ALA Diet|ALA replaced by oleic acid
260943|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
260944|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
260945|NCT02210754|Other|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
260946|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
260947|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
260948|NCT02210754|Other|Marlboro Cigarette|cigarettes
260949|NCT02210728|Drug|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
260950|NCT02210728|Behavioral|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
260951|NCT02210715|Drug|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
260952|NCT02210715|Other|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
260953|NCT02210702|Drug|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
260954|NCT02210702|Drug|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
260955|NCT02210689|Drug|clindamycin phosphate vaginal cream 2%|
260956|NCT02210676|Other|PROMIS Upper Extremity|
260957|NCT02210676|Other|Likert Pain Scale|
260958|NCT02210676|Other|Mallet Finger Extensor Lag Measurement|
260959|NCT02210663|Drug|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
260960|NCT02210650|Procedure|Ureteral stone removal|Ureteral stone removal by the surgical procedure called Ureteroscopy
260961|NCT02210650|Procedure|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and Ureteral stone removal by the surgical procedure called Ureteroscopy
260962|NCT02210624|Biological|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
260963|NCT02210611|Procedure|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
260964|NCT02210611|Procedure|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
260965|NCT02210598|Device|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
260966|NCT02210598|Device|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
260967|NCT02210598|Drug|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
260968|NCT02210585|Other|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)~92 weeks : spontaneous training (supervised by phone every month)"
260969|NCT02210572|Dietary Supplement|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
260970|NCT02210572|Dietary Supplement|Low- FODMAPs diet|
260971|NCT02210559|Drug|FG-3019|FG-3019 is administered in TREATMENT ARM A ONLY on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion. The dose level is 35 mg/kg.
260972|NCT02210559|Drug|Gemcitabine|Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 1000 mg/m2.
260973|NCT02210559|Drug|Nab-paclitaxel|Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 125 mg/m2.
260974|NCT02210546|Other|Magnetic Resonance Imaging (MRI)|
260975|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|
260976|NCT02210520|Device|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
260978|NCT02210520|Device|laser|1 W/cm², 2 minutes in 6 points around the back spine
260979|NCT02210507|Other|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
260980|NCT02210507|Other|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
260981|NCT02210507|Other|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
260982|NCT02210494|Drug|Secretrol|
260983|NCT02210468|Device|APIC-CF, 4 cc|
260984|NCT02210468|Device|APIC-CF, 2 cc|
260985|NCT02210468|Other|Placebo Comparator: Saline|Placebo Comparator: Saline
260986|NCT02210455|Behavioral|Strongest Families FASD intervention|
260987|NCT02210455|Other|Psychoeducation|
260988|NCT02210442|Behavioral|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
260989|NCT02210442|Other|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
260990|NCT02210429|Procedure|Elbow Fracture Fixation|
260991|NCT02210416|Procedure|inguinal hernia surgery|
260992|NCT02210403|Device|transcranial direct current stimulation (tDCS)|
260993|NCT02210390|Behavioral|Psycho education|Psycho-education Sessions will be offered weekly basis
260994|NCT02210377|Other|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
260995|NCT02210377|Other|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
260996|NCT02210364|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
260997|NCT02210364|Drug|capecitabine|capecitabine 150 mg tablets
260998|NCT02210351|Device|MRI test|
260999|NCT02210338|Device|Karl Storz C-MAC|
261000|NCT02210338|Device|Bonfils Intubation Fibrescope|
261001|NCT02210325|Drug|solithromycin|
261002|NCT02210325|Drug|ceftriaxone|
261003|NCT02210325|Drug|azithromycin|
261004|NCT02210299|Other|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
261005|NCT02210286|Dietary Supplement|Magtein|
261006|NCT02210273|Device|Solace Bladder Control (Vesair) Balloon|Subjects may undergo treatment every 12 months until study completion.
261007|NCT02210273|Device|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control (Vesair) Balloon
261008|NCT02210260|Procedure|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.~PLUS~Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
261009|NCT02210260|Procedure|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
261010|NCT02210260|Drug|Bupivacaine|
261011|NCT02210260|Drug|Diamorphine|500mcg
261012|NCT02210260|Device|A Painbuster® catheter|
261013|NCT02210260|Device|25G Whitacre needle|
261014|NCT02210247|Drug|EXPAREL|
261015|NCT02210234|Dietary Supplement|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
261016|NCT02210234|Dietary Supplement|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
261017|NCT02210208|Device|Mepitel® Ag|"A soft silicone wound contact layer that allows exudates to pass vertically into a secondary absorbent dressing. The product provides fixation and protection of the tissues and has antimicrobial properties.~This silicone net dressing will be used to prevent lifting and adherence of skin grafts to the dressings, as well as to prevent pain, and promote healing."
261018|NCT02210208|Device|Mepilex® Transfer Ag|"Mepilex® Transfer Ag is a soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.~Mepilex® Transfer Ag consists of a Safetac® adhesive layer and compressed polyurethane foam containing silver sulphate and activated carbon. Safetac® is a unique adhesive technology that minimizes pain to patients and trauma to wounds and the surrounding skin. It minimizes risk for maceration by sealing the wound margins; ensuring exudate does not spread to the surrounding skin."
261019|NCT02210195|Drug|aprepitant|125 mg daily for 8 weeks.
261020|NCT02210195|Drug|Placebo|Placebo daily for 8 weeks.
261021|NCT02210195|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
261022|NCT02210182|Drug|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
261023|NCT02210182|Other|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
261024|NCT02210169|Drug|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
261079|NCT02209753|Drug|BIRB 796 BS, high dose|
261080|NCT02209753|Drug|Placebo|
261081|NCT02209740|Other|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
261025|NCT02210156|Dietary Supplement|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
261026|NCT02210156|Other|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
261027|NCT02210117|Biological|Bevacizumab|Given IV
261028|NCT02210117|Procedure|Biopsy|Undergo biopsy
261029|NCT02210117|Biological|Ipilimumab|Given IV
261030|NCT02210117|Other|Laboratory Biomarker Analysis|Correlative studies
261031|NCT02210117|Procedure|Metastasectomy|Undergo metastasectomy
261032|NCT02210117|Biological|Nivolumab|Given IV
261033|NCT02210117|Procedure|Therapeutic Conventional Surgery|Undergo nephrectomy
261034|NCT02210104|Drug|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
261035|NCT02210104|Drug|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
261036|NCT02210104|Biological|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10^10 cells/m^2 on Day 0.
261037|NCT02210091|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
261038|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
261039|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
261040|NCT02210078|Biological|Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes|Given IV
261041|NCT02210065|Biological|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
261042|NCT02210052|Device|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
261043|NCT02210039|Device|SECM Probe|Imaging of the esophagus using SECM probe and system.
261044|NCT02210026|Device|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
261045|NCT02210000|Drug|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
261046|NCT02210000|Drug|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
261047|NCT02209987|Drug|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
261048|NCT02209987|Drug|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
261049|NCT02209974|Drug|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
261050|NCT02209974|Drug|Inhaled Placebo|
261051|NCT02209948|Drug|Temozolomide|
261052|NCT02209935|Other|Early Rehabilitation Protocol|
261053|NCT02209935|Other|Usual care|
261054|NCT02209922|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
261055|NCT02209922|Device|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
261056|NCT02209909|Drug|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
261057|NCT02209909|Drug|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
261058|NCT02209896|Device|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
261059|NCT02209870|Behavioral|E-checklist Group|The patient group after E-checklist system deployed
261060|NCT02209844|Drug|BI 44847|
261061|NCT02209844|Drug|Placebo|
261062|NCT02209831|Device|BIBR 796 BS|single dose
261063|NCT02209831|Drug|Pantoprazole|5 days
261064|NCT02209818|Radiation|Laser Irradiation One dose|
261065|NCT02209818|Radiation|Laser Irradiation Two doses|
261066|NCT02209805|Drug|BIRB 796 BS, low dose|
261067|NCT02209805|Drug|BIRB 796 BS, high dose|
261068|NCT02209805|Drug|Placebo|
261069|NCT02209792|Drug|Placebo|
261070|NCT02209792|Drug|BIBR 796 BS, 5 mg|
261071|NCT02209792|Drug|BIBR 796 BS, 20 mg|
261072|NCT02209779|Drug|BIBR 796 BS|
261073|NCT02209779|Drug|Placebo|
261074|NCT02209766|Drug|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
261075|NCT02209766|Drug|Placebo|"st cohort: Dose 1(2g) D5884(n=3) in Japanese~nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
261076|NCT02209753|Drug|BIRB 796 BS, low dose|
261077|NCT02209753|Drug|BIRB 796 BS, medium dose 1|
261078|NCT02209753|Drug|BIRB 796 BS, medium dose 2|
261082|NCT02209727|Drug|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
261083|NCT02209714|Drug|BIIF 1149 BS|
261084|NCT02209714|Drug|Placebo|
261085|NCT02209701|Drug|Porfiromycin|
261086|NCT02209688|Drug|ESR 1150 CL|
261087|NCT02209688|Drug|Placebo|
261088|NCT02209675|Other|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
261089|NCT02209662|Device|APIC-PRP|APIC-PRP
261090|NCT02209662|Other|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
261091|NCT02209649|Drug|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
261092|NCT02209649|Drug|Lacidipine|
261093|NCT02209649|Drug|Telmisartan|
261094|NCT02209636|Drug|Lanthanum carbonate|Non-calcium containing phosphorus binder
261095|NCT02209636|Drug|placebo|Table identical to lanthanum carbonate but with no active ingredient
261096|NCT02209636|Drug|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
261097|NCT02209636|Drug|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
261098|NCT02209636|Procedure|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
261099|NCT02209636|Procedure|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
261100|NCT02209636|Procedure|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
261101|NCT02209623|Biological|TDAP|
261102|NCT02209610|Device|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
261103|NCT02209610|Drug|Intrathecal Fentanyl|Mu-opioid receptor agonist
261104|NCT02209597|Drug|Wellbutrin XL® 300mg|
261105|NCT02209597|Drug|300mg bupropion XL 1|
261106|NCT02209597|Drug|300mg bupropion XL 2|
261107|NCT02209597|Drug|300mg bupropion XL 3|
261108|NCT02209571|Other|Venous blood markers|Routine venous blood sampling
261109|NCT02209558|Behavioral|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
261110|NCT02209545|Drug|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
261111|NCT02209545|Drug|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
261112|NCT02209532|Device|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
261113|NCT02209519|Drug|Metronidazole (male partner)|500 mg PO BID for 7 days
261114|NCT02209519|Other|Placeob (male partner)|matching placebo capsules PO BID for 7 days
261115|NCT02209506|Drug|MLN3126|MLN3126 tablets
261116|NCT02209506|Drug|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
261117|NCT02209493|Behavioral|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
261118|NCT02209493|Behavioral|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
261119|NCT02209480|Behavioral|Alexander Technique|
261120|NCT02209480|Device|Heat pad application|
261121|NCT02209480|Behavioral|guided imagery|
261122|NCT02209467|Other|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
261123|NCT02209454|Drug|Enantyum® oral solution|One dose of 25 mg DKP oral solution
261124|NCT02209454|Drug|Keral® tablet|One dose of 25 mg DKP tablet
261125|NCT02209441|Drug|Phase I Dose-finding Study of Sorafenib Study|
261126|NCT02209428|Drug|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
261127|NCT02209415|Behavioral|standard follow-up|Outpatient clinic visits
261128|NCT02209415|Procedure|PET/CT and EUS|PET/CT and EUS
261129|NCT02209402|Behavioral|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
261130|NCT02209389|Device|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
261131|NCT02209376|Biological|CART-EGFRvIII T cells|
261132|NCT02209363|Device|auto-adjusting positive airway pressure|nightly use for 6 months
261133|NCT02209363|Other|Nasal dilator strips|nightly use for 6 months
261134|NCT02209350|Procedure|Aorta-femoral bypass|"Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.~Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.~After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end."
261135|NCT02209350|Procedure|Recanalization and stenting of aorta-iliac segment|"Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.~Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter)."
261271|NCT02208388|Device|Fractional flow reserve guided treatment|
261136|NCT02209350|Drug|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
261137|NCT02209337|Device|SRS|
261138|NCT02209324|Drug|ASP2151|
261139|NCT02209311|Procedure|Oral mucosa biopsy|
261140|NCT02209311|Procedure|Sinus lift with implantation of tissue engineered construction|
261141|NCT02209311|Device|Dental implant|
261142|NCT02209298|Device|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
261143|NCT02209285|Behavioral|ACHRU - Community Partnership Program|Individuals in the ACHRU - CPP for Older Adults with Multiple Chronic Conditions group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
261144|NCT02209272|Drug|bacteriostatic saline|
261145|NCT02209272|Drug|buffered lidocaine|
261146|NCT02209259|Other|PROMIS Upper Extremity Function|
261147|NCT02209259|Other|Pain intensity|
261148|NCT02209259|Other|PROMIS depression|
261149|NCT02209259|Other|Positive affect negative affect scale (PANAS)|
261150|NCT02209259|Other|standard PCS|
261151|NCT02209259|Other|positively-adjusted version of the PCS|
261152|NCT02209246|Other|PROMIS CAT Pain Interference|
261153|NCT02209246|Other|PROMIS CAT Pain Behavior|
261154|NCT02209246|Other|PROMIS CAT Physical Function|
261155|NCT02209246|Other|MISS-21|
261156|NCT02209233|Other|Massage Therapy|
261157|NCT02209220|Device|Positive airway pressure for the treatment of OSA|
261158|NCT02209207|Device|Treadmill|
261159|NCT02209207|Other|walking training|
261160|NCT02209194|Device|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
261161|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
261162|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
261163|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
261164|NCT02209181|Drug|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
261165|NCT02209155|Drug|R-verapamil 75 mg tablet|
261166|NCT02209155|Drug|Placebo|
261167|NCT02209142|Other|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
261168|NCT02209142|Other|psychometric data collection|
261169|NCT02209116|Other|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
261170|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid|
261171|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid formulation|
261172|NCT02209103|Dietary Supplement|Identical looking placebo|
261173|NCT02209090|Procedure|maternal modified sims position|Maternal Modified Sims position during at least 40 minutes for each 60 minutes
261174|NCT02209090|Procedure|maternal free positions|At least 40 minutes each hour during labour
261175|NCT02209077|Device|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
261176|NCT02209064|Device|Pericardial access|Access to the pericardium to enable further treatments.
261177|NCT02209051|Other|AMNIOEXCEL|Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.
261178|NCT02209051|Other|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
261179|NCT02209038|Behavioral|Expanded AD Choice|
261180|NCT02209038|Behavioral|Expanded Life-sustaining Therapy Choice|
261181|NCT02209025|Dietary Supplement|Theobromine|Theobromine a compound for cocoa
261182|NCT02209025|Dietary Supplement|Placebo drink|
261183|NCT02209012|Drug|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
261184|NCT02209012|Drug|Topical Solution Vehicle|Vehicle PDT given in CP0108
261185|NCT02209012|Device|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
261186|NCT02208999|Device|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
261187|NCT02208986|Drug|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
261188|NCT02208973|Drug|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
261189|NCT02208973|Drug|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
261230|NCT02208622|Dietary Supplement|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
261231|NCT02208609|Other|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
261232|NCT02208609|Other|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
261272|NCT02208375|Drug|Capivasertib|Given PO
261190|NCT02208960|Device|Neonatal Kit|"Contents of the neonatal kit:~Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~Sunflower oil emollient (50 mL)~ThermoSpot~Mylar infant sleeve~Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
261191|NCT02208960|Behavioral|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:~Eye contact and talking to children~Responsive feeding and caregiving~Singing songs, including those with gentle touch"
261192|NCT02208947|Behavioral|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
261193|NCT02208947|Behavioral|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
261194|NCT02208934|Drug|PBF-999|5, 10, 20 and 40 mg of PBF-999
261195|NCT02208934|Drug|Placebo|Placebo for all dosis of PBF-999
261196|NCT02208908|Other|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
261197|NCT02208882|Drug|BMS-986120|
261198|NCT02208882|Drug|Placebo|
261199|NCT02208882|Drug|Midazolam|
261200|NCT02208856|Drug|BIBR 796 BS|
261201|NCT02208856|Drug|Placebo|
261202|NCT02208856|Other|high fat standardized breakfast|
261203|NCT02208843|Drug|Afatinib|Afatinib tablet once daily until progression
261204|NCT02208830|Other|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
261205|NCT02208830|Other|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
261206|NCT02208804|Device|Holmium-166-poly (L-lactic acid) microspheres|
261207|NCT02208791|Drug|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
261208|NCT02208791|Drug|No intervention|
261209|NCT02208778|Drug|Duloxetine|54 participants will be allocated for duloxetine treatment
261210|NCT02208778|Drug|Remifentanil|27 participants will be allocated to Remifentanil infusion
261211|NCT02208778|Drug|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
261212|NCT02208778|Drug|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
261213|NCT02208765|Device|Stress Single Photon Emission Computed Tomography|
261214|NCT02208752|Other|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
261215|NCT02208739|Procedure|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
261216|NCT02208739|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
261217|NCT02208726|Other|Sucrose pillules|Unmedicated sucrose pillules
261218|NCT02208726|Other|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
261219|NCT02208713|Biological|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
261220|NCT02208700|Other|Oxepa|Therapeutic nutrition with EPA, GLA< and antioxidants
261221|NCT02208700|Other|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
261222|NCT02208687|Behavioral|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
261223|NCT02208687|Other|Control group|Usual care
261224|NCT02208674|Other|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
261225|NCT02208635|Other|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (~30 µg Zn/g).
261226|NCT02208635|Other|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
261227|NCT02208635|Other|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
261228|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
261229|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
261388|NCT02207647|Other|no intervention|
261233|NCT02208596|Drug|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
261234|NCT02208596|Drug|propofol|
261235|NCT02208596|Drug|Etomidate|
261236|NCT02208583|Drug|Docetaxel & Prednisone|Docetaxel & Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
261237|NCT02208583|Drug|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
261238|NCT02208583|Drug|cisplatin & Etoposide|cisplatin & Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
261239|NCT02208583|Drug|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
261240|NCT02208570|Other|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
261241|NCT02208570|Drug|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
261242|NCT02208570|Other|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
261243|NCT02208557|Procedure|Reinforcement with Absorbable Mesh|
261244|NCT02208557|Radiation|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.~The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
261245|NCT02208557|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
261246|NCT02208544|Procedure|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
261247|NCT02208544|Device|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
261248|NCT02208544|Radiation|FDG-PET/CT|Head and Neck FDG-PET/CT
261249|NCT02208531|Behavioral|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
261250|NCT02208518|Procedure|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
261251|NCT02208518|Device|EUS-elastography|
261252|NCT02208505|Drug|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
261253|NCT02208505|Drug|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
261254|NCT02208492|Drug|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
261255|NCT02208492|Drug|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
261256|NCT02208479|Other|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
261257|NCT02208466|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
261258|NCT02208466|Drug|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
261259|NCT02208466|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
261260|NCT02208466|Drug|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
261261|NCT02208453|Device|InSpace Implantation|InSpace device Implantation
261262|NCT02208440|Procedure|Best Repair of torn Rotator Cuff|
261263|NCT02208440|Device|InSpace™ system|
261264|NCT02208427|Drug|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
261265|NCT02208427|Drug|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
261266|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
261267|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
261268|NCT02208401|Procedure|conventional cold snare polypectomy|conventional cold snare polypectomy
261269|NCT02208401|Procedure|Cold snare polypectomy with suction|Cold snare polypectomy with suction
261270|NCT02208388|Device|computed tomography perfusion guided treatment|
261273|NCT02208375|Other|Laboratory Biomarker Analysis|Correlative studies
261274|NCT02208375|Drug|Olaparib|Given PO
261275|NCT02208375|Other|Pharmacological Study|Correlative studies
261276|NCT02208375|Drug|Vistusertib|Given PO
261277|NCT02208362|Biological|IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes|Given via intratumoral or intracavitary or intraventricular catheter
261278|NCT02208362|Other|laboratory biomarker analysis|Correlative studies
261279|NCT02208362|Other|quality-of-life assessment|Ancillary studies
261280|NCT02208362|Procedure|Magnetic Resonance Imaging|Correlative studies
261281|NCT02208362|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative studies
261282|NCT02208362|Biological|IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes|Given via intratumoral and intraventricular catheter
261283|NCT02208362|Biological|Vaccine Therapy|Given IL13 [EQ]BBzeta/truncated CD19[t]+ Tn/mem via intratumoral or intraventricular catheter
261284|NCT02208362|Procedure|Magnetic Resonance Imaging|Correlative studies
261285|NCT02208362|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative Studies
261286|NCT02208362|Other|Laboratory Biomarker Analysis|Correlative Studies
261287|NCT02208362|Other|Quality of Life Assessment|Ancillary Studies
261288|NCT02208349|Device|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
261289|NCT02208349|Device|traditional direct laryngoscopy (DL)|
261290|NCT02208336|Other|medical chart review|Ancillary studies
261291|NCT02208323|Device|Bubble CPAP|Respiratory assistance
261292|NCT02208310|Drug|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
261293|NCT02208310|Drug|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
261294|NCT02208297|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
261295|NCT02208297|Drug|Vehicle Gel (BID)|One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
261296|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
261297|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
261298|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
261299|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
261300|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
261301|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
261302|NCT02208258|Device|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
261303|NCT02208245|Device|Ultrasound: Axillary block|Ultrasound guided axillary block
261304|NCT02208245|Device|Ultrasound: Infraclavicular block|Ultrasound guided infraclvicular block
261305|NCT02208245|Drug|Ropivacaine|20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
261306|NCT02208232|Procedure|cataract surgery|cataract surgery with implantation of intraocular lens
261307|NCT02208219|Behavioral|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
261308|NCT02208219|Behavioral|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
261309|NCT02208219|Behavioral|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:~Passive mobilization: controlled manipulation of movements to release a joint.~Stretch and progressive resistance training.~Task-specific training: reaching and manipulation of different objects.~Intense physical training: repetition of sequence of movements."
261310|NCT02208193|Behavioral|Cognitive and psycho-behavioral effects of an artistic dimension|
261311|NCT02208180|Behavioral|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.~Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
261312|NCT02208167|Biological|HXTC infusion|
261313|NCT02208154|Drug|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
261389|NCT02207634|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
261314|NCT02208154|Drug|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10^5 units. SOD will be applied to the mouth 4 times daily until extubation.
261315|NCT02208154|Drug|Selective Digestive Decontamination (SDD)|"SDD consists of both:~SOD (described elsewhere)~AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u, to be administered via the nasogastric tube.~The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)"
261316|NCT02208128|Drug|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
261317|NCT02208115|Dietary Supplement|Meal composition - Low versus high GI.|
261318|NCT02208102|Procedure|Radio-frequency catheter ablation|
261319|NCT02208089|Procedure|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
261320|NCT02208089|Procedure|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.~UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
261321|NCT02208076|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
261322|NCT02208063|Drug|Telavancin|
261323|NCT02208063|Drug|Vancomycin|
261324|NCT02208063|Drug|Daptomycin|
261325|NCT02208063|Drug|Synthetic penicillin|
261326|NCT02208063|Drug|Cefazolin|
261327|NCT02208050|Drug|Fampridine|
261328|NCT02208050|Drug|Placebo|
261329|NCT02208037|Drug|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
261330|NCT02208037|Drug|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
261331|NCT02208037|Drug|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
261332|NCT02208037|Drug|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
261333|NCT02208037|Drug|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
261334|NCT02208037|Drug|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
261335|NCT02208037|Drug|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
261336|NCT02208037|Drug|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.~Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.~Cyclophosphamide [50 mg/kg ideal body weight (IBW); if ABW < IBW, use ABW] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
261337|NCT02208024|Radiation|Stereotactic Body Radiation Therapy|
261338|NCT02207998|Drug|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
261339|NCT02207998|Drug|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
261340|NCT02207985|Procedure|Allogeneic hematopoietic stem cell transplantation|
261341|NCT02207972|Device|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
261342|NCT02207972|Procedure|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
261343|NCT02207959|Drug|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
261344|NCT02207959|Procedure|White-light examination|standard white light examination
261345|NCT02207959|Procedure|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
261346|NCT02207946|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
261347|NCT02207946|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
261348|NCT02207933|Procedure|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
261349|NCT02207933|Procedure|Gait training|Gait training only for 3 times a week for 6 weeks.
261350|NCT02207920|Biological|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
261351|NCT02207920|Biological|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
261352|NCT02207920|Biological|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
261353|NCT02207920|Biological|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
261354|NCT02207907|Drug|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
261355|NCT02207907|Drug|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
261356|NCT02207881|Drug|VDO gel|VDO gel
261357|NCT02207881|Drug|placebo|matching placebo gel
261358|NCT02207855|Drug|Chloroprocaine|
261359|NCT02207829|Drug|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
261360|NCT02207829|Drug|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
261361|NCT02207829|Drug|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
261362|NCT02207829|Drug|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
261363|NCT02207816|Procedure|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
261364|NCT02207816|Biological|Malaria Vaccine 257049 (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
261365|NCT02207816|Biological|Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
261366|NCT02207816|Biological|Cell-culture rabies vaccine (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
261367|NCT02207816|Biological|TritanrixHepB/Hib (MALARIA-055 PRI)|Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).
261368|NCT02207816|Biological|Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)|Administered orally, during the MALARIA-055 study (NCT00866619).
261369|NCT02207803|Behavioral|Transition Assistance Program|
261370|NCT02207790|Drug|E2609|
261371|NCT02207790|Drug|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
261372|NCT02207777|Procedure|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose 16-18% of their body weight.
261373|NCT02207777|Behavioral|Low-calorie diet|Subjects will meet with a dietitian and/or behaviorist over approximately 4-6 months to lose 16-18% of their body weight.
261374|NCT02207777|Procedure|SG|Sleeve Gastrectomy (SG) is a surgical procedure to help subjects lose 16-18% of their body weight.
261375|NCT02207764|Behavioral|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
261376|NCT02207738|Device|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
261377|NCT02207738|Device|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
261378|NCT02207725|Biological|Andexanet|
261379|NCT02207725|Other|Placebo|
261380|NCT02207712|Device|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
261381|NCT02207712|Drug|Ranibizumab|Standard ranibizumab treatment only
261382|NCT02207699|Drug|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
261383|NCT02207699|Drug|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
261384|NCT02207699|Drug|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
261385|NCT02207699|Drug|Placebo|8 placebo perles given by mouth once
261386|NCT02207673|Procedure|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
261387|NCT02207660|Drug|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
261390|NCT02207634|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
261391|NCT02207634|Drug|Background Statin Therapy|Participants were required to be on a stable, high- to moderate-intensity statin background therapy consisting of an effective statin dose, ie, at least atorvastatin 20 mg daily or equivalent, and where locally approved, highly effective statin therapy (defined as at least atorvastatin 40 mg daily or equivalent) was recommended.
261392|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
261393|NCT02207621|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
261394|NCT02207621|Other|Placebo|1 drop QD, AM, OU
261395|NCT02207621|Drug|AR-13324 Ophthalmic Solution 0.02% BID|1 drop BID, AM/PM, OU
261396|NCT02207608|Drug|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
261397|NCT02207608|Drug|BCG (Immucist®)|Usual BCG treatment
261398|NCT02207595|Drug|UCB5857|"Active Substance: UCB5857~Pharmaceutical Form: Capsule~Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~Route of Administration: Oral Use"
261399|NCT02207595|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Capsule~Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg~Route of Administration: Oral Use"
261400|NCT02207582|Device|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
261401|NCT02207582|Device|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
261402|NCT02207569|Device|CoreValve Evolut R TAVR system|
261403|NCT02207556|Drug|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:~Patient has completed 1 year of doxycycline therapy~Patient develops any grade 3-4 toxicity related to doxycycline use."
261404|NCT02207543|Other|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
261405|NCT02207530|Drug|MEDI4736|MEDI4736 monotherapy
261406|NCT02207517|Procedure|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
261407|NCT02207504|Drug|Crizotinib|Crizotinib is an ATP‐competitive small‐molecule inhibitor of the ALK, c‐Met/HGFR, RON, and ROS receptor tyrosine kinases.
261408|NCT02207504|Drug|Enzalutamide|Enzalutamide is an androgen receptor signaling inhibitor.
261409|NCT02207491|Drug|Timolol maleate Ophthalmic Solution 0.5% BID|1 drop BID, AM/PM, OU
261410|NCT02207491|Drug|AR-13324 Ophthalmic Solution 0.02%|1 drop once daily (QD), PM, OU
261411|NCT02207491|Other|Placebo|1 drop QD, AM, OU
261412|NCT02207478|Procedure|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
261413|NCT02207478|Procedure|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
261414|NCT02207465|Radiation|Radiotherapy|
261415|NCT02207465|Drug|Gemcitabine 1000 mg|
261416|NCT02207465|Drug|nab-paclitaxel 125 mg|
261417|NCT02207452|Device|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
261418|NCT02207452|Drug|Salbutamol|Salbutamol 5mg nebulised single dose
261419|NCT02207452|Drug|Ipratropium|Ipratropium 500mcg nebulised single dose
261420|NCT02207452|Device|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
261421|NCT02207439|Drug|Nelfinavir (Viracept®) 1250 mg|
261422|NCT02207439|Drug|FMISO|
261423|NCT02207426|Drug|Tobramycin|
261424|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
261425|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
261426|NCT02207400|Drug|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
261427|NCT02207400|Drug|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
261428|NCT02207387|Drug|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
261429|NCT02207387|Behavioral|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
261430|NCT02207387|Other|Music|
261431|NCT02207374|Drug|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
261432|NCT02207374|Drug|DPP-4 inhibitor|Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
261433|NCT02207361|Drug|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
261434|NCT02207361|Drug|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
261435|NCT02207348|Drug|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
261436|NCT02207335|Drug|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
261437|NCT02207335|Drug|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
261438|NCT02207322|Other|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
261439|NCT02207309|Drug|Pazopanib|
261440|NCT02207309|Drug|Placebo (for Pazopanib)|
261441|NCT02207296|Device|Plethysmographic variability index|
261442|NCT02207270|Behavioral|Same day discharge|Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
261443|NCT02207270|Behavioral|Overnight Stay|Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
261444|NCT02207257|Drug|PER977|Reversal of edoxaban-induced anticoagulation
261445|NCT02207257|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
261446|NCT02207257|Drug|Edoxaban|
261447|NCT02207244|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
261448|NCT02207244|Drug|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
261449|NCT02207244|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
261450|NCT02207244|Drug|Placebo for adalimumab|Placebo for adalimumab [two 0.8 milliliter (mL) injections] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
261451|NCT02207231|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
261452|NCT02207231|Drug|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
261453|NCT02207231|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
261454|NCT02207231|Drug|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
261455|NCT02207218|Drug|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
261456|NCT02207205|Drug|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
261457|NCT02207192|Other|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.~Pulmonary function tests were performed both in the sitting and then in the supine position."
261458|NCT02207179|Device|LumaScan Image Guided Surgery|
261459|NCT02207140|Dietary Supplement|HOWARU Restore|
261460|NCT02207127|Procedure|MRI, DISE, and Surgery|
261461|NCT02207114|Other|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
261462|NCT02207101|Dietary Supplement|E-OJ-01 (OXYJUN)|
261463|NCT02207101|Dietary Supplement|Placebo|
261464|NCT02207088|Drug|ombitasvir/paritaprevir/ritonavir|tablet
261465|NCT02207088|Drug|dasabuvir|tablet
261466|NCT02207088|Drug|Ribavirin|tablet
261467|NCT02207075|Radiation|[C11]PK-1195 PET scan|PET scan with tracer [C11]PK-1195
261468|NCT02207062|Drug|Ibrutinib|Given PO
261469|NCT02207062|Other|Laboratory Biomarker Analysis|Correlative studies
261470|NCT02207049|Behavioral|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
261471|NCT02207049|Behavioral|No Snacking|Caloric needs will be provided to preschoolers within three meals
261472|NCT02207036|Behavioral|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
261473|NCT02207036|Behavioral|Smokefree.gov|referral to the NCI Smokefree.gov website
261523|NCT02206607|Drug|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
261524|NCT02206594|Procedure|Descemetorhexis|
261474|NCT02207023|Behavioral|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
261475|NCT02207010|Biological|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
261476|NCT02206984|Drug|Tamoxifen|
261477|NCT02206984|Drug|Anastrozole|
261478|NCT02206984|Drug|Fulvestrant|
261479|NCT02206971|Other|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
261480|NCT02206958|Behavioral|Defeating Urinary Incontinence with Exercise Training|"12 week multi-component program. Continence program administered by a nurse practitioner during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.~2. Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor."
261481|NCT02206945|Behavioral|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
261482|NCT02206945|Behavioral|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
261483|NCT02206932|Drug|Sofosbuvir + Simeprevir|
261484|NCT02206906|Behavioral|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
261485|NCT02206893|Behavioral|Self-monitoring via Smartphone|
261486|NCT02206893|Behavioral|Peer support via Smartphone|
261487|NCT02206893|Behavioral|Professional support via Smartphone|
261488|NCT02206893|Behavioral|Self-monitoring via Web (Static)|
261489|NCT02206867|Biological|LBAL|Anti-inflammatory agents
261490|NCT02206867|Biological|Humira|Anti-inflammatory agents
261491|NCT02206854|Drug|R-flurbiprofen|200 mg gelatine capsule once orally
261492|NCT02206841|Procedure|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
261493|NCT02206841|Device|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
261494|NCT02206841|Device|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
261495|NCT02206841|Device|Transient elastography|Transient elastography will be performed for evaluate fibrosis of liver.
261496|NCT02206815|Drug|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
261497|NCT02206815|Drug|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
261498|NCT02206802|Drug|5% minoxidil topical foam|5% minoxidil topical foam
261499|NCT02206789|Drug|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
261500|NCT02206789|Drug|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
261501|NCT02206776|Drug|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
261502|NCT02206776|Drug|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
261503|NCT02206763|Drug|Momelotinib (MMB)|Tablet(s) administered orally once or twice daily
261504|NCT02206763|Drug|Erlotinib|Tablet(s) administered orally once daily.
261505|NCT02206750|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
261506|NCT02206750|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
261507|NCT02206737|Device|No nicotine e-cigarette|
261508|NCT02206737|Device|Low dose nicotine e-cigarette|
261509|NCT02206737|Device|High dose nicotine e-cigarette|
261510|NCT02206724|Radiation|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
261511|NCT02206711|Drug|BMS-955176|Single dose of drug on Day 1
261512|NCT02206685|Drug|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
261513|NCT02206685|Drug|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
261514|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
261515|NCT02206659|Drug|Telmisartan|
261516|NCT02206659|Drug|Placebo|
261517|NCT02206646|Drug|Metalyse|
261518|NCT02206633|Device|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
261519|NCT02206620|Drug|Donepezil|
261520|NCT02206607|Drug|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
261521|NCT02206607|Drug|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
261522|NCT02206607|Drug|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
261525|NCT02206581|Device|Hydration Monitor|
261527|NCT02206555|Drug|emtricitabine/tenofovir disoproxil fumarate|
261528|NCT02206542|Device|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
261529|NCT02206542|Other|Physical therapy|
261530|NCT02206542|Device|Electroacupuncture|
261531|NCT02206529|Behavioral|Social Network Engagement+Std Treatment|
261532|NCT02206529|Behavioral|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
261533|NCT02206516|Device|Transcranial Direct Current Stimulation|
261534|NCT02206503|Drug|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
261535|NCT02206503|Drug|Lenalidomide|
261536|NCT02206503|Drug|Dexamethasone|
261537|NCT02206490|Drug|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
261538|NCT02206490|Drug|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
261539|NCT02206477|Drug|Dimethyl Sulfoxide|
261540|NCT02206477|Drug|Saline 0.9%|
261541|NCT02206464|Biological|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
261542|NCT02206464|Biological|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
261543|NCT02206438|Device|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
261544|NCT02206438|Device|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
261545|NCT02206425|Drug|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261546|NCT02206425|Drug|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261547|NCT02206425|Drug|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261548|NCT02206425|Drug|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261549|NCT02206425|Dietary Supplement|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261550|NCT02206425|Drug|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261551|NCT02206425|Drug|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261552|NCT02206425|Drug|Pomalidomide|Pomalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
261553|NCT02206386|Other|MHTraining-Net|See Arm Description for more details.
261554|NCT02206386|Other|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
261555|NCT02206360|Procedure|Endoscopic Ultrasound|
261556|NCT02206360|Procedure|Magnetic Resonance Imaging (MRI)|
261557|NCT02206347|Behavioral|attention focus|
261558|NCT02206334|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
261559|NCT02206321|Procedure|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
261560|NCT02206321|Procedure|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
261561|NCT02206308|Biological|Chimeric anti-CD20 monoclonal antibody|
261562|NCT02206295|Drug|selexipag|
261563|NCT02206269|Device|Alair System|The Alair system is used for doing bronchial thermoplasty.
261564|NCT02206256|Drug|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
261565|NCT02206256|Behavioral|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
261566|NCT02206243|Drug|Embozene Microspheres|Intraarterial application
261567|NCT02206230|Radiation|Hypofractionated radiation therapy|
261568|NCT02206230|Radiation|Standard radiation therapy|
261569|NCT02206217|Device|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
261570|NCT02206204|Drug|selexipag|
261571|NCT02206204|Drug|placebo for selexipag|
261572|NCT02206204|Drug|moxifloxacin|
261573|NCT02206204|Drug|moxifloxacin-matching placebo|
261574|NCT02206178|Drug|N-acetylcysteine combination with acetaminophen|
261575|NCT02206178|Drug|Placebo|
261576|NCT02206165|Drug|Candesartan 8mg|Once a day, 8 weeks
261577|NCT02206165|Drug|Candesartan 16mg|Once a day, 8 weeks
261578|NCT02206165|Drug|Amlodipine 5mg|Once a day, 8 weeks
261579|NCT02206165|Drug|Amlodipine 10mg|Once a day, 8 weeks
261626|NCT02205814|Drug|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
261627|NCT02205814|Drug|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
261580|NCT02206152|Drug|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
261581|NCT02206152|Drug|Placebo|
261582|NCT02206126|Behavioral|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
261583|NCT02206113|Behavioral|Standing workstation|
261584|NCT02206100|Drug|PER977|reversal of edoxaban-induced anticoagulation
261585|NCT02206100|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
261586|NCT02206100|Drug|enoxaparin|
261587|NCT02206087|Drug|PER977|Reversal of heparin-induced anticoagulation
261588|NCT02206087|Drug|Placebo|Reversal of heparin-induced anticoagulation
261589|NCT02206087|Drug|Heparin Sodium|
261590|NCT02206074|Dietary Supplement|Beetroot|
261591|NCT02206061|Behavioral|School-Based Asthma Care for Teens (SB-ACT)|
261592|NCT02206061|Behavioral|Directly Observed Therapy|
261593|NCT02206061|Behavioral|Asthma Education|
261594|NCT02206048|Drug|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
261595|NCT02206048|Procedure|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
261596|NCT02206035|Drug|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant
261597|NCT02206035|Drug|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11
261598|NCT02206035|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
261599|NCT02206022|Drug|Remifentanil|Pain's evaluation for Remifentanil Group
261600|NCT02206022|Drug|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
261601|NCT02206009|Device|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
261602|NCT02205996|Drug|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
261603|NCT02205996|Device|Euglycaemic Hypoglycaemic Insulin clamp|
261604|NCT02205983|Drug|2 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
261605|NCT02205983|Drug|1000 mg Acetaminophen|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
261606|NCT02205983|Drug|4 mg hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
261607|NCT02205983|Drug|dextrose|We are administering dextrose to healthy volunteers for our placebo group.
261608|NCT02205970|Device|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
261609|NCT02205970|Device|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
261610|NCT02205944|Other|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg & Borg, 2001).~Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
261611|NCT02205931|Other|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
261612|NCT02205931|Drug|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
261613|NCT02205918|Other|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
261614|NCT02205918|Other|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
261615|NCT02205905|Drug|14C PER977|Open-label, single dose
261616|NCT02205892|Drug|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
261617|NCT02205892|Drug|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
261618|NCT02205879|Drug|Pregabalin|
261619|NCT02205879|Drug|Placebo|
261620|NCT02205866|Other|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
261621|NCT02205853|Other|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
261622|NCT02205853|Other|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
261623|NCT02205840|Drug|SI-614|1 drop in each eye
261624|NCT02205840|Drug|Vehicle|1 drop in each eye
261625|NCT02205827|Other|Single-arm|collection of blood for assessment of whole blood clotting time
261628|NCT02205814|Drug|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
261629|NCT02205814|Drug|Placebo comparator|Single intra-articular injection of placebo
261630|NCT02205801|Procedure|Superficial Cervical Plexus Block|0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
261631|NCT02205801|Procedure|Local Wound Infiltration|0.50% Marcaine is injected at the site of incision (10mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
261632|NCT02205801|Drug|0.9% saline|
261633|NCT02205801|Drug|Marcaine|
261634|NCT02205775|Drug|Atorvastatin|80 + 40 mg pre PCI
261635|NCT02205775|Drug|Rosuvastatin|40 + 40 mg before PCI
261636|NCT02205775|Drug|Rosuvastatin|5 mg twice before PCI (+ 10 mg ezetimibe)
261637|NCT02205775|Drug|Ezetimibe|10 mg twice before PCI (+ 5 mg rosuvastatin)
261638|NCT02205775|Drug|placebo|twice before PCI
261639|NCT02205762|Drug|Prednisone|Stratum I
261640|NCT02205762|Drug|Vinblastine|Stratum I
261641|NCT02205762|Drug|mercaptopurine|Stratum I
261642|NCT02205762|Drug|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
261643|NCT02205762|Drug|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
261644|NCT02205762|Drug|Cytosine Arabinoside|
261645|NCT02205762|Drug|2-chlorodeoxyadenosine|
261646|NCT02205762|Procedure|hematopoietic stem cell transplantation (RIC-HSCT)|
261647|NCT02205762|Biological|Intravenous immunoglobulin|
261648|NCT02205749|Behavioral|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
261649|NCT02205749|Behavioral|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
261650|NCT02205749|Behavioral|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
261651|NCT02205736|Other|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
261652|NCT02205723|Behavioral|Asthma teaching in ER|Asthma teaching
261653|NCT02205723|Behavioral|Smartphone Asthma Control|Smartphone Asthma Control
261654|NCT02205710|Other|Computerized cognitive training|
261655|NCT02205710|Other|Computerized games|
261656|NCT02205697|Behavioral|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
261657|NCT02205684|Other|Computer game skills training|Playing Nintendo Wii Sports
261658|NCT02205684|Other|Physical activity|Aerobic High Intensity Training (HIT)
261659|NCT02205671|Behavioral|Building Better Caregivers Small-group Workshop|
261660|NCT02205645|Device|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.~The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
261661|NCT02205632|Device|MPS II|
261662|NCT02205619|Device|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
261663|NCT02205619|Device|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
261664|NCT02205619|Device|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
261665|NCT02205606|Drug|HGP0816 5mg|P.O.
261666|NCT02205606|Drug|HGP0816 10mg|P.O.
261667|NCT02205606|Drug|HGP0816 20mg|P.O.
261668|NCT02205606|Drug|HCP1306 5/10mg|P.O.
261669|NCT02205606|Drug|HCP1306 10/10mg|P.O.
261670|NCT02205606|Drug|HCP1306 20/10mg|P.O.
261671|NCT02205593|Behavioral|Control|Regular follow-up and treatment WITHOUT behavioural intervention
261672|NCT02205580|Drug|continuous intravenous sufentanil 0.02μg•kg－1•h－1 infusion|
261673|NCT02205580|Drug|continuous intravenous sufentanil 0.03μg•kg－1•h－1 infusion|
261674|NCT02205580|Drug|continuous intravenous sufentanil 0.04μg•kg－1•h－1 infusion|
261675|NCT02205567|Dietary Supplement|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
261676|NCT02205554|Drug|Omnitram|Nine 20 mg doses administered every 6 hours
261677|NCT02205554|Drug|Tramadol|Nine 50 mg doses administered every 6 hours.
261678|NCT02205554|Drug|Placebo|Nine doses administered every 6 hours.
261679|NCT02205541|Drug|Eculizumab|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
261680|NCT02205541|Drug|Placebo|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.~ECZ or placebo will be administrated intravenously as a 30-minute injection"
261681|NCT02205528|Drug|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
261682|NCT02205528|Drug|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
261683|NCT02205528|Drug|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
261684|NCT02205528|Drug|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
261685|NCT02205515|Drug|Everolimus|Everolimus is a novel derivative of rapamycin.
261686|NCT02205502|Drug|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
261687|NCT02205502|Drug|Normal saline|
261688|NCT02205489|Drug|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
261689|NCT02205489|Drug|cetirizine|Pharmaceutical form:tablet Route of administration: oral
261690|NCT02205489|Drug|ranitidine|Pharmaceutical form:tablet Route of administration: oral
261691|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
261692|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
261693|NCT02205489|Drug|aciclovir|Pharmaceutical form:tablet Route of administration: oral
261694|NCT02205489|Drug|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
261695|NCT02205489|Drug|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
261696|NCT02205489|Drug|paracetamol|Pharmaceutical form:tablet Route of administration: oral
261697|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
261698|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
261699|NCT02205463|Drug|KD019|
261700|NCT02205450|Drug|Recombinant Somatropin|
261701|NCT02205411|Device|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
261702|NCT02205411|Device|Control VAD|The HeartMate II® VAD or HVAD®
261703|NCT02205398|Drug|INC280|
261704|NCT02205398|Drug|cetuximab|
261705|NCT02205385|Procedure|Targeted Muscle Reinnervation|
261706|NCT02205385|Procedure|Traction Neurectomy|
261707|NCT02205372|Drug|MT-3995|
261708|NCT02205372|Drug|Placebo|
261709|NCT02205359|Device|aCRT ON|CRT device with AdaptivCRT enabled
261710|NCT02205359|Device|aCRT OFF|CRT device with AdaptivCRT disabled
261711|NCT02205333|Biological|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
261712|NCT02205333|Biological|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
261713|NCT02205333|Biological|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
261714|NCT02205333|Biological|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
261715|NCT02205320|Biological|DRL_PG|
261716|NCT02205320|Biological|Pegfilgrastim Form A|
261717|NCT02205320|Biological|Pegfilgrastim Form B|
261718|NCT02205307|Device|PINPOINT|
261719|NCT02205307|Device|SPY Elite|
261720|NCT02205294|Other|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
261721|NCT02205281|Behavioral|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
261722|NCT02205268|Procedure|Near infrared spectroscopy neurofeedback training|
261723|NCT02205255|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
261724|NCT02205255|Drug|Placebo|
261725|NCT02205242|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
261726|NCT02205242|Device|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
261727|NCT02205242|Drug|Placebo|
261728|NCT02205229|Drug|Multi-ingredient, topical compounded medications|
261729|NCT02205216|Device|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
261730|NCT02205216|Device|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
261771|NCT02204956|Behavioral|Sustained Care|The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.
261731|NCT02205216|Behavioral|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:~cognitive training: attentional strategies (mental counting, mental obstacle)~transfer training: everyday activities~motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
261732|NCT02205203|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
261733|NCT02205203|Other|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
261734|NCT02205190|Drug|Fimasartan|
261735|NCT02205190|Drug|Rosuvastatin|
261736|NCT02205190|Drug|Fimasartan/Rosuvastatin combination|
261737|NCT02205177|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
261738|NCT02205164|Drug|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
261739|NCT02205164|Drug|Palonosetron|Aloxi 0.25mg
261740|NCT02205151|Drug|Fimasartan|
261741|NCT02205151|Drug|Amlodipine|
261742|NCT02205151|Drug|Fimasartan/Amlodipine combination|
261743|NCT02205138|Drug|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
261744|NCT02205112|Drug|Nemonoxacin|
261745|NCT02205112|Drug|Levofloxacin|
261746|NCT02205099|Drug|SKL15508|
261747|NCT02205099|Drug|Placebo|
261748|NCT02205086|Other|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.~Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
261749|NCT02205073|Drug|Placebo RD + AVP SD|Placebo (matching to study drug) repeat doses + intranasal AVP single dose
261750|NCT02205073|Drug|Placebo RD + Placebo SD|Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
261751|NCT02205073|Drug|RG7314 RD + AVP SD|RG7314 repeat doses + intranasal AVP single dose
261752|NCT02205060|Other|virtual reality exposure treatment|
261753|NCT02205060|Other|cognitive and behavioral approaches therapy|
261754|NCT02205047|Drug|Cisplatin|
261755|NCT02205047|Drug|5-fluorouracil or Capecitabine|
261756|NCT02205047|Drug|Trastuzumab|
261757|NCT02205047|Drug|Pertuzumab|
261758|NCT02205047|Procedure|gastrectomy|D2 gastrectomy
261759|NCT02205034|Drug|oxytocin|Intranasal administration
261760|NCT02205021|Other|No intervention|
261761|NCT02205008|Procedure|surgery|Total or subtotal gastrectomy with D2
261762|NCT02205008|Drug|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
261763|NCT02205008|Drug|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2~1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
261764|NCT02204995|Procedure|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
261765|NCT02204995|Procedure|Trapeziectomy|Trapeziectomy
261766|NCT02204982|Drug|Duvelisib|PI3K Inhibitor
261767|NCT02204982|Drug|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
261768|NCT02204982|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
261769|NCT02204969|Dietary Supplement|Lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water~Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
261770|NCT02204969|Device|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
261772|NCT02204956|Behavioral|Usual Care|Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
261773|NCT02204943|Device|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
261774|NCT02204943|Drug|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
261775|NCT02204930|Drug|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
261776|NCT02204917|Drug|OPTISON|Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.
261777|NCT02204904|Genetic|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
261778|NCT02204891|Dietary Supplement|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
261779|NCT02204891|Dietary Supplement|Probiotics|One capsule twice daily for 30 days
261780|NCT02204878|Drug|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
261781|NCT02204865|Device|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
261782|NCT02204852|Drug|Iloprost+eptifibatide|
261783|NCT02204852|Drug|Placebo|
261784|NCT02204839|Drug|Basal insulin dose|
261785|NCT02204826|Drug|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.~KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
261786|NCT02204826|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
261787|NCT02204813|Drug|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
261788|NCT02204813|Drug|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
261789|NCT02204813|Drug|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
261790|NCT02204813|Drug|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.~Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
261791|NCT02204787|Device|transcranial direct current stimulation|
261792|NCT02204761|Radiation|Proton Beam Radiation Therapy|Undergo proton beam re-irradiation therapy
261793|NCT02204748|Device|DePuy Attune posterior stabilizing fixed bearing knee system|
261794|NCT02204735|Behavioral|Eat majority of calories in the morning|
261795|NCT02204735|Behavioral|Eat the majority of calories in the evening|
261796|NCT02204722|Drug|600mg/day of Imatinib|
261797|NCT02204722|Drug|400mg/day of Imatinib|
261798|NCT02204709|Other|2N Trout|Diploid/2N trout source
261799|NCT02204709|Other|3N Trout|Triploid/3N trout source
261800|NCT02204709|Other|Tilapia|Tilapia/control fish source
261801|NCT02204696|Procedure|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
261802|NCT02204683|Drug|Aflibercept|Intravitreal aflibercept
261803|NCT02204670|Other|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
261804|NCT02204657|Device|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
261805|NCT02204644|Drug|Flumatinib 600mg qd|
261806|NCT02204644|Drug|Imatinib 400mg qd|
261807|NCT02204631|Other|Head and Neck Educational Handbook|
261808|NCT02204618|Device|cochlear implantation|
261809|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
261810|NCT02204605|Behavioral|Video-based Consensus Opinion|
261811|NCT02204579|Drug|NPSP795|
261812|NCT02204566|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
261813|NCT02204553|Drug|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
261857|NCT02204228|Device|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
261814|NCT02204540|Behavioral|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
261815|NCT02204527|Dietary Supplement|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
261816|NCT02204527|Dietary Supplement|placebo pill|Placebo
261817|NCT02204514|Procedure|Surgery for external snapping hip|
261818|NCT02204501|Drug|Midazolam 5mg Syrup|"All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.~On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.~On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B."
261819|NCT02204501|Drug|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
261820|NCT02204501|Drug|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
261821|NCT02204488|Procedure|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
261822|NCT02204488|Procedure|Trapeziectomy|Trapeziectomy
261823|NCT02204475|Drug|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
261824|NCT02204475|Drug|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
261825|NCT02204475|Drug|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
261826|NCT02204475|Drug|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
261827|NCT02204462|Drug|FBnTP|A PET imaging radiotracer
261828|NCT02204449|Behavioral|Cardiac Rehabilitation Peer Mentorship|
261829|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
261830|NCT02204423|Procedure|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
261831|NCT02204410|Dietary Supplement|Omega-3 Fatty Acid|
261832|NCT02204410|Drug|ADHD Medication|
261833|NCT02204397|Drug|INGAP Peptide, Ustekinumab|
261834|NCT02204384|Other|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
261835|NCT02204384|Dietary Supplement|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
261836|NCT02204384|Other|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
261837|NCT02204371|Drug|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
261838|NCT02204371|Drug|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
261839|NCT02204358|Procedure|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.~If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
261840|NCT02204345|Drug|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
261841|NCT02204345|Drug|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
261842|NCT02204345|Drug|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
261843|NCT02204332|Drug|Cabazitaxel|
261844|NCT02204332|Other|Best Supportive Care|
261845|NCT02204319|Device|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
261846|NCT02204306|Genetic|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
261847|NCT02204293|Drug|Canakinumab|Canakinumab will be injected subcutaneously in a dose of 4mg/kg body weight up to a maximum of 300 mg every 4 weeks.
261848|NCT02204293|Drug|Placebo Injection|Placebo will be injected subcutaneously every 4 weeks
261849|NCT02204293|Drug|Canakinumab|For responders on week 24 possibility of open-label treatment with Canakinumab sc every 4 weeks for further 2 years. There will be the possibility to make a downtitration, according to specific criteria.
261850|NCT02204267|Other|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
261851|NCT02204267|Device|ECG|
261852|NCT02204254|Device|Radiofrequence|Associated to arm radiofrequence
261853|NCT02204254|Drug|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
261854|NCT02204241|Drug|Carfilzomib|
261855|NCT02204241|Drug|Cyclophosphamide|
261856|NCT02204241|Drug|Dexamethasone|
261938|NCT02203656|Drug|Testosterone|Testosterone injection
261858|NCT02204215|Device|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
261859|NCT02204215|Other|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
261860|NCT02204202|Drug|[18F]FDG|10 millicuries (mCi) of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
261861|NCT02204202|Drug|[18F]ISO-1|8 mCi of [18F]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
261862|NCT02204189|Drug|TongFuSan|TongFuSan 1g
261863|NCT02204176|Other|Exercise info|"Discussion:~benefits of exercise~types of exercise~exercise guidelines~components of an exercise session~how to reduce risk of injuries"
261864|NCT02204176|Other|Implementation intentions|"Discussion of:~barriers to exercise and how to address/overcome barriers~how to create detailed exercise plans"
261865|NCT02204176|Other|Industriousness|"Discussion of:~realistic monitoring of efforts related to exercise~reaching and pushing past thresholds for sustained effort for exercise"
261866|NCT02204176|Device|pedometer|
261867|NCT02204163|Drug|Eutropin|
261868|NCT02204163|Drug|Genotropin|
261869|NCT02204150|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
261870|NCT02204137|Other|Falls Risk Questionnaire|
261871|NCT02204137|Other|Cancer and Aging Research Group Geriatric Assessment|
261872|NCT02204137|Other|Falls Efficacy Scale-International (FES-1)|
261873|NCT02204137|Other|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
261874|NCT02204124|Device|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
261875|NCT02204124|Device|Standard of care scissors, ligatures, clips, and sutures|
261876|NCT02204111|Other|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
261877|NCT02204098|Biological|Mammaglobin-A DNA Vaccine|
261878|NCT02204098|Procedure|Optional biopsy|
261879|NCT02204085|Drug|GO-203-2c|
261880|NCT02204085|Drug|GO-203-2c + Decitabine|
261881|NCT02204072|Drug|BI 836845|
261882|NCT02204072|Drug|Enzalutamide|
261883|NCT02204072|Drug|Enzalutamide|
261884|NCT02204059|Drug|hMAb BIWA 4|
261885|NCT02204046|Drug|BIWA 4|
261886|NCT02204033|Drug|99mTc - labelled hMAb BIWA 4|
261887|NCT02204033|Drug|186 Re - labelled hMAb BIWA 4|
261888|NCT02204033|Drug|unlabelled hMAb BIWA 4 - low dose|
261889|NCT02204033|Drug|unlabelled hMAb BIWA 4 - medium dose|
261890|NCT02204033|Drug|unlabelled hMAb BIWA 4 - high dose|
261891|NCT02204020|Drug|5-azacytidine (5-aza) maintenance therapy after transplant|The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
261892|NCT02204007|Device|3D imaging & surrogate bone model|3D imaging & surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
261893|NCT02203994|Device|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
261894|NCT02203968|Drug|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
261895|NCT02203968|Drug|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
261896|NCT02203955|Drug|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
261897|NCT02203955|Drug|Maltodextrin|4 chews (maltodextrin) daily for 12 months
261898|NCT02203942|Other|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
261899|NCT02203916|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
261900|NCT02203916|Drug|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
261901|NCT02203903|Biological|Tumor associated antigen lymphocytes (TAA-T)|TAA-T may be generated from donors or recipients and will be tested for specificity to 3 tumor antigens commonly found in hematological malignancies (WT1, PRAME, and SURVIVIN,). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
261902|NCT02203877|Dietary Supplement|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
261903|NCT02203877|Dietary Supplement|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
261904|NCT02203864|Biological|BIBW2 component A|BIBW2 without IL-2 secreting cell line
261905|NCT02203864|Biological|BIBW2 component B|BIBW2 with IL-2 secreting cell line
261906|NCT02203851|Drug|Risankizumab|Risankizumab administered by subcutaneous (SC) injection
261934|NCT02203669|Other|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
261907|NCT02203838|Drug|RBP-7000|"120-mg RBP-7000 dose delivered by subcutaneous injection every 28 days for a total of 13 injections (for roll-over participants, the first two injections took place under study RB-US-09-0010).~A one-time down-titration to 90 mg RBP-7000 is permitted at the investigator's discretion should the participant have tolerability issues. Participants who received the 90-mg dose of RBP-7000 and exhibited a worsening in psychiatric symptoms could receive a one-time up-titration back to 120 mg RBP-7000 at the discretion of the investigator.~RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner."
261908|NCT02203825|Biological|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
261909|NCT02203812|Drug|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
261910|NCT02203812|Drug|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
261911|NCT02203799|Biological|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
261912|NCT02203786|Drug|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
261913|NCT02203786|Drug|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).~Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
261914|NCT02203786|Drug|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
261915|NCT02203786|Drug|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.~Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
261916|NCT02203786|Behavioral|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
261917|NCT02203773|Drug|Posaconazole|Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
261918|NCT02203773|Drug|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
261919|NCT02203773|Drug|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
261920|NCT02203773|Drug|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
261921|NCT02203760|Drug|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
261922|NCT02203760|Drug|Pazopanib|Pazopanib 800 mg orally once daily
261923|NCT02203747|Other|Administration of patient self-assessment|
261924|NCT02203734|Procedure|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
261925|NCT02203734|Procedure|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
261926|NCT02203721|Device|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
261927|NCT02203721|Device|TECNIS Monofocal IOL, Model ZCB00|
261928|NCT02203708|Other|Supportive Program for Mother with BPD (SuPMother-B).|"The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.~Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids."
261929|NCT02203695|Drug|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
261930|NCT02203695|Radiation|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
261931|NCT02203682|Drug|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
261932|NCT02203682|Drug|placebo|Tablet placebo for 12 weeks
261933|NCT02203669|Other|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
261935|NCT02203656|Drug|Placebo|placebo supplement
261936|NCT02203656|Dietary Supplement|Nutritional Supplement|protein supplement
261937|NCT02203656|Behavioral|In-home exercise|In-home exercise program
261939|NCT02203643|Drug|Carfilzomib|
261943|NCT02203630|Drug|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
261944|NCT02203630|Drug|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
261945|NCT02203617|Behavioral|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
261946|NCT02203617|Behavioral|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
261947|NCT02203604|Biological|aldesleukin|Given IV
261948|NCT02203604|Biological|ipilimumab|Given IV
261949|NCT02203604|Other|laboratory biomarker analysis|Correlative studies
261950|NCT02203591|Drug|3M CHG/IPA Prep C|Apply topically.
261951|NCT02203591|Drug|3M CHG/IPA Prep CH|Apply topically.
261952|NCT02203591|Drug|ChloraPrep Clear|Apply topically.
261953|NCT02203591|Drug|Normal Saline|Apply topically.
261954|NCT02203578|Drug|romidepsin|Given IV
261955|NCT02203578|Other|laboratory biomarker analysis|Correlative studies
261956|NCT02203565|Drug|Dakin's solution|Applied topically
261957|NCT02203565|Radiation|radiation therapy|Undergo radiation therapy
261958|NCT02203565|Other|questionnaire administration|Ancillary studies
261959|NCT02203565|Other|laboratory biomarker analysis|Optional correlative studies
261960|NCT02203552|Drug|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
261961|NCT02203552|Other|placebo|Placebo given by mouth for 9 weeks
261962|NCT02203552|Other|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
261963|NCT02203552|Other|Questionnaire administration|The CES-D and STAI will be administrated weekly.
261964|NCT02203539|Other|exposure to normal light|exposure for 60 minutes in duration
261965|NCT02203539|Other|exposure to bright light|exposure to bright light for 60 minutes of duration
261966|NCT02203539|Other|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
261967|NCT02203526|Drug|Isavuconazole|Isavuconazole to begin at least 3 days (and up to 7 days) prior to ibrutinib and continue throughout chemotherapy (cycles 1-6)
261968|NCT02203526|Drug|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1- A); given every 21 days for cycles 1-6 (Arms 1-B, 2 and 3)
261969|NCT02203526|Biological|Rituximab (R)|Rituximab (R) given with TEDD and TEDDI every 3 weeks for cycles 1-6 (all arms)
261970|NCT02203526|Drug|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on days 1 and day 5 of cycles 2-6 (all arms)
261971|NCT02203526|Drug|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
261972|NCT02203526|Drug|Ibrutinib (Arms 2 and 3)|Ibrutinib given on day -3 to day -1 on cycle 1 (Arms 2 and 3)
261973|NCT02203526|Drug|Ibrutinib (Arm 1 - Closed with Amendment G)|Ibrutinib given on day -14 to day -1 on cycle 1 (Arm 1)
261974|NCT02203513|Drug|LY2606368|105 mg/m^2 IV once every 14 days of a 28 day cycle
261975|NCT02203500|Drug|Lacidipine|
261976|NCT02203500|Drug|Telmisartan|
261977|NCT02203487|Drug|BIIF 1149 BS - single rising dose|
261978|NCT02203487|Drug|Placebo|
261979|NCT02203474|Drug|Tiotropium HFA BAI 5 mcg|
261980|NCT02203474|Drug|Tiotropium 18 mcg Capsule|
261981|NCT02203474|Drug|Placebo|Placebo
261982|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
261983|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
261984|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
261985|NCT02203448|Device|Facet Wedge spinal system|
261986|NCT02203422|Drug|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
261987|NCT02203422|Drug|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
261988|NCT02203409|Procedure|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
261989|NCT02203396|Drug|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
261990|NCT02203383|Device|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
261991|NCT02203370|Device|NIRS - Near-infrared spectroscopy|
261992|NCT02203357|Biological|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
261993|NCT02203331|Drug|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
261994|NCT02203331|Drug|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
261995|NCT02203331|Drug|Anastrozole|Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
261996|NCT02203331|Drug|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
261997|NCT02203305|Device|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
261998|NCT02203305|Other|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
261999|NCT02203292|Behavioral|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb < 9.0 g/dL
262000|NCT02203292|Behavioral|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb < 7.0 g/dL
262001|NCT02203279|Other|Rebase II Fast|It is going to be used a direct relining material
262002|NCT02203279|Other|Flexacryl|This is going to be used as a second direct relining material
262003|NCT02203279|Other|Vertex|This is going to be used as an indirect relining material
262004|NCT02203266|Device|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
262005|NCT02203266|Behavioral|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
262006|NCT02203253|Drug|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
262007|NCT02203253|Drug|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
262008|NCT02203253|Drug|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
262009|NCT02203240|Other|Cocoa|
262010|NCT02203240|Other|Placebo|
262011|NCT02203227|Dietary Supplement|Placebo|
262012|NCT02203227|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
262013|NCT02203227|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
262014|NCT02203227|Dietary Supplement|MaQxan|
262015|NCT02203214|Device|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
262016|NCT02203188|Procedure|Lid debridgement scaling|
262017|NCT02203175|Drug|saline|Before the anesthesia induction, 5 ml isotonic saline
262018|NCT02203175|Drug|fentanyl|before the anesthesia induction 50 mcgr fentanyl
262019|NCT02203175|Drug|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
262020|NCT02203162|Device|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
262021|NCT02203149|Drug|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
262022|NCT02203149|Drug|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
262023|NCT02203149|Drug|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
262024|NCT02203149|Drug|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
262025|NCT02203136|Procedure|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
262026|NCT02203136|Procedure|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
262027|NCT02203123|Device|Ultrasound|
262028|NCT02203123|Drug|normal saline|
262029|NCT02203097|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
262030|NCT02203097|Drug|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
262031|NCT02203084|Other|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
262032|NCT02203058|Other|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
262033|NCT02203058|Other|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
262034|NCT02203045|Other|Total Knee Arthroplasty|
262035|NCT02203032|Drug|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
262036|NCT02203032|Drug|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
262037|NCT02203032|Drug|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
262038|NCT02203032|Drug|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
262039|NCT02203019|Drug|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
262040|NCT02203019|Drug|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
262041|NCT02203019|Drug|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
262042|NCT02203006|Biological|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
262043|NCT02202993|Drug|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.~This will be given concurrently with hypofractionated radiation therapy."
262044|NCT02202980|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
262045|NCT02202980|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
262046|NCT02202980|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
262047|NCT02202980|Drug|VOX|100 mg tablet administered orally once daily with food
262285|NCT02201238|Drug|Diclofenac sodium|Diclofenac sodium
262048|NCT02202967|Drug|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
262049|NCT02202967|Drug|Placebo|Placebo contains lactose granules
262050|NCT02202954|Other|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.~The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
262051|NCT02202941|Other|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
262052|NCT02202941|Other|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
262053|NCT02202928|Biological|DC-CIK|8×10^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
262054|NCT02202928|Radiation|Radiotherapy|45~50 Gy in 25-28 fractions.
262055|NCT02202928|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
262056|NCT02202915|Behavioral|Behavioral Checklist|
262057|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
262058|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
262059|NCT02202889|Behavioral|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
262060|NCT02202876|Drug|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
262061|NCT02202876|Other|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
262062|NCT02202876|Other|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30~The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
262063|NCT02202863|Dietary Supplement|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
262064|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
262065|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
262066|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
262067|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
262068|NCT02202824|Other|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
262069|NCT02202811|Behavioral|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
262070|NCT02202798|Device|Syringe device|
262071|NCT02202785|Drug|MLN0264|MLN0264 IV infusion
262072|NCT02202772|Drug|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
262073|NCT02202772|Drug|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
262074|NCT02202772|Drug|Cisplatin|Intravesical installation of Cisplatin for 2hours
262075|NCT02202759|Drug|MLN0264|MLN0264 IV infusion
262076|NCT02202746|Drug|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
262077|NCT02202733|Other|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
262078|NCT02202720|Drug|Sevoflurane|Short term sedation with sevoflurane in ICU
262079|NCT02202707|Drug|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
262080|NCT02202694|Behavioral|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
262081|NCT02202681|Device|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
262082|NCT02202668|Device|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
262083|NCT02202642|Procedure|collagenase|Cultured limbal stem cells transplantation
262084|NCT02202629|Other|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
262085|NCT02202616|Drug|Glycopyrronium /Indacaterol maleate|Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
262086|NCT02202603|Drug|Teriparatide|single oral tablet
262087|NCT02202603|Drug|Teriparatide|subcutaneous standard injection
262088|NCT02202603|Drug|placebo|Oral placebo
262089|NCT02202590|Device|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
262090|NCT02202577|Drug|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
262091|NCT02202577|Drug|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
262092|NCT02202564|Procedure|LT|Orthotopic LT
262093|NCT02202564|Drug|ADV-TK|
262094|NCT02202564|Drug|ganciclovir|
262095|NCT02202551|Drug|ADS-5102|
262096|NCT02202538|Device|Indego|Indego
262097|NCT02202525|Drug|Micardis®|
262098|NCT02202525|Drug|Other hypertensives|
262099|NCT02202512|Drug|Placebo|tablets
262100|NCT02202512|Drug|Cimetidine|
262101|NCT02202512|Drug|Placebo|tablets
262102|NCT02202512|Drug|Placebo|tablets
262103|NCT02202512|Drug|BI 1060469 high dose|tablets
262104|NCT02202512|Drug|BI 1060469 low dose|tablets
262105|NCT02202512|Drug|Naproxen|
262106|NCT02202512|Drug|BI 1021958|tablets
262107|NCT02202499|Drug|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
262108|NCT02202499|Other|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
262109|NCT02202499|Other|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
262110|NCT02202486|Other|Brain MRI|Brain MRI with gadolinium contrast
262111|NCT02202473|Drug|Lamivudine|
262112|NCT02202473|Drug|Lamivudine+Oxymatrine Capsules|
262113|NCT02202447|Drug|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
262114|NCT02202447|Other|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
262115|NCT02202434|Device|Lotus Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
262116|NCT02202434|Device|CoreValve/Evolut R Transcatheter Aortic Valve Replacement System|Procedure: Transcatheter aortic valve replacement (TAVR)
262117|NCT02202434|Device|LOTUS Edge Valve System|Procedure: Transcatheter aortic valve replacement (TAVR)
262118|NCT02202421|Behavioral|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
262119|NCT02202408|Drug|SKI2670|Oral, Single Dose
262120|NCT02202408|Drug|Placebo|Same shape as the experimental drug
262121|NCT02202395|Drug|LTS 0.25mg|use LTS 0.25mg/d
262122|NCT02202395|Drug|LTS 0.5mg|use LTS 0.5mg/d
262123|NCT02202395|Drug|LTS 1.0mg|use LTS 1.0mg/d
262124|NCT02202395|Drug|Placebo|use placebo once daily
262125|NCT02202382|Drug|Korean Red Ginseng, Varicocelectomy|
262126|NCT02202382|Drug|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
262127|NCT02202382|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
262128|NCT02202369|Other|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
262129|NCT02202369|Other|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
262130|NCT02202356|Drug|ALS-008176|
262131|NCT02202356|Drug|Placebo|
262132|NCT02202343|Behavioral|school based health and nutrition education|
262286|NCT02201238|Drug|Menthol|Menthol
262133|NCT02202330|Other|Video Arm|"5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
262134|NCT02202317|Device|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
262135|NCT02202304|Drug|Chlorhexidine/Thymol varnish|This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
262136|NCT02202291|Genetic|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
262137|NCT02202265|Dietary Supplement|Olive oil|30ml a day of olive oil
262138|NCT02202265|Dietary Supplement|Nuts|30g a day of nuts
262139|NCT02202265|Dietary Supplement|Control diet|Diet based on standard guidelines
262140|NCT02202252|Procedure|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
262141|NCT02202252|Procedure|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
262142|NCT02202252|Procedure|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
262143|NCT02202239|Drug|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
262144|NCT02202239|Drug|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
262145|NCT02202239|Drug|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
262146|NCT02202239|Drug|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
262147|NCT02202239|Drug|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
262148|NCT02202239|Drug|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.~During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
262149|NCT02202239|Drug|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
262150|NCT02202239|Drug|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
262151|NCT02202226|Drug|Lu AF35700|
262152|NCT02202226|Drug|Placebo|
262153|NCT02202213|Drug|Placebo|
262154|NCT02202213|Drug|Lu AF11167|
262155|NCT02202200|Drug|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg~All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
262156|NCT02202187|Drug|GSK2140944|Investigational Study Drug
262157|NCT02202187|Other|Placebo|Placebo
262158|NCT02202174|Device|Supraglottic Airway Device|
262159|NCT02202161|Drug|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
262160|NCT02202161|Drug|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
262161|NCT02202161|Drug|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
262162|NCT02202161|Drug|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
262163|NCT02202135|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
262164|NCT02202135|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
262165|NCT02202135|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
262166|NCT02202122|Other|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
262167|NCT02202109|Behavioral|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
262168|NCT02202109|Behavioral|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
262169|NCT02202096|Other|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
262170|NCT02202096|Other|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
262346|NCT02200809|Device|MR-guided focal laser ablation|
262171|NCT02202096|Other|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
262172|NCT02202096|Other|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
262173|NCT02202096|Other|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
262174|NCT02202096|Other|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
262175|NCT02202096|Other|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
262176|NCT02202096|Other|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
262177|NCT02202096|Other|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
262178|NCT02202096|Other|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
262179|NCT02202096|Other|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
262180|NCT02202083|Other|Cook Balloon|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.~This group is term gestaion,with bishop score less than 6."
262181|NCT02202070|Drug|onabotulinumtoxinA|
262182|NCT02202057|Other|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
262183|NCT02202057|Other|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
262184|NCT02202044|Device|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
262185|NCT02202031|Behavioral|Paced Respiration|Participants will use a small, commercially-available guided-breathing device to practice breathing at a rate slower than 10 breaths per minute. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
262186|NCT02202031|Behavioral|Music Therapy|Participants will use an identical appearing device, programmed to play quiet, relaxing music, while monitoring spontaneous breathing. Participants will be instructed to use their devices for at least 15 minutes per day for 12 weeks.
262187|NCT02202018|Other|Active KT intervention|"Provider & patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space~Educational white board presentations promoting home dialysis~Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial & national averages~A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.~Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
262188|NCT02202005|Drug|Nevirapine|Nevirapine 400mg PR tablet
262189|NCT02202005|Drug|Viramune®|Viramune® 400 mg Retardtabletten
262190|NCT02201992|Other|Clinical Observation|Undergo observation
262191|NCT02201992|Drug|Crizotinib|Given PO
262192|NCT02201992|Other|Laboratory Biomarker Analysis|Correlative studies
262193|NCT02201979|Procedure|Vertical breast lift with implants|
262194|NCT02201953|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
262195|NCT02201953|Drug|SOF|400 mg tablet administered orally once daily
262196|NCT02201953|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
262197|NCT02201940|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
262198|NCT02201940|Drug|Placebo|Tablet administered orally once daily
262199|NCT02201927|Device|galvanic vestibular stimulation|
262200|NCT02201914|Drug|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
262345|NCT02200822|Drug|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
262201|NCT02201914|Drug|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
262202|NCT02201914|Drug|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
262203|NCT02201901|Drug|SOF/VEL|400/100 mg tablets administered orally once daily
262204|NCT02201901|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
262205|NCT02201888|Behavioral|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
262206|NCT02201888|Other|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
262207|NCT02201888|Other|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
262208|NCT02201849|Drug|Study Drug|
262209|NCT02201849|Drug|Active Control|
262210|NCT02201849|Drug|Placebo|
262211|NCT02201836|Other|One time music therapy|
262212|NCT02201836|Other|Group music therapy|
262213|NCT02201823|Drug|ABTL0812|ABTL0812. Five cohorts and one extension phase.
262214|NCT02201810|Behavioral|Rate reduction intervention|
262215|NCT02201810|Behavioral|Recycling Group|
262216|NCT02201810|Behavioral|Choice Group|
262217|NCT02201810|Behavioral|Proactive QL|
262218|NCT02201797|Other|DCE MRI|
262219|NCT02201784|Drug|Levobupivacaine|Comparison of Equipotent doses
262220|NCT02201784|Drug|Ropivacaine|Comparison of equipotent doses
262221|NCT02201771|Drug|Aspirin|
262222|NCT02201771|Drug|Ticagrelor|
262223|NCT02201758|Dietary Supplement|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
262224|NCT02201758|Other|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
262225|NCT02201732|Procedure|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
262226|NCT02201732|Procedure|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
262227|NCT02201706|Procedure|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
262228|NCT02201693|Dietary Supplement|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
262229|NCT02201693|Dietary Supplement|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
262230|NCT02201667|Drug|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
262231|NCT02201667|Drug|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
262232|NCT02201667|Drug|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
262233|NCT02201667|Procedure|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
262234|NCT02201654|Other|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
262235|NCT02201641|Radiation|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
262236|NCT02201641|Radiation|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
262237|NCT02201641|Device|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
262238|NCT02201641|Device|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
262239|NCT02201628|Device|Nasopharyngeal and oesophageal temperature probes|
262240|NCT02201615|Other|Perineal massage in childbirth|
262241|NCT02201602|Drug|Gliclazide|
262242|NCT02201602|Drug|Glibenclamide|
262243|NCT02201589|Device|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
262287|NCT02201225|Dietary Supplement|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
262244|NCT02201576|Drug|Bortezomib|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
262245|NCT02201576|Drug|Plasma exchanges and intravenous immunoglobulins|"Five plasma exchanges +0.1 g/kg of intravenous immunoglobulins at the end of each course~four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)~oral dexamethasone (20 mg po at day-1, day-3, day-5, day-7 of the two first intravenous immunoglobulins courses)"
262246|NCT02201563|Drug|Minocycline|Oral minocycline (100mg twice a day) for 3 months
262247|NCT02201537|Device|renal echography|"Renal biopsy will be performed at 3 and 12 months.~The functional imaging examinations will be held as follows:~Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS"
262248|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
262249|NCT02201524|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
262250|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
262251|NCT02201524|Other|Placebo|Subjects will receive placebo for 4 weeks
262252|NCT02201511|Drug|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
262253|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
262254|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
262255|NCT02201511|Drug|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
262256|NCT02201498|Procedure|Pulpotomies with Formocresol/OZE and Biodentine|
262257|NCT02201485|Device|Stent|
262258|NCT02201485|Device|Balloon|
262259|NCT02201472|Device|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
262260|NCT02201459|Drug|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
262261|NCT02201459|Drug|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and~Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
262262|NCT02201420|Drug|Tc 99m tilmanocept|
262263|NCT02201407|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
262264|NCT02201394|Drug|Ticagrelor loading dose|Single loading dose of Ticagrelor 180 mg
262265|NCT02201394|Drug|Aspirin loading dose|Single loading dose of Aspirin 325 mg
262266|NCT02201394|Drug|Ticagrelor maintenance dose|Ticagrelor 90 mg twice daily x 7 days
262267|NCT02201394|Drug|Aspirin maintenance dose|Aspirin 81 mg once daily x 7 days
262268|NCT02201381|Drug|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
262269|NCT02201368|Drug|Triheptanoin (SpezialölÒ 107®)|"Randomization: Treatment with Triheptanoin for 6 months~Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
262270|NCT02201368|Dietary Supplement|MCT (Medium-Chain Triglycerides)|"Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months~Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months~Crossover: Treatment with Triheptanoin for 6 months"
262271|NCT02201355|Radiation|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
262272|NCT02201342|Drug|Udenafil|Drug
262273|NCT02201329|Drug|Azacitidine|Azacitidine (subcutaneous)
262274|NCT02201329|Drug|Volasertib|Volasertib escalating doses (intravenous)
262275|NCT02201316|Drug|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
262276|NCT02201316|Drug|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
262277|NCT02201316|Drug|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
262278|NCT02201303|Drug|Danirixin|Powdered form for in-vitro administration to blood sample
262279|NCT02201303|Other|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
262280|NCT02201290|Drug|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
262281|NCT02201290|Drug|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
262282|NCT02201277|Device|Filter Placed|
262283|NCT02201251|Drug|Topiramate|Topiramate weight based dosing for participants 2 to <10 years of age not to exceed 350 mg/day, as tolerated; not to exceed 400 mg/day in participants 10-15 years of age, as tolerated.
262284|NCT02201251|Drug|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
262288|NCT02201225|Dietary Supplement|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
262289|NCT02201212|Drug|Everolimus|
262290|NCT02201199|Drug|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
262291|NCT02201199|Drug|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
262292|NCT02201199|Drug|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
262293|NCT02201186|Other|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
262294|NCT02201173|Behavioral|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
262295|NCT02201160|Dietary Supplement|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
262296|NCT02201147|Procedure|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
262297|NCT02201147|Procedure|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
262298|NCT02201147|Device|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
262299|NCT02201147|Device|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
262300|NCT02201134|Drug|sevoflurane|
262301|NCT02201121|Other|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
262302|NCT02201108|Drug|Teriflunomide|Pharmaceutical form:film-coated tablet Route of administration: oral
262303|NCT02201108|Drug|Placebo|Pharmaceutical form:tablet Route of administration: oral
262304|NCT02201095|Device|Forced air warming|
262305|NCT02201095|Device|Conduction warming mattress|
262306|NCT02201082|Procedure|Airway clearance technique|
262307|NCT02201082|Drug|Amikacin nebulization|
262308|NCT02201069|Behavioral|health coaching|
262309|NCT02201056|Drug|TAK-935|TAK-935 oral solution
262310|NCT02201056|Drug|Placebo|TAK-935 placebo-matching oral solution
262311|NCT02201043|Drug|Thalidomide 150mg|
262312|NCT02201043|Drug|Thalidomide 100mg|
262313|NCT02201043|Drug|Placebo|
262314|NCT02201030|Biological|NBP606|A single intramuscular injection into the thigh
262315|NCT02201030|Biological|Prevnar13|A single intramuscular injection into the thigh
262316|NCT02201004|Drug|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
262317|NCT02201004|Drug|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
262318|NCT02201004|Drug|placebo|Pharmaceutical form:tablet Route of administration: oral
262319|NCT02200991|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
262320|NCT02200991|Drug|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
262321|NCT02200991|Drug|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
262322|NCT02200978|Drug|ATO|Given IV
262323|NCT02200978|Drug|RIF|Given orally
262324|NCT02200978|Drug|ATRA|Given orally
262325|NCT02200978|Drug|mitoxantrone|Given IV
262326|NCT02200978|Drug|Ara-C|Given IV
262327|NCT02200978|Drug|MTX|Given orally
262328|NCT02200978|Drug|6MP|Given orally
262329|NCT02200978|Other|intrathecal injection|Ara-C and dexamethasone
262330|NCT02200965|Other|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
262331|NCT02200952|Drug|recombinant LH|recombinant LH twice/day for 10 days from pick up
262332|NCT02200939|Device|Bioinductive implant|
262333|NCT02200939|Device|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
262334|NCT02200926|Other|Loaded breathing training|7 days/weeks, for 8 weeks
262335|NCT02200926|Other|Unloaded breathing training|7 days/week, for 8 weeks
262336|NCT02200926|Other|Placebo|7 days/week, for 8 weeks
262337|NCT02200913|Other|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
262338|NCT02200913|Other|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
262339|NCT02200900|Other|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
262340|NCT02200900|Other|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
262341|NCT02200900|Other|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
262342|NCT02200900|Other|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
262343|NCT02200848|Drug|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
262347|NCT02200796|Other|Control Meal|High carbohydrate meal
262348|NCT02200796|Other|Low Protein Meal|Omelet with 15 g of protein
262349|NCT02200796|Other|Moderate Protein Meal|Omelet with 30 g of protein
262350|NCT02200796|Other|High Protein Meal|Omelet with 45 g of protein
262351|NCT02200783|Device|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
262352|NCT02200783|Device|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
262353|NCT02200783|Device|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
262354|NCT02200770|Biological|MEDI-551|
262355|NCT02200770|Other|Placebo|Matching placebo
262356|NCT02200757|Drug|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
262357|NCT02200757|Drug|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
262358|NCT02200731|Behavioral|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
262359|NCT02200718|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
262360|NCT02200718|Biological|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
262361|NCT02200705|Device|Ice-Sense3TM|
262362|NCT02200653|Drug|High dose of MICARDIS®, once daily|
262363|NCT02200653|Drug|Low dose of MICARDIS®, once daily|
262364|NCT02200653|Drug|Low dose of COZAAR® / LORZAAR®, once daily|
262365|NCT02200653|Drug|High dose of COZAAR® / LORZAAR®, once daily|
262366|NCT02200653|Drug|Placebo|
262367|NCT02200640|Drug|High dose of Micardis®, once daily|
262368|NCT02200640|Drug|Low dose of Micardis®, once daily|
262369|NCT02200640|Drug|Low dose of COZAAR®, once daily|
262370|NCT02200640|Drug|High dose of COZAAR®, once daily|
262371|NCT02200640|Drug|Placebo|
262372|NCT02200614|Drug|Darolutamide (BAY1841788)|Darolutamide 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg.
262373|NCT02200614|Drug|Placebo|Matching placebo 2 tablets twice daily with food.
262374|NCT02200601|Device|Seipher Wellness|
262375|NCT02200575|Drug|Telmisartan|
262376|NCT02200562|Drug|ipilimumab and dabrafenib|
262377|NCT02200549|Device|Control group|Neither cycle training nor inspiratory muscle training.
262378|NCT02200549|Device|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
262379|NCT02200549|Device|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
262380|NCT02200536|Other|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
262381|NCT02200536|Other|Infant oral health pamphlet|Infant oral health pamphlet
262382|NCT02200523|Device|SARA electrode|
262383|NCT02200523|Device|Gold cup|
262384|NCT02200510|Behavioral|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
262385|NCT02200510|Behavioral|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
262386|NCT02200484|Behavioral|Combined parent training and obesity prevention program|
262387|NCT02200484|Behavioral|Wellness program (active contact control)|
262388|NCT02200471|Device|VeinViewer|
262389|NCT02200458|Device|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
262390|NCT02200445|Drug|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
262391|NCT02200432|Other|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
262392|NCT02200419|Other|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
262393|NCT02200406|Drug|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
262394|NCT02200393|Device|Abdominal FES|"Stimulation intensity was adjusted on a channel by channel basis until a strong visible contraction of the abdominal muscles is observed. During the session, manual adjustment of both the stimulation intensity (to compensate for fatigue) and the duty cycle is possible.~Four pairs of surface electrodes were placed on the participant's abdomen. One pair will be placed on both the right and left side of the rectus abdominis around the naval. One pair of electrodes will also be placed on both the right and left side of the external oblique muscles with one electrode being placed just below the participant's bottom rib and the other below this with a separation of around 3cm."
262395|NCT02200380|Drug|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
262396|NCT02200380|Drug|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
262397|NCT02200367|Behavioral|e-mental health collaborative programme|
262398|NCT02200367|Other|Usual Care|
262399|NCT02200354|Drug|pemetrexed with bevacizumab|
262400|NCT02200341|Behavioral|MBCT|
262401|NCT02200341|Behavioral|PRT-PsyEd|
262402|NCT02200328|Drug|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
262403|NCT02200328|Drug|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
262404|NCT02200315|Other|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
262405|NCT02200276|Biological|Influenza|
262406|NCT02200263|Dietary Supplement|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
262407|NCT02200263|Dietary Supplement|Placebo|two softgels once-daily with a meal
262408|NCT02200237|Biological|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
262409|NCT02200237|Biological|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
262410|NCT02200224|Other|Rapid Testing|
262411|NCT02200211|Device|iPad®|Binocular therapy on iPad®
262412|NCT02200211|Other|Patching 2 hours per day, 7 days per week|
262413|NCT02200198|Other|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
262414|NCT02200198|Other|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
262415|NCT02200198|Other|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
262416|NCT02200185|Drug|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:~SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
262417|NCT02200185|Drug|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
262418|NCT02200185|Drug|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
262419|NCT02200172|Other|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
262420|NCT02200172|Other|Placebo|
262421|NCT02200159|Drug|Sedation with dexmedetomidine|
262422|NCT02200146|Drug|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
262423|NCT02200146|Drug|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
262424|NCT02200133|Other|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
262425|NCT02200107|Behavioral|self management education|
262426|NCT02200094|Drug|Low dose of Telmisartan, once daily|
262427|NCT02200094|Drug|High dose of Telmisartan, once daily|
262428|NCT02200081|Drug|MGN1703|
262429|NCT02200081|Other|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
262430|NCT02200068|Other|SANOIA Website|
262431|NCT02200055|Device|Bodystat Quadscan 4000|"Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.~Bioimpedance Assessment"
262432|NCT02200042|Radiation|Image Guided Radiation Therapy|Patients undergo 15 fractions of image-guided radiation therapy delivered over 19-26 or 27-34 days.
262433|NCT02200029|Drug|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
262434|NCT02200029|Drug|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
262435|NCT02200016|Procedure|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
262436|NCT02200016|Procedure|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
262437|NCT02200016|Device|B Braun Contiplex S catheter|
262438|NCT02200003|Behavioral|attention bias modification for anxiety|
262439|NCT02199977|Other|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
262440|NCT02199977|Other|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
262441|NCT02199977|Other|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
262442|NCT02199964|Drug|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
262443|NCT02199964|Drug|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
262444|NCT02199951|Drug|Dihydroartemisinin and piperaquine|Antimalarial
262445|NCT02199938|Other|Identification and characterization of molecular markers in musculoskeletal tumors|
262446|NCT02199925|Drug|Gammaplex 5%|
262447|NCT02199912|Procedure|Biopsy of adipose and muscular tissue|
262448|NCT02199912|Other|Blood sampling|
262449|NCT02199912|Other|Calorimetry|
262450|NCT02199912|Other|Impedance measure|Evaluation of physical composition (non-invasive method)
262451|NCT02199912|Other|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
262452|NCT02199912|Other|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
262453|NCT02199912|Other|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
262454|NCT02199912|Other|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
262455|NCT02199912|Other|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
262456|NCT02199899|Drug|BIIF 1149 BS - single rising doses|
262457|NCT02199899|Drug|Placebo|
262458|NCT02199886|Drug|BIBH 1|labeled with eight to ten millicurie of 131I
262459|NCT02199873|Drug|BIIX 1 XX - single rising dose|
262460|NCT02199873|Drug|Placebo|
262461|NCT02199860|Drug|SD I|
262462|NCT02199860|Drug|SD II|
262463|NCT02199860|Drug|Placebo|
262464|NCT02199847|Drug|Pharmaton® Caplets|
262465|NCT02199847|Drug|Placebo|
262466|NCT02199834|Behavioral|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
262467|NCT02199834|Behavioral|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
262468|NCT02199821|Dietary Supplement|Formula with soybean oil, medium-chain triglycerides|
262469|NCT02199821|Dietary Supplement|Soybean oil formula commonly used in the hospital|
262470|NCT02199795|Device|Contralaterally Controlled Neuromuscular Electrical Stimulation|
262471|NCT02199795|Device|Cyclic Neuromuscular Electrical Stimulation|
262472|NCT02199782|Other|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
262473|NCT02199769|Other|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
262474|NCT02199743|Drug|Lurasidone|Compare to haloperidol and perphenazine
262475|NCT02199743|Drug|Haloperidol|Compare to lurasidone
262476|NCT02199743|Drug|Perphenazine|Compare to lurasidone
262477|NCT02199717|Device|Accelerometer|
262478|NCT02199704|Other|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders & Turner, 1999) and up to ten sessions of support. This is a case series study."
262479|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
262480|NCT02199691|Biological|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197Conjugate Vaccine|0.5 mL, IM
262481|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
262482|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
262483|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
262484|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
262485|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
262486|NCT02199678|Drug|Placebo|placebo
262487|NCT02199678|Drug|ketamine 25 mg|ketamine
262488|NCT02199678|Drug|ketamine 35 mg|ketamine
262489|NCT02199678|Drug|ketamine 50 mg|ketamine
262490|NCT02199665|Drug|selinexor|Given PO
262491|NCT02199665|Drug|carfilzomib|Given IV
262492|NCT02199665|Drug|dexamethasone|Given PO or IV
262493|NCT02199652|Drug|Prazosin|
262494|NCT02199652|Drug|Placebo|
262495|NCT02199626|Device|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
262496|NCT02199613|Drug|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
262497|NCT02199600|Device|GMK Sphere Knee Replacement|
262498|NCT02199587|Behavioral|Presence of medical clown during endocrine test|
262499|NCT02199574|Drug|EXPAREL|133 mg EXPAREL in 10 mL.
262500|NCT02199561|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
262501|NCT02199548|Other|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
262502|NCT02199522|Procedure|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
262503|NCT02199509|Drug|Levetiracetam|Anticonvulsant
262569|NCT02199041|Biological|G-CSF|Given either by intravenous infusion or subcutaneously daily until absolute neutrophil count (ANC) >2000 for 3 consecutive days.
262570|NCT02199041|Drug|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
262797|NCT02197156|Drug|10 mg HC-ER|Single dose
262504|NCT02199496|Biological|Stelara (ustekinumab)|The purpose of this study is to assess the safety/tolerability and efficacy of using Stelara (ustekinumab) in subjects with common variable immunodeficiency or selective IgG subclass deficiency (functional agammaglobulinemia) who have associated symptomatic gastrointestinal inflammation (CVID enteropathy). Subjects will receive a treatment dose of 270 mg will be injected subcutaneously in subjects by qualified nursing staff on the Day 0 study visit. Subjects will then receive a follow up treatment dose of 90 mg at Week 8, Week 16, Week 24, Week 32 and Week 40 and be followed for a total of 48 weeks.
262505|NCT02199457|Device|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
262506|NCT02199457|Device|SVSS and reference devices|Body temperature taken with infrared thermometer
262507|NCT02199457|Device|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
262508|NCT02199457|Device|SVSS and reference devices|Measurement of respiration rate
262509|NCT02199444|Drug|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
262510|NCT02199444|Drug|Placebo|
262511|NCT02199431|Drug|Lu AF11167|
262512|NCT02199431|Drug|Itraconazole|
262513|NCT02199418|Drug|Paclitaxel|
262514|NCT02199418|Drug|Cisplatin|
262515|NCT02199405|Other|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
262516|NCT02199405|Other|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
262517|NCT02199405|Other|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
262518|NCT02199405|Other|Cervical traction|
262519|NCT02199392|Drug|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
262520|NCT02199379|Drug|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
262521|NCT02199366|Procedure|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
262522|NCT02199353|Other|Stimulation of Activities Daily Living|"Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
262523|NCT02199353|Other|Conventional ADLOccupational Therapy|"Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.~The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
262524|NCT02199340|Other|iStep exercise test|newly developed submaximal exercise test
262525|NCT02199340|Other|CPET exercise test|maximal gold standard exercise test
262526|NCT02199327|Drug|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
262527|NCT02199327|Drug|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
262528|NCT02199314|Procedure|Intraoperative Neurophysiologic Monitoring|transcranial motor evoked potentials are collected prior to the administration of desflurane (under intravenous anesthesia) and again after desflurane is added for at least 5 minutes and is at 3%.
262529|NCT02199314|Drug|Desflurane|
262530|NCT02199301|Procedure|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
262531|NCT02199262|Other|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
262532|NCT02199262|Other|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
262533|NCT02199262|Other|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
262534|NCT02199249|Device|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
262535|NCT02199249|Device|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
262536|NCT02199236|Radiation|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
262571|NCT02199041|Drug|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
262572|NCT02199041|Drug|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
262573|NCT02199041|Radiation|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
262623|NCT02198651|Other|Placebo|Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
262537|NCT02199236|Drug|concurrent capecitabine or 5-FU|"Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.~Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days."
262538|NCT02199236|Behavioral|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
262539|NCT02199223|Drug|regorafenib + panitumumab|
262540|NCT02199210|Other|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
262541|NCT02199197|Drug|Radium Ra 223 Dichloride|Radium Ra 223 Dichloride, 55 kilobecquerel (kBq)/kg body weight, administered as a bolus intravenous (IV) injection (up to 1 minute) on Day 1 of each cycle for 6 cycles.
262542|NCT02199197|Drug|Enzalutamide|Enzalutamide 160 mg administered orally once a day (continuously) for 6 cycles.
262543|NCT02199184|Drug|Cyclophosphamide|Given IV
262544|NCT02199184|Drug|Doxorubicin Hydrochloride|Given IV
262545|NCT02199184|Drug|Etoposide|Given IV
262546|NCT02199184|Biological|Ofatumumab|Given IV
262547|NCT02199184|Drug|Prednisone|Given PO
262548|NCT02199184|Biological|Rituximab|Given IV
262549|NCT02199184|Drug|Vincristine Sulfate|Given IV
262550|NCT02199171|Drug|carboplatin|Given via HIPEC
262551|NCT02199158|Procedure|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
262552|NCT02199145|Procedure|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
262553|NCT02199119|Behavioral|Exercise|30 min of moderate exercise on a treadmill
262554|NCT02199119|Behavioral|TV viewing|watching TV (animated children's programming) for 30 min
262555|NCT02199119|Behavioral|Sitting quietly|Sitting quietly for 30 min
262556|NCT02199106|Device|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)~Arms: Left temporal verum cTBS"
262557|NCT02199106|Device|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings~Arms: Left temporal placebo cTBS"
262558|NCT02199093|Other|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
262559|NCT02199093|Other|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
262560|NCT02199080|Other|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
262561|NCT02199054|Other|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
262562|NCT02199054|Other|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
262563|NCT02199054|Other|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
262564|NCT02199041|Drug|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
262565|NCT02199041|Drug|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
262566|NCT02199041|Drug|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
262567|NCT02199041|Drug|Melphalan|Given by intravenous infusion as part of the preparative regimen.
262568|NCT02199041|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
262750|NCT02197429|Other|Acupuncture|
262574|NCT02199041|Biological|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
262575|NCT02199041|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
262576|NCT02199028|Drug|Hyaluronidase|150 units/ml - subjects injected 1 milliliter (ml) into the catheter hub prior to connecting the insulin infusion set on Day 1 and 3 of infusion set wear.
262577|NCT02199028|Other|Control|No hyaluronidase administered into insulin infusion set.
262578|NCT02199015|Device|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
262579|NCT02199002|Device|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
262580|NCT02198989|Behavioral|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
262581|NCT02198963|Drug|Hypochlorous acid solution 106 mg/L|test product
262582|NCT02198963|Drug|0.1% (w/v) Sodium Lauryl Sulfate|positive control
262583|NCT02198963|Drug|0.9% Physiological Saline, USP|negative control
262584|NCT02198937|Other|Blood sample|
262585|NCT02198924|Drug|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
262586|NCT02198924|Drug|placebo|control patients are supplied with the corresponding placebo with the same instructions.
262587|NCT02198911|Other|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
262588|NCT02198911|Other|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
262589|NCT02198911|Other|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
262590|NCT02198898|Device|GUARDIX-SG|
262591|NCT02198872|Other|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
262592|NCT02198872|Other|Land Group|Patients of this group perform physical training on bicycle.
262593|NCT02198859|Drug|Lithium Carbonate|
262594|NCT02198846|Device|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
262595|NCT02198846|Drug|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
262596|NCT02198833|Biological|Urine Culture|Obtain urine culture every third day
262597|NCT02198833|Device|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
262598|NCT02198833|Device|Scanning Electron Microscopy|Houston Site Only
262599|NCT02198833|Procedure|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
262600|NCT02198833|Procedure|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
262601|NCT02198820|Drug|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
262602|NCT02198820|Drug|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
262603|NCT02198807|Drug|Fosmidomycin-Piperaquine|
262604|NCT02198794|Drug|SD-809|SD-809 tablets dose titrated for 6 weeks until optimal dose is reached. The dose is maintained for the duration of the study.
262605|NCT02198794|Drug|Placebo|I week period of randomized withdrawal
262606|NCT02198755|Device|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
262607|NCT02198755|Device|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
262608|NCT02198742|Device|Miller blade|To participate in the study the subjects must have >500 intubations with the miller blade.
262609|NCT02198742|Device|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
262610|NCT02198742|Device|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
262611|NCT02198729|Procedure|Endoscopic Submucosal Dissection|
262612|NCT02198729|Procedure|Endoscopic Mucosal Resection|
262613|NCT02198716|Procedure|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
262614|NCT02198716|Procedure|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
262615|NCT02198703|Dietary Supplement|Probiotics bacterial strains|
262616|NCT02198703|Dietary Supplement|Placebo|
262617|NCT02198690|Other|Mammography decision aid|
262618|NCT02198690|Other|Home safety pamphlet|
262619|NCT02198677|Procedure|Anterior to posterior pressures|Anterior to posterior pressures
262620|NCT02198677|Procedure|Lateral glide|Lateral glide
262621|NCT02198664|Biological|AR101 - Peanut protein capsule|characterized peanut allergen provided in break apart capsules for oral immunotherapy
262622|NCT02198651|Biological|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
262624|NCT02198638|Biological|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
262625|NCT02198625|Other|Moderate FiO2 and Protective Lung Ventilation Using|
262626|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
262627|NCT02198599|Procedure|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
262628|NCT02198560|Device|RS-3000 Lite|
262629|NCT02198547|Drug|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
262630|NCT02198547|Drug|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
262631|NCT02198534|Device|Methodology of visual acuity assessment|
262632|NCT02198508|Drug|DFX(Deferasirox)|
262633|NCT02198508|Drug|DFP(Deferiprone)|
262634|NCT02198495|Drug|Supplementation of ferric carboxymaltose|
262635|NCT02198495|Drug|Supplementation of iron sucrose|
262636|NCT02198482|Drug|Volasertib|
262637|NCT02198482|Drug|Cytarabine|
262638|NCT02198482|Drug|Daunorubicin|
262639|NCT02198482|Drug|Mitoxantrone|
262640|NCT02198469|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
262641|NCT02198469|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
262642|NCT02198443|Drug|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
262643|NCT02198443|Drug|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
262644|NCT02198417|Drug|Metformin ER|Treatment with metformin ER for 12 weeks
262645|NCT02198404|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
262646|NCT02198378|Drug|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
262647|NCT02198378|Drug|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
262648|NCT02198352|Drug|BIBN 4096 BS - in single rising doses|
262649|NCT02198352|Drug|Placebo|
262650|NCT02198339|Drug|BIBN 4096 BS|
262651|NCT02198339|Drug|Placebo|
262652|NCT02198326|Drug|BIBN 4096 BS- in single rising doses|
262653|NCT02198326|Drug|Placebo|
262654|NCT02198313|Drug|BIIX 1 XX - D1|
262655|NCT02198313|Drug|BIIX 1 XX - D2|
262656|NCT02198313|Drug|BIIX 1 XX - D3|
262657|NCT02198313|Drug|Placebo|
262658|NCT02198300|Procedure|Coronary angioplasty with stent implantation|
262659|NCT02198300|Drug|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
262660|NCT02198287|Drug|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
262661|NCT02198287|Drug|Placebo|
262662|NCT02198274|Drug|BIBH 1|100 mg/week
262663|NCT02198261|Drug|5% minoxidil topical foam|5% minoxidil topical foam
262664|NCT02198248|Drug|Rituximab|Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
262665|NCT02198248|Drug|Glucocorticoids|"Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule."
262666|NCT02198235|Drug|Dexamethasone|
262667|NCT02198235|Drug|Buprenorphine|
262668|NCT02198209|Drug|Liraglutide|"acute study: one injection of 0.6 mg s.c. before IVGTT~chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
262669|NCT02198196|Behavioral|Weight Talk-Mindfulness|
262670|NCT02198183|Device|Casmed Fore-Sight Elite|
262671|NCT02198183|Device|Non-invasive Cardiac Output Monitor (NICOM)|
262672|NCT02198170|Drug|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
262673|NCT02198170|Drug|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
262674|NCT02198157|Other|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
262675|NCT02198144|Other|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
262676|NCT02198131|Procedure|laser therapy|Undergo pulsed dye laser
262677|NCT02198131|Other|questionnaire administration|Ancillary studies
262678|NCT02198118|Other|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
262679|NCT02198105|Device|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:~PTA with Cutting-Balloon (60-120 seconds).~PTA with DC-Balloon (60 seconds).~Technical success is defined as~no recoil >30%~no dissection >Type B~no stenting >30% of lesion length."
262680|NCT02198092|Other|Epi proColon Testing|"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.~For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."
262681|NCT02198079|Biological|Sputum|
262682|NCT02198066|Other|Dry Sterile Dressing|Described in Arm Description.
262683|NCT02198066|Other|Metallic Silver Dressing|Described in Arm Description.
262684|NCT02198066|Other|Ionic Silver Dressing|Described in Arm Description.
262685|NCT02198040|Other|Manual Therapy|"5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~15 minutes. Passive muscle stretching (within the limits of mobility).~15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
262686|NCT02198040|Other|Educational group|"Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
262687|NCT02198027|Drug|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
262688|NCT02198027|Other|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
262689|NCT02198014|Other|Manual Therapy|"5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.~10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.~10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.~10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.~10 minutes. Local cryotherapy with ice pack."
262690|NCT02198014|Other|Educational Physiotherapy|"Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique."
262691|NCT02198001|Drug|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10"
262692|NCT02198001|Procedure|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
262693|NCT02197988|Drug|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
262694|NCT02197988|Drug|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
262695|NCT02197975|Drug|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
262696|NCT02197975|Drug|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
262697|NCT02197975|Drug|Placebo MDI|Placebo MDI. Administered as 2 inhalations
262698|NCT02197962|Device|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
262699|NCT02197962|Device|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
262700|NCT02197923|Procedure|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
262701|NCT02197923|Procedure|endometrial biopsy|transcervical endometrial biopsy
262702|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
262703|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
262704|NCT02197897|Drug|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
262705|NCT02197884|Drug|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
262706|NCT02197884|Drug|Itraconazole 200 mg|Itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
262707|NCT02197884|Drug|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
262708|NCT02197871|Dietary Supplement|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
262709|NCT02197845|Behavioral|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
262710|NCT02197845|Behavioral|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
262711|NCT02197832|Procedure|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
262712|NCT02197832|Procedure|control procedure|Using pipelle catheter without entering the uterine cavity.
262713|NCT02197832|Device|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
262714|NCT02197819|Device|Sling|
262715|NCT02197819|Device|External Rotation Brace|
262716|NCT02197806|Drug|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
262717|NCT02197806|Drug|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
262718|NCT02197806|Drug|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
262719|NCT02197793|Behavioral|Community Mobilization Program|
262720|NCT02197767|Drug|rituximab|1000 mg infusion
262721|NCT02197754|Other|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.~The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
262722|NCT02197741|Drug|opiate with bolus|
262723|NCT02197728|Device|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
262724|NCT02197715|Behavioral|Computer-adaptive SAFE|
262725|NCT02197715|Behavioral|Face-to-face SAFE|
262726|NCT02197715|Behavioral|Usual Care|
262727|NCT02197702|Dietary Supplement|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
262728|NCT02197702|Dietary Supplement|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
262729|NCT02197689|Device|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
262730|NCT02197676|Drug|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.~A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
262731|NCT02197663|Procedure|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.~The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
262732|NCT02197650|Drug|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
262733|NCT02197637|Drug|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
262734|NCT02197598|Drug|nalmefene|
262735|NCT02197585|Procedure|Inguinal mesh hernioplasty|
262736|NCT02197572|Drug|MLN0128|MLN0128 capsules
262737|NCT02197559|Procedure|DES group|all the participants in this group will be performed with drug -eluting stents
262738|NCT02197559|Procedure|BMS group|all the participants in this group will be performed with bare-metal stents
262739|NCT02197546|Other|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
262740|NCT02197533|Other|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
262741|NCT02197520|Drug|Insulin Peglispro|Administered subcutaneously (SC), (U-100 formulation)
262742|NCT02197520|Drug|Insulin Glargine|Administered subcutaneously (SC), (U-100 formulation)
262743|NCT02197520|Drug|Insulin Lispro|Administered subcutaneously (SC), (U-100 formulation)
262744|NCT02197507|Device|Digitized sensor|Measure of grip strength of the dominant hand
262745|NCT02197494|Drug|Valsartan|320mg tablets
262746|NCT02197481|Procedure|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
262747|NCT02197481|Device|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
262748|NCT02197455|Drug|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
262749|NCT02197442|Drug|Valsartan|
262751|NCT02197416|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
262752|NCT02197403|Drug|Dexmedetomidine|200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion
262753|NCT02197403|Drug|Propofol|25~75mcg/kg/min continuous infusion
262754|NCT02197390|Behavioral|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
262755|NCT02197390|Behavioral|Obesity chronic care model|
262756|NCT02197390|Behavioral|Physical activity, healthy eating, water drinking, healthy sleep promotion|
262757|NCT02197390|Behavioral|Environment, policy, systems changes in clinic setting only|
262758|NCT02197390|Behavioral|No intervention|No intervention.
262759|NCT02197390|Behavioral|Environment, policy, and systems changes in schools, early child care education & recreation|
262760|NCT02197377|Device|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
262761|NCT02197377|Device|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.The supraglottic airway devices were deflated fully before insertion. After placement an effective airway was defined as the presence of normal thoracoabdominal movement and a square-wave end-tidal carbon dioxide trace.
262762|NCT02197351|Procedure|White light biopsy|Endoscopy with biopsies guided by high definition white light
262763|NCT02197351|Procedure|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
262764|NCT02197351|Procedure|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
262765|NCT02197338|Other|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
262766|NCT02197325|Device|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
262767|NCT02197312|Device|NobelProcera Bridge Shaded Zirconia|
262768|NCT02197299|Dietary Supplement|L-carnitine|
262769|NCT02197299|Dietary Supplement|Placebo|
262770|NCT02197286|Drug|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
262771|NCT02197286|Drug|Placebo|Daily dose of a single gelatin placebo capsule.
262772|NCT02197273|Drug|Liposomal bupivacaine|
262773|NCT02197273|Drug|Standard of care analgesia|
262774|NCT02197260|Drug|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
262775|NCT02197247|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
262776|NCT02197247|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
262777|NCT02197247|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
262778|NCT02197247|Procedure|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
262779|NCT02197247|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
262780|NCT02197234|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
262781|NCT02197234|Drug|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
262782|NCT02197234|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
262783|NCT02197234|Procedure|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
262784|NCT02197234|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
262785|NCT02197221|Drug|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
262786|NCT02197221|Drug|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
262787|NCT02197208|Procedure|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
262788|NCT02197208|Procedure|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is >/= 17 mm and the endometrium measures >/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
262789|NCT02197208|Device|ultrasound|
262790|NCT02197195|Dietary Supplement|Chocolate Milk|
262791|NCT02197195|Dietary Supplement|Fruit Drink|
262792|NCT02197195|Behavioral|Exercise|
262793|NCT02197182|Drug|LUXSOL copper containing cream|Active comparator arm
262794|NCT02197182|Drug|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
262795|NCT02197169|Drug|Single intratumoral injection of DNX-2401|"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)~No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
262796|NCT02197169|Drug|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
262798|NCT02197156|Drug|20 mg HC-ER|Single dose
262799|NCT02197156|Drug|30 mg HC-ER|Single dose
262800|NCT02197156|Drug|40 mg HC-ER|Single dose
262801|NCT02197156|Drug|10 mg HC / 325 mg APAP|Single dose
262802|NCT02197156|Drug|Matching Placebo|Single dose
262803|NCT02197143|Drug|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
262804|NCT02197143|Drug|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
262805|NCT02197143|Drug|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
262806|NCT02197130|Drug|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
262807|NCT02197130|Drug|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
262808|NCT02197130|Other|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
262809|NCT02197117|Device|Remote ischemic conditioning|
262810|NCT02197117|Device|Control|
262811|NCT02197104|Drug|citocoline|
262812|NCT02197091|Other|questionnaire administration|Ancillary studies
262813|NCT02197091|Other|medical chart review|Ancillary studies
262814|NCT02197065|Drug|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
262815|NCT02197065|Drug|Placebo|
262816|NCT02197039|Drug|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
262817|NCT02197039|Procedure|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
262818|NCT02197026|Drug|Hylan G-F 20|
262819|NCT02197026|Drug|Standard treatment|Standard drug treatment at the discretion of the investigator
262820|NCT02197026|Procedure|Physiotherapy|
262821|NCT02197026|Procedure|Hydrotherapy|
262822|NCT02197000|Dietary Supplement|DIM-Avail 100mg|DIM 100 mg*1 daily for 2 years
262823|NCT02196987|Other|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
262824|NCT02196987|Other|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
262825|NCT02196974|Procedure|cryobiopsy|
262826|NCT02196961|Drug|Nivolumab|adjuvant treatment of completely resected Merkel cell carcinoma
262827|NCT02196948|Other|Electrolysis Percutaneous Therapeutic (EPTE)|
262828|NCT02196948|Other|Eccentric exercise|
262829|NCT02196935|Other|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
262830|NCT02196922|Device|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
262831|NCT02196922|Other|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
262832|NCT02196909|Other|motor function and strength assessment|
262833|NCT02196909|Other|NMR assessment|
262834|NCT02196909|Other|24h urine and serum collection|
262835|NCT02196896|Other|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
262836|NCT02196896|Other|Information|The patients receive online information about depression once a week for 90 days.
262837|NCT02196883|Procedure|Transforaminal Epidural Steroid Injection|
262838|NCT02196857|Drug|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
262839|NCT02196857|Drug|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
262840|NCT02196844|Behavioral|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
262841|NCT02196844|Behavioral|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
262842|NCT02196844|Other|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
262843|NCT02196831|Drug|tesamorelin|
262844|NCT02196831|Drug|Placebo|inactive substance that looks like tesamorelin
262845|NCT02196818|Device|Mpact Acetabular Shell|Total Hip Replacement
262846|NCT02196805|Drug|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
262847|NCT02196805|Drug|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
262848|NCT02196792|Device|E-Poly liner|E-Poly liner with a titanium cup
262849|NCT02196792|Device|ArComXL liner|ArComXL liner with a titanium cup
262850|NCT02196792|Device|32 mm femoral head|Stem with a 32 mm CoCr femoral head
262851|NCT02196792|Device|36 mm femoral head|Stem with a 36 mm CoCr femoral head
262852|NCT02196766|Other|Bioclean First Care EX / comfilcon A|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
262853|NCT02196766|Other|Aosept Clearcare / comfilcon A|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
262854|NCT02196753|Other|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient`s weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.~In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV> 40% of the background."
262855|NCT02196740|Drug|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
262856|NCT02196740|Drug|creosote|Pulp removal,Root canal irrigation and disinfection
262857|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
262858|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
262859|NCT02196714|Drug|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
262860|NCT02196714|Drug|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
262861|NCT02196701|Drug|Adalimumab|Administered by subcutaneous injection every other week.
262862|NCT02196701|Drug|Methotrexate|Methotrexate was provided as 2.5 mg tablets for oral administration.
262863|NCT02196688|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
262864|NCT02196688|Drug|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
262865|NCT02196675|Device|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
262866|NCT02196662|Drug|IBD98-M:|single adiministration
262867|NCT02196662|Drug|IBD98-M without HA|single adiministration
262868|NCT02196662|Drug|Delzicol|single adiministration
262869|NCT02196649|Device|Endoscopic Clip|
262870|NCT02196636|Drug|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
262871|NCT02196636|Drug|RO6806127|Administered orally with approximately 240 mL of buffer
262872|NCT02196623|Other|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
262873|NCT02196623|Other|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
262874|NCT02196610|Other|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
262875|NCT02196571|Other|Structured Exercise|
262876|NCT02196558|Drug|E6011|
262877|NCT02196545|Behavioral|Exercise|
262878|NCT02196532|Device|Device: Optical coherence tomography|
262879|NCT02196519|Device|Sylys Surgical Sealant|
262880|NCT02196506|Drug|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
262881|NCT02196506|Drug|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
262882|NCT02196493|Drug|Azithromycin|250mg azithromycin three times per week for 12 weeks
262883|NCT02196480|Biological|anti-TNF|Anti-tumor necrosis factor therapy
262884|NCT02196467|Biological|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
262885|NCT02196467|Procedure|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
262886|NCT02196454|Other|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
262887|NCT02196441|Drug|2% tetracaine local anaesthetic drops|topical anaesthetic drops
262888|NCT02196441|Drug|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
262928|NCT02196129|Drug|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
262929|NCT02196129|Drug|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
262930|NCT02196116|Other|PET|PET Scan with [18F]-Flutemetamol
262931|NCT02196116|Other|MRI|
262932|NCT02196116|Other|neuropsychological tests|
262933|NCT02196103|Device|Double balloon cervical catheter|
262889|NCT02196428|Other|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
262890|NCT02196415|Device|Biplanar Radiography|standard biplanar radiography of the foot
262891|NCT02196389|Device|Nasal dilator Nasanita|Nasal Dilator
262892|NCT02196389|Device|Nasal dilator Nozovent|
262893|NCT02196389|Device|Nasal dilator Breath Right|
262894|NCT02196389|Device|Nasal dilator Airmax|
262895|NCT02196376|Other|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
262896|NCT02196376|Other|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
262897|NCT02196376|Other|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn."
262898|NCT02196376|Behavioral|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
262899|NCT02196350|Behavioral|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
262900|NCT02196350|Behavioral|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
262901|NCT02196350|Behavioral|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
262902|NCT02196324|Drug|serlopitant|NK1 receptor antagonist
262903|NCT02196324|Drug|Placebo|Placebo
262904|NCT02196298|Device|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
262905|NCT02196298|Other|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
262906|NCT02196285|Biological|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
262907|NCT02196272|Behavioral|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:~- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
262908|NCT02196259|Drug|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
262909|NCT02196207|Drug|Eloctate Prophylaxis|Prevention Trial, Arm A: Eloctate (65 IU/kg) will be administered weekly by intravenous infusion for up to 48 weeks in previously untreated children with severe hemophilia A beginning before the first bleed.
262910|NCT02196207|Drug|Emicizumab Prophylaxis|Prevention Trial, Arm B: Emicizumab (1.5 mg/kg) will be administered weekly by subcutaneous injection for up to 48 weeks in previously untreated children with severe hemophilia A.
262911|NCT02196207|Drug|Eloctate ITI plus Emicizumab|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion plus Emicizumab (1.5 mg/kg) weekly by subcutaneous injection will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
262912|NCT02196207|Drug|Eloctate ITI|Eradication Trial, Arm A: Eloctate (100 IU/kg) ITI every other day by intravenous infusion will be administered for up to 48 weeks as immune tolerance in children and adults with severe hemophilia A and high-titer inhibitors.
262913|NCT02196194|Drug|Tiotropium|
262914|NCT02196181|Drug|Dabrafenib|Given PO
262915|NCT02196181|Drug|Dabrafenib Mesylate|Given PO
262916|NCT02196181|Drug|Trametinib|Given PO
262917|NCT02196181|Drug|Trametinib Dimethyl Sulfoxide|Given PO
262918|NCT02196168|Drug|Cisplatin|Given IV
262919|NCT02196168|Other|Laboratory Biomarker Analysis|Correlative studies
262920|NCT02196168|Other|Pharmacological Study|Correlative studies
262921|NCT02196168|Other|Placebo|Given PO
262922|NCT02196168|Drug|WEE1 Inhibitor AZD1775|Given PO
262923|NCT02196155|Drug|Botulinum toxin A|"Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.~In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc.."
262924|NCT02196155|Drug|cortisone|
262925|NCT02196155|Drug|Saline|
262926|NCT02196142|Drug|Cortisol 20mg|Drug: Cortisol 20mg
262927|NCT02196142|Drug|Placebo Mannitol|Drug: Placebo Mannitol
262934|NCT02196090|Behavioral|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
262935|NCT02196090|Device|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
262936|NCT02196077|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
262937|NCT02196077|Drug|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
262938|NCT02196077|Drug|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
262939|NCT02196077|Drug|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
262940|NCT02196077|Drug|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
262941|NCT02196051|Other|Exercise Training|Six weeks of exercise
262942|NCT02196038|Behavioral|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
262943|NCT02196038|Behavioral|Attention Control|Usual care with bi-weekly contact from study staff
262944|NCT02196025|Device|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
262945|NCT02196012|Behavioral|Intervention group|
262946|NCT02196012|Behavioral|attention control condition|
262947|NCT02195999|Other|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
262948|NCT02195999|Other|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
262949|NCT02195999|Other|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
262950|NCT02195999|Other|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
262951|NCT02195986|Drug|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
262952|NCT02195986|Drug|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
262953|NCT02195986|Drug|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
262954|NCT02195973|Drug|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
262955|NCT02195960|Dietary Supplement|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
262956|NCT02195960|Dietary Supplement|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
262957|NCT02195947|Drug|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
262958|NCT02195934|Other|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
262959|NCT02195934|Other|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
262960|NCT02195921|Other|single point Neiguan(CV12) plus antiemetic drug|
262961|NCT02195921|Other|single point Zusanli(ST36) plus antiemetic drug|
262962|NCT02195921|Other|matching points Zusanli(ST36)and Neiguan(CV12) plus antiemetic drug|
262963|NCT02195921|Drug|only antiemetic drug|
262964|NCT02195908|Other|single point Neiguan(PC6) plus antiemetic drug|
262965|NCT02195908|Other|single point Zhongwan(CV12) plus antiemetic drug|
262966|NCT02195908|Other|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
262967|NCT02195908|Drug|only antiemetic drug|
262968|NCT02195895|Drug|Alendronate|Weekly oral alendronate 70 mg for 12 months
262969|NCT02195895|Dietary Supplement|Calcium|Daily oral 1000 mg Calcium
262970|NCT02195895|Dietary Supplement|Vitamin D|Daily oral 1000 IU
262971|NCT02195882|Procedure|Exercise program of the scapular muscle stabilizers|
262972|NCT02195869|Drug|Ibrutinib|
262973|NCT02195856|Dietary Supplement|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
262974|NCT02195856|Dietary Supplement|Placebo|
262975|NCT02195843|Other|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.~The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
262976|NCT02195843|Other|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
262977|NCT02195843|Device|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
262978|NCT02195830|Other|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
262979|NCT02195817|Drug|Selincro® 18 mg with continuous psychosocial support: Cohort A|
262980|NCT02195817|Other|Initial psychosocial support: Cohort B|
262981|NCT02195804|Drug|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
262982|NCT02195804|Drug|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
262983|NCT02195804|Drug|Ranitidine hydrochloride|
262984|NCT02195791|Drug|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
262985|NCT02195791|Drug|Placebo|Placebo (oral) 1 tab once daily for 7 days
262986|NCT02195765|Drug|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
262987|NCT02195765|Procedure|Open flap debridement|Open flap debridement
262988|NCT02195752|Other|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
262989|NCT02195726|Procedure|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
262990|NCT02195726|Procedure|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
262991|NCT02195713|Device|Accuryn|Accuryn is a novel electronic urine output monitor
262992|NCT02195700|Drug|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
262993|NCT02195700|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks.
262994|NCT02195687|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
262995|NCT02195687|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
262996|NCT02195661|Dietary Supplement|Melatonin|
262997|NCT02195661|Drug|Chloral Hydrate|
262998|NCT02195648|Other|Suboccipital inhibition|"Experimental: Suboccipital inhibition~The intervention group will receive a session of 20 minutes (5 minutes for the patient's reception, 10 for treatment and the following 5 minutes for rest and hemodynamic stabilization), twice a week for 4 weeks. The intervention will consist of suboccipital muscle inhibition and interferential current on the occipital muscles."
262999|NCT02195635|Drug|Telotristat etiprate|500 mg telotristat etiprate
263000|NCT02195635|Drug|Octreotide acetate|200 µg octreotide acetate three times daily
263001|NCT02195622|Device|Lumenis VersaCut Morcellator|
263002|NCT02195622|Device|Wolf Piranha Morcellator|
263003|NCT02195609|Dietary Supplement|Omega-3|600 mg oral twice a day
263004|NCT02195609|Dietary Supplement|Soy Isoflavones|54.4 mg oral twice a day
263005|NCT02195596|Other|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse."
263006|NCT02195596|Other|Low intensity aerobic exercise+strength|"Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.~--------------------------------------------------------------------------------"
263007|NCT02195583|Drug|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
263008|NCT02195583|Drug|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
263009|NCT02195583|Drug|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
263010|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
263011|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
263012|NCT02195583|Drug|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
263013|NCT02195570|Other|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
263014|NCT02195570|Behavioral|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
263015|NCT02195557|Drug|Synvisc®|
263016|NCT02195544|Drug|Synvisc®|
263017|NCT02195531|Behavioral|Education and feedback|The education leaflets are information concerning Obstructive Sleep Apna (OSA) and CPAP treatment. The feedback reports are CPAP usage patterns.
263018|NCT02195518|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
263019|NCT02195492|Drug|Synvisc®|
263020|NCT02195479|Drug|Velcade|Participants will receive velcade 1.3 mg/m^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
263021|NCT02195479|Drug|Melphalan|Participants will receive melphalan 9 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
263022|NCT02195479|Drug|Prednisone|Participants will receive prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
263023|NCT02195479|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or study end.
263024|NCT02195479|Drug|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab infusion as pre medication and prednisone substitute.
263025|NCT02195466|Drug|Tipranavir (TPV)|500 mg bid on days 7-14
263026|NCT02195466|Drug|Ritonavir (RTV)|200 mg bid on days 7-14
263027|NCT02195466|Drug|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
263028|NCT02195453|Drug|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po."
263029|NCT02195453|Drug|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po."
263030|NCT02195440|Drug|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
263031|NCT02195427|Device|TEOSYAL® RHA Global Action|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 30G1/2 disposable sterile needles."
263032|NCT02195427|Device|TEOSYAL® RHA Deep Lines|"A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus equi bacteria, formulated to a concentration of 23 mg/mL and 0.3% w/w lidocaine in a physiologic buffer. It is supplied in individual treatment syringes with 27G1/2 disposable sterile needles."
263033|NCT02195414|Device|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
263034|NCT02195401|Other|Cleanroom|Cleanroom with air the quality of the pre-industrial age
263035|NCT02195388|Other|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
263036|NCT02195375|Drug|Flutiform 500/20 µg BID|
263037|NCT02195375|Drug|Flutiform 250/10 µg BID|
263038|NCT02195375|Drug|Seretide Accuhaler 50/500 µg BID|
263039|NCT02195349|Biological|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
263040|NCT02195349|Biological|Placebo|Commercial saline solution administered by IV over approximately 2 hours
263041|NCT02195336|Device|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
263042|NCT02195336|Drug|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
263043|NCT02195336|Drug|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
263044|NCT02195323|Biological|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
263045|NCT02195310|Device|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
263046|NCT02195310|Device|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
263047|NCT02195297|Other|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
263048|NCT02195284|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
263049|NCT02195284|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
263050|NCT02195284|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
263051|NCT02195284|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
263052|NCT02195271|Device|Transcranial Direct Current Stimulation (tDCS)|
263053|NCT02195271|Drug|Melatonin|
263054|NCT02195245|Device|memsorb|
263055|NCT02195232|Drug|Isoquercetin|
263056|NCT02195219|Procedure|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
263057|NCT02195219|Other|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
263058|NCT02195193|Other|Integrated care|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
263059|NCT02195180|Drug|ERY001|
263060|NCT02195180|Drug|Gemcitabine|
263061|NCT02195180|Drug|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
263098|NCT02194829|Drug|Gemcitabine Hydrochloride|Given IV
263099|NCT02194829|Other|Laboratory Biomarker Analysis|Correlative studies
263100|NCT02194829|Drug|Nab-paclitaxel|Given IV
263101|NCT02194829|Other|Pharmacological Study|Correlative studies
263102|NCT02194829|Other|Placebo|Given PO
263222|NCT02194075|Drug|Fluvoxamine+sugar pill|
263062|NCT02195167|Drug|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
263063|NCT02195154|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.~The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
263064|NCT02195141|Radiation|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
263065|NCT02195141|Radiation|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
263066|NCT02195115|Procedure|Laparoscopic Cholecystectomy|
263067|NCT02195115|Drug|amitriptyline|
263068|NCT02195115|Other|low-fat and low cholesterol diet|
263069|NCT02195102|Device|Transcatheter aortic valve Replacement|
263070|NCT02195089|Drug|BLS_ILS_E710c 500mg|- 2 capsules per day for 20 days (week 1,2,4 & 8)
263071|NCT02195089|Drug|BLS_ILB_710c 1000mg|- 4 capsules per day for 20 days (week 1,2,4 & 8)
263072|NCT02195089|Drug|BLS_ILS_E710c 1500mg|- 6 capsules per day for 8 weeks (week 1,2,4 & 8)
263073|NCT02195076|Other|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
263074|NCT02195024|Procedure|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
263075|NCT02195011|Device|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
263076|NCT02195011|Drug|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
263077|NCT02194998|Drug|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
263078|NCT02194998|Drug|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
263079|NCT02194998|Drug|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (all participants (version 1); only participants with HCV genotype 1a (version2))
263080|NCT02194985|Drug|migalastat HCl 150 mg|Capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on the days between migalastat HCl.
263081|NCT02194972|Drug|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
263082|NCT02194959|Behavioral|Peer PN|Navigation by Peer Patient Navigators
263083|NCT02194959|Behavioral|Pro PN|Navigation by Standard Hospital Navigators
263084|NCT02194946|Drug|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
263085|NCT02194946|Drug|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
263086|NCT02194933|Drug|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
263087|NCT02194920|Procedure|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
263088|NCT02194907|Device|Functional Magnetic Resonance Imaging|Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior insula cortex (experimental group) or primary auditory cortex (placebo comparator).
263089|NCT02194894|Drug|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
263090|NCT02194881|Drug|CF patients with a G551D mutation and treated with Ivacaftor|
263091|NCT02194868|Biological|Recipients|"Adult recipient:~collected 20 ml pre-transplant~collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,~collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360~Children recipients~collected residual blood pre-transplant~collected residual blood on day 20 post-transplant at engraftment for cell phenotype,~collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
263092|NCT02194868|Biological|Donors|"Adult donors :~collected 20 ml of blood, (if possible before granulocyte colony-stimulating factor (GCSF) administration)~collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.~Children donors samples~collected residual blood~2ml of bone marrow (bottom of tube)"
263093|NCT02194855|Drug|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
263094|NCT02194855|Drug|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
263095|NCT02194842|Drug|Ra223|
263096|NCT02194842|Drug|Enzalutamide|
263097|NCT02194829|Drug|Adavosertib|Given PO
263103|NCT02194790|Behavioral|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
263104|NCT02194777|Drug|BIBN 4096 BS - in single rising doses|
263105|NCT02194777|Drug|Placebo|
263106|NCT02194764|Drug|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
263107|NCT02194764|Drug|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
263108|NCT02194751|Biological|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
263109|NCT02194738|Other|Clinical Observation|Undergo observation
263110|NCT02194738|Drug|Crizotinib|Given PO
263111|NCT02194738|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue
263112|NCT02194738|Drug|Erlotinib|Given PO
263113|NCT02194738|Drug|Erlotinib Hydrochloride|Given PO
263114|NCT02194738|Biological|Nivolumab|Given IV
263115|NCT02194738|Other|Placebo|Given PO
263116|NCT02194712|Other|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
263117|NCT02194699|Biological|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
263118|NCT02194699|Other|Placebo|Placebo subcutaneous injection
263119|NCT02194686|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
263120|NCT02194686|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
263121|NCT02194673|Other|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
263122|NCT02194673|Other|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
263123|NCT02194673|Other|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
263124|NCT02194634|Drug|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
263125|NCT02194634|Other|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
263126|NCT02194634|Procedure|Laser|Laser treatment at first month, then repeated as needed.
263127|NCT02194634|Other|Sham laser|Sham laser at first month, then repeated as needed.
263128|NCT02194621|Drug|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
263129|NCT02194621|Drug|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
263130|NCT02194621|Drug|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
263131|NCT02194608|Device|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
263132|NCT02194595|Drug|Basal insulin and exenatide|
263133|NCT02194595|Drug|Basal insulin only|
263134|NCT02194595|Drug|Basal insulin and bolus insulin|
263135|NCT02194569|Drug|Citrate|
263136|NCT02194556|Drug|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
263137|NCT02194556|Drug|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
263138|NCT02194517|Device|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
263139|NCT02194504|Other|Dietary advice, Western|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
263140|NCT02194504|Other|Dietary advice, Targeted|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
263141|NCT02194491|Other|[11C]AS2471907|intravenous radiotracer
263142|NCT02194491|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
263143|NCT02194491|Drug|ASP3662|oral
263144|NCT02194478|Behavioral|Meditation|30 minute, 8 week meditation
263145|NCT02194465|Drug|LY2623091|Administered orally
263146|NCT02194465|Drug|Tadalafil|Administered orally
263147|NCT02194465|Drug|Spironolactone|Administered orally
263148|NCT02194465|Drug|Placebo|Administered orally
263149|NCT02194452|Radiation|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
263150|NCT02194452|Procedure|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
263221|NCT02194075|Drug|Fluvoxamine+Methylphenidate hydrochloride|
263151|NCT02194452|Procedure|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
263152|NCT02194452|Other|laboratory biomarker analysis|Correlative studies
263153|NCT02194426|Drug|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
263154|NCT02194413|Procedure|therapeutic touch|receiving healing touch
263155|NCT02194413|Other|quality-of-life assessment|Ancillary studies
263156|NCT02194413|Other|questionnaire administration|Ancillary studies
263157|NCT02194400|Biological|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
263158|NCT02194387|Dietary Supplement|Dietary Intervention|Record dietary intake 4-7 days per week
263159|NCT02194387|Dietary Supplement|Dietary Intervention|Record dietary intake 1 day per week
263160|NCT02194387|Other|Internet-Based Intervention|Receive email coaching
263161|NCT02194387|Other|Internet-Based Intervention|Participate in social networking
263162|NCT02194387|Other|Laboratory Biomarker Analysis|Correlative studies
263163|NCT02194387|Other|Questionnaire Administration|Ancillary studies
263164|NCT02194387|Behavioral|Telephone-Based Intervention|Receive telephone coaching
263165|NCT02194387|Behavioral|Telephone-Based Intervention|Receive text messages
263166|NCT02194374|Procedure|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.~Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
263167|NCT02194374|Drug|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.~FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
263168|NCT02194374|Drug|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
263169|NCT02194374|Drug|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.~BR Regimen: 375-500 mg/m2 by vein on Day -4."
263170|NCT02194374|Drug|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.~FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
263171|NCT02194361|Drug|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
263172|NCT02194361|Drug|Placebo|
263173|NCT02194348|Drug|BIBN 4096 BS - in single rising doses|
263174|NCT02194348|Drug|Placebo|
263175|NCT02194335|Drug|BIBN 4096 BS - in single rising doses|
263176|NCT02194335|Drug|Placebo|
263177|NCT02194322|Drug|BIBN 4096 BS - in single rising doses|
263178|NCT02194322|Drug|Placebo|
263179|NCT02194309|Drug|Telmisartan low|
263180|NCT02194309|Drug|Telmisartan high|
263181|NCT02194309|Drug|amlodipine|
263182|NCT02194296|Drug|Ambroxol hydrochloride - lozenge|
263183|NCT02194296|Drug|Ambroxol hydrochloride - syrup|
263184|NCT02194283|Drug|Ambroxol - in single rising doses|
263185|NCT02194283|Drug|Placebo|
263186|NCT02194270|Drug|Ambroxol hydrochloride - soft pastille|
263187|NCT02194270|Drug|Ambroxol hydrochloride - syrup - low dose|
263188|NCT02194270|Drug|Ambroxol hydrochloride - syrup - high dose|
263189|NCT02194257|Drug|[14C]-cyclohexane ambroxol oral solution|
263190|NCT02194257|Drug|[14C]-benzyl ambroxol oral solution|
263191|NCT02194257|Drug|Ambroxol lozenge|
263192|NCT02194244|Drug|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
263193|NCT02194244|Drug|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
263194|NCT02194231|Drug|Trabectedin|Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
263195|NCT02194218|Drug|Nevirapine, low dose|50 mg
263196|NCT02194218|Drug|Nevirapine, high dose|100 mg
263197|NCT02194205|Drug|COMBIVENT HFA|
263198|NCT02194205|Drug|Placebo HFA|
263199|NCT02194205|Drug|COMBIVENT CFC|
263200|NCT02194205|Drug|Placebo CFC|
263201|NCT02194192|Drug|Placebo|Normal saline 10 ml
263202|NCT02194192|Drug|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
263203|NCT02194192|Drug|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
263204|NCT02194179|Drug|NVP XR 400 mg (KCR 25%)|
263205|NCT02194179|Drug|NVP XR 400 mg (KCR 20%)|
263206|NCT02194179|Drug|NVP XR 300 mg (KCR 25%)|
263207|NCT02194179|Drug|NVP XR 300 mg (KCR 20%)|
263208|NCT02194179|Other|high-fat breakfast|
263209|NCT02194179|Drug|NVP IR 200 mg (Viramune®)|
263210|NCT02194166|Drug|Trastuzumab|Trastuzumab IV or SC will be administered as described.
263211|NCT02194166|Drug|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
263212|NCT02194166|Drug|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
263213|NCT02194153|Drug|Metalyse weight-adjusted|
263214|NCT02194140|Other|oral iodinated contrast material|diluted in water
263215|NCT02194127|Drug|Anthocyan capsules|
263216|NCT02194127|Drug|Placebo|
263217|NCT02194114|Other|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
263218|NCT02194101|Procedure|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
263219|NCT02194088|Drug|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
263220|NCT02194088|Drug|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
263223|NCT02194062|Drug|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
263224|NCT02194062|Drug|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
263225|NCT02194062|Drug|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
263226|NCT02194049|Drug|BKM120|Given PO
263227|NCT02194049|Drug|cisplatin|Given IV
263228|NCT02194049|Drug|etoposide|Given IV
263229|NCT02194036|Behavioral|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
263230|NCT02194036|Behavioral|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
263231|NCT02194023|Drug|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
263232|NCT02194023|Drug|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
263233|NCT02194023|Drug|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
263234|NCT02194023|Drug|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
263235|NCT02193997|Other|Fiber|
263236|NCT02193997|Other|Fiber|
263237|NCT02193997|Other|Placebo|
263238|NCT02193984|Behavioral|Peer support|
263239|NCT02193971|Device|BS-DES (Biostable polymer drug-eluting stent)|
263240|NCT02193971|Device|BD-DES (Biodegradable polymer drug-eluting stent)|
263241|NCT02193971|Drug|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
263242|NCT02193958|Drug|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
263243|NCT02193932|Other|EEG Triggered fMRI using Micro Maglink|
263244|NCT02193906|Other|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
263245|NCT02193906|Other|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
263246|NCT02193893|Other|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
263247|NCT02193893|Other|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
263248|NCT02193880|Device|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
263249|NCT02193867|Drug|Sebelipase Alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL-D. Dosing occurred once weekly for up to 3 years.
263250|NCT02193854|Device|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
263251|NCT02193841|Procedure|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
263252|NCT02193841|Device|Curette|A small surgical instrument with a rounded edge designed for scraping
263253|NCT02193841|Device|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
263254|NCT02193828|Biological|Collagenase clostridium histolyticum|Single injection into nodule
263255|NCT02193828|Biological|Placebo|Single injection into nodule
263256|NCT02193815|Drug|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
263257|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 4% solution
263258|NCT02193815|Drug|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
263259|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 2% Ointment
263260|NCT02193815|Drug|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
263261|NCT02193815|Drug|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
263262|NCT02193802|Device|PillCam® COLON 2 and PillCam Crohn's capsules|"Patient preparation for PillCam® COLON 2 and PillCam Crohn's capsule procedure:~Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.~Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator."
263587|NCT02191462|Dietary Supplement|Niagen 1000mg|
263263|NCT02193789|Procedure|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
263264|NCT02193789|Device|Covered Self-expandable Metallic Stents|
263265|NCT02193776|Drug|PA-824|oral
263266|NCT02193776|Drug|bedaquiline|oral
263267|NCT02193776|Drug|moxifloxacin|oral
263268|NCT02193776|Drug|pyrazinamide|oral
263269|NCT02193776|Drug|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
263270|NCT02193763|Procedure|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
263271|NCT02193750|Dietary Supplement|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
263272|NCT02193750|Dietary Supplement|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
263273|NCT02193750|Dietary Supplement|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
263274|NCT02193737|Procedure|Early oral fluid recovery.|
263275|NCT02193737|Procedure|Delayed oral fluid recovery.|
263276|NCT02193724|Other|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
263277|NCT02193724|Other|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
263278|NCT02193711|Other|Topical Arthritis Cream|
263279|NCT02193698|Drug|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
263280|NCT02193672|Drug|[18F] Fluciclatide|[18F] Fluciclatide given by vein before PET/CT scan.
263281|NCT02193672|Procedure|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
263282|NCT02193672|Behavioral|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
263283|NCT02193659|Dietary Supplement|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
263284|NCT02193633|Drug|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
263285|NCT02193633|Drug|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
263286|NCT02193620|Drug|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
263287|NCT02193620|Drug|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
263288|NCT02193620|Drug|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
263289|NCT02193607|Procedure|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
263290|NCT02193607|Procedure|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
263291|NCT02193594|Radiation|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
263292|NCT02193594|Procedure|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
263293|NCT02193594|Drug|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA＜1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA＞1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
263294|NCT02193581|Device|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
263295|NCT02193568|Procedure|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
263296|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
263297|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Undergo craniotomy
263298|NCT02193568|Other|Arm II (intubated general anesthesia)|Ancillary studies
263299|NCT02193568|Procedure|Arm I (light sedation)|Undergo craniotomy
263300|NCT02193568|Other|Arm I (light sedation)|Ancillary studies
263301|NCT02193555|Device|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
263302|NCT02193503|Other|Treatment|Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
263303|NCT02193490|Drug|DNase|DNase 0.1% eye drops four times a day for 8 weeks
263304|NCT02193490|Drug|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
263305|NCT02193477|Device|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
263306|NCT02193477|Device|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
263307|NCT02193451|Procedure|Urodynamics|Diagnostic test for urinary storage and voiding function
263308|NCT02193451|Procedure|Usual care|
263309|NCT02193438|Other|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
263310|NCT02193438|Other|Placebo|Tomato juice intake
263311|NCT02193425|Drug|F-18FDG|18F- Fluorodeoxyglucose (FDG)-PET session to assess the association between functional connectivity (FC) and glucose metabolism in the human brain.
263312|NCT02193425|Device|MRI|Two MRI/MRS sessions to evaluate test-retest reliability of functional connectivity (FC) at rest as well as during task performance.
263313|NCT02193412|Procedure|noxious stimulus|standardized noxious stimulus with tetanic stimulation
263314|NCT02193412|Procedure|change in operating table slope: head-down tilt position|-30°
263315|NCT02193412|Procedure|change in operating table slope: head-up tilt position|+30°
263316|NCT02193399|Other|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.~The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
263317|NCT02193386|Other|No intervention, no follow-up, only registration|Usual Care
263318|NCT02193386|Other|Intervention period|Predefined intervention program
263319|NCT02193373|Other|Osteopathic Manual Medicine|Osteopathic Manual Medicine
263320|NCT02193373|Other|Sham|Osteopathic Manual Medicine
263321|NCT02193360|Drug|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
263322|NCT02193347|Biological|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
263323|NCT02193347|Biological|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin one day prior to receiving the first PEPIDH1M vaccine.
263324|NCT02193347|Drug|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
263325|NCT02193334|Drug|KP-100IT|
263326|NCT02193334|Drug|Placebo|
263327|NCT02193321|Biological|Amniotic Membrane Patch|
263328|NCT02193308|Drug|Telmisartan/Amlodipine FDC|
263329|NCT02193308|Drug|Telmisartan|
263330|NCT02193308|Drug|Amlodipine|
263331|NCT02193295|Behavioral|Dietary consultations|Dietary consultations and caloric restriction to reduce liver and intra myocellular fat content and improve tissue specific insulin sensitivity
263332|NCT02193282|Other|Clinical Observation|Undergo observation
263333|NCT02193282|Drug|Erlotinib|Given PO
263334|NCT02193282|Drug|Erlotinib Hydrochloride|Given PO
263335|NCT02193282|Other|Laboratory Biomarker Analysis|Correlative studies
263336|NCT02193282|Other|Placebo|Given PO
263337|NCT02193269|Drug|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
263338|NCT02193269|Drug|Minocycline|you will receive 200 mg as a single daily dose for 4 days
263339|NCT02193256|Drug|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
263340|NCT02193256|Drug|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
263341|NCT02193256|Drug|Placebo|
263342|NCT02193217|Drug|MT-1303-Low|
263343|NCT02193217|Drug|MT-1303-High|
263344|NCT02193217|Drug|Fingolimod|
263345|NCT02193217|Drug|Placebo|
263346|NCT02193204|Behavioral|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
263347|NCT02193204|Behavioral|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
263348|NCT02193191|Drug|Plerixafor|
263349|NCT02193178|Device|comfilcon A Toric|Contact lenses
263350|NCT02193165|Drug|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
263351|NCT02193165|Drug|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
263441|NCT02192515|Drug|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
263588|NCT02191423|Drug|Oxytocin|administered pre-fMRI assessment
263352|NCT02193165|Drug|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
263353|NCT02193152|Drug|Pazopanib|
263354|NCT02193139|Drug|WL8713, 6 mg|
263355|NCT02193139|Drug|WL8713, 12 mg|
263356|NCT02193139|Drug|WL8713, 18 mg|
263357|NCT02193139|Drug|WL8713, 24 mg|
263358|NCT02193139|Drug|Placebo|
263359|NCT02193126|Other|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
263360|NCT02193113|Drug|KVD001 Injection|A novel plasma kallikrein inhibitor
263361|NCT02193087|Drug|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
263362|NCT02193087|Drug|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
263363|NCT02193087|Drug|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
263364|NCT02193087|Drug|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
263365|NCT02193074|Drug|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
263366|NCT02193074|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
263367|NCT02193061|Biological|Rotarix|
263368|NCT02193061|Biological|RotaTeq|
263369|NCT02193048|Other|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
263370|NCT02193035|Other|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
263371|NCT02193022|Drug|Miltefosine|
263372|NCT02193009|Behavioral|SipSmarter|6-month behavioral trial
263373|NCT02193009|Behavioral|MoveMore|6 month behavioral trial
263374|NCT02192996|Dietary Supplement|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
263375|NCT02192970|Drug|Bevacizumab|
263376|NCT02192957|Device|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.~Ottawa AF Cardioversion"
263377|NCT02192944|Drug|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
263378|NCT02192944|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
263379|NCT02192931|Drug|Creatine monohydrate|
263380|NCT02192918|Behavioral|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
263381|NCT02192918|Behavioral|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
263382|NCT02192918|Behavioral|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
263383|NCT02192905|Behavioral|Diabetes Prevention Program Lifestyle Intervention|
263384|NCT02192892|Dietary Supplement|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
263385|NCT02192892|Dietary Supplement|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
263386|NCT02192892|Dietary Supplement|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
263387|NCT02192892|Dietary Supplement|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
263388|NCT02192892|Dietary Supplement|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
263389|NCT02192892|Dietary Supplement|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
263390|NCT02192892|Dietary Supplement|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
263391|NCT02192892|Dietary Supplement|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
263392|NCT02192892|Dietary Supplement|Commercial porridge flour|Porridge from commercial porridge flour
263393|NCT02192892|Dietary Supplement|Commercial porridge bar|Porridge from commercial porridge bar
263394|NCT02192892|Dietary Supplement|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
263442|NCT02192515|Drug|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
263443|NCT02192502|Drug|human albumin 5%|
263444|NCT02192502|Drug|HES 130/0.4 (Voluven)|
263445|NCT02192489|Drug|CC-220 0.3 mg Daily|
263446|NCT02192489|Drug|CC-220 0.6mg Daily|
263395|NCT02192879|Device|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
263396|NCT02192879|Device|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
263397|NCT02192879|Drug|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
263398|NCT02192853|Drug|sitagliptin|"In randomized order:~Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
263399|NCT02192853|Drug|Placebo|Day 4: placebo tablet
263400|NCT02192840|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
263401|NCT02192827|Drug|Dexamethasone Sodium Phosphate Injection|
263402|NCT02192814|Drug|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide~Pharmaceutical form: Solution for intravenous (iv) infusion~Concentration: adapted on concentration of oral dose in EP0009~Route of Administration: Drip infusion"
263403|NCT02192788|Radiation|Stereotactic Body Radiation Therapy for Oligometastases|
263404|NCT02192775|Drug|MV-NIS|one dose in conjunction with a 4 day course intravenously
263405|NCT02192762|Behavioral|Withdrawal regulation training|Withdrawal coping skills
263406|NCT02192762|Behavioral|Relaxation training|Relaxation skills instruction
263407|NCT02192749|Biological|Umbilical cord mesenchymal stem cells|
263408|NCT02192736|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
263409|NCT02192723|Drug|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day), twice per day, 8 weeks
263410|NCT02192723|Drug|Risperidone|2~6mg/day, twice per day, 8 weeks
263411|NCT02192723|Drug|Olanzapine|Olanzapine, 400~750mg/day, twice per day, 8 weeks
263412|NCT02192723|Drug|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
263413|NCT02192723|Device|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
263414|NCT02192723|Drug|Ziprasidone|Ziprasidone 80~160mg/day, twice per day, 8 weeks
263415|NCT02192710|Procedure|electronic tab|classic use of an electronic tab with age specific games
263416|NCT02192710|Drug|Midazolam oral intake|
263417|NCT02192697|Drug|ASP8273|Oral administration
263418|NCT02192684|Drug|Pioglitazone|45 mg daily Insulin sensitizing
263419|NCT02192684|Drug|placebo|Compare with pioglitazone
263420|NCT02192671|Procedure|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
263421|NCT02192671|Procedure|Radiofrequency Ablation|
263422|NCT02192645|Drug|Sanfujiu|
263423|NCT02192645|Drug|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
263424|NCT02192632|Drug|Epiduo once daily with detailed instruction for how to apply it|
263425|NCT02192632|Drug|Epiduo- once daily, simple instruction for application|
263426|NCT02192632|Drug|BPO once daily|
263427|NCT02192619|Other|observational|
263428|NCT02192606|Device|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
263429|NCT02192606|Device|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
263430|NCT02192593|Behavioral|Computer CBT|
263431|NCT02192580|Drug|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
263432|NCT02192567|Drug|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.~Step 2: 30 subjects will use the dose determined in Step 1."
263433|NCT02192541|Drug|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for vascular endothelial growth factor A (VEGF-A), vascular endothelial growth factor B (VEGF-B), and placenta growth factor (PIGF) and thus confers anti-angiogenic activity
263434|NCT02192541|Drug|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
263435|NCT02192515|Drug|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
263436|NCT02192515|Drug|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
263437|NCT02192515|Drug|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
263438|NCT02192515|Drug|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
263439|NCT02192515|Drug|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
263440|NCT02192515|Drug|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
263447|NCT02192489|Drug|Placebo|
263448|NCT02192476|Other|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
263449|NCT02192476|Other|California tri-pull taping (CTPT)|Two types of tape was used, a self-adhesive 1.5ʺ cotton undercover tape and a 1ʺ rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape.
263450|NCT02192463|Drug|NVP ER 300 mg (KCR 20%) Medium Release|
263451|NCT02192463|Drug|NVP ER 300 mg (KCR 25%) Medium Release|
263452|NCT02192463|Drug|NVP ER 300 mg (KCR 30%) Slow Release|
263453|NCT02192463|Drug|NVP ER 400 mg (KCR 25%) Medium Release|
263454|NCT02192463|Drug|NVP ER 300 mg (KCR 40%) Slow Release|
263455|NCT02192463|Drug|NVP ER 300 mg (ECR 20%) Fast Release|
263456|NCT02192463|Drug|NVP ER 400 mg (KCR 20%) Medium Release|
263457|NCT02192463|Drug|NVP ER 400 mg (KCR 30%) Slow Release|
263458|NCT02192463|Drug|NVP ER 400 mg (KCR 40%) Slow Release|
263459|NCT02192463|Drug|NVP ER 400 mg (ECR 20%) Fast Release|
263460|NCT02192463|Drug|Nevirapine immediate release (IR) 200 mg|
263461|NCT02192450|Drug|Insulin aspart/glargine|
263462|NCT02192450|Drug|Insulin aspart/degludec|
263463|NCT02192437|Other|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
263464|NCT02192424|Drug|Metformin alone|
263465|NCT02192424|Drug|Metformin + Intermittent Insulin Therapy|
263466|NCT02192411|Drug|Lidocaine|1/4 dose lidocaine
263467|NCT02192398|Drug|Guanfacine|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo~To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
263468|NCT02192398|Drug|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:~guanfacine (2mg)~guanfacine (1mg)~placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
263469|NCT02192359|Biological|Carboxylesterase-expressing Allogeneic Neural Stem Cells|Given intracranially
263470|NCT02192359|Drug|Irinotecan|Given IV
263471|NCT02192359|Drug|Irinotecan Hydrochloride|Given IV
263472|NCT02192359|Other|Laboratory Biomarker Analysis|Correlative studies
263473|NCT02192359|Other|Pharmacological Study|Correlative studies
263474|NCT02192346|Drug|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
263475|NCT02192346|Drug|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
263476|NCT02192346|Drug|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
263477|NCT02192346|Drug|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
263478|NCT02192346|Drug|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
263479|NCT02192346|Drug|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
263480|NCT02192346|Drug|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
263481|NCT02192346|Drug|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
263482|NCT02192346|Drug|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
263483|NCT02192333|Procedure|Management of Therapy Complications|Receive survivorship care
263484|NCT02192333|Other|Quality-of-Life Assessment|Ancillary studies
263485|NCT02192333|Other|Questionnaire Administration|Ancillary studies
263486|NCT02192333|Behavioral|Telephone-Based Intervention|Receive phone-based booster intervention
263487|NCT02192320|Drug|Atorvastatin|20 mg (every evening orally) for 5 weeks
263488|NCT02192320|Drug|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
263489|NCT02192307|Device|Potassium oxalate|
263490|NCT02192294|Drug|Oral Bosutinib|a single dose of 500 mg oral bosutinib
263491|NCT02192294|Drug|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
263492|NCT02192281|Other|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
263493|NCT02192268|Other|PEP|
263494|NCT02192268|Other|HFOO|
263495|NCT02192268|Other|Assisted Coughing|
263496|NCT02192255|Behavioral|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
263497|NCT02192242|Other|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
263498|NCT02192229|Drug|50.000 IU vitamin D3 (Biodal 50,000 IU)|
263538|NCT02191891|Drug|BI 836845|Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
263499|NCT02192229|Drug|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
263500|NCT02192216|Behavioral|Exercise|
263501|NCT02192203|Drug|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
263502|NCT02192203|Drug|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
263503|NCT02192203|Drug|Menthol Only Gel|3% menthol
263504|NCT02192203|Drug|Placebo Only Gel|0.09% menthol
263505|NCT02192190|Drug|LY2951742|Administered subcutaneously (SC)
263506|NCT02192190|Other|Placebo- oral|Administered orally
263507|NCT02192190|Other|Placebo - SC|Administered SC
263508|NCT02192190|Drug|Celecoxib|Administered orally
263509|NCT02192164|Behavioral|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
263510|NCT02192138|Procedure|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
263511|NCT02192138|Device|Pleural catheter|
263512|NCT02192138|Device|Pleural manometer|
263513|NCT02192125|Device|REWIRE-System|"The REWIRE rehabilitation platform consists of three hierarchical components:~patient station (PS), which is installed in the home environment of the patient:~Includes:~Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking~Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;~Includes:~Laptop MySQL- database~station networking (NS), which allows a combination of a several of HS. database"
263514|NCT02192099|Drug|Rapastinel (225 mg/450 mg IV administration)|Investigators began treatment in RAP-MD-05 based on the dose level to which the patient was assigned during participation in GLYX13-C-202; patients originally assigned to rapastinel 5 mg/kg received rapastinel 225 mg, and patients originally assigned to rapastinel 10 mg/kg received rapastinel 450 mg. Investigators had the option to decrease the dose level from 450 to 225 mg if a patient experienced an adverse event(s) that the investigator believed may be associated with rapastinel
263515|NCT02192086|Other|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).~a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
263516|NCT02192086|Other|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).~a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
263517|NCT02192073|Procedure|Suprapectoral Biceps tenodesis|
263518|NCT02192073|Procedure|Subpectoral biceps tenodesis|
263519|NCT02192060|Other|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
263520|NCT02192060|Other|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
263521|NCT02192047|Other|Palm Olein|8 weeks
263522|NCT02192047|Other|IE Palm olein|8 weeks
263523|NCT02192047|Other|IE soybean oil-based|8 weeks
263524|NCT02192034|Behavioral|Navigation|
263525|NCT02192021|Drug|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
263526|NCT02192008|Biological|Salmonella Typhi|
263527|NCT02192008|Biological|Salmonella Paratyphi|
263528|NCT02191995|Behavioral|yoga|
263529|NCT02191982|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
263530|NCT02191969|Behavioral|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
263531|NCT02191956|Behavioral|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
263532|NCT02191943|Device|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
263533|NCT02191943|Device|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
263534|NCT02191930|Drug|B-CAP|
263535|NCT02191930|Drug|Brentuximab Vedotin|
263536|NCT02191917|Procedure|Respiratory muscle strength measurements by different techniques.|
263537|NCT02191904|Other|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
263539|NCT02191891|Drug|afatinib|Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
263540|NCT02191878|Drug|TKM-080301|TKM-080301 intravenous infusion
263541|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
263542|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
263543|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
263544|NCT02191852|Drug|Seresis®|
263545|NCT02191839|Drug|Alpha 1-Antitrypsin|
263546|NCT02191826|Drug|SOM0226|Oral
263547|NCT02191813|Drug|Seresis®|
263548|NCT02191813|Drug|Placebo|
263549|NCT02191787|Drug|Seresis®|
263550|NCT02191787|Drug|Placebo|
263551|NCT02191774|Procedure|Medical abortion at home|Medical abortion using Mifepristone at the clinic followed by Cytotec at home
263552|NCT02191761|Drug|SM04755|Escalating Doses
263553|NCT02191748|Procedure|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
263554|NCT02191748|Drug|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
263555|NCT02191735|Device|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
263556|NCT02191735|Device|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
263557|NCT02191722|Behavioral|reading comics booklet|
263558|NCT02191709|Drug|Dextromethorphan syrup|
263559|NCT02191709|Drug|Dextromethorphan soft pastilles|
263560|NCT02191696|Device|IMED-4 recording|
263561|NCT02191670|Drug|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
263562|NCT02191657|Drug|Deferiprone|Oral iron chelator
263563|NCT02191644|Dietary Supplement|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
263564|NCT02191644|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
263565|NCT02191631|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
263566|NCT02191618|Device|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
263567|NCT02191605|Behavioral|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
263568|NCT02191605|Behavioral|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
263569|NCT02191579|Biological|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
263570|NCT02191579|Drug|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
263571|NCT02191566|Drug|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
263572|NCT02191566|Drug|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
263573|NCT02191553|Behavioral|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
263574|NCT02191553|Behavioral|Loving-kindness meditation|Following Kristin Neff protocol
263575|NCT02191553|Behavioral|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
263576|NCT02191553|Behavioral|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
263577|NCT02191540|Drug|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
263578|NCT02191527|Device|PIMA® for quantitative analysis of CD4-count|
263579|NCT02191527|Device|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
263580|NCT02191527|Device|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
263581|NCT02191501|Procedure|Pyloric restriction|"The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.~However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested."
263582|NCT02191488|Drug|5-aminolevulinic acid|
263583|NCT02191475|Drug|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
263584|NCT02191475|Drug|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
263585|NCT02191462|Dietary Supplement|Niagen 100mg|
263586|NCT02191462|Dietary Supplement|Niagen 300mg|
263589|NCT02191423|Drug|placebo|administered pre-fMRI assessment
263590|NCT02191423|Behavioral|Dyadic psychotherapy|
263591|NCT02191410|Procedure|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio > 0.3, RR 60 breaths min-1 and a FGF of < 2 L min-1, using a second identical ventilator with low compliant internal circuit
263592|NCT02191410|Procedure|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
263593|NCT02191397|Drug|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
263594|NCT02191397|Drug|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
263595|NCT02191397|Drug|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
263596|NCT02191397|Drug|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
263597|NCT02191384|Drug|Orcinoside|oral, twice per day
263598|NCT02191371|Drug|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
263599|NCT02191371|Drug|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
263600|NCT02191345|Behavioral|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
263601|NCT02191332|Drug|Viramune|
263602|NCT02191319|Drug|Viramune®|
263603|NCT02191293|Drug|Viramune® tablets|
263604|NCT02191280|Drug|Antistax®, low dose|
263605|NCT02191280|Drug|Antistax®, high dose|
263606|NCT02191280|Drug|Placebo|
263607|NCT02191267|Radiation|[F18]-T807|[F18]-T807 PET Scan to measure tau deposition in the brain.
263608|NCT02191267|Radiation|[F18]-Florbetapir|[F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
263609|NCT02191267|Device|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
263610|NCT02191267|Genetic|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
263611|NCT02191254|Drug|Antistax®|
263612|NCT02191254|Drug|Placebo|
263613|NCT02191241|Drug|Red Vine Leaf Extract|
263614|NCT02191228|Drug|Linagliptin - single dose|
263615|NCT02191228|Drug|Linagliptin - Multiple dose|
263616|NCT02191215|Drug|Nevirapine (Viramune®)|
263617|NCT02191202|Drug|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
263618|NCT02191189|Drug|Nevirapine suspension, into Enterion™ capsule|
263619|NCT02191189|Drug|Nevirapine suspension|
263620|NCT02191176|Drug|Dextromethorphan syrup - low dose|
263621|NCT02191176|Drug|Dextromethorphan syrup - high dose|
263622|NCT02191176|Drug|Placebo|
263623|NCT02191163|Drug|Antistax®|
263624|NCT02191163|Drug|Placebo|
263625|NCT02191137|Drug|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
263626|NCT02191124|Drug|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
263627|NCT02191124|Drug|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
263628|NCT02191111|Behavioral|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
263629|NCT02191098|Drug|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
263630|NCT02191085|Procedure|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
263631|NCT02191072|Drug|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
263632|NCT02191059|Drug|Icotinib|
263633|NCT02191059|Drug|Docetaxel|
263634|NCT02191046|Device|squeezable bottle|nasal irrigation twice daily for 2 weeks period
263635|NCT02191046|Device|syringe 20 ml|nasal irrigation twice daily for 2 weeks
263636|NCT02191033|Behavioral|Smoking counseling|
263637|NCT02191033|Behavioral|Text messaging|
263638|NCT02191033|Drug|Nicotine patch|
263639|NCT02191020|Drug|Total glucosides of paeony & Acitretin Capsules|
263640|NCT02191020|Drug|Acitretin Capsules|
263641|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
263642|NCT02191007|Drug|Calcipotriol Betamethasone ointment|
263643|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Urea Cream|
263644|NCT02190994|Drug|Hydrocortisone|used intravenously
263645|NCT02190994|Drug|Prednisone|used as tablet form
263646|NCT02190981|Device|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
263647|NCT02190968|Behavioral|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
263648|NCT02190968|Behavioral|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
263649|NCT02190903|Other|General endotracheal anesthesia|"General Anesthesia~Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol."
263650|NCT02190903|Other|Regional (spinal) Anesthesia|Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed.
263651|NCT02190890|Procedure|Dry needling|
263652|NCT02190890|Procedure|Control|
263653|NCT02190851|Device|TENS|"Two electrodes are attached around the internal malleolus and connected to the TENS unit.~The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
263654|NCT02190851|Device|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
263655|NCT02190838|Drug|Metformin|per os 850 mg BID
263656|NCT02190838|Drug|Melatonin|per os 3 mg daily
263657|NCT02190838|Drug|Dacarbazine|IV 1 hour 1000 mg/m^2 once in 28 days
263658|NCT02190825|Device|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
263659|NCT02190812|Device|Forearm supporter|The forearm supporter be use in tennis elbow.
263660|NCT02190812|Device|Grip ball|
263661|NCT02190799|Biological|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
263662|NCT02190786|Drug|KUX-1151|
263663|NCT02190760|Drug|Dexamethasone|
263664|NCT02190760|Drug|Bupivacaine|
263665|NCT02190747|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
263666|NCT02190747|Drug|Placebo|
263667|NCT02190734|Other|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
263668|NCT02190734|Other|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
263669|NCT02190734|Other|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
263670|NCT02190721|Drug|tbo-filgrastim|5 μg/kg
263671|NCT02190708|Drug|PQ912|from day2 up to day6 twice daily oral dose of PQ912
263672|NCT02190708|Drug|Midazolam|single oral dose on day1 and day 6
263673|NCT02190708|Drug|Omeprazole|single oral dose on day1 and day6
263674|NCT02190695|Drug|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
263675|NCT02190695|Drug|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
263676|NCT02190695|Drug|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
263677|NCT02190669|Other|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
263678|NCT02190643|Behavioral|Cessation counseling with adherence focus|
263679|NCT02190643|Behavioral|Cessation counseling without adherence focus|
263680|NCT02190630|Device|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
263681|NCT02190617|Behavioral|Enhanced Clinic+ Unified Plan + CHW|"Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.~Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.~Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
263682|NCT02190617|Behavioral|Enhanced Clinic+ Unified Management Plan|"Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.~Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
263683|NCT02190617|Behavioral|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
263684|NCT02190604|Drug|Placebo|Capsule- oral dose
263685|NCT02190604|Drug|QBW251|Capsule - oral dose
263686|NCT02190591|Device|Peanut Labor Ball|Peanut Labor Ball
263687|NCT02190578|Device|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
263688|NCT02190565|Dietary Supplement|Food supplement|Randomized double-blind, placebo-controlled
263689|NCT02190552|Device|EmboTrap® Revascularization Device|
263690|NCT02190539|Other|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
263691|NCT02190526|Drug|Mesalazine(asacol 800 mg)|
263692|NCT02190526|Drug|Amitriptyline|
263693|NCT02190526|Drug|placebo like asacol|
263694|NCT02190526|Drug|placebo like amitriptyline|
263695|NCT02190500|Other|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
263696|NCT02190474|Behavioral|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
263697|NCT02190461|Procedure|Early Respiratory Rehabilitation Program|
263698|NCT02190461|Procedure|Conventional Respiratory Rehabilitation Program|
263699|NCT02190448|Dietary Supplement|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
263700|NCT02190448|Dietary Supplement|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
263701|NCT02190435|Device|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
263702|NCT02190435|Device|Conventional technique|Conventional Technique
263703|NCT02190409|Device|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
263704|NCT02190383|Behavioral|Habit Reversal Training|awareness training, competing response training
263705|NCT02190370|Behavioral|Resources activation|
263706|NCT02190357|Drug|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
263707|NCT02190344|Device|8-channel paddle coil|MRI Coil
263708|NCT02190331|Other|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
263709|NCT02190331|Other|Control Group physical education classes|Only performed the physical education classes
263710|NCT02190318|Drug|Losartan|
263711|NCT02190318|Drug|spirolactone|
263712|NCT02190318|Other|blank control|
263713|NCT02190305|Device|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
263714|NCT02190279|Drug|18F DCFBC|Each subject will receive a single intravenous (i.v.) dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
263715|NCT02190279|Drug|Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)|
263716|NCT02190227|Device|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
263717|NCT02190201|Device|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
263718|NCT02190201|Device|Direct laryngoscope|A kind of traditional laryngoscopes
263719|NCT02190188|Device|Wedge Insole 5mm|
263720|NCT02190188|Device|Knee Brace|
263721|NCT02190162|Drug|Tantum Verde® mouthwash|
263722|NCT02190162|Other|Placebo mouthwash|Mouthwash with placebo solution
263723|NCT02190149|Biological|ADVATE (Antihemophilic Factor [Recombinant])|
263724|NCT02190149|Biological|RIXUBIS (Coagulation Factor IX [Recombinant])|
263725|NCT02190136|Other|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
263726|NCT02190136|Other|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
263763|NCT02189850|Drug|BLI800 - Dose 2|BLI800 oral solution
263727|NCT02190136|Other|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
263728|NCT02190123|Drug|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
263729|NCT02190097|Other|Paleolithic diet|see procedures section for more details
263730|NCT02190097|Other|American Diabetes Association diet|see procedures section
263731|NCT02190084|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
263732|NCT02190058|Drug|DS-1971a|suspension
263733|NCT02190058|Drug|placebo|placebo matching DS-1971a
263734|NCT02190045|Other|Wii-Fit exercises|Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks
263735|NCT02190045|Other|Cognitive remediation exercises|Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
263736|NCT02190032|Device|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
263737|NCT02190032|Device|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
263738|NCT02190019|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
263739|NCT02189980|Other|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
263740|NCT02189980|Other|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
263741|NCT02189980|Other|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
263742|NCT02189967|Radiation|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
263743|NCT02189967|Radiation|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
263744|NCT02189954|Procedure|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
263745|NCT02189954|Procedure|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
263746|NCT02189941|Drug|Deferiprone sustained-release|Deferiprone sustained-release tablets
263747|NCT02189941|Drug|Deferiprone immediate-release|Deferiprone immediate-release tablets
263748|NCT02189928|Device|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.~The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
263749|NCT02189928|Other|Usual care|
263750|NCT02189915|Drug|Creatine monohydrate|
263751|NCT02189902|Dietary Supplement|4000 IU/d D3 over 12 weeks|
263752|NCT02189902|Dietary Supplement|7000 IU/d D3 over 12 weeks|
263753|NCT02189889|Drug|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
263754|NCT02189889|Drug|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
263755|NCT02189876|Behavioral|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
263756|NCT02189876|Behavioral|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
263757|NCT02189863|Device|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
263758|NCT02189863|Device|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
263759|NCT02189863|Device|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
263760|NCT02189863|Device|Comfilcon A MF|Multifocal contact lenses worn in both eyes
263761|NCT02189863|Device|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
263762|NCT02189850|Drug|BLI800 - Dose 1|BLI800 oral solution
263764|NCT02189837|Biological|Evolocumab|Administered by subcutaneous injection
263765|NCT02189837|Drug|Atorvastatin|Administered by mouth
263766|NCT02189837|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
263767|NCT02189837|Drug|Placebo to Atorvastatin|Administered by mouth
263768|NCT02189824|Biological|Partially HLA-matched unrelated donor cells|
263769|NCT02189811|Biological|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
263770|NCT02189811|Biological|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
263771|NCT02189811|Biological|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
263772|NCT02189811|Biological|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
263773|NCT02189811|Biological|tOPV|tOPV till 22 weeks of age
263774|NCT02189798|Device|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
263775|NCT02189798|Device|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
263776|NCT02189772|Drug|Metadoxine extended release|MG01CI
263777|NCT02189772|Drug|Placebo|Inactive drug
263778|NCT02189759|Other|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
263779|NCT02189759|Other|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
263780|NCT02189759|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
263781|NCT02189759|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
263782|NCT02189746|Other|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
263783|NCT02189746|Other|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
263784|NCT02189746|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
263785|NCT02189746|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
263786|NCT02189733|Biological|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
263787|NCT02189720|Drug|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine per tablet.~Amifampridine Phosphateis given based on Investigator assessment of optimal neuromuscular benefit. Doses range from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day, with a maximum single dose of 20 mg."
263788|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
263789|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
263790|NCT02189707|Other|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
263791|NCT02189694|Device|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
263792|NCT02189694|Device|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
263793|NCT02189694|Device|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
263794|NCT02189681|Procedure|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
263795|NCT02189681|Procedure|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
263796|NCT02189681|Device|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
263797|NCT02189668|Drug|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
263798|NCT02189655|Procedure|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
263799|NCT02189629|Drug|CD5789 (trifarotene)|
263800|NCT02189616|Behavioral|SMS reminder|send weekly mobile phone short message reminders to the intervention group
263801|NCT02189616|Other|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
263802|NCT02189616|Other|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
263803|NCT02189603|Biological|Recombinant (E. Coli) Hepatitis E Vaccine|
263804|NCT02189590|Device|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
263805|NCT02189590|Device|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
263806|NCT02189577|Drug|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
263807|NCT02189577|Drug|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
263808|NCT02189564|Behavioral|Feedback about good performance|
263809|NCT02189564|Behavioral|Feedback about good performance + money|
263810|NCT02189564|Behavioral|Feedback about average performance|
263811|NCT02189551|Behavioral|Gait training with Lokomat Pro|
263812|NCT02189551|Behavioral|Gait training with Lokomat Pro FreeD|
263813|NCT02189538|Dietary Supplement|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
263814|NCT02189538|Dietary Supplement|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
263815|NCT02189512|Other|blood sampling|cases - blood sampling controles - blood sampling
263816|NCT02189499|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
263817|NCT02189473|Radiation|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
263818|NCT02189447|Procedure|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
263819|NCT02189434|Other|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.~These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
263820|NCT02189421|Device|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
263821|NCT02189408|Biological|Platelet rich plasma|
263822|NCT02189395|Drug|NPH and regular insulin|
263823|NCT02189395|Drug|glargine and humalog|
263824|NCT02189382|Device|Potassium Oxalate|
263825|NCT02189382|Other|Water|
263826|NCT02189369|Other|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
263827|NCT02189369|Other|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
263828|NCT02189356|Behavioral|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
263829|NCT02189356|Behavioral|standard care|standard pregnancy follow up
263830|NCT02189343|Drug|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
263831|NCT02189330|Drug|Tafamidis|20 mg of current commercial formulation.
263832|NCT02189330|Drug|Tafamidis|12.2 mgA free acid tablet.
263833|NCT02189330|Drug|Tafamidis|20 mg new soft gelatin capsule.
263834|NCT02189330|Drug|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
263835|NCT02189330|Drug|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
263836|NCT02189317|Drug|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
263837|NCT02189304|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
263838|NCT02189304|Drug|PT009|PT009 administered as 2 inhalations
263839|NCT02189304|Drug|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
263840|NCT02189291|Procedure|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
263841|NCT02189291|Procedure|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
263842|NCT02189278|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
263843|NCT02189265|Other|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
263844|NCT02189252|Drug|Epanova|
263845|NCT02189252|Drug|Lovaza|
263846|NCT02189239|Drug|Zeller Entspannung film coated tablet|
263847|NCT02189239|Drug|Placebo|
263848|NCT02189239|Other|No Treatment|
263849|NCT02189226|Device|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
263850|NCT02189213|Drug|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
263851|NCT02189213|Drug|Fluoxetine|Fluoxetine will be administered to treat anxiety disorders in children and adolescents.
263852|NCT02189213|Drug|Escitalopram|Lexapro will be administered to treat anxiety disorders in children and adolescents.
263853|NCT02189200|Dietary Supplement|oat bran - 40g|oat bran - 40g per day
263854|NCT02189200|Dietary Supplement|refined rice flour- 40g|refined rice flour - 40g per day
263855|NCT02189187|Behavioral|Mindfulness|
263856|NCT02189187|Behavioral|Psychoeducation|
263857|NCT02189174|Drug|CLR457|
263858|NCT02189161|Device|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
263951|NCT02188537|Drug|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
263952|NCT02188524|Other|Exercise|Tai Chi and Compensatory Stepping
264086|NCT02187445|Drug|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
263859|NCT02189135|Device|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
263860|NCT02189122|Drug|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
263861|NCT02189122|Drug|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
263862|NCT02189122|Drug|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
263863|NCT02189122|Drug|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
263864|NCT02189122|Drug|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
263865|NCT02189122|Drug|Placebo|Subjects will take matching placebo for five days.
263866|NCT02189109|Drug|NVX-108|0.2% emulsion administered i.v.
263867|NCT02189096|Other|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
263868|NCT02189096|Other|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
263869|NCT02189083|Drug|TSD|"TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.~High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks."
263870|NCT02189057|Other|AssureRx GeneSight genotyping results|
263871|NCT02189057|Other|Treatment as usual|
263872|NCT02189044|Other|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.~During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.~In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.~In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
263873|NCT02189031|Device|Tactor array|
263874|NCT02189031|Device|Bypass Tactor|
263875|NCT02189018|Other|Active Exercise|Active exercise on a treadmill
263876|NCT02189018|Other|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
263877|NCT02189018|Other|Weight loss and active exercise|Weight loss and active exercise on a treadmill
263878|NCT02189018|Other|Ad lib activity at home|Ad lib activity at home
263879|NCT02189005|Dietary Supplement|Study dietary supplement (PreCrea 600 mg capsules)|Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
263880|NCT02189005|Dietary Supplement|Placebo|
263881|NCT02188966|Device|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
263882|NCT02188953|Drug|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
263883|NCT02188953|Drug|Calcium carbonate placebo|
263884|NCT02188940|Behavioral|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
263885|NCT02188940|Behavioral|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
263886|NCT02188940|Behavioral|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
263915|NCT02188732|Behavioral|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
264085|NCT02187471|Drug|Placebo capsule|Placebo capsule for oral use, matching pregabalin capsule
263887|NCT02188940|Other|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
263888|NCT02188940|Other|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.~*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
263889|NCT02188927|Other|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
263890|NCT02188927|Behavioral|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
263891|NCT02188914|Radiation|Positron emission tomography scan|
263892|NCT02188914|Other|Magnetic resonance imaging|
263893|NCT02188901|Other|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) [GE healthcare]
263894|NCT02188888|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
263895|NCT02188875|Behavioral|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
263896|NCT02188875|Behavioral|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
263897|NCT02188849|Other|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
263898|NCT02188849|Drug|Creatine|Creatine powder 5 g day
263899|NCT02188836|Device|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
263900|NCT02188836|Device|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
263901|NCT02188823|Behavioral|Low carbohydrate diet|
263902|NCT02188810|Biological|PAL|Single dose administered intramuscularly.
263903|NCT02188810|Biological|TIV|Single dose administered intramuscularly .
263904|NCT02188797|Behavioral|Group MI risk reduction program|
263905|NCT02188784|Drug|Polysaccharide Iron Complex 150 mg|Oral Iron
263906|NCT02188784|Drug|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
263907|NCT02188771|Device|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
263908|NCT02188758|Other|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
263909|NCT02188745|Drug|17B-estradiol|Anti-estrogen
263910|NCT02188745|Drug|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
263911|NCT02188745|Drug|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
263912|NCT02188745|Drug|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
263913|NCT02188732|Behavioral|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):~Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
263914|NCT02188732|Behavioral|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
263949|NCT02188537|Drug|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
263950|NCT02188537|Drug|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
264655|NCT02183415|Drug|BI 1356 BS, medium dose|
263916|NCT02188719|Biological|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is <50/mm^3 or when the maximal dose of 4.5/mg/kg has been given.
263917|NCT02188719|Biological|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
263918|NCT02188719|Drug|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
263919|NCT02188719|Drug|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )~TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF~EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
263920|NCT02188719|Drug|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
263921|NCT02188719|Drug|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
263922|NCT02188719|Drug|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
263923|NCT02188719|Drug|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
263924|NCT02188719|Drug|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
263925|NCT02188719|Procedure|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.~Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level >/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level </=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
263926|NCT02188719|Procedure|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
263927|NCT02188719|Procedure|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
263928|NCT02188719|Procedure|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
263929|NCT02188680|Other|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
263930|NCT02188667|Other|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
263931|NCT02188667|Other|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
263932|NCT02188654|Drug|Metformin|500mg/day retarded formulation of metformin
263933|NCT02188654|Drug|Placebo|500 mg/day of placebo tablets
263934|NCT02188641|Other|Diet|
263935|NCT02188641|Other|Exercise|
263936|NCT02188641|Other|Diet and Exercise|
263937|NCT02188641|Other|Healthy Lifestyle (Control) Group|
263938|NCT02188628|Device|H-Man|H-man is a portable end-effector planar upper limb robot.
263939|NCT02188628|Other|Additional Conventional Therapy|Repetitive goals based arm therapy
263940|NCT02188615|Procedure|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
263941|NCT02188615|Drug|Cisplatin|only Radical Chemoradiotherapy
263942|NCT02188615|Device|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
263943|NCT02188589|Device|INEX nasal implant|Treatment group may receive unilateral or bilateral INEX nasal implants (maximum of 4, 2 per side)
263944|NCT02188576|Drug|high dose TXA|
263945|NCT02188576|Drug|Low dose TXA|
263946|NCT02188563|Other|Comprehensive smoking cessation intervention|
263947|NCT02188563|Behavioral|Enhanced usual care|
263948|NCT02188550|Drug|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented~The duration of the study will be until disease progression~Everolimus and Letrozole will be administered as noted below;~6.1.1 Dosing regimen~Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
263953|NCT02188511|Other|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to < 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
263954|NCT02188511|Other|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
263955|NCT02188511|Other|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
263956|NCT02188511|Other|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
263957|NCT02188511|Other|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).~Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
263958|NCT02188498|Procedure|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
263959|NCT02188485|Behavioral|ENGAGE|Up to 10 sessions delivered in the home.
263960|NCT02188472|Drug|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
263961|NCT02188472|Drug|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
263962|NCT02188472|Drug|Placebo|Placebo: 2 tablets should be taken twice daily
263963|NCT02188459|Drug|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
263964|NCT02188446|Behavioral|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
263965|NCT02188433|Behavioral|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
263966|NCT02188420|Device|Transcranial Magnetic Stimulation (Magstim)|
263967|NCT02188407|Drug|Sevoflurane|MAC 3-5 V% during surgery
263968|NCT02188407|Drug|Propofol|Propofol group (P group)- The group anaesthesied with propofol
263969|NCT02188394|Drug|Anesthetic blockades with bupivacaine|
263970|NCT02188394|Drug|Isotonic saline injection|
263971|NCT02188381|Other|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
263972|NCT02188368|Drug|POM|
263973|NCT02188368|Drug|Steroids|
263974|NCT02188368|Drug|PLD|
263975|NCT02188368|Drug|CFZ|
263976|NCT02188368|Drug|BTZ|
263977|NCT02188368|Drug|CLA|
263978|NCT02188368|Drug|Other drugs|
263979|NCT02188368|Drug|CY|
263980|NCT02188342|Behavioral|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
263981|NCT02188316|Device|Jumbo forceps|comparison of different polypectomy devices
263982|NCT02188316|Device|Hot biopsy forceps|comparison of different polypectomy devices
263983|NCT02188303|Drug|LY2944876|Administered SC
263984|NCT02188303|Drug|Placebo|Administered SC
263985|NCT02188277|Drug|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
263986|NCT02188277|Drug|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
263987|NCT02188264|Drug|Cyclosporine|Given PO
263988|NCT02188264|Other|Laboratory Biomarker Analysis|Correlative studies
263989|NCT02188264|Other|Pharmacological Study|Correlative studies
263990|NCT02188264|Drug|Selumetinib|Given PO
263991|NCT02188251|Dietary Supplement|Activamp|
263992|NCT02188251|Other|Placebo|
263993|NCT02188238|Other|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
263994|NCT02188225|Procedure|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
263995|NCT02188225|Drug|fluoxetine|10 mg/ daily
263996|NCT02188212|Device|NobelProcera Crown Shaded Zirconia|
263997|NCT02188186|Drug|Initial triple combination|Initial triple combination arm
263998|NCT02188186|Drug|Conventional treatment|Conventioanl treament with dose escalation
263999|NCT02188173|Drug|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
264000|NCT02188160|Drug|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
264316|NCT02185794|Drug|SOF/GS-5816|Sofosbuvir (SOF) 400 mg/GS-5816 100 mg FDC tablet administered orally once daily
264001|NCT02188160|Drug|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
264002|NCT02188147|Device|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
264003|NCT02188121|Drug|Simvastatin|3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
264004|NCT02188121|Drug|Losartan|Angiotensin II receptor antagonist
264005|NCT02188108|Other|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
264006|NCT02188082|Drug|IvabRadine hemisulfate Sustained-release Tablets|
264007|NCT02188082|Drug|placebo|
264008|NCT02188043|Behavioral|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.~Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
264009|NCT02188030|Other|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
264010|NCT02188030|Other|Individual Exercise Program|"The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.~During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session."
264011|NCT02188017|Drug|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
264012|NCT02187991|Drug|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
264013|NCT02187991|Drug|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
264014|NCT02187978|Other|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
264015|NCT02187978|Other|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
264016|NCT02187952|Behavioral|Behavioral feeding intervention|Behavioral feeding intervention will include escape extinction.
264017|NCT02187939|Other|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
264018|NCT02187913|Dietary Supplement|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
264019|NCT02187900|Drug|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
264020|NCT02187900|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
264021|NCT02187887|Behavioral|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
264022|NCT02187874|Procedure|delayed umbilical cord occlusion|
264023|NCT02187874|Procedure|early umbilical cord occlusion|
264024|NCT02187874|Drug|Oxytocin|
264025|NCT02187861|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
264026|NCT02187861|Drug|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
264027|NCT02187861|Drug|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
264028|NCT02187848|Drug|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
264029|NCT02187822|Drug|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
264030|NCT02187822|Procedure|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
264031|NCT02187809|Drug|Clobazam|
264032|NCT02187783|Drug|LEE011|Study drug was provided in 200 mg and 50 mg hard gelatin capsules to be taken orally
264033|NCT02187770|Device|IMED-4|Non invasive recording electrode used to assess lung fluid
264034|NCT02187757|Dietary Supplement|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
264035|NCT02187757|Dietary Supplement|Placebo|
264036|NCT02187744|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
264037|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
264038|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
264039|NCT02187744|Biological|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
264040|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
264041|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
264042|NCT02187718|Procedure|Sentinel Node Procedure under Local Anaesthesia|
264043|NCT02187718|Procedure|Sentinel Node Procedure under General Anaesthesia|
264044|NCT02187705|Drug|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
264045|NCT02187692|Behavioral|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
264046|NCT02187679|Drug|Abobotulinum toxin A|
264047|NCT02187640|Behavioral|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
264048|NCT02187640|Behavioral|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
264049|NCT02187627|Drug|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6924963 injected will be </=10 micrograms (mcg), injection volume </=20 milliliters (mL). Target injected activity for [11C]RO6924963 will be 370-740 megabecquerel (MBq) [10-20 millicurie (mCi)].
264050|NCT02187627|Drug|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6931643 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [11C]RO6931643 will be 370-740 MBq (10-20 mCi).
264051|NCT02187627|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [18F]RO6958948 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of [18F] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
264052|NCT02187614|Drug|Diclofenac|
264053|NCT02187614|Drug|Morphine|
264054|NCT02187614|Drug|Paracetamol|
264055|NCT02187614|Drug|Placebos|
264056|NCT02187601|Device|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
264057|NCT02187601|Device|BreathID|BreathID is the name of the original Exalenz breath analyzer system
264058|NCT02187588|Drug|Eschscholtzia Californica - low dose|
264059|NCT02187588|Drug|Eschscholtzia Californica - high dose|
264060|NCT02187588|Drug|Ibuprofen|
264061|NCT02187588|Drug|Eschscholtzia Californica - low dose Placebo|
264062|NCT02187588|Drug|Eschscholtzia Californica - high dose Placebo|
264063|NCT02187588|Drug|Ibuprofen Placebo|
264064|NCT02187575|Drug|UHAC 62 XX tablet|
264065|NCT02187575|Drug|UHAC 62 XX capsule|
264066|NCT02187562|Drug|Meloxicam|
264067|NCT02187562|Drug|Aspirin|
264068|NCT02187549|Device|HYMOVIS|Intra-articular injection
264069|NCT02187549|Device|Placebo|Intra-Articular Injection
264070|NCT02187536|Drug|Telmisartan|
264071|NCT02187536|Drug|Simvastatin|
264072|NCT02187536|Drug|Telmisartan placebo|
264073|NCT02187523|Drug|Hydrochlorothiazide|
264074|NCT02187523|Drug|Telmisartan|
264075|NCT02187523|Drug|Telmisartan/HCTZ FDC|
264076|NCT02187510|Procedure|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
264077|NCT02187510|Procedure|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
264078|NCT02187497|Drug|Low dose of BIBR 277|
264079|NCT02187497|Drug|Medium dose of BIBR 277|
264080|NCT02187497|Drug|High dose of BIBR 277|
264081|NCT02187484|Drug|BIBR 277|
264082|NCT02187471|Drug|DS-5565|DS-5565 15 mg QD or BID; tablet for oral use
264083|NCT02187471|Drug|Pregabalin|Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule
264084|NCT02187471|Drug|Placebo tablet|Placebo tablet for oral use, matching DS-5565 tablet
264087|NCT02187419|Other|Hypnosis|"Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.~However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings."
264088|NCT02187406|Procedure|Modified ankle athletic taping|
264089|NCT02187406|Procedure|Traditional ankle athletic taping|
264090|NCT02187367|Biological|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
264091|NCT02187354|Drug|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment & no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) & 28μg/day for the escalated dose after dose step should not be exceeded.
264092|NCT02187354|Other|Extension of LTFU as per ProtocolAmendment7 7Jun18|LTFU (Long Term Follow-Up) will extend past 18 months for patients already ended the study/still on study or to be enrolled at European sites if they did not receive a transplantation after blinatumomab treatment. For subjects to be included in the additional LTFU, data will be captured until subjects are 18yrs old (every 6 months by phone contact). The following will be captured: relapse (medullary or extra-medullary relapse and its specific location), second tumor (which type), alive/died and cause of death, hospitalization and reason for hospitalization.
264093|NCT02187341|Dietary Supplement|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
264094|NCT02187341|Dietary Supplement|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
264095|NCT02187328|Other|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
264096|NCT02187328|Other|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
264097|NCT02187315|Device|Chrono-chemotherapy pump:Melodie|
264098|NCT02187315|Device|Routine intravenous drip|
264099|NCT02187315|Drug|induction chemotherapy|
264100|NCT02187315|Drug|cisplatin chrono-chemotherapy|
264101|NCT02187315|Radiation|intensity-modulated radiation therapy|
264102|NCT02187315|Drug|cisplatin routine-chemotherapy|
264103|NCT02187302|Drug|CRLX101|
264104|NCT02187302|Drug|Bevacizumab|
264105|NCT02187302|Drug|Standard of Care (Investigator Choice)|
264106|NCT02187289|Device|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
264107|NCT02187289|Device|Compression Sleeve, daytime wear|
264108|NCT02187289|Device|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
264109|NCT02187276|Drug|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
264110|NCT02187250|Drug|metformin|
264111|NCT02187250|Drug|liraglutide|
264112|NCT02187250|Drug|roflumilast|
264113|NCT02187237|Device|YOLO TOUCH Low Level Laser|
264114|NCT02187224|Drug|Progesterone|
264115|NCT02187224|Drug|Placebo (for Progesterone)|
264116|NCT02187211|Drug|Minocycline|
264117|NCT02187211|Drug|Placebo (for Minocycline)|
264118|NCT02187198|Drug|Buprenorphine|
264119|NCT02187185|Other|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
264120|NCT02187185|Other|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
264121|NCT02187172|Drug|Ustekinumab|
264122|NCT02187172|Drug|Placebo|
264123|NCT02187159|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
264124|NCT02187159|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
264125|NCT02187159|Drug|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
264126|NCT02187159|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
264127|NCT02187133|Drug|Carfilzomib|"Given IV; DL (Dose Level)~Twice Weekly~DL -1 and DL1: 15 mg/m^2~Weekly~DL 1.5: 20,27,27 mg/m^2~DL 2: 20,36,36 mg/m^2~DL 3: 20,56,56 mg/m^2~DL 4: 20,70,70 mg/m^2"
264128|NCT02187133|Drug|Bendamustine|"Given IV; DL (Dose Level)~DL -1: 75 mg/m^2~DL 1,1.5, 2, 3, and 4: 90 mg/m^2"
264129|NCT02187133|Drug|Rituximab|Given IV; 375 mg/m^2
264266|NCT02186119|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
264130|NCT02187120|Drug|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
264131|NCT02187120|Drug|Placebo|
264132|NCT02187107|Drug|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
264133|NCT02187107|Drug|rtv|100 mg tablet of Norvir®
264134|NCT02187094|Drug|TC-6499|
264135|NCT02187094|Drug|Placebo|
264136|NCT02187081|Procedure|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
264137|NCT02187081|Procedure|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
264138|NCT02187068|Drug|Dexmedetomidine|Dexmedetomidine administered intravenously
264139|NCT02187055|Drug|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
264140|NCT02187055|Drug|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
264141|NCT02187055|Biological|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
264142|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
264143|NCT02187042|Other|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
264144|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
264145|NCT02187029|Other|Placebo|Daily dosing (tablet) for 14 days
264146|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
264147|NCT02187029|Other|Placebo|Daily dosing (tablets) for 14 days
264148|NCT02187016|Device|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
264149|NCT02187016|Device|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
264150|NCT02187016|Device|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
264151|NCT02187016|Device|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
264152|NCT02187003|Drug|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
264153|NCT02187003|Other|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
264154|NCT02186990|Drug|propofol|2,5 mg/kg
264155|NCT02186990|Drug|etomidate|0,3 mg/kg
264156|NCT02186990|Drug|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
264157|NCT02186977|Device|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
264158|NCT02186977|Drug|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
264159|NCT02186977|Drug|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
264160|NCT02186964|Procedure|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
264161|NCT02186964|Procedure|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
264162|NCT02186964|Procedure|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
264163|NCT02186951|Drug|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
264164|NCT02186951|Drug|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
264165|NCT02186938|Device|FloTrac|
264166|NCT02186912|Device|Nobel Active, Nobel Procera IBO|
264167|NCT02186899|Other|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
264168|NCT02186899|Other|General Anesthesia femoral bolus|
264169|NCT02186899|Other|General anesthesia femoral continuous|
264170|NCT02186886|Drug|Golimumab|Physiological Intermolecular Modification Spectroscopy
264171|NCT02186873|Drug|Placebo|Participants will receive matching placebo.
264172|NCT02186873|Drug|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
264173|NCT02186860|Biological|Third generation CAR-T cells|Given IV
264174|NCT02186847|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiation therapy
264175|NCT02186847|Drug|Carboplatin|Given IV
264176|NCT02186847|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiation therapy
264177|NCT02186847|Other|Laboratory Biomarker Analysis|Correlative studies
264178|NCT02186847|Drug|Metformin Hydrochloride|Given PO
264179|NCT02186847|Drug|Paclitaxel|Given IV
264180|NCT02186847|Radiation|Volume Modulated Arc Therapy|Undergo radiation therapy
264181|NCT02186834|Drug|Selinexor|Selinexor orally as outlined in the study treatment arm.
264182|NCT02186834|Drug|Liposomal doxorubicin|Pegylated liposomal doxorubicin at a starting dose of 20 mb/m² as outlined in the treatment arm.
264267|NCT02186119|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
264268|NCT02186106|Drug|Cholecalciferol|
264269|NCT02186080|Drug|Gemigliptin|
264183|NCT02186834|Drug|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
264184|NCT02186821|Drug|Ceritinib|Ceritinib was dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) orally,once daily, on a continuous dosing cycle. A complete treatment cycle was defined as 28 days. There were no breaks between dosing cycles.
264185|NCT02186808|Device|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
264186|NCT02186782|Drug|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
264187|NCT02186782|Drug|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
264188|NCT02186769|Drug|Risperdal® Consta®|
264189|NCT02186769|Drug|LY03004|
264190|NCT02186756|Other|EMG-Biofeedback and Usual care|Please refer to arm description
264191|NCT02186743|Other|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
264192|NCT02186730|Behavioral|Stressbusters|cCBT
264193|NCT02186730|Behavioral|Websites|Self help websites
264194|NCT02186717|Dietary Supplement|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
264195|NCT02186704|Device|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
264196|NCT02186691|Other|MRI|
264197|NCT02186678|Other|PET-CT|
264198|NCT02186665|Drug|calcitriol ointment|
264199|NCT02186665|Drug|placebo comparator|
264200|NCT02186652|Drug|Pantoprazole|
264201|NCT02186626|Biological|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
264202|NCT02186626|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
264203|NCT02186613|Behavioral|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
264204|NCT02186600|Drug|Calcium Carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
264205|NCT02186600|Drug|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
264206|NCT02186600|Drug|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
264207|NCT02186600|Behavioral|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
264208|NCT02186587|Device|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
264209|NCT02186574|Drug|Tenofovir disoproxil|
264210|NCT02186574|Drug|Placebo Oral Tablet|
264211|NCT02186561|Device|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
264212|NCT02186548|Procedure|Closed surgical technique|"Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone~The bone covering the canine is being removed~Attachment with a chain is bonded to the exposed tooth~The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery~The canine is orthodontically moved beneath the palatal mucosa"
264213|NCT02186548|Procedure|Open surgical technique|"Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth~Pack/filling material is applied on the tooth~Spontaneous eruption of the palatally impacted canine is allowed expected~The canine is orthodontically moved above the mucosa"
264214|NCT02186535|Dietary Supplement|Vitamin D and Calcium|
264215|NCT02186509|Radiation|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
264216|NCT02186509|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
264217|NCT02186509|Drug|Alisertib|Given PO
264218|NCT02186509|Procedure|Quality-of-life assessment|Ancillary studies
264219|NCT02186496|Drug|CKD-330 8/5mg|
264220|NCT02186496|Drug|Candesartan 8mg and Amlodipine 5mg|
264221|NCT02186483|Drug|Metformin|Metformin,1000mg, once daily
264222|NCT02186483|Drug|Rosuvastatin|Rosuvastatin, 20 mg, once daily
264223|NCT02186483|Drug|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
264224|NCT02186470|Radiation|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
264225|NCT02186470|Radiation|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
264226|NCT02186470|Radiation|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
264227|NCT02186470|Procedure|therapeutic conventional surgery|Lumpectomy
264228|NCT02186457|Drug|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
264229|NCT02186457|Other|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
264230|NCT02186444|Other|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
264270|NCT02186080|Drug|Placebo|
264231|NCT02186444|Other|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
264232|NCT02186431|Device|senofilcon A|
264233|NCT02186418|Genetic|Gene transfer|"Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector~Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor~Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells."
264234|NCT02186405|Drug|LEVOTHYROXINE|administration of levothyroxine
264235|NCT02186392|Device|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
264236|NCT02186379|Behavioral|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
264237|NCT02186379|Behavioral|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
264238|NCT02186366|Other|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
264239|NCT02186366|Drug|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
264240|NCT02186353|Behavioral|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
264241|NCT02186340|Procedure|Inspiratory muscle training|
264242|NCT02186327|Behavioral|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
264243|NCT02186314|Device|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
264244|NCT02186314|Device|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
264245|NCT02186301|Drug|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
264246|NCT02186301|Drug|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
264247|NCT02186288|Other|High-flow nasal cannula oxygen|
264248|NCT02186275|Drug|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|"Weight at inclusion < 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.~Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance."
264249|NCT02186275|Drug|Vitamin D3 800 UI/day then 800 UI/day|"Weight < 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance~Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance"
264250|NCT02186249|Drug|Nivolumab|
264251|NCT02186249|Drug|Ipilimumab|
264252|NCT02186223|Device|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
264253|NCT02186210|Device|prewarming|recovery slope StO2
264254|NCT02186197|Other|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
264255|NCT02186184|Device|Orthokeratology|
264256|NCT02186184|Device|Spectacle|
264257|NCT02186171|Biological|Romosozumab|Administered by subcutaneous injection once a month.
264258|NCT02186171|Drug|Placebo|Administered by subcutaneous injection once a month.
264259|NCT02186158|Drug|Vitamin C|
264260|NCT02186158|Drug|Placebo|
264261|NCT02186145|Drug|Association of metronidazole; nystatin and dexamethasone|
264262|NCT02186145|Drug|Flagyl|Vaginal cream of metronidazole and nystatin
264263|NCT02186132|Drug|Atropine 0.6 mg|Atropine 0.6 mg intravenous
264264|NCT02186132|Drug|Atropine 1.2 mg|Atropine 1.2 mg intravenous
264265|NCT02186119|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
264271|NCT02186067|Other|Referral System|"Primary Level:~Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)~Secondary Level:~Community health center at Aga Khan University will serve as the secondary care center.~Family physician will manage patients with CVD, CKD or more than 3 drugs.~Tertiary care:~Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.~Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
264272|NCT02186054|Device|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
264273|NCT02186041|Device|Sacral Nerve Modulation|
264274|NCT02186028|Drug|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
264275|NCT02186015|Drug|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
264276|NCT02186002|Drug|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
264277|NCT02186002|Drug|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
264278|NCT02186002|Drug|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
264279|NCT02186002|Drug|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
264280|NCT02186002|Drug|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
264281|NCT02186002|Drug|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
264282|NCT02186002|Drug|Placebo|
264283|NCT02185989|Other|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
264284|NCT02185976|Other|cartoon|5 different cartoons which will be recorded on a tablet PC.
264285|NCT02185963|Drug|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
264286|NCT02185950|Device|ultrasound|
264287|NCT02185950|Device|paraffin|
264288|NCT02185950|Device|endermotherapy|
264289|NCT02185937|Dietary Supplement|cola|imatinib intake with coca-cola
264290|NCT02185924|Drug|Parecoxib|
264291|NCT02185924|Drug|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
264292|NCT02185924|Drug|N/S 0.9%|
264293|NCT02185898|Other|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
264294|NCT02185898|Other|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
264295|NCT02185898|Other|Electronic cigarette #1|Electronic cigarette
264296|NCT02185898|Other|Electronic cigarette #2|Electronic cigarette
264297|NCT02185898|Other|Electronic cigarette #3|Electronic cigarette
264298|NCT02185898|Other|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
264299|NCT02185885|Procedure|Increased bloodpressure during CPB.|
264300|NCT02185872|Other|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
264301|NCT02185872|Other|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
264302|NCT02185859|Drug|Lidocaine|The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
264303|NCT02185859|Drug|Magnesium Sulfate|the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
264304|NCT02185859|Drug|Saline|the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
264305|NCT02185846|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
264306|NCT02185846|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
264307|NCT02185833|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
264308|NCT02185833|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
264309|NCT02185820|Drug|Carfilzomib|
264310|NCT02185820|Drug|Pomalidomide|
264311|NCT02185820|Drug|Dexamethasone|
264312|NCT02185807|Procedure|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
264313|NCT02185807|Procedure|control group|The control patients receive verbal information and discussion from their physicians.
264314|NCT02185794|Drug|GS-9857|GS-9857 tablets administered orally once daily
264315|NCT02185794|Drug|Placebo to match GS-9857|Placebo to match GS-9857 tablets administered orally once daily
264525|NCT02184312|Drug|Nevirapine (VIRAMUNE®)|
264317|NCT02185781|Other|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.~The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
264318|NCT02185768|Drug|idarubicin|
264319|NCT02185768|Device|Dc- Beads 300-500µm|
264320|NCT02185755|Other|Internet-Based Glucose Monitoring System|
264321|NCT02185755|Drug|Normal Medication Positive Control|
264322|NCT02185742|Behavioral|Strength Based Case Management|
264323|NCT02185729|Drug|Intralipid|Infusion of Intralipid (soybean-derived fat)
264324|NCT02185729|Drug|ClinOleic|Infusion of ClinOleic (olive oil-based)
264325|NCT02185729|Drug|Dextrose|Infusion of dextrose (sugar) without fat
264326|NCT02185729|Other|Saline (control)|Infusion of 0.9% normal saline
264327|NCT02185716|Drug|Levobupivacaine 0.25 %|
264328|NCT02185716|Drug|Levobupivacaine 0.5%|
264329|NCT02185703|Device|Chordate System S020 in treatment mode|
264330|NCT02185703|Device|Chordate System S020 in placebo mode|
264331|NCT02185690|Drug|Binimetinib|"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.~MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."
264332|NCT02185690|Drug|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
264333|NCT02185690|Drug|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
264334|NCT02185677|Other|Clinical evaluation|
264335|NCT02185677|Other|neuropsychological battery test|
264336|NCT02185677|Other|MRI|
264337|NCT02185677|Other|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
264338|NCT02185664|Procedure|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
264339|NCT02185664|Device|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
264340|NCT02185651|Drug|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
264341|NCT02185638|Other|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
264342|NCT02185625|Device|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
264343|NCT02185612|Behavioral|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
264344|NCT02185599|Device|DySIS|Colposcopy performed with the DySIS digital colposcope
264345|NCT02185586|Procedure|laparoscopic cholecystectomy|
264346|NCT02185573|Procedure|Bulk fill|This is one of the composite restoration application techniques
264347|NCT02185573|Procedure|SonicFill|This is the recent intervention under evaluation
264348|NCT02185560|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
264349|NCT02185547|Drug|Zoloft|Sertraline treatment 25 mg
264350|NCT02185547|Behavioral|ICBT|Internet behavioral cognitive therapy only
264351|NCT02185534|Drug|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
264352|NCT02185521|Other|patient assessment|Patient clinician status assessment based on Hemodynamic Instability Indicator (HII) trend. The HII indicator combines existing data such as physiologic parameters (Heart Rate, HR; Blood Pressure, BP), laboratory measurements (Albumin; Hematocrit, HCT; Bicarbonate; White Blood Cell, WBC; Blood Urea Nitrogen, BUN), and ADT information (age). HII will be displayed on charting workstation (Workstation on Wheels, WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
264353|NCT02185495|Behavioral|Observer nodule detection|Radiologists will detect the nodules.
264354|NCT02185495|Device|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
264355|NCT02185482|Behavioral|Physician Supported Care|
264356|NCT02185482|Other|Usual care|
264357|NCT02185469|Procedure|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
264358|NCT02185469|Procedure|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
264359|NCT02185469|Drug|sulfur hexafluoride (SF6)|
264360|NCT02185469|Device|5/8-in 25-gauge needle|
264361|NCT02185469|Device|laser|intraoperative laser retinopexy
264362|NCT02185456|Drug|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
264363|NCT02185456|Drug|Standard of care|oral metronidazole 500 mg twice a day for 7 days
264364|NCT02185443|Radiation|SBRT|"60Gy in 3 fractions (20Gy/fraction) over 14 days~60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
264365|NCT02185430|Drug|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
264366|NCT02185430|Drug|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
264367|NCT02185417|Drug|Hydrochlorothiazide (HCTZ)|Thiazide-type diuretic. Daily dose of 50 or 25 mg for duration of the study.
264368|NCT02185417|Drug|Chlorthalidone|Thiazide-type diuretic. Daily dose of 25 or 12.5 mg for duration of the study.
264369|NCT02185404|Device|wearing the iStride device|The device mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This device does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. This research aims to test the iStride on individuals with stroke in their own home in order to determine if the related effects that we saw in the clinic, can also benefit patients at home.
264370|NCT02185391|Procedure|Audience Response System|patients use during oral presentations an audience response system
264371|NCT02185391|Behavioral|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
264372|NCT02185378|Procedure|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
264373|NCT02185378|Procedure|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
264374|NCT02185365|Radiation|Magnetic Resonance Imaging (MRI)|Patients will undergo 2 different MRIs of the affected hip. Both MRIs assess hip cartilage degeneration. A contrast agent, Gadolinium, will be used to visualize cartilage during the MRI. The contrast agent is injected through an intravenous (a small plastic tube inserted into a vein in the patients' arm) before the MRI.
264375|NCT02185352|Drug|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
264376|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
264377|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
264378|NCT02185326|Drug|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
264379|NCT02185313|Other|visual stimulus to follow|
264380|NCT02185300|Drug|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
264381|NCT02185300|Drug|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
264382|NCT02185261|Drug|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
264383|NCT02185248|Behavioral|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
264384|NCT02185235|Device|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.~Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.~Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
264385|NCT02185235|Device|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
264386|NCT02185235|Other|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.~Repeat this exercise to 20 minutes each session."
264387|NCT02185222|Drug|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
264388|NCT02185222|Drug|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
264389|NCT02185209|Drug|Placebo|Place capsule to mimic antibiotics
264390|NCT02185209|Drug|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
264391|NCT02185209|Drug|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
264392|NCT02185209|Drug|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
264393|NCT02185196|Drug|Vitamin D3|20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
264394|NCT02185196|Drug|Placebo|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
264395|NCT02185183|Drug|Alequel|Alequel
264396|NCT02185170|Procedure|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
264397|NCT02185170|Device|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
264398|NCT02185170|Device|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
264399|NCT02185157|Other|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
264400|NCT02185157|Other|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
264401|NCT02185144|Behavioral|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
264402|NCT02185144|Behavioral|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
264403|NCT02185131|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
264404|NCT02185131|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
264405|NCT02185118|Drug|oxygen|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
264406|NCT02185118|Drug|Sevoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
264407|NCT02185118|Drug|Isoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.~Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
264408|NCT02185105|Device|comfilcon A MTO|Randomized to a test lens in one eye and control lens in the other as a matched pair.
264409|NCT02185105|Device|comfilcon A|Randomized to a test lens in one eye and control lens in the other as a matched pair.
264410|NCT02185092|Dietary Supplement|Lactobacillus GG|probiotic supplement
264411|NCT02185092|Other|Sugar pill|placebo
264412|NCT02185079|Behavioral|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
264413|NCT02185079|Behavioral|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
264414|NCT02185066|Drug|Atorvastatin 20mg and Metformin XR 500mg (Reference)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
264415|NCT02185066|Drug|CJ-30056 20/500mg (Test)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
264416|NCT02185053|Drug|CPC-201|
264417|NCT02185040|Drug|CC-220|0.3 mg oral capsules once every other day with or without food
264418|NCT02185040|Drug|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
264419|NCT02185040|Drug|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
264420|NCT02185040|Drug|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
264421|NCT02185040|Drug|Placebo|Matching oral placebo daily
264422|NCT02185027|Other|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
264423|NCT02185014|Drug|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
264424|NCT02185001|Procedure|Direct Medial Patellofemoral Ligament (MPFL) Repair|The MPFL will be repaired directly at the site of the traumatic injury.
264425|NCT02185001|Procedure|Physical therapy|Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
264426|NCT02184988|Biological|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
264427|NCT02184975|Procedure|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
264428|NCT02184975|Procedure|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
264429|NCT02184949|Procedure|Percutaneous Coronary Intervention|
264430|NCT02184949|Procedure|Primary Percutaneous Coronary Intervention|
264431|NCT02184936|Other|standard of care|
264432|NCT02184923|Other|presentation of visual vertical|
264433|NCT02184910|Drug|pepsinogen and gastrin|
264434|NCT02184897|Drug|lenograstim 10 microgram/kg/day|
264435|NCT02184884|Device|MACE after OPCAB|
264436|NCT02184884|Device|without MACE after OPCAB|
264437|NCT02184871|Other|exposure to different risk factors and molecular assessment|
264438|NCT02184858|Drug|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
264439|NCT02184845|Device|Implant NobelActive 3.0|
264440|NCT02184832|Drug|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
264441|NCT02184832|Other|Low tryptophan diet|
264442|NCT02184832|Other|High tryptophan diet|
264443|NCT02184819|Drug|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
264444|NCT02184819|Drug|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
264445|NCT02184806|Procedure|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
264446|NCT02184806|Procedure|heterotopic graft|"put under the skin~the ovarian fragments can be put under the skin of the abdomen"
264447|NCT02184793|Device|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
264448|NCT02184767|Drug|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
264449|NCT02184754|Procedure|Magnetic endoscope imaging (MEI)|
264450|NCT02184741|Drug|GB-0998|Subjects recieved GB-0998 at a dose of 400mg/kg/day for five days until the 6th gestational week.
264451|NCT02184741|Drug|Placebo|Subjects recieved saline of the same volume as GB-0998 for five days until the 6th gestational week.
264452|NCT02184728|Device|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
264453|NCT02184715|Other|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
264454|NCT02184689|Drug|fexinidazole|
264455|NCT02184676|Biological|Analysis of early immune modifications|"blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~cord blood sampling~stool sampling in mothers and newborns at birth (day 7)~blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
264456|NCT02184676|Other|Collection of clinical and socio-demographic data|"Questionnaire filled in by clinicians at enrollment and at birth~Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
264457|NCT02184663|Other|without APA program|Control Arm : chemotherapy alone
264458|NCT02184663|Other|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
264459|NCT02184650|Other|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
264460|NCT02184637|Drug|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
264461|NCT02184637|Drug|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
264462|NCT02184637|Drug|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
264463|NCT02184624|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
264464|NCT02184624|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
264465|NCT02184624|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
264466|NCT02184624|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
264467|NCT02184624|Device|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
264468|NCT02184624|Device|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
264469|NCT02184611|Drug|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
264470|NCT02184611|Drug|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
264471|NCT02184598|Behavioral|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
264526|NCT02184299|Drug|Nevirapine|
264527|NCT02184299|Drug|Prednisone|
264528|NCT02184286|Drug|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
264472|NCT02184598|Behavioral|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
264473|NCT02184585|Drug|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
264474|NCT02184585|Drug|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
264475|NCT02184585|Drug|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
264476|NCT02184572|Biological|Priorix|1 dose administered subcutaneously in the triceps region of left arm at Day 0
264477|NCT02184572|Biological|M-M-R II|1 dose administered subcutaneously in the triceps region of left arm at Day 0
264478|NCT02184572|Biological|Varivax|1 dose administered subcutaneously in the triceps region of right arm at Day 0
264479|NCT02184572|Biological|Havrix|1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
264480|NCT02184572|Biological|Prevnar 13|1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
264481|NCT02184559|Drug|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
264482|NCT02184559|Device|The infiltration continues catheter|
264483|NCT02184533|Drug|sodium selenite|Given PO
264484|NCT02184533|Radiation|radiation therapy|Undergo radiation therapy
264485|NCT02184533|Other|laboratory biomarker analysis|Correlative studies
264486|NCT02184533|Other|pharmacological study|Correlative studies
264487|NCT02184533|Other|questionnaire administration|Ancillary studies
264488|NCT02184520|Device|TRANSITION|
264489|NCT02184520|Device|REVERE|
264490|NCT02184507|Dietary Supplement|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
264491|NCT02184507|Dietary Supplement|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
264492|NCT02184507|Dietary Supplement|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
264493|NCT02184507|Drug|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
264494|NCT02184494|Device|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|"Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.~Whole Body Vibration"
264495|NCT02184481|Behavioral|Working memory training|
264496|NCT02184481|Behavioral|Placebo training|
264497|NCT02184468|Other|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
264498|NCT02184455|Biological|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
264499|NCT02184442|Device|TAVR Implantation with SAPIEN XT|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
264500|NCT02184442|Device|TAVR Implantation with SAPIEN|Inoperable operable patients requiring the transcatheter aortic heart valve replacement
264501|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
264502|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
264503|NCT02184429|Drug|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
264504|NCT02184429|Drug|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
264505|NCT02184429|Drug|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
264506|NCT02184429|Drug|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
264507|NCT02184429|Drug|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
264508|NCT02184416|Other|observational|The study is non interventional. All drugs will be prescribed
264509|NCT02184390|Other|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
264510|NCT02184364|Drug|Low dose of Klimadynon®|
264511|NCT02184364|Drug|Medium dose of Klimadynon®|
264512|NCT02184364|Drug|High dose of Klimadynon®|
264513|NCT02184364|Drug|Oestrofeminal®|
264514|NCT02184364|Drug|Placebo|
264515|NCT02184351|Drug|Roxanes's clotrimazole troches|
264516|NCT02184351|Drug|Mycelex® troches|
264517|NCT02184338|Drug|BIBR 1017 BS powder|
264518|NCT02184338|Drug|Placebo|PEG 400
264519|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets|
264520|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
264521|NCT02184325|Drug|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
264522|NCT02184312|Drug|Nevirapine XR low dose|
264523|NCT02184312|Drug|Nevirapine XR medium dose|
264524|NCT02184312|Drug|Nevirapine XR high dose|
264529|NCT02184286|Drug|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
264530|NCT02184273|Drug|Magnesium metamizol|
264531|NCT02184273|Drug|Placebo|
264532|NCT02184260|Drug|Metamizole|
264533|NCT02184260|Drug|Placebo|
264534|NCT02184247|Drug|anhydrous theophylline, 350 mg|
264535|NCT02184247|Drug|anhydrous theophylline, 300 mg|
264536|NCT02184234|Drug|Antistax film coated tablets|
264537|NCT02184221|Device|High frequency stimulation|The parameter of DMS: alpha frequency
264538|NCT02184221|Device|Low frequency stimulation|The parameter of DMS: 0.5Hz
264539|NCT02184195|Drug|Olaparib|Tablet -100mg
264540|NCT02184195|Drug|Olaparib|Tablet-150mg
264541|NCT02184195|Drug|Placebo|Match Olaparib 100mg placebo
264542|NCT02184195|Drug|Placebo|Match Olaparib 150mg placebo
264543|NCT02184182|Procedure|VLS ablation/portal ligation/hepatectomy|"Step1:~exploratory laparoscopy to exclude extrahepatic disease~right portal vein ligation if surgically feasible~RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)~radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible~CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1~Step 2: only if FRL/body weight > 0.5~- laparoscopic/laparotomic right trisectionectomy"
264544|NCT02184169|Device|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
264545|NCT02184169|Device|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
264546|NCT02184156|Biological|Ampion <5 kDa ultrafiltrate of 5% human serum albumin|4 mL intra-articular injection of Ampion
264547|NCT02184156|Biological|Placebo|Saline
264548|NCT02184143|Behavioral|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
264549|NCT02184143|Other|Education|Patient education
264550|NCT02184130|Other|transcranial magnetic stimulation and motion stimuli|
264551|NCT02184117|Drug|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
264552|NCT02184117|Drug|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
264553|NCT02184117|Drug|Resting conditions|Baseline measurement of aortic and coronary pressures
264554|NCT02184104|Dietary Supplement|Caffeine|
264555|NCT02184091|Drug|Nevirapine|
264556|NCT02184078|Drug|Nevirapine|
264557|NCT02184078|Drug|Rifabutin|
264558|NCT02184065|Drug|Meloxicam|
264559|NCT02184052|Drug|Meloxicam|7.5 mg or 15 mg
264560|NCT02184026|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
264561|NCT02184013|Procedure|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
264562|NCT02183987|Other|Active Knowledge Translation Intervention|"Access to CSN guidelines, & provider- & patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space & disseminated to patients.~Educational whiteboard video will be made available as a resource for clinic staff & patients.~Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (>3 months) starting dialysis early (eGFR >10.5 ml/min), for all incident dialysis patients from the clinic, with provincial & national average comparisons. These reports, & the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.~Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines & evidence supporting an intent-to-defer strategy, & will receive follow-up."
264563|NCT02183974|Procedure|Peptest|
264564|NCT02183961|Other|Restech|
264565|NCT02183961|Other|Peptest|
264566|NCT02183961|Other|Detection of pepsin in adenoid specimen|
264567|NCT02183948|Drug|Oxytocin|
264568|NCT02183948|Drug|Placebo|
264569|NCT02183935|Device|Duodena-jejunal liner|
264570|NCT02183922|Dietary Supplement|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
264571|NCT02183922|Dietary Supplement|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
264572|NCT02183922|Dietary Supplement|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
264573|NCT02183909|Other|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
264574|NCT02183909|Behavioral|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
264575|NCT02183909|Other|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
264576|NCT02183909|Drug|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
264577|NCT02183896|Biological|Platelet-rich plasma (PRP)|
264578|NCT02183896|Drug|Saline|
264649|NCT02183441|Drug|BI 1356|
264650|NCT02183441|Drug|Ritonavir|
264651|NCT02183428|Drug|BI 1356|
264652|NCT02183428|Drug|Glyburide|
264653|NCT02183428|Drug|BI 1356 + Glyburide|
264654|NCT02183415|Drug|BI 1356 BS, low dose|
264579|NCT02183883|Drug|Afatinib|"40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.~EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade > 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg."
264580|NCT02183870|Drug|Crizotinib|250mg crizotinib bid until end of treatment
264581|NCT02183857|Device|Ultrasound|
264582|NCT02183857|Other|Landmark|
264583|NCT02183844|Behavioral|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
264584|NCT02183831|Device|Insertion of the capsular tension ring|
264585|NCT02183805|Drug|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
264586|NCT02183792|Drug|Tolvaptan|
264587|NCT02183792|Drug|Furosemide|
264588|NCT02183779|Procedure|post-occlusive hyperemia|
264589|NCT02183779|Procedure|cooling box|
264590|NCT02183779|Drug|L-NMMA and Fluconazole dermic injection|
264591|NCT02183766|Dietary Supplement|Galactooligosaccharide prebiotic|6 mL once a day
264592|NCT02183766|Drug|Maltodextrin|6 mL once a day
264593|NCT02183753|Other|wood smoke|
264594|NCT02183753|Other|clean air|
264595|NCT02183740|Behavioral|Multifaceted educational program|
264596|NCT02183727|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
264597|NCT02183727|Procedure|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
264598|NCT02183714|Drug|Songha Night ®|
264599|NCT02183714|Drug|Placebo|
264600|NCT02183701|Drug|Telmisartan|
264601|NCT02183701|Drug|Losartan + Hydrochlorothiazide|
264602|NCT02183701|Drug|Placebo|
264603|NCT02183688|Drug|Low dose ASA|
264604|NCT02183688|Drug|High dose ASA|
264605|NCT02183688|Drug|Low dose paracetamol|
264606|NCT02183688|Drug|High dose paracetamol|
264607|NCT02183688|Drug|Caffeine|
264608|NCT02183688|Drug|Placebo|
264609|NCT02183675|Drug|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
264610|NCT02183675|Drug|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
264611|NCT02183675|Drug|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
264612|NCT02183662|Drug|BI 224436|
264613|NCT02183662|Drug|Placebo to BI 224436|
264614|NCT02183649|Drug|pentoxyverine citrate|
264615|NCT02183649|Drug|Placebo|
264616|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
264617|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
264618|NCT02183636|Drug|Linagliptin tablet|5 mg
264619|NCT02183636|Drug|pioglitazone tablet (Actos®)|45 mg
264620|NCT02183623|Drug|Simvastatin|
264621|NCT02183623|Drug|10 mg BI 1356 BS|
264622|NCT02183610|Drug|[14C] BI 1356 as oral (p.o.) solution|
264623|NCT02183610|Drug|[14C] BI 1356 solution for i.v. infusion|
264624|NCT02183584|Drug|Rifampicin|
264625|NCT02183584|Drug|Linagliptin|
264626|NCT02183571|Drug|Merck Glucophage® high dose|Part I: Treatment A
264627|NCT02183571|Drug|BMS Glucophage® high dose|Part I: Treatment B
264628|NCT02183571|Drug|Merck Glucophage® low dose|Part II: Treatment C
264629|NCT02183571|Drug|BMS Glucophage® low dose|Part II: Treatment D
264630|NCT02183558|Other|OGTT by randomization|
264631|NCT02183558|Other|OGTT by indication|
264632|NCT02183545|Drug|BI 1060469|single rising doses given as tablet
264633|NCT02183545|Drug|Placebo|given as tablet (matching placebo of BI 1060469)
264634|NCT02183532|Drug|BI 1356 BS|single dose
264635|NCT02183532|Drug|BI 1356 BS|multiple doses
264636|NCT02183519|Drug|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
264637|NCT02183519|Other|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
264638|NCT02183506|Drug|Metformin|
264639|NCT02183506|Drug|BI 1356 BS|
264640|NCT02183493|Drug|BI 1356|
264641|NCT02183480|Drug|Linagliptin, low dose|
264642|NCT02183480|Drug|Linagliptin, medium dose|
264643|NCT02183480|Drug|Linagliptin, high dose|
264644|NCT02183467|Drug|BI 1356, low dose|
264645|NCT02183467|Drug|BI 1356, high dose|
264646|NCT02183467|Drug|Placebo|
264647|NCT02183467|Drug|Moxifloxacin|
264648|NCT02183454|Device|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
264656|NCT02183415|Drug|BI 1356 BS, high dose|
264657|NCT02183415|Drug|Placebo|
264658|NCT02183402|Drug|Digoxin|
264659|NCT02183402|Drug|BI 1356|
264660|NCT02183389|Drug|Warfarin|
264661|NCT02183389|Drug|BI 1356|
264662|NCT02183376|Drug|BI 1356|
264663|NCT02183363|Drug|BI 1356 - Tablet TFII|
264664|NCT02183363|Drug|BI 1356 - Tablet iFF|
264665|NCT02183363|Drug|BI 1356 - Tablet TFIIb|
264666|NCT02183350|Drug|BI 1356 BS - single rising dose|
264667|NCT02183350|Drug|Placebo|
264668|NCT02183337|Drug|BI 1356|
264669|NCT02183337|Drug|BI 1356 + Pioglitazone|
264670|NCT02183337|Drug|Pioglitazone|
264671|NCT02183324|Drug|Low dose of BI 1356 BS|
264672|NCT02183324|Drug|Medium dose of BI 1356 BS|
264673|NCT02183324|Drug|High dose of BI 1356 BS|
264674|NCT02183324|Drug|Placebo|
264675|NCT02183311|Drug|BI 1356 BS - single rising dose|
264676|NCT02183311|Drug|BI 1356 BS - multiple rising dose|
264677|NCT02183311|Drug|Placebo|
264678|NCT02183298|Drug|BI 1356 BS - intravenous|
264679|NCT02183298|Drug|BI 1356 BS - Tablet|
264680|NCT02183298|Drug|Placebo|
264681|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 soft gelatine capsules|
264682|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 film-coated tablets|
264683|NCT02183285|Dietary Supplement|Placebo film-coated tablets (fct)|
264684|NCT02183285|Dietary Supplement|Placebo soft gelatine capsules|
264685|NCT02183272|Drug|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
264686|NCT02183272|Drug|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
264687|NCT02183259|Drug|ESR 1150 CL, Capsule, oral|
264688|NCT02183259|Drug|ESR 1150 CL, solution, intravenous|
264689|NCT02183246|Drug|Porfiromycin|
264690|NCT02183246|Drug|Placebo|
264691|NCT02183246|Radiation|Radiotherapy|
264692|NCT02183233|Drug|Eschscholtzia Californica|
264693|NCT02183233|Drug|Eschscholtzia Californica Placebo|
264694|NCT02183220|Drug|Metamizol|
264695|NCT02183220|Drug|Acetylsalicylic acid (ASA)|
264696|NCT02183220|Drug|Metamizol placebo|
264697|NCT02183220|Drug|ASA placebo|
264698|NCT02183207|Procedure|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
264699|NCT02183194|Device|Lutonix Paclitaxel Drug Coated Balloon|
264700|NCT02183181|Drug|Meloxicam capsule|
264701|NCT02183181|Drug|Meloxicam tablet|
264702|NCT02183168|Drug|Meloxicam suppository|
264703|NCT02183168|Drug|Meloxicam tablet|
264704|NCT02183168|Drug|Indomethacin|
264705|NCT02183155|Drug|Meloxicam - low|
264706|NCT02183155|Drug|Meloxicam - medium|
264707|NCT02183155|Drug|Meloxicam - high|
264708|NCT02183155|Drug|Placebo|
264709|NCT02183155|Drug|Extended-release indomethacin|
264710|NCT02183142|Drug|Mobic, China, 7.5 mg|
264711|NCT02183142|Drug|Mobic, Germany, 7.5 mg|
264712|NCT02183129|Drug|Diclofenac|
264713|NCT02183129|Drug|Meloxicam|
264714|NCT02183116|Drug|Meloxicam|
264715|NCT02183103|Drug|meloxicam rapid release tablet, 12mg, UH AC62MU|
264716|NCT02183090|Drug|Meloxicam ampoule|
264717|NCT02183090|Drug|Meloxicam tablet|
264718|NCT02183077|Drug|Meloxicam gel|
264719|NCT02183077|Drug|Meloxicam tablet|
264720|NCT02183064|Drug|Meloxicam|
264721|NCT02183064|Drug|NSAID|
264722|NCT02183051|Drug|Meloxicam 7.5 mg|
264723|NCT02183051|Drug|Meloxicam 3.75 mg|
264724|NCT02183051|Drug|Meloxicam 1.875 mg|
264725|NCT02183051|Drug|Ibuprofen 200 mg|
264726|NCT02183051|Drug|Placebo|
264727|NCT02183051|Drug|Meloxicam 15 mg|
264728|NCT02183051|Drug|Ibuprofen 400 mg|
264729|NCT02183038|Drug|Meloxicam low|
264730|NCT02183038|Drug|Meloxicam high|
264731|NCT02183038|Drug|Naproxen sodium|
264732|NCT02183038|Drug|Meloxicam placebo low|
264733|NCT02183038|Drug|Meloxicam placebo high|
264734|NCT02183038|Drug|Naproxen sodium placebo|
264735|NCT02183025|Drug|Meloxicam 7.5 mg|
264736|NCT02183025|Drug|Meloxicam 15 mg|
264737|NCT02183025|Drug|Mefenamic acid 500 mg|
264738|NCT02183025|Drug|Placebo matching 7.5 mg meloxicam|
264739|NCT02183025|Drug|Placebo matching 15 mg meloxicam|
264740|NCT02183025|Drug|Placebo matching 500 mg mefenamic acid|
264741|NCT02183012|Drug|Ibuprofen extrudate|
264742|NCT02183012|Drug|Ibuprofen lysinate|
264743|NCT02183012|Drug|Ibuprofen|
264744|NCT02182999|Device|Wound infiltration catheter|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
264745|NCT02182999|Drug|NaCl 0.9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
264746|NCT02182999|Drug|Ropivacaine 0.2%|The catheter is connected to the perfusor line filled with Ropivacaine 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
264747|NCT02182986|Procedure|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
264748|NCT02182986|Drug|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
264749|NCT02182973|Dietary Supplement|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.~GI-subscores from the Finnegan NAS Scoring system will be computed."
264750|NCT02182960|Drug|Ibuprofen syrup|
264751|NCT02182960|Drug|Brufen syrup|
264752|NCT02182947|Device|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
264753|NCT02182934|Drug|Ginsana|
264754|NCT02182934|Drug|Placebo|
264755|NCT02182908|Other|PET-Scan|PET-Scan
264756|NCT02182895|Drug|Saxagliptin|2.5-5 mg daily
264757|NCT02182882|Drug|GINSANA|
264758|NCT02182882|Drug|Placebo|
264759|NCT02182869|Drug|Combivent® HFA inhalation aerosol|
264760|NCT02182869|Drug|Combivent® CFC inhalation aerosol|
264761|NCT02182856|Drug|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
264762|NCT02182856|Drug|Ipratropium 500 µg|
264763|NCT02182856|Drug|Salbutamol sulphate 3 mg|
264764|NCT02182856|Drug|Salbutamol sulphate 6 mg|
264765|NCT02182843|Biological|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
264766|NCT02182830|Drug|Empagliflozin low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
264767|NCT02182830|Drug|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
264768|NCT02182830|Drug|Empagliflozin high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
264769|NCT02182804|Device|Olympus|narrow band imaging with magnification
264770|NCT02182804|Device|Cellvizio|probe-based confocal laser endomicroscopy
264771|NCT02182791|Drug|Nevirapine|
264772|NCT02182791|Drug|EE/NET|
264773|NCT02182778|Drug|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
264774|NCT02182778|Drug|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
264775|NCT02182765|Drug|Nevirapine|
264776|NCT02182765|Drug|Amprenavir|
264777|NCT02182765|Drug|Abacavir|
264778|NCT02182752|Drug|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
264779|NCT02182752|Drug|Ropivacaine|Interscalene block using ropivacaine
264780|NCT02182739|Drug|Meloxicam|tablets or injectable solution
264781|NCT02182726|Drug|MOBEC|
264782|NCT02182713|Drug|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
264783|NCT02182713|Drug|Salbutamol|Salbutamol 100 mcg per puff
264784|NCT02182700|Drug|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
264785|NCT02182687|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
264786|NCT02182687|Procedure|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
264787|NCT02182687|Drug|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
264788|NCT02182674|Drug|Placebo Combivent HFA|
264789|NCT02182674|Drug|Combivent HFA|
264790|NCT02182674|Drug|Combivent (CFC)|
264791|NCT02182674|Drug|Placebo Combivent (CFC)|
264792|NCT02182661|Drug|Ba253BINEB|
264793|NCT02182648|Drug|etomidate|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~infusion of etomidate at 2 minutes before anesthesia induction"
264794|NCT02182648|Drug|propofol|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~infusion of propofol at 2 minutes before anesthesia induction"
264795|NCT02182648|Drug|sevoflurane|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~inhale sevoflurane for anesthesia induction and maintenance"
264796|NCT02182635|Drug|Ba253BINEB|
264797|NCT02182622|Drug|Docetaxel|
264798|NCT02182622|Drug|Prednisone|
264799|NCT02182622|Drug|LDE225|
264800|NCT02182609|Drug|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
264801|NCT02182596|Drug|Mylotarg|Dose level study
264802|NCT02182583|Drug|Ba253MDI|
264803|NCT02182583|Drug|Ba253BINEB|
264804|NCT02182570|Drug|WAL 801 CL dry syrup|
264805|NCT02182557|Drug|WAL 801 CL Dry Syrup|
264806|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup|
264807|NCT02182557|Drug|WAL 801 CL Dry Syrup placebo|
264808|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup placebo|
264809|NCT02182544|Drug|WAL801CL dry syrup|
264810|NCT02182544|Drug|Ketotifen fumarate dry syrup|
264811|NCT02182544|Drug|Ketotifen fumarate dry syrup placebo|
264812|NCT02182544|Drug|WAL 801 CL dry syrup placebo|
264813|NCT02182531|Drug|Epinastine|
264814|NCT02182531|Drug|Pseudoephedrine|
264815|NCT02182531|Drug|Epinastine + Pseudoephedrine combination|
264816|NCT02182518|Drug|Epinastine|
264817|NCT02182518|Drug|Pseudoephedrine|
264818|NCT02182518|Drug|Placebo|Placebo during run-in period
264819|NCT02182505|Drug|Berodual® Respimat®, low dose|
264820|NCT02182505|Drug|Berodual® Respimat®, high dose|
264821|NCT02182505|Drug|Berodual® MDI|
264822|NCT02182492|Drug|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
264823|NCT02182492|Drug|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
264824|NCT02182479|Drug|Berodual® via Respimat®, high dose|
264825|NCT02182479|Drug|Berodual® via Respimat®, low dose|
264826|NCT02182479|Drug|Berodual® via MDI, high dose|
264827|NCT02182479|Drug|Placebo Respimat®|
264828|NCT02182479|Drug|Placebo MDI|
264829|NCT02182466|Device|Colon capsule endoscopy|
264830|NCT02182453|Drug|BI 10773 - single rising dose|
264831|NCT02182453|Drug|Placebo|
264832|NCT02182440|Biological|recAP|One hour infusions once daily for three days
264833|NCT02182440|Other|Placebo|1 hour IV infusion once daily for 3 days
264834|NCT02182414|Drug|BI 207127 NA (TF-I)|200 mg tablet
264835|NCT02182414|Drug|BI 207127 NA (TF-II)|400 mg tablet
264836|NCT02182414|Drug|BI 207127 NA delayed release|400 mg tablet
264837|NCT02182414|Drug|BI 207127 NA extended release (10% HPMC)|400 mg tablet
264838|NCT02182414|Drug|BI 207127 NA extended release (15% PEO)|400 mg tablet
264839|NCT02182414|Drug|BI 207127 NA extended release (20% HPMC)|400 mg tablet
264840|NCT02182401|Drug|BI 207127 NA|Days 3-8 and days 25-30
264841|NCT02182401|Drug|BI 201335 NA|Days 15-30
264842|NCT02182401|Drug|Midazolam|Days 1, 7, 23 and 29
264843|NCT02182401|Drug|Tolbutamide|Days 1, 7, 23 and 29
264844|NCT02182388|Drug|Placebo|
264845|NCT02182388|Drug|BI 207127 NA powder for solution|
264846|NCT02182388|Drug|BI 207127 NA tablet|
264847|NCT02182375|Drug|BI 201335 NA|
264848|NCT02182375|Drug|Raltegravir|
264849|NCT02182362|Drug|BI 201335 NA|
264850|NCT02182362|Drug|Placebo|
264851|NCT02182349|Drug|BI 201335 NA soft gelatin capsule|
264852|NCT02182349|Drug|[14C]-BI 201335 NA radiolabelled drug|
264853|NCT02182336|Drug|BI 201335 NA|"480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10~240 mg BI 201335 NA bid from day 11 to 23"
264854|NCT02182336|Drug|Caffeine|days 1, 10 and 19
264855|NCT02182336|Drug|Warfarin sodium|days 1, 10 and 19
264856|NCT02182336|Drug|Vitamin K|days 1, 10 and 19
264857|NCT02182336|Drug|Omeprazole|days 1, 10 and 19
264858|NCT02182336|Drug|Dextromethorphan hydrobromide|days 1, 10 and 19
264859|NCT02182336|Drug|Midazolam HCl solution|Days 3 and 21
264860|NCT02182336|Drug|Midazolam HCl oral syrup|days 1, 10 and 19
264861|NCT02182336|Drug|Digoxin|Days 2 and 20
264862|NCT02182323|Drug|BI 201335 NA|
264863|NCT02182323|Drug|Placebo solution|
264864|NCT02182310|Drug|BI 201335 low dose|
264865|NCT02182310|Drug|BI 201335 placebo|
264866|NCT02182310|Drug|Moxifloxacin|
264867|NCT02182310|Drug|BI 201335 high dose|
264868|NCT02182297|Drug|BI 201335 NA in single rising doses|
264869|NCT02182297|Drug|Placebo|
264870|NCT02182284|Drug|low dose BI 201335 NA soft gelatine capsule (SGC)|
264871|NCT02182284|Drug|high dose BI 201335 NA soft gelatine capsule (SGC)|
264872|NCT02182284|Drug|low dose BI 201335 NA powder in bottle (PIB)|
264873|NCT02182284|Drug|high dose BI 201335 NA powder in bottle (PIB)|
264874|NCT02182271|Drug|BI 201335 ZW - single rising dose|
264875|NCT02182271|Drug|Placebo|
264876|NCT02182258|Drug|BIBF 1120 soft gelatine capsule|
264877|NCT02182258|Drug|BIBF 1120 intravenous solution|
264878|NCT02182258|Drug|Placebo ampoule|
264879|NCT02182245|Drug|BIBF 1120|
264880|NCT02182245|Drug|Paclitaxel|
264881|NCT02182245|Drug|Carboplatin|
264882|NCT02182232|Drug|BIBF 1120|
264883|NCT02182232|Drug|Paclitaxel|
264884|NCT02182232|Drug|Carboplatin|
264885|NCT02182219|Drug|BIBF 1120|
264886|NCT02182206|Drug|BIBF 1120|
264887|NCT02182193|Drug|BIBF 1120 capsules charge 1|
264888|NCT02182193|Drug|BIBF 1120 capsules charge 2|
264889|NCT02182193|Drug|BIBF 1120 drinking solution|
264890|NCT02182167|Drug|IV N-acetylcysteine (NAC)|
264891|NCT02182167|Drug|Water|
264892|NCT02182154|Drug|BIBF 1120 ES|
264893|NCT02182141|Drug|BIBF 1120 ES|
264894|NCT02182128|Drug|BIBF 1120|
264895|NCT02182115|Drug|antiseptic bundle|"Chlorhexidine gluconate liquid soap for bathing daily.~Chlorhexidine gluconate mouthrinse to use twice daily.~Nasal mupirocin to apply twice daily."
264896|NCT02182115|Drug|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
264897|NCT02182102|Drug|BIBF 1120|
264898|NCT02182102|Drug|Pemetrexed|
264899|NCT02182076|Drug|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
264900|NCT02182063|Drug|BIBF 1120 low dose|
264901|NCT02182063|Drug|BIBF 1120 high dose|
264902|NCT02182050|Drug|BIBF 1120 ES low dose|
264903|NCT02182050|Drug|BIBF 1120 ES high dose|
264904|NCT02182050|Drug|Placebo to BIBF 1120 ES|
264905|NCT02182037|Drug|Single rising doses of BIBT 1011 BS|
264906|NCT02182037|Drug|BIBT 1011 BS placebo|
264907|NCT02182024|Drug|Dabigatran etexilate high dose|
264908|NCT02182024|Drug|Dabigatran etexilate low dose|
264909|NCT02182011|Drug|Tenecteplase|
264910|NCT02182011|Drug|Alteplase|
264911|NCT02182011|Drug|Streptokinase|
264912|NCT02181998|Drug|Full dose tenecteplase|
264913|NCT02181998|Drug|Unfractioned heparin|
264914|NCT02181998|Drug|Enoxaparin|
264915|NCT02181985|Drug|Full dose TNK-tPA|
264916|NCT02181985|Drug|Half dose TNK-tPA|
264917|NCT02181985|Drug|Heparin|
264918|NCT02181985|Drug|Enoxaparin|
264919|NCT02181985|Drug|Abciximab|
264920|NCT02181972|Drug|Gingko biloba|
264921|NCT02181972|Drug|Placebo|
264922|NCT02181959|Drug|Pharmaton® with DMAE|
264923|NCT02181959|Drug|Pharmaton® without DMAE|
264924|NCT02181959|Drug|Placebo|
264925|NCT02181946|Drug|Fluconazole|
264926|NCT02181946|Drug|Nevirapine|
264927|NCT02181933|Drug|Nevirapine|
264928|NCT02181933|Drug|Zidovudine (ZDV)|
264929|NCT02181933|Drug|Lamivudine (3TC)|
264930|NCT02181920|Drug|Metamizole|
264931|NCT02181920|Drug|Diclofenac|
264932|NCT02181920|Drug|Diclofenac placebo|
264933|NCT02181920|Drug|Metamizole placebo|
264934|NCT02181907|Drug|UH-AC 62 XX tablet|
264935|NCT02181907|Drug|UH-AC 62 XX capsule|
264936|NCT02181881|Behavioral|DuoPACT|Intervention sessions are administered weekly by a counselor.
264937|NCT02181881|Behavioral|Life Steps|Intervention sessions are administered weekly by a counselor.
264938|NCT02181868|Other|Biodegradable and titanium fixation used in mandibular fractures.|
264939|NCT02181855|Procedure|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
264940|NCT02181842|Drug|Pioglitazone|Pioglitazone tablets
264941|NCT02181829|Radiation|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
264942|NCT02181816|Drug|Azilsartan/Amlodipine|Azilsartan/Amlodipine combination tablets LD & HD
264943|NCT02181803|Drug|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 14 mg, 16 mg, 20 mg, or 40 mg
264944|NCT02181803|Drug|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
264945|NCT02181803|Drug|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
264946|NCT02181790|Device|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
264947|NCT02181790|Drug|Acitretin|17.5mg/d
264948|NCT02181777|Behavioral|GRASP|GRoup trAining for Social skills in Psychosis
264949|NCT02181777|Behavioral|Standard care|Treatment as usual
264950|NCT02181764|Drug|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
264951|NCT02181751|Other|Trauma Focused Cognitive Behavioural Therapy Group|Throughout the length of a year children will participate in trauma focused cognitive behavioural group therapy (TF-CBT) with 7 other children in his/her cohort. The group will take place either on site at the Be Brave Ranch, or via skype in their own homes with their parent or caregiver present. In total children will receive over 200 hours of TF-CBT group therapy.
264952|NCT02181738|Drug|Nivolumab|
264953|NCT02181738|Drug|Doxorubicin|
264954|NCT02181738|Drug|Vinblastine|
264955|NCT02181738|Drug|Dacarbazine|
264956|NCT02181725|Behavioral|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
264957|NCT02181725|Behavioral|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
264958|NCT02181712|Biological|Mesenchymal stem cell 0.5|0.5 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
264959|NCT02181712|Biological|Mesenchymal stem cell 1.0|1 million MSC per Kg will be infused intravenously. Product will be infused at the rate of 2 - 3 ml/minute during the first 15 minutes and may be adjusted up to 5ml/minutes if tolerable. It is anticipated that the infusion will be completed within approximately 3 hours.
264960|NCT02181699|Drug|KHK2823|single agent KHK2823
264961|NCT02181673|Drug|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
264962|NCT02181673|Drug|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
264963|NCT02181660|Drug|Gilteritinib|oral
264964|NCT02181647|Behavioral|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
264965|NCT02181634|Drug|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
264966|NCT02181621|Device|Iodosorb|Cadexomer iodine gel
264967|NCT02181621|Device|Solosite gel|Hydrogel
264968|NCT02181595|Other|Group reading and discussion|
264969|NCT02181582|Drug|Emapunil|Single peroral administration
264970|NCT02181582|Device|PET|Positron emission tomography, which creates images by detecting radioactivity.
264971|NCT02181556|Drug|FOLFIR + Aflibercept|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
264972|NCT02181543|Drug|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
264973|NCT02181530|Other|No Intervention|No treatment (intervention) is being administered as part of this study.
264974|NCT02181517|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
265118|NCT02180555|Other|Oral glucose tolerance test|
264975|NCT02181517|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
264976|NCT02181517|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
264977|NCT02181504|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
264978|NCT02181504|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
264979|NCT02181504|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
264980|NCT02181491|Other|[11C]-P943|
264981|NCT02181478|Drug|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
264982|NCT02181478|Drug|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
264983|NCT02181478|Radiation|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
264984|NCT02181478|Drug|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
264985|NCT02181478|Drug|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
264986|NCT02181478|Procedure|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
264987|NCT02181478|Procedure|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10^6cells/kg (+/-20%).
264988|NCT02181465|Biological|G17DT|
264989|NCT02181439|Device|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
264990|NCT02181426|Drug|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
264991|NCT02181413|Drug|Ixazomib Citrate|Ixazomib citrate capsules
264992|NCT02181413|Drug|Placebo|Ixazomib citrate placebo-matching capsules
264993|NCT02181400|Device|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.~The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
264994|NCT02181387|Drug|Acetaminophen|administered every 6 hours by mouth up to 4 doses
264995|NCT02181387|Drug|Placebo|
264996|NCT02181361|Drug|aspirin plus hirudin|hirudin two tables, three times a day and aspirin 100mg, once daily.
264997|NCT02181361|Drug|Warfarin|An initial dose of Warfarin is 1.5mg,once daily. 3 days later,we check the international normalized ratio(INR) values and adjust the warfarin dose make INR between 2-3 steady.Then, we maintain this warfarin dose.
264998|NCT02181348|Drug|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
264999|NCT02181348|Drug|placebo (edible oil)|
265000|NCT02181335|Drug|Respimat® Budesonide low dose|
265001|NCT02181335|Drug|Respimat® Budesonide high dose|
265002|NCT02181335|Drug|Turbohaler® Budesonide|
265003|NCT02181335|Drug|Placebo|
265004|NCT02181322|Drug|Meloxicam - low dose|
265005|NCT02181322|Drug|Meloxicam - medium dose|
265006|NCT02181322|Drug|Meloxicam - high dose|
265007|NCT02181309|Drug|Meloxicam, low dose|
265008|NCT02181309|Drug|Meloxicam, medium dose|
265009|NCT02181309|Drug|Meloxicam, high dose|
265010|NCT02181296|Drug|ropivacaine|
265011|NCT02181283|Behavioral|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
265012|NCT02181283|Behavioral|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.~Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
265013|NCT02181270|Other|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
265014|NCT02181270|Other|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
265524|NCT02177448|Drug|BIBR277 medium dose|
265525|NCT02177448|Drug|BIBR277 high dose|
265015|NCT02181257|Combination Product|Extracorporeal Photopheresis (ECP)|Procedure Extracorporeal Photopheresis Treatments will be performed using one of twoTherakos systems. Both systems used the drug Methoxsalen
265016|NCT02181244|Other|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
265017|NCT02181244|Other|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
265018|NCT02181231|Drug|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
265019|NCT02181231|Drug|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
265020|NCT02181231|Drug|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
265021|NCT02181218|Drug|Romidepsin|
265022|NCT02181218|Drug|Gemcitabine|
265023|NCT02181218|Drug|Oxaliplatin|
265024|NCT02181218|Drug|Dexamethasone|
265025|NCT02181218|Drug|Pegfilgrastim|
265026|NCT02181205|Drug|bupivacaine|
265027|NCT02181205|Drug|placebo|
265028|NCT02181192|Device|PET/CT|PET/CT
265029|NCT02181192|Radiation|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
265030|NCT02181192|Radiation|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
265031|NCT02181179|Behavioral|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
265032|NCT02181166|Other|Kinesiotherapy|
265033|NCT02181166|Other|Isquemic compression|
265034|NCT02181166|Other|High voltage electrical stimulation|
265035|NCT02181153|Other|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
265036|NCT02181140|Device|EUS guided FNA and fine needle punction|punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
265037|NCT02181127|Device|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
265038|NCT02181114|Behavioral|Expert System Coaching|Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
265039|NCT02181101|Drug|FEC-DocGemzar adjuvant chemotherapy|
265040|NCT02181101|Drug|FEC-Doc adjuvant chemotherapy|
265041|NCT02181101|Drug|Zoledronic acid i.v. 2 years|
265042|NCT02181101|Drug|Zoledronic acid i.v. 5 years|
265043|NCT02181088|Biological|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10^9 vp
265044|NCT02181088|Biological|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10^10 vp
265045|NCT02181088|Biological|MVA RH5 low dose|MVA RH5 at 1 x 10^8 pfu
265046|NCT02181088|Biological|MVA RH5 full dose|MVA RH5 at 2 x 10^8 pfu
265047|NCT02181075|Drug|ThermoDox® (LTLD)|ThermoDox® (LTLD) infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
265048|NCT02181075|Device|Focused Ultrasound of Target Liver Tumour|Whilst the ThermoDox® was circulating in the blood stream, the JC200 Therapeutic Ultrasound device was used to induce mild hyperthermia in a single (region of) a target liver tumour.
265049|NCT02181075|Diagnostic Test|Pre-LTLD Biopsy of Target Liver Tumour|
265050|NCT02181075|Diagnostic Test|Post-LTLD Biopsy of Target Liver Tumour|
265051|NCT02181075|Diagnostic Test|Post-LTLD+FUS (Post-FUS) Biopsy of Target Liver Tumour|
265052|NCT02181075|Device|Thermometry of Target Tumour|A clinically approved thermistor or thermocouple was placed in the target liver tumour for real-time thermometry.
265053|NCT02181062|Behavioral|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.~The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.~Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.~The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
265054|NCT02181036|Other|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
265055|NCT02181023|Drug|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
265056|NCT02181023|Drug|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
265113|NCT02180581|Dietary Supplement|Probiotic (2 * 10^9 cfu/day)|Combination of two probiotics (2 * 10^9 cfu/day) or probiotics for 6 months
265114|NCT02180581|Dietary Supplement|Placebo|Placebo for 6 months
265115|NCT02180568|Procedure|Lipiodol|Lipiodol-guided lung localization technique
265116|NCT02180568|Procedure|Hookwire|Hookwire-guided lung localization technique
265117|NCT02180568|Drug|Lipiodol|
265057|NCT02181010|Behavioral|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
265058|NCT02180997|Drug|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
265059|NCT02180997|Drug|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
265060|NCT02180997|Drug|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
265061|NCT02180984|Device|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
265062|NCT02180971|Procedure|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
265063|NCT02180971|Procedure|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
265064|NCT02180932|Biological|periodontal pocket samples|
265065|NCT02180919|Device|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
265066|NCT02180893|Other|Paravertebral Block|Paravertebral nerve block injection
265067|NCT02180893|Other|Placebo Comparator|"No block~Patients who did not receive PVB"
265068|NCT02180880|Drug|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
265069|NCT02180867|Drug|Doxorubicin|Given IV
265070|NCT02180867|Drug|Doxorubicin Hydrochloride|Given IV
265071|NCT02180867|Drug|Ifosfamide|Given IV
265072|NCT02180867|Drug|Pazopanib|Given PO
265073|NCT02180867|Drug|Pazopanib Hydrochloride|Given PO
265074|NCT02180867|Radiation|Radiation Therapy|Undergo radiation therapy
265075|NCT02180867|Procedure|Therapeutic Conventional Surgery|Undergo surgery
265076|NCT02180854|Other|Control group|
265077|NCT02180854|Other|Increased monitoring frequency|
265078|NCT02180841|Dietary Supplement|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
265079|NCT02180841|Dietary Supplement|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
265080|NCT02180841|Dietary Supplement|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
265081|NCT02180828|Drug|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
265082|NCT02180828|Drug|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
265083|NCT02180815|Device|ReVENT Sleep Apnea System|
265084|NCT02180802|Behavioral|motivational interviewing|
265085|NCT02180802|Behavioral|motivational interviewing with parental involvement|
265086|NCT02180802|Behavioral|Control group|
265087|NCT02180789|Drug|Tamsulosin OCAS|oral
265088|NCT02180776|Other|Summit 456 TLSO|Thoracolumbarsacral orthosis
265089|NCT02180763|Biological|Gammanorm|Sub-Q IgG
265090|NCT02180750|Other|Memory Work Therapy|
265091|NCT02180750|Other|Standard care|Pediatric clinic, ART
265092|NCT02180737|Drug|Dexmeditomedine|
265093|NCT02180724|Drug|Acalabrutinib|
265094|NCT02180711|Drug|acalabrutinib|
265095|NCT02180711|Drug|rituximab (IV)|
265096|NCT02180711|Drug|Lenalidomide|
265097|NCT02180698|Other|Laboratory Biomarker Analysis|Correlative studies
265098|NCT02180698|Radiation|Radiation Therapy|Undergo radiation therapy
265099|NCT02180698|Drug|TLR4 Agonist GLA-SE|Given intratumorally
265100|NCT02180685|Other|Anchor fixation|
265101|NCT02180672|Drug|Nasal Fluticasone|One spray per nostril, per day.
265102|NCT02180672|Drug|Placebo|One spray per nostril, per day.
265103|NCT02180659|Drug|sublingual buprenorphine tablets|
265104|NCT02180659|Drug|Buprenorphine implant|
265105|NCT02180659|Drug|placebo implants|
265106|NCT02180659|Drug|sublingual placebo tablets|
265107|NCT02180646|Other|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
265108|NCT02180646|Other|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
265109|NCT02180633|Other|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
265110|NCT02180620|Other|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
265111|NCT02180620|Other|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
265112|NCT02180620|Other|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
265119|NCT02180529|Drug|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
265120|NCT02180529|Drug|Placebo|
265121|NCT02180516|Drug|Meloxicam|
265122|NCT02180516|Drug|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
265123|NCT02180503|Drug|BI 1356 BS PIB - low dose|
265124|NCT02180503|Drug|BI 1356 BS tablet - low dose|
265125|NCT02180503|Drug|BI 1356 BS PIB - high dose|
265126|NCT02180503|Drug|BI 1356 BS tablet - high dose|
265127|NCT02180503|Drug|BI 1356 BS tablet - high dose with food|
265128|NCT02180490|Drug|UHAC 62 XX tablet|
265129|NCT02180490|Drug|UHAC 62 XX capsule|
265130|NCT02180477|Drug|UHAC 62 XX - TF1 tablet|
265131|NCT02180477|Drug|UHAC 62 XX - TF2 tablet|
265132|NCT02180477|Drug|UHAC 62 XX - capsules|
265133|NCT02180464|Drug|LAS41004|
265134|NCT02180464|Drug|control|
265135|NCT02180438|Drug|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
265136|NCT02180425|Drug|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
265137|NCT02180425|Drug|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
265138|NCT02180412|Biological|Panhematin|Glucose loading
265139|NCT02180412|Other|Glucose|Glucose is administered to both groups as routine care.
265140|NCT02180386|Behavioral|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
265141|NCT02180360|Other|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.~In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.~An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
265142|NCT02180347|Device|Contact lenses|
265143|NCT02180334|Drug|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
265144|NCT02180334|Drug|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
265145|NCT02180334|Drug|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
265146|NCT02180321|Drug|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
265147|NCT02180321|Drug|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
265148|NCT02180308|Device|PET/MRI|Simultaneous PET/MRI (3T system)
265149|NCT02180295|Biological|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
265150|NCT02180295|Biological|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
265151|NCT02180295|Biological|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
265152|NCT02180282|Device|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.~The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
265153|NCT02180269|Drug|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
265154|NCT02180269|Drug|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
265155|NCT02180269|Drug|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
265156|NCT02180269|Drug|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
265157|NCT02180256|Procedure|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
265158|NCT02180243|Behavioral|Yoga/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
265159|NCT02180243|Other|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
265160|NCT02180230|Device|Shorty implants|Dental implant insertion to maxilla or mandible
265161|NCT02180217|Drug|LCI699|LCI699
265162|NCT02180217|Drug|LCI699 matching placebo|LCI699 matching placebo
265163|NCT02180204|Drug|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
265164|NCT02180204|Drug|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
265165|NCT02180191|Other|Comparison of the gut microbiota composition|
265166|NCT02180178|Other|observational only- no intervention|
265167|NCT02180165|Drug|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
265168|NCT02180165|Drug|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
265526|NCT02177448|Drug|Enalapril low dose|
265527|NCT02177448|Drug|Enalapril medium dose|
265169|NCT02180152|Behavioral|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
265170|NCT02180139|Device|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
265171|NCT02180126|Other|Follow-up|Follow-up of of patients with borderline positive ANCA test results
265172|NCT02180113|Device|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
265173|NCT02180100|Drug|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
265174|NCT02180100|Drug|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
265175|NCT02180087|Drug|Ketoprofen|
265176|NCT02180061|Biological|Pembrolizumab|IV infusion
265177|NCT02180048|Dietary Supplement|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
265178|NCT02180048|Dietary Supplement|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
265179|NCT02180048|Dietary Supplement|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
265180|NCT02180035|Dietary Supplement|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
265181|NCT02180035|Dietary Supplement|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
265182|NCT02180035|Behavioral|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
265183|NCT02180022|Drug|Placebo|After randomization, placebo was treated for 12 weeks
265184|NCT02180022|Drug|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
265185|NCT02179996|Biological|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
265186|NCT02179996|Biological|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
265187|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
265188|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
265189|NCT02179970|Drug|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
265190|NCT02179931|Drug|Flupentixol/melitracen film-coated tablet|
265191|NCT02179931|Drug|Flupentixol/melitracen coated tablet (Deanxit®)|
265192|NCT02179918|Drug|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
265193|NCT02179918|Drug|MK-3475|2 mg/kg q3wks, IV
265194|NCT02179892|Drug|Bupivacaine Extended-Release Liposome Injection (Exparel)|266mg/30mL of Exparel will be injected via unilateral TAP block
265195|NCT02179892|Drug|Bupivacaine and Dexamethasone Injection|As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
265196|NCT02179892|Drug|IV Acetaminophen|Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
265197|NCT02179892|Drug|Oral Acetaminophen|Oral acetaminophen 650 mg every 6 hours.
265198|NCT02179879|Other|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
265199|NCT02179866|Drug|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) [14C]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
265200|NCT02179853|Drug|Anakinra|First two doses IV followed by SQ dosing
265201|NCT02179840|Procedure|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
265202|NCT02179814|Drug|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
265203|NCT02179814|Drug|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
265204|NCT02179814|Drug|Placebo|Placebo at the second, third and fourth medication intake time point
265205|NCT02179788|Behavioral|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
265248|NCT02179580|Drug|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
265249|NCT02179567|Drug|Docetaxel|Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
265250|NCT02179567|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
265528|NCT02177448|Drug|Enalapril high dose|
265529|NCT02177448|Drug|Placebo matching BIBR277|
265206|NCT02179788|Drug|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:~Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)~Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)~Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.~The trial duration is 28 days (with a +/- 3 day cushion)"
265207|NCT02179788|Drug|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:~Days 1-7, take 1 capsule with evening meal~Days 8-14, take 3 capsules with evening meal~Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal~Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
265208|NCT02179775|Drug|propranolol|
265209|NCT02179775|Drug|Quince's oxymel|
265210|NCT02179775|Drug|placebo|
265211|NCT02179762|Behavioral|moderate exercise intervention|Perform moderate exercise therapy
265212|NCT02179762|Behavioral|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
265213|NCT02179762|Other|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
265214|NCT02179762|Other|laboratory biomarker analysis|Correlative studies
265215|NCT02179762|Behavioral|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
265216|NCT02179762|Behavioral|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
265217|NCT02179762|Behavioral|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
265218|NCT02179762|Behavioral|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
265219|NCT02179749|Drug|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
265220|NCT02179749|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
265221|NCT02179749|Drug|Mifepristone 600 mg daily|Mifepristone, 300 mg tablets, Two tablets daily/am plus two placebo tablets daily/am for 1-week duration.
265222|NCT02179749|Drug|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
265223|NCT02179736|Device|Restylane|
265224|NCT02179723|Device|Leukosan Adhesive|Leukosan adhesive applied to one wound
265225|NCT02179723|Device|Transcutaneous suture|Transcutaneous suture applied to one wound
265226|NCT02179710|Behavioral|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
265227|NCT02179697|Other|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
265228|NCT02179697|Procedure|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
265229|NCT02179684|Procedure|Baby-sitter surgery N. fascialis|
265230|NCT02179684|Other|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
265231|NCT02179671|Drug|Gefitinib|Gefitinib once daily followed by MEDI4736
265232|NCT02179671|Drug|AZD9291|AZD9291 once daily followed by MEDI4736
265233|NCT02179671|Drug|Selumetinib+Docetaxel|Selumetinib twice daily + docetaxel, followed by MEDI4736
265234|NCT02179671|Drug|Tremelimumab|Tremelimumab every 4 weeks followed by MEDI4736
265235|NCT02179658|Drug|OPT-80|oral
265236|NCT02179658|Drug|vancomycin|oral
265237|NCT02179645|Drug|GRC 27864|
265238|NCT02179645|Drug|Celecoxib|
265239|NCT02179645|Drug|Placebo|
265240|NCT02179632|Behavioral|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
265241|NCT02179619|Device|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
265242|NCT02179619|Device|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
265243|NCT02179606|Device|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
265244|NCT02179606|Device|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
265245|NCT02179593|Other|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
265246|NCT02179593|Other|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
265247|NCT02179580|Drug|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
265251|NCT02179541|Other|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
265252|NCT02179528|Drug|Etoposide|
265253|NCT02179515|Biological|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
265254|NCT02179502|Drug|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
265255|NCT02179502|Drug|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
265256|NCT02179502|Drug|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
265257|NCT02179502|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
265258|NCT02179489|Procedure|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
265259|NCT02179476|Device|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
265260|NCT02179424|Behavioral|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
265261|NCT02179424|Behavioral|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
265262|NCT02179424|Behavioral|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
265263|NCT02179424|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
265264|NCT02179424|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
265265|NCT02179424|Behavioral|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
265266|NCT02179411|Other|tilt test|
265267|NCT02179398|Biological|Allocation to the Lab-score group|
265268|NCT02179398|Biological|Allocation to the control group|
265269|NCT02179385|Behavioral|Health Coaching|
265270|NCT02179372|Dietary Supplement|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
265271|NCT02179372|Dietary Supplement|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
265272|NCT02179359|Drug|Reduced Toxicity Ablative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan~Stem Cell Infusion Day 0"
265273|NCT02179359|Drug|Reduced Intensity Preparative Regimen|"Alemtuzumab~Cyclophosphamide~Fludarabine~Total Body Irradiation (TBI)~Stem Cell Infusion Day 0"
265274|NCT02179359|Drug|Myeloablative Preparative Regimen|"Alemtuzumab~Cyclophosphamide~Busulfan~Stem Cell Infusion Day 0"
265275|NCT02179333|Other|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
265276|NCT02179320|Procedure|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
265277|NCT02179320|Device|acupuncture needle 0,25 x 40mm|
265278|NCT02179307|Behavioral|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
265279|NCT02179294|Drug|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
265280|NCT02179294|Drug|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol~PCA bolus remifentanil 40 μg~Lockout interval 2 minutes~In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
265281|NCT02179281|Device|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
265282|NCT02179268|Drug|sertraline|50mg, 50-150mg/d,qd for one year
265283|NCT02179268|Drug|citalopram|20mg, 20-40mg/d,qd,for one year
265284|NCT02179268|Drug|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
265285|NCT02179268|Drug|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
265286|NCT02179268|Behavioral|control|50min, every week for three months, every month, for nine months
265287|NCT02179255|Drug|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
265390|NCT02178384|Procedure|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
265288|NCT02179255|Drug|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
265289|NCT02179242|Other|Cardiac rehab|
265290|NCT02179229|Dietary Supplement|CONTROL|Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
265291|NCT02179229|Dietary Supplement|SYNBIOTIC|Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
265292|NCT02179216|Other|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
265293|NCT02179216|Other|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
265294|NCT02179190|Device|BARREL VRD|The Barrel VRD was implanted as adjunctive to embolic coils in subjects with wide necked bifurcating aneurysms within the Middle Cerebral and Basilar Arteries.
265295|NCT02179177|Drug|Apixaban|Drug is taken by mouth twice a day for 6 months
265296|NCT02179177|Drug|Placebo|
265297|NCT02179151|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
265298|NCT02179151|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
265299|NCT02179138|Drug|TFV 1% gel|
265300|NCT02179125|Device|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
265301|NCT02179112|Procedure|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
265302|NCT02179099|Device|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
265303|NCT02179086|Radiation|3-dimensional conformal radiation therapy|Undergo standard-dose 3D-CRT
265304|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
265305|NCT02179086|Radiation|photon beam radiation therapy|Undergo dose-escalated and -intensified photon IMRT
265306|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo dose-escalated and -intensified photon IMRT
265307|NCT02179086|Radiation|proton beam radiation therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
265308|NCT02179086|Drug|temozolomide|Given PO
265309|NCT02179086|Other|laboratory biomarker analysis|Correlative studies
265310|NCT02179047|Procedure|coronary angiography|percutaneous coronary intervention. coronary angiography.
265311|NCT02179034|Drug|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
265312|NCT02179034|Other|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
265313|NCT02179034|Other|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
265314|NCT02179008|Drug|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
265315|NCT02179008|Drug|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
265316|NCT02179008|Drug|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
265317|NCT02179008|Drug|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
265318|NCT02179008|Drug|DE-117 High Dose ophthalmic solution|High Dose DE-117
265319|NCT02179008|Drug|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
265320|NCT02178995|Drug|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:~Placebo 20mg of methylphenidate or 10mg of methylphenidate.~At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
265321|NCT02178956|Drug|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
265322|NCT02178956|Drug|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
265323|NCT02178956|Other|Placebo|Orally two times daily
265324|NCT02178930|Other|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
265325|NCT02178917|Other|Neurofeedback therapy|
265326|NCT02178917|Other|No neurofeedback therapy|
265327|NCT02178904|Procedure|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
265328|NCT02178891|Device|extra short implant|
265329|NCT02178878|Genetic|Progress, Pain|Progress, Pain
265330|NCT02178852|Device|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
265331|NCT02178839|Dietary Supplement|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
265332|NCT02178839|Dietary Supplement|Maltodextrin|8.5 g/d Maltodextrin
265333|NCT02178826|Device|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
265334|NCT02178826|Device|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
265335|NCT02178813|Drug|Administration of minocycline|"Administration of minocycline with the following schedule:~Day prior to procedure: 800mg p.o., 700mg p.o.~Day of procedure: 600mg i.v., 500mg p.o.~Day after procedure: 400mg p.o., 400mg p.o."
265336|NCT02178800|Drug|GSK1265744 Tablets|30-mg tablets, taken orally
265337|NCT02178800|Drug|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection"
265338|NCT02178800|Drug|Placebo for GSK1265744 Tablets|Taken orally
265391|NCT02178384|Device|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
265339|NCT02178800|Drug|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
265340|NCT02178761|Device|drug-eluting balloon|angioplasty completed with drug-eluting balloons
265341|NCT02178761|Device|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
265342|NCT02178761|Device|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
265343|NCT02178761|Device|Stent System|stenting with either bare-metal stents or drug-eluting stents
265344|NCT02178748|Biological|MVA85A|Single dose of 1x10^8pfu MVA85A intramuscular vaccination
265345|NCT02178735|Procedure|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
265346|NCT02178735|Procedure|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
265347|NCT02178722|Drug|MK-3475|IV infusion
265348|NCT02178722|Drug|INCB024360|Oral daily dosing
265349|NCT02178709|Drug|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:~Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle~Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle~Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.~5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
265350|NCT02178696|Other|Placebo, identified as placebo to participants|White tablets
265351|NCT02178696|Drug|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
265352|NCT02178696|Other|"Placebo, identifed to participants as Active medication"|Blue Capsule
265353|NCT02178683|Drug|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
265354|NCT02178670|Biological|CSC-DC|
265355|NCT02178657|Drug|Autologous bone marrow mononuclear cell intra-arterial injection|
265356|NCT02178644|Drug|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
265357|NCT02178631|Behavioral|Deprexis|Online self-help
265358|NCT02178631|Other|CAU|Care as usual
265359|NCT02178618|Device|Deployment of Partially covered biliary self expandable metal stent|
265360|NCT02178618|Device|Deployment of uncovered biliary self expandable metal stent|
265361|NCT02178605|Procedure|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
265362|NCT02178592|Drug|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
265363|NCT02178592|Drug|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
265364|NCT02178566|Drug|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
265365|NCT02178553|Drug|Epidural|
265366|NCT02178553|Drug|Intercostal Bupivicaine (Exparel)|
265367|NCT02178540|Drug|Placebo|one dose (4 capsules) of placebo
265368|NCT02178540|Device|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
265369|NCT02178527|Other|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
265370|NCT02178527|Other|Usual Care|Usual general podiatry care provded by UK National Health Service
265371|NCT02178514|Other|Formula fed with BabyNes Nutrition System|
265372|NCT02178501|Dietary Supplement|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
265373|NCT02178488|Drug|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
265374|NCT02178488|Other|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
265375|NCT02178449|Drug|Dexamethasone acetate|
265376|NCT02178449|Drug|Placebo|
265377|NCT02178449|Drug|Ropivacaine|
265378|NCT02178436|Drug|gemcitabine hydrochloride|Given IV
265379|NCT02178436|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
265380|NCT02178436|Drug|selinexor|Given PO
265381|NCT02178436|Other|pharmacological study|Correlative studies
265382|NCT02178436|Other|laboratory biomarker analysis|Correlative studies
265383|NCT02178423|Procedure|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
265384|NCT02178410|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
265385|NCT02178410|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
265386|NCT02178410|Dietary Supplement|Fish oil placebo|Fish oil placebo
265387|NCT02178410|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
265388|NCT02178397|Drug|ERLOTINIB WITH CHEMOTHERAPY|
265389|NCT02178397|Drug|CHEMOTHERAPY ONLY|
265392|NCT02178384|Procedure|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
265393|NCT02178371|Procedure|mCIMT|
265394|NCT02178358|Drug|LY2157299|Administered orally
265395|NCT02178358|Drug|Sorafenib|Administered orally
265396|NCT02178358|Drug|Placebo|Administered orally
265397|NCT02178345|Procedure|diffusion weighted (DW) MRI|
265398|NCT02178345|Procedure|dynamic contrast agent (DCE) MRI|
265399|NCT02178332|Other|Yhteispeli, whole school programme|
265400|NCT02178332|Other|Two theoretical lectures|
265401|NCT02178319|Procedure|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
265402|NCT02178319|Procedure|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
265403|NCT02178306|Drug|Telmisartan low dose|
265404|NCT02178306|Drug|Telmisartan high dose|patients switch to high dose if mean SBP >= 85 mmHg after 4 weeks of treatment
265405|NCT02178306|Drug|Placebo|Run-in phase
265406|NCT02178293|Drug|Benzidamine hydrochloride|
265407|NCT02178293|Drug|Ketoprofen lysine salt|
265408|NCT02178280|Other|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
265409|NCT02178267|Dietary Supplement|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
265410|NCT02178254|Drug|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
265411|NCT02178254|Drug|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
265412|NCT02178241|Drug|Eribulin Mesylate|Given IV
265413|NCT02178241|Drug|Gemcitabine Hydrochloride|Given IV
265414|NCT02178215|Other|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
265415|NCT02178215|Other|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
265416|NCT02178202|Behavioral|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
265417|NCT02178202|Device|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
265418|NCT02178189|Other|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
265419|NCT02178189|Other|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
265420|NCT02178176|Behavioral|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.~We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
265421|NCT02178176|Behavioral|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
265422|NCT02178163|Other|cytology specimen collection procedure|Correlative studies
265423|NCT02178163|Other|laboratory biomarker analysis|Correlative studies
265424|NCT02178150|Dietary Supplement|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
265425|NCT02178150|Dietary Supplement|Placebo|
265426|NCT02178137|Drug|Diacerien|
265427|NCT02178137|Drug|Glucosamine/Chondroitin|
265428|NCT02178137|Drug|Placebo|
265429|NCT02178124|Drug|Donepezil|
265430|NCT02178124|Drug|placebo|
265431|NCT02178111|Other|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
265432|NCT02178111|Procedure|episiotomy|
265433|NCT02178098|Drug|ETC-1002|ETC-1002 capsules taken once daily
265434|NCT02178098|Drug|Placebo|Placebo capsules taken once daily
265435|NCT02178085|Other|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
265436|NCT02178072|Drug|5-Azacitadine|
265437|NCT02178059|Drug|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
265438|NCT02178059|Drug|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
265439|NCT02178046|Device|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
265484|NCT02177695|Drug|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
265440|NCT02178033|Drug|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
265441|NCT02178020|Device|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
265442|NCT02178020|Device|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
265443|NCT02177994|Drug|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
265444|NCT02177981|Procedure|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
265445|NCT02177981|Procedure|Control|The cuff will be placed around the arm but not inflated.
265446|NCT02177968|Other|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
265447|NCT02177955|Drug|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
265448|NCT02177955|Drug|10 mg diazepam|10 mg midazolam 45 minutes before surgery
265449|NCT02177942|Other|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
265450|NCT02177942|Other|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
265451|NCT02177929|Other|adapted canoeing, hadbike and conventional physiotherapy|"The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.~The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.~Individuals in the conventional physiotherapy group will make stretching and strengthening exercises."
265452|NCT02177916|Other|Education|
265453|NCT02177903|Device|Bair Paws Patient Adjustable Warming System|Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
265454|NCT02177890|Device|Transcutaneous vagal nerve stimulation|
265455|NCT02177890|Device|Sham vagal nerve stimulation|
265456|NCT02177864|Dietary Supplement|Fiber|
265457|NCT02177864|Other|Placebo (low fiber bar)|
265458|NCT02177851|Dietary Supplement|Single oral iron dose of 120 mg per day for 3 consecutive days|
265459|NCT02177851|Dietary Supplement|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
265460|NCT02177838|Biological|cetuximab|Given IV
265461|NCT02177838|Drug|cisplatin|Given IV
265462|NCT02177838|Radiation|external beam radiation therapy|Undergo EBRT
265463|NCT02177838|Other|laboratory biomarker analysis|Correlative studies
265464|NCT02177825|Drug|Imatinib Mesylate|oral administration
265465|NCT02177812|Drug|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
265466|NCT02177812|Drug|ATRA|ATRA (Tretinoin) will be supplied as a 10 mg capsule for oral administration. The initial dosing regimen will be continuous oral twice daily dosing
265467|NCT02177786|Drug|Selonsertib|Tablets administered orally once daily
265468|NCT02177786|Drug|Placebo to match selonsertib|Tablets administered orally once daily
265469|NCT02177773|Procedure|Computed Tomography (CT)|Undergo Gallium Ga 68-DOTA-TOC PET/CT
265470|NCT02177773|Drug|Gallium Ga 68-Edotreotide|Given Intravenously (IV) before imaging
265471|NCT02177773|Procedure|Magnetic Resonance Imaging (MRI)|Undergo gallium Ga 68-DOTA-TOC PET/MRI
265472|NCT02177773|Procedure|Positron Emission Tomography (PET)|Undergo gallium Ga 68-DOTA-TOC PET in combination with CT or MRI
265473|NCT02177760|Drug|Sirolimus|
265474|NCT02177747|Other|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
265475|NCT02177747|Device|Smartphone|
265476|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
265477|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
265478|NCT02177734|Biological|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
265479|NCT02177721|Biological|Collection of samples|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to Sponsor for determination of raxibacumab concentrations.~Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to Sponsor for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for TNA or ADA."
265480|NCT02177695|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
265481|NCT02177695|Drug|Cisplatin|"Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).~Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops."
265482|NCT02177695|Drug|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
265483|NCT02177695|Drug|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
265485|NCT02177695|Drug|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
265486|NCT02177682|Drug|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
265487|NCT02177669|Other|quick Contrast Sensitivity Function test|
265488|NCT02177656|Behavioral|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
265489|NCT02177643|Drug|Diacerein|Diacerein oral capsules
265490|NCT02177643|Drug|Placebo|Placebo oral capsules
265491|NCT02177630|Other|Endomyocardial Biopsy|
265492|NCT02177617|Drug|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
265493|NCT02177617|Behavioral|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
265494|NCT02177617|Procedure|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
265495|NCT02177604|Other|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (6-8 x 15 second all out sprints on a cycle ergometer interspersed by 2 minutes recovery)"
265496|NCT02177604|Other|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
265497|NCT02177604|Other|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
265498|NCT02177578|Drug|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
265499|NCT02177578|Radiation|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
265500|NCT02177578|Radiation|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:~Initial treatment plan:~Will be prescribed to 46 Gy in 2 Gy fractions~Cone down treatment plan:~Will be prescribed to 14 Gy in 2 Gy fractions"
265501|NCT02177565|Biological|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
265502|NCT02177552|Drug|Carboplatin|
265503|NCT02177552|Drug|Docetaxel|
265504|NCT02177552|Drug|Capecitabine|
265505|NCT02177552|Drug|Epirubicin|
265506|NCT02177552|Drug|Oxaliplatin|
265507|NCT02177539|Drug|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
265508|NCT02177539|Drug|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
265509|NCT02177526|Device|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
265510|NCT02177513|Drug|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
265511|NCT02177513|Drug|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
265512|NCT02177513|Drug|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
265513|NCT02177513|Drug|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
265514|NCT02177513|Drug|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
265515|NCT02177500|Drug|Telmisartan + hydrochlorothiazide|
265516|NCT02177500|Drug|Telmisartan|
265517|NCT02177500|Drug|Placebo|
265518|NCT02177487|Drug|Telmisartan/hydrochlorothiazide|
265519|NCT02177474|Behavioral|Telephone based peer support|
265520|NCT02177461|Drug|Telmisartan|
265521|NCT02177461|Drug|Enalapril|
265522|NCT02177461|Drug|Clonidine|
265530|NCT02177448|Drug|Placebo matching enalapril|
265531|NCT02177435|Drug|Telmisartan|
265532|NCT02177435|Drug|Telmisartan/Hydrochlorothiazide|
265533|NCT02177435|Drug|Placebo|
265534|NCT02177422|Drug|Telmisartan|telmisartan 80 mg once daily
265535|NCT02177422|Drug|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure < 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
265536|NCT02177409|Drug|Telmisartan|
265537|NCT02177409|Device|Amlodipine|
265538|NCT02177409|Drug|Placebo|
265539|NCT02177396|Drug|Telmisartan|
265540|NCT02177396|Drug|Valsartan|
265541|NCT02177396|Drug|Placebo|
265542|NCT02177383|Dietary Supplement|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
265543|NCT02177383|Dietary Supplement|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
265544|NCT02177370|Drug|Fenoterol MDI|
265545|NCT02177370|Drug|DSCG MDI|
265546|NCT02177357|Drug|Pramipexole|
265547|NCT02177357|Drug|Placebo|
265548|NCT02177344|Drug|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
265549|NCT02177344|Drug|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
265550|NCT02177344|Drug|Atrovent|Two puffs, 4 times daily by oral inhalation
265551|NCT02177344|Drug|Placebo|
265552|NCT02177331|Drug|Lacidipine|
265553|NCT02177318|Drug|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
265554|NCT02177305|Drug|0.02 mcg tiotropium solution|
265555|NCT02177305|Drug|0.04 mcg tiotropium solution|
265556|NCT02177305|Drug|0.08 mcg tiotropium solution|
265557|NCT02177305|Drug|0.16 mcg tiotropium solution|
265558|NCT02177305|Drug|0.28 mcg tiotropium solution|
265559|NCT02177305|Drug|0.40 mcg tiotropium solution|
265560|NCT02177305|Drug|Placebo solution|
265561|NCT02177292|Radiation|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
265562|NCT02177279|Other|Visit A high wheat bran|
265563|NCT02177279|Other|Visit B normal wheat bran|
265564|NCT02177279|Other|Follow up normal (8days) and high (1day) bran consumption|
265565|NCT02177266|Drug|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
265566|NCT02177266|Drug|Placebo|The placebo will match the study drug.
265567|NCT02177253|Drug|Ipratropium bromide / Salbutamol|
265568|NCT02177253|Drug|Placebo Inhalation solution|
265569|NCT02177253|Drug|Ipratropium bromide|
265570|NCT02177253|Drug|COMBIVENT Inhalation Aerosol|
265571|NCT02177253|Drug|Placebo Inhalation Aerosol|
265572|NCT02177240|Device|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
265573|NCT02177240|Device|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
265574|NCT02177227|Device|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
265575|NCT02177214|Procedure|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
265576|NCT02177201|Other|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
265577|NCT02177201|Other|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
265578|NCT02177188|Device|LBNP Lower Bodi Negative Pressure Chamber|
265579|NCT02177175|Drug|Carvedilol|
265580|NCT02177175|Other|placebo|
265581|NCT02177162|Other|Education to physiotherapists|
265582|NCT02177149|Device|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
265626|NCT02176863|Biological|Flebogamma 5% DIF|Human plasma-derived immunoglobulin
265627|NCT02176863|Other|Placebo|Normal saline solution
265628|NCT02176850|Drug|Micardis®|
265629|NCT02176837|Drug|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
265715|NCT02176200|Drug|Berodual® Respimat®, low inspiratory flow rate|
265583|NCT02177149|Device|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
265584|NCT02177136|Drug|OCA|
265585|NCT02177136|Drug|Placebo|
265586|NCT02177123|Device|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
265587|NCT02177097|Biological|Blood samples|4 x 10 ml blood samples.
265588|NCT02177084|Device|PTNS|
265589|NCT02177071|Drug|INFLIXIMAB|
265590|NCT02177071|Drug|AZATHIOPRINE|
265591|NCT02177071|Drug|MERCAPTOPURINE|
265592|NCT02177071|Drug|Methotrexate|
265593|NCT02177058|Other|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
265594|NCT02177058|Other|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
265595|NCT02177045|Drug|Sonovue, Bracco|Intravenous injection
265596|NCT02177032|Biological|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
265597|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
265598|NCT02177032|Biological|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
265599|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
265600|NCT02177019|Other|Personalized health plan|
265601|NCT02177006|Behavioral|Sun Protection Program|"The intervention includes two phases:~Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.~Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
265602|NCT02176980|Behavioral|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
265603|NCT02176980|Behavioral|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
265604|NCT02176967|Drug|Carboplatin|Given IV
265605|NCT02176967|Other|Clinical Observation|Undergo clinical observation
265606|NCT02176967|Drug|Cyclophosphamide|Given IV
265607|NCT02176967|Drug|Doxorubicin Hydrochloride|Given IV
265608|NCT02176967|Drug|Etoposide|Given IV
265609|NCT02176967|Other|Laboratory Biomarker Analysis|Correlative studies
265610|NCT02176967|Other|Pharmacological Study|Optional correlative studies
265611|NCT02176954|Device|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
265612|NCT02176954|Device|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
265613|NCT02176954|Device|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.~Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
265614|NCT02176928|Device|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.~AutoPAP treatment 7 nights a week for four months (16 weeks)."
265615|NCT02176928|Device|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.~Sham PAP treatment 7 nights a week for four months (16 weeks)./"
265616|NCT02176915|Behavioral|Group program|
265617|NCT02176915|Behavioral|Print Materials|
265618|NCT02176902|Behavioral|behavioral dietary intervention|Receive dietary counseling
265619|NCT02176902|Behavioral|behavioral dietary intervention|Receive guidelines for low-fat diet
265620|NCT02176902|Dietary Supplement|omega-3 fatty acid|Given PO
265621|NCT02176902|Other|laboratory biomarker analysis|Correlative studies
265622|NCT02176889|Dietary Supplement|Lactospore|Bacillus coagulans MTCC 5856
265623|NCT02176889|Other|Placebo|
265624|NCT02176876|Drug|GS-5745|GS-5745 400 mg administered intravenously
265625|NCT02176876|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
265801|NCT02175420|Biological|BCG|
265630|NCT02176824|Behavioral|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
265631|NCT02176824|Behavioral|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
265632|NCT02176824|Other|Treatment as usual|
265633|NCT02176785|Device|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
265634|NCT02176772|Other|Stable iron isotopes, non-drug intervention|
265635|NCT02176759|Other|Administration of rice fortified with regular FePP|
265636|NCT02176759|Other|Administration of rice fortified with regular FePP with citrate added during extrusion|
265637|NCT02176759|Other|Administration of rice fortified with regular FePP and citrate added at consumption|
265638|NCT02176759|Other|Administration of rice fortified with ferrous sulphate|
265639|NCT02176746|Biological|cancer stem cell vaccine|
265640|NCT02176733|Drug|cyclosporine|
265641|NCT02176720|Drug|FDOPA PET|[18F]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
265642|NCT02176694|Behavioral|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
265643|NCT02176681|Drug|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 3 months
265644|NCT02176681|Drug|Insulin|Insulin
265645|NCT02176668|Drug|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
265646|NCT02176668|Drug|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
265647|NCT02176668|Drug|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
265648|NCT02176668|Drug|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
265649|NCT02176655|Drug|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
265650|NCT02176655|Drug|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
265651|NCT02176642|Drug|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
265652|NCT02176642|Device|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
265653|NCT02176642|Drug|Placebo|Tablet taken by mouth daily for 6 weeks
265654|NCT02176629|Other|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
265655|NCT02176629|Other|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
265656|NCT02176616|Procedure|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
265657|NCT02176616|Procedure|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
265658|NCT02176590|Behavioral|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
265659|NCT02176590|Other|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
265660|NCT02176577|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
265661|NCT02176564|Drug|inhaled bronchodilator|
265662|NCT02176551|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
265663|NCT02176551|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
265664|NCT02176538|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days
265665|NCT02176538|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
265666|NCT02176525|Drug|BI 207127 NA|
265667|NCT02176525|Drug|Placebo|
265668|NCT02176512|Drug|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
265669|NCT02176512|Drug|BIBR 277 SE|Treatment B - Monocomponent
265670|NCT02176512|Drug|HCTZ|Treatment B -Monocomponent
265671|NCT02176499|Drug|Telmisartan, low dose|
265672|NCT02176499|Drug|Telmisartan, high dose|
265673|NCT02176499|Drug|Placebo|
265674|NCT02176486|Drug|Ixazomib|Ixazomib capsules.
265675|NCT02176486|Drug|Placebo|Ixazomib placebo-matching capsules.
265676|NCT02176473|Behavioral|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
265677|NCT02176460|Drug|Colchicine|0.5mg twice daily for 16 weeks
265678|NCT02176460|Drug|Placebo|1 tablet twice daily
265679|NCT02176434|Procedure|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
265680|NCT02176434|Biological|hematopoietic stem cell|
265681|NCT02176421|Device|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
265682|NCT02176408|Behavioral|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
265802|NCT02175420|Biological|TFV|
265683|NCT02176408|Behavioral|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
265684|NCT02176408|Behavioral|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
265685|NCT02176395|Drug|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
265686|NCT02176395|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
265687|NCT02176395|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
265688|NCT02176382|Drug|denosumab|denosumab subcutaneous injection
265689|NCT02176382|Drug|teriparatide|teriparatide daily subcutaneous injection
265690|NCT02176382|Drug|Zoledronic acid|zoledronic acid infusion
265691|NCT02176369|Drug|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
265692|NCT02176356|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
265693|NCT02176356|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
265694|NCT02176356|Device|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
265695|NCT02176356|Device|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
265696|NCT02176356|Device|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
265697|NCT02176343|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
265698|NCT02176330|Other|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
265699|NCT02176330|Other|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
265700|NCT02176317|Biological|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
265701|NCT02176304|Drug|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
265702|NCT02176304|Drug|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
265703|NCT02176291|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
265704|NCT02176291|Drug|Placebo|matched placebo
265705|NCT02176278|Other|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
265706|NCT02176278|Other|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c<7%, BP<130/80 mmHg, LDL-C<1.8 mmol/l, triglyceride<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
265707|NCT02176278|Other|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
265708|NCT02176265|Device|Qvanteq bioactive coronary stent|PCI
265709|NCT02176252|Drug|AZD1722|
265710|NCT02176252|Drug|Placebo|
265711|NCT02176226|Behavioral|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
265712|NCT02176213|Drug|Pomalidomide|4 mg PO x 21 days
265713|NCT02176213|Drug|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
265714|NCT02176213|Drug|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
265716|NCT02176200|Drug|Berodual® Respimat®, medium inspiratory flow rate|
265717|NCT02176200|Drug|Berodual® Respimat®, high inspiratory flow rate|
265718|NCT02176200|Drug|Berodual® HFA-MDI, low inspiratory flow rate|
265719|NCT02176200|Drug|Berodual® HFA-MDI, medium inspiratory flow rate|
265720|NCT02176200|Drug|Berodual® HFA-MDI, high inspiratory flow rate|
265721|NCT02176187|Drug|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
265722|NCT02176187|Drug|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
265723|NCT02176161|Drug|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
265724|NCT02176148|Drug|fluocinonide 0.05% cream|
265725|NCT02176135|Drug|Auranofin|3 mg tablets
265726|NCT02176122|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
265727|NCT02176122|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
265728|NCT02176096|Dietary Supplement|Glycosade|
265729|NCT02176083|Behavioral|Text message management prompts|
265730|NCT02176057|Drug|Azithromycin|
265731|NCT02176044|Drug|Sodium Nitroprusside infusion|
265732|NCT02176044|Other|Placebo|
265733|NCT02176031|Drug|Natalizumab|
265734|NCT02176031|Drug|Methylprednisolone|
265735|NCT02176018|Drug|Dextromethorphan and quinidine|
265736|NCT02176018|Drug|Placebo|
265737|NCT02176005|Device|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
265738|NCT02176005|Drug|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
265739|NCT02176005|Other|Negative Control|Moxifloxacin is used alone
265740|NCT02175979|Dietary Supplement|enriched enteral nutrition|enriched enteral tube feeding perioperative
265741|NCT02175979|Dietary Supplement|standard|standard of care
265742|NCT02175966|Drug|DCV/ASV/BMS-791325|
265743|NCT02175966|Drug|Ribavirin|
265744|NCT02175966|Drug|Sofosbuvir|
265745|NCT02175966|Drug|Peginterferon α-2a|
265746|NCT02175953|Behavioral|Psychotherapy|The program is designed for 10 participants and consists of two modules of caregiver education followed by ten psychotherapeutic group modules. The major overarching topics will be (i) caregiver´s emotional and physical limits, (ii) conscious and unconscious feelings and emotions towards the people with dementia and (iii) activation of caregivers´ social resources. Duration of each module is planned to be 90 minutes including a relaxation exercise at the end of each module.
265747|NCT02175927|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
265748|NCT02175927|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
265749|NCT02175927|Drug|Metronidazole|antibiotic of each quadruple therapy
265750|NCT02175927|Drug|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
265751|NCT02175927|Drug|Tetracycline|antibiotic of classical quadruple therapy
265752|NCT02175914|Drug|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
265753|NCT02175901|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
265754|NCT02175901|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
265755|NCT02175901|Drug|Amoxicillin|antibiotic of each quadruple therapy
265756|NCT02175901|Drug|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
265757|NCT02175901|Drug|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
265758|NCT02175888|Dietary Supplement|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
265759|NCT02175888|Dietary Supplement|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
265760|NCT02175797|Device|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
265761|NCT02175784|Drug|ipragliflozin|oral
265762|NCT02175784|Drug|placebo|oral
265763|NCT02175771|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
265764|NCT02175771|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.~During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
265765|NCT02175771|Drug|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.~During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
265766|NCT02175771|Drug|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.~During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
265767|NCT02175771|Drug|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
265768|NCT02175758|Drug|SOF|SOF administered orally once daily
265769|NCT02175758|Drug|RBV|RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
265770|NCT02175745|Drug|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
265771|NCT02175745|Procedure|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
265803|NCT02175407|Drug|ASP1707|oral
265772|NCT02175745|Procedure|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
265773|NCT02175745|Procedure|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
265774|NCT02175732|Behavioral|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
265775|NCT02175732|Behavioral|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.~During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
265776|NCT02175706|Device|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
265777|NCT02175706|Device|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
265778|NCT02175680|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
265779|NCT02175667|Procedure|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
265780|NCT02175654|Drug|Regorafenib|
265781|NCT02175641|Behavioral|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
265782|NCT02175641|Behavioral|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
265783|NCT02175628|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.~Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
265784|NCT02175602|Drug|Escitalopram|10 milligrams administered each morning
265785|NCT02175602|Drug|Sertraline|50 milligrams administered each morning
265786|NCT02175602|Drug|DCV 3DAA FDC|Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
265787|NCT02175602|Drug|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
265788|NCT02175589|Other|Colchicine Cessation|Colchicine Cessation
265789|NCT02175576|Device|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
265790|NCT02175576|Device|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
265791|NCT02175563|Device|Audiovisual feedback from smartphone based app|
265792|NCT02175550|Device|NR CC|
265793|NCT02175537|Behavioral|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
265794|NCT02175511|Device|Cloud-based home BP monitoring|"a sphygmomanometer-style BP measurement device (Microlife®, WatchBP Home) that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network."
265795|NCT02175498|Drug|Homoeopathic medicines|4 pills once a week of the indicated Similimum
265796|NCT02175485|Drug|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
265797|NCT02175472|Device|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
265798|NCT02175472|Device|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
265799|NCT02175446|Drug|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
265800|NCT02175433|Drug|AGS67E|intravenous (IV) infusion
265807|NCT02175381|Drug|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
265808|NCT02175381|Drug|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
265809|NCT02175368|Device|Adhese One F Upgrade|
265810|NCT02175355|Drug|Low dose of Micardis®|
265811|NCT02175355|Drug|Medium dose of Micardis®|
265812|NCT02175355|Drug|High dose of Micardis®|
265813|NCT02175355|Drug|Hydrochlorothiazide|
265814|NCT02175355|Drug|Placebo|
265815|NCT02175342|Drug|Tiotropium 0.625 mcg/puff|
265816|NCT02175342|Drug|Tiotropium 1.25 mcg/puff|
265817|NCT02175342|Drug|Tiotropium 2.5 mcg/puff|
265818|NCT02175342|Drug|Tiotropium 5 mcg/puff|
265819|NCT02175342|Drug|Placebo solution|
265820|NCT02175342|Drug|Tiotropium-18 lactose powder|
265821|NCT02175342|Drug|Placebo lactose powder|
265822|NCT02175342|Drug|Tiotropium 10 mcg/puff|
265823|NCT02175342|Device|Respimat|
265824|NCT02175342|Device|Handihaler|
265825|NCT02175329|Device|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
265826|NCT02175329|Device|Manually layered veneering|
265827|NCT02175316|Device|Enhanced External Counterpulsation|Enhanced External Counterpulsation
265828|NCT02175303|Biological|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals.
265829|NCT02175277|Drug|Darbepoetin Alfa|The first dose of darbepoetin alfa was the same as that administered at the last dosing visit of the active treatment period in Study 20090160. Doses could be increased up to a maximum of 500 μg every two weeks (Q2W).
265830|NCT02175264|Genetic|Blood sample|
265831|NCT02175251|Procedure|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
265832|NCT02175251|Procedure|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
265833|NCT02175251|Procedure|Sham Comparator|10 session in 5 days with sham-controlled
265834|NCT02175238|Drug|BI 691751 fasted|single dose BI 691751 in fasted state
265835|NCT02175238|Drug|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
265836|NCT02175225|Drug|Deferoxamine Mesylate|
265837|NCT02175225|Drug|Placebo (for Deferoxamine Mesylate)|
265838|NCT02175212|Drug|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months"
265839|NCT02175212|Drug|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~Bicalutamide 50 mg tablet every day for 2 months~Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
265840|NCT02175212|Radiation|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
265841|NCT02175212|Radiation|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
265842|NCT02175199|Device|Lotrafilcon B contact lenses with color printing|
265843|NCT02175199|Device|Phemfilcon A contact lenses with color printing|
265844|NCT02175186|Drug|ALBIS|
265845|NCT02175186|Drug|Placebo|
265846|NCT02175173|Drug|Rufinamide|Administration of Inoveron 100mg or 200mg Tablets
265847|NCT02175160|Other|Braking and functionality|
265848|NCT02175134|Other|Blood and Ascites ELISPOT|
265849|NCT02175121|Drug|Placebo|Tablet, once daily for 28 days
265850|NCT02175121|Drug|PF-06291874|Tablet, 15 mg, once daily for 28 days
265851|NCT02175121|Drug|PF-06291874|Tablet, 35 mg, once daily for 28 days
265852|NCT02175121|Drug|PF-06291874|Tablet, 75 mg, once daily for 28 days
265853|NCT02175121|Drug|PF-06291874|Tablet, 150 mg, once daily for 28 days
265854|NCT02175095|Drug|Regorafenib|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy).
265855|NCT02175082|Other|Cycling at Forced rate|
265856|NCT02175082|Other|Cycling at self-selected rate|
265857|NCT02175069|Procedure|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
265858|NCT02175069|Drug|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
265859|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
265860|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
265861|NCT02175069|Drug|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
265862|NCT02175069|Procedure|Shoulder Surgery|As per individual requirement (patient-dependent)
265863|NCT02175056|Biological|HL2351|Dose-escalation For 5 level dose groups A ~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
265864|NCT02175056|Biological|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
265865|NCT02175043|Procedure|atrial electrogram and liner ablation|"The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients~The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
265866|NCT02175030|Drug|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
265867|NCT02175030|Drug|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
265868|NCT02175017|Drug|ONO-4538|
265869|NCT02175004|Drug|IONIS-TTR Rx|300 mg IONIS-TTR Rx administered once weekly
265870|NCT02174991|Drug|Rho-Kinase Inhibitor (AR-12286)|
265871|NCT02174978|Biological|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
265872|NCT02174978|Other|P falciparum Controlled Human Malaria Infection (CHMI)|
265873|NCT02174965|Device|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
265874|NCT02174965|Device|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
265875|NCT02174952|Behavioral|Self-help version of the New Forest Parenting Programme|
265876|NCT02174939|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
265877|NCT02174939|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
265878|NCT02174926|Procedure|Elective laparoscopic sigmoid resection|
265879|NCT02174926|Dietary Supplement|Conservative treatment|Written lifestyle guidance and fiber supplements
265880|NCT02174913|Device|bispectral index|Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
265881|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
265882|NCT02174900|Drug|Artemether-Lumefantrine (AL) combination|
265883|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
265884|NCT02174887|Drug|Nab-paclitaxel + Gemcitabine|"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days~The patients will receive 2 cycles of treatment every 28 days:"
265885|NCT02174861|Drug|Erenumab|Administered by subcutaneous injection once a month
265886|NCT02174848|Drug|Deferiprone oral solution|Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day
265887|NCT02174835|Drug|AVP-786|
265888|NCT02174835|Drug|AVP-923|
265889|NCT02174822|Drug|AVP-786|
265890|NCT02174822|Drug|Paroxetine|
265891|NCT02174822|Drug|Duloxetine|
265892|NCT02174809|Behavioral|Use of 5As to discuss gestational weight gain|
265893|NCT02174809|Behavioral|Usual care|
265894|NCT02174796|Procedure|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
265895|NCT02174796|Procedure|orthopedic treatment|orthopedic treatment by vacuum bell.
265896|NCT02174783|Other|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
265897|NCT02174783|Other|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
265898|NCT02174783|Other|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
265899|NCT02174770|Other|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
265900|NCT02174770|Other|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
265901|NCT02174757|Drug|Inersan|Probiotic
265902|NCT02174757|Drug|Doxycycline|Antibiotic
265903|NCT02174744|Other|numeric pain rating scale|
265904|NCT02174731|Drug|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
265905|NCT02174731|Drug|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
265906|NCT02174718|Dietary Supplement|Transdermal D Patch|
265907|NCT02174718|Dietary Supplement|Oral vitamin D3|
265908|NCT02174718|Dietary Supplement|Placebo patch|
265909|NCT02174718|Dietary Supplement|Oral placebo|
265910|NCT02174705|Drug|Sucrose|Sucrose 24% orally prior to vaccine injections
265911|NCT02174705|Drug|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
265912|NCT02174692|Other|Exercise|"One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum~2 mins rest between sets"
265913|NCT02174679|Drug|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
265914|NCT02174666|Dietary Supplement|Red clover extract|Aglycone isoflavones 80mg/d
265915|NCT02174666|Dietary Supplement|Supplementation (placebo)|
265916|NCT02174653|Drug|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
265917|NCT02174653|Drug|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
265918|NCT02174640|Dietary Supplement|Coffee|Coffee Beverage
265919|NCT02174640|Dietary Supplement|Water|Water
265920|NCT02174627|Drug|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
265921|NCT02174627|Drug|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
265922|NCT02174614|Behavioral|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
266005|NCT02173964|Drug|water|same amount of water for pinverin administration
265923|NCT02174614|Behavioral|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
265924|NCT02174614|Behavioral|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
265925|NCT02174588|Drug|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
265926|NCT02174588|Drug|propofol|propofol are used for sedation drug
265927|NCT02174575|Drug|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
265928|NCT02174575|Drug|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
265929|NCT02174562|Behavioral|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
265930|NCT02174562|Behavioral|Enhanced Usual Care|Usual care enhanced with education and attention
265931|NCT02174549|Drug|Tirapazamine|Intra-arterial injection into the tumor feeding artery
265932|NCT02174549|Procedure|Transarterial embolization (TAE)|Lipiodol and Gelfoam used to embolize tumor vessels and induce tumor hypoxia
265933|NCT02174536|Biological|Decidual stromal cells|Decidual stromal cells (approximately 1x10^6 cells/kg) will be infused intravenously.
265934|NCT02174536|Biological|Placebo|
265935|NCT02174523|Drug|40mg lurasidone|
265936|NCT02174523|Drug|placebo|
265937|NCT02174510|Drug|20mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
265938|NCT02174510|Drug|40mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
265939|NCT02174510|Drug|80mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
265940|NCT02174510|Drug|placebo|
265941|NCT02174458|Procedure|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
265942|NCT02174445|Drug|Imatinib|Imatinib, 400 to 800 mg p.o., daily
265943|NCT02174445|Drug|Nilotinib|300mg p.o., twice-daily
265944|NCT02174432|Drug|nalbuphine HCl ER 90 mg BID|nalbuphine HCl ER 90 mg BID for up to 50 weeks
265945|NCT02174432|Drug|nalbuphine HCl ER 120 mg BID|nalbuphine HCl ER 120 mg BID for up to 50 weeks
265946|NCT02174432|Drug|nalbuphine HCl ER 180 mg BID|nalbuphine HCl ER 180 mg BID for up to 50 weeks
265947|NCT02174419|Drug|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
265948|NCT02174419|Drug|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
265949|NCT02174419|Drug|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
265950|NCT02174406|Procedure|breast ultrasound|
265951|NCT02174406|Procedure|DBT (Full field digital mammography + tomosynthesis)|
265952|NCT02174393|Drug|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
265953|NCT02174393|Procedure|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.~For this protocol, the needle depth will be increased over the 3 sessions:~Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.~Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
265954|NCT02174393|Drug|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):~Gentle Antioxidant Soothing Cleanser daily~Soothing Recovery Ointment and Sheer Physical Sunscreen~On Day 2-7:~AM: Physical sheer sunscreen and recovery ointment~PM: Retinol/Vitamin C in the evening and soothing recovery ointment~On Day 7:~AM: BD Hydrating Day/Night Cream~PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
265955|NCT02174393|Drug|Post-Universal Peel Skin Care|"Gentle Antioxidant Soothing Cleanser daily~Physical Sunscreen daily~Soothing recovery ointment fortified with silver only when peeling occurs~After completely peeling, vitamin c product in the morning and the retinol in the evening"
265956|NCT02174380|Other|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
265957|NCT02174367|Device|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
265958|NCT02174328|Drug|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
265959|NCT02174328|Drug|Placebo|Placebo once a day until 36 week
265960|NCT02174315|Behavioral|Contingency Management|
265961|NCT02174289|Device|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
265962|NCT02174276|Drug|Tenofovir disoproxil fumarate|TDF 300 mg tablet administered orally once daily
265963|NCT02174276|Biological|GS-4774|GS-4774 subcutaneous injection administered every 4 weeks for a total of 6 doses
265964|NCT02174263|Biological|tocilizumab|Given IV
265965|NCT02174263|Other|laboratory biomarker analysis|Correlative studies
265966|NCT02174263|Other|quality-of-life assessment|Ancillary studies
265967|NCT02174250|Drug|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
265968|NCT02174250|Drug|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
265969|NCT02174237|Drug|LNP1892|Tablets of two strengths (5 and 25 mg)
265970|NCT02174237|Drug|Placebo|Matching placebo
265971|NCT02174224|Behavioral|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
265972|NCT02174224|Behavioral|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
265973|NCT02174224|Behavioral|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
265974|NCT02174211|Drug|Ranibizumab|Intravitreal injection of ranibizumab
265975|NCT02174211|Drug|Aflibercept|Intravitreal injection of aflibercept
265976|NCT02174198|Device|BioOss Collagen at the time of implant placement|Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
265977|NCT02174185|Behavioral|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
265978|NCT02174172|Drug|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
265979|NCT02174172|Drug|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
265980|NCT02174172|Drug|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
265981|NCT02174172|Drug|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles (Cycle = 21 days).
265982|NCT02174172|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
265983|NCT02174172|Drug|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles (Cycle = 21 days).
265984|NCT02174159|Drug|MK-8507|MK-8507 administered as a single oral dose
265985|NCT02174146|Procedure|non-surgical periodontal therapy|supra and subgingival debridement
265986|NCT02174120|Drug|propofol|
265987|NCT02174120|Drug|etomidate|
265988|NCT02174107|Radiation|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1*8 Gy; 5*4 Gy and 10*3 Gy
265989|NCT02174107|Procedure|Percutaneous vertebroplasty|
265990|NCT02174094|Drug|Clobazam|
265991|NCT02174094|Drug|Placebo|
265992|NCT02174068|Drug|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
265993|NCT02174055|Behavioral|Patient Interviews|participate in a brief interview
265994|NCT02174055|Behavioral|newly developed questionnaire|Will be provided to approximately 10 geriatric experts (clinicians/researchers). Interviews with the geriatric experts will take place concurrently with the cognitive interviews being performed with participants. Approximately 10 geriatric experts will review draft items and participate in a brief interview. 10-16 patients will review draft items and participate in a cognitive interview. 15 older patients will complete the draft measure in order to generate preliminary psychometric data. All interviews will be audio recorded and transcribed by Ubiqus Transcription Company. The audio recordings are uploaded through Ubiqus's secure server and the transcribed audio is returned to the research staff within 48 hours.
265995|NCT02174042|Drug|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
265996|NCT02174029|Procedure|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
265997|NCT02174029|Procedure|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
265998|NCT02174029|Procedure|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
265999|NCT02174016|Dietary Supplement|Ketogenic diet|
266000|NCT02174003|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
266001|NCT02173990|Drug|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1~FOLFIRI :~Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :~5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.~*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
266002|NCT02173977|Other|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
266003|NCT02173977|Other|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
266004|NCT02173964|Drug|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
266006|NCT02173951|Drug|Deferiprone|"in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.~Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.~Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6 will start deferiprone 75 mg/kg/d"
266007|NCT02173938|Other|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
266008|NCT02173912|Drug|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
266009|NCT02173912|Drug|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
266010|NCT02173899|Biological|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
266011|NCT02173899|Biological|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
266012|NCT02173899|Biological|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
266013|NCT02173886|Drug|Bupropion SR and XL|
266014|NCT02173873|Drug|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
266015|NCT02173860|Procedure|FFR-guided surgical revascularization|
266016|NCT02173860|Procedure|Angio-guided surgical revascularization|
266017|NCT02173847|Procedure|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
266018|NCT02173847|Device|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
266019|NCT02173847|Device|Diode laser|Low power, near infrared diode laser for welding the surgical wound
266020|NCT02173834|Other|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
266021|NCT02173821|Procedure|Blood sampling|Blood sample will be collected at a single visit
266022|NCT02173808|Biological|levonorgestrel butanoate|
266023|NCT02173795|Drug|Berodual® Respimat®|
266024|NCT02173795|Drug|Berodual® MA HFA|
266025|NCT02173782|Drug|Berodual® Respimat ® high dose|
266026|NCT02173782|Drug|Berodual® Respimat ® low dose|
266027|NCT02173782|Drug|Berodual® MDI|
266028|NCT02173782|Drug|Placebo|
266029|NCT02173769|Drug|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
266030|NCT02173769|Drug|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
266031|NCT02173756|Drug|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
266032|NCT02173756|Drug|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
266033|NCT02173743|Other|PRP|platelet enriched autologous blood plasma
266034|NCT02173743|Other|Control|Regular barbotage/care as usual
266035|NCT02173730|Drug|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
266036|NCT02173730|Drug|Pantoprazole|Pantoprazole tablet 40 mg
266037|NCT02173717|Drug|Dabigatran etexilate|150 mg Dabigatran etexilate
266038|NCT02173717|Drug|Rifampicin|600 mg Rifampicin
266039|NCT02173704|Biological|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
266040|NCT02173704|Biological|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
266041|NCT02173691|Drug|Tiotropium inhalation powder capsules|
266042|NCT02173691|Drug|Salmeterol inhalation aerosol|
266043|NCT02173691|Drug|Placebo inhalation aerosol|
266044|NCT02173691|Drug|Placebo inhalation powder capsules|
266045|NCT02173678|Drug|COMBIVENT® HFA-MDI|
266046|NCT02173678|Drug|COMBIVENT® CFC-MDI|
266047|NCT02173678|Drug|Placebo HFA-MDI|
266048|NCT02173665|Drug|BI 1356 BS - Powder in bottle (PIB)|
266049|NCT02173665|Drug|BI 1356 BS - Tablet|
266050|NCT02173665|Drug|Placebo|
266051|NCT02173652|Drug|BI 1356, high dose|
266052|NCT02173652|Drug|BI 1356, low dose|
266053|NCT02173639|Drug|BI 1356/metformin|fixed dose combination tablet
266054|NCT02173639|Drug|BI 1356|
266055|NCT02173639|Drug|Metformin|
266056|NCT02173626|Behavioral|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
266057|NCT02173613|Other|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:~It is highly recommended to stop antibiotics if PCT <0.1ng/ml, and the recommended stop if 0.1ng/ml <PCT <0.25 ng / ml.~It is recommended to continue treatment if 0.25 ng / ml <PCT ng / ml.~Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
266058|NCT02173600|Behavioral|Group-level Intensive dietary Counselling|
266059|NCT02173600|Behavioral|Individual-level Intensive Dietary Counselling|
266103|NCT02173236|Other|platform-switched implants|
266104|NCT02173236|Other|platform-matched implant|
266105|NCT02173223|Drug|Rho-Kinase Inhibitor|
266060|NCT02173587|Dietary Supplement|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
266061|NCT02173587|Dietary Supplement|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
266062|NCT02173574|Drug|DEB025|
266063|NCT02173574|Drug|EDP239|
266064|NCT02173561|Behavioral|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
266065|NCT02173561|Behavioral|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
266066|NCT02173548|Drug|Anakinra|
266067|NCT02173548|Drug|Placebo|
266068|NCT02173535|Device|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
266069|NCT02173535|Device|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
266070|NCT02173535|Device|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
266071|NCT02173535|Device|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
266072|NCT02173535|Device|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
266073|NCT02173522|Device|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
266074|NCT02173509|Other|Multidisciplinary and multifaceted educational intervention.|Outreach visits (40 minutes) which included a PowerPoint presentation and impress materials: poster; flyers; participation certificate and articles mentioned in the presentation. This outreach visit aimed to change the knowledge-attitudes previously identified in a previous study as being associated with poor prescribing of antibiotics in the case of physicians and propensity to dispense antibiotics without medical prescription in the case of pharmacists.
266075|NCT02173496|Other|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
266076|NCT02173483|Procedure|Quadriceps graft|
266077|NCT02173470|Other|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
266078|NCT02173457|Drug|Chiglitazar|Take orally
266079|NCT02173457|Drug|Sitagliptin|Take orally
266080|NCT02173444|Other|Blood test|
266081|NCT02173418|Drug|Phrenic nerve block with Ropivacaine|
266082|NCT02173418|Drug|Phrenic nerve block with saline|
266083|NCT02173405|Drug|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
266084|NCT02173405|Drug|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
266085|NCT02173392|Drug|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
266086|NCT02173379|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.~The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
266087|NCT02173379|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition~Stent lengths: 8, 12, 15, 18, 23, and 28 mm~For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
266088|NCT02173366|Behavioral|Change Club Intervention|
266089|NCT02173353|Device|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
266090|NCT02173327|Device|Continuously helm CPAP|6 hours
266091|NCT02173327|Device|Intermittent Mask CPAP|10min every 2 hour for 18 hours
266092|NCT02173314|Other|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
266093|NCT02173301|Drug|XP23829 400 mg QD|active dose 1
266094|NCT02173301|Drug|XP 23829 800 mg QD|active dose 2
266095|NCT02173301|Drug|XP23829 400 mg BID|active dose 3
266096|NCT02173301|Drug|Placebo|nonactive
266097|NCT02173288|Drug|Standard medical therapy|
266098|NCT02173288|Drug|Tolvaptan|
266099|NCT02173288|Drug|Midodrine|
266100|NCT02173262|Drug|G-CSF|
266101|NCT02173262|Drug|Ciprofloxacin|
266102|NCT02173249|Drug|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
266106|NCT02173184|Biological|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
266107|NCT02173184|Biological|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
266108|NCT02173171|Other|Information collection|Q3M Information collection
266109|NCT02173158|Drug|lomitapide|
266110|NCT02173145|Drug|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
266111|NCT02173145|Drug|placebo|Placebo will be given 3 times a wek over a period of 3 months.
266112|NCT02173132|Drug|Acetyl-L-carnitine|
266113|NCT02173132|Other|Placebo|
266114|NCT02173119|Other|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
266115|NCT02173106|Drug|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
266116|NCT02173093|Biological|IL-2|Given SC
266117|NCT02173093|Biological|GD2Bi-aATC|Given IV
266118|NCT02173093|Biological|GM-CSF|Given SC
266119|NCT02173093|Other|laboratory evaluations of immune responses|Correlative studies
266120|NCT02173080|Other|PLD-Q|polycystic liver disease questionnaire
266121|NCT02173054|Other|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
266122|NCT02173054|Other|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
266123|NCT02173054|Other|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
266124|NCT02173041|Other|Prevention Awareness Groups (PAG)|
266125|NCT02173041|Other|Standard Care|
266126|NCT02173015|Other|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
266127|NCT02173002|Other|myIBDcoach|
266128|NCT02173002|Other|Standard care|
266129|NCT02172976|Drug|Gemcitabine|
266130|NCT02172976|Drug|Oxaliplatin|
266131|NCT02172976|Drug|5-Fluorouracil|
266132|NCT02172976|Drug|Irinotecan|
266133|NCT02172976|Drug|Natriumfolinate|
266134|NCT02172963|Biological|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10^6 cells/kg.
266135|NCT02172950|Biological|rVIII‑SingleChain|Recombinant single-chain coagulation factor VIII
266136|NCT02172937|Biological|Decidual Stromal Cells thawed in plasma|
266137|NCT02172937|Biological|Decidual Stromal Cells thawed in human albumin|
266138|NCT02172924|Biological|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
266139|NCT02172924|Biological|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
266140|NCT02172911|Biological|1.1 mL of INO-3112 (combination) delivered via IM EP|Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 in the deltoid followed immediately by EP with CELLECTRA®-5P.
266141|NCT02172885|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
266142|NCT02172872|Drug|standard combination chemotherapy|"Cycle 1~daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days~cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~Cycle 2~daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days~cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.~Cycle 3 (mini-ICE)~idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~etoposide (100 mg/m²) infusion (1 hr) for 3 days~Cycle 4 (mini-ICE) (optional)~idarubicin (8 mg/m²) infusion (15-30 min) for 3 days~cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days~etoposide (100 mg/m²) infusion (1 hr) for 3 days"
266143|NCT02172872|Drug|decitabine|"Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days~Cycle 2~if bone marrow (BM) blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~Cycle 3~if BM blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days~if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days~Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days~Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days~Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
266144|NCT02172859|Dietary Supplement|lumiVida™|
266145|NCT02172859|Dietary Supplement|Placebo|
266146|NCT02172846|Radiation|Proton beam radiation therapy (PBT)|
266147|NCT02172846|Drug|Paclitaxel|
266148|NCT02172846|Drug|Carboplatin|
266149|NCT02172820|Behavioral|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
266150|NCT02172807|Drug|Tiotropium low|Tiotropium 18 µg inhalation capsule
266151|NCT02172807|Drug|Tiotropium high|Tiotropium 36 µg inhalation capsule
266152|NCT02172807|Drug|Placebo MDI|Placebo metered dose inhaler (MDI)
266153|NCT02172807|Drug|Placebo inhalation capsule|
266154|NCT02172807|Drug|Oxitropium|Oxitropium MDI (100 µg/puff)
266155|NCT02172794|Drug|Tiotropium|
266156|NCT02172794|Drug|Placebo to tiotropium|
266157|NCT02172794|Drug|Salmeterol|
266158|NCT02172794|Drug|Placebo to salmeterol|
266159|NCT02172781|Drug|Ipratropium - unit dose vial|
266160|NCT02172781|Drug|Tiotropium - inhalation capsule|
266161|NCT02172781|Drug|Placebo matching tiotropium|
266162|NCT02172781|Drug|Placebo matching ipratropium|
266222|NCT02172391|Drug|Placebo inhalation powder capsules|
266163|NCT02172768|Other|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
266164|NCT02172768|Other|daily dosing|micafungin daily for 8 days
266165|NCT02172768|Drug|micafungin|
266166|NCT02172755|Drug|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
266167|NCT02172742|Drug|BIA 2-093|BIA 2-093 1200 mg once-daily
266168|NCT02172742|Drug|Placebo|matching placebo
266169|NCT02172742|Drug|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
266170|NCT02172729|Drug|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
266171|NCT02172716|Procedure|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.~Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
266172|NCT02172703|Device|Non-invasive ICP measurement device|"The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.~The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA)."
266173|NCT02172690|Procedure|Laparoscopic Staging|Laparoscopic Staging
266174|NCT02172677|Behavioral|Episodic memory task|
266175|NCT02172677|Device|fMRI|
266176|NCT02172664|Procedure|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
266177|NCT02172664|Procedure|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
266178|NCT02172664|Device|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
266179|NCT02172651|Drug|Vitamin D3|
266180|NCT02172638|Procedure|Fast-Track Protocol|
266181|NCT02172638|Procedure|Usual management|
266182|NCT02172625|Dietary Supplement|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
266183|NCT02172625|Other|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
266184|NCT02172612|Other|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
266185|NCT02172599|Behavioral|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
266186|NCT02172586|Drug|Telmisartan|
266187|NCT02172586|Drug|Losartan|
266188|NCT02172586|Drug|Hydrochlorothiazide|
266189|NCT02172573|Drug|Pramipexole|
266190|NCT02172573|Drug|Bromocriptine|
266191|NCT02172573|Drug|Placebo pramipexole|
266192|NCT02172573|Drug|Placebo bromocriptine|
266193|NCT02172560|Drug|Tiotropium|
266194|NCT02172547|Drug|Spiriva|
266195|NCT02172534|Drug|Tiotropium bromide low|
266196|NCT02172534|Drug|Tiotropium bromide medium|
266197|NCT02172534|Drug|Tiotropium bromide high|
266198|NCT02172534|Drug|Placebo|
266199|NCT02172521|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
266200|NCT02172508|Drug|Tiotropium Inhalation Capsule|
266201|NCT02172508|Drug|Placebo Lactose Capsule|
266202|NCT02172495|Drug|Tiotropium bromide|Tiotropium bromide 18 micrograms
266203|NCT02172482|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
266204|NCT02172469|Drug|Tiotropium inhalation powder capsule|
266205|NCT02172469|Drug|Placebo Metered Dose Inhaler|
266206|NCT02172469|Drug|Ipratropium Bromide Metered Dose Inhaler|
266207|NCT02172469|Drug|Placebo inhalation powder capsule|
266208|NCT02172456|Drug|99mTc-radiolabelled tiotropium|
266209|NCT02172456|Drug|non-radiolabelled tiotropium|
266210|NCT02172443|Drug|tiotropium inhalation powder capsules|
266211|NCT02172443|Drug|Atrovent|
266212|NCT02172443|Drug|placebo to Atrovent|
266213|NCT02172443|Drug|placebo to tiotropium inhalation capsules|
266214|NCT02172430|Drug|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
266215|NCT02172430|Drug|Tersigan®|2 puffs of oxitropium three times daily via MDI
266216|NCT02172417|Drug|Cimetidine + Tiotropium|
266217|NCT02172417|Drug|Ranitidine + Tiotropium|
266218|NCT02172417|Drug|Tiotropium|
266219|NCT02172404|Device|Placebo capsule administered via the HandiHaler®|
266220|NCT02172404|Device|Ipratropium metered dose inhaler (MDI)|
266221|NCT02172391|Drug|Tiotropium inhalation powder capsules|
266223|NCT02172378|Drug|Tiotropium inhalation capsules|
266224|NCT02172378|Drug|Placebo inhalation capsules|
266225|NCT02172352|Drug|Ba 679 BR low dose|
266226|NCT02172352|Drug|Ba 679 BR middle dose|
266227|NCT02172352|Drug|Ba 679 BR high dose|
266228|NCT02172352|Drug|Placebo inhalation powder|
266229|NCT02172339|Drug|Tiotropium, solution ampoules|
266230|NCT02172326|Drug|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
266231|NCT02172313|Drug|semaglutide|For oral administration.
266232|NCT02172300|Drug|Tiotropium inhalation capsules|
266233|NCT02172300|Drug|Placebo inhalation capsules|
266234|NCT02172287|Drug|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
266235|NCT02172287|Drug|Salmeterol|Inhalation aerosol twice daily
266236|NCT02172287|Drug|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
266237|NCT02172287|Drug|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
266238|NCT02172274|Drug|[14C]-BI 10773 - oral solution|
266239|NCT02172261|Drug|BI 10773|
266240|NCT02172261|Drug|Glimepiride|
266241|NCT02172248|Drug|BI 10773|
266242|NCT02172248|Drug|Metformin|
266243|NCT02172235|Drug|Pioglitazone|
266244|NCT02172235|Drug|Pioglitazone - low dose|
266245|NCT02172235|Drug|BI 10773 - low dose|
266246|NCT02172235|Drug|BI 10773 - medium dose|
266247|NCT02172235|Drug|BI 10773 - high dose|
266248|NCT02172222|Drug|BI 10773|
266249|NCT02172222|Drug|Linagliptin|
266250|NCT02172209|Drug|BI 10773|
266251|NCT02172196|Drug|BI 10773|
266252|NCT02172196|Drug|Sitagliptin|
266253|NCT02172183|Drug|Psychopharmacological treatment|methylphenidate or atomoxetine
266254|NCT02172183|Behavioral|CBT group|
266255|NCT02172170|Drug|BI 10773 single rising dose|
266256|NCT02172170|Drug|Placebo|
266257|NCT02172157|Drug|BI 1744 CL i.v.|
266258|NCT02172157|Drug|BI 1744 CL oral|
266259|NCT02172144|Drug|BI 1744 CL solution for inhalation|
266260|NCT02172144|Drug|Placebo matching BI 1744 CL|
266261|NCT02172144|Drug|Moxifloxacin (Avalox®)|
266262|NCT02172131|Drug|BI 1744 CL|
266263|NCT02172131|Drug|Placebo|
266264|NCT02172118|Drug|BI 1774 CL|
266265|NCT02172105|Drug|BI 1744 CL|
266266|NCT02172105|Drug|Placebo|
266267|NCT02172092|Drug|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
266268|NCT02172079|Other|Real mobilization-with-movement (MWM)|
266269|NCT02172079|Other|Sham mobilization-with-movement (MWM)|
266270|NCT02172066|Behavioral|Narrative Exposure Therapy (NET)|
266271|NCT02172053|Other|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
266272|NCT02172053|Other|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
266273|NCT02172040|Drug|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
266274|NCT02172040|Drug|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
266275|NCT02172040|Drug|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
266276|NCT02172040|Drug|Matched placebo capsule for over-encapsulated amlodipine besylate tablet|Matched placebo capsule for over-encapsulated amlodipine besylate tablet once a day for two weeks
266277|NCT02172027|Device|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
266278|NCT02172014|Drug|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
266279|NCT02172014|Drug|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
266280|NCT02172001|Drug|Iron isomaltoside 1000|
266281|NCT02172001|Drug|Natrium Chloride 0,9%|100 ml or 5 ml
266282|NCT02171988|Drug|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
266283|NCT02171988|Drug|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
266284|NCT02171988|Drug|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
266285|NCT02171988|Drug|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
266286|NCT02171975|Procedure|pre-procedure ultrasound guided paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
266428|NCT02170987|Drug|Placebo|
266429|NCT02170974|Drug|BIBR 1048 MS polymorph II|
266287|NCT02171975|Procedure|Conventional landmark guided midline spinal anaesthetic|Spinal anaesthesia was administered based on conventional landmark based midline approach.
266288|NCT02171962|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
266289|NCT02171949|Biological|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
266290|NCT02171936|Other|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
266291|NCT02171910|Drug|Doxapram|
266292|NCT02171910|Drug|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
266293|NCT02171897|Procedure|Osteosynthesis|
266294|NCT02171897|Procedure|Total hip replacement|
266295|NCT02171884|Other|Sample of cord blood|
266296|NCT02171884|Other|Sample of placenta|
266297|NCT02171871|Other|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
266298|NCT02171845|Other|surgical biopsies|
266299|NCT02171832|Drug|BI 1744 CL, low dose|
266300|NCT02171832|Drug|BI 1744 CL, high dose|
266301|NCT02171819|Biological|IVACFLU-A/H5N1, 7.5 mcg|Contains 7.5 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose.
266302|NCT02171819|Biological|IVACFLU-A/H5N1, 15 mcg|Contains 15 mcg HA and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose
266303|NCT02171819|Other|Placebo Comparator|PBS, pH 7.2 in 0.5 mL single-dose vials.
266304|NCT02171806|Drug|BI 1744 CL|
266305|NCT02171806|Drug|Placebo|
266306|NCT02171793|Drug|BI 1744 CL|
266307|NCT02171793|Drug|Placebo|
266308|NCT02171780|Drug|BI 1744 CL|
266309|NCT02171780|Drug|Placebo|
266310|NCT02171767|Drug|BIBW 2992 MA2 - single rising dose|
266311|NCT02171754|Drug|BIBW 2992|
266312|NCT02171754|Drug|Ritonavir|
266313|NCT02171741|Drug|BIBW 2992|continuous daily dosing for 20 or 13 days
266314|NCT02171741|Drug|Docetaxel|single infusion on day 1
266315|NCT02171728|Drug|BIBW 2992|
266316|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
266317|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
266318|NCT02171715|Drug|BIBW 2992 MA2|powder for oral solution
266319|NCT02171702|Drug|BIBW 2992|
266320|NCT02171689|Drug|[14C]- BIBW 2992 MA2|
266321|NCT02171676|Drug|Docetaxel|
266322|NCT02171676|Drug|BIBW 2992|
266323|NCT02171663|Drug|BIBW 2992|
266324|NCT02171650|Drug|BIBW 2992|
266325|NCT02171637|Drug|BIBW 2992|escalating doses
266326|NCT02171624|Drug|dabigatran etexilate|
266327|NCT02171624|Drug|quinidine|
266328|NCT02171611|Drug|Dabigatran etexilate pellets|
266329|NCT02171611|Drug|Dabigatran etexilate powder|
266330|NCT02171611|Drug|Dabigatran etexilate capsule|
266331|NCT02171598|Drug|Clopidogrel|
266332|NCT02171598|Drug|Dabigatran high dose|
266333|NCT02171598|Drug|Dabigatran low dose|
266334|NCT02171585|Drug|Dabigatran etexilate|
266335|NCT02171585|Drug|Clarithromycin|
266336|NCT02171572|Drug|Dabigatran etexilate low|
266337|NCT02171572|Drug|Dabigatran etexilate high|
266338|NCT02171559|Drug|Enoxaparin prefilled syringes|
266339|NCT02171559|Drug|Dabigatran etexilate capsules|
266340|NCT02171546|Drug|Dabigatran etexilate capsules|
266341|NCT02171546|Drug|Quinidine sulfate tablets|
266342|NCT02171546|Drug|Fexofenadine tablets|
266343|NCT02171533|Drug|dabigatran|
266344|NCT02171533|Drug|Verapamil|
266345|NCT02171533|Drug|Verapamil ER|
266346|NCT02171520|Drug|Dabigatran etexilate generation I|
266347|NCT02171520|Drug|Dabigatran etexilate generation II|
266348|NCT02171507|Drug|Dabigatran etexilate|
266349|NCT02171507|Drug|Diclofenac|
266350|NCT02171494|Drug|IVAX Warfarin|
266351|NCT02171494|Drug|BMS Coumadin|
266352|NCT02171481|Drug|Dabigatran etexilate polymorph II|
266353|NCT02171481|Drug|Dabigatran etexilate polymorph I|
266354|NCT02171468|Drug|Dabigatran high dose|
266355|NCT02171468|Drug|Dabigatran low dose|
266356|NCT02171455|Drug|Dabigatran etexilate low dose|
266357|NCT02171455|Drug|Dabigatran etexilate medium dose|
266358|NCT02171455|Drug|Dabigatran etexilate high dose|
266359|NCT02171455|Drug|Placebo|
266360|NCT02171442|Drug|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
266361|NCT02171442|Drug|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
266362|NCT02171429|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
266363|NCT02171429|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.
266364|NCT02171429|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).
266365|NCT02171429|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC Q4W.
266366|NCT02171416|Drug|Rilonacept|
266367|NCT02171416|Drug|Placebo|
266368|NCT02171390|Drug|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
266369|NCT02171390|Drug|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
266370|NCT02171377|Device|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
266371|NCT02171377|Other|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
266372|NCT02171377|Device|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
266373|NCT02171377|Other|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
266374|NCT02171364|Procedure|Virtual ablation in based 3D CT of patient who diagnosed AF|
266375|NCT02171364|Procedure|conventional ablation based on physician's personal experience|
266376|NCT02171351|Device|effect of neuromuscular electrostimulation (NMES)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of neuromuscular electrostimulation (NMES).
266377|NCT02171351|Device|effect of neuro electrostimulation (NES)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of neuro electrostimulation (NES)
266378|NCT02171351|Other|effect of voluntary contractions (VC)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of voluntary contractions (VC)
266379|NCT02171338|Other|PCT-level|PCT-level is available to the treating doctor.
266380|NCT02171338|Behavioral|Antibiotic treatment based on PCT-level|"PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.~The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above."
266381|NCT02171325|Drug|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
266382|NCT02171312|Device|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
266383|NCT02171312|Behavioral|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
266384|NCT02171299|Procedure|Wound infiltration with local anaesthetic|
266385|NCT02171299|Drug|Ropivacaine|
266386|NCT02171273|Behavioral|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
266387|NCT02171273|Behavioral|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
266388|NCT02171273|Behavioral|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
266389|NCT02171260|Drug|Eribulin Mesylate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
266390|NCT02171247|Drug|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
266391|NCT02171247|Drug|Visipaque 320|Visipaque 320 is standard protocol.
266392|NCT02171234|Drug|Placebo|
266393|NCT02171234|Drug|BIA 2-093|
266394|NCT02171221|Drug|Oral DFP-11207|
266395|NCT02171208|Drug|dimethyl fumarate - Reference form|single dose 240 mg
266396|NCT02171208|Drug|dimethyl fumarate - Test form|single dose 240 mg
266397|NCT02171195|Drug|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
266398|NCT02171195|Drug|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
266399|NCT02171182|Drug|Qutenza|capsaicin patch
266400|NCT02171156|Drug|nintedanib|soft gelatin capsule
266401|NCT02171143|Drug|ASP2409|intravenous (IV)
266402|NCT02171143|Drug|Placebo|intravenous (IV)
266403|NCT02171130|Drug|Nasal Glucagon|3 mg nasal glucagon powder
266404|NCT02171117|Procedure|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
266405|NCT02171117|Biological|HLA-mismatched donor peripheral stem cell infusion|
266406|NCT02171104|Biological|Stem Cell Transplantation|Infusion given on Day 0
266407|NCT02171104|Drug|IMD Preparative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan"
266408|NCT02171104|Drug|Osteopetrosis Only Preparative Regimen|"Anti-thymocyte Globulin (ATG)~Fludarabine~Busulfan~Thiotepa"
266409|NCT02171104|Drug|Osteopetrosis Haploidentical Only Preparative Regimen|"Rituximab~Alemtuzumab~Busulfan~Fludarabine"
266410|NCT02171104|Drug|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
266411|NCT02171104|Drug|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
266412|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
266413|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
266414|NCT02171065|Device|sham|
266415|NCT02171065|Device|ABSORB BVS|
266416|NCT02171052|Drug|Dabigatran etexilate|
266417|NCT02171052|Drug|Digoxin|
266418|NCT02171039|Drug|Dabigatran|
266419|NCT02171039|Drug|Atorvastatin|
266420|NCT02171026|Drug|Dabigatran etexilate|
266421|NCT02171026|Drug|Amiodarone|
266422|NCT02171013|Drug|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
266423|NCT02171013|Drug|Dabigatran polymorph I|
266424|NCT02171000|Drug|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
266425|NCT02170987|Drug|Dabigatran etexilate low|
266426|NCT02170987|Drug|Dabigatran etexilate high|
266427|NCT02170987|Drug|Moxifloxacin|
266430|NCT02170974|Drug|BIBR 1048 MS polymorph I|
266431|NCT02170948|Drug|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
266432|NCT02170935|Drug|BIBR 1048 capsule|
266433|NCT02170922|Drug|BIBR 1048 MS tablet|
266434|NCT02170922|Drug|BIBR 1048 MS solution|
266435|NCT02170909|Drug|BIBR 1048 MS low dose|
266436|NCT02170909|Drug|BIBR 1048 MS medium dose|
266437|NCT02170909|Drug|BIBR 1048 MS high dose|
266438|NCT02170896|Drug|BIBR 1048 MS Capsule A|
266439|NCT02170896|Drug|BIBR 1048 MS Capsule B|
266440|NCT02170896|Drug|BIBR 1048 MS Capsule C|
266441|NCT02170896|Drug|BIBR 1048 MS Capsule D|
266442|NCT02170896|Drug|BIBR 1048 MS tartaric acid solution|
266443|NCT02170896|Drug|Pantoprazole|
266444|NCT02170883|Other|Interactive SMS|
266445|NCT02170883|Other|Usual care|
266446|NCT02170870|Drug|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
266447|NCT02170870|Drug|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
266448|NCT02170870|Drug|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
266449|NCT02170857|Drug|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
266450|NCT02170844|Drug|BIBR 1048 MS|
266451|NCT02170844|Drug|Placebo of BIBR 1048 MS|
266452|NCT02170831|Drug|BIBR 1048 MS low|
266453|NCT02170831|Drug|BIBR 1048 MS medium 1|
266454|NCT02170831|Drug|BIBR 1048 MS medium 2|
266455|NCT02170831|Drug|BIBR 1048 MS high|
266456|NCT02170831|Drug|BIBR 1048 MS placebo|
266457|NCT02170818|Other|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
266458|NCT02170818|Other|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
266459|NCT02170805|Drug|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
266460|NCT02170805|Drug|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
266461|NCT02170805|Drug|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
266462|NCT02170805|Drug|Pantoprazole|Pantoprazole 40 mg
266463|NCT02170792|Drug|BIBR 1048 MS|Low, medium or high dose
266464|NCT02170792|Drug|Ranitidine|150mg
266465|NCT02170779|Behavioral|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
266466|NCT02170779|Other|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
266467|NCT02170766|Drug|BIBR 1048 low1|
266468|NCT02170766|Drug|BIBR 1048 low2|
266469|NCT02170766|Drug|BIBR 1048 medium|
266470|NCT02170766|Drug|BIBR 1048 high|
266471|NCT02170766|Drug|Pantoprazole|
266472|NCT02170753|Procedure|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
266473|NCT02170753|Procedure|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
266474|NCT02170740|Drug|BIBR 1048 MS - low dose|
266475|NCT02170740|Drug|BIBR 1048 MS - high dose|
266476|NCT02170740|Drug|BIBR 1048 MS + Pantoprazole|
266477|NCT02170727|Drug|DCV/ASV/BMS-791325|
266478|NCT02170714|Other|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
266479|NCT02170701|Drug|BIBR 1048|Ascending doses (in mg) given twice daily
266480|NCT02170688|Drug|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
266481|NCT02170688|Other|Weight calculation|
266482|NCT02170675|Drug|Dabigatran etexilate|
266483|NCT02170675|Drug|Ketoconazole|
266484|NCT02170662|Drug|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
266485|NCT02170662|Drug|Placebo|
266486|NCT02170649|Drug|BIA 2-093|
266487|NCT02170636|Drug|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
266488|NCT02170636|Drug|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
266489|NCT02170636|Drug|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
266490|NCT02170636|Drug|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
266491|NCT02170636|Drug|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
266492|NCT02170636|Drug|Pantoprazole|40 mg Pantoprazole
266493|NCT02170623|Drug|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
266494|NCT02170623|Drug|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
266495|NCT02170623|Drug|Pantoprazole|40 mg pantoprazole
266496|NCT02170623|Drug|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
266497|NCT02170610|Drug|BIBR 1048 MS|
266498|NCT02170610|Drug|Pantoprazole|
266499|NCT02170597|Drug|BIBR 1048 MS HPMC capsule|
266500|NCT02170597|Drug|BIBR 1048 MS gelatine capsule|
266501|NCT02170584|Drug|BIBR 953 ZW IV|
266502|NCT02170584|Drug|BIBR 1048 MS tablet|
266503|NCT02170584|Drug|BIBR 1048 MS oral solution|
266504|NCT02170584|Drug|BIBR 953 ZW IV Placebo|
266505|NCT02170571|Drug|Dabigatran etexilate|
266506|NCT02170558|Device|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
266507|NCT02170545|Other|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
266508|NCT02170532|Drug|levalbuterol|0.5 ml. levalbuterol
266509|NCT02170532|Drug|saline|0.5ml saline
266510|NCT02170532|Other|levalbuterol MDI|
266511|NCT02170532|Device|breath actuated nebulizer|
266512|NCT02170532|Device|aerochamber max|
266513|NCT02170532|Drug|ipratroprium|
266514|NCT02170519|Drug|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
266515|NCT02170506|Device|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
266516|NCT02170467|Other|assessment of the intestinal permeability|
266517|NCT02170454|Procedure|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
266518|NCT02170415|Drug|Protective analgesia|"Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.~For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day."
266519|NCT02170415|Other|Pain education|Participant will receive a pain education leaflet
266520|NCT02170415|Behavioral|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
266521|NCT02170415|Procedure|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
266522|NCT02170415|Other|Daily visits from pain team whilst in hospital|
266523|NCT02170402|Biological|Octocog alfa (recombinant human coagulation factor VIII)|"Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants~Part 2: On-demand treatment regimen~Part 3: Prophylaxis treatment regimen"
266524|NCT02170389|Other|Laboratory Biomarker Analysis|Correlative studies
266525|NCT02170389|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
266526|NCT02170389|Biological|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
266527|NCT02170376|Drug|BIA 9-1067|BIA 9-1067 25 mg and 50 mg
266528|NCT02170376|Drug|Entacapone|Entacapone (ENT), over-encapsulated tablet 200 mg
266529|NCT02170376|Drug|Placebo|PLC, placebo
266530|NCT02170376|Drug|Levodopa/carbidopa|Levodopa/carbidopa, tablet 100/25 mg
266531|NCT02170363|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
266532|NCT02170350|Procedure|Meditation therapy|Use brief mindful meditation practice
266533|NCT02170350|Other|Quality-of-life assessment|Ancillary studies
266534|NCT02170350|Other|Questionnaire administration|Ancillary studies
266535|NCT02170337|Drug|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
266536|NCT02170337|Drug|Placebo|Contains no active drug
266537|NCT02170324|Drug|Exenatide|
266538|NCT02170324|Drug|Placebo|
266539|NCT02170311|Drug|Z-213|
266540|NCT02170298|Drug|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
266541|NCT02170285|Device|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
266542|NCT02170285|Device|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
266543|NCT02170272|Behavioral|Home-based Lymphedema Care Program|Undergo HBLCP
266544|NCT02170259|Other|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
266545|NCT02170259|Other|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
266880|NCT02168010|Drug|Neurotropin|Analgesic drug as positive control
266546|NCT02170259|Other|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
266547|NCT02170246|Drug|Telmisartan|
266548|NCT02170220|Drug|Vortioxetine|Vortioxetine tablets
266549|NCT02170207|Drug|Lansoprazole|Lansoprazole 30 mg injection
266550|NCT02170194|Behavioral|Resilience Enhancement Training via Smart Phone|
266551|NCT02170194|Behavioral|Daily Text Messages|
266552|NCT02170181|Radiation|SBRT|SBRT to Oligometastases
266553|NCT02170168|Other|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
266554|NCT02170142|Device|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
266555|NCT02170129|Device|50% AAB plus 50% autologous bone|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.~Both groups received tapered implants with an anodised surface."
266556|NCT02170129|Device|100% AAB|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).~A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface."
266557|NCT02170116|Drug|BIBR 1048 MS dose 1|
266558|NCT02170116|Drug|BIBR 1048 MS dose 2|
266559|NCT02170116|Drug|BIBR 1048 MS dose 3|
266560|NCT02170116|Drug|BIBR 1048 MS dose 4|
266561|NCT02170116|Drug|BIBR 1048 MS dose 5|
266562|NCT02170116|Drug|Placebo to BIBR 1048 MS|
266563|NCT02170103|Procedure|percutaneous intervention (PCI)|
266564|NCT02170103|Drug|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
266565|NCT02170103|Procedure|Ultrasound|Intermittent high MI (Mechanical Index) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MHz;pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
266566|NCT02170090|Drug|Gemcitabine|Gemcitabine 1000mg/m2
266567|NCT02170090|Drug|Cisplatin|Cisplatin 25mg/m2
266568|NCT02170090|Drug|Capecitabine|Capecitabine 1250mg/m2
266569|NCT02170077|Drug|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
266570|NCT02170077|Drug|Placebo|Placebo tablets administered orally
266571|NCT02170064|Drug|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
266572|NCT02170051|Behavioral|CBSST-CCT|
266573|NCT02170051|Behavioral|Goal focused supportive contact|
266574|NCT02170038|Drug|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
266575|NCT02170038|Drug|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
266576|NCT02170025|Drug|Riociguat (Adempas, BAY63-2521)|Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
266577|NCT02170025|Drug|Placebo|Participants received matching placebo tid.
266578|NCT02170012|Drug|PF-06743649|20 mg tablet once daily dosing for 14 days
266579|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
266580|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
266581|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
266582|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
266583|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
266584|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
266585|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
266586|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
266587|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
266588|NCT02169999|Other|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
266589|NCT02169986|Behavioral|electronic reminders|
266881|NCT02168010|Drug|Placebo|Blank tablet as placebo.
266590|NCT02169973|Drug|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
266591|NCT02169973|Drug|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
266592|NCT02169960|Behavioral|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
266593|NCT02169960|Behavioral|Breaking Free|Online based intervention for Drug and Alcohol Use
266594|NCT02169960|Behavioral|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
266595|NCT02169960|Behavioral|Resiliency Training|Op Volle Kracht (OVK)
266596|NCT02169947|Behavioral|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
266597|NCT02169947|Behavioral|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
266598|NCT02169934|Drug|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
266599|NCT02169921|Device|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.~TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are participated in this arm."
266600|NCT02169908|Device|Thermotest|
266601|NCT02169908|Device|von Frey hairs|
266602|NCT02169895|Drug|BIA 9-1067|
266603|NCT02169895|Drug|Placebo|
266604|NCT02169895|Drug|Prolopa®|levodopa/benserazide 100/25 mg
266605|NCT02169882|Drug|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.~Patients receiving 1350 mg rifampicin will not receive any placebo tablet.~With this arrangement, every subject will receive 3 tablets of study drugs."
266606|NCT02169882|Drug|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.~Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
266607|NCT02169882|Drug|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.~Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
266608|NCT02169882|Drug|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
266609|NCT02169869|Device|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
266610|NCT02169869|Device|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
266611|NCT02169856|Behavioral|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
266612|NCT02169856|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
266613|NCT02169856|Drug|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
266614|NCT02169856|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
266615|NCT02169856|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
266616|NCT02169856|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
266617|NCT02169856|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
266618|NCT02169856|Drug|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
266619|NCT02169856|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
266620|NCT02169843|Drug|Sevoflurane|inhale Sevoflurane
266621|NCT02169843|Drug|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
266622|NCT02169843|Drug|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
266623|NCT02169830|Drug|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
266624|NCT02169830|Drug|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
266625|NCT02169817|Drug|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
266626|NCT02169817|Drug|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
266627|NCT02169804|Drug|Androxal 25 mg|
266628|NCT02169791|Drug|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
266629|NCT02169778|Behavioral|Intermittent energy restricted diet|
266630|NCT02169778|Behavioral|Continuous energy restricted diet|
266631|NCT02169765|Other|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
266632|NCT02169765|Other|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
266633|NCT02169752|Drug|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
266978|NCT02167204|Procedure|Computed Tomography|Undergo 18F-FLT PET/CT
266634|NCT02169739|Device|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
266635|NCT02169726|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
266636|NCT02169713|Drug|Mirabegron|Oral
266637|NCT02169713|Drug|Solifenacin succinate|Oral
266638|NCT02169713|Drug|Tamsulosin HCl|Oral
266639|NCT02169713|Drug|Placebo|Oral
266640|NCT02169700|Procedure|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
266641|NCT02169687|Device|HIFU|High Intensity focalized Ultrasounds
266642|NCT02169674|Biological|EngerixB, GlaxoSmithKline Vaccines|
266643|NCT02169661|Other|Burger and Beetroot Study|50% fat, 10% beetroot extract
266644|NCT02169648|Drug|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
266645|NCT02169635|Procedure|macular buckle|macular buckle with a three-armed silicone capsule
266646|NCT02169609|Drug|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.~Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
266647|NCT02169596|Drug|Ticagrelor|Blood tests taken for flow cytometry
266648|NCT02169596|Other|EndoPAT - endothelial assessment|
266649|NCT02169583|Drug|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
266650|NCT02169583|Drug|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
266651|NCT02169583|Drug|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
266652|NCT02169583|Drug|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
266653|NCT02169570|Dietary Supplement|Vitamin D|
266654|NCT02169570|Dietary Supplement|Calcium|
266655|NCT02169570|Dietary Supplement|Placebo Vit D|
266656|NCT02169570|Dietary Supplement|Placebo Calcium|
266657|NCT02169557|Drug|Fexinidazole|
266658|NCT02169544|Drug|Abatacept|
266659|NCT02169531|Drug|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
266660|NCT02169505|Drug|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
266661|NCT02169479|Drug|BIA 9-1067|OPC, Opicapone
266662|NCT02169479|Drug|Placebo|PLC, Placebo
266663|NCT02169479|Drug|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
266664|NCT02169466|Drug|BIA 9-1067|OPC, Opicapone
266665|NCT02169466|Drug|Placebo|PLC, Placebo
266666|NCT02169466|Drug|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
266667|NCT02169453|Drug|BIA 9-1067|OPC, Opicapone
266668|NCT02169453|Drug|Placebo|PLC, Placebo
266669|NCT02169453|Drug|Sinemet® CR 100/25|Controlled-release levodopa/carbidopa 100/25 mg
266670|NCT02169440|Drug|BIA 9-1067|BIA 9-1067 25 mg
266671|NCT02169440|Drug|Warfarin|Warfarin 25 mg
266672|NCT02169427|Drug|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
266673|NCT02169414|Drug|BIA 9-1067 5 mg|OPC, Opicapone
266674|NCT02169414|Drug|BIA 9-1067 25 mg|OPC, Opicapone
266675|NCT02169414|Drug|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
266676|NCT02169414|Drug|Placebo|PLC, Placebo
266677|NCT02169414|Drug|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
266678|NCT02169401|Device|Implantation with the commercially available Axium Neurostimulator|
266679|NCT02169388|Drug|Probiotic|Microbial composition using probiotic
266680|NCT02169388|Drug|placebo（for probiotic）|microbiota modulation using placebo
266681|NCT02169375|Other|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
266682|NCT02169362|Device|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
266683|NCT02169349|Other|laboratory biomarker analysis|
266684|NCT02169349|Other|Next Generation Sequencing|
266685|NCT02169349|Genetic|DNA Analysis|
266686|NCT02169336|Drug|Intranasal Dexmedetomidine|
266687|NCT02169336|Other|Intranasal Placebo|
266688|NCT02169323|Other|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
266979|NCT02167204|Radiation|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
266689|NCT02169297|Procedure|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter [maximum pump infusion rate]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
266690|NCT02169297|Procedure|PCA only|Patients received intravenous PCA post-operatively
266691|NCT02169284|Drug|Erlotinib Hydrochloride|Given PO
266692|NCT02169284|Other|Laboratory Biomarker Analysis|Correlative studies
266693|NCT02169284|Other|Pharmacological Study|Correlative studies
266694|NCT02169284|Other|Placebo|Given PO
266695|NCT02169284|Other|Quality-of-Life Assessment|Ancillary studies
266696|NCT02169284|Procedure|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
266697|NCT02169271|Drug|Aspirin|Given PO
266698|NCT02169271|Other|Laboratory Biomarker Analysis|Correlative studies
266699|NCT02169271|Other|Placebo|Given PO
266700|NCT02169258|Procedure|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis > 70% of the major epicardial vessels and bypass graft vessel or their major branches (> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
266701|NCT02169245|Other|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
266702|NCT02169232|Device|Videolaryngoscope|
266703|NCT02169232|Device|Fiberoptic|
266704|NCT02169219|Drug|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.~Prednisone will be tapered over 8 weeks as follows:~60mg for 2 weeks~40mg for 2 weeks~30mg for 1 week~20mg for 1 week~10mg for 1 week~5mg for 1 week"
266705|NCT02169219|Drug|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
266706|NCT02169206|Radiation|Bilateral shoulder anteroposterior radiography|"Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~In the same position, the patient only elevates the arm up to 90 degrees of abduction."
266707|NCT02169193|Radiation|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
266708|NCT02169180|Drug|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
266709|NCT02169167|Device|Resin salve treatment|Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
266710|NCT02169167|Device|Octenidine treatment|Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
266711|NCT02169154|Drug|1% Diclofenac Sodium|1% diclofenac sodium
266712|NCT02169154|Drug|3% Menthol|3% Menthol
266713|NCT02169154|Drug|0.09% Menthol|0.09% Menthol
266714|NCT02169154|Drug|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
266715|NCT02169154|Drug|0.9% Saline|0.9% Saline
266716|NCT02169141|Other|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
266717|NCT02169115|Drug|Omalizumab|150mg, s.c., every 4 weeks
266718|NCT02169115|Drug|Omalizumab|300mg, s.c., every 4 weeks
266719|NCT02169115|Drug|Placebo|Placebo, s.c., every 4 weeks
266720|NCT02169102|Other|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
266721|NCT02169102|Radiation|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
266722|NCT02169102|Radiation|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
266723|NCT02169102|Radiation|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
266795|NCT02168556|Behavioral|Video|Subject watches an informational video prior to undergoing urodynamic testing.
266796|NCT02168556|Other|Standard of care|Standard of care
266724|NCT02169089|Drug|Spironolactone|Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
266725|NCT02169089|Drug|Placebo|Placebo
266726|NCT02169076|Device|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
266727|NCT02169063|Radiation|carbon-11 acetate|Given IV
266728|NCT02169063|Radiation|fluorine F 18 sodium fluoride|Given IV
266729|NCT02169063|Procedure|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
266730|NCT02169063|Other|laboratory biomarker analysis|Correlative studies
266731|NCT02169037|Procedure|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
266732|NCT02169037|Procedure|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
266733|NCT02169024|Behavioral|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
266734|NCT02169011|Procedure|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
266735|NCT02169011|Procedure|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
266736|NCT02168998|Behavioral|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
266737|NCT02168985|Behavioral|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
266738|NCT02168972|Device|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
266739|NCT02168959|Drug|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
266740|NCT02168946|Drug|Vabomere|Vabomere for IV injection, administered as a 2 g/2 g dose
266741|NCT02168946|Drug|Best Available Therapy|Antibiotic(s) chosen by Investigator
266742|NCT02168933|Device|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
266743|NCT02168933|Device|Sham laser|Sham laser treatment to the control side biweekly for a total of 8 weeks.
266744|NCT02168920|Drug|2 mg/day|Once daily for 10 weeks
266745|NCT02168920|Drug|3 mg/day|Once daily for 10 weeks
266746|NCT02168920|Drug|6 mg/day|Once daily for 10 weeks
266747|NCT02168920|Drug|Placebo (0 mg/day)|Once daily for 10 weeks
266748|NCT02168907|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
266749|NCT02168907|Drug|bendamustine hydrochloride|Given IV
266750|NCT02168907|Biological|rituximab|Given IV
266751|NCT02168907|Other|laboratory biomarker analysis|Correlative studies
266752|NCT02168894|Procedure|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.~Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.~Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
266753|NCT02168894|Procedure|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
266754|NCT02168894|Behavioral|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
266755|NCT02168881|Drug|Misoprostol|
266756|NCT02168881|Drug|Dinoprostone|
266757|NCT02168855|Drug|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
266758|NCT02168855|Behavioral|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
266759|NCT02168842|Drug|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
266760|NCT02168842|Drug|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
266761|NCT02168829|Drug|Rivaroxaban|
266762|NCT02168829|Drug|Acetylsalicylic acid|
266797|NCT02168543|Drug|Alendronate|
266798|NCT02168543|Drug|Placebo|
266799|NCT02168530|Drug|placebo|matching placebo administered daily orally
266800|NCT02168530|Drug|vismodegib|vismodegib 150 mg administered daily orally
266980|NCT02167204|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET/CT
266763|NCT02168816|Drug|Intravenous Antibacterial Agent|Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
266764|NCT02168816|Drug|Oral Antibacterial Agent|Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
266765|NCT02168803|Drug|Evacetrapib|Administered orally
266766|NCT02168790|Device|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
266767|NCT02168777|Drug|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
266768|NCT02168777|Drug|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.~In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
266769|NCT02168764|Device|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
266770|NCT02168751|Drug|propofol|
266771|NCT02168751|Drug|Sevoflurane|
266772|NCT02168738|Drug|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
266773|NCT02168738|Drug|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
266774|NCT02168738|Drug|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.~The dose contains 50 mg 13C-DHA. The wash-out period is four months"
266775|NCT02168725|Drug|briciclib|
266776|NCT02168712|Other|Moderate continuous exercise training|
266777|NCT02168712|Other|Interval exercise training|
266778|NCT02168699|Other|Ultrasound examination of the axilla|
266779|NCT02168686|Genetic|ADVM-043|Gene transfer vector administration
266780|NCT02168660|Drug|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
266781|NCT02168647|Behavioral|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
266782|NCT02168647|Other|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
266783|NCT02168634|Drug|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
266784|NCT02168634|Drug|Placebo|1cc normal saline, local injection
266785|NCT02168621|Procedure|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
266786|NCT02168621|Procedure|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
266787|NCT02168608|Other|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
266788|NCT02168608|Other|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
266789|NCT02168595|Drug|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
266790|NCT02168595|Drug|Placebo|
266791|NCT02168582|Behavioral|physiotherapy as usual in primary care|
266792|NCT02168569|Drug|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to <15kg, two tablets per dose for those 15 to <25kg, and three tablets per dose for those 25 to <35kg.
266793|NCT02168569|Drug|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children <9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
266794|NCT02168556|Behavioral|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
266801|NCT02168491|Drug|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
266802|NCT02168491|Drug|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
266803|NCT02168478|Drug|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
266804|NCT02168478|Other|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
266805|NCT02168478|Other|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
266806|NCT02168465|Behavioral|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
266807|NCT02168452|Procedure|sentinel lymph node biopsy(SLNB)|"incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.~double check after removal of the sentinel lymph node~sending frozen biopsy"
266808|NCT02168439|Drug|Dexmedetomidine|
266809|NCT02168439|Drug|Midazolam|
266810|NCT02168426|Procedure|Guardix|Applying 6g of guardix during abdominal surgery
266811|NCT02168426|Procedure|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
266812|NCT02168400|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS will be performed with Neuroelectrics Starstim Enobio 20, an approved research device without an investigational device exemption due to meeting criteria for non-significant risk. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
266813|NCT02168387|Device|continuous high frequency oscillator (CHFO)|
266814|NCT02168387|Drug|Acetylcysteine|
266815|NCT02168387|Drug|dornase alfa|
266816|NCT02168374|Other|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
266817|NCT02168361|Drug|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
266818|NCT02168361|Drug|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
266819|NCT02168361|Drug|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
266820|NCT02168361|Drug|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
266821|NCT02168348|Other|biological examination at consultations at 3 and 6 months|
266822|NCT02168335|Other|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
266823|NCT02168335|Other|Sea salt|Unmedicated sea salt
266824|NCT02168322|Device|collagen membrane|bovine collagen membrane used for selective tissue regeneration
266825|NCT02168322|Device|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
266826|NCT02168309|Drug|Labetalol|Titrate up for blood pressure control
266827|NCT02168309|Drug|Nifedipine|Titrate up to achieve blood pressure control
266828|NCT02168296|Dietary Supplement|Plant-based ingredient added to starchy meal|
266829|NCT02168296|Dietary Supplement|Plant-based ingredient added to liquid|
266830|NCT02168296|Dietary Supplement|No Plant-based ingredient|
266831|NCT02168283|Combination Product|treatment arm|Hypertonic peritoneal dialysis cycles
266832|NCT02168283|Behavioral|Control arm|Dietary counseling
266833|NCT02168270|Dietary Supplement|ascorbic acid|Given IV
266834|NCT02168270|Drug|temozolomide|Given PO
266835|NCT02168270|Other|quality-of-life assessment|Ancillary studies
266836|NCT02168270|Other|laboratory biomarker analysis|Correlative studies
266837|NCT02168257|Device|RAM Cannula|
266838|NCT02168257|Device|Binasal Prong CPAP|
266839|NCT02168244|Other|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
266840|NCT02168244|Other|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
266841|NCT02168231|Procedure|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
266842|NCT02168218|Other|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
266843|NCT02168205|Drug|Pomalidomide|Capsules
266844|NCT02168205|Other|Caffeine|Capsules
266845|NCT02168205|Other|Tobacco|Cigarettes
266846|NCT02168192|Behavioral|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
266847|NCT02168192|Behavioral|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
266848|NCT02168179|Procedure|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
266849|NCT02168179|Other|questionnaire administration|Ancillary studies
266850|NCT02168166|Behavioral|Executive Function Training|
266851|NCT02168166|Behavioral|Placebo|Placebo version of executive function training
266852|NCT02168153|Other|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
266853|NCT02168153|Other|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
266854|NCT02168140|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
266855|NCT02168140|Drug|bendamustine hydrochloride|Given IV
266856|NCT02168127|Drug|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
266857|NCT02168127|Drug|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
266858|NCT02168114|Other|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
266859|NCT02168114|Procedure|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
266860|NCT02168101|Drug|MLN9708|"Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy.~Cohort 1: 2.3mg single weekly dose~Cohort 2: 3mg single weekly dose~Cohort 3: 4mg single weekly dose~Expansion Phase: An additional 20 patients will receive MLN9708 at the MTD"
266861|NCT02168075|Drug|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
266862|NCT02168075|Drug|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
266863|NCT02168075|Drug|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
266864|NCT02168075|Drug|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
266865|NCT02168062|Behavioral|Behavioral Dietary Intervention|Receive individualized nutrition counseling
266866|NCT02168062|Other|Counseling|Receive individualized symptom management service counseling
266867|NCT02168062|Other|Educational Intervention|Review educational modules
266868|NCT02168062|Behavioral|Exercise Intervention|Receive individualized exercise counseling
266869|NCT02168062|Drug|Goserelin Acetate|Given SC
266870|NCT02168062|Other|Laboratory Biomarker Analysis|Correlative studies
266871|NCT02168062|Drug|Leuprolide Acetate|Given SC or IM
266872|NCT02168062|Other|Quality-of-Life Assessment|Ancillary studies
266873|NCT02168062|Drug|Triptorelin Pamoate|Given IM
266874|NCT02168049|Device|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
266875|NCT02168049|Device|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
266876|NCT02168049|Device|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
266877|NCT02168023|Device|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
266878|NCT02168023|Device|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
266879|NCT02168010|Drug|Analgecine|Analgesic drug under test
266882|NCT02167971|Other|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
266883|NCT02167971|Other|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
266884|NCT02167958|Drug|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).~For decreased creatinine clearance (< 61 mL/min) determined by the Cockcroft Formula:~Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr)~Fludarabine dosage should be reduced per standard of care."
266885|NCT02167958|Drug|Cyclophosphamide|"Pre-transplant~Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW~Post-transplant~Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.~Cyclophosphamide [50mg/kg] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours.~."
266886|NCT02167958|Drug|Mesna|"Pre-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.~Post-transplant~Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
266887|NCT02167958|Radiation|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
266888|NCT02167958|Other|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
266889|NCT02167958|Drug|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
266890|NCT02167958|Drug|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
266891|NCT02167958|Drug|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is > 1,000/mm3 for three consecutive days.
266892|NCT02167945|Drug|ABT-450/r/ABT-267|tablet
266893|NCT02167945|Drug|ABT-333|tablet
266894|NCT02167945|Drug|Ribavirin (RBV)|tablet
266895|NCT02167932|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
266896|NCT02167919|Device|Microspheres|Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
266897|NCT02167906|Other|arterial stiffness measurement|
266898|NCT02167893|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
266899|NCT02167867|Device|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
266900|NCT02167867|Device|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
266901|NCT02167854|Drug|BYL719|
266902|NCT02167854|Drug|LJM716|
266903|NCT02167854|Drug|TRASTUZUMAB|
266904|NCT02167841|Behavioral|Knee-Chest Position|
266905|NCT02167828|Behavioral|Social Support|
266906|NCT02167815|Device|Mepilex XT|Experimental arm
266907|NCT02167815|Other|standard care|
266908|NCT02167789|Device|Paradym CRT 8770|
266981|NCT02167191|Behavioral|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
267020|NCT02166892|Other|Specially designed plates|
266909|NCT02167776|Behavioral|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
266910|NCT02167763|Device|VeraCept Intrauterine Copper Contraceptive|
266911|NCT02167763|Device|TCu380 IUD|
266912|NCT02167750|Other|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
266913|NCT02167737|Behavioral|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.~Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
266914|NCT02167737|Behavioral|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.~Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
266915|NCT02167724|Other|Bucco-dental examination|
266916|NCT02167724|Other|Blood sample|
266917|NCT02167724|Other|Clinical and social questionnaire|
266918|NCT02167711|Drug|SIRT Yttrium-90|
266919|NCT02167698|Device|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
266920|NCT02167698|Other|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
266921|NCT02167698|Drug|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
266922|NCT02167698|Other|Restrictive fluid therapy|Fluid & hemodynamics would be titrated as per pre-designed decision-making protocols
266923|NCT02167698|Drug|sedo-analgesia titration|
266924|NCT02167698|Other|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
266925|NCT02167698|Other|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care & bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
266926|NCT02167698|Other|Biomarker Assay|Biomarker Assay for patients in both arms
266927|NCT02167685|Drug|CMX001|
266928|NCT02167659|Device|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and <10% above pre-surgical baseline.
266929|NCT02167646|Procedure|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
266930|NCT02167633|Procedure|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
266931|NCT02167633|Radiation|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
266932|NCT02167633|Radiation|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.~Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
266933|NCT02167633|Drug|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
266934|NCT02167633|Drug|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
266935|NCT02167620|Drug|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
266936|NCT02167620|Drug|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
266937|NCT02167607|Dietary Supplement|Active Comparator|Purple Potato
266938|NCT02167607|Dietary Supplement|Placebo Comparator|Placebo Comparator
266939|NCT02167594|Drug|18F-AV-1451|
266940|NCT02167594|Drug|florbetapir F18|
266941|NCT02167568|Genetic|Genetic|
266942|NCT02167555|Dietary Supplement|Active Comparator|Wild Blueberry Beverage
266943|NCT02167555|Dietary Supplement|Placebo Comparator|Placebo Beverage
266976|NCT02167230|Procedure|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
267019|NCT02166905|Drug|Poly ICLC|Given SC
266944|NCT02167542|Device|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
266945|NCT02167542|Device|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.~Oxygen flow will be titrated by the investigator to ensure SpO2>92%."
266946|NCT02167516|Drug|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
266947|NCT02167516|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
266948|NCT02167490|Procedure|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
266949|NCT02167477|Device|Macintosh laryngoscopy|Tracheal intubation
266950|NCT02167477|Device|Storz C-MAC, standard blade|Tracheal intubation
266951|NCT02167477|Device|Storz C-MAC, D-BLADE|Tracheal intubation
266952|NCT02167464|Drug|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
266953|NCT02167464|Other|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
266954|NCT02167464|Drug|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
266955|NCT02167451|Drug|Maraviroc|
266956|NCT02167438|Device|Hem-Avert Perianal Stabilizer|
266957|NCT02167425|Other|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
266958|NCT02167386|Behavioral|Enhanced PrEP Adherence|
266959|NCT02167386|Behavioral|Standard PrEP Adherence|
266960|NCT02167373|Other|Cogito Companion Intervention|
266961|NCT02167373|Device|mobile phone application|
266962|NCT02167360|Drug|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
266963|NCT02167347|Behavioral|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
266964|NCT02167334|Device|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
266965|NCT02167334|Procedure|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
266966|NCT02167321|Drug|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
266967|NCT02167321|Drug|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
266968|NCT02167308|Device|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
266969|NCT02167269|Device|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
266970|NCT02167256|Drug|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
266971|NCT02167256|Drug|AZD0530 125mg daily|Patients with plasma drug level <100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
266972|NCT02167256|Drug|Placebo|50% of patients will receive placebo treatment for the duration of the study.
266973|NCT02167243|Behavioral|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
266974|NCT02167243|Other|Standard of care|Subjects receive standard of care
266975|NCT02167230|Procedure|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
266977|NCT02167217|Drug|Prednisolone|Prednisolone (5mg per kg) will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
266982|NCT02167178|Other|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
266983|NCT02167178|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
266984|NCT02167178|Other|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
266985|NCT02167178|Other|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
266986|NCT02167165|Drug|Digoxin|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
266987|NCT02167152|Other|Ischemic preconditionin|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
266988|NCT02167139|Drug|Humira (adalimumab)|
266989|NCT02167139|Drug|SB5 (proposed biosimilar to adalimumab)|
266990|NCT02167126|Device|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
266991|NCT02167126|Device|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
266992|NCT02167087|Procedure|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
266993|NCT02167074|Device|25G FNA needle|
266994|NCT02167074|Device|20G ProCore FNB needle|
266995|NCT02167061|Drug|DA-1229_01|complex single administration
266996|NCT02167061|Drug|E+M|co-administration of 2 drugs
266997|NCT02167061|Drug|DA-1229_01 fast|
266998|NCT02167061|Drug|DA-1229_01 fed|
266999|NCT02167048|Drug|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
267000|NCT02167035|Drug|Combigan Two Times Daily (BID)|
267001|NCT02167035|Drug|Simbrinza Three Times Daily (TID)|
267002|NCT02167022|Other|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
267003|NCT02167009|Device|Embosphere Microspheres|Embosphere Microspheres are indicated for use in embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
267004|NCT02166996|Procedure|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
267005|NCT02166996|Procedure|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
267006|NCT02166983|Other|computer-assisted cognitive training|Complete Lumosity cognitive exercises
267007|NCT02166983|Other|cognitive intervention|Complete Active Journaling cognitive exercises
267008|NCT02166983|Procedure|mind-body intervention procedure|Complete relaxation exercises
267009|NCT02166983|Other|memory intervention|Complete compensatory strategies
267010|NCT02166983|Other|questionnaire administration|Ancillary studies
267011|NCT02166970|Device|Metallic stent deployment in hilar obstruction|Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
267012|NCT02166957|Procedure|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.~The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.~The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
267013|NCT02166944|Drug|tamoxifen 40 mg daily for one year|both arms with riluzole daily
267014|NCT02166931|Dietary Supplement|Chicken Essence|BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
267015|NCT02166905|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
267016|NCT02166905|Drug|Epacadostat|Given PO
267017|NCT02166905|Other|Laboratory Biomarker Analysis|Correlative studies
267018|NCT02166905|Other|Pharmacological Study|Correlative studies
267021|NCT02166879|Behavioral|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
267022|NCT02166866|Other|Quality of Life Questionairre and Education|
267023|NCT02166853|Drug|sevoflurane|Sedation with inhaled sevoflurane
267024|NCT02166853|Drug|midazolam|Sedation with intravenous midazolam
267025|NCT02166840|Procedure|Plastic stent (7-10Fr)|
267026|NCT02166840|Procedure|Self Expanding Metal Stent|
267027|NCT02166827|Device|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
267028|NCT02166827|Device|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
267029|NCT02166814|Drug|Fimasartan and Rosuvastatin|
267030|NCT02166814|Drug|Fimasartan|
267031|NCT02166814|Drug|Rosuvastatin|
267032|NCT02166801|Behavioral|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand & Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
267033|NCT02166801|Behavioral|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
267034|NCT02166788|Procedure|Inguinal Lymphadenectomy|
267035|NCT02166788|Procedure|Ilio-inguinal Lymphadenectomy|
267036|NCT02166762|Procedure|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
267037|NCT02166749|Procedure|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
267038|NCT02166736|Device|iFR|Treatment guided by Instantaneous wave-free ratio (iFR®)
267039|NCT02166736|Device|FFR|Intervention guided by Fractional Flow Reserve
267040|NCT02166723|Device|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
267041|NCT02166723|Device|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
267042|NCT02166710|Device|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
267043|NCT02166710|Device|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
267044|NCT02166697|Drug|candesartan cilexetil|candesartan cilexetil tablets
267045|NCT02166684|Device|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject~Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.~Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks~Subjects use Medisana BS 440 BT scale daily~In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.~Subjects self-measure fasting blood glucose twice per week for 13 weeks.~Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
267046|NCT02166671|Biological|HBV booster vaccination 1dose|
267091|NCT02166333|Dietary Supplement|200 IU/d cholecalciferol|
267047|NCT02166658|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
267048|NCT02166645|Other|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
267049|NCT02166645|Other|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
267050|NCT02166632|Procedure|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
267051|NCT02166632|Procedure|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
267052|NCT02166619|Device|tDCS + physical therapy|"Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.~Other: Physical Therapy"
267053|NCT02166606|Device|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
267054|NCT02166593|Drug|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
267055|NCT02166593|Drug|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
267056|NCT02166567|Procedure|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
267057|NCT02166567|Procedure|Swim-up|Semen processing will be carried out with the conventional swim-up method.
267058|NCT02166554|Other|Saline|On the day of initial surgery
267059|NCT02166554|Device|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
267060|NCT02166541|Procedure|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
267061|NCT02166541|Procedure|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
267062|NCT02166541|Procedure|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
267063|NCT02166489|Biological|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
267064|NCT02166476|Drug|Meropenem-Vaborbactam|Meropenem-vaborbactam
267065|NCT02166476|Drug|Piperacillin-Tazobactam|Piperacillin-tazobactam
267066|NCT02166476|Drug|Levofloxacin|Levofloxacin
267067|NCT02166476|Drug|Saline|Saline
267068|NCT02166463|Biological|Bleomycin Sulfate|Given IV or SC
267069|NCT02166463|Drug|Brentuximab Vedotin|Given IV
267070|NCT02166463|Drug|Cyclophosphamide|Given IV
267071|NCT02166463|Drug|Doxorubicin Hydrochloride|Given IV
267072|NCT02166463|Drug|Etoposide|Given IV
267073|NCT02166463|Other|Laboratory Biomarker Analysis|Correlative studies
267074|NCT02166463|Other|Pharmacological Study|Correlative studies
267075|NCT02166463|Drug|Prednisone|Given PO
267076|NCT02166463|Other|Quality-of-Life Assessment|Ancillary studies
267077|NCT02166463|Other|Questionnaire Administration|Ancillary studies
267078|NCT02166463|Drug|Vincristine Sulfate|Given IV
267079|NCT02166450|Drug|Nystatin|100 000 IU every 6 h as a suspension
267080|NCT02166424|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
267081|NCT02166424|Dietary Supplement|Olive oil|
267082|NCT02166411|Procedure|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
267083|NCT02166411|Procedure|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
267084|NCT02166398|Drug|UI15AML055MT|tab, PO
267085|NCT02166398|Drug|Amosartan 5/50|tab, PO
267086|NCT02166372|Other|Observation of natural course of Diabetes Mellitus Type 2|
267087|NCT02166359|Drug|Extraneal (Icodextrin)|
267088|NCT02166359|Drug|Glucose solution|
267089|NCT02166346|Drug|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
267090|NCT02166346|Drug|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
267092|NCT02166333|Dietary Supplement|1000 IU/d cholecalciferol|
267093|NCT02166333|Dietary Supplement|2000 IU/d cholecalciferol|
267094|NCT02166333|Dietary Supplement|4000 IU/d cholecalciferol|
267095|NCT02166320|Device|Partially covered SEMS|
267096|NCT02166320|Device|Fully covered SEMS|
267097|NCT02166294|Other|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
267098|NCT02166294|Procedure|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
267099|NCT02166268|Drug|AVANZ Phleum pratense 15,000 SQ+|
267100|NCT02166268|Drug|Placebo|
267101|NCT02166255|Biological|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
267102|NCT02166255|Other|laboratory biomarker analysis|Correlative studies
267103|NCT02166242|Drug|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
267104|NCT02166229|Drug|Divalproex sodium|
267105|NCT02166190|Procedure|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
267106|NCT02166190|Procedure|Stenting only|Stenting only
267107|NCT02166177|Drug|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
267108|NCT02166164|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
267109|NCT02166164|Other|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
267110|NCT02166164|Other|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.~4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
267111|NCT02166151|Drug|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
267112|NCT02166138|Procedure|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
267113|NCT02166125|Procedure|Endosuturing|Endoscopic suturing
267114|NCT02166112|Procedure|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
267115|NCT02166099|Procedure|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
267116|NCT02166086|Procedure|Endoscopy|Endoscopy involving advanced imaging techniques
267117|NCT02166060|Drug|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
267118|NCT02166047|Drug|GS-9620|GS-9620 tablets administered orally every 7 days
267119|NCT02166047|Drug|Placebo to match GS-9620|Placebo to match GS-9620 tablets administered orally every 7 days
267120|NCT02166034|Behavioral|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
267121|NCT02166021|Biological|Mesenchymal stem cells|A culture of purified MSCs was prepared under aseptic conditions, and cultured for 4 weeks, until they reached confluency, and were then harvested. After sterility was confirmed, the cells resuspended in normal saline at a concentration of 10 × 106/mL to 15 × 106/mL.
267122|NCT02166008|Drug|Repamipide|
267123|NCT02166008|Drug|Placebo|
267124|NCT02165995|Procedure|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
267125|NCT02165995|Procedure|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
267126|NCT02165969|Procedure|endoscopic endonasal surgery with UPSIT|
267127|NCT02165956|Dietary Supplement|New Infant Cereal|New Infant Cereal
267128|NCT02165956|Dietary Supplement|Standard Infant Cereal|Standard Infant Cereal
267129|NCT02165943|Device|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
267130|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
267131|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
267132|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
267133|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
267255|NCT02164916|Drug|irinotecan hydrochloride|Given IV
267134|NCT02165917|Procedure|Excision plus hyaluronic acid gel|Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
267135|NCT02165917|Procedure|Excision only|Excision of endometriosis foci by laparoscopic standard methods only.
267136|NCT02165904|Biological|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
267137|NCT02165891|Drug|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
267138|NCT02165891|Procedure|primary video-assisted thorascopic surgery|
267139|NCT02165865|Procedure|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
267140|NCT02165852|Procedure|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
267141|NCT02165852|Procedure|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
267142|NCT02165839|Behavioral|Brief Behavioral Therapy for Insomnia (BBT-I)|
267143|NCT02165839|Behavioral|Healthy Eating Education Learning (HEAL)|
267144|NCT02165826|Drug|Roflumilast|Roflumilast tablets
267145|NCT02165826|Drug|Roflumilast Placebo|Roflumilast placebo-matching tablets
267146|NCT02165826|Drug|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
267147|NCT02165813|Drug|Nitazoxanide|
267148|NCT02165813|Drug|Placebo|
267149|NCT02165800|Procedure|L-PANP-TME|
267150|NCT02165800|Procedure|O-PANP-TME|
267151|NCT02165774|Device|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
267152|NCT02165774|Device|Turning ON the neuromodulator|
267153|NCT02165761|Device|GORE® Hybrid Vascular Graft|
267154|NCT02165761|Device|Non-heparin bonded synthetic graft|
267155|NCT02165735|Behavioral|patient activation training|Patient activation training involves six, 90-minute, group (8-12 person) training sessions facilitated by trained peers and training staff and one (20-30 minute) pre-visit coaching session conducted by staff. The hands on group training includes: 1) HIV education; 2) use of a handheld smart device; 3) use of an HIV electronic personal health record app that runs on the smart device; 4) identification of patients' visit need priorities and skills for communicating with their HIV provider. The pre-visit coaching includes identification of patient concerns and patient behavioral rehearsal for asking about these concerns.
267156|NCT02165735|Other|Usual care|Usual HIV care
267157|NCT02165722|Behavioral|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit [chronic and acute] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
267158|NCT02165709|Procedure|Salpingectomy|
267159|NCT02165709|Procedure|Traditional sterilization|
267160|NCT02165696|Other|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
267161|NCT02165696|Other|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
267162|NCT02165670|Device|Coronary stenting with CE-marked stent|
267163|NCT02165657|Device|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
267164|NCT02165644|Drug|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.~If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
267165|NCT02165644|Drug|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
267166|NCT02165618|Other|Medication review, based on but not limited to the RASP list|"Systematic approach:~Medication reconciliation~Applying the RASP list~Expert review (not based on the RASP list)~Multidisciplinary discussion"
267167|NCT02165605|Drug|HylaCare|cream
267168|NCT02165605|Drug|Placebo|placebo
267169|NCT02165579|Other|1 cohort, standard care, observational|This is one cohort standard care observational study. 40 diabetic patients admitted to Parkland hospital with a foot infection. We will enroll a representative cross section of subjects with diabetic foot infection. Patient will be consented and will receive therapy based on standard protocols. Currently patients with suspected osteomyelitis have bone biopsies to identify bacterial pathogens and verify MRI diagnosis. Repeat bone biopsies are performed at the end of therapy to verify that osteomyelitis has been successfully treated. Serum to measure procalcitonin will be obtained at baseline, week 3 and week 6. Tissue samples will be obtained at Baseline, Week 3 and Week 6 for tissue culture.
267170|NCT02165566|Drug|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
267171|NCT02165566|Drug|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
267172|NCT02165553|Dietary Supplement|Hibiscus sabdariffa calyces extract as a cold drink|
267173|NCT02165540|Other|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
267174|NCT02165527|Procedure|Lunar iXDA scan|Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
267175|NCT02165514|Procedure|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
267176|NCT02165475|Behavioral|Biofeedback|
267177|NCT02165475|Drug|Loperamide|
267178|NCT02165475|Drug|Stool bulking agent (stericulia or isphagula husk)|
267179|NCT02165475|Other|Combination of biofeedback and medical treatment|
267180|NCT02165462|Other|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
267181|NCT02165449|Drug|Ketamine|Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
267182|NCT02165436|Other|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
267183|NCT02165436|Other|Control|No intervention will be assessed for this group.
267184|NCT02165423|Behavioral|myFAMI iPad application|
267185|NCT02165410|Procedure|ASL-MRI|ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
267186|NCT02165410|Procedure|Diffusion tensor imaging (diffusion MRI)|Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
267187|NCT02165410|Procedure|Eye-tracking|Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
267188|NCT02165410|Procedure|Cognitive profile|Children will be asked to perform certain tasks, adapted for their age.
267189|NCT02165397|Drug|Ibrutinib|Subjects will receive 420 mg of Ibrutinib orally. Other Name: PCI-32765
267190|NCT02165397|Drug|Placebo|Subjects will receive placebo capsules orally.
267191|NCT02165397|Drug|Rituximab|Drug: rituximab Subjects will receive rituximab 375mg/m2 intravenously Other Name: Rituxan
267192|NCT02165384|Device|Ear tube placement with the Hummingbird TTS|Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
267193|NCT02165371|Behavioral|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
267194|NCT02165345|Drug|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (>=) 30 kg: every 2 weeks; sJIA participants <30 kg: every 2 weeks; sJIA participants >/= 30 kg: once weekly
267195|NCT02165332|Drug|Part 1: SAD RO7033877|Single dose
267196|NCT02165332|Drug|Part 1: SAD placebo|Single dose
267197|NCT02165332|Drug|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
267198|NCT02165332|Drug|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
267199|NCT02165332|Drug|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
267200|NCT02165332|Drug|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
267201|NCT02165319|Device|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
267202|NCT02165319|Device|Tapered|Tapered-shaped tube will be used during general anesthesia.
267203|NCT02165306|Behavioral|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.~Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.~Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
267204|NCT02165306|Behavioral|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
267256|NCT02164916|Drug|vemurafenib|Given PO
267205|NCT02165293|Drug|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
267206|NCT02165280|Behavioral|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
267207|NCT02165267|Biological|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
267208|NCT02165267|Biological|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
267209|NCT02165267|Biological|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
267210|NCT02165254|Behavioral|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
267211|NCT02165254|Behavioral|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
267212|NCT02165228|Behavioral|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
267213|NCT02165228|Behavioral|Nutrition Enhancement|Nutrition education class and behavioral intervention
267214|NCT02165215|Drug|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
267215|NCT02165215|Drug|Placebo|Participants will receive placebo (matched to etrolizumab) SC injection Q4W.
267216|NCT02165202|Drug|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
267217|NCT02165202|Drug|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
267218|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
267219|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
267220|NCT02165189|Drug|Ribavirin|Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram ([kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
267221|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
267222|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
267223|NCT02165176|Drug|Oral cannabis|
267224|NCT02165163|Other|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
267225|NCT02165150|Other|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
267226|NCT02165124|Device|Artificial Embolization Device|Embosphere Microspheres
267227|NCT02165111|Drug|Onabotulinumtoxin A|
267228|NCT02165111|Drug|sterile saline solution|
267229|NCT02165098|Drug|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
267230|NCT02165098|Drug|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
267231|NCT02165098|Drug|Cariprazine capsule|Cariprazine capsule - fasted
267232|NCT02165098|Drug|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
267233|NCT02165098|Drug|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
267234|NCT02165046|Drug|Budesonide|
267235|NCT02165046|Drug|Procaterol|
267236|NCT02165033|Drug|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
267237|NCT02165020|Device|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
267238|NCT02165007|Drug|peripheral blood stem cell graft that are CD34+ selected|Before transplant patients will undergo reduced intensity preparatory regimen consisting of Hydroxyurea, ATG, Fludarabine, Thiotepa, Melphalan. Hydroxyurea will be given at Day -50 to -10, rabbit ATG day -9 to -7 (test dose ATG on day -10), Fludarabine day -8 to -4, Thiotepa Day -4, Melphalan day -3, -2, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year
267239|NCT02164981|Drug|sodium nitroprusside|intravenous
267240|NCT02164981|Other|Placebo|Placebo
267241|NCT02164955|Drug|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
267242|NCT02164929|Procedure|TAP block|
267243|NCT02164929|Procedure|Epidural|
267244|NCT02164929|Procedure|Paravertebral block|
267245|NCT02164929|Drug|Acetaminophen 1g IV|
267246|NCT02164929|Drug|Dexamethasone 4mg|
267247|NCT02164929|Drug|Midazolam up to 2mg|
267248|NCT02164929|Drug|Propofol 1-2.5 mg/kg|
267249|NCT02164929|Drug|Sevoflurane to keep a bispectral index of between 40-60|
267250|NCT02164929|Drug|Local infiltration with 10 mL of plain ropivacaine 0.25%|
267251|NCT02164929|Drug|Lidocaine|1.5% lidocaine
267252|NCT02164929|Drug|Epinephrine|1:200,000 epinephrine
267253|NCT02164929|Drug|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
267254|NCT02164916|Biological|cetuximab|Given IV
267257|NCT02164903|Other|QoL Survey Booklet|
267258|NCT02164890|Other|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
267259|NCT02164877|Drug|pectin|Patients allocated to experiment group will receive 15g pectin each day
267260|NCT02164864|Drug|Dabigatran Etexilate 110mg|Active treatment
267261|NCT02164864|Drug|Warfarin 3mg|Active comparator
267262|NCT02164864|Drug|Aspirin|Active comparator
267263|NCT02164864|Drug|Dabigatran Etexilate 150mg|Active treatment
267264|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
267265|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
267266|NCT02164864|Drug|Warfarin 5mg|Active comparator
267267|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
267268|NCT02164864|Drug|Warfarin 1mg|Active comparator
267269|NCT02164838|Drug|Axitinib|
267270|NCT02164825|Drug|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
267271|NCT02164825|Drug|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
267272|NCT02164812|Drug|Moxifloxacin|
267273|NCT02164812|Drug|Placebo|
267274|NCT02164812|Drug|Efavirenz|
267275|NCT02164773|Drug|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
267276|NCT02164773|Drug|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
267277|NCT02164760|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
267278|NCT02164747|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
267279|NCT02164734|Device|Endotracheal intubation|
267280|NCT02164734|Device|Laryngeal mask airway|
267281|NCT02164734|Drug|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
267282|NCT02164721|Device|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
267283|NCT02164708|Behavioral|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
267284|NCT02164695|Procedure|PPCI plus RIPC|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
267285|NCT02164695|Procedure|PPCI only|All patients randomized to PPCI only arm, the blood pressure cuff will be applied to the arm or the calf but will not be inflated.
267286|NCT02164682|Procedure|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
267287|NCT02164682|Procedure|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
267288|NCT02164656|Behavioral|mindfulness for smokers|
267289|NCT02164643|Drug|Flutemetamol (18F)|
267290|NCT02164643|Drug|Florbetapir (18F)|
267291|NCT02164630|Behavioral|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
267292|NCT02164630|Other|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
267293|NCT02164617|Other|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
267294|NCT02164604|Drug|intravitreal injection of 0.03ml ranibizumab|
267295|NCT02164578|Drug|Rivaroxaban|
267296|NCT02164578|Drug|Aspirin|
267297|NCT02164565|Drug|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
267298|NCT02164565|Drug|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
267299|NCT02164552|Dietary Supplement|Vitamin D3 pills|Dietary supplement
267300|NCT02164552|Other|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
267301|NCT02164539|Drug|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
267302|NCT02164539|Drug|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
267303|NCT02164539|Drug|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
267304|NCT02164526|Other|Routine therapy|Routine therapy
267305|NCT02164513|Drug|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
267306|NCT02164513|Drug|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
267307|NCT02164513|Drug|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
267308|NCT02164500|Drug|Ruxolitinib|
267309|NCT02164474|Behavioral|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at ~85-90% peak oxygen uptake [VO2peak] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at ~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
267310|NCT02164461|Biological|ADXS11-001|
267311|NCT02164448|Drug|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
267312|NCT02164448|Drug|the control group|saline infusion from induction of anesthesia to end of surgery
267313|NCT02164435|Procedure|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
267314|NCT02164422|Drug|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
267315|NCT02164422|Drug|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
267316|NCT02164422|Drug|Placebo|
267317|NCT02164409|Procedure|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
267318|NCT02164396|Device|Spectacle Lens|Spectacle Lens Only
267319|NCT02164396|Device|Habitual Soft Contact Lens|subject's own contact lens
267320|NCT02164396|Device|Test Lens|senofilcon A or narafilcon A
267321|NCT02164383|Drug|Nicotine patch|4-week starter kit of nicotine patch
267322|NCT02164383|Behavioral|Cessation Counseling|5 brief counseling sessions
267323|NCT02164383|Device|Mobile Games|
267324|NCT02164357|Procedure|EVT (endovascular treatment )|
267325|NCT02164357|Procedure|IVT (intravenous thrombolytic therapy)|
267326|NCT02164344|Dietary Supplement|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
267327|NCT02164331|Behavioral|JNC guideline training|Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
267328|NCT02164318|Other|Handgrip training|
267329|NCT02164318|Drug|Nitroglycerin ointment|
267330|NCT02164305|Other|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
267331|NCT02164305|Other|Neuromuscular group|Closed-chain exercise for shoulder muscles
267332|NCT02164305|Other|Control|No exercise training
267333|NCT02164292|Procedure|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
267334|NCT02164279|Other|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( < or > than 100mg/L)
267335|NCT02164266|Drug|Placebo|Matching placebo daily oral administration
267336|NCT02164266|Drug|RO6799477|Daily oral administration of RO6799477
267337|NCT02164253|Drug|Deferiprone|30 mg/kg per day, oral use
267338|NCT02164240|Drug|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
267339|NCT02164240|Drug|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
267340|NCT02164227|Other|Respiratory pattern|
267341|NCT02164214|Drug|etanercept Treatment|
267342|NCT02164188|Behavioral|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
267343|NCT02164175|Device|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
267344|NCT02164162|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
267390|NCT02163811|Behavioral|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.~VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
267641|NCT02162121|Procedure|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS>4
267345|NCT02164162|Other|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
267346|NCT02164149|Other|Patients with primary colon cancer|CT scan two days after surgery
267347|NCT02164136|Procedure|L-PANP-TME|
267348|NCT02164136|Procedure|O-PANP-TME|
267349|NCT02164123|Other|Spinal mobilization|Experimental group
267350|NCT02164123|Other|Spinal Mobilization II|Active comparator group
267351|NCT02164123|Other|Placebo|Placebo group
267352|NCT02164110|Biological|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
267353|NCT02164110|Biological|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2~Method of administration: oral administration~Dose of drug to be administered: 1.5 mL/dose"
267354|NCT02164097|Drug|ODSH|
267355|NCT02164084|Drug|SB204|SB204 Gel with hydrogel
267356|NCT02164084|Drug|Vehicle Gel|Vehicle Gel with hydrogel
267357|NCT02164071|Other|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
267358|NCT02164058|Device|TandemHeart System|
267359|NCT02164058|Procedure|Percutaneous coronary intervention|
267360|NCT02164045|Drug|BMS-663068|BMS-663068
267361|NCT02164032|Drug|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
267362|NCT02164032|Drug|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
267363|NCT02164032|Other|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
267364|NCT02164019|Procedure|long-stem cemented hemiarthroplasty (LSCH)|
267365|NCT02164019|Procedure|intramedullary nailing (IMN)|
267366|NCT02164019|Behavioral|questionnaires|
267367|NCT02164006|Drug|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
267368|NCT02163993|Drug|Galcanezumab|Administered SQ
267369|NCT02163993|Drug|Placebo|Administered SQ
267370|NCT02163980|Drug|Caudal ropivacaine + normal saline|
267371|NCT02163980|Drug|Caudal ropivacaine + dexmedetomidine|
267372|NCT02163967|Device|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
267373|NCT02163954|Drug|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
267374|NCT02163954|Drug|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
267375|NCT02163941|Behavioral|Compassion Training|
267376|NCT02163928|Other|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
267377|NCT02163915|Drug|TAK-137|TAK-137 tablets
267378|NCT02163915|Drug|TAK-137 Placebo|TAK-137 placebo-matching tablets
267379|NCT02163902|Drug|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
267380|NCT02163902|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
267381|NCT02163876|Drug|HuCNS-SC cells|surgery arm
267382|NCT02163863|Device|Femoropopliteal stenting|
267383|NCT02163850|Device|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
267384|NCT02163850|Device|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
267385|NCT02163837|Drug|rifaximine|
267386|NCT02163824|Drug|KPI-121 0.25%|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
267387|NCT02163824|Drug|KPI-121 1.0%|KPI-121 drug product will be supplied as 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
267388|NCT02163824|Drug|Vehicle of KPI-121 0.25%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
267389|NCT02163824|Drug|Vehicle of KPI-121 1.0%|Placebo control arms will receive the same bottles containing vehicle of KPI-121 including all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
267391|NCT02163811|Behavioral|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
267392|NCT02163798|Behavioral|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
267393|NCT02163798|Behavioral|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
267394|NCT02163785|Procedure|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
267395|NCT02163772|Procedure|Intracordal hyaluronate injection|
267396|NCT02163759|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
267397|NCT02163759|Other|Adalimumab Placebo|Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.
267398|NCT02163759|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).
267399|NCT02163759|Other|Etrolizumab Placebo|Placebo matching to etrolizumab will be administered SC Q4W.
267400|NCT02163746|Procedure|CO2 (carbon dioxide) laser|
267401|NCT02163746|Procedure|Surgical Deroofing|
267402|NCT02163733|Drug|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
267403|NCT02163733|Procedure|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
267404|NCT02163733|Other|Dietary Fasted|Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
267405|NCT02163733|Other|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
267406|NCT02163733|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
267407|NCT02163720|Drug|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
267408|NCT02163707|Drug|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
267409|NCT02163694|Drug|Paclitaxel|Day 1 of 21-day cycle
267410|NCT02163694|Drug|Veliparib|Veliparib on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
267411|NCT02163694|Drug|Carboplatin|Day 1 of 21-day cycle
267412|NCT02163694|Other|Placebo|Placebo on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
267413|NCT02163681|Drug|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
267414|NCT02163668|Other|Yoga Group|8 months of Yoga training
267415|NCT02163655|Drug|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
267416|NCT02163655|Drug|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
267417|NCT02163642|Device|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
267418|NCT02163629|Behavioral|Stress management|
267419|NCT02163616|Drug|Misoprostol|800 mcg of sublingual misoprostol
267420|NCT02163603|Procedure|Pelvic osteotomy|
267421|NCT02163590|Other|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
267422|NCT02163590|Other|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
267423|NCT02163590|Other|Placebo|Intervention that mimics the experimental procedures
267424|NCT02163577|Biological|burosumab|solution for SC injection
267425|NCT02163564|Behavioral|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
267426|NCT02163538|Device|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
267427|NCT02163538|Device|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
267428|NCT02163525|Procedure|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
267429|NCT02163525|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
267430|NCT02163525|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
267431|NCT02163499|Drug|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
267432|NCT02163486|Device|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
267642|NCT02162121|Drug|Mepivacaine 1%|
267433|NCT02163486|Device|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.~I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
267434|NCT02163473|Procedure|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
267435|NCT02163473|Procedure|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
267436|NCT02163460|Procedure|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde [Health Ministry registry]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
267437|NCT02163460|Procedure|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
267438|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
267439|NCT02163447|Drug|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
267440|NCT02163447|Drug|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
267441|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
267442|NCT02163447|Drug|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
267443|NCT02163434|Drug|Gabapentin|
267444|NCT02163434|Drug|Metoclopramide|
267445|NCT02163421|Drug|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
267446|NCT02163421|Drug|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
267447|NCT02163408|Other|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
267448|NCT02163395|Device|FullCeram implant|FullCeram implantation
267449|NCT02163382|Device|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
267450|NCT02163382|Device|Neurovent Monitor XIII|RIP jacket installation
267451|NCT02163382|Device|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
267452|NCT02163382|Device|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
267453|NCT02163382|Device|Neurovent Monitor XIII|Second period with conventional NIV settings
267454|NCT02163369|Drug|Peppermint and Lavender Essential Oils|
267455|NCT02163356|Drug|Fenretinide/LXS Oral Powder|Oral Powder
267456|NCT02163356|Drug|Ketoconazole|Oral Tablet
267457|NCT02163356|Drug|Vincristine|IV
267458|NCT02163330|Drug|Acetazolamide|
267459|NCT02163330|Drug|sugar pill|
267460|NCT02163317|Radiation|stereotactic radiosurgery|Undergo MRI-guided focal SRS
267461|NCT02163317|Device|magnetic resonance imaging|Undergo staging MRI with contrast
267462|NCT02163317|Other|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
267463|NCT02163317|Procedure|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
267464|NCT02163317|Procedure|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
267465|NCT02163317|Behavioral|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
267466|NCT02163304|Other|Sucrose|
267467|NCT02163304|Other|Artificial Sweetner|
267468|NCT02163304|Other|Tasteless Solution|
267469|NCT02163291|Drug|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
267470|NCT02163278|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
267471|NCT02163278|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
267472|NCT02163265|Procedure|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
267473|NCT02163252|Behavioral|Standard|
267474|NCT02163252|Behavioral|Early Intervention|
267475|NCT02163239|Device|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
267476|NCT02163226|Radiation|Hypofractionated Radiation Treatment|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
267477|NCT02163226|Radiation|One Radiation Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
267478|NCT02163226|Behavioral|Questionnaire|Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
267479|NCT02163213|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
267480|NCT02163187|Device|Implantation of the InterStimTM|
267481|NCT02163187|Behavioral|MSK BFI questionnaires|
267482|NCT02163187|Behavioral|The Low Anterior Resection Score (LARS) questionnaires|
267483|NCT02163187|Behavioral|The EuroQOL5D questionnaires|
267484|NCT02163187|Behavioral|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
267643|NCT02162121|Drug|Levobupivacaine 0,5%|
267485|NCT02163174|Drug|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
267486|NCT02163174|Drug|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
267487|NCT02163161|Drug|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
267488|NCT02163161|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
267489|NCT02163161|Drug|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
267490|NCT02163148|Behavioral|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
267491|NCT02163122|Procedure|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
267492|NCT02163122|Other|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
267493|NCT02163122|Biological|Cat allergen (FelD1)|
267494|NCT02163083|Procedure|ICG|Improvement of detection of positive lymphnodes
267495|NCT02163070|Dietary Supplement|whey drink,|consumption of 220 milliliters of whey drink three times a week,
267496|NCT02163070|Dietary Supplement|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
267497|NCT02163070|Dietary Supplement|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
267498|NCT02163057|Biological|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device|Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 (VGX-3100 and INO-9012) via IM+EP with CELLECTRA®-5P. All subjects will receive a total of 4 doses of immunotherapy
267499|NCT02163031|Device|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
267500|NCT02163018|Drug|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
267501|NCT02163018|Drug|Placebo|Subcutaneous administration of increasing doses of placebo
267502|NCT02163005|Drug|Gadolinium|-agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
267503|NCT02162992|Other|No intervention|Observational
267504|NCT02162979|Drug|sildenafil|sildenafil 50mg BID for 2 weeks
267505|NCT02162979|Drug|Placebo|
267506|NCT02162966|Drug|High Dose Colistin|High Dose Colistin
267507|NCT02162966|Drug|Standard Dose Colistin|Standard Dose Colistin
267508|NCT02162940|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
267509|NCT02162940|Other|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
267510|NCT02162927|Dietary Supplement|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
267511|NCT02162927|Dietary Supplement|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
267512|NCT02162914|Drug|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
267513|NCT02162914|Drug|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
267514|NCT02162901|Behavioral|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
267515|NCT02162901|Behavioral|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
267516|NCT02162901|Behavioral|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
267517|NCT02162901|Behavioral|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
267518|NCT02162901|Behavioral|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
267519|NCT02162888|Drug|Test Product (Bendamustine)|
267520|NCT02162875|Drug|Praziquantel|Six different treatment strategies with praziquantel
267521|NCT02162862|Behavioral|Behavioral Counseling|
267522|NCT02162862|Drug|bupropion-SR|
267523|NCT02162849|Drug|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
267524|NCT02162849|Drug|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
267644|NCT02162121|Drug|Ropivacaine 0,2%|
267645|NCT02162121|Drug|Ketorolac 30mg|
267525|NCT02162849|Drug|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
267526|NCT02162849|Drug|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
267527|NCT02162849|Behavioral|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
267528|NCT02162849|Behavioral|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
267529|NCT02162849|Other|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
267530|NCT02162849|Other|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
267531|NCT02162836|Drug|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
267532|NCT02162823|Procedure|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
267533|NCT02162810|Drug|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
267534|NCT02162810|Drug|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
267535|NCT02162797|Dietary Supplement|Zinc supplementation|Intervention group A: Patients who will orally receive zinc for 3 months.
267536|NCT02162797|Dietary Supplement|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
267537|NCT02162784|Drug|Budesonide/Procaterol, 180/10mcg X1|one puff
267538|NCT02162784|Drug|Budesonide/procaterol 180/10 mcg X 2|2 puffs
267539|NCT02162784|Drug|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
267540|NCT02162771|Biological|Rituximab|
267541|NCT02162771|Biological|CT-P10|
267542|NCT02162771|Drug|Cyclophosphamide|
267543|NCT02162771|Drug|Vincristine|
267544|NCT02162771|Drug|Prednisone|
267545|NCT02162758|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules
267546|NCT02162758|Drug|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
267547|NCT02162745|Drug|Isotonic solution (NaCl 0.9%)|
267548|NCT02162745|Drug|Hypertonic solution (NaCl 3%)|
267549|NCT02162732|Device|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
267550|NCT02162719|Drug|Ipatasertib|Participants will receive ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
267551|NCT02162719|Drug|Paclitaxel|Participants will receive paclitaxel 80 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
267552|NCT02162719|Drug|Placebo|Participants will receive oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
267553|NCT02162706|Other|Non intervention study|
267554|NCT02162693|Biological|Mesenchymal progenitor cells|Administrated for intra-articular injection
267555|NCT02162693|Biological|Sodium Hyaluronate|
267556|NCT02162680|Drug|1% lidocaine|
267557|NCT02162680|Drug|bacteriostatic normal saline (BNS)|
267558|NCT02162667|Drug|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
267559|NCT02162654|Procedure|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
267560|NCT02162654|Procedure|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
267561|NCT02162641|Procedure|Sentinel lymph node biopsy|
267562|NCT02162628|Device|Exair Prolapse Repair System|
267563|NCT02162628|Procedure|Total Native Tissue Repair|
267564|NCT02162615|Device|Restorelle Direct Fix A|
267565|NCT02162615|Device|Restorelle Direct Fix P|
267566|NCT02162615|Procedure|Native Tissue Repair Anterior|
267567|NCT02162615|Procedure|Native Tissue Repair Posterior|
267568|NCT02162589|Procedure|POEM|Per oral endoscopic myotomy
267569|NCT02162576|Device|Propeller Health intervention|The Propeller intervention works through the provision of information to patients and their providers. With the Propeller sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp and geographic location. Actuation data are then securely transmitted to Propeller Health where the information is also compiled into individual reports via mobile apps, online dashboards, email reports and text message reminders that are returned to the patient. This communication provides an ongoing assessment of their management based on the national guidelines, together with personalized information to help encourage and support self-management. Each participant was invited to share reports with his or her healthcare provider, but this was not required.
267639|NCT02162121|Procedure|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
267570|NCT02162563|Drug|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
267571|NCT02162563|Drug|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
267572|NCT02162563|Drug|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks~FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
267573|NCT02162550|Drug|Bydureon|once weekly injection
267574|NCT02162550|Drug|placebo|once weekly injection
267575|NCT02162537|Drug|Cisplatin|Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
267576|NCT02162537|Drug|Pemetrexed|500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
267577|NCT02162537|Drug|Bevacizumab|7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
267578|NCT02162537|Radiation|Cerebral Radiotherapy|Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
267579|NCT02162524|Behavioral|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
267580|NCT02162511|Device|CliniMACS CD34+ cell enrichment and T-cell depletion|
267581|NCT02162498|Behavioral|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.~The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
267582|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler|
267583|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler with charcoal|
267584|NCT02162485|Drug|Seretide Diskus|
267585|NCT02162485|Drug|Seretide Diskus with charcoal|
267586|NCT02162446|Drug|satoreotide trizoxetan|
267587|NCT02162433|Drug|Normal Saline|to arms 2,4. Serves as the placebo.
267588|NCT02162433|Drug|Dexmedetomidine|to arms 1,3
267589|NCT02162420|Drug|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
267590|NCT02162420|Drug|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
267591|NCT02162420|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
267592|NCT02162420|Radiation|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
267593|NCT02162420|Biological|Stem Cell Transplant|Stem cell transplant on day 0.
267594|NCT02162420|Drug|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
267595|NCT02162407|Drug|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
267596|NCT02162407|Drug|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
267597|NCT02162394|Device|Observational ambulatory ECG monitoring|
267598|NCT02162381|Drug|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
267599|NCT02162381|Other|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
267600|NCT02162355|Drug|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
267601|NCT02162355|Drug|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
267602|NCT02162355|Drug|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
267603|NCT02162355|Drug|Placebo|1 or 2 matching placebo tablets once daily for 10 days
267604|NCT02162342|Other|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
267605|NCT02162329|Behavioral|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.~Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
267606|NCT02162329|Procedure|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.~Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
267640|NCT02162121|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times a day
267695|NCT02161692|Drug|Etoposide|
267607|NCT02162329|Procedure|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.~Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
267608|NCT02162329|Behavioral|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
267609|NCT02162316|Drug|Motilitone®|
267610|NCT02162316|Drug|A-Cilin®, Clari® and Pantoline®|
267611|NCT02162303|Drug|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
267612|NCT02162303|Drug|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
267613|NCT02162290|Other|Interval exercise training|Exercise bouts in low and high intensities
267614|NCT02162290|Other|Continuous exercise training|
267615|NCT02162277|Device|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
267616|NCT02162264|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
267617|NCT02162251|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
267618|NCT02162238|Device|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
267619|NCT02162225|Drug|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.~On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
267620|NCT02162212|Other|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
267621|NCT02162212|Other|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c < 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is <130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
267622|NCT02162199|Drug|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
267623|NCT02162199|Drug|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
267624|NCT02162173|Procedure|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
267625|NCT02162160|Device|probiotic creme|Probiotic creme applied
267626|NCT02162160|Drug|Placebo|Creme without probiotics applied in same manner
267627|NCT02162134|Other|sugar free chewing gum|Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
267628|NCT02162134|Other|sugared chewing gum|Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
267629|NCT02162134|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
267630|NCT02162134|Drug|Inj. Midazolam 0.7mg/kg 45 min before surgery|Inj . Midazolam 0.7 mg/kg given as premedication.
267631|NCT02162134|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
267632|NCT02162134|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia.
267633|NCT02162134|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
267634|NCT02162134|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
267635|NCT02162134|Drug|Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
267636|NCT02162134|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
267637|NCT02162121|Procedure|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
267638|NCT02162121|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
267646|NCT02162121|Drug|Buprenorphine 0,2mg|
267647|NCT02162121|Device|Stimulong, Pajunk, Germany.|
267648|NCT02162121|Procedure|Continuous lumbar plexus: non-stimulating catheter|
267649|NCT02162082|Device|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
267650|NCT02162069|Device|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
267651|NCT02162056|Device|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffolds for coronary artery disease.
267652|NCT02162030|Behavioral|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
267653|NCT02162017|Other|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
267654|NCT02162017|Other|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
267655|NCT02162004|Procedure|Continuous Correction|
267656|NCT02161991|Drug|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
267657|NCT02161991|Drug|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
267658|NCT02161965|Drug|Rivaroxaban|20mg or 15mg
267659|NCT02161965|Drug|Fluindione|
267660|NCT02161965|Drug|Warfarin|
267661|NCT02161952|Drug|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
267662|NCT02161952|Drug|Matched equivalent placebo|
267663|NCT02161939|Drug|Daclatasvir (BMS-790052)|
267664|NCT02161939|Drug|Sofosbuvir|
267665|NCT02161926|Other|dietary restrictions|Dietary restrictions during 8 weeks
267666|NCT02161913|Behavioral|Multi-Family Group Treatment|
267667|NCT02161913|Behavioral|SCI Education Control Group|
267668|NCT02161900|Other|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
267669|NCT02161874|Device|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
267670|NCT02161874|Device|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
267671|NCT02161861|Other|cFFE increase the fusiogenic capacities of a gamete|
267672|NCT02161848|Other|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
267673|NCT02161835|Other|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
267674|NCT02161822|Drug|simvastatin|simvastatin 80mg qd for 5weeks
267675|NCT02161809|Behavioral|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
267676|NCT02161796|Drug|FG-4592|Oral
267677|NCT02161796|Drug|Placebo|Oral
267678|NCT02161783|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
267679|NCT02161783|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
267680|NCT02161783|Radiation|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
267681|NCT02161783|Biological|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
267682|NCT02161770|Drug|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
267683|NCT02161770|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
267684|NCT02161770|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
267685|NCT02161757|Biological|Tralokinumab|Subcutaneous injection
267686|NCT02161757|Other|Placebo|Subcutaneous injection
267687|NCT02161744|Biological|ADSCs administration|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
267688|NCT02161731|Drug|Evacetrapib|Oral administration
267689|NCT02161731|Drug|Warfarin|Oral administration
267690|NCT02161718|Drug|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
267691|NCT02161718|Drug|Placebo + olanzapine|Oral tablet, taken once daily
267692|NCT02161705|Drug|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
267693|NCT02161705|Drug|Saline|Up to 0.8 mL/kg of normal saline administered
267694|NCT02161692|Drug|Cyclophosphamide|
267698|NCT02161692|Drug|Carboplatin|High dose carboplatin
267699|NCT02161679|Drug|IMMU-132 infusion is administered to participants in one arm for the study|
267700|NCT02161679|Drug|IMMU-132 plus Carboplatin infusion|
267701|NCT02161653|Drug|Prednisone plus Metadoxine|
267702|NCT02161653|Drug|Pentoxifylline plus Metadoxine|
267703|NCT02161627|Device|Saluda Medical External Trial System|
267704|NCT02161627|Device|Saluda Medical External Trial System|
267705|NCT02161614|Drug|Estradiol valerate|
267706|NCT02161614|Drug|Placebo|
267707|NCT02161601|Procedure|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
267708|NCT02161588|Drug|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
267709|NCT02161588|Drug|placebo|Once-daily oral administration as tablets.
267710|NCT02161575|Drug|Ranibizumab|Intraveal injections of 0.5mg ranibizumab
267711|NCT02161562|Drug|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
267712|NCT02161562|Drug|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
267713|NCT02161549|Device|Motus Gl CleanUp System|
267714|NCT02161536|Device|Motus Cleansing System|
267715|NCT02161510|Drug|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
267716|NCT02161484|Procedure|Continuous Lumbar Plexus Block|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
267717|NCT02161484|Procedure|Parasacral Nerve Block|A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
267718|NCT02161484|Drug|Ropivacine 0.2%|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
267719|NCT02161484|Drug|Bupivacaine 0.0625%|In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
267720|NCT02161458|Drug|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
267721|NCT02161458|Drug|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
267722|NCT02161458|Drug|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
267723|NCT02161458|Drug|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
267724|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fed state
267725|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fasted state
267726|NCT02161432|Drug|BI 187004|single dose BI 187004 given as oral solution
267727|NCT02161419|Drug|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
267728|NCT02161419|Drug|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
267729|NCT02161406|Drug|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
267730|NCT02161406|Drug|Placebo|125 mg of Placebo
267731|NCT02161393|Behavioral|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
267732|NCT02161393|Behavioral|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
267733|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
267734|NCT02161380|Drug|injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
267735|NCT02161380|Drug|injection of scAAV2-P1ND4v2 2.4 X10e10vg (High)|injection of Total Volume of each intravitreal injection is 100 µL
267736|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)|injection of Total Volume of each intravitreal injection is 100 µL
267737|NCT02161367|Drug|Simethicone|"Pharmacological category: antiflatulent~160mg Simethicone orally, 4 times a day for the first five postoperative days"
267738|NCT02161367|Drug|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.~Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
267739|NCT02161354|Drug|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
267740|NCT02161354|Drug|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
267741|NCT02161354|Drug|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
267742|NCT02161328|Other|EIT belt|
267743|NCT02161302|Device|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
267744|NCT02161302|Device|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
267745|NCT02161276|Drug|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
267746|NCT02161276|Drug|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
267747|NCT02161263|Other|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
267748|NCT02161250|Dietary Supplement|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
267749|NCT02161250|Dietary Supplement|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
267750|NCT02161237|Drug|Advagraf®|oral
267751|NCT02161224|Drug|FG-4592|Oral
267752|NCT02161211|Behavioral|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
267753|NCT02161211|Behavioral|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
267754|NCT02161211|Behavioral|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
267755|NCT02161198|Dietary Supplement|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
267756|NCT02161198|Dietary Supplement|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
267757|NCT02161185|Drug|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
267758|NCT02161159|Biological|botulinum toxin Type A|botulinum toxin Type A administered in accordance with physician standard practice.
267759|NCT02161146|Drug|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
267760|NCT02161146|Drug|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
267761|NCT02161146|Drug|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
267762|NCT02161133|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
267763|NCT02161133|Behavioral|Health Education|Health Education provides didactic information about Gulf War Illness
267764|NCT02161120|Other|Traditional Finnish rye bread|
267765|NCT02161120|Other|Low FODMAP rye bread|
267766|NCT02161107|Biological|Grass-SPIRE|Intradermal injection
267767|NCT02161107|Biological|Placebo|Intradermal injection
267768|NCT02161094|Behavioral|Give incentives to physicians based on their patient's HbA1c improvement|
267769|NCT02161094|Behavioral|Give incentives to patients based on their own HbA1c improvement|
267770|NCT02161081|Procedure|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
267771|NCT02161055|Drug|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.~• Amount of insulin (u) = [fasting blood glucose (mmol/L) × 18-100] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
267772|NCT02161029|Device|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
267773|NCT02161029|Device|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
267774|NCT02161016|Device|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
267775|NCT02161003|Procedure|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
267776|NCT02161003|Procedure|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
267777|NCT02160990|Drug|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
267778|NCT02160990|Drug|Placebo|placebo subcutaneously twice daily for 30 days
267779|NCT02160977|Procedure|total knee arthroplasty|
267780|NCT02160951|Drug|LGH447|LGH447, QD
267781|NCT02160938|Other|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.~At the age of 3, the following exams will be performed and are described below:~The Vineland-II Adaptive Behavior Scale (VABS)~Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)~Children will also be photographed (for review by the study dysmorphologist)"
267782|NCT02160925|Other|Preoperative 99mTc-Sestamibi SPECT/CT|
267783|NCT02160899|Drug|ISIS-APO(a)Rx|
267784|NCT02160899|Drug|Placebo|
267785|NCT02160886|Behavioral|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
267786|NCT02160886|Behavioral|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.~The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.~The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .~The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
267787|NCT02160873|Other|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
267788|NCT02160873|Other|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
267789|NCT02160847|Behavioral|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
267790|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
267791|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
267792|NCT02160821|Procedure|Caudal Epidural|Ultrasound Guided Caudal Block
267793|NCT02160821|Procedure|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
267794|NCT02160808|Drug|Secretin|Drug to stimulate pancreatic secretion
267795|NCT02160808|Drug|Placebo|
267796|NCT02160782|Drug|LUM001|LUM001 will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.
267797|NCT02160782|Drug|Placebo|Placebo will be administered orally once daily during randomized withdrawal period
267798|NCT02160756|Drug|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
267799|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
267800|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
267801|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
267802|NCT02160743|Dietary Supplement|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
267803|NCT02160730|Drug|R-roscovitine|See Arm Description
267804|NCT02160704|Drug|Enclomiphene citrate|25 mg daily for 16 weeks
267805|NCT02160704|Other|Placebo|placebo daily for 16 weeks
267806|NCT02160691|Device|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
267807|NCT02160678|Drug|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
267808|NCT02160678|Drug|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
267809|NCT02160678|Drug|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
267810|NCT02160665|Drug|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
267811|NCT02160665|Drug|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
267812|NCT02160665|Drug|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
267813|NCT02160652|Procedure|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
267814|NCT02160639|Other|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
267815|NCT02160626|Drug|A-101 Vehicle|Placebo control
267816|NCT02160626|Drug|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
267817|NCT02160626|Drug|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
267818|NCT02160613|Procedure|Open flap debridement|an access flap
267819|NCT02160600|Other|Standard multiphase CT|
267820|NCT02160600|Other|split bolus Dual energy CT|
267821|NCT02160587|Drug|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
267867|NCT02160249|Behavioral|Community-based rehabilitation|
267822|NCT02160587|Drug|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
267823|NCT02160587|Other|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
267824|NCT02160574|Drug|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
267825|NCT02160574|Drug|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
267826|NCT02160574|Drug|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
267827|NCT02160574|Other|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
267828|NCT02160561|Other|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
267829|NCT02160548|Drug|Standard care|Standard management for OP poisoning
267830|NCT02160548|Drug|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
267831|NCT02160548|Drug|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
267832|NCT02160535|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
267833|NCT02160522|Device|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
267834|NCT02160509|Device|IPhone based realtime remote ultrasound interpretation|
267835|NCT02160496|Behavioral|Weight loss interventional study with 20% protein-diet|
267836|NCT02160496|Behavioral|Weight loss interventional study with 27% protein-diet|
267837|NCT02160496|Behavioral|Weight loss interventional study with 35% protein-diet|
267838|NCT02160483|Other|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
267839|NCT02160470|Behavioral|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
267840|NCT02160470|Behavioral|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
267841|NCT02160470|Behavioral|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
267842|NCT02160470|Behavioral|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
267843|NCT02160457|Other|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis~The instrumented gait analysis consists of four steps:~Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)~Impairment-Focused Interpretation~Recommendation for interdisciplinary interventions~Dissemination of recommendations~The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
267844|NCT02160444|Behavioral|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
267845|NCT02160431|Behavioral|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
267846|NCT02160418|Behavioral|Financial Incentives|
267847|NCT02160418|Behavioral|Cognitive Incentives|
267848|NCT02160418|Behavioral|Financial and Cognitive Incentives|
267849|NCT02160405|Dietary Supplement|native potato|
267850|NCT02160392|Procedure|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
267851|NCT02160379|Other|standard test meal|
267852|NCT02160366|Other|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
267853|NCT02160353|Drug|Abiraterone acetate, Prednisolone|
267854|NCT02160314|Device|pessary|disposable, single-use pessary
267855|NCT02160314|Device|Absorbent pad|
267856|NCT02160301|Drug|Gabapentin|PO
267857|NCT02160301|Drug|Acetaminophen|PO
267858|NCT02160301|Drug|Acetaminophen|IV
267859|NCT02160301|Drug|Celecoxib|PO
267860|NCT02160301|Drug|Dexamethasone|IV
267861|NCT02160301|Drug|Oxycodone|PO
267862|NCT02160288|Drug|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
267863|NCT02160288|Drug|Normal Saline|Dispensed in a 5 cc syringe
267864|NCT02160275|Device|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
267865|NCT02160275|Device|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
267866|NCT02160262|Drug|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
267868|NCT02160249|Other|Facility based care|
267869|NCT02160236|Drug|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
267870|NCT02160236|Drug|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
267871|NCT02160236|Drug|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
267872|NCT02160223|Drug|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
267873|NCT02160223|Drug|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
267874|NCT02160210|Device|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
267875|NCT02160197|Device|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
267876|NCT02160197|Device|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
267877|NCT02160184|Device|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
267878|NCT02160171|Device|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
267879|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
267880|NCT02160158|Drug|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
267881|NCT02160158|Drug|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
267882|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
267883|NCT02160158|Drug|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
267884|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
267885|NCT02160158|Drug|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
267886|NCT02160158|Drug|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
267887|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
267888|NCT02160158|Drug|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
267889|NCT02160145|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
267890|NCT02160145|Drug|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
267891|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
267892|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
267893|NCT02160119|Other|MRI-based techniques|fMRI, DTI
267894|NCT02160119|Other|EEG|ERP
267895|NCT02160106|Drug|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
267896|NCT02160080|Drug|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
267897|NCT02160067|Drug|Second generation BTDS patch|
267898|NCT02160067|Drug|First generation BuTrans patch|
267899|NCT02160054|Drug|Graceptor®|oral
267900|NCT02160041|Drug|BGJ398|BGJ398 was dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
267901|NCT02160028|Other|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
267902|NCT02160028|Other|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
267903|NCT02160015|Drug|Ibrutinib|Given PO
267904|NCT02160015|Other|Laboratory Biomarker Analysis|Correlative studies
267905|NCT02160015|Drug|Lenalidomide|Given PO
267906|NCT02160015|Biological|Rituximab|Given IV
267907|NCT02160002|Procedure|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
267908|NCT02160002|Procedure|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
267909|NCT02159989|Drug|Sapanisertib|Given PO
267910|NCT02159989|Biological|Ziv-Aflibercept|Given IV
267911|NCT02159976|Drug|Pantoprazole|Pantoprazole 40mg bid
267912|NCT02159976|Drug|Amoxicillin|Amoxicillin 1000mg bid
267913|NCT02159976|Drug|Clarithromycin|Clarithromycin 500mg bid
267914|NCT02159976|Drug|Metronidazole|Metronidazole 500mg tid
267915|NCT02159976|Drug|Tetracycline|Tetracycline 1000mg bid
267916|NCT02159976|Drug|Bismuth|Bismuth 600mg bid
267917|NCT02159963|Other|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
267918|NCT02159963|Other|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
267919|NCT02159963|Other|Optional training|8 weeks of optional home based, unsupervised training.
267920|NCT02159963|Other|Control|8 weeks of control period. Participants are doing daily living.
267921|NCT02159950|Other|Laboratory Biomarker Analysis|Correlative studies
267922|NCT02159950|Biological|Sipuleucel-T|Given IV
267923|NCT02159950|Drug|Tasquinimod|Given PO
268094|NCT02158520|Biological|Ipilimumab|Given IV
267924|NCT02159937|Other|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
267925|NCT02159911|Drug|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.~The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
267926|NCT02159898|Device|EndoMAXX Endoluminal Valve Technology (EVT)|
267927|NCT02159898|Device|EndoMAXX|
267928|NCT02159885|Other|Telemonitoring|
267929|NCT02159872|Drug|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
267930|NCT02159859|Drug|Ertapenem|Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
267931|NCT02159833|Other|Intranasal challenge with active substance (food protein)|
267932|NCT02159833|Other|Intranasal challenge with placebo|
267933|NCT02159820|Drug|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
267934|NCT02159820|Drug|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve [AUC] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
267935|NCT02159807|Drug|Bupivacaine|The dose of bupivacaine administered intrathecally during placement of the spinal anesthetic.
267936|NCT02159807|Drug|Fentanyl|20 micrograms routinely administered in combination in the spinal anesthetic
267937|NCT02159794|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
267938|NCT02159781|Procedure|periodontal treatment - scaling and root planning|
267939|NCT02159768|Device|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
267940|NCT02159755|Drug|Ibrutinib|Given PO
267941|NCT02159755|Other|Laboratory Biomarker Analysis|Correlative studies
267942|NCT02159755|Drug|Palbociclib|Given PO
267943|NCT02159755|Other|Pharmacological Study|Correlative studies
267944|NCT02159742|Other|Data Collection|
267945|NCT02159729|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
267946|NCT02159729|Drug|ATX-101 (1 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
267947|NCT02159729|Drug|ATX-101 (2 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
267948|NCT02159729|Drug|ATX-101 (4 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
267949|NCT02159716|Biological|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
267950|NCT02159703|Procedure|TORS|
267951|NCT02159703|Radiation|Adjuvant Radiation Therapy|
267952|NCT02159690|Drug|Enzalutamide|160mg
267953|NCT02159690|Drug|Abiraterone acetate|1000mg
267954|NCT02159690|Drug|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
267955|NCT02159690|Drug|Dutasteride|0.5mg
267956|NCT02159690|Drug|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
267957|NCT02159677|Device|EIM Measurements|
267958|NCT02159664|Other|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
267959|NCT02159651|Drug|tacrolimus|oral
267960|NCT02159638|Device|Guardian Enlite sensor|Sensor insertion
267961|NCT02159638|Device|Dexcom G4 platinum sensor|Sensor insertion
267962|NCT02159625|Device|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
267963|NCT02159612|Other|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
267964|NCT02159599|Drug|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
267965|NCT02159599|Drug|Lamivudine|Lamivudine (300mg) : QD
267966|NCT02159599|Drug|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
267967|NCT02159573|Biological|natalizumab|Administered as per routine clinical practice
267968|NCT02159573|Drug|dimethyl fumarate|Administered as per routine clinical practice
267969|NCT02159560|Device|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
267970|NCT02159547|Drug|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
267971|NCT02159547|Other|Normal Saline|50 ml normal saline
267972|NCT02159534|Other|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
267973|NCT02159521|Device|EkoSonic Endovascular System|ultrasound catheter directed thrombolysis
268095|NCT02158520|Other|Laboratory Biomarker Analysis|Correlative studies
267974|NCT02159508|Behavioral|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
267975|NCT02159495|Drug|cyclophosphamide|Given IV
267976|NCT02159495|Biological|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
267977|NCT02159495|Other|laboratory biomarker analysis|Correlative studies
267978|NCT02159495|Biological|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
267979|NCT02159495|Drug|Fludarabine Phosphate|Given IV
267980|NCT02159482|Drug|Interferon Alfa-2a|
267981|NCT02159469|Combination Product|Testosterone enanthate auto-injector|Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
267982|NCT02159456|Other|Continuous enteral feeding via infusion pump|
267983|NCT02159456|Other|Intermittent enteral feeding via gravity-based infusion|
267984|NCT02159430|Other|Clinical and psychopathological assessment of HAE patients|
267985|NCT02159417|Other|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:~Knowledge of the disease~Food~Physical Activity and care of feet~The therapeutics"
267986|NCT02159404|Biological|Immunotherapy|
267987|NCT02159391|Behavioral|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
267988|NCT02159378|Other|Fructosamines|
267989|NCT02159365|Drug|Elotuzumab|
267990|NCT02159365|Drug|Lenalidomide|
267991|NCT02159365|Drug|Dexamethasone|
267992|NCT02159352|Drug|Daclatasvir|
267993|NCT02159352|Drug|Darunavir|
267994|NCT02159352|Drug|Ritonavir|
267995|NCT02159352|Drug|Lopinavir/Ritonavir|
267996|NCT02159326|Drug|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
267997|NCT02159326|Drug|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
267998|NCT02159313|Drug|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
267999|NCT02159300|Behavioral|experience brain activity recording|Intervention: experience brain activity recording
268000|NCT02159287|Drug|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
268001|NCT02159287|Drug|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
268002|NCT02159261|Drug|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
268003|NCT02159248|Drug|Tolfenamic acid + gemcitabine + radiation|"Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).~Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day)."
268004|NCT02159222|Procedure|Additional physical therapy|
268005|NCT02159196|Drug|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
268006|NCT02159196|Drug|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
268007|NCT02159196|Drug|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
268008|NCT02159183|Device|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
268009|NCT02159183|Device|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
268010|NCT02159170|Biological|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
268011|NCT02159157|Behavioral|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
268012|NCT02159144|Other|cold stress|
268013|NCT02159131|Drug|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
268014|NCT02159131|Drug|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
268015|NCT02159131|Drug|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
268016|NCT02159118|Device|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
268017|NCT02159118|Device|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
268018|NCT02159105|Device|FAST scan and non-invasive hemoglobin measurement|"A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.~Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours)."
268019|NCT02159092|Behavioral|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
268020|NCT02159079|Other|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
268021|NCT02159066|Drug|LGX818|Combination of LGX818 and MEK162 (Part I)
268022|NCT02159066|Drug|MEK162|Combination of LGX818 and MEK162 (Part I)
268023|NCT02159066|Drug|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
268024|NCT02159066|Drug|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
268025|NCT02159066|Drug|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
268026|NCT02159066|Drug|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
268027|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
268028|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
268029|NCT02159053|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
268030|NCT02159040|Drug|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
268031|NCT02159040|Drug|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
268032|NCT02159027|Drug|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
268033|NCT02159027|Drug|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
268034|NCT02159014|Behavioral|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
268035|NCT02159014|Behavioral|Online, video prompted, individual aerobic dance|Supported online activity intervention
268036|NCT02159014|Behavioral|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
268037|NCT02159014|Behavioral|Self-paced online aerobic dance activity|Self paced physical activity
268038|NCT02159014|Behavioral|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
268039|NCT02159001|Device|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
268040|NCT02158988|Procedure|HIPEC|"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
268041|NCT02158975|Drug|MLN9708|
268042|NCT02158962|Behavioral|Behavioral - Education|"Behavioral - Education~3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
268043|NCT02158949|Behavioral|mROAD|
268044|NCT02158936|Drug|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
268045|NCT02158936|Drug|Azacitidine|Subcutaneous Injection (IV if local standard)
268046|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets
268047|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets will be supplied
268048|NCT02158923|Procedure|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
268049|NCT02158923|Procedure|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
268050|NCT02158923|Procedure|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
268051|NCT02158910|Drug|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
268052|NCT02158897|Other|Prolon diet|3 cycles of a 5-day Prolon diet very month
268053|NCT02158884|Device|IDEO brace|All participants will receive the IDEO brace.
268096|NCT02158520|Drug|Nab-paclitaxel|Given IV
268097|NCT02158520|Other|Pharmacological Study|Correlative studies
268098|NCT02158507|Drug|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
268249|NCT02157298|Drug|Placebo tablet|Placebo tablet. Oral dose
268298|NCT02156804|Drug|Nivolumab (BMS-936558)|
268299|NCT02156791|Biological|gpASIT+TM|
268054|NCT02158871|Behavioral|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
268055|NCT02158871|Behavioral|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
268056|NCT02158858|Drug|CPI-0610|
268057|NCT02158858|Drug|Ruxolitinib|
268058|NCT02158845|Drug|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
268059|NCT02158845|Drug|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
268060|NCT02158832|Device|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current >sensation threshold & maintained at a level that is comfortable/painless & does not elicit skeletal muscle contractions (~5mA, <10mA).~Needle locations are in the vicinity of nerves that supply the affected upper limb:~EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', ~15⁰ perpendicular to the skin, ~15⁰ lateral to the midline. Depth: ~1.5 cm (secure anchorage).~EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' ~15⁰ perpendicular to the skin, ~15⁰ medial. Depth: ~1.5 cm (secure anchorage)."
268061|NCT02158819|Device|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
268062|NCT02158806|Drug|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
268063|NCT02158806|Drug|Placebo|Matching placebo capsule containing inert bulking agent
268064|NCT02158793|Procedure|Craniomaxillofacial allotransplantation|Transplantation of donor face
268065|NCT02158780|Procedure|Scrotal Orchidopexy|Single incision
268066|NCT02158780|Procedure|Inguinal Orchidopexy|Double Incision (Standard)
268067|NCT02158767|Biological|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
268068|NCT02158754|Diagnostic Test|Corus CAD (ASGES)|
268069|NCT02158741|Behavioral|Home Visits and Lifestyle Education Support|
268070|NCT02158715|Device|Site of smartphone on chest compressor' arm|
268071|NCT02158702|Drug|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
268072|NCT02158689|Drug|Letrozole|
268073|NCT02158689|Drug|human menopausal gonadotropin (hMG)|
268074|NCT02158676|Dietary Supplement|Prebiotic|Fructooligosaccharides
268075|NCT02158676|Dietary Supplement|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
268076|NCT02158676|Other|Placebo|Maltodextrin
268077|NCT02158663|Device|Repetitive Transcranial Magnetic Stimulation|TMS Device
268078|NCT02158650|Behavioral|Video-Based Informed Consent|
268079|NCT02158624|Drug|Intravitreal Lucentis 0.5mg|
268080|NCT02158611|Other|Lifestyle counseling|
268081|NCT02158598|Drug|Vitamin D chewable tablet supplementation|
268082|NCT02158598|Drug|Vitamin D pill supplementation|
268083|NCT02158585|Drug|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, 100 mg twice a day and 150mg twice a day during titration; 150mg twice a day or 100mg twice a day for the 12-week study period; 150mg once a day or 100mg once a day for Week 1 of the taper; and 75mg once a day, or 50mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
268084|NCT02158585|Drug|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
268085|NCT02158572|Drug|AG200-15|Transdermal contraceptive delivery system
268086|NCT02158559|Drug|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
268087|NCT02158559|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
268088|NCT02158546|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
268089|NCT02158546|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
268090|NCT02158533|Drug|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
268091|NCT02158533|Drug|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
268092|NCT02158533|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
268093|NCT02158520|Biological|Bevacizumab|Given IV
268099|NCT02158494|Device|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
268100|NCT02158494|Device|Sham Device|The sham device is visually identical to the CN-NINM device, and offers a non-zero, minimally perceivable stimulation.
268101|NCT02158481|Dietary Supplement|A capsule containing both polyphenols and carotenoids|
268102|NCT02158481|Dietary Supplement|Placebo intervention|Placebo intervention
268103|NCT02158468|Device|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
268104|NCT02158468|Device|Postconditioning|After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
268105|NCT02158455|Procedure|NT SVG grafts|
268106|NCT02158442|Procedure|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
268107|NCT02158442|Drug|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
268108|NCT02158429|Other|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
268109|NCT02158403|Other|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
268110|NCT02158390|Behavioral|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC~A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
268111|NCT02158377|Device|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
268112|NCT02158377|Device|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
268113|NCT02158364|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
268114|NCT02158351|Procedure|liver and white adipose tissue biopsies|
268115|NCT02158338|Other|Asthma|mothers who have children that have been diagnosed with respiratory issues
268116|NCT02158338|Other|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
268117|NCT02158325|Procedure|anterior capsulorhexis sizes|Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0~3.9, 4.0~5.0, 5.1~6.0 mm in diameter)
268118|NCT02158312|Device|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
268119|NCT02158299|Drug|Avitene|
268120|NCT02158299|Drug|Sapylin|
268121|NCT02158299|Behavioral|axillary drainage|
268122|NCT02158299|Other|reexamine|
268123|NCT02158286|Other|Measuring emptying rate from the gastric tube|
268124|NCT02158273|Drug|Sugar Pill|145 mg/day, oral pill, 9 days
268125|NCT02158273|Drug|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
268126|NCT02158260|Behavioral|Position changing|
268127|NCT02158234|Drug|Cisplatin|Cisplatin 15 mg/m^2 prior to each fraction
268128|NCT02158234|Radiation|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
268129|NCT02158221|Drug|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
268130|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
268131|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
268132|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube|
268133|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes|
268134|NCT02158195|Biological|blood samples|
268135|NCT02158182|Drug|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
268136|NCT02158182|Drug|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
268137|NCT02158182|Drug|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
268138|NCT02158182|Drug|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.~Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.~Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
268139|NCT02158156|Behavioral|Exercise|Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
268140|NCT02158143|Dietary Supplement|vitamin D3|
268141|NCT02158117|Drug|nasal naloxone|one puff in one nostril with the subject is lying down
268142|NCT02158104|Procedure|Deep dry needling|
268143|NCT02158091|Drug|IPI-145|oral PI3K delta/gamma inhibitor
268144|NCT02158091|Drug|Fludarabine|intravenous chemotherapy
268145|NCT02158091|Drug|Cyclophosphamide|intravenous chemotherapy
268146|NCT02158091|Drug|Rituximab|intravenous immunotherapy
268204|NCT02157610|Behavioral|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
268147|NCT02158078|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
268148|NCT02158065|Other|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
268149|NCT02158052|Drug|Tacrolimus|Tacrolimus starting on Day -1
268150|NCT02158052|Drug|Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
268151|NCT02158052|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques.
268152|NCT02158052|Drug|Bone marrow transplant from a related donor|Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
268153|NCT02158052|Radiation|Total body irradiation 400 centigray (200 cGy X 2)|On transplant day -1
268154|NCT02158039|Drug|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
268155|NCT02158039|Drug|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
268156|NCT02158013|Other|Levorag Emulgel|
268157|NCT02158013|Drug|Diltiazem|
268158|NCT02158000|Other|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
268159|NCT02157987|Drug|bevacuzimab spray|
268160|NCT02157974|Drug|Byetta 5Mcg Pen Injection|10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola
268161|NCT02157948|Drug|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
268162|NCT02157948|Drug|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
268163|NCT02157935|Drug|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
268164|NCT02157935|Drug|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
268165|NCT02157935|Other|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
268166|NCT02157935|Other|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
268167|NCT02157922|Drug|alginate oligosaccharide|Inhalation
268168|NCT02157909|Device|Lotrafilcon B sphere modified design contact lenses|
268169|NCT02157909|Device|Lotrafilcon B sphere contact lenses|
268170|NCT02157883|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
268171|NCT02157883|Drug|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
268172|NCT02157883|Drug|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
268173|NCT02157831|Biological|CP-870,893|
268174|NCT02157818|Drug|midazolam|
268175|NCT02157818|Drug|Dexmedetomidine|
268176|NCT02157805|Other|beef meat|"Meat cooking conditions~st condition : beef meat cooked during 5 minutes at 55°C~nd condition : beef meat cooked during 30 minutes à 90°C"
268177|NCT02157792|Drug|M6620|
268178|NCT02157792|Drug|Gemcitabine|
268179|NCT02157792|Drug|Cisplatin|
268180|NCT02157792|Drug|Etoposide|
268181|NCT02157792|Drug|Carboplatin|
268182|NCT02157792|Drug|Irinotecan|
268183|NCT02157779|Behavioral|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
268184|NCT02157779|Behavioral|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
268185|NCT02157766|Behavioral|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
268186|NCT02157766|Behavioral|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
268187|NCT02157766|Behavioral|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
268188|NCT02157740|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
268189|NCT02157727|Device|Infants hospitalized in health facilities performing Tele-expertise|
268190|NCT02157714|Drug|PRX002|
268191|NCT02157714|Other|Placebo|
268192|NCT02157701|Dietary Supplement|Polyherbal capsule|
268193|NCT02157701|Dietary Supplement|Placebo capsule|
268194|NCT02157688|Other|no intervention : case control study|
268195|NCT02157675|Dietary Supplement|Polyherbal capsule|
268196|NCT02157675|Dietary Supplement|Placebo capsule|
268197|NCT02157649|Drug|IR Tablet under Fasted conditions|Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
268198|NCT02157649|Drug|ER Tablet under Fed Conditions|Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
268199|NCT02157649|Drug|ER Tablet under Fasted Conditions|Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
268200|NCT02157636|Drug|CPI-0610|
268201|NCT02157623|Drug|Levulan|Levulan application followed by Red or Blue light PDT on randomized treatment fields
268202|NCT02157623|Other|Red Light Photodynamic Therapy|Aktilite™ (red lamp) after Levulan application on randomized treatment field
268203|NCT02157623|Other|Blue Light Photodynamic Therapy|Blu-U® (blue lamp) after Levulan application on randomized treatment field
268457|NCT02155504|Drug|Placebo|oral
268205|NCT02157610|Drug|Nicotine Patch|Participants receive a 12-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke >10 cigarettes/day receive 8 weeks of 21 mg, 2 week of 14 mg, and 2 week of 7 mg patches. Those who smoke <10 cigarettes/day receive 8 weeks of 14 mg and 4 weeks of 7 mg patches.
268206|NCT02157610|Behavioral|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
268207|NCT02157610|Procedure|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
268208|NCT02157610|Behavioral|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
268209|NCT02157610|Drug|Nicotine lozenge|Participants receive a 12-week supply of nicotine lozenges. All participants receive 12 weeks of 2mg lozenges.
268210|NCT02157597|Other|NIRS based management|"Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair~Deepen anesthesia with volatile or intravenous agent.~Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
268211|NCT02157597|Other|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
268212|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
268213|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
268214|NCT02157571|Drug|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
268215|NCT02157571|Drug|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
268216|NCT02157571|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
268217|NCT02157571|Drug|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
268218|NCT02157558|Drug|Fexofenadine|All subjects will receive 180 mg fexofenadine
268219|NCT02157558|Drug|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
268220|NCT02157532|Procedure|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
268221|NCT02157532|Drug|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
268222|NCT02157519|Other|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
268223|NCT02157506|Drug|CXL-1427|
268224|NCT02157506|Drug|Placebo|
268225|NCT02157493|Behavioral|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
268226|NCT02157493|Behavioral|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
268227|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
268228|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
268229|NCT02157467|Drug|BMS-955176|
268230|NCT02157467|Drug|Ortho Cyclen|
268231|NCT02157454|Other|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
268232|NCT02157441|Procedure|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
268233|NCT02157428|Drug|Flumazenil|
268234|NCT02157428|Drug|saline|
268235|NCT02157415|Device|Uro-Tainer Polihexanide 0.02%|Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
268236|NCT02157402|Behavioral|Social marketing activities and pop-up events to promote healthy lifestyles|
268237|NCT02157389|Other|Administration of a pharmacological placebo|
268238|NCT02157376|Drug|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
268239|NCT02157376|Drug|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
268240|NCT02157363|Procedure|Repositioning|
268241|NCT02157363|Procedure|Single positioning|
268242|NCT02157350|Procedure|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
268243|NCT02157337|Drug|Atorvastatin|80 mg (PO) once daily for 6 days
268244|NCT02157337|Drug|placebo|80 mg (PO) once daily for 6 days
268245|NCT02157324|Drug|acalabrutinib|
268246|NCT02157324|Drug|ACP-319|
268247|NCT02157311|Drug|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
268248|NCT02157298|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
268250|NCT02157285|Behavioral|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
268251|NCT02157272|Drug|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
268252|NCT02157246|Other|Pimonidazole|
268253|NCT02157246|Other|F-MISO PET|
268254|NCT02157246|Other|pCT|
268255|NCT02157246|Other|Functional MRI|
268256|NCT02157246|Procedure|Biopsy|
268257|NCT02157246|Procedure|Blood sample|
268258|NCT02157233|Behavioral|Rest|
268259|NCT02157233|Behavioral|Exercise|
268260|NCT02157220|Device|Fixed bearing prosthesis|
268261|NCT02157220|Device|Mobile bearing prosthesis|
268262|NCT02157207|Dietary Supplement|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
268263|NCT02157207|Other|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
268264|NCT02157181|Drug|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
268265|NCT02157168|Behavioral|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.~IG1: The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months. At month 6, the participant will receive a call from the telephone interviewer to administer the informed patient choice survey."
268266|NCT02157155|Biological|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
268267|NCT02157142|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
268268|NCT02157129|Device|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
268269|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
268270|NCT02157116|Drug|cisplatin|
268271|NCT02157116|Drug|Docetaxel|
268272|NCT02157116|Drug|Pegfilgrastim|
268273|NCT02157103|Drug|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
268274|NCT02157090|Other|Herpes Patch SOS (Hansaplast®)|
268275|NCT02157090|Other|Herpes vesicle patch of Compeed®|
268276|NCT02157077|Drug|Aflibercept|Intravitreal Injection
268277|NCT02157051|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
268278|NCT02157051|Other|Laboratory Biomarker Analysis|Correlative studies
268279|NCT02157038|Device|Pedometer|
268280|NCT02157038|Device|MRI|
268281|NCT02157025|Device|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
268282|NCT02157025|Other|Usual Care procedures during Humphrey perimetry for children|
268283|NCT02157012|Drug|The effectiveness of Xeljanz in rheumatoid arthritis patients|
268284|NCT02156999|Device|Ibandronic acid, vitamin D|
268285|NCT02156973|Other|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
268286|NCT02156960|Drug|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
268287|NCT02156960|Drug|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
268288|NCT02156960|Drug|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
268289|NCT02156947|Procedure|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
268290|NCT02156934|Biological|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
268291|NCT02156921|Other|App-based training|
268292|NCT02156908|Drug|D-serine|D-serine 60 mg/kg
268293|NCT02156908|Drug|Placebo|
268294|NCT02156869|Other|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
268295|NCT02156843|Drug|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
268296|NCT02156843|Drug|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
268297|NCT02156817|Other|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
268300|NCT02156778|Behavioral|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus~extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.~3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.~6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.~12-Mo clinical visit and outcome assessment."
268301|NCT02156778|Behavioral|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).~Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.~Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).~Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.~AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).~12-Mo clinical visit and outcome assessment."
268302|NCT02156752|Behavioral|ACT|Treatment is based on Acceptance and Commitment Therapy
268303|NCT02156752|Behavioral|SR|Treatment is based on Self-Regulation theory.
268304|NCT02156752|Behavioral|WLO|Treatment is based on cooking tips and demonstrations.
268305|NCT02156739|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
268306|NCT02156739|Drug|Gadobutrol|Given IV
268307|NCT02156739|Drug|Gadoxetate Disodium|Given IV
268308|NCT02156726|Drug|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
268309|NCT02156713|Behavioral|CIMT Camp|
268310|NCT02156700|Procedure|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
268311|NCT02156687|Device|Y mesh|Y mesh
268312|NCT02156687|Device|Dual flat mesh|Dual flat mesh
268313|NCT02156674|Drug|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
268314|NCT02156661|Drug|Oxytocin|
268315|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
268316|NCT02156635|Device|Transcranial direct current stimulation|
268317|NCT02156635|Behavioral|Constraint-Induced Movement Therapy|
268318|NCT02156635|Other|Placebo|
268319|NCT02156609|Device|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
268320|NCT02156596|Drug|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
268321|NCT02156596|Drug|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
268322|NCT02156596|Drug|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
268323|NCT02156596|Drug|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
268324|NCT02156570|Drug|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
268325|NCT02156557|Biological|Colon KCC Heptapeptide|"Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.~The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.~The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.~We will obtain copies of your endoscopy report and any pathology reports."
268326|NCT02156544|Drug|CKD-519|
268327|NCT02156544|Drug|placebo|
268328|NCT02156531|Behavioral|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
268329|NCT02156531|Behavioral|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
268330|NCT02156518|Procedure|Vocal Function Exercises|Vocal Function Exercises
268331|NCT02156518|Procedure|Vocal Hygiene|Vocal Hygiene
268332|NCT02156505|Procedure|placement of double bare stent|
268333|NCT02156505|Device|DoubleBare stent|
268334|NCT02156492|Drug|Evacetrapib|Administered orally.
268335|NCT02156492|Drug|Simvastatin|Administered orally.
268336|NCT02156492|Drug|Atorvastatin|Administered orally.
268337|NCT02156466|Drug|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
268338|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
268339|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
268340|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
268341|NCT02156466|Drug|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
268342|NCT02156453|Procedure|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
268343|NCT02156440|Dietary Supplement|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
268344|NCT02156440|Dietary Supplement|Placebo|
268345|NCT02156427|Device|VITICELL|graft of autologus cells (kaeratonicytes and melanocytes) obtained after trypsinization of thin skin biopsy resuspended into hyaluronic acid
268346|NCT02156427|Device|PLACEBO|hyaluronic acid alone
268347|NCT02156414|Procedure|Radical Prostatectomy|Radical Prostatectomy
268348|NCT02156414|Procedure|Extended Lymphadenectomy|Extended Lymphadenectomy
268349|NCT02156388|Biological|GW003|freeze-dried powder；single SC injection
268350|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
268351|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
268352|NCT02156362|Other|follow up visit|At least 1 follow up visit per year will be done and an additional visit if needed.
268353|NCT02156349|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
268354|NCT02156349|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
268355|NCT02156336|Drug|Ranolazine|Oral administration, BID; for a maximum of 51 days.
268356|NCT02156336|Drug|Placebo|Oral administration, BID; for a maximum of 51 days.
268357|NCT02156323|Drug|CMS|Multiple doses of CMS over 2.5 days
268358|NCT02156323|Drug|RO7033877|Multiple doses of RO7033877 over 2.5 days
268359|NCT02156323|Drug|RO7033877 + CMS|Multiple doses of RO7033877 and CMS over 2.5 days
268360|NCT02156284|Behavioral|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour~Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
268361|NCT02156271|Drug|ramelteon|
268362|NCT02156271|Drug|placebo|
268363|NCT02156258|Device|FFDM Mammography|Standard mammography image collection
268364|NCT02156258|Device|DBT Mammography|Collection of breast images using DBT mammography
268365|NCT02156245|Other|conventional rehabilitation program (including concentric cycle ergometer)|
268366|NCT02156245|Other|cycling included into a conventional rehabilitation program|
268367|NCT02156232|Procedure|TIPS|TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. TIPS revision was planned if any evidence of shunt dysfunction was seen.
268368|NCT02156232|Procedure|embolization|Embolization of SPSS was conducted via the same jugular vein before TIPS implantation. The major procedures included (a)angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b)embolization of SPSS with coils of varying diameters, which resulted in the SPSS disappearing at postembolization angiography.
268369|NCT02156219|Other|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.~The implementation of the measure of separation of men and women on the subway consists of three operational tasks:~Control: Surveillance that men do not use cars corresponding to women.~Dosage: Regulation of entry women.~Assignment: Of the women, to the part of the platform where the first wagons stop."
268370|NCT02156206|Behavioral|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.~When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
268371|NCT02156193|Procedure|Prophylactic clip|Prophylactic clipping
268372|NCT02156193|Procedure|No prophylactic management|No prophylaxis
268373|NCT02156167|Device|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
268374|NCT02156154|Drug|Intravenous Acetaminophen|
268375|NCT02156141|Other|Supervised high intensity training|8 weeks of supervised training
268376|NCT02156141|Other|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
268377|NCT02156141|Other|Control period|8 weeks with no training.
268378|NCT02156141|Other|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
268379|NCT02156128|Behavioral|Cogmed working memory training|
268380|NCT02156128|Behavioral|Control group|
268381|NCT02156089|Other|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
268382|NCT02156076|Drug|BMS-919373|
268383|NCT02156076|Drug|Placebo (Matching with BMS-919373)|
268384|NCT02156063|Drug|NT100|
268385|NCT02156063|Drug|Placebo|
268458|NCT02155478|Device|ISERT 250 (HOYA, Japan): a standard IOL|
268386|NCT02156050|Device|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
268387|NCT02156037|Behavioral|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
268388|NCT02156037|Behavioral|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
268389|NCT02156024|Drug|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
268390|NCT02155985|Drug|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
268391|NCT02155985|Drug|Placebo|Placebo for aspirin
268392|NCT02155972|Dietary Supplement|Bifidobacterium infantis|Probiotic supplement
268393|NCT02155972|Other|Placebo|Placebo capsules
268394|NCT02155959|Device|toric intraocular lens|toric intraocular lens
268395|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
268396|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
268397|NCT02155933|Other|Blood sampling|Blood sampling for later hormone measurements
268398|NCT02155920|Drug|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
268399|NCT02155894|Behavioral|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
268400|NCT02155894|Behavioral|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.~The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.~Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.~During telephone consultation, updated clinical test results will be available through the electronic medical system."
268401|NCT02155881|Drug|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
268402|NCT02155881|Drug|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
268403|NCT02155868|Other|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it.~In case of rSO2 decrease less than 60% correct:~head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood < 35 mmHg; mean arterial pressure < 60 mmHg; central venous pressure > 10 mmHg; cardiac index < 2.0 l/min/m2; mixed venous oxygen saturation < 60%; hemoglobin < 65 g/L during cardiopulmonary bypass or hemoglobin < 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
268404|NCT02155868|Other|Standard treatment|Standard treatment
268405|NCT02155855|Other|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
268406|NCT02155855|Other|Control|Routine care
268407|NCT02155842|Behavioral|High intensity endurance exercise|
268408|NCT02155842|Behavioral|Moderate continuous endurance exercise|
268409|NCT02155829|Drug|Riluzole|
268410|NCT02155829|Drug|Placebo (for Riluzole)|
268411|NCT02155816|Dietary Supplement|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
268412|NCT02155816|Dietary Supplement|Omega 3|Omega 3 daily for 8 weeks.
268413|NCT02155816|Dietary Supplement|Placebo|Medium chain triglycerides
268414|NCT02155803|Drug|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
268415|NCT02155790|Device|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
268416|NCT02155777|Drug|OrthoNovum 1/35|
268417|NCT02155764|Device|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
268418|NCT02155764|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
268419|NCT02155764|Device|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
268459|NCT02155478|Device|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
268460|NCT02155465|Drug|Ruxolitinib|"Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID"
268461|NCT02155465|Drug|Erlotinib|Erlotinib 150mg PO QD
268703|NCT02153593|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
268420|NCT02155751|Behavioral|Nutrition Lifestyle Intervention Program (NLIP)|The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
268421|NCT02155751|Behavioral|Exercise Lifestyle Intervention Program (ELIP)|The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
268422|NCT02155738|Drug|IV Acetaminophen|
268423|NCT02155738|Drug|IV normal saline|IV normal saline
268424|NCT02155725|Drug|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
268425|NCT02155725|Drug|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
268426|NCT02155712|Device|Triathlon Tritanium Knee|Cementless
268427|NCT02155712|Device|Triathlon Knee|Cemented
268428|NCT02155699|Behavioral|Exercise 1|65% of VO2max and 2 sessions per week
268429|NCT02155699|Behavioral|Exercise 2|85% intensity and 3 sessions per peek
268430|NCT02155686|Device|Biosensors|Device: Biometric sensors; Home automation; telecare
268431|NCT02155686|Device|Home automation|
268432|NCT02155673|Drug|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
268433|NCT02155660|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
268434|NCT02155660|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
268435|NCT02155660|Drug|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
268436|NCT02155660|Drug|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
268437|NCT02155647|Drug|Avelumab|Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
268438|NCT02155634|Drug|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
268439|NCT02155621|Genetic|Genome sequencing|Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
268440|NCT02155608|Device|Active eTNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. Participant deemed to be positive responders to blinded active treatment will be invited to continue open eTNS in a 12 month extension period.
268441|NCT02155608|Device|Sham eTNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks, followed by one week of observation and followup while remaining blinded following treatment discontinuation. At the conclusion of the blinded trial, participants randomized to the sham group will be offered 4 weeks of open eTNS treatment. Participants deemed to be positive responders to open treatment will be invited to continue open nightly eTNS in a 12 month extension period.
268442|NCT02155595|Other|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
268443|NCT02155595|Other|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
268444|NCT02155582|Drug|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
268445|NCT02155569|Procedure|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
268446|NCT02155569|Procedure|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
268447|NCT02155543|Drug|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
268448|NCT02155543|Drug|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
268449|NCT02155543|Drug|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
268450|NCT02155543|Drug|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
268451|NCT02155530|Drug|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
268452|NCT02155530|Drug|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
268453|NCT02155517|Drug|Evaluation of propofol effect|"The study will make in two stages:~STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
268454|NCT02155517|Drug|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
268455|NCT02155504|Drug|ASP3700|oral
268456|NCT02155504|Drug|itraconazole|oral
268462|NCT02155452|Procedure|ALA Test group|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.~The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
268463|NCT02155439|Drug|5-fluorouracil|antimitotic drug
268464|NCT02155439|Drug|Triamcinolone|
268465|NCT02155400|Device|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
268466|NCT02155400|Device|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
268467|NCT02155374|Drug|Sliding scale insulin|
268468|NCT02155374|Drug|Intermediate acting insulin|
268469|NCT02155374|Behavioral|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
268470|NCT02155374|Drug|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
268471|NCT02155374|Drug|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
268472|NCT02155361|Drug|Topical Citrullus colocynthis fruit oil (1%)|
268473|NCT02155361|Drug|Topical vehicle oil|
268474|NCT02155348|Procedure|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
268475|NCT02155348|Procedure|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
268476|NCT02155348|Device|Lentis LS-313|
268477|NCT02155335|Drug|Prefilled Syringe delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
268478|NCT02155335|Drug|Smartject Device delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
268479|NCT02155322|Biological|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
268480|NCT02155322|Biological|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
268481|NCT02155309|Drug|Scopolamine|
268482|NCT02155309|Drug|Placebo|
268483|NCT02155296|Behavioral|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults—RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building—RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building—As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
268484|NCT02155283|Device|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
268485|NCT02155270|Procedure|Corneal precut 600µm|
268486|NCT02155270|Procedure|Corneal stabincision|
268487|NCT02155257|Drug|Modafinil|
268488|NCT02155257|Drug|Gabapentin|
268489|NCT02155257|Drug|Placebo|
268490|NCT02155218|Other|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
268491|NCT02155218|Other|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
268492|NCT02155218|Other|gadolinium contrast|
268493|NCT02155205|Drug|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
268494|NCT02155205|Drug|Placebo|Matching placebo
268495|NCT02155205|Drug|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
268496|NCT02155192|Drug|No Intervention|
268497|NCT02155166|Drug|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
268498|NCT02155166|Drug|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
268499|NCT02155153|Other|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
268500|NCT02155140|Dietary Supplement|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
268501|NCT02155127|Behavioral|walking|
268502|NCT02155101|Drug|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
268503|NCT02155101|Drug|ART with 2 NRTIs plus LPV/r (or ATV/r)|Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
268504|NCT02155088|Drug|BYL719|Dose escalation beginning at 250 mg/day
268505|NCT02155088|Drug|Gemcitabine|Dose escalation beginning at 800 mg/m^2
268506|NCT02155088|Drug|(nab)-paclitaxel|125 mg/m^2 dose
268507|NCT02155075|Device|MIRA device imaging|MIRA device imaging for adjunctive detection of breast cancer. Arm 1 administarte result
268508|NCT02155062|Other|Whole grain rye|
268509|NCT02155062|Other|Whole grain wheat|
268510|NCT02155062|Other|Refined cereal|
268511|NCT02155049|Drug|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
268512|NCT02155036|Other|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) ~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
268513|NCT02155023|Drug|Insulin dosing|
268514|NCT02155023|Device|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
268515|NCT02155010|Drug|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
268516|NCT02155010|Drug|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
268517|NCT02154984|Behavioral|behavioral dietary intervention|Follow tRD
268518|NCT02154984|Behavioral|telephone-based intervention|Receive coaching calls
268519|NCT02154984|Other|laboratory biomarker analysis|Correlative studies
268520|NCT02154932|Drug|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
268521|NCT02154932|Drug|single dose misoprostol|1 dose, 1 hours, prior surgery
268522|NCT02154919|Procedure|Percutaneous coronary intervention|
268523|NCT02154906|Device|DFDBA|
268524|NCT02154906|Device|autologous platelet rich fibrin|
268525|NCT02154893|Device|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
268526|NCT02154893|Device|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
268527|NCT02154893|Device|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
268528|NCT02154880|Procedure|PFT|Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
268529|NCT02154880|Procedure|lab work|The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
268530|NCT02154880|Procedure|6MWT|The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
268531|NCT02154880|Other|questionnaires|TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
268532|NCT02154867|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
268533|NCT02154867|Other|Placebo fecal transplant|Fecal transplantation with own feces
268534|NCT02154854|Drug|Tacrolimus targeted half-dose|
268535|NCT02154854|Drug|Tacrolimus targeted plain dose|
268536|NCT02154841|Behavioral|Questionnaire, taste test, visual food test|
268537|NCT02154828|Behavioral|Integrative practices|
268538|NCT02154815|Other|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, and 24 months
268539|NCT02154802|Behavioral|video: community member|
268540|NCT02154802|Behavioral|video: physician|
268541|NCT02154802|Behavioral|video: choice of video|
268542|NCT02154789|Drug|polidocanol|
268543|NCT02154789|Procedure|infra-red coagulation|
268544|NCT02154789|Procedure|cryotherapy|
268545|NCT02154776|Drug|LEE011|3 weeks on and 1 week off
268546|NCT02154776|Drug|Buparlisib|daily
268547|NCT02154776|Drug|Letrozole|2.5 mg daily;
268548|NCT02154763|Drug|Ropivacaine|
268549|NCT02154763|Drug|Normal Saline|
268550|NCT02154750|Device|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
268551|NCT02154750|Device|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
268552|NCT02154737|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
268553|NCT02154737|Drug|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
268554|NCT02154724|Device|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
268555|NCT02154724|Device|DBS|The aDBS s applied for two hous in DBS modality.
268556|NCT02154698|Other|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
268557|NCT02154698|Other|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
268558|NCT02154685|Behavioral|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
268559|NCT02154685|Behavioral|Non-Retrieval Extinction|Neutral cue exposure.
268560|NCT02154659|Device|24hr pH monitoring|
268561|NCT02154646|Drug|LY2157299|Administered orally
268562|NCT02154646|Drug|Gemcitabine|Administered IV
268563|NCT02154633|Behavioral|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
268704|NCT02153580|Drug|cyclophosphamide|Given IV
268564|NCT02154633|Behavioral|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
268565|NCT02154620|Procedure|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
268566|NCT02154620|Device|Synthes TCP volar plate|
268567|NCT02154607|Device|CO2-Laser Treatment|
268568|NCT02154594|Drug|Acacia catechu|
268569|NCT02154594|Drug|Chlorhexidine gluconate|
268570|NCT02154594|Other|Distilled water|
268571|NCT02154581|Device|SLActive implant|
268572|NCT02154568|Drug|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
268573|NCT02154555|Procedure|debridement|post-operative debridement at 1 week follow-up visit
268574|NCT02154542|Device|Neurovent Monitor XIII|
268575|NCT02154529|Drug|Tesevatinib|
268576|NCT02154516|Device|ODH Hip System|
268577|NCT02154503|Device|topical 5% Minoxidil (Microneedling)|
268578|NCT02154490|Drug|Docetaxel|Given IV
268579|NCT02154490|Biological|Durvalumab|Given IV
268580|NCT02154490|Drug|Erlotinib Hydrochloride|Given PO
268581|NCT02154490|Drug|FGFR Inhibitor AZD4547|Given PO
268582|NCT02154490|Biological|Ipilimumab|Given IV
268583|NCT02154490|Other|Laboratory Biomarker Analysis|Correlative studies
268584|NCT02154490|Biological|Nivolumab|Given IV
268585|NCT02154490|Drug|Palbociclib|Given PO
268586|NCT02154490|Other|Pharmacological Study|Correlative studies
268587|NCT02154490|Biological|Rilotumumab|Given IV
268588|NCT02154490|Drug|Talazoparib|Given PO
268589|NCT02154490|Drug|Taselisib|Given PO
268590|NCT02154490|Biological|Tremelimumab|Given IV
268591|NCT02154477|Drug|intranasal insulin|insulin
268592|NCT02154477|Drug|placebo (intranasal saline)|saline
268593|NCT02154464|Drug|Paracetamol|
268594|NCT02154464|Drug|Placebo|
268595|NCT02154451|Device|Infrared Imaging Device- ALIAS|Infrared Camera
268596|NCT02154438|Drug|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
268597|NCT02154425|Procedure|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
268598|NCT02154425|Biological|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
268599|NCT02154412|Other|Respiratory Training|Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
268600|NCT02154399|Drug|EF5|Given IV
268601|NCT02154399|Other|Laboratory Biomarker Analysis|Correlative studies
268602|NCT02154399|Procedure|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
268603|NCT02154399|Other|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
268604|NCT02154386|Device|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
268605|NCT02154360|Drug|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
268606|NCT02154347|Drug|KAD-1229|
268607|NCT02154347|Drug|Placebo|
268608|NCT02154347|Drug|Insulin|
268609|NCT02154334|Drug|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
268610|NCT02154334|Drug|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
268611|NCT02154334|Drug|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
268612|NCT02154321|Device|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
268613|NCT02154308|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
268614|NCT02154295|Device|Infraredx Test Catheter|
268615|NCT02154282|Behavioral|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
268616|NCT02154269|Drug|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
268617|NCT02154269|Drug|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
268618|NCT02154256|Behavioral|Increasing incentives|Offer incentives that increase over time.
268619|NCT02154256|Behavioral|Decreasing incentives|offer incentives that decrease over time
268620|NCT02154256|Behavioral|stable incentives|offer incentives that are stable over time, but higher than usual care
268621|NCT02154243|Drug|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
268622|NCT02154243|Other|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
268623|NCT02154230|Dietary Supplement|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
268624|NCT02154230|Dietary Supplement|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
268625|NCT02154217|Drug|Bimatoprost|
268626|NCT02154217|Drug|Latanoprost/Timolol|
268627|NCT02154191|Procedure|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
268628|NCT02154178|Other|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
268629|NCT02154165|Other|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
268630|NCT02154152|Drug|Homoeopathic Medicine causticum 200c|
268631|NCT02154139|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
268632|NCT02154126|Device|Continuous Glucose Monitoring Device (Senseonics)|
268633|NCT02154113|Device|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
268634|NCT02154113|Device|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
268635|NCT02154100|Dietary Supplement|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
268636|NCT02154100|Dietary Supplement|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
268637|NCT02154087|Biological|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
268638|NCT02154074|Drug|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
268639|NCT02154074|Drug|Isoflurane|inhale Isoflurane 1.5MAC
268640|NCT02154074|Drug|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
268641|NCT02154074|Drug|normal saline|the same volume of saline + Isoflurane during operation
268642|NCT02154061|Drug|IIV Flu Vaccine|This is an FDA approved and tested Inactivated Flu Vaccine.
268643|NCT02154061|Drug|Metronidazole|This is a standard antibiotic
268644|NCT02154061|Drug|Neomycin|This is a standard antibiotic.
268645|NCT02154061|Drug|Vancomycin|This is a standard antibiotic.
268646|NCT02154048|Drug|Ropivacaine|
268647|NCT02154048|Drug|Dexamethasone|
268648|NCT02154048|Other|Placebo|
268649|NCT02153983|Drug|Colchicine 0.6Mg Cap|Colchicine 0.6 mg given twice daily
268650|NCT02153983|Drug|Placebo capsules given|Placebo capsules given twice daily
268651|NCT02153983|Drug|Colchicine 0.6Mg Tab|Open-label colchicine
268652|NCT02153957|Behavioral|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
268653|NCT02153944|Drug|Propanolol|placebo to be given during study visit
268654|NCT02153944|Drug|Methylphenidate|60mg during study visit
268655|NCT02153918|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
268656|NCT02153918|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
268657|NCT02153905|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
268658|NCT02153905|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
268659|NCT02153905|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
268660|NCT02153905|Biological|Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)|Day 0: MAGE-A3-A1 transduced peripheral blood lymphocytes (PBL) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
268661|NCT02153892|Device|GDS Accucinch System|Percutaneous Coronary Intervention
268662|NCT02153879|Drug|Fenofibrate|fenofibrate 145/day for 12 weeks
268663|NCT02153879|Drug|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
268664|NCT02153866|Biological|rotavirus vaccine|3ml/dose, oral
268665|NCT02153866|Biological|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
268666|NCT02153866|Biological|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
268667|NCT02153840|Drug|PSORI-CM01（YXBCM01） granule|
268668|NCT02153840|Drug|placebo|
268669|NCT02153827|Other|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
268670|NCT02153827|Other|General Shoulder exercise|general exercise consisting of active shoulder movements
268700|NCT02153606|Other|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
268671|NCT02153814|Procedure|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
268672|NCT02153814|Procedure|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
268673|NCT02153801|Procedure|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|"For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.~For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.~For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
268674|NCT02153788|Drug|Temazepam|Temazepam 15 mg orally at bedtime
268675|NCT02153788|Drug|Placebo|
268676|NCT02153775|Behavioral|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
268677|NCT02153762|Drug|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
268678|NCT02153762|Drug|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
268679|NCT02153749|Behavioral|Cognitive Regulation of Craving|"Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life."
268680|NCT02153749|Behavioral|Mindfulness-Based Regulation of Craving|"Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical."
268681|NCT02153736|Behavioral|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
268682|NCT02153723|Drug|Glatiramer Acetate|
268683|NCT02153710|Behavioral|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
268684|NCT02153710|Behavioral|Phonomotor Therapy|Experimental therapy.
268685|NCT02153697|Device|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
268686|NCT02153697|Drug|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
268687|NCT02153671|Biological|A(H5N1) inactivated influenza vaccine (IIV)|Prepared from the NIBRG-23 vaccine virus strain. One vaccine dose (0.5 ml) contained 15 mg of influenza A(H5N1) virus hemagglutinin (HA), adjuvanted with aluminum hydroxide. Two doses were administered intramuscularly 28 days apart.
268688|NCT02153671|Biological|A(H5N2) live attenuated influenza vaccine (LAIV)|Two doses of A(H5N2) live attenuated influenza vaccine (LAIV) administered 28 days apart, approximately 1.5 years prior to receiving A(H5N1) IIV
268689|NCT02153658|Procedure|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
268690|NCT02153658|Procedure|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
268691|NCT02153645|Drug|240mg Amantadine HCl ER tablets|
268692|NCT02153645|Drug|Placebo tablets|
268693|NCT02153645|Drug|320mg Amantadine HCl ER tablets|
268694|NCT02153632|Drug|amantadine HCl ER|Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
268695|NCT02153632|Drug|Placebo|subjects are given an identical placebo tablet
268696|NCT02153619|Behavioral|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
268697|NCT02153619|Behavioral|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSKCC Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
268698|NCT02153619|Behavioral|questionnaires assessments|
268699|NCT02153606|Drug|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
268701|NCT02153593|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
268702|NCT02153593|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
268705|NCT02153580|Other|laboratory biomarker analysis|Correlative studies
268706|NCT02153580|Drug|Bendamustine Hydrochloride|Given IV
268707|NCT02153580|Drug|Etoposide|Given IV
268708|NCT02153580|Drug|Fludarabine Phosphate|Given IV
268709|NCT02153580|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
268710|NCT02153567|Drug|Escitalopram|Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.
268711|NCT02153567|Other|Placebo|Placebo will be given for the next 10 weeks.
268712|NCT02153554|Behavioral|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
268713|NCT02153541|Drug|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
268714|NCT02153541|Other|Mineral oil|50% of participants will receive the mineral oil. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
268715|NCT02153528|Drug|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
268716|NCT02153528|Drug|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
268717|NCT02153515|Other|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
268718|NCT02153502|Drug|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
268719|NCT02153502|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
268720|NCT02153489|Drug|Aclidinium bromide|
268721|NCT02153489|Drug|Placebo|
268722|NCT02153476|Drug|2.0mg of ALG-1001|
268723|NCT02153476|Drug|Balanced Salt Solution|
268724|NCT02153463|Behavioral|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
268725|NCT02153450|Drug|metformin hydrochloride|Given PO
268726|NCT02153450|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
268727|NCT02153437|Drug|BMS-919373|
268728|NCT02153437|Drug|Sotalol|
268729|NCT02153437|Drug|Placebo for BMS-919373|
268730|NCT02153424|Drug|Apixaban|
268731|NCT02153398|Drug|D961H sachet 10 mg|
268732|NCT02153398|Drug|D961H capsule 10mg|
268733|NCT02153398|Drug|D961H capsule 20 mg|
268734|NCT02153385|Other|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
268735|NCT02153372|Other|BMC2012|
268736|NCT02153359|Device|High Efficiency Particulate Air Cleaner|
268737|NCT02153359|Device|Sham air cleaner|
268738|NCT02153346|Other|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
268739|NCT02153346|Other|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
268740|NCT02153333|Procedure|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
268741|NCT02153320|Procedure|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
268742|NCT02153307|Device|Implantable loop recorders system Reveal ICM LINQ®,|
268743|NCT02153294|Procedure|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
268744|NCT02153294|Procedure|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
268745|NCT02153281|Other|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
268746|NCT02153268|Procedure|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).~BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
268747|NCT02153229|Radiation|Photodynamic Therapy|
268748|NCT02153229|Procedure|Radical Pleurectomy|
268749|NCT02153229|Radiation|Chemotherapy|
268750|NCT02153229|Drug|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
268751|NCT02153203|Behavioral|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
268752|NCT02153203|Other|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
268753|NCT02153190|Device|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
268754|NCT02153190|Device|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
268755|NCT02153177|Procedure|Rotator cuff repair|Arthroscopic procedure
268756|NCT02153177|Drug|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
268757|NCT02153177|Drug|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
269030|NCT02151136|Drug|Sterile water|
268758|NCT02153151|Other|Cytology specimen|Correlative studies
268759|NCT02153151|Other|Laboratory biomarker analysis|Correlative studies
268760|NCT02153138|Device|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:~The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.~The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
268761|NCT02153138|Device|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
268762|NCT02153138|Device|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
268763|NCT02153125|Drug|Eplerenone|
268764|NCT02153112|Biological|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
268765|NCT02153112|Biological|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
268766|NCT02153112|Biological|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
268767|NCT02153112|Biological|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
268768|NCT02153112|Drug|Placebo|Placebo saline solution
268769|NCT02153099|Drug|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
268770|NCT02153099|Drug|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
268771|NCT02153086|Drug|Ramelteon|Ramelteon tablets 8 mg
268772|NCT02153073|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
268773|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
268774|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
268775|NCT02153047|Behavioral|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
268776|NCT02153021|Radiation|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.~Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
268777|NCT02152995|Procedure|Computed Tomography|Undergo iodine I-124 PET/CT
268778|NCT02152995|Radiation|Iodine I 124|Undergo iodine I-124 PET/CT
268779|NCT02152995|Radiation|Iodine I-131|Given PO
268780|NCT02152995|Other|Laboratory Biomarker Analysis|Correlative studies
268781|NCT02152995|Other|Pharmacodynamic Study|Correlative studies
268782|NCT02152995|Procedure|Positron Emission Tomography|Undergo iodine I-124 PET/CT
268783|NCT02152995|Drug|Trametinib|Given PO
268784|NCT02152982|Other|Laboratory Biomarker Analysis|Correlative studies
268785|NCT02152982|Other|Placebo|Given PO
268786|NCT02152982|Other|Quality-of-Life Assessment|Ancillary studies
268787|NCT02152982|Drug|Temozolomide|Given PO
268788|NCT02152982|Drug|Veliparib|Given PO
268789|NCT02152969|Drug|Telmisartan|
268790|NCT02152969|Drug|Amlodipine|
268791|NCT02152969|Drug|Chlorthalidone|
268792|NCT02152956|Drug|Flotetuzumab|Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
268793|NCT02152943|Drug|Everolimus|Given PO
268794|NCT02152943|Other|Laboratory Biomarker Analysis|Correlative studies
268795|NCT02152943|Drug|Letrozole|Given PO
268796|NCT02152943|Biological|Trastuzumab|Given IV
268797|NCT02152930|Drug|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
268798|NCT02152917|Drug|Tranexamic acid|
268799|NCT02152917|Drug|Floseal®|
268800|NCT02152891|Behavioral|CHAP-EMS/CP@clinic|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
268801|NCT02152878|Device|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
268802|NCT02152878|Device|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
268803|NCT02152865|Drug|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
268804|NCT02152865|Drug|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
268805|NCT02152852|Behavioral|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
268806|NCT02152839|Behavioral|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
268807|NCT02152826|Device|Potassium oxalate|Professional application
268808|NCT02152813|Behavioral|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
268809|NCT02152800|Drug|valacyclovir hydrocholoride|
268810|NCT02152787|Drug|Injection of propofol 1.0mg/kg|
268811|NCT02152787|Drug|propofol 0.5mg/kg|
268812|NCT02152787|Drug|normal saline|
268813|NCT02152774|Drug|Rho-Kinase Inhibitor|
268814|NCT02152761|Drug|bimagrumab|Bimagrumab was administered as intravenous infusion starting on Day 1 until week 20.
268815|NCT02152761|Other|placebo|Matching placebo was administered as intravenous infusion starting on Day 1 until week 20.
268816|NCT02152748|Genetic|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
268817|NCT02152735|Procedure|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
268818|NCT02152709|Biological|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
268819|NCT02152709|Biological|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
268820|NCT02152696|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
268821|NCT02152696|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
268822|NCT02152696|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
268823|NCT02152683|Device|Renova|Low- Intensity Shockwave
268824|NCT02152670|Drug|Methylphenidate|
268825|NCT02152670|Drug|Alpha Methyl Para Tyrosine (AMPT)|
268826|NCT02152670|Other|[11C]PHNO|
268827|NCT02152670|Other|[11C]raclopride|
268828|NCT02152657|Other|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
268829|NCT02152631|Drug|Abemaciclib|Administered orally
268830|NCT02152631|Drug|Erlotinib|Administered orally
268831|NCT02152618|Other|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
268832|NCT02152605|Drug|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
268833|NCT02152605|Drug|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
268834|NCT02152592|Drug|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
268835|NCT02152592|Drug|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
268836|NCT02152579|Drug|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
268837|NCT02152566|Device|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
268838|NCT02152553|Drug|Hydrocortisone|
268839|NCT02152553|Drug|Placebo|
268840|NCT02152540|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
268841|NCT02152540|Device|Sham rTMS|Placebo Device that simulates active rTMS treatment
268842|NCT02152514|Drug|Intrathecal Morphine/Sufentanil|
268843|NCT02152514|Device|PCA|
268844|NCT02152501|Other|Exercise Energy Expenditure 300 kcal/day|
268845|NCT02152501|Other|Exercise Energy Expenditure 600 kcal/day|
268846|NCT02152475|Drug|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
268847|NCT02152475|Device|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
268848|NCT02152462|Other|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
268849|NCT02152449|Dietary Supplement|Oral nutritional supplementation|
268850|NCT02152436|Other|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
268851|NCT02152423|Drug|LOVENOX|
268852|NCT02152423|Drug|ENOXAMED|
268853|NCT02152410|Device|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
268854|NCT02152410|Drug|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS> 30).
268855|NCT02152397|Behavioral|Therapist-led brief intervention (TBI)|
268856|NCT02152384|Drug|Insulin Peglispro|Administered SC
268857|NCT02152384|Drug|Insulin Lispro|Administered SC
268858|NCT02152384|Drug|Insulin Glargine|Administered SC
268859|NCT02152371|Drug|Dulaglutide|Administered SQ
268860|NCT02152371|Drug|Placebo|Administered SQ
268861|NCT02152371|Drug|Insulin Glargine|Administered SQ
268862|NCT02152371|Drug|Metformin|Administered orally
268863|NCT02152358|Drug|Aciclovir|Intravenous 15 mg/kg/d during 14 days
268864|NCT02152358|Drug|Ganciclovir|intravenous 10 mg/kg/d for 14 days
268865|NCT02152358|Drug|Placebo|
268866|NCT02152345|Drug|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.~Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
268867|NCT02152345|Drug|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.~Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.~(standard of care)"
268868|NCT02152345|Drug|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.~720 mg by mouth every 12 hours (Day 0)(1080 mg AA).~(standard of care)"
268869|NCT02152345|Drug|rATG|"1.5 mg/kg IV daily on Day 0-3.~(standard of care)"
268870|NCT02152345|Drug|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.~(standard of care)"
268871|NCT02152345|Procedure|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
268872|NCT02152332|Drug|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
268873|NCT02152332|Drug|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
268874|NCT02152332|Drug|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
268875|NCT02152332|Drug|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
268876|NCT02152332|Drug|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
268877|NCT02152319|Device|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
268878|NCT02152319|Procedure|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
268879|NCT02152306|Drug|Fimasartan and Amlodipine|
268880|NCT02152306|Drug|Fimasartan|
268881|NCT02152280|Drug|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
268882|NCT02152280|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
268883|NCT02152267|Device|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
268884|NCT02152254|Drug|Targeted Therapy Based on Molecular Profiling|Molecular profiling results are used to assign targeted therapy. Patients receive targeted therapy by participating in a Phase I or a Phase II clinical trial. If a clinical trial is not available, and a commercially available targeted therapy exists (Food and Drug Administration [FDA]-approved for another indication), patients can receive the FDA-approved drug.
268885|NCT02152254|Drug|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
268886|NCT02152228|Drug|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
268887|NCT02152215|Procedure|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
268888|NCT02152215|Procedure|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
268889|NCT02152202|Other|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
268890|NCT02152202|Other|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
268891|NCT02152189|Other|Screening for Fabry disease|
268892|NCT02152176|Device|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
268893|NCT02152163|Drug|IV Ibuprofen|
268894|NCT02152163|Drug|placebo|
268895|NCT02152150|Other|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
268896|NCT02152150|Other|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
268897|NCT02152137|Drug|efatutazone|Given PO
268898|NCT02152137|Drug|paclitaxel|Given IV
268899|NCT02152111|Dietary Supplement|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
268900|NCT02152111|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months.
268901|NCT02152098|Procedure|Acute Early onset of rehabilitation|Early onset of rehabilitation
268902|NCT02152098|Procedure|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
268903|NCT02152098|Procedure|Chronic Exercise|Exercise
268904|NCT02152098|Procedure|Chronic Control|Control
268905|NCT02152085|Device|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
268906|NCT02152085|Device|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
268907|NCT02152072|Other|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
268908|NCT02152059|Drug|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
268909|NCT02152046|Procedure|ROP exam with spring loaded retractor|
268910|NCT02152046|Procedure|ROP exam with screw retractor|
268911|NCT02152033|Behavioral|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
268912|NCT02152033|Behavioral|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
268913|NCT02152020|Behavioral|Survey|
268914|NCT02152007|Drug|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
268915|NCT02151994|Drug|BIA 5-1058|oral administration
268916|NCT02151994|Drug|Placebo|oral administration
268917|NCT02151981|Drug|Chemotherapy|Randomization to either AZD9291 or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (AZD9291:platinum-based doublet-chemotherapy) ratio
268918|NCT02151981|Drug|Cross-over to AZD9291|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with AZD9291 80mg, once daily. These subjects may continue treatment with AZD9291 even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.~Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to AZD9291."
268919|NCT02151968|Procedure|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
268920|NCT02151968|Procedure|Ultrasound-Guidance|"Device: Ultrasound Machine~Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
268921|NCT02151955|Behavioral|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
268922|NCT02151929|Device|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
268923|NCT02151929|Device|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
268924|NCT02151916|Other|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
268925|NCT02151916|Other|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
268926|NCT02151903|Drug|DI-Leu16-IL2|DI-Leu16-IL2
268927|NCT02151890|Biological|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
268928|NCT02151877|Drug|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
268929|NCT02151877|Drug|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
268930|NCT02151864|Drug|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
268931|NCT02151851|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol~Pharmaceutical Form: Prefilled syringes~Concentration: 200 mg/ml~Route of administration: Subcutaneous injection"
268932|NCT02151851|Drug|Methotrexate|"Active substance: Methotrexate~Pharmaceutical form: Tablet~Concentration: Maximum dose 10 mg per week~Route of administration: Oral"
268933|NCT02151851|Other|Placebo|"Active substance: Placebo~Pharmaceutical form: Prefilled syringes~Concentration: 0.9 % saline~Route of Administration: Subcutaneous injection"
268934|NCT02151825|Dietary Supplement|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
268935|NCT02151825|Other|Placebo|3 capsules of Maltodextrin per day
268936|NCT02151812|Device|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
268937|NCT02151812|Device|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
268938|NCT02151799|Procedure|Abdominoplasty and liposuction|
268939|NCT02151786|Drug|Lansoprazole|Lansoprazole intravenous 30 mg
268940|NCT02151773|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
268941|NCT02151760|Drug|18F-DCFPyL|
268942|NCT02151734|Drug|KALOMIN™ Tab.|
268943|NCT02151734|Drug|Umckamin syrup|
268944|NCT02151721|Drug|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
268945|NCT02151708|Drug|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
268946|NCT02151708|Drug|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
268947|NCT02151695|Procedure|panretinal photocoagulation|
268948|NCT02151695|Drug|Aflibercept intravitreal injections|
268949|NCT02151682|Drug|Tapentadol prolonged release|
268950|NCT02151682|Drug|Morphine prolonged release|
268951|NCT02151669|Behavioral|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
268952|NCT02151656|Drug|F17464|
268953|NCT02151656|Drug|Placebo|
268954|NCT02151643|Drug|PT20|Modified ferric oxide adipate tablets
268955|NCT02151643|Drug|Placebo|Placebo tablets matched to each PT20 dose arm
268956|NCT02151630|Drug|Pyruvic acid|
268957|NCT02151630|Drug|Salicylic Acid|
268958|NCT02151617|Drug|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
268959|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
268960|NCT02151617|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
268961|NCT02151617|Drug|Placebo|Placebo tablet once daily dosing for 14 days
268962|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
268963|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
268964|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
268965|NCT02151617|Drug|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
268966|NCT02151617|Drug|PF-06743649|Tablet, to be decided dose, once daily, 14 days
268967|NCT02151617|Drug|Placebo|Tablet, once daily, 14 days
268968|NCT02151604|Drug|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
268969|NCT02151591|Drug|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:~Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
268970|NCT02151578|Other|home/community case management|
268971|NCT02151565|Device|HTEMS|
268972|NCT02151565|Device|TENS|
268973|NCT02151552|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
268974|NCT02151552|Drug|[18F](+/-)NOS|7 mCi of [18F](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
268975|NCT02151539|Other|medical chart review|Ancillary studies
268976|NCT02151539|Other|quality-of-life assessment|Ancillary studies
268977|NCT02151526|Genetic|LentiGlobin BB305 Drug Product|"autologous CD34+ hematopoietic stem cells (HSCs) transduced with the LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene~Subjects with beta-thalassemia major will undergo HSC procurement by bone marrow harvest or apheresis after mobilization with filgrastim, a granulocyte-colony stimulating factor (G-CSF), alone or in combination with plerixafor, as decided by the clinical transplant team.~Stem cell mobilization by is contraindicated in sickle cell disease (SCD), as it could induce a sickle cell crisis; thus, procurement of HSCs for subjects with severe SCD will be conducted by bone marrow harvest."
268978|NCT02151513|Device|Intrathecal Pump Placement|
268979|NCT02151500|Behavioral|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
268980|NCT02151487|Drug|Ropivacaine|Ropivacaine alone
268981|NCT02151487|Drug|Ropivacaine and dexamethasone|Ropivacaine combination with dexamethasone
268982|NCT02151487|Drug|Ropivacaine and clonidine|Ropivacaine combination with clonidine
268983|NCT02151487|Drug|Ropivacaine, dexamethasone and clonidine|Ropivacaine combination with dexamethasone and clonidine
268984|NCT02151474|Drug|INCB047986|
268985|NCT02151474|Drug|Placebo|
268986|NCT02151461|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
268987|NCT02151461|Drug|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
268988|NCT02151461|Drug|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
268989|NCT02151461|Drug|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
268990|NCT02151448|Biological|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
268991|NCT02151448|Drug|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
268992|NCT02151448|Drug|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
268993|NCT02151448|Biological|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
268994|NCT02151422|Behavioral|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
268995|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
268996|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
268997|NCT02151409|Drug|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
268998|NCT02151396|Behavioral|Working memory training|
268999|NCT02151396|Device|Functional magnetic resonance imaging (fMRI)|
269000|NCT02151383|Drug|Serelaxin|Serelaxin was administered intravenously for up to 48 hours.
269001|NCT02151357|Drug|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
269002|NCT02151344|Biological|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
269003|NCT02151344|Biological|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
269004|NCT02151331|Behavioral|External Facilitation|Non-responding sites randomized to receive external facilitation
269005|NCT02151331|Behavioral|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
269006|NCT02151305|Drug|Propofol, remifentanil|
269007|NCT02151305|Drug|Sevoflurane|
269008|NCT02151279|Other|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
269009|NCT02151279|Other|Control|
269010|NCT02151266|Behavioral|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
269011|NCT02151266|Behavioral|Exercise Only|
269012|NCT02151266|Behavioral|Stretching and Flexibility|
269013|NCT02151253|Drug|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
269014|NCT02151253|Drug|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
269015|NCT02151240|Drug|Foscarnet Sodium|
269016|NCT02151240|Drug|Acyclovir|
269017|NCT02151214|Other|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
269018|NCT02151201|Behavioral|Influenza vaccination video education|Influenza vaccination video education
269019|NCT02151201|Behavioral|Hand washing video education|Hand washing video education
269020|NCT02151188|Dietary Supplement|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
269021|NCT02151188|Device|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
269022|NCT02151175|Device|LIFUP|
269023|NCT02151162|Behavioral|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
269024|NCT02151162|Dietary Supplement|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
269025|NCT02151162|Behavioral|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
269026|NCT02151162|Dietary Supplement|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
269027|NCT02151149|Drug|nab-paclitaxel|
269028|NCT02151149|Drug|Carboplatin|
269029|NCT02151136|Drug|24% sucrose|
269031|NCT02151136|Other|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
269032|NCT02151110|Biological|MEDI4920 3 mg|Participants received single IV dose of MEDI4920 3 milligram (mg) infused on Day 1.
269033|NCT02151110|Biological|MEDI4920 10 mg|Participants received single IV dose of MEDI4920 10 mg infused on Day 1.
269034|NCT02151110|Biological|MEDI4920 30 mg|Participants received single IV dose of MEDI4920 30 mg infused on Day 1.
269035|NCT02151110|Biological|MEDI4920 100 mg|Participants received single IV dose of MEDI4920 100 mg infused on Day 1.
269036|NCT02151110|Biological|MEDI4920 300 mg|Participants received single IV dose of MEDI4920 300 mg infused on Day 1.
269037|NCT02151110|Biological|MEDI4920 1000 mg|Participants received single IV dose of MEDI4920 1000 mg infused on Day 1.
269038|NCT02151110|Biological|MEDI4920 3000 mg|Participants received single IV dose of MEDI4920 3000 mg infused on Day 1.
269039|NCT02151110|Other|Placebo|Participants received single IV dose of placebo matching with MEDI4920 infused on Day 1.
269040|NCT02151084|Drug|Selumetinib|
269041|NCT02151084|Drug|Cisplatin|
269042|NCT02151084|Drug|Gemcitabine|
269043|NCT02151071|Device|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
269044|NCT02151071|Device|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
269045|NCT02151058|Drug|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
269046|NCT02151058|Drug|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
269047|NCT02151058|Other|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
269048|NCT02151045|Procedure|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
269049|NCT02151045|Procedure|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
269050|NCT02151032|Behavioral|Booklet|Participants read a booklet about colorectal cancer screening tests.
269051|NCT02151032|Behavioral|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
269052|NCT02151032|Behavioral|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
269053|NCT02151032|Behavioral|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
269054|NCT02151032|Behavioral|Questionnaires|Questionnaire completion before and after viewing the program.
269055|NCT02151019|Radiation|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
269056|NCT02151006|Drug|DHEA|
269057|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
269058|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
269059|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
269060|NCT02150967|Drug|BGJ398 (infigratinib)|Capsule for oral use
269061|NCT02150954|Drug|pitocin|
269062|NCT02150941|Device|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
269063|NCT02150941|Device|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
269064|NCT02150928|Drug|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
269065|NCT02150915|Other|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
269066|NCT02150902|Procedure|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF >10g, FTI > 500 g-sec and minimum ablation duration >10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
269144|NCT02150317|Procedure|TACE+Sorafenib|TACE followed by Sorafenib
269145|NCT02150317|Procedure|TACE|TACE alone
269146|NCT02150291|Dietary Supplement|Folic acid|
269147|NCT02150291|Drug|Neurobion|
269148|NCT02150291|Drug|placebo|
269196|NCT02149914|Device|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
269067|NCT02150902|Procedure|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
269068|NCT02150889|Behavioral|Running Program|16 week supervised running program
269069|NCT02150889|Behavioral|Yoga Program|once weekly supervised yoga
269070|NCT02150863|Device|Ultrapulse Carbon Dioxide Laser|
269071|NCT02150863|Device|Cellutome epidermal harvesting system|
269072|NCT02150837|Other|5 & 2 & 2 Plan|Medifast has developed the 5 & 2 & 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 & 2 & 2 Plan consists of 5 Medifast meal replacements, 2 Lean & Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, >72g protein, >100g of carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
269073|NCT02150837|Other|4 & 2 & 1 Plan|Medifast has developed the 4 & 2 & 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 & 2 & 1 Plan consists of 4 Medifast meal replacements, 2 Lean & Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, >72g protein, >100g carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
269074|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily
269075|NCT02150824|Drug|Placebo|BI 187004 medium dose matching placebo once daily
269076|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
269077|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily add on to background metformin
269078|NCT02150824|Drug|Placebo|BI 187004 low dose matching placebo once daily
269079|NCT02150824|Drug|BI 187004|BI 187004 medium dose once daily
269080|NCT02150824|Drug|BI 187004|BI 187004 low dose once daily
269081|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily
269082|NCT02150798|Other|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
269083|NCT02150798|Other|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
269084|NCT02150785|Drug|Streptokinase|
269085|NCT02150772|Procedure|Shear Wave Elastography (SWE)|
269086|NCT02150759|Drug|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
269087|NCT02150759|Drug|Fentanyl|add dexmedetomidine during position change
269088|NCT02150759|Drug|Ketamine|add dexmedetomidine during position change
269089|NCT02150746|Procedure|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
269090|NCT02150746|Procedure|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
269091|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
269092|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
269093|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
269094|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
269095|NCT02150720|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
269096|NCT02150720|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
269097|NCT02150720|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
269098|NCT02150707|Drug|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
269099|NCT02150707|Drug|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
269100|NCT02150694|Procedure|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
269101|NCT02150694|Procedure|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
269102|NCT02150694|Other|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
269103|NCT02150694|Other|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
269149|NCT02150278|Behavioral|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
269150|NCT02150265|Behavioral|SMART manual cognitive behavioral therapy|
269104|NCT02150681|Behavioral|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
269105|NCT02150668|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|
269106|NCT02150668|Behavioral|Homework Support Intervention (HSI)|
269107|NCT02150655|Biological|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
269108|NCT02150655|Biological|Placebo|
269109|NCT02150616|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
269110|NCT02150616|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
269111|NCT02150616|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
269112|NCT02150616|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
269113|NCT02150590|Drug|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
269114|NCT02150590|Drug|sham oxygen (room air)|
269115|NCT02150577|Behavioral|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
269116|NCT02150564|Device|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
269117|NCT02150564|Procedure|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
269118|NCT02150551|Biological|Allogeneic bone marrow-derived mesenchymal stromal cells|This study is a pilot phase 1 study of patients with moderately to severely active Crohn Disease (CD) and ulcerative colitis (UC) (≥ 18 years, Mayo score: ≥6 or CDAI: ˃ 220; <18 years, Pediatric Crohn's Disease Activity Index (PCDAI) :> 30) or Pediatric Ulcerative Colitis Activity Index (PUCAI) : >34). A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 4 consecutive weeks, with the option of an additional 4 weeks of treatment, at the discretion of the principal investigator.
269119|NCT02150538|Device|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
269120|NCT02150538|Device|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
269121|NCT02150525|Dietary Supplement|omega-3 fatty acid|Given PO (by mouth) daily
269122|NCT02150525|Other|placebo|Given PO(by mouth)daily
269123|NCT02150525|Behavioral|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
269124|NCT02150512|Device|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV >10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still >10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
269125|NCT02150512|Device|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
269126|NCT02150499|Drug|levalbuterol tartrate HFA inhalation aerosol|
269127|NCT02150499|Drug|placebo|
269128|NCT02150473|Drug|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
269129|NCT02150473|Drug|Placebo|Placebo the same amount as adalimumab
269130|NCT02150460|Procedure|One-site peribulbar injection|injection into the inferior medial orbital compartment
269131|NCT02150460|Procedure|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
269132|NCT02150447|Drug|Proton pump inhibitor|Lansoprazole 30 mg, daily
269133|NCT02150447|Drug|Placebo|Placebo, daily
269134|NCT02150434|Device|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
269135|NCT02150434|Drug|Compressed air|compressed air delivered at a fixed flow of 2 L/min
269136|NCT02150434|Drug|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
269137|NCT02150408|Other|PET-CT|
269138|NCT02150395|Other|music therapy|
269139|NCT02150356|Other|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
269140|NCT02150356|Other|Control|Diet based on refined cereal products for a period of 8 weeks.
269141|NCT02150343|Drug|HDM-SPIRE|1 dose every 4 weeks
269142|NCT02150343|Drug|Placebo|1 dose every 4 weeks
269143|NCT02150330|Drug|Dehydroepiandrosterone (DHEAS)|
269151|NCT02150252|Drug|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
269152|NCT02150239|Procedure|operation|
269153|NCT02150226|Device|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
269154|NCT02150213|Procedure|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
269155|NCT02150213|Procedure|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
269156|NCT02150213|Procedure|Sonogram|Sonogram of the uterus (females only)
269157|NCT02150213|Procedure|Biopsy|Uterine endometrial biopsy (females only)
269158|NCT02150213|Drug|BGG492|No study-drug was administered in this study
269159|NCT02150200|Other|shorter hospitalization stay|
269160|NCT02150200|Other|questionnaires|
269161|NCT02150187|Dietary Supplement|HCap Formula|Pill should be taken every other day during the treatment phase.
269162|NCT02150187|Dietary Supplement|Placebo|Similar pills without active ingredients
269163|NCT02150174|Behavioral|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.~Then (initial test), they recall half of word pairs or restudy the other half.~In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
269164|NCT02150161|Drug|Lidocaine/ ketamine|
269165|NCT02150161|Drug|Fentanyl|
269166|NCT02150148|Behavioral|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
269167|NCT02150135|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
269168|NCT02150122|Dietary Supplement|Vitamin D3|
269169|NCT02150109|Device|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
269170|NCT02150109|Device|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
269171|NCT02150096|Other|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
269172|NCT02150096|Other|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
269173|NCT02150096|Other|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
269174|NCT02150083|Procedure|OR retrograde fill|
269175|NCT02150070|Drug|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
269176|NCT02150070|Drug|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
269177|NCT02150057|Device|Breg Fusion Unloading Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
269178|NCT02150044|Device|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
269179|NCT02150031|Drug|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
269180|NCT02150031|Drug|1% Chlorhexidine|subgingival irrigation
269181|NCT02150031|Drug|1% Chlorhexidine|supragingival irrigation
269182|NCT02150031|Procedure|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
269183|NCT02150031|Drug|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
269184|NCT02150031|Procedure|Tooth extraction|dental extraction
269185|NCT02150018|Other|non invasive ventilation|
269186|NCT02150005|Procedure|Periodontal treatment|
269187|NCT02149992|Dietary Supplement|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
269188|NCT02149992|Device|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
269189|NCT02149992|Device|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
269190|NCT02149979|Device|Temperature Controlled Laser Soldering|This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
269191|NCT02149966|Drug|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
269192|NCT02149966|Drug|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
269193|NCT02149953|Dietary Supplement|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
269194|NCT02149940|Other|heart-failure related pharmaceutical intervention|
269195|NCT02149927|Drug|Sevoflurane|
269235|NCT02149641|Radiation|Intensity modulated radiotherapy with chemotherapy|
269197|NCT02149914|Device|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
269198|NCT02149914|Device|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
269199|NCT02149914|Other|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
269200|NCT02149914|Drug|PPI|
269201|NCT02149901|Drug|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
269202|NCT02149901|Drug|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
269203|NCT02149901|Other|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
269204|NCT02149901|Other|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
269205|NCT02149888|Drug|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
269206|NCT02149875|Drug|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
269207|NCT02149875|Drug|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
269208|NCT02149875|Drug|Placebo|100 ml saline intravenous infusion once daily for 10 days.
269209|NCT02149862|Other|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
269210|NCT02149849|Procedure|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
269211|NCT02149836|Drug|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).~Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).~Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).~Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).~Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.~Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:~250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
269212|NCT02149823|Drug|Syntocinon 24 Intranasal Units (IU)|
269213|NCT02149823|Drug|Syntocinon 40 Intranasal Units (IU)|
269214|NCT02149823|Drug|Intranasal Placebo|
269215|NCT02149810|Behavioral|Automatic Self Transcending Meditation|as above
269216|NCT02149797|Procedure|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
269217|NCT02149797|Procedure|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
269218|NCT02149797|Procedure|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
269219|NCT02149784|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy`
269220|NCT02149771|Procedure|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
269221|NCT02149771|Device|endovascular stents implantation|Bare stents implant within portal vein.
269222|NCT02149771|Procedure|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
269223|NCT02149758|Drug|Etoricoxib|
269224|NCT02149745|Procedure|Calling the patient's name|calling the patient's name during anesthesia reversal
269225|NCT02149745|Procedure|Not calling the patient's name|giving verbal stimulus other than the patient's name during anesthesia reversal
269226|NCT02149732|Biological|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
269227|NCT02149719|Other|Desensitisation using boiled peanut|
269228|NCT02149719|Other|Desensitisation using boiled peanut (deferred start)|
269229|NCT02149706|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
269230|NCT02149706|Biological|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
269231|NCT02149693|Other|high-fidelity simulation and teamwork training|
269232|NCT02149693|Other|traditional resuscitation training|
269233|NCT02149667|Device|total hip arthroplasty implant|
269234|NCT02149654|Device|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
269236|NCT02149628|Drug|propofol|
269238|NCT02149615|Other|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
269239|NCT02149602|Radiation|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
269240|NCT02149589|Procedure|Mechanical ventilation|
269241|NCT02149576|Procedure|Low Dose Computed Tomography Imaging|
269242|NCT02149576|Procedure|Chest Radiograph Imaging|
269243|NCT02149563|Device|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
269244|NCT02149550|Other|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
269245|NCT02149550|Other|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
269246|NCT02149550|Other|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
269247|NCT02149550|Other|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
269248|NCT02149550|Other|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
269249|NCT02149550|Other|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
269250|NCT02149537|Drug|hydroxyurea|
269251|NCT02149524|Drug|Herceptin (trastuzuamb)|Intravenous administration
269252|NCT02149524|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
269253|NCT02149459|Radiation|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
269254|NCT02149459|Drug|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
269255|NCT02149459|Behavioral|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
269256|NCT02149446|Device|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
269257|NCT02149433|Drug|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
269258|NCT02149433|Drug|Placebo|
269259|NCT02149420|Drug|VAY736|
269260|NCT02149420|Drug|Placebo|
269261|NCT02149407|Drug|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
269262|NCT02149407|Procedure|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
269263|NCT02149407|Other|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
269264|NCT02149394|Other|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.~The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
269265|NCT02149394|Other|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
269266|NCT02149381|Behavioral|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
269267|NCT02149381|Behavioral|Befriending|Social support intervention, sessions once per week
269268|NCT02149381|Other|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
269269|NCT02149355|Other|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
269270|NCT02149342|Drug|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
269271|NCT02149342|Drug|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
269272|NCT02149329|Drug|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
269273|NCT02149316|Procedure|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
269274|NCT02149316|Procedure|control|a deflated cuff placed on the right upper arm
269275|NCT02149303|Drug|Dabigatran 75 mg|PO BID
269276|NCT02149303|Drug|Dabigatran 150 mg|PO BID
269277|NCT02149290|Device|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; activity data collection; ability to perform a health survey; ability to guide patients through a walk test
269278|NCT02149277|Drug|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
269279|NCT02149264|Drug|Testosterone gel (FE 999303)|
269280|NCT02149251|Genetic|Pre-genetic diagnosis|
269281|NCT02149238|Dietary Supplement|flavanol|
269282|NCT02149238|Dietary Supplement|methylxanthine|
269283|NCT02149238|Dietary Supplement|flavanol + methylxanthine|
269284|NCT02149225|Drug|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.~Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.~The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
269285|NCT02149225|Drug|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.~Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.~GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
269286|NCT02149212|Drug|Phlebotonic|Aminaftone -- 75 mg BID
269287|NCT02149212|Device|Stent|Iliac Vein Stenting
269288|NCT02149212|Procedure|Limb elastic compression support|CEAP 3-5 > 20-30 mmHg compression stockings CEAP 6 > elastic bandages
269289|NCT02149212|Procedure|Unna boot dressing|CEAP 6 > Unna boot dressing
269290|NCT02149199|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
269291|NCT02149199|Drug|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
269292|NCT02149199|Drug|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
269293|NCT02149186|Device|iCTuS-L|
269294|NCT02149173|Procedure|Computed Tomography|Undergo F-18 FES PET/CT
269295|NCT02149173|Procedure|Computed Tomography|Undergo FDG PET/CT
269296|NCT02149173|Drug|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
269297|NCT02149173|Drug|Fludeoxyglucose F-18|Undergo FDG PET/CT
269298|NCT02149173|Other|Laboratory Biomarker Analysis|Correlative studies
269299|NCT02149173|Procedure|Positron Emission Tomography|Undergo F-18 FES PET/CT
269300|NCT02149173|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
269301|NCT02149160|Drug|FRM-0334|
269302|NCT02149160|Drug|Placebo|
269303|NCT02149134|Dietary Supplement|TeHF2013-01|
269304|NCT02149121|Biological|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
269305|NCT02149121|Drug|Rituxan|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
269306|NCT02149121|Drug|MabThera|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
269307|NCT02149108|Drug|Nintedanib (BIBF 1120)|
269308|NCT02149108|Drug|Placebo|
269309|NCT02149108|Drug|BSC|
269310|NCT02149108|Drug|BSC|
269311|NCT02149095|Drug|TransCon PEG treprostinil|
269312|NCT02149082|Device|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
269313|NCT02149056|Behavioral|observation|
269314|NCT02149056|Other|Impaired Glucose Tolerance|Impaired Glucose Tolerance
269315|NCT02149043|Device|Thermography|Thermographic imaging of the patient's abdomen surface
269316|NCT02149043|Procedure|Colonoscopy|Endoscopic examination of the colon
269317|NCT02149030|Other|Cytological screening in A1 and A3|Cytological screening.
269318|NCT02149017|Radiation|SNUBH-NM-333(18F)|5-10 mCi
269319|NCT02148978|Drug|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
269320|NCT02148965|Behavioral|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
269321|NCT02148952|Behavioral|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
269786|NCT02145377|Biological|Placebo|Oral dose of sodium bicarbonate buffer
269787|NCT02145377|Biological|Shanchol|Licensed comparator
269322|NCT02148913|Drug|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
269323|NCT02148913|Drug|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
269324|NCT02148913|Drug|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
269325|NCT02148913|Drug|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
269326|NCT02148874|Biological|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
269327|NCT02148861|Drug|insulin 287|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
269328|NCT02148861|Drug|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
269329|NCT02148861|Drug|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
269330|NCT02148848|Drug|Risedronate|Take risedronate 35 mg orally every week
269331|NCT02148835|Other|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
269332|NCT02148835|Other|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
269333|NCT02148809|Radiation|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
269334|NCT02148796|Drug|Broncho-Vaxom|Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma SA, Switzerland; Storage: Store in the original package
269335|NCT02148796|Other|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
269336|NCT02148783|Drug|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with [11C]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
269337|NCT02148783|Drug|Placebo|
269338|NCT02148770|Device|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
269339|NCT02148757|Procedure|Doppler Ultrasound|
269340|NCT02148744|Biological|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
269341|NCT02148744|Biological|Placebo|
269342|NCT02148731|Other|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
269343|NCT02148718|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
269344|NCT02148705|Drug|NexoBrid|
269345|NCT02148705|Procedure|Standard of Care (SOC)|
269346|NCT02148705|Drug|Gel Vehicle|
269347|NCT02148692|Procedure|Higher PEEP|
269348|NCT02148692|Procedure|Lower PEEP|
269349|NCT02148679|Other|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
269350|NCT02148679|Other|Usual care|Standardized advice to restrict dietary sodium intake to < 2000 mg/day
269351|NCT02148653|Other|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
269352|NCT02148653|Other|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
269353|NCT02148640|Drug|Innovator infliximab|
269354|NCT02148640|Drug|Biosimilar infliximab|
269355|NCT02148627|Drug|LY3041658 (SC)|Administered SC
269356|NCT02148627|Drug|LY3041658 (IV)|Administered as slow IV infusion
269357|NCT02148627|Drug|Placebo|Administered as slow IV infusion
269358|NCT02148614|Drug|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
269359|NCT02148614|Drug|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
269360|NCT02148601|Other|Fecal Microbiota Transplantation|
269361|NCT02148601|Drug|Standard Antibiotic Therapy|
269788|NCT02145364|Device|Ultherapy® treatment|Microfocused ultrasound treatment
269362|NCT02148601|Drug|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
269363|NCT02148588|Drug|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)~Assessment of spontaneous and evoked pain responses~Completion of NPSI questionnaire~Mapping of the affected limb"
269364|NCT02148575|Behavioral|Self-Management Group|
269365|NCT02148575|Behavioral|Symptom Management Group|
269366|NCT02148549|Drug|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
269367|NCT02148536|Procedure|Transjugular intrahepatic portosystemic shunt|
269368|NCT02148523|Behavioral|Comparison to peers|
269369|NCT02148523|Behavioral|Adherence feedback|
269370|NCT02148523|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
269371|NCT02148510|Device|Monobloc|Construction fitted to upper and lower jaw
269372|NCT02148510|Device|Bibloc|Biblock construction
269373|NCT02148497|Procedure|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
269374|NCT02148484|Behavioral|Prolonged Exposure for Adolescents|
269375|NCT02148484|Behavioral|Client Centered Therapy|
269376|NCT02148458|Other|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
269377|NCT02148458|Other|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
269378|NCT02148445|Other|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
269379|NCT02148445|Other|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
269380|NCT02148445|Drug|Nicotine replacement therapy|
269381|NCT02148432|Drug|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
269382|NCT02148432|Drug|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
269383|NCT02148419|Other|no intervention|
269384|NCT02148406|Behavioral|Yoga Skills Training (YST)|Undergo YST
269385|NCT02148406|Other|questionnaire administration|Ancillary studies
269386|NCT02148406|Other|fatigue and depressive symptom assessment and management|Ancillary studies
269387|NCT02148406|Other|psychological stress assessment|Ancillary studies
269388|NCT02148406|Other|laboratory biomarker analysis|Correlative studies
269389|NCT02148406|Other|Attention Control|
269390|NCT02148393|Procedure|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).~In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
269391|NCT02148393|Procedure|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
269392|NCT02148393|Drug|Pregnyl®|1500 IU
269393|NCT02148393|Drug|Utrogestan®|200 mg tid
269394|NCT02148393|Drug|Progynova®|2 mg bid
269395|NCT02148393|Device|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
269396|NCT02148380|Drug|pemetrexed plus carboplatin|
269397|NCT02148380|Drug|gefitinib|
269398|NCT02148367|Drug|Erythropoietin|"This is a double blind randomized placebo-cotrolled study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.~Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
269399|NCT02148354|Behavioral|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
269400|NCT02148341|Other|Community of Practice Facilitation|
269401|NCT02148341|Other|Usual Care|
269402|NCT02148328|Biological|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
269403|NCT02148328|Biological|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
269404|NCT02148328|Biological|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
269405|NCT02148328|Biological|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
269406|NCT02148315|Behavioral|garden|
269407|NCT02148302|Device|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
269408|NCT02148289|Dietary Supplement|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
269409|NCT02148289|Dietary Supplement|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
269410|NCT02148263|Device|senofilcon A|
269411|NCT02148250|Drug|U-500 insulin|Subjects are randomized to receive 100 or 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
269412|NCT02148237|Behavioral|Contingency Management|Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
269413|NCT02148211|Other|Data collection|Initial and follow-up data will be collected using questionnaires.
269414|NCT02148198|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
269415|NCT02148198|Dietary Supplement|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
269416|NCT02148185|Drug|MT-1303|
269417|NCT02148172|Procedure|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
269418|NCT02148172|Procedure|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
269419|NCT02148159|Device|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
269420|NCT02148159|Device|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
269421|NCT02148146|Drug|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
269422|NCT02148133|Drug|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
269423|NCT02148133|Drug|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
269424|NCT02148120|Drug|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
269425|NCT02148120|Drug|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
269426|NCT02148120|Drug|Placebo|
269427|NCT02148107|Drug|BI 691751|BI 691751 Dose 1
269428|NCT02148107|Drug|BI 691751|BI 691751 Dose 2
269429|NCT02148107|Drug|BI 691751|BI 691751 Dose 3
269430|NCT02148107|Drug|BI 691751|BI 691751 Dose 4
269431|NCT02148107|Drug|BI 691751|BI 691751 Dose 5
269432|NCT02148107|Drug|BI 691751|BI 691751 Dose 6
269433|NCT02148107|Drug|Placebo|Placebo
269434|NCT02148094|Drug|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
269435|NCT02148068|Procedure|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
269436|NCT02148055|Other|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
269437|NCT02148029|Other|Exercise|Upper and Lower extremity exercise
269438|NCT02148029|Other|Control|Standard care: anticoagulation, compression & ad-lib ambulation
269439|NCT02148016|Procedure|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
269440|NCT02148016|Procedure|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
269441|NCT02148016|Procedure|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.~The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
269442|NCT02148016|Procedure|PRK only (Traditional Technique)|PRK alone will be performed.
269443|NCT02148016|Drug|Levofloxacin|
269444|NCT02148016|Drug|Betamethasone|
269445|NCT02148016|Drug|Limbal stem cells (LSCs)|
269446|NCT02148003|Procedure|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
269447|NCT02148003|Procedure|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
269448|NCT02148003|Device|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
269449|NCT02147990|Drug|Rociletinib|Rociletinib will be administered to patients orally
269450|NCT02147977|Dietary Supplement|dietary supplement: n-3 PUFA|
269451|NCT02147977|Dietary Supplement|olive oil|
269452|NCT02147964|Drug|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months [all subjects]
269453|NCT02147964|Drug|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months [all subjects]
269454|NCT02147964|Drug|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
269455|NCT02147964|Drug|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
269456|NCT02147964|Drug|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
269457|NCT02147964|Drug|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
269458|NCT02147964|Drug|placebo ketoconazole|placebo ketoconazole daily for 4 months
269459|NCT02147951|Drug|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
269460|NCT02147938|Drug|Tacrolimus|oral
269461|NCT02147925|Drug|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
269462|NCT02147925|Drug|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
269463|NCT02147925|Drug|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
269464|NCT02147912|Other|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
269465|NCT02147899|Drug|SYM-1219|
269466|NCT02147899|Drug|Placebo|
269467|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
269468|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|
269469|NCT02147873|Drug|birinapant|
269470|NCT02147873|Drug|Azacitidine|
269471|NCT02147873|Drug|Placebo|
269472|NCT02147860|Device|Diabetes Assistant (DiAs) with USS Virginia|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
269473|NCT02147860|Other|Sensor Augmented Pump Therapy|Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
269474|NCT02147847|Behavioral|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
269475|NCT02147847|Behavioral|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
269476|NCT02147834|Drug|Ranolazine|"Ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
269477|NCT02147834|Drug|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet~500mg tablet two times per day for 7 days then,~500mg tablet (1000mg) two times per day for 15 weeks"
269478|NCT02147821|Procedure|No Pleural Chest Tube|
269479|NCT02147808|Drug|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
269480|NCT02147808|Drug|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup [2mg/mL]).
269481|NCT02147769|Device|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
269482|NCT02147756|Device|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).~Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
269483|NCT02147756|Device|Repair|
269484|NCT02147743|Behavioral|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
269485|NCT02147743|Behavioral|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
269486|NCT02147730|Procedure|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
269487|NCT02147730|Procedure|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
269488|NCT02147717|Device|Laser stimulation|"Infants will be divided in 2 groups:~Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS~Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.~This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
269489|NCT02147717|Device|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
269880|NCT02144675|Drug|cytarabine|Given IV
269490|NCT02147704|Dietary Supplement|High-sodium diet|"One of high- or low sodium intake for 7 days during each period~High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
269491|NCT02147704|Dietary Supplement|low-sodium diet|"One of high- or low sodium intake for 7 days during each period~Low sodium intake : 50 mmol/day by diet"
269492|NCT02147691|Drug|Azelaic acid 15%|Applied to the face each AM and PM
269493|NCT02147691|Drug|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
269494|NCT02147678|Drug|Etomidate|
269495|NCT02147678|Drug|Propofol|
269496|NCT02147678|Drug|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2~0.4 μg/kg/min.
269497|NCT02147678|Drug|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
269498|NCT02147665|Other|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
269499|NCT02147652|Other|Personalized music|
269500|NCT02147639|Dietary Supplement|Sodium Nitrate|
269501|NCT02147639|Dietary Supplement|Sodium Nitrate - double dose|
269502|NCT02147639|Dietary Supplement|Placebo|
269503|NCT02147639|Procedure|Increased exercise intensity|
269504|NCT02147626|Behavioral|Web-based educational and motivational modules|
269505|NCT02147626|Behavioral|Information and Screening Group|
269506|NCT02147613|Other|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
269507|NCT02147613|Other|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
269508|NCT02147587|Drug|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
269509|NCT02147587|Drug|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
269510|NCT02147574|Procedure|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
269511|NCT02147561|Biological|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
269512|NCT02147548|Drug|etifoxine|
269513|NCT02147548|Drug|lorazepam|
269514|NCT02147548|Drug|Placebo|
269515|NCT02147535|Drug|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
269516|NCT02147522|Behavioral|Self-care management|AHH behavioral intervention is provided by promotoras
269517|NCT02147509|Drug|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
269518|NCT02147509|Drug|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
269519|NCT02147509|Other|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
269520|NCT02147509|Drug|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
269521|NCT02147496|Other|Dietary Intervention|
269522|NCT02147483|Behavioral|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
269523|NCT02147483|Behavioral|Treatment as usual|Treatment usually provided by clinician
269524|NCT02147470|Drug|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
269525|NCT02147431|Drug|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.~Each treatment period will be followed by a hypoglycaemic clamp"
269526|NCT02147431|Drug|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.~Each treatment period will be followed by a hypoglycaemic clamp."
269527|NCT02147392|Drug|[11C]ER-176|
269528|NCT02147379|Drug|Lurasidone|
269529|NCT02147366|Behavioral|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
269530|NCT02147366|Behavioral|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
269531|NCT02147353|Drug|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
269532|NCT02147353|Drug|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
269533|NCT02147301|Device|LC Bead|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):~Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first."
269534|NCT02147288|Device|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
269535|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 14 days|
269536|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 28 days|
269537|NCT02147249|Drug|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
269538|NCT02147236|Behavioral|Social Skills Training|
269539|NCT02147223|Dietary Supplement|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
269881|NCT02144675|Other|laboratory biomarker analysis|Correlative studies
269540|NCT02147223|Dietary Supplement|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
269541|NCT02147210|Other|biological analysis|
269542|NCT02147197|Drug|Ulipristal acetate (UPA)|UPA tablet
269543|NCT02147197|Drug|Placebo|Matching placebo tablet.
269544|NCT02147171|Dietary Supplement|VisionAce|
269545|NCT02147171|Dietary Supplement|Placebo|
269546|NCT02147158|Drug|Ulipristal acetate (UPA)|Ulipristal acetate (UPA) tablet.
269547|NCT02147158|Drug|Placebo|Matching placebo tablet.
269548|NCT02147132|Drug|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
269549|NCT02147132|Drug|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
269550|NCT02147132|Drug|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
269551|NCT02147132|Drug|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
269552|NCT02147119|Procedure|Coronary angiography|
269553|NCT02147106|Other|Videoconsultation|
269554|NCT02147093|Device|Test (multi-focal)|contact lens was to be worn a daily wear.
269555|NCT02147093|Device|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
269556|NCT02147080|Behavioral|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
269557|NCT02147080|Behavioral|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
269558|NCT02147067|Drug|Ranolazine|Ranolazine 1,000 mg twice daily
269559|NCT02147067|Drug|Placebo|Placebo
269560|NCT02147054|Drug|Rocuronium|
269561|NCT02147054|Drug|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
269562|NCT02147041|Drug|EGCG(Epigallocatechin Gallate)|500mg, three times a day, duration:12 weeks
269563|NCT02147041|Drug|Placebo|
269564|NCT02147028|Radiation|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
269565|NCT02147028|Radiation|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
269566|NCT02147015|Drug|Glucocorticoids|
269567|NCT02147015|Drug|Antibiotics|
269568|NCT02147015|Drug|Inhaled corticosteroid (ICS)|
269569|NCT02147015|Drug|Long-Acting Muscarinic Antagonists(LAMA)|
269570|NCT02147015|Drug|Short-acting beta2-agonist (SABA)|
269571|NCT02147015|Other|Physical treatments|
269572|NCT02147015|Drug|long-acting beta2-agonist (LABA)|
269573|NCT02147002|Dietary Supplement|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
269574|NCT02146989|Other|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
269575|NCT02146976|Drug|propofol|introvenious infusion of propofol
269576|NCT02146976|Drug|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
269577|NCT02146937|Drug|Bicalutamide plus Finasteride- Combination therapy|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
269578|NCT02146924|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes|Given IV
269579|NCT02146924|Biological|CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
269580|NCT02146924|Other|Laboratory Biomarker Analysis|Correlative studies
269581|NCT02146911|Drug|Bupropion|
269582|NCT02146911|Drug|Varenicline|
269583|NCT02146911|Behavioral|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
269584|NCT02146898|Other|Position|
269585|NCT02146885|Other|Weight Control|Weight Control
269586|NCT02146846|Drug|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
269587|NCT02146833|Drug|Selinexor|Comparison of different dosages and dosing schedules of drug.
269588|NCT02146820|Device|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
269589|NCT02146807|Device|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
269590|NCT02146794|Device|Renal denervation|Renal denervation
269591|NCT02146781|Biological|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
269636|NCT02146443|Other|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
269882|NCT02144662|Drug|Ranibizumab|0.5mg ranibizumab intravitreal injection
269592|NCT02146781|Other|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
269593|NCT02146742|Drug|ASP1707|oral
269594|NCT02146742|Drug|Placebo|oral
269595|NCT02146729|Procedure|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
269596|NCT02146729|Procedure|Open Treatment|Midline posterior incision with instrumentation.
269597|NCT02146716|Other|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
269598|NCT02146703|Drug|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m2 iv on day 1, 8~S-1 60 mg/day po on day 1-14"
269599|NCT02146690|Other|osteopathic manipulative treatment|
269600|NCT02146690|Other|sham therapy|
269601|NCT02146690|Other|usual care|
269602|NCT02146677|Other|Osteopathic manipulative treatment|
269603|NCT02146677|Other|Sham therapy|
269604|NCT02146677|Other|Usual care|
269605|NCT02146664|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
269606|NCT02146664|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
269607|NCT02146651|Drug|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
269608|NCT02146651|Drug|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
269609|NCT02146651|Drug|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
269610|NCT02146651|Drug|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
269611|NCT02146638|Drug|Morphine|
269612|NCT02146638|Drug|Fentanyl|
269613|NCT02146625|Drug|CJ-40002|
269614|NCT02146612|Other|Amino Acid Supplement Group|Group receiving nutritional supplement
269615|NCT02146599|Other|Administration of patient self-assessment|
269616|NCT02146573|Behavioral|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
269617|NCT02146573|Behavioral|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:~CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.~Help patients/families navigate decisions in concert with preferences and beliefs~Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.~Serve as point person for active intensivists on service and other specialists~Help resolve conflict when multiple providers have different opinions on course of action"
269618|NCT02146547|Drug|Aripiprazole|Administration in once-a-day schedule without regard to meals.
269619|NCT02146547|Drug|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
269620|NCT02146547|Drug|Paliperidone|Administration once a day orally standardised in relation to food intake.
269621|NCT02146547|Drug|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
269622|NCT02146534|Drug|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
269623|NCT02146534|Drug|Placebo|placebo will be taken PO BID
269624|NCT02146508|Procedure|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
269625|NCT02146508|Device|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
269626|NCT02146495|Device|EEG-NF|
269627|NCT02146482|Other|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
269628|NCT02146469|Biological|2 doses with an 3 months interval|varicella vaccination
269629|NCT02146469|Biological|A second dose with an 1 year interval|varicella vaccine
269630|NCT02146469|Biological|A second dose with an 3 year interval|varicella vaccine
269631|NCT02146469|Biological|A second dose with an 5 year interval|varicella vaccine
269632|NCT02146469|Biological|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
269633|NCT02146469|Biological|1 dose MMR|MMR
269634|NCT02146456|Drug|Tranexamic Acid|
269635|NCT02146443|Other|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
269675|NCT02146209|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
269637|NCT02146443|Device|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
269638|NCT02146430|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
269639|NCT02146430|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
269640|NCT02146430|Drug|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
269641|NCT02146430|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
269642|NCT02146417|Procedure|Low pressure pneumoperitoneum|
269643|NCT02146417|Procedure|Normal pressure pneumoperitoneum (12 mmHg)|
269644|NCT02146417|Procedure|Deep neuromuscular block|
269645|NCT02146404|Other|hypoglycemia|Blood glucose levels will be kept at ~3.0 mmol/l
269646|NCT02146404|Other|euglycemia|Blood glucose levels will be kept at ~5.0 mmol/l
269647|NCT02146391|Drug|Androxal 25 mg Capsules|
269648|NCT02146378|Drug|Vyndaqel|20mg/day
269649|NCT02146365|Procedure|nasopharyngeal swab|
269650|NCT02146352|Device|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
269651|NCT02146339|Other|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
269652|NCT02146339|Other|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
269653|NCT02146339|Other|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
269654|NCT02146339|Other|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
269655|NCT02146339|Other|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
269656|NCT02146339|Other|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.~Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
269657|NCT02146326|Behavioral|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
269658|NCT02146326|Behavioral|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
269659|NCT02146313|Drug|DMUC4064A|Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
269660|NCT02146300|Biological|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
269661|NCT02146287|Other|Cycled Light|"Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.~Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630)."
269662|NCT02146261|Drug|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
269663|NCT02146261|Drug|Placebo|Subcutaneous administration of placebo
269664|NCT02146248|Drug|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
269665|NCT02146248|Drug|DepoProvera|injectable hormonal contraceptive
269666|NCT02146235|Behavioral|Psycho-Music Therapy|
269667|NCT02146222|Drug|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
269668|NCT02146222|Drug|docetaxel|Given IV
269669|NCT02146222|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
269670|NCT02146222|Procedure|positron emission tomography/computed tomography|Undergo FLT PET/CT
269671|NCT02146222|Other|pharmacological study|Correlative studies
269672|NCT02146222|Other|laboratory biomarker analysis|Correlative studies
269673|NCT02146209|Drug|Metronidazole benzoate|Single oral dose of 400 mg
269674|NCT02146209|Drug|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
269676|NCT02146196|Device|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
269677|NCT02146196|Device|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
269678|NCT02146183|Dietary Supplement|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
269679|NCT02146183|Dietary Supplement|Placebo Corn Starch|500 mg/day
269680|NCT02146157|Dietary Supplement|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
269681|NCT02146157|Dietary Supplement|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
269682|NCT02146144|Procedure|ILM Peeling|"common surgical procedure:~For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens~For all patients:~Central and peripheral 25 Gauge vitrectomy~dissection of the epimacular membrane~injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity~Intraoperative picture to see the possible spontaneous ILM peeling~If no spontaneous ILM peeling, the patient will be randomized at the operating block~Specific surgical procedure:~• • Randomization into two groups:~Arm 1: no peeling, where the ILM peeling will not be made~Arm 2: active peeling, where the ILM peeling will be made"
269683|NCT02146131|Device|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
269684|NCT02146131|Device|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
269685|NCT02146118|Drug|Erlotinib|Erlotinib 150 mg/day q 4 weeks
269686|NCT02146118|Dietary Supplement|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
269687|NCT02146105|Other|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
269688|NCT02146092|Procedure|Incentive spirometry|
269689|NCT02146092|Other|Physiotherapy|Standard of care exercise training and supervision
269690|NCT02146079|Drug|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
269691|NCT02146079|Drug|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
269692|NCT02146066|Biological|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
269693|NCT02146053|Dietary Supplement|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
269694|NCT02146053|Dietary Supplement|Placebo|placebo capsules: methyl cellulose
269695|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks.
269696|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
269697|NCT02146014|Other|Placebo|"Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.~In the placebo group the current will be off."
269698|NCT02146014|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
269699|NCT02146001|Other|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
269700|NCT02146001|Other|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
269701|NCT02145988|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
269702|NCT02145988|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
269741|NCT02145715|Drug|Velcade|
269742|NCT02145715|Drug|Thalidomide|
269743|NCT02145715|Drug|Dexamethasone|
269744|NCT02145715|Drug|Panobinostat|
269883|NCT02144649|Dietary Supplement|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
269986|NCT02143908|Dietary Supplement|lysine supplementation|
269703|NCT02145975|Drug|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
269704|NCT02145975|Drug|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
269705|NCT02145962|Device|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
269706|NCT02145962|Device|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
269707|NCT02145949|Drug|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
269708|NCT02145949|Drug|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
269709|NCT02145936|Other|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
269710|NCT02145923|Procedure|Peripheral blood stem cell mobilisation and collection|
269711|NCT02145923|Drug|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
269712|NCT02145923|Drug|Bone marrow derived allogeneic MMSCs infusion|
269713|NCT02145923|Procedure|Autologous peripheral blood stem cells infusion|
269714|NCT02145910|Drug|Vemurafenib|Given PO
269715|NCT02145910|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
269716|NCT02145910|Radiation|Radiosurgery (SRS)|Undergo SRS
269717|NCT02145897|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
269718|NCT02145897|Biological|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
269719|NCT02145897|Other|Control|
269720|NCT02145884|Drug|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
269721|NCT02145871|Other|standard fluid management|
269722|NCT02145871|Other|fluid management guided by the EV1000|
269723|NCT02145858|Device|Blood drainage post cardiac surgery using PleuraFlow System|
269724|NCT02145845|Device|Injectable SIS|Injectable SIS
269725|NCT02145832|Drug|Fluconazole|
269726|NCT02145832|Drug|Micafungin|
269727|NCT02145819|Drug|hCG|
269728|NCT02145819|Other|LH peak|
269729|NCT02145793|Behavioral|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
269730|NCT02145780|Dietary Supplement|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
269731|NCT02145780|Dietary Supplement|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
269732|NCT02145767|Drug|Progesterone|
269733|NCT02145767|Drug|Placebo|
269734|NCT02145754|Other|MKP media|one half of skin specimen was put in MKP media
269735|NCT02145754|Other|BSK-H media|one half of skin specimen was put in BSK-H media
269736|NCT02145741|Drug|Xentuzumab, low dose, every week (qw)|Patient to receive low dose of Xentuzumab IV
269737|NCT02145741|Drug|Xentuzumab, middle dose, qw|Patient to receive middle dose of Xentuzumab IV
269738|NCT02145741|Drug|Xentuzumab, high dose, qw|Patient to receive high dose of Xentuzumab IV
269739|NCT02145728|Behavioral|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
269740|NCT02145728|Behavioral|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
269745|NCT02145702|Other|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
269746|NCT02145702|Procedure|Standard Care Dialysis|12 weeks of standard of care.
269747|NCT02145689|Biological|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
269748|NCT02145676|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
269749|NCT02145676|Drug|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
269750|NCT02145650|Other|No Intervention|There is no intervention administered in this study.
269751|NCT02145637|Drug|Afatinib plus Ruxolitinib combination therapy|
269752|NCT02145624|Drug|Repevax|vaccine
269753|NCT02145624|Drug|Boostrix-IPV|vaccine
269754|NCT02145611|Drug|Glibenclamide|Glibenclamide
269755|NCT02145611|Drug|Vildagliptin|Vildagliptin
269756|NCT02145598|Drug|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
269757|NCT02145598|Drug|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
269758|NCT02145585|Device|Test of pharmacologic anesthesia robot (labVIEW® software)|
269759|NCT02145559|Drug|Metformin XR|
269760|NCT02145559|Drug|Delayed Metformin|
269761|NCT02145559|Drug|Sirolimus|
269762|NCT02145546|Drug|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
269763|NCT02145546|Drug|Propafenone|150mg per 8 hours, 3 times per day
269764|NCT02145546|Drug|Sotalol|80mg twice per day.
269765|NCT02145520|Drug|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
269766|NCT02145520|Other|placebo|use of placebo with standard therapy
269767|NCT02145507|Drug|SOLX|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
269768|NCT02145494|Radiation|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
269769|NCT02145481|Behavioral|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
269770|NCT02145481|Behavioral|CAD Education|Education for patients with coronary artery disease
269771|NCT02145468|Drug|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
269772|NCT02145468|Drug|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
269773|NCT02145468|Drug|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
269774|NCT02145455|Device|Unity Total Knee Replacement System|
269775|NCT02145455|Device|Unity Total Knee Replacement System|
269776|NCT02145442|Dietary Supplement|Obex|Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
269777|NCT02145429|Behavioral|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.~Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
269778|NCT02145403|Drug|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.~Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
269779|NCT02145403|Drug|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
269780|NCT02145390|Procedure|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~Cystoscopic evaluation~Bimanual examination under anesthesia,~Transurethral resection of the bladder tumor,~Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
269781|NCT02145390|Radiation|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
269782|NCT02145390|Behavioral|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
269783|NCT02145390|Behavioral|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
269784|NCT02145377|Biological|PXVX0200 10E8|Oral dose of PXVX0200 10E8
269785|NCT02145377|Biological|PXVX0200 10E9|Oral dose of PXVX0200 10E9
270031|NCT02143557|Other|MCT formula|
269789|NCT02145351|Device|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
269790|NCT02145351|Device|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
269791|NCT02145338|Drug|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
269792|NCT02145338|Other|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
269793|NCT02145325|Drug|Expanded Tregs|
269794|NCT02145312|Drug|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
269795|NCT02145299|Device|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
269796|NCT02145299|Device|CROSSER CTO Device|
269797|NCT02145286|Radiation|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
269798|NCT02145273|Behavioral|Interpersonal Psychotherapy for Depression -Group|
269799|NCT02145260|Drug|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
269800|NCT02145260|Drug|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
269801|NCT02145247|Drug|hCG|"3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.~4. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
269802|NCT02145234|Drug|BMS-986089|
269803|NCT02145234|Drug|Placebo matching with BMS-986089|
269804|NCT02145221|Other|Music Therapy|
269805|NCT02145208|Device|TIND System|An implant
269806|NCT02145195|Dietary Supplement|Vitamin D3 (cholecalciferol)|
269807|NCT02145182|Drug|Eculizumab|Eculizumab is a complement component 5 inhibitor.
269808|NCT02145182|Drug|Placebo|0.9% sodium chloride
269809|NCT02145169|Drug|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
269810|NCT02145156|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
269811|NCT02145156|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
269812|NCT02145156|Behavioral|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
269813|NCT02145143|Drug|Vemurafenib|
269814|NCT02145143|Device|serial 124I PET/CT|
269815|NCT02145143|Drug|thyrotropin alpha|
269816|NCT02145130|Biological|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
269817|NCT02145130|Biological|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
269818|NCT02145117|Behavioral|MBSR|Behavioral
269819|NCT02145104|Drug|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
269820|NCT02145091|Drug|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
269821|NCT02145091|Drug|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
269822|NCT02145091|Drug|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
269823|NCT02145091|Drug|Placebo|An oral placebo (lactose pill).
269824|NCT02145078|Drug|docetaxel|Given IV
269825|NCT02145078|Drug|pemetrexed disodium|Given IV
269826|NCT02145078|Drug|gemcitabine hydrochloride|Given IV
269827|NCT02145078|Other|laboratory biomarker analysis|Correlative studies
269828|NCT02145065|Drug|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
269829|NCT02145065|Device|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
269830|NCT02145052|Other|Continuous suture|A continuous suture is considered standard of care.
269831|NCT02145052|Other|Interrupted suture|Interrupted sutures are considered standard of care.
269832|NCT02145039|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
269833|NCT02145039|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
269834|NCT02145039|Radiation|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
269835|NCT02145039|Biological|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
269836|NCT02145026|Drug|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
269837|NCT02145013|Procedure|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
269838|NCT02145000|Biological|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
269839|NCT02145000|Biological|Placebo|
269939|NCT02144259|Drug|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
269840|NCT02144987|Biological|Bone Marrow CD133+ Stem Cell Transplantation|"Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.~BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.~The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.~CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization~Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients~Hysteroscopy will be performed 2-3 months after stem cell transplantation~Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
269841|NCT02144948|Drug|e.-coli-nissle|1 ml qd for 24 weeks
269842|NCT02144922|Drug|Pitavastatin|statin
269843|NCT02144922|Other|Control|Life style modification alone
269844|NCT02144909|Behavioral|Partners in Care with Semi-Structured Support Group|
269845|NCT02144896|Other|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
269846|NCT02144883|Behavioral|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
269847|NCT02144883|Behavioral|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
269848|NCT02144870|Behavioral|Habit Reversal Training|awareness training, competing response training
269849|NCT02144870|Behavioral|Resources activation|
269850|NCT02144857|Drug|etanercept|50 mg
269851|NCT02144857|Drug|ustekinumab|45 mg
269852|NCT02144857|Drug|cyclosporine|Cyclosporine 2.5-3 mg/kgr
269853|NCT02144857|Drug|Secukinumab|300 mg
269854|NCT02144857|Drug|Apremilast|30mg
269855|NCT02144844|Behavioral|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
269856|NCT02144831|Drug|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
269857|NCT02144818|Drug|Ovitrel|Triggering of ovulation with Ovitrel
269858|NCT02144818|Drug|Decapeptyl|Triggering with GnRH agonist
269859|NCT02144805|Procedure|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
269860|NCT02144805|Procedure|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
269861|NCT02144792|Drug|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
269862|NCT02144779|Behavioral|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
269863|NCT02144779|Behavioral|Usual Care|usual hospital care, not assigned to palliative care team
269864|NCT02144766|Drug|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
269865|NCT02144766|Drug|saline|caudal block with 1 ml/kg of saline
269866|NCT02144753|Dietary Supplement|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
269867|NCT02144753|Drug|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
269868|NCT02144740|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
269869|NCT02144740|Dietary Supplement|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
269870|NCT02144727|Procedure|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
269871|NCT02144727|Procedure|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
269872|NCT02144714|Biological|SB5|
269873|NCT02144714|Biological|EU sourced Humira®|
269874|NCT02144714|Biological|US sourced Humira®|
269875|NCT02144701|Dietary Supplement|Lactobacillus rhamnosus GG|Given PO
269876|NCT02144701|Other|laboratory biomarker analysis was not performed because of no differences in the clinical outcomes|Correlative studies
269877|NCT02144688|Drug|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
269878|NCT02144675|Drug|choline magnesium trisalicylate|Given PO
269879|NCT02144675|Drug|idarubicin|Given IV
269884|NCT02144649|Dietary Supplement|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
269885|NCT02144649|Other|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
269886|NCT02144649|Other|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
269887|NCT02144636|Dietary Supplement|herbalife protein shake|
269888|NCT02144623|Drug|Valproate|
269889|NCT02144610|Biological|HGF Plasmid (AMG0001)|IM
269890|NCT02144610|Biological|Matching Placebo|IM
269891|NCT02144597|Dietary Supplement|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
269892|NCT02144597|Dietary Supplement|Control diet|The control diet will be a conventional food diet aiming to provide 800 to 1000 kcal/day. It will be prescribed by the dietitian at the Imperial Weight Centre.
269893|NCT02144584|Drug|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
269894|NCT02144584|Drug|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
269895|NCT02144571|Behavioral|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
269896|NCT02144558|Other|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
269897|NCT02144545|Procedure|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
269898|NCT02144545|Procedure|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
269899|NCT02144545|Procedure|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
269900|NCT02144545|Procedure|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
269901|NCT02144532|Device|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
269902|NCT02144519|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
269903|NCT02144506|Other|T&E|
269904|NCT02144506|Other|OTAGO|
269905|NCT02144493|Other|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
269906|NCT02144493|Other|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
269907|NCT02144480|Behavioral|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
269908|NCT02144480|Behavioral|traditional training|usual care: conventional rehabilitation
269909|NCT02144467|Device|MRI|fMRI, sMRI, ASL and DTI
269910|NCT02144454|Dietary Supplement|Saturated fat|
269911|NCT02144454|Dietary Supplement|Monounsaturated fat|
269912|NCT02144454|Dietary Supplement|n-6 polyunsaturated fat|
269913|NCT02144441|Drug|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
269914|NCT02144415|Drug|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
269915|NCT02144415|Drug|EB-1020 800 mg|8 x EB-1020 100-mg capsules
269916|NCT02144415|Drug|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
269917|NCT02144415|Drug|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
269918|NCT02144415|Drug|Placebo|8 x matching placebo capsules
269919|NCT02144402|Other|infant formula with DHASCO|
269920|NCT02144402|Other|infant formula with DHASCO-B|
269921|NCT02144389|Drug|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally~1 g of corn/soybean oil (50%/50%), administered orally"
269922|NCT02144389|Dietary Supplement|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
269923|NCT02144389|Dietary Supplement|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
269924|NCT02144376|Dietary Supplement|Ispaghula|
269925|NCT02144376|Dietary Supplement|Maltodextrin|
269926|NCT02144350|Procedure|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
269927|NCT02144350|Procedure|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
269928|NCT02144337|Behavioral|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
269929|NCT02144324|Device|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
269930|NCT02144311|Procedure|PET/CT Scan|
269931|NCT02144311|Procedure|MRI|
269932|NCT02144285|Drug|LY3113593|Administered IV
269933|NCT02144285|Drug|LY3113593|Administered SC
269934|NCT02144285|Drug|Placebo|Administered IV
269935|NCT02144285|Drug|Placebo|Administered SC
269936|NCT02144272|Drug|LY3114062 SC|LY3114062 administered SC.
269937|NCT02144272|Drug|Placebo|Placebo administered SC.
269938|NCT02144272|Drug|LY3114062 IV|LY3114062 administered IV.
269940|NCT02144259|Drug|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
269941|NCT02144246|Other|Non-hormonal period|
269942|NCT02144246|Drug|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
269943|NCT02144233|Procedure|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
269944|NCT02144233|Procedure|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
269945|NCT02144220|Other|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
269946|NCT02144207|Device|Glidescope|
269947|NCT02144194|Drug|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
269948|NCT02144194|Drug|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
269949|NCT02144181|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
269950|NCT02144168|Dietary Supplement|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
269951|NCT02144168|Dietary Supplement|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
269952|NCT02144155|Drug|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
269953|NCT02144155|Drug|Placebo|placebo drug
269954|NCT02144142|Biological|Moisturizer with each subject's own antimicrobial bacteria|
269955|NCT02144129|Other|active Whole Body Electromyostimulation|
269956|NCT02144129|Other|Passive WB-EMS|
269957|NCT02144129|Device|WB-EMS application|
269958|NCT02144116|Other|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
269959|NCT02144116|Other|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
269960|NCT02144103|Other|Subtenon administration of autologous ADRC|
269961|NCT02144103|Procedure|Liposuction|
269962|NCT02144103|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
269963|NCT02144090|Device|Fractional flow reserve measurement|Fractional flow reserve measurement
269964|NCT02144077|Drug|BF-200 ALA|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
269965|NCT02144077|Drug|methyl-aminolevulinate|Topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
269966|NCT02144064|Drug|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
269967|NCT02144051|Drug|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
269968|NCT02144038|Drug|LGH447|pan-PIM inhibitor
269969|NCT02144038|Drug|BYL719|PI3K-alpha inhibitor
269970|NCT02144025|Drug|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
269971|NCT02144012|Drug|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
269972|NCT02144012|Drug|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
269973|NCT02144012|Drug|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m^2) or 100 mg/m^2 Q3W.
269974|NCT02143973|Drug|nalbuphine HCl ER 60mg BID|nalbuphine HCl ER 60mg BID for up to 24 weeks
269975|NCT02143973|Drug|nalbuphine HCl ER 90mg BID|nalbuphine HCl ER 90mg BID for up to 24 weeks
269976|NCT02143973|Drug|nalbuphine HCl ER 120mg BID|nalbuphine HCl ER 120mg BID for up to 24 weeks
269977|NCT02143960|Device|VelaShape III|Subjects will receive one treatment to their entire waist / love‐handle/ flanks area in a split‐waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
269978|NCT02143960|Device|CoolSculpt|Noninvasive Cryolipolysis
269979|NCT02143947|Device|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
269980|NCT02143947|Device|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
269981|NCT02143934|Drug|Primaquine|
269982|NCT02143934|Drug|Placebo|Sugar pills, appearance identical to Primaquine tablets
269983|NCT02143934|Drug|Chloroquine|
269984|NCT02143934|Drug|Artemether Lumefantrine|
269985|NCT02143921|Behavioral|Training intervention|Intervention group service providers received intervention training
269987|NCT02143908|Dietary Supplement|Placebo|
269988|NCT02143882|Drug|Fluenz|Live attenuated influenza vaccine
269989|NCT02143869|Device|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
269990|NCT02143856|Drug|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
269991|NCT02143843|Drug|Bimatoprost|Bimatoprost Ocular Insert used continuously for 7 months, then replaced with a new Bimatoprost Ocular Insert and used continuously for another 6 months.
269992|NCT02143830|Drug|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
269993|NCT02143830|Drug|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
269994|NCT02143830|Drug|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
269995|NCT02143830|Drug|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
269996|NCT02143830|Drug|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
269997|NCT02143830|Biological|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
269998|NCT02143817|Dietary Supplement|L-citrulline supplementation|
269999|NCT02143817|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
270000|NCT02143804|Biological|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
270001|NCT02143791|Procedure|Burst stimulation|
270002|NCT02143791|Device|Prodigy system|
270003|NCT02143778|Device|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
270004|NCT02143765|Drug|Mitiglinide|three times a day, orally, for 12 weeks
270005|NCT02143765|Drug|Acarbose|three times a day, orally, for 12 weeks
270006|NCT02143752|Behavioral|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
270007|NCT02143752|Behavioral|Quit Line|see arm
270008|NCT02143726|Drug|sorafenib|Given PO
270009|NCT02143726|Drug|everolimus|Given PO
270010|NCT02143713|Drug|Elagolix|Elagolix tablets administered orally
270011|NCT02143700|Other|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
270012|NCT02143687|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
270013|NCT02143687|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
270014|NCT02143687|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
270015|NCT02143687|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
270016|NCT02143674|Other|Muscle stretching and Strength Training|"Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.~Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol."
270017|NCT02143674|Other|Educated about physical exercises|
270018|NCT02143648|Drug|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
270019|NCT02143648|Drug|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
270020|NCT02143648|Drug|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
270021|NCT02143635|Drug|HDM201|
270022|NCT02143635|Drug|ancillary treatment|
270023|NCT02143622|Biological|LJM716|antibody
270024|NCT02143622|Biological|cetuximab|antibody
270025|NCT02143609|Drug|oxygen|Nocturnal nasal oxygen during stay at 2048 m
270026|NCT02143609|Drug|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
270027|NCT02143596|Other|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
270028|NCT02143570|Drug|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
270029|NCT02143570|Procedure|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
270030|NCT02143557|Other|Fat-Modified Breast Milk|
270032|NCT02143544|Device|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
270033|NCT02143531|Drug|4 mg of Ondansetron IV|
270034|NCT02143531|Drug|1mg of Haloperidol IV|
270035|NCT02143518|Biological|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
270036|NCT02143518|Biological|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
270037|NCT02143505|Drug|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
270038|NCT02143479|Drug|Tacrolimus|oral
270039|NCT02143466|Drug|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
270040|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
270041|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
270042|NCT02143466|Drug|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
270043|NCT02143466|Drug|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
270044|NCT02143466|Drug|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
270045|NCT02143466|Drug|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent [4 days on/3 days off]) to further investigate the safety and tolerability of this combination.
270046|NCT02143466|Drug|Part B - AZD9291 in combination with MEDI4736|"Part B - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.~Note: Enrolment into the patient cohort that evaluated AZD9291 treatment in combination with MEDI4736 as 1st line treatment has been terminated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis), and is no longer being evaluated in this study."
270047|NCT02143466|Drug|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC.
270048|NCT02143466|Drug|Part C - AZD9291 in combination with AZD6094 (Japan only)|Part C combination cohort - AZD9291 80mg OD administered in combination with AZD6094 400mg OD (AZD6094 dose in which DLTs have not been identified in the Japanese monotherapy cohort) in order to confirm the safety, tolerability, pharmacokinetics and preliminary anti-tumor activities of this combination in Japanese subjects. The 400mg OD dosing schedule will be initiated in the first cohort. The dose may be subsequently reduced in further cohorts in response to emerging safety, or PK findings or other reasons identified in the savolitinib programme.
270049|NCT02143466|Drug|Part D - AZD9291 in combination with AZD6094|Part D - AZD9291 80mg OD administered in combination with AZD6094 300mg OD to further evaluate the safety, tolerability, pharmacokinetics and antitumor activity in terms of ORR and PFS in patients with locally advanced or metastatic cMET positive EGFRm+ and T790M-negative NSCLC, following progression on EGFR-TKI treatment. The choice of AZD6094 dose of 300 mg is based on results from preclinical and clinical studies. Clinical testing of the 300 mg OD dose will enable better assessment of impact of lower AZD6094 exposure on overall tolerability and hepatotoxicity risk as well as exploration of the efficacy and overall safety profiles with a dose meaningfully lower than the current dose of 600 mg OD.
270050|NCT02143453|Other|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
270051|NCT02143453|Other|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
270052|NCT02143440|Behavioral|The initial assessment of daily insulin dose.|
270053|NCT02143427|Behavioral|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.~Arms: Social Skills Training"
270279|NCT02141698|Drug|Esomeprazole|Esomeprazole tablets
270280|NCT02141672|Drug|Voclosporin High Dose|
270054|NCT02143427|Behavioral|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.~Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
270055|NCT02143414|Biological|Blinatumomab|Given IV
270056|NCT02143414|Drug|Dasatinib|Given PO
270057|NCT02143414|Other|Laboratory Biomarker Analysis|Correlative studies
270058|NCT02143414|Drug|Mercaptopurine|Given PO
270059|NCT02143414|Drug|Methotrexate|Given PO
270060|NCT02143414|Drug|Methotrexate Sodium|Given PO
270061|NCT02143414|Drug|Prednisone|Given PO
270062|NCT02143414|Drug|Vincristine|Given IV
270063|NCT02143414|Drug|Vincristine Sulfate|Given IV
270064|NCT02143401|Other|Laboratory Biomarker Analysis|Correlative studies
270065|NCT02143401|Biological|Navitoclax|Given PO
270066|NCT02143401|Other|Pharmacological Study|Correlative studies
270067|NCT02143401|Drug|Sorafenib|Given PO
270068|NCT02143401|Drug|Sorafenib Tosylate|Given PO
270069|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
270070|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
270071|NCT02143375|Device|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
270072|NCT02143362|Drug|Anesthesia induction,propofol, remifentanil ,cisatracurium|"Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~Intermittent injection cisatracurium (0.15mg/kg).~A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
270073|NCT02143362|Drug|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~Target Controlled Infusion remifentanil , targeted plasma concentrations are 3~6ng/ml ,maintain heart rate to 60~100 beats per minute and mean blood pressure to 70~105 mmHg.~Intermittent injection cisatracurium (0.05mg/kg)."
270074|NCT02143362|Procedure|Awaken test|"Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~Patients will receive initial anesthesia after finish awaken test."
270075|NCT02143349|Dietary Supplement|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
270076|NCT02143349|Other|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
270077|NCT02143336|Procedure|subcuticular suture|
270078|NCT02143336|Procedure|Skin staples|
270079|NCT02143323|Drug|Augmentin tablet|
270080|NCT02143310|Device|EVP|
270081|NCT02143284|Device|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
270082|NCT02143271|Drug|KHK7580|Oral administration
270083|NCT02143258|Procedure|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
270084|NCT02143245|Other|percutaneous synovial biopsy|
270085|NCT02143232|Device|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
270086|NCT02143219|Drug|Oxaliplatine|Oxaliplatine : 85mg/m², 2-hours IV infusion (D1), then,
270087|NCT02143219|Drug|Folinic acid|Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
270088|NCT02143219|Drug|Irinotecan|"Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts~Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.~Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance."
270089|NCT02143219|Drug|5-FU|"5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:~If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one~If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course."
270090|NCT02143193|Behavioral|Skin-to-Skin Contact|
270091|NCT02143167|Drug|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.~The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
270092|NCT02143167|Drug|Placebo|
270181|NCT02142569|Device|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
270093|NCT02143141|Drug|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
270094|NCT02143141|Drug|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
270095|NCT02143115|Procedure|Optical colonoscopy|Examination of the colon with a colonoscope
270096|NCT02143115|Radiation|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
270097|NCT02143089|Device|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
270098|NCT02143076|Behavioral|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
270099|NCT02143076|Behavioral|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
270100|NCT02143076|Behavioral|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.~In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
270101|NCT02143063|Behavioral|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
270102|NCT02143063|Behavioral|prize contingency management on a variable interval schedule for cocaine abstinence|
270103|NCT02143063|Behavioral|standard care|
270104|NCT02143050|Drug|Dabrafenib|
270105|NCT02143050|Drug|Trametinib|
270106|NCT02143050|Drug|Metformin|
270107|NCT02143037|Behavioral|prize contingency management for attending treatment|
270108|NCT02143037|Behavioral|usual care|
270109|NCT02143024|Behavioral|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
270110|NCT02143024|Behavioral|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
270111|NCT02143011|Other|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
270112|NCT02143011|Other|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
270113|NCT02142998|Other|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
270114|NCT02142998|Other|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
270115|NCT02142985|Drug|Plasmagel|vascular filling with 500 ml of colloid solution (plasmagel) over 30 minutes
270116|NCT02142959|Drug|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
270117|NCT02142959|Drug|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
270118|NCT02142959|Drug|Lotion vehicle/Placebo|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
270119|NCT02142959|Radiation|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
270120|NCT02142933|Other|vagino-perineal swab|
270121|NCT02142920|Drug|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
270122|NCT02142894|Device|CST001|
270123|NCT02142881|Other|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of <130 mmHg.
270124|NCT02142881|Other|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
270125|NCT02142868|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
270275|NCT02141711|Drug|TAK-438|TAK-438 tablets
270276|NCT02141711|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
270126|NCT02142868|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
270127|NCT02142855|Behavioral|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
270128|NCT02142855|Behavioral|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
270129|NCT02142842|Biological|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
270130|NCT02142829|Drug|EXPAREL|
270131|NCT02142829|Drug|On-Q Pain Ball|bupivacaine HCl 0.25%
270132|NCT02142816|Device|Doppler|Fluid therapy guided by doppler
270133|NCT02142816|Other|PVI`|Fluid therapy guided by PVI
270134|NCT02142803|Biological|Bevacizumab|Given IV
270135|NCT02142803|Other|Laboratory Biomarker Analysis|Correlative studies
270136|NCT02142803|Other|Pharmacological Study|Correlative studies
270137|NCT02142803|Drug|Sapanisertib|Given PO
270138|NCT02142790|Drug|paclitaxel liposome injection|
270139|NCT02142777|Drug|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
270140|NCT02142777|Drug|Placebo|The placebo has no active ingredients but is made to look like the study drug.
270141|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
270142|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
270143|NCT02142751|Drug|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
270144|NCT02142751|Drug|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
270145|NCT02142751|Drug|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
270146|NCT02142738|Drug|Pembrolizumab|Pembrolizumab IV solution
270147|NCT02142738|Drug|Paclitaxel|Paclitaxel IV solution
270148|NCT02142738|Drug|Carboplatin|Carboplatin IV solution
270149|NCT02142738|Drug|Pemetrexed|Pemetrexed IV solution
270150|NCT02142738|Drug|Cisplatin|Cisplatin IV solution
270151|NCT02142738|Drug|Gemcitabine|Gemcitabine IV solution
270152|NCT02142725|Drug|LT-02|four times per day
270153|NCT02142725|Drug|LT-02|two times per day
270154|NCT02142725|Drug|Placebo|four times per day
270155|NCT02142712|Drug|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
270156|NCT02142712|Drug|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
270157|NCT02142712|Drug|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
270158|NCT02142712|Drug|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
270159|NCT02142699|Drug|Heme arginate|
270160|NCT02142686|Device|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
270161|NCT02142686|Device|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
270162|NCT02142686|Device|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
270163|NCT02142673|Device|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
270164|NCT02142673|Device|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
270165|NCT02142673|Device|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
270166|NCT02142660|Procedure|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
270167|NCT02142647|Behavioral|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
270168|NCT02142647|Behavioral|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
270169|NCT02142634|Drug|Budesonide granules 9 mg|per day
270170|NCT02142634|Drug|Placebo granules|per day
270171|NCT02142621|Other|transpyloric feeding|
270172|NCT02142621|Other|gastric feeding|
270173|NCT02142608|Drug|BR55|
270174|NCT02142595|Drug|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
270175|NCT02142595|Drug|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
270176|NCT02142582|Dietary Supplement|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
270177|NCT02142582|Dietary Supplement|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
270178|NCT02142569|Drug|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
270179|NCT02142569|Drug|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
270180|NCT02142569|Drug|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
270182|NCT02142556|Drug|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
270183|NCT02142543|Drug|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
270184|NCT02142543|Drug|Placebo Comparator|
270185|NCT02142530|Drug|Carfilzomib|
270186|NCT02142530|Drug|Belinostat|
270187|NCT02142517|Procedure|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
270188|NCT02142517|Procedure|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
270189|NCT02142504|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
270190|NCT02142504|Drug|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
270191|NCT02142478|Behavioral|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:~Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.~Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.~Opportunities to attend daily.~Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
270192|NCT02142478|Behavioral|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.~The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
270193|NCT02142452|Behavioral|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
270194|NCT02142452|Other|Usual Prenatal Care|
270195|NCT02142439|Behavioral|Strength training|Three times per week with strength training
270196|NCT02142400|Drug|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
270197|NCT02142400|Drug|placebo|matching placebo capsules to DS-1093 capsules
270198|NCT02142387|Other|BLS CPR program with dispatcher assisted CPR simulation|
270199|NCT02142361|Device|enfilcon A|Silicone hydrogel toric lenses.
270200|NCT02142335|Drug|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 & 3 (days 1 & 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
270201|NCT02142322|Drug|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
270202|NCT02142309|Drug|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
270203|NCT02142309|Drug|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) <45 mL/min
270204|NCT02142309|Drug|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
270205|NCT02142309|Drug|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
270206|NCT02142296|Drug|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
270207|NCT02142283|Device|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
270208|NCT02142283|Other|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
270209|NCT02142257|Procedure|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
270210|NCT02142257|Device|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
270211|NCT02142244|Procedure|Near infra red sentinel node biopsy|Explicated in the protocol arm
270212|NCT02142244|Drug|Indocyanine green|Explicated in the protocol arm
270213|NCT02142244|Device|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
270214|NCT02142231|Device|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
270215|NCT02142231|Device|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
270216|NCT02142218|Drug|Nivolumab|
270217|NCT02142205|Biological|BG00002|IV Infusion
270218|NCT02142192|Drug|natalizumab|Administered as specified in the treatment arm
270219|NCT02142179|Behavioral|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
270220|NCT02142166|Procedure|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
270221|NCT02142166|Procedure|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
270222|NCT02142153|Drug|F901318|"Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.~Pharmacokinetic profile"
270223|NCT02142153|Drug|Placebo|Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
270224|NCT02142140|Behavioral|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
270225|NCT02142140|Behavioral|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
270226|NCT02142140|Behavioral|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
270227|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
270228|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
270229|NCT02142127|Drug|14C-labelled GFT505 120 mg|
270230|NCT02142114|Device|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
270231|NCT02142088|Device|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
270232|NCT02142075|Drug|Daptomycin|
270233|NCT02142049|Drug|Ibrutinib|Ibrutinib
270234|NCT02142049|Drug|DA-EPOCH-R|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
270235|NCT02142049|Drug|Lenalidomide|Lenalidomide
270236|NCT02142036|Drug|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
270237|NCT02142010|Drug|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
270238|NCT02141997|Biological|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
270239|NCT02141997|Biological|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
270240|NCT02141958|Drug|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
270241|NCT02141958|Drug|Placebo|A matching placebo will be used to keep the study double-blind.
270242|NCT02141932|Procedure|Bed-side pocket size ultrasound imaging|
270243|NCT02141932|Device|GE Ultrasound Vscan|
270244|NCT02141919|Radiation|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
270277|NCT02141698|Drug|TAK-438|TAK-438 tablets
270278|NCT02141698|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
270245|NCT02141906|Device|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
270246|NCT02141893|Behavioral|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
270247|NCT02141893|Behavioral|CALMA|Family Education Intervention on management of pediatric asthma
270248|NCT02141854|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
270249|NCT02141854|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
270250|NCT02141854|Drug|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
270251|NCT02141854|Drug|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
270252|NCT02141828|Drug|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
270253|NCT02141815|Dietary Supplement|Arabinoxylan-oligosaccharides|
270254|NCT02141815|Dietary Supplement|Maltodextrine|
270255|NCT02141802|Behavioral|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
270256|NCT02141802|Behavioral|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
270257|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
270258|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
270259|NCT02141776|Device|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
270260|NCT02141776|Other|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
270261|NCT02141763|Drug|UCB4940 40 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
270262|NCT02141763|Drug|UCB4940 80 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
270263|NCT02141763|Drug|UCB4940 160 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
270264|NCT02141763|Drug|UCB4940 240 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
270265|NCT02141763|Drug|UCB4940 320 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
270266|NCT02141763|Drug|UCB4940 560 mg|"Active Substance: UCB4940~Pharmaceutical Form: solution~Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~Route of Administration: intravenous"
270267|NCT02141763|Other|Placebo|"Pharmaceutical Form: solution~Concentration: 0.9 % sodium chloride~Route of Administration: intravenous"
270268|NCT02141737|Drug|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
270269|NCT02141737|Drug|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
270270|NCT02141737|Drug|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
270271|NCT02141737|Drug|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
270272|NCT02141737|Drug|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
270273|NCT02141737|Drug|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
270274|NCT02141724|Other|Positioning consultation|Assessment of pain,bedsores and postural troubles
270281|NCT02141672|Drug|Voclosporin Low Dose|
270282|NCT02141672|Drug|Placebo|
270283|NCT02141659|Drug|TAK-385|TAK-385 Tablets.
270284|NCT02141646|Behavioral|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
270285|NCT02141646|Behavioral|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
270286|NCT02141633|Procedure|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
270287|NCT02141633|Procedure|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
270288|NCT02141633|Drug|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
270289|NCT02141633|Drug|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
270290|NCT02141620|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
270291|NCT02141620|Drug|n-Acetylcysteine|
270292|NCT02141620|Drug|Placebo|
270293|NCT02141581|Biological|Fluzone® (IM)|This vaccine is given intramuscularly (IM)
270294|NCT02141581|Biological|Fluzone® Intradermal (ID)|This vaccine is given intradermally (ID)
270295|NCT02141581|Biological|2011-2012 FluMist®|This vaccine is given intranasally
270296|NCT02141568|Other|Medical and Psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
270297|NCT02141555|Drug|Vaginal Misoprostol|Misoprostol inserted into vagina
270298|NCT02141555|Drug|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
270299|NCT02141542|Drug|Tremelimumab|
270300|NCT02141542|Drug|MEDI3617|
270301|NCT02141529|Procedure|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
270302|NCT02141529|Procedure|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
270303|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
270304|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
270305|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
270306|NCT02141490|Drug|Ferumoxytol|7.5mg/kg intravenous (IV) infusion
270307|NCT02141490|Diagnostic Test|Magnetic Resonance Imaging (MRI)|3 MRIs: pre-infusion, 24 and 48 hours post-infusion
270308|NCT02141477|Drug|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
270309|NCT02141477|Drug|Decitabine|"Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.~Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
270310|NCT02141451|Drug|Rituximab|Rituximab 375 mg/m2 IV after day +28 (as late as day 75) re-staging and again 1 and 7 weeks later
270311|NCT02141451|Drug|INCB7839|INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
270312|NCT02141438|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|This is a non-interventional study, the drug is used in its authorized indication from commercial supply. The decision to treat with Radium-223 will be agreed upon between the physician and the patient independently and prior to providing the patient study information. Treatment with Radium-223 should follow the approved local product information.
270313|NCT02141425|Drug|ASP015K|oral
270314|NCT02141425|Drug|Placebo|oral
270315|NCT02141412|Drug|dexmedetomidine 0.25 µg/kg IV|
270316|NCT02141412|Drug|dexmedetomidine 0.5 µg/kg IV|
270317|NCT02141412|Drug|dexmedetomidine 1 µg/kg IV|
270318|NCT02141412|Drug|Placebo Comparator|Patients in Group IV will receive same volume of normal saline at closure of sevoflurane
270319|NCT02141399|Drug|ALKS 5461|Sublingual tablet, taken daily
270320|NCT02141386|Other|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
270321|NCT02141373|Device|Glubran 2|
270322|NCT02141360|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
270323|NCT02141347|Drug|Tremelimumab|Tremelimumab administered intravenously
270324|NCT02141347|Drug|MEDI4736|MEDI4736 administered intravenously.
270325|NCT02141321|Drug|Misoprostol|
270326|NCT02141321|Drug|Placebo|
270327|NCT02141295|Drug|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
270328|NCT02141295|Drug|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
270329|NCT02141295|Drug|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
270330|NCT02141295|Drug|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
270331|NCT02141295|Drug|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
270332|NCT02141282|Drug|ABT-199|ABT-199 monotherapy
270333|NCT02141256|Dietary Supplement|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
270334|NCT02141243|Procedure|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
270801|NCT02137616|Drug|Aripiprazole|Aripiprazole tablets
270335|NCT02141243|Procedure|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
270336|NCT02141243|Procedure|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
270337|NCT02141230|Drug|Alli® 60 mg|Participants purchasing Alli®
270338|NCT02141217|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
270339|NCT02141217|Drug|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
270340|NCT02141204|Biological|HRV Liquid|Two doses administered orally according to a 0, 1 month schedule.
270341|NCT02141204|Biological|HRV Lyophilized|Two doses administered orally according to a 0, 1 month schedule.
270342|NCT02141191|Drug|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
270343|NCT02141178|Drug|Bupivacaine|
270344|NCT02141178|Drug|Exparel|
270345|NCT02141165|Device|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
270346|NCT02141139|Drug|NSAIDS (ketorolac and ibuprofen)|
270347|NCT02141126|Other|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
270348|NCT02141126|Other|Usual care|Standard inpatient 'usual care' physiotherapy
270349|NCT02141113|Drug|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)"
270350|NCT02141113|Drug|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)~mg Guanfacine Hydrochloride (orally)"
270351|NCT02141100|Drug|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
270352|NCT02141087|Drug|Pirfenidone|
270353|NCT02141074|Drug|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
270354|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation A|
270355|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation B|
270356|NCT02141048|Behavioral|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
270357|NCT02141035|Drug|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
270358|NCT02141035|Drug|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
270359|NCT02141022|Other|plasticity-based computerized cognitive remediation program|
270360|NCT02141022|Drug|Gileyna|
270361|NCT02141009|Biological|Prevnar 13|
270362|NCT02140996|Drug|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
270363|NCT02140983|Drug|Liraglutide|90 days of liraglutide up to 1.8mg/day.
270364|NCT02140983|Drug|Placebo|Placebo medication
270365|NCT02140970|Drug|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
270366|NCT02140970|Drug|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
270367|NCT02140957|Behavioral|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
270368|NCT02140931|Drug|Injections|Intra-muscular injections
270369|NCT02140918|Drug|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
270370|NCT02140918|Drug|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
270371|NCT02140918|Drug|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
270372|NCT02140918|Drug|Placebo|
270373|NCT02140892|Procedure|respiratory physical therapy manual technique- Autogenic Drainage|
270374|NCT02140892|Device|respiratory physical therapy technique- IPV|
270375|NCT02140879|Dietary Supplement|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
270852|NCT02137239|Drug|Thymoglobulin|
270376|NCT02140879|Dietary Supplement|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
270377|NCT02140866|Other|Hand Exercise|
270378|NCT02140866|Other|Compensatory Intervention Program (CIP)|
270379|NCT02140840|Drug|Trametinib|2 mg of Trametinib daily by mouth in 28 day cycles
270380|NCT02140827|Other|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
270381|NCT02140814|Dietary Supplement|Niacinamide|
270382|NCT02140801|Drug|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
270383|NCT02140801|Drug|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
270384|NCT02140788|Drug|Metformin|
270385|NCT02140788|Drug|Fish Oil|
270386|NCT02140775|Behavioral|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
270387|NCT02140762|Biological|MenABCWY|Subjects received one dose of 0.5 mL MenABCWY vaccine (intramuscular (IM) injection) at day 1 and a second dose after 2 months.
270388|NCT02140762|Other|Placebo|0.5 mL saline solution (IM)
270389|NCT02140762|Biological|MenACWY|Subjects received one dose of 0.5 mL placebo (IM) at day 1 and one dose of 0.5 mL MenACWY vaccine (IM) after 2 months.
270390|NCT02140749|Dietary Supplement|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
270391|NCT02140749|Dietary Supplement|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
270392|NCT02140749|Dietary Supplement|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
270393|NCT02140749|Dietary Supplement|Placebo|Chewing tablets without short-chain Fructooligosaccharides
270394|NCT02140736|Drug|Epoetin biosimilar|
270395|NCT02140723|Radiation|preoperative short course radiation|
270396|NCT02140710|Procedure|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
270397|NCT02140697|Dietary Supplement|Hippophae rhamnoides L. Leaf Extract (3g/day)|Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
270398|NCT02140697|Dietary Supplement|Placebo (3g/day)|Placebo (3g/day), parallel design
270399|NCT02140684|Device|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
270400|NCT02140658|Behavioral|multiple health education interventions|
270401|NCT02140658|Behavioral|conventional health education|
270402|NCT02140645|Drug|linagliptin|non-randomized
270403|NCT02140632|Procedure|Local methylprednisolone acetate and lidnocaine injection|
270404|NCT02140632|Device|wrist splinting|
270405|NCT02140619|Behavioral|multiple health education interventions|
270406|NCT02140606|Drug|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
270407|NCT02140593|Drug|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
270408|NCT02140593|Drug|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
270409|NCT02140580|Device|Minimally invasive surfactant therapy|Active Comparator
270410|NCT02140580|Other|Continuation on CPAP|Sham Comparator
270411|NCT02140554|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
270412|NCT02140554|Biological|Plerixafor|Plerixafor is administered by subcutaneous injection prior to apheresis.
270413|NCT02140528|Biological|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
270414|NCT02140528|Biological|Placebo|
270415|NCT02140515|Drug|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
270416|NCT02140515|Drug|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
270417|NCT02140489|Drug|amosartan|
270418|NCT02140489|Drug|rosuvastatin|
270419|NCT02140489|Drug|amosartan and rosuvastatin|
270420|NCT02140476|Device|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
270421|NCT02140476|Procedure|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
270422|NCT02140450|Drug|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
270423|NCT02140450|Drug|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
270424|NCT02140450|Drug|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
270425|NCT02140450|Drug|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
270426|NCT02140450|Drug|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
270427|NCT02140437|Drug|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
270428|NCT02140437|Drug|Anastrozole|standard endocrine therapy
270429|NCT02140411|Drug|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
270853|NCT02137239|Drug|Belatacept|
270430|NCT02140398|Procedure|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
270431|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
270432|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
270433|NCT02140385|Device|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
270434|NCT02140385|Device|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
270435|NCT02140385|Device|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
270436|NCT02140372|Drug|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
270437|NCT02140359|Behavioral|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
270438|NCT02140346|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
270439|NCT02140346|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
270440|NCT02140333|Drug|Erlotinib|100mg vs. 150mg
270441|NCT02140320|Drug|RV1729 single dose|Safety and tolerability of single dose
270442|NCT02140320|Drug|RV1729 matching placebo single dose|Safety and tolerability of single dose
270443|NCT02140320|Drug|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
270444|NCT02140320|Drug|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
270445|NCT02140320|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
270446|NCT02140320|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
270447|NCT02140307|Behavioral|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
270448|NCT02140294|Dietary Supplement|Polymeric nutritional supplements|
270449|NCT02140294|Dietary Supplement|Standard Nutrional Treatment|
270450|NCT02140281|Drug|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
270451|NCT02140281|Drug|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
270452|NCT02140268|Drug|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
270453|NCT02140268|Drug|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
270454|NCT02140268|Drug|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
270455|NCT02140255|Drug|Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
270456|NCT02140255|Drug|Nevirapine (NVP)|Administered orally. Dosed according to study step/participant's age/participant's weight.
270457|NCT02140255|Drug|Lopinavir/Ritonavir (LPV/r)|Administered orally. Dosed according to study step and participant's age.
270458|NCT02140255|Drug|Raltegravir (RAL)|Administered orally. Dosed according to study step and participant's age.
270459|NCT02140255|Drug|VRC01|40 mg/kg administered subcutaneously
270460|NCT02140242|Drug|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
270461|NCT02140242|Procedure|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
270462|NCT02140229|Device|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
270463|NCT02140229|Other|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
270464|NCT02140229|Other|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
270465|NCT02140203|Other|Yoga Training|one-year experimental training (three times per week and one hour per session)
270466|NCT02140164|Drug|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
270467|NCT02140151|Drug|Ranibizumab 0.5mg|
270468|NCT02140138|Biological|CV9104|
270469|NCT02140138|Device|needle free injection device (Tropis®)|
270470|NCT02140125|Drug|ASP2408|subcutaneous administration
270471|NCT02140125|Drug|Placebo|subcutaneous administration
270472|NCT02140112|Biological|Trichuris suis ova|
270473|NCT02140112|Other|Placebo|
270474|NCT02140099|Behavioral|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
270475|NCT02140099|Behavioral|Control Condition (Classroom Activities)|
270476|NCT02140086|Behavioral|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
270854|NCT02137239|Drug|mycophenolate mofetil(MMF)|
270477|NCT02140073|Drug|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
270478|NCT02140073|Drug|omeprazole|40mg in the morning
270479|NCT02140060|Drug|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
270480|NCT02140060|Drug|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
270481|NCT02140060|Drug|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
270482|NCT02140060|Drug|Brinzolamide 1% ophthalmic suspension AZOPT®|
270483|NCT02140060|Drug|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
270484|NCT02140060|Drug|Travoprost solution vehicle|Inactive ingredients used for masking purposes
270485|NCT02140060|Drug|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
270486|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
270487|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
270488|NCT02140047|Biological|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
270489|NCT02140034|Procedure|Extensive Peritoneal Lavage|
270490|NCT02140021|Procedure|Biospecimen Collection|Undergo anal, cervical, vaginal, and oral sample collection
270491|NCT02140021|Other|Laboratory Biomarker Analysis|Correlative studies
270492|NCT02140008|Device|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
270493|NCT02140008|Device|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
270494|NCT02139995|Behavioral|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
270495|NCT02139982|Procedure|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
270496|NCT02139982|Drug|ropivacaine|Different concentration of ropivacaine
270497|NCT02139969|Device|GreenLight XPS Laser System|
270498|NCT02139956|Device|ultrasonography|open
270499|NCT02139943|Drug|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
270500|NCT02139943|Drug|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
270501|NCT02139943|Drug|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
270502|NCT02139930|Behavioral|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
270503|NCT02139930|Behavioral|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
270504|NCT02139930|Behavioral|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
270505|NCT02139917|Behavioral|Transitional community based palliative care|"transitional palliative care include:-~telephone follow up for early identification of signs and symptoms~relief of signs and symptoms encountered~home visit with spiritual support"
270506|NCT02139904|Drug|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
270507|NCT02139904|Other|Active Symptom Control|
270508|NCT02139891|Device|Cardiac Resynchronization Therapy with MultiPoint Pacing|
270509|NCT02139878|Other|Wild blueberry juice|
270510|NCT02139878|Other|Placebo wild blueberry juice|
270511|NCT02139865|Behavioral|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
270512|NCT02139865|Behavioral|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
270513|NCT02139852|Dietary Supplement|Capsaicin|
270514|NCT02139839|Other|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
270515|NCT02139839|Drug|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
270516|NCT02139826|Drug|IX-01|
270517|NCT02139813|Procedure|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:~a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His~a narrow gastric tube will be calibrated to be approximately 1.5 cm wide~an Omega loop of 200 cm~a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
270518|NCT02139813|Procedure|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:~a small gastric pouch (about 30cc)~an antecolic alimentary limb~a gastro-jejunal anastomosis using a linear stapler~a 150cm long alimentary limb~a 50cm biliary limb~a latero-lateral jejuno-jejunal anastomosis~closure of the mesenteric defects"
270519|NCT02139800|Procedure|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
270520|NCT02139800|Procedure|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
270521|NCT02139787|Other|Radio Story|
270522|NCT02139787|Other|Control -listened to a brochure|
270523|NCT02139774|Behavioral|Walk with Ease|A six week walking program by the Arthritis Foundation
270524|NCT02139761|Drug|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
270557|NCT02139514|Behavioral|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
270855|NCT02137239|Drug|Corticosteroids|
270525|NCT02139761|Drug|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
270526|NCT02139748|Procedure|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
270527|NCT02139748|Procedure|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
270528|NCT02139735|Other|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
270529|NCT02139735|Other|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.~Active stretching of the masseter muscles with mouth opening and closed lips"
270530|NCT02139735|Other|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
270531|NCT02139722|Behavioral|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
270532|NCT02139709|Dietary Supplement|Ganglioside|
270533|NCT02139709|Dietary Supplement|Placebo|
270534|NCT02139696|Radiation|PET and MRI|Patients will be imaged using PET and MRI at baseline, and twice during treatment
270535|NCT02139683|Device|HIFU treatment|HIFU treatment in patients with fibroadenoma
270536|NCT02139657|Biological|RIG-C|
270537|NCT02139644|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
270538|NCT02139644|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
270539|NCT02139644|Drug|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
270540|NCT02139644|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
270541|NCT02139644|Drug|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
270542|NCT02139631|Other|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
270543|NCT02139618|Drug|Methyl Aminolevulinate (MAL)|
270544|NCT02139618|Drug|Placebo|
270545|NCT02139605|Procedure|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
270546|NCT02139592|Drug|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
270547|NCT02139579|Drug|Bevacizumab|7.5 mg/kg every 3 weeks
270548|NCT02139566|Behavioral|Video consent (high-tech)|Consent provided by an animated video with captions
270549|NCT02139566|Behavioral|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
270550|NCT02139566|Behavioral|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
270551|NCT02139566|Behavioral|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
270552|NCT02139566|Behavioral|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
270553|NCT02139553|Procedure|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
270554|NCT02139540|Drug|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
270555|NCT02139540|Drug|Placebo|50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup
270556|NCT02139527|Device|Total Disc Replacement|
270856|NCT02137239|Drug|Everolimus(EVL)|
270558|NCT02139501|Drug|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
270559|NCT02139488|Other|Fiducial markers|
270560|NCT02139488|Other|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
270561|NCT02139475|Procedure|Colonoscopy|
270562|NCT02139462|Other|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
270563|NCT02139462|Other|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
270564|NCT02139449|Procedure|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
270565|NCT02139436|Other|FES-row-training|
270566|NCT02139436|Other|Arms-only-row training|
270567|NCT02139423|Other|CMV PCR|
270568|NCT02139410|Procedure|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
270569|NCT02139397|Drug|DFMO|
270570|NCT02139397|Drug|Bortezomib|
270571|NCT02139371|Other|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
270572|NCT02139358|Drug|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200 mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
270573|NCT02139358|Drug|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
270574|NCT02139358|Drug|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q 21 days.
270575|NCT02139345|Device|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
270576|NCT02139345|Device|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
270577|NCT02139332|Behavioral|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
270578|NCT02139332|Behavioral|Resource & Referral Group|The Resource & Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
270579|NCT02139319|Drug|Botulinum toxin|
270580|NCT02139319|Drug|Placebo|
270581|NCT02139306|Drug|Ataluren (PTC124®)|
270582|NCT02139306|Drug|Placebo|
270583|NCT02139293|Device|PrimeStim|Intermittent auricular vagus nerve stimulation at different ear points
270584|NCT02139280|Drug|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
270585|NCT02139267|Biological|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
270586|NCT02139241|Drug|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
270587|NCT02139241|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
270588|NCT02139228|Biological|Hib-CRM197|No vaccine administered in V37_07E2 study
270589|NCT02139228|Biological|Hib-TT|No vaccine administered in V37_07E2 study
270590|NCT02139202|Behavioral|Social Influence|
270591|NCT02139202|Behavioral|Electronic Pill Bottles|
270592|NCT02139202|Behavioral|Financial Incentives|
270593|NCT02139189|Device|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
270594|NCT02139176|Behavioral|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
270595|NCT02139176|Behavioral|patient referral|A patient agrees to recruit their partner using the invitation.
270596|NCT02139163|Other|Cohort Study|
270597|NCT02139150|Radiation|[18F] FLT|
270598|NCT02139150|Device|PET/CT scans|
270599|NCT02139137|Other|Computerized Cognitive Training - active|Cognitive training using working memory span task
270600|NCT02139137|Other|Computerized cognitive training - sham|Sham training condition
270601|NCT02139124|Drug|Placebo|Oral placebo capsule
270602|NCT02139124|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
270603|NCT02139124|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
270604|NCT02139124|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
270605|NCT02139124|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
270606|NCT02139111|Drug|Placebo|Oral placebo capsule
270607|NCT02139111|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
270608|NCT02139111|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
270609|NCT02139111|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
270610|NCT02139111|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
270857|NCT02137239|Drug|Tacrolimus(TAC)|
270611|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
270612|NCT02139098|Drug|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
270613|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
270614|NCT02139098|Drug|Placebo|Placebo
270615|NCT02139085|Device|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
270616|NCT02139085|Device|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
270617|NCT02139072|Device|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
270618|NCT02139072|Procedure|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
270619|NCT02139059|Procedure|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
270620|NCT02139059|Procedure|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
270621|NCT02139046|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
270622|NCT02139046|Drug|Febuxostat XR|Febuxostat XR over-encapsulated capsules
270623|NCT02139046|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
270624|NCT02139046|Drug|Colchicine|Colchicine tablets
270625|NCT02139046|Drug|Naproxen|Naproxen tablets
270626|NCT02139046|Drug|Lansoprazole|Lansoprazole capsules
270627|NCT02139033|Drug|Retaine™|
270628|NCT02139020|Other|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
270629|NCT02139007|Drug|Alendronate|
270630|NCT02138994|Device|Next Science Wound Gel|
270631|NCT02138994|Drug|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:~Subject may continue the application of Neosporin until wound closure or~Subject may cross over to the treatment group for 3 months"
270632|NCT02138981|Procedure|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
270633|NCT02138981|Procedure|Immediate Resection|patients received immediate surgical resection.
270634|NCT02138968|Other|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
270635|NCT02138955|Drug|Liposomeal curcumin|
270636|NCT02138942|Device|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
270637|NCT02138929|Drug|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
270638|NCT02138929|Drug|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.~Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
270639|NCT02138916|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
270640|NCT02138916|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
270641|NCT02138916|Drug|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
270642|NCT02138903|Other|trans thoracic echocardiography|
270643|NCT02138890|Device|APS|Intra-articular Injection
270644|NCT02138890|Device|Saline|Intra-articular injection
270645|NCT02138877|Procedure|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
270646|NCT02138877|Procedure|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
270647|NCT02138864|Radiation|18F-FP-(+)-DTBZ|no available
270648|NCT02138851|Dietary Supplement|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
270649|NCT02138851|Dietary Supplement|Placebo (300g/day)|Placebo (300g/day), parallel design
270650|NCT02138838|Drug|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
270651|NCT02138838|Dietary Supplement|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
270652|NCT02138825|Drug|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
270653|NCT02138825|Drug|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
270702|NCT02138435|Other|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
270703|NCT02138422|Biological|Xilonix|
270654|NCT02138812|Drug|BAY1161909|Given orally, with a starting dose of 0.75 mg twice daily from C1D1 onwards in a 2 days on/5 days off dosing schedule as single agent treatment in Cycle 1 (14 days), and from C2D8 onwards in a 2 days on/5 days off dosing schedule in 28-day cycles. For single-dose PK cohort: a single oral dose on C1D1
270655|NCT02138812|Drug|Paclitaxel|75 mg/m^2 (initial dose escalation) or 90 mg/m^2 (second dose escalation), weekly intravenously (IV) infusion on D1, D8, and D15 of the 28-day cycles from C2D1
270656|NCT02138799|Drug|enzalutamide|oral
270657|NCT02138799|Drug|rifampin|oral
270658|NCT02138786|Drug|selinexor|60 mg, may be increased to 80 mg after Cycle 1
270659|NCT02138773|Drug|Tamsulosin formulation-A|oral
270660|NCT02138773|Drug|Tamsulosin formulation-B|oral
270661|NCT02138760|Procedure|MRI UroNav fusion biopsy|
270662|NCT02138747|Drug|Mirabegron|Oral
270663|NCT02138747|Drug|Tolterodine ER|Oral
270664|NCT02138734|Biological|BCG+ALT-803|"BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG+ALT-803 for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG+ALT-803 for patients with eligible disease at 3 months in phase IIb is included."
270665|NCT02138734|Biological|BCG|"BCG will be administered via intravesical instillation weekly for 6 consecutive weeks for induction. Phase IIb includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6, 12, & 18 months.~An additional 6 week re-induction of BCG for patients with eligible disease at 3 months in phase IIb is included."
270666|NCT02138721|Procedure|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
270667|NCT02138708|Other|Pharmacological test of pulmonary endothelial|
270668|NCT02138682|Drug|l-123 Ioflupane|5 millicuries of Ioflupane
270669|NCT02138669|Device|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
270670|NCT02138656|Other|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
270671|NCT02138656|Other|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
270672|NCT02138643|Procedure|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
270673|NCT02138643|Procedure|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
270674|NCT02138630|Dietary Supplement|Capsaicin|
270675|NCT02138630|Dietary Supplement|Placebo|Sugar capsule
270676|NCT02138617|Drug|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
270677|NCT02138617|Drug|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
270678|NCT02138617|Drug|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
270679|NCT02138617|Drug|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
270680|NCT02138591|Procedure|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
270681|NCT02138591|Procedure|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
270682|NCT02138591|Procedure|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
270683|NCT02138578|Radiation|SBRT|
270684|NCT02138578|Radiation|RFA|
270685|NCT02138565|Procedure|Gastric by-pass surgery|
270686|NCT02138552|Drug|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
270687|NCT02138552|Drug|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
270688|NCT02138539|Other|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
270689|NCT02138539|Drug|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
270690|NCT02138526|Drug|pazopanib|pazopanib 800mg OD without food
270691|NCT02138526|Other|continental breakfast|pazopanib 600mg OD with food
270692|NCT02138513|Behavioral|Mindfulness Based Cognitive Therapy|This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
270693|NCT02138500|Drug|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
270694|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
270695|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
270696|NCT02138487|Other|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
270697|NCT02138487|Other|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
270698|NCT02138474|Other|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
270699|NCT02138474|Other|Placebo|Unmedicated sucrose pillules
270700|NCT02138448|Behavioral|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
270701|NCT02138435|Other|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
270705|NCT02138409|Drug|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
270706|NCT02138409|Drug|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
270707|NCT02138396|Drug|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
270708|NCT02138396|Drug|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
270709|NCT02138396|Drug|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
270710|NCT02138383|Drug|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
270711|NCT02138383|Drug|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
270712|NCT02138383|Drug|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
270713|NCT02138357|Drug|buprenorphine transdermal delivery system (BTDS)|
270714|NCT02138357|Drug|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
270715|NCT02138331|Biological|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
270716|NCT02138318|Other|High definition (HD) endoscopy|
270717|NCT02138318|Other|chromoendoscopy|
270718|NCT02138305|Device|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
270719|NCT02138305|Procedure|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
270720|NCT02138292|Drug|Trametinib (2mg)/Digoxin (.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.~Digoxin (0.25mg) will be administered orally on a daily basis.~On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
270721|NCT02138266|Device|Topcon Specular Microscope SP-1P|
270722|NCT02138266|Device|Konan Specular Microscope CELLCHEK XL|
270723|NCT02138253|Drug|IDN-6556|
270724|NCT02138253|Drug|Placebo|Placebo control
270725|NCT02138240|Behavioral|Social network intervention|The intervention combined a social network approach with strategies that address public housing residents' challenges related to the built environment to improve dietary habits. Given the frequent intake of sugar-sweetened beverages (SSB) in this population, the intervention focused on reducing added sugar intake through the reduced consumption of SSB.
270726|NCT02138227|Behavioral|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
270727|NCT02138227|Behavioral|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
270728|NCT02138214|Procedure|Thyroidectomy|Undergo total thyroidectomy
270729|NCT02138214|Procedure|Central lymph node dissection|Undergo total thyroidectomy with ipsilateral prophylactic CND
270730|NCT02138214|Other|Quality-of-life assessment|Voice evaluation, interviews, ancillary studies
270731|NCT02138162|Drug|enzalutamide|oral
270732|NCT02138136|Drug|Lubiprostone|12 or 24 mcg capsules twice daily (BID) for 9 months
270733|NCT02138123|Procedure|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
270734|NCT02138123|Procedure|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
270735|NCT02138110|Device|Neuro-Spinal Scaffold|
270736|NCT02138084|Drug|BMS-663068|BMS-663068
270737|NCT02138084|Drug|Rifabutin|Rifabutin
270738|NCT02138084|Drug|Ritonavir|Ritonavir
270739|NCT02138058|Drug|Topiramate|
270740|NCT02138058|Behavioral|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
270741|NCT02138045|Drug|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
270742|NCT02138045|Drug|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
270743|NCT02138032|Behavioral|Gains Framed Message|
270744|NCT02138032|Behavioral|Loss Framed Message|
270745|NCT02138019|Procedure|Fibrin Glue assisted external eye surgery|
270746|NCT02138019|Device|Fibrin glue|
270747|NCT02138006|Drug|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
270748|NCT02138006|Drug|Standard insulin treatment|Insulin Mixtard
270749|NCT02137993|Drug|A-prexa|A-prexa 5-20 mg for 6 weeks
270750|NCT02137993|Drug|Zyprexa|Zyprexa 5-20 mg for 6 weeks
270751|NCT02137967|Procedure|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medicament for primary molars
270752|NCT02137967|Procedure|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament for primary molars
270753|NCT02137967|Drug|2.5% NaOCl|
270754|NCT02137967|Drug|20% Formocresol|
270755|NCT02137954|Drug|Lidocaine|
270756|NCT02137954|Drug|Placebo|
270757|NCT02137941|Behavioral|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
271323|NCT02133976|Behavioral|cognitive therapy|
270758|NCT02137941|Behavioral|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
270759|NCT02137928|Drug|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
270760|NCT02137928|Drug|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
270761|NCT02137915|Biological|Human Central Nervous System Stem Cells|
270762|NCT02137902|Behavioral|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
270763|NCT02137902|Behavioral|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
270764|NCT02137889|Drug|VAY736|VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
270765|NCT02137876|Procedure|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
270766|NCT02137863|Drug|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.~1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
270767|NCT02137863|Drug|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
270768|NCT02137863|Drug|0.9 % NaCl|"100 ml/10min infusion just before the angiography~1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
270769|NCT02137850|Drug|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
270770|NCT02137837|Drug|Fulvestrant|
270771|NCT02137837|Drug|Anastrozole|
270772|NCT02137837|Drug|Everolimus|
270773|NCT02137837|Drug|Placebo - Anastrozole|
270774|NCT02137837|Drug|Placebo - Everolimus|
270775|NCT02137824|Procedure|sinus floor elevation|
270776|NCT02137811|Other|MICK Assay|An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
270777|NCT02137798|Device|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude < o.5 mV) will also be ablated.
270778|NCT02137785|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
270779|NCT02137785|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
270780|NCT02137785|Device|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
270781|NCT02137772|Drug|Letermovir|Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.
270782|NCT02137772|Drug|Placebo|Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
270783|NCT02137759|Radiation|Standard Radiation Therapy|Radiation therapy to 60 Gy
270784|NCT02137759|Drug|Standard Temozolomide|Temozolomide given orally
270785|NCT02137759|Drug|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
270786|NCT02137746|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
270787|NCT02137733|Drug|Bisoprolol|
270788|NCT02137733|Drug|Carvedilol|
270789|NCT02137720|Behavioral|Telephonic Diabetes Self-Management Support|
270790|NCT02137720|Other|Educational Print Materials|
270791|NCT02137707|Drug|Gilenya|All patients will receive Gilenya
270792|NCT02137694|Other|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
270793|NCT02137681|Drug|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
270794|NCT02137668|Drug|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
270795|NCT02137642|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
270796|NCT02137642|Drug|Placebo|Double blind placebo will be delivered once by injection during study procedure.
270797|NCT02137629|Drug|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
270798|NCT02137616|Drug|risperidone|Risperdal tablets
270799|NCT02137616|Drug|olanzapine|olanzapine tablets
270800|NCT02137616|Drug|Quetiapine|quetiapine tablets
270802|NCT02137603|Other|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
270803|NCT02137590|Dietary Supplement|Spanish Black Radish product|
270804|NCT02137577|Procedure|DEB catheter|DEB catheter (trade name: Litos/Tulip)
270805|NCT02137577|Procedure|common PTA balloon catheter|common PTA balloon catheter
270806|NCT02137564|Drug|gamma secretase inhibitor PF-03084014|Given PO
270807|NCT02137564|Other|pharmacological study|Correlative studies
270808|NCT02137564|Other|laboratory biomarker analysis|Correlative studies
270809|NCT02137551|Other|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
270810|NCT02137538|Drug|Letrozole|
270811|NCT02137538|Drug|Anastrozole|
270812|NCT02137525|Drug|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
270813|NCT02137525|Drug|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
270814|NCT02137525|Drug|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
270815|NCT02137525|Drug|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
270816|NCT02137525|Drug|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
270817|NCT02137525|Drug|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
270818|NCT02137512|Device|Closed-Loop Control System|"This investigational device system included the following components:~DiAs - a smart-phone medical platform;~Dexcom G4 Platinum CGM system connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;~Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;~Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network~Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
270819|NCT02137512|Device|Sensor-Augmented Pump (SAP)|"This commercial device system included the following components:~Dexcom G4 Platinum CGM system;~Roche Accu-Chek insulin pump"
270820|NCT02137499|Device|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
270821|NCT02137473|Other|Human milk-based fortifier|
270822|NCT02137473|Other|Bovine protein-based fortifier|
270823|NCT02137447|Device|Negative Pressure treatment|
270824|NCT02137434|Other|Dietary calcium|Dietary calcium from skimmed milk
270825|NCT02137434|Dietary Supplement|Supplementary calcium|Supplementary calcium from calcium carbonate
270826|NCT02137421|Dietary Supplement|Resveratrol (3, 4´, 5 trihydroxystilbene)|Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
270827|NCT02137408|Dietary Supplement|Docosahexaenoic acid 200 mg|Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
270828|NCT02137408|Drug|Docosahexaenoic acid 1000 mg|Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
270829|NCT02137395|Drug|Dexamethasone|dexamethasone administration, intravenously
270830|NCT02137395|Drug|Placebo|saline administration intravenously
270831|NCT02137382|Drug|Creon®|active comparator
270832|NCT02137382|Drug|Creon N|experimental drug
270833|NCT02137369|Drug|Escitalopram|Escitalopram, 20mg-40mg daily for 12 weeks
270834|NCT02137369|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
270835|NCT02137369|Other|Combination treatment (Escitalopram + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
270836|NCT02137356|Radiation|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.~50.4-55 Gy"
270837|NCT02137356|Drug|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
270838|NCT02137356|Drug|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
270839|NCT02137343|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
270840|NCT02137343|Drug|Placebo|Placebo
270841|NCT02137343|Drug|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
270842|NCT02137343|Drug|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
270843|NCT02137330|Device|Swallowable Obalon® Gastric Balloon|
270844|NCT02137317|Device|LAPPE (locally adapted personal protective equipment)|"Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.~Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.~Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes."
270845|NCT02137304|Device|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
270846|NCT02137278|Drug|Vasoactive drug therapies|Continue current vasoactive therapy
270847|NCT02137278|Other|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
270848|NCT02137265|Drug|Clomiphene|Clomiphene citrate 50 mg orally daily
270849|NCT02137265|Drug|Placebo|One pill every other day
270850|NCT02137252|Drug|Naltrexone|
270851|NCT02137252|Drug|Sugar Pill|
270858|NCT02137226|Drug|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
270859|NCT02137226|Drug|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
270860|NCT02137213|Drug|Naloxone|Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1
270861|NCT02137213|Drug|Placebo|Normal saline will be added to oral methadone preparations as placebo.
270862|NCT02137200|Procedure|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
270863|NCT02137200|Procedure|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
270864|NCT02137187|Procedure|AV junction ablation|AV junction ablation
270865|NCT02137187|Device|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
270866|NCT02137187|Drug|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
270867|NCT02137187|Device|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
270868|NCT02137174|Other|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
270869|NCT02137161|Drug|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
270870|NCT02137161|Drug|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
270871|NCT02137148|Device|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
270872|NCT02137135|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
270873|NCT02137135|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
270874|NCT02137135|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
270875|NCT02137122|Device|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
270876|NCT02137122|Device|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
270877|NCT02137109|Drug|natalizumab|Administered as specified in the treatment arm.
270878|NCT02137096|Drug|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
270879|NCT02137096|Drug|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
270880|NCT02137096|Drug|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
270881|NCT02137096|Procedure|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
270882|NCT02137083|Drug|Docetaxel|75mg/m2 D2 every 21 days
270883|NCT02137083|Drug|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
270884|NCT02137070|Procedure|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
270885|NCT02137070|Other|Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
270886|NCT02137044|Behavioral|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care was delivered through an interdisciplinary team, organized around a CC manager (CCM) who guided the patient through various aspects of care during the 16-week treatment phase. The team also included the patient's MS physician and the CC Supervisors, a group of clinicians who were experts of the study domain . The CCM offered all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient had both pain and depression, he or she received care management and collaborative medical management for both.
270887|NCT02137031|Device|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
270888|NCT02137018|Device|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
270889|NCT02137018|Device|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
270890|NCT02136992|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
270891|NCT02136992|Drug|placebo|placebo will be taken two tablets 3 times a day during the whole study process
270892|NCT02136979|Drug|Propofol|group of patients with propofol-based anesthesia
270893|NCT02136979|Drug|Sevoflurane|group of patients with sevoflurane-based anesthesia
270894|NCT02136966|Other|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
270895|NCT02136953|Behavioral|Exercise|12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
270896|NCT02136953|Behavioral|Cognitive Behavioural Therapy (CBT)|CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
270897|NCT02136940|Drug|AMA0076|
270898|NCT02136940|Drug|Placebo|
270899|NCT02136927|Drug|SPARC1210|
270900|NCT02136927|Drug|Reference1210|
270901|NCT02136914|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
270902|NCT02136914|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
270903|NCT02136901|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
270904|NCT02136901|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
270905|NCT02136901|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
270906|NCT02136901|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
270907|NCT02136888|Drug|Ponesimod Placebo|
270908|NCT02136888|Drug|Moxifloxacin Placebo|
270909|NCT02136888|Drug|Ponesimod 10 mg|
270910|NCT02136888|Drug|Ponesimod 20 mg|
270911|NCT02136888|Drug|Ponesimod 40 mg|
270912|NCT02136888|Drug|Ponesimod 60 mg|
270913|NCT02136888|Drug|Ponesimod 80 mg|
270914|NCT02136888|Drug|Ponesimod 100 mg|
270915|NCT02136888|Drug|Moxifloxacin 400 mg|
270916|NCT02136875|Drug|Double dose of Salmeterol + Fluticasone Propionate|
270917|NCT02136875|Behavioral|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
270918|NCT02136875|Drug|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.~Standing prescriptions for exacerbation:~1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.~2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
270919|NCT02136823|Drug|sugar pill|
270920|NCT02136823|Drug|Riluzole|
270921|NCT02136823|Drug|Isradipine|
270922|NCT02136823|Drug|Memantine|
270923|NCT02136823|Procedure|Therapeutic muscle stretching|
270924|NCT02136797|Biological|CMVpp65 Specific T-cells|
270925|NCT02136784|Drug|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
270926|NCT02136784|Drug|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
270927|NCT02136784|Drug|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
270928|NCT02136784|Drug|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
270929|NCT02136784|Drug|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
270930|NCT02136784|Drug|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
270931|NCT02136784|Drug|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
270966|NCT02136446|Device|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
270932|NCT02136771|Dietary Supplement|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
270933|NCT02136771|Dietary Supplement|Placebo|
270934|NCT02136758|Behavioral|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
270935|NCT02136745|Behavioral|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
270936|NCT02136732|Other|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
270937|NCT02136732|Other|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
270938|NCT02136719|Procedure|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
270939|NCT02136706|Procedure|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
270940|NCT02136693|Drug|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
270941|NCT02136693|Drug|Placebo|3.5 g /day of inert compound for 180 days after STARR
270942|NCT02136680|Other|CASA Education|Basic palliative care competencies for outpatient use.
270943|NCT02136654|Behavioral|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
270944|NCT02136641|Drug|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
270945|NCT02136641|Drug|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
270946|NCT02136641|Drug|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
270947|NCT02136628|Procedure|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.~Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
270948|NCT02136589|Drug|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
270949|NCT02136576|Device|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
270950|NCT02136576|Device|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
270951|NCT02136576|Device|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
270952|NCT02136550|Behavioral|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
270953|NCT02136537|Device|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
270954|NCT02136537|Other|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
270955|NCT02136524|Drug|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
270956|NCT02136524|Drug|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
270957|NCT02136511|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
270958|NCT02136511|Drug|Rituximab|Rituximab administered intravenously starting at 375 mg/m^2 at Week 0 and continuing with a dose of 500 mg/m^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
270959|NCT02136498|Drug|Varenicline|Standard 12 week course of varenicline, provided in both arms
270960|NCT02136498|Behavioral|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
270961|NCT02136498|Behavioral|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
270962|NCT02136485|Behavioral|Mindfulness-based stress reduction (MBSR)|8 sessions of MBSR
270963|NCT02136485|Other|waiting list control|
270964|NCT02136459|Other|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
270965|NCT02136459|Other|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
271324|NCT02133976|Behavioral|mindfulness training|
270967|NCT02136446|Device|Pajunk® Nerve Block Catheter|Nerve Block Catheter
270968|NCT02136433|Device|Tablet - self exercise|
270969|NCT02136433|Other|GRASP self exercise|
270970|NCT02136420|Drug|Promethazine|Subject receives promethazine
270971|NCT02136420|Behavioral|Hyper gravity training|Subject receives hypergravity training before testing
270972|NCT02136420|Drug|Placebo|Placebo
270973|NCT02136420|Behavioral|No hypergravity training|Subjects do not receive normal Earth gravity
270974|NCT02136394|Other|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
270975|NCT02136381|Behavioral|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.~Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.~Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.~Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
270976|NCT02136381|Behavioral|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).~The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.~Participants in the control group will be assessment after two months."
270977|NCT02136368|Behavioral|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
270978|NCT02136368|Behavioral|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
270979|NCT02136368|Behavioral|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
270980|NCT02136355|Radiation|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
270981|NCT02136342|Drug|chlorogenic acid|
270982|NCT02136329|Drug|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate.~The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.~Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
270983|NCT02136316|Drug|ASP7962|Oral
270984|NCT02136316|Drug|Placebo|Oral
270985|NCT02136303|Dietary Supplement|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
270986|NCT02136303|Other|S2: Kale extract versus kale purée|
270987|NCT02136303|Other|S3: Kale extract: AMD-patients|
270988|NCT02136290|Behavioral|Prepackaged meals|Portion-controlled prepackaged meals
270989|NCT02136290|Behavioral|Usual Care|Usual care dietary counseling
270990|NCT02136277|Drug|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
270991|NCT02136264|Other|PCFA interventional dietary counselling|
270992|NCT02136264|Other|conventional DASH diet counselling|
270993|NCT02136238|Device|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
270994|NCT02136238|Device|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
270995|NCT02136225|Behavioral|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
270996|NCT02136212|Behavioral|Approach-positive AAT|
270997|NCT02136212|Behavioral|Control AAT|
270998|NCT02136199|Other|Active Implementation of ShareEBM Toolkit|
270999|NCT02136199|Other|Passive Dissemination of Share EBM|
271000|NCT02136186|Device|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
271001|NCT02136173|Device|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
271002|NCT02136160|Behavioral|attitude change, behavioral change|
271003|NCT02136160|Behavioral|prevention program|
271004|NCT02136147|Drug|methylphenidate medication|
271005|NCT02136147|Drug|atomoxetine medication|
271006|NCT02136147|Drug|lisdexamphetamine medication|
271007|NCT02136147|Drug|guanfacine medication|
271008|NCT02136134|Drug|Daratumumab|Daratumumab will be administered as an IV infusion at a dose of 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter.
271009|NCT02136134|Drug|VELCADE (Bortezomib)|VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
271010|NCT02136134|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
271011|NCT02136121|Device|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
271012|NCT02136108|Other|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
271013|NCT02136108|Other|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
271014|NCT02136095|Procedure|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
271015|NCT02136082|Behavioral|Asha Support + Training|
271016|NCT02136082|Behavioral|Asha Support + Food|
271017|NCT02136082|Behavioral|Asha Support + Training + Food|
271018|NCT02136082|Behavioral|Asha Support Only|
271019|NCT02136069|Drug|etrolizumab|105 mg administered by subcutaneous injection (Q4W) until Week 52
271020|NCT02136069|Drug|infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
271021|NCT02136069|Other|placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
271022|NCT02136069|Other|placebo (injection)|administered by SC injection Q4W until Week 52
271023|NCT02136056|Behavioral|Self-management program (SMP)|A self-management course
271024|NCT02136043|Device|PBASE system 1.1 (active treatment)|
271025|NCT02136030|Drug|Liposomal amphotericin B|4mg/kg/day, IV infusion
271026|NCT02136030|Drug|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
271027|NCT02136004|Device|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
271028|NCT02135991|Behavioral|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
271029|NCT02135991|Behavioral|Project CHOICE|Sites will receive standard training for Project CHOICE.
271030|NCT02135978|Other|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
271031|NCT02135965|Drug|2mg of Albuterol|2mg of Albuterol on metabolic rate
271032|NCT02135965|Drug|4mg of Albuterol|4mg of Albuterol on metabolic rate
271033|NCT02135965|Drug|100mg of Caffeine|100mg of caffeine on metabolic rate
271034|NCT02135965|Drug|200mg of Caffeine|200mg of Caffeine on metabolic rate
271035|NCT02135965|Drug|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
271036|NCT02135965|Drug|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
271037|NCT02135965|Drug|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
271038|NCT02135965|Drug|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
271039|NCT02135952|Procedure|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
271040|NCT02135952|Other|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
271041|NCT02135952|Drug|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
271042|NCT02135939|Behavioral|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
271043|NCT02135926|Device|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
271044|NCT02135926|Other|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
271045|NCT02135913|Dietary Supplement|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
271046|NCT02135900|Drug|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
271047|NCT02135887|Drug|MB-6|6# TID with meal
271048|NCT02135887|Drug|Placebo|6# TID with meal
271049|NCT02135874|Drug|Clofarabine|Given IV
271050|NCT02135874|Drug|Cytarabine|Given IV
271051|NCT02135874|Drug|Dexamethasone|Given IV
271052|NCT02135874|Drug|Idarubicin|Given IV
271053|NCT02135874|Biological|Rituximab|Given IV
271054|NCT02135874|Drug|Sorafenib|Given PO
271055|NCT02135874|Drug|Sorafenib Tosylate|Given PO
271056|NCT02135874|Drug|Vincristine|Given IV
271057|NCT02135874|Drug|Vincristine Sulfate|Given IV
271058|NCT02135861|Procedure|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
271059|NCT02135861|Other|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
271060|NCT02135848|Drug|GSK1278863|GSK1278863
271061|NCT02135848|Drug|Placebo|Placebo
271062|NCT02135835|Drug|Shenfu Zhusheye|
271063|NCT02135835|Drug|5% glucose injection|
271064|NCT02135822|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
271065|NCT02135822|Drug|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
271066|NCT02135809|Device|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
271067|NCT02135796|Other|Echocardiography|
271115|NCT02135419|Device|infrared photocoagulation therapy|Undergo infrared coagulation
271068|NCT02135783|Procedure|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
271069|NCT02135783|Procedure|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
271070|NCT02135770|Drug|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
271071|NCT02135744|Behavioral|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
271072|NCT02135731|Other|Medication review software with pictures|The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
271073|NCT02135718|Device|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
271074|NCT02135718|Device|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
271075|NCT02135705|Drug|Lomitapide|As prescribed by Physician.
271076|NCT02135692|Biological|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
271077|NCT02135692|Drug|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
271078|NCT02135679|Radiation|Radiotherapy|
271079|NCT02135666|Procedure|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
271080|NCT02135653|Radiation|Radiotherapy|
271081|NCT02135653|Other|Eischens Yoga|
271082|NCT02135640|Drug|denosumab 60mg|solution
271083|NCT02135640|Drug|denosumab 120 mg|solution
271084|NCT02135640|Drug|placebo|solution
271085|NCT02135627|Drug|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
271086|NCT02135627|Other|Current standard therapy|
271087|NCT02135614|Drug|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
271088|NCT02135614|Drug|Presatovir placebo|Presatovir placebo tablets administered orally
271089|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
271090|NCT02135588|Drug|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
271091|NCT02135575|Behavioral|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
271092|NCT02135562|Dietary Supplement|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
271093|NCT02135562|Other|Informational Material|Receive carbohydrate reintroduction handout
271094|NCT02135562|Other|Dietary Education|Receive education on nutrition label reading for carbohydrates
271095|NCT02135562|Dietary Supplement|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
271096|NCT02135562|Other|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
271097|NCT02135549|Dietary Supplement|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
271098|NCT02135549|Drug|Placebo Oral Tablet|Placebo comparator
271099|NCT02135536|Biological|NGM282|NGM282
271100|NCT02135523|Radiation|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
271101|NCT02135510|Drug|metoclopramide|
271102|NCT02135510|Drug|dexamethason|
271103|NCT02135510|Drug|palonosetron|
271104|NCT02135484|Drug|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
271105|NCT02135471|Drug|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
271106|NCT02135471|Drug|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
271107|NCT02135458|Other|Telemonitoring|
271108|NCT02135458|Other|Conventional care|
271109|NCT02135445|Drug|TAK-385|TAK-385 tablet
271110|NCT02135445|Drug|Degarelix|Degarelix injection
271111|NCT02135432|Drug|Ivacaftor|
271112|NCT02135432|Drug|Placebo|
271113|NCT02135419|Drug|imiquimod|Applied topically
271114|NCT02135419|Drug|fluorouracil|Applied topically
271116|NCT02135419|Device|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
271117|NCT02135419|Device|laser therapy|Undergo laser therapy
271118|NCT02135419|Other|clinical observation|Undergo active monitoring
271119|NCT02135419|Other|laboratory biomarker analysis|Correlative studies
271120|NCT02135406|Biological|CART-19 T cells|
271121|NCT02135393|Dietary Supplement|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
271122|NCT02135380|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
271123|NCT02135380|Biological|Autologous Adipose Derived MSCs (ADMSCs)|Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
271124|NCT02135380|Other|Control|Standard Therapy
271125|NCT02135367|Biological|PRP|injections of Platelet rich Plasma
271126|NCT02135354|Drug|Azithromycin|"From day 1 up to and including day 3: 500 mg azithromycin PO once a day~From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
271127|NCT02135354|Drug|Placebo|"From day 1 up to and including day 3: 500 mg placebo PO once a day~From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
271128|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
271129|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
271130|NCT02135328|Behavioral|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
271131|NCT02135328|Behavioral|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
271132|NCT02135315|Drug|Isosorbide Dinitrate|"continuous infusion of Isosorbide dinitrate (40 mg per 40 ml) depending on the systolic blood pressure value.~SBP: under 120 mmHg : no drug SBP: 120 to 130: 1 mg per hour SBP: 130 to 140: 2 mg per hour SBP: 140 to 150: 3 mg per hour SBP: 150 to 160: 4 mg per hour SBP: above 160 mmHg : 6 mg per hour"
271133|NCT02135315|Drug|Labetalol or nicardipine|continuous infusion of Labetalol (Trandate) or Nicardipine (Loxen) are used if the arterial pressure objectives are not reached with the Isosorbide Dinitrate alone.
271134|NCT02135302|Drug|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
271135|NCT02135276|Drug|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
271136|NCT02135263|Drug|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
271137|NCT02135263|Drug|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
271138|NCT02135250|Drug|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
271139|NCT02135250|Other|placebo|the placebo is not drug.
271140|NCT02135237|Behavioral|Prize Contingency Management for Alcohol Abstinence|The systematic reinforcement of desired behaviors and the withholding of reinforcement for undesired behaviors
271141|NCT02135237|Behavioral|Standard Care|
271142|NCT02135224|Drug|Fentanyl|
271143|NCT02135224|Drug|Normal saline|
271144|NCT02135211|Behavioral|Lifestyle counseling|
271145|NCT02135198|Drug|2 mg AZD7325|A single 2 mg oral dose of AZD7325
271146|NCT02135198|Drug|10 mg AZD7325|A single 10 mg oral dose of AZD7325
271147|NCT02135198|Drug|Placebo|A single oral dose
271148|NCT02135185|Other|custom work endurance|Experimental: Rehabilitation effort
271149|NCT02135185|Behavioral|dietary management adapted to the nutritional status|dietary management adapted to the nutritional status
271150|NCT02135172|Behavioral|Sitting|
271151|NCT02135172|Behavioral|Standing|
271152|NCT02135172|Behavioral|Walking|
271153|NCT02135159|Drug|TDM1|administration of the TDM1 by IV perfusion
271154|NCT02135159|Radiation|Brain Sequential RT|local RT
271155|NCT02135146|Drug|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
271156|NCT02135146|Drug|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
271157|NCT02135133|Drug|Idelalisib|150 mg BID Oral Daily
271158|NCT02135133|Drug|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
271159|NCT02135120|Drug|Combined spinal epidural anesthesia technique with intrathecal morphine|
271160|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
271281|NCT02134288|Drug|Belatacept|
271282|NCT02134288|Drug|Everolimus|
271161|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
271162|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
271163|NCT02135107|Drug|Rabeprazole|Rabeprazole 20 mg was administered orally twice daily during the treatment period for 8 weeks (unblinded).
271164|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 mg or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered once daily during the maintenance period (double-blind).
271165|NCT02135107|Drug|Rabeprazole|Rabeprazole 10 or 20 mg were administered orally twice daily during the treatment period (unblinded), and 10 mg was administered twice daily during the maintenance period (double-blind).
271166|NCT02135094|Device|Active ultrasound therapy device|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
271167|NCT02135094|Device|Placebo ultrasound therapy device|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
271168|NCT02135068|Device|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
271169|NCT02135068|Other|Snacking|Up to 45 g of oral glucose via Gatorade
271170|NCT02135055|Other|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
271171|NCT02135055|Drug|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
271172|NCT02135055|Drug|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
271173|NCT02135055|Procedure|Sedation interruption|Sedation interruption is performed at 8 am every morning.
271174|NCT02135042|Drug|Cisplatin|Given IV
271175|NCT02135042|Other|Clinical Observation|Undergo clinical observation
271176|NCT02135042|Drug|Fluorouracil|Given IV
271177|NCT02135042|Drug|Gemcitabine Hydrochloride|Given IV
271178|NCT02135042|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
271179|NCT02135042|Other|Laboratory Biomarker Analysis|Correlative studies
271180|NCT02135042|Drug|Paclitaxel|Given IV
271181|NCT02135042|Other|Quality-of-Life Assessment|Ancillary studies
271182|NCT02135029|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
271183|NCT02135029|Drug|Atorvastatin|Atorvastatin PO QD
271184|NCT02135029|Other|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
271185|NCT02135029|Other|Placebo for atorvastatin|PO QD
271186|NCT02135016|Drug|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
271187|NCT02135016|Drug|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
271188|NCT02135016|Drug|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
271189|NCT02135003|Other|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
271190|NCT02134990|Drug|Oshadi D and Oshadi R|Anti cancer agents
271191|NCT02134990|Drug|Docetaxel|Chemotheraphy
271192|NCT02134977|Drug|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
271193|NCT02134964|Drug|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
271194|NCT02134964|Drug|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
271195|NCT02134951|Drug|Ketamine|intravenous infusion of saline solution with ketamine
271196|NCT02134951|Drug|Normal saline|Normal saline will be used for placebo in this group
271197|NCT02134938|Dietary Supplement|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
271198|NCT02134925|Other|Laboratory Biomarker Analysis|Correlative studies
271199|NCT02134925|Biological|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
271200|NCT02134925|Other|Quality-of-Life Assessment|Ancillary studies
271201|NCT02134925|Other|Saline|Given SC
271202|NCT02134912|Drug|crizotinib|Given PO
271203|NCT02134912|Drug|pemetrexed disodium|Given IV
271204|NCT02134912|Other|laboratory biomarker analysis|Correlative studies
271205|NCT02134912|Other|pharmacological study|Correlative studies
271206|NCT02134899|Drug|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
271207|NCT02134899|Drug|Calcineurin inhibitors maintenance|Usual treatment
271208|NCT02134886|Drug|Erlotinib Hydrochloride|Given PO
271209|NCT02134886|Other|Laboratory Biomarker Analysis|Correlative studies
271210|NCT02134886|Other|Pharmacological Study|Correlative studies
271211|NCT02134886|Other|Quality-of-Life Assessment|Ancillary studies
271212|NCT02134873|Other|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
271213|NCT02134860|Other|Bed rest|8 days of full bed rest
271214|NCT02134860|Other|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
271215|NCT02134860|Other|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
271216|NCT02134860|Other|Cognitive testing|Daily testing of memory and concentration using standardized tests
271217|NCT02134860|Other|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
271218|NCT02134860|Other|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
271219|NCT02134860|Other|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
271220|NCT02134847|Other|SCS intervention schedule|
271221|NCT02134834|Drug|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
271222|NCT02134834|Drug|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
271223|NCT02134821|Procedure|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
271224|NCT02134808|Drug|Creatine|Creatine is a nutritional supplement.
271225|NCT02134808|Drug|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
271226|NCT02134795|Device|TNM (trade name), a form of brainstem Stimulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation acts on the brainstem.
271227|NCT02134782|Behavioral|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
271228|NCT02134782|Other|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
271229|NCT02134769|Device|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
271230|NCT02134756|Drug|NutraStem Active|
271231|NCT02134743|Procedure|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
271232|NCT02134730|Behavioral|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
271233|NCT02134717|Drug|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
271234|NCT02134717|Procedure|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
271235|NCT02134717|Procedure|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
271236|NCT02134717|Procedure|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
271237|NCT02134704|Other|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
271238|NCT02134691|Behavioral|Prolonged Exposure|
271239|NCT02134691|Behavioral|Applied Relaxation|
271240|NCT02134678|Behavioral|self-system therapy|
271241|NCT02134678|Behavioral|cognitive therapy|
271242|NCT02134652|Other|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:~FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic~Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
271243|NCT02134639|Procedure|68Ga-DOTATOC PET-CT Imaging|
271244|NCT02134626|Drug|Simvastatin|40mg / pill, one pill orally once a day for three months
271245|NCT02134626|Drug|Placebo pill|
271246|NCT02134613|Other|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
271247|NCT02134600|Dietary Supplement|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:~400, 800, 1200, 2400 and 3000 mg/m2."
271283|NCT02134275|Behavioral|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
271248|NCT02134587|Other|Multifaceted educational intervention|"Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.~Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material~Distribution of educational material~Practical class to explain the correct fill of adverse drug events form~Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
271249|NCT02134574|Biological|hematologic malignancy|hematologic malignancy with a sampling of blood
271250|NCT02134561|Behavioral|psychological interview|
271251|NCT02134561|Radiation|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
271252|NCT02134561|Other|cognitive tests|
271253|NCT02134561|Other|neurological tests|
271254|NCT02134522|Device|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
271255|NCT02134509|Behavioral|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
271256|NCT02134509|Behavioral|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
271257|NCT02134496|Procedure|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
271258|NCT02134483|Biological|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
271259|NCT02134470|Drug|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
271260|NCT02134457|Biological|ranibizumab|
271261|NCT02134444|Behavioral|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
271262|NCT02134444|Behavioral|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
271263|NCT02134431|Device|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
271264|NCT02134418|Behavioral|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
271265|NCT02134405|Drug|Rebamipide|Rebamipide 100mg tid
271266|NCT02134405|Drug|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
271267|NCT02134405|Drug|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
271268|NCT02134392|Biological|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
271269|NCT02134379|Device|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
271270|NCT02134366|Drug|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
271271|NCT02134366|Drug|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
271272|NCT02134366|Drug|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
271273|NCT02134353|Drug|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
271274|NCT02134353|Drug|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
271275|NCT02134340|Drug|[I-124]-CPD-1028 Injection|A single intravenous dose of [I-124]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
271276|NCT02134340|Biological|CPD-1061|[Optional] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of [I-124]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
271277|NCT02134327|Drug|Combination of Dexmedetomidine with Midazolam|
271278|NCT02134314|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units per kilogram intravenous infusion administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
271279|NCT02134314|Drug|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose at 24 hours post-operatively. Total: 2 doses
271280|NCT02134301|Drug|Oritavancin|
271284|NCT02134275|Behavioral|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
271285|NCT02134262|Drug|Cyclophosphamide or Bendamustine|Cyclophosphamide [1.5 g/m^2 x 1 day Intravenous (IV)] or Bendamustine [120 mg/m^2 x 2 days Intravenous (IV)] is administered as Pre-treatment medication of CD19-CAR-T.
271286|NCT02134262|Genetic|Dose Level -1|CD19-CAR-T [1 x 10^5 cells/kg x 1 day and 2 x 10^5 cells/kg x 1 day Intravenous (IV)] are administered.
271287|NCT02134262|Genetic|Dose Level 1|CD19-CAR-T [1/3 x 10^6 cells/kg x 1 day and 2/3 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
271288|NCT02134262|Genetic|Dose Level 2|CD19-CAR-T [1 x 10^6 cells/kg x 1 day and 2 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
271289|NCT02134262|Genetic|Dose Level 3|CD19-CAR-T [1/3 x 10^7 cells/kg x 1 day and 2/3 x 10^7 cells/kg x 1 day Intravenous (IV)] are administered.
271290|NCT02134249|Drug|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
271291|NCT02134249|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
271292|NCT02134223|Behavioral|Dialectical behavior therapy|"in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.~DBT participants will be assigned to the next available individual therapist and relevant skills training group.~Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module."
271293|NCT02134223|Other|Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT|
271294|NCT02134210|Drug|Etanercept|Head-to-head comparison
271295|NCT02134210|Drug|CHS-0214|
271296|NCT02134197|Drug|Lupartumab Amadotin (BAY1129980)|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
271297|NCT02134184|Biological|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
271298|NCT02134171|Other|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
271299|NCT02134158|Device|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.~All the investigations will associate with clinical, functional and 3D motion analysis assessments."
271300|NCT02134132|Biological|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
271301|NCT02134132|Other|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
271302|NCT02134119|Dietary Supplement|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth
271303|NCT02134119|Drug|Placebo|Sugar pill manufactured to mimic dietary supplement
271304|NCT02134106|Drug|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
271305|NCT02134106|Drug|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
271306|NCT02134093|Drug|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03~0.05 mg/kg), sufentanil(0. 5~0.8 μg/kg), etomidate ( 0.2~0.6mg/kg) and rocuronium(0.6mg/kg)
271307|NCT02134093|Drug|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
271308|NCT02134093|Drug|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
271309|NCT02134093|Drug|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3~6 mg/kg/h）, remifentanil （0.05~0.3 μg/kg/min）is required to maintain Entropy within 40~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05~0.1mg/kg） as needed to maintain muscle relaxation.
271310|NCT02134080|Drug|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
271311|NCT02134080|Drug|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
271312|NCT02134067|Drug|TAS-119|
271313|NCT02134067|Drug|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
271314|NCT02134041|Other|traumatic brain injury|mild TBI, GCS >/=13 after traumatic brain injury
271315|NCT02134028|Drug|dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution~Route of administration: Subcutaneous"
271316|NCT02134015|Drug|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
271317|NCT02134015|Drug|Erlotinib|Oral erlotinib 150 mg/day
271318|NCT02134015|Drug|Placebo|Placebo infusion every 3 weeks
271319|NCT02134002|Drug|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
271320|NCT02134002|Drug|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
271321|NCT02133989|Drug|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
271322|NCT02133989|Drug|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
271325|NCT02133976|Behavioral|behavioral therapy|
271326|NCT02133976|Other|treatment as usual|
271327|NCT02133950|Procedure|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
271328|NCT02133950|Procedure|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
271329|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
271330|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a lyophilized formulation
271331|NCT02133924|Drug|natalizumab|Natalizumab 300mg on days 0 and 14.
271332|NCT02133924|Drug|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
271333|NCT02133911|Drug|Ranolazine|
271334|NCT02133898|Other|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
271335|NCT02133885|Drug|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
271336|NCT02133885|Other|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
271337|NCT02133872|Drug|Minocycline 100mg Group|Subjects will be randomized to receive Minocycline 100mg
271338|NCT02133872|Drug|Minocycline 200mg Group|Subjects will be randomized to receive Minocycline 200mg.
271339|NCT02133846|Drug|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
271340|NCT02133846|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
271341|NCT02133846|Drug|Placebo|500mL 0.9% sodium chloride
271342|NCT02133846|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
271343|NCT02133833|Device|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
271344|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fasted|
271345|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fed|
271346|NCT02133820|Drug|12 hourly capsule strong painkiller with antagonist fasted)|
271347|NCT02133820|Drug|4 mg 12 hourly capsule strong painkiller with antagonist fed|
271348|NCT02133807|Procedure|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
271349|NCT02133794|Device|Tomosynthesis|
271350|NCT02133781|Biological|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
271351|NCT02133781|Biological|FluMist® 2009-2010 Formula|This vaccine is given intranasally
271352|NCT02133755|Drug|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
271353|NCT02133742|Drug|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
271354|NCT02133742|Drug|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
271355|NCT02133729|Other|Blood sampling and OGTT|
271356|NCT02133716|Other|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
271357|NCT02133716|Behavioral|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
271358|NCT02133703|Behavioral|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
271359|NCT02133703|Behavioral|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
271360|NCT02133703|Behavioral|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
271361|NCT02133703|Behavioral|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
271362|NCT02133703|Behavioral|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
271491|NCT02132767|Drug|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
271492|NCT02132754|Biological|MK-4166|
271363|NCT02133690|Biological|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
271364|NCT02133690|Other|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
271365|NCT02133677|Drug|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
271366|NCT02133664|Drug|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
271367|NCT02133664|Drug|Placebo|placebo lipoic acid and placebo oil
271368|NCT02133638|Drug|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
271369|NCT02133638|Drug|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
271370|NCT02133625|Drug|carboplatin|
271371|NCT02133625|Drug|pioglitazone|
271372|NCT02133612|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
271373|NCT02133599|Drug|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
271374|NCT02133586|Other|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
271375|NCT02133586|Other|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
271376|NCT02133573|Drug|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
271377|NCT02133573|Drug|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
271378|NCT02133560|Behavioral|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
271379|NCT02133560|Behavioral|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
271380|NCT02133560|Behavioral|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.~Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
271381|NCT02133534|Drug|Atorvastatin|
271382|NCT02133521|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
271383|NCT02133521|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
271384|NCT02133495|Procedure|Non Cadaveric Human Acellular Dermal Tissue|
271385|NCT02133482|Drug|Placebo|placebo solution
271386|NCT02133482|Drug|BI 639667|oral solution BI 639667, single rising doses
271387|NCT02133469|Biological|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
271388|NCT02133469|Biological|Hib Vaccine|Single Dose
271389|NCT02133443|Device|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
271390|NCT02133443|Device|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
271391|NCT02133430|Device|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
271392|NCT02133417|Device|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
271393|NCT02133404|Drug|ASP7991|oral
271394|NCT02133404|Drug|Cinacalcet|oral
271395|NCT02133404|Drug|Placebo|oral
271396|NCT02133391|Other|Centralized Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques, which are implemented centrally.
271397|NCT02133391|Other|Practice-based Reminder/Recall|Method of increasing immunization delivery using reminder/recall techniques, which are implemented at the practice level.
271398|NCT02133378|Device|Hemopatch|Baxter Hemopatch
271399|NCT02133378|Behavioral|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
271400|NCT02133365|Behavioral|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
271401|NCT02133352|Drug|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
271402|NCT02133339|Drug|TRN-157|
271403|NCT02133339|Drug|Placebo|
271404|NCT02133326|Drug|Caldolor|Subject will be given Caldolor by IV prior to surgery.
271405|NCT02133326|Drug|Ofirmev|Subject will be given Ofirmev prior to surgery.
271406|NCT02133300|Other|electrical stimulation|
271407|NCT02133287|Device|AVI® Arsenic trioxide drug eluting stent delivery system|
271408|NCT02133287|Device|Firebird2® sirolimus eluting stent system|
271409|NCT02133274|Behavioral|Brief Psychosocial Intervention|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
271410|NCT02133274|Other|Early Palliative Care|Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
271411|NCT02133235|Procedure|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
271412|NCT02133235|Procedure|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
271413|NCT02133222|Procedure|blood sample|
271414|NCT02133209|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
271415|NCT02133209|Behavioral|Stress Management for Headaches|Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
271416|NCT02133196|Drug|Aldesleukin|Aldesleukin at 720,000 (Arm 1) or 72,000 (Arm 2) IU/kg IV based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in Arm 1 and 12 doses in Arm 2.
271417|NCT02133196|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
271418|NCT02133196|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hour.
271419|NCT02133196|Biological|Young TIL|On day 0, TIL will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
271420|NCT02133183|Other|Laboratory Biomarker Analysis|Correlative studies
271421|NCT02133183|Other|Pharmacological Study|Correlative studies
271422|NCT02133183|Drug|Sapanisertib|Given PO
271423|NCT02133183|Procedure|Therapeutic Conventional Surgery|Undergo surgery
271424|NCT02133170|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
271425|NCT02133170|Behavioral|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
271426|NCT02133170|Behavioral|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
271427|NCT02133157|Drug|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
271428|NCT02133144|Behavioral|overeating fat|
271429|NCT02133144|Behavioral|overeating carbohydrate|
271430|NCT02133131|Drug|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
271431|NCT02133131|Drug|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
271432|NCT02133118|Drug|individual SUs, insulin, pioglitazone|
271433|NCT02133105|Drug|Levosimendan|
271434|NCT02133105|Drug|Dobutamine|
271435|NCT02133092|Other|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
271436|NCT02133079|Biological|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
271437|NCT02133066|Procedure|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
271438|NCT02133066|Device|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
271439|NCT02133066|Procedure|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
271440|NCT02133053|Other|Medical Device, drug-like|Ectoin Allergy Nasal Spray
271441|NCT02133053|Drug|Beclomethasone|Beclomethasone nasal spray
271442|NCT02133027|Procedure|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
271443|NCT02133027|Device|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
271444|NCT02133014|Procedure|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
271445|NCT02133014|Drug|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
271446|NCT02133001|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
271447|NCT02133001|Drug|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
271448|NCT02132988|Biological|OPT-822/OPT-821|
271449|NCT02132975|Device|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
271450|NCT02132975|Procedure|Biopsies using UroStation® (image fusion)|
271451|NCT02132962|Dietary Supplement|Amino acid infusion|
271452|NCT02132962|Other|Bloodsamples, Biopsies.|
271453|NCT02132949|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m^2 IV on Day 1 of each cycle q3w.
271454|NCT02132949|Drug|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m^2) intravenous (IV) given on Day 1 of each cycle q2w.
271455|NCT02132949|Drug|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m^2 IV for the first cycle and the dose may be escalated to 100 mg/m^2 for subsequent cycles q3w.
271456|NCT02132949|Drug|Doxorubicin|Participants will receive doxorubicin 60 mg/m^2 IV on Day 1 of each cycle q2w.
271457|NCT02132949|Drug|Epirubicin|Participants will receive epirubicin 100 mg/m^2 IV on Day 1 of each cycle q3w.
271458|NCT02132949|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV given weekly.
271459|NCT02132949|Drug|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
271460|NCT02132949|Drug|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
271461|NCT02132936|Drug|LEO 90100 aerosol foam|
271462|NCT02132936|Drug|Aerosol foam vehicle|
271463|NCT02132936|Drug|Calcipotriol BDP gel|
271464|NCT02132936|Drug|Gel vehicle|
271465|NCT02132923|Biological|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
271466|NCT02132910|Other|RESTORE Intervention|
271467|NCT02132897|Drug|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
271468|NCT02132897|Drug|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
271469|NCT02132884|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
271470|NCT02132884|Procedure|therapeutic procedure|Receive standard of care treatment
271471|NCT02132884|Drug|targeted therapy|Receive specific targeted therapy
271472|NCT02132884|Other|laboratory biomarker analysis|Correlative studies
271473|NCT02132871|Device|Impedance cardiography Physioflow ®|
271474|NCT02132858|Other|cytology specimen collection procedure|Correlative studies
271475|NCT02132858|Other|laboratory biomarker analysis|Correlative studies
271476|NCT02132845|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
271477|NCT02132845|Drug|targeted therapy|Receive target-directed therapy
271478|NCT02132845|Procedure|therapeutic procedure|Receive standard of care therapy
271479|NCT02132845|Other|laboratory biomarker analysis|Correlative studies
271480|NCT02132832|Drug|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
271481|NCT02132832|Drug|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
271482|NCT02132819|Other|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
271483|NCT02132819|Other|feeding during transfusion|The feeding process will be continued during the transfusion
271484|NCT02132806|Procedure|Piezosurgery with biomaterial mp3 + bracket|
271485|NCT02132806|Procedure|Piezosurgery with biomaterial mp3|
271486|NCT02132806|Procedure|Piezosurgery|
271487|NCT02132793|Behavioral|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
271488|NCT02132793|Behavioral|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
271489|NCT02132767|Drug|Amiodarone|"Amiodarone Initial Dose~Oral: 400 mg po TID for 3 days is recommended~For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose~Oral: at least 200 mg/day to be continued until 60 days after randomization~If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
271490|NCT02132767|Procedure|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
271493|NCT02132754|Biological|Pembrolizumab|
271494|NCT02132728|Other|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
271495|NCT02132715|Behavioral|Resistance Exercise|
271496|NCT02132715|Behavioral|KAATSU exercise|
271497|NCT02132702|Device|Ekso|
271498|NCT02132689|Drug|Actilyse (Thrombolytic therapy)|
271499|NCT02132689|Drug|Heparine (Standard anticoagulation therapy)|
271500|NCT02132663|Other|Control: Marketed routine infant formula|
271501|NCT02132663|Other|An investigational infant formula containing an alternate source of DHA|
271502|NCT02132650|Behavioral|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
271503|NCT02132650|Behavioral|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
271504|NCT02132637|Drug|Insulin Peglispro|Administered SQ
271505|NCT02132637|Drug|Insulin Glargine|Administered SQ
271506|NCT02132624|Biological|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
271507|NCT02132611|Device|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
271508|NCT02132598|Drug|cabozantinib|
271509|NCT02132585|Procedure|Speckle tracking echocardiography|
271510|NCT02132572|Device|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
271511|NCT02132559|Drug|DHEA|
271512|NCT02132546|Drug|Chlorhexidine|
271513|NCT02132533|Drug|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
271514|NCT02132533|Drug|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
271515|NCT02132533|Other|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
271516|NCT02132520|Device|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
271517|NCT02132520|Behavioral|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
271518|NCT02132494|Behavioral|Physical activity|
271519|NCT02132481|Other|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
271520|NCT02132481|Other|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
271521|NCT02132481|Other|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
271522|NCT02132481|Other|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
271523|NCT02132468|Drug|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
271524|NCT02132455|Procedure|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
271525|NCT02132442|Dietary Supplement|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
271526|NCT02132429|Drug|AMG 333|Oral administration available in varying dose strength.
271527|NCT02132429|Drug|Placebo|Placebo containing no active drug
271528|NCT02132416|Drug|NSAID|Will be used if tolerated.
271529|NCT02132416|Drug|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
271530|NCT02132416|Drug|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
271531|NCT02132416|Drug|Paracetamol|1g QID will be given to all patients unless allergies.
271532|NCT02132416|Procedure|Surgical management|Fracture stabilization
271533|NCT02132403|Drug|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
271534|NCT02132403|Drug|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
271535|NCT02132403|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
271536|NCT02132390|Drug|Goserelin|
271537|NCT02132390|Drug|Toremifene|
271859|NCT02129751|Drug|Placebo|placebo arm
271538|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
271539|NCT02132338|Behavioral|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
271540|NCT02132325|Behavioral|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
271541|NCT02132312|Drug|OMS302|
271542|NCT02132312|Drug|Phenylephrine HCl|
271543|NCT02132299|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
271544|NCT02132299|Biological|Normal Saline (Placebo)|
271545|NCT02132299|Biological|PfSPZ Challenge|Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
271546|NCT02132286|Drug|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
271547|NCT02132273|Other|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
271548|NCT02132260|Drug|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
271549|NCT02132260|Drug|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
271550|NCT02132260|Drug|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
271551|NCT02132247|Drug|Diclofenac hydroxyethylpyrrolidine|
271552|NCT02132234|Drug|Etanercept|biological treatment according to rheumatologic indication
271553|NCT02132234|Drug|Adalimumab|biological treatment according to rheumatologic indication
271554|NCT02132234|Drug|Certolizumab|biological treatment according to rheumatologic indication
271555|NCT02132234|Drug|Infliximab|biological treatment according to rheumatologic indication
271556|NCT02132221|Behavioral|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
271557|NCT02132195|Drug|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
271558|NCT02132182|Biological|Blood draw|The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
271559|NCT02132169|Drug|Drug: AC-170 0.24%|
271560|NCT02132169|Drug|AC-170 0%|
271561|NCT02132143|Radiation|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
271562|NCT02132143|Radiation|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
271563|NCT02132130|Drug|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
271564|NCT02132117|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
271565|NCT02132117|Drug|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
271566|NCT02132104|Procedure|Uterine application of amnion membrane|Uterine application of amnion membrane following hysteroscopic adhesiolysis.
271567|NCT02132104|Device|Foley balloon|Uterine application of Foley balloon
271568|NCT02132104|Drug|Femoston|Hormones treatment after surgery.
271569|NCT02132091|Other|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
271570|NCT02132091|Dietary Supplement|400 IU Vitamin E|once each day in morning; oral pill form
271571|NCT02132091|Dietary Supplement|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
271572|NCT02132065|Drug|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
271573|NCT02132039|Other|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
271574|NCT02132039|Other|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
271575|NCT02132026|Drug|Denosumab|
271576|NCT02132026|Drug|Alendronic Acid|
271577|NCT02132026|Drug|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
271578|NCT02132026|Drug|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
271579|NCT02132013|Behavioral|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
271580|NCT02132000|Drug|toremifene or tamoxifen|
271581|NCT02131961|Drug|Collagenase ointment|250 collagenase units/g
271582|NCT02131961|Device|Modified Contact Cast System|1 Unit
271583|NCT02131948|Drug|Intranasal insulin|Intranasal spray
271584|NCT02131948|Drug|Intranasal placebo|Intranasal spray
271585|NCT02131922|Procedure|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
271586|NCT02131922|Procedure|Dental Hygienization Treatment|
271587|NCT02131922|Drug|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
271588|NCT02131909|Procedure|mirror therapy|During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image
271589|NCT02131909|Procedure|bimanual rehabilitation exercises|During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
271590|NCT02131896|Other|Interventional arm-Mediterranean diet|
271591|NCT02131896|Other|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
271592|NCT02131883|Behavioral|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
271593|NCT02131883|Other|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
271594|NCT02131870|Dietary Supplement|L plantarum DSM 9843 or placebo|
271595|NCT02131857|Behavioral|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
271596|NCT02131844|Other|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
271597|NCT02131844|Other|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
271598|NCT02131818|Drug|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
271599|NCT02131818|Drug|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
271600|NCT02131805|Radiation|Electronic Skin Surface Brachytherapy|
271601|NCT02131805|Behavioral|Quality of life assessment|
271602|NCT02131792|Procedure|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
271603|NCT02131779|Behavioral|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
271604|NCT02131779|Behavioral|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
271605|NCT02131766|Device|Diabetes Assistant (DiAs)|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
271606|NCT02131753|Drug|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
271607|NCT02131740|Other|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest & eye rubbing for a further 1 minute.
271608|NCT02131740|Other|No eye rubbing|This eye will not be rubbed
271609|NCT02131727|Behavioral|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
271610|NCT02131727|Behavioral|Ask Me 3|"Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers."
271611|NCT02131714|Behavioral|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
271612|NCT02131714|Behavioral|lifestyle counseling|
271613|NCT02131701|Behavioral|Physical activity|
271614|NCT02131688|Drug|Mitoxantrone Hydrochloride Liposome|
271615|NCT02131675|Dietary Supplement|Boost shake|Blood draw after mixed-meal consumption
271616|NCT02131662|Drug|BAY1002670|Subjects received 4 milligram (mg) Vilaprisan (VPR) tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
271617|NCT02131662|Drug|BAY1002670|Subjects received 2 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
271618|NCT02131662|Drug|BAY1002670|Subjects received 1 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
271619|NCT02131662|Drug|BAY1002670|Subjects received 0.5 mg VPR tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
271620|NCT02131662|Drug|Placebo|Subjects received matching placebo tablet once daily orally for 12 weeks (84 days) from the first week of the menstrual cycle following randomization.
271621|NCT02131649|Device|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
271622|NCT02131636|Drug|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
271623|NCT02131636|Drug|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
271624|NCT02131597|Drug|Guadecitabine|Given SC
271625|NCT02131584|Other|Questionnaire Administration|Ancillary studies
271626|NCT02131584|Drug|Ruxolitinib Phosphate|Given PO
271627|NCT02131558|Procedure|ICG Dye|ICG Dye injections
271628|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
271629|NCT02131545|Drug|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
271630|NCT02131545|Drug|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
271631|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
271632|NCT02131532|Behavioral|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
271633|NCT02131519|Procedure|internal jugular vein catheter placement|
271634|NCT02131506|Drug|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die
271635|NCT02131493|Drug|S-1, Gemcitabine|
271636|NCT02131480|Drug|Doxorubicin|60 mg/m²
271637|NCT02131480|Drug|Trabectedin|1,1 mg/m²
271638|NCT02131467|Drug|Perampanel|oral drug
271639|NCT02131454|Other|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
271640|NCT02131441|Procedure|laparoscopic hepatectomy|
271641|NCT02131441|Procedure|open liver resection|
271642|NCT02131402|Device|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
271643|NCT02131402|Device|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
271644|NCT02131402|Device|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
271645|NCT02131389|Device|Iconacy Hip System|
271646|NCT02131376|Procedure|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
271647|NCT02131376|Procedure|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
271648|NCT02131363|Device|Ingrowing Toenail Treatment Kit|detailed in arm description
271649|NCT02131350|Procedure|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
271650|NCT02131350|Drug|Ranibizumab|
271651|NCT02131337|Other|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
271652|NCT02131324|Drug|DFD06 Cream|
271653|NCT02131324|Drug|Clobetasol Propionate Cream 0.05%|
271654|NCT02131311|Device|disposable, single-use pessary|
271655|NCT02131298|Drug|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
271656|NCT02131298|Drug|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
271657|NCT02131285|Other|Sensory training|
271658|NCT02131272|Drug|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
271659|NCT02131272|Drug|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
271660|NCT02131272|Behavioral|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
271661|NCT02131259|Drug|Afatinib dimaleate|20mg - 50mg
271662|NCT02131246|Drug|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
271663|NCT02131246|Drug|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
271664|NCT02131233|Drug|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
271665|NCT02131233|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily
271666|NCT02131233|Drug|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
271667|NCT02131233|Drug|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
271668|NCT02131233|Drug|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
271669|NCT02131220|Drug|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
271670|NCT02131220|Drug|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
271671|NCT02131220|Drug|normal saline|intracoronary bolus infusion using selective catheter during PCI
271672|NCT02131207|Device|magnetic resonance imaging|Undergo pelvic MRI
271673|NCT02131207|Procedure|prostate biopsy|Undergo prostate biopsy
271674|NCT02131194|Dietary Supplement|Lenstatin|Dietary Supplement Lenstatin
271675|NCT02131194|Drug|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
271676|NCT02131155|Drug|Placebo|Once daily
271677|NCT02131155|Drug|Afatinib|Once daily
271678|NCT02131142|Device|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
271679|NCT02131129|Device|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
271680|NCT02131129|Device|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).~Ten sessions over a two week duration"
271681|NCT02131116|Behavioral|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
271682|NCT02131116|Behavioral|Treatment as Usual|Treatment as Usual
271683|NCT02131103|Other|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.~Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
271684|NCT02131090|Device|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
271685|NCT02131090|Device|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
271686|NCT02131090|Device|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
271687|NCT02131077|Biological|ALLO-ASC-TI|
271688|NCT02131077|Drug|Placebo|
271689|NCT02131064|Drug|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg*min/mL q3w
271690|NCT02131064|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infusion q3w
271691|NCT02131064|Drug|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
271692|NCT02131064|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
271693|NCT02131064|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
271694|NCT02131038|Other|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
271695|NCT02131012|Drug|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
271696|NCT02130999|Drug|tasimelteon 20 mg capsule|
271697|NCT02130999|Drug|tasimelteon 2 mg I.V.|
271698|NCT02130986|Other|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
271699|NCT02130986|Other|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (<1 hour goal) provide clinicians the procalcitonin result.
271700|NCT02130986|Other|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --~Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation~< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)~0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)~> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)~> 0.5 -- Very likely -- Antibiotics strongly recommended(2)~Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.~For outpatients, antibiotic duration based on level (> 0.25-0.5 ug/L:3 days; > 0.5-1.0 ug/L:5 days; >1.0 ug/L:7 days). Physician follow-up is recommended."
271701|NCT02130986|Other|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
271702|NCT02130973|Drug|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
271703|NCT02130973|Drug|Experimental Cyclic Regimen|Experimental Cyclic Regimen
271704|NCT02130947|Behavioral|Exercise|
271705|NCT02130934|Procedure|Cardiac 3D MRI|
271734|NCT02130817|Drug|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
271735|NCT02130817|Drug|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
271736|NCT02130817|Drug|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
271737|NCT02130804|Drug|Salsalate (4 g/day)|Given orally twice daily
271738|NCT02130804|Drug|Placebo (4 g/day)|Given orally twice daily
271706|NCT02130921|Behavioral|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.~Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.~Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
271707|NCT02130908|Other|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
271708|NCT02130908|Other|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
271709|NCT02130908|Other|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
271710|NCT02130895|Other|STOPP Criteria Decision Support Content|"55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with >=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation."
271711|NCT02130882|Drug|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
271712|NCT02130882|Other|Placebo|A sterile solution containing 20 mM histidine/histidine-HCl, 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
271713|NCT02130869|Biological|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
271714|NCT02130869|Biological|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
271715|NCT02130869|Biological|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
271716|NCT02130869|Drug|Busulfan|Given IV - Group A only.
271717|NCT02130869|Drug|Melphalan|Given IV - All groups.
271718|NCT02130869|Biological|GM-CSF|Given SQ - All groups.
271719|NCT02130869|Drug|Bendamustine|Given IV - Group B only.
271720|NCT02130869|Drug|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
271721|NCT02130869|Drug|Cytarabine|Given IV - Group B only.
271722|NCT02130869|Drug|Carboplatin|Given IV - Group C only.
271723|NCT02130869|Device|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
271724|NCT02130869|Biological|G-CSF|Given SQ - All Groups.
271725|NCT02130869|Drug|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
271726|NCT02130869|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
271727|NCT02130856|Device|Neonatal kit|"Contents of the neonatal kit:~Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~Sunflower oil emollient (50 mL)~ThermoSpot~Mylar infant sleeve~Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker."
271728|NCT02130843|Device|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
271729|NCT02130830|Drug|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
271730|NCT02130830|Drug|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
271731|NCT02130817|Drug|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
271732|NCT02130817|Drug|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
271733|NCT02130817|Procedure|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
271739|NCT02130791|Behavioral|Sleep|
272100|NCT02128113|Drug|1% Omaveloxolone Ophthalmic Suspension|1% ophthalmic suspension of RTA 408
271740|NCT02130778|Drug|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
271741|NCT02130778|Other|500 ml 0.9% saline|infusion of saline
271742|NCT02130765|Device|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
271743|NCT02130752|Device|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
271744|NCT02130752|Device|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
271745|NCT02130739|Procedure|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
271746|NCT02130739|Procedure|mastectomy|mastectomy with/without breast reconstruction
271747|NCT02130739|Drug|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
271748|NCT02130739|Drug|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
271749|NCT02130739|Drug|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
271750|NCT02130726|Procedure|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
271751|NCT02130726|Procedure|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
271752|NCT02130713|Drug|Third generation fluoroquinolone|Prulifloxacin 600 mg
271753|NCT02130713|Dietary Supplement|Nutritional supplement + third generation fluoroquinolone|Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
271754|NCT02130700|Drug|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
271755|NCT02130700|Drug|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
271756|NCT02130687|Drug|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.~In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
271757|NCT02130687|Drug|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
271758|NCT02130687|Drug|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
271759|NCT02130687|Other|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
271760|NCT02130674|Drug|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
271761|NCT02130661|Drug|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
271762|NCT02130661|Drug|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
271763|NCT02130661|Drug|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
271764|NCT02130648|Other|A sampling of blood|A sampling of blood de 14 ml
271765|NCT02130635|Drug|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
271766|NCT02130635|Drug|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
271767|NCT02130635|Drug|PLACEBO|Lactose administered using a matching dry powder inhaler device
271768|NCT02130622|Drug|Promethazine|
271769|NCT02130622|Drug|Sugar pill|
271770|NCT02130609|Device|Skintel|
271771|NCT02130596|Behavioral|Acceptance-Based Behavioral Intervention|
271772|NCT02130596|Other|Nutritional Counselling|
271773|NCT02130583|Behavioral|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
271774|NCT02130583|Behavioral|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
271775|NCT02130570|Other|Multi-Model Intensive Discharge Intervention|"Inpatient medication safety interventions~Inpatient discharge advocate~Structured visiting nurse (VNA) appointments~Post-discharge phone call by primary care personnel within 2 business days of discharge~Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge~Improved communication between inpatient and primary care teams~High-risk patients will receive additional interventions as needed:~Home pharmacist visit~Enrollment in the Partners integrated Care Management Program (iCMP)~Enrollment in telemedicine programs for patients with CHF~Palliative care consultation regarding goals of care~Novel health information technology to facilitate communication and transfer of clinical information"
271776|NCT02130557|Drug|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.[1] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
271818|NCT02130206|Other|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
271819|NCT02130206|Other|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
271777|NCT02130557|Drug|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.~Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
271778|NCT02130531|Drug|Emixustat HCl Tablet|Tablet for oral administration
271779|NCT02130531|Other|Placebo Tablet|Tablet for oral administration
271780|NCT02130518|Drug|Auriclosene Irrigation Solution, 0.2%|
271781|NCT02130518|Drug|Auriclosene Vehicle Solution|
271782|NCT02130505|Dietary Supplement|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
271783|NCT02130492|Radiation|FDG|The intervention arm consists of treatment with increasing doses of [18F]-Fluorodeoxyglucose.
271784|NCT02130479|Behavioral|Contingency Management-Family Engagement|
271785|NCT02130479|Behavioral|Treatment as Usual|
271786|NCT02130466|Biological|Pembrolizumab|IV infusion
271787|NCT02130466|Drug|Dabrafenib|oral capsule
271788|NCT02130466|Drug|Trametinib|oral tablet
271789|NCT02130453|Drug|Regadenoson|0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
271790|NCT02130440|Drug|Resveratrol nasal spray|
271791|NCT02130427|Radiation|Radiation Therapy|
271792|NCT02130414|Drug|Sandimmun® IV|2 mg/kg IV
271793|NCT02130414|Drug|CyCol® capsules|37.5 mg CyCol® capsules
271794|NCT02130401|Device|TNM (thermoneuromodulation device)|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
271795|NCT02130388|Dietary Supplement|Zinc|
271796|NCT02130375|Procedure|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
271797|NCT02130336|Behavioral|Aerobic interval training|
271798|NCT02130336|Behavioral|Continuous moderate-intensity exercise|
271799|NCT02130323|Drug|Imiquimod|12.5mg (5%) once a week vaginally for 16 weeks
271800|NCT02130323|Procedure|Loop Electrosurgical Excision Procedure|Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
271801|NCT02130310|Biological|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
271802|NCT02130310|Other|Placebo injection|Normal saline injected at each centimeter of ulcer bed
271803|NCT02130297|Device|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
271804|NCT02130284|Device|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
271805|NCT02130271|Drug|Radioactive dye|The radioactive dye [11C]PBR28 will be administered through an intravenous line (IV).
271806|NCT02130271|Radiation|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
271807|NCT02130271|Other|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
271808|NCT02130258|Device|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
271809|NCT02130258|Procedure|Epidural Steroid Injection (ESI)|Subjects will receive an ESI by their clinical physician as part of their clinical treatment. This procedure is not given as part of the research study.
271810|NCT02130245|Procedure|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
271811|NCT02130245|Procedure|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
271812|NCT02130232|Behavioral|Lifestyle Intervention|
271813|NCT02130232|Other|Usual Care|
271814|NCT02130219|Device|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
271815|NCT02130219|Device|Brain MRI/CT|"1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume."
271816|NCT02130219|Procedure|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
271817|NCT02130206|Other|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
271820|NCT02130206|Other|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
271821|NCT02130193|Drug|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
271822|NCT02130193|Drug|Placebo|Subjects will receive danirixin matching placebo
271823|NCT02130167|Drug|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
271824|NCT02130154|Other|18-FDG PET CT scan and 123I-MIBG SPECT scan|
271825|NCT02130141|Dietary Supplement|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
271826|NCT02130141|Other|Dietary counselling|Usual snacks are limited.
271827|NCT02130128|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
271828|NCT02130115|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
271829|NCT02130102|Device|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:~tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
271830|NCT02130089|Behavioral|Intensive Tailored Education|
271831|NCT02130063|Drug|iron isomaltoside 1000 (Monofer®)|
271832|NCT02130063|Drug|iron sucrose (Venofer®)|
271833|NCT02130037|Behavioral|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
271834|NCT02130037|Other|psychotherapy|standard psychotherapy for eating disorders
271835|NCT02130024|Drug|Ranibizumab 0.5 mg|Administered as an intravitreal injection
271836|NCT02130024|Drug|Aflibercept 2.0 mg|Administered as an intravitreal injection
271837|NCT02130011|Other|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
271838|NCT02129998|Other|IVF/ICSI treatment|
271839|NCT02129985|Drug|Exenatide|Exenatide (10 ug/bid for 3 months)
271840|NCT02129985|Drug|Metformin|Metformin 850 mg/bid for 3 months
271841|NCT02129972|Device|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.~Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.~In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.~In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
271842|NCT02129946|Other|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
271843|NCT02129933|Drug|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.~* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
271844|NCT02129933|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
271845|NCT02129920|Other|This is an observational study|
271846|NCT02129894|Device|abdominal Binder|placement of abdominal binder
271847|NCT02129881|Biological|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
271848|NCT02129868|Device|Closed-loop (Android Closed-Loop platform)|"The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.~The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes."
271849|NCT02129829|Drug|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
271850|NCT02129816|Drug|Bryophyllum|
271851|NCT02129803|Device|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
271852|NCT02129803|Device|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
271853|NCT02129790|Behavioral|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
271854|NCT02129777|Drug|Namilumab|Namilumab subcutaneous injection
271855|NCT02129777|Drug|Placebo|Placebo subcutaneous injection
271856|NCT02129764|Drug|Prednisone|
271857|NCT02129764|Drug|Allopurinol|
271858|NCT02129751|Drug|bupropion hydrobromide|study drug
271860|NCT02129738|Device|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
271861|NCT02129725|Drug|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
271862|NCT02129725|Drug|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
271863|NCT02129712|Behavioral|Cognitive training|
271864|NCT02129699|Drug|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
271865|NCT02129699|Other|None, standard chemotherapy only|"Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):~Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1"
271866|NCT02129686|Procedure|Immediate Acupuncture Group|
271867|NCT02129686|Procedure|Delayed Acupuncture Group|
271868|NCT02129673|Drug|VS101 Insert Dose A|Sustained release of latanoprost into the eye
271869|NCT02129673|Drug|VS101 Insert Dose B|Sustained release of latanoprost into the eye
271870|NCT02129673|Drug|VS101 Insert Dose C|Sustained release of latanoprost into the eye
271871|NCT02129673|Drug|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
271872|NCT02129660|Drug|Dose 1 of glycopyrrolate, 2.0% QD|Dose 1 of glycopyrrolate Topical Wipes
271873|NCT02129660|Drug|Dose 2 of glycopyrrolate, 3.0% QD|Dose 2 of glycopyrrolate Topical Wipes
271874|NCT02129660|Drug|Dose 1 of glycopyrronium, 2.5% QD|Dose 1 of glycopyrronium Topical Wipes
271875|NCT02129660|Drug|Dose 2 of glycopyrronium, 3.75% QD|Dose 2 of glycopyrronium Topical Wipes
271876|NCT02129660|Other|Vehicle|Vehicle Topical Wipes
271877|NCT02129647|Drug|Axitinib|
271878|NCT02129634|Device|CB-PTA|
271879|NCT02129634|Device|DEB-PTA|
271880|NCT02129621|Procedure|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
271881|NCT02129621|Drug|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
271882|NCT02129608|Device|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
271883|NCT02129608|Drug|Lorcaserin|10 mg pills twice daily for 12 weeks.
271884|NCT02129595|Dietary Supplement|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
271885|NCT02129595|Dietary Supplement|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
271886|NCT02129582|Radiation|total marrow irradiation|Undergo TMI
271887|NCT02129582|Drug|fludarabine phosphate|Given IV
271888|NCT02129582|Drug|busulfan|Given IV or PO
271889|NCT02129582|Procedure|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
271890|NCT02129582|Biological|anti-thymocyte globulin|Given IV
271891|NCT02129582|Drug|tacrolimus|Given IV or PO
271892|NCT02129582|Drug|methotrexate|Given IV
271893|NCT02129582|Other|laboratory biomarker analysis|Correlative studies
271894|NCT02129569|Other|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
271895|NCT02129569|Behavioral|behavioral intervention|Receive individualized walking prescription and wear pedometer
271896|NCT02129569|Other|counseling intervention|Receive supplemental counseling support over the phone
271897|NCT02129569|Other|educational intervention|Receive NCI educational booklets and a link to the ACS website
271898|NCT02129569|Other|telephone-based intervention|Receive calls that are primarily social in nature
271899|NCT02129569|Other|questionnaire administration|Ancillary studies
271900|NCT02129569|Other|quality-of-life assessment|Ancillary studies
271901|NCT02129556|Drug|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
271902|NCT02129543|Procedure|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis per protocol.
271903|NCT02129530|Behavioral|Community Social Mobilization program|
271904|NCT02129517|Other|IMPACT intervention|Tailored, web-based educational short video clips
271905|NCT02129517|Other|Online education materials|Online NCI-based educational materials
271906|NCT02129517|Other|survey administration|Ancillary studies
271907|NCT02129504|Device|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
271908|NCT02129478|Drug|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.~Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
272052|NCT02128464|Procedure|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
272053|NCT02128464|Procedure|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
271909|NCT02129439|Drug|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.~SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)~The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.~No modifications are permitted to the dosing regimen except for premature study discontinuation."
271910|NCT02129439|Drug|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.~The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.~The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
271911|NCT02129426|Drug|Ketamine|
271912|NCT02129426|Drug|Midazolam|
271913|NCT02129426|Drug|Dexmedetomidine|
271914|NCT02129413|Device|Delta system|
271915|NCT02129400|Drug|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
271916|NCT02129400|Drug|Aer medicinalis Linde 100%|
271917|NCT02129374|Procedure|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
271918|NCT02129361|Behavioral|Adapted Screening and Brief Intervention (Adapted SBI)|
271919|NCT02129361|Behavioral|Screening & Education Attention Control|
271920|NCT02129348|Drug|Lithium|
271921|NCT02129348|Drug|Placebo|
271922|NCT02129335|Other|stress|stress level and survival
271923|NCT02129322|Drug|Sorafenib|
271924|NCT02129322|Drug|S-1|
271925|NCT02129322|Drug|Oxaliplatin|
271926|NCT02129309|Procedure|Forearm plethysmography|Dose response study
271927|NCT02129309|Procedure|Haemodynamic studies|Dose response study
271928|NCT02129296|Device|Air filled balloon|Balloon filled with air according to the manufacturing company orders
271929|NCT02129296|Device|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
271930|NCT02129283|Behavioral|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
271931|NCT02129270|Drug|Lidocaine HCl 2% .|comparison of different dosages of drug
271932|NCT02129270|Drug|Lidocaine HCl 1%|comparison of different dosages of drug
271933|NCT02129257|Drug|AFLIBERCEPT|
271934|NCT02129257|Drug|Irinotecan|
271935|NCT02129257|Drug|5-Fluorouracil|
271936|NCT02129257|Drug|Folinic Acid|
271937|NCT02129244|Other|NCM-Plus|"The NCM will follow the domains of the chronic care model by:~Assuring effective, efficient clinical care and self-management support~Promoting clinical care consistent with scientific evidence and patient preferences~Organizing data to facilitate efficient, effective care~Empowering and preparing patients to manage their health and health-care needs~Mobilizing community resources to meet the needs of patients"
271938|NCT02129231|Drug|calcined magnesia|We ensured the patient took the drug at night before meals
271939|NCT02129231|Drug|Ezetimibe/simvastatin|We ensured the patient took the drug at night before meals
271940|NCT02129231|Drug|Rosuvastatin|We ensured the patient took the drug at night before meals
271941|NCT02129218|Other|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
271942|NCT02129218|Other|laboratory biomarker analysis|Correlative studies
271943|NCT02129218|Behavioral|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
271944|NCT02129218|Behavioral|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
271945|NCT02129218|Behavioral|Low glycemic load|
271946|NCT02129218|Behavioral|Medium Glycemic Load|
271947|NCT02129205|Drug|PF-06650808|Dose Escalation Phase [Part 1] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
271948|NCT02129205|Drug|PF-06650808|Dose Expansion Phase [Part 2] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
271949|NCT02129192|Drug|Amlodipine 5mg capsule|Amlodipine 5mg capsule
271950|NCT02129192|Drug|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
271951|NCT02129192|Drug|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
271952|NCT02129179|Drug|Glucagon-Like Peptide 1|
271953|NCT02129166|Drug|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
271954|NCT02129166|Drug|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.~Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
272142|NCT02127749|Drug|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
271955|NCT02129153|Behavioral|LIFT (Parent Information)|"Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication~Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish."
271956|NCT02129140|Device|Hernia graft/mesh|observational group
271957|NCT02129127|Device|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
271958|NCT02129114|Device|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
271959|NCT02129114|Device|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
271960|NCT02129101|Drug|Azacitidine|Given SC or IV
271961|NCT02129101|Drug|Decitabine|Given IV
271962|NCT02129101|Other|Laboratory Biomarker Analysis|Correlative studies
271963|NCT02129101|Other|Quality-of-Life Assessment|Ancillary studies
271964|NCT02129101|Drug|Sonidegib|Given PO
271965|NCT02129088|Drug|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
271966|NCT02129088|Drug|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
271967|NCT02129075|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
271968|NCT02129075|Other|Laboratory Biomarker Analysis|Correlative studies
271969|NCT02129075|Biological|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Given SC
271970|NCT02129075|Other|Pharmacological Study|Correlative studies
271971|NCT02129075|Biological|Recombinant Flt3 Ligand|Given SC
271972|NCT02129062|Drug|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
271973|NCT02129062|Other|Laboratory Biomarker Analysis|Correlative studies
271974|NCT02129049|Other|educational intervention|Participate in the Enhancing Connections Telephone Program
271975|NCT02129049|Behavioral|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
271976|NCT02129049|Other|questionnaire administration|Ancillary studies
271977|NCT02129023|Device|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
271978|NCT02128997|Device|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
271979|NCT02128984|Dietary Supplement|Symbiotic Formula with DHA and antioxidants|6 months intervention.
271980|NCT02128984|Dietary Supplement|Standard Formula|6 months intervention.
271981|NCT02128971|Dietary Supplement|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
271982|NCT02128971|Dietary Supplement|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
271983|NCT02128971|Dietary Supplement|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
271984|NCT02128971|Dietary Supplement|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
271985|NCT02128971|Dietary Supplement|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
271986|NCT02128971|Dietary Supplement|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
271987|NCT02128958|Drug|CF102|orally q12h
271988|NCT02128958|Drug|Placebo|orally q12 hours
271989|NCT02128945|Other|[18F] - Fludarabine PET/CT|[18F] - Fludarabine PET/CT before treatment
271990|NCT02128932|Drug|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
271991|NCT02128932|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
271992|NCT02128919|Device|tDCS|Transcranial Direct Current Stimulation
271993|NCT02128906|Drug|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
271994|NCT02128906|Radiation|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
271995|NCT02128906|Drug|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
271996|NCT02128906|Drug|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
271997|NCT02128893|Drug|Isavuconazole|oral
271998|NCT02128893|Drug|Esomeprazole|oral
271999|NCT02128880|Behavioral|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
272000|NCT02128880|Behavioral|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
272001|NCT02128867|Other|Assisted Autogenic Drainage (AAD)|
272002|NCT02128867|Other|bouncing and AAD|
272003|NCT02128867|Other|bouncing|
272054|NCT02128451|Drug|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
272055|NCT02128451|Drug|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
272227|NCT02126943|Drug|Opsumit (macitentan)|10 mg tablets
272004|NCT02128854|Behavioral|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
272005|NCT02128841|Drug|Rivaroxaban|Direct Factor Xa Inhibitor
272006|NCT02128828|Drug|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
272007|NCT02128815|Other|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
272008|NCT02128802|Procedure|Gastric Bypass|
272009|NCT02128802|Other|Weight Loss Program|
272010|NCT02128789|Other|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
272011|NCT02128776|Other|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
272012|NCT02128776|Other|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
272013|NCT02128763|Drug|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
272014|NCT02128763|Drug|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
272015|NCT02128750|Other|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
272016|NCT02128737|Behavioral|Sleep|
272017|NCT02128724|Drug|BKM120|Buparlisib is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). Buparlisib is supplied as 10mg and 50mg hard gelatin capsules.
272018|NCT02128698|Dietary Supplement|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
272019|NCT02128698|Dietary Supplement|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
272020|NCT02128698|Behavioral|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
272021|NCT02128698|Behavioral|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
272022|NCT02128685|Drug|Dydrogesterone|
272023|NCT02128685|Drug|Placebo|
272024|NCT02128672|Procedure|Spinal Cord Stimulator Lead Placement|
272025|NCT02128659|Behavioral|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
272026|NCT02128646|Drug|EXPAREL|
272027|NCT02128646|Drug|Ketorolac|
272028|NCT02128646|Procedure|laparoscopic abdominal hernia repair|
272029|NCT02128646|Procedure|an open surgery for abdominal hernia repair|
272030|NCT02128633|Drug|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
272031|NCT02128633|Drug|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
272032|NCT02128633|Drug|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
272033|NCT02128620|Behavioral|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
272034|NCT02128607|Device|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
272035|NCT02128607|Device|Sham|
272036|NCT02128594|Behavioral|Serosorting Intervention|Single session, behavioral intervention
272037|NCT02128581|Drug|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
272038|NCT02128581|Other|Saline|
272039|NCT02128568|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
272040|NCT02128555|Procedure|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
272041|NCT02128555|Procedure|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
272042|NCT02128542|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
272043|NCT02128542|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
272044|NCT02128516|Other|oral powder in sachet|
272045|NCT02128503|Other|HBV DNA level monitoring|HBV DNV level being monitoring regularly
272046|NCT02128490|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
272047|NCT02128490|Drug|Febuxostat XR|Febuxostat over-encapsulated capsules
272048|NCT02128490|Drug|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
272049|NCT02128490|Drug|Colchicine|Colchicine tablets
272050|NCT02128490|Drug|Naproxen|Naproxen tablets
272051|NCT02128490|Drug|Lansoprazole|Lansoprazole capsules
272056|NCT02128425|Drug|FOLFOXIRI|"irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~*reduced in UGT1A1 7/7 patients"
272057|NCT02128425|Drug|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
272058|NCT02128412|Device|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
272059|NCT02128412|Device|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
272060|NCT02128373|Procedure|Usual care|Health care provided by physician, physician's nurse, and social worker
272061|NCT02128373|Other|computer-assisted intervention|Caregiver will virtually attend visit using the CLOSER intervention
272062|NCT02128373|Other|Distress Thermometer|Average score of a one item scale (range 0-10) where higher scores indicate more distress
272063|NCT02128373|Other|Profile of Mood States (POMS-B)|average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
272064|NCT02128373|Other|Quality of Life: Functional Assessment in Cancer Therapy - (FACT)|Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
272065|NCT02128373|Other|Tension-Anxiety Subscale|six item scale which asks to qualitatively describe which areas in you life are causing stress
272066|NCT02128360|Drug|Letrozole, Gonadotropins|
272067|NCT02128360|Drug|Gonadotropins|
272068|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
272069|NCT02128334|Drug|Eligard 45 mg Exposure|Subcutaneous injections
272070|NCT02128321|Drug|Isavuconazole|oral
272071|NCT02128321|Drug|Repaglinide|oral
272072|NCT02128321|Drug|Caffeine|oral
272073|NCT02128308|Drug|Levofloxacin and Streptomycin added|
272074|NCT02128308|Drug|Moxifloxacin and Kanamycin added|
272075|NCT02128295|Device|Electric breast pump - A|
272076|NCT02128295|Device|Electric breast pump - B|
272077|NCT02128282|Drug|CX-4945|API powder-in-capsule in 200 mg strength.
272078|NCT02128282|Drug|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
272079|NCT02128282|Drug|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.
272080|NCT02128269|Biological|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
272081|NCT02128256|Device|Cerament G|
272082|NCT02128243|Drug|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
272083|NCT02128243|Drug|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.~Two-Drug combinations:~FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)~Three-drug combinations:~EOX/EOF FLOT"
272084|NCT02128230|Drug|MEL-CFZ-TD-PACE|Melphalan and Carfilzomib will be given into a central venous catheter. Dexamethasone is a pill that is taken by mouth daily for 4 days. Thalidomide is a capsule taken by mouth for 4 days. Cisplatin, Adriamycin, Cyclophosphamide and Etoposide are all given into the vein (IV) by a continuous infusion through a central catheter for 4 days. After completion of the four days of continuous chemotherapy, a drug G-CSF will be given. This is a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy.
272085|NCT02128217|Drug|Sofosbuvir|Participants received one 400 mg tablet of sofosbuvir (SOF) orally every morning with food
272086|NCT02128217|Drug|Ribavirin|Participants received weight-based ribavirin RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV was based on subject's weight at entry. Changes in weight after entry did not require a change in dose. Doses were only changed for toxicity management.
272087|NCT02128217|Drug|Ledipasvir/Sofosbuvir|Participants received one daily fixed-dose combination tablet orally every morning of 90 mg of Ledipasvir (LDV) and 400 mg of SOF.
272088|NCT02128204|Device|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
272089|NCT02128204|Device|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
272090|NCT02128191|Drug|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
272091|NCT02128191|Drug|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
272092|NCT02128178|Drug|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
272093|NCT02128178|Drug|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
272094|NCT02128165|Device|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
272095|NCT02128165|Device|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
272096|NCT02128152|Device|Ekso exoskeleton|
272097|NCT02128126|Drug|ISA101/ISA101b|Four dose levels ISA101/ISA101b
272098|NCT02128113|Drug|Placebo|Opthalmic suspension manufactured to mimic RTA 408 suspension
272099|NCT02128113|Drug|0.5% Omaveloxolone Ophthalmic Suspension|0.5% ophthalmic suspension of RTA 408
272101|NCT02128100|Drug|Folfirinox|"Oxaliplatin 85 mg/m² for over 2 hours,~Leucovorin 400n mg/m² for over 2 hours,~Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion~Fluorouracil 400 mg/m² as a fast infusion over 15 minutes~Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
272102|NCT02128100|Radiation|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
272103|NCT02128087|Behavioral|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
272104|NCT02128087|Behavioral|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
272105|NCT02128074|Drug|KRX-0502|1g tablets of KRX-0502
272106|NCT02128061|Drug|Lenalidomide|
272107|NCT02128061|Drug|Rituximab|
272108|NCT02128048|Device|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
272109|NCT02128035|Procedure|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.~Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
272110|NCT02128022|Drug|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
272111|NCT02128022|Drug|Glibenclamide|Oral Glibenclamide 5mg
272112|NCT02128009|Other|osteoporosis|
272113|NCT02127996|Drug|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
272114|NCT02127996|Drug|placebo|Normal saline
272115|NCT02127983|Behavioral|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.~Front line public health personnel and community leaders were sensitised to support the intervention"
272116|NCT02127983|Behavioral|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
272117|NCT02127970|Drug|Dalbavancin|Dalbavancin IV infusion over 30 minutes.
272118|NCT02127970|Drug|Dalbavancin-matching Placebo|Dalbavancin-matching placebo IV infusion over 30 minutes.
272119|NCT02127957|Other|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
272120|NCT02127931|Device|Groundskeeper|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
272121|NCT02127918|Drug|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
272122|NCT02127905|Biological|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
272123|NCT02127892|Biological|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
272124|NCT02127892|Biological|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
272125|NCT02127892|Biological|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
272126|NCT02127892|Device|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
272127|NCT02127879|Device|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
272128|NCT02127879|Device|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
272129|NCT02127866|Drug|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
272130|NCT02127866|Drug|Foster 100/6 µg|"Active comparator~Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
272131|NCT02127853|Drug|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
272132|NCT02127853|Drug|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
272133|NCT02127840|Drug|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
272134|NCT02127827|Device|Automated Ambulatory Glycemic Controller (AAGC)|
272135|NCT02127814|Dietary Supplement|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
272136|NCT02127801|Drug|REGN1908-1909|
272137|NCT02127801|Drug|placebo|
272138|NCT02127788|Drug|Micafungin|intravenous
272139|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 1)|
272140|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 2)|
272141|NCT02127762|Behavioral|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
272143|NCT02127749|Drug|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
272144|NCT02127736|Drug|Amitriptyline|
272145|NCT02127736|Drug|Placebo|
272146|NCT02127723|Device|Hyaluronic acid injection (Macroalne VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
272147|NCT02127710|Drug|AZD6094|AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
272148|NCT02127697|Drug|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
272149|NCT02127697|Drug|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
272150|NCT02127697|Drug|salbutamol/ albuterol|Taken as rescue medication
272151|NCT02127684|Drug|ranibizumab|ranibizumab 0.3mg intravitreally monthly
272152|NCT02127684|Drug|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
272153|NCT02127671|Other|IDEAL intervention|
272154|NCT02127671|Other|Control|
272155|NCT02127658|Other|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
272156|NCT02127658|Other|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
272157|NCT02127645|Procedure|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
272158|NCT02127645|Procedure|LRT-TEM|TEM following 46 Gy RT
272159|NCT02127645|Procedure|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
272160|NCT02127645|Procedure|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
272161|NCT02127632|Device|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
272162|NCT02127632|Device|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson & Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.~Other Names:~LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
272163|NCT02127619|Device|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
272164|NCT02127606|Device|Vibration with tilt-table standing|
272165|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
272166|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
272167|NCT02127580|Procedure|BAV|
272168|NCT02127580|Procedure|without BAV|
272169|NCT02127567|Other|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
272170|NCT02127567|Other|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
272171|NCT02127541|Other|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
272172|NCT02127515|Procedure|Non Invasive Prenatal Testing|
272173|NCT02127515|Procedure|Invasive Prenatal Testing|
272174|NCT02127489|Drug|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
272175|NCT02127476|Drug|KHK6640|Single ascending dose and multiple ascending doses administration
272176|NCT02127476|Drug|Matching Placebo|Single ascending dose and multiple ascending doses administration
272177|NCT02127463|Drug|MC-1101|Topically, two times a day, morning and bedtime
272178|NCT02127463|Drug|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
272179|NCT02127437|Drug|Lanreotide|120 mg, subcutaneously, once every 4 weeks
272180|NCT02127437|Drug|saline|0,5 ml, subcutaneously, once every 4 weeks
272181|NCT02127424|Procedure|Nurse-driven HIV targeted screening|
272182|NCT02127424|Procedure|Current practice|
272183|NCT02127411|Behavioral|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
272184|NCT02127398|Biological|fecal microbiota|fecal microbiota in capsule form
272224|NCT02126969|Radiation|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
272225|NCT02126969|Drug|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
272226|NCT02126956|Drug|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
272185|NCT02127372|Drug|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.~Phase 1 dose levels are:~Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg~Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg~Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg~Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg~Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg~Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg~Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
272186|NCT02127372|Drug|Docetaxel|
272187|NCT02127372|Drug|Cisplatin|
272188|NCT02127320|Drug|Rosuvastatin 20mg|
272189|NCT02127320|Drug|Ezetimibe 10mg|
272190|NCT02127320|Drug|Rosuvastatin 20mg + Ezetimibe 10mg|
272191|NCT02127294|Device|transcatheter patent foreman ovale closure|
272192|NCT02127281|Device|Prevena|Device will be applied at end of procedure over closed incision.
272193|NCT02127268|Drug|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
272194|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
272195|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
272196|NCT02127242|Procedure|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
272197|NCT02127229|Procedure|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
272198|NCT02127216|Behavioral|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
272199|NCT02127190|Drug|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
272200|NCT02127190|Drug|Placebo|
272201|NCT02127177|Device|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
272202|NCT02127164|Device|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
272203|NCT02127151|Drug|BMN 673|Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
272204|NCT02127138|Device|Sirolimus eluting Drug stent|Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
272205|NCT02127125|Drug|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
272206|NCT02127125|Drug|Synbiotic|Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
272207|NCT02127125|Drug|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
272208|NCT02127112|Procedure|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
272209|NCT02127112|Procedure|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
272210|NCT02127086|Other|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
272211|NCT02127073|Drug|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
272212|NCT02127060|Drug|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
272213|NCT02127060|Drug|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
272214|NCT02127047|Drug|Sitagliptin|
272215|NCT02127047|Drug|Exercise|
272216|NCT02127034|Drug|Mirabegron|oral
272217|NCT02127034|Drug|Solifenacin|oral
272218|NCT02127034|Drug|Digoxin|oral
272219|NCT02127021|Drug|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
272220|NCT02127021|Drug|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
272221|NCT02127008|Procedure|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
272222|NCT02127008|Procedure|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
272223|NCT02126995|Drug|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
272228|NCT02126930|Other|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
272229|NCT02126930|Other|Routine care|Patients randomized to this arm will receive care in the habitual manner.
272230|NCT02126917|Drug|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
272231|NCT02126917|Drug|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
272232|NCT02126917|Drug|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
272233|NCT02126904|Drug|IVA group|
272234|NCT02126891|Procedure|Tests|Individual parameters of echocardiography and heart rate variability
272235|NCT02126878|Drug|Kenalog|
272236|NCT02126865|Drug|Placebo to BI 1060469|tablet
272237|NCT02126865|Drug|BI 1060469 Healthy|tablet
272238|NCT02126865|Drug|Placebo to BI 1060469 asthmatics|tablet
272239|NCT02126865|Drug|BI 1060469 asthmatics|tablet
272240|NCT02126852|Device|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
272241|NCT02126852|Device|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
272242|NCT02126852|Device|Electromyography (EMG)|Neuromuscular monitoring
272243|NCT02126839|Drug|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
272244|NCT02126839|Drug|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
272245|NCT02126839|Drug|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
272246|NCT02126826|Drug|BI 1026706|Multiple Rising Doses (oral solution, tablet)
272247|NCT02126826|Drug|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
272248|NCT02126813|Procedure|increased interventional threshold for urinary bladder catheterization (800 ml)|
272249|NCT02126813|Procedure|Current used interventional threshold for urinary bladder catheterization (500 ml)|
272250|NCT02126813|Device|Intermittent bladder catheter|
272251|NCT02126787|Behavioral|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes & Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
272252|NCT02126787|Behavioral|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, & Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, & Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
272253|NCT02126761|Biological|Adjuvanted, trivalent subunit influenza vaccine|Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
272254|NCT02126761|Biological|Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
272255|NCT02126761|Biological|Antigen level modified adjuvanted, trivalent subunit influenza vaccine|Group 3 is experimental with double the usual antigen dosage
272256|NCT02126761|Biological|Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
272257|NCT02126748|Other|inhalation 4ml hypertonic saline 3% 3x/day|
272258|NCT02126748|Device|Intrapulmonary Percussive Ventilation|
272259|NCT02126748|Procedure|Assisted Autogenic Drainage|
272260|NCT02126722|Procedure|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
272261|NCT02126722|Device|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
272262|NCT02126722|Other|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
272263|NCT02126722|Other|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
272264|NCT02126709|Drug|Repigel|Repigel will be used as the intervention in the treatment group
272265|NCT02126683|Drug|Hydroxychloroquine|
272266|NCT02126670|Drug|ACT01|
272267|NCT02126670|Drug|Comp01|
272268|NCT02126670|Drug|Comp02|
272269|NCT02126670|Drug|Comp03|
272270|NCT02126670|Drug|Comp04|
272271|NCT02126657|Drug|70% glycolic acid|
272272|NCT02126644|Drug|70% glycolic acid|
272273|NCT02126579|Biological|Peptide Vaccine (LPV7) + Tetanus peptide|1.5 mL administered half intradermally and half subcutaneously.
272274|NCT02126579|Other|PolyICLC|1 mL administered half intradermally and half subcutaneously
272275|NCT02126579|Other|Resiquimod|500 mg applied to vaccine site after vaccine administration
272276|NCT02126579|Other|IFA|2 mL administered half intradermally and half subcutaneously
272277|NCT02126566|Device|Administration of light therapy - measurement of results before and after therapy|
272278|NCT02126553|Other|Laboratory Biomarker Analysis|Correlative studies
272279|NCT02126553|Drug|Lenalidomide|Given PO
272280|NCT02126540|Device|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
272281|NCT02126527|Drug|auranofin|Given PO
272282|NCT02126527|Drug|sirolimus|Given PO
272283|NCT02126527|Other|laboratory biomarker analysis|Correlative studies
272284|NCT02126527|Other|pharmacological study|Correlative studies
272285|NCT02126514|Drug|AZD3293|7 subjects will receive AZD3293
272286|NCT02126501|Other|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
272287|NCT02126488|Behavioral|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
272288|NCT02126488|Behavioral|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
272289|NCT02126488|Behavioral|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
272290|NCT02126462|Biological|Na-APR-1 (M74)/Alhydrogel®|
272291|NCT02126462|Biological|Na-GST-1/Alhydrogel®|
272292|NCT02126462|Biological|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
272293|NCT02126449|Other|Fasting mimicking diet|
272294|NCT02126436|Other|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:~using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
272295|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
272296|NCT02126423|Other|Conjunctival and nasopharyngeal swabs|For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
272297|NCT02126397|Procedure|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
272298|NCT02126397|Procedure|polyps resection with bipolar electrode|
272299|NCT02126384|Drug|pneumovax vaccination|vaccination
272300|NCT02126371|Drug|LEO32731|
272301|NCT02126358|Drug|Gemigliptin and/or Rosuvastatin|
272302|NCT02126345|Device|MASTER SL femoral stem and DELTA TT acetabular cup|
272303|NCT02126332|Other|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
272304|NCT02126332|Other|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
272305|NCT02126319|Behavioral|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
272306|NCT02126319|Behavioral|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
272307|NCT02126306|Drug|Beta Glucosylceramide|Beta Glucosylceramide
272308|NCT02126306|Drug|Placebo|normal saline
272309|NCT02126293|Drug|Zinc Supplement|
272310|NCT02126293|Procedure|Repeat blood and urine tests|
272311|NCT02126280|Other|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
272312|NCT02126267|Procedure|Scaling and root planing|Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
272313|NCT02126267|Procedure|Full mouth disinfection|Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
272314|NCT02126267|Drug|Chlorhexidine gel and gluconate|application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
272315|NCT02126267|Drug|Chlorhexidine gluconate solution|Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
272316|NCT02126267|Drug|Azithromycin|Azithromycin (500 mg) once daily for 3 consecutive days.
272317|NCT02126254|Device|Hemodynamic group|NICAS guided treatment
272318|NCT02126241|Other|NICaS guided CRT optimization|"Baseline CO measurement by NICaS~AV delay optimization:~AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS~The AV delay yielding the maximal CO, will be considered the optimal AV delay~The device will be programmed using the optimal AV delay~VV delay optimization:~After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS~The VV delay yielding the maximal CO, will be considered the optimal VV delay~The device will be programmed using the optimal VV delay"
272319|NCT02126215|Procedure|MRI CO2 and O2 stress testing|Pre and post operatively
272320|NCT02126202|Procedure|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
272321|NCT02126163|Behavioral|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
272322|NCT02126137|Drug|Ezetimibe|
272323|NCT02126124|Device|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
272324|NCT02126124|Device|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
272325|NCT02126111|Biological|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
272326|NCT02126111|Biological|DEPIGOID Placebo|Placebo for subcutaneous administration
272327|NCT02126085|Procedure|Endovascular recanalisation|"Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept"
272328|NCT02126072|Dietary Supplement|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
272329|NCT02126072|Dietary Supplement|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
272330|NCT02126059|Behavioral|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.~small group intervention (8-12 per group), expected total number of group is 5."
272331|NCT02126059|Behavioral|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.~small group intervention (8-12 per group), total number of group is 5."
272332|NCT02126059|Behavioral|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
272333|NCT02126046|Genetic|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
272334|NCT02126033|Procedure|take blood samples|
272335|NCT02126020|Drug|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
272336|NCT02126007|Behavioral|Sleep and Rhythm Intervention|
272337|NCT02126007|Behavioral|Dietary Modifications|
272338|NCT02125994|Procedure|Interscalene nerve block|
272339|NCT02125981|Drug|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
272340|NCT02125981|Drug|Placebo|taking placebo drug
272341|NCT02125968|Other|interactive video game|short- and medium-term therapeutic effects
272342|NCT02125968|Other|therapeutic exercise|short- and medium-term therapeutic effects
272343|NCT02125955|Dietary Supplement|Prebiotic fiber|Dissolved in water.
272344|NCT02125955|Dietary Supplement|Placebo|Dissolved in water
272345|NCT02125942|Behavioral|Central Meditation and Imagery Therapy|mindfulness, guided imagery, meditation
272346|NCT02125929|Procedure|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
272347|NCT02125929|Procedure|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
272348|NCT02125929|Procedure|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
272349|NCT02125916|Other|oxygen therapy|
272350|NCT02125903|Drug|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
272351|NCT02125890|Drug|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
272352|NCT02125877|Drug|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
272353|NCT02125877|Drug|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
272354|NCT02125864|Drug|Aflibercept|
272355|NCT02125851|Other|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
272356|NCT02125851|Other|Honey|esophageal mucosal contact time of honey vs sucralose slurry
272357|NCT02125838|Device|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
272358|NCT02125838|Device|Endotracheal Tube|ETT
272359|NCT02125812|Other|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
272360|NCT02125812|Other|scaling and root planing|scaling and root planing
272361|NCT02125799|Device|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
272362|NCT02125786|Radiation|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
272363|NCT02125786|Procedure|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
272364|NCT02125786|Drug|^1^8F-Fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
272365|NCT02125786|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
272366|NCT02125786|Device|Photon therapy|Participants will receive one or both: Photon or proton therapy.
272367|NCT02125786|Device|Proton therapy|Participants will receive one or both: Photon or proton therapy.
272368|NCT02125773|Behavioral|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
272369|NCT02125760|Other|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
272370|NCT02125760|Other|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
272371|NCT02125747|Other|No Respiratory Therapy|Patients received conventional treatment.
272372|NCT02125747|Other|Respiratory Therapy|"Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period."
272373|NCT02125734|Drug|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
272374|NCT02125734|Drug|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
272375|NCT02125721|Drug|CBTD 0-3 gm|Oral CBTD 0-3 gm dose/day for 7 days, dose escalation
272376|NCT02125708|Device|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
272377|NCT02125695|Procedure|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
272378|NCT02125695|Procedure|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
272379|NCT02125695|Procedure|Skin Biopsy|As described in the treatment arm
272380|NCT02125682|Drug|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
272381|NCT02125682|Drug|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
272382|NCT02125669|Procedure|Laser treatment|Pulsed dye laser 595nm
272383|NCT02125669|Device|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
272384|NCT02125656|Other|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
272385|NCT02125643|Drug|Caffeine|
272386|NCT02125643|Other|Flour|Flour will be administered as the placebo.
272387|NCT02125630|Procedure|Surgery|Surgery to primary tumor
272388|NCT02125630|Drug|Systemic therapy|Systemic therapy based on tumor phenotype
272389|NCT02125617|Drug|Abiraterone|1000 mg/day
272390|NCT02125617|Drug|Prednisolone|10 mg/day
272391|NCT02125604|Drug|dimethyl fumarate|capsules administered according to the prevailing product label
272392|NCT02125591|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
272393|NCT02125591|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
272394|NCT02125578|Drug|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
272606|NCT02123849|Other|Laboratory Biomarker Analysis|Correlative studies
272395|NCT02125578|Drug|Placebo|Each participant will receive placebo every other week or every 4 weeks.
272396|NCT02125565|Other|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
272397|NCT02125552|Procedure|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
272398|NCT02125552|Procedure|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
272399|NCT02125539|Behavioral|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
272400|NCT02125539|Behavioral|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
272401|NCT02125526|Device|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
272402|NCT02125513|Drug|carboplatin and paclitaxel followed by surgery|
272403|NCT02125500|Drug|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
272404|NCT02125487|Behavioral|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
272405|NCT02125487|Behavioral|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
272406|NCT02125474|Radiation|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
272407|NCT02125461|Drug|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
272408|NCT02125461|Other|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
272409|NCT02125448|Device|MRI and PET-CT|
272410|NCT02125435|Drug|ASP2408|intravenous
272411|NCT02125435|Drug|Placebo|intravenous
272412|NCT02125422|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
272413|NCT02125409|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
272414|NCT02125409|Procedure|Screening colonoscopy|
272415|NCT02125396|Other|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
272416|NCT02125396|Other|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
272417|NCT02125383|Procedure|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
272418|NCT02125383|Procedure|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
272419|NCT02125370|Other|Qualitative and survey|
272420|NCT02125357|Drug|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
272421|NCT02125357|Drug|Enzalutamide|160mg PO OD as per standard of care.
272422|NCT02125344|Drug|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
272423|NCT02125344|Drug|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
272424|NCT02125344|Drug|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
272425|NCT02125344|Drug|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
272426|NCT02125344|Drug|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
272427|NCT02125344|Drug|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
272428|NCT02125344|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
272429|NCT02125344|Drug|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is <70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is <50 kg, both dosages will be reduced to 500 mg each.
272430|NCT02125331|Procedure|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
272431|NCT02125318|Drug|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
272432|NCT02125305|Drug|Metformin|
272433|NCT02125292|Drug|Mesalamine|
272434|NCT02125279|Drug|Calcitriol|
272435|NCT02125266|Drug|V404|Sustained Release
272436|NCT02125253|Drug|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
272437|NCT02125253|Drug|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
272438|NCT02125253|Drug|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
272439|NCT02125240|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
272440|NCT02125240|Drug|Placebo|1 tablet three times daily by mouth
272441|NCT02125227|Drug|Rosuvastatin, Metformin, YH14755|single dose
272442|NCT02125227|Drug|YH14755|single dose
272443|NCT02125214|Device|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
272444|NCT02125201|Drug|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
272445|NCT02125188|Drug|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
272446|NCT02125188|Drug|saline|saline 100ml ivdrip before surgery
272447|NCT02125175|Radiation|Hypofractionated IMRT boost Radiotherapy|
272448|NCT02125162|Drug|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
272449|NCT02125149|Other|Exercise Intervention|
272450|NCT02125136|Drug|Gem/nab-Pac|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
272451|NCT02125136|Drug|FOLFIFINOX|"All patient receive:~2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle."
272452|NCT02125123|Other|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
272453|NCT02125123|Other|Counseling|Dietary counseling
272454|NCT02125110|Device|MRI|
272455|NCT02125110|Other|neuropsychological assessment|
272456|NCT02125097|Device|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
272457|NCT02125084|Drug|Everolimus|
272458|NCT02125084|Drug|Enzalutamide|
272459|NCT02125071|Other|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
272460|NCT02125058|Procedure|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
272461|NCT02125058|Procedure|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
272462|NCT02125045|Dietary Supplement|L-GSH|Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
272463|NCT02125045|Dietary Supplement|Placebo|Placebo will be prepared using the same excipients of the dietary supplement without active substance.
272464|NCT02125032|Device|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
272465|NCT02125032|Device|Placebo Transcranial low voltage electromagnetic fields|
272466|NCT02125006|Behavioral|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
272467|NCT02124993|Other|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
272468|NCT02124980|Behavioral|Recovery Line|
272469|NCT02124967|Other|Exercise|A one hour exercise class including both aerobic activity and resistance training
272470|NCT02124954|Drug|TA-8995|
272471|NCT02124954|Drug|Midazolam|
272472|NCT02124954|Drug|Digoxin|
272473|NCT02124941|Drug|N-acetyl cysteine|Upon completion of baseline (abstinence) 1H-MRS scanning, CU and HC subjects will participate in two additional 1H-MRS scans, including after 2 weeks of placebo and 2 weeks of NAC administration (3600 mg/day) given in double-blind, randomized, counterbalanced order.
272474|NCT02124941|Diagnostic Test|[18F]FDG PET scan|All subjects will undergo [18F]FDG PET to establish previously demonstrated reductions in glucose utilization in PFC and assess VS/nucleus accumbent metabolism at baseline.
272475|NCT02124941|Diagnostic Test|1H MRS|All subjects will undergo three magnetic resonance spectroscopy (1H-MRS) scans at 7T, including before and after two-weeks of placebo and NAC administration.
272476|NCT02124941|Diagnostic Test|[11C]APP311 PET scan|All subjects will undergo [11C]APP311 PET imaging to investigate whether there are differences in synaptic integrity / neuronal plasticity in the brains of individuals abstinent from cocaine compared to healthy controls at baseline.
272477|NCT02124928|Procedure|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
272478|NCT02124902|Drug|Docetaxel|
272479|NCT02124902|Drug|Carboplatin|
272480|NCT02124902|Procedure|FDG-PET/MR|"Prior to initialization of Cycle 1 and completion of cycle 1 (preferably on cycle 2 day 1)~This is not optional for final 30 participants enrolled on the study"
272481|NCT02124889|Behavioral|Weekly Internet surveys|Subjects will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
272482|NCT02124863|Device|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
272483|NCT02124850|Drug|Motolimod|
272484|NCT02124850|Drug|Cetuximab|
272485|NCT02124850|Drug|Nivolumab|
272486|NCT02124837|Behavioral|Park walk during lunch break|
272487|NCT02124837|Behavioral|Relaxation during lunch break|
272488|NCT02124824|Drug|BQ-123|Endothelin subtype A antagonist
272489|NCT02124811|Drug|Minocycline|
272490|NCT02124798|Device|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
272491|NCT02124785|Procedure|Blood sampling|At Years 21 to 25 after their second vaccine dose.
272492|NCT02124772|Drug|Trametinib|Trametinib is available in tablet (0.125mg, 0.5mg, 2mg dose) as well as in powder form for Oral Solution (0.05mg/mL dose). It is recommended that subjects drink 4 to 6 mL of water/kg body weight following dosing.
272493|NCT02124772|Drug|Dabrafenib|Dabrafenib is available in capsules (50mg and 75mg) as well as in powder form for Oral Suspension (10 mg/mL dose) and taken twice a day. It is recommended that subjects drink approximately 1 ounce (30 mL) of water for every 10 pounds of body weight following dosing.
272494|NCT02124759|Drug|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
272495|NCT02124759|Drug|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
272496|NCT02124759|Drug|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
272497|NCT02124746|Drug|Momelotinib|Momelotinib tablets administered orally once daily
272498|NCT02124733|Procedure|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
272499|NCT02124720|Behavioral|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
272500|NCT02124707|Drug|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
272501|NCT02124707|Drug|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
272502|NCT02124707|Drug|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
272503|NCT02124694|Behavioral|HTUG|HTUG is a group psychotherapy...
272504|NCT02124681|Drug|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
272505|NCT02124681|Other|Placebo|Placebo PO for 13±1 weeks
272506|NCT02124668|Drug|Enzalutamide|oral
272507|NCT02124655|Drug|Essential oils|
272508|NCT02124655|Drug|0.2% chlorhexidine|
272509|NCT02124655|Drug|Sterile water|
272510|NCT02124642|Dietary Supplement|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
272511|NCT02124642|Dietary Supplement|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
272512|NCT02124590|Other|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
272513|NCT02124590|Other|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
272514|NCT02124564|Drug|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.~4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .~The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
272515|NCT02124525|Drug|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
272516|NCT02124512|Drug|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
272517|NCT02124512|Other|Placebo|80 mg placebo once daily
272518|NCT02124486|Procedure|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
272519|NCT02124486|Behavioral|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
272520|NCT02124473|Other|Homeopathy|
272521|NCT02124473|Other|Placebo|
272522|NCT02124460|Behavioral|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
272523|NCT02124447|Drug|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
272524|NCT02124447|Drug|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
272525|NCT02124447|Drug|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
272526|NCT02124447|Drug|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
272527|NCT02124421|Procedure|Cytoreductive Surgery (CRS)|Cytoreductive surgery
272528|NCT02124421|Drug|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
272529|NCT02124421|Other|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
272530|NCT02124421|Procedure|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
272531|NCT02124421|Drug|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
272532|NCT02124421|Drug|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
272533|NCT02124421|Drug|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
272534|NCT02124421|Drug|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
272535|NCT02124408|Behavioral|Personalized Behavioral Intervention|
272536|NCT02124395|Other|Health-related Quality of Life in Rare Kidney Stone Questionnaire|
272537|NCT02124369|Drug|Abraxane|125mg/m2, IV, on days 1,8 & 15 of each 28 day cycle, up to 6 cycles.
272538|NCT02124369|Drug|Gemcitabine|1000mg/m2, IV, on days 1,8 & 15 of a 28 day cycle, up to 6 cycles.
272539|NCT02124356|Other|Evaluation of functional performance|
272540|NCT02124343|Other|Interval Exercise|
272541|NCT02124330|Dietary Supplement|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
272542|NCT02124330|Dietary Supplement|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
272543|NCT02124330|Dietary Supplement|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
272544|NCT02124317|Drug|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
272545|NCT02124317|Drug|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
272546|NCT02124304|Device|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
272547|NCT02124291|Device|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
272548|NCT02124278|Drug|PUL-042 Inhalation Solution|
272549|NCT02124265|Drug|CeraLyte 90|"This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used."
272550|NCT02124252|Behavioral|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
272551|NCT02124252|Behavioral|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
272552|NCT02124239|Drug|Ingenol mebutate|
272553|NCT02124226|Drug|Methotrexate|7.5 mg/week + folic acid the day after
272554|NCT02124226|Drug|Placebo|matched placebo
272555|NCT02124213|Drug|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
272556|NCT02124213|Drug|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
272557|NCT02124213|Drug|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.~This Cohort is optional."
272558|NCT02124200|Device|EGO/CE4, 9mg nicotine|
272559|NCT02124187|Device|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
272560|NCT02124187|Device|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
272561|NCT02124187|Device|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
272607|NCT02123849|Other|Placebo|Given PO
272562|NCT02124174|Drug|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily~*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
272563|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
272564|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
272565|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
272566|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
272567|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
272568|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
272569|NCT02124148|Drug|Prexasertib|Administered IV
272570|NCT02124148|Drug|Cisplatin|Administered IV
272571|NCT02124148|Drug|Cetuximab|Administered IV
272572|NCT02124148|Drug|G-CSF|Administered SC
272573|NCT02124148|Drug|Pemetrexed|Administered IV
272574|NCT02124148|Drug|Fluorouracil|Administered IV
272575|NCT02124148|Drug|LY3023414|Administered PO
272576|NCT02124148|Drug|Leucovorin|Administered IV
272577|NCT02124135|Behavioral|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.~Participants in the clinic arm will receive the education intervention in the clinic.~Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
272578|NCT02124122|Biological|Lactobacillus reuteri|Probiotic
272579|NCT02124122|Biological|Placebo|Placebo
272580|NCT02124083|Drug|Vorinostat|Histone deactylase inhibitor
272581|NCT02124070|Drug|rh Growth Hormone|
272582|NCT02124044|Drug|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
272583|NCT02124044|Drug|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
272584|NCT02124018|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
272585|NCT02124018|Device|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
272586|NCT02124005|Drug|Bupivacaine|
272587|NCT02123992|Device|Elevate Apical and Posterior|
272588|NCT02123992|Procedure|Native Tissue Repair for pelvic organ prolapse|
272589|NCT02123979|Drug|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
272590|NCT02123966|Drug|Sirolimus|
272591|NCT02123953|Drug|TAK-438|TAK-438 tablets
272592|NCT02123953|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
272593|NCT02123940|Device|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
272594|NCT02123927|Drug|TAK-438|TAK-438 tablets
272595|NCT02123927|Drug|Placebo|TAK-438 placebo-matching tablets
272596|NCT02123914|Other|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
272597|NCT02123914|Other|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
272598|NCT02123914|Other|No exercise|"Sedentary control.~Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,~Nasal peak flow measurement,~Nasal blood flow measurement,~Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
272599|NCT02123901|Other|Walking Meditation|"Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week."
272600|NCT02123901|Other|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
272601|NCT02123901|Other|No exercise|Sedentary life style.
272602|NCT02123888|Radiation|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
272603|NCT02123875|Other|Physiotherapy|
272604|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
272605|NCT02123849|Drug|Aspirin|Given PO
272608|NCT02123836|Biological|NK cells|"7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.~Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.~NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.~The NK cells will then be infused into the vein, through a peripheral catheter."
272609|NCT02123823|Drug|Everolimus|10mg dose
272610|NCT02123823|Drug|Everolimus|at recommended dose as per Phase I data
272611|NCT02123823|Drug|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
272612|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
272613|NCT02123823|Drug|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
272614|NCT02123823|Drug|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
272615|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
272616|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
272617|NCT02123810|Other|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
272618|NCT02123758|Drug|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
272619|NCT02123758|Drug|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
272620|NCT02123758|Drug|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
272621|NCT02123745|Device|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
272622|NCT02123732|Dietary Supplement|DbXell|
272623|NCT02123732|Dietary Supplement|Placebo|
272624|NCT02123719|Other|Surgery|
272625|NCT02123693|Other|Osteopathic manipulative treatment|
272626|NCT02123693|Other|Sham Therapy|
272627|NCT02123693|Other|No Intervention|
272628|NCT02123654|Drug|Daclatasvir|
272629|NCT02123654|Drug|Asunaprevir|
272630|NCT02123654|Drug|DCV 3DAA|
272631|NCT02123654|Other|Placebo for DCV 3DAA|
272632|NCT02123654|Other|Placebo for Daclatasvir|
272633|NCT02123654|Other|Placebo for Asunaprevir|
272634|NCT02123641|Other|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
272635|NCT02123641|Other|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
272636|NCT02123641|Other|Control|No training
272637|NCT02123628|Drug|duration of the antibiotic therapy|
272638|NCT02123615|Drug|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.~Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
272639|NCT02123615|Drug|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.~Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."
272640|NCT02123615|Drug|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
272641|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.
272642|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.
272643|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
272644|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
272645|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
272646|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
272647|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
272648|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
272649|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
272650|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
272651|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
272652|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
272653|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
272654|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
272655|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
272656|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
272657|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
272658|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
272659|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
272660|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
272661|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
272662|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
272663|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
272664|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
272665|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
272666|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
272667|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
272668|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
272669|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
272670|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
272671|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
272672|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
272673|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
272674|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
272675|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
272676|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
272677|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
272678|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
272679|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
272680|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
272681|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
272682|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
272683|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
272684|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
272685|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
272686|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
272687|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
272688|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
272689|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
272690|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
272691|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
272692|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
272693|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
272694|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
272695|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
272840|NCT02122445|Device|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
272696|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
272697|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
272698|NCT02123602|Other|core stabilization|
272699|NCT02123602|Other|lower extremity training only|
272700|NCT02123589|Drug|Deep sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
272701|NCT02123589|Drug|Deep and daily interruption of sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
272702|NCT02123589|Drug|Light sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
272703|NCT02123576|Drug|Pentoxyfylline|
272704|NCT02123576|Drug|Placebo|
272705|NCT02123576|Drug|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
272706|NCT02123563|Other|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
272707|NCT02123563|Other|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
272708|NCT02123537|Device|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
272709|NCT02123524|Drug|Rivaroxaban|
272710|NCT02123524|Drug|Placebo|
272711|NCT02123511|Drug|acetylcysteine|Oral rinse
272712|NCT02123511|Other|placebo|Oral rinse
272713|NCT02123511|Other|quality-of-life assessment|Ancillary studies
272714|NCT02123511|Other|questionnaire administration|Ancillary studies
272715|NCT02123498|Drug|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
272716|NCT02123498|Drug|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
272717|NCT02123498|Drug|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
272718|NCT02123498|Procedure|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
272719|NCT02123498|Procedure|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
272720|NCT02123485|Device|Low frequency (1 hz) rTMS, as add-on to ECT|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
272721|NCT02123485|Device|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
272722|NCT02123472|Drug|Cephalexin|Administered Orally
272723|NCT02123459|Drug|Cephalexin|Administered orally
272724|NCT02123446|Drug|Cephalexin|Administered orally.
272725|NCT02123433|Biological|pneumococcal conjugate 13 valent vaccine|"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).~Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.~Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
272726|NCT02123420|Device|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).~Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, St-Stevens-Woluwe, Belgium)."
272727|NCT02123407|Drug|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
272728|NCT02123407|Procedure|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
272729|NCT02123394|Other|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
272885|NCT02122081|Drug|tacrolimus|Given IV or PO
272886|NCT02122081|Drug|methotrexate|Given IV
272730|NCT02123394|Other|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
272731|NCT02123381|Radiation|preoperative radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.~Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f."
272732|NCT02123381|Drug|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
272733|NCT02123368|Drug|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
272734|NCT02123368|Biological|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
272735|NCT02123368|Biological|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
272736|NCT02123355|Drug|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
272737|NCT02123355|Procedure|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35~40 mmHg，pulse oxygen saturation is more than 95%.
272738|NCT02123355|Drug|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
272739|NCT02123355|Drug|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
272740|NCT02123355|Drug|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
272741|NCT02123342|Behavioral|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
272742|NCT02123329|Behavioral|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
272743|NCT02123329|Other|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
272744|NCT02123316|Biological|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
272745|NCT02123316|Biological|Placebo|Placebo for subcutaneous injection
272746|NCT02123290|Drug|DSM265 400mg|
272747|NCT02123290|Drug|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
272748|NCT02123290|Drug|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
272749|NCT02123277|Device|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
272750|NCT02123264|Drug|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
272751|NCT02123251|Behavioral|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
272752|NCT02123238|Other|bed positioning|
272753|NCT02123212|Other|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
272754|NCT02123212|Other|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
272755|NCT02123212|Other|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
272756|NCT02123199|Drug|Indacaterol (Onbrez®) /QAB149|
272757|NCT02123186|Other|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
272833|NCT02122510|Drug|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
272834|NCT02122510|Drug|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
272835|NCT02122497|Procedure|abdominal aortic surgery|
272758|NCT02123160|Behavioral|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
272759|NCT02123160|Behavioral|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
272760|NCT02123134|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
272761|NCT02123134|Drug|Placebo|Phosphate buffered saline placebo for injection
272762|NCT02123121|Drug|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
272763|NCT02123121|Drug|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
272764|NCT02123121|Other|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
272765|NCT02123121|Other|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
272766|NCT02123108|Drug|Basiliximab|Peri-operative 40 mg IV dose and 20mg IV postoperative dose will be given in the treatment arm
272767|NCT02123082|Device|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
272768|NCT02123082|Device|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
272769|NCT02123069|Device|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
272770|NCT02123069|Drug|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
272771|NCT02123069|Drug|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
272772|NCT02123069|Drug|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
272773|NCT02123069|Drug|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
272774|NCT02123056|Drug|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
272775|NCT02123056|Drug|Matching Placebo|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
272776|NCT02123043|Behavioral|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
272777|NCT02123043|Behavioral|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
272778|NCT02123017|Drug|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
272779|NCT02123017|Drug|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
272780|NCT02123017|Drug|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
272781|NCT02123004|Drug|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
272782|NCT02123004|Drug|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
272783|NCT02122978|Behavioral|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
272784|NCT02122978|Behavioral|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
272785|NCT02122978|Behavioral|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
272786|NCT02122965|Other|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
272787|NCT02122952|Biological|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
272788|NCT02122939|Drug|Escitalopram|
272836|NCT02122484|Drug|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
272837|NCT02122471|Drug|Plecanatide|
272838|NCT02122471|Drug|Placebo|
272839|NCT02122458|Device|mild-gain hearing aids|open-fit hearing aids with mild amplification in the high frequencies.
272789|NCT02122926|Other|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:~Inpatient protocol for adjusting the discharge diabetes regimen;~Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~Visiting nurse intervention after discharge;~Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~Follow-up with PCP or endocrinologist within 1 week of discharge."
272790|NCT02122913|Drug|Larotrectinib (Vitrakvi, BAY2757556)|BAY2757556 will be administered orally as capsule or in liquid form over continuous 28-day cycles.
272791|NCT02122887|Behavioral|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
272792|NCT02122874|Device|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
272793|NCT02122874|Other|1200 Kcal diet|
272794|NCT02122861|Biological|ID-LV305|pembrolizumab
272795|NCT02122848|Device|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
272796|NCT02122835|Behavioral|aerobic exercise training|12 weeks of supervised aerobic exercise training
272797|NCT02122822|Biological|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
272798|NCT02122809|Drug|Chiauranib|Take orally
272799|NCT02122796|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
272800|NCT02122783|Device|ADR™ brace resistance|
272801|NCT02122783|Device|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
272802|NCT02122770|Drug|MLN4924|MLN4924 intravenous solution.
272803|NCT02122770|Drug|Fluconazole|Fluconazole tablets.
272804|NCT02122770|Drug|Itraconazole|Itraconazole oral solution.
272805|NCT02122770|Drug|Docetaxel|Docetaxel intravenous solution.
272806|NCT02122770|Drug|Carboplatin|Carboplatin intravenous solution.
272807|NCT02122770|Drug|Paclitaxel|Paclitaxel intravenous solution.
272808|NCT02122757|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
272809|NCT02122744|Device|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.~The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
272810|NCT02122731|Drug|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
272811|NCT02122718|Drug|Allopurinol|
272812|NCT02122718|Drug|Placebo|
272813|NCT02122705|Device|VPIA remifentanil|Vital signs controlled patient assisted intravenous analgesia using remifentanil
272814|NCT02122692|Drug|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
272815|NCT02122692|Drug|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
272816|NCT02122692|Drug|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
272817|NCT02122679|Drug|Tranexamic Acid|
272818|NCT02122679|Drug|placebo|
272819|NCT02122666|Procedure|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
272820|NCT02122653|Other|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
272821|NCT02122653|Device|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
272822|NCT02122627|Drug|Vitamin D|Colecalciferol 16.800 IU per week
272823|NCT02122627|Drug|Placebo|
272824|NCT02122614|Behavioral|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
272825|NCT02122614|Behavioral|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
272826|NCT02122601|Drug|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
272827|NCT02122562|Drug|Ketamine|Treatment
272828|NCT02122562|Other|Alcohol Infusion|Biomarker
272829|NCT02122549|Device|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
272830|NCT02122536|Drug|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
272831|NCT02122536|Drug|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
272832|NCT02122523|Procedure|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
272841|NCT02122432|Other|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.~Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)~Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
272842|NCT02122419|Other|lateral|spinal anesthesia performed during lateral position
272843|NCT02122419|Other|sitting|spinal anesthesia performed during sitting position
272844|NCT02122406|Other|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
272845|NCT02122393|Drug|Sertraline|
272846|NCT02122393|Behavioral|Cognitive Behavioural Therapy|
272847|NCT02122380|Drug|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
272848|NCT02122380|Drug|Placebo|1 placebo pill by mouth per day for 30 days
272849|NCT02122367|Other|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
272850|NCT02122354|Behavioral|"Hide and Seek videogame"|
272851|NCT02122341|Device|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
272852|NCT02122328|Procedure|Sequential laser photocoagulation of communicating vessels.|
272853|NCT02122328|Procedure|Selective laser photocoagulation of communicating vessels|
272854|NCT02122315|Other|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
272855|NCT02122315|Other|Physical therapy|Best-evidence physical therapy intervention
272856|NCT02122302|Device|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
272857|NCT02122289|Device|Application of Smartphone|Weekly questionnaire on smartphone
272858|NCT02122289|Other|No application Smartphone|No weekly questionnaire on smartphone
272859|NCT02122276|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
272860|NCT02122250|Behavioral|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
272861|NCT02122250|Behavioral|Static web-based materials|Static web-based materials
272862|NCT02122237|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
272863|NCT02122224|Other|High fiber breakfast|Breakfast will contain 10-11g fiber.
272864|NCT02122224|Other|High Protein Breakfast|Breakfast will contain 19-20g of protein.
272865|NCT02122224|Other|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
272866|NCT02122211|Drug|Betaine supplement|
272867|NCT02122198|Drug|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
272868|NCT02122198|Drug|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
272869|NCT02122198|Drug|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
272870|NCT02122198|Drug|Placebo|placebo
272871|NCT02122185|Drug|metformin hydrochloride|Given PO
272872|NCT02122185|Drug|placebo|Given PO
272873|NCT02122185|Drug|Chemotherapy|Participants will received standard chemotherapy (6-8 cycles). Specific regimen to be given is at the discretion of their treating physician.
272874|NCT02122172|Drug|afatinib dimaleate|Given PO
272875|NCT02122172|Other|laboratory biomarker analysis|Correlative studies
272876|NCT02122159|Biological|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
272877|NCT02122146|Drug|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
272878|NCT02122146|Drug|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
272879|NCT02122133|Device|PC 400|
272880|NCT02122120|Dietary Supplement|HEN|Patients with tube feeding with FSMP for at least twelve months
272881|NCT02122094|Behavioral|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
272882|NCT02122081|Radiation|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
272883|NCT02122081|Drug|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
272884|NCT02122081|Biological|anti-thymocyte globulin|
272887|NCT02122081|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
272888|NCT02122081|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
272889|NCT02122081|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
272890|NCT02122081|Other|laboratory biomarker analysis|Correlative studies
272891|NCT02122068|Behavioral|Central Meditation and Imagery Therapy|4 week long meditation and mindfulness intervention
272892|NCT02122068|Behavioral|Relaxation cd|
272893|NCT02122055|Drug|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
272894|NCT02122055|Procedure|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
272895|NCT02122055|Procedure|Screen of weaning|1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
272896|NCT02122055|Drug|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
272897|NCT02122055|Drug|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
272898|NCT02122055|Drug|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
272899|NCT02122042|Biological|HBOT|
272900|NCT02122029|Behavioral|Lifestyle counselling|Behavioral techniques for weight management
272901|NCT02122029|Procedure|Bariatric Surgery|Vertical Banding Gastroplasty
272902|NCT02122016|Device|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
272903|NCT02122016|Other|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
272904|NCT02122003|Drug|Sorafenib|Sorafenib 400 mg bid
272905|NCT02121990|Drug|Paclitaxel,|
272906|NCT02121990|Drug|Bevacizumab|
272907|NCT02121990|Drug|Cisplatin|
272908|NCT02121990|Drug|Olaparib|
272909|NCT02121977|Device|Elevate Anterior and Apical|
272910|NCT02121977|Procedure|Native Tissue Repair for pelvic organ prolapse|
272911|NCT02121964|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
272912|NCT02121964|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
272913|NCT02121951|Procedure|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
272914|NCT02121951|Procedure|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
272915|NCT02121951|Drug|MAC|Incremental doses are given to the targed sedation and analgesia
272916|NCT02121912|Device|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
272917|NCT02121912|Device|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
272918|NCT02121886|Procedure|venous reconstruction with the parietal peritoneum|
272919|NCT02121873|Device|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
272920|NCT02121873|Device|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
272921|NCT02121873|Device|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
272922|NCT02121860|Drug|IDN-6556|
272923|NCT02121847|Drug|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
272924|NCT02121847|Drug|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
272925|NCT02121834|Drug|LY3050258|
272926|NCT02121834|Drug|Placebo|
272927|NCT02121821|Behavioral|SMS reminder messages|The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
272928|NCT02121808|Procedure|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
272929|NCT02121808|Procedure|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
272930|NCT02121795|Drug|FTC/TDF|200/300 mg FDC tablets administered orally once daily
272931|NCT02121795|Drug|F/TAF|Tablets administered orally once daily
272932|NCT02121795|Drug|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
272933|NCT02121795|Drug|FTC/TDF Placebo|Tablets administered orally once daily
272934|NCT02121795|Drug|F/TAF Placebo|Tablets administered orally once daily
272935|NCT02121782|Biological|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
272936|NCT02121782|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
272937|NCT02121769|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
272938|NCT02121756|Drug|Dipyridamole|Dipyridamole 100 mg four (4) times daily for 24 weeks from Baseline to Week 24
272939|NCT02121756|Drug|Placebo, then Dipyridamole|Placebo for Dipyridamole four (4) times daily for 12 weeks from Baseline to Week 12 followed by Dipyridamole 100mg four (4) times daily for 12 weeks from Week 12 to Week 24
272940|NCT02121743|Device|strattice|use of a strattice
272941|NCT02121743|Procedure|No strattice|no use of a strattice
272942|NCT02121717|Drug|Chiglitazar|Take orally
272943|NCT02121717|Drug|Placebo|Take orally
272944|NCT02121704|Device|Magnetic Endoscope Imaging (Scope Guide)|
272945|NCT02121691|Behavioral|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
272946|NCT02121678|Other|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:~Week 0-4: 70-80 % of 1-RM~Week 5-8: 75-86 % of 1-RM~Week 9-12: 80-92% of 1-RM~Participants trains unilateral, the opposite site serves as reference.~MMN patients train elbow (flexion/extension) and wrist (flexion/extension)~CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
272947|NCT02121678|Other|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.~Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
272948|NCT02121665|Drug|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
272949|NCT02121665|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
272950|NCT02121652|Behavioral|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
272951|NCT02121652|Behavioral|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
272952|NCT02121639|Drug|Placebo|
272953|NCT02121639|Drug|AZD5363|
272954|NCT02121613|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
272955|NCT02121613|Drug|Tamsulosine LP|Oral administration - 0.4 mg daily.
272956|NCT02121613|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
272957|NCT02121613|Drug|Placebo matching Tamsulosine LP|Oral administration - daily.
272958|NCT02121600|Other|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.
272959|NCT02121600|Radiation|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
272960|NCT02121600|Radiation|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
272961|NCT02121587|Behavioral|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
272962|NCT02121574|Device|Zero flux and ingestible thermometers|
272963|NCT02121561|Behavioral|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
272995|NCT02121379|Behavioral|pulmonary rehabilitation|
272996|NCT02121366|Procedure|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
273220|NCT02119663|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
272964|NCT02121548|Behavioral|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
272965|NCT02121548|Behavioral|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
272966|NCT02121535|Drug|T80/A5 mg FDC tablet|
272967|NCT02121535|Drug|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
272968|NCT02121535|Drug|H12.5 mg tablet|
272969|NCT02121535|Drug|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
272970|NCT02121535|Drug|H12.5 mf tablet|A HCTZ 12.5 mg tablet
272971|NCT02121535|Drug|T80/A5/H12.5 mg FDC tablet|
272972|NCT02121522|Drug|BI 144807|twice daily
272973|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
272974|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
272975|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
272976|NCT02121496|Behavioral|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad — the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
272977|NCT02121483|Drug|empagliflozin medium dose|
272978|NCT02121483|Drug|empagliflozin high dose|
272979|NCT02121483|Drug|empagliflozin low dose|
272980|NCT02121457|Dietary Supplement|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
272981|NCT02121457|Dietary Supplement|selenium|
272982|NCT02121444|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|
272983|NCT02121444|Device|BETACONNECT auto-injector.|
272984|NCT02121431|Behavioral|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
272985|NCT02121418|Drug|Cytarabine|Given IV
272986|NCT02121418|Drug|Decitabine|Given IV
272987|NCT02121418|Other|Laboratory Biomarker Analysis|Correlative studies
272988|NCT02121405|Procedure|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
272989|NCT02121405|Radiation|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
272990|NCT02121405|Drug|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
272991|NCT02121405|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
272992|NCT02121392|Device|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
272993|NCT02121392|Device|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
272994|NCT02121392|Drug|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
272997|NCT02121353|Drug|Lucentis|Single‐use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha‐trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra‐vitreal
272998|NCT02121353|Drug|PF582|Single‐use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha‐trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra‐vitreal
272999|NCT02121340|Behavioral|Behavioral Activation|
273000|NCT02121327|Other|disease management|disease management program include self management education
273001|NCT02121327|Other|usual care|usual care group receive regular outpatient treatment
273002|NCT02121314|Drug|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
273003|NCT02121301|Drug|SkQ1|
273004|NCT02121301|Drug|Placebo SkQ1 (Vehicle)|
273005|NCT02121288|Drug|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
273006|NCT02121288|Drug|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
273007|NCT02121275|Device|Ultrasound of the lungs|Ultrasound examination of the lungs
273008|NCT02121275|Device|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
273009|NCT02121262|Drug|700 μg dexamethasone|700 μg dexamethasone intravitreal injection in the study eye on day 1, month 5, and month 10.
273010|NCT02121262|Procedure|Laser Photocoagulation|Laser photocoagulation on day 1, and on months 3, 6, and 9, if retreatment indicated.
273011|NCT02121249|Device|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
273012|NCT02121249|Procedure|free hand technique|"No specific device is necessary in the free hand technique"
273013|NCT02121223|Device|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (>=16atm) for at least 15 seconds.
273014|NCT02121223|Device|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
273015|NCT02121210|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
273016|NCT02121197|Drug|Ozurdex|
273017|NCT02121184|Drug|Routine oxytocin|per regular oxytocin protocols
273018|NCT02121184|Drug|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
273019|NCT02121171|Device|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
273020|NCT02121171|Procedure|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
273021|NCT02121158|Device|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
273022|NCT02121158|Other|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
273023|NCT02121145|Biological|Vivotif|3 oral doses
273024|NCT02121145|Biological|Typherix|one intramuscular dose
273025|NCT02121119|Drug|Lidocaine|Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
273026|NCT02121119|Drug|Bupivacaine|Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
273027|NCT02121106|Behavioral|Cognitive Remediation|
273028|NCT02121106|Behavioral|Sham Cognitive Remediation|
273029|NCT02121093|Procedure|vibration|
273030|NCT02121080|Drug|REGN2222(SAR438584)|
273031|NCT02121080|Drug|placebo|
273032|NCT02121067|Drug|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
273033|NCT02121041|Drug|Amlodipine|Amlodipine 5 mg or 10 mg
273034|NCT02121041|Drug|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
273035|NCT02121041|Drug|Losartan|Losartan 50 mg or 100 mg
273036|NCT02121015|Behavioral|Share|
273037|NCT02121015|Behavioral|Self-Directed|
273038|NCT02121002|Drug|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
273039|NCT02121002|Drug|Voltaren Topical Gel, 1%|Opaque, white gel
273040|NCT02121002|Drug|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
273041|NCT02120989|Behavioral|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
273042|NCT02120976|Drug|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
273043|NCT02120976|Drug|JTT-252|Subjects will receive JTT-252
273044|NCT02120963|Behavioral|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
273045|NCT02120950|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
273046|NCT02120950|Other|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
273047|NCT02120937|Behavioral|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
273048|NCT02120924|Drug|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
273049|NCT02120911|Drug|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
273050|NCT02120898|Drug|Imiquimod|Subjects will apply the assigned test article to the designated treatment area (full face or balding scalp) identified by the investigator at Visit 1. The assigned test article will be applied once daily for two, 2-week treatment cycles separated by a 2-week no treatment interval.
273051|NCT02120885|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
273052|NCT02120872|Drug|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
273053|NCT02120872|Biological|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
273054|NCT02120872|Procedure|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
273055|NCT02120859|Device|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
273056|NCT02120859|Device|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
273057|NCT02120846|Other|Flywheel leg-press resistance exercise|
273058|NCT02120833|Device|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
273059|NCT02120833|Drug|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
273060|NCT02120820|Behavioral|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
273061|NCT02120820|Behavioral|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
273062|NCT02120820|Other|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
273063|NCT02120820|Behavioral|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
273064|NCT02120807|Drug|Certolizumab|
273065|NCT02120807|Drug|cisplatin|
273066|NCT02120807|Drug|pemetrexed|
273067|NCT02120794|Device|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
273068|NCT02120781|Biological|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
273069|NCT02120781|Drug|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
273070|NCT02120768|Procedure|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
273071|NCT02120755|Biological|AmnioClear™ Human Allograft Amniotic Membrane|
273072|NCT02120742|Behavioral|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
273100|NCT02120547|Drug|Cenicriviroc in moderate liver impaired|Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
273101|NCT02120508|Device|rTMS|To test the efficacy of this specific setting.
273073|NCT02120729|Other|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 2 days of admission. Buccal cell DNA is analyzed for 21 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
273074|NCT02120716|Behavioral|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
273075|NCT02120703|Drug|Pregabalin|Pregablin 75 mg per oral two times a day
273076|NCT02120703|Drug|Gabapentin|Gabapentin 200 mg twice daily per oral
273077|NCT02120690|Device|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
273078|NCT02120677|Drug|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
273079|NCT02120664|Drug|Florbetapir (18F)|
273080|NCT02120664|Drug|11C-PiB|
273081|NCT02120651|Procedure|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
273082|NCT02120651|Procedure|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
273083|NCT02120638|Drug|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, ＞70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, ＞70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, ＞50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
273084|NCT02120638|Drug|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, ＞70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, ＞50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
273085|NCT02120625|Device|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
273086|NCT02120612|Other|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
273087|NCT02120599|Dietary Supplement|ready-to-use supplementary food|
273088|NCT02120599|Dietary Supplement|corn-soy blend|
273089|NCT02120599|Dietary Supplement|iron|
273090|NCT02120599|Dietary Supplement|folic acid|
273091|NCT02120599|Dietary Supplement|UNIMMAP|
273092|NCT02120586|Other|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
273093|NCT02120586|Other|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.~The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
273094|NCT02120573|Other|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
273095|NCT02120573|Other|Workshop using Educational Film|workshops using film review about CPR
273096|NCT02120573|Other|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
273097|NCT02120573|Other|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
273098|NCT02120560|Procedure|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
273099|NCT02120547|Drug|Cenicriviroc in mild liver impaired|Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
273221|NCT02119663|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
273102|NCT02120495|Procedure|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
273103|NCT02120482|Device|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
273104|NCT02120469|Drug|everolimus|Given PO
273105|NCT02120469|Drug|eribulin mesylate|Given IV
273106|NCT02120469|Other|pharmacological study|Correlative studies
273107|NCT02120469|Other|laboratory biomarker analysis|Optional correlative studies
273108|NCT02120456|Drug|LEO 43204|
273109|NCT02120456|Drug|Placebo|
273110|NCT02120443|Device|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
273111|NCT02120430|Other|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
273112|NCT02120417|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 15 mg BID (starting dose)"
273113|NCT02120417|Drug|Capecitabine|Capecitabine 2000 mg/m^2 daily given as 1000 mg/m^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
273114|NCT02120417|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
273115|NCT02120404|Drug|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours."
273116|NCT02120391|Other|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
273117|NCT02120365|Drug|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
273118|NCT02120365|Drug|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
273119|NCT02120352|Drug|GSK744|White to almost white oval shaped film coated 30 mg tablets for oral administration.
273120|NCT02120352|Drug|GSK744 LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
273121|NCT02120352|Drug|TMC278 LA|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
273122|NCT02120352|Drug|ABC/3TC|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
273123|NCT02120352|Drug|RPV|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
273124|NCT02120339|Drug|Carvedilol|
273125|NCT02120326|Device|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~2 mA intensity~Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
273126|NCT02120326|Device|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.~Stimulation parameters:~The intensity of the stimulation current is 2 mA~The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
273127|NCT02120313|Other|inpatient rehabilitation|
273128|NCT02120313|Other|outpatient rehabilitation|
273129|NCT02120300|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
273130|NCT02120300|Drug|SOF|400 mg tablet administered orally once daily
273131|NCT02120300|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
273132|NCT02120287|Drug|Bevacizumab|Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
273133|NCT02120287|Procedure|Magnetic Resonance Spectroscopy (MRS)|Subjects will have MRS prior to BZ-SRS.
273134|NCT02120287|Procedure|Border Zone Stereotactic Radiosurgery (BZ-SRS)|The 'border zone' of the tumor will be targeted by SRS in a single session.
273135|NCT02120274|Drug|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
273136|NCT02120274|Drug|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
273137|NCT02120261|Drug|Normal Saline|Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
273217|NCT02119676|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth~Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
273335|NCT02118792|Drug|AN2728 Topical Ointment, 2%|
273138|NCT02120261|Drug|Lidocaine Hydrochloride|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
273139|NCT02120261|Drug|Triamcinolone acetonide|Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
273140|NCT02120248|Other|Telephone-based breastfeeding peer counseling|
273141|NCT02120222|Drug|selinexor|Given PO
273142|NCT02120222|Other|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
273143|NCT02120196|Drug|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
273144|NCT02120196|Drug|Norfloxacin|FDA approved:400mg once daily
273145|NCT02120183|Behavioral|Psycho-educational support group therapy|"Weekly sessions lasting 60 minutes. Topics addressed each week:~Week 1: Coping with the diagnosis of loved one and dealing with uncertainty~Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)~Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)~Week 4: The emotions of caregiving (handling emotional reactivity)"
273146|NCT02120170|Procedure|Colon polypectomy|
273147|NCT02120157|Drug|Cyclophosphamide|Chemotherapy administration
273148|NCT02120157|Radiation|TBI|Radiation Therapy
273149|NCT02120157|Drug|Busulfan|Chemotherapy Administered
273150|NCT02120157|Other|Unmanipulated Bone Marrow|Bone Marrow Transplant
273151|NCT02120157|Drug|Tacrolimus|Immunosuppressive Drug Administered
273152|NCT02120157|Drug|Mycophenolate mofetil|Immunosuppressive Drug Administered
273153|NCT02120144|Other|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
273154|NCT02120144|Other|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
273155|NCT02120118|Radiation|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
273156|NCT02120118|Other|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
273157|NCT02120118|Drug|Cisplatin|30mg/m2
273158|NCT02120118|Drug|Taxotere|20mg/m2
273159|NCT02120092|Drug|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
273160|NCT02120092|Drug|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
273161|NCT02120092|Drug|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)"
273162|NCT02120092|Drug|Placebo|7x 300mg acetylsalicylic acid placebo
273163|NCT02120079|Drug|Lotemax|Lotemax (loteprednol etabonate) 0.5% will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
273164|NCT02120079|Drug|Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)|Soothe Tired Eyes Lubricant Eye Drop will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
273165|NCT02120079|Diagnostic Test|In Vivo Confocal Microscopy (IVCM)|In vivo confocal microscopy (IVCM) is a new imaging method, which allows visualization of the corneal structures at the cellular level. With a magnification of 800 times, it makes it possible to detect and quantify changes in the epithelial layers and sub-basal nerve plexus.
273166|NCT02120066|Procedure|Vitrectomy for submacular hemorrhage|
273167|NCT02120066|Drug|subretinal injection of tissue-plasminogen activator|
273168|NCT02120053|Device|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
273169|NCT02120053|Device|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
273170|NCT02120040|Other|evaluation of anxiety with psychosocial scales|
273171|NCT02120027|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
273172|NCT02120027|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
273173|NCT02120014|Procedure|blood volume measurement|"Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream."
273174|NCT02120014|Procedure|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
273175|NCT02120001|Device|ETT cleaning maneuver|"EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.~We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
273176|NCT02119988|Procedure|TIPS|TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. TIPS revision was planned if any evidence of shunt dysfunction was seen.
273218|NCT02119676|Drug|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
273177|NCT02119988|Procedure|Embolization|Embolization of SPSS was conducted via the same jugular vein before TIPS implantation. The major procedures included (a)angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b)embolization of SPSS with coils of varying diameters, which resulted in the SPSS disappearing at postembolization angiography.
273178|NCT02119975|Behavioral|Working memory training|
273179|NCT02119975|Behavioral|Placebo training|
273180|NCT02119962|Behavioral|Working memory training|
273181|NCT02119962|Behavioral|Placebo training|
273182|NCT02119949|Behavioral|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
273183|NCT02119949|Behavioral|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
273184|NCT02119936|Behavioral|Heart Rate Variability Biofeedback Tool|The Heart Rate Variability Biofeedback tool (emWave 2) will capture heart rate variability (HRV) before and after deep breathing exercises are used among participants. Participants will be able to visualize changes in their HRV and then fill-out self-reported anxiety measures to determine if the breathing exercises and visualization of HRV affected anxiety.
273185|NCT02119923|Behavioral|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
273186|NCT02119923|Behavioral|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
273187|NCT02119910|Behavioral|Technology Supported Manual|
273188|NCT02119897|Device|Low Level Light Therapy|
273189|NCT02119884|Drug|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
273190|NCT02119884|Drug|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
273191|NCT02119871|Procedure|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
273192|NCT02119871|Procedure|Right Pleura Open|Right pleura open Left ventricular apical drainage
273193|NCT02119858|Drug|indocyanine green solution|Given transperineally
273194|NCT02119858|Other|diffuse optical imaging|Undergo near infrared fluorescence imaging
273195|NCT02119858|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
273196|NCT02119858|Procedure|therapeutic lymphadenectomy|Undergo lymphadenectomy
273197|NCT02119845|Device|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
273198|NCT02119832|Device|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
273199|NCT02119819|Drug|LY2944876|Administered SC
273200|NCT02119819|Drug|Exenatide extended-release|Administered SC
273201|NCT02119819|Drug|Placebo|Administered SC
273202|NCT02119806|Drug|Benzodiazepine|Receive as premedication in the Benzodiazepine group.
273203|NCT02119806|Drug|Fentanyl|Receive as maintenance in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive as maintenance in the Non-Benzodiazepine group.
273204|NCT02119806|Drug|Propofol|Receive postoperatively in the Benzodiazepine group. Can receive as premedication in the Non-Benzodiazepine group. Receive postoperatively in the Non-Can receive as premedication in the Non-Benzodiazepine group.
273205|NCT02119793|Device|YVOIRE contour|YVOIRE contour injection into the anteromedial malar region
273206|NCT02119780|Device|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
273207|NCT02119780|Device|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
273208|NCT02119754|Drug|Plurogel PN|
273209|NCT02119728|Drug|HPPH|Undergo photodynamic therapy with HPPH
273210|NCT02119728|Device|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
273211|NCT02119728|Procedure|therapeutic conventional surgery|Undergo standard of care surgery
273212|NCT02119715|Drug|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
273213|NCT02119715|Drug|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
273214|NCT02119715|Drug|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
273215|NCT02119689|Other|Diabetic Patients|measuring CD34 cell function in relation to diabetic retinopathy status
273216|NCT02119689|Other|Healthy Controls|measuring CD34 cell function
273219|NCT02119676|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
273222|NCT02119663|Drug|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
273223|NCT02119650|Drug|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
273224|NCT02119650|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
273225|NCT02119650|Drug|Pemetrexed|500 mg/m^2 administered as an intravenous infusion over 10 minutes
273226|NCT02119650|Drug|Cisplatin|75 mg/m^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
273227|NCT02119611|Other|Deep Brain Stimulation Management|Therapy
273228|NCT02119572|Behavioral|peer support|
273229|NCT02119572|Other|usual education lectures|
273230|NCT02119559|Other|Blood analysis by EPISPOT and CellSearch®|
273231|NCT02119546|Other|Aerobic exercise|Aerobic exercise and dual-task training
273232|NCT02119546|Other|Stretch exercise|Stretch exercise & sitting balance
273233|NCT02119520|Drug|Platelet rich fibrin +Atorvastatin|
273234|NCT02119520|Drug|Platelet rich fibrin|
273235|NCT02119520|Procedure|open flap debridement|
273236|NCT02119507|Device|Curodont Repair|Single application on Day 0
273237|NCT02119507|Other|No treatment - control|
273238|NCT02119481|Behavioral|Mindfulness-based stress reduction|
273239|NCT02119481|Behavioral|Expressive writing condition|
273240|NCT02119468|Drug|ixazomib citrate|Given orally
273241|NCT02119468|Drug|dexamethasone|Given orally
273242|NCT02119468|Drug|pomalidomide|Given orally
273243|NCT02119468|Other|laboratory biomarker analysis|Correlative studies
273244|NCT02119455|Device|Vibration Device|Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
273245|NCT02119442|Device|Transcather Valve Implantation|Transcather Valve Implantation
273246|NCT02119429|Dietary Supplement|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
273247|NCT02119429|Dietary Supplement|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
273248|NCT02119416|Drug|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.~Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
273249|NCT02119416|Drug|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
273250|NCT02119416|Drug|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.~Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
273251|NCT02119403|Other|There are no other inteventions.|This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
273252|NCT02119390|Behavioral|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
273253|NCT02119390|Other|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
273254|NCT02119390|Other|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
273255|NCT02119377|Other|questionnaire|
273256|NCT02119364|Other|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
273257|NCT02119351|Device|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
273258|NCT02119351|Device|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
273259|NCT02119338|Drug|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
273260|NCT02119325|Dietary Supplement|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
273261|NCT02119325|Dietary Supplement|0% fibre|Placebo is an energy matched powdered beverage
273262|NCT02119299|Device|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
273263|NCT02119286|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
273264|NCT02119286|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
273265|NCT02119286|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
273266|NCT02119286|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
273267|NCT02119273|Drug|Prednisone|See arm description
273268|NCT02119273|Drug|Placebo|See arm description
273269|NCT02119260|Drug|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
273270|NCT02119260|Drug|GSK2798745 suspension|Aqueous suspension of GSK2798745 (>=0.5 mg)
273271|NCT02119260|Drug|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (>=0.5 mg)
273272|NCT02119260|Drug|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
273273|NCT02119260|Drug|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
273274|NCT02119260|Drug|Placebo capsule|Matching white opaque placebo blend filled capsule
273275|NCT02119247|Device|CHF 6001 dry powder for inhalation via NEXThaler®|
273276|NCT02119247|Device|CHF 6001 DPI capsules for inhalation via Aerolizer|
273277|NCT02119234|Drug|Beclometasone/formoterol/glycopyrrolate|
273278|NCT02119234|Drug|Placebo|
273279|NCT02119221|Drug|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of [14C]
273280|NCT02119208|Behavioral|Intensity and timing of exercise|
273281|NCT02119195|Procedure|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
273282|NCT02119182|Behavioral|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
273283|NCT02119182|Behavioral|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
273284|NCT02119182|Procedure|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
273285|NCT02119182|Procedure|Blood Draw for Plasma, DNA, Serum, RNA|Blood Draw for Plasma, DNA, Serum, RNA at baseline, in hospital (if applicable), 2 weeks, and 6 months (DNA at baseline only).
273286|NCT02119169|Device|Pigtail catheter|pigtail catheter for pleural drainage
273287|NCT02119156|Drug|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
273288|NCT02119143|Dietary Supplement|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
273289|NCT02119143|Dietary Supplement|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
273290|NCT02119130|Device|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
273291|NCT02119117|Dietary Supplement|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
273292|NCT02119117|Dietary Supplement|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
273293|NCT02119104|Drug|Prevenar (13v)|Prevenar (13v)
273294|NCT02119091|Drug|Moxifloxacin|
273295|NCT02119078|Other|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
273296|NCT02119065|Procedure|positron emission tomography|Undergo PET/CT scan
273297|NCT02119065|Procedure|computed tomography|Undergo PET/CT scan
273298|NCT02119052|Drug|octeotride|
273299|NCT02119052|Drug|placebo|
273300|NCT02119039|Device|RGTA OTR 4120 (CACICOL20)|
273301|NCT02119039|Device|Genteal HA eye drops|
273302|NCT02119026|Drug|Capecitabine|"800mg/m2 bid d1-14~± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
273303|NCT02119026|Drug|Capecitabine|1000mg/m2 bid d1-14,
273304|NCT02119026|Drug|Bevacizumab|7,5 mg/kg given on d1 q3w
273305|NCT02119026|Drug|Oxaliplatin|130mg/m2 iv. d 1 q3w
273306|NCT02119026|Drug|Irinotecan|200mg/m2 iv. d 1 q3w .
273307|NCT02119013|Drug|Octeotride|
273308|NCT02119013|Drug|Placebo|
273309|NCT02119000|Drug|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
273310|NCT02119000|Drug|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3~At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:~PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
273311|NCT02118987|Drug|Omalizumab|
273312|NCT02118974|Procedure|Hysterectomy|Hysterectomy
273313|NCT02118961|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
273314|NCT02118961|Biological|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
273315|NCT02118948|Behavioral|Abuse-focused intervention|
273316|NCT02118948|Behavioral|Sexual behavior-focused intervention|
273317|NCT02118935|Other|Previously marketed cow's mlik-based infant formula|
273318|NCT02118935|Other|Marketed cow's milk-based infant formula with prebiotics|
273319|NCT02118922|Procedure|Brillouin imaging|
273320|NCT02118909|Drug|Pracinostat|
273321|NCT02118909|Drug|Itraconazole|
273322|NCT02118909|Drug|Ciprofloxacin|
273323|NCT02118896|Drug|FK506E|oral
273324|NCT02118883|Other|Essentia Water|
273325|NCT02118883|Other|Bottled water|
273326|NCT02118870|Drug|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
273327|NCT02118870|Drug|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
273328|NCT02118857|Other|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
273329|NCT02118844|Drug|rocuronium|
273330|NCT02118831|Biological|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
273331|NCT02118831|Drug|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
273332|NCT02118831|Drug|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
273333|NCT02118831|Drug|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
273334|NCT02118818|Genetic|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
273336|NCT02118792|Drug|Matching vehicle control|
273337|NCT02118779|Behavioral|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
273338|NCT02118766|Drug|AN2728 Topical Ointment, 2%|
273339|NCT02118766|Drug|Matching vehicle control|
273340|NCT02118753|Drug|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
273341|NCT02118727|Drug|Memantine|All randomized patients will be instructed to take one tablet once a day for the first week from a blinded bottle that contains 10 mg tablets or matching placebo. At week two, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week three, patients will be instructed to take two tablets in the morning from the 10 mg bottle and one tablet from the 10 mg bottle or the matching placebo bottle in the evening. At week four patients will be instructed to take two pills twice a day from the 10 mg bottle or matching placebo.
273342|NCT02118727|Drug|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first week from a blinded bottle that contains 10 mg tablets or matching placebo. At week two, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week three, patients will be instructed to take two tablets in the morning from the 10 mg bottle and one tablet from the 10 mg bottle or the matching placebo bottle in the evening. At week four patients will be instructed to take two pills twice a day from the 10 mg bottle or matching placebo.
273343|NCT02118714|Drug|Atrasentan|Atrasentan
273344|NCT02118701|Other|Shared Decision-Making educational training|
273345|NCT02118688|Drug|Risperidone|
273346|NCT02118688|Drug|Trazodone|
273347|NCT02118688|Drug|Placebo|
273348|NCT02118675|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
273349|NCT02118675|Other|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
273350|NCT02118675|Other|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
273351|NCT02118675|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
273352|NCT02118675|Other|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
273353|NCT02118675|Other|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
273354|NCT02118675|Other|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
273355|NCT02118662|Other|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
273356|NCT02118662|Other|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
273357|NCT02118662|Other|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
273385|NCT02118441|Device|Ultrasound-guided Radial Artery Catheter Insertion|
273386|NCT02118441|Device|Direct Palpation-guided Radial Artery Catheter insertion|
273358|NCT02118662|Other|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
273359|NCT02118649|Behavioral|Game|
273360|NCT02118623|Behavioral|Moderated discussion board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.~The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
273361|NCT02118623|Behavioral|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~What is bipolar disorder? - Content about symptoms and diagnosis~Stress and triggers of illness~Medication and the biological basis of bipolar disorder~Depression - Symptoms, early detection and helpful strategies~Mania and hypomania - Symptoms, early detection and helpful strategies."
273362|NCT02118623|Behavioral|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
273363|NCT02118610|Drug|L-tetrahydropalmatine (30mg)|Active comparator
273364|NCT02118610|Drug|Sugar pill|Placebo
273365|NCT02118597|Drug|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
273366|NCT02118597|Drug|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
273367|NCT02118597|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
273368|NCT02118597|Drug|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
273369|NCT02118584|Drug|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 9 years or until either commercial availability or the Sponsor's decision to terminate the study.
273370|NCT02118558|Device|Negative Pressure Wound Therapy (NPWT)|
273371|NCT02118558|Drug|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
273372|NCT02118532|Device|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
273373|NCT02118519|Biological|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
273374|NCT02118506|Other|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
273375|NCT02118506|Other|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.~Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.~Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.~Finally, they were submitted to a physical gait training. They executed 400 steps.~They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
273376|NCT02118493|Device|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
273377|NCT02118480|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
273378|NCT02118480|Other|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
273379|NCT02118467|Drug|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
273380|NCT02118467|Drug|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
273381|NCT02118467|Drug|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
273382|NCT02118467|Drug|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
273383|NCT02118454|Behavioral|Daily IVR Calls Intervention|
273384|NCT02118454|Behavioral|Weekly IVR Survey Only|
273387|NCT02118428|Device|Mirasol-treated Whole Blood|Transfusion with fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
273388|NCT02118428|Biological|Untreated Whole Blood|Transfusion with untreated fresh Whole Blood
273389|NCT02118415|Other|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
273390|NCT02118402|Dietary Supplement|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
273391|NCT02118389|Dietary Supplement|Glucerna|Glucerna 52g meal replacement
273392|NCT02118376|Drug|Exenatide|5ug bid,Subcutaneous injection
273393|NCT02118350|Behavioral|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
273394|NCT02118337|Biological|MEDI0680|anti-PD-1
273395|NCT02118337|Biological|Durvalumab|anti-PD-L1
273396|NCT02118337|Biological|Nivolumab|anti PD-1
273397|NCT02118324|Behavioral|Exergaming Program|Participants will exercise through exergaming play.
273398|NCT02118311|Biological|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
273399|NCT02118311|Drug|Fludarabine|Fludarabine 30mg/m^2 IV over 1 hour on days -6 through -2 from transplant
273400|NCT02118311|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
273401|NCT02118311|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
273402|NCT02118285|Drug|Fludarabine|Fludarabine 25 mg/m^2 IV on days -6 through -2 from NK cell infusion
273403|NCT02118285|Drug|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
273404|NCT02118285|Biological|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
273405|NCT02118285|Biological|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
273406|NCT02118285|Drug|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
273407|NCT02118272|Device|Physica KR|
273408|NCT02118259|Other|Before-after study|"The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.~The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.~The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.~During the second observational phase, the same data as in the first observational phase will be collected a second time."
273409|NCT02118246|Device|Dry Needling|Dry needling was performed for one week, three times a week.
273410|NCT02118246|Device|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
273411|NCT02118220|Other|Concussion Questionnaire|
273412|NCT02118207|Other|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
273413|NCT02118181|Dietary Supplement|HMB|
273414|NCT02118168|Other|No intervention|No intervention is foreseen in this Observational Study
273415|NCT02118155|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
273416|NCT02118142|Dietary Supplement|Betaine|6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
273417|NCT02118142|Dietary Supplement|Dextrose|6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
273418|NCT02118129|Behavioral|an educational video|
273419|NCT02118129|Other|wait listed|
273420|NCT02118116|Other|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
273421|NCT02118103|Procedure|Spinal Manipulation|Lumbar spinal manipulation
273422|NCT02118090|Drug|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
273423|NCT02118090|Drug|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
273424|NCT02118077|Biological|G17DT|
273425|NCT02118064|Biological|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
273426|NCT02118051|Drug|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle> 14mm.
273427|NCT02118051|Drug|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles> 17 mm are observed
273428|NCT02118051|Drug|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
273429|NCT02118025|Procedure|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
273430|NCT02118025|Procedure|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
273431|NCT02118012|Other|Chlorcyclizine HCL plus Ribavirin|RBV+ chlorcyclizine HCl (75 mg twice daily)
273432|NCT02118012|Other|Chlorcyclizine HCL Only|chlorcyclizine HCl (75 mg twice daily)
273433|NCT02117999|Device|Cross-linking with iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
273434|NCT02117999|Device|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
273435|NCT02117986|Drug|colistin|One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
273436|NCT02117973|Procedure|iAssist Technique using Persona system vs. the conventional technique using Persona system|
273437|NCT02117960|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
273438|NCT02117960|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
273439|NCT02117947|Behavioral|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
273440|NCT02117947|Behavioral|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
273441|NCT02117934|Biological|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
273442|NCT02117934|Biological|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
273443|NCT02117921|Behavioral|One-on-one interview and educational sessions. Reading material for educational series provided.|A one-on-one interview with the patient and the principal investigator and group educational sessions.
273444|NCT02117908|Device|RESMED AUTOSET S9|Continuous positive pressure during surgery
273445|NCT02117895|Procedure|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
273446|NCT02117895|Procedure|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
273447|NCT02117869|Other|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
273448|NCT02117869|Other|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
273449|NCT02117869|Other|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
273450|NCT02117856|Procedure|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
273451|NCT02117856|Procedure|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
273452|NCT02117856|Procedure|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
273453|NCT02117856|Device|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
273454|NCT02117856|Device|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
273455|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
273456|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
273457|NCT02117843|Device|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
273458|NCT02117830|Drug|Androxal 25 mg capsules|
273459|NCT02117830|Drug|Androxal 250 Capsules|
273460|NCT02117830|Drug|Placebo Capsules|
273461|NCT02117830|Drug|Moxifloxacin 400 mg|
273462|NCT02117817|Drug|BKM120|
273463|NCT02117817|Drug|Nabpaclitaxel|Given IV
273464|NCT02117804|Other|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
273465|NCT02117791|Drug|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
273466|NCT02117778|Procedure|Continuous Nerve Block|
273467|NCT02117765|Drug|Ustekinumab|
273468|NCT02117752|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
273469|NCT02117752|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
273470|NCT02117752|Drug|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
273471|NCT02117752|Drug|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
273472|NCT02117739|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
273473|NCT02117739|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
273474|NCT02117726|Drug|Dexmedetomidine,midazolam|
273475|NCT02117726|Drug|Propofol,midazolam|
273476|NCT02117713|Drug|LUM001|LUM001 will be administered as oral solution once daily based on participant's weight in dose adjustment manner. The dose will be escalated from 14, 35, 70, 140 and 280 mcg/kg/day for 4-week dose escalation period. During 8-weeks of dose optimization period, drug will be adjusted in titrated manner and will continue dosing to complete the stable dosing and safety monitoring periods for up to 96 weeks of cumulative LUM001 exposure in this study. Dosing during, long-term optional follow-up treatment periods 1 and 2 will be maintained at the same dose levels as at weeks 96 and 144 for participants rolling over into these treatment periods respectively.
273477|NCT02117700|Dietary Supplement|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
273478|NCT02117700|Dietary Supplement|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
273479|NCT02117700|Other|Placebo twice/day|Placebo capsules twice/day for 16 weeks
273480|NCT02117687|Drug|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
273481|NCT02117687|Drug|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
273482|NCT02117674|Procedure|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
273483|NCT02117674|Procedure|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
273484|NCT02117674|Procedure|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
273485|NCT02117661|Dietary Supplement|L-carnitine capsules|Oral
273486|NCT02117661|Dietary Supplement|Cellulose capsules|oral
273487|NCT02117648|Drug|Abemaciclib|Administered orally
273488|NCT02117648|Drug|Clarithromycin|Administered orally
273489|NCT02117635|Biological|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
273490|NCT02117622|Drug|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
273491|NCT02117609|Dietary Supplement|New DELICAL formula|3 months with the option of continuing until 6 months.
273492|NCT02117609|Dietary Supplement|Standard DELICAL formula|3 months with the option of continuing until 6 months.
273493|NCT02117596|Drug|Sirolimus|"Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
273494|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
273495|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
273496|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
273497|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
273498|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
273499|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
273500|NCT02117570|Biological|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
273501|NCT02117557|Procedure|Single incision laparoscopic surgery|
273502|NCT02117557|Procedure|Conventional laparoscopic surgery|
273503|NCT02117544|Device|Lotrafilcon B multifocal contact lenses (new)|
273504|NCT02117544|Device|Lotrafilcon B multifocal contact lenses|
273505|NCT02117518|Other|blood drawing|
273506|NCT02117505|Drug|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
273507|NCT02117505|Drug|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5*30 mg tablet=150 mg) in one of the treatment periods.
273508|NCT02117492|Procedure|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
273509|NCT02117479|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
273510|NCT02117479|Drug|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
273511|NCT02117479|Drug|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
273512|NCT02117466|Drug|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
273513|NCT02117466|Drug|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
273514|NCT02117453|Drug|Rosuvastatin|Rosuvastatin 20 mg/day
273515|NCT02117453|Drug|Placebo|Placebo
273516|NCT02117427|Biological|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
273517|NCT02117414|Device|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
273518|NCT02117414|Other|Waiting Period Visit|Waiting period time will equate to 1 hour
273519|NCT02117401|Drug|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
273520|NCT02117401|Drug|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
273521|NCT02117401|Drug|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children~Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
273522|NCT02117401|Drug|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
273523|NCT02117401|Drug|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
273524|NCT02117388|Behavioral|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
273525|NCT02117388|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
273526|NCT02117388|Behavioral|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
273527|NCT02117375|Device|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
273528|NCT02117375|Other|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
273529|NCT02117375|Other|brain MRI follow-up|
273530|NCT02117362|Biological|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
273531|NCT02117362|Biological|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
273532|NCT02117362|Biological|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
273533|NCT02117362|Biological|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
273534|NCT02117362|Biological|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
273535|NCT02117349|Drug|Raplixa plus Gelatin Sponge|During the surgical procedure on Day 1 (Visit 2), subjects will be initially treated with Raplixa plus gelatin sponge at the target bleeding site and the time to stop bleeding will be assessed. Subjects may be retreated with Raplixa and gelatin sponge treatment as necessary during the 5-minute assessment period.
273536|NCT02117349|Drug|Gelatin Sponge|During the surgical procedure on Day 1 (Visit 2), subjects will be initially treated with a gelatin sponge alone at the target bleeding site and the time to stop bleeding will be assessed. Subjects may be retreated with gelatin sponge during the 5-minute time to stop bleeding assessment period.
273537|NCT02117336|Drug|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.~Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.~Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
273538|NCT02117310|Drug|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
273539|NCT02117297|Drug|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
273540|NCT02117271|Device|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
273541|NCT02117271|Other|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
273542|NCT02117258|Drug|Z-360|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
273543|NCT02117258|Drug|Placebo|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
273544|NCT02117232|Device|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
273545|NCT02117232|Device|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
273546|NCT02117219|Biological|MEDI4736 Evaluate MEDI4736 in MDS|MEDI4736 will be administered by IV infusion
273547|NCT02117219|Drug|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
273548|NCT02117219|Biological|tremelimumab|tremelimumab will be administered by IV infusion
273549|NCT02117206|Drug|L-arginine (L-arginine Veyron)|
273550|NCT02117206|Drug|Nacl|
273551|NCT02117193|Other|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
273552|NCT02117193|Other|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
273553|NCT02117180|Other|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
273554|NCT02117167|Drug|AZD2014|Target: m-TOR
273555|NCT02117167|Drug|AZD4547|Target: FGFR
273556|NCT02117167|Drug|AZD5363|Target: AKT
273557|NCT02117167|Drug|AZD8931|Target: HER2, EGFR
273558|NCT02117167|Drug|Selumetinib|Target: MEK
273559|NCT02117167|Drug|Vandetanib|Target : VEGF, EGFR
273560|NCT02117167|Drug|Standard maintenance for squamous NSCLC|
273561|NCT02117167|Drug|Pemetrexed|Standard maintenance for non squamous NSCLC
273562|NCT02117167|Drug|Durvalumab|Target: PD-L1
273563|NCT02117167|Drug|savolitinib|target : MET
273564|NCT02117167|Drug|Olaparib|target : PARP
273565|NCT02117154|Device|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
273566|NCT02117141|Drug|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
273567|NCT02117141|Drug|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
273568|NCT02117128|Drug|Tranexamic acid|
273569|NCT02117115|Radiation|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
273570|NCT02117115|Drug|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
273571|NCT02117102|Other|Bladder and lumbar stimulation technic|
273572|NCT02117089|Device|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
273573|NCT02117076|Drug|Gabapentin immediate release|up to 1200 mg per day
273574|NCT02117076|Drug|Gabapentin enacarbil extended release|up to 1200 mg per day
273575|NCT02117063|Behavioral|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
273576|NCT02117050|Drug|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
273577|NCT02117037|Other|blood sample|
273578|NCT02117024|Drug|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
273579|NCT02117024|Drug|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
273580|NCT02117024|Drug|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~Vinorelbine~Erlotinib~Gemcitabine~Paclitaxel~Docetaxel~Pemetrexed"
273581|NCT02117011|Other|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
273582|NCT02116998|Biological|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.~GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:~GB104: ABC transporter, substrate-binding protein~GB144: Maltose/maltodextrin binding protein, ABC transporter~GB152: Hypothetical protein~GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).~Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
273583|NCT02116998|Biological|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
273584|NCT02116998|Biological|Streptococcus pneumoniae inoculation|Intranasal inoculation of S. Pneumoniae (80,000 CFU/100μl per nostril) serotype 6B.
273585|NCT02116985|Device|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
273586|NCT02116985|Device|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
273587|NCT02116972|Drug|FX006 32 mg|Single 5 mL IA injection
273588|NCT02116972|Drug|Placebo|Single 5 mL IA injection
273589|NCT02116972|Drug|FX006 16 mg|Single 5 mL IA injection
273590|NCT02116959|Drug|Melphalan|
273591|NCT02116959|Drug|Carboplatin|
273592|NCT02116959|Drug|Etoposide|
273593|NCT02116959|Drug|Vincristine|
273594|NCT02116946|Biological|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
273595|NCT02116946|Other|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
273596|NCT02116933|Procedure|Adipose Derived Stem Cells|Adipose derived stem cells harvested from autologous lipoaspirate
273597|NCT02116933|Procedure|SVF Enriched Autologous Fat Grafting|Cell assisted lipotransfer
273598|NCT02116907|Drug|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
273599|NCT02116894|Biological|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
273600|NCT02116894|Drug|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
273601|NCT02116881|Procedure|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
273602|NCT02116868|Device|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
273603|NCT02116868|Drug|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
273604|NCT02116868|Drug|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
273605|NCT02116855|Other|according to the efficacy of AJBRs|
273606|NCT02116842|Drug|0.1% bupivacaine|Epidural block in early labour.
273607|NCT02116842|Drug|0.075% bupivacaine|Epidural block in early labour.
273608|NCT02116842|Drug|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
273609|NCT02116829|Other|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
273610|NCT02116829|Other|Olive oil|
273611|NCT02116816|Dietary Supplement|Polyphenol|Polyphenol
273612|NCT02116803|Drug|dovitinib|Dovitinib was available in two formulations: capsules of 100 mg strength, and tablets of 100 mg strength and taken orally.
273613|NCT02116803|Drug|fulvestrant|Fulvestrant is generally available as solution for injection in pre-filled syringes containing 250 mg of fulvestrant in 5 mL solution.
273614|NCT02116790|Drug|Naproxen|Subjects will take one 250mg Naproxen capsule
273615|NCT02116790|Drug|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
273616|NCT02116790|Drug|Sinemet|Subjects will take one 25mg/100mg Sinemet.
273617|NCT02116790|Drug|Placebo|Subjects will take two placebos.
273618|NCT02116777|Other|Laboratory Biomarker Analysis|Correlative studies
273619|NCT02116777|Other|Pharmacological Study|Correlative studies
273620|NCT02116777|Drug|Talazoparib|Given PO
273621|NCT02116777|Drug|Temozolomide|Given PO
273622|NCT02116738|Procedure|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
273623|NCT02116725|Other|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
273624|NCT02116725|Other|Plain shower gel|Standard shower gel (Sanex).
273625|NCT02116725|Other|Distilled water|Sterile distilled Water.
273626|NCT02116712|Drug|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
273627|NCT02116699|Other|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
273628|NCT02116699|Other|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
273629|NCT02116686|Device|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
273630|NCT02116673|Other|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
273631|NCT02116673|Other|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
273632|NCT02116660|Drug|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
273633|NCT02116660|Drug|Nevirapine|Nevirapine (NVP) 200 mg tablets
273634|NCT02116660|Drug|Lamivudine|Lamivudine (3TC) 150 mg tablets
273635|NCT02116660|Drug|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
273636|NCT02116660|Drug|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
273637|NCT02116660|Drug|Lopinavir|Lopinavir (LPV) 200 mg tablets
273638|NCT02116660|Drug|Ritonavir|Ritonavir (r) 100 mg tablets
273639|NCT02116660|Drug|Atazanavir|Atazanavir (ATV) 300 mg tablets
273640|NCT02116660|Drug|Darunavir|Darunavir (DAR) 400 mg tablets
273641|NCT02116647|Behavioral|Psychoanalytic therapy|
273642|NCT02116634|Biological|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
273643|NCT02116621|Behavioral|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
273644|NCT02116621|Device|smartphone|
273645|NCT02116608|Drug|Betadine|Apply locally as needed.
273646|NCT02116608|Drug|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
273647|NCT02116608|Drug|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
273648|NCT02116595|Other|high or low acid diet|high or low acid diets
273649|NCT02116582|Drug|Enzalutamide|Participants received 160 mg of enzalutamide (soft capsules) orally once daily.
273700|NCT02116192|Behavioral|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
273701|NCT02116179|Behavioral|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
273702|NCT02116140|Other|[C11]Acetate and HED PET|
273650|NCT02116569|Drug|Daratumumab|Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
273651|NCT02116556|Drug|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
273652|NCT02116556|Drug|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
273653|NCT02116543|Drug|TD-6450|
273654|NCT02116543|Drug|Placebo|
273655|NCT02116530|Drug|Olanzapine|oral
273656|NCT02116530|Drug|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
273657|NCT02116530|Drug|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
273658|NCT02116530|Other|Placebo|oral
273659|NCT02116517|Dietary Supplement|green tea extract|500 mg three times per day
273660|NCT02116517|Dietary Supplement|Placebo|cellulose 500mg three times a day for 6 weeks
273661|NCT02116504|Procedure|Sampling of blood|Sampling of blood for dosage of antibodies
273662|NCT02116491|Device|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
273663|NCT02116478|Procedure|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
273664|NCT02116465|Drug|Levodopa Carbidopa immediate release tablets|oral administration
273665|NCT02116452|Dietary Supplement|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
273666|NCT02116426|Biological|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
273667|NCT02116426|Biological|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
273668|NCT02116426|Biological|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
273669|NCT02116413|Procedure|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
273670|NCT02116413|Procedure|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
273671|NCT02116400|Other|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
273672|NCT02116400|Other|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
273673|NCT02116400|Biological|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
273674|NCT02116387|Other|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
273675|NCT02116387|Device|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
273676|NCT02116374|Other|Physiopathology study|
273677|NCT02116361|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
273678|NCT02116361|Drug|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
273679|NCT02116348|Drug|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
273680|NCT02116335|Drug|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
273681|NCT02116335|Drug|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
273682|NCT02116322|Procedure|EUS-FNA with Corkscrew technique|
273683|NCT02116322|Device|Expect 19 G Flex needle|
273684|NCT02116309|Drug|Rectal Indomethacin|
273685|NCT02116309|Drug|Epinephrine|
273686|NCT02116296|Behavioral|ToyBox-intervention|
273687|NCT02116283|Behavioral|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
273688|NCT02116283|Other|Smartphone|Participants will use an Android-based smartphone as their own for one month
273689|NCT02116270|Biological|Blood sample|3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
273690|NCT02116257|Drug|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
273691|NCT02116257|Drug|PCA regimen|
273692|NCT02116244|Drug|Civamide Nasal Spray|
273693|NCT02116231|Drug|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
273694|NCT02116231|Radiation|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
273695|NCT02116218|Procedure|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
273696|NCT02116218|Procedure|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
273697|NCT02116205|Biological|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
273698|NCT02116205|Biological|Placebo|0.9% sodium chloride
273699|NCT02116192|Behavioral|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)~● Aim for less than 25g fructose daily."
273772|NCT02115698|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
273703|NCT02116127|Device|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
273704|NCT02116127|Device|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
273705|NCT02116114|Other|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
273706|NCT02116101|Dietary Supplement|Bright Momchilovtsi Yogurt|"Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus~Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo."
273707|NCT02116101|Dietary Supplement|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
273708|NCT02116088|Behavioral|Teacher Coaching|
273709|NCT02116075|Procedure|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
273710|NCT02116075|Procedure|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
273711|NCT02116062|Device|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
273712|NCT02116062|Device|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
273713|NCT02116062|Device|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
273714|NCT02116049|Behavioral|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
273715|NCT02116049|Behavioral|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
273716|NCT02116036|Drug|Rivaroxaban|
273717|NCT02116023|Other|Orange flavored beverage|
273718|NCT02116010|Drug|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
273719|NCT02116010|Drug|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
273720|NCT02116010|Drug|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
273721|NCT02115997|Drug|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
273722|NCT02115997|Drug|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day [mg/kg/day]) at the discretion of investigator given daily until participants are off the drug.
273723|NCT02115997|Drug|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
273724|NCT02115984|Drug|Panagen|
273725|NCT02115984|Drug|Placebo|
273726|NCT02115984|Procedure|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
273727|NCT02115971|Other|Jumping exercise|Total 120min exercise
273728|NCT02115971|Other|Strength exercise|Total 120 min exercise
273729|NCT02115958|Biological|cancer stem cell vaccine|
273730|NCT02115945|Other|DN4 test|The DN4 test was used to evaluate neuropathic pain.
273731|NCT02115945|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
273732|NCT02115945|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
273733|NCT02115945|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
273734|NCT02115945|Procedure|femoral block|
273735|NCT02115945|Procedure|epidural block|
273736|NCT02115932|Other|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
273773|NCT02115698|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
274504|NCT02110628|Procedure|Roux-en-Y anastomosis|Roux-en-Y anastomosis
273737|NCT02115919|Drug|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
273738|NCT02115919|Drug|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
273739|NCT02115906|Other|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
273740|NCT02115906|Other|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.~Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
273741|NCT02115906|Other|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
273742|NCT02115893|Dietary Supplement|Sodium Nitrate|
273743|NCT02115893|Dietary Supplement|Sodium Chloride|
273744|NCT02115880|Behavioral|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
273745|NCT02115867|Dietary Supplement|Probiotic|Symprove probiotic
273746|NCT02115854|Other|labial biopsy|
273747|NCT02115841|Device|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
273748|NCT02115828|Drug|Vismodegib|
273749|NCT02115815|Biological|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
273750|NCT02115815|Biological|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
273751|NCT02115815|Biological|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
273752|NCT02115815|Biological|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
273753|NCT02115815|Biological|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
273754|NCT02115815|Biological|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
273755|NCT02115815|Biological|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
273756|NCT02115802|Device|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
273757|NCT02115789|Behavioral|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
273758|NCT02115776|Drug|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
273759|NCT02115776|Drug|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
273760|NCT02115776|Drug|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
273761|NCT02115763|Drug|Caffeine|
273762|NCT02115763|Drug|Placebo|
273763|NCT02115750|Drug|Etanercept|Head-to-head comparison
273764|NCT02115750|Drug|CHS-0214|
273765|NCT02115737|Behavioral|Dialectical Behavior Therapy Skills Group|
273766|NCT02115737|Behavioral|Psychoeducation group treatment|
273767|NCT02115724|Dietary Supplement|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
273768|NCT02115724|Other|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
273769|NCT02115724|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
273770|NCT02115724|Drug|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
273771|NCT02115711|Behavioral|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
274716|NCT02109133|Drug|Atracurium|
273774|NCT02115698|Dietary Supplement|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
273775|NCT02115698|Dietary Supplement|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
273776|NCT02115698|Dietary Supplement|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
273777|NCT02115685|Other|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
273778|NCT02115672|Drug|BL-8040|BL-8040 will be added to imatinib to improve CML response.
273779|NCT02115659|Drug|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
273780|NCT02115659|Drug|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
273781|NCT02115646|Device|fractionated carbon dioxide laser|patients will have serial laser treatments
273782|NCT02115633|Device|Walkasins ON|Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.
273783|NCT02115633|Device|Walkasins OFF|Subjects will be wearing a device that is turned off.
273784|NCT02115620|Other|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
273785|NCT02115607|Drug|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
273786|NCT02115594|Drug|Fulvestrant|
273787|NCT02115594|Drug|Entinostat|
273788|NCT02115594|Drug|Placebo|
273789|NCT02115581|Drug|Coenzyme Q10|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
273790|NCT02115581|Drug|Placebo|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
273791|NCT02115555|Behavioral|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
273792|NCT02115555|Behavioral|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
273793|NCT02115555|Behavioral|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
273794|NCT02115542|Drug|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (<30% fat) breakfast.
273795|NCT02115529|Drug|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
273796|NCT02115529|Drug|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
273797|NCT02115516|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
273798|NCT02115516|Biological|0.9% Sodium Chloride (Placebo)|
273799|NCT02115490|Drug|Bisphosphonates|
273800|NCT02115477|Procedure|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
273801|NCT02115464|Drug|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
273802|NCT02115464|Radiation|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
273803|NCT02115425|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
273804|NCT02115425|Other|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
273805|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
273806|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
273807|NCT02115425|Other|add name here|
273808|NCT02115386|Drug|Nilotinib|300 mg
273809|NCT02115373|Drug|Tepotinib|Participants received a single oral dose of Tepotinib 300 milligram (mg) in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
273810|NCT02115373|Drug|Tepotinib|Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease, intolerable toxicity, death, or withdrawal from treatment.
273893|NCT02114801|Device|electric toothbrush linked|Tooth brushing
273894|NCT02114801|Device|off electric toothbrush|Tooth brushing
273895|NCT02114788|Other|Internet-based|
273896|NCT02114775|Drug|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
273811|NCT02115360|Drug|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
273812|NCT02115360|Drug|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
273813|NCT02115347|Drug|Ertugliflozin 15 mg|Tablet
273814|NCT02115334|Behavioral|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
273815|NCT02115334|Behavioral|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
273816|NCT02115334|Behavioral|health education|health education of the children with DD.
273817|NCT02115321|Drug|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
273818|NCT02115321|Drug|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
273819|NCT02115321|Drug|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
273820|NCT02115308|Drug|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
273821|NCT02115295|Drug|Cladribine|Given IV
273822|NCT02115295|Drug|Cytarabine|Given IV
273823|NCT02115295|Drug|Gilteritinib|Given PO
273824|NCT02115295|Drug|Idarubicin|Given IV
273825|NCT02115295|Other|Laboratory Biomarker Analysis|Correlative studies
273826|NCT02115295|Drug|Midostaurin|Given PO
273827|NCT02115295|Drug|Venetoclax|Given PO
273828|NCT02115282|Drug|Entinostat|Given PO
273829|NCT02115282|Drug|Exemestane|Given PO
273830|NCT02115282|Drug|Goserelin|Given PO
273831|NCT02115282|Drug|Goserelin Acetate|Given SC
273832|NCT02115282|Other|Placebo|Given PO
273833|NCT02115282|Other|Quality-of-Life Assessment|Ancillary studies
273834|NCT02115256|Drug|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
273835|NCT02115256|Drug|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
273836|NCT02115243|Drug|Ipilimumab|
273837|NCT02115230|Procedure|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
273838|NCT02115217|Device|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
273839|NCT02115217|Device|Sham kinesiotape|KT put with no effects
273840|NCT02115204|Drug|Epirubicin|
273841|NCT02115204|Drug|Cyclophosphamide|
273842|NCT02115204|Drug|Docetaxel|
273843|NCT02115204|Drug|Methotrexate|
273844|NCT02115204|Drug|5-fluorouracil|
273845|NCT02115191|Device|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
273846|NCT02115191|Procedure|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
273847|NCT02115178|Other|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
273848|NCT02115165|Drug|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
273849|NCT02115152|Drug|fluorouracil|
273850|NCT02115152|Drug|capecitabine|
273851|NCT02115152|Drug|cyclophosphamide|
273852|NCT02115152|Drug|Epirubicin|
273853|NCT02115139|Drug|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
273854|NCT02115126|Biological|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be > 1.5.~Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be > 1.5.~Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
273897|NCT02114775|Drug|Sildenafil|50 mg by mouth daily
273898|NCT02114775|Drug|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
274717|NCT02109133|Drug|Neostigmine|
273855|NCT02115126|Biological|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.~DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.~Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
273856|NCT02115113|Drug|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
273857|NCT02115113|Drug|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration.
273858|NCT02115100|Procedure|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
273859|NCT02115087|Procedure|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
273860|NCT02115087|Drug|Morphine|
273861|NCT02115074|Drug|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
273862|NCT02115074|Drug|Celebrex|"Dose levels : 100 mg twice a day (< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
273863|NCT02115061|Device|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
273864|NCT02115061|Device|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
273865|NCT02115048|Drug|Letrozole|
273866|NCT02115048|Drug|Afatinib|
273867|NCT02115035|Drug|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
273868|NCT02114983|Other|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
273869|NCT02114970|Other|Randomized- paper consent|
273870|NCT02114970|Other|Randomized- Tablet-delivered consent|
273871|NCT02114970|Other|Focus Group- paper and tablet consent|
273872|NCT02114957|Dietary Supplement|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
273873|NCT02114944|Device|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
273874|NCT02114944|Device|CPAP|Patient treated, as per attending physician's decision, with CPAP
273875|NCT02114944|Device|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
273876|NCT02114944|Device|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
273877|NCT02114931|Biological|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
273878|NCT02114918|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
273879|NCT02114918|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
273880|NCT02114905|Behavioral|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
273881|NCT02114892|Drug|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
273882|NCT02114892|Drug|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
273883|NCT02114879|Behavioral|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
273884|NCT02114879|Behavioral|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
273885|NCT02114840|Procedure|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
273886|NCT02114840|Procedure|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
273887|NCT02114840|Procedure|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
273888|NCT02114827|Behavioral|Video|23-minute video
273889|NCT02114827|Behavioral|FAQ Sheet|
273890|NCT02114814|Behavioral|Experimental: Diabetes Self Management|
273891|NCT02114814|Behavioral|General Health Education|
273892|NCT02114801|Device|manual brushing|Tooth brushing
273899|NCT02114762|Procedure|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
273900|NCT02114749|Device|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
273901|NCT02114736|Procedure|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
273902|NCT02114736|Drug|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
273903|NCT02114723|Device|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.~The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
273904|NCT02114710|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
273905|NCT02114697|Drug|Statin therapy|Statin therapy includes rosuvastatin 20 mg administered orally, once a day, for the duration of the trial, which is 3 years. Participants may also receive a different type of statin as prescribed by their cardiologist based on clinical judgement.
273906|NCT02114697|Behavioral|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
273907|NCT02114684|Drug|moxifloxacin|[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)]
273908|NCT02114671|Drug|Faldaprevir high dose|capsules, oral
273909|NCT02114671|Drug|Placebo|capsule, oral
273910|NCT02114671|Drug|Ciprofloxacin|tablets, oral
273911|NCT02114671|Drug|Faldaprevir low dose|capsules, oral
273912|NCT02114658|Drug|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
273913|NCT02114645|Drug|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
273914|NCT02114645|Drug|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
273915|NCT02114645|Drug|4 mg oral estradiol valerate|estrofem is given twice a day
273916|NCT02114632|Dietary Supplement|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
273917|NCT02114619|Drug|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
273918|NCT02114619|Drug|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
273919|NCT02114619|Drug|High dose|We will administer 200 micro currie of iodine per thyroid gram
273920|NCT02114606|Device|Cytosponge™ Cell Collection Device|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
273921|NCT02114593|Behavioral|Parent support program|Parent support program
273922|NCT02114580|Other|physical training|"Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).~Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises."
273923|NCT02114567|Other|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
273924|NCT02114528|Drug|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
273925|NCT02114528|Procedure|Catheter ablation|Ventricular tachycardia catheter ablation.
273926|NCT02114515|Behavioral|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
273927|NCT02114515|Behavioral|Navigator intervention|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
273928|NCT02114515|Behavioral|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
273929|NCT02114502|Drug|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
273930|NCT02114502|Drug|SAHA|1,000 mg by mouth on Days -8 to -3.
273931|NCT02114502|Drug|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
273932|NCT02114502|Drug|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
273933|NCT02114502|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
273934|NCT02114502|Procedure|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
273935|NCT02114502|Drug|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
273936|NCT02114502|Drug|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
273937|NCT02114502|Drug|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
273938|NCT02114502|Drug|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
273939|NCT02114502|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
273940|NCT02114489|Drug|ibandronate|Unique perfusion of ibandronate 3 mg IV
273941|NCT02114489|Drug|Placebo|
273942|NCT02114476|Device|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
273943|NCT02114476|Device|Placebo|
273944|NCT02114463|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
273945|NCT02114463|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
273946|NCT02114463|Drug|ropivacaine|0.2% ropivacaine
273947|NCT02114463|Drug|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
273948|NCT02114450|Behavioral|Robot-assisted training with the H2 lower limb powered exoskeleton|The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
273949|NCT02114450|Behavioral|Supervised motor practice|Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
273950|NCT02114437|Device|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
273951|NCT02114437|Device|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
273952|NCT02114424|Device|Positional vibrator belt|Belt with vibarator to avoid sleep supine
273953|NCT02114411|Procedure|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
273954|NCT02114411|Procedure|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
273955|NCT02114398|Other|usual treatment|usual treatment
273956|NCT02114398|Other|usual treatment + sophrology|usual treatment + sophrology
273957|NCT02114385|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
273958|NCT02114385|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine, 0.5-mL intramuscular injection
273959|NCT02114359|Drug|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
273960|NCT02114359|Drug|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
273961|NCT02114359|Drug|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
273962|NCT02114359|Drug|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
273963|NCT02114359|Drug|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 1000mg/m2 po bid)
273964|NCT02114359|Drug|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 30mg/m2 po bid)
273965|NCT02114359|Drug|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
273966|NCT02114346|Drug|Atorvastatin|
273967|NCT02114346|Drug|Placebo|
273968|NCT02114346|Drug|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
273969|NCT02114333|Biological|Zostavax|0.65ml, subcutaneous
273970|NCT02114333|Biological|HZ/su vaccine|0.5ml, intramuscular
273971|NCT02114333|Biological|Placebo|0.65ml, subcutaneous
273972|NCT02114320|Device|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
273973|NCT02114307|Device|REVITIVE IX|neuromuscular electrical stimulation device
273974|NCT02114294|Other|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
273975|NCT02114294|Other|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
274053|NCT02113800|Drug|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
273976|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
273977|NCT02114281|Other|Care|
273978|NCT02114281|Other|Not care|
273979|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
273980|NCT02114268|Drug|Placebo|Participants received placebo on Day 1.
273981|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
273982|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
273983|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
273984|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
273985|NCT02114255|Other|Placebo|Administration of 0.9% NaCl.
273986|NCT02114255|Biological|BCG|Vaccination with the live attenuated BCG vaccine.
273987|NCT02114242|Other|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
273988|NCT02114242|Other|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
273989|NCT02114229|Drug|alisertib|Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
273990|NCT02114229|Drug|methotrexate|Methotrexate will be given at a dose of 5 g/m^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m^2/dose.
273991|NCT02114229|Drug|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
273992|NCT02114229|Drug|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
273993|NCT02114229|Drug|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
273994|NCT02114229|Drug|etoposide|"Etoposide will be given 100 mg/m^2 IV infusion.~In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
273995|NCT02114229|Drug|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL*hr.
273996|NCT02114229|Drug|vincristine|Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
273997|NCT02114229|Procedure|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
273998|NCT02114229|Radiation|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
273999|NCT02114216|Procedure|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
274000|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
274001|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
274002|NCT02114203|Drug|placebo for PDE9i|oral dose, every 12 hours for 28 days
274003|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
274004|NCT02114190|Behavioral|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
274005|NCT02114190|Behavioral|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
274006|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
274007|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
274008|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
274009|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
274010|NCT02114164|Device|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
274011|NCT02114164|Device|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
274012|NCT02114151|Drug|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
274013|NCT02114151|Drug|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
274014|NCT02114138|Procedure|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
274015|NCT02114138|Diagnostic Test|urine collection|urine collection will be performed on both the control group and hospitalized participants
274016|NCT02114125|Behavioral|Physical Activity|group-based physical activity
274017|NCT02114125|Behavioral|Cognitive Training|individual-based, multi-domains cognitive training
274018|NCT02114112|Other|NCPAP cycling|
274019|NCT02114112|Other|NCPAP continuous|
274020|NCT02114099|Drug|Atorvastatin|10 mg qd x1 year
274021|NCT02114073|Drug|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
274022|NCT02114073|Drug|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
274023|NCT02114060|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
274024|NCT02114060|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
274025|NCT02114060|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
274026|NCT02114060|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
274027|NCT02114060|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
274028|NCT02114060|Biological|Placebo|0.9% Normal Saline (NaCl)
274029|NCT02114021|Drug|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
274030|NCT02114021|Drug|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
274031|NCT02114021|Drug|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
274032|NCT02114008|Other|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
274033|NCT02113995|Other|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
274034|NCT02113982|Drug|SL-401|
274035|NCT02113969|Device|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
274036|NCT02113956|Behavioral|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
274037|NCT02113943|Drug|Citalopram 30mg|
274038|NCT02113930|Biological|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
274039|NCT02113930|Genetic|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
274040|NCT02113917|Biological|Identification of biological markers|
274041|NCT02113904|Drug|Adalimumab|6 injections (one every 15 days during 3 months)
274042|NCT02113891|Drug|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.~(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
274043|NCT02113878|Drug|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
274044|NCT02113878|Drug|Cisplatin|Cisplatin is a chemotherapy drug
274045|NCT02113878|Radiation|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
274046|NCT02113839|Procedure|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
274047|NCT02113839|Procedure|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
274048|NCT02113839|Procedure|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
274049|NCT02113839|Procedure|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
274050|NCT02113826|Drug|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
274051|NCT02113813|Drug|naquotinib|oral
274052|NCT02113813|Drug|midazolam|oral
275317|NCT02104622|Device|ReWalk Rehabilitation 2.0|
274054|NCT02113787|Procedure|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
274055|NCT02113774|Other|antimicrobial treatment according to in-vitro susceptibility|
274056|NCT02113748|Other|Downhill walking training|Walk on a treadmill with a negative inclination.
274057|NCT02113748|Other|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
274058|NCT02113735|Drug|H.P. Acthar® Gel (repository corticotropin injection)|
274059|NCT02113735|Drug|Placebo|
274060|NCT02113722|Procedure|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
274061|NCT02113722|Procedure|Standard of Care|Medical therapy
274062|NCT02113709|Device|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
274063|NCT02113709|Device|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
274064|NCT02113696|Dietary Supplement|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
274065|NCT02113696|Dietary Supplement|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
274066|NCT02113670|Other|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
274067|NCT02113657|Drug|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
274068|NCT02113644|Other|Lifestyle intervention|
274069|NCT02113631|Drug|Telaprevir|
274070|NCT02113631|Drug|Boceprevir|
274071|NCT02113631|Drug|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
274072|NCT02113631|Drug|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
274073|NCT02113618|Behavioral|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
274074|NCT02113618|Behavioral|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
274075|NCT02113605|Other|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
274076|NCT02113592|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
274077|NCT02113579|Device|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
274078|NCT02113579|Other|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
274079|NCT02113566|Drug|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
274080|NCT02113553|Drug|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
274081|NCT02113540|Drug|Atorvastatin|
274082|NCT02113449|Drug|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
274083|NCT02113436|Drug|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
274084|NCT02113436|Drug|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
274085|NCT02113423|Radiation|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID*2F
274086|NCT02113410|Behavioral|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
274087|NCT02113410|Behavioral|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) attended twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
274088|NCT02113397|Drug|TOBI™ Podhaler™ 112 mg inhaled twice daily|
274089|NCT02113397|Drug|Colistimethate 75 mg inhaled two times daily|
274090|NCT02113384|Other|Observational study.|Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
274091|NCT02113371|Behavioral|Intervention|
274092|NCT02113358|Drug|Intravenous colloid bolus with Voluven|
274093|NCT02113345|Behavioral|Metamemory Cognitive Intervention|Metamemory Cognitive Intervention
274094|NCT02113332|Drug|Liraglutide|
274095|NCT02113332|Drug|Placebo|
274096|NCT02113319|Drug|dasatinib|dasatinib 50 mg and 20 mg During one year
274197|NCT02112643|Dietary Supplement|Sodium selenite|A 100 microgram pill will be orally administered twice a day for 6 months.
274097|NCT02113306|Device|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
274098|NCT02113306|Device|sham stimulation|electrodes will be put upside down
274099|NCT02113293|Drug|CyclASol®|Cyclosporine A Solution
274100|NCT02113293|Drug|Placebo (vehicle)|Vehicle Solution
274101|NCT02113280|Procedure|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
274102|NCT02113280|Procedure|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
274103|NCT02113267|Drug|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
274104|NCT02113267|Drug|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
274105|NCT02113254|Other|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
274106|NCT02113241|Drug|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
274107|NCT02113241|Drug|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
274108|NCT02113215|Procedure|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
274109|NCT02113202|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
274110|NCT02113202|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
274111|NCT02113189|Other|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
274112|NCT02113189|Other|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
274113|NCT02113189|Other|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
274114|NCT02113176|Drug|Minocycline|
274115|NCT02113163|Drug|Metformin Eicosapentaenoate|
274116|NCT02113163|Drug|Metformin HCl and Vascepa|
274117|NCT02113150|Drug|remifentanil|renal function
274118|NCT02113150|Drug|Ketamine|renal function
274119|NCT02113137|Drug|group 1: drug: chlorine dioxide|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
274120|NCT02113137|Device|group 2: device: small tooth brush for tongue cleaning|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
274121|NCT02113111|Behavioral|Fasting|Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
274122|NCT02113098|Other|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
274123|NCT02113098|Other|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
274124|NCT02113085|Behavioral|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
274125|NCT02113072|Drug|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
274126|NCT02113072|Drug|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
274127|NCT02113072|Drug|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
274128|NCT02113046|Procedure|pancreatico-jejunal anastomosis|
274129|NCT02113046|Procedure|traditional anastomosis|
274130|NCT02113033|Device|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
274131|NCT02113020|Drug|TAK-233|Oral administration of TAK-233
274132|NCT02113020|Drug|Placebo|Oral admininstration of Placebo
274133|NCT02113007|Drug|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
274134|NCT02112994|Drug|Sebelipase Alfa|IV infusion of sebelipase alfa
274135|NCT02112981|Device|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
274136|NCT02112981|Device|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
274137|NCT02112968|Procedure|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
274138|NCT02112968|Procedure|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
274139|NCT02112968|Procedure|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
274140|NCT02112955|Behavioral|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
274141|NCT02112955|Behavioral|Usual care|Usual care such as hospital-based or community-based health education or services.
274142|NCT02112942|Drug|IDX21459|
274143|NCT02112942|Drug|Matching Placebo|
274144|NCT02112929|Drug|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
274145|NCT02112916|Drug|Bortezomib|Given IV
274146|NCT02112916|Drug|Cyclophosphamide|Given IV
274147|NCT02112916|Drug|Cytarabine|Given IT, IV, or SC
274148|NCT02112916|Drug|Daunorubicin|Given IV
274149|NCT02112916|Drug|Daunorubicin Hydrochloride|Given IV
274150|NCT02112916|Drug|Dexamethasone|Given PO or IV
274151|NCT02112916|Drug|Doxorubicin|Given IV
274152|NCT02112916|Drug|Doxorubicin Hydrochloride|Given IV
274153|NCT02112916|Drug|Etoposide|Given IV
274154|NCT02112916|Drug|Hydrocortisone Sodium Succinate|Given IT
274155|NCT02112916|Drug|Ifosfamide|Given IV
274156|NCT02112916|Drug|Leucovorin Calcium|Given PO or IV
274157|NCT02112916|Drug|Mercaptopurine|Give PO
274158|NCT02112916|Drug|Methotrexate|Given IT, IV, or PO
274159|NCT02112916|Drug|Pegaspargase|Given IV
274160|NCT02112916|Radiation|Radiation Therapy|Undergo radiation therapy
274161|NCT02112916|Drug|Thioguanine|Given PO
274162|NCT02112916|Drug|Vincristine|Given IV
274163|NCT02112916|Drug|Vincristine Sulfate|Given IV
274164|NCT02112903|Drug|Encapsulated vortioxetine IR tablet, 20 mg|
274165|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 5.5)|
274166|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 6.0)|
274167|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 7.0)|
274168|NCT02112890|Other|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
274169|NCT02112877|Device|Veniti Vici™ Venous Stent System|
274170|NCT02112864|Drug|Dexamethasone|10 mg (2.5 ml)
274171|NCT02112864|Drug|Normal Saline|2.5 mL normal saline
274172|NCT02112851|Other|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
274173|NCT02112838|Drug|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
274174|NCT02112838|Drug|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
274175|NCT02112838|Drug|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
274176|NCT02112825|Behavioral|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
274177|NCT02112812|Drug|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
274178|NCT02112812|Drug|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
274179|NCT02112812|Drug|Eradication therapy for Helicobacter pylori|
274180|NCT02112799|Drug|NVR 3-778|
274181|NCT02112799|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
274182|NCT02112799|Drug|Pegasys|
274183|NCT02112786|Device|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
274184|NCT02112760|Other|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
274185|NCT02112747|Other|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
274186|NCT02112734|Drug|Vitamin D|400 IU/daily until age 12 months
274187|NCT02112734|Drug|placebo|identical placebo daily
274188|NCT02112721|Dietary Supplement|Vitamin D|
274189|NCT02112721|Dietary Supplement|Placebo|
274190|NCT02112708|Other|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
274191|NCT02112708|Other|Control Group usual care|In the control group the depression is treated as usual with the conventional treatment.
274192|NCT02112695|Other|[11C]diprenorphine|3 micrograms [11C]diprenorphine - intravenous use - 1 time
274193|NCT02112682|Procedure|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
274194|NCT02112669|Device|VasQ|
274195|NCT02112656|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
274196|NCT02112656|Drug|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
274284|NCT02112110|Drug|BMS-791325|
274285|NCT02112110|Drug|[13C]-BMS-791325|
274198|NCT02112643|Dietary Supplement|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
274199|NCT02112630|Drug|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
274200|NCT02112630|Drug|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
274201|NCT02112630|Drug|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
274202|NCT02112630|Drug|Boceprevir|800 mg PO three times daily starting at week 4
274203|NCT02112617|Radiation|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
274204|NCT02112604|Device|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
274205|NCT02112604|Device|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
274206|NCT02112604|Other|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
274207|NCT02112604|Other|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
274208|NCT02112604|Other|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
274209|NCT02112604|Drug|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
274210|NCT02112591|Procedure|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
274211|NCT02112591|Procedure|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
274212|NCT02112578|Drug|Meclizine|25 mg, 3 times per day up to 30 days
274213|NCT02112578|Drug|Dimenhydrinate|50 mg, 3 times per day up to 30 days
274214|NCT02112565|Drug|RNR inhibitor COH29|Given PO
274215|NCT02112565|Other|laboratory biomarker analysis|Correlative studies
274216|NCT02112565|Other|pharmacological study|Correlative studies
274217|NCT02112552|Drug|Paclitaxel|Given IV
274218|NCT02112552|Drug|Carboplatin|Given IP
274219|NCT02112552|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
274220|NCT02112552|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
274221|NCT02112552|Other|Quality-of-Life Assessment|Ancillary studies
274222|NCT02112552|Other|Laboratory Biomarker Analysis|Correlative studies
274223|NCT02112539|Other|platelet aggregation measurement|
274224|NCT02112526|Drug|Acalabrutinib|
274225|NCT02112500|Biological|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
274226|NCT02112487|Drug|Macitentan|10 mg once daily
274227|NCT02112474|Device|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
274228|NCT02112474|Device|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
274229|NCT02112474|Device|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
274230|NCT02112461|Behavioral|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
274231|NCT02112448|Drug|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
274232|NCT02112448|Drug|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
274233|NCT02112448|Drug|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
274234|NCT02112448|Drug|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
274235|NCT02112435|Device|Somnyx ®|Active mandibular advancement splint
274236|NCT02112435|Device|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
274237|NCT02112422|Drug|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
274238|NCT02112422|Drug|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
274239|NCT02112409|Procedure|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
274240|NCT02112409|Procedure|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
274241|NCT02112396|Behavioral|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
274242|NCT02112383|Behavioral|Cognitive behavior group therapy|For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
274243|NCT02112383|Behavioral|Internet-based cognitive behavior therapy|For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
274244|NCT02112370|Drug|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
274245|NCT02112370|Other|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
274246|NCT02112344|Radiation|IMRT|
274247|NCT02112331|Other|Raw human milk|
274248|NCT02112331|Other|Pasteurized human milk|
274249|NCT02112331|Other|Pasteurized-homogenized human milk|
274250|NCT02112331|Other|Gastric samples|
274251|NCT02112305|Drug|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
274252|NCT02112305|Drug|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
274253|NCT02112292|Drug|tetrahydrocannabinol|
274254|NCT02112292|Drug|cannabidiol|
274255|NCT02112292|Drug|Placebo|
274256|NCT02112279|Biological|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy~1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.~Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
274257|NCT02112266|Other|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
274258|NCT02112266|Other|no mail support|follow-up without mail support
274259|NCT02112253|Device|Deep brain stimulator ventral electrode up to 2 mA|
274260|NCT02112253|Device|Deep brain stimulator ventral electrode up to 3 mA|
274261|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 2 mA|
274262|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 3 mA|
274263|NCT02112253|Device|Deep brain stimulator empirical programming|
274264|NCT02112240|Other|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
274265|NCT02112240|Drug|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
274266|NCT02112240|Other|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
274267|NCT02112240|Procedure|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
274268|NCT02112240|Radiation|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
274269|NCT02112227|Other|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
274270|NCT02112214|Drug|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
274271|NCT02112214|Other|Placebo|Placebo for bismuth-based quadruple therapy
274272|NCT02112201|Behavioral|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
274273|NCT02112188|Behavioral|In-depth Patient Interviews|
274274|NCT02112188|Behavioral|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
274275|NCT02112175|Drug|Lenalidomide|
274276|NCT02112162|Radiation|fludeoxyglucose F 18|Undergo FDG PET/MRI
274277|NCT02112162|Device|positron emission tomography|Undergo FDG PET/MRI
274278|NCT02112162|Device|magnetic resonance imaging|Undergo FDG PET/MRI
274279|NCT02112162|Other|laboratory biomarker analysis|Correlative studies
274280|NCT02112149|Behavioral|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
274281|NCT02112136|Other|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
274282|NCT02112123|Drug|Icariin|
274283|NCT02112123|Dietary Supplement|Matching placebo|
274286|NCT02112097|Drug|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
274287|NCT02112097|Drug|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine)~.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
274288|NCT02112097|Drug|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
274289|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
274290|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
274291|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
274292|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
274293|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
274294|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.~The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
274295|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
274296|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
274297|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
274298|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
274299|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
274300|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
274301|NCT02112097|Drug|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
274302|NCT02112097|Drug|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
274303|NCT02112097|Drug|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
274454|NCT02111018|Procedure|CVVH|
274304|NCT02112097|Drug|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
274305|NCT02112097|Drug|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
274306|NCT02112084|Behavioral|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
274307|NCT02112071|Behavioral|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
274308|NCT02112058|Behavioral|A Family-Strengthening Program for Low-Income Families|"The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.~Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.~The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program."
274309|NCT02112045|Drug|Granix|
274310|NCT02112045|Drug|High dose melphalan (HDR)|
274311|NCT02112045|Procedure|Autologous Stem Cell Transplant (ASCT)|
274312|NCT02112032|Drug|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
274313|NCT02112032|Drug|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
274314|NCT02112019|Procedure|Sialoendoscopy|
274315|NCT02112019|Drug|saline|
274316|NCT02112019|Drug|hydrocortisone|
274317|NCT02112006|Procedure|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
274318|NCT02112006|Procedure|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
274319|NCT02111993|Device|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
274320|NCT02111993|Device|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
274321|NCT02111980|Device|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
274322|NCT02111967|Other|Questionnaire administration|
274323|NCT02111967|Other|Laboratory biomarker analysis|
274324|NCT02111954|Diagnostic Test|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
274325|NCT02111941|Other|Laboratory Biomarker Analysis|Correlative studies
274326|NCT02111941|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
274327|NCT02111928|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
274328|NCT02111915|Behavioral|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
274329|NCT02111915|Other|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
274330|NCT02111889|Other|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|[11C] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and [15O]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
274331|NCT02111863|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
274332|NCT02111863|Drug|Fludarabine|Fludarabine 25 mg/m^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
274333|NCT02111863|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
274334|NCT02111863|Biological|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
274335|NCT02111850|Biological|Anti-MAGE-A3-DP4 TCR PBL|Day 0: cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
274455|NCT02110992|Drug|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
274336|NCT02111850|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg /day X 2 days over 1 hr.
274337|NCT02111850|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2 /day IVPB daily over 30 minutes for 5 days.
274338|NCT02111850|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
274339|NCT02111837|Other|Standard infant formula|
274340|NCT02111837|Other|Standard infant formula with PL1|
274341|NCT02111837|Other|Standard infant formula with PL2|
274342|NCT02111824|Device|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
274343|NCT02111824|Drug|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
274344|NCT02111811|Other|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
274345|NCT02111798|Drug|Bupropion XL|Cocaine dependent methadone maintenance patients will receive usual care at their methadone clinic. All study participants will be able to earn financial incentives throughout the study for stopping cocaine use. In addition, they will receive double blind medication (active vs placebo) daily at the methadone clinic. Active medication is bupropion XL 300mg/day. Participants will see research staff 3 times per week to deliver urine specimens and may be awarded financial incentives if these test cocaine negative.
274346|NCT02111798|Drug|placebo|Cocaine dependent methadone maintenance patients will receive usual care at their methadone clinic. All study participants will be able to earn financial incentives throughout the study for stopping cocaine use. In addition, they will receive double blind medication (active vs placebo) daily at the methadone clinic. Participants will see research staff 3 times per week to deliver urine specimens and may be awarded financial incentives if these test cocaine negative.
274347|NCT02111785|Drug|Dexamethasone|Treatment with a short course of oral dexamethasone
274348|NCT02111785|Procedure|Burr Hole Craniostomy|Treatment with surgical burr hole craniostomy and evacuation of SDH
274349|NCT02111772|Biological|Rhinovirus|
274350|NCT02111759|Procedure|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
274351|NCT02111759|Procedure|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
274352|NCT02111746|Drug|Exparel|Participants will receive 266mg of liposomal bupivicaine (equivalent of one 1.3% 20ml vial of EXPAREL®) diluted in 60ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
274353|NCT02111746|Drug|Bupivacaine hydrochloride|Participants will receive 125mg of bupivacaine hydrochloride (equivalent of one 0.25% 50ml or five 0.25% 10ml vials ) diluted in 30ml of preservative-free normal (0.9%) sterile saline for a total volume of 80mL. Drug will be administered at the end of the procedure just prior to wound closure.
274354|NCT02111746|Drug|Patient Controlled Analgesia (PCA)|Patients will have access to the standard Patient Controlled Analgesia (PCA) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10 minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs. Patients will receive PCA until the third postoperative day
274355|NCT02111733|Other|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
274356|NCT02111720|Behavioral|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
274357|NCT02111720|Behavioral|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
274358|NCT02111707|Drug|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
274359|NCT02111694|Behavioral|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
274360|NCT02111681|Device|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
274361|NCT02111655|Device|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.~QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
274362|NCT02111655|Procedure|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
274363|NCT02111655|Procedure|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
274364|NCT02111655|Procedure|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
274365|NCT02111655|Procedure|urea method|Quarterly recirculation with urea method.
274456|NCT02110992|Radiation|Stereotactic Radiation|SBRT will be given over 5 fractions separated by > 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
274457|NCT02110979|Behavioral|Use of a PDA to assist shared decision making|
274366|NCT02111642|Other|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
274367|NCT02111629|Drug|Fluconazole and Secnidazole|
274368|NCT02111616|Behavioral|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
274369|NCT02111616|Behavioral|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
274370|NCT02111603|Drug|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
274371|NCT02111590|Drug|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
274372|NCT02111577|Biological|Dendritic Cells DCVAC|DCVAC is the experimental therapy
274373|NCT02111577|Biological|Placebo|DCVAC placebo is experimental vaccine placebo
274374|NCT02111577|Drug|Docetaxel|Docetaxel and prednisone is Standard of Care First Line Chemotherapy
274375|NCT02111577|Drug|Taxotere|
274376|NCT02111564|Drug|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening greater than or equal to (>=)50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
274377|NCT02111564|Drug|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from >=30 to less than (<)50 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
274378|NCT02111564|Drug|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
274379|NCT02111551|Drug|DMXB-A 150 mg|
274380|NCT02111551|Other|placebo|
274381|NCT02111551|Drug|DMXB-A 75 mg|
274382|NCT02111538|Other|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
274383|NCT02111512|Drug|Administration of Live attenuated influenza vaccine (LAIV)|
274384|NCT02111499|Drug|LAS41004-IMP1|daily topical application
274385|NCT02111499|Drug|LAS41004 IMP2|daily topical application
274386|NCT02111499|Drug|LAS41004 IMP3|daily topical application
274387|NCT02111499|Drug|LAS41004 IMP4|daily topical application
274388|NCT02111499|Drug|LAS41004 IMP6|daily topical application
274389|NCT02111499|Drug|LAS41004 IMP5|once daily, topical
274390|NCT02111486|Other|breakfast|
274391|NCT02111473|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
274392|NCT02111460|Radiation|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
274393|NCT02111447|Drug|Propofol|Propofol infusion with nasal oxygen
274394|NCT02111447|Drug|Propofol|Propofol infusion with an LMA
274395|NCT02111447|Drug|Sevoflurane|Sevoflurane with an LMA
274396|NCT02111447|Drug|Isoflurane|Isoflurane with an LMA
274397|NCT02111434|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
274398|NCT02111421|Drug|Dexmedetomidine 01|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
274399|NCT02111421|Drug|Dexmetomidine 02|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
274400|NCT02111382|Other|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.~When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.~The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
274401|NCT02111382|Other|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.~The CV4 sham will be performed by a registered physiotherapist."
274402|NCT02111369|Drug|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
274403|NCT02111369|Procedure|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
274404|NCT02111356|Device|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
274458|NCT02110966|Drug|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
274405|NCT02111343|Other|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.~Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
274406|NCT02111330|Drug|PBF-509|
274407|NCT02111330|Drug|Placebo|
274408|NCT02111317|Drug|ASP015K|oral
274409|NCT02111317|Drug|verapamil|oral
274410|NCT02111304|Drug|iOWH032|
274411|NCT02111291|Biological|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
274412|NCT02111291|Biological|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
274413|NCT02111278|Other|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
274414|NCT02111278|Other|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
274415|NCT02111278|Other|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
274416|NCT02111265|Drug|Remifentanil|"Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~Remifentanil is stopped before skin closure"
274417|NCT02111265|Drug|Cisatracurium|"Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.~Cisatracurium is stopped before skin closure."
274418|NCT02111265|Drug|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
274419|NCT02111265|Device|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
274420|NCT02111252|Drug|TAK-850|TAK-850 injection
274421|NCT02111239|Device|CTA|pelvic/abdominal CTA scan
274422|NCT02111239|Device|MRA|pelvic/abdominal MRA scan
274423|NCT02111226|Other|SMS text messaging|short message service
274424|NCT02111213|Behavioral|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
274425|NCT02111213|Behavioral|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
274426|NCT02111200|Drug|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
274427|NCT02111200|Drug|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
274428|NCT02111187|Drug|LDE225|Sonidegib was given as an oral drug at 800mg daily for 28 days prior to prostetoctomy
274429|NCT02111174|Device|Scrambler Therapy|
274430|NCT02111174|Device|Sham Therapy|
274431|NCT02111161|Drug|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
274432|NCT02111161|Drug|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
274433|NCT02111148|Procedure|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
274434|NCT02111148|Procedure|Nitrazine|Nitrazine detection in vaginal wash
274435|NCT02111148|Drug|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
274436|NCT02111135|Biological|b-OPV|
274437|NCT02111135|Biological|m-OPV2|
274438|NCT02111135|Biological|m-IPV HD|
274439|NCT02111135|Biological|t-IPV|
274440|NCT02111122|Drug|Sodium Oxybate|
274441|NCT02111109|Device|Side Stream Dark Field Microscopy|
274442|NCT02111096|Drug|LY2409021|Administered orally
274443|NCT02111096|Drug|Sitagliptin|Administered orally
274444|NCT02111096|Drug|Placebo|Administered orally
274445|NCT02111096|Drug|Metformin|Administered orally
274446|NCT02111096|Drug|Sulfonylurea|Administered orally
274447|NCT02111083|Biological|Insulin Lispro|LY275585 administered SC.
274448|NCT02111070|Biological|IL-YANG FLU Vaccine|0.5mL
274449|NCT02111044|Drug|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
274450|NCT02111044|Drug|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
274451|NCT02111044|Drug|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
274452|NCT02111044|Drug|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
274453|NCT02111018|Device|CytoSorb Device|
274459|NCT02110966|Drug|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
274460|NCT02110953|Combination Product|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
274461|NCT02110953|Procedure|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
274462|NCT02110940|Other|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.~Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
274463|NCT02110940|Other|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
274464|NCT02110927|Device|Transcutaneous microcurrent|Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
274465|NCT02110927|Device|Aerobic exercise|50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
274466|NCT02110914|Behavioral|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
274467|NCT02110901|Drug|PRT-201|
274468|NCT02110901|Drug|Placebo|
274469|NCT02110888|Device|Subcutaneous peripheral nerve stimulation|
274470|NCT02110888|Other|SCS Only|
274471|NCT02110862|Other|Transittime. Defecography|
274472|NCT02110849|Radiation|Proton|Proton Therapy for Prostate Cancer
274473|NCT02110836|Dietary Supplement|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
274474|NCT02110836|Dietary Supplement|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
274475|NCT02110810|Drug|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
274476|NCT02110810|Drug|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
274477|NCT02110797|Other|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
274478|NCT02110784|Drug|Eurartesim tablets|dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
274479|NCT02110771|Behavioral|GAÏA - facial affect recognition targeted|"2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).~The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage."
274480|NCT02110771|Behavioral|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
274481|NCT02110758|Other|Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track & coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track & coordinate care, and measure and improve performance.
274482|NCT02110745|Drug|Sevofluorane|Comparison of different induction drugs and techniques
274483|NCT02110745|Drug|Propofol|Comparison of different induction drugs and techniques
274484|NCT02110732|Dietary Supplement|Lactobacillus rhamnosus GG|
274485|NCT02110719|Drug|Celebrex|
274486|NCT02110719|Drug|Gabapentin|
274487|NCT02110719|Drug|IV acetaminophen|
274488|NCT02110719|Drug|oral acetaminophen|
274489|NCT02110719|Drug|oral ibuprofen|
274490|NCT02110719|Drug|percocet|
274491|NCT02110719|Drug|vicodin|
274492|NCT02110719|Drug|Oxycodone|
274493|NCT02110719|Drug|dilaudid|
274494|NCT02110719|Drug|Dexamethasone|
274495|NCT02110719|Drug|zofran|
274496|NCT02110706|Drug|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
274497|NCT02110706|Drug|Placebo|The placebo group will receive a vehicle control infusion
274498|NCT02110693|Other|Interviewer and tablet administration of the TAPS Tool|All participant will self-administer substance use screening instrument (TAPS Tool) on a tablet computer and will be administered the TAPS Tool by an interviewer.
274499|NCT02110680|Device|Sports TENS 2|transcutaneous electric stimulation
274500|NCT02110667|Device|Transperineal Ultrasound|
274501|NCT02110654|Drug|Montelukast|
274502|NCT02110654|Drug|mometasone furoate nasal spray|
274503|NCT02110641|Behavioral|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
274505|NCT02110628|Procedure|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
274506|NCT02110615|Other|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
274507|NCT02110602|Other|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
274508|NCT02110602|Other|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
274509|NCT02110589|Device|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
274510|NCT02110563|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.~Starting dose: 0.1mg/kg/dose~Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.~Number of cycles: until progression or unacceptable toxicity develops."
274511|NCT02110550|Other|IPS.emmax endocrown|
274512|NCT02110537|Procedure|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
274513|NCT02110537|Procedure|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
274514|NCT02110537|Drug|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
274515|NCT02110524|Device|Percutaneous Transluminal Angioplasty|
274516|NCT02110511|Other|blended lentils|blended lentils burritto breakfast
274517|NCT02110511|Other|whole lentils|whole lentils breakfast burritto
274518|NCT02110511|Other|no lentils|No lentils control breakfast burritto
274519|NCT02110485|Other|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
274520|NCT02110472|Device|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
274521|NCT02110459|Drug|POL7080|Intravenous infusion
274522|NCT02110446|Drug|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.~SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
274523|NCT02110446|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
274524|NCT02110433|Device|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
274525|NCT02110433|Device|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
274526|NCT02110433|Device|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP < 100 pg/ml or remaining stable (< 30% increase).
274527|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered as a single dose
274528|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered as a single dose
274529|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered as a single dose
274530|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered as a single dose
274531|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered as a single dose
274532|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered daily for 14 days
274533|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered daily for 14 days
274534|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered daily for 14 days
274535|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered daily for 14 days
274536|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered daily for 14 days
274537|NCT02110420|Drug|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
274538|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered as a single oral dose
274539|NCT02110420|Drug|CC-90001|CC-90001 720mg will be administered as a single oral dose
274540|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered daily for 14 days
274541|NCT02110407|Device|tDCS|transcranial direct current stimulation (tDCS)
274542|NCT02110407|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
274543|NCT02110394|Other|bendamustine|Routine practice
274544|NCT02110394|Other|rituximab|Routine practice
274545|NCT02110381|Device|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.~Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
274546|NCT02110381|Device|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.~Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
274547|NCT02110368|Drug|Testosterone Topical Gel, 1.62% Metered Pump|
274548|NCT02110368|Drug|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
274549|NCT02110355|Drug|AMG 232|Given as an oral tablet in escalating doses
274550|NCT02110355|Drug|Trametinib|Trametinib is an anti-cancer agent
274551|NCT02110355|Drug|Dabrafenib|Dabrafenib is an anti-cancer agent
274552|NCT02110342|Drug|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of [14C] PF-04449913
274553|NCT02110329|Genetic|evaluation of the recurrence rate according to molecular analysis|
274554|NCT02110316|Other|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
274555|NCT02110303|Drug|Ticagrelor|oral, 90mg tablets, twice daily, 12 month duration
274556|NCT02110303|Drug|Placebo|Oral tablet (identical to ticagrelor), twice daily, 12 month duration
274557|NCT02110277|Device|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
274558|NCT02110264|Drug|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
274559|NCT02110264|Behavioral|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
274560|NCT02110264|Behavioral|ETAU|Participants assigned to the ETAU group will receive drug education.
274561|NCT02110251|Behavioral|Supervised Exercise Therapy|
274562|NCT02110238|Device|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
274563|NCT02110238|Device|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
274564|NCT02110225|Drug|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
274565|NCT02110225|Drug|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
274566|NCT02110225|Drug|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
274567|NCT02110212|Procedure|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
274568|NCT02110212|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
274569|NCT02110186|Device|Dynamic Stabilization|
274570|NCT02110186|Procedure|Discectomy|
274571|NCT02110186|Device|Instrumentation and fusion|
274572|NCT02110147|Drug|uridine triacetate|
274573|NCT02110134|Device|Revlite Laser System|Revlite Laser System for the Treatment of Melasma
274574|NCT02110121|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
274575|NCT02110121|Device|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
274576|NCT02110108|Device|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
274577|NCT02110095|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
274578|NCT02110082|Biological|Urelumab|
274579|NCT02110082|Biological|Cetuximab|
274580|NCT02110069|Drug|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 months (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
274581|NCT02110069|Drug|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
274582|NCT02110056|Device|tDCS|transcranial direct current stimulation (tDCS)
274583|NCT02110056|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
274584|NCT02110043|Device|tDCS|transcranial direct current stimulation (tDCS)
274585|NCT02110043|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
274586|NCT02110030|Device|Transcutaneous nerve stimulation|"The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain."
274587|NCT02110030|Device|Interferential Currents|"The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain)."
274588|NCT02110017|Other|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
274589|NCT02110004|Procedure|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
274590|NCT02110004|Device|Picasso NAV Catheter|
274591|NCT02109991|Device|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
274592|NCT02109965|Drug|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
274593|NCT02109965|Drug|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
274594|NCT02109965|Drug|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
274595|NCT02109939|Genetic|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.~The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.~tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
274596|NCT02109926|Other|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
274597|NCT02109913|Drug|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
274598|NCT02109900|Other|Serum Progesterone Levels|
274599|NCT02109874|Biological|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
274600|NCT02109874|Biological|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
274601|NCT02109861|Drug|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
274602|NCT02109861|Drug|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
274603|NCT02109861|Drug|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
274604|NCT02109809|Radiation|total nodal irradiation|Undergo TLI
274605|NCT02109809|Other|laboratory biomarker analysis|Correlative studies
274606|NCT02109809|Other|questionnaire administration|Ancillary studies
274607|NCT02109796|Device|transcranial Direct current stimulation|
274608|NCT02109783|Dietary Supplement|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
274609|NCT02109783|Dietary Supplement|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
274610|NCT02109783|Dietary Supplement|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
274611|NCT02109757|Other|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
274612|NCT02109757|Other|Education only|
274613|NCT02109744|Drug|Decitabine|
274614|NCT02109731|Other|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
274615|NCT02109718|Drug|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
274616|NCT02109718|Drug|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
274617|NCT02109692|Other|blood sample|dosage of miRNA
274618|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
274619|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
274620|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
274621|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
274622|NCT02109666|Drug|Abatacept|
274623|NCT02109653|Drug|LGX818|Oral LGX818 300mg daily
274624|NCT02109640|Drug|Targinact|Post-operative analgesia
274625|NCT02109640|Drug|Oxycodone|Postoperative analgesia
274626|NCT02109640|Procedure|Laparoscopic segmental colectomy|
274627|NCT02109627|Drug|Ficlatuzumab|5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
274628|NCT02109627|Drug|Cytarabine|2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
274629|NCT02109614|Drug|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
274630|NCT02109614|Drug|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
274631|NCT02109601|Other|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
274632|NCT02109601|Other|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
274633|NCT02109588|Behavioral|A supervised physical exercise program|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
274634|NCT02109575|Diagnostic Test|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
274635|NCT02109562|Drug|RBP-7000|RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
274636|NCT02109562|Drug|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
274637|NCT02109562|Drug|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
274638|NCT02109536|Device|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
274639|NCT02109523|Behavioral|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
274640|NCT02109523|Behavioral|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
274641|NCT02109523|Behavioral|Routine discharge counseling|
274642|NCT02109510|Drug|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
274643|NCT02109510|Drug|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
274644|NCT02109510|Procedure|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
274645|NCT02109497|Drug|PBT2|PBT2 250 mg administered
274646|NCT02109484|Biological|P2-VP8 Subunit Vaccine 10mcg|10 mcg
274647|NCT02109484|Biological|P2-VP8 Subunit Vaccine 30 mcg|30 mcg
274648|NCT02109484|Biological|P2-VP8 Subunit Vaccine 60mcg|60 mcg
274649|NCT02109484|Other|Placebo|
274650|NCT02109458|Device|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
274651|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
274652|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
274653|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
274654|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
274655|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
274656|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
274657|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
274658|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
274659|NCT02109432|Behavioral|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
274660|NCT02109432|Behavioral|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
274661|NCT02109432|Behavioral|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
274662|NCT02109419|Other|HHT-G|Helping Hands Technology global cognitive function assessment
274663|NCT02109419|Other|HHT-D|Helping Hands Technology depression assessment
274664|NCT02109419|Other|Geriatric Depression Scale (DGS)|Geriatric Depression Scale (DGS)
274665|NCT02109419|Other|MMSE|Mini Mental State Exam
274666|NCT02109406|Drug|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
274667|NCT02109406|Drug|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
274668|NCT02109406|Drug|Placebo MDI|Placebo MDI administered as two inhalations BID
274718|NCT02109120|Procedure|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
274928|NCT02107430|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
274669|NCT02109393|Other|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.~All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
274670|NCT02109393|Other|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
274671|NCT02109380|Behavioral|Bed rest|
274672|NCT02109354|Biological|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of >1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
274673|NCT02109354|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
274674|NCT02109354|Biological|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
274675|NCT02109354|Biological|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
274676|NCT02109354|Biological|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
274677|NCT02109354|Biological|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
274678|NCT02109354|Biological|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
274679|NCT02109354|Biological|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
274680|NCT02109341|Drug|Paclitaxel bound albumine|
274681|NCT02109328|Drug|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.~In the randomized phase, Experimental arm will consist of the following drugs:~Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.~Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
274682|NCT02109328|Drug|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
274683|NCT02109328|Drug|Placebo|Placebo oral tablets
274684|NCT02109315|Drug|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
274685|NCT02109315|Drug|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
274686|NCT02109302|Procedure|Blood sample|
274687|NCT02109302|Procedure|Skin biopsy|
274688|NCT02109302|Other|Questionnaire|
274689|NCT02109289|Drug|etanercept|Etanercept is a tumor necrosis factor antagonist
274690|NCT02109276|Device|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
274691|NCT02109276|Device|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
274692|NCT02109263|Procedure|saccharose versus breast-feeding|saccharose versus breast-feeding
274693|NCT02109250|Drug|Caprelsa|Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
274694|NCT02109237|Procedure|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
274695|NCT02109224|Drug|Ibrutinib|Given PO
274696|NCT02109224|Other|Laboratory Biomarker Analysis|Correlative studies
274697|NCT02109224|Other|Pharmacological Study|Correlative studies
274698|NCT02109211|Device|Intubation with Magill forceps|
274699|NCT02109211|Device|Intubation with altered Magill forceps|
274700|NCT02109198|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
274701|NCT02109198|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
274702|NCT02109185|Drug|Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.|
274703|NCT02109185|Drug|Nasonex® Nasal Spray, 50 μg/actuation|
274704|NCT02109185|Drug|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|
274705|NCT02109185|Drug|Placebo Nasal Spray, 50 μL/actuation|
274706|NCT02109172|Drug|TD-4208|
274707|NCT02109172|Drug|Placebo|
274708|NCT02109159|Other|A short online video with emotional content|
274709|NCT02109159|Other|A short online video with less emotional content|
274710|NCT02109146|Drug|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization should be used in the experimental group
274711|NCT02109146|Other|No intervention No Transcatheter Arterial Chemoembolization|
274712|NCT02109133|Procedure|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
274713|NCT02109133|Procedure|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
274714|NCT02109133|Drug|Rocuronium|
274715|NCT02109133|Drug|Sugammadex|
274719|NCT02109107|Device|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
274720|NCT02109081|Drug|Dexamethasone|
274721|NCT02109081|Drug|Placebo|
274722|NCT02109068|Behavioral|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
274723|NCT02109068|Behavioral|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
274724|NCT02109055|Other|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
274725|NCT02109055|Other|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
274726|NCT02109042|Drug|Blosozumab|Administered subcutaneously
274727|NCT02109029|Drug|Insulin Peglispro|Administered IV
274728|NCT02109029|Drug|Human Insulin|Administered IV
274729|NCT02109016|Drug|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.~Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
274730|NCT02109003|Device|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
274731|NCT02109003|Device|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
274732|NCT02108990|Drug|Acetaminophen|
274733|NCT02108977|Other|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
274734|NCT02108977|Other|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
274735|NCT02108964|Drug|EGF816|EGF816 will be dosed once daily. On the first day of each treatment Cycle, the patient receives an adequate drug supply for self-administration at home. The investigator must emphasize compliance with the study treatment and will instruct the patient to take EGF816 exactly as prescribed.
274736|NCT02108951|Drug|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
274737|NCT02108925|Drug|Oxygen|supplementary oxygen during exercise
274738|NCT02108912|Other|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
274739|NCT02108912|Other|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
274740|NCT02108899|Behavioral|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.~In the second phase (initial test), they recall one text or restudy the other one.~In the third phase (final test) which takes place 2 days later, they recall both texts."
274741|NCT02108886|Drug|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
274742|NCT02108886|Drug|Placebo|empty capsule filled with sugar
274743|NCT02108886|Other|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
274744|NCT02108860|Drug|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
274745|NCT02108860|Drug|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
274746|NCT02108847|Drug|.2% Ropivacaine|
274747|NCT02108847|Drug|Saline|
274748|NCT02108847|Procedure|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
274749|NCT02108834|Procedure|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
274793|NCT02108535|Drug|Silver Sulphadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
274794|NCT02108522|Biological|Multivirus Specific T cells|
274929|NCT02107430|Radiation|Standard radiotherapy|radiotherapy
274750|NCT02108834|Procedure|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
274751|NCT02108821|Biological|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
274752|NCT02108808|Drug|Ticagrelor|
274753|NCT02108808|Drug|Prasugrel or Clopidogrel|
274754|NCT02108795|Drug|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
274755|NCT02108795|Drug|Placebo|
274756|NCT02108782|Drug|dovitinib lactate|Given PO
274757|NCT02108782|Other|pharmacological study|Correlative studies
274758|NCT02108782|Other|laboratory biomarker analysis|Correlative studies
274759|NCT02108769|Behavioral|Yogic Breathing|"Chanting Om~Sharp deep inhalation through nostrils~Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.~Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.~Yogic Breathing:~Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.~Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.~Hold breath in this position for about 16 seconds.~Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.~Go to step a)."
274760|NCT02108769|Behavioral|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
274761|NCT02108756|Drug|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
274762|NCT02108756|Drug|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
274763|NCT02108743|Drug|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
274764|NCT02108743|Drug|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
274765|NCT02108730|Procedure|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
274766|NCT02108717|Device|Remote CT reading using the iPhone|
274767|NCT02108717|Device|CT reading using LCD monitor|
274768|NCT02108704|Drug|Helicobacter pylori eradication therapy|
274769|NCT02108704|Drug|Placebo|
274770|NCT02108691|Dietary Supplement|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
274771|NCT02108691|Dietary Supplement|Placebo|Placebo (2.5g/day)
274772|NCT02108678|Behavioral|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
274773|NCT02108678|Behavioral|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
274774|NCT02108665|Radiation|Radiographic hysterosalpingography|
274775|NCT02108665|Radiation|Magnetic resonance imaging hysterosalpingography|
274776|NCT02108652|Drug|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
274777|NCT02108639|Drug|DCV 3DAA FDC|
274778|NCT02108639|Drug|BMS-791325|
274779|NCT02108626|Drug|Nicotine|E-Cigarette with nicotine cartridge
274780|NCT02108626|Drug|Placebo|E-Cigarette with 0mg nicotine cartridge
274781|NCT02108613|Behavioral|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
274782|NCT02108613|Behavioral|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
274783|NCT02108613|Behavioral|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
274784|NCT02108600|Drug|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
274785|NCT02108587|Device|optical coherence tomography|Undergo optical coherence tomography
274786|NCT02108574|Device|Placebo Filter|
274787|NCT02108574|Device|Rhinix Nasal Filter|
274788|NCT02108561|Other|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
274789|NCT02108548|Drug|ASP7657|oral
274790|NCT02108548|Drug|Placebo|oral
274791|NCT02108548|Drug|naproxen|oral
274792|NCT02108535|Drug|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
274839|NCT02108145|Procedure|unilateral metal stent insertion|
274976|NCT02107053|Dietary Supplement|PJ|
274795|NCT02108496|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
274796|NCT02108496|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
274797|NCT02108496|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
274798|NCT02108496|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
274799|NCT02108483|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
274800|NCT02108483|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
274801|NCT02108470|Other|Dental consultation using OHIP|The S-OHIP[M] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
274802|NCT02108457|Radiation|[18F]Fluorothymidine (FLT) PET/CT Imaging|
274803|NCT02108431|Device|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
274804|NCT02108431|Device|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
274805|NCT02108418|Drug|TG-2349 as the original formulation|single oral dose under fed condition
274806|NCT02108418|Drug|TG-2349 as a new capsule formulation|single oral dose under fed condition
274807|NCT02108379|Device|Rhinix Nasal Filters|
274808|NCT02108366|Drug|Celecoxib|Celecoxib 200mg daily
274809|NCT02108366|Drug|Oseltamivir|Oseltamivir 75mg bid
274810|NCT02108366|Drug|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
274811|NCT02108353|Drug|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
274812|NCT02108353|Drug|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
274813|NCT02108340|Procedure|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
274814|NCT02108327|Procedure|surgical blade|Using surgical blade all the time of surgery
274815|NCT02108327|Procedure|electrocautery|Using electrocautery all the time except at skin incision
274816|NCT02108314|Behavioral|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
274817|NCT02108301|Drug|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
274818|NCT02108288|Drug|OPC-1085EL ophthalmic solution|
274819|NCT02108288|Drug|Carteolol long-acting ophthalmic solution|
274820|NCT02108288|Drug|Latanoprost ophthalmic solution|
274821|NCT02108262|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
274822|NCT02108262|Biological|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
274823|NCT02108249|Device|Annex™ Adjacent Level System|
274824|NCT02108236|Device|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
274825|NCT02108223|Drug|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
274826|NCT02108223|Drug|r-LH supplementation|recombinant luteinizing hormone
274827|NCT02108223|Drug|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
274828|NCT02108210|Drug|Anakinra|
274829|NCT02108210|Drug|Placebo|
274830|NCT02108197|Device|Continuous positive airway pressure (S9, ResMed)|
274831|NCT02108184|Drug|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
274832|NCT02108184|Drug|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
274833|NCT02108184|Drug|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
274834|NCT02108184|Drug|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
274835|NCT02108171|Drug|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
274836|NCT02108171|Drug|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
274837|NCT02108158|Drug|Azzalure|
274838|NCT02108145|Procedure|bilateral metal stent insertion|
274840|NCT02108132|Biological|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
274841|NCT02108132|Biological|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
274842|NCT02108119|Dietary Supplement|Probiotics|
274843|NCT02108119|Dietary Supplement|Control placebo|
274844|NCT02108106|Drug|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
274845|NCT02108106|Drug|Placebo|
274846|NCT02108093|Procedure|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
274847|NCT02108015|Procedure|Brain Imaging (PET)|
274848|NCT02108015|Procedure|Aterial Line|
274849|NCT02108015|Procedure|Blood Sampling|
274850|NCT02108002|Drug|Vorinostat|
274851|NCT02107989|Device|MRI|MRI of the brain is routinely used to identify abnormal areas of cortex in patients with medically refractory epilepsy. MRI evaluations of brain may be performed at field strengths of 1.5 T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk.
274852|NCT02107989|Device|MEG|"MEG/EEG:~Magnetoencephalogra phy (MEG) is commonly used during epilepsy pre- surgical evaluations to help with localizing epileptic foci. MEG will be obtained as clinically indicated, usually in patients with unclear seizure focus localization who are undergoing presurgical evaluation, particularly when they have frequent interictal discharges on EEG. MEG records very small magnetic fields generated by the brain at rest, or in response to a task or to epileptic activity. Resting state MEG/EEG analysis will be used for research purposes only."
274853|NCT02107963|Biological|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
274854|NCT02107963|Drug|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
274855|NCT02107963|Drug|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
274856|NCT02107950|Biological|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
274857|NCT02107950|Drug|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
274858|NCT02107937|Biological|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
274859|NCT02107937|Biological|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
274860|NCT02107937|Drug|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
274861|NCT02107924|Procedure|APPI of TKR-Stimulan|
274862|NCT02107898|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
274863|NCT02107898|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
274864|NCT02107898|Drug|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
274865|NCT02107885|Drug|DS-1971|6 subjects in each group will receive DS-1971.
274866|NCT02107885|Drug|placebo|2 subjects in each group will receive placebo.
274867|NCT02107872|Drug|REGN1500|
274868|NCT02107872|Drug|placebo|
274869|NCT02107859|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (10-, 10-, and 20-mg/kg morning, midday and evening, respectively) for 192 weeks
274870|NCT02107846|Drug|PRX-112|
274871|NCT02107833|Drug|OPRX-106|
274872|NCT02107820|Behavioral|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
274873|NCT02107820|Device|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
274874|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
274875|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
274876|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
274877|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
274878|NCT02107794|Other|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
274879|NCT02107781|Device|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
274926|NCT02107443|Behavioral|Geriatric Assessment Targeted Recommendations|"Recommendations are made based on areas patients were impaired in on the Geriatric Assessment. They include referrals, tests, medication review, instructions, and support services. The choice of which recommendation to implement is left to the discretion of the physician.~Treatment modifications"
274927|NCT02107443|Behavioral|Geriatric Assessment (GA)|A GA measures the issues important to older patients, including function, psychological status, cognitive abilities, social support, and the impact of medical problems on quality of life.
274880|NCT02107768|Other|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .~Two fitness goals was to be achieved during the training session~1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.~2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
274881|NCT02107755|Biological|ipilimumab|Given IV
274882|NCT02107755|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
274883|NCT02107755|Other|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
274884|NCT02107742|Procedure|Normal speed lidocaine injection|30 seconds
274885|NCT02107742|Procedure|Slow lidocaine injection|speed 45 seconds
274886|NCT02107742|Procedure|Fast lidocaine injection|speed 15 seconds
274887|NCT02107729|Procedure|Large needle gauge lidocaine injection|21 G
274888|NCT02107729|Procedure|Normal needle gauge lidocaine injection|23 G
274889|NCT02107729|Procedure|Small needle gauge lidocaine injection|27 G
274890|NCT02107716|Procedure|Lidocaine injection with bicarbonate|bicarbonate added to change pH
274891|NCT02107716|Procedure|lidocaine injection|Lidocaine injection with pH unchanged
274892|NCT02107703|Drug|Abemaciclib|Administered Orally
274893|NCT02107703|Drug|Fulvestrant|Administered IM
274894|NCT02107703|Drug|Placebo|Administered Orally
274895|NCT02107690|Procedure|Low temperature lidocaine injection|4 °C
274896|NCT02107690|Procedure|Room temperature lidocaine injection|20 °C
274897|NCT02107690|Procedure|Body temperature lidocaine injection|37 °C
274898|NCT02107664|Radiation|Palliative RT for bone cancer pain|
274899|NCT02107638|Procedure|OMM treatment arm|"OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion."
274900|NCT02107638|Other|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
274901|NCT02107625|Behavioral|Diet A i.e. Low FODMAP diet|
274902|NCT02107625|Behavioral|Diet B, i.e. Traditional IBS diet|
274903|NCT02107612|Device|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
274904|NCT02107612|Other|Denture|
274905|NCT02107599|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
274906|NCT02107586|Procedure|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
274907|NCT02107586|Procedure|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
274908|NCT02107573|Procedure|Rotator Cuff Repair without Suprascapular Nerve decompression|Traditional rotator cuff repair without Suprascapular nerve decompression
274909|NCT02107573|Procedure|Rotator Cuff Repair with Suprascapular Nerve decompression|Traditional rotator cuff repair with Suprascapular nerve decompression
274910|NCT02107547|Procedure|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
274911|NCT02107547|Procedure|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
274912|NCT02107534|Behavioral|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
274913|NCT02107521|Other|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
274914|NCT02107521|Other|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
274915|NCT02107495|Device|Samsung LABGEO IVD-A20 CHF Test|
274916|NCT02107482|Device|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
274917|NCT02107482|Device|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
274918|NCT02107469|Drug|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
274919|NCT02107469|Drug|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
274920|NCT02107469|Drug|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
274921|NCT02107469|Drug|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
274922|NCT02107469|Other|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
274923|NCT02107469|Other|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
274924|NCT02107456|Device|Dry Needling|Dry needling was performed for one week, three times a week.
274925|NCT02107443|Behavioral|Geriatric Assessment Summary|Complete summary of results from the Geriatric Assessment
275045|NCT02106598|Drug|fluorescent cRGDY-PEG-Cy5.5-C dots|
274930|NCT02107417|Device|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
274931|NCT02107417|Device|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
274932|NCT02107404|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
274933|NCT02107391|Biological|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
274934|NCT02107391|Drug|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
274935|NCT02107391|Drug|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
274936|NCT02107378|Biological|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
274937|NCT02107378|Drug|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
274938|NCT02107365|Drug|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
274939|NCT02107365|Drug|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
274940|NCT02107365|Drug|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
274941|NCT02107365|Drug|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
274942|NCT02107339|Drug|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
274943|NCT02107339|Drug|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
274944|NCT02107326|Device|Webdia Software|
274945|NCT02107313|Drug|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
274946|NCT02107313|Drug|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
274947|NCT02107300|Drug|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
274948|NCT02107300|Drug|Placebo Comparator|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
274949|NCT02107287|Radiation|IMRT Technique|
274950|NCT02107274|Drug|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
274951|NCT02107274|Drug|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
274952|NCT02107261|Drug|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
274953|NCT02107248|Behavioral|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
274954|NCT02107248|Behavioral|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
274955|NCT02107235|Drug|oral rigosertib|
274956|NCT02107235|Drug|cisplatin|
274957|NCT02107235|Radiation|Radiotherapy|
274958|NCT02107222|Device|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
274959|NCT02107209|Procedure|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
274960|NCT02107196|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
274961|NCT02107196|Drug|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
274962|NCT02107183|Device|Optiflow (Fisher & Paykel Healthcare)|This device delivers high-flow oxygen through nasal cannula
274963|NCT02107183|Device|Venturi mask|This device delivers low-flow oxygen at predetermined concentrations
274964|NCT02107170|Drug|Sevoflurane|sevoflurane-based general anesthesia
274965|NCT02107170|Drug|Propofol|total intravenous anesthesia
274966|NCT02107170|Drug|Remifentanil|
274967|NCT02107157|Device|755nm Laser with Cap Array|
274968|NCT02107144|Drug|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
274969|NCT02107131|Drug|Intravitreal ranibizumab 0.3mg|
274970|NCT02107118|Biological|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
274971|NCT02107118|Other|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
274972|NCT02107105|Behavioral|Questionnaires|Questionnaires completed regarding participant's quality of life and utilities. Questionnaires completed before surgery for rectal cancer and at multiple time points after the completion of surgery.
274973|NCT02107092|Drug|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
274974|NCT02107079|Drug|Melatonin|swallowing 1 piece, collecting saliva afterwards
274975|NCT02107066|Behavioral|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
274977|NCT02107053|Drug|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
274978|NCT02107027|Device|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
274979|NCT02107027|Device|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).~A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
274980|NCT02107014|Drug|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
274981|NCT02107001|Procedure|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
274982|NCT02106988|Radiation|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
274983|NCT02106988|Drug|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
274984|NCT02106988|Drug|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
274985|NCT02106988|Drug|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
274986|NCT02106988|Drug|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
274987|NCT02106988|Drug|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
274988|NCT02106975|Drug|Ascorbic Acid|Intervention
274989|NCT02106975|Drug|Placebo: 5% Dextrose in water|Placebo
274990|NCT02106962|Drug|Topical Tranexamic Acid 5% with bacitracin|Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
274991|NCT02106962|Other|Topical Tranexamic Acid 25% with bacitracin|Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
274992|NCT02106949|Device|SMS contact with patient after discharge in intervention group|
274993|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
274994|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
274995|NCT02106923|Drug|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
274996|NCT02106923|Drug|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
274997|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
274998|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
274999|NCT02106910|Device|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
275000|NCT02106897|Drug|BIIB059|See Arm Descriptions
275001|NCT02106897|Drug|Placebo|See Arm Descriptions
275002|NCT02106884|Drug|Nab-paclitaxel|
275003|NCT02106884|Drug|Gemcitabine|
275004|NCT02106871|Drug|Sildenafil|50mg of Sildenafil daily for 4 weeks
275005|NCT02106858|Drug|Regorafenib (Stivarga,BAY73-4506)|Patients treated by Physician with Stivarga under approved local prescriptions
275006|NCT02106845|Drug|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
275007|NCT02106845|Drug|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
275008|NCT02106845|Drug|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
275009|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
275010|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
275011|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
275012|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
275013|NCT02106819|Behavioral|Testing of emotional communication ability|Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
275014|NCT02106819|Procedure|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
275015|NCT02106806|Dietary Supplement|Zinc|35 mg of elemental zinc twice daily for 16 weeks
275016|NCT02106806|Other|Placebo|One capsule, twice daily for 16 weeks
275017|NCT02106793|Drug|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
275018|NCT02106793|Drug|Identical placebo solution|Identical placebo solution
275019|NCT02106780|Drug|14C-labeled ASP1707|oral
275020|NCT02106767|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
275021|NCT02106767|Drug|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
275022|NCT02106754|Behavioral|Brief Intervention|
275023|NCT02106754|Behavioral|Brief Intervention with Coaching|
275024|NCT02106754|Behavioral|Treatment as Usual|
275025|NCT02106741|Behavioral|Relaxation acupressure|"The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
275026|NCT02106741|Behavioral|Stimulating acupressure|"The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).~A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.~Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
275027|NCT02106728|Behavioral|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
275028|NCT02106728|Behavioral|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
275029|NCT02106715|Other|Training|Two exercises for training of core stability and mobility.
275030|NCT02106702|Behavioral|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
275031|NCT02106702|Behavioral|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
275032|NCT02106689|Device|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
275033|NCT02106689|Device|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
275034|NCT02106663|Procedure|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
275035|NCT02106663|Procedure|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
275036|NCT02106650|Drug|Folotyn and Leucovorin|
275037|NCT02106650|Drug|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
275038|NCT02106650|Drug|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
275039|NCT02106637|Drug|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
275040|NCT02106637|Drug|placebo|placebo
275041|NCT02106624|Other|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
275042|NCT02106611|Other|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
275043|NCT02106611|Procedure|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
275044|NCT02106611|Procedure|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
275046|NCT02106585|Drug|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
275047|NCT02106572|Drug|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
275048|NCT02106572|Drug|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
275049|NCT02106559|Drug|porfimer sodium|Given IV
275050|NCT02106559|Procedure|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
275051|NCT02106559|Drug|photodynamic therapy|Undergo PDT
275052|NCT02106546|Drug|carboplatin|Intravenous infusion
275053|NCT02106546|Drug|veliparib|Oral Capsule
275054|NCT02106546|Drug|paclitaxel|Intravenous infusion
275055|NCT02106546|Drug|placebo|Oral Capsule
275056|NCT02106533|Other|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
275057|NCT02106520|Drug|Bevacizumab|
275058|NCT02106520|Drug|placebo|
275059|NCT02106507|Drug|apalutamide|apalutamide, 240 mg/day, oral
275060|NCT02106507|Drug|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
275061|NCT02106494|Drug|APF530|
275062|NCT02106494|Drug|Ondansetron|
275063|NCT02106494|Drug|Ondansetron placebo|
275064|NCT02106494|Drug|APF530 placebo|
275065|NCT02106494|Drug|Fosaprepitant|
275066|NCT02106494|Drug|Dexamethasone|
275067|NCT02106481|Drug|Femoral Nerve Catheters|"Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.~Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)"
275068|NCT02106481|Drug|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
275069|NCT02106468|Drug|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
275070|NCT02106468|Drug|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
275071|NCT02106455|Drug|Sodium risedronate|Sodium risedronate tablets
275072|NCT02106442|Drug|Sodium risedronate|Sodium risedronate tablets
275073|NCT02106416|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
275074|NCT02106403|Other|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
275075|NCT02106403|Other|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
275076|NCT02106403|Other|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
275077|NCT02106390|Biological|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
275078|NCT02106390|Biological|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
275079|NCT02106364|Drug|Insulin Peglispro|Administered SQ
275080|NCT02106364|Drug|Insulin Glargine|Administered SQ
275081|NCT02106351|Drug|AbobotulinumtoxinA|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
275082|NCT02106338|Other|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
275083|NCT02106338|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
275084|NCT02106325|Drug|Ketamine|IV of Ketamine (.25mg/kg)
275085|NCT02106325|Drug|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
275086|NCT02106312|Radiation|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
275087|NCT02106299|Device|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
275088|NCT02106299|Device|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
275089|NCT02106286|Drug|Bisoprolol|
275090|NCT02106273|Device|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
275091|NCT02106273|Device|LMA-ProsealTM|
275092|NCT02106260|Drug|CLS003|
275093|NCT02106247|Drug|BI 1181181 high dose|two tablet
275094|NCT02106247|Drug|BI 1181181 low dose|one tablet
275095|NCT02106247|Drug|Placebo|tablet
275096|NCT02106234|Other|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
275097|NCT02106221|Other|Intervention|Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
275098|NCT02106221|Other|Control|Will receive payments based on achievement in meeting goals.
275099|NCT02106208|Other|Cheese diet|
275100|NCT02106208|Other|Butter diet|
275101|NCT02106208|Other|CHO diet|
275102|NCT02106208|Other|MUFA diet|
275103|NCT02106208|Other|PUFA diet|
275104|NCT02106195|Drug|KD025|
275105|NCT02106182|Drug|Silodosin|
275106|NCT02106182|Other|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.~Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
275107|NCT02106182|Other|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
275108|NCT02106182|Other|12 weeks|
275109|NCT02106169|Behavioral|Therapeutic education group|
275110|NCT02106156|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
275111|NCT02106156|Drug|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
275112|NCT02106143|Device|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
275113|NCT02106130|Drug|Rebamipide|oral administration, 3 times/day
275114|NCT02106130|Drug|Mosapride citrate|oral administration, 3 times/day
275115|NCT02106104|Drug|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
275116|NCT02106104|Drug|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
275117|NCT02106091|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
275118|NCT02106078|Behavioral|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).~The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
275119|NCT02106078|Behavioral|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:~What is bipolar disorder? - Content about symptoms and diagnosis~Stress and triggers of illness~Medication and the biological basis of bipolar disorder~Depression - Symptoms, early detection and helpful strategies~Mania and hypomania - Symptoms, early detection and helpful strategies"
275120|NCT02106078|Behavioral|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
275121|NCT02106065|Behavioral|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
275122|NCT02106065|Other|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
275123|NCT02106052|Other|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
275124|NCT02106052|Other|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
275125|NCT02106039|Procedure|intensive monitoring|
275126|NCT02106026|Other|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
275127|NCT02106000|Device|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
275128|NCT02105987|Drug|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
275129|NCT02105987|Drug|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
275130|NCT02105974|Drug|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
275131|NCT02105974|Drug|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
275132|NCT02105961|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
275133|NCT02105961|Drug|Placebo|Sterile 0.9percent sodium chloride solution
275134|NCT02105948|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
275135|NCT02105948|Drug|Placebo|Sterile 0.9% sodium chloride solution
275136|NCT02105922|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
275137|NCT02105922|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
275138|NCT02105922|Procedure|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
275139|NCT02105909|Other|GWAS|
275140|NCT02105883|Other|Use of identification badge during scenarios|
275141|NCT02105870|Drug|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
275142|NCT02105857|Other|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
275143|NCT02105831|Other|Contrast ultrasound skeletal muscle perfusion imaging|1. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
275144|NCT02105805|Behavioral|Dietetic group sessions|Group sessions to improve dietary adherence
275145|NCT02105792|Drug|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
275146|NCT02105779|Other|Targeted Cognitive Training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
275147|NCT02105779|Other|Social Cognitive Training|We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
275148|NCT02105766|Drug|Alemtuzumab|Immunosuppressant
275149|NCT02105766|Drug|Sirolimus|Immunosuppressant
275150|NCT02105766|Drug|Cyclophosphamide|Immunosuppressant
275151|NCT02105766|Drug|Pentostatin|Immunosuppressant
275152|NCT02105766|Procedure|Radiotherapy|Immunosuppressant and myelosuppressant
275153|NCT02105753|Device|1210nm Diode Laser treatments|
275154|NCT02105740|Behavioral|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
275155|NCT02105740|Behavioral|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
275156|NCT02105727|Behavioral|Community-based salt reduction|
275157|NCT02105714|Procedure|Stool culturing for pathogenic bacteria|
275158|NCT02105714|Procedure|Kato-Katz technique|
275159|NCT02105714|Procedure|Baermann technique|
275160|NCT02105714|Device|Mini-FLOTAC|
275161|NCT02105714|Device|Crypto/Giardia Duo Strip|
275162|NCT02105714|Procedure|Formalin-ether concentration technique|
275163|NCT02105714|Device|CCA RDT|
275164|NCT02105714|Procedure|Koga agar plate culture|
275165|NCT02105714|Procedure|Kinyoun staining|
275166|NCT02105714|Device|Multiplex PCR|
275167|NCT02105714|Procedure|Metagenomics analysis|
275168|NCT02105701|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
275169|NCT02105701|Drug|Ribavirin|200 mg capsule
275170|NCT02105688|Drug|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
275266|NCT02104960|Other|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
275171|NCT02105688|Drug|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
275172|NCT02105675|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
275173|NCT02105675|Drug|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
275174|NCT02105662|Drug|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
275175|NCT02105649|Other|Strengthening exercise + Electrical stimulation of calf muscle|
275176|NCT02105649|Other|selected physical therapy program|
275177|NCT02105636|Drug|Nivolumab|
275178|NCT02105636|Drug|Cetuximab|
275179|NCT02105636|Drug|Methotrexate|
275180|NCT02105636|Drug|Docetaxel|
275181|NCT02105623|Behavioral|Standard Therapy|Risk factor control Diet Exercise for 24months
275182|NCT02105623|Drug|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
275183|NCT02105610|Drug|desflurane, isoflurane, sevoflurane|
275184|NCT02105610|Drug|total intravenous anesthetics|
275185|NCT02105597|Other|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
275186|NCT02105584|Device|Implantation of LAA closure device|
275187|NCT02105571|Behavioral|Intervention|
275188|NCT02105558|Drug|Epidural anesthesia|"￼An epidural involves injecting pain-blocking medication into a space between the vertebrae and the spinal fluid; it usually takes about 15 minutes to work.~Epidurals will be placed in a sterile fashion using a 17g Tuohy needle to locate the epidural space via loss-of-resistance to saline at the lumbar vertebral level. 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine will then be used for test dose to exclude intrathecal or intravenous placement of the catheter. Epidural solution composed of 5ml of 0.2% ropivacaine and another 5 ml of 0.2% ropivacaine will then be administered."
275189|NCT02105558|Drug|Combined spinal and epidural anesthesia|"A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes.~The epidural space will be located with a 17g Tuohy needle and dural puncture performed with 25g Pencan needle via needle-through-needle technique. Spinal injection of 2ml 0.2% ropivacaine will then be performed and spinal needle removed. An epidural catheter will then be placed and test dose performed with 3 ml of 1.5% lidocaine with 5ug/ml of epinephrine. Maintenance dose will be via an epidural pump using 0.2% ropivacaine at a rate of 12 ml/hr."
275190|NCT02105545|Other|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
275191|NCT02105532|Other|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
275192|NCT02105532|Other|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
275193|NCT02105519|Biological|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
275194|NCT02105506|Drug|Tachosil patch|
275195|NCT02105493|Drug|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
275196|NCT02105493|Drug|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
275197|NCT02105480|Device|Computer aided auscultation (CAA)|
275198|NCT02105467|Drug|Grazoprevir 100mg / Elbasvir 50 mg FDC|
275199|NCT02105467|Drug|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
275200|NCT02105454|Drug|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
275201|NCT02105454|Drug|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
275202|NCT02105454|Drug|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
275203|NCT02105441|Device|Cochlear implant|Implantable hearing device
275204|NCT02105428|Behavioral|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
275205|NCT02105415|Drug|Ketamine / Propofol Admixture|
275206|NCT02105415|Drug|Etomidate|
275207|NCT02105402|Behavioral|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
275208|NCT02105389|Behavioral|Individualized Yoga Intervention|
275209|NCT02105376|Device|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
275210|NCT02105363|Other|measure of skin movement on surface of the back|
275211|NCT02105363|Other|Measurement of skin movement on surface of back|
275212|NCT02105350|Drug|MEK 162|
275213|NCT02105350|Drug|Gemcitabine|
275214|NCT02105350|Drug|Oxaliplatin|
275215|NCT02105324|Device|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
275216|NCT02105324|Other|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
275217|NCT02105311|Device|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
275218|NCT02105311|Drug|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
275219|NCT02105285|Drug|OPC-1085EL ophthalmic solution|
275220|NCT02105285|Drug|Carteolol long-acting ophthalmic solution|
275221|NCT02105272|Drug|OPC-1085EL ophthalmic solution|
275222|NCT02105272|Drug|Latanoprost ophthalmic solution|
275223|NCT02105259|Behavioral|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
275224|NCT02105259|Other|Waiting list|Waiting list, where participants wait for delayed treatment
275225|NCT02105246|Behavioral|Referral to home-based cardiac rehab|Home-based cardiac rehab is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
275226|NCT02105246|Behavioral|Referral to center-based cardiac rehab|Center-based cardiac rehab is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
275227|NCT02105233|Biological|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
275228|NCT02105220|Other|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
275229|NCT02105207|Other|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
275230|NCT02105207|Other|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
275231|NCT02105194|Drug|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
275232|NCT02105181|Device|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
275233|NCT02105168|Procedure|Blood sample|Optional
275234|NCT02105168|Procedure|Tumorous biopsy|Optional
275235|NCT02105168|Procedure|Healthy material sample|Optional
275236|NCT02105155|Drug|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
275237|NCT02105155|Drug|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
275238|NCT02105142|Behavioral|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
275239|NCT02105142|Behavioral|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
275240|NCT02105142|Behavioral|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
275241|NCT02105129|Drug|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
275242|NCT02105129|Drug|Placebo|Oral administration
275243|NCT02105116|Drug|fludarabine phosphate|Given IV
275244|NCT02105116|Drug|cytarabine|Given IV
275245|NCT02105116|Biological|donor lymphocytes|Undergo infusion of donor lymphocytes
275246|NCT02105116|Other|laboratory biomarker analysis|Correlative studies
275247|NCT02105116|Drug|G-CSF|Given IV
275248|NCT02105103|Device|Accu-Chek® Insight Insulin Pump|A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
275249|NCT02105090|Drug|Anesthetics, Local|
275250|NCT02105090|Drug|Sodium Chloride 0.9%|
275251|NCT02105077|Drug|Anesthesia with inhalative application of xenon gas|
275252|NCT02105064|Device|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
275253|NCT02105064|Device|SHAM rTMS|Sham rTMS, without brain stimulation
275254|NCT02105038|Other|Spinner knob|
275255|NCT02105038|Other|No Knob|
275256|NCT02105012|Drug|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
275257|NCT02105012|Drug|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
275258|NCT02105012|Drug|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
275259|NCT02105012|Drug|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
275260|NCT02105012|Drug|Placebo MDI|Placebo MDI administered as 2 inhalations BID
275261|NCT02104999|Device|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
275262|NCT02104986|Drug|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
275263|NCT02104986|Drug|Vepeside-ifosfamide-Cisplatin|
275264|NCT02104973|Behavioral|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
275265|NCT02104960|Other|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
275316|NCT02104635|Behavioral|Delivery of a Post-Partum Package|
275267|NCT02104960|Other|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
275268|NCT02104947|Drug|idarucizumab|idarucizumab
275269|NCT02104934|Procedure|Adductor Canal Block|
275270|NCT02104908|Procedure|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
275271|NCT02104908|Procedure|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
275272|NCT02104895|Radiation|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
275273|NCT02104895|Radiation|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
275274|NCT02104882|Radiation|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
275275|NCT02104869|Biological|Trivalent influenza vaccine (inactivated and fragmented).|
275276|NCT02104856|Device|Alair System (Bronchial Thermoplasty)|
275277|NCT02104843|Drug|Daclatasvir, Asunaprevir and BMS-791325 FDC|
275278|NCT02104843|Drug|BMS-791325|
275279|NCT02104843|Drug|Rosuvastatin|
275280|NCT02104830|Biological|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
275281|NCT02104830|Biological|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
275282|NCT02104830|Biological|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
275283|NCT02104830|Biological|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
275284|NCT02104830|Biological|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
275285|NCT02104817|Drug|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
275286|NCT02104817|Drug|corn oil control|corn oil control arm
275287|NCT02104804|Drug|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
275288|NCT02104804|Drug|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
275289|NCT02104791|Drug|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
275290|NCT02104778|Drug|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
275291|NCT02104778|Drug|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
275292|NCT02104765|Drug|LY2951742|Administered subcutaneously.
275293|NCT02104765|Drug|Placebo|Administered subcutaneously.
275294|NCT02104752|Drug|Curcumin|360 mg/day (divided into twice daily oral doses)
275295|NCT02104752|Drug|Placebo|"Inactive, matched placebo (Sugar Pill)"
275296|NCT02104739|Drug|Exenatide|Single subcutaneous injection (10 mcg)
275297|NCT02104739|Drug|Saxagliptin|Single dose orally (5 mg)
275298|NCT02104739|Drug|Exenatide extended-release (ER)|Subcutaneous injection (2mg) weekly for 6 weeks
275299|NCT02104739|Other|Placebo|Placebo tablets and Placebo (normal saline) injections
275300|NCT02104726|Other|Fluoroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with fluoroscopy will deliver the steroid more accurately and see better outcomes.
275301|NCT02104726|Other|Blind Steroid Injection|Want to compare it to fluoroscopy guided, with assumption that it will be less effective in reducing pain
275302|NCT02104713|Biological|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose~Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.~Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.~Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.~Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.~Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
275303|NCT02104700|Drug|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
275304|NCT02104687|Procedure|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
275305|NCT02104687|Procedure|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
275306|NCT02104674|Drug|lebrikizumab|Given SC on Days 1, 29, and 57
275307|NCT02104674|Drug|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
275308|NCT02104674|Other|placebo|SC injection given on Days 1, 29, and 57
275309|NCT02104661|Drug|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
275310|NCT02104661|Drug|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
275311|NCT02104648|Other|Placebo RO4602522|Daily oral doses
275312|NCT02104648|Drug|RO4602522|Daily oral doses
275313|NCT02104648|Drug|RO4602522|Single, oral dose
275314|NCT02104648|Drug|moxifloxacin|400 mg oral dose given on Day 1 or 11
275315|NCT02104648|Other|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
275318|NCT02104609|Drug|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
275319|NCT02104596|Device|Xylitol|
275320|NCT02104583|Drug|Eleclazine|Eleclazine tablets administered orally
275321|NCT02104583|Drug|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
275322|NCT02104570|Other|Kinesio taping with tension|
275323|NCT02104570|Other|Kinesio taping without tension|
275324|NCT02104570|Other|Fatigue protocol|
275325|NCT02104557|Other|Non intervention|Non intervention
275326|NCT02104557|Other|Non intervention|Non intervention
275327|NCT02104505|Drug|Gamma Tocopherol 700 mg capsules,|2 capsules daily
275328|NCT02104505|Drug|Placebo|Safflower oil capsules
275329|NCT02104492|Other|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
275330|NCT02104492|Other|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
275331|NCT02104466|Procedure|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
275332|NCT02104453|Procedure|airway maneuver|"Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.~Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)"
275333|NCT02104440|Biological|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
275334|NCT02104427|Drug|TG-0054 combined with G-CSF|
275335|NCT02104414|Drug|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
275336|NCT02104414|Drug|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
275337|NCT02104414|Drug|Normal Saline|30mL Normal Saline
275338|NCT02104401|Device|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
275339|NCT02104388|Drug|SJP-0035 Ophthalmic Solution|
275340|NCT02104388|Drug|Vehicle of SJP-0035 Ophthalmic Solution|
275341|NCT02104375|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
275342|NCT02104362|Radiation|exclusive single-fraction irradiation|
275343|NCT02104349|Behavioral|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
275344|NCT02104336|Drug|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
275345|NCT02104323|Drug|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
275346|NCT02104310|Drug|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
275347|NCT02104297|Drug|deksmedetomidine|deksmedetomidine infused during operation 0.2 mcg/kg/hour
275348|NCT02104297|Drug|Remifentanil|Remifentanil infused during operation 0.2 mcg/kg/min
275349|NCT02104297|Drug|Saline|During operation saline infused equal volüme of deksmedetomidine and remifentanil
275350|NCT02104284|Procedure|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.~Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
275351|NCT02104271|Procedure|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
275352|NCT02104271|Procedure|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.~All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
275353|NCT02104258|Other|Physiotherapy ASPETAR|Standardized physiotherapy protocol
275354|NCT02104258|Other|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
275355|NCT02104245|Drug|Ciprofloxacin dispersion for inhalation|
275356|NCT02104245|Drug|Placebo|
275357|NCT02104232|Behavioral|THPP-I|
275358|NCT02104232|Behavioral|EUC|
275359|NCT02104193|Drug|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
275360|NCT02104193|Radiation|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
275361|NCT02104180|Device|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
275362|NCT02104180|Device|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
275363|NCT02104167|Device|ROIC interbody cage with VerteBRIDGE plating|
275364|NCT02104154|Device|Samsung LABGEO PT10 Hepatic Panel|
275365|NCT02104141|Device|ROIA Interbody Cage with VerteBRIDGE plating|
275366|NCT02104128|Drug|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
275367|NCT02104115|Other|MRI scanners|
275368|NCT02104115|Other|VAS Symptom scores|
275369|NCT02104102|Other|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
275370|NCT02104102|Other|Kinesiotherapy|Hands movements.
275371|NCT02104089|Device|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
275372|NCT02104076|Device|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
275373|NCT02104063|Procedure|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
275374|NCT02104050|Drug|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
275375|NCT02104050|Drug|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
275376|NCT02104037|Procedure|Lumbar puncture|
275377|NCT02104024|Other|Contrast Enhanced Ultrasound Scanning|
275378|NCT02104011|Drug|Propranolol|
275379|NCT02103998|Drug|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
275380|NCT02103998|Drug|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
275381|NCT02103985|Drug|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
275382|NCT02103972|Dietary Supplement|GM080|
275383|NCT02103972|Dietary Supplement|Maltodextrin|
275384|NCT02103959|Drug|CMX-2043|Slow bolus IV administration of CMX-2043
275385|NCT02103959|Drug|Placebo comparator|Slow bolus IV administration of PBS
275386|NCT02103946|Procedure|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
275387|NCT02103946|Procedure|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
275388|NCT02103907|Other|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
275559|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
275389|NCT02103894|Drug|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an [18F]MNI-777 PET imaging visit. For individuals with AD or CTE, [18F]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by [18F]florbetapir imaging) and tau protein uptake (measured by [18F]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, [123I]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
275390|NCT02103881|Drug|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
275391|NCT02103881|Drug|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
275392|NCT02103868|Behavioral|Tobacco Cessation Counseling|Doing group and personal counseling for tobacco cessation
275393|NCT02103855|Drug|Belatacept|
275394|NCT02103842|Drug|Omega-3 fatty acids|
275395|NCT02103829|Behavioral|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
275396|NCT02103829|Behavioral|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
275397|NCT02103829|Behavioral|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
275398|NCT02103816|Device|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
275399|NCT02103790|Device|Home NIV installation|
275400|NCT02103777|Drug|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
275401|NCT02103764|Drug|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
275402|NCT02103764|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
275403|NCT02103738|Other|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
275404|NCT02103725|Drug|pimecrolimus 10 mg/g cream|
275405|NCT02103725|Drug|Vehicle cream|
275406|NCT02103712|Other|Qualitative|
275407|NCT02103699|Drug|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
275408|NCT02103686|Drug|Lyrica|
275409|NCT02103686|Drug|Experimental drug|sustained release formulation of pregabalin
275410|NCT02103686|Dietary Supplement|High fat meal|
275411|NCT02103686|Dietary Supplement|fasted|
275412|NCT02103673|Drug|DAOIB|Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
275413|NCT02103673|Drug|Placebo|Intervention drug: placebo by mouth. Duration: 6 weeks
275414|NCT02103660|Drug|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
275415|NCT02103660|Drug|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
275416|NCT02103647|Drug|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
275417|NCT02103647|Drug|sustained release tablet|sustained release tablet
275418|NCT02103634|Device|NaF PET/MRI|
275419|NCT02103634|Device|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
275420|NCT02103634|Device|FDG PET/CT|
275421|NCT02103621|Behavioral|Unified Protocol (UP)|
275422|NCT02103621|Behavioral|Taper and Monitoring (TAP-M)|
275423|NCT02103608|Device|Glide|6 facial hair reduction treatments with the Glide device, two weeks apart.
275424|NCT02103595|Device|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
275425|NCT02103595|Device|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
275426|NCT02103582|Other|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
275427|NCT02103569|Drug|FDC of Daclatasvir, Asunaprevir and BMS-791325|
275428|NCT02103569|Drug|FDC of Norethindrone and Ethinyl Estradiol|
275429|NCT02103569|Drug|BMS-791325|
275430|NCT02103556|Other|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
275431|NCT02103556|Dietary Supplement|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
275432|NCT02103556|Dietary Supplement|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
275433|NCT02103543|Other|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
275434|NCT02103543|Procedure|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
275435|NCT02103543|Drug|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
275436|NCT02103530|Other|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
275437|NCT02103517|Dietary Supplement|Omega -3 fatty acids|Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
275438|NCT02103517|Dietary Supplement|Placebo: Corn oil|Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
275439|NCT02103504|Device|DePuy Attune posterior stabilized fixed bearing total knee replacement|
275440|NCT02103491|Dietary Supplement|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
275441|NCT02103491|Dietary Supplement|Placebo administration|
275442|NCT02103478|Drug|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
275443|NCT02103478|Drug|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
275444|NCT02103465|Drug|Rotigotine|transdermal patch
275445|NCT02103465|Drug|Placebo|transdermal patch
275446|NCT02103452|Procedure|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
275447|NCT02103439|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
275448|NCT02103439|Drug|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
275449|NCT02103426|Drug|ASP0113|intramuscular injection
275450|NCT02103426|Drug|Placebo|intramuscular injection
275451|NCT02103413|Device|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
275452|NCT02103413|Device|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
275453|NCT02103400|Other|Experimental group|Exercise Training Group
275454|NCT02103400|Other|Control group|Exercise control group
275455|NCT02103387|Behavioral|Cognitive Behavioral Training|Cognitive Behavioral Training [CBT] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
275456|NCT02103387|Behavioral|Relaxation Training|Relaxation Training [RT] (muscle relaxation, deep breathing, guided imagery, meditation)
275457|NCT02103387|Behavioral|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
275458|NCT02103374|Drug|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
275459|NCT02103374|Drug|Placebo|1 capsule lactose during 48 weeks
275460|NCT02103335|Drug|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
275461|NCT02103335|Drug|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
275462|NCT02103335|Drug|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
275463|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
275464|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
275465|NCT02103309|Device|Nelfilcon A contact lenses|
275466|NCT02103309|Device|Etafilcon A contact lenses|
275467|NCT02103296|Procedure|Drawing admission labs from cord blood|
275468|NCT02103296|Procedure|Drawing admission labs from infant blood|
275469|NCT02103283|Drug|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
275470|NCT02103270|Drug|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
275471|NCT02103270|Drug|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
275472|NCT02103270|Drug|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
275473|NCT02103257|Drug|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
275474|NCT02103257|Drug|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
275475|NCT02103244|Drug|Carboplatin|carboplatin will be dosed according to newly developed dosing algorithm.
275476|NCT02103218|Behavioral|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
275558|NCT02102646|Procedure|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
275477|NCT02103218|Behavioral|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
275478|NCT02103205|Dietary Supplement|Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin|
275479|NCT02103205|Dietary Supplement|Formula with low iron concentration (2mg/L) without lactoferrin|
275480|NCT02103205|Dietary Supplement|Formula with normal iron concentration (8 mg/L) without lactoferrin|
275481|NCT02103192|Other|Anti-Oxidant Drink|
275482|NCT02103179|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
275483|NCT02103166|Drug|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
275484|NCT02103166|Drug|Physiological serum|100 ml of physiological serum (0.9% NaCl).
275485|NCT02103153|Device|Picosure Laser System|
275486|NCT02103140|Behavioral|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
275487|NCT02103140|Behavioral|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
275488|NCT02103127|Device|755nm Alexandrite laser with lens array|
275489|NCT02103114|Drug|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:~Units required = ((100%- baseline ATIII level*%) X body weight)/1.4~expressed as a % normal level based on functional ATIII assay"
275490|NCT02103114|Other|Placebo|Normal saline placebo
275491|NCT02103101|Other|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
275492|NCT02103101|Genetic|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
275493|NCT02103088|Behavioral|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
275494|NCT02103075|Device|Neuromuscular electrical stimulation|All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
275495|NCT02103062|Drug|ABI-007|
275496|NCT02103049|Drug|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
275497|NCT02103036|Procedure|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
275498|NCT02103036|Procedure|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
275499|NCT02103036|Device|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.~Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
275500|NCT02103036|Device|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
275501|NCT02103023|Drug|Imiquimod ointment|5% 250mg imiquimod ointment
275502|NCT02103023|Drug|Aqueous cream|aqueous cream
275503|NCT02103023|Biological|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
275504|NCT02103023|Biological|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
275505|NCT02102984|Device|covered biliary stents|endoscopic placement of covered biliary stents
275506|NCT02102984|Device|uncovered biliary stents|endoscopic placement of uncovered biliary stents
275507|NCT02102971|Procedure|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
275508|NCT02102958|Behavioral|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
275509|NCT02102958|Behavioral|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
275510|NCT02102945|Procedure|Computed tomography perfusion|Computed tomography perfusion of the head
275511|NCT02102932|Drug|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
275512|NCT02102932|Drug|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
275513|NCT02102932|Drug|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
275514|NCT02102932|Drug|850 mg metformin|850mg metformin tablet
275515|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
275516|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
275517|NCT02102932|Drug|850 mg metformin|850 mg metformin
275518|NCT02102932|Drug|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
275519|NCT02102932|Drug|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
275520|NCT02102932|Drug|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
275521|NCT02102932|Drug|500 mg metformin|500 mg metformin
275522|NCT02102932|Drug|500 mg metformin|500 mg metformin
275523|NCT02102919|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
275524|NCT02102919|Device|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
275525|NCT02102919|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
275526|NCT02102919|Device|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
275527|NCT02102906|Procedure|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
275528|NCT02102880|Genetic|the polymerase chain reaction (PCR)|
275529|NCT02102854|Drug|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent & treat acute rejection in organ transplantation
275530|NCT02102841|Procedure|Skin biopsy|
275531|NCT02102841|Procedure|Skin suction blister|
275532|NCT02102841|Biological|Mantoux test|
275533|NCT02102828|Device|extended compression|Home use of extended compression therapy and aspirin
275534|NCT02102828|Other|Aspirin|standard therapy of aspirin
275535|NCT02102815|Drug|Dexamethasone|Dexamethasone 0.15mg/kg mixed with NSS up to 50 mL IV slowly push over 5 minutes
275536|NCT02102815|Drug|Normal saline|NSS 50 mL IV slowly push over 5 minutes
275537|NCT02102802|Drug|Low or Medium dose MDMA|Participants receiving 30 or 75 mg MDMA
275538|NCT02102802|Drug|Full dose MDMA|Participants receiving 125 mg MDMA
275539|NCT02102789|Drug|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
275540|NCT02102789|Drug|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.~This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
275541|NCT02102776|Procedure|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
275542|NCT02102776|Procedure|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
275543|NCT02102776|Procedure|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
275544|NCT02102776|Procedure|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
275545|NCT02102750|Drug|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
275546|NCT02102737|Drug|6-DIG|injection of 6-DIG
275547|NCT02102737|Procedure|clamp|hyperinsulinemic euglycemic clamp
275548|NCT02102724|Dietary Supplement|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
275549|NCT02102724|Dietary Supplement|Placebo|Gelcaps that contain 1 gram of oleic sunflower oil
275550|NCT02102711|Dietary Supplement|Vitamin A oral drops|
275551|NCT02102698|Drug|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
275552|NCT02102685|Procedure|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
275553|NCT02102685|Procedure|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
275554|NCT02102672|Drug|Trimetazidine|
275555|NCT02102659|Genetic|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
275556|NCT02102659|Genetic|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
275557|NCT02102646|Drug|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
275560|NCT02102633|Drug|Bosutinib|Bosutinib 500 mg orally
275561|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
275562|NCT02102620|Drug|Intra-articular injection with corticosteroid|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
275563|NCT02102620|Drug|Intra-articular injection with lidocaine|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
275564|NCT02102607|Other|age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
275565|NCT02102594|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
275566|NCT02102581|Procedure|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
275567|NCT02102555|Drug|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
275568|NCT02102555|Drug|placebo|placebo (IV normal saline)
275569|NCT02102529|Procedure|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
275570|NCT02102516|Drug|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing >=31.8 kg received 31.5 mg (1 spray/2 nostrils).~Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
275571|NCT02102503|Behavioral|Standard Treatment|
275572|NCT02102503|Behavioral|MI and Medication review|
275573|NCT02102490|Drug|Abemaciclib|Administered orally
275574|NCT02102477|Procedure|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
275575|NCT02102477|Other|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
275576|NCT02102464|Device|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
275577|NCT02102438|Drug|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.~After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
275578|NCT02102438|Drug|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
275579|NCT02102438|Drug|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
275580|NCT02102425|Procedure|Patients with or without bandage over exit site|
275581|NCT02102412|Biological|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
275582|NCT02102399|Behavioral|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
275583|NCT02102399|Behavioral|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
275584|NCT02102373|Device|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
275585|NCT02102360|Device|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
275586|NCT02102360|Device|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
275587|NCT02102347|Other|exercise|
275588|NCT02102347|Other|Phototherapy|
275589|NCT02102321|Drug|albendazole|
275590|NCT02102321|Drug|placebo|
275591|NCT02102308|Other|Exercise|Multicomponent exercise
275592|NCT02102308|Other|Education classes|
275593|NCT02102295|Drug|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
275594|NCT02102295|Drug|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
275595|NCT02102269|Device|actimove sling|
275596|NCT02102269|Device|shoulderlift|
275597|NCT02102256|Device|Auditory Brainstem Implant|
275598|NCT02102243|Drug|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
275599|NCT02102243|Drug|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
275674|NCT02101853|Drug|Vincristine Sulfate|Given IV
275776|NCT02101073|Biological|ALX-0061|single dose, intravenous
275600|NCT02102243|Drug|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
275601|NCT02102243|Procedure|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
275602|NCT02102243|Procedure|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
275603|NCT02102243|Procedure|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
275604|NCT02102243|Procedure|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
275605|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
275606|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)|This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
275607|NCT02102230|Behavioral|Desensitization Treatment for Insomnia|"This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing."
275608|NCT02102217|Procedure|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
275609|NCT02102204|Drug|Etelcalcetide|Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
275610|NCT02102191|Device|e-cigarette|smoking cigarette without tobacco
275611|NCT02102191|Device|cigarette|smoking cigarette with tobacco
275612|NCT02102178|Other|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.~The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
275613|NCT02102178|Other|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
275614|NCT02102178|Other|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.~Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
275615|NCT02102178|Other|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
275675|NCT02101840|Drug|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
275616|NCT02102165|Procedure|metastatic lesion biopsy|a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
275617|NCT02102152|Drug|Tobramycin|
275618|NCT02102139|Drug|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.~The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP > ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
275619|NCT02102139|Drug|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
275620|NCT02102126|Procedure|Renal denervation|
275621|NCT02102113|Drug|Placebo|placebo
275622|NCT02102113|Drug|Very Low Dose THC|Subjects will receive 0.010mg/kg.
275623|NCT02102113|Drug|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
275624|NCT02102100|Drug|nicotine|In each of 3 test sessions, subjects in each arm will receive a randomized sequence of three intravenous infusions (30 sec each), one hour apart. The infusions will consist of saline, nicotine (.25 mg / 70kg) and nicotine (0.5 mg / 70 kg). The randomized sequence will remain the same between test sessions for a given subject.
275625|NCT02102100|Drug|menthol|In each of 3 test sessions, subjects will take 6 inhalations from the study e-cigarette, one inhalation every 15 seconds, of the randomized menthol condition for that test session ust prior to each intravenous infusion. The menthol conditions are: 3.2% menthol, 0.5% menthol and tobacco-flavor only (0.0% menthol)
275626|NCT02102087|Device|Initial Specimen Diversion Device (ISDD)|
275627|NCT02102087|Device|Lab standard practice (LSP)|
275628|NCT02102061|Other|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
275629|NCT02102048|Drug|Atazanavir|
275630|NCT02102035|Procedure|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
275631|NCT02102022|Drug|ADI-PEG 20 plus modified FOLFOX6|
275632|NCT02102009|Dietary Supplement|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).~Time of intervention: 3 months."
275633|NCT02102009|Other|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
275634|NCT02101996|Other|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
275635|NCT02101983|Drug|Cytosine Arabinoside|
275636|NCT02101970|Dietary Supplement|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
275637|NCT02101970|Other|Placebo Capsule|
275638|NCT02101970|Other|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
275639|NCT02101957|Drug|RP103|
275640|NCT02101957|Drug|Placebo|
275641|NCT02101944|Drug|Carfilzomib|Given IV
275642|NCT02101944|Drug|Dexamethasone|Given IV
275643|NCT02101944|Other|Laboratory Biomarker Analysis|Correlative studies
275644|NCT02101944|Biological|Pelareorep|Given IV
275645|NCT02101931|Drug|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
275646|NCT02101918|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
275647|NCT02101918|Other|Laboratory Biomarker Analysis|Correlative studies
275648|NCT02101918|Biological|Ziv-Aflibercept|Given IV
275649|NCT02101905|Other|Laboratory Biomarker Analysis|Correlative studies
275650|NCT02101905|Drug|Lapatinib|Given PO
275651|NCT02101905|Drug|Lapatinib Ditosylate|Given PO
275652|NCT02101905|Other|Pharmacological Study|Correlative studies
275653|NCT02101905|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
275654|NCT02101892|Drug|Amitriptyline|per os, daily, evening
275655|NCT02101892|Drug|placebo|per os, daily, evening
275656|NCT02101866|Drug|Vapendavir 300 mg tablet|tablet - single dose
275657|NCT02101866|Drug|Vapendavir 132 mg capsules|2 capsules - single dose
275658|NCT02101853|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
275659|NCT02101853|Drug|Asparaginase|Given IM or IV
275660|NCT02101853|Biological|Blinatumomab|Given IV
275661|NCT02101853|Drug|Cyclophosphamide|Given IV
275662|NCT02101853|Drug|Cytarabine|Given IT and IV or SC
275663|NCT02101853|Drug|Dexamethasone|Given PO or IV
275664|NCT02101853|Drug|Etoposide|Given IV
275665|NCT02101853|Other|Laboratory Biomarker Analysis|Correlative studies
275666|NCT02101853|Drug|Leucovorin Calcium|Given IV or PO
275667|NCT02101853|Drug|Mercaptopurine|Given PO
275668|NCT02101853|Drug|Methotrexate|Given IT, IV, and PO
275669|NCT02101853|Drug|Mitoxantrone Hydrochloride|Given IV
275670|NCT02101853|Drug|Pegaspargase|Given IV
275671|NCT02101853|Other|Pharmacological Study|Correlative studies
275672|NCT02101853|Drug|Therapeutic Hydrocortisone|Given IT
275673|NCT02101853|Drug|Thioguanine|Given PO
275676|NCT02101840|Drug|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
275677|NCT02101840|Drug|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
275678|NCT02101814|Procedure|Roux-en-Y gastric bypass (bariatric surgery)|
275679|NCT02101801|Other|vegetables from fresh or recycled water|
275680|NCT02101801|Other|receives vegetables from fresh water or recycled waste water farms|
275681|NCT02101788|Drug|Letrozole|Given PO
275682|NCT02101788|Drug|Paclitaxel|Given IV
275683|NCT02101788|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
275684|NCT02101788|Other|Quality-of-Life Assessment|Ancillary studies
275685|NCT02101788|Drug|Tamoxifen|Given PO
275686|NCT02101788|Drug|Tamoxifen Citrate|Given PO
275687|NCT02101788|Drug|Topotecan|Given IV
275688|NCT02101788|Drug|Topotecan Hydrochloride|Given IV
275689|NCT02101788|Drug|Trametinib|Given PO
275690|NCT02101788|Drug|Trametinib Dimethyl Sulfoxide|Given PO
275691|NCT02101775|Drug|Adavosertib|Given PO
275692|NCT02101775|Drug|Gemcitabine Hydrochloride|Given IV
275693|NCT02101775|Other|Laboratory Biomarker Analysis|Correlative studies
275694|NCT02101775|Other|Pharmacological Study|Correlative studies
275695|NCT02101775|Other|Placebo|Given PO
275696|NCT02101775|Other|Questionnaire Administration|Ancillary studies
275697|NCT02101749|Biological|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
275698|NCT02101736|Drug|Cabozantinib|This is an open label Phase II clinical trial. For both cohorts, subjects will receive cabozantinib orally in continuous cycles. Each cycle is 28 days. In absence of progressive disease or dose limiting toxicity (DLT), subjects may continue therapy for a total of 12 cycles. Subjects with radiographic response (20% or greater reduction in tumor volume) at the end of 12 cycles can continue on therapy for up to an additional year. However, subjects who do not achieve 15% reduction in tumor volume after 8 cycles will be considered treatment failure and taken off study. Subjects will be carefully monitored for toxicities associated with cabozantinib.
275699|NCT02101723|Dietary Supplement|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
275700|NCT02101723|Dietary Supplement|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
275701|NCT02101723|Dietary Supplement|Placebo|Placebo powder without micronutrients
275702|NCT02101710|Drug|Elantan SR 60 mg|"Trade Name: Elantan~Active Substance: Isosorbide 5-mononitrate~Pharmaceutical form: Tablet~Concentration: 60 mg~Route of Administration: Oral administration"
275703|NCT02101710|Drug|Imdur SR 60 mg|"Trade Name: Elantan~Active Substance: Isosorbide 5-mononitrate~Pharmaceutical form: Tablet~Concentration: 60 mg~Route of Administration: Oral administration"
275704|NCT02101697|Behavioral|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.~Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.~Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.~Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.~Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
275705|NCT02101684|Drug|Orteronel 300mg BID|
275706|NCT02101658|Other|clinic-based weight measurements|
275707|NCT02101645|Procedure|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
275708|NCT02101645|Procedure|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
275709|NCT02101632|Dietary Supplement|Bee Venom Ointment|2 weeks
275710|NCT02101632|Other|Vaseline Ointment|2 weeks
275711|NCT02101606|Drug|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
275712|NCT02101593|Drug|ADI-PEG 20|
275713|NCT02101580|Drug|ADI-PEG 20|
275714|NCT02101567|Drug|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head|In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
275715|NCT02101567|Drug|Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv|In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
275716|NCT02101554|Drug|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
275717|NCT02101554|Drug|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
275718|NCT02101541|Procedure|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
275719|NCT02101515|Other|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
275720|NCT02101502|Other|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
275721|NCT02101489|Other|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
275722|NCT02101476|Drug|Percocet|10mg/650mg
275723|NCT02101476|Drug|Xartemis|15mg/650mg
275724|NCT02101463|Device|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
275725|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
275726|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
275727|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
275728|NCT02101450|Procedure|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
275729|NCT02101437|Procedure|miRNA within 24hr|miRNA within 24hr
275730|NCT02101437|Procedure|miRNA after 1 week|miRNA after 1 week
275731|NCT02101437|Procedure|miRNA after 1 month|miRNA after 1 month
275732|NCT02101411|Diagnostic Test|PRU(Platelet reactivity unit)|measure by VeryfyNow.
275733|NCT02101398|Device|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
275734|NCT02101398|Device|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
275735|NCT02101398|Device|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
275736|NCT02101398|Device|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
275737|NCT02101398|Device|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
275738|NCT02101385|Drug|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
275739|NCT02101385|Other|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
275740|NCT02101372|Behavioral|treatment as usual|case management
275741|NCT02101372|Behavioral|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
275742|NCT02101359|Drug|T2380|200 microlitres of T2380 will be administrated intracamerally
275743|NCT02101359|Drug|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
275744|NCT02101359|Drug|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
275745|NCT02101346|Dietary Supplement|Mixed High Fat Diet|Healthy, Round 1
275746|NCT02101346|Dietary Supplement|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
275747|NCT02101346|Dietary Supplement|Monounsaturated fat diet|Healthy, Round 1
275748|NCT02101346|Dietary Supplement|Polyunsaturated fat diet|Healthy, Round 1
275749|NCT02101346|Dietary Supplement|Triolein 13C|Healthy, Round 2
275750|NCT02101346|Dietary Supplement|Low fat|Healthy, Round 1
275751|NCT02101333|Drug|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
275752|NCT02101320|Device|TRECAM|using the camera during the surgery
275753|NCT02101294|Device|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout [actual home row placement order: asdeihotlrn], plus substitutions on the upper row [qwfgjyuk;p] and bottom row [zxcvb'm,.] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
275754|NCT02101294|Device|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
275755|NCT02101281|Drug|rhNGF 20 µg/mL|1 drop for each eye, twice daily for 28 day
275756|NCT02101281|Drug|rhNGF 4 µg/mL|1 drop each eye, twice daily for 28 day
275757|NCT02101268|Drug|Momelotinib|Momelotinib tablet administered orally once daily
275758|NCT02101268|Drug|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
275759|NCT02101255|Device|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation~Application on Day 0 and Day 360"
275760|NCT02101255|Device|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
275761|NCT02101229|Drug|Insulin, Asp(B28)-|"the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient"
275762|NCT02101216|Drug|Prurisol|Experimental Drug
275763|NCT02101216|Drug|Ziagen|Active comparator
275764|NCT02101203|Drug|Placebo|
275765|NCT02101203|Drug|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
275766|NCT02101190|Drug|BIA 9-1067|Opicapone, OPC
275767|NCT02101164|Biological|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
275768|NCT02101164|Drug|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
275769|NCT02101151|Dietary Supplement|Vitamin D3(cholecalciferol)|
275770|NCT02101138|Drug|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
275771|NCT02101125|Drug|BMS-986020|
275772|NCT02101125|Drug|Rosuvastatin|
275773|NCT02101112|Drug|Apixaban|
275774|NCT02101099|Device|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
275775|NCT02101086|Other|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
275777|NCT02101073|Biological|ALX-0061|single dose, subcutaneous
275778|NCT02101060|Other|exercise|16-week progressive aerobic and resistance exercise training
275779|NCT02101047|Drug|Phenylephrine|
275780|NCT02101034|Biological|Cetuximab|
275781|NCT02101034|Drug|PD 0332991|
275782|NCT02101021|Drug|Momelotinib|Tablet (s) administered orally once or twice daily
275783|NCT02101021|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
275784|NCT02101021|Drug|Nab-paclitaxel|Intravenously administered over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
275785|NCT02101021|Drug|Gemcitabine|Intravenously administered over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
275786|NCT02101008|Drug|disulfiram and chelated zinc|
275787|NCT02100995|Behavioral|Intervention Simultaneously Targeting Obesity and Pain|
275788|NCT02100995|Behavioral|Weight Loss/Weight Self-Management|
275789|NCT02100995|Behavioral|Chronic Pain Self-Management|
275790|NCT02100982|Other|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
275791|NCT02100982|Other|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
275792|NCT02100969|Drug|HIZENTRA ®|
275793|NCT02100956|Drug|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
275794|NCT02100956|Drug|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
275795|NCT02100930|Biological|Anti-GD2 3F8 Monoclonal Antibody|
275796|NCT02100930|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
275797|NCT02100930|Drug|oral isotretinoin|
275798|NCT02100917|Drug|DMB-3111|
275799|NCT02100917|Drug|trastuzumab|
275800|NCT02100904|Procedure|Radiofrequency ablation of fibroids|
275801|NCT02100904|Procedure|Myomectomy of fibroids|
275802|NCT02100891|Procedure|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
275803|NCT02100891|Drug|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
275804|NCT02100865|Device|Solar powered oxygen|
275805|NCT02100865|Device|Oxygen from cylinders|
275806|NCT02100852|Drug|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
275807|NCT02100839|Drug|AEM-28|Solution for injection
275808|NCT02100839|Drug|Normal Saline|0.9% saline for injection
275809|NCT02100826|Drug|Cephalexin|Administered orally.
275810|NCT02100813|Drug|LEO 43204|
275811|NCT02100813|Drug|Placebo|
275812|NCT02100800|Other|MR and CT measurements of emphysema quantification|
275813|NCT02100787|Other|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
275814|NCT02100761|Drug|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance <50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
275815|NCT02100748|Drug|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
275816|NCT02100748|Drug|Morphine|Morphine 4 mg will be administered every 4 hours
275817|NCT02100748|Drug|Placebo|Placebo will be administered every 4 hours
275818|NCT02100735|Other|Sedation protocol|Nursing driven sedation protocol
275819|NCT02100722|Procedure|FFR guided PCI|
275820|NCT02100722|Procedure|CABG|
275821|NCT02100709|Device|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
275822|NCT02100696|Drug|Etrozulimab|Participants will receive 105 mg etrolizumab administered by SC injection Q4W.
275823|NCT02100696|Drug|Placebo|Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.
275824|NCT02100683|Device|PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter < 4 mm.
275825|NCT02100670|Drug|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
275826|NCT02100670|Drug|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
275827|NCT02100670|Drug|3% menthol|To be applied four times daily for 10 days.
275828|NCT02100670|Drug|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
275829|NCT02100657|Drug|Plitidepsin|
275830|NCT02100657|Drug|Bortezomib|
275831|NCT02100657|Drug|Dexamethasone|
275878|NCT02100371|Drug|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
275879|NCT02100319|Drug|Azilsartan|Azilsartan tablets
275880|NCT02100306|Behavioral|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
276074|NCT02099058|Drug|Erlotinib|It is administered orally everyday.
275832|NCT02100644|Drug|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
275833|NCT02100631|Biological|PXVX0200|
275834|NCT02100631|Biological|Placebo|
275835|NCT02100618|Procedure|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
275836|NCT02100605|Device|Phytosun, decongestant, nasal spray|one time application of the nasal spray
275837|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
275838|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
275839|NCT02100579|Drug|Bupivacaine|10 ml of 0.25% bupivacaine
275840|NCT02100579|Drug|Preservative free normal saline|10 ml of preservative free normal saline
275841|NCT02100566|Behavioral|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
275842|NCT02100566|Behavioral|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
275843|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
275844|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
275845|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
275846|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
275847|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
275848|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
275849|NCT02100540|Drug|I placebo capsule|I placebo capsule
275850|NCT02100540|Drug|II RDC 0.3mg capsule|II RDC 0.3mg capsule
275851|NCT02100540|Drug|III RDC 0.6mg capsule|III RDC 0.6mg capsule
275852|NCT02100527|Drug|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
275853|NCT02100527|Drug|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
275854|NCT02100514|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
275855|NCT02100514|Other|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
275856|NCT02100488|Device|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
275857|NCT02100488|Other|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
275858|NCT02100475|Drug|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.~Dose individually adjusted."
275859|NCT02100475|Drug|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
275860|NCT02100462|Drug|Chlorthalidone 12.5 mg|
275861|NCT02100462|Drug|Hydrochlorothiazide 25 mg|
275862|NCT02100462|Drug|Aspirin 81 mg|
275863|NCT02100449|Other|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
275864|NCT02100449|Other|Lung ultrasound and Doppler (Day 0 and Day 3 to 5)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
275865|NCT02100436|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
275866|NCT02100423|Dietary Supplement|curcumin|Given PO
275867|NCT02100423|Dietary Supplement|cholecalciferol|Given PO
275868|NCT02100423|Other|laboratory biomarker analysis|Correlative studies
275869|NCT02100423|Other|pharmacological study|Correlative studies
275870|NCT02100410|Device|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
275871|NCT02100410|Device|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
275872|NCT02100410|Device|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
275873|NCT02100410|Device|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
275874|NCT02100410|Device|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
275875|NCT02100410|Device|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
275876|NCT02100397|Biological|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
275877|NCT02100384|Procedure|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
275881|NCT02100306|Behavioral|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
275882|NCT02100293|Drug|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
275883|NCT02100293|Drug|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
275884|NCT02100280|Drug|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
275885|NCT02100267|Drug|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
275886|NCT02100254|Behavioral|behavioral intervention|View personal narrative informational video
275887|NCT02100254|Behavioral|behavioral intervention|View fact-based informational video
275888|NCT02100241|Procedure|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
275889|NCT02100228|Drug|Apixaban|Oral, 2.5 or 5 mg BID
275890|NCT02100228|Drug|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
275891|NCT02100215|Other|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
275892|NCT02100215|Other|Expert Modeling|70 minutes of expert modeling videos
275893|NCT02100215|Other|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
275894|NCT02100202|Other|Placebo|
275895|NCT02100202|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
275896|NCT02100202|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
275897|NCT02100202|Dietary Supplement|MaQxan (Tagetes erecta flower extract)|
275898|NCT02100189|Other|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
275899|NCT02100189|Procedure|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
275900|NCT02100189|Other|Laboratory Biomarker Analysis|Correlative studies
275901|NCT02100176|Other|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
275902|NCT02100176|Drug|Rotigotine|Rotigotine 2-8 mg/24 h
275903|NCT02100163|Behavioral|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
275904|NCT02100163|Behavioral|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
275905|NCT02100163|Other|Standard treatment|
275906|NCT02100150|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
275907|NCT02100150|Drug|Placebo|Strawberry flavored solution 0.5% v/v in Water for Injection
275908|NCT02100137|Other|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
275909|NCT02100124|Behavioral|Reproductive Life Planning (RLP)|
275910|NCT02100124|Behavioral|Contraceptive Action Planning|
275911|NCT02100124|Behavioral|Contraception information|
275912|NCT02100085|Biological|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
275913|NCT02100072|Device|Nd:YAG 1440 nm laser|
275914|NCT02100059|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
275915|NCT02100046|Drug|Zarontin® (ethosuximide) and Stodal®|
275916|NCT02100033|Device|acupuncture|
275917|NCT02100020|Other|Direct Referral to physical activity|Participants randomized to the Direct Referral to Physical Activity Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
275918|NCT02100007|Drug|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
275919|NCT02100007|Drug|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
275920|NCT02099994|Biological|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
275921|NCT02099994|Biological|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
275922|NCT02099994|Biological|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
275923|NCT02099994|Biological|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
275924|NCT02099981|Drug|Aminoguanidine|
275925|NCT02099968|Behavioral|Comprehensive Lifestyle Modification|"Fasting (1st week), followed by:~Vegetarian and modified DASH diet (plant-based, low-salt)~Aerobic exercise~Stress reduction techniques: progressive muscle relaxation, meditation, yoga"
275978|NCT02099500|Procedure|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
275926|NCT02099968|Behavioral|Standard Lifestyle Modification / modified DASH|"Modified DASH (vegetarian focused, plant-based, low-salt)~Aerobic exercise~Stress reduction techniques: progressive muscle relaxation"
275927|NCT02099955|Drug|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
275928|NCT02099942|Device|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:~as stand-alone intervention~as a bridge to transcatheter aortic valve replacement (TAVR)~as a bridge to surgical aortic valve replacement (SAVR)~as an intraprocedural predilatation prior to TAVR"
275929|NCT02099929|Other|Coffee with Sugar|300mL of Coffee with 30g of Sugar
275930|NCT02099929|Other|Coffee without Sugar|300mL of Coffee without Sugar
275931|NCT02099929|Other|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
275932|NCT02099929|Other|Water with Sugar|300mL of Water with 30g of Sugar
275933|NCT02099929|Other|Water without Sugar|300mL of Water without Sugar
275934|NCT02099916|Drug|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
275935|NCT02099916|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
275936|NCT02099903|Device|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
275937|NCT02099890|Dietary Supplement|Omega-3|
275938|NCT02099890|Dietary Supplement|Vegetation Protein Powder|
275939|NCT02099890|Dietary Supplement|InflanNox|
275940|NCT02099890|Dietary Supplement|Anti-oxidant Network|
275941|NCT02099890|Dietary Supplement|Chlorella|
275942|NCT02099877|Drug|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
275943|NCT02099864|Drug|Enzalutamide|Given PO
275944|NCT02099864|Other|Laboratory Biomarker Analysis|Correlative studies
275945|NCT02099851|Device|Carotid body ablation (Cibiem)|
275946|NCT02099838|Drug|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
275947|NCT02099838|Drug|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
275948|NCT02099825|Drug|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
275949|NCT02099799|Behavioral|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
275950|NCT02099786|Other|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
275951|NCT02099786|Other|Standard of care|Hearing testing done in the audiology clinic after oncology referral or patient self referral
275952|NCT02099760|Device|STD testing (GC/Ct/trich)|
275953|NCT02099747|Drug|hATG|
275954|NCT02099747|Drug|CsA|
275955|NCT02099747|Drug|Eltrombopag|
275956|NCT02099734|Behavioral|Questionnaires|
275957|NCT02099734|Other|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
275958|NCT02099721|Device|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
275959|NCT02099708|Drug|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
275960|NCT02099695|Drug|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
275961|NCT02099695|Drug|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
275962|NCT02099682|Drug|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
275963|NCT02099669|Other|Red Blood Cell Transfusions|
275964|NCT02099656|Drug|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
275965|NCT02099656|Drug|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
275966|NCT02099656|Drug|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
275967|NCT02099656|Drug|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
275968|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent|
275969|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent|
275970|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent|
275971|NCT02099604|Drug|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
275972|NCT02099591|Drug|Naloxegol|Opioid Antagonist
275973|NCT02099578|Dietary Supplement|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
275974|NCT02099578|Dietary Supplement|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
275975|NCT02099578|Dietary Supplement|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
275976|NCT02099539|Biological|ALT-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
275977|NCT02099513|Device|The Mobile Health Platform|
276075|NCT02099045|Device|Point of Care Ultrasonography|
275979|NCT02099500|Other|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
275980|NCT02099487|Radiation|Radiation|hypofractionated IMRT
275981|NCT02099474|Other|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
275982|NCT02099461|Drug|Denosumab|Single sucutaneous dose
275983|NCT02099461|Procedure|Percutaneous core needle breast biopsy|
275984|NCT02099435|Device|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
275985|NCT02099409|Device|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
275986|NCT02099396|Drug|Docetaxel+lobaplatin|
275987|NCT02099396|Drug|Gemcitabine+lobaplatin|
275988|NCT02099383|Other|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
275989|NCT02099357|Dietary Supplement|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
275990|NCT02099357|Dietary Supplement|Placebo|
275991|NCT02099357|Dietary Supplement|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
275992|NCT02099344|Device|Artegraft|Surgical placement of graft for hemodialysis access
275993|NCT02099344|Device|Propaten|Surgical placement of graft for hemodialysis access
275994|NCT02099331|Drug|Melatonin|
275995|NCT02099331|Drug|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
275996|NCT02099318|Other|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
275997|NCT02099318|Other|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
275998|NCT02099305|Other|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
275999|NCT02099292|Drug|Rituximab and DexaBEAM|combination treatment
276000|NCT02099279|Device|echocardiography examination|patients underwent echocardiography examination
276001|NCT02099266|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
276002|NCT02099253|Drug|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
276003|NCT02099253|Drug|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
276004|NCT02099240|Drug|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
276005|NCT02099240|Procedure|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
276006|NCT02099214|Device|3Tesla cardiac MRI|
276007|NCT02099214|Device|Electrocardiogram (EKG)|
276008|NCT02099214|Biological|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
276009|NCT02099214|Biological|Pregnancy test|Beta-hCG
276010|NCT02099214|Device|Echocardiography at rest|Transthoracic echocardiograph
276011|NCT02099214|Biological|Urinary pregnancy test|
276012|NCT02099214|Device|3Tesla abdominal MRI|
276013|NCT02099201|Drug|ACT-389949 40 mg|
276014|NCT02099201|Drug|ACT-389949 200 mg|Predicted dose
276015|NCT02099201|Drug|ACT-389949 800 mg|Predicted dose
276016|NCT02099201|Drug|ACT-389949 (Group C1 dose to be selected)|
276017|NCT02099201|Drug|ACT-389949 (Group C2 dose to be selected)|
276018|NCT02099201|Drug|Placebo|
276019|NCT02099188|Drug|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
276020|NCT02099188|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
276021|NCT02099188|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
276022|NCT02099188|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
276023|NCT02099188|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
276024|NCT02099188|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
276025|NCT02099188|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
276026|NCT02099188|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
276027|NCT02099188|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
276072|NCT02099058|Drug|ABBV-399|It is administered by infusion in 21-day dosing cycles.
276073|NCT02099058|Drug|ABBV-399|It is administered by infusion in 28-day dosing cycles.
276028|NCT02099188|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
276029|NCT02099175|Drug|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
276030|NCT02099175|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
276031|NCT02099175|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
276032|NCT02099175|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
276033|NCT02099175|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
276034|NCT02099175|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
276035|NCT02099175|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
276036|NCT02099175|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"Particle boost with ENI:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost with ENI:~HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
276037|NCT02099175|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.~Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
276038|NCT02099175|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.~Particle boost:~HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.~Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed.~Concomitant chemotherapy will be administered only in case of radiotherapy with photon beams exclusively."
276039|NCT02099162|Device|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
276040|NCT02099136|Procedure|UV Light Therapy|Undergo UV-irradiation
276041|NCT02099136|Other|Placebo|Given PO
276042|NCT02099136|Drug|Celecoxib|Given PO
276043|NCT02099136|Procedure|Biopsy|Undergo skin biopsy
276044|NCT02099136|Other|Imaging Biomarker Analysis|Correlative studies
276045|NCT02099123|Drug|Atorvastatin|Atorvastatin 20 mg tablet
276046|NCT02099123|Drug|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
276047|NCT02099110|Drug|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
276048|NCT02099110|Drug|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
276049|NCT02099110|Drug|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
276050|NCT02099110|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
276051|NCT02099110|Drug|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
276052|NCT02099110|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
276053|NCT02099110|Drug|Metformin >= 1500 mg/day|Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
276054|NCT02099110|Biological|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
276055|NCT02099110|Drug|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
276056|NCT02099097|Other|web-based video game (Quit IT)|
276057|NCT02099097|Behavioral|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
276058|NCT02099097|Other|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
276059|NCT02099084|Drug|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
276060|NCT02099084|Drug|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
276061|NCT02099071|Drug|ACT-389949 1 mg|
276062|NCT02099071|Drug|ACT-389949 5 mg|
276063|NCT02099071|Drug|ACT-389949 20 mg|
276064|NCT02099071|Drug|ACT-389949 50 mg|
276065|NCT02099071|Drug|ACT-389949 100 mg|
276066|NCT02099071|Drug|ACT-389949 200 mg|
276067|NCT02099071|Drug|ACT-389949 500 mg|
276068|NCT02099071|Drug|ACT-389949 1000 mg|
276069|NCT02099071|Drug|Placebo|
276070|NCT02099058|Drug|Osimertinib|It is administered orally everyday.
276071|NCT02099058|Drug|Nivolumab|It is an intravenous infusion administered every 14 days.
276076|NCT02099032|Other|3g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
276077|NCT02099032|Other|5g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
276078|NCT02099032|Other|Unfortified cheese product consumption|Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
276079|NCT02099006|Drug|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
276080|NCT02099006|Drug|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
276081|NCT02099006|Drug|Ketoprofen|To be applied topically at a 10% concentration
276082|NCT02099006|Drug|Ketamine|To be applied topically at a 10% concentration
276083|NCT02099006|Drug|Loperamide|To be applied topically at a 5% concentration
276084|NCT02099006|Drug|Gabapentin|To be applied topically at a 6% concentration
276085|NCT02099006|Drug|placebo|Compounding base to be used alone as a placebo
276086|NCT02098993|Drug|Unfractionated heparin|
276087|NCT02098980|Dietary Supplement|Vitamin D|
276088|NCT02098967|Drug|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
276089|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
276090|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose </= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
276091|NCT02098954|Drug|Gemcitabine platinum combined with erlotinib|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.
276092|NCT02098928|Behavioral|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
276093|NCT02098928|Device|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
276094|NCT02098915|Drug|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
276095|NCT02098915|Other|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
276096|NCT02098902|Behavioral|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
276097|NCT02098889|Drug|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
276098|NCT02098889|Drug|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
276099|NCT02098876|Device|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
276100|NCT02098876|Device|Xience Xpedition everolimus eluting stent|PCI with Xience stent
276101|NCT02098837|Drug|Dolutegravir|Dolutegravir 50mg once daily
276102|NCT02098824|Drug|Galantamine|Single administration of capsule containing 16 mg of Galantamine
276103|NCT02098824|Drug|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
276104|NCT02098824|Drug|Placebo|Single administration of capsule containing placebo
276105|NCT02098811|Device|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
276106|NCT02098811|Device|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
276107|NCT02098798|Procedure|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
276108|NCT02098798|Procedure|HD Colonoscopy + iSCAN|
276109|NCT02098798|Procedure|HD Colonoscopy + dye spray|
276110|NCT02098785|Drug|Caffeine citrate|Oral solution
276111|NCT02098772|Drug|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
276112|NCT02098772|Drug|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
276113|NCT02098759|Device|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
276114|NCT02098746|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
276115|NCT02098733|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
276116|NCT02098720|Drug|Conbercept|
276117|NCT02098707|Other|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
276145|NCT02098499|Drug|Diphenhydramine|25mg IV
276146|NCT02098486|Drug|Moxifloxacin|
276118|NCT02098694|Other|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.~Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
276119|NCT02098668|Other|Fertility treatment|Fertility treatment
276120|NCT02098655|Other|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
276121|NCT02098642|Other|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
276122|NCT02098642|Other|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
276123|NCT02098629|Drug|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
276124|NCT02098629|Drug|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.~Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
276125|NCT02098629|Drug|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
276126|NCT02098616|Drug|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
276127|NCT02098616|Drug|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
276128|NCT02098603|Behavioral|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
276129|NCT02098590|Biological|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
276130|NCT02098590|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
276131|NCT02098590|Biological|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
276132|NCT02098590|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
276133|NCT02098590|Drug|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
276134|NCT02098577|Other|Crossover|Crossover cycle
276135|NCT02098577|Other|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
276136|NCT02098564|Other|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
276137|NCT02098564|Other|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
276138|NCT02098551|Other|SPT and APT|"All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.~Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone."
276139|NCT02098538|Drug|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
276140|NCT02098512|Drug|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:~42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1~84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1~105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
276141|NCT02098512|Procedure|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
276142|NCT02098512|Drug|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
276143|NCT02098499|Drug|Haloperidol|5mg IV
276144|NCT02098499|Drug|Metoclopramide 10mg|10mg IV
276150|NCT02098460|Drug|Atorvastatin, Probucol, Cilostazol|
276151|NCT02098447|Device|PrimeStim|
276152|NCT02098434|Behavioral|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
276153|NCT02098421|Drug|Oxytocin|Use of oxytocin while the Foley bulb is in place
276154|NCT02098408|Behavioral|Cognitive remediation|"Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.~The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients."
276155|NCT02098408|Behavioral|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
276156|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
276157|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
276158|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
276159|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
276160|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
276161|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
276162|NCT02098382|Device|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
276163|NCT02098369|Behavioral|Written education material (basic)|Education material on COPD distributed to all participants.
276164|NCT02098369|Behavioral|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
276165|NCT02098369|Behavioral|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
276166|NCT02098369|Behavioral|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
276167|NCT02098356|Other|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
276168|NCT02098343|Drug|APR-246|Intravenous infusion.
276169|NCT02098343|Drug|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
276170|NCT02098330|Drug|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
276171|NCT02098330|Drug|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
276172|NCT02098317|Drug|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
276173|NCT02098317|Drug|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
276174|NCT02098304|Device|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
276175|NCT02098291|Drug|G17DT|
276176|NCT02098278|Drug|CAT-2003|
276177|NCT02098278|Drug|Placebo|
276178|NCT02098265|Device|Functional Electric Stimulation (FES)|FES uses low energy electrical pulses to artificially generate body movements in individuals with muscle paralysis. FES can be used to generate muscle contraction in otherwise paralyzed limbs to restore function.
276179|NCT02098265|Behavioral|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
276180|NCT02098265|Other|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
276181|NCT02098265|Other|EEG|EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
276182|NCT02098265|Other|RecoveriX|RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
276183|NCT02098265|Other|Delay|10 week delay before intervention
276184|NCT02098265|Device|BCI-FES|
276185|NCT02098252|Procedure|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
276186|NCT02098252|Radiation|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
276187|NCT02098252|Procedure|Embolization|Curative embolization, when the lesion is considered curable by embolization.
276188|NCT02098239|Drug|G17DT|
276189|NCT02098213|Other|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
276190|NCT02098213|Other|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
276191|NCT02098200|Device|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
276192|NCT02098187|Drug|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
276193|NCT02098187|Drug|At target dose MP-3180|MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
276194|NCT02098187|Drug|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
276195|NCT02098187|Drug|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
276196|NCT02098187|Device|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
276197|NCT02098187|Other|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
276198|NCT02098174|Drug|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
276199|NCT02098174|Other|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
276200|NCT02098161|Other|Laboratory Biomarker Analysis|Correlative studies
276201|NCT02098161|Other|Questionnaire Administration|Ancillary studies
276202|NCT02098161|Drug|Smac Mimetic LCL161|Given PO
276203|NCT02098148|Drug|Xenon|
276204|NCT02098148|Drug|Placebo|
276205|NCT02098135|Device|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
276206|NCT02098109|Drug|XM02 Filgrastim|
276207|NCT02098109|Drug|Filgrastim|
276208|NCT02098109|Procedure|Apheresis|
276209|NCT02098109|Drug|Plerixafor|
276210|NCT02098109|Procedure|Stem Cell Transplant|
276211|NCT02098096|Other|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:~Familiarization~Acclimatization~Progression~Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.~All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
276212|NCT02098096|Other|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
276213|NCT02098057|Dietary Supplement|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
276214|NCT02098057|Drug|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio~Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
276215|NCT02098031|Other|Improving nutrition knowledge among mothers|
276216|NCT02098018|Behavioral|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
276217|NCT02098018|Behavioral|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
276218|NCT02098005|Other|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
276219|NCT02098005|Other|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
276220|NCT02097992|Drug|Roflumilast Placebo|Placebo pill
276221|NCT02097992|Drug|Roflumilast|500 Ug ORAL TABLET
276222|NCT02097979|Behavioral|Glaucoma Educational Intervention|
276223|NCT02097966|Drug|Daclatasvir|
276224|NCT02097966|Drug|Sofosbuvir|
276225|NCT02097966|Drug|Ribavirin|
276226|NCT02097953|Drug|Daptomycin|
276227|NCT02097953|Drug|Rifampin|
276228|NCT02097940|Other|proprioceptive exercises|Exercises with movements, jumping and imbalance.
276312|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
276313|NCT02097329|Drug|famotidine|20 mg oral tablet 10 hours before and 2 hours after palbociclib
276229|NCT02097927|Behavioral|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
276230|NCT02097914|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
276231|NCT02097901|Procedure|Microfracture|Rotator Cuff Repair AND Microfracture
276232|NCT02097901|Procedure|NO microfracture|Rotator Cuff Repair without microfracture
276233|NCT02097875|Drug|BLZ-100|
276234|NCT02097862|Procedure|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
276235|NCT02097849|Drug|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
276236|NCT02097849|Biological|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
276237|NCT02097849|Biological|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
276238|NCT02097849|Biological|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
276239|NCT02097849|Drug|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
276240|NCT02097836|Device|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
276241|NCT02097823|Drug|Olanzapine|
276242|NCT02097823|Drug|Aprepitant|
276243|NCT02097810|Drug|Entrectinib|
276244|NCT02097797|Other|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
276245|NCT02097797|Other|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
276246|NCT02097784|Procedure|Echocardiography|
276247|NCT02097771|Device|LMA SupremeTM|
276248|NCT02097771|Device|AuraOnceTM|
276249|NCT02097758|Device|Transcatheter device closure|"Closure of atrial septal defect with device~choosing device size with 3D image and the formula~we do not use sizing balloon for choosing of the device size"
276250|NCT02097745|Drug|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
276251|NCT02097745|Drug|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
276252|NCT02097732|Drug|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
276253|NCT02097732|Procedure|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
276254|NCT02097719|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
276255|NCT02097719|Drug|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
276256|NCT02097719|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
276257|NCT02097719|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
276258|NCT02097706|Drug|NMDA receptor antagonist (active drug)|
276259|NCT02097706|Other|Lactose packed capsule (inert/inactive arm)|
276260|NCT02097680|Drug|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
276261|NCT02097680|Drug|Placebo|One placebo capsule every two days during four months
276262|NCT02097654|Other|SENATOR software generated pharmacotherapy advice report.|
276263|NCT02097641|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stromal Cells was administered intravenously over approximately 60-80 minutes.
276264|NCT02097641|Biological|Plasma-Lyte A|Plasma-Lyte A placebo was administered intravenously over approximately 60-80 minutes.
276265|NCT02097628|Procedure|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
276266|NCT02097628|Procedure|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
276267|NCT02097615|Procedure|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
276268|NCT02097615|Other|deionized water|application every 24 hours six weeks
276269|NCT02097589|Drug|Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
276270|NCT02097589|Drug|Pneumovax 23|Pneumovax 23 injected once, intramuscularly at Day 7.
276271|NCT02097589|Other|Placebo (lactose pill)|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
276272|NCT02097576|Other|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
276467|NCT02096250|Other|Ferrous fumarate|
276273|NCT02097576|Other|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
276274|NCT02097563|Behavioral|High Intensity Training|This is a training method involving a live workshop followed by high intensity technical consultation.
276275|NCT02097563|Behavioral|Low Intensity Training|Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
276276|NCT02097550|Other|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
276277|NCT02097537|Drug|Methacholine Chloride (SK-1211)|
276278|NCT02097524|Drug|Sarilumab|
276279|NCT02097524|Drug|Tocilizumab|
276280|NCT02097511|Drug|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
276281|NCT02097511|Drug|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
276282|NCT02097511|Drug|Metoprolol|Metoprolol Tartrate 100 mg once a day
276283|NCT02097498|Other|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
276284|NCT02097498|Other|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
276285|NCT02097485|Drug|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
276286|NCT02097485|Drug|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
276287|NCT02097472|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
276288|NCT02097472|Biological|Synflorix|"1 dose (0.5 mL) contains:~1 μg of each of the following pneumococcal polysaccharide serotypes:~1, 5, 6B, 7F, 9V, 14, and 23 F~And 3 μg of the following pneumococcal polysaccharide serotypes:~4, 18C and 19F.~The serotypes are conjugated to either:~protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
276289|NCT02097472|Biological|Pentavac|"Each PFS contains 0.5 ml (single dose):~Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
276290|NCT02097472|Other|Saline|0.9% Sodium Chloride Injection, USP
276291|NCT02097459|Drug|Anastrozole|
276292|NCT02097459|Drug|Tamoxifen|
276293|NCT02097459|Drug|Toremifene|
276294|NCT02097446|Device|Guardix-FL|
276295|NCT02097446|Device|Interceed|
276296|NCT02097433|Drug|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
276297|NCT02097420|Device|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
276298|NCT02097407|Drug|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
276299|NCT02097407|Drug|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
276300|NCT02097394|Drug|Combizym|Combizym( 1 tablet, po, tid)
276301|NCT02097394|Drug|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
276302|NCT02097394|Drug|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
276303|NCT02097381|Drug|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.~The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
276304|NCT02097368|Procedure|tongue strength measurement|tongue strength measurement
276305|NCT02097368|Procedure|respiratory function measurement|respiratory function measurement
276306|NCT02097368|Procedure|swallowing tests|swallowing tests
276307|NCT02097368|Other|Magnetic resonance imaging|Magnetic resonance imaging
276308|NCT02097355|Other|TriVox for clinical care|Use TriVox disease modules to manage patients
276309|NCT02097342|Drug|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
276310|NCT02097342|Drug|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
276311|NCT02097342|Drug|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
276314|NCT02097329|Drug|rabeprazole|2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
276315|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
276316|NCT02097329|Drug|antacid|30 mL orally once (2h before palbociclib)
276317|NCT02097329|Drug|antacid|30 mL orally once (2h after palbociclib)
276318|NCT02097316|Device|JewelPump|
276319|NCT02097316|Device|usual insulin pump|
276320|NCT02097303|Drug|Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone|Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
276321|NCT02097290|Device|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
276322|NCT02097277|Biological|BMS-986036|
276323|NCT02097277|Biological|Placebo (Matching with BMS-986036)|
276324|NCT02097264|Drug|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
276325|NCT02097264|Drug|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
276326|NCT02097264|Drug|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).~1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
276327|NCT02097251|Drug|UX003|Open Label
276328|NCT02097238|Drug|Eribulin Mesylate|Given IV
276329|NCT02097238|Other|Pharmacological Study|Correlative studies
276330|NCT02097225|Drug|Dabrafenib|Given PO
276331|NCT02097225|Other|Laboratory Biomarker Analysis|Correlative studies
276332|NCT02097225|Drug|Onalespib|Given IV
276333|NCT02097225|Other|Pharmacological Study|Correlative studies
276334|NCT02097225|Drug|Trametinib|Given PO
276335|NCT02097199|Other|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
276336|NCT02097186|Procedure|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
276337|NCT02097173|Drug|Methotrexate|
276338|NCT02097160|Other|Vitamin D fortified yogurt and cheese products|
276339|NCT02097160|Other|Control Group 1|
276340|NCT02097147|Drug|Vilazodone 20 mg|Oral administration, once per day.
276341|NCT02097147|Drug|Vilazodone 40 mg|Oral administration, once per day.
276342|NCT02097147|Drug|Paroxetine 20 mg|Oral administration, once per day.
276343|NCT02097147|Drug|Placebo|Oral administration, once per day.
276344|NCT02097134|Drug|Melphalan|Given IA
276345|NCT02097121|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
276346|NCT02097108|Drug|Raltegravir|
276347|NCT02097082|Device|STANZA Drug-eluting resorbable Scaffold|
276348|NCT02097069|Dietary Supplement|Folic acid|Folic acid 400 mcg/day
276349|NCT02097069|Dietary Supplement|Myo-inositol|myo-inositol 2000 mg twice a day
276350|NCT02097069|Dietary Supplement|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
276351|NCT02097069|Dietary Supplement|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
276352|NCT02097056|Drug|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
276353|NCT02097043|Drug|DA-7218|
276354|NCT02097043|Drug|Placebo|
276355|NCT02097030|Device|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
276356|NCT02097030|Device|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
276357|NCT02097030|Device|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
276358|NCT02097017|Drug|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
276359|NCT02097017|Other|placebo comparator|
276360|NCT02097004|Biological|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
276361|NCT02097004|Biological|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
276362|NCT02097004|Drug|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
276363|NCT02096991|Other|Can 1|drink the beverage in a can and a glass bottle
276364|NCT02096991|Other|Can 2|Consume two canned beverage
276365|NCT02096991|Other|Glass|consume two glass bottled beverage
276366|NCT02096978|Procedure|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
276367|NCT02096965|Drug|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
276468|NCT02096250|Other|NaFeEDTA + ferrous fumarate|
276368|NCT02096965|Drug|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
276369|NCT02096952|Drug|Methylphenidate extended-release liquid formulation|
276370|NCT02096939|Procedure|Adrenal extirpation|
276371|NCT02096939|Drug|Antihypertensive medication|
276372|NCT02096926|Drug|Placebo|
276373|NCT02096926|Drug|Ibuprofen|400 mg PO
276374|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period."
276375|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).~In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment."
276376|NCT02096900|Drug|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
276377|NCT02096900|Drug|Midazolam|
276378|NCT02096887|Behavioral|Patient Education|"Patient Education using the following two instruments:~Framingham Risk Score calculator:~Know your numbers patient booklet"
276379|NCT02096874|Drug|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
276380|NCT02096861|Biological|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
276381|NCT02096861|Biological|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
276382|NCT02096835|Device|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
276383|NCT02096835|Device|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
276384|NCT02096835|Drug|Tropisetron|will be given at the start of skin closure
276385|NCT02096835|Drug|Dexamethasone|will be given after induction
276386|NCT02096822|Behavioral|Facilitated tucking + non-nutritive sucking|
276387|NCT02096822|Other|non-nutritive sucking|
276388|NCT02096809|Procedure|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
276389|NCT02096809|Device|Cochlear Baha BI300/BA400 Implant System|
276390|NCT02096783|Other|informational intervention|Given scripted intervention
276391|NCT02096783|Other|counseling intervention|Given standard counseling
276392|NCT02096783|Other|questionnaire administration|Ancillary studies
276393|NCT02096757|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
276394|NCT02096757|Other|Pro-Omega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
276395|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Oppanol
276396|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
276397|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
276398|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
276399|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Vistanex
276400|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
276401|NCT02096718|Drug|Afatinib healthy|
276402|NCT02096718|Drug|Afatinib severe renally impaired|
276403|NCT02096718|Drug|Afatinib moderate renally impaired|
276404|NCT02096705|Drug|Dapagliflozin|Tablet
276405|NCT02096705|Drug|Dapagliflozin Placebo|Tablet
276406|NCT02096692|Device|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
276407|NCT02096692|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
276408|NCT02096679|Drug|AZD9291|Volunteer will receive a single oral dose of 20 mg [14C]-AZD9291 as a solution on Day 1
276409|NCT02096666|Drug|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
276410|NCT02096653|Procedure|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
276411|NCT02096653|Procedure|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
276412|NCT02096640|Procedure|Type of surgical teqnique for tracheostomy|
276413|NCT02096614|Drug|TBI-1201|TBI-1201(5*10^8 or 5*10^9) is administered.
276414|NCT02096614|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
276415|NCT02096614|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
276416|NCT02096601|Drug|Levodopa and carbidopa SC solution|Levodopa and carbidopa SC solution
276417|NCT02096601|Drug|Oral levodopa and carbidopa|Oral levodopa and carbidopa
276418|NCT02096588|Drug|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
276419|NCT02096588|Drug|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
276469|NCT02096237|Device|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
276470|NCT02096224|Drug|Sevoflurane|Sevoflurane will be used.
276471|NCT02096224|Drug|Desflurane|Desflurane will be used
276957|NCT02092454|Drug|Benzocaine|topical otic solution
276420|NCT02096575|Other|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.~NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.~All patients will get local anesthesia via a standardized PCB."
276421|NCT02096562|Other|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
276422|NCT02096562|Other|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
276423|NCT02096536|Drug|Vancomycin|vancomycin administration based on decision of treating physician
276424|NCT02096523|Other|Blood collection for platelet protein samples|
276425|NCT02096510|Drug|Solu-Cortef|administration by pump for minimum 2 weeks
276426|NCT02096510|Drug|Cortef|tablet treatment 2 ro 3 times per day for 14 days
276427|NCT02096484|Behavioral|Group Metacognitive Therapy|
276428|NCT02096484|Behavioral|Mindfulness Meditation Therapy|
276429|NCT02096471|Drug|PD-0325901|
276430|NCT02096458|Drug|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
276431|NCT02096445|Device|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
276432|NCT02096445|Other|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
276433|NCT02096432|Behavioral|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
276434|NCT02096432|Behavioral|Usual Community Care|Community standard care as usual
276435|NCT02096419|Drug|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).~They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.~On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
276436|NCT02096406|Drug|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
276437|NCT02096406|Drug|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
276438|NCT02096393|Device|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
276439|NCT02096393|Device|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
276440|NCT02096380|Drug|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
276441|NCT02096380|Drug|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC~Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.~A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
276442|NCT02096367|Other|Gait analysis|
276443|NCT02096367|Other|Kinematic gait analysis in lower limb|
276444|NCT02096367|Other|Analysis of static posture|
276445|NCT02096367|Other|Gait on treadmill|Treadmill during 2 minutes
276446|NCT02096367|Device|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
276447|NCT02096354|Drug|RRx-001|
276448|NCT02096354|Drug|Regorafenib|
276449|NCT02096354|Drug|Irinotecan|To be dosed after RRx-001 or regorafenib
276450|NCT02096341|Drug|RRx-001|"RRx-001 Dose level 1 (16 mg/m2) twice weekly~RRx-001 Dose level 2 (27 mg/m2) twice weekly"
276451|NCT02096328|Drug|POL7080|Intravenous infusion
276452|NCT02096315|Drug|POL7080|Intravenous infusion
276453|NCT02096302|Dietary Supplement|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
276454|NCT02096302|Dietary Supplement|Standard formula|Standard formula without probiotics
276455|NCT02096289|Drug|Thioridazine|
276456|NCT02096276|Other|Data collection|Initial and follow-up data will be collected using questionnaires.
276457|NCT02096263|Biological|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
276458|NCT02096263|Biological|Pediarix|3 doses administered intramuscularly in the right thigh
276459|NCT02096263|Biological|ActHIB|4 doses administered intramuscularly in the upper left thigh
276460|NCT02096263|Biological|Pentacel|4 doses administered intramuscularly in the right thigh
276461|NCT02096263|Biological|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
276462|NCT02096263|Biological|Infanrix|1 dose administered intramuscularly in the right thigh
276463|NCT02096263|Biological|Hiberix|1 dose administered intramuscularly in the left thigh
276464|NCT02096263|Biological|Prevnar13|3 doses administered intramuscularly in the lower left thigh
276465|NCT02096263|Biological|Rotarix|2 doses administered orally
276466|NCT02096250|Other|NaFeEDTA|
276472|NCT02096211|Device|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
276473|NCT02096185|Radiation|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
276474|NCT02096185|Radiation|2 dimensional digital imaging|
276475|NCT02096159|Drug|trimethoprim-sulfamethoxazole|
276476|NCT02096159|Other|placebo|
276477|NCT02096146|Procedure|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
276478|NCT02096146|Procedure|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
276479|NCT02096133|Drug|Cholecalciferol|Vitamin D3 solution
276480|NCT02096133|Other|Placebo comparator|Placebo comparator
276481|NCT02096107|Drug|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
276482|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
276483|NCT02096094|Procedure|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
276484|NCT02096094|Procedure|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
276485|NCT02096094|Procedure|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
276486|NCT02096081|Drug|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
276487|NCT02096081|Drug|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
276488|NCT02096068|Drug|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
276489|NCT02096068|Drug|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
276490|NCT02096055|Drug|Cladribine|Given IV
276491|NCT02096055|Drug|Guadecitabine|Given SC
276492|NCT02096055|Drug|Idarubicin|Given IV
276493|NCT02096042|Drug|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.~Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
276494|NCT02096042|Drug|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
276495|NCT02096029|Other|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
276496|NCT02096029|Behavioral|Ask, Advise, Refer (physician brief advice)|
276497|NCT02096016|Procedure|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
276498|NCT02096003|Drug|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
276499|NCT02096003|Drug|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
276500|NCT02095990|Drug|Hydroquinone|
276501|NCT02095990|Drug|Placebo|
276502|NCT02095977|Procedure|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
276503|NCT02095977|Procedure|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.~For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
276504|NCT02095977|Procedure|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
276505|NCT02095951|Drug|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
276506|NCT02095938|Drug|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
276507|NCT02095899|Drug|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
276508|NCT02095886|Drug|BMS-955176|BMS-955176
276509|NCT02095873|Dietary Supplement|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
276510|NCT02095873|Dietary Supplement|Placebo|Mannitol, 108 mg
276511|NCT02095860|Drug|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
276512|NCT02095847|Procedure|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
276513|NCT02095847|Drug|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
276514|NCT02095834|Drug|Bendamustine Hydrochloride|Given IV
276515|NCT02095834|Drug|Carfilzomib|Given IV
276516|NCT02095834|Drug|Dexamethasone|Given PO or IV
276517|NCT02095834|Other|Laboratory Biomarker Analysis|Correlative studies
276518|NCT02095808|Procedure|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
276519|NCT02095795|Device|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
276520|NCT02095795|Other|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
276521|NCT02095782|Drug|Intercalated combination of chemotherapy and erlotinib|"Primary therapy stage:~Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.~Maintenance therapy stage:~Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death."
276522|NCT02095756|Other|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
276523|NCT02095756|Other|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
276524|NCT02095743|Device|implanted port for chemo administration (X-port isp)|
276525|NCT02095743|Device|Use of a PICC line for chemo administration (PowerPICC SOLO²)|The description of the device could found on the published marketing authorisation
276526|NCT02095730|Drug|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
276527|NCT02095730|Drug|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
276528|NCT02095730|Device|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
276529|NCT02095730|Device|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
276530|NCT02095717|Drug|Curcumin|
276531|NCT02095717|Drug|Placebo|
276532|NCT02095717|Drug|Taxotere|
276533|NCT02095704|Drug|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
276534|NCT02095704|Drug|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
276535|NCT02095691|Device|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
276536|NCT02095678|Procedure|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
276537|NCT02095678|Device|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to <8 seconds and validate quantifiable techniques which improve liver image quality
276538|NCT02095665|Drug|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
276539|NCT02095665|Drug|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
276540|NCT02095665|Drug|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
276541|NCT02095626|Drug|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
276542|NCT02095626|Drug|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
276543|NCT02095613|Other|traditional food|
276544|NCT02095613|Other|food that is nutrient dense|
276545|NCT02095600|Radiation|Radiosurgical thalamotomy|
276546|NCT02095587|Drug|IPI-145|25 mg single oral capsule
276547|NCT02095574|Drug|[14C]ABT-199 (GDC-0199)|[14C]ABT-199 will be administered as a single oral administration
276548|NCT02095561|Other|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
276549|NCT02095548|Drug|SM04690, 0.03mg/2mL|
276550|NCT02095548|Drug|SM04690, 0.07mg/2mL|
276551|NCT02095548|Drug|SM04690, 0.23mg/2mL|
276552|NCT02095548|Drug|Placebo|
276553|NCT02095535|Drug|Chlorhexidine gluconate|antiseptic
276554|NCT02095522|Drug|Colchicine|Colchicine 1mg per day for one month
276555|NCT02095522|Drug|Placebo|Placebo
276556|NCT02095509|Drug|Enoxaparin|Drug class: Low-molecular weight heparin
276557|NCT02095496|Device|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
276558|NCT02095496|Device|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
276559|NCT02095470|Device|video laryngoscope|newly developed innovatory device
276560|NCT02095470|Device|traditional laryngoscope|traditional way for intubation
276561|NCT02095457|Behavioral|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
276562|NCT02095444|Drug|Menstrual blood stem cells|10*7 cells/kg, intravenous injection for 4 times during two weeks
276563|NCT02095418|Drug|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
276564|NCT02095418|Drug|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
276565|NCT02095405|Drug|Caffeine|"SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.~AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring."
276566|NCT02095405|Other|Placebo|"SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.~AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring."
276567|NCT02095392|Dietary Supplement|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate [1g phosphorus/d]
276568|NCT02095392|Dietary Supplement|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [0,5 g calcium]
276569|NCT02095392|Dietary Supplement|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [1 g calcium]
276570|NCT02095392|Dietary Supplement|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
276571|NCT02095379|Other|oligosecretary|not abvailable
276572|NCT02095366|Drug|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
276573|NCT02095366|Drug|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
276574|NCT02095366|Drug|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.~Pain is controlled by:~at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV~at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV~at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
276575|NCT02095366|Drug|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.~Pain is controlled by:~at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg~at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg~at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
276576|NCT02095340|Other|Positive Interpretation Bias Training|
276577|NCT02095340|Other|Neutral Interpretation Bias Training|
276578|NCT02095314|Biological|Pentavalen|Batch 5010613
276579|NCT02095301|Other|Herbal Beverage|
276580|NCT02095288|Procedure|Blood draw|This is a single blood donation, no drugs or devices administered
276581|NCT02095262|Other|reactive auditory training|
276582|NCT02095262|Other|Interactive auditory training|
276583|NCT02095249|Drug|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
276584|NCT02095236|Behavioral|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
276585|NCT02095223|Device|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
276586|NCT02095223|Behavioral|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
276587|NCT02095210|Other|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
276588|NCT02095197|Drug|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
276589|NCT02095184|Drug|Anastrozole|1 mg daily
276590|NCT02095184|Drug|Letrozole|2.5 mg daily
276591|NCT02095171|Drug|PRX002|
276592|NCT02095171|Other|Placebo|
276593|NCT02095158|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
276594|NCT02095145|Other|Laboratory Biomarker Analysis|Correlative studies
276595|NCT02095145|Other|Pharmacological Study|Correlative studies
276596|NCT02095145|Other|Placebo|Given PO
276597|NCT02095145|Drug|Pomegranate-Extract Pill|Given PO
276598|NCT02095132|Drug|Adavosertib|Given PO
276599|NCT02095132|Drug|Irinotecan|Given PO
276600|NCT02095132|Drug|Irinotecan Hydrochloride|Given PO
276639|NCT02094872|Other|quality-of-life assessment|Ancillary studies
276601|NCT02095119|Drug|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
276602|NCT02095119|Drug|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is >/= 60. The administration form will be intravenously.
276603|NCT02095119|Drug|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation < 60). The administration form will be intravenously.
276604|NCT02095119|Procedure|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
276605|NCT02095106|Device|Waterproof Cast|
276606|NCT02095106|Device|Traditional cast|
276607|NCT02095093|Device|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
276608|NCT02095093|Device|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
276609|NCT02095080|Dietary Supplement|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
276610|NCT02095067|Device|Video consultation|
276611|NCT02095054|Drug|Regorafenib|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.~Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."
276612|NCT02095054|Drug|Cetuximab|"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."
276613|NCT02095054|Behavioral|Questionnaire|Symptom questionnaire completed at each study visit.
276614|NCT02095028|Behavioral|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
276615|NCT02094989|Other|posture dependence of VCG-ECG-transformation|
276616|NCT02094976|Device|Jackson surgical table|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
276617|NCT02094976|Device|Wilson frame|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
276618|NCT02094976|Device|Chest roll|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
276619|NCT02094963|Drug|Ticagrelor|180mg loading and 90mg bid
276620|NCT02094963|Drug|Clopidogrel|600mg loading and 75mg qd
276621|NCT02094950|Procedure|Acupuncture|
276622|NCT02094937|Drug|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
276623|NCT02094937|Drug|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
276624|NCT02094937|Drug|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
276625|NCT02094937|Drug|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
276626|NCT02094937|Drug|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
276627|NCT02094937|Drug|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
276628|NCT02094924|Drug|GSK587323|Single dose of FDC tablet formulation to be taken orally.
276629|NCT02094924|Drug|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
276630|NCT02094911|Behavioral|Combined lifestyle intervention|"10-month intervention period with:~weekly group-based sports lessons supervised by a physiotherapist~individual dietary advice by a dietician~case management by practice nurse~maintenance programme to guide subjects to maintain lifestyle behaviour change"
276631|NCT02094911|Other|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
276632|NCT02094898|Drug|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
276633|NCT02094885|Biological|Bioseal Fibrin Sealant|
276634|NCT02094885|Other|Manual Compression|
276635|NCT02094872|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
276636|NCT02094872|Drug|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
276637|NCT02094872|Procedure|therapeutic procedure|
276638|NCT02094872|Other|laboratory biomarker analysis|Correlative studies
276640|NCT02094846|Behavioral|Voice messages|Voice messages reinforced with self-efficacy
276641|NCT02094833|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
276642|NCT02094833|Biological|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
276643|NCT02094807|Drug|NSAID|Will be used if other drugs are not tolerated.
276644|NCT02094807|Procedure|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
276645|NCT02094807|Drug|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
276646|NCT02094807|Drug|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
276647|NCT02094807|Procedure|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
276648|NCT02094794|Drug|etoposide|Given IV
276649|NCT02094794|Drug|cyclophosphamide|Given IV
276650|NCT02094794|Radiation|total marrow irradiation|Undergo TMLI
276651|NCT02094794|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
276652|NCT02094794|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
276653|NCT02094781|Dietary Supplement|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
276654|NCT02094781|Dietary Supplement|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
276655|NCT02094781|Dietary Supplement|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
276656|NCT02094768|Dietary Supplement|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
276657|NCT02094768|Dietary Supplement|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
276658|NCT02094755|Other|Blood draw only|Blood draw only
276659|NCT02094742|Procedure|biopsy|
276660|NCT02094729|Drug|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
276661|NCT02094729|Drug|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
276662|NCT02094729|Drug|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
276663|NCT02094729|Drug|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
276664|NCT02094716|Drug|Permethrin Foam 4%|Topical application, single whole-body treatment
276665|NCT02094716|Drug|Permethrin Foam 5%|Topical application, single whole-body treatment
276666|NCT02094716|Drug|Vehicle Foam|Topical application, single whole-body treatment
276667|NCT02094703|Drug|Levofloxacin|
276668|NCT02094703|Drug|Solifenacin succinate|
276669|NCT02094703|Drug|Placebo (for Solifenacin succinate)|
276670|NCT02094690|Device|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
276671|NCT02094690|Device|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
276672|NCT02094677|Device|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
276673|NCT02094677|Device|etafilcon A|Participants were randomized to wear etafilcon A control lens.
276674|NCT02094677|Device|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
276675|NCT02094664|Device|Heated and humidified oxygen|
276676|NCT02094651|Drug|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
276677|NCT02094651|Other|Placebo|The placebo is an inactive substance that looks like the active drug.
276678|NCT02094625|Drug|N-Acetylcysteine|"NAC will be administered intravenously over ~60 minutes starting 4 hours following completion of cisplatin chemotherapy.~Three dose levels have been pre-determined:~Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg~Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg.~As of August 2018: Dose escalation completed with MTD not reached. Dose level 3 (450mg/kg) selected for expansion with NAC."
276679|NCT02094612|Device|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
276680|NCT02094612|Behavioral|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
276681|NCT02094599|Drug|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
276682|NCT02094599|Drug|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
276683|NCT02094599|Drug|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
276684|NCT02094586|Biological|PXVX0200|comparing 3 lots of PXVX0200
276685|NCT02094586|Biological|Placebo|
276686|NCT02094573|Drug|Brigatinib|Brigatinib tablets
276687|NCT02094560|Drug|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
276688|NCT02094547|Dietary Supplement|New infant formula|New infant formula
276689|NCT02094547|Dietary Supplement|Standard infant formula|Standard infant formula
276690|NCT02094547|Dietary Supplement|Breastfeeding|Exclusive breastfeeding or less tan 25% formula intake
276691|NCT02094534|Biological|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
276692|NCT02094534|Other|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
276693|NCT02094521|Drug|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
276694|NCT02094482|Device|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
276695|NCT02094469|Drug|Cilostazol|Oral, Bid, 24 weeks
276696|NCT02094456|Procedure|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
276697|NCT02094456|Procedure|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
276698|NCT02094443|Drug|Alisporivir|ALV 100 and 200 mg soft gel capsules administered orally
276699|NCT02094443|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
276700|NCT02094430|Drug|biological: human fibrinogen concentrate|
276701|NCT02094417|Drug|AMG531|Subcutaneous, weekly injection
276702|NCT02094391|Drug|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
276703|NCT02094378|Drug|Esketamine|84 mg esketamine administered intranasally
276704|NCT02094378|Drug|Placebo|Placebo administered intranasally
276705|NCT02094365|Drug|ALS-008176|
276706|NCT02094365|Drug|vehicle|
276707|NCT02094352|Drug|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
276708|NCT02094352|Drug|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
276709|NCT02094352|Drug|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
276710|NCT02094352|Drug|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
276711|NCT02094339|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
276712|NCT02094339|Procedure|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
276713|NCT02094339|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
276714|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
276715|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
276716|NCT02094339|Drug|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
276717|NCT02094313|Drug|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
276718|NCT02094300|Device|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
276719|NCT02094287|Drug|dimetindene|receiving either dimetindene or a placebo (saline) via infusion
276720|NCT02094287|Behavioral|instruction|information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
276721|NCT02094287|Other|conditioning|classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
276722|NCT02094274|Drug|LAS40468|
276723|NCT02094274|Drug|Salmeterol/fluticasone propionate|
276724|NCT02094274|Drug|Placebo|
276725|NCT02094261|Drug|AZD9291|Once daily tablet 80 mg
276726|NCT02094248|Drug|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
276727|NCT02094248|Drug|control|Normal saline，1ml/day, s.c injection
276728|NCT02094235|Drug|E6005 0.05%|
276729|NCT02094235|Drug|Placebo|0.5 g placebo ointment
276730|NCT02094235|Drug|E6005 0.2%|
276731|NCT02094222|Drug|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
276915|NCT02092792|Drug|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
276732|NCT02094209|Device|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
276733|NCT02094196|Other|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
276734|NCT02094183|Other|GLP-1|GLP-1
276735|NCT02094183|Dietary Supplement|low calorie diet|low calorie diet
276736|NCT02094157|Drug|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
276737|NCT02094157|Drug|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
276738|NCT02094144|Other|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
276739|NCT02094144|Other|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
276740|NCT02094131|Other|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
276741|NCT02094131|Other|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
276742|NCT02094118|Biological|Point-of-care washed red blood cell transfusion.|
276743|NCT02094118|Biological|Standard of care red blood cell transfusion.|
276744|NCT02094105|Procedure|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
276745|NCT02094092|Other|ProTectis drops (five drops per day) for 21 days|
276746|NCT02094092|Other|Placebo drops (five drops per day) for 21 days|
276747|NCT02094079|Other|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
276748|NCT02094066|Drug|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
276749|NCT02094066|Drug|serum physiologic|preoperative 100 cc ıv serum physiologic
276750|NCT02094053|Drug|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
276751|NCT02094053|Drug|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
276752|NCT02094053|Drug|Placebo|placebo (oral) once daily, for 24 weeks
276753|NCT02094040|Behavioral|Receive municipality-based follow-up visit|Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
276754|NCT02094027|Behavioral|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
276755|NCT02094027|Other|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
276756|NCT02094014|Behavioral|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
276757|NCT02094014|Behavioral|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
276758|NCT02094014|Behavioral|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
276759|NCT02094001|Radiation|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
276760|NCT02093988|Drug|Topical TXA|
276761|NCT02093988|Drug|Intravenous TXA|
276762|NCT02093975|Device|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.~Video consultation"
276763|NCT02093962|Drug|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
276764|NCT02093962|Drug|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.~Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
276765|NCT02093949|Procedure|Routine substrate ablation without pulmonary vein Isolation|
276766|NCT02093949|Procedure|Routine conventional ablation with pulmonary vein Isolation|
276767|NCT02093923|Drug|DX-2930|DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody
276768|NCT02093923|Drug|Placebo|Placebo
276769|NCT02093910|Drug|Monosialotetrahexosylganglioside|
276770|NCT02093897|Biological|rVIII-SingleChain|
276771|NCT02093884|Other|Text Messaging Intervention|
276772|NCT02093884|Other|Standard Referral|
276916|NCT02092766|Drug|artesunate|
276917|NCT02092766|Drug|quinine|
276773|NCT02093871|Device|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
276774|NCT02093845|Device|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
276775|NCT02093845|Device|SYNERGY stent|Percutaneous coronary intervention involving use of stent
276776|NCT02093832|Other|There are no specific Intervention|are no specific Intervention
276777|NCT02093819|Drug|Placebo to BI 416970|single rising doses
276778|NCT02093819|Drug|BI 416970|single rising doses
276779|NCT02093806|Other|measurment|
276780|NCT02093793|Device|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
276781|NCT02093780|Behavioral|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
276782|NCT02093780|Behavioral|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
276783|NCT02093767|Dietary Supplement|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
276784|NCT02093754|Procedure|MRI and biopsy|
276785|NCT02093741|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
276786|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
276787|NCT02093728|Drug|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
276788|NCT02093728|Drug|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
276789|NCT02093728|Drug|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
276790|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
276791|NCT02093728|Drug|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
276792|NCT02093728|Drug|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
276793|NCT02093728|Drug|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
276794|NCT02093702|Behavioral|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
276795|NCT02093702|Behavioral|Unstructured Physical Activity and Exercise Education|
276796|NCT02093689|Drug|Part 1 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
276797|NCT02093689|Drug|Part 2 OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
276798|NCT02093689|Drug|Part 2 Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
276799|NCT02093676|Behavioral|"experimental protocol treatment The New Authority"|
276800|NCT02093663|Drug|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the subjects weight<br>&lt;br&gt;-900 mg/day for subjects weighing 18 to less than or equal to 23kg<br>&lt;br&gt;-1200 mg/day for subjects weighing &gt;23 to less than or equal to35kg<br>&lt;br&gt;-1800 mg/day for subjects weighing &gt;35 to less than or equal to 50kg<br>&lt;br&gt;-2400 mg/day for subjects weighing &gt;50 to less than or equal to 90kg.
276801|NCT02093663|Drug|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the subjects weight<br>&lt;br&gt;<br>&lt;br&gt;•1800 mg/day for subjects weighing 18 to less than or equal to 23kg<br>&lt;br&gt;•2400 mg/day for subjects weighing &gt;23 to less than or equal to35kg<br>&lt;br&gt;•3600 mg/day for subjects weighing &gt;35 to less than or equal to 50kg<br>&lt;br&gt;•4800 mg/day for subjects weighing &gt;50 to less than or equal to 90kg.
276802|NCT02093650|Drug|black cohosh extract|Black cohosh extract 80 mg
276803|NCT02093650|Drug|Placebo|Soy bean oil
276804|NCT02093637|Other|Placebo acupuncture|Placebo Comparator
276805|NCT02093637|Other|Battlefield Acupuncture|Experimental
276806|NCT02093611|Dietary Supplement|Placebo|
276807|NCT02093611|Dietary Supplement|ATP|400 mg of ATP
276808|NCT02093598|Drug|Temsirolimus|
276809|NCT02093585|Drug|abacavir (600 mg QD)|
276810|NCT02093585|Drug|tenofovir (245 mg QD)|
276811|NCT02093572|Other|3 standard meals/day|
276812|NCT02093572|Other|2 meals/day (omit breakfast)|
276813|NCT02093559|Behavioral|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
276814|NCT02093546|Procedure|Biospecimen Collection|Undergo collection of blood and tumor
276815|NCT02093533|Drug|Eculizumab|
276816|NCT02093520|Procedure|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
276817|NCT02093520|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
276818|NCT02093507|Other|parents manipulation|parents perform manipulation the child foot to correct the deformity
276819|NCT02093494|Device|Initial Specimen Diversion Device (ISDD)|
276820|NCT02093494|Procedure|Lab standard practice (LSP)|
276821|NCT02093494|Device|Peripheral Intravenous Catheters (PIVC)|
276822|NCT02093481|Other|Test meal|
276823|NCT02093481|Other|Reference|
276824|NCT02093481|Other|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
276825|NCT02093481|Other|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
276826|NCT02093468|Drug|MST-188|
276827|NCT02093468|Drug|Saline|
276828|NCT02093455|Dietary Supplement|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
276829|NCT02093455|Dietary Supplement|Placebo|
276830|NCT02093442|Procedure|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
276831|NCT02093429|Drug|INCB047986|INCB047986 will be supplied as tablets.
276832|NCT02093403|Drug|decitabine|Given IV
276833|NCT02093403|Drug|selinexor|Given PO
276834|NCT02093403|Other|pharmacological study|Correlative studies
276835|NCT02093403|Other|laboratory biomarker analysis|Correlative studies
276836|NCT02093390|Drug|TAK-385|TAK-385 tablets
276837|NCT02093390|Drug|Fluconazole|Fluconazole tablets
276838|NCT02093390|Drug|Atorvastatin|Atorvastatin tablets
276839|NCT02093377|Device|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
276840|NCT02093351|Drug|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
276841|NCT02093351|Drug|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
276842|NCT02093351|Drug|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
276843|NCT02093351|Drug|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
276844|NCT02093351|Procedure|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
276845|NCT02093338|Dietary Supplement|Lactobacillus fermentum CECT5716|
276846|NCT02093338|Other|Placebo Comparator: maltodextrin|Placebo
276847|NCT02093325|Drug|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
276848|NCT02093325|Drug|Placebo|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
276849|NCT02093312|Dietary Supplement|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
276850|NCT02093299|Drug|Clopidogrel|a blood sample is drawn on all patients to determine responder status
276851|NCT02093273|Biological|tOPV pilot batch|the tOPV vaccine is given orally
276852|NCT02093273|Biological|tOPV commercial batch|tOPV vaccine is given orally
276853|NCT02093260|Biological|Vaccine|"Flubio (Influenza HA) Vaccine~The vaccine will be given intramuscularly."
276854|NCT02093234|Behavioral|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
276855|NCT02093234|Behavioral|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
276856|NCT02093234|Behavioral|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
276857|NCT02093221|Biological|180 mg/kg Alpha1-PI|
276858|NCT02093221|Biological|90 mg/kg Alpha1-PI|
276859|NCT02093221|Biological|Placebo|
276860|NCT02093195|Drug|Bosentan|
276861|NCT02093195|Drug|Symbicort turbuhaler|
276862|NCT02093169|Drug|Part A: Lu AF35700|One 30 mg single dose for one day; orally
276863|NCT02093169|Drug|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
276864|NCT02093156|Other|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
276865|NCT02093143|Drug|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
276866|NCT02093130|Dietary Supplement|Pomegranate Juice|
276867|NCT02093130|Dietary Supplement|Placebo|
276868|NCT02093117|Procedure|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
276869|NCT02093117|Procedure|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
276870|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
276918|NCT02092753|Other|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
276958|NCT02092454|Drug|Placebo|topical otic solution
276871|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
276872|NCT02093078|Behavioral|CARD|"Intervention: CARD~This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
276873|NCT02093052|Behavioral|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
276874|NCT02093052|Behavioral|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
276875|NCT02093039|Device|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
276876|NCT02093026|Drug|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
276877|NCT02093026|Drug|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
276878|NCT02093026|Drug|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
276879|NCT02093026|Drug|Folic Acid|Participants will receive folic acid >= 5 mg/week or equivalent.
276880|NCT02093013|Other|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
276881|NCT02093000|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
276882|NCT02092987|Other|Social work support|All study participants will be provided access to social support services at Riverstone Senior Life services
276883|NCT02092987|Other|Educational material|All participants receive educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
276884|NCT02092974|Procedure|tDCS|
276885|NCT02092974|Drug|Citalopram|
276886|NCT02092974|Other|sham-tDCS + placebo|
276887|NCT02092961|Drug|Fostamatinib|Fostamatinib 100mg twice daily.
276888|NCT02092961|Drug|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
276889|NCT02092961|Drug|Placebo of Fostamatinib|Placebo bid for 6 weeks.
276890|NCT02092961|Drug|Placebo of Adalimumab|Placebo injection once every two weeks.
276891|NCT02092948|Radiation|[124I] PSCA-Minibody PET/CT imaging of the whole body|Whole body Imaging
276892|NCT02092935|Drug|SMT19969|
276893|NCT02092935|Drug|Vancomycin|
276894|NCT02092922|Drug|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
276895|NCT02092922|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
276896|NCT02092909|Drug|IMO-8400|IMO-8400 at escalating dose levels by subcutaneous injection
276897|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
276898|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
276899|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
276900|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
276901|NCT02092883|Drug|ACTH|PK PET scan before and after ACTH treatment
276902|NCT02092870|Drug|Adipose derived stem cells|ASCs harvested from autologous lipoaspirate
276903|NCT02092857|Dietary Supplement|Arachidonic acid (25 mg/100 kcal )|
276904|NCT02092857|Dietary Supplement|Arachidonic acid (34 mg/100 kcal)|
276905|NCT02092857|Dietary Supplement|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
276906|NCT02092844|Behavioral|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
276907|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 1
276908|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 2
276909|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 3
276910|NCT02092831|Drug|GDC-0941|Single dose Phase 2 tablet formulation
276911|NCT02092818|Drug|Riociguat (Adempas, BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
276912|NCT02092805|Procedure|Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)|
276913|NCT02092805|Procedure|Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).|
276914|NCT02092792|Drug|DLYE5953A|Escalating doses of DLYE5953A
276919|NCT02092753|Other|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
276920|NCT02092753|Other|"Experimental 2: Low glycämic and insulinemic diet (LOGI)"|"Nutritional intervention: patients were instructed to follow the LOGI diet regimen"
276921|NCT02092727|Behavioral|Behavioral Interventions for Dialysis Facilities|"Educational seminars and monthly educational webinars~Peer-to-peer mentoring program~Bulletin boards about transplantation~Facility-specific feedback reports detailing transplant referral data for their center compared to state average~Formulate a facility-specific improvement plan to increase transplant referrals.~Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.~Monthly monitoring and reporting of patient referrals to ESRD Network~Conduct a patient and family education session about transplantation~Host a movie day to show Living ACTS (About Choices in Transplantation & Sharing) video"
276922|NCT02092714|Other|laboratory biomarker analysis|Correlative studies
276923|NCT02092701|Drug|Cholecalciferol|
276924|NCT02092688|Device|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
276925|NCT02092662|Other|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
276926|NCT02092662|Other|Healthy controls|no treatment
276927|NCT02092649|Dietary Supplement|Omega-3 Complete|
276928|NCT02092649|Dietary Supplement|Placebo Pill|
276929|NCT02092636|Other|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
276930|NCT02092636|Other|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
276931|NCT02092636|Other|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
276932|NCT02092623|Device|Transvaginal posterior mesh|A trocar-free fixation system with low-weight mesh
276933|NCT02092610|Device|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
276934|NCT02092610|Device|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
276935|NCT02092597|Drug|Exenatide|
276936|NCT02092597|Drug|Linagliptin|
276937|NCT02092597|Drug|Gliclazide|
276938|NCT02092584|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
276939|NCT02092584|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
276940|NCT02092571|Drug|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
276941|NCT02092558|Drug|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
276942|NCT02092558|Drug|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
276943|NCT02092545|Other|Ketogenic diet|
276944|NCT02092532|Drug|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
276945|NCT02092532|Procedure|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
276946|NCT02092519|Device|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
276947|NCT02092519|Device|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
276948|NCT02092506|Drug|10 day triple therapy|10 day triple therapy
276949|NCT02092506|Drug|10 day sequential therapy|10 day sequential therapy
276950|NCT02092506|Drug|10 day concomitant therapy|10 day concomitant therapy
276951|NCT02092493|Device|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
276952|NCT02092480|Behavioral|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
276953|NCT02092467|Drug|tofacitinib|Oral tablet, 5 mg BID
276954|NCT02092467|Drug|tofacitinib|Oral tablet, 10 mg BID
276955|NCT02092467|Biological|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
276956|NCT02092467|Biological|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
276959|NCT02092441|Other|Alcohol prep pad group|Subjects inhale scent of alcohol pad
276960|NCT02092441|Other|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
276961|NCT02092428|Other|Image Quality|"The following procedures may be conducted as part of this study:~Coronary MRI scan with no contrast~Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg~MRI scan with an oral beta blocker (metoprolol)~Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)~Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
276962|NCT02092428|Other|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
276963|NCT02092415|Device|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
276964|NCT02092402|Other|Fecal transplantation|
276965|NCT02092376|Drug|Cholecalciferol|
276966|NCT02092376|Drug|Placebo|
276967|NCT02092363|Drug|OMP-54F28, Paclitaxel and Carboplatin|
276968|NCT02092350|Drug|Grazoprevir|Grazoprevir 100 mg tablet
276969|NCT02092350|Drug|Elbasvir|Elbasvir 50 mg tablet
276970|NCT02092350|Drug|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
276971|NCT02092350|Drug|Placebo to Elbasvir|Placebo tablet matched to elbasvir
276972|NCT02092337|Other|computer-assisted speech training|
276973|NCT02092324|Other|Laboratory Biomarker Analysis|Correlative studies
276974|NCT02092324|Other|Quality-of-Life Assessment|Ancillary studies
276975|NCT02092324|Other|Questionnaire Administration|Ancillary studies
276976|NCT02092324|Drug|Ruxolitinib Phosphate|Given PO
276977|NCT02092311|Procedure|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
276978|NCT02092311|Procedure|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
276979|NCT02092298|Drug|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
276980|NCT02092298|Drug|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
276981|NCT02092298|Drug|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
276982|NCT02092285|Drug|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
276983|NCT02092272|Behavioral|instructional exercise video source|instructional exercise video source
276984|NCT02092246|Device|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
276985|NCT02092246|Device|Unguided injection|Needle placement will take place without ultrasound machine guidance
276986|NCT02092220|Device|Bionic Pancreas|
276987|NCT02092220|Device|Insulin pump with or without CGM|
276988|NCT02092207|Drug|KL7016 900mg|oral administration, 150mg 3tab, bid
276989|NCT02092207|Drug|KL7016 600mg|oral administration, 150mg 3tab, bid
276990|NCT02092207|Drug|Placebo|oral administration, 150mg 3tab, bid
276991|NCT02092194|Procedure|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
276992|NCT02092194|Procedure|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
276993|NCT02092181|Drug|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
276994|NCT02092181|Drug|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
276995|NCT02092168|Drug|BIA 9-1067|
276996|NCT02092142|Biological|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
276997|NCT02092116|Drug|Romidepsin|Latency reversing agent
276998|NCT02092116|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
276999|NCT02092116|Biological|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
277000|NCT02092103|Procedure|Cord Milking|See description in cord milking arm.
277001|NCT02092090|Behavioral|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
277002|NCT02092077|Drug|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
277003|NCT02092077|Drug|somatropin|Dose may be adjusted as required
277004|NCT02092051|Device|Continuous glucose monitoring with DexCom G4 platina|
277005|NCT02092038|Drug|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
277006|NCT02092038|Radiation|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
277007|NCT02092038|Procedure|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
277008|NCT02092038|Procedure|craniotomy and tumor resection|maximal safe resection
277009|NCT02092025|Drug|Azilsartan|Azilsartan tablets
277150|NCT02090933|Other|Laboratory Biomarker Analysis|Correlative studies
277010|NCT02092012|Drug|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
277011|NCT02092012|Drug|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
277012|NCT02091999|Drug|enfortumab vedotin|intravenous (IV) infusion
277013|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
277014|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
277015|NCT02091986|Other|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
277016|NCT02091973|Drug|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
277017|NCT02091973|Drug|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
277018|NCT02091960|Drug|Enzalutamide|Capsules for oral administration
277019|NCT02091960|Drug|Trastuzumab|Intravenous infusion (IV) or subcutaneous injection if it is standard of care within a country
277020|NCT02091947|Device|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
277021|NCT02091934|Procedure|Wavefront-guided PRK|Wavefront-guided PRK
277022|NCT02091934|Procedure|Wavefront-optimized PRK|Wavefront-optimized PRK
277023|NCT02091921|Drug|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
277024|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
277025|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
277026|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
277027|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
277028|NCT02091895|Procedure|probe-based confocal laser endomicroscopy|"After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.~Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.~Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this."
277029|NCT02091882|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one IEM tablet approximately every 2 hours, for a total of 4 ingestions. The subject will ingest one 10 mg aripiprazole-embedded IEM tablet without food (Hour 0), one placebo-embedded IEM tablet without food (approximately Hour 2), one placebo-embedded IEM tablet with a high fat meal (approximately Hour 4), and one placebo-embedded IEM tablet without food (approximately Hour 6). Aripiprazole-embedded IEM tablets are being tested along with the placebo-embedded IEM tables to assess any differences in accuracy of IEM detection and latency. The time of ingestion will be recorded by clinic staff, and the time of IEM detection by the MIND1 System phone will be evaluated to determine the period of latency.
277030|NCT02091869|Other|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
277031|NCT02091869|Device|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
277032|NCT02091856|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
277033|NCT02091843|Procedure|DBS of the Basolateral Nucleus of the Amygdala|
277034|NCT02091843|Device|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
277035|NCT02091830|Drug|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
277036|NCT02091830|Other|Physiotherapy|
277037|NCT02091830|Drug|Cortisone Injection|
277038|NCT02091830|Other|Others|
277039|NCT02091817|Drug|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
277040|NCT02091817|Drug|Placebo|Placebo will be given to control group and experimental group as well.
277041|NCT02091804|Behavioral|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
277042|NCT02091804|Behavioral|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
277043|NCT02091791|Procedure|Traction sessions|
277044|NCT02091778|Device|Fast gelling dressing|
277045|NCT02091765|Behavioral|Internet-based cognitive behavioral therapy.|
277151|NCT02090933|Procedure|UV Light Therapy|Undergo UV-irradiation
277319|NCT02089425|Drug|Placebo|Placebo comparator
277320|NCT02089412|Drug|E2006|
277046|NCT02091752|Drug|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to <200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
277047|NCT02091739|Drug|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
277048|NCT02091739|Drug|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
277049|NCT02091739|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
277050|NCT02091726|Procedure|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
277051|NCT02091713|Other|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
277052|NCT02091700|Other|Indocyanine Green ICG|
277053|NCT02091674|Device|Hyaluronic acid|Injected gel
277054|NCT02091661|Procedure|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
277055|NCT02091661|Radiation|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
277056|NCT02091648|Behavioral|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
277057|NCT02091648|Behavioral|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
277058|NCT02091635|Drug|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
277059|NCT02091635|Drug|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
277060|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
277061|NCT02091609|Other|dental interproximal brush|use of this to maintain oral hygiene
277062|NCT02091609|Other|dental floss|use of this to maintain oral hygiene
277063|NCT02091596|Drug|PluroGel N|Study Drug
277064|NCT02091596|Drug|PluroGel|PluroGel Vehicle Placebo Comparator
277065|NCT02091583|Dietary Supplement|Butter, sunflower and safflower oil|
277066|NCT02091583|Dietary Supplement|High Oleic Canola Oil and DHA (HOCO-DHA)|
277067|NCT02091583|Dietary Supplement|Barley beta-glucan|
277068|NCT02091583|Dietary Supplement|HOCO-DHA and Barley beta-glucan|
277069|NCT02091570|Other|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
277070|NCT02091557|Drug|GnRH-analogue|
277071|NCT02091544|Other|Lifestyle intervention|
277072|NCT02091531|Drug|MLN0128|
277073|NCT02091518|Behavioral|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
277074|NCT02091518|Device|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
277075|NCT02091505|Drug|Ranibizumab|
277076|NCT02091492|Drug|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
277077|NCT02091492|Drug|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
277276|NCT02089750|Other|Orthotics|
277321|NCT02089399|Drug|Sevikar(amlodipne/olmesartan)|Treatment AB
277078|NCT02091479|Drug|UFH Early group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
277079|NCT02091479|Drug|UFH Late group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).~Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
277080|NCT02091466|Device|pre-warming|warming patients 30 minutes prior to anesthesia
277081|NCT02091453|Behavioral|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
277082|NCT02091453|Behavioral|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
277083|NCT02091440|Device|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
277084|NCT02091414|Drug|mycophenolate mofetil (MMF)|1.0 g PO BID
277085|NCT02091414|Drug|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
277086|NCT02091414|Drug|corticosteroids|As per the practice of each participating center
277087|NCT02091401|Device|Springfusor infusion pump|
277088|NCT02091401|Other|IV administration|
277089|NCT02091401|Drug|Magnesium Sulfate|
277090|NCT02091388|Drug|LY03004|
277091|NCT02091388|Drug|Risperdal® Consta®|
277092|NCT02091375|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
277093|NCT02091375|Drug|Placebo control|Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
277094|NCT02091362|Drug|LY2409021|Administered orally
277095|NCT02091362|Drug|Placebo|Administered orally
277096|NCT02091362|Drug|Metformin|Administered as background therapy.
277097|NCT02091349|Other|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
277098|NCT02091349|Other|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
277099|NCT02091336|Drug|Metformin|patients treatment
277100|NCT02091336|Drug|Glyburide|patients treatment
277101|NCT02091323|Procedure|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 ~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
277102|NCT02091310|Drug|Placebo|
277103|NCT02091310|Drug|GFT505|
277104|NCT02091310|Drug|Moxifloxacin 400 mg|
277105|NCT02091297|Drug|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
277106|NCT02091297|Drug|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
277107|NCT02091297|Drug|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.~The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
277108|NCT02091297|Drug|Morphine|
277109|NCT02091284|Device|transcranial Direct Current Stimulation|Direct currents were transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode was placed over F3 according to the 10-20 international system while the anode was placed over the contralateral F4 region. The currents flowed continuously for 20 minutes with an intensity of 2 milliamperes.
277110|NCT02091245|Drug|KPT-330|
277111|NCT02091232|Biological|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
277112|NCT02091219|Drug|Vitamin D|2400 IU/day by mouth for 16 weeks
277113|NCT02091219|Drug|25(OH)D3|20 micrograms/day by mouth for 16 weeks
277316|NCT02089438|Drug|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
277114|NCT02091206|Drug|GWP42003-P 5 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/milliliter (mL) cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
277115|NCT02091206|Drug|Placebo control|Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
277116|NCT02091206|Drug|GWP42003-P 10 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
277117|NCT02091206|Drug|GWP42003-P 20 mg/kg/day Dose|GWP42003-P was an oral solution containing 25 mg/mL CBD or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants were randomly assigned to receive either 5, 10 or 20 mg/kg/day.
277118|NCT02091193|Dietary Supplement|Krill Oil (Supplement A)|
277119|NCT02091193|Dietary Supplement|Placebo (Supplement B)|
277120|NCT02091180|Drug|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
277121|NCT02091180|Drug|Control|Saline infusion
277122|NCT02091167|Device|transcranial Direct Current Stimulation|Direct currents are transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current is delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode is placed over F3 according to the 10-20 international system while the anode is placed over the contralateral F4 region. The currents flows continuously for 20 minutes with an intensity of 2 milliamperes.
277123|NCT02091154|Behavioral|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.~Fruit or vegetable on every tray~Meet requirements for vegetable varieties~50% of all grains must be whole grain~Milk must be 1% or skim; flavored milk must be skim"
277124|NCT02091154|Behavioral|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:~56''x72'' vinyl sign with the words [school mascot] Cafe~8.5''x11'' signs describing the foods offered on a specific day~2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.~Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
277125|NCT02091154|Behavioral|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:~Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.~Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.~Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
277126|NCT02091141|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277127|NCT02091141|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277128|NCT02091141|Drug|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277129|NCT02091141|Drug|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277130|NCT02091141|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277131|NCT02091141|Drug|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277132|NCT02091141|Drug|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277133|NCT02091141|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
277134|NCT02091115|Dietary Supplement|dairy drink with probiotic culture|The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
277135|NCT02091115|Dietary Supplement|Dairy drink|
277136|NCT02091102|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
277137|NCT02091089|Device|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
277138|NCT02091076|Device|Silk fibroin with bioactive coating layer dressing|
277139|NCT02091076|Device|Bactigras wound dressing|
277140|NCT02091063|Drug|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
277141|NCT02091050|Other|2D HDR planning|HDR planning using simple radiograph (2D)
277142|NCT02091050|Other|3D HDR planning|HDR planning using computed tomography (3D)
277143|NCT02091024|Dietary Supplement|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
277144|NCT02091024|Dietary Supplement|Placebo|Placebo 200mg, twice a day
277145|NCT02090998|Procedure|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
277146|NCT02090998|Drug|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
277147|NCT02090985|Procedure|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
277148|NCT02090959|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
277149|NCT02090933|Drug|Celecoxib|Given PO
277152|NCT02090920|Drug|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
277153|NCT02090907|Drug|Levothyroxine|
277154|NCT02090907|Drug|Placebo|
277155|NCT02090894|Device|UV Light (Laser Genesis)|
277156|NCT02090881|Other|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
277157|NCT02090868|Other|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
277158|NCT02090842|Dietary Supplement|Ca-caseinate|
277159|NCT02090842|Dietary Supplement|Maltodextrin|
277160|NCT02090842|Dietary Supplement|Whey protein isolate|
277161|NCT02090829|Drug|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
277162|NCT02090829|Other|Placebo|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.~Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.~One dose equals 6 spray puffs (3 puffs in each nostril)."
277163|NCT02090816|Procedure|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
277164|NCT02090790|Drug|iv dexamethasone|2 ml 8 mg iv dexamethasone
277165|NCT02090790|Drug|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
277166|NCT02090790|Drug|serum physiologic|2 ml iv serum physiologic
277167|NCT02090777|Behavioral|Health Coach|
277168|NCT02090764|Drug|Ozenoxacin|
277169|NCT02090764|Drug|Placebo|
277170|NCT02090738|Drug|Acetazolamide group|
277171|NCT02090738|Drug|Standard regimen group|
277172|NCT02090725|Drug|3-4 Diaminopyridine|
277173|NCT02090712|Procedure|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
277174|NCT02090686|Device|Pulsatile Cupping|"8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.~Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)"
277175|NCT02090686|Device|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
277176|NCT02090673|Drug|Exenatide|
277177|NCT02090660|Other|ICG Localization with Spy thoracoscope localization|
277178|NCT02090647|Behavioral|aesthetic outcome|
277179|NCT02090634|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
277180|NCT02090634|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
277181|NCT02090621|Procedure|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
277182|NCT02090608|Drug|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
277183|NCT02090595|Behavioral|MBCT-C|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
277184|NCT02090595|Behavioral|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
277185|NCT02090582|Other|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
277186|NCT02090582|Other|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
277187|NCT02090569|Device|Functional micro-Doppler Sonography (fmDS)|"Craniotomy according to MRI images~Dura opening~Sulcal Localization using neuronavigation~Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.~Exeresis of the dysplasic tissue~Control using fmDS before wound closure"
277188|NCT02090556|Drug|Abatacept|
277189|NCT02090543|Drug|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
277190|NCT02090543|Drug|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
277322|NCT02089399|Drug|crestor(Rosuvastatin)|Treatment AB/Treatment C
277191|NCT02090530|Other|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
277192|NCT02090517|Device|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
277193|NCT02090517|Device|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
277194|NCT02090517|Device|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
277195|NCT02090517|Procedure|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
277196|NCT02090504|Drug|Sodium Oxybate (SMO)|
277197|NCT02090504|Drug|Oxazepam|
277198|NCT02090478|Other|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
277199|NCT02090478|Other|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
277200|NCT02090465|Drug|Ingenol Mebutate|No intervention: observation of routine use of Picato®
277201|NCT02090452|Device|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
277202|NCT02090439|Drug|Silodosin|
277203|NCT02090426|Other|Link2Care|
277204|NCT02090413|Drug|dimethyl fumarate|
277205|NCT02090413|Drug|acetylsalicylic acid|enteric-coated capsule
277206|NCT02090413|Drug|ASA-Placebo|matched placebo
277207|NCT02090400|Drug|Bazedoxifene|20 mg Oral daily for 12 months
277208|NCT02090400|Drug|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
277209|NCT02090387|Other|ONS without AN777|2 servings a day
277210|NCT02090387|Other|ONS containing AN777|2 servings a day
277211|NCT02090374|Other|TLR Agonist|Preceding incremental ascending dose study to be used to assess top safe dose.
277212|NCT02090374|Other|Tuberculin nasal challenge|Preceding incremental ascending dose study to be used to assess safe top dose.
277213|NCT02090374|Other|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
277214|NCT02090361|Procedure|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
277215|NCT02090348|Drug|dimethyl fumarate|Administered as specified in the treatment arm
277216|NCT02090335|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
277217|NCT02090335|Behavioral|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
277218|NCT02090322|Procedure|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.~When there is a Retinopathy of prematurity type 1, is the indication for the infection"
277219|NCT02090309|Drug|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
277220|NCT02090309|Drug|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
277221|NCT02090296|Drug|Hydroxyurea|
277222|NCT02090296|Other|Placebo|
277223|NCT02090283|Drug|SD-101 dermal cream (6%)|SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
277224|NCT02090257|Behavioral|TRANSIT|Educational Modules, staff follow up.
277225|NCT02090244|Drug|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
277226|NCT02090231|Device|rTMS, Magstim Rapid2|5 Hz rTMS
277227|NCT02090218|Device|I-Gel|I-Gel supraglottic airway device
277228|NCT02090218|Device|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
277229|NCT02090205|Procedure|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
277230|NCT02090205|Procedure|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
277231|NCT02090205|Procedure|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
277232|NCT02090205|Device|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
277233|NCT02090205|Device|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
277234|NCT02090192|Procedure|WBV training|
277235|NCT02090192|Procedure|PRT training|
277236|NCT02090166|Other|Blood test|a blood test will be taken from each patient
277237|NCT02090153|Drug|S-1|40~60mg bid，d1~7 q2W
277238|NCT02090153|Drug|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
277239|NCT02090140|Procedure|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
277317|NCT02089438|Drug|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
277318|NCT02089425|Drug|K-103-IP|
277240|NCT02090140|Procedure|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
277241|NCT02090127|Drug|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
277242|NCT02090114|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
277243|NCT02090114|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
277244|NCT02090114|Drug|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
277245|NCT02090114|Drug|Enzalutamide (Cohort A = CLOSED TO ACCRUAL)|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
277246|NCT02090101|Drug|ANAKINRA|
277247|NCT02090088|Drug|Not applicable- observational study|
277248|NCT02090075|Drug|apixaban|5 po or 2.5 po bid.
277249|NCT02090075|Drug|warfarin|
277250|NCT02090049|Dietary Supplement|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
277251|NCT02090049|Dietary Supplement|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
277252|NCT02090036|Drug|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
277253|NCT02090036|Drug|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
277254|NCT02090010|Procedure|Seldinger technique|"The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.~After that catheter is passed over the guidewire into the vessel."
277255|NCT02090010|Procedure|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
277256|NCT02089997|Drug|Sodium Risedronate|Sodium risedronate tablets
277257|NCT02089984|Behavioral|Internet Based CBT Training|
277258|NCT02089958|Procedure|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
277259|NCT02089932|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
277260|NCT02089932|Drug|Placebo|
277261|NCT02089919|Biological|cancer stem cell vaccine|
277262|NCT02089893|Device|Fundus photography|Non-mydriatic fundus photographs
277263|NCT02089880|Device|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
277264|NCT02089880|Device|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
277265|NCT02089867|Other|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
277266|NCT02089867|Drug|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
277267|NCT02089867|Dietary Supplement|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
277268|NCT02089854|Drug|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
277269|NCT02089841|Drug|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
277270|NCT02089828|Other|autologous purified CD34+ cells|
277271|NCT02089828|Other|autologous peripheral blood mononuclear cells|
277272|NCT02089815|Behavioral|Home based exercise|modified Otago exercise program to simple designed home based exercise program
277273|NCT02089815|Other|fall prevention education and counseling|
277274|NCT02089802|Drug|Pazopanib|
277275|NCT02089763|Biological|pegylated recombinant human arginase|
277277|NCT02089750|Other|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
277278|NCT02089750|Other|Wait List|
277279|NCT02089737|Drug|Panitumumab|Panitumumab for intravenous infusion
277280|NCT02089698|Device|Mini-flared|Mini-flared Kelman tip
277281|NCT02089698|Device|Reversed tip|Reversed Kelman tip
277282|NCT02089685|Biological|Pembrolizumab|
277283|NCT02089685|Biological|PegIFN-2b|
277284|NCT02089685|Biological|Ipilimumab|
277285|NCT02089672|Device|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
277286|NCT02089659|Drug|Doravirine|Following an overnight fast, a single tablet of 100 mg doravirine was be administered orally
277287|NCT02089633|Biological|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
277288|NCT02089620|Drug|Yasmin|will be used every 21 days for three months by the patient
277289|NCT02089620|Dietary Supplement|Calver|Calver will be given daily for 3 months
277290|NCT02089620|Drug|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
277291|NCT02089620|Drug|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
277292|NCT02089607|Device|Thoracoabdominal Aortic Aneurysm Arm|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.~The graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches). The arteries to the liver, intestine, and kidneys will be have a stent (small tubular stainless steel structures) to help keep the arteries open and aligned with the fenestrations or branches."
277293|NCT02089607|Device|Aortic Arch Aneurysm Arm|The endovascular graft includes the main aortic arch portion and one to three cuffs (side branches) that allow the graft to be located in the aortic arch. The number of cuffs is decided based on the anatomy of your aneurysm. The arteries in the aortic arch are the innominate artery (Zone 0), left common carotid artery (Zone 1) and the left subclavian artery (Zone 2). These arteries supply the right arm and right side of the brain, the left side of the brain and the left arm, respectively. The main aortic endovascular graft will be connected into the innominate artery, left common carotid artery and left subclavian artery using additional stents into the branch vessels.
277294|NCT02089594|Drug|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
277295|NCT02089594|Drug|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
277296|NCT02089581|Drug|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
277297|NCT02089581|Drug|MRXXX|MRXXX
277298|NCT02089581|Drug|MR1XXX|
277299|NCT02089581|Drug|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
277300|NCT02089568|Drug|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
277301|NCT02089568|Drug|Normal Saline|Placebo - 0.9% saline
277302|NCT02089555|Procedure|Lumbar puncture|Cerebrospinal fluid (CSF) will be collected via lumbar puncture. During lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid. The procedure involves inserting a thin, hollow needle between the two lower vertebrae (lumbar region), through the spinal membrane (dura) and into the spinal canal and extracting a small amount of fluid. The procedure takes about 45 minutes.
277303|NCT02089555|Procedure|Blood draw|One tube of blood will be collected in an ethylenediaminetetraacetic acid (EDTA)-K2 plasma tube for DNA analysis.
277304|NCT02089555|Procedure|Magnetic Resonance Imaging (MRI)|Each participant will undergo Magnetic Resonance Imaging (MRI) analysis using a modified Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol with a 3 Tesla (3T) MRI Scan. The exam takes approximately 20 minutes.
277305|NCT02089542|Other|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
277306|NCT02089529|Drug|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
277307|NCT02089529|Drug|Placebo|Placebo with no information, positive information and neutral information
277308|NCT02089503|Other|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
277309|NCT02089490|Device|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
277310|NCT02089477|Other|Support group|"The participants in the intervention group receives the intervention and support consisting of:~Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.~SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
277311|NCT02089464|Device|NBS-guided rTMS|
277312|NCT02089464|Device|Sham rTMS|
277313|NCT02089464|Procedure|Task oriented rehabilitation|
277314|NCT02089451|Drug|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
277315|NCT02089438|Drug|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
277323|NCT02089386|Drug|Tamoxifen|
277325|NCT02089373|Procedure|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
277326|NCT02089373|Procedure|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
277327|NCT02089347|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
277328|NCT02089347|Biological|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
277329|NCT02089334|Drug|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
277330|NCT02089308|Drug|Test treatment : V0116 transdermal patch|
277331|NCT02089308|Drug|Reference treatment : Nicotine transdermal patch|
277332|NCT02089295|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
277333|NCT02089295|Drug|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
277334|NCT02089295|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
277335|NCT02089282|Device|Ultrasound|
277336|NCT02089256|Drug|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.~GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
277337|NCT02089243|Procedure|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
277338|NCT02089243|Procedure|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
277339|NCT02089230|Drug|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.~Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
277340|NCT02089217|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy
277341|NCT02089217|Device|Carotid Stenting (CAS)|Carotid stenting
277342|NCT02089217|Other|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
277343|NCT02089217|Other|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
277344|NCT02089204|Radiation|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
277345|NCT02089204|Radiation|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
277346|NCT02089204|Radiation|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
277347|NCT02089191|Device|Nelfilcon A contact lenses|
277348|NCT02089191|Device|Stenfilcon A contact lenses|
277349|NCT02089178|Procedure|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
277350|NCT02089178|Procedure|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
277351|NCT02089178|Drug|propofol-remifentanil|
277352|NCT02089178|Drug|sevoflurane-remifentanil|
277353|NCT02089165|Dietary Supplement|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
277354|NCT02089165|Dietary Supplement|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
277355|NCT02089165|Dietary Supplement|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
277356|NCT02089152|Other|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
277357|NCT02089139|Device|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
277358|NCT02089139|Other|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:~medications (analgesics, NSAIDs, muscle relaxants),~physical therapy,~manual techniques,~transcutaneous electrical nerve stimulation (TENS),~blocks"
277359|NCT02089126|Drug|Gemigliptin/Glimepiride combination|
277360|NCT02089113|Drug|Dexamethasone|
277361|NCT02089113|Procedure|Placebo Vehicle|
277362|NCT02089100|Radiation|stereotactic body radiation therapy|
277363|NCT02089100|Radiation|Systemic treatment|
277364|NCT02089087|Biological|CFZ533|Single dose at varying dosage levels depending on treatment assignment
277365|NCT02089087|Drug|Placebo|
277366|NCT02089074|Behavioral|Drug use counselling|
277367|NCT02089061|Drug|BMS-919373|
277368|NCT02089061|Drug|Rosuvastatin|
277369|NCT02089061|Drug|Atorvastatin|
277370|NCT02089048|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
277371|NCT02089035|Dietary Supplement|MUFA-rich dairy products (UHT milk, cheese and butter)|
277372|NCT02089035|Dietary Supplement|Conventional dairy products (UHT milk, cheese, butter)|
277373|NCT02089022|Other|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
277374|NCT02089009|Other|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
277375|NCT02089009|Other|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
277376|NCT02089009|Other|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
277377|NCT02088996|Device|longwave diathermy on high power and interferential therapy|
277378|NCT02088996|Device|longwave diathermy on low power|
277379|NCT02088983|Dietary Supplement|CDP-Choline|Capsule
277380|NCT02088983|Dietary Supplement|Cellulose|Capsule
277381|NCT02088970|Device|Crosslinking|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.~Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
277382|NCT02088970|Drug|antibiotic treatment|"If not the contact lens wearer -> Cocci Gram positive cocci~Vancomycin + Fortum~If contact lens wearer -> Gram negative bacillus~Fortum + Amiklin~If corticosteroids, immunosuppression, latent evolution -> Fungus.~= Fortum + vancomycin + Fungizone"
277383|NCT02088957|Drug|Brivaracetam intravenous solution|"Active Substance: Brivaracetam~Pharmaceutical Form: Solution for infusion~Concentration: 10 mg/mL~Route of Administration: Intravenous bolus use"
277384|NCT02088957|Drug|Brivaracetam oral tablets|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)~Route of Administration: Oral use"
277385|NCT02088957|Drug|Phenytoin intravenous solution|"Active Substance: Phenytoin~Pharmaceutical Form: Solution for infusion~Concentration: 50 mg/mL~Route of Administration: Intravenous use"
277386|NCT02088957|Drug|Phenytoin oral tablets|"Active Substance: Phenytoin~Pharmaceutical Form: Tablet~Concentration: Weight based~Route of Administration: Oral use"
277387|NCT02088944|Drug|Infliximab|
277388|NCT02088931|Biological|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease <50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
277389|NCT02088918|Drug|Nateglinide|
277390|NCT02088918|Drug|Nateglinide/Metformin|
277391|NCT02088918|Drug|Metformin|
277392|NCT02088905|Behavioral|Parent Child Interaction Therapy|Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
277393|NCT02088892|Drug|BCG SSI|Intradermal injection
277394|NCT02088892|Drug|BCG Tice|Intradermal injection
277395|NCT02088879|Behavioral|chest compression with kneeling position|
277396|NCT02088879|Behavioral|chest compression with standing position|
277397|NCT02088866|Drug|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
277398|NCT02088853|Dietary Supplement|high fat diet (hfd)|Sixty % of the energy content is based on fat.
277399|NCT02088853|Dietary Supplement|high carb diet|Sixty % of the energy content is based on carbohydrates.
277400|NCT02088827|Other|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
277401|NCT02088827|Other|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
277402|NCT02088814|Behavioral|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
277403|NCT02088801|Device|Airtraq, blade without channel for tracheal tube intubation|Intubation
277404|NCT02088801|Device|KingVision , blade without channel for tracheal tube intubation|
277405|NCT02088801|Device|A.P. Advance, blade without channel for tracheal tube intubation|
277406|NCT02088801|Device|Macintosh|
277407|NCT02088788|Device|Board|Also has radio-dense pelvic shielding
277408|NCT02088788|Device|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
277409|NCT02088775|Procedure|PET scan|Undergo PET-CT scan
277410|NCT02088775|Procedure|CT Scan|Undergo PET-CT scan
277411|NCT02088775|Procedure|hepatic artery embolization|Undergo standard radioembolization
277412|NCT02088762|Procedure|surgical excision|comparison of safety margin 1 versus 2 cm
277413|NCT02088749|Behavioral|lifestyle intervention for obesity|
277414|NCT02088736|Device|Intraosseous|
277415|NCT02088736|Device|Intravenous|
277749|NCT02086188|Drug|Mirabegron|see detailed information in associated Arm Description
277416|NCT02088723|Behavioral|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
277417|NCT02088710|Behavioral|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
277418|NCT02088697|Drug|Placebo|
277419|NCT02088697|Drug|ASC-01|
277420|NCT02088684|Drug|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
277421|NCT02088684|Drug|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
277422|NCT02088684|Drug|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
277423|NCT02088684|Drug|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
277424|NCT02088671|Drug|Propofol induction followed by randomized doses of desflurane|Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
277425|NCT02088671|Device|Recording of EEG using NeuroSENSE|"The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.~The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.~Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest."
277426|NCT02088671|Other|Data collection|"Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.~The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).~The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).~The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information."
277427|NCT02088671|Other|Drug: Emergence by stepping down the desflurane ET|Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
277428|NCT02088658|Behavioral|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
277429|NCT02088645|Drug|177Lu-PP-F11N|
277430|NCT02088632|Biological|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
277431|NCT02088632|Other|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
277432|NCT02088619|Behavioral|Quality of Life Therapy (QOLT)|
277433|NCT02088619|Behavioral|Heart Healthy Education (HHE)|
277434|NCT02088593|Device|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
277435|NCT02088593|Behavioral|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
277436|NCT02088580|Procedure|Triple Chronotherapy|
277437|NCT02088567|Procedure|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
277438|NCT02088567|Other|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
277439|NCT02088554|Device|Model 400 aortic valve bioprosthesis|
277440|NCT02088541|Drug|Selinexor|20 mg oral tablets
277441|NCT02088541|Drug|Hydroxyurea|
277442|NCT02088541|Drug|Ara-C|
277443|NCT02088541|Drug|Azacitidine|
277444|NCT02088541|Drug|Decitabine|
277445|NCT02088528|Device|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
277446|NCT02088528|Procedure|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
277447|NCT02088515|Drug|Nedaplatin|
277448|NCT02088515|Drug|Cisplatin|
277449|NCT02088515|Drug|Docetaxel|
277450|NCT02088502|Drug|N-acetylcysteine|
277451|NCT02088502|Drug|Theophylline|
277452|NCT02088502|Drug|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
277453|NCT02088489|Device|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
277454|NCT02088489|Device|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
277455|NCT02088463|Procedure|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
277456|NCT02088463|Procedure|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
277457|NCT02088463|Device|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
277458|NCT02088450|Drug|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
277459|NCT02088437|Other|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
277460|NCT02088437|Other|Usual Care|once daily physiotherapy whilst acute hospital inpatient
277461|NCT02088424|Other|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
277462|NCT02088411|Drug|Diclofenac|
277463|NCT02088411|Dietary Supplement|Wobenzym|
277464|NCT02088411|Other|Placebo|
277465|NCT02088398|Drug|ACY-1215|
277466|NCT02088385|Device|Hemospray|
277467|NCT02088385|Device|Combined Conventional Technique|
277468|NCT02088372|Device|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
277469|NCT02088359|Other|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
277470|NCT02088359|Other|Continue near darkness|We covered the incubator with blanket all days.
277471|NCT02088346|Other|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
277472|NCT02088333|Behavioral|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
277473|NCT02088333|Behavioral|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
277474|NCT02088307|Dietary Supplement|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
277475|NCT02088294|Behavioral|Lifestyle Education (LS)|See arm description
277476|NCT02088294|Behavioral|LS + Stress Reduction Guided Imagery|See Arm Description
277477|NCT02088294|Behavioral|LS + Activity/Eating Guided Imagery|See arm description
277478|NCT02088281|Drug|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
277479|NCT02088268|Other|wound healing|wound healing
277480|NCT02088255|Procedure|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
277481|NCT02088255|Procedure|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
277482|NCT02088242|Drug|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
277483|NCT02088242|Drug|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
277484|NCT02088216|Drug|N-acetylcysteine|600mg po twice a day for 12 months
277485|NCT02088216|Other|On-demand treatment|receive as-needed therapy
277486|NCT02088203|Dietary Supplement|Dose 1|Russian Tarragon Nutrasorb 0.3 g
277487|NCT02088203|Dietary Supplement|Dose 2|Russian Tarragon Nutrasorb 1 g
277488|NCT02088203|Dietary Supplement|Dose 0|Placebo
277489|NCT02088203|Dietary Supplement|Dose 3|Russian Tarragon Nutrasorb 3 g
277490|NCT02088203|Dietary Supplement|Dose 4|Russian Tarragon Nutrasorb 10 g
277491|NCT02088203|Dietary Supplement|Dose 5|Russian Tarragon Nutrasorb 20 g
277492|NCT02088203|Dietary Supplement|Dose 6|Russian Tarragon Nutrasorb 30 g
277493|NCT02088190|Procedure|Sleeve gastrectomy|Type of bariatric surgery
277494|NCT02088177|Drug|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
277495|NCT02088151|Device|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
277496|NCT02088138|Device|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
277497|NCT02088138|Device|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
277498|NCT02088125|Other|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
277499|NCT02088125|Other|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
277500|NCT02088112|Drug|Gefitinib|Gefitinib QD
277501|NCT02088112|Drug|MEDI4736|MEDI4736 IV Q2W
277502|NCT02088099|Other|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
277503|NCT02088099|Other|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
277504|NCT02088086|Behavioral|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
277505|NCT02088086|Behavioral|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
277506|NCT02088086|Behavioral|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
277507|NCT02088073|Drug|Sodium zirconium cyclosilicate|Sodium zirconium cyclosilicate
277508|NCT02088073|Drug|Placebo|Randomized to mimic doses of experimental drug administered once daily with breakfast for 28 days (maintenance phase)
277509|NCT02088060|Drug|Cannabidiol|Cannabidiol capsules
277510|NCT02088060|Drug|Olanzapine|Olanzapine capsules
277511|NCT02088060|Drug|Placebo Cannabidiol|Placebo cannabidiol capsules
277512|NCT02088060|Drug|Placebo Olanzapine|Placebo olanzapine capsules
277513|NCT02088047|Device|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
277514|NCT02088034|Behavioral|Prometra led intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
277515|NCT02088034|Drug|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
277516|NCT02088034|Other|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
277517|NCT02088021|Device|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
277518|NCT02088008|Drug|cinidipine, valsartan|
277519|NCT02087995|Device|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
277520|NCT02087969|Procedure|Dry Needling|
277521|NCT02087969|Procedure|Stretching|
277522|NCT02087956|Behavioral|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
277523|NCT02087956|Behavioral|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
277524|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
277525|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
277526|NCT02087943|Drug|Placebo|Orally twice a day (BID)
277527|NCT02087943|Drug|Placebo|Orally twice a day (BID)
277528|NCT02087917|Drug|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
277529|NCT02087917|Drug|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
277530|NCT02087904|Biological|ABT-981|
277531|NCT02087904|Other|Placebo|
277532|NCT02087891|Behavioral|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
277533|NCT02087891|Behavioral|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
277534|NCT02087891|Behavioral|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
277535|NCT02087865|Drug|donepezil HCL|
277536|NCT02087865|Drug|Placebo|
277537|NCT02087852|Other|salvia for germline DNA|
277538|NCT02087852|Behavioral|the Kidney Cancer Questionnaire|
277539|NCT02087852|Behavioral|Family History Questionnaire (when applicable)|
277540|NCT02087826|Other|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
277541|NCT02087826|Drug|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
277542|NCT02087813|Drug|Alpha1-antitrypsin|
277543|NCT02087813|Drug|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
277544|NCT02087800|Behavioral|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
277545|NCT02087800|Behavioral|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
277546|NCT02087787|Behavioral|BMT Legal Clinic|2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
277547|NCT02087774|Behavioral|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
277548|NCT02087748|Drug|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
277549|NCT02087748|Drug|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
277550|NCT02087735|Dietary Supplement|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
277551|NCT02087722|Drug|KI1001|
277552|NCT02087722|Drug|Placebo|
277553|NCT02087709|Other|Low-calorie diet|
277554|NCT02087696|Drug|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
277555|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
277556|NCT02087683|Other|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
277557|NCT02087670|Other|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
277558|NCT02087670|Other|exercise protocol no supervised|Exercise program at the community
277559|NCT02087657|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
277560|NCT02087644|Biological|CYT003|Injections
277561|NCT02087644|Biological|Placebo|Injections
277562|NCT02087631|Drug|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
277563|NCT02087618|Other|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
277564|NCT02087618|Other|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
277565|NCT02087592|Behavioral|Structured exercise training plus mediterranean diet|
277566|NCT02087579|Drug|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
277567|NCT02087579|Drug|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
277568|NCT02087579|Drug|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
277569|NCT02087579|Drug|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
277570|NCT02087579|Drug|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
277571|NCT02087579|Drug|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
277986|NCT02084485|Drug|PH-797804|30 MG Single dose
277572|NCT02087579|Drug|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
277573|NCT02087566|Drug|600 mg linezolid|
277574|NCT02087553|Biological|Transfusion of red blood cells|(non-experimental) PRBC transfusion
277575|NCT02087553|Biological|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
277576|NCT02087540|Drug|Telmisartan 80mg|
277577|NCT02087540|Drug|Rosuvastatin 20mg|
277578|NCT02087540|Drug|Rosuvastatin 10mg|
277579|NCT02087540|Drug|Placebo(for Telmisartan 80mg)|
277580|NCT02087540|Drug|Placebo(for Rosuvastatin 20mg)|
277581|NCT02087540|Drug|Placebo(for Rosuvastatin 10mg)|
277582|NCT02087527|Drug|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
277583|NCT02087527|Drug|Normal Saline|IV normal saline every 6 hours for 48 hours
277584|NCT02087514|Procedure|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
277585|NCT02087514|Other|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.~A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.~The number of weeks in storage are as follows:~1 week~2 weeks~3 weeks~4 weeks~5 weeks~6 weeks"
277586|NCT02087501|Device|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
277587|NCT02087488|Other|auricular acupuncture(AA)|"Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.~Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.~Treatment frequency: every 3 days.~Duration: 4 weeks."
277588|NCT02087488|Other|placebo AA|"Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).~Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.~Treatment frequency: every 3 days.~Duration: 4 weeks."
277589|NCT02087488|Drug|Eszopiclone|"Dosage form: tablet.~Dosage: 1 piece (3mg).~Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.~Production license: NO. H20100074 approved by the state.~Treatment frequency: 15 mins before going to bed everyday.~Duration: 4 weeks."
277590|NCT02087475|Drug|Irinotecan|
277591|NCT02087475|Drug|5-fluorouracil|
277592|NCT02087475|Radiation|Local radiotherapy|
277593|NCT02087475|Procedure|R0 resection|
277594|NCT02087462|Other|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.~Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.~Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.~Duration: 6 weeks."
277595|NCT02087462|Other|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
277596|NCT02087462|Drug|Voltaren|"Medication: 50 mg, twice per day~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
277597|NCT02087462|Drug|Vitamin B1|"Medication: 10mg, twice per day.~Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.~Duration: 6 weeks."
277598|NCT02087449|Device|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
277599|NCT02087436|Device|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
277600|NCT02087436|Device|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
277601|NCT02087423|Drug|MEDI4736|MEDI4736 (durvalumab) by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier. Patients who achieve CR, PR or SD through the end of the initial 12-month treatment period can restart treatment with MEDI4736 (durvalumab) when they eventually do progress. This retreatment period can continue for as long as the investigator considers to patient to be receiving clinical benefit.
277602|NCT02087397|Other|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
277603|NCT02087397|Biological|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
277604|NCT02087384|Biological|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
277605|NCT02087384|Drug|Placebo|injection of 0.9% saline
277606|NCT02087332|Drug|Prolonged release Torasemide (Britomar)|
277607|NCT02087332|Drug|Torasemide (Diuver)|
277608|NCT02087319|Other|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
277609|NCT02087306|Drug|CMX001|CMX001 administered twice weekly, dose depending on weight.
277610|NCT02087293|Behavioral|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
277611|NCT02087267|Procedure|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
277612|NCT02087241|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
277613|NCT02087241|Drug|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
277614|NCT02087241|Drug|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
277615|NCT02087241|Drug|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
277616|NCT02087228|Device|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
277617|NCT02087228|Device|radiofrequency energy ablation device|
277618|NCT02087215|Drug|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
277619|NCT02087215|Drug|Placebo|
277620|NCT02087202|Drug|Magnesium Sulfate|magnesium sulfate is added to the patients
277621|NCT02087202|Drug|ketamine|ketamine is added to the patients.
277622|NCT02087189|Device|First ICD/CRT-D implantation or upgrade from pacemaker|
277623|NCT02087176|Drug|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
277624|NCT02087176|Drug|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
277625|NCT02087176|Drug|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
277626|NCT02087176|Drug|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
277627|NCT02087163|Device|Movement Enhancement Technique|Conventional Orthodontic treatment
277628|NCT02087163|Device|Clear Aligner|Orthodontic treatment with Clear Aligner
277629|NCT02087150|Device|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
277630|NCT02087137|Behavioral|Memory and Aging Program|
277631|NCT02087124|Other|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
277632|NCT02087111|Drug|Telaprevir|375 mg film coated tablets
277633|NCT02087111|Drug|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
277634|NCT02087111|Drug|Ribavirin|200 mg tablets
277635|NCT02087098|Drug|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
277636|NCT02087085|Drug|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye using Brimo DDS® applicator on Day 1, and every 3 months through Month 21.
277637|NCT02087085|Other|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
277638|NCT02087072|Other|Collaborative visit with provider and pharmacist|
277639|NCT02087059|Drug|Ruxolitinib|
277640|NCT02087046|Device|Deep Brain Stimulation with the Libra System|Deep Brain Stimulation programmed to eliminate tremor
277641|NCT02087033|Dietary Supplement|ritmonutra|2 tablets a day by mouth for 4 weeks
277642|NCT02087033|Dietary Supplement|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
277643|NCT02087020|Procedure|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (> 9 litre) with 0.9 % sodium chloride and then closed.
277644|NCT02087007|Drug|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
277645|NCT02087007|Drug|placebo|100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
277646|NCT02086994|Drug|misoprostol|given after the delivery of the anterior shoulder of the baby.
277647|NCT02086994|Drug|carbetocin|given after delivery of anterior shoulder
277648|NCT02086968|Drug|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
277649|NCT02086968|Drug|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
277650|NCT02086955|Behavioral|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
277651|NCT02086942|Drug|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
277652|NCT02086942|Drug|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
277653|NCT02086942|Drug|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
277654|NCT02086929|Drug|Trazodone|
277655|NCT02086929|Drug|Venlafaxine|
277656|NCT02086903|Drug|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
277657|NCT02086903|Drug|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
277658|NCT02086890|Device|Electro-acupuncture|
277659|NCT02086890|Device|Laser Acupuncture|
277660|NCT02086890|Device|Transcorneal Electrical Stimulation|
277661|NCT02086890|Device|Sham Electro-acupuncture|
277662|NCT02086890|Device|Sham laser acupuncture|
277663|NCT02086890|Device|Sham transcorneal electrical stimulation|
277664|NCT02086864|Drug|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
277665|NCT02086864|Drug|Placebo lactose/sucrose pill|
277666|NCT02086864|Behavioral|Homeopathic consultation|
277667|NCT02086851|Behavioral|Lifestyle Intervention|
277668|NCT02086851|Behavioral|Parent Motivational Interviewing|
277669|NCT02086838|Drug|Theragran Hematinic|
277670|NCT02086838|Drug|low molecular weight iron dextran|
277671|NCT02086825|Drug|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
277672|NCT02086825|Drug|Lactulose|20g dose titrated
277673|NCT02086799|Drug|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
277674|NCT02086799|Drug|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
277675|NCT02086786|Drug|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.~Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
277676|NCT02086773|Biological|Red blood cell transfusion|
277677|NCT02086760|Other|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
277678|NCT02086760|Radiation|Scintigraphy|
277679|NCT02086747|Drug|Acetaminophen|100 ml iv, 4 times a day for 72 hours
277680|NCT02086747|Drug|Isotonic|100 ml iv, 4 times a day for 72 hours
277681|NCT02086734|Other|Perfusion-CT|"Baseline Perfusion CT-Scan (before AAT)~Follow-Up I Perfusion-CT Scan 7 days after start with AAT~Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
277682|NCT02086721|Drug|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
277683|NCT02086708|Device|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
277684|NCT02086669|Procedure|Pneumatic dilatation|
277685|NCT02086669|Procedure|Laparoscopic myotomy|
277686|NCT02086656|Drug|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
277687|NCT02086643|Procedure|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
277688|NCT02086630|Behavioral|Heart to Heart|
277689|NCT02086617|Other|ultrasound of aorta|
277690|NCT02086604|Drug|Brentuximab vedotin|
277691|NCT02086604|Drug|Lenalidomide|
277692|NCT02086591|Drug|Doxycycline|
277693|NCT02086578|Device|Breast MRI|
277694|NCT02086578|Behavioral|Breast-Q© questionnaire|
277695|NCT02086578|Radiation|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
277696|NCT02086565|Behavioral|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
277697|NCT02086565|Behavioral|Portal training|training in use of patient portal
277698|NCT02086552|Other|Laboratory Biomarker Analysis|Correlative studies
277699|NCT02086552|Drug|Lenalidomide|Given PO
277700|NCT02086552|Drug|Sonidegib|Given PO
277701|NCT02086539|Other|Large Envelope|
277702|NCT02086539|Other|Priority Mail|
277703|NCT02086539|Other|Amazon|
277704|NCT02086526|Drug|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
277705|NCT02086513|Drug|LDE225|Treatment with LDE225
277706|NCT02086500|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
277707|NCT02086500|Other|Saline control|Saline Control
277750|NCT02086188|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
277751|NCT02086175|Drug|Imprime PGG|
277708|NCT02086487|Drug|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript > 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at > 12 months; i.e (BCR-ABL1 0.1 -1%)"
277709|NCT02086474|Drug|Hyaluronan|Intra-articular injection
277710|NCT02086474|Drug|Bupivacaine|Extra-capsular injection
277711|NCT02086461|Device|Pneumatic pyloric dilatation|
277712|NCT02086461|Other|15 mm pyloric balloon dilatation|
277713|NCT02086448|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
277714|NCT02086448|Device|sham-CPAP|
277715|NCT02086448|Other|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
277716|NCT02086435|Procedure|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
277717|NCT02086435|Procedure|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
277718|NCT02086422|Drug|ivabradine|
277719|NCT02086422|Drug|Placebo|
277720|NCT02086422|Other|Exercise|
277721|NCT02086409|Dietary Supplement|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
277722|NCT02086409|Dietary Supplement|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
277723|NCT02086396|Dietary Supplement|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
277724|NCT02086396|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
277725|NCT02086370|Procedure|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
277726|NCT02086370|Procedure|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
277727|NCT02086357|Procedure|SWUE|
277728|NCT02086344|Procedure|PBS|TLH plus PBS
277729|NCT02086344|Procedure|TLH _adnexal preservation|TLH without PBS
277730|NCT02086331|Procedure|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
277731|NCT02086331|Behavioral|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
277732|NCT02086331|Procedure|Contrast enhanced ultrasound|
277733|NCT02086318|Other|OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
277734|NCT02086305|Behavioral|Transitional Care Model|Symptom assessment and management, care goal setting, post-discharge support
277735|NCT02086305|Behavioral|Usual care|Usual care is the routine practice in the hospital
277736|NCT02086292|Procedure|2 ml 1% Lidocaine|
277737|NCT02086292|Procedure|1 ml 2% Lidocaine|
277738|NCT02086279|Drug|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
277739|NCT02086266|Other|PILATES|
277740|NCT02086266|Other|PFMT and AES|
277741|NCT02086253|Drug|BQ-788 and/or BQ-123|
277742|NCT02086240|Drug|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
277743|NCT02086227|Drug|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
277744|NCT02086227|Drug|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
277745|NCT02086214|Device|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
277746|NCT02086214|Device|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
277747|NCT02086201|Behavioral|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
277748|NCT02086201|Behavioral|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
277753|NCT02086162|Behavioral|Web-based motivational decision support system|
277754|NCT02086162|Behavioral|NCI Education|
277755|NCT02086149|Behavioral|Aerobic Exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
277756|NCT02086149|Behavioral|Health Education|12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
277757|NCT02086123|Procedure|Epidural Analgesia|Bupivacaine + Fentanyl
277758|NCT02086123|Procedure|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
277759|NCT02086110|Dietary Supplement|Synbiotic|
277760|NCT02086110|Dietary Supplement|Prebiotic|
277761|NCT02086097|Drug|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
277762|NCT02086097|Drug|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
277763|NCT02086097|Drug|PLACEBO|INACTIVE SUGAR PILLS
277764|NCT02086084|Device|NIV|Standard care
277765|NCT02086084|Device|ECCO2R|Application of ECCO2R in addition to NIV
277766|NCT02086071|Procedure|re biopsy|re biopsy depending on the location of the pathology
277767|NCT02086045|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
277768|NCT02086032|Drug|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
277769|NCT02086032|Drug|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
277770|NCT02086032|Drug|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
277771|NCT02086019|Drug|Conservative Arm|crossover to angiogram only if predefined criteria met
277772|NCT02086019|Procedure|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
277773|NCT02086006|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
277774|NCT02085980|Device|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
277775|NCT02085967|Drug|rifampin 600 mg|
277776|NCT02085967|Drug|itraconazole 200 mg|
277777|NCT02085967|Drug|midazolam 2 mg with bupropion 75 mg|
277778|NCT02085967|Drug|E2006|
277779|NCT02085941|Procedure|Cryoablation|Type and number (Mean 3, range 1-10) of cryoprobe(s) used depend on size and shape of target lesion
277780|NCT02085941|Device|Biopsy|If target lesion has not been previously biopsied, a core biopsy may be taken prior to the cryoablation.
277781|NCT02085928|Other|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|"The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).~The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.~The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon."
277782|NCT02085915|Other|strip Peri Screen|
277783|NCT02085902|Drug|Ropivacaine|
277784|NCT02085889|Other|no intervention: observational study|observational
277785|NCT02085876|Other|2 additional MRI sequences|
277786|NCT02085876|Other|An additional blood sample|
277787|NCT02085863|Drug|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
277788|NCT02085863|Drug|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
277789|NCT02085837|Other|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
277790|NCT02085837|Other|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
277791|NCT02085837|Other|Universal Dietary education|To improve diet and health
277792|NCT02085837|Other|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
277793|NCT02085837|Other|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
277794|NCT02085837|Other|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
277795|NCT02085824|Drug|Enoxaparin|
277796|NCT02085824|Drug|rivaroxaban|
277797|NCT02085824|Drug|dabigatran|
277798|NCT02085811|Other|radiography standard|
277799|NCT02085798|Other|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
277800|NCT02085785|Behavioral|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials [e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
277801|NCT02085785|Behavioral|Self-directed control group|Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group [e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
277802|NCT02085785|Other|Screened only|Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
277803|NCT02085772|Other|Blood samples at 37-38 Weeks of amenorrhea|
277804|NCT02085772|Other|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
277805|NCT02085746|Other|Defining Sexual Activity Questionnaire|
277806|NCT02085720|Device|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
277807|NCT02085707|Procedure|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
277808|NCT02085707|Procedure|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
277809|NCT02085694|Drug|Lactobacillus brevis CD2|
277810|NCT02085681|Other|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
277811|NCT02085681|Other|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
277812|NCT02085668|Device|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
277813|NCT02085655|Drug|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
277814|NCT02085655|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
277815|NCT02085655|Drug|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
277816|NCT02085655|Drug|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
277817|NCT02085655|Drug|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
277818|NCT02085655|Drug|Thalidomide|100-200mg, PO, after chemotherapy
277819|NCT02085642|Other|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
277820|NCT02085642|Other|Sham needle|Retractable needle with no skin puncture
277821|NCT02085629|Biological|Donor M reg (Mreg_UKR)|"Experimental: M reg treatment~Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description)."
277822|NCT02085616|Behavioral|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
277823|NCT02085616|Behavioral|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
277824|NCT02085603|Drug|Saracatinib|
277825|NCT02085603|Drug|Placebo|
277826|NCT02085590|Biological|BCG vaccine|
277827|NCT02085590|Biological|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
277828|NCT02085577|Drug|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
277829|NCT02085577|Drug|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
277830|NCT02085577|Drug|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
277831|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
277832|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
277833|NCT02085577|Drug|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
277834|NCT02085577|Drug|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
277835|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
277836|NCT02085577|Drug|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
277837|NCT02085564|Procedure|Peritoneal washing cytology|The methode is describes in the detailed study description
277838|NCT02085551|Device|Mechanical Thrombectomy by the Indigo System|
277839|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
277840|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
277841|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
277842|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
277843|NCT02085525|Other|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.~Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
277940|NCT02084784|Drug|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
277941|NCT02084784|Drug|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
277844|NCT02085512|Procedure|Neurocognitive retraining Web Based Intervention|"Neurobehavioral training will be delivered through the web, with prompting for training tasks accomplished through daily emails that include a single integrated log-in system using a customized implementation with OneLogin. All training tasks have game-like features making them visually engaging, and motivating. The training tasks provide immediate feedback about performance, and are specifically designed to target circuitry critical for executive functioning (EF) and emotional reactivity."
277845|NCT02085512|Other|Control, web-based tasks|No training modules
277846|NCT02085499|Device|non-synchronized NIMV|"During the study each infant will undergo a 2-hour period of NIMV at a frequency of 30 cycles per minute.~NIMV will be provided by a time cycled, pressure limited neonatal ventilator (Puritan Bennett 840, Covidien, Boulder, CO)."
277847|NCT02085499|Device|Synchronized NIMV|"During the study each infant will undergo a 2-hour period of S-NIMV at a frequency of 30 cycles per minute.~S-NIMV will be provided by a time cycled, pressure limited neonatal ventilator, with leak compensation capacity and nasal flow triggered ventilation (Puritan Bennett 840, Covidien, Boulder, CO). Synchronization will be achieved by the leak compensation software and the internal sensor of the ventilator."
277848|NCT02085486|Device|Ultrasound-assisted puncture|Portable ultrasound device
277849|NCT02085486|Other|Standard|Standard inspection, palpation.
277850|NCT02085473|Biological|Tralokinumab 300 mg|Participants will receive 300 milligram (mg) tralokinumab when delivered as a 2 milliliter (mL) subcutaneous injection at different flow rates.
277851|NCT02085460|Drug|Placebo|
277852|NCT02085460|Drug|2% Rebamipide liquid|
277853|NCT02085460|Drug|4% Rebamipide liquid|
277854|NCT02085447|Behavioral|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
277855|NCT02085434|Behavioral|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
277856|NCT02085421|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
277857|NCT02085408|Drug|clofarabine|Given IV
277858|NCT02085408|Drug|daunorubicin hydrochloride|Given IV
277859|NCT02085408|Other|clinical observation|Undergo clinical observation
277860|NCT02085408|Drug|cytarabine|Given IV
277861|NCT02085408|Drug|decitabine|Given IV
277862|NCT02085408|Other|laboratory biomarker analysis|Correlative studies
277863|NCT02085408|Procedure|quality-of-life assessment|Ancillary studies
277864|NCT02085408|Other|questionnaire administration|Ancillary studies
277865|NCT02085395|Drug|SR-T100 ® Gel|
277866|NCT02085382|Procedure|Kangaroo Mother Care|"The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.~When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered."
277867|NCT02085382|Procedure|Conventional Mother Care|"This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.~Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted."
277868|NCT02085356|Behavioral|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.~Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
277869|NCT02085343|Behavioral|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
277870|NCT02085343|Behavioral|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
277983|NCT02084511|Drug|Celecoxib|Celecoxib capsule
277984|NCT02084498|Device|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
277871|NCT02085343|Behavioral|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
277872|NCT02085330|Device|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
277873|NCT02085317|Drug|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
277874|NCT02085317|Drug|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
277875|NCT02085304|Procedure|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
277876|NCT02085304|Radiation|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
277877|NCT02085304|Radiation|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
277878|NCT02085304|Drug|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
277879|NCT02085291|Drug|Norepinephrine|Norepinephrine infusion to titrate MAP to usual level
277880|NCT02085291|Drug|Crystalloid|Patients received 500 ml crystalloid for fluid challenge within 20 minutes, then a PLR test was performed to predict fluid responsiveness. If the patient was fluid responsive, more 500 ml crystalloids were given until fluid nonresponsive. If the MAP still not achieved the target value, NE was increased to achieve the target one.
277881|NCT02085278|Device|Apollo Micro Catheter device|Detachable Tip Micro catheter
277882|NCT02085265|Drug|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
277883|NCT02085265|Drug|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
277884|NCT02085252|Drug|Leuprorelin|Solution for injection
277885|NCT02085252|Drug|Bicalutamide|Bicalutamide tablets
277886|NCT02085239|Drug|Lidocaine Ropivacaine|"8-10 ml of Lidocaine given by subcutaneous injection~8-10 ml of Ropivacaine given by subcutaneous injection"
277887|NCT02085239|Drug|Lidocaine alone|
277888|NCT02085226|Other|Creative Engagement Intervention|"The CEI has 5 component stages which map the participant's journey with the Artist~Meeting with Artist, discuss interests, stroke and explore initial creative goals.~Introduction to materials and mark making to create interpretations of established images.~From mark making and interpretations to developing personal project ideas.~Turning personal project ideas into creative finished pieces.~Review of completed work, mounting and display of work, future plans.~It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes."
277889|NCT02085226|Other|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
277890|NCT02085213|Drug|Glyceryl Trinitrate|
277891|NCT02085213|Drug|Matched Placebo|Matched placebo
277892|NCT02085200|Other|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
277893|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
277894|NCT02085187|Other|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.~There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
277895|NCT02085161|Drug|placebo to tiotropium + olodaterol|comparator
277896|NCT02085161|Drug|tiotropium+olodaterol|tiotropium 5 mcg once daily
277897|NCT02085161|Drug|tiotropium +olodaterol|olodaterol 5 mcg once daily fixed dose combination
277898|NCT02085161|Drug|tiotropium|tiotropium 5 mcg once daily fixed dose combination
277985|NCT02084498|Behavioral|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
277899|NCT02085148|Drug|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
277900|NCT02085148|Drug|Vincristine (Cellcristin®)|Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
277901|NCT02085148|Drug|Irinotecan (Irinotecan Cell pharm®)|Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
277902|NCT02085135|Drug|ALKS 5461|Sublingual tablet taken once daily
277903|NCT02085122|Other|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
277904|NCT02085109|Dietary Supplement|Fat milkshake|
277905|NCT02085109|Dietary Supplement|Theobromine|
277906|NCT02085096|Behavioral|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
277907|NCT02085083|Behavioral|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:~Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.~Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse~Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.~MyHealth Passport~Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
277908|NCT02085083|Behavioral|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
277909|NCT02085070|Drug|MK-3475|IV MK-3475
277910|NCT02085057|Procedure|Functional Magnetic Resonance Imaging|
277911|NCT02085044|Dietary Supplement|Ready-to-Used Supplement Food administration|
277912|NCT02085031|Procedure|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
277913|NCT02085031|Procedure|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
277914|NCT02085018|Drug|Omeprazole|Drug
277915|NCT02085018|Drug|Matched placebo|Matched placebo
277916|NCT02085005|Drug|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
277917|NCT02085005|Drug|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
277918|NCT02085005|Drug|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
277919|NCT02084992|Other|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
277920|NCT02084992|Other|Telephonic disease management|
277921|NCT02084979|Behavioral|telepsychiatry evaluation|telepsychiatry evaluation and consultation to primary care
277922|NCT02084966|Procedure|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
277923|NCT02084953|Drug|BMS-791325|
277924|NCT02084953|Drug|Moxifloxacin|
277925|NCT02084953|Drug|Placebo matching BMS-791325|
277926|NCT02084940|Drug|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
277927|NCT02084927|Biological|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
277928|NCT02084914|Procedure|Endometrial scratching|Group A: pipelle Group B: sound
277929|NCT02084901|Device|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
277930|NCT02084901|Device|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
277931|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
277932|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
277933|NCT02084862|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
277934|NCT02084862|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
277935|NCT02084836|Other|Functional Magnetic Resonance Imaging|
277936|NCT02084823|Biological|cancer stem cell vaccine|
277937|NCT02084810|Drug|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.~Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
277938|NCT02084810|Drug|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
277939|NCT02084797|Drug|V2R (Vasopressin 2 receptor)|All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
277942|NCT02084771|Drug|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
277943|NCT02084771|Biological|Oral Salt and Water|Oral salt capsules and water, based on patient weight
277944|NCT02084758|Dietary Supplement|Nitrate supplementation|7 days of supplementation with sodium nitrate solution
277945|NCT02084758|Dietary Supplement|Placebo supplementation|7 days of supplementation with sodium chloride solution
277946|NCT02084745|Device|Boston keratoprosthesis type 1|The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
277947|NCT02084745|Device|Glaucoma drainage device|The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
277948|NCT02084732|Drug|Sorafenib|drug
277949|NCT02084719|Device|Oraquick HCV Rapid Antibody Test|
277950|NCT02084719|Device|Standard algorithm|
277951|NCT02084706|Procedure|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
277952|NCT02084706|Drug|2% Lidocaine|
277953|NCT02084706|Drug|Triamcinolone (20 g)|
277954|NCT02084706|Procedure|J-tip lidocaine administration|
277955|NCT02084706|Procedure|Triamcinolone (20 g) Injection over the A1 pulley.|
277956|NCT02084693|Device|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
277957|NCT02084680|Behavioral|community health workers|community health workers offering individual prenatal education to pregnant women
277958|NCT02084654|Drug|Exenatide 5 and 10 mcg 2 times a day|
277959|NCT02084654|Drug|placebo|
277960|NCT02084641|Other|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
277961|NCT02084628|Drug|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
277962|NCT02084615|Drug|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
277963|NCT02084602|Drug|Artesunate|Orally administration of artesunate 4mg/Kg by three days
277964|NCT02084602|Drug|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
277965|NCT02084589|Other|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
277966|NCT02084589|Other|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
277967|NCT02084576|Drug|Nepafenac|One drop in the study eye 3 times daily for 30 days
277968|NCT02084576|Drug|Ketorolac|One drop in the study eye 4 times daily for 30 days
277969|NCT02084563|Drug|Induction Chemotherapy|"Induction chemotherapy for patients with AML eligible for intensive chemotherapy:~Cytarabine 200 mg/m2 IV continuous infusion days 1-7~Daunorubicin 90 mg/m2 intravenous piggyback days 1-3"
277970|NCT02084563|Drug|Consolidation Chemotherapy|"Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles"
277971|NCT02084563|Drug|Autologous Stem Cell Transplantation|"Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2"
277972|NCT02084563|Drug|Allogeneic Stem Cell Transplantation|"Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4"
277973|NCT02084563|Drug|Low Dose Cytarabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
277974|NCT02084563|Drug|Decitabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
277975|NCT02084550|Dietary Supplement|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
277976|NCT02084550|Other|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
277977|NCT02084537|Procedure|Endoscopic treatment|Treated by single or multiple transmural cystogastrostomy tracts, 15mm balloon dilation, two 7fr double pigtail plastic stents or lumen-apposing metal stents and nasocystic drainage catheter, with or without endoscopic necrosectomy as needed.
277978|NCT02084537|Procedure|Minimally invasive surgical necrosectomy|Video-assisted retroperitoneal debridement (VARD) or laparoscopic cystogastrostomy with internal debridement.
277979|NCT02084524|Procedure|Malnutrition screening and perioperative nutritional support|"Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines~Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)~Implementation of an adapted nutritional support based on ESPEN Guidelines"
277980|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
277981|NCT02084511|Drug|BI 1026706|BI 1026706
277982|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
277987|NCT02084485|Drug|Placebo|matching placebo
277988|NCT02084472|Other|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
277989|NCT02084472|Other|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
277990|NCT02084472|Other|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
277991|NCT02084459|Behavioral|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
277992|NCT02084446|Drug|Everolimus|Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
277993|NCT02084446|Drug|Very Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
277994|NCT02084446|Drug|Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
277995|NCT02084446|Drug|Steroids|Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
277996|NCT02084446|Drug|Thymoglobulin|All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
277997|NCT02084446|Drug|Sodium Mycophenolate|Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
277998|NCT02084433|Procedure|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
277999|NCT02084433|Procedure|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
278000|NCT02084420|Drug|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
278001|NCT02084420|Drug|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
278002|NCT02084407|Other|Clinical examination, skin biopsy, blood and urine sampling|
278003|NCT02084381|Device|MCO-Ci 400|hemodialysis
278004|NCT02084381|Device|Revaclear 400|hemodialysis
278005|NCT02084368|Procedure|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
278006|NCT02084368|Procedure|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8~10mg at L2-3 or L3-4.
278007|NCT02084368|Drug|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
278008|NCT02084368|Drug|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8~10mg.
278009|NCT02084355|Drug|oral oxycodone|
278010|NCT02084355|Drug|oral hydromorphone|
278011|NCT02084355|Drug|fentanyl patch|
278012|NCT02084342|Drug|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
278013|NCT02084342|Drug|normal saline|100ml, IV for 30min,before incision.
278014|NCT02084342|Drug|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
278015|NCT02084329|Device|Weighted Compression Vest|
278016|NCT02084316|Behavioral|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
278017|NCT02084316|Behavioral|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.~After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.~Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
278018|NCT02084303|Other|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
278019|NCT02084290|Behavioral|Shared Decision Making Program|This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
278020|NCT02084277|Device|Self-ligating brackets (SLB)|
278021|NCT02084277|Device|Conventional brackets (CB)|
278022|NCT02084251|Drug|PB-119|
278401|NCT02081183|Drug|Cyclophosphamide, Induction Phase|0.5 - 1 g/m^2 IV pulse once per month
278023|NCT02084238|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
278024|NCT02084225|Procedure|ultrasound guided regional nerve block|participants were the physicians performing the procedure
278025|NCT02084212|Other|Microperimetry|
278026|NCT02084199|Drug|GLPG0634|100 mg oral tablet, intake once daily for 10 days
278027|NCT02084186|Other|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
278028|NCT02084186|Other|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
278029|NCT02084173|Behavioral|MET + CRA|
278030|NCT02084147|Device|positron emission tomography|Undergo PET
278031|NCT02084147|Device|computed tomography|Undergo CT
278032|NCT02084147|Device|magnetic resonance imaging|Undergo MRI
278033|NCT02084134|Drug|hydrocortisone|100mg at the time of surgery
278034|NCT02084134|Drug|dexamethasone|0.5mg every 6 hours for a total of four doses
278035|NCT02084121|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
278036|NCT02084108|Other|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
278037|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
278038|NCT02084082|Drug|Linagliptin|1x Linagliptin tablet
278039|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
278040|NCT02084069|Drug|Atorvastatin|
278041|NCT02084056|Drug|Linagliptin|Linagliptin
278042|NCT02084056|Drug|Metformin|Metformin
278043|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
278044|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 15 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
278045|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 25 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
278046|NCT02084017|Device|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
278047|NCT02084017|Device|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
278048|NCT02084004|Drug|Bifidobacterium viable pharmaceutics|
278049|NCT02084004|Drug|Berberine Hydrochloride|
278050|NCT02083991|Drug|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
278051|NCT02083978|Other|MRI scanning|
278052|NCT02083965|Biological|rFVIIIFc|Administered as specified in the treatment arm.
278053|NCT02083952|Other|Swaddle Blanket|Two arms involve varying time spent in blanket
278054|NCT02083926|Drug|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
278055|NCT02083926|Drug|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
278056|NCT02083913|Behavioral|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
278057|NCT02083900|Device|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
278058|NCT02083900|Drug|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
278059|NCT02083887|Biological|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10^10 vp and MVA ME-TRAP 1 x 10^8 pfu
278060|NCT02083874|Drug|CBD|
278061|NCT02083861|Device|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
278062|NCT02083848|Other|7T MRI|Ultra high field magnetic resonance imaging
278063|NCT02083822|Procedure|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
278064|NCT02083809|Drug|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
278065|NCT02083809|Drug|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
278066|NCT02083796|Procedure|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
278067|NCT02083796|Procedure|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
278068|NCT02083796|Procedure|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
278069|NCT02083796|Procedure|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
278070|NCT02083783|Drug|TRI102|formulation containing active moiety
278071|NCT02083783|Other|Placebo|formulation without active moiety
278072|NCT02083770|Behavioral|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
278073|NCT02083744|Behavioral|PsychoEducational Support|
278074|NCT02083744|Behavioral|Usual Care|Standard Heart Failure Care
278075|NCT02083731|Biological|MSCs|
278076|NCT02083718|Biological|PBSC|
278077|NCT02083718|Biological|MSCs|
278078|NCT02083705|Procedure|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
278079|NCT02083705|Procedure|3:1 CPR|CPR using 3:1 ratio (control group)
278080|NCT02083692|Drug|Metformin|
278081|NCT02083679|Drug|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m^2 on Day 1 plus gemcitabine 1250 mg/m^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
278082|NCT02083679|Drug|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m^2 plus pemetrexed 500 mg/m^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
278083|NCT02083679|Drug|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute [mg/mL/min] plus paclitaxel 225 mg/m^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
278084|NCT02083679|Drug|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
278085|NCT02083666|Drug|SOBI002|Test Product
278086|NCT02083666|Drug|Placebo|Reference product
278087|NCT02083653|Drug|Sym004 (12 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
278088|NCT02083653|Drug|Sym004 (9/6 mg/kg)|Sym004 is a 1:1 mixture of two mAbs (futuximab and modotuximab) which bind to two non-overlapping epitopes of the EGFR.
278089|NCT02083653|Other|Best Supportive Care (BSC)|BSC is the best palliative care as per Investigator's discretion, excluding antineoplastic agents. BSC may include, but is not limited to, antibiotics, analgesics, antiemetics, blood transfusions, and nutritional support.
278090|NCT02083653|Drug|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
278091|NCT02083653|Drug|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
278092|NCT02083640|Drug|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
278093|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
278094|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
278095|NCT02083627|Drug|rosuvastatin|Oral
278096|NCT02083627|Drug|fidaxomicin|Oral
278097|NCT02083614|Procedure|to clamp or release the catheter for 2 days before removal|
278098|NCT02083601|Behavioral|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
278099|NCT02083601|Behavioral|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
278100|NCT02083588|Device|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
278101|NCT02083575|Drug|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
278102|NCT02083575|Drug|deferiprone , deferesarox|iron chelator
278103|NCT02083549|Other|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
278104|NCT02083536|Radiation|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
278193|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
278194|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
278195|NCT02082834|Other|abdominal MDCT examination|
278105|NCT02083536|Drug|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
278106|NCT02083523|Behavioral|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
278107|NCT02083523|Behavioral|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
278108|NCT02083510|Drug|Colchicine|
278109|NCT02083497|Other|rigid bandage|
278110|NCT02083497|Other|elastic bands|
278111|NCT02083497|Other|without the use of banding|
278112|NCT02083484|Biological|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
278113|NCT02083471|Dietary Supplement|Specific Oral Tolerance Induction with Egg or Cow's milk|
278114|NCT02083458|Procedure|Catheterization of the axillary vein.|
278115|NCT02083445|Other|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
278116|NCT02083445|Other|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
278117|NCT02083445|Device|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
278118|NCT02083445|Other|Intermittent hypobaric hypoxia|
278119|NCT02083432|Behavioral|5 session of CBT performed by specially trained dentists|"A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.~The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV)."
278120|NCT02083419|Device|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
278121|NCT02083406|Drug|800mg OZ439 prototype formulation 1|
278122|NCT02083406|Drug|800mg OZ439 prototype formulation 2|
278123|NCT02083406|Drug|800mg OZ439 prototype formulation 3|
278124|NCT02083406|Drug|960mg PQP|
278125|NCT02083380|Drug|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
278126|NCT02083380|Drug|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
278127|NCT02083380|Drug|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
278128|NCT02083354|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
278129|NCT02083354|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
278130|NCT02083341|Device|Lelo® Siri vibrator|external vibration device
278131|NCT02083341|Device|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
278132|NCT02083328|Dietary Supplement|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
278133|NCT02083328|Dietary Supplement|Placebo (Mannitol)|Mannitol filled in gelatine capsules
278134|NCT02083315|Drug|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
278135|NCT02083315|Drug|TRV130 3 mg|TRV130 3 mg IV x 1 dose
278136|NCT02083315|Drug|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
278137|NCT02083315|Drug|Morphine 10 mg|Morphine 10 mg IV x 1 dose
278138|NCT02083315|Drug|Placebo|Dextrose 5% in water IV x 1 dose
278139|NCT02083302|Behavioral|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
278140|NCT02083302|Behavioral|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.~Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
278141|NCT02083302|Behavioral|SCREAM Theater Dose 4|Booster Session
278142|NCT02083289|Drug|ONO-9054|
278143|NCT02083289|Drug|Latanoprost|
278144|NCT02083276|Drug|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
278145|NCT02083263|Device|Bilevel|3 months
278146|NCT02083263|Device|PEP mask|3 months
278147|NCT02083250|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
278148|NCT02083250|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
278149|NCT02083250|Biological|Anti-Thymocyte Globulin|Given IV
278150|NCT02083250|Drug|Busulfan|Given IV
278151|NCT02083250|Drug|Clofarabine|Given IV
278152|NCT02083250|Drug|Fludarabine Phosphate|Given IV
278153|NCT02083250|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
278154|NCT02083250|Other|Pharmacological Study|Correlative studies
278155|NCT02083250|Drug|Vorinostat|Given PO
278156|NCT02083237|Behavioral|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
278157|NCT02083211|Drug|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
278158|NCT02083211|Device|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
278159|NCT02083185|Drug|Relugolix|Relugolix tablets
278160|NCT02083185|Drug|Leuprorelin|Leuprorelin subcutaneous injection
278161|NCT02083172|Device|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
278162|NCT02083120|Device|NHF therapy|AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
278163|NCT02083120|Other|Long term Oxygen Therapy (LOT)|Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
278164|NCT02083107|Drug|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
278165|NCT02083107|Other|Placebo|
278166|NCT02083081|Behavioral|Community level intervention|Community intervention plus individual counseling
278167|NCT02083068|Biological|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 6
278168|NCT02083068|Biological|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015, at month 0
278169|NCT02083068|Biological|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
278170|NCT02083055|Drug|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
278171|NCT02083055|Drug|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
278172|NCT02083029|Procedure|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
278173|NCT02083016|Device|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
278174|NCT02083016|Device|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
278175|NCT02083003|Dietary Supplement|Polyamine low-diet|
278176|NCT02083003|Dietary Supplement|Liberal alimentation|
278177|NCT02082990|Behavioral|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
278178|NCT02082990|Behavioral|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
278179|NCT02082977|Drug|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
278180|NCT02082964|Other|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
278181|NCT02082964|Other|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
278182|NCT02082951|Behavioral|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
278183|NCT02082951|Behavioral|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
278184|NCT02082938|Device|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
278185|NCT02082925|Other|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
278186|NCT02082912|Drug|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
278187|NCT02082912|Other|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
278188|NCT02082912|Device|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
278189|NCT02082899|Drug|Active Comparator EBI-005 5 mg/mL|
278190|NCT02082899|Drug|Placebo Comparator|
278191|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
278192|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
278196|NCT02082808|Drug|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
278197|NCT02082808|Drug|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
278198|NCT02082782|Procedure|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
278199|NCT02082769|Drug|Febuxostat|
278200|NCT02082769|Drug|Allopurinol|
278201|NCT02082756|Drug|Bifidobacterium viable pharmaceutics|
278202|NCT02082756|Drug|Berberine Hydrochloride|
278203|NCT02082743|Behavioral|Outdoor activity in recess time|Outdoor activity in recess time
278204|NCT02082730|Device|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
278205|NCT02082717|Drug|potassium chloride replacement|
278206|NCT02082717|Drug|Experimental - 4% Sodium Bicarbonate|
278207|NCT02082704|Behavioral|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
278208|NCT02082704|Behavioral|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
278209|NCT02082691|Drug|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
278210|NCT02082678|Drug|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
278211|NCT02082678|Drug|Placebo|Inactive ingredient matching the active medication in appearance
278212|NCT02082665|Drug|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
278213|NCT02082665|Drug|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
278214|NCT02082665|Drug|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
278215|NCT02082652|Drug|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
278216|NCT02082639|Biological|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
278217|NCT02082639|Biological|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
278218|NCT02082626|Drug|Eribulin mesylate|
278219|NCT02082613|Procedure|Lord´s procedure|
278220|NCT02082613|Procedure|Sclerotherapy|
278221|NCT02082600|Other|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
278222|NCT02082600|Other|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
278223|NCT02082561|Behavioral|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
278224|NCT02082548|Other|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
278225|NCT02082522|Drug|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
278226|NCT02082522|Procedure|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
278227|NCT02082522|Drug|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
278228|NCT02082496|Drug|Liraglutide|S.c. liraglutide 3.0mg once daily
278317|NCT02081859|Device|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
278229|NCT02082483|Other|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
278230|NCT02082470|Other|follow-up care|Undergo survivorship care planning
278231|NCT02082470|Other|active surveillance|Undergo cancer surveillance
278232|NCT02082470|Other|questionnaire administration|Ancillary studies
278233|NCT02082457|Drug|YKP10811 5mg|
278234|NCT02082457|Drug|YKP10811 20mg|
278235|NCT02082457|Drug|YKP10811 placebo|
278236|NCT02082444|Other|Skipping lunch|
278237|NCT02082418|Dietary Supplement|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
278238|NCT02082418|Dietary Supplement|Whey|commercially available whey protein
278239|NCT02082418|Dietary Supplement|Casein|commercially available casein protein
278240|NCT02082405|Drug|bortezomib|Given SC or IV
278241|NCT02082405|Drug|cyclophosphamide|Given PO
278242|NCT02082405|Drug|dexamethasone|Given PO
278243|NCT02082405|Other|laboratory biomarker analysis|Optional correlative studies
278244|NCT02082405|Other|quality-of-life assessment|Ancillary studies
278245|NCT02082392|Drug|Escitalopram|
278246|NCT02082379|Behavioral|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
278247|NCT02082366|Device|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
278248|NCT02082340|Behavioral|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
278249|NCT02082340|Other|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
278250|NCT02082340|Other|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
278251|NCT02082340|Behavioral|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
278252|NCT02082340|Behavioral|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
278253|NCT02082327|Drug|IV migalastat HCl|
278254|NCT02082327|Drug|IV placebo|
278255|NCT02082327|Drug|oral migalastat HCl|
278256|NCT02082314|Procedure|RFA Vertebroplasty|
278257|NCT02082288|Other|Edessy ICSI Outcome Embryo Score|"EIOS:~Age (ys) >35 (0) 30-35 (1) <30 (2) No of retrived oocyte <5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos <2 (0) 2-4 (1) >4 (2) No of good quality embryos <3 (0) 3-5 (1) >5 (2) No of embryos transferred -------- (0) ≤2 (1) >2 (2)"
278258|NCT02082275|Other|OB Nest|"Reduction in the number of clinic office visits~Assignment to a specific nursing care team~Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.~Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.~Augmentation of in-person visits between care providers and patients with video conversations.~Maternal outcomes will be monitored through surveys and questionnaires."
278259|NCT02082262|Drug|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
278260|NCT02082249|Drug|ABT-SLV187|Dose levels will be individually optimized
278261|NCT02082236|Drug|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
278262|NCT02082236|Drug|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
278263|NCT02082236|Drug|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
278264|NCT02082236|Drug|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
278265|NCT02082223|Behavioral|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
278266|NCT02082210|Drug|Emibetuzumab|Administered Intravenously (IV)
278267|NCT02082210|Drug|Ramucirumab|Administered Intravenously (IV)
278268|NCT02082197|Drug|ABT-SLV176|ABT-SLV176 administered daily
278269|NCT02082184|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
278270|NCT02082184|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
278271|NCT02082171|Other|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
278318|NCT02081859|Other|Conventional Criteria|
278606|NCT02079662|Other|Counseling|Undergo counseling
278272|NCT02082158|Other|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
278273|NCT02082145|Device|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
278274|NCT02082119|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
278275|NCT02082106|Other|Alpine skiing|
278276|NCT02082106|Other|cross country skiing|
278277|NCT02082106|Other|Indoor training (cycling)|
278278|NCT02082093|Device|Telemedicine System|
278279|NCT02082080|Other|Education|
278280|NCT02082080|Other|Social support|
278281|NCT02082067|Procedure|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
278282|NCT02082067|Procedure|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
278283|NCT02082067|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
278284|NCT02082067|Procedure|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
278285|NCT02082067|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
278286|NCT02082067|Drug|Ropivacaine 0,75%|
278287|NCT02082067|Drug|Levobupivacaine 0,5%|
278288|NCT02082067|Drug|Levobupivacaine 0,125%|
278289|NCT02082067|Drug|Ketorolac 30mg|
278290|NCT02082067|Drug|Morphine|
278291|NCT02082067|Device|stimulong sono, Pajunk, Germany|
278292|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
278293|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
278294|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
278295|NCT02082054|Drug|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
278296|NCT02082054|Drug|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
278297|NCT02082028|Device|BGStar|
278298|NCT02082028|Device|glucose meter|
278299|NCT02082015|Device|Low frequency rTMS|Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
278300|NCT02081989|Procedure|Renal denervation|Renal denervation
278301|NCT02081976|Behavioral|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
278302|NCT02081976|Other|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
278303|NCT02081963|Drug|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
278304|NCT02081963|Drug|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
278305|NCT02081950|Biological|Enoxaparin sodium|comparison of 2 different administration of drug
278306|NCT02081937|Biological|anti-CD19-CAR vector-transduced T cells|
278307|NCT02081924|Other|Kisspeptin 0.1|"Participants will receive kisspeptin hormone at a dose rate of 0.1nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
278308|NCT02081924|Other|Saline|"Participants will receive placebo (saline) via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
278309|NCT02081924|Other|Kisspeptin 0.3|"Participants will receive kisspeptin hormone at a dose rate of 0.3 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
278310|NCT02081924|Other|Kisspeptin 1.0|"Participants will receive kisspeptin hormone at a dose rate of 1.0 nmol/kg/hour via a subcutaneous pump device for 8 days during the early follicular phase of their menstrual cycle.~LH, FSH and oestradiol will be measured on day 1 and 8, at 10minute intervals for 8 hours and on Days 3 and 5 they will have a single blood measurement of the same hormones."
278311|NCT02081911|Procedure|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
278312|NCT02081911|Procedure|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
278313|NCT02081911|Procedure|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
278314|NCT02081898|Dietary Supplement|LCD|approximate 100 kcal/d caloric deficit
278315|NCT02081885|Procedure|Tricalcium Phosphate / Chitosan|
278316|NCT02081885|Procedure|Autologous Graft|
278319|NCT02081846|Other|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
278320|NCT02081846|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
278321|NCT02081794|Other|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
278322|NCT02081794|Other|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
278323|NCT02081781|Procedure|Probing|"A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner."
278324|NCT02081768|Radiation|90yttrium colloid|90yttrium colloid will be inserted into a sellar/parasellar cyst
278325|NCT02081755|Drug|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 12 months
278326|NCT02081755|Drug|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 12 months
278327|NCT02081755|Drug|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 12 months
278328|NCT02081755|Drug|CellCept|CellCept: 500 mg to 1500 mg BID for 12 months
278329|NCT02081755|Drug|Imuran|0.5 mg/kg to 2 mg/kg QD for 12 months
278330|NCT02081703|Drug|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
278331|NCT02081703|Drug|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
278332|NCT02081703|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
278333|NCT02081703|Drug|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
278334|NCT02081690|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
278335|NCT02081677|Device|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
278336|NCT02081677|Device|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
278337|NCT02081677|Device|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
278338|NCT02081677|Device|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
278339|NCT02081664|Behavioral|lifestyle intervention|
278340|NCT02081651|Dietary Supplement|Parmigiano Reggiano cheese|
278341|NCT02081638|Drug|Aspirin|Daily Asprin daily
278342|NCT02081638|Drug|Lipitor|Daily Lipitor daily
278343|NCT02081625|Drug|NS-065/NCNP-01|"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:~Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"
278344|NCT02081612|Behavioral|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
278345|NCT02081612|Procedure|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
278346|NCT02081599|Drug|Teneli (Teneligliptin)|
278347|NCT02081599|Drug|Placebo|
278348|NCT02081599|Drug|Insulin|
278349|NCT02081586|Behavioral|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
278350|NCT02081586|Device|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
278351|NCT02081586|Other|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
278352|NCT02081573|Behavioral|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
278353|NCT02081560|Drug|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
278354|NCT02081534|Drug|AZD1722|AZD1722, oral tablet
278355|NCT02081534|Drug|Placebo|Placebo bid, double dummy technique
278356|NCT02081521|Behavioral|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
278357|NCT02081508|Behavioral|Interference onset|Temporal duration of interference onset.
278358|NCT02081495|Drug|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
278359|NCT02081495|Drug|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
278360|NCT02081482|Radiation|18F-FDG PET|
278361|NCT02081469|Other|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
278362|NCT02081456|Other|Soft Tissue Mobilization|Patients in the STM group received treatment in supine, with their head resting on one pillow and the involved UE positioned in abduction and external rotation to preload the neural structures of the upper limb. Manual pressure was applied to the soft tissues of the upper quadrant in a deep, stroking manner with the intention to improve the mobility of the soft tissues surrounding the pathway of the neural structures of the upper limb as well as any tender or tight tissues. The therapist spent approximately 7 minutes on the neck and scapular region, 4 minutes on the upper arm, and 4 minutes on the forearm and hand. The therapist was allowed to vary the time spent on each region according to his/her assessment of the patient's condition. The procedure lasted a total of 15 minutes.
278363|NCT02081456|Device|Therapeutic Ultrasound|Patients received therapeutic US applied for a period of 5 minutes to the most painful region of the neck, then a second 5-minute dose at the most painful region of the upper extremity. The US dose was 0.5 w/cm2, with sonation time 50% and frequency 1 MHz.40,52 The patient lay supine with the hand of the involved upper extremity placed on the abdomen and the elbow supported on a pillow. The two US doses and interaction time with the patient lasted a total of 15 minutes in an attempt to have equal patient/therapist contact between the two groups.
278364|NCT02081443|Drug|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
278365|NCT02081443|Drug|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
278366|NCT02081430|Procedure|CT Manipulation|
278367|NCT02081430|Procedure|Upper trapezius stretch|
278368|NCT02081417|Behavioral|Seeking Safety|SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
278369|NCT02081404|Drug|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
278370|NCT02081404|Drug|Placebo|placebo
278371|NCT02081391|Drug|Tapentadol 4 mg/mL|Participants will receive tapentadol solution orally (by mouth) every 4 hours for up to 72 hours.
278372|NCT02081391|Drug|Tapentadol 20 mg/mL|Participants aged from 6 months to less than 18 years with body weight greater than or equal to 20 kg will receive tapentadol 20 mg/mL solution orally every 4 hours for up to 72 hours. The dose during the first 24 hours will be 1.25 mg/kg. After 24 hours, the dose can be reduced to 1.0 mg/kg, based on investigator's judgment. Dose of tapentadol 20 mg/mL solution for participants aged birth to less than 2 years with body weight greater than or equal to 20 kg will be decided based on the forthcoming pharmacokinetic (PK) data.
278373|NCT02081391|Other|Placebo|Matching placebo solution will be administered orally every 4 hours up to 72 hours.
278374|NCT02081378|Drug|ABL001|ABL001 will be administered orally in a dose escalation schedule.
278375|NCT02081378|Drug|ABL001 + Nilotinib|ABL001 and Nilotinib will be administered orally in CML patients
278376|NCT02081378|Drug|ABL001|ABL001 will be administered orally in Ph+ ALL patients
278377|NCT02081378|Drug|ABL001+imatinib|ABL001 and imatinib will be administered orally in CML patients
278378|NCT02081378|Drug|ABL001+dasatinib|ABL001+dasatinib will be administered orally in CML patients
278379|NCT02081365|Behavioral|Computerized Dental Anxiety Treatment|The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
278380|NCT02081352|Other|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
278381|NCT02081352|Other|Standard care|
278382|NCT02081339|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|
278383|NCT02081326|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
278384|NCT02081326|Biological|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
278385|NCT02081313|Other|Biopsy|
278386|NCT02081313|Other|Blood sample|
278387|NCT02081300|Drug|Oral testosterone undecanoate, LPCN 1021|
278388|NCT02081300|Drug|Topical testosterone gel 1.62 %|
278389|NCT02081287|Drug|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
278390|NCT02081287|Drug|Lamotrigine|Dose up to 200 mg per day over 10 weeks
278391|NCT02081274|Procedure|Surgery for congenital heart disease|
278392|NCT02081261|Procedure|Coronary artery bypass surgery|coronary artery bypass surgery
278393|NCT02081248|Other|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
278394|NCT02081248|Other|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
278395|NCT02081235|Procedure|surgery for congenital heart disease|surgery for congenital heart disease
278396|NCT02081222|Procedure|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
278397|NCT02081209|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
278398|NCT02081196|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
278399|NCT02081183|Drug|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
278400|NCT02081183|Drug|Cyclophosphamide, Maintenance Phase|0.5-1 g/m^2 IV pulse once every 3 months
278402|NCT02081183|Drug|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
278403|NCT02081170|Procedure|Autologous platelet concentrate|"pars plana vitrectomy~internal limiting membrane removal~Fluid-air exchange~Intravitreal autologous platelet concentrate injection~Intravitreal gas (14% C3F8) injection~Keep prone position for 7-14 days after surgery"
278404|NCT02081157|Device|GalaFlex Mesh|
278405|NCT02081144|Other|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of ~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
278406|NCT02081144|Drug|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
278407|NCT02081144|Drug|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
278408|NCT02081144|Behavioral|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
278409|NCT02081131|Procedure|Open surgery|pancreatic head resection by open method
278410|NCT02081131|Procedure|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
278411|NCT02081118|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
278412|NCT02081118|Drug|Placebo|Placebo for HM11260C
278413|NCT02081105|Other|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
278414|NCT02081079|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
278415|NCT02081066|Other|cardiovascular risk factors|
278416|NCT02081053|Device|STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System|Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
278417|NCT02081040|Other|Not applicable (observational study with no active intervention)|
278418|NCT02081027|Drug|Riluzole|
278419|NCT02081027|Drug|placebo|
278420|NCT02081014|Drug|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
278421|NCT02081001|Drug|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
278422|NCT02081001|Drug|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
278423|NCT02080975|Other|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
278424|NCT02080962|Radiation|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
278425|NCT02080962|Radiation|40 Gy in 10 fractions|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
278426|NCT02080949|Radiation|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
278427|NCT02080923|Behavioral|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
278428|NCT02080910|Behavioral|Psychoeducation|
278429|NCT02080871|Device|Stenting of the Common and/or External Iliac Arteries|Balloon expandable stenting of iliac occlusive disease.
278430|NCT02080858|Drug|Ticagrelor + Apixaban + ASA|
278431|NCT02080858|Drug|Ticagrelor + Apixaban|
278432|NCT02080845|Dietary Supplement|no caffeine|
278433|NCT02080845|Dietary Supplement|high caffeine|
278434|NCT02080845|Dietary Supplement|no theobromine|
278435|NCT02080845|Dietary Supplement|low theobromine|
278436|NCT02080845|Dietary Supplement|high theobromine|
278437|NCT02080832|Drug|Citalopram|20 mg or 40 mg daily for 8 weeks
278438|NCT02080832|Drug|Placebo|Placebo daily for 8 weeks
278439|NCT02080819|Drug|levodopa/carbidopa 400/100 BID|"Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance."
278440|NCT02080806|Device|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
278441|NCT02080793|Other|Questionnaire|
278442|NCT02080780|Drug|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
278443|NCT02080780|Drug|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 & Day 8 to the perianal area (~2.5 cm [1 inch]; ~8.5 mg)
278444|NCT02080767|Drug|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
278445|NCT02080754|Other|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
278607|NCT02079662|Behavioral|Exercise Intervention|Undergo IO intervention
278446|NCT02080754|Other|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
278447|NCT02080741|Other|Blood sample of 12 ml|
278448|NCT02080728|Drug|Ropivacaine 500mg/100ml Naropeine|
278449|NCT02080728|Drug|0.9% sodium chloride BAXTER|
278450|NCT02080715|Drug|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
278451|NCT02080715|Drug|Placebo|
278452|NCT02080702|Device|Monosyn|Monosyn will be used to perform the gastrointestinal anastomoses
278453|NCT02080689|Other|Decipher|
278454|NCT02080663|Procedure|Proximal row carpectomy|
278455|NCT02080650|Device|Mesenchymal-marker based ferrofluid (c-MET)|
278456|NCT02080650|Device|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
278457|NCT02080637|Drug|Ambrisentan|Once daily oral dosing
278458|NCT02080637|Other|Placebo|
278459|NCT02080624|Drug|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.~A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.~A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.~Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.~A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
278460|NCT02080598|Behavioral|2 cigarettes in 15 minutes|
278461|NCT02080585|Behavioral|Physical Activity advice.|Subjects receive advice regarding physical activities.
278462|NCT02080559|Biological|4CMenB|0.5ml IM
278463|NCT02080546|Procedure|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
278464|NCT02080546|Procedure|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
278465|NCT02080546|Device|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
278466|NCT02080533|Other|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
278467|NCT02080520|Dietary Supplement|Nattokinase|
278468|NCT02080520|Dietary Supplement|Placebo|
278469|NCT02080507|Device|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
278470|NCT02080507|Device|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
278471|NCT02080494|Drug|Tranexamic Acid|
278472|NCT02080481|Device|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
278473|NCT02080481|Device|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
278474|NCT02080468|Drug|lomitapide|20 mg
278475|NCT02080468|Drug|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
278476|NCT02080455|Drug|lomitapide|20 mg dose
278477|NCT02080455|Drug|Atorvastatin|80 mg
278478|NCT02080442|Other|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
278479|NCT02080429|Procedure|Passive Descent|
278480|NCT02080429|Procedure|Pushing|
278481|NCT02080416|Drug|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
278482|NCT02080403|Drug|2.5 mg Chlorhexidine gluconate chip|Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
278483|NCT02080390|Procedure|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
278484|NCT02080377|Drug|Glibenclamide|
278485|NCT02080377|Drug|Insulin|
278486|NCT02080364|Drug|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
278487|NCT02080364|Drug|Placebo|Placebo administered orally, once daily for 18 months
278488|NCT02080351|Behavioral|Simple cognitive task|
278489|NCT02080338|Device|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
278490|NCT02080325|Other|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
278491|NCT02080325|Other|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
278492|NCT02080312|Drug|Magnevist (gadopentetate dimeglumine)|
278608|NCT02079662|Other|Laboratory Biomarker Analysis|Correlative studies
278493|NCT02080299|Procedure|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
278494|NCT02080299|Procedure|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
278495|NCT02080286|Behavioral|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
278496|NCT02080286|Device|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
278497|NCT02080286|Device|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.~The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
278498|NCT02080273|Drug|Colgate Cavity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), Colgate Cavity Protection toothpaste is a control treatment.
278499|NCT02080273|Drug|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. Colgate Total toothpaste is the active comparator toothpaste
278500|NCT02080273|Drug|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), Parodontax toothpaste is the active comparator toothpaste
278501|NCT02080260|Drug|regorafenib|Single agent drug therapy with regorafenib
278502|NCT02080247|Drug|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
278503|NCT02080247|Drug|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
278504|NCT02080234|Drug|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
278505|NCT02080234|Radiation|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
278506|NCT02080221|Drug|FOLFOXA|
278507|NCT02080208|Device|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
278508|NCT02080195|Drug|Cyclophosphamide|14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.
278509|NCT02080195|Drug|Fludarabine|30 mg/m^2/day on Days -6 through -2.
278510|NCT02080195|Drug|Tacrolimus|Starting on Day 5. Dose will be adjusted according to blood levels.
278511|NCT02080195|Drug|Mycophenolate Mofetil|15 mg/kg three times per day from Day 5 to Day 35.
278512|NCT02080195|Drug|Rabbit antithymocyte globulin|0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.
278513|NCT02080195|Radiation|Total body irradiation|200 centigray on Day -1.
278514|NCT02080195|Biological|Allogeneic bone marrow transplant|Infusion on Day 0.
278515|NCT02080182|Drug|Acetylcysteine|
278516|NCT02080182|Drug|placebo acetylcysteine|
278517|NCT02080169|Drug|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
278518|NCT02080169|Drug|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.~If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
278519|NCT02080169|Drug|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS <3.
278520|NCT02080156|Device|CPAP|
278521|NCT02080143|Device|Thermal Adhesion Patch|
278522|NCT02080143|Device|Thermal Adhesion Patch|
278523|NCT02080130|Dietary Supplement|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
278524|NCT02080130|Dietary Supplement|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
278525|NCT02080130|Other|Placebo|Placebo
278526|NCT02080117|Procedure|kidney transplantation, living or deceased donor|
278527|NCT02080104|Drug|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
278528|NCT02080078|Drug|Theophylline|
278529|NCT02080078|Drug|Erlotinib|
278530|NCT02080065|Procedure|living donor liver transplantation|
278531|NCT02080052|Device|Robot-assisted prostate biopsy|
278532|NCT02080039|Device|Electrical Stimulation|
278533|NCT02080026|Biological|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
278534|NCT02080026|Biological|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
278535|NCT02080026|Drug|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
278609|NCT02079662|Other|Quality-of-Life Assessment|Ancillary studies
278610|NCT02079662|Other|Questionnaire Administration|Ancillary studies
278536|NCT02080026|Drug|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.~One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
278537|NCT02080013|Other|radiofrequency|ClosureFAST
278538|NCT02080000|Other|Optimisation of V-V timing using R wave on surface ECG|
278539|NCT02080000|Other|Standard V-V timing settings|
278540|NCT02079987|Behavioral|ED-to-home care transition intervention|The Area Agency on Aging coach's role is to build self-management capabilities for the patient and their caregiver. During each contact, the coach reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists patients use the PHR to document and maintain vital information and to communicate with providers.
278541|NCT02079987|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating ED physician and nurse as is the standard of care.
278542|NCT02079974|Drug|Pravastatin|20 mg pravastatin sodium daily for 3 months
278543|NCT02079961|Dietary Supplement|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
278544|NCT02079961|Behavioral|BCC|"Behavior Change Campaign (BCC)~A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health."
278545|NCT02079948|Drug|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a~Blood draw at each monthly visit~Cognitive performance testing to assess memory performance~Physical function testing to assess walking speed and measure muscle endurance~Pain assessment testing to assess the presence and location of daily pain~Self-reported function and quality of life to measure disability and mobility limitations, and~Depression assessment testing to assess participants' level of depression."
278546|NCT02079948|Drug|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a~Blood draw at each monthly visit~Cognitive performance testing to assess memory performance~Physical function testing to assess walking speed and measure muscle endurance~Pain assessment testing to assess the presence and location of daily pain~Self-reported function and quality of life to measure disability and mobility limitations, and~Depression assessment testing to assess participants' level of depression"
278547|NCT02079948|Procedure|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
278548|NCT02079948|Procedure|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
278549|NCT02079935|Behavioral|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
278550|NCT02079935|Behavioral|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
278551|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278552|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278553|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278554|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278555|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278556|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278557|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278558|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
278559|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
278560|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
278561|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
278562|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
278563|NCT02079909|Drug|T-817MA-H|224 mg or 448 mg T-817 MA once daily
278564|NCT02079909|Drug|T-817MA-L|224 mg T-817 MA once daily
278565|NCT02079909|Drug|Placebo|Placebo
278566|NCT02079896|Drug|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
278567|NCT02079896|Drug|Placebo|
278568|NCT02079870|Drug|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
278569|NCT02079870|Drug|placebo|Solution for subcutaneous (s.c. - under the skin) injection
278570|NCT02079857|Other|Standard protocol|Subjects will receive a standard treatment
278571|NCT02079857|Other|Individualized protocol|Subjects will receive an individualized treatment
278572|NCT02079857|Other|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
278573|NCT02079844|Drug|Roflumilast|Roflumilast tablets
278574|NCT02079844|Drug|Placebo|Roflumilast placebo-matching tablets
278710|NCT02078947|Behavioral|Usual Care|
278575|NCT02079844|Drug|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
278576|NCT02079831|Behavioral|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.~Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
278577|NCT02079831|Behavioral|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
278578|NCT02079831|Behavioral|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
278579|NCT02079818|Device|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
278580|NCT02079805|Drug|Azilsartan|Azilsartan tablets
278581|NCT02079805|Drug|Telmisartan|Telmisartan tablets
278582|NCT02079792|Procedure|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
278583|NCT02079792|Procedure|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
278584|NCT02079779|Other|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
278585|NCT02079779|Other|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
278586|NCT02079766|Drug|florbetapir F 18|
278587|NCT02079766|Drug|18F-AV-1451|
278588|NCT02079753|Device|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
278589|NCT02079753|Device|Combination system of a portable and a stationary device.|"Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)"
278590|NCT02079740|Biological|Navitoclax|Given PO
278591|NCT02079740|Drug|Trametinib|Given PO
278592|NCT02079727|Drug|chondroitin sulfate|
278593|NCT02079727|Drug|celecoxib|
278594|NCT02079727|Drug|placebo|
278595|NCT02079701|Biological|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
278596|NCT02079701|Biological|Placebo|
278597|NCT02079688|Drug|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
278598|NCT02079688|Drug|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
278599|NCT02079675|Drug|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
278600|NCT02079675|Drug|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
278601|NCT02079675|Drug|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
278602|NCT02079662|Other|Behavioral, Psychological or Informational Intervention|Undergo IO intervention
278603|NCT02079662|Other|Best Practice|Undergo standard of care
278604|NCT02079662|Other|Cognitive Intervention|Undergo IO intervention
278605|NCT02079662|Other|Computer-Assisted Intervention|Undergo IO intervention
278611|NCT02079649|Drug|AL-53817 Ophthalmic Solution, 0.1%|
278612|NCT02079649|Drug|AL-78843 Ophthalmic Solution, 0.03%|
278613|NCT02079649|Drug|Dexamethasone Ophthalmic Suspension, 0.1%|
278614|NCT02079649|Drug|AL-53817 Vehicle|Inactive ingredients used for masking purposes
278615|NCT02079636|Drug|Abemaciclib|Administered orally
278616|NCT02079636|Drug|Pemetrexed|Administered IV
278617|NCT02079636|Drug|Gemcitabine|Administered IV
278618|NCT02079636|Drug|Ramucirumab|Administered IV
278619|NCT02079636|Drug|LY3023414|Administered orally
278620|NCT02079636|Drug|Pembrolizumab|Administered IV
278621|NCT02079623|Procedure|Electroporation/ Nano knife treatment|
278622|NCT02079623|Device|NanoKnife|
278623|NCT02079610|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
278624|NCT02079610|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
278625|NCT02079571|Dietary Supplement|Coconut water|250 ml Coconut water for each subject
278626|NCT02079571|Dietary Supplement|ginger tea|250 ml for each subject
278627|NCT02079558|Drug|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
278628|NCT02079558|Drug|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
278629|NCT02079545|Drug|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
278630|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
278631|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
278632|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
278633|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
278634|NCT02079532|Drug|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
278635|NCT02079519|Drug|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
278636|NCT02079506|Drug|Candesartan|
278637|NCT02079506|Drug|Rosuvastatin|
278638|NCT02079493|Device|Total Knee Arthroplasty|Knee replacement
278639|NCT02079480|Drug|BMS-986090|
278640|NCT02079480|Drug|Placebo matching with BMS-986090|
278641|NCT02079480|Drug|Keyhole limpet hemocyanin|
278642|NCT02079467|Procedure|Unrestricted rehabilitation|Standard care range of motion restrictions will not be used
278643|NCT02079467|Procedure|Standard rehabilitation|Standard care range of motion restrictions will remain in place
278644|NCT02079428|Other|No interventions|
278645|NCT02079415|Other|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
278646|NCT02079402|Drug|Isotonic crystalloids|
278647|NCT02079389|Device|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.~All patients are given an CT scan of the abdomen after 3 months."
278648|NCT02079376|Device|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
278649|NCT02079363|Other|No interventions, this is an observational study|
278650|NCT02079350|Drug|%6 HES and %4 Gelofusine|
278651|NCT02079337|Drug|Rocuronium|
278652|NCT02079337|Drug|sugammadex|
278653|NCT02079337|Drug|placebo|
278654|NCT02079324|Biological|GX-051|intratumoral injection
278655|NCT02079311|Device|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
278656|NCT02079311|Device|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
278657|NCT02079298|Drug|Treatment with fluconazole.|
278658|NCT02079298|Drug|2. Treatment with both fluconazole and Ibuprofen.|
278659|NCT02079298|Drug|3. Treatment with ibuprofen.|
278660|NCT02079298|Other|4. No treatment with either fluconazole nor ibuprofen.|
278661|NCT02079285|Procedure|EUS-FNA|
278662|NCT02079272|Other|Helical tomotherapy for breast cancer|"At baseline, before helical tomotherapy is performed, for each included woman will have:~measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)~cardiologic examination including echocardiography for measurement of strain and strain rate~a CT coronary angiogram for measurement of coronary plaque indexes~Helical tomotherapy will be performed for all women included in the cohort.~At the end of tomotherapy, follow-up will include:~measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy~cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy~A CT coronary angiogram 24 months after radiotherapy"
278663|NCT02079259|Procedure|Ultrafiltration|
278664|NCT02079246|Drug|Idalopirdine 60 mg|once daily, encapsulated tablets, orally
278665|NCT02079233|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
278666|NCT02079220|Drug|Arm A|"Capecitabine~Oxaliplatin~Ziv-aflibercept"
278667|NCT02079220|Drug|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
278668|NCT02079207|Biological|NBP606|13-valent peumococcal conjugate vaccine(13vPnC)
278669|NCT02079207|Biological|Prodiax-23|23-valent peumococcal polysaccharide vaccine(23vPS)
278670|NCT02079194|Drug|P2Y12 antagonist monotherapy|
278671|NCT02079194|Drug|aspirin plus P2Y12 antagonist|
278672|NCT02079181|Radiation|fluorine F 18 d-FMAU|Given IV
278673|NCT02079181|Procedure|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
278674|NCT02079181|Procedure|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
278675|NCT02079168|Drug|RXI-109|
278676|NCT02079168|Drug|Placebo|
278677|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
278678|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo R-LESS RP
278679|NCT02079155|Other|laboratory biomarker analysis|Correlative studies
278680|NCT02079155|Other|quality-of-life assessment|Ancillary studies
278681|NCT02079155|Other|questionnaire administration|Ancillary studies
278682|NCT02079142|Behavioral|High Intensity Strategy: Train-the-trainer|"Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT. Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.~Trainers will then return to Washington University to be trained in how to train their other staff members in IPT."
278683|NCT02079142|Behavioral|Low Intensity Strategy: Expert Consultation|Investigators will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depression.
278684|NCT02079116|Other|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~60 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
278685|NCT02079116|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
278686|NCT02079103|Device|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
278687|NCT02079103|Behavioral|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
278688|NCT02079090|Drug|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
278689|NCT02079090|Drug|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
278690|NCT02079077|Drug|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
278691|NCT02079077|Drug|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
278692|NCT02079064|Drug|Desflurane|Inhalational anesthetic
278693|NCT02079064|Drug|Propofol|Intravenous anesthetic that can be given by continuous infusion
278694|NCT02079051|Behavioral|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
278695|NCT02079051|Behavioral|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
278696|NCT02079038|Device|Totalis|
278697|NCT02079038|Device|Sham|
278698|NCT02079025|Device|High-resolution ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
278699|NCT02079025|Device|Standard ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using standard of care ultrasound system
278700|NCT02079012|Behavioral|10-week walking program|
278701|NCT02078986|Other|Whole Body Electromyostimulation|Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks
278702|NCT02078986|Other|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
278703|NCT02078973|Drug|15 mg tolvaptan|15 mg pr day for 1 day
278704|NCT02078973|Drug|30 mg tolvaptan|30 mg pr day for 1 day
278705|NCT02078973|Drug|45 mg tolvaptan|45 mg pr day for 1 day
278706|NCT02078973|Drug|Placebo|1 tablet Unikalk pr day for 1 day
278707|NCT02078960|Drug|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
278708|NCT02078947|Behavioral|High Intensity Exercise|
278709|NCT02078947|Behavioral|Moderate Continuous Exercise|
278711|NCT02078934|Procedure|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
278712|NCT02078921|Drug|Sodium Nitrate|
278713|NCT02078921|Drug|Placebo|
278714|NCT02078908|Drug|Sodium nitrite, 40 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
278715|NCT02078908|Drug|Sodium nitrite, 120 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
278716|NCT02078908|Drug|Sodium nitrite, 240 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
278717|NCT02078908|Drug|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
278718|NCT02078895|Drug|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
278719|NCT02078882|Biological|abatacept|125 mg subcutaneously each week for 24 weeks
278720|NCT02078869|Drug|Progesterone in oil|
278721|NCT02078869|Drug|vaginal progesterone suppositories|
278722|NCT02078856|Drug|A3384|
278723|NCT02078843|Drug|Gallium-68-DOTATATE PET/CT (index test)|Somatostatin-based imaging tracer
278724|NCT02078843|Drug|Indium-111-Octreoscan (standard test)|Somatostatin-based imaging tracer
278725|NCT02078830|Device|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
278726|NCT02078830|Device|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
278727|NCT02078817|Drug|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
278728|NCT02078804|Procedure|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
278729|NCT02078791|Drug|Botox infiltration|botox cervical infiltration in a group
278730|NCT02078791|Behavioral|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
278731|NCT02078791|Other|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
278732|NCT02078778|Device|CPAP|3 months of CPAP treatment
278733|NCT02078752|Drug|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
278734|NCT02078752|Drug|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
278735|NCT02078739|Behavioral|Yoga Program at home using internet technology|
278736|NCT02078726|Drug|Glucagon|glucagon (hormone produced by the body)
278737|NCT02078726|Drug|Placebo|
278738|NCT02078713|Behavioral|Contraceptive Decision Support Tool|"The decision support tool:~Provides an educational session about different aspects of contraception~Elicits patient preferences about different aspects of contraception~Identifies potential contraindications to certain contraceptive methods~Allows the patient to view details about and compare available contraceptive methods~Suggests methods most appropriate based on the patient's preferences~Collects questions the patient may have for her provider~Generates a printout the patient can bring to her contraceptive counseling visit"
278739|NCT02078700|Other|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
278740|NCT02078687|Dietary Supplement|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
278741|NCT02078687|Dietary Supplement|Enfalac Premature Formula, Mead Johnson Nutritionals|"Group 3 received Enfalac containing:~68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml"
278742|NCT02078687|Dietary Supplement|Mothers own milk|Group 1 received mothers own milk without fortification
278743|NCT02078674|Biological|Monovalent Avian Influenza VLP (H7N9)|
278744|NCT02078674|Biological|Matrix-M1™ adjuvant|
278745|NCT02078674|Biological|Placebo|
278746|NCT02078661|Drug|PG101|A topical gel containing either 1% or 0.25% PG101 active.
278747|NCT02078648|Biological|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated).
278748|NCT02078648|Drug|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
278749|NCT02078635|Behavioral|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
278750|NCT02078635|Behavioral|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
278972|NCT02076711|Drug|Metoprololsuccinate|
278751|NCT02078622|Other|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
278752|NCT02078609|Drug|LGH447|LGH447 in patients with AML or MDS
278753|NCT02078609|Drug|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
278754|NCT02078596|Drug|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
278755|NCT02078583|Drug|Fentanyl|
278756|NCT02078583|Drug|Remifentanil|
278757|NCT02078583|Drug|Normal saline|
278758|NCT02078557|Drug|MK-8892|
278759|NCT02078544|Other|Integrated Molecular Analysis|
278760|NCT02078518|Other|Questionnaires|
278761|NCT02078505|Behavioral|diet|Carbohydrate poor diet
278762|NCT02078492|Drug|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
278763|NCT02078492|Drug|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
278764|NCT02078492|Drug|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
278765|NCT02078479|Procedure|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
278766|NCT02078479|Procedure|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
278767|NCT02078466|Other|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
278768|NCT02078453|Procedure|Dental treatment|Dental treatment of all dental needs present in the children related or not to the dental caries.
278769|NCT02078440|Drug|Bromocriptine mesylate|Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
278770|NCT02078427|Biological|ADVATE|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
278771|NCT02078427|Biological|ADYNOVI|Antihemophilic Factor (Recombinant) Pegylated
278772|NCT02078388|Drug|Doxorubicin|
278773|NCT02078375|Dietary Supplement|Protein|whey protein plus casein protein
278774|NCT02078375|Dietary Supplement|Carbohydrate (Placebo)|The twice daily placebo will consist of a carbohydrate and a small amount of protein
278775|NCT02078375|Other|Resistance Exercise Program|All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
278776|NCT02078349|Drug|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA >2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
278777|NCT02078336|Drug|Midazolam Mylan|
278778|NCT02078336|Drug|Lorazepam Mylan|
278779|NCT02078336|Drug|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
278780|NCT02078323|Drug|Linaclotide|
278781|NCT02078323|Drug|Placebo|
278782|NCT02078310|Drug|ITI-007|ITI-007 for Part 1
278783|NCT02078310|Drug|Placebo|ITI-007 for Part 1
278784|NCT02078310|Drug|ITI-007|ITI-007 for Part 2
278785|NCT02078310|Drug|Placebo|Placebo for Part 2
278786|NCT02078284|Biological|CPP|One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
278787|NCT02078284|Biological|LSP|
278788|NCT02078271|Other|FBDG group|The group received food based dietary guidelines for complementary feeding
278789|NCT02078271|Other|Stimulation|The group received psychosocial stimulation
278790|NCT02078271|Other|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
278791|NCT02078271|Other|Control group|
278792|NCT02078258|Behavioral|ABMT|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
278793|NCT02078245|Other|MRI|MRI
278794|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
278795|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.~randomization: puncture with either 22G needle or 19G flex needle"
278796|NCT02078219|Drug|RDEA3170|Oral Treatment
278797|NCT02078219|Drug|Allopurinol|Oral Treatment
278798|NCT02078219|Drug|Placebo|Oral Treatment
278799|NCT02078206|Other|Neurocognitive stimulation|
278800|NCT02078193|Drug|Belatacept|Patients will be converted from their MMF to Belatacept
278801|NCT02078180|Drug|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
278802|NCT02078167|Other|nutraceutical combination (red yeast rice, policosanols and berberine)|
278803|NCT02078141|Drug|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
278804|NCT02078128|Dietary Supplement|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
278805|NCT02078128|Drug|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
278806|NCT02078102|Drug|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
278807|NCT02078102|Drug|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
278808|NCT02078089|Drug|Morphine|Morphine will be given to patients as part of their standard care
278809|NCT02078089|Drug|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
278810|NCT02078076|Device|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
278973|NCT02076711|Drug|Placebo|Placebo
278811|NCT02078063|Drug|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
278812|NCT02078063|Drug|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
278813|NCT02078050|Other|Phrenic nerves magnetic stimulations|
278814|NCT02078037|Device|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
278815|NCT02078037|Other|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
278816|NCT02078024|Drug|IVM plus ALB|
278817|NCT02078024|Drug|IVM|
278818|NCT02078011|Device|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
278819|NCT02077998|Radiation|carbon C 14 oxaliplatin|Given IV
278820|NCT02077998|Drug|oxaliplatin|Given IV
278821|NCT02077998|Other|laboratory biomarker analysis|Correlative studies
278822|NCT02077985|Behavioral|Sensory Adapted Dental Environment|See study arm description.
278823|NCT02077972|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
278824|NCT02077959|Drug|lenalidomide|Given PO
278825|NCT02077959|Biological|pidilizumab|Given IV
278826|NCT02077959|Other|pharmacological study|Correlative studies
278827|NCT02077959|Other|laboratory biomarker analysis|Correlative studies
278828|NCT02077946|Drug|liraglutide|No treatment given.
278829|NCT02077946|Drug|sitagliptin|No treatment given.
278830|NCT02077933|Drug|alpelisib|"alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.~In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.~In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.~In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.~In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily."
278831|NCT02077933|Drug|everolimus|"everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.~In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation."
278832|NCT02077933|Drug|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
278833|NCT02077920|Drug|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China~Drug administration and preparation:~Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions~Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
278834|NCT02077920|Drug|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
278835|NCT02077920|Device|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
278836|NCT02077920|Device|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
278837|NCT02077907|Dietary Supplement|Super Cereal Plus (SC+)|
278838|NCT02077907|Dietary Supplement|Super Cereal (SC), fortified oil, sugar|
278839|NCT02077907|Dietary Supplement|Plumpy Sup|
278840|NCT02077907|Dietary Supplement|Corn Soy Blend 14 (CSB14) and fortified oil|
278841|NCT02077881|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
278842|NCT02077881|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
278843|NCT02077881|Drug|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth~Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
278844|NCT02077868|Other|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
278845|NCT02077868|Drug|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
278846|NCT02077842|Device|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
278847|NCT02077842|Device|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
278848|NCT02077829|Behavioral|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
278849|NCT02077803|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
278850|NCT02077803|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
278851|NCT02077803|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
278852|NCT02077803|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
278853|NCT02077790|Device|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
278854|NCT02077777|Drug|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
278855|NCT02077764|Procedure|OCT and coronary angiography|
278856|NCT02077764|Procedure|Right heart cat.|
278857|NCT02077764|Radiation|PET|
278858|NCT02077764|Procedure|Echocardiography|
278859|NCT02077764|Procedure|exercise test|
278860|NCT02077764|Other|blood samples|
278861|NCT02077751|Drug|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
278862|NCT02077738|Device|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
278863|NCT02077725|Other|interdisciplinary polypharmacy clinic visit|
278864|NCT02077712|Drug|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
278865|NCT02077699|Dietary Supplement|Lactobacillus casei DG|Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
278866|NCT02077686|Behavioral|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
278867|NCT02077660|Dietary Supplement|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
278868|NCT02077660|Other|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
278869|NCT02077634|Drug|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
278870|NCT02077634|Drug|abiraterone acetate + prednisone|ormon therapy will be stopped
278871|NCT02077621|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
278872|NCT02077621|Drug|Placebo|500 mL normal saline
278873|NCT02077595|Device|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
278874|NCT02077569|Drug|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
278875|NCT02077556|Drug|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
278876|NCT02077556|Drug|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell < 4000/mcL)
278877|NCT02077556|Drug|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
278878|NCT02077556|Drug|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
278879|NCT02077556|Drug|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
278880|NCT02077543|Device|Brain Tissue Imprint - Medical Device (ProTool)|genomic, transcriptomic and proteomic studies.
278881|NCT02077517|Procedure|Roux en Y Gastric Bypass|
278882|NCT02077504|Other|MEG and MRI|CONDUCTOME
278883|NCT02077491|Other|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
278884|NCT02077478|Device|Remifentanil and propofol administration using TCI|
278885|NCT02077478|Device|Remifentanil and propofol administration using MCI|
278886|NCT02077465|Drug|GS-5745|400 mg GS-5745 administered intravenously
278887|NCT02077465|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
278888|NCT02077452|Drug|HMS5552|
278889|NCT02077452|Drug|Placebo|
278890|NCT02077439|Device|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
278891|NCT02077439|Device|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
278892|NCT02077439|Other|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
278893|NCT02077426|Other|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
278894|NCT02077413|Procedure|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
278974|NCT02076698|Procedure|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
278895|NCT02077413|Procedure|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
278896|NCT02077413|Procedure|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
278897|NCT02077413|Procedure|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
278898|NCT02077400|Drug|Cephazolin|Cephazolin
278899|NCT02077387|Behavioral|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
278900|NCT02077387|Behavioral|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
278901|NCT02077374|Drug|IDN-6556|25 mg BID for 28 days
278902|NCT02077374|Other|Placebo|Placebo BID for 28 Days
278903|NCT02077361|Genetic|rAAV2.REP1 vector|No additional details needed.
278904|NCT02077348|Drug|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
278905|NCT02077348|Drug|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
278906|NCT02077335|Radiation|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:~Prostate :~V100 > 95%~V150 30-35%~V200 < 15%~D90 > 90% (12,15Gy)~Bladder~• V75 < 1cc~Rectum~• V75 < 1cc~Urethra~V125 = 0cc D10 < 120%~Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
278907|NCT02077322|Device|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
278908|NCT02077322|Device|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
278909|NCT02077309|Drug|Linagliptin|
278910|NCT02077309|Drug|Placebo|
278911|NCT02077270|Procedure|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
278912|NCT02077257|Drug|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
278913|NCT02077244|Behavioral|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
278914|NCT02077231|Drug|Vitamin A|use one drop in the eye
278915|NCT02077231|Drug|carbomer eye gel|use one drop in the eye
278916|NCT02077218|Procedure|computed tomography|Undergo cardiac CT
278917|NCT02077218|Other|cytology specimen collection procedure|Undergo collection of blood samples
278918|NCT02077218|Other|laboratory biomarker analysis|Correlative studies
278919|NCT02077218|Other|questionnaire administration|Ancillary studies
278920|NCT02077205|Behavioral|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
278921|NCT02077192|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
278922|NCT02077179|Behavioral|HIP Program|"The entirety of the HIP Program is delivered through an interactive mobile website.~The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.~The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays."
278923|NCT02077166|Drug|Ibrutinib|
278924|NCT02077166|Drug|Lenalidomide|
278925|NCT02077166|Drug|Rituximab|
278926|NCT02077153|Behavioral|Reminiscence therapy|
278927|NCT02077153|Behavioral|Active participation in group setting|
278928|NCT02077140|Drug|MDT-10013|
278929|NCT02077140|Drug|Standard of care for pain|
278930|NCT02077114|Biological|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
278931|NCT02077101|Other|Questionnaire|
278932|NCT02077101|Other|Interview|
278933|NCT02077088|Other|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
278934|NCT02077075|Behavioral|Web-based weight loss program|A 4-week web-based wellness program.
278935|NCT02077075|Behavioral|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
278975|NCT02076698|Drug|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
278936|NCT02077049|Device|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.~The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.~This serious games program is instructed individually by experienced physiotherapists."
278937|NCT02077049|Other|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
278938|NCT02077036|Device|Kinetic Oscillation Stimulation Device|
278939|NCT02077036|Device|Kinetic Oscillation Stimulation Device in placebo mode|
278940|NCT02077010|Drug|Milrinone|Milrinone is both the active comparison and experimental arm. The intervention arm will receive milrinone via inhalation of a nebulizer solution. The active comparison arm will receive milrinone via a continuous intravenous infusion.
278941|NCT02076997|Drug|Methotrexate|"Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."
278942|NCT02076984|Procedure|Laparoscopic incisional or ventral hernia repair|
278943|NCT02076958|Behavioral|Community Health Advisor education|
278944|NCT02076945|Procedure|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
278945|NCT02076932|Behavioral|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
278946|NCT02076919|Drug|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
278947|NCT02076919|Drug|LHA510 Vehicle|Inactive ingredients used for masking purposes
278948|NCT02076906|Device|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
278949|NCT02076893|Drug|gabapentin|The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
278950|NCT02076893|Drug|Tramadol|Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
278951|NCT02076893|Drug|Ibuprofen|Both study arms will receive as needed (PRN) ibuprofen to take home.
278952|NCT02076893|Drug|Placebo|Simple syrup suspension
278953|NCT02076880|Other|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.~usual breakfast of the patient (possibly limited in quantity)~midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
278954|NCT02076880|Other|No caloric restriction|No change in eating habits to patients in this arm
278955|NCT02076867|Behavioral|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
278956|NCT02076867|Behavioral|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
278957|NCT02076854|Behavioral|Text-Message Intervention|
278958|NCT02076841|Device|interferon beta-1a|Administered as specified in the treatment arm
278959|NCT02076828|Drug|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
278960|NCT02076828|Drug|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
278961|NCT02076828|Drug|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
278962|NCT02076815|Drug|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
278963|NCT02076815|Drug|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
278964|NCT02076802|Behavioral|physical exercises|
278965|NCT02076776|Behavioral|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
278966|NCT02076776|Behavioral|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
278967|NCT02076776|Behavioral|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
278968|NCT02076750|Dietary Supplement|Vitamin D3 (cholecalciferol)|
278969|NCT02076737|Device|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
278970|NCT02076724|Device|Biological mesh|
278971|NCT02076724|Device|Synthetic mesh|
278976|NCT02076685|Drug|isoniazid|dose adjustment according to the pharmacogenomic results
278977|NCT02076672|Drug|Artichoke WPC|Artichoke WPC 500 mg capsules. Dose = 1000 mg (2 - 500 mg capsules) just before breakfast and 1000 mg (2 - 500 mg capsules) before dinner. Duration: daily for a period of 90 days.
278978|NCT02076659|Drug|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.~F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
278979|NCT02076659|Drug|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).~Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
278980|NCT02076646|Drug|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
278981|NCT02076646|Drug|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
278982|NCT02076646|Drug|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
278983|NCT02076633|Drug|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
278984|NCT02076620|Drug|L19TNFα|L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
278985|NCT02076620|Drug|Doxorubicin|Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
278986|NCT02076607|Procedure|Arthrodesis|Posterior approach to toracolumbar spine fusion.
278987|NCT02076607|Device|Brace|Toracolumbar imobilization
278988|NCT02076594|Drug|Docetaxel|Powder for solution for infusion
278989|NCT02076594|Drug|Epirubicin|Solution for infusion
278990|NCT02076594|Drug|Oxaliplatin|Powder for solution for infusion
278991|NCT02076594|Drug|Capecitabine|Film coated tablets
278992|NCT02076568|Behavioral|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
278993|NCT02076555|Behavioral|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
278994|NCT02076542|Behavioral|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
278995|NCT02076529|Drug|Ramosetron 0.3mg|
278996|NCT02076529|Drug|Ramosetron 0.45mg|
278997|NCT02076529|Drug|Ramosetron 0.6mg|
278998|NCT02076516|Device|Drug-eluting stent: CORACTO®|
278999|NCT02076503|Procedure|PET-MR 18f-FACBC|
279000|NCT02076503|Procedure|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
279001|NCT02076490|Other|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
279002|NCT02076477|Radiation|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors〉3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
279003|NCT02076477|Drug|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
279004|NCT02076477|Drug|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
279005|NCT02076477|Drug|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
279006|NCT02076464|Behavioral|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
279007|NCT02076451|Drug|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
279008|NCT02076438|Dietary Supplement|Probiotics|Randomized to receive probiotics or placebo
279009|NCT02076425|Behavioral|PCIT-ED|
279010|NCT02076412|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg PO bid (morning and evening) over the course of 24 weeks.
279011|NCT02076412|Drug|Placebo|Placebo tablet PO bid (morning and evening)
279012|NCT02076399|Drug|Fostamatinib disodium|Fostamatinib (100 mg PO bid or 150 mg PO bid)
279013|NCT02076399|Drug|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
279014|NCT02076386|Drug|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
279015|NCT02076373|Drug|recombinant human Erythropoietin|i.v. administration
279016|NCT02076373|Drug|Placebo|i.v. administration
279017|NCT02076360|Behavioral|Preoperative Video|Patients will watch preoperative instructional video
279018|NCT02076347|Behavioral|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
279019|NCT02076347|Behavioral|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
279020|NCT02076334|Other|Far Infrared Fabric|
279021|NCT02076334|Other|Spandex|
279022|NCT02076321|Drug|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
279023|NCT02076321|Drug|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
279024|NCT02076308|Other|Electroacupuncture and physical therapy|real electroacupuncture
279025|NCT02076308|Other|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
279026|NCT02076282|Other|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast~For patients: 1 MRI scan with contrast"
279027|NCT02076269|Other|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
279028|NCT02076256|Behavioral|The helping relationships intervention program|
279029|NCT02076243|Drug|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
279030|NCT02076230|Drug|[14C] TH-302 (Label 1)|[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
279031|NCT02076230|Drug|[14C] TH-302 (Label 2)|[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
279032|NCT02076230|Drug|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
279033|NCT02076217|Drug|Copper T-380 IUD|
279034|NCT02076217|Drug|LNG IUD|
279035|NCT02076217|Device|Contraceptive implant Nexplanon|
279036|NCT02076217|Drug|Depo-Provera|
279037|NCT02076204|Behavioral|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
279038|NCT02076191|Drug|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
279039|NCT02076191|Drug|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
279040|NCT02076178|Drug|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
279041|NCT02076178|Drug|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
279042|NCT02076178|Drug|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
279043|NCT02076178|Drug|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
279044|NCT02076165|Behavioral|Acceptance and the Behavioral Changes to Treat Insomnia|Participants attended 5 individual sessions incorporating behavioral treatment components plus acceptance and commitment therapy (ACT) with a trained instructor.
279045|NCT02076165|Behavioral|Cognitive behavioral therapy for insomnia|Participants attended 5 individual sessions incorporating behavioral and cognitive therapy components with a trained instructor.
279046|NCT02076152|Device|FMISO PET|
279047|NCT02076152|Device|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
279048|NCT02076152|Drug|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
279049|NCT02076152|Drug|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
279050|NCT02076139|Dietary Supplement|Nyaditum resae® 10e4|
279051|NCT02076139|Dietary Supplement|Nyaditum resae® 10e5|
279052|NCT02076139|Other|Distilled water|
279053|NCT02076113|Procedure|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
279091|NCT02075723|Dietary Supplement|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
279054|NCT02076113|Procedure|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
279055|NCT02076113|Procedure|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
279056|NCT02076100|Drug|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
279057|NCT02076087|Procedure|Liposuction/lipectomy|Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
279058|NCT02076074|Radiation|accelerated partial breast irradiation|Undergo HG-PBI
279059|NCT02076022|Device|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™~The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.~To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
279060|NCT02076022|Procedure|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
279061|NCT02076009|Drug|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards.
279062|NCT02076009|Drug|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
279063|NCT02076009|Drug|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants > 75 years old or with a body mass index < 18.5).
279064|NCT02075983|Biological|GTU®-multiHIV B clade|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
279065|NCT02075970|Drug|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."
279066|NCT02075970|Drug|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
279067|NCT02075944|Behavioral|High intensity aerobic exercise|
279068|NCT02075944|Behavioral|Low intensity aerobic exercise|
279069|NCT02075931|Other|Physical activity feedback with group meetings|Physical activity feedback
279070|NCT02075931|Other|Control|No intervention
279071|NCT02075892|Dietary Supplement|Mushroom Blend|Scivation
279072|NCT02075892|Dietary Supplement|Placebo|
279073|NCT02075879|Behavioral|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
279074|NCT02075879|Other|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
279075|NCT02075840|Drug|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
279076|NCT02075840|Drug|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
279077|NCT02075827|Behavioral|Competitive video game|1 hour playing video game
279078|NCT02075827|Behavioral|Little Big Planet|1 hour playing video game
279079|NCT02075801|Other|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
279080|NCT02075801|Other|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.~C.Control Group: The defective restorations did not receive any treatment."
279081|NCT02075788|Other|Commercial white bread|
279082|NCT02075788|Other|Corn based products (porridge etc.)|
279083|NCT02075788|Other|Millet based products (porridge etc.)|
279084|NCT02075762|Procedure|Transbronchial biopsy|
279085|NCT02075762|Procedure|Cryoprobe biopsy|
279086|NCT02075762|Procedure|VATS biopsy|
279087|NCT02075749|Drug|Triamcinolone Acetonide|
279088|NCT02075749|Drug|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
279089|NCT02075736|Procedure|KTP laser|
279090|NCT02075736|Procedure|TUR-P|device
279092|NCT02075723|Behavioral|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
279093|NCT02075710|Other|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
279094|NCT02075710|Other|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
279095|NCT02075710|Other|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
279096|NCT02075710|Other|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
279097|NCT02075710|Other|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
279098|NCT02075710|Other|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
279099|NCT02075684|Procedure|Renal Biopsy|
279100|NCT02075671|Drug|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
279101|NCT02075671|Device|Blu-U Light Therapy|Intervention used in experimental and sham arms
279102|NCT02075671|Other|Placebo vehicle only|Intervention only includes the placebo vehicle solution
279103|NCT02075658|Device|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
279104|NCT02075658|Device|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
279105|NCT02075645|Other|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
279106|NCT02075632|Drug|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
279107|NCT02075619|Drug|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
279108|NCT02075619|Drug|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
279109|NCT02075619|Drug|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
279110|NCT02075606|Drug|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
279111|NCT02075593|Drug|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
279112|NCT02075580|Behavioral|psychological support (interactive/cognitive strategies)|"cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)~metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)~psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)~questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
279113|NCT02075567|Procedure|Experimental|
279114|NCT02075554|Device|CALIBER|Expandable interbody spacer
279115|NCT02075541|Biological|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
279116|NCT02075541|Drug|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
279117|NCT02075528|Drug|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
279118|NCT02075515|Biological|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
279119|NCT02075502|Behavioral|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
279120|NCT02075502|Procedure|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
279121|NCT02075502|Procedure|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
279122|NCT02075489|Other|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for ~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for ~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
279123|NCT02075489|Other|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
279124|NCT02075476|Procedure|Hemiarthroplasty|
279125|NCT02075476|Procedure|reverse arthroplasty|
279126|NCT02075463|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
279127|NCT02075463|Drug|Placebo|Matching placebo tablet for GSK1278863
279128|NCT02075450|Device|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
279129|NCT02075450|Other|Just in Time Video|CPR Just in Time training video administered before the simulation case
279130|NCT02075437|Behavioral|Feeling and Body Investigators with Functional Abdominal Pain|"Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation."
279131|NCT02075437|Behavioral|Treatment Strategies|"identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~incorporate caregivers as role models and facilitators based on attachment research."
279132|NCT02075424|Other|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.~Only one sampling will occur to doctors who are assigned to a single workstation.~Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.~To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.~There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.~They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
279133|NCT02075411|Drug|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Males Single shot peripheral nerve block"
279134|NCT02075411|Drug|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.~Females Single shot peripheral nerve block"
279135|NCT02075411|Device|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
279136|NCT02075411|Device|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
279137|NCT02075385|Procedure|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
279138|NCT02075372|Other|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
279139|NCT02075333|Dietary Supplement|Ingestion of solution|Participants will ingest the solution
279140|NCT02075333|Dietary Supplement|Rinising of solution|Participants rinse the solution in the oral cavity
279141|NCT02075320|Device|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.~Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
279142|NCT02075307|Dietary Supplement|Blueberry Powder|
279143|NCT02075307|Dietary Supplement|Placebo|
279144|NCT02075294|Drug|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.~Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
279145|NCT02075281|Biological|HM11260C|Glucagon-like peptide-1 analogue
279146|NCT02075281|Biological|Placebo|
279147|NCT02075268|Drug|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
279148|NCT02075255|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
279149|NCT02075255|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
279150|NCT02075255|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
279151|NCT02075242|Drug|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
279152|NCT02075242|Drug|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
279153|NCT02075229|Device|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
279154|NCT02075216|Procedure|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
279155|NCT02075216|Biological|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
279205|NCT02074839|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
279156|NCT02075203|Biological|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK & a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 & saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
279157|NCT02075203|Drug|Placebo|Saline
279158|NCT02075203|Biological|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
279159|NCT02075190|Other|Therapeutic Computerized intervention|Remediation training intervention
279160|NCT02075190|Other|Nontherapeutic computerized intervention|Online gaming intervention
279161|NCT02075177|Drug|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
279162|NCT02075177|Drug|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
279163|NCT02075164|Dietary Supplement|Fructose|High oral Fructose challenge (150g per day for 56 days)
279164|NCT02075164|Dietary Supplement|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
279165|NCT02075151|Procedure|Bronchial Thermoplasty|Bronchial thermoplasty
279166|NCT02075125|Drug|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
279167|NCT02075125|Drug|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
279168|NCT02075112|Drug|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
279169|NCT02075112|Radiation|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
279170|NCT02075112|Drug|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
279171|NCT02075099|Other|tensing exercises|Donors will do tensing exercises during blood donation
279172|NCT02075099|Other|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
279173|NCT02075086|Drug|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
279174|NCT02075073|Biological|SB3|
279175|NCT02075073|Biological|EU sourced Herceptin®|
279176|NCT02075073|Biological|US sourced Herceptin®|
279177|NCT02075060|Procedure|IPOI (pre-operative)|
279178|NCT02075060|Procedure|IPOP (post-operative)|
279179|NCT02075047|Drug|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
279180|NCT02075047|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
279181|NCT02075034|Drug|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
279182|NCT02075021|Drug|Lenalidomide|
279183|NCT02075021|Drug|nab-paclitaxel|
279184|NCT02075008|Drug|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
279185|NCT02074995|Biological|BVS857|Group 1A&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
279186|NCT02074995|Other|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
279187|NCT02074982|Drug|AIN457 300 mg|
279188|NCT02074982|Drug|ustekinumab 45/90 mg|
279189|NCT02074982|Drug|placebo secukinumab|Placebo
279190|NCT02074969|Device|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
279191|NCT02074969|Device|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
279192|NCT02074956|Biological|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
279193|NCT02074956|Biological|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
279194|NCT02074943|Biological|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
279195|NCT02074930|Device|Microporation by P.L.E.A.S.E. Professional / Prick needle|
279196|NCT02074917|Procedure|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
279197|NCT02074904|Drug|Topiramate|
279198|NCT02074904|Drug|Placebo|
279199|NCT02074891|Drug|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
279200|NCT02074878|Drug|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
279201|NCT02074878|Drug|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
279202|NCT02074878|Drug|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
279203|NCT02074865|Biological|biological samples|
279204|NCT02074852|Other|Foley urethral catheter|
279206|NCT02074813|Other|Inspiratory muscle training|Inspiratory muscle training
279207|NCT02074800|Drug|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
279208|NCT02074800|Drug|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
279209|NCT02074800|Drug|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
279210|NCT02074787|Device|Thermography|Standard thermographic images
279211|NCT02074787|Device|Laser Doppler|standard laser doppler analysis
279212|NCT02074787|Device|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
279213|NCT02074774|Device|IntellO2|Automated FiO2 regulator that responds to pulse oximetry measures
279214|NCT02074774|Other|Manual control|Standard practice of manually titrating FiO2 as needed.
279215|NCT02074761|Device|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
279216|NCT02074735|Drug|Placebo|Inactive ingredient matching the active comparator in appearance
279217|NCT02074735|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
279218|NCT02074709|Drug|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
279219|NCT02074709|Drug|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV~First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
279220|NCT02074683|Procedure|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
279221|NCT02074683|Procedure|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
279222|NCT02074670|Other|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
279223|NCT02074657|Biological|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
279224|NCT02074644|Procedure|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
279225|NCT02074644|Procedure|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
279226|NCT02074631|Drug|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
279227|NCT02074631|Drug|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
279228|NCT02074618|Other|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
279229|NCT02074605|Biological|Interferon alpha|
279230|NCT02074592|Behavioral|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
279231|NCT02074592|Behavioral|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
279232|NCT02074579|Drug|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
279233|NCT02074579|Drug|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
279234|NCT02074566|Other|Cryoballoon ablation|PVI using cryoballoon
279235|NCT02074553|Drug|Part 1 (Fasted): Treatment A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment A (capsule formulation containing 50% SLS) on Day 1 of any of the four intervention periods in Part 1.
279236|NCT02074553|Drug|Part 1 (Fasted): Treatment B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment B (capsule formulation containing 25% SLS) on Day 1 of any of the four intervention periods in Part 1.
279237|NCT02074553|Drug|Part 1 (Fasted): Treatment C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment C (capsule formulation containing 12.5% SLS) on Day 1 of any of the four intervention periods in Part 1.
279307|NCT02074163|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279238|NCT02074553|Drug|Part 1 (Fasted): Treatment D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment D (capsule formulation containing 3% SLS) on Day 1 of any of the four intervention periods in Part 1.
279239|NCT02074553|Drug|Part 2 (Fed): Treatment A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment A (capsule formulation containing 50% SLS) on Day 1 of any of the four intervention periods in Part 2.
279240|NCT02074553|Drug|Part 2 (Fed): Treatment B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment B (capsule formulation containing 25% SLS) on Day 1 of any of the four intervention periods in Part 2.
279241|NCT02074553|Drug|Part 2 (Fed): Treatment C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment C (capsule formulation containing 12.5% SLS) on Day 1 of any of the four intervention periods in Part 2.
279242|NCT02074553|Drug|Part 2 (Fed): Treatment D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment D (capsule formulation containing 3% SLS) on Day 1 of any of the four intervention periods in Part 2.
279243|NCT02074540|Other|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
279244|NCT02074514|Drug|Sofosbuvir|400 mg tablet administered orally once daily
279245|NCT02074514|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
279246|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge."
279247|NCT02074488|Other|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
279248|NCT02074488|Other|Informational Brochure|Informational Brochure on falls prevention
279249|NCT02074475|Other|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
279250|NCT02074436|Drug|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
279251|NCT02074436|Other|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
279252|NCT02074423|Dietary Supplement|MealShape cinnamon extract|Acute administration of 1 g PO (2 capsules of 500 mg)
279253|NCT02074423|Dietary Supplement|Placebo|Acute administration of 1 g PO (2 capsules of 500 mg)
279254|NCT02074410|Drug|OMS643762|
279255|NCT02074410|Drug|Placebo|
279256|NCT02074397|Procedure|Distant extrafascial injection|
279257|NCT02074397|Procedure|Subfascial injection|
279258|NCT02074384|Device|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
279259|NCT02074384|Device|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
279260|NCT02074384|Other|Clinician|Survey of clinicians after study visits
279261|NCT02074358|Drug|Apixaban|
279262|NCT02074358|Drug|Cofact (4-Factor PCC)|
279263|NCT02074358|Drug|Beriplex P/N (4-Factor PCC)|
279264|NCT02074358|Drug|Placebo (Saline solution)|
279265|NCT02074345|Biological|TAK-816|TAK-816 intramuscular injection
279266|NCT02074332|Behavioral|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight&obese students Family physical activities Parent involvement
279267|NCT02074332|Behavioral|Health education|Knowledge of obesity prevention and control
279268|NCT02074319|Drug|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
279269|NCT02074306|Device|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
279270|NCT02074306|Device|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
279271|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
279272|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
279273|NCT02074293|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
279274|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279275|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
279276|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
279423|NCT02073344|Other|no intervention|no renal replacement therapy
279277|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279278|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279279|NCT02074293|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279280|NCT02074293|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279281|NCT02074293|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279282|NCT02074293|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279283|NCT02074293|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
279284|NCT02074293|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
279285|NCT02074293|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
279286|NCT02074280|Drug|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
279287|NCT02074267|Drug|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
279288|NCT02074267|Drug|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
279289|NCT02074241|Other|Expression analysis|Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
279290|NCT02074228|Drug|Methylphenidate (Concerta)|
279291|NCT02074215|Other|Aerobic exercises|Aerobic exercises + dual task
279292|NCT02074215|Other|Stretch exercise|Stretch exercise
279293|NCT02074202|Drug|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
279294|NCT02074202|Drug|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
279295|NCT02074189|Drug|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
279296|NCT02074163|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
279297|NCT02074163|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
279298|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279299|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279300|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279301|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 24,|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279302|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279303|NCT02074163|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279304|NCT02074163|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279305|NCT02074163|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279306|NCT02074163|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
279460|NCT02073097|Biological|rituximab|Given IV
279308|NCT02074163|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
279309|NCT02074163|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
279310|NCT02074150|Drug|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs."
279311|NCT02074150|Drug|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.~Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
279312|NCT02074150|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
279313|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279314|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279315|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279316|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279317|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279318|NCT02074150|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279319|NCT02074150|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279320|NCT02074150|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279321|NCT02074150|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279322|NCT02074150|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
279323|NCT02074150|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
279324|NCT02074150|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
279325|NCT02074137|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
279326|NCT02074137|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
279327|NCT02074137|Drug|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
279328|NCT02074098|Device|Macintosh laryngoscope|Direct Laryngoscope
279329|NCT02074098|Device|Glidescope|Videolaryngoscope-1
279330|NCT02074098|Device|Airwayscope|Videolaryngoscope-2
279331|NCT02074072|Device|15 degree left-lateral tilt wedges|The wedges are made of aluminium
279332|NCT02074072|Device|30 degree left-lateral tilt wedges|The wedges are made of aluminium
279333|NCT02074059|Drug|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
279334|NCT02074059|Device|nCPAP alone|nCPAP therapy
279335|NCT02074046|Biological|cancer stem cell vaccine|
279336|NCT02074020|Drug|Blisibimod|Administered via subcutaneous injection once per week
279337|NCT02074020|Drug|Placebo|Administered via subcutaneous injection once per week
279338|NCT02074007|Drug|AR01|drops administered as needed for pain
279461|NCT02073097|Drug|cyclophosphamide|Given IV
279339|NCT02074007|Drug|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
279340|NCT02073994|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
279341|NCT02073968|Drug|Carboplatin|Given IV
279342|NCT02073968|Procedure|Computed Tomography|Undergo PET-adjusted IMRT
279343|NCT02073968|Radiation|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
279344|NCT02073968|Drug|Paclitaxel|Given IV
279345|NCT02073968|Procedure|Positron Emission Tomography|Undergo PET-adjusted IMRT
279346|NCT02073968|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
279347|NCT02073929|Drug|Liraglutide for 26 weeks|GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks
279348|NCT02073929|Drug|placebo|Placebo s.c. daily for 26 weeks
279349|NCT02073916|Drug|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
279350|NCT02073916|Drug|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
279351|NCT02073916|Drug|Abraxane|albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor
279352|NCT02073903|Behavioral|Patient Survey|
279353|NCT02073903|Behavioral|Provider Survey|
279354|NCT02073851|Device|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
279355|NCT02073838|Drug|Ribavirin|
279356|NCT02073838|Drug|Vismodegib|
279357|NCT02073838|Drug|Decitabine|
279358|NCT02073825|Behavioral|Web Brief Intervention (WBI)|4-session WBI
279359|NCT02073812|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
279360|NCT02073799|Procedure|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
279361|NCT02073786|Device|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
279362|NCT02073786|Device|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
279363|NCT02073773|Drug|Levodopa|"Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.~Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth."
279364|NCT02073773|Other|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
279365|NCT02073760|Other|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
279366|NCT02073747|Drug|Normal Saline|One hour inhaled normal saline
279367|NCT02073747|Drug|Albuterol|One hour inhaled ten milligrams of albuterol
279368|NCT02073734|Drug|Dexamethasone|Dexamethasone 8mg/IV
279369|NCT02073734|Drug|Placebo|Placebo given IV
279370|NCT02073721|Other|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
279371|NCT02073721|Other|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
279372|NCT02073695|Procedure|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
279373|NCT02073695|Device|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
279374|NCT02073695|Other|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
279375|NCT02073695|Other|Functional outcome forms filled in|
279376|NCT02073695|Other|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
279377|NCT02073695|Other|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
279378|NCT02073682|Drug|Edoxaban|After the 5 day treatment with LMWH, patients receive edoxaban 60 mg once daily (QD) as 2 × 30 mg tablets (or 1 x 30 mg tablet QD for patients requiring dose adjustment) for the remainder of the treatment period.
279379|NCT02073682|Drug|Dalteparin|Dalteparin was administered via subcutaneous injection at a dose of 200 IU/kg (maximum daily dose 18,000 IU) for 30 days, and at a dose of 150 IU/kg from Day 31 to the end of treatment.
279380|NCT02073682|Drug|Low molecular weight heparin|Therapeutic doses of subcutaneous LMWH were administered for at least 5 days (to patients in the edoxaban group); this 5-day period may have included the pre-randomization LMWH (if applicable). The choice of parenteral LMWH was up to the treating physician.
279381|NCT02073669|Procedure|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
279382|NCT02073656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
279422|NCT02073344|Procedure|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
279383|NCT02073656|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
279384|NCT02073630|Other|active cerebellar stimulation|
279385|NCT02073630|Other|sham cerebellar stimulation|
279386|NCT02073617|Radiation|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
279387|NCT02073604|Other|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
279388|NCT02073604|Other|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
279389|NCT02073591|Other|Ceradan Cream|
279390|NCT02073591|Other|Ceradan Wash|
279391|NCT02073578|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
279392|NCT02073565|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
279393|NCT02073565|Device|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
279394|NCT02073552|Drug|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
279395|NCT02073552|Drug|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
279396|NCT02073539|Device|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
279397|NCT02073539|Device|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
279398|NCT02073526|Drug|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
279399|NCT02073513|Device|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.~The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
279400|NCT02073513|Device|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
279401|NCT02073500|Other|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.~HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
279402|NCT02073487|Drug|T-DM1|antibody-drug conjugate of trastuzumab and emtansine
279403|NCT02073487|Drug|Trastuzumab|anti-Her2 monoclonal antibody
279404|NCT02073487|Drug|Lapatinib|Dual tyrosine kinase inhibitor (HER2 and EGFR)
279405|NCT02073487|Drug|Abraxane|albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.
279406|NCT02073487|Drug|Paclitaxel|chemotherapy - microtubule inhibitor
279407|NCT02073487|Drug|Pertuzumab|anti-HER2 monoclonal antibody
279408|NCT02073474|Drug|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
279409|NCT02073461|Drug|CD1579 2.5%|
279410|NCT02073461|Drug|CD1579 5%|
279411|NCT02073461|Drug|Vehicle|
279412|NCT02073448|Drug|GK530G|
279413|NCT02073448|Drug|CD0271|
279414|NCT02073448|Drug|CD1579|
279415|NCT02073435|Behavioral|Donor pain management|"The evidence-based donor pain management solution entails the following elements:~Preoperative Assessment and Management:~Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)~Bowel preparation (e.g. Colace or Golytely)~Patient Postoperative Pain Education - Educational handout on postoperative pain~At the end of the case in OR:~Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)~I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is > 500cc)~I.V. Steroids (Dexamethasone or Solumedrol)~Postoperative Management:~NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)~Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))~Postoperative Assessment:~o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression"
279416|NCT02073422|Device|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
279417|NCT02073422|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
279418|NCT02073396|Diagnostic Test|Blood test|Patients will undergo the tests of thrombosis, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study.
279419|NCT02073383|Procedure|Axillary brachial plexus block|
279420|NCT02073357|Procedure|Light general anaesthesia (BIS = 50)|
279421|NCT02073357|Procedure|deep general anaesthesia (BIS = 35)|
279424|NCT02073318|Other|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
279425|NCT02073318|Other|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session~weeks"
279426|NCT02073305|Other|No Sleep Apnea|No intervention
279427|NCT02073305|Other|Sleep Apnea - untreated|No intervention
279428|NCT02073305|Device|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
279429|NCT02073292|Procedure|c-RFA|
279430|NCT02073292|Procedure|tRFA|
279431|NCT02073279|Drug|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
279432|NCT02073279|Drug|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
279433|NCT02073266|Procedure|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
279434|NCT02073253|Other|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
279435|NCT02073240|Behavioral|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:~Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility~Audits and Feedback of performance~A TB IC collaborative membership~A standardized unit-level daily checklist of critical IC activities"
279436|NCT02073227|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
279437|NCT02073227|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
279438|NCT02073227|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
279439|NCT02073227|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
279440|NCT02073214|Other|Probiotic|Standard treatment plus probiotic
279441|NCT02073214|Other|Placebo|Standard treatment plus placebo
279442|NCT02073201|Other|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
279443|NCT02073201|Other|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
279444|NCT02073201|Other|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
279445|NCT02073188|Device|iBGStar|
279446|NCT02073188|Device|Traditional Glucometer|
279447|NCT02073175|Drug|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
279448|NCT02073162|Procedure|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
279449|NCT02073149|Dietary Supplement|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
279450|NCT02073149|Dietary Supplement|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
279451|NCT02073149|Dietary Supplement|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
279452|NCT02073136|Other|Diet with phosphate containing additives|
279453|NCT02073136|Other|Diet without phosphate containing additives|
279454|NCT02073123|Drug|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~If > 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~If >1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If >1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
279455|NCT02073123|Drug|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
279456|NCT02073123|Drug|Nivolumab|Nivolumab administered intravenously at 240 mg every 2 weeks.
279457|NCT02073123|Drug|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
279458|NCT02073110|Device|Percutaneous Optical Biopsy (OCT and DRS)|
279459|NCT02073097|Drug|carfilzomib|Given IV
279462|NCT02073097|Drug|doxorubicin hydrochloride|Given IV
279463|NCT02073097|Drug|vincristine sulfate|Given IV
279464|NCT02073097|Drug|prednisone|Given PO
279465|NCT02073084|Drug|K-877 Low Dose|K-877 Low Dose
279466|NCT02073084|Drug|Moxifloxacin|
279467|NCT02073084|Other|Placebo|
279468|NCT02073084|Drug|K-877 High Dose|K-877 High Dose
279469|NCT02073071|Other|Preterm infant formula per standard of care|Commercially available preterm infant formula
279470|NCT02073058|Device|No treatment|
279471|NCT02073045|Other|educational intervention|Receive educational handouts
279472|NCT02073045|Other|lymphedema survey|Ancillary studies
279473|NCT02073032|Other|No intervention, only observation|
279474|NCT02073019|Drug|BL-8040|
279475|NCT02073019|Drug|Placebo|
279476|NCT02073006|Dietary Supplement|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
279477|NCT02072993|Drug|AZD1979|Single dose, oral solution administration
279478|NCT02072993|Drug|Placebo to match|Single dose, oral solution administration
279479|NCT02072980|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses
279480|NCT02072967|Other|Ribomustin|Routine practice
279481|NCT02072967|Other|rituximab|Routine practice
279482|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
279483|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
279484|NCT02072941|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
279485|NCT02072928|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
279486|NCT02072915|Procedure|Suction|
279487|NCT02072889|Other|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
279488|NCT02072863|Drug|Oprozomib|Study subjects will receive oprozomib administered orally.
279489|NCT02072863|Drug|Melphalan|Study subjects will receive melphalan 9 mg/m2.
279490|NCT02072863|Drug|Prednisone|Study subjects will receive prednisone 60 mg/m2.
279491|NCT02072850|Device|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
279492|NCT02072850|Other|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (< 12 hours, days 2, 7-10 and at 6 months).
279493|NCT02072824|Drug|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
279494|NCT02072824|Drug|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
279495|NCT02072824|Drug|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
279496|NCT02072811|Drug|DAC|"DNR 60 mg/m2 0,5h infusion iv on 1-3 days~2-CdA 5 mg/m2 2h. infusion iv on 1-5 days~Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days"
279497|NCT02072811|Drug|CLAG|"G-CSF 30MU sc, on 0-5 days~Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days~Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days~Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day"
279498|NCT02072811|Drug|Consolidation, I HAM cycle|"Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days~Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days"
279499|NCT02072811|Drug|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
279500|NCT02072811|Drug|Consolidation, III HiDAraC cycle|"Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days~2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C"
279501|NCT02072798|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
279502|NCT02072785|Drug|Vincristine Sulfate Liposome|
279503|NCT02072785|Drug|Vincristine Sulfate|
279504|NCT02072772|Behavioral|Positively Smoke Free group treatment|See Arm Description
279505|NCT02072772|Behavioral|Standard Care|See Arm Description
279506|NCT02072759|Dietary Supplement|Carnitine supplement|"Carnitine supplement (oral ingestion with meals)~Total dosage of 2g carnitine per day for 36 days.~1 carnitine supplement at breakfast (500mg)~1 carnitine supplement at lunch (500mg)~2 carnitine supplements at diner (2x 500mg=1000mg)"
279507|NCT02072759|Dietary Supplement|Placebo|
279508|NCT02072746|Dietary Supplement|Zinc|
279509|NCT02072746|Dietary Supplement|Placebo|
279510|NCT02072733|Other|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
279511|NCT02072720|Drug|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
279512|NCT02072707|Procedure|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
279513|NCT02072707|Procedure|Endocardial VT Ablation|Endocardial Only VT ablation
279514|NCT02072694|Other|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
279515|NCT02072694|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:~300 mL final volume of the solution.~Time of oral ingestion inferior than 2 minutes.~30 minutes before the radiopharmaceutical injection.~12 hours fasting minimum."
279516|NCT02072668|Drug|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
279517|NCT02072668|Drug|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
279518|NCT02072655|Procedure|socio-aesthetic care|"care of the face~skin cleansing with cleansing milk to remove impurities~a gentle scrub to exfoliate and cleanse the skin~a relaxing massage~moisturizing mask~application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~care manicure / pedicure,~massages~makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship."
279519|NCT02072642|Device|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
279520|NCT02072642|Device|Placebo light therapy|4 weeks with Placebo light therapy
279521|NCT02072629|Other|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
279522|NCT02072616|Other|Pancreatic adenocarcinoma diagnosis|
279523|NCT02072603|Other|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
279524|NCT02072603|Other|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
279525|NCT02072577|Behavioral|Video|"The student watched the video prepared individually in the ward where they were interned.~After this step, the student demonstrated again the procedure for oral hygiene.~At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially."
279526|NCT02072564|Other|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
279527|NCT02072525|Biological|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
279528|NCT02072525|Biological|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
279529|NCT02072525|Biological|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
279530|NCT02072525|Biological|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
279531|NCT02072512|Drug|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
279532|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
279533|NCT02072512|Drug|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
279534|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
279535|NCT02072499|Procedure|KTP Green Light Prostatectomy|
279536|NCT02072499|Device|Green Light|
279537|NCT02072499|Procedure|Open prostatectomy|
279538|NCT02072486|Other|Laboratory Biomarker Analysis|Correlative studies
279539|NCT02072486|Drug|Sorafenib Tosylate|Given PO
279540|NCT02072473|Procedure|Coronary sinus / left-sided slow pathway ablation|"Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:~coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by~left-sided slow pathway ablation, using trans-septal approach."
279541|NCT02072460|Other|electromyography|
279542|NCT02072460|Other|electroencephalography|
279543|NCT02072460|Other|approaches from psychophysics|
279544|NCT02072447|Drug|YH4808 PO and [14C]-YH4808 IV|
279545|NCT02072434|Drug|Edoxaban|Edoxaban 30 mg tablets for oral administration
279546|NCT02072434|Drug|Warfarin|Warfarin tablet, 1.0 or 2.5 mg, for oral administration
279547|NCT02072434|Drug|Enoxaparin|Enoxaparin per label, at prescribed dose until PT INR at least 2.0
279548|NCT02072421|Procedure|PCI|
279549|NCT02072408|Drug|aflibercept|"Three monthly intravitreal aflibercept (2mg) injections~Five bimonthly intravitreal aflibercept (2mg) injections~Rescue treatment: Verteporfin photodynamic therapy~Loss of five ETDRS letters or one Snellen line of vision from baseline~Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection~Presence of active polyp on indocyanine green angiography"
279550|NCT02072395|Procedure|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
279551|NCT02072382|Drug|Metformin|metformin 850mg twice a day for eight weeks
279552|NCT02072382|Drug|Placebo|
279553|NCT02072369|Other|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
279554|NCT02072369|Other|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
279555|NCT02072356|Radiation|yttrium Y 90 glass microspheres|Given Interartrial
279556|NCT02072356|Other|laboratory biomarker analysis|Alpha-fetoprotein assay
279557|NCT02072343|Device|No-DCCM|
279558|NCT02072343|Device|DCCM|
279559|NCT02072343|Other|Water 5ml in tracheal tube|
279560|NCT02072343|Other|Water 10ml in tracheal tube|
279561|NCT02072330|Drug|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
279562|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
279563|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
279564|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
279565|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
279566|NCT02072317|Drug|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
279567|NCT02072317|Drug|taxol|taxol 135 mg/m2, every three weeks for a cycle
279568|NCT02072304|Behavioral|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
279569|NCT02072304|Behavioral|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
279570|NCT02072291|Drug|Nifedipine|PO Nifedipine 5mg single dose
279571|NCT02072278|Drug|Vortioxetine 10 mg|
279572|NCT02072278|Drug|Vortioxetine 20 mg|
279573|NCT02072278|Drug|Escitalopram 15 mg|
279574|NCT02072278|Drug|Placebo|
279575|NCT02072265|Device|Infrared thermal images|
279576|NCT02072252|Behavioral|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
279577|NCT02072239|Device|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
279578|NCT02072226|Drug|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
279579|NCT02072226|Drug|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
279580|NCT02072226|Drug|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
279581|NCT02072226|Drug|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
279582|NCT02072213|Drug|GL2702 GLARS-NF1|0.4mg once a day
279583|NCT02072213|Drug|Omix Ocas|0.4mg once a day
279584|NCT02072200|Drug|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
279585|NCT02072187|Dietary Supplement|Active|
279586|NCT02072187|Dietary Supplement|Placebo|
279587|NCT02072174|Drug|Anaferon for Children|Anaferon for children: For oral use.
279588|NCT02072161|Drug|ETC-1002|ETC-1002 capsules, taken once daily oral
279589|NCT02072161|Drug|Placebo|Placebo capsules, taken once daily oral
279590|NCT02072161|Drug|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
279591|NCT02072148|Procedure|PET/CT|PET scan or CT scan q 4 months for 5 years
279592|NCT02072148|Radiation|Radiotherapy|Postoperative XRT 5000 cGy
279593|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5000 cGy"
279594|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation~Postoperative XRT 5600 cGy"
279595|NCT02072135|Drug|Exparel|
279596|NCT02072096|Drug|Glimepiride|Administered orally
279597|NCT02072096|Drug|Metformin|Administered orally
279598|NCT02072096|Drug|Pioglitazone|Administered orally
279599|NCT02072096|Drug|Acarbose|Administered orally
279600|NCT02072096|Drug|Linagliptin|Administered orally
279601|NCT02072096|Drug|Sitagliptin|Administered orally
279602|NCT02072096|Drug|Liraglutide|Administered subcutaneously (SC)
279603|NCT02072096|Drug|Insulin Glargine|Administered SC
279604|NCT02072096|Drug|Exenatide once weekly (QW)|Administered SC
279605|NCT02072096|Drug|Exenatide twice daily (BID)|Administered SC
279606|NCT02072083|Drug|Dexmedetomidine|via intranasal route 1 mcg/kg
279607|NCT02072083|Drug|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
279608|NCT02072070|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
279609|NCT02072070|Drug|Placebo|Placebo control(Normal Saline)
279610|NCT02072057|Drug|Ruxolitinib|
279611|NCT02072044|Drug|Anlotinib|Anlotinib p.o. qd
279612|NCT02072031|Drug|Anlotinib|Anlotinib p.o. qd
279613|NCT02072031|Drug|Sunitinib maleate|Sunitinib 50 mg p.o. qd
279614|NCT02072018|Drug|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
279615|NCT02072018|Drug|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
279616|NCT02072005|Other|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
279617|NCT02071979|Device|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
279673|NCT02071537|Drug|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
279674|NCT02071537|Drug|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
279675|NCT02071524|Drug|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
279618|NCT02071979|Device|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
279619|NCT02071979|Device|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
279620|NCT02071979|Procedure|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
279621|NCT02071966|Drug|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
279622|NCT02071966|Drug|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
279623|NCT02071953|Device|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
279624|NCT02071953|Device|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
279625|NCT02071940|Drug|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
279626|NCT02071927|Drug|CB-839|Single-agent CB-839
279627|NCT02071927|Drug|CB-Aza|CB-839 in combination with standard dose azacitidine
279628|NCT02071914|Drug|CT-P27|
279629|NCT02071914|Drug|Placebo|
279630|NCT02071901|Drug|eltrombopag olamine|Given PO
279631|NCT02071888|Drug|CB-839|Glutaminase inhibitor
279632|NCT02071888|Drug|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
279633|NCT02071888|Drug|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
279634|NCT02071875|Device|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
279635|NCT02071862|Drug|CB-839|CB-839 monotherapy
279636|NCT02071862|Drug|Pac-CB|CB-839 in combination with standard dose paclitaxel
279637|NCT02071862|Drug|CBE|CB-839 in combination with standard dose everolimus
279638|NCT02071862|Drug|CB-Erl|CB-839 in combination with standard dose erlotnib
279639|NCT02071862|Drug|CBD|CB-839 in combination with standard dose docetaxel
279640|NCT02071862|Drug|CB-Cabo|CB-839 in combination with standard dose cabozantinib
279641|NCT02071849|Device|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
279642|NCT02071836|Behavioral|Right Turns web application|
279643|NCT02071836|Behavioral|Treatment as usual|
279644|NCT02071823|Drug|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
279645|NCT02071810|Drug|BIA 9-1067|
279646|NCT02071810|Drug|Placebo|
279647|NCT02071797|Device|Induced Therapeutic Hypothermia|Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
279648|NCT02071771|Device|Nelfilcon A toric contact lenses|
279649|NCT02071771|Device|Etafilcon A toric contact lenses|
279650|NCT02071758|Biological|LEISH-F3 + SLA-SE|
279651|NCT02071758|Biological|LEISH-F3 + GLA-SE|
279652|NCT02071732|Device|real repetitive Transcranial Magnetic Stimulation|
279653|NCT02071732|Device|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
279654|NCT02071706|Device|PET/MRI system|Enrolled subject undergoes PET/MR scan
279655|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point."
279656|NCT02071667|Other|Blood draw|
279657|NCT02071654|Device|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
279658|NCT02071641|Drug|Sunitinib|
279659|NCT02071615|Drug|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
279660|NCT02071615|Drug|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
279661|NCT02071615|Drug|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
279662|NCT02071615|Drug|placebo|
279663|NCT02071602|Drug|CD-NP|Randomized 1:1:1
279664|NCT02071589|Drug|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
279665|NCT02071589|Drug|Nifedipine oral solution|6 mL of Nife Par solution
279666|NCT02071576|Device|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
279667|NCT02071563|Dietary Supplement|CSB14|
279668|NCT02071563|Dietary Supplement|RUSF1|
279669|NCT02071563|Dietary Supplement|SC+|
279670|NCT02071550|Device|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
279671|NCT02071550|Device|FORESIGHT and INVOS monitor|
279672|NCT02071537|Drug|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
279676|NCT02071524|Drug|Cristalloid administration|Only Ringer Lactate administration
279677|NCT02071511|Procedure|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
279678|NCT02071511|Procedure|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
279679|NCT02071498|Device|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
279680|NCT02071498|Other|oral and written information|oral and written information about the most common errors of patients
279681|NCT02071472|Other|DP medication reconciliation|
279682|NCT02071459|Drug|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
279683|NCT02071459|Drug|placebo|initial period (4 weeks) followed by 8 weeks
279684|NCT02071433|Procedure|Saphenous nerve blockade|
279685|NCT02071433|Procedure|Femoral nerve blockade|
279686|NCT02071420|Behavioral|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
279687|NCT02071420|Behavioral|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
279688|NCT02071420|Behavioral|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
279689|NCT02071420|Device|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
279690|NCT02071407|Drug|Midazolam|"For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.~Morphine can be used to supply adequate analgesia."
279691|NCT02071407|Drug|Placebo|
279692|NCT02071394|Drug|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
279693|NCT02071394|Other|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
279694|NCT02071381|Drug|DW330SR 45mg|
279695|NCT02071381|Drug|DW1030 75mg|
279696|NCT02071368|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
279697|NCT02071368|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
279698|NCT02071368|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
279699|NCT02071368|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
279700|NCT02071355|Drug|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
279701|NCT02071355|Drug|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
279702|NCT02071342|Procedure|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
279703|NCT02071329|Drug|Vaccine FP-01.1|
279704|NCT02071329|Drug|Placebo|
279705|NCT02071329|Other|Virus Challenge|
279706|NCT02071316|Drug|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
279707|NCT02071316|Drug|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
279708|NCT02071303|Drug|Tramadol|Tramadol 100mg will be given to 70 women before the procedure.
279709|NCT02071303|Drug|Celecoxib|Celecoxib 200mg will be given to 70 women before the procedure.
279710|NCT02071303|Drug|Placebo|A placebo will be given to 70 women before the procedure.
279711|NCT02071290|Device|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet~Remote Ischemic Conditioning"
279712|NCT02071277|Other|Pressure targeted modes|Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
279713|NCT02071264|Behavioral|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
279714|NCT02071251|Procedure|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
279715|NCT02071238|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
279716|NCT02071238|Behavioral|Group Consultation|Informed consent discussion in group-format
279717|NCT02071225|Drug|bendamustine|70 milligrams per square meter (mg/m^2) given by intravenous (IV) infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
279718|NCT02071225|Drug|obinutuzumab|1000 mg given by IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
279719|NCT02071212|Drug|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
279805|NCT02070549|Drug|Trametinib|Given PO
279806|NCT02070536|Other|sRAGE|
279720|NCT02071199|Drug|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
279721|NCT02071199|Drug|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
279722|NCT02071199|Drug|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
279723|NCT02071186|Device|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.~To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
279724|NCT02071186|Other|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
279725|NCT02071186|Other|Standard of care|
279726|NCT02071173|Device|ACUITY X4 quadripolar coronary venous lead|The ACUITY X4 leads are intended for chronic left ventricular pacing and sensing. The leads have 3 tip configuration designs (straight tip, short tip spiral, and long tip spiral), which is intended to provide choices for patients with different anatomies.
279727|NCT02071173|Device|RELIANCE 4-FRONT defibrillation lead|The RELIANCE 4-FRONT leads are designed for right-side heart applications within the ventricle, atrium, and superior vena cava. It is intended for permanent sensing, pacing, and defibrillation when used with a compatible ICD or CRT-D.
279728|NCT02071160|Drug|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
279729|NCT02071147|Other|No Clinical Follow up|
279730|NCT02071147|Other|Quality of Life questionnaire|
279731|NCT02071147|Other|Patient satisfaction Questionnaire|Conducted at Research clinic.
279732|NCT02071134|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
279733|NCT02071121|Drug|BIIB061|BIIB061 capsules for oral administration
279734|NCT02071121|Drug|Placebo|BIIB061 matching placebo capsules
279735|NCT02071121|Drug|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
279736|NCT02071108|Device|Shockwave Lithoplasty System|
279737|NCT02071095|Drug|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
279738|NCT02071095|Drug|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
279739|NCT02071082|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
279740|NCT02071069|Drug|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
279741|NCT02071069|Drug|irinotecan|180 mg/m2 IV every 2 weeks
279742|NCT02071069|Drug|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
279743|NCT02071043|Drug|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3
279744|NCT02071043|Drug|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
279745|NCT02071030|Procedure|Third molar removal|Surgically removing the third molar in the lower jaw
279746|NCT02071004|Drug|DS-1040b|IV of 6 mg given once over 30 minutes
279747|NCT02071004|Drug|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
279748|NCT02070991|Drug|Macitentan|oral tablet, 10 mg once daily
279749|NCT02070991|Drug|Placebo|matching placebo
279750|NCT02070978|Drug|Atacicept 75 mg|Participants who received atacicept 75 milligram (mg) as once-weekly subcutaneous injection in the core study ADDRESS II continued to receive this dose during this LTE study. Participants in this reporting arm received the medication up to a maximum of 143.7 weeks.
279751|NCT02070978|Drug|Atacicept 150 mg|Participants who received placebo in the core study ADDRESS II switched to receive atacicept 150 mg as once-weekly subcutaneous injection for up to a maximum of 97.7 weeks during this LTE study.
279752|NCT02070978|Drug|Atacicept 150 mg|Participants who received atacicept 150 mg in core study ADDRESS II continued to receive atacicept 150 mg as once-weekly subcutaneous injection during this LTE study up to a maximum of 97.9 weeks.
279753|NCT02070965|Drug|DFD01 Spray|
279754|NCT02070965|Drug|Comp01 Lotion|
279755|NCT02070952|Radiation|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
279756|NCT02070939|Drug|PF-06260414|Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
279757|NCT02070939|Drug|Placebo|Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
279758|NCT02070939|Drug|PF-06260414|Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
279759|NCT02070939|Drug|Placebo|Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
279760|NCT02070939|Drug|PF-06260414|Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
279761|NCT02070939|Drug|Placebo|Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
279762|NCT02070900|Device|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
279807|NCT02070523|Drug|VDCLD regimen|
280059|NCT02068443|Drug|Alogliptin|Alogliptin tablets
279763|NCT02070900|Other|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
279764|NCT02070874|Behavioral|telehealth enhanced pain management|
279765|NCT02070861|Other|Ventricular pacing and passive leg raise|Ventricular pacing and passive leg raise
279766|NCT02070848|Other|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
279767|NCT02070848|Other|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
279768|NCT02070848|Other|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
279769|NCT02070835|Device|ReCell®|ReCell® and skin graft
279770|NCT02070835|Procedure|skin graft|split-thickness skin graft
279771|NCT02070809|Procedure|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
279772|NCT02070809|Procedure|split-thickness skin graft method|This method is traditional split-thickness skin graft
279773|NCT02070796|Drug|Rotigotine PR2.2.1|"Treatment A:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."
279774|NCT02070796|Drug|Rotigotine PR2.1.1|"Treatment B:~Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."
279775|NCT02070783|Drug|ARA290|
279776|NCT02070783|Drug|Placebo|
279777|NCT02070770|Dietary Supplement|Very low calorie diet|
279778|NCT02070770|Other|Standard weight loss diet|
279779|NCT02070757|Drug|Ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta (β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
279780|NCT02070757|Drug|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
279781|NCT02070744|Drug|VX-661|Tablet, oral use
279782|NCT02070744|Drug|Ivacaftor|Film coated tablet, oral use
279783|NCT02070744|Drug|Placebo matched to VX-661|Tablet, oral use
279784|NCT02070744|Drug|Placebo matched to Ivacaftor|Film coated tablet, oral use
279785|NCT02070731|Device|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
279786|NCT02070718|Drug|Standard Dose Kappa Agonist|
279787|NCT02070718|Drug|Half Dose Kappa Agonist|
279788|NCT02070718|Other|Placebo|
279789|NCT02070705|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
279790|NCT02070705|Drug|Ferumoxytol|Given IV
279791|NCT02070692|Drug|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
279792|NCT02070692|Drug|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
279793|NCT02070679|Drug|Vitamin E|
279794|NCT02070666|Behavioral|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).~Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure < 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.~Fraction of inspired oxygen inspired oxygen fraction (FiO2) > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cmH2O"
279795|NCT02070666|Behavioral|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).~Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.~· FiO2 > 0.21 to maintain oxygen saturation 90-92%.~PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).~Plateau pressure ≤ 25 cm H2O."
279796|NCT02070666|Other|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
279797|NCT02070653|Drug|Ticagrelor|
279798|NCT02070653|Drug|Placebo|
279799|NCT02070640|Drug|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
279800|NCT02070640|Device|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
279801|NCT02070627|Drug|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
279802|NCT02070627|Device|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
279803|NCT02070588|Device|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
279804|NCT02070575|Other|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
279808|NCT02070510|Drug|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
279809|NCT02070510|Drug|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
279810|NCT02070510|Drug|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
279811|NCT02070510|Drug|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
279812|NCT02070497|Other|case management|case management group will accept the case manager's service; the control group will just accept the routine care
279813|NCT02070484|Biological|NuCel|
279814|NCT02070484|Biological|Demineralized Bone Matrix|
279815|NCT02070471|Drug|Placebo|Placebo
279816|NCT02070471|Drug|LC28-0126 Dose A|LC28-0126 Dose A
279817|NCT02070471|Drug|LC28-0126 Dose B|LC28-0126 Dose B
279818|NCT02070471|Drug|LC28-0126 Dose C|LC28-0126 Dose C
279819|NCT02070458|Drug|ixazomib|Given PO
279820|NCT02070458|Drug|mitoxantrone hydrochloride|Given IV
279821|NCT02070458|Drug|etoposide|Given IV
279822|NCT02070458|Drug|cytarabine|Given IV
279823|NCT02070432|Drug|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
279824|NCT02070419|Procedure|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
279825|NCT02070419|Radiation|stereotactic radiosurgery|Undergo SBRT
279826|NCT02070406|Drug|cyclophosphamide|Given IV
279827|NCT02070406|Drug|fludarabine phosphate|Given IV
279828|NCT02070406|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
279829|NCT02070406|Biological|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
279830|NCT02070406|Biological|aldesleukin|Given SC
279831|NCT02070406|Radiation|fludeoxyglucose F 18|Correlative studies
279832|NCT02070406|Procedure|positron emission tomography|Correlative studies
279833|NCT02070406|Other|laboratory biomarker analysis|Correlative studies
279834|NCT02070393|Radiation|Proton|14-24 Radiation treatments using Protons
279835|NCT02070380|Drug|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
279836|NCT02070380|Drug|Dotarem|Dotarem administered at 0.1 mmol/kg
279837|NCT02070380|Drug|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
279838|NCT02070367|Other|Somatosensory rehabilitation|
279839|NCT02070367|Other|Usual treatment: physiotherapy|
279840|NCT02070341|Drug|Polyethylene Glycol|
279841|NCT02070341|Drug|Picosalax|
279842|NCT02070328|Other|Registry|
279843|NCT02070302|Drug|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
279844|NCT02070302|Drug|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
279845|NCT02070289|Drug|PF-06372865|Tablets, 2.5 mg BID, 14 days
279846|NCT02070289|Drug|Placebo|Tablets, BID, 14 days
279847|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
279848|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
279849|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
279850|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
279851|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
279852|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
279853|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
279854|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
279855|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
279856|NCT02070276|Procedure|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
279857|NCT02070276|Procedure|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
279858|NCT02070250|Behavioral|From Cancer to Health (C2H-D)|From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
279859|NCT02070237|Drug|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
279860|NCT02070224|Other|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
279861|NCT02070224|Other|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
279862|NCT02070211|Dietary Supplement|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
279895|NCT02069860|Device|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone and a sealing cap, a twofold valve system and a catheter are connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation.
280321|NCT02066337|Drug|Ozonated olive oil gel|
279863|NCT02070211|Other|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
279864|NCT02070211|Dietary Supplement|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
279865|NCT02070198|Drug|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
279866|NCT02070198|Drug|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
279867|NCT02070198|Drug|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
279868|NCT02070185|Behavioral|2 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
279869|NCT02070185|Behavioral|7 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
279870|NCT02070159|Drug|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
279871|NCT02070159|Drug|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
279872|NCT02070159|Drug|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
279873|NCT02070133|Drug|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
279874|NCT02070133|Drug|Placebo|Placebo once a day during 12 weeks
279875|NCT02070120|Drug|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
279876|NCT02070120|Procedure|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
279877|NCT02070107|Other|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
279878|NCT02070081|Procedure|Roux-en-Y gastric bypass surgery or sleeve surgery|
279879|NCT02070068|Device|PINPOINT System|
279880|NCT02070055|Other|No intervention|
279881|NCT02070042|Drug|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
279882|NCT02070042|Drug|Placebo|Placebo capsules (olive oil) twice a day
279883|NCT02070029|Procedure|Acupuncture|"Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.~Physical Exam: inspection of tongue and palpation of central and peripheral pulses.~Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire~- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees"
279884|NCT02070016|Device|Transcranial Magnetic Stimulation|
279885|NCT02070003|Behavioral|Motivational Interviewing and Physician Guided Opioid Weaning|
279886|NCT02069990|Drug|Cholecalciferol|
279887|NCT02069977|Drug|Aripiprazole|
279888|NCT02069951|Other|Practice a procedural module on a simulator|
279889|NCT02069925|Behavioral|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
279890|NCT02069925|Behavioral|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
279891|NCT02069912|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
279892|NCT02069899|Drug|NI-0501|In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous study, and upon request of the treating physician, patients will continue receiving NI-0501 in the context of this study.
279893|NCT02069886|Drug|deferasirox|125, 250, 500 mg dispersable tablets
279894|NCT02069873|Behavioral|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
279896|NCT02069847|Drug|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.~The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.~Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
279897|NCT02069834|Drug|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
279898|NCT02069834|Drug|Arm 2 (control)|Continuation of existing HAART at the time of randomization
279899|NCT02069821|Drug|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
279900|NCT02069808|Drug|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
279901|NCT02069808|Drug|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
279902|NCT02069808|Drug|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
279903|NCT02069808|Drug|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
279904|NCT02069808|Procedure|Transvaginal ultrasound guided needle aspiration of oocytes|
279905|NCT02069795|Other|Voice recording|
279906|NCT02069782|Other|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
279907|NCT02069769|Behavioral|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
279908|NCT02069743|Other|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
279909|NCT02069730|Drug|Selinexor|
279910|NCT02069730|Drug|EGFR or HER2 Inhibitor|
279911|NCT02069730|Drug|FGFR Inhibitor|
279912|NCT02069730|Drug|C-KIT Inhibitor|
279913|NCT02069730|Drug|Anti-androgen|
279914|NCT02069730|Drug|NOTCH Inhibitor|
279915|NCT02069730|Drug|MEK or PI3K Inhibitor|
279916|NCT02069717|Other|Not applicable-observational study|
279917|NCT02069704|Drug|Bevacizumab biosimilar (BEVZ92)|"Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
279918|NCT02069704|Drug|Avastin® (bevacizumab, reference product)|"Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
279919|NCT02069691|Device|virtual reality-cycling training system|
279920|NCT02069665|Other|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
279921|NCT02069665|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
279922|NCT02069665|Drug|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
279923|NCT02069665|Drug|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
279924|NCT02069665|Drug|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
279925|NCT02069665|Drug|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
279926|NCT02069665|Drug|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
279927|NCT02069665|Drug|Ibuprofen Suspension|taken under prescription
279928|NCT02069665|Drug|salbutamol|taken under prescription
279929|NCT02069652|Behavioral|Lifestyle Counseling|Lifestyle Counseling
279930|NCT02069639|Other|no treatment|
279931|NCT02069626|Procedure|compression time of the laparoscopic linear stapler|
279932|NCT02069600|Device|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.~The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
279933|NCT02069587|Dietary Supplement|pomegranate|
279934|NCT02069574|Procedure|non-surgical periodontal therapy|
280015|NCT02068820|Device|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
279935|NCT02069561|Dietary Supplement|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
279936|NCT02069535|Biological|AVANZ Cupressus|AVANZ Cupressus
279937|NCT02069522|Other|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
279938|NCT02069522|Other|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
279939|NCT02069496|Biological|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
279940|NCT02069483|Behavioral|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
279941|NCT02069483|Behavioral|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
279942|NCT02069470|Behavioral|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
279943|NCT02069444|Procedure|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
279944|NCT02069444|Procedure|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
279945|NCT02069431|Drug|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
279946|NCT02069431|Other|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
279947|NCT02069418|Radiation|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
279948|NCT02069418|Radiation|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
279949|NCT02069405|Other|Relaxation Music|
279950|NCT02069392|Behavioral|Cognitive remediation training|
279951|NCT02069392|Drug|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
279952|NCT02069379|Drug|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
279953|NCT02069379|Drug|Placebo|Placebo capsules prepared identically to Metformin capsules
279954|NCT02069366|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive dronabinol.
279955|NCT02069366|Drug|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive placebo.
279956|NCT02069353|Device|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
279957|NCT02069353|Device|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
279958|NCT02069340|Drug|zoledronic acid|Given IV
279959|NCT02069340|Other|pharmacological study|Correlative studies
279960|NCT02069314|Dietary Supplement|Whey protein supplementation|subjects are asked to consume a smoothie with whey protein added
279961|NCT02069314|Dietary Supplement|Carbohydrate (polycose) supplementation|Subjects are asked to consume a beverage with polycose added
279962|NCT02069301|Behavioral|Integrated Depression/Microfinance Group|LIFE-DM Integrated Depression and Microfinance group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
279963|NCT02069301|Other|Treatment as Usual|National Guideline for antidepressant care
279964|NCT02069301|Other|Livelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
279965|NCT02069288|Drug|Fludrocortisone|50 µg of fludrocortisone per os
279966|NCT02069288|Drug|Placebo|1 tablet of placebo per os
279967|NCT02069275|Other|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
279968|NCT02069275|Other|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
279969|NCT02069262|Other|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
279970|NCT02069249|Behavioral|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
280016|NCT02068820|Device|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
280060|NCT02068443|Drug|Metformin hydrochloride|Metformin hydrochloride tablets
279971|NCT02069249|Behavioral|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
279972|NCT02069236|Other|G6PD Test|All subjects are tested by multiple G6PD tests
279973|NCT02069223|Procedure|Gastrectomy|
279974|NCT02069223|Procedure|BPD-DS|
279975|NCT02069210|Other|Blood transfusion|Intraoperative blood transfusion
279976|NCT02069197|Other|Ketogenic diet|ketogenic diet will consist of 3:1[fat]:[protein+carbohydrate]weight ratio with 1600 kcal restriction. Diet will last 9 months.
279977|NCT02069197|Drug|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
279978|NCT02069197|Other|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
279979|NCT02069184|Drug|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
279980|NCT02069184|Other|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
279981|NCT02069158|Drug|PF-05212384|iv administrartion
279982|NCT02069158|Drug|Paclitaxel|iv administration
279983|NCT02069158|Drug|Carboplatin|iv administration
279984|NCT02069145|Drug|OMP-54F28 with Sorafenib|
279985|NCT02069132|Drug|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
279986|NCT02069119|Drug|OPC-108459|
279987|NCT02069119|Drug|Placebo|
279988|NCT02069106|Dietary Supplement|Pro-Omega LDL|
279989|NCT02069106|Other|Placebo|
279990|NCT02069093|Drug|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
279991|NCT02069093|Drug|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
279992|NCT02069093|Drug|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
279993|NCT02069080|Drug|64-Cu-plerixafor|"Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.~The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion."
279994|NCT02069041|Biological|Ramucirumab|Administered IV.
279995|NCT02069041|Drug|FOLFOX4|Administered IV.
279996|NCT02069015|Behavioral|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
279997|NCT02069002|Behavioral|Cognitive-Behavioral Therapy (CBT)|
279998|NCT02069002|Behavioral|Applied relaxation group therapy|
279999|NCT02069002|Behavioral|Information session (psychoeducation)|
280000|NCT02068950|Behavioral|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
280001|NCT02068937|Drug|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)
280002|NCT02068937|Drug|Furosemide|This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
280003|NCT02068924|Other|Slow freezing versus vitrification|
280004|NCT02068911|Device|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
280005|NCT02068898|Drug|XS003|
280006|NCT02068898|Drug|Tasigna|
280007|NCT02068885|Behavioral|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
280008|NCT02068872|Procedure|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
280009|NCT02068859|Drug|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
280010|NCT02068859|Drug|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
280011|NCT02068846|Drug|Ciprofloxacin|Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
280012|NCT02068846|Drug|Placebo|Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
280013|NCT02068833|Procedure|Gastrectomy|
280014|NCT02068833|Procedure|BPD-DS|
280058|NCT02068456|Drug|Roflumilast|
280017|NCT02068807|Dietary Supplement|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
280018|NCT02068807|Dietary Supplement|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
280019|NCT02068794|Other|Laboratory Biomarker Analysis|Correlative studies
280020|NCT02068794|Procedure|Mesenchymal Stem Cell Transplantation|Given IP
280021|NCT02068794|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
280022|NCT02068781|Dietary Supplement|Low-sodium diet|50 mmol NaCl per 24h
280023|NCT02068781|Dietary Supplement|High-sodium diet|250 mmol NaCl per 24h
280024|NCT02068768|Device|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
280025|NCT02068742|Other|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
280026|NCT02068703|Behavioral|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
280027|NCT02068703|Behavioral|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
280028|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
280029|NCT02068690|Drug|Placebo|Placebo
280030|NCT02068690|Drug|Placebo|Placebo
280031|NCT02068690|Drug|BI 425809 tablet|BI 425809 tablet
280032|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
280033|NCT02068677|Other|Sympathetic response|Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg.
280034|NCT02068677|Other|no sympathetic response|no Sympathetic response will be defined as change in heart rate by <10 bpm and change in BP <10mmHg.
280035|NCT02068664|Behavioral|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
280036|NCT02068651|Behavioral|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
280037|NCT02068638|Procedure|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
280038|NCT02068638|Procedure|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
280039|NCT02068638|Procedure|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
280040|NCT02068638|Procedure|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
280041|NCT02068625|Drug|Rasagiline|Rasagiline 1mg daily orally for 7 days
280042|NCT02068625|Drug|Placebo|Oral treatment with placebo for 7 days
280043|NCT02068612|Behavioral|Moderate Intensity Continuous Training+Interval Training|
280044|NCT02068612|Behavioral|Low Intensity Continuous Training|
280045|NCT02068599|Drug|TV-45070|TV-45070 ointment administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
280046|NCT02068599|Drug|Placebo|Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
280047|NCT02068586|Drug|Sunitinib|Given PO
280048|NCT02068586|Drug|Valproic Acid|Given PO
280049|NCT02068573|Device|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
280050|NCT02068573|Device|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
280051|NCT02068560|Drug|dDAVP infusion|
280052|NCT02068547|Biological|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
280053|NCT02068547|Biological|Bone Marrow Aspirate|
280054|NCT02068521|Drug|somavaratan|Subcutaneous injection
280055|NCT02068508|Drug|Pioglitazone|Pioglitazone Tablets
280056|NCT02068495|Drug|Candesartan cilexetil/Amlodipine besilate|Candesartan cilexetil/Amlodipine besilate tablets
280057|NCT02068482|Drug|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
280061|NCT02068443|Drug|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
280062|NCT02068430|Drug|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
280063|NCT02068430|Other|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
280064|NCT02068417|Device|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
280065|NCT02068404|Drug|Nifedipine|
280066|NCT02068391|Behavioral|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
280067|NCT02068391|Behavioral|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at ~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
280068|NCT02068378|Device|CMPE Optical Sensor Device|Christie Medical Physics & Enginieering visual feedback with optical sensing device.
280069|NCT02068365|Drug|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
280070|NCT02068352|Drug|OPA-15406|0.3% or 1% OPA-15406 topical ointment, applied twice daily for 8 weeks
280071|NCT02068352|Drug|Placebo|
280072|NCT02068339|Drug|Oltipraz 1 (90mg)|
280073|NCT02068339|Drug|Placebo|
280074|NCT02068339|Drug|Oltipraz 2 (120mg)|
280075|NCT02068326|Behavioral|Mentalization Based Treatment|
280076|NCT02068326|Behavioral|Treatment As Usual|Treatment As Usual
280077|NCT02068313|Radiation|Toxicity and outcome measures of IMRT|
280078|NCT02068287|Drug|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
280079|NCT02068261|Behavioral|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
280080|NCT02068261|Behavioral|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
280081|NCT02068248|Dietary Supplement|Soluble Fibre|
280082|NCT02068235|Drug|Ponesimod 5mg i.v.|
280083|NCT02068235|Drug|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
280084|NCT02068235|Drug|Ponesimod 10 mg tablet|
280085|NCT02068222|Drug|ABT-450/ritonavir (r)|Tablet
280086|NCT02068222|Drug|ABT-530|Tablet
280087|NCT02068222|Drug|Ribavirin (RBV)|Tablet
280088|NCT02068209|Drug|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
280089|NCT02068209|Drug|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
280090|NCT02068196|Procedure|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
280091|NCT02068196|Drug|Ipilimumab|
280092|NCT02068170|Drug|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
280093|NCT02068157|Other|Laboratory Biomarker Analysis|Correlative studies
280094|NCT02068157|Drug|Photodynamic Therapy|Undergo image-guided I-PDT
280095|NCT02068157|Drug|Porfimer Sodium|Given IV
280096|NCT02068144|Dietary Supplement|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
280097|NCT02068144|Other|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
280098|NCT02068131|Drug|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
280099|NCT02068131|Drug|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
280100|NCT02068118|Device|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
280101|NCT02068105|Drug|ALKS 5461|Sublingual tablet
280102|NCT02068105|Drug|Placebo|Sublingual tablet
280103|NCT02068092|Drug|Hydroxytyrosol|
280104|NCT02068079|Drug|Vemurafenib and Trientine|
280105|NCT02068053|Drug|[14C] BMS-986020|
280106|NCT02068040|Dietary Supplement|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
280107|NCT02068027|Drug|Clonidine Gel 0.1%|
280108|NCT02068027|Drug|Placebo|
280109|NCT02068001|Procedure|Roux-en-Y Gastric Bypass|
280322|NCT02066311|Drug|Nelfinavir|
280110|NCT02067988|Device|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
280111|NCT02067975|Drug|Tryptophan|
280112|NCT02067975|Drug|Placebo|
280113|NCT02067962|Biological|Blood sample|Blood sample
280114|NCT02067949|Drug|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
280115|NCT02067936|Drug|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
280116|NCT02067936|Drug|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
280117|NCT02067936|Drug|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
280118|NCT02067936|Drug|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
280119|NCT02067910|Drug|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
280120|NCT02067884|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
280121|NCT02067884|Procedure|shear wave elastography|Undergo SWE
280122|NCT02067884|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
280123|NCT02067884|Device|Philips Shear Wave Elastography|Equipment used for SWE
280124|NCT02067871|Other|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
280125|NCT02067871|Other|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
280126|NCT02067858|Radiation|Stereotactic Radiosurgery|
280127|NCT02067845|Behavioral|Adapted Many Men, Many Voices (3MV) group level intervention|"The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.~Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.~Delivery methods include discussion, role-plays and risk-reduction planning."
280128|NCT02067845|Behavioral|A group-based HIV/STI prevention intervention for women who have sex with women|
280129|NCT02067819|Device|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
280130|NCT02067819|Device|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
280131|NCT02067806|Drug|Spinal administration of chloroprocaine|
280132|NCT02067793|Drug|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
280133|NCT02067793|Drug|Placebo|Single intravenous injection into the arm on Day 0
280134|NCT02067793|Drug|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
280135|NCT02067793|Drug|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
280136|NCT02067780|Drug|Levofloxacin 500mg|One tablet per day for 7days.
280137|NCT02067767|Drug|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):~group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;~group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
280138|NCT02067741|Drug|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
280139|NCT02067728|Behavioral|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
280140|NCT02067728|Behavioral|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
280141|NCT02067715|Drug|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
280142|NCT02067702|Procedure|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
280143|NCT02067689|Device|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
280144|NCT02067676|Biological|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
280145|NCT02067676|Drug|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
280146|NCT02067663|Device|Paragard|The IUD will be placed as part of standard clinical care.
280147|NCT02067663|Drug|Mirena|The IUD will be placed as part of standard clinical care.
280148|NCT02067624|Other|Thai massage|
280149|NCT02067611|Drug|X0002|Parallel Assignment
280150|NCT02067611|Drug|Placebo|Parallel Assignment
280151|NCT02067598|Other|scapular exercise|
280152|NCT02067585|Dietary Supplement|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
280153|NCT02067572|Other|Saline mouthwash|
280154|NCT02067572|Other|Salvia mouthwash|
280155|NCT02067559|Behavioral|ICU Diary|Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
280156|NCT02067559|Behavioral|Psychoeducation|The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
280157|NCT02067546|Device|Experimental toilet seat|
280158|NCT02067546|Device|Standard toilet seat|
280159|NCT02067533|Procedure|soft tissue repair in flexion position|
280160|NCT02067533|Procedure|soft tissue repair in extension position|
280161|NCT02067520|Drug|intrathecal hydromorphone (IT hydromorphone)|
280162|NCT02067507|Behavioral|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
280163|NCT02067507|Behavioral|Staff training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities
280164|NCT02067507|Behavioral|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
280165|NCT02067494|Other|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
280166|NCT02067494|Other|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
280167|NCT02067481|Behavioral|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
280168|NCT02067468|Device|HPV test|QIAGEN - The Digene HPV test®
280169|NCT02067468|Procedure|COLPOSCOPY|Colposcopy routine health services
280170|NCT02067468|Device|cytology|Cytology routine health services
280171|NCT02067455|Other|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
280172|NCT02067442|Drug|oral acetaminophen|1000 milligrams given orally before surgery
280173|NCT02067442|Drug|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
280174|NCT02067429|Procedure|Limbal Relaxing Incisions|
280175|NCT02067429|Device|Toric Intraocular Lens|
280176|NCT02067416|Drug|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
280177|NCT02067416|Drug|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
280178|NCT02067403|Other|Pressure-support Eadi optimization|
280179|NCT02067377|Dietary Supplement|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
280180|NCT02067377|Dietary Supplement|Placebo (for serum bovine immunoglobulin)|
280181|NCT02067364|Device|Fit & Function test|
280182|NCT02067351|Behavioral|Mindfulness|Meditation, body scan, yoga.
280183|NCT02067338|Drug|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
280184|NCT02067338|Drug|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
280185|NCT02067325|Other|Thai massage|
280186|NCT02067312|Other|Thai massage|
280187|NCT02067299|Drug|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
280188|NCT02067299|Other|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
280189|NCT02067273|Device|Transcranial Magnetic Stimulation (TMS)|
280190|NCT02067260|Device|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
280191|NCT02067260|Device|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
280192|NCT02067247|Device|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
280193|NCT02067234|Other|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
280194|NCT02067234|Behavioral|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
280195|NCT02067221|Device|RIRS|"RIRS arm~Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
280196|NCT02067221|Device|MPCNL|"MPCNL arm~A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
280323|NCT02066298|Drug|Mometasone 220mcg BID|Mometasone is an ICS
280197|NCT02067208|Device|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
280198|NCT02067195|Drug|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
280199|NCT02067195|Drug|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
280200|NCT02067182|Drug|Dabigatran|"Antral pulmonary vein ablation for patients with AF~left atrial fibrosis/electrical scar assessment by electroanatomical mapping~followed by 6 months OAC (3 months blanking period + 3 months observation period)~in case of AF-recurrence in month 4-6: re- pulmonary vein ablation~followed again by 6 months OAC (3 months blanking period + 3 months observation period)~AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:~Experimental arm (group A): OAC with dabigatran for 12 months~Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
280201|NCT02067169|Biological|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
280202|NCT02067156|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
280203|NCT02067143|Drug|Prephase PDN + CY|
280204|NCT02067143|Drug|Cycle 1 Induction|
280205|NCT02067143|Drug|Cycle 2 Induction / Early consolidation|
280206|NCT02067143|Drug|Cycle 3 Early consolidation|
280207|NCT02067143|Drug|Cycle 4 Consolidation|
280208|NCT02067143|Drug|Cycle 5 Consolidation|
280209|NCT02067143|Drug|Cycle 6 Consolidation|
280210|NCT02067143|Drug|Cycle 7 Consolidation|
280211|NCT02067143|Drug|Cycle 8 Reinduction|
280212|NCT02067143|Drug|Maintenance|If MRD negative MRD u/k SR
280213|NCT02067143|Procedure|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
280214|NCT02067130|Procedure|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
280215|NCT02067117|Drug|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
280216|NCT02067104|Drug|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
280217|NCT02067104|Drug|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
280218|NCT02067091|Device|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery~Percutaneous coronary intervention"
280219|NCT02067078|Drug|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
280220|NCT02067078|Drug|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
280221|NCT02067078|Drug|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
280222|NCT02067065|Drug|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
280223|NCT02067065|Drug|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
280224|NCT02067065|Procedure|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
280225|NCT02067052|Procedure|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
280226|NCT02067052|Procedure|Surgery|Vulvectomy & lymphadenectomy
280227|NCT02067039|Device|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home & Sure Check HIV tests
280228|NCT02067026|Dietary Supplement|Aleurone|
280229|NCT02067026|Dietary Supplement|Placebo|
280230|NCT02067013|Drug|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
280231|NCT02067013|Other|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
280232|NCT02067000|Behavioral|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
280274|NCT02066727|Drug|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
280275|NCT02066727|Drug|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
280276|NCT02066688|Drug|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
280233|NCT02066987|Behavioral|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
280234|NCT02066987|Behavioral|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).~I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
280235|NCT02066987|Behavioral|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
280236|NCT02066974|Genetic|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
280237|NCT02066948|Other|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
280238|NCT02066948|Other|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
280239|NCT02066948|Other|meal pattern|skew or even
280240|NCT02066948|Dietary Supplement|even|even amount of protein distributed between each meal
280241|NCT02066948|Dietary Supplement|skew|a skewed amount of protein is distributed between each meal
280242|NCT02066935|Other|kidney transplant patient|kidney transplanted patients for at least one year
280243|NCT02066922|Device|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
280244|NCT02066922|Device|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
280245|NCT02066922|Device|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
280246|NCT02066909|Drug|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
280247|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
280248|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
280249|NCT02066909|Drug|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
280250|NCT02066909|Drug|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
280251|NCT02066909|Drug|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
280252|NCT02066909|Drug|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
280253|NCT02066909|Drug|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
280254|NCT02066909|Drug|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
280255|NCT02066896|Device|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
280256|NCT02066896|Device|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
280257|NCT02066870|Drug|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
280258|NCT02066870|Drug|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.~Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
280259|NCT02066857|Device|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
280260|NCT02066857|Device|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
280261|NCT02066844|Drug|Celestone|2cc
280262|NCT02066844|Drug|Lidocaine|5cc
280263|NCT02066831|Behavioral|Telemedical coaching|
280264|NCT02066831|Other|Telemedicine|
280265|NCT02066818|Drug|Lidocaine/tetracaine patch|
280266|NCT02066818|Drug|1% lidocaine|
280267|NCT02066805|Drug|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
280268|NCT02066792|Drug|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
280269|NCT02066792|Drug|Placebo|Sugar pill
280270|NCT02066792|Behavioral|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
280271|NCT02066766|Other|No treatment given|Patients will fill out a questionnaire by interview.
280272|NCT02066753|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
280273|NCT02066740|Device|EverFlex™ stent with Entrust™ delivery system|
280277|NCT02066688|Drug|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
280278|NCT02066688|Drug|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
280279|NCT02066675|Drug|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
280280|NCT02066662|Drug|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
280281|NCT02066649|Drug|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
280282|NCT02066649|Procedure|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
280283|NCT02066636|Drug|Nivolumab|
280284|NCT02066623|Device|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
280285|NCT02066610|Other|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
280286|NCT02066610|Other|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
280287|NCT02066610|Other|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
280288|NCT02066610|Other|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
280289|NCT02066597|Device|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
280290|NCT02066584|Other|Sibling oocyte incubation|
280291|NCT02066571|Drug|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
280292|NCT02066571|Drug|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
280293|NCT02066558|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
280294|NCT02066558|Other|Placebo|
280295|NCT02066545|Drug|CLS001 Topical Gel|
280296|NCT02066545|Drug|CLS001 Topical Gel Vehicle|
280297|NCT02066532|Drug|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
280298|NCT02066532|Drug|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab > 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
280299|NCT02066519|Behavioral|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
280300|NCT02066506|Other|asymptomatic group|2 visits with MRI
280301|NCT02066506|Other|symptomatic group|2 visits with MRI
280302|NCT02066467|Device|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
280303|NCT02066454|Drug|Apixaban|2.5mg x 2 per day during 6 months
280304|NCT02066441|Dietary Supplement|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
280305|NCT02066441|Other|Placebo|
280306|NCT02066428|Biological|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
280307|NCT02066428|Biological|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
280308|NCT02066415|Biological|Erenumab|Administered once a month subcutaneously by authorized investigational site study staff.
280309|NCT02066415|Drug|Placebo|Administered once a month subcutaneously by authorized investigational site study staff.
280310|NCT02066402|Drug|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
280311|NCT02066402|Drug|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
280312|NCT02066402|Drug|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
280313|NCT02066402|Drug|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
280314|NCT02066389|Drug|Placebo|Tablets for oral administration
280315|NCT02066389|Drug|Upadacitinib|Tablets for oral administration
280316|NCT02066363|Dietary Supplement|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
280317|NCT02066363|Dietary Supplement|Parenteral nutrition|Supportive parenteral nutrition.
280318|NCT02066350|Procedure|Single pancreas transplantation|
280319|NCT02066337|Procedure|scaling and root planing|
280320|NCT02066337|Drug|placebo gel|
280324|NCT02066298|Drug|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
280325|NCT02066298|Drug|Placebo|
280326|NCT02066285|Drug|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
280327|NCT02066246|Device|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
280328|NCT02066246|Device|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
280329|NCT02066233|Device|EG Scan II (transnasal endoscopy)|
280330|NCT02066233|Procedure|Standard Endoscopy|
280331|NCT02066220|Radiation|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks~LR Arm after Amendment (Protocol version 11- 17 Nov 2014):~Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
280332|NCT02066220|Drug|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
280333|NCT02066220|Radiation|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
280334|NCT02066220|Drug|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
280335|NCT02066207|Drug|Fenofibrate|
280336|NCT02066207|Drug|Atorvastatin|
280337|NCT02066194|Procedure|Electroacupuncture|
280338|NCT02066181|Other|Laboratory Biomarker Analysis|Optional correlative studies
280339|NCT02066181|Other|Placebo|Given PO
280340|NCT02066181|Other|Quality-of-Life Assessment|Optional ancillary studies
280341|NCT02066181|Drug|Sorafenib Tosylate|Given PO
280342|NCT02066155|Behavioral|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
280343|NCT02066155|Behavioral|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
280344|NCT02066142|Device|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
280345|NCT02066142|Device|Ultrasound|
280346|NCT02066129|Drug|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
280347|NCT02066129|Drug|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
280348|NCT02066116|Procedure|Kinect-based rehabilitation plus occupational therapy|The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
280349|NCT02066116|Other|sham virtual rehabilitation education plus occupational therapy|For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
280350|NCT02066103|Drug|Paclitaxel|
280351|NCT02066090|Device|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks~common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
280352|NCT02066090|Device|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks~sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)~placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
280353|NCT02066077|Drug|Etomidate|
280354|NCT02066077|Drug|Propofol|
280355|NCT02066077|Device|Bilateral temporal MECT|
280356|NCT02066077|Device|The right temporal MECT|
280357|NCT02066077|Device|Bilateral frontal MECT|
280358|NCT02066064|Procedure|Standard Colonoscopy|Standard Colonoscopy
280359|NCT02066064|Procedure|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
280360|NCT02066051|Device|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
280361|NCT02066051|Procedure|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
280362|NCT02066038|Drug|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
280363|NCT02066012|Other|dysmetabolic iron overload syndrome|
280364|NCT02065986|Drug|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
280365|NCT02065973|Biological|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
280366|NCT02065960|Radiation|Stereotactic body radiotherapy (SBRT)|
280367|NCT02065947|Procedure|paravertebral block|catheter with 3-level-injection
280368|NCT02065947|Drug|fentanyl, propofol, atracurium|endotracheal intubation
280369|NCT02065947|Drug|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
280370|NCT02065947|Device|catheter with 3-level-injection|
280371|NCT02065947|Drug|sevoflurane and 50% oxygen in air|
280372|NCT02065934|Other|cardio-pulmonary resuscitation|
280373|NCT02065895|Device|HIGH error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 1.33 times the true glucose value (analogous to higher gain lower target).
280374|NCT02065895|Device|NO error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL and glucose-value-used-for-control equal to the true glucose value.
280375|NCT02065895|Device|LOW error|Overnight and breakfast closed-loop control were performed using a target glucose of 120 mg/dL but with the glucose-value-used-for-control equal to 0.8 times the true glucose value (analogous to lower gain higher target).
280376|NCT02065882|Biological|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
280377|NCT02065869|Biological|BPX-501 T cells|1x10E6 cells/kg infused on Day 0
280378|NCT02065869|Drug|rimiducid|0.4mg/kg to a maximum of 40 mg administered IV to treat GVHD
280379|NCT02065856|Biological|AVANZ Salsola|AVANZ Salsola
280380|NCT02065843|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
280381|NCT02065843|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
280382|NCT02065843|Drug|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
280383|NCT02065843|Drug|midazolam|15 mg/single dose/1 hour before dental surgery
280384|NCT02065830|Device|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.~The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
280385|NCT02065817|Other|stable isotope of cholesterol|
280386|NCT02065804|Drug|Bupivacaine|injection, once, 5 min
280387|NCT02065791|Drug|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
280388|NCT02065791|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily
280389|NCT02065778|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
280390|NCT02065765|Biological|Ramucirumab|Administered intravenously (IV)
280391|NCT02065752|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
280392|NCT02065752|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
280393|NCT02065752|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
280394|NCT02065752|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
280395|NCT02065739|Drug|JNJ-42165279|Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
280396|NCT02065739|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
280397|NCT02065726|Dietary Supplement|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
280398|NCT02065726|Other|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
280399|NCT02065713|Drug|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
280400|NCT02065713|Drug|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
280401|NCT02065713|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
280402|NCT02065700|Drug|Filgotinib|Tablets administered orally
280403|NCT02065687|Drug|Carboplatin|Given IV
280404|NCT02065687|Other|Laboratory Biomarker Analysis|Correlative studies
280405|NCT02065687|Drug|Metformin Hydrochloride|Given PO
280406|NCT02065687|Drug|Paclitaxel|Given IV
280407|NCT02065687|Other|Placebo|Given PO
280408|NCT02065687|Other|Quality-of-Life Assessment|Ancillary studies
280409|NCT02065687|Other|Questionnaire Administration|Ancillary studies
280410|NCT02065674|Drug|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
280411|NCT02065635|Procedure|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
280412|NCT02065635|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
280413|NCT02065622|Drug|Adalimumab|
280414|NCT02065622|Other|Placebo|
280415|NCT02065609|Drug|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
280416|NCT02065609|Drug|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
280417|NCT02065596|Drug|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
280461|NCT02065323|Drug|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
280418|NCT02065596|Procedure|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
280419|NCT02065570|Drug|Adalimumab|
280420|NCT02065557|Biological|Adalimumab|Subcutaneous (SC) injection
280421|NCT02065544|Behavioral|behavioral weight loss and exercise|Weight loss and exercise counseling
280422|NCT02065531|Other|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
280423|NCT02065531|Other|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
280424|NCT02065518|Device|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 21-30% of MVC during weeks 3-6 and 31-40% of MVC during weeks 6-9, 41-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
280425|NCT02065518|Behavioral|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved. At week 7, participants will be given a weighted vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
280426|NCT02065518|Behavioral|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
280427|NCT02065505|Other|Mat Pilates|
280428|NCT02065505|Other|Water Pilates|
280429|NCT02065492|Drug|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
280430|NCT02065492|Drug|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
280431|NCT02065479|Drug|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
280432|NCT02065479|Drug|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
280433|NCT02065466|Drug|nab-paclitaxel|
280434|NCT02065466|Drug|Temozolomide|
280435|NCT02065466|Drug|Bevacizumab|
280436|NCT02065453|Device|disposable device (Ligasure, Covidien)|"One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon."
280437|NCT02065453|Device|Reusable device|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
280438|NCT02065440|Drug|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
280439|NCT02065440|Drug|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
280440|NCT02065427|Behavioral|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
280441|NCT02065414|Other|Listerine Advance Gum Defense|
280442|NCT02065414|Other|Mouth rinse containing Chlorhexidine|
280443|NCT02065414|Other|Mouth rinse containing 5% Hydroalcohol|
280444|NCT02065401|Drug|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
280445|NCT02065401|Drug|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
280446|NCT02065401|Drug|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
280447|NCT02065388|Behavioral|Standard of care dosing for warfarin|
280448|NCT02065388|Genetic|Genotype-guided dosingTaiwan algorithm for warfarin|
280449|NCT02065388|Genetic|Genotype-guided dosing IWPC algorithm for warfarin|
280450|NCT02065375|Drug|RTA 408 0.5% Ophthalmic Suspension|
280451|NCT02065375|Drug|RTA 408 1.0% Ophthalmic Suspension|
280452|NCT02065375|Drug|Placebo|
280453|NCT02065362|Biological|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:~Dose Level 1:~Day 0: 2 x 10^7 cells/m^2~Day 14: 2 x 10^7 cells/m^2~The doses are calculated according to the total T cell number."
280454|NCT02065362|Biological|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.~Each patient will receive infusions according to the following dosing schedule:~Dose Level 2:~Cy/Flu on Days -4 to -2 and then 4 x 10^7 cells/m^2 on Day 0, Day 1 or Day 2~Dose Level 3:~Cy/Flu on Days -4 to -2 and then 1 x 10^8 cells/m^2 on Day 0, Day 1, or Day 2"
280455|NCT02065349|Drug|ASP8477|oral
280456|NCT02065349|Drug|Placebo|oral
280457|NCT02065336|Drug|ARC-520|
280458|NCT02065336|Drug|Placebo|
280459|NCT02065336|Drug|entecavir|
280460|NCT02065336|Drug|chlorpheniramine|In all cohorts, each participant received an 8 mg dose of oral chlorpheniramine 2 hours prior to each administration of ARC-520 Injection.
280753|NCT02062905|Other|Placebo Vehicle|
280462|NCT02065323|Drug|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
280463|NCT02065310|Other|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.~Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 & 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
280464|NCT02065297|Other|1 blood sample|
280465|NCT02065297|Other|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
280466|NCT02065284|Other|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
280467|NCT02065271|Dietary Supplement|herbal supplement|
280468|NCT02065271|Other|placebo supplement|
280469|NCT02065258|Other|Breathing exercise|"It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.~All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana"
280470|NCT02065258|Other|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
280471|NCT02065245|Biological|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
280472|NCT02065245|Biological|Placebo|Placebo
280473|NCT02065232|Drug|Tilmanocept|
280474|NCT02065232|Drug|Sulfur Colloid|
280475|NCT02065219|Drug|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
280476|NCT02065219|Drug|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
280477|NCT02065193|Behavioral|ADOS/ADI-R/Clinical assessment|
280478|NCT02065180|Dietary Supplement|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
280479|NCT02065180|Dietary Supplement|placebo|
280480|NCT02065167|Biological|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
280481|NCT02065154|Drug|Cyclophosphamide|
280482|NCT02065141|Other|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
280483|NCT02065128|Other|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
280484|NCT02065115|Other|Cryotherapy (ice pack)|
280485|NCT02065089|Other|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
280486|NCT02065076|Drug|Sodium polystyrene sulfonate|
280487|NCT02065076|Drug|Lactose with carob gum|
280488|NCT02065063|Drug|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
280489|NCT02065063|Drug|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
280490|NCT02065050|Other|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
280491|NCT02065037|Device|room temperature air insufflation|control arm
280492|NCT02065037|Device|warmed carbon dioxide insufflation|comparator arm
280493|NCT02065024|Dietary Supplement|b-cryptoxanthin plus phytosterols|
280494|NCT02065011|Drug|UshStat|Long-term follow up of patients who received UshStat in a previous study
280495|NCT02064998|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
280496|NCT02064998|Behavioral|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
280497|NCT02064998|Behavioral|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
280498|NCT02064985|Drug|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
280790|NCT02062632|Drug|Doxepin Hydrochloride|Given orally
280499|NCT02064972|Other|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
280500|NCT02064959|Other|Hypothermia|rapid induction of hypothermia to 35°C followed by maintenance at 33°C
280501|NCT02064946|Dietary Supplement|vitamin D|50,000IU/week of vitamin D3
280502|NCT02064946|Dietary Supplement|Placebo|
280503|NCT02064920|Drug|Placebo|Placebo for donepezil hydrochloride capsule
280504|NCT02064920|Drug|Donepezil|5 mg donepezil hydrochloride capsule.
280505|NCT02064920|Drug|Donepezil|10 mg donepezil hydrochloride capsule.
280506|NCT02064907|Drug|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
280507|NCT02064907|Drug|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
280508|NCT02064894|Drug|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
280509|NCT02064894|Drug|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
280510|NCT02064894|Drug|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
280511|NCT02064881|Drug|Metformin glycinate|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs) .
280512|NCT02064881|Drug|Metformin Hydrochloride|All patients are going to begin the treatment with one tablet orally at night, 30 minutes before dinner (1 tablet of 620 mg glycinate metformin or one 500 mg tablet of metformin hydrochloride) and the dose will be administrated every 3 days to complete the dose of 2 tablets in the morning 30 minutes before breakfast and 2 tablets in the evening 30 minutes before dinner (1240 mg metformin glycinate every 12 hours or 1000 mg metformin hydrochloride every 12 hrs)
280513|NCT02064868|Drug|Serelaxin|30 µg/kg/day IV infusion
280514|NCT02064868|Drug|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, beta blockers and aldosterone receptor antagonists, etc.
280515|NCT02064842|Drug|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
280516|NCT02064842|Drug|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
280517|NCT02064842|Drug|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
280518|NCT02064842|Drug|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV [80 mg/mL strength]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
280519|NCT02064829|Drug|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
280520|NCT02064829|Drug|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
280521|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
280522|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
280523|NCT02064803|Procedure|Gastro-entero anastomosis only|Gastro-entero anastomosis only
280524|NCT02064803|Procedure|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
280525|NCT02064777|Drug|Tacrolimus|
280526|NCT02064764|Device|Renal nerve denervation|
280527|NCT02064764|Device|Cryoablation|
280528|NCT02064751|Device|CRT with MultiPoint Pacing|
280529|NCT02064751|Procedure|Hemodynamic measurements for CRT device programming|
280530|NCT02064738|Behavioral|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
280531|NCT02064725|Drug|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
280532|NCT02064712|Other|Low CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
280533|NCT02064712|Other|High CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
280534|NCT02064699|Biological|CMV Infection|"Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV."
280535|NCT02064686|Other|Exhaled breath temperature|
280536|NCT02064673|Drug|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
280537|NCT02064673|Drug|placebo|placebo orally twice a day
280538|NCT02064660|Device|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
280539|NCT02064647|Other|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
280540|NCT02064647|Other|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
280541|NCT02064621|Drug|Candesartan 32mg|Candesartan 32mg 1T, PO, QD for 9days
280542|NCT02064621|Drug|Candesartan 32mg/Amlodipine 10mg|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
280543|NCT02064608|Drug|AZD2014|mTOR inhibitor
280544|NCT02064595|Procedure|External fixator|Treatment with external fixation
280545|NCT02064595|Procedure|Intramedullary nail|Fracture treated with intramedullary nail
280546|NCT02064582|Drug|Enzalutamide|160mg by mouth each day
280547|NCT02064582|Drug|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
280548|NCT02064582|Radiation|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
280549|NCT02064569|Genetic|GS010|
280550|NCT02064556|Drug|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
280551|NCT02064556|Drug|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
280552|NCT02064543|Other|GAITRite|mobility test assessing gait parameters
280553|NCT02064543|Other|ADPM|mobility test assessing gait parameters
280554|NCT02064530|Drug|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
280555|NCT02064530|Drug|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
280556|NCT02064530|Drug|serum physiologic|21 ml serum physiologic is applied interfasially
280557|NCT02064517|Device|MTA|Creation of a barrier apicale in the MTA
280558|NCT02064517|Device|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
280559|NCT02064504|Drug|GSK961081|Dry white to off white powder
280560|NCT02064504|Drug|Fluticasone furoate|Dry white powder
280561|NCT02064491|Drug|Erlotinib|
280562|NCT02064491|Drug|Chemotherapy|
280563|NCT02064465|Drug|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
280564|NCT02064465|Drug|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
280565|NCT02064452|Other|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
280566|NCT02064452|Behavioral|Placebo Comparator|Enhanced Usual Community Care-Waitlist
280567|NCT02064439|Drug|BAY 59-7939|10 mg tablet once daily for 12 months
280568|NCT02064439|Drug|BAY 59-7939|20 mg tablet once daily for 12 months
280569|NCT02064439|Drug|ASA|100 mg tablet once daily for 12 months
280570|NCT02064426|Drug|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
280571|NCT02064426|Biological|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
280572|NCT02064413|Device|ESS310 (BAY1454032)|
280573|NCT02064400|Other|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
280574|NCT02064400|Other|Semi-structured patient interview|Semi-structured patient interview
280575|NCT02064387|Drug|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
280576|NCT02064374|Drug|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
280577|NCT02064374|Drug|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
280578|NCT02064374|Drug|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
280579|NCT02064361|Other|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
280580|NCT02064348|Drug|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
280581|NCT02064348|Drug|placebo|Solution for s.c. injection or tablets for oral administration
280582|NCT02064348|Drug|moxifloxacin|Tablets for oral administration
280583|NCT02064335|Behavioral|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
280584|NCT02064322|Device|SImmetry Implant|"The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.~The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
280585|NCT02064309|Device|Beta-Air device for encapsulation of transplanted human islets|
280586|NCT02064296|Device|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device.
280587|NCT02064296|Device|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
280588|NCT02064283|Procedure|Diffusion MRI|
280589|NCT02064270|Device|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
280590|NCT02064270|Device|Standard postsurgical dressings|Use of Standard postsurgical dressings
280791|NCT02062632|Other|Placebo|Given orally
280591|NCT02064257|Behavioral|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
280592|NCT02064244|Other|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
280593|NCT02064231|Device|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
280594|NCT02064231|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
280595|NCT02064231|Device|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
280596|NCT02064231|Device|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
280597|NCT02064231|Device|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
280598|NCT02064218|Drug|Anti-hypertensive drugs|
280599|NCT02064205|Dietary Supplement|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
280600|NCT02064205|Dietary Supplement|glucose syrup|Glucose syrup is used a control product for the polydextrose
280601|NCT02064166|Drug|Intranasal Insulin|"treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;~placebo arm: normal saline, daily, intranasally, for 4 weeks."
280602|NCT02064153|Procedure|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
280603|NCT02064153|Procedure|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
280604|NCT02064140|Drug|Rocuronium|
280605|NCT02064114|Procedure|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
280606|NCT02064114|Procedure|control group|Followed for a period of 3,6 and 12 months after the procedure.
280607|NCT02064101|Procedure|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
280608|NCT02064088|Drug|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
280609|NCT02064088|Drug|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
280610|NCT02064075|Drug|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
280611|NCT02064075|Drug|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
280612|NCT02064062|Biological|Autologous Mesenchymal Stem Cells|
280613|NCT02064049|Drug|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
280614|NCT02064036|Radiation|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
280615|NCT02064036|Drug|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
280616|NCT02064036|Drug|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
280617|NCT02064023|Device|insulin pump|subjects in the experimental arm will administer insulin using a pump
280618|NCT02064023|Other|multiple daily insulin injection|Subjects will continue with usual insulin injections
280619|NCT02064010|Drug|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
280620|NCT02064010|Drug|Placebo|Placebo tablet, administered orally for 4 weeks
280621|NCT02063997|Drug|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
280622|NCT02063997|Drug|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
280623|NCT02063997|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
280624|NCT02063997|Drug|Placebo|Placebo tablets once daily for 12 weeks
280625|NCT02063997|Drug|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
280626|NCT02063984|Behavioral|Behavior Therapy|Weekly individual counseling sessions with teen and parent(s) to review and discuss contingency management abstinence-based incentives
280627|NCT02063984|Behavioral|Working Memory Training|25 computer-delivered sessions of neurocognitive training
280628|NCT02063971|Other|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
280629|NCT02063958|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
280630|NCT02063945|Drug|Methylphenidate|
280631|NCT02063945|Drug|Risperidone|
280632|NCT02063932|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
280633|NCT02063919|Other|the mucosal microbiome in the biopsy specimen was analysed|
280634|NCT02063880|Other|Urgent ART|Children will be started on HAART <48 hours after enrollment.
280635|NCT02063880|Other|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
280636|NCT02063867|Drug|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.~Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
280637|NCT02063854|Drug|NE-58095 IR|NE-58095 IR tablets
280638|NCT02063854|Drug|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
280639|NCT02063854|Drug|NE-58095 DR|NE-58095 DR tablets
280640|NCT02063854|Drug|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
280641|NCT02063841|Device|lead-free protective drape containing bismuth and antimony (RADPAD®)|
280642|NCT02063841|Device|sterile identical sham drape|
280643|NCT02063828|Device|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 12 weeks.
280644|NCT02063828|Device|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 12 weeks.
280645|NCT02063828|Device|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 12 weeks.
280646|NCT02063815|Procedure|Fissure sealant application|
280647|NCT02063802|Drug|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
280648|NCT02063802|Dietary Supplement|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
280649|NCT02063802|Drug|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
280650|NCT02063802|Behavioral|Healthy habits program|
280651|NCT02063789|Drug|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
280652|NCT02063750|Other|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.~Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
280653|NCT02063750|Other|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
280654|NCT02063737|Behavioral|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
280655|NCT02063737|Behavioral|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
280656|NCT02063724|Biological|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
280657|NCT02063711|Behavioral|Yoga intervention|
280658|NCT02063698|Drug|auranofin|Given PO
280659|NCT02063698|Other|placebo|Given PO
280660|NCT02063698|Other|questionnaire administration|Ancillary studies
280661|NCT02063685|Drug|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:~Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.~or 6 courses of:~Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
280662|NCT02063685|Drug|Observation|not maintenance therapy and followed-up with MRD monitoring.
280663|NCT02063685|Drug|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
280664|NCT02063685|Drug|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
280665|NCT02063685|Drug|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
280666|NCT02063672|Device|Lutonix DCB|
280667|NCT02063672|Device|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
280668|NCT02063659|Drug|Telotristat etiprate|Telotristat etiprate tablets
280669|NCT02063659|Drug|Placebo|Placebo-matching telotristat etiprate tablets
280670|NCT02063646|Dietary Supplement|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
280671|NCT02063646|Dietary Supplement|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.~Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
280672|NCT02063620|Drug|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
280673|NCT02063607|Biological|Peginterferon lambda|
280674|NCT02063594|Drug|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
280675|NCT02063594|Drug|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
280676|NCT02063581|Drug|ipatasertib (Capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
280677|NCT02063581|Drug|ipatasertib (Tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
280678|NCT02063568|Drug|Oxytocin|
280679|NCT02063555|Biological|DAR-901|
280680|NCT02063555|Biological|BCG|
280681|NCT02063555|Biological|Sterile saline|
280682|NCT02063529|Drug|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
280683|NCT02063529|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
280684|NCT02063516|Device|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
280685|NCT02063516|Device|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
280686|NCT02063503|Other|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
280687|NCT02063490|Behavioral|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)~+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
280688|NCT02063477|Dietary Supplement|Placebo|The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
280689|NCT02063477|Dietary Supplement|Oligopin®|"Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:~- TOTAL POLYPHENOL CONTENT > 96~MONOMERS + PHENOLIC ACIDS 30~DIMERS >15~OTHER OLIGOMERS 50~PROCYANIDINS CONTENT (GPC) > 67~The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule"
280690|NCT02063451|Dietary Supplement|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
280691|NCT02063438|Procedure|Pericostal suture technique|
280692|NCT02063438|Procedure|Intracostal suture technique|
280693|NCT02063425|Drug|Fluoxetine|1 pill of 20mg / day, during 3 months
280694|NCT02063425|Drug|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
280695|NCT02063386|Drug|AZD1722|Single oral dose 15 mg of [14C]AZD1722
280696|NCT02063373|Other|Hyaluronic acid|treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
280697|NCT02063360|Drug|BMS-663068|BMS-663068
280698|NCT02063360|Drug|Darunavir (DRV)|Darunavir (DRV)
280699|NCT02063360|Drug|Ritonavir (RTV)|Ritonavir (RTV)
280700|NCT02063360|Drug|Etravirine (ETR)|Etravirine (ETR)
280701|NCT02063334|Dietary Supplement|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
280702|NCT02063334|Dietary Supplement|Placebo|
280703|NCT02063308|Dietary Supplement|Oxaloacetate (OAA)|
280704|NCT02063295|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
280705|NCT02063295|Drug|ZGN-440 for injectable suspension|
280706|NCT02063269|Drug|Rivastigmine|9-18mg/rivastigmine for 52 weeks
280707|NCT02063256|Dietary Supplement|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
280708|NCT02063256|Other|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
280709|NCT02063243|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
280710|NCT02063230|Drug|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
280711|NCT02063230|Drug|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
280712|NCT02063217|Drug|Sodium Oxybate|Sodium oxybate h.s.
280713|NCT02063217|Behavioral|Sleep deprivation|36hr sleep deprivation
280714|NCT02063204|Drug|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
280715|NCT02063178|Behavioral|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
280716|NCT02063178|Behavioral|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
280717|NCT02063178|Behavioral|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
280718|NCT02063178|Behavioral|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
280719|NCT02063178|Behavioral|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
280720|NCT02063178|Behavioral|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
280792|NCT02062632|Other|Quality-of-Life Assessment|Ancillary studies
280721|NCT02063178|Behavioral|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
280722|NCT02063178|Behavioral|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
280723|NCT02063178|Behavioral|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
280724|NCT02063178|Behavioral|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
280725|NCT02063178|Behavioral|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
280726|NCT02063165|Dietary Supplement|High Linoleic Safflower Oil|2 tsp per day (~10g of oil)
280727|NCT02063139|Drug|Flutiform 50/5 ug (2 puffs bid) pMDI|
280728|NCT02063139|Drug|Fluticasone 50 ug (2puffs bid) pMDI|
280729|NCT02063139|Drug|Beclometasone Autohaler 50 ug (2 puffs bid)|
280730|NCT02063126|Dietary Supplement|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)~Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
280731|NCT02063126|Dietary Supplement|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
280732|NCT02063113|Other|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
280733|NCT02063100|Drug|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
280734|NCT02063100|Drug|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
280735|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
280736|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
280737|NCT02063100|Drug|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
280738|NCT02063087|Other|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
280739|NCT02063061|Device|Sham treatment|Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
280740|NCT02063061|Device|ESWT treatment|ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
280741|NCT02063048|Behavioral|Text Message Based Weight Loss Support|
280742|NCT02063035|Drug|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
280743|NCT02063035|Drug|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
280744|NCT02063022|Drug|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
280745|NCT02063022|Drug|Intensified chemotherapy|"Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks~Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment~Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
280746|NCT02062996|Drug|Oxymetazoline|
280747|NCT02062983|Drug|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.~Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
280748|NCT02062970|Biological|blood draw|
280749|NCT02062944|Drug|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
280750|NCT02062931|Biological|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.~Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .~Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
280751|NCT02062918|Device|Abdominal belt|
280752|NCT02062905|Drug|Dexamethasone|
280754|NCT02062892|Drug|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
280755|NCT02062892|Drug|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
280756|NCT02062879|Drug|Ketamine|Ketamine administered as patient-controlled analgesia.
280757|NCT02062879|Drug|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
280758|NCT02062866|Procedure|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
280759|NCT02062866|Procedure|Second Intent|The wound will not be sutured, and allowed to heal on its own.
280760|NCT02062853|Other|Video Group|Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
280761|NCT02062853|Other|Verbal Group|The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
280762|NCT02062840|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
280763|NCT02062840|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
280764|NCT02062840|Device|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
280765|NCT02062840|Other|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
280766|NCT02062827|Biological|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
280767|NCT02062801|Drug|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
280768|NCT02062801|Drug|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
280769|NCT02062788|Dietary Supplement|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
280770|NCT02062775|Procedure|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
280771|NCT02062775|Procedure|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
280772|NCT02062775|Procedure|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures >2cm
280773|NCT02062762|Behavioral|Online-MBSR|8 week mindfulness based stress reduction online
280774|NCT02062762|Behavioral|Expressive Writing Online|Online distributed expressive writing intervention as active control
280775|NCT02062749|Drug|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
280776|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
280777|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
280778|NCT02062710|Drug|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
280779|NCT02062710|Drug|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
280780|NCT02062710|Drug|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
280781|NCT02062710|Drug|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
280782|NCT02062697|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
280783|NCT02062697|Procedure|Liquid-PAP smear|
280784|NCT02062684|Drug|Blisibimod|
280785|NCT02062684|Drug|Placebo|
280786|NCT02062671|Procedure|renal denervation|
280787|NCT02062658|Drug|Ketamine|0.5mg/kg IV
280788|NCT02062658|Behavioral|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
280789|NCT02062645|Drug|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
280793|NCT02062632|Other|Questionnaire Administration|Ancillary studies
280794|NCT02062619|Behavioral|Computer-based behavioural word reading therapy|"Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.~Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)"
280795|NCT02062619|Other|Real tDCS|Real tDCS 20 minutes per session, three times per week
280796|NCT02062619|Other|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
280797|NCT02062606|Device|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
280798|NCT02062593|Procedure|Coronary angioplasty|Percutaneous coronary intervention with drug-eluting stents and modern techniques
280799|NCT02062580|Biological|BCG|
280800|NCT02062541|Other|Funct. assessment+fast rehabilitation|
280801|NCT02062541|Other|Funct. assessment+usual rehabilitation|
280802|NCT02062541|Other|usual assessment+fast rehabilitation|
280803|NCT02062528|Dietary Supplement|omega-3 fatty acids|highly dosed in EPA
280804|NCT02062528|Dietary Supplement|placebo|
280805|NCT02062515|Drug|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
280806|NCT02062502|Biological|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
280807|NCT02062502|Biological|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
280808|NCT02062502|Biological|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
280809|NCT02062489|Drug|Tamoxifen|20 mg(2#)/day, PO, daily
280810|NCT02062489|Drug|Placebo|2#/day, PO, daily
280811|NCT02062476|Dietary Supplement|Lactobacillus GG|
280812|NCT02062463|Drug|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 mcg)
280813|NCT02062463|Drug|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 mcg)
280814|NCT02062450|Device|Primary surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
280815|NCT02062450|Device|Revision surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
280816|NCT02062424|Other|DIPI|
280817|NCT02062411|Behavioral|CBT only|Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
280818|NCT02062411|Behavioral|CBT with booster sessions|Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
280819|NCT02062398|Device|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
280820|NCT02062385|Biological|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
280821|NCT02062385|Biological|Placebo to V260|Placebo control
280822|NCT02062385|Biological|OPV|Oral poliovirus vaccine administered according to the standard of care
280823|NCT02062385|Biological|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
280824|NCT02062372|Device|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
280825|NCT02062372|Procedure|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
280826|NCT02062359|Biological|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.~On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
280827|NCT02062359|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
280828|NCT02062359|Drug|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
280829|NCT02062359|Drug|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
280830|NCT02062346|Drug|BQ123|Intravenous infusion of BQ123 ( selective ETA antagonist )
280831|NCT02062346|Drug|BQ123/788|or BQ123/788 (mixed ETA/B antagonists)
280832|NCT02062346|Drug|Placebo|Intravenous infusion of saline
280833|NCT02062333|Drug|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
280834|NCT02062333|Drug|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
280835|NCT02062281|Biological|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
280836|NCT02062281|Biological|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
280837|NCT02062281|Biological|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
280838|NCT02062268|Behavioral|health education & law enforcement|
280839|NCT02062255|Drug|Aspirin|
280840|NCT02062255|Dietary Supplement|Omega 3 FFA|
280924|NCT02061657|Drug|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
280925|NCT02061657|Drug|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
280841|NCT02062242|Other|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
280842|NCT02062242|Other|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
280843|NCT02062242|Other|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
280844|NCT02062242|Other|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
280845|NCT02062203|Drug|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
280846|NCT02062203|Drug|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
280847|NCT02062203|Drug|Placebo|Single oral dose of placebo
280848|NCT02062203|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
280849|NCT02062190|Drug|resveratrol|"100mg 2x/day~1 month"
280850|NCT02062177|Drug|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
280851|NCT02062177|Drug|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged < 70, 0.03 mg/Kg if aged > 70.
280852|NCT02062164|Procedure|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
280853|NCT02062164|Other|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
280854|NCT02062151|Other|Acupuncture|Acupuncture
280855|NCT02062138|Other|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
280856|NCT02062138|Other|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
280857|NCT02062138|Other|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
280858|NCT02062112|Other|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
280859|NCT02062099|Drug|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
280860|NCT02062086|Dietary Supplement|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
280861|NCT02062073|Drug|Abametapir Lotion 0.74% w/w|
280862|NCT02062073|Other|0.1% sodium lauryl sulfate|
280863|NCT02062073|Other|saline 0.9%|
280864|NCT02062073|Other|Vehicle Lotion|
280865|NCT02062060|Drug|Abametapir Lotion 0.74% w/w|
280866|NCT02062060|Drug|Vehicle Lotion|
280867|NCT02062047|Procedure|FMSRP|FMSRP in a maximum of 24 hours.
280868|NCT02062047|Drug|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
280869|NCT02062047|Procedure|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
280870|NCT02062047|Other|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
280871|NCT02062034|Drug|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
280872|NCT02062034|Drug|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
280873|NCT02062034|Drug|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
280874|NCT02062021|Other|No intervention|
280875|NCT02062008|Device|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
280876|NCT02061995|Drug|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
280877|NCT02061982|Dietary Supplement|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
280878|NCT02061969|Drug|linagliptin|5mg linagliptin tablets
280879|NCT02061969|Drug|insulin glargine|
280926|NCT02061644|Other|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
280927|NCT02061631|Drug|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
280928|NCT02061631|Drug|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
280929|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
280880|NCT02061930|Procedure|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
280881|NCT02061917|Other|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
280882|NCT02061917|Other|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
280883|NCT02061917|Other|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
280884|NCT02061904|Radiation|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
280885|NCT02061904|Other|Short Form Health Survey 12|questionnaire for general health monitoring
280886|NCT02061904|Other|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
280887|NCT02061904|Other|VAS-pain|questionnaire for pain monitoring
280888|NCT02061904|Other|Harris Hip Score|questionnaire for hip function monitoring
280889|NCT02061891|Procedure|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
280890|NCT02061891|Procedure|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
280891|NCT02061878|Drug|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
280892|NCT02061878|Drug|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
280893|NCT02061865|Drug|REGN2176-3|
280894|NCT02061852|Device|Simeox|
280895|NCT02061852|Procedure|Physiotherapy|
280896|NCT02061839|Other|Sunscream with visible light protection|
280897|NCT02061839|Other|Sunscream|
280898|NCT02061813|Drug|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
280899|NCT02061813|Drug|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
280900|NCT02061813|Drug|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
280901|NCT02061813|Drug|Placebo|
280902|NCT02061800|Device|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
280903|NCT02061800|Drug|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
280904|NCT02061800|Drug|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
280905|NCT02061800|Drug|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
280906|NCT02061800|Drug|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
280907|NCT02061800|Drug|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
280908|NCT02061800|Drug|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
280909|NCT02061800|Drug|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
280910|NCT02061800|Drug|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
280911|NCT02061774|Drug|Acetaminophen|1 gram of intravenous Acetaminophen
280912|NCT02061774|Drug|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
280913|NCT02061761|Biological|BMS-986016|
280914|NCT02061761|Biological|BMS-936558|
280915|NCT02061748|Drug|Observational|Retrospective Chart Review
280916|NCT02061722|Radiation|PET Imaging with [18F]MNI-659|"The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.~The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.~The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
280917|NCT02061709|Biological|Ragweed-SPIRE|
280918|NCT02061709|Biological|Placebo|
280919|NCT02061696|Device|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
280920|NCT02061696|Procedure|Standard Manual Compression|Closure procedure by Manual Compression
280921|NCT02061683|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
280922|NCT02061670|Biological|Ragweed-SPIRE|Intradermal injection
280923|NCT02061670|Biological|Placebo|
280930|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
280931|NCT02061618|Behavioral|Bollywood Dance Exercise|
280932|NCT02061605|Device|Laser Tissue Welding Device|Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
280933|NCT02061592|Device|etafilcon A|
280934|NCT02061592|Device|etafilcon A|
280935|NCT02061579|Behavioral|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
280936|NCT02061553|Behavioral|Motivation|Control condition in which participants receive a single session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements.
280937|NCT02061553|Behavioral|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the planning of rewarding activities). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
280938|NCT02061553|Behavioral|BA-Tech|Participants undergo a total of 8 sessions with a therapist. During these sessions, participants learn about the principles of BA (the translation of important life values into the planning of rewarding activities that support those values). The participants' values are explored and an activity schedule is created collaboratively by participants and therapists based on those values. Reminders to complete the scheduled activities will then be delivered by text once the schedule is made. Participants in this arm will also be monitoring their daily activities (and rating them based on enjoyment and perceived achievement) using a cell phone application.
280939|NCT02061540|Drug|LUM001|LUM001 oral dose
280940|NCT02061527|Procedure|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
280941|NCT02061527|Procedure|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
280942|NCT02061527|Procedure|Reconstruction with implant|Immediate breast reconstruction with implant
280943|NCT02061527|Procedure|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
280944|NCT02061527|Procedure|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
280945|NCT02061514|Procedure|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
280946|NCT02061514|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
280947|NCT02061501|Other|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
280948|NCT02061501|Other|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
280949|NCT02061488|Other|open-loop night|During the open-loop night the patient is using his insulin pump as usual
280950|NCT02061488|Other|closed-loop night|During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
280951|NCT02061475|Drug|Lidocaine Patches|
280952|NCT02061462|Procedure|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
280953|NCT02061449|Drug|Romidepsin|
280954|NCT02061449|Drug|Poly ICLC|
280955|NCT02061449|Radiation|Focal lesional radiation|
280956|NCT02061423|Biological|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
280957|NCT02061410|Device|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
280958|NCT02061397|Drug|Simvastatin|Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
280959|NCT02061384|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
280960|NCT02061384|Drug|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
280961|NCT02061371|Other|virtual therapy|
280962|NCT02061371|Other|conventional physiotherapy|
280963|NCT02061358|Drug|UV-4B 3 mg|Oral solution, single dose
280964|NCT02061358|Drug|UV-4B 10 mg|Oral solution, single dose
280965|NCT02061358|Drug|UV-4B 30 mg|Oral solution, single dose
280966|NCT02061358|Drug|UV-4B 90 mg|Oral solution, single dose
280967|NCT02061358|Drug|UV-4B 180 mg|Oral solution, single dose
280968|NCT02061358|Drug|UV-4B 360 mg|Oral solution, single dose
280969|NCT02061358|Drug|UV-4B 720 mg|Oral solution, single dose
280970|NCT02061358|Drug|UV-4B 1000 mg|Oral solution, single dose
280971|NCT02061358|Drug|Placebo|Oral solution, single dose
280972|NCT02061332|Biological|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
280973|NCT02061319|Behavioral|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
280974|NCT02061293|Drug|Psilocybin|
280975|NCT02061293|Drug|Diphenhydramine|
280976|NCT02061293|Behavioral|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
280977|NCT02061280|Drug|fluticasone/salmeterol 250/50 Dry Powder Inhaler|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, administered twice daily for 12 weeks after randomization
280978|NCT02061280|Drug|fluticasone/salmeterol 100/50 Dry Powder Inhaler|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler administered twice daily for 12 weeks after randomization
280979|NCT02061280|Drug|fluticasone 100mcg Dry Powder Inhaler|Participants will receive Flovent Diskus 100mcg Dry Powder Inhaler administered twice daily for 12 weeks after randomization
280980|NCT02061267|Dietary Supplement|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
280981|NCT02061267|Dietary Supplement|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
280982|NCT02061267|Dietary Supplement|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
280983|NCT02061267|Dietary Supplement|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
280984|NCT02061254|Device|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
280985|NCT02061254|Device|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
280986|NCT02061254|Device|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
280987|NCT02061254|Procedure|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
280988|NCT02061241|Procedure|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
280989|NCT02061241|Procedure|Pacing in other suitable vein|Pacing in other suitable vein
280990|NCT02061228|Device|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
280991|NCT02061215|Other|CMV viral load|
280992|NCT02061202|Drug|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
280993|NCT02061202|Drug|Placebo|placebo training inhaler with the same instructions as the experimental group.
280994|NCT02061189|Other|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
280995|NCT02061176|Procedure|Transanal Haemorrhoidal Dearterialization|
280996|NCT02061176|Procedure|Open Haemorrhoidectomy|
280997|NCT02061163|Device|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
280998|NCT02061163|Drug|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
280999|NCT02061137|Drug|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
281000|NCT02061124|Drug|Sevelamer 1600 mg TID for 7 days|
281001|NCT02061124|Drug|Placebo 1600 mg TID for 7 days|
281002|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
281003|NCT02061098|Dietary Supplement|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
281004|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
281005|NCT02061098|Dietary Supplement|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
281006|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
281007|NCT02061098|Dietary Supplement|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
281008|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
281009|NCT02061098|Dietary Supplement|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
281010|NCT02061085|Drug|Eribulina|
281011|NCT02061072|Other|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
281012|NCT02061059|Other|block 1|shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
281013|NCT02061059|Other|block 2|shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
281014|NCT02061059|Other|standard|patient wears shoes produced with standard method
281015|NCT02061059|Other|with measurements|patient wears shoes produced with plantar pressure measurements
281016|NCT02061046|Device|CPAP therapy|8 weeks of CPAP therapy
281017|NCT02061020|Drug|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
281018|NCT02061007|Drug|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
281019|NCT02061007|Drug|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
281020|NCT02061007|Procedure|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
281021|NCT02060994|Other|No intervention|No intervention
281022|NCT02060981|Behavioral|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
281023|NCT02060981|Behavioral|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
281024|NCT02060981|Behavioral|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
281025|NCT02060968|Device|Promus PREMIER|
281026|NCT02060955|Biological|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
281027|NCT02060955|Drug|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
281028|NCT02060929|Drug|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
281029|NCT02060916|Drug|PAZ320|Single-center pilot study, open label dose escalation design
281030|NCT02060903|Drug|Abametapir Lotion 0.74% w/w|
281031|NCT02060903|Drug|Vehicle Lotion|
281032|NCT02060890|Other|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
281033|NCT02060877|Other|observational study: use of patient questionnaires|observational study, there is no study intervention, only patient questionnaires
281034|NCT02060864|Dietary Supplement|AN-PEP|Two pills are consumed in the morning with a breakfast
281035|NCT02060864|Dietary Supplement|Placebo|
281036|NCT02060851|Drug|Iron sucrose|
281037|NCT02060851|Drug|EPO|
281038|NCT02060838|Procedure|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
281039|NCT02060825|Device|Regional saturation monitor|
281040|NCT02060812|Procedure|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
281041|NCT02060812|Procedure|Group II, SSNB alone|This is same as the Group I, SSNB & ANB, but ANB was performed with placebo(10mL normal saline).
281042|NCT02060786|Drug|generic clopidogrel (Plavitor® )|
281043|NCT02060786|Drug|original clopidogrel (Plavix® )|
281044|NCT02060747|Behavioral|Coordinator-based post fracture program|
281045|NCT02060734|Procedure|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
281046|NCT02060734|Other|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
281047|NCT02060721|Drug|Macitentan|Macitentan 10mg, oral tablet, once daily
281048|NCT02060708|Device|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
281049|NCT02060682|Device|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
281050|NCT02060669|Drug|Xeloda|Xeloda
281051|NCT02060656|Drug|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
281052|NCT02060656|Drug|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
281053|NCT02060656|Drug|Rituximab|375mg/m2 IV D1, D15 every 28 days
281054|NCT02060656|Drug|Cisplatin|100mg/m2 IV D15 every 28 days
281055|NCT02060656|Drug|Lenalidomide|25mg PO D1-21 every 28 days
281056|NCT02060630|Procedure|Open surgical revascularization|
281057|NCT02060630|Device|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
281058|NCT02060617|Behavioral|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
281059|NCT02060617|Procedure|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
281060|NCT02060617|Procedure|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
281061|NCT02060617|Procedure|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
281062|NCT02060604|Drug|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
281063|NCT02060604|Drug|Ranibizumab|3 monthly ranibizumab, then as needed
281064|NCT02060591|Drug|Exparel|
281065|NCT02060591|Drug|Marcaine|
281066|NCT02060578|Other|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
281067|NCT02060552|Drug|Diacerein|oral administration of IL-1βinhibitory
281068|NCT02060552|Drug|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
281069|NCT02060552|Drug|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
281070|NCT02060539|Device|Biofinity XR|
281071|NCT02060526|Drug|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase [rhHNS]
281072|NCT02060500|Procedure|Cardiaplication|
281073|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
281074|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
281075|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
281076|NCT02060474|Drug|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
281077|NCT02060461|Device|FS200 femtosecond laser LASIK|
281078|NCT02060461|Device|IntraLase femtosecond laser LASIK|
281079|NCT02060448|Behavioral|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
281080|NCT02060448|Behavioral|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
281081|NCT02060435|Other|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
281082|NCT02060422|Behavioral|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
281083|NCT02060422|Behavioral|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
281084|NCT02060409|Genetic|spliceosome|spliceosome mutations
281085|NCT02060396|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
281086|NCT02060383|Drug|Pasireotide s.c.|Administered to Cushing's disease participants.
281087|NCT02060383|Drug|Sitagliptin|Taken for approximately 16 weeks during the core study phase or until the drug was found not to be effective
281088|NCT02060383|Drug|Liraglutide|Participant switched to liraglutide if sitagliptin was found not to be effective.
281089|NCT02060383|Drug|Insulin|"Participant took insulin for 16 weeks. Insulin was also administered as rescue therapy in the incretin-based therapy arm if required.~Insulin was administered to the BL-insulin group at the discretion of the Principal Investigator.~Note: OAD and No OAD groups within the non-randomized arm did not take Insulin."
281090|NCT02060383|Drug|Pasireotide LAR|Administered to Acromegaly participants.
281176|NCT02059694|Other|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
281091|NCT02060383|Drug|Metformin|"If previously normo-glycemic participants experienced increase in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they started anti-diabetic treatment using metformin. If they continued to experience increase in their fasting blood glucose within the first 16 weeks, they were randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks. Metformin treatment was not required for the BL Insulin and OAD groups, within the non-randomized arm, but may have been prescribed at the discretion of the investigator.~Note: No OAD group within the non-randomized arm did not take metformin."
281092|NCT02060370|Drug|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
281093|NCT02060370|Behavioral|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
281094|NCT02060357|Device|Optical coherence tomography|
281095|NCT02060318|Drug|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
281096|NCT02060305|Drug|Bevacizumab intra-articular injection|Bevacizumab, 20~40mg, intra-articular injection every 28 days for 4 times
281097|NCT02060279|Other|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
281098|NCT02060279|Other|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
281099|NCT02060266|Drug|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
281100|NCT02060253|Drug|ganetespib|Given IV
281101|NCT02060253|Drug|paclitaxel|Given IV
281102|NCT02060253|Biological|trastuzumab|Given IV
281103|NCT02060253|Biological|pertuzumab|Given IV
281104|NCT02060240|Behavioral|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
281105|NCT02060227|Procedure|Open Latarjet procedure|
281106|NCT02060227|Procedure|Arthroscopic Bankart repair|
281107|NCT02060201|Drug|Saxagliptin|
281108|NCT02060201|Drug|Dapagliflozin|
281109|NCT02060201|Drug|Saxagliptin/Dapagliflozin FDC|
281110|NCT02060188|Drug|Ipilimumab|
281111|NCT02060188|Drug|Nivolumab|
281112|NCT02060188|Drug|Cobimetinib|
281113|NCT02060188|Drug|Daratumumab|
281114|NCT02060188|Drug|anti-LAG-3 antibody|
281115|NCT02060175|Device|Cilotax drug-eluting stents implantation|
281116|NCT02060175|Device|DESyne drug-eluting stents implantation|
281117|NCT02060162|Other|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
281118|NCT02060149|Drug|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
281119|NCT02060149|Drug|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
281120|NCT02060149|Drug|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
281121|NCT02060149|Drug|No nebulization|No nebulization will be given to the patients.
281122|NCT02060123|Behavioral|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:~Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
281123|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
281124|NCT02060110|Device|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
281125|NCT02060110|Device|MADIT-CRT ICD ONLY ARM|
281126|NCT02060097|Dietary Supplement|Cocoa flavanol beverage|
281127|NCT02060097|Dietary Supplement|Placebo beverage|
281128|NCT02060084|Drug|a control group|the same dose of luke warm water
281129|NCT02060084|Drug|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5*107CFU), twice per day, for 2 weeks
281130|NCT02060071|Other|Blood test|Blood test
281173|NCT02059720|Procedure|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
281174|NCT02059707|Device|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
281131|NCT02060058|Drug|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
281132|NCT02060045|Other|Bundle implementation|
281133|NCT02060032|Drug|1.2% Atorvastatin local drug delivery|
281134|NCT02060032|Drug|1.2% simvastatin local drug delivery|
281135|NCT02060032|Drug|Placebo local drug delivery|
281136|NCT02060019|Drug|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
281137|NCT02060006|Drug|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
281138|NCT02059993|Device|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
281139|NCT02059980|Behavioral|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
281140|NCT02059980|Behavioral|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
281141|NCT02059967|Drug|Paclitaxel|Given IV
281142|NCT02059967|Radiation|image-guided adaptive radiation therapy|Undergo IGART
281143|NCT02059967|Drug|carboplatin|Given IV
281144|NCT02059954|Procedure|Hysterectomy|
281145|NCT02059928|Device|Intraosseous Device|
281146|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
281147|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
281148|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
281149|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
281150|NCT02059902|Drug|Lidocaine|Lidocaine infusion runs for a total of 24 hours
281151|NCT02059902|Other|Placebo|Normal saline runs for a total of 24 hours
281152|NCT02059889|Device|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
281153|NCT02059889|Device|4-dimensional computed tomography|Undergo 4D CT
281154|NCT02059889|Radiation|fludeoxyglucose F 18|Undergo FDG-PET
281155|NCT02059889|Device|FDG-PET|Undergo FDG-PET
281156|NCT02059876|Drug|carboplatin and paclitaxel and or without trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer
281157|NCT02059863|Behavioral|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
281158|NCT02059850|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
281159|NCT02059850|Drug|Cyclophosphamide|Given IV
281160|NCT02059850|Other|Laboratory Biomarker Analysis|Correlative studies
281161|NCT02059837|Procedure|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
281162|NCT02059824|Device|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.~If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
281163|NCT02059811|Other|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
281164|NCT02059811|Other|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
281165|NCT02059785|Drug|Pinocembrin for Injection|
281166|NCT02059772|Drug|ranibizumab|
281167|NCT02059772|Procedure|micropulse diode laser|
281168|NCT02059759|Drug|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
281169|NCT02059759|Drug|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
281170|NCT02059759|Drug|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
281171|NCT02059746|Other|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
281172|NCT02059733|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
281175|NCT02059694|Drug|Hyaluronidase|
281177|NCT02059681|Other|Autologous bone marrow derived-CD133+ cells|Cell therapy
281178|NCT02059668|Biological|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
281179|NCT02059655|Drug|Bimatoprost|
281180|NCT02059655|Drug|Eye drop solution|Artificial tear drops
281181|NCT02059642|Drug|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
281182|NCT02059642|Drug|placebo|Placebo 1400 mg administered orally once daily
281183|NCT02059629|Device|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
281184|NCT02059629|Device|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
281185|NCT02059616|Drug|Amlodipine 5mg|Daily oral administration for 8 weeks
281186|NCT02059616|Drug|Amlodipine 10mg|Daily oral administration for 8 weeks
281187|NCT02059616|Drug|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
281188|NCT02059616|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
281189|NCT02059603|Procedure|Electroacupuncture|
281190|NCT02059603|Procedure|Fast-track program|
281191|NCT02059590|Drug|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
281192|NCT02059577|Dietary Supplement|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
281193|NCT02059564|Drug|HM11260C|doses of 6 mg, 16 mg
281194|NCT02059564|Drug|Placebo|Normal saline solution
281195|NCT02059564|Drug|Victoza|doses of 1.8 mg
281196|NCT02059551|Procedure|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
281197|NCT02059538|Other|Adipose tissue biopsies (omental and subcutaneous) liver|
281198|NCT02059538|Radiation|CT-scan|
281199|NCT02059538|Other|Stools sampling|
281200|NCT02059538|Other|DNA sampling|
281201|NCT02059538|Other|Blood sampling|
281202|NCT02059538|Other|Urine sampling|
281203|NCT02059538|Radiation|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
281204|NCT02059512|Procedure|coronary artery bypass grafting with administration of autologous bone marrow stem cells|
281205|NCT02059512|Procedure|coronary artery bypass grafting with administration of 0.9 % NaCl (sodium chloride) 0.2 ml|
281206|NCT02059499|Drug|imiquimod|Given intra-anally
281207|NCT02059499|Drug|fluorouracil|Given intra-anally
281208|NCT02059499|Other|questionnaire administration|Ancillary studies
281209|NCT02059499|Other|laboratory biomarker analysis|Correlative studies
281210|NCT02059486|Behavioral|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
281211|NCT02059473|Procedure|Rotator cuff repair|Physiotherapy & Surgery
281212|NCT02059473|Procedure|Physiotherapy|
281213|NCT02059460|Drug|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
281214|NCT02059460|Drug|placebo|
281215|NCT02059447|Other|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
281216|NCT02059447|Behavioral|Mindfulness Based Cognitive Therapy|
281217|NCT02059447|Behavioral|Relaxation Therapy|
281218|NCT02059434|Drug|LAS190792 Dose 1|
281219|NCT02059434|Drug|LAS190792 Dose 2|
281220|NCT02059434|Drug|LAS190792 Dose 3|
281221|NCT02059434|Drug|LAS190792 Dose 4|
281222|NCT02059434|Drug|LAS190792 Dose 5|
281223|NCT02059434|Drug|LAS190792 Dose 6|
281224|NCT02059434|Drug|LAS190792 Dose 1 (Part 2)|
281225|NCT02059434|Drug|LAS190792 Dose 2 (Part 2)|
281226|NCT02059434|Drug|Tiotropium 18 μg|
281227|NCT02059434|Drug|Indacaterol 150 μg|
281228|NCT02059434|Drug|Placebo|
281229|NCT02059421|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"- Therapy session administered by a clinical psychologist using web-based video conferencing software.~Therapy sessions will include:~Sleep restriction therapy~Stimulus control instructions~Sleep hygiene education"
281230|NCT02059421|Other|Johrei therapy|"Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.~Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.~Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.~Therapy will be administered without physical contact.~During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
281231|NCT02059408|Other|Screen-Educate|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
281232|NCT02059408|Other|Screen-Educate and Intensify Treatment|The CKD CDSS plus pharmacist (CDSS PLUS) extends beyond CDSS alone. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys <45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
281233|NCT02059395|Other|Mastery based learning|Participants are allowed to follow the course content at their own speed
281234|NCT02059395|Other|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
281235|NCT02059382|Behavioral|ChiRunning training|
281236|NCT02059382|Behavioral|unblinded accelerometer|
281237|NCT02059382|Behavioral|participation in online social network|
281238|NCT02059382|Behavioral|participation in study website|
281239|NCT02059382|Behavioral|Technology support for behavior change|
281240|NCT02059369|Procedure|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
281241|NCT02059369|Procedure|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
281242|NCT02059330|Drug|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
281243|NCT02059330|Drug|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
281244|NCT02059330|Drug|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
281245|NCT02059330|Drug|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
281246|NCT02059330|Drug|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
281247|NCT02059317|Other|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
281248|NCT02059317|Other|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
281249|NCT02059317|Other|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
281250|NCT02059304|Device|Measurement of cervical length with embryo transfer catheter|
281251|NCT02059291|Drug|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
281252|NCT02059291|Drug|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
281253|NCT02059278|Drug|T-2345|T-2345 Ophthalmic Solution
281254|NCT02059278|Drug|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
281255|NCT02059265|Drug|Dasatinib|Given PO
281256|NCT02059265|Other|Laboratory Biomarker Analysis|Correlative studies
281257|NCT02059252|Device|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
281258|NCT02059239|Drug|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
281259|NCT02059239|Drug|Carmustine|300 mg/m2 on Day -6
281260|NCT02059239|Drug|Etoposide|100 mg/m2 on days -5 to -2
281261|NCT02059239|Drug|Melphalan|140mg/m2 on Day -1
281262|NCT02059239|Drug|Cytarabine|200 mg/m2 on days -5 to -2
281263|NCT02059239|Drug|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
281264|NCT02059239|Biological|Autologous Stem Cell Transplantation|
281265|NCT02059239|Biological|Allogeneic Stem Cell Transplantation|
281266|NCT02059239|Drug|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
281267|NCT02059226|Behavioral|cognitive behavioural therapy|Internet-based CBT
281268|NCT02059226|Other|Internet-based resource page|Static webpage
281269|NCT02059213|Drug|Ibrance|
281270|NCT02059213|Drug|Bicalutamide|
281271|NCT02059213|Drug|Zoladex|
281272|NCT02059213|Drug|Lupron Depot|
281273|NCT02059200|Behavioral|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
281274|NCT02059187|Drug|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
281400|NCT02058251|Drug|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
281275|NCT02059187|Drug|Lantus™|Lantus™ (insulin glargine [rDNA origin]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
281276|NCT02059187|Drug|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
281277|NCT02059174|Drug|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
281278|NCT02059174|Drug|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
281279|NCT02059174|Drug|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
281280|NCT02059161|Drug|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
281281|NCT02059161|Drug|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
281282|NCT02059161|Drug|Prandial Insulin|Participants will continue their prandial insulin during the study.
281283|NCT02059148|Drug|LY2835219|Administered orally.
281284|NCT02059135|Biological|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
281285|NCT02059135|Other|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
281286|NCT02059109|Procedure|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
281287|NCT02059096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
281288|NCT02059083|Behavioral|Heart rate variability biofeedback|
281289|NCT02059083|Behavioral|CBT|
281290|NCT02059070|Drug|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
281291|NCT02059070|Drug|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
281292|NCT02059057|Device|LVRC System|
281293|NCT02059044|Other|ISTOP-ADE|Interactive Voice Response System + Pharmacist
281294|NCT02059031|Drug|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
281295|NCT02059031|Drug|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
281296|NCT02059031|Drug|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
281297|NCT02059018|Drug|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
281298|NCT02059018|Drug|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
281299|NCT02059018|Drug|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
281300|NCT02059005|Behavioral|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
281301|NCT02059005|Behavioral|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
281302|NCT02058992|Drug|Ramelteon|Ramelteon 8 mg tablets
281303|NCT02058979|Drug|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
281304|NCT02058979|Drug|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
281305|NCT02058966|Drug|Entacapone|Entacapone 200 mg oral dose
281306|NCT02058966|Drug|Methamphetamine|Methamphetamine 20 mg oral dose
281307|NCT02058966|Drug|Placebo|capsules compounded to be of similar appearance to the active drugs
281308|NCT02058953|Procedure|Craniotomy scheduled|Resection of affected brain tissue
281309|NCT02058953|Procedure|Collection for non-craniotomy|CSF, Blood, biopsy
281310|NCT02058940|Drug|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
281311|NCT02058927|Drug|Measles vaccine|measles revaccination administered at 12 months from start of ART
281312|NCT02058914|Dietary Supplement|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
281313|NCT02058914|Dietary Supplement|High Glucose sweetened beverage|HG-sweetened beverage
281314|NCT02058901|Drug|Sunitinib|
281315|NCT02058875|Drug|Myfortic®|
281316|NCT02058875|Drug|Neoral®|
281317|NCT02058875|Drug|Cellcept®|
281318|NCT02058875|Drug|Prednisone|
281319|NCT02058849|Drug|Beetroot|10g Beetroot powder mixed with 4-8 oz.
281320|NCT02058849|Other|Placebo|Placebo
281321|NCT02058836|Drug|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
281674|NCT02056197|Other|Stable surface exercises|Stable surface exercises
281322|NCT02058836|Procedure|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
281323|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
281324|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
281325|NCT02058823|Drug|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
281326|NCT02058823|Drug|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
281327|NCT02058810|Device|Nasal high flow|
281328|NCT02058810|Device|Conventional nasal oxygen|
281329|NCT02058797|Behavioral|Coherence Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
281330|NCT02058797|Behavioral|Cognitive Behavioral Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
281331|NCT02058784|Drug|pracinostat|
281332|NCT02058758|Device|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
281333|NCT02058745|Behavioral|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
281334|NCT02058745|Behavioral|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
281335|NCT02058745|Behavioral|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
281336|NCT02058732|Other|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
281337|NCT02058706|Drug|enzalutamide|Given PO
281338|NCT02058706|Drug|bicalutamide|Given PO
281339|NCT02058706|Procedure|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
281340|NCT02058706|Drug|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
281341|NCT02058706|Drug|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
281342|NCT02058706|Other|laboratory biomarker analysis|Correlative studies
281343|NCT02058693|Drug|mixed salts amphetamine|adjunctive to ADT
281344|NCT02058680|Biological|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.~In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
281345|NCT02058667|Radiation|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
281346|NCT02058654|Drug|Creatine|Creatine powder (5 g)
281347|NCT02058654|Drug|Placebo|Bulking agent powder (5 g)
281348|NCT02058641|Drug|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
281349|NCT02058628|Drug|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
281350|NCT02058628|Drug|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
281351|NCT02058615|Behavioral|Male Spouse Transition Toolkit|
281352|NCT02058602|Other|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
281353|NCT02058589|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
281354|NCT02058589|Drug|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
281355|NCT02058576|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
281356|NCT02058576|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
281357|NCT02058563|Biological|Priorix®|1 dose administered as a subcutaneous (SC) injection.
281358|NCT02058563|Biological|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
281359|NCT02058550|Other|survey administration|Receive reminder email survey
281360|NCT02058550|Other|computer-assisted intervention|Receive reminder email survey
281361|NCT02058550|Behavioral|telephone-based intervention|Receive reminder phone call
281362|NCT02058537|Drug|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
281363|NCT02058524|Biological|fecal microbiota transplantation|
281401|NCT02058251|Drug|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
281439|NCT02057939|Drug|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
281364|NCT02058511|Drug|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
281365|NCT02058511|Procedure|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
281366|NCT02058498|Behavioral|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
281367|NCT02058485|Drug|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
281368|NCT02058485|Drug|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
281369|NCT02058472|Drug|G3041|
281370|NCT02058472|Drug|SEVIKAR®|
281371|NCT02058459|Device|Holaira™ Lung Denervation System with energy delivery|
281372|NCT02058459|Device|Holaira™ Lung Denervation System without energy delivery|
281373|NCT02058446|Drug|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
281374|NCT02058433|Other|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
281375|NCT02058433|Other|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
281376|NCT02058420|Drug|Low tocotrienols group|300 mg tocotrienols daily
281377|NCT02058420|Drug|High tocotrienols group|600 mg tocotrienols daily
281378|NCT02058407|Drug|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
281379|NCT02058407|Drug|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
281380|NCT02058407|Drug|Placebo solution|Matching placebo to GSK2793660 solution
281381|NCT02058407|Drug|Placebo capsule|Matching placebo to GSK2793660 capsule
281382|NCT02058394|Procedure|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
281383|NCT02058381|Drug|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
281384|NCT02058381|Drug|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
281385|NCT02058368|Drug|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
281386|NCT02058368|Drug|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
281387|NCT02058368|Drug|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
281388|NCT02058368|Drug|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
281389|NCT02058355|Behavioral|Consequences List Feedback|
281390|NCT02058355|Behavioral|Personalized Normative Feedback|
281391|NCT02058342|Behavioral|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
281392|NCT02058329|Other|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
281393|NCT02058316|Device|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
281394|NCT02058303|Drug|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
281395|NCT02058303|Drug|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
281396|NCT02058290|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
281397|NCT02058290|Drug|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
281398|NCT02058277|Drug|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
281399|NCT02058264|Drug|BBI-4000|
281402|NCT02058212|Drug|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
281403|NCT02058199|Drug|rivaroxaban|Single dose pharmacodynamic study
281404|NCT02058186|Drug|oral vitamin D|
281405|NCT02058186|Drug|Placebo|
281406|NCT02058173|Drug|150 mg/daily chloroquine compare to placebo for 12 week|
281407|NCT02058173|Drug|Chloroquine|
281408|NCT02058173|Drug|placebo|
281409|NCT02058160|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.~Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
281410|NCT02058160|Drug|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.~After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
281411|NCT02058160|Drug|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
281412|NCT02058147|Drug|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
281413|NCT02058147|Drug|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
281414|NCT02058147|Drug|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
281415|NCT02058147|Drug|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
281416|NCT02058134|Device|cardioPAT cell saver|
281417|NCT02058121|Behavioral|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
281418|NCT02058121|Behavioral|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a physician, dietician and/or physiotherapist.
281419|NCT02058108|Drug|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
281420|NCT02058108|Drug|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
281421|NCT02058095|Drug|Tadalafil|Tadalafil 5 mg tablet
281422|NCT02058095|Drug|Placebo|Placebo tablet
281423|NCT02058082|Procedure|Intracytoplasmic sperm injection|
281424|NCT02058069|Device|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
281425|NCT02058056|Radiation|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
281426|NCT02058030|Device|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.~The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
281427|NCT02058017|Drug|OPB-51602|
281428|NCT02058004|Procedure|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
281429|NCT02057991|Other|educational intervention|Watch an educational video
281430|NCT02057991|Procedure|CAM exercise therapy|Watch a mindfulness exercise video
281431|NCT02057991|Other|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
281432|NCT02057991|Other|questionnaire administration|Ancillary studies
281433|NCT02057991|Other|laboratory biomarker analysis|Correlative studies
281434|NCT02057978|Procedure|EXCEL DES implatation|Implant DES for CAD cases
281435|NCT02057978|Procedure|EXCEL-II DES implantation|Implant DES for CAD cases
281436|NCT02057965|Drug|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight
281437|NCT02057952|Behavioral|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
281438|NCT02057939|Drug|enzalutamide|160 mg orally once daily for six months
281440|NCT02057939|Radiation|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
281441|NCT02057926|Drug|The effect of tetracycline in degradation and permeability of collagen membranes.|
281442|NCT02057913|Drug|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
281443|NCT02057900|Biological|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
281444|NCT02057887|Drug|HM10660A|
281445|NCT02057887|Drug|Pegasys|180 mcg Pegasys SC once weekly
281446|NCT02057874|Device|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
281447|NCT02057874|Drug|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
281448|NCT02057848|Other|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
281449|NCT02057848|Other|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
281450|NCT02057848|Other|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
281451|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
281452|NCT02057835|Drug|BI 691751 high dose|BI 691751 high dose
281453|NCT02057835|Drug|BI 691751 middle dose|BI 691751 middle dose
281454|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
281455|NCT02057835|Drug|BI 691751 low dose 1|BI 691751 low dose 1
281456|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
281457|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
281458|NCT02057835|Drug|BI 691751 low dose 2|BI 691751 low dose 2
281459|NCT02057822|Procedure|Cytokins assay in tears|
281460|NCT02057796|Device|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:~Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.~TB treatment will depend on the result of the tests:~Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
281461|NCT02057796|Drug|ART (Atripla, Truvada, Efavirenz, Combivir)|"ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.~ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
281462|NCT02057796|Drug|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
281463|NCT02057783|Other|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
281464|NCT02057770|Drug|busulfan|
281465|NCT02057770|Drug|fludarabine phosphate|
281466|NCT02057770|Radiation|total-body irradiation (TBI)|
281467|NCT02057770|Procedure|Stem cell transplant|
281468|NCT02057770|Drug|cyclophosphamide|
281469|NCT02057770|Drug|tocilizumab|
281470|NCT02057757|Drug|Nitazoxanide|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.~Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
281471|NCT02057757|Drug|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
281472|NCT02057731|Genetic|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
281473|NCT02057718|Drug|LUM001|LUM001 oral dose up to twice a day (BID).
281474|NCT02057692|Drug|LUM001|LUM001 administered orally
281475|NCT02057692|Drug|Placebo|Placebo administered orally
281476|NCT02057679|Drug|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
281477|NCT02057679|Drug|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
281478|NCT02057666|Drug|Tasquinimod|A patient will initially receive 0.25 mg/day dose which will then be titrated through 0.5 mg/day (from Day 15) to a maximum of 1mg/day (from Day 29). If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
281479|NCT02057666|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food (preferably the main evening meal).
281480|NCT02057640|Drug|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
281481|NCT02057640|Drug|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
281482|NCT02057640|Drug|MLN9708|4mg on day 1, 8, 15, 28
281670|NCT02056223|Drug|Intravenous paracetamol|15 mg/Kg every 6 hours for three days
281483|NCT02057627|Behavioral|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
281484|NCT02057627|Behavioral|Placebo Comparator|Standard care plus depression monitoring by phone
281485|NCT02057601|Drug|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
281486|NCT02057588|Procedure|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
281487|NCT02057575|Drug|PG324 Ophthalmic Solution 0.01%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
281488|NCT02057575|Drug|PG324 Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
281489|NCT02057575|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
281490|NCT02057575|Drug|Latanoprost Ophthalmic Solution 0.005%|1 drop in the evening (PM), once daily (QD), both eyes (OU)
281491|NCT02057549|Drug|Haloperidol|Intravenous dose of haloperidol 5 mg.
281492|NCT02057549|Drug|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
281493|NCT02057536|Other|Arm A Directed exercise program|
281494|NCT02057536|Other|Observation|
281495|NCT02057523|Drug|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
281496|NCT02057484|Drug|Tacrolimus|oral
281497|NCT02057471|Drug|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
281498|NCT02057458|Drug|Acute (1 hour) Sildenafil|Exercise capacity and vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
281499|NCT02057458|Drug|Sub-Chronic (4 weeks) Sildenafil|Exercise capacity and vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
281500|NCT02057458|Drug|Placebo|Sugar pill designed to mimic the sildenafil treatment
281501|NCT02057445|Drug|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
281502|NCT02057445|Other|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
281503|NCT02057432|Device|intra-operative MRI|Patients will undergo an MRI during surgery.
281504|NCT02057406|Drug|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
281505|NCT02057406|Drug|High EPA|
281506|NCT02057406|Other|Placebo|
281507|NCT02057393|Drug|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
281508|NCT02057393|Drug|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
281509|NCT02057393|Drug|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
281510|NCT02057380|Drug|linsitinib|oral
281511|NCT02057380|Drug|erlotinib|oral
281512|NCT02057380|Drug|paclitaxel|Intravenous (IV) infusion
281513|NCT02057380|Drug|Bortezomib|Subcutaneous or IV
281514|NCT02057380|Drug|Dexamethasone|IV, Oral
281515|NCT02057367|Drug|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
281516|NCT02057367|Drug|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
281517|NCT02057354|Behavioral|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
281518|NCT02057354|Behavioral|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
281519|NCT02057341|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
281520|NCT02057328|Drug|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
281573|NCT02057081|Behavioral|Group Health Education (GHE)|GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
281574|NCT02057068|Behavioral|SLEEP-E Dyads Intervention|Described in arm/group description
281521|NCT02057328|Drug|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
281522|NCT02057315|Drug|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
281523|NCT02057315|Drug|Placebo|One dose of matching placebo over 3 bilateral applications.
281524|NCT02057302|Drug|Xuezhikang capsule|
281525|NCT02057289|Drug|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
281526|NCT02057276|Device|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
281527|NCT02057276|Device|Sham Repetitive Transcranial Magnetic Stimulation|
281528|NCT02057276|Other|Occupational Therapy|
281529|NCT02057263|Drug|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
281530|NCT02057263|Drug|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
281531|NCT02057263|Drug|Placebo|Participants will receive 4 doses of placebo during the course of the study.
281532|NCT02057250|Drug|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
281533|NCT02057250|Device|Auto-Injector Device (AID)|
281534|NCT02057250|Device|Pre-filled Syringe (PFS)|
281535|NCT02057250|Drug|Methotrexate|Dispensed according to local practice.
281536|NCT02057250|Drug|Sulfasalazine|Dispensed according to local practice.
281537|NCT02057250|Drug|Leflunomide|Dispensed according to local practice.
281538|NCT02057250|Drug|Hydroxychloroquine|Dispensed according to local practice.
281539|NCT02057237|Drug|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
281540|NCT02057224|Procedure|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
281541|NCT02057211|Biological|autologous mesenchymal stem cell transplantation|
281542|NCT02057211|Procedure|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
281543|NCT02057198|Drug|Fidaxomicin|
281544|NCT02057198|Drug|Metronidazole|
281545|NCT02057198|Drug|Vancomycin|
281546|NCT02057185|Behavioral|Study questionnaire|Questionnaire based on work situation of enrolled patients.
281547|NCT02057185|Behavioral|SF-36 Questionnaire|Version 1.6
281548|NCT02057172|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
281549|NCT02057172|Drug|liraglutide|Liraglutide is a GLP-1 agonist.
281550|NCT02057172|Drug|Placebo|Placebo
281551|NCT02057159|Biological|NeuroVax|
281552|NCT02057159|Biological|IFA Placebo|IFA Placebo
281553|NCT02057146|Procedure|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
281554|NCT02057133|Drug|LY2835219|Administered orally.
281555|NCT02057133|Drug|Letrozole|Administered orally.
281556|NCT02057133|Drug|Anastrozole|Administered orally.
281557|NCT02057133|Drug|Tamoxifen|Administered orally.
281558|NCT02057133|Drug|Exemestane|Administered orally.
281559|NCT02057133|Drug|Everolimus|Administered orally.
281560|NCT02057133|Drug|Trastuzumab|Administered IV infusion.
281561|NCT02057133|Drug|LY3023414|Administered orally.
281562|NCT02057133|Drug|Fulvestrant|Administered IM.
281563|NCT02057133|Drug|Pertuzumab|Administered IV infusion.
281564|NCT02057133|Drug|Loperamide|Administered orally.
281565|NCT02057133|Drug|Endocrine therapy|Endocrine therapy administered orally.
281566|NCT02057120|Procedure|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
281567|NCT02057120|Device|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
281568|NCT02057107|Radiation|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
281569|NCT02057107|Drug|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):~Cetuximab, 400 mg/m2~Days 0 and 8 (The 1st and 2nd week of radiosurgery):~Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
281570|NCT02057107|Drug|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
281571|NCT02057094|Dietary Supplement|Protein, High-Protein, and Control|
281572|NCT02057081|Behavioral|Multifamily Group for mTBI for Couples|MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
281575|NCT02057055|Other|Soap 300000027003|
281577|NCT02057042|Behavioral|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
281578|NCT02057042|Behavioral|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
281579|NCT02057029|Behavioral|BCI Assay Results|The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
281580|NCT02057003|Drug|DAA against HCV|
281581|NCT02056990|Other|Advice|
281582|NCT02056977|Other|Titration|Individualized PEEP according to PEEP titration monitored by EIT
281583|NCT02056977|Other|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
281584|NCT02056951|Procedure|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:~health education~exercise therapy~back school~physical treatments~psychological interventions in groups and individual counselling~rehabilitation/social counselling."
281585|NCT02056951|Procedure|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:~education about low back pain~behavioural exercise therapy~coping with pain~relaxation~work related informations"
281586|NCT02056938|Drug|Anti-Thymocyte Globulins treatment|
281587|NCT02056938|Drug|Basiliximab treatment|
281588|NCT02056925|Other|Echocardiography|
281589|NCT02056912|Genetic|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
281590|NCT02056912|Biological|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
281591|NCT02056899|Drug|Gabapentin|
281592|NCT02056886|Procedure|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
281593|NCT02056873|Device|DBS System|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS."
281594|NCT02056873|Device|DBS System (RBS Setting)|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.~Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.~Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention."
281595|NCT02056860|Procedure|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
281596|NCT02056860|Procedure|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
281597|NCT02056860|Procedure|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
281598|NCT02056860|Procedure|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
281599|NCT02056860|Procedure|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
281600|NCT02056847|Drug|Pitavastatin calcium 4mg|taking once a day
281601|NCT02056847|Drug|Pitavastatin calcium 2mg|Taking once a day
281602|NCT02056834|Device|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
281603|NCT02056808|Drug|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
281604|NCT02056795|Device|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
281671|NCT02056223|Drug|Intravenous ibuprofen|10 -5-5 mg/Kg once a day for three days
281672|NCT02056210|Drug|Mozobil|Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
281605|NCT02056795|Device|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
281606|NCT02056782|Drug|PGX-ODSH-2013-AML-1|"Eligible patients will receive idarubicin at 12 mg/m2 days 1-3 of induction plus a seven-day continuous infusion of cytarabine at 100 mg/m2/day days 1-7 of induction. For consolidation, patients younger than 60 will receive cytarabine at 3 grams/m2 over 3 hours every 12 hours days 1, 3, and 5 of the cycle. Patients over 60 will come off study following induction.~In induction, ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first idarubicin dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for 24 hours daily for seven consecutive days (days 1-7) for a total of 168 hours of continuous ODSH infusion.~In consolidation, ODSH will be administered as a 4 mg/kg bolus 30 minutes after completion of the first 3-hour infusion of cytarabine, followed immediately by a continuous ODSH intravenous infusion of 0.25 mg/kg/hour for 24 hours daily for five consecutive days (days 1-5) for a total of 120 hours of continuous ODSH infusion."
281607|NCT02056769|Radiation|CT Perfusion|Quantitative CT Perfusion imaging
281608|NCT02056756|Drug|Carfilzomib|
281609|NCT02056743|Drug|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
281610|NCT02056743|Drug|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
281611|NCT02056743|Dietary Supplement|Red ginseng|During 4~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
281612|NCT02056743|Dietary Supplement|Fermented-red ginseng|During 4~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
281613|NCT02056730|Drug|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
281614|NCT02056717|Drug|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
281615|NCT02056717|Drug|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
281616|NCT02056704|Device|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
281617|NCT02056691|Procedure|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
281618|NCT02056691|Procedure|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
281619|NCT02056678|Drug|acetaminophen, IV preparation|
281620|NCT02056665|Drug|MINOCYCLINE|Pill Minocycline 50 mg capsule
281621|NCT02056665|Drug|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
281622|NCT02056652|Device|Bioteque cup pessary|
281623|NCT02056639|Device|Bioteque cup pessary|
281624|NCT02056626|Drug|carvedilol|
281625|NCT02056600|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
281626|NCT02056600|Drug|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
281627|NCT02056587|Drug|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
281628|NCT02056574|Drug|NA-1|
281629|NCT02056574|Drug|Placebo|
281630|NCT02056535|Behavioral|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
281631|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
281632|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
281633|NCT02056483|Other|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
281634|NCT02056470|Device|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
281635|NCT02056470|Device|Total Knee Replacement|total Knee replacement implant
281636|NCT02056470|Device|Freedom Total Knee System|Total Knee replacement implant
281637|NCT02056457|Behavioral|Responsible Fatherhood or Healthy Marriage Program|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
281638|NCT02056457|Behavioral|Other services in the community|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
281639|NCT02056444|Drug|Tranexamic Acid|
281640|NCT02056431|Behavioral|IVR Intervention Group|Participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
281641|NCT02056418|Dietary Supplement|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
281642|NCT02056418|Drug|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
281643|NCT02056405|Drug|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
281644|NCT02056405|Drug|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
281645|NCT02056392|Drug|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
281646|NCT02056392|Drug|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
281647|NCT02056392|Drug|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
281648|NCT02056379|Drug|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
281649|NCT02056379|Drug|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
281650|NCT02056366|Drug|α-lipoic acid|α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
281651|NCT02056353|Device|LOGIC-Insulin algorithm|
281652|NCT02056353|Device|Paper protocol|
281653|NCT02056340|Drug|Atorvastatin|
281654|NCT02056340|Drug|Placebo|
281655|NCT02056327|Device|A novel monitoring suite of sensors will be inserted into the standard oral device.|
281656|NCT02056314|Other|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
281657|NCT02056314|Other|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
281658|NCT02056301|Drug|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
281659|NCT02056301|Drug|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
281660|NCT02056288|Drug|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
281661|NCT02056288|Drug|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
281662|NCT02056275|Other|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
281663|NCT02056275|Other|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
281664|NCT02056262|Other|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
281665|NCT02056262|Biological|Saliva sampling|A saliva sample will be harvested.
281666|NCT02056262|Biological|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
281667|NCT02056249|Other|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
281668|NCT02056236|Drug|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.~The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
281669|NCT02056236|Other|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.~Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
281673|NCT02056197|Other|Placebo|Shortwave
281675|NCT02056197|Other|Unstable surface exercises|
281676|NCT02056184|Drug|Adalimumab|
281677|NCT02056171|Drug|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
281678|NCT02056171|Other|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
281679|NCT02056145|Procedure|LFCNB|LFCNB - Normal Saline solution 10 cc
281680|NCT02056145|Procedure|FNB|FNB - Normal saline solution 10 cc
281681|NCT02056145|Procedure|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
281682|NCT02056145|Procedure|FNB|FNB - Chirocaine 0.25%, 20 cc
281683|NCT02056132|Other|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
281684|NCT02056119|Device|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~Aerosol treatment delivered per physician order.~Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
281685|NCT02056119|Device|Jet Nebulizer Arm|"Physician order received for subject, randomization to jet nebulizer occurred.~Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
281686|NCT02056106|Drug|antidepressant therapy|
281687|NCT02056093|Device|PSV mode|Application of PSV in all patients
281688|NCT02056093|Device|PAV mode|Application of PAV mode in all patients
281689|NCT02056093|Device|NAVA|
281690|NCT02056067|Behavioral|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
281691|NCT02056067|Behavioral|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
281692|NCT02056054|Other|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
281693|NCT02056054|Other|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
281694|NCT02056054|Other|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
281695|NCT02056054|Other|Adult non-transplant patients with auto-immune hepatitis|"75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
281696|NCT02056054|Other|Adult non-transplant subjects with chronic hepatitis C virus|"For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
281697|NCT02056054|Other|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
281698|NCT02056054|Other|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
281699|NCT02056041|Procedure|Hepatectomy|
281700|NCT02056028|Procedure|Hepatic resection|
281701|NCT02056015|Drug|[68Ga]MLN6907|IV Administration of [68Ga]MLN6907 on Day 1
281702|NCT02056002|Other|Usual Care|- Standard CPAP educational training
281703|NCT02056002|Other|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy~Standard CPAP educational training~Eight phone conversations with Peer Buddy over 3 months~Subsequent 3 months use of phone system to contact Peer Buddy as needed~One Month Visit:~- Home visit to collect CPAP information~Three Month Visit:~Questionnaires~Psycho Motor Vigilance Test (PVT) Video Game~Collect CPAP information~Measure weight~Measure blood pressure~Six Month Visit:~Questionnaires~PVT (Video game)~Collect CPAP information~Measure Weight~Measure Blood Pressure~Evaluate the program and Peer Buddy"
281704|NCT02056002|Other|Usual Care|- Educational Brochures
281705|NCT02056002|Other|Usual Care|- Educational DVD videos mailed to participant
281706|NCT02055989|Radiation|Dose-escalated radiotherapy level 1|
281707|NCT02055989|Radiation|Sequential dose-escalated radiotherapy level 2|
282129|NCT02052817|Other|Optimal Medical Therapy - Debridement|
281708|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
281709|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
281710|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
281711|NCT02055976|Drug|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
281712|NCT02055976|Drug|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
281713|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
281714|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
281715|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
281716|NCT02055976|Drug|Placebo|Placebo Q14D SC for 16 week
281717|NCT02055963|Drug|Minocycline|100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
281718|NCT02055963|Drug|Placebo|Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
281719|NCT02055963|Behavioral|Questionnaires|Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
281720|NCT02055950|Procedure|Storage of kidney in refrigerated solution|
281721|NCT02055950|Procedure|Kidney perfused by pulsatile machine|
281722|NCT02055937|Procedure|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
281723|NCT02055924|Drug|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
281724|NCT02055911|Drug|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
281725|NCT02055898|Drug|Sodium Oxybate|
281726|NCT02055898|Other|placebo (fresh potable water)|
281727|NCT02055872|Drug|Intravenous albumin|
281728|NCT02055872|Drug|Normal saline|
281729|NCT02055859|Radiation|Radiosurgery|
281730|NCT02055846|Procedure|Realisation of blood sample, urinary sample and tumor biopsy|
281731|NCT02055833|Dietary Supplement|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
281732|NCT02055833|Other|Nutritional counseling|Nutritional counseling
281733|NCT02055820|Drug|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) on Days 4−10 of Cycle 1 and Days 1−10 of Cycles 2−8 during Phase I and MTD will be administered according to the same schedule during Phase II.
281734|NCT02055820|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
281735|NCT02055820|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
281736|NCT02055820|Drug|Rituximab|Rituximab 375 mg/m^2 dose will be administered IV on Day 1 of every 21-day cycle.
281737|NCT02055820|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
281738|NCT02055820|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
281739|NCT02055820|Drug|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
281740|NCT02055807|Other|PEEP and recruitment maneuvers|
281741|NCT02055807|Other|ZEEP (no PEEP nor recruitment maneuver)|
281742|NCT02055794|Procedure|Suturing of the perineal skin|
281743|NCT02055794|Procedure|Closing perineal skin with surgical glue|
281744|NCT02055794|Procedure|No suturing of the perineal skin|
281745|NCT02055781|Drug|Pacritinib|
281746|NCT02055781|Drug|Best Available Therapy|
281747|NCT02055742|Device|illumigene CT and NG assays, illumipro-10|
281748|NCT02055729|Biological|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
281749|NCT02055729|Biological|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 & 28)
281750|NCT02055729|Biological|Stool sample|Stool samples will be collected on days 0 and 28.
281751|NCT02055729|Biological|Urine sample|Urine samples will be collected on days 0 and 28.
281752|NCT02055716|Drug|Sulforadex|
281753|NCT02055716|Drug|alpha-cyclodextrin|
281754|NCT02055703|Drug|E2609|
281755|NCT02055703|Drug|itraconazole|
281756|NCT02055703|Drug|rifampin|
281757|NCT02055703|Drug|digoxin|
281758|NCT02055703|Drug|donepezil|
281759|NCT02055690|Drug|Pazopanib|Tyrosine Kinase Inhibitor
281760|NCT02055690|Drug|Fosbretabulin|Vascular Disrupting Agent
281761|NCT02055664|Drug|Ropivacaine 0.2%|
281762|NCT02055664|Drug|Chlorure de sodium 0.9%|
281763|NCT02055651|Behavioral|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
281764|NCT02055638|Drug|SRX246|capsules
281765|NCT02055638|Drug|Placebo|
281766|NCT02055625|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
281767|NCT02055586|Other|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
281768|NCT02055586|Device|positron emission tomography|Undergo FLT-PET/MRI
281769|NCT02055586|Device|magnetic resonance imaging|Undergo FLT-PET/MRI
281770|NCT02055573|Other|Ready To Learn (RTL)|See arm description
281771|NCT02055573|Other|All Babies Cry (ABC)|See arm description
281772|NCT02055547|Drug|MK-8521|Single dose 100 mcg sc injection in a treatment period (Part 1)
281773|NCT02055547|Drug|MK-8521|Single dose 150 mcg sc injection in a treatment period (Part 1)
281774|NCT02055547|Drug|MK-8521|Single dose 300 mcg sc injection in a treatment period (Part 1)
281775|NCT02055547|Drug|MK-8521|Single dose 200 mcg sc injection in a treatment period (Part 1)
281776|NCT02055547|Drug|Mk-8521|Single dose 175 mcg sc injection in a treatment period (Part 1)
281777|NCT02055547|Drug|Placebo|Single dose placebo sc injection in a treatment period (Part 1)
281778|NCT02055547|Drug|MK-8521|50 mcg sc injection once each day for 5 days (Part 2)
281779|NCT02055547|Drug|MK-8521|74 mcg sc injection once each day for 5 days (Part 2)
281780|NCT02055547|Drug|MK-8521|100 mcg sc injection once each day for 5 days (Part 2)
281781|NCT02055547|Drug|MK-8521|125 mcg sc injection once each day for 5 days (Part 2)
281782|NCT02055547|Drug|MK-8521|150 mcg sc injection once each day for 5 days (Part 2)
281783|NCT02055547|Drug|MK-8521|72 mcg sc injection once each day for 7 days (Part 2)
281784|NCT02055547|Drug|MK-8521|125 mcg sc injection once each day for 7 days (Part 2)
281785|NCT02055547|Drug|Placebo|Placebo sc injection once each day for 10 days (Part 2)
281786|NCT02055547|Drug|Placebo|Placebo sc injection once each day for 14 days (Part 2)
281787|NCT02055547|Drug|MK-8521|Single low dose sc injection in a treatment period (Part 3)
281788|NCT02055547|Drug|MK-8521|Single high dose sc injection in a treatment period (Part 3)
281789|NCT02055547|Drug|Placebo|Single Placebo sc injection in a treatment period (Part 3)
281790|NCT02055534|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
281791|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
281792|NCT02055521|Procedure|Blood sample, biopsy|
281793|NCT02055508|Behavioral|Exercise Intervention|
281794|NCT02055508|Other|Care-Management-Phone-Calls|
281795|NCT02055482|Drug|Molidustat (BAY85-3934)|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
281796|NCT02055482|Biological|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
281797|NCT02055456|Drug|Nandrolone Decanoate|
281798|NCT02055443|Other|12-lead holter monitor application|"-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.~The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.~After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
281799|NCT02055430|Procedure|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
281800|NCT02055430|Procedure|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
281801|NCT02055430|Procedure|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
281802|NCT02055417|Behavioral|Personal Approaches to Treatment Choices for HIV|
281803|NCT02055417|Behavioral|Stress Reduction Skills Program|
281804|NCT02055404|Device|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
281805|NCT02055404|Device|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
281806|NCT02055391|Behavioral|Behavioral Weight Loss|Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
281807|NCT02055391|Behavioral|Enhanced Behavioral Weight Loss|Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
281808|NCT02055378|Drug|Atropine|topical 0.125% atropine eye drops
281809|NCT02055378|Device|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
281810|NCT02055365|Biological|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
281811|NCT02055352|Drug|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
281812|NCT02055352|Drug|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
281813|NCT02055352|Drug|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
281814|NCT02055352|Drug|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
281815|NCT02055339|Device|Fisher & Paykel heated humidified high flow nasal cannula|
281816|NCT02055339|Device|InfantFlow/RAM nasal continuous positive airway pressure|
281817|NCT02055326|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
281818|NCT02055326|Behavioral|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
282130|NCT02052791|Drug|nusinersen|Administered by intrathecal (IT) injection
282131|NCT02052778|Drug|TAS-120|
281819|NCT02055326|Behavioral|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
281820|NCT02055300|Drug|LY03005|
281821|NCT02055300|Drug|Placebo|
281822|NCT02055300|Other|Meal|
281823|NCT02055300|Drug|Pristiq|
281824|NCT02055287|Drug|LY03004|
281825|NCT02055274|Drug|LY03003|
281826|NCT02055274|Drug|Neupro|
281827|NCT02055261|Device|Low frequency DBS of the pedunculopontine nucleus|
281828|NCT02055196|Biological|carboxylesterase-expressing allogeneic neural stem cells|Given via intracerebral catheter
281829|NCT02055196|Drug|irinotecan hydrochloride|Given IV
281830|NCT02055196|Other|laboratory biomarker analysis|Correlative studies
281831|NCT02055183|Drug|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
281832|NCT02055170|Drug|finasteride 5mg oral daily|
281833|NCT02055157|Drug|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
281834|NCT02055131|Drug|aspirin|
281835|NCT02055118|Biological|idursulfase-IT|10mg
281836|NCT02055118|Other|No IT treatment|Standard of Care
281837|NCT02055105|Procedure|miRNA in Sepsis|miRNA in Sepsis
281838|NCT02055079|Drug|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
281839|NCT02055079|Drug|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
281840|NCT02055066|Drug|ARGX-111|
281841|NCT02055053|Drug|0.5% Bupivicaine|Local anesthetic
281842|NCT02055027|Other|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
281843|NCT02055014|Drug|Liraglutide|
281844|NCT02055014|Device|Duodenal-jejunal bypass liner - Endobarrier device|
281845|NCT02054988|Other|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San Diego, California]) was measured at baseline and after 10-days of coffee intake."
281846|NCT02054988|Other|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
281847|NCT02054975|Drug|Vitamin D2 + vitamin D3|higher dose vitamin D
281848|NCT02054975|Drug|Vitamin D3|lower dose vitamin D
281849|NCT02054949|Drug|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
281850|NCT02054936|Drug|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
281851|NCT02054936|Drug|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
281852|NCT02054923|Procedure|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
281853|NCT02054923|Behavioral|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
281854|NCT02054910|Procedure|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
281855|NCT02054910|Procedure|Sham|Patients will not receive celiac plexus block during endoscopy.
281856|NCT02054897|Drug|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
281857|NCT02054897|Drug|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
281858|NCT02054884|Drug|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
281859|NCT02054884|Drug|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m^2 on days 1, 8, 15 of each 28 day cycle.~Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
281860|NCT02054871|Procedure|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
281861|NCT02054858|Procedure|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
281955|NCT02054247|Device|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
281862|NCT02054845|Behavioral|Body awareness therapy|"Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.~Specifically the following techniques will be applied:~Body scan~Psychoeducation~Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)~Body Awareness Training~Exposure training (imaginary exposure to induce response fluctuations)~Training in cueing techniques to overcome problems with initiation and freezing~Visual Feedback training~Relaxation techniques"
281863|NCT02054845|Other|Physical therapy|Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
281864|NCT02054832|Dietary Supplement|Glycosade|
281865|NCT02054819|Other|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
281866|NCT02054819|Other|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
281867|NCT02054806|Biological|Pembrolizumab|IV infusion
281868|NCT02054793|Drug|Itraconazole|100 mg 200 mg 300 mg
281869|NCT02054793|Drug|Orteronel|300 mg
281870|NCT02054780|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
281871|NCT02054780|Behavioral|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
281872|NCT02054767|Drug|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
281873|NCT02054754|Drug|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
281874|NCT02054754|Drug|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
281875|NCT02054754|Drug|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
281876|NCT02054754|Drug|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
281877|NCT02054754|Drug|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
281878|NCT02054754|Drug|Placebo|
281879|NCT02054741|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
281880|NCT02054741|Other|Quality-of-Life Assessment|Ancillary studies
281881|NCT02054741|Other|Survey Administration|Ancillary studies
281882|NCT02054728|Other|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).~The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
281883|NCT02054715|Behavioral|print educational intervention|print educational intervention
281884|NCT02054715|Behavioral|multimedia psychoeducational intervention|multimedia psychoeducational intervention
281885|NCT02054702|Drug|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
281886|NCT02054702|Drug|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
281887|NCT02054689|Radiation|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
281888|NCT02054676|Radiation|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):~Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;~Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).~All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
281905|NCT02054585|Other|NaCl 0.9%|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
282257|NCT02051764|Drug|18F-AV-1451|
281889|NCT02054676|Procedure|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.~Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).~The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:~implant drill slippage deeper than planned;~implant threads coverage;~etc."
281890|NCT02054676|Device|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.~Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.~Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.~Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).~Bone and soft tissue augmentation are made if necessary after dental implant placement."
281891|NCT02054676|Radiation|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.~Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).~Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
281892|NCT02054676|Drug|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
281893|NCT02054676|Procedure|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.~The time after surgery is case depending before provisional and final crown placement.~Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.~Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
281894|NCT02054663|Drug|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
281895|NCT02054650|Other|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
281896|NCT02054650|Other|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
281897|NCT02054637|Drug|Lanreotide|
281898|NCT02054624|Behavioral|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by group telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months."
281899|NCT02054624|Behavioral|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by email.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 you will receive you will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help you maintain lost weight."
281900|NCT02054624|Behavioral|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.~Phase 1 will be 4 months of weight loss treatment~Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.~The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.~During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months."
281901|NCT02054624|Behavioral|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test
281902|NCT02054611|Other|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
281903|NCT02054611|Other|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
281904|NCT02054598|Behavioral|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
281954|NCT02054247|Device|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
282258|NCT02051764|Drug|Florbetapir F 18|
281906|NCT02054585|Other|NaCl 0.9 +5% dextrose|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.~Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
281907|NCT02054572|Drug|[¹⁴C]Etelcalcetide|750 nCi of [¹⁴C]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
281908|NCT02054559|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
281909|NCT02054559|Radiation|Radiotherapy|
281910|NCT02054520|Drug|HyperAcute®-Melanoma (HAM) Immunotherapy|
281911|NCT02054520|Drug|Ipilimumab|
281912|NCT02054520|Drug|Pembrolizumab|
281913|NCT02054520|Drug|Nivolumab|
281914|NCT02054507|Behavioral|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
281915|NCT02054481|Drug|BI 655066|Medium dose
281916|NCT02054481|Drug|BI 655066|High dose
281917|NCT02054481|Drug|Ustekinumab|
281918|NCT02054481|Drug|BI 655066|Low dose
281919|NCT02054468|Drug|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
281920|NCT02054468|Drug|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
281921|NCT02054468|Drug|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
281922|NCT02054468|Drug|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
281923|NCT02054468|Drug|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
281924|NCT02054468|Drug|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
281925|NCT02054468|Drug|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
281926|NCT02054468|Drug|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
281927|NCT02054468|Drug|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
281928|NCT02054455|Dietary Supplement|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
281929|NCT02054455|Dietary Supplement|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
281930|NCT02054442|Drug|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
281931|NCT02054442|Drug|Methotrexate|
281932|NCT02054429|Drug|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
281933|NCT02054416|Device|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
281934|NCT02054377|Other|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.~It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.~A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
281935|NCT02054364|Behavioral|FBT and CRT|
281936|NCT02054364|Behavioral|FBT and art therapy|
281937|NCT02054351|Drug|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
281938|NCT02054338|Drug|Vinflunine+Gemcitabine|Vinflunine 320 mg/m² IV on day 1 and.Gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
281939|NCT02054338|Drug|Paclitaxel+Gemcitabine|paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
281940|NCT02054325|Drug|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
281941|NCT02054325|Drug|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
281942|NCT02054312|Behavioral|Family Based Interpersonal Psychotherapy (FB-IPT)|
281943|NCT02054312|Behavioral|Client Centered Therapy (CCT)|
281944|NCT02054299|Drug|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
281945|NCT02054299|Drug|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
281946|NCT02054299|Drug|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
281947|NCT02054299|Drug|Drug application Proguanil|Proguanil: 200mg, single oral application
281948|NCT02054299|Drug|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
281949|NCT02054299|Drug|Drug application Thiamine|Thiamine: 200mg, single oral application
281950|NCT02054286|Biological|THV01-1|Intramuscular injection of THV01-1 (week 0)
281951|NCT02054286|Biological|THV01-2|Intramuscular injection of THV01-2 (week 8)
281952|NCT02054286|Biological|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
281953|NCT02054260|Drug|Surgicel|
282526|NCT02049515|Drug|IPI-145 (duvelisib)|PI3K Inhibitor
282527|NCT02049515|Drug|Ofatumumab|
281956|NCT02054247|Device|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
281957|NCT02054221|Procedure|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
281958|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
281959|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
281960|NCT02054208|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals~High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
281961|NCT02054208|Other|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
281962|NCT02054195|Behavioral|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
281963|NCT02054195|Behavioral|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
281964|NCT02054182|Drug|Vitamin D|Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
281965|NCT02054156|Drug|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
281966|NCT02054156|Drug|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
281967|NCT02054156|Drug|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
281968|NCT02054143|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
281969|NCT02054143|Drug|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
281970|NCT02054130|Drug|Placebo|Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
281971|NCT02054130|Drug|MEDI9929 70 mg|Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
281972|NCT02054130|Drug|MEDI9929 210 mg|Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
281973|NCT02054130|Drug|MEDI9929 280 mg|Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
281974|NCT02054117|Other|Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
281975|NCT02054104|Biological|H1299 Lysate Vaccine|H1299 cell lysate vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and NED.
281976|NCT02054104|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
281977|NCT02054104|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
281978|NCT02054091|Dietary Supplement|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
281979|NCT02054078|Drug|Bevacizumab|Bevacizumab200mg by intrapleural administration
281980|NCT02054078|Drug|Pulvis talci|Pulvis talci 4g by intrapleural administration
281981|NCT02054065|Other|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
281982|NCT02054052|Drug|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
281983|NCT02054039|Device|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
281984|NCT02054039|Device|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
281985|NCT02054026|Behavioral|Reducing the Risk|
281986|NCT02054013|Procedure|Prostatic artery embolization|
281987|NCT02054013|Procedure|monopolar transurethral prostatectomy|
281988|NCT02054000|Drug|Tirofiban|Intracoronary administering of Tirofiban
281989|NCT02054000|Other|Placebo|Intracoronary serum physiologic
281990|NCT02053987|Other|Intensive rehabilitation in the home.|
281991|NCT02053974|Drug|Spironolactone|Spironolactone
281992|NCT02053974|Other|Placebo|Placebo
281993|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
281994|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
281995|NCT02053948|Procedure|Pursestring Wound Closure|
281996|NCT02053948|Procedure|Gunsight Skin Incision and Closure Technique|
281997|NCT02053935|Drug|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
281998|NCT02053922|Drug|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
281999|NCT02053922|Drug|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . [Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
282000|NCT02053922|Drug|Misoprostol|Misoprostol (200 mcg Tablet) [Misotac, Sigma Pharmaceutical Industries, SAE, Egypt] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
282001|NCT02053909|Drug|Aspirin|
282002|NCT02053909|Drug|Ticagrelor|
282003|NCT02053883|Drug|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
282004|NCT02053883|Drug|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
282005|NCT02053870|Other|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
282006|NCT02053870|Drug|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
282007|NCT02053857|Dietary Supplement|RUTF|
282008|NCT02053857|Dietary Supplement|RUTF-P|
282009|NCT02053857|Drug|Amoxicillin|
282010|NCT02053844|Other|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
282011|NCT02053844|Other|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
282012|NCT02053818|Drug|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
282013|NCT02053818|Drug|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
282014|NCT02053805|Other|PSA|PSA. Serum & plasma will be stored for future investigations
282015|NCT02053805|Other|IPSS questionnaire|the validated International Prostate Symptom Score
282016|NCT02053805|Other|DRE (Digital Rectal Examination )|physical examination for the prostate gland
282017|NCT02053805|Other|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
282018|NCT02053805|Procedure|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
282019|NCT02053805|Procedure|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
282020|NCT02053792|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
282021|NCT02053779|Drug|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
282022|NCT02053766|Drug|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
282023|NCT02053766|Drug|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
282024|NCT02053766|Drug|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
282025|NCT02053753|Drug|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
282026|NCT02053753|Drug|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
282027|NCT02053740|Drug|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
282028|NCT02053740|Drug|Routine western medicine|
282029|NCT02053727|Drug|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
282030|NCT02053727|Drug|Placebo|
282031|NCT02053714|Behavioral|Diabetes self-management and education|
282032|NCT02053688|Device|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
282033|NCT02053688|Device|Toric Soft Contact Lenses|astigmatism correction using toric optics
282034|NCT02053675|Drug|Vasopressin infusion|
282035|NCT02053662|Procedure|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
282036|NCT02053649|Behavioral|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
282037|NCT02053649|Other|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
282038|NCT02053636|Drug|lucitanib|
282039|NCT02053610|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
282040|NCT02053610|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
282041|NCT02053610|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
282042|NCT02053597|Drug|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
282598|NCT02048943|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
282043|NCT02053597|Drug|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
282044|NCT02053584|Device|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
282045|NCT02053584|Device|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
282046|NCT02053571|Procedure|TIPS with 3D Overlay|
282047|NCT02053558|Drug|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
282048|NCT02053558|Drug|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
282049|NCT02053545|Drug|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF~Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF~Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
282050|NCT02053532|Procedure|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
282051|NCT02053519|Drug|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
282052|NCT02053519|Drug|Mygliol Oil|Matched placebo comparator
282053|NCT02053506|Dietary Supplement|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
282054|NCT02053506|Dietary Supplement|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
282055|NCT02053506|Dietary Supplement|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
282056|NCT02053493|Drug|Isosorbide Mononitrate|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
282057|NCT02053493|Drug|Placebo|"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
282058|NCT02053467|Other|Champlain BASE eConsult Service|After undergoing registration, which includes orientation and brief training on the use of the service, physicians randomized to intervention arm will be able to submit patient-specific clinical questions to specialists through a secure, web-based application. Specialists are asked to respond within 7 days and, for each eConsult, are able to: (1) provide a recommendation, (2) request more information, or (3) recommend a face-to-face referral. The communication between PCPs and specialists is iterative and the discussion can occur back and forth until, ultimately, the PCP closes the case.
282059|NCT02053454|Drug|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
282060|NCT02053454|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
282061|NCT02053428|Procedure|percutaneous image-guided gastrostomy|
282062|NCT02053415|Dietary Supplement|Krill oil low dose|3 capsules krill oil per day
282063|NCT02053415|Dietary Supplement|Krill oil high dose|9 capsules krill oil per day
282064|NCT02053402|Drug|Vitamin D|Vitamin D daily for six months
282065|NCT02053389|Behavioral|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
282066|NCT02053389|Behavioral|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
282067|NCT02053376|Drug|Regorafenib|regorafenib (120 mg) (160 mg for second and subsequent treatment cycles)orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
282068|NCT02053363|Drug|Tranexamic Acid (Cyklokapron)|
282069|NCT02053350|Drug|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
282070|NCT02053337|Device|Self adhesive foam dressing|Self adhesive foam dressing
282071|NCT02053324|Combination Product|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
282072|NCT02053311|Drug|Orteronel|300mg orteronel
282073|NCT02053311|Drug|Placebo|Placebo
282074|NCT02053298|Drug|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
282075|NCT02053272|Drug|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
282076|NCT02053272|Drug|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
282077|NCT02053259|Behavioral|Adaptive Goals|
282078|NCT02053259|Behavioral|Reinforcement|
282079|NCT02053259|Behavioral|Static Goals|
282080|NCT02053246|Drug|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
282127|NCT02052830|Behavioral|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
282128|NCT02052817|Device|Optimal Medical Therapy Debridement + Toad Brace|
282081|NCT02053233|Device|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.~The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
282082|NCT02053233|Device|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
282083|NCT02053220|Biological|Colo-Ad1|Oncolytic virus
282084|NCT02053207|Behavioral|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
282085|NCT02053194|Behavioral|Pharmacist-led educational intervention|1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
282086|NCT02053181|Drug|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
282087|NCT02053168|Device|Resorbable Mesh|Phasix Mesh
282088|NCT02053155|Behavioral|Computer based patient education|
282089|NCT02053142|Drug|Acyclovir|Single dose of acyclovir 200mg was given for pk study
282090|NCT02053142|Drug|Placebo|
282091|NCT02053129|Other|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
282092|NCT02053129|Other|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
282093|NCT02053116|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
282094|NCT02053116|Drug|Placebo|Tablet, 0 mg, twice daily, 2 weeks
282095|NCT02053103|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
282096|NCT02053103|Drug|Placebo|Tablet, 0 mg, twice daily, 6 weeks
282097|NCT02053090|Behavioral|Group Education and Stretching|
282098|NCT02053090|Procedure|Group Acupuncture|
282099|NCT02053064|Genetic|SAF-301|
282100|NCT02053051|Device|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
282101|NCT02053051|Drug|Novorapid|Multiple daily injections(MDI) of insulin
282102|NCT02053038|Device|iFR|Treatment guided by instantaneous wave-free ratio
282103|NCT02053038|Device|FFR|Treatment guided by Fractional Flow Reserve
282104|NCT02053025|Dietary Supplement|mycoprotein|
282105|NCT02053025|Dietary Supplement|control protein|
282106|NCT02053012|Device|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
282107|NCT02052999|Drug|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
282108|NCT02052999|Other|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
282109|NCT02052999|Drug|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
282110|NCT02052986|Other|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
282111|NCT02052973|Other|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
282112|NCT02052960|Drug|Tomuzotuximab|720 mg i.v. weekly
282113|NCT02052960|Drug|Cetuximab|250 mg/sqm BSA i.v. weekly
282114|NCT02052960|Drug|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
282115|NCT02052947|Radiation|SPECT-DaTscan|"Measurement of fixation of DaTscan® in the caudate and lenticular nucleus~LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted)."
282116|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
282117|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
282118|NCT02052921|Procedure|Rectal resection|Surgical rectal resection
282119|NCT02052921|Other|Observation|
282120|NCT02052908|Other|Laboratory Biomarker Analysis|Correlative studies
282121|NCT02052908|Drug|Naproxen|Given PO
282122|NCT02052908|Other|Placebo|Given PO
282123|NCT02052882|Biological|romiplostim|
282124|NCT02052869|Procedure|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
282125|NCT02052843|Behavioral|Steps to Success|
282126|NCT02052843|Behavioral|Traditional Healthy Families|
282132|NCT02052765|Device|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
282133|NCT02052752|Drug|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
282134|NCT02052752|Drug|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
282135|NCT02052752|Drug|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
282136|NCT02052739|Drug|SAGE-547|Intravenous
282137|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
282138|NCT02052726|Biological|Placebo|Placebo administered at Month 0, 1, and 3.
282139|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
282140|NCT02052726|Biological|placebo|Placebo administered at Day 1, 8, and 30.
282141|NCT02052713|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
282142|NCT02052713|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
282143|NCT02052687|Drug|LFX453 H1|LFX453 high dose cream 1
282144|NCT02052687|Drug|LFX453 L1|LFX453 low dose cream 1
282145|NCT02052687|Drug|LFX453 H2|LFX453 high dose cream 2
282146|NCT02052687|Drug|LFX453 L2|LFX453 low dose cream 2
282147|NCT02052687|Drug|Imiquimod|Imiquimod cream
282148|NCT02052687|Drug|Placebo 1|Placebo cream 1
282149|NCT02052687|Drug|Placebo 2|Placebo cream 2
282150|NCT02052674|Device|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
282151|NCT02052674|Device|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
282152|NCT02052661|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
282153|NCT02052648|Drug|Indoximod|
282154|NCT02052648|Drug|Temozolomide|
282155|NCT02052648|Drug|Bevacizumab|
282156|NCT02052648|Radiation|Stereotactic Radiation|
282157|NCT02052635|Drug|ticagrelor|Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
282158|NCT02052635|Drug|clopidogrel|Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
282159|NCT02052609|Drug|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
282160|NCT02052609|Drug|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
282161|NCT02052596|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
282162|NCT02052596|Biological|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
282163|NCT02052583|Procedure|therapeutic hypothermia at 32 ° C|
282164|NCT02052583|Procedure|therapeutic hypothermia at 34 ° C|
282165|NCT02052557|Drug|Bupivacaine|30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
282166|NCT02052557|Drug|Bupivacaine liposome suspension|30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
282167|NCT02052531|Drug|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
282168|NCT02052531|Other|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
282169|NCT02052518|Behavioral|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
282170|NCT02052505|Procedure|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
282171|NCT02052492|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
282172|NCT02052479|Other|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
282173|NCT02052440|Drug|Baclofen|Treatment arm: baclofen 10mg tid
282174|NCT02052440|Drug|Placebo|Sugar pill by mouth three times daily
282175|NCT02052427|Device|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
282176|NCT02052427|Device|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (<1mL) of autologous blood
282177|NCT02052414|Drug|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.~In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
282178|NCT02052401|Other|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
282179|NCT02052388|Drug|Daptomycin|Active Comparator
282180|NCT02052388|Drug|Brilacidin|Experimental Drug
282181|NCT02052375|Drug|ASP2408|subcutaneous injection
282182|NCT02052375|Drug|Placebo|subcutaneous injection
282183|NCT02052362|Drug|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
282184|NCT02052349|Drug|ABT-333|Dose of ABT-333
282185|NCT02052336|Drug|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
282186|NCT02052336|Drug|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
282187|NCT02052336|Drug|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
282188|NCT02052323|Drug|Artesunate/mefloquine (AS/MQ)|"artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours~mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours~primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
282189|NCT02052310|Drug|FG-4592 (roxadustat)|Drug will be dosed orally three times a week.
282190|NCT02052310|Drug|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
282191|NCT02052297|Other|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
282192|NCT02052284|Other|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
282193|NCT02052271|Device|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
282194|NCT02052258|Drug|Oxytocin|
282195|NCT02052232|Other|Experimental protein powder sachet|mixed with 8 oz. water
282196|NCT02052232|Other|Control protein powder sachet|mixed with 8 oz. water
282197|NCT02052219|Drug|Blisibimod|Blisibimod administered subcutaneously
282198|NCT02052219|Drug|Placebo|Placebo administered subcutaneously
282199|NCT02052206|Procedure|Shoulder replacement surgery|
282200|NCT02052193|Drug|Dabrafenib|Measurement of toxicity related to UV exposure
282201|NCT02052193|Drug|Vemurafenib|Measurement of toxicity related to UV exposure
282202|NCT02052180|Drug|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
282203|NCT02052180|Drug|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
282204|NCT02052167|Device|methotrexate prefilled pen|
282205|NCT02052154|Biological|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
282206|NCT02052141|Biological|CINRYZE 500|500 Units of CINRYZE administered by IV injection
282207|NCT02052141|Biological|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
282208|NCT02052128|Drug|onapristone|
282209|NCT02052115|Behavioral|12 month exercise and weight loss intervention|
282210|NCT02052102|Radiation|Radiation therapy|
282211|NCT02052089|Procedure|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
282212|NCT02052089|Procedure|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (<0.2 mJ/mm2) or high energy (>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
282213|NCT02052089|Procedure|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
282214|NCT02052089|Procedure|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
282215|NCT02052076|Behavioral|Meal pattern|
282216|NCT02052063|Device|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
282217|NCT02052063|Device|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
282218|NCT02052050|Other|core stability|
282471|NCT02049957|Drug|MLN0128|Phase 1B: 2, 3, 4, or 5 mg once daily; Phase 2: dose determined after Phase 1B
282219|NCT02052037|Dietary Supplement|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
282220|NCT02052037|Dietary Supplement|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.~During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks."
282221|NCT02052024|Drug|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
282222|NCT02052024|Drug|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
282223|NCT02052011|Drug|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
282224|NCT02052011|Drug|Placebo|
282225|NCT02051985|Other|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).~Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).~Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
282226|NCT02051985|Other|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).~Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).~In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
282227|NCT02051972|Device|Implanted with a Nanostim leadless pacemaker system|
282228|NCT02051959|Device|Anodal stimulation of M1 + sham|8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
282229|NCT02051959|Device|Sham + Anodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
282230|NCT02051959|Device|Cathodal stimulation of M1 + sham|8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
282231|NCT02051959|Device|Sham + Cathodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
282232|NCT02051946|Device|Retroject Device|
282233|NCT02051946|Drug|ethacrynic acid injection|
282234|NCT02051946|Drug|balanced salt solution|
282235|NCT02051933|Drug|Botox|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
282236|NCT02051933|Drug|Placebo|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).~45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
282237|NCT02051907|Device|KAM1403 Gel|
282238|NCT02051907|Device|aloevera gel|
282239|NCT02051894|Drug|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.~If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
282240|NCT02051881|Other|Taking intestinal biopsies|
282241|NCT02051868|Drug|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
282242|NCT02051868|Drug|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
282243|NCT02051868|Drug|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
282244|NCT02051868|Drug|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
282245|NCT02051842|Drug|Metadoxine|
282246|NCT02051829|Other|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
282247|NCT02051816|Device|Video Laryngoscopy|
282248|NCT02051816|Device|Apneic Oxygenation|
282249|NCT02051816|Device|Direct Laryngoscopy|
282250|NCT02051816|Device|No Apneic Oxygenation|
282251|NCT02051803|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
282252|NCT02051803|Behavioral|Health Education (HE)|
282253|NCT02051790|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
282254|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 1|Containing macro and micronutrients
282255|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 2|Containing macro and micronutrients
282256|NCT02051777|Dietary Supplement|Dietary Advice|
282259|NCT02051751|Drug|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
282260|NCT02051751|Drug|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
282261|NCT02051738|Drug|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
282262|NCT02051738|Drug|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
282263|NCT02051725|Other|Active life-style intervention|
282264|NCT02051712|Behavioral|exercise training|individualized exercise training
282265|NCT02051712|Behavioral|Adherence measures|Measures to increase adherence to exercise training
282266|NCT02051699|Procedure|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
282267|NCT02051686|Drug|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
282268|NCT02051686|Drug|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
282269|NCT02051673|Biological|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
282270|NCT02051660|Behavioral|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
282271|NCT02051660|Behavioral|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
282272|NCT02051634|Drug|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
282273|NCT02051634|Drug|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
282274|NCT02051621|Drug|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
282275|NCT02051621|Procedure|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
282276|NCT02051621|Procedure|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
282277|NCT02051608|Drug|Gantenerumab|Gantenerumab will be administered as SC injection Q4W
282278|NCT02051608|Drug|Placebo|Placebo will be administered as SC injection Q4W
282279|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
282280|NCT02051582|Procedure|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
282281|NCT02051582|Procedure|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.~A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.~Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
282282|NCT02051569|Dietary Supplement|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
282283|NCT02051556|Behavioral|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
282284|NCT02051556|Behavioral|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
282285|NCT02051556|Behavioral|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
282286|NCT02051543|Behavioral|Brief Behavioral Treatment of Insomnia -Military Version|
282287|NCT02051530|Dietary Supplement|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
282472|NCT02049957|Drug|Fulvestrant|Phase 1B: 500 mg monthly; Phase 2: 250 or 500 mg monthly
282473|NCT02049957|Drug|Exemestane|25 mg once daily
282288|NCT02051504|Behavioral|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
282289|NCT02051504|Dietary Supplement|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
282290|NCT02051504|Procedure|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
282291|NCT02051504|Procedure|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
282292|NCT02051504|Procedure|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
282293|NCT02051504|Procedure|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
282294|NCT02051504|Other|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
282295|NCT02051491|Device|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
282296|NCT02051491|Device|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
282297|NCT02051478|Other|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
282298|NCT02051478|Other|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
282299|NCT02051465|Device|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
282300|NCT02051465|Device|Removal without overtube|Endoscopic removal of polyp without overtube
282301|NCT02051452|Drug|Methylphenidate|
282302|NCT02051452|Other|Saline|
282303|NCT02051439|Procedure|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
282304|NCT02051426|Other|D-serine|single P.O. administration of D-serine (2.1g)
282305|NCT02051426|Other|Placebo|single P.O. administration of Placebo
282306|NCT02051413|Drug|Venlafaxine extended release|antidepressant drug
282307|NCT02051400|Device|the McGrath® MAC video laryngoscope|
282308|NCT02051400|Device|the GlidesScope® Ranger video laryngoscope|
282309|NCT02051400|Device|the Macintosh laryngoscope|
282310|NCT02051387|Drug|Cannabidiol CR|
282311|NCT02051387|Drug|Cannabidiol|
282312|NCT02051387|Drug|Amisulpride|
282313|NCT02051387|Drug|Olanzapine|
282314|NCT02051387|Drug|Quetiapine|
282315|NCT02051387|Drug|Risperidone|
282316|NCT02051387|Drug|Placebo|
282317|NCT02051374|Procedure|Decompression alone|
282318|NCT02051374|Procedure|Decompression followed by fusion with instrumentation|
282319|NCT02051348|Biological|Pylopass|Pylopass
282320|NCT02051348|Biological|Placebo|Placebo
282321|NCT02051335|Drug|Roflumilast|Roflumilast tablets
282322|NCT02051335|Drug|Roflumilast placebo|Roflumilast placebo-matching tablets
282323|NCT02051335|Drug|Donepezil|Donepezil overencapsulated tablets
282324|NCT02051335|Drug|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
282325|NCT02051335|Drug|Scopolamine|Scopolamine subcutaneous injection
282326|NCT02051322|Device|Jet Nebulizer|
282327|NCT02051322|Device|Trunk Mask Nebulizer|
282328|NCT02051322|Device|Aerobika Nebulizer|
282329|NCT02051309|Drug|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
282330|NCT02051309|Drug|Placebo|
282331|NCT02051296|Drug|Minocycline|RCT blinded placebo trial
282332|NCT02051296|Drug|placebo|RCT blinded placebo trial
282333|NCT02051283|Other|RFA|RFA
282334|NCT02051270|Other|Descriptive study|More than 65 years old elders
282335|NCT02051257|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
282336|NCT02051257|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
282337|NCT02051257|Other|Laboratory Biomarker Analysis|Correlative studies
282338|NCT02051231|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
282339|NCT02051218|Drug|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
282340|NCT02051218|Drug|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
282341|NCT02051192|Behavioral|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
282474|NCT02049944|Drug|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
282475|NCT02049931|Device|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
282479|NCT02049905|Drug|Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)|
282342|NCT02051192|Other|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
282343|NCT02051153|Drug|Modafinil|Modafinil (2-[(Diphenylmethyl) sulfinyl]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg & Carter, 2008).
282344|NCT02051153|Drug|Placebo|
282345|NCT02051140|Dietary Supplement|Freeze-dried Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
282346|NCT02051140|Dietary Supplement|Strawberry Placebo|12g blue, strawberry-flavored powder, twice daily with water, for 90 days
282347|NCT02051127|Other|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
282348|NCT02051101|Other|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
282349|NCT02051088|Procedure|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
282350|NCT02051088|Procedure|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
282351|NCT02051088|Device|drug-coated balloons and/or drug-eluting stents|
282352|NCT02051075|Biological|PXN sperm treatment|immotile sperm activation with PXN
282353|NCT02051075|Biological|Sperm activation with PXN and oocyte activation|
282354|NCT02051062|Biological|One 5 mL of blood will be collected.|The blood sample should be collected no later than 24 hours post BAT® administration. To ensure sufficient detectable circulating levels of BAT® for pharmacokinetic analysis the target window of time for collection should be between 6 and 24 hours post-BAT® administration.
282355|NCT02051036|Procedure|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
282356|NCT02051023|Drug|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
282357|NCT02051023|Drug|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
282358|NCT02050971|Biological|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
282359|NCT02050971|Biological|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
282360|NCT02050958|Drug|OXP001|
282361|NCT02050958|Drug|Ibuprofen|
282362|NCT02050945|Behavioral|Resistance training|
282363|NCT02050945|Behavioral|Endurance training|
282364|NCT02050932|Dietary Supplement|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
282365|NCT02050919|Drug|Epirubicin Hydrochloride|Given IV
282366|NCT02050919|Radiation|External Beam Radiation Therapy|Undergo EBRT
282367|NCT02050919|Drug|Ifosfamide|Given IV
282368|NCT02050919|Other|Laboratory Biomarker Analysis|Correlative studies
282369|NCT02050919|Drug|Sorafenib Tosylate|Given PO
282370|NCT02050919|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
282371|NCT02050906|Behavioral|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
282372|NCT02050906|Behavioral|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
282373|NCT02050906|Other|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
282374|NCT02050906|Behavioral|telephone based counseling|Undergo behavioral activity and nutritional counseling
282375|NCT02050906|Procedure|quality-of-life assessment|Ancillary studies
282376|NCT02050906|Other|questionnaire administration|Ancillary studies
282377|NCT02050893|Drug|sedatives(Midazolam and Propofol)|
282378|NCT02050841|Biological|octaplas|Octaplas S/D Plasma
282379|NCT02050828|Drug|AKB-9778|
282380|NCT02050828|Drug|ranibizumab|
282381|NCT02050828|Drug|Placebo|
282382|NCT02050828|Drug|Sham|
282383|NCT02050815|Drug|MEK162|
282384|NCT02050802|Drug|Moxifloxacin 400 mg|
282385|NCT02050802|Drug|Macitentan 10 mg|
282386|NCT02050802|Drug|Macitentan 30 mg|
282387|NCT02050802|Other|Placebo|
282388|NCT02050789|Behavioral|flexible duty hours|If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
282389|NCT02050776|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
282476|NCT02049931|Device|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
282477|NCT02049931|Device|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
282390|NCT02050763|Behavioral|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau & Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska & DiClemente, 1983; Prochaska & Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.~We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
282391|NCT02050724|Drug|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
282392|NCT02050724|Device|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
282393|NCT02050724|Device|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
282394|NCT02050711|Behavioral|Pulmonary rehabilitation|
282395|NCT02050711|Other|Usual care|
282396|NCT02050698|Procedure|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
282397|NCT02050698|Procedure|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
282398|NCT02050685|Other|All patients incoming in the sleep study centre for a PSG|All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
282399|NCT02050672|Dietary Supplement|Myo-inositol|
282400|NCT02050672|Other|untreated|
282401|NCT02050646|Other|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
282402|NCT02050646|Other|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
282403|NCT02050607|Other|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
282404|NCT02050594|Drug|Ipilimumab|
282405|NCT02050555|Dietary Supplement|Placebo|
282406|NCT02050555|Dietary Supplement|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
282407|NCT02050542|Procedure|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
282408|NCT02050542|Procedure|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
282409|NCT02050529|Drug|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
282410|NCT02050529|Drug|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
282411|NCT02050516|Other|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
282412|NCT02050477|Procedure|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
282413|NCT02050451|Dietary Supplement|Ensure Plus®|
282414|NCT02050451|Dietary Supplement|Multivitamin|
282415|NCT02050438|Procedure|Total Knee Arthroplasty|
282416|NCT02050425|Device|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
282417|NCT02050425|Device|CPAP|Patients continue therapeutic CPAP therapy
282418|NCT02050412|Other|Cat fur scratch test|
282419|NCT02050399|Other|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
282420|NCT02050386|Other|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
282421|NCT02050386|Other|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
282422|NCT02050373|Radiation|Low-Level laser|
282423|NCT02050360|Drug|Sildenafil 40 mg|
282424|NCT02050360|Drug|Sildenafil 80 mg|
282425|NCT02050360|Drug|Placebo|
282426|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:~Dose Level 1: 5 ×10^5 cells/kg~Dose Level 2: 1×10^6 cells/kg~Dose Level 3: 5×10^6 cells/kg"
282427|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:~Dose Level one: 1x10^5 cells/kg~Dose Level 2: 5x10^5 cells/kg~Dose Level 3: 1x10^6 cells/kg"
282428|NCT02050334|Drug|CC100|CC100 reconstituted in diluent
282429|NCT02050334|Drug|Placebo|Diluent. Amount to match CC100 dose.
282430|NCT02050321|Drug|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
282431|NCT02050321|Drug|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
282478|NCT02049905|Drug|Aldoxorubicin|
282480|NCT02049892|Other|Metal Ion Levels|
282432|NCT02050308|Other|Internet-All Nations Breath of Life (I-ANBL)|"Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session~Weekly procedures will follow the same format as for the first session"
282433|NCT02050308|Other|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
282434|NCT02050308|Drug|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
282435|NCT02050295|Procedure|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
282436|NCT02050295|Procedure|Sham washout|Infusion of saline to maintain catheter patency.
282437|NCT02050295|Drug|Saline|
282438|NCT02050282|Other|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
282439|NCT02050269|Drug|Iohexol|Iohexol, 300 mg/mL
282440|NCT02050256|Other|continuing medical education and electronic decision support|
282441|NCT02050256|Other|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
282442|NCT02050243|Drug|5ALA|20mg/kg of oral suspension of 5ALA
282443|NCT02050230|Biological|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
282444|NCT02050217|Procedure|Neurally Adjusted Ventilatory Assist|
282445|NCT02050204|Behavioral|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
282446|NCT02050191|Behavioral|www.princetonlivingwell.com|
282447|NCT02050178|Drug|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
282448|NCT02050165|Dietary Supplement|KIND Bars|Consumption of KIND Bars for 12 weeks
282449|NCT02050165|Dietary Supplement|Typical American Snack|Consumption of typical American snacks for 12 weeks
282450|NCT02050152|Behavioral|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
282451|NCT02050152|Drug|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
282452|NCT02050139|Dietary Supplement|L-cysteine|
282453|NCT02050139|Other|Placebo|
282454|NCT02050126|Device|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
282455|NCT02050113|Device|Custom Made Fenestrated or Branched Stent Graft|The surgeon will place a custom made graft, t-Branch device or modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. This surgery is done through small incisions in the groin.
282456|NCT02050087|Device|Simple sling.|
282457|NCT02050087|Device|Neutral brace|
282458|NCT02050074|Drug|Colesevelam|
282459|NCT02050074|Drug|Metformin|
282460|NCT02050074|Other|Placebo|
282461|NCT02050061|Other|compression stocking|study the impact of compression stocking
282462|NCT02050048|Other|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:~initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour~LR fluid infusion during the procedure at 5 cc/kg/hr~Post-procedure bolus of 20 cc/kg over 90 minutes"
282463|NCT02050035|Other|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
282464|NCT02050009|Drug|metformin hydrochloride|Given PO
282465|NCT02050009|Drug|carboplatin|Given IV
282466|NCT02050009|Drug|paclitaxel|Given IV
282467|NCT02050009|Other|laboratory biomarker analysis|Correlative studies
282468|NCT02049983|Device|Use of Levita Magnetics Grasper|
282469|NCT02049970|Drug|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
282470|NCT02049970|Drug|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
282481|NCT02049879|Drug|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
282482|NCT02049866|Drug|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
282483|NCT02049853|Device|"NTproBNP measurement with point of care device Cobash232 in the POCT group"|
282484|NCT02049840|Device|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
282485|NCT02049827|Other|participation in the study|
282486|NCT02049814|Drug|Metformin|Metformin tablets
282487|NCT02049814|Drug|Voglibose|Voglibose tablets
282488|NCT02049814|Drug|Acarbose|Acarbose tablets
282489|NCT02049801|Drug|MEK inhibitor MEK162|Given PO
282490|NCT02049801|Drug|idarubicin|Given IV
282491|NCT02049801|Drug|cytarabine|Given IV
282492|NCT02049801|Other|pharmacological study|Correlative studies
282493|NCT02049801|Other|laboratory biomarker analysis|Correlative studies
282494|NCT02049788|Behavioral|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
282495|NCT02049788|Behavioral|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
282496|NCT02049775|Procedure|NBI|
282497|NCT02049762|Drug|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
282498|NCT02049749|Behavioral|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
282499|NCT02049736|Drug|Telbivudine|
282500|NCT02049710|Behavioral|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
282501|NCT02049710|Behavioral|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
282502|NCT02049697|Drug|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
282503|NCT02049684|Procedure|Patch|
282504|NCT02049671|Drug|Growth Hormone Therapy|
282505|NCT02049632|Procedure|Omission of axillary clearance|
282506|NCT02049619|Device|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
282507|NCT02049606|Drug|LAYLA tablet|1 Tablet twice a day
282508|NCT02049606|Drug|CENATONE tablet|2 Tablets once a day
282509|NCT02049593|Drug|PARP inhibitor BMN-673|Given PO
282510|NCT02049593|Drug|temozolomide|Given PO
282511|NCT02049593|Drug|irinotecan hydrochloride|Given IV
282512|NCT02049593|Other|pharmacological study|Correlative studies
282513|NCT02049593|Other|laboratory biomarker analysis|Correlative studies
282514|NCT02049580|Drug|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
282515|NCT02049580|Drug|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:~CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
282516|NCT02049580|Drug|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.~Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)~Cyclophosphamide [50 mg/kg/day IBW] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
282517|NCT02049567|Device|FluidVision Lens|Intraocular lens designed to restore visual function at all distances.
282518|NCT02049554|Other|Preconception Care Screener|
282519|NCT02049541|Drug|PI3K inhibitor BKM120|Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
282520|NCT02049541|Biological|rituximab|Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
282521|NCT02049541|Other|Pharmacodynamics|Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
282522|NCT02049541|Other|Correlative studies|Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
282523|NCT02049528|Drug|CC-122|CC-122
282524|NCT02049528|Drug|CC-122|CC-122
282528|NCT02049502|Biological|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
282529|NCT02049502|Procedure|sigmoidoscopy|
282530|NCT02049489|Biological|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
282531|NCT02049476|Drug|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.~Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
282532|NCT02049450|Drug|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
282533|NCT02049437|Drug|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
282534|NCT02049437|Drug|Placebo|"Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
282535|NCT02049411|Drug|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
282536|NCT02049411|Drug|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
282537|NCT02049385|Drug|Diazoxide|A nondiuretic vasodilator thiazide-related agent
282538|NCT02049385|Drug|Placebo|Placebo
282539|NCT02049359|Other|Texting|Bidirectional texting once weekly for 12 weeks
282540|NCT02049346|Drug|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.~Doses of erythropoetin were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
282541|NCT02049346|Drug|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.~If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
282542|NCT02049346|Drug|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.~Doses of MIRCERA were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.~The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
282543|NCT02049333|Procedure|Phacoemulsification|
282544|NCT02049333|Procedure|Endoscopic Cycloplasty (ECPL)|
282545|NCT02049320|Drug|Remifentanil|
282546|NCT02049307|Drug|Losartan 100mg daily|
282547|NCT02049307|Drug|Matching placebo|
282548|NCT02049294|Biological|Omalizumab (Xolair)|
282549|NCT02049294|Drug|Placebo|
282550|NCT02049281|Drug|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
282551|NCT02049268|Drug|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
282552|NCT02049268|Drug|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
282553|NCT02049268|Drug|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
282554|NCT02049255|Drug|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
282555|NCT02049255|Drug|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
282556|NCT02049242|Procedure|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
282599|NCT02048943|Other|pharmacological study|Correlative studies
282600|NCT02048943|Other|laboratory biomarker analysis|Correlative studies
282601|NCT02048930|Device|Budesonide Easyhaler|
282602|NCT02048930|Device|Budesonide dry powder inhaler|
282557|NCT02049242|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
282558|NCT02049229|Device|percutaneous coronary intervention|Optimax-stent implantation
282559|NCT02049229|Device|percutaneous coronary intervention|Synergy stent implantation
282560|NCT02049216|Other|Flexible tape|Flexible, elasticised, adhesive athletic tape
282561|NCT02049216|Other|Fixomull|
282562|NCT02049216|Other|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
282563|NCT02049203|Drug|Ataciguat|
282564|NCT02049203|Drug|Placebo|
282565|NCT02049190|Drug|onapristone|
282566|NCT02049190|Drug|abiraterone|
282567|NCT02049164|Drug|AR08|
282568|NCT02049164|Drug|Placebo|
282569|NCT02049151|Drug|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
282570|NCT02049151|Drug|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
282571|NCT02049151|Drug|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
282572|NCT02049151|Drug|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent [%] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
282573|NCT02049138|Drug|ABT-494|
282574|NCT02049112|Device|Salivary equivalent|14-day treatment with salivary equivalent sticks
282575|NCT02049112|Device|Aequasyal|14-day treatment with Aequasyal oral spray
282576|NCT02049112|Device|Biotene|14-day treatment with Biotene oral spray
282577|NCT02049086|Behavioral|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
282578|NCT02049086|Behavioral|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
282579|NCT02049073|Drug|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
282580|NCT02049073|Drug|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
282581|NCT02049060|Drug|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks~•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
282582|NCT02049047|Drug|Everolimus|Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
282583|NCT02049034|Other|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.~Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
282584|NCT02049034|Other|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
282585|NCT02049021|Device|MECTA SPECTRUM 5000Q ECT|
282586|NCT02049021|Procedure|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
282587|NCT02049008|Other|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
282588|NCT02049008|Other|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
282589|NCT02048982|Behavioral|Guideline|Physicians will receive information on the Choosing Wisely Guideline
282590|NCT02048982|Behavioral|Cost|Physicians will receive cost information.
282591|NCT02048982|Behavioral|Victim|Physicians will receive information on an identifiable victim.
282592|NCT02048969|Drug|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
282593|NCT02048969|Drug|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
282594|NCT02048956|Other|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
282595|NCT02048956|Other|Control group|Standard exercises of hydrotherapy
282596|NCT02048943|Drug|dovitinib lactate|Given PO
282597|NCT02048943|Drug|gemcitabine hydrochloride|Given IV
282681|NCT02048384|Drug|metformin alone (Arm A)|metformin alone
282603|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
282604|NCT02048917|Drug|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
282605|NCT02048917|Drug|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
282606|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
282607|NCT02048917|Drug|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
282608|NCT02048917|Drug|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
282609|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
282610|NCT02048917|Drug|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
282611|NCT02048917|Drug|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
282612|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
282613|NCT02048917|Drug|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
282614|NCT02048917|Drug|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
282615|NCT02048904|Drug|Sitagliptin|Sitagliptin 100 mg/day for 3 months
282616|NCT02048904|Drug|Placebo|Placebo 1 pill/day for 3 months
282617|NCT02048891|Drug|GnRH agonist trigger|
282618|NCT02048891|Drug|hCG trigger|
282619|NCT02048865|Drug|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
282620|NCT02048865|Drug|Placebo drug|placebo drug 2.5mg BID for 6 months
282621|NCT02048852|Other|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
282622|NCT02048852|Other|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
282623|NCT02048852|Other|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
282624|NCT02048852|Other|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
282625|NCT02048826|Device|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
282626|NCT02048826|Device|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
282627|NCT02048826|Device|FINGER III|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting III
282628|NCT02048813|Drug|Cyclophosphamide|Given IV
282629|NCT02048813|Drug|Fludarabine Phosphate|Given IV
282630|NCT02048813|Drug|Ibrutinib|Given PO
282631|NCT02048813|Other|Laboratory Biomarker Analysis|Correlative studies
282632|NCT02048813|Other|Pharmacogenomic Study|Correlative studies
282633|NCT02048813|Other|Quality-of-Life Assessment|Ancillary studies
282634|NCT02048813|Biological|Rituximab|Given IV
282635|NCT02048800|Drug|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged < 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged > 12 months)
282636|NCT02048787|Drug|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
282637|NCT02048774|Behavioral|Designation of Social Positioning|
282638|NCT02048761|Drug|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
282639|NCT02048761|Drug|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
282640|NCT02048748|Device|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
282641|NCT02048748|Device|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
282642|NCT02048722|Drug|regorafenib|Given PO
282643|NCT02048709|Drug|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
282644|NCT02048696|Other|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
282645|NCT02048683|Drug|Short term sedation with sevoflurane in ICU|
282646|NCT02048670|Device|Balance Belt|Vestibular habituation therapy worn under the clothes around the waist that uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and gait
282647|NCT02048657|Device|Foley Airway Stylet Tool|
282648|NCT02048657|Device|introducer-tool|
282649|NCT02048644|Drug|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
282650|NCT02048644|Drug|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
282651|NCT02048618|Drug|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
282652|NCT02048618|Drug|Placebo|placebo oral tablets, intake once daily for 20 weeks
282653|NCT02048605|Behavioral|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
282654|NCT02048605|Behavioral|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
282655|NCT02048592|Dietary Supplement|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support |(Nutridrink) for another 8 weeks."
282656|NCT02048592|Dietary Supplement|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
282657|NCT02048579|Behavioral|Behavior Therapy + Motivational Interviewing|
282658|NCT02048566|Device|ImaCor PM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
282659|NCT02048566|Device|ImaCor SM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
282660|NCT02048566|Other|Control PM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
282661|NCT02048566|Other|Control SM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
282662|NCT02048553|Device|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
282663|NCT02048553|Procedure|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
282664|NCT02048540|Biological|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
282665|NCT02048540|Drug|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
282666|NCT02048540|Procedure|Gastrectomy|
282667|NCT02048527|Other|Global|Single medium for the culture of embryos from Day1 to Day 5
282668|NCT02048527|Other|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
282669|NCT02048514|Device|The Nellix® EndoVascular Aneurysm Sealing System|
282670|NCT02048501|Other|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
282671|NCT02048501|Other|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
282672|NCT02048501|Other|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
282673|NCT02048501|Other|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
282674|NCT02048488|Drug|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
282675|NCT02048475|Other|desflurane|changing concentration
282676|NCT02048423|Drug|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
282677|NCT02048410|Dietary Supplement|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
282678|NCT02048410|Other|low satured diet|
282679|NCT02048397|Other|Pulmonary Rehabilitation|
282680|NCT02048397|Dietary Supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
282682|NCT02048384|Drug|metformin (Arm B)|rapamycin + metformin
282683|NCT02048384|Drug|rapamycin (Arm B)|rapamycin + metformin
282684|NCT02048371|Drug|Regorafenib|
282685|NCT02048371|Drug|Placebo|
282686|NCT02048358|Drug|2B3-201|
282687|NCT02048358|Drug|Placebo|
282688|NCT02048358|Drug|Methylprednisolone hemisuccinate|
282689|NCT02048345|Drug|Suspension Fasted State|
282690|NCT02048345|Drug|Suspension Fed State|
282691|NCT02048345|Drug|Solution Fasted State|
282692|NCT02048345|Drug|Solution Fed State|
282693|NCT02048332|Biological|Viral specific CTL Infusion|"CTL's will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the following:~Blood adenovirus PCR ≥ 1,000~Blood CMV PCR ≥ 500~Blood EBV PCR ≥ 9,000~Plasma BKV PCR >1,000~Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.~Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis~Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation.~Evidence of symptomatic BK virus infection, which may include symptomatic hemorrhagic cystitis."
282694|NCT02048319|Drug|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
282695|NCT02048319|Procedure|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
282696|NCT02048319|Drug|Placebo|Saline solution, injected as placebo
282697|NCT02048306|Behavioral|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
282698|NCT02048306|Behavioral|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
282699|NCT02048293|Drug|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
282700|NCT02048293|Drug|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
282701|NCT02048293|Drug|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
282702|NCT02048280|Procedure|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
282703|NCT02048280|Other|NAVA level|Increase NAVA level every 3 minutes
282704|NCT02048267|Procedure|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
282705|NCT02048254|Radiation|brachytherapy|
282706|NCT02048254|Radiation|IMRT|
282707|NCT02048241|Behavioral|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
282708|NCT02048241|Other|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
282709|NCT02048241|Drug|Intuniv|Weekly administration of medication in doses as per protocol
282710|NCT02048228|Drug|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
282711|NCT02048228|Drug|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
282712|NCT02048215|Drug|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
282713|NCT02048215|Drug|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
282714|NCT02048215|Drug|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
282715|NCT02048215|Other|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
282716|NCT02048189|Drug|LEVEMIR|
282717|NCT02048189|Drug|APIDRA|
282718|NCT02048150|Biological|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
282719|NCT02048150|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
282720|NCT02048150|Other|diffuse optical imaging|Undergo IOOI
282721|NCT02048150|Other|pharmacological study|Correlative studies
282722|NCT02048150|Other|Laboratory Biomarker|Correlative studies
282723|NCT02048150|Other|Questionnaire|Ancillary studies
282724|NCT02048137|Device|Transcranial direct current stimulation|
282725|NCT02048124|Device|25g standard needle|
282726|NCT02048124|Device|25d ProCor needle|
282727|NCT02048111|Biological|IB1001|"Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.~The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.~The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator."
282728|NCT02048098|Drug|Vaginal misoprostol|400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
282729|NCT02048098|Drug|Buccal misoprostol|400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
282730|NCT02048085|Drug|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
282731|NCT02048085|Drug|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
282732|NCT02048072|Drug|Gilenya|Autonomic testing during first dose administration of Gilenya.
282733|NCT02048059|Drug|ANG1005|
282734|NCT02048033|Device|Endogastric suturing|The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
282735|NCT02048020|Drug|paclitaxel|Given IV
282736|NCT02048020|Drug|carboplatin|Given IV
282737|NCT02048020|Radiation|intensity-modulated radiation therapy|Undergo IMRT
282738|NCT02048020|Procedure|quality-of-life assessment|Ancillary studies
282739|NCT02048007|Drug|Azithromycin|Biannual mass oral azithromycin to children
282740|NCT02048007|Drug|Placebo|Biannual mass oral placebo to children
282741|NCT02047994|Drug|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.~Esomeprazole 40 mg bid for 10 days~Clarithromycin 500 mg bid for 10 days~Amoxicillin 1000 mg bid for 10 days"
282742|NCT02047981|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
282743|NCT02047981|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years. In Niger during year 3, all communities will be offered azithroymcin.
282744|NCT02047968|Behavioral|wake therapy|
282745|NCT02047955|Procedure|Shoulder Arthroplasty|
282746|NCT02047942|Behavioral|Center-based cardiac rehabilitation|
282747|NCT02047942|Behavioral|Home-based training with telemonitoring guidance|
282748|NCT02047929|Other|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
282749|NCT02047903|Drug|Afatinib|50, 40, 30 or 20 mg
282750|NCT02047890|Drug|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
282751|NCT02047890|Drug|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
282752|NCT02047864|Dietary Supplement|Creatine monohydrate|
282753|NCT02047851|Other|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
282754|NCT02047838|Other|Anti-mullerian hormone (AMH) level dosage.|
282755|NCT02047838|Other|Follicle-stimulating hormone (FSH) level dosage.|
282756|NCT02047838|Other|Antral follicle count (AFC).|
282757|NCT02047825|Other|Upper limbs intervention|An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
282758|NCT02047825|Other|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
282759|NCT02047799|Dietary Supplement|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
282760|NCT02047799|Dietary Supplement|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
282761|NCT02047773|Other|Duration|If bacterial load checked on day 7 is less than 10^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
283056|NCT02045849|Drug|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
282762|NCT02047773|Drug|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
282763|NCT02047773|Drug|Meropenem|
282764|NCT02047747|Drug|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
282765|NCT02047734|Drug|Ozanimod 0.5 mg|Oral capsule, daily for 24 months
282766|NCT02047734|Drug|Ozanimod 1 mg|Oral capsule, daily for 24 months
282767|NCT02047734|Drug|Ozanimod placebo|Oral capsule, daily for 24 months
282768|NCT02047734|Drug|Interferon β-1a|Intramuscular injection, 30 µg, weekly for 24 months
282769|NCT02047734|Drug|IFN β-1a placebo|Intramuscular injection, weekly for 24 months
282770|NCT02047721|Behavioral|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
282771|NCT02047721|Behavioral|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by ~2000 kcal/week.
282772|NCT02047708|Drug|Zibotentan|Selective endothelin-A antagonist
282773|NCT02047682|Behavioral|Biopsychosocial|
282774|NCT02047682|Behavioral|Reference|
282775|NCT02047669|Behavioral|Biopsychosocial|
282776|NCT02047669|Behavioral|Reference|
282777|NCT02047656|Drug|LFF269|LFF269 capsules twice daily (b.i.d)
282778|NCT02047656|Drug|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
282779|NCT02047643|Device|Computer algorithm to initiate pump suspension|If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
282780|NCT02047630|Drug|Generic latanoprost|
282781|NCT02047630|Drug|Brand-name latanoprost|
282782|NCT02047617|Device|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
282783|NCT02047617|Device|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
282784|NCT02047604|Drug|SAN-300|
282785|NCT02047604|Drug|Placebo|
282786|NCT02047578|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
282787|NCT02047565|Drug|60mg edoxaban|
282788|NCT02047565|Drug|180mg edoxaban|
282789|NCT02047565|Drug|50 IU/kg Beriplex P/N|
282790|NCT02047565|Drug|25 IU/kg Beriplex P/N|
282791|NCT02047565|Drug|10 IU/kg Beriplex P/N|
282792|NCT02047552|Drug|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
282793|NCT02047552|Drug|Oxandrolone|10 mg PO Q12 hours for seven days
282794|NCT02047552|Drug|IV iron placebo|100 mL normal saline
282795|NCT02047552|Drug|Oxandrolone placebo|similar color and size sugar pill
282796|NCT02047539|Drug|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
282797|NCT02047539|Drug|Placebo|
282798|NCT02047513|Drug|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
282799|NCT02047513|Drug|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
282800|NCT02047500|Drug|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
282801|NCT02047500|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
282802|NCT02047500|Drug|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
282803|NCT02047474|Drug|oxaliplatin|Given IV
282804|NCT02047474|Drug|leucovorin calcium|Given IV
282805|NCT02047474|Drug|irinotecan hydrochloride|Given IV
282806|NCT02047474|Drug|fluorouracil|Given IV
282807|NCT02047474|Procedure|therapeutic conventional surgery|Undergo surgical resection
282808|NCT02047474|Other|laboratory biomarker analysis|Correlative studies
282809|NCT02047461|Drug|ORGN001 (formerly ALXN1101)|IV infusion
282810|NCT02047448|Procedure|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
282861|NCT02047136|Other|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
283057|NCT02045836|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
282811|NCT02047435|Behavioral|Information, event and workshops at a cartoon museum|"An event at the Storm P. Museum consisting of:~A guided tour at the museum~A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~The museum serves a refreshment and offer participants a season pass to the museum.~And~Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life."
282812|NCT02047435|Behavioral|Information and event at a cartoon museum|"1. An event at the Storm P. Museum consisting of:~A guided tour at the museum~A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~The museum serves a refreshment and offer participants a season pass to the museum."
282813|NCT02047422|Drug|Furosemide|furosemide (doubling previous furosemide dose)
282814|NCT02047422|Drug|metolazone|metolazone (add 2.5mg qod)
282815|NCT02047422|Drug|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
282816|NCT02047422|Drug|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
282817|NCT02047383|Other|Respiratory infection|An assessment of the patients included in the study will be conducted
282818|NCT02047370|Other|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
282819|NCT02047370|Other|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
282820|NCT02047357|Other|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
282821|NCT02047344|Drug|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
282822|NCT02047331|Procedure|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
282823|NCT02047331|Procedure|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
282824|NCT02047318|Drug|LUM001|Dosing of LUM001 with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 560 micrograms per kilogram (mcg/kg).
282825|NCT02047305|Device|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
282826|NCT02047292|Device|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
282827|NCT02047292|Device|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
282828|NCT02047292|Device|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
282829|NCT02047279|Procedure|maze procedure|"The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases."
282830|NCT02047279|Procedure|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
282831|NCT02047279|Procedure|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
282832|NCT02047266|Procedure|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
282833|NCT02047266|Procedure|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time>250seconds).
282901|NCT02046824|Device|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
282834|NCT02047266|Procedure|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time>450seconds).
282835|NCT02047266|Device|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
282836|NCT02047266|Device|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
282837|NCT02047253|Drug|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
282838|NCT02047253|Drug|Dexamethasone|Administered prior to administration of Study drug
282839|NCT02047253|Drug|Acyclovir|Administered orally twice daily
282840|NCT02047227|Drug|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
282841|NCT02047227|Drug|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
282842|NCT02047227|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
282843|NCT02047214|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
282844|NCT02047214|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
282845|NCT02047201|Radiation|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
282846|NCT02047201|Radiation|PET/CT|Assessing tumor response using FDG-PET/CT.
282847|NCT02047201|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
282848|NCT02047201|Drug|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
282849|NCT02047201|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
282850|NCT02047175|Drug|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
282851|NCT02047175|Drug|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
282852|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
282853|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
282854|NCT02047162|Drug|Bismuth subsalicylate|
282855|NCT02047162|Other|Placebo|Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
282856|NCT02047149|Drug|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
282857|NCT02047149|Drug|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
282858|NCT02047149|Drug|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
282859|NCT02047149|Drug|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
282860|NCT02047136|Other|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
282862|NCT02047123|Dietary Supplement|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
282863|NCT02047110|Drug|placebo for risankizumab|Placebo for risankizumab administered by subcutaneous (SC) injection
282864|NCT02047110|Drug|risankizumab|Risankizumab administered by subcutaneous (SC) injection
282865|NCT02047097|Drug|dimethyl fumarate|Provided under routine clinical care
282866|NCT02047071|Device|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
282867|NCT02047045|Procedure|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
282868|NCT02047045|Drug|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 8 weeks.
282869|NCT02047032|Procedure|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
282870|NCT02047032|Drug|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
282871|NCT02047032|Procedure|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
282872|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
282873|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
282874|NCT02047019|Drug|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
282875|NCT02047019|Drug|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
282876|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
282877|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
282878|NCT02047006|Drug|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:~Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.~Effect of dialysis on levels of rivaroxaban:~Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
282879|NCT02046993|Behavioral|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
282880|NCT02046993|Behavioral|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
282881|NCT02046980|Procedure|Gufoni|
282882|NCT02046980|Procedure|Vibration|
282883|NCT02046980|Procedure|Sham|
282884|NCT02046967|Procedure|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
282885|NCT02046967|Procedure|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
282886|NCT02046941|Behavioral|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
282887|NCT02046928|Drug|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
282888|NCT02046915|Drug|Imnovid (pomalidomide)|
282889|NCT02046915|Drug|Dexamethasone|
282890|NCT02046915|Drug|Endoxan (Cyclophosphamide)|
282891|NCT02046889|Behavioral|Bicycle Training Intervention|
282892|NCT02046876|Other|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
282893|NCT02046863|Device|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
282894|NCT02046850|Drug|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
282895|NCT02046850|Drug|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
282896|NCT02046850|Drug|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
282897|NCT02046850|Drug|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
282898|NCT02046837|Behavioral|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
282899|NCT02046837|Behavioral|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
282900|NCT02046837|Behavioral|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
282975|NCT02046369|Drug|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
282976|NCT02046369|Drug|Placebo|Placebo Comparator once daily
283563|NCT02041546|Drug|Lung lavage with surfactant|
282902|NCT02046824|Device|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
282903|NCT02046824|Device|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
282904|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
282905|NCT02046811|Behavioral|Patient activation and education (PAE)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
282906|NCT02046811|Behavioral|PAE plus physician activation (PAE + MD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
282907|NCT02046811|Behavioral|PAE physician activation, plus teledermoscopy (PAE +MD +TD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
282908|NCT02046798|Drug|ASP3652|oral
282909|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
282910|NCT02046772|Drug|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
282911|NCT02046772|Drug|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
282912|NCT02046772|Drug|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
282913|NCT02046759|Other|Pharmacist- Intervention|Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
282914|NCT02046759|Other|Routine Care|Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
282915|NCT02046746|Other|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
282916|NCT02046733|Drug|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
282917|NCT02046733|Drug|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
282918|NCT02046720|Drug|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.~The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
282919|NCT02046707|Other|initial evaluation|
282920|NCT02046707|Other|Period of cardiac rehabilitation|
282921|NCT02046707|Other|final evaluation|
282922|NCT02046707|Other|Concentric and eccentric exercise sessions|
282923|NCT02046694|Drug|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
282924|NCT02046668|Drug|spironolactone|spironolactone 25mg daily for 12 weeks
282925|NCT02046655|Drug|Corifollitropin alfa|
282926|NCT02046655|Drug|rFSH|
282927|NCT02046642|Behavioral|Maternal rest in left lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
282928|NCT02046642|Behavioral|Maternal rest in right lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
282929|NCT02046629|Drug|Teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
282930|NCT02046629|Drug|cholestyramine|Pharmaceutical form:power Route of administration: oral
282931|NCT02046616|Drug|Tocilizumab|Tocilizumab 162 mg will be administered subcutaneously QW.
282932|NCT02046616|Drug|Methotrexate|Methotrexate dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
283141|NCT02045134|Dietary Supplement|Placebo|Soluble corn flour not rich in anthocyanins
282933|NCT02046616|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs (same non-biologic DMARD that participant was receiving at time of study entry). Dosing is not specified by the protocol and will be given as per standard practice. Participants must be at a stable dose that was initiated at least 4 weeks prior to baseline.
282934|NCT02046603|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.
282935|NCT02046603|Drug|DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
282936|NCT02046603|Drug|Oral Corticosteroids|Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
282937|NCT02046603|Drug|Methotrexate|Methotrexate per investigator's discretion.
282938|NCT02046590|Drug|Propofol|
282939|NCT02046590|Other|General anesthesia|
282940|NCT02046577|Dietary Supplement|Vitamin D3|Cholecalciferol administration
282941|NCT02046577|Dietary Supplement|Placebo|Placebo liquid
282942|NCT02046564|Drug|ASC-01|
282943|NCT02046564|Drug|Placebo|
282944|NCT02046551|Drug|Atomoxetine|
282945|NCT02046551|Drug|Placebo|
282946|NCT02046538|Drug|Leucovorin|400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
282947|NCT02046538|Drug|Oxaliplatin|85 mg/m2 IV over two hours
282948|NCT02046538|Drug|5-FU|400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
282949|NCT02046538|Drug|Irinotecan|180 mg/m2 IV over 90 minutes
282950|NCT02046525|Biological|Autologous fecal microbiota therapy|
282951|NCT02046525|Other|Placebo|Saline enema
282952|NCT02046512|Dietary Supplement|Probiotic|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
282953|NCT02046512|Other|Placebo|Sugar pill
282954|NCT02046499|Drug|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
282955|NCT02046499|Drug|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
282956|NCT02046486|Drug|Ticagrelor 180mg whole tablets|
282957|NCT02046486|Drug|Ticagrelor 180mg crushed and dispersed|
282958|NCT02046473|Procedure|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
282959|NCT02046460|Drug|Acetylsalicylic acid|Acetylsalicylic acid, 300mg o.p.d.
282960|NCT02046460|Drug|Vitamin K antagonist|Vitamin K-antagonists, target INR 2.0-3.0
282961|NCT02046447|Drug|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
282962|NCT02046447|Other|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
282963|NCT02046447|Other|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
282964|NCT02046447|Other|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
282965|NCT02046434|Drug|Glycerol Phenylbutyrate|
282966|NCT02046421|Drug|mifepristone|Given PO
282967|NCT02046421|Drug|carboplatin|Given IV
282968|NCT02046421|Drug|gemcitabine hydrochloride|Given IV
282969|NCT02046421|Other|laboratory biomarker analysis|Correlative studies
282970|NCT02046421|Other|pharmacological study|Correlative studies
282971|NCT02046408|Other|Computer Tablet|
282972|NCT02046395|Drug|amlodipine, hydralazine, terazosin or hydrochlorothiazide|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
282973|NCT02046382|Drug|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
282974|NCT02046382|Drug|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
282977|NCT02046343|Behavioral|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
282978|NCT02046343|Behavioral|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
282979|NCT02046343|Other|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
282980|NCT02046343|Other|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
282981|NCT02046330|Device|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
282982|NCT02046317|Drug|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
282983|NCT02046317|Device|Echogenic needle|The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
282984|NCT02046317|Device|Standard of care needle|The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
282985|NCT02046317|Device|Ultrasound|"The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles."
282986|NCT02046304|Drug|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
282987|NCT02046304|Radiation|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
282988|NCT02046291|Drug|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
282989|NCT02046278|Device|LifeSeal™ Kit|
282990|NCT02046265|Behavioral|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
282991|NCT02046265|Behavioral|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
282992|NCT02046265|Behavioral|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
282993|NCT02046265|Behavioral|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
282994|NCT02046239|Procedure|Suture Group|
282995|NCT02046239|Biological|Staple Group (control)|
282996|NCT02046226|Device|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
282997|NCT02046213|Drug|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
282998|NCT02046200|Drug|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
282999|NCT02046200|Drug|Placebo|Matched placebo
283000|NCT02046200|Drug|Alcohol|
283001|NCT02046187|Dietary Supplement|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
283002|NCT02046187|Radiation|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
283003|NCT02046187|Drug|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
283004|NCT02046174|Biological|RENCA macrobeads|
283005|NCT02046161|Procedure|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
283006|NCT02046148|Biological|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
283007|NCT02046148|Biological|Placebo|Intramuscular injection - Normal saline
283008|NCT02046135|Drug|Sodium Bicarbonate|
283009|NCT02046135|Drug|Sodium Chloride|
283010|NCT02046122|Drug|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
283054|NCT02045849|Drug|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
283055|NCT02045849|Drug|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
283011|NCT02046122|Drug|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.~Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
283012|NCT02046122|Biological|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.~Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2~Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
283013|NCT02046109|Procedure|Repair|
283014|NCT02046109|Procedure|Replace|
283015|NCT02046096|Device|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
283016|NCT02046096|Device|Cook Celect® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
283017|NCT02046083|Drug|arachid|
283018|NCT02046070|Drug|Cyclophosphamide|Cyclophosphamide tablets
283019|NCT02046070|Drug|Ixazomib|Ixazomib capsules
283020|NCT02046070|Drug|Dexamethasone|Dexamethasone tablets
283021|NCT02046057|Procedure|PNB of SLN|Percutaneous biopsy of sentinel node
283022|NCT02046044|Drug|Digoxin|
283023|NCT02046044|Drug|Ivabradine|
283024|NCT02046031|Drug|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
283025|NCT02046018|Other|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
283026|NCT02046018|Other|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
283027|NCT02046018|Other|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
283028|NCT02046005|Behavioral|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
283029|NCT02046005|Behavioral|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
283030|NCT02046005|Behavioral|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
283031|NCT02045992|Dietary Supplement|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
283032|NCT02045979|Drug|BI 695501|BI 695501 single s.c. injection
283033|NCT02045979|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
283034|NCT02045979|Drug|adalimumab-US source|adalimumab-US source single s.c. injection.
283035|NCT02045966|Drug|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
283036|NCT02045966|Drug|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
283037|NCT02045966|Drug|BMS-791325|
283038|NCT02045953|Device|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
283039|NCT02045953|Device|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
283040|NCT02045940|Drug|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
283041|NCT02045940|Drug|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
283042|NCT02045927|Other|sedation monitoring with RASS score|
283043|NCT02045927|Other|sedation monitoring with BIS-Guided monitoring|
283044|NCT02045914|Other|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
283045|NCT02045901|Drug|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
283046|NCT02045901|Drug|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
283047|NCT02045888|Device|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
283048|NCT02045888|Biological|Placebo|Placebo is visually matched solution
283049|NCT02045875|Drug|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
283050|NCT02045862|Drug|Solifenacin succinate|Participants received solifenacin 5 mg orally once a day at the same time each day.
283051|NCT02045862|Drug|Mirabegron|Participants received mirabegron 50 mg orally once a day at the same time each day.
283052|NCT02045862|Drug|Placebo to match solifenacin|Participants received placebo to match solifenacin 5 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
283053|NCT02045862|Drug|Placebo to match mirabegron|Participants received placebo to match mirabegron 50 mg orally once a day at the same time each day. This intervention was given to maintain the blind during the study.
283058|NCT02045836|Biological|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
283059|NCT02045810|Drug|Levobupivacaine|
283060|NCT02045810|Drug|Saline|
283061|NCT02045797|Drug|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
283062|NCT02045797|Drug|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
283063|NCT02045784|Dietary Supplement|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
283064|NCT02045784|Other|Breast milk|Unlimited breast feeding
283065|NCT02045771|Behavioral|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
283066|NCT02045771|Behavioral|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
283067|NCT02045758|Device|Fingerstick|
283068|NCT02045758|Device|TAP20-C|
283069|NCT02045745|Biological|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
283070|NCT02045732|Biological|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
283071|NCT02045732|Biological|Placebo|Bi-Weekly Subcutaneous Injections X 6
283072|NCT02045732|Biological|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
283073|NCT02045732|Biological|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
283074|NCT02045719|Drug|uncaria tomentosa (cat´s claw)|
283075|NCT02045706|Other|Community Health Worker Trainings|
283076|NCT02045693|Drug|Methadone|
283077|NCT02045693|Drug|DCV 3DAA FDC|
283078|NCT02045693|Drug|BMS-791325|
283079|NCT02045693|Drug|Buprenorphine|
283080|NCT02045693|Drug|Naloxone|
283081|NCT02045667|Drug|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.~Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
283082|NCT02045667|Drug|Placebo|Placebo tablets do not contain any active medicinal component.
283083|NCT02045641|Procedure|pleuracentesis|Direct needle drainage of pleural effusions with dynamic ultrasound technique
283084|NCT02045628|Behavioral|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
283085|NCT02045615|Procedure|Proposed technique for removal of the Wichita Fusion Nail|
283086|NCT02045602|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
283087|NCT02045602|Drug|Gemcitabine|1000 mg/m2 intravenous administration
283088|NCT02045602|Drug|Abraxane®|125 mg/m2 intravenous administration
283089|NCT02045589|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
283090|NCT02045589|Drug|Gemcitabine|1000 mg/m2 intravenous administration
283091|NCT02045589|Drug|Abraxane®|125 mg/m2 intravenous administration
283092|NCT02045576|Device|sleep position trainer|
283093|NCT02045576|Device|Oral Appliance Therapy|
283094|NCT02045563|Other|prise de sang|
283095|NCT02045563|Other|magnetic resonance imaging and magnetic resonance spectroscopy|
283096|NCT02045550|Drug|Prospan Syrup|2.5 ml twice daily for 4 weeks
283097|NCT02045524|Other|Deep muscle injection|
283098|NCT02045524|Other|Sub-Q Injection|
283099|NCT02045511|Behavioral|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
283100|NCT02045511|Device|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
283101|NCT02045498|Device|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
283102|NCT02045472|Drug|VIS410|
283103|NCT02045472|Drug|Placebo|
283104|NCT02045459|Behavioral|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
283105|NCT02045446|Radiation|Stereotactic Body Radiation Therapy|
283106|NCT02045446|Drug|Maintenance chemotherapy|Maintenance chemotherapy
283140|NCT02045147|Behavioral|Grp 4 Normal Cognition, High Activation|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
283107|NCT02045433|Radiation|SABR Boost Therapy|"Initial Pelvic (+/- Para-aortic) fractionated external beam Radiation with 45 Gy to combined PTV with a boost to 55Gy for PET positive/CT enlarged nodes;~Image Guided Hypofractionated Radiation Treatment boost to Cervix High risk CTV/PTV 28GY/4 fx.~Patients will receive 4 fractions of 7 Gy each via stereotactic body radiation as boost therapy to a volume that encompasses the cervical tumor. A minimum of 40 hours should separate each treatment."
283108|NCT02045394|Other|Chest X-ray|
283109|NCT02045394|Other|computed tomography of the chest|
283110|NCT02045394|Procedure|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
283111|NCT02045381|Procedure|MRI Group|A single research MRI
283112|NCT02045368|Drug|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.
283113|NCT02045355|Other|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
283114|NCT02045342|Other|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
283115|NCT02045342|Other|Placebo|Ingest 500ml of placebo prior to metabolic measures.
283116|NCT02045303|Device|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
283117|NCT02045303|Device|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
283118|NCT02045290|Drug|Metformin|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
283119|NCT02045290|Drug|Placebo|
283120|NCT02045277|Drug|IDP-118 Lotion|Lotion
283121|NCT02045277|Drug|IDP-118 Monad HP Lotion|Active Comparator
283122|NCT02045277|Drug|IDP-118 Monad Taz Lotion|Active Comparator
283123|NCT02045277|Drug|IDP-118 Vehicle Lotion|Vehicle
283124|NCT02045264|Drug|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
283125|NCT02045251|Drug|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
283126|NCT02045238|Drug|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
283127|NCT02045238|Radiation|Chest X-Ray|
283128|NCT02045238|Other|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
283129|NCT02045225|Behavioral|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
283130|NCT02045212|Drug|RPh201|SC injection twice a week during 13/26 weeks
283131|NCT02045212|Drug|Placebo|SC injection twice a week during 13/26 weeks
283132|NCT02045199|Device|Tested product : V0111 cream|Application twice a day during 28 days
283133|NCT02045199|Device|Placebo|Application twice a day during 28 days
283134|NCT02045186|Other|Assessment of Oral HPV Infection|"Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:~Polymerase chain reaction (PCR) for HPV DNA.~Fluorescent in-situ hybridization (FISH).~Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry."
283135|NCT02045173|Other|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
283136|NCT02045173|Device|Polysomnography/polygraphy|1 night polysomnography/polygraphy
283137|NCT02045147|Behavioral|Grp 1 Low Cognition, Low Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
283138|NCT02045147|Behavioral|Grp 2 Low Cognition, High Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
283139|NCT02045147|Behavioral|Grp 3 Normal Cognition, Low Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
283564|NCT02041546|Drug|Bolus surfactant|
283142|NCT02045134|Dietary Supplement|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
283143|NCT02045121|Device|Indwelling Pleural Catheter|
283144|NCT02045121|Procedure|Talc Pleurodesis|
283145|NCT02045108|Behavioral|Active Retraining|
283146|NCT02045108|Device|Sham TDCS|
283147|NCT02045108|Device|Active TDCS|
283148|NCT02045108|Behavioral|Sham Retraining|
283149|NCT02045095|Drug|MLN7243|"Dose escalation stage Schedule A: Intravenous infusion on Days 1, 4, 8, 11 for a 21-day treatment cycle.~Schedule B: Intravenous infusion on Days 1, 8, 15 for a 28-day treatment cycle.~Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)."
283150|NCT02045082|Procedure|Corneal sampling|Slit lamp corneal sampling with a Swab
283151|NCT02045069|Drug|2 days Ivermectin|200-400 µg/kg once daily for 2 days and placebo once daily at D3
283152|NCT02045069|Drug|3 days Ivermectin|200 -400 µg/kg once daily for 3 days
283153|NCT02045069|Drug|Placebo|Placebo once daily for 3 days
283154|NCT02045056|Drug|Gemfibrozil|
283155|NCT02045056|Drug|Placebo|
283156|NCT02045030|Drug|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
283157|NCT02045017|Drug|Pomalidomide and Dexamethasone|
283158|NCT02044991|Drug|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
283159|NCT02044991|Drug|Placebo Injection|A placebo injection
283160|NCT02044978|Device|Zoledronate-coated dental implant|
283161|NCT02044965|Other|Antibiotic|2 mg/kg per day via oral ingestion.
283162|NCT02044965|Drug|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
283163|NCT02044952|Drug|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
283164|NCT02044939|Other|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
283165|NCT02044913|Behavioral|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
283166|NCT02044887|Other|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
283167|NCT02044874|Drug|APD356-lorcaserin hydrochloride|
283168|NCT02044874|Drug|Placebo|
283169|NCT02044861|Drug|PFK-158|IV dose escalation
283170|NCT02044848|Drug|Secukinumab|
283171|NCT02044848|Drug|Placebo|Placebo
283172|NCT02044835|Drug|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
283173|NCT02044822|Drug|Idelalisib|150 mg tablets administered orally twice daily
283174|NCT02044822|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly x 8 weeks
283175|NCT02044809|Drug|Cannabidiol|
283176|NCT02044809|Drug|Placebo|
283177|NCT02044796|Drug|Cladribine|Given IV
283178|NCT02044796|Drug|Cytarabine|Given IV
283179|NCT02044796|Biological|Filgrastim|Given SC
283180|NCT02044796|Other|Laboratory Biomarker Analysis|Correlative studies
283181|NCT02044796|Drug|Mitoxantrone Hydrochloride|Given IV
283182|NCT02044783|Behavioral|Behavioral Counseling|
283183|NCT02044757|Behavioral|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
283184|NCT02044744|Behavioral|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
283185|NCT02044731|Behavioral|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
283186|NCT02044705|Behavioral|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
283187|NCT02044679|Other|Water|
283188|NCT02044679|Other|No intervention|
283189|NCT02044666|Device|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
283190|NCT02044653|Drug|GX-E2|Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
283191|NCT02044653|Drug|GX-E2|Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
283192|NCT02044653|Drug|GX-E2|Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
283193|NCT02044653|Drug|NESP|Each Group of Hemodialysis (n=30) will be administered NESP 30ug
283565|NCT02041533|Biological|Nivolumab|
283194|NCT02044653|Drug|MIRCERA|Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
283195|NCT02044640|Procedure|Appendectomy|
283196|NCT02044627|Drug|[14C-ETC-1002]|
283197|NCT02044614|Other|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
283198|NCT02044601|Drug|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.~Phase II: Maximum tolerated dose from Phase I."
283199|NCT02044601|Drug|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
283200|NCT02044601|Drug|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
283201|NCT02044601|Drug|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
283202|NCT02044601|Radiation|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
283203|NCT02044588|Biological|HBsAg positive kidney allograft donor|
283204|NCT02044562|Dietary Supplement|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
283205|NCT02044562|Dietary Supplement|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
283206|NCT02044549|Drug|carbetocin|Oxycontin analogue
283207|NCT02044549|Drug|Syntometrine|Uterotonins
283208|NCT02044536|Other|No intervention|retrospective data review
283209|NCT02044523|Device|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
283210|NCT02044510|Drug|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
283211|NCT02044510|Drug|Placebo|Matched placebo capsules to the intervention arm
283212|NCT02044497|Drug|oral oxycodone|
283213|NCT02044484|Behavioral|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.~Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.~The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.~At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
283214|NCT02044471|Other|Remote Ischemic Conditioning (using Sphygmomanometer)|"Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.~Patient in control group will not perform this."
283215|NCT02044458|Device|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
283216|NCT02044445|Procedure|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
283217|NCT02044432|Other|ginger compress|Kidney ginger compress
283218|NCT02044419|Drug|lomitapide|
283219|NCT02044406|Drug|BI 1181181|single dose (low to high dose)
283220|NCT02044406|Drug|BI 1181181, R|powder for oral solution
283221|NCT02044406|Drug|BI 1181181, T2|tablet, fasted
283222|NCT02044406|Drug|Placebo to BI 1181181|Placebo to BI 1181181
283223|NCT02044406|Drug|BI 1181181, T1|tablet, fed
283224|NCT02044393|Drug|itraconazole|multiple doses of itraconazole given as capsules
283225|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
283226|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
283227|NCT02044380|Drug|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
283228|NCT02044367|Drug|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
283229|NCT02044367|Drug|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
283230|NCT02044367|Drug|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
283231|NCT02044354|Drug|Taxotere|
283232|NCT02044354|Drug|Jevtana|
283233|NCT02044341|Drug|AR01|drops administered an needed for pain
283234|NCT02044341|Drug|Glycerin ear drops|placebo drops administered for ear pain
283235|NCT02044328|Drug|Icotinib|Icotinib is administered 125 mg three times per day.
283236|NCT02044315|Device|ICD programming|
283237|NCT02044302|Drug|Bupivacaine|
283238|NCT02044302|Drug|Botulinum Toxins|
283239|NCT02044302|Drug|Analgesics|
283240|NCT02044276|Drug|lipegfilgrastim|6 mg
283241|NCT02044276|Drug|pegfilgrastim|6 mg
283242|NCT02044263|Behavioral|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
283243|NCT02044263|Behavioral|face-to-face CBT-i|
283244|NCT02044250|Drug|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
283245|NCT02044250|Drug|Aspirin|Aspirin 100~200mg 1~2tab P.O. daily
283246|NCT02044237|Behavioral|Decoupling|
283247|NCT02044237|Behavioral|Progressive relaxation|
283248|NCT02044224|Drug|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).~Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.~Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
283280|NCT02043886|Drug|Acarbose|Acarbose 50 mg by mouth given during Meal Test
283281|NCT02043886|Drug|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
283566|NCT02041533|Drug|Gemcitabine|
283249|NCT02044211|Behavioral|Collaborative Care for Heart Failure|"Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.~After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist."
283250|NCT02044211|Behavioral|Collaborative Care for Depression|"The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable."
283251|NCT02044198|Biological|FMP2.1/AS01B|50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
283252|NCT02044185|Drug|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
283253|NCT02044172|Procedure|Radical prostatectomy|radical prostatectomy
283254|NCT02044172|Radiation|Conformal radiation therapy|Conformal radiation therapy, external beam
283255|NCT02044172|Other|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
283256|NCT02044159|Drug|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
283257|NCT02044159|Other|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
283258|NCT02044146|Drug|Ticagrelor, Prasugrel, Clopidogrel|
283259|NCT02044133|Other|Dosage Vitamine D|
283260|NCT02044120|Drug|niraparib|
283261|NCT02044120|Drug|Temozolomide|
283262|NCT02044120|Drug|Irinotecan|
283263|NCT02044107|Behavioral|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc & ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc & antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
283264|NCT02044094|Drug|Buprenorphine|A subcutaneous depot injection of buprenorphine 300 mg was delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into systemic circulation over an extended period of time.
283265|NCT02044094|Drug|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE sublingual film stabilization period) or as soon as they start to experience withdrawal symptoms. SUBOXONE sublingual film may be initially administered several times daily until a stable dose between 8 mg and 24 mg daily is established.
283266|NCT02044094|Drug|hydromorphone|"Hydromorphone IM challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE sublingual film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are randomly administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular (IM) injection daily in varying blinded sequences.~Additionally, hydromorphone can also be earned during the afternoon Reinforcing effects tasks sessions up to the same randomized dose received in the hydromorphone challenge that morning (or money can be chosen)."
283267|NCT02044094|Drug|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
283268|NCT02044081|Drug|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
283269|NCT02044081|Drug|Placebo|Placebo is the vehicle without C16G2
283270|NCT02044081|Drug|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
283271|NCT02044003|Device|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
283272|NCT02043990|Device|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
283273|NCT02043977|Drug|propofol injectable emulsion|
283274|NCT02043964|Procedure|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
283275|NCT02043951|Device|Lutonix Drug Coated Balloon Catheter|
283276|NCT02043938|Device|SedLine EEG sensor|Test subjects in each group will receive the same device intervention (SedLine EEG) to monitor their EEG waves.
283277|NCT02043925|Drug|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
283278|NCT02043912|Drug|Haloperidol|
283279|NCT02043899|Drug|[124I]meta-Iodobenzylguanidine|Single intravenous administration of [124I]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq [124I]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
283282|NCT02043860|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
283283|NCT02043860|Procedure|Autologous Transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
283284|NCT02043860|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant.
283285|NCT02043860|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
283286|NCT02043847|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, or 9Gy.
283287|NCT02043847|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant.
283288|NCT02043847|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
283289|NCT02043847|Procedure|Autologous transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue.
283290|NCT02043834|Other|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
283291|NCT02043821|Drug|Capecitabine|14days
283292|NCT02043821|Other|placebo|14 days
283293|NCT02043795|Device|BVS, Abbott Vascular|The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
283294|NCT02043782|Device|Coloplast Test|Newly developed 1-piece convex ostomy product
283295|NCT02043782|Device|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
283296|NCT02043782|Device|Competitor soft convex|A commercially available soft convex product
283297|NCT02043756|Drug|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
283298|NCT02043756|Drug|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
283299|NCT02043743|Biological|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
283300|NCT02043730|Drug|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
283301|NCT02043730|Drug|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
283302|NCT02043717|Dietary Supplement|Vitamin D|"Supplementing oral cholecalciferol according to the new guidelines by:~Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism [Internet]. 2012 May [cited 2012 Oct 31];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505"
283303|NCT02043704|Drug|IV Acetaminophen|Details covered in arm description.
283304|NCT02043691|Device|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
283305|NCT02043691|Device|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
283306|NCT02043691|Device|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Zenith or Cook TX2 device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
283307|NCT02043678|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kiloBecquerel per kilogram (kBq/kg) body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles.(nominal change to 55 kBq/kg after implementation of National Institute of Standards and Technology (NIST) update)
283308|NCT02043678|Drug|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
283309|NCT02043678|Drug|Abiraterone|All study subjects will receive treatment with oral abiraterone acetate (1000 mg once daily),with best supportive care
283310|NCT02043678|Drug|Prednisone/Prednisolone|All study subjects will receive treatment with oral prednisone/prednisolone (5 mg twice daily), with best supportive care
283311|NCT02043665|Biological|CVA21/pembrolizumab|
283312|NCT02043652|Drug|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
283313|NCT02043652|Drug|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
283314|NCT02043626|Other|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
283339|NCT02043548|Drug|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
283315|NCT02043626|Other|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
283316|NCT02043626|Other|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
283317|NCT02043626|Other|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
283318|NCT02043613|Other|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.~The differences with the physical surroundings of exercise is the primary intervention for this study."
283319|NCT02043613|Other|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
283320|NCT02043600|Behavioral|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
283321|NCT02043600|Behavioral|Self-care|Self-care books are provided for self-directed use
283322|NCT02043587|Drug|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
283323|NCT02043587|Drug|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
283324|NCT02043587|Drug|PEG-asp|2,000 IU/m2 IV for ages </= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A & 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
283325|NCT02043587|Drug|CTX|750 mg/m2 IV, days 1 &15 for subjects <40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 & 16 for subjects < 40 years of age if day 14 bone marrow M2 or M3; Courses 1A & 2A
283326|NCT02043587|Drug|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A & 2A; Maintenance: Monthly, days 1-5
283327|NCT02043587|Drug|Liposomal AraC|25 mg intrathecal (IT), on days 1 & 15 during Courses 1A & 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
283328|NCT02043587|Drug|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B & 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
283329|NCT02043587|Drug|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B & 2B
283330|NCT02043587|Drug|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C & 2C
283331|NCT02043587|Drug|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C & 2C
283332|NCT02043587|Drug|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
283333|NCT02043587|Drug|Rituximab|375 mg/m2 IV once daily on days 1 & 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C & 2A
283334|NCT02043587|Drug|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
283335|NCT02043574|Behavioral|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
283336|NCT02043574|Behavioral|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
283337|NCT02043561|Other|induction of urge by rectal distension|
283338|NCT02043548|Drug|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
283340|NCT02043535|Device|Delivery of precise levels of carbon dioxide with the RA-MR™ Virtual Sequential Gas Delivery System.|"All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using a target level of carbon dioxide (CO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using persantine as the stress agent.~Myocardial perfusion stress testing"
283341|NCT02043535|Device|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (approximately 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic persantine stress Rb-82 PET MPI.
283342|NCT02043522|Drug|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
283343|NCT02043509|Behavioral|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
283344|NCT02043496|Behavioral|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
283345|NCT02043496|Behavioral|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
283346|NCT02043457|Other|phenotyping|
283347|NCT02043444|Radiation|FDG PET-CT|
283348|NCT02043405|Behavioral|Weight loss and exercise training intervention|Combined weight loss and exercise training intervention
283349|NCT02043405|Behavioral|Weight loss Only Intervention|Weight loss Only Intervention
283350|NCT02043392|Device|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
283351|NCT02043379|Drug|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
283352|NCT02043379|Other|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
283353|NCT02043366|Drug|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
283354|NCT02043366|Drug|Butorphanol|Butorphanol is intravenously administrated
283355|NCT02043366|Drug|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
283356|NCT02043366|Drug|Remifentanil|Remifentanil is intravenously administrated
283357|NCT02043366|Drug|Sufentanil|Sufentanil is intravenously administrated
283358|NCT02043340|Drug|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
283359|NCT02043340|Device|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
283360|NCT02043340|Procedure|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
283361|NCT02043314|Drug|Isoniazida|
283362|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
283363|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
283364|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
283365|NCT02043288|Drug|NC-6004|"Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"
283366|NCT02043288|Drug|Gemcitabine|"Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"
283367|NCT02043275|Other|Leg training|Lower body resistance training twice per week for one hour each time.
283368|NCT02043275|Other|Arm training|Upper body resistance training twice per week for one hour each time.
283369|NCT02043262|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
283370|NCT02043262|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
283371|NCT02043249|Other|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
283372|NCT02043236|Behavioral|Healthy bones pamphlet|written educational material
283373|NCT02043236|Behavioral|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
283374|NCT02043236|Behavioral|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
283375|NCT02043223|Dietary Supplement|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
283376|NCT02043223|Dietary Supplement|Vitamin A (6 wk postpartum)|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
283377|NCT02043223|Dietary Supplement|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
283378|NCT02043223|Dietary Supplement|Placebo|Placebo supplementation, both at <3-day and 6-wk postpartum.
283379|NCT02043210|Behavioral|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
283380|NCT02043210|Behavioral|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
283381|NCT02043184|Behavioral|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
283382|NCT02043171|Dietary Supplement|Placebo|A Placebo comparator
283383|NCT02043171|Drug|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
283384|NCT02043171|Behavioral|Non-Exercise|This group will not participate in 3 times per week strength training
283385|NCT02043171|Behavioral|Exercise|This group will participate in a supervised 3 times per week strength training program
283386|NCT02043158|Behavioral|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
283387|NCT02043158|Behavioral|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
283388|NCT02043145|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
283389|NCT02043132|Drug|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
283390|NCT02043132|Drug|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
283391|NCT02043119|Behavioral|Breastfeeding Clinic|
283392|NCT02043106|Other|plantar vibration|
283393|NCT02043093|Behavioral|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:~Introduction to school and community partners. Staff advisors for the program are identified and trained.~A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.~Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
283394|NCT02043080|Other|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
283395|NCT02043067|Other|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
283396|NCT02043054|Drug|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.~BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or~BMI < 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
283397|NCT02043054|Drug|Sitagliptin|Sitagliptin (Januvia®, Merck & Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
283398|NCT02043041|Other|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
283399|NCT02043028|Device|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
283400|NCT02043028|Device|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
283401|NCT02043015|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
283479|NCT02042391|Drug|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
283402|NCT02043015|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
283403|NCT02043015|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
283404|NCT02043015|Drug|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
283405|NCT02043015|Other|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
283406|NCT02043015|Behavioral|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
283407|NCT02043015|Behavioral|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
283408|NCT02043002|Procedure|18F-FDG-PET scan|
283409|NCT02042989|Drug|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
283410|NCT02042989|Drug|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.~Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
283411|NCT02042976|Behavioral|Mindfulness-based cognitive therapy|
283412|NCT02042976|Behavioral|Pulmonary rehabilitation|
283413|NCT02042950|Drug|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
283414|NCT02042937|Other|Exercise|Exercise to improve gluteus maximus recruitment
283415|NCT02042924|Radiation|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
283416|NCT02042924|Device|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
283417|NCT02042911|Drug|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
283418|NCT02042898|Other|Restrictive Transfusion Strategy|
283419|NCT02042898|Other|Liberal transfusion strategy|
283420|NCT02042885|Drug|OPB-111001|
283421|NCT02042872|Drug|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
283422|NCT02042859|Device|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
283423|NCT02042846|Device|SportWelding Fiji Anchor|
283424|NCT02042820|Other|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
283425|NCT02042807|Drug|Placebo|
283426|NCT02042807|Drug|MCS®|
283427|NCT02042781|Drug|PG545|PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
283428|NCT02042755|Device|trifocal intraocular lens|Standard cataract surgery
283429|NCT02042742|Dietary Supplement|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
283430|NCT02042742|Dietary Supplement|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
283431|NCT02042729|Drug|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
283522|NCT02041975|Dietary Supplement|Nutriose FB06|Wheat dextrin soluble fibre
283523|NCT02041975|Dietary Supplement|Placebo|
283567|NCT02041533|Drug|Cisplatin|
283432|NCT02042729|Drug|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
283433|NCT02042729|Drug|E2022 Matching Placebo- Current Formula Tape|
283434|NCT02042729|Drug|E2022 Matching Placebo- New Formula Tape|
283435|NCT02042716|Other|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
283436|NCT02042703|Device|anterior segment OCT|
283437|NCT02042690|Procedure|Haplo-identical HSCT|Haplo-identical Protocol: myeloablative human leukocyte antigen (HLA) haploidentical stem cell transplantation (haplo-SCT) using pretransplant ATG and granulocyte colony-stimulating factor (G-CSF)-stimulated grafts (ATG+G-CSF) GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
283438|NCT02042690|Drug|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
283439|NCT02042664|Drug|BYETTA treatment|
283440|NCT02042664|Drug|Metformine|
283441|NCT02042651|Device|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
283442|NCT02042651|Device|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
283443|NCT02042638|Drug|hCG 1500 IU three times a week|
283444|NCT02042638|Drug|Pregnyl (hCG) ampule 1500 IU/three times a week|
283445|NCT02042625|Procedure|Nasopharyngeal|
283446|NCT02042612|Drug|Sedation with sevoflurane during 48-hr in ICU|
283447|NCT02042599|Drug|Sedation with sevoflurane during 48-hr in ICU|
283448|NCT02042586|Other|Analysis of movement before total hip replacement|
283449|NCT02042586|Other|Analysis of movement after total hip replacement|
283450|NCT02042573|Device|rTMS|
283451|NCT02042573|Drug|SSRI (SEROPLEX ou ZOLOFT)|
283452|NCT02042573|Other|Genetic samples|
283453|NCT02042560|Other|Blood samples|
283454|NCT02042560|Other|Spleen samples|
283455|NCT02042547|Other|Tissue samples from the right atrium|
283456|NCT02042547|Other|Blood samples|
283457|NCT02042534|Drug|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
283458|NCT02042534|Drug|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
283459|NCT02042521|Drug|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
283460|NCT02042521|Drug|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
283461|NCT02042508|Other|strengthening|
283462|NCT02042508|Other|hybrid training programme|
283463|NCT02042495|Drug|Metformin|
283464|NCT02042482|Dietary Supplement|Coenzyme Q10U, L-carnitine|
283465|NCT02042456|Device|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
283466|NCT02042456|Device|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
283467|NCT02042456|Device|Full Field Digital Mammography|
283468|NCT02042443|Drug|Capecitabine|Given PO
283469|NCT02042443|Drug|Fluorouracil|Given IV
283470|NCT02042443|Other|Laboratory Biomarker Analysis|Correlative studies
283471|NCT02042443|Drug|Leucovorin Calcium|Given IV
283472|NCT02042443|Drug|Trametinib|Given PO
283473|NCT02042430|Drug|Epacadostat|Given PO
283474|NCT02042430|Other|Laboratory Biomarker Analysis|Correlative studies
283475|NCT02042430|Procedure|Therapeutic Conventional Surgery|Undergo surgery
283476|NCT02042417|Device|INRatio2 and CoaguChek|
283477|NCT02042404|Device|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
283478|NCT02042391|Drug|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
283480|NCT02042391|Drug|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
283481|NCT02042391|Drug|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
283482|NCT02042378|Drug|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
283483|NCT02042365|Procedure|ERAS (Enhanced recovery after surgery)|
283484|NCT02042352|Other|pH glove|
283485|NCT02042339|Drug|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
283486|NCT02042326|Drug|Sirolimus|For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
283487|NCT02042313|Other|continuous epidural infusion|
283488|NCT02042313|Other|combined paravertebral infusion and single shot of TAP block|
283489|NCT02042300|Device|XIENCE Xpedition/Alpine/Sierra|
283490|NCT02042287|Device|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
283491|NCT02042287|Drug|Metronidazole|Oral antibiotic
283492|NCT02042274|Dietary Supplement|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
283493|NCT02042248|Biological|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
283494|NCT02042235|Behavioral|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
283495|NCT02042222|Drug|Hydroxyurea|
283496|NCT02042196|Drug|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
283497|NCT02042196|Drug|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
283498|NCT02042196|Drug|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
283499|NCT02042196|Drug|Climara|0.075mg/d transdermal patch will be placed on skin.
283500|NCT02042196|Drug|Placebo transdermal patch|Inactive transdermal patch
283501|NCT02042183|Drug|Lubiprostone|12 mcg or 24 mcg administered orally twice daily (BID)
283502|NCT02042183|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
283503|NCT02042170|Drug|human growth hormone self-injection|
283504|NCT02042157|Behavioral|Bidet use|Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
283505|NCT02042157|Other|Regular toileting|Patients in the control arm will toilet as usual.
283506|NCT02042144|Drug|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
283507|NCT02042131|Behavioral|Treatment As Usual (TAU)|
283508|NCT02042131|Behavioral|Standard Crisis Response Plan (S-CRP)|
283509|NCT02042131|Behavioral|Enhanced Crisis Response Plan (E-CRP)|
283510|NCT02042118|Device|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
283511|NCT02042118|Device|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
283512|NCT02042092|Device|Ultrasound|
283513|NCT02042092|Device|MRA|
283514|NCT02042079|Procedure|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
283515|NCT02042066|Device|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
283516|NCT02042053|Device|PET/CT|
283517|NCT02042053|Device|PET/MRI|
283518|NCT02042027|Drug|Gamunex-C|Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
283519|NCT02042014|Drug|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
283520|NCT02042001|Drug|Immediate switch to TDF/FTC/RPV|
283521|NCT02042001|Drug|Switch to TDF/FTC/RPV after 24 weeks|Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV
283524|NCT02041962|Behavioral|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
283525|NCT02041962|Other|Educational Control|
283526|NCT02041936|Device|NanoKnife IRE System|
283527|NCT02041923|Behavioral|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
283528|NCT02041910|Biological|Stem Cells|MSCs injection intratesticular
283529|NCT02041910|Biological|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
283530|NCT02041897|Procedure|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
283531|NCT02041884|Behavioral|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
283532|NCT02041884|Behavioral|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
283533|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
283534|NCT02041871|Dietary Supplement|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
283535|NCT02041871|Dietary Supplement|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
283536|NCT02041858|Other|Altered Alarm Settings|An altered set of alarm parameter settings
283537|NCT02041845|Radiation|45 Gy in 30 fractions|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
283538|NCT02041845|Radiation|60 Gy in 40 fractions|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
283539|NCT02041832|Other|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
283540|NCT02041832|Device|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
283541|NCT02041819|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
283542|NCT02041793|Procedure|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
283543|NCT02041793|Procedure|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
283544|NCT02041780|Procedure|Shearwave electrography|
283545|NCT02041767|Drug|Ertapenem|One single injection of 1g of ertapenem before surgery
283546|NCT02041754|Device|IQP-AK-102|
283547|NCT02041754|Device|Placebo|
283548|NCT02041741|Behavioral|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
283549|NCT02041741|Behavioral|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
283550|NCT02041715|Drug|TKM-100802 for Injection|IV infusion
283551|NCT02041715|Drug|Placebo|IV infusion
283552|NCT02041702|Diagnostic Test|Non-Diagnostic Cardiac MRI scan|
283553|NCT02041689|Behavioral|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
283554|NCT02041689|Behavioral|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
283555|NCT02041689|Behavioral|Guided Activities|"This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.~The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.~For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.~The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment."
283556|NCT02041676|Procedure|Chest physiotherapy|
283557|NCT02041676|Procedure|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
283558|NCT02041663|Biological|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
283559|NCT02041650|Drug|Ticagrelor|
283560|NCT02041611|Procedure|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
283561|NCT02041598|Other|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
283562|NCT02041572|Behavioral|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
283571|NCT02041520|Drug|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
283572|NCT02041520|Other|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
283573|NCT02041507|Other|Air insufflation method.|Air insufflation colonoscopy.
283574|NCT02041507|Other|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
283575|NCT02041507|Other|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
283576|NCT02041494|Device|Ventralight|
283577|NCT02041494|Device|Strattice|
283578|NCT02041481|Drug|MEK inhibitor MEK162|Given PO
283579|NCT02041481|Drug|leucovorin calcium|Given IV
283580|NCT02041481|Drug|fluorouracil|Given IV
283581|NCT02041481|Drug|oxaliplatin|Given IV
283582|NCT02041481|Other|pharmacological study|Correlative studies
283583|NCT02041481|Other|Laboratory Biomarker Analysis|Correlative Studies
283584|NCT02041455|Drug|Melatonin and Placebo|
283585|NCT02041455|Drug|Amitriptyline and Placebo|
283586|NCT02041455|Drug|Melatonin and Amitriptylin|
283587|NCT02041442|Procedure|Electrical mapping of the urinary bladder|
283588|NCT02041429|Drug|Ruxolitinib|
283589|NCT02041429|Drug|Paclitaxel|
283590|NCT02041390|Other|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
283591|NCT02041390|Other|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
283592|NCT02041377|Device|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
283593|NCT02041351|Drug|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
283594|NCT02041338|Drug|Paclitaxel and carboplatin|
283595|NCT02041338|Drug|Paclitaxel|
283596|NCT02041338|Drug|Epirubicin and Paclitaxel|
283597|NCT02041325|Drug|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
283598|NCT02041325|Drug|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
283599|NCT02041312|Other|No intervention|No intervention will be needed.
283600|NCT02041299|Drug|Deferiprone|
283601|NCT02041299|Drug|Deferoxamine|
283602|NCT02041286|Device|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
283603|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
283604|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
283605|NCT02041273|Drug|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
283606|NCT02041260|Drug|Cabozantinib|
283607|NCT02041247|Biological|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
283608|NCT02041234|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
283609|NCT02041234|Drug|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
283610|NCT02041234|Drug|Xenical|Xenical: Up to 120 mg tds
283611|NCT02041234|Drug|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
283612|NCT02041234|Drug|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
283613|NCT02041221|Drug|SPARC1316 Dose 1|The subjects will receive SPARC1316.
283614|NCT02041221|Drug|Placebo|
283615|NCT02041221|Drug|SPARC1316 Dose 2|
283616|NCT02041221|Drug|SPARC1316 Dose 3|
283617|NCT02041221|Drug|SPARC1316 Dose 4|
283618|NCT02041221|Drug|SPARC1316 Dose 5|
283619|NCT02041208|Procedure|kidney transplantation|kidney transplantation
283620|NCT02041195|Drug|RM-493|
283621|NCT02041195|Drug|Placebo|
283622|NCT02041182|Behavioral|Pre-Visit Questionnaire|
283623|NCT02041169|Other|Subsequent walking performance|Subsequent walking performance
283624|NCT02041156|Other|aerobic and resistance training|
283625|NCT02041156|Other|aerobic combined with balance training|
283626|NCT02041143|Dietary Supplement|Milk protein|Study product will provide 25 g of protein to subjects.
283627|NCT02041143|Dietary Supplement|Placebo|Product with no protein
283628|NCT02041130|Device|Renal Denervation|
283629|NCT02041117|Drug|Rosuvastatin|Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
283783|NCT02039843|Other|Emotional Support Dog|-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran.
283630|NCT02041104|Dietary Supplement|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
283631|NCT02041104|Dietary Supplement|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 4 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
283632|NCT02041091|Drug|Tabalumab Auto-Injector|Administered SC
283633|NCT02041091|Drug|Tabalumab Prefilled Syringe|Administered SC
283634|NCT02041078|Procedure|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
283635|NCT02041078|Procedure|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
283636|NCT02041065|Device|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
283637|NCT02041065|Device|CUSA induced dissection|Ultrasound based destruction of the liver
283638|NCT02041052|Procedure|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
283639|NCT02041052|Procedure|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
283640|NCT02041026|Dietary Supplement|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
283641|NCT02041013|Other|Taking Card|Recordable greeting card-style discharge instruction card
283642|NCT02041000|Other|Adipose Derived Stem Cells|
283643|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (low dose).
283644|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (high dose).
283645|NCT02040987|Drug|Placebo|Placebo oral solution - one single dose
283646|NCT02040987|Drug|Moxifloxacin|Moxifloxacin tablet - one single dose
283647|NCT02040961|Device|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
283648|NCT02040948|Device|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
283649|NCT02040935|Drug|Trastuzumab|600 mg SC Q3W by SID
283650|NCT02040909|Drug|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
283651|NCT02040883|Drug|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
283652|NCT02040883|Drug|Tandospirone|Tandospirone，30mg per day
283653|NCT02040870|Drug|LDK378|750 mg once daily
283654|NCT02040857|Drug|Palbociclib|CDK 4/6 inhibitor
283655|NCT02040857|Drug|Endocrine Therapy|Endocrine Therapy
283656|NCT02040844|Drug|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
283657|NCT02040844|Drug|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
283658|NCT02040844|Drug|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
283659|NCT02040831|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
283660|NCT02040831|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
283661|NCT02040818|Drug|tigecycline, N-acetylcysteine, heparin combination|
283662|NCT02040818|Device|guide-wire exchange|
283663|NCT02040805|Behavioral|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
283664|NCT02040805|Behavioral|Peer Facilitated Manualized Support Group|Sixteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
283665|NCT02040792|Drug|TD-4208|
283666|NCT02040792|Drug|Placebo|
283667|NCT02040779|Drug|Beclomethasone dipropionate breath-actuated inhaler|Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
283668|NCT02040779|Drug|Placebo breath-actuated inhaler|Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
283669|NCT02040779|Drug|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
283670|NCT02040766|Drug|Beclomethasone dipropionate BAI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a breath-actuated inhaler (BAI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
283671|NCT02040766|Drug|Placebo BAI|Placebo was delivered by a single inhalation using a breath-actuated inhaler (BAI) twice each day.
283672|NCT02040766|Drug|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
283673|NCT02040766|Drug|Beclomethasone dipropionate MDI|Beclomethasone dipropionate (BDP), was delivered by a single inhalation using a metered-dose inhaler (MDI) at levels of 40 mcg or 80 mcg per inhalation, twice each day.
283674|NCT02040766|Drug|Placebo MDI|Placebo was delivered by a single inhalation using a metered-dose inhaler (MDI) twice each day.
283675|NCT02040753|Behavioral|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
283676|NCT02040727|Behavioral|Resistance Training|Supervised strength training 3 days per week for 24 weeks
283677|NCT02040727|Behavioral|No Resistance Training|No supervised strength training throughout the study
283678|NCT02040714|Procedure|osteotomy|Surgical procedures that improve femoral head containment
283679|NCT02040714|Procedure|multiple epiphyseal drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
283680|NCT02040662|Procedure|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
283681|NCT02040662|Procedure|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
283682|NCT02040662|Procedure|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:~patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)~paracetamol 1000 mg iv every 8 hrs~ketoprofen 100 mg iv every 12 hrs"
283683|NCT02040649|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
283684|NCT02040649|Other|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
283685|NCT02040636|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV|0.5 mL, Intramuscular
283686|NCT02040636|Biological|Hepatitis B vaccine|0.5 ml, Intramuscular
283687|NCT02040623|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
283688|NCT02040623|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
283689|NCT02040623|Other|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
283690|NCT02040610|Radiation|Hypofractionated Proton Therapy|
283691|NCT02040597|Drug|Beclometasone/Formoterol/Glycopyrrolate|
283692|NCT02040584|Drug|Minimisation of TAC|•EVR: Treatment started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR was adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may have been modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation was obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR were between 3-8 ng/mL, minimisation of TAC began, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which were levels that should have been maintained until Week 52 post-transplant. •MMF was withdrawn at the same time that EVR was introduced. •oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted
283693|NCT02040584|Drug|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should have been maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs was maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids was administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids was permitted (e.g. in patients with a history of HCV). It was recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should have followed the same administration protocol for corticosteroids based on history of HCV.
283694|NCT02040571|Device|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
283695|NCT02040571|Device|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.~In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.~Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
283696|NCT02040558|Drug|MNK-010|
283784|NCT02039830|Behavioral|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
283697|NCT02040532|Drug|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
283698|NCT02040519|Behavioral|Filling out voiding diaries.|
283699|NCT02040506|Drug|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
283700|NCT02040493|Radiation|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
283701|NCT02040480|Drug|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
283702|NCT02040480|Drug|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
283703|NCT02040454|Drug|Paclitaxel|
283704|NCT02040454|Procedure|Standard Therapy|
283705|NCT02040441|Drug|Spironolactone|
283706|NCT02040441|Drug|Placebo|
283707|NCT02040441|Drug|Standard care|Standard diabetes care
283708|NCT02040428|Biological|EVARREST™ Fibrin Sealant Patch|
283709|NCT02040428|Biological|Topical hemostat|
283710|NCT02040415|Drug|DW-1030(eperisone HCl) 75mg|
283711|NCT02040415|Drug|Myonal Tab.(eperisone HCl) 50mg|
283712|NCT02040415|Drug|Placebo drug of DW-1030|
283713|NCT02040415|Drug|Placebo drug of Myonal Tab.|
283714|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
283715|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
283716|NCT02040389|Behavioral|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
283717|NCT02040389|Behavioral|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
283718|NCT02040376|Drug|Metformin|Metformin and placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
283719|NCT02040376|Drug|Placebo|Metformin and placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
283720|NCT02040363|Procedure|Muscular biopsy|
283721|NCT02040363|Other|5-10 weeks sport training|
283722|NCT02040350|Drug|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
283723|NCT02040324|Device|Laryngeal mask with gastric access|
283724|NCT02040324|Device|Endotracheal tube|
283725|NCT02040311|Drug|Topiramate 96 mg daily|
283726|NCT02040311|Drug|Topiramate 192 mg daily|
283727|NCT02040311|Drug|Placebo|
283728|NCT02040298|Drug|Clemastine|4mg tablet twice daily
283729|NCT02040298|Drug|Placebo|Placebo tablet twice daily
283730|NCT02040285|Drug|Bisacodyl & PEG-CS|"the day before the CTC:~low fiber diet~at 15.00: 2 tablets of bisacodyl (5 mg)~at 17.00: 1 litre of PEG-CS~liquid diet~the day of the exam:~at home: 2 tablets of bisacodyl (5 mg)~at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
283731|NCT02040285|Drug|Iopamidol|"the day before CTC:~low fiber diet~at 15.00: 90 ml of Iopamidol in 250 ml of water~at 17.00: 90 ml of Iopamidol in 250 ml of water~at 20.00: start liquid diet"
283732|NCT02040272|Procedure|(Extended) pleurectomy decortication|
283733|NCT02040246|Drug|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
283734|NCT02040246|Drug|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
283735|NCT02040233|Drug|BAY1067197 (10 mg)|10 mg BAY1067197 for 7 d treatment once daily as oral application
283736|NCT02040233|Drug|BAY1067197|The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
283737|NCT02040233|Drug|Placebo (10 mg)|10 mg Placebo for 7 d treatment once daily as oral application
283738|NCT02040233|Drug|Placebo|5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
283739|NCT02040220|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
283740|NCT02040207|Drug|AM-101|AM-101 gel for intratympanic injection
283741|NCT02040194|Drug|AM-101|AM-101 gel for intratympanic injection
283742|NCT02040194|Drug|Placebo|Placebo gel for intratympanic injection
283743|NCT02040155|Device|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
283744|NCT02040142|Procedure|HIPEC|
283745|NCT02040142|Drug|Mitomycin C|
283746|NCT02040129|Device|Acrysof Toric IOL|Lens implantation following cataract surgery
283747|NCT02040116|Drug|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
283748|NCT02040103|Device|pneumatic compression|All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
283874|NCT02039115|Drug|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
283749|NCT02040090|Drug|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
283750|NCT02040090|Biological|KamRAB|
283751|NCT02040090|Biological|FDA approved commercially available HRIG product|
283752|NCT02040077|Behavioral|Computer + Fluency|
283753|NCT02040077|Behavioral|Computer Only|
283754|NCT02040077|Behavioral|Treatment as Usual|
283755|NCT02040064|Drug|Gefitinib|Oral tablet
283756|NCT02040064|Drug|Tremelimumab|IV
283757|NCT02040051|Behavioral|Sound isolation / Music therapy|"Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.~Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)"
283758|NCT02040038|Behavioral|LIVE|3-D Virtual Environment for DSMT/S
283759|NCT02040038|Behavioral|Website|2-D Website participation for DSMT/S
283760|NCT02040012|Drug|AZP-531|
283761|NCT02040012|Drug|Placebo|
283762|NCT02039999|Other|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
283763|NCT02039999|Other|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
283764|NCT02039999|Other|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
283765|NCT02039973|Behavioral|Task-sharing approach to group therapy|"Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions."
283766|NCT02039973|Behavioral|Enhanced standard of care|
283767|NCT02039960|Drug|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
283768|NCT02039947|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
283769|NCT02039947|Drug|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
283770|NCT02039934|Other|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.~Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
283771|NCT02039908|Drug|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
283772|NCT02039895|Radiation|HITS|Helical irradiation of the total skin by helical tomotherapy
283773|NCT02039869|Device|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
283774|NCT02039869|Drug|Proton pump inhibitor|Acid suppressing medication (over the counter)
283775|NCT02039869|Drug|Sucralfate|Coating agent for damaged intestinal lining.
283776|NCT02039856|Other|Multilevel stakeholder engagement|Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings
283777|NCT02039856|Other|Quality improvement (QI) education/training|Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
283778|NCT02039856|Other|Technical support|Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)
283779|NCT02039856|Other|Formative feedback|Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development
283780|NCT02039856|Other|External practice facilitation|Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread
283781|NCT02039856|Other|National policy guidance|VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
283782|NCT02039843|Other|Service Dog or Emotional Support Dog|"Emotional Support Dog. Service Dog - an assistance dog specifically trained to perform tasks that are specific to the person's disability and has public access privileges.~-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran."
283875|NCT02039089|Drug|E2006 2.5 mg|
283876|NCT02039089|Drug|E2006 10 mg|
283877|NCT02039089|Drug|E2006 25 mg|
283785|NCT02039830|Behavioral|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
283786|NCT02039817|Drug|IDN-6556|
283787|NCT02039804|Drug|Corticosteroids|Intra-bursal injection
283788|NCT02039804|Device|Hyaluronic acid|Intra-bursal injection
283789|NCT02039791|Biological|Nimotuzumab|200mg/w,weekly, 6 weeks
283790|NCT02039791|Drug|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
283791|NCT02039791|Drug|Paclitaxel|"175 mg/m2, d1~1 cycle/21d, 2 cycles."
283792|NCT02039778|Radiation|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:~The postoperative surgical bed + edema + margin & the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
283793|NCT02039765|Drug|Brimonidine tartrate|
283794|NCT02039752|Other|Treatment|
283795|NCT02039739|Device|Orsiro™ Drug Eluting Stent group|
283796|NCT02039726|Drug|Quizartinib|no details to specify
283797|NCT02039726|Drug|Salvage Chemotherapy|No details to specify.
283798|NCT02039713|Device|DeSyne drug eluting stent group|
283799|NCT02039700|Drug|Lesinurad 400 mg|
283800|NCT02039700|Drug|[14C]lesinurad (100 μg per 10 mL)|
283801|NCT02039687|Drug|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
283802|NCT02039687|Other|Placebo|Formulation buffer
283803|NCT02039674|Biological|Pembrolizumab|IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy
283804|NCT02039674|Drug|Paclitaxel|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
283805|NCT02039674|Drug|Carboplatin|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
283806|NCT02039674|Biological|Bevacizumab|IV on Day 1 of each 3-week cycle
283807|NCT02039674|Drug|Pemetrexed|IV on Day 1 of each 3-week cycle
283808|NCT02039674|Biological|Ipilimumab|IV on Day 1 of each 3-week cycle for a maximum of 4 administrations
283809|NCT02039674|Drug|Erlotinib|Orally (PO) once daily (QD)
283810|NCT02039674|Drug|Gefitinib|PO QD
283811|NCT02039661|Drug|Lidocaine Spray|These patients received 2 puff lidocaine spray
283812|NCT02039661|Drug|Placebo|
283813|NCT02039648|Other|Rumex acetosa L. extract|
283814|NCT02039648|Other|Placebo|
283815|NCT02039635|Dietary Supplement|Korean Red Ginseng|Given Orally
283816|NCT02039635|Dietary Supplement|Placebo|Given Orally
283817|NCT02039596|Other|Diet|
283818|NCT02039583|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
283819|NCT02039570|Other|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
283820|NCT02039557|Genetic|NiCord®/CordIn™|
283821|NCT02039544|Drug|Xuebi formula|
283822|NCT02039544|Drug|placebo|
283823|NCT02039531|Biological|Plasma rich in growth factors|
283824|NCT02039531|Drug|Hyaluronic Acid|
283825|NCT02039518|Drug|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
283826|NCT02039518|Other|observation group|observation group
283827|NCT02039505|Drug|Vedolizumab|Vedolizumab intravenous infusion
283828|NCT02039505|Drug|Vedolizumab placebo|Vedolizumab placebo
283829|NCT02039492|Procedure|Sympathetic Renal Denervation|
283830|NCT02039492|Drug|Treatment with aldactone|
283831|NCT02039479|Drug|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
283832|NCT02039479|Drug|Placebo|Placebo as ADD-on to every necessary treatment as usual
283833|NCT02039466|Procedure|volume controlled ventilation|
283834|NCT02039466|Procedure|pressure controlled ventilation|
283835|NCT02039453|Drug|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
283836|NCT02039453|Drug|pethidine dose|pethidine dose 50mg, IV bolus (25mg if < 50kg or >70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
283837|NCT02039440|Other|Blood draw|One-time blood draw
283838|NCT02039427|Drug|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
283839|NCT02039427|Other|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
283840|NCT02039427|Drug|Placebo|Normal saline 2 ml
283841|NCT02039401|Biological|VM202|
283842|NCT02039388|Procedure|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
283843|NCT02039375|Other|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
283844|NCT02039362|Drug|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
283845|NCT02039349|Drug|PF-05190457|
283846|NCT02039336|Drug|Dacomitinib|
283847|NCT02039336|Drug|PD-0325901|
283848|NCT02039336|Drug|Docetaxel|
283849|NCT02039323|Drug|Tenofovir|
283850|NCT02039323|Drug|Maraviroc|
283878|NCT02039089|Drug|Placebo|
283879|NCT02039076|Drug|avatrombopag|
283851|NCT02039297|Other|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
283852|NCT02039284|Device|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
283853|NCT02039284|Device|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
283854|NCT02039284|Device|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
283855|NCT02039284|Device|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
283856|NCT02039271|Other|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
283857|NCT02039258|Drug|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
283858|NCT02039245|Drug|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
283859|NCT02039232|Device|Pedicle screw system|
283860|NCT02039219|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
283861|NCT02039219|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
283862|NCT02039206|Device|Deep TMS|1Hz Stimulation
283863|NCT02039193|Behavioral|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, & Brown, 1992; Borkovec & Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
283864|NCT02039180|Drug|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
283865|NCT02039180|Drug|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
283866|NCT02039180|Drug|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
283867|NCT02039167|Device|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
283868|NCT02039154|Behavioral|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
283869|NCT02039154|Behavioral|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
283870|NCT02039141|Other|Every Little Step Counts Intervention|"Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc."
283871|NCT02039128|Dietary Supplement|Krill oil or Fish oil|
283872|NCT02039128|Dietary Supplement|Placebo|
283873|NCT02039115|Drug|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
283880|NCT02039063|Drug|E6011 2 mg/kg|
283886|NCT02039037|Device|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
283887|NCT02039037|Device|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
283888|NCT02039024|Drug|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
283889|NCT02039011|Drug|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
283890|NCT02039011|Drug|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
283891|NCT02038998|Device|Exer-Rest® TL|Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
283892|NCT02038985|Other|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
283893|NCT02038972|Genetic|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
283894|NCT02038959|Other|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
283895|NCT02038946|Drug|Nivolumab|
283896|NCT02038933|Drug|Nivolumab|
283897|NCT02038920|Drug|Vedolizumab|Vedolizumab intravenous injection
283898|NCT02038920|Drug|Vedolizumab placebo|Vedolizumab placebo
283899|NCT02038907|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
283900|NCT02038907|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
283901|NCT02038894|Drug|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
283902|NCT02038894|Drug|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
283903|NCT02038894|Drug|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
283904|NCT02038894|Drug|Propofol|
283905|NCT02038881|Biological|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
283906|NCT02038868|Drug|ASP4901|oral
283907|NCT02038868|Drug|Tamsulosin|oral
283908|NCT02038868|Drug|Placebo|oral
283909|NCT02038855|Behavioral|Integrated Intervention for Dual Problems and Early Action|Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
283910|NCT02038842|Biological|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
283911|NCT02038842|Biological|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
283912|NCT02038842|Biological|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
283913|NCT02038829|Drug|Placebo|Placebo
283914|NCT02038829|Drug|SUN101 3 mcg|SUN-101 3 mcg bid
283915|NCT02038829|Drug|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
283916|NCT02038829|Drug|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
283917|NCT02038829|Drug|SUN-101 50 mcg|SUN-101 50 mcg bid
283918|NCT02038829|Drug|Aclidinium|Aclidinium 400 mcg bid
283919|NCT02038816|Drug|Deferasirox + Azacitidine|"Deferasirox:~20 mg/kg/d for < 14ml/kg/mo pRBCs (~ <4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
283920|NCT02038816|Drug|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
283921|NCT02038790|Drug|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
283922|NCT02038790|Drug|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
283923|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
284076|NCT02037672|Drug|metformin and roflumilast|
283924|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
283925|NCT02038777|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
283926|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
283927|NCT02038777|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
283928|NCT02038777|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
283929|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
283930|NCT02038777|Drug|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
283931|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
283932|NCT02038777|Drug|LDAC|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
283933|NCT02038764|Drug|Placebo|Placebo
283934|NCT02038764|Biological|PF-06342674 Dose A|Multiple SC Doses
283935|NCT02038764|Biological|PF-06342674 Dose B|Multiple SC Doses
283936|NCT02038764|Biological|PF-06342674 Dose C|Multiple SC Doses
283937|NCT02038764|Biological|PF-06342674 Dose D|Multiple SC Doses
283938|NCT02038738|Drug|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
283939|NCT02038712|Dietary Supplement|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
283940|NCT02038712|Dietary Supplement|Fasted condition|Subjects will consume 600mL plain water.
283941|NCT02038712|Procedure|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
283942|NCT02038712|Behavioral|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
283943|NCT02038712|Procedure|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
283944|NCT02038699|Drug|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
283945|NCT02038686|Device|PFN-A|
283946|NCT02038673|Drug|ASP5878|oral
283947|NCT02038660|Device|Balloon angioplasty|
283948|NCT02038647|Drug|Alisertib|Alisertib tablets
283949|NCT02038647|Drug|Placebo|Placebo matching tablets
283950|NCT02038647|Drug|Paclitaxel|Paclitaxel intravenous injection
283951|NCT02038634|Drug|Betamethasone|
283952|NCT02038634|Device|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
283953|NCT02038621|Drug|Paclitaxel|
283954|NCT02038621|Drug|Oxaliplatin and Capecitabine|Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\PR\SD,then randomized into this clinical trial.
283955|NCT02038608|Device|PET|
283956|NCT02038595|Radiation|PET imaging|
283957|NCT02038582|Other|POC CD4 Testing|Point of Care CD4 testing
283958|NCT02038582|Other|CD4 Referral|Referral to CD4 testing
283959|NCT02038582|Behavioral|Lay Counselor Follow-up|Follow-up from a lay counselor
283960|NCT02038582|Behavioral|Clinic Accompaniment|Accompaniment to the clinic by a counselor
283961|NCT02038582|Behavioral|Clinic Referral|Referral to clinic
283962|NCT02038582|Behavioral|SMS Reminder|SMS reminder for male circumcision
283963|NCT02038582|Behavioral|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
283964|NCT02038582|Other|POC VL|POC VL testing for HIV infected persons on ART
283965|NCT02038582|Other|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
283966|NCT02038569|Drug|LEO 80185 gel|
283967|NCT02038556|Behavioral|cognitive behaviorial therapy -Insomnia|
283968|NCT02038543|Drug|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
283969|NCT02038491|Procedure|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
283970|NCT02038478|Biological|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
283971|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
283972|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
283973|NCT02038452|Drug|Depo-Medrone|Steroid Injection
283974|NCT02038452|Device|Wrist Splint|Simple wrist splint
283975|NCT02038439|Behavioral|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
283976|NCT02038439|Behavioral|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
283977|NCT02038439|Behavioral|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
283978|NCT02038426|Biological|BLOOD SAMPLES|
283979|NCT02038426|Device|Radiographs of the sacroiliac joints|
283980|NCT02038426|Device|Radiographs of heels|
283981|NCT02038426|Device|SCAN|
283982|NCT02038400|Device|KINETUBE medical Device|
283983|NCT02038400|Device|insertion of tympanic ventilation tubes (tympanostomy)|
283984|NCT02038387|Behavioral|normocaloric low cholesterol diet|
283985|NCT02038374|Procedure|biopsies|
283986|NCT02038361|Genetic|blood draw|
283987|NCT02038348|Device|PET with 18F-FDOPA|
283988|NCT02038335|Drug|DMPA|Depot medroxyprogesterone acetate
283989|NCT02038335|Drug|NET-EN|Norethisterone enantate
283990|NCT02038335|Drug|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
283991|NCT02038335|Device|LNG-I|Levonorgestrel subdermal implant
283992|NCT02038335|Device|ENG-I|Etonogestrel subdermal implant
283993|NCT02038335|Device|Cu-IUD|Copper IUD
283994|NCT02038322|Device|The Stork - Conception Aid|
283995|NCT02038296|Procedure|transarterial chemoembolization|
283996|NCT02038257|Procedure|MKTP (melanocyte keratinocyte transplant procedure)|Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
283997|NCT02038257|Device|Collagen Dressing|Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
283998|NCT02038257|Device|Vaseline Impregnated Gauze|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
283999|NCT02038257|Device|Carbon Dioxide Laser|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
284000|NCT02038257|Device|Dermabrasion|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
284001|NCT02038244|Other|Multimodal integrative medicine inpatient treatment program|
284002|NCT02038231|Behavioral|Parenting Mindfully Program|see Arm Description.
284003|NCT02038231|Other|Parent Education Program|See Arm Description.
284004|NCT02038218|Drug|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.~Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:~Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;~Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.~Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
284005|NCT02038192|Behavioral|Living with Hope Program|"The Living with Hope Program is based on the research team's grounded theory study Hope and Connection. The film  Connecting with Hope reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer."
284006|NCT02038192|Behavioral|Stories of the Present|Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
284007|NCT02038179|Drug|Allopurinol|Participants who received allopurinol as urate lowering therapy, at a daily dose of 300 mg once daily by mouth for a 4 week duration during the first or second phase of the study.
284008|NCT02038179|Drug|Placebo|Participants who received placebo tablet (matching Allopurinol 300 mg) daily by mouth for a 4 week duration during the first or second phase of the study.
284009|NCT02038153|Drug|Lenalidomide|Given PO
284010|NCT02038153|Other|Laboratory Biomarker Analysis|Correlative studies
284011|NCT02038140|Device|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
284012|NCT02038114|Behavioral|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
284013|NCT02038101|Behavioral|Education and Feedback|"Formal Rounds on AUC for TTE~Appropriate Use for TTE Application for Smartphone~Individualized Feedback Reports provided by email"
284014|NCT02038075|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|
284015|NCT02038075|Behavioral|Treatment As Usual (TAU)|
284016|NCT02038062|Procedure|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
284017|NCT02038049|Drug|VAY736|Single intravenous infusion of VAY736 (10 mg/kg)
284018|NCT02038049|Drug|Placebo|Placebo to VAY736
284019|NCT02038036|Drug|Best Available Therapy|Best Available Therapy as selected by the investigator from the below: 1. Hydroxyurea 2. IFN/PEG-IFN 3. Pipobroman 4. Anagrelide 5. IMIDs 6. Observation only
284020|NCT02038036|Drug|ruxolitinib|Supplied as tablets. Starting dose of 10 mg bid. Based on efficacy and safety parameters, dose may be increased or decreased. Maximum dose allowed is 25mg bid.
284021|NCT02038023|Drug|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
284022|NCT02038010|Drug|PI3K inhibitor BYL719|Given PO
284023|NCT02038010|Biological|ado-trastuzumab emtansine|Given IV
284024|NCT02038010|Other|pharmacological study|Correlative studies
284025|NCT02038010|Other|laboratory biomarker analysis|Optional correlative studies
284026|NCT02037997|Drug|docetaxel|docetaxel 75mg/m2 ivgtt D1
284027|NCT02037997|Drug|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
284028|NCT02037997|Drug|Erlotinib|Erlotinib 150mg qd
284029|NCT02037984|Biological|Prevnar 13®|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 µg each), and 6B (4.4 µg) in each 0.5 mL dose.
284030|NCT02037984|Biological|V114 1x:1x:1x|V114 1x:1x:1x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 125 µg of Aluminum Phosphate Adjuvant (APA).
284152|NCT02037165|Drug|Celecoxib|Celecoxib hard capsule
284031|NCT02037984|Biological|V114 2x:2x:2x|V114 2x:2x:2x contains 4.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
284032|NCT02037984|Biological|V114 2x:1x:2x|V114 2x:1x:2x contains 4.0 μg of polysaccharide serotypes 6A, 18C, 19A, 19F, and 23F; 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 7F, 9V, 14, 22F, and 33F; 8.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
284033|NCT02037984|Biological|V114 1x:1x:2x|V114 1x:1x:2x contains 2.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 4.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
284034|NCT02037984|Biological|V114 0.5x:0.5x:2x|V114 0.5x:0.5x:2x contains 1.0 μg of polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; 2.0 μg of polysaccharide serotype 6B; and 250 µg of APA.
284035|NCT02037971|Procedure|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
284036|NCT02037971|Other|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
284037|NCT02037958|Device|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
284038|NCT02037958|Device|Endotracheal Tube|Patients who receive endotracheal intubation
284039|NCT02037945|Procedure|18F-FCH PET Scan|
284040|NCT02037932|Device|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
284041|NCT02037919|Other|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
284042|NCT02037919|Other|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
284043|NCT02037906|Radiation|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
284044|NCT02037906|Radiation|Constant Energy SWL|Constant dose at 20 kv
284045|NCT02037906|Radiation|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
284046|NCT02037893|Drug|Antipyrine and Benzocaine otic solution|antipyrine 54 mg and benzocaine 14 mg
284047|NCT02037893|Drug|Antipyrine Otic Solution|Antipyrine 54 mg and glycerine dehydrated to 1.0 mL
284048|NCT02037893|Drug|Benzocaine Otic Solution|benzocaine 14 mg and glycerine dehydrated to 1.0 mL
284049|NCT02037893|Drug|Placebo Otic solution|Placebo otic solution will be glycerin that is dehydrated
284050|NCT02037880|Procedure|Lumbar puncture|
284051|NCT02037880|Device|Magnetic Resonance Imaging (MRI) of the brain|
284052|NCT02037867|Device|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
284053|NCT02037854|Other|Nutrient formulation|
284054|NCT02037841|Other|Nursing-driven clinical pathway for management of inpatient asthma|
284055|NCT02037815|Drug|20% mannitol solution, 125 ml, IV infusion in 15 min|
284056|NCT02037815|Drug|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
284057|NCT02037802|Device|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
284058|NCT02037802|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
284059|NCT02037802|Drug|Propofol|fentanyl propofol atracurium besylate
284060|NCT02037802|Drug|Bupivacaine|
284061|NCT02037802|Drug|Fentanyl|
284062|NCT02037776|Drug|Rikkunshito|- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
284063|NCT02037776|Drug|Rikkunshito placebo|- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
284064|NCT02037750|Behavioral|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
284065|NCT02037737|Drug|Abatacept|
284066|NCT02037724|Dietary Supplement|supplement containing 60 mg iron sulfate|control agent
284067|NCT02037724|Dietary Supplement|iron rich food supplement (60 mg iron)|contains 60 mg of iron
284068|NCT02037724|Dietary Supplement|iron rich food supplement (10 mg iron)|contains 10 mg iron
284069|NCT02037724|Dietary Supplement|supplement containing 10 mg iron sulfate|control agent
284070|NCT02037711|Drug|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
284071|NCT02037711|Drug|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
284072|NCT02037698|Device|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
284073|NCT02037685|Behavioral|Motivational Interviewing (MINT)|"MINT has the following basic structure and goals:~Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.~Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.~Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon"
284074|NCT02037685|Other|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
284075|NCT02037672|Drug|metformin|
284077|NCT02037659|Procedure|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
284078|NCT02037646|Other|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
284079|NCT02037646|Other|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
284080|NCT02037646|Procedure|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
284081|NCT02037646|Other|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
284082|NCT02037646|Other|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
284083|NCT02037646|Other|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
284084|NCT02037633|Drug|Fentanyl|Fentanyl IV
284085|NCT02037633|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
284086|NCT02037633|Drug|ropivacaine|
284087|NCT02037620|Device|5-6-5 Specify electrode|
284088|NCT02037620|Device|Restore Advance Pulse Generator|
284089|NCT02037594|Behavioral|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
284090|NCT02037594|Behavioral|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
284091|NCT02037594|Behavioral|PrEP Information (Active Control)|Standard of Care Information about PrEP
284092|NCT02037594|Behavioral|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
284093|NCT02037581|Behavioral|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
284094|NCT02037581|Behavioral|Standard Care|Standard care as being offered by private psychiatrists
284095|NCT02037568|Behavioral|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
284096|NCT02037555|Biological|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
284097|NCT02037555|Other|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
284098|NCT02037542|Behavioral|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
284099|NCT02037529|Drug|Eribulin Mesylate|Given IV
284100|NCT02037529|Other|Laboratory Biomarker Analysis|Correlative studies
284101|NCT02037529|Drug|Paclitaxel|Given IV
284102|NCT02037529|Other|Quality-of-Life Assessment|Ancillary studies
284103|NCT02037516|Device|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
284104|NCT02037516|Drug|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
284105|NCT02037516|Device|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
284106|NCT02037503|Drug|Ketamine|
284107|NCT02037503|Drug|Saline|
284108|NCT02037490|Behavioral|Grow2Gether|"Participants in this intervention will:~Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~View educational videos addressing topics related to healthy infant growth~Create photos/videos modeling healthy behaviors and post them to the group~Provide and receive feedback on posts~Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person."
284109|NCT02037477|Drug|Vonoprazan|Vonoprazan tablets
284110|NCT02037477|Drug|Esomeprazole|Esomeprazole capsules
284111|NCT02037477|Drug|Rabeprazole sodium|Rabeprazole sodium tablets
284112|NCT02037464|Dietary Supplement|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
284113|NCT02037451|Procedure|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
284114|NCT02037438|Other|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention utilized standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
284148|NCT02037178|Other|Second ultrasound interpretation|The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
284149|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
284150|NCT02037165|Drug|Pregabalin|Pregabalin hard capsule
284151|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
284115|NCT02037438|Other|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention implemented new methodologies for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal was designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
284116|NCT02037425|Drug|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
284117|NCT02037412|Drug|Ticagrelor|Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
284118|NCT02037412|Drug|Clopidogrel|Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
284119|NCT02037399|Drug|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
284120|NCT02037399|Drug|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.~At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
284121|NCT02037386|Device|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
284122|NCT02037373|Biological|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
284123|NCT02037373|Biological|Plasma|Plasma as prescribed by the treating physician.
284124|NCT02037360|Behavioral|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
284125|NCT02037360|Behavioral|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
284126|NCT02037347|Drug|Palifermin|
284127|NCT02037334|Device|CERVICAL ASPIRATOR 3.2|No intervention is done except for measuring the stiffness of the cervix in pregnant women
284128|NCT02037308|Dietary Supplement|Bread|
284129|NCT02037295|Drug|Oral Vancomycin|Oral vancomycin versus placebo
284130|NCT02037295|Other|Nutritional (over and underfeeding)|Overfeeding and underfeeding
284131|NCT02037295|Other|Oral Vancomycin|Oral vancomycin versus placebo
284132|NCT02037282|Drug|Anti-influenza IVIG|
284133|NCT02037256|Drug|bortezomib|Given IV
284134|NCT02037256|Biological|filgrastim|Given SC
284135|NCT02037256|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
284136|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment|Compound level meeting
284137|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
284138|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
284139|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
284140|NCT02037230|Drug|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
284141|NCT02037230|Drug|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
284142|NCT02037230|Radiation|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
284143|NCT02037217|Device|ExAblate Transcranial MRgFUS System|
284144|NCT02037204|Other|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
284145|NCT02037191|Drug|Methotrexate|"Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
284146|NCT02037191|Drug|Placebo|"Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):~methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
284147|NCT02037178|Other|First ultrasound reading|First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
284153|NCT02037152|Behavioral|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
284154|NCT02037139|Other|Screening|Standard care screening
284155|NCT02037139|Other|Brochure|Participants are given an illustrated educational brochure
284156|NCT02037139|Behavioral|Education|Participants undergo a in-person educational intervention
284157|NCT02037126|Drug|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
284158|NCT02037126|Drug|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
284159|NCT02037087|Behavioral|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
284160|NCT02037087|Behavioral|Care seeking|"Danger-sign recognition~Reminders for government projects"
284161|NCT02037087|Behavioral|Full bank of SMS|"Danger-sign recognition~Reminders for government projects~Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression"
284162|NCT02037074|Drug|Drug: EVP-6308|Arms 1, 2, 3
284163|NCT02037074|Drug|Placebo|Arm 4
284164|NCT02037061|Drug|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
284165|NCT02037061|Other|Normal Saline|
284166|NCT02037048|Drug|oxaliplatin|Given IV
284167|NCT02037048|Drug|leucovorin calcium|Given IV
284168|NCT02037048|Drug|fluorouracil|Given IV
284169|NCT02037048|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
284170|NCT02037048|Radiation|radiation therapy|Undergo radiation therapy
284171|NCT02037048|Drug|carboplatin|Given IV
284172|NCT02037048|Drug|paclitaxel|Given IV
284173|NCT02037035|Drug|Ketamine|
284174|NCT02037022|Behavioral|Pivotal Response Treatment Package (PRT-P)|
284175|NCT02037009|Other|Health care organization (anesthetic surveillance)|
284176|NCT02036983|Procedure|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
284177|NCT02036983|Procedure|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
284178|NCT02036983|Procedure|Opioid IV medications (Control)|Standard anesthetic technique.
284179|NCT02036970|Drug|Bardoxolone methyl|
284180|NCT02036970|Drug|Placebo|
284181|NCT02036957|Procedure|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
284182|NCT02036957|Procedure|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
284183|NCT02036931|Device|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
284184|NCT02036931|Drug|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
284185|NCT02036931|Device|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
284186|NCT02036918|Drug|Sipuleucel-T|
284187|NCT02036918|Procedure|Lymph Node Biopsy|
284188|NCT02036905|Other|Cervical and thoracic mobilization|Described in arm description
284189|NCT02036905|Other|cervical and thoracic manipulation|described in arm description
284190|NCT02036892|Behavioral|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
284191|NCT02036892|Behavioral|Lifestyle counseling|Lifestyle counseling
284192|NCT02036879|Drug|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
284193|NCT02036866|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
284194|NCT02036866|Other|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
284195|NCT02036866|Other|No Intervention|Patients will be instructed to maintain their usual activity level.
284196|NCT02036853|Drug|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (~1-4g/kg/day, depending on age).~Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
284197|NCT02036840|Drug|Antibiotic|
284198|NCT02036827|Drug|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
284199|NCT02036814|Behavioral|Program Health Education|
284200|NCT02036801|Other|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
284383|NCT02035618|Other|Exercises|Strengthening and stretching
284201|NCT02036788|Other|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
284202|NCT02036788|Other|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
284203|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
284204|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
284205|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
284206|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
284207|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
284208|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
284209|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
284210|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
284211|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
284212|NCT02036775|Drug|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
284213|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
284214|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
284215|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
284216|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
284217|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
284218|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
284219|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
284220|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
284221|NCT02036762|Other|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
284222|NCT02036749|Procedure|nerve block|quadratus lumborum block
284223|NCT02036736|Drug|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL~Sufentanil (0.15 mg / kg intravenously (IV))~Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
284224|NCT02036736|Drug|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)~Sufentanil (0.15 mg / kg IV)~Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
284225|NCT02036723|Drug|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
284226|NCT02036723|Drug|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
284227|NCT02036697|Drug|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
284228|NCT02036697|Drug|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
284229|NCT02036697|Drug|Morphine|morphine 150 mcg.
284230|NCT02036697|Drug|Fentanyl|15 mcg
284231|NCT02036684|Behavioral|Prehabilitation (PREHAB)|
284232|NCT02036671|Device|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
284233|NCT02036658|Behavioral|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
284234|NCT02036658|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction will be completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
284235|NCT02036645|Biological|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
284236|NCT02036645|Biological|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
284237|NCT02036645|Biological|IV Placebo|Placebo for IV injection
284238|NCT02036645|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
284239|NCT02036632|Device|Eye Patching|
284240|NCT02036606|Behavioral|questionary|
284241|NCT02036593|Behavioral|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
284242|NCT02036580|Biological|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
284243|NCT02036580|Biological|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
284244|NCT02036580|Other|Placebo|
284245|NCT02036554|Drug|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
284246|NCT02036554|Drug|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
284247|NCT02036554|Drug|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
284248|NCT02036541|Device|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
284249|NCT02036528|Drug|Gentamicin Topical Gel|
284250|NCT02036528|Drug|Ciprofloxacin|
284251|NCT02036528|Drug|Doxycycline|
284475|NCT02034929|Device|Standard colonoscopy|Standard colonoscopy
284252|NCT02036515|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
284253|NCT02036515|Drug|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
284254|NCT02036515|Drug|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
284255|NCT02036515|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
284256|NCT02036515|Drug|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
284257|NCT02036515|Drug|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
284258|NCT02036515|Biological|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
284259|NCT02036515|Drug|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
284260|NCT02036502|Biological|Pembrolizumab|Intravenous (IV) infusion
284261|NCT02036502|Drug|Lenalidomide|Oral capsule
284262|NCT02036502|Drug|Dexamethasone|Oral tablet
284263|NCT02036502|Drug|Carfilzomib|IV infusion
284264|NCT02036489|Drug|Vincristine|
284265|NCT02036489|Drug|Daunorubicin|
284266|NCT02036489|Drug|Prednisone|
284267|NCT02036489|Drug|L-asparaginase|
284268|NCT02036489|Drug|Ciclophosphamide|
284269|NCT02036489|Drug|Metotrexate|
284270|NCT02036489|Drug|ARA-C|
284271|NCT02036489|Drug|Hidrocortisone|
284272|NCT02036489|Drug|Mercaptopurine|
284273|NCT02036489|Drug|VP-16|
284274|NCT02036489|Drug|Dexametasone|
284275|NCT02036476|Drug|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
284276|NCT02036463|Drug|Prednisone|
284277|NCT02036463|Drug|Placebo|
284278|NCT02036450|Device|Implantable loop recorder (Medtronic Reveal LINQ(TM))|The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, oral anticoagulation is initiated. Decision about specific type of oral anticoagulation, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
284279|NCT02036437|Drug|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
284280|NCT02036437|Drug|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
284281|NCT02036424|Drug|Ozurdex|intravitreal steroid
284282|NCT02036424|Drug|Bevacizumab|antiVEGF
284283|NCT02036398|Device|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
284284|NCT02036398|Device|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
284285|NCT02036372|Drug|Liraglutide|
284286|NCT02036372|Drug|Insulin bolus|
284287|NCT02036372|Drug|GIK infusion|continuous infusion
284288|NCT02036359|Drug|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
284289|NCT02036359|Drug|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
284290|NCT02036346|Dietary Supplement|Oral Ηydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium citrate, food additives and water.
284291|NCT02036346|Other|Advise on calculated oral fluid requirements|
284292|NCT02036346|Other|No nutritional advice will be given|
284293|NCT02036320|Device|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
284294|NCT02036307|Dietary Supplement|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
284295|NCT02036307|Dietary Supplement|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
284296|NCT02036294|Other|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
284297|NCT02036294|Other|Usual Care|Standard Healthcare Services
284298|NCT02036281|Drug|Substance P-Saporin|
284299|NCT02036268|Behavioral|Standard|Standard ostomy education
284300|NCT02036268|Behavioral|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
284301|NCT02036268|Behavioral|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
284302|NCT02036255|Drug|Taurolidine Urokinase|
284303|NCT02036255|Drug|Taurolidine Heparin|
284476|NCT02034916|Drug|talazoparib|
284304|NCT02036242|Drug|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
284305|NCT02036242|Drug|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
284306|NCT02036242|Drug|Ropivacaine|
284307|NCT02036229|Drug|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
284308|NCT02036203|Device|SCu300A IUB|Spherical copper contraceptive
284309|NCT02036203|Device|TCu380A IUD|T-shaped copper IUD
284310|NCT02036177|Device|SCu300A IUB intrauterine device|Spherical copper IUD
284311|NCT02036177|Device|T380A IUD|T-shaped copper IUD
284312|NCT02036164|Radiation|Pelvic radiation|"Radiation:~Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks~Brachytherapy 30-35 Gy for 4-5 times"
284313|NCT02036164|Drug|Cisplatin|Cisplatin 40 mg/m2 i.v.
284314|NCT02036164|Drug|Paclitaxel|Paclitaxel 175 mg m2 i.v.
284315|NCT02036164|Drug|Carboplatin|Carboplatin AUC 5 i.v.
284316|NCT02036151|Drug|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
284317|NCT02036151|Drug|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
284318|NCT02036138|Procedure|Laparoscopic Sleeve Gastrectomy|
284319|NCT02036138|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
284320|NCT02036138|Drug|Advanced Medical Therapy|
284321|NCT02036125|Device|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
284322|NCT02036125|Drug|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
284323|NCT02036112|Procedure|conventional ELAPE|device
284324|NCT02036112|Procedure|Individual ELAPE|device
284325|NCT02036099|Other|Driving in Mild Dementia Decision Tool|Study participants will be screening patients for fitness to drive using our DMD-DT, instead of using their usual care strategies.
284326|NCT02036086|Drug|Vemurafenib|Drug
284327|NCT02036086|Drug|Cobimetinib|Drug
284328|NCT02036073|Drug|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
284329|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
284330|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
284331|NCT02036047|Device|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
284332|NCT02036047|Device|Regular polypectomy snare (Snare Master, SD-210U-10)|
284333|NCT02036034|Device|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
284334|NCT02036034|Device|warming blanket|warming blanket placed on torso of patient under the drape.
284335|NCT02036008|Other|Liver MRI with Gdfos|"Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd."
284336|NCT02036008|Other|Liver MRI with EcGd|"Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging."
284337|NCT02035995|Other|Pregnant volunteers with GDM|
284338|NCT02035982|Drug|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
284339|NCT02035982|Drug|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
284340|NCT02035969|Behavioral|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.~For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
284341|NCT02035956|Biological|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
284342|NCT02035943|Dietary Supplement|Insulin separated|separate continuos infusion of insulin
284343|NCT02035943|Dietary Supplement|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
284344|NCT02035930|Drug|dexmedetomidine|
284345|NCT02035917|Device|Locking plate|
284346|NCT02035917|Device|Non-Locking plate|
284347|NCT02035904|Drug|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
284348|NCT02035904|Drug|saline|patient controlled infusion from the 2nd day after surgery
284349|NCT02035904|Drug|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
284350|NCT02035904|Device|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
284351|NCT02035904|Drug|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
284352|NCT02035904|Drug|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
284353|NCT02035891|Drug|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
284354|NCT02035891|Drug|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
284355|NCT02035878|Other|Probiotics|probiotic intervention: 400mg of probiotic capsule
284356|NCT02035878|Drug|Placebo|placebo comparator
284357|NCT02035852|Other|MRI|3T MRI vs. 7T MRI
284358|NCT02035839|Device|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
284359|NCT02035839|Device|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
284360|NCT02035839|Device|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
284361|NCT02035826|Behavioral|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
284362|NCT02035813|Drug|Ribociclib|Ribociclib/Everolimus in combination with endocrine therapy
284363|NCT02035813|Drug|Eribulin|
284364|NCT02035800|Drug|Adalimumab|Patient will received medication as standard of care
284365|NCT02035787|Drug|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
284366|NCT02035774|Procedure|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
284367|NCT02035748|Drug|Ocriplasmin|0.5 mg/0.2 mL solution for injection
284368|NCT02035735|Procedure|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
284369|NCT02035722|Behavioral|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
284370|NCT02035722|Behavioral|Video|AMD-related information is presented as in the form of a video
284371|NCT02035709|Drug|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
284372|NCT02035696|Biological|Trivalent influenza vaccine (TIVc)|
284373|NCT02035696|Biological|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
284374|NCT02035683|Procedure|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
284375|NCT02035670|Other|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.~The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
284376|NCT02035657|Biological|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
284377|NCT02035644|Drug|Jinlida granules|
284378|NCT02035644|Drug|placebo granules|
284379|NCT02035631|Behavioral|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
284380|NCT02035631|Behavioral|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
284381|NCT02035631|Behavioral|Minimal diet intervention|Some basic diet recommendations
284382|NCT02035631|Behavioral|Minimal physical activity intervention|Some basic recommendations on physical activity
284384|NCT02035618|Other|Exercises + Manual Therapy|Mobilization; massage; post-isometric relaxation; strengthening; stretching
284385|NCT02035605|Drug|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
284386|NCT02035605|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
284387|NCT02035592|Other|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
284388|NCT02035592|Other|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
284389|NCT02035592|Other|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
284390|NCT02035579|Behavioral|Aerobic Training Intervention|
284391|NCT02035579|Behavioral|Stretching Intervention|
284392|NCT02035566|Other|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
284393|NCT02035553|Drug|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
284394|NCT02035553|Drug|Placebo|Placebo, two tablets, once daily by mouth
284395|NCT02035540|Other|Decellularized human valves|
284396|NCT02035527|Drug|sorafenib tosylate|Given daily PO in the a.m.
284397|NCT02035527|Drug|cisplatin|Given IV over 1 hour following Docetaxel administration
284398|NCT02035527|Drug|docetaxel|Given IV 1 hour prior to cisplatin administration
284399|NCT02035527|Other|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
284400|NCT02035514|Biological|Bone marrow autologous mesenchymal stem cells transplantation|
284401|NCT02035501|Drug|L-Tyrosine|
284402|NCT02035501|Drug|Placebo|
284403|NCT02035488|Drug|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
284404|NCT02035475|Device|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
284405|NCT02035449|Device|McGrath MAC|McGrath MAC is a videolaryngoscope
284406|NCT02035436|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
284407|NCT02035436|Other|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
284408|NCT02035423|Dietary Supplement|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
284409|NCT02035423|Dietary Supplement|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
284410|NCT02035423|Dietary Supplement|Non-Fortified Milk|Daily consumption of non-fortified milk
284411|NCT02035410|Procedure|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
284412|NCT02035397|Drug|Botulinum Toxin Type A|
284413|NCT02035397|Drug|Saline solution|
284414|NCT02035384|Drug|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
284415|NCT02035371|Drug|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
284416|NCT02035371|Drug|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
284417|NCT02035358|Biological|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.~Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
284418|NCT02035345|Drug|Carboplatin|
284419|NCT02035332|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
284420|NCT02035306|Other|non invasive co-oximetry haemaglobin measurement|
284421|NCT02035293|Other|PEP|
284422|NCT02035267|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
284423|NCT02035267|Drug|Placebo|Phosphate buffered saline placebo for injection.
284424|NCT02035254|Other|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
284425|NCT02035241|Dietary Supplement|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
284426|NCT02035241|Dietary Supplement|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
284427|NCT02035241|Dietary Supplement|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
284477|NCT02034903|Other|Feedings warmed with commercial warmer|
284428|NCT02035241|Dietary Supplement|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
284429|NCT02035241|Dietary Supplement|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
284430|NCT02035241|Dietary Supplement|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
284431|NCT02035228|Device|Abdominal Stimulation - low / early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the first half of exhalation"
284432|NCT02035228|Device|Abdominal stimulation - low/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current for the second half of exhalation"
284433|NCT02035228|Device|Abdominal Stimulation - low/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at low stimulation current throughout exhalation"
284434|NCT02035228|Device|Abdominal stimulation - med/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the first half of exhalation"
284435|NCT02035228|Device|Abdominal stimulation - med/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current for the second half of exhalation"
284436|NCT02035228|Device|Abdominal Stimulation - med/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at medium stimulation current throughout exhalation"
284437|NCT02035228|Device|Abdominal Stimulation - high/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current for the first half of exhalation"
284438|NCT02035228|Device|Abdominal Stimulation - high/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at hig stimulation current for the second half of exhalation"
284439|NCT02035228|Device|Abdominal Stimulation - high/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.~Stimulation is applied at high stimulation current throughout exhalation"
284440|NCT02035215|Drug|Atorvastatin 20mg|
284441|NCT02035215|Drug|Omega-3-acids ethylesters 90 4g|
284442|NCT02035215|Other|Placebo(Omega-3-acids ethylesters 90)|
284443|NCT02035202|Behavioral|CBT2go|CBT administered using mobile intervention.
284444|NCT02035202|Device|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
284445|NCT02035163|Procedure|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
284446|NCT02035150|Dietary Supplement|Oatmeal|A breakfast consisting of oatmeal
284447|NCT02035150|Dietary Supplement|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
284448|NCT02035150|Dietary Supplement|No Breakfast|A breakfast consisting of plain water
284449|NCT02035137|Radiation|131I-MIBG|
284450|NCT02035137|Drug|Vincristine|
284451|NCT02035137|Drug|Irinotecan|
284452|NCT02035137|Drug|Vorinostat|
284453|NCT02035124|Drug|BKM 120|
284454|NCT02035124|Drug|Cabazitaxel|
284455|NCT02035111|Drug|Tianshu capsule|
284456|NCT02035111|Drug|Sugar pill|
284457|NCT02035098|Other|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
284458|NCT02035085|Drug|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
284459|NCT02035072|Drug|Gemcitabine|Gemcitabine 1000 mg/m2
284460|NCT02035072|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2
284461|NCT02035072|Radiation|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
284462|NCT02035046|Procedure|Samplings of blood|
284463|NCT02035046|Procedure|Sampling of urine|
284464|NCT02035046|Procedure|Measure of the blood pressure|
284465|NCT02035046|Procedure|glycemia test|
284466|NCT02035020|Drug|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
284467|NCT02035007|Device|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
284468|NCT02034994|Behavioral|Eating behavior and physical activity change|A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
284469|NCT02034981|Drug|Crizotinib|"Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.~-250 mg twice daily for adults ≥ 18 years of age~280 mg/m² twice daily for children and adolescents aged from 1 to 17 (except ALCL).~165 mg/m² twice daily for ALCL patients aged from 1 to 17."
284470|NCT02034968|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
284471|NCT02034955|Radiation|Post-operative Adaptive Radiation Therapy|
284472|NCT02034942|Other|Non-sedation|
284473|NCT02034942|Other|Sedation, control|
284474|NCT02034929|Device|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
284478|NCT02034890|Drug|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
284479|NCT02034877|Biological|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
284480|NCT02034877|Procedure|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
284481|NCT02034864|Other|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
284482|NCT02034864|Other|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
284483|NCT02034838|Drug|atazanavir 300mg boosted with ritonavir 50 mg|"atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.~atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)"
284484|NCT02034825|Other|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
284485|NCT02034812|Other|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
284486|NCT02034799|Biological|Bioseal Fibrin Sealant|
284487|NCT02034799|Other|Standard of Care (SoC)|
284488|NCT02034786|Procedure|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.~The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
284489|NCT02034786|Biological|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
284490|NCT02034786|Procedure|Transdermal injection|Transdermal injection of hyaluronic acid only.
284491|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 14 days
284492|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
284493|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 28 days
284494|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
284495|NCT02034773|Drug|Placebo|Placebo will be administered once daily for up to 28 days
284496|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
284497|NCT02034773|Drug|CC-220|CC-220 1mg (once every 7 days for 28 days)
284498|NCT02034773|Drug|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
284499|NCT02034760|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
284500|NCT02034760|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
284501|NCT02034760|Dietary Supplement|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
284502|NCT02034760|Dietary Supplement|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
284503|NCT02034760|Dietary Supplement|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
284504|NCT02034747|Drug|Advagraf|oral
284505|NCT02034747|Drug|Corticosteroid|oral
284506|NCT02034734|Drug|ASP3652|oral
284507|NCT02034721|Dietary Supplement|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
284508|NCT02034721|Dietary Supplement|Placebo|Placebo
284509|NCT02034708|Drug|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
284510|NCT02034708|Drug|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
284511|NCT02034682|Drug|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
284512|NCT02034682|Drug|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
284513|NCT02034669|Device|Laminectomy|surgical laminectomy with glial scar resection
284514|NCT02034669|Device|Intradural space|ADSCs injection into Intradural space at damage site
284515|NCT02034669|Device|Intrathecal|ADSCs Intrathecal into lumbar puncture
284516|NCT02034669|Device|Intravenous|ADSCs intravenous
284517|NCT02034643|Procedure|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
284518|NCT02034630|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
284519|NCT02034617|Behavioral|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
284520|NCT02034604|Drug|Naftofidil|
284521|NCT02034604|Drug|Tamsulosin|
284523|NCT02034591|Dietary Supplement|Boost Plus|
284524|NCT02034578|Drug|Apixaban|
284525|NCT02034565|Drug|Apixaban|
284526|NCT02034552|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST [National Institute of Standards and Technology] update) every 4 weeks x 6 doses intravenous slow bolus
284527|NCT02034552|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
284528|NCT02034552|Drug|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
284529|NCT02034552|Drug|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
284530|NCT02034539|Device|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
284531|NCT02034526|Device|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
284532|NCT02034526|Device|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
284533|NCT02034513|Drug|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
284534|NCT02034513|Drug|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
284535|NCT02034513|Drug|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
284536|NCT02034500|Biological|S. sonnei 1790GAHB|
284537|NCT02034500|Biological|Placebo|
284538|NCT02034487|Other|retrospective data collection|
284539|NCT02034474|Drug|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
284540|NCT02034474|Drug|Placebo|intravenously via iv drip over 60 min
284541|NCT02034461|Device|Utah Slanted Electrode Array|This study is using the microelectrode array device for scientific purposes only. This device will not be promoted or test marketed, and is not available for commercial distribution. There will be no costs to the participants for this device. This study is not aimed at collecting data for pre-market approval.
284542|NCT02034448|Procedure|Continuous Renal Replacement Therapy|
284543|NCT02034435|Other|glucose and insulin testing|
284544|NCT02034422|Dietary Supplement|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
284545|NCT02034422|Other|Exercise rehabilitation|8 weeks of exercise rehabilitation
284546|NCT02034409|Device|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
284547|NCT02034409|Device|Sham Comparator|20 minutes daily for 48 weeks
284548|NCT02034396|Procedure|Blood Draw|One blood draw at enrollment
284549|NCT02034383|Other|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
284550|NCT02034383|Other|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
284551|NCT02034383|Other|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
284552|NCT02034383|Other|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
284553|NCT02034383|Other|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
284554|NCT02034370|Device|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
284555|NCT02034370|Device|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
284556|NCT02034357|Other|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
284557|NCT02034357|Other|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
284558|NCT02034344|Procedure|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
284559|NCT02034344|Procedure|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
284560|NCT02034344|Procedure|Urine collection|Urine will be collected from all participants.
284561|NCT02034331|Drug|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
284562|NCT02034331|Drug|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
284563|NCT02034331|Drug|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
284564|NCT02034331|Other|Heat application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
284565|NCT02034292|Drug|Clopidogrel|
284566|NCT02034292|Drug|Aspirin|
284567|NCT02034292|Drug|APD791|
284569|NCT02034279|Drug|Albumin|Intravenous infusion of 20% albumin
284570|NCT02034266|Dietary Supplement|Omega-3 supplementation|5 mL twice daily, administered under the tongue
284571|NCT02034253|Drug|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
284572|NCT02034227|Drug|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
284573|NCT02034214|Behavioral|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
284574|NCT02034214|Other|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
284575|NCT02034214|Behavioral|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
284576|NCT02034201|Drug|Lisdexamfetamine|
284577|NCT02034201|Drug|Placebo|
284578|NCT02034188|Biological|Umbilical cord mesenchymal stem cells|
284579|NCT02034175|Device|SomnaPatch|SomnaPatch is a standalone flexible diagnostic skin-adhesive patch with electronics inside. The patch is placed on the patient's face.
284580|NCT02034175|Device|Polysomnography|Polysomnography performed in a sleep lab is considered a gold standard in diagnosing the sleep breathing disorders.
284581|NCT02034162|Drug|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
284582|NCT02034162|Drug|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
284583|NCT02034149|Behavioral|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
284584|NCT02034149|Behavioral|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
284585|NCT02034149|Behavioral|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
284586|NCT02034136|Dietary Supplement|Ginsenoside|3.0 g/ d for 28 days
284587|NCT02034136|Dietary Supplement|Dietary fiber fill|3g/day, 28days
284588|NCT02034123|Drug|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
284589|NCT02034110|Drug|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis.
284590|NCT02034110|Drug|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
284591|NCT02034097|Drug|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
284592|NCT02034097|Drug|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
284593|NCT02034084|Procedure|left radial approach|Coronary diagnostic procedures performed through left radial approach
284594|NCT02034084|Procedure|Right radial approach|coronary diagnostic procedures performed through right radial approach
284595|NCT02034071|Drug|DCCR|
284596|NCT02034071|Drug|Placebo|
284597|NCT02034058|Device|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
284598|NCT02034045|Other|Community Paramedicine|
284599|NCT02034045|Other|Usual Care|
284600|NCT02034032|Procedure|Regenexx SD|stem cell treatment
284601|NCT02034032|Behavioral|Exercise Therapy|exercise therapy control
284602|NCT02034019|Drug|Dexamethasone|
284603|NCT02034019|Drug|Punctum Plug|
284604|NCT02034006|Drug|Ranibizumab|All patients received a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per Committee for Human Medicinal Products (CHMP)approval. Further injections might have been required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, was evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment was allowed provided at least 14 days of intercurrence.
284605|NCT02033993|Drug|Nab-Paclitaxel|
284606|NCT02033993|Drug|Paclitaxel|
284607|NCT02033980|Device|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
284608|NCT02033967|Procedure|vasodilator induced hypovolemia|
284609|NCT02033941|Drug|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
284610|NCT02033941|Drug|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
284611|NCT02033915|Other|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
284612|NCT02033902|Drug|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
284613|NCT02033889|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
284614|NCT02033889|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
284615|NCT02033889|Drug|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
284616|NCT02033889|Other|Glimepiride|Open-label Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period.
284617|NCT02033889|Drug|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
284618|NCT02033889|Biological|Basal Insulin|Basal insulin will be administered in the initial 26-week period for participants with glucose values exceeding protocol-specified values and for participants requiring rescue therapy in the 78-week extension period. Dosing and titration of basal insulin is at the discretion of the Investigator.
284619|NCT02033889|Drug|Metformin|Metformin >=1500 mg/day, orally, once a day
284620|NCT02033876|Drug|Ursodiol|
284621|NCT02033850|Behavioral|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
284622|NCT02033824|Other|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
284623|NCT02033824|Procedure|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
284624|NCT02033798|Drug|Tamsulosin|Once Daily 0.2mg per oral for 6 months
284625|NCT02033772|Procedure|Thoracoscopic surgery|
284626|NCT02033759|Device|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
284627|NCT02033759|Other|Anxiety Questionnaire|21 item questionnaire
284628|NCT02033759|Other|Traditional Circumferential Measurements|
284629|NCT02033746|Device|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
284630|NCT02033733|Drug|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
284631|NCT02033733|Drug|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
284632|NCT02033720|Other|No treatment|No therapeutic hypothermia was induced.
284633|NCT02033720|Other|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
284634|NCT02033707|Drug|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
284635|NCT02033681|Procedure|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
284636|NCT02033681|Procedure|Saline Solution|Saline solution is injected into the tissue as a placebo control.
284637|NCT02033668|Drug|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
284638|NCT02033668|Drug|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
284639|NCT02033668|Drug|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
284640|NCT02033655|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
284641|NCT02033655|Behavioral|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
284642|NCT02033642|Behavioral|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to train parents or family members of adolescent/young adult participants with intellectual disability to monitor diet and physical activity behavior, set goals, provide support and reinforcement, and assess and make changes to the home environment.
284643|NCT02033642|Behavioral|Maintenance|The Maintenance condition in this study is a 12-session intervention for parent/family member of adolescents with intellectual disability, designed to teach families to continue lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports and prevent relapse.
284644|NCT02033629|Drug|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
284645|NCT02033629|Drug|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
284646|NCT02033629|Drug|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
284647|NCT02033616|Biological|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
284648|NCT02033616|Biological|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
284649|NCT02033603|Drug|Ropivacaine|30mls of 0.5% ropivacaine
284650|NCT02033590|Device|Biodegradable (purified) surgical silk scaffold|
284651|NCT02033577|Procedure|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
284652|NCT02033577|Procedure|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
284653|NCT02033564|Device|Macintosh/Miller Laryngoscope|
284654|NCT02033564|Device|Glidescope Laryngoscope|
284655|NCT02033551|Drug|Veliparib|
284656|NCT02033551|Drug|Carboplatin|
284657|NCT02033551|Drug|Paclitaxel|
284658|NCT02033551|Drug|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
284659|NCT02033538|Drug|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
284660|NCT02033525|Drug|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
284661|NCT02033525|Other|Rehabilitation|Standard rehabilitation program
284662|NCT02033512|Drug|Transdermal Hormone Replacement Therapy|"The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.~All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
284663|NCT02033512|Drug|Transdermal Nanoformulation|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
284664|NCT02033512|Drug|Transdermal formulation|66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
284665|NCT02033499|Behavioral|SMBG|Blood glucose levels are tested once daily.
284666|NCT02033486|Device|TOBI + DBT|
284667|NCT02033473|Drug|Apelin|An apelin clamp in which an apelin infusion will be administered
284668|NCT02033473|Drug|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
284669|NCT02033460|Other|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
284670|NCT02033460|Other|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
284671|NCT02033460|Other|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
284672|NCT02033447|Other|Magnetic Nanoparticle Injection|
284673|NCT02033434|Drug|Intranasal Ketamine|Atomized Intranasal Ketamine, 50mg
284674|NCT02033408|Drug|AB (antibiotics)|"PO Vancomycin 250mgX4/d for 3 weeks~PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks~PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks~Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
284675|NCT02033408|Drug|CS (corticosteroids) Only|"methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)~PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
284676|NCT02033369|Drug|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day.
284677|NCT02033356|Procedure|Adductor canal block with lidocaine 1%|US-guided adductor canal block
284678|NCT02033356|Drug|Lidocaine|
284679|NCT02033343|Radiation|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
284680|NCT02033330|Dietary Supplement|phenolics form orange peel|
284681|NCT02033317|Drug|patiromer|15 grams/day (5 grams 3 times daily) administered orally
284682|NCT02033291|Procedure|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
284683|NCT02033278|Drug|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
284684|NCT02033278|Drug|Placebo infusion|Placebo infusion plus conventional medical treatment (as indicated by clinician)
284685|NCT02033265|Procedure|Brachial plexus block|Ultrasound guided axillary brachial plexus block
284686|NCT02033252|Device|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
284687|NCT02033239|Drug|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
284688|NCT02033239|Drug|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
284689|NCT02033226|Device|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
284690|NCT02033226|Device|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
284691|NCT02033213|Other|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
284692|NCT02033213|Other|Liberal group|"A group of patients who received > 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.~The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
284693|NCT02033200|Drug|Stendra 200 mg|
284694|NCT02033200|Drug|Placebo|
284695|NCT02033187|Other|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
284696|NCT02033187|Other|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
284697|NCT02033174|Other|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
284698|NCT02033174|Other|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
284699|NCT02033161|Behavioral|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.~Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.~The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
284700|NCT02033148|Drug|icotinib hydrochloride|Given PO
284701|NCT02033148|Other|laboratory biomarker analysis|Correlative studies
284702|NCT02033148|Other|pharmacological study|Correlative studies
284703|NCT02033135|Procedure|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
284704|NCT02033135|Other|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
284705|NCT02033135|Device|Zilver PTX|
284706|NCT02033122|Other|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
284707|NCT02033122|Other|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
284708|NCT02033109|Drug|PC-1005|Intravaginal use
284709|NCT02033109|Drug|HEC gel|
284710|NCT02033096|Drug|Stannsoporfin|No intervention was administered during this observational study
284711|NCT02033096|Drug|Placebo Control|No intervention was administered during this observational study
284712|NCT02033096|Other|Phototherapy (as needed)|No intervention was administered during this observational study
284713|NCT02033083|Device|Laminaria|
284714|NCT02033083|Device|Dilapan-S|
284715|NCT02033057|Procedure|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
284716|NCT02033044|Other|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
284717|NCT02033044|Other|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
284718|NCT02033031|Drug|Lucentis intravitreal injection|Lucentis intravitreal injection
284719|NCT02033031|Drug|Avastin intravitreal injection|Avastin intravitreal injection
284720|NCT02033018|Drug|Aflibercept Injection|Aflibercept intravitreal injection
284721|NCT02032979|Behavioral|Psychiatric test|
284722|NCT02032966|Procedure|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
284723|NCT02032966|Procedure|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
284724|NCT02032953|Dietary Supplement|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
284725|NCT02032953|Drug|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg*min. Ten minuts after starting the insulin, and when the the blood glucose is<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
284726|NCT02032927|Drug|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
284727|NCT02032927|Drug|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.~During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.~The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
284728|NCT02032901|Drug|Daclatasvir|
284729|NCT02032901|Drug|Sofosbuvir|
284730|NCT02032888|Drug|Daclatasvir|
284731|NCT02032888|Drug|Sofosbuvir|
284732|NCT02032875|Drug|Daclatasvir|
284733|NCT02032875|Drug|Sofosbuvir|
284734|NCT02032875|Drug|Ribavirin|
284735|NCT02032862|Drug|Sage extract, 3400 mg , DER 1:17|
284736|NCT02032849|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
284737|NCT02032849|Device|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
284738|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
284739|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
284740|NCT02032823|Drug|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
284741|NCT02032823|Drug|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
284742|NCT02032810|Drug|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
284743|NCT02032810|Drug|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
284744|NCT02032797|Drug|Progesterone|
284745|NCT02032784|Drug|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
284746|NCT02032784|Other|No Octreotide|No drug
284747|NCT02032771|Device|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
284748|NCT02032758|Drug|Propranolol|Single oral dose of 10 mg propranolol
284749|NCT02032758|Device|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
284750|NCT02032758|Procedure|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
284751|NCT02032758|Device|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
284752|NCT02032732|Other|leukocyte esterase test|leukocyte esterase test on fluid removed by intra-articular aspiration
284753|NCT02032719|Behavioral|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
284754|NCT02032719|Behavioral|Lifestyle counseling|Lifestyle counseling
284755|NCT02032706|Device|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
284756|NCT02032693|Dietary Supplement|Everycell™|
284757|NCT02032693|Other|Placebo|
284758|NCT02032680|Behavioral|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
284759|NCT02032680|Behavioral|In-persons multi-family psycho-educational treatment|This intervention will provide the VA's evidence-based, in-person delivered, multi-family psychoeducational treatment, termed Multi-Family group (MFG). This intervention is delivered to Veterans and their families or other supporters using an in-person format.
284760|NCT02032680|Other|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
284761|NCT02032667|Behavioral|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
284762|NCT02032654|Drug|Flucloxacillin|
284763|NCT02032654|Drug|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
284764|NCT02032641|Device|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
284765|NCT02032628|Behavioral|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
284766|NCT02032615|Dietary Supplement|Education plus Gudness Nutritional Bar|
284767|NCT02032615|Other|Education|
284768|NCT02032602|Other|Deep Dry Needling|
284769|NCT02032589|Behavioral|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
284770|NCT02032576|Device|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
284771|NCT02032563|Drug|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
284772|NCT02032550|Other|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
284773|NCT02032537|Drug|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
284774|NCT02032537|Drug|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
284775|NCT02032524|Drug|GZ402666|Pharmaceutical form: lyophilized powder reconstituted for infusion Route of administration: intravenous
284776|NCT02032498|Drug|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
284777|NCT02032485|Drug|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
284778|NCT02032472|Other|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
284779|NCT02032446|Biological|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2~§ MSC doses:~3 patients → 3 infusions of 1x106 cells /kg~3 patients → 3 infusions of 2x106 cells /kg~3 patients → 3 infusions of 3x106 cells /kg"
284780|NCT02032433|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
284781|NCT02032433|Drug|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
284782|NCT02032420|Behavioral|STAR|
284783|NCT02032420|Behavioral|ART|
284784|NCT02032407|Drug|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
284785|NCT02032394|Drug|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
284786|NCT02032394|Drug|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
284787|NCT02032394|Drug|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
285080|NCT02030132|Behavioral|Feedback compared to 75th percentile|
284788|NCT02032381|Other|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
284789|NCT02032368|Procedure|transarterial chemoembolization (TACE)|
284790|NCT02032355|Procedure|spinal anesthesia|
284791|NCT02032342|Device|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
284792|NCT02032342|Device|Arndt® blocker|Arndt® blocker for selective lobar deflation
284793|NCT02032342|Device|Cohen blocker|Cohen blocker for selective lobar deflation
284794|NCT02032342|Device|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
284795|NCT02032329|Device|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
284796|NCT02032316|Device|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
284797|NCT02032303|Procedure|Assessment of coronary flow reserve|
284798|NCT02032303|Procedure|Percutaneous Coronary Intervention|
284799|NCT02032303|Drug|Ticagrelor loading|
284800|NCT02032303|Drug|Prasugrel loading|
284801|NCT02032290|Procedure|Assessment of Coronary Flow Reserve|
284802|NCT02032290|Procedure|Percutaneous coronary intervention|
284803|NCT02032290|Drug|ticagrelor loading|
284804|NCT02032290|Drug|Clopidogrel loading|
284805|NCT02032277|Drug|Cyclophosphamide|Cyclophosphamide
284806|NCT02032277|Drug|Placebo|Placebo for Carboplatin
284807|NCT02032277|Drug|Doxorubicin|Doxorubicin
284808|NCT02032277|Drug|Paclitaxel|Paclitaxel
284809|NCT02032277|Drug|Carboplatin|Carboplatin
284810|NCT02032277|Drug|Veliparib|Veliparib
284811|NCT02032277|Drug|Placebo|Placebo for Veliparib
284812|NCT02032264|Other|Comprehensive Chromosome Screening|On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
284813|NCT02032264|Other|Morphologically Best|Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
284814|NCT02032251|Drug|oral administration of ginger|Oral administration of ginger in patients with infertility.
284815|NCT02032251|Drug|Placebo|
284816|NCT02032238|Device|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
284817|NCT02032225|Other|Skin biopsy|
284818|NCT02032212|Other|EVP unflavoured|
284819|NCT02032212|Other|EVP flavoured|
284820|NCT02032212|Other|Nicotine inhalator|15 mg nicotine Nicorette
284821|NCT02032212|Other|Conventional cigarette|
284822|NCT02032186|Drug|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
284823|NCT02032173|Drug|Main group|Patient will start in the main group with 6 monthly ranimizumab IVTs until month 5. Additional mandatory IVTs will be done at months 8 and 11. At months 14, 17, 20 and 23, IVTs will be done if BCVA loss is comprised between 9 and 5 letters (included). If patient did not loose more than 4 letters, no injection has to be performed at the visit. Criteria to stay in the main group are : 1°) at Month 3, 4 letters (included) improvement compared to baseline (Day 0) OR an improvement in CSF ≥ 0.1 log OCT compared to baseline (Day 0); 2°) at Month 6, a stable VA is obtained based on the months 4, 5 and 6 BCVA score; 3°) at Months 8, 11, 14, 17, 20 and 23, no BCVA decrease by more than 10 letters (excluded) compared with the highest BCVA score since the beginning of the study.
284824|NCT02032160|Biological|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
284825|NCT02032160|Biological|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
284826|NCT02032147|Drug|NGF group|This group will be treated with NGF 18u per day im for 60 days
284827|NCT02032134|Biological|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
284828|NCT02032121|Procedure|Blood specimen|
284829|NCT02032121|Procedure|Echocardiography|
284830|NCT02032108|Behavioral|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.~Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
284831|NCT02032095|Drug|GB-0998|
284832|NCT02032082|Other|Carbone monoxide|
284833|NCT02032069|Other|no intervention|
284834|NCT02032056|Dietary Supplement|Probiotic (10^9 CFU/day)|
284835|NCT02032056|Dietary Supplement|Probiotic (10^8 CFU/day)|
284836|NCT02032056|Other|Placebo|
284837|NCT02032043|Drug|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
284838|NCT02032017|Procedure|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
284839|NCT02032017|Procedure|Percutaneous assisted approach|
284840|NCT02032017|Procedure|Anterolateral approach|
284841|NCT02032017|Other|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
285081|NCT02030132|Behavioral|Forgiveness|
284842|NCT02032004|Biological|Allogeneic Mesenchymal Precursor Cells (MPC)|Rexlemestrocel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo,and cryopreserved
284843|NCT02032004|Other|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
284844|NCT02031991|Biological|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
284845|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
284846|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
284847|NCT02031965|Biological|oncolytic HSV-1716|Given IT
284848|NCT02031965|Drug|dexamethasone|Given IV
284849|NCT02031965|Procedure|therapeutic conventional surgery|Undergo surgical resection
284850|NCT02031965|Other|laboratory biomarker analysis|Correlative studies
284851|NCT02031952|Procedure|hepatectomy combined with lymphadenectomy|
284852|NCT02031952|Procedure|hepatectomy alone|
284853|NCT02031939|Drug|Induction and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy(capecitabine combine with oxaliplatin) alone with standard chemoradiotherapy before surgery.
284854|NCT02031939|Radiation|standard chemoradiotherapy|All rectal patients in this group will receive standard chemoradiotherapy and surgical resection.
284855|NCT02031926|Device|Positive expiratory pressure|
284856|NCT02031900|Device|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
284857|NCT02031887|Dietary Supplement|formula with synbiotics|
284858|NCT02031887|Dietary Supplement|formula without synbiotics|
284859|NCT02031861|Drug|nifedipine CR tablets (Xin Ran)|
284860|NCT02031861|Drug|nifedipine CR tablets (Adalat)|
284861|NCT02031848|Other|Diet Intervention|
284862|NCT02031848|Other|Assessments and Diet Intake|
284863|NCT02031835|Procedure|BWSTT (3 days a week for maximum of 20 minutes session)|
284864|NCT02031822|Procedure|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
284865|NCT02031796|Other|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
284866|NCT02031783|Dietary Supplement|Mixture of glucose and fructose|
284867|NCT02031783|Dietary Supplement|glucose|
284868|NCT02031770|Drug|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
284869|NCT02031770|Other|Control|subjects will receive no treatment
284870|NCT02031757|Other|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
284871|NCT02031757|Other|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
284872|NCT02031744|Drug|erlotinib [Tarceva]|150 mg oral administration once daily
284873|NCT02031744|Drug|Placebo|15 mg/kg intravenous administration every 3 weeks
284874|NCT02031744|Drug|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
284875|NCT02031731|Drug|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
284876|NCT02031731|Drug|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
284877|NCT02031731|Drug|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
284878|NCT02031718|Behavioral|Virtual Counseling|
284879|NCT02031705|Procedure|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
284880|NCT02031705|Procedure|control group|Control group was performed no additional cavotricuspid isthmus ablation.
284881|NCT02031692|Drug|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
284882|NCT02031679|Drug|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
284883|NCT02031679|Drug|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
284884|NCT02031666|Drug|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
284885|NCT02031666|Drug|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
284886|NCT02031640|Drug|Beclomethasone dipropionate|
284887|NCT02031640|Drug|Placebo|
284888|NCT02031640|Drug|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
284889|NCT02031627|Device|pneumatic compression - 1 hour per day|Pneumatic compression treatment once per day (1 hour)
284890|NCT02031627|Device|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day in the AM & PM (2 hours)
284891|NCT02031627|Device|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM & PM (4 hours)
284892|NCT02031614|Procedure|Phlebotomy|Withdrawal of 500 mL of whole blood.
284893|NCT02031601|Drug|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
284894|NCT02031601|Drug|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
284895|NCT02031601|Drug|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
284896|NCT02031601|Drug|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
284897|NCT02031601|Drug|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
284898|NCT02031601|Drug|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
284899|NCT02031601|Drug|Erlotinib|150mg po once a day daily until disease progression
284900|NCT02031601|Drug|Gefitinib|250mg po once a day daily until disease progression
284901|NCT02031601|Drug|Icotinib|125mg po three times a day daily until disease progression
284902|NCT02031575|Behavioral|Interactive Treatment|Mobile phone text messaging service about reproductive health
284903|NCT02031575|Behavioral|Basic Treatment|Mobile phone text messaging service about reproductive health
284904|NCT02031575|Other|Control, comparator arm|
284905|NCT02031562|Other|chiropractic|chiropractic
284906|NCT02031562|Other|physical therapy|physical therapy
284907|NCT02031549|Other|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
284908|NCT02031536|Drug|everolimus|Given PO
284909|NCT02031536|Other|placebo|Given PO
284910|NCT02031536|Other|laboratory biomarker analysis|Correlative studies
284911|NCT02031523|Drug|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
284912|NCT02031523|Drug|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
284913|NCT02031510|Drug|placebo|transversus abdominis plane block with saline 0.9%
284914|NCT02031510|Drug|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
284915|NCT02031510|Drug|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
284916|NCT02031497|Dietary Supplement|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
284917|NCT02031497|Dietary Supplement|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
284918|NCT02031471|Drug|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
284919|NCT02031458|Drug|Atezolizumab|1200 mg IV every 3 weeks
284920|NCT02031445|Drug|MRX-6|
284921|NCT02031445|Other|Placebo|
284922|NCT02031432|Drug|Cebranopadol|Cebranopadol 200 µg to 1000 µg per day taken once a day in the morning.
284923|NCT02031419|Drug|CC-122|2mg or 3 mg administered orally once daily
284924|NCT02031419|Drug|CC-223|20mg or 30mg administered orally once daily.
284925|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
284926|NCT02031419|Drug|CC-122|2mg or 3mg administered orally once daily.
284927|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
284928|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
284929|NCT02031419|Drug|CC-223|20mg or 30mg per day administered orally daily.
284930|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
284931|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
284932|NCT02031406|Other|Post-discharge counseling on medication adherence & literacy|
284933|NCT02031380|Device|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
284934|NCT02031367|Drug|Triamcinolone Acetonide|Corticosteroid arm
284935|NCT02031367|Other|Platelet Rich Plasma|Platelet Rich Plasma
284936|NCT02031354|Dietary Supplement|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
284937|NCT02031328|Radiation|Stereotactic Ablative Radiation|
284938|NCT02031302|Device|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
284939|NCT02031289|Drug|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).~Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.~Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."
284940|NCT02031276|Drug|risankizumab IV|risankizumab administered by IV infusion
284941|NCT02031276|Drug|risankizumab SC|risankizumab administered by SC injection
284942|NCT02031276|Drug|Placebo|Placebo for risankizumab administered by IV infusion
284943|NCT02031263|Procedure|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
284944|NCT02031250|Drug|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
284945|NCT02031250|Drug|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
284946|NCT02031250|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
284947|NCT02031250|Radiation|Boost Radiation to Hypoperfused Volumes|
285184|NCT02029547|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
284948|NCT02031237|Radiation|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
284949|NCT02031237|Radiation|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
284950|NCT02031237|Radiation|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
284951|NCT02031237|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
284952|NCT02031224|Behavioral|Conventional low protein diet|
284953|NCT02031224|Dietary Supplement|Very low protein diet supplemented with Ketosteril|
284954|NCT02031211|Drug|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
284955|NCT02031211|Drug|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
284956|NCT02031198|Drug|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
284957|NCT02031185|Behavioral|FitBit only|Participants will use the FitBit device
284958|NCT02031185|Behavioral|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
284959|NCT02031146|Procedure|Lumbar puncture|
284960|NCT02031107|Device|cTBS|
284961|NCT02031107|Device|cathodal tDCS|
284962|NCT02031107|Device|sham stimulation|
284963|NCT02031094|Other|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
284964|NCT02031081|Drug|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
284965|NCT02031081|Drug|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
284966|NCT02031068|Behavioral|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:~Sub-maximal aerobic training for up to 15 minutes~Light coordination and sport-specific exercises for up to 10 minutes~Visualization and imagery techniques~Home program~A physiotherapist will supervise the rehabilitation."
284967|NCT02031068|Behavioral|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:~An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
284968|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of [14C]FTD administered as an oral solution on Day 1 (mass balance part)
284969|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of [14C]TPI administered as an oral solution on Day 1 (mass balance part)
284970|NCT02031055|Drug|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
284971|NCT02031016|Drug|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
284972|NCT02031016|Drug|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
284973|NCT02031016|Drug|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
284974|NCT02031003|Dietary Supplement|Infant formula|Infant formula
284975|NCT02030990|Drug|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
284976|NCT02030990|Drug|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
284977|NCT02030977|Dietary Supplement|Resveratrol|
284978|NCT02030977|Other|placebo|
284979|NCT02030964|Drug|DFMO|
284980|NCT02030964|Drug|Celecoxib|
284981|NCT02030964|Drug|Cyclophosphamide|
284982|NCT02030964|Drug|Topotecan|
284983|NCT02030938|Device|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
284984|NCT02030925|Drug|IW-3718|
284985|NCT02030925|Drug|Matching Placebo|
284986|NCT02030912|Drug|3 doses of amoxicillin daily for 7 days|
284987|NCT02030912|Drug|2 doses of minocycline daily for five days|
284988|NCT02030912|Other|2 doses of placebo daily for five days|
284989|NCT02030899|Procedure|Cage fusion|Randomized selection of surgery type
284990|NCT02030899|Procedure|Plate fusion|Randomized selection of surgery type
284991|NCT02030886|Device|Sensimed Triggersfish®|All subjects will be monitored by Sensimed Triggerfish for 24 hours.
284992|NCT02030873|Other|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
284993|NCT02030860|Drug|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
284994|NCT02030860|Drug|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
284995|NCT02030860|Drug|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
284996|NCT02030847|Biological|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10^8 transduced CAR T cells
284997|NCT02030847|Biological|CART-19|As of June 2014, dose was reduced to a single dose of 1-5x10^7 CART-19 cells.
285185|NCT02029534|Drug|Atorvastatin 20 mg|
284998|NCT02030847|Biological|CART-19|In the protocol amendment in November 2014, the dose remained 1-5 x 10^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.
284999|NCT02030847|Biological|CART-19|In the protocol amendment in May 2015, the dose was changed to 1-5 x 10^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10^7), 30% on Day 2 (3x10^7-1.5x10^8), 60% on Day 3 (6x10^7-3x10^8).
285000|NCT02030834|Biological|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
285001|NCT02030821|Drug|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
285002|NCT02030821|Drug|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
285003|NCT02030808|Drug|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
285004|NCT02030808|Drug|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
285005|NCT02030795|Other|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
285006|NCT02030795|Other|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
285007|NCT02030782|Other|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
285008|NCT02030782|Other|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
285009|NCT02030769|Drug|Pronase|use pronase to improve visibility during endoscopical iodine staining
285010|NCT02030769|Drug|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
285011|NCT02030756|Device|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
285012|NCT02030756|Device|sham non-vibrating capsule|patients will receive sham non-vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
285013|NCT02030743|Other|Visual training|6 training sessions with computerised visual attention paradigm
285014|NCT02030730|Behavioral|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
285015|NCT02030717|Drug|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
285016|NCT02030717|Drug|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
285017|NCT02030691|Device|Nasal continuous airway positive pressure (nCPAP)|
285018|NCT02030691|Device|Nasal high frequency percussive ventilation (nHFPV)|
285019|NCT02030678|Drug|irinotecan|Irinotecan monotherapy (trade name: Aili; batches 180103AG [40 mg] and 171231AG [100 mg]) will be administered intravenously at a dose of 100 mg/m2 on days 1 and 8 of each 3-week cycle.
285020|NCT02030665|Behavioral|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
285021|NCT02030665|Behavioral|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
285022|NCT02030665|Behavioral|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
285023|NCT02030652|Procedure|Intermittent nasal positive pressure positive ventilation.|
285024|NCT02030652|Procedure|CPAP|Nasal continuous positive airway pressure
285025|NCT02030639|Drug|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
285026|NCT02030626|Device|active or placebo rTMS or active or placebo tDCS|
285027|NCT02030613|Genetic|Blood test|
285028|NCT02030600|Drug|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
285029|NCT02030600|Drug|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
285030|NCT02030587|Procedure|Radiofrequency Ablation|
285031|NCT02030587|Procedure|Laparoscopic Adrenalectomy|
285032|NCT02030574|Drug|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
285033|NCT02030561|Drug|Trastuzumab + NK cells|
285034|NCT02030535|Drug|olodaterol|free combination with tiotropium
285035|NCT02030535|Drug|tiotropium|free combination with olodaterol
285036|NCT02030535|Drug|Placebo|
285037|NCT02030535|Drug|tiotropium|fixed dose combination with olodaterol
285038|NCT02030535|Drug|olodaterol|fixed dose combination with tiotropium
285039|NCT02030522|Behavioral|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
285040|NCT02030509|Other|Quick diagnosis program|
285186|NCT02029534|Drug|Atorvastatin 80 mg|
285393|NCT02027961|Drug|Trametinib|Oral dose of 2 mg trametinib tablet.
285041|NCT02030496|Procedure|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
285042|NCT02030496|Other|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
285043|NCT02030483|Drug|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
285044|NCT02030483|Drug|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
285045|NCT02030483|Drug|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
285046|NCT02030470|Other|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
285047|NCT02030457|Drug|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
285048|NCT02030457|Drug|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
285049|NCT02030444|Procedure|PET-MRI and EBUS-TBNA|
285050|NCT02030431|Device|Dynaloc|
285051|NCT02030431|Device|Cancellous screws|
285052|NCT02030418|Device|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
285053|NCT02030405|Drug|Ixazomib|Given orally (PO)
285054|NCT02030392|Behavioral|Intervention group|Cognitive-behavioral intervention
285055|NCT02030392|Behavioral|Active control group|Education and information
285056|NCT02030379|Behavioral|QPL-CT|Use the QPL-CT to prioritize questions
285057|NCT02030353|Behavioral|Self-regulation plus activity monitoring|Individual in-person session, digital smart scale, online intervention, and an activity monitor.
285058|NCT02030353|Behavioral|Self-regulation|Individual in-person session, digital smart scale, and online intervention.
285059|NCT02030340|Procedure|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
285060|NCT02030314|Drug|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
285061|NCT02030301|Biological|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
285062|NCT02030301|Biological|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
285063|NCT02030301|Biological|PBS|Phosphate-buffered saline
285064|NCT02030288|Behavioral|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
285065|NCT02030275|Drug|RXI-109|surgery.
285066|NCT02030275|Drug|Placebo|surgery.
285067|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
285068|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
285069|NCT02030249|Behavioral|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
285070|NCT02030249|Behavioral|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
285071|NCT02030249|Behavioral|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
285072|NCT02030236|Device|Cooling|Temperature reached Duration of exposure to cold.
285073|NCT02030223|Procedure|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
285074|NCT02030197|Behavioral|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
285075|NCT02030197|Other|Control Group|no treatment
285076|NCT02030184|Drug|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
285077|NCT02030171|Other|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
285078|NCT02030145|Procedure|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
285079|NCT02030145|Procedure|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
285082|NCT02030132|Behavioral|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
285083|NCT02030132|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
285084|NCT02030119|Behavioral|Financial Incentives|
285085|NCT02030119|Behavioral|Daily feedback|
285086|NCT02030093|Behavioral|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
285087|NCT02030080|Behavioral|Financial incentives|
285088|NCT02030080|Behavioral|Teams|
285089|NCT02030080|Behavioral|Framing of feedback|
285090|NCT02030080|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
285091|NCT02030067|Drug|RX-3117|escalating doses (Phase 1)
285092|NCT02030054|Drug|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
285093|NCT02030054|Drug|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
285094|NCT02030041|Drug|Vitamin D|Vitamin D will be given to achieve normal serum levels
285095|NCT02030041|Drug|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
285096|NCT02030041|Drug|Placebo|Placebo will be provided to the study participants
285097|NCT02030028|Drug|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
285098|NCT02030015|Drug|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
285099|NCT02030015|Other|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
285100|NCT02030002|Device|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
285101|NCT02030002|Device|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
285102|NCT02029989|Device|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids"
285103|NCT02029989|Device|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c"
285104|NCT02029989|Device|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate"
285105|NCT02029989|Device|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
285106|NCT02029989|Device|Waist and Hip circumference|"Measurement for Central Obesity~Waist and Hip circumference"
285107|NCT02029989|Behavioral|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
285108|NCT02029976|Behavioral|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
285109|NCT02029976|Behavioral|Mailed monthly newsletters|Newsletters
285110|NCT02029963|Device|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
285111|NCT02029963|Behavioral|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
285112|NCT02029950|Drug|Cytarabine|Given IV
285113|NCT02029950|Drug|Daunorubicin Hydrochloride|Given IV
285114|NCT02029950|Drug|Etoposide|Given IV
285115|NCT02029950|Drug|Idarubicin Hydrochloride|Given IV
285116|NCT02029950|Other|Laboratory Biomarker Analysis|Correlative studies
285117|NCT02029950|Other|Pharmacological Study|Correlative studies
285118|NCT02029950|Drug|Pomalidomide|Given PO
285119|NCT02029937|Drug|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
285120|NCT02029924|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
285121|NCT02029924|Drug|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
285122|NCT02029911|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
285123|NCT02029898|Drug|Remifentanil|
285124|NCT02029898|Drug|sodium chloride 0,9%|
285125|NCT02029885|Device|Investigational Therapy (Surround Sound)|
285126|NCT02029885|Device|Sham Control|
285127|NCT02029872|Drug|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
285128|NCT02029872|Drug|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
285129|NCT02029872|Drug|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
285130|NCT02029859|Procedure|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
285131|NCT02029846|Drug|Standard Treatment|traditional drugs only
285132|NCT02029846|Drug|Incretin-Based Treatment|incretin-based drugs
285133|NCT02029833|Other|Regular Canola Oil|
285134|NCT02029833|Other|High Oleic Canola Oil|
285135|NCT02029833|Other|Western Type Diet - Common Dietary Oils|
285136|NCT02029820|Device|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
285137|NCT02029794|Procedure|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
285138|NCT02029794|Procedure|visual inspection with acetic acid (VIA)|
285139|NCT02029794|Drug|3-5% acetic acid|
285140|NCT02029781|Procedure|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
285141|NCT02029755|Procedure|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
285142|NCT02029755|Procedure|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
285143|NCT02029755|Procedure|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
285144|NCT02029742|Behavioral|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
285145|NCT02029742|Behavioral|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
285146|NCT02029729|Drug|omaveloxolone|
285147|NCT02029716|Drug|RTA 408 Lotion 0.5%, 1%, 3%|
285148|NCT02029716|Drug|Lotion vehicle/placebo|
285149|NCT02029703|Device|Synvisc-One Injection|
285150|NCT02029703|Other|Sham Injection|
285151|NCT02029690|Drug|ADI-PEG 20|
285152|NCT02029664|Device|Visual distortion increment based on the gait pattern|
285153|NCT02029651|Device|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
285154|NCT02029651|Procedure|Conventional occupational therapy|conventional occupational therapy
285155|NCT02029638|Biological|anti-thymocyte globulin|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
285156|NCT02029638|Drug|Fludarabine|Fludarabine at dose 30 mg/m^2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
285157|NCT02029638|Drug|Cyclophosphamide|"Low dose pre-transplant cyclophosphamide will be administered intravenously (IV) over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplant cyclophosphamide is 14.5 mg/kg/day.~High dose cyclophosphamide [50mg/kg (Ideal Body Weight)] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given IV over 1-2 hours depending on volume."
285158|NCT02029638|Radiation|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
285159|NCT02029638|Drug|acetaminophen|650 mg orally prior to antithymocyte globulin infusion.
285160|NCT02029638|Drug|diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
285161|NCT02029638|Drug|methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
285162|NCT02029638|Biological|bone marrow transplant|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0.
285163|NCT02029638|Drug|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
285164|NCT02029638|Drug|mycophenolate mofetil|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
285165|NCT02029638|Drug|prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
285166|NCT02029638|Drug|filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day 5 post-transplant until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
285167|NCT02029625|Drug|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
285168|NCT02029625|Drug|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
285169|NCT02029612|Drug|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
285170|NCT02029612|Behavioral|Phone Counseling|Each participant counseled on quitting smoking at baseline.
285171|NCT02029612|Behavioral|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
285172|NCT02029612|Behavioral|Breath Test|Breath test performed at 3 month and 6 month visit.
285173|NCT02029612|Behavioral|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
285174|NCT02029612|Behavioral|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
285175|NCT02029599|Drug|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
285176|NCT02029599|Drug|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
285177|NCT02029599|Drug|Methotrexate|7.5-15mg per week，All patients should be used
285178|NCT02029599|Drug|Acetaminophen tablets|Oral,0.5g, 1~2 times a day, when vas=10
285179|NCT02029586|Drug|MB12066 200mg|oral administration, 100mg bid
285180|NCT02029586|Drug|Placebo|oral administration, 100mg bid
285181|NCT02029573|Drug|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
285182|NCT02029573|Drug|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
285183|NCT02029573|Radiation|Radiotherapy|60 Gy in 30 fractions
286541|NCT02018601|Procedure|paravertebral block|
285187|NCT02029521|Dietary Supplement|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
285188|NCT02029521|Dietary Supplement|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
285189|NCT02029508|Procedure|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
285190|NCT02029508|Procedure|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
285191|NCT02029508|Procedure|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
285192|NCT02029495|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
285193|NCT02029495|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
285194|NCT02029495|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
285195|NCT02029482|Drug|ACT-128800|
285196|NCT02029482|Drug|Placebo|
285197|NCT02029469|Device|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
285198|NCT02029456|Drug|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
285199|NCT02029443|Drug|acalabrutinib|
285200|NCT02029430|Drug|aldoxorubicin|
285201|NCT02029417|Drug|cytarabine|Given SC
285202|NCT02029417|Drug|omacetaxine mepesuccinate|Given SC
285203|NCT02029417|Drug|decitabine|Given IV
285204|NCT02029417|Other|laboratory biomarker analysis|Correlative studies
285205|NCT02029404|Procedure|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
285206|NCT02029404|Procedure|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.~An information sheet will be released at the discharge and the medical indication for any rescue doses at home.~The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
285207|NCT02029391|Other|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
285208|NCT02029391|Other|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
285209|NCT02029378|Drug|Eculizumab|
285210|NCT02029365|Other|Autoquestionnary|autoquestionnary completed during the consultation for infertility
285211|NCT02029365|Other|semi-structured interview|phone interview
285212|NCT02029352|Drug|Sinecatechins 10%|
285213|NCT02029352|Drug|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
285214|NCT02029339|Device|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
285215|NCT02029339|Device|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
285216|NCT02029313|Drug|Montelukast|
285217|NCT02029313|Drug|Montelukast sodium|
285218|NCT02029300|Other|Fiberoptic Intubation through the nasal route|
285219|NCT02029300|Other|Fiberoptic intubation through the oral route|
285220|NCT02029287|Other|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
285221|NCT02029287|Other|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines|Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
285222|NCT02029274|Drug|BAF312|BAF312 was provided as film-coated tablets in strengths of 0.25, 0,5, 1 and 2 mg for oral administration.
285223|NCT02029274|Drug|Placebo|Matching placebo to BAF312 as tablets for oral administration.
285224|NCT02029248|Other|Quality of life questionnaire|
286542|NCT02018601|Drug|dexketoprofen|
285225|NCT02029235|Drug|Acetaminophen/Ibuprofen|Postoperatively, subjects will be given acetaminophen 500 mg / ibuprofen 400mg every 4 hours, as needed, for one week or until essentially pain-free
285226|NCT02029235|Drug|Acetaminophen/Hydrocodone|Postoperatively, subjects will be given acetaminophen 325 mg / hydrocodone 5 mg every 4 hours, as needed, for one week or until essentially pain-free
285227|NCT02029209|Drug|Anlotinib|Anlotinib QD
285228|NCT02029209|Drug|Placebo Capsule|Placebo capsule QD
285229|NCT02029196|Other|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
285230|NCT02029196|Other|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
285231|NCT02029183|Device|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
285232|NCT02029183|Device|bi-level positive airway pressure|
285233|NCT02029170|Procedure|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
285234|NCT02029170|Procedure|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
285235|NCT02029157|Drug|ARQ197|
285236|NCT02029157|Drug|Placebo|
285237|NCT02029131|Behavioral|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
285238|NCT02029118|Drug|Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
285239|NCT02029118|Device|acupoint|select acupoint according to traditional Chinese medicine
285240|NCT02029118|Drug|Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.|foundation treatment
285241|NCT02029105|Biological|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
285242|NCT02029079|Dietary Supplement|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
285243|NCT02029066|Drug|SR-T100 gel|2g of SR-T100 will topical apply on 100 cm^2 once for 24 hours.
285244|NCT02029053|Device|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.~Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.~The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.~The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.~Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
285245|NCT02029040|Drug|3% Hypertonic Saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
285246|NCT02029040|Drug|0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
285247|NCT02029027|Device|GYNEFFIK(R)|Vaginal electro-stimulation medical device
285248|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
285249|NCT02029014|Device|LAA closure system|
285250|NCT02029001|Drug|Nilotinib (400 mg BID)|Patient with advanced pigmented villonodular synovitis and tumors with mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
285251|NCT02029001|Drug|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy or loss of one copy + loss of expression using immunohistochemistry).
285252|NCT02029001|Drug|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDFGRB, FLT3, BRAF (other than V600 mutations), CRAF, HRAS, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
285253|NCT02029001|Drug|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
285254|NCT02029001|Drug|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT* or amplification /translocation of the genes and/or of the ligands.
285255|NCT02029001|Drug|Olaparib (300 mg BID)|Mutation BRCA1/2 (somatic and germline) or BRCA like and mutations of HDR pathway genes (RAD51 family gene, PALB2, ATM, etc...); except in prostate or stomach; except for patients eligible to Olaparib's available labels in France.
285256|NCT02029001|Combination Product|Durvalumab + Tremelimumab|Any molecular types of tumor (which are known to be immunogenic or with high mutation load), except lung, urothelial and head and neck or CNS tumors, or patients who fulfill conditions to receive any other MTT of the MOST Plus study.
285257|NCT02028988|Drug|Enzalutamide|
285345|NCT02028390|Device|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
285258|NCT02028988|Radiation|External Beam Radiation|"Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.~EBRT shall receive prescription doses to the PTV 75.6- 79.2 Gy delivered in 1.8 Gy fractions."
285259|NCT02028975|Other|Measure the threshold of detection for linoleic acid|
285260|NCT02028975|Other|Oral stimulation tests|
285261|NCT02028975|Other|Venous blood samples|
285262|NCT02028975|Other|Samples for genetic studies (ancillary study)|
285263|NCT02028962|Behavioral|Lifestyle counseling|
285264|NCT02028949|Drug|Zavedos®|
285265|NCT02028949|Other|Blood samples|
285266|NCT02028936|Other|Grape juice R@isol|
285267|NCT02028936|Other|Commercially-available grape juice|
285268|NCT02028923|Drug|Morphine gel|Topical
285269|NCT02028923|Other|Neutral gel|Topical
285270|NCT02028910|Drug|Ondansetron|"The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.~The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.~The dosage should be adjusted according to the weight of the child"
285271|NCT02028897|Other|Conventional embryo culture|
285272|NCT02028897|Other|Enclosed embryo culture|
285273|NCT02028884|Drug|Satralizumab|Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
285274|NCT02028884|Drug|Placebo|Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
285275|NCT02028884|Drug|Baseline Treatment|As specified in the protocol, one of the following drugs at a stable dose is required as monotherapy for baseline treatment during the double-blind period: azathioprine (AZA); mycophenolate mofetil (MMF); or oral corticosteroids (CS). For participants aged 12 to 17 years at the time of informed consent, baseline treatment with AZA or MMF in combination with oral CS is also permitted. Change or termination of baseline treatment is only permitted during the open-label extension period.
285276|NCT02028871|Drug|Intranasal Insulin|
285277|NCT02028871|Drug|Placebo|
285278|NCT02028845|Device|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
285279|NCT02028845|Device|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
285280|NCT02028832|Procedure|PIM consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
285281|NCT02028832|Procedure|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
285282|NCT02028819|Drug|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
285283|NCT02028819|Drug|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
285284|NCT02028806|Drug|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
285285|NCT02028780|Drug|Placebo to dose|placebo
285286|NCT02028780|Drug|Idarucizumab|short infusion
285287|NCT02028780|Drug|Placebo to Idarucizumab|Placebo to Idarucizumab
285288|NCT02028780|Drug|dabigatran|2 capsules dabigatran
285289|NCT02028780|Drug|Idarucizumab|short infusion
285290|NCT02028767|Drug|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
285291|NCT02028767|Drug|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
285292|NCT02028767|Drug|Metformin 500 mg|Metformin 500 mg tablet
285293|NCT02028767|Drug|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
285294|NCT02028754|Drug|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
285295|NCT02028754|Drug|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
285296|NCT02028754|Drug|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
285297|NCT02028741|Other|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
285298|NCT02028715|Drug|Placebo|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
285299|NCT02028715|Drug|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
285300|NCT02028702|Dietary Supplement|Placebo|water with color
285301|NCT02028702|Dietary Supplement|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
285302|NCT02028689|Drug|Lesinurad 400 mg|
285303|NCT02028689|Drug|Metformin 850 mg|
285304|NCT02028689|Drug|Furosemide 40 mg|
285346|NCT02028377|Procedure|PET/MRI|PET/MRI
285347|NCT02028364|Drug|Everolimus|10mg orally daily
285348|NCT02028364|Drug|Exemestane|25mg orally daily
285349|NCT02028338|Combination Product|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
285350|NCT02028338|Combination Product|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing 25 mg dapivirine
285462|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
286543|NCT02018601|Drug|paracetamol|
285305|NCT02028676|Other|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
285306|NCT02028676|Other|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
285307|NCT02028676|Drug|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
285308|NCT02028676|Drug|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
285309|NCT02028676|Drug|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
285310|NCT02028676|Drug|Once-daily ABC+3TC|
285311|NCT02028676|Drug|Twice-daily ABC+3TC|
285312|NCT02028676|Drug|Continued cotrimoxazole prophylaxis|
285313|NCT02028676|Other|Stopped cotrimoxazole prophylaxis|
285314|NCT02028663|Drug|CJ-12420|Once daily, Oral administration
285315|NCT02028663|Drug|Esomeprazole|Once daily, Oral administration
285316|NCT02028650|Biological|the first donor's stem cell|HLA-matched stem cell infusion
285317|NCT02028650|Biological|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
285318|NCT02028637|Other|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
285319|NCT02028624|Behavioral|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
285320|NCT02028598|Drug|Treatment 1|An oral single dose administration
285321|NCT02028598|Drug|Treatment 2|An oral single dose administration
285322|NCT02028598|Drug|Treatment 3|Co-administration of oral single doses
285323|NCT02028585|Dietary Supplement|Low-fat milk group|
285324|NCT02028559|Device|Propulse 1|Move kidney stones with Propulse 1 device.
285325|NCT02028546|Procedure|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.~regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
285326|NCT02028533|Drug|Oxytocin|
285327|NCT02028533|Drug|Placebo|
285328|NCT02028507|Drug|Palbociclib|
285329|NCT02028507|Drug|Capecitabine|
285330|NCT02028507|Drug|Exemestane|
285331|NCT02028507|Drug|Fulvestrant|
285332|NCT02028494|Drug|Capecitabine|Two dosages comparison
285333|NCT02028481|Procedure|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
285334|NCT02028468|Procedure|hemiarthroplasty|
285335|NCT02028455|Biological|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
285336|NCT02028442|Biological|Enadenotucirev|Oncolytic virus
285337|NCT02028429|Drug|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
285338|NCT02028416|Drug|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.~the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
285339|NCT02028403|Drug|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
285340|NCT02028403|Drug|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
285341|NCT02028390|Device|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
285342|NCT02028390|Device|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
285343|NCT02028390|Device|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
285344|NCT02028390|Device|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
285351|NCT02028325|Drug|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
285352|NCT02028312|Drug|Loteprednol etabonate|
285353|NCT02028312|Drug|Artificial Tears|
285354|NCT02028312|Drug|Restasis|
285355|NCT02028299|Procedure|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
285356|NCT02028286|Drug|CLS001|
285357|NCT02028260|Drug|Modafinil|200 mg daily
285358|NCT02028260|Drug|Placebo|similar appearing inert tablet
285359|NCT02028247|Behavioral|Personalized Cognitive-behavioral therapy|
285360|NCT02028247|Behavioral|Standard Practice Cognitive-behavioral therapy|
285361|NCT02028234|Drug|Pantoprazole,|os, 20 mg, once per day, for 30 days
285362|NCT02028234|Drug|Omeprazole|os, 20 mg, once per day, for 30 days
285363|NCT02028221|Drug|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
285364|NCT02028221|Drug|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
285365|NCT02028208|Biological|Mercury, Aluminum, Palladium|T.R.U.E. Test metal allergen panels containing ascending doses of mercury, aluminum or palladium
285366|NCT02028195|Other|Health check|"The program includes four components:~Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).~The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).~Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.~Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview."
285367|NCT02028182|Biological|Lyral®|T.R.U.E. Test allergen panel (0.40 mg/cm^2, 0.20 mg/cm^2, 0.10 mg/cm^2 and negative control)
285368|NCT02028156|Other|Partially Hydrolyzed Infant Formula|Commercially available infant formula
285369|NCT02028143|Device|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
285370|NCT02028143|Device|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
285371|NCT02028143|Procedure|Pulmonary vein isolation|
285372|NCT02028143|Procedure|ICE catheter placed through one of two existing 8F sheaths|
285373|NCT02028130|Procedure|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
285374|NCT02028117|Biological|Enadenotucirev|Oncolytic Virus
285375|NCT02028104|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
285376|NCT02028078|Drug|Insulin human|Induces hypoglycaemia
285377|NCT02028065|Drug|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
285378|NCT02028065|Drug|Placebo|Placebo administered as a single IV bolus over 10 seconds
285379|NCT02028052|Procedure|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
285380|NCT02028052|Device|22 gauge Vizishot needles|
285381|NCT02028039|Drug|IPI-145|75 mg orally twice daily for 4 weeks.
285382|NCT02028039|Behavioral|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
285383|NCT02028026|Drug|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
285384|NCT02028026|Drug|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
285385|NCT02028000|Procedure|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
285386|NCT02028000|Procedure|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
285387|NCT02028000|Procedure|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
285388|NCT02027987|Drug|valproate acid|valproate acid is a common drug which is applied for epilepsy prevention and treatment.
285389|NCT02027974|Device|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
285390|NCT02027974|Device|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
285391|NCT02027961|Biological|Durvalumab|Intravenous dose of 3 or 10 mg/kg durvalumab.
285392|NCT02027961|Drug|Dabrafenib|Oral dose of 150 mg dabrafenib capsule.
285394|NCT02027948|Other|nutritional and functional assessments|"Patients will undergo nutritional & functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, & baseline weight loss. Patients will receive chemotherapy & radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) & radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, & post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, & Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished & receive the appropriate intervention."
285395|NCT02027935|Drug|Cyclophosphamide|300 mg/m2 by vein 2 days prior to T cell infusion.
285396|NCT02027935|Procedure|CD8+ T Cells|T cells administered at a dose of 10^10 cells/m2 by vein on Day 0.
285397|NCT02027935|Drug|Interleukin-2|250,000 U/m2 administered subcutaneously every 12 hours begins within 6 hours of T cell infusion and continues for a total of 14 days On Day 0 to Day +14.
285398|NCT02027935|Drug|Ipilimumab|3 mg/kg by vein 24 hours after T cell infusion. Subsequent infusions administered on Days +22, +43 and +64.
285399|NCT02027922|Other|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
285400|NCT02027909|Device|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
285401|NCT02027896|Other|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
285402|NCT02027883|Device|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
285403|NCT02027883|Device|Educated T shock setting|Experimental Parameter Set 2 Programming Values
285404|NCT02027870|Device|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
285405|NCT02027857|Device|EIT monitoring|
285406|NCT02027857|Device|non-invasive ICP monitoring|
285407|NCT02027844|Behavioral|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
285408|NCT02027844|Behavioral|parental presence|parental presence during inhalational induction of sevoflurane
285409|NCT02027831|Drug|Indocyanine Green|
285410|NCT02027818|Drug|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
285411|NCT02027805|Biological|T-Guard|
285412|NCT02027792|Other|Cabbage leave wraps|
285413|NCT02027792|Drug|Diclofenac Gel|
285414|NCT02027779|Biological|GreenGene™ F|"Prophylaxis safety and efficacy substudy:~intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days"
285415|NCT02027779|Biological|GreenGene™ F|"On-demand safety and efficacy substudy:~minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg"
285416|NCT02027766|Other|Calf muscle stretching|
285417|NCT02027753|Drug|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
285418|NCT02027753|Drug|Metformin|Pharmaceutical form: tablet Route of administration: oral
285419|NCT02027753|Drug|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
285420|NCT02027753|Drug|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
285421|NCT02027740|Dietary Supplement|almond|
285422|NCT02027727|Other|No Intervention|no intervention- tihs is an observational study
285423|NCT02027701|Biological|IgPro20|
285424|NCT02027688|Other|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
285425|NCT02027688|Other|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
285426|NCT02027675|Other|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
285427|NCT02027675|Other|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
285428|NCT02027662|Drug|Osvaren Granules|
285429|NCT02027662|Drug|Osvaren film-coated tablets|
285430|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-F)|The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
285431|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-T)|The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
285463|NCT02027415|Dietary Supplement|Beet juice|2 cups of beet juice will be given before the car ride
285464|NCT02027415|Dietary Supplement|Orange juice|2 cups of orange juice will be given before the car ride
285465|NCT02027402|Procedure|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
285466|NCT02027376|Drug|LDE225|
285467|NCT02027376|Drug|Docetaxel|
285663|NCT02025634|Drug|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
285432|NCT02027623|Behavioral|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
285433|NCT02027623|Behavioral|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
285434|NCT02027597|Other|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
285435|NCT02027597|Other|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
285436|NCT02027597|Other|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
285437|NCT02027584|Other|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
285438|NCT02027571|Behavioral|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
285439|NCT02027558|Behavioral|Insomnia treatment & PAP adherence|Manual-based cognitive behavioral treatment focusing on sleep, sleep apnea, and PAP adherence provided by allied health personnel in individual sessions.
285440|NCT02027558|Behavioral|General sleep education|Manual-based non-directive general sleep education program provided by allied health personnel in individual sessions.
285441|NCT02027545|Behavioral|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
285442|NCT02027545|Behavioral|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
285443|NCT02027545|Behavioral|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
285444|NCT02027545|Behavioral|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
285445|NCT02027532|Drug|Cefazolin|
285446|NCT02027532|Drug|Vancomycin|
285447|NCT02027519|Other|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:~Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results~Self-administer HIV rapid test and read test results~Provide study staff with self-testing result~Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
285448|NCT02027493|Drug|Reiferon R|subcutaneous injection of 100 μg/m2
285449|NCT02027493|Drug|Ribavirin|15 mg/kg daily on two divided doses
285450|NCT02027467|Dietary Supplement|StemAlive®|
285451|NCT02027467|Dietary Supplement|Placebo (For StemAlive®)|
285452|NCT02027454|Drug|GSK1265744|White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
285453|NCT02027454|Drug|GSK1265744 matching placebo|GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
285454|NCT02027454|Drug|Moxifloxacin|Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
285455|NCT02027441|Other|Standard Counseling and Testing|"Individuals who opt for standard counseling and testing will complete the following procedures:~• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines"
285456|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
285457|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
285458|NCT02027428|Drug|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
285459|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
285460|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
285461|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
285664|NCT02025621|Drug|Levosimendan|
285468|NCT02027363|Drug|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
285469|NCT02027363|Other|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
285470|NCT02027350|Device|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
285471|NCT02027337|Drug|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
285472|NCT02027337|Drug|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
285473|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
285474|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
285475|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
285476|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
285477|NCT02027324|Drug|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
285478|NCT02027324|Drug|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
285479|NCT02027311|Drug|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
285480|NCT02027311|Drug|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
285481|NCT02027311|Drug|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders > 80 years old were administered 25mg iv bolus.
285482|NCT02027298|Drug|Abatacept|by SC injection of 125 mg weekly for 6 months
285483|NCT02027285|Dietary Supplement|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) of the same manufacturer.~The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
285484|NCT02027272|Drug|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
285485|NCT02027259|Behavioral|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
285486|NCT02027246|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
285487|NCT02027233|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
285488|NCT02027220|Drug|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
285489|NCT02027220|Drug|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
285490|NCT02027220|Drug|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
285491|NCT02027220|Drug|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
285492|NCT02027207|Biological|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.~Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
285493|NCT02027207|Biological|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
285494|NCT02027194|Drug|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
285495|NCT02027194|Drug|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
285496|NCT02027194|Drug|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
285497|NCT02027181|Device|Device FreeO2 v2.0|"Automatic adjustment of oxygen through the Free O2 device.~FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
285498|NCT02027181|Device|Device FreeO2 v2.0|"Manual adjustment of oxygen without the assistance of the FreeO2 device.~Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
285499|NCT02027168|Other|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
285500|NCT02027155|Drug|AR09 solution|moderate levels of sedation
285501|NCT02027155|Drug|placebo|Sterile Saline, USP
285649|NCT02025751|Drug|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
285502|NCT02027142|Other|Pittsburgh Sleep Quality Index.|"Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score > 5 was indicated poor sleep quality."
285503|NCT02027142|Other|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
285504|NCT02027142|Other|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
285505|NCT02027142|Other|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
285506|NCT02027129|Other|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
285507|NCT02027116|Biological|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
285508|NCT02027103|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
285509|NCT02027103|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
285510|NCT02027090|Drug|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
285511|NCT02027090|Drug|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
285512|NCT02027077|Behavioral|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
285513|NCT02027077|Behavioral|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
285514|NCT02027064|Drug|Interferon-alpha|
285515|NCT02027038|Device|Pelvic belt application|
285516|NCT02027025|Drug|SPARC1103 low dose|once daily
285517|NCT02027025|Drug|SPARC1103 high dose|once daily
285518|NCT02027025|Drug|SPARC Placebo|
285519|NCT02027012|Device|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
285520|NCT02026986|Behavioral|sleep deprivation|sleep deprivation for one night
285521|NCT02026973|Drug|Fulvestrant|
285522|NCT02026973|Drug|Anastrozole|
285523|NCT02026973|Drug|Placebo|
285524|NCT02026973|Drug|Somatostatin|
285525|NCT02026960|Device|RNA extraction and amplification from biopsy specimens|
285526|NCT02026947|Drug|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
285527|NCT02026947|Drug|Placebo|
285528|NCT02026934|Device|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
285529|NCT02026921|Drug|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
285530|NCT02026921|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
285531|NCT02026908|Device|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
285532|NCT02026895|Genetic|Genetic blood sample|
285533|NCT02026882|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
285534|NCT02026869|Drug|Metformin|Metformin is taken either orally or vaginally every 12 hours
285535|NCT02026856|Drug|sodium selenite pentahydrate|
285536|NCT02026856|Other|placebo - continuous saline NaCl 50 ml|
285537|NCT02026817|Drug|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
285538|NCT02026817|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
285539|NCT02026817|Drug|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
285540|NCT02026791|Device|I-gel|"The patient was monitored at 1-5 minute intervals.~While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted."
285650|NCT02025751|Drug|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
285651|NCT02025738|Device|MAGNET APPLICATION|
285652|NCT02025738|Device|REPROGRAMING|
285653|NCT02025738|Device|NO ACTION|
285654|NCT02025725|Drug|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
285655|NCT02025725|Drug|Placebo Nasal Spray|nasal spray formulation with vehicle only
285541|NCT02026791|Device|Supreme-LMA|"The patient was monitored at 1-5 minute intervals.~While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.~After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).~Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted."
285542|NCT02026778|Drug|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.~The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
285543|NCT02026778|Drug|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.~The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
285544|NCT02026765|Device|traditional lens|A random eyes with traditional lens
285545|NCT02026765|Device|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
285546|NCT02026739|Procedure|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
285547|NCT02026739|Procedure|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
285548|NCT02026713|Other|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
285549|NCT02026700|Device|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
285550|NCT02026687|Drug|Epidural|
285551|NCT02026687|Drug|Intrathecal|
285552|NCT02026674|Device|FloRite|Disposable home use urine flow meter.
285553|NCT02026622|Behavioral|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
285554|NCT02026622|Device|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
285555|NCT02026622|Device|transcranial doppler and TPI|transcranial doppler TPI
285556|NCT02026622|Behavioral|explicitative interview|
285557|NCT02026609|Other|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
285558|NCT02026609|Other|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
285559|NCT02026596|Procedure|Magnetic resonance imaging|
285560|NCT02026596|Procedure|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
285561|NCT02026583|Drug|Simvastatin|
285562|NCT02026570|Behavioral|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
285563|NCT02026570|Behavioral|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
285564|NCT02026544|Device|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
285565|NCT02026531|Other|3-Helium gas|3-Helium gas for MRI contrast
285566|NCT02026518|Dietary Supplement|Soy isoflavones|
285567|NCT02026518|Dietary Supplement|cholecalciferol|
285568|NCT02026518|Dietary Supplement|Placebo of soy isoflavones|
285569|NCT02026518|Dietary Supplement|placebo of cholecalciferol|
285570|NCT02026505|Drug|Bortezomib|
285571|NCT02026492|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
285572|NCT02026492|Other|Methacholine challenge|nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
285573|NCT02026492|Other|Exercise challenge in room temperature|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
285574|NCT02026479|Drug|Dexamethasone Phosphate|5mg; postauricular injection
285575|NCT02026479|Drug|Dexamethasone Phosphate|10mg; postauricular injection
285576|NCT02026479|Drug|Ginaton|40mg/pill, 3times/day,oral
285577|NCT02026453|Other|Pharmacist obtains admission medication history|
285578|NCT02026453|Other|Pharmacy technician obtains admission medication history|
285579|NCT02026414|Dietary Supplement|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
285580|NCT02026414|Other|Exercise|
285581|NCT02026401|Biological|NGM282|
285582|NCT02026401|Biological|Placebo|
285583|NCT02026362|Biological|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
285584|NCT02026362|Other|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
285585|NCT02026349|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
285586|NCT02026349|Drug|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
285656|NCT02025712|Drug|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
285665|NCT02025621|Drug|Placebo|matching placebo
285666|NCT02025608|Drug|Pramipexole|
285587|NCT02026336|Other|electronic nose|"Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile."
285588|NCT02026323|Other|acupuncture|acupuncture
285589|NCT02026310|Drug|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
285590|NCT02026310|Drug|glargine and metformin|
285591|NCT02026297|Drug|Tranexamic Acid|1 gram IV over 10 minutes
285592|NCT02026297|Drug|Placebo; Normal Saline|0.9% Normal Saline
285593|NCT02026284|Other|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
285594|NCT02026271|Biological|Ad-RTS-hIL-12|"2.0 x 10^11 viral particles (vp) per injection or 1.0 x 10^12 viral particles (vp) per injection~one intratumoral injection of Ad-RTS-hIL-12"
285595|NCT02026271|Drug|veledimex|"4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)~14 oral daily doses of veledimex~1 Expansion cohort at a single dose level at or below MTD"
285596|NCT02026258|Procedure|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
285597|NCT02026258|Device|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
285598|NCT02026245|Device|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:~5DT 'dataglove 14 Ultra' Electronic glove (commercially available)~New 'Tyndall/UU' developmental dataglove"
285599|NCT02026232|Drug|Hydroxychloroquine|200mg twice daily
285600|NCT02026232|Other|Hydroxychloroquine Placebo|200mg placebo twice daily
285601|NCT02026219|Drug|Clopidogrel|Clopidogrel 600mg loading
285602|NCT02026219|Drug|Ticagrelor|Ticagrelor 180mg loading
285603|NCT02026206|Device|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
285604|NCT02026206|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
285605|NCT02026193|Procedure|oocyte vitrification|
285606|NCT02026193|Procedure|embryo freezing|
285607|NCT02026180|Device|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
285608|NCT02026167|Behavioral|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
285609|NCT02026141|Drug|Dexmedetomidine|
285610|NCT02026141|Drug|Normal Saline Placebo|
285611|NCT02026115|Behavioral|PAINReportIt|PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
285612|NCT02026115|Behavioral|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
285657|NCT02025712|Drug|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
285658|NCT02025686|Drug|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
285659|NCT02025686|Other|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
285660|NCT02025660|Drug|Mw, 0.3ml x three days sc|
285661|NCT02025660|Drug|Placebo|
285662|NCT02025634|Drug|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
285613|NCT02026115|Behavioral|PAINUCope|We tested the prototype of the PAINUCope component of the intervention in three completed studies. PAINUCope is a multimedia, computer generated tool that provides tailored patient information to overcome their misconceptions about pain and to help them engage in self-care activities that contribute to reducing their pain. PAINUCope focuses on two crucial aspects of pain management: 1) reporting cancer pain; and 2) safe and effective use of pain medicines. All the educational materials were written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person living with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt govern the specific health information that is shared with the patient via PAINUCope.
285614|NCT02026102|Behavioral|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
285615|NCT02026089|Biological|Varicella vaccine|Varivax 0.5ml subcutaneous injection
285616|NCT02026076|Other|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
285617|NCT02026063|Drug|Telotristat etiprate|Telotristat etiprate tablet (250 mg)
285618|NCT02026050|Procedure|intraarticular dexamethasone|2ml 8 mg dexamethasone administration for intraarticular
285619|NCT02026050|Procedure|interscalene dexamethasone|2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
285620|NCT02026050|Procedure|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
285621|NCT02026037|Behavioral|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
285622|NCT02026011|Drug|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
285623|NCT02026011|Drug|Placebo|Sugar pill, matched to the active study medication in capsule size and color
285624|NCT02025998|Drug|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
285625|NCT02025998|Other|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
285626|NCT02025985|Drug|Selinexor|35 mg/m2 twice weekly, 50 mg/m2 twice weekly, 50 mg/m2 once weekly, or 60 mg/m2 twice weekly. Cycles are 4 weeks.
285627|NCT02025972|Procedure|Allogeneic umbilical cord blood therapy|
285628|NCT02025959|Behavioral|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders|
285629|NCT02025933|Other|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
285630|NCT02025933|Other|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
285631|NCT02025933|Other|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
285632|NCT02025920|Other|Salmon Group|
285633|NCT02025920|Other|Cod Group|
285634|NCT02025920|Other|Meat Group|
285635|NCT02025907|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
285636|NCT02025907|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
285637|NCT02025907|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily.
285638|NCT02025881|Drug|Carboplatin + etoposide|"Carboplatin 160 mg/m2 Day 1 to day 5 As an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).~Etoposide 100 mg/m2 D ay 1 to day 5 As an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle."
285639|NCT02025881|Drug|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1 As an intravenously infusion over 1 hour dilution in 200 ml/m² of 5% glucose saline or sodium chloride 9 mg/ml (0.9%)
285640|NCT02025881|Drug|Cyclophosphamide + Busilvex|"Cyclophosphamide Level 1 20 mg/kg/day Level 2 30 mg/kg/day Level 3 40 mg/kg/day Level 4 50 mg/kg/day~Busilvex < 9 kgs 0.8 mg/kg/dose - 3.2 mg/kg/day 9 à < 16 kgs 0.96 mg/kg/dose - 3.84 mg/kg/day 16 à 23 kgs 0.88 mg/kg/dose - 3.52 mg/kg/day > 23 à 34 kgs 0.76 mg/kg/dose - 3.04 mg/kg/day > 34 kgs 0.64 mg/kg/dose"
285641|NCT02025868|Behavioral|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
285642|NCT02025868|Drug|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|"Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.~Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)"
285643|NCT02025855|Drug|Methadone|
285644|NCT02025855|Drug|Placebo|
285645|NCT02025803|Drug|TAS-114/capecitabine|"Part 1 (dose-escalation phase):~Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated~Part 2 (expansion phase):~TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
285646|NCT02025790|Procedure|Per Oral Endoscopic Myotomy (POEM)|"Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~Long endoscopic myotomy is performed 10 cm proximal to GEJ extending~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
285647|NCT02025790|Procedure|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
285648|NCT02025777|Device|Capsule Endoscopy|
285667|NCT02025608|Drug|Placebo|
285668|NCT02025582|Device|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
285669|NCT02025569|Other|Strain Counterstrain|
285670|NCT02025569|Other|Sham strain counterstrain|
285671|NCT02025556|Biological|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
285672|NCT02025556|Biological|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
285673|NCT02025556|Biological|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
285674|NCT02025543|Other|MRI|R2 MRI scan
285675|NCT02025530|Other|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
285676|NCT02025517|Other|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
285677|NCT02025504|Device|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
285678|NCT02025491|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
285679|NCT02025478|Biological|Breastmilk|"A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
285680|NCT02025465|Drug|Metoprolol|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team."
285681|NCT02025465|Drug|Diltiazem|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team."
285682|NCT02025452|Other|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
285683|NCT02025452|Dietary Supplement|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
285684|NCT02025452|Other|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
285685|NCT02025439|Device|rTMS|
285686|NCT02025439|Drug|Amantadine|
285687|NCT02025426|Drug|Phenylephrine|
285688|NCT02025426|Drug|Ephedrine|
285689|NCT02025413|Device|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
285690|NCT02025400|Other|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
285691|NCT02025400|Other|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
285692|NCT02025387|Behavioral|Physical activity feedback|
285693|NCT02025387|Behavioral|Usual care except physical activity measurement|
285694|NCT02025374|Drug|Hyperbaric levobupivacaine|
285695|NCT02025374|Drug|Hyperbaric bupivacaine % 0.5|
285696|NCT02025361|Drug|intrarectal lidocaine gel|intrarectal local anesthetic application
285697|NCT02025361|Drug|periprostatic nerve blockade|periprostatic local anesthetic application
285698|NCT02025348|Drug|IntelliCap|Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
285699|NCT02025322|Behavioral|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.~Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
285700|NCT02025309|Device|Neuromuscular monitorisation|
285701|NCT02025296|Device|U-healthcare|use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
285826|NCT02024360|Behavioral|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
285702|NCT02025283|Procedure|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA]
285703|NCT02025270|Biological|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
285704|NCT02025257|Other|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
285705|NCT02025244|Procedure|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
285706|NCT02025244|Procedure|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
285707|NCT02025231|Radiation|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
285708|NCT02025218|Drug|Gefitinib standard dose|
285709|NCT02025205|Device|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
285710|NCT02025192|Drug|Tucatinib|Administered twice per day, orally.
285711|NCT02025192|Drug|Capecitabine|1000mg/m^2 administered twice per day, orally in Days 1-14 of each 21-day cycle.
285712|NCT02025192|Drug|Trastuzumab|Administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
285713|NCT02025179|Drug|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
285714|NCT02025179|Device|Vibration|Vibration 10 min/day for 12 months
285715|NCT02025166|Drug|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
285716|NCT02025166|Drug|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
285717|NCT02025153|Other|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
285718|NCT02025140|Device|Computer controlled anesthesia|The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
285719|NCT02025140|Device|conventional anesthesia syringe|Active control
285720|NCT02025127|Other|Enteral nutrition|Enteral nutrition introduced via a feeding tube
285721|NCT02025114|Drug|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
285722|NCT02025088|Procedure|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
285723|NCT02025088|Procedure|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
285724|NCT02025075|Drug|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
285725|NCT02025062|Other|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
285726|NCT02025049|Drug|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
285727|NCT02025049|Drug|Placebo|mannitol-based DP-b99 look-alike
285728|NCT02025036|Drug|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
285729|NCT02025036|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
285730|NCT02025036|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
285731|NCT02025023|Drug|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
285732|NCT02025023|Drug|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
285733|NCT02025023|Procedure|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
285734|NCT02025023|Drug|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
285735|NCT02025010|Drug|abiraterone acetate|Daily four 250 mg tablets (1,000 mg) of AA taken orally for 28 day cycles. No food should be consumed for at least two hours before the dose and for at least one hour after the dose. The tablets should be swallowed whole with water. Tablets should not be crushed or chewed.
285736|NCT02025010|Drug|prednisone|Take with food 5 mg Oral Twice daily
285827|NCT02024334|Drug|Leflunomide|
285828|NCT02024308|Drug|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
285737|NCT02025010|Procedure|pre-treatment and progression tumor biopsies|Participants will undergo pre-treatment and progression tumor biopsies. After the progression biopsy is performed, protocol therapy will be discontinued. Participants who stop protocol therapy before receiving four cycles of AA will not be asked to undergo the second biopsy.
285738|NCT02025010|Genetic|assessment of serum corticosteroid intermediates and ACTH|•Participants will undergo assessment of serum corticosteroid intermediates and ACTH at baseline and subsequent treatment visits for correlation with symptoms of mineralocorticoid excess.
285739|NCT02024997|Other|Magnetic Resonance Imaging (MRI)|
285740|NCT02024984|Drug|Clomiphene Citrate|"Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.~Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle."
285741|NCT02024971|Drug|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
285742|NCT02024945|Drug|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
285743|NCT02024932|Drug|BVS857|BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
285744|NCT02024932|Drug|Placebo|Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
285745|NCT02024919|Drug|intracoronary administration of diltiazem|
285746|NCT02024919|Drug|intracoronary injection of 5 mL saline|
285747|NCT02024906|Dietary Supplement|soy protein isolate (SPI)|
285748|NCT02024906|Dietary Supplement|milk protein isolate (MPI)|
285749|NCT02024893|Other|Observational study|"Observation and type of data collected are listged in detail under 'description"
285750|NCT02024880|Device|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
285751|NCT02024880|Device|Conventional catheter group|A standard embryo catheter
285752|NCT02024867|Drug|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
285753|NCT02024854|Behavioral|skin-to-skin|
285754|NCT02024854|Behavioral|standard care|
285755|NCT02024841|Drug|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
285756|NCT02024828|Other|Early/Slow|
285757|NCT02024828|Other|Early/Fast|
285758|NCT02024828|Other|Late/Slow|
285759|NCT02024828|Other|Late/Fast|
285760|NCT02024815|Radiation|External Beam radiotherapy|External Beam radiotherapy
285761|NCT02024789|Drug|Placebo|Orally twice daily, 26 weeks
285762|NCT02024789|Drug|RG1662|120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
285763|NCT02024789|Drug|RG1662|240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
285764|NCT02024776|Behavioral|Prehabilitation|Tailored exercise training program
285765|NCT02024763|Behavioral|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
285766|NCT02024750|Behavioral|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
285767|NCT02024737|Other|MRI lung imaging (not an intervention per se but the focus of the study)|"The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).~This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD."
285768|NCT02024724|Drug|Bupivacaine|4 mL of 0.25% bupivacaine
285769|NCT02024724|Drug|Triamcinolone|40 mg of Triamcinolone
285770|NCT02024724|Drug|Dexamethasone|4 mg of Dexamethasone
285771|NCT02024711|Device|EYEFILL® C.-US Viscoelastic|EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
285772|NCT02024711|Device|Healon® Viscoelastic (CONTROL)|Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.
285773|NCT02024698|Device|omafilcon A|contact lens
285774|NCT02024698|Device|etafilcon A|contact lens
285829|NCT02024308|Drug|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
285830|NCT02024295|Drug|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
286064|NCT02022358|Drug|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
285775|NCT02024685|Behavioral|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
285776|NCT02024685|Behavioral|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
285777|NCT02024672|Other|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
285778|NCT02024659|Drug|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
285779|NCT02024659|Other|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
285780|NCT02024646|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
285781|NCT02024646|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
285782|NCT02024646|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
285783|NCT02024633|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
285784|NCT02024633|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
285785|NCT02024620|Behavioral|Behavioral activation plus mobile app|
285786|NCT02024620|Behavioral|Standard behavioral activation|
285787|NCT02024607|Drug|BBI608|
285788|NCT02024607|Drug|Fluorouracil|
285789|NCT02024607|Drug|Oxaliplatin|
285790|NCT02024607|Drug|Leucovorin|
285791|NCT02024607|Drug|Irinotecan|
285792|NCT02024607|Drug|Bevacizumab|
285793|NCT02024607|Drug|Capecitabine|
285794|NCT02024607|Drug|Regorafenib|
285795|NCT02024594|Drug|Nitrous Oxide-Oxygen conscious sedation|
285796|NCT02024594|Behavioral|cognitive-behavioral therapy|
285797|NCT02024581|Drug|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
285798|NCT02024581|Drug|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
285799|NCT02024568|Drug|Pregabalin|See arm description
285800|NCT02024568|Drug|Placebo|See arm description
285801|NCT02024555|Drug|Levofloxacin|
285802|NCT02024555|Drug|Ethambutol|
285803|NCT02024555|Drug|Azithromycin|
285804|NCT02024555|Drug|Rifampin|
285805|NCT02024555|Drug|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
285806|NCT02024542|Other|Surgery|Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing & counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
285807|NCT02024529|Biological|Ampion|kDa ultrafiltrate of 5% human serum albumin
285808|NCT02024529|Biological|Placebo|Saline
285809|NCT02024516|Other|50 gr concentrated pomegranate juice|
285810|NCT02024477|Drug|Saxagliptin|5 mg tablet once daily for 12 weeks
285811|NCT02024477|Drug|Placebo|1 tablet daily for 12 weeks
285812|NCT02024464|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
285813|NCT02024464|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
285814|NCT02024451|Device|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
285815|NCT02024451|Device|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
285816|NCT02024438|Drug|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
285817|NCT02024438|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
285818|NCT02024425|Dietary Supplement|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
285819|NCT02024425|Dietary Supplement|Control supplement|
285820|NCT02024412|Drug|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
285821|NCT02024412|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
285822|NCT02024399|Other|Exercise|Strength training, aerobic exercise and core strengthening, running
285823|NCT02024386|Drug|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
285824|NCT02024373|Drug|Atorvastatin|20 mg (every evening orally) for 8 weeks
285825|NCT02024373|Drug|placebo|20 mg (every evening orally) for 8 weeks
285945|NCT02023411|Drug|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneously every day at 8-9 pm
285831|NCT02024295|Drug|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
285832|NCT02024295|Drug|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
285833|NCT02024282|Device|Use of C-reactive protein (CRP) point of care test|
285834|NCT02024282|Other|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.~We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
285835|NCT02024282|Device|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
285836|NCT02024269|Biological|Adipose Derived Stem Cells|
285837|NCT02024256|Other|Cold pads soaked in Magnesium sulfate solution|
285838|NCT02024256|Other|Cold pads soaked in water|
285839|NCT02024243|Procedure|Punch Tissue Biopsy|Subjects will have two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) collected on days 0, 14, and 28. Biopsies will not be collected if the wound has closed by day 14 or 28.
285840|NCT02024230|Drug|Warfarin or Rivaroxaban|No limitations of previous medication (Warfarin or new oral anticoagulant drugs or no anticoagulant drug) and type of stent (bare metal stent or drug eluting stent) in both arms
285841|NCT02024217|Radiation|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
285842|NCT02024204|Drug|Fluticasone propionate 230mcg for 3 Months|
285843|NCT02024204|Drug|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
285844|NCT02024204|Drug|Salmeterol 21mcg for 3 Months|
285845|NCT02024191|Dietary Supplement|Glutamine|
285846|NCT02024178|Procedure|Ultrasound Imaging|
285847|NCT02024152|Drug|JDP-205 IV high dose|
285848|NCT02024152|Drug|JDP-205 IV low dose|
285849|NCT02024152|Drug|JDP-205 IM|
285850|NCT02024152|Drug|Control: Zyrtec|
285851|NCT02024139|Other|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
285852|NCT02024139|Other|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
285853|NCT02024126|Other|Exercise therapy|Exercise therapy
285854|NCT02024113|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
285855|NCT02024087|Drug|Dalantercept plus sorafenib|Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
285856|NCT02024074|Other|Sestamibi (Tc-MBI) scan of the breast|Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
285857|NCT02024061|Behavioral|Peer support|
285858|NCT02024061|Behavioral|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
285859|NCT02024048|Other|OCT|Optical coherence tomography in enhanced depth imaging mode
285860|NCT02024035|Radiation|Radiotherapy|
285861|NCT02024022|Drug|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
285862|NCT02024022|Drug|Individualized approach|
285863|NCT02024009|Drug|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
285864|NCT02024009|Radiation|60Gy in 30#|
285865|NCT02024009|Radiation|50.4Gy in 28#|
285866|NCT02024009|Drug|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
285867|NCT02024009|Drug|Capecitabine|Given in combination with gemcitabine, known as GemCap.
285868|NCT02024009|Drug|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
285869|NCT02023996|Radiation|89Zr-DFO-trastuzumab|
285870|NCT02023996|Device|PET imaging|
285871|NCT02023983|Other|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
285872|NCT02023983|Other|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
285873|NCT02023970|Device|Patients receiving animal-derived bioprosthetic heart valves.|
285874|NCT02023970|Other|Echocardiography (1)|
285875|NCT02023970|Other|Echocardiography (2)|
285876|NCT02023970|Other|Echocardiography (3)|
285877|NCT02023970|Biological|Blood sample (1)|
285878|NCT02023970|Biological|Blood sample (2)|
285879|NCT02023970|Biological|Blood sample (3)|
285880|NCT02023957|Behavioral|Interactive computer-assisted screening (iCAS)|
285881|NCT02023944|Other|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
285946|NCT02023411|Other|Placebo|Placebo
285882|NCT02023931|Drug|Broccoli Sprout Extract (BSE)|"The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane."
285883|NCT02023918|Drug|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
285884|NCT02023905|Drug|Everolimus|
285885|NCT02023905|Drug|Temozolomide|
285886|NCT02023892|Drug|atorvastatin|
285887|NCT02023892|Drug|placebo|
285888|NCT02023879|Drug|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
285889|NCT02023879|Drug|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
285890|NCT02023879|Drug|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
285891|NCT02023879|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
285892|NCT02023866|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release capsules
285893|NCT02023853|Procedure|ultrasonic|
285894|NCT02023853|Procedure|erythritol|
285895|NCT02023853|Drug|metronidazole gel|
285896|NCT02023840|Drug|metronidazole gel|
285897|NCT02023840|Procedure|ultrasonics|
285898|NCT02023840|Procedure|erythritol|
285899|NCT02023840|Drug|placebo|
285900|NCT02023827|Behavioral|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
285901|NCT02023801|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
285902|NCT02023788|Biological|PNEUMOSTEM|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10^7 cells/kg High Dose Group (6 patients): 2.0 x 10^7 cells/kg~* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study."
285903|NCT02023775|Device|Melody valve implantation|
285904|NCT02023749|Dietary Supplement|Nut group|
285905|NCT02023736|Other|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
285906|NCT02023736|Other|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
285907|NCT02023723|Dietary Supplement|Monster Energy Drink|16oz Monster Energy drinks - 2 consumed within 60 minutes
285908|NCT02023723|Dietary Supplement|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
285909|NCT02023710|Drug|Paclitaxel|175 mg/m^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
285910|NCT02023710|Drug|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
285911|NCT02023710|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
285912|NCT02023697|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
285913|NCT02023684|Drug|control saline|Surgical bed irrigation with saline 40ml
285914|NCT02023684|Drug|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
285915|NCT02023684|Drug|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
285916|NCT02023658|Other|pMTCT systems analysis and improvement|Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
285917|NCT02023645|Dietary Supplement|active supplement|tablet
285918|NCT02023645|Other|placebo|tablet
285919|NCT02023632|Behavioral|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
285947|NCT02023398|Device|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
285948|NCT02023398|Device|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
285949|NCT02023385|Device|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
285950|NCT02023385|Device|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
286023|NCT02022709|Drug|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
285920|NCT02023632|Behavioral|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
285921|NCT02023632|Behavioral|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
285922|NCT02023606|Drug|SPN-810M|
285923|NCT02023593|Drug|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
285924|NCT02023580|Behavioral|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 & 10) Support of HIV disclosure and perceived responsibility."
285925|NCT02023567|Drug|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
285926|NCT02023554|Drug|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.~Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
285927|NCT02023554|Drug|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
285928|NCT02023541|Radiation|Proton beam therapy|
285929|NCT02023515|Behavioral|Emotional brain training|Stress management based program
285930|NCT02023515|Behavioral|Behavioral weight loss|Standard behavioral weight loss
285931|NCT02023502|Other|collection of urine and blood sample|
285932|NCT02023489|Device|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
285933|NCT02023489|Other|Meal Tolerance Test|"A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.~At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T)."
285934|NCT02023489|Other|Hyperglycemic-hyperinsulinemic clamp|"All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.~At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at ~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with [1-13C]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS."
285935|NCT02023476|Radiation|MRI|MRI- imaging on the upper arm
285936|NCT02023463|Drug|Enzalutamide|Given PO
285937|NCT02023463|Drug|Goserelin acetate|Given SC
285938|NCT02023463|Drug|Leuprolide acetate|Given IM or SC
285939|NCT02023463|Radiation|Radiation therapy|Undergo image-guided radiation therapy
285940|NCT02023450|Drug|saquinavir and ritonavir|micro and low dose
285941|NCT02023450|Drug|saquinavir and ritonavir|standard dose
285942|NCT02023437|Device|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
285943|NCT02023437|Device|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
285944|NCT02023424|Drug|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
287194|NCT02013388|Drug|N91115|Given PO only on Day 1
285951|NCT02023372|Biological|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
285952|NCT02023359|Drug|Everolimus and exemestane|
285953|NCT02023346|Behavioral|surveys and cognitive tests|
285954|NCT02023333|Drug|Regorafenib|All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
285955|NCT02023320|Dietary Supplement|Low dose of blueberry dry powder|
285956|NCT02023320|Dietary Supplement|High dose of blueberry dry powder|
285957|NCT02023307|Device|V-Loc Suture|
285958|NCT02023294|Procedure|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
285959|NCT02023294|Procedure|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
285960|NCT02023281|Behavioral|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
285961|NCT02023268|Device|T2762|1 drop in each eye 3 to 6 times daily during 84 days
285962|NCT02023268|Device|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
285963|NCT02023255|Drug|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
285964|NCT02023255|Other|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
285965|NCT02023242|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
285966|NCT02023242|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
285967|NCT02023229|Dietary Supplement|Branched-chain aminoacids|
285968|NCT02023229|Other|High-fiber high protein diet|
285969|NCT02023216|Device|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
285970|NCT02023203|Procedure|Totally Extraperitoneal laparoscopic inguinal hernia repair|Laparoscopic hernioplasty
285971|NCT02023164|Drug|JDP-205 Injection|
285972|NCT02023164|Drug|Diphenhydramine|
285973|NCT02023151|Drug|Omalizumab|
285974|NCT02023138|Other|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
285975|NCT02023138|Other|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
285976|NCT02023125|Drug|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
285977|NCT02023125|Drug|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
285978|NCT02023125|Other|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
285979|NCT02023125|Other|Standard Meal|Standard meal served prior to alectinib administration
285980|NCT02023112|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
285981|NCT02023112|Drug|Ribavirin|Capsule
285982|NCT02023099|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
285983|NCT02023099|Drug|Placebo|Tablet
285984|NCT02023086|Procedure|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
285985|NCT02023086|Procedure|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
285986|NCT02023086|Procedure|Visual field testing|"Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.~In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later."
286020|NCT02022722|Procedure|Pelvic Rehabilitation|Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
286021|NCT02022709|Drug|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
286022|NCT02022709|Drug|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
285987|NCT02023086|Procedure|Oxygen flow at the optic nerve head measurement|"Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.~During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer."
285988|NCT02023086|Drug|Tropicamide|Used to dilate patient's pupil during testing
285989|NCT02023086|Device|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
285990|NCT02023047|Drug|Nifedipine 12 mg coated suppositories|
285991|NCT02023034|Other|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
285992|NCT02023021|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
285993|NCT02023021|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
285994|NCT02023008|Procedure|yoga therapy|Undergo integral yoga intervention with videoconferencing
285995|NCT02023008|Other|internet-based intervention|Undergo integral yoga intervention with videoconferencing
285996|NCT02023008|Other|questionnaire administration|Ancillary studies
285997|NCT02022982|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
285998|NCT02022982|Drug|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
285999|NCT02022956|Drug|Lorcaserin|
286000|NCT02022930|Device|Hydros|
286001|NCT02022930|Device|Hydros-TA|
286002|NCT02022930|Drug|Triamcinolone Acetonide|
286003|NCT02022917|Drug|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
286004|NCT02022904|Device|Near infrared (NIR) emissive nanotechnology|
286005|NCT02022891|Behavioral|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
286006|NCT02022878|Procedure|PCI of CTO|
286007|NCT02022852|Drug|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
286008|NCT02022852|Drug|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
286009|NCT02022826|Device|SmartPill Monitoring System|
286010|NCT02022813|Dietary Supplement|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
286011|NCT02022800|Other|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
286012|NCT02022787|Other|patients with renal cell carcinoma|Chemokines that may be elevated in patients with RCC
286013|NCT02022774|Drug|Fimasartan|Fimasartan 60 ~ 120 mg/po take one tablet once a day
286014|NCT02022761|Drug|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
286015|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
286016|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
286017|NCT02022748|Drug|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
286018|NCT02022735|Device|Deep Brain Stimulation|
286019|NCT02022722|Drug|Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride|The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
286024|NCT02022709|Drug|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
286025|NCT02022709|Drug|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
286026|NCT02022709|Behavioral|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
286027|NCT02022696|Genetic|Lentiviral Gene Transfer|
286028|NCT02022683|Device|ELVR (Endoscopic Lung Volume Reduction) with Zephyr Valves|
286029|NCT02022670|Drug|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
286030|NCT02022670|Drug|Sodium Nitrite|80 mg/d or 160 mg/d
286031|NCT02022657|Drug|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
286032|NCT02022644|Drug|nanoliposomal irinotecan|The drug named here (nanoliposomal irinotecan) will be used in varying amounts, based on tumor volume.
286033|NCT02022631|Other|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
286034|NCT02022631|Other|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
286035|NCT02022605|Device|Hands-on EMS training|A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
286036|NCT02022605|Other|Standard training|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
286037|NCT02022592|Drug|Lormetazepam|
286038|NCT02022592|Drug|Midazolam|
286039|NCT02022579|Procedure|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
286040|NCT02022566|Behavioral|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
286041|NCT02022553|Procedure|usual rectal cancer surgery|
286042|NCT02022553|Procedure|RACHEL|
286043|NCT02022540|Drug|PAN-90806 Ophthalmic Solution|
286044|NCT02022540|Drug|Lucentis|
286045|NCT02022527|Drug|Acetyl Salicylic Acid|
286046|NCT02022527|Drug|Warfarin|
286047|NCT02022527|Drug|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
286048|NCT02022514|Other|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
286049|NCT02022514|Drug|Conventional medical treatment|
286050|NCT02022501|Drug|DE-120|
286051|NCT02022488|Drug|midazolam|Group M
286052|NCT02022488|Drug|alfentanil|Group MA
286053|NCT02022488|Drug|ketamine|Group MK
286054|NCT02022475|Drug|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
286055|NCT02022475|Other|placebo|2 placebo capsules will be applied as a single dose
286056|NCT02022462|Behavioral|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.~The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
286057|NCT02022449|Behavioral|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
286058|NCT02022436|Drug|contrast ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
286059|NCT02022423|Behavioral|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
286060|NCT02022423|Behavioral|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals, a personalized website with an online community, and tailored tips.
286061|NCT02022410|Other|CAS after primary and revision TKA|CAS and RAPT
286062|NCT02022384|Other|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
286063|NCT02022371|Procedure|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
286065|NCT02022358|Drug|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
286066|NCT02022358|Drug|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
286067|NCT02022345|Procedure|Percutaneous Coronary Intervention|
286068|NCT02022319|Device|Ultrasonographic Shear Wave Elastography|
286069|NCT02022306|Drug|TD-6450|
286070|NCT02022306|Drug|Placebo|
286071|NCT02022293|Drug|Atorvastatin|Patients in this group will take 20mg per night.
286072|NCT02022293|Other|Placebo|
286073|NCT02022280|Drug|Lansoprazole|
286074|NCT02022254|Drug|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
286075|NCT02022254|Drug|placebo|Semaglutide placebo will be administered s.c.
286076|NCT02022254|Drug|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
286077|NCT02022254|Drug|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
286078|NCT02022241|Drug|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
286079|NCT02022228|Drug|triptorelin|0.2 mg triptorelin, ih
286080|NCT02022228|Drug|hCG|1000 IU hCG, im
286081|NCT02022228|Drug|hCG|500IU hCG, im
286082|NCT02022215|Drug|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
286083|NCT02022215|Drug|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
286084|NCT02022215|Drug|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
286085|NCT02022189|Procedure|Renal Biopsy|
286086|NCT02022176|Other|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
286087|NCT02022176|Other|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
286088|NCT02022176|Other|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
286089|NCT02022163|Biological|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
286090|NCT02022163|Biological|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
286091|NCT02022163|Biological|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
286092|NCT02022163|Biological|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
286093|NCT02022163|Biological|Placebo|Placebo, 2 doses given 21 days apart
286094|NCT02022150|Behavioral|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
286095|NCT02022137|Dietary Supplement|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
286096|NCT02022137|Dietary Supplement|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
286097|NCT02022137|Dietary Supplement|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
286098|NCT02022124|Drug|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
286099|NCT02022111|Behavioral|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
286100|NCT02022111|Behavioral|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
286101|NCT02022111|Other|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patientsand their usual care providers.
286126|NCT02021890|Behavioral|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
286102|NCT02022111|Other|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
286103|NCT02022111|Other|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
286104|NCT02022098|Drug|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
286105|NCT02022098|Radiation|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
286106|NCT02022098|Drug|Debio 1143|Debio 1143 solution
286107|NCT02022098|Drug|Placebo|Matching placebo solution
286108|NCT02022085|Device|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
286109|NCT02022072|Device|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
286110|NCT02022059|Drug|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
286111|NCT02022059|Drug|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
286112|NCT02022046|Other|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
286113|NCT02022033|Drug|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
286114|NCT02022007|Drug|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks~Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
286115|NCT02022007|Drug|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks~Remain at 1 pill (5mg dose) for remainder of study"
286116|NCT02022007|Drug|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks~Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
286117|NCT02021968|Biological|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
286118|NCT02021968|Biological|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
286119|NCT02021968|Biological|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
286120|NCT02021955|Behavioral|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
286121|NCT02021942|Drug|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
286122|NCT02021929|Drug|Sorafenib|"Sorafenib is a kinase inhibitor indicated for the treatment of:~Unresectable hepatocellular carcinoma~Advanced renal cell carcinoma~Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"
286123|NCT02021929|Drug|Placebo|
286124|NCT02021903|Other|V1: HGPO + meal and V2: placebo + meal|"Ambulatory polysomnography for the night preceding each test~Usual antiparkinsonian treatments at their usual dose and timing~Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~continuous digital blood pressure monitoring by Nexfin®~blood pressure monitoring at brachial artery~continuous polysomnographic recording~synchronized continuous digital audiovisual recording~glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
286125|NCT02021903|Other|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"Ambulatory polysomnography for the night preceding each test~Usual antiparkinsonian treatments at their usual dose and timing~Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test~During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :~continuous digital blood pressure monitoring by Nexfin®~blood pressure monitoring at brachial artery~continuous polysomnographic recording~synchronized continuous digital audiovisual recording~glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
286127|NCT02021890|Behavioral|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
286128|NCT02021864|Drug|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
286129|NCT02021864|Drug|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
286130|NCT02021851|Drug|Dexamethasone and aprepitant|
286131|NCT02021851|Drug|Dexamethasone and ondansetron|
286132|NCT02021838|Other|Lethality Assessment Program|
286133|NCT02021838|Other|Domestic Violence High Risk Team|
286134|NCT02021825|Drug|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
286135|NCT02021812|Device|Branched TAG® Device|
286136|NCT02021799|Dietary Supplement|Moringa and Lactobacillus rhamnosus GR-1|
286137|NCT02021786|Behavioral|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
286138|NCT02021773|Biological|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
286139|NCT02021773|Biological|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
286140|NCT02021773|Biological|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
286141|NCT02021760|Procedure|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
286142|NCT02021669|Drug|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
286143|NCT02021669|Drug|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
286144|NCT02021656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily without regard to food
286145|NCT02021643|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
286146|NCT02021643|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
286147|NCT02021643|Drug|PEG|Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
286148|NCT02021630|Other|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
286149|NCT02021617|Device|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver—a small battery-powered drill—and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
286150|NCT02021604|Drug|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
286151|NCT02021591|Behavioral|Mobile Diabetes Detective (MoDD)|MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior.
286152|NCT02021578|Behavioral|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
286153|NCT02021578|Behavioral|Written information|Reading materials about depression
286154|NCT02021565|Behavioral|Immediate Intervention Group|Assistive Technology (AT) Specialists, experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform three activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, AT Specialists also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, AT Specialists provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
286155|NCT02021565|Other|Delayed Intervention Control Group|Receives the in-home training intervention six weeks after completing the initial baseline assessment. This allows for a control comparison group while still providing the intervention to all participants.
286156|NCT02021552|Other|blood sampling|5 ml blood sampling
286157|NCT02021539|Procedure|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
286158|NCT02021539|Biological|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
286239|NCT02020915|Procedure|ultrasound guided lateral sphincterotomy|
286240|NCT02020902|Other|Cetrizine hydrochloride|As provided on the patient information leaflet
286159|NCT02021539|Drug|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
286160|NCT02021539|Procedure|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
286161|NCT02021526|Drug|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
286162|NCT02021513|Dietary Supplement|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
286163|NCT02021513|Dietary Supplement|Olive Oil|Placebo group
286164|NCT02021500|Drug|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
286165|NCT02021474|Drug|Histamine Dihydrochloride|
286166|NCT02021474|Drug|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|
286167|NCT02021461|Drug|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
286168|NCT02021461|Drug|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
286169|NCT02021461|Drug|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
286170|NCT02021448|Other|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
286171|NCT02021435|Dietary Supplement|salt substitute|Free salt substitute provided
286172|NCT02021422|Drug|anakinra|Dosage Route Administration 100 mg SC Every Other Day
286173|NCT02021422|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
286174|NCT02021422|Drug|Irinotecan|Irinotecan 180 mg/m2 90 minutes
286175|NCT02021422|Drug|fluorouracil|fluorouracil 2400 mg/m2 48 hours
286176|NCT02021409|Drug|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
286177|NCT02021409|Biological|Darbepoetin alfa|
286178|NCT02021396|Procedure|Embolization|this arm of the study was interventional (splenic artery embolization)
286179|NCT02021383|Behavioral|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.~Participants in the Contest only and Control group were not eligible to receive these meetings."
286180|NCT02021383|Behavioral|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
286181|NCT02021370|Drug|BAY85-3934|25mg Tablet
286182|NCT02021370|Drug|Placebo|Matching placebo tablet
286183|NCT02021357|Behavioral|hyperboloid associated with the exercise of proprioceptive|
286184|NCT02021357|Other|hyperboloid|
286185|NCT02021344|Behavioral|Mental Health First Aid|Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
286186|NCT02021331|Device|immediate implant placement without provisionalization|
286187|NCT02021331|Device|immediate implant placement with immediate provisionalization|
286188|NCT02021318|Drug|Roxadustat|oral
286189|NCT02021318|Drug|darbepoetin alfa|subcutaneous or intravenous injection
286190|NCT02021292|Drug|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
286191|NCT02021292|Drug|Placebo|Matching placebo oral tablet, to be taken once daily.
286192|NCT02021279|Device|MatriStem Pelvic Floor Matrix|
286193|NCT02021279|Procedure|native tissue repair|
286194|NCT02021266|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
286195|NCT02021253|Dietary Supplement|Probiotic|Lactibiane TOLERANCE vs Placebo
286196|NCT02021253|Dietary Supplement|Placebo|
286197|NCT02021240|Drug|Ketamine|
286198|NCT02021240|Drug|Dexamethasone|
286199|NCT02021240|Drug|Normal Saline|
286200|NCT02021227|Procedure|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for > 1 hour
286201|NCT02021214|Drug|Methylphenidate|
286202|NCT02021214|Drug|Placebo|
286203|NCT02021201|Drug|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
286204|NCT02021201|Drug|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
286205|NCT02021175|Behavioral|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
286206|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
286336|NCT02020161|Drug|Idarubicin|
286337|NCT02020161|Drug|methotrexate|
286207|NCT02021149|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
286208|NCT02021149|Behavioral|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
286209|NCT02021149|Other|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
286210|NCT02021149|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
286211|NCT02021136|Device|Rebel Reliever|Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
286212|NCT02021136|Other|Control|Usual antalgic treatment + physical exercises recommendations
286213|NCT02021123|Drug|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
286214|NCT02021110|Drug|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
286215|NCT02021097|Drug|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
286216|NCT02021097|Drug|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
286217|NCT02021084|Dietary Supplement|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
286218|NCT02021084|Dietary Supplement|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
286219|NCT02021071|Radiation|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
286220|NCT02021071|Radiation|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
286221|NCT02021058|Other|Experimental Formula|Experimental formula
286222|NCT02021058|Other|Standard control formula|Standard Infant formula
286223|NCT02021045|Device|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
286224|NCT02021032|Device|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
286225|NCT02021019|Procedure|Renal Denervation|Renal Denervation
286226|NCT02021006|Drug|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
286227|NCT02021006|Other|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
286228|NCT02021006|Drug|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
286229|NCT02021006|Drug|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
286230|NCT02021006|Drug|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs~Physicians can chose one the following schedules:~nitrofurantoin 1.5-2 mg/kg per day~amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)~cefixime 2 mg/kg per day~trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
286231|NCT02020980|Biological|Botulinum toxin type A|"This is an observational study designed to reflect the clinical practice in real life as closely as possible.~Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines."
286232|NCT02020967|Other|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
286233|NCT02020954|Procedure|ECG, echocardiography, cardiac MRI, sera biomarkers|
286234|NCT02020941|Drug|carfilzomib|Given IV
286235|NCT02020941|Drug|dexamethasone|Given IV or PO
286236|NCT02020941|Other|laboratory biomarker analysis|Correlative studies
286237|NCT02020928|Device|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
286238|NCT02020915|Procedure|lateral sphincterotomy|
286241|NCT02020889|Biological|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
286242|NCT02020889|Drug|Placebo|Placebo will be available as 0.9% sodium chloride
286243|NCT02020876|Other|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
286244|NCT02020863|Device|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
286245|NCT02020837|Procedure|Lymphaticovenous Micro-Anastomosis|
286246|NCT02020824|Behavioral|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
286247|NCT02020824|Other|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
286248|NCT02020824|Other|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
286249|NCT02020824|Other|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
286250|NCT02020824|Other|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
286251|NCT02020811|Device|Sentinel|
286252|NCT02020798|Other|Dietary Intervention|
286253|NCT02020785|Other|Higher phosphorus period|"Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives."
286254|NCT02020785|Other|Lower phosphorus period|"Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives."
286255|NCT02020772|Other|coordinating primary health care|
286256|NCT02020772|Other|usual primary health care|
286257|NCT02020759|Device|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral microembolism
286258|NCT02020746|Drug|EscharEx|
286259|NCT02020746|Drug|Gel Vehicle|
286260|NCT02020733|Device|Balloon catheter|
286261|NCT02020733|Device|metal cannula|
286262|NCT02020720|Procedure|Biopsy|Undergo image-guided biopsy
286263|NCT02020720|Procedure|Computed Tomography|Undergo 18F-DOPA-PET/CT
286264|NCT02020720|Procedure|Diffusion Weighted Imaging|Undergo DTI
286265|NCT02020720|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
286266|NCT02020720|Other|Laboratory Biomarker Analysis|Correlative studies
286267|NCT02020720|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
286268|NCT02020720|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
286269|NCT02020720|Procedure|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
286270|NCT02020707|Biological|Bevacizumab|Given IV
286271|NCT02020707|Other|Laboratory Biomarker Analysis|Correlative studies
286272|NCT02020707|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
286273|NCT02020707|Other|Pharmacological Study|Correlative studies
286274|NCT02020694|Drug|Vitamin D|
286275|NCT02020694|Drug|Placebo (for vitamin D)|
286276|NCT02020681|Device|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
286277|NCT02020681|Other|Placebo|Formulation of Curodont Repair without the peptide P11-4
286278|NCT02020681|Device|Fluoride|Single application on day D90
286279|NCT02020668|Other|Physiotherapy|
286280|NCT02020668|Other|Wait list control|
286281|NCT02020655|Other|Shear- force model|Shear- force model
286282|NCT02020642|Procedure|Renal transplantation|Renal transplantation from cadaveric or live donor
286283|NCT02020629|Drug|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
286284|NCT02020616|Drug|LY3053102|Administered SC
286285|NCT02020616|Drug|Exenatide ER|Administered SC
286286|NCT02020616|Drug|Placebo|Administered SC
286287|NCT02020616|Drug|Metformin|Administered orally (PO)
286288|NCT02020603|Device|epinephrine injection plus soft coagulation using hemostatic forceps|
286289|NCT02020603|Device|epinephrine injection plus argon plasma coagulation|
286290|NCT02020590|Drug|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
286291|NCT02020577|Drug|Cetuximab( erbitux®)|once per week
286292|NCT02020577|Drug|Afatinib|once per day
286293|NCT02020564|Behavioral|Speed of Processing Training|
286294|NCT02020564|Behavioral|Placebo Control|
286295|NCT02020551|Drug|Lidocaine Spray|
286296|NCT02020551|Drug|Placebo|
286297|NCT02020538|Other|Low-chloride perioperative intravenous fluid strategy|The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
286383|NCT02019758|Drug|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
286298|NCT02020525|Procedure|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
286299|NCT02020525|Procedure|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
286300|NCT02020512|Drug|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
286301|NCT02020499|Drug|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
286302|NCT02020486|Drug|Perampanel|2 mg up to 4 mg
286303|NCT02020486|Drug|Perampanel|2 mg up to 6 mg
286304|NCT02020460|Device|Subdural trial lead|
286305|NCT02020460|Device|Epidural trial lead|
286306|NCT02020434|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
286307|NCT02020421|Device|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
286308|NCT02020421|Device|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
286309|NCT02020421|Device|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
286310|NCT02020421|Device|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
286311|NCT02020408|Drug|[11C]raclopride|1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
286312|NCT02020408|Drug|[11C]DASB|BPND of [11C]DASB.
286313|NCT02020408|Drug|amphetamine|The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
286314|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
286315|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
286316|NCT02020382|Device|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
286317|NCT02020369|Biological|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
286318|NCT02020356|Behavioral|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
286319|NCT02020356|Behavioral|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
286320|NCT02020343|Behavioral|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
286321|NCT02020330|Drug|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
286322|NCT02020330|Drug|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
286323|NCT02020317|Behavioral|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
286324|NCT02020304|Drug|combined spinal epidural|Combined Spinal Epidural
286325|NCT02020291|Drug|Foxy-5|
286326|NCT02020278|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets~Dosage: Depending on age & weight:~Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: Subjects may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
286327|NCT02020265|Device|EEG neurofeedback|
286328|NCT02020252|Other|Touchscreen Computer Program|A program which allows patients to see information on a computer screen regarding cancer care, and specifically clinical trials
286329|NCT02020239|Other|Exercise|
286330|NCT02020226|Drug|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
286331|NCT02020213|Drug|Posaconazole|400 mg po bid for 8 weeks
286332|NCT02020200|Drug|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.
286333|NCT02020200|Drug|Placebo|
286334|NCT02020187|Other|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
286335|NCT02020161|Drug|Atra|
286338|NCT02020135|Drug|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
286339|NCT02020122|Drug|Duloxetine|duloxetine 60mg
286340|NCT02020122|Drug|Pregabalin|pregabalin 150mg
286341|NCT02020122|Drug|Placebo|non active placebo
286342|NCT02020109|Radiation|splenic irradiation|
286343|NCT02020096|Procedure|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.3 to 0.5 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
286344|NCT02020096|Procedure|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.3 to 0.5 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.3mA, otherwise intraneural needle position should be suspected.
286345|NCT02020070|Drug|Degarelix|
286346|NCT02020070|Drug|Ipilimumab|
286347|NCT02020070|Procedure|Radical Prostatectomy|
286348|NCT02020057|Procedure|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
286349|NCT02020044|Other|Endothelial Keratoplasty|
286350|NCT02020031|Drug|Vancomycin|
286351|NCT02020018|Device|Prevena Incision Management System|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
286352|NCT02020018|Other|Conventional sterile dry wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after sternotomy
286353|NCT02020005|Other|Non-flavored 2mg nicotine gum|
286354|NCT02020005|Other|Non-flavored 4mg nicotine gum|
286355|NCT02020005|Other|Mint-flavored 2mg nicotine gum|
286356|NCT02020005|Other|Mint-flavored 4mg nicotine gum|
286357|NCT02020005|Other|Non-flavored nicotine inhaler|
286358|NCT02020005|Other|Mint-flavored nicotine ihaler|
286359|NCT02019979|Drug|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
286360|NCT02019979|Behavioral|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
286361|NCT02019953|Other|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
286362|NCT02019953|Other|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
286363|NCT02019953|Other|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
286364|NCT02019940|Drug|Riluzole|
286365|NCT02019927|Device|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
286366|NCT02019901|Other|Nurse-led clinic|
286367|NCT02019875|Drug|Rifampin|P450 inducer
286368|NCT02019875|Drug|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
286369|NCT02019875|Other|Grapefruit Juice|CYP3A4 inhibitor in intestine
286370|NCT02019875|Other|Placebo|
286371|NCT02019862|Device|TRJ® Total Hip Arthroplasty|
286372|NCT02019849|Device|Plasmafit® Total Hip Arthroplasty|
286373|NCT02019836|Other|Determining maternal and neonatal vitamin D levels|
286374|NCT02019823|Behavioral|Informational SMS-text|
286375|NCT02019823|Behavioral|Interactive SMS-text|
286376|NCT02019823|Behavioral|Enhanced usual care|
286377|NCT02019810|Drug|Norepinephrine|
286378|NCT02019810|Drug|Dobutamine and norepinephrine|
286379|NCT02019797|Drug|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
286380|NCT02019784|Drug|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
286381|NCT02019784|Drug|Placebo Oral Tablet|Placebo Oral Tablet
286382|NCT02019758|Drug|Oral Viscous Budesonide|Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
288097|NCT02005783|Drug|Epirubicin|Epirubicin:90mg/m2, d1, q3w*4
286384|NCT02019758|Drug|Placebo slurry|Slurry of sucralose - 4 mL twice daily
286385|NCT02019758|Drug|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
286386|NCT02019745|Biological|LAIV|Standard dose of LAIV administered by a licensed health care providers.
286387|NCT02019732|Other|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
286388|NCT02019719|Drug|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
286389|NCT02019719|Drug|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
286390|NCT02019706|Drug|DOTATATE PET-CT|68Ga-DOTATATE
286391|NCT02019706|Drug|F-DOPA PET CT|F-DOPA PET CT
286392|NCT02019706|Drug|OCTREOTIDE|OCTREOTIDE SCAN
286393|NCT02019706|Radiation|CT Scan|Routine CT scan
286394|NCT02019706|Device|MRI|Routine MRI and gated MRI
286395|NCT02019693|Drug|INC280|Supplied by Novartis as film-coated tablet for oral use.
286396|NCT02019667|Drug|SGS-742|
286397|NCT02019667|Drug|Placebo|
286398|NCT02019641|Other|Aerobic Exercise Training (AET)|walking on a treadmill at vigorous intensity for up to 45 minutes
286399|NCT02019641|Other|No exercise|
286400|NCT02019628|Dietary Supplement|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
286401|NCT02019615|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
286402|NCT02019602|Procedure|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
286403|NCT02019602|Procedure|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
286404|NCT02019602|Procedure|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
286405|NCT02019602|Biological|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.~Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection~Concentration: 200 mg/ml~Route of Administration: Subcutaneous Use"
286406|NCT02019589|Drug|Progesterone|
286407|NCT02019589|Drug|Placebo|
286408|NCT02019576|Radiation|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if < 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
286409|NCT02019563|Procedure|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
286410|NCT02019563|Procedure|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
286411|NCT02019550|Device|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
286412|NCT02019550|Device|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
286413|NCT02019537|Procedure|Steroid injection into the subacromial space|"Group: Steroid~Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~The number of injections : only once during the study period~Injection site : subacromial space~Material : 25-gauze spinal needle~Subacromial injections were performed using ultrasonographic guidance."
286414|NCT02019537|Procedure|Allogeneic PRP injection into the subacromial space|"Group: Allogeneic PRP~Total volume of injection drugs: 4ml~The number of injections : only once during the study period~Injection site : subacromial space~Material : 25-gauze spinal needle~Subacromial injections were performed using ultrasonographic guidance."
286415|NCT02019524|Biological|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
286455|NCT02019277|Drug|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
286456|NCT02019277|Drug|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
286544|NCT02018588|Dietary Supplement|tryptophan|graded levels of tryptophan will be given to each subject
286416|NCT02019524|Biological|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
286417|NCT02019524|Biological|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
286418|NCT02019498|Behavioral|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
286419|NCT02019498|Other|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
286420|NCT02019485|Drug|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
286421|NCT02019485|Drug|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
286422|NCT02019472|Biological|adalimumab 40 mg|SC injections
286423|NCT02019472|Biological|sirukumab 100 mg|SC injections
286424|NCT02019472|Biological|sirukumab 50 mg|SC injections
286425|NCT02019472|Drug|Placebo|SC injections
286426|NCT02019459|Other|Very low nicotine content cigarettes|
286427|NCT02019459|Other|standard nicotine content cigarettes|
286428|NCT02019446|Device|Laser Treatment YAG laser|YAG Laser / FOX Laser
286429|NCT02019446|Drug|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
286430|NCT02019433|Device|Structan®|
286431|NCT02019420|Drug|Tedizolid phosphate|Tedizolid phosphate IV 200 mg once daily
286432|NCT02019420|Drug|Linezolid|Linezolid IV 600 mg twice daily
286433|NCT02019407|Procedure|PVI, CTI block|"PVI (pulmonary isolation)~Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation~Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip."
286434|NCT02019407|Procedure|PVI|PVI (pulmonary isolation)
286435|NCT02019394|Drug|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
286436|NCT02019381|Dietary Supplement|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
286437|NCT02019381|Dietary Supplement|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
286438|NCT02019381|Dietary Supplement|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
286439|NCT02019368|Dietary Supplement|Placebo|
286440|NCT02019368|Dietary Supplement|Aged garlic extract|
286441|NCT02019355|Drug|5-fluorouracil 5% cream|
286442|NCT02019355|Drug|Calcipotriol 0.005% ointment|
286443|NCT02019355|Drug|Vaseline|
286444|NCT02019342|Other|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
286445|NCT02019342|Other|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
286446|NCT02019329|Other|Placebo|Oral daily administration from Days 1-12
286447|NCT02019329|Drug|RO5545965|Oral daily administration from Days 1-12
286448|NCT02019329|Drug|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
286449|NCT02019316|Dietary Supplement|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
286450|NCT02019316|Dietary Supplement|Isoenergetic Control|Participants will ingest 500ml of Gatorade 3 times during an exercise session.
286451|NCT02019303|Procedure|FNA and Core biopsy|Both procedures will be performed on the same lymph node
286452|NCT02019290|Drug|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
286453|NCT02019290|Drug|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
286454|NCT02019277|Drug|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
286457|NCT02019277|Drug|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an IV infusion every 3 weeks.
286458|NCT02019277|Drug|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 mg SC every 3 weeks.
286459|NCT02019264|Drug|Lorcaserin hydrochloride|APD356 10 mg twice daily
286460|NCT02019264|Drug|Placebo|Placebo twice daily
286461|NCT02019251|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
286462|NCT02019251|Device|MRI|
286463|NCT02019238|Other|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
286464|NCT02019225|Other|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
286465|NCT02019186|Dietary Supplement|Vitamin C|<30 kg 250 mg 30-60 kg 500 mg >60 kg 750 mg
286466|NCT02019186|Dietary Supplement|Vitamin E|<30 kg 100 IU, 30-60 kg 200 IU, >60 kg 300 IU
286467|NCT02019173|Behavioral|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
286468|NCT02019160|Drug|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
286469|NCT02019160|Drug|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
286470|NCT02019134|Behavioral|relaxation exercise|relaxation exercise
286471|NCT02019134|Other|ususal care|
286472|NCT02019108|Other|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
286473|NCT02019108|Other|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
286474|NCT02019095|Other|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
286475|NCT02019082|Device|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
286476|NCT02019082|Device|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
286477|NCT02019069|Drug|liposomal cytarabine-daunorubicin CPX-351|Given IV
286478|NCT02019056|Drug|Placebo /bid P.O|
286479|NCT02019056|Drug|MG-1|
286480|NCT02019056|Drug|MG-2 : MG1000mg, Placebo /bid P.O|
286481|NCT02019056|Drug|metadoxine|
286482|NCT02019043|Other|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
286483|NCT02019017|Drug|Botulinum Toxin Type A 25 IU|
286484|NCT02019017|Drug|Botulinum Toxin Type A 50 IU|
286485|NCT02019004|Drug|Onabotulinum Toxin A|
286486|NCT02019004|Drug|Incobotulinum Toxin A|
286487|NCT02018991|Procedure|Everolimus-Eluting Stent (EES)|Patients treated with EES
286488|NCT02018991|Procedure|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
286489|NCT02018991|Procedure|Biolimus-Eluting-Stent (BES)|Patients treated with BES
286490|NCT02018978|Behavioral|Comprehensive Triaged HIV Prevention (CTHP)|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.~Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.~Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.~Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
286491|NCT02018965|Drug|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
286492|NCT02018965|Drug|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.~Participants will continue to take their ART treatment as prescribed throughout the study."
286536|NCT02018653|Behavioral|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
286537|NCT02018627|Drug|Xeris glucagon|The subject is given an injection of xeris glucagon
286538|NCT02018627|Drug|Lilly glucagon|The subject is given an injection of lilly glucagon
286493|NCT02018952|Other|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).~Day 0 :~Information of patient and no opposition getting~Clinical exam~Laboratory tests~Radiography of the targeted joint~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day 4 :~Clinical exam~Laboratory tests~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Day15 :~Clinical exam~Laboratory tests~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~M3 :~Clinical exam~Laboratory tests~Radiography of the targeted joint~Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)~Functional outcome"
286494|NCT02018939|Other|Pharmacokinetic profiling|Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
286495|NCT02018926|Drug|Mocetinostat|Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
286496|NCT02018926|Drug|Azacitidine|Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
286497|NCT02018900|Dietary Supplement|Ecologic 825/scFOS|
286498|NCT02018900|Dietary Supplement|Placebo|
286499|NCT02018887|Drug|LY2969822|Capsules administered orally
286500|NCT02018887|Drug|Placebo|Capsules administered orally
286501|NCT02018874|Drug|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~Dose level -1: 300 mg Q.D.~Dose level -0.5: 400 mg Q.D.~Dose level 1: 400 mg Q.D.~Dose level 1.5: 500 mg Q.D.~Dose level 2 : 500 mg Q.D."
286502|NCT02018874|Drug|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
286503|NCT02018861|Drug|Parsaclisib|
286504|NCT02018861|Drug|Itacitinib|
286505|NCT02018861|Drug|Rituximab|
286506|NCT02018861|Drug|Ifosfamide|
286507|NCT02018861|Drug|Carboplatin|
286508|NCT02018861|Drug|Etoposide|
286509|NCT02018848|Behavioral|Attention Training Program|
286510|NCT02018835|Device|MRI|
286511|NCT02018835|Device|cardiac echography transthoracic|
286512|NCT02018822|Device|urethane dimethacrylate|Experimental urethane dimethacrylate resin based composite resin for teeth used with prime and Bond Elect bonding agent
286513|NCT02018822|Device|TPH3|light-cured resin composite for teeth
286514|NCT02018822|Device|Esthet-X HD|light cured resin composite for teeth made by Dentsply Caulk
286515|NCT02018809|Behavioral|Medication Adherence Partner|
286516|NCT02018809|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
286517|NCT02018796|Drug|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
286518|NCT02018783|Procedure|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
286519|NCT02018783|Procedure|Sensodyne|Digital application for 60 seconds.
286520|NCT02018783|Procedure|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
286521|NCT02018783|Procedure|Cocorico|Digital application for 60 seconds
286522|NCT02018770|Radiation|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
286523|NCT02018770|Radiation|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
286524|NCT02018757|Drug|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
286525|NCT02018757|Drug|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
286526|NCT02018731|Drug|Metformin and Metformin & L-Citrulline|
286527|NCT02018731|Drug|L-Citrulline and Metformin & L-Citrulline|
286528|NCT02018718|Device|Magnetic Resonance Imaging (MRI)|
286529|NCT02018692|Dietary Supplement|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
286530|NCT02018692|Dietary Supplement|Placebo:Starch|Starch powder
286531|NCT02018679|Procedure|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
286532|NCT02018679|Procedure|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
286533|NCT02018666|Device|NAVA endotracheal tube|
286534|NCT02018653|Drug|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
286535|NCT02018653|Other|Placebo|1 by mouth every 6 hours for up to 6 days.
286539|NCT02018614|Other|algoplus|
286545|NCT02018575|Dietary Supplement|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
286546|NCT02018575|Dietary Supplement|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
286547|NCT02018562|Device|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
286548|NCT02018549|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
286549|NCT02018536|Drug|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
286550|NCT02018536|Drug|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
286551|NCT02018536|Drug|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
286552|NCT02018536|Drug|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
286553|NCT02018536|Drug|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
286554|NCT02018536|Drug|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
286555|NCT02018536|Drug|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
286556|NCT02018523|Drug|Lenalidomide|lenalidomide 10mg/day orally until disease progression
286557|NCT02018510|Biological|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
286558|NCT02018510|Biological|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
286559|NCT02018510|Biological|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
286560|NCT02018510|Biological|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
286561|NCT02018510|Biological|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
286562|NCT02018510|Biological|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
286563|NCT02018484|Procedure|Unicompartmental Knee Replacement|
286564|NCT02018471|Behavioral|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
286565|NCT02018458|Biological|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
286566|NCT02018458|Biological|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
286567|NCT02018445|Device|Accell Evo3 Demineralized Bone Matrix|
286568|NCT02018432|Drug|Roflumilast escalation dosage|"This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.~Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks"
286569|NCT02018432|Drug|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
286570|NCT02018419|Biological|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
286571|NCT02018419|Procedure|Cryoablation|Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
286572|NCT02018406|Drug|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
286573|NCT02018406|Drug|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
286574|NCT02018380|Other|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
286575|NCT02018367|Drug|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
286800|NCT02016495|Drug|Placebo|
286576|NCT02018354|Procedure|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith & Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
286577|NCT02018354|Procedure|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
286578|NCT02018341|Other|homeopathic remedy in 30C potency|
286579|NCT02018341|Other|Placebo|
286580|NCT02018328|Dietary Supplement|Curcumin|
286581|NCT02018315|Drug|Triheptanoin|Triheptanoin is a 7-carbon medium chain triglyceride
286582|NCT02018302|Drug|Triheptanoin|
286583|NCT02018289|Procedure|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
286584|NCT02018289|Procedure|No triclosan|Suture of the abdominal wall with suture without triclosan coat
286585|NCT02018276|Drug|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
286586|NCT02018276|Drug|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
286587|NCT02018263|Drug|Cocaine hydrochloride|
286588|NCT02018263|Behavioral|Exercise|
286589|NCT02018263|Drug|Nicotine|
286590|NCT02018250|Drug|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
286591|NCT02018250|Drug|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
286592|NCT02018237|Behavioral|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
286593|NCT02018237|Behavioral|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
286594|NCT02018224|Procedure|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
286595|NCT02018224|Procedure|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
286596|NCT02018211|Other|control|passive recovery following exercise test
286597|NCT02018211|Device|graduated compression socks|graduated compression socks worn after test exercise
286598|NCT02018211|Device|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
286599|NCT02018198|Diagnostic Test|FebriDx|Point of Care Host Immune Response Test
286600|NCT02018185|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
286601|NCT02018185|Device|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
286602|NCT02018172|Drug|somatropin|
286603|NCT02018159|Drug|menotropin|
286604|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
286605|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
286606|NCT02018133|Drug|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
286607|NCT02018133|Drug|Placebo|
286608|NCT02018120|Procedure|connective tissue graft|
286609|NCT02018120|Procedure|platelet rich fibrin|
286610|NCT02018107|Diagnostic Test|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
286611|NCT02018107|Diagnostic Test|PET scan|PET scan
286612|NCT02018094|Drug|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
286613|NCT02018094|Drug|Iodine|Intra-operative skin preparation prior to incision to skin.
286614|NCT02018094|Drug|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
286615|NCT02018094|Drug|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
286616|NCT02018094|Drug|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
286617|NCT02018094|Drug|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
286618|NCT02018081|Drug|Levofloxacin|8 blood sampling by patients between the 48th and 60th
286619|NCT02018068|Other|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
286801|NCT02016482|Biological|Adalimumab|
286620|NCT02018068|Other|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
286621|NCT02018055|Drug|Ticagrelor|
286622|NCT02018055|Drug|Clopidogrel|
286623|NCT02018042|Drug|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
286624|NCT02018029|Other|cardiac resynchronisation therapy|
286625|NCT02017964|Drug|Carboplatin|Given IV
286626|NCT02017964|Other|Cognitive Assessment|Optional ancillary studies
286627|NCT02017964|Drug|Cyclophosphamide|Given IV
286628|NCT02017964|Drug|Etoposide|Given IV
286629|NCT02017964|Other|Laboratory Biomarker Analysis|Correlative studies
286630|NCT02017964|Drug|Methotrexate|Given IV
286631|NCT02017964|Drug|Vincristine Sulfate|Given IV
286632|NCT02017938|Procedure|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
286633|NCT02017925|Behavioral|exercise intervention|Undergo pulmonary rehabilitation
286634|NCT02017925|Procedure|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
286635|NCT02017925|Procedure|quality-of-life assessment|Ancillary studies
286636|NCT02017925|Other|questionnaire administration|Ancillary studies
286637|NCT02017912|Biological|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
286638|NCT02017912|Biological|Placebo|Excipient administration by combined intramuscular and intrathecal administration
286639|NCT02017899|Biological|S. sonnei 1790GAHB|
286640|NCT02017899|Biological|Placebo|
286641|NCT02017886|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
286642|NCT02017886|Dietary Supplement|Placebo|Placebo tablet twice daily for three weeks
286643|NCT02017873|Drug|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
286644|NCT02017860|Drug|Everolimus|Everolimus will be provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration
286645|NCT02017834|Procedure|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
286646|NCT02017821|Behavioral|high intensity aerobic training|
286647|NCT02017795|Other|electronic asthma action plan (eAAP)|An electronic asthma action plan (eAAP) will be provided to intervention group
286648|NCT02017795|Other|written asthma action plan (WAAP)|A written asthma action plan will be given to control group arm
286649|NCT02017782|Device|Dust|Dust (250-300µg/m3),
286650|NCT02017782|Device|Ozone|(0,1ppm ozone),
286651|NCT02017782|Device|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
286652|NCT02017782|Device|Placebo (Filtered air)|Placebo treatment (Filtered air <20 ug/m3)
286653|NCT02017730|Drug|BMS-986020|
286654|NCT02017730|Drug|[11C]BMT-136088|
286655|NCT02017717|Biological|Nivolumab|
286656|NCT02017717|Biological|Bevacizumab|
286657|NCT02017717|Biological|Ipilimumab|
286658|NCT02017704|Radiation|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
286659|NCT02017704|Drug|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
286660|NCT02017704|Radiation|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
286661|NCT02017704|Drug|FOLFOX6|"Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion~Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions~5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
286662|NCT02017704|Procedure|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:~Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.~Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
286663|NCT02017691|Device|Near Infrared Spectroscopy|If crSO2 is <10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable >10th centile, or if crSO2 is > 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
286664|NCT02017691|Device|Pulse-oximetry|If SpO2 remains <10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is >90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
286665|NCT02017678|Biological|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
286666|NCT02017639|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
286667|NCT02017639|Drug|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
286668|NCT02017626|Biological|mCyp c 1|2 patient groups with different doses of allergen.
286669|NCT02017613|Drug|RP6530|Escalating doses starting at 25 mg BID
286670|NCT02017600|Drug|ND-420|ND-420 50 mg/m2 on day1
286671|NCT02017600|Procedure|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
286672|NCT02017600|Drug|Cisplatin|cisplatin 70 mg/m2 on day1
286673|NCT02017600|Drug|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
286674|NCT02017574|Behavioral|Reaching Task|Learn a reaching task that requires coordination of the arm segments
286675|NCT02017561|Behavioral|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
286676|NCT02017561|Drug|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
286677|NCT02017548|Behavioral|Life-extension default advance directive|
286678|NCT02017548|Behavioral|Comfort default advance directive|
286679|NCT02017535|Drug|Fluoxetine|Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter.
286680|NCT02017535|Behavioral|Interpersonal Psychotherapy|Adolescent randomized to an increase in therapy (4 extra therapy sessions)
286681|NCT02017522|Device|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.~Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
286682|NCT02017509|Procedure|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
286683|NCT02017509|Procedure|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
286684|NCT02017509|Procedure|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
286685|NCT02017509|Genetic|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
286686|NCT02017470|Other|Gender-tailored women's heart health outpatient programme|
286687|NCT02017457|Biological|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~Patients with a sibling donor will receive:~5x10exp7 CD3+/kg on day 1 of cycle 2~5x10exp7 CD3+/kg on day 1 of cycle 4~10x10exp7 CD3+/kg on day 1 of cycle 6~Patients with an unrelated donor will receive:~1x10exp7 CD3+/kg on day 1 of cycle 2~5x10exp7 CD3+/kg on day 1 of cycle 4~10x10exp7 CD3+/kg on day 1 of cycle 6"
286688|NCT02017457|Drug|Azacytidine|"Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped."
286689|NCT02017444|Drug|AZD4017|
286690|NCT02017444|Other|Placebo|Matched placebo (matched to AZD4017 arm)
286691|NCT02017431|Other|Allergen|Subject specific allergen is inhaled on day 1 of the triad
286692|NCT02017431|Other|Saline|Saline is inhaled on day 1 of the triad
286693|NCT02017431|Other|Particle depleted diesel exhaust|High-efficiency particulate filtration of diesel exhaust
286694|NCT02017418|Dietary Supplement|zeaxanthin|softgel
286695|NCT02017418|Dietary Supplement|combinatory supplement|softgel
286696|NCT02017405|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
286697|NCT02017405|Other|Matching Placebo|
286698|NCT02017392|Drug|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
286699|NCT02017379|Drug|Erythromycin|
286700|NCT02017379|Drug|Metoclopromide|
286701|NCT02017366|Other|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
286702|NCT02017353|Dietary Supplement|Curcuphyt|
286703|NCT02017340|Drug|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
286704|NCT02017340|Drug|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
286705|NCT02017327|Drug|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
286706|NCT02017327|Drug|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
286707|NCT02017327|Drug|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
286708|NCT02017314|Drug|Morphine|
286709|NCT02017301|Other|Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference
286710|NCT02017275|Device|BuMA|This group will contain 1175 subjects.
286711|NCT02017275|Device|EXCEL|This group will contain 1175 subjects.
286712|NCT02017262|Behavioral|Self-management group|8 weekly sessions of group self-management
286713|NCT02017262|Behavioral|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
286714|NCT02017249|Drug|arginine in powder form|
286715|NCT02017249|Drug|Silica and cellulose placebo powder|
286716|NCT02017236|Drug|Volitinib|600mg Volitinib ,single dose,oral
286717|NCT02017223|Device|Knowme Device Wear|
286718|NCT02017210|Other|Longitudinal study|Metabolic health, anthropometry, body fat distribution, liver lipid will be followed up in individuals previously studied at the Clinical Research Facility.
286719|NCT02017197|Drug|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
286720|NCT02017197|Drug|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
286721|NCT02017197|Drug|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
286722|NCT02017184|Biological|Noninvasive core temperature thermistor|
286723|NCT02017171|Drug|Allopurinol|
286724|NCT02017171|Drug|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
286725|NCT02017158|Other|Virtual Sprouts|The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
286726|NCT02017145|Drug|Chloraprep|
286727|NCT02017132|Dietary Supplement|Pomegranate extract|
286728|NCT02017119|Drug|Comparison between Lactulose and Lactulose-Paraffin|
286729|NCT02017106|Procedure|Endovenous Laser ablation and concomitant phlebectomies|
286730|NCT02017106|Procedure|Endovenous Laser ablation and sequential phlebectomies|
286731|NCT02017093|Device|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
286732|NCT02017093|Device|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
286733|NCT02017067|Procedure|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
286734|NCT02017054|Other|Cath|No intervention - registry
286735|NCT02017041|Device|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
286736|NCT02017041|Device|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
286737|NCT02017015|Drug|nab-paclitaxel|nab-paclitaxel at 125 mg/m^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
286738|NCT02017015|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
286739|NCT02017002|Procedure|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
286740|NCT02017002|Procedure|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
286741|NCT02016989|Device|RGTA OTR4120 (CACICOL20)|
286742|NCT02016989|Device|physiological salt solution|
286743|NCT02016976|Drug|EMLA Analgesic Cream|
286744|NCT02016976|Drug|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
286745|NCT02016963|Biological|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
286746|NCT02016924|Drug|ATV|Capsules administered once daily according to dosing recommendations per product monograph
286747|NCT02016924|Drug|DRV|Tablets administered once daily according to dosing recommendations per product monograph
286748|NCT02016924|Drug|Cobicistat|Tablets administered orally once daily with food
286749|NCT02016924|Drug|BR|Prior to implementation protocol amendment 7, Background Regimen (BR) must include 2 nucleoside reverse transcriptase inhibitors (NRTI). After implementation of protocol amendment 7, BR must include 2 NRTIs and a third agent per local prescribing guidelines.
286750|NCT02016911|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
286751|NCT02016898|Procedure|Placement of the sponge|
286752|NCT02016898|Drug|Mitomycin-C|
286753|NCT02016885|Drug|glycopyrrolate, 1.0%|glycopyrrolate Topical Wipes, 1.0%
286754|NCT02016885|Drug|glycopyrrolate, 2.0%|glycopyrrolate Topical Wipes, 2.0%
286755|NCT02016885|Drug|glycopyrrolate, 3.0%|glycopyrrolate Topical Wipes, 3.0%
286756|NCT02016885|Drug|glycopyrrolate, 4.0%|glycopyrrolate Topical Wipes, 4.0%
286757|NCT02016885|Other|Vehicle|Vehicle Topical Wipes
286758|NCT02016872|Drug|18F-FMISO|
286759|NCT02016872|Other|PET/CT|
286760|NCT02016859|Other|Immature Platelet Fraction|
286761|NCT02016846|Drug|Liraglutide|
286762|NCT02016846|Drug|Placebo|
286763|NCT02016833|Procedure|Blood Sampling|Sampling of 80mL of whole blood
286764|NCT02016820|Drug|Omeprazole (suspension)|1 mg/kg/day
286765|NCT02016820|Other|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
286766|NCT02016807|Device|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
286767|NCT02016781|Procedure|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant.from a fully matched related (6/6) or unrelated (8/8) donor. The specific transplant treatment regimen will be at the discretion of the treating physician but is required to be reduced-intensity.
286768|NCT02016781|Procedure|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
286769|NCT02016768|Procedure|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
286770|NCT02016755|Biological|HGF Plasmid|Intramuscular injection in the affected limb.
286771|NCT02016742|Drug|RDC5|
286772|NCT02016729|Drug|AMG 232|Given an an oral tablet in escalating doses.
286773|NCT02016729|Drug|Trametinib|Trametinib is an oral tablet given in a fixed dose.
286774|NCT02016716|Drug|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
286775|NCT02016716|Drug|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
286776|NCT02016716|Drug|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
286777|NCT02016716|Drug|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
286778|NCT02016703|Other|Erythritol drink|
286779|NCT02016703|Other|Placebo drink|
286780|NCT02016664|Drug|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
286781|NCT02016651|Behavioral|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
286782|NCT02016638|Other|Polysomnography and ambulatory blood pressure recording|
286783|NCT02016625|Drug|Faldaprevir|
286784|NCT02016625|Drug|Faldaprevir|
286785|NCT02016625|Drug|Cyclosporine|
286786|NCT02016625|Drug|Tacrolimus|
286787|NCT02016612|Device|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
286788|NCT02016599|Other|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
286789|NCT02016586|Dietary Supplement|Maternal Nutritional Supplement|S348S0
286790|NCT02016573|Device|Renal Denervation|Renal Denervation Catheter
286791|NCT02016560|Drug|florbetapir F 18|
286792|NCT02016560|Drug|18F-AV-1451|
286793|NCT02016547|Procedure|abciximab IV and thrombectomy|
286794|NCT02016547|Drug|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
286795|NCT02016534|Drug|AMG 337|AMG 337 300mg orally daily.
286796|NCT02016521|Other|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
286797|NCT02016521|Other|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
286798|NCT02016508|Drug|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
286799|NCT02016495|Dietary Supplement|Magnesium plus alpha-lipoic acid|
286803|NCT02016469|Other|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
286804|NCT02016469|Other|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
286805|NCT02016469|Dietary Supplement|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
286806|NCT02016456|Device|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
286807|NCT02016456|Device|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
286808|NCT02016443|Drug|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
286809|NCT02016443|Drug|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
286810|NCT02016430|Behavioral|MeLT Dietary intervention|Mediterranean diet containing food with low TMAO content.
286811|NCT02016430|Behavioral|TLC Dietary intervention|Standard American Heart Association (AHA) recommendations for dietary counseling
286812|NCT02016430|Behavioral|MeLT dietary intervention with TMAO|Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
286813|NCT02016417|Drug|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
286814|NCT02016417|Drug|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
286815|NCT02016404|Other|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
286816|NCT02016404|Other|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
286817|NCT02016391|Drug|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
286818|NCT02016378|Behavioral|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
286819|NCT02016378|Behavioral|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
286820|NCT02016365|Drug|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
286821|NCT02016365|Drug|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
286822|NCT02016352|Biological|patient CSF extraction with hydrocephalus|CSF extraction
286823|NCT02016352|Biological|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
286824|NCT02016339|Behavioral|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
286825|NCT02016339|Behavioral|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
286826|NCT02016326|Device|HD Colon|High Definition White Light
286827|NCT02016326|Device|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
286828|NCT02016326|Device|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
286829|NCT02016313|Other|physiotherapy|
286830|NCT02016300|Device|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
286831|NCT02016300|Device|Non-Bracing|Microfracture performed with no post-operative unloader bracing
286832|NCT02016287|Other|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
286833|NCT02016274|Other|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
286834|NCT02016261|Drug|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
286835|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
286836|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
286837|NCT02016235|Drug|Phosphorus Supplement|250 mg po qid
286838|NCT02016222|Procedure|tears sampling|
286839|NCT02016209|Drug|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
286840|NCT02016196|Drug|Rifaximin|"6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS~--------------------------------------------------------------------------------"
286841|NCT02016196|Drug|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
286842|NCT02016183|Drug|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
286843|NCT02016170|Drug|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
286844|NCT02016170|Drug|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
286845|NCT02016170|Drug|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:~A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.~B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
286846|NCT02016157|Drug|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
286847|NCT02016118|Device|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
286848|NCT02016105|Drug|GP2017 Adalimumab|
286849|NCT02016105|Drug|Humira ® Adalimumab|
286850|NCT02016079|Dietary Supplement|omega-3|200 ml fruit drink containing omega-3
286851|NCT02016066|Drug|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
286852|NCT02016066|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
286853|NCT02016040|Procedure|High Intensity Focused Ultrasound|
286854|NCT02016027|Drug|Carica folia|
286855|NCT02016014|Device|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
286856|NCT02016014|Behavioral|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
286857|NCT02016001|Other|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
286858|NCT02016001|Other|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
286859|NCT02015988|Drug|Fenofibrate|
286860|NCT02015988|Drug|Simvastatin|
286861|NCT02015962|Drug|Intravenous potassium chloride|
286862|NCT02015962|Drug|Oral potassium chloride|
286863|NCT02015949|Drug|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
286864|NCT02015949|Drug|Placebo|Twice daily placebo tablet for two weeks
286865|NCT02015936|Behavioral|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
286866|NCT02015936|Other|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
286867|NCT02015923|Procedure|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
286868|NCT02015923|Drug|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
286869|NCT02015910|Drug|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
286870|NCT02015910|Drug|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
286871|NCT02015897|Procedure|Physical TherapyA|"Group A:~Skin care~Manual lymphatic drainage~Bandaging using Coban™2Lite~Guidance on physical activity"
286872|NCT02015897|Procedure|Physical TherapyB|"Group B:~Skin care~Bandaging using Coban™2Lite~Guidance on physical activity"
286873|NCT02015871|Drug|Degarelix|
286874|NCT02015858|Procedure|Chest drain withdrawal|
286875|NCT02015858|Device|Pain Monitor|
286876|NCT02015845|Device|Accuvein|
286877|NCT02015845|Device|Routine technique|Placement of peripheral intravenous catheters using the routine technique
286878|NCT02015832|Device|Coronary stent|
286879|NCT02015832|Radiation|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
287000|NCT02014961|Genetic|Whole-exome sequencing|Whole-exome sequencing (WES)
286880|NCT02015832|Device|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
286881|NCT02015832|Device|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
286882|NCT02015832|Device|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
286883|NCT02015819|Biological|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
286884|NCT02015819|Drug|flucytosine|Given orally
286885|NCT02015819|Drug|leucovorin calcium|Given orally
286886|NCT02015819|Other|pharmacological study|Correlative studies
286887|NCT02015819|Other|laboratory biomarker analysis|Correlative studies
286888|NCT02015806|Behavioral|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
286889|NCT02015806|Behavioral|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
286890|NCT02015806|Behavioral|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
286891|NCT02015793|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
286892|NCT02015793|Biological|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
286893|NCT02015780|Drug|Fasiglifam|Fasiglifam tablets
286894|NCT02015780|Drug|Placebo|Fasiglifam placebo-matching tablets
286895|NCT02015780|Drug|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
286896|NCT02015754|Drug|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
286897|NCT02015754|Device|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
286898|NCT02015754|Procedure|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
286899|NCT02015741|Device|EEG monitoring with Bispectral Index and NeuroSENSE|
286900|NCT02015741|Behavioral|Clinical observation|Patients will be observed during awake periods and during natural sleep.
286901|NCT02015728|Device|Tumor biology testing|"Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide."
286902|NCT02015728|Drug|Temozolomide|"Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
286903|NCT02015728|Drug|Etoposide|"Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
286904|NCT02015728|Drug|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
286905|NCT02015728|Drug|Everolimus|Everolimus is an mTOR pathway inhibitor.
286906|NCT02015728|Drug|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
286907|NCT02015728|Drug|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
286908|NCT02015715|Drug|RO6864018|A single oral ascending dose of RO6864018 capsules on Day 1.
286909|NCT02015715|Drug|Placebo|A single oral dose of placebo matching RO6864018 capsules on Day 1.
286910|NCT02015702|Other|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
286911|NCT02015702|Other|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
286912|NCT02015689|Behavioral|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
286913|NCT02015689|Behavioral|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
286914|NCT02015689|Behavioral|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
286915|NCT02015689|Behavioral|CDC VIS|CDC Vaccine Information Statement (VIS)
286916|NCT02015676|Drug|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
286917|NCT02015676|Drug|paclitaxel|60 mg/m^2 IV weekly; dose increased to 70 mg/m^2, and subsequently 80 mg/m^2, after 2 treatment cycles with no evidence of DLT until disease progression
286918|NCT02015676|Drug|Myocet|40 mg/m^2 IV weekly; dose increased to 50 mg/m^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
286919|NCT02015663|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
286920|NCT02015650|Drug|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
286921|NCT02015650|Drug|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
286922|NCT02015637|Drug|Delafloxacin|single dose
286923|NCT02015637|Drug|Ceftriaxone|single dose
286924|NCT02015611|Dietary Supplement|Vitamin D|2,000 IU/ day of Vitamin D3
286925|NCT02015611|Dietary Supplement|Placebo|Placebo
286926|NCT02015598|Drug|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
286927|NCT02015598|Device|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
286928|NCT02015585|Procedure|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
286929|NCT02015585|Procedure|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
286930|NCT02015585|Procedure|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
286931|NCT02015572|Behavioral|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
286932|NCT02015572|Other|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
286933|NCT02015559|Drug|mucoadhesive oral wound rinse|Given PO
286934|NCT02015559|Other|laboratory biomarker analysis|Correlative studies
286935|NCT02015546|Drug|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
286936|NCT02015533|Drug|CR8020|CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
286937|NCT02015533|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion.
286938|NCT02015520|Drug|Clazakizumab|
286939|NCT02015520|Drug|Placebo (Matching with Clazakizumab)|
286940|NCT02015507|Drug|ivacaftor|
286941|NCT02015507|Drug|VX-661|
286942|NCT02015507|Drug|ciprofloxacin|
286943|NCT02015494|Biological|VAX2012Q|Recombinant influenza HA vaccine delivered IM
286944|NCT02015481|Drug|Cabaletta|
286945|NCT02015468|Other|Early mobilization|Early weightbearing and physiotherapy
286946|NCT02015468|Other|Late mobilization|Late mobilization, none-weightbearing and home exercises
286947|NCT02015455|Other|Epidemiologic benchmarks included in lumbar imaging reports|Epidemiologic benchmarks inserted into lumbar imaging reports
286948|NCT02015442|Dietary Supplement|Sucrose|
286949|NCT02015429|Dietary Supplement|Pasta meal with added fractions or control with no fractions|
286950|NCT02015416|Biological|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
286951|NCT02015403|Drug|Standard Care + NAC (N -ACETYLCYSTEINE)|
286952|NCT02015403|Drug|Standard Care (in control arm)|
286953|NCT02015390|Procedure|Masquelet defect reconstruction|The Masquelet defect reconstruction is a two-stage technique for the treatment of large segmental bone defects. It involves creating a biomembrane using a PMMA cement spacer within the defect. Subsequently, 6-8 weeks later the cement spacer is removed and the space with the biomembrane is packed with autogenous bone grafting harvested using Reamer-Irrigator-Aspirator (RIA) or allogeneic bone graft. The decision regarding the graft option is left for the treating physician, following the discussion with the patient. The biomembrane serves as a biological enclosure for the graft, and constitutes a source of vascular supply and growth factors, thereby providing an excellent milieu for the graft to consolidate and heal the defect.
286954|NCT02015390|Procedure|Titanium cage reconstruction|The cylindrical titanium mesh cage technique is a single-stage surgical procedure that immediately restores limb anatomy and alignment, and provides limb stability sufficient enough for early, unrestricted mobilization while permitting bone and soft tissue healing. After aseptic defect and soft tissue bed is achieved, the reconstruction procedure involves the implantation of a fenestrated cylindrical titanium cage packed with simultaneously harvested autogenous bone graft using Reamer-Irrigator-Aspirator (RIA) or with allogeneic bone graft. The decision about the graft option is left for the treating physician, following the discussion with the patient. The cage provide a biomechanical enclosure for the graft, allows the graft to be loaded, and, thereby consolidate and heal the defect.
286955|NCT02015377|Other|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
286956|NCT02015364|Procedure|Controlled early mobilization|1. The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 - 8.
287001|NCT02014948|Other|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
287002|NCT02014935|Other|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.~Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
287003|NCT02014922|Drug|TheraTears® Lubricant Eye Drop|
286957|NCT02015351|Drug|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
286958|NCT02015325|Behavioral|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health & Hygiene education program.
286959|NCT02015312|Drug|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
286960|NCT02015312|Drug|Placebo|"Pharmaceutical formulation: capsules~Dose:~400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
286961|NCT02015299|Drug|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
286962|NCT02015299|Drug|placebo|one tablet matching placebo/day for 26 weeks
286963|NCT02015286|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
286964|NCT02015273|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
286965|NCT02015260|Drug|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
286966|NCT02015260|Drug|Placebo|Placebo
286967|NCT02015247|Procedure|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
286968|NCT02015234|Drug|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
286969|NCT02015221|Device|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
286970|NCT02015221|Device|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
286971|NCT02015208|Drug|Ruxolitinib|20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
286972|NCT02015195|Other|Acetic Acid (5%)|
286973|NCT02015195|Other|Sodium Bicarbonate Slurry (50%)|
286974|NCT02015195|Other|Papain Slurry (70%)|
286975|NCT02015195|Other|Ammonia (10%)|
286976|NCT02015195|Drug|Lidocaine (4%)|
286977|NCT02015195|Other|Isopropyl Alcohol (70%)|
286978|NCT02015195|Other|Hot Tap Water (40 degrees Celsius)|
286979|NCT02015195|Other|No treatment|
286980|NCT02015182|Other|Blood sample for bupivicaine pharmacokinetics|"Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).~Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA)."
286981|NCT02015169|Drug|Lapatinib|lapatinib 1250mg qd daily up to 8 cycles (3 weeks * 8 cycles = 24 weeks)
286982|NCT02015156|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
286983|NCT02015156|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
286984|NCT02015130|Other|Individual treatment|See detailed description
286985|NCT02015117|Other|Laboratory Biomarker Analysis|Correlative studies
286986|NCT02015117|Other|Pharmacological Study|Correlative studies
286987|NCT02015117|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
286988|NCT02015117|Drug|Trametinib|Given PO
286989|NCT02015117|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
286990|NCT02015104|Biological|TICE Bacillus Calmette-Guerin (BCG)|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
286991|NCT02015104|Biological|PANVAC|A recombinant virus vector vaccine containing genes for human CEA, MUC-1 and three co-stimulatory molecules (designated TRICOM): B7.1, ICAM-1 (intercellular adhesion molecule-1), and LFA-3 (leukocyte function-associated antigen-3).
286992|NCT02015091|Biological|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
286993|NCT02015065|Drug|Vandetanib|Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
286994|NCT02015039|Drug|BoNT Injections|
286995|NCT02015039|Procedure|Occupational Therapy|
286996|NCT02015000|Procedure|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
286997|NCT02014987|Behavioral|Training programmes|"Runners with a high body mass index follow two types of training programmes:~a running programme of 3 kilometres per week~a running programme 6 kilometres per week~The amount of running will be increased with 10 % per week."
286998|NCT02014961|Procedure|Dermal biopsy|Skin biopsy
286999|NCT02014961|Behavioral|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
287143|NCT02013817|Drug|fludarabine|Every 4 weeks, 6 cycles
287004|NCT02014922|Drug|TheraTears® preservative-free single-use containers|
287005|NCT02014922|Dietary Supplement|TheraTears® Nutrition|
287006|NCT02014922|Other|TheraTears® TheraLid® Eyelid Cleanser|
287007|NCT02014909|Biological|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
287008|NCT02014896|Other|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
287009|NCT02014883|Drug|GLUT1 DS|
287010|NCT02014870|Other|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
287011|NCT02014870|Other|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
287012|NCT02014870|Other|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
287013|NCT02014857|Procedure|Gingival Crevicular Fluid Sampling|
287014|NCT02014844|Drug|aldoxorubicin|
287015|NCT02014831|Drug|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
287016|NCT02014831|Drug|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :~PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.~IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.~CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.~In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
287017|NCT02014818|Device|CoCr-EES|
287018|NCT02014805|Radiation|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
287019|NCT02014779|Behavioral|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
287020|NCT02014779|Behavioral|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
287021|NCT02014766|Procedure|Interscalene block|Ultrasound-guided interscalene block is performed.
287022|NCT02014766|Procedure|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
287023|NCT02014753|Device|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
287024|NCT02014740|Drug|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
287025|NCT02014740|Drug|Metformin|
287026|NCT02014727|Biological|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
287027|NCT02014727|Biological|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
287028|NCT02014727|Biological|Group B2 : Placebo|
287029|NCT02014714|Drug|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
287030|NCT02014714|Drug|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
287031|NCT02014701|Procedure|Echocardiogram|"Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.~Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software."
287032|NCT02014675|Device|SD01 ICD lead|
287033|NCT02014662|Other|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
287034|NCT02014649|Drug|20 mg laninamivir octanoate|
287035|NCT02014649|Drug|Placebo|
287036|NCT02014649|Drug|40 mg laninamivir octanoate|
287037|NCT02014636|Drug|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
287038|NCT02014636|Drug|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
287039|NCT02014623|Other|Grass pollen sublingual immunotherapy tablet|
287040|NCT02014623|Drug|Control|
287041|NCT02014597|Device|HOCD|comparison of HOCD results between subjects with and without glaucoma
287042|NCT02014584|Drug|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
287043|NCT02014584|Drug|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
287044|NCT02014571|Drug|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
287045|NCT02014571|Drug|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
287046|NCT02014558|Drug|Gilteritinib|Participants received gilteritinib oral tablets (10 mg, 40 mg or 100 mg, depending on the dose) once daily without food allowed for at least 2 hours before and 1 hour after dosing starting from day -2 and day of cycle 1, for continuous 28-day cycles.
287047|NCT02014558|Drug|Voriconazole|Participants received 200 mg voriconazole tablets daily every 12 hours starting from day 16 of cycle 1 through day 1 of cycle 2.
287048|NCT02014558|Drug|Midazolam|Participants received a single oral dose of 2 mg of midazolam syrup on day -1 and day 15 of cycle 1.
287049|NCT02014558|Drug|Cephalexin|Participants received a single oral dose of 500 mg cephalexin tablet or capsule on day -1 and day 15 of cycle 1.
287050|NCT02014545|Drug|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
287051|NCT02014545|Other|Placebo|Only standard treatment of whole brain radiation therapy is done.
287052|NCT02014532|Drug|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
287053|NCT02014532|Drug|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
287054|NCT02014519|Procedure|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
287055|NCT02014519|Other|Data collection|Active questioning
287056|NCT02014506|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -2
287057|NCT02014506|Drug|Cyclophosphamide|50 mg/kg IV on day -3 and -2
287058|NCT02014506|Biological|anti-thymocyte globulin|
287059|NCT02014506|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
287060|NCT02014506|Radiation|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 & -4 (severe aplastic anemia)
287061|NCT02014506|Procedure|TCRαβ-depleted hematopoietic cell transplantation|
287062|NCT02014506|Device|CliniMACS|Immunogenetic depletion of TCRαβ cells
287063|NCT02014493|Procedure|High Flow Nasal Cannulae (HFNC)|HFNC 6 l/pr.min
287064|NCT02014493|Procedure|Continuous Positive Airway Pressure (CPAP)|CPAP 6 l/pr.min
287065|NCT02014480|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
287066|NCT02014480|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
287067|NCT02014480|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
287068|NCT02014467|Drug|Denosumab|Injection
287069|NCT02014467|Drug|Placebo|Injection
287070|NCT02014467|Dietary Supplement|Elemental Calcium|Oral, at least 600 mg
287071|NCT02014467|Dietary Supplement|Vitamin D|Oral, at least 400 IU
287072|NCT02014454|Drug|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.~The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
287073|NCT02014441|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
287074|NCT02014428|Dietary Supplement|Hyaluronic acid|
287075|NCT02014428|Drug|Placebo|
287076|NCT02014415|Procedure|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
287077|NCT02014402|Biological|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
287078|NCT02014402|Biological|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
287079|NCT02014376|Drug|3% SD-101 dermal cream|applied topically once a day for 90 days
287080|NCT02014376|Drug|6% SD-101 dermal cream|applied topically once a day for 90 days
287081|NCT02014376|Drug|Vehicle (0% SD-101)|applied topically once a day for 90 days
287082|NCT02014363|Drug|ETS6103 (low dose)|
287083|NCT02014363|Drug|ETS6103 (high dose)|
287084|NCT02014363|Drug|Amitriptyline|
287085|NCT02014350|Device|DePuy Delta Xtend Reverse TSA|
287086|NCT02014337|Drug|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
287087|NCT02014324|Procedure|Endosonography|"Complete endosonographic mediastinal staging is performed in 2 steps:~Systematic EBUS (airways)~Systematic EUS-B (esophagus)"
287088|NCT02014311|Procedure|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
287089|NCT02014311|Procedure|CTA guided treatment strategy|CTA guided treatment strategy
287090|NCT02014298|Radiation|non-ablative fractional laser|3 treatments with 4-6 weeks interval
287091|NCT02014298|Other|control|observation, comparison to laser-treated area
287092|NCT02014285|Procedure|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
287093|NCT02014272|Drug|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
287094|NCT02014272|Drug|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
287095|NCT02014259|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
287096|NCT02014233|Dietary Supplement|Omega-3|
287097|NCT02014233|Dietary Supplement|Olive oil|
287098|NCT02014220|Other|dietary treatment|
287099|NCT02014207|Other|dietary treatment|
287100|NCT02014194|Behavioral|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
287101|NCT02014181|Dietary Supplement|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
287144|NCT02013817|Drug|cyclophosphamide|Every 4 weeks, 3 cycles
287145|NCT02013804|Drug|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
287146|NCT02013791|Drug|Vehicle|Vehicle of cyclosporine administered as per protocol
287147|NCT02013791|Other|Sham|Sham administered to non-study eye as per protocol on Day 1
287102|NCT02014168|Biological|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
287103|NCT02014168|Biological|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.~0.9% saline placebo."
287104|NCT02014155|Other|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
287105|NCT02014155|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
287106|NCT02014142|Drug|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
287107|NCT02014129|Drug|LY2835219|Administered orally
287108|NCT02014116|Drug|LY3009120 capsule|Administered orally.
287109|NCT02014103|Drug|Tacrolimus|Administration of each formulation will be determined by sequence.
287110|NCT02014090|Other|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
287111|NCT02014077|Procedure|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy( VATS )for retained haemothorax
287112|NCT02014077|Procedure|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
287113|NCT02014064|Drug|Atomoxetine|"MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).~Control Group Schedule:~Day 1: 40mg @ 8:00am~Day 2: 40mg @ 8:00am~Day 3: 40mg @ 8:00am, 40mg @ 8:00pm~Day 4: 40mg @ 8:00am, 40mg @ 8:00pm~Day 5: 40mg @ 8:00am, 40mg @ 8:00pm~Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
287114|NCT02014064|Other|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan & cognitive testing session)
287115|NCT02014051|Drug|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.~The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle."
287116|NCT02014025|Procedure|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
287117|NCT02014025|Procedure|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
287118|NCT02013999|Other|Virtual reality program for upper extremity rehabilitation|
287119|NCT02013999|Other|standard occupational therapy|
287120|NCT02013986|Drug|etomidate|0.3mg/kg IV only once during induction of general anesthesia
287121|NCT02013986|Drug|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
287122|NCT02013986|Drug|propofol|2mg/kg IV only once during induction of general anesthesia
287123|NCT02013973|Other|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
287124|NCT02013960|Drug|Cytotec|Cytotec medication compared with cytotec and laminaria
287125|NCT02013947|Other|2 weeks of exercise in low and moderate altitude|"Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).~Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate)."
287126|NCT02013934|Dietary Supplement|Probiotic|
287127|NCT02013934|Dietary Supplement|Placebo|
287128|NCT02013921|Other|Physical activity|
287129|NCT02013908|Procedure|Acupuncture plus standard ED management|
287130|NCT02013908|Procedure|Standard ED management alone|
287131|NCT02013895|Device|99mTc-GSA|
287132|NCT02013882|Procedure|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
287133|NCT02013869|Device|Flow-I|Desflurane Dialed setting 18 %
287134|NCT02013869|Device|Asys|Desflurane dialed 18%
287135|NCT02013856|Dietary Supplement|Low Epicatechin and procyanidin|70 mg epicatechin and 65 mg procyanidins once daily for 28 days
287136|NCT02013856|Dietary Supplement|High Epicatechin and procyanidin|140 mg epicatechin and 130 mg procyanidins once daily for 28 days
287137|NCT02013856|Dietary Supplement|High procyanidin|No epicatechin and 130 mg procyanidins once daily for 28 days
287138|NCT02013856|Dietary Supplement|Placebo|Placebo control once daily for 28 days
287139|NCT02013843|Behavioral|Community-based treatment of overweight and obesity|"Community based treatment of overweight and obese children using the Holbaek-method."
287140|NCT02013830|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
287141|NCT02013830|Drug|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
287142|NCT02013817|Drug|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
287148|NCT02013791|Drug|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
287149|NCT02013778|Drug|HCQ|
287150|NCT02013765|Drug|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
287151|NCT02013752|Device|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
287152|NCT02013726|Device|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
287153|NCT02013726|Device|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
287154|NCT02013700|Biological|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
287155|NCT02013700|Biological|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
287156|NCT02013687|Biological|Pfs25 VLP- FhCMB|
287157|NCT02013674|Biological|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
287158|NCT02013661|Procedure|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
287159|NCT02013648|Drug|Dasatinib|
287160|NCT02013648|Drug|Cytarabine|
287161|NCT02013648|Drug|Daunorubicin|
287162|NCT02013648|Drug|Idarubicin|
287163|NCT02013622|Drug|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
287164|NCT02013609|Drug|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
287165|NCT02013596|Other|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
287166|NCT02013596|Other|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
287167|NCT02013583|Other|No intervention|This is an observational registry. No interventions are required or provided.
287168|NCT02013570|Drug|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
287169|NCT02013557|Behavioral|Text-message reminder|
287170|NCT02013544|Drug|Placebo|
287171|NCT02013544|Drug|Prasterone (DHEA)|
287172|NCT02013531|Drug|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
287173|NCT02013518|Behavioral|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
287174|NCT02013505|Other|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
287175|NCT02013492|Drug|propranolol hydrochloride|Given PO
287176|NCT02013492|Other|Correlative Studies|"Correlative studies will be conducted using the following materials:~Plasma derived from peripheral blood.~Peripheral blood mononuclear cells (PBMC) derived from patient blood~Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.~Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease."
287177|NCT02013479|Dietary Supplement|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
287178|NCT02013479|Dietary Supplement|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
287179|NCT02013466|Dietary Supplement|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
287180|NCT02013466|Dietary Supplement|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
287181|NCT02013466|Dietary Supplement|Bolus ONS C|High casein-protein, high-caloric control product.
287182|NCT02013466|Dietary Supplement|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
287183|NCT02013453|Drug|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
287184|NCT02013453|Drug|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
287185|NCT02013453|Drug|5FU|Administered by infusion.
287186|NCT02013453|Drug|Paclitaxel|Administered by infusion.
287187|NCT02013453|Drug|Pemetrexed|Administered by infusion.
287188|NCT02013427|Drug|Naproxen|Take one 500mg naproxen capsule twice a day.
287189|NCT02013427|Drug|Placebo|Take one placebo capsule twice a day.
287190|NCT02013427|Drug|Omeprazole|Take one 20mg omeprazole capsule twice a day.
287191|NCT02013414|Device|3D ultrasound-guided biopsy|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
287192|NCT02013388|Drug|N91115|Given PO daily for 14 days
287193|NCT02013388|Drug|Placebo|Given PO daily for 14 days
287195|NCT02013388|Drug|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
287196|NCT02013375|Procedure|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
287197|NCT02013375|Drug|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
287198|NCT02013375|Radiation|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
287199|NCT02013375|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
287200|NCT02013375|Drug|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
287201|NCT02013362|Drug|Pralatrexate injection|
287202|NCT02013362|Dietary Supplement|Vitamin B12|
287203|NCT02013362|Dietary Supplement|Folic Acid|
287204|NCT02013349|Device|coronary intervention|
287205|NCT02013336|Drug|MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide|
287206|NCT02013323|Drug|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
287207|NCT02013323|Drug|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
287208|NCT02013310|Drug|HT-0712|
287209|NCT02013310|Drug|Placebo|
287210|NCT02013297|Radiation|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.~For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.~For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.~For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.~For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
287211|NCT02013271|Device|Lutonix Paclitaxel Drug Coated Balloon (DCB)|Patients exposed to the DCB as part of their routine care.
287212|NCT02013258|Drug|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
287213|NCT02013258|Other|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
287214|NCT02013245|Biological|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
287215|NCT02013245|Biological|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
287216|NCT02013232|Drug|Aripiprazole|
287217|NCT02013219|Drug|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
287218|NCT02013219|Drug|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
287219|NCT02013219|Drug|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
287220|NCT02013206|Drug|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
287221|NCT02013193|Device|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
287222|NCT02013193|Device|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
287223|NCT02013167|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
287224|NCT02013167|Drug|Standard of Care Chemotherapy|"FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 & 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients > 60 years: Idarubicin 5 mg/m² day 1 & 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5~HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents~High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.~Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
287225|NCT02013154|Drug|DKN-01|Administered by IV infusion
287226|NCT02013154|Drug|Paclitaxel|Administered by IV infusion
287227|NCT02013154|Drug|Pembrolizumab|Administered by IV infusion
287228|NCT02013141|Drug|Telavancin|
287229|NCT02013128|Drug|Ublituximab|Ublituximab (IV infusion)
287230|NCT02013128|Drug|Ibrutinib|Ibrutinib oral daily dose
287231|NCT02013115|Drug|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
287397|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
287232|NCT02013102|Drug|Decitabine Injection|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
287233|NCT02013089|Drug|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
287234|NCT02013089|Drug|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
287235|NCT02013089|Drug|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
287236|NCT02013089|Drug|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
287237|NCT02013089|Drug|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
287238|NCT02013050|Drug|SGX942|
287239|NCT02013050|Drug|Placebo|
287240|NCT02013037|Drug|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.~On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.~On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.~On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.~On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
287241|NCT02013024|Other|cryopreservation technique|
287242|NCT02013011|Procedure|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
287243|NCT02012998|Biological|HBVAXPRO 5µg|0.5mL intramuscular injection
287244|NCT02012985|Biological|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
287245|NCT02012985|Drug|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
287246|NCT02012972|Behavioral|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
287247|NCT02012959|Drug|Tolvaptan|
287248|NCT02012946|Drug|Levosimendan|patient receiving levosimendan
287249|NCT02012946|Drug|Dobutamine|patient receiving dobutamine
287250|NCT02012933|Drug|3,4-diaminopyridine|10mg tablets for up to 100mg per day
287251|NCT02012920|Drug|Seviteronel: given orally once daily in 28 day cycles|
287252|NCT02012881|Behavioral|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
287253|NCT02012881|Behavioral|Usual practice|Normal curriculum
287254|NCT02012868|Procedure|bariatric surgery|
287255|NCT02012855|Behavioral|Exercise|
287256|NCT02012855|Other|Diet (meal type)|
287257|NCT02012842|Other|Non surgical periodontal treatment|Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
287258|NCT02012829|Behavioral|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
287259|NCT02012816|Other|Peer‐referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
287260|NCT02012803|Procedure|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
287261|NCT02012803|Other|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
287262|NCT02012790|Other|Diet|The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
287263|NCT02012777|Drug|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
287264|NCT02012751|Device|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
287265|NCT02012738|Behavioral|FORNET|"8 individual sessions:~1 lifeline~6 exposure sessions~1 outlook"
287266|NCT02012738|Behavioral|CBT|"7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice."
287398|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
287267|NCT02012738|Other|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
287268|NCT02012738|Other|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
287269|NCT02012725|Drug|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
287270|NCT02012712|Behavioral|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.~Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE‐3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
287271|NCT02012686|Device|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
287272|NCT02012673|Device|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
287273|NCT02012660|Other|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
287274|NCT02012647|Procedure|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
287275|NCT02012647|Procedure|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
287276|NCT02012608|Drug|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
287277|NCT02012608|Drug|Placebo|For subjects undergoing breast conserving therapy
287278|NCT02012595|Other|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand [11C]donepezil
287279|NCT02012582|Drug|VAS203|i.v. infusion
287280|NCT02012582|Drug|Saline|i.v. infusion
287281|NCT02012569|Drug|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
287282|NCT02012569|Drug|Placebo|
287283|NCT02012556|Drug|Tesamorelin|
287284|NCT02012543|Dietary Supplement|Agar jelly|
287285|NCT02012530|Procedure|HA|HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
287286|NCT02012530|Procedure|PRP|PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
287287|NCT02012517|Drug|Prolonged antibiotic treatment|
287288|NCT02012517|Drug|Short antibiotic course (standard of care)|
287289|NCT02012491|Drug|Misoprostol|
287290|NCT02012491|Drug|Mifepristone|
287291|NCT02012478|Behavioral|MI- informed SMS program|
287292|NCT02012465|Biological|Insulin protocol|"Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.~The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.~Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours~The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro)."
287293|NCT02012452|Behavioral|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
287294|NCT02012452|Behavioral|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
287295|NCT02012439|Behavioral|Mindfulness Based Cognitive Therapy|
287296|NCT02012439|Behavioral|Cognitive Therapy|
287297|NCT02012426|Behavioral|Weight management program|
287298|NCT02012413|Device|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
287299|NCT02012413|Device|Placebo - Sham PST|"Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes"
287347|NCT02012088|Drug|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
287300|NCT02012400|Other|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks. The control group receives ordinary instructions.
287301|NCT02012387|Biological|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
287302|NCT02012387|Biological|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
287303|NCT02012387|Biological|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
287304|NCT02012374|Behavioral|Intensive Language Action Therapy|
287305|NCT02012361|Procedure|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.
287306|NCT02012361|Procedure|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.
287307|NCT02012361|Procedure|Muscle Biopsy|During the course of the operation a small muscle biopsy will be collected.
287308|NCT02012348|Other|Antibacterial soap with triclocarban|
287309|NCT02012348|Other|Antibacterial soap + benzalkonium chloride|
287310|NCT02012348|Other|Control soap|
287311|NCT02012335|Drug|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
287312|NCT02012322|Dietary Supplement|Coenzyme Q10|100mg/day for three months
287313|NCT02012322|Dietary Supplement|Coenzyme Q10|300mg/day for three months
287314|NCT02012322|Dietary Supplement|Placebo|Three month period
287315|NCT02012309|Biological|PCV-13|
287316|NCT02012309|Biological|PPSV-23|
287317|NCT02012296|Drug|enzalutamide|Given PO
287318|NCT02012296|Drug|mifepristone|Given PO
287319|NCT02012296|Other|laboratory biomarker analysis|Correlative studies
287320|NCT02012296|Other|pharmacological study|Correlative studies
287321|NCT02012283|Other|Food consumption|Cooked vegetables with spices or without spices
287322|NCT02012270|Procedure|PRINCIPLES technique|"Principles technique for closure of midline laparotomy incisions~closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)~the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other~the SL/WL ratio should be at least 4/1~SL/WL = (150cm x number of sutures used) - (the suture remnants)~the mean stitch length should be less than 4 cm (suture length / number of stitches placed)"
287323|NCT02012270|Procedure|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
287324|NCT02012257|Procedure|AMSA nerve block injectio|Sites of injection
287325|NCT02012244|Drug|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
287326|NCT02012244|Drug|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
287327|NCT02012231|Drug|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
287328|NCT02012218|Drug|ADT|
287329|NCT02012218|Drug|Brexpiprazole|
287330|NCT02012205|Procedure|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
287331|NCT02012192|Drug|Ganetespib|
287332|NCT02012192|Drug|Paclitaxel|
287333|NCT02012179|Other|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
287334|NCT02012166|Drug|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
287335|NCT02012166|Drug|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
287336|NCT02012166|Drug|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
287337|NCT02012166|Drug|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
287338|NCT02012166|Drug|Placebo|Placebo administered orally in 240 mL of water
287339|NCT02012166|Biological|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
287340|NCT02012166|Biological|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
287341|NCT02012166|Biological|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
287342|NCT02012153|Biological|Mesenchymal Stromal Cells|
287343|NCT02012140|Drug|ticagrelor|
287344|NCT02012114|Other|Cysteamine bitartrate|No intervention
287345|NCT02012101|Device|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
287346|NCT02012101|Device|oxygen therapy|
287396|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
287348|NCT02012088|Drug|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
287349|NCT02012075|Drug|Extended-Release Carvedilol Sulfate|
287350|NCT02012075|Drug|Sustained-release Metoprolol Succinate|
287351|NCT02012062|Drug|TPF neoadjuvant chemotherapy|
287352|NCT02012062|Drug|Concurrent chemotherapy with cisplatin during radiotherapy|
287353|NCT02012062|Drug|Concurrent nimotuzumab during radiotherapy|
287354|NCT02012062|Radiation|Radical radiotherapy|
287355|NCT02012049|Drug|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
287356|NCT02012049|Drug|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
287357|NCT02012036|Drug|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.~The detection with Hexvix should be in accordance with local Summary of Product Characteristics [SmPC].~Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
287358|NCT02012023|Device|Low anterior resection|
287359|NCT02012023|Device|tube ileostomy|
287360|NCT02012023|Device|loop ileostomy|
287361|NCT02012023|Device|accept reversal operation|
287362|NCT02012023|Device|remove the tube ileostomy|
287363|NCT02012010|Procedure|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
287364|NCT02012010|Procedure|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
287365|NCT02011997|Procedure|patients undergo cVATS segmentectomy|
287366|NCT02011997|Procedure|Patients undergo cVATS lobectomy|
287367|NCT02011971|Drug|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
287368|NCT02011958|Drug|Liposomal Amphotericin B|"40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)"
287369|NCT02011958|Drug|Miltefosine|"Orally taken every day during 28 days~1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)"
287370|NCT02011945|Drug|Dasatinib|
287371|NCT02011945|Drug|Nivolumab|
287372|NCT02011919|Device|Echopulse|HIFU Under ultrasound guidance
287373|NCT02011906|Dietary Supplement|omega 3|
287374|NCT02011906|Dietary Supplement|vitamin E|
287375|NCT02011906|Dietary Supplement|placebo of omega 3|
287376|NCT02011906|Dietary Supplement|placebo of vitamin E|
287377|NCT02011893|Device|Tonic Stimulation|Prodigy Neurostimulation System with associated components
287378|NCT02011893|Device|Burst Stimulation|Prodigy Neurostimulation System with associated components
287379|NCT02011880|Dietary Supplement|Chinese Herbs|"Dietary Supplement:Experiment group:~Fructus Cnidii,Psoralea Corylifolin L.，monkshood~-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity~Dietary Supplement:Contrast Group:~Breast Cancer Postoperative Prescription~-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
287380|NCT02011867|Device|Cork Electrode|
287381|NCT02011854|Device|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
287382|NCT02011854|Device|Acupuncture|
287383|NCT02011841|Drug|Rifaximin|rifaximin 1200 mg/day orally for 6 months
287384|NCT02011841|Drug|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
287385|NCT02011828|Drug|Ergocalciferol|50,000 IU/week
287386|NCT02011828|Drug|Placebo|Placebo tablet
287387|NCT02011802|Device|Algosteril TM|
287388|NCT02011802|Device|Sorbact TM|
287389|NCT02011789|Dietary Supplement|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
287390|NCT02011789|Dietary Supplement|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
287391|NCT02011763|Biological|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
287392|NCT02011750|Drug|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
287393|NCT02011750|Drug|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
287394|NCT02011737|Drug|naftopidil 75mg|
287395|NCT02011724|Device|Apligraf|
287399|NCT02011685|Behavioral|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
287400|NCT02011685|Behavioral|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
287401|NCT02011672|Other|nutrient-enriched milk|
287402|NCT02011672|Other|regular milk|
287403|NCT02011659|Drug|Ramosetron|
287404|NCT02011646|Behavioral|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
287405|NCT02011646|Behavioral|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
287406|NCT02011633|Drug|HCP1201 500/10mg|500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
287407|NCT02011633|Drug|Metformin SR 500mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
287408|NCT02011633|Drug|Rosuvastatin 10mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
287409|NCT02011620|Other|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
287410|NCT02011594|Drug|Nimotuzumab|400mg Q2W intravenously
287411|NCT02011594|Drug|Placebo|Normal saline
287412|NCT02011568|Other|Therapeutic Hypothermia|
287413|NCT02011542|Drug|VSL#3|This is a probiotic mixture
287414|NCT02011542|Drug|Placebo|This is a pill with inactive ingredients.
287415|NCT02011529|Other|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
287416|NCT02011516|Drug|Baclofen|
287417|NCT02011516|Behavioral|Psychosocial|
287418|NCT02011516|Drug|Placebo|
287419|NCT02011503|Procedure|Multi-layer compression therapy|Application of multi-layer compression therapy.
287420|NCT02011503|Other|Application of dHACM|Application of dHACM to ulcer.
287421|NCT02011490|Drug|sugammadex|sugammadex 4 mg/kg IV bolus
287422|NCT02011477|Other|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
287423|NCT02011477|Other|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
287424|NCT02011464|Drug|Exparel|Exparel is infiltrated into posterior compartment for pain control
287425|NCT02011464|Other|Saline|Saline is infiltrated into posterior compartment for control
287426|NCT02011451|Drug|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
287427|NCT02011451|Drug|Placebo Comparator:|
287428|NCT02011438|Behavioral|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
287429|NCT02011425|Device|mandibular advancement appliance|mandibular advancement appliance
287430|NCT02011399|Procedure|Brain Computer Interface for Mu Rhythm|"Device: Brain Computer Interface Subjects will wear an EEG (electrode) cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate a computer. Subjects will be asked to participate in 4-20 sessions.~Arms: Brain Computer Interface Keyboard"
287431|NCT02011386|Drug|Treatment|
287432|NCT02011373|Procedure|fixation technique using a sterile synthetic liquid tissue glue: IFABOND™|
287433|NCT02011360|Other|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
287434|NCT02011360|Other|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
287435|NCT02011347|Drug|Ketamine|
287436|NCT02011347|Drug|Placebo|
287437|NCT02011334|Drug|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
287438|NCT02011321|Drug|clevidipine|clevidipine infusion x4 hours
287439|NCT02011308|Device|Green light Laser|Laser vs TURP
287440|NCT02011308|Device|Transurethral Resection of the Prostate (TURP)|Laser vs TURP
287441|NCT02011295|Procedure|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
287442|NCT02011295|Other|Bone Marrow Aspirate injection|
287443|NCT02011282|Other|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
287444|NCT02011269|Biological|Trichuris Suis Ova|
287445|NCT02011256|Device|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
287446|NCT02011230|Other|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
287447|NCT02011217|Other|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
287448|NCT02011217|Other|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
287449|NCT02011217|Other|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
287450|NCT02011204|Device|Electrical impedance myography (EIM)|"In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.~EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time."
287451|NCT02011191|Dietary Supplement|Biotin Supplementation|10,000 micrograms biotin supplement daily for 8 weeks
287452|NCT02011191|Dietary Supplement|Sugar Pill|Identical sugar pill, identical bottle as the biotin supplementation group
287453|NCT02011178|Procedure|Optimal medical treatment and surgery|
287454|NCT02011178|Procedure|Optimal medical treatment|
287455|NCT02011165|Procedure|Positioning measuring device|A tennis ball in the night shirt will prevent supine position during sleep.
287456|NCT02011139|Behavioral|Cognitive-behavioral group therapy|
287457|NCT02011126|Drug|Imetelstat Sodium|Given IV
287458|NCT02011126|Other|Laboratory Biomarker Analysis|Optional correlative studies
287459|NCT02011113|Drug|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
287460|NCT02011113|Drug|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
287461|NCT02011100|Dietary Supplement|Carnosine|
287462|NCT02011087|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
287463|NCT02011048|Procedure|Endoscopic components separation|Endoscopic components separation hernia repair
287464|NCT02011022|Drug|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
287465|NCT02011022|Drug|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
287466|NCT02011009|Other|HIV seropositive patients|During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
287467|NCT02010996|Procedure|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
287468|NCT02010996|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
287469|NCT02010983|Other|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
287470|NCT02010970|Drug|Group 1 AZD3293|AZD3293 oral solution
287471|NCT02010970|Drug|Group 2 AZD3293|AZD3293 oral solution
287472|NCT02010970|Drug|Group 3 AZD3293|AZD3293 oral solution
287473|NCT02010970|Drug|Group 1 Itraconazole|itraconazole capsule
287474|NCT02010970|Drug|Group 2 Diltiazem|Diltiazem ER tablet
287475|NCT02010970|Drug|Group 3 Midazolam|midazolam syrup
287476|NCT02010957|Other|FDG positron emission tomography|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
287477|NCT02010957|Other|Iodometomidate imaging|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
287478|NCT02010944|Drug|solifenacin succinate|oral
287479|NCT02010944|Drug|mirabegron|oral
287480|NCT02010944|Drug|mirabegron/solifenacin succinate|oral
287481|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
288099|NCT02005783|Drug|Docetaxel|Docetaxel:75mg/m2, d1, q3w*4
287482|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
287483|NCT02010918|Drug|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
287484|NCT02010905|Drug|Losartan|
287485|NCT02010905|Drug|Placebo|
287486|NCT02010892|Procedure|Stent Grafting (ESR)|
287487|NCT02010892|Procedure|Open Surgery (OSR)|
287488|NCT02010866|Behavioral|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP and others who seek counseling (due to other reasons for referral)
287489|NCT02010853|Other|IRMf|"evaluation in resting state fMRI during three successive visits:~During the acute phase within 24 hours~In 72 hours~In 3 months"
287490|NCT02010840|Behavioral|Psychoeducation program|
287491|NCT02010827|Biological|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
287492|NCT02010827|Biological|Oral glucose tolerance test, day A|
287493|NCT02010827|Biological|intravenous iv glucose infusion, day B|
287494|NCT02010801|Procedure|irreversible electroporation|
287495|NCT02010801|Device|nanoknife AngioDynamics US Ltd|
287496|NCT02010788|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
287497|NCT02010775|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
287498|NCT02010775|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
287499|NCT02010762|Drug|Vitamin D|25.000 IU oral drops
287500|NCT02010762|Drug|Placebo|placebo oral drops
287501|NCT02010736|Other|Single treadmill gait training with additional loading|
287502|NCT02010723|Procedure|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
287503|NCT02010723|Drug|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
287504|NCT02010710|Device|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
287505|NCT02010697|Behavioral|Messages targeting nonsmokers|
287506|NCT02010697|Behavioral|Messages targeting smokers|
287507|NCT02010684|Behavioral|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
287508|NCT02010671|Other|Survey|Survey
287509|NCT02010658|Other|Cognitive Aid|
287510|NCT02010645|Drug|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
287511|NCT02010645|Drug|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
287512|NCT02010632|Drug|Generic clopidogrel product Apolets®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
287513|NCT02010632|Drug|Original clopidogrel product Plavix®|"Clopidogrel 75 mg once daily for 7 days~Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
287514|NCT02010619|Behavioral|Cognitive behavior therapy|
287515|NCT02010619|Behavioral|Supportive therapy|
287516|NCT02010606|Biological|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.
287517|NCT02010606|Biological|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
287518|NCT02010593|Drug|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR,
287519|NCT02010593|Drug|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
287520|NCT02010567|Drug|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
287521|NCT02010567|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
287644|NCT02009449|Drug|nivolumab|Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
287522|NCT02010567|Radiation|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.~Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if <T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.~Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV 1 and PTV 2 shall be no less than 95% of the protocol specified dose for that volume."
287523|NCT02010567|Procedure|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
287524|NCT02010554|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
287525|NCT02010554|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
287526|NCT02010502|Dietary Supplement|Beetroot juice|
287527|NCT02010502|Dietary Supplement|Beetroot powder|
287528|NCT02010502|Dietary Supplement|Placebo|
287529|NCT02010489|Other|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
287530|NCT02010463|Other|Exercise|
287531|NCT02010450|Other|Wearable Blanket (Sleep Sack)|
287532|NCT02010450|Other|Incentive Item|
287533|NCT02010437|Drug|Sodium Tetradecyl Sulphate (STS)|
287534|NCT02010424|Other|control group|standard IVF protocol
287535|NCT02010424|Device|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
287536|NCT02010411|Drug|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
287537|NCT02010398|Other|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
287538|NCT02010398|Other|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
287539|NCT02010398|Other|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
287540|NCT02010385|Drug|Octreotide|
287541|NCT02010385|Drug|Saline|
287542|NCT02010372|Other|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
287543|NCT02010372|Other|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
287544|NCT02010359|Drug|Lovaza|Lovaza 4 grams per day
287545|NCT02010359|Drug|Placebo|Placebo pill
287546|NCT02010346|Procedure|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
287547|NCT02010333|Drug|Ha44 Gel 0.74% w/w|
287548|NCT02010320|Other|Computer dosing|Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates
287549|NCT02010320|Other|Standard dose determination|Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
287550|NCT02010307|Other|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
287551|NCT02010294|Genetic|DNA samples, GAS strains|DNA samples,GAS strains
287552|NCT02010281|Device|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
287553|NCT02010268|Other|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
287554|NCT02010255|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
287555|NCT02010255|Drug|RBV|RBV tablets administered orally in a divided daily dose
287556|NCT02010242|Drug|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
287557|NCT02010242|Drug|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
287558|NCT02010216|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
287559|NCT02010203|Biological|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
287560|NCT02010203|Biological|Placebo|Injection containing sterile solution but no cells
287561|NCT02010203|Biological|BCG|Vaccine derived from a live bacterium
287562|NCT02010164|Dietary Supplement|Co-enzyme Q10|600mg for 3 months
287563|NCT02010151|Other|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
287564|NCT02010138|Procedure|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
287565|NCT02010138|Procedure|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
287566|NCT02010112|Other|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
287567|NCT02010099|Drug|PP110 Gel|
287568|NCT02010099|Drug|PP110 Medicated wipes|
287569|NCT02010099|Drug|Preparation-H Cream|
287570|NCT02010086|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
287571|NCT02010086|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
287572|NCT02010060|Behavioral|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week [KKW]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
287573|NCT02010060|Behavioral|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
287574|NCT02010047|Device|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
287575|NCT02010034|Drug|Omegaven|Omegaven will be used in place of soy oil Intralipid
287576|NCT02010021|Drug|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
287577|NCT02010008|Behavioral|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
287578|NCT02009995|Behavioral|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
287579|NCT02009995|Behavioral|AT plus Primarily Home-Based Resistance Band Training|"The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.~Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
287580|NCT02009982|Procedure|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
287581|NCT02009982|Device|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
287582|NCT02009956|Device|Subjects receiving DESyne Novolimus Eluting CSS|
287583|NCT02009943|Drug|Ferric carboxymaltose|One time dosing
287584|NCT02009943|Drug|Iron sucrose|Goal-directed dosing
287585|NCT02009878|Drug|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
287586|NCT02009865|Drug|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
287587|NCT02009865|Drug|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
287588|NCT02009839|Behavioral|Meeky Mouse program|
287589|NCT02009839|Other|Computer Games|
287590|NCT02009826|Radiation|[18F]-PBR111 Positron Emission Tomography (PET)|[18F]-PBR111 radioligand to assess binding to TSPO
287591|NCT02009826|Behavioral|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
287592|NCT02009826|Biological|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
287593|NCT02009813|Procedure|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
288100|NCT02005770|Drug|Sevoflurane|
287594|NCT02009800|Biological|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
287595|NCT02009787|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
287596|NCT02009787|Drug|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
287597|NCT02009774|Procedure|NBI Function|
287598|NCT02009761|Drug|BI 655064|subcutaneous injection
287599|NCT02009748|Dietary Supplement|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
287600|NCT02009748|Dietary Supplement|Placebo|oral administration of placebo (vehicle) once daily
287601|NCT02009735|Device|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
287602|NCT02009722|Drug|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
287603|NCT02009722|Drug|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
287604|NCT02009709|Drug|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
287605|NCT02009709|Device|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
287606|NCT02009709|Device|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
287607|NCT02009696|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
287608|NCT02009696|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
287609|NCT02009670|Dietary Supplement|13C inulin|Oral 13C inulin
287610|NCT02009670|Other|Placebo|Oral maltodextrin
287611|NCT02009644|Device|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
287612|NCT02009631|Drug|Veliparib (ABT-888)|
287613|NCT02009631|Drug|Placebo|
287614|NCT02009618|Drug|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
287615|NCT02009618|Drug|placebo|
287616|NCT02009605|Drug|Icotinib|125mg, oral administration, three times per day.
287617|NCT02009592|Drug|Rifaximin|Both arms receive Rifaximin
287618|NCT02009579|Drug|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
287619|NCT02009579|Drug|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
287620|NCT02009566|Radiation|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
287621|NCT02009553|Other|Information sheet|
287622|NCT02009553|Other|No information sheet|
287623|NCT02009540|Drug|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
287624|NCT02009540|Drug|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
287625|NCT02009527|Drug|N-hydroxy-nor-arginine|
287626|NCT02009527|Drug|NaCl|
287627|NCT02009514|Other|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
287628|NCT02009501|Device|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
287629|NCT02009501|Device|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
287630|NCT02009488|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
287631|NCT02009488|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
287632|NCT02009488|Drug|Placebo|One placebo capsule (inactive medication) once daily.
287633|NCT02009475|Other|Interval exercise training|
287634|NCT02009475|Other|Continues aerobic training|
287635|NCT02009462|Drug|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
287636|NCT02009449|Drug|Pegilodecakin|Daily subcutaneous injections of pegilodecakin up to 12 months
287637|NCT02009449|Drug|Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Day 1 of every 21 day cycle
287638|NCT02009449|Drug|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Intravenous administration on Day 1 and 2 of every 14 day cycle
287639|NCT02009449|Drug|gemcitabine/nab-paclitaxel|Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
287640|NCT02009449|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
287641|NCT02009449|Drug|Pazopanib|Pazopanib will be administered orally daily continuously
287642|NCT02009449|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
287643|NCT02009449|Drug|Paclitaxel|"Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)~• Paclitaxel 80 mg/ m2 IV"
288101|NCT02005770|Drug|Propofol|
287645|NCT02009449|Drug|Gemcitabine/carboplatin|gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
287646|NCT02009436|Drug|Azacitidine|Given via nebulizer
287647|NCT02009436|Other|Laboratory Biomarker Analysis|Correlative studies
287648|NCT02009436|Other|Pharmacological Study|Correlative studies
287649|NCT02009423|Drug|Masitinib|
287650|NCT02009423|Drug|Placebo|
287651|NCT02009410|Drug|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
287652|NCT02009410|Drug|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
287653|NCT02009397|Drug|Ipilimumab|
287654|NCT02009397|Drug|GM-CSF|
287655|NCT02009384|Drug|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
287656|NCT02009371|Device|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
287657|NCT02009371|Device|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
287658|NCT02009358|Other|mental health promotion|
287659|NCT02009332|Drug|ABI-009|
287660|NCT02009306|Drug|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).~Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
287661|NCT02009306|Drug|Standard subcutaneous medication|"Subcutaneous as needed medication will include:~Opioids for pain or dyspnoea~Diamorphine~Oxycodone~Fentanyl~Benzodiazepine and / or anti-psychotic for agitation~Midazolam~Levomepromazine~Haloperidol Anti-emetic for nausea~Cyclizine~Metoclopramide~Haloperidol~Levomepromazine~Anti-secretory drug for respiratory secretions~Glycopyrronium~Hyoscine butylbromide~Hyoscine hydrobromide"
287662|NCT02009306|Drug|Epistatus Alone|"Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
287663|NCT02009293|Other|Cough monitor|questionnaires about cough and quality of life
287664|NCT02009280|Drug|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
287665|NCT02009280|Drug|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
287666|NCT02009267|Device|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
287667|NCT02009267|Procedure|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation—including the sensation of pain—by blocking the transmission of signals through nerve fibers in or near the spinal cord.
287668|NCT02009267|Procedure|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
287669|NCT02009254|Other|Dietary treatment|
287670|NCT02009241|Other|Pulmonary Rehabilitation|
287671|NCT02009228|Procedure|Ovarian cystectomy|
287672|NCT02009215|Drug|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
287673|NCT02009202|Drug|polyethylene glycol|
287674|NCT02009202|Drug|picosulphate|
287675|NCT02009189|Drug|2% Taurolidine Lock|Catheter lock with 2% Taurolidine
287676|NCT02009189|Drug|1.35% Taurolidine|Catheter lock with 1.35% Taurolidine + citrate
287677|NCT02009176|Procedure|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
287678|NCT02009176|Procedure|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
287679|NCT02009163|Drug|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
287680|NCT02009163|Other|Placebo|Placebo capsule once per day (double-blind period)
287681|NCT02009137|Device|EVERA|EVERA apply for 12 weeks
287682|NCT02009137|Device|ESTES|ESTES apply for 12 weeks
287683|NCT02009124|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
287715|NCT02008877|Drug|Sirolimus|4mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
287716|NCT02008864|Drug|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
287717|NCT02008864|Drug|Placebo|Placebo tablet/ 2 times per day
287718|NCT02008851|Biological|Neo-kidney augment|Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
287719|NCT02008838|Dietary Supplement|Synbiotic|
287720|NCT02008838|Dietary Supplement|Placebo|
287684|NCT02009111|Behavioral|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 — 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 — 12 hrs).
287685|NCT02009098|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
287686|NCT02009072|Procedure|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
287687|NCT02009072|Procedure|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
287688|NCT02009059|Device|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
287689|NCT02009046|Behavioral|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
287690|NCT02009046|Behavioral|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
287691|NCT02009046|Behavioral|SEI Curriculum + 3 School Components|Participants receive SEI classroom curriculum and all three school wide components. The peer education/advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. The clinical services linkages includes health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed.
287692|NCT02009046|Behavioral|Control Curriculum + 1 School Component|Participants receive control classroom curriculum and one of the three school wide components, the clinical services linkages. This component includes health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed.
287693|NCT02009033|Drug|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
287694|NCT02009033|Drug|Hydroxyethylstarch|
287695|NCT02009007|Drug|dopamine|continuous infusion during operation
287696|NCT02009007|Drug|phenylephrine|continuous infusion of phenylephrine during operation
287697|NCT02008994|Other|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
287698|NCT02008981|Drug|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
287699|NCT02008981|Drug|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
287700|NCT02008981|Drug|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
287701|NCT02008981|Drug|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
287702|NCT02008968|Drug|allopurinol 300 mg./day|
287703|NCT02008968|Other|No intervention|
287704|NCT02008968|Drug|Normouricemic|
287705|NCT02008955|Dietary Supplement|Lysine intake provided as a milkshake|There are 7 different lysine test levels ranging from 10 to 80 mg of lysine per kilogram body weight per day (10 - 80 mg/kg/d)
287706|NCT02008942|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
287707|NCT02008942|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
287708|NCT02008929|Biological|MG4101|Ex vivo expanded allogeneic NK cell
287709|NCT02008916|Drug|Secukinumab|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17).
287710|NCT02008916|Drug|Placebo secukinumab|Placebo to AIN457 (Secukinumab)
287711|NCT02008890|Biological|Secukinumab 300mg|Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered
287712|NCT02008890|Biological|Secukinumab 150mg|secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered
287713|NCT02008890|Biological|Placebo|secukinumab placebo s.c. (two PFS injections of placebo) self-administered
287714|NCT02008877|Drug|ganetespib|Phase 1 Dose 1: 150 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 1 Dose 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour; Phase 2: 200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
287721|NCT02008825|Device|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
287722|NCT02008825|Device|Usual non suction Bougie|Usual non suction Bougie
287723|NCT02008812|Device|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.~The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
287724|NCT02008799|Procedure|Bone marrow stem cell injection|Injection should be in testis and testicular artery
287725|NCT02008786|Drug|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
287726|NCT02008786|Drug|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
287727|NCT02008786|Drug|placebo|Placebo
287728|NCT02008773|Drug|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
287729|NCT02008773|Drug|placebo|placebo capsules 6/day oral for 16 weeks
287730|NCT02008760|Dietary Supplement|Omega Krill with D3|
287731|NCT02008747|Drug|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
287732|NCT02008734|Drug|PD0332991|
287733|NCT02008721|Drug|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
287734|NCT02008721|Drug|Placebo|Placebo
287735|NCT02008708|Behavioral|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
287736|NCT02008708|Other|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
287737|NCT02008695|Behavioral|adult microfinance|"Female piglet provided to household member. Participants agrees to repay participants' loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households"
287738|NCT02008695|Behavioral|Youth microfinance only|One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
287739|NCT02008695|Behavioral|youth and adult micro finance|One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
287740|NCT02008682|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
287741|NCT02008682|Drug|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
287742|NCT02008669|Procedure|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
287743|NCT02008669|Other|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.~Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
287744|NCT02008669|Other|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):~Fatigue (EMIF-SEP)~Dysphagia (DYMUS)~Food intake (semi-structured questionnaire)~Depression (BDI-II)~Daily energy expenditure (NAP)~Visual analog scale to study quality of sleep"
287745|NCT02008656|Drug|Oxaliplatin (OXAL)|
287746|NCT02008656|Drug|5-Fluorouracil (5-FU)|
287747|NCT02008656|Drug|Leucovorin|
287748|NCT02008656|Drug|Capecitabine (Xeloda®)|
287749|NCT02008656|Radiation|intensity modulated radiotherapy (IMRT)|
287750|NCT02008656|Behavioral|Quality of Life Questionnaires|
287751|NCT02008656|Procedure|DRE-Endoscopy|
287752|NCT02008643|Other|filling questionnary to quality of life|filling questionnary to quality of life
287753|NCT02008630|Other|Animal-assisted activity|
287754|NCT02008630|Other|Animal-assisted therapy|
287755|NCT02008617|Drug|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
287756|NCT02008617|Drug|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
287757|NCT02008591|Procedure|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
287758|NCT02008578|Biological|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
287759|NCT02008578|Biological|Placebo|
287760|NCT02008565|Drug|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
287761|NCT02008565|Drug|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
287833|NCT02008071|Behavioral|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
287855|NCT02007837|Drug|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
287762|NCT02008565|Behavioral|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
287763|NCT02008565|Behavioral|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
287764|NCT02008552|Genetic|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
287765|NCT02008539|Drug|MSC_apceth_101|
287766|NCT02008526|Behavioral|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
287767|NCT02008526|Behavioral|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
287768|NCT02008513|Biological|AFFITOPE® AD02|
287769|NCT02008513|Biological|Placebo|
287770|NCT02008500|Other|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
287771|NCT02008500|Other|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
287772|NCT02008500|Other|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
287773|NCT02008487|Other|Wound powder application|Powder application to wound per protocol.
287774|NCT02008474|Behavioral|Online weight loss + incentives for behavior 3 months|Participants will receive monetary incentives for submitting their behavior change information into a study website
287775|NCT02008474|Behavioral|Online weight loss + incentives for weight loss at month 3|Participants will receive an incentive for meeting their weight loss goal at month 3.
287776|NCT02008474|Behavioral|Online weight loss + Incentives for behavior 12 months|Participants will receive incentives for submitting behavior change information over the course of 12 months.
287777|NCT02008474|Behavioral|Online weight loss + Incentives for weight loss 12 months|Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
287778|NCT02008461|Procedure|radiofrequency ablation|
287779|NCT02008461|Drug|botulinum toxin injection|
287780|NCT02008448|Procedure|Pulmonary vein isolation|
287781|NCT02008448|Procedure|Linear Lesion Ablation|
287782|NCT02008448|Drug|BT injection|
287783|NCT02008435|Behavioral|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
287784|NCT02008435|Behavioral|Standard GLB|This arm is the standard Group Lifestyle Balance program
287785|NCT02008422|Drug|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
287786|NCT02008422|Drug|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
287787|NCT02008422|Drug|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
287788|NCT02008409|Device|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
287789|NCT02008396|Drug|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapeutic activities during experimental sessions .
287790|NCT02008396|Drug|MDMA|Participants receive a capsule of 75 or 100 mg during the first of two experimental sessions and a capsule of 100 or 125 mg MDMA on the second of two experimental sessions. They will receive MDMA along with selected therapeutic activities during each experimental session.
287791|NCT02008383|Biological|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
287792|NCT02008383|Drug|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.~Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
287793|NCT02008370|Drug|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
287794|NCT02008357|Drug|Placebo|Administered IV
287795|NCT02008357|Drug|Solanezumab|Administered IV
287796|NCT02008344|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
287797|NCT02008344|Drug|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.~Day 1: 1800 mg twice daily (loading doses)~Days 2 through 5: 800 mg twice daily"
287854|NCT02007850|Drug|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
287856|NCT02007837|Other|Daily text reminder text messages|
287857|NCT02007824|Device|ULSD-12D|wound cleansing and debridement using ULSD-12D
287798|NCT02008331|Dietary Supplement|SYNBIOTIC|"INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.~PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water."
287799|NCT02008318|Drug|Galunisertib|Administered orally
287800|NCT02008318|Drug|Placebo|Administered orally
287801|NCT02008305|Device|protocol of optimization ALARA|
287802|NCT02008305|Device|protocol of optimization Philips|
287803|NCT02008292|Drug|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
287804|NCT02008279|Biological|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
287805|NCT02008279|Biological|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
287806|NCT02008279|Biological|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
287807|NCT02008279|Biological|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
287808|NCT02008279|Drug|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
287809|NCT02008253|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
287810|NCT02008240|Procedure|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
287811|NCT02008240|Procedure|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
287812|NCT02008227|Drug|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
287813|NCT02008227|Drug|Docetaxel|75 mg/m^2 IV infusion on Day 1 of each 21-day cycle
287814|NCT02008214|Drug|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
287815|NCT02008214|Drug|Placebo|Placebo matching pentoxifylline dosage
287816|NCT02008201|Dietary Supplement|vitamin D|
287817|NCT02008188|Device|Closed Loop Control with the Advisory/Automated Adaptive (AAA) Control system|During the experimental week, subjects will wear a standard CGM and insulin pump during the day and will follow their usual diabetes care. During the nighttime hours, the subjects will return to the study site and will resume closed-loop control overnight from 23:00-07:00. This study design will also allow for testing of system transitions from CGM-augmented pump therapy to closed loop control and back to CGM-augmented pump therapy.
287818|NCT02008175|Radiation|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
287819|NCT02008162|Drug|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
287820|NCT02008149|Other|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
287821|NCT02008136|Drug|Botulinum Toxins|intramuscular injections
287822|NCT02008123|Drug|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
287823|NCT02008110|Drug|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
287824|NCT02008110|Drug|CA125 guided strategy|Consider statins in all patients in the active arm
287825|NCT02008110|Drug|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
287826|NCT02008110|Other|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
287827|NCT02008110|Drug|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
287828|NCT02008110|Drug|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
287829|NCT02008097|Device|GE LOGIQ E9 Ultrasound System|"Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound."
287830|NCT02008084|Drug|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
287831|NCT02008084|Drug|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
287832|NCT02008071|Behavioral|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
287858|NCT02007824|Device|SONOCA-180|wound cleansing and debridement using SONOCA-180
287834|NCT02008058|Behavioral|Survey|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
287835|NCT02008045|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
287836|NCT02008045|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
287837|NCT02008032|Device|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
287838|NCT02008019|Drug|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
287839|NCT02008019|Drug|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
287840|NCT02008006|Drug|BeEAM|"High Dose Chemotherapy (HDT) containing :~Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)~Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)~Melphalan 140 mg/m2 on D-2~HDT will be followed by an Autologous Stem Cell Transplantation on D0"
287841|NCT02007993|Other|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.~Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
287842|NCT02007993|Other|Tongue Scraper|The pacient will scrap the tongue 10 times.
287843|NCT02007954|Device|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
287844|NCT02007941|Drug|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
287845|NCT02007928|Other|Rispéridone, aripiprazole, olanzapine|"Study:~We propose a prospective, interventional multicenter study.~Method:~Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.~The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
287846|NCT02007915|Drug|Pamidronate Disodium|Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
287847|NCT02007902|Other|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|"Patient inclusion at birth~Total plasma protein values measurement on cord blood sample at birth~Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler~Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth~Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 [regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy] will be monitored over 24 hours after birth."
287848|NCT02007889|Drug|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
287849|NCT02007876|Behavioral|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.~Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
287850|NCT02007863|Procedure|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
287851|NCT02007863|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
287852|NCT02007863|Drug|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
287853|NCT02007863|Drug|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
287859|NCT02007811|Biological|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
287860|NCT02007798|Drug|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
287861|NCT02007798|Drug|normal saline|100 ml per bag
287862|NCT02007785|Behavioral|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
287863|NCT02007772|Device|nHF|nasal high-flow is used over a period of 6 weeks (outpatient)
287864|NCT02007772|Device|BiPAP|BiPAP is used over a period of 6 weeks (outpatient)
287865|NCT02007759|Device|VitalStim|This group will receive active VitalStim treatment.
287866|NCT02007759|Device|Sham VitalStim|This group will receive a sham VitalStim intervention.
287867|NCT02007746|Other|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
287868|NCT02007746|Other|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
287869|NCT02007746|Procedure|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
287870|NCT02007733|Other|Serial Weights|We will collect serial weights on all children enrolled in this study.
287871|NCT02007733|Other|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
287872|NCT02007733|Other|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
287873|NCT02007720|Drug|Serelaxin|Intravenous infusion
287874|NCT02007720|Drug|Placebo|Intravenous infusion
287875|NCT02007720|Other|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
287876|NCT02007707|Behavioral|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
287877|NCT02007707|Behavioral|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
287878|NCT02007694|Behavioral|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
287879|NCT02007681|Behavioral|Reduction of sedentary time by breaking it with low intensity physical activity|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
287880|NCT02007668|Other|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
287881|NCT02007655|Drug|Eliquis|
287882|NCT02007642|Procedure|Blood sampling / Body fluid sampling|"During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.~Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite..."
287883|NCT02007629|Drug|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
287884|NCT02007616|Other|Non-action video game training|Based on cognitive training Lumosity
287885|NCT02007603|Drug|Administration of Amoxicillin / clavulanic acid|Patients receive amoxicillin / clavulanic acid due to clinical necessity
287886|NCT02007603|Drug|Ampicillin / sulbactam|Patients receive ampicillin / sulbactam due to clinical necessity
287887|NCT02007603|Procedure|Blooddraws for pharmacokinetic profiling|Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
287888|NCT02007590|Device|Aerosure 25 Hz|Active Aerosure device
287889|NCT02007590|Device|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
287890|NCT02007577|Drug|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
287891|NCT02007577|Drug|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
287928|NCT02007200|Drug|Soy Isoflavones|Given PO
287929|NCT02007200|Other|Survey Administration|Ancillary studies
287930|NCT02007187|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
287970|NCT02006849|Drug|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
288098|NCT02005783|Drug|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w*4
287892|NCT02007564|Behavioral|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
287893|NCT02007551|Behavioral|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
287894|NCT02007525|Behavioral|Yoga intervention|Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
287895|NCT02007512|Drug|Enzalutamide|160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.
287896|NCT02007512|Drug|exemestane|25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.
287897|NCT02007512|Drug|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
287898|NCT02007512|Drug|exemestane|50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.
287899|NCT02007486|Other|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
287900|NCT02007460|Behavioral|Exercise|multidirectional unilateral hopping exercise
287901|NCT02007447|Drug|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
287902|NCT02007434|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
287903|NCT02007434|Drug|Placebo|Phosphate buffered saline placebo for injection
287904|NCT02007434|Other|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
287905|NCT02007434|Drug|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
287906|NCT02007434|Drug|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
287907|NCT02007434|Drug|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
287908|NCT02007434|Other|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
287909|NCT02007421|Procedure|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
287910|NCT02007421|Procedure|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
287911|NCT02007408|Drug|Paracervical block|
287912|NCT02007408|Drug|Lidocaine spray|
287913|NCT02007408|Drug|Paracervical block + lidocaine spray|
287914|NCT02007369|Behavioral|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
287915|NCT02007369|Behavioral|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
287916|NCT02007356|Biological|IFN-γ positive selected T-cells|
287917|NCT02007330|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
287918|NCT02007330|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
287919|NCT02007317|Drug|Oshadi D & Oshadi R|Anti tumor agents
287920|NCT02007304|Behavioral|Eccentric exercise training|12 weeks of lower leg eccentric training
287921|NCT02007278|Drug|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
287922|NCT02007278|Drug|glimepiride|
287923|NCT02007278|Drug|Metformin|
287924|NCT02007252|Drug|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
287925|NCT02007252|Drug|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
287926|NCT02007239|Drug|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
287927|NCT02007200|Other|Laboratory Biomarker Analysis|Correlative studies
287931|NCT02007187|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
287932|NCT02007187|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
287933|NCT02007174|Drug|Bevacizumab|
287934|NCT02007174|Drug|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
287935|NCT02007174|Drug|Medical Treatment|Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.
287936|NCT02007174|Procedure|Argon laser treatment|
287937|NCT02007161|Drug|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
287938|NCT02007148|Drug|capecitabine|twice a day
287939|NCT02007148|Drug|Docetaxel|cycles repeated every 3 weeks
287940|NCT02007122|Other|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
287941|NCT02007122|Other|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
287942|NCT02007096|Drug|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight <100kg: 50ml total; weight >100kg: 60ml total
287943|NCT02007096|Drug|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight <100kg: 50ml; weight >100kg: 60ml
287944|NCT02007083|Procedure|Bilateral laminotomy (BL)|
287945|NCT02007083|Procedure|Unilateral laminotomy with crossover (UL)|
287946|NCT02007083|Procedure|Spinous Process Osteotomy (SPO)|
287947|NCT02007070|Biological|Pembrolizumab|Intravenous infusion
287948|NCT02007057|Procedure|Suprascapular nerve block|
287949|NCT02007057|Procedure|Interscalene nerve block|
287950|NCT02007044|Drug|Ibrutinib|"Ibrutinib Subgroup 1 started on Day 1 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle.~Ibrutinib Subgroup 2 started on Day 2 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle.~Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions."
287951|NCT02007044|Drug|Rituximab|Rituximab 375 mg/m2 given intravenously on Day 1, Day 8, Day 15, and Day 22 , and then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
287952|NCT02007018|Device|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
287953|NCT02007018|Other|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending > 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
287954|NCT02007005|Drug|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
287955|NCT02006992|Other|RTF Infant Formula|a RTF extensively hydrolyzed infant formula
287956|NCT02006992|Other|Powder Infant Formula|a powdered extensively hydrolyzed infant formula.
287957|NCT02006979|Other|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
287958|NCT02006966|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
287959|NCT02006966|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
287960|NCT02006953|Procedure|Bolus feeding schedule following gastrostomy tube placement|
287961|NCT02006953|Procedure|Continuous chimney feeds following gastrostomy tube placement|
287962|NCT02006940|Device|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
287963|NCT02006927|Device|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
287964|NCT02006914|Dietary Supplement|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
287965|NCT02006901|Procedure|microdecompression|a minimal invasive surgical technique
287966|NCT02006901|Procedure|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
287967|NCT02006888|Drug|IBI-10090|
287968|NCT02006888|Drug|Placebo|Placebo
287969|NCT02006875|Device|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
287971|NCT02006836|Dietary Supplement|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
287972|NCT02006836|Dietary Supplement|Glucose|We dissolved 50 g of glucose in 200 ml water.
287973|NCT02006836|Other|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
287974|NCT02006836|Drug|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
287975|NCT02006836|Drug|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
287976|NCT02006810|Behavioral|Induction of endothelial function variations|
287977|NCT02006797|Other|reconciliation|medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
287978|NCT02006771|Other|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
287979|NCT02006771|Other|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
287980|NCT02006771|Other|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
287981|NCT02006771|Other|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
287982|NCT02006758|Device|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
287983|NCT02006745|Drug|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
287984|NCT02006745|Drug|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA >25 but <1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA >1000 iU/mL at week 4).
287985|NCT02006732|Drug|olodaterol|fixed dose combination
287986|NCT02006732|Drug|tiotropium|fixed dose combination
287987|NCT02006732|Drug|placebo|
287988|NCT02006719|Biological|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
287989|NCT02006719|Other|Placebo|Placebo injection
287990|NCT02006706|Drug|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
287991|NCT02006706|Drug|methotrexate|10 - 25 mg/week
287992|NCT02006706|Drug|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
287993|NCT02006693|Device|XEN® Gel Stent|The XEN® Gel Stent (XEN45 implant) was placed in the study eye.
287994|NCT02006693|Procedure|Cataract Surgery|Participants diagnosed with a cataract elected to have cataract surgery.
287995|NCT02006667|Drug|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
287996|NCT02006667|Drug|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
287997|NCT02006667|Drug|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
287998|NCT02006654|Drug|Placebo|Once daily, matching placebo capsules, orally
287999|NCT02006654|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
288000|NCT02006641|Drug|Placebo|Once daily, matching placebo capsules, orally
288001|NCT02006641|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
288002|NCT02006628|Drug|Placebo|Placebo oral solution (0 milligrams [mg]/mL CBD) contained the excipients sesame oil, ethanol, sucralose, and strawberry flavoring.
288003|NCT02006628|Drug|GWP42003|GWP42003 was an oral solution containing 100 mg/mL CBD dissolved in the excipients sesame oil, ethanol, sucralose and strawberry flavoring.
288004|NCT02006615|Device|rTMS|5Hz rTMS over M1 and inferior frontal lobe
288005|NCT02006602|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
288006|NCT02006602|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
288007|NCT02006589|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
288008|NCT02006589|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
288009|NCT02006576|Drug|600 mg ibuprofen three times daily for 48 weeks|
288010|NCT02006576|Other|Placebo three times daily|
288011|NCT02006537|Drug|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
288012|NCT02006524|Device|`MyDiagnostick|
288013|NCT02006511|Device|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
288014|NCT02006511|Other|Standard of Care wound therapy|Gauze type dressing.
288015|NCT02006498|Drug|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
288016|NCT02006498|Drug|Placebo|Placebo capsule with same appearances as study drug
288017|NCT02006485|Drug|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
288018|NCT02006485|Drug|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
288019|NCT02006485|Drug|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
288020|NCT02006472|Drug|Pridopidine|22.5 mg and 45 mg capsules
288021|NCT02006472|Other|Placebo|Capsules matching drug
288022|NCT02006433|Device|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
288023|NCT02006420|Device|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
288024|NCT02006407|Radiation|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
288025|NCT02006407|Device|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
288026|NCT02006407|Behavioral|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
288027|NCT02006394|Dietary Supplement|Fish Oil|fish oil capsules
288028|NCT02006394|Dietary Supplement|Polyphenol Capsules|delphinidin polyphenol capsules
288029|NCT02006394|Dietary Supplement|Corn Oil Capsules|Corn Oil Capsules
288030|NCT02006394|Dietary Supplement|Corn starch capsules|Maltodextrin capsules
288031|NCT02006394|Other|Reduced glycemic index bread products|Made by Zone Labs
288032|NCT02006394|Other|Market variety bread products|placebo bread products
288033|NCT02006368|Other|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.~After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
288034|NCT02006355|Drug|Ropivacaine|
288035|NCT02006342|Drug|Insulin Glargine|
288036|NCT02006342|Drug|Regular Insulin|
288037|NCT02006329|Device|acupuncture|
288038|NCT02006316|Procedure|Microsurgical subinguinal varicocelectomy|
288039|NCT02006303|Procedure|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
288040|NCT02006303|Procedure|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
288041|NCT02006290|Drug|PF-06412562|single oral split dose 30+20 mg QD
288042|NCT02006290|Drug|Placebo|tablet, matching placebo, QD
288043|NCT02006277|Drug|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
288044|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
288045|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
288046|NCT02006277|Drug|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
288047|NCT02006277|Drug|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
288048|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
288049|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
288050|NCT02006277|Drug|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
288051|NCT02006277|Drug|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
288052|NCT02006264|Drug|TDF Intravaginal Ring|The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
288053|NCT02006264|Drug|Placebo Intravaginal Ring|The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.
288054|NCT02006238|Device|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
288055|NCT02006238|Device|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
288056|NCT02006225|Drug|Plerixafor|
288057|NCT02006212|Procedure|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
288058|NCT02006199|Behavioral|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
288059|NCT02006186|Behavioral|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
288060|NCT02006173|Drug|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
288061|NCT02006173|Drug|Normal Saline|
288062|NCT02006160|Drug|dalfampridine|10 mg bid
288063|NCT02006160|Drug|placebo|10 mg bid
288064|NCT02006147|Drug|TLC399|Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.
288065|NCT02006121|Drug|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
288066|NCT02006121|Drug|Placebo|Sodium chloride 9 mg/ml
288067|NCT02006108|Drug|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
288068|NCT02006108|Other|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
288069|NCT02006095|Other|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
288070|NCT02006095|Behavioral|Neuropsychological testing|
288071|NCT02006082|Device|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
288072|NCT02006069|Device|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.~The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
288073|NCT02006056|Drug|Ondansetron|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
288074|NCT02006043|Drug|Erlotinib 150mg|
288075|NCT02006030|Drug|ADI-PEG 20|
288076|NCT02006030|Drug|Transarterial chemoembolization|
288077|NCT02006017|Other|Evidence summary alone plus a recommendation|
288078|NCT02006017|Other|Evidence summary alone|
288079|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
288080|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
288081|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
288082|NCT02005939|Dietary Supplement|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
288083|NCT02005926|Procedure|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
288084|NCT02005900|Drug|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
288085|NCT02005887|Drug|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
288086|NCT02005887|Drug|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
288087|NCT02005887|Drug|letrozole|Letrozole 2.5 mg orally every day for 6 cycles
288088|NCT02005861|Procedure|bone marrow cells transplantation on collagen scaffold|"120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.~An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.~After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant."
288089|NCT02005848|Biological|Alpha-1 Antitrypsin|
288090|NCT02005848|Other|Placebo|Placebo
288091|NCT02005835|Other|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
288092|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic~Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
288093|NCT02005822|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
288094|NCT02005809|Procedure|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
288095|NCT02005796|Other|Dietary intervention|
288096|NCT02005783|Drug|DBD|DBD:one dose of medicine twice per day, orally
288102|NCT02005757|Drug|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
288103|NCT02005757|Drug|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
288104|NCT02005744|Drug|CKD-501|CKD-501 0.5mg, PO(per oral), once
288105|NCT02005731|Device|Low intensity linear focused shockwave device ('Renova')|
288106|NCT02005718|Drug|Cholecalciferol|
288107|NCT02005705|Other|Outpatient Management of Low-risk Patients|"Labs will be obtained within 2-3 days of discharge from ED~Clinic visit will be scheduled within 3 days of discharge from ED~EGD will be scheduled within 7 days of discharge from ED~Phone follow-up at day 7 and 30"
288108|NCT02005705|Other|Inpatient Management of Low-risk Patients|"Labs will be obtained on day of discharge or day 2-3~EGD will be performed in the hospital~Phone follow-up at day 7 and 30"
288109|NCT02005692|Device|DynaSense sensor|
288110|NCT02005679|Behavioral|application of the mini-mental state test|
288111|NCT02005666|Drug|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
288112|NCT02005666|Drug|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
288113|NCT02005666|Drug|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
288114|NCT02005653|Drug|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
288115|NCT02005653|Drug|Albendazole|Experimental
288116|NCT02005653|Drug|Doxycycline|Experimental
288117|NCT02005627|Drug|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
288118|NCT02005627|Drug|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
288119|NCT02005614|Procedure|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.~Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
288120|NCT02005601|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
288121|NCT02005601|Drug|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
288122|NCT02005588|Drug|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
288123|NCT02005588|Drug|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
288124|NCT02005575|Drug|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
288125|NCT02005575|Drug|Placebo|
288126|NCT02005562|Drug|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (*) height (h)/ liter(L).
288127|NCT02005562|Drug|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
288128|NCT02005562|Drug|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
288129|NCT02005562|Drug|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
288130|NCT02005562|Drug|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
288131|NCT02005549|Drug|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
288132|NCT02005549|Drug|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
288133|NCT02005549|Drug|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
288134|NCT02005536|Biological|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
288135|NCT02005523|Drug|RNS60|
288136|NCT02005523|Drug|Saline|
288137|NCT02005510|Behavioral|Mailed in-home high-risk HPV testing kit|
288138|NCT02005510|Other|Usual care|
288139|NCT02005497|Other|HealthLinks|
288140|NCT02005484|Drug|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
288141|NCT02005471|Drug|Bendamustine|Bendamustine will be administered at a dose of 70 mg/m^2 via IV infusion on Days 1 and 2 of each 28-day cycle, for 6 cycles.
288142|NCT02005471|Drug|Venetoclax|Venetoclax will be administered at an initial dose of 20 mg via tablet orally QD, incremented weekly up to a maximum dose of 400 mg during a 5-week ramp-up period. Venetoclax will be continued at 400 mg QD from Week 6 (Day 1 of Cycle 1 of combination therapy) onwards up to disease progression (PD) or 2 years, whichever occurs first.
288143|NCT02005471|Drug|Rituximab|Rituximab will be administered at a dose of 375 mg/m^2 via IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m^2 on Day 1 of Cycles 2-6.
288144|NCT02005458|Drug|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
288145|NCT02005458|Drug|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
288146|NCT02005458|Drug|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
288147|NCT02005458|Drug|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
288148|NCT02005445|Device|CPAP|Continuous positive airway pressure
288149|NCT02005445|Behavioral|HLSE|Healthy living and sleep education
288150|NCT02005432|Drug|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
288151|NCT02005432|Drug|panfotocoagulation (PASCAL)|
288152|NCT02005432|Drug|panfotocoagulation (PRP) single shoot (ETDRS)|
288153|NCT02005419|Drug|Gemcitabine|Patients receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
288154|NCT02005419|Drug|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
288155|NCT02005419|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
288156|NCT02005406|Device|Experimental group and control groupl|JET
288157|NCT02005393|Device|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
288158|NCT02005380|Other|Text-based task|Participants are required to take text-based exercise.
288159|NCT02005380|Other|Graphic-based Task|Participants are required to take the graphic-based exercise.
288160|NCT02005367|Behavioral|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.~Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
288161|NCT02005367|Behavioral|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
288162|NCT02005354|Device|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (>50Hz and below the pain threshold for the patient).
288163|NCT02005354|Drug|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
288164|NCT02005341|Device|nanOSS|
288165|NCT02005341|Device|Autograft|
288166|NCT02005328|Device|Tested product : DC161-DP0291|Application of product in the mouth twice daily
288167|NCT02005328|Device|Tested product : DC161-DP0292|Application of product in the mouth twice daily
288168|NCT02005328|Device|Tested product : DC161-DP0293|Application of product in the mouth twice daily
288169|NCT02005328|Device|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
288170|NCT02005315|Drug|Vantictumab|Administered intravenous (IV) infusion.
288171|NCT02005315|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
288172|NCT02005315|Drug|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
288173|NCT02005302|Drug|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
288174|NCT02005302|Drug|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
288175|NCT02005302|Dietary Supplement|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
288176|NCT02005302|Dietary Supplement|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
288177|NCT02005289|Biological|MOR00208|Given by IV infusion
288178|NCT02005289|Drug|lenalidomide|Given PO
288179|NCT02005289|Other|Correlative Studies|Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
288180|NCT02005276|Behavioral|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
288181|NCT02005276|Behavioral|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
288182|NCT02005276|Behavioral|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
288183|NCT02005263|Procedure|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
288184|NCT02005237|Behavioral|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
288225|NCT02004821|Dietary Supplement|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
288355|NCT02003638|Drug|Niacin|Niacin titrated to 6000 mg daily
288185|NCT02005224|Other|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
288186|NCT02005211|Drug|AZD3293|Oral solution
288187|NCT02005211|Drug|Placebo|Oral solution
288188|NCT02005198|Other|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
288189|NCT02005172|Device|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
288190|NCT02005159|Other|Microbiological studies|
288191|NCT02005120|Drug|Bevacizumab|Intrapleural administration of bevacizumab
288192|NCT02005120|Drug|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
288193|NCT02005107|Drug|Venlafaxine IR and Venlafaxine XR|
288194|NCT02005081|Device|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
288195|NCT02005081|Device|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
288196|NCT02005068|Drug|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
288197|NCT02005055|Procedure|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
288198|NCT02005042|Behavioral|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
288199|NCT02005029|Drug|Erythromycin|
288200|NCT02005029|Drug|placebo|
288201|NCT02005016|Behavioral|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
288202|NCT02005003|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
288203|NCT02005003|Procedure|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
288204|NCT02005003|Biological|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
288205|NCT02005003|Procedure|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
288206|NCT02005003|Behavioral|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
288207|NCT02005003|Behavioral|Memory task|Participants perform short memory tasks on each visit
288208|NCT02005003|Behavioral|Food consumption task|Participants are given a selection of food items to consume on each visit
288209|NCT02004990|Procedure|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
288210|NCT02004977|Behavioral|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
288211|NCT02004951|Device|Misago RX|
288212|NCT02004951|Device|Zilver PTX|
288213|NCT02004938|Device|Sonosite Titan Ultrasound Machine|
288214|NCT02004912|Other|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
288215|NCT02004899|Drug|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
288216|NCT02004886|Drug|MK-0893|10 mg and 100 mg tablets
288217|NCT02004886|Drug|Metformin|500 mg metformin tablets
288218|NCT02004886|Drug|Placebo|Placebo tablets matching MK-0893
288219|NCT02004886|Drug|Placebo|Placebo tablets matching metformin
288220|NCT02004873|Device|Micra Pacemaker Implant|
288221|NCT02004860|Drug|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
288222|NCT02004860|Drug|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
288223|NCT02004847|Device|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
288224|NCT02004834|Drug|levobupivacaine|Comparing: 0,5% levobupivacaine with 2% lidocaine
288226|NCT02004795|Radiation|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
288227|NCT02004782|Drug|Prednisolone|Daily prednisolone is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Prednisolone is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE.
288228|NCT02004782|Drug|Placebo Oral Tablet|Daily placebo is taken for 6 weeks, at a dose of 40mg in week 1, 30mg in week 2, 20mg week 3 and 4, 10mg in week 5, and 5mg in week 6. Placebo is taken in the morning. Treatment commences the day of the procedure, with the dose taken with a sip of water prior to discharge. The 6-week treatment regimen is given after both the 1st and 2nd stage CBE
288229|NCT02004769|Drug|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
288230|NCT02004769|Drug|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
288231|NCT02004769|Drug|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
288232|NCT02004756|Other|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
288233|NCT02004743|Behavioral|Intervention|"Psychological guidelines and PET~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
288234|NCT02004743|Other|Treatment as usual|"Participants will experience treatment as usual.~Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
288235|NCT02004730|Device|ABSORB implantation|ABSORB implantation for long (> 24mm) single vessel disease
288236|NCT02004717|Drug|DS-8895a|
288237|NCT02004704|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion~Route of administration: intravenous infusion"
288238|NCT02004691|Drug|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.~Route of administration: intravenous infusion"
288239|NCT02004691|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.~Route of administration: intravenous infusion"
288240|NCT02004678|Drug|DS-1150b|
288241|NCT02004678|Other|Placebo|
288242|NCT02004652|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
288243|NCT02004652|Drug|Placebo|Vitamin, 50mg, tablet.
288244|NCT02004639|Radiation|Masticators sparing techniques|
288245|NCT02004639|Other|electro-acupunture treatment|electro-acupunture treatment and sham-EA
288246|NCT02004626|Drug|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
288247|NCT02004626|Drug|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records."
288248|NCT02004613|Drug|Dexmedetomidine|Dexmedetomidine
288249|NCT02004613|Drug|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
288250|NCT02004600|Procedure|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
288251|NCT02004587|Drug|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
288252|NCT02004574|Drug|Calcipotriol/betamethasone dipropionate gel|"All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks."
288253|NCT02004548|Drug|Metatinib Tromethamine|
288254|NCT02004535|Procedure|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
288255|NCT02004522|Drug|Duvelisib|PI3K Inhibitor
288256|NCT02004522|Drug|Ofatumumab|monoclonal antibody
288257|NCT02004509|Drug|anticoagulant by physician criteria|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
288258|NCT02004496|Device|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
288310|NCT02004093|Drug|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
288311|NCT02004080|Other|Intensive Care treatment|intensive care treatment
288312|NCT02004067|Drug|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
288259|NCT02004483|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
288260|NCT02004470|Procedure|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
288261|NCT02004457|Behavioral|ABBT|
288262|NCT02004457|Other|TAU|
288263|NCT02004418|Radiation|11C-Choline|
288264|NCT02004405|Other|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
288265|NCT02004405|Other|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
288266|NCT02004392|Drug|EVP-6124|
288267|NCT02004366|Drug|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
288268|NCT02004366|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
288269|NCT02004366|Drug|Linagliptin|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
288270|NCT02004366|Drug|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
288271|NCT02004366|Drug|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
288272|NCT02004353|Device|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
288273|NCT02004340|Device|ear vagus nerve stimulator|
288274|NCT02004327|Drug|DW1029M300mg|DW1029M300mg PO Once
288275|NCT02004327|Drug|DW1029M600mg|DW1029M300mg 2 tablets Once
288276|NCT02004327|Drug|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
288277|NCT02004314|Drug|Chloroquine|
288278|NCT02004301|Drug|Radiolabelled T4 Tablet|
288279|NCT02004301|Drug|Radiolabelled T6 Tablet|
288280|NCT02004288|Dietary Supplement|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken once a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
288281|NCT02004275|Drug|pomalidomide|given PO
288282|NCT02004275|Drug|ixazomib|given PO
288283|NCT02004275|Drug|dexamethasone|given PO
288284|NCT02004262|Biological|GVAX Pancreas Vaccine|
288285|NCT02004262|Biological|CRS-207|
288286|NCT02004262|Drug|Chemotherapy|Investigator's choice of one of the following commercially available products: gemcitabine; capecitabine; fluorouracil with or without leucovorin; irinotecan; or erlotinib.
288287|NCT02004262|Drug|cyclophosphamide|
288288|NCT02004236|Device|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
288289|NCT02004236|Device|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
288290|NCT02004236|Device|tRNS with sham|the subjects receive 35 session with sham
288291|NCT02004223|Radiation|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
288292|NCT02004210|Procedure|transarterial radioembolization (TARE)|transarterial radioembolization
288293|NCT02004210|Procedure|transarterial chemoembolization (TACE)|transarterial chemoembolization
288294|NCT02004197|Drug|Quadruple Allopathic therapy|
288295|NCT02004197|Drug|Pylorex plus|
288296|NCT02004184|Drug|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
288297|NCT02004184|Drug|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
288298|NCT02004171|Other|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
288299|NCT02004171|Drug|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
288300|NCT02004158|Behavioral|Positive psychology intervention|
288301|NCT02004145|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
288302|NCT02004145|Behavioral|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
288303|NCT02004132|Drug|Axiron|Solution administered topically using pump and applicator
288304|NCT02004119|Drug|KHK4577|
288305|NCT02004119|Drug|Placebo|
288306|NCT02004106|Drug|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
288307|NCT02004093|Drug|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
288308|NCT02004093|Drug|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
288309|NCT02004093|Drug|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
288313|NCT02004067|Drug|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
288314|NCT02004054|Other|measure of pupil diameter|The measure will use infra-red cameras
288315|NCT02004041|Drug|VLY-686|capsules containing 50 mg VLY-686
288316|NCT02004041|Drug|Placebo|Sugar capsule to mimic VLY-686 50 mg capsule
288317|NCT02004028|Drug|VS-6063|
288318|NCT02004015|Drug|injection of placebo|0.5 mg/kg milligram(s)/kilogram
288319|NCT02004015|Drug|injection of NMBA|
288320|NCT02004002|Behavioral|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
288321|NCT02004002|Behavioral|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
288322|NCT02003989|Other|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
288323|NCT02003976|Procedure|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
288324|NCT02003976|Other|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
288325|NCT02003963|Behavioral|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.~The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
288326|NCT02003950|Other|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
288327|NCT02003937|Behavioral|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
288328|NCT02003924|Drug|Enzalutamide|160 mg by mouth once daily
288329|NCT02003924|Drug|Placebo|Sugar pill to mimic enzalutamide
288330|NCT02003911|Drug|Azithromycin|Azithromycin suspension (200mg/5mL)
288331|NCT02003911|Drug|Placebo|
288332|NCT02003898|Device|Medtronic MiniMed 530G Insulin Pump|
288333|NCT02003885|Drug|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.~After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.~Reduction of BP is managed by the increment of phenylephrine infusion"
288334|NCT02003872|Device|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
288335|NCT02003833|Device|Poly-L-lactic acid|Sculptra injections
288336|NCT02003833|Device|Placebo comparator|saline injections
288337|NCT02003820|Behavioral|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
288338|NCT02003794|Drug|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
288339|NCT02003768|Drug|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
288340|NCT02003768|Drug|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
288341|NCT02003755|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
288342|NCT02003742|Drug|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
288343|NCT02003742|Drug|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
288344|NCT02003729|Device|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
288345|NCT02003703|Biological|Recombinant Hepatitis B Virus Vaccine|
288346|NCT02003690|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy
288347|NCT02003690|Behavioral|Standard of Care Psychotherapy|Standard of Care Psychotherapy
288348|NCT02003690|Drug|Pharmacotherapy|Standard of Care Pharmacotherapy
288349|NCT02003677|Drug|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
288350|NCT02003677|Drug|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
288351|NCT02003664|Drug|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
288352|NCT02003664|Drug|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
288353|NCT02003651|Dietary Supplement|Quick Defense|Echinacea product from Gaia Herbs.
288354|NCT02003651|Dietary Supplement|Placebo|Placebo
288356|NCT02003638|Drug|Placebo|Placebo provided in the same pill quantity as niacin arm
288357|NCT02003625|Drug|GCSF|
288358|NCT02003625|Drug|meloxicam|
288359|NCT02003625|Drug|Placebo|
288360|NCT02003612|Other|Not applicable - observational study|No intervention exists as this is a retrospective observational study
288361|NCT02003599|Device|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
288362|NCT02003599|Device|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
288363|NCT02003586|Dietary Supplement|plant-based ingredient|
288364|NCT02003586|Dietary Supplement|No plant-based ingredient|
288365|NCT02003573|Drug|decitabine iv|decitabine iv fixed dose
288366|NCT02003573|Drug|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
288367|NCT02003560|Radiation|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
288368|NCT02003547|Drug|AMA0076|
288369|NCT02003547|Drug|Placebo|
288370|NCT02003534|Drug|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
288371|NCT02003521|Device|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
288372|NCT02003495|Biological|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
288373|NCT02003495|Biological|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
288374|NCT02003495|Biological|MPV-A Vaccine Group|0.5ml, intramuscular
288375|NCT02003495|Biological|MCV-AC Vaccine Group|0.5ml, intramuscular
288376|NCT02003495|Biological|Hib Vaccine Group|0.5ml, intramuscular
288377|NCT02003482|Radiation|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
288378|NCT02003482|Device|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
288379|NCT02003469|Device|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
288380|NCT02003456|Drug|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
288381|NCT02003443|Behavioral|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
288382|NCT02003404|Device|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
288383|NCT02003404|Device|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
288384|NCT02003391|Drug|Beta-blocker monotherapy|Per participant's current prescribed therapy
288385|NCT02003391|Drug|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
288386|NCT02003378|Device|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
288387|NCT02003378|Device|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
288388|NCT02003365|Drug|FX006 10 mg|Extended-release formulation
288389|NCT02003365|Drug|FX006 40 mg|Extended-release formulation
288390|NCT02003365|Drug|TCA IR 40 mg|Immediate-release formulation
288391|NCT02003352|Procedure|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
288392|NCT02003339|Other|Additional RMIs|
288393|NCT02003326|Other|Inflammatory markers|
288394|NCT02003313|Biological|Group T|0.5ml, Intramuscular
288395|NCT02003313|Biological|Group C|0.5ml, Intramuscular
288396|NCT02003287|Other|VFSS|Videofluoroscopic Swallow Study
288397|NCT02003287|Other|FEES|Fiberoptic Endoscopic Swallow Study
288398|NCT02003274|Other|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
288451|NCT02002949|Procedure|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
288739|NCT02000505|Device|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
288399|NCT02003274|Other|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.~Metabolic tests:~A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
288400|NCT02003261|Behavioral|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.~UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
288401|NCT02003261|Other|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
288402|NCT02003248|Device|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
288403|NCT02003235|Device|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
288404|NCT02003222|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
288405|NCT02003222|Biological|Blinatumomab|Given IV
288406|NCT02003222|Drug|Cyclophosphamide|Given IV
288407|NCT02003222|Drug|Cytarabine|Given IT, IV, or SC
288408|NCT02003222|Drug|Daunorubicin|Given IV
288409|NCT02003222|Drug|Daunorubicin Hydrochloride|Given IV
288410|NCT02003222|Drug|Dexamethasone|Given PO
288411|NCT02003222|Drug|Etoposide|Given IV
288412|NCT02003222|Other|Laboratory Biomarker Analysis|Correlative studies
288413|NCT02003222|Drug|Mercaptopurine|Given PO
288414|NCT02003222|Drug|Methotrexate|Given PO, IT or IV
288415|NCT02003222|Drug|Pegaspargase|Given IM or IV
288416|NCT02003222|Drug|Prednisone|Given PO
288417|NCT02003222|Biological|Rituximab|Given IV
288418|NCT02003222|Drug|Vincristine|Given IV
288419|NCT02003222|Drug|Vincristine Sulfate|Given IV
288420|NCT02003209|Drug|Aromatase Inhibition Therapy|Given at the investigator's discretion
288421|NCT02003209|Drug|Carboplatin|Given IV
288422|NCT02003209|Other|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
288423|NCT02003209|Drug|Docetaxel|Given IV
288424|NCT02003209|Drug|Goserelin Acetate|Given SC
288425|NCT02003209|Other|Laboratory Biomarker Analysis|Correlative studies
288426|NCT02003209|Biological|Pertuzumab|Given IV
288427|NCT02003209|Other|Quality-of-Life Assessment|Ancillary studies
288428|NCT02003209|Procedure|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
288429|NCT02003209|Biological|Trastuzumab|Given IV
288430|NCT02003209|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
288431|NCT02003183|Radiation|[F-18]FDDNP|Each participant was injected with [F-18]FDDNP, a radiolabeled molecular imaging probe, prior to receiving a PET scan.
288432|NCT02003157|Procedure|hypnosis during embryo transfer or usual transfer procedure|
288433|NCT02003144|Biological|eculizumab|
288434|NCT02003131|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
288435|NCT02003118|Drug|AKR 202|
288436|NCT02003118|Drug|Placebo|
288437|NCT02003092|Drug|RX-5902|escalating doses (mg)
288438|NCT02003079|Behavioral|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
288439|NCT02003066|Procedure|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
288440|NCT02003066|Procedure|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
288441|NCT02003053|Device|Inspiratory Muscle Trainer|
288442|NCT02003040|Device|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
288443|NCT02003027|Drug|BT injection|
288444|NCT02003014|Drug|Pioglitazone|Pioglitazone Tablets
288445|NCT02003001|Drug|Botulinum Toxin|
288446|NCT02002988|Procedure|endomyocardial BT injection|
288447|NCT02002975|Drug|Pioglitazone|Pioglitazone tablets
288448|NCT02002962|Procedure|radiofrequency ablation|
288449|NCT02002962|Drug|Botulinum Toxin Type A injection|
288450|NCT02002949|Procedure|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
288594|NCT02001675|Device|magnetic resonance imaging (MRI)|
288595|NCT02001675|Device|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
288452|NCT02002936|Drug|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.~The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).~From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
288453|NCT02002923|Procedure|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
288454|NCT02002923|Drug|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
288455|NCT02002897|Device|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
288456|NCT02002897|Device|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
288457|NCT02002884|Drug|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
288458|NCT02002884|Drug|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% odium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
288459|NCT02002884|Drug|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
288460|NCT02002871|Device|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
288461|NCT02002858|Drug|Nicotine Patch|
288462|NCT02002858|Behavioral|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
288463|NCT02002858|Behavioral|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
288464|NCT02002845|Device|robotic surgery using the da Vinci Surgical System|
288465|NCT02002832|Drug|Lurasidone tablets|Lurasidone tablets (40or80mg/day) and Risperidone tablets(Placebo)
288466|NCT02002832|Drug|Risperidone tablets|Risperidone tablets(2-6mg/day) and Lurasidone tablets(Placebo)
288467|NCT02002819|Drug|levetiracetam|
288468|NCT02002806|Other|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
288469|NCT02002806|Other|Placebo Injection|
288470|NCT02002793|Other|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
288471|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
288472|NCT02002780|Behavioral|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
288473|NCT02002767|Drug|GS-5816|GS-5816 100 mg (2 x 50 mg tablets) administered orally
288474|NCT02002754|Drug|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
288475|NCT02002741|Drug|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
288476|NCT02002741|Drug|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
288477|NCT02002715|Drug|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
288478|NCT02002702|Drug|Serelaxin|Intravenous infusion
288479|NCT02002702|Drug|Placebo|Placebo
288480|NCT02002689|Drug|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
288481|NCT02002663|Drug|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
288482|NCT02002663|Drug|Methylprednisolone 1mg/kg|
288483|NCT02002663|Drug|saline 0.9%|
288484|NCT02002650|Drug|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
288596|NCT02001662|Procedure|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
288485|NCT02002650|Drug|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
288486|NCT02002637|Device|Latella Knee Implant System|
288487|NCT02002624|Device|PSI|
288488|NCT02002624|Device|Conventional instrumentation|
288489|NCT02002611|Drug|Lobeglitazone|
288490|NCT02002611|Drug|Warfarin|
288491|NCT02002598|Drug|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.~Dose escalation is as follows:~-1 | 60 mg/m2~| 70 mg/m2~| 70 mg/m2~| 90 mg/m2~| 90mg/m2~| 90 mg/m2"
288492|NCT02002598|Drug|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.~Dose Escalation is as follows:~-1 | 27 mg/m2~| 27 mg/m2~| 36 mg/m2~| 36 mg/m2~| 45 mg/m2~| 56 mg/m2"
288493|NCT02002598|Drug|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
288494|NCT02002585|Procedure|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
288495|NCT02002572|Other|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
288496|NCT02002533|Behavioral|Brief Behavioral Therapy|Undergo BBT intervention
288497|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo BBT intervention
288498|NCT02002533|Other|Educational Intervention|Undergo HEAL
288499|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo HEAL
288500|NCT02002507|Other|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
288501|NCT02002494|Other|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
288502|NCT02002481|Other|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
288503|NCT02002468|Other|Test result sent by letter|
288504|NCT02002468|Other|Test result conveyed by general practitioners|
288505|NCT02002455|Device|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
288506|NCT02002442|Other|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
288507|NCT02002429|Procedure|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
288508|NCT02002429|Procedure|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
288509|NCT02002429|Procedure|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
288510|NCT02002403|Drug|Danazol|
288511|NCT02002390|Drug|Fingolimod|A sphingosine-1-phosphate receptor regulator
288512|NCT02002377|Drug|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
288513|NCT02002364|Procedure|tracheal intubation|
288514|NCT02002325|Drug|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
288515|NCT02002325|Other|Standard care|Standard treatment for acute stroke without intravenous alteplase.
288516|NCT02002312|Drug|Lu-177-DOTA-girentuximab|"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.~Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
288517|NCT02002286|Drug|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
288518|NCT02002286|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
288519|NCT02002273|Procedure|Switching level of suction|
288520|NCT02002260|Device|Levonorgestrel intrauterine system|
288521|NCT02002260|Drug|Combined oral contraceptives|
288522|NCT02002247|Drug|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
288523|NCT02002247|Drug|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
288597|NCT02001662|Procedure|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
288598|NCT02001649|Genetic|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
288524|NCT02002234|Procedure|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
288525|NCT02002234|Procedure|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
288526|NCT02002221|Drug|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
288527|NCT02002221|Drug|Placebo|Matching placebo of vildagliptin 50 mg twice daily
288528|NCT02002221|Drug|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
288529|NCT02002221|Drug|Metformin|Patients continued their prescribed metformin dose, if applicable.
288530|NCT02002208|Drug|OC000459|Oral CRTH2 antagonist
288531|NCT02002195|Drug|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
288532|NCT02002195|Drug|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
288533|NCT02002182|Biological|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
288534|NCT02002169|Other|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
288535|NCT02002169|Other|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
288536|NCT02002156|Biological|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
288537|NCT02002156|Biological|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
288538|NCT02002156|Biological|NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
288539|NCT02002143|Behavioral|Group Appointments|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).~Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
288540|NCT02002143|Behavioral|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
288541|NCT02002130|Drug|Placebo GABA and Placebo GAD-alum|Maltodextrin as a placebo formulation for GABA Placebo GAD-alum injection
288542|NCT02002130|Drug|GABA and Placebo GAD-alum|Oral Active GABA with Placebo GAD-alum
288543|NCT02002130|Drug|Active Oral GABA and Active GAD-alum injection|Active Oral GABA and Active GAD-alum injection
288544|NCT02002117|Other|DNA mass|DNA mass spectrometry
288545|NCT02002091|Other|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
288546|NCT02002078|Drug|methylprednisolon|
288547|NCT02002065|Biological|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
288548|NCT02002065|Biological|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
288549|NCT02002052|Drug|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
288550|NCT02002052|Radiation|Standard Radiotherapy, 60 Gy in 30 fractions.|
288551|NCT02002052|Radiation|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
288552|NCT02002039|Drug|Erythropoietin|500 units /kg /day every other day for 5 doses
288553|NCT02002026|Procedure|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
288554|NCT02002000|Drug|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
288599|NCT02001649|Genetic|SNP genotyping|
288740|NCT02000505|Device|Metronome|5 minutes chest-compression-only CPR, using a metronome
288555|NCT02002000|Drug|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
288556|NCT02001987|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
288557|NCT02001987|Drug|Methotrexate|Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
288558|NCT02001987|Drug|csDMARDs|csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
288559|NCT02001974|Drug|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
288560|NCT02001948|Drug|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
288561|NCT02001948|Drug|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
288562|NCT02001948|Device|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
288563|NCT02001948|Drug|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
288564|NCT02001935|Drug|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
288565|NCT02001922|Other|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
288566|NCT02001909|Drug|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
288567|NCT02001909|Drug|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
288568|NCT02001896|Drug|gemcitabine; cisplatin or carboplatin; erlotinib|
288569|NCT02001896|Drug|erlotinib|
288570|NCT02001883|Drug|Association low-dose statin and nutraceuticals|
288571|NCT02001870|Procedure|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
288572|NCT02001870|Procedure|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
288573|NCT02001857|Drug|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
288574|NCT02001844|Device|Trial Foot Orthoses (FOs)|"Trial Group:~The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.~Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
288575|NCT02001844|Device|placebo foot orthoses (FOs)|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).~The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
288576|NCT02001831|Dietary Supplement|Supplement|
288577|NCT02001831|Dietary Supplement|Placebo|
288578|NCT02001818|Drug|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
288579|NCT02001792|Procedure|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
288580|NCT02001792|Device|pulse oximeter|
288581|NCT02001779|Device|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
288582|NCT02001779|Device|Conventional biliary SEMS|A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
288583|NCT02001766|Behavioral|Exercise training|
288584|NCT02001753|Device|CMR|
288585|NCT02001740|Drug|Triamcinalone (steroid) and lidocaine|receive once
288586|NCT02001740|Other|Lidocaine|receive once
288587|NCT02001727|Other|13C-Urea breath test for Helicobacter Pylori|
288588|NCT02001727|Other|Questionaire|
288589|NCT02001714|Behavioral|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
288590|NCT02001701|Procedure|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
288591|NCT02001688|Biological|Kamada-API for Inhalation, 80mg|
288592|NCT02001688|Drug|Placebo|
288593|NCT02001688|Biological|Kamada-API for Inhalation, 160mg|
288600|NCT02001636|Drug|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
288601|NCT02001636|Drug|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
288602|NCT02001623|Drug|Tisotumab Vedotin (HuMax-TF-ADC)|
288603|NCT02001610|Dietary Supplement|Acidophilus pearls|"Acidophilus pearls are encapsulated using patented process~Subjects take one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
288604|NCT02001610|Dietary Supplement|Hard shell gelatin capsules|"Hard-shelled gelatin capsule with same microbial formulation as pearl supplement~Subjects consume one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
288605|NCT02001584|Drug|Baclofen|
288606|NCT02001584|Drug|Memantine|
288607|NCT02001584|Drug|Placebo|
288608|NCT02001571|Drug|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
288609|NCT02001558|Drug|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
288610|NCT02001558|Other|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
288611|NCT02001519|Drug|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
288612|NCT02001506|Drug|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks~Docetaxel 75 mg/m2, every 3 weeks"
288613|NCT02001480|Device|12 lead Holter|12 lead Holter measurements will be performed for 7 days
288614|NCT02001480|Device|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
288615|NCT02001467|Other|Simulation-based training|
288616|NCT02001428|Drug|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
288617|NCT02001415|Other|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
288618|NCT02001415|Other|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
288619|NCT02001415|Other|Orthokeratology|Orthokeratology lenses.
288620|NCT02001389|Drug|EVP-6308|Arms 1, 2, 3, 4
288621|NCT02001376|Other|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
288622|NCT02001376|Other|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
288623|NCT02001376|Other|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
288624|NCT02001363|Drug|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
288625|NCT02001363|Drug|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
288626|NCT02001350|Other|Ultrasonography|
288627|NCT02001337|Other|medical chart review|baseline, quarterly follow-up for 24 months
288628|NCT02001337|Other|survey administration|baseline
288629|NCT02001337|Other|Specimen collection|baseline
288630|NCT02001324|Other|Web-based data collection|
288631|NCT02001324|Other|Paper-based data collection|
288632|NCT02001311|Drug|Chlorhexidine gluconate|
288633|NCT02001298|Drug|remifentanil|
288634|NCT02001298|Drug|nitroprusside|
288635|NCT02001285|Drug|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
288636|NCT02001272|Drug|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
288637|NCT02001272|Drug|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
288638|NCT02001272|Drug|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
288639|NCT02001259|Drug|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
288640|NCT02001259|Drug|epidural lidocaine|add into catheter at 48 hr after surgery
288641|NCT02001246|Behavioral|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
288642|NCT02001246|Behavioral|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
288643|NCT02001233|Biological|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
288687|NCT02000921|Other|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
288688|NCT02000921|Other|CN cigarettes|Experimental cigarettes with conventional nicotine content.
289109|NCT01997749|Dietary Supplement|Ketogenic meals|
288644|NCT02001220|Procedure|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.~The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
288645|NCT02001220|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
288646|NCT02001207|Other|Salivary cortisol test|
288647|NCT02001194|Behavioral|Individual Incentives|
288648|NCT02001194|Behavioral|Team Incentives|
288649|NCT02001194|Behavioral|Individual plus Team Incentives|
288650|NCT02001181|Drug|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
288651|NCT02001181|Drug|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
288652|NCT02001168|Drug|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
288653|NCT02001168|Drug|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
288654|NCT02001168|Drug|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
288655|NCT02001168|Drug|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
288656|NCT02001155|Procedure|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
288657|NCT02001142|Other|Exercise|single session of exercise
288658|NCT02001129|Behavioral|Automated Telephone System|Participants receive automated reminder phone calls.
288659|NCT02001129|Behavioral|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
288660|NCT02001129|Behavioral|Usual Care|Participants receive a standard reminder letter in the mail.
288661|NCT02001116|Other|Quality Improvement intervention|"Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.~Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
288662|NCT02001103|Drug|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.~The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
288663|NCT02001103|Drug|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
288664|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
288665|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Pain (CBT-P)|
288666|NCT02001064|Behavioral|Application + Standard of care|Care4Today mobile application will send automated medication alert messages to HIV+ persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV+ persons who experience adherence difficulties over standard of care.
288667|NCT02001051|Procedure|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
288668|NCT02001051|Other|Observation|Observation for 6 months prior to surgery
288669|NCT02001038|Other|Survey|
288670|NCT02001025|Device|Absorb scaffold|
288671|NCT02001025|Device|Xience stent|
288672|NCT02001012|Drug|Artemether-lumefantrine combination|
288673|NCT02001012|Drug|Chloroquine|
288674|NCT02000999|Other|brushing of bile duct strictures for cytology|
288675|NCT02000986|Behavioral|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
288676|NCT02000973|Drug|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
288677|NCT02000973|Drug|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
288678|NCT02000973|Drug|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
288679|NCT02000973|Drug|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
288680|NCT02000960|Drug|Triheptanoin|Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
288681|NCT02000947|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
288682|NCT02000947|Drug|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
288683|NCT02000947|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
288684|NCT02000934|Drug|TAK-659|"Dose escalation stage (Part A) Modified 3+3 dose escalation in participants with advanced solid tumor/lymphoma, with no effective treatment available projected.~Dose expansion stage (Part B) CLL, DLBCL, iNHL, MCL, and PTLD Expansion Cohorts in participants with relapsed or refractory diseases."
288685|NCT02000921|Other|VLNC cigarettes|Modified risk tobacco product
288686|NCT02000921|Other|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
288689|NCT02000908|Device|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
288690|NCT02000908|Other|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
288691|NCT02000908|Other|Physiotherapy|Chiropractic massage and lymphedema treatment
288692|NCT02000882|Drug|BKM120|
288693|NCT02000882|Drug|capecitabine|
288694|NCT02000882|Drug|Trastuzumab|
288695|NCT02000856|Dietary Supplement|Beetroot juice|
288696|NCT02000843|Procedure|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
288697|NCT02000830|Drug|Stannsoporfin|Stannsoporfin administered by intramuscular (IM) injection
288698|NCT02000830|Drug|Placebo|Matching placebo administered by IM injection
288699|NCT02000817|Biological|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
288700|NCT02000817|Biological|Placebo|Placebo is available 0.9% w/v sodium chloride
288701|NCT02000804|Drug|darapladib 160mg|drug
288702|NCT02000791|Other|Comparison of fibreoptic view|
288703|NCT02000778|Drug|EC17|
288704|NCT02000765|Drug|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing [14C] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
288705|NCT02000765|Drug|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing [14C] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
288706|NCT02000752|Device|Acupuncture|
288707|NCT02000752|Device|Sham acupuncture|Sham point acupuncture
288708|NCT02000739|Genetic|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
288709|NCT02000726|Drug|Placebo|
288710|NCT02000726|Drug|Citalopram|
288711|NCT02000726|Drug|Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session|Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
288712|NCT02000713|Other|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
288713|NCT02000713|Other|Clinical Exam|Brief neurological exam will be performed.
288714|NCT02000700|Drug|Canagliflozin 100 mg|One 100-mg tablet of canagliflozin orally administered daily for 14 days.
288715|NCT02000700|Drug|Canagliflozin 50 mg|One 50-mg tablet of canagliflozin orally administered daily for 14 days.
288716|NCT02000700|Drug|Canagliflozin 300 mg|One 300-mg tablet of canagliflozin orally administered daily for 14 days.
288717|NCT02000700|Drug|Placebo|One matching placebo tablet orally administered at baseline phase.
288718|NCT02000674|Drug|Succinylcholine : 1mg/kg|
288719|NCT02000674|Drug|Rocuronium : 1.2 mg/kg|
288720|NCT02000661|Device|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
288721|NCT02000635|Other|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
288722|NCT02000622|Drug|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
288723|NCT02000622|Drug|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:~Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days~Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days~Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days"
288724|NCT02000609|Drug|CHF 1535 NEXThaler 800/48|
288725|NCT02000609|Drug|CHF 1535 NEXThaler 200/12|
288726|NCT02000609|Drug|CHF 1535 NEXThaler PLACEBO|
288727|NCT02000609|Drug|CHF 1535 pMDI 200/12|
288728|NCT02000609|Drug|CHF1535 pMDI 800/48|
288729|NCT02000596|Drug|Trastuzumab plus Pertuzumab|
288730|NCT02000596|Drug|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
288731|NCT02000596|Drug|Chemotherapy with Eribulin|
288732|NCT02000583|Other|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
288733|NCT02000583|Other|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
288734|NCT02000570|Procedure|Sitting position (neurosurgery)|
288735|NCT02000544|Device|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
288736|NCT02000531|Drug|Erlotinib|150 mg oral dose of erlotinib given once daily
288737|NCT02000531|Drug|Chemotherapy|Cisplatin (75 mg/m^2 intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
288738|NCT02000518|Radiation|external beam radiotherapy|
288741|NCT02000505|Device|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
288742|NCT02000492|Behavioral|Football|
288743|NCT02000492|Behavioral|Running|
288744|NCT02000492|Behavioral|Circuit training|
288745|NCT02000479|Other|training|
288746|NCT02000466|Other|Data collection|Initial and follow-up data will be collected using questionnaires
288747|NCT02000453|Drug|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
288748|NCT02000440|Drug|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
288749|NCT02000427|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
288750|NCT02000414|Drug|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
288751|NCT02000401|Drug|Ketorolac Tromethamine|
288752|NCT02000388|Drug|Ketorolac Tromethamine|
288753|NCT02000388|Other|Standard of Care|
288754|NCT02000375|Drug|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
288755|NCT02000362|Biological|Stem cells|
288756|NCT02000349|Other|PGD|PGD using Next generation sequencing
288757|NCT02000336|Drug|Prednisolone|To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
288758|NCT02000336|Drug|Placebo|
288759|NCT02000323|Other|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day.~nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
288760|NCT02000323|Other|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.~The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.~After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.~Patients are targeted to receive calories for 25 kcal/kg/day."
288761|NCT02000297|Procedure|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
288762|NCT02000297|Procedure|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
288763|NCT02000271|Procedure|Vaginal packing|
288764|NCT02000271|Procedure|No vaginal packing|
288765|NCT02000258|Procedure|Double-bundle ACL reconstruction|
288766|NCT02000258|Device|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
288767|NCT02000245|Behavioral|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
288768|NCT02000245|Behavioral|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
288769|NCT02000219|Biological|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner.
288770|NCT02000206|Drug|Propofol|
288771|NCT02000206|Drug|Ketamine|
288772|NCT02000206|Drug|Alfentanil|
288773|NCT02000193|Drug|fulvestrant|"Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.~The treatment will continue until disease progression or intolerable AE."
288774|NCT02000180|Behavioral|Progressive Group|
288775|NCT02000154|Drug|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
288776|NCT02000141|Procedure|Endoscopic Mucosal Resection|
288777|NCT02000128|Device|bioimpedance monitoring|To assess the body composition using Multi-frequency bioelectrical impedance analysis
288778|NCT02000128|Other|clinical monitoring|clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
288779|NCT02000115|Device|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
288780|NCT02000115|Device|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
288781|NCT02000102|Drug|Intravitreal Injection of Aflibercept|
288782|NCT02000089|Drug|Human synthetic secretin|I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
288824|NCT01999868|Drug|ABA Placebo|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
288783|NCT02000076|Behavioral|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
288784|NCT02000076|Behavioral|Full sleep|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
288785|NCT02000050|Drug|FOLFOX4|FOLFOX4
288786|NCT02000050|Radiation|Tomotherapy|Tomotherapy
288787|NCT02000050|Procedure|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
288788|NCT02000037|Device|IR Reflexotherapy|"18 IR reflexotherapy sessions :~Once a week for 12 weeks at the beginning of the study~Once a week for 3 weeks, 9 months after the beginning of the study~Once a week for 3 weeks, 15 months after the beginning of the study"
288789|NCT02000037|Behavioral|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
288790|NCT02000024|Behavioral|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
288791|NCT02000024|Behavioral|National Diabetes Education Program|
288792|NCT02000011|Other|comprehensive geriatric assessment (CGA)|
288793|NCT02000011|Other|Geriatric intervention plan (GIP)|
288794|NCT01999998|Radiation|Radiotherapy|
288795|NCT01999985|Drug|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
288796|NCT01999985|Drug|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
288797|NCT01999985|Drug|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
288798|NCT01999985|Drug|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
288799|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
288800|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
288801|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
288802|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
288803|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
288804|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
288805|NCT01999959|Procedure|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
288806|NCT01999946|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
288807|NCT01999933|Radiation|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
288808|NCT01999933|Drug|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
288809|NCT01999933|Drug|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
288810|NCT01999933|Drug|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
288811|NCT01999920|Drug|Vilazodone|10mg to 40mg per day for 12 weeks
288812|NCT01999920|Drug|Placebo|One to two pills per day for 12 weeks
288813|NCT01999907|Dietary Supplement|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
288814|NCT01999907|Dietary Supplement|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
288815|NCT01999907|Other|Placebo|placebo given in a 2ml dose by mouth at baseline.
288816|NCT01999894|Drug|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
288817|NCT01999881|Behavioral|exercise intervention|Receive aerobic and exercise intervention
288818|NCT01999881|Procedure|standard follow-up care|Receive usual care
288819|NCT01999881|Procedure|quality-of-life assessment|Ancillary studies
288820|NCT01999881|Other|laboratory biomarker analysis|Correlative studies
288821|NCT01999868|Biological|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.~Dose:~Participants who weigh <= 100 kg at study entry will receive 45 mg of ustekinumab.~Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab."
288822|NCT01999868|Biological|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.~Dose:~125 mg sub-cutaneous injection"
288823|NCT01999868|Drug|UST Placebo|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
288825|NCT01999855|Other|Phoniatric tests|
288826|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
288827|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
288828|NCT01999842|Biological|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
288829|NCT01999829|Drug|citrate of caffeine|
288830|NCT01999829|Drug|placebo|
288831|NCT01999816|Behavioral|Lifestyle Redesign|Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
288832|NCT01999803|Drug|sNN0029|
288833|NCT01999803|Drug|Placebo|
288834|NCT01999790|Procedure|blepharotomy|upper eyelid surgery by blepharotomy
288835|NCT01999790|Procedure|posterior approach|upper eyelid surgery by posterior approach
288836|NCT01999777|Drug|USL261|
288837|NCT01999777|Drug|Placebo|
288838|NCT01999764|Drug|QLT091001|QLT091001 administered orally at multiple time points.
288839|NCT01999764|Other|Placebo|Placebo is administered orally at multiple time points.
288840|NCT01999751|Device|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
288841|NCT01999738|Drug|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.~EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
288842|NCT01999725|Drug|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
288843|NCT01999725|Drug|Placebo|Matching placebo capsules or matching suspension
288844|NCT01999712|Procedure|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
288845|NCT01999699|Biological|HEPLISAV|
288846|NCT01999686|Drug|DLBS3233|
288847|NCT01999686|Drug|Metformin XR|
288848|NCT01999686|Drug|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
288849|NCT01999686|Drug|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
288850|NCT01999673|Biological|bavituximab|
288851|NCT01999673|Drug|Docetaxel|
288852|NCT01999673|Other|Placebo (for bavituximab)|
288853|NCT01999660|Device|SpaceOAR™ implantation|
288854|NCT01999647|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
288855|NCT01999647|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
288856|NCT01999647|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
288857|NCT01999647|Procedure|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
288858|NCT01999647|Drug|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
288859|NCT01999634|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
288860|NCT01999595|Device|Control TENS|Control TENS was the application of electrical stimulation via skin with no current
288861|NCT01999595|Device|Sham TENS|"Sham TENS was the application of electrical stimulation via skin with no current on the participant, who was told TENS is at a turn-on level whether or not you feel it"
288862|NCT01999595|Device|High frequency TENS with large pads|High frequency TENS was delivered on large electrodes
288863|NCT01999595|Device|Low frequency TENS with large pads|Low frequency TENS was delivered on large electrodes
288864|NCT01999595|Device|High frequency TENS with small pads|High frequency TENS was delivered on small electrodes
288865|NCT01999595|Device|Low frequency TENS with small pads|Low frequency TENS was delivered on small electrodes
288866|NCT01999582|Biological|Sotatercept|Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
288867|NCT01999582|Biological|Sotatercept|Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
288868|NCT01999569|Drug|Letrozole|Letrozole administered daily through the time of ovulation.
288869|NCT01999543|Dietary Supplement|plant-based dietary supplement|
288870|NCT01999543|Other|Placebo|
288871|NCT01999530|Drug|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
288872|NCT01999517|Drug|Intravenous Nitroglycerin|
288873|NCT01999517|Drug|IV Fluids|
288874|NCT01999504|Other|PAL-2|meal
288875|NCT01999504|Other|TFH-1|Meal
288876|NCT01999504|Other|Reference|Meal
288916|NCT01999218|Drug|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
288877|NCT01999465|Device|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (300 us)~Ch1 Ramp+ (2 seconds)~On Time 1 (10 seconds)~Ch1 Ramp - (2 seconds)"
288878|NCT01999465|Device|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.~Rate(35 Hz)~Width (48 us)~Ch1 Ramp+ (0 seconds)~On Time 1 (0 seconds)~Ch1 Ramp - (0 seconds)"
288879|NCT01999452|Behavioral|Paleolithic diet|
288880|NCT01999452|Behavioral|Diabetes diet|
288881|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|"An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.~Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete."
288882|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
288883|NCT01999426|Other|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
288884|NCT01999413|Drug|OMEGAVEN|AML Study treatment induction phase
288885|NCT01999413|Drug|Daunorubicin|AML Study treatment induction phase
288886|NCT01999413|Drug|Cytarabine|AML Study treatment induction phase
288887|NCT01999400|Drug|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
288888|NCT01999400|Drug|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
288889|NCT01999400|Drug|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
288890|NCT01999400|Drug|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
288891|NCT01999387|Dietary Supplement|Allergenic food|
288892|NCT01999361|Drug|Myfortic|treatment with myfortic
288893|NCT01999348|Drug|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
288894|NCT01999335|Drug|Oprozomib|Study subjects will receive oprozomib tablets once daily on Days 1-5 and 15-19 (QD × 5 bimonthly schedule) of each 28-day treatment cycle.
288895|NCT01999335|Drug|Pomalidomide|Study subjects will receive pomalidomide once-daily on Days 1-21 of every 28-day cycle.
288896|NCT01999335|Drug|Dexamethasone|Study subjects will receive dexamethasone once daily on days 1-2, 8-9, 15-16, and 22-23 of every 28-day cycle.
288897|NCT01999322|Drug|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
288898|NCT01999322|Drug|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
288899|NCT01999309|Drug|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
288900|NCT01999309|Drug|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
288901|NCT01999296|Device|Use of Thunderbeat (TM) in laparoscopic surgery|
288902|NCT01999283|Other|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
288903|NCT01999283|Other|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
288904|NCT01999270|Drug|Irinotecan|"Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
288905|NCT01999270|Drug|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
288906|NCT01999270|Device|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
288907|NCT01999257|Other|Online pre-test genetic education tool|See Arm Descriptions above.
288908|NCT01999244|Behavioral|Self-monitoring skills|
288909|NCT01999244|Behavioral|Technology|
288910|NCT01999244|Behavioral|Interventionist Contact|
288911|NCT01999231|Biological|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
288912|NCT01999218|Drug|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
288913|NCT01999218|Drug|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
288914|NCT01999218|Drug|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
288915|NCT01999218|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
288917|NCT01999218|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
288918|NCT01999218|Drug|Sitagliptin|Open label, oral, once daily, rescue medication as required.
288919|NCT01999205|Behavioral|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
288920|NCT01999192|Drug|Tregalizumab|humanized anti-CD4 mAb
288921|NCT01999192|Drug|Placebo|identical end formulation buffer
288922|NCT01999179|Drug|Heparin, Low-Molecular-Weight, or direct oral anticoagulants|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
288923|NCT01999166|Radiation|radiography (X-ray)|
288924|NCT01999166|Genetic|DNA sampling|
288925|NCT01999153|Drug|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
288926|NCT01999153|Drug|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
288927|NCT01999114|Drug|Buprenorphine transdermal patch|Buprenorphine patch applied transdermally
288928|NCT01999114|Drug|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
288929|NCT01999114|Drug|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
288930|NCT01999114|Drug|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
288931|NCT01999101|Drug|Px-104|28 days treatment
288932|NCT01999088|Other|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
288933|NCT01999088|Other|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
288934|NCT01999075|Device|Lung Volume Recruitment (LVR)|LVR will be used twice per day
288935|NCT01999075|Other|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
288936|NCT01999062|Other|IMRT + CT + MR scan|
288937|NCT01999023|Dietary Supplement|Low protein formula group|Low protein formula formula (28.5 g) twice a day
288938|NCT01999010|Device|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
288939|NCT01998997|Behavioral|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
288940|NCT01998984|Drug|ingenol mebutate|
288941|NCT01998984|Other|Placebo|
288942|NCT01998971|Drug|Daratumumab|Administered by intravenous infusion in combination with the applicable backbone treatment.
288943|NCT01998971|Drug|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
288944|NCT01998971|Drug|Pomalidomide|Administered orally in accordance with product labeling and local standards.
288945|NCT01998971|Drug|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
288946|NCT01998971|Drug|Melphalan|Administered orally in accordance with product labeling and local standards.
288947|NCT01998971|Drug|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
288948|NCT01998971|Drug|Thalidomide|Administered orally in accordance with product labeling and local standards.
288949|NCT01998971|Drug|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
288950|NCT01998971|Drug|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
288951|NCT01998971|Drug|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
288952|NCT01998971|Drug|Lenalidomide|Administered orally in accordance with product labeling and local standards.
288953|NCT01998971|Drug|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
288954|NCT01998958|Drug|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
288955|NCT01998958|Drug|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
288956|NCT01998958|Drug|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
288957|NCT01998958|Drug|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
288958|NCT01998958|Drug|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
289073|NCT01998074|Dietary Supplement|extensively hydrolyzed rice protein formula|
288959|NCT01998945|Behavioral|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
288960|NCT01998945|Behavioral|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
288961|NCT01998919|Drug|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
288962|NCT01998919|Drug|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
288963|NCT01998919|Drug|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
288964|NCT01998919|Drug|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
288965|NCT01998919|Drug|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
288966|NCT01998906|Drug|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
288967|NCT01998906|Drug|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
288968|NCT01998906|Drug|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
288969|NCT01998906|Drug|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
288970|NCT01998893|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
288971|NCT01998880|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
288972|NCT01998880|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
288973|NCT01998880|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
288974|NCT01998854|Device|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
288975|NCT01998841|Drug|Crenezumab|Crenezumab will be administered subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
288976|NCT01998841|Drug|Placebo|Placebo matched to crenezumab will be administered subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.
288977|NCT01998828|Drug|Momelotinib|Momelotinib tablet administered orally once daily
288978|NCT01998815|Procedure|Laparoscopic Roux-en-Y gastric bypass surgery|
288979|NCT01998802|Drug|Active Comparator EBI-005|
288980|NCT01998802|Drug|Placebo Comparator|
288981|NCT01998789|Drug|Everolimus|Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
288982|NCT01998789|Drug|Standard Tacrolimus|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.~Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
288983|NCT01998776|Drug|Misoprostol|Misoprostol 200ug four times daily
288984|NCT01998776|Drug|Placebo|Placebo Starch four times daily
288985|NCT01998763|Dietary Supplement|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
288986|NCT01998763|Dietary Supplement|Vitamin D3|Vitamin D3 2000 IU per day
288987|NCT01998724|Behavioral|Tai Chi|24 week tai chi intervention designed for individuals with COPD
288988|NCT01998724|Behavioral|Group Walking|24 week group walking intervention
288989|NCT01998711|Behavioral|Memory group|Five 1-1.5 hour weekly session of memory training
288990|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
288991|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
288992|NCT01998685|Drug|Propofol|
288993|NCT01998685|Drug|remifentanyl|
288994|NCT01998685|Drug|Midazolam|
288995|NCT01998685|Drug|Fentanyl|
288996|NCT01998685|Drug|Sevoflurane|
288997|NCT01998672|Drug|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
288998|NCT01998672|Drug|Placebo|Drinking solution
288999|NCT01998659|Drug|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
289000|NCT01998659|Drug|Placebo|Oral drinking solution
289001|NCT01998646|Drug|ASP4058|Oral tablet
289002|NCT01998646|Drug|Placebo|Oral tablet
289003|NCT01998633|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
289004|NCT01998620|Drug|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
289005|NCT01998620|Drug|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
289006|NCT01998620|Drug|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
289007|NCT01998607|Other|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
289074|NCT01998061|Drug|EGFR tyrosine kinase inhibitor|Arm A
289110|NCT01997736|Device|Ablation|
289008|NCT01998594|Procedure|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
289009|NCT01998581|Device|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
289010|NCT01998581|Device|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
289011|NCT01998568|Other|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
289012|NCT01998555|Other|CBT|
289013|NCT01998542|Biological|AlloVax|Personalized anti-cancer vaccine Intradermal injection AlloSimt followed immediately by the intradermal injection of CRCL
289014|NCT01998542|Biological|CRCL|autologous tumor-derived chaperone protein mixture
289015|NCT01998542|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
289016|NCT01998542|Other|PlasmaLyteA with 1% human serum albumin|PlasmaLyteA with 1% human serum albumin, packaged, labeled and shipped to appear the same as the active experimental products and under the same storage conditions.
289017|NCT01998529|Drug|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
289018|NCT01998529|Drug|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
289019|NCT01998503|Drug|Bortezomib|
289020|NCT01998503|Drug|dexamethasone|Given orally
289021|NCT01998503|Biological|filgrastim|Given subcutaneous
289022|NCT01998503|Procedure|autologous hematopoietic stem cell transplantation (ASCT)|Given on day 0
289023|NCT01998503|Drug|Melphalan|
289024|NCT01998490|Other|Animal-assisted activity|
289025|NCT01998490|Other|Robot-assisted activity|
289026|NCT01998477|Biological|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain [A/H1N1-like, A/H3N2-like, and B-like]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
289027|NCT01998477|Biological|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain [A/ H1N1-like, A/H3N2-like, and B-like]) IM injection recommended by the WHO for the 2013‑2014 influenza season in the Northern Hemisphere.
289028|NCT01998451|Drug|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
289029|NCT01998438|Drug|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
289030|NCT01998399|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
289031|NCT01998399|Drug|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
289032|NCT01998386|Other|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
289033|NCT01998386|Other|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
289034|NCT01998386|Other|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
289035|NCT01998386|Other|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
289075|NCT01998061|Drug|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
289190|NCT01996956|Other|volume expansion|fluid loading of 10 ml/kg colloid or blood product
289036|NCT01998373|Behavioral|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
289037|NCT01998360|Procedure|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
289038|NCT01998360|Procedure|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
289039|NCT01998347|Drug|Paclitaxel liposome|
289040|NCT01998347|Drug|Cisplatin|
289041|NCT01998347|Drug|5-fluorouracil|
289042|NCT01998334|Other|CVVH 6h|CVVH 6h for first three days
289043|NCT01998334|Other|CVVH 10h|CVVH 10h for first three days
289044|NCT01998334|Other|CVVHDF 6h|CVVHDF 6h for first three days
289045|NCT01998321|Other|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation & PSI designing and PSI production
289046|NCT01998321|Other|conventional technique for TKA|
289047|NCT01998308|Drug|Crespine gel|50 Knees will have single injection of Crespine gel
289048|NCT01998308|Drug|Intragel|50 Knees will have single injection of 2 ampules of Intragel
289049|NCT01998308|Drug|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
289050|NCT01998308|Drug|Monovisc|50 Knees will have single injection of Monovisc
289051|NCT01998295|Drug|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
289052|NCT01998256|Device|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
289053|NCT01998243|Device|Intragastric Balloon (IGB), group A|the intervention was to place An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM) endoscopically under conscious sedation and was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors (PPI), and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
289054|NCT01998243|Other|diet, control group B|the intervention in this cotrol group B was only 1200 Kilocalories (Kcal) diet
289055|NCT01998230|Dietary Supplement|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
289056|NCT01998217|Drug|Remifentanil|Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
289057|NCT01998217|Drug|Flurbiprofen and remifentanil|Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
289058|NCT01998191|Other|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
289059|NCT01998191|Other|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
289060|NCT01998191|Other|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.~to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
289061|NCT01998165|Drug|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
289062|NCT01998152|Procedure|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
289063|NCT01998126|Drug|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
289064|NCT01998126|Drug|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
289065|NCT01998126|Drug|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
289066|NCT01998126|Drug|Nivolumab|
289067|NCT01998113|Drug|Glyburide vs Insulin trials|Affecting groups 1 and 2
289068|NCT01998113|Drug|Metformin vs Insulin trials|Affecting groups 3 and 4
289069|NCT01998113|Drug|Metformin vs Glyburide trials|Affecting groups 5 and 6
289070|NCT01998100|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
289071|NCT01998100|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
289072|NCT01998087|Behavioral|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
289076|NCT01998048|Procedure|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
289077|NCT01998048|Procedure|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
289078|NCT01998035|Drug|Romidepsin|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.~Dose escalation (10, 14 mg/m2)"
289079|NCT01998035|Drug|Oral 5-Azacitidine|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.~Dose escalation (100, 200, 300 mg)"
289080|NCT01998009|Other|fecal occult blood tests|
289081|NCT01997983|Device|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
289082|NCT01997970|Behavioral|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
289083|NCT01997970|Behavioral|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
289084|NCT01997957|Drug|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
289085|NCT01997944|Biological|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
289086|NCT01997944|Biological|Pegasys|180 mcg dosing every week
289087|NCT01997931|Device|Bispectral Index Sedation monitor|
289088|NCT01997905|Device|AtriClip LAA Exclusion Device|
289089|NCT01997879|Drug|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
289090|NCT01997866|Other|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
289091|NCT01997866|Other|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
289092|NCT01997853|Drug|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
289093|NCT01997853|Drug|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
289094|NCT01997840|Drug|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
289095|NCT01997827|Device|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
289096|NCT01997827|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
289097|NCT01997814|Drug|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
289098|NCT01997814|Drug|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
289099|NCT01997801|Drug|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
289100|NCT01997801|Drug|NS infusion|Normal saline will be infused intraoperatively.
289101|NCT01997788|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
289102|NCT01997788|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
289103|NCT01997788|Drug|Demerol on demand|Demerol 25 mg intravenously when pain scores more than 5.
289104|NCT01997775|Drug|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 > 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
289105|NCT01997762|Dietary Supplement|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
289106|NCT01997762|Dietary Supplement|Placebo|
289107|NCT01997749|Dietary Supplement|Ketocal 4:1 (Nutricia)|
289108|NCT01997749|Dietary Supplement|Control diet: Regular diet offered at the hospitals|
289111|NCT01997723|Device|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
289112|NCT01997723|Other|Polysomnography|One attended diagnostic sleep study.
289113|NCT01997723|Device|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
289114|NCT01997723|Device|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
289115|NCT01997710|Device|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
289116|NCT01997710|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
289117|NCT01997697|Other|behavior change program|behavior change program among patients with obesity
289118|NCT01997684|Procedure|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.~If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.~Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.~Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
289119|NCT01997684|Procedure|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
289120|NCT01997671|Other|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
289121|NCT01997658|Drug|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
289122|NCT01997658|Drug|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
289123|NCT01997645|Procedure|LIFT|
289124|NCT01997645|Procedure|RAF|
289125|NCT01997632|Biological|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
289126|NCT01997632|Biological|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
289127|NCT01997606|Other|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
289128|NCT01997606|Other|placebo|
289129|NCT01997593|Drug|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
289130|NCT01997580|Drug|escitalopram|SSRI antidepressant
289131|NCT01997567|Drug|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
289132|NCT01997567|Drug|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
289133|NCT01997554|Other|Blood sample|An extra blood sample of 10 ml is collected
289134|NCT01997528|Device|Change of blood flow or sweep gas flow ( ILA Activve)|
289135|NCT01997515|Drug|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
289136|NCT01997515|Drug|placebo|Group P (placebo) will receive the same amount of saline.
289137|NCT01997502|Device|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.~Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.~No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
289138|NCT01997502|Other|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
289139|NCT01997489|Drug|Enzyme replacement|Observational study of current treatment and with no comparative groups
289191|NCT01996943|Drug|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
289192|NCT01996943|Drug|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
289140|NCT01997476|Procedure|Combined EUS, e-PFT and sEUS Testing|"advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.~Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
289141|NCT01997463|Drug|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
289142|NCT01997437|Device|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
289143|NCT01997424|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
289144|NCT01997424|Device|FibroScan, Echosens, Paris, France|
289145|NCT01997411|Drug|Nasal Glucagon|
289146|NCT01997411|Drug|Intramuscular Glucagon|
289147|NCT01997385|Procedure|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
289148|NCT01997385|Procedure|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
289149|NCT01997372|Drug|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) ＞1×109/L.
289150|NCT01997333|Drug|CDX-011|
289151|NCT01997333|Drug|Capecitabine|
289152|NCT01997320|Other|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
289153|NCT01997320|Other|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
289154|NCT01997294|Drug|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
289155|NCT01997281|Dietary Supplement|dietary fiber-enriched cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)~one serving of steamed egg is added for dinner and breakfast"
289156|NCT01997281|Other|conventional cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)~amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)~one serving (40g) of steamed egg is added for dinner and breakfast"
289157|NCT01997268|Drug|Placebo|Corn Oil
289158|NCT01997268|Drug|SC401B 2 capsules|
289159|NCT01997268|Drug|SC401B 4 capsules|
289160|NCT01997268|Drug|SC401B 6 capsules|
289161|NCT01997255|Drug|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
289162|NCT01997229|Biological|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
289163|NCT01997229|Drug|Placebo|Placebo
289164|NCT01997216|Device|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
289165|NCT01997216|Device|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
289166|NCT01997203|Drug|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
289167|NCT01997190|Biological|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
289168|NCT01997164|Drug|REGN910-3|
289169|NCT01997164|Drug|REGN910|
289170|NCT01997164|Drug|Intravitreal Aflibercept Injection (IAI)|
289171|NCT01997151|Behavioral|Healthy Pregnancy: Step by Step|
289172|NCT01997138|Drug|Anakinra 100 mg in 2 ml saline IA|
289173|NCT01997125|Device|Neural Bridge System|Implanted device
289174|NCT01997112|Drug|Paracetamol|
289175|NCT01997112|Drug|Placebo oral capsule|
289176|NCT01997099|Device|CADD®-Solis VIP Pump|
289177|NCT01997099|Device|CADD™ Solis Medication Safety Software Administrator|
289178|NCT01997086|Procedure|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
289179|NCT01997086|Procedure|Microendoscopic discectomy (MED)|Microendoscopic discectomy
289180|NCT01997060|Behavioral|Intensive Lifestyle Intervention|
289181|NCT01997034|Behavioral|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
289182|NCT01997021|Other|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
289183|NCT01997021|Other|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
289184|NCT01997021|Other|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
289185|NCT01997008|Behavioral|Intervention|Positive Affect Skills Training
289186|NCT01996995|Device|Nd:YAG laser pulse therapy|
289187|NCT01996995|Device|Sham procedure|Sham procedure
289188|NCT01996982|Device|CCS Device|Core Cooling System Device
289189|NCT01996969|Drug|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
289193|NCT01996930|Drug|Haelan tape (steroid impregnated tape)|Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
289194|NCT01996930|Drug|Silver Nitrate|Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
289195|NCT01996917|Device|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
289196|NCT01996904|Procedure|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
289197|NCT01996904|Procedure|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
289198|NCT01996891|Other|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
289199|NCT01996865|Drug|Lenalidomide|
289200|NCT01996865|Drug|Rituximab|
289201|NCT01996852|Behavioral|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.~Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.~Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
289202|NCT01996852|Drug|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.~To increase external validity, participants will be given the choice of using Sildenafil in the study."
289203|NCT01996852|Device|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).~The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
289204|NCT01996839|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
289205|NCT01996839|Drug|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
289206|NCT01996839|Drug|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
289207|NCT01996839|Drug|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
289208|NCT01996826|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
289209|NCT01996826|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
289210|NCT01996813|Device|Thigh-high compression stockings|The intervention in this study are thigh-high compression stockings manufactured by Covidien.
289211|NCT01996800|Procedure|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
289212|NCT01996800|Procedure|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
289213|NCT01996787|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
289214|NCT01996787|Device|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
289215|NCT01996761|Drug|porcine brain peptide (Cerebrolysin)|
289216|NCT01996761|Drug|Placebo|
289217|NCT01996748|Drug|DF277|Two administrations daily for 7 days
289218|NCT01996748|Drug|Placebo|Two administrations daily for 7 days
289219|NCT01996735|Drug|Ticagrelor 180 mg single dose|
289220|NCT01996735|Drug|Placebo|
289221|NCT01996709|Device|Hydrogen peroxide-based contact lens solution|
289222|NCT01996709|Device|Habitual contact lens solution|Biguanide-preserved
289223|NCT01996709|Device|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
289224|NCT01996696|Drug|Metformin|Metformin 500 mg PO TID x 30-36 months
289225|NCT01996696|Drug|Placebo|Identical placebo TID x 30-36 months
289226|NCT01996683|Drug|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation"
289228|NCT01996644|Drug|Placebo vs Setraline|Placebo
289229|NCT01996644|Drug|Setraline|250mg DCS
289230|NCT01996618|Drug|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
289231|NCT01996605|Drug|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
289232|NCT01996605|Drug|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
289233|NCT01996605|Drug|Placebo|placebo will be administered spinally
289234|NCT01996579|Dietary Supplement|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
289235|NCT01996579|Other|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
289236|NCT01996540|Other|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
289237|NCT01996527|Device|3-Tesla magnetic resonance imaging|3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
289238|NCT01996527|Device|CEST-MRI|Undergo CEST-MRI
289239|NCT01996527|Device|DW-MRI|Undergo DWI-MRI
289240|NCT01996527|Device|DCE-MRI|Undergo DCE-MRI
289241|NCT01996527|Device|DSC-MRI|Undergo DSC-MRI
289242|NCT01996527|Drug|IV administration of gadolinium-containing contrast agent|Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
289243|NCT01996514|Dietary Supplement|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
289244|NCT01996514|Dietary Supplement|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
289245|NCT01996514|Behavioral|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
289246|NCT01996514|Behavioral|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
289247|NCT01996501|Drug|Olanzapine Orally Disintegrating 5mg Tablets|
289248|NCT01996488|Drug|Olanzapine Orally Disintegrating Tablets 5mg|
289249|NCT01996475|Drug|Escitalopram Oxalate Tablets|
289250|NCT01996462|Drug|Escitalopram Oxalate Tablets|
289251|NCT01996449|Drug|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
289252|NCT01996449|Drug|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
289253|NCT01996449|Procedure|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
289254|NCT01996449|Procedure|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
289255|NCT01996449|Procedure|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
289256|NCT01996449|Procedure|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
289257|NCT01996449|Procedure|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
289258|NCT01996449|Procedure|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
289259|NCT01996436|Drug|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
289260|NCT01996436|Drug|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
289261|NCT01996436|Drug|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
289262|NCT01996423|Dietary Supplement|Vitamin D3|
289263|NCT01996423|Dietary Supplement|Placebo|
289264|NCT01996410|Device|Acupuncture|
289265|NCT01996397|Procedure|Cardiac resynchronization therapy device implantation|
289266|NCT01996384|Procedure|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
289267|NCT01996384|Procedure|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
289268|NCT01996384|Drug|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
289269|NCT01996371|Device|Pedicle Screw|
289270|NCT01996358|Drug|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
289271|NCT01996358|Drug|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
289272|NCT01996358|Drug|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
289273|NCT01996345|Procedure|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
289274|NCT01996332|Drug|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
289275|NCT01996319|Drug|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
289276|NCT01996319|Drug|Placebo|Placebo once a day via Breezhaler® device
289277|NCT01996306|Biological|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
289278|NCT01996306|Drug|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
289279|NCT01996306|Drug|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
289280|NCT01996306|Drug|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
289281|NCT01996306|Drug|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
289282|NCT01996306|Biological|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
289283|NCT01996306|Drug|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
289284|NCT01996306|Drug|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
289285|NCT01996293|Drug|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
289286|NCT01996280|Behavioral|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
289287|NCT01996280|Behavioral|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
289288|NCT01996267|Drug|PTC+Pertuzumab|Cycle repeated every 21 days
289289|NCT01996267|Drug|FEC-T+Pertuzumab|Cycle is repeated every 21 days
289290|NCT01996254|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
289291|NCT01996241|Behavioral|Multi-level, structural and norms-based intervention|Receive multi-level, structural and norms-based intervention
289292|NCT01996228|Device|Stem Cell Educator|
289293|NCT01996202|Drug|Ipilumimab|
289294|NCT01996202|Radiation|Radiation|
289295|NCT01996189|Device|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
289296|NCT01996189|Device|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
289297|NCT01996176|Behavioral|Intervention group|"The intervention consists of four components, which as described below:~Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.~Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.~Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.~Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project."
289298|NCT01996176|Behavioral|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
289299|NCT01996150|Drug|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
289300|NCT01996137|Device|VASST II treadmill|Supervised treadmill training under physiotherapist
289301|NCT01996124|Drug|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
289302|NCT01996124|Drug|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
289303|NCT01996111|Procedure|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
289304|NCT01996111|Procedure|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
289305|NCT01996111|Procedure|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
289306|NCT01996111|Procedure|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
289307|NCT01996098|Drug|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
289308|NCT01996098|Drug|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
289309|NCT01996085|Drug|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:~hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2)~hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~balanced profile"
289310|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
289311|NCT01996085|Drug|Nebivolol|"Beta-blocker recommended in case of:~1.hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min)"
289312|NCT01996085|Drug|Indapamide/hydrochlorothiazide|"hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm)~hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
289313|NCT01996085|Drug|Amlodipine|1/ SVRI > 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
289314|NCT01996085|Drug|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
289315|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
289316|NCT01996085|Drug|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
289317|NCT01996085|Drug|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
289318|NCT01996085|Drug|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
289319|NCT01996072|Drug|EC17|
289320|NCT01996059|Procedure|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
289321|NCT01996059|Procedure|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
289322|NCT01996046|Other|FDG PET/CT scan|[18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
289323|NCT01995981|Drug|Pazopanib|
289324|NCT01995968|Other|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:~FGR was mentioned in medical charts~OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)~OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts~OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)~OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
289325|NCT01995955|Procedure|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
289326|NCT01995929|Procedure|transnasal functional endoscopy|
289327|NCT01995916|Behavioral|Mindfulness Intervention|The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
289328|NCT01995916|Behavioral|Social Support Group|The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
289329|NCT01995903|Diagnostic Test|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
289330|NCT01995890|Drug|nepafenac|
289376|NCT01995487|Device|BioNIR|drug-eluting stent
289377|NCT01995487|Device|Resolute|drug-eluting stent
289378|NCT01995474|Other|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
289331|NCT01995877|Procedure|Subjects scheduled for IVC filter placement|"Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.~The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.~The IVUS procedure will add about 30-45 minutes to the filter placement procedure."
289332|NCT01995864|Behavioral|CTI-TS|"The following briefly describes the three phases of CTI-TS:~Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.~Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.~Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual."
289333|NCT01995838|Drug|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
289334|NCT01995838|Drug|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
289335|NCT01995825|Drug|lamotrigine|lamotrigine tablet 100mg twice a day for two weeks
289336|NCT01995812|Behavioral|Hula and heart health education|
289337|NCT01995799|Device|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
289338|NCT01995786|Device|Goal Directed Fluid Therapy FloTrac/Vigileo|
289339|NCT01995734|Drug|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
289340|NCT01995721|Biological|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
289341|NCT01995708|Biological|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10^6 LCs per vaccine x 3.
289342|NCT01995708|Other|Standard of care|No vaccines
289343|NCT01995695|Biological|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
289344|NCT01995695|Biological|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
289345|NCT01995669|Other|Laboratory Biomarker Analysis|Correlative studies
289346|NCT01995669|Drug|Lenalidomide|Given PO
289347|NCT01995669|Biological|Obinutuzumab|Given IV
289348|NCT01995656|Drug|Placebo - Capsule|Administered orally
289349|NCT01995656|Drug|LY3108743 - Capsule|Administered orally
289350|NCT01995656|Drug|Placebo - Solution|Administered orally
289351|NCT01995656|Drug|LY3108743 - Solution|Administered orally
289352|NCT01995643|Dietary Supplement|Active Capsule|GSE Capsule
289353|NCT01995643|Dietary Supplement|Placebo Capsule|Placebo Capsule
289354|NCT01995630|Device|AMO Tecnis ZA9003|
289355|NCT01995630|Device|AMO Sensar AR40e|
289356|NCT01995617|Biological|Placebo|normal saline, 0.5 mL per dose
289357|NCT01995617|Biological|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
289358|NCT01995617|Biological|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
289359|NCT01995617|Biological|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
289360|NCT01995617|Biological|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
289361|NCT01995617|Biological|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
289362|NCT01995617|Biological|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
289363|NCT01995604|Other|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
289364|NCT01995604|Other|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
289365|NCT01995578|Drug|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
289366|NCT01995565|Other|PLR|
289367|NCT01995552|Device|External Loop Recorder|
289368|NCT01995539|Behavioral|therapy regimen|Subjects will be recommend changes in therapy regimens.
289369|NCT01995526|Drug|Insulin Peglispro|
289370|NCT01995513|Drug|Enzalutamide|160 mg by mouth once daily
289371|NCT01995513|Drug|Abiraterone|1000 mg by mouth once daily
289372|NCT01995513|Drug|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
289373|NCT01995513|Drug|Prednisone|5 mg by mouth twice daily
289374|NCT01995500|Device|BioNIR|drug-eluting stent
289375|NCT01995500|Device|Resolute|drug-eluting stent
289379|NCT01995474|Other|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
289380|NCT01995461|Drug|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
289381|NCT01995448|Biological|Blood test|Residue of blood further to NFS.
289382|NCT01995435|Device|Telemedicine refraction|
289383|NCT01995435|Device|Traditional refraction|
289384|NCT01995422|Other|Physical activity program|One hour sessions of active walking occurring three times a week during three months
289385|NCT01995409|Behavioral|No smoking material provided in households with newborn infants|
289386|NCT01995396|Procedure|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
289387|NCT01995396|Procedure|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
289388|NCT01995383|Other|LS followed by NS diet condition|LS diet period followed by NS diet period
289389|NCT01995383|Other|NS followed by LS diet condition|NS diet period followed by LS diet period
289390|NCT01995383|Drug|Placebo|Single oral administrations
289391|NCT01995383|Drug|Placebo|2 single oral administrations
289392|NCT01995383|Drug|RO6836191|Orally administered, single ascending doses
289393|NCT01995383|Drug|RO6836191|2 single oral doses
289394|NCT01995383|Drug|RO6836191|Intravenous administration
289395|NCT01995370|Drug|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
289396|NCT01995370|Drug|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
289397|NCT01995370|Drug|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
289398|NCT01995357|Device|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
289399|NCT01995357|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
289400|NCT01995357|Device|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
289401|NCT01995344|Drug|Cyclophosphamide|
289402|NCT01995344|Drug|Fludarabine|
289403|NCT01995344|Genetic|Tumour Infiltrating Lymphocytes|
289404|NCT01995344|Drug|Interleukin-2|
289405|NCT01995331|Drug|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.~Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was >1×109/L."
289406|NCT01995318|Other|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
289407|NCT01995305|Genetic|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
289408|NCT01995305|Genetic|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
289409|NCT01995292|Device|bronchoscope|
289410|NCT01995292|Device|Enk Fiberoptic Atomizer|
289411|NCT01995279|Device|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
289412|NCT01995279|Other|Sham Ultrasound|Ultrasound turned off.
289413|NCT01995266|Drug|Asunaprevir|
289414|NCT01995266|Drug|Daclatasvir|
289415|NCT01995253|Device|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
289416|NCT01995253|Device|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
289417|NCT01995240|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
289418|NCT01995227|Biological|AlloVax|Personalized anti-cancer vaccine
289419|NCT01995227|Biological|CRCL|Personalized anti-cancer vaccine
289420|NCT01995227|Biological|AlloStim|ID injections IV infusion
289421|NCT01995214|Drug|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
289422|NCT01995214|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
289423|NCT01995201|Drug|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
289424|NCT01995201|Drug|methotrexate|stable dose
289425|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
289509|NCT01994629|Biological|MenACWY-CRM|MenACWY-CRM
289426|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
289427|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
289428|NCT01995188|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
289429|NCT01995188|Drug|Carboplatin|Carboplatin fixed dose of AUC=6 mg/mL*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
289430|NCT01995188|Drug|DNIB0600A|DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
289431|NCT01995175|Procedure|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
289432|NCT01995175|Procedure|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
289433|NCT01995175|Other|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
289434|NCT01995162|Device|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
289435|NCT01995149|Behavioral|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
289436|NCT01995136|Drug|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
289437|NCT01995123|Behavioral|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
289438|NCT01995123|Behavioral|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
289439|NCT01995123|Behavioral|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
289440|NCT01995110|Other|high-fat meal A|
289441|NCT01995110|Other|high-fat meal B|
289442|NCT01995110|Other|high-fat meal C|
289443|NCT01995097|Behavioral|Scheduled Gradual Reduction Text Messages|
289444|NCT01995097|Behavioral|Support Text Messages|
289445|NCT01995084|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
289446|NCT01995071|Drug|ABT-493|Tablet
289447|NCT01995071|Drug|ABT-530|Tablet
289448|NCT01995071|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
289449|NCT01995071|Drug|Ribavirin (RBV)|Tablet
289450|NCT01995058|Drug|cabozantinib|Tablets taken orally
289451|NCT01995058|Drug|abiraterone|Tablets taken orally daily
289452|NCT01995058|Drug|prednisone|Tablets taken orally twice daily
289453|NCT01995045|Drug|Triamcinolone|Retrobulbar anesthesia
289454|NCT01995045|Drug|Bupivicaine Hydrochloride|Retrobulbar anesthesia
289455|NCT01995032|Drug|750 mg metformin and 7.5 g L-citrulline daily p.o.|
289456|NCT01995032|Drug|Placebo|
289457|NCT01995019|Drug|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
289458|NCT01995019|Drug|Physiologic saline|1 ml intra-articular placebo
289459|NCT01995006|Drug|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
289460|NCT01995006|Drug|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
289461|NCT01994993|Drug|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
289462|NCT01994993|Drug|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
289463|NCT01994993|Drug|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
289464|NCT01994993|Drug|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
289465|NCT01994993|Drug|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
289466|NCT01994980|Drug|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
289467|NCT01994967|Drug|Levobupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
289468|NCT01994967|Drug|Bupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
289469|NCT01994954|Other|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
289470|NCT01994941|Drug|Clopidogrel|"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."
289471|NCT01994941|Drug|Ticagrelor|"A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used."
289472|NCT01994928|Device|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
289473|NCT01994928|Device|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
289474|NCT01994928|Procedure|Intubation|Intubation
289475|NCT01994915|Other|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
289476|NCT01994902|Device|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
289477|NCT01994902|Device|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
289478|NCT01994889|Drug|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
289479|NCT01994889|Drug|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
289480|NCT01994889|Drug|Placebo|Placebo in soft gel capsules administered once a day for 30 months
289481|NCT01994876|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
289482|NCT01994876|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
289483|NCT01994863|Device|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
289484|NCT01994863|Device|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products~Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
289485|NCT01994850|Drug|brentuximab vedotin|Trade name: Adcetris
289486|NCT01994837|Drug|ABT-199|Tablet
289487|NCT01994824|Drug|rabbit antithymocyte globulin|Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
289488|NCT01994785|Diagnostic Test|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
289489|NCT01994772|Procedure|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
289490|NCT01994772|Procedure|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
289491|NCT01994759|Other|Training|Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
289492|NCT01994759|Drug|Glucocorticosteroid injection|"Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.~Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections)."
289493|NCT01994759|Behavioral|Reduction in impact|advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
289494|NCT01994746|Drug|Nasal Glucagon|
289495|NCT01994746|Drug|Intramuscular Glucagon|
289496|NCT01994733|Drug|Calcium carbonate ( Intensive phosphate control)|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
289497|NCT01994733|Drug|Calcium carbonate (Liberalized phosphate control)|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
289498|NCT01994720|Drug|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
289499|NCT01994720|Drug|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
289500|NCT01994707|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
289501|NCT01994707|Procedure|Placebo|Deflated cuff on arm for 30 minutes.
289502|NCT01994668|Drug|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
289503|NCT01994668|Drug|Placebo|A single intravenous administration of 0.9% saline over 1 minute
289504|NCT01994655|Other|Doing exercise|We want to investigate the effects of exercise on climacteric symptoms
289505|NCT01994655|Other|Doing exercise|Doing exercise at least 6 months including walking, running, yoga etc.
289506|NCT01994642|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
289507|NCT01994642|Drug|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
289508|NCT01994642|Drug|Placebo Sterile Otic Suspension|
289510|NCT01994629|Biological|MenACWY-TT|MenACWY-TT
289511|NCT01994616|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
289512|NCT01994603|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
289513|NCT01994603|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
289514|NCT01994590|Drug|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
289515|NCT01994590|Drug|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
289516|NCT01994590|Drug|Prednisone|5 mg by mouth twice daily.
289517|NCT01994538|Other|Longer therapy duration|14 days of antimicrobial treatment
289518|NCT01994538|Other|Shorter therapy duration|7 days of antimicrobial treatment
289519|NCT01994525|Biological|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
289520|NCT01994525|Biological|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
289521|NCT01994525|Other|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
289522|NCT01994512|Procedure|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
289523|NCT01994512|Procedure|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
289524|NCT01994499|Device|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
289525|NCT01994499|Drug|Medical drainage|Medical pleural drainage
289526|NCT01994486|Drug|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
289527|NCT01994473|Drug|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
289528|NCT01994473|Drug|Placebo|single oral dose placebo
289529|NCT01994473|Drug|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
289530|NCT01994460|Drug|Linezolid|
289531|NCT01994460|Drug|Ethambutol|
289532|NCT01994447|Other|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
289533|NCT01994434|Procedure|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
289534|NCT01994421|Other|Kinesiotape|
289535|NCT01994408|Other|default intensification|The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
289536|NCT01994395|Device|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
289537|NCT01994395|Other|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
289538|NCT01994382|Drug|Cerdulatinib (PRT062070)|
289539|NCT01994369|Drug|EC17|
289540|NCT01994356|Behavioral|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
289541|NCT01994356|Behavioral|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
289542|NCT01994343|Other|Global posture reeducation|An assessment of the women is performed using global posture reeducation.
289543|NCT01994330|Drug|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
289544|NCT01994317|Other|Algorithm|IV sedation dosing calculated by algorithm
289545|NCT01994317|Other|Standard care|IV sedation dosing calculated by standard care.
289546|NCT01994304|Behavioral|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
289547|NCT01994291|Drug|Ranibizumab|"Intravitreal Injection supplied as:~10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~Adminstered once a month for 12 weeks"
289548|NCT01994291|Drug|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks"
289549|NCT01994291|Drug|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
289550|NCT01994291|Drug|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
289551|NCT01994278|Device|Peri Clean|
289552|NCT01994265|Drug|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
289553|NCT01994265|Drug|Dabigatran|
289554|NCT01994252|Device|Optimal Medical therapy plus ICD|
289555|NCT01994252|Device|Optimal Medical therapy plus CRT/ICD|
289556|NCT01994239|Drug|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
289557|NCT01994239|Radiation|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
289558|NCT01994226|Drug|Low-dose colchicine|"Route of Administration: Tablet - Oral Use~Dose: 500 mcg (one tablet) every eight hours for four days"
289559|NCT01994226|Drug|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use~Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
289560|NCT01994213|Drug|Famitinib|Famitinib 25 mg p.o. qd
289561|NCT01994200|Other|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
289562|NCT01994200|Other|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
289563|NCT01994187|Procedure|Carotid endarterectomy|
289564|NCT01994187|Procedure|carotid angioplasty|
289565|NCT01994161|Procedure|intracranial stenting|"all the participants in this group will be performed with intracranial stenting~--------------------------------------------------------------------------------"
289566|NCT01994148|Procedure|Laparoscopy|In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
289567|NCT01994135|Other|Reference food|Reference food will be used to which test food samples will be compared to.
289568|NCT01994135|Other|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
289569|NCT01994135|Other|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
289570|NCT01994109|Drug|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
289571|NCT01994109|Other|PLACEBO|
289572|NCT01994096|Drug|Caspofungin|
289573|NCT01994083|Drug|Placebo|Administered orally
289574|NCT01994083|Drug|IX-01|Administered orally
289575|NCT01994070|Drug|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
289576|NCT01994070|Drug|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
289577|NCT01994044|Procedure|Cervical fusion|
289578|NCT01994031|Drug|Paclitaxel liposome injection|
289579|NCT01994031|Drug|Paclitaxel injection|
289580|NCT01994005|Behavioral|Facebook|Facebook page with contraception information used for counseling
289581|NCT01994005|Behavioral|Pamphlet|Contraceptive knowledge pamphlets
289582|NCT01993979|Drug|Chemotherapy|
289583|NCT01993979|Other|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
289584|NCT01993953|Other|BodyPump|Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
289585|NCT01993953|Other|Personal training|Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
289586|NCT01993953|Other|Resistance training with instructor|Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT`s from group B will also serve as training instructors.
289587|NCT01993940|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
289588|NCT01993940|Drug|Placebo|Placebo tablet taken orally once a day
289589|NCT01993927|Drug|Voglibose|Voglibose Tablets / Voglibose OD Tablets
289684|NCT01993251|Drug|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
290326|NCT01988428|Drug|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
289590|NCT01993901|Other|CSRT led telephone follow up|Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
289591|NCT01993888|Biological|EVARREST® Fibrin Sealant Patch|
289592|NCT01993888|Other|Standard of Care (SoC)|
289593|NCT01993875|Drug|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
289594|NCT01993875|Drug|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
289595|NCT01993862|Other|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
289596|NCT01993849|Drug|N-Acetylcysteine (NAC)|This is the medication N-acetylcysteine (NAC)
289597|NCT01993849|Other|Placebo|Placebo, designed to match in appearance to NAC
289598|NCT01993836|Drug|Total intravenous anesthesia with propofol|
289599|NCT01993836|Drug|General anesthesia with isoflurane|
289600|NCT01993823|Drug|G238|Five drops into the ear canal twice daily for 14 days
289601|NCT01993823|Drug|Clotrimazole|Five drops into the ear canal twice daily for 14 days
289602|NCT01993810|Drug|Carboplatin|Given IV
289603|NCT01993810|Drug|Cisplatin|Given IV
289604|NCT01993810|Biological|Durvalumab|Given IV
289605|NCT01993810|Drug|Etoposide|Given IV
289606|NCT01993810|Drug|Paclitaxel|Given IV
289607|NCT01993810|Drug|Pemetrexed Disodium|Given IV
289608|NCT01993810|Radiation|Photon Beam Radiation Therapy|Undergo photon beam radiation therapy
289609|NCT01993810|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
289610|NCT01993810|Other|Quality-of-Life Assessment|Ancillary studies
289611|NCT01993810|Other|Questionnaire Administration|Ancillary studies
289612|NCT01993797|Other|Lung US|
289613|NCT01993784|Drug|nimotuzumab|
289614|NCT01993771|Procedure|Surgery with general anaesthesia.|
289615|NCT01993771|Procedure|Raw EEG|
289616|NCT01993758|Procedure|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
289617|NCT01993758|Procedure|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
289618|NCT01993732|Procedure|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
289619|NCT01993719|Drug|Aldesleukin|720,000 IU/kg IV every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
289620|NCT01993719|Drug|Fludarabine|25 mg/m2/day IVPB daily for 5 days or 30 mg/m2 IV once
289621|NCT01993719|Drug|Cyclophosphamide|60 mg/kg/day X 2 days IV or 30 mg/kg/day X 2 days IV. Days -5 to -3 (low- dose arm-CLOSED): Cyclophosphamide 300 mg/m2 IV over 60 minutes.
289622|NCT01993719|Biological|Young Tumor Infiltrating Lymphocytes (Young TIL)|Day 0: Cells will be infused intravenously (IV)
289623|NCT01993719|Drug|Pembrolizumab (Keytruda)|2 mg/kg IV on Days -2, 21 (+/- 2 days), 42 (+/- 2 days), and 63 (+/- 2 days).
289624|NCT01993706|Drug|VRC-HIVMAB060-00-AB|
289625|NCT01993693|Device|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
289626|NCT01993693|Device|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
289627|NCT01993680|Drug|Pyridostigmine bromide|"Drug doses during the trial:~Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
289628|NCT01993680|Drug|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
289629|NCT01993667|Drug|Low Dose Acetazolamide|Administration of low dose acetazolamide
289630|NCT01993667|Drug|Normal Dose Acetazolamide|Administration of normal dose acetazolamide
289631|NCT01993654|Procedure|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
289632|NCT01993641|Drug|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
289633|NCT01993641|Drug|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
289634|NCT01993641|Drug|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.~The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
289635|NCT01993628|Other|Rey figure test|
289636|NCT01993628|Other|MRI|
289637|NCT01993615|Procedure|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
289683|NCT01993264|Other|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
289638|NCT01993615|Procedure|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
289639|NCT01993602|Procedure|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.~The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.~The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.~Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
289640|NCT01993589|Drug|comparison of pain relievers during curattage|
289641|NCT01993589|Drug|comparison of pain relievers|
289642|NCT01993589|Drug|comparison of pain relievers during curattage|
289643|NCT01993589|Drug|comparison of pain relievers during curattage|
289644|NCT01993589|Drug|comparison of pain relievers during curattage|
289645|NCT01993576|Drug|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
289646|NCT01993563|Other|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).~IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.~EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.~MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
289647|NCT01993563|Other|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
289648|NCT01993550|Behavioral|Telephone counseling|
289649|NCT01993550|Behavioral|Education|
289650|NCT01993537|Drug|Vitamin D|
289651|NCT01993524|Dietary Supplement|probiotic|antibiotic plus probiotic
289652|NCT01993524|Other|placebo|antibiotic plus placebo
289653|NCT01993498|Procedure|blood sampling|blood samples collection
289654|NCT01993472|Drug|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
289655|NCT01993472|Drug|Capecitabine|
289656|NCT01993459|Drug|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
289657|NCT01993459|Drug|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
289658|NCT01993446|Drug|DRM02|
289659|NCT01993446|Other|Vehicle|
289660|NCT01993433|Drug|DRM02|
289661|NCT01993433|Other|Vehicle|
289662|NCT01993420|Drug|DRM02|
289663|NCT01993420|Other|Vehicle|
289664|NCT01993407|Behavioral|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
289665|NCT01993407|Behavioral|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
289666|NCT01993394|Other|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
289667|NCT01993394|Other|gas mixture|breathing air, 44.5%O2 or 100%O2
289668|NCT01993368|Other|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:~T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).~Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)~Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
289669|NCT01993355|Other|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
289670|NCT01993355|Other|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
289671|NCT01993355|Behavioral|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
289672|NCT01993342|Other|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
289673|NCT01993342|Other|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
289674|NCT01993329|Drug|Gefapixant 50 mg|
289675|NCT01993329|Drug|Gefapixant 300 mg|
289676|NCT01993329|Drug|Placebo (for AF219)|sugar pill manufactured to mimic gefapixant 50 mg and 300 mg tablets
289677|NCT01993316|Device|Mitsar 201 neurofeedback|
289678|NCT01993290|Drug|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
289679|NCT01993277|Device|Nexalin Brain Stimulator|
289680|NCT01993277|Device|Fischer Wallace Stimulator|
289681|NCT01993277|Device|David Delight Stimulator|
289682|NCT01993277|Behavioral|Relaxation Therapy|
289685|NCT01993251|Drug|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
289686|NCT01993251|Drug|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
289687|NCT01993251|Drug|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
289688|NCT01993238|Device|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
289689|NCT01993238|Drug|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
289690|NCT01993225|Drug|Androxal 12.5 mg/25 mg|
289691|NCT01993225|Drug|Placebo Capsules|
289692|NCT01993225|Drug|AndroGel 1.62%|
289693|NCT01993225|Drug|Placebo Gel|
289694|NCT01993212|Drug|Androxal 12.5 mg or 25 mg|
289695|NCT01993212|Drug|AndroGel 1.62%|
289696|NCT01993212|Drug|Placebo Capsules|
289697|NCT01993212|Drug|Placebo Gel|
289698|NCT01993199|Procedure|deep biopsy via ESD technique|
289699|NCT01993186|Drug|UX007 (triheptanoin)|Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. UX007 is manufactured by chemical synthesis from glycerol and heptanoic acid. UX007 (triheptanoin) is a liquid, intended for oral (PO) administration.
289700|NCT01993186|Drug|Placebo Oil|
289701|NCT01993173|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
289702|NCT01993173|Biological|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
289703|NCT01993173|Biological|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
289704|NCT01993160|Drug|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
289705|NCT01993160|Radiation|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
289706|NCT01993160|Radiation|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
289707|NCT01993147|Drug|Methylphenidate|20mgs of methlyphenidate or placebo to be administered one hour before fMRI and task performance.
289708|NCT01993147|Drug|Placebo|20mgs of methylphenidate or a placebo to be administered one hour before fMRI and task performance.
289709|NCT01993134|Procedure|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
289710|NCT01993134|Procedure|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
289711|NCT01993121|Other|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
289712|NCT01993108|Drug|Methylphenidate|One dose 40mgs of methylphenidate one hour before fMRI scanning.
289713|NCT01993108|Drug|Naltrexone|One dose 40mgs of naltrexone one hour before fMRI scanning.
289714|NCT01993108|Drug|Placebo|One dose of placebo one hour before fMRI scanning.
289715|NCT01993095|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
289716|NCT01993095|Behavioral|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
289717|NCT01993082|Behavioral|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
289718|NCT01993069|Behavioral|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
289719|NCT01993056|Behavioral|"FIFA 11+"|
289720|NCT01993056|Behavioral|"no FIFA 11+"|
289721|NCT01993030|Device|HQ® Matrix Medical Wound Dressing|
289722|NCT01993030|Device|Sidaiyi® wound dressing|
289723|NCT01993017|Other|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.~CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
289724|NCT01993017|Drug|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.~Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
289725|NCT01993017|Other|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
289726|NCT01993017|Other|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
289727|NCT01993017|Other|No intervention|
289728|NCT01992991|Device|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
289729|NCT01992978|Procedure|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
289730|NCT01992978|Procedure|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
289731|NCT01992965|Other|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
289732|NCT01992952|Drug|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
289733|NCT01992952|Drug|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
289734|NCT01992952|Drug|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
289735|NCT01992939|Other|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
289736|NCT01992939|Other|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
289737|NCT01992926|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
289738|NCT01992913|Behavioral|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
289739|NCT01992913|Other|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
289740|NCT01992913|Behavioral|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
289741|NCT01992900|Drug|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
289742|NCT01992900|Drug|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
289743|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
289744|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
289745|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
289746|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
289747|NCT01992874|Drug|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
289748|NCT01992861|Procedure|Computed Tomography|Undergo FDG PET/CT
289749|NCT01992861|Procedure|Diffusion Weighted Imaging|Undergo DW MRI
289750|NCT01992861|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
289751|NCT01992861|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
289752|NCT01992861|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
289753|NCT01992861|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
289754|NCT01992848|Other|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
289755|NCT01992848|Other|4-day food diary|
289756|NCT01992848|Other|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
289757|NCT01992848|Radiation|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
289758|NCT01992835|Other|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
289759|NCT01992835|Other|placebo|
289760|NCT01992822|Other|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm.
289761|NCT01992809|Dietary Supplement|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
289762|NCT01992796|Drug|Irbesartan|75 mg/per os/for 15 days
289763|NCT01992783|Dietary Supplement|Hi-maize resistant starch|13.5 g/day
289764|NCT01992783|Dietary Supplement|Maltodextrin|13.5 g/day
289765|NCT01992770|Behavioral|Hierarchical graded exposure|"Individual Behavioural goal identification, depending on risk profile~(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid."
289766|NCT01992770|Behavioral|Graded activity|"Individual Behavioural goal identification, depending on risk profile~(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention."
289767|NCT01992770|Behavioral|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
289768|NCT01992731|Other|Drug: Follitropine Bèta|
289769|NCT01992718|Procedure|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).~A patient survey will be included."
289828|NCT01992198|Procedure|oral care by chlorhexidine gluconate|oral care by 0.2% chlorhexidine gluconate twice daily
289829|NCT01992198|Procedure|enteral nutrition|
289830|NCT01992198|Drug|Somatostatin|
290484|NCT01987232|Drug|Carfilzomib|Administered by intravenous infusion.
289770|NCT01992718|Procedure|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.~Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
289771|NCT01992705|Other|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
289772|NCT01992705|Drug|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
289773|NCT01992705|Drug|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
289774|NCT01992705|Drug|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
289775|NCT01992679|Behavioral|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
289776|NCT01992666|Genetic|Blood sampling|Immunologic and genetic analysis from a single blood sample.
289777|NCT01992653|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
289778|NCT01992653|Drug|Doxorubicin|Doxorubicin will be administered at 50 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
289779|NCT01992653|Drug|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
289780|NCT01992653|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
289781|NCT01992653|Drug|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
289782|NCT01992653|Drug|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
289783|NCT01992653|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
289784|NCT01992627|Device|HILTERAPIA HIRO 3.0|High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
289785|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
289786|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
289787|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
289788|NCT01992601|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)|"For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.~For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period."
289789|NCT01992588|Drug|Faster-acting insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
289790|NCT01992588|Drug|insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.~The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
289791|NCT01992562|Drug|Ziconotide|
289792|NCT01992562|Drug|placebo|
289793|NCT01992549|Biological|Human-cl rhFVIII|
289794|NCT01992536|Biological|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
289795|NCT01992536|Biological|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
289796|NCT01992536|Biological|Placebo|Saline solution for injection (0.5mL)
289797|NCT01992523|Drug|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
289798|NCT01992523|Drug|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
289799|NCT01992497|Dietary Supplement|Probiotic|
289887|NCT01991860|Drug|APD421- Amisulpride for IV injection|APD421 ( Amisulpride) at 5mg given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
290485|NCT01987232|Drug|Carboplatin|Administered by intravenous infusion.
289800|NCT01992471|Behavioral|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
289801|NCT01992471|Behavioral|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
289802|NCT01992471|Other|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
289803|NCT01992471|Behavioral|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
289804|NCT01992471|Behavioral|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
289805|NCT01992393|Behavioral|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
289806|NCT01992380|Drug|18F-AV-1451|
289807|NCT01992367|Drug|ASLAN003 ACTIVE|This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
289808|NCT01992354|Device|PET MR Device|GE PET/MRI system
289809|NCT01992341|Drug|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
289810|NCT01992341|Drug|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
289811|NCT01992328|Drug|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
289812|NCT01992315|Device|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
289813|NCT01992289|Drug|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
289814|NCT01992276|Biological|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
289815|NCT01992276|Biological|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
289816|NCT01992276|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
289817|NCT01992263|Dietary Supplement|Vitamin D (600 IU)|Daily oral dose for 12 months
289818|NCT01992263|Dietary Supplement|Vitamin D (2000 IU)|Daily oral dose for 12 months
289819|NCT01992263|Dietary Supplement|Vitamin D (4000 IU)|Daily oral dose for 12 months
289820|NCT01992263|Other|Placebo|Daily oral dose for 12 months
289821|NCT01992250|Device|Visica 2 Treatment System|Cryoablation
289822|NCT01992224|Other|early mechanical Ventilation|"Fulfillment of three or more criteria below:~respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation"
289823|NCT01992224|Other|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
289824|NCT01992211|Drug|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
289825|NCT01992211|Drug|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
289826|NCT01992211|Drug|BCWP_C003|Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
289827|NCT01992198|Drug|cefoperazone + metronidazole|"1.Clinical parameters (2 of 3):~1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h"
289831|NCT01992198|Drug|Meropenem|"All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.~1.Clinical parameters (2 of 3):~1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):~1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h"
289832|NCT01992185|Drug|Photocil for Vitiligo|Photocil for Vitiligo
289833|NCT01992185|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
289834|NCT01992172|Drug|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
289835|NCT01992172|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
289836|NCT01992159|Drug|Romosozumab|Administered by subcutaneous injection
289837|NCT01992159|Drug|Placebo|Administered by subcutaneous injection
289838|NCT01992146|Drug|Target-controlled naloxone-infusion|
289839|NCT01992146|Drug|Placebo|
289840|NCT01992133|Dietary Supplement|Vitamin D3|
289841|NCT01992133|Dietary Supplement|Placebo|
289842|NCT01992120|Other|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
289843|NCT01992120|Other|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
289844|NCT01992107|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
289845|NCT01992107|Biological|TIV1c|Licensed Influenza Vaccine
289846|NCT01992107|Biological|TIV2c|Novartis Investigational Vaccine
289847|NCT01992094|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
289848|NCT01992094|Biological|TIV1c|Licensed Influenza Vaccine
289849|NCT01992094|Biological|TIV2c|Novartis Investigational Vaccine
289850|NCT01992081|Device|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
289851|NCT01992081|Other|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
289852|NCT01992055|Behavioral|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
289853|NCT01992055|Behavioral|Education & relaxation training|The Education & Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
289854|NCT01992042|Drug|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
289855|NCT01992042|Drug|Pimonidazole|
289856|NCT01992029|Other|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
289857|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy at M0
289858|NCT01992029|Procedure|Lumbar puncture|Lumbar puncture at M0 and M12
289859|NCT01992029|Procedure|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
289860|NCT01992029|Other|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
289861|NCT01992029|Procedure|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
289862|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy for patient explored for myopathy
289863|NCT01992029|Procedure|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
289864|NCT01992029|Device|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
289865|NCT01992016|Drug|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
289866|NCT01991990|Drug|placebo|Single i.v. infusion
289867|NCT01991990|Drug|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
289868|NCT01991977|Procedure|Diffusion Weighted Imaging|Undergo DTI
289869|NCT01991977|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
289870|NCT01991977|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
289871|NCT01991977|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
289872|NCT01991977|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET
289873|NCT01991977|Other|Quality-of-Life Assessment|Ancillary studies
289874|NCT01991977|Drug|Temozolomide|Receive temozolomide
289875|NCT01991964|Other|laryngeal ultrasound|
289876|NCT01991951|Drug|warfarin|
289877|NCT01991938|Drug|VS-5584|
289878|NCT01991925|Other|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionaires and focusgroup interviews
289879|NCT01991912|Procedure|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
289880|NCT01991899|Biological|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
289881|NCT01991899|Biological|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
289882|NCT01991886|Device|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
289883|NCT01991873|Drug|Maintenance Chemotherapy|
289884|NCT01991873|Drug|Panitumumab (Within maintenance phase)|
289885|NCT01991873|Drug|mFOLFOX6 (Within re-induction phase)|
289886|NCT01991873|Drug|Panitumumab (Within re-induction phase)|
289888|NCT01991860|Drug|Placebo|Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
289889|NCT01991847|Behavioral|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
289890|NCT01991834|Procedure|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
289891|NCT01991834|Drug|Cefazolin|Intravenous administration of 1 g of cefazolin
289892|NCT01991834|Drug|Placebo|Intravenous administration of saline sterile solution
289893|NCT01991821|Drug|APD421|
289894|NCT01991821|Drug|Placebo|
289895|NCT01991808|Radiation|Radiotherapy|
289896|NCT01991795|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
289897|NCT01991795|Drug|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
289898|NCT01991782|Other|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
289899|NCT01991769|Behavioral|47 min moderate intensity training|
289900|NCT01991769|Behavioral|exercise healthy volunteers|
289901|NCT01991769|Behavioral|control; no exercise training|
289902|NCT01991756|Device|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
289903|NCT01991743|Drug|Group 2.5|Administration of bupivacaine 2.5 mg.
289904|NCT01991743|Drug|Group 5|Administration of 5 mg bupivacaine
289905|NCT01991743|Drug|Group 7.5|Administration of 7.5 mg bupivacaine
289906|NCT01991743|Drug|Group 10|Administration of 10mg bupivacaine.
289907|NCT01991717|Device|Victus|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
289908|NCT01991717|Device|Conventional Phaco|The capsulotomy as well as the lens fragmentation is performed manually.
289909|NCT01991691|Device|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
289910|NCT01991678|Drug|145 mg/m2 NKTR 102|
289911|NCT01991678|Drug|120 mg/m2 NKTR 102|
289912|NCT01991678|Drug|50 mg/m2 NKTR 102|
289913|NCT01991665|Other|Digital examination|
289914|NCT01991665|Other|Sonography evaluation|
289915|NCT01991639|Other|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
289916|NCT01991626|Dietary Supplement|micronutrient powder|
289917|NCT01991626|Dietary Supplement|micronutrient powder (containing FeSO4), phytase|
289918|NCT01991626|Dietary Supplement|Iron pyrophosphate (FePP)|
289919|NCT01991626|Dietary Supplement|Iron sulphate|
289920|NCT01991613|Dietary Supplement|liquid protein supplement|The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
289921|NCT01991600|Dietary Supplement|ferrous sulphate|
289922|NCT01991600|Dietary Supplement|ferric iron oxide-organic acid (Fe-OA)|
289923|NCT01991587|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
289924|NCT01991587|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
289925|NCT01991587|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
289926|NCT01991587|Biological|Placebo|A single dose of placebo
289927|NCT01991574|Drug|Calcium acetate|
289928|NCT01991574|Dietary Supplement|Iron Hydroxide Adipate|
289929|NCT01991574|Drug|Placebo|methylcellulose capsules
289930|NCT01991561|Biological|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
289931|NCT01991561|Biological|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
289932|NCT01991561|Biological|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
289933|NCT01991561|Biological|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
289934|NCT01991561|Biological|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
289935|NCT01991561|Biological|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
289936|NCT01991548|Device|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
289937|NCT01991535|Device|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.~Device model: Stellar 150® (ResMed, Australia)."
289938|NCT01991535|Device|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.~Device model: Stellar 150® (ResMed, Australia)."
289939|NCT01991535|Device|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.~Device model: Stellar 150® (ResMed, Australia)."
289940|NCT01991522|Behavioral|Curriculum Group|
289941|NCT01991522|Behavioral|Self-directed learning group|
289942|NCT01991509|Biological|LBR-101 IV|LBR-101 Administered Intravenously
289943|NCT01991509|Biological|LBR-101 SC|LBR-101 Administered Subcutaneously
289944|NCT01991483|Drug|LY2928057|Administered intravenously
289945|NCT01991483|Drug|Placebo|Administered intravenously
289946|NCT01991470|Device|Enlite sensors|Subject wears enlite sensor first and followed by enlite 3 sensor.
289947|NCT01991457|Drug|Fludarabine|
289948|NCT01991457|Procedure|Total Body Irradiation|
289949|NCT01991444|Other|TAVI|no Intervention planned, Observation only
289950|NCT01991405|Device|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
289951|NCT01991392|Device|Nasogastric tube|For nasogastric decompression.
289952|NCT01991392|Device|No nasogastric tube|For nasogastric decompression.
289953|NCT01991379|Drug|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
289954|NCT01991379|Drug|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
289955|NCT01991379|Other|Blood draws|
289956|NCT01991379|Procedure|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
289957|NCT01991353|Procedure|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
289958|NCT01991353|Procedure|Without PRP|Standard of care meniscal repair without augmentation.
289959|NCT01991327|Drug|Androxal|
289960|NCT01991327|Drug|Placebo|
289961|NCT01991314|Drug|Ferrous sulphate|200mg tablets.
289962|NCT01991301|Drug|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
289963|NCT01991288|Procedure|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
289964|NCT01991288|Procedure|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
289965|NCT01991275|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
289966|NCT01991275|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
289967|NCT01991249|Other|blood draw|
289968|NCT01991236|Behavioral|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
289969|NCT01991236|Behavioral|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
289970|NCT01991223|Drug|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
289971|NCT01991223|Drug|NS infusion|Normal saline will be infused during surgery
289972|NCT01991210|Drug|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
289973|NCT01991210|Drug|PLD|PLD will be administered at a dose of 40 mg/m^2 IV every 4 weeks.
289974|NCT01991197|Drug|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
289975|NCT01991197|Drug|Gliclazide|"Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
289976|NCT01991197|Drug|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
289977|NCT01991197|Drug|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
289978|NCT01991184|Drug|GDC-0853|Multiple escalating doses
289979|NCT01991171|Other|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
289980|NCT01991158|Drug|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
289981|NCT01991158|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
289982|NCT01991158|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
289983|NCT01991158|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
289984|NCT01991145|Procedure|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
289985|NCT01991145|Biological|Erythropoietin alfa|
289986|NCT01991145|Other|Rehabilitation|Active rehabilitation
289987|NCT01991145|Procedure|Placebo UCB|
289988|NCT01991145|Biological|Placebo EPO|
289989|NCT01991132|Other|MediView 2.0 software|
289990|NCT01991119|Drug|Propafenone|
289991|NCT01991119|Drug|Dronedarone|
289992|NCT01991106|Behavioral|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
289993|NCT01991106|Behavioral|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
289994|NCT01991106|Dietary Supplement|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
289995|NCT01991080|Behavioral|biofeedback|Patients will go through biofeedback sessions
289996|NCT01991080|Drug|Wheatgerm juice|Patient will drink wheatgerm juice
290486|NCT01987232|Drug|Etoposide|Administered by intravenous infusion.
289997|NCT01991067|Biological|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
289998|NCT01991054|Dietary Supplement|vitamin D3|
289999|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
290000|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
290001|NCT01991002|Behavioral|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
290002|NCT01990976|Device|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
290003|NCT01990976|Procedure|Biopsy|biopsy of the vastus lateralis muscle
290004|NCT01990950|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
290005|NCT01990937|Drug|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
290006|NCT01990924|Radiation|15 FPS|X-ray pictures
290007|NCT01990924|Radiation|7.5 FPS|X-ray pictures
290008|NCT01990911|Device|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
290009|NCT01990911|Drug|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
290010|NCT01990898|Drug|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
290011|NCT01990885|Drug|BL-7010|
290012|NCT01990885|Drug|Placebo|
290013|NCT01990872|Dietary Supplement|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
290014|NCT01990872|Dietary Supplement|Placebo|Placebo (0 micrograms vitamin D3/day)
290015|NCT01990859|Biological|Ipilimumab|
290016|NCT01990846|Drug|Flufirvitide 3|
290017|NCT01990846|Drug|Placebo for Flufirvitide-3|
290018|NCT01990820|Device|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
290019|NCT01990820|Procedure|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.~Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.~After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
290020|NCT01990807|Drug|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
290021|NCT01990781|Drug|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
290022|NCT01990781|Drug|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
290023|NCT01990781|Drug|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
290024|NCT01990781|Drug|N: Normal saline (placebo)|Normal saline: 2ml
290025|NCT01990768|Drug|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
290026|NCT01990768|Drug|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
290027|NCT01990768|Drug|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
290028|NCT01990755|Behavioral|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
290029|NCT01990755|Other|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
290030|NCT01990755|Drug|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
290031|NCT01990755|Dietary Supplement|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
290032|NCT01990755|Drug|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
290033|NCT01990742|Behavioral|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
290034|NCT01990729|Dietary Supplement|ARTRA|ARTRA (glucosamine and chondroitin sulfate)
290093|NCT01990144|Drug|Bendamustine+Rituximab|"Patients will receive :~Rituximab 375 mg/m2 intravenously on day 1*~Bendamustine 90 mg/m2 intravenously on days 2 and 3** Treatment will be administered on a 28-day cycle basis.~Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.~After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
290552|NCT01986764|Drug|Estradiol|
290035|NCT01990716|Other|Colonic Biopsy|"Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.~The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.~Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.~For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time."
290036|NCT01990703|Drug|Levonorgestrel IUD|Timing of IUD insertion
290037|NCT01990690|Drug|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:~Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
290038|NCT01990677|Drug|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
290039|NCT01990677|Drug|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
290040|NCT01990664|Device|senofilcon A|
290041|NCT01990664|Device|senofilcon A for Astigmatism|
290042|NCT01990638|Other|exercise capacity test|
290043|NCT01990625|Device|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
290044|NCT01990612|Procedure|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score < 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
290045|NCT01990599|Other|Nasopharyngeal Tube|
290046|NCT01990586|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
290047|NCT01990573|Drug|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
290048|NCT01990573|Drug|0.5mg/kg IV methadon HCl|Group II will receive 0.5mg/kg IV methadone HCl.
290049|NCT01990573|Other|control no methadone|The control group will not receive methadone.
290050|NCT01990560|Drug|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
290051|NCT01990534|Drug|Brentuximab vedotin|Brentuximab vedotin IV infusion
290052|NCT01990521|Procedure|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
290053|NCT01990521|Device|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.~A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
290054|NCT01990508|Behavioral|Targeted beverage education and financial incentives|
290055|NCT01990508|Behavioral|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
290056|NCT01990495|Other|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
290057|NCT01990495|Other|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
290058|NCT01990482|Dietary Supplement|caffe|
290059|NCT01990482|Dietary Supplement|Water|
290060|NCT01990469|Drug|Gemigliptin|DPP-4 inhibitor
290061|NCT01990469|Drug|Gemigliptin placebo|Placebo of Gemigliptin
290062|NCT01990456|Device|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
290063|NCT01990456|Device|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
290064|NCT01990443|Drug|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
290065|NCT01990443|Drug|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
290094|NCT01990131|Other|Cognitive Anxiety Sensitivity Treatment|
290095|NCT01990131|Other|Physical Health Education Training|
290096|NCT01990118|Drug|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
290097|NCT01990118|Drug|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
290098|NCT01990092|Other|Metanx|Metanx is a prescription medical food.
290099|NCT01990092|Other|Placebo|
290100|NCT01990079|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
290066|NCT01990430|Behavioral|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.~The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
290067|NCT01990417|Other|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
290068|NCT01990404|Drug|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
290069|NCT01990404|Drug|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
290070|NCT01990391|Dietary Supplement|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
290071|NCT01990391|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
290072|NCT01990378|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
290073|NCT01990352|Drug|Pegylated liposomal doxorubicin|
290074|NCT01990339|Drug|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.~For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.~• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
290075|NCT01990326|Drug|XAF5 Gel|
290076|NCT01990326|Drug|Placebo Gel|
290077|NCT01990313|Device|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
290078|NCT01990300|Drug|Alogliptin/Pioglitazone|Alogliptin/Pioglitazone combination tablets
290079|NCT01990287|Device|SCS and PNfS|Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
290080|NCT01990287|Device|SCS Alone|Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
290081|NCT01990274|Procedure|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
290082|NCT01990274|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
290083|NCT01990261|Drug|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
290084|NCT01990235|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
290085|NCT01990209|Drug|Orteronel|
290086|NCT01990196|Drug|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
290087|NCT01990196|Drug|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
290088|NCT01990196|Drug|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
290089|NCT01990196|Drug|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.~Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
290090|NCT01990183|Device|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home ‐ session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
290091|NCT01990183|Other|Standard Care|Current care advices in the management of preterm infants in the first months of life
290092|NCT01990157|Drug|TAB08|Weekly intravenous administration in escalating doses.
290218|NCT01989312|Drug|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
290219|NCT01989312|Drug|Lidocaine|
290220|NCT01989312|Drug|Epinephrine|
290221|NCT01989312|Drug|Levobupivacaine|
290101|NCT01990079|Drug|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
290102|NCT01990079|Other|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
290103|NCT01990079|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
290104|NCT01990079|Other|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
290105|NCT01990066|Behavioral|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
290106|NCT01990053|Behavioral|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
290107|NCT01990001|Other|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
290108|NCT01989988|Procedure|LMGB|
290109|NCT01989988|Procedure|LRYGB|
290110|NCT01989988|Procedure|SADJB|
290111|NCT01989962|Other|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
290112|NCT01989949|Drug|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
290113|NCT01989936|Drug|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
290114|NCT01989936|Drug|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
290115|NCT01989936|Drug|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
290116|NCT01989923|Other|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
290117|NCT01989923|Device|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
290118|NCT01989910|Drug|Raltegravir|Raltegravir 400mg oral twice daily
290119|NCT01989910|Drug|Efavirenz|Efavirenz 600mg oral at bedtime
290120|NCT01989897|Drug|saline with 1mg/ml Histamine base|
290121|NCT01989897|Drug|diluent, saline with HSA--phenol|
290122|NCT01989884|Drug|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
290123|NCT01989871|Behavioral|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
290222|NCT01989299|Device|ILR implantation|
290223|NCT01989286|Other|Assessment|The posture, motor development and balance are going to be assessed.
290224|NCT01989273|Device|Ultrasound of inferior vena cava|
290653|NCT01986036|Dietary Supplement|Calcium|Soluble calcium powder.
290124|NCT01989858|Other|peri-operative cht|"CHT treatment have to be chosen between the following associations:~Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or~Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line."
290125|NCT01989858|Other|post-operative CHT|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously~or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line."
290126|NCT01989858|Other|peri-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~5FU 225 mg/m² given as a continuous iv infusion or~capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
290127|NCT01989858|Other|post-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:~EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or~ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.~The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:~5FU 225 mg/m² given as a continuous iv infusion or~capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
290128|NCT01989845|Drug|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
290129|NCT01989819|Other|skin biopsy|
290130|NCT01989806|Device|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
290131|NCT01989806|Device|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
290132|NCT01989793|Drug|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
290133|NCT01989793|Drug|Placebo|Placebo will be given to those in placebo arm
290134|NCT01989780|Drug|Paclitaxel|
290135|NCT01989780|Drug|Bevacizumab|
290136|NCT01989780|Drug|Letrozole|
290137|NCT01989780|Drug|Anastrozole|
290138|NCT01989780|Drug|Exemestane|
290139|NCT01989780|Drug|Fulvestrant|
290140|NCT01989780|Drug|Goserelin|
290141|NCT01989780|Drug|leuprorelin|
290142|NCT01989780|Drug|LHRH Analogs + Aromatase inhibitors|
290143|NCT01989767|Behavioral|control Rehabilitation as usual|Rehabilitation as usual
290144|NCT01989767|Behavioral|education|Education as add on to to rehabilitation as usual
290145|NCT01989754|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
290146|NCT01989754|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
290147|NCT01989754|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
290148|NCT01989741|Other|Sleep restriction|4 hours sleep by night during one week
290149|NCT01989728|Procedure|psychiatric examination and feedback|
290150|NCT01989715|Other|analyzing the position of the body, muscle activity|
290151|NCT01989702|Other|Fermented blueberry drink|
290152|NCT01989702|Other|Placebo drink|
290153|NCT01989702|Other|Sachets with probiotic bacterial powder|
290154|NCT01989702|Other|Sachets with placebo powder|
290155|NCT01989689|Drug|Etanercept|Etanercept 50mg twice weekly
290156|NCT01989689|Drug|Placebo|
290157|NCT01989676|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
290158|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
290159|NCT01989676|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
290160|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
290161|NCT01989663|Drug|1% vaginally applied tenofovir gel|
290162|NCT01989663|Drug|Tenofovir film- 10mg|
290163|NCT01989663|Drug|Tenofovir Film-40 mg|
290164|NCT01989663|Other|HEC Placebo Gel|
290165|NCT01989663|Other|Placebo Vaginal Film|
290166|NCT01989650|Other|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
290167|NCT01989650|Other|No break|No break will be provided
290168|NCT01989637|Dietary Supplement|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
290169|NCT01989637|Dietary Supplement|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
290170|NCT01989611|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
290171|NCT01989598|Other|Laboratory Biomarker Analysis|Correlative studies
290172|NCT01989598|Other|Pharmacological Study|Correlative studies
290173|NCT01989598|Drug|Trametinib|Given PO
290174|NCT01989598|Drug|Uprosertib|Given PO
290175|NCT01989585|Drug|Dabrafenib|Given PO
290176|NCT01989585|Other|Laboratory Biomarker Analysis|Correlative studies
290177|NCT01989585|Biological|Navitoclax|Given PO
290178|NCT01989585|Other|Pharmacological Study|Correlative studies
290179|NCT01989585|Drug|Trametinib|Given PO
290180|NCT01989572|Other|Laboratory Biomarker Analysis|Correlative studies
290181|NCT01989572|Other|Placebo|Given GM-CSF placebo SC
290182|NCT01989572|Other|Placebo|Given peptide placebo SC
290183|NCT01989572|Biological|Sargramostim|Given SC
290184|NCT01989572|Biological|Tyrosinase Peptide|Given SC
290185|NCT01989559|Biological|gp100:209-217(210M) Peptide Vaccine|Given SC
290186|NCT01989559|Biological|HPV 16 E7:12-20 Peptide Vaccine|Given SC
290187|NCT01989559|Other|Laboratory Biomarker Analysis|Correlative studies
290188|NCT01989546|Drug|BMN 673|PARP inhibitor; has been shown to cause single-agent synthetic lethality in BRCA1/2- and PTEN-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in DNA repair pathways.
290189|NCT01989533|Biological|Ad4-mgag|Ad4 live virus vaccine with an HIV insert
290190|NCT01989533|Biological|Ad4-EnvC150|Ad4 live virus vaccine with an HIV insert
290191|NCT01989533|Biological|gp 120 Protein Boost|HIV protein boost
290192|NCT01989520|Drug|Phase IIb formulation|Single oral dose 45mg AZD5069
290193|NCT01989520|Drug|Putative phase III formulation|Single oral dose 45mg AZD5069
290194|NCT01989520|Drug|Slow dissolution variant 1|Single oral dose 45mg AZD5069
290195|NCT01989520|Drug|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
290196|NCT01989520|Drug|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
290197|NCT01989507|Drug|Nicotine|
290198|NCT01989507|Behavioral|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
290199|NCT01989494|Device|Pedometer|All groups will receive a pedometer to measure their daily steps
290200|NCT01989468|Biological|Secukinumab|Secukinumab 150 mg provided in a 1 mL autoinjector (1 autoinjector for 150 mg dose, 2 autoinjectors for 300 mg dose)
290201|NCT01989468|Biological|Placebo|Secukinumab placebo provided in 1 mL autoinjector
290202|NCT01989455|Drug|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
290203|NCT01989455|Drug|Placebo|Placebo: normal saline solution.
290204|NCT01989442|Device|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
290205|NCT01989442|Device|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
290206|NCT01989429|Drug|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
290207|NCT01989416|Drug|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
290208|NCT01989416|Drug|Soap|The ICU patients will be bathing with Soap
290209|NCT01989403|Other|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
290210|NCT01989325|Drug|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
290211|NCT01989325|Drug|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
290212|NCT01989325|Drug|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
290213|NCT01989325|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
290214|NCT01989312|Procedure|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
290215|NCT01989312|Procedure|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
290216|NCT01989312|Device|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
290217|NCT01989312|Device|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
290225|NCT01989260|Device|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
290226|NCT01989247|Behavioral|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
290227|NCT01989234|Drug|YKP10811|
290228|NCT01989234|Drug|Placebo|
290229|NCT01989221|Drug|Sancuso®|Drug: Placebo
290230|NCT01989208|Other|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
290231|NCT01989195|Drug|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT~CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)~CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
290232|NCT01989182|Device|Spiration Valve System|
290233|NCT01989182|Other|Medical Management|
290234|NCT01989169|Drug|Midazolam|
290235|NCT01989169|Drug|SSP-004184SS|
290236|NCT01989156|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
290237|NCT01989156|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
290238|NCT01989156|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
290239|NCT01989143|Drug|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
290240|NCT01989143|Drug|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
290241|NCT01989143|Drug|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
290242|NCT01989143|Drug|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
290243|NCT01989143|Drug|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
290244|NCT01989143|Drug|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
290245|NCT01989130|Device|Roche AMPLICOR CT/NG|
290246|NCT01989130|Device|Cepheid Xpert CT/NG Test|
290247|NCT01989091|Device|B-Lock|Antimicrobial Catheter Lock Solution
290248|NCT01989091|Drug|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
290249|NCT01989078|Drug|Losartan|"Adults and Children >50 kg:~Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.~Those with SBP <100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.~Children <50 kg weight:~Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
290250|NCT01989065|Behavioral|Lifestyle counseling|see arm description
290251|NCT01989065|Behavioral|Text Messaging|See Arm Description
290252|NCT01989052|Drug|CTO|
290253|NCT01989052|Drug|Lomustine|
290254|NCT01989026|Biological|BCG|
290255|NCT01989013|Other|biweekly intervention|10 step craniosacral therapy protocol through manual therapy at feet , thoracic diaphragm, neck and cranium
290256|NCT01989000|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
290257|NCT01989000|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
290258|NCT01989000|Drug|Gemcitabine|1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
290259|NCT01989000|Radiation|Radiotherapy|A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
290260|NCT01989000|Procedure|Pancreaticoduodenectomy|
290261|NCT01988987|Other|Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
290262|NCT01988974|Behavioral|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
290263|NCT01988974|Behavioral|Healthy Sleep|Participants will receive a 45 minute face to face instruction about sleep hygiene
290264|NCT01988961|Biological|Golimumab|SC injections
290265|NCT01988948|Other|Various biological sampling|
290266|NCT01988935|Behavioral|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
290267|NCT01988935|Behavioral|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
290268|NCT01988922|Drug|ketamine|0.4 mg/kg oral racemic ketamine
290269|NCT01988909|Drug|WR 279,396|Paromomycin + Gentamicin Topical Cream
290270|NCT01988896|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose as specified via IV infusion.
290271|NCT01988896|Drug|Cobimetinib|Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
290272|NCT01988883|Drug|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
290273|NCT01988883|Drug|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
290274|NCT01988883|Drug|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
290275|NCT01988870|Radiation|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
290276|NCT01988857|Biological|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
290277|NCT01988844|Other|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
290278|NCT01988831|Drug|Propranolol hydrochloride|This intervention apply to Propranolol group
290279|NCT01988831|Drug|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
290280|NCT01988818|Device|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
290281|NCT01988818|Device|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
290282|NCT01988805|Other|Blood Draw|
290283|NCT01988792|Dietary Supplement|Human milk fortifiers|
290284|NCT01988779|Drug|oral levofloxacin|
290285|NCT01988779|Drug|nebulized levofloxacin|
290286|NCT01988714|Other|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
290287|NCT01988714|Other|(CG) plus evidence-based SE|(CG) plus evidence-based SE
290288|NCT01988701|Other|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
290289|NCT01988688|Device|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
290290|NCT01988675|Radiation|Whole Brain Irradiation|
290291|NCT01988675|Radiation|Partial Brain Irradiation|
290292|NCT01988675|Behavioral|Neuropsychological Testing|
290293|NCT01988675|Behavioral|Quality of Life Questionnaire|
290294|NCT01988675|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
290295|NCT01988662|Procedure|Neovascular Age-related Macular Degeneration|Blood measurement
290296|NCT01988649|Drug|Intranasal Oxytocin|Administration of intranasal Oxytocin
290297|NCT01988649|Drug|Placebo (saline)|Administration of normal saline intranasally.
290298|NCT01988636|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
290299|NCT01988636|Drug|Placebo|Placebo
290300|NCT01988623|Behavioral|Pivotal Response Treatment (PRT)|
290301|NCT01988610|Drug|28 days treatment with Mifepristone.|
290302|NCT01988597|Other|Dry eyes|
290303|NCT01988584|Biological|Umbilical Cord Blood Stem Cells|Autologous umbilical cord blood banked with the Cord Blood Registry.
290304|NCT01988584|Other|Saline Infusion (Placebo)|A total of 10 children (5 from each cohort) will be randomized to a placebo infusion at the baseline visit and then have the opportunity to cross-over to stem cell treatment at the 1yr. visit.
290305|NCT01988584|Biological|Bone Marrow Stem Cells|Autologous stem cells from bone marrow harvest.
290306|NCT01988571|Drug|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
290307|NCT01988571|Drug|Placebo|One placebo tablet taken each morning orally for 24 months.
290308|NCT01988558|Drug|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
290309|NCT01988558|Dietary Supplement|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
290310|NCT01988545|Other|1,5 nmol/kg,GLP-1 sc injection|
290311|NCT01988545|Other|1,5 nmol/kg GLP-1 9-36amide, sc injection|
290312|NCT01988545|Other|Exendin-4 ;10 ug,sc injection|
290313|NCT01988545|Other|saline|
290314|NCT01988532|Other|No treatment given|Subject will only fill out a questionnaire
290315|NCT01988519|Procedure|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
290316|NCT01988519|Procedure|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
290317|NCT01988506|Drug|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
290318|NCT01988493|Drug|Tepotinib 300 mg|Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
290319|NCT01988493|Drug|Tepotinib 500 mg|Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
290320|NCT01988493|Drug|Tepotinib 1000 mg|Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
290321|NCT01988493|Drug|Tepotinib|Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
290322|NCT01988493|Drug|Sorafenib|Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
290323|NCT01988480|Procedure|Image-guided surgery|Placement on residual bone around the implant
290324|NCT01988480|Procedure|Sinus lift surgery|Allograft bone
290325|NCT01988467|Other|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
290327|NCT01988415|Device|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
290328|NCT01988402|Drug|allopurinol|
290329|NCT01988402|Drug|Placebo (sugar pill)|
290330|NCT01988389|Dietary Supplement|whole apples (WA)|
290331|NCT01988389|Dietary Supplement|apple juice (AJ)|
290332|NCT01988376|Device|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
290333|NCT01988376|Device|Conventional Pap smear|Conventional Pap smear
290334|NCT01988363|Procedure|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
290335|NCT01988337|Device|Resin infiltration|The study is a split-mouth design. One tooth with a proximal caries lesion will randomly receive the infiltrating resin (Icon) while the other will receive a placebo, according to the manufactores´ instruction for Icon. In short, teeth will be isolated with a rubber dam and the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured, followed by polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
290336|NCT01988337|Other|Mock treatment|"For the mock treatment the procedure will be identical to the Resin Infiltration intervention, with the exception that a placebo will be used. Essentialy, syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with solutions having the same consistency and color as the Icon material."
290337|NCT01988324|Other|FDHT-PET scan|
290338|NCT01988324|Other|FES-PET scan|
290339|NCT01988324|Other|CT-scan|
290340|NCT01988324|Other|Bone scintigraphy|
290341|NCT01988324|Other|Tumor biopsy|
290342|NCT01988311|Drug|psilocybin|dose manipulation as described in the protocol
290343|NCT01988298|Drug|Ibuprofen|Ibuprofen 400 mg each 8 hours
290344|NCT01988298|Drug|Acetaminophen|Control group
290345|NCT01988285|Other|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
290346|NCT01988285|Other|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
290347|NCT01988272|Device|SPECT/CT imaging|Patients will undergo scanning on the above system.
290348|NCT01988259|Procedure|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
290349|NCT01988259|Procedure|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
290350|NCT01988259|Procedure|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
290351|NCT01988259|Procedure|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
290352|NCT01988246|Drug|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
290353|NCT01988246|Drug|Sham|Sham injection. No actual injection. No medication is used.
290354|NCT01988233|Behavioral|BAILAMOS© Dance Program|
290355|NCT01988233|Behavioral|Health Education Control Group|
290356|NCT01988220|Other|sensory retraining|
290357|NCT01988220|Other|repeated sensory input|sensory stimulation without attentive learning focus
290358|NCT01988207|Behavioral|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
290359|NCT01988207|Behavioral|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
290360|NCT01988194|Device|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
290361|NCT01988181|Device|BVM-UF biofeedback|The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
290362|NCT01988181|Device|Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)|For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
290363|NCT01988168|Procedure|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
290553|NCT01986764|Drug|Placebo|Placebo capsules will be filled with lactose powder.
290364|NCT01988168|Procedure|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
290365|NCT01988155|Other|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
290366|NCT01988155|Other|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
290367|NCT01988142|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
290368|NCT01988129|Other|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
290369|NCT01988116|Drug|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
290370|NCT01988116|Drug|Placebo|
290371|NCT01988103|Drug|Apremilast|20 mg tablet twice a day for 68 weeks
290372|NCT01988103|Drug|Apremilast|30 mg tablet twice a day for 68 weeks
290373|NCT01988103|Drug|Placebo|Placebo tablet twice a day for 16 weeks
290374|NCT01988090|Drug|800 IU Vitamin D Supplement|Standard Dose
290375|NCT01988090|Drug|50,000 IU Vitamin D supplement|High Dose
290376|NCT01988077|Biological|Adoptive cell transfer|Adoptive cell transfer
290377|NCT01988077|Drug|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
290378|NCT01988064|Other|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
290379|NCT01988064|Other|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
290380|NCT01988012|Biological|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
290381|NCT01987999|Dietary Supplement|Acetogenins|
290382|NCT01987986|Biological|Collagenase Clostridium Histolyticum|injectible intervention
290383|NCT01987986|Biological|Placebo|
290384|NCT01987973|Procedure|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
290385|NCT01987973|Procedure|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
290386|NCT01987960|Drug|Placebo|Once daily, tablets, orally
290387|NCT01987960|Drug|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
290388|NCT01987947|Drug|Placebo|Two administrations by subcutaneous injection
290389|NCT01987947|Drug|Quilizumab|Two administrations by subcutaneous injection
290390|NCT01987908|Drug|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
290391|NCT01987908|Other|Placebo|
290392|NCT01987895|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
290393|NCT01987895|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
290394|NCT01987895|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
290395|NCT01987895|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
290396|NCT01987856|Procedure|Blastocyst morphology|microscopic examination only
290397|NCT01987843|Drug|MT-1303-Low|
290398|NCT01987843|Drug|MT-1303-Middle|
290399|NCT01987843|Drug|MT-1303-High|
290400|NCT01987843|Drug|Placebo|
290401|NCT01987830|Device|MRI-PET|"[11C] temozolomide for PET scan and a contrast dye for the MRI scan~Drawing blood to assess the radioactivity of [11C] temozolomide"
290481|NCT01987271|Device|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
290554|NCT01986751|Drug|Clonidine|
290402|NCT01987830|Device|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of [11C] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
290403|NCT01987817|Biological|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
290404|NCT01987817|Biological|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
290405|NCT01987804|Drug|Oxytocin 100 i.u.|
290406|NCT01987804|Drug|Oxytocin 400 i.u.|
290407|NCT01987804|Drug|Placebo|
290408|NCT01987778|Other|Resistance training|Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
290409|NCT01987765|Drug|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
290410|NCT01987752|Drug|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
290411|NCT01987739|Drug|200 mg almorexant|
290412|NCT01987739|Drug|400 mg almorexant|
290413|NCT01987739|Drug|1000 mg almorexant|
290414|NCT01987739|Drug|20 mg zolpidem|
290415|NCT01987739|Drug|40 mg zolpidem|
290416|NCT01987739|Drug|placebo|
290417|NCT01987726|Other|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
290418|NCT01987726|Other|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
290419|NCT01987713|Behavioral|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
290420|NCT01987700|Device|FLEX-HD|
290421|NCT01987700|Device|Strattice|
290422|NCT01987687|Behavioral|Exercise|Exercise at 55% of maximum power output for 30 min.
290423|NCT01987687|Behavioral|Rest|Rest for 30 min
290424|NCT01987687|Behavioral|Delay|Delay between exercise and OGTT
290425|NCT01987674|Dietary Supplement|Pre-meal protein drink|
290426|NCT01987674|Other|Water drink|
290427|NCT01987661|Device|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
290428|NCT01987661|Device|Airtrap|"Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.~AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time."
290429|NCT01987648|Procedure|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
290430|NCT01987635|Device|MEMO 3D ring|The experimental MEMO 3D ring is placed.
290431|NCT01987635|Device|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
290432|NCT01987635|Procedure|3D Echocardiography|
290433|NCT01987622|Procedure|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
290434|NCT01987622|Procedure|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
290435|NCT01987609|Drug|Hylenex|
290436|NCT01987609|Drug|Normal Saline|
290437|NCT01987596|Biological|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
290438|NCT01987583|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
290482|NCT01987258|Behavioral|Interval Walking|
290483|NCT01987258|Behavioral|Continuous walking|
290439|NCT01987583|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
290440|NCT01987570|Drug|Allopurinol|
290441|NCT01987570|Drug|Placebo|
290442|NCT01987557|Behavioral|rate group|walking with a high cadence (steps per minute)
290443|NCT01987557|Behavioral|magnitude treadmill group|
290444|NCT01987557|Behavioral|regular treadmill walking|
290445|NCT01987544|Other|Ergometer Training|
290446|NCT01987544|Other|Motivation|
290447|NCT01987531|Other|left ventricular epicardial pacing lead|
290448|NCT01987518|Other|Procedure surgery behavioral and genetic diagnosis|Observational Study
290449|NCT01987518|Procedure|quality of life after different type of surgery|
290450|NCT01987505|Drug|Rituximab|1400 mg will be injected subcutaneously (SC).
290451|NCT01987492|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
290452|NCT01987492|Drug|Placebo|Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
290453|NCT01987479|Drug|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
290454|NCT01987479|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
290455|NCT01987479|Drug|Methotrexate|Methotrexate will be administered per investigator's discretion.
290456|NCT01987466|Biological|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
290457|NCT01987453|Drug|LDV/SOF|Tablet(s) administered orally once daily
290458|NCT01987453|Drug|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
290459|NCT01987440|Drug|lubricating gel|
290460|NCT01987427|Drug|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
290461|NCT01987427|Drug|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
290462|NCT01987427|Drug|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
290463|NCT01987414|Behavioral|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
290464|NCT01987414|Device|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
290465|NCT01987414|Other|No treatment|Participants will maintain their daily routines during the no treatment period.
290466|NCT01987388|Other|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
290467|NCT01987388|Other|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
290468|NCT01987388|Other|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
290469|NCT01987388|Other|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
290470|NCT01987375|Drug|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
290471|NCT01987362|Drug|RO6870810|Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
290472|NCT01987349|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
290473|NCT01987349|Biological|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
290474|NCT01987323|Drug|Subconjunctival injection of liposomal latanoprost|
290475|NCT01987310|Drug|atorvastatin|atorvastatin 20 mg per day for 6 months
290476|NCT01987310|Behavioral|lifestyle counseling|lifestyle modification by dietician counseling and follow up
290477|NCT01987297|Drug|ATRA+Arsenic|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients."
290478|NCT01987297|Drug|ATRA+Chemo|"ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients."
290479|NCT01987284|Drug|SER100|
290480|NCT01987284|Drug|Placebo|
290555|NCT01986751|Drug|ropivacaine|
290487|NCT01987219|Drug|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
290488|NCT01987219|Drug|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
290489|NCT01987219|Other|placebo|Saline solution 3 cc NA
290490|NCT01987206|Device|MPC control algorithm|
290491|NCT01987206|Device|PID control algorithm|
290492|NCT01987167|Drug|ACTHAR|Injectable Gel
290493|NCT01987154|Other|Marketed cow milk-based premature infant formula|
290494|NCT01987154|Other|Marketed extensively hydrolyzed casein infant formula|
290495|NCT01987141|Other|EMR Intervention|Electronic medical record flag/notification in the patient's chart
290496|NCT01987128|Procedure|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
290497|NCT01987128|Procedure|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
290498|NCT01987128|Drug|Ropivacaine|
290499|NCT01987128|Device|PAJUNK SonoPlex 22G needle.|
290500|NCT01987115|Procedure|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
290501|NCT01987115|Procedure|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
290502|NCT01987102|Drug|Calcium Folinate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
290503|NCT01987102|Drug|[6R] 5,10-methylenetetrahydrofolate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug [6R] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.~All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate® dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
290504|NCT01987089|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
290505|NCT01987076|Drug|Prednisone|"Prednisone:~Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
290506|NCT01987076|Drug|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
290507|NCT01987037|Behavioral|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
290508|NCT01987024|Device|Actim Partus® test|
290509|NCT01987024|Other|usual procedure|
290510|NCT01987011|Biological|MG1109|
290511|NCT01987011|Biological|Placebo|
290512|NCT01986998|Drug|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
290513|NCT01986998|Drug|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
290514|NCT01986985|Device|PET/MRI system|Compared to PET CT
290515|NCT01986972|Other|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
290556|NCT01986738|Radiation|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
290557|NCT01986738|Device|Active Breathing Control Device (ABC)|
290558|NCT01986738|Device|Computed Tomography Scan (CT)|
290654|NCT01986036|Dietary Supplement|Porridge-based breakfast.|Oats and water.
290655|NCT01986023|Behavioral|SMS- Short Messaging Service|
290656|NCT01986010|Biological|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
292575|NCT01970657|Biological|No treatment|None specified
290516|NCT01986972|Other|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
290517|NCT01986959|Procedure|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
290518|NCT01986959|Procedure|Without Periodontal dressing|The dressing was not inserted.
290519|NCT01986946|Other|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
290520|NCT01986946|Drug|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
290521|NCT01986933|Drug|nemolizumab (CIM331)|
290522|NCT01986933|Other|Placebo|
290523|NCT01986920|Drug|A-101 25%|Low Dose Concentration of A-101 applied to one of 4 Target Lesions
290524|NCT01986920|Drug|A-101 32.5%|Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
290525|NCT01986920|Drug|A-101 40%|High Dose Concentration A-101 applied to one of 4 Target Lesions
290526|NCT01986920|Drug|A-101 Vehicle|Placebo applied to one of 4 Target Lesions
290527|NCT01986907|Drug|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
290528|NCT01986894|Drug|Placebo|Single oral dose of Placebo
290529|NCT01986894|Drug|Pomalidomide|Single oral dose of 4 mg pomalidomide
290530|NCT01986894|Drug|Pomalidomide|Single oral dose of 20 mg pomalidomide
290531|NCT01986894|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
290532|NCT01986881|Drug|Ertugliflozin|Oral, once daily, up to 6.1 years
290533|NCT01986881|Drug|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to 6.1 years
290534|NCT01986868|Other|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
290535|NCT01986855|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
290536|NCT01986855|Drug|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
290537|NCT01986855|Drug|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
290538|NCT01986855|Drug|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
290539|NCT01986842|Dietary Supplement|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
290540|NCT01986829|Device|Microwave ablation|"Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
290541|NCT01986829|Device|Cryoablation|"Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
290542|NCT01986829|Device|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
290543|NCT01986829|Other|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
290544|NCT01986829|Other|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
290545|NCT01986803|Device|Percutaneous Coronary Intervention|"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."
290546|NCT01986790|Behavioral|Plain Language|
290547|NCT01986790|Behavioral|Plain Language + Visuals|
290548|NCT01986790|Behavioral|Plain Language + Narratives|
290549|NCT01986777|Drug|lisdexamfetamine|
290550|NCT01986777|Drug|Placebo|The placebo capsules will be filled with lactose.
290551|NCT01986764|Drug|Lisdexamfetamine|
290559|NCT01986725|Behavioral|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
290560|NCT01986725|Behavioral|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
290561|NCT01986699|Procedure|Laparoscopic Assisted Polypectomy|
290562|NCT01986686|Procedure|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
290563|NCT01986673|Drug|5% Sildenafil Cream (SST-6006)|5 % Sildenafil Cream
290564|NCT01986673|Drug|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
290565|NCT01986660|Drug|Ibuprofen Cream (SST-0225)|
290566|NCT01986647|Behavioral|On the Move exercise - exercise leader|exercise physiologists
290567|NCT01986647|Behavioral|Standard program - exercise leader|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by research staff who are PTs, PTAs, or exercise physiologists
290568|NCT01986647|Behavioral|On the Move exercise - staff activity personnel|this is a group exercise program focusing on the timing and coordination of walking. The program is taught by a person from the facility that the research team trained.
290569|NCT01986647|Behavioral|Standard program - staff activity personnel|This is an impairment-based exercise program focusing on flexibility, strength and endurance and is taught by a member of the facility that the research staff trained.
290570|NCT01986634|Device|Laser Treatment|Patient will have split face laser resurfacing. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
290571|NCT01986608|Drug|Lacosamide infusion|"Strength: 10 mg/mL for infusion~Form: solution for infusion~Dosage: 200 mg, single dose~Duration: 30-minute infusion or 60-minute infusion"
290572|NCT01986608|Drug|Lacosamide oral|"Strength: 200 mg~Form: film-coated tablet~Dosage: 200 mg, single dose~Duration: single oral intake"
290573|NCT01986582|Drug|Oxymetazoline|Intranasal application
290574|NCT01986582|Other|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
290575|NCT01986582|Other|Placebo (lactose powder)|Intranasal application
290576|NCT01986569|Drug|[18F]fluoroestradiol (FES)|[18F]FES PET/CT will be performed 90 min (± 10 min) after administration of [18F]FES. Patients will undergo core needle biopsy or surgery within 15 days after [18F]FES PET; or patients will undergo core needle biopsy within 30 days before [18F]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
290577|NCT01986556|Drug|Lesinurad 400 mg (Site 1)|
290578|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot A)|
290579|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot B)|
290580|NCT01986543|Drug|drug administration|
290581|NCT01986530|Dietary Supplement|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
290582|NCT01986530|Other|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
290583|NCT01986517|Behavioral|No feedback|Therapists will receive no feedback.
290584|NCT01986517|Behavioral|Feedback after every fourth session|
290585|NCT01986491|Drug|JNJ 39393406 30 mg solid X|Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
290586|NCT01986491|Drug|JNJ 39393406 30 mg solid Y|Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
290587|NCT01986491|Drug|JNJ 39393406 120 mg solid X|Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
290588|NCT01986491|Drug|JNJ 39393406 120 mg solid Y|Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
290589|NCT01986491|Drug|JNJ 39393406 30 mg solution|Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
290590|NCT01986465|Drug|Depomedrol|
290591|NCT01986465|Drug|Placebo|
290592|NCT01986452|Device|CPAP therapy|
290593|NCT01986452|Other|Support|
290594|NCT01986426|Drug|LTX-315 consecutive lesions|"Dose escalation:~Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)"
290595|NCT01986426|Drug|LTX-315|"Dose escalation:~Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection"
290596|NCT01986426|Drug|LTX-315 + ipilimumab|Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
290597|NCT01986426|Drug|LTX-315 + pembrolizumab|Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
290598|NCT01986413|Device|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
290599|NCT01986413|Device|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
290600|NCT01986413|Device|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
290601|NCT01986400|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
290602|NCT01986387|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
290603|NCT01986374|Drug|HCG is introduced|must have good blastocysts
290604|NCT01986361|Drug|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
290605|NCT01986361|Drug|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
290606|NCT01986348|Drug|Selinexor|One cycle is 28 days (4 weeks).
290607|NCT01986335|Biological|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
290608|NCT01986322|Biological|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
290609|NCT01986322|Biological|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
290610|NCT01986309|Drug|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
290611|NCT01986309|Drug|Normal saline|Sodium Chloride 0.9% infusion
290612|NCT01986296|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
290613|NCT01986283|Drug|Capsule|Taken once
290614|NCT01986283|Drug|PF-00345439|40 mg capsule swallowed whole, taken once
290615|NCT01986283|Drug|PF-00345439|40 mg capsule chewed, taken once
290616|NCT01986283|Drug|oxycodone|40 mg solution, taken once
290617|NCT01986270|Drug|Placebo|Matching Placebo
290618|NCT01986270|Drug|Eletriptan 40 mg|40mg oral
290619|NCT01986270|Drug|Eletriptan 80 mg|80mg oral
290620|NCT01986270|Drug|Sumatriptan 25 mg|25mg oral
290621|NCT01986270|Drug|Sumatriptan 50 mg|50mg oral
290622|NCT01986257|Behavioral|Emotion Regulation Group Therapy (ERGT).|
290623|NCT01986231|Drug|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
290624|NCT01986218|Drug|BMS-986115|
290625|NCT01986205|Combination Product|Hyperbaric Oxygen|Hyperbaric oxygen (USP oxygen >99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
290626|NCT01986205|Combination Product|Minimal pressure air|Room air delivered in a hyperbaric chamber with minimal pressurization.
290627|NCT01986192|Drug|rivaroxaban|
290628|NCT01986192|Drug|Warfarin|
290629|NCT01986179|Other|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
290630|NCT01986179|Other|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
290631|NCT01986166|Drug|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
290632|NCT01986166|Drug|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
290633|NCT01986140|Device|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
290634|NCT01986140|Other|Control No treatment|No treatment to prevent hair loss
290635|NCT01986127|Drug|Adalimumab|single intralesional administration during endoscopy process
290636|NCT01986127|Drug|placebo|single intralesional administration during endoscopy
290637|NCT01986114|Drug|SM-13496|
290638|NCT01986101|Drug|Placebo|Placebo comparator
290639|NCT01986101|Drug|SM-13496|SM-13496 20mg for Days 1-7 and beginning Day 8 flexibly dosed 20-60 mg/day for Weeks 2-6
290640|NCT01986101|Drug|SM-13496|SM-13496 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6, 80 mg/day on Day 7 and beginning Day 8 flexibly dosed 80-120 mg/day for Weeks 2-6
290641|NCT01986088|Drug|Placebo|matching placebo
290642|NCT01986088|Drug|Eletriptan 40 mg|40mg oral
290643|NCT01986088|Drug|Eletriptan 80 mg|80mg oral
290644|NCT01986088|Drug|Sumatriptan 50 mg|50mg oral
290645|NCT01986088|Drug|Sumatriptan 100 mg|100mg oral
290646|NCT01986075|Behavioral|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
290647|NCT01986075|Drug|Mixed amphetamine salts|80 mg/day of Adderall-XR
290648|NCT01986075|Drug|Computer-assisted CBT plus placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
290649|NCT01986062|Drug|AR11|
290650|NCT01986062|Drug|Placebo|
290651|NCT01986049|Drug|Bupivicaine|
290652|NCT01986036|Dietary Supplement|Protein|Milk-Protein
290657|NCT01986010|Biological|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
290658|NCT01986010|Biological|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
290659|NCT01986010|Biological|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
290660|NCT01986010|Biological|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
290661|NCT01986010|Biological|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
290662|NCT01986010|Other|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
290663|NCT01986010|Biological|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
290664|NCT01986010|Other|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
290665|NCT01985984|Radiation|Radiation alone|Radiation alone
290666|NCT01985984|Radiation|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
290667|NCT01985971|Radiation|PET/CT Imaging|
290668|NCT01985958|Device|Radiation therapy|
290669|NCT01985945|Other|Yoga|
290670|NCT01985932|Device|MRI|
290671|NCT01985919|Other|Obtaining human tissue for basic research or biospecimen bank|
290672|NCT01985906|Procedure|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
290673|NCT01985906|Device|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
290674|NCT01985893|Drug|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
290675|NCT01985867|Dietary Supplement|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10^8 CFU, twice daily, orally for 4 weeks)
290676|NCT01985867|Dietary Supplement|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
290677|NCT01985854|Drug|Propofol|
290678|NCT01985854|Drug|Desflurane|
290679|NCT01985841|Drug|Bevacizumb|Avastin
290680|NCT01985841|Drug|5-Fluorouracil|5-FU
290681|NCT01985841|Drug|Epirubicin|Farmorubicin
290682|NCT01985841|Drug|Cyclophosphamide|Endoxan
290683|NCT01985841|Drug|Docetaxel|Taxotere
290684|NCT01985828|Radiation|CyberKnife|
290685|NCT01985828|Other|Androgen Deprivation Therapy (ADT)|
290686|NCT01985828|Radiation|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
290687|NCT01985815|Device|VC/VS stimulation|
290688|NCT01985802|Other|Pacing|
290689|NCT01985789|Drug|Diphenhydramine|
290690|NCT01985789|Drug|cetirizine|
290691|NCT01985789|Drug|desloratadine|
290692|NCT01985789|Drug|placebo|
290693|NCT01985776|Procedure|Exercise intervention|Functional stabilisation exercise for the trunk.
290694|NCT01985776|Procedure|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
290695|NCT01985763|Drug|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
290696|NCT01985750|Drug|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
290697|NCT01985750|Drug|placebo|"Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
290698|NCT01985737|Other|Sample collection|
290699|NCT01985724|Drug|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
290700|NCT01985724|Drug|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
290701|NCT01985724|Drug|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
290702|NCT01985724|Drug|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
290703|NCT01985724|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
290704|NCT01985711|Device|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.~Secondly, usual diabetes outpatient care for 6 months."
290705|NCT01985711|Other|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
290706|NCT01985711|Behavioral|usual diabetes outpatient care|
290707|NCT01985698|Procedure|Robotic-assisted resection.|Robotic-assisted abdominoperineal resection.
290708|NCT01985698|Procedure|Laparoscopic resection|Laparoscopic abdominoperineal resection
290709|NCT01985698|Procedure|Open surgery|Open abdominoperineal resection
290710|NCT01985685|Drug|Thiamine|200 mg IV thiamine
290711|NCT01985672|Procedure|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
290712|NCT01985646|Procedure|surgery treatment|one staged pull-through left-colectomy
290713|NCT01985646|Behavioral|anal dilation|anal dilation
290714|NCT01985646|Behavioral|colonic lavage|colonic lavage
290715|NCT01985646|Drug|oral probiotic|oral probiotic
290748|NCT01985360|Procedure|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
290790|NCT01985087|Radiation|Hypofractionated radiotherapy|Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
291933|NCT01975675|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
290716|NCT01985633|Biological|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
290717|NCT01985633|Biological|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
290718|NCT01985620|Behavioral|Educational intervention|
290719|NCT01985607|Dietary Supplement|new extensively hydrolysed formula|
290720|NCT01985607|Dietary Supplement|Extensively hydrolysed formula|
290721|NCT01985594|Drug|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
290722|NCT01985594|Drug|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
290723|NCT01985581|Drug|Guanfacine extended release|
290724|NCT01985581|Drug|Placebo|
290725|NCT01985581|Drug|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
290726|NCT01985568|Behavioral|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
290727|NCT01985568|Behavioral|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
290728|NCT01985555|Drug|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
290729|NCT01985542|Drug|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
290730|NCT01985529|Other|Exercise|
290731|NCT01985516|Other|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
290732|NCT01985516|Other|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
290733|NCT01985490|Procedure|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
290734|NCT01985477|Drug|Lenalidomide|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.~Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.~Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.~Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment."
290735|NCT01985477|Drug|Dexamethasone|"Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.~Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.~Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22."
290736|NCT01985477|Drug|All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.~Phase II Group A: ATRA starting dose: MTD from Phase I.~Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.~Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.~Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days."
290737|NCT01985464|Biological|Umbilical cord mesenchymal stem cells|
290738|NCT01985451|Drug|Pemetrexe|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
290739|NCT01985451|Drug|Temozolomide|Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
290740|NCT01985438|Procedure|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
290741|NCT01985438|Procedure|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
290742|NCT01985425|Drug|Colchicine|
290743|NCT01985425|Drug|Colchicine Placebo|
290744|NCT01985399|Behavioral|Neuropsychological testing|Neuropsychological testing
290745|NCT01985386|Dietary Supplement|GDS capsule with meal|GDS capsule with meal
290746|NCT01985386|Dietary Supplement|Ferrous sulfate with meal|Ferrous sulfate with meal
290747|NCT01985373|Drug|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
290870|NCT01984424|Drug|Ezetimibe|Ezetimibe was supplied as 10 mg tablets, over-encapsulated for blinding.
290749|NCT01985360|Procedure|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
290750|NCT01985360|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
290751|NCT01985360|Behavioral|Lifestyle|Diet, physical activity, smoking cessation
290752|NCT01985360|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
290753|NCT01985347|Device|CPAP|Continuous positive airway pressure( CPAP)
290754|NCT01985334|Drug|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
290755|NCT01985334|Drug|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
290756|NCT01985334|Drug|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
290757|NCT01985334|Drug|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
290758|NCT01985334|Drug|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
290759|NCT01985334|Drug|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
290760|NCT01985334|Drug|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
290761|NCT01985321|Drug|ethanol/glycolic acid solution|ethanol/glycolic acid solution
290762|NCT01985321|Drug|Placebo/Ethanol|ethanol solution
290763|NCT01985308|Device|MRT-Active|
290764|NCT01985308|Device|MRT-SHAM|
290765|NCT01985295|Drug|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
290766|NCT01985282|Behavioral|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
290767|NCT01985269|Other|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
290768|NCT01985256|Biological|Toca 511|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antifungal 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after the second administration of Toca 511,patients will begin 7-day course of oral 5-FC, repeated every 4 weeks for the duration of the study.
290769|NCT01985256|Drug|Toca FC|
290770|NCT01985243|Behavioral|Nutrition and agriculture|The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
290771|NCT01985243|Behavioral|Iron-rich food & business literacy|The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings & business literacy program for young female adolescents to encourage them to stay in school.
290772|NCT01985230|Device|ReActiv8 Implantable Stimulation System implanted and activated.|
290773|NCT01985204|Dietary Supplement|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
290774|NCT01985204|Dietary Supplement|Placebo tablet|Placebo tablet without iodine
290775|NCT01985191|Drug|SAR405838|"Pharmaceutical form:capsule~Route of administration: oral"
290776|NCT01985191|Drug|Pimasertib|"Pharmaceutical form: capsule~Route of administration: oral"
290777|NCT01985178|Dietary Supplement|Omega-3 Fatty Acid Supplement|
290778|NCT01985165|Drug|Imrecoxib|
290779|NCT01985152|Drug|Azilsartan Trimethylethanolamine|
290780|NCT01985152|Drug|Placebo|
290781|NCT01985139|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
290782|NCT01985139|Biological|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
290783|NCT01985126|Drug|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
290784|NCT01985126|Drug|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
290785|NCT01985126|Drug|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
290786|NCT01985126|Drug|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
290787|NCT01985126|Drug|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
290788|NCT01985126|Drug|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
290789|NCT01985100|Other|hyperbaric oxygen chamber|
291111|NCT01982682|Drug|Mycophenolate mofetil|Given IV
290791|NCT01985087|Drug|Temozolomide|During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
290792|NCT01985074|Behavioral|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
290793|NCT01985061|Drug|BX2|
290794|NCT01985061|Drug|BX3|
290795|NCT01985061|Drug|BX4-Suspended|Suspended
290796|NCT01985035|Behavioral|Diet|Reduction of energy intake in order to weight loss
290797|NCT01985022|Behavioral|PII with IES|This is an individualized parent-implemented intervention (PII) offered weekly to teach parents how to embed strategies to support social communication skills for 25 hours a week within everyday routines, activities, and places for 9 months. In addition parent will receive twice weekly the IES condition of the study.
290798|NCT01985022|Behavioral|IES|Parents will receive information, education, and support. They once a week for 75 minutes.
290799|NCT01985009|Device|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
290800|NCT01984996|Device|Freedom ProFlor Inguinal Hernia Implant|
290801|NCT01984983|Biological|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
290802|NCT01984983|Other|0.9% saline placebo|
290803|NCT01984970|Device|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
290804|NCT01984957|Procedure|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
290805|NCT01984944|Other|Autistic functional exploration|"50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~25 childs with urinary sample, Circadian rhythms assessed with actometer"
290806|NCT01984944|Other|Control functional exploration|"50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~25 childs with urinary sample, Circadian rhythms assessed with actometer"
290807|NCT01984931|Drug|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
290808|NCT01984931|Drug|Metoclopramide hydrochloride monohydrate|
290809|NCT01984918|Other|SMS reminder|A text message reminder via Short Message Service (SMS) will be sent to remind subjects 7-10 days before his colonoscopy appointment
290810|NCT01984918|Other|Non-SMS reminder|No Stext message reminder via Short Message Service (SMS) will be sent
290811|NCT01984892|Drug|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.~Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.~Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.~Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.~Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.~Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.~Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy~Follow Up via phone every 3 months for 30months, after completion of treatments."
290812|NCT01984879|Other|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
290813|NCT01984853|Other|OBSERVATIONAL REGISTRY|
290814|NCT01984840|Device|Telemedicine|
290815|NCT01984827|Drug|Moxifloxacin|"a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours~a single oral dose of 400mg Moxifloxacin plus C-peptide~a single oral dose of 400mg Moxifloxacin~placebo~Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
290816|NCT01984827|Other|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
290817|NCT01984814|Biological|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
290818|NCT01984801|Drug|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
290819|NCT01984801|Drug|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
290820|NCT01984801|Drug|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
290821|NCT01984801|Other|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
290822|NCT01984801|Other|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
290823|NCT01984801|Other|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
290824|NCT01984801|Other|Patch only|Only patch will be applied
290825|NCT01984788|Drug|BCX4161|
290826|NCT01984788|Drug|Placebo|
290827|NCT01984775|Drug|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% [5 milligram (mg)/gram (g)], 1% [10 mg/g], and 2% [20 mg/g]).
290828|NCT01984775|Drug|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
290829|NCT01984775|Drug|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
290830|NCT01984775|Drug|Negative control|Negative control contains petrolatum.
290831|NCT01984762|Procedure|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
290832|NCT01984762|Procedure|sleeve gastrectomy|SG = sleeve gastrectomy
290833|NCT01984749|Drug|Febuxostat|"Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.~The starting dose of the investigational product (febuxostat) will be 10 mg/day.~The dose will be increased to 20 mg/day at Week 4.~The aim is to increase the dose to 40 mg/day at Week 8."
290834|NCT01984736|Drug|Experimental: EVP-6124|
290835|NCT01984723|Drug|Experimental: EVP-6124|
290836|NCT01984710|Device|Medtronic Activa PC+S System|
290837|NCT01984697|Biological|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
290838|NCT01984684|Drug|delafloxacin|
290839|NCT01984684|Drug|vancomycin|
290840|NCT01984684|Drug|aztreonam|
290841|NCT01984671|Behavioral|Mobile Pain Coping Skills Training|
290842|NCT01984658|Biological|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
290843|NCT01984645|Other|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
290844|NCT01984632|Procedure|Single-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).
290845|NCT01984632|Procedure|Multi-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
290846|NCT01984619|Device|Cryotherapy for the utilization of wrinkle reduction (iovera)|
290847|NCT01984606|Drug|Empagliflozin|Empagliflozin once daily
290848|NCT01984606|Drug|Placebo|Placebo matching empagliflozin
290849|NCT01984606|Drug|Sitagliptin|Sitagliptin once daily
290850|NCT01984606|Drug|Placebo|Placebo matching sitagliptin
290851|NCT01984593|Other|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.~The two yoga exercises were:~Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and~Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
290852|NCT01984580|Drug|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
290853|NCT01984567|Dietary Supplement|Vitamin E|Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg
290854|NCT01984567|Dietary Supplement|Lipoic acid|Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
290855|NCT01984567|Dietary Supplement|Control|Daily consumption of 3 placebo capsules
290856|NCT01984541|Biological|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
290857|NCT01984528|Biological|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
290858|NCT01984515|Behavioral|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
290859|NCT01984502|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
290860|NCT01984489|Drug|Placebo|
290861|NCT01984489|Drug|SHR117887|
290862|NCT01984463|Drug|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
290863|NCT01984463|Drug|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
290864|NCT01984450|Procedure|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):~ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
290865|NCT01984450|Procedure|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):~MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
290866|NCT01984450|Device|implant with a collagen + fibrin gel mixture|
290867|NCT01984424|Drug|Atorvastatin|Atorvastatin was supplied as over-encapsulated 20 mg tablets
290868|NCT01984424|Drug|Placebo to Atorvastatin|Placebo matching to atorvastatin supplied as over-encapsulated tablets
290869|NCT01984424|Other|Placebo to Ezetimibe|Placebo matching to Ezetimibe supplied as over-encapsulated tablets.
290871|NCT01984424|Other|Placebo to Evolocumab|Placebo matching to evolocumab supplied as single-use prefilled autoinjector/pen(s)
290872|NCT01984424|Drug|Evolocumab|Evolocumab supplied as single-use prefilled autoinjector/pen(s)
290873|NCT01984411|Procedure|Radial Technical|Vascular Access for cardiac catheterization
290874|NCT01984411|Procedure|Femoral Technical|Vascular Access for cardiac catheterization
290875|NCT01984411|Drug|Omnipaque|
290876|NCT01984398|Drug|12.5 mg Androxal Formulation A|Single dose of 12.5 mg Androxal formulation A
290877|NCT01984398|Drug|12.5 mg Androxal Formulation B|Single dose of 12.5 mg Androxal Formulation B
290878|NCT01984398|Drug|25 mg Androxal Formulation A|Single dose of 25 mg Androxal formulation A
290879|NCT01984398|Drug|25 mg Androxal Formulation B|Single dose of 25 mg Androxal formulation B
290880|NCT01984372|Drug|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
290881|NCT01984359|Other|Obtaining Human tissue|
290882|NCT01984346|Device|Convergent Procedure EPi-Sense-AF Guided Coagulation System|Convergent Epicardial Endocardial Ablation Procedure
290883|NCT01984346|Device|Endocardial Catheter Ablation|Endocardial Catheter Ablation only
290884|NCT01984333|Behavioral|Online cognitive training|Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
290885|NCT01984320|Procedure|ICSI|Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
290886|NCT01984294|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
290887|NCT01984294|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
290888|NCT01984294|Drug|GS-9669|GS-9669 tablet(s) administered orally once daily
290889|NCT01984281|Behavioral|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
290890|NCT01984268|Drug|ACTHAR|
290891|NCT01984255|Drug|Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV|Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
290892|NCT01984255|Drug|Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.|Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
290893|NCT01984242|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody|Atezolizumab will be administered according to the dosage schedule mentioned in the arm description.
290894|NCT01984242|Drug|Bevacizumab|Bevacizumab will be administered according to the dosage schedule mentioned in the arm description.
290895|NCT01984242|Drug|Sunitinib|Sunitinib will be administered according to the dosage schedule mentioned in the arm description.
290896|NCT01984229|Drug|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
290897|NCT01984229|Drug|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
290898|NCT01984216|Procedure|Roux-en-Y for the gastrojejunostomy reconstruction|
290899|NCT01984216|Procedure|Billroth II for the gastrojejunostomy reconstruction|
290900|NCT01984203|Other|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
290901|NCT01984203|Other|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).~The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.~Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)~The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
290902|NCT01984177|Drug|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. ~15 minutes after Corticorelin/saline injection, [11C]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure ([11C]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
290903|NCT01984164|Drug|Candesartan|blinded
290904|NCT01984164|Drug|Lisinopril|Blinded
291112|NCT01982669|Other|No Intervention|
292135|NCT01974089|Other|Dysphagia|Oropharyngeal dysphagia assessed by Volume-Viscosity Svallowing Test
290905|NCT01984138|Drug|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
290906|NCT01984138|Drug|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
290907|NCT01984125|Other|Point-of-Care Prompt|
290908|NCT01984112|Device|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
290909|NCT01984112|Device|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
290910|NCT01984099|Drug|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
290911|NCT01984099|Drug|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
290912|NCT01984086|Drug|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
290913|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
290914|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
290915|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
290916|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
290917|NCT01984086|Drug|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
290918|NCT01984086|Drug|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
290919|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
290920|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
290921|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
290922|NCT01984086|Drug|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
290923|NCT01984086|Drug|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
290924|NCT01984073|Drug|ER Niacin Oral Fat Challenge|Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
290925|NCT01984073|Drug|IR Niacin Oral Fat Challenge|Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
290926|NCT01984073|Other|Placebo Oral Fat Challenge|Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
290927|NCT01984060|Other|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
290928|NCT01984047|Drug|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
290929|NCT01984047|Drug|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
290930|NCT01984034|Behavioral|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
290931|NCT01984034|Other|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
290932|NCT01984021|Device|Acupuncture|
290933|NCT01984021|Device|Sham acupuncture|
290934|NCT01984008|Drug|Picosulfate sodium, magnesium oxide, citric acid|
290935|NCT01983969|Drug|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
290936|NCT01983969|Drug|Vorinostat|1000 mg by vein on Day -11 through Day -2.
290937|NCT01983969|Drug|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
291263|NCT01981473|Other|no intervention|
292136|NCT01974076|Device|Active tDCS + CBT|
290938|NCT01983969|Drug|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
290939|NCT01983969|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
290940|NCT01983969|Drug|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
290941|NCT01983969|Other|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
290942|NCT01983969|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
290943|NCT01983969|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
290944|NCT01983969|Drug|Rituximab|375 mg/m2 by vein on Days -9.
290945|NCT01983956|Behavioral|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
290946|NCT01983943|Dietary Supplement|Hydroxytyrosol, the active ingredient in olive oil.|A 40mg capsule will be taken once daily for 6 months.
290947|NCT01983943|Dietary Supplement|Placebo|A 40mg placebo will be taken once per day for 6 months.
290948|NCT01983943|Behavioral|Nutrition counseling|Nutrition counseling on eating a healthy diet will be offered once at baseline.
290949|NCT01983943|Device|Endopat|An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
290950|NCT01983930|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan Kriya meditation (12 minute duration) for 12 weeks.
290951|NCT01983930|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
290952|NCT01983917|Behavioral|Diabetes Mobile Application|
290953|NCT01983904|Device|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
290954|NCT01983891|Other|Cooking course|6-week nutrition education and cooking course
290955|NCT01983878|Drug|Ramucirumab|Administered IV
290956|NCT01983865|Other|Exposure to birch pollen|
290957|NCT01983826|Dietary Supplement|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
290958|NCT01983826|Other|Placebo|Microcrystalline cellulose (daily) for 8 weeks
290959|NCT01983813|Other|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:~Contact via email, phone or text every 2-4 weeks~Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.~Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.~Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
290960|NCT01983813|Other|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
290961|NCT01983800|Drug|Isoflurane|
290962|NCT01983800|Drug|Propofol/midazolam|
290963|NCT01983774|Drug|Esomeprazole|
290964|NCT01983774|Drug|Placebo|Sugar pill
290965|NCT01983761|Drug|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
290966|NCT01983761|Drug|Fludarabine, Melphalan, ATG (Reduced Intensity)|
290967|NCT01983748|Biological|Autologous Dendritic Cells loaded with autologous Tumor RNA|
290968|NCT01983735|Drug|TELMINUVO Tab. (80/2.5mg)|"Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.~With the others investigation product placebo 1 tab QD 2 weeks."
290969|NCT01983735|Drug|TELMINUVO Tab. (80/5mg)|"Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.~With the others investigation product placebo 1 tab QD 6 weeks."
290970|NCT01983735|Drug|S-amlodipine 2.5mg|"S-amlodipine 2.5mg QD 2 weeks~With the others investigation product placebo 1 tab QD 2 weeks."
290971|NCT01983735|Drug|S-amlodipine 5mg|"S-amlodipine 5mg QD 6weeks~With the others investigation product placebo 1 tab QD 6 weeks."
290972|NCT01983722|Drug|Stiripentol|
290973|NCT01983709|Biological|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV 4 days prior to undergoing a planned prostatectomy.~The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
290974|NCT01983696|Other|5% oxygen concentration|the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
290975|NCT01983683|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
290976|NCT01983683|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
290977|NCT01983683|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
290978|NCT01983683|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
290979|NCT01983670|Other|Temporal electrical stimulation|
290980|NCT01983657|Drug|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
290981|NCT01983657|Procedure|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
291575|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
290982|NCT01983644|Device|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
290983|NCT01983644|Device|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
290984|NCT01983631|Other|Whole body vibration training|
290985|NCT01983618|Procedure|Interscalene nerve block and catheter|
290986|NCT01983618|Procedure|Interscalene catheter|
290987|NCT01983605|Device|LARIAT Suture Delivery Device|LAA exclusion procedure
290988|NCT01983592|Other|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
290989|NCT01983592|Other|Unmedicated lactose/sucrose globule|
290990|NCT01983579|Procedure|Intraocular anti-VEGF injection|
290991|NCT01983579|Device|SENSIMED Triggerfish|
290992|NCT01983566|Drug|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
290993|NCT01983566|Drug|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
290994|NCT01983566|Drug|BI 207127|BI 207127 as a single dose in fasted state
290995|NCT01983566|Drug|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
290996|NCT01983540|Biological|DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study
290997|NCT01983540|Biological|DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.
290998|NCT01983540|Biological|Infanrix hexa + Prevenar + Rotarix vaccine|Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
290999|NCT01983527|Procedure|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
291000|NCT01983527|Drug|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
291001|NCT01983514|Drug|8IU intranasal oxytocin|
291002|NCT01983514|Drug|24 IU intranasal oxytocin|
291003|NCT01983514|Drug|1 IU intravenous oxytocin|
291004|NCT01983514|Drug|Placebo|
291005|NCT01983501|Drug|Tucatinib (ONT-380)|Given twice per day, orally
291006|NCT01983501|Drug|T-DM1|Given intravenously once every 21 days
291007|NCT01983475|Drug|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
291008|NCT01983475|Drug|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
291009|NCT01983462|Drug|Clonidine|
291010|NCT01983462|Drug|Hydrochlorothiazide|
291011|NCT01983462|Drug|Placebo|
291012|NCT01983449|Drug|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
291013|NCT01983436|Other|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
291014|NCT01983423|Device|Endometrial Biopsy|An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
291015|NCT01983410|Behavioral|The risk assessment questionnaire|
291016|NCT01983410|Other|Blood specimens|
291017|NCT01983410|Other|tumor tissue samples will be requested|
291018|NCT01983397|Other|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
291019|NCT01983397|Other|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
291020|NCT01983384|Other|Anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
291021|NCT01983371|Drug|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
292137|NCT01974076|Device|Sham tDCS + CBT|
291022|NCT01983371|Other|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
291023|NCT01983358|Drug|JPI-289|PARP-1 inhibitor
291024|NCT01983358|Other|Placebo|Placebo
291025|NCT01983345|Procedure|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
291026|NCT01983319|Device|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
291027|NCT01983319|Device|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
291028|NCT01983319|Behavioral|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
291029|NCT01983306|Drug|SP-333 1 mg|Tablet
291030|NCT01983306|Drug|SP-333 3 mg|Tablet
291031|NCT01983306|Drug|SP-333 6 mg|Tablet
291032|NCT01983306|Drug|Placebo|Tablet
291033|NCT01983293|Device|QLV based implant strategy|
291034|NCT01983293|Device|Standard of care implant strategy|
291035|NCT01983280|Other|Healing Touch|
291036|NCT01983267|Drug|cannabis|use of cannabis oil or cigarets
291037|NCT01983254|Behavioral|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
291038|NCT01983254|Other|education program|web-based, ICU-specific education program
291039|NCT01983241|Biological|Alpha-1 MP|
291040|NCT01983241|Other|0.9% Sodium Chloride for Injection, USP|
291041|NCT01983228|Behavioral|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
291042|NCT01983215|Device|Prevena vac|
291043|NCT01983189|Procedure|transcranial magnetic stimulation|1 hz transcranial magnetic stimulation
291044|NCT01983163|Other|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
291045|NCT01983163|Other|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
291046|NCT01983150|Behavioral|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
291047|NCT01983150|Behavioral|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
291048|NCT01983137|Drug|Targinact® (oxycodone/naloxone)|
291049|NCT01983124|Drug|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.~Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
291050|NCT01983111|Drug|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
291051|NCT01983111|Drug|tramadol/acetaminophen|"Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
291052|NCT01983085|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
291053|NCT01983085|Device|Standard of Care|Dressing changed as per normal clinical practice
291054|NCT01983072|Dietary Supplement|Infant formula|
291055|NCT01983072|Other|Breastfeeding|Breastfeeding
291056|NCT01983046|Drug|Three different mixture of acetate, butyrate and propionate and palcebo|
291057|NCT01983033|Behavioral|Drop It training session|8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
291058|NCT01983033|Behavioral|treatment as usual|12 weeks of no intervention other than treatment as usual
291059|NCT01983020|Drug|Lidocaine|
291060|NCT01983020|Drug|Ketamine|
291061|NCT01983020|Other|Saline|
291062|NCT01983007|Procedure|High-intensity exercise|Performance of high-intensity exercise
291063|NCT01983007|Procedure|Low-intensity exercise|Performance of low-intensity exercise
291064|NCT01982994|Behavioral|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
291065|NCT01982981|Other|water provision|perception behavioral change at the beginning and at the end of the intervention
291066|NCT01982981|Other|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
291067|NCT01982968|Procedure|Surgery|Full fundoplication surgery for the treatment of abnormal GER
291068|NCT01982955|Drug|Tepotinib|Tepotinib will be administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment. RP2D will be determined as per safety monitoring committee (SMC) discretion.
292665|NCT01970124|Drug|KPS-0373, Low dose|
291069|NCT01982955|Drug|Gefitinib|Gefitinib will be administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment.
291070|NCT01982955|Drug|Pemetrexed|Pemetrexed will be administered at a dose of 500 milligram per square meter (mg/m^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
291071|NCT01982955|Drug|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
291072|NCT01982955|Drug|Carboplatin|Carboplatin will be administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered
291073|NCT01982942|Drug|ibudilast|Subjects randomly assigned to the ibudilast (MN-166) cohort will receive up to 100 mg/day for 96 weeks.
291074|NCT01982942|Drug|Placebo oral capsule|Subjects randomly assigned to the placebo cohort will receive placebo oral capsule for 96 weeks.
291075|NCT01982929|Procedure|TAP block (Bupivacaine 0.25% with epinephrine)|Ultrasound guided TAP blocks
291076|NCT01982929|Procedure|Sham block control|A blunt needleless syringe was firmly pressed on either side of the abdomen.
291077|NCT01982916|Drug|AGR tablet|
291078|NCT01982916|Drug|Placebo (for AGR tablet and/or Active Comparator)|
291079|NCT01982916|Drug|Active Comparator|
291080|NCT01982890|Other|Control|No intervention as this group is simply followed prospectively.
291081|NCT01982877|Behavioral|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
291082|NCT01982877|Behavioral|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
291083|NCT01982864|Drug|Gentamicin|"The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.~Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…).~The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD)."
291084|NCT01982851|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
291085|NCT01982851|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
291086|NCT01982838|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
291087|NCT01982838|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
291088|NCT01982825|Behavioral|Online intervention arm|See online intervention arm
291089|NCT01982825|Behavioral|Online control arm|See online control arm
291090|NCT01982812|Drug|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
291091|NCT01982812|Drug|Standard AED|Active comparitor, Standard AED
291092|NCT01982799|Drug|Oral placebo|placebo
291093|NCT01982799|Drug|Oral ibuprofen|Ibuprofen
291094|NCT01982799|Drug|oral naproxen|naproxen
291095|NCT01982799|Drug|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
291096|NCT01982786|Radiation|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
291097|NCT01982786|Radiation|Brachytherapy|Brachytherapy boost
291098|NCT01982773|Behavioral|Virtual Hope Box Smartphone App|Smartphone app
291099|NCT01982773|Behavioral|Enhanced Treatment as Usual|Printed materials
291100|NCT01982760|Drug|DDAVP|Patients Receiving DDAVP prior to operation
291101|NCT01982747|Drug|MGN-Placebo|
291102|NCT01982747|Drug|Placebo-MGN|
291103|NCT01982734|Dietary Supplement|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
291104|NCT01982721|Device|Locking mechanism for prosthetic knee|
291105|NCT01982695|Drug|Losartan|
291106|NCT01982695|Drug|Lisinopril|
291107|NCT01982682|Radiation|Total-Body Irradiation (TBI)|Undergo TBI
291108|NCT01982682|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
291109|NCT01982682|Drug|Cyclophosphamide|Given IV
291110|NCT01982682|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
291113|NCT01982656|Other|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
291114|NCT01982643|Drug|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
291115|NCT01982630|Drug|MK-8521|
291116|NCT01982630|Drug|Liraglutide|
291117|NCT01982630|Drug|Placebo|
291118|NCT01982617|Other|Motivational Interviewing|
291119|NCT01982617|Other|Psychoeducation|
291120|NCT01982604|Drug|TI-Inhalation Powder A|Inhaled Insulin
291121|NCT01982604|Drug|TI-Inhalation Powder B|Inhaled Insulin
291122|NCT01982591|Other|laboratory biomarker analysis|Correlative studies
291123|NCT01982591|Other|questionnaire administration|Ancillary studies
291124|NCT01982578|Dietary Supplement|Genistein|Subjects will be randomized 1:1 to receive 360 days of double blind treatment of genistein.
291125|NCT01982578|Other|Placebo|360 days of double blind treatment of placebo.
291126|NCT01982565|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
291127|NCT01982565|Other|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
291128|NCT01982539|Drug|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
291129|NCT01982513|Device|Ultrasound|The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
291130|NCT01982487|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
291131|NCT01982487|Drug|IDO1 inhibitor INCB024360|Given PO
291132|NCT01982487|Other|laboratory biomarker analysis|Correlative studies
291133|NCT01982487|Other|pharmacological study|Correlative studies
291134|NCT01982474|Biological|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
291135|NCT01982474|Other|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
291136|NCT01982461|Drug|Rosuvastatin|10mg,once daily
291137|NCT01982461|Drug|Crestor®|10mg,once daily
291138|NCT01982448|Drug|Cisplatin|75 mg/m2 IV q 3 weeks x 4 cycles
291139|NCT01982448|Drug|Paclitaxel|80mg/m2 weekly x 12 weeks (4 cycles).
291140|NCT01982435|Drug|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
291141|NCT01982435|Drug|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
291142|NCT01982422|Behavioral|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
291143|NCT01982422|Behavioral|Standard of Care|Normal standard-of-care for pregnancy.
291144|NCT01982409|Biological|Live Attenuated Varicella Vaccine|
291145|NCT01982396|Drug|ABC Twice Daily|
291146|NCT01982396|Drug|ABC Once Daily|
291147|NCT01982396|Drug|3TC Once Daily|
291148|NCT01982396|Drug|3TC Twice Daily|
291149|NCT01982383|Device|Micropulse Laser Treatment|
291150|NCT01982383|Other|No treatment|
291151|NCT01982357|Device|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
291152|NCT01982344|Device|mini-exchange-room|
291153|NCT01982331|Biological|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
291154|NCT01982331|Other|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
291155|NCT01982318|Drug|VitroGro® ECM|
291156|NCT01982318|Drug|Dulbecco's Phosphate Buffered Saline|
291157|NCT01982305|Procedure|Simulator|Axillary nerve anatomy lecture plus training with the simulator.
291158|NCT01982305|Procedure|Cadaver|Axillary nerve anatomy lecture plus training with the cadaver model.
291159|NCT01982292|Drug|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
291160|NCT01982292|Drug|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
291161|NCT01982266|Device|GRADION™ Hip Total Cartilage Replacement (TCR)™|
291162|NCT01982253|Drug|Fasiglifam|Fasiglifam tablets
291163|NCT01982253|Drug|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
291164|NCT01982240|Drug|Plecanatide|Plecanatide tablets QD for 12 weeks
291165|NCT01982240|Drug|Placebo|Matching placebo tablets QD for 12 weeks
291166|NCT01982240|Drug|Bisacodyl|Rescue medication
291167|NCT01982227|Drug|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
291168|NCT01982214|Device|sedentary|No intervention
291169|NCT01982214|Device|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
291170|NCT01982201|Drug|Lesinurad 400 mg|
291171|NCT01982201|Drug|Tums 500 mg and 750 mg|
291172|NCT01982201|Drug|MINTOX 10 mL|
291173|NCT01982175|Biological|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.~Escalation to 30mg/day should be accomplished in 3~7 days.~Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.~More than 30mg daily or 90mg weekly dose is prohibited~--------------------------------------------------------------------------------"
292138|NCT01974050|Behavioral|Text message surveillance|
291174|NCT01982149|Genetic|Group 1|Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
291175|NCT01982149|Genetic|Group 2|Correlate gene expression data from nasal and bronchial epithelium
291176|NCT01982149|Genetic|Group 3|Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
291177|NCT01982136|Procedure|end-to-end urethroplasty|
291178|NCT01982136|Procedure|substitution urethroplasty (buccal mucosa)|
291179|NCT01982136|Procedure|substitution urethroplasty (pedicled skin flap)|
291180|NCT01982123|Diagnostic Test|SPECT/CT|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT mid-radiation and post-radiation
291181|NCT01982123|Procedure|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
291182|NCT01982123|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
291183|NCT01982123|Drug|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
291184|NCT01982110|Behavioral|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
291185|NCT01982110|Behavioral|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
291186|NCT01982097|Drug|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
291187|NCT01982071|Drug|Micafungin|Intravenous (IV)
291188|NCT01982058|Other|communication intervention|
291189|NCT01982058|Other|counseling intervention|
291190|NCT01982058|Other|nutrition intervention|
291191|NCT01982058|Other|questionnaire administration|
291192|NCT01982045|Device|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
291193|NCT01982045|Other|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
291194|NCT01982032|Procedure|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
291195|NCT01982032|Device|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
291196|NCT01982032|Device|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
291197|NCT01982019|Behavioral|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
291198|NCT01982006|Procedure|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.~Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.~Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
291199|NCT01982006|Device|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.~Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.~Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
291200|NCT01981993|Biological|Urinary proteomic analysis|
291201|NCT01981980|Other|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
291202|NCT01981980|Other|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
291203|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
291204|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
291205|NCT01981954|Drug|Solifenacin succinate|Oral suspension
291206|NCT01981941|Drug|Gabapentin enacarbil|Oral
291207|NCT01981928|Drug|ASP7962|Oral
291208|NCT01981928|Drug|Placebo|Oral
291209|NCT01981915|Procedure|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
291210|NCT01981915|Procedure|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
291211|NCT01981902|Device|Non-Invasive Optical Spectroscopic|Non-Invasive Optical Spectroscopic
291212|NCT01981889|Drug|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
291213|NCT01981863|Drug|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
291214|NCT01981863|Drug|Placebo|Placebo administered in same volume as in experimental arm.
291215|NCT01981850|Biological|PRM-151|IV infusion
291216|NCT01981837|Drug|ALN-TTRSC (revusiran) for subcutaneous administration|
291217|NCT01981811|Drug|Aripiprazole|
291218|NCT01981811|Device|Ingestible Event Marker (IEM)|
291264|NCT01981460|Procedure|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
291265|NCT01981447|Drug|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
291576|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
292176|NCT01973712|Procedure|Retrograde Intramedullary Nailing (RIMN)|
291219|NCT01981798|Behavioral|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
291220|NCT01981772|Drug|4% lidocaine with 1:100,000 epinephrine|
291221|NCT01981772|Drug|4% buffered lidocaine with 1:100,000 epinephrine|
291222|NCT01981759|Drug|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
291223|NCT01981759|Other|Placebo|Participants will receive 12 weekly administrations of placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
291224|NCT01981759|Behavioral|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
291225|NCT01981746|Procedure|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
291226|NCT01981733|Device|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
291227|NCT01981720|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
291228|NCT01981707|Device|F-Choline-PET|
291229|NCT01981694|Drug|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
291230|NCT01981694|Drug|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
291231|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
291232|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
291233|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
291234|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
291235|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
291236|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
291237|NCT01981668|Drug|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
291238|NCT01981655|Drug|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
291239|NCT01981655|Drug|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
291240|NCT01981642|Other|Recording of LVAD data during routine visits and daily life.|Noninvasive diagnostic intervention.
291241|NCT01981642|Other|Recording of daily activity using wristwatch accelerometers.|Noninvasive diagnostic intervention.
291242|NCT01981629|Device|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
291243|NCT01981616|Drug|Vedolizumab|Vedolizumab for intravenous infusion
291244|NCT01981616|Drug|Placebo|Placebo intravenous infusion
291245|NCT01981616|Biological|Hepatitis B vaccine|
291246|NCT01981616|Biological|Oral cholera vaccine|
291247|NCT01981603|Other|navigator|
291248|NCT01981590|Device|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
291249|NCT01981564|Behavioral|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
291250|NCT01981564|Behavioral|Standard Asthma Education Control Group|Asthma Express home nurse visits for asthma education
291251|NCT01981551|Drug|PF-03084014|Treatment with the selective small-molecule >=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
291252|NCT01981525|Drug|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
291253|NCT01981499|Drug|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
291254|NCT01981499|Drug|Placebo|Placebo tablets
291255|NCT01981499|Drug|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
291256|NCT01981499|Drug|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
291257|NCT01981499|Drug|10 mg cetirizine|Single 10 mg dose of cetirizine
291258|NCT01981499|Drug|Placebo|Placebo tablets
291259|NCT01981486|Drug|Placebo Tablets|BID modified-release tablets
291260|NCT01981486|Drug|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
291261|NCT01981473|Other|no intervention|
291262|NCT01981473|Other|no intervention|
291266|NCT01981434|Other|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. The game incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
291267|NCT01981408|Drug|[^14C]-LY2801653|Administered orally
291268|NCT01981395|Drug|Fenobam|Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
291269|NCT01981395|Drug|Placebo|A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
291270|NCT01981369|Drug|Dexmedetomidine|Intravenous sedation with dexmedetomidine
291271|NCT01981369|Drug|Propofol|Intravenous sedation with propofol
291272|NCT01981369|Procedure|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
291273|NCT01981356|Behavioral|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to~experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.~Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
291274|NCT01981356|Other|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
291275|NCT01981343|Dietary Supplement|A-F Betafood|
291276|NCT01981343|Other|Placebo|
291277|NCT01981330|Biological|aMSC|aMSC injected into the vocal fold of the patient
291278|NCT01981330|Biological|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
291279|NCT01981317|Behavioral|Stepped Care Cognitive Behavioral Therapy|
291280|NCT01981317|Behavioral|Cognitive Behavioral Therapy|
291281|NCT01981291|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
291282|NCT01981291|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.~Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
291283|NCT01981291|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
291284|NCT01981291|Procedure|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
291285|NCT01981291|Drug|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
291286|NCT01981278|Drug|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
291287|NCT01981278|Drug|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
291288|NCT01981252|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
291289|NCT01981239|Device|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
291290|NCT01981226|Device|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
291291|NCT01981200|Other|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
291292|NCT01981187|Drug|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
291293|NCT01981174|Procedure|30-gauge needle|
291294|NCT01981174|Procedure|32-gauge needle|
291295|NCT01981161|Procedure|biological samples and clinical data|
291296|NCT01981148|Device|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
291297|NCT01981135|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
291456|NCT01979757|Other|Puregraft|
291457|NCT01979757|Other|Centrifugation|
291577|NCT01978691|Dietary Supplement|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
291298|NCT01981135|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
291299|NCT01981122|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
291300|NCT01981122|Drug|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
291301|NCT01981096|Behavioral|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
291302|NCT01981096|Behavioral|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
291303|NCT01981083|Dietary Supplement|Egg albumin-based protein supplement|
291304|NCT01981083|Dietary Supplement|Renal-specific oral supplement|
291305|NCT01981070|Behavioral|Mindfulness Intervention for Parents|See Study Arms
291306|NCT01981070|Behavioral|Support and Information for Parents|See Study Arms
291307|NCT01981057|Other|Numeta|parenteral receipt prescribed with Numeta
291308|NCT01981057|Other|Individual|parenteral receipt prescribed individually
291309|NCT01981044|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
291310|NCT01981031|Drug|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
291311|NCT01981031|Drug|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
291312|NCT01981018|Other|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|"ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:~Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.~Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.~Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print."
291313|NCT01981005|Drug|RO5424802|Single oral doses followed by IV or oral administration of a 14C-labeled tracer
291314|NCT01980992|Drug|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
291315|NCT01980979|Drug|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
291316|NCT01980966|Drug|MHAA549A|IV dose
291317|NCT01980966|Drug|Placebo|IV dose
291318|NCT01980966|Drug|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
291319|NCT01980953|Drug|GDC-0032 Phase III Tablet|Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
291320|NCT01980953|Drug|GDC-0032 Tablet|Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
291321|NCT01980953|Drug|GDC-0032 Capsule|Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
291322|NCT01980940|Drug|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
291323|NCT01980940|Drug|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
291324|NCT01980940|Drug|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
291325|NCT01980940|Drug|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
291326|NCT01980940|Drug|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
291327|NCT01980940|Drug|Placebo|Placebo gel applied topically.
291328|NCT01980940|Drug|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
291329|NCT01980940|Drug|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
291330|NCT01980927|Procedure|NUCCA atlas correction|"A chiropractic procedure involving correcting a misalignment of the atlas or top vertebra in the spine."
291331|NCT01980901|Device|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
291332|NCT01980888|Drug|Idelalisib|150 mg tablet administered orally twice daily
291333|NCT01980888|Drug|Bendamustine|Administered intravenously at a starting dose of 90 mg/m^2 for up to 6 cycles. Dosing will be based on mg/m^2 of body surface area.
291334|NCT01980888|Drug|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m^2 on Day 1 (Week 0) and 500 mg/m^2 thereafter for a total of 6 infusions
291335|NCT01980888|Drug|Placebo|Placebo to match idelalisib administered orally twice daily
291336|NCT01980875|Drug|Idelalisib|150 mg tablet administered orally twice daily
291337|NCT01980875|Drug|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
291338|NCT01980875|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
291339|NCT01980849|Drug|Nadroparin, long term|
291340|NCT01980849|Drug|Nadroparin: short-term|
291341|NCT01980836|Biological|Seasonal influenza vaccine|
291569|NCT01978743|Drug|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
291578|NCT01978691|Dietary Supplement|Polydextrose|Studied as a prebiotic
291579|NCT01978691|Other|Placebo|Control
291342|NCT01980823|Drug|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.~Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening~Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
291343|NCT01980823|Drug|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).~Dosage/Frequency: 80 mg once a day at bedtime~Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
291344|NCT01980823|Procedure|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
291345|NCT01980810|Drug|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
291346|NCT01980810|Drug|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
291347|NCT01980771|Behavioral|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
291348|NCT01980771|Behavioral|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
291349|NCT01980758|Procedure|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
291350|NCT01980745|Drug|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
291351|NCT01980745|Drug|Placebo|
291352|NCT01980732|Drug|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
291353|NCT01980706|Drug|Baclofen|Baclofen is a GABA-B agonist
291354|NCT01980706|Drug|Placebo|Pill containing no pharmacologically active substance.
291355|NCT01980693|Device|SonicBone ultrasound|The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
291356|NCT01980680|Drug|hCG|
291357|NCT01980680|Drug|Progesterone and Estradiol|
291358|NCT01980667|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
291359|NCT01980667|Drug|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
291360|NCT01980654|Drug|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
291361|NCT01980654|Drug|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
291362|NCT01980641|Behavioral|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
291363|NCT01980641|Device|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
291364|NCT01980628|Drug|ibrutinib|
291365|NCT01980615|Drug|Inhaled BGF (PT010) Dose 1|
291366|NCT01980615|Drug|Inhaled BGF (PT010) Dose 2|
291367|NCT01980615|Drug|Inhaled BGF (PT010) Dose 3|
291368|NCT01980615|Drug|Inhaled GFF (PT003)|
291369|NCT01980615|Drug|Inhaled Symbicort Dose 1|
291370|NCT01980615|Drug|Inhaled Symbicort Dose 2|
291371|NCT01980602|Procedure|Supervised Exercise program|
291372|NCT01980589|Drug|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
291373|NCT01980589|Drug|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
291374|NCT01980589|Drug|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
291375|NCT01980563|Procedure|ultrasound|
291376|NCT01980563|Procedure|combined monitoring|
291377|NCT01980550|Drug|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
291378|NCT01980537|Procedure|Magnetic wire navigation|
291379|NCT01980537|Procedure|Conventional wire navigation|
291380|NCT01980524|Drug|acipimox|
291381|NCT01980524|Drug|Placebo Oral Capsule|
291382|NCT01980498|Drug|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
291383|NCT01980498|Drug|Physician choice-Usual care (PC-UC)|"The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.~If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice."
291580|NCT01978678|Drug|Pulmicort|
291384|NCT01980485|Behavioral|Lung Age feedback and exhaled carbon monoxide|"In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.~If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.~Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation."
291385|NCT01980485|Behavioral|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
291386|NCT01980472|Biological|bevacizumab, carboplatin and paclitaxel|4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
291387|NCT01980459|Dietary Supplement|magnesium lactate|Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
291388|NCT01980446|Procedure|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
291389|NCT01980433|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
291390|NCT01980433|Other|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
291391|NCT01980433|Other|WCRS|Writer's cramp rating scale
291392|NCT01980433|Other|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
291393|NCT01980433|Other|visual analog scale of discomfort writing and parameters collected on touchpad|
291394|NCT01980420|Procedure|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
291395|NCT01980407|Drug|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
291396|NCT01980394|Procedure|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
291397|NCT01980381|Other|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
291398|NCT01980368|Other|Educational Intervention|Receive readings and attend book club
291399|NCT01980368|Behavioral|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
291400|NCT01980368|Other|Questionnaire Administration|Ancillary studies
291401|NCT01980355|Drug|Tranexamic Acid|
291402|NCT01980355|Other|Placebo|
291403|NCT01980342|Drug|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
291404|NCT01980329|Drug|Maraviroc|
291405|NCT01980316|Drug|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
291406|NCT01980316|Drug|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
291407|NCT01980303|Drug|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
291408|NCT01980277|Drug|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
291409|NCT01980264|Device|Harmonic Generation Microscopy|Harmonic Generation Microscopy is a nonlinear optical microscopy.
291410|NCT01980238|Device|cannula ileostomy|
291411|NCT01980238|Device|loop ileostomy|
291412|NCT01980238|Device|LAR|
291413|NCT01980225|Procedure|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
291414|NCT01980199|Drug|Fexinidazole|"600 mg tablets given orally, after the main daily meal~at the daily dose of 1800 mg (3 tablets) once a day for 4 days~continued by 1200mg (2 tablets)once a day for 6 days"
291415|NCT01980186|Device|TUS transcranial 2D ultrasound|
291416|NCT01980173|Procedure|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
291417|NCT01980173|Device|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
291418|NCT01980160|Device|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
291419|NCT01980160|Device|Unactivated Nometex Device|
291570|NCT01978730|Drug|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
291581|NCT01978665|Drug|prednisone|
291582|NCT01978652|Biological|Peginterferon Beta-1a|As specified in the treatment arm
291583|NCT01978626|Behavioral|App modules|
291420|NCT01980147|Behavioral|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
291421|NCT01980121|Device|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
291422|NCT01980108|Other|water|water
291423|NCT01980095|Drug|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~Rifabutin 150 mg~Amoxicillin 3000 mg~Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days."
291424|NCT01980095|Drug|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
291425|NCT01980082|Drug|Cefazolin|Antibiotic
291426|NCT01980082|Drug|Placebo|Placebo
291427|NCT01980069|Drug|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
291428|NCT01980069|Drug|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
291429|NCT01980056|Drug|Vosaroxin|Dose level 1: Vosaroxin 50 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg^m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg^m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
291430|NCT01980043|Procedure|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
291431|NCT01980030|Drug|Romiplostim|
291432|NCT01980017|Behavioral|Ottawa Model for Smoking Cessation|
291433|NCT01980004|Dietary Supplement|Potassium Citrate Supplementation|20 mEq taken twice daily
291434|NCT01980004|Other|Dietary Education|Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
291435|NCT01979991|Procedure|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.~Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
291436|NCT01979978|Other|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
291437|NCT01979965|Drug|Ranolazine (Active drug)|Ranolazine therapy for three months
291438|NCT01979965|Drug|Placebo|Placebo therapy for three months
291439|NCT01979952|Drug|Matching Placebo|twice daily dosing
291440|NCT01979952|Drug|Nintedanib|gelating capsule
291441|NCT01979939|Drug|DCV/ASV/BMS-791325|
291442|NCT01979926|Drug|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
291443|NCT01979913|Drug|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
291444|NCT01979900|Drug|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
291445|NCT01979900|Drug|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
291446|NCT01979887|Procedure|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
291447|NCT01979874|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
291448|NCT01979874|Other|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
291449|NCT01979861|Device|AEGEA Vapor System(TM)|vapor endometrial ablation
291450|NCT01979835|Device|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
291451|NCT01979822|Other|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
291452|NCT01979809|Behavioral|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
291453|NCT01979796|Device|Ecig 24 mg nicotine|Cigalike
291454|NCT01979796|Device|Ecig 0 mg nicotine|Cigalike
291455|NCT01979796|Device|Nicotine free inhalator|Plastic CIG a Like
291458|NCT01979744|Procedure|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
291459|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
291460|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
291461|NCT01979744|Procedure|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
291462|NCT01979731|Other|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
291463|NCT01979731|Other|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
291464|NCT01979718|Device|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
291465|NCT01979692|Procedure|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
291466|NCT01979692|Device|CT guided trans thoracic needle biopsy|
291467|NCT01979679|Drug|Lurasidone 80 mg|
291468|NCT01979679|Drug|Lurasidone 120 mg|
291469|NCT01979679|Drug|Lurasidone 160 mg|
291470|NCT01979666|Drug|nitrate patch|patients in the study group will get a nitrate patch
291471|NCT01979666|Drug|placebo patch|control group patients will get a placebo patch
291472|NCT01979666|Device|MRI scan|MRI scan after 6 weeks of treatment
291473|NCT01979653|Drug|dexmedetomidine alone or dexmedetomidine + midazolam|
291474|NCT01979640|Procedure|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
291475|NCT01979640|Procedure|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
291476|NCT01979640|Procedure|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
291477|NCT01979627|Procedure|transulnar approach interventional procedure|
291478|NCT01979627|Procedure|transradial approach interventional procedure|
291479|NCT01979614|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
291480|NCT01979614|Other|Placebo|5% v/v glucose solution
291481|NCT01979601|Drug|LGT209|150 mg lyophilized powder in glass vial
291482|NCT01979601|Drug|Placebo|Placebo comparator
291483|NCT01979588|Other|What's Going Around tool|Provider has access to the What's Going Around tool
291484|NCT01979588|Other|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
291485|NCT01979536|Drug|Brentuximab Vedotin|Given IV
291486|NCT01979536|Drug|Crizotinib|Given PO
291487|NCT01979536|Drug|Cyclophosphamide|Given IV
291488|NCT01979536|Drug|Cytarabine|Given IT and IV
291489|NCT01979536|Drug|Dexamethasone|Given PO or IV
291490|NCT01979536|Drug|Doxorubicin Hydrochloride|Given IV
291491|NCT01979536|Drug|Etoposide|Given IV
291492|NCT01979536|Drug|Ifosfamide|Given IV
291493|NCT01979536|Drug|Methotrexate|Given IT and IV
291494|NCT01979523|Other|Laboratory Biomarker Analysis|Correlative studies
291495|NCT01979523|Other|Pharmacological Study|Correlative studies
291496|NCT01979523|Drug|Trametinib|Given PO
291497|NCT01979523|Drug|Uprosertib|Given PO
291498|NCT01979510|Drug|MK-0663B|MK-0663B once daily for 8 days.
291499|NCT01979510|Drug|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
291500|NCT01979510|Drug|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
291501|NCT01979497|Procedure|Suture with Adhesive Stripping|
291502|NCT01979497|Procedure|Suture without Adhesive Stripping|
291503|NCT01979484|Drug|PPI-668 capsule|
291504|NCT01979484|Drug|PPI-668 tablet|
291571|NCT01978730|Drug|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
291584|NCT01978626|Behavioral|Traditional CBT-I|
291505|NCT01979471|Other|Advanced Care|"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:~Patient assessment~Laboratory assessment of HbA1c and lipids~Individual assessment of CVD risk and education about this risk~Calculation of cardiovascular risk will be facilitated by an online tool~Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options~Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.~Regular communication with the patient's family physician after each contact with the patient~Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."
291506|NCT01979458|Device|PSE|
291507|NCT01979445|Drug|Cangrelor|Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.
291508|NCT01979445|Drug|Clopidogrel|Clopidogrel 600 mg single oral dose
291509|NCT01979445|Drug|Prasugrel|Prasugrel 60 mg single oral dose
291510|NCT01979432|Other|Cardiovascular evaluation|
291511|NCT01979406|Biological|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
291512|NCT01979406|Biological|Ad4-PA-1|Ad4-PA will be given at 10^9, 10^10 and 10^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
291513|NCT01979406|Biological|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles~Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
291514|NCT01979393|Drug|Cabozantinib|
291515|NCT01979393|Drug|Placebo|
291516|NCT01979380|Drug|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
291517|NCT01979380|Drug|placebo|PO, once in the morning
291518|NCT01979367|Device|Anodyne|Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
291519|NCT01979354|Drug|Spinal morphine|0.15 mg spinal morphine
291520|NCT01979341|Procedure|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
291521|NCT01979328|Device|geko|
291522|NCT01979328|Device|Plaster cast|
291523|NCT01979302|Other|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
291524|NCT01979302|Other|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
291525|NCT01979289|Other|computerized cognitive remediation|
291526|NCT01979289|Other|computerized cognitive remediation:Control|
291527|NCT01979276|Drug|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
291528|NCT01979276|Drug|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
291529|NCT01979276|Drug|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
291530|NCT01979263|Other|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
291531|NCT01979263|Other|Placebo Computer Task|Computer task that does not actively modify attention bias
291532|NCT01979250|Procedure|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
291533|NCT01979237|Procedure|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
291534|NCT01979224|Other|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
291535|NCT01979211|Drug|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
291536|NCT01979211|Radiation|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
291537|NCT01979185|Drug|Simvastatin|
291538|NCT01979185|Drug|SSP-004184SS|
291539|NCT01979159|Behavioral|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
291540|NCT01979146|Other|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
291541|NCT01979133|Drug|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
291572|NCT01978730|Drug|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
291573|NCT01978717|Procedure|epidural anesthesia|
291574|NCT01978717|Procedure|general anesthesia|Patients received general anesthesia for surgery
291771|NCT01977144|Other|Comprehensive Chromosomal Screening|
291542|NCT01979107|Behavioral|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.~At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
291543|NCT01979081|Other|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
291544|NCT01979055|Behavioral|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
291545|NCT01979055|Behavioral|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
291546|NCT01979029|Procedure|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
291547|NCT01979029|Procedure|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
291548|NCT01979016|Drug|dupilumab|"Dupilumab is an anti-interleukin 4 monoclonal antibody (Anti-IL-4R alpha mAb) that is being studied for the treatment of moderate-to-severe eczema.~[In addition to active dupilumab treatment, patients are also required to apply a topical emollient twice daily from day -7 through day 8 as background treatment.]"
291549|NCT01979016|Drug|placebo|"Placebo is a look-alike substance with no active medication~[In addition to receiving placebo, patients are also required to apply a topical emollient twice daily from day -7 through day 8 as background treatment]"
291550|NCT01979003|Drug|Fluorescein|
291551|NCT01978964|Biological|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
291552|NCT01978951|Behavioral|Integrated Chronic Kidney Disease care|Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
291553|NCT01978951|Behavioral|Conventional CKD care|group counselling about optimal diets for CKD patients
291554|NCT01978938|Drug|Eravacycline|
291555|NCT01978938|Drug|Levofloxacin|
291556|NCT01978925|Other|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.~The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
291557|NCT01978912|Drug|KTP-001|KTP-001 is one time dose intradiscally.
291558|NCT01978899|Behavioral|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
291559|NCT01978899|Behavioral|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
291560|NCT01978873|Drug|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
291561|NCT01978873|Drug|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
291562|NCT01978860|Device|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
291563|NCT01978821|Procedure|Autologous bone marrow mononuclear cell transplantation|
291564|NCT01978795|Other|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
291565|NCT01978795|Other|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
291566|NCT01978782|Drug|raltegravir|
291567|NCT01978782|Drug|citalopram|
291568|NCT01978756|Other|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
291585|NCT01978613|Drug|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
291586|NCT01978613|Drug|placebo|Tablets for one-daily oral administration.
291587|NCT01978600|Drug|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
291588|NCT01978600|Drug|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
291589|NCT01978587|Drug|JTZ-951|
291590|NCT01978574|Behavioral|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
291591|NCT01978574|Behavioral|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
291592|NCT01978561|Biological|Post dosing with NT100|
291593|NCT01978561|Other|Post dosing with Placebo|
291594|NCT01978548|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
291595|NCT01978548|Drug|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
291596|NCT01978548|Drug|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
291597|NCT01978535|Drug|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
291598|NCT01978535|Drug|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
291599|NCT01978522|Other|Randomisation of questionnaire receipt.|"The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.~Self-completion questionnaire handed to participants immediately after completing the CAPI."
291600|NCT01978509|Drug|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
291601|NCT01978509|Drug|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
291602|NCT01978509|Drug|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
291603|NCT01978496|Drug|Placebo|matching placebo
291604|NCT01978496|Drug|Eletriptan 20 mg|20mg oral
291605|NCT01978496|Drug|Eletriptan 40 mg|40mg oral
291606|NCT01978496|Drug|Eletriptan 80 mg|80mg oral
291607|NCT01978483|Drug|Denosumab|
291608|NCT01978483|Radiation|UVB exposure|
291609|NCT01978483|Drug|Diphenylcyclopropenone|
291610|NCT01978483|Drug|Normal Saline|
291611|NCT01978470|Device|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
291612|NCT01978457|Drug|cocaine hydrochloride|
291613|NCT01978457|Drug|propranolol|
291614|NCT01978457|Drug|placebo|
291615|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy plus CME|
291616|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy|
291617|NCT01978431|Drug|cocaine hydrochloride|
291618|NCT01978431|Drug|methylphenidate|
291619|NCT01978418|Drug|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
291620|NCT01978418|Drug|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
291621|NCT01978405|Drug|Alpha lipoic acid|
291622|NCT01978392|Behavioral|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
291623|NCT01978366|Drug|HT-100|May be administered in either fed or fasted state
291624|NCT01978353|Behavioral|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
291625|NCT01978353|Behavioral|Psychoeducation|Participants receive information about memory functioning and aging
291626|NCT01978327|Drug|GSK2647544|repeat dose
291627|NCT01978327|Drug|drug-drug interaction|drug-drug interaction
291628|NCT01978314|Device|75 mg / 6 mL VFI™|Visible fluorescent injectate, a mixture of two different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
291629|NCT01978301|Drug|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
291630|NCT01978301|Drug|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
291631|NCT01978275|Device|stimulong 100, pajunk, germany|simulating catheter
291632|NCT01978275|Device|plexolong 100, pajunk, germany|nonstimulating catheter
291633|NCT01978262|Biological|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
291634|NCT01978249|Procedure|Systemic chemotherapy|
291635|NCT01978249|Procedure|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
291772|NCT01977131|Other|Cells|
292666|NCT01970111|Drug|KPS-0373, High dose|
291636|NCT01978236|Drug|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
291637|NCT01978236|Drug|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
291638|NCT01978223|Procedure|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
291639|NCT01978210|Device|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
291640|NCT01978184|Drug|gemcitabine|
291641|NCT01978184|Drug|abraxane|
291642|NCT01978184|Drug|hydroxychloroquine|
291643|NCT01978158|Drug|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
291644|NCT01978145|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
291645|NCT01978145|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
291646|NCT01978132|Procedure|forearm ischemia and reperfusion|both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
291647|NCT01978119|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
291648|NCT01978119|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
291649|NCT01978093|Biological|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
291650|NCT01978093|Biological|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
291651|NCT01978093|Biological|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
291652|NCT01978093|Biological|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
291653|NCT01978093|Biological|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
291654|NCT01978093|Biological|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
291655|NCT01978080|Device|Kinesia HomeView|
291656|NCT01978067|Procedure|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
291657|NCT01978054|Other|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
291658|NCT01978041|Other|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
291659|NCT01978041|Other|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
291660|NCT01978041|Other|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
291661|NCT01978041|Other|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
291662|NCT01978041|Other|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
291663|NCT01978041|Other|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
291664|NCT01978028|Drug|ferric carboxymaltose|
291665|NCT01978028|Drug|placebo|
291666|NCT01978015|Drug|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
291667|NCT01978015|Drug|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
291668|NCT01978015|Drug|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
291669|NCT01978015|Drug|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
291670|NCT01978002|Behavioral|Pain sensitivity testing|
291671|NCT01978002|Behavioral|Urodynamic testing|
291672|NCT01977989|Drug|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
291673|NCT01977976|Procedure|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
291674|NCT01977937|Drug|Gabapentin 250mg/5mL NDC:59762-5025-01|
291675|NCT01977937|Drug|Simple Syrup|
291676|NCT01977924|Dietary Supplement|one month polyphenols supplementation (600mg)|
291677|NCT01977924|Dietary Supplement|placebo (microcrystalline cellulose)|
291678|NCT01977911|Other|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
291679|NCT01977898|Drug|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
291680|NCT01977898|Drug|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
291681|NCT01977885|Behavioral|High Protein Diet|All participants will be individually counseled by an RD for ~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
291682|NCT01977885|Behavioral|Exercise|Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or ~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
291683|NCT01977872|Behavioral|A worksite activity-diet intervention|
291684|NCT01977859|Drug|Nesiritide|
291685|NCT01977859|Drug|Saline|
291686|NCT01977833|Other|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
291687|NCT01977833|Other|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
291688|NCT01977820|Drug|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
291689|NCT01977820|Drug|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
291690|NCT01977807|Device|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
291691|NCT01977794|Drug|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
292667|NCT01970111|Drug|KPS-0373, Low dose|
291692|NCT01977794|Drug|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
291693|NCT01977781|Drug|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
291694|NCT01977781|Drug|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
291695|NCT01977768|Biological|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
291696|NCT01977768|Biological|Placebo|
291697|NCT01977755|Drug|danegaptide|
291698|NCT01977755|Drug|Placebo|
291699|NCT01977742|Other|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
291700|NCT01977742|Other|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
291701|NCT01977729|Drug|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
291702|NCT01977729|Behavioral|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
291703|NCT01977703|Other|Ultra Conservative ICD Programming|
291704|NCT01977703|Other|Traditional ICD Programming|
291705|NCT01977690|Device|Clavicle Brace|
291706|NCT01977677|Radiation|radiation therapy|Undergo radiation therapy
291707|NCT01977677|Drug|temozolomide|Given PO
291708|NCT01977677|Drug|plerixafor|Given IV
291709|NCT01977677|Other|laboratory biomarker analysis|Correlative studies
291710|NCT01977677|Other|pharmacological study|Correlative studies
291711|NCT01977664|Other|no intervention|
291712|NCT01977651|Drug|Enzalutamide|Oral
291713|NCT01977638|Drug|CXD101|Capsules, administered orally
291714|NCT01977625|Drug|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
291715|NCT01977625|Other|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
291716|NCT01977612|Device|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
291717|NCT01977612|Device|Stainless steel staples|Skin closure using stainless steel staples.
291718|NCT01977599|Other|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
291719|NCT01977586|Other|Magnetic Resonance Imaging (MRI)|
291720|NCT01977573|Drug|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
291721|NCT01977573|Drug|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
291722|NCT01977560|Behavioral|Optimum Lifestyle Intervention|Participants will follow a high-protein, low-carbohydrate diet and participate in supervised exercise.
291723|NCT01977560|Behavioral|Standard Care|Participants will be given advice on exercise and the American Diabetes Association diet, as if they went to a Diabetes clinic.
291724|NCT01977547|Biological|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
291725|NCT01977534|Device|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating [formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating].
291726|NCT01977521|Device|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
291727|NCT01977521|Device|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
291728|NCT01977508|Device|ePTFE vascular access grafts|
291773|NCT01977118|Drug|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
292867|NCT01968720|Drug|CAT-2003|
291729|NCT01977495|Behavioral|Financial Incentive: Fixed Lottery|Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
291730|NCT01977482|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
291731|NCT01977482|Drug|Placebo|Matching placebo tablet for GSK1278863
291732|NCT01977482|Drug|rhEPO|rhEPO will be procured from local market
291733|NCT01977469|Behavioral|Low intensity resistance training|The LIRT group initiated the resistance training for UL with 30% of the 1RM, with 5% increases each nine sessions; therefore, the maximum load was 45% of the 1RM. The LL training initiated with 30% of the 1RM, increasing 7% each nine sessions, thus, the maximum load was 51% of the 1RM. Each exercise session consisted of three sets of 15 repetitions, with a 2 minutes interval between sets.
291734|NCT01977469|Behavioral|High intensity resistance training|the initial load for HIRT group was 60% of 1RM for UL with 5% increases each nine sessions; therefore, the maximum load reached 75% of the 1RM. The LL training initiated with 60% of the 1RM with 7% increments each nine sessions, as a result, the maximum load after 36 sessions was 81% of the 1RM. These patients underwent three sets of eight repetitions, with two minutes intervals between sets.
291735|NCT01977469|Behavioral|Aerobic training|Patients underwent an aerobic training in cycle ergometer, with load intensity determined as the same load the patient presented a VO2 value of 70-80% of the peak VO2 obtained in the symptom-limited CPET. Each session of aerobic training lasted 20-30min according to patient's tolerance.
291736|NCT01977456|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
291737|NCT01977443|Drug|APD-209 Eye drops|
291738|NCT01977443|Drug|APD-209 Placebo Eye drops|
291739|NCT01977430|Drug|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
291740|NCT01977417|Drug|Salsalate|
291741|NCT01977417|Drug|Placebo|
291742|NCT01977378|Drug|Sustained-Release Desvenlafaxine Hydrochloride|
291743|NCT01977378|Drug|Sustained-Release Venlafaxine Hydrochloride|
291744|NCT01977365|Behavioral|Growth promotion based on child centered approach|"- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.~Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.~Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.~- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
291745|NCT01977352|Drug|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
291746|NCT01977352|Drug|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
291747|NCT01977339|Drug|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
291748|NCT01977339|Drug|Bupivacaine|20 cc of 0.25% bupivacaine
291749|NCT01977326|Behavioral|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
291750|NCT01977326|Other|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
291751|NCT01977300|Drug|Valproate|serum level of 50 to 125 ug/L
291752|NCT01977300|Drug|Lithium|serum levels of 0.6 to 1.2 mmol/L
291753|NCT01977300|Drug|Risperidone|1 to 6 mg/day
291754|NCT01977300|Drug|Olanzapine|5 to 25 mg/day
291755|NCT01977300|Other|Placebo|manufactured to mimic risperidone and olanzapine
291756|NCT01977287|Device|Functional Electrical Stimulation|
291757|NCT01977287|Device|Ankle Foot Orthosis|
291758|NCT01977274|Other|gynecological cancer|blood and tumor samples
291759|NCT01977261|Procedure|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
291760|NCT01977261|Procedure|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
291761|NCT01977248|Behavioral|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
291762|NCT01977235|Drug|Irinotecan|
291763|NCT01977235|Drug|Cisplatin|
291764|NCT01977222|Device|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
291765|NCT01977209|Drug|Gossypol|
291766|NCT01977209|Drug|Placebo|
291767|NCT01977196|Biological|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
291768|NCT01977183|Dietary Supplement|MSPrebiotic|Potato Resistant Starch
291769|NCT01977170|Biological|Hib/PRP-T vaccine|Hib liquid vaccine
291770|NCT01977157|Device|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
291774|NCT01977118|Other|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
291775|NCT01977105|Behavioral|Grow Together peer group|"Participants in this intervention will:~Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.~Complete an intervention video activity approximately weekly:~1. View educational videos addressing topics related to healthy infant growth~2. Create photos/videos modeling healthy behaviors and post them to the group~3. Provide and receive feedback on posts~4. Be encouraged to share information with key caregivers of their child~Attend group party soon after enrollment, to meet peers and group leader in person.~Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.~Have basic program information provided to pediatrician to enhance conversation during office visits."
291776|NCT01977092|Behavioral|Motivational interviewing case management|
291777|NCT01977092|Behavioral|Resource referrals|
291778|NCT01977079|Other|procalcitonin|
291779|NCT01977066|Behavioral|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
291780|NCT01977066|Behavioral|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
291781|NCT01977053|Other|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:~Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~Nominative notebook containing details of chemotherapy administered and medical contacts.~Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
291782|NCT01977027|Other|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
291783|NCT01977001|Device|MigraineBoxTM|
291784|NCT01976988|Drug|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
291785|NCT01976962|Radiation|Stereotactic body RT with MR-guided boost|Patients will receive radiotherapy over 5 fractions delivered once per week over 29 days, with 7.25 Gy per fraction to the whole prostate and 8 Gy per fraction to the dominant intraprostatic lesion. There will be a minimum of 120 hours and maximum of 192 hours between fractions. The entire course of treatment should be completed within no less than 27 days and no longer than 30 days.
291786|NCT01976949|Behavioral|online social-networking intervention|
291787|NCT01976936|Drug|Low Dose Lovastatin|80 mg daily for 3 days
291788|NCT01976936|Other|Placebo|Placebo for 3 days
291789|NCT01976936|Drug|High Dose Lovastatin|640 mg daily for 3 days
291790|NCT01976923|Drug|Intravitreal bevacizumab|A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
291791|NCT01976923|Procedure|Small-gauge pars plana vitrectomy|
291792|NCT01976910|Drug|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
291793|NCT01976897|Other|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
291794|NCT01976897|Other|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
291795|NCT01976897|Other|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.~The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
291796|NCT01976871|Drug|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
291797|NCT01976858|Drug|PEX168|A injection administered subcutaneously
291798|NCT01976845|Drug|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
291799|NCT01976845|Drug|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
291800|NCT01976845|Drug|Saline|Saline 2 ml IV, in the pre-op area as a premedication
291801|NCT01976832|Behavioral|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
291802|NCT01976832|Behavioral|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.~The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
291803|NCT01976819|Device|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
291804|NCT01976806|Drug|Aspirin|
291805|NCT01976806|Drug|Docosahexaenoic acid|
292570|NCT01970722|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IP or IV
291806|NCT01976806|Drug|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
291807|NCT01976780|Drug|Artesunate|
291808|NCT01976780|Drug|Artemether Lumefantrine|
291809|NCT01976780|Drug|Mefloquine|
291810|NCT01976754|Drug|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
291811|NCT01976741|Drug|Rogaratinib (BAY1163877)|Oral administration twice daily. Starting dose is 100 mg per patient in the first cohort and will be escalated in other cohorts depending on any dose-limiting toxicities.
291812|NCT01976728|Drug|Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump|
291813|NCT01976728|Drug|Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump|
291814|NCT01976728|Drug|Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump|
291815|NCT01976728|Drug|Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)|
291816|NCT01976702|Behavioral|Enhanced Behavioral Skills Training|
291817|NCT01976676|Dietary Supplement|5-methyltetrahydrofolate|
291818|NCT01976676|Dietary Supplement|folic Acid|
291819|NCT01976663|Device|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
291820|NCT01976663|Device|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
291821|NCT01976650|Drug|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
291822|NCT01976637|Other|no compression|no compression stockings worn during the study
291823|NCT01976637|Device|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
291824|NCT01976624|Drug|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
291825|NCT01976611|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
291826|NCT01976598|Other|Sub-Sensory Stimulation|Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
291827|NCT01976585|Drug|rhuFlt3L/CDX-301|"rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.~RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7."
291828|NCT01976585|Drug|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
291829|NCT01976572|Drug|colestilan|
291830|NCT01976572|Drug|candesartan|
291831|NCT01976559|Device|Tympanic Membrane Displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration."
291832|NCT01976559|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
291833|NCT01976546|Device|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
291834|NCT01976520|Biological|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
291835|NCT01976507|Drug|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
291836|NCT01976494|Device|The domestic PCA equipment 'Accufuser Omnibus®'|"Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
291886|NCT01976104|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
291887|NCT01976091|Drug|scAAVrh74.tMCK.hSGCA|
291888|NCT01976078|Drug|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
291889|NCT01976065|Drug|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
291890|NCT01976065|Other|Standard Treatment|Standard Treatment no use of study drug
291837|NCT01976494|Device|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.~Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.~Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.~After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.~After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
291838|NCT01976481|Device|sunbed exposure|exposure to sunbed ultraviolet radiation
291839|NCT01976468|Other|SCC metastasis|occurrence of SCC metastasis
291840|NCT01976455|Other|20% fewer calories|
291841|NCT01976455|Other|40% fewer calories|
291842|NCT01976429|Other|flight/diving simulation|measurement of ET function during simulated flight/diving in pressure chamber
291843|NCT01976429|Other|ET function testing at ambient pressure|ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
291844|NCT01976429|Other|nasal video-endoscopy|examination of nose, nasopharynx,and Eustachian tube orifice
291845|NCT01976416|Drug|Hydroxyurea|
291846|NCT01976416|Drug|Placebo|
291847|NCT01976403|Behavioral|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
291848|NCT01976390|Drug|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
291849|NCT01976390|Drug|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
291850|NCT01976364|Drug|Tofacitinib|Tofacitinib 5 mg tablet twice daily
291851|NCT01976364|Drug|Tofacitinib|Tofactinib 10 mg tablet twice daily
291852|NCT01976364|Drug|Methotrexate|Methotrexate 7.5-20 mg weekly
291853|NCT01976364|Drug|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
291854|NCT01976338|Drug|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
291855|NCT01976338|Other|Sham injection|Sham intravitreal injection
291856|NCT01976325|Other|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
291857|NCT01976312|Other|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
291858|NCT01976312|Drug|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
291859|NCT01976299|Device|AVERT|
291860|NCT01976286|Other|Salicylic Acid Peels|
291861|NCT01976286|Other|Glycolic Acid Peels|
291862|NCT01976273|Device|1064nm Q-switch Laser|
291863|NCT01976273|Other|Glycolic Acid Peels|
291864|NCT01976260|Device|Fractional Radiofrequency|
291865|NCT01976260|Device|1550-nm Fractional Photothermolysis|
291866|NCT01976247|Device|High Intensity Focused Ultrasound Device|
291867|NCT01976247|Device|Noninvasive Cryolipolysis Device|
291868|NCT01976234|Other|Fresh RBC|Patients will receive fresh blood only
291869|NCT01976234|Other|Old RBC|
291870|NCT01976221|Behavioral|Prioritization|team-based multifaceted case-based interactive training program in priority setting and waiting time decision
291871|NCT01976208|Drug|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg~750mg，then dosing interval is every 2 weeks.
291872|NCT01976208|Drug|placebo|
291873|NCT01976195|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
291874|NCT01976195|Drug|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
291875|NCT01976182|Drug|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
291876|NCT01976182|Drug|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
291877|NCT01976169|Drug|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.~A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.~Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
291878|NCT01976156|Dietary Supplement|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
291879|NCT01976156|Dietary Supplement|Placebo|Placebo consists of rice flour
291880|NCT01976143|Drug|NKTR-102|
291881|NCT01976130|Procedure|Bronchoscopy|
291882|NCT01976117|Device|enose|
291883|NCT01976104|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
291884|NCT01976104|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
291885|NCT01976104|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
292571|NCT01970722|Other|Quality-of-Life Assessment|Ancillary studies
291891|NCT01976039|Other|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx with the aid of saline instillation
291892|NCT01976026|Device|Flow Diversion|
291893|NCT01976026|Device|Best Standard Therapy|
291894|NCT01976013|Device|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
291895|NCT01976000|Procedure|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
291896|NCT01975987|Device|Bonfils fiberscope|
291897|NCT01975974|Device|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
291898|NCT01975961|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
291899|NCT01975948|Other|Mental Health Practice Support Program|"training and (2) practice support.~Three half day workshop sessions over a 24 week period.~Practice support:~3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
291900|NCT01975948|Other|Treatment as Usual|Physicians manage patients with depression as usual
291901|NCT01975935|Drug|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
291902|NCT01975935|Drug|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
291903|NCT01975922|Behavioral|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
291904|NCT01975909|Device|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
291905|NCT01975896|Behavioral|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
291906|NCT01975870|Other|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
291907|NCT01975857|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
291908|NCT01975857|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
291909|NCT01975844|Other|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.~Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
291910|NCT01975831|Drug|MEDI4736|Anti-PD-L1
291911|NCT01975831|Drug|Tremelimumab|Anti-CTLA-4
291912|NCT01975818|Drug|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
291913|NCT01975818|Biological|Epoetin alfa/beta|
291914|NCT01975805|Other|Chlorhexidine Gluconate|
291915|NCT01975805|Other|Povidone Iodine|
291916|NCT01975779|Drug|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
291917|NCT01975779|Drug|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
291918|NCT01975779|Drug|Cohort B1: Lu AE58054|Two single oral doses 60 mg with >=7 days washout.
291919|NCT01975766|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
291920|NCT01975766|Device|External beam radiation therapy|
291921|NCT01975753|Drug|Morphine|
291922|NCT01975753|Drug|Fentanyl|
291923|NCT01975740|Other|Sham manual diaphragm release technique|
291924|NCT01975740|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
291925|NCT01975727|Drug|Placebo|Injection of placebo (saline 0.9%)
291926|NCT01975727|Drug|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
291927|NCT01975727|Drug|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
291928|NCT01975727|Drug|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
291929|NCT01975714|Drug|Preservative-free latanoprost|
291930|NCT01975714|Drug|Preservative-free bimatoprost|
291931|NCT01975701|Drug|BGJ398|Capsule for oral use.
291932|NCT01975688|Drug|Sativex|"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."
291934|NCT01975675|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
291935|NCT01975662|Drug|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
291936|NCT01975662|Drug|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
291937|NCT01975649|Drug|Tribulus Terrestris|patients will use 750 mg/day during 120 days
291938|NCT01975649|Other|Placebo|patients will use placebo pills with the same shape of the drug
291939|NCT01975636|Drug|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
291940|NCT01975623|Device|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
291941|NCT01975610|Drug|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
291942|NCT01975610|Drug|Placebo|Twice daily for 28 days
291943|NCT01975597|Procedure|Bone marrow aspirates and biopsy|
291944|NCT01975584|Behavioral|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
291945|NCT01975571|Device|Cochlear® Nucleus™ Hybrid L24|The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
291946|NCT01975571|Device|Cochlear® Nucleus™ Hybrid S12|The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
291947|NCT01975558|Biological|Sampling at baseline, one week after baseline, two weeks after baseline|
291948|NCT01975558|Biological|Sampling at baseline, during radiotherapy and after|
291949|NCT01975545|Drug|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
291950|NCT01975545|Drug|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
291951|NCT01975519|Drug|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
291952|NCT01975480|Drug|Desvenlafaxine|
291953|NCT01975467|Device|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
291954|NCT01975454|Drug|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
291955|NCT01975454|Drug|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
291956|NCT01975441|Drug|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
291957|NCT01975441|Drug|Albendazole|Albendazole 400mg
291958|NCT01975441|Drug|Ivermectin|Ivermectin 200 mcg/kg
291959|NCT01975428|Device|Withings Blood Pressure monitor|Home blood pressure monitor. Participants will measure their blood pressure 2 times per day up to 3 times per week.
291960|NCT01975428|Device|iBG Star Blood Glucose Monitor|Participants will measure their blood glucose up to 4 times per day, every day.
291961|NCT01975428|Device|Alive Cor Portable ECG mopnitor|Portable electrocardiogram. Subjects will monitor their cardiac rhythms only when they have symptoms.
291962|NCT01975428|Behavioral|Diese Management Program|
291963|NCT01975389|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
291964|NCT01975389|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
291965|NCT01975376|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
292002|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
292572|NCT01970722|Procedure|Therapeutic Conventional Surgery|Undergo surgery
291966|NCT01975376|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
291967|NCT01975363|Dietary Supplement|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
291968|NCT01975363|Other|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
291969|NCT01975363|Other|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
291970|NCT01975363|Other|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
291971|NCT01975337|Drug|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
291972|NCT01975324|Drug|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
291973|NCT01975324|Drug|Placebo|placebo (sugar pill) twice a day for two weeks
291974|NCT01975311|Other|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
291975|NCT01975311|Other|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
291976|NCT01975298|Drug|Laquinimod|Oral Administration
291977|NCT01975298|Drug|Avonex®|Interferon β1A 30 μg/0.5mL administered Intra Muscular
291978|NCT01975285|Drug|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
291979|NCT01975285|Drug|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
291980|NCT01975272|Drug|Ferinject|
291981|NCT01975272|Drug|Ferrous fumarate|
291982|NCT01975272|Drug|Placebo for ferrous fumarate|
291983|NCT01975272|Drug|Placebo for ferinject|
291984|NCT01975259|Drug|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution & have glucose levels recorded up to every 30 mins for 2hours
291985|NCT01975259|Drug|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution & have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
291986|NCT01975259|Drug|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
291987|NCT01975259|Drug|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
291988|NCT01975259|Drug|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
291989|NCT01975259|Drug|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).~After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
291990|NCT01975259|Other|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
291991|NCT01975259|Other|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
291992|NCT01975259|Other|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
291993|NCT01975259|Device|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid & every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
291994|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
291995|NCT01975246|Drug|hydrochlorothiazide|tablet
291996|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
291997|NCT01975246|Drug|Placebo|placebo matching hydrochlorothiazide tablet
291998|NCT01975233|Device|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
291999|NCT01975220|Drug|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
292000|NCT01975220|Drug|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
292001|NCT01975220|Drug|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
292573|NCT01970683|Dietary Supplement|VSL #3 BID|
292868|NCT01968720|Drug|Placebo|
292003|NCT01975220|Drug|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
292004|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
292005|NCT01975207|Behavioral|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
292006|NCT01975207|Behavioral|Internet Intervention|"One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice"
292007|NCT01975207|Behavioral|Depression Treatment Pathway|"There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family."
292008|NCT01975194|Drug|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
292009|NCT01975168|Device|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
292010|NCT01975155|Other|food questionnaire|
292011|NCT01975155|Other|Urinary mycotoxin test|
292012|NCT01975142|Drug|Trastuzumab - Emtansine|
292013|NCT01975129|Drug|Vagitocin|
292014|NCT01975116|Drug|azurin-derived cell-penetrating peptide p28|Given IV
292015|NCT01975103|Procedure|Topcon Endpoint Management|
292016|NCT01975090|Device|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
292017|NCT01975077|Drug|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
292018|NCT01975064|Drug|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
292019|NCT01975064|Drug|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
292020|NCT01975051|Drug|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
292021|NCT01975025|Procedure|Short daily dialysis for 2 weeks|
292022|NCT01975012|Drug|Rilpivirine|"For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules [2.5 mg/g]) each day with a meal.~For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.~For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available."
292023|NCT01974986|Other|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
292024|NCT01974986|Other|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
292025|NCT01974986|Other|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
292026|NCT01974973|Procedure|Autologous bone marrow mononuclear cell transplantation|Intrathecal autologous bone marrow mononuclear cell transplantation
292027|NCT01974947|Other|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
292028|NCT01974934|Drug|Desvenlafaxine Succinate|
292029|NCT01974921|Device|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
292030|NCT01974908|Procedure|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
292031|NCT01974895|Biological|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
292032|NCT01974895|Biological|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
292033|NCT01974882|Other|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
292034|NCT01974869|Drug|Anti-tumor necrosis factor alpha agents|Treatment with biologics
292035|NCT01974843|Drug|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
292036|NCT01974843|Drug|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
292037|NCT01974817|Biological|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
292038|NCT01974804|Procedure|MRI|
292039|NCT01974791|Behavioral|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
292040|NCT01974778|Dietary Supplement|Meal|Meal
292486|NCT01971398|Behavioral|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
292041|NCT01974765|Drug|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
292042|NCT01974752|Drug|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
292043|NCT01974752|Drug|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
292044|NCT01974752|Drug|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
292045|NCT01974739|Drug|Hydrochloorthiazide|
292046|NCT01974739|Drug|placebo|
292047|NCT01974726|Other|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
292048|NCT01974726|Other|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
292049|NCT01974726|Other|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
292050|NCT01974726|Other|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
292051|NCT01974726|Other|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
292052|NCT01974726|Other|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
292053|NCT01974726|Other|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
292054|NCT01974726|Other|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
292087|NCT01974466|Other|Goal A|controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
292055|NCT01974726|Other|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
292056|NCT01974700|Drug|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
292057|NCT01974687|Drug|Uprifosbuvir|Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
292058|NCT01974687|Drug|Placebo|Matching placebo to uprifosbuvir capsule administered by mouth.
292059|NCT01974687|Drug|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
292060|NCT01974674|Procedure|Allogeneic transplantation of intrahepatic islet|
292061|NCT01974661|Biological|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
292062|NCT01974648|Drug|propofol|
292063|NCT01974648|Drug|propofol and remifentanil|
292064|NCT01974635|Device|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
292065|NCT01974622|Drug|Visudyne|Half fluence verteporfin
292066|NCT01974609|Drug|Narcotic|Hydrocodone 5mg + acetaminophen 325 mg
292067|NCT01974609|Drug|non-narcotic|ibuprofen 600mg + acetaminophen 325 mg
292068|NCT01974596|Dietary Supplement|Probiotic tablets of Lactobacillus reuteri|
292069|NCT01974596|Dietary Supplement|Placebo tablets|
292070|NCT01974583|Procedure|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
292071|NCT01974583|Procedure|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
292072|NCT01974583|Procedure|covered with paraffin gauze|Group C covered with paraffin gauze
292073|NCT01974570|Dietary Supplement|Marealis refined peptide concentrate|2 tablets, once per day before noon
292074|NCT01974570|Dietary Supplement|Placebo|2 tablets, once per day before noon
292075|NCT01974557|Other|Exercise|
292076|NCT01974544|Drug|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
292077|NCT01974544|Procedure|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
292078|NCT01974544|Procedure|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
292079|NCT01974544|Drug|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
292080|NCT01974544|Drug|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration >4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (>4.0 mmol/L).
292081|NCT01974544|Behavioral|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
292082|NCT01974518|Drug|Rituximab and Cyclophosphamide IV|
292083|NCT01974505|Device|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
292084|NCT01974492|Procedure|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
292085|NCT01974492|Procedure|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
292086|NCT01974479|Biological|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
292088|NCT01974466|Other|Goal B|"controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:~1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
292089|NCT01974453|Radiation|Radiation dose|Radiation dose adsorbed by operators
292090|NCT01974440|Drug|Bendamustine|90 milligram per meter square (mg/m^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
292091|NCT01974440|Drug|Rituximab|375 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
292092|NCT01974440|Drug|Cyclophosphamide|750 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
292093|NCT01974440|Drug|Doxorubicin|50 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
292094|NCT01974440|Drug|Vincristine|1.4 mg/m^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
292095|NCT01974440|Drug|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
292096|NCT01974440|Drug|PCI-32765 (Ibrutinib)|560 mg (4*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
292097|NCT01974440|Drug|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
292098|NCT01974414|Drug|orally administered cedar honey|
292099|NCT01974401|Device|supragingival irrigators containing chlorhexidine|patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
292100|NCT01974388|Procedure|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
292101|NCT01974388|Procedure|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
292102|NCT01974375|Drug|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing <40 kg)
292103|NCT01974375|Drug|Fluconazole|Fluconazole 100~200mg/day, IV care until oral medication becomes possible
292104|NCT01974362|Device|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
292105|NCT01974362|Device|Monolithic Zirconia|rehabilitation with monolithic zirconia implant-prosthesis
292106|NCT01974362|Device|Zirconia-Feldspathic|restore dental implants with a zirconia suprastructure and feldspathic veneers
292107|NCT01974349|Drug|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
292108|NCT01974336|Drug|ursodeoxycholic acid|
292109|NCT01974323|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
292110|NCT01974323|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
292111|NCT01974310|Procedure|Vitrectomy & Intraocular gas fill|
292112|NCT01974310|Procedure|Postoperative face-down positioning|
292113|NCT01974297|Drug|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
292114|NCT01974297|Drug|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
292115|NCT01974284|Drug|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
292116|NCT01974258|Drug|Cobimetinib|Escalating dose
292117|NCT01974258|Drug|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
292118|NCT01974258|Drug|Onartuzumab|Administered by IV infusion every 2 weeks
292119|NCT01974258|Drug|Vemurafenib|Orally administered twice daily
292120|NCT01974245|Drug|Cholecalciferol|100,000 IU/week for 12 weeks
292121|NCT01974245|Drug|Placebo|100 drops/ week for 12 weeks
292122|NCT01974206|Biological|ASP0113|intramuscular injection
292123|NCT01974206|Drug|Placebo|intramuscular injection
292124|NCT01974193|Drug|Floseal|application of floseal on intervention arm
292125|NCT01974167|Drug|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
292126|NCT01974167|Drug|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
292127|NCT01974154|Other|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
292128|NCT01974154|Other|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
292129|NCT01974141|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
292130|NCT01974141|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
292131|NCT01974128|Procedure|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
292132|NCT01974115|Device|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
292133|NCT01974102|Behavioral|Lifestyle counseling|Active and control participants will receive nutritional and physical activity counseling.
292134|NCT01974102|Behavioral|Mindfulness Based Stress Reduction|Active participants will receive 8 weeks of Mindfulness Based Stress Reduction therapy.
292139|NCT01974037|Dietary Supplement|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups
292140|NCT01974037|Dietary Supplement|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups
292141|NCT01974024|Drug|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
292142|NCT01974011|Procedure|Performing dorsal penile nerve block (DPNB)|
292143|NCT01973998|Drug|Roflumilast|PDE4 inhibitor
292144|NCT01973998|Drug|Placebo|Inactive substance.
292145|NCT01973985|Other|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
292146|NCT01973985|Other|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.~Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.~Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.~Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
292147|NCT01973985|Procedure|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
292148|NCT01973985|Procedure|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
292149|NCT01973972|Behavioral|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
292150|NCT01973972|Behavioral|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
292151|NCT01973946|Other|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
292152|NCT01973933|Drug|Metformin and Pyrimethamine|
292153|NCT01973920|Drug|Oshadi Icp|
292154|NCT01973907|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.~Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.~Intervention end: Patient is free from vasoactive medication support and shock is reversed."
292155|NCT01973894|Procedure|Blood and urine sampling|"Blood and urine sampling will follow this schedule:~24h: blood (3ml)~48h: blood (3ml) and urine~End of infusion: blood (3ml)~6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.~Then all frozen samples will be analyzed to get Midazolam concentrations."
292156|NCT01973881|Procedure|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.~Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
292157|NCT01973868|Drug|Regorafenib (Stivarga, BAY73-4506)|
292158|NCT01973868|Drug|Cetuximab (ERBITUX)|
292159|NCT01973855|Drug|Western Medicine|Physical cooling,Hydrocortisone
292160|NCT01973855|Drug|TCM and Western Medicine|Third Infectious diseases soup recipe
292161|NCT01973842|Drug|0.1 mg triptorelin|
292162|NCT01973842|Drug|0.2 mg triptorelin|
292163|NCT01973842|Drug|0.4 mg triptorelin|
292164|NCT01973829|Other|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
292165|NCT01973816|Drug|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
292166|NCT01973816|Procedure|rectal shaving; rectal disc excision; colorectal resection|
292167|NCT01973816|Drug|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
292168|NCT01973816|Drug|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
292169|NCT01973790|Drug|Z-338|100mg TID
292170|NCT01973777|Device|IUB|intrauterine contraceptive device
292171|NCT01973764|Procedure|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
292172|NCT01973764|Procedure|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
292173|NCT01973751|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
292174|NCT01973725|Drug|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
292175|NCT01973712|Procedure|Locked Compression Plating|
292177|NCT01973699|Other|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
292178|NCT01973686|Behavioral|Physical activity|
292179|NCT01973673|Behavioral|Bone health educational materials|
292180|NCT01973660|Drug|Lapatinib|
292181|NCT01973660|Drug|Trastuzumab|
292182|NCT01973660|Drug|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
292183|NCT01973660|Drug|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
292184|NCT01973647|Behavioral|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
292185|NCT01973647|Behavioral|COPD Education|Six weekly sessions of COPD education
292186|NCT01973647|Behavioral|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
292187|NCT01973634|Radiation|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
292188|NCT01973634|Radiation|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
292189|NCT01973634|Radiation|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
292190|NCT01973634|Radiation|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
292191|NCT01973608|Drug|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
292192|NCT01973608|Drug|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
292193|NCT01973608|Drug|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
292194|NCT01973608|Drug|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
292195|NCT01973608|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
292196|NCT01973595|Dietary Supplement|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
292197|NCT01973595|Other|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
292198|NCT01973569|Drug|denosumab|denosumab administered subcutaneously
292199|NCT01973569|Drug|placebo|placebo administered subcutaneously to match denosumab
292200|NCT01973556|Other|Pharmacist-Physician Collaborative Medication Therapy Management|
292201|NCT01973543|Biological|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
292202|NCT01973530|Procedure|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
292203|NCT01973530|Procedure|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
292204|NCT01973517|Drug|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
292205|NCT01973517|Drug|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
292206|NCT01973504|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
292207|NCT01973504|Drug|Control|Crystalloid solution IV infusion drip to keep vein open
292208|NCT01973491|Drug|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
292209|NCT01973478|Device|DBS|
292210|NCT01973478|Device|SHAM|
292211|NCT01973465|Biological|Stool|Implanting fecal matter via colonscope
292212|NCT01973452|Drug|Dexmedetomidine|
292213|NCT01973452|Drug|Placebo|
292214|NCT01973439|Other|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
292215|NCT01973439|Other|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
292359|NCT01972399|Procedure|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
292216|NCT01973426|Device|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
292217|NCT01973413|Device|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
292218|NCT01973413|Device|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
292219|NCT01973413|Device|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
292220|NCT01973400|Dietary Supplement|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
292221|NCT01973400|Dietary Supplement|Placebo|Placebo
292222|NCT01973387|Drug|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
292223|NCT01973387|Drug|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
292224|NCT01973374|Behavioral|Text Message Intervention|
292225|NCT01973361|Device|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
292226|NCT01973361|Device|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
292227|NCT01973348|Device|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
292228|NCT01973348|Device|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
292229|NCT01973348|Device|2-hour patching|2-hour patching for moderate amblyopia
292230|NCT01973348|Device|6-hour patching|6-hour patching for severe amblyopia
292231|NCT01973335|Drug|Combination therapy with acetazolamide and low-dose loop diuretics|"Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~If diuresis <1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
292232|NCT01973335|Drug|High-dose loop diuretics|"Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~If diuresis <1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
292233|NCT01973335|Drug|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is >5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
292234|NCT01973322|Other|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
292235|NCT01973322|Other|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
292236|NCT01973322|Other|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
292237|NCT01973322|Biological|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
292238|NCT01973309|Drug|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
292239|NCT01973296|Behavioral|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
292240|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
292241|NCT01973283|Drug|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
292242|NCT01973270|Behavioral|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
292243|NCT01973257|Procedure|imaging diagnostics|
292244|NCT01973244|Drug|somapacitan|"A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation."
292245|NCT01973244|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
292246|NCT01973231|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
292247|NCT01973231|Drug|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
292248|NCT01973218|Biological|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
292249|NCT01973218|Biological|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
292250|NCT01973218|Biological|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
292251|NCT01973205|Drug|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
292252|NCT01973205|Drug|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
292253|NCT01973179|Radiation|Radiation therapy|Radiation therapy with protons
292254|NCT01973166|Device|Picosecond Q-switched Laser Treatment|
292255|NCT01973166|Device|Nanosecond Q-switched Laser Treatment|
292256|NCT01973153|Behavioral|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
292257|NCT01973153|Behavioral|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
292258|NCT01973153|Behavioral|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
292259|NCT01973140|Drug|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
292260|NCT01973140|Drug|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
292261|NCT01973127|Other|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
292262|NCT01973127|Other|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
292263|NCT01973114|Drug|Latanoprost|
292264|NCT01973114|Other|Placebo|
292265|NCT01973101|Drug|Cisplatin|50 mg/m2 - Day 1
292266|NCT01973101|Drug|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
292267|NCT01973101|Drug|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
292268|NCT01973101|Radiation|Radiotherapy|45 Gy
292269|NCT01973101|Radiation|Brachytherapy|80 Gy
292270|NCT01973062|Biological|rituximab|Given IV
292271|NCT01973062|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
292272|NCT01973049|Drug|Daclatasvir|
292273|NCT01973049|Drug|Asunaprevir|
292274|NCT01973049|Drug|BMS-791325|
292275|NCT01973049|Drug|Ribavirin|
292276|NCT01973049|Drug|Placebo matching Ribavirin|
292277|NCT01973036|Device|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
292278|NCT01973036|Drug|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
292279|NCT01973023|Other|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
292280|NCT01973010|Other|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
292281|NCT01973010|Drug|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
292282|NCT01972997|Device|SENSIMED Triggerfish|
292283|NCT01972984|Drug|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
292284|NCT01972971|Other|patient education|one by one patient education
292285|NCT01972958|Other|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
292286|NCT01972945|Procedure|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
292287|NCT01972945|Procedure|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
292288|NCT01972932|Dietary Supplement|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
292289|NCT01972932|Dietary Supplement|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
292290|NCT01972919|Radiation|Radiation Therapy|Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction.
292291|NCT01972919|Drug|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg 1m2 IV weekly x 6 doses. Capecitabine 825 mg/mm2 po bid Monday-Friday on days of radiation use 500mg tablets.
292292|NCT01972906|Device|moxibustion|apply moxibustion according to traditional Chinese medicine
292293|NCT01972906|Drug|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
292294|NCT01972893|Drug|ZYD1|"Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
292295|NCT01972893|Drug|Placebo|"Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
292296|NCT01972880|Drug|ASP1941|Oral
292297|NCT01972867|Device|NanoKnife Procedure|Under general anesthesia and with paralytic on board, patients will have monopolar probes inserted bracketing the tumor. A total of 90 electrical pulses will be delivered to irreversibly electroporate the tissue.
292298|NCT01972854|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
292299|NCT01972854|Drug|placebo solution|0.0% riboflavin ophthalmic solution
292300|NCT01972854|Device|KXL System|30mW/cm2
292301|NCT01972841|Drug|Solifenacin succinate|Oral tablet
292302|NCT01972841|Drug|Mirabegron|Oral tablet
292303|NCT01972841|Drug|Placebo to match solifenacin succinate|Oral tablet
292304|NCT01972841|Drug|Placebo to match mirabegron|Oral tablet
292305|NCT01972828|Drug|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
292306|NCT01972828|Drug|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
292307|NCT01972789|Drug|Ranibizumab|Ranibizumab solution for injection is commercially supplied in two presentations: as a pre-filled syringe (containing 1.65 mg of ranibizumab in 0.165 mL solution) and as a vial (containing 2.3 mg of ranibizumab in 0.23 mL solution) corresponding to a recommended dose of 0.5 mg (0.05 mL) given as a single intravitreal injection. It will be prescribed and administered by the investigator or designee
292308|NCT01972776|Drug|QBM076|Supplied in 25 mg and 75 mg capsules
292309|NCT01972776|Drug|Placebo|Matching placebo capsules
292310|NCT01972763|Drug|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
292311|NCT01972750|Drug|Dovitinib|daily oral intake of capsule
292312|NCT01972737|Biological|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
292313|NCT01972724|Drug|Pioglitazone|Pioglitazone tablets
292314|NCT01972724|Drug|Metformin|Metformin as prescribed in clinical practice
292315|NCT01972724|Drug|Sulfonylurea|Sulfonylurea as prescribed in clinical practice
292316|NCT01972711|Drug|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
292317|NCT01972711|Drug|Amisulpride|Amisulpride as a single oral dose of 400 mg
292318|NCT01972711|Drug|Placebo|single oral dose placebo
292360|NCT01972399|Procedure|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
292361|NCT01972386|Device|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
292362|NCT01972373|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
292363|NCT01972373|Device|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
292405|NCT01972061|Device|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
292319|NCT01972698|Other|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).~Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.~A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.~Participant will have access to an ultrasound simulator.~Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.~An investigator will supervise the sessions but will not interfere with the self-learning process.~- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
292320|NCT01972698|Other|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.~Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).~Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
292321|NCT01972685|Procedure|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
292322|NCT01972685|Procedure|Transbronchial Biopsy|
292323|NCT01972685|Procedure|VATS biopsy|
292324|NCT01972672|Drug|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
292325|NCT01972659|Drug|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
292326|NCT01972659|Drug|Magnesium Sulphate|"Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion"
292327|NCT01972659|Drug|sugammadex|4 mg/kg iv bolus at the end of the surgery
292328|NCT01972633|Procedure|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
292329|NCT01972633|Procedure|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
292330|NCT01972620|Drug|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
292331|NCT01972607|Other|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
292332|NCT01972594|Procedure|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
292333|NCT01972594|Device|Accelerometer(ActivPAL)|
292334|NCT01972581|Other|Reaction Time Training|
292335|NCT01972568|Drug|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
292336|NCT01972568|Drug|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
292337|NCT01972568|Drug|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
292338|NCT01972555|Procedure|Minimally invasive aortic valve replacement|
292339|NCT01972555|Procedure|Conventional aortic valve replacement|
292340|NCT01972542|Dietary Supplement|Oral fat tolerance test|
292341|NCT01972529|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
292342|NCT01972529|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
292343|NCT01972529|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
292344|NCT01972529|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
292345|NCT01972516|Drug|Tivozanib|
292346|NCT01972503|Drug|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
292347|NCT01972503|Procedure|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
292348|NCT01972490|Drug|avastin+chemotherapy of mFOLFOX6 or FOLFIRI|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
292349|NCT01972490|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|mFOLFOX-6 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV400mg/m2 on days 1 infused during 2 hours, followed by FU 400 mg/m2 intravenous bolus then 2400 mg/m2 continuous infusion for 46 hours of 2400 mg/m2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
292350|NCT01972477|Drug|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
292351|NCT01972477|Other|Placebo|Placebo will be given every day for 8 weeks.
292352|NCT01972464|Drug|Progesterone|oral micronized progesterone
292353|NCT01972464|Drug|Placebo|
292354|NCT01972451|Procedure|Colonoscopy with enhanced dye|
292355|NCT01972438|Drug|ASEDs|Experimental Intervention
292356|NCT01972438|Drug|Saline|Control Intervention
292357|NCT01972425|Other|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
292358|NCT01972412|Behavioral|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
292364|NCT01972347|Drug|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
292365|NCT01972347|Drug|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
292366|NCT01972334|Biological|FMT|as explained in study arm
292367|NCT01972334|Biological|placebo|salt water or saline will be given as placebo
292368|NCT01972321|Other|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:~Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.~Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians~Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
292369|NCT01972321|Behavioral|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
292370|NCT01972321|Other|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
292371|NCT01972308|Behavioral|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to accomplishing medical advice, and transfer of information between provider and patient.
292372|NCT01972308|Behavioral|Usual Care|Subjects receive asthma care from their proivders in the participating practices which generally follow asthma guidelines
292373|NCT01972282|Device|WATCHMAN Left Atrial Appendage Closure|
292374|NCT01972269|Drug|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
292375|NCT01972269|Drug|Lidocaine|2% lidocaine
292376|NCT01972243|Other|no intervention|
292377|NCT01972230|Drug|Sevoflurane|
292378|NCT01972230|Drug|Diprivan + Remifentanil TCI|
292379|NCT01972217|Drug|Olaparib|Olaparib bid
292380|NCT01972217|Drug|Placebo|Placebo bid
292381|NCT01972217|Drug|Abiraterone|Abiraterone 1000 mg
292382|NCT01972217|Drug|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
292383|NCT01972204|Behavioral|Intensive adherence instruction|Instruction with educational brochure
292384|NCT01972204|Behavioral|Control|Instruction as per usual practice
292385|NCT01972178|Drug|PRC-4016|
292386|NCT01972178|Drug|Placebo|
292387|NCT01972178|Drug|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
292388|NCT01972165|Procedure|Mini-incision carpal tunnel release|
292389|NCT01972165|Procedure|Endoscopic carpal tunnel release|
292390|NCT01972152|Drug|G-Pen(TM) 1 mg|
292391|NCT01972152|Drug|Lilly Glucagon(TM) 1 mg|
292392|NCT01972152|Drug|G-Pen(TM) 0.5 mg|
292393|NCT01972139|Device|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
292394|NCT01972139|Other|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
292395|NCT01972139|Device|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
292396|NCT01972113|Dietary Supplement|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
292397|NCT01972113|Dietary Supplement|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
292398|NCT01972113|Dietary Supplement|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
292399|NCT01972100|Device|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
292400|NCT01972100|Other|isokinetic exercise|
292401|NCT01972100|Device|Placebo low-level laser therapy|
292402|NCT01972087|Behavioral|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
292403|NCT01972074|Drug|Memantine|Capsule
292404|NCT01972074|Other|Placebo|Capsule
292439|NCT01971710|Behavioral|Community leader engagement|Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
292406|NCT01972048|Behavioral|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
292407|NCT01972048|Other|Print brochure|Mailed print brochure about breast cancer screening and community resources.
292408|NCT01972035|Drug|Valacyclovir|Experimental Arm
292409|NCT01972035|Drug|Valganciclovir|Standard of care
292410|NCT01972022|Device|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
292411|NCT01972022|Device|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
292412|NCT01972009|Procedure|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
292413|NCT01971983|Other|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
292414|NCT01971983|Other|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
292415|NCT01971983|Other|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
292416|NCT01971970|Biological|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
292417|NCT01971970|Biological|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
292418|NCT01971918|Biological|anti drug antibodies dosage|anti drug antibodies dosage
292419|NCT01971892|Other|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
292420|NCT01971892|Other|Standard oxygen therapy with facial mask|facial Venturi mask
292421|NCT01971879|Procedure|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
292422|NCT01971879|Procedure|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.~The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
292423|NCT01971853|Drug|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
292424|NCT01971853|Drug|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
292425|NCT01971840|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
292426|NCT01971827|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
292427|NCT01971814|Drug|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
292428|NCT01971801|Dietary Supplement|Vitamin D3 50,000 IU|Capsule given by mouth once a week
292429|NCT01971801|Other|Placebo|One capsule given by mouth weekly
292430|NCT01971788|Device|Optical Coherence Tomography of the infarct related artery|
292431|NCT01971775|Device|Ultrasonically activated Shears|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
292432|NCT01971775|Device|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
292433|NCT01971762|Behavioral|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
292434|NCT01971762|Behavioral|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
292435|NCT01971749|Procedure|Coronary stent procedure (CSP)|
292436|NCT01971749|Procedure|Coronary-artery bypass grafting (CABG)|
292437|NCT01971723|Other|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
292438|NCT01971723|Other|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
292440|NCT01971710|Behavioral|Community days|The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
292441|NCT01971710|Behavioral|Community Peer Groups|Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
292442|NCT01971684|Drug|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
292443|NCT01971671|Other|no intervention.|
292444|NCT01971658|Drug|Thalidomide®|
292445|NCT01971658|Drug|Cyclophosphamide|
292446|NCT01971658|Drug|Velcade®|
292447|NCT01971658|Drug|Dexaméthasone|
292448|NCT01971645|Drug|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
292449|NCT01971645|Drug|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
292450|NCT01971632|Drug|Oxycodone & naloxone combination, prolonged release|
292451|NCT01971632|Drug|placebo oxycodone / naloxone|
292452|NCT01971606|Drug|Rosuvastatin|"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."
292453|NCT01971593|Drug|Eplerenone|
292454|NCT01971580|Drug|Ambrisentan|
292455|NCT01971567|Device|HIRREM|
292456|NCT01971554|Drug|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
292457|NCT01971554|Drug|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
292458|NCT01971541|Behavioral|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
292459|NCT01971541|Behavioral|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
292460|NCT01971528|Device|Electronic muscle stimulator|Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
292461|NCT01971528|Other|Muscle strength training|Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
292462|NCT01971515|Drug|MSC2363318A|"Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.~Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle)."
292463|NCT01971515|Drug|MSC2363318A plus Trastuzumab|"Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion."
292464|NCT01971515|Drug|MSC2363318A plus Tamoxifen|"Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.~Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).~Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration."
292465|NCT01971502|Drug|Placebo to BI 1060469|single rising doses
292466|NCT01971502|Drug|BI 1060469|food effect
292467|NCT01971502|Drug|BI 1060469|single rising doses
292468|NCT01971489|Drug|Buparlisib|Given PO
292469|NCT01971489|Drug|Cisplatin|Given IV
292470|NCT01971489|Drug|Gemcitabine Hydrochloride|Given IV
292471|NCT01971489|Other|Laboratory Biomarker Analysis|Correlative studies
292472|NCT01971489|Other|Pharmacological Study|Correlative studies
292473|NCT01971489|Other|Questionnaire Administration|Ancillary studies
292474|NCT01971476|Drug|volasertib|intravenous administration on day 1of a treatment course
292475|NCT01971463|Other|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
292476|NCT01971450|Drug|Iloprost (Ventavis, BAYQ6256)|
292477|NCT01971437|Procedure|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
292478|NCT01971424|Dietary Supplement|Mg oxide|
292479|NCT01971424|Other|healthy diet|
292480|NCT01971411|Drug|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
292481|NCT01971411|Procedure|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
292482|NCT01971411|Behavioral|Usual sun exposure documentation|
292483|NCT01971411|Behavioral|Dietary intake of calcium, vitamin D, magnesium|
292484|NCT01971398|Behavioral|Positive FASD education brochure|Exposure to a positive FASD education brochure
292485|NCT01971398|Behavioral|Negative FASD education brochure|Exposure to a negative FASD education brochure
292487|NCT01971385|Drug|Squaric Acid solution|
292489|NCT01971346|Drug|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
292490|NCT01971320|Device|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
292491|NCT01971307|Other|SGE-PsyScan|
292492|NCT01971281|Device|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
292493|NCT01971281|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
292494|NCT01971281|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
292495|NCT01971268|Device|Dental Implant|place dental implants according to manufacturer guidelines
292496|NCT01971268|Device|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
292497|NCT01971268|Device|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
292498|NCT01971255|Biological|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
292499|NCT01971242|Drug|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
292500|NCT01971242|Other|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
292501|NCT01971229|Other|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
292502|NCT01971229|Other|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
292503|NCT01971216|Behavioral|Relaxation|
292504|NCT01971203|Drug|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
292505|NCT01971203|Behavioral|CBT|16 weeks of treatment
292506|NCT01971190|Drug|Intravitreal Aflibercept injection|"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~Central subfield thickness is thicker than the previous exam~BCVA letter score is worse than the previous exam (because of the persistent CSC)"
292507|NCT01971190|Drug|Sham injection|"Sham injection at baseline, at 1 month, and at 2 month.~At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~Central subfield thickness is thicker than the previous exam~BCVA letter score is worse than the previous exam (because of the persistent CSC)"
292508|NCT01971190|Procedure|Half-fluence photodynamic therapy|"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.~The PRN treatment method was decided by investigator's discretion.~Of patient who had persistent intra- or subretina fluid on SD-OCT~Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness~Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).~Central subfield thickness is thicker than the previous exam~BCVA letter score is worse than the previous exam (because of the persistent CSC)"
292509|NCT01971177|Device|Femtosecond laser cataract surgery|"The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.~The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.~Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.~All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform."
292510|NCT01971177|Procedure|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
292511|NCT01971164|Drug|JTZ-951|Subjects will receive JTZ-951 or Placebo
292512|NCT01971164|Drug|Placebo|
292513|NCT01971151|Behavioral|Exposure therapy|"Treatment protocol:~1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments."
292514|NCT01971138|Other|this is a survey|
292515|NCT01971112|Dietary Supplement|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
292516|NCT01971099|Drug|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
292517|NCT01971099|Other|Placebo|patients will take one pill a day (the same shape of the drug)
292518|NCT01971073|Device|transcranial direct current stimulation|"arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions )."
292574|NCT01970657|Biological|No treatment specified|No intervention
292519|NCT01971073|Device|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
292520|NCT01971060|Device|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
292521|NCT01971047|Drug|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG >180 per the following formula:~Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose"
292522|NCT01971047|Drug|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose > 180, per the following formula:~Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin~Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin~Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin~Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose"
292523|NCT01971034|Drug|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
292524|NCT01971034|Drug|Metformin|850mg, PO, every 8 hours, daily.
292525|NCT01971021|Device|PICC or subcutaneous venous port|
292526|NCT01971008|Device|Elastic abdominal binder|
292527|NCT01971008|Device|Placebo binder|
292528|NCT01970995|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
292529|NCT01970995|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
292530|NCT01970995|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
292531|NCT01970982|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
292532|NCT01970982|Other|Smoking abstinence (SA)|SA for 5 days in confinement
292533|NCT01970982|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
292534|NCT01970943|Other|Placebo|Placebo will be compared to No Intervention.
292535|NCT01970930|Procedure|Blood specimen|4 green top tube 40 cc of blood draw
292536|NCT01970917|Device|Olixia pure eye drops|
292537|NCT01970917|Device|Placebo|0.9% physiological saline solution
292538|NCT01970904|Drug|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
292539|NCT01970904|Drug|Ribavirin|Ribavirin tablets of various strengths for oral administration
292540|NCT01970904|Drug|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
292541|NCT01970891|Device|neuromuscular stimulation device|effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait relief
292542|NCT01970878|Drug|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
292543|NCT01970878|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
292544|NCT01970878|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
292545|NCT01970878|Drug|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
292546|NCT01970865|Drug|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
292547|NCT01970865|Drug|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
292548|NCT01970852|Other|Standard tablet computer|No special enhancements or links to personal health information.
292549|NCT01970852|Other|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
292550|NCT01970839|Device|tourniquet, sensory nerve conduction abnormality|
292551|NCT01970826|Procedure|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
292552|NCT01970826|Procedure|Sterilized Aseptic|Operatory room will be prepared totally aseptic
292553|NCT01970826|Procedure|Sterilized Clean|Operatory room will be prepared clean but not aseptic
292554|NCT01970826|Procedure|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
292555|NCT01970826|Procedure|Partial Rehabilitation|two or more implants to support partial rehabilitation
292556|NCT01970826|Procedure|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
292557|NCT01970813|Device|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
292558|NCT01970813|Device|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
292559|NCT01970800|Drug|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
292560|NCT01970787|Device|Radiofrequency Ablation (RFA) using the HALO Ablation System|
292561|NCT01970774|Other|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
292562|NCT01970748|Drug|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
292563|NCT01970748|Procedure|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
292564|NCT01970735|Biological|Blood test|
292565|NCT01970722|Drug|Carboplatin|Given IP or IV
292566|NCT01970722|Drug|Cisplatin|Given IP
292567|NCT01970722|Drug|Gemcitabine Hydrochloride|Given IP or IV
292568|NCT01970722|Other|Laboratory Biomarker Analysis|Correlative studies
292569|NCT01970722|Drug|Paclitaxel|Given IP or IV
292576|NCT01970644|Radiation|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
292577|NCT01970631|Behavioral|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).
292578|NCT01970631|Other|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
292579|NCT01970618|Drug|RV1162 single dose|Safety and tolerability of single escalating doses
292580|NCT01970618|Drug|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
292581|NCT01970618|Drug|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
292582|NCT01970618|Drug|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
292583|NCT01970618|Drug|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
292584|NCT01970618|Drug|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
292585|NCT01970605|Procedure|Surgical reconstruction|"In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.~Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.~Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible."
292586|NCT01970592|Behavioral|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
292587|NCT01970579|Device|Paclitaxel coated balloon|"Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD~Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~If two treatment balloons are necessary overlap between the balloon must be 10 mm~Inflation pressure 7-10 atm~Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
292588|NCT01970579|Device|uncoated PTA catheter|"Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD~Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)~Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)~If two treatment balloons are necessary overlap between the balloon must be 10 mm~Inflation pressure 7-10 atm~Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
292589|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
292590|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
292591|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
292592|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
292593|NCT01970553|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
292594|NCT01970553|Drug|Gemcitabine|1000 mg vial, powder for injectable solution
292595|NCT01970540|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
292596|NCT01970540|Drug|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
292597|NCT01970527|Biological|Ipilimumab|Given IV
292598|NCT01970527|Other|Laboratory Biomarker Analysis|Correlative studies
292599|NCT01970527|Other|Pharmacological Study|Correlative studies
292600|NCT01970527|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
292601|NCT01970514|Device|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
292602|NCT01970501|Drug|bucindolol hydrochloride|
292603|NCT01970501|Drug|metoprolol succinate|
292604|NCT01970501|Other|Placebo oral capsule|
292605|NCT01970488|Biological|Adalimumab|Administered by subcutaneous injection
292606|NCT01970488|Biological|ABP 501|Administered by subcutaneous injection
292607|NCT01970475|Biological|ABP 501|Solution for subcutaneous injection in pre-filled syringe
292608|NCT01970475|Biological|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
292609|NCT01970462|Drug|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
292610|NCT01970462|Drug|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
292611|NCT01970449|Biological|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
292612|NCT01970449|Biological|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
292613|NCT01970449|Biological|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
292614|NCT01970449|Biological|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
292615|NCT01970449|Biological|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
292616|NCT01970449|Biological|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
292617|NCT01970449|Biological|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
292618|NCT01970449|Device|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
292619|NCT01970436|Other|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
292620|NCT01970423|Device|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
292621|NCT01970423|Device|conventional right ventricular stimulation|
292622|NCT01970410|Drug|teriflunomide|14 mg oral teriflunomide daily
292623|NCT01970397|Device|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
292624|NCT01970397|Device|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
292625|NCT01970384|Device|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
292626|NCT01970384|Device|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
292627|NCT01970371|Drug|plazomicin|
292628|NCT01970371|Drug|colistin|
292629|NCT01970371|Drug|meropenem|
292630|NCT01970371|Drug|tigecycline|
292631|NCT01970371|Drug|antibiotic of Investigator's choice|
292632|NCT01970358|Biological|Poly-ICLC|
292633|NCT01970358|Biological|Peptides|
292634|NCT01970345|Drug|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
292635|NCT01970345|Drug|Placebo/saline|Placebo
292636|NCT01970332|Procedure|Revascularization Surgery|
292637|NCT01970332|Other|Supervised exercise therapy|
292638|NCT01970306|Device|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
292639|NCT01970293|Other|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
292640|NCT01970280|Drug|Enoxaparin|
292641|NCT01970267|Procedure|Laser Ablation of Floaters|
292642|NCT01970267|Procedure|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
292643|NCT01970254|Other|HBV screening tests|Three (3) hepatitis B virus (HBV) infection tests: HBsAg, anti-HBc, and anti-HBs
292644|NCT01970254|Behavioral|HBV risk assessment survey|Estimated time to complete the HBV risk assessment tool is 5 minutes.
292645|NCT01970241|Drug|NPH|NPH given per study table based on steroid dose and patient weight in kg.
292646|NCT01970241|Drug|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
292647|NCT01970228|Diagnostic Test|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
292648|NCT01970215|Drug|TA-8995|
292649|NCT01970215|Drug|Atorvastatin|
292650|NCT01970215|Drug|Rosuvastatin|
292651|NCT01970215|Drug|TA-8995 0mg (placebo)|
292652|NCT01970215|Drug|Placebo Statin|
292653|NCT01970202|Drug|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
292654|NCT01970202|Drug|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
292655|NCT01970202|Other|Control|no treatment
292656|NCT01970176|Drug|Tadalafil|
292657|NCT01970176|Drug|Placebo|
292658|NCT01970163|Other|DermACELL|Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
292659|NCT01970163|Other|GraftJacket|Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
292660|NCT01970163|Other|Conventional Care Dressings|"Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:~If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.~Hydrogels can also be used if the wound is in need of moisture.~For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.~A secondary dressing may be desired to add either loft or cushion."
292661|NCT01970150|Device|rTMS real|
292662|NCT01970137|Drug|KPS-0373, High dose|
292663|NCT01970137|Drug|KPS-0373, Low dose|
292664|NCT01970124|Drug|KPS-0373, High dose|
292668|NCT01970098|Drug|KPS-0373, High dose|28 weeks
292669|NCT01970098|Drug|KPS-0373, Low dose|28 weeks
292670|NCT01970098|Drug|Placebo|28 weeks
292671|NCT01970072|Drug|Remimazolam Tosylate|
292672|NCT01970072|Drug|Midazolam|
292673|NCT01970059|Drug|Extended-Release Carvedilol Sulfate|
292674|NCT01970059|Drug|Sustained-release Metoprolol Succinate|
292675|NCT01970046|Drug|Placebo/Metformin|"Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks~Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks~Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
292676|NCT01970046|Drug|SP2086 50 mg b.i.d/Metformin|"Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks~Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks~Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
292677|NCT01970046|Drug|SP2086 50 mg q.d./Metformin|"Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks~Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks~Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
292678|NCT01970033|Drug|Placebo|"Run in period ：oral tablets of Placebo twice daily for 2 weeks~Phase A : oral tablets of Placebo twice daily for 24 weeks~Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
292679|NCT01970033|Drug|SP2086 50 mg b.i.d.|"Run-in period: placebo twice daily for 2 weeks~Phase A:SP2086 50 mg b.i.d for 24 weeks~Phase B:SP2086 50 mg b.i.d for 28 weeks"
292680|NCT01970033|Drug|SP2086 100 mg q.d.|"Run-in period:placebo twice daily for 2 weeks~Phase A: SP2086 100 mg q.d. for 24 weeks~Phase B: SP2086 100 mg q.d. for 28 weeks"
292681|NCT01970020|Drug|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
292682|NCT01970007|Device|Zilver Vena Venous Stent|stenting
292683|NCT01969994|Other|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (−)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
292684|NCT01969994|Other|(−)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (−)-epicatechin and a single-carbon-14 radiolabeled (−)-[2-14C]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (−)-[2-14C]epicatechin.
292685|NCT01969981|Procedure|PICC placement with Sherlock 3CG|
292686|NCT01969968|Other|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
292687|NCT01969955|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
292688|NCT01969942|Biological|allogeneic stem cell transplantation|
292689|NCT01969942|Drug|Clyclophosphamide|
292690|NCT01969942|Drug|Fludarabina|
292691|NCT01969942|Drug|Busulfan|
292692|NCT01969942|Drug|Melphalan|
292693|NCT01969929|Procedure|20G Vitrectomy|
292694|NCT01969929|Procedure|23G vitrectomy|
292695|NCT01969916|Drug|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
292696|NCT01969903|Drug|Precedex injection|
292697|NCT01969890|Drug|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
292698|NCT01969877|Drug|cetuximab|
292699|NCT01969877|Drug|cisplatin|
292700|NCT01969864|Behavioral|HRSA Video Intervention|
292701|NCT01969864|Behavioral|PI Video Intervention|
292702|NCT01969864|Behavioral|CDC Health Website Intervention|
292703|NCT01969851|Drug|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).~Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
292704|NCT01969838|Drug|Momelotinib|Momelotinib tablet administered orally once daily
292705|NCT01969838|Drug|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
292706|NCT01969838|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
292707|NCT01969838|Drug|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
292708|NCT01969825|Behavioral|Massage|
292709|NCT01969812|Device|Evie Slow-release Insemination Device|
292710|NCT01969812|Other|Traditional Intrauterine Insemination|
292711|NCT01969799|Drug|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
292712|NCT01969799|Drug|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
292713|NCT01969786|Other|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
292714|NCT01969773|Drug|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
292715|NCT01969773|Drug|Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
292716|NCT01969760|Behavioral|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
292717|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
292718|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
292719|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
292720|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
292721|NCT01969747|Drug|Empagliflozin medium|Empagliflozin medium
292722|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
292723|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
292724|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
292725|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
292726|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
292727|NCT01969747|Drug|Empagliflozin low|Empagliflozin low
292728|NCT01969747|Drug|Empagliflozin high|Empagliflozin high
292729|NCT01969734|Device|Zephyr endobronchial valve placement|
292730|NCT01969721|Drug|fluticasone propionate|low dose
292731|NCT01969721|Drug|salmeterol|
292732|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
292733|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
292734|NCT01969721|Drug|tiotropium|tiotropium high dose
292735|NCT01969721|Drug|olodaterol|
292736|NCT01969721|Drug|olodaterol|
292737|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
292738|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
292739|NCT01969721|Drug|tiotropium|tiotropium low dose
292740|NCT01969721|Drug|fluticasone propionate|low dose
292741|NCT01969721|Drug|salmeterol|
292742|NCT01969708|Drug|aflibercept|
292743|NCT01969708|Drug|bevacizumab|
292744|NCT01969695|Drug|ABT-199|ABT-199 continuous once daily dosing
292745|NCT01969682|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
292746|NCT01969682|Drug|Rifampin|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
292747|NCT01969669|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
292748|NCT01969669|Drug|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
292749|NCT01969656|Drug|2MD|
292750|NCT01969656|Drug|Calcitriol|
292751|NCT01969656|Drug|Placebo|
292752|NCT01969643|Drug|SGN-LIV1A|SGN-LIV1A will be given by intravenous infusion (into the vein; IV)
292753|NCT01969643|Drug|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
292754|NCT01969630|Device|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
292755|NCT01969630|Device|PES|Systematic Paclitaxel eluting stent angioplasty
292756|NCT01969617|Drug|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
292757|NCT01969617|Drug|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
292758|NCT01969604|Behavioral|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.~The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.~Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:~• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
292759|NCT01969591|Procedure|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
292760|NCT01969591|Other|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
292761|NCT01969578|Drug|bicalutamide + triptorelin|
292762|NCT01969578|Drug|Cisplatin + Doxorubicin|
292763|NCT01969578|Drug|Carboplatin + Paclitaxel|
292764|NCT01969565|Drug|Carfilzomib|
292765|NCT01969565|Drug|Dexamethasone|
292766|NCT01969539|Drug|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
292767|NCT01969539|Drug|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
292768|NCT01969526|Other|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
292769|NCT01969513|Procedure|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
292770|NCT01969513|Procedure|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
292771|NCT01969500|Behavioral|Mobile Application|
292772|NCT01969500|Behavioral|Treatment as Usual (TAU)|
292773|NCT01969487|Other|Preoperative warm-up on simulator|
292774|NCT01969474|Drug|Cannabis|Cannabis capsules given once daily for a month
292775|NCT01969474|Drug|Placebo|Placebo
292776|NCT01969461|Behavioral|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
292777|NCT01969448|Procedure|Inframammary Fold Incision or Lateral Radial Incision|
292778|NCT01969448|Procedure|Lateral Radial Incision|
292779|NCT01969448|Procedure|Inframammary Fold Incision|
292780|NCT01969448|Device|Laser-assisted fluorescence angiography|
292781|NCT01969448|Drug|Indocyanine Green|
292782|NCT01969435|Drug|Carmustine|
292783|NCT01969435|Drug|Etoposide phosphate|
292784|NCT01969435|Drug|Cytarabine|
292785|NCT01969435|Drug|Melphalan HCl (propylene glycol-free)|
292786|NCT01969422|Procedure|observation|intervention is the contact with online question answering serice ad subseudd
292787|NCT01969409|Drug|Rituximab|i.v. rituximab given on two occasions 14 days apart.
292788|NCT01969409|Drug|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
292789|NCT01969396|Device|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
292790|NCT01969396|Device|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
292791|NCT01969383|Other|Heated pool training|
292792|NCT01969370|Behavioral|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
292793|NCT01969357|Drug|Placebo|Tablets(n=4),once daily for 84 days
292794|NCT01969357|Drug|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
292795|NCT01969357|Drug|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
292796|NCT01969357|Drug|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
292797|NCT01969357|Drug|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
292798|NCT01969331|Dietary Supplement|Normia|One capsule twice a day/14 days
292799|NCT01969331|Dietary Supplement|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
292800|NCT01969318|Drug|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
292801|NCT01969318|Drug|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
292802|NCT01969318|Drug|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
292803|NCT01969305|Behavioral|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
292804|NCT01969305|Behavioral|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:~Facts and Myth about HIV. HIV/STIs modes of transmission;~Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;~Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
292805|NCT01969292|Other|Colometer|Real time software based image analysis tool.
292806|NCT01969292|Other|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
292807|NCT01969266|Drug|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
292808|NCT01969266|Drug|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
292809|NCT01969240|Other|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the emergency department visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
292810|NCT01969227|Drug|Subanesthetic ketamine|Ketamine drip at a subanesthetic infusion rate (low dose ketamine 5 - 10 mcg/kg/min)
292811|NCT01969214|Device|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally~1 tablet, 3 times a day"
292812|NCT01969201|Drug|Urofollitrophin|
292813|NCT01969201|Drug|Follitrophin alpha|
292814|NCT01969175|Other|Low-glycemic-load and milk-free diet|
292815|NCT01969162|Procedure|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
292816|NCT01969149|Drug|Exenatide|
292817|NCT01969149|Drug|Insulin|
292818|NCT01969136|Drug|Drug: EVP-6124|
292819|NCT01969136|Drug|Placebo|
292820|NCT01969123|Drug|Drug: EVP-6124|
292821|NCT01969123|Drug|Placebo|
292822|NCT01969110|Dietary Supplement|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
292823|NCT01969097|Device|tDCS|transcranial direct current stimulation (tDCS)
292824|NCT01969097|Behavioral|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
292825|NCT01969084|Drug|Linagliptin|
292826|NCT01969084|Drug|Placebo|
292869|NCT01968707|Drug|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Apply topically.
292827|NCT01969084|Other|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
292828|NCT01969084|Other|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
292829|NCT01969084|Other|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
292830|NCT01969071|Drug|Levosimendan|The effects of levosimendan on renal function
292831|NCT01969071|Drug|Dobutamine|Standard Inotropic agent
292832|NCT01969058|Drug|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
292833|NCT01969045|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
292834|NCT01969045|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
292835|NCT01969032|Drug|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
292836|NCT01969019|Drug|methylprednisolone, prednisone|
292837|NCT01969006|Drug|Marcaine ½%|
292838|NCT01969006|Procedure|Needle prick|
292839|NCT01968993|Device|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
292840|NCT01968980|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
292841|NCT01968980|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
292842|NCT01968967|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
292843|NCT01968967|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
292844|NCT01968954|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
292845|NCT01968954|Other|Placebo|subcutaneous injection, every 2 weeks for 12 months
292846|NCT01968941|Radiation|Stereotactic Body Radiotherapy (SBRT)|
292847|NCT01968941|Radiation|Conventional Radiotherapy (CRT)|
292848|NCT01968915|Drug|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
292849|NCT01968915|Drug|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
292850|NCT01968902|Biological|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
292851|NCT01968902|Biological|Placebo|Saline injection on the day of injection visit
292852|NCT01968889|Other|Non invasive phrenic nerve stimulation|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
292853|NCT01968876|Other|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
292854|NCT01968850|Drug|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
292855|NCT01968837|Other|Cervical cancer screening|
292856|NCT01968824|Procedure|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
292857|NCT01968811|Device|Avance Foam dressing kit|
292858|NCT01968798|Drug|Aspirin|100mg enteric-coated aspirin, taken daily
292859|NCT01968798|Drug|Placebo|100mg enteric-coated placebo, taken daily
292860|NCT01968785|Radiation|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
292861|NCT01968785|Radiation|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
292862|NCT01968772|Other|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
292863|NCT01968759|Drug|Sevelamer|
292864|NCT01968759|Drug|Ramipril and Irbesartan|
292865|NCT01968733|Drug|Solithromycin|
292866|NCT01968733|Drug|Moxifloxacin|
292870|NCT01968707|Other|Normal Saline|Apply topically.
292871|NCT01968707|Drug|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
292872|NCT01968707|Drug|3M CHG/IPA Prep Tint 26-mL|Apply topically
292873|NCT01968694|Drug|IV Lidocaine|
292874|NCT01968694|Drug|IV diphenhydramine|
292875|NCT01968681|Procedure|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
292876|NCT01968668|Drug|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
292877|NCT01968668|Drug|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
292878|NCT01968668|Drug|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
292879|NCT01968668|Drug|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
292880|NCT01968668|Drug|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
292881|NCT01968668|Drug|Placebo|Placebo tablet once daily in the morning
292882|NCT01968668|Drug|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
292883|NCT01968668|Drug|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
292884|NCT01968655|Biological|OBI-1|
292885|NCT01968642|Behavioral|Educational Intervention|
292886|NCT01968629|Drug|Eovist|
292887|NCT01968616|Drug|Ranibizumab, 0.5mg, Intravitreal|
292888|NCT01968590|Drug|Cholecalciferol|DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
292889|NCT01968577|Drug|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
292890|NCT01968564|Drug|Placebo pill|sugar and other inert substances
292891|NCT01968564|Drug|High-dose curcumin pill|2000mg curcumin pill/day
292892|NCT01968564|Drug|Low-dose curcumin pill|500mg curcumin pill/day
292893|NCT01968551|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
292894|NCT01968551|Drug|DRV|800 mg tablet administered orally once daily
292895|NCT01968551|Drug|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
292896|NCT01968538|Radiation|Radiation Therapy|
292897|NCT01968525|Biological|pre-oxygen|3 min of preoxygenation before anesthesia induction.
292898|NCT01968512|Device|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
292899|NCT01968512|Device|Sham|Same character of Transcranial Direct Current Stimulation but without current
292900|NCT01968486|Drug|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
292901|NCT01968486|Drug|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
292902|NCT01968486|Drug|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
292903|NCT01968473|Device|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
292904|NCT01968460|Drug|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
292905|NCT01968460|Drug|Placebo|placebo
292906|NCT01968460|Drug|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
292907|NCT01968447|Other|hypocapnia|
292908|NCT01968447|Other|normocapnia|
292909|NCT01968434|Device|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
292910|NCT01968434|Drug|carbocisteine cough syrup|Mucolytic
292911|NCT01968421|Drug|OM-85|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
292912|NCT01968408|Dietary Supplement|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
292913|NCT01968408|Dietary Supplement|Placebo|
292914|NCT01968395|Drug|Caspofungin 70 mg|Intravenous use
292915|NCT01968382|Drug|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
292916|NCT01968382|Drug|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
292971|NCT01967953|Procedure|EVLP Group|"EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.~Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy"
292917|NCT01968369|Dietary Supplement|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
292918|NCT01968356|Drug|3M CHG/IPA Prep Colorless|Apply topically.
292919|NCT01968356|Drug|3M CHG/IPA Prep Tint|CHG 2%/IPA 70%
292920|NCT01968356|Drug|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Apply topically.
292921|NCT01968356|Other|Normal Saline|Apply topically.
292922|NCT01968343|Behavioral|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
292923|NCT01968343|Other|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
292924|NCT01968330|Behavioral|Go!®to sleep|
292925|NCT01968317|Drug|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
292926|NCT01968317|Drug|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
292927|NCT01968304|Other|Iron status follow up|
292928|NCT01968291|Behavioral|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
292929|NCT01968278|Other|Baked milk|
292930|NCT01968265|Drug|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
292931|NCT01968265|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
292932|NCT01968252|Other|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
292933|NCT01968239|Drug|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
292934|NCT01968226|Drug|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis >50% who are undergoing planned carotid endarterectomy will be imaged under PET with [F-18] RDG-K5
292935|NCT01968213|Drug|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
292936|NCT01968213|Drug|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
292937|NCT01968200|Drug|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
292938|NCT01968187|Drug|FE 992097|
292939|NCT01968187|Drug|Placebo|
292940|NCT01968161|Drug|Asenapine|
292941|NCT01968135|Drug|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
292942|NCT01968135|Drug|Placebo Sugar Pill|Placebo Sugar Pill
292943|NCT01968122|Device|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
292944|NCT01968109|Biological|Relatlimab|
292945|NCT01968109|Biological|Nivolumab|
292946|NCT01968109|Biological|BMS-986213|Relatlimab + Nivolumab
292947|NCT01968096|Device|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
292948|NCT01968083|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
292949|NCT01968083|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
292950|NCT01968070|Drug|LY3127760|Administered orally
292951|NCT01968070|Drug|Celecoxib|Administered orally
292952|NCT01968070|Drug|Placebo|Administered orally
292953|NCT01968057|Drug|Baricitinib|Administered orally
292954|NCT01968057|Drug|Ciclosporin|Administered orally
292955|NCT01968044|Drug|Gemigliptin|
292956|NCT01968044|Drug|Placebo to Linagliptin|
292957|NCT01968031|Drug|Istradefylline 40 mg|Istradefylline 40 mg and placebo
292958|NCT01968031|Drug|Istradefylline 20 mg|Istradefylline 20 mg and placebo
292959|NCT01968031|Drug|Placebo|Placebo
292960|NCT01968018|Drug|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
292961|NCT01968005|Drug|Etoreat®(Etodolac-Lidocaine Topical Patch)|
292962|NCT01968005|Drug|Placebo|
292963|NCT01967992|Behavioral|Behavioral: Low Carbohydrate, Ketogenic Diet|
292964|NCT01967992|Behavioral|American Diabetes Association Diet|
292965|NCT01967992|Behavioral|Mindfulness and Positive Affect Skills|
292966|NCT01967979|Drug|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
292967|NCT01967979|Drug|fluoxetine|Multiple doses
292968|NCT01967979|Drug|itraconazole|Multiple doses
292969|NCT01967966|Drug|GDC-0032|Single oral dose
292970|NCT01967966|Drug|GDC-0032|Single IV dose
292972|NCT01967940|Drug|TAF|25 mg tablet administered orally once daily with food
292973|NCT01967940|Drug|Placebo|Tablets to match TAF administered orally once daily with food
292974|NCT01967940|Drug|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
292975|NCT01967940|Drug|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
292976|NCT01967940|Drug|ATV|300 mg tablet administered orally once daily.
292977|NCT01967927|Drug|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
292978|NCT01967914|Other|PVI|Measurement of PVI (plethysmography variability index)
292979|NCT01967901|Behavioral|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
292980|NCT01967888|Drug|Reparixin|Solution for intravenous (IV) infusion; 2.772 mg/kg body weight/hour administered at 0.25 mL/kg/hour
292981|NCT01967888|Drug|Placebo|Physiologic solution administered at 0.25 mL/kg/hour
292982|NCT01967875|Drug|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
292983|NCT01967875|Drug|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
292984|NCT01967862|Procedure|computed tomography|Undergo CT
292985|NCT01967862|Procedure|bone scan|Undergo bone scan
292986|NCT01967862|Procedure|3-Tesla magnetic resonance imaging|Undergo axial MRI
292987|NCT01967862|Procedure|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
292988|NCT01967862|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
292989|NCT01967862|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
292990|NCT01967862|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
292991|NCT01967862|Other|laboratory biomarker analysis|Correlative studies
292992|NCT01967849|Diagnostic Test|Oral Glucose tolerance test|
292993|NCT01967836|Device|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
292994|NCT01967823|Biological|Anti-NY ESO-1 mTCR PBL|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
292995|NCT01967823|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
292996|NCT01967823|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
292997|NCT01967823|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
292998|NCT01967810|Drug|ANG1005|ANG1005 at a starting dose of 650 mg/m2 by intravenous infusion once every 3 weeks
292999|NCT01967810|Drug|Bevacizumab|For patients enrolled in the bevacizumab-refractory in recurrent GBM (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
293000|NCT01967797|Behavioral|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
293001|NCT01967784|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
293002|NCT01967771|Drug|DTG|DTG will be supplied as 50 mg tablet to be administered orally
293003|NCT01967771|Drug|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
293004|NCT01967758|Biological|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10^7cfu
293005|NCT01967758|Biological|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10^8cfu
293006|NCT01967758|Biological|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10^9cfu
293007|NCT01967758|Drug|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
293008|NCT01967745|Procedure|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
293009|NCT01967745|Procedure|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
293010|NCT01967732|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
293011|NCT01967732|Other|CC|Single use of subject's own conventional cigarette (CC)
293012|NCT01967732|Other|NNS|Single administration of 1 mg of nicotine
293013|NCT01967719|Other|mTHS 2.2|Single use of mTHS 2.2
293014|NCT01967719|Other|mCC|Single use of subject's own mCC
293015|NCT01967719|Other|NNS|Single administration of 1 mg of nicotine
293016|NCT01967706|Other|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
293017|NCT01967706|Other|mCC|Single use of subject's own menthol cigarette (mCC)
293018|NCT01967706|Other|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
293019|NCT01967693|Procedure|Retrospective analysis of data|Retrospective data analysis
293020|NCT01967680|Procedure|Non-sedation for intubated, mechanically ventilated patients|
293021|NCT01967680|Procedure|Controlgroup, sedation with daily wake-up trial|
293022|NCT01967667|Dietary Supplement|Liposomal glutathione|Escalating dose steps
293023|NCT01967667|Dietary Supplement|Placebo|escalating dose steps
293024|NCT01967654|Other|Technical Assistance, training and clinical reminders|
293025|NCT01967654|Other|Referral to Community Health Worker|
293026|NCT01967641|Drug|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
293027|NCT01967628|Dietary Supplement|Vitamin D3 (cholecalciferol)|
293028|NCT01967628|Dietary Supplement|Placebo Sugar Pill|
293029|NCT01967589|Drug|NNC0113-0987|Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
293030|NCT01967589|Drug|placebo|Once-daily doses for oral administration
293031|NCT01967576|Drug|Axitinib (AG-013736)|5 mg twice a day on a 28-day cycle.
293032|NCT01967550|Drug|diclofenac diethylamine, DDEA 2.32% gel|
293033|NCT01967550|Drug|Placebo|
293034|NCT01967537|Drug|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
293035|NCT01967537|Procedure|Radio-guided surgery|Using 68Gallium DOTATATE
293036|NCT01967524|Drug|botulinum toxin A + ropivacaïne|"D0 :~Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~QDSA (Saint-Antoine pain questionnaire)~QCD (Pain questionnaire)~MPI (Multidimensional Pain Inventory)~Beck scale~HAD (Hospital Anxiety and Depression scale)~SF36 (Short Form 36)~injection of botulinum toxin A associated with ropivacaïne~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
293037|NCT01967524|Drug|Ropivacaïne|"D0 :~Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)~QDSA (Saint-Antoine pain questionnaire)~QCD (Pain Questionnaire)~MPI (Multidimensional Pain Inventory)~Beck scale~HAD (Hospital Anxiety and Depression scale)~SF36 (Short Form 36)~injection of ropivacaïne alone~D30, D90, D120 and D150 (phone call): Calcul of the average of EN~D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
293038|NCT01967498|Drug|Montelukast|
293039|NCT01967485|Other|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
293040|NCT01967485|Other|Treatment as usual|Children will receive stimulant treatment for ADHD.
293041|NCT01967472|Drug|amodiaquine-artesunate (AQAS) fixed-dose|
293042|NCT01967472|Drug|Artemether-lumefantrine combination (AL) dispersable|
293043|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
293044|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
293045|NCT01967433|Drug|Diphenhydramine|
293046|NCT01967433|Drug|Placebo|
293047|NCT01967420|Behavioral|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
293048|NCT01967420|Behavioral|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
293049|NCT01967407|Procedure|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
293050|NCT01967394|Other|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
293051|NCT01967394|Other|No use of social media|No social media ads will be available in these counties.
293052|NCT01967381|Drug|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
293053|NCT01967368|Drug|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
293054|NCT01967368|Drug|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
293055|NCT01967355|Other|lipid apheresis|
293056|NCT01967342|Behavioral|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
293057|NCT01967342|Behavioral|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
293058|NCT01967342|Other|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
293059|NCT01967329|Drug|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
293060|NCT01967329|Drug|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
293061|NCT01967329|Drug|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
293062|NCT01967290|Device|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
293063|NCT01967290|Device|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
293064|NCT01967277|Device|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
293065|NCT01967277|Device|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
293066|NCT01967264|Drug|Udenafil|Udenafil tablets
293067|NCT01967264|Drug|Placebo|Placebo tablets
293068|NCT01967251|Drug|Udenafil|Udenafil tablets
293069|NCT01967251|Drug|Placebo|Udenafil placebo-matching tablets
293070|NCT01967238|Biological|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
293071|NCT01967225|Drug|Tedizolid Phosphate (Sivextro, BAY1192631)|BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
293072|NCT01967225|Drug|Linezolid|Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
293073|NCT01967212|Device|Game-based swallow biofeedback|"The intervention are divided into two parts：~Traditional swallowing training 30 min by speech therapist.~Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
293074|NCT01967212|Behavioral|Swallow training without biofeedback|"The intervention are divided into two parts：~Traditional swallowing training 30 min by speech therapist.~Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
293075|NCT01967199|Device|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
293076|NCT01967199|Device|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
293077|NCT01967186|Procedure|Intraportal islet transplantation|
293078|NCT01967186|Procedure|Intramuscular islet transplantation|
293079|NCT01967186|Procedure|Intramuscular transpl with stemcells|
293080|NCT01967186|Procedure|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
293081|NCT01967173|Drug|Flovent Diskus® 100 mcg|Flovent is an ICS
293082|NCT01967173|Drug|Flovent Diskus® 250 mcg|Flovent is an ICS
293083|NCT01967173|Drug|Flovent Diskus® 500 mcg|Flovent is an ICS
293084|NCT01967173|Drug|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
293085|NCT01967173|Drug|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
293086|NCT01967147|Drug|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
293087|NCT01967147|Drug|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
293088|NCT01967134|Biological|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
293089|NCT01967121|Device|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
293090|NCT01967121|Other|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
293091|NCT01967108|Other|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
293092|NCT01967095|Drug|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 & D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 & D2, & will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 & 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 & 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
293093|NCT01967082|Behavioral|APPSPIRE|Given APPSPIRE app
293094|NCT01967082|Behavioral|Focus Group|Attend focus group
293095|NCT01967082|Other|Survey Administration|Complete survey
293096|NCT01967069|Drug|DFD01 Spray|
293097|NCT01967069|Drug|Vehicle Spray|
293098|NCT01967043|Drug|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
293099|NCT01967017|Drug|Lidocaine|
293100|NCT01967017|Drug|Placebo|
293196|NCT01966328|Drug|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
293101|NCT01967004|Device|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
293102|NCT01966978|Drug|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
293103|NCT01966978|Drug|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
293104|NCT01966978|Drug|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
293105|NCT01966978|Drug|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180
293106|NCT01966965|Drug|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
293107|NCT01966965|Drug|NEDAX|AS SPECIFIED AT THE LEAFLET
293108|NCT01966926|Behavioral|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
293109|NCT01966913|Drug|Bevacizumab|
293110|NCT01966913|Drug|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
293111|NCT01966900|Biological|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
293112|NCT01966887|Genetic|MYDICAR-single intracoronary infusion|AAV1/Serca2a
293113|NCT01966887|Genetic|Placebo; single intracoronary infusion|single intracoronary infusion
293114|NCT01966861|Other|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score >14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required [CPIS>6], hemglobin>8g/dl triggers transfusion)
293115|NCT01966848|Device|Wich prosthesis is used|
293116|NCT01966835|Behavioral|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
293117|NCT01966822|Drug|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
293118|NCT01966822|Drug|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
293119|NCT01966809|Drug|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:~Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
293120|NCT01966783|Drug|Budesonide 2 mg suppository|per day
293121|NCT01966783|Drug|Budesonide 4 mg suppository|per day
293122|NCT01966783|Drug|Mesalazine 1 g suppository|per day
293123|NCT01966783|Drug|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
293124|NCT01966770|Device|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
293125|NCT01966770|Device|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
293126|NCT01966770|Device|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
293127|NCT01966770|Device|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
293128|NCT01966770|Device|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
293129|NCT01966770|Device|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
293130|NCT01966731|Drug|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
293131|NCT01966718|Drug|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
293197|NCT01966328|Drug|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
293198|NCT01966302|Drug|BPS-314d-MR|15-150 mcg po BID,
293132|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet."
293133|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet."
293134|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form."
293135|NCT01966692|Drug|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
293136|NCT01966692|Drug|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
293137|NCT01966692|Drug|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
293138|NCT01966692|Drug|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3*~*(The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation."
293139|NCT01966679|Drug|AZD7325|
293140|NCT01966679|Drug|Placebo|
293141|NCT01966666|Drug|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
293142|NCT01966666|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
293143|NCT01966666|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
293144|NCT01966666|Drug|Placebo|500mL 0.9% sodium chloride.
293145|NCT01966653|Drug|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
293146|NCT01966653|Drug|fosfomycin|fosfomycin 3g po single dose
293147|NCT01966640|Biological|Basophil Activation Test|blood sample for Basophil Activation Test
293148|NCT01966627|Other|ogtt|oral glucose tolerance test
293149|NCT01966627|Other|genotyping|genotyping to look for risk alleles
293150|NCT01966627|Other|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
293151|NCT01966627|Other|stool sample|stool sample taken to investigate metabolites
293152|NCT01966627|Other|liver biopsy|liver biopsy to examine for cellular change and steatosis
293153|NCT01966614|Drug|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
293154|NCT01966614|Other|Placebo|Single intraprostatic bilateral injection of vehicle only
293155|NCT01966601|Drug|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
293156|NCT01966601|Drug|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
293157|NCT01966601|Drug|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
293158|NCT01966601|Drug|Placebo|Placebo continuous intravenous infusion
293159|NCT01966588|Other|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
293160|NCT01966588|Other|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
293161|NCT01966575|Drug|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
293162|NCT01966562|Behavioral|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
293163|NCT01966562|Behavioral|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
293164|NCT01966549|Drug|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
293165|NCT01966549|Drug|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
293166|NCT01966536|Procedure|CD133+ cells transplantation into ovarian artery of one ovary|
293194|NCT01966341|Behavioral|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
293199|NCT01966289|Drug|CY|CY is administered intravenously at 200 mg/m2
293167|NCT01966523|Behavioral|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
293168|NCT01966523|Other|Control|
293169|NCT01966510|Other|Cord Blood Transplantation|
293170|NCT01966484|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
293171|NCT01966484|Drug|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
293172|NCT01966471|Drug|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
293173|NCT01966471|Drug|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
293174|NCT01966471|Drug|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
293175|NCT01966471|Drug|Paclitaxel|IV infusion of paclitaxel 80 mg/m^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
293176|NCT01966471|Drug|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
293177|NCT01966471|Drug|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
293178|NCT01966471|Drug|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter [mg/m^2] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m^2 in the first cycle and escalate to 100 mg/m^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
293179|NCT01966471|Drug|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
293180|NCT01966471|Drug|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
293181|NCT01966458|Device|HeartWare® VAS (HVAD)|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
293182|NCT01966458|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
293183|NCT01966445|Biological|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
293184|NCT01966432|Behavioral|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
293185|NCT01966432|Behavioral|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
293186|NCT01966419|Drug|ornithine phenylacetate|dose levels predicated on level of hepatic decompensation
293187|NCT01966419|Drug|placebo intravenous infusion|visually identical to active experimental
293188|NCT01966406|Device|Nasogastric tube|
293189|NCT01966406|Other|No nasogastric tube|
293190|NCT01966393|Other|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
293191|NCT01966380|Device|Leia|
293192|NCT01966367|Biological|CD34 Stem Cell Selection Therapy|The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
293193|NCT01966354|Procedure|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.~In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
293195|NCT01966341|Drug|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
293200|NCT01966289|Biological|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
293201|NCT01966289|Drug|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
293202|NCT01966276|Drug|Methyl-P plus Nutrient Formula|"Week 1 (take the following together twice a day-at breakfast and lunch)~One tablet of Methyl-P (5mg)~Four tablets of CFS Nutrient Formula~Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~Two tablets of Methyl-P (10mg)~Four tablets of CFS Nutrient Formula"
293203|NCT01966276|Drug|Methyl-P plus Nutrient matched placebos|"Week 1 (take the following together twice a day-at breakfast and lunch)~One tablet of Methyl-P Placebo~Four tablets of CFS Nutrient Placebo~Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):~Two tablets of Methyl-P Placebo~Four tablets of CFS Nutrient Placebo"
293204|NCT01966263|Procedure|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
293205|NCT01966263|Procedure|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
293206|NCT01966263|Procedure|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
293207|NCT01966263|Procedure|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
293208|NCT01966250|Device|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.~Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
293209|NCT01966250|Device|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
293210|NCT01966224|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
293211|NCT01966198|Other|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
293212|NCT01966185|Other|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
293213|NCT01966172|Drug|Ibuprofen|oral ibuprofen 400mg 4 times daily
293214|NCT01966172|Drug|Gabapentin|Oral Gabapentin 300mg twice daily
293215|NCT01966172|Drug|Morphine|10 mg morphine orally 4 times daily
293216|NCT01966172|Drug|Paracetamol|oral paracetamol 1000mg four times daily
293217|NCT01966159|Device|SYNERGY Investigational Device|percutaneous coronary intervention
293218|NCT01966159|Device|PE Plus Investigational Device|percutaneous coronary intervention
293219|NCT01966146|Device|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
293220|NCT01966133|Drug|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
293221|NCT01966120|Drug|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
293222|NCT01966120|Drug|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
293223|NCT01966120|Procedure|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
293224|NCT01966107|Drug|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
293225|NCT01966107|Drug|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
293226|NCT01966081|Other|Blood sample|
293227|NCT01966081|Other|tissue samples from abdominal subcutaneous adipose|
293228|NCT01966068|Other|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
293229|NCT01966055|Drug|Solithromycin|
293230|NCT01966042|Procedure|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
293231|NCT01966042|Procedure|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
293352|NCT01965184|Behavioral|Cognitive-Behavioral Therapy for Aggression|
293232|NCT01966042|Procedure|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
293233|NCT01966042|Biological|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
293234|NCT01966029|Drug|BMN 110|All pateints receive treatment with BMN 110
293235|NCT01966016|Procedure|Pacing|"In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.~In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared"
293236|NCT01966003|Drug|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
293237|NCT01966003|Drug|Paclitaxel|Administered 200 mg/m² IV Q3W
293238|NCT01966003|Drug|ABP 215|Administered 15 mg/kg Q3W by IV infusion
293239|NCT01966003|Drug|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
293240|NCT01965990|Other|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
293241|NCT01965977|Drug|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
293242|NCT01965964|Procedure|Questionnaire|
293243|NCT01965951|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
293244|NCT01965951|Other|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, ~30 mins each session.
293245|NCT01965938|Device|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
293246|NCT01965938|Device|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
293247|NCT01965925|Drug|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
293248|NCT01965925|Drug|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
293249|NCT01965912|Drug|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
293250|NCT01965899|Device|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
293251|NCT01965886|Procedure|Medial approach|Total knee replacement performed through a longitudinal incision medial to the patella
293252|NCT01965886|Procedure|Keblish approach|Total knee replacement performed through a longitudinal incision lateral to the patella
293253|NCT01965873|Dietary Supplement|Enteral nutrition|Same as arm description
293254|NCT01965860|Other|additional curriculum|
293255|NCT01965847|Behavioral|Medication therapy management|
293256|NCT01965834|Drug|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance < 50 mL/min will receive a reduced dose of 54 mg orally daily.
293257|NCT01965821|Device|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
293258|NCT01965821|Device|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
293259|NCT01965808|Drug|LY2157299|Administered orally
293260|NCT01965795|Dietary Supplement|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain‐Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
293261|NCT01965795|Dietary Supplement|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
293262|NCT01965782|Drug|[^14C]-LY3023703|Administered orally
293353|NCT01965184|Behavioral|Supportive Psychotherapy (SPT)|
293263|NCT01965769|Other|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
293264|NCT01965756|Drug|Metformin|
293265|NCT01965756|Drug|Placebos|
293266|NCT01965743|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
293267|NCT01965730|Drug|epsilon-aminocaproic acid (EACA)|
293268|NCT01965704|Drug|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
293269|NCT01965704|Drug|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
293270|NCT01965691|Dietary Supplement|Protein intake|"Oral consumption of eight hourly experimental meals-~4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil~4 isotopically labeled experimental meals."
293271|NCT01965678|Other|Osteopathic Manipulative Treatment|
293272|NCT01965665|Device|MediHoney HCS dressing|
293273|NCT01965652|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
293274|NCT01965652|Drug|Placebo|Placebo tablet taken orally once a day
293275|NCT01965639|Other|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
293276|NCT01965626|Drug|Oseltamivir|Oseltamivir 75 mg twice per day, 10 consecutive days
293277|NCT01965626|Drug|Dexamethasone|HD-DXM (orally at 40 mg daily for 4d)
293278|NCT01965613|Biological|Xilonix|IV
293279|NCT01965600|Drug|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
293280|NCT01965600|Drug|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
293281|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
293282|NCT01965600|Drug|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
293283|NCT01965600|Drug|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
293284|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
293285|NCT01965587|Procedure|novasure mirena IUS combined|novasure mirena IUS combined
293286|NCT01965574|Procedure|Trendelenburg position|
293287|NCT01965561|Device|CRoC|Use of Combat Ready Clamp (CRoC)
293288|NCT01965561|Device|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
293289|NCT01965561|Device|JETT|Use of Junctional Emergency Treatment Tool (JETT)
293290|NCT01965561|Device|SJT|Use of SAM Junctional Tourniquet (SJT)
293291|NCT01965548|Procedure|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:~splenectomy~splenic artery embolisation~non-operative management~any combination of the three treatments mentioned"
293292|NCT01965535|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
293293|NCT01965535|Drug|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing < 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
293294|NCT01965535|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
293295|NCT01965535|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
293296|NCT01965522|Drug|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
293297|NCT01965522|Drug|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
293298|NCT01965522|Drug|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
293299|NCT01965522|Drug|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
293300|NCT01965509|Drug|PEX168 or placebo|injection has to administered subcutaneously weekly
293301|NCT01965496|Drug|PEX168|A injection administered subcutaneously
293302|NCT01965483|Radiation|once-weekly breast irradiation|
293303|NCT01965470|Other|Combination Prevention|
293304|NCT01965470|Other|Enhanced Care|
293305|NCT01965431|Drug|BI 207127|Medium dose oral administration
293306|NCT01965431|Drug|BI 207127 placebo|
293307|NCT01965431|Drug|Faldaprevir placebo|
293308|NCT01965431|Drug|Faldaprevir|Medium dose oral administration
293309|NCT01965431|Drug|Moxifloxacin (Avalox®)|
293310|NCT01965418|Drug|Fufang Biejia Ruangan Tablet|
293311|NCT01965418|Drug|Placebo|
293312|NCT01965405|Drug|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
293313|NCT01965405|Behavioral|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
293314|NCT01965405|Behavioral|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
293315|NCT01965405|Behavioral|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
293316|NCT01965405|Behavioral|No additional treatment|No additional treatment will be given.
293351|NCT01965210|Other|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
293317|NCT01965405|Behavioral|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
293318|NCT01965405|Behavioral|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
293319|NCT01965392|Other|Health education intervention|'Health education intervention'
293320|NCT01965379|Other|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
293321|NCT01965379|Other|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
293322|NCT01965366|Behavioral|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
293323|NCT01965366|Drug|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
293324|NCT01965353|Drug|Panobinostat|- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
293325|NCT01965353|Drug|Dexamethasone|Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
293326|NCT01965353|Drug|Lenalidomide|Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
293327|NCT01965353|Drug|Bortezomib|Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
293328|NCT01965340|Other|Systematic Therapeutic Drug Monitoring for the intervention group|
293329|NCT01965327|Drug|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.~All doses will be administered via subcutaneous injection."
293330|NCT01965314|Other|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
293331|NCT01965314|Other|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
293332|NCT01965301|Drug|BP1.5375 suspension|single oral dose
293333|NCT01965301|Drug|Diphenhydramine|single oral dose of Diphenhydramine 50mg
293334|NCT01965301|Drug|Placebo|Single oral dose
293335|NCT01965288|Device|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
293336|NCT01965288|Device|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
293337|NCT01965275|Drug|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
293338|NCT01965262|Device|Hema-copolymer Lens|contact lens
293339|NCT01965262|Device|etafilcon A Lens|contact lens
293340|NCT01965249|Device|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HRT48mm
293341|NCT01965249|Device|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
293342|NCT01965236|Dietary Supplement|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
293343|NCT01965236|Dietary Supplement|Placebo|
293344|NCT01965223|Radiation|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
293345|NCT01965223|Radiation|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
293346|NCT01965210|Other|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
293347|NCT01965210|Other|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
293348|NCT01965210|Other|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
293349|NCT01965210|Other|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
293350|NCT01965210|Other|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
293354|NCT01965158|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
293355|NCT01965158|Drug|Placebo|Placebo tablet taken orally once a day
293356|NCT01965145|Drug|Gevokizumab|Sterile solution administered subcutaneously
293357|NCT01965145|Drug|Placebo|Sterile solution administered subcutaneously
293358|NCT01965132|Drug|Biologic DMARD|
293359|NCT01965119|Drug|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
293360|NCT01965106|Drug|QPI-1007 Injection|1.5 mg QPI-1007 Injection
293361|NCT01965106|Drug|(including placebo)|Sham injection procedure
293362|NCT01965093|Procedure|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
293363|NCT01965093|Procedure|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
293364|NCT01965080|Drug|Exemestane|One tablet Exemestane 25 mg daily
293365|NCT01965067|Drug|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state"
293366|NCT01965054|Dietary Supplement|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
293367|NCT01965041|Drug|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
293368|NCT01965028|Device|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
293369|NCT01965015|Device|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
293370|NCT01965002|Device|MRgHIFU|The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
293371|NCT01965002|Drug|Aspirin|325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
293372|NCT01965002|Drug|Enoxaparin|40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
293373|NCT01964989|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
293374|NCT01964989|Biological|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
293375|NCT01964963|Drug|Alogliptin|Alogliptin tablets
293376|NCT01964937|Biological|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
293377|NCT01964937|Biological|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10^8 PFU.
293378|NCT01964937|Biological|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10^6 PFU IM, for a planned maximum dose of 1.1×10^7 PFU.
293379|NCT01964937|Biological|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
293380|NCT01964937|Biological|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
293381|NCT01964924|Drug|Akt Inhibitor GSK2141795|Given PO
293382|NCT01964924|Other|Laboratory Biomarker Analysis|Correlative studies
293383|NCT01964924|Drug|Trametinib|Given PO
293384|NCT01964911|Drug|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN <3/10 : non opioids, EN 3-5/10 : weak opioids, EN>5/10 : strong opioids).~If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.~In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
293385|NCT01964898|Behavioral|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
293386|NCT01964898|Behavioral|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
293387|NCT01964898|Drug|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
293388|NCT01964898|Other|Printed Self-help materials for Smoking Cessation|
293389|NCT01964885|Dietary Supplement|IQP-AS-105|
293390|NCT01964885|Dietary Supplement|Placebo|
293391|NCT01964872|Drug|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
293392|NCT01964872|Drug|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
293393|NCT01964872|Drug|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
293394|NCT01964872|Drug|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
293395|NCT01964872|Drug|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
293396|NCT01964872|Drug|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
293397|NCT01964872|Drug|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
293398|NCT01964859|Biological|autologous skin fibroblasts|
293399|NCT01964846|Dietary Supplement|Resveratrol, curcumin|
293400|NCT01964846|Dietary Supplement|Placebo|
293401|NCT01964833|Procedure|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.~Patient will receive sham PDT."
293402|NCT01964833|Procedure|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
293403|NCT01964820|Behavioral|Positive Affect Skills Training|"Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.~The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.~For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012)."
293404|NCT01964807|Other|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
293405|NCT01964807|Other|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
293406|NCT01964807|Other|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
293407|NCT01964807|Other|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
293408|NCT01964807|Other|Moist snuff|Use moist snuff for 30 minutes
293409|NCT01964807|Other|sham smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
293410|NCT01964807|Other|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
293411|NCT01964807|Other|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
293412|NCT01964807|Other|sham moist snuff|Chew gum for 30 minutes
293413|NCT01964781|Drug|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
293414|NCT01964781|Drug|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
293415|NCT01964781|Drug|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
293416|NCT01964781|Drug|tranexamic acid plus saline|
293417|NCT01964781|Drug|saline|
293418|NCT01964768|Other|Skin prick-test|
293419|NCT01964755|Drug|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
293420|NCT01964755|Drug|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
293421|NCT01964755|Drug|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
293422|NCT01964755|Biological|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
293423|NCT01964755|Drug|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
293424|NCT01964755|Drug|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
293425|NCT01964742|Genetic|blood samples|
293426|NCT01964729|Device|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
293427|NCT01964729|Device|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
293428|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
293429|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
293430|NCT01964703|Drug|Rubus occidentalis extract|
293431|NCT01964677|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
293432|NCT01964664|Behavioral|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
293433|NCT01964664|Behavioral|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
293434|NCT01964651|Drug|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
293435|NCT01964651|Drug|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
293436|NCT01964651|Drug|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
293437|NCT01964651|Drug|Placebo|Matching placebo orally administered once daily for 10 days.
293438|NCT01964638|Procedure|Targeted Biopsy|
293439|NCT01964625|Other|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
293440|NCT01964599|Dietary Supplement|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
293441|NCT01964599|Dietary Supplement|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
293442|NCT01964599|Dietary Supplement|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
293443|NCT01964599|Dietary Supplement|Control|
293444|NCT01964586|Drug|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
293445|NCT01964586|Drug|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
293446|NCT01964586|Drug|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
293447|NCT01964573|Drug|Rotigotine|"Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
293448|NCT01964573|Other|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.~Frequency:~Day 1-3: 2 mg patch once daily~Day 4-6: 4 mg patch once daily"
293449|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: oral solution~Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)~Route of administration: oral use"
293450|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: tablet~Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)~Route of administration: oral use"
293451|NCT01964547|Drug|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
293452|NCT01964547|Drug|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
293453|NCT01964534|Drug|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
293454|NCT01964534|Drug|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
293455|NCT01964534|Drug|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
293456|NCT01964521|Device|Mepilex Transfer Ag|A soft silicone wound contact layer that absorbs and transfers exudate, maintains a moist wound healing environment and has antimicrobial properties.
293457|NCT01964508|Other|Fine needle aspiration|
293458|NCT01964495|Drug|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
293459|NCT01964495|Drug|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
293460|NCT01964495|Drug|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
293461|NCT01964482|Other|Strength training|Strength training followed by intake of a protein drink
293462|NCT01964469|Behavioral|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
293463|NCT01964456|Other|Joint perception task|
293464|NCT01964456|Behavioral|Body Shape Questionnaire|
293465|NCT01964456|Other|Measure of the heart rate|
293466|NCT01964430|Drug|nab-Paclitaxel 125 mg/m2|nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles
293467|NCT01964430|Drug|gemcitabine 1000 mg/m2|nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles
293468|NCT01964430|Drug|gemcitabine 1000 mg/m2|Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles
293469|NCT01964417|Drug|Colonoscopy after bowel cleansing|
293470|NCT01964404|Drug|Marijuana|
293471|NCT01964404|Drug|Dronabinol|
293472|NCT01964404|Drug|Placebo|
293473|NCT01964391|Drug|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
293474|NCT01964391|Drug|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
293475|NCT01964391|Drug|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
293476|NCT01964391|Drug|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
293477|NCT01964391|Drug|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
293478|NCT01964391|Drug|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
293479|NCT01964391|Drug|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
293480|NCT01964378|Drug|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
293481|NCT01964378|Drug|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
293482|NCT01964365|Drug|Cresto 20mg|tablet, rosuvastatin 20mg
293483|NCT01964365|Drug|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
293484|NCT01964365|Drug|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
293485|NCT01964352|Drug|tiotropium|fixed dose combination
293486|NCT01964352|Drug|placebo|
293487|NCT01964352|Drug|olodaterol|fixed dose combination
293488|NCT01964352|Drug|tiotropium|fixed dose combination
293489|NCT01964352|Drug|tiotropium|
293490|NCT01964352|Drug|olodaterol|fixed dose combination
293491|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
293492|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
293493|NCT01964326|Drug|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
293494|NCT01964300|Biological|peginterferon alfa-2b|Given SC
293495|NCT01964300|Other|laboratory biomarker analysis|Correlative studies
293496|NCT01964287|Drug|GEMBRAX|
293497|NCT01964287|Drug|FOLFIRINOX|
293498|NCT01964261|Device|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 2 NeuroPort Arrays (Pt) and 1 NeuroPort Array (SIROF). Each Pt array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface. The SIROF Array is similar to the Pt Array, the only difference is a change in the tip of the electrodes from platinum to sputtered iridium oxide film (SIROF).
293499|NCT01964248|Drug|Placebo|Placebo cream applied 2 hours before blood sample
293500|NCT01964248|Drug|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
293501|NCT01964235|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
293502|NCT01964235|Drug|Placebo|Placebo will be administered orally and continuously on a twice a day dosing schedule.
293503|NCT01964222|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
293504|NCT01964196|Drug|ASP1517|Oral administration
293505|NCT01964196|Drug|Placebo|Oral
293506|NCT01964183|Drug|tolterodine|Oral
293507|NCT01964183|Drug|mirabegron|Oral
293508|NCT01964170|Drug|degarelix|subcutaneous
293509|NCT01964170|Drug|Goserelin|subcutaneous
293510|NCT01964157|Drug|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
293511|NCT01964144|Drug|Dovitinib|Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
293512|NCT01964131|Drug|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2).~Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
293513|NCT01964131|Drug|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
293514|NCT01964118|Other|Intermittent Fasting group|Intermittent fasting for 12 months
293515|NCT01964118|Other|control group|usual diet for 6 months and intermittent fasting for other 6 months
293516|NCT01964105|Device|3D Imaging|
293517|NCT01964092|Behavioral|Individual Placement and Support|
293518|NCT01964092|Behavioral|Ordinary employment schemes|
293519|NCT01964079|Drug|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
293520|NCT01964079|Drug|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
293521|NCT01964066|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography balloon dilatation
293522|NCT01964066|Procedure|Thoracic epidural analgesia|Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
293523|NCT01964066|Procedure|Premedication|For premedication used trimeperidine 2%-1ml intravenously.
293524|NCT01964053|Behavioral|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
293613|NCT01963403|Drug|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
293614|NCT01963403|Drug|Placebo|1 pill per day; daily during study participation (up to 84 days)
293525|NCT01964053|Behavioral|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
293526|NCT01964040|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.~After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
293527|NCT01964027|Drug|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
293528|NCT01964014|Drug|advagrf|"All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat."
293529|NCT01964001|Dietary Supplement|Vitamin B-6|Vitamin B-6 50 mg/d
293530|NCT01964001|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg
293531|NCT01964001|Dietary Supplement|Vitamin B-6+Coenzyme Q10|Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
293532|NCT01964001|Other|Placebo|starch
293533|NCT01963988|Procedure|Transurethral Coagulation (TUC)|
293534|NCT01963988|Procedure|Transurethral Resection(TUR)|
293535|NCT01963962|Drug|Copper IUD|
293536|NCT01963962|Drug|Levonorgestrel IUD|
293537|NCT01963936|Device|Supreme LMA|
293538|NCT01963936|Device|Facial mask|
293539|NCT01963923|Behavioral|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
293540|NCT01963910|Drug|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
293541|NCT01963910|Drug|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
293542|NCT01963884|Procedure|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
293543|NCT01963884|Radiation|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
293544|NCT01963884|Other|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
293545|NCT01963871|Other|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
293546|NCT01963858|Procedure|Functional relaxation|Functional relaxation during colonoscopy
293547|NCT01963858|Procedure|No relaxation|No relaxation during colonoscopy
293548|NCT01963845|Drug|Sitagliptin|
293549|NCT01963845|Drug|Placebo|
293550|NCT01963832|Drug|Fluoxetine|
293551|NCT01963832|Drug|Placebo|
293552|NCT01963832|Procedure|eCMIT|
293553|NCT01963832|Procedure|Usual Care|
293554|NCT01963819|Other|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
293555|NCT01963806|Behavioral|Smartphone-supplemented iCBT|"The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support."
293556|NCT01963806|Behavioral|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
293557|NCT01963806|Other|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
293558|NCT01963793|Drug|Aprepitant|Aprepitant gel (10 mg/g)
293559|NCT01963793|Drug|Placebo|gel without active component
293560|NCT01963780|Device|OCS Lung Preservation|
293561|NCT01963767|Drug|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract*~Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
293562|NCT01963767|Dietary Supplement|Placebo|
293563|NCT01963754|Device|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
293564|NCT01963754|Drug|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
293565|NCT01963754|Drug|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
293615|NCT01963390|Drug|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
293566|NCT01963741|Drug|leukotriene D4|Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was <30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
293567|NCT01963741|Drug|histamine|Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was <30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
293568|NCT01963728|Drug|Insulin, Isophane|daily dosing based on fasting morning glucose levels
293569|NCT01963728|Drug|insulin glargine|daily dose based on fasting morning glucose levels
293570|NCT01963715|Drug|IMGN289|
293571|NCT01963702|Drug|Docetaxol|
293572|NCT01963702|Drug|Oxaliplatin|
293573|NCT01963702|Drug|Capecitabine|
293574|NCT01963689|Other|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
293575|NCT01963689|Other|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
293576|NCT01963689|Other|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
293577|NCT01963676|Device|tDCS|
293578|NCT01963676|Device|Sham stimulation|
293579|NCT01963663|Drug|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
293580|NCT01963663|Drug|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
293581|NCT01963637|Device|gastric tomodensitometry with gas at 3 months and 12 months|
293582|NCT01963624|Device|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
293583|NCT01963611|Drug|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
293584|NCT01963611|Drug|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
293585|NCT01963611|Drug|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
293586|NCT01963611|Drug|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
293587|NCT01963611|Drug|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
293588|NCT01963598|Drug|REGN1033 (SAR391786)|
293589|NCT01963598|Drug|placebo|
293590|NCT01963572|Other|SG will be screened every time when they visit the clinics.|
293591|NCT01963559|Drug|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
293592|NCT01963546|Other|different types of anesthesia|
293593|NCT01963546|Drug|Dexmedetomidine|After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
293594|NCT01963507|Behavioral|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
293595|NCT01963494|Behavioral|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
293596|NCT01963494|Behavioral|Individual planning intervention|Target persons form action plans on their own.
293597|NCT01963494|Behavioral|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
293598|NCT01963481|Drug|Exemestane|
293599|NCT01963481|Drug|Cyclophosphamide|
293600|NCT01963468|Behavioral|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
293601|NCT01963455|Biological|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
293602|NCT01963442|Radiation|Chest X-ray|at Day 0, Day 30 and relapse
293603|NCT01963442|Biological|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
293604|NCT01963442|Drug|Augmentin|2 tablets 3 times a day for 5 days from Day 3
293605|NCT01963442|Drug|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
293606|NCT01963442|Drug|Beta-Lactams|administered from Day 0 to Day 3
293607|NCT01963429|Procedure|radiofrequency ablation|"* RFA(radiofrequency ablation )~RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)~performed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm~the duration of a single RFA session was 10 min to 15 min."
293608|NCT01963429|Radiation|Proton beam therapy|"* Proton~66 GyE /10 fx, 6.6 GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume),TLV30<40%,and/orRLV30<30%)"
293609|NCT01963416|Dietary Supplement|macro- and micro-nutrient matched control (240 ml)|
293610|NCT01963416|Dietary Supplement|Orange juice|
293611|NCT01963416|Dietary Supplement|whole orange fruit|
293612|NCT01963416|Dietary Supplement|Processed whole orange|
293616|NCT01963377|Device|O2 through nasal cannulae|supplementation of O2 through nasal cannulae during bronchoscopy
293617|NCT01963377|Device|O2-channel|supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
293618|NCT01963364|Dietary Supplement|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
293619|NCT01963364|Dietary Supplement|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
293620|NCT01963338|Device|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
293621|NCT01963338|Device|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
293622|NCT01963338|Drug|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
293623|NCT01963325|Drug|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
293624|NCT01963312|Procedure|Transarterial Supraselective Embolization of the prostate|
293625|NCT01963312|Procedure|Transurethral Resection of the prostate|
293626|NCT01963299|Drug|5 ml Ropivacaine 10% + physiological saline|
293627|NCT01963299|Drug|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
293628|NCT01963286|Device|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
293629|NCT01963273|Procedure|Video Assisted Ablation of Pilonidal Sinus|
293630|NCT01963260|Drug|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
293631|NCT01963260|Drug|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
293632|NCT01963234|Behavioral|Seva|Patients were given access to use Seva. This is a mobile application that uses social and behavioral theories to help support people after alcohol use disorder recovery.
293633|NCT01963221|Radiation|fludeoxyglucose(18f)|
293634|NCT01963221|Other|blood sample|
293635|NCT01963221|Other|cardiac and aortic magnetic resonance imaging|
293636|NCT01963221|Other|carotid femoral pulse wave velocity|
293637|NCT01963221|Radiation|positron emission tomography|
293638|NCT01963221|Radiation|computed tomography|
293639|NCT01963208|Drug|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
293640|NCT01963208|Drug|Placebo|placebo
293641|NCT01963195|Drug|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
293642|NCT01963182|Drug|Irinotecan|
293643|NCT01963169|Behavioral|TO-BoneHealth Program (Bone Power Program)|The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
293644|NCT01963169|Behavioral|TO-BoneHealth Plus Program (Bone Power Plus Program)|This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
293645|NCT01963156|Behavioral|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.~Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
293646|NCT01963143|Biological|Gammaplex (5%)|
293647|NCT01963143|Biological|Gammaplex 10|
293648|NCT01963117|Radiation|Combined hyperthermia and radiation therapy|
293649|NCT01963104|Procedure|Automated hearing test|Subjects will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293650|NCT01963104|Procedure|Pure-tone Screener test|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293651|NCT01963104|Procedure|Digits-in-noise test|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293652|NCT01963104|Procedure|No screening test|This group of subjects will not receive a screening test. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293653|NCT01963104|Procedure|Automated hearing test/Motivation video|Subjects will take an automated hearing test that presents tones at different pitches and volumes.Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293654|NCT01963104|Procedure|Pure-tone Screener/Motivation video|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293655|NCT01963104|Procedure|Digits-in-noise test/Motivational video|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293656|NCT01963104|Procedure|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293657|NCT01963104|Procedure|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
293658|NCT01963104|Procedure|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.~Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care."
293659|NCT01963091|Drug|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
293660|NCT01963091|Drug|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
293661|NCT01963078|Drug|Oxytocin|
293662|NCT01963078|Drug|Placebo|
293663|NCT01963052|Drug|AGS15E|intravenous (IV) infusion
293664|NCT01963039|Device|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
293665|NCT01963039|Procedure|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
293707|NCT01962688|Device|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
293708|NCT01962688|Device|Sham ultrasound|sham ultrasound to facilitate blinding
293751|NCT01962415|Drug|Thiotepa|IV administration at 200 mg/m2/dose
293666|NCT01963026|Other|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module [17] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. [17]. Intervention B will be called 'ToCUEST variability' in the present project.
293667|NCT01963026|Other|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
293668|NCT01963013|Device|Non-returning catheter valve|
293669|NCT01963013|Device|Conventional urine bag|
293670|NCT01962987|Drug|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
293671|NCT01962987|Other|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
293672|NCT01962974|Biological|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
293673|NCT01962961|Dietary Supplement|PharmaNAC (N-acetylcysteine)|"PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.~PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days)."
293674|NCT01962961|Dietary Supplement|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
293675|NCT01962948|Drug|paclitaxel|Given IV
293676|NCT01962948|Drug|ganetespib|Given IV
293677|NCT01962948|Other|laboratory biomarker analysis|Correlative studies
293678|NCT01962935|Drug|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
293679|NCT01962935|Drug|Placebo|Part A - multiple ascending dose daily
293680|NCT01962935|Drug|AZD5069|Part B - one dose decided after part A, twice a day
293681|NCT01962922|Drug|LCP-Tacro|once-daily extended release tablet
293682|NCT01962922|Drug|Tacrolimus -IR|twice daily capsules
293683|NCT01962909|Drug|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
293684|NCT01962896|Drug|Erlotinib|
293685|NCT01962896|Drug|Sirolimus|
293686|NCT01962883|Other|Osteopathic treatment|"The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.~Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release~Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.~Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.~Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye."
293687|NCT01962870|Drug|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
293688|NCT01962870|Drug|Placebo|
293689|NCT01962857|Behavioral|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
293690|NCT01962844|Dietary Supplement|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
293691|NCT01962844|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months
293692|NCT01962831|Drug|Dinoprostone|
293693|NCT01962831|Device|Single balloon foley catheter|
293694|NCT01962818|Other|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
293695|NCT01962805|Drug|Proellex Formulation A|
293696|NCT01962805|Drug|Proellex Formulation B|
293697|NCT01962792|Drug|Ibrutinib|
293698|NCT01962792|Drug|Carfilzomib|
293699|NCT01962792|Drug|Dexamethasone|
293700|NCT01962779|Other|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
293701|NCT01962766|Behavioral|Myofunctionnal therapy|
293702|NCT01962766|Behavioral|instructions|
293703|NCT01962753|Drug|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
293704|NCT01962740|Device|Drug-eluting stent implantation|
293705|NCT01962714|Behavioral|Loving-Kindness Meditation|12-week loving-kindness meditation course
293706|NCT01962714|Behavioral|Cognitive Processing Therapy|12-week CPT course
293709|NCT01962675|Device|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
293710|NCT01962675|Behavioral|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
293711|NCT01962662|Other|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
293712|NCT01962662|Other|U/E exercise|strengthening and stretching
293713|NCT01962649|Biological|ICG|
293714|NCT01962649|Device|Optical molecular imaging|
293715|NCT01962636|Drug|Fludarabine|25 mg/m^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
293716|NCT01962636|Drug|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
293717|NCT01962636|Radiation|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
293718|NCT01962636|Drug|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
293719|NCT01962636|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
293720|NCT01962636|Biological|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
293721|NCT01962623|Other|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
293722|NCT01962610|Other|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
293723|NCT01962597|Other|aerobic exercise|
293724|NCT01962597|Other|resistance training|
293725|NCT01962571|Drug|Erythropoietin alfa|
293726|NCT01962571|Drug|Placebo|
293727|NCT01962558|Device|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
293728|NCT01962558|Device|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
293729|NCT01962545|Drug|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
293730|NCT01962532|Drug|Part 1: JNJ-42756493|JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
293731|NCT01962532|Drug|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
293732|NCT01962519|Dietary Supplement|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
293733|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
293734|NCT01962493|Other|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
293735|NCT01962493|Drug|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
293736|NCT01962480|Procedure|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson & Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
293737|NCT01962467|Drug|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
293738|NCT01962467|Drug|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
293739|NCT01962467|Drug|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
293740|NCT01962454|Drug|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
293741|NCT01962454|Drug|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
293742|NCT01962454|Drug|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
293743|NCT01962441|Drug|SOF|400 mg tablet administered orally once daily
293744|NCT01962441|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
293745|NCT01962441|Drug|Peg-IFN|180 µg administered via subcutaneous injection once weekly
293746|NCT01962428|Drug|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
293747|NCT01962415|Drug|Hydroxyurea|Oral administration at 30 mg/kg/day.
293748|NCT01962415|Drug|Alemtuzumab|"Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.~Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only."
293749|NCT01962415|Drug|Fludarabine|IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
293750|NCT01962415|Drug|Melphalan|IV administration at 70 mg/m2/dose.
293752|NCT01962402|Drug|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
293753|NCT01962402|Behavioral|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
293754|NCT01962389|Device|Winsor Laser Catheter|
293755|NCT01962376|Drug|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
293756|NCT01962376|Drug|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
293757|NCT01962363|Drug|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
293758|NCT01962350|Device|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
293759|NCT01962337|Drug|FPA008|Infusion
293760|NCT01962337|Drug|Placebo|Infusion
293761|NCT01962324|Radiation|SIB Dose-Escalation Radiotherapy|
293762|NCT01962311|Procedure|lumbar puncture|lumbar puncture at enrollment in study
293763|NCT01962298|Drug|sugammadex 2mg/kg|
293764|NCT01962298|Drug|neostigmine|
293765|NCT01962298|Drug|sugammadex 4mg/kg|
293766|NCT01962298|Drug|placebo|
293767|NCT01962298|Drug|Single rocuronium dose|
293768|NCT01962298|Drug|Repeated rocuronium dose|
293769|NCT01962298|Drug|Continuous rocuronium infusion|
293770|NCT01962285|Drug|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
293771|NCT01962272|Behavioral|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
293772|NCT01962272|Dietary Supplement|Forticare®.|
293773|NCT01962259|Behavioral|Physical activity|
293774|NCT01962246|Drug|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
293775|NCT01962246|Other|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
293776|NCT01962233|Biological|mesenchymal stem cells|"Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.~Intravenous infusion of umbilical cord derived mesenchymal stem cells"
293777|NCT01962220|Behavioral|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).~Mama Mshauri tasks will include:~Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.~Providing tailored individualized health education during home visits.~Additional intervention components include:~Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.~Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
293778|NCT01962207|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
293779|NCT01962194|Device|Deep Brain Stimulation|"In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer."
293780|NCT01962181|Drug|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
293781|NCT01962181|Drug|Placebo|
293782|NCT01962168|Device|Evolution® Biliary Stent - Uncovered|Commercially available device
293783|NCT01962142|Other|Assessment of activity capacities|
293784|NCT01962129|Biological|Sampling of blood|
293785|NCT01962116|Drug|Citrate 4%|
293786|NCT01962116|Drug|unfractionated heparin|
293787|NCT01962103|Drug|nab-paclitaxel|nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
293788|NCT01962103|Drug|nab-paclitaxel|IV infusion
293789|NCT01962090|Other|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
293790|NCT01962090|Other|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
293791|NCT01962077|Procedure|MedCem MTA pulpotomies in primary teeth.|
293792|NCT01962064|Behavioral|Cognitive assessment|
293793|NCT01962064|Other|Brain imaging examination MRI|
293794|NCT01962051|Device|Amplatzer Cardiac Plug|
293795|NCT01962038|Behavioral|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
293796|NCT01962038|Behavioral|Stretching Exercises|Gym and home based stretching exercises
293797|NCT01962038|Behavioral|Cognitive Training|Group-based cognitive training
293798|NCT01962025|Procedure|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
293799|NCT01962012|Device|AcceleDent Aura|
293800|NCT01962012|Device|Sham Device|
293801|NCT01961999|Procedure|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
293802|NCT01961999|Procedure|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:~persistent and refractory oliguria (<0,5ml/Kg/h >12h), despite therapy refractory extravascular fluid overload azotemia >40mmol/L or 240mg/dL metabolic acidosis (pH<7,2) hyperkaliemia (k+>6mmol/L)"
293803|NCT01961986|Procedure|TSR - traditional subscapularis release|Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
293804|NCT01961986|Procedure|TSR - rotator cuff sparing|Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
293805|NCT01961973|Procedure|Cultured Chondrocytes|This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
293806|NCT01961973|Procedure|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
293807|NCT01961960|Biological|ASP7374|intramuscular
293808|NCT01961947|Biological|ASP7374|subcutaneous
293809|NCT01961947|Biological|approved egg-derived TIV|subcutaneous
293810|NCT01961934|Drug|Sodium Acetate C11 PET/CT Imaging|
293811|NCT01961921|Drug|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
293812|NCT01961908|Drug|Proellex|
293813|NCT01961895|Procedure|Continuous lumbar plexus (LP) block analgesia|
293814|NCT01961895|Drug|Intravenous patient-controlled analgesia|
293815|NCT01961882|Drug|OCV-501|
293816|NCT01961882|Drug|Placebo|
293817|NCT01961869|Other|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
293818|NCT01961869|Other|Intermed release BRB confection|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
293819|NCT01961869|Other|Prolong release BRB confection|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
293820|NCT01961856|Drug|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
293821|NCT01961856|Drug|Ticagrelor|Ticagrelor 180mg loading dose
293822|NCT01961843|Drug|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
293823|NCT01961843|Drug|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
293824|NCT01961830|Drug|ME1100 inhalation solution|
293825|NCT01961817|Other|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack & Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
293826|NCT01961817|Other|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack & Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
293827|NCT01961804|Drug|Reversion|Administration of prothrombin complex concentrates: KANOKAD before CT Scan
293828|NCT01961791|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
293829|NCT01961778|Device|Radio-Frequency Ablation|
293830|NCT01961778|Device|Cryotherapy|
293831|NCT01961765|Drug|cabozantinib|
293832|NCT01961752|Drug|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
293833|NCT01961752|Drug|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
293834|NCT01961752|Drug|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
293835|NCT01961739|Drug|2% lidocaine|Topical application, twice per day for 15 consecutive days
293836|NCT01961739|Drug|placebo|topical application, twice per day for 15 consecutive days
293837|NCT01961726|Biological|Placebo|Coronary Sinus Delivery
293838|NCT01961726|Biological|30 mg dose of JVS-100|Coronary Sinus Delivery
293839|NCT01961726|Biological|45 mg dose of JVS-100|Coronary Sinus Delivery
293840|NCT01961700|Other|Physiotherapy|Physiotherapy treatment
293841|NCT01961687|Device|Resorbable Mesh|Phasix Mesh
293887|NCT01961297|Drug|Sodium oxybate|Sodium oxybate
293842|NCT01961674|Dietary Supplement|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
293843|NCT01961661|Dietary Supplement|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 capsule/die for 1 month"
293844|NCT01961661|Dietary Supplement|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
293845|NCT01961648|Device|Rebreathing bag|
293846|NCT01961648|Device|Sham rebreathing|
293847|NCT01961648|Device|Mask|
293848|NCT01961635|Device|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
293849|NCT01961635|Device|Zirconia abutments|place zirconia abutment on the day of implant placement
293850|NCT01961635|Device|Titanium Abutments|place titanium abutment on the day of implant placement
293851|NCT01961635|Device|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
293852|NCT01961635|Procedure|Subcrestal|place implant 2mm below crestal bone
293853|NCT01961635|Device|platform-switch|abutment platform is narrow than implant diameter
293854|NCT01961635|Procedure|one-time one-abutment|place the final abutment on the day of surgery and not remove it
293855|NCT01961635|Procedure|Torque 20 n/cm2|the amount of torque applied to the abutment
293856|NCT01961622|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
293857|NCT01961622|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
293858|NCT01961609|Biological|Secukinumab (AIN457)|Secukinumab was supplied in 150mg pre-filled syringes.
293859|NCT01961596|Other|Cooling Ice Spray|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test."
293860|NCT01961596|Other|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
293861|NCT01961583|Drug|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
293862|NCT01961557|Device|EA-KAFO|This study tests a single device that contains multiple potential configurations as outlined in Table 1 of the protocol. Each participant be evaluated in multiple configurations, minimally including the baseline configuration and the motor assist condition at the knee.
293863|NCT01961544|Drug|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
293864|NCT01961531|Device|Accuboost APBI|28Gy delivered in 5 daily fractions
293865|NCT01961505|Drug|Topical compound tripterygium|Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
293866|NCT01961505|Drug|Placebo|The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
293867|NCT01961492|Other|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
293868|NCT01961479|Behavioral|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
293869|NCT01961479|Other|Waiting list|During the waiting period, participants receive no treatment.
293870|NCT01961466|Other|psychological and social self-administered questionnaires|
293871|NCT01961453|Drug|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
293872|NCT01961453|Drug|Placebo capsule|One capsule of placebo administered once daily at 8 am.
293873|NCT01961427|Dietary Supplement|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
293874|NCT01961427|Dietary Supplement|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
293875|NCT01961414|Drug|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
293876|NCT01961401|Behavioral|exercise|
293877|NCT01961388|Drug|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
293878|NCT01961388|Drug|Metformin|Oral, dosage of Metformin as per the directions of treating physician
293879|NCT01961375|Drug|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
293880|NCT01961349|Drug|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
293881|NCT01961349|Drug|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
293882|NCT01961349|Drug|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
293883|NCT01961336|Drug|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
293884|NCT01961323|Drug|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
293885|NCT01961310|Biological|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
293886|NCT01961310|Biological|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
293888|NCT01961284|Device|Zygomatic implant placement|
293889|NCT01961284|Device|conventional implants and augmentation of maxilla|
293890|NCT01961271|Drug|Buprenorphine transdermal patch|Please see Arm Description.
293891|NCT01961258|Other|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
293892|NCT01961245|Device|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
293893|NCT01961219|Procedure|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
293894|NCT01961219|Procedure|Arthroscopic capsular release|Arthroscopic capsular release
293895|NCT01961206|Other|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
293896|NCT01961193|Device|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
293897|NCT01961193|Device|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
293898|NCT01961180|Drug|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
293899|NCT01961180|Drug|Placebo|Placebo
293900|NCT01961167|Device|Stenting of common and/or external iliacs|Balloon expandable stenting of iliac occlusive disease
293901|NCT01961154|Drug|Asthma medication reduction|The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
293902|NCT01961128|Behavioral|Exercise Intervention|
293903|NCT01961115|Drug|Epacadostat|Given PO
293904|NCT01961115|Biological|MELITAC 12.1 Peptide Vaccine|Given ID/SC
293905|NCT01961102|Procedure|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
293906|NCT01961089|Device|Galilei Lens Professional|Measurement device
293907|NCT01961089|Device|IOLMaster|Measurement device
293908|NCT01961089|Device|Lenstar|Measurement device
293909|NCT01961076|Other|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
293910|NCT01961063|Drug|busulfan|Given IV
293911|NCT01961063|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
293912|NCT01961063|Other|pharmacological study|Correlative studies
293913|NCT01961063|Other|laboratory biomarker analysis|Correlative studies
293914|NCT01961050|Behavioral|Dual-Focused Brief Physician Intervention (DFBPI)|The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
293915|NCT01961050|Other|Services as usual|Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
293916|NCT01961037|Other|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
293917|NCT01960998|Behavioral|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
293918|NCT01960998|Behavioral|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
293919|NCT01960985|Other|Physicaltherapy|
293920|NCT01960972|Other|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
293921|NCT01960946|Dietary Supplement|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
293922|NCT01960933|Procedure|Percutaneous coronary intervention|
293923|NCT01960933|Procedure|FFR|
293924|NCT01960920|Other|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
293925|NCT01960920|Other|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
293926|NCT01960920|Other|Clean air|No pollution and no filter mask
293927|NCT01960907|Device|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
293928|NCT01960868|Other|standard physiotherapy|
293929|NCT01960868|Other|experimental physical therapy|
293930|NCT01960855|Drug|ABT-494|ABT-494 capsule administered orally twice daily (BID).
293931|NCT01960855|Drug|Placebo|Placebo for ABT-494 capsule administered orally twice daily (BID).
293932|NCT01960842|Drug|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
293933|NCT01960842|Device|CADD-Legacy® 1400 ambulatory infusion pump|
293934|NCT01960842|Device|PEG tube|percutaneous endoscopic gastrostomy tube
293935|NCT01960842|Device|J-tube|jejunal tube
293936|NCT01960829|Drug|Everolimus|
293937|NCT01960816|Device|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
294034|NCT01960049|Procedure|ropivacaine + iv PCA|
294035|NCT01960049|Procedure|saline and IV PCA|
293938|NCT01960803|Radiation|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
293939|NCT01960777|Procedure|Onstep|
293940|NCT01960777|Procedure|Laparoscopic repair|
293941|NCT01960764|Drug|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
293942|NCT01960764|Other|Control|
293943|NCT01960751|Other|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
293944|NCT01960738|Other|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
293945|NCT01960725|Biological|RV5 (Pentavalent Rotavirus Vaccine)|
293946|NCT01960712|Device|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
293947|NCT01960686|Biological|Low dose RSV F Antigen|
293948|NCT01960686|Biological|High dose RSV F Antigen|
293949|NCT01960686|Biological|Dose 1 of Aluminum Adjuvant|
293950|NCT01960686|Biological|Dose 2 of Aluminum Adjuvant|
293951|NCT01960686|Biological|Dose 3 of Aluminum Adjuvant|
293952|NCT01960686|Biological|Dose 4 of Aluminum Adjuvant|
293953|NCT01960686|Biological|Placebo|
293954|NCT01960673|Device|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
293955|NCT01960673|Device|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
293956|NCT01960673|Device|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
293957|NCT01960673|Device|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
293958|NCT01960660|Dietary Supplement|Omega-3 Fatty Acids|
293959|NCT01960647|Device|Percutaneous transluminal angioplasty with uncoated balloon|
293960|NCT01960647|Device|Percutaneous transluminal angioplasty with Paclitaxel balloon|
293961|NCT01960621|Drug|cyclodextrin|intravenous
293962|NCT01960608|Other|24_hours_urine_sodium|
293963|NCT01960595|Procedure|IV fentanyl PCA|
293964|NCT01960595|Procedure|local bupivacaine infiltration and post-OP IV fentanyl PCA|
293965|NCT01960595|Procedure|Nerve Blocks and post-OP IV fentanyl PCA|
293966|NCT01960582|Behavioral|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
293967|NCT01960569|Drug|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
293968|NCT01960569|Other|Placebo assigned to arm 2|
293969|NCT01960556|Other|Simulation Training|Simulation training provided to one group
293970|NCT01960543|Drug|fentanyl 15 microg|
293971|NCT01960543|Drug|Bupivacaine 7 mg|
293972|NCT01960543|Drug|Bupivacaine 9 mg|
293973|NCT01960543|Drug|Levobupivacaine 7 mg|
293974|NCT01960543|Drug|Levobupivacaine 9 mg|
293975|NCT01960530|Drug|Hydrocortisone granules|Multi-particulate granules
293976|NCT01960530|Drug|Hydrocortisone Tablet|Standard hydrocortisone tablets
293977|NCT01960530|Drug|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
293978|NCT01960530|Other|Dexamethasone|Challenge agent
293979|NCT01960517|Device|ACS Catheter|
293980|NCT01960504|Device|Percutaneous Coronary Intervention (DREAMS) stenting|
293981|NCT01960491|Device|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
293982|NCT01960478|Biological|(for each intervention)|
293983|NCT01960478|Other|Blood test|
293984|NCT01960465|Device|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
293985|NCT01960452|Behavioral|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
293986|NCT01960426|Other|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
293987|NCT01960426|Other|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
293988|NCT01960413|Drug|Montelukast added to Hydroxyurea|
293989|NCT01960413|Drug|Placebo added to Hydroxyurea|
293990|NCT01960400|Device|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
294036|NCT01960036|Behavioral|Mindful Awareness in Body-oriented Therapy|
294037|NCT01960036|Behavioral|Womens Health Education|
294197|NCT01959074|Drug|Naftopidil|Naftopidil 75mg 1T qd hs
293991|NCT01960400|Device|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
293992|NCT01960387|Drug|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
293993|NCT01960387|Drug|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
293994|NCT01960374|Drug|Selumetinib|1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
293995|NCT01960361|Device|ICE dental implant|ICE- Implant Classical Esthetic implant
293996|NCT01960348|Drug|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
293997|NCT01960348|Drug|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
293998|NCT01960335|Dietary Supplement|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
293999|NCT01960335|Dietary Supplement|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
294000|NCT01960335|Other|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
294001|NCT01960322|Behavioral|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
294002|NCT01960309|Other|Minimal invasive cardiac imaging|"Coronary CT angiography (CCTA)~Coronary magnetic resonance imaging (CMR)~Echocardiography"
294003|NCT01960296|Drug|Clopidogrel|Continue home dose of clopidogrel into surgery
294004|NCT01960296|Drug|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
294005|NCT01960283|Drug|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.~After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
294006|NCT01960283|Drug|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.~For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
294007|NCT01960270|Device|Device: INTERSTIM II|A second stimulator is implanted on controlateral site
294008|NCT01960257|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
294009|NCT01960257|Other|SOC DOT|
294010|NCT01960231|Other|OGTT|
294011|NCT01960205|Drug|Saxagliptin|5mg a day for 6 months
294012|NCT01960205|Drug|saxagliptin|2.5 mg a day for 6 months
294013|NCT01960205|Drug|metformin|500mg three times a day for 6 months
294014|NCT01960205|Other|lifestyle intervention|lifestyle intervention for 6 months
294015|NCT01960192|Drug|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
294016|NCT01960192|Drug|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
294017|NCT01960179|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
294018|NCT01960166|Behavioral|Active Distraction|iPad will be used as active distraction
294019|NCT01960166|Behavioral|Passive Distraction|child will watch TV as passive distraction
294020|NCT01960153|Drug|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
294021|NCT01960153|Drug|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
294022|NCT01960140|Drug|Baricitinib|Administered orally
294023|NCT01960140|Drug|Simvastatin|Administered orally
294024|NCT01960127|Behavioral|Aerobic exercise|
294025|NCT01960114|Drug|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
294026|NCT01960114|Drug|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
294027|NCT01960101|Other|LactoXeros|
294028|NCT01960101|Device|Aequasyal|
294029|NCT01960088|Drug|HPV vaccine|
294030|NCT01960075|Drug|Fosphenytoin|
294031|NCT01960075|Drug|Levetiracetam|
294032|NCT01960075|Drug|Valproic acid|
294033|NCT01960062|Device|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
294285|NCT01958372|Drug|cisplatin|Given IV
294038|NCT01960023|Drug|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
294039|NCT01960023|Drug|Neratinib|"Phase I portion of the study:~Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day~Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
294040|NCT01960010|Drug|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
294041|NCT01960010|Drug|Vehicle|Vehicle dosed BID
294042|NCT01959997|Procedure|Redo PVI|
294043|NCT01959997|Procedure|PVI + RDN|
294044|NCT01959984|Other|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
294045|NCT01959984|Other|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
294046|NCT01959971|Drug|alirocumab|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
294047|NCT01959971|Drug|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: Subcutaneous"
294048|NCT01959958|Other|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
294049|NCT01959945|Biological|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
294050|NCT01959945|Biological|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
294051|NCT01959932|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
294052|NCT01959932|Other|Smoking abstinence (SA)|SA for 5 days in confinement
294053|NCT01959932|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
294054|NCT01959919|Device|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
294055|NCT01959880|Device|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
294056|NCT01959867|Device|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
294057|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
294058|NCT01959854|Device|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
294059|NCT01959854|Device|xanthan gum|0.2% xanthan gum preservative free
294060|NCT01959841|Drug|ASP2151|200 mg once daily or 400 mg once daily
294061|NCT01959841|Drug|valaciclovir|1000 mg three times daily
294062|NCT01959828|Drug|IK-3001|
294063|NCT01959802|Procedure|Vitrectomy|
294064|NCT01959776|Procedure|Vitrectomy|
294065|NCT01959763|Behavioral|Weight loss counseling program|Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
294066|NCT01959750|Behavioral|problem-based sessions|weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
294067|NCT01959737|Procedure|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
294068|NCT01959724|Other|Vitrectomy|
294069|NCT01959711|Procedure|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
294070|NCT01959711|Procedure|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
294071|NCT01959698|Drug|Carboplatin|Given IV
294072|NCT01959698|Drug|Carfilzomib|Given IV
294073|NCT01959698|Drug|Etoposide|Given IV
294074|NCT01959698|Drug|Ifosfamide|Given IV
294075|NCT01959698|Other|Laboratory Biomarker Analysis|Correlative studies
294076|NCT01959698|Other|Pharmacological Study|Correlative studies
294077|NCT01959698|Biological|Rituximab|Given IV
294078|NCT01959685|Drug|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
294079|NCT01959685|Drug|Placebo|Placebo, single dose
294080|NCT01959672|Procedure|4-Dimensional Computed Tomography|Correlative studies
294081|NCT01959672|Drug|Fluorouracil|Given IV
294082|NCT01959672|Drug|Gemcitabine Hydrochloride|Given IV
294083|NCT01959672|Other|Laboratory Biomarker Analysis|Correlative studies
294084|NCT01959672|Drug|Leucovorin Calcium|Given IV
294085|NCT01959672|Drug|Nelfinavir Mesylate|Given PO
294086|NCT01959672|Biological|Oregovomab|Given IV
294087|NCT01959672|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
294088|NCT01959672|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
294089|NCT01959646|Dietary Supplement|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
294139|NCT01959425|Other|Off OAT Group (Test)|Discontinuation of OAT Therapy
294140|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
294090|NCT01959646|Other|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
294091|NCT01959646|Dietary Supplement|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
294092|NCT01959633|Drug|Vemurafenib|Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
294093|NCT01959633|Drug|Peg-interferon|"In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only~In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD."
294094|NCT01959633|Drug|Cobimetinib|Cobimetinib 60 mg o.d. (21 days on followed by 7 days off)
294095|NCT01959620|Behavioral|1-Session Exposure Therapy|One exposure therapy session lasting one hour
294096|NCT01959620|Behavioral|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
294097|NCT01959607|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
294098|NCT01959607|Other|CC|Single use of subject's own cigarette (CC)
294099|NCT01959607|Other|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
294100|NCT01959594|Drug|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
294101|NCT01959594|Drug|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
294102|NCT01959594|Drug|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
294103|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
294104|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
294105|NCT01959581|Device|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
294106|NCT01959568|Procedure|Vitrectomy and tamponade|"In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location."
294107|NCT01959555|Other|No treatment given|Patients will not be treated with any specific product. Data collection only.
294108|NCT01959542|Device|MRI|
294109|NCT01959542|Other|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
294110|NCT01959542|Other|Androgen Deprivation Therapy (ADT)|Patients will receive ADT as part of their standard clinical care, as determined by their clinician.
294111|NCT01959542|Radiation|External Beam Radiation Therapy (EBRT)|Patients will receive EBRT as part of their standard clinical care, as determined by their clinician.
294112|NCT01959529|Drug|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
294113|NCT01959529|Drug|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
294114|NCT01959516|Drug|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
294115|NCT01959516|Drug|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
294116|NCT01959516|Drug|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
294117|NCT01959516|Drug|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
294118|NCT01959503|Device|Progel Vascular Sealant|
294119|NCT01959503|Device|Gelfoam Plus|
294120|NCT01959490|Biological|trastuzumab|Given IV
294121|NCT01959490|Biological|Pertuzumab|Given IV
294122|NCT01959490|Drug|docetaxel|Given IV
294123|NCT01959490|Drug|carboplatin|Given IV
294124|NCT01959490|Drug|doxorubicin|Given IV
294125|NCT01959490|Drug|cyclophosphamide|Given IV
294126|NCT01959490|Drug|paclitaxel|Given IV
294127|NCT01959490|Drug|Bevacizumab|
294128|NCT01959477|Drug|busulfan|Given IV
294129|NCT01959477|Drug|etoposide|Given IV
294130|NCT01959477|Drug|cyclophosphamide|Given IV
294131|NCT01959477|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
294132|NCT01959477|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
294133|NCT01959464|Drug|Crinone vaginal progesterone gel|Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
294134|NCT01959464|Drug|Placebo vaginal gel|Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
294135|NCT01959451|Drug|Prasugrel|see Arm description
294136|NCT01959451|Drug|Clopidogrel|see arm description
294137|NCT01959438|Drug|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
294138|NCT01959438|Drug|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
294286|NCT01958372|Drug|etoposide|Given IV
294141|NCT01959412|Drug|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
294142|NCT01959412|Drug|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
294143|NCT01959412|Drug|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
294144|NCT01959412|Drug|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
294145|NCT01959412|Drug|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
294146|NCT01959412|Drug|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
294147|NCT01959399|Drug|ASP015K|oral tablet
294148|NCT01959399|Drug|Rosuvastatin|oral tablet
294149|NCT01959386|Drug|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
294150|NCT01959373|Procedure|electroencephalograms (EEG)|
294151|NCT01959373|Procedure|electro-myography (EMG)|
294152|NCT01959360|Procedure|Direct lateral|Total hip replacement; direct lateral approach
294153|NCT01959360|Procedure|minimal invasive|Total hip replacement; minimal invasive approach
294154|NCT01959360|Procedure|modified minimal invasive|Total hip replacement; modified minimal invasive approach
294155|NCT01959347|Procedure|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health & Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
294156|NCT01959347|Other|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
294157|NCT01959334|Drug|Nasal Glucagon (NG)|
294158|NCT01959334|Drug|Glucagon IM|
294159|NCT01959308|Other|N.A.|
294160|NCT01959295|Drug|ASP2151|200 mg once daily
294161|NCT01959295|Drug|ASP2151 placebo|once daily
294162|NCT01959282|Drug|Placebo|Participants will receive placebo once daily
294163|NCT01959282|Drug|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
294164|NCT01959282|Drug|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
294165|NCT01959282|Drug|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
294166|NCT01959282|Drug|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
294167|NCT01959269|Drug|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
294168|NCT01959256|Behavioral|Visual perceptual learning|24 times of training for visual perceptual learning
294169|NCT01959243|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
294170|NCT01959243|Drug|Vehicle|Ophthalmic solution to be applied as directed.
294171|NCT01959243|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
294172|NCT01959243|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
294173|NCT01959230|Drug|Brimonidine Tartrate|Ophthalmic solution to be applied as directed.
294174|NCT01959230|Drug|Vehicle|Ophthalmic solution to be applied as directed.
294175|NCT01959230|Drug|Sodium Fluorescein|For use as needed during the study for evaluating corneal damage.
294176|NCT01959230|Drug|Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP|For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
294177|NCT01959217|Behavioral|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
294178|NCT01959204|Drug|Oxycodone|Pain
294179|NCT01959191|Drug|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
294180|NCT01959165|Drug|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
294181|NCT01959165|Drug|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
294182|NCT01959165|Drug|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
294183|NCT01959165|Drug|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
294184|NCT01959152|Device|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
294185|NCT01959139|Drug|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
294186|NCT01959139|Drug|Oxaliplatin|85 mg/m^2, on Day 2, IV over 2 hours
294187|NCT01959139|Drug|Leucovorin|400 mg/m^2, on Day 2, IV over 2 hours
294188|NCT01959139|Drug|Irinotecan|180 mg/m^2, on Day 2, IV over 1.5 hours
294189|NCT01959139|Drug|5-fluorouracil|2,400 mg/m^2, Days 2-4, IV over 46 hours
294190|NCT01959126|Behavioral|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
294191|NCT01959113|Biological|Autologous Microbiome Transplant|
294192|NCT01959113|Other|Placebo Arm|
294193|NCT01959100|Drug|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
294194|NCT01959100|Drug|Placebo|250 mg x 3/week during a meal for a period of 2 years
294195|NCT01959087|Procedure|single port surgery|Single port surgery can be converted in multiport surgery if necessary
294196|NCT01959087|Procedure|Multiport surgery|
294198|NCT01959074|Drug|Placebo for Naftopidil|Placebo 1T qd hs
294199|NCT01959074|Drug|Standard treatment|aceclofenac 100mg on demand
294200|NCT01959061|Drug|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
294201|NCT01959061|Drug|Oxaliplatin|100~150mg, every 4 weeks, transhepatic arterial infusion
294202|NCT01959061|Drug|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
294203|NCT01959048|Drug|fecal microbiota transplantation|
294204|NCT01959035|Drug|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
294205|NCT01959022|Drug|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
294206|NCT01959009|Other|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).~All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.~Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
294207|NCT01958996|Drug|idarubicin|
294208|NCT01958983|Behavioral|Music Therapy Group Session|
294209|NCT01958970|Drug|PINTA 745|"PINTA 745 will be administered once weekly by IV infusion.~Cohort dose schedules:~3mg/kg weekly for 12 weeks~3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
294210|NCT01958970|Drug|Placebo|"Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~3mg/kg weekly for 12 weeks~3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
294211|NCT01958957|Drug|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
294212|NCT01958944|Drug|Nitric oxide|
294213|NCT01958918|Drug|Ranibizumab|0.5 mg intravitreal injection
294214|NCT01958918|Drug|Aflibercept|2 mg intravitreal injection
294215|NCT01958905|Drug|Artemether-lumefantrine fixed combination|
294216|NCT01958892|Procedure|TURP, TUERP|
294217|NCT01958879|Drug|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
294218|NCT01958879|Drug|ringer without corticosteroid|200 mL Ringer solution
294219|NCT01958866|Drug|Tinospora Crispa-extract Product|
294220|NCT01958866|Drug|Acetaminophen|
294221|NCT01958866|Other|Placebo|
294222|NCT01958853|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
294223|NCT01958840|Behavioral|Behavioral Activation for Depression Treatment|
294224|NCT01958840|Behavioral|Supportive Counseling|
294225|NCT01958827|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
294226|NCT01958814|Drug|Salbutamol|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
294227|NCT01958814|Drug|Placebo|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
294228|NCT01958801|Other|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
294229|NCT01958801|Other|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
294230|NCT01958788|Behavioral|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
294231|NCT01958775|Drug|GLP-2|single subcutaneous dose of 1500mcg
294232|NCT01958775|Drug|Placebo|
294233|NCT01958762|Other|Invitation for oral cavity cancer screening|
294234|NCT01958749|Procedure|Fat graft with Platelet Rich Plasma|
294235|NCT01958736|Other|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
294236|NCT01958736|Other|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
294237|NCT01958723|Other|Hospitalists|Introduction of Problem Specific Templates
294238|NCT01958684|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
294239|NCT01958684|Device|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
294240|NCT01958671|Drug|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
294241|NCT01958671|Drug|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
294242|NCT01958671|Drug|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
294243|NCT01958671|Drug|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
294287|NCT01958372|Drug|pemetrexed disodium|Given IV
294244|NCT01958671|Drug|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
294245|NCT01958671|Drug|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
294246|NCT01958645|Drug|MEDI8111|MEDI8111 lyophilisate for solution for infusion
294247|NCT01958645|Other|Placebo|Placebo for MEDI8111 saline solution for infusion
294248|NCT01958632|Procedure|Nerve reconstruction|
294249|NCT01958619|Drug|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
294250|NCT01958619|Drug|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
294251|NCT01958619|Drug|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
294252|NCT01958619|Drug|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
294253|NCT01958606|Other|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
294254|NCT01958606|Other|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
294255|NCT01958593|Drug|Placebo|Placebo administered in two experimental sessions; may take part in Stage 2 upon learning condition assignment
294256|NCT01958593|Drug|3,4-methylenedioxymethamphetamine|Participants receive full-dose MDMA during two experimental sessions; after learning their condition assignment, participants will receive a third full-dose session.
294257|NCT01958593|Behavioral|Psychotherapy|Psychotherapy before and after experimental sessions
294258|NCT01958580|Drug|Gemcitabine Hydrochloride|Given IV
294259|NCT01958580|Drug|Docetaxel|Given IV
294260|NCT01958580|Radiation|Internal Radiation Therapy|Undergo brachytherapy
294261|NCT01958580|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
294262|NCT01958580|Radiation|External Beam Radiation Therapy|Undergo EBRT
294263|NCT01958580|Other|Laboratory Biomarker Analysis|Correlative studies
294264|NCT01958567|Other|Optical Coherence Tomography|
294265|NCT01958554|Behavioral|Intervention Group|
294266|NCT01958541|Behavioral|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
294267|NCT01958541|Behavioral|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
294268|NCT01958515|Other|research blood draw and tissue biopsy|research blood draw and tissue biopsy
294269|NCT01958502|Genetic|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
294270|NCT01958489|Drug|Evacetrapib|Administered orally
294271|NCT01958489|Drug|Pravastatin|Administered orally
294272|NCT01958476|Drug|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
294273|NCT01958476|Drug|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
294274|NCT01958476|Drug|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally >8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores <8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
294275|NCT01958463|Procedure|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
294276|NCT01958450|Procedure|Er:YAG laser|acne scar treatment using Er:YAG laser
294277|NCT01958450|Procedure|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
294278|NCT01958437|Device|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
294279|NCT01958398|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback.
294280|NCT01958398|Behavioral|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
294281|NCT01958385|Device|placement of g-Cath EZ suture anchors|
294282|NCT01958385|Procedure|Sham procedure|
294283|NCT01958385|Behavioral|Diet and Exercise|A structured diet and exercise plan
294284|NCT01958372|Dietary Supplement|soy isoflavones|Given PO
294288|NCT01958372|Radiation|radiation therapy|Undergo RT
294289|NCT01958359|Behavioral|Short IVR|IVR-based alcohol diary with feedback
294290|NCT01958359|Behavioral|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
294291|NCT01958346|Other|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
294292|NCT01958346|Other|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
294293|NCT01958346|Device|Fiberoptic Intubation|
294294|NCT01958333|Procedure|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
294295|NCT01958333|Procedure|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
294296|NCT01958333|Procedure|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
294297|NCT01958320|Other|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
294298|NCT01958320|Other|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
294299|NCT01958320|Drug|NSAID|Indomethacin, ibuprofen or acetaminophen will be used as standard of care treatment
294300|NCT01958307|Behavioral|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
294301|NCT01958294|Device|MICHI Neuroprotection System|
294302|NCT01958281|Drug|SOF|Tablet(s) administered orally once daily
294303|NCT01958281|Drug|RBV|200 mg tablet administered orally once daily
294304|NCT01958281|Drug|LDV/SOF|90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
294305|NCT01958268|Procedure|Pretest and validation of a translated questionnaire|
294306|NCT01958255|Behavioral|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
294307|NCT01958242|Other|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
294308|NCT01958216|Other|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
294309|NCT01958190|Drug|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.~Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
294310|NCT01958190|Drug|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
294311|NCT01958177|Biological|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
294312|NCT01958164|Drug|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
294313|NCT01958164|Drug|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
294314|NCT01958164|Drug|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
294315|NCT01958164|Drug|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
294316|NCT01958151|Other|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
294317|NCT01958138|Drug|comparison of group-P (low dose propofol with isoflurane) versus group-D (alone isoflurane)|"In both groups, 5 minutes prior to LMA removal, the isoflurane concentration will be adjusted to predetermine value. In group-P, the isoflurane MAC will be 0.5 or less and in group-D, the isoflurane MAC will be 1.2 and the both groups will be ventilated with 50% oxygen and 50% nitrous oxide with a total inflow of 6 L/min and will be maintained until the exhaled end-tidal isoflurane concentration will be same as the inhaled concentration.~The LMA will be removed with cuff inflated in both groups. In group-P, the propofol 1mg/kg at isoflurane 0.5 MAC or less will be given and after 20 seconds the LMA will be removed, In group-D, the LMA will be removed once the set 1.2 MAC of isoflurane achieved and after that the isoflurane and nitrous oxide will be turned off in both group-P & group-D and throat will be suctioned and 100% oxygen will be administered until the patient regain consciousness."
294318|NCT01958125|Device|gammaCore|Vagal stimulation
294319|NCT01958112|Drug|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
294320|NCT01958112|Drug|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
294321|NCT01958099|Behavioral|Education|
294375|NCT01957683|Device|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
294376|NCT01957670|Device|Lacrima medical Prototypes|
294377|NCT01957657|Drug|BI 207127|oral administration
294378|NCT01957657|Drug|faldaprevir|oral administration
294379|NCT01957657|Drug|BI 207127|oral administration
294380|NCT01957657|Drug|BI 207127|oral administration
294322|NCT01958086|Device|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. Key features include sterile, single use electrodes that provide access to a localized population of individual cells. The Neural Communication system is primarily composed of two NeuroPort Arrays. The main component of the NeuroPort Array is an array comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and has a platinum tip that is 100-200 microns in length. The Patient Pedestal is made from titanium and is 19 mm wide at the skin interface.
294323|NCT01958073|Drug|Conjugated Estrogen Vaginal Cream|
294324|NCT01958073|Drug|Estradiol Ring|
294325|NCT01958073|Drug|Placebo|
294326|NCT01958060|Drug|BI 1034020|intravenous part
294327|NCT01958060|Drug|Placebo to BI 1034020|intravenous part
294328|NCT01958047|Drug|ASP3652|Oral
294329|NCT01958034|Dietary Supplement|Bilberry extract|
294330|NCT01958021|Drug|LEE011|Ribociclib was administered orally at a dose of 600 mg once daily (three 200 mg capsules).
294331|NCT01958021|Drug|Letrozole|Letrozole 2.5 mg tablets taken orally.
294332|NCT01958021|Drug|LEE011 Placebo|Matching ribociclib placebo was the control drug and was administered orally once daily.
294333|NCT01958008|Drug|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
294334|NCT01958008|Drug|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
294335|NCT01958008|Drug|BI 113608 high dose b.i.d.|Film-coated tablet
294336|NCT01958008|Drug|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
294337|NCT01958008|Drug|BI 113608 low dose b.i.d.|Film-coated tablet
294338|NCT01958008|Drug|BI 113608 medium dose b.i.d.|Film-coated tablet
294339|NCT01957995|Drug|nanosomal docetaxel lipid suspension|Given IV
294340|NCT01957995|Other|pharmacological study|Correlative studies
294341|NCT01957969|Device|Sacral Nerve Stimulation|
294342|NCT01957956|Other|Laboratory Biomarker Analysis|Correlative studies
294343|NCT01957956|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
294344|NCT01957956|Drug|Temozolomide|Given PO
294345|NCT01957943|Dietary Supplement|SMOFLipid|
294346|NCT01957943|Dietary Supplement|equivalent volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
294347|NCT01957930|Other|Intensified conventional insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
294348|NCT01957930|Drug|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
294349|NCT01957917|Other|NAC (Nutritional Assessment and Counseling)|
294350|NCT01957917|Other|Cash Transfer|
294351|NCT01957917|Other|Food Assistance|
294352|NCT01957904|Device|ArterX Surgical Sealant|
294353|NCT01957878|Biological|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
294354|NCT01957878|Biological|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
294355|NCT01957865|Device|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
294356|NCT01957865|Device|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
294357|NCT01957852|Other|FloSeal|
294358|NCT01957839|Drug|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
294359|NCT01957826|Other|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
294360|NCT01957826|Other|placebo intervention|placebo administration
294361|NCT01957813|Behavioral|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.~Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
294362|NCT01957813|Other|Standard Health Services|Peer education and health services
294363|NCT01957800|Behavioral|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
294364|NCT01957800|Behavioral|Usual Care|Participants will record their weight and complete surveys online.
294365|NCT01957787|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
294366|NCT01957774|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
294367|NCT01957774|Drug|Placebo|
294368|NCT01957748|Behavioral|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
294369|NCT01957735|Drug|BP31510 monotherapy|
294370|NCT01957735|Drug|BP31510 in combination with chemotherapy|
294371|NCT01957722|Procedure|Microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
294372|NCT01957722|Biological|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
294373|NCT01957709|Other|Laboratory Biomarker Analysis|Correlative studies
294374|NCT01957709|Biological|Recombinant Interferon Gamma|Given subcutaneously weekly for four weeks prior to surgery.
294381|NCT01957657|Drug|BI 207127|oral administration
294382|NCT01957657|Drug|faldaprevir|oral administration
294383|NCT01957657|Drug|faldaprevir|oral administration
294384|NCT01957657|Drug|faldaprevir|oral administration
294385|NCT01957644|Drug|Azacitidine|
294386|NCT01957644|Drug|Volasertib|
294387|NCT01957631|Drug|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
294388|NCT01957631|Biological|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
294389|NCT01957592|Other|No treatment given|Patients will fill out a questionnaire by interview.
294390|NCT01957579|Drug|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
294391|NCT01957566|Procedure|APS|
294392|NCT01957553|Device|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
294393|NCT01957553|Device|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
294394|NCT01957540|Drug|Ticagrelor|
294395|NCT01957540|Drug|Prasugrel|
294396|NCT01957527|Device|Peripheral arterial tonometry (EndoPAT)|
294397|NCT01957514|Other|Cytology Specimen Collection Procedure|Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
294398|NCT01957514|Other|Laboratory Biomarker Analysis|Correlative studies
294399|NCT01957514|Other|Quality-of-Life Assessment|Ancillary studies
294400|NCT01957514|Other|Questionnaire Administration|Ancillary studies
294401|NCT01957501|Other|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
294402|NCT01957488|Device|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
294403|NCT01957488|Device|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
294404|NCT01957488|Device|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
294405|NCT01957475|Device|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
294406|NCT01957475|Device|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
294407|NCT01957462|Device|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
294408|NCT01957462|Device|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
294409|NCT01957449|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
294410|NCT01957449|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
294411|NCT01957436|Drug|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
294412|NCT01957436|Radiation|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
294413|NCT01957436|Other|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
294414|NCT01957436|Drug|Docetaxel|6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
294415|NCT01957423|Dietary Supplement|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
294416|NCT01957423|Dietary Supplement|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
294417|NCT01957410|Drug|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
294418|NCT01957410|Drug|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
294419|NCT01957397|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
294420|NCT01957397|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
294421|NCT01957397|Device|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
294422|NCT01957384|Device|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
294423|NCT01957384|Device|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
294424|NCT01957384|Device|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:~Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,~Dansac: Nova 1 & Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate~Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate~ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate~B. Braun: Flexima Active & Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
294459|NCT01957059|Drug|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 3 mg/kg"
294425|NCT01957371|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
294426|NCT01957358|Behavioral|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
294427|NCT01957345|Other|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)~signalisation test is made by flow cytometry~Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.~Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
294428|NCT01957332|Procedure|Molecular imaging|On the day of FES-injection&scan or the day after FES-injection, 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
294429|NCT01957332|Procedure|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET.
294430|NCT01957319|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
294431|NCT01957319|Drug|sugar pill|
294432|NCT01957306|Dietary Supplement|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
294433|NCT01957293|Drug|Salbutamol|single oral administration, 4 mg
294434|NCT01957293|Drug|Placebo|single oral administration
294435|NCT01957280|Drug|patritumab|
294436|NCT01957228|Procedure|bone biopsies|
294437|NCT01957215|Drug|Indomethacin|Topical indomethacin
294438|NCT01957215|Drug|Placebo|Placebo patch
294439|NCT01957202|Drug|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
294440|NCT01957202|Drug|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
294441|NCT01957202|Drug|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
294442|NCT01957202|Drug|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
294443|NCT01957189|Drug|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
294444|NCT01957176|Drug|ELT|Subjects will be dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets will be white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain ELT olamine equivalent to 20 mg of ELT per gram of powder.
294445|NCT01957163|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
294446|NCT01957163|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
294447|NCT01957163|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
294448|NCT01957163|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
294449|NCT01957150|Drug|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
294450|NCT01957150|Drug|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
294451|NCT01957137|Device|InterStim® (Device Programming)|
294452|NCT01957124|Procedure|PRF (Platelet-Rich Fibrin)|
294453|NCT01957098|Dietary Supplement|Placebo comparator: 0% pentose|14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
294454|NCT01957098|Dietary Supplement|Active comparator: 4% D-xylose|
294455|NCT01957098|Dietary Supplement|Active comparator: 8% D-xylose|
294456|NCT01957098|Dietary Supplement|Active comparator: 8% L-arabinose|
294457|NCT01957085|Other|Observation only, no intervention|HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory
294458|NCT01957072|Behavioral|Behaviour change intervention|"The behaviour change intervention consists of~feedback via a web-based food diary~'coaching' with problem-solving and implementation plans~The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.~The maintenance phase consists of 3 telephone calls and 4 reminder emails."
294460|NCT01957059|Drug|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:~• 4-6 mg/kg"
294461|NCT01957059|Drug|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
294462|NCT01957059|Drug|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
294463|NCT01957059|Drug|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
294464|NCT01957046|Drug|Laxative|
294465|NCT01957033|Behavioral|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
294466|NCT01957033|Behavioral|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
294467|NCT01957033|Behavioral|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
294468|NCT01957033|Other|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
294469|NCT01957033|Other|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
294470|NCT01957033|Other|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
294471|NCT01957033|Other|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
294472|NCT01957033|Other|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
294473|NCT01957033|Other|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
294474|NCT01957007|Drug|Docetaxel|Docetaxel will be administered IV.
294475|NCT01957007|Drug|vantictumab|Vantictumab will be administered intravenously
294476|NCT01956994|Dietary Supplement|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
294477|NCT01956994|Dietary Supplement|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
294478|NCT01956981|Drug|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
294479|NCT01956981|Drug|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
294480|NCT01956955|Drug|enoxaparin ,alteplase, unfractionated heparin|
294481|NCT01956942|Device|Micropulse Laser Trabeculoplasty|
294482|NCT01956942|Device|Selective Laser Trabeculoplasty|
294483|NCT01956929|Drug|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
294484|NCT01956929|Drug|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
294485|NCT01956916|Dietary Supplement|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
294486|NCT01956916|Dietary Supplement|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)~1 cps/die for 12 months"
294487|NCT01956903|Genetic|Allogenic Mesenchymal Stem Cell|"Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)"
294488|NCT01956890|Drug|PET|18F-FLT PET and MRI of the breast
294489|NCT01956864|Drug|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
294490|NCT01956838|Dietary Supplement|umami|intraduodenal infusion of umami tastant
294491|NCT01956838|Dietary Supplement|bitter|intraduodenal infusion of bitter tastant
294492|NCT01956838|Dietary Supplement|sweet|intraduodenal infusion of sweet tastant
294493|NCT01956825|Dietary Supplement|"slim water"|
294494|NCT01956812|Drug|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
294495|NCT01956812|Drug|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
294496|NCT01956812|Drug|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
294497|NCT01956786|Drug|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
294498|NCT01956786|Drug|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
294499|NCT01956786|Drug|Amlodipine|5mg amlodipine,once daily
294500|NCT01956773|Other|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
294575|NCT01956097|Dietary Supplement|HX106 1180mg|
294576|NCT01956097|Dietary Supplement|Placebo|
294501|NCT01956760|Other|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
294502|NCT01956747|Procedure|venapunction|
294503|NCT01956747|Procedure|bone marrow punction|
294504|NCT01956734|Procedure|DNX2401 and Temozolomide|"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.~Temozolomide oral 14 days after virus injection."
294505|NCT01956721|Procedure|Exercise training,|
294506|NCT01956721|Procedure|Muscle biopsy|
294507|NCT01956708|Procedure|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
294508|NCT01956695|Drug|Lenalidomide|
294509|NCT01956695|Drug|Rituximab|
294510|NCT01956682|Dietary Supplement|HA formula + starch + L. reuteri|
294511|NCT01956669|Drug|Pazopanib GW786034|Pazopanib is supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension is a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
294512|NCT01956656|Drug|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
294513|NCT01956643|Other|gum chewing|gum chewing
294514|NCT01956643|Other|Control|Routine care during NPO
294515|NCT01956630|Biological|Genetically modified DCs plus CIK cells|
294516|NCT01956630|Biological|Donor leukocyte infusions (DLI)|
294517|NCT01956617|Other|lumbar plexus block|
294518|NCT01956604|Drug|Clonidine|
294519|NCT01956604|Drug|Placebo|
294520|NCT01956591|Drug|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
294521|NCT01956578|Other|Breathing Exercise Cohort|All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
294522|NCT01956565|Other|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
294523|NCT01956552|Other|biopsy or cytopuncture|
294524|NCT01956526|Device|CORolla™ TAA device|
294525|NCT01956513|Other|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
294526|NCT01956500|Dietary Supplement|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
294527|NCT01956500|Dietary Supplement|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
294528|NCT01956487|Drug|Propafenone|Comparison of drug from 2 manufacturing sites
294529|NCT01956474|Other|Theralight crosslinking and Riboflavin|Corneal Collagen cross linking with UV light and riboflavin
294530|NCT01956448|Device|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
294531|NCT01956435|Device|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
294532|NCT01956422|Device|Continuous Positive Airway Pressure(CPAP)|
294533|NCT01956422|Device|Venturi Mask FiO2 40%|
294534|NCT01956409|Drug|18F-FCH|
294535|NCT01956409|Drug|Magnevist|
294536|NCT01956396|Device|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
294537|NCT01956383|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
294538|NCT01956370|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
294539|NCT01956370|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
294540|NCT01956357|Other|Aquatic exercise|
294541|NCT01956357|Other|Land Exercise|
294542|NCT01956344|Behavioral|Cognitive Behavioral Therapy|Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
294577|NCT01956084|Drug|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
294578|NCT01956084|Drug|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
294543|NCT01956318|Behavioral|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
294544|NCT01956305|Drug|DS-7309|DS-7309 powder in bottle
294545|NCT01956305|Drug|placebo|placebo to match DS-7309 powder in bottle
294546|NCT01956305|Drug|Metformin|Metformin 500mg tablet for Cohort F
294547|NCT01956279|Drug|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
294548|NCT01956279|Drug|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
294549|NCT01956266|Behavioral|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
294550|NCT01956253|Drug|Neratinib|240 mg orally once daily
294551|NCT01956240|Procedure|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
294552|NCT01956240|Procedure|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
294553|NCT01956227|Behavioral|Home-based exercise|exercise to look at balance and lower limb strength record in diary
294554|NCT01956227|Behavioral|Education|sessions to discuss self-management ideas to modify risk of falling
294555|NCT01956227|Behavioral|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
294556|NCT01956214|Other|FES Exercise|receive FES while exercising
294557|NCT01956214|Other|Mock FES Exercise|participants will receive Mock FES
294558|NCT01956201|Drug|Atorvastatin 20mg|[Atorvastatin Run-in Period] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) [Treatment Period] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) [Extension Period] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
294559|NCT01956201|Drug|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
294560|NCT01956201|Other|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
294561|NCT01956188|Dietary Supplement|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
294562|NCT01956188|Dietary Supplement|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
294563|NCT01956175|Device|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
294564|NCT01956175|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
294565|NCT01956162|Device|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
294566|NCT01956162|Device|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
294567|NCT01956149|Drug|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
294568|NCT01956136|Behavioral|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
294569|NCT01956136|Other|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
294570|NCT01956123|Drug|Follitropin Delta (FE 999049)|
294571|NCT01956123|Drug|Follitropin Alfa (GONAL-F)|
294572|NCT01956110|Drug|Follitropin Delta (FE 999049)|
294573|NCT01956110|Drug|Follitropin Alfa (GONAL-F)|
294574|NCT01956097|Dietary Supplement|HX106 590mg|
294579|NCT01956071|Device|WAPD|The objective was to assess workers' acceptability of the Pennington Pedal Desk.
294580|NCT01956058|Radiation|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
294581|NCT01956045|Other|Patient's capacity|
294582|NCT01956019|Device|MRI scanning|
294583|NCT01956006|Drug|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
294584|NCT01955980|Drug|Budesonide|Inhalation
294585|NCT01955980|Drug|Budesonide|Nasal Spray
294586|NCT01955967|Drug|Lidocaine|
294587|NCT01955954|Device|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of abnormal breathing patterns.
294588|NCT01955928|Behavioral|Online Cognitive behavioral treatment for insomnia|
294589|NCT01955889|Behavioral|Mobile Health Technology|
294590|NCT01955889|Behavioral|Stretching & Strengthening Exercises|
294591|NCT01955889|Behavioral|Walking with Pedometer|
294592|NCT01955876|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
294593|NCT01955863|Procedure|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
294594|NCT01955863|Procedure|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
294595|NCT01955863|Procedure|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
294596|NCT01955850|Behavioral|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
294597|NCT01955837|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
294598|NCT01955837|Drug|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
294599|NCT01955824|Drug|1% lignocaine|
294600|NCT01955824|Drug|2% lignocaine|
294601|NCT01955811|Drug|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
294602|NCT01955798|Procedure|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
294603|NCT01955798|Procedure|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
294604|NCT01955798|Device|Trocar|
294605|NCT01955798|Device|Veress needle|
294606|NCT01955785|Device|pressure controlled ventilator|
294607|NCT01955785|Device|Pressure Regulated Volume Controlled Ventilator|
294608|NCT01955772|Drug|Enteral nutrition alanyl-glutamin, Dipeptiven|Enteral nutrition versus parenteral nutrition
294609|NCT01955759|Drug|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
294610|NCT01955759|Drug|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
294611|NCT01955759|Drug|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
294612|NCT01955733|Drug|BI 695500|
294613|NCT01955720|Drug|BI 655075|
294614|NCT01955720|Drug|BI 655075|
294615|NCT01955720|Drug|Placebo|
294616|NCT01955720|Drug|BI 655075|
294617|NCT01955720|Drug|Placebo|
294618|NCT01955720|Drug|Placebo|
294619|NCT01955720|Drug|Placebo|
294620|NCT01955720|Drug|BI 655075|
294621|NCT01955707|Drug|natalizumab|Administered as described in the treatment arm
294622|NCT01955707|Drug|Placebo|Matched placebo
294623|NCT01955694|Drug|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
294624|NCT01955694|Drug|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
294625|NCT01955694|Drug|Placebo|matching placebo
294626|NCT01955668|Drug|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
294627|NCT01955655|Drug|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
294628|NCT01955655|Other|Placebo|
294629|NCT01955642|Drug|Clopidogrel|75 mg milligrams per days of PLAVIX
294630|NCT01955629|Drug|Aflibercept AVE0005|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
294631|NCT01955629|Drug|Oxaliplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
294632|NCT01955629|Drug|Capecitabine|Pharmaceutical form: Tablets; Route of administration: Oral
294633|NCT01955616|Drug|RM-131|
294634|NCT01955616|Drug|Placebo|
294635|NCT01955603|Drug|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
294636|NCT01955603|Drug|placebo|Placebo administered corresponding to NNC0215-0384 treatment
294637|NCT01955590|Behavioral|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
294638|NCT01955590|Behavioral|EMDR|8-12 sessions of manualized EMDR
294639|NCT01955590|Behavioral|Treatment as usual|8-12 sessions of treatment of usual
294640|NCT01955577|Drug|Placebo orally everyday|
294641|NCT01955577|Drug|Vitamin D3 cholecalciferol|
294642|NCT01955564|Drug|NW-3509a|single dose
294643|NCT01955551|Behavioral|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
294644|NCT01955551|Behavioral|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
294645|NCT01955538|Other|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
294646|NCT01955538|Other|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
294647|NCT01955538|Other|Mixed physical activity|20 weeks, 1 hour/week.
294648|NCT01955512|Drug|Clopidogrel|Clopidogrel 75mg daily for 7 days
294649|NCT01955512|Drug|Placebo|Matched placebo
294650|NCT01955499|Drug|Ibrutinib|Given PO
294651|NCT01955499|Drug|Lenalidomide|Given PO
294652|NCT01955499|Other|Pharmacological Study|Correlative studies
294653|NCT01955486|Other|flight simulation|
294654|NCT01955473|Drug|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
294655|NCT01955460|Biological|Aldesleukin|Given IV
294656|NCT01955460|Drug|Cyclophosphamide|Given IV
294657|NCT01955460|Drug|Fludarabine Phosphate|Given IV
294658|NCT01955460|Other|Laboratory Biomarker Analysis|Correlative studies
294659|NCT01955460|Biological|NGFR-transduced Autologous T Lymphocytes|Given IV
294660|NCT01955460|Biological|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
294661|NCT01955447|Dietary Supplement|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
294662|NCT01955447|Dietary Supplement|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
294663|NCT01955447|Dietary Supplement|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
294664|NCT01955447|Dietary Supplement|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
294665|NCT01955434|Drug|Cyclophosphamide|Given PO
294666|NCT01955434|Other|Laboratory Biomarker Analysis|Correlative studies
294667|NCT01955434|Other|Pharmacological Study|Correlative studies
294668|NCT01955434|Other|Quality-of-Life Assessment|Ancillary studies
294669|NCT01955434|Drug|Smac Mimetic LCL161|Given PO
294670|NCT01955421|Drug|Erlotinib 100mg qd|
294671|NCT01955421|Drug|Gefitinib 250mg qd|
294672|NCT01955408|Other|Questionnaires, anticholinergic treatment, urodynamic study|
294673|NCT01955395|Behavioral|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
294674|NCT01955382|Drug|Actidose Aqua|Actidose Aqua (oAC) (Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
294675|NCT01955382|Drug|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
294676|NCT01955382|Drug|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer's directions.
294677|NCT01955356|Procedure|Scratching|Endometrial biopsy
294678|NCT01955330|Procedure|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
294679|NCT01955317|Behavioral|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
294680|NCT01955317|Behavioral|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
294681|NCT01955304|Drug|fruquintinib|Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
294736|NCT01954901|Procedure|Hyperbaric oxygen therapy|
294682|NCT01955291|Device|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
294683|NCT01955291|Other|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
294684|NCT01955278|Device|Definitive end colostomy with mesh|In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.
294685|NCT01955278|Other|Conventional definitive end colostomy|
294686|NCT01955265|Behavioral|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
294687|NCT01955265|Behavioral|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
294688|NCT01955252|Drug|Azithromycin|"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).~Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.~Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.~For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"
294689|NCT01955239|Radiation|Intensity-modulated Radiotherapy|
294690|NCT01955226|Other|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
294691|NCT01955226|Other|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
294692|NCT01955213|Drug|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
294693|NCT01955200|Drug|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
294694|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
294695|NCT01955200|Drug|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
294696|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
294697|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
294698|NCT01955187|Drug|TACROLIMUS|Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
294699|NCT01955187|Drug|RITUXIMAB|A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
294700|NCT01955187|Drug|METHYLPREDNISOLONE|Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
294701|NCT01955187|Drug|CYCLOPHOSPHAMIDE|Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
294702|NCT01955174|Drug|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
294703|NCT01955174|Other|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
294704|NCT01955161|Drug|Placebo|Once daily, matching placebo capsules, orally
294705|NCT01955161|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
294706|NCT01955135|Drug|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
294707|NCT01955135|Drug|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
294708|NCT01955135|Drug|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
294709|NCT01955122|Device|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
295294|NCT01950884|Behavioral|Lifestyle|lifestyle
294710|NCT01955109|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
294711|NCT01955096|Procedure|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
294712|NCT01955096|Procedure|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
294713|NCT01955083|Device|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
294714|NCT01955083|Device|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
294715|NCT01955070|Other|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
294716|NCT01955057|Behavioral|Research interviews|
294717|NCT01955057|Behavioral|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
294718|NCT01955057|Behavioral|Projective methods (Thematic apperception Test, Rorschach)|
294719|NCT01955057|Behavioral|Carbon monoxide test|
294720|NCT01955044|Dietary Supplement|LCPUFA supplement|
294721|NCT01955044|Dietary Supplement|placebo|
294722|NCT01955031|Other|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
294723|NCT01955031|Other|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
294724|NCT01955018|Device|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
294725|NCT01955005|Behavioral|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
294726|NCT01955005|Other|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
294727|NCT01954992|Drug|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
294728|NCT01954992|Drug|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
294729|NCT01954979|Drug|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
294730|NCT01954966|Drug|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
294731|NCT01954966|Drug|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
294732|NCT01954940|Device|Whole Body Vibration Therapy|
294733|NCT01954927|Drug|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
294734|NCT01954927|Drug|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
294735|NCT01954914|Drug|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
294737|NCT01954888|Procedure|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
294738|NCT01954888|Procedure|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
294739|NCT01954862|Other|Air Insufflation method.|Air Insufflation method.
294740|NCT01954862|Other|CO2 insufflation|CO2 insufflation.
294741|NCT01954862|Other|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
294742|NCT01954862|Other|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
294743|NCT01954862|Other|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
294744|NCT01954862|Other|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
294745|NCT01954849|Dietary Supplement|Probiotic formulation|
294746|NCT01954836|Behavioral|initial fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
294747|NCT01954836|Behavioral|Secondary fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
294748|NCT01954823|Device|e-diary|"The e-diary can collect data on:~Medical data: information on diseases, treatments and attending physicians~Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data~Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails~Reports: textual and graphical reports of the data in the diary can be created"
294749|NCT01954810|Biological|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
294750|NCT01954784|Drug|fludarabine phosphate|
294751|NCT01954784|Radiation|total-body irradiation|Undergo TBI
294752|NCT01954784|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
294753|NCT01954784|Drug|cyclosporine|Given PO
294754|NCT01954784|Drug|mycophenolate mofetil|Given PO
294755|NCT01954784|Drug|bortezomib|Given SC
294756|NCT01954784|Drug|lenalidomide|Given PO
294757|NCT01954784|Other|laboratory biomarker analysis|Correlative studies
294758|NCT01954771|Behavioral|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
294759|NCT01954771|Other|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
294760|NCT01954758|Other|personalized Embryo Transfer (pET)|
294761|NCT01954758|Other|Frozen Embryo Transfer (FET)|
294762|NCT01954758|Other|Fresh Embryo Transfer (ET)|
294763|NCT01954745|Drug|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
294764|NCT01954732|Drug|metformin hydrochloride|Given PO
294765|NCT01954732|Other|pharmacological study|Correlative studies
294766|NCT01954719|Procedure|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
294767|NCT01954719|Procedure|control group|surgeon not dilated cervix after surgery
294768|NCT01954706|Other|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
294769|NCT01954706|Other|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
294770|NCT01954693|Drug|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
294771|NCT01954693|Drug|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
294772|NCT01954680|Behavioral|COGFLEX-skill building levels|"COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder."
294773|NCT01954680|Behavioral|COGFLEX-control condition|"In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks."
294774|NCT01954654|Device|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
294775|NCT01954654|Other|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
294976|NCT01953328|Biological|Evolocumab|Administered by subcutaneous injection
294776|NCT01954641|Other|ACCURE Navigator|"The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions."
294777|NCT01954641|Other|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
294778|NCT01954628|Drug|AQX-1125|Synthetic SHIP1 activator
294779|NCT01954628|Drug|Placebo|Placebo control
294780|NCT01954615|Drug|5 mg ACT-281959 prodrug formulation I (Group A)|
294781|NCT01954615|Drug|20 mg ACT-281959 prodrug formulation I (Group B)|
294782|NCT01954615|Drug|ACT-281959 prodrug formulation I (Groups C to G doses to be defined)|
294783|NCT01954615|Drug|ACT-281959 prodrug formulation II (Group G dose to be defined)|
294784|NCT01954615|Drug|ACT-246475 (Group G dose to be defined)|
294785|NCT01954615|Drug|Placebo (Groups A to F)|
294786|NCT01954602|Procedure|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
294787|NCT01954602|Procedure|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
294788|NCT01954589|Drug|ACT-462206 5 mg|
294789|NCT01954589|Drug|ACT-462206 25 mg|
294790|NCT01954589|Drug|ACT-462206 100mg|
294791|NCT01954589|Drug|ACT-462206 200mg|
294792|NCT01954589|Drug|ACT-462206 400mg|
294793|NCT01954589|Drug|ACT-462206 1000 mg|
294794|NCT01954589|Drug|ACT-462206 1500mg|
294795|NCT01954589|Drug|Almorexant 400mg|
294796|NCT01954589|Drug|Placebo|
294797|NCT01954576|Device|NovoTTF-100A|
294798|NCT01954576|Procedure|Quality-of-life assessment|
294799|NCT01954576|Genetic|Laboratory biomarker analysis|
294800|NCT01954563|Biological|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
294801|NCT01954550|Behavioral|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
294802|NCT01954550|Behavioral|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
294803|NCT01954524|Drug|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:~CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
294804|NCT01954511|Other|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
294805|NCT01954511|Other|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
294806|NCT01954511|Device|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
294807|NCT01954498|Dietary Supplement|Walnuts|
294808|NCT01954498|Dietary Supplement|OTC multivitamin|
294809|NCT01954485|Procedure|Dental implant placement with a final prosthetic abutment|
294810|NCT01954472|Behavioral|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).~Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
294811|NCT01954472|Behavioral|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.~Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
294812|NCT01954459|Device|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
294813|NCT01954459|Device|Continuous glucose sensor|Glucose sensor inserted without warming patch
294814|NCT01954446|Device|3M|Conventional measuring of BP
294815|NCT01954446|Device|ContiPressTM|"New way of measuring BP - ContiPressTM~Investigational device"
294816|NCT01954446|Device|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
294817|NCT01954433|Procedure|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
294818|NCT01954433|Procedure|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
294919|NCT01953770|Drug|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
294819|NCT01954433|Procedure|Resection interposition suspension arthroplasty (RISA)|"One of five surgical techniques can be used in this study, as routinely performed by each surgeon:~RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping~RISA with FCR-Ligament modified according to Weilby~RISA with APL-Ligament (abductor pollicis longus ligament)~RISA with Graftjacket modified according to Weilby~Resection arthroplasty"
294820|NCT01954420|Behavioral|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
294821|NCT01954420|Other|Attention Control|Standard care + Cancer education
294822|NCT01954407|Behavioral|Smoking-Related Messages|
294823|NCT01954394|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
294824|NCT01954394|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
294825|NCT01954381|Device|transthoracic echocardiographic|
294826|NCT01954381|Device|Doppler ultrasound.|
294827|NCT01954381|Biological|blood samples|
294828|NCT01954368|Drug|Placebo|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
294829|NCT01954368|Drug|Sufentanil|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.~Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
294830|NCT01954355|Drug|LDE225|400, 600 and 800 mg OD
294831|NCT01954355|Drug|Paclitaxel|80 mg/m2 (days 1, 8, 15)
294832|NCT01954316|Drug|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
294833|NCT01954303|Other|Progress of CHD|
294834|NCT01954290|Drug|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
294835|NCT01954290|Drug|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
294836|NCT01954290|Drug|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
294837|NCT01954277|Device|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
294838|NCT01954277|Device|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
294839|NCT01954264|Procedure|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
294840|NCT01954264|Other|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
294841|NCT01954251|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
294842|NCT01954251|Biological|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
294843|NCT01954238|Drug|GCC-4401C|"Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion."
294844|NCT01954238|Drug|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
294845|NCT01954238|Drug|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
294846|NCT01954225|Other|Udumbara Sutra|The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
294847|NCT01954212|Other|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:~Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.~Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.~Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
294920|NCT01953757|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
294921|NCT01953757|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
294922|NCT01953744|Drug|Fluconazole|Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
294977|NCT01953328|Other|Placebo to Evolocumab|Administered by subcutaneous injection
294848|NCT01954199|Procedure|Neurodynamic Group|"All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.~In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;~In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;~In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner."
294849|NCT01954186|Drug|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
294850|NCT01954186|Procedure|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
294851|NCT01954173|Radiation|3D conformal radiation therapy|Undergo conformal radiation therapy
294852|NCT01954160|Device|Symplicity Renal Denervation|Renal denervation
294853|NCT01954147|Drug|GLP-1|GLP-1 therapy
294854|NCT01954147|Biological|SC|Stem cell infusion
294855|NCT01954147|Other|Standard Medical Treatment|Standard Medical Treatment
294856|NCT01954121|Drug|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.~Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)~Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid~Down-titration Period (Week 30 up to Week 33)"
294857|NCT01954121|Drug|Carbamazepine|"Immediate release tablets at a strength of 200 mg.~Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)~Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid~Down-titration Period (Week 30 up to Week 33)"
294858|NCT01954108|Device|hyaluronic acid sodium salt|
294859|NCT01954108|Device|ESWT|
294860|NCT01954082|Drug|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.~Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
294861|NCT01954082|Drug|Placebo|% glucose(dextrose)
294862|NCT01954069|Device|Semi-quantitative pregnancy test|
294863|NCT01954056|Drug|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
294864|NCT01954056|Drug|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
294865|NCT01954043|Drug|Dabrafenib 150 mg twice a day (BID)|Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
294866|NCT01954043|Drug|Rabeprazole 40 mg once daily (OD)|Rabeprazole dosed at 40mg each morning on Days 16 to 19
294867|NCT01954043|Drug|Rifampin 600 mg OD|Rifampin dosed at 600mg each morning on Days 20 to 29
294868|NCT01954030|Drug|CTO and Bevacizumab|
294869|NCT01954030|Drug|CTO alone|
294870|NCT01954017|Biological|STP206|Live Biotherapeutic
294871|NCT01954017|Other|Control|Sterile Water
294872|NCT01953991|Device|Dentures|Removable prosthesis to replace missing teeth
294873|NCT01953978|Drug|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
294874|NCT01953978|Other|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
294875|NCT01953978|Drug|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
294876|NCT01953978|Drug|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
294877|NCT01953978|Drug|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
294878|NCT01953978|Drug|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
294879|NCT01953952|Procedure|therapeutic conventional surgery|Undergo transoral eHNS
294880|NCT01953952|Radiation|intensity-modulated radiation therapy|Undergo IMRT
294881|NCT01953952|Drug|cisplatin|Given IV
294882|NCT01953952|Procedure|quality-of-life assessment|Ancillary studies
294883|NCT01953952|Other|laboratory biomarker analysis|Correlative studies
294884|NCT01953939|Other|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
294885|NCT01953926|Drug|Neratinib|240 mg administered orally, once daily with food, continuously in 28 day cycles
294886|NCT01953926|Drug|Paclitaxel|80mg/m^2 administered IV on Days 1, 8, and 15 of every 4 week cycle
294887|NCT01953926|Drug|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15, and 29; then once every 4 weeks thereafter month, then Day 1 of every 4 week cycle
294888|NCT01953926|Drug|Trastuzumab|Initial dose of 8 mg/kg of trastuzumab administered IV on Day 1, followed by 6 mg/kg IV once every 3 weeks thereafter
294889|NCT01953913|Drug|Afatinib|Patient will receive afatinib once daily
294923|NCT01953744|Drug|Meglumine Antimoniate|Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
294978|NCT01953315|Biological|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
295241|NCT01951287|Other|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
294890|NCT01953900|Genetic|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.~Dose Level 1: 1x10^6 cells/m^2~Dose Level 2: 1x10^7 cells/m^2~The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:~Dose Level 7: 1 x 10^7 cells/m2~Dose Level 8: 1 x 10^8 cells/m^2~Dose levels 9-11 will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine prior to administration of the T cells.~Dose Level 9: 1 x 10^8 cells/m^2~Dose Level 10: 5 x 10^8 cells/m^2~Dose Level 11: 1 x 10^9 cells/m^2~The previously planned dose levels 3-6 will not be studied."
294891|NCT01953900|Biological|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
294892|NCT01953900|Drug|Fludarabine|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m^2/day followed by Fludarabine 30 mg/m^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
294893|NCT01953900|Drug|Cyclophosphamide|Pre-infusion lymphodepletion for dose levels 9-11: Patients will receive 3 daily doses of cyclophosphamide together with fludarabine to induce lymphopenia, finishing at least 24 hours before T cell infusion. Cyclophosphamide will be given at a dose of 500 mg/m^2/day followed by Fludarabine 30 mg/m^2/day. Infusions should be given following hospital/pharmacy recommendations however at a minimum the cyclophosphamide should be infused over 1 hour and the fludarabine should be infused over 30 minutes. Mesna, IV hydration, and anti-emetics will be provided following local institutional guidelines. T cell infusion will take place the day after completion of chemotherapy. Zostavax will be administered two weeks after infusion of T cells.
294894|NCT01953887|Drug|EC905|Oral
294895|NCT01953887|Drug|solifenacin|oral
294896|NCT01953887|Drug|tamsulosin|oral
294897|NCT01953874|Device|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
294898|NCT01953874|Drug|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
294899|NCT01953861|Drug|EC905|Oral
294900|NCT01953848|Drug|EC905|Oral
294901|NCT01953835|Drug|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
294902|NCT01953835|Drug|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
294903|NCT01953835|Drug|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
294904|NCT01953835|Drug|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
294905|NCT01953822|Other|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
294906|NCT01953809|Drug|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
294907|NCT01953809|Drug|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
294908|NCT01953809|Drug|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
294909|NCT01953809|Drug|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
294910|NCT01953796|Drug|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
294911|NCT01953783|Drug|IXAZOMIB|
294912|NCT01953770|Drug|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
294913|NCT01953770|Drug|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
294914|NCT01953770|Drug|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
294915|NCT01953770|Drug|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
294916|NCT01953770|Drug|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
294917|NCT01953770|Drug|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
294918|NCT01953770|Radiation|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients >3 years of age
294924|NCT01953731|Drug|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.~In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
294925|NCT01953731|Drug|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
294926|NCT01953705|Drug|Omega 3 PUFA|fish oil concentrate standardized to long chain n-3 PUFA content
294927|NCT01953705|Drug|Placebo|
294928|NCT01953692|Biological|Pembrolizumab|IV infusion
294929|NCT01953692|Drug|Lenalidomide|oral capsules
294930|NCT01953679|Drug|Ulipristal Acetate|
294931|NCT01953666|Other|Rehabilitation program|"Rehabilitation program with an occupational therpasit~3 training sessions (one hour) per week for a month (12 sessions)"
294932|NCT01953666|Other|Self - Training at home|Only instructions for a self - training at home
294933|NCT01953653|Behavioral|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
294934|NCT01953640|Other|Laboratory Biomarker Analysis|Correlative studies
294935|NCT01953640|Other|Quality-of-Life Assessment|Ancillary studies
294936|NCT01953627|Procedure|Surgical procedure with the system Kymerax|
294937|NCT01953627|Device|The system Kymerax|
294938|NCT01953614|Other|Chiropractic adjustment|
294939|NCT01953614|Other|Sham adjustment|
294940|NCT01953601|Drug|Verubecestat 12 mg (Parts 1 and 2)|Verubecestat 12 mg oral tablet, given once daily.
294941|NCT01953601|Drug|Verubecestat 40 mg (Parts 1 and 2)|Verubecestat 40 mg oral tablet, given once daily. Verubecestat 40 mg given to participants in Arm C continuing to study Part 2.
294942|NCT01953601|Other|Placebo (Part 1)|Placebo matching verubecestat, given once daily as an oral tablet.
294943|NCT01953588|Drug|fulvestrant|Fulvestrant 500 mg IM
294944|NCT01953588|Drug|anastrozole|Anastrozole 1 mg oral tablet
294945|NCT01953575|Device|Mucosal Impedance|"Mucosal impedance- a (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) 5 cm above where your stomach and esophagus meet for 5 seconds.~At 10 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds~And at 20 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds.~This will determine if people with eosinophilic esophagitis (EoE) have an increased esophageal mucosa impedance (food getting into the esophageal tissue)."
294946|NCT01953549|Procedure|physical fitness training|
294947|NCT01953549|Procedure|relaxation|
294948|NCT01953536|Drug|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
294949|NCT01953536|Drug|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m^2.
294950|NCT01953536|Drug|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
294951|NCT01953536|Drug|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
294952|NCT01953536|Drug|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
294953|NCT01953523|Procedure|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
294954|NCT01953510|Biological|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
294955|NCT01953510|Biological|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
294956|NCT01953497|Drug|URC102|
294957|NCT01953497|Drug|Placebo|
294958|NCT01953484|Other|Change in extracorporeal carbon dioxide removal|
294959|NCT01953471|Other|Allergic rhinitis|Questionnaire
294960|NCT01953445|Drug|paclitaxel|
294961|NCT01953445|Drug|BKM120|
294962|NCT01953432|Drug|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
294963|NCT01953432|Drug|Placebo|Matched placebo daily dosing
294964|NCT01953419|Drug|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
294965|NCT01953406|Drug|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
294966|NCT01953406|Drug|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
294967|NCT01953393|Other|Low-dose TNF-alpha|
294968|NCT01953380|Behavioral|extended information|
294969|NCT01953367|Drug|Vantobra (tobramycin)|Inhalation
294970|NCT01953367|Drug|TOBI (tobramycin)|Inhalation
294971|NCT01953354|Biological|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
294972|NCT01953354|Biological|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
294973|NCT01953341|Drug|AMG 333|Oral administration available in varying dose strength.
294974|NCT01953341|Drug|Placebo|Placebo containing no active drug
294975|NCT01953328|Drug|Atorvastatin|Administered orally once a day
294979|NCT01953302|Procedure|"modified open mesh technique"|We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
294980|NCT01953276|Device|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
294981|NCT01953263|Other|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
294982|NCT01953237|Behavioral|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
294983|NCT01953237|Device|Smartphone|
294984|NCT01953224|Behavioral|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
294985|NCT01953224|Device|Smartphone|
294986|NCT01953211|Drug|combined oral contraceptives|
294987|NCT01953198|Other|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
294988|NCT01953185|Other|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone & Russo, 2006).
294989|NCT01953185|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
294990|NCT01953172|Dietary Supplement|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
294991|NCT01953172|Other|Placebo|Placebo
294992|NCT01953159|Other|Blood Collection|
294993|NCT01953159|Other|Patient Questionnaires|
294994|NCT01953133|Behavioral|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
294995|NCT01953120|Drug|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
294996|NCT01953107|Other|Oral Ferrous Fumarate|
294997|NCT01953107|Other|Placebo|
294998|NCT01953094|Procedure|Screening Anal Pap Smear - No High Resolution Anoscopy|
294999|NCT01953094|Procedure|Screening Anal Pap Smear - With High Resolution Anoscopy|
295000|NCT01953081|Drug|TD-8954|
295001|NCT01953081|Drug|Metoclopramide|
295002|NCT01953055|Radiation|Stereotactic ablative radiotherapy|
295003|NCT01953042|Behavioral|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
295004|NCT01953029|Procedure|cardiac imajing|Cardiac MRI
295005|NCT01953003|Drug|vinflunine|intravenous administration day 1 once every 3 weeks, 280 mg/m²
295006|NCT01953003|Drug|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
295007|NCT01952990|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
295008|NCT01952977|Dietary Supplement|Test breakfast|
295009|NCT01952964|Other|JUC spray dressing|"Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.~Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals."
295010|NCT01952951|Drug|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
295011|NCT01952951|Radiation|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
295012|NCT01952938|Procedure|LINK SL versus EnduRo|
295013|NCT01952925|Procedure|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
295014|NCT01952912|Procedure|PkEP|
295015|NCT01952912|Procedure|OP|
295016|NCT01952886|Drug|Granisetron|
295017|NCT01952886|Drug|Ondansetron|
295018|NCT01952873|Other|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
295019|NCT01952873|Other|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
295020|NCT01952860|Other|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
295021|NCT01952860|Behavioral|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
295022|NCT01952847|Other|Placebo|"mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.~Radiation Therapy to Esophagus Patient Group - Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times."
295023|NCT01952847|Drug|Glutamine|"mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.~Radiation Therapy to Esophagus Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times."
295024|NCT01952847|Behavioral|Questionnaires|"Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.~Questionnaire completion for Radiation Therapy to Esophagus Patient Group: At baseline, Week 3, 4, 5, and 7 of radiation, and at end of study visit."
295025|NCT01952834|Dietary Supplement|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
295026|NCT01952834|Drug|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
295027|NCT01952821|Other|Six-Minute Walk Test|
295028|NCT01952821|Other|10-Meter Walk Test|
295029|NCT01952821|Other|30-Second Chair Stand|
295030|NCT01952821|Other|Linear Analog Scale of Function|
295031|NCT01952821|Other|Modified Brief Fatigue Inventory|
295032|NCT01952821|Other|FACIT-Fatigue|
295033|NCT01952808|Behavioral|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
295034|NCT01952808|Behavioral|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
295035|NCT01952795|Behavioral|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
295036|NCT01952782|Drug|Kisspeptin 112-121|Subjects will receive up to 10 intravenous doses of kisspeptin 112-121
295037|NCT01952782|Drug|Naloxone|Subjects will receive one intravenous dose of naloxone followed by an intravenous infusion of naloxone.
295038|NCT01952782|Drug|Gonadotropin Releasing Hormone (GnRH)|Subjects will receive up to 10 doses of intravenous Gonadotropin Releasing Hormone (GnRH)
295039|NCT01952769|Biological|MDV9300|"The study will be done in the following manner:~Evaluation of MDV9300 and radiation-~Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.~Cohort B -3 patiens: if no toxicity >grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given~Evaluation of MDV9300 and cyclophosphamide~After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:~Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
295040|NCT01952756|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
295041|NCT01952756|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
295042|NCT01952743|Procedure|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
295043|NCT01952743|Procedure|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
295044|NCT01952730|Biological|GVAX|
295045|NCT01952704|Behavioral|Aerobic exercise|
295046|NCT01952704|Behavioral|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
295047|NCT01952691|Device|kinesiotaping|correction method was used to align hallux.
295048|NCT01952678|Other|DaTscan™ - Non-Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
295049|NCT01952678|Other|DaTscan™ - Caucasian Participants|Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
295050|NCT01952665|Device|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
295051|NCT01952665|Device|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
295052|NCT01952652|Drug|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
295053|NCT01952652|Drug|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
295054|NCT01952639|Dietary Supplement|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
295055|NCT01952626|Drug|Ondansetron|intravenous injection
295056|NCT01952626|Drug|Palonosetron|intravenous injection
295057|NCT01952613|Device|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
295058|NCT01952587|Biological|A peripheral blood sample|A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
295059|NCT01952574|Drug|Erenumab|Administered once a month (QM) by subcutaneous injection
295060|NCT01952574|Drug|Placebo|Administered once a month by subcutaneous injection
295061|NCT01952561|Drug|dapivirine ring|
295062|NCT01952548|Drug|K-312|
295063|NCT01952548|Drug|Placebo|
295064|NCT01952535|Drug|HMS5552|
295065|NCT01952535|Drug|Placebo|
295066|NCT01952522|Behavioral|Weighted brace|People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
295067|NCT01952522|Behavioral|Non weighted brace|People will be given a brace with no weight they will have to wear all the day during three months.
295068|NCT01952496|Other|Assisted Standing Treatment Program|"Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months.~Arm: Force-measuring platform"
295069|NCT01952470|Drug|Dornase Alfa|Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
295070|NCT01952470|Drug|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
295071|NCT01952457|Device|Zilver PTX|
295072|NCT01952457|Device|prosthetic bypass|
295073|NCT01952444|Biological|ETI-204|A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
295074|NCT01952444|Drug|Ciprofloxacin|A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
295075|NCT01952431|Device|Total Lung Capacity (TLC) testing|Comparison of TLC results
295076|NCT01952418|Device|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
295077|NCT01952405|Behavioral|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
295078|NCT01952353|Procedure|Preoprative TACE|
295079|NCT01952353|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
295080|NCT01952340|Dietary Supplement|Flaxseed|Milled flaxseed
295081|NCT01952340|Dietary Supplement|Placebo|Wheat germ/wheat bran and mixed dietary oils
295082|NCT01952327|Device|The pleurapump system|Implantation of the pleurapump system
295083|NCT01952314|Drug|Naftopidil 75mg|naftopidil 75mg 1T qd hs
295084|NCT01952314|Drug|Placebo for Naftopidil|Placebo 1T qd hs
295085|NCT01952314|Drug|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
295086|NCT01952301|Device|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
295087|NCT01952301|Device|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
295088|NCT01952288|Drug|simvastatin|simvastatin 40 mg/day for 12 months
295089|NCT01952288|Drug|Placebo Oral Tablet|placebo comparator
295090|NCT01952275|Procedure|Collection of biological samples|
295091|NCT01952262|Other|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
295092|NCT01952249|Drug|Demcizumab|administered intravenously
295093|NCT01952249|Drug|Taxol|administered intravenously
295094|NCT01952236|Behavioral|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 1,271 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
295095|NCT01952236|Behavioral|Web Only|A Web-based PC-delivered best practices smoking cessation intervention.
295096|NCT01952223|Drug|Cabazitaxel|Cabazitaxel administered at 25mg/m2 as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
295097|NCT01952223|Radiation|Pelvic radiotherapy|"Prostate+pelvic RT (2 Gy fractions, 5 times per week):~Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
295098|NCT01952223|Radiation|prostate radiotherapy|"Prostate-only RT (2 Gy fractions, 5 times per week):~Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)~Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
295099|NCT01952210|Behavioral|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
295100|NCT01952210|Behavioral|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
295101|NCT01952197|Other|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
295102|NCT01952184|Device|CBSvit HS device|closed vitrification with closed storage
295103|NCT01952184|Device|Cryotop SC device|open vitrification with closed storage
295104|NCT01952145|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
295105|NCT01952145|Drug|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
295106|NCT01952132|Drug|OMS643762|
295107|NCT01952132|Drug|Placebo|
295108|NCT01952119|Other|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
295109|NCT01952106|Other|play computer game|
295110|NCT01952093|Behavioral|Home-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the home.
295111|NCT01952093|Behavioral|Clinic-based intervention program|The intervention had been done in the previous intervention study. The intervention included in-hospital and after-discharge service. After-discharge intervention performed at 0, 1, 2, 4, 6, 9, 12 months of age at the clinic.
295112|NCT01952080|Drug|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
295113|NCT01952067|Procedure|line-to-line reaming and cementing technique|
295114|NCT01952067|Procedure|standard over-reaming with 2 broach sizes|
295115|NCT01952054|Drug|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
295116|NCT01952041|Behavioral|Device: Smartphone|
295117|NCT01952041|Behavioral|Treatment as usual|
295118|NCT01952015|Biological|Secukinumab|Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).
295119|NCT01952002|Other|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
295120|NCT01951989|Drug|Imiglucérase (drug) pharmacokinetics|
295121|NCT01951976|Other|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
295122|NCT01951976|Other|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
295123|NCT01951963|Drug|Ketamine|
295124|NCT01951963|Drug|Morphine|
295125|NCT01951950|Drug|Nicardipine|
295126|NCT01951950|Drug|Esmolol|
295127|NCT01951937|Dietary Supplement|Fish Meals|Meals containing salmon
295128|NCT01951937|Dietary Supplement|Placebo|No fish meals
295129|NCT01951924|Drug|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
295130|NCT01951924|Drug|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
295131|NCT01951911|Drug|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
295132|NCT01951911|Drug|Placebo|
295133|NCT01951898|Drug|Montelukast|10mg/day, once a daily after dinner, for 28dyas
295134|NCT01951885|Drug|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1. Tac will be administered IV over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
295135|NCT01951885|Drug|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient < 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
295136|NCT01951885|Drug|Mycophenolate mofetil|Patients will receive Mycophenolate beginning on day +1. Patients >40 kg will receive Mycophenolate 1000 mg twice a day. Mycophenolate should be given orally twice a day. IV formulation may be used if the patient cannot tolerate oral route. Patients < 40 kg will receive MMF 45 mg/kg/day (15 mg/kg three times a day). MMF may be given orally or intravenously as per institutional protocol
295137|NCT01951885|Drug|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
295240|NCT01951287|Other|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
295138|NCT01951872|Behavioral|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
295139|NCT01951859|Other|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
295140|NCT01951846|Drug|BIBF 1120|
295141|NCT01951833|Device|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
295142|NCT01951820|Drug|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
295143|NCT01951820|Drug|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
295144|NCT01951820|Drug|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
295145|NCT01951807|Behavioral|Psychotherapy|
295146|NCT01951781|Other|blood sample|"blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)~When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood."
295147|NCT01951768|Drug|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
295148|NCT01951768|Drug|Systemic Antibiotic|"Antibiotics options per protocol:~Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h"
295149|NCT01951742|Biological|ANT-1401|Active
295150|NCT01951742|Biological|Vehicle|Vehicle
295151|NCT01951729|Drug|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
295152|NCT01951729|Drug|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
295153|NCT01951729|Drug|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
295154|NCT01951729|Drug|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
295155|NCT01951729|Drug|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
295156|NCT01951729|Drug|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
295157|NCT01951729|Drug|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
295158|NCT01951729|Drug|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.~Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.~Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
295159|NCT01951716|Drug|Graded Glucose Infusion with Placebo|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
295160|NCT01951716|Drug|Graded Glucose Infusion with GIP Alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
295161|NCT01951716|Drug|Graded Glucose Infusion with xenin-25 alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
295162|NCT01951716|Drug|Graded Glucose Infusion with GIP plus xenin-25|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.~Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.~The study is finished at 240 minutes."
295163|NCT01951716|Drug|Meal Tolerance Test with Placebo|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
295164|NCT01951716|Drug|Meal Tolerance Test with xenin-25|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.~Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.~The study is finished at 300 minutes."
295165|NCT01951703|Device|senofilcon A|Control, senfilcon A
295166|NCT01951703|Device|senofilcon A|Test, senofilcon A
295167|NCT01951690|Drug|defactinib (VS-6063)|
295168|NCT01951677|Drug|HBsAg|Standard hepatitis B vaccine antigen
295169|NCT01951677|Biological|PreS HBsAg|preS hepatitis B surface antigen
295170|NCT01951677|Biological|Advax-1(TM)|Adjuvant formulated with vaccine antigen
295171|NCT01951677|Biological|Advax-2(TM)|Adjuvant formulated with vaccine antigen
295172|NCT01951677|Biological|Advax-3(TM)|Adjuvant formulated with vaccine antigen
295173|NCT01951677|Biological|Alum|Adjuvant formulated with vaccine antigen
295174|NCT01951664|Other|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
295175|NCT01951664|Behavioral|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
295176|NCT01951664|Behavioral|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
295177|NCT01951664|Behavioral|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
295178|NCT01951664|Other|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
295179|NCT01951651|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
295180|NCT01951651|Drug|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
295181|NCT01951638|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
295182|NCT01951638|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
295183|NCT01951638|Drug|Placebo|
295184|NCT01951625|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
295185|NCT01951625|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
295186|NCT01951625|Drug|Placebo|
295187|NCT01951612|Behavioral|Executive Function Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
295188|NCT01951612|Behavioral|Psychoeducational Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
295189|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
295190|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
295191|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
295192|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
295193|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
295194|NCT01951586|Drug|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
295195|NCT01951586|Drug|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
295196|NCT01951586|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
295292|NCT01950923|Procedure|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
295197|NCT01951586|Drug|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
295198|NCT01951586|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
295199|NCT01951573|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
295200|NCT01951573|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
295201|NCT01951560|Drug|Valproic Acid|By infusion over 1 hour
295202|NCT01951560|Drug|Isotonic saline solution|By infusion over 1 hour
295203|NCT01951547|Procedure|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
295204|NCT01951547|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
295205|NCT01951534|Behavioral|Breast Reconstruction Decisional Aid (BRDA)|
295206|NCT01951534|Behavioral|Usual Care|
295207|NCT01951521|Radiation|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
295208|NCT01951508|Drug|Methylphenidate|60mg per os, single dose
295209|NCT01951508|Drug|Modafinil|600mg per os, single dose
295210|NCT01951508|Drug|MDMA|125mg per os, single dose
295211|NCT01951508|Drug|Placebo|per os
295212|NCT01951482|Drug|Pemetrexed/cisplatin|receive Pemetrexed/cisplatin every 21 days
295213|NCT01951482|Drug|Bevacizumab and Pemetrexed/cisplatin|receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
295214|NCT01951469|Drug|Gefitinib and Pemetrexed/cisplatin|Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days
295215|NCT01951469|Drug|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
295216|NCT01951456|Behavioral|Resistance training|
295217|NCT01951456|Behavioral|Health and Wellness|
295218|NCT01951443|Dietary Supplement|Ginseng|400mg of encapsulated Rg3-KRG
295219|NCT01951443|Dietary Supplement|Wheat Bran|400mg of encapsulated wheat bran
295220|NCT01951430|Drug|Antibiotic and antifungal drugs|
295221|NCT01951417|Drug|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
295222|NCT01951417|Other|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
295223|NCT01951417|Other|Foam Wash|Foam Wash (twice daily)
295224|NCT01951404|Drug|Allopurinol|
295225|NCT01951404|Drug|Placebo (for allopurinol)|
295226|NCT01951391|Other|Soap|Commercially available soap will be used to wash the subject's forearms
295227|NCT01951378|Device|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS > 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
295228|NCT01951378|Device|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
295229|NCT01951378|Drug|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
295230|NCT01951352|Other|Soap|
295231|NCT01951339|Drug|Sitagliptin|100 mg sitagliptin
295232|NCT01951339|Drug|Glimepiride|"Active Comparator~2mg glimepiride"
295233|NCT01951339|Drug|Placebo|2 mg placebo once daily
295234|NCT01951339|Drug|Placebo|100 mg placebo once daily for three months
295235|NCT01951326|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
295236|NCT01951326|Drug|Placebo|5 placebo capsules administered orally BID
295237|NCT01951313|Other|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (< 2g) and low carotenoid (< 2000µg) meal as the 2nd meal.
295238|NCT01951300|Other|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
295239|NCT01951287|Other|Acute beverage (water) consumption|Acute beverage consumption includes water.
295293|NCT01950884|Drug|Ezetimibe|Ezetimibe tablets
295242|NCT01951287|Other|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
295243|NCT01951287|Other|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
295244|NCT01951287|Other|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
295245|NCT01951274|Drug|VPD-737|NK1 Receptor Antagonist
295246|NCT01951274|Drug|Placebo|
295247|NCT01951261|Procedure|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
295248|NCT01951248|Device|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
295249|NCT01951235|Drug|Imeglimin|
295250|NCT01951235|Drug|Placebo|
295251|NCT01951222|Drug|V0162|
295252|NCT01951222|Other|Placebo|
295253|NCT01951209|Drug|Rifaximin|550mg orally twice daily for 12 weeks
295254|NCT01951209|Drug|Placebo|Matched placebo
295255|NCT01951183|Drug|Placebo|RO681135 placebo subcutaneously daily
295256|NCT01951183|Drug|RO6811135|Subcutaneously daily
295257|NCT01951170|Drug|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
295258|NCT01951157|Drug|Docetaxel|Powder for solution for infusion
295259|NCT01951157|Drug|Gemcitabine|Powder for solution for infusion
295260|NCT01951157|Drug|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
295261|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
295262|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
295263|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
295264|NCT01951144|Drug|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
295265|NCT01951118|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
295266|NCT01951105|Drug|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
295267|NCT01951105|Drug|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
295268|NCT01951105|Drug|Placebo|Take two placebo capsules three times a day for 12 weeks.
295269|NCT01951092|Other|Text messaging|
295270|NCT01951079|Drug|Intra-amniotic injection of DIGOXIN|
295271|NCT01951066|Drug|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
295272|NCT01951066|Drug|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
295273|NCT01951053|Drug|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
295274|NCT01951053|Drug|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
295275|NCT01951053|Drug|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
295276|NCT01951027|Drug|GX-G3 12.5 μg/kg or Placebo|Single SC injection
295277|NCT01951027|Drug|GX-G3 25 μg/kg or Placebo|Single SC injection
295278|NCT01951027|Drug|GX-G3 50 μg/kg or Placebo|Single SC injection
295279|NCT01951027|Drug|GX-G3 100 μg/kg or Placebo|Single SC injection
295280|NCT01951014|Other|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
295281|NCT01951001|Drug|Prasugrel|For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
295282|NCT01950988|Device|Manual toothbrush reference|
295283|NCT01950988|Procedure|Measure of the dental plaque|
295284|NCT01950988|Device|Manual toothbrush Broscyl®|
295285|NCT01950975|Biological|Peripheral blood samples in EDTA tubes|
295286|NCT01950975|Procedure|Skin biopsies|
295287|NCT01950962|Other|Sampling of blood|
295288|NCT01950949|Other|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
295289|NCT01950936|Other|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
295290|NCT01950923|Drug|sildenafil citrate|Given PO
295291|NCT01950923|Other|placebo|Given PO
295295|NCT01950871|Device|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
295296|NCT01950858|Biological|Weight reduction|
295297|NCT01950845|Device|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
295298|NCT01950845|Device|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
295299|NCT01950832|Other|Investigating clinically normal patients with optic coherence tomography|
295300|NCT01950819|Biological|Induction therapy|All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
295301|NCT01950819|Drug|Corticosteroids|All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.
295302|NCT01950819|Drug|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
295303|NCT01950819|Drug|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
295304|NCT01950806|Other|Pecan-containing diet|
295305|NCT01950806|Other|Nut-free diet|
295306|NCT01950793|Drug|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only Steroid"
295307|NCT01950793|Drug|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.~One injection only"
295308|NCT01950780|Drug|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
295309|NCT01950754|Behavioral|standing with both feet|
295310|NCT01950754|Behavioral|descent of the platform|
295311|NCT01950754|Behavioral|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
295312|NCT01950741|Drug|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
295313|NCT01950728|Device|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 100 Hz.
295314|NCT01950728|Device|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 100 Hz.
295315|NCT01950728|Device|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 100 Hz.
295316|NCT01950715|Device|sacral nerve stimulation|Sacral nerve stimulation
295317|NCT01950702|Procedure|Laryngoscope assisted lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis."
295318|NCT01950702|Procedure|Lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.~Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.~After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand."
295319|NCT01950689|Drug|Nimorazole|
295320|NCT01950689|Radiation|Radiotherapy|
295321|NCT01950676|Device|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
295322|NCT01950663|Device|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
295323|NCT01950650|Behavioral|No treatment given|Survey conducted through computer-assisted telephone interviewing.
295324|NCT01950650|Behavioral|survey|Survey conducted via the Internet.
295325|NCT01950637|Behavioral|No treatment given|Completion of 90-item online questionnaire.
295326|NCT01950637|Behavioral|survey|Completion of 58-item online questionnarie.
295327|NCT01950611|Drug|Bortezomib|Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
295328|NCT01950598|Procedure|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
295329|NCT01950598|Procedure|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
295330|NCT01950585|Drug|Hydroxyurea|
295331|NCT01950559|Other|Oral food challenge|Oral food challenge to determine allergy to soy
295332|NCT01950546|Drug|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
295333|NCT01950533|Procedure|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
295334|NCT01950507|Drug|Budesonide|Entocort EC 3 mg given orally three times daily for at least 14 days
295335|NCT01950507|Drug|Fluconazole|400 mg orally once daily for CrCl greater than or equal to 50 ml/min
295336|NCT01950507|Drug|Voriconazole|Subjects in Cohort 1 who are not established on voriconazole will receive a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours
295337|NCT01950507|Drug|Micafungin|Micafungin will be dosed as 100 mg as an intravenous infusion once daily at 09:00 for inpatients, and 200 mg to 300 mg as an intravenous infusion administered two to three times weekly for outpatients
295338|NCT01950494|Other|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
295339|NCT01950481|Drug|LDK378|Oral LDK378 750 mg once
295340|NCT01950468|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
295341|NCT01950468|Drug|DaTscan|A single intravenous dose of 3 to 5 mCi
295342|NCT01950455|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
295343|NCT01950442|Device|Balloon dilation|
295344|NCT01950416|Drug|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
295345|NCT01950416|Drug|Clopidogrel 600mg loading dose and 150mg maintenance dose|
295346|NCT01950403|Drug|linaclotide acetate|Given PO
295347|NCT01950403|Other|placebo|Given PO
295348|NCT01950403|Other|pharmacological study|Correlative studies
295349|NCT01950403|Other|laboratory biomarker analysis|Correlative studies
295350|NCT01950390|Biological|Bevacizumab|Given IV
295351|NCT01950390|Biological|Ipilimumab|Given IV
295352|NCT01950364|Drug|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
295353|NCT01950364|Drug|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
295354|NCT01950351|Other|Laboratory Biomarker Analysis|Correlative studies
295355|NCT01950351|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
295356|NCT01950351|Other|Quality-of-Life Assessment|Ancillary studies
295357|NCT01950338|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
295358|NCT01950325|Biological|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
295359|NCT01950312|Drug|gevokizumab|
295360|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
295361|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
295362|NCT01950299|Drug|Placebo|Placebo 0.67 ml injections twice daily
295363|NCT01950273|Drug|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
295364|NCT01950273|Drug|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
295365|NCT01950260|Drug|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
295366|NCT01950260|Other|Placebo|Placebo to start at 4 weeks after RAI
295367|NCT01950247|Drug|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
295368|NCT01950247|Drug|SOC|
295369|NCT01950234|Drug|ACTH|Acthar gel
295370|NCT01950234|Drug|Placebo|Placebo
295371|NCT01950221|Dietary Supplement|POMx|"POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract."
295372|NCT01950221|Other|Placebo|
295373|NCT01950195|Procedure|Stereotactic Radiosurgery (SRS)|
295374|NCT01950195|Biological|Ipilimumab|
295375|NCT01950182|Drug|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
295376|NCT01950182|Drug|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
295377|NCT01950169|Drug|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
295378|NCT01950169|Other|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
295379|NCT01950169|Dietary Supplement|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
295380|NCT01950156|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
295381|NCT01950143|Dietary Supplement|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
295382|NCT01950143|Dietary Supplement|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
295383|NCT01950143|Dietary Supplement|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
295384|NCT01950130|Procedure|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
295385|NCT01950117|Procedure|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
295386|NCT01950117|Procedure|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
295387|NCT01950104|Other|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
295388|NCT01950104|Other|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
295389|NCT01950091|Behavioral|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
295390|NCT01950091|Other|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
295391|NCT01950065|Device|iovera|
295392|NCT01950052|Dietary Supplement|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
295393|NCT01950039|Drug|Betaine|Betaine or placebo administered orally in divided doses over 3 months.
295394|NCT01950039|Drug|Placebo|Placebo administered orally in divided doses over 3 months
295395|NCT01950026|Procedure|cryotherapy application|"Height, weight and BMI verification~subjects in supine position after 20 minutes of resting~cryotherapy application by cold thermal bag (thermoGel brand) size P~15-20 cm above the ASIS~temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil"
295396|NCT01950013|Behavioral|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
295397|NCT01950013|Behavioral|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
295398|NCT01950000|Drug|Fentanyl|
295399|NCT01950000|Other|Placebo|
295400|NCT01949987|Other|two hours|
295401|NCT01949987|Other|one hour|
295402|NCT01949974|Drug|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
295403|NCT01949974|Other|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
295404|NCT01949961|Other|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for ~30 minutes, using a Bracco infusion pump.
295405|NCT01949961|Other|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
295406|NCT01949948|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
295407|NCT01949948|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
295408|NCT01949935|Drug|Mupirocin|
295409|NCT01949922|Procedure|Injection of autologous muscle fibers into the anal sphincter.|
295410|NCT01949922|Procedure|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
295411|NCT01949922|Behavioral|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
295412|NCT01949922|Drug|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
295413|NCT01949909|Biological|CH-Alum50|intramuscular administration to Swiss volunteers of Alhydrogel and P27A antigen (50 microg)
295414|NCT01949909|Biological|CH-GLA2.5/50|intramuscular administration to Swiss volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
295415|NCT01949909|Biological|TZ Ver|intramuscular administration of Rabies vaccine Verorub TM to in Phase IIb only to 8 Tanzanian volunteers in three injections
295416|NCT01949909|Biological|TZ Alum 50|intramuscular administration to Tanzanian volunteers of Alhydrogel and P27A antigen (50 microg)
295417|NCT01949909|Biological|TZ GLA 2.5/10|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5 microg ) together with the P27A antigen (10 microg)
295418|NCT01949909|Biological|TZ GLA5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (5 microg) together with the P27A antigen (50 microg)
295419|NCT01949909|Biological|TZ GLA2.5/50|intramuscular administration to Tanzanian volunteers of GLA-SE (2.5microg) together with the P27A antigen (50 microg)
295420|NCT01949896|Other|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
295421|NCT01949896|Other|Control group: continue feedings|Feedings will be continued in this group.
295422|NCT01949883|Drug|CPI-0610|
295423|NCT01949870|Drug|Cisplatin|day1 and day8 at each cycle
295424|NCT01949870|Drug|Gemcitabine|day1 and day8 at each cycle
295425|NCT01949870|Drug|Selumetinib|25mg/day, 50mg/day and 75mg/day
295566|NCT01948817|Drug|Deferasirox|Deferasirox 20mg/kg taken BID
295426|NCT01949857|Biological|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
295427|NCT01949857|Biological|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
295428|NCT01949857|Biological|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
295429|NCT01949857|Biological|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose.
295430|NCT01949844|Drug|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
295431|NCT01949844|Drug|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
295432|NCT01949844|Device|Myocardial perfusion MRI|
295433|NCT01949831|Other|Assessment of functional ability in combination with follow-up at home|
295434|NCT01949818|Drug|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
295435|NCT01949818|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
295436|NCT01949805|Drug|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
295437|NCT01949805|Drug|Hydroxyurea|Hydroyurea capsules taken daily po
295438|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
295439|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
295440|NCT01949779|Device|TransForm™ Occlusion Balloon Catheter|TransForm™ Occlusion Balloon Catheter
295441|NCT01949766|Drug|Glycerol phenylbutyrate|
295442|NCT01949753|Behavioral|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
295443|NCT01949753|Behavioral|Exposure therapy|Exposure with response prevention without pharmacological facilitation
295444|NCT01949740|Other|questionnaire administration|Ancillary studies
295445|NCT01949740|Procedure|quality-of-life assessment|Ancillary studies
295446|NCT01949727|Other|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
295447|NCT01949714|Procedure|Removal of adrenal tumor|
295448|NCT01949701|Biological|HLA-A*0201restricted URLC10 peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*0201restricted URLC10 peptides with adjuvant.
295449|NCT01949688|Biological|HLA-A*2402 or A*0201 restricted peptides|"Open Label, Non-Randomized, Safety/Efficacy study:~HLA-A*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.~HLA-A*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant."
295450|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
295451|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
295452|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
295453|NCT01949662|Drug|Lorazepam|3 mg by vein one time only.
295454|NCT01949662|Drug|Placebo|Placebo consisting of preservative free 0.9% normal saline given one time by vein.
295455|NCT01949662|Drug|Haloperidol decanoate|8 mg/day by vein.
295456|NCT01949662|Behavioral|Questionnaires|Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
295457|NCT01949649|Behavioral|Peer-Led Group Intervention|
295458|NCT01949649|Behavioral|Internet-Based Intervention|
295459|NCT01949649|Behavioral|Clinician-Led Group Intervention|
295460|NCT01949649|Behavioral|Education Video|
295461|NCT01949636|Other|Functional Magnetic Resonance Imaging|
295462|NCT01949623|Other|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
295463|NCT01949610|Drug|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
295464|NCT01949597|Procedure|laparoscopic surgery for deep endometriosis|
295465|NCT01949584|Device|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
295466|NCT01949571|Drug|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
295467|NCT01949558|Behavioral|Dietary Intervention|
295468|NCT01949545|Drug|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
295469|NCT01949532|Drug|Carfilzomib|Carfilzomib was administered by IV injection.
295567|NCT01948804|Drug|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
296190|NCT01943552|Drug|placebo|normal saline
295470|NCT01949519|Drug|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
295471|NCT01949506|Radiation|SBRT|Stereotactic Body Radiation Therapy
295472|NCT01949493|Device|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
295473|NCT01949493|Other|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
295474|NCT01949480|Procedure|Thoracotomy|
295475|NCT01949480|Procedure|Video-Assisted Thoracoscopic Surgery (VATS)|
295476|NCT01949467|Drug|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
295477|NCT01949454|Drug|Fluorometholone 0.1% ophthalmic solution|
295478|NCT01949454|Other|Artificial tears (Placebo)|Artificial tears (Placebo)
295479|NCT01949441|Biological|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
295480|NCT01949441|Biological|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
295481|NCT01949402|Other|Computed Tomography|"The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.~Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit."
295482|NCT01949402|Other|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
295483|NCT01949402|Other|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
295484|NCT01949402|Other|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
295485|NCT01949389|Behavioral|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
295486|NCT01949363|Drug|Cefixime|Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
295487|NCT01949350|Dietary Supplement|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
295488|NCT01949350|Dietary Supplement|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
295489|NCT01949350|Dietary Supplement|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
295490|NCT01949337|Drug|enzalutamide|Enzalutamide 160 mg daily, orally
295491|NCT01949337|Drug|abiraterone|abiraterone 1000 mg daily, orally
295492|NCT01949337|Drug|prednisone|prednisone 5 mg twice daily, orally
295493|NCT01949324|Biological|Ciliary neurotrophic factor (CNTF)|Ciliary neurotrophic factor released from NT-501 encapsulated cell implant
295494|NCT01949324|Procedure|Sham procedure|Sham surgery for Sham arm
295495|NCT01949324|Device|NT-501 Implant|NT-501 encapsulated cell implant
295496|NCT01949324|Procedure|NT-501 Implant procedure|Surgery to implant device for NT-501 encapsulated cell implant releasing human ciliary neurotrophic factor arm
295497|NCT01949311|Drug|Dupilumab|
295498|NCT01949298|Procedure|dental implant placement|
295499|NCT01949285|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
295500|NCT01949272|Device|esophageal pressure mesurement|"EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement"
295501|NCT01949233|Drug|Irbesartan 150-300mg capsules daily for 6 months|
295502|NCT01949233|Drug|Doxycycline 100-200mg capsules daily for 6 months|
295503|NCT01949233|Drug|Doxycycline placebo capsules daily for 6 months|
295504|NCT01949233|Drug|Irbesartan placebo capsules daily for 6 months|
295505|NCT01949207|Procedure|EVLA|Endovenous laser ablation of great saphenous vein
295506|NCT01949207|Procedure|phlebectomies|removal of incompetent veins
295507|NCT01949207|Procedure|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
295508|NCT01949194|Drug|Regorafenib|"The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories."
295509|NCT01949181|Procedure|Lung surgery|
295510|NCT01949168|Drug|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
295511|NCT01949168|Drug|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
295512|NCT01949168|Drug|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
295513|NCT01949155|Drug|OTO-201|Single, intratympanic injection
295514|NCT01949155|Drug|Sham|Simulated single, intratympanic injection
295515|NCT01949142|Drug|OTO-201|Single, intratympanic injection
295516|NCT01949142|Drug|Sham|Simulated single, intratympanic injection
295517|NCT01949129|Drug|VP16|60 mg/kg BW,1 day
295518|NCT01949129|Radiation|TBI|2 x 2Gy/day , 3 days (total 12Gy)
295519|NCT01949129|Drug|Thiotepa|2x5 mg/kg BW, 1 day
295520|NCT01949129|Drug|Treosulfan|14g/m² BS, 3 days
295521|NCT01949129|Drug|Fludarabine|30 mg/m² BS, 5 days
295522|NCT01949129|Drug|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
295523|NCT01949129|Drug|ATG Thymoglobulin|MD: ATG Thymo: 2,5mg/kg BW/d 3 days.
295524|NCT01949129|Drug|Cyclophosphamide|50mg/kg BW/d 2 days with Mesna
295525|NCT01949129|Drug|Grafalon|MD: 15mg/kg BW/d 3 days MMD: 10mg/kg BW/d 3 days
295526|NCT01949116|Drug|LDMTX|"LDMTX 5 mg: one 5-mg capsule by mouth once weekly~LDMTX 10 mg: two 5-mg capsules by mouth once weekly~LDMTX 15 mg: three 5-mg capsules by mouth once weekly"
295527|NCT01949116|Drug|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly~Placebo 10 mg: two 5-mg capsules by mouth once weekly~Placebo 15 mg: three 5-mg capsules by mouth once weekly"
295528|NCT01949116|Dietary Supplement|Folic acid|1-mg tablet of folic acid by mouth once a day
295529|NCT01949103|Drug|TD-1607|
295530|NCT01949103|Drug|Placebo|
295531|NCT01949090|Biological|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
295532|NCT01949090|Biological|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
295533|NCT01949064|Device|Grindcare|
295534|NCT01949064|Device|Michigan-type occlusal splint|
295535|NCT01949051|Drug|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
295536|NCT01949051|Drug|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
295537|NCT01949038|Drug|Oral alprazolam|
295538|NCT01949038|Drug|Sublingual alprazolam|
295539|NCT01949038|Drug|Oral placebo|
295540|NCT01949038|Drug|Sublingual placebo|
295541|NCT01949025|Other|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
295542|NCT01949012|Other|Capnography|Capnography waveform and capnometry readings
295543|NCT01948999|Procedure|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
295544|NCT01948999|Procedure|SHAM ECT|Anesthesia and concomitant muscular paralysis
295545|NCT01948999|Drug|Anesthesia|Temporary induced state of analgesia
295546|NCT01948986|Drug|Ertugliflozin|Single oral administration of 3 X 5 mg tablets.
295547|NCT01948973|Device|Subsensory|The stimulation is here set to 90% of the sensory threshold
295548|NCT01948973|Device|OFF|The stimulation is here turned OFF
295549|NCT01948973|Drug|Suprasensory|The stimulation is here set suprasensory
295550|NCT01948960|Drug|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
295551|NCT01948947|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
295552|NCT01948947|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
295553|NCT01948934|Procedure|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
295554|NCT01948921|Drug|placebo|
295555|NCT01948921|Drug|Meperidine|
295556|NCT01948908|Drug|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
295557|NCT01948895|Drug|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
295558|NCT01948882|Device|ESS505 (BAY1454033)|
295559|NCT01948869|Device|Phoenix II (BAY81-2996)|
295560|NCT01948869|Device|Phoenix I (BAY81-2996)|
295561|NCT01948856|Drug|J022X ST|"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~First month: 4 consecutive days per week during 3 consecutive weeks~5 next months: 4 consecutive days per month at monthly intervals"
295562|NCT01948856|Drug|Placebo|"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~First month: 4 consecutive days per week during 3 consecutive weeks~5 next months: 4 consecutive days per month at monthly intervals"
295563|NCT01948843|Drug|ADI-PEG 20|
295564|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
295565|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
295568|NCT01948804|Drug|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
295569|NCT01948804|Drug|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
295570|NCT01948804|Drug|GnRH antagonist protocol (Cetrotide, Serono)|
295571|NCT01948791|Drug|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
295572|NCT01948778|Device|oXiris™ filter|
295573|NCT01948778|Device|Toraymyxin Filter|
295574|NCT01948778|Device|Standard of Care|
295575|NCT01948765|Drug|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
295576|NCT01948765|Drug|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
295577|NCT01948752|Other|Nutrition information on menus|
295578|NCT01948739|Device|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
295579|NCT01948726|Radiation|Hypofractionation with simultaneous integrated boost|
295580|NCT01948713|Other|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
295581|NCT01948713|Other|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
295582|NCT01948700|Behavioral|Motivational Interviewing|
295583|NCT01948700|Other|Education|
295584|NCT01948674|Behavioral|Computerized tasks|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
295585|NCT01948661|Dietary Supplement|Mirtoselect® + Meriva®|
295586|NCT01948661|Dietary Supplement|Placebo|
295587|NCT01948648|Drug|Colesevelam|Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
295588|NCT01948648|Dietary Supplement|Fish Oil|In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
295589|NCT01948648|Drug|Combination of fish oil and colesevelam|combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
295590|NCT01948635|Device|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
295591|NCT01948635|Device|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
295592|NCT01948622|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
295593|NCT01948622|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
295594|NCT01948596|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
295595|NCT01948583|Drug|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
295596|NCT01948557|Behavioral|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.~Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
295597|NCT01948531|Drug|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
295598|NCT01948518|Drug|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
295599|NCT01948505|Drug|Intravenous acetaminophen|
295600|NCT01948505|Drug|Placebo for IV acetaminophen|
295601|NCT01948492|Dietary Supplement|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
295602|NCT01948479|Device|Optimised instant offloading insole|
295603|NCT01948466|Behavioral|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
295604|NCT01948453|Dietary Supplement|Garlic|Garlic tablet in adjunct to medical treatment
295605|NCT01948440|Behavioral|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
295606|NCT01948414|Procedure|electroencephalography|
295607|NCT01948414|Biological|Blood sampling|
295608|NCT01948414|Behavioral|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
295609|NCT01948401|Drug|LABA|long-acting beta-agonist treatment
295610|NCT01948401|Drug|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
295611|NCT01948401|Drug|prednisolone|additional 0.5 mg/kg orally for 7 days
295612|NCT01948388|Drug|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
295613|NCT01948375|Device|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
295614|NCT01948375|Device|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
295615|NCT01948362|Drug|Sulforadex|Active compound
295616|NCT01948362|Drug|Alpha cyclodextrin|Placebo control
295617|NCT01948349|Other|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
295618|NCT01948349|Other|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
295619|NCT01948336|Drug|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
295620|NCT01948336|Drug|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
295621|NCT01948336|Drug|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
295622|NCT01948323|Behavioral|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
295623|NCT01948310|Drug|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
295624|NCT01948310|Behavioral|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
295625|NCT01948310|Drug|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
295626|NCT01948297|Drug|Debio1347 (CH5183284)|Debio1347 (CH5183284) tablets for oral administration
295627|NCT01948284|Procedure|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
295628|NCT01948284|Procedure|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
295629|NCT01948284|Device|Suction Unit|
295630|NCT01948271|Drug|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
295631|NCT01948258|Device|Clearblue Advanced Fertility Monitor|Clearblue Advanced Fertility Monitor used for one menstrual cycle in a home setting
295632|NCT01948245|Device|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
295633|NCT01948245|Device|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
295634|NCT01948232|Drug|Perindopril|Angiotensin converting enzyme inhibitor
295635|NCT01948219|Device|ENTegral Artificial Larynx implant|
295636|NCT01948193|Biological|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
295637|NCT01948180|Biological|baltaleucel-T|Autologous EBV-specific T-cells
295638|NCT01948167|Behavioral|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
295639|NCT01948167|Behavioral|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
295640|NCT01948141|Drug|nintedanib|Given PO
295641|NCT01948128|Drug|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
295642|NCT01948128|Other|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
295742|NCT01947257|Other|the direct measure of the pulmonary pressures|by right catheterization
296115|NCT01944215|Other|External Heating|Heating Pad and warm blanket robe
295643|NCT01948115|Drug|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).~Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
295644|NCT01948089|Behavioral|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
295645|NCT01948089|Behavioral|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
295646|NCT01948076|Device|resident with GE vscan|resident with GE vscan
295647|NCT01948063|Drug|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
295648|NCT01948063|Dietary Supplement|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
295649|NCT01948050|Device|non-invasive transcranial direct current stimulation (tDCS)|
295650|NCT01948037|Other|hydrotherapy|30-minutes/per day,for 4weeks
295651|NCT01948037|Other|hydrotherapy|30-minutes/per day;4weeks
295652|NCT01948024|Drug|SAPHRIS|10 mg BID sublingual tablet
295653|NCT01948024|Drug|Asenapine|10 mg BID sublingual tablet
295654|NCT01948011|Drug|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
295655|NCT01948011|Drug|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
295656|NCT01947998|Drug|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
295657|NCT01947998|Drug|Warfarin|For VTE prevention, DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, warfarin.
295658|NCT01947998|Drug|Antiplatelet drugs|For the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor
295659|NCT01947985|Drug|Rivaroxoban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
295660|NCT01947985|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
295661|NCT01947972|Dietary Supplement|Tailored protein fortification|4-4.5g of protein/kg/d
295662|NCT01947959|Drug|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).~The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).~The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).~Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
295663|NCT01947959|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
296189|NCT01943565|Drug|spinal anesthesia|bupivacaine 0.75% 1.6 mL (12mg)
295664|NCT01947946|Biological|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
295665|NCT01947946|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
295666|NCT01947933|Biological|Mirikizumab- IV|Administered IV
295667|NCT01947933|Biological|Mirikizumab - SC|Administered SC
295668|NCT01947933|Biological|Placebo - IV|Administered IV
295669|NCT01947920|Drug|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
295670|NCT01947920|Drug|Placebo|Size-matching capsules containing an appropriate inactive excipient
295671|NCT01947907|Drug|ACP-001|Once weekly subcutaneous injection
295672|NCT01947907|Drug|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
295673|NCT01947894|Other|Non Interventional Study|Non Interventional Study
295674|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
295675|NCT01947855|Drug|Empagliflozin|Empagliflozin low dose
295676|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
295677|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
295678|NCT01947855|Drug|Empagliflozin|Empagliflozin high dose tablet once daily
295679|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
295680|NCT01947842|Device|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
295681|NCT01947803|Drug|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
295682|NCT01947790|Drug|pioglitazone group|
295683|NCT01947790|Drug|Metformin group|
295684|NCT01947777|Drug|IPI-145|25 mg oral capsule
295685|NCT01947777|Drug|Rifampin|2x 300 mg oral capsule
295686|NCT01947764|Behavioral|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.~In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:~Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.~Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.~Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
295687|NCT01947751|Procedure|CVC exchange|CVC exchange when related infection is suspected
295688|NCT01947751|Drug|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
295689|NCT01947738|Drug|VBY-891|Cathepsin S inhibitor
295690|NCT01947738|Drug|Placebo|
295691|NCT01947712|Dietary Supplement|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
295692|NCT01947712|Dietary Supplement|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
295693|NCT01947699|Drug|Glyburide|
295694|NCT01947699|Device|Continuous glucose monitor|
295695|NCT01947686|Device|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
295696|NCT01947673|Other|Mindfulness Meditation|
295697|NCT01947673|Other|Health Education|
295698|NCT01947660|Drug|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
295699|NCT01947660|Drug|Systemic analgesia|Systemic analgesia as usual
295700|NCT01947647|Behavioral|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
295701|NCT01947647|Behavioral|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
295702|NCT01947634|Other|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
295703|NCT01947608|Drug|LDK378|750 mg. orally
295739|NCT01947270|Other|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:~Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.~Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
295704|NCT01947595|Behavioral|intensified lifestyle intervention|"physical activity 6 hours per week, 50% guided activity~recorded by an accelerometer (Aipermotion 440)~16 sessions per year with a lifestyle advisor~nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
295705|NCT01947595|Behavioral|normal lifestyle intervention|"physical activity 3 hours per week~recorded by an accelerometer (Aipermotion 440)~8 sessions per year with a lifestyle advisor~nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
295706|NCT01947595|Behavioral|Single lifestyle advice|"- Single Health care advice and lifestyle advice (30 minutes) at the beginning~recommend the individual target weight (5% less, if BMI 25> kg/m²)"
295707|NCT01947582|Device|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
295708|NCT01947569|Biological|Biological|
295709|NCT01947556|Drug|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
295710|NCT01947530|Procedure|Navigational Bronchoscopy|
295711|NCT01947530|Procedure|Standard Bronchoscopy|
295712|NCT01947517|Device|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
295713|NCT01947517|Device|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
295714|NCT01947504|Behavioral|eudcation and support intervention|
295715|NCT01947491|Drug|DFD01 Spray|
295716|NCT01947491|Drug|Comp01 Lotion|
295717|NCT01947491|Drug|Vehicle Lotion|
295718|NCT01947491|Drug|Vehicle Spray|
295719|NCT01947478|Device|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
295720|NCT01947478|Device|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
295721|NCT01947465|Biological|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
295722|NCT01947452|Behavioral|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
295723|NCT01947452|Behavioral|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
295724|NCT01947439|Procedure|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
295725|NCT01947426|Dietary Supplement|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
295726|NCT01947426|Dietary Supplement|Control (milk without DHA)|mothers consuming placebo product and their neonates
295727|NCT01947413|Other|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
295728|NCT01947413|Other|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
295729|NCT01947413|Other|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
295730|NCT01947400|Other|Hospitalists|AIDET Training
295731|NCT01947374|Procedure|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
295732|NCT01947374|Procedure|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
295733|NCT01947348|Procedure|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
295734|NCT01947335|Device|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
295735|NCT01947322|Drug|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
295736|NCT01947309|Drug|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
295737|NCT01947283|Behavioral|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
295738|NCT01947283|Behavioral|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
295740|NCT01947257|Other|the measure TRVMAX|by transthoracic echocardiography
295741|NCT01947257|Other|the measure of the pulmonary artery|by transesophageal ultrasound
295743|NCT01947244|Behavioral|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
295744|NCT01947244|Behavioral|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
295745|NCT01947231|Other|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
295746|NCT01947231|Other|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
295747|NCT01947218|Procedure|bronchial biopsies|
295748|NCT01947218|Other|Determination of CO in exhaled air|
295749|NCT01947205|Drug|paracetamol|
295750|NCT01947205|Drug|dexketoprofen trometamol|
295751|NCT01947205|Drug|suction curettage|
295752|NCT01947205|Drug|suction curettage|
295753|NCT01947205|Other|without drug|
295754|NCT01947192|Procedure|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
295755|NCT01947192|Procedure|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
295756|NCT01947179|Behavioral|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
295757|NCT01947166|Dietary Supplement|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
295758|NCT01947153|Drug|Metformin|Free combination
295759|NCT01947153|Drug|Linagliptin|Fixed dose combination
295760|NCT01947153|Drug|Metformin|Combination
295761|NCT01947153|Drug|Linagliptin|Free combination
295762|NCT01947140|Drug|Pralatrexate|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
295763|NCT01947140|Drug|Romidepsin|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
295764|NCT01947114|Drug|Propofol|
295765|NCT01947114|Drug|Ketamine|
295766|NCT01947114|Drug|Remifentanil|
295767|NCT01947101|Biological|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
295768|NCT01947088|Behavioral|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
295769|NCT01947062|Drug|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
295770|NCT01947062|Drug|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
295771|NCT01947049|Other|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
295772|NCT01947023|Drug|Dabrafenib|Given PO
295773|NCT01947023|Drug|Dabrafenib Mesylate|Given PO
295774|NCT01947023|Drug|Lapatinib|Given PO
295775|NCT01947023|Drug|Lapatinib Ditosylate|Given PO
295776|NCT01947010|Biological|Prevenar 13|
295777|NCT01947010|Biological|Pneumovax|
295778|NCT01946997|Other|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
295779|NCT01946984|Procedure|ERCP|endoscopy, retrograde cholangio-pancreaticography.
295780|NCT01946984|Drug|Diclofenac hydroxyethylpyrrolidine|
295781|NCT01946984|Drug|Normal Saline|
295782|NCT01946971|Drug|Lansoprazole|
295783|NCT01946971|Drug|Placebo|
295784|NCT01946958|Behavioral|Training in PC Triple P|PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
295785|NCT01946958|Other|Care As Usual|Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
295786|NCT01946945|Genetic|Next Generation Sequencing after Blastocyst biopsy|PGD using blastocyst biopsy and testing of the biopsy by NGS
295787|NCT01946932|Other|Temperature treatment|
295788|NCT01946906|Drug|Rifaximin|
295789|NCT01946893|Behavioral|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
295790|NCT01946893|Behavioral|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
295791|NCT01946880|Drug|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
295792|NCT01946880|Drug|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
295793|NCT01946880|Drug|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
295794|NCT01946867|Device|NBTXR3|
295795|NCT01946854|Behavioral|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.~Completion of 3 quality of life questionnaires every 3 months for 1 year."
295796|NCT01946841|Dietary Supplement|RealDiet®Renal|
295797|NCT01946828|Device|FIM|Field Induced Mydriasis device
295798|NCT01946815|Drug|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
295799|NCT01946802|Device|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
295800|NCT01946789|Biological|ALT-803|Intravenous infusion for dose level 1-5; subcutaneous injection for dose level 5a-8; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
295801|NCT01946776|Device|implantable heart rate monitor|Implantation of Reveal XT
295802|NCT01946763|Behavioral|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
295803|NCT01946763|Behavioral|pre operative education|
295804|NCT01946750|Biological|Serum|
295805|NCT01946750|Biological|Stools|
295806|NCT01946750|Biological|Saliva|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
295807|NCT01946750|Biological|Whole blood|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
295808|NCT01946737|Radiation|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
295809|NCT01946737|Radiation|Active Comparator: Invasive coronary angiography (ICA)|
295810|NCT01946711|Drug|Budesonide|Inhalation
295811|NCT01946711|Drug|Budesonide|Nasal spray
295812|NCT01946672|Procedure|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
295813|NCT01946659|Behavioral|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
295814|NCT01946659|Other|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
295815|NCT01946646|Drug|S-1-CCRT|
295816|NCT01946633|Device|magnetic-controlled capsule endoscopy(Navicam)|
295817|NCT01946620|Drug|Flutiform|
295818|NCT01946620|Drug|Formoterol|
295819|NCT01946607|Drug|Citalopram|
295820|NCT01946607|Drug|Placebo|
295821|NCT01946594|Other|Acetaminophen|
295822|NCT01946594|Other|Placebo|
295823|NCT01946581|Procedure|Cataract Surgery|
295824|NCT01946568|Drug|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients <5 years of age.
295825|NCT01946555|Drug|Morphine|
295826|NCT01946555|Drug|Fentanyl|
295827|NCT01946555|Drug|Methadone|
295828|NCT01946555|Drug|Buprenorphine|
295829|NCT01946555|Drug|Oxycodone|
295830|NCT01946555|Drug|Hydromorphone|
295831|NCT01946555|Drug|Tapentadol|
295832|NCT01946542|Drug|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
295833|NCT01946542|Other|placebo|
295834|NCT01946529|Drug|vincristine|Dosage and route of administration: Infants < 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m^2 IV day 1 (max. dose 2 mg).
295835|NCT01946529|Drug|doxorubicin|Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2.
295836|NCT01946529|Drug|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
295837|NCT01946529|Drug|ifosfamide|Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5.
295838|NCT01946529|Drug|etoposide|Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5.
295839|NCT01946529|Drug|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m^2 PO once daily, days 1-5.
295840|NCT01946529|Drug|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m^2 IV once day 1 and day 8.
295841|NCT01946529|Drug|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
295842|NCT01946529|Drug|sorafenib|Dosage and route of administration: 90 mg/m^2/dose PO BID
295843|NCT01946529|Procedure|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
295844|NCT01946529|Radiation|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
295845|NCT01946477|Drug|Pomalidomide|
295846|NCT01946477|Drug|Dexamethasone|
295847|NCT01946477|Drug|Daratumumab|
295848|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
295849|NCT01946438|Biological|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
295850|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
295851|NCT01946438|Biological|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
295852|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
295853|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
295854|NCT01946412|Drug|Ivacaftor|
295855|NCT01946399|Drug|Ozurdex implant|Intravitreal injection of Dexamethasone implant
295856|NCT01946386|Drug|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
295857|NCT01946386|Drug|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
295858|NCT01946386|Drug|LEO 90100 Aerosol, foam, vehicle|
295859|NCT01946386|Drug|Daivobet® ointment|
295860|NCT01946386|Drug|Dermovate® cream|
295861|NCT01946386|Drug|Synalar® ointment|
295862|NCT01946373|Drug|Cyclophosphamide|
295863|NCT01946373|Drug|Fludarabine|
295864|NCT01946373|Biological|T cells|
295865|NCT01946373|Biological|Interleukin-2|
295866|NCT01946373|Biological|Dendritic cell vaccine|
295867|NCT01946360|Device|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
295868|NCT01946347|Other|mixed meal|"Baguette Cheese Gourmet (Crocodile:~180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g."
295869|NCT01946347|Other|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
295870|NCT01946334|Device|anorectal manometry and high-resolution three-dimensional|
295871|NCT01946321|Other|Post-amputation functional rehabilitation (normal clinical practice)|
295872|NCT01946308|Other|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
295873|NCT01946295|Drug|Famotidine|100mg x 2 p.o.
295874|NCT01946295|Drug|Placebo|
295875|NCT01946282|Other|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
295876|NCT01946282|Other|FIT plus Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
295877|NCT01946269|Other|Goal-directed Resuscitation Therapy (GDT)|"A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.~The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.~When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~The final step will be red blood transfusion to reach a hematocrit higher than 28%.~If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
295878|NCT01946269|Other|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
295879|NCT01946256|Drug|Amoxicillin|
295880|NCT01946256|Drug|Erythromycin|
295881|NCT01946243|Drug|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
295882|NCT01946217|Other|questionnaire administration|Ancillary studies
295883|NCT01946204|Drug|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
295884|NCT01946204|Drug|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
295885|NCT01946191|Behavioral|Health coach electronic communication and support|Health coach reviews responses to weight-related surveys and provides feedback and advice
295886|NCT01946191|Behavioral|Online self-monitoring|Tracking weight, calories, fat grams, and physical activity in electronic personal health record
295887|NCT01946191|Behavioral|Real-time updates to Primary Care physicians|Primary care physicians will receive updates through electronic health record system before each scheduled appointment
295888|NCT01946178|Device|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
295889|NCT01946165|Drug|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
295890|NCT01946165|Drug|Prednisone|5 mg by mouth once daily for each 28 day cycle.
295891|NCT01946165|Drug|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
295892|NCT01946165|Drug|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
295893|NCT01946152|Drug|Dexamethasone|Given PO
295894|NCT01946152|Biological|Filgrastim-sndz|Given SC
295895|NCT01946152|Other|Laboratory Biomarker Analysis|Correlative studies
295896|NCT01946152|Drug|Pomalidomide|Given PO
295897|NCT01946139|Procedure|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
295898|NCT01946139|Other|laboratory biomarker analysis|Correlative studies
295899|NCT01946139|Other|questionnaire administration|Ancillary studies
295900|NCT01946139|Procedure|quality-of-life assessment|Ancillary studies
295901|NCT01946126|Other|No Intervention|There is no intervention in this study.
295902|NCT01946100|Genetic|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
295903|NCT01946087|Procedure|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) & 5 min reperfusion (deflation)
295904|NCT01946087|Procedure|Control group|keeping the cuff deflated
295905|NCT01946074|Drug|paclitaxel|Paclitaxel will be administered by intravenous infusion.
295906|NCT01946074|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion.
295907|NCT01946074|Drug|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels.
295908|NCT01946074|Drug|ABBV-181|ABBV-181 will be administered by intravenous infusion.
295909|NCT01946061|Drug|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
295910|NCT01946048|Biological|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.~Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
295911|NCT01946035|Drug|Doxazosin XL|
295912|NCT01946035|Other|Placebo|
295913|NCT01946022|Drug|randomization between the two GnRH analogues (agonist and antagonist)|
295914|NCT01946009|Drug|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
295915|NCT01945996|Behavioral|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
295916|NCT01945996|Behavioral|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
295917|NCT01945983|Drug|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
295918|NCT01945983|Drug|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
295919|NCT01945970|Other|Black tea extract|Black tea extract
295920|NCT01945970|Other|Positive control|Positive control
295921|NCT01945970|Other|Placebo|Placebo
295922|NCT01945957|Drug|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)~For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
295923|NCT01945944|Drug|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
295924|NCT01945944|Drug|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
295925|NCT01945931|Other|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
295926|NCT01945918|Behavioral|Self-management support education|Same as Arm Description
295927|NCT01945918|Behavioral|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
295928|NCT01945918|Behavioral|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
295929|NCT01945905|Other|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
295930|NCT01945905|Other|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
295931|NCT01945892|Drug|Ozurdex|"- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
295932|NCT01945879|Drug|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
295933|NCT01945866|Drug|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
295934|NCT01945866|Drug|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
295935|NCT01945866|Procedure|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
295936|NCT01945853|Device|7 Tesla MRI|
295937|NCT01945840|Procedure|Roux en Y Gastric Bypass Surgery|
295938|NCT01945840|Other|Gut hormone infusion (high dose)|
295939|NCT01945840|Other|Gut hormone infusion (low dose)|
295940|NCT01945840|Other|Placebo infusion|
295941|NCT01945840|Other|Very low calorie diet|
295942|NCT01945827|Device|DeltaMaxx Microcoil System|
295943|NCT01945814|Drug|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
295944|NCT01945814|Drug|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
295945|NCT01945801|Drug|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
295946|NCT01945801|Other|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
295947|NCT01945801|Drug|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
295948|NCT01945788|Drug|Teriparatide (rDNA origin)|
295949|NCT01945775|Drug|talazoparib|Until progression or unacceptable toxicity develops
295950|NCT01945775|Drug|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
295951|NCT01945762|Drug|Vandetanib 300 mg|Vandetanib commercial tablets
295952|NCT01945749|Drug|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
295953|NCT01945749|Drug|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
295954|NCT01945749|Other|Exercise therapy|"The exercise is commenced 2 weeks after injection.~The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.~In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities."
295955|NCT01945736|Drug|Methadone|To determine the PK of enteral methadone in children > or = 90 days and <18 years treated for opiate withdrawal per routine medical care.
295956|NCT01945710|Drug|Eribulin-LF|
295957|NCT01945684|Drug|Botulinum toxin type A|Maximum dose 360 U
295958|NCT01945645|Behavioral|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
295959|NCT01945632|Device|conventional gracey curettes|
295960|NCT01945632|Device|Vertically oscillating ultrasonic device|
295961|NCT01945632|Device|piezoelectric ultrasonic scraper|
295962|NCT01945619|Biological|Trivirus-Specific CTLs|Patients will receive up to 2 x 10^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
295963|NCT01945606|Drug|Placebo (treatment 1)|Oral administration of placebo tablets
295964|NCT01945606|Drug|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
295965|NCT01945593|Biological|BAX855|Antihemophilic Factor (Recombinant), PEGylated
295966|NCT01945580|Procedure|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
295967|NCT01945567|Device|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
295968|NCT01945567|Device|Empirical unblinded deep brain stimulation programming|
295969|NCT01945554|Procedure|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
295970|NCT01945554|Procedure|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
295971|NCT01945554|Drug|Mephamesone|
295972|NCT01945554|Drug|0.5% bupivacaine (Bupivacain®)|
295973|NCT01945554|Drug|Kenacort®|
295974|NCT01945541|Device|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
296014|NCT01945099|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
296015|NCT01945099|Drug|hyaluronidase|
296016|NCT01945099|Drug|Lispro-PH20|
295975|NCT01945528|Drug|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.~Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
295976|NCT01945528|Drug|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
295977|NCT01945515|Device|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
295978|NCT01945515|Device|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
295979|NCT01945489|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
295980|NCT01945489|Drug|Normal saline|Normal saline (placebo) injected into the detrusor.
295981|NCT01945476|Drug|midazolam premedication|"On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.~Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total."
295982|NCT01945450|Drug|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
295983|NCT01945450|Drug|Ampicillin|
295984|NCT01945450|Drug|Gentamycin|
295985|NCT01945450|Drug|Clindamycin|
295986|NCT01945437|Drug|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
295987|NCT01945424|Biological|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
295988|NCT01945411|Device|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
295989|NCT01945411|Device|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
295990|NCT01945398|Other|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
295991|NCT01945398|Other|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
295992|NCT01945385|Behavioral|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
295993|NCT01945372|Other|EEG NeuroFeedback|
295994|NCT01945346|Drug|PRX167700|Oral capsule
295995|NCT01945346|Drug|Placebo|Oral capsule
295996|NCT01945333|Behavioral|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
295997|NCT01945294|Drug|Boceprevir|800 mg three times daily orally
295998|NCT01945294|Biological|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
295999|NCT01945294|Drug|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
296000|NCT01945281|Drug|Caspofungin|
296001|NCT01945281|Drug|Amphotericin B Deoxycholate|
296002|NCT01945268|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
296003|NCT01945268|Other|Sterile saline|0.5 ml dose injected intramuscularly
296004|NCT01945242|Drug|Alogliptin|Alogliptin tablets
296005|NCT01945216|Drug|Alogliptin|Alogliptin tablets
296006|NCT01945190|Device|Electroacupuncture|
296007|NCT01945177|Device|narrow band imaging|narrow band imaging
296008|NCT01945177|Device|white light endoscopy|white light endoscopy
296009|NCT01945164|Drug|XL999|The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
296010|NCT01945151|Other|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
296011|NCT01945138|Device|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
296012|NCT01945125|Other|rhTSH Group|Patients receiving rhTSH for RIT stimulation
296013|NCT01945112|Device|Paper Tape|Applied to blister prone areas of the foot
296017|NCT01945086|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
296018|NCT01945086|Drug|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
296019|NCT01945086|Other|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
296020|NCT01945073|Behavioral|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
296021|NCT01945073|Other|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
296022|NCT01945060|Device|heart rate Control to Range System (hrCTR) using DiAs Platform|"Diabetes Assistant (DiAs) Medical Platform System~A smart-phone medical platform (DiAs);~Continuous Glucose Monitor;~Insulin pump;~Bluetooth connection;~Remote Monitoring Server."
296023|NCT01945060|Other|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
296024|NCT01945047|Drug|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
296025|NCT01945047|Drug|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
296026|NCT01945034|Drug|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
296027|NCT01945034|Drug|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
296028|NCT01945034|Drug|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
296029|NCT01945034|Drug|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
296030|NCT01945021|Drug|Crizotinib|
296031|NCT01944995|Device|glasses broadband|
296032|NCT01944995|Device|nasal CPAP|
296033|NCT01944982|Biological|Expanded haploidentical natural killer cells (NKAEs)|
296034|NCT01944969|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
296035|NCT01944943|Drug|Vismodegib|150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
296036|NCT01944930|Device|Laparoscopic narrow band imaging|
296037|NCT01944930|Device|Standard white-light laparoscopy|
296038|NCT01944904|Dietary Supplement|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
296039|NCT01944904|Dietary Supplement|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
296040|NCT01944865|Other|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
296041|NCT01944865|Other|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
296042|NCT01944852|Drug|Icodextrin|
296043|NCT01944839|Drug|E10030|
296044|NCT01944839|Drug|ranibizumab|
296045|NCT01944839|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
296046|NCT01944826|Other|Registry of patients with Tako-Tsubo cardiomyopathy|
296047|NCT01944813|Behavioral|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
296048|NCT01944800|Drug|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
296049|NCT01944800|Drug|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/> 75 years or < 60 kg
296050|NCT01944787|Other|Routine|IV Hydration at 125 cc hour
296051|NCT01944787|Other|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
296052|NCT01944774|Drug|Nemonoxacin 500 mg|IV Infusion, once daily for 7~14 days
296053|NCT01944774|Drug|Nemonoxacin 650 mg|IV Infusion, once daily for 7~14 days
296054|NCT01944774|Drug|Moxifloxacin 400 mg|IV Infusion, once daily for 7~14 days
296055|NCT01944761|Behavioral|Exercise Program|Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes. First, training in a circuit of developmentally appropriate activities (30 minutes) will occur. Second, the training circuit will be followed by participation in an organized sport (i.e. 30 minutes of floor hockey, basketball, or indoor soccer). Following the workout sessions the children will receive a healthy snack and have an opportunity for socialization (30 minutes).
296056|NCT01944748|Behavioral|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
296057|NCT01944735|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
296058|NCT01944735|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
296111|NCT01944215|Dietary Supplement|Meal|effect of meal
296112|NCT01944215|Other|Exercise|effect of exercise
296113|NCT01944215|Radiation|Sestamibi|reduce radiation dose
296059|NCT01944722|Device|BD Onclarity™ HPV assay on BD Viper™ LT|The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
296060|NCT01944722|Procedure|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
296061|NCT01944709|Biological|Dendritic cell application|
296062|NCT01944696|Other|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
296063|NCT01944683|Other|Placebo|
296064|NCT01944683|Drug|GGF2|
296065|NCT01944683|Drug|Midazolam|
296066|NCT01944670|Device|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
296067|NCT01944657|Device|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
296068|NCT01944657|Drug|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
296069|NCT01944644|Device|Active Low Field Magnetic Stimulation|Active Low Field Magnetic Stimulation treatments will be delivered with a prototype LFMS device manufactured by Tal Medical. LFMS sessions consist of proton echo-planar magnetic resonance spectroscopic imaging (EP-MRSI) and will be 20min in duration. LFMS exposes subjects to magnetic fields of the same magnitude and frequency used in clinical MR-Spectroscopic imaging of the brain.
296070|NCT01944644|Device|Sham Low Field Magnetic Stimulation|Sham Low Field Magnetic Stimulation will consist of a three-dimensional spoiled gradient echo sequence of the same duration as active LFMS and which provides auditory stimulation indistinguishable from active treatment.
296071|NCT01944631|Device|Placebo|Nasal spray saline
296072|NCT01944631|Device|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
296073|NCT01944618|Drug|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor [DPP 4 inhibitor] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
296074|NCT01944592|Behavioral|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
296075|NCT01944592|Behavioral|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
296076|NCT01944579|Other|Blackberries|Participants will receive blackberries as part of a controlled diet.
296077|NCT01944579|Other|Control|Participants will receive a control food (jello) as part of a controlled diet.
296078|NCT01944566|Biological|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
296079|NCT01944553|Device|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.~Stabilisation in treatment for spine degenerative disease"
296080|NCT01944540|Procedure|Optimized ESD with snaring|
296081|NCT01944540|Procedure|Conventional ESD|
296082|NCT01944501|Procedure|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
296083|NCT01944501|Procedure|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
296084|NCT01944488|Drug|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
296085|NCT01944462|Behavioral|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
296086|NCT01944449|Dietary Supplement|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
296114|NCT01944215|Drug|Caffeine Tablet|effect of caffeine
296087|NCT01944449|Dietary Supplement|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
296088|NCT01944449|Dietary Supplement|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
296089|NCT01944436|Drug|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
296090|NCT01944423|Drug|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
296091|NCT01944423|Drug|Pill Placebo|
296092|NCT01944423|Drug|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
296093|NCT01944423|Behavioral|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
296094|NCT01944410|Biological|PRP injection|injection of PRP to traumatic bone cyst defect
296095|NCT01944384|Drug|aldactone|aldactone 25 mg for 6 months
296096|NCT01944371|Drug|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
296097|NCT01944332|Procedure|gamete treatment|Patient specimen will be selected through a synthetic, sterile, single-use, culture-tested mesh. The specimen will then be placed in a 37°C environment. After 30 minutes, the selected portion is retrieved from the other side of the mesh. The spermatozoa will be prepared in the standard fashion and utilized for injection or intrauterine insemination after exposure to a membrane permeabilizing agent. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO).
296098|NCT01944319|Drug|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
296099|NCT01944319|Drug|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
296100|NCT01944293|Drug|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
296101|NCT01944293|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
296102|NCT01944280|Other|massage|
296103|NCT01944267|Procedure|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared surgical area will be measured apico-coronally and mesio-distally."
296104|NCT01944267|Procedure|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.~Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision made. Gingiva coronal to horizontal incision remains intact.~Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
296105|NCT01944267|Procedure|apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.~Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.~No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.~Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
296106|NCT01944254|Procedure|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
296107|NCT01944254|Procedure|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
296108|NCT01944254|Procedure|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
296109|NCT01944228|Device|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
296110|NCT01944228|Device|Sham Stimulation|Catheter placed in the IJV without stimulation
296116|NCT01944202|Behavioral|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
296117|NCT01944189|Dietary Supplement|Food|"Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (> 5 to >15 kg receive 1 tablet and 15 to > 25 kg receive 2 tablets)~Food arms:~Standard arm = Milk~Experimental arm = maize porridge plus oil~Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)~Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)"
296118|NCT01944176|Drug|simvastatin, placebo|
296119|NCT01944163|Other|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
296120|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
296121|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
296122|NCT01944137|Other|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
296123|NCT01944124|Behavioral|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
296124|NCT01944124|Behavioral|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
296125|NCT01944111|Device|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
296126|NCT01944098|Drug|Lidocaine|
296127|NCT01944098|Drug|Placebo|
296128|NCT01944085|Drug|Acetaminophen|Syrup
296129|NCT01944085|Drug|Ibuprofen|Syrup
296130|NCT01944085|Other|Vitamin C|Syrup
296131|NCT01944072|Other|Aerobic exercise training intensity|
296132|NCT01944059|Drug|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
296133|NCT01944059|Other|Placebo (l-alanine)|Theramine like placebo comparator
296134|NCT01944046|Drug|Placebo Nasal Spray|This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except there will we no oxytocin added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.
296135|NCT01944046|Drug|Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and months 1 and 2 until achieving the target dose of 24 IU BID at Month 2. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking.
296136|NCT01944033|Drug|Bricanyl/Iprovent|5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
296137|NCT01944033|Drug|Bricanyl|5 mg Terbutaline sulfate (2ml) + 3ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
296138|NCT01944020|Device|CPAP|use of CPAP each night for 2 months
296139|NCT01944007|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
296140|NCT01943994|Drug|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
296141|NCT01943994|Drug|Nicotine Replacement Therapy (NRT)|
296142|NCT01943968|Other|Blood test|
296143|NCT01943955|Behavioral|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
296144|NCT01943942|Drug|Montelukast 10 mg|Reference product
296145|NCT01943942|Drug|Montelukast 10 mg|Test product
296146|NCT01943916|Device|Imagio OA/US (US and OA/US)|opto-acoustic plus gray scale ultrasound
296147|NCT01943916|Device|Imagio gray scale ultrasound|gray scale ultrasound alone
296148|NCT01943890|Device|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
296149|NCT01943890|Procedure|Physiotherapy|
296150|NCT01943877|Procedure|scaling root planing|scaling root planing
296151|NCT01943877|Drug|Propolis|experimental
296152|NCT01943864|Drug|Trametinib (single tablet)|The drug substance is blended with inert
296153|NCT01943864|Drug|Trametinib (Multiple tablet)|The drug substance is blended with inert
296154|NCT01943851|Drug|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
296155|NCT01943838|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
296156|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
296157|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
296158|NCT01943825|Biological|CYD Dengue and Japanese Encephalitis Vaccines|0.5 mL, Subcutaneous (CYD) Intramuscular (JE)
296159|NCT01943825|Biological|Japanese Encephalitis and CYD Dengue Vaccines|0.5 mL, Intramuscular (JE), Subcutaneous (CYD)
296160|NCT01943812|Drug|Estradiol and progeterone|Estradiol and progesterone
296161|NCT01943799|Biological|GS-4774|Administered as a subcutaneous injection every 4 weeks for a total of 6 doses
296162|NCT01943799|Drug|OAV Regimen|Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
296163|NCT01943786|Drug|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
296164|NCT01943773|Procedure|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.~BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.~ASSESSMENT OF INTERVENTION EFFECTIVENESS:~Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.~POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
296165|NCT01943773|Procedure|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
296166|NCT01943760|Drug|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
296167|NCT01943760|Drug|0.9% saline|
296168|NCT01943734|Behavioral|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
296169|NCT01943721|Drug|VISION5 Product|
296170|NCT01943708|Device|SPAP|Novel Auto-algorithm for Auto-CPAP device
296171|NCT01943708|Device|CPAP|Standard CPAP therapy
296172|NCT01943695|Behavioral|Aerobic Training|
296173|NCT01943695|Behavioral|Educational Information|Subjects will be given material regarding cancer and it's impact.
296174|NCT01943695|Behavioral|Supervised Home Based Training|Patients that elect supervised home based training will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
296175|NCT01943682|Drug|CPX-351|Comparison of Different doses of drug
296176|NCT01943669|Device|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
296177|NCT01943656|Device|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
296178|NCT01943643|Procedure|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
296179|NCT01943630|Drug|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
296180|NCT01943630|Drug|Vehicle|Administration of Vehicle once a day (overnight)
296181|NCT01943617|Drug|Entecavir|anti-viral therapy
296182|NCT01943617|Drug|Thymosin-α|anti-viral and antitherapy
296183|NCT01943604|Other|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
296184|NCT01943604|Other|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
296185|NCT01943591|Device|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
296186|NCT01943565|Drug|Hydromorphone 25mcg|Intrathecal Hydromorphone 25mcg
296187|NCT01943565|Drug|Hydromorphone 50mcg|Intrathecal Hydromorphone 50mcg
296188|NCT01943565|Drug|Hydromorphone 100mcg|Intrathecal Hydromorphone 100mcg
296191|NCT01943552|Drug|ipratropium bromide|ipratropium bromide
296192|NCT01943539|Device|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
296193|NCT01943526|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
296194|NCT01943513|Biological|BIIB023|Intravenous (IV) infusions
296195|NCT01943513|Biological|Placebo|Matched placebo
296196|NCT01943487|Drug|EC905|Oral
296197|NCT01943487|Drug|verapamil|Oral
296198|NCT01943474|Device|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
296199|NCT01943474|Device|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
296200|NCT01943461|Drug|Avelumab|Avelumab will be administered in study location using a protocol-defined dose escalation scheme until confirmed complete response (CR), confirmed progression, unacceptable toxicity, or withdrawal from the trial or investigational medicinal product (IMP) occurs.
296201|NCT01943435|Drug|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
296202|NCT01943435|Procedure|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
296203|NCT01943435|Other|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
296204|NCT01943435|Other|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
296205|NCT01943435|Other|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
296206|NCT01943422|Drug|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
296207|NCT01943422|Drug|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
296208|NCT01943409|Drug|Intralipid|soybean oil-based lipid emulsion
296209|NCT01943409|Drug|ClinOleic|olive oil-based lipid emulsion
296210|NCT01943396|Procedure|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
296211|NCT01943383|Genetic|iPSC|Single blood draw for the production of induced pluripotent stem cells.
296212|NCT01943370|Other|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
296213|NCT01943370|Other|Routine Irrigation|Routine initiation of saline irrigation
296214|NCT01943357|Behavioral|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
296215|NCT01943344|Device|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
296216|NCT01943318|Procedure|Liver biopsy|Histologic evaluation
296217|NCT01943318|Device|Hepatic venous pressure gradient (HVPG) measurement|Hepatic venous pressure gradient (HVPG) measurement
296218|NCT01943305|Biological|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
296219|NCT01943305|Biological|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
296220|NCT01943292|Drug|Defactinib|
296221|NCT01943279|Other|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
296222|NCT01943279|Other|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
296223|NCT01943266|Dietary Supplement|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
296224|NCT01943253|Device|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
296225|NCT01943253|Device|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
296226|NCT01943240|Drug|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
296227|NCT01943240|Drug|10 cc of 0.375% ropivacaine pectoral nerve block|
296228|NCT01943227|Other|controlled positive pressure ventilation 9ml/kg tidal volume|controlled positive pressure ventilation 9ml/kg tidal volume
296229|NCT01943227|Other|controlled positive pressure ventilation 6ml/kg tidal volume|controlled positive pressure ventilation 6ml/kg tidal volume
296230|NCT01943201|Device|new bedsheet|sleeping 5 nights on the new bedsheet
296231|NCT01943201|Device|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
296232|NCT01943188|Radiation|stereotactic body radiation therapy|Undergo SBRT
296233|NCT01943188|Drug|cyclophosphamide|Given PO
296234|NCT01943188|Biological|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
296235|NCT01943188|Other|laboratory biomarker analysis|Correlative studies
296236|NCT01943162|Behavioral|CPT|
296237|NCT01943136|Drug|papaya 1% extract ointment|
296238|NCT01943136|Drug|mupirocin 2% ointment|
296239|NCT01943123|Dietary Supplement|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
296240|NCT01943123|Dietary Supplement|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
296241|NCT01943110|Device|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
296242|NCT01943110|Device|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
296243|NCT01943084|Drug|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
296244|NCT01943084|Drug|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
296245|NCT01943071|Behavioral|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
296246|NCT01943058|Drug|megestrol acetate|Given PO
296247|NCT01943058|Device|levonorgestrel-releasing intrauterine system|Given IUD
296248|NCT01943058|Other|laboratory biomarker analysis|Correlative studies
296249|NCT01943058|Other|questionnaire administration|Ancillary studies
296250|NCT01943045|Biological|NGM282|
296251|NCT01943045|Other|Placebo|
296252|NCT01943019|Drug|Linagliptin|
296253|NCT01943006|Drug|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
296254|NCT01943006|Drug|Placebo cream without active substance|
296255|NCT01942993|Drug|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
296256|NCT01942980|Radiation|Radiation therapy Brain metastasis in breast cancer|Radiation
296257|NCT01942967|Other|Echocardiography|"Measurement of:~Left ventricular output (LVO).~Right ventricular output (RVO).~Assessment of the Mesenteric Artery Flow."
296258|NCT01942967|Other|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
296259|NCT01942954|Other|Mobile health cognitive stimulation|
296260|NCT01942941|Device|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
296261|NCT01942928|Other|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
296262|NCT01942928|Other|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
296263|NCT01942915|Biological|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
296264|NCT01942902|Device|Continuous Glucose Monitoring System|
296265|NCT01942889|Dietary Supplement|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
296266|NCT01942876|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
296267|NCT01942876|Behavioral|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
296268|NCT01942863|Procedure|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
296269|NCT01942863|Procedure|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
296270|NCT01942863|Other|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
296271|NCT01942837|Drug|Enzalutamide|"Administration: 160 mg orally once daily. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.~Dosing: 160 mg orally taken once daily as four 40 mg capsules."
296272|NCT01942824|Behavioral|Text Messages|
296273|NCT01942811|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
296274|NCT01942798|Device|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
296275|NCT01942798|Device|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
296276|NCT01942785|Drug|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
296277|NCT01942772|Device|Ankle-Foot Orthosis|
296278|NCT01942746|Dietary Supplement|Blueberry Juice S2|Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
296279|NCT01942746|Dietary Supplement|Blueberry Capsules S2|Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
296280|NCT01942746|Dietary Supplement|Placebo Capsule S2|Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
296281|NCT01942746|Dietary Supplement|Placebo Juice L1|Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
296282|NCT01942746|Dietary Supplement|Blueberry Juice L1|Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
296283|NCT01942733|Drug|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
296284|NCT01942720|Device|Capsule endoscopy and Ileocolonoscopy tests|
296285|NCT01942707|Procedure|abdominoplasty with Scarpa`s Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
296286|NCT01942707|Procedure|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
296287|NCT01942694|Dietary Supplement|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
296288|NCT01942694|Other|Placebo|Administered as one soft-gel pill daily by mouth
296289|NCT01942681|Drug|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
296290|NCT01942668|Drug|Estradiol|
296291|NCT01942668|Drug|Progesterone|
296292|NCT01942668|Drug|Placebo|
296293|NCT01942655|Other|Blood sample and recto-colic biopsies|
296294|NCT01942629|Other|their will be no intervention in any of the groups, the study is retrospective|
296295|NCT01942616|Other|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
296296|NCT01942616|Other|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
296297|NCT01942616|Other|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
296298|NCT01942590|Drug|Clenbuterol|
296299|NCT01942590|Drug|Placebo|
296300|NCT01942577|Device|NoSting|Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
296301|NCT01942551|Drug|Tadalafil|
296302|NCT01942551|Drug|Dutasteride|
296303|NCT01942538|Device|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
296304|NCT01942538|Device|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
296305|NCT01942525|Other|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
296306|NCT01942512|Device|Endovascular treatment of intracranial aneurysm|
296307|NCT01942499|Other|Community-based exercise program|
296308|NCT01942486|Device|Investigational Coating|
296309|NCT01942473|Device|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
296310|NCT01942460|Drug|Ferumoxytol|
296311|NCT01942447|Biological|FMT|
296312|NCT01942447|Drug|Vancomycin|
296313|NCT01942421|Procedure|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
296314|NCT01942408|Procedure|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
296345|NCT01942161|Drug|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
296315|NCT01942395|Behavioral|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
296316|NCT01942395|Behavioral|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
296317|NCT01942382|Drug|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
296318|NCT01942369|Drug|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).~Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
296319|NCT01942356|Procedure|TIVA - Hypotension|"Defined as: MAP < 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~Give 200 mL Fluid Bolus~If not successful, give ephedrine 5 mg bolus~Repeat from 1.) if even is not resolved after 3.)"
296320|NCT01942356|Procedure|TIVA - Hypertension|"Defined as: SBP > 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.~1.) Labetalol 5 mg IV will be administered"
296321|NCT01942356|Procedure|TIVA - Bradycardia|"Defined as: Heart rate < 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
296322|NCT01942356|Procedure|TIVA - Tachycardia|"Defined as: Heart Rate > 90 beats/min~If associated with normal NIBP (MAP > 60 mmHg and SAP < 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.~If associated with hypertension (SAB > 140 mmHg): proceed with the management of the hypotention during maintenance protocol.~If associated with hypotension (MAP < 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol."
296323|NCT01942356|Procedure|INH - Hypotension|"Defined as: MAP < 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~give a 200 ml fluid bolus (crystalloid).~If not successful, give ephedrine 5 mg bolus.~If not successful decrease volatile by 0.1 MAC.~Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations"
296324|NCT01942356|Procedure|INH - Hypertension|"Defined as: SBP > 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.~increase Sevoflurane by 0.1 MAC~If not successful after 3 minutes (SBP >130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.~If still not successful (SBP >130% of baseline), Labetolol 5mg IV will be administered."
296325|NCT01942356|Procedure|INH - Bradycardia|"Defined as: Heart Rate < 45 beats/min~1.) Bolus of 0.2 mg glycopyrrolate"
296326|NCT01942356|Procedure|INH - Tachycardia|"Defined as: Heart rate > 90 beats/min~if associated with normal NIBP (MAP > 70% of baseline and SBP <130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).~If associated with hypertension (SBP >130% of baseline) : proceed with the management of the hypertension during maintenance protocol.~If associated with hypotension (MAP < 70% of baseline) : proceed with the management of the hypotension during maintenance protocol."
296327|NCT01942343|Drug|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
296328|NCT01942330|Procedure|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
296329|NCT01942317|Other|Balneotherapy|
296330|NCT01942304|Procedure|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
296331|NCT01942304|Procedure|Anorganic bovine bone mineral in direct sinus augmentation|
296332|NCT01942291|Drug|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
296333|NCT01942278|Other|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
296334|NCT01942265|Drug|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
296335|NCT01942265|Drug|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
296336|NCT01942265|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
296337|NCT01942239|Device|real time continuous glucose monitoring|
296338|NCT01942187|Drug|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
296339|NCT01942187|Drug|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
296340|NCT01942187|Behavioral|Problem Solving Therapy|Weekly specialized psychotherapy
296341|NCT01942174|Biological|Prevenar 13|Vaccination at the beginning of the study (day 0)
296342|NCT01942174|Biological|Pneumo23 / Pneumovax|Vaccination 2 months later the beginning of the study NB : Vaccine Pneumo23 has been replaced by equivalent vaccine Pneumovax in September 2017 because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company
296343|NCT01942174|Drug|Methotrexate - Immediate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
296344|NCT01942174|Drug|Methotrexate - Delay|"For period group, methotrexate is Initiated & month after the antipneumococcal vaccination by prevenar 13"
296346|NCT01942161|Drug|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
296347|NCT01942161|Drug|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
296348|NCT01942148|Drug|Aripiprazole|
296349|NCT01942135|Drug|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
296350|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
296351|NCT01942135|Drug|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
296352|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
296353|NCT01942122|Drug|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
296354|NCT01942122|Drug|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
296355|NCT01942122|Drug|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
296356|NCT01942109|Drug|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
296357|NCT01942109|Drug|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
296358|NCT01942083|Drug|OPB-111077|
296359|NCT01942070|Device|Bioresorbable vascular scaffold|
296360|NCT01942070|Device|Durable polymer everolimus-eluting metallic stent|
296361|NCT01942044|Device|Promus element, Xience prime, and Nobori|
296362|NCT01942031|Behavioral|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
296363|NCT01942018|Procedure|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
296364|NCT01941992|Drug|SAMITAL®|
296365|NCT01941992|Drug|Placebo sachets|
296366|NCT01941979|Drug|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
296367|NCT01941966|Drug|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
296368|NCT01941966|Drug|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
296369|NCT01941966|Radiation|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
296370|NCT01941953|Drug|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
296371|NCT01941940|Drug|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
296372|NCT01941940|Drug|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
296373|NCT01941927|Drug|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 andMEK2 activation and kinase activity.
296374|NCT01941927|Drug|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Sincephosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA.GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
296375|NCT01941914|Drug|Calcium chloride|
296376|NCT01941901|Drug|Calcium electroporation|Intratumoral injection, once only treatment.
296377|NCT01941901|Drug|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
296378|NCT01941888|Drug|Propofol|
296379|NCT01941888|Drug|Midazolam|
296380|NCT01941888|Device|Target Controlled Infusion|
296381|NCT01941875|Drug|Progesterone Effervescent Vaginal Tablets|Experimental
296382|NCT01941862|Behavioral|Psychoeducation and Cognitive Bias Modification|
296383|NCT01941849|Drug|Vandetanib|100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
296384|NCT01941849|Radiation|131I-mIBG|Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
296385|NCT01941836|Drug|ETC-1002|Patients receive ETC-1002
296386|NCT01941836|Drug|Ezetimibe|Patients receive ezetimibe
296387|NCT01941810|Dietary Supplement|bovine lactoferrin supplement|Given PO
296388|NCT01941810|Other|questionnaire administration|Ancillary studies
296389|NCT01941810|Procedure|quality-of-life assessment|Ancillary studies
296390|NCT01941810|Other|laboratory biomarker analysis|Correlative studies
296391|NCT01941797|Behavioral|interruption of oral hygiene|
296392|NCT01941784|Other|educational intervention|Undergo health education program
296393|NCT01941784|Other|counseling intervention|Undergo health education program
296394|NCT01941784|Behavioral|telephone-based intervention|Receive follow-up phone calls
296395|NCT01941784|Other|questionnaire administration|Ancillary studies
296396|NCT01941784|Procedure|quality-of-life assessment|Ancillary studies
296397|NCT01941771|Drug|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
296433|NCT01941524|Drug|Beractant instillation|aEEG and NRs monitoring during beractant instillation
296602|NCT01940276|Drug|Abiraterone acetate|
296398|NCT01941771|Drug|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
296399|NCT01941758|Biological|trivalent influenza vaccine|
296400|NCT01941758|Other|laboratory biomarker analysis|Correlative studies
296401|NCT01941745|Drug|Half normal saline|2 ml/kg
296402|NCT01941745|Drug|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
296403|NCT01941745|Drug|High dose rhCC10|5 mg/kg in 2 ml/kg
296404|NCT01941732|Drug|Sildenafil|
296405|NCT01941719|Behavioral|Enhanced foot care education|Personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
296406|NCT01941719|Behavioral|Standard Foot Care Education|"At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams."
296407|NCT01941706|Behavioral|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
296408|NCT01941693|Behavioral|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
296409|NCT01941693|Behavioral|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
296410|NCT01941667|Behavioral|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families."
296411|NCT01941667|Other|Usual Care|Usual care as defined by by the Cardiology Department.
296412|NCT01941654|Radiation|preemptive local ablative therapy|
296413|NCT01941654|Drug|Oral TKI|
296414|NCT01941641|Drug|neoadjuvant FOLFOXIRI|
296415|NCT01941641|Drug|Capecitabine|
296416|NCT01941628|Drug|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
296417|NCT01941628|Drug|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
296418|NCT01941615|Drug|faldaprevir|oral doses for 10 days (period B)
296419|NCT01941615|Drug|Microgynon®|oral doses for 23 days (period A+B)
296420|NCT01941615|Drug|BI 207127|oral doses for 10 days (period B)
296421|NCT01941602|Drug|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
296422|NCT01941602|Procedure|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
296423|NCT01941589|Drug|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
296424|NCT01941589|Drug|corticosteroids only|IV corticosteroids only
296425|NCT01941576|Drug|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
296426|NCT01941576|Drug|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
296427|NCT01941563|Drug|Condoliase|1.25U, intradiscal injection, one time
296428|NCT01941563|Drug|placebo|
296429|NCT01941550|Drug|Cabazitaxel chemotherapy|given in 6 cycles
296430|NCT01941537|Drug|ILV-094|IV infusion of ILV-094
296431|NCT01941537|Drug|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
296432|NCT01941524|Drug|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
296434|NCT01941511|Drug|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
296435|NCT01941498|Device|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
296436|NCT01941498|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
296437|NCT01941485|Device|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
296438|NCT01941485|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
296439|NCT01941472|Other|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
296440|NCT01941446|Drug|Eravacyline and Moxifloxacin|
296441|NCT01941433|Behavioral|Arthritis Health Journal|
296442|NCT01941407|Drug|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
296443|NCT01941394|Biological|Mesenchymal stem cells|Mesenchymal stem cells infusion
296444|NCT01941381|Procedure|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
296445|NCT01941368|Dietary Supplement|Placebo|
296446|NCT01941368|Dietary Supplement|HMB-FA|
296447|NCT01941368|Procedure|High Intensity Interval Training|
296448|NCT01941355|Behavioral|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
296449|NCT01941355|Behavioral|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
296450|NCT01941342|Procedure|Pancreatoduodenectomy|
296451|NCT01941342|Procedure|ENBD and Pancreatoduodenectomy|
296452|NCT01941342|Procedure|EBD and Pancreatoduodenectomy|
296453|NCT01941342|Procedure|PTCD and Pancreatoduodenectomy|
296454|NCT01941329|Procedure|Panretinal Photocoagulation (PRP)|
296455|NCT01941329|Drug|Intravitreous injection of ranibizumab|
296456|NCT01941316|Drug|Carfilzomib|20/36 * mg/m2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
296457|NCT01941316|Drug|Irinotecan|125 mg/m2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
296458|NCT01941277|Behavioral|Current Recommendations Exercise Group|
296459|NCT01941277|Behavioral|Intensive Exercise Group|
296460|NCT01941264|Other|community based screening and treatment|Already described in intervention arm description.
296461|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|"individualized α frequency~left DLPFC 110% motor threshold (MT)~13-15 sessions for 3 weeks"
296462|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|- placebo treatment: sham coil
296463|NCT01941225|Drug|Inhaled iloprost 5.0 mcg|Single administration
296464|NCT01941225|Drug|Placebo|Single administration
296465|NCT01941212|Behavioral|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
296466|NCT01941199|Drug|DA-1229|
296467|NCT01941199|Drug|metformin|
296468|NCT01941199|Drug|DA-1229 + metformin|
296469|NCT01941186|Other|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
296470|NCT01941173|Biological|ziv-aflibercept|Given IV
296471|NCT01941173|Drug|leucovorin calcium|Given IV
296472|NCT01941173|Drug|irinotecan hydrochloride|Given IV
296473|NCT01941173|Drug|fluorouracil|Given IV
296474|NCT01941160|Dietary Supplement|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
296475|NCT01941160|Dietary Supplement|Placebo|Placebo capsule twice daily
296476|NCT01941147|Device|pulsed ELF-MF|(75 Hz, 1,8 mT)
296477|NCT01941134|Drug|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
296478|NCT01941121|Behavioral|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
296479|NCT01941108|Behavioral|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
296480|NCT01941095|Drug|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
296481|NCT01941095|Drug|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
296482|NCT01941095|Drug|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
296598|NCT01940315|Biological|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
296483|NCT01941095|Drug|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
296484|NCT01941095|Drug|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
296485|NCT01941095|Drug|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.
296486|NCT01941095|Drug|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
296487|NCT01941082|Drug|RO6867461|Single or multiple ascending dose by intravitreal injection
296488|NCT01941069|Behavioral|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
296489|NCT01941069|Behavioral|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
296490|NCT01941056|Biological|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
296491|NCT01941056|Other|laboratory biomarker analysis|Correlative studies
296492|NCT01941043|Drug|CERC-301|
296493|NCT01941043|Other|Placebo|
296494|NCT01941030|Device|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
296495|NCT01941030|Device|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
296496|NCT01941004|Drug|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
296497|NCT01941004|Drug|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
296498|NCT01940991|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
296499|NCT01940991|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
296500|NCT01940978|Drug|Methylphenidate ER|Watson generic, starting dose 18mg QD
296501|NCT01940978|Drug|Cyproheptadine|cyproheptadine hydrochloride
296502|NCT01940965|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
296503|NCT01940965|Drug|biguanide|Pharmaceutical form:tablet Route of administration: oral
296504|NCT01940965|Drug|TZD|Pharmaceutical form:tablet Route of administration: oral
296505|NCT01940965|Drug|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
296506|NCT01940965|Drug|glinide|Pharmaceutical form:tablet Route of administration: oral
296507|NCT01940952|Drug|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
296508|NCT01940952|Drug|Placebo + Donepezil 5mg or 10mg|
296509|NCT01940952|Drug|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
296510|NCT01940939|Device|Repetitive Transcranial Magnetic Stimulation|The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
296511|NCT01940926|Drug|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
296512|NCT01940913|Dietary Supplement|Probiotic capsules|
296513|NCT01940913|Dietary Supplement|Placebo capsules|
296514|NCT01940900|Drug|E10030|
296515|NCT01940900|Drug|ranibizumab|
296516|NCT01940900|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
296517|NCT01940887|Drug|E10030|
296518|NCT01940887|Drug|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
296519|NCT01940887|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
296520|NCT01940848|Drug|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
296521|NCT01940848|Drug|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
296522|NCT01940835|Procedure|Upper endoscopy with small bowel biopsies and brushings.|
296523|NCT01940835|Other|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
296524|NCT01940835|Other|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
296525|NCT01940822|Other|Energy Drink|
296526|NCT01940822|Other|Placebo Drink|
296527|NCT01940809|Drug|Dabrafenib|Given PO
296528|NCT01940809|Biological|Ipilimumab|Given IV
296529|NCT01940809|Other|Laboratory Biomarker Analysis|Correlative studies
296530|NCT01940809|Biological|Nivolumab|Given IV
296531|NCT01940809|Drug|Trametinib|Given PO
296532|NCT01940796|Drug|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
296533|NCT01940783|Radiation|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
296534|NCT01940783|Device|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
296535|NCT01940757|Biological|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
296599|NCT01940315|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
296600|NCT01940302|Dietary Supplement|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
296603|NCT01940276|Drug|Prednisone|
296536|NCT01940744|Procedure|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
296537|NCT01940744|Procedure|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
296538|NCT01940731|Drug|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
296539|NCT01940718|Drug|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
296540|NCT01940705|Other|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
296541|NCT01940705|Other|Hearing-Aid DVD|Take-home DVD about hearing aids
296542|NCT01940705|Behavioral|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
296543|NCT01940705|Other|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
296544|NCT01940692|Drug|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
296545|NCT01940692|Drug|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
296546|NCT01940679|Dietary Supplement|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
296547|NCT01940653|Drug|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.~Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
296548|NCT01940640|Dietary Supplement|DHA|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
296549|NCT01940640|Dietary Supplement|control|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
296550|NCT01940627|Dietary Supplement|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
296551|NCT01940627|Dietary Supplement|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
296552|NCT01940614|Other|Water deprivation test|Classical water deprivation test alone
296553|NCT01940614|Other|Water deprivation test|classical water deprivation test plus plasma copeptin cut-off levels
296554|NCT01940614|Other|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
296555|NCT01940601|Drug|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
296556|NCT01940601|Drug|Filgrastim|Filgrastim 5 μg/kg
296557|NCT01940588|Behavioral|Neuropsychoanalytic therapy|Psychotherapy, medication management
296558|NCT01940575|Device|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
296559|NCT01940575|Device|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
296560|NCT01940562|Drug|eltrombopag|"Children ≥= 40 kg BW:~From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).~Children 20-40 kg BW:~From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).~Children < 20 kg BW:~From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
296561|NCT01940549|Device|Trauma Focused Therapy + tDCS|
296562|NCT01940536|Drug|Tranexamic Acid|antifibrinolytic
296563|NCT01940536|Drug|Placebo|Placebo
296564|NCT01940523|Drug|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
296565|NCT01940523|Drug|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
296566|NCT01940510|Drug|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
296567|NCT01940510|Drug|rifampin|Multiple doses Days 8-16 and Days 17-20
296568|NCT01940497|Drug|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
296569|NCT01940497|Drug|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
296570|NCT01940497|Drug|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
296571|NCT01940497|Drug|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
296572|NCT01940484|Drug|Methoxy polyethylene glycol epoetin beta|
296573|NCT01940471|Drug|TAF|25 mg tablet administered orally once daily
296574|NCT01940471|Drug|TDF|300 mg tablet administered orally once daily
296575|NCT01940471|Drug|TAF Placebo|Tablet administered orally once daily
296576|NCT01940471|Drug|TDF Placebo|Tablet administered orally once daily
296577|NCT01940445|Device|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
296578|NCT01940445|Device|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
296579|NCT01940432|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
296580|NCT01940432|Behavioral|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
296581|NCT01940419|Drug|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
296582|NCT01940419|Drug|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
296583|NCT01940406|Procedure|Stimulation procedure|Device
296584|NCT01940393|Drug|Cetirizine|Drug administration
296585|NCT01940393|Drug|Desloratadine|Drug Administration
296586|NCT01940393|Drug|Fexofenadine|Drug administration
296587|NCT01940393|Drug|Ebastine|Drug administration
296588|NCT01940393|Drug|Bilastine|Drug administration
296589|NCT01940367|Device|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
296590|NCT01940367|Device|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:~Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.~The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:~Mode: Burst~Cycle: 10 seconds~Frequency: 10 Hz~Pulse Width: 250 µs~Intensity: to subject comfort level"
296591|NCT01940354|Device|AccuCath IV Catheter System|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
296592|NCT01940354|Device|Conventional IV Catheter System|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
296593|NCT01940341|Drug|TAF|25 mg tablet administered orally once daily
296594|NCT01940341|Drug|TDF|300 mg tablet administered orally once daily
296595|NCT01940341|Drug|TAF Placebo|Tablet administered orally once daily
296596|NCT01940341|Drug|TDF Placebo|Tablet administered orally once daily
296597|NCT01940328|Device|Transchoracic ultrasound Doppler|
296601|NCT01940289|Device|Algometric meter readings for perception of pain|
296604|NCT01940263|Dietary Supplement|Anthocyanin|
296605|NCT01940263|Dietary Supplement|Placebo|
296606|NCT01940250|Drug|Magnesium Sulphate|MgSO4 IV infusion
296607|NCT01940250|Drug|Sterile water|H2O IV infusion
296608|NCT01940237|Behavioral|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
296609|NCT01940224|Drug|Pregabalin|Preoperative administration of pregabalin 300mg
296610|NCT01940224|Drug|Placebo|Preoperative administration of placebo
296611|NCT01940224|Drug|Morphine|Postoperative administration of morphine via PCA pump for 48h
296612|NCT01940185|Device|LINX device|
296613|NCT01940172|Drug|Birinapant|"Dose Escalation:~Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"
296614|NCT01940172|Drug|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
296615|NCT01940159|Drug|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
296616|NCT01940159|Drug|Placebo|single oral dose placebo
296617|NCT01940146|Drug|SPARC Placebo|Placebo
296618|NCT01940146|Drug|SPARC1310 I|SPARC1310 I
296619|NCT01940146|Drug|SPARC1310 II|SPARC1310 II
296620|NCT01940146|Drug|SPARC1310 III|SPARC1310 III
296621|NCT01940133|Drug|PQR309|Dosing will be orally, once a day for the duration of the trial.
296622|NCT01940120|Device|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
296623|NCT01940107|Other|evaluations|Only evaluations
296624|NCT01940107|Procedure|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
296625|NCT01940094|Drug|5 mg Prednisone|Subjects will remain on daily prednisone dose of 5 mg
296626|NCT01940094|Drug|0 mg Prednisone|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
296627|NCT01940081|Other|Transthoracic echocardiography|
296628|NCT01940081|Other|Exercise test|
296629|NCT01940081|Other|24-hour Holter electrocardiogram|
296630|NCT01940081|Other|Contrast-enhanced magnetic resonance imaging|
296631|NCT01940081|Other|123-iodine metaiodobenzylguanidine imaging|
296632|NCT01940081|Other|Blood samples|
296633|NCT01940081|Genetic|Genetic analysis|
296634|NCT01940081|Procedure|Invasive electrophysiological study|
296635|NCT01940081|Procedure|Endomyocardial biopsy|
296636|NCT01940081|Procedure|Intraoperative biopsy|
296637|NCT01940081|Procedure|Intraoperative mapping and/or ablation|
296638|NCT01940068|Dietary Supplement|Amino acid based formula|
296639|NCT01940055|Behavioral|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
296640|NCT01940055|Behavioral|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
296641|NCT01940042|Behavioral|CO2 was removed by means of trandelenburg positions|
296642|NCT01940016|Behavioral|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
296643|NCT01940016|Behavioral|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
296644|NCT01940003|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
296645|NCT01939990|Drug|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
296646|NCT01939990|Drug|Nebivolol|5 to 10mg per day
296647|NCT01939977|Drug|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
296648|NCT01939977|Drug|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
296649|NCT01939964|Other|Activation Mist|Activation Mist topical spray
296650|NCT01939951|Dietary Supplement|Activation Energy Serum|7 drops or 21 drops twice daily
296651|NCT01939938|Device|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
296652|NCT01939925|Other|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
296653|NCT01939925|Other|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
296654|NCT01939912|Drug|Adenosine|Antiarrhythmic agent.
296780|NCT01939028|Procedure|lymphadenectomy|Undergo para-aortic lymphadenectomy
296655|NCT01939899|Drug|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
296656|NCT01939886|Drug|Mefloquine - Artesunate|
296657|NCT01939886|Drug|Artemether-lumefantrine combination|
296658|NCT01939873|Behavioral|KRISTELLER|
296659|NCT01939860|Other|Written and verbal patient education on hypertension and its treatment|
296660|NCT01939847|Other|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
296661|NCT01939834|Device|AAA control|"AAA control is a method to determine insulin dosing to keep glucose in range. AAA control is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the AAA control and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.~AAA control will be tested in 40 hours sessions and 5 consecutive overnight sessions."
296662|NCT01939834|Other|CGM + insulin pump at home|The subject will be on their home insulin pump and using a CGM per their usual care.
296663|NCT01939821|Behavioral|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
296664|NCT01939821|Behavioral|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
296665|NCT01939808|Other|Splint Neutral|
296666|NCT01939808|Other|Splint Extended|
296667|NCT01939795|Other|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
296668|NCT01939782|Other|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
296669|NCT01939782|Other|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
296670|NCT01939769|Other|Exercise - Low-intensity exercise|
296671|NCT01939769|Other|Exercise - High-intensity exercise|
296672|NCT01939756|Device|Intravesical baobab oil|Intravesical baobab oil
296673|NCT01939743|Drug|Diclofenac suppository plus lidocaine gel|
296674|NCT01939743|Drug|Lidocaine gel only|
296675|NCT01939730|Drug|Rituximab|375 mg/m^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
296676|NCT01939730|Drug|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
296677|NCT01939717|Other|Dance group|"Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.~Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class."
296678|NCT01939704|Other|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
296679|NCT01939704|Other|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
296680|NCT01939691|Drug|Difluprednate|Difluprednate 0.05% - corticosteroid eyedrop
296681|NCT01939691|Drug|Nepafenac|Nepafenac 0.1% - NSAID eyedrop
296682|NCT01939691|Drug|Prednisolone acetate|prednisolone acetate 1% - corticosteroid eyedrop
296683|NCT01939665|Device|"NanoKnife Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
296684|NCT01939652|Procedure|Restrictive VS Standard Fluid Regime|
296685|NCT01939652|Drug|Drag: Crystalloids and Colloids|
296686|NCT01939639|Drug|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
296687|NCT01939639|Drug|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
296688|NCT01939626|Device|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
296689|NCT01939613|Drug|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
296690|NCT01939600|Other|Starch-free breakfast|Starch-free breakfast alone
296691|NCT01939600|Other|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
296692|NCT01939600|Other|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
296693|NCT01939600|Other|Amioca|Starch-free breakfast plus 56.4g amioca starch
296694|NCT01939587|Drug|PBF-680 5 mg|
296695|NCT01939587|Drug|PBF-680 20 mg|
296696|NCT01939587|Drug|Placebo|
296782|NCT01939015|Device|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
296697|NCT01939574|Other|Chemoradiation Therapy|"Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.~Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
296698|NCT01939574|Other|Adjuvant Therapy|"Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.~Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
296699|NCT01939561|Drug|Lamotrigine|
296700|NCT01939561|Drug|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
296701|NCT01939548|Drug|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
296702|NCT01939548|Drug|Placebo|Placebo BID until the Week 12 visit
296703|NCT01939548|Drug|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
296704|NCT01939535|Other|No intervention|Evaluation of an imaging technique ic MRI
296705|NCT01939522|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|
296706|NCT01939509|Drug|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
296707|NCT01939509|Drug|Bisoprolol|
296708|NCT01939496|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
296709|NCT01939496|Drug|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
296710|NCT01939483|Drug|irinotecan hydrochloride|Given IV
296711|NCT01939483|Other|laboratory biomarker analysis|Correlative studies
296712|NCT01939457|Drug|Misoprostol|
296713|NCT01939444|Drug|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
296714|NCT01939444|Drug|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
296715|NCT01939418|Drug|RAD001|Afinitor 5mg qd. po.
296716|NCT01939418|Drug|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
296717|NCT01939418|Drug|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
296718|NCT01939405|Behavioral|built environment use counseling|
296719|NCT01939392|Device|Renal Denervation (OneShot™ Renal Denervation System)|
296720|NCT01939379|Drug|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
296721|NCT01939379|Drug|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
296722|NCT01939366|Drug|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
296723|NCT01939366|Drug|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
296724|NCT01939366|Drug|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
296725|NCT01939366|Drug|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
296726|NCT01939366|Drug|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
296727|NCT01939353|Drug|EB-1020 SR|100-500 mg flexible titration
296728|NCT01939353|Drug|Matching Placebo|
296729|NCT01939327|Drug|Lenalidomide/Rituximab|
296730|NCT01939314|Drug|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
296731|NCT01939314|Drug|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
296732|NCT01939301|Drug|Inhaled Nitric Oxide|Nitric Oxide + oxygen
296733|NCT01939301|Drug|Sham|Nitrogen + Oxygen
296734|NCT01939288|Device|Neuromuscular stimulation, followed by intermittent pneumatic compression|
296735|NCT01939288|Device|Intermittent pneumatic compression, followed by neuromuscular stimulation|
296736|NCT01939275|Radiation|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
296737|NCT01939275|Device|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
296738|NCT01939275|Other|laboratory biomarker analysis|Correlative studies
296739|NCT01939275|Procedure|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
296740|NCT01939262|Other|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
296741|NCT01939262|Other|Control|Participants assigned to the control group will be instructed to follow their usual diets.
296742|NCT01939249|Device|Abbott Laboratories Xience|
296743|NCT01939249|Device|Biotronik Orsiro|
296744|NCT01939236|Drug|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
296781|NCT01939015|Device|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
296783|NCT01939002|Drug|BIIB017|
296745|NCT01939236|Drug|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.~1 bag of drug 2 times per day for 28 days according to syndrome differentiation.~For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
296746|NCT01939223|Drug|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
296747|NCT01939223|Drug|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
296748|NCT01939210|Other|Educational Intervention|Participate in breathing training sessions
296749|NCT01939210|Other|Meditation Therapy|Participate in breathing training sessions
296750|NCT01939210|Other|Questionnaire Administration|Ancillary studies
296751|NCT01939197|Drug|ABT-450/r/ABT-267|tablet
296752|NCT01939197|Drug|ABT-333|tablet
296753|NCT01939197|Drug|ribavirin|tablet
296754|NCT01939184|Drug|WC3055|12.5, 25, 50 or 75 mg dose
296755|NCT01939184|Other|Placebo|Placebo
296756|NCT01939171|Drug|Thymoglobulin|
296757|NCT01939158|Biological|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
296758|NCT01939158|Biological|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
296759|NCT01939145|Drug|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
296760|NCT01939145|Device|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
296761|NCT01939132|Drug|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
296762|NCT01939106|Device|One Piece Drainable Pouch|
296763|NCT01939093|Drug|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
296764|NCT01939093|Dietary Supplement|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
296765|NCT01939093|Drug|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
296766|NCT01939080|Procedure|Exercise training with supervised sessions|
296767|NCT01939067|Device|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
296768|NCT01939067|Device|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
296769|NCT01939054|Drug|Nimotuzumab|
296770|NCT01939054|Drug|docetaxel|
296771|NCT01939054|Drug|capecitabine|
296772|NCT01939041|Device|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
296773|NCT01939041|Device|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
296774|NCT01939041|Behavioral|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
296775|NCT01939028|Procedure|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
296776|NCT01939028|Procedure|sentinel lymph node biopsy|Undergo SLN biopsy
296777|NCT01939028|Drug|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
296778|NCT01939028|Drug|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
296779|NCT01939028|Procedure|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
296785|NCT01938989|Device|Clear clip-on glasses|Clip-on glasses with no light filtering properties
296786|NCT01938989|Device|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
296787|NCT01938976|Behavioral|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
296788|NCT01938963|Behavioral|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
296789|NCT01938950|Other|Aerobic Exercise|
296790|NCT01938950|Other|Resistance Exercise|
296791|NCT01938950|Other|Aerobic and Resistance Exercise|
296792|NCT01938937|Device|Transcranial bright light device|
296793|NCT01938937|Device|Transcranial sham device|
296794|NCT01938924|Device|GekoTM|electrical neuromuscular stimulation
296795|NCT01938911|Drug|Syntocinon-Spray|Intranasal oxytocin (24 IU)
296796|NCT01938911|Drug|Placebo of syntocinon|Intranasal administration
296797|NCT01938911|Behavioral|Social support|Social support from the best friend
296798|NCT01938898|Other|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:~Male & Study & Confidentiality~Male & Study~Male & Project & Confidentiality~Male & Project~Female & Project & Confidentiality~Female & Project~Female & Study & Confidentiality~Female & Study~Neutral & Study & Confidentiality~Neutral & Study~Neutral & Project & Confidentiality~Neutral & Project"
296799|NCT01938872|Procedure|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
296800|NCT01938859|Drug|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
296801|NCT01938859|Drug|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
296802|NCT01938859|Drug|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
296803|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
296804|NCT01938846|Drug|exemestane|exemestane once daily
296805|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
296806|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
296807|NCT01938846|Drug|paclitaxel|paclitaxel once weekly
296808|NCT01938833|Drug|Romidepsin|
296809|NCT01938833|Drug|Abraxane|
296810|NCT01938820|Drug|entecavir|anti-viral therapy
296811|NCT01938820|Drug|Thymosin-α|antiviral and antifibrosis therapy
296812|NCT01938807|Behavioral|CareCoach mobile application to assist in diabetes management|
296813|NCT01938781|Drug|entecavir|antiviral therapy
296814|NCT01938781|Drug|Peg-IFN|antiviral and antifibrosis therapy
296815|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 60 mg dextrose
296816|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 80 mg dextrose
296817|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 100 mg dextrose
296818|NCT01938742|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, & 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
296819|NCT01938742|Drug|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 & 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
296820|NCT01938729|Procedure|Liver resection and placement of hepatic artery infusion pump|
296821|NCT01938729|Drug|FLOXURIDINE|
296822|NCT01938729|Drug|DEXAMETHASONE|
296823|NCT01938729|Drug|GEMCITABINE|
296824|NCT01938716|Drug|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
296825|NCT01938690|Device|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
296826|NCT01938677|Radiation|Initial Gamma knife radiosurgery|
296827|NCT01938664|Drug|Candesartan with CBT|8 mg, po (by mouth)
296828|NCT01938664|Other|Placebo with CBT|
296829|NCT01938651|Procedure|high field strength magnetic resonance imaging|Undergo 7T MRI
296830|NCT01938651|Procedure|magnetic resonance spectroscopic imaging|Undergo 31P MRS
296831|NCT01938651|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
296832|NCT01938651|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
296833|NCT01938651|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
296834|NCT01938638|Drug|BAY1143572|
296835|NCT01938625|Drug|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
296836|NCT01938625|Drug|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
296837|NCT01938625|Drug|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
296885|NCT01938261|Drug|0.45 % saline solution|Placebo
296886|NCT01938248|Drug|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
296838|NCT01938625|Drug|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
296839|NCT01938625|Drug|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
296840|NCT01938612|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
296841|NCT01938612|Drug|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
296842|NCT01938599|Drug|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
296843|NCT01938599|Drug|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
296844|NCT01938586|Other|Steri-Strip|
296845|NCT01938586|Other|Superficial sutures|
296846|NCT01938573|Drug|Cisplatin|Given IV
296847|NCT01938573|Drug|Gemcitabine Hydrochloride|Given IV
296848|NCT01938573|Drug|Sirolimus|Given PO
296849|NCT01938573|Procedure|Cystectomy|Undergo cystectomy when appropriate
296850|NCT01938560|Other|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
296851|NCT01938547|Drug|clevidipine|
296852|NCT01938534|Drug|Helicobacter pylori eradication|
296853|NCT01938521|Dietary Supplement|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
296854|NCT01938521|Dietary Supplement|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
296855|NCT01938508|Drug|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
296856|NCT01938495|Device|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
296857|NCT01938482|Drug|0.3% GSK1940029 gel|Will be supplied as gel for topical application
296858|NCT01938482|Drug|1% GSK1940029 gel|Will be supplied as gel for topical application
296859|NCT01938482|Drug|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
296860|NCT01938469|Other|Liquid Meal|
296861|NCT01938469|Other|Solid Meal|
296862|NCT01938456|Drug|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
296863|NCT01938456|Drug|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
296864|NCT01938456|Drug|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter^2 or 75 mcg/body
296865|NCT01938443|Drug|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
296866|NCT01938443|Drug|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
296867|NCT01938430|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
296868|NCT01938430|Drug|RBV|RBV tablets administered orally in a divided daily dose
296869|NCT01938417|Drug|tobramycin|
296870|NCT01938404|Biological|Octaplas|Octoplas infusion solution for IV administration
296871|NCT01938404|Drug|Standard Plasma|Plasma given as replacement fluid
296872|NCT01938391|Device|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
296873|NCT01938378|Biological|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
296874|NCT01938352|Biological|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
296875|NCT01938352|Biological|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
296876|NCT01938339|Device|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
296877|NCT01938326|Procedure|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
296878|NCT01938313|Procedure|ERAS perioperative cares|"Patient's preoperative counseling & education before surgery~No Bowel preparation~Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Fluid restriction & Management by pulse contour analysis or transesophageal doppler~Early mobilization~Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~Epidural patient controlled analgesics (no opioids analgesics)~Postoperative Nausea Active Control~Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~Perioperative High content Oxygen therapy~No drain insertion~No Levin tube~Patients will be discharged at POD#4 if there's no problem."
296879|NCT01938313|Procedure|Conventional perioperative cares|"No Patient's preoperative counseling & education before surgery~Bowel preparation~No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)~Conventional Mobilization~Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)~IV PCA~Postoperative Nausea Control if needed~No Thromboembolism prophylaxis~No or Low Content Oxygen therapy~Routine drain insertion~Levin tube insertion if needed"
296880|NCT01938300|Drug|Magnesium Sulfate|
296881|NCT01938300|Drug|Normal saline|
296882|NCT01938287|Device|SENSIMED Triggerfish|
296883|NCT01938274|Other|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
296887|NCT01938248|Drug|aspirin|aspirin 81 mg once daily
296888|NCT01938235|Drug|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
296889|NCT01938235|Drug|Placebo|Intravenous bolus and 24-hour infusion of placebo
296890|NCT01938222|Procedure|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
296891|NCT01938209|Other|seated thoracic manipulation|seated general thoracic spine manipulation
296892|NCT01938209|Other|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
296893|NCT01938196|Drug|KWA-0711|
296894|NCT01938196|Drug|Placebo|
296895|NCT01938183|Procedure|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
296896|NCT01938183|Drug|Metronidazole tablet|750 mg metronidazole tablets
296897|NCT01938183|Drug|placebo gel|semi-solid suspension containing carbopol
296898|NCT01938183|Drug|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
296899|NCT01938170|Biological|FluMist|Subjects receiving Flumist vaccine
296900|NCT01938157|Procedure|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
296901|NCT01938144|Drug|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
296902|NCT01938144|Drug|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
296903|NCT01938144|Drug|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
296904|NCT01938131|Device|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
296905|NCT01938118|Behavioral|Obesity Prevention Group|
296906|NCT01938118|Behavioral|Injury Prevention Group|
296907|NCT01938105|Other|Nimotuzumab+chemoradiotherapy|"Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~--------------------------------------------------------------------------------"
296908|NCT01938092|Drug|Diazepam|
296909|NCT01938092|Drug|Placebo|
296910|NCT01938079|Drug|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
296911|NCT01938079|Other|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
296912|NCT01938066|Device|Procellera|bioelectric wound dressing
296913|NCT01938066|Device|negative pressure therapy|
296914|NCT01938053|Other|Call when test results are ready|Patients are called when the test results are ready
296915|NCT01938053|Other|Text message when test results are ready|Patients receive a text message when results are ready
296916|NCT01938053|Other|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
296917|NCT01938040|Drug|ibuprofen|single preoperative dose prior to surgery
296918|NCT01938040|Other|sugar water/placebo|single preoperative dose prior to surgery
296919|NCT01938027|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
296920|NCT01938001|Drug|Rituximab|Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
296921|NCT01938001|Drug|Lenalidomide|Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
296922|NCT01938001|Drug|Placebo|Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
296923|NCT01937988|Other|Doula Arm|
296924|NCT01937975|Drug|Grazoprevir|100 mg oral tablet administered once a day for 10 days
296925|NCT01937975|Drug|Elbasvir|50 mg oral tablet administered once a day for 10 days
296926|NCT01937949|Device|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the leg (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
296927|NCT01937936|Behavioral|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
296928|NCT01937936|Behavioral|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
296929|NCT01937910|Behavioral|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
296930|NCT01937897|Other|Bi-lateral massage|Unilateral massage on the left side of the body.
296931|NCT01937884|Drug|Parenteral Nutrition|
296932|NCT01937871|Drug|5 mg Tadalafil|Administered orally
296933|NCT01937871|Drug|Placebo|Administered orally
296934|NCT01937871|Drug|0.2 mg Tamsulosin|Administered orally
296935|NCT01937832|Drug|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
296936|NCT01937832|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
296937|NCT01937819|Device|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
296938|NCT01937806|Drug|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
296939|NCT01937806|Drug|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
296940|NCT01937793|Other|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
296941|NCT01937793|Other|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
296942|NCT01937767|Drug|Remimazolam|
296943|NCT01937767|Drug|Propofol|
296944|NCT01937767|Drug|Sevoflurane|
296945|NCT01937767|Drug|Remifentanil|
296946|NCT01937767|Drug|Fentanyl|
296947|NCT01937767|Drug|Rocuronium|
296948|NCT01937754|Dietary Supplement|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
296949|NCT01937754|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
296950|NCT01937728|Drug|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA < 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
296951|NCT01937728|Drug|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
296952|NCT01937728|Drug|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.~Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
296953|NCT01937728|Drug|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
296954|NCT01937728|Drug|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
296955|NCT01937728|Drug|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.~Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
296956|NCT01937715|Drug|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
296957|NCT01937715|Drug|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
296958|NCT01937715|Biological|Bevacizumab|5 mg/m^2 every 2 weeks or 7.5 mg/m^2 every 3 weeks
296959|NCT01937715|Drug|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
296960|NCT01937702|Other|0.9% NaCl (sodium chloride)|
296961|NCT01937689|Drug|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
296962|NCT01937663|Drug|KWA-0711|
296963|NCT01937650|Drug|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
296964|NCT01937637|Behavioral|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
296965|NCT01937624|Device|Diagnostic Ultrasound|
296966|NCT01937624|Radiation|X-ray imaging|
296967|NCT01937611|Drug|Dexmedetomidine|Dexmedetomidine
296968|NCT01937611|Drug|Midazolam|Midazolam
296969|NCT01937598|Drug|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
296970|NCT01937598|Other|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
296971|NCT01937598|Drug|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
296972|NCT01937598|Drug|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
296973|NCT01937585|Behavioral|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
296974|NCT01937585|Behavioral|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
296975|NCT01937572|Other|Visionaire system (Knee MRI)|
296976|NCT01937572|Other|No Knee MRI|
296977|NCT01937559|Biological|Tranexaminic Acid (TXA)|1.5g of TXA in 100ml normal saline solution
296978|NCT01937559|Drug|Normal saline|
296979|NCT01937546|Procedure|Primary delivery of anterior shoulder|
296980|NCT01937546|Procedure|Primary delivery posterior shoulder|
296981|NCT01937533|Procedure|Magnetic Resonance Imaging using an endovaginal receiver coil|
296982|NCT01937520|Device|acupuncture|One half of subjects will receive a standardized acupuncture regiment
296983|NCT01937520|Device|no acupuncture|placebo
296984|NCT01937507|Drug|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
297168|NCT01936129|Drug|Placebo (buffered normal saline w/v)|
296985|NCT01937494|Drug|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
296986|NCT01937481|Behavioral|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
296987|NCT01937468|Other|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
296988|NCT01937468|Drug|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
296989|NCT01937455|Biological|rAAV1-PG9DP|4x10^12 vg administered intramuscularly
296990|NCT01937455|Biological|rAAV1-PG9DP|4x10^13 vg administered intramuscularly
296991|NCT01937455|Biological|rAAV1-PG9DP|8x10^13 vg administered intramuscularly
296992|NCT01937455|Biological|rAAV1-PG9DP|1.2x10^14 vg administered intramuscularly
296993|NCT01937442|Drug|Thalidomide Celgene™|200mg once daily and by mouth
296994|NCT01937429|Device|Colonoscopy with blue Indigo Carmin®|
296995|NCT01937429|Device|Standard colonoscopy with insufflation of air|
296996|NCT01937416|Biological|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
296997|NCT01937390|Drug|Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation|Respimat® inhaler and cartridge Solution for inhalation
296998|NCT01937390|Drug|Indacterol 300 µg|inhalation powder
296999|NCT01937390|Drug|Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule|HandiHaler® device Inhalation powder, hard capsule
297000|NCT01937390|Drug|Indacterol 150 µg|inhalation powder
297001|NCT01937364|Drug|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
297002|NCT01937364|Drug|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
297003|NCT01937351|Device|Pantheris System|
297004|NCT01937338|Drug|AZD7624|nebuliser solution; 20 mg/mL for inhalation
297005|NCT01937338|Drug|Placebo|nebuliser solution for inhalation
297006|NCT01937325|Drug|ivacaftor|active arm
297007|NCT01937325|Drug|placebo|active arm
297008|NCT01937312|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
297009|NCT01937312|Drug|Vehicle|Inactive ingredients used as a placebo comparator
297010|NCT01937312|Drug|Prostaglandin analogue|
297011|NCT01937299|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
297012|NCT01937299|Drug|Vehicle|Inactive ingredients used as a placebo comparator
297013|NCT01937299|Drug|Travoprost 0.004% ophthalmic solution|
297014|NCT01937260|Drug|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
297015|NCT01937247|Procedure|Patients will be inducted in the induction room|The patients will be inducted in the induction room
297016|NCT01937247|Procedure|Redesigned process|The registered nurse will call in the house keeper to start cleaning of the OR (parallel processing) before the patient exits the room
297017|NCT01937247|Drug|patient will be reversed with sugammadex 4mg/kg IV|The patient will be reversed with sugammadex 4mg/kg IV, and then extubated before being moved out of the OR
297018|NCT01937247|Procedure|STANDARD PROCESS|standard process
297019|NCT01937234|Drug|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses."
297020|NCT01937234|Drug|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses."
297021|NCT01937221|Other|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
297022|NCT01937208|Radiation|intensity modulated radiation therapy in both arms|
297023|NCT01937208|Drug|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
297024|NCT01937195|Device|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
297025|NCT01937182|Drug|Citalopram|Citalopram 10-40 mg per day administered orally
297026|NCT01937182|Drug|Placebo|1/2-2 tablets per day with no intrinsic drug activity
297027|NCT01937169|Behavioral|Motor Task|A motor task executed for 30 minutes after drug adminidtration
297028|NCT01937169|Drug|Levodopa tablet|
297029|NCT01937169|Behavioral|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
297030|NCT01937169|Drug|Placebo pill|
297031|NCT01937156|Drug|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
297032|NCT01937156|Drug|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
297033|NCT01937143|Behavioral|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
297034|NCT01937143|Behavioral|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
297035|NCT01937143|Behavioral|Control|General information about infant immunizations at birth of a newborn infant
297036|NCT01937130|Drug|IDN-6556|
297037|NCT01937130|Other|Placebo|
297038|NCT01937117|Procedure|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
297039|NCT01937117|Drug|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
297040|NCT01937117|Drug|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
297041|NCT01937104|Drug|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2~- adjust MAC to maintain BIS between 40-60"
297042|NCT01937104|Drug|Remifentanil|"Adjuvant continuous administration~- adjust effect site concentration to maintain changes of vital sign below 20%"
297043|NCT01937104|Device|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
297044|NCT01937104|Procedure|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
297045|NCT01937104|Procedure|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
297046|NCT01937104|Procedure|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
297047|NCT01937078|Drug|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
297048|NCT01937065|Other|No treatment|
297049|NCT01937052|Other|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
297050|NCT01937052|Behavioral|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
297051|NCT01937039|Procedure|Sample collection|Blood, tissue, urine, and other samples may be collected
297052|NCT01937026|Drug|Baricitinib|Administered orally
297053|NCT01937026|Drug|Probenecid|Administered orally
297054|NCT01937013|Drug|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
297055|NCT01937013|Drug|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
297056|NCT01936974|Drug|Gemcitabine|Patient to receive gemzar
297057|NCT01936974|Drug|Bevacizumab|Patient to receive avastin
297058|NCT01936974|Drug|Carboplatin|Patient to receive carboplatin
297059|NCT01936974|Drug|Cisplatin|Patient to receive cisplatin
297060|NCT01936974|Drug|Oxaliplatin|Patient to receive Oxaliplatin
297061|NCT01936961|Drug|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
297062|NCT01936961|Radiation|Hypofractionated Radiotherapy|
297063|NCT01936948|Procedure|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
297064|NCT01936935|Other|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
297065|NCT01936935|Other|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
297066|NCT01936922|Device|GaitAid®|Provides visual and auditory cues for walking.
297067|NCT01936909|Drug|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
297068|NCT01936909|Drug|Anakinra (weeks 3-12)|
297069|NCT01936909|Drug|Placebo|
297070|NCT01936896|Drug|Alpha 1-Antitrypsin|
297071|NCT01936883|Radiation|HDR|High dose rate brachytherapy
297072|NCT01936883|Radiation|LDR|Low dose rate brachytherapy boost
297073|NCT01936870|Drug|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
297235|NCT01935778|Drug|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
297074|NCT01936857|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
297075|NCT01936857|Drug|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
297076|NCT01936844|Drug|Anakinra (high dose)|Anakinra 100 mg daily twice daily for days 1, 2, and 3
297077|NCT01936844|Drug|Anakinra (standard dose)|Anakinra 100 mg daily for days 4-14
297078|NCT01936844|Drug|Placebo|Placebo twice daily for days 1, 2, and 3
297079|NCT01936844|Drug|Placebo|Placebo daily for days 4-14
297080|NCT01936831|Drug|Isoniazid|
297081|NCT01936831|Dietary Supplement|Vitamin B6|
297082|NCT01936805|Drug|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
297083|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
297084|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
297085|NCT01936753|Behavioral|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
297086|NCT01936740|Procedure|cataract surgery|
297087|NCT01936727|Procedure|cataract surgery|
297088|NCT01936714|Procedure|cataract surgery|
297089|NCT01936701|Procedure|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
297090|NCT01936688|Drug|MK-3222 200 mg|MK-3222 200 mg administered SC.
297091|NCT01936688|Drug|MK-3222 100 mg|MK-3222 100 mg administered SC.
297092|NCT01936688|Drug|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
297093|NCT01936688|Drug|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
297094|NCT01936688|Drug|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
297095|NCT01936675|Other|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
297096|NCT01936662|Device|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
297097|NCT01936662|Device|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
297098|NCT01936649|Drug|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
297099|NCT01936636|Drug|Fentanyl|
297100|NCT01936623|Behavioral|Computerized Brief Intervention|No additional information needed.
297101|NCT01936610|Other|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
297102|NCT01936610|Other|lecture|Describe advantages and disadvantages in one 90-min session
297103|NCT01936597|Other|Therapeutic and preventive strategies|Single set (control Arm)
297104|NCT01936597|Other|Therapeutic and preventive strategies|Controller
297105|NCT01936597|Other|Therapeutic and preventive strategies|Audio
297106|NCT01936584|Procedure|TAPP repair for inguinal hernias|
297107|NCT01936584|Procedure|TEP repair for inguinal hernia|
297108|NCT01936584|Other|EuraHS-QoL questionnaire|questionnaire administration
297109|NCT01936584|Other|Carolina Comfort Scale|questionnaire administration
297110|NCT01936571|Other|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
297111|NCT01936558|Other|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
297112|NCT01936545|Drug|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
297113|NCT01936545|Drug|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
297114|NCT01936532|Drug|MLN9708|"Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.~Consolidation therapy~Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.~Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.~Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months."
297115|NCT01936532|Drug|Lenalidomide|
297116|NCT01936532|Drug|Dexamethasone|
297117|NCT01936519|Drug|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
297118|NCT01936519|Drug|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
297119|NCT01936506|Behavioral|Cognitive Training A|
297120|NCT01936506|Behavioral|Cognitive Training B|
297121|NCT01936493|Genetic|DNA analysis|At a future time DNA analysis will be performed
297122|NCT01936493|Other|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
297123|NCT01936480|Drug|Moxifloxacin 400mg once time|
297124|NCT01936480|Drug|Placebo|
297574|NCT01933022|Drug|Eligard|Subcutaneous Injection
297125|NCT01936467|Device|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
297126|NCT01936467|Device|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
297127|NCT01936441|Behavioral|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
297128|NCT01936441|Behavioral|Menopause Education Control (MEC)|See Experimental Arm Description
297129|NCT01936428|Other|interview|
297130|NCT01936415|Device|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
297131|NCT01936415|Device|Regenerex|
297132|NCT01936402|Behavioral|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
297133|NCT01936389|Drug|AR-12286|
297134|NCT01936363|Drug|Pimasertib once daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
297135|NCT01936363|Drug|Pimasertib placebo|Placebo matching Pimasertib administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
297136|NCT01936363|Drug|SAR245409 placebo|Placebo matching SAR245409 administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
297137|NCT01936363|Drug|SAR245409|SAR245409 administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
297138|NCT01936363|Drug|Pimasertib twice daily|Pimasertib administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever came first.
297139|NCT01936350|Drug|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
297140|NCT01936350|Drug|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
297141|NCT01936337|Drug|DLX105 Hydrogel|topical administration on psoriatic plaque
297142|NCT01936337|Drug|Placebo|topical administration on psoriatic plaque
297143|NCT01936324|Drug|Olumacostat Glasaretil Gel, 7.5%|Gel containing Olumacostat Glasaretil
297144|NCT01936324|Other|Olumacostat Glasaretil Gel, Vehicle|Vehicle (placebo) gel
297145|NCT01936311|Behavioral|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
297146|NCT01936298|Device|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
297147|NCT01936298|Device|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
297148|NCT01936285|Drug|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
297149|NCT01936285|Drug|Placebo|
297150|NCT01936272|Device|Chhabra Shunt Placement|
297151|NCT01936272|Procedure|ETV/CPC|
297152|NCT01936246|Dietary Supplement|Increased protein|
297153|NCT01936233|Drug|Aspirin|Aspirin 0.1 QD po
297154|NCT01936233|Drug|Lamivudine|LAminvudine 0.1 QD po
297155|NCT01936220|Behavioral|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
297156|NCT01936220|Behavioral|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
297157|NCT01936220|Behavioral|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
297158|NCT01936194|Dietary Supplement|DHA+EPA|
297159|NCT01936194|Dietary Supplement|High Olive Oil|
297160|NCT01936194|Dietary Supplement|DHA|
297161|NCT01936181|Drug|Remicade (infliximab)|
297162|NCT01936181|Drug|SB2 (proposed biosimilar to infliximab)|
297163|NCT01936168|Device|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
297164|NCT01936168|Procedure|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
297165|NCT01936155|Device|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
297166|NCT01936142|Device|Use of RenalGuard|
297167|NCT01936129|Drug|Copaxone|
297169|NCT01936116|Device|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
297170|NCT01936116|Device|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
297171|NCT01936103|Drug|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
297172|NCT01936103|Drug|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
297173|NCT01936090|Drug|Bortezomib|Given IV
297174|NCT01936090|Radiation|Total-Body Irradiation|Undergo TBI
297175|NCT01936090|Drug|Melphalan|Given IV
297176|NCT01936090|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
297177|NCT01936090|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
297178|NCT01936090|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
297179|NCT01936090|Other|Laboratory Biomarker Analysis|Correlative studies
297180|NCT01936077|Drug|Recombinant LH (Luveris)|150 IU recombinant LH daily.
297181|NCT01936064|Dietary Supplement|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
297182|NCT01936064|Drug|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
297183|NCT01936038|Other|CPAP|CPAP
297184|NCT01936038|Procedure|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
297185|NCT01936025|Drug|Dextromethorphan|
297186|NCT01936025|Drug|Sitagliptin|
297187|NCT01936025|Drug|Placebo|
297188|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
297189|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
297190|NCT01935999|Device|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
297191|NCT01935986|Dietary Supplement|probiotic|
297192|NCT01935986|Dietary Supplement|placebo|
297193|NCT01935973|Other|Laboratory Biomarker Analysis|Correlative studies
297194|NCT01935973|Drug|Trametinib|Given PO
297195|NCT01935973|Drug|Uprosertib|Given PO
297196|NCT01935960|Other|Laboratory Biomarker Analysis|Correlative studies
297197|NCT01935960|Other|Pharmacological Study|Correlative studies
297198|NCT01935960|Other|Placebo|Given PO
297199|NCT01935960|Drug|Retinoid 9cUAB30|Given PO
297200|NCT01935947|Drug|Azacitidine|Given SC
297201|NCT01935947|Drug|Azacitidine|Given PO
297202|NCT01935947|Drug|Docetaxel|Given IV
297203|NCT01935947|Drug|Entinostat|Given PO
297204|NCT01935947|Drug|Gemcitabine Hydrochloride|Given IV
297205|NCT01935947|Drug|Irinotecan Hydrochloride|Given IV
297206|NCT01935947|Other|Laboratory Biomarker Analysis|Correlative studies
297207|NCT01935947|Drug|Pemetrexed Disodium|Given IV
297208|NCT01935934|Drug|Cabozantinib S-malate|Given PO
297209|NCT01935934|Other|Laboratory Biomarker Analysis|Correlative studies
297210|NCT01935934|Other|Pharmacological Study|Correlative studies
297211|NCT01935921|Biological|Cetuximab|Given IV
297212|NCT01935921|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
297213|NCT01935921|Biological|Ipilimumab|Given IV
297214|NCT01935921|Other|Laboratory Biomarker Analysis|Correlative studies
297215|NCT01935908|Drug|levetiracetam|
297216|NCT01935895|Behavioral|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
297217|NCT01935882|Drug|Artemether-lumefantrine combination|
297218|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
297219|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
297220|NCT01935869|Drug|LEO 90100|
297221|NCT01935869|Drug|Vehicle|
297222|NCT01935869|Drug|Petrolatum ointment|
297223|NCT01935856|Drug|KHK7580|Oral administration
297224|NCT01935843|Biological|CART-HER-2|
297225|NCT01935830|Radiation|[11c] LAAM|intravenous administration of 15-20 mCi of [11c] LAAM.
297226|NCT01935830|Drug|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
297227|NCT01935830|Drug|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
297228|NCT01935817|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
297229|NCT01935817|Drug|Placebo|
297230|NCT01935804|Drug|Pioglitazone|30 mg/daily for 12 months
297231|NCT01935804|Drug|Metformin|850 mg/daily for 12 months
297232|NCT01935791|Drug|Glucagon|Hormone
297233|NCT01935791|Drug|Saline|Control
297234|NCT01935778|Drug|Docetaxel and capecitabine and oxaliplatin|Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
297236|NCT01935765|Other|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
297237|NCT01935765|Other|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
297238|NCT01935765|Other|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
297239|NCT01935765|Other|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
297240|NCT01935765|Other|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
297241|NCT01935765|Other|Electrocardiogram (ECG)|Electrocardiogram (ECG)
297242|NCT01935765|Other|Carotid echography|Carotid echography
297243|NCT01935765|Other|Blood pressure|Blood pressure
297244|NCT01935752|Other|blood samples|blood samples
297245|NCT01935752|Other|vascular echotracking|endothelial function study and virtual histology study
297246|NCT01935713|Drug|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
297247|NCT01935713|Drug|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
297248|NCT01935713|Drug|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, >2 packs per day).
297249|NCT01935700|Drug|Colchicine|"Adjustment the dosage of colchicine during study:~The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
297250|NCT01935687|Device|Using of instrumented wheel|Using of instrumented wheel
297251|NCT01935687|Device|Using of ergometer roller|Using of ergometer roller
297252|NCT01935674|Drug|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
297253|NCT01935674|Drug|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
297254|NCT01935648|Drug|Ropivacaine|
297255|NCT01935635|Biological|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2*105-1*106 cells per time,total 12 times;
297256|NCT01935622|Drug|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
297257|NCT01935622|Drug|placebo|Placebo 1 tablet every 12 hours for 14 days
297258|NCT01935609|Behavioral|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
297259|NCT01935596|Drug|ropivacaïne|spinal anesthesia.
297260|NCT01935596|Drug|lévobupivacaïne|
297261|NCT01935583|Behavioral|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
297262|NCT01935570|Drug|Magnesium chloride (ChronoMag Smart Tablet®)|
297263|NCT01935570|Drug|Magnesium carbonate (Mag2® Tablet)|
297264|NCT01935557|Drug|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
297265|NCT01935557|Drug|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
297266|NCT01935544|Device|Botulinum toxin injection|
297267|NCT01935531|Drug|3% diclofenac in 2.5% hyaluronic acid gel|
297268|NCT01935518|Drug|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
297269|NCT01935505|Behavioral|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
297270|NCT01935505|Drug|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
297271|NCT01935505|Behavioral|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
297272|NCT01935505|Behavioral|Consulting+Telephone+Drug intervention|Include all the above interventions
297364|NCT01934712|Drug|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
297440|NCT01934023|Drug|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
297441|NCT01934023|Drug|Placebo|
297273|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"st line:~Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.~Bevacizumab until PD or unacceptable toxicity~At PD patients will go to the 2nd treatment line.~nd line:~Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.~At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
297274|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B~st line~Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity~Bevacizumab until PD or unacceptable toxicity~At PD < 3 months after last paclitaxel start 2nd treatment line.~At PD ≥ 3 months after last paclitaxel, start another 4 cycles~Bevacizumab until the next PD or unacceptable toxicity~At the next PD start the 2nd treatment line.~nd line:~Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity~At PD < 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.~At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine~At the next PD start 3rd treatment line."
297275|NCT01935479|Drug|AK159|transdermal administration of teriparatide acetate
297276|NCT01935479|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
297277|NCT01935479|Drug|Placebo|Placebo AK159
297278|NCT01935466|Drug|Pioglitazone|Ever users of Pioglitazone
297279|NCT01935453|Biological|Recombinant hGM-CSF Herpes Simplex Virus Injection|
297280|NCT01935440|Behavioral|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
297281|NCT01935440|Behavioral|Prevention & Testing Control|7 group sessions
297282|NCT01935414|Device|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
297283|NCT01935414|Device|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
297284|NCT01935388|Other|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
297285|NCT01935375|Behavioral|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
297286|NCT01935375|Behavioral|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
297287|NCT01935362|Dietary Supplement|Citrus supplement|
297288|NCT01935362|Dietary Supplement|Placebo|
297289|NCT01935336|Drug|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
297290|NCT01935323|Other|High Intensity Interval Training|
297291|NCT01935323|Other|Moderate Intensity Training|
297292|NCT01935310|Drug|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.~During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
297293|NCT01935297|Behavioral|Exercise|endurance and resistance exercise 3x/week for 8 weeks
297294|NCT01935271|Dietary Supplement|Muscle Armor Supplement|
297295|NCT01935271|Dietary Supplement|Placebo|
297296|NCT01935258|Other|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
297297|NCT01935258|Other|care as usual|usual care of the general practitioner
297298|NCT01935245|Device|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.~The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
297299|NCT01935245|Device|Conventional extracorporeal circulation|
297300|NCT01935219|Behavioral|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
297301|NCT01935219|Behavioral|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
297302|NCT01935219|Behavioral|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
297303|NCT01935206|Drug|Naloxone (2 mg/kg)|
297304|NCT01935206|Drug|Placebo|
297305|NCT01935193|Drug|lysine acetylsalicylate|
297306|NCT01935180|Device|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
297307|NCT01935167|Drug|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
297308|NCT01935167|Drug|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
297309|NCT01935167|Drug|Placebo|Placebo 2 tablets b.i.d.
297310|NCT01935154|Drug|Vx-001|
297311|NCT01935154|Drug|Placebo|
297312|NCT01935141|Procedure|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
297313|NCT01935141|Device|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
297314|NCT01935141|Drug|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
297315|NCT01935128|Drug|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
297316|NCT01935115|Drug|Propofol|Propofol anesthesia for ECT
297317|NCT01935115|Drug|Ketamine|Ketamine anesthesia for ECT
297318|NCT01935089|Drug|Pegylated Interferon alpha 2b|1µg/kg/week
297319|NCT01935076|Behavioral|Neonatal exposure to maternal obesity|
297396|NCT01934361|Drug|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
297442|NCT01934010|Drug|AM-101|AM-101 gel for intratympanic injection
297320|NCT01935063|Behavioral|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
297321|NCT01935063|Other|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
297322|NCT01935050|Behavioral|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
297323|NCT01935024|Other|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
297324|NCT01935011|Other|PD, DBS|PD DBS frequency on swallowing function
297325|NCT01934972|Other|CR + DCS (D-cycloserine)|CR + DCS
297326|NCT01934972|Other|CR + placebo|CR + placebo
297327|NCT01934959|Drug|Bifico|
297328|NCT01934946|Other|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
297329|NCT01934946|Other|home rehabilitation|6 times home rehabilitation services within 3 months
297330|NCT01934933|Drug|celebrex|
297331|NCT01934933|Drug|Enbrel|
297332|NCT01934933|Drug|Enbrel plus Celebrex|
297333|NCT01934907|Other|Washing of packed RBC by normal saline|
297334|NCT01934894|Drug|cabazitaxel|
297335|NCT01934894|Drug|lapatinib|
297336|NCT01934881|Device|voltage adjustment only|Only voltage will be adjusted in all programming sections.
297337|NCT01934881|Device|Combined parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
297338|NCT01934868|Drug|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
297339|NCT01934868|Drug|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
297340|NCT01934842|Device|TAP20-C|
297341|NCT01934842|Device|SAFE-T-FILL|
297342|NCT01934829|Drug|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .~BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
297343|NCT01934816|Other|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
297344|NCT01934803|Dietary Supplement|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
297345|NCT01934803|Dietary Supplement|Placebo|
297346|NCT01934790|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
297347|NCT01934777|Drug|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
297348|NCT01934777|Drug|placebo pearls|placebo
297349|NCT01934751|Other|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
297350|NCT01934751|Other|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
297351|NCT01934738|Drug|PF-06273340|Tablets, 100 mg TID, 14 days
297352|NCT01934738|Drug|Placebo|Tablets, TID, 14 days
297353|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
297354|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
297355|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
297356|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
297357|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
297358|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
297359|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
297360|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
297361|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
297362|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
297363|NCT01934712|Drug|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
297365|NCT01934699|Device|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
297366|NCT01934699|Device|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
297367|NCT01934686|Other|No treatment given|Patients will fill out a questionnaire by interview.
297368|NCT01934673|Other|No treatment given|Patients will fill out a questionnaire by interview.
297369|NCT01934647|Drug|MK-8892|Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892
297370|NCT01934634|Drug|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
297371|NCT01934634|Drug|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
297372|NCT01934634|Drug|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
297373|NCT01934621|Behavioral|Strategy Training|
297374|NCT01934621|Behavioral|Attention Control|
297375|NCT01934608|Behavioral|Refill synch|
297376|NCT01934595|Dietary Supplement|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
297377|NCT01934582|Drug|UT-15C SR|
297378|NCT01934582|Drug|treprostinil diethanolamine|Open label study drug.
297379|NCT01934569|Drug|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
297380|NCT01934556|Drug|Ranibizumab 0.3 mg intravitreal injection|
297381|NCT01934556|Device|Guided Laser Photocoagulation|
297382|NCT01934543|Other|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
297383|NCT01934543|Other|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
297384|NCT01934530|Procedure|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.~Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
297385|NCT01934504|Procedure|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
297386|NCT01934491|Behavioral|Cognitive Training A|
297387|NCT01934491|Behavioral|Cognitive Training B|
297388|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
297389|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
297390|NCT01934439|Device|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
297391|NCT01934413|Behavioral|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
297392|NCT01934413|Other|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
297393|NCT01934374|Behavioral|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
297394|NCT01934361|Drug|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
297395|NCT01934361|Drug|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
297443|NCT01933997|Drug|Metadoxine (MG01CI )|
297397|NCT01934361|Drug|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
297398|NCT01934348|Behavioral|Psychological First Aid|
297399|NCT01934348|Behavioral|Usual victim advocacy Services|
297400|NCT01934335|Drug|Vandetanib|
297401|NCT01934335|Other|Placebo|
297402|NCT01934322|Other|Case Management|"Furnish specific assistance and to provide referrals for the patients:~If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.~If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.~If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.~In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
297403|NCT01934309|Behavioral|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
297404|NCT01934296|Device|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
297405|NCT01934283|Device|urine folly catheter|
297406|NCT01934270|Other|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
297407|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
297408|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
297409|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
297410|NCT01934244|Device|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
297411|NCT01934231|Drug|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
297412|NCT01934218|Device|Gel-One|
297413|NCT01934218|Device|PBS|
297414|NCT01934205|Drug|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
297415|NCT01934205|Drug|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
297416|NCT01934192|Drug|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
297417|NCT01934192|Drug|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
297418|NCT01934192|Drug|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
297419|NCT01934192|Drug|Placebo IV|Placebo will be administered IV every 6 hours
297420|NCT01934179|Other|cytology specimen collection procedure|Undergo blood sample collection
297421|NCT01934179|Other|laboratory biomarker analysis|Correlative studies
297422|NCT01934179|Other|questionnaire administration|Ancillary studies
297423|NCT01934166|Drug|Nalmefene 18 mg|One single oral dose of 18 mg
297424|NCT01934153|Drug|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
297425|NCT01934140|Biological|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
297426|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
297427|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
297428|NCT01934127|Biological|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
297429|NCT01934101|Drug|CHR-5154|CHR-5154
297430|NCT01934101|Drug|Placebo|Placebo
297431|NCT01934088|Drug|Propofol|
297432|NCT01934088|Drug|Midazolam|
297433|NCT01934088|Drug|Fentanyl|
297434|NCT01934075|Behavioral|Mental health treatment|6 sessions of individual mental health counseling.
297435|NCT01934062|Procedure|Surgery|"All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.~--------------------------------------------------------------------------------"
297436|NCT01934049|Procedure|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
297437|NCT01934049|Drug|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
297438|NCT01934036|Dietary Supplement|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
297439|NCT01934036|Drug|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
297444|NCT01933984|Drug|salmeterol/fluticasone|Each puff contains 25 mcg salmeterol /250 mcg fluticasone
297445|NCT01933984|Drug|ipatropium/salbutamol|Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg
297446|NCT01933984|Drug|Methylprednisolone|
297447|NCT01933984|Drug|Additional broncho-dilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
297448|NCT01933984|Other|Determining personal target airway resistance|Three consecutive doses of 4, 8 and 16 puffs of fenoterol MDI (100 mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15 minutes apart. The airway resistance measured 15 minutes later is assigned as this patient's personal target airway resistance.
297449|NCT01933984|Device|Ventilator support|
297450|NCT01933971|Drug|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
297451|NCT01933971|Drug|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.~Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
297452|NCT01933958|Drug|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
297453|NCT01933945|Procedure|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
297454|NCT01933945|Drug|Sorafenib (Nexavar, BAY43-9006)|
297455|NCT01933932|Drug|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
297456|NCT01933932|Drug|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
297457|NCT01933932|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
297458|NCT01933932|Drug|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
297459|NCT01933919|Drug|Fluvoxamine maleate|Film-coated tablet containing 25 mg of fluvoxamine maleate
297460|NCT01933919|Drug|Placebo|Placebo tablet matching to fluvoxamine maleate
297461|NCT01933906|Drug|P1101|
297462|NCT01933880|Drug|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
297463|NCT01933880|Other|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
297464|NCT01933867|Procedure|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
297465|NCT01933867|Procedure|Air insufflation insertion|
297466|NCT01933841|Device|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
297467|NCT01933841|Procedure|Notify the provider|"Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio."
297468|NCT01933828|Procedure|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
297469|NCT01933828|Procedure|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
297470|NCT01933828|Device|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
297471|NCT01933815|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
297472|NCT01933815|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
297473|NCT01933802|Biological|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
297474|NCT01933789|Behavioral|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
297475|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
297476|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
297477|NCT01933763|Drug|REGN1193|
297478|NCT01933763|Other|Placebo|
297479|NCT01933750|Device|PresVIEW Device Implantation|
297571|NCT01933035|Other|Immune Thrombocytopenics|Full blood count with extended platelet parameters
297480|NCT01933737|Device|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
297481|NCT01933737|Device|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
297482|NCT01933724|Drug|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
297483|NCT01933724|Drug|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
297484|NCT01933711|Drug|rituximab|
297485|NCT01933698|Drug|amoxicillin|Comparison of pharmacokinetics of both formulations
297486|NCT01933685|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
297487|NCT01933685|Biological|AIDSVAX B/E Placebo|1 mL per injection
297488|NCT01933672|Drug|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
297489|NCT01933672|Drug|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
297490|NCT01933672|Drug|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
297491|NCT01933659|Drug|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
297492|NCT01933633|Behavioral|Exercise|
297493|NCT01933607|Device|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
297494|NCT01933594|Drug|Romidepsin|RMD administered over 4 hours via an intravenous (IV) catheter.
297495|NCT01933594|Drug|Placebo for Romidepsin|Placebo for RMD administered over 4 hours via an IV catheter.
297496|NCT01933568|Radiation|SABR|combined CFRT and SABR with concurrent cisplatin
297497|NCT01933568|Drug|Cisplatin|combined CFRT and SABR with concurrent cisplatin
297498|NCT01933555|Behavioral|Empowerment Program|
297499|NCT01933542|Drug|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
297500|NCT01933542|Drug|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
297501|NCT01933542|Drug|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
297502|NCT01933542|Drug|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
297503|NCT01933529|Drug|ARA 290|ARA 290 is injected s.c. once daily during the study period
297504|NCT01933516|Drug|GP2013|GP2013
297505|NCT01933503|Drug|OCA 5 mg|
297506|NCT01933503|Drug|OCA 10 mg|
297507|NCT01933503|Drug|OCA 25 mg|
297508|NCT01933490|Other|high carbohydrate test meal|
297509|NCT01933490|Other|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
297510|NCT01933490|Other|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
297511|NCT01933477|Other|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
297512|NCT01933464|Drug|Cromolyn Sodium|
297513|NCT01933464|Drug|Normal Saline|
297514|NCT01933451|Other|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
297515|NCT01933438|Other|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
297516|NCT01933438|Other|Control|Standard treatment
297517|NCT01933425|Drug|rocuronium|
297518|NCT01933425|Drug|sugammadex|
297519|NCT01933425|Drug|placebo|
297520|NCT01933412|Biological|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
297521|NCT01933412|Biological|Engerix B Hepatitis B Vaccine|
297522|NCT01933399|Other|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
297523|NCT01933399|Other|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
297524|NCT01933399|Other|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
297525|NCT01933386|Device|SoundBite|Non-surgical removable bone conduction device via the teeth.
297526|NCT01933373|Procedure|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
297527|NCT01933373|Procedure|Dor|Anterior partial fundoplication plus myotomy.
297528|NCT01933360|Drug|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
297529|NCT01933360|Drug|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
297530|NCT01933360|Drug|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
297531|NCT01933360|Drug|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
297532|NCT01933360|Drug|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
297533|NCT01933360|Drug|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
297534|NCT01933360|Drug|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
297535|NCT01933360|Drug|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
297536|NCT01933347|Drug|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
297572|NCT01933035|Other|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
297573|NCT01933035|Other|Control Population|Full blood count with extended platelet parameters
297537|NCT01933334|Drug|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
297538|NCT01933321|Biological|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
297539|NCT01933308|Other|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
297540|NCT01933308|Other|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
297541|NCT01933308|Other|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
297542|NCT01933295|Behavioral|Cognitive Behavioral Therapy for Insomnia|
297543|NCT01933295|Behavioral|Sleep Education|
297544|NCT01933295|Behavioral|Sleep Restriction Therapy|
297545|NCT01933282|Drug|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
297546|NCT01933282|Drug|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
297547|NCT01933269|Drug|FACBC|
297548|NCT01933256|Drug|HIP2B|
297549|NCT01933256|Drug|Placebo|
297550|NCT01933243|Drug|Fish oil|Participants will take 4 capsules daily
297551|NCT01933243|Drug|Placebo pill|Participants will take 4 capsules daily
297552|NCT01933230|Device|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.~2 hour neck cooling period"
297553|NCT01933217|Drug|Methylphenidate|
297554|NCT01933217|Drug|Placebo|
297555|NCT01933204|Other|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
297556|NCT01933204|Drug|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
297557|NCT01933191|Behavioral|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
297558|NCT01933191|Behavioral|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
297559|NCT01933178|Device|Cirrus AS-OCT|
297560|NCT01933165|Device|LipiView|
297561|NCT01933152|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
297562|NCT01933139|Other|Audio-visual presentation|
297563|NCT01933126|Drug|HCG injection|
297564|NCT01933126|Drug|Placebo|
297565|NCT01933113|Device|Deep Brain Stimulation of the Lateral Hypothalamic Area|Deep Brain Stimulation of the Lateral Hypothalamic Area
297566|NCT01933100|Other|Experimental Diet|Macronutrient composition of experimental diet were carbohydrate 55~70%, protein 7~20%, fat 15~25%, fiber provided by the experimental diet was designed to adequate intake 20g/day for women
297567|NCT01933087|Behavioral|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
297568|NCT01933061|Drug|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
297569|NCT01933061|Drug|Abraxane|Abraxane 150 mg/m^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
297570|NCT01933048|Drug|FluMist|FluMist Intranasal Vaccine
297575|NCT01932996|Drug|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
297576|NCT01932996|Behavioral|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
297577|NCT01932983|Device|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
297578|NCT01932970|Drug|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
297579|NCT01932957|Procedure|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
297580|NCT01932957|Procedure|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
297581|NCT01932944|Device|No treatment|
297582|NCT01932931|Dietary Supplement|cholecalciferol (50ug)|The aim of the study was to investigate the effect of high dose vitamin D3 supplementation on the muscoloskeletal system among patients treated with antidepressants due to a diagnosis of major depressive disorder
297583|NCT01932918|Drug|Patient controlled analgesia|"PCA with morphine in liver transplant:~Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~PCA with morphine and ketorolac:~Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
297584|NCT01932905|Device|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
297585|NCT01932879|Other|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
297586|NCT01932879|Other|Jello|
297587|NCT01932866|Other|diabetic risk score|
297588|NCT01932840|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
297589|NCT01932827|Behavioral|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
297590|NCT01932801|Drug|XR-NTX+HRC|
297591|NCT01932801|Other|Placebo+HRC|
297592|NCT01932801|Behavioral|HRC|
297593|NCT01932788|Drug|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
297594|NCT01932788|Drug|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
297595|NCT01932775|Device|GlucoTab System|
297596|NCT01932762|Drug|Grazoprevir|100 mg every day (QD) orally
297597|NCT01932762|Drug|Elbasvir|50 mg QD orally
297598|NCT01932762|Drug|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
297599|NCT01932749|Device|Transcranial Magnetic stimulation|
297600|NCT01932736|Other|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
297601|NCT01932723|Behavioral|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
297602|NCT01932710|Procedure|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
297603|NCT01932697|Drug|Docetaxel|Given IV
297604|NCT01932697|Radiation|Hyperfractionation|Undergo hyperfractionated IMRT
297605|NCT01932697|Radiation|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
297606|NCT01932697|Other|Laboratory Biomarker Analysis|Correlative studies
297607|NCT01932697|Other|Quality-of-Life Assessment|Ancillary studies
297608|NCT01932684|Other|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
297609|NCT01932684|Other|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
297610|NCT01932684|Device|5000 Voldyne ® Sherwood Medical, USA|
297611|NCT01932684|Device|Silicone face mask|
297612|NCT01932658|Biological|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
297613|NCT01932632|Other|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
297722|NCT01931709|Device|positron emission tomography|Undergo FDG PET
297614|NCT01932606|Drug|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
297615|NCT01932606|Drug|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
297616|NCT01932593|Procedure|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
297617|NCT01932580|Drug|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
297618|NCT01932567|Other|Physiotherapy|
297619|NCT01932567|Procedure|Electrical impedance tomography|
297620|NCT01932554|Drug|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
297621|NCT01932554|Drug|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
297622|NCT01932554|Other|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
297623|NCT01932554|Drug|Ibuprofen|Scheduled ibuprofen,~10 mg/kg every 6-8 hours
297624|NCT01932554|Drug|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
297625|NCT01932554|Other|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
297626|NCT01932554|Other|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
297627|NCT01932541|Drug|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
297628|NCT01932528|Drug|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as [14C]-LX1606.
297629|NCT01932515|Behavioral|A revised screening instrument for use in Deaf children|
297630|NCT01932502|Drug|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:~Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.~Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.~Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.~Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.~The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.~Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
297631|NCT01932502|Drug|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
297632|NCT01932502|Drug|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:~Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
297633|NCT01932502|Drug|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
297634|NCT01932502|Drug|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
297635|NCT01932489|Procedure|Biopsy of a metastatic lesion.|
297636|NCT01932476|Dietary Supplement|Gluten Challenge|Three-day gluten containing dietary challenge.
297637|NCT01932476|Dietary Supplement|Sham Challenge|Three-day sham (gluten free) dietary challenge
297638|NCT01932463|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
297639|NCT01932450|Procedure|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
297640|NCT01932450|Drug|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
297641|NCT01932437|Biological|ETI-204|monoclonal antibody
297642|NCT01932437|Other|Placebo|Placebo for ETI-204
297643|NCT01932424|Device|Pelorus 1500|a bedside blood propofol measurement device
297644|NCT01932424|Drug|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
297645|NCT01932385|Drug|Sorafenib|
297646|NCT01932385|Other|Best Supportive Care|
297647|NCT01932372|Drug|Tofacitinib (Xeljanz)|5 mg Tablet BID
297648|NCT01932372|Drug|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
297649|NCT01932359|Other|rapidly absorbable suture (Vicryl Rapide)|
297650|NCT01932359|Other|non-absorbable suture (Ethilon)|
297651|NCT01932333|Drug|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
297652|NCT01932333|Drug|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
297653|NCT01932333|Drug|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
297685|NCT01932086|Dietary Supplement|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
297654|NCT01932320|Drug|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
297655|NCT01932320|Drug|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
297656|NCT01932320|Drug|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
297657|NCT01932320|Drug|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
297658|NCT01932307|Procedure|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
297659|NCT01932281|Dietary Supplement|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
297660|NCT01932281|Dietary Supplement|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
297661|NCT01932268|Drug|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
297662|NCT01932255|Procedure|prophylactic spinal tap|
297663|NCT01932255|Procedure|no prophylactic spinal tap|
297664|NCT01932242|Biological|ETI-204|Monoclonal Antibody
297665|NCT01932242|Other|Placebo|Placebo for ETI-204
297666|NCT01932229|Drug|Afatinib treatment|
297667|NCT01932216|Procedure|Cholecystectomy|Gallbladder removal
297668|NCT01932203|Drug|aspirin|100mg once a day
297669|NCT01932203|Drug|cilostazol|200mg once a day
297670|NCT01932190|Procedure|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
297671|NCT01932190|Procedure|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
297672|NCT01932177|Drug|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
297673|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
297674|NCT01932177|Drug|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
297675|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
297676|NCT01932164|Procedure|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
297677|NCT01932164|Procedure|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
297678|NCT01932151|Drug|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.~In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
297679|NCT01932138|Other|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
297680|NCT01932138|Other|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
297681|NCT01932112|Drug|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
297682|NCT01932099|Device|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
297683|NCT01932086|Dietary Supplement|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
297684|NCT01932086|Dietary Supplement|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
297721|NCT01931709|Radiation|fludeoxyglucose F 18|Undergo FDG PET
297686|NCT01932086|Dietary Supplement|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
297687|NCT01932086|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
297688|NCT01932073|Device|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
297689|NCT01932060|Drug|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
297690|NCT01932034|Device|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
297691|NCT01932021|Procedure|adipose tissue grafting|
297692|NCT01931995|Device|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
297693|NCT01931995|Procedure|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
297694|NCT01931982|Drug|Victoza|
297695|NCT01931956|Device|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
297696|NCT01931943|Drug|selatinib ditosilate tablets|
297697|NCT01931930|Dietary Supplement|Perilla extract|
297698|NCT01931930|Dietary Supplement|Maltodextrin|
297699|NCT01931917|Behavioral|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
297700|NCT01931917|Behavioral|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
297701|NCT01931878|Drug|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
297702|NCT01931878|Drug|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
297703|NCT01931865|Drug|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
297704|NCT01931852|Procedure|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
297705|NCT01931852|Other|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
297706|NCT01931839|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
297707|NCT01931839|Drug|Ivacaftor|Film-coated tablet, oral use
297708|NCT01931826|Procedure|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
297709|NCT01931826|Procedure|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
297710|NCT01931800|Biological|Sampling of blood|
297711|NCT01931787|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
297712|NCT01931761|Drug|[C14] selumetinib (oral)|Single oral administration [C14] 75mg
297713|NCT01931748|Drug|MELSMON|
297714|NCT01931748|Drug|UNCNT|
297715|NCT01931735|Procedure|Randomized Meniscectomy|Arthroscopic meniscectomy
297716|NCT01931735|Procedure|Randomized Lavage|Arthroscopic Lavage
297717|NCT01931735|Procedure|Standard of Care Meniscectomy Pre-Amend|Arthroscopic meniscectomy
297718|NCT01931735|Procedure|Standard of Care Meniscectomy Post-Amend|Arthroscopic meniscectomy
297719|NCT01931722|Dietary Supplement|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
297720|NCT01931722|Behavioral|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
297723|NCT01931709|Device|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
297724|NCT01931709|Other|laboratory biomarker analysis|Correlative studies
297725|NCT01931696|Device|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
297726|NCT01931696|Device|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
297727|NCT01931683|Drug|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
297728|NCT01931683|Device|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
297729|NCT01931670|Other|placebo|
297730|NCT01931670|Drug|Elagolix|
297731|NCT01931657|Drug|Mifepristone prior to Mirena|
297732|NCT01931657|Drug|Placebo prior to Mirena insertion|
297733|NCT01931631|Behavioral|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
297734|NCT01931631|Behavioral|ADA diet|Diet in accordance with the American Diabetes Association
297735|NCT01931618|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
297736|NCT01931618|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
297737|NCT01931618|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
297738|NCT01931605|Device|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
297739|NCT01931592|Drug|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
297740|NCT01931592|Drug|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
297741|NCT01931579|Device|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
297742|NCT01931566|Drug|Pioglitazone|Pioglitazone SR tablets
297743|NCT01931566|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets
297744|NCT01931553|Other|Standardized attending morning rounds|
297745|NCT01931540|Behavioral|Exercise Training|Three times a week, for four months.
297746|NCT01931527|Drug|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
297747|NCT01931514|Drug|Torrent's Montelukast Sodium chewable Tablets 5mg|
297748|NCT01931514|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
297749|NCT01931501|Drug|Torrent's Montelukast Sodium Chewable Tablets 5mg|
297750|NCT01931501|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
297751|NCT01931488|Other|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
297752|NCT01931488|Device|SPECT imaging|
297753|NCT01931475|Drug|Duloxetine|Administered orally
297754|NCT01931475|Drug|Placebo|Administered orally
297755|NCT01931462|Device|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
297756|NCT01931449|Procedure|Modified method of digestive tract reconstruction|
297757|NCT01931449|Procedure|Routine digestive tract reconstruction|
297758|NCT01931436|Drug|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
297759|NCT01931423|Behavioral|Placental cord drainage|
297760|NCT01931410|Drug|Misoprostol|
297761|NCT01931384|Drug|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
297762|NCT01931384|Drug|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
297763|NCT01931371|Procedure|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
297764|NCT01931371|Procedure|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
297765|NCT01931358|Biological|ALVAC-HIV|1 mL intramuscular injection containing 10^6 CCID50/dose
297766|NCT01931358|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
297767|NCT01931358|Biological|ALVAC-HIV Placebo|1 mL per injection
297768|NCT01931358|Biological|AIDSVAX B/E Placebo|1 mL per injection
297769|NCT01931345|Behavioral|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
297770|NCT01931345|Behavioral|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
297771|NCT01931332|Procedure|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
297772|NCT01931332|Procedure|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
297773|NCT01931319|Drug|Intravenous baclofen|
297774|NCT01931306|Drug|Afatinib|BIBW2992 low to medium dose once daily
297775|NCT01931293|Dietary Supplement|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
297776|NCT01931280|Behavioral|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
297777|NCT01931267|Behavioral|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
297778|NCT01931267|Behavioral|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
297779|NCT01931241|Drug|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
297780|NCT01931228|Procedure|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
297781|NCT01931228|Procedure|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
297782|NCT01931215|Other|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
297783|NCT01931215|Other|TAP-block with ropivacaine and clonidine|
297784|NCT01931202|Drug|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
297785|NCT01931189|Biological|NI-071|100mg/vial
297786|NCT01931189|Biological|Infliximab|100mg/vial
297787|NCT01931176|Biological|rDEN2Δ30-7169 vaccine|Administered at a dose of 10^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
297788|NCT01931176|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
297789|NCT01931163|Drug|Everolimus|
297790|NCT01931150|Drug|Topical Dapsone 5% Gel|
297791|NCT01931150|Other|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
297792|NCT01931150|Drug|oral antibiotics|
297793|NCT01931137|Drug|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
297794|NCT01931124|Behavioral|High Intensity Training|
297795|NCT01931124|Behavioral|Moderate Intensity Training|
297796|NCT01931098|Drug|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
297797|NCT01931098|Drug|pazopanib|600 mg orally, daily until progression, up to one year.
297798|NCT01931085|Drug|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
297799|NCT01931072|Behavioral|High-intensity interval training|Interval training 3 times a week for 8 weeks
297800|NCT01931072|Behavioral|Moderate training|Moderate training 3 times a week for 8 weeks
297801|NCT01931059|Drug|Risperidone|We gave oral liquid of risperidone one time 1-2 mg depending on subject's weight.
297802|NCT01931059|Other|Placebo|We gave oral liquid without active risperidone (pt and provider were both double blinded)
297803|NCT01931046|Drug|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
297804|NCT01931033|Drug|Intranasal Oxytocin|
297805|NCT01931020|Drug|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
298131|NCT01928615|Drug|Chemotherapy|Standard chemotherapy for early breast cancer.
297806|NCT01931020|Drug|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
297807|NCT01931007|Drug|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
297808|NCT01931007|Drug|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
297809|NCT01930955|Drug|Amoxicillin|β-lactam antibiotics
297810|NCT01930942|Radiation|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
297811|NCT01930929|Procedure|Bariatric surgery|
297812|NCT01930916|Device|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
297813|NCT01930916|Other|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
297814|NCT01930903|Device|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
297815|NCT01930890|Biological|BIIB023|
297816|NCT01930890|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
297817|NCT01930890|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
297818|NCT01930877|Drug|Lidocaine|Lidocaine iv bolus followed by infusion
297819|NCT01930877|Other|Placebo (normal saline)|Normal saline bolus followed by infusion
297820|NCT01930864|Drug|metformin|metformin up to 2500mg/d
297821|NCT01930864|Drug|irinotecan|Irinotecan 350 mg/m² IV q21d
297822|NCT01930851|Procedure|Gastric bypass operation|
297823|NCT01930838|Procedure|Gastric bypass operation|
297824|NCT01930812|Procedure|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
297825|NCT01930812|Procedure|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
297826|NCT01930812|Drug|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
297827|NCT01930799|Behavioral|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
297828|NCT01930786|Drug|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
297829|NCT01930773|Device|Genotyping|Patients harboring CYP2C19 *2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
297830|NCT01930773|Device|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
297831|NCT01930760|Behavioral|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
297832|NCT01930760|Behavioral|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
297833|NCT01930747|Drug|rocuronium|measure effect on laparoscopic workspace
297834|NCT01930747|Drug|Sevoflurane|1 MAC sevoflurane inhalation is given
297835|NCT01930747|Drug|remifentanyl|remifentanyl is given in infusion
297836|NCT01930734|Drug|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
297837|NCT01930734|Drug|Normal Saline|Normal Saline solution 0.9% Placebo Arm
297838|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 60 degrees.
297839|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
297840|NCT01930708|Drug|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
297841|NCT01930682|Drug|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
298284|NCT01927523|Other|Match|An intensive math tutoring program.
297842|NCT01930682|Procedure|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
297843|NCT01930682|Procedure|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
297844|NCT01930669|Other|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.~Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.~MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
297845|NCT01930643|Device|EMS|HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
297846|NCT01930630|Device|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
297847|NCT01930617|Procedure|Burr hole surgery with various drainage techniques|"Surgical technique~Continuous irrigation and drainage~Passive subdural drain~Active subgaleal drain"
297848|NCT01930604|Drug|Botox (onabotulinumtoxinA)|
297849|NCT01930604|Drug|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
297850|NCT01930604|Drug|NaCl (placebo)|
297851|NCT01930591|Drug|Ticagrelor|180 mg bolus followed by 90 mg BID
297852|NCT01930591|Drug|Clopidogrel|300 mg bolus followed by 75 mg OD
297853|NCT01930578|Other|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
297854|NCT01930578|Other|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
297855|NCT01930578|Other|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.~An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
297856|NCT01930565|Other|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
297857|NCT01930565|Other|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
297858|NCT01930552|Drug|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
297859|NCT01930552|Drug|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
297860|NCT01930552|Drug|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
297861|NCT01930552|Drug|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
297862|NCT01930539|Device|Ultraviolet B lamp|Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
297863|NCT01930526|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
297864|NCT01930500|Behavioral|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
297865|NCT01930500|Behavioral|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
297866|NCT01930487|Dietary Supplement|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
297867|NCT01930487|Dietary Supplement|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
297868|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
297869|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
297870|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
297871|NCT01930461|Biological|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
297872|NCT01930435|Device|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
297873|NCT01930422|Device|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
297874|NCT01930422|Device|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
297875|NCT01930409|Behavioral|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:~Health Status~Medication Management~Activity/Exercise Prescription and Goal-Setting~Falls Prevention~Clarification of Appointments~Coordination of Post-Discharge Home Services~What To Do If a Problem Arises"
297876|NCT01930409|Behavioral|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
297877|NCT01930396|Drug|Tinzaparin|
297878|NCT01930396|Drug|Unfractionated Heparin|
297879|NCT01930396|Drug|Placebo (for Tinzaparin)|0.9% Normal Saline
297880|NCT01930396|Drug|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
297881|NCT01930370|Drug|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
297882|NCT01930370|Drug|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
297883|NCT01930357|Biological|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
297884|NCT01930357|Biological|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
297885|NCT01930344|Device|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
297886|NCT01930344|Device|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
297887|NCT01930331|Drug|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
297888|NCT01930331|Drug|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
297889|NCT01930318|Drug|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
297890|NCT01930292|Drug|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
297891|NCT01930292|Drug|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
297892|NCT01930292|Drug|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
297893|NCT01930292|Drug|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
297894|NCT01930279|Other|Blood withdrawal|Blood withdrawal
297895|NCT01930266|Dietary Supplement|Experimental|
297896|NCT01930266|Behavioral|Active comparator|
297897|NCT01930253|Drug|Bortezomib|
297898|NCT01930240|Drug|TRIA-662|1-MNA Chloride
297899|NCT01930240|Drug|Placebo|Double-blind placebo
297900|NCT01930227|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
297901|NCT01930227|Other|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
297902|NCT01930214|Device|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
297903|NCT01930201|Procedure|Caudal epidural block|
297904|NCT01930201|Other|General anesthesia|
297905|NCT01930188|Drug|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
297906|NCT01930188|Drug|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
297907|NCT01930188|Drug|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
297908|NCT01930188|Drug|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
297909|NCT01930175|Drug|VAY736|VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner.
297910|NCT01930175|Drug|Placebo to VAY736|Placebo to VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner. All patients that receive placebo will be offered open-label VAY736.
297911|NCT01930175|Drug|VAY736|VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner, following a safety review.
297912|NCT01930162|Drug|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
298285|NCT01927510|Behavioral|Early mobilisation|
297913|NCT01930149|Behavioral|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
297914|NCT01930136|Behavioral|Calorie restriction (25%)|
297915|NCT01930136|Behavioral|Ad libitum health diet|
297916|NCT01930123|Other|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have a standard of care , liver biopsy followed by , and co-localization of liver biopsy with MR."
297917|NCT01930110|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
297918|NCT01930110|Other|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
297919|NCT01930097|Other|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
297920|NCT01930084|Other|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
297921|NCT01930084|Other|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
297922|NCT01930084|Behavioral|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
297923|NCT01930084|Other|Non-cash Financial Incentives|Non-cash Financial Incentives
297924|NCT01930071|Device|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
297925|NCT01930058|Drug|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
297926|NCT01930045|Drug|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
297927|NCT01930045|Drug|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
297928|NCT01930019|Drug|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
297929|NCT01930006|Drug|MGCD265|
297930|NCT01929993|Procedure|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
297931|NCT01929993|Procedure|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
297932|NCT01929980|Drug|Bortezomib|
297933|NCT01929954|Biological|Gintuit|One time placement of Gintuit over socket graft.
297934|NCT01929954|Device|Bio-Gide|One time placement of Bio-Gide over socket graft.
297935|NCT01929941|Drug|INCB047986|Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
297936|NCT01929941|Drug|INCB047986|INCB047986 tablets administered orally at the protocol specified dose and frequency
297937|NCT01929941|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
297938|NCT01929941|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
297939|NCT01929915|Procedure|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
297940|NCT01929915|Drug|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
297941|NCT01929889|Drug|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
297942|NCT01929876|Drug|Cobimetinib|10 milligram (mg) (2* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
297943|NCT01929876|Drug|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
297944|NCT01929863|Drug|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID [45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period]
297945|NCT01929863|Drug|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
297946|NCT01929863|Drug|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
297947|NCT01929850|Procedure|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
297948|NCT01929850|Behavioral|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
297949|NCT01929837|Device|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
297950|NCT01929837|Device|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
297951|NCT01929837|Device|sham E-field navigated rTMS|
297952|NCT01929837|Device|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
297953|NCT01929824|Other|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
297954|NCT01929811|Drug|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
297955|NCT01929811|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
297956|NCT01929811|Drug|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
297957|NCT01929811|Drug|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
297958|NCT01929798|Device|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
297959|NCT01929759|Drug|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
297960|NCT01929746|Biological|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
297961|NCT01929720|Behavioral|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
297962|NCT01929707|Drug|LY3050258|
297963|NCT01929707|Drug|Placebo|
297964|NCT01929694|Dietary Supplement|Berocca Boost|
297965|NCT01929694|Dietary Supplement|Placebo|
297966|NCT01929681|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
297967|NCT01929668|Drug|polyethylene glycol|
297968|NCT01929668|Drug|Ascorbic Acid|
297969|NCT01929655|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
297970|NCT01929642|Drug|Sirolimus|
297971|NCT01929642|Drug|Everolimus|
297972|NCT01929629|Drug|Part A|Single ascending doses
297973|NCT01929629|Drug|Part B|Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
297974|NCT01929616|Drug|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
297975|NCT01929603|Procedure|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
297976|NCT01929603|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
297977|NCT01929603|Drug|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
297978|NCT01929590|Drug|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
297979|NCT01929590|Drug|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
297980|NCT01929590|Drug|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
297981|NCT01929577|Drug|ASP015K|oral tablet
297982|NCT01929564|Other|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
297983|NCT01929564|Other|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
297984|NCT01929551|Other|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
297985|NCT01929551|Other|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
297986|NCT01929551|Other|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
297987|NCT01929551|Other|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
297988|NCT01929551|Other|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
297989|NCT01929551|Other|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
297990|NCT01929551|Other|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
297991|NCT01929538|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
297992|NCT01929538|Device|covered self-expanding biliary metal stent, 12mm in diameter|
297993|NCT01929538|Device|covered self-expanding biliary metal stent, 10mm in diameter|
297994|NCT01929512|Drug|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
297995|NCT01929512|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
298417|NCT01926314|Device|PHENIX Neuromuscular Stimulation Therapy System device|
297996|NCT01929512|Drug|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
297997|NCT01929499|Biological|cytokine-induced killer cells|
297998|NCT01929486|Biological|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
297999|NCT01929460|Drug|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
298000|NCT01929460|Other|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
298001|NCT01929434|Other|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
298002|NCT01929434|Biological|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
298003|NCT01929421|Drug|Gemcitabine/S-1|
298004|NCT01929395|Device|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
298005|NCT01929382|Drug|interferon gamma 1b|Standard therapy vs dose titration
298006|NCT01929356|Procedure|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
298007|NCT01929343|Drug|lidocaine following cue-induced craving|as described in Arm Description
298008|NCT01929343|Drug|lidocaine following neutral stimulus|as described in Arm Description
298009|NCT01929343|Drug|saline|as described in Arm Description
298010|NCT01929330|Drug|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
298011|NCT01929330|Drug|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
298012|NCT01929317|Drug|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
298013|NCT01929317|Drug|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
298014|NCT01929317|Drug|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
298015|NCT01929304|Other|Survey|
298016|NCT01929291|Biological|Boostrix|Single intramuscular injection
298017|NCT01929291|Other|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
298018|NCT01929278|Drug|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
298019|NCT01929278|Other|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
298020|NCT01929278|Other|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril [approximately 2 cm x 2 cm]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
298021|NCT01929265|Drug|Bendamustine|"INDUCTION PHASE~Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):~Rituximab: 375 mg/sqm iv, day 1*~Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice~Repeat cycles every 28 days for a total of 4 cycles~*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.~CONSOLIDATION PHASE~Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):~Rituximab: 375 mg/sqm iv day 1~Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice~Rituximab two monthly doses~Rituximab: 375 mg/sqm iv week 24 and 28"
298022|NCT01929252|Drug|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
298023|NCT01929252|Drug|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
298024|NCT01929239|Drug|Anti-PSMA Designer T Cells|
298025|NCT01929226|Biological|ETI-204|Monoclonal Antibody
298026|NCT01929226|Other|Placebo|Placebo for ETI-204
298027|NCT01929213|Drug|Udenafil|Udenafil is administered
298028|NCT01929213|Drug|Bosentan|Bosentan is administered
298029|NCT01929213|Drug|Udenafil/Bosentan|Udenafil and Bosentan are administered
298030|NCT01929200|Drug|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
298031|NCT01929200|Drug|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
298032|NCT01929187|Drug|Phytonail|
298033|NCT01929187|Drug|Loceryl|
298034|NCT01929161|Drug|Oxytocin|24 International Units
298035|NCT01929161|Drug|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
298036|NCT01929161|Behavioral|Lovingkindness Meditation|
298037|NCT01929161|Behavioral|Mindfulness Meditation|
298038|NCT01929148|Procedure|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
298039|NCT01929148|Procedure|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
298040|NCT01929135|Drug|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
298041|NCT01929135|Drug|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
298042|NCT01929122|Dietary Supplement|Placebo-Control Meals and Snacks|
298043|NCT01929122|Dietary Supplement|Cooked Navy Bean Powder Meals and Snacks|
298044|NCT01929122|Dietary Supplement|Rice Bran Meals and Snacks|
298045|NCT01929109|Drug|LY2409021|Administered orally
298046|NCT01929096|Drug|Compound Edaravone Injection|
298047|NCT01929096|Drug|Edaravone Injection|
298048|NCT01929083|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
298049|NCT01929083|Drug|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
298050|NCT01929083|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
298051|NCT01929070|Drug|HCP1007|
298052|NCT01929070|Drug|Omarco and Crestor|
298053|NCT01929057|Procedure|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
298054|NCT01929057|Procedure|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
298055|NCT01929044|Drug|654-II (anisodamine)|10mg injection
298056|NCT01929044|Drug|Buscopan® (hyoscine butylbromide)|20mg injection
298057|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
298058|NCT01929031|Drug|ibuprofen|tablet.
298059|NCT01929031|Drug|ibuprofen|tablet
298060|NCT01929031|Drug|caffeine|tablet
298061|NCT01929031|Drug|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
298062|NCT01929031|Drug|placebo|tablet
298063|NCT01929031|Drug|placebo|tablet
298064|NCT01929031|Drug|caffeine|tablet
298065|NCT01929031|Drug|ibuprofen|tablet
298066|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
298067|NCT01929018|Behavioral|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
298068|NCT01929018|Behavioral|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
298069|NCT01929018|Behavioral|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
298070|NCT01929005|Other|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
298071|NCT01928992|Device|3D|subjects that underwent 3D mammography
298072|NCT01928992|Device|2D|those subjects that underwent 2D mammography
298073|NCT01928979|Other|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
298074|NCT01928966|Other|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
298075|NCT01928940|Drug|dabrafenib|150 mg twice daily
298076|NCT01928940|Drug|trametinib|2 mg once daily
298077|NCT01928927|Drug|Telmisartan|
298078|NCT01928914|Drug|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
298079|NCT01928914|Drug|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
298080|NCT01928914|Drug|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
298081|NCT01928914|Drug|moxifloxacin|moxifloxacine given on Day 3 only
298082|NCT01928914|Drug|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
298083|NCT01928914|Drug|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
298084|NCT01928901|Drug|administration of Sinupret|
298085|NCT01928901|Drug|administration of Bronchipret|
298086|NCT01928901|Drug|administration of Sinupret Placebo|
298087|NCT01928901|Drug|administration of Bronchipret Placebo|
298088|NCT01928888|Drug|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
298089|NCT01928888|Drug|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
298090|NCT01928888|Drug|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
298091|NCT01928875|Device|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
298092|NCT01928875|Device|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
298093|NCT01928862|Drug|Prepopik® ½ Sachet x 2 (9-12 years)|
298094|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (9-12 years)|
298095|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
298096|NCT01928862|Drug|Prepopik® 1 Sachet x 2 (13-16 years)|
298097|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
298130|NCT01928615|Drug|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
298098|NCT01928849|Drug|Valproic Acid|"Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital."
298099|NCT01928849|Other|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
298100|NCT01928823|Behavioral|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
298101|NCT01928823|Drug|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
298102|NCT01928810|Behavioral|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
298103|NCT01928797|Device|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
298104|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
298105|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
298106|NCT01928771|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
298107|NCT01928771|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
298108|NCT01928758|Drug|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
298109|NCT01928758|Drug|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
298110|NCT01928732|Behavioral|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
298111|NCT01928732|Behavioral|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
298112|NCT01928719|Drug|Reduced Nicotine Content Cigarettes|Cigarettes contain 11.6, 7.4, 3.3, 1.4, 0.7, and 0.2 mg nicotine per cigarette
298113|NCT01928719|Drug|Same Nicotine Content Cigarettes|about 11.6 mg nicotine per cigarette
298114|NCT01928706|Other|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
298115|NCT01928706|Other|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
298116|NCT01928693|Drug|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
298117|NCT01928693|Drug|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
298118|NCT01928693|Drug|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
298119|NCT01928680|Drug|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
298120|NCT01928667|Other|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
298121|NCT01928654|Device|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
298122|NCT01928654|Device|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
298123|NCT01928628|Drug|Lercanidipine 10mg|
298124|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg|
298125|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg|
298126|NCT01928628|Drug|Lercanidipin 10mg Placebo|
298127|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg Placebo|
298128|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg Placebo|
298129|NCT01928615|Drug|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
298132|NCT01928602|Behavioral|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, & adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
298133|NCT01928602|Behavioral|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
298134|NCT01928589|Radiation|PBI with sequential chemotherapy|270 cGy x15
298135|NCT01928589|Other|PBI with concurrent chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
298136|NCT01928576|Drug|Azacitidine|
298137|NCT01928576|Drug|Entinostat|
298138|NCT01928576|Drug|Nivolumab|
298139|NCT01928563|Drug|Dapoxetine|
298140|NCT01928563|Drug|Udenafil|
298141|NCT01928563|Drug|Udenafil+Dapoxetine|
298142|NCT01928537|Drug|rigosertib sodium|
298143|NCT01928524|Drug|DOS2W|Docetaxel (30-35 mg/m2), Oxaliplatin (70 mg/m2) and S1 (30-50 mg/2) will be given every 2nd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered
298144|NCT01928524|Drug|DOS3W|Docetaxel (25 mg/m2), Oxaliplatin (100 mg/m2) and S1 (40-60 mg/2) will be given every 3rd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered
298145|NCT01928511|Drug|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
298146|NCT01928511|Drug|Nucleos(t)ide analogue therapy|
298147|NCT01928498|Device|Paclitaxel Eluting Balloon Angioplasty|
298148|NCT01928498|Device|Percutaneous Transluminal Angioplasty (PTA)|
298149|NCT01928485|Other|active surveillance|Undergo active surveillance
298150|NCT01928485|Drug|Sunphenon|Given PO
298151|NCT01928485|Other|laboratory biomarker analysis|Correlative studies
298152|NCT01928485|Other|Questionnaire Administration|Ancillary studies
298153|NCT01928472|Biological|H7N9c low dose with adjuvant|
298154|NCT01928472|Biological|H7N9c medium dose with adjuvant|
298155|NCT01928472|Biological|H7N9c high dose with adjuvant|
298156|NCT01928472|Biological|H7N9c high dose without adjuvant|
298157|NCT01928459|Drug|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
298158|NCT01928459|Drug|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
298159|NCT01928446|Drug|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
298160|NCT01928446|Drug|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
298161|NCT01928433|Drug|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
298162|NCT01928433|Drug|Finafloxacin placebo i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
298163|NCT01928433|Drug|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
298164|NCT01928433|Drug|Finafloxacin placebo tablets once daily|Administered as four tablets
298165|NCT01928433|Drug|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
298166|NCT01928433|Drug|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
298167|NCT01928433|Drug|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
298168|NCT01928433|Drug|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
298169|NCT01928420|Drug|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
298170|NCT01928420|Drug|Placebo|Subjects with Alzheimer's Disease placebo comparator
298171|NCT01928407|Drug|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
298172|NCT01928407|Drug|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
298173|NCT01928394|Biological|Nivolumab|
298174|NCT01928394|Biological|Ipilimumab|
298175|NCT01928394|Drug|Cobimetinib|
298176|NCT01928381|Drug|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
298177|NCT01928381|Drug|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
298178|NCT01928381|Drug|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
298179|NCT01928368|Drug|AMG 282|Single dose either subcutaneously or intravenously on day 1.
298180|NCT01928368|Drug|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
298181|NCT01928342|Drug|Coenzyme A|Coenzyme A 400mg per day
298182|NCT01928342|Drug|Placebo|Capsule without coenzyme A.
298183|NCT01928329|Drug|Exenatide (Bydureon®)|
298184|NCT01928329|Drug|Placebo|
298185|NCT01928316|Drug|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
298186|NCT01928316|Drug|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
298187|NCT01928290|Drug|Irinotecan|
298188|NCT01928290|Drug|Trastuzumab|
298189|NCT01928290|Drug|Oxaliplatin|
298190|NCT01928290|Drug|Leucovorin|
298191|NCT01928290|Drug|Fluorouracil|
298192|NCT01928264|Behavioral|Physical activity|
298377|NCT01926665|Drug|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
298418|NCT01926314|Other|usual home care without device|
298193|NCT01928251|Behavioral|Informed early monetary incentive|"Participants will be informed at 1 week after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
298194|NCT01928251|Behavioral|Uninformed early monetary incentive|"Participants will be informed at 3 months after the baseline recruitment about the monetary incentive of quitting.~Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
298195|NCT01928238|Device|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
298196|NCT01928238|Device|Noninvasive pressure support ventilation (NPSV)|
298197|NCT01928225|Biological|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
298198|NCT01928212|Device|Optical coherence tomography|
298199|NCT01928199|Drug|Sitagliptin|
298200|NCT01928199|Drug|Placebo|
298201|NCT01928186|Drug|Fluorothymidine F-18|Undergo FLT PET
298202|NCT01928186|Procedure|Positron Emission Tomography|Undergo FLT PET
298203|NCT01928186|Other|Laboratory Biomarker Analysis|Correlative studies
298204|NCT01928186|Drug|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
298205|NCT01928173|Behavioral|Abbreviated cognitive behavioral therapy|see arm description
298206|NCT01928173|Behavioral|Sleep education/sleep hygiene|see arm description
298207|NCT01928160|Drug|pemetrexed disodium|Given IV
298208|NCT01928160|Drug|carboplatin|Given IV
298209|NCT01928160|Drug|cisplatin|Given IV
298210|NCT01928160|Drug|erlotinib hydrochloride|Given PO
298211|NCT01928160|Other|laboratory biomarker analysis|Correlative studies
298212|NCT01928147|Drug|PPI-383|
298213|NCT01928147|Drug|Placebo|
298214|NCT01928134|Dietary Supplement|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
298215|NCT01928134|Dietary Supplement|Vit K2+CaCO3|
298216|NCT01928121|Other|Care provided by AF expert program|
298217|NCT01928108|Behavioral|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
298218|NCT01928108|Behavioral|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
298219|NCT01928082|Drug|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
298220|NCT01928069|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
298221|NCT01928056|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
298222|NCT01928043|Drug|Curcumin|
298223|NCT01928030|Biological|recombinant human hyaluronidase|Given SC
298224|NCT01928004|Device|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
298225|NCT01928004|Procedure|Conventional reline|conventional reline of the existing mandibular complete denture
298226|NCT01927991|Behavioral|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
298227|NCT01927965|Drug|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
298228|NCT01927952|Procedure|Kirschner wire|Surgical fixation utiliziing Kirschner wire
298229|NCT01927952|Procedure|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
298230|NCT01927952|Procedure|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
298231|NCT01927926|Dietary Supplement|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
298232|NCT01927926|Dietary Supplement|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
298233|NCT01927913|Drug|SPD602|32, 50 or 75 mg/kg/day BID, capsule
298234|NCT01927913|Drug|Deferasirox|Per approved country specific label
298235|NCT01927900|Dietary Supplement|HMO|
298236|NCT01927900|Dietary Supplement|Glucose|
298237|NCT01927887|Drug|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
298378|NCT01926652|Drug|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.~Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
298238|NCT01927887|Device|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
298239|NCT01927874|Procedure|Infiltration|injection of local anesthetic, associated with general anesthesia
298240|NCT01927874|Procedure|Spinal block|injection of anesthetic
298241|NCT01927874|Drug|Bupivacaine|10ml 0.5% bupivacaine.
298242|NCT01927874|Drug|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
298243|NCT01927861|Drug|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
298244|NCT01927848|Dietary Supplement|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
298245|NCT01927848|Dietary Supplement|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
298246|NCT01927835|Biological|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
298247|NCT01927835|Biological|NYVAC-HIV-PT1 vaccine|≥ 5x10^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10^8 PFU/ml; administered IM
298248|NCT01927835|Biological|NYVAC-HIV-PT4 vaccine|≥ 5x10^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10^7 PFU/ml; administered IM
298249|NCT01927835|Biological|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
298250|NCT01927835|Biological|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
298251|NCT01927757|Biological|Etanercept|Administered by subcutaneous injection
298252|NCT01927757|Drug|Methotrexate|Background methotrexate at least 15 mg weekly
298253|NCT01927744|Drug|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
298254|NCT01927744|Drug|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
298255|NCT01927744|Other|Placebo|150 mg by mouth daily continuously until the day before surgery.
298256|NCT01927744|Behavioral|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
298257|NCT01927744|Behavioral|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
298258|NCT01927744|Drug|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
298259|NCT01927731|Drug|Eltrombopag Olamine|Given PO
298260|NCT01927731|Other|Laboratory Biomarker Analysis|Correlative studies
298261|NCT01927718|Drug|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
298262|NCT01927718|Drug|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
298263|NCT01927718|Behavioral|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
298264|NCT01927705|Biological|FURESTEM-AD Inj.|
298265|NCT01927692|Other|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
298266|NCT01927692|Other|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
298267|NCT01927679|Drug|Vitamin E|
298268|NCT01927679|Drug|Eucerin|Control
298269|NCT01927666|Dietary Supplement|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
298270|NCT01927640|Drug|Dexmedetomidine|During Visit 2 (Cocaine Study Day), intranasal cocaine will be administered. If randomized to this active drug arm, dexmedetomidine (0.3-0.6 mcg/kg) will then be administered followed by repeat myocardial contrast echocardiography.
298271|NCT01927627|Drug|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
298272|NCT01927614|Radiation|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).~The CT scan protocol will comprise 3 steps.~Prospectively gated calcium scoring.~Stress-myocardial CT perfusion.~Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
298273|NCT01927588|Drug|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
298274|NCT01927588|Drug|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
298275|NCT01927575|Device|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
298276|NCT01927575|Device|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
298277|NCT01927575|Device|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
298278|NCT01927562|Device|Fractyl Duodenal Remodeling System|
298279|NCT01927549|Procedure|Immediate multivessel PCI|
298280|NCT01927549|Procedure|Culprit Lesion only PCI|
298281|NCT01927536|Device|White LED Flashlight|white light setting
298282|NCT01927536|Device|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
298283|NCT01927523|Behavioral|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
298286|NCT01927497|Procedure|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
298287|NCT01927497|Procedure|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
298288|NCT01927484|Drug|25 mg/week oral methotrexate tablets|
298289|NCT01927484|Drug|25mg/week oral placebo tablets|
298290|NCT01927458|Device|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
298291|NCT01927445|Other|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
298292|NCT01927419|Drug|Nivolumab|
298293|NCT01927419|Drug|Ipilimumab|
298294|NCT01927419|Drug|Placebo|Matching nivolumab
298295|NCT01927406|Drug|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
298296|NCT01927406|Drug|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
298297|NCT01927393|Other|palliative care|Receive PCPI
298298|NCT01927393|Behavioral|educational intervention|Receive education sessions
298299|NCT01927393|Procedure|quality-of-life assessment|Ancillary studies
298300|NCT01927393|Other|questionnaire administration|Ancillary studies
298301|NCT01927393|Behavioral|telephone-based intervention|Receive telephone contacts
298302|NCT01927380|Other|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
298303|NCT01927367|Other|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
298304|NCT01927341|Drug|MEK162|Tablet for oral use, 15 mg, BID
298305|NCT01927341|Drug|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
298306|NCT01927328|Drug|Iron isomaltoside 1000|
298307|NCT01927315|Drug|Fenofibrate 145 mg|Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.
298308|NCT01927315|Drug|Placebo|Oral Placebo tablets once daily
298309|NCT01927302|Behavioral|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
298310|NCT01927302|Behavioral|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
298311|NCT01927302|Behavioral|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
298312|NCT01927302|Behavioral|No Treatment|No treatment will be administered.
298313|NCT01927289|Procedure|Proximal Brachial Plexus vs Distal Forearm Block|"Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.~Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach"
298314|NCT01927276|Other|Gluten Free Flour|
298315|NCT01927276|Other|Wheat Flour|
298316|NCT01927263|Biological|NI-071|100mg/vial
298317|NCT01927263|Biological|Infliximab|100mg/vial
298318|NCT01927250|Behavioral|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
298319|NCT01927237|Other|HLR|
298320|NCT01927237|Other|EHR|
298321|NCT01927224|Drug|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
298322|NCT01927224|Drug|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
298323|NCT01927224|Drug|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
298324|NCT01927198|Drug|Placebo|
298325|NCT01927198|Drug|RDEA3170 5 mg|
298326|NCT01927198|Drug|RDEA3170 10 mg|
298327|NCT01927198|Drug|RDEA3170 12.5 mg|
298379|NCT01926639|Biological|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
298419|NCT01926301|Procedure|continuous veno-venous hemodialysis|
298328|NCT01927185|Device|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
298329|NCT01927185|Device|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
298330|NCT01927172|Device|AirSonea|
298331|NCT01927159|Biological|ID93 + GLA-SE|
298332|NCT01927159|Other|Placebo|
298333|NCT01927120|Drug|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
298334|NCT01927120|Drug|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
298335|NCT01927120|Drug|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
298336|NCT01927107|Dietary Supplement|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
298337|NCT01927094|Dietary Supplement|Probiotic|Comparison of probiotics vs. ORS
298338|NCT01927094|Dietary Supplement|ORS|ORS ad libitum
298339|NCT01927081|Behavioral|discussion group|Participants engage in discussions regarding issues related to coping with advanced cancer and pain
298340|NCT01927081|Behavioral|gentle exercise|Patients learn gentle exercise and breathing techniques
298341|NCT01927068|Device|CVI Paclitaxel-Coated PTA Balloon Catheter|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
298342|NCT01927055|Drug|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
298343|NCT01927055|Drug|Placebo|Placebo to match droxidopa capsules and strength designations
298344|NCT01927042|Behavioral|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
298345|NCT01927042|Behavioral|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
298346|NCT01927029|Drug|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
298347|NCT01927029|Drug|Placebo|
298348|NCT01927016|Procedure|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
298349|NCT01927003|Procedure|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
298350|NCT01926990|Device|perfusion computed tomography|Undergo perfusion CT
298351|NCT01926977|Drug|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
298352|NCT01926977|Drug|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
298353|NCT01926951|Device|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
298354|NCT01926912|Drug|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
298355|NCT01926899|Drug|Bortezomib administration|
298356|NCT01926886|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose) and 6 mg/kg (maintenance dose) IV infusion q3w; Trastuzumab 600 mg q3w SC injection will be administered as per the schedule specified in the arm.
298357|NCT01926860|Biological|Prevenar13|
298358|NCT01926860|Biological|Hepatitis A vaccine|
298359|NCT01926847|Drug|Riociguat (Adempas, BAY63-2521)|
298360|NCT01926847|Drug|Placebo|
298361|NCT01926834|Drug|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
298362|NCT01926834|Drug|placebo|normal saline, 500ml,i.v.,qd, for 7 days
298363|NCT01926821|Drug|Sonifilan|Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
298364|NCT01926795|Procedure|Short leg cast|
298365|NCT01926795|Procedure|No Immobilization|
298366|NCT01926782|Drug|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
298367|NCT01926782|Drug|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
298368|NCT01926782|Drug|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
298369|NCT01926769|Drug|Metformin|
298370|NCT01926756|Procedure|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
298371|NCT01926756|Procedure|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
298372|NCT01926743|Procedure|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
298373|NCT01926730|Other|Restriction diet|Selected food items will be limited in the participants diet
298374|NCT01926678|Other|Swedish massage therapy|
298375|NCT01926678|Other|Light touch therapy|
298376|NCT01926665|Drug|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
298420|NCT01926288|Drug|Entecavir maleate tablets|
298380|NCT01926626|Drug|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)~Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
298381|NCT01926626|Drug|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)~Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
298382|NCT01926613|Behavioral|Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.
298383|NCT01926613|Behavioral|Supported Employment|Supported Employment is an evidence based vocational rehabilitation program
298384|NCT01926587|Drug|oral rigosertib|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
298385|NCT01926587|Drug|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
298386|NCT01926574|Behavioral|long rehabilitation program|
298387|NCT01926574|Behavioral|short rehabilitation program|
298388|NCT01926574|Behavioral|Acceptance and commitment therapy (ACT)|
298389|NCT01926561|Other|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
298390|NCT01926548|Drug|CJ Imatinib mesylate tablet|
298391|NCT01926548|Drug|Gleevec film-coated tablet 2 x 100mg|
298392|NCT01926535|Procedure|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
298393|NCT01926535|Device|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
298394|NCT01926522|Device|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
298395|NCT01926522|Other|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
298396|NCT01926509|Drug|MK-8892|
298397|NCT01926509|Drug|Placebo for MK-8892|
298398|NCT01926496|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
298399|NCT01926496|Drug|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
298400|NCT01926483|Other|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
298401|NCT01926470|Procedure|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
298402|NCT01926470|Procedure|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
298403|NCT01926457|Other|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success~diabetes education~blood glucose monitoring~medications as needed per California Diabetes and Pregnancy established protocol~growth ultrasounds~antenatal testing"
298404|NCT01926444|Drug|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
298405|NCT01926431|Other|Exercise|
298406|NCT01926431|Other|Rest|
298407|NCT01926418|Behavioral|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.~Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
298408|NCT01926405|Procedure|saliva collection|collection of saliva
298409|NCT01926392|Drug|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
298410|NCT01926392|Drug|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
298411|NCT01926379|Behavioral|Combination intervention components|"The CIP will contain programmatic, structural, and psychosocial components, including:~use of a clinical algorithm by providers;~identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);~review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;~reimbursement of transportation costs for monthly clinic visits; and~real-time adherence support using IVR via mobile phones and trained Peer Educators."
298412|NCT01926379|Drug|Isoniazid Prevention Therapy|Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
298413|NCT01926366|Drug|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
298414|NCT01926366|Drug|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
298415|NCT01926327|Biological|PRP injection|Injection of PRP in patients with knee osteoarthritis.
298416|NCT01926327|Biological|Placebo|
298421|NCT01926288|Drug|blank Baraclude tablets|
298422|NCT01926288|Drug|Blank maleate entecavir tablets|
298423|NCT01926288|Drug|Baraclude tablets|
298424|NCT01926275|Device|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
298425|NCT01926275|Device|NPPV|noninvasive positive pressure ventilation
298426|NCT01926275|Device|IMT|inspiratory muscle training
298427|NCT01926262|Behavioral|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
298428|NCT01926236|Other|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
298429|NCT01926236|Drug|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
298430|NCT01926236|Drug|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
298431|NCT01926236|Drug|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
298432|NCT01926223|Other|Home visiting|
298433|NCT01926210|Other|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
298434|NCT01926210|Other|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
298435|NCT01926197|Drug|Oxaliplatin|
298436|NCT01926197|Radiation|SBRT|
298437|NCT01926197|Drug|Irinotecan|
298438|NCT01926197|Drug|Leucovorin|
298439|NCT01926197|Drug|5FU|
298440|NCT01926184|Behavioral|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
298441|NCT01926184|Behavioral|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
298442|NCT01926171|Drug|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
298443|NCT01926158|Drug|Denosumb|Prefilled syringe of 1 mL denosumab solution
298444|NCT01926158|Drug|Placebo (for denosumab)|
298445|NCT01926132|Drug|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
298446|NCT01926132|Drug|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
298447|NCT01926119|Device|Transcranial Magnetic Stimulation|
298448|NCT01926106|Device|nIPPV|one of the twins was randomly allocated to nIPPV
298449|NCT01926106|Device|nCPAP|another of the twins was allocated to nCPAP
298450|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU— Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
298451|NCT01926054|Drug|Acthar gel|
298452|NCT01926041|Other|Smoking cessation clinics|Participants in this group can receive their medications up to 16 weeks within one year. Each participant also receives counseling from a well-trained full-time research assistant for individualized smoking cessation techniques at each visit.
298453|NCT01926028|Biological|NDV-3A|0.5mL injection IM
298454|NCT01926028|Biological|NDV-3|0.5mL injection IM
298455|NCT01926028|Biological|Placebo|aluminum hydroxide and buffered saline
298456|NCT01926015|Biological|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
298457|NCT01926015|Biological|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
298458|NCT01926002|Drug|Low-Dose MK-8351|Single administration of low-dose MK-8351.
298459|NCT01926002|Drug|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
298460|NCT01926002|Drug|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
298461|NCT01925989|Biological|LY2605541|Administered SQ
298462|NCT01925989|Biological|Insulin Glargine|Administered SQ
298463|NCT01925976|Behavioral|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
298464|NCT01925950|Drug|orBec|
298465|NCT01925950|Drug|Placebo|
298466|NCT01925937|Drug|Atorvastatin|
298467|NCT01925937|Drug|Coenzyme Q10|
298468|NCT01925937|Drug|placebo for coenzyme Q10|
298469|NCT01925924|Other|Resin-modified glass ionomer cement|This material contains fluoride
298470|NCT01925924|Other|Composite resin|This material does not include fluoride
298471|NCT01925911|Drug|IPI-145|25 mg BID Oral Capsule
298472|NCT01925911|Drug|Midazolam|2 mg midazolam syrup
298473|NCT01925898|Drug|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
298474|NCT01925898|Drug|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
298475|NCT01925885|Procedure|PVI Ablation|PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
298476|NCT01925885|Procedure|FIRM Ablation|Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
298477|NCT01925859|Drug|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
298478|NCT01925833|Procedure|Both insertion and withdrawal|inspection and polypectomy during both insertion and withdrawal of colonoscopy
298479|NCT01925833|Procedure|Only withdrawal|inspection and polypectomy during only withdrawal of colonoscopy
298480|NCT01925820|Drug|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
298481|NCT01925807|Behavioral|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
298482|NCT01925794|Device|COBRA PzF|
298483|NCT01925781|Drug|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
298484|NCT01925781|Other|STAM 1100mAh CE4 eGo Clearomizer|
298485|NCT01925768|Drug|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
298486|NCT01925768|Drug|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
298487|NCT01925755|Other|Rivaroxaban ( Xarelto, BAY59-7939)|Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
298488|NCT01925742|Other|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
298489|NCT01925742|Other|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
298490|NCT01925742|Other|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
298491|NCT01925742|Other|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
298492|NCT01925742|Other|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
298493|NCT01925729|Biological|ragweed|ragweed arm only
298494|NCT01925729|Biological|histamine|histamine arm only
298495|NCT01925729|Drug|pseudoephedrine|pseudoephedrine arm only
298496|NCT01925729|Drug|Oxymetazoline|oxymetazoline arm only
298497|NCT01925716|Other|Corn oil|corn oil 56 g/day for 21 days
298498|NCT01925716|Other|Olive oil|olive oil 56 g /day for 21 days
298499|NCT01925703|Drug|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
298500|NCT01925690|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
298501|NCT01925690|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
298502|NCT01925677|Device|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
298503|NCT01925664|Behavioral|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
298504|NCT01925651|Radiation|No Bolus|no bolus use
298505|NCT01925651|Radiation|Alternate Bolus|0.5cm bolus use in alternate days
298506|NCT01925651|Radiation|Continuous Bolus|0.5 cm bolus use in continuous days
298507|NCT01925638|Drug|BAY86-9766|
298508|NCT01925638|Drug|Ketoconazole|
298509|NCT01925625|Biological|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
298510|NCT01925612|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
298511|NCT01925612|Drug|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
298512|NCT01925612|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
298513|NCT01925612|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
298514|NCT01925612|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
298515|NCT01925612|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
298516|NCT01925612|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
298517|NCT01925573|Device|Optune(NOVOTTF-100A)|
298518|NCT01925560|Other|Agave Inulin|3x3 Latin square with 3 periods
298519|NCT01925560|Other|Placebo|control- 0 (zero) grams/day inulin
298520|NCT01925547|Dietary Supplement|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
298521|NCT01925547|Dietary Supplement|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
298522|NCT01925534|Device|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
298523|NCT01925534|Device|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
298524|NCT01925521|Drug|Part1 : OPS-2071|single oral dose under fasted condition
298525|NCT01925521|Drug|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
298526|NCT01925521|Drug|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
298527|NCT01925521|Drug|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
298528|NCT01925495|Other|varied middle-ear pressure|
298529|NCT01925495|Drug|varied middle-ear gas composition|
298530|NCT01925495|Other|varied ear-canal pressure|
298531|NCT01925482|Drug|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
298532|NCT01925482|Drug|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
298533|NCT01925482|Drug|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
298534|NCT01925482|Drug|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
298535|NCT01925482|Drug|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
298536|NCT01925482|Drug|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
298537|NCT01925469|Drug|Benzocaine|
298538|NCT01925469|Drug|Saline spray|A saline spray will be used in the placebo group
298539|NCT01925456|Drug|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
298540|NCT01925443|Other|Low level laser therapy|Will be performed irradiation with low-intensity laser in quadriceps muscle
298541|NCT01925430|Device|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
298542|NCT01925430|Device|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
298543|NCT01925417|Biological|RBX2660 (microbiota suspension)|
298544|NCT01925404|Behavioral|Free physical activity classes|100 hours of free activity classes will be provided
298545|NCT01925404|Behavioral|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
298546|NCT01925391|Drug|Tono-pen XL Applanation tonometer + Ocu-film +|
298547|NCT01925378|Drug|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
298548|NCT01925365|Dietary Supplement|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
298549|NCT01925365|Dietary Supplement|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
298550|NCT01925352|Drug|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
298551|NCT01925339|Device|Test (immediate restoration)|Test (immediate restoration)
298552|NCT01925339|Device|Control: delayed restoration|Control: delayed restoration
298553|NCT01925313|Drug|CJ-30044|20.51mg a day,PO,QD
298554|NCT01925313|Drug|TALION TAB. 10mg|10mg a day,PO,BID
298555|NCT01925300|Drug|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
298556|NCT01925300|Drug|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
298557|NCT01925300|Drug|Concor 5mg 2T and Crestor 20 mg 1Tab|
298558|NCT01925287|Dietary Supplement|curcumin|500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
298559|NCT01925274|Drug|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
298560|NCT01925274|Drug|irinotecan|90 minutes IV infusion of irinotecan 180mg/m^2 on days 1 and 15 of each cycle
298561|NCT01925274|Drug|Cetuximab|120 minute IV infusion of cetuximab 400mg/m^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
298562|NCT01925274|Drug|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m^2 on days 1 and 15 of each cycle
298563|NCT01925261|Drug|TPX-100 50mg|
298564|NCT01925261|Drug|TPX-100 100mg|
298565|NCT01925261|Drug|TPX-100 200mg|
298566|NCT01925261|Drug|TPX-100 20mg|
298567|NCT01925261|Drug|Placebo|
298568|NCT01925248|Dietary Supplement|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
298569|NCT01925248|Dietary Supplement|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
298570|NCT01925235|Procedure|remote ischemic preconditioning|
298571|NCT01925209|Drug|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
298572|NCT01925209|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
298573|NCT01925183|Drug|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
298574|NCT01925183|Drug|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients <75kg; orally
298575|NCT01925183|Drug|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
298576|NCT01925170|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
298577|NCT01925170|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
298578|NCT01925170|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
298579|NCT01925157|Biological|LY3090106 - SQ|Administered SQ.
298580|NCT01925157|Biological|LY3090106 - IV|Administered IV.
298581|NCT01925157|Biological|Placebo - SQ|Administered SQ.
298582|NCT01925144|Drug|Baricitinib|Administered orally
298583|NCT01925144|Drug|Omeprazole|Administered orally
298584|NCT01925131|Drug|cyclophosphamide|Given IV
298585|NCT01925131|Drug|vincristine sulfate|Given IV
298586|NCT01925131|Drug|prednisone|Given PO
298587|NCT01925131|Biological|inotuzumab ozogamicin|Given IV
298588|NCT01925131|Other|laboratory biomarker analysis|Correlative studies
298589|NCT01925118|Biological|Irradiated donor lymphocyte infusion|
298590|NCT01925105|Other|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
298591|NCT01925092|Drug|mifepristone|tablets
298592|NCT01925079|Behavioral|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.~Patient education:~Routine education at discharge.~4 education brochures will be delivered to patients.~Calendar with healthy tips will be delivered to patients before discharge.~A follow-up brochure with medical expert letter.~A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).~Telephone follow ups will be performed according to a standard communication document.~At discharge, patients will be given a brochure for future follow up."
298593|NCT01925079|Other|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.~Patient education:~Routine education at discharge.~A follow-up brochure without medical expert letter.~At discharge, patients will be given a brochure for future follow up."
298594|NCT01925066|Drug|Vancomycin|
298595|NCT01925053|Other|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
298596|NCT01925053|Other|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
298597|NCT01925040|Device|Placement of restoration|Placement of restorations
298598|NCT01925027|Device|Nano+ DES|All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
298599|NCT01925014|Diagnostic Test|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
298600|NCT01925014|Diagnostic Test|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
298601|NCT01925001|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
298602|NCT01925001|Drug|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
298603|NCT01924988|Device|Prostatic Embolization with Embosphere Micropsheres|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudendal or obturator branches as well.~The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
298604|NCT01924975|Procedure|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
298605|NCT01924975|Device|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
298606|NCT01924975|Device|A 22 or 24 G intravenous catheter|
298607|NCT01924962|Device|revascularisation|revascularisation of chronic occluded coronary artery
298608|NCT01924949|Drug|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
298609|NCT01924936|Behavioral|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
298610|NCT01924910|Dietary Supplement|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
298611|NCT01924910|Dietary Supplement|Placebo|
298612|NCT01924897|Behavioral|Exercise training|
298613|NCT01924871|Drug|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
298614|NCT01924871|Drug|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
298615|NCT01924858|Drug|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of [18F]-GSK2647544 and a PET scan.
298616|NCT01924858|Drug|[18F]GSK2647544 IV bolus|[18F]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
298617|NCT01924845|Drug|BMN 701|BMN 701 20 mg/kg for intravenous administration over approximately 4 hours every 2 weeks over a 24-week Treatment Period (total of 13 doses), and every 2 weeks over a 240-week Extension Period (up to 120 additional doses).
298618|NCT01924832|Drug|dimethyl fumarate|tablet
298619|NCT01924819|Drug|Epirubicin + cisplatin + 5-fluorouracil OR epirubicin + cisplatin + capecitabine OR epirubicin + oxaliplatin + capecitabine OR 5-Fluorouracil + leucovorin + oxaliplatin + docetaxel|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).~Epirubicin 50 mg/m2 IV day 1, Cisplatin 60 mg/m2 IV day 1, Capecitabine (X = Xeloda) 625mg/m2, bid days 1-21 (ECX chemotherapy)~Epirubicin 50mg/m2 IV day 1, Oxaliplatin (O) 130mg/m2 IV day 1, Capecitabine 625mg/m2, bid days 1-21 (EOX chemotherapy)~5-Fluorouracil 2600 mg/m² IV 24 h infusion day 1, Leucovorin (L) 200 mg/m² IV day 1, Oxaliplatin 85 mg/m² IV day 1, Docetaxel (T) 50 mg/m² IV day 1 (FLOT chemotherapy)"
298674|NCT01924481|Dietary Supplement|Low caffeine|
298620|NCT01924819|Radiation|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).~Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
298621|NCT01924819|Procedure|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers [Siewert Type II and Siewert Type III] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
298622|NCT01924806|Device|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
298623|NCT01924806|Device|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
298624|NCT01924793|Drug|DAS181-F02 Dry Powder in Bulk|Administered via DPI
298625|NCT01924793|Drug|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
298626|NCT01924780|Device|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
298627|NCT01924780|Device|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
298628|NCT01924780|Device|NEMOS Device sham stimulation 10 minutes|
298629|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
298630|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
298631|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
298632|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
298633|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
298634|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
298635|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
298636|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
298637|NCT01924741|Procedure|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
298638|NCT01924728|Device|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
298639|NCT01924728|Device|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
298640|NCT01924715|Behavioral|ISTDP|An emotion focused brief psychotherapy format.
298641|NCT01924702|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
298642|NCT01924702|Device|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
298643|NCT01924689|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
298644|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
298645|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
298646|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
298647|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
298648|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
298649|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
298650|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
298651|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
298652|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
298653|NCT01924637|Drug|Faster-acting insulin aspart|"A single dose will be administered subcutaneously (under the skin) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
298654|NCT01924637|Drug|insulin aspart|"A single dose will be administered subcutaneously (under the skin)) in the abdomen.~Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
298655|NCT01924624|Drug|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
298656|NCT01924611|Procedure|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
298657|NCT01924611|Procedure|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.~This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.~This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
298658|NCT01924598|Device|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
298659|NCT01924572|Procedure|cord clamping at 2 minutes|
298660|NCT01924572|Procedure|cord clamping at 5 minutes|
298661|NCT01924572|Procedure|cord milking|
298662|NCT01924559|Other|standard clothing|
298663|NCT01924559|Other|Biohazard gear|
298664|NCT01924559|Device|Direct Laryngoscopy|
298665|NCT01924559|Device|Glidescope|
298666|NCT01924559|Device|Supraglottic Airway|
298667|NCT01924546|Other|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
298668|NCT01924533|Drug|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
298669|NCT01924533|Drug|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
298670|NCT01924533|Drug|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
298671|NCT01924520|Drug|FK949E|Oral
298672|NCT01924507|Device|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
298673|NCT01924481|Dietary Supplement|High Caffeine|
298675|NCT01924481|Dietary Supplement|High theobromine|
298676|NCT01924481|Dietary Supplement|low theobromine|
298677|NCT01924481|Dietary Supplement|No theobromine|
298678|NCT01924468|Drug|Oral methylphenidate and Oral haloperidol|
298679|NCT01924429|Drug|Lisdexamfetamine|Escalating stepped dose titration: 30, 50 or 70mg
298680|NCT01924416|Behavioral|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
298681|NCT01924416|Behavioral|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
298682|NCT01924403|Procedure|Staple Closure|
298683|NCT01924403|Procedure|Vertical Mattress Closure|
298684|NCT01924403|Procedure|Running Subcuticular Closure|
298685|NCT01924390|Device|Mineralized freeze-dried bone allograft alone|
298686|NCT01924390|Device|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
298687|NCT01924377|Procedure|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance >5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
298688|NCT01924377|Procedure|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
298689|NCT01924364|Device|Tissue Genesis Cell Isolation System™ (TGI CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101, NCT01345591) will be used for comparison.
298690|NCT01924364|Procedure|Standard of care fat grafting|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time.
298691|NCT01924351|Radiation|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis|
298692|NCT01924338|Device|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
298693|NCT01924338|Device|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
298694|NCT01924338|Procedure|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
298695|NCT01924325|Drug|Apixaban|orally active direct factor Xa inhibitor
298696|NCT01924325|Drug|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
298697|NCT01924325|Drug|Aspirin|a non-steroidal anti-inflammatory drug
298698|NCT01924325|Drug|placebo|
298699|NCT01924312|Behavioral|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
298700|NCT01924299|Drug|Baricitinib|Administered orally
298701|NCT01924299|Drug|Ketoconazole|Administered orally
298702|NCT01924299|Drug|Fluconazole|Administered orally
298703|NCT01924286|Drug|Prednisone|
298704|NCT01924286|Drug|Placebo|
298705|NCT01924273|Drug|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
298706|NCT01924260|Drug|alisertib|Given PO
298707|NCT01924260|Drug|gemcitabine|Given IV
298708|NCT01924247|Behavioral|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
298709|NCT01924247|Behavioral|Standard treatment by family physician|Standard treatment by family physician.
298710|NCT01924234|Drug|Morphine|
298711|NCT01924234|Drug|Remifentanil|
298712|NCT01924208|Biological|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
298713|NCT01924208|Biological|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
298714|NCT01924208|Procedure|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
298715|NCT01924195|Drug|Anlotinib|Anlotinib QD po.
298716|NCT01924195|Drug|Placebo capsule|Placebo QD po.
298717|NCT01924182|Device|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
298718|NCT01924182|Other|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
298719|NCT01924169|Drug|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.~If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
298720|NCT01924169|Biological|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
298721|NCT01924169|Biological|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
298722|NCT01924156|Biological|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
298723|NCT01924143|Drug|TD-9855|radiolabeled (100 µCi [14C]-Labeled) TD-9855 (20 mg)
298724|NCT01924130|Other|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
298725|NCT01924130|Behavioral|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
298726|NCT01924130|Behavioral|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
298727|NCT01924130|Behavioral|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
298728|NCT01924117|Other|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
298729|NCT01924104|Drug|Low molecular weight heparin|2500 mIU/day, subcutaneously
298730|NCT01924104|Drug|Low dose aspirin|75 mg/day, orally
298731|NCT01924104|Drug|Heparin & aspirin|Aspirin (70 mg/day, orally) & heparin (40 mg/day, subcutaneously)
298732|NCT01924104|Other|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
298733|NCT01924091|Drug|Dapivirine gel|
298734|NCT01924091|Drug|Dapivirine film|
298735|NCT01924078|Drug|Capecitabine|metronomic use: capecitabine 500mg/tid
298736|NCT01924078|Drug|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
298737|NCT01924065|Procedure|Cardioversion|Electrical cardioversion
298738|NCT01924065|Drug|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
298739|NCT01924052|Drug|CGRP|Calcitonin-gene-related-peptide (CGRP)
298740|NCT01924039|Behavioral|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
298741|NCT01924039|Other|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
298742|NCT01924013|Dietary Supplement|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
298743|NCT01924013|Dietary Supplement|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
298744|NCT01924000|Drug|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
298745|NCT01924000|Drug|Placebo|
298746|NCT01923987|Radiation|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
298747|NCT01923987|Drug|Chemotherapy|"Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1~Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1~Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2~5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).~Bevacizumab 5 mg/kg IV over 90 mins on Day 1~Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.~FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses~Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
298748|NCT01923987|Procedure|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
298749|NCT01923974|Drug|Melatonin 10 mg|
298750|NCT01923974|Drug|Melatonin 100 mg|
298751|NCT01923974|Drug|Placebo|
298752|NCT01923961|Procedure|HDF NaCl|
298753|NCT01923961|Procedure|Hemodialysis|
298754|NCT01923961|Procedure|Standard Predilution Hemodiafiltration|
298755|NCT01923948|Drug|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
298756|NCT01923948|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
298757|NCT01923935|Drug|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)
298758|NCT01923935|Drug|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)
298759|NCT01923922|Radiation|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
298760|NCT01923909|Drug|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
298761|NCT01923909|Drug|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
298762|NCT01923896|Behavioral|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
298763|NCT01923896|Drug|d-cycloserine (DCS)|
298764|NCT01923896|Drug|Placebo|lactose powder
298765|NCT01923883|Procedure|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
298766|NCT01923883|Device|Echoendoscope Olympus GF-UCT240|
298767|NCT01923870|Drug|Androxal 25 mg|
298768|NCT01923857|Drug|Androxal 25 mg|
298769|NCT01923844|Drug|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached > 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
298770|NCT01923831|Drug|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
298771|NCT01923831|Drug|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
298772|NCT01923818|Drug|rivaroxaban|orally active direct factor Xa inhibitor
298773|NCT01923818|Drug|Aspirin|non-steroidal anti-inflammatory drugs
298774|NCT01923818|Drug|placebo|
298775|NCT01923805|Device|Vitagel|Vitagel
298776|NCT01923766|Drug|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.~Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
298777|NCT01923753|Device|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
298778|NCT01923753|Device|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
298779|NCT01923753|Device|Sham Aerosure|Deactivated but identical Aerosure HFAO device
298780|NCT01923740|Device|XIENCE V EECSS|Subjects receiving XIENCE V
298781|NCT01923740|Device|Absorb BVS System|Subjects receiving Absorb BVS System
298782|NCT01923727|Biological|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
298783|NCT01923701|Behavioral|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
298784|NCT01923688|Other|Informatics Alert/Nurse/physician responders|
298785|NCT01923675|Other|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
298786|NCT01923675|Other|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
298787|NCT01923675|Other|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
298880|NCT01922960|Other|micro-imaging|micro-imaging
298788|NCT01923675|Other|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
298789|NCT01923662|Device|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
298790|NCT01923649|Drug|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
298791|NCT01923649|Drug|Placebo|Placebo for somatuline slow release 90 mg
298792|NCT01923636|Other|detection of CMV|Clinical, radiological and laboratory (virological and immunological) standardized reports
298793|NCT01923623|Drug|Ropivacaine block|
298794|NCT01923610|Biological|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
298795|NCT01923597|Drug|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
298796|NCT01923584|Drug|EPI-743 400mg|
298797|NCT01923584|Drug|EPI-743 200mg|
298798|NCT01923571|Other|intraoperative BGC measure|
298799|NCT01923558|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
298800|NCT01923545|Drug|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
298801|NCT01923545|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
298802|NCT01923519|Procedure|bronchofiberscopy|
298803|NCT01923506|Radiation|stereotactic body radiation therapy|Undergo SBRT
298804|NCT01923506|Procedure|quality-of-life assessment|Ancillary studies
298805|NCT01923506|Other|laboratory biomarker analysis|Correlative studies
298806|NCT01923493|Other|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
298807|NCT01923493|Other|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
298808|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
298809|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
298810|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
298811|NCT01923467|Behavioral|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
298812|NCT01923467|Drug|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
298813|NCT01923454|Procedure|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
298814|NCT01923454|Drug|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
298815|NCT01923454|Procedure|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
298816|NCT01923428|Drug|AZD1722|
298817|NCT01923428|Drug|Placebo|
298818|NCT01923415|Procedure|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
298819|NCT01923415|Procedure|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
298820|NCT01923415|Procedure|No intervention, urine collection|Urine will be collected from all participants.
298821|NCT01923389|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
298822|NCT01923389|Drug|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
298823|NCT01923376|Drug|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
298824|NCT01923376|Drug|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
298825|NCT01923363|Drug|Piperacillin/Tazobactam Standard Dose to High Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose. Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
298826|NCT01923350|Behavioral|Weight Reduction Intervention|"The weight trial intervention components were:~Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).~Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.~Print mailings/emailings~3 Get Ready e-messages in the four weeks before the weight intervention began~Pedometers and program guides. (IVR users received printed activity logs with their program guides.)~Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
298881|NCT01922947|Behavioral|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
298882|NCT01922947|Behavioral|Active Control Condition|20-minute health counseling
298827|NCT01923350|Behavioral|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
298828|NCT01923350|Behavioral|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
298829|NCT01923350|Behavioral|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
298830|NCT01923337|Drug|irinotecan hydrochloride|Given IV
298831|NCT01923337|Drug|alisertib|Given PO
298832|NCT01923324|Behavioral|Physician telephone consultation|Pain physician support for family physician treating patient
298833|NCT01923324|Behavioral|Usual family physician care|Usual family physician care without telephone consultation with pain physician
298834|NCT01923311|Drug|EVG|Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily
298835|NCT01923311|Drug|Background regimen|Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
298836|NCT01923298|Drug|Estradiol|
298837|NCT01923285|Device|AXIUM Neurostimulator System|
298838|NCT01923285|Device|Control Spinal Cord Stimulation Device|
298839|NCT01923272|Device|AlphaCore Device|Active stimulation to the vagal nerve
298840|NCT01923272|Device|AlphaCore|Active AlphaCore treatment
298841|NCT01923259|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
298842|NCT01923246|Behavioral|Single WEB intervention|Brief WEB intervention recieved once
298843|NCT01923246|Behavioral|Repeated WEB intervention|WEB intervention recieved twice.
298844|NCT01923246|Behavioral|Single IVR intervention|IVR intervention recieved once
298845|NCT01923246|Behavioral|Repeated IVR intervention|IVR intervention recieved twice
298846|NCT01923233|Biological|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
298847|NCT01923220|Drug|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
298848|NCT01923220|Other|Aloe Vera Jel|To be applied topically once daily
298849|NCT01923207|Drug|DX-2930|
298850|NCT01923207|Drug|Placebo|placebo, subcutaneous administration
298851|NCT01923194|Drug|Highly Purified Urofollitropin|for Injection
298852|NCT01923194|Drug|Recombinant Human Follitropin Alfa|for Injection
298853|NCT01923181|Drug|semaglutide|Once-daily oral administration as tablets.
298854|NCT01923181|Drug|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
298855|NCT01923181|Drug|oral placebo|Once-daily oral administration as tablets.
298856|NCT01923168|Drug|alpelisib|BYL719 + Letrozole
298857|NCT01923168|Drug|buparlisib|BKM120 + Letrozole
298858|NCT01923168|Drug|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
298859|NCT01923155|Procedure|Colonoscopy|
298860|NCT01923142|Biological|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
298861|NCT01923142|Biological|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
298862|NCT01923129|Drug|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
298863|NCT01923116|Drug|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
298864|NCT01923090|Drug|Finasteride|Finasteride 5mg once daily for 3 weeks
298865|NCT01923090|Drug|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
298866|NCT01923077|Drug|Simvastatin|usual care with Simvastatin
298867|NCT01923077|Drug|Rosuvastatin|rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
298868|NCT01923064|Drug|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
298869|NCT01923064|Drug|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
298870|NCT01923038|Procedure|First arm: patients ventilated with zero end expiratory pressure|
298871|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure|
298872|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
298873|NCT01923025|Drug|RO5545965|Single dose
298874|NCT01923012|Drug|Vitamin K2 (Menaquinone)|
298875|NCT01922999|Drug|Melatonin|patients will receive placebo, 1mg melatonin or 3mg melatonin
298876|NCT01922986|Device|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
298877|NCT01922986|Device|sham rTMS|20 minutes of sham rTMS stimulation
298878|NCT01922986|Behavioral|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
298879|NCT01922973|Other|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
298883|NCT01922934|Behavioral|Commercial weight loss program|vouchers for Weight Watchers
298884|NCT01922934|Behavioral|Colorado Weigh|Group behavioral weight loss program
298885|NCT01922934|Dietary Supplement|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
298886|NCT01922934|Drug|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
298887|NCT01922934|Behavioral|Recreation center passes|1 year pass to a Denver recreation center
298888|NCT01922921|Biological|HER-2/neu Intracellular Domain Protein|Given ID
298889|NCT01922921|Other|Laboratory Biomarker Analysis|Correlative studies
298890|NCT01922921|Biological|Pertuzumab|Given per standard of care
298891|NCT01922921|Other|Placebo|Given PO
298892|NCT01922921|Biological|Polysaccharide-K|Given PO
298893|NCT01922921|Biological|Trastuzumab|Given per standard of care
298894|NCT01922908|Biological|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
298895|NCT01922908|Biological|Placebo Comparator|Normal saline
298896|NCT01922895|Dietary Supplement|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
298897|NCT01922895|Drug|Placebo for Probiotic|Capsule manufactured without active ingredients.
298898|NCT01922882|Behavioral|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
298899|NCT01922869|Dietary Supplement|Flavonoids|
298900|NCT01922856|Biological|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
298901|NCT01922856|Other|No Intervention|Controls only receive challenge
298902|NCT01922843|Drug|DP001 softgel capsules|
298903|NCT01922843|Drug|Placebo|
298904|NCT01922830|Dietary Supplement|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
298905|NCT01922830|Dietary Supplement|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
298906|NCT01922817|Drug|Saxagliptin|5mg saxagliptin
298907|NCT01922804|Dietary Supplement|K2 vitamin|K2 vitamin tablet
298908|NCT01922804|Dietary Supplement|Placebo|Placebo tablets
298909|NCT01922791|Dietary Supplement|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
298910|NCT01922778|Procedure|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
298911|NCT01922765|Drug|amoxicillin, clarithromycin, metronidazole, rabeprazole|
298912|NCT01922752|Drug|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.~Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
298913|NCT01922739|Drug|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
298914|NCT01922739|Drug|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
298915|NCT01922713|Other|white maize and a corn oil capsule|~ 0 ug RAE/d
298916|NCT01922713|Other|orange maize and a corn oil capsule|~600 ug RAE/d
298917|NCT01922713|Other|white maize and a vitamin A capsule|600 ug RAE/d
298918|NCT01922687|Drug|amlodipine plus atorvastatin (Caduet)|
298919|NCT01922687|Drug|amlodipine (Norvasc)|
298920|NCT01922674|Procedure|Standard open tension-free inguinal hernia repair with mesh|
298921|NCT01922661|Drug|REGN1908-1909|
298922|NCT01922661|Other|placebo|
298923|NCT01922648|Procedure|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
298924|NCT01922635|Other|Valadation of the metrological properties of questionnaire of quality of life|
298925|NCT01922596|Drug|Ropivacaine|
298926|NCT01922596|Drug|Placebo|
298927|NCT01922583|Drug|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
298928|NCT01922570|Dietary Supplement|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
298929|NCT01922557|Device|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
298930|NCT01922518|Procedure|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
298931|NCT01922518|Procedure|Apex pacing|Put RV lead around the apex
298932|NCT01922505|Drug|PPI triple therapy|
298933|NCT01922492|Procedure|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.~After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
298934|NCT01922492|Drug|Oral anti-diabetic drugs|"Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.~Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
299489|NCT01918553|Other|Intra ocular Pressure (IOP)|
299490|NCT01918553|Other|retinal imaging (OPTOMAP)|
298935|NCT01922479|Drug|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
298936|NCT01922479|Drug|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
298937|NCT01922466|Procedure|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol~- Increment Protocol as~1st week - SC 0.2cc/day, 2 days/week~2nd week - SC 0.4cc/day, 2 days/week~3nd week - SC 0.8cc/day, 2 days/week"
298938|NCT01922466|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
298939|NCT01922453|Other|Music and Sound|
298940|NCT01922440|Drug|Combination product (Natpara) and drug or supplements [Disease and drug registry]|Interventions evaluated are combination product (Natpara) and either drug or supplements (Calcium and vitamin D)
298941|NCT01922427|Drug|RNS60|
298942|NCT01922414|Device|Laser|Patients will undergo laser lithotripsy durin PNL
298943|NCT01922414|Device|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
298944|NCT01922401|Other|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
298945|NCT01922388|Device|Bilateral deep brain stimulation of the subthalamic nucleus|
298946|NCT01922375|Drug|Naftopidil|
298947|NCT01922362|Device|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
298948|NCT01922362|Device|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
298949|NCT01922349|Drug|BI 113608|Medium dose (Multiple dosing)
298950|NCT01922349|Drug|Placebo|Placebo (Multiple dosing)
298951|NCT01922349|Drug|BI 113608|Low dose (Multiple dosing)
298952|NCT01922349|Drug|Placebo|Placebo (Single dosing)
298953|NCT01922349|Drug|BI 113608|High dose (Single dosing)
298954|NCT01922349|Drug|BI 113608|Medium dose (Single dosing)
298955|NCT01922349|Drug|BI 113608|Low dose (Single dosing)
298956|NCT01922349|Drug|BI 113608|High dose (Multiple dosing)
298957|NCT01922336|Biological|SB2|IV infusion
298958|NCT01922336|Biological|EU Remicade|IV infusion
298959|NCT01922336|Biological|US Remicade|IV infusion
298960|NCT01922310|Behavioral|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.~The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
298961|NCT01922297|Other|Day Treatment MDFT-HIV|MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
298962|NCT01922297|Other|Day Treatment SAU|Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall & Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
298963|NCT01922284|Biological|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
298964|NCT01922284|Biological|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
298965|NCT01922284|Biological|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
298966|NCT01922284|Biological|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
298967|NCT01922271|Drug|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
298968|NCT01922271|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
298969|NCT01922271|Drug|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
298970|NCT01922271|Drug|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
298971|NCT01922271|Drug|Salbutamol|Used as resuce medication
298972|NCT01922258|Drug|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
298973|NCT01922245|Device|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
298974|NCT01922219|Behavioral|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
298975|NCT01922206|Behavioral|TRACK Intervention|"TRACK Intervention~3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
298976|NCT01922193|Drug|Highly Purified Urofollitropin|for injection
298977|NCT01922193|Drug|Recombinant Human Follitropin Alfa|for injection
299102|NCT01921374|Biological|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
298978|NCT01922180|Radiation|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
298979|NCT01922167|Dietary Supplement|Leucine|
298980|NCT01922167|Dietary Supplement|Alanine|
298981|NCT01922154|Drug|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
298982|NCT01922141|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
298983|NCT01922141|Drug|Amlodipine|Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
298984|NCT01922141|Drug|Ramipril|Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
298985|NCT01922141|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
298986|NCT01922128|Drug|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
298987|NCT01922115|Drug|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
298988|NCT01922115|Drug|Placebo|
298989|NCT01922102|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
298990|NCT01922102|Drug|Ranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
298991|NCT01922102|Drug|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
298992|NCT01922089|Drug|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
298993|NCT01922076|Drug|Adavosertib|Given PO
298994|NCT01922076|Other|Laboratory Biomarker Analysis|Correlative studies
298995|NCT01922076|Other|Pharmacological Study|Correlative studies
298996|NCT01922076|Radiation|Radiation Therapy|Undergo radiation therapy
298997|NCT01922063|Behavioral|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
298998|NCT01922063|Behavioral|Sham neck massage|20x 30 minutes sessions of neck massage
298999|NCT01922050|Drug|LEO 43204 Formulation 1|
299000|NCT01922050|Drug|LEO 43204 Formulation 2|
299001|NCT01922050|Drug|LEO 43204 Formulation 1 Dose X|
299002|NCT01922050|Drug|LEO 43204 Formulation 1 Dose Y|
299003|NCT01922050|Drug|LEO 43204 Formulation 2 Dose XX|
299004|NCT01922050|Drug|LEO 43204 Formulation 2 Dose YY|
299005|NCT01922050|Drug|Placebo Formulation 1|
299006|NCT01922050|Drug|Placebo Formulation 2|
299007|NCT01922037|Drug|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
299008|NCT01922024|Device|LRT55 Testing|Testing on the Unyvero LRT55
299009|NCT01922011|Drug|Daptomycin|IV daptomycin Infusion A in 12 to <18 years old (7 mg/kg); in 7 to < 12 year olds (9 mg/kg); in 24 months to <7 year olds (12 mg/kg); in 12 to <24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
299010|NCT01922011|Drug|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
299011|NCT01922011|Drug|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
299012|NCT01921998|Procedure|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
299013|NCT01921985|Drug|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
299014|NCT01921985|Drug|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
299015|NCT01921972|Drug|Galantamine CR|24 mg/day with dose-titration over twelve weeks
299016|NCT01921972|Drug|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
299017|NCT01921972|Drug|Placebo|Placebo will be similar in appearance to Memantine
299018|NCT01921959|Behavioral|Intervention|Postpartum women are randomized to intervention or control group
299019|NCT01921946|Drug|Fimasartan|
299020|NCT01921946|Drug|Rosuvastatin|
299021|NCT01921933|Device|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
299022|NCT01921920|Drug|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
299023|NCT01921907|Drug|AD17137 topical treatment|
299024|NCT01921907|Drug|Placebo|
299025|NCT01921894|Dietary Supplement|Cholecalciferol|vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
299026|NCT01921881|Other|St John's wort|
299027|NCT01921868|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
299028|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
299029|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
299030|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
299031|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
299032|NCT01921855|Drug|Placebo|Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
299033|NCT01921842|Behavioral|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
299034|NCT01921829|Drug|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
299035|NCT01921816|Device|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
299036|NCT01921803|Radiation|hypofractionation|
299037|NCT01921790|Biological|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
299038|NCT01921790|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
299039|NCT01921790|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
299040|NCT01921790|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
299041|NCT01921790|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
299042|NCT01921777|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
299043|NCT01921777|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
299044|NCT01921764|Behavioral|Workplace physical exercise|
299045|NCT01921764|Behavioral|Home physical exercise|
299046|NCT01921751|Radiation|low intensity radiation therapy|50.4 Gy in 28 1.8 Gy fractions (IMRT or 3D-CRT), 5 days/week, starting 3-5 weeks after the last dose of induction chemotherapy
299047|NCT01921751|Drug|Capecitabine|825 mg/m2 PO twice daily, 5 days/week, beginning on the first day of radiation therapy and ending on the last day of radiation therapy.
299048|NCT01921751|Drug|Gemcitabine|1000 mg/m2 weekly as a 30 minute infusion after nab-Paclitaxel, three weeks on and 1 week off [1 cycle = 4 weeks]
299049|NCT01921751|Radiation|high intensity radiation therapy|63 Gy intensity-modulated radiation therapy (IMRT) in 28 2.25 Gy fractions, 5 days/week, starts 3-5 weeks after the last dose of induction chemotherapy
299050|NCT01921751|Drug|nab-Paclitaxel|125 mg/m2 weekly as a 30-40 minute infusion, three weeks on and 1 week [1 cycle = 4 weeks]
299051|NCT01921738|Drug|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
299052|NCT01921738|Drug|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
299053|NCT01921738|Drug|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
299054|NCT01921738|Drug|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
299055|NCT01921725|Device|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
299056|NCT01921712|Drug|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
299057|NCT01921712|Drug|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
299058|NCT01921712|Drug|Active comparator|Randomized single dose of inhaled active comparator product
299059|NCT01921699|Procedure|taking blood samples from healthy people|
299060|NCT01921686|Other|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
299061|NCT01921673|Drug|Dovitinib and docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off~In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
299062|NCT01921647|Drug|YH4808|
299063|NCT01921647|Drug|Nexium|
299064|NCT01921647|Drug|Amoxicillin|
299065|NCT01921647|Drug|clarithromycin|
299066|NCT01921634|Other|Modified Pathologic Analysis|
299067|NCT01921621|Behavioral|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
299068|NCT01921621|Behavioral|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
299181|NCT01920867|Procedure|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
299069|NCT01921608|Device|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
299070|NCT01921595|Other|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
299071|NCT01921595|Other|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
299072|NCT01921582|Drug|Methylphenidate|"Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.~Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
299073|NCT01921582|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:~Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;~Phase 2 aims to reduce food intake and restructure eating-related cognitions;~Phase 3 focuses upon relapse prevention"
299074|NCT01921569|Behavioral|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
299075|NCT01921569|Other|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
299076|NCT01921569|Other|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
299077|NCT01921556|Behavioral|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
299078|NCT01921543|Device|ITP Stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
299079|NCT01921543|Device|CI/BNST stimulation|"Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision"
299080|NCT01921543|Device|No stimulation|
299081|NCT01921530|Procedure|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
299082|NCT01921530|Procedure|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
299083|NCT01921517|Device|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
299084|NCT01921517|Device|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
299085|NCT01921504|Device|Acupuncture|"Acupuncture treatment~Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)~Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 ~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
299086|NCT01921491|Procedure|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
299087|NCT01921491|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
299088|NCT01921452|Device|Quantitative POC TSH Kit|A drop (approximately 30 microliter [mcL]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
299089|NCT01921452|Device|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
299090|NCT01921452|Device|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
299091|NCT01921439|Behavioral|Personalized Feedback|Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
299092|NCT01921426|Drug|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
299093|NCT01921413|Device|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
299094|NCT01921387|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
299095|NCT01921387|Drug|Carmustine|Given IV
299096|NCT01921387|Drug|Cytarabine|Given IV
299097|NCT01921387|Drug|Etoposide|Given IV
299098|NCT01921387|Other|Laboratory Biomarker Analysis|Correlative studies
299099|NCT01921387|Drug|Melphalan|Given IV
299100|NCT01921387|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
299101|NCT01921387|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
299103|NCT01921374|Biological|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
299104|NCT01921374|Biological|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
299105|NCT01921374|Biological|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
299106|NCT01921374|Biological|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
299107|NCT01921361|Drug|Levobupivacaine|Intrathecal 3ml (15 mg)
299108|NCT01921361|Drug|Dexmedetomidine|Intrathecal 3 microgram (diluted 1/10, 0.3 ml)
299109|NCT01921361|Drug|Dexmedetomidine|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)
299110|NCT01921361|Drug|sodium chloride|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
299111|NCT01921348|Device|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
299112|NCT01921348|Device|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
299113|NCT01921335|Drug|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
299114|NCT01921335|Drug|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
299115|NCT01921335|Drug|Trastuzumab|6 mg/kg IV every 3 weeks
299116|NCT01921322|Device|Pump|722 Paradigm Real-Time System
299117|NCT01921322|Other|CGMS Gold|Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
299118|NCT01921309|Device|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
299119|NCT01921309|Device|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
299120|NCT01921296|Drug|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
299121|NCT01921283|Device|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
299122|NCT01921283|Drug|no- BIS sensor attachment|
299123|NCT01921270|Drug|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.~Muscles that may be included for in injection for OMD with Jaw Closing:~Medial Pterygoid 50 units, Masseter 25 units~Muscles that may be included in injection for OMD with Jaw Opening:~Lateral Pterygoid 50 units, Anterior digastrics 10 units~Muscle that will be included in injection for OMD with Tongue Protrusion:~Genioglossus 7.5 units"
299124|NCT01921257|Drug|Cat-PAD|
299125|NCT01921257|Drug|Placebo|
299126|NCT01921244|Other|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
299127|NCT01921231|Drug|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
299128|NCT01921231|Drug|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
299129|NCT01921218|Drug|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
299130|NCT01921218|Drug|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
299131|NCT01921218|Drug|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
299132|NCT01921218|Drug|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
299436|NCT01918852|Drug|Capecitabine|
299133|NCT01921205|Drug|Lacosamide|"Subjects <30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
299134|NCT01921205|Other|Placebo|"Subjects <30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)~Subjects ≥30 kg to <50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)~Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
299135|NCT01921192|Drug|Folic Acid, vit B6 and B12|
299136|NCT01921192|Drug|Placebo|
299137|NCT01921179|Behavioral|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
299138|NCT01921179|Behavioral|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
299139|NCT01921166|Drug|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
299140|NCT01921166|Drug|Leuprolide flare|Leuprolide flare ovulation induction
299141|NCT01921153|Other|Healthy meal plates and trays|The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
299142|NCT01921140|Drug|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
299143|NCT01921140|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
299144|NCT01921140|Other|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
299145|NCT01921140|Other|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
299146|NCT01921114|Device|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
299147|NCT01921114|Device|Bard® Dual-Lumen PowerPICC SOLO2®|
299148|NCT01921101|Behavioral|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
299149|NCT01921101|Other|control|participants will receive standard care for nutrition received from hospital admission to discharge
299150|NCT01921088|Other|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
299151|NCT01921088|Behavioral|Ambulatory Training|Subjects are provided with an ambulatory training.
299152|NCT01921075|Other|normal dietary behavior|normal dietary behavior during examination days
299153|NCT01921075|Other|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
299154|NCT01921062|Behavioral|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
299155|NCT01921036|Procedure|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
299156|NCT01921036|Procedure|combined exercise|Moderate endurance and resistance exercise once a week over six months
299157|NCT01921010|Drug|Niaspan|See Arm Description
299158|NCT01921010|Drug|Placebo|See Arm Description
299159|NCT01920984|Drug|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
299160|NCT01920971|Radiation|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
299161|NCT01920958|Other|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
299162|NCT01920945|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
299163|NCT01920932|Drug|brentuximab vedotin|Given intravenously (IV).
299164|NCT01920932|Drug|etoposide|Given IV.
299165|NCT01920932|Drug|prednisone|Given orally (PO).
299166|NCT01920932|Drug|doxorubicin|Given IV.
299167|NCT01920932|Drug|cyclophosphamide|Given IV.
299168|NCT01920932|Drug|Dacarbazine(R)|Given IV.
299169|NCT01920932|Drug|filgrastim|Given subcutaneously (SQ) as clinically indicated.
299170|NCT01920932|Other|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
299171|NCT01920932|Radiation|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
299172|NCT01920919|Drug|Dexamethasone|
299173|NCT01920919|Drug|Placebo|
299174|NCT01920906|Procedure|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
299175|NCT01920893|Drug|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
299176|NCT01920893|Drug|Dupilumab|Solution for injection; Subcutaneous injection.
299177|NCT01920893|Drug|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
299178|NCT01920880|Other|Quantitative Sensory Testing analysis|
299179|NCT01920867|Procedure|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
299180|NCT01920867|Procedure|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
299437|NCT01918852|Drug|Teysuno|
299438|NCT01918852|Drug|Bevacizumab|
299182|NCT01920867|Procedure|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
299183|NCT01920867|Procedure|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
299184|NCT01920854|Drug|soluble ferric pyrophosphate|
299185|NCT01920854|Drug|Placebo|
299186|NCT01920841|Other|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
299187|NCT01920841|Other|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
299188|NCT01920815|Other|No interventions|
299189|NCT01920802|Drug|olanzapine|5mg BID up to 4 weeks
299190|NCT01920802|Drug|iloperidone|6 mg BID up to 4 weeks
299191|NCT01920802|Drug|Placebo|BID up to 4 weeks
299192|NCT01920789|Radiation|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
299193|NCT01920789|Radiation|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
299194|NCT01920776|Other|ultrasound examination|
299195|NCT01920776|Other|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
299196|NCT01920763|Other|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
299197|NCT01920750|Biological|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
299198|NCT01920750|Biological|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
299199|NCT01920750|Other|Mock Antigen|Physiological saline
299200|NCT01920737|Drug|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
299201|NCT01920737|Drug|Vincristine|
299202|NCT01920737|Drug|Prednisone|
299203|NCT01920737|Drug|PEG-Asparaginase|
299204|NCT01920737|Drug|Methotrexate|
299205|NCT01920737|Drug|6-MP (6-Mercaptopurine)|
299206|NCT01920737|Drug|Cyclophosphamide|
299207|NCT01920737|Drug|Cytarabine|
299208|NCT01920737|Drug|Leucovorin|
299209|NCT01920737|Drug|Dexamethasone|
299210|NCT01920737|Other|Blood draw|
299211|NCT01920737|Device|CT/PET scans|PET or CT scan every 6 months for 3 years
299212|NCT01920711|Drug|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
299213|NCT01920711|Drug|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
299214|NCT01920698|Device|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
299215|NCT01920698|Other|control|
299216|NCT01920685|Other|Anxiety intervention|
299217|NCT01920672|Behavioral|Timed Planned Activity|
299218|NCT01920672|Behavioral|Home Safety and Education Program|
299219|NCT01920659|Behavioral|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
299220|NCT01920659|Behavioral|REHIT|6 weeks 3 x week (20sec intervals)
299221|NCT01920646|Other|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
299222|NCT01920620|Behavioral|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
299223|NCT01920620|Behavioral|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
299224|NCT01920607|Device|magnetic anal sphincter|
299225|NCT01920607|Device|sacral nerve stimulation|
299226|NCT01920594|Drug|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
299227|NCT01920594|Drug|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
299228|NCT01920568|Biological|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
299229|NCT01920568|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance <=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
299230|NCT01920568|Drug|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
299231|NCT01920568|Drug|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
299491|NCT01918553|Other|axial length (IOL master)|
299232|NCT01920568|Dietary Supplement|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
299233|NCT01920568|Dietary Supplement|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
299234|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
299235|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
299236|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
299237|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
299238|NCT01920555|Drug|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
299239|NCT01920542|Drug|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
299240|NCT01920542|Drug|no dexmedetomidine|no administration of dexmedetomidine on control group
299241|NCT01920529|Other|aerobic exercise|Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
299242|NCT01920516|Drug|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
299243|NCT01920503|Drug|Doxorubicin|Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
299244|NCT01920490|Device|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
299245|NCT01920490|Device|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
299246|NCT01920477|Biological|Ofatumumab|Ofatumumab (human monoclonal antibody) was provided in prefilled glass syringes initial syringes contained 0.6ml (60mg) of concentration 100 mg/m: drug product subsequently modified to 0.4 mL (20mg) concentration (50mg/ML) drug product
299247|NCT01920477|Biological|Placebo|Placebo to match the active doses will consist of prefilled glass syringes filled with normal saline.
299248|NCT01920451|Behavioral|Cognitive-Behavioral Therapy for Insomnia (CBTI)|See arm description.
299249|NCT01920438|Procedure|Percutaneous Endoscopic Gastrostomy|PEG
299250|NCT01920438|Procedure|Radiologically-guided insertion of Gastrostomy|RIG
299251|NCT01920425|Device|Kinesia HomeView|Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
299252|NCT01920425|Other|Hand-written diary|Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
299253|NCT01920412|Device|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
299254|NCT01920399|Drug|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
299255|NCT01920399|Drug|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
299256|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
299257|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
299258|NCT01920373|Drug|Group A (corticosteroid injection group)|
299259|NCT01920373|Biological|Group B (platelet rich plasma injection group)|
299260|NCT01920360|Other|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
299261|NCT01920360|Other|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
299262|NCT01920360|Other|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
299263|NCT01920334|Drug|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
299264|NCT01920334|Drug|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
299265|NCT01920321|Procedure|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
299266|NCT01920308|Device|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
299267|NCT01920295|Device|Cryoballoon ablation|
299268|NCT01920282|Drug|Nebivolol|
299269|NCT01920282|Other|Lifestyle Modification|
299270|NCT01920282|Other|Nebivolol plus Lifestyle Modification|
299271|NCT01920269|Procedure|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
299439|NCT01918839|Device|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
299440|NCT01918839|Device|Restylane-L|Restylane-L injected into wrinkle treatment area
299441|NCT01918826|Device|TENS|
299272|NCT01920269|Drug|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
299273|NCT01920269|Device|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
299274|NCT01920256|Other|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
299275|NCT01920256|Other|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
299276|NCT01920243|Behavioral|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
299277|NCT01920230|Behavioral|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams & Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
299278|NCT01920230|Behavioral|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
299279|NCT01920204|Drug|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
299280|NCT01920191|Biological|IMA 950|
299281|NCT01920191|Biological|Poly ICLC|
299282|NCT01920191|Other|Immunomonitoring|Blood samples, DTH analysis
299283|NCT01920178|Device|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
299284|NCT01920165|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
299285|NCT01920152|Biological|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
299286|NCT01920152|Device|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
299287|NCT01920139|Procedure|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
299288|NCT01920139|Procedure|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
299289|NCT01920139|Other|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
299290|NCT01920126|Drug|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
299291|NCT01920126|Drug|Saline|
299292|NCT01920113|Drug|Dexmedetomidine - remifentanil group|
299293|NCT01920113|Drug|Propofol - remifentanil group|
299294|NCT01920087|Drug|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
299295|NCT01920087|Drug|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
299296|NCT01920074|Drug|Nitroglycerin Ointment 0.4%|
299297|NCT01920061|Drug|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
299298|NCT01920061|Drug|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m^2
299299|NCT01920061|Drug|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m^2
299300|NCT01920061|Drug|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
299301|NCT01920048|Procedure|Percutaneous Coronary Intervention|
299302|NCT01920048|Drug|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
299484|NCT01918566|Dietary Supplement|300ml tap water with 450ppm lactisole|
299303|NCT01920048|Device|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
299304|NCT01920035|Device|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
299305|NCT01920022|Drug|Mifepristone|Day one of medical abortion
299306|NCT01920022|Drug|etonorgestrel|
299307|NCT01920009|Behavioral|Pharmacist counselling session with a motivational interview|"The intervention:~The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.~The intervention group consultation:~Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.~The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
299308|NCT01919996|Drug|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
299309|NCT01919970|Other|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
299310|NCT01919970|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
299311|NCT01919957|Other|No intervention|
299312|NCT01919944|Drug|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
299313|NCT01919944|Drug|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
299314|NCT01919918|Drug|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
299315|NCT01919905|Dietary Supplement|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
299316|NCT01919892|Drug|Lithium|
299317|NCT01919879|Drug|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
299318|NCT01919879|Drug|Cetuximab|Cetuximab administered intravenously
299319|NCT01919866|Other|Transplantation of CD3/CD19 depleted stem cells|
299320|NCT01919853|Behavioral|Mindfulness-Based Stress Reduction|
299321|NCT01919853|Behavioral|Attention Control|
299322|NCT01919840|Procedure|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
299323|NCT01919840|Other|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
299324|NCT01919827|Biological|Endobronchial infusion of adult mesenchymal stem cells|
299325|NCT01919827|Biological|Autologous mesenchymal stem cells derived from bone marrow|
299326|NCT01919814|Dietary Supplement|Appethyl™|Four hours after breakfast participants will be given a small amount of liquid to drink that will contain Appethyl™. They will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. Participants are not expected to eat all of the pizza.
299327|NCT01919814|Other|Placebo|Four hours after breakfast, participants will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). Participants will not know which they are getting and it will be decided randomly, like flipping a coin. Participants will be presented with a pizza in a quantity more than they could reasonably be expected to eat 5 hours after the start of their lunch meal and be asked to eat to their satisfaction over 30 minutes. They are not expected to eat all of the pizza.
299328|NCT01919801|Drug|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
299329|NCT01919801|Drug|Placebo|
299330|NCT01919788|Drug|Insulin (Insuman Rapid)|
299331|NCT01919788|Drug|Glucose|
299332|NCT01919788|Other|Saline|
299333|NCT01919749|Other|treated recommended|Treatment will be recommended after reviewing the profiling analysis
299334|NCT01919736|Behavioral|Gait Retraining|
299335|NCT01919723|Drug|Ticagrelor|Ticagrelor loading dose
299336|NCT01919723|Drug|Eptifibatide|i.v. infusion
299337|NCT01919710|Drug|rHSA/GCSF|for treatment of neutropenia
299338|NCT01919697|Drug|Plecanatide|
299339|NCT01919684|Drug|LGD-6972|
299340|NCT01919684|Drug|Placebo (Captisol®)|
299341|NCT01919671|Drug|Tongxinluo capsule|for 90 days
299342|NCT01919671|Drug|placebo capsule|for 90 days
299343|NCT01919658|Procedure|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
299344|NCT01919645|Other|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
299485|NCT01918553|Other|clinical parameters|
299486|NCT01918553|Other|visual acuity exams|
299345|NCT01919632|Behavioral|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
299346|NCT01919619|Biological|Ipilimumab|Given IV
299347|NCT01919619|Drug|Lenalidomide|Given PO
299348|NCT01919606|Drug|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
299349|NCT01919593|Drug|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
299350|NCT01919593|Drug|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
299351|NCT01919554|Biological|SLIT tablets of HDM allergen extracts|
299352|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
299353|NCT01919541|Device|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
299354|NCT01919541|Device|hyperinsulinemic euglycemic hyperaminoacid clamp|
299355|NCT01919541|Dietary Supplement|whey protein supplementation|
299356|NCT01919541|Other|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
299357|NCT01919528|Procedure|ultrasound|catheterization of the axillary vein under ultrasound guidance
299358|NCT01919515|Device|ZR Crown|This is an esthetic primary molar crown.
299359|NCT01919515|Device|Stainless Steel Crown|This is a conventional stainless steel crown.
299360|NCT01919502|Device|Semi-quantitative urine pregnancy test|
299361|NCT01919489|Drug|Liraglutide + OADs|Liraglutide subcutaneously daily
299362|NCT01919489|Drug|Glargine + OADs|Glargine once daily subcutaneously
299363|NCT01919476|Other|Bagel|
299364|NCT01919476|Other|Cream Cheese|
299365|NCT01919476|Other|Almond Butter|
299366|NCT01919463|Behavioral|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
299367|NCT01919463|Device|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
299368|NCT01919450|Drug|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
299369|NCT01919450|Radiation|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
299370|NCT01919437|Device|Web-Enabled Cognitive Neuropsychological Evaluation System|
299371|NCT01919424|Drug|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system~Low risk - commonly used to diagnose asthma"
299372|NCT01919424|Device|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
299373|NCT01919424|Device|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing~Roxon Medi-Tech, Montreal, PQ, Canada"
299374|NCT01919411|Drug|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
299375|NCT01919411|Drug|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
299376|NCT01919398|Drug|LY2940680|Administered orally
299377|NCT01919385|Device|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
299378|NCT01919372|Device|Telemedic assistance with a technological system|
299379|NCT01919372|Other|Standard care|
299380|NCT01919359|Dietary Supplement|Multizyme Cellular Vitality Cyruta Plus SHEP|
299381|NCT01919346|Drug|Eculizumab|
299382|NCT01919346|Drug|Normal Saline|
299383|NCT01919320|Device|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
299384|NCT01919320|Device|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
299385|NCT01919307|Other|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
299386|NCT01919294|Drug|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
299387|NCT01919281|Behavioral|strength training|
299388|NCT01919281|Behavioral|interval training|
299389|NCT01919268|Device|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
299487|NCT01918553|Other|retinophotography|
299488|NCT01918553|Other|SD-OCT|
299390|NCT01919268|Device|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
299391|NCT01919255|Drug|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
299392|NCT01919255|Drug|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
299393|NCT01919242|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
299394|NCT01919229|Drug|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
299395|NCT01919229|Drug|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
299396|NCT01919216|Drug|Citalopram|
299397|NCT01919203|Drug|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
299398|NCT01919190|Drug|EXPAREL|
299399|NCT01919190|Drug|Placebo|
299400|NCT01919177|Dietary Supplement|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
299401|NCT01919177|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
299402|NCT01919164|Drug|Sprifermin 100 microgram (mcg)|Sprifermin will be administered at a dose of 100 mcg in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
299403|NCT01919164|Drug|Sprifermin 100 microgram (mcg)|Sprifermin will be administered at a dose of 100 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
299404|NCT01919164|Drug|Sprifermin 30 microgram (mcg)|Sprifermin will be administered at a dose of 30 mcg in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
299405|NCT01919164|Drug|Sprifermin 30 microgram (mcg)|Sprifermin will be administered at a dose of 30 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
299406|NCT01919164|Drug|Placebo|Matching placebo will be administered in 2 cycles (at Months 6 and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
299407|NCT01919164|Drug|Placebo|Matching placebo will be administered in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
299408|NCT01919125|Drug|IDX719|IDX719 supplied as 50 mg tablets.
299409|NCT01919112|Device|tDCS|Anodal tDCS will be administered with swallowing exercises
299410|NCT01919086|Drug|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m^2, days 1, 8, 15 and 22
299411|NCT01919086|Drug|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
299412|NCT01919086|Drug|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
299413|NCT01919073|Behavioral|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
299414|NCT01919073|Behavioral|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
299415|NCT01919047|Drug|Betanis|Oral
299416|NCT01919021|Other|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
299417|NCT01919021|Other|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
299418|NCT01919021|Procedure|Assessment of Gastric motor and sensory function|
299419|NCT01919008|Drug|FK949E|Oral
299420|NCT01918995|Drug|Regadenoson|Intravenous (IV)
299421|NCT01918995|Drug|Placebo|Intravenous (IV)
299422|NCT01918956|Biological|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
299423|NCT01918943|Device|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
299424|NCT01918930|Biological|MGA271|MGA271 anti-B7-H3 monoclonal antibody
299425|NCT01918917|Drug|Levobupivacaine|intraarticular
299426|NCT01918917|Drug|Dexmedetomidine|intraarticular 1 ml (100 mcg)
299427|NCT01918917|Drug|Morphine|intravenously, patient-controlled analgesia
299428|NCT01918904|Drug|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
299429|NCT01918904|Drug|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
299430|NCT01918891|Behavioral|Nurse Practitioner Only|
299431|NCT01918891|Behavioral|Nurse Practitioner + Health Coach|
299432|NCT01918878|Drug|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
299433|NCT01918865|Drug|ISIS-PTP1BRx|
299434|NCT01918865|Drug|Placebo|
299435|NCT01918865|Drug|daily OAD (metformin and/or sulfonylurea)|
299442|NCT01918813|Drug|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
299443|NCT01918800|Behavioral|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
299444|NCT01918800|Behavioral|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
299445|NCT01918787|Device|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
299446|NCT01918774|Behavioral|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
299447|NCT01918761|Drug|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 iV (q21d) Dacomitinib 45mg orally (continuous)
299448|NCT01918748|Device|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
299449|NCT01918735|Drug|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
299450|NCT01918735|Drug|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.~Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
299451|NCT01918722|Drug|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
299452|NCT01918722|Drug|placebo|placebo herbal medicine, one dose,bid, for 10 days
299453|NCT01918722|Drug|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
299454|NCT01918709|Drug|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
299455|NCT01918709|Drug|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
299456|NCT01918709|Drug|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
299457|NCT01918709|Drug|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
299458|NCT01918709|Drug|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
299459|NCT01918709|Drug|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
299460|NCT01918696|Behavioral|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
299461|NCT01918696|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
299462|NCT01918696|Behavioral|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
299463|NCT01918683|Radiation|TACE transarterial chemoembolization|
299464|NCT01918683|Radiation|stereotatic body radiotherapy (SBRT)|
299465|NCT01918670|Procedure|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
299466|NCT01918657|Drug|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
299467|NCT01918657|Drug|walnut powder|escalating doses of walnut powder
299468|NCT01918644|Radiation|stereotactic body radiation therapy|Undergo SBRT
299469|NCT01918644|Drug|capecitabine|Given PO
299470|NCT01918644|Procedure|therapeutic conventional surgery|Undergo definitive surgery
299471|NCT01918644|Procedure|magnetic resonance imaging|Optional correlative studies
299472|NCT01918644|Other|laboratory biomarker analysis|Optional correlative studies
299473|NCT01918631|Drug|tenofovir disoproxil fumarate|
299474|NCT01918631|Drug|Entecavir|
299475|NCT01918605|Device|Diluted spacer|
299476|NCT01918605|Device|Non-diluted spacer|
299477|NCT01918592|Device|MRI/acetate-PET imaging|
299478|NCT01918579|Procedure|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
299479|NCT01918566|Dietary Supplement|tap water|
299480|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
299481|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
299482|NCT01918566|Dietary Supplement|25g Fructose in 300ml tap water|
299483|NCT01918566|Dietary Supplement|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
299492|NCT01918540|Procedure|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
299493|NCT01918540|Procedure|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
299494|NCT01918540|Device|MS-30 femoral stem|This is the stem used in the study.
299495|NCT01918527|Drug|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
299496|NCT01918527|Drug|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
299497|NCT01918514|Drug|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
299498|NCT01918501|Procedure|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
299499|NCT01918488|Dietary Supplement|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
299500|NCT01918488|Drug|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
299501|NCT01918475|Drug|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
299502|NCT01918475|Drug|Placebo|1ml of NaCl 0.9% is administered intravenously
299503|NCT01918449|Other|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
299504|NCT01918436|Behavioral|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
299505|NCT01918436|Other|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
299506|NCT01918423|Behavioral|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
299507|NCT01918410|Device|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
299508|NCT01918410|Device|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
299509|NCT01918397|Drug|Levofloxacin|Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4benzoxazine-6-carboxylic acid hemihydrate.
299510|NCT01918397|Drug|Optimized background regimen (OBR)|"For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses."
299511|NCT01918384|Drug|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
299512|NCT01918384|Drug|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
299513|NCT01918371|Drug|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
299514|NCT01918358|Drug|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
299515|NCT01918358|Drug|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
299516|NCT01918358|Drug|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
299517|NCT01918358|Drug|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
299518|NCT01918358|Drug|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
299519|NCT01918358|Drug|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
299520|NCT01918345|Behavioral|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
299557|NCT01918124|Drug|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
299558|NCT01918124|Drug|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
299559|NCT01918111|Procedure|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
299560|NCT01918111|Drug|adenosine infusion treatment|Continue hypertensive medication
299561|NCT01918098|Drug|Oxycodone/naloxone prolonged release tablets|
299521|NCT01918345|Behavioral|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
299522|NCT01918332|Drug|Valsartan 160mg|
299523|NCT01918332|Drug|Rosuvastatin 20mg|
299524|NCT01918332|Drug|Valsartan 160mg placebo|
299525|NCT01918332|Drug|Rosuvastatin 20mg placebo|
299526|NCT01918319|Behavioral|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
299527|NCT01918306|Drug|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.~In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~--------------------------------------------------------------------------------"
299528|NCT01918306|Other|laboratory biomarker analysis|correlative studies
299529|NCT01918306|Other|pharmacological study|correlative studies
299530|NCT01918306|Procedure|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
299531|NCT01918306|Drug|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
299532|NCT01918293|Device|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
299533|NCT01918280|Procedure|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
299534|NCT01918254|Drug|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
299535|NCT01918254|Drug|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
299536|NCT01918254|Drug|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
299537|NCT01918241|Drug|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
299538|NCT01918241|Drug|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
299539|NCT01918241|Drug|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
299540|NCT01918241|Drug|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
299541|NCT01918228|Behavioral|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
299542|NCT01918215|Device|ICD|
299543|NCT01918215|Device|ILR|
299544|NCT01918202|Drug|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
299545|NCT01918202|Drug|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.~This cohort is optional."
299546|NCT01918202|Drug|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
299547|NCT01918189|Behavioral|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
299548|NCT01918176|Drug|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
299549|NCT01918176|Drug|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
299550|NCT01918163|Dietary Supplement|Pomegranate pills|
299551|NCT01918150|Device|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
299552|NCT01918150|Device|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
299553|NCT01918137|Dietary Supplement|chocolate bar|
299554|NCT01918137|Dietary Supplement|Porridge|
299555|NCT01918124|Radiation|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
299556|NCT01918124|Drug|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
299562|NCT01918085|Other|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
299563|NCT01918085|Other|Strata strip|An adhesive strip made of the Strata adhesive
299564|NCT01918072|Other|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
299565|NCT01918059|Procedure|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
299566|NCT01918059|Procedure|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
299567|NCT01918059|Procedure|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
299568|NCT01918033|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
299569|NCT01918033|Drug|Placebo|Matching placebo to desloratadine 5 mg tablets
299570|NCT01918020|Behavioral|Go Wild with Fruits and Veggies!|Fruits and Vegetables
299571|NCT01918020|Behavioral|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
299572|NCT01918007|Procedure|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of Obstructive SDB.
299573|NCT01917994|Behavioral|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
299574|NCT01917994|Behavioral|Appointment Reminders|
299575|NCT01917981|Device|Personal Heart Rhythm Monitor|
299576|NCT01917968|Device|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
299577|NCT01917968|Procedure|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
299578|NCT01917942|Device|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
299579|NCT01917942|Other|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
299580|NCT01917929|Device|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
299581|NCT01917916|Drug|Placebo|Placebo
299582|NCT01917916|Drug|BI 655064|
299583|NCT01917916|Drug|BI 655064|
299584|NCT01917916|Drug|BI 655064|
299585|NCT01917916|Drug|Placebo|Placebo
299586|NCT01917916|Drug|BI 655064|
299587|NCT01917916|Drug|Placebo|
299588|NCT01917916|Drug|Placebo|Placebo
299589|NCT01917903|Behavioral|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
299590|NCT01917903|Behavioral|Identification of at risk variables|Participants will complete walking under three conditions: walking alone, walking while talking to an investigator in person, and walking while talking to an investigator on a cell phone. Spatiotemporal measures of gait will be collected.
299591|NCT01917890|Dietary Supplement|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
299592|NCT01917890|Dietary Supplement|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
299593|NCT01917877|Drug|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
299594|NCT01917877|Drug|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
299595|NCT01917864|Behavioral|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
299596|NCT01917838|Behavioral|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.~The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
299597|NCT01917825|Drug|MDT-15|
299598|NCT01917812|Device|Digital Activity Tracker|
299599|NCT01917812|Other|Smart Text Messaging|
299600|NCT01917799|Drug|Aspirin|75mg tab of LDA once daily for 7 months
299601|NCT01917799|Drug|Heparin|0.4 mL/day of the Enoxaparin
299602|NCT01917786|Device|ECG|
299603|NCT01917773|Drug|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
299604|NCT01917773|Drug|Bisacodyl|
299605|NCT01917747|Behavioral|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
299606|NCT01917747|Behavioral|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
299607|NCT01917734|Other|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
299608|NCT01917721|Drug|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.
299609|NCT01917721|Drug|Placebo|Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
299610|NCT01917708|Drug|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
299611|NCT01917695|Drug|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
299612|NCT01917695|Radiation|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
299613|NCT01917695|Radiation|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
299614|NCT01917695|Procedure|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
299615|NCT01917682|Procedure|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
299616|NCT01917656|Drug|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
299617|NCT01917656|Drug|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
299618|NCT01917656|Drug|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
299619|NCT01917630|Drug|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
299620|NCT01917630|Drug|placebo|
299621|NCT01917617|Drug|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)~Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
299622|NCT01917617|Drug|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion~Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
299623|NCT01917604|Procedure|open exposure|the open surgical methods of exposing the canine is compared with control
299624|NCT01917604|Procedure|closed exposure|closed exposure is compared with control
299625|NCT01917591|Device|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
299626|NCT01917591|Device|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
299627|NCT01917578|Device|Ultrasound|"Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size refers to WHO standards."
299628|NCT01917578|Procedure|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
299629|NCT01917578|Procedure|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
299630|NCT01917578|Device|Pathologic Large Tissue Selected Table|"Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.~Each piece of breast tissues by cutting with the table has 3mm thickness."
299631|NCT01917578|Device|Leica TP1020|"Procedure:~Alcohol 70 % 1h~Alcohol 80 % 1h~Alcohol 85 % 1h~Alcohol 90 % 1h~Alcohol 95 % 1h~Alcohol Ⅰ 100 % 1h~Alcohol Ⅱ 100 % 1h~Xylene Ⅰ 2h~Xylene Ⅱ 2h~Xylene Ⅲ 2h~Paraffin 6h~Paraffin 6h"
299632|NCT01917578|Device|Pathologic Large Tissue Embedded Table|"The table is made of brass .It is applying for a chinese patent.~The table can simultaneously embed 8 piece of breast tissues."
299633|NCT01917578|Device|Leica SM2000 R|Each of paraffin section has 4 um thickness.
299634|NCT01917578|Procedure|HE Stain|"Procedure:~Xylene Ⅰ 60℃ 15-20 minutes~Xylene Ⅱ 60℃ 15-20 minutes~Alcohol 100% Ⅰ 3-5 minutes~Alcohol 100% Ⅱ 3-5 minutes~Alcohol 95% Ⅱ 3-5 minutes~Alcohol 90% Ⅱ 3-5 minutes~Wash in running tap water for 3 minutes~Hematoxylin 5-10 minutes~Wash in running tap water for 3 minutes~Differentiate in 1% acid alcohol for 30 seconds~Wash in running tap water for 1 minute~Bluing in 0.2% ammonia water for 30-60 seconds~Wash in running tap water for 3 minutes~Counterstain in eosin Y solution for 30-60 seconds~Wash in running tap water for 1 minute~Alcohol 90% Ⅱ 2-3 minutes~Alcohol 95% Ⅱ 2-3 minutes~Alcohol 100% Ⅱ 3-5 minutes~Alcohol 100% Ⅱ 3-5 minutes~Xylene Ⅲ 5-10 minutes~Xylene Ⅳ 5-10 minutes~Mounting with neutral resin"
299799|NCT01916252|Drug|Dexamethasone acetate|
299635|NCT01917578|Device|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
299636|NCT01917578|Device|Epson V600|"Each slice that has been microscopically outlined is scanned by Epson V600.~Every image by scanning should be saved as JPG."
299637|NCT01917578|Device|MRI|"Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size refers to WHO standards.~The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
299638|NCT01917578|Procedure|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:~Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.~Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.~Observe the shrinkage modes in three-dimensional space.~According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.~According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.~B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
299639|NCT01917578|Device|Mammography|"Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.~Measurement of tumor size and calcification extent refers to WHO standards.~Calcification extent is not only measured in mammography image but also under microscope."
299640|NCT01917578|Drug|TAC,TC,TA,CAF,CEF|"TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)~TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)~TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)~CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)~CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
299641|NCT01917578|Drug|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.~TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)~AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)~TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)~TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.~CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
299642|NCT01917552|Drug|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
299643|NCT01917539|Device|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
299644|NCT01917539|Device|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
299645|NCT01917526|Device|oxygen mask|
299646|NCT01917526|Device|oxygen cannula|
299647|NCT01917513|Device|G-EYE™ colonoscopy|G-EYE™ colonoscopy
299648|NCT01917513|Device|Standard Colonoscopy|Standard Colonoscopy
299649|NCT01917474|Dietary Supplement|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
299650|NCT01917474|Dietary Supplement|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
299651|NCT01917448|Drug|Morphine|spinal morphine 0.15 mg
299652|NCT01917448|Other|control|Patient receive only local infiltration without spinal analgesia
299653|NCT01917435|Device|video-stylet|
299654|NCT01917435|Device|fiberoptic bronchoscope|
299655|NCT01917409|Device|conventional laryngoscopy|the device is to assist nasotracheal intubation
299656|NCT01917409|Device|video-stylet|the device is to guide the nasotracheal tube into trachea
299657|NCT01917396|Drug|Fleet enema|
299658|NCT01917383|Drug|Trabodenoson|Ophthalmic eye drop
299659|NCT01917383|Drug|Latanoprost|Ophthalmic eye drop
299660|NCT01917383|Drug|Timolol|Ophthalmic eye drop
299661|NCT01917370|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
299662|NCT01917357|Biological|Quinvaxem in Uniject|
299663|NCT01917357|Biological|Quinvaxem in single dose vials|
299664|NCT01917344|Other|MRI|
299665|NCT01917331|Drug|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
299666|NCT01917331|Drug|Beclometasone/Formoterol|Active comparator
299667|NCT01917318|Drug|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.~During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
299668|NCT01917318|Drug|Placebo|During 8 weeks subjects will receive oral placebo
299669|NCT01917305|Device|platform-shifted implant|
299670|NCT01917292|Procedure|One-Stage Full-Mouth Disinfection|"Basic oral hygiene instructions~Dental extractions will be performed (only in cases of teeth that could not be saved)~Standard cycle of supragingival ultrasonic scaling and polishing~Scaling and root planning after the administration of local anesthesia, four quadrants in one session~Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
299671|NCT01917292|Procedure|Periodontal care|"Basic oral hygiene instructions~Standard cycle of supragingival ultrasonic scaling and polishing"
299672|NCT01917279|Drug|Docetaxel plus Capecitabine|Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
299673|NCT01917279|Drug|Capecitabine|Capecitabine 500 mg/m2 three times daily on days 1-21 of each 3-week cycle
299674|NCT01917279|Drug|Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3 week cycle
299675|NCT01917253|Device|Standard Device for peripheral vein cannulation|
299676|NCT01917253|Device|Long Catheters for peripheral vein cannulation|
299677|NCT01917240|Other|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
299678|NCT01917227|Behavioral|Video|
299679|NCT01917214|Other|Sutent: Observational Study|Sutent oral therapy
299680|NCT01917201|Procedure|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
299681|NCT01917201|Procedure|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
299682|NCT01917188|Behavioral|Full simulation and education|
299683|NCT01917188|Behavioral|See simulation room, usual education|
299684|NCT01917162|Device|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
299685|NCT01917162|Device|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
299686|NCT01917149|Drug|Benazepril|
299687|NCT01917149|Drug|Valsartan|
299688|NCT01917149|Drug|Metoprolol|
299689|NCT01917136|Drug|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
299690|NCT01917136|Drug|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
299691|NCT01917136|Other|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
299692|NCT01917123|Drug|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
299693|NCT01917110|Device|omafilcon A|
299694|NCT01917110|Device|Spectacle|
299695|NCT01917097|Drug|Dexmedetomidine|
299696|NCT01917084|Other|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
299697|NCT01917071|Other|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
299698|NCT01917058|Drug|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
299699|NCT01917058|Drug|placebo|
299700|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
299701|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
299702|NCT01917045|Drug|Morphine|morphine 0. 5mg/ml
299703|NCT01917032|Dietary Supplement|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
299704|NCT01917032|Dietary Supplement|placebo|
299705|NCT01917019|Drug|Placebo|matching placebo tablets
299706|NCT01917019|Drug|BIIB041 (fampridine)|fampridine prolonged-release tablets
299707|NCT01917006|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
299708|NCT01917006|Drug|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
299709|NCT01916993|Drug|NBI-98854 50 mg capsule|
299710|NCT01916980|Drug|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
299711|NCT01916967|Drug|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
299712|NCT01916967|Drug|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
299713|NCT01916954|Drug|3-day artemether-lumefantrine|
299714|NCT01916954|Drug|5-day artemether-lumefantrine|
299715|NCT01916941|Drug|Prazosin|
299716|NCT01916941|Drug|Placebo|
299717|NCT01916915|Drug|Tramadol infusion via wound catheter|
299718|NCT01916915|Drug|Levobupivacaine|
299719|NCT01916902|Drug|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
299720|NCT01916902|Drug|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
299721|NCT01916902|Procedure|Optical Coherence Tomography|
299722|NCT01916889|Other|RACY test|
299723|NCT01916876|Other|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.~On day 3 they will be contacted telephonically to:~i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance~Reminders via SMS to attend there OPD appointment(s)~Medical out-patient review at 2-weeks and 6 weeks if required~Medical telephonic hot-line for advice"
299724|NCT01916863|Drug|LX4211 400 mg|
299725|NCT01916863|Drug|canagliflozin 300 mg|
299726|NCT01916863|Drug|LX4211 Placebo|
299727|NCT01916850|Drug|LX4211 400 mg|
299728|NCT01916850|Drug|LX4211 800 mg|
299729|NCT01916850|Drug|LX4211 Placebo|
299730|NCT01916837|Other|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
299731|NCT01916837|Other|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
299732|NCT01916837|Procedure|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
299733|NCT01916824|Drug|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
299734|NCT01916798|Drug|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up & another dose at the day of embryo Transfer.
299735|NCT01916785|Drug|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
299736|NCT01916772|Other|no interventions|no interventions
299737|NCT01916759|Drug|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
299738|NCT01916746|Procedure|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
299739|NCT01916733|Drug|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
299740|NCT01916720|Drug|SB-480848 40 mg|Study Drug
299741|NCT01916720|Drug|SB-480848 80 mg|Study Drug
299742|NCT01916720|Drug|Placebo|Study Drug
299743|NCT01916707|Drug|Dosing of enoxaparin for VTE prophylaxis|
299744|NCT01916694|Device|Blue tooth enabled glucose meter with smart phone application|
299745|NCT01916694|Behavioral|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
299746|NCT01916681|Device|Cervical Foley & Misoprostol|A cervical foley combined with misoprostol will be used to induce the patient.
299747|NCT01916681|Drug|Misoprostol Alone|Misoprostol will be used alone to induce the patient
299748|NCT01916681|Device|Cervical Foley Alone|A cervical foley alone will be used to induce the patient
299749|NCT01916681|Device|Cervical Foley & Pitocin|A cervical foley combined with pitocin will be used to induce the patient
299750|NCT01916655|Behavioral|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
299751|NCT01916655|Behavioral|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
299752|NCT01916655|Behavioral|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
299753|NCT01916642|Drug|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
299754|NCT01916642|Drug|Lidocaine 1.5mg/kg|same as other
299755|NCT01916642|Drug|Lidocaine 2mg/kg|same as other
299756|NCT01916642|Drug|Lidocaine 2.5mg/kg|same as other
299757|NCT01916629|Drug|Photocil for Psoriasis|Photocil for Psoriasis
299758|NCT01916629|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
299759|NCT01916616|Behavioral|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
299760|NCT01916603|Behavioral|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
299761|NCT01916590|Drug|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
299762|NCT01916590|Drug|placebo|
299763|NCT01916577|Drug|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
299764|NCT01916564|Other|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
299765|NCT01916564|Other|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy~Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy~2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
299766|NCT01916525|Behavioral|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
299767|NCT01916499|Other|3 tesla magnetic resonance imaging findings; coronary artery status|
299768|NCT01916499|Other|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
299769|NCT01916486|Behavioral|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
299770|NCT01916486|Behavioral|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
299771|NCT01916486|Behavioral|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
299772|NCT01916473|Other|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
299773|NCT01916473|Other|Continuous wound infusion|Continuous wound infusion via catheter
299774|NCT01916460|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
299775|NCT01916460|Device|19 guage fine needle aspiration needle|
299776|NCT01916447|Drug|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
299777|NCT01916447|Drug|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
299778|NCT01916447|Drug|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
299779|NCT01916434|Other|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
299780|NCT01916434|Other|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
299781|NCT01916434|Other|No salmon|The placebo group will continue to consume their habitual diet.
299782|NCT01916421|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
299783|NCT01916408|Drug|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
299784|NCT01916408|Drug|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
299785|NCT01916395|Drug|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
299786|NCT01916382|Drug|Nitisinone|drug
299787|NCT01916369|Biological|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
299788|NCT01916356|Other|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
299789|NCT01916343|Procedure|Study Laparoscopic Curriculum|
299790|NCT01916317|Drug|0.5% lignocaine 60mM|
299791|NCT01916304|Drug|Levothyroxine sodium new formulation|Levothyroxine tablets
299792|NCT01916291|Drug|Propess insertion group|
299793|NCT01916278|Device|Emervel Lips Lidocaine|
299794|NCT01916278|Device|Juvéderma Volbella with Lidocaine|
299795|NCT01916265|Drug|Glucagon|
299796|NCT01916252|Drug|bortezomib (Velcade ®)|
299797|NCT01916252|Drug|lenalidomide (Revlimid®)|
299798|NCT01916252|Drug|busulfan (Busilvex ®)|
299801|NCT01916239|Dietary Supplement|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
299802|NCT01916239|Dietary Supplement|Pomegranate extract formulation-1|New pomegranate extract formulation-1
299803|NCT01916239|Dietary Supplement|Pomegranate extract formulation-2|New pomegranate extract formulation-2
299804|NCT01916226|Drug|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
299805|NCT01916226|Drug|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
299806|NCT01916226|Drug|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
299807|NCT01916226|Drug|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
299808|NCT01916213|Procedure|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
299809|NCT01916200|Drug|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
299810|NCT01916187|Drug|Imetelstat|
299811|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
299812|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
299813|NCT01916161|Other|Questionnaire|
299814|NCT01916148|Drug|18F-DOPA|18F-DOPA is a PET scan radiotracer.
299815|NCT01916135|Radiation|[18F]-SKI-249380|
299816|NCT01916135|Procedure|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
299817|NCT01916135|Other|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic & metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
299818|NCT01916122|Drug|Fluorestradiol (FES)|
299819|NCT01916122|Procedure|PET/CT Imaging|
299820|NCT01916109|Drug|Gemcitabine|
299821|NCT01916109|Drug|Carboplatin|
299822|NCT01916109|Drug|Panitumumab|
299823|NCT01916109|Procedure|radical cystectomy|
299824|NCT01916096|Device|Delica Device|
299825|NCT01916057|Device|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
299826|NCT01916044|Other|Ultrasound|Measure of Uterine Segment by Ultrasound
299827|NCT01916031|Behavioral|Education|
299828|NCT01916018|Other|Clinical and radiologic exams and blood samples|
299829|NCT01916005|Device|18F-FDG PET/CT|
299830|NCT01915992|Other|blood samples|
299831|NCT01915979|Biological|Plasma rich in growth factors (PRGF)|
299832|NCT01915979|Drug|Celestone cronodose (Bethametasone)|
299833|NCT01915966|Dietary Supplement|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
299834|NCT01915966|Dietary Supplement|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
299835|NCT01915940|Drug|Bimatoprost|Bimatoprost ocular insert
299836|NCT01915940|Drug|Timolol 0.5%|Timolol 0.5% solution
299837|NCT01915940|Drug|Placebo Eye Drops|Placebo topical eye drops
299838|NCT01915940|Device|Placebo Ocular Insert|Ocular insert without any active drug
299839|NCT01915927|Drug|MSC-AFP|
299840|NCT01915914|Drug|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
299841|NCT01915901|Drug|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
299842|NCT01915901|Drug|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
299843|NCT01915901|Drug|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
299953|NCT01914952|Dietary Supplement|HMB free acid|0.8 g HMB free acid
299954|NCT01914939|Drug|Oxytocin|
299844|NCT01915888|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
299845|NCT01915875|Other|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
299846|NCT01915849|Drug|LIK066|LIK066 15 mg, 50 mg and 150 mg
299847|NCT01915849|Drug|Placebo|
299848|NCT01915836|Other|web-based video game (Quit IT)|
299849|NCT01915836|Behavioral|Questionnaires|
299850|NCT01915836|Behavioral|Evaluation Interview|
299851|NCT01915823|Drug|azelastine hydrochloride and fluticasone propionate|
299852|NCT01915823|Drug|Dymista vehicle|
299853|NCT01915810|Behavioral|Exercise Intervention|Complete SCwPA intervention
299854|NCT01915810|Other|Laboratory Biomarker Analysis|Correlative studies
299855|NCT01915810|Drug|Nicotine Patch|Receive nicotine patch
299856|NCT01915810|Other|Questionnaire Administration|Ancillary studies
299857|NCT01915810|Other|Tobacco Cessation Counseling|Receive smoking cessation counseling
299858|NCT01915797|Other|blood and tumor samples|all tumor pathology associated with anomaly of development
299859|NCT01915784|Device|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
299860|NCT01915784|Device|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
299861|NCT01915771|Drug|lomitapide|20 mg dose
299862|NCT01915758|Drug|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
299863|NCT01915758|Drug|vehicle gel|vehicle gel
299864|NCT01915745|Other|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
299865|NCT01915732|Drug|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
299866|NCT01915732|Drug|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
299867|NCT01915719|Procedure|Early non invasive ventilation|
299868|NCT01915719|Procedure|Oxygen therapy only|
299869|NCT01915706|Procedure|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
299870|NCT01915693|Radiation|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
299871|NCT01915667|Drug|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
299872|NCT01915667|Drug|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
299873|NCT01915667|Drug|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
299874|NCT01915654|Procedure|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
299875|NCT01915641|Device|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
299876|NCT01915628|Device|BioMatrix Flex|Percutaneous coronary intervention
299877|NCT01915615|Other|None - this is an observational study|None - this is an observational study
299878|NCT01915602|Drug|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
299879|NCT01915602|Drug|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
299880|NCT01915589|Drug|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
299881|NCT01915576|Drug|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
299882|NCT01915576|Drug|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
299883|NCT01915576|Drug|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
299884|NCT01915563|Procedure|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
299885|NCT01915550|Drug|Metformin|
299886|NCT01915550|Drug|Humulin Insulin Mixtard|
299887|NCT01915537|Drug|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
299888|NCT01915537|Drug|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
299889|NCT01915524|Biological|CV9202|Intradermal injection of CV9202
299890|NCT01915524|Radiation|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
299891|NCT01915498|Drug|AG-221|AG-221 administered orally on every day of 28 day cycles until disease progression or unacceptable toxicities. Multiple doses.
299892|NCT01915485|Radiation|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
299893|NCT01915472|Drug|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
299894|NCT01915459|Biological|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
299895|NCT01915459|Biological|Botulinum toxin type A(Botox®)|
299896|NCT01915433|Other|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
299897|NCT01915433|Other|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
299898|NCT01915381|Other|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
299899|NCT01915368|Behavioral|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
299900|NCT01915368|Behavioral|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
299901|NCT01915368|Behavioral|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
299902|NCT01915355|Device|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
299903|NCT01915342|Device|Focal muscular vibration|
299904|NCT01915329|Device|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted."
299905|NCT01915329|Device|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
299906|NCT01915316|Other|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
299907|NCT01915303|Drug|Pasireotide with or without cabergoline|The trial consists of Pasireotide-untreated patients will start pasireotide 0.6mg twice a day for 8 weeks. If biochemical control is not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose will be increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline will be added and patients will begin combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline wlil be increased to 1.0mg once a day. Patients can also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients will continue with the combination treatment for 8 weeks. If biochemical control is not achieved by the end of the 8 week period, the dose of cabergoline will be increased to 1mg once a day.
299908|NCT01915277|Drug|Dexmedetomidine|
299909|NCT01915264|Drug|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
299910|NCT01915212|Biological|HSV529|The vaccine was administered intramuscularly (deltoid muscle) as a 0.5 ml solution containing 1 x 10(7) plaque forming units on day 0, one month after the first dose (day 30) and then six months after the first dose (day 180).
299911|NCT01915212|Other|Placebo|Sodium Chloride 0.9%
299912|NCT01915199|Other|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
299913|NCT01915186|Dietary Supplement|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
299914|NCT01915173|Drug|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
299915|NCT01915173|Drug|Placebo|Lactose tablets
299916|NCT01915173|Behavioral|Expanded Interview|
299917|NCT01915173|Behavioral|Standard Interview|
299918|NCT01915160|Behavioral|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
299919|NCT01915160|Behavioral|TF-CBT|Treatment as usual.
299920|NCT01915147|Drug|OXN PR followed by OxyPR tablets|
299921|NCT01915147|Drug|OxyPR followed by OXN PR tablets|
299922|NCT01915134|Drug|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
299923|NCT01915134|Drug|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
299924|NCT01915121|Behavioral|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
299955|NCT01914939|Behavioral|Social Skills focused CBT|
299956|NCT01914939|Behavioral|Stress management/relaxation training|
299957|NCT01914939|Drug|placebo drug|
299925|NCT01915121|Behavioral|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
299926|NCT01915108|Drug|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
299927|NCT01915095|Device|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
299928|NCT01915095|Device|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
299929|NCT01915095|Other|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
299930|NCT01915095|Other|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
299931|NCT01915082|Drug|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
299932|NCT01915082|Drug|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
299933|NCT01915069|Drug|Cilostazol|
299934|NCT01915056|Other|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
299935|NCT01915043|Other|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
299936|NCT01915030|Other|High protein diet|controlled feeding trail. Both arms are caloric restricted
299937|NCT01915030|Other|standard protein diet|
299938|NCT01915017|Behavioral|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
299939|NCT01915017|Behavioral|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
299940|NCT01915017|Behavioral|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
299941|NCT01915017|Other|Treatment as Usual|Standard medication follow up and limited case management
299942|NCT01915004|Other|Educational Intervention|Bladder Training Video
299943|NCT01914991|Procedure|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
299944|NCT01914991|Procedure|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
299945|NCT01914978|Other|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
299946|NCT01914978|Other|Food allergy treatment as usual|
299947|NCT01914965|Drug|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
299948|NCT01914965|Drug|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
299949|NCT01914952|Dietary Supplement|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
299950|NCT01914952|Dietary Supplement|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
299951|NCT01914952|Dietary Supplement|HMB free acid mixed in water|0.8 g HMB free acid in water
299952|NCT01914952|Dietary Supplement|CaHMB in water|1.0 g CaHMB powder mixed in water
299958|NCT01914926|Drug|Metoprolol|
299960|NCT01914913|Biological|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
299961|NCT01914900|Drug|docetaxel, cisplatin, 5 fluorouracil|
299962|NCT01914887|Drug|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
299963|NCT01914874|Behavioral|Mindfulness Meditation|
299964|NCT01914848|Other|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
299965|NCT01914848|Other|Control Group|A routine care discharge planning with the social service
299966|NCT01914835|Behavioral|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).~The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
299967|NCT01914822|Drug|methylphenidate hydrochloride|
299968|NCT01914822|Drug|Sugar pill (placebo)|
299969|NCT01914809|Other|samples blood|
299970|NCT01914809|Other|biopsy placentaire|
299971|NCT01914796|Drug|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
299972|NCT01914796|Drug|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
299973|NCT01914783|Other|ultrafine particles|exposure to ultrafine particles
299974|NCT01914783|Other|ultrafine particles and ozone|exposure to ultrafine particles and ozone
299975|NCT01914783|Other|clean air|Exposure to clean air.
299976|NCT01914770|Drug|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
299977|NCT01914770|Drug|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
299978|NCT01914770|Drug|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
299979|NCT01914757|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
299980|NCT01914757|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
299981|NCT01914744|Drug|Entecavir|entecavir 0.5 mg/day PO
299982|NCT01914744|Drug|Lamivudine|lamivudine 100 mg/day PO
299983|NCT01914731|Drug|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
299984|NCT01914718|Drug|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
299985|NCT01914705|Procedure|Landmark Procedure|Using Landmarks to guide SCVC placement
299986|NCT01914705|Procedure|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
299987|NCT01914692|Drug|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
299988|NCT01914679|Device|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
299989|NCT01914666|Drug|Duloxetine|Administered orally
299990|NCT01914653|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
299991|NCT01914627|Drug|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
299992|NCT01914627|Drug|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
299993|NCT01914601|Device|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
299994|NCT01914601|Device|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
299995|NCT01914588|Procedure|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
299996|NCT01914588|Other|Standard care|"Detailed instruction about medical therapy and lifestyle counseling~Telephonic support by a geriatrician, available from Monday to Friday, two hours/day~Follow-up visits"
299997|NCT01914575|Device|Mapping with the Acutus Medical System followed by Ablation|
299998|NCT01914562|Drug|OCA 10 mg|OCA 10 mg tablet oral
299999|NCT01914562|Drug|OCA 25 mg|OCA 25 mg tablet oral
300000|NCT01914523|Device|Macintosh|Laryngeal exposure and tracheal intubation using that device
300001|NCT01914523|Device|King Vision|Laryngeal exposure and tracheal intubation using that device
300002|NCT01914523|Device|Glidescope|Laryngeal exposure and tracheal intubation using that device
300003|NCT01914523|Device|AirTraq|Laryngeal exposure and tracheal intubation using that device
300004|NCT01914510|Drug|ENMD-2076|
300005|NCT01914497|Device|Acutus Medical System Mapping|
300006|NCT01914484|Drug|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
300007|NCT01914484|Drug|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).~No intra-patient dose-escalation will occur. JAK inhibitor"
300008|NCT01914471|Behavioral|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
300009|NCT01914458|Procedure|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
300010|NCT01914445|Drug|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
300011|NCT01914432|Drug|YH16410|
300012|NCT01914432|Drug|Rosuvastatin|
300013|NCT01914432|Drug|Telmisartan|
300014|NCT01914432|Drug|YH16410 placebo|
300015|NCT01914432|Drug|Rosuvastatin placebo|
300016|NCT01914432|Drug|Telmisartan placebo|
300017|NCT01914419|Drug|Oxytocin|
300018|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
300019|NCT01914406|Other|continuous moderate training|Continued exercise 45 min.
300020|NCT01914393|Drug|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
300021|NCT01914380|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
300022|NCT01914367|Biological|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
300023|NCT01914367|Biological|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
300024|NCT01914341|Other|Music|Live music played on the pentatonically tuned children's harp
300025|NCT01914315|Behavioral|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
300026|NCT01914315|Other|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
300027|NCT01914302|Device|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300028|NCT01914302|Device|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300029|NCT01914302|Device|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300030|NCT01914302|Device|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300031|NCT01914302|Device|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300032|NCT01914302|Device|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300033|NCT01914302|Device|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300034|NCT01914302|Device|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
300035|NCT01914289|Procedure|Resection|
300036|NCT01914289|Radiation|Radiotherapy|
300037|NCT01914263|Biological|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10^9 cord blood-derived cytokine indued killer cells.
300083|NCT01913899|Other|Occupational/ physical therapy|
300084|NCT01913899|Other|Mirror therapy|- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
300085|NCT01913886|Procedure|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
300086|NCT01913873|Other|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
300038|NCT01914250|Drug|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
300039|NCT01914237|Device|Castor Stent Graft|Endovascular Repair of Aortic Dissection
300040|NCT01914224|Behavioral|dietary education of low sodium and high potassium consumption|
300041|NCT01914224|Behavioral|dietary education of low sodium consumption only|
300042|NCT01914211|Drug|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
300043|NCT01914211|Procedure|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If > 5Kg draw 20% of circulating blood volume without PRBC replacement)
300044|NCT01914198|Other|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
300045|NCT01914185|Other|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
300046|NCT01914172|Other|online questionairres|see group descriptions
300047|NCT01914159|Drug|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
300048|NCT01914146|Other|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
300049|NCT01914146|Other|No Insulin|Study session will occur prior to initiation of insulin therapy.
300050|NCT01914133|Drug|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
300051|NCT01914133|Drug|Placebo|Placebo given prior to meal the standardized meal
300052|NCT01914107|Procedure|real-time monitoring and instruction of cancer pain|as description in arm
300053|NCT01914107|Procedure|standard cancer pain care|as description in arm
300054|NCT01914094|Behavioral|Prehab|
300055|NCT01914081|Other|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
300056|NCT01914081|Other|Placebo|Patients will receive one uncoated caplet containing placebo, twice daily for the 12 month intervention period
300057|NCT01914068|Other|Supervised exercise in hospital|
300058|NCT01914055|Device|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
300059|NCT01914055|Device|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
300060|NCT01914042|Drug|Morphine|
300061|NCT01914042|Drug|Milnacipran|
300062|NCT01914016|Other|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
300063|NCT01913990|Drug|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
300064|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
300065|NCT01913977|Device|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
300066|NCT01913977|Device|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
300067|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
300068|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
300069|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
300070|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
300071|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
300072|NCT01913964|Drug|Acetylcarnitine|
300073|NCT01913964|Drug|Placebo|(sugar pill)
300074|NCT01913951|Drug|vosaroxin|Given IV over 10 minutes on Day 1 and 4
300075|NCT01913951|Drug|Azacitidine|Given SC or IV over 15 minutes on days 1-7
300076|NCT01913925|Other|Tyrosine-Containing Food Bar|
300077|NCT01913925|Other|Placebo Bar|
300078|NCT01913912|Drug|LDX.|"In this study 3 different doses of LDX will be used:~30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
300079|NCT01913912|Drug|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
300080|NCT01913912|Device|computer task (Go/No-Go task)|
300081|NCT01913912|Device|EEG|event-related potentials (ERP) and heart rate measurements
300082|NCT01913912|Device|pupil size measurements (by using eye tracking)|
300087|NCT01913860|Behavioral|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
300088|NCT01913847|Drug|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
300089|NCT01913847|Drug|Placebo|Oral placebo TID for 12 weeks
300090|NCT01913834|Drug|Forsteo|Subcutaneous administration 20 micrograms
300091|NCT01913834|Drug|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
300092|NCT01913808|Drug|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
300093|NCT01913808|Drug|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
300094|NCT01913795|Other|integrated pest management|integrated pest management and environmental strategy
300095|NCT01913795|Other|air purifier|air purifiers
300096|NCT01913795|Other|Sham air purifier|sham air purifiers
300097|NCT01913769|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
300098|NCT01913756|Dietary Supplement|Gamalost (Norwegian traditional cheese)|
300099|NCT01913756|Dietary Supplement|Gouda-type cheese|
300100|NCT01913730|Drug|Bortezomib|
300101|NCT01913730|Drug|Dexamethasone|
300102|NCT01913717|Radiation|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
300103|NCT01913704|Device|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.~The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
300104|NCT01913691|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
300105|NCT01913678|Other|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
300106|NCT01913678|Other|Complete diet|The participants will be given all dietary items in their diet with no additional products.
300107|NCT01913678|Other|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
300108|NCT01913665|Other|B.lactis|
300109|NCT01913665|Other|Inulin|
300110|NCT01913665|Other|B.Lactis +Inulin|
300111|NCT01913665|Other|Placebo|
300112|NCT01913652|Drug|Cabazitaxel|
300113|NCT01913639|Drug|Regorafenib|
300114|NCT01913639|Drug|5-Fluorouracil|
300115|NCT01913639|Drug|Leucovorin|
300116|NCT01913639|Drug|Oxaliplatin|
300117|NCT01913626|Behavioral|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
300118|NCT01913613|Device|IASD|IASD device implantation
300119|NCT01913600|Device|Resolute Integrity Stent|Drug eluting stent (DES)
300120|NCT01913587|Device|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
300121|NCT01913587|Procedure|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
300122|NCT01913574|Device|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
300123|NCT01913574|Procedure|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
300124|NCT01913561|Device|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.~The electrodes are dry, textile ECG electrodes."
300125|NCT01913561|Device|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
300126|NCT01913535|Drug|CERC-501|"Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).~High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
300298|NCT01912274|Drug|Pracinostat|Elderly newly diagnosed patients will all receive pracinostat
300299|NCT01912274|Drug|Azacitidine|Elderly newly diagnosed patients will all receive azacitadine
300300|NCT01912261|Drug|Placebo|one capsule orally daily times 84 days
300127|NCT01913535|Drug|Placebo|"For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).~For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.~For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
300128|NCT01913522|Procedure|Pulmonary Vein Isolation|
300129|NCT01913509|Device|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
300130|NCT01913509|Device|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
300131|NCT01913496|Other|ebalance|using the ebalance application for 14 weeks
300132|NCT01913483|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
300133|NCT01913483|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
300134|NCT01913470|Drug|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
300135|NCT01913457|Radiation|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
300136|NCT01913444|Drug|Recombinant Antithrombin|
300137|NCT01913431|Drug|Baracle Tab.®|
300138|NCT01913431|Drug|Baraclude Tab.®|
300139|NCT01913418|Drug|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
300140|NCT01913418|Drug|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
300141|NCT01913405|Biological|PEGylated Recombinant factor VIII (rFVIII)|Lyophilized powder and solvent for solution for injection
300142|NCT01913392|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
300143|NCT01913379|Drug|MDV3100|Oral
300144|NCT01913379|Drug|Gemfibrozil|Oral
300145|NCT01913379|Drug|Itraconazole|Oral
300146|NCT01913366|Behavioral|CM-PST|
300147|NCT01913366|Behavioral|SG-PST|
300148|NCT01913353|Biological|MVA BN®|0.5 ml MVA BN® with a nominal titre of 1x10E8 TCID50, administered as a subcutaneous injection
300149|NCT01913353|Biological|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
300150|NCT01913340|Drug|Erythropoietin|1000 U/kg/dose IV x 5 doses
300151|NCT01913340|Drug|Normal saline|placebo: NS IV x 5 doses
300152|NCT01913327|Drug|Aripiprazole|
300153|NCT01913327|Drug|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
300154|NCT01913327|Drug|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
300155|NCT01913314|Drug|[^14C]-LY2835219|Administered as oral solution
300156|NCT01913301|Drug|Alagebrium|
300157|NCT01913288|Other|Biological Maternal Sounds|
300158|NCT01913275|Procedure|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
300159|NCT01913275|Procedure|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
300160|NCT01913262|Behavioral|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
300161|NCT01913249|Procedure|LIFT|Ligation of intersphincteric fistula tract
300162|NCT01913236|Other|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
300163|NCT01913223|Device|Nestis® jet injector system with a bi-functional catheter|
300164|NCT01913210|Dietary Supplement|Ginseng|
300165|NCT01913197|Other|An MRI-based technique to identify prostate cancer|
300166|NCT01913184|Device|AKITA|
300167|NCT01913171|Other|Exercise|
300168|NCT01913158|Drug|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
300169|NCT01913158|Drug|Placebo suppository|Hydrogenated palm kernel oil suppositories
300170|NCT01913145|Device|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
300171|NCT01913132|Device|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
300172|NCT01913119|Drug|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.~Dose and administration: 4-hour infusion of 14 mg/m2"
300213|NCT01912846|Behavioral|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.~Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.~Facilitating EOL care discussions throughout the dying process.~A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
300301|NCT01912261|Drug|Polysaccharide iron complex|150 mg daily orally times 84 days
300302|NCT01912248|Other|strength training|strength training, lower limb.
300173|NCT01913106|Drug|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
300174|NCT01913080|Other|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:~Personal information and emergency contact(s)~Physician names and contact information~Insurance information~Medications, vitamins and supplements~Surgeries~Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.~The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
300175|NCT01913067|Drug|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
300176|NCT01913067|Procedure|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
300177|NCT01913054|Drug|Fentanyl Injection|
300178|NCT01913054|Drug|Etomidate Fat Emulsion Injection|
300179|NCT01913054|Drug|Propofol Injection|
300180|NCT01913028|Drug|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
300181|NCT01913028|Drug|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
300182|NCT01913015|Drug|abiraterone acetate|Given PO
300183|NCT01913015|Dietary Supplement|dietary intervention|Receive low fat breakfast
300184|NCT01913015|Dietary Supplement|dietary intervention|Receive high fat breakfast
300185|NCT01913015|Other|pharmacological study|Correlative studies
300186|NCT01913015|Other|questionnaire administration|Ancillary studies
300187|NCT01913015|Other|laboratory biomarker analysis|Correlative studies
300188|NCT01913002|Drug|LX4211 800 mg|
300189|NCT01913002|Drug|LX4211 2000 mg|
300190|NCT01913002|Drug|moxifloxacin 400 mg|
300191|NCT01913002|Drug|LX4211 Placebo|
300192|NCT01912989|Behavioral|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
300193|NCT01912976|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
300194|NCT01912976|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
300195|NCT01912963|Drug|Pertuzumab|
300196|NCT01912963|Drug|Trastuzumab|
300197|NCT01912963|Drug|eribulin|
300198|NCT01912950|Device|Prowave LX IPL|
300199|NCT01912937|Device|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
300200|NCT01912924|Device|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
300201|NCT01912898|Device|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
300202|NCT01912885|Device|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
300203|NCT01912885|Device|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
300204|NCT01912885|Device|TENS 2-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
300205|NCT01912885|Device|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
300206|NCT01912885|Device|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
300207|NCT01912872|Drug|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
300208|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
300209|NCT01912872|Drug|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
300210|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg). Patients were instructed to take the inhaled budesonide doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
300211|NCT01912872|Drug|Formoterol|Formoterol 12ug. Patients were instructed to take the inhaled formoterol doses every 12 hours following the specific administration instructions as per the manufactures' prescription information.
300212|NCT01912859|Behavioral|Nutrition/physical activity intervention|Nutrition/physical activity intervention
300254|NCT01912612|Drug|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
300303|NCT01912235|Other|2-15N glutamine|Glutamine with N15 isotope tracer
300214|NCT01912846|Behavioral|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
300215|NCT01912820|Dietary Supplement|green tea extract|Given PO
300216|NCT01912820|Drug|quercetin|Given PO
300217|NCT01912820|Other|placebo|Given PO
300218|NCT01912820|Procedure|therapeutic conventional surgery|Undergo prostatectomy
300219|NCT01912820|Other|laboratory biomarker analysis|Correlative studies
300220|NCT01912807|Drug|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
300221|NCT01912807|Drug|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
300222|NCT01912794|Other|Sensory Intervention|"full sensory information, whose participants will practice balancing tasks without constraint sensory body;~sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;~control, whose participants will exercise activities involving cognitive and upper limbs."
300223|NCT01912781|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
300224|NCT01912781|Device|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
300225|NCT01912781|Device|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
300226|NCT01912768|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
300227|NCT01912768|Device|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
300228|NCT01912768|Device|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
300229|NCT01912755|Drug|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
300230|NCT01912755|Drug|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
300231|NCT01912742|Behavioral|Very-low calorie diet (VLCD)|
300232|NCT01912742|Behavioral|Low calorie diet (LCD)|
300233|NCT01912729|Behavioral|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
300234|NCT01912729|Behavioral|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
300235|NCT01912716|Drug|high dose indomethacin|patients randomized to this intervention receive 200mg indomethacin
300236|NCT01912716|Drug|standard dose indomethacin|patients randomized to this intervention receive 100mg indomethacin
300237|NCT01912703|Other|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
300238|NCT01912690|Other|aerobic training|
300239|NCT01912690|Other|aerobic and strength training|
300240|NCT01912677|Drug|Nifedipine|
300241|NCT01912677|Drug|Labetalol|
300242|NCT01912677|Drug|Methyldopa|
300243|NCT01912651|Drug|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
300244|NCT01912638|Device|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
300245|NCT01912638|Drug|Provisc|Provisc is an cohesive viscoelastic.
300246|NCT01912625|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
300247|NCT01912625|Drug|Carboplatin|Given IV
300248|NCT01912625|Radiation|Image Guided Radiation Therapy|Undergo IGRT
300249|NCT01912625|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
300250|NCT01912625|Other|Laboratory Biomarker Analysis|Correlative studies
300251|NCT01912625|Drug|Paclitaxel|Given IV
300252|NCT01912625|Other|Pharmacological Study|Correlative studies
300253|NCT01912625|Drug|Trametinib|Given PO
300255|NCT01912599|Device|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
300256|NCT01912599|Device|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
300257|NCT01912586|Other|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
300258|NCT01912573|Drug|Intranasal (IN) naloxone|
300259|NCT01912573|Drug|Intravenous (IV) naloxone|
300260|NCT01912573|Drug|Intramuscular (IM) naloxone|
300261|NCT01912573|Drug|Intraosseus (IO) naloxone|
300262|NCT01912560|Drug|CAT-2003|
300263|NCT01912560|Drug|Placebo|
300264|NCT01912560|Drug|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
300265|NCT01912547|Procedure|Blood draw for TEG analysis|Blood drawn for TEG analysis
300266|NCT01912534|Drug|Valsartan|40, 80 and 160 mg tablets of Valsartan
300267|NCT01912534|Drug|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
300268|NCT01912521|Behavioral|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
300269|NCT01912495|Drug|Boceprevir|
300270|NCT01912482|Other|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
300271|NCT01912482|Other|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
300272|NCT01912469|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
300273|NCT01912469|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
300274|NCT01912456|Biological|Low-volume C1-esterase inhibitor|
300275|NCT01912456|Biological|Higher-volume C1-esterase inhibitor|
300276|NCT01912456|Biological|Low-volume placebo|
300277|NCT01912456|Biological|Higher-volume placebo|
300278|NCT01912443|Drug|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
300279|NCT01912430|Behavioral|ICC (Integrated Care Coaching) Intervention Group|
300280|NCT01912417|Other|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
300281|NCT01912404|Drug|IDN-6556|25 mg BID for 28 days
300282|NCT01912404|Drug|Placebo|Placebo controlled
300283|NCT01912391|Drug|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
300284|NCT01912391|Drug|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
300285|NCT01912378|Drug|Oxytocin|
300286|NCT01912378|Drug|Placebo nasal spray|
300287|NCT01912365|Procedure|Above Elbow Cast|
300288|NCT01912365|Procedure|Long Arm Splint|
300289|NCT01912352|Drug|Methylphenidate|
300290|NCT01912339|Device|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
300291|NCT01912339|Procedure|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
300292|NCT01912326|Device|Pacemaker Implantation|Implantation of a dual chamber pacemaker
300293|NCT01912313|Procedure|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
300294|NCT01912300|Behavioral|experimental condition: Passvice Video game; Avtive Video game; Exercise|
300295|NCT01912287|Behavioral|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
300296|NCT01912287|Behavioral|Stress Education|Active control group (12 sessions)
300297|NCT01912287|Behavioral|Yoga|12 sessions, mindfulness components
300304|NCT01912235|Other|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
300305|NCT01912235|Other|1-13C glutamine|Glutamine carbon isotope tracer
300306|NCT01912222|Drug|IXAZOMIB|
300307|NCT01912209|Behavioral|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
300308|NCT01912196|Drug|MSI-195|
300309|NCT01912196|Drug|Placebo|
300310|NCT01912183|Behavioral|Communication through PHR outside clinic|
300311|NCT01912183|Behavioral|Monitoring device in PHR|
300312|NCT01912183|Device|Physical activity and sleep monitor|
300313|NCT01912183|Other|PHR|Access to their PHR
300314|NCT01912170|Dietary Supplement|Fish oil|
300315|NCT01912170|Dietary Supplement|Flaxseed oil|
300316|NCT01912157|Behavioral|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
300317|NCT01912144|Other|Coffee|
300318|NCT01912131|Behavioral|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
300319|NCT01912131|Behavioral|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
300320|NCT01912131|Behavioral|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences,
300321|NCT01912131|Behavioral|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
300322|NCT01912131|Behavioral|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
300323|NCT01912118|Drug|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
300324|NCT01912118|Drug|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
300325|NCT01912105|Device|Airway medix closed suction system|
300326|NCT01912105|Device|standard closed suctioning systems|
300327|NCT01912092|Device|Askina Calgitrol paste|
300328|NCT01912066|Drug|Stillen|
300329|NCT01912066|Drug|Cytotec (reference drug)|
300330|NCT01912066|Drug|NSAID (Aceclofenac)|
300331|NCT01912053|Radiation|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
300332|NCT01912040|Drug|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
300333|NCT01912027|Procedure|Open Latarjet technique|
300334|NCT01912027|Procedure|Arthroscopic Latarjet techniques|
300335|NCT01912014|Behavioral|Psychosocial support and counselling|
300336|NCT01912001|Other|Telephone follow-up|
300337|NCT01912001|Other|Sympton Assessment|
300338|NCT01911975|Drug|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
300339|NCT01911975|Drug|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
300340|NCT01911962|Procedure|transvaginal laparoscopic surgery|
300341|NCT01911949|Drug|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
300342|NCT01911936|Drug|LM716|
300343|NCT01911923|Procedure|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
300344|NCT01911923|Procedure|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
300345|NCT01911910|Behavioral|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
300346|NCT01911897|Device|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
300347|NCT01911884|Behavioral|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
300348|NCT01911871|Biological|Blood sample|a blood sample was taken on the day of inclusion
300349|NCT01911858|Device|Askina Calgitrol Paste|
300350|NCT01911845|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
300351|NCT01911845|Drug|ABT-333|Tablet
300352|NCT01911845|Drug|Ribavirin (RBV)|Tablet
300353|NCT01911832|Procedure|esophagojejunostomy after total gastrectomy|
300354|NCT01911832|Procedure|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
300355|NCT01911832|Procedure|wide tube reconstruction after subtotal gastrectomy|
300356|NCT01911832|Procedure|narrow tube reconstruction after subtotal gastrectomy|
300357|NCT01911819|Procedure|Sinus augmentation|
300358|NCT01911819|Drug|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
300359|NCT01911819|Drug|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
300360|NCT01911819|Drug|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
300361|NCT01911806|Device|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
300362|NCT01911806|Procedure|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
300363|NCT01911793|Device|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
300364|NCT01911780|Drug|placebo|placebo matching amlodipine capsule
300365|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
300366|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
300367|NCT01911780|Drug|amlodipine|capsule
300368|NCT01911767|Drug|Dimethyl fumarate|Administered as specified in treatment arm.
300369|NCT01911767|Drug|Peginterferon beta-1a|Administered as specified in treatment arm.
300370|NCT01911754|Biological|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
300371|NCT01911741|Drug|MDV3100|Oral
300372|NCT01911728|Drug|MDV3100|Oral
300373|NCT01911728|Drug|Pioglitazone|Oral
300374|NCT01911728|Drug|Warfarin|Oral
300375|NCT01911728|Drug|Omeprazole|Oral
300376|NCT01911728|Drug|Midazolam|Oral
300377|NCT01911715|Drug|MDV3100|Oral
300378|NCT01911702|Other|Standard fluidic resuscitation.|"Goals:~arterial pressure mean ≥ 65 mmHg or equal to the pre-operative~diuretic rhythm ≥ 1 ml / Kg / h~venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%~BE> - 3~Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
300379|NCT01911702|Other|Volemic small treatment|"Goals of the treatment:~arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values~diuretic rhythm ≥ 0.5 ml / kg / h~venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG~BE> - 5~PVC goal not necessary~To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be > 10-15 ml / kg / h an infusion of furosemide should be initiated"
300380|NCT01911676|Drug|PF-03463275|
300381|NCT01911676|Drug|Placebo|
300382|NCT01911663|Dietary Supplement|KRG|500 mg Korea red ginseng (KRG)
300383|NCT01911663|Dietary Supplement|Placebo|500 mg placebo
300384|NCT01911650|Other|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
300385|NCT01911650|Other|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
300386|NCT01911650|Other|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
300387|NCT01911637|Drug|VBY-036|Study drug VBY-036
300388|NCT01911637|Drug|Placebo|Placebo
300389|NCT01911624|Drug|direct thrombin inhibition|
300390|NCT01911624|Drug|enoxaparin|
300391|NCT01911611|Drug|RO6870868|Single ascending doses
300392|NCT01911611|Drug|placebo|Single ascending doses
300393|NCT01911598|Drug|5-FU|5-FU will be administered as per schedule specified in the respective arm.
300394|NCT01911598|Drug|Carboplatin|Carboplatin will be administered as per schedule specified in the respective arm.
300395|NCT01911598|Drug|Cisplatin|Cisplatin will be administered as per schedule specified in the respective arm.
300396|NCT01911598|Drug|MEHD7945A|MEHD7945A will be administered as per schedule specified in the respective arms.
300397|NCT01911598|Drug|Paclitaxel|Paclitaxel will be administered as per schedule specified in the respective arm.
300398|NCT01911585|Behavioral|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
300399|NCT01911559|Device|standing-frame|
300400|NCT01911546|Drug|everolimus + low-dose tacrolimus|Patients are supplied everolimus (Zortress) + prograf
300401|NCT01911533|Procedure|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
300402|NCT01911533|Procedure|No extracorporeal CO2-removal|Patients are their own control group.
300403|NCT01911520|Drug|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
300404|NCT01911520|Drug|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
300405|NCT01911520|Procedure|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
300406|NCT01911520|Procedure|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
300407|NCT01911507|Drug|INC280|Given PO
300408|NCT01911507|Drug|erlotinib hydrochloride|Given PO
300409|NCT01911494|Behavioral|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
300410|NCT01911494|Device|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (>160mmHg systolic) or proteinuria (>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
300411|NCT01911494|Drug|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
300412|NCT01911494|Drug|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
300413|NCT01911481|Other|hydration|
300414|NCT01911468|Drug|metformin|
300415|NCT01911468|Drug|liraglutide|
300416|NCT01911468|Drug|metformin and liraglutide|
300417|NCT01911455|Drug|acamprosate|
300418|NCT01911455|Drug|Placebo|
300419|NCT01911442|Drug|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
300420|NCT01911442|Drug|Lurasidone|Lurasidone 60 mg once daily
300421|NCT01911442|Drug|Placebo|Placebo
300422|NCT01911429|Drug|Lurasidone 40 mg|Lurasidone 40 mg once daily
300423|NCT01911429|Drug|Lurasidone 80 mg|Lurasidone 80 mg once daily
300424|NCT01911429|Drug|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
300425|NCT01911416|Drug|LDE225|
300426|NCT01911403|Procedure|Manual compression|Closure procedure by Manual compression
300427|NCT01911403|Device|Angio-Seal|Closure procedure by angio-Seal
300428|NCT01911390|Dietary Supplement|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
300429|NCT01911390|Dietary Supplement|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
300430|NCT01911390|Dietary Supplement|Control arm|No bean or rice bran additive in smoothie or muffin.
300431|NCT01911390|Dietary Supplement|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
300432|NCT01911377|Drug|Botulinum Toxin Type A|
300433|NCT01911377|Drug|Normal Saline for Injection|
300434|NCT01911364|Drug|BDP/FF/GB|Superiority over Tiotropium
300435|NCT01911364|Drug|Tiotropium|Superiority of CHF5993 over Tiotropium
300436|NCT01911364|Drug|BDP/FF + Tiotropium|non inferiority vs CHF5993
300437|NCT01911351|Drug|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
300438|NCT01911338|Device|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
300439|NCT01911338|Device|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
300440|NCT01911325|Drug|Buparlisib|
300441|NCT01911325|Drug|Buparlisib matching placebo|
300442|NCT01911325|Drug|Docetaxel|
300443|NCT01911312|Device|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
300444|NCT01911312|Device|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
300445|NCT01911299|Dietary Supplement|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
300446|NCT01911299|Dietary Supplement|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
300447|NCT01911286|Procedure|Apnea test - Standard|
300448|NCT01911286|Procedure|Apnea test - CPAP|
300449|NCT01911273|Drug|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
300450|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
300451|NCT01911273|Other|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
300452|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
300453|NCT01911260|Dietary Supplement|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
300454|NCT01911260|Other|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
300455|NCT01911247|Drug|Metformin|Metformin 850 mg once daily
300456|NCT01911234|Biological|TNF-Kinoid|IM administration
300457|NCT01911234|Other|Placebo|IM administration
300458|NCT01911221|Biological|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
300459|NCT01911208|Behavioral|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
300460|NCT01911208|Behavioral|Control|Non-intervention control.
300461|NCT01911195|Drug|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
300462|NCT01911195|Other|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
300463|NCT01911182|Other|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
300464|NCT01911169|Drug|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
300465|NCT01911156|Drug|Continue NA treatment|Prescribed NA during the 72 week study period
300466|NCT01911156|Drug|Discontinue NA Treatment|Discontinue NA Treatment
300467|NCT01911104|Behavioral|Exercise|10 weeks of aerobic exercise
300468|NCT01911091|Behavioral|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
300469|NCT01911078|Procedure|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
300470|NCT01911078|Device|EnligHTN™ Renal Denervation System.|
300471|NCT01911065|Biological|Zostavax™|In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
300472|NCT01911052|Other|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
300473|NCT01911052|Other|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
300474|NCT01911039|Biological|Regulatory T Cells|
300475|NCT01911026|Other|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
300476|NCT01911013|Procedure|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
300477|NCT01911013|Device|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
300478|NCT01911013|Device|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
300479|NCT01911000|Radiation|RT and hyperthermia after TACE|
300480|NCT01910987|Drug|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
300481|NCT01910987|Drug|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
300482|NCT01910987|Drug|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
300483|NCT01910987|Drug|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
300484|NCT01910974|Procedure|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
300485|NCT01910961|Procedure|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
300486|NCT01910948|Drug|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
300487|NCT01910935|Behavioral|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
300488|NCT01910909|Radiation|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
300630|NCT01909856|Drug|Dexamethasone|Dexamethasone 10mg d1-3
300489|NCT01910896|Device|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
300490|NCT01910883|Drug|Finafloxacin i.v. solution 200 mg|
300491|NCT01910883|Drug|Finafloxacin i.v. solution 400 mg|
300492|NCT01910883|Drug|Finafloxacin i.v. solution 600 mg|
300493|NCT01910883|Drug|Finafloxacin i.v. solution 800 mg|
300494|NCT01910883|Drug|Finafloxacin i.v. solution 1000 mg|
300495|NCT01910883|Drug|Placebo i.v. solution|
300496|NCT01910870|Drug|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
300497|NCT01910870|Drug|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
300498|NCT01910857|Behavioral|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
300499|NCT01910844|Drug|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
300500|NCT01910844|Drug|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
300501|NCT01910831|Drug|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
300502|NCT01910818|Device|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
300503|NCT01910818|Other|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
300504|NCT01910805|Behavioral|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
300505|NCT01910792|Device|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
300506|NCT01910779|Procedure|100 joule as first biphasic shock energy|
300507|NCT01910779|Procedure|120 joule as first biphasic shock energy|
300508|NCT01910766|Drug|Coenzyme Q10|no more details
300509|NCT01910766|Drug|clomiphene citrate|
300510|NCT01910753|Procedure|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
300511|NCT01910740|Other|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
300512|NCT01910740|Other|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
300513|NCT01910740|Other|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
300514|NCT01910727|Behavioral|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
300515|NCT01910714|Behavioral|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
300516|NCT01910714|Behavioral|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
300517|NCT01910701|Behavioral|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
300631|NCT01909856|Drug|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
300637|NCT01909804|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
300518|NCT01910688|Device|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
300519|NCT01910675|Drug|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
300520|NCT01910675|Drug|FFP|4 units Octaplas. Additional fibrinogen if needed.
300521|NCT01910662|Other|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
300522|NCT01910662|Other|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
300523|NCT01910662|Other|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
300524|NCT01910662|Other|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
300525|NCT01910649|Drug|Drisapersen|Subcutaneous and Intravenous
300526|NCT01910636|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
300527|NCT01910636|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
300528|NCT01910623|Other|Health Related Quality of Life (HRQOL) measures|
300529|NCT01910610|Biological|FOLFIRI-cetuximab|
300530|NCT01910610|Biological|mFOLFOX6-bevacizumab|
300531|NCT01910610|Biological|OPTIMOX-bevacizumab|
300532|NCT01910610|Biological|irinotecan-based chemo + bevacizumab|
300533|NCT01910610|Biological|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
300534|NCT01910610|Biological|XELOX + bevacizumab|
300535|NCT01910597|Drug|SBG|
300536|NCT01910584|Procedure|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
300537|NCT01910571|Drug|P7435|
300538|NCT01910571|Other|Placebo|
300539|NCT01910558|Dietary Supplement|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
300540|NCT01910558|Dietary Supplement|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
300541|NCT01910558|Dietary Supplement|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
300542|NCT01910545|Drug|OTS167IV|
300543|NCT01910532|Drug|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
300544|NCT01910519|Biological|H5N1 vaccine plus AS03 adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus with AS03 adjuvant, administered 21 (+/- 3) days apart."
300545|NCT01910519|Biological|H5N1 vaccine without adjuvant|"Administered vaccine: [GlaxoSmithKline] Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant.~Participants receive 2 intramuscular doses of Influenza A (H5N1) Virus without adjuvant, administered 21 (+/- 3) days apart."
300546|NCT01910506|Drug|RDEA3170 10 mg|
300547|NCT01910493|Behavioral|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
300548|NCT01910480|Drug|NBI-98854 50 mg capsule once daily|
300549|NCT01910480|Drug|Ketoconazole 400 mg (200 mg twice daily)|
300550|NCT01910467|Device|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
300551|NCT01910467|Device|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
300552|NCT01910454|Behavioral|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
300632|NCT01909843|Biological|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
300633|NCT01909830|Drug|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.~Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
300634|NCT01909817|Procedure|Routine coronary angiogram|
300553|NCT01910454|Behavioral|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
300554|NCT01910441|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
300555|NCT01910441|Drug|Glimepiride|Glimepiride 1-6 mg once daily
300556|NCT01910441|Drug|Metformin|Metformin (1000-1500 mg daily)
300557|NCT01910428|Drug|L-asparaginase encapsulated in RBC|"50 IU/kg IV~100 IU/kg IV~150 IU/kg IV~200 IU/kg IV"
300558|NCT01910415|Drug|Lumacaftor|
300559|NCT01910415|Drug|Lumacaftor Placebo|
300560|NCT01910415|Drug|Ivacaftor|
300561|NCT01910415|Drug|Ivacaftor Placebo|
300562|NCT01910415|Drug|moxifloxacin hydrochloride|
300563|NCT01910402|Drug|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
300564|NCT01910402|Drug|Atazanavir|Atazanavir capsule 300 mg
300565|NCT01910402|Drug|Ritonavir|Ritonavir tablet 100 mg
300566|NCT01910402|Drug|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
300567|NCT01910389|Drug|Tadalafil|
300568|NCT01910389|Drug|Placebo for tadalafil|
300569|NCT01910363|Drug|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
300570|NCT01910363|Drug|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
300571|NCT01910350|Behavioral|Kin KeeperSM Cancer Prevention Intervention|
300572|NCT01910350|Other|Standard of care|
300573|NCT01910337|Device|Use the Polar Cardiac rate meter|
300574|NCT01910324|Behavioral|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
300575|NCT01910324|Behavioral|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
300576|NCT01910311|Drug|Baricitinib|Administered orally
300577|NCT01910311|Drug|Rifampicin|Administered orally
300578|NCT01910298|Procedure|Breast reconstruction, direct to implant with Strattice|
300579|NCT01910298|Procedure|Two stage breast reconstruction|
300580|NCT01910285|Drug|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
300581|NCT01910285|Drug|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
300582|NCT01910272|Device|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
300583|NCT01910259|Drug|Amiloride|Comparison with placebo
300584|NCT01910259|Drug|Riluzole|Comparison with placebo
300585|NCT01910259|Drug|Fluoxetine|Comparison with placebo
300586|NCT01910259|Drug|Placebo|Placebo comparator
300587|NCT01910246|Drug|Metformin|
300588|NCT01910220|Drug|REGN1033 (SAR391786)|
300589|NCT01910220|Other|placebo|
300590|NCT01910194|Drug|Luyxumia versus Lantus|
300591|NCT01910181|Drug|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
300592|NCT01910155|Drug|Ciprofloxacin/Dexamethasone|
300593|NCT01910155|Drug|Ciprodex (R)|
300594|NCT01910155|Drug|Placebo|
300595|NCT01910142|Dietary Supplement|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
300596|NCT01910142|Dietary Supplement|calcium|
300597|NCT01910129|Device|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
300598|NCT01910116|Drug|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
300599|NCT01910116|Drug|Placebo|The study medication and placebo were identical in appearance.
300600|NCT01910090|Drug|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
300601|NCT01910090|Drug|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
300602|NCT01910077|Drug|Tacrobell capsule 1mg|1 capsule, oral, over the period I&II(crossover)
300603|NCT01910077|Drug|Prograf capsule 1mg|1 capsule, oral, over the period I&II(crossover)
300604|NCT01910064|Drug|GK530G|
300605|NCT01910038|Drug|corticoids+ tocilizumab 8mg/Kg/4 weeks|
300606|NCT01910025|Drug|ADI-PEG 20|
300607|NCT01910012|Drug|ADI-PEG 20|
300635|NCT01909804|Drug|SOF|400 mg tablet administered orally once daily
300636|NCT01909804|Drug|VEL|Tablet administered orally once daily
300691|NCT01909453|Drug|vemurafenib|Tablets in bottles or blisters 240 mg
300608|NCT01909999|Procedure|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.~The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
300609|NCT01909999|Procedure|Clinical parameters evaluation|"The following parameters were assessed:~Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;~Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
300610|NCT01909999|Procedure|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
300611|NCT01909999|Procedure|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
300612|NCT01909999|Procedure|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
300613|NCT01909999|Drug|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
300614|NCT01909986|Drug|[14C]ONO-4053|Single dose [14C]ONO-4053
300615|NCT01909973|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
300616|NCT01909960|Other|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE"
300617|NCT01909947|Other|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:~A 60-minute period while the infant receives any mode of conventional mechanical ventilation~A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
300618|NCT01909934|Drug|brentuximab vedotin|Brentuximab vedotin will be administered as a single intravenous (IV) infusion over 30 minutes on Day 1 of each 3 week cycle for up to a maximum of 16 cycles and should be administered for a minimum of 8 cycles for patients who achieve stable disease or better.
300619|NCT01909908|Device|ECM|ECM in saline applied to wound
300620|NCT01909908|Biological|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
300621|NCT01909908|Device|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
300622|NCT01909895|Other|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
300623|NCT01909895|Other|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
300624|NCT01909895|Other|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
300625|NCT01909895|Other|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
300626|NCT01909882|Other|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
300627|NCT01909869|Device|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
300628|NCT01909856|Drug|Palonosetron|Palonosetron 0.25mg d1,d3
300629|NCT01909856|Drug|Granisetron|Granisetron 3mg d1-3
300638|NCT01909791|Procedure|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
300639|NCT01909791|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
300640|NCT01909791|Procedure|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
300641|NCT01909791|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
300642|NCT01909778|Drug|BI 201335|single oral doses
300643|NCT01909765|Other|Dorsal slit|Skin and mucosa incision made together
300644|NCT01909765|Other|Double incision|Skin and mucosa incision made separately
300645|NCT01909752|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
300646|NCT01909752|Biological|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
300647|NCT01909752|Drug|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
300648|NCT01909752|Drug|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
300649|NCT01909752|Biological|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
300650|NCT01909739|Drug|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
300651|NCT01909739|Drug|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
300652|NCT01909726|Other|ScreenPlay|Interactive technology
300653|NCT01909713|Drug|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
300654|NCT01909700|Device|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
300655|NCT01909687|Device|Blood glucose monitoring systems|
300656|NCT01909674|Device|Switch CPAP mask type|
300657|NCT01909661|Other|Damira/Celia peptide hydrolyzed casein|
300658|NCT01909661|Other|Picot riz/Celia rice/Sanutri arroz|
300659|NCT01909648|Other|Blood withdrawal|
300660|NCT01909648|Genetic|Blood withdrawal|
300661|NCT01909635|Behavioral|Food Feelings|
300662|NCT01909635|Behavioral|Other Feelings|
300663|NCT01909622|Dietary Supplement|Vitamin D|
300664|NCT01909622|Dietary Supplement|No vitamin D|
300665|NCT01909609|Other|AAP Documents|
300666|NCT01909609|Other|Parent Survival Guide|
300667|NCT01909596|Other|Without orthoses|Condition control
300668|NCT01909596|Device|6° lateral wedge insoles|Insoles with a lateral inclination set at 6°
300669|NCT01909596|Device|10° lateral wedge insoles|Insoles with a lateral inclination set at 10°
300670|NCT01909596|Device|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
300671|NCT01909596|Device|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
300672|NCT01909596|Device|7° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 7°
300673|NCT01909596|Device|8° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 8°
300674|NCT01909596|Device|9° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 9°
300675|NCT01909596|Device|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
300676|NCT01909596|Device|Orthotist integrated lateral customized foot orthoses|Foot orthoses with arch support and integrated lateral inclination set according to orthotist experience
300677|NCT01909596|Device|Orthotist lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set according to orthotist experience
300678|NCT01909583|Other|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
300679|NCT01909570|Procedure|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
300680|NCT01909570|Procedure|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
300681|NCT01909557|Drug|Acetyl-L-carnitine|
300682|NCT01909557|Drug|placebo|
300683|NCT01909544|Other|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
300684|NCT01909492|Procedure|Blood Draw|Patients will provide a serum sample for research.
300685|NCT01909492|Procedure|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
300686|NCT01909479|Drug|MOD-4023|Individualized once weekly dose of MOD-4023
300687|NCT01909479|Other|Placebo|Once weekly administration of placebo
300688|NCT01909466|Drug|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
300689|NCT01909453|Drug|LGX818|LGX818- Orally 100 mg and 50 mg capsules
300690|NCT01909453|Drug|MEK162|MEK162- Orally 15 mg tablets
300692|NCT01909440|Behavioral|exercise intervention|Receive whole body RT
300693|NCT01909440|Dietary Supplement|nutritional supplementation|Given whey protein supplementation PO
300694|NCT01909440|Procedure|quality-of-life assessment|Ancillary studies
300695|NCT01909440|Other|questionnaire administration|Ancillary studies
300696|NCT01909440|Other|pharmacological study|Correlative studies
300697|NCT01909440|Other|laboratory biomarker analysis|Correlative studies
300698|NCT01909427|Drug|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
300699|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
300700|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
300701|NCT01909427|Drug|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
300702|NCT01909427|Drug|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
300703|NCT01909427|Drug|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
300704|NCT01909427|Drug|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
300705|NCT01909414|Biological|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
300706|NCT01909414|Biological|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10^8 TCID50 dose IM.
300707|NCT01909414|Biological|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
300708|NCT01909414|Biological|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
300709|NCT01909401|Drug|boceprevir|
300710|NCT01909388|Radiation|MRI-TRUS fusion guided real time HDR|
300711|NCT01909349|Behavioral|self-regulation|Web-based support for behavior change regarding physical activity and fruit & vegetable consumption
300712|NCT01909336|Drug|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
300713|NCT01909336|Drug|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
300714|NCT01909336|Drug|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
300715|NCT01909323|Other|maltitol 85% / FOS15%|
300716|NCT01909323|Other|maltitol alone|
300717|NCT01909323|Other|maltitol 68% / FOS 32%|
300718|NCT01909323|Other|maltitol 50% / FOS 50%|
300719|NCT01909323|Other|FOS alone|
300720|NCT01909323|Other|Placebo|
300721|NCT01909310|Procedure|head extension|the lungs are ventilated with the patient´s head extended
300722|NCT01909310|Procedure|neutral position|the lungs are ventilated with the patient´s head in neutral position
300723|NCT01909310|Procedure|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
300724|NCT01909297|Device|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
300725|NCT01909297|Device|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
300726|NCT01909297|Device|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
300727|NCT01909284|Device|Acupuncture|"BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture."
300728|NCT01909284|Procedure|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
300729|NCT01909271|Behavioral|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
300730|NCT01909271|Other|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
300731|NCT01909258|Other|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.~The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
300732|NCT01909258|Other|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.~Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
300733|NCT01909258|Other|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.~Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
300734|NCT01909245|Biological|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
300735|NCT01909232|Device|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
300736|NCT01909232|Device|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
300737|NCT01909219|Drug|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
300738|NCT01909193|Behavioral|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
300739|NCT01909193|Behavioral|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
300740|NCT01909180|Device|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
300741|NCT01909167|Behavioral|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
300742|NCT01909167|Other|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
300743|NCT01909154|Biological|Mesenchymal stromal cell therapy|Stem cells administration locally
300744|NCT01909141|Drug|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
300745|NCT01909141|Drug|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
300746|NCT01909141|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of > 18 mm or till day 20 of the cycle
300747|NCT01909141|Other|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
300748|NCT01909141|Other|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
300749|NCT01909141|Other|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
300750|NCT01909141|Other|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
300751|NCT01909141|Other|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
300752|NCT01909141|Other|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
300753|NCT01909128|Dietary Supplement|fermented milk|fermented milk with Lactobacillus CBA-L74
300754|NCT01909128|Dietary Supplement|fermented rice|fermented rice wit Lactobacillus CBA-L74
300755|NCT01909115|Dietary Supplement|Vitamin D3|
300756|NCT01909102|Behavioral|ACT-based intervention|
300757|NCT01909102|Behavioral|usual care|
300758|NCT01909089|Drug|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.~Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:~effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.~Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
300759|NCT01909076|Behavioral|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
300760|NCT01909076|Behavioral|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
300761|NCT01909076|Behavioral|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
300762|NCT01909076|Behavioral|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
300763|NCT01909076|Behavioral|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
300851|NCT01908465|Drug|Ebastine|
300764|NCT01909063|Dietary Supplement|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
300765|NCT01909063|Dietary Supplement|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
300766|NCT01909063|Dietary Supplement|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
300767|NCT01909037|Dietary Supplement|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
300768|NCT01909024|Procedure|Coil embolisation|transjugular coil embolisation of pelvic veins
300769|NCT01909024|Procedure|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
300770|NCT01909011|Device|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
300771|NCT01909011|Device|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
300772|NCT01908998|Other|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
300773|NCT01908985|Procedure|high intensity focused ultrasound for cyclodestruction in the eye|
300774|NCT01908972|Drug|Prednisolone|2mg/kg/day for 16weeks
300775|NCT01908972|Drug|Propranolol|2mg/kg/day for 16weeks
300776|NCT01908959|Behavioral|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
300777|NCT01908946|Behavioral|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
300778|NCT01908933|Device|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
300779|NCT01908920|Other|Osteopathic manipulative treatment|
300780|NCT01908920|Other|SHAM|
300781|NCT01908920|Other|CONTROL|
300782|NCT01908907|Dietary Supplement|DHA oil|Therapy Group:DHA oil administered at 50 mg/d (0.18ml) as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
300783|NCT01908907|Dietary Supplement|(MCT) Control oil|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion enterally with feedings or by gavage tube if the infant has one.
300784|NCT01908894|Drug|BIOD-123|
300785|NCT01908894|Drug|BIOD-125|
300786|NCT01908894|Drug|Humalog|
300787|NCT01908881|Behavioral|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
300788|NCT01908881|Behavioral|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
300789|NCT01908868|Other|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
300790|NCT01908868|Other|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
300791|NCT01908868|Other|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
300792|NCT01908855|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
300793|NCT01908855|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:~20 weekly sessions individual therapy (à 50) minutes"
300794|NCT01908842|Drug|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
300795|NCT01908842|Drug|BNX sublingual film|Buprenorphine/naloxone sublingual film
300796|NCT01908842|Drug|Buprenorphine|Buprenorphine sublingual tablets
300797|NCT01908829|Drug|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
300798|NCT01908829|Drug|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
300799|NCT01908829|Drug|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
300800|NCT01908829|Drug|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
300801|NCT01908829|Drug|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
300802|NCT01908829|Drug|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
300852|NCT01908465|Drug|Placebo|
300803|NCT01908829|Drug|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
300804|NCT01908829|Drug|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
300805|NCT01908816|Drug|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
300806|NCT01908803|Drug|AL-60371/AL-817 otic suspension|
300807|NCT01908803|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
300808|NCT01908790|Device|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
300809|NCT01908790|Device|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
300810|NCT01908777|Other|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
300811|NCT01908764|Drug|AL-60371 otic suspension|
300812|NCT01908751|Procedure|Sliding Hip Screw|
300813|NCT01908751|Procedure|Cancellous Screws|
300814|NCT01908751|Drug|Vitamin D|
300815|NCT01908751|Drug|Vitamin D Placebo|
300816|NCT01908738|Drug|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.~Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
300817|NCT01908738|Drug|10%lidocaine spray|
300818|NCT01908725|Drug|Lamazym|ERT, i.v. infusions weekly
300819|NCT01908712|Drug|Lamazym|ERT, i.v. infusions weekly
300820|NCT01908699|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
300821|NCT01908699|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
300822|NCT01908686|Behavioral|Pivotal Response Training|Behavioral intervention for autism
300823|NCT01908673|Behavioral|HRV biofeedback|
300824|NCT01908673|Behavioral|ASTM|
300825|NCT01908660|Drug|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
300826|NCT01908647|Behavioral|RT fMRI|Real-time fMRI with neurofeedback.
300827|NCT01908647|Behavioral|Cognitive Training|Computer based attention training.
300828|NCT01908647|Behavioral|Control RT fMRI|Control condition for real-time fMRI.
300829|NCT01908647|Behavioral|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
300830|NCT01908634|Dietary Supplement|Milk-based Strawberry Beverage|
300831|NCT01908634|Dietary Supplement|Water-Based Strawberry Beverage|
300832|NCT01908634|Dietary Supplement|Milk-based Fruit-Mixed Beverage|
300833|NCT01908634|Dietary Supplement|Water-Based Fruit-Mixed Beverage|
300834|NCT01908621|Drug|G-CSF (filgrastim)|
300835|NCT01908621|Drug|Cytosine arabinoside + G-CSF (filgrastim)|
300836|NCT01908595|Drug|M518101|
300837|NCT01908582|Drug|Evacetrapib|Administered orally
300838|NCT01908582|Drug|Rifampin|Administered orally
300839|NCT01908569|Other|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
300840|NCT01908569|Other|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
300841|NCT01908556|Drug|Letrozole|
300842|NCT01908543|Drug|Ferrous sulphate 200mg oral tablet|Administration by mouth
300843|NCT01908530|Device|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
300844|NCT01908517|Behavioral|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
300845|NCT01908504|Other|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan — also called computerized tomography or just CT — combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
300846|NCT01908491|Device|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
300847|NCT01908491|Device|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
300848|NCT01908478|Drug|Veliparib|
300849|NCT01908478|Drug|Gemcitabine|
300850|NCT01908478|Radiation|Intensity modulated radiation therapy|
300853|NCT01908452|Drug|Pyridoxine|1200 mg/d during 12 weeks
300854|NCT01908439|Other|whole-body vibration|High amplitude whole-body vibration
300855|NCT01908426|Drug|Cabozantinib tablets|
300856|NCT01908426|Drug|Placebo tablets|
300857|NCT01908413|Drug|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
300858|NCT01908400|Biological|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
300859|NCT01908387|Drug|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
300860|NCT01908374|Dietary Supplement|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
300861|NCT01908361|Behavioral|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.~During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
300862|NCT01908361|Behavioral|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.~During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
300863|NCT01908361|Behavioral|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
300864|NCT01908348|Dietary Supplement|Erythritol|
300865|NCT01908335|Drug|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
300866|NCT01908335|Drug|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
300867|NCT01908335|Drug|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
300868|NCT01908335|Drug|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
300869|NCT01908322|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
300870|NCT01908309|Drug|Iobitridol 350|
300871|NCT01908309|Drug|Iodixanol 320|
300872|NCT01908296|Drug|FK949E|Oral
300873|NCT01908296|Drug|fluvoxamine|Oral
300874|NCT01908283|Biological|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
300875|NCT01908270|Behavioral|Yoga|
300876|NCT01908270|Other|Usual care|
300877|NCT01908257|Drug|lesinurad 400 mg|
300878|NCT01908257|Drug|ranitidine 150 mg|
300879|NCT01908257|Drug|lesinurad 400 mg + ranitidine 150 mg|
300880|NCT01908244|Other|Music|Pentatonic music
300881|NCT01908205|Drug|Intranasal Oxytocin|
300882|NCT01908205|Drug|Placebo|
300883|NCT01908192|Drug|NaBen®|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
300884|NCT01908192|Drug|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
300885|NCT01908166|Procedure|ultrasound elasticity imaging|Undergo ultrasound elastography
300886|NCT01908140|Drug|Aclidinium Bromide / Formoterol Fumarate|
300887|NCT01908140|Drug|Salmeterol / Fluticasone|
300888|NCT01908127|Behavioral|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
300889|NCT01908127|Behavioral|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
300890|NCT01908127|Drug|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
300891|NCT01908127|Procedure|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
300892|NCT01908114|Behavioral|Enhanced Community mobilization|
300893|NCT01908114|Biological|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
300894|NCT01908101|Drug|Eribulin Mesylate|Given IV
300895|NCT01908101|Other|Laboratory Biomarker Analysis|Correlative studies
300896|NCT01908088|Biological|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
300897|NCT01908075|Drug|FP/SAL|
300898|NCT01908075|Drug|BDP/FOR|
300899|NCT01908062|Drug|Extended Release Naltrexone|
300900|NCT01908062|Other|Treatment As usual|
300901|NCT01908049|Dietary Supplement|Probiotic.|
300902|NCT01908049|Dietary Supplement|Placebo|
300903|NCT01908023|Behavioral|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
300904|NCT01908010|Drug|ABT-354|ABT-354 Low Dose
300905|NCT01908010|Drug|ABT-354|ABT-354 High Dose
300906|NCT01908010|Drug|Placebo|Placebo
300907|NCT01907997|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
300908|NCT01907997|Drug|normal saline infusion|In group C, the patients receive same volume of normal saline
300909|NCT01907984|Drug|Diclofenac|
300910|NCT01907984|Drug|Midazolam|
300911|NCT01907945|Behavioral|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
300912|NCT01907945|Behavioral|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
300913|NCT01907932|Device|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
300914|NCT01907906|Device|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
300915|NCT01907893|Behavioral|Trauma Collaborative Care Plus Treatment as Usual|
300916|NCT01907880|Drug|Pamidronate|90mg IV once every 4 weeks for 3 cycles
300917|NCT01907880|Drug|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
300918|NCT01907880|Drug|placebo|
300919|NCT01907867|Drug|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
300920|NCT01907854|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
300921|NCT01907854|Drug|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
300922|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
300923|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
300924|NCT01907841|Other|Ischemic Preconditioning|
300925|NCT01907828|Device|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
300926|NCT01907828|Device|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
300927|NCT01907815|Drug|Akt Inhibitor GSK2141795|Given PO
300928|NCT01907815|Other|Laboratory Biomarker Analysis|Correlative studies
300929|NCT01907815|Drug|Trametinib|Given PO
300930|NCT01907802|Drug|Dabrafenib|Given PO
300931|NCT01907802|Other|Laboratory Biomarker Analysis|Correlative studies
300932|NCT01907802|Other|Pharmacogenomic Study|Correlative studies
300933|NCT01907802|Other|Pharmacological Study|Correlative studies
300934|NCT01907789|Other|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
300935|NCT01907789|Procedure|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
300936|NCT01907789|Procedure|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
300937|NCT01907789|Behavioral|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
300938|NCT01907789|Procedure|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.~Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
300939|NCT01907789|Behavioral|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.~Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
300940|NCT01907776|Drug|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
300941|NCT01907776|Drug|ME1100 placebo inhalation solution|Vehicle placebo
300942|NCT01907763|Drug|SOTB07 200mg|
300943|NCT01907763|Drug|SOTB07 400mg|
300944|NCT01907763|Drug|SOTB 200mg placebo|Placebo of SOTB07 200mg
300945|NCT01907763|Drug|SOTB 400mg placebo|Placebo of SOTB07 400mg
300946|NCT01907750|Device|biliary drainage tube|
300947|NCT01907737|Other|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
300948|NCT01907737|Other|Active PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
300949|NCT01907737|Other|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
300950|NCT01907737|Other|Sham PNS|No current will be delivered to the radial, ulnar and median nerves.
300951|NCT01907724|Drug|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
300952|NCT01907724|Drug|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
300953|NCT01907724|Drug|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
300954|NCT01907724|Drug|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
300955|NCT01907711|Device|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
300956|NCT01907698|Behavioral|Vaginal intercourse|vaginal intercourse at least twice a week
300957|NCT01907685|Drug|AVE8062|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
300958|NCT01907685|Drug|Docetaxel|"Pharmaceutical form: solution for infusion~Route of administration: Intravenous"
300959|NCT01907672|Procedure|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
300960|NCT01907659|Other|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
300961|NCT01907646|Device|bladder training|vescical catheter
300962|NCT01907646|Procedure|No bladder training|
300963|NCT01907633|Drug|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
300964|NCT01907620|Other|blood sample|
300965|NCT01907607|Drug|PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.|"PD-0332991 dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.~Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
300966|NCT01907594|Drug|D-cycloserine|
300967|NCT01907594|Drug|Nicotine Replacement Therapy (patch)|
300968|NCT01907594|Behavioral|Smoking Cue Exposure|
300969|NCT01907594|Behavioral|Progressive Muscle Relaxation|
300970|NCT01907594|Drug|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
300971|NCT01907581|Other|Quality of life questionnaires|
300972|NCT01907542|Procedure|stapled skin closure|as above
300973|NCT01907542|Procedure|monocryl skin suture|as above
300974|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
300975|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
300976|NCT01907516|Device|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
300977|NCT01907516|Behavioral|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
300978|NCT01907503|Procedure|Evaluation of the balance of force platform|
300979|NCT01907490|Drug|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
300980|NCT01907477|Other|Samples taken at the clinical hematology unit|
300981|NCT01907464|Other|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
300982|NCT01907464|Other|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
300983|NCT01907464|Other|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
300984|NCT01907464|Other|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
300985|NCT01907425|Other|Blood samples|
300986|NCT01907412|Behavioral|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
300987|NCT01907399|Other|Blood samples|
300988|NCT01907386|Other|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
300989|NCT01907373|Drug|olmesartan medoxomil|
300990|NCT01907373|Drug|olmesartan medoxomil+probenecid|
300991|NCT01907360|Drug|B-HLD200 54mg capsules|
300992|NCT01907360|Drug|C-HLD200 54mg capsules|
300993|NCT01907334|Drug|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
300994|NCT01907334|Drug|Flovent Diskus 100 µg|Flovent Diskus 100 µg
300995|NCT01907334|Drug|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
300996|NCT01907334|Drug|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
300997|NCT01907321|Behavioral|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
300998|NCT01907321|Behavioral|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
300999|NCT01907321|Drug|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
301000|NCT01907321|Behavioral|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
301001|NCT01907321|Radiation|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
301002|NCT01907308|Drug|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
301003|NCT01907308|Drug|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
301004|NCT01907282|Behavioral|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
301005|NCT01907282|Behavioral|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
301006|NCT01907269|Behavioral|Video-based Intervention|Video clips delivered by DVD and Internet
301007|NCT01907256|Procedure|inverted V incision|It is a type of incision
301008|NCT01907256|Procedure|stair step incisions|It is a type of incision
301009|NCT01907243|Procedure|spreader flap|producing of upper lateral cartilage flap as a spreader flap
301010|NCT01907230|Drug|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
301011|NCT01907217|Device|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
301012|NCT01907217|Drug|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
301013|NCT01907217|Drug|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
301014|NCT01907204|Drug|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
301015|NCT01907204|Drug|Budesonide|Budesonide by metered dose inhaler
301016|NCT01907204|Drug|Budesonide|Budesonide by nebulization
301017|NCT01907191|Drug|liposomal bupivacaine|(Ultrasound guided injection of liposomal bupivacaine)
301018|NCT01907191|Drug|Bupivacaine|(around the anterior, lateral and medial aspect of hip joint)
301019|NCT01907165|Drug|Temozolomide|
301020|NCT01907165|Drug|Disulfiram|
301021|NCT01907165|Dietary Supplement|Copper gluconate|
301022|NCT01907152|Other|Protein enriched yoghurt drink and bread|
301092|NCT01906671|Drug|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
301132|NCT01906242|Other|sodium bicarbonate|
301023|NCT01907139|Behavioral|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
301024|NCT01907139|Behavioral|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
301025|NCT01907139|Behavioral|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
301026|NCT01907126|Behavioral|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
301027|NCT01907126|Behavioral|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
301028|NCT01907113|Drug|BI 10773|oral administration
301029|NCT01907113|Drug|BI 10773|oral administration
301030|NCT01907113|Drug|BI 10773|oral administration
301031|NCT01907113|Drug|BI 10773|oral administration
301032|NCT01907113|Drug|BI 10773|oral administration
301033|NCT01907100|Drug|Nintedanib|triple kinase inhibitor; 200mg starting dose
301034|NCT01907100|Drug|Pemetrexed|backbone chemo
301035|NCT01907100|Drug|Cisplatin|backbone chemo
301036|NCT01907100|Drug|Cisplatin|backbone chemo
301037|NCT01907100|Drug|Pemetrexed|backbone chemo
301038|NCT01907100|Drug|Placebo|Nintedanib matching placebo
301039|NCT01907087|Biological|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
301040|NCT01907074|Drug|Cholates|Cholates is given intravenously (IV push) and by mouth, once per study visit
301041|NCT01907061|Drug|N-acetylcysteine|drug will be administered via IV,NG
301042|NCT01907061|Drug|Placebo|placebo or NAC will be given
301043|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
301044|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
301045|NCT01907035|Behavioral|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
301046|NCT01907035|Other|Usual care|
301047|NCT01907022|Device|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.~Arms: Left DLPFC Butterfly Coil"
301048|NCT01907009|Drug|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
301049|NCT01907009|Drug|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.~After the third cycle patient will receive 263mcg/day for 10 days."
301050|NCT01906996|Procedure|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
301051|NCT01906996|Procedure|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
301052|NCT01906983|Other|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
301053|NCT01906970|Device|ClampArt|
301093|NCT01906658|Drug|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
301133|NCT01906242|Other|chlorhexidine|
301054|NCT01906957|Other|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
301055|NCT01906957|Other|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
301056|NCT01906944|Drug|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
301057|NCT01906944|Drug|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
301058|NCT01906931|Device|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
301059|NCT01906931|Device|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
301060|NCT01906918|Procedure|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
301061|NCT01906905|Device|Transcranial Magnetic Stimulation|
301062|NCT01906892|Other|Group drumming (participatory)|Active participation in group drumming workshops
301063|NCT01906892|Other|Group drumming (live)|Listening to live performances of group drumming
301064|NCT01906892|Other|Group drumming (recorded)|Listening to recorded performances of group drumming
301065|NCT01906892|Other|Comparative activity|Taking part in a literary-based activity
301066|NCT01906879|Drug|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
301067|NCT01906866|Drug|Circadin 2/5/10 mg|Active arm
301068|NCT01906866|Drug|Placebo|
301069|NCT01906853|Biological|BCG|
301070|NCT01906840|Drug|Turmeric|
301071|NCT01906840|Drug|placebo|
301072|NCT01906814|Drug|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
301073|NCT01906814|Drug|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
301074|NCT01906801|Drug|Glucosamine sulfate|
301075|NCT01906801|Drug|Diacerein|
301076|NCT01906801|Drug|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
301077|NCT01906788|Drug|Artemether Lumefantrine|
301078|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
301079|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
301080|NCT01906775|Other|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
301081|NCT01906762|Drug|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
301082|NCT01906762|Drug|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
301083|NCT01906749|Drug|Colchicine|0.5mg once daily orally
301084|NCT01906749|Drug|Placebo|
301085|NCT01906723|Device|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
301086|NCT01906710|Other|integrated medicines management|"PITH includes the following interventions:~A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
301087|NCT01906697|Procedure|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
301088|NCT01906697|Procedure|middle turbinate resection|middle turbinate resection
301089|NCT01906697|Procedure|middle turbinate medialization|middle turbinate medialization
301090|NCT01906684|Drug|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
301091|NCT01906671|Drug|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
301094|NCT01906645|Other|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
301095|NCT01906632|Biological|DC-CIK Immunotherapy|
301096|NCT01906606|Behavioral|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
301097|NCT01906580|Drug|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
301098|NCT01906580|Drug|Entecavir|0.5mg,oral administration every day
301099|NCT01906554|Other|Egg Dose|Different quantities of eggs
301100|NCT01906541|Genetic|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
301101|NCT01906528|Drug|Mivacurium|Effect of Mivacurium in males vs females
301102|NCT01906515|Device|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
301103|NCT01906502|Device|Sensimed Triggerfish|
301104|NCT01906489|Drug|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
301105|NCT01906489|Drug|Placebo|Oral placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
301106|NCT01906476|Behavioral|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
301107|NCT01906476|Behavioral|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
301108|NCT01906450|Drug|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
301109|NCT01906450|Drug|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
301110|NCT01906437|Device|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
301111|NCT01906424|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
301112|NCT01906411|Dietary Supplement|Dopamine depletion vs. Balanced aminoacid drink|
301113|NCT01906398|Other|ketogenic diet|KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction
301114|NCT01906385|Drug|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
301115|NCT01906372|Drug|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
301116|NCT01906359|Other|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
301117|NCT01906359|Other|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
301118|NCT01906359|Other|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
301119|NCT01906346|Drug|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
301120|NCT01906346|Drug|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
301121|NCT01906333|Other|Exercise|
301122|NCT01906333|Other|Glucose|
301123|NCT01906333|Other|Fasted|
301124|NCT01906320|Behavioral|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).~The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.~Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
301125|NCT01906307|Drug|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
301126|NCT01906294|Drug|antidiabetic treatment (ATC A10B)|
301127|NCT01906281|Other|Blood analyse, arthrocentesis, ultrasound examination|
301128|NCT01906268|Other|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
301129|NCT01906268|Other|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.~Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
301130|NCT01906242|Other|water|
301131|NCT01906242|Other|sodium hypochlorite|
301134|NCT01906216|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
301135|NCT01906216|Procedure|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
301136|NCT01906203|Device|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
301137|NCT01906190|Biological|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
301138|NCT01906164|Drug|ALS-008176|
301139|NCT01906164|Drug|Placebo|
301140|NCT01906151|Device|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
301141|NCT01906138|Device|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
301142|NCT01906125|Drug|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
301143|NCT01906125|Drug|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
301144|NCT01906125|Drug|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
301145|NCT01906112|Procedure|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
301146|NCT01906099|Other|nutritional intervention|
301147|NCT01906099|Other|life style modification|
301148|NCT01906086|Other|nutritional intervention|
301149|NCT01906086|Other|life style intervention|
301150|NCT01906073|Drug|intranasal fentanyl spray|
301151|NCT01906073|Drug|slow release morphine|
301152|NCT01906060|Device|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
301153|NCT01906034|Behavioral|Exercise with supervision|
301154|NCT01906034|Behavioral|Home-based without supervision|
301155|NCT01906021|Procedure|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
301156|NCT01906021|Procedure|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
301157|NCT01906008|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
301158|NCT01906008|Drug|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
301159|NCT01906008|Behavioral|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
301160|NCT01906008|Behavioral|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
301161|NCT01905982|Procedure|reflectory breathing therapy|duration:2x60 minutes
301162|NCT01905982|Procedure|conventional breathing therapy|duration:4x30 minutes
301163|NCT01905956|Dietary Supplement|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
301164|NCT01905956|Dietary Supplement|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
301165|NCT01905943|Drug|Bendamustine|Bendamustine: 90 milligram per millilitre square (mg/m^2) IV over 60 minutes once daily (QD) Day 1-2 in participants previously untreated or 70 mg/m^2 I.V. over 60 minutes QD Day 1-2 in participants with relapsed/refractory disease. In non-fit participants only, investigators may opt at their own discretion to use lower initial doses of bendamustine, i.e., bendamustine 70 mg/m^2 in previously untreated participants, and bendamustine 50 mg/m^2 in relapsed/refractory subjects (over 60 minutes qd Day 1-2 for each administration).
301166|NCT01905943|Drug|Chlorambucil|Chlorambucil 0.5 mg/kg p.o. qd on Day 1 and Day 15 in non-fit participants only.
301167|NCT01905943|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 I.V. over 15-30 minutes qd Day 1-3 or Cyclophosphamide 250 mg/m^2 p.o. QD Day 1-3 in fit participants only.
301168|NCT01905943|Drug|Fludarabine|Fludarabine 25 mg/m^2 I.V. over 30 minutes QD Day 1-3 or Fludarabine 40 mg/m^2 per os (p.o.) QD Day 1-3 in fit participants only.
301169|NCT01905943|Drug|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
301170|NCT01905930|Device|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
301171|NCT01905930|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
301172|NCT01905917|Other|Tele-rehabilitation|
301173|NCT01905904|Drug|sevorane|Sevorane 4% Sevorane 7%
301207|NCT01905540|Drug|SSP-004184SS|Disodium salt
301208|NCT01905527|Other|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
301693|NCT01901770|Other|educational intervention|Receive HPV vaccination educational materials
301174|NCT01905891|Procedure|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
301175|NCT01905878|Drug|DLBS1033|
301176|NCT01905813|Drug|INCB040093|Escalating doses starting at 100 mg every day (QD)
301177|NCT01905813|Drug|INCB040093|INCB040093 monotherapy - dose to be determined at completion of Phase I of the study
301178|NCT01905813|Drug|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
301179|NCT01905800|Device|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
301180|NCT01905774|Drug|Deferasirox|
301181|NCT01905748|Other|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
301182|NCT01905735|Drug|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
301183|NCT01905735|Drug|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
301184|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
301185|NCT01905722|Other|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
301186|NCT01905709|Biological|Human fecal matter|
301187|NCT01905696|Drug|Oral N-acetylcysteine|
301188|NCT01905683|Drug|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
301189|NCT01905670|Device|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
301190|NCT01905657|Biological|Pembrolizumab|Participants who experienced disease progression on docetaxel may have been eligible to crossover to receive pembrolizumab.
301191|NCT01905657|Drug|Docetaxel|Participants who initially receive docetaxel may be eligible to crossover to receive pembrolizumab.
301192|NCT01905644|Procedure|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
301193|NCT01905631|Drug|Aurstat Anti-Itch Hydrogel (Aurstat)|Subjects will apply Aurstat Anti-Itch Hydrogel 2 times daily or as needed for up to three days to reduce itching. Subjects will also fill out a study diary assessing adverse events or other events they experience during the trial.
301194|NCT01905618|Behavioral|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
301195|NCT01905618|Behavioral|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
301196|NCT01905618|Behavioral|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
301197|NCT01905618|Behavioral|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
301198|NCT01905605|Drug|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
301199|NCT01905605|Drug|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
301200|NCT01905592|Drug|niraparib|Until progression or unacceptable toxicity develops
301201|NCT01905592|Drug|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies
301202|NCT01905579|Procedure|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
301203|NCT01905566|Drug|Clopidogrel|75mg once a day
301204|NCT01905566|Drug|Ticagrelor|90mg twice a day
301205|NCT01905553|Drug|SSP-004184SS|Disodium salt
301206|NCT01905540|Drug|SSP-004184AQ|Magnesium salt
301209|NCT01905527|Other|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
301210|NCT01905527|Other|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
301211|NCT01905514|Device|internet mobile application|
301212|NCT01905501|Drug|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
301213|NCT01905501|Drug|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
301214|NCT01905475|Drug|POL6326|
301215|NCT01905475|Drug|Placebo|
301216|NCT01905462|Other|Data Collection|Analyses of data collected within the CPRD GOLD database.
301217|NCT01905462|Biological|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
301218|NCT01905449|Behavioral|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
301219|NCT01905436|Drug|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
301220|NCT01905423|Drug|Albendazole and diethylcarbamazine|Albendazole 400 mg plus diethylcarbamazine 6 mg/kg once yearly vs twice yearly
301221|NCT01905410|Drug|VVZ-149 Injection|VVZ-149 in water for injection
301222|NCT01905410|Drug|placebo|water for injection
301223|NCT01905397|Device|Conventional wound therapy|Sterile bandages and wound coverings
301224|NCT01905397|Device|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
301225|NCT01905384|Device|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
301226|NCT01905384|Device|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
301227|NCT01905371|Drug|Dextroamphetamine|
301228|NCT01905371|Other|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
301229|NCT01905371|Drug|Placebo|
301230|NCT01905345|Procedure|Training|
301231|NCT01905332|Other|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
301232|NCT01905332|Other|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
301233|NCT01905319|Other|Blood collecting for storage of samples|
301234|NCT01905306|Procedure|computer guided implant planning|
301235|NCT01905306|Procedure|free hand implants placement|
301236|NCT01905293|Other|Feeding Study|
301237|NCT01905280|Procedure|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
301238|NCT01905280|Procedure|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
301239|NCT01905267|Behavioral|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
301240|NCT01905254|Device|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
301241|NCT01905254|Other|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
301242|NCT01905228|Drug|CBL0137|All doses are on Days 1, 8 and 15 of every 28 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops
301243|NCT01905215|Biological|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
301244|NCT01905215|Biological|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
301245|NCT01905215|Biological|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
301246|NCT01905215|Biological|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
301247|NCT01905215|Biological|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
301248|NCT01905215|Biological|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
301249|NCT01905215|Drug|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
301250|NCT01905202|Drug|Secretrol|
301694|NCT01901770|Other|educational intervention|Receive influenza vaccination educational materials
301251|NCT01905189|Procedure|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
301252|NCT01905176|Other|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
301253|NCT01905176|Other|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
301254|NCT01905176|Other|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 & 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 & 2
301255|NCT01905163|Procedure|Tumor Debulking Surgery by laparoscopy|
301256|NCT01905150|Drug|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin
301257|NCT01905150|Drug|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
301258|NCT01905150|Dietary Supplement|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
301259|NCT01905137|Drug|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
301260|NCT01905137|Drug|placebo|
301261|NCT01905124|Drug|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
301262|NCT01905124|Drug|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
301263|NCT01905111|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
301264|NCT01905098|Other|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.~The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.~On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
301265|NCT01905098|Other|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
301266|NCT01905085|Device|No intervention|
301267|NCT01905072|Other|Education Home Visits|"Intervention will include educational home visits on:~Growth monitoring and feedback~Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.~Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.~Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.~Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
301268|NCT01905059|Drug|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
301269|NCT01905059|Drug|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
301270|NCT01905046|Drug|metformin hydrochloride|given PO
301271|NCT01905046|Other|placebo|given PO
301272|NCT01905020|Other|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
301273|NCT01905020|Other|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
301274|NCT01905007|Device|Defibrillation testing|Defibrillation testing at initial ICD implantation
301275|NCT01904994|Procedure|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
301276|NCT01904994|Procedure|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing.~2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
301322|NCT01904604|Biological|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
301323|NCT01904591|Dietary Supplement|Selenium|"Selenium 50 micrograms daily per oral~1 year of treatment"
301324|NCT01904591|Dietary Supplement|Vitamin E|"Vitamin E 400 international units daily per oral~1 year of treatment"
301277|NCT01904994|Behavioral|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
301278|NCT01904994|Behavioral|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.~Telephone call within 7 days of missed appointment for all patients."
301279|NCT01904994|Other|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
301280|NCT01904981|Drug|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
301281|NCT01904981|Drug|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
301282|NCT01904929|Other|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.~This series of test will be repeated 72 hours later for the study reproducibility.~It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
301283|NCT01904916|Procedure|Histological biopsy procedure|
301284|NCT01904903|Drug|Trastuzumab|HER2 therapy
301285|NCT01904903|Drug|Pertuzumab|HER2 therapy
301286|NCT01904903|Drug|Ado Trastuzumab Emtansine|HER2 therapy
301287|NCT01904890|Behavioral|CRC Prevention and Screening Education|Refer to Arm Description
301288|NCT01904890|Behavioral|Nutrition Education|Refer to Arm Description
301289|NCT01904877|Behavioral|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
301290|NCT01904864|Drug|elemental iron (NovaFerrum®)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
301291|NCT01904864|Drug|elemental iron (Ferrous Sulfate)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
301292|NCT01904812|Other|Questionnaire about quality of life and satisfaction|
301293|NCT01904799|Other|Cognitive Assessment test|
301294|NCT01904786|Drug|Melatonin|
301295|NCT01904786|Drug|placebo|
301296|NCT01904773|Drug|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
301297|NCT01904760|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
301298|NCT01904760|Drug|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
301299|NCT01904747|Drug|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
301300|NCT01904747|Drug|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
301301|NCT01904747|Drug|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
301302|NCT01904747|Drug|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
301303|NCT01904734|Drug|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
301304|NCT01904721|Drug|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
301305|NCT01904721|Drug|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
301306|NCT01904721|Drug|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
301307|NCT01904708|Other|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
301308|NCT01904695|Drug|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
301309|NCT01904695|Drug|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
301310|NCT01904682|Drug|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
301311|NCT01904656|Behavioral|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
301312|NCT01904656|Behavioral|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
301313|NCT01904643|Drug|lenalidomide|Given PO
301314|NCT01904643|Drug|mitoxantrone hydrochloride|Given IV
301315|NCT01904643|Drug|etoposide|Given IV
301316|NCT01904643|Drug|cytarabine|Given IV
301317|NCT01904630|Genetic|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
301318|NCT01904617|Other|Dextrose|
301319|NCT01904617|Other|Normal Saline|
301320|NCT01904604|Biological|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
301321|NCT01904604|Biological|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
301325|NCT01904578|Other|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
301326|NCT01904578|Other|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
301327|NCT01904565|Radiation|Hyperthermia and Proton Beam|"Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade~Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
301328|NCT01904552|Device|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
301329|NCT01904539|Drug|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
301330|NCT01904526|Drug|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
301331|NCT01904513|Dietary Supplement|Pasteurized Whole Milk|
301332|NCT01904513|Dietary Supplement|Lactobacillus rhamnosus GR-1|
301333|NCT01904500|Drug|Pre-operative cefazolin|
301334|NCT01904487|Radiation|[11C]flumazenil|[11C]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
301335|NCT01904487|Drug|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
301336|NCT01904474|Other|Next.Step - e-therapeutic intervention program|
301337|NCT01904474|Other|Standard treatment protocol|
301338|NCT01904461|Device|Vacuum device|
301339|NCT01904461|Procedure|Conventional surgery|
301340|NCT01904448|Device|Auditory Brainstem Implantation in Children|
301341|NCT01904422|Procedure|conventional periodontal treatment|
301342|NCT01904409|Drug|Placebo|
301343|NCT01904409|Drug|Rifaximin SSD 40 mg IR tablet|
301344|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet|
301345|NCT01904409|Drug|Rifaximin SSD 40 mg SER tablet|
301346|NCT01904409|Drug|Rifaximin SSD 80 mg SER tablet|
301347|NCT01904409|Drug|Rifaximin SSD 80mgIR/80mgSER tablet|
301348|NCT01904396|Drug|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
301349|NCT01904383|Drug|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
301350|NCT01904357|Drug|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
301351|NCT01904357|Drug|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
301352|NCT01904344|Device|Sensor testing and validation|
301353|NCT01904318|Drug|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
301354|NCT01904318|Drug|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
301355|NCT01904318|Drug|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
301356|NCT01904318|Drug|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
301357|NCT01904318|Drug|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
301358|NCT01904318|Drug|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
301359|NCT01904318|Drug|Placebo|Placebo single dose administration
301360|NCT01904292|Drug|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
301361|NCT01904279|Drug|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
301362|NCT01904266|Procedure|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
301363|NCT01904266|Procedure|GA + sham block|Injection of 1 cc saline subcutaneously
301364|NCT01904253|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
301365|NCT01904253|Drug|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
301366|NCT01904253|Drug|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
301367|NCT01904227|Behavioral|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
301368|NCT01904227|Behavioral|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
301369|NCT01904214|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
301422|NCT01903902|Device|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length < 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
301370|NCT01904188|Device|Gene Z or other rapid diagnostic techniques developed in our lab (as of 2018 not using Gene Z regularly)|The Gene Z device or other rapid diagnostic techniques that we have developed in our lab will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device or other rapid diagnostic techniques developed in our lab will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
301371|NCT01904162|Drug|400 mg finafloxacin (2 x 200 mg tablets)|
301372|NCT01904149|Drug|Placebo|Placebo single oral dose (first 8 hours)
301373|NCT01904149|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
301374|NCT01904149|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
301375|NCT01904149|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
301376|NCT01904149|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
301377|NCT01904149|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
301378|NCT01904149|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
301379|NCT01904136|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
301380|NCT01904136|Procedure|Bone Marrow Transplantation|Undergo allogeneic PBSC or bone marrow transplant
301381|NCT01904136|Drug|Cyclophosphamide|Given IV
301382|NCT01904136|Drug|Fludarabine Phosphate|Given IV
301383|NCT01904136|Other|Laboratory Biomarker Analysis|Correlative studies
301384|NCT01904136|Drug|Melphalan|Given IV
301385|NCT01904136|Drug|Mycophenolate Mofetil|Given PO
301386|NCT01904136|Biological|Natural Killer Cell Therapy|Given IV
301387|NCT01904136|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
301388|NCT01904136|Drug|Tacrolimus|Given IV and PO
301389|NCT01904136|Radiation|Total-Body Irradiation|Undergo TBI
301390|NCT01904123|Other|Laboratory Biomarker Analysis|Correlative studies
301391|NCT01904123|Other|Pharmacological Study|Correlative studies
301392|NCT01904123|Drug|STAT3 Inhibitor WP1066|Given PO
301393|NCT01904110|Drug|Risedronate/Cholecalciferol combination(montly)|once a month
301394|NCT01904110|Drug|Risedronate/Cholecalciferol combination(weekly)|once a week
301395|NCT01904097|Drug|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
301396|NCT01904097|Other|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
301397|NCT01904097|Other|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
301398|NCT01904084|Device|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
301399|NCT01904084|Device|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
301400|NCT01904071|Procedure|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
301401|NCT01904071|Procedure|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
301402|NCT01904071|Drug|IVMS (IV Morphine)|Intravenous Morphine
301403|NCT01904058|Drug|LUM001|
301404|NCT01904058|Drug|Placebo|
301405|NCT01904058|Drug|Ursodeoxycholic Acid|
301406|NCT01904045|Other|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
301407|NCT01904045|Other|tacrolimus Prograf|intake of Prograf twice daily for 3 months
301408|NCT01904032|Drug|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
301409|NCT01904032|Drug|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
301410|NCT01904006|Procedure|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
301411|NCT01904006|Procedure|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
301412|NCT01903993|Drug|Docetaxel|Participants received starting dose of 75 mg/m^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
301413|NCT01903993|Drug|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram [mg/kg]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
301414|NCT01903980|Other|No intervention. It is a retrospective study|No intervention. It is a retrospective study
301415|NCT01903954|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
301416|NCT01903954|Drug|placebo|Orally b.i.d.
301417|NCT01903954|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
301418|NCT01903954|Drug|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
301419|NCT01903941|Behavioral|Aerobic Exercise|
301420|NCT01903941|Behavioral|Only Counseling|
301421|NCT01903928|Biological|ASP0113|injection
301423|NCT01903889|Other|clinic based intervention|counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
301424|NCT01903889|Other|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
301425|NCT01903876|Behavioral|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
301426|NCT01903876|Behavioral|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
301427|NCT01903863|Biological|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
301428|NCT01903850|Device|spray cryotherapy|spray cryotherapy
301429|NCT01903837|Drug|Samidorphan (Low Dose)|Tablets taken once daily
301430|NCT01903837|Drug|Samidorphan (Medium Dose)|Tablets taken once daily
301431|NCT01903837|Drug|Samidorphan (High Dose)|Tablets taken once daily
301432|NCT01903837|Drug|Placebo|Tablets taken once daily
301433|NCT01903837|Drug|Olanzapine|Tablets taken once daily
301434|NCT01903824|Drug|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
301435|NCT01903824|Drug|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
301436|NCT01903824|Drug|modafinil|modafinil 200 mg tablet, over-encapsulated
301437|NCT01903824|Drug|Placebo|Placebos formulated to match each active drug
301438|NCT01903811|Drug|Carfilzomib|Given IV
301439|NCT01903811|Drug|Dexamethasone|Given IV
301440|NCT01903811|Other|Laboratory Biomarker Analysis|Correlative studies
301441|NCT01903798|Drug|Mycophenolate mofetil|Immunosuppressive agent
301442|NCT01903798|Drug|Prednisolone|Corticosteroid
301443|NCT01903798|Drug|Rilonacept|
301444|NCT01903785|Drug|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
301445|NCT01903785|Drug|Placebo|
301446|NCT01903772|Other|Inspiratory Muscle Training|
301447|NCT01903759|Other|Blood samples|
301448|NCT01903733|Drug|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
301449|NCT01903720|Drug|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
301450|NCT01903707|Other|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
301451|NCT01903707|Other|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
301452|NCT01903694|Drug|Sorafenib + Pravastatin|
301453|NCT01903694|Drug|Sorafenib|
301454|NCT01903681|Drug|Circadin 2 mg|First arm lower dose
301455|NCT01903681|Drug|Circadin 10 mg|Second arm higher dose
301456|NCT01903655|Other|telomere length|
301457|NCT01903642|Other|proteomic analysis|
301458|NCT01903629|Device|MCE|MCE first, followed by standard gastroscopy
301459|NCT01903629|Device|Standard gastroscopy|
301460|NCT01903590|Procedure|TVT surgery TOT surgery|
301461|NCT01903577|Other|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
301462|NCT01903577|Other|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
301463|NCT01903564|Device|magnetocardiography|recording of magnetic heart activity
301464|NCT01903564|Device|postnatal ECG|postnatal ECG
301465|NCT01903564|Device|fetal echocardiography|fetal echocardiography
301466|NCT01903551|Device|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
301467|NCT01903538|Device|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
301468|NCT01903538|Device|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
301469|NCT01903525|Drug|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
301470|NCT01903512|Procedure|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
301471|NCT01903499|Other|Other: Bean patty|
301472|NCT01903499|Other|Other: Beef patty|
301833|NCT01900782|Biological|Intervention A|Prefilled syringe.
301473|NCT01903486|Drug|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
301474|NCT01903473|Drug|Rapamycin|"Rapamycin will be started within 2 weeks after inclusion. Rapamycin will be given at 2-6 mg loading dose for one day, followed by approximately 1 mg daily to achieve a target trough level of 5 to 10 ng/mL. The frequency of trough level measurements will be done according to the investigator choice; Rapamycin may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.~Calcineurin inhibitor discontinuation within 2 weeks after rapamycin initiation. No other modification of immunosuppressive drugs and in particular no decrease in the dose of steroids (unless necessary for side effects)."
301475|NCT01903473|Other|T regulatory cells|"One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 60-90 days after first day of rapamycin administration and after calcineurin inhibitor discontinuation. The infusion procedure will take one hour.~Low-dose Il-2 (1x106 IU/day) will be started the day of DTI and will be continued for a period of 2months in order to expand infused donor Tregs."
301476|NCT01903460|Drug|LUM001|
301477|NCT01903460|Drug|Placebo|
301478|NCT01903447|Drug|SSRI|
301479|NCT01903447|Behavioral|CBT|
301480|NCT01903434|Drug|Evacetrapib|Administered orally
301481|NCT01903421|Drug|Spinal anesthesia group: bupivacaine 10-15mg|
301482|NCT01903421|Drug|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
301483|NCT01903421|Genetic|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
301484|NCT01903421|Other|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
301485|NCT01903421|Behavioral|Montreal Cognitive Assessment (MOCA) and MMSE|
301486|NCT01903408|Radiation|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
301487|NCT01903395|Behavioral|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
301488|NCT01903369|Device|Shear Wave Elastography|Shear wave elastography
301489|NCT01903356|Drug|Trajenta duo|Linagliptin and Metformin
301490|NCT01903343|Device|shear wave elastography|ultrasound
301491|NCT01903330|Drug|ERC1671|Given intradermally
301492|NCT01903330|Drug|GM-CSF|Given intradermally
301493|NCT01903330|Drug|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
301494|NCT01903330|Drug|Oral Control (Sucrose pill)|Given PO
301495|NCT01903330|Drug|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
301496|NCT01903330|Drug|Bevacizumab|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
301497|NCT01903317|Other|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
301498|NCT01903317|Other|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B [UVB] or ultraviolet A and psoralen [PUVA]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
301499|NCT01903317|Other|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
301500|NCT01903304|Other|Olive Oil|3 months intervention
301501|NCT01903291|Drug|dimethyl fumarate|As described in the treatment arm
301502|NCT01903278|Drug|PEG-IFN-SA /RBV|
301503|NCT01903278|Drug|Pegasys /RBV|
301504|NCT01903265|Drug|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
301505|NCT01903265|Drug|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
301506|NCT01903252|Drug|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
301507|NCT01903252|Drug|Asacol 400 mg|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
301508|NCT01903239|Procedure|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
301509|NCT01903226|Other|High intensity training|
301510|NCT01903226|Other|Moderate intensity training|
301511|NCT01903213|Drug|bixalomer|Oral
301512|NCT01903200|Drug|FK949E|Oral
301513|NCT01903187|Device|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
301514|NCT01903187|Procedure|Sham|Renal artery angiogram
301515|NCT01903174|Device|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
301516|NCT01903161|Procedure|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
301517|NCT01903161|Procedure|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
301518|NCT01903135|Procedure|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
301519|NCT01903135|Procedure|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.~Medical history, previous treatments."
301520|NCT01903122|Drug|Cevimeline|
301521|NCT01903109|Drug|Cevimeline|
301522|NCT01903096|Behavioral|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
301523|NCT01903096|Drug|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
301524|NCT01903083|Drug|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
301525|NCT01903083|Drug|Gemcitabine|Three doses of gemcitabine (1000 mg / m^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
301526|NCT01903083|Radiation|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
301527|NCT01903083|Procedure|Pancreaticoduodenectomy|Surgical resection.
301528|NCT01903070|Drug|Linagliptin|
301529|NCT01903057|Drug|azithromycin|
301530|NCT01903057|Drug|ivermectin|
301531|NCT01903057|Drug|albendazole|
301532|NCT01903057|Drug|placebo|
301533|NCT01903044|Procedure|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
301534|NCT01903031|Device|Nuvaring|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
301535|NCT01903031|Drug|EFV|Participants received EFV 600 mg daily with two or more NRTIs
301536|NCT01903031|Drug|ATV/r|Participants received ATV/r 300 mg/ 100 mg daily with tenofovir and one or more additional NRTIs
301537|NCT01903031|Drug|TDF|Participants received 300 mg of tenofovir in Arm C
301538|NCT01903031|Drug|NRTIs|Participants received two or more NRTIs in Arm B and one or more NRTIs in Arm C
301539|NCT01903018|Drug|P276-00|
301540|NCT01903018|Radiation|Radiation Therapy|
301541|NCT01903018|Drug|Cisplatin|
301542|NCT01903005|Drug|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
301543|NCT01902992|Drug|Depiquick Birch (DPG103)|
301544|NCT01902992|Drug|Placebo|
301545|NCT01902979|Behavioral|Lifestyle intervention|
301546|NCT01902966|Drug|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
301547|NCT01902966|Behavioral|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
301548|NCT01902966|Behavioral|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
301549|NCT01902966|Behavioral|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
301550|NCT01902953|Drug|Lymphoseek and VBD Sln dissection|See detailed description of study design
301551|NCT01902940|Other|Natural History|Assessment of natural history in IBM and CCFDN
301552|NCT01902927|Other|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
301553|NCT01902914|Procedure|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
301554|NCT01902901|Genetic|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
301555|NCT01902901|Genetic|Carrier status testing|Carrier status testing
301556|NCT01902888|Device|GORE® VIABAHN® Endoprosthesis|
301557|NCT01902875|Drug|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
301558|NCT01902875|Biological|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
301559|NCT01902862|Drug|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
301560|NCT01902862|Drug|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
301561|NCT01902849|Other|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:~T0- before the induction of anesthesia (venous cannula insertion time)~T1- after induction but before starting surgery~In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml~In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%~T2, T3- at 2 and 24 hours after surgery"
301562|NCT01902836|Biological|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:~Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
301563|NCT01902836|Biological|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
301564|NCT01902823|Behavioral|Services from a Nurse Navigator|Services from a Nurse Navigator
301565|NCT01902810|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization
301566|NCT01902810|Drug|Placebo|Placebo by mouth given daily throughout hospitalization
301567|NCT01902797|Other|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
301568|NCT01902784|Behavioral|Storytelling Interview|
301569|NCT01902771|Biological|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
301570|NCT01902771|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
301571|NCT01902771|Other|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
301572|NCT01902771|Procedure|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
301573|NCT01902758|Drug|ambrisentan and theophylline|
301574|NCT01902758|Drug|placebo|placebo for comparison group
301575|NCT01902745|Behavioral|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
301576|NCT01902732|Device|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
301577|NCT01902719|Behavioral|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
301578|NCT01902719|Behavioral|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
301579|NCT01902719|Behavioral|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
301580|NCT01902693|Other|No intervention for this study|No intervention
301581|NCT01902680|Radiation|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
301582|NCT01902667|Procedure|Magnetic Resonance Imaging|
301583|NCT01902654|Other|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
301584|NCT01902654|Other|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
301585|NCT01902654|Other|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
301586|NCT01902641|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
301587|NCT01902641|Drug|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
301588|NCT01902641|Drug|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
301589|NCT01902589|Other|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.~The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.~4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
301590|NCT01902563|Other|Osteopathic Manipulative Treatment|
301591|NCT01902550|Drug|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
301592|NCT01902550|Drug|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
301593|NCT01902550|Drug|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
301594|NCT01902537|Drug|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
301595|NCT01902524|Drug|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
301596|NCT01902511|Drug|G-CSF+Erythropoetin|
301597|NCT01902511|Drug|G-CSF|
301598|NCT01902498|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
301599|NCT01902498|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
301600|NCT01902498|Drug|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
301601|NCT01902485|Other|Timing of Contraceptive Initiation in Medical Abortion|
301602|NCT01902459|Biological|EVARREST™ Fibrin Sealant Patch|EVARREST™ Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
301830|NCT01900795|Drug|V117957|V117957 4.5 mg suspension taken orally after surgery.
301603|NCT01902459|Other|Standard of Care|Standard of Care will be manual compression (MC) with or without a topical absorbable hemostat (TAH) or any other adjunctive hemostasis technique that is deemed by the surgeon to be his/her standard of care.
301604|NCT01902446|Drug|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
301605|NCT01902433|Procedure|Astym|
301606|NCT01902394|Other|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
301607|NCT01902394|Other|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
301608|NCT01902381|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
301609|NCT01902368|Other|gluten free diet|
301610|NCT01902355|Procedure|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
301611|NCT01902355|Procedure|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
301612|NCT01902342|Drug|Oseltamivir 75 mg 1 cap|
301613|NCT01902329|Drug|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
301614|NCT01902329|Drug|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
301615|NCT01902303|Drug|Matching Placebo|Sublingual micro dosing of placebo for 7 days
301616|NCT01902303|Drug|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
301617|NCT01902290|Biological|Placebo|Placebo administered SC
301618|NCT01902290|Biological|210 mg brodalumab|210 mg brodalumab administered SC
301619|NCT01902264|Drug|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
301620|NCT01902251|Drug|Enzalutamide tablet|Oral
301621|NCT01902251|Drug|Enzalutamide capsule|Oral
301622|NCT01902238|Procedure|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
301623|NCT01902225|Drug|Istodax|
301624|NCT01902225|Drug|Doxil|
301625|NCT01902212|Other|Oral Nutritional Supplement|
301626|NCT01902199|Behavioral|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
301627|NCT01902186|Drug|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
301628|NCT01902186|Drug|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
301629|NCT01902173|Drug|Akt Inhibitor GSK2141795|Given PO
301630|NCT01902173|Drug|Dabrafenib|Given PO
301631|NCT01902173|Other|Laboratory Biomarker Analysis|Correlative studies
301632|NCT01902173|Other|Pharmacological Study|Correlative studies
301633|NCT01902173|Drug|Trametinib|Given PO
301634|NCT01902160|Drug|Brentuximab Vedotin|Given IV
301635|NCT01902160|Other|Laboratory Biomarker Analysis|Correlative studies
301636|NCT01902160|Drug|Temsirolimus|Given IV
301637|NCT01902147|Other|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
301638|NCT01902134|Drug|Placebo|Placebo single oral dose (first 8 hours)
301639|NCT01902134|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
301640|NCT01902134|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
301641|NCT01902134|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
301642|NCT01902134|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
301643|NCT01902134|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
301644|NCT01902134|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
301645|NCT01902121|Drug|Technosphere® Insulin 10U + 20U|Inhaled Insulin
301646|NCT01902121|Drug|Technosphere® Insulin 30U|Inhaled Insulin
301647|NCT01902108|Drug|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
301648|NCT01902108|Drug|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
301692|NCT01901783|Procedure|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
301649|NCT01902095|Device|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
301650|NCT01902095|Device|Tooth paste (control)|Active Comparator
301651|NCT01902082|Drug|Mesenchymal stem cells|
301652|NCT01902082|Drug|Placebo|
301653|NCT01902069|Dietary Supplement|Phospholean|"Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).~PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994)."
301654|NCT01902069|Dietary Supplement|Placebo|Placebo consists of rice flour
301655|NCT01902056|Procedure|One layer allograft|The acellular dermal matrix was placed on the facial surface.
301656|NCT01902056|Procedure|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
301657|NCT01902017|Drug|Ketotifen|5 mg PO bid
301658|NCT01902017|Drug|Placebo|5 mg placebo PO bid
301659|NCT01902004|Drug|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
301660|NCT01902004|Drug|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
301661|NCT01902004|Drug|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
301662|NCT01901991|Procedure|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
301663|NCT01901991|Procedure|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
301664|NCT01901978|Behavioral|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
301665|NCT01901965|Behavioral|Neuromuscular electrical stimulation|
301666|NCT01901965|Behavioral|eccentric training|
301667|NCT01901952|Behavioral|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
301668|NCT01901952|Behavioral|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
301669|NCT01901939|Other|exercise|daily tailored low level pedaling exercise at bedside
301670|NCT01901926|Procedure|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
301671|NCT01901913|Device|MD-bolus calculator for pre-meal bolus|
301672|NCT01901913|Device|No MD-bolus calculator for pre-meal bolus|
301673|NCT01901887|Drug|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
301674|NCT01901887|Drug|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
301675|NCT01901874|Device|Carotid Artery Stenting|Carotid Artery Stenting with the GORE® Carotid Stent
301676|NCT01901861|Drug|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
301677|NCT01901861|Drug|Placebo|Placebo is given before meal ingestion
301678|NCT01901848|Behavioral|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
301679|NCT01901848|Drug|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
301680|NCT01901848|Drug|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
301681|NCT01901848|Behavioral|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
301682|NCT01901848|Behavioral|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
301683|NCT01901835|Procedure|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
301684|NCT01901835|Other|survey administration|Ancillary studies
301685|NCT01901835|Procedure|quality-of-life assessment|Ancillary studies
301686|NCT01901822|Procedure|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
301687|NCT01901822|Procedure|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
301688|NCT01901809|Drug|Furosemide|
301689|NCT01901809|Drug|Dopamine|
301690|NCT01901796|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
301691|NCT01901783|Procedure|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
301834|NCT01900782|Biological|Intervention B|Prefilled syringe.
301695|NCT01901757|Drug|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
301696|NCT01901757|Drug|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
301697|NCT01901744|Procedure|Cataract Surgery|
301698|NCT01901731|Procedure|transjugular coil embolisation of pelvic veins|
301699|NCT01901731|Procedure|endovenous treatment of leg varicose veins|
301700|NCT01901705|Drug|Indigo naturalis ointment|The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
301701|NCT01901705|Drug|Placebo|The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake [Blue #32] and 45.2% Allura Red AC aluminum lake [Red #40] powders), Vaseline, microcrystalline wax, and olive oil.
301702|NCT01901692|Radiation|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
301703|NCT01901692|Drug|Sorafenib|Sorafenib 800 mg/day orally
301704|NCT01901679|Drug|Celebrex|200 mg PO BID
301705|NCT01901666|Drug|Growth Hormone|"All GH deficient patients with bone age <14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.~Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
301706|NCT01901653|Drug|Rovalpituzumab tesirine (SC16LD6.5)|
301707|NCT01901640|Drug|DA-8159 (Udenafil)|
301708|NCT01901614|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
301709|NCT01901614|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
301710|NCT01901614|Drug|Retrobulbar Block or General Anesthesia|
301711|NCT01901614|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
301712|NCT01901614|Drug|Topical Anesthesia|
301713|NCT01901614|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
301714|NCT01901601|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.~The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
301715|NCT01901601|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.~In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
301716|NCT01901601|Drug|Retrobulbar Block or General Anesthesia|
301717|NCT01901601|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
301718|NCT01901601|Drug|Topical Anesthesia|
301719|NCT01901601|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
301720|NCT01901588|Drug|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
301721|NCT01901588|Other|Placebo|intraoperative dose of intravenous placebo
301722|NCT01901575|Drug|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
301723|NCT01901562|Device|Ductoscopic papillomectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
301794|NCT01901055|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
301831|NCT01900795|Drug|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
301724|NCT01901549|Procedure|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
301725|NCT01901549|Drug|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
301726|NCT01901549|Drug|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
301727|NCT01901536|Behavioral|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.~Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.~Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
301728|NCT01901523|Behavioral|Reporting of discrepancy to journal|
301729|NCT01901510|Drug|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
301730|NCT01901510|Other|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
301731|NCT01901497|Device|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
301732|NCT01901484|Drug|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
301733|NCT01901471|Drug|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.~The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
301734|NCT01901471|Drug|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).~Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.~CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.~Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.~CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.~The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
301735|NCT01901458|Device|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
301736|NCT01901458|Device|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
301737|NCT01901445|Behavioral|Educational action with focal group|
301738|NCT01901432|Drug|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:~50 mg b.i.d.,~100 mg b.i.d.;~150 mg b.i.d.,~200 mg b.i.d.;~150 mg t.i.d.;~200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
301739|NCT01901419|Drug|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
301740|NCT01901393|Drug|IV ibuprofen|
301741|NCT01901393|Drug|Ketorolac|
301742|NCT01901380|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|
301743|NCT01901367|Dietary Supplement|nutritional intervention|Receive nutritional intervention
301744|NCT01901367|Behavioral|exercise intervention|Receive exercise intervention
301745|NCT01901367|Other|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
301746|NCT01901367|Behavioral|counseling intervention|Receive phone counseling with a trained health coach
301747|NCT01901367|Other|quality-of-life assessment|Ancillary studies
301748|NCT01901367|Other|laboratory biomarker analysis|Correlative studies
301749|NCT01901367|Other|questionnaire administration|Ancillary studies
301750|NCT01901354|Other|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
301751|NCT01901354|Other|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
301752|NCT01901341|Drug|CB-5945|
301753|NCT01901341|Drug|Placebo|
301754|NCT01901328|Drug|CB-5945|
301755|NCT01901328|Drug|Placebo|
301795|NCT01901055|Device|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
301756|NCT01901315|Procedure|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
301757|NCT01901315|Procedure|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
301758|NCT01901302|Drug|CB-5945|
301759|NCT01901302|Drug|Placebo|
301760|NCT01901289|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
301761|NCT01901276|Drug|Omeprazole 40 mg bid|As above.
301762|NCT01901263|Behavioral|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
301763|NCT01901250|Dietary Supplement|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
301764|NCT01901250|Dietary Supplement|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
301765|NCT01901250|Behavioral|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
301766|NCT01901250|Device|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
301767|NCT01901250|Device|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
301768|NCT01901237|Behavioral|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
301769|NCT01901224|Drug|Metformin 1000 mg|
301770|NCT01901224|Drug|Placebo|
301771|NCT01901211|Other|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
301772|NCT01901198|Biological|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
301773|NCT01901198|Biological|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
301774|NCT01901185|Drug|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
301775|NCT01901172|Drug|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
301776|NCT01901172|Drug|RO5503781|Daily for 5 days followed by 23 days rest per cycle
301777|NCT01901172|Drug|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
301778|NCT01901172|Drug|RO5503781|Single doses Days 1 and 11
301779|NCT01901172|Drug|posaconazole|Multiple doses Days 8-14
301780|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (tablet)
301781|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (capsule)
301782|NCT01901146|Drug|ABP 980|ABP 980 was administered at an initial dose of 8 mg/kg over a 90-minute intravenous (IV) infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
301783|NCT01901146|Drug|Trastuzumab|Trastuzumab was administered at an initial dose of 8 mg/kg over a 90-minute IV infusion, then 6 mg/kg IV infusion Q3W for all subsequent cycles.
301784|NCT01901146|Drug|Paclitaxel|Paclitaxel, 175 mg/m² Q3W for 4 cycles (or 80 mg/m² QW for 12 cycles, if local standard of care).
301785|NCT01901146|Procedure|Lumpectomy or Mastectomy with Sentinel Node or Axillary Node Dissection|
301786|NCT01901133|Drug|MDV3100|Oral
301787|NCT01901120|Drug|Betanis|oral
301788|NCT01901107|Drug|Kiklin capsules|oral
301789|NCT01901094|Procedure|Axillary Lymph Node Dissection (ALND)|
301790|NCT01901094|Radiation|Nodal Radiation Therapy|
301791|NCT01901094|Radiation|Axillary Radiation Therapy|
301792|NCT01901081|Device|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.~After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
301793|NCT01901068|Device|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
301832|NCT01900795|Drug|Placebo|Placebo taken orally after surgery.
301796|NCT01901042|Dietary Supplement|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
301797|NCT01901042|Dietary Supplement|Maltodextrin|Control patients will receive sachets containing maltodextrin
301798|NCT01901016|Behavioral|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
301799|NCT01901016|Behavioral|Schultz's autogenic training|Schultz's autogenic training
301800|NCT01901003|Drug|Lorazepam|
301801|NCT01901003|Other|no premedication|
301802|NCT01901003|Drug|Placebo (microcrystalline celluloses)|
301803|NCT01900990|Device|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
301804|NCT01900977|Other|Universal Testing with immediate ART|"• Combination prevention package including:~o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
301805|NCT01900977|Other|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:~House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
301806|NCT01900977|Other|Standard of Care|
301807|NCT01900964|Procedure|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
301808|NCT01900964|Procedure|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
301809|NCT01900951|Drug|Temozolomide|
301810|NCT01900938|Procedure|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
301811|NCT01900938|Procedure|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
301812|NCT01900938|Drug|Midazolam|
301813|NCT01900938|Drug|Propofol|
301814|NCT01900925|Procedure|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
301815|NCT01900925|Procedure|Pragmatic low back pain treatment|"advise to stay active,~discourage bed rest,~appropriate medication use,~reassurance.~Short term use of manipulation/medication,~supervised exercise,~cognitive behavioral therapy,~multidisciplinary treatment,~termination of use of modalities."
301816|NCT01900912|Other|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
301817|NCT01900899|Procedure|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
301818|NCT01900886|Other|Peginterferon alfa-2a|Treatment as usual clinical practice
301819|NCT01900886|Drug|Ribavirin|Treatment as usual clinical practice
301820|NCT01900873|Device|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
301821|NCT01900873|Device|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
301822|NCT01900860|Dietary Supplement|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
301823|NCT01900847|Drug|Ketamine|0.3mg/kg ketamine
301824|NCT01900847|Drug|Morphine|Dosage of morphine determined by treating physician
301825|NCT01900847|Drug|placebo|saline of same volume as appropriate weight based dose of ketamine
301826|NCT01900834|Other|No treatment given|The participants will not receive any treatment
301827|NCT01900808|Device|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
301828|NCT01900808|Device|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
301829|NCT01900808|Device|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
301835|NCT01900782|Biological|Placebo|Prefilled syringe to match experimental drug and active comparator.
301836|NCT01900769|Drug|Blood Volume Dilution|
301837|NCT01900756|Behavioral|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
301838|NCT01900743|Drug|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
301839|NCT01900743|Drug|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
301840|NCT01900730|Drug|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
301841|NCT01900730|Drug|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
301842|NCT01900730|Behavioral|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
301843|NCT01900730|Behavioral|Pill Diary|Patient given a pill diary to record the time each dose taken.
301844|NCT01900730|Behavioral|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
301845|NCT01900717|Drug|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
301846|NCT01900717|Drug|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
301847|NCT01900704|Drug|SER120 750 ng|SER120 750 ng
301848|NCT01900704|Drug|SER120 1500 ng|SER120 1500 ng
301849|NCT01900704|Drug|Placebo|Placebo
301850|NCT01900691|Device|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
301851|NCT01900678|Device|VytronUS Ablation System|Pulmonary vein isolation.
301852|NCT01900665|Drug|Solanezumab|Administered Intravenously (IV)
301853|NCT01900665|Drug|Placebo|Administered IV
301854|NCT01900652|Drug|Emibetuzumab|Administered IV
301855|NCT01900652|Drug|Erlotinib|Administered Orally
301856|NCT01900639|Behavioral|change time of intake of aspirin|
301857|NCT01900626|Drug|epidural catheter|epidural catheter with 0.3% ropivacaine
301858|NCT01900613|Behavioral|Ninos Sanos Familia Sana|
301859|NCT01900600|Other|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
301860|NCT01900600|Other|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
301861|NCT01900587|Drug|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
301862|NCT01900587|Drug|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
301863|NCT01900574|Drug|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
301864|NCT01900561|Behavioral|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
301865|NCT01900561|Behavioral|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
301866|NCT01900548|Dietary Supplement|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
301867|NCT01900548|Dietary Supplement|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
301868|NCT01900548|Dietary Supplement|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
301869|NCT01900548|Other|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
301870|NCT01900522|Drug|ITI-214 Dose A|ITI-214 Dose A Oral Solution
301871|NCT01900522|Drug|ITI-214 Dose B|ITI-214 Oral Solution Dose B
301872|NCT01900522|Drug|ITI-214 Dose C|ITI-214 Dose C Oral Solution
301873|NCT01900522|Drug|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
301874|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
301875|NCT01900522|Drug|ITI-214 Dose E|ITI-214 Dose E Oral Solution
301876|NCT01900522|Drug|ITI-214 Dose F|ITI-214 Dose F Oral Solution
301877|NCT01900522|Drug|ITI-214 Dose G|ITI-214 Dose G Oral Solution
301878|NCT01900522|Drug|ITI-214 Dose H|ITI-214 Dose H Oral Solution
301879|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
301880|NCT01900509|Drug|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
301881|NCT01900509|Drug|Clofarabine|Route of administration: IV days 1-5.
301882|NCT01900509|Drug|Etoposide|Route of administration: IV days 1-5.
301883|NCT01900509|Drug|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
301884|NCT01900509|Drug|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
301885|NCT01900496|Biological|Brentuximab vedotin|Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.
301886|NCT01900496|Biological|Rituximab|Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m^2 IV. Additional doses are given at three and six months post week 27.
301887|NCT01900470|Behavioral|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
301888|NCT01900457|Other|electromyography|
301889|NCT01900457|Other|electroencephalography|
301890|NCT01900457|Other|approaches from psychophysics|
301891|NCT01900444|Biological|IMOJEV|0.5 mL, Subcutaneous
301892|NCT01900431|Drug|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
301893|NCT01900431|Drug|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
301894|NCT01900431|Drug|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
301895|NCT01900431|Drug|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
301896|NCT01900431|Other|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
301897|NCT01900418|Behavioral|Walk with Ease|An evidence-based walking program
301898|NCT01900405|Drug|Dexmedetomidine|
301899|NCT01900392|Behavioral|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
301900|NCT01900379|Procedure|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
301901|NCT01900379|Other|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
301902|NCT01900366|Procedure|Fat Biopsy|Fat biopsy
301903|NCT01900353|Other|brushing methods|
301904|NCT01900340|Dietary Supplement|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
301905|NCT01900340|Drug|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
301906|NCT01900340|Dietary Supplement|Saline|IV saline infusion and intraduodenal administration of nutrients
301907|NCT01900340|Drug|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
301908|NCT01900327|Radiation|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
301909|NCT01900327|Drug|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
301910|NCT01900327|Procedure|Surgery|Upfront pancreato-duodenectomy
301911|NCT01900327|Drug|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
301912|NCT01900314|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
301913|NCT01900301|Drug|Scopolamine|Participants will be randomized to either, .4mg/.01 mL Scopolamine, .5mg/.01 mL Scopolamine or .6mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
301914|NCT01900301|Drug|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
301915|NCT01900288|Behavioral|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
301916|NCT01900288|Behavioral|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
301917|NCT01900275|Other|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
301918|NCT01900262|Other|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
301919|NCT01900262|Other|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
301920|NCT01900262|Other|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
301921|NCT01900249|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
301922|NCT01900249|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
301923|NCT01900249|Drug|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
301966|NCT01899833|Diagnostic Test|99mTc-Sestamibi|An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
301967|NCT01899820|Drug|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
301968|NCT01899820|Drug|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
301969|NCT01899807|Device|OssDsign AB|
301970|NCT01899794|Procedure|TVT-O/Oxytrol|
301971|NCT01899794|Device|TVT-O|
301924|NCT01900236|Behavioral|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
301925|NCT01900210|Behavioral|WaySafe|
301926|NCT01900197|Drug|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
301927|NCT01900184|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
301928|NCT01900184|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
301929|NCT01900171|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
301930|NCT01900171|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
301931|NCT01900158|Drug|Amphinex, Gemcitabine and Cisplatin|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
301932|NCT01900106|Drug|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
301933|NCT01900106|Drug|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
301934|NCT01900093|Drug|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
301935|NCT01900080|Other|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
301936|NCT01900080|Other|Standard ART Initiation|Standard ART Initiation
301937|NCT01900080|Other|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count >500 cells/mm3 (CD4 count within 7 days of HIV test)
301938|NCT01900080|Other|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count >500 cells/mm3
301939|NCT01900067|Device|BARRIER® EasyWarm Active Self-Warming Blanket|
301940|NCT01900054|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
301941|NCT01900041|Drug|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
301942|NCT01900041|Drug|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
301943|NCT01900028|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
301944|NCT01900028|Drug|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
301945|NCT01900028|Drug|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
301946|NCT01900015|Drug|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
301947|NCT01900015|Drug|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
301948|NCT01900002|Other|Laboratory Biomarker Analysis|Correlative studies
301949|NCT01900002|Other|Quality-of-Life Assessment|Ancillary studies
301950|NCT01900002|Drug|Sorafenib|Given PO
301951|NCT01900002|Drug|Sorafenib Tosylate|Given PO
301952|NCT01900002|Radiation|Yttrium Y 90 Glass Microspheres|Given IA
301953|NCT01899989|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
301954|NCT01899989|Drug|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
301955|NCT01899976|Device|X-Suit NIR Covered Biliary Stent|
301956|NCT01899924|Behavioral|Event Related Potentials recording|
301957|NCT01899911|Device|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
301958|NCT01899898|Other|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:~Pictorial representation of various food items and exchange lists will be provided.~Instead of weights, we will provide standardized measures~We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~We will formulate recipes and diets based on locally available and culturally acceptable foods.~We will develop a parent instruction manual.~We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
301959|NCT01899898|Drug|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
301960|NCT01899885|Procedure|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.~Focus on fast track with multimodal standardized intervention:~standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)~GDT-LiDCO fluid management pre-, per- and postoperative~Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score~Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
301961|NCT01899872|Behavioral|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
301962|NCT01899872|Behavioral|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
301963|NCT01899859|Drug|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
301964|NCT01899859|Drug|Placebo|GR-MD-02 Placebo
301965|NCT01899846|Drug|Hydroxyprogesterone caproate 250 mg/ml|
301973|NCT01899781|Drug|Antibiotic-Cefamezin|
301974|NCT01899768|Drug|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
301975|NCT01899768|Drug|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
301976|NCT01899755|Drug|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
301977|NCT01899755|Drug|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
301978|NCT01899755|Drug|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
301979|NCT01899742|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
301980|NCT01899742|Drug|Tiotropium 18 mcg|Inhalation Powder
301981|NCT01899729|Drug|IMO-8400 Regimen 1|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
301982|NCT01899729|Drug|IMO-8400 Regimen 2|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
301983|NCT01899729|Drug|IMO-8400 Regimen 3|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
301984|NCT01899729|Drug|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
301985|NCT01899729|Drug|IMO-8400 Regimen 4|IMO-8400 0.6 mg/kg q wk x 12 wk by subcutaneous injection
301986|NCT01899716|Other|Exercise|
301987|NCT01899703|Drug|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
301988|NCT01899703|Drug|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
301989|NCT01899703|Drug|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
301990|NCT01899690|Drug|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
301991|NCT01899677|Other|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
301992|NCT01899677|Drug|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
301993|NCT01899664|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
301994|NCT01899638|Drug|UMEC/VI 125/25 mcg|Combination in high dose
301995|NCT01899638|Drug|UMEC/VI 62.5/25 mcg|Combination in low dose
301996|NCT01899638|Drug|UMEC 125 mcg|LAMA mono in high dose
301997|NCT01899638|Drug|UMEC 62.5 mcg|LAMA mono in low dose
301998|NCT01899638|Drug|VI 25 mcg|LABA mono
301999|NCT01899625|Behavioral|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
302000|NCT01899625|Behavioral|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
302001|NCT01899599|Drug|Gatipotuzumab|start dose 500mg at C0D1 maintenance dose 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.
302002|NCT01899599|Drug|Placebo|start dose matching 500mg at C0D1 maintenance dose matching 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.
302003|NCT01899586|Other|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
302004|NCT01899586|Other|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
302005|NCT01899573|Device|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
302006|NCT01899560|Procedure|Measure lung and chest wall elastance with esophageal catheter|"Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated [9]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.~A low flow pressure/volume curve from 0 to 40 cmH2O will be performed."
302007|NCT01899560|Other|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
302008|NCT01899547|Procedure|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
302009|NCT01899547|Procedure|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
302010|NCT01899534|Other|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
302011|NCT01899521|Procedure|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
302012|NCT01899521|Dietary Supplement|Zinc sulfate 220 mg once daily|
302013|NCT01899521|Dietary Supplement|S-adenosylmethionine 400 mg twice daily|
302014|NCT01899508|Procedure|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
302015|NCT01899508|Device|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
302016|NCT01899495|Other|High sodium diet and low sodium diet|Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
302017|NCT01899482|Other|Manual Lymphatic Drainage|
302018|NCT01899482|Behavioral|Education|Behavioral education.
302019|NCT01899469|Procedure|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
302020|NCT01899469|Procedure|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)~20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
302021|NCT01899469|Procedure|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
302022|NCT01899456|Device|Catheter-based renal denervation|
302023|NCT01899443|Other|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
302024|NCT01899430|Drug|liraglutide|
302025|NCT01899430|Drug|metformin|
302026|NCT01899417|Device|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
302027|NCT01899404|Biological|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
302028|NCT01899378|Dietary Supplement|Lactobacillus reuteri DSM 17938|10^8 CFU
302029|NCT01899378|Dietary Supplement|Bifidobacterium longum infantis|10^9 CFU
302030|NCT01899352|Procedure|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
302031|NCT01899339|Other|Ultra sound energy along with tPA to treat submassive pulmonary embolism|
302032|NCT01899326|Drug|Desipramine Hydrochloride|Given PO
302033|NCT01899326|Biological|Filgrastim|Given PO
302034|NCT01899326|Other|Laboratory Biomarker Analysis|Correlative studies
302035|NCT01899313|Behavioral|CBT- based SMS text messaging intervention|
302036|NCT01899313|Behavioral|CBT group therapy|
302037|NCT01899300|Device|Metal Stent (WallFlex™ Esophageal RX)|
302038|NCT01899287|Behavioral|group education|"The experimental intervention consists of:~A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.~C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
302039|NCT01899274|Device|bant iPhone application|
302040|NCT01899261|Radiation|Stereotactic Radiosurgery|Undergo SBRT
302041|NCT01899248|Drug|Sevoflurane|
302042|NCT01899248|Drug|Desflurane|
302043|NCT01899235|Device|drug eluting balloon|
302044|NCT01899235|Device|drug eluting stent|
302045|NCT01899222|Device|Handheld fundus photography|diagnostic imaging with two types of retina camera
302046|NCT01899209|Procedure|STARR|
302047|NCT01899209|Procedure|Laparoscopic Ventral Rectopexy|
302048|NCT01899196|Biological|blood sampling,|
302049|NCT01899183|Procedure|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
302050|NCT01899170|Procedure|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
302051|NCT01899170|Device|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
302052|NCT01899170|Drug|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
302053|NCT01899144|Drug|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
302054|NCT01899144|Drug|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
302055|NCT01899144|Drug|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
302056|NCT01899131|Device|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
302057|NCT01899118|Radiation|Preoperative irradiation|50.4Gy/28F/5.5w
302058|NCT01899118|Drug|Nimotuzumab|400mg/w，0-5w
302059|NCT01899118|Drug|Oxaliplatin|130mg/m2 d1
302060|NCT01899118|Drug|Capecitabine|825mg/m2 bid d1-5/w,1-5w
302061|NCT01899105|Drug|lumacaftor|
302062|NCT01899105|Drug|ivacaftor|
302063|NCT01899092|Drug|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
302064|NCT01899066|Drug|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.~chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
302065|NCT01899066|Drug|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
302066|NCT01899053|Drug|TAK-228|TAK-228 Capsules
302067|NCT01899053|Drug|TAK-117|TAK-117 Capsules
302068|NCT01899040|Device|neuromodulation for episodic migraine headache|
302069|NCT01899027|Drug|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
302070|NCT01899027|Drug|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
302071|NCT01899001|Behavioral|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
302072|NCT01899001|Behavioral|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
302073|NCT01898975|Other|500ml fluid loading|Fluid loading to evaluate fluid responsiveness
302074|NCT01898962|Procedure|Complete Surgical Removal|
302075|NCT01898962|Radiation|Stereotactic Radiosurgery|
302076|NCT01898962|Radiation|Ablative external beam radiation dose|
302077|NCT01898962|Procedure|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
302078|NCT01898962|Radiation|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
302079|NCT01898949|Other|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
302080|NCT01898936|Procedure|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.~The laser settings will be as follows:~The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.~The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
302081|NCT01898936|Device|Only photodynamic therapy|
302082|NCT01898923|Drug|WH-1 ointment|
302083|NCT01898923|Other|Aquacel® Hydrofiber® dressing|
302084|NCT01898910|Procedure|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
302085|NCT01898910|Procedure|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
302086|NCT01898910|Drug|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
302087|NCT01898897|Procedure|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
302088|NCT01898897|Procedure|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
302089|NCT01898884|Drug|VP 20629|
302090|NCT01898884|Drug|Placebo|
302091|NCT01898871|Dietary Supplement|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
302092|NCT01898858|Device|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
302093|NCT01898858|Device|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
302094|NCT01898858|Device|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
302095|NCT01898845|Drug|LEE011|
302096|NCT01898819|Drug|Dexmedetomidine|
302098|NCT01898806|Drug|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
302099|NCT01898806|Drug|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
302100|NCT01898806|Drug|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
302101|NCT01898806|Drug|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
302102|NCT01898793|Drug|Fludarabine|
302103|NCT01898793|Drug|Cyclophosphamide|
302104|NCT01898793|Procedure|Leukapheresis|
302105|NCT01898793|Biological|Cytokine-induced killer cells|
302106|NCT01898793|Biological|IL-2|
302107|NCT01898793|Drug|ALT-803|
302108|NCT01898793|Procedure|Peripheral blood for correlative studies|-Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
302109|NCT01898793|Procedure|Bone marrow for correlative studies|-Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
302110|NCT01898780|Procedure|pancreaticojejunostomy with horizontal mattress suture|
302111|NCT01898780|Procedure|pancreaticojejunostomy with interrupted suture|
302112|NCT01898754|Other|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
302113|NCT01898741|Radiation|24 Gy in 3 fractions|
302114|NCT01898728|Drug|topical povidone-iodine after premedication with topical liquid eye drops|
302115|NCT01898728|Drug|topical povidone-iodine after premedication with topical gel|
302116|NCT01898715|Drug|ATR-101|
302117|NCT01898702|Behavioral|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
302118|NCT01898689|Drug|perineural infusion|"A continuous peripheral nerve block—also termed perineural local anesthetic infusion—involves the insertion of a tiny tube (a catheter) through the skin and adjacent to a peripheral nerve, followed by local anesthetic (numbing medicine) administration via the catheter, providing pain control following surgery. Continuous peripheral nerve blocks may be provided in the hospital setting, but the use of lightweight, portable pumps permits infusion at home as well."
302119|NCT01898676|Drug|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
302120|NCT01898676|Drug|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
302121|NCT01898663|Biological|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
302122|NCT01898650|Other|MR scan|
302123|NCT01898637|Other|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
302124|NCT01898637|Device|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
302125|NCT01898624|Drug|mirabegron|oral
302126|NCT01898611|Drug|Ghrelin|Ghrelin
302127|NCT01898611|Drug|Placebo|Saline will be used as a placebo
302128|NCT01898598|Drug|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
302129|NCT01898598|Drug|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
302130|NCT01898585|Drug|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
302131|NCT01898572|Other|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
302132|NCT01898559|Other|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
302133|NCT01898546|Procedure|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
302134|NCT01898546|Procedure|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
302135|NCT01898520|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
302136|NCT01898520|Drug|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
302137|NCT01898507|Other|Low nicotine cigarettes|15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
302138|NCT01898494|Procedure|therapeutic conventional surgery|Undergo transoral surgical resection
302139|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo low-dose IMRT
302140|NCT01898494|Drug|cisplatin|Given IV
302141|NCT01898494|Drug|carboplatin|Given IV
302142|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
302143|NCT01898494|Other|laboratory biomarker analysis|Correlative studies
302144|NCT01898494|Other|quality-of-life assessment|Ancillary studies
302145|NCT01898468|Procedure|Pericostal Closure Technique|
302146|NCT01898468|Procedure|Intracostal Closure Technique|
302147|NCT01898455|Device|RhinoChill intranasal cooling|The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
302148|NCT01898442|Drug|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
302149|NCT01898442|Drug|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
302150|NCT01898442|Drug|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
302151|NCT01898429|Device|SCC DBS|Deep Brain Stimulator
302152|NCT01898416|Drug|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
302153|NCT01898403|Drug|Indocyanine green solution|Administered peri-tumoral and intradermally
302154|NCT01898403|Drug|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
302155|NCT01898403|Diagnostic Test|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
302156|NCT01898390|Procedure|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
302157|NCT01898377|Drug|Imatinib mesylate, Mycophenolate mofetil|
302158|NCT01898364|Drug|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
302159|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.~The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.~The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
302160|NCT01898338|Drug|Fosfomycin 2gr/6h iv|
302161|NCT01898338|Drug|Daptomycin 10mg/kg/24h iv|
302162|NCT01898325|Device|Fibroscan|Fibroscan
302163|NCT01898312|Drug|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
302164|NCT01898299|Device|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
302165|NCT01898299|Device|Sham tDCS|Sham (inactive) tDCS treatment
302166|NCT01898286|Drug|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
302167|NCT01898273|Drug|I-124-CLR1404|single-dose, intravenous
302168|NCT01898260|Device|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
302169|NCT01898260|Device|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
302170|NCT01898247|Other|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
302171|NCT01898234|Device|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
302172|NCT01898234|Device|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
302173|NCT01898234|Device|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
302174|NCT01898234|Device|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
302175|NCT01898221|Drug|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a ~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
302176|NCT01898221|Procedure|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
302177|NCT01898208|Device|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
302178|NCT01898208|Behavioral|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
302179|NCT01898208|Other|Bacterial culture|This test identifies the pathogen responsible for an infection.
302180|NCT01898208|Other|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
302181|NCT01898195|Drug|Varenicline|Varenicline will be provided for three months.
302182|NCT01898195|Behavioral|Text Message|Text messages will be developed twice daily for three months
302291|NCT01897441|Other|Laboratory Biomarker Analysis|Correlative studies
302183|NCT01898195|Behavioral|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
302184|NCT01898182|Other|Kinetin, N6-furfuryladenine, 0.1%|
302185|NCT01898169|Other|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
302186|NCT01898156|Drug|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.~Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
302187|NCT01898143|Other|Whole body vibration|
302188|NCT01898130|Biological|bevacizumab|Given IV
302189|NCT01898130|Procedure|quality-of-life assessment|Ancillary studies
302190|NCT01898117|Drug|Carbo/cyclo|
302191|NCT01898117|Drug|Carbo/cyclo + atezolizumab|
302192|NCT01898117|Drug|Paclitaxel|
302193|NCT01898117|Drug|Paclitaxel + Atezolizumab|
302194|NCT01898104|Radiation|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
302195|NCT01898104|Drug|Valproic Acid|
302196|NCT01898104|Drug|Capecitabine|
302197|NCT01898091|Drug|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
302198|NCT01898091|Drug|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
302199|NCT01898078|Drug|Alisertib|Alisertib ECT
302200|NCT01898065|Drug|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
302201|NCT01898052|Drug|single anaesthetic drug|inject periarticular tissue of the knee after implantation
302202|NCT01898052|Drug|multimodal drug injection|inject periarticular tissue of the knee
302203|NCT01898039|Biological|A2/4-1BBL melanoma vaccine|On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
302204|NCT01898039|Procedure|DNP sensititzation|"Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.~On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm."
302205|NCT01898039|Drug|Cyclophosphamide|On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
302206|NCT01898026|Dietary Supplement|Bread|Samples of white bread, with or without the addition of PGX fibre blend
302207|NCT01898026|Dietary Supplement|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
302208|NCT01898026|Dietary Supplement|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
302209|NCT01898026|Dietary Supplement|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
302210|NCT01898013|Drug|Pregnenolone|
302211|NCT01898013|Drug|Placebo|
302212|NCT01898000|Behavioral|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
302213|NCT01898000|Behavioral|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
302214|NCT01897987|Biological|Pneumostem®|
302215|NCT01897987|Biological|normal saline|
302216|NCT01897974|Other|Survey|Families complete survey to measure medication compliance.
302217|NCT01897961|Other|Anticorps anti-PLA2R1|
302218|NCT01897948|Other|Milk-based beverage without DHA|
302219|NCT01897948|Other|Milk-based beverage with DHA at mid level|
302220|NCT01897948|Other|Milk-based beverage with DHA at high level|
302221|NCT01897922|Other|An investigational infant formula containing a probiotic source|
302222|NCT01897922|Other|Control: Marketed routine infant formula|
302223|NCT01897896|Drug|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
302224|NCT01897870|Behavioral|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
302225|NCT01897857|Device|duplex Doppler ultrasonography|
302226|NCT01897844|Drug|ITF2984 (100, 2000, 3000 mcg bid)|
302227|NCT01897844|Drug|Placebo|
302228|NCT01897831|Drug|xin te mie|durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
302229|NCT01897818|Device|communication system P300 Speller|
302230|NCT01897805|Drug|Heart-protecting Musk Pill|
302231|NCT01897805|Drug|Placebo|
302232|NCT01897792|Dietary Supplement|Vitamin C|
302233|NCT01897792|Dietary Supplement|Vitamin E|
302234|NCT01897792|Dietary Supplement|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
302235|NCT01897792|Drug|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
302292|NCT01897441|Drug|Paclitaxel|Given IV
302293|NCT01897441|Biological|Trastuzumab|Given IV
302236|NCT01897779|Drug|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
302237|NCT01897779|Drug|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
302238|NCT01897779|Drug|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
302239|NCT01897779|Drug|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
302240|NCT01897766|Drug|Somatropin|0.23 mg to 0.48 mg/kg/week
302241|NCT01897753|Drug|growth hormone|36 months
302242|NCT01897740|Drug|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
302243|NCT01897727|Drug|Spironolactone|
302244|NCT01897727|Drug|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
302245|NCT01897714|Drug|Melflufen|
302246|NCT01897714|Drug|Dexamethasone|
302247|NCT01897701|Biological|Monovalent Avian Influenza VLP (H7N9)|
302248|NCT01897701|Biological|Adjuvant 1|
302249|NCT01897701|Biological|Placebo|
302250|NCT01897688|Biological|Islet Cell Transplant|
302251|NCT01897675|Procedure|Incision and Drainage with packing (wick) placement|
302252|NCT01897675|Procedure|Abscess drainage with loop placement|
302253|NCT01897662|Dietary Supplement|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
302254|NCT01897662|Dietary Supplement|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
302255|NCT01897649|Dietary Supplement|NUTRIOSE FB06|15g/day NUTRIOSE FB06
302256|NCT01897649|Dietary Supplement|GLUCIDEX 21|15g/day GLUCIDEX 21
302257|NCT01897636|Procedure|EUS-guided fine-needle injection of DCs vaccinations|
302258|NCT01897623|Other|ultrasound of aorta|
302259|NCT01897610|Drug|Immuncell-LC|intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour
302260|NCT01897597|Drug|BI 144807 high dose|oral solution
302261|NCT01897597|Drug|BI 144807 intermediate dose|tablet
302262|NCT01897597|Drug|BI 144807 intermediate dose|tablet
302263|NCT01897597|Drug|BI 144807 intermediate dose|tablet
302264|NCT01897597|Drug|BI 144807 intermediate dose|tablet
302265|NCT01897597|Drug|BI 144807 intermediate dose|oral solution
302266|NCT01897597|Drug|BI 144807 high dose|tablet
302267|NCT01897584|Other|inverse IE|in only one group changes of I:E ratio would be applied
302268|NCT01897571|Drug|Tazemetostat|
302269|NCT01897558|Device|Pacemaker implantation|
302270|NCT01897545|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
302271|NCT01897545|Procedure|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
302272|NCT01897532|Drug|Placebo|placebo matching tablets
302273|NCT01897532|Drug|Linagliptin|
302274|NCT01897519|Drug|Placebo|Placebo infusion
302275|NCT01897519|Drug|ABT-719|Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
302276|NCT01897493|Drug|Evacetrapib|Administered orally
302277|NCT01897493|Drug|Digoxin|Administered orally
302278|NCT01897480|Biological|LY2875358|Administered IV
302279|NCT01897480|Drug|Erlotinib|Administered Orally
302280|NCT01897467|Behavioral|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
302281|NCT01897467|Behavioral|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
302282|NCT01897454|Drug|Fluorouracil|Given IV
302283|NCT01897454|Drug|Gemcitabine Hydrochloride|Given IV
302284|NCT01897454|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
302285|NCT01897454|Drug|Irinotecan Hydrochloride|Given IV
302286|NCT01897454|Drug|Leucovorin Calcium|Given IV
302287|NCT01897454|Drug|Oxaliplatin|Given IV
302288|NCT01897441|Drug|Cyclophosphamide|Given IV
302289|NCT01897441|Other|Cytology Specimen Collection Procedure|Correlative studies
302290|NCT01897441|Drug|Doxorubicin Hydrochloride|Given IV
302294|NCT01897428|Drug|Test-Bepotastine salicylate 9.64 mg|
302295|NCT01897428|Drug|Reference-bepotastine besilate 10 mg|
302296|NCT01897415|Biological|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
302297|NCT01897402|Biological|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
302298|NCT01897402|Biological|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
302299|NCT01897389|Drug|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
302300|NCT01897389|Drug|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
302301|NCT01897389|Drug|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
302302|NCT01897389|Drug|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
302303|NCT01897389|Drug|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
302304|NCT01897376|Procedure|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
302305|NCT01897376|Procedure|vertical skin incision|vertical skin incision at time of cesarean section
302306|NCT01897363|Other|Infants with Prader-Willi Syndrome|Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
302307|NCT01897350|Other|Cardiac magnetic resonance imaging|
302308|NCT01897337|Drug|Aprepitant|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
302309|NCT01897337|Drug|placebo|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
302310|NCT01897324|Drug|Growth hormone (Norditropin, Novo nordisk)|
302311|NCT01897311|Device|transcutaneous electrical nerve stimulation|
302312|NCT01897298|Behavioral|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
302313|NCT01897285|Device|AQUACEL® foam adhesive dressing|
302314|NCT01897272|Behavioral|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
302315|NCT01897259|Drug|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
302316|NCT01897259|Behavioral|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
302317|NCT01897259|Drug|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
302318|NCT01897259|Drug|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
302319|NCT01897246|Procedure|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
302320|NCT01897246|Procedure|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
302321|NCT01897233|Drug|Lumacaftor|
302322|NCT01897233|Drug|Ivacaftor|
302323|NCT01897207|Biological|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
302324|NCT01897181|Device|Hearing aids|Using hearing aids for 12 months
302325|NCT01897168|Device|No intervention|
302326|NCT01897155|Other|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
302327|NCT01897155|Other|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
302328|NCT01897142|Biological|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
302329|NCT01897142|Drug|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
302330|NCT01897142|Biological|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
302331|NCT01897142|Drug|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
302332|NCT01897142|Biological|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
302333|NCT01897142|Drug|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
302334|NCT01897142|Biological|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
302335|NCT01897142|Drug|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
302336|NCT01897142|Biological|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
302337|NCT01897142|Drug|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
302338|NCT01897142|Biological|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
302339|NCT01897142|Drug|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
302340|NCT01897116|Drug|Hydroxychloroquine (HCQ)|
302341|NCT01897116|Drug|Vemurafenib (VEM)|
302342|NCT01897090|Other|Elimination Diet|
302343|NCT01897090|Other|Dietary Guidelines for Americans|
302344|NCT01897077|Drug|Peanut Dissolving Film|
302345|NCT01897064|Behavioral|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
302346|NCT01897064|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
302347|NCT01897051|Drug|Rifaximin + propranolol|"Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
302348|NCT01897051|Drug|Propranolol + Placebo|"Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)~Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.~(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).~If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
302349|NCT01897038|Drug|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
302350|NCT01897038|Drug|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
302351|NCT01897025|Device|real-tDCS with MI-BCI|As in Arm Description
302352|NCT01897012|Drug|Alisertib|Given PO
302353|NCT01897012|Other|Laboratory Biomarker Analysis|Correlative studies
302354|NCT01897012|Drug|Romidepsin|Given IV
302355|NCT01896999|Drug|Brentuximab Vedotin|Given IV
302356|NCT01896999|Biological|Ipilimumab|Given IV
302357|NCT01896999|Biological|Nivolumab|Given IV
302358|NCT01896973|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
302359|NCT01896960|Drug|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
302360|NCT01896934|Drug|Sertraline|50-200mg daily
302361|NCT01896921|Drug|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
302362|NCT01896908|Other|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
302363|NCT01896895|Drug|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
302364|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
302365|NCT01896895|Drug|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
302366|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).~Open-Label Extension: up to 35 Units per eye."
302367|NCT01896882|Other|Sodium restriction|
302368|NCT01896869|Drug|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
302369|NCT01896869|Biological|Vaccine|5x10^8 cells administered in 6 intradermal injections
302370|NCT01896869|Drug|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
302371|NCT01896856|Drug|SGI-110|
302372|NCT01896856|Drug|Irinotecan|
302373|NCT01896856|Drug|regorafenib|
302374|NCT01896856|Drug|TAS-102|
302375|NCT01896843|Drug|STX107|
302376|NCT01896830|Biological|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
302377|NCT01896830|Biological|0.9% normal saline|0.5 mL, intramuscular
302378|NCT01896791|Procedure|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation : the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
302379|NCT01896791|Procedure|Sham Stimulation|Sham Stimulation- appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
302380|NCT01896778|Procedure|Hyperthermia Treatment|Undergo B-WARM
302381|NCT01896778|Other|Laboratory Biomarker Analysis|Correlative studies
303073|NCT01891357|Drug|paclitaxel|
303074|NCT01891357|Drug|lapatinib|
302382|NCT01896765|Behavioral|Intensive Prevention Program|"Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
302383|NCT01896765|Other|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
302384|NCT01896739|Biological|Eutravac|
302385|NCT01896726|Drug|Baricitinib|Administered orally
302386|NCT01896726|Drug|Microgynon|Administered orally
302387|NCT01896713|Other|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
302388|NCT01896700|Drug|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
302389|NCT01896700|Drug|Placebo|Escalating matched dose of placebo
302390|NCT01896687|Device|Scrambler|Electrotherapy
302391|NCT01896661|Drug|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
302392|NCT01896661|Drug|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
302393|NCT01896635|Biological|FMT infusions|Active FMT derived from healthy anonymous pre-screened donors
302394|NCT01896635|Other|Placebo infusion|Placebo infusion not containing any donor microbial material
302395|NCT01896622|Drug|Ritonavir|Impact on dabigatran PK/PD
302396|NCT01896622|Drug|Cobicistat|Impact on dabigatran PK/PD
302397|NCT01896609|Biological|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
302398|NCT01896609|Drug|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
302399|NCT01896609|Drug|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
302400|NCT01896609|Drug|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
302401|NCT01896596|Biological|Menjugate|Administered with routine vaccinations at 3 months of age
302402|NCT01896596|Biological|Menitorix|Administered with routine vaccinations at 3 months
302403|NCT01896596|Biological|NeisVac-C|Administered with routine vaccinations at 3 months
302404|NCT01896583|Drug|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
302405|NCT01896583|Drug|Placebo|
302406|NCT01896570|Procedure|Catheter ablation of subsequent atrial tachycardia|
302407|NCT01896557|Drug|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
302408|NCT01896557|Drug|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
302409|NCT01896557|Drug|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit, Open label 75 mg once a day will be given to all individuals as part of the protocol (since main outcome of interest is clopidogrel effect. Actual comparison arms are double blind ranitidine and omeprazole
302410|NCT01896544|Dietary Supplement|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
302411|NCT01896544|Dietary Supplement|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
302412|NCT01896531|Drug|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
302413|NCT01896531|Drug|Ipatasertib|Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
302414|NCT01896531|Drug|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
302415|NCT01896531|Drug|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
302416|NCT01896531|Drug|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
302417|NCT01896518|Drug|Nicotine polacrilex|
302418|NCT01896518|Drug|Tobacco lozenge|
302419|NCT01896505|Drug|KCP-330|
302420|NCT01896492|Drug|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
302421|NCT01896479|Drug|Cabozantinib (XL184) 140 mg|
302422|NCT01896479|Drug|Cabozantinib (XL184) 60 mg|
302423|NCT01896479|Drug|Placebo tablet|
302424|NCT01896479|Drug|Placebo capsule|
302425|NCT01896466|Device|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
302426|NCT01896466|Behavioral|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
302427|NCT01896453|Procedure|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
302428|NCT01896453|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
302429|NCT01896440|Drug|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
302430|NCT01896427|Drug|21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione|single dose of dexamethasone (8mg) will injected
302431|NCT01896414|Dietary Supplement|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
302432|NCT01896414|Dietary Supplement|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
302433|NCT01896401|Device|InSeal's Vascular Closure Device|
302434|NCT01896388|Drug|Ifenprodil Tartrate|
302435|NCT01896388|Drug|Placebo|
302436|NCT01896349|Other|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
302437|NCT01896349|Drug|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
302438|NCT01896349|Drug|sertraline|
302439|NCT01896349|Drug|paroxetine|
302440|NCT01896349|Drug|Citalopram|
302441|NCT01896349|Drug|escitalopram|
302442|NCT01896349|Drug|fluvoxamine|
302443|NCT01896349|Drug|Venlafaxine|
302444|NCT01896349|Drug|Duloxetine|
302445|NCT01896349|Drug|Bupropion|
302446|NCT01896349|Drug|Lithium|
302447|NCT01896349|Drug|Risperidone|
302448|NCT01896349|Drug|tranylcypromine|
302449|NCT01896349|Drug|Imipramine|
302450|NCT01896349|Drug|amitriptyline|
302451|NCT01896349|Drug|Clomipramine|
302452|NCT01896349|Drug|nortriptyline|
302453|NCT01896349|Drug|trazodone|
302454|NCT01896349|Drug|Mirtazapine|
302455|NCT01896349|Drug|sulpiride|
302456|NCT01896336|Drug|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate~1 QD~Stilnox - 10mg oral zolpidem hemitartrate~1 QD"
302457|NCT01896323|Drug|CC-223|CC-223 20 mg tablets
302458|NCT01896323|Drug|Ketoconazole|Ketoconazole 400 mg tablets
302459|NCT01896310|Device|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
302460|NCT01896297|Drug|Pradaxa, dabigatran etexilate|75mg BID by oral
302461|NCT01896284|Drug|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
302462|NCT01896271|Drug|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
302463|NCT01896271|Radiation|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
302464|NCT01896245|Drug|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
302465|NCT01896245|Drug|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
302466|NCT01896245|Drug|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
302467|NCT01896232|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
302468|NCT01896232|Drug|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
302469|NCT01896232|Drug|Oral Placebo|Administered orally once a day.
302470|NCT01896232|Drug|Intravenous Placebo|Administered intravenously (IV) three times per week.
302471|NCT01896219|Device|Navigation station (IMACTIS-CT®)|
302472|NCT01896219|Device|CT|Reference method for gestures (carried out under CT) guidance
302473|NCT01896206|Device|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
302474|NCT01896193|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
302475|NCT01896193|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
302476|NCT01896180|Drug|ALZ-1101|ALZ-1101 Ophthalmic Solution
302477|NCT01896180|Drug|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
302478|NCT01896167|Other|Hypoxia|Inhalation of hypoxic air (8-12% oxygen content)
302479|NCT01896167|Other|Placebo|Inhalation of atmospheric air
302480|NCT01896154|Dietary Supplement|NPS|Comparison of multiple dietary non-digestible polysaccharides
302481|NCT01896128|Drug|Armodafinil|
302482|NCT01896128|Drug|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
302483|NCT01896115|Device|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
302484|NCT01896102|Genetic|Lenti-D Drug Product|Lenti-D Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with Lenti-D lentiviral vector encoding human adrenoleukodystrophy protein, suspended in a cryopreservative solution) is administered intravenously. Lenti-D Drug Product is administered by IV infusion following myeloablative conditioning with busulfan and cyclophosphamide.
302485|NCT01896076|Other|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.~First, investigators place the transducer at the sacral cornua to obtain a transverse view.~In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
302486|NCT01896063|Procedure|Electroacupuncture|
302487|NCT01896050|Drug|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
302488|NCT01896050|Drug|Tamoxifen|Patients were treated with tamoxifen for up to one year
302489|NCT01896037|Dietary Supplement|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
302490|NCT01896024|Behavioral|Psychiatric Management|
302491|NCT01896024|Behavioral|Motive-oriented therapeutic relationship/Plan Analysis|
302492|NCT01896011|Biological|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
302493|NCT01896011|Other|Placebo|Placebo 20 mcg injection pen
302494|NCT01895998|Drug|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
302495|NCT01895985|Drug|Latanoprostene bunod|
302496|NCT01895972|Drug|Latanoprostene bunod|
302497|NCT01895959|Drug|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
302498|NCT01895959|Device|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
302499|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
302500|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
302501|NCT01895933|Device|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site~merocel in the inflated state maintained for 36~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
302502|NCT01895920|Other|Blood sample|
302503|NCT01895894|Drug|Mycophenolate mofetil|Mycophenolate mofetil 20~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
302504|NCT01895881|Drug|Estradiol|
302505|NCT01895881|Drug|Placebo|
302506|NCT01895868|Other|Simulation-based ultrasound training|
302507|NCT01895855|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
302508|NCT01895855|Biological|placebo|
302509|NCT01895842|Drug|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."
302510|NCT01895829|Procedure|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
302511|NCT01895829|Drug|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
302512|NCT01895816|Dietary Supplement|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus & ZINGIBER OFFICINALE & Onion & Ocimum basilicum & Cinnamomum zelanicum & Citrullus lanatus & Citrullus vulgaris & Daucus carota
302513|NCT01895790|Device|Pancreatic Duct Stent Placement|
302514|NCT01895777|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
302515|NCT01895777|Drug|standard of care|Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
302516|NCT01895764|Drug|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
302517|NCT01895764|Drug|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
302518|NCT01895751|Procedure|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
302519|NCT01895738|Behavioral|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
302520|NCT01895699|Other|Contrast agent|
302521|NCT01895673|Other|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
302522|NCT01895660|Behavioral|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
302523|NCT01895647|Device|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
302524|NCT01895634|Device|Rev-01|Treatment arm patients have used Rev-01 at least once
302525|NCT01895621|Procedure|Median nerve decompression at the wrist|Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
302526|NCT01895621|Dietary Supplement|Alpha lipoic acid post median nerve decompression|Daily supplementation of alpha lipoic acid
302527|NCT01895608|Behavioral|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
302528|NCT01895608|Behavioral|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
302529|NCT01895608|Behavioral|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
302530|NCT01895608|Behavioral|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
302531|NCT01895595|Behavioral|Guided Imagery|
302532|NCT01895595|Behavioral|Digital Storytelling|
302533|NCT01895582|Other|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)~1 blood dry tube (5ml)"
302534|NCT01895569|Drug|Metformin|Metformin will be added to therapy for the first threre months.
302535|NCT01895569|Drug|Pioglitazone|In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin, pioglitazone will be added.
302536|NCT01895569|Drug|Sitagliptin|In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
302537|NCT01895556|Other|Information|
302538|NCT01895556|Other|Control|
302539|NCT01895543|Drug|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
302540|NCT01895530|Dietary Supplement|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
302541|NCT01895517|Other|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
302542|NCT01895517|Other|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
302543|NCT01895504|Device|ColoAssist|Screening colonoscopy with the test instrument
302544|NCT01895504|Device|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
302545|NCT01895491|Biological|VM206DNA|
302546|NCT01895491|Biological|VM206Ad|
302547|NCT01895478|Behavioral|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
302548|NCT01895465|Device|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
302549|NCT01895452|Drug|ALKS 9072, Low Dose|Intramuscular injection, given monthly
302550|NCT01895452|Drug|ALKS 9072, High Dose|Intramuscular injection, given monthly
302551|NCT01895439|Biological|Autologous Mesenchymal Stem Cells|
302552|NCT01895413|Procedure|Bone marrow aspiration|Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
302553|NCT01895400|Drug|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
302554|NCT01895400|Drug|Placebo|Take placebo drug 1T bid po medication for 8 weeks
302555|NCT01895387|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
302556|NCT01895387|Dietary Supplement|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
302557|NCT01895374|Procedure|laser treatments|
302558|NCT01895374|Other|amniotic membrane application|
302559|NCT01895374|Device|hydrocolloid application|
302560|NCT01895361|Drug|SelG1|
302561|NCT01895361|Drug|Placebo|
302562|NCT01895348|Drug|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
302563|NCT01895348|Drug|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
302564|NCT01895348|Drug|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
302565|NCT01895335|Drug|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
302566|NCT01895322|Drug|OPC-41061|
302567|NCT01895309|Drug|Enbrel (etanercept)|
302568|NCT01895309|Drug|SB4 (proposed biosimilar to etanercept)|
302569|NCT01895296|Drug|Pasireotide|somatostatin analogue pasireotide
302570|NCT01895296|Drug|Placebo|placebo s.c.
302571|NCT01895283|Behavioral|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
302572|NCT01895270|Drug|Isradipine|Isradipine extended release formulation
302573|NCT01895270|Drug|Placebo|Placebo will consist of microcrystalline cellulose.
302574|NCT01895257|Device|HAI-90Y radioembolization (SIR-spheres injection)|"Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~Hepatic Angiogram~Liver-Lung Break-Through Nuclear Scan"
302575|NCT01895257|Drug|systemic chemotherapy LV5FU2|"Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure."
302576|NCT01895244|Drug|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
302577|NCT01895231|Drug|Iron isomaltoside 1000 (Monofer®)|
302578|NCT01895231|Drug|Placebo|
302579|NCT01895218|Drug|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
302580|NCT01895218|Other|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
302581|NCT01895205|Drug|Iron isomaltoside 1000|
302582|NCT01895205|Drug|Red blood cell transfusion|
302583|NCT01895192|Other|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
302584|NCT01895179|Other|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
303075|NCT01891357|Drug|trastuzumab|
302585|NCT01895179|Other|Grazing|Grazing involves eating meals spread out over the course of the day.
302586|NCT01895166|Procedure|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
302587|NCT01895166|Procedure|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
302588|NCT01895140|Device|Renal denervation device|
302589|NCT01895127|Drug|Eculizumab|
302590|NCT01895127|Biological|Immunoglobulin|
302591|NCT01895127|Procedure|Plasmapheresis|
302592|NCT01895101|Drug|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
302593|NCT01895101|Drug|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
302594|NCT01895088|Device|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
302595|NCT01895075|Drug|Inhaled budesonide|Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
302596|NCT01895075|Drug|Normal saline|2 ml normal saline by inhalation
302597|NCT01895062|Device|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.~The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
302598|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
302599|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
302600|NCT01895036|Drug|Naltrexone|
302601|NCT01895023|Drug|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
302602|NCT01895023|Drug|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
302603|NCT01895023|Drug|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
302604|NCT01895010|Device|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
302605|NCT01895010|Drug|tropisetron|only tropisetron 6mg before TACE
302606|NCT01894997|Device|Neuromuscular electrical stimulator|
302607|NCT01894997|Device|AV Impulse System Model 6000|
302608|NCT01894984|Drug|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
302609|NCT01894984|Drug|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
302610|NCT01894971|Device|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
302611|NCT01894958|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
302612|NCT01894958|Drug|Placebo|Strawberry flavored solution
302613|NCT01894932|Behavioral|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams & Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
302614|NCT01894932|Behavioral|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
302615|NCT01894919|Biological|Bexsero® vaccine (1 dose at study month zero)|
302616|NCT01894919|Biological|Bexsero® vaccine (2 doses 1 month apart)|
302617|NCT01894906|Drug|Soluble Ferric Pyrophosphate|
302618|NCT01894906|Other|Placebo|
302619|NCT01894880|Procedure|early SSC|bonding straight after birth
302620|NCT01894880|Procedure|late SSC|bonding after termination of operation
302621|NCT01894867|Dietary Supplement|magnesium|supply magnesium oxide for 6 weeks
302622|NCT01894867|Dietary Supplement|Placebo|
302623|NCT01894854|Procedure|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
302624|NCT01894841|Behavioral|Coping Long Term with Active Suicide|an intervention to reduce suicide behavior in Veterans recently hospitalized for suicide attempt or ideation with intent.
302625|NCT01894828|Dietary Supplement|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
302626|NCT01894815|Drug|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
302627|NCT01894815|Device|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
302628|NCT01894815|Other|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
303076|NCT01891344|Drug|Oral rucaparib|600 mg BID
302629|NCT01894802|Device|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
302630|NCT01894789|Drug|Ticagrelor|Blinded administration of ticagrelor for 10 days
302631|NCT01894789|Drug|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
302632|NCT01894776|Drug|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
302633|NCT01894776|Drug|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
302634|NCT01894763|Device|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
302635|NCT01894750|Behavioral|group-based skill building self-care program|
302636|NCT01894737|Other|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
302637|NCT01894737|Other|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
302638|NCT01894724|Device|NeuroSave device|
302639|NCT01894711|Drug|Trastuzumab|Treatment with trastuzumab in HER2 positive patients
302640|NCT01894685|Drug|Mesalazine|Mesalazine 3 grams, once daily for six months
302641|NCT01894685|Drug|Placebo|Placebo 3 grams, once daily for six months
302642|NCT01894672|Drug|LGX818|
302643|NCT01894659|Other|24% oral sucrose|
302644|NCT01894659|Other|30% oral glucose|
302645|NCT01894646|Radiation|Positron Emission Tomography (PET) Imaging|
302646|NCT01894633|Drug|Chloroquine|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
302647|NCT01894633|Radiation|Total brain radiotherapy|30 Gy in 10 daily fractions from Monday to Friday
302648|NCT01894620|Device|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
302649|NCT01894620|Device|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
302650|NCT01894607|Procedure|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
302651|NCT01894607|Drug|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.~Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
302652|NCT01894607|Behavioral|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
302653|NCT01894594|Drug|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.~Weekly schedule:~0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: *~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: *~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing~* to the closest dose of 650 mg (7.74 mEq)~Ideal Body Weight is defined by the following formulas (Devine Calculation):~Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
302654|NCT01894581|Dietary Supplement|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
302655|NCT01894581|Drug|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
302656|NCT01894568|Drug|Insulin Peglispro|Administered SC using a prefilled pen.
302657|NCT01894568|Drug|Insulin Glargine|Administered SC using a prefilled pen
302658|NCT01894568|Drug|Oral Antihyperglycemic Medications (OAMs)|Administered orally
302659|NCT01894555|Drug|Aspirin|81 mg daily for 4 weeks
302660|NCT01894542|Dietary Supplement|Cod protein from presscake|6g protein per day for 8wk
302661|NCT01894542|Dietary Supplement|Cod protein from presscake + stickwater|6 g protein per day for 8 wk
302662|NCT01894542|Dietary Supplement|Control|
302663|NCT01894516|Drug|GLPG0634|
302664|NCT01894516|Drug|Placebo|
302665|NCT01894503|Drug|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
302666|NCT01894477|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
302667|NCT01894477|Drug|Fludarabine Phosphate|Intravenously administered Fludarabine Phosphate
302668|NCT01894477|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
302669|NCT01894477|Radiation|Total-Body Irradiation|Undergo TBI
302670|NCT01894477|Drug|Treosulfan|Intravenously administered Treosulfan
302671|NCT01894477|Other|Laboratory Biomarker Analysis|Correlative Studies
302672|NCT01894464|Behavioral|Teacher led intervention|
302673|NCT01894451|Drug|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
302711|NCT01894165|Drug|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
302712|NCT01894165|Drug|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
302674|NCT01894451|Procedure|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
302675|NCT01894451|Procedure|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
302676|NCT01894451|Procedure|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
302677|NCT01894438|Behavioral|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
302678|NCT01894438|Behavioral|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
302679|NCT01894412|Biological|Etanercept (Enbrel)|
302680|NCT01894412|Biological|HD203|
302681|NCT01894399|Drug|HM61713|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
302682|NCT01894386|Drug|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
302683|NCT01894386|Drug|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
302684|NCT01894386|Drug|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
302685|NCT01894386|Drug|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
302686|NCT01894373|Drug|Adoptive Immunotherapy|Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
302687|NCT01894373|Biological|CIK|
302688|NCT01894360|Drug|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
302689|NCT01894347|Other|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
302690|NCT01894334|Drug|Ulinastatin|
302691|NCT01894334|Drug|Tranexamic acid|
302692|NCT01894334|Drug|Edaravone|
302693|NCT01894308|Drug|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
302694|NCT01894295|Dietary Supplement|Placebo|Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
302695|NCT01894295|Dietary Supplement|Vitamin D analogue|1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
302696|NCT01894282|Procedure|Manual Therapy|Manual Therapy Arm
302697|NCT01894282|Procedure|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
302698|NCT01894269|Drug|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
302699|NCT01894256|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
302700|NCT01894243|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
302701|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization
302702|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
302703|NCT01894230|Genetic|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele
302704|NCT01894217|Genetic|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele; reporting of test results to provider and participant
302705|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
302706|NCT01894191|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
302707|NCT01894191|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
302708|NCT01894191|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
302709|NCT01894178|Device|Parker Flex-Tip® tracheal tube|
302710|NCT01894178|Device|Portex® Tracheal Tube|
302782|NCT01893606|Drug|N-acetyl-D-glucosamine|
302713|NCT01894152|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
302714|NCT01894139|Other|High-Protein/Low-GI Diet|
302715|NCT01894139|Other|Low-protein/High-GI Diet|
302716|NCT01894126|Behavioral|Two-way SMS Dialogue|
302717|NCT01894126|Behavioral|One-way SMS Messaging|
302718|NCT01894113|Procedure|transbronchial lung biopsy|
302719|NCT01894100|Device|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
302720|NCT01894087|Behavioral|TBI - Cohort 1|
302721|NCT01894087|Behavioral|TBI - Cohort 2|
302722|NCT01894074|Behavioral|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
302723|NCT01894074|Behavioral|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
302724|NCT01894061|Biological|Bevacizumab|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.
302725|NCT01894061|Device|NovoTTF-l00A|NovoTTF-100A will be worn continuously.
302726|NCT01894061|Other|Quality of Life Assessment|Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
302727|NCT01894048|Drug|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
302728|NCT01894035|Drug|Iloprost (Ventavis, BAYQ 6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
302729|NCT01894022|Drug|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
302730|NCT01894009|Procedure|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
302731|NCT01894009|Procedure|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
302732|NCT01893996|Drug|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
302733|NCT01893996|Drug|Placebo|
302734|NCT01893983|Behavioral|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
302735|NCT01893970|Behavioral|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
302736|NCT01893970|Behavioral|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
302737|NCT01893957|Procedure|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
302738|NCT01893957|Procedure|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
302739|NCT01893957|Device|Neurodyn High Volt Model (IBRAMED)|
302740|NCT01893944|Other|virtual reality|customized applications using virtual and augmented reality to be developed.
302741|NCT01893931|Behavioral|ED Discharge & Medication Call|Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
302742|NCT01893931|Behavioral|Placebo Comparator|
302743|NCT01893905|Drug|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
302744|NCT01893905|Drug|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
302745|NCT01893892|Dietary Supplement|levocarnitine|Given PO
302746|NCT01893892|Other|placebo|Given PO
302747|NCT01893892|Other|questionnaire administration|Ancillary studies
302748|NCT01893879|Drug|placebo for study drug|Given PO
302749|NCT01893879|Drug|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
302750|NCT01893879|Other|laboratory biomarker analysis|Correlative studies
302751|NCT01893866|Drug|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
302752|NCT01893866|Drug|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
302783|NCT01893606|Drug|placebo|
303077|NCT01891331|Drug|VT-1161|
302753|NCT01893853|Other|Exercise Intervention|Exercise intervention trials will consist of a steady-state bout of exercise at ~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
302754|NCT01893840|Device|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
302755|NCT01893827|Drug|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
302756|NCT01893827|Drug|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
302757|NCT01893814|Dietary Supplement|Probiotics|
302758|NCT01893814|Dietary Supplement|Control|
302759|NCT01893801|Drug|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
302760|NCT01893801|Drug|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
302761|NCT01893801|Drug|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
302762|NCT01893788|Drug|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
302763|NCT01893788|Drug|Eplerenone|50 to 100 mg daily for 48 weeks
302764|NCT01893775|Biological|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
302765|NCT01893762|Biological|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
302766|NCT01893762|Biological|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
302767|NCT01893749|Behavioral|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
302768|NCT01893736|Other|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
302769|NCT01893736|Other|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
302770|NCT01893723|Procedure|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
302771|NCT01893723|Procedure|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
302772|NCT01893710|Procedure|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.~Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
302773|NCT01893697|Other|HRCT scan in a specific postural position|HRCT Scan taken in supine and lateral position
302774|NCT01893684|Behavioral|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
302775|NCT01893684|Behavioral|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
302776|NCT01893684|Behavioral|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
302777|NCT01893658|Drug|Omalizumab|administration of a single dose together with the standard treatment
302778|NCT01893658|Drug|Prednisone|standard treatment
302779|NCT01893645|Device|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
302780|NCT01893632|Drug|gabapentin|
302781|NCT01893632|Drug|Placebo|
302784|NCT01893593|Other|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
302785|NCT01893593|Other|Control|Guideline summary and data feedback from a baseline medical record review
302786|NCT01893580|Behavioral|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
302787|NCT01893580|Behavioral|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:~Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
302788|NCT01893580|Behavioral|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:~Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
302789|NCT01893580|Behavioral|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.~The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
302790|NCT01893567|Drug|Clobex Spray|
302791|NCT01893554|Biological|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1, 3, and 4: 10^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).~For participants in Group 2: 10^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
302792|NCT01893554|Biological|Placebo|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
302793|NCT01893541|Procedure|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
302794|NCT01893541|Drug|PROPRANOLOL|The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
302795|NCT01893541|Device|a multiband ligation device|
302796|NCT01893528|Drug|REGN2009|
302797|NCT01893528|Other|placebo|
302798|NCT01893515|Drug|PRC-4016|
302799|NCT01893515|Drug|Placebo|
302800|NCT01893502|Behavioral|Telephone counselling from Quitline|
302801|NCT01893489|Other|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
302802|NCT01893476|Other|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
302803|NCT01893463|Device|iTClamp50|
302804|NCT01893450|Drug|Methimazole|
302805|NCT01893450|Drug|Bromocriptine|
302806|NCT01893450|Drug|Pentoxifylline|
302807|NCT01893437|Drug|RO6799477|Single doses of RO6799477
302808|NCT01893424|Drug|Sativex buccal spray|buccal spray
302809|NCT01893424|Drug|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
302810|NCT01893411|Drug|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
302811|NCT01893411|Drug|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
302933|NCT01892540|Other|questionnaire administration|Ancillary studies
302812|NCT01893411|Drug|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
302813|NCT01893398|Other|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
302814|NCT01893385|Drug|Vitamin D (drug)|
302815|NCT01893372|Drug|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
302816|NCT01893372|Drug|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
302817|NCT01893359|Drug|riboflavin ophthalmic solution, 0% dextran|
302818|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
302819|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
302820|NCT01893359|Procedure|Laser-assisted in situ keratomileusis|
302821|NCT01893346|Drug|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
302822|NCT01893333|Procedure|Nerve sparing radical hysterectomy|"Nerve sparing radical hysterectomy~sparing hypogastric nerve~sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
302823|NCT01893320|Drug|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.~Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
302824|NCT01893320|Drug|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
302825|NCT01893307|Radiation|Intensity-Modulated X-Ray Therapy (IMRT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).~Treating physician evaluate each patient for possible chemotherapy."
302826|NCT01893307|Radiation|Intensity-Modulated Proton Beam Therapy (IMPT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).~Treating physician evaluate each patient for possible chemotherapy."
302827|NCT01893307|Procedure|Modified barium swallow (MBS)|Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.
302828|NCT01893307|Behavioral|Questionnaires|Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy.
302829|NCT01893294|Drug|gemcitabine hydrochloride|Given IT
302830|NCT01893294|Drug|fluorouracil|Given IV
302831|NCT01893294|Radiation|radiation therapy|Undergo radiation therapy
302832|NCT01893294|Other|laboratory biomarker analysis|Correlative studies
302833|NCT01893281|Drug|Topical Testosterone Solution|Administered topically to axillae.
302834|NCT01893242|Drug|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
302835|NCT01893242|Drug|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
302836|NCT01893229|Drug|Lithium|Lithium is used as a mood stabiliser
302837|NCT01893229|Drug|Valproate|Valproate is used as a mood stabiliser
302838|NCT01893229|Drug|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
302839|NCT01893229|Drug|Quetiapine|Quetiapine is used as a mood stabiliser
302840|NCT01893229|Drug|Olanzapine|Olanzapine is used as a mood stabiliser.
302841|NCT01893229|Drug|Ziprasidone|Ziprasidone is used as a mood stabiliser
302842|NCT01893203|Drug|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
302843|NCT01893203|Drug|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
302844|NCT01893190|Drug|Nimodipine|Based upon Investigator Judgement
302845|NCT01893190|Drug|Nimodipine Microparticles|Based upon Investigator Judgement
302846|NCT01893177|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
302847|NCT01893164|Procedure|simple decompression|decompression of the ulnar nerve
302848|NCT01893164|Procedure|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
302849|NCT01893164|Procedure|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
302850|NCT01893151|Drug|Iguratimod|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
302851|NCT01893151|Drug|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
302852|NCT01893138|Biological|Roll-in|Placebo control is the vehicle solution used for the study product, AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
302853|NCT01893138|Other|Placebo|Placebo control is the vehicle solution used for the study product.
302854|NCT01893138|Biological|AMDC for USR|AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
302855|NCT01893125|Drug|CNV2197944|
302856|NCT01893125|Drug|Placebo|
303078|NCT01891331|Drug|Fluconazole|
303079|NCT01891318|Radiation|radiosurgery|Undergo radiosurgery
302857|NCT01893112|Behavioral|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training & Education Center for health).
302858|NCT01893112|Behavioral|Breast Cancer Screening|
302859|NCT01893099|Drug|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
302860|NCT01893099|Device|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
302861|NCT01893086|Procedure|LH alone|LH, laparoscopic hysterectomy
302862|NCT01893086|Procedure|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
302863|NCT01893073|Behavioral|Mindful walking program|
302864|NCT01893060|Drug|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
302865|NCT01893060|Drug|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
302866|NCT01893060|Drug|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
302867|NCT01893060|Other|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
302868|NCT01893047|Behavioral|live music|live harp music
302869|NCT01893047|Behavioral|recorded music|recorded harp music
302870|NCT01893034|Procedure|Arthroscopic treatment of femoroacetabular impingement|
302871|NCT01893034|Other|Physiotherapy and activity modification|
302872|NCT01893008|Other|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.~Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.~Training will be started after the chemoradiation period (if applicable)."
302873|NCT01892995|Drug|Ketamine|
302874|NCT01892982|Behavioral|Problem Solving Education tailored to NICU|
302875|NCT01892930|Radiation|stereotactic body radiation therapy|Undergo SBRT
302876|NCT01892930|Procedure|therapeutic conventional surgery|Undergo partial or radical nephrectomy
302877|NCT01892930|Other|laboratory biomarker analysis|Correlative studies
302878|NCT01892904|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
302879|NCT01892891|Drug|VBY-036|Cathepsin S inhibitor
302880|NCT01892878|Procedure|VerteLoc|Single Arm
302881|NCT01892865|Other|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
302882|NCT01892865|Other|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
302883|NCT01892852|Procedure|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
302884|NCT01892839|Other|low dialysate flow, smaller dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.
302885|NCT01892839|Other|high dialysate flow, larger dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
302886|NCT01892826|Drug|hCG|5000IU
302887|NCT01892813|Drug|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302888|NCT01892813|Drug|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302889|NCT01892813|Drug|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302890|NCT01892813|Drug|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302891|NCT01892813|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302892|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302893|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302894|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
302895|NCT01892813|Behavioral|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
302896|NCT01892813|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
302897|NCT01892813|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
303080|NCT01891318|Procedure|therapeutic conventional surgery|Undergo surgical resection
304231|NCT01882530|Drug|Nefopam|
302898|NCT01892813|Behavioral|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
302899|NCT01892813|Behavioral|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
302900|NCT01892800|Procedure|Lung resection|
302901|NCT01892787|Drug|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
302902|NCT01892787|Drug|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
302903|NCT01892774|Procedure|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
302904|NCT01892761|Drug|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
302905|NCT01892748|Drug|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
302906|NCT01892748|Drug|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
302907|NCT01892722|Drug|Interferon beta-1a i.m. injections|Administration once weekly via i.m. injections.
302908|NCT01892722|Drug|Fingolimod oral capsules|Administration orally once daily.
302909|NCT01892722|Drug|Placebo oral capsule|Placebo capsule required for double-dummy masking to blind formulations.
302910|NCT01892722|Drug|Placebo i.m. injection|Placebo i.m. injection required for double-dummy masking to blind formulations.
302911|NCT01892709|Drug|Hydromorphone|
302912|NCT01892696|Device|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
302913|NCT01892683|Drug|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
302914|NCT01892670|Other|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
302915|NCT01892657|Drug|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
302916|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
302917|NCT01892644|Other|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
302918|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
302919|NCT01892631|Other|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
302920|NCT01892631|Other|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
302921|NCT01892618|Drug|Prevenar 13|13-valent pneumococcal conjugated vaccine
302922|NCT01892618|Drug|Pneumovax|23-valent pneumococcal polysaccharide vaccine
302923|NCT01892605|Behavioral|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
302924|NCT01892592|Behavioral|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
302925|NCT01892579|Behavioral|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
302926|NCT01892579|Other|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
302927|NCT01892566|Other|mHealth Intervention|See arm description
302928|NCT01892553|Device|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit~Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min~Cathodal tDCS: Intensity of 1.25 mA during 15 min~Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
302929|NCT01892540|Procedure|positron emission tomography/computed tomography|Undergo PET/CT
302930|NCT01892540|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
302931|NCT01892540|Device|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
302932|NCT01892540|Radiation|gadopentetate dimeglumine|Undergo DTPA-PET/MRI
304232|NCT01882530|Drug|Ketoprofen|
302934|NCT01892527|Drug|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
302935|NCT01892514|Procedure|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
302936|NCT01892501|Procedure|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.~Pathological samples are taken :~3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
302937|NCT01892501|Device|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
302938|NCT01892488|Drug|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Experimental intervention:~Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
302939|NCT01892488|Drug|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.~Control intervention:~Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
302940|NCT01892475|Behavioral|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:~Accurately predicting step target attainment the following months (SGD10)~Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
302941|NCT01892475|Behavioral|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
302942|NCT01892449|Other|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
302943|NCT01892449|Other|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
302944|NCT01892436|Drug|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
302945|NCT01892436|Drug|Placebo|Placebo
302946|NCT01892423|Other|Cetaphil Moisturizing Lotion Daily Advance|
302947|NCT01892410|Other|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
302948|NCT01892397|Device|Optune (NovoTTF-100A)|
302949|NCT01892384|Drug|Placebo|matching placebo
302950|NCT01892384|Drug|BI 409306|low dose
302951|NCT01892384|Drug|BI 409306|medium dose
302952|NCT01892384|Drug|BI 409306|high dose
302953|NCT01892371|Drug|Azacitidine|Given SC or IV
302954|NCT01892371|Drug|Cytarabine|Given SC
302955|NCT01892371|Other|Pharmacodynamic Study|Correlative studies
302956|NCT01892371|Drug|Quizartinib|Given PO
302957|NCT01892358|Behavioral|SKIN Intervention|
302958|NCT01892358|Other|Treatment as Usual|
302959|NCT01892345|Drug|Eculizumab|Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
302960|NCT01892345|Drug|Placebo|Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
302961|NCT01892332|Drug|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.~Conversely, block success resulted in a reduction in concentration by 0.1%."
302962|NCT01892319|Drug|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
302963|NCT01892319|Drug|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
302964|NCT01892306|Behavioral|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
302965|NCT01892306|Drug|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
303064|NCT01891448|Other|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
303065|NCT01891435|Drug|Oral paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
302966|NCT01892293|Drug|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
302967|NCT01892280|Behavioral|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
302968|NCT01892280|Behavioral|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
302969|NCT01892267|Device|PEG-J placement|PEG-J placement
302970|NCT01892254|Drug|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
302971|NCT01892254|Drug|Placebo|Placebo (to metformin)
302972|NCT01892241|Drug|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
302973|NCT01892241|Drug|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
302974|NCT01892228|Behavioral|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
302975|NCT01892215|Procedure|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
302976|NCT01892215|Procedure|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
302977|NCT01892202|Other|Cohort|
302978|NCT01892189|Drug|Ketamine|Ketamine intravenous administration.
302979|NCT01892189|Drug|TAK-063|TAK-063 tablets
302980|NCT01892189|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
302981|NCT01892176|Dietary Supplement|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
302982|NCT01892163|Device|Ozurdex|Dexamethasone implant (Ozurdex)
302983|NCT01892150|Other|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
302984|NCT01892137|Drug|Ingenol mebutate gel 0.05%|Once daily for 2 consecutive days
302985|NCT01892124|Behavioral|Motivational Interviewing/Cognitive Behavioral-based Therapy|
302986|NCT01892111|Other|Structured exercise program.|
302987|NCT01892098|Dietary Supplement|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
302988|NCT01892098|Dietary Supplement|Placebo|Cellulose pill given as placebo
302989|NCT01892085|Behavioral|Early initiation|Initiation of breast milk expression <1 hour following delivery.
302990|NCT01892085|Behavioral|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
302991|NCT01892085|Behavioral|Late initiation|Initiation of milk expression >3-6 hours following delivery.
302992|NCT01892072|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
302993|NCT01892059|Procedure|Segmental artery clamping|Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
302994|NCT01892059|Procedure|Main renal artery clamping|Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
302995|NCT01892046|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
302996|NCT01892033|Behavioral|Aerobic Exercise|12 weeks of brisk walking
302997|NCT01892020|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
302998|NCT01892020|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
302999|NCT01892007|Behavioral|Cogmed RM - Online adaptive working memory training intervention|
303000|NCT01892007|Behavioral|Cogmed RM - Online (non-adaptive, placebo) working memory training intervention|
303001|NCT01891994|Drug|Eltrombopag|administration of eltrombopag for 6 months
303002|NCT01891981|Drug|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
303003|NCT01891968|Drug|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 21 day cycle.
303004|NCT01891955|Behavioral|Healthy diet A|"Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
303005|NCT01891955|Behavioral|Healthy diet B|"Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
303006|NCT01891942|Procedure|twitch by magstim|
303066|NCT01891435|Drug|Intravenous paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
303067|NCT01891435|Drug|Intramuscular diclofenac|after giving medicine temperature is checked every 30 minutes for 2 hours
303068|NCT01891409|Device|Male circumcision using the Shang Ring device|
303069|NCT01891396|Device|Hyaluronic Acid and TH|
303070|NCT01891396|Device|Hyaluronic Acid|
303071|NCT01891396|Device|Saline|Saline placebo packaged to look identical to comparator syringes.
304233|NCT01882530|Drug|Morphine|
303007|NCT01891929|Behavioral|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.~After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
303008|NCT01891929|Behavioral|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.~In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
303009|NCT01891916|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
303010|NCT01891890|Drug|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
303011|NCT01891890|Drug|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
303012|NCT01891890|Drug|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
303013|NCT01891864|Drug|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
303014|NCT01891864|Drug|Enbrel|Enbrel is used as reference product to GP2015.
303015|NCT01891851|Drug|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
303016|NCT01891851|Drug|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
303017|NCT01891838|Procedure|Volume controlled ventilation|
303018|NCT01891838|Procedure|Pressure-controlled ventilation|
303019|NCT01891825|Procedure|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
303020|NCT01891825|Procedure|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
303021|NCT01891812|Drug|Nitrous oxide 50%|
303022|NCT01891799|Other|Option B+|"Using one low toxicity triple ARV regimen [(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)] for all women, rather than adapting regimens by CD4+~Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART~Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
303023|NCT01891786|Behavioral|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
303024|NCT01891786|Behavioral|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
303025|NCT01891773|Behavioral|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
303026|NCT01891760|Device|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
303027|NCT01891760|Device|Profore|Four-layer compression bandaging therapy.
303028|NCT01891747|Drug|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I & phase II)
303029|NCT01891747|Drug|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I & Phase II)
303030|NCT01891747|Dietary Supplement|Vitamin C|250 mg vitamin C once a day (oral) - Phase I & Phase II
303031|NCT01891734|Other|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
303032|NCT01891734|Other|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
303033|NCT01891721|Behavioral|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
303034|NCT01891721|Behavioral|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
303035|NCT01891721|Behavioral|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
303036|NCT01891708|Other|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
303037|NCT01891695|Radiation|39.6 Gy radiation|
303038|NCT01891682|Other|Observational|Observational, Translational non-treatment study
303039|NCT01891669|Drug|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
303040|NCT01891669|Drug|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
303041|NCT01891656|Behavioral|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller & Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
303042|NCT01891656|Behavioral|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere & Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman & Massey, 2008). As discussed by Hester & Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
303043|NCT01891643|Drug|Lenalidomide|
303044|NCT01891643|Drug|Dexamethasone|
303045|NCT01891643|Biological|Elotuzumab|
303046|NCT01891617|Other|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
303047|NCT01891604|Dietary Supplement|breast milk with Bifidobacterium Longum subp. Infantis R0033|
303048|NCT01891604|Dietary Supplement|breast milk|
303049|NCT01891591|Procedure|Roux-en-Y gastric bypass (RYGP)|
303050|NCT01891565|Behavioral|Feedback|
303051|NCT01891526|Drug|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
303052|NCT01891513|Behavioral|Exercise|All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
303053|NCT01891513|Drug|ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
303054|NCT01891513|Drug|Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
303055|NCT01891513|Drug|Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
303056|NCT01891500|Drug|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
303057|NCT01891500|Drug|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
303058|NCT01891500|Drug|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
303059|NCT01891487|Drug|Track A|Bimatoprost 0.03% solution applied to eyebrow
303060|NCT01891487|Drug|Track B|Refresh Tears applied to eyebrows
303061|NCT01891474|Device|U-health care|voice inception technique based U-healthcare service
303062|NCT01891461|Drug|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
303063|NCT01891448|Other|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
303072|NCT01891357|Procedure|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
303081|NCT01891318|Procedure|quality-of-life assessment|Ancillary studies
303082|NCT01891305|Drug|VT-1161|
303083|NCT01891305|Drug|placebo|
303084|NCT01891292|Drug|Enalapril|0.25-0.35 mg/kg/day
303085|NCT01891292|Drug|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
303086|NCT01891279|Other|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
303087|NCT01891279|Other|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
303088|NCT01891266|Procedure|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
303089|NCT01891266|Procedure|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
303090|NCT01891253|Device|non-invasive determination of cardiac output|
303091|NCT01891227|Drug|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
303092|NCT01891227|Drug|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
303093|NCT01891214|Other|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
303094|NCT01891201|Drug|Oxytocin|Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
303095|NCT01891175|Procedure|Elective caesarean section under spinal anaesthesia.|Patients with scheduled caesarean.
303096|NCT01891175|Procedure|Elective caesarean section under spinal anaesthesia.|
303097|NCT01891136|Drug|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
303098|NCT01891123|Device|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
303099|NCT01891123|Drug|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
303100|NCT01891110|Procedure|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
303101|NCT01891110|Procedure|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
303102|NCT01891110|Procedure|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
303103|NCT01891097|Procedure|Acupuncture plus auricular acupuncture|"Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.~Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours."
303104|NCT01891097|Procedure|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
303105|NCT01891084|Drug|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
303106|NCT01891084|Drug|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
303107|NCT01891084|Drug|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
303108|NCT01891071|Procedure|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
303109|NCT01891058|Device|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
303110|NCT01891045|Behavioral|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
303111|NCT01891045|Behavioral|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
303112|NCT01891019|Drug|Thalidomide oral|Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.
303113|NCT01891006|Device|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
303114|NCT01891006|Other|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
303115|NCT01890993|Drug|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
303154|NCT01890707|Procedure|Endotracheal intubation|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
304327|NCT01881958|Drug|DiaPep277®|
303116|NCT01890980|Biological|WT-1-vaccine Montanide + GM-CSF|Treatment of 6 injections over 12 weeks, administered on weeks 0, 2, 4, 6, 8, and 10. All receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination and may be self administered with appropriate instruction. Participants keep a logbook noting the time and placement of the injection, and will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide which will be administered by a nurse (not self-administered) subcutaneously to the same anatomical site as the GM-CSF as marked by the patient or treating healthcare professional by a permanent marker pen.
303117|NCT01890980|Biological|Montanide adjuvant + GM-CSF|Treatment of 6 injections over 12 weeks, administered on weeks 0, 2, 4, 6, 8, and 10. All receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination and may be self administered with appropriate instruction. Participants keep a logbook noting the time and placement of the injection, and will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide which will be administered by a nurse (not self-administered) subcutaneously to the same anatomical site as the GM-CSF as marked by the patient or treating healthcare professional by a permanent marker pen.
303118|NCT01890967|Drug|LY3015014|Administered SC
303119|NCT01890967|Drug|Placebo|Administered SC
303120|NCT01890967|Drug|Statin|Administered orally
303121|NCT01890967|Drug|Ezetimibe|Administered orally
303122|NCT01890954|Device|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
303123|NCT01890941|Drug|KCT-0809 ophthalmic solution|
303124|NCT01890941|Drug|Placebo|
303125|NCT01890915|Other|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
303126|NCT01890902|Drug|Ketoprofen 10% Cream|
303127|NCT01890902|Drug|Placebo|
303128|NCT01890889|Dietary Supplement|Ad-Chol-Pre|
303129|NCT01890889|Dietary Supplement|Half-dose Ad-Chol-Pre|
303130|NCT01890889|Other|Defatted egg yolk without the active ingredient of the other two interventions|
303131|NCT01890876|Other|Walking uphill|ascending about 500 m
303132|NCT01890876|Other|Walking downhill|descending about 500 m
303133|NCT01890863|Drug|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
303134|NCT01890863|Drug|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
303135|NCT01890850|Other|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
303136|NCT01890837|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
303137|NCT01890837|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
303138|NCT01890811|Dietary Supplement|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
303139|NCT01890798|Drug|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
303140|NCT01890785|Drug|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
303141|NCT01890772|Drug|Telaprevir|
303142|NCT01890772|Drug|Peginterferon alfa-2a|
303143|NCT01890772|Drug|Ribavirin|
303144|NCT01890772|Dietary Supplement|Vitamin D|
303145|NCT01890759|Biological|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
303146|NCT01890746|Drug|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects > 60 years: daunorubicin dose was adjusted to 60mg /m2.
303147|NCT01890746|Drug|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
303148|NCT01890746|Drug|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of the Investigational Product (IP) was to be increased to 300 mg if platelet counts were <100 Gi/L. IP continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) was used and after 7 days, the dose of IP was increased to 150 mg if platelet counts were <100 Gi/L.
303149|NCT01890746|Drug|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given was matching 300 mg Eltrombopag if platelet counts were <100 Gi/L. Placebo continued until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily was used and after 7 days, the placebo matching 150 mg Eltrombopag was given if platelet counts were <100 Gi/L.
303150|NCT01890733|Device|Best Repair of torn Rotator Cuff|
303151|NCT01890733|Device|InSpace™ system|
303152|NCT01890720|Device|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
303153|NCT01890720|Other|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
303155|NCT01890707|Procedure|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
303156|NCT01890707|Drug|Fentanyl (Sublimaze TM)|
303157|NCT01890707|Drug|fluoromethyl hexafluoroisopropyl ether (Sevoflurane TM)|
303158|NCT01890707|Drug|Succinylcholine (Suxamethonium chloride)|
303159|NCT01890707|Drug|Rocuronium (Zemuron TM)|
303160|NCT01890707|Drug|Propofol (Diprivan TM)|
303161|NCT01890707|Drug|Ketamine|
303162|NCT01890694|Drug|Tolvaptan|15 mg once daily
303163|NCT01890694|Drug|Placebo|15 mg once daily
303164|NCT01890694|Behavioral|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
303165|NCT01890694|Behavioral|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
303166|NCT01890694|Biological|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
303167|NCT01890694|Biological|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
303168|NCT01890694|Procedure|Ascites Evaluation|Ascites will be assessed at every visit.
303169|NCT01890694|Procedure|Edema|Edema will be assessed at every visit.
303170|NCT01890681|Behavioral|Baby NAP SACC|
303171|NCT01890681|Behavioral|Back to Sleep|
303172|NCT01890668|Other|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
303173|NCT01890668|Other|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :~Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.~Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.~To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.~A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.~Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.~The follow-up for each patient is 6 months"
303174|NCT01890655|Drug|MT-1303-Low|
303175|NCT01890655|Drug|MT-1303-Middle|
303176|NCT01890655|Drug|MT-1303-High|
303177|NCT01890642|Device|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
303178|NCT01890642|Other|Pain Ease Spray|Cold Spray used to anesthetize the skin
303179|NCT01890642|Drug|1% buffered lidocaine|Lidocaine placed using Jet Injection
303180|NCT01890642|Other|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
303181|NCT01890642|Other|Sucrose|Oral Sucrose used for children < 1 year
303182|NCT01890629|Drug|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
303183|NCT01890616|Device|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
303184|NCT01890603|Other|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
303185|NCT01890603|Other|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
303186|NCT01890590|Device|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
303187|NCT01890577|Drug|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
303188|NCT01890564|Other|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
303189|NCT01890564|Other|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
303190|NCT01890564|Other|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
303191|NCT01890551|Other|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
303192|NCT01890538|Drug|Administration of 100 mg dimenhydrinate intravenous|
303193|NCT01890538|Drug|2 g piracetam intravenous|
303194|NCT01890499|Dietary Supplement|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
303195|NCT01890473|Drug|Abatacept|
303196|NCT01890447|Other|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
303197|NCT01890434|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
303309|NCT01889680|Drug|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
303198|NCT01890421|Drug|Gadobutrol (Gadovist, Gadavist, BAY86-4875)|Participants received gadobutrol at the total approved standard dose of 0.1 millimole per kilogram body weight (mmol/kg BW) in 2 separate bolus injections: 0.05 mmol/kg BW at peak pharmacologic stress and 0.05 mmol/kg BW at rest via a power injector.
303199|NCT01890408|Drug|wound infusion ropivacaine|"Laparotomy Hepatic surgery :~Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
303200|NCT01890395|Other|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
303201|NCT01890382|Dietary Supplement|Whey protein|30 g in total; twice a day (morning and evening)
303202|NCT01890382|Dietary Supplement|whey plus creatine|whey protein combined with creatine (30 g and 6.0 g in total; twice a day, respectively)
303203|NCT01890382|Dietary Supplement|leucine supplementation|7.5 g/d in total; three times per day
303204|NCT01890382|Dietary Supplement|soy protein|30 g in total; twice a day
303205|NCT01890382|Dietary Supplement|creatine|6.0 g in total; twice a day
303206|NCT01890382|Dietary Supplement|placebo|
303207|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
303208|NCT01890369|Dietary Supplement|3g Leucine|Dissolved in 250ml water.
303209|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
303210|NCT01890356|Device|Transcranial electrical stimulation|
303211|NCT01890343|Drug|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
303212|NCT01890343|Drug|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
303213|NCT01890330|Other|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
303214|NCT01890330|Other|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
303215|NCT01890317|Procedure|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
303216|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
303217|NCT01890278|Radiation|Whole Brain IMRT|
303218|NCT01890278|Radiation|Conventional Whole Brain RT|
303219|NCT01890265|Drug|FG-3019|FG-3019, 30 mg/kg by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
303220|NCT01890265|Drug|Placebo|Placebo, 30 mg/kg by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
303221|NCT01890265|Drug|Sub-study: Pirfenidone|Subjects in the Active Comparator Arm are receiving background treatment with IPF-approved medications during the study according to the instructions in their respective labels and the prescribing physician.
303222|NCT01890265|Drug|Sub-study: Nintedanib|Subjects in this Active Comparator Arm are receiving background treatment with IPF-approved medications during the study according to the instructions in their respective labels and the prescribing physician.
303223|NCT01890265|Drug|Sub-study: FG-3019|FG-3019 by intravenous infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with FG-3019 in all active comparator subjects will be administered at a dose of 15 mg/kg for the first two dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.
303224|NCT01890265|Drug|Sub-study: Placebo|Placebo by intravenous infusion every 3 weeks for a total of 8 infusions over 21 weeks. Initial treatment with placebo in all active comparator subjects will be administered at a dose of 15 mg/kg for the first two dose administrations. If these are well tolerated, all following study drug administrations will be at 30 mg/kg.
303225|NCT01890252|Device|Hyper CL|The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
303226|NCT01890252|Drug|saline solution|saline solution of 5% NaCl
303227|NCT01890239|Other|Care Programme for the Last Days of Life|The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
303228|NCT01890226|Behavioral|Mobile Personal Health Record App.|
303229|NCT01890213|Biological|AVX701|
303230|NCT01890200|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
303231|NCT01890200|Drug|Ribavirin|conventional treatment of Hepatitis C
303232|NCT01890200|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
303233|NCT01890200|Drug|Placebo|Placebo, without acting ingredient.
303234|NCT01890161|Drug|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
303235|NCT01890161|Drug|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
303236|NCT01890148|Drug|AZD5069|oral BD administration of 45 mg AZD5069
303237|NCT01890135|Drug|Zibotentan (ZD4054)|10 mg
303238|NCT01890135|Drug|placebo|randomized double blind
303239|NCT01890122|Drug|Alogliptin|Alogliptin tablets
303240|NCT01890122|Drug|Metformin HCl|Metformin HCl capsules
303241|NCT01890122|Drug|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
303242|NCT01890122|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets
303243|NCT01890122|Drug|Metformin Placebo|Metformin placebo-matching capsules
303244|NCT01890122|Drug|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
303245|NCT01890109|Biological|Erenumab|Administered via subcutaneous injection.
303246|NCT01890109|Drug|Placebo|Administered via subcutaneous injection
303310|NCT01889667|Drug|ORMD-0801 Dose # 1|Oral Insulin Formulation
304758|NCT01878435|Other|Travel subsidy|
303247|NCT01890096|Radiation|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
303248|NCT01890096|Radiation|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
303249|NCT01890083|Behavioral|Exercise|
303250|NCT01890083|Behavioral|Health Education|
303251|NCT01890070|Dietary Supplement|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
303252|NCT01890070|Dietary Supplement|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
303253|NCT01890070|Dietary Supplement|Red wine|Italian Organic Red Wine
303254|NCT01890070|Dietary Supplement|Olive Oil|Italian Organic Olive Oil
303255|NCT01890070|Dietary Supplement|Wild mixed greens|Italian organic wild mixed greens
303256|NCT01890070|Dietary Supplement|Chestnut|Italian Organic Chestnut
303257|NCT01890070|Other|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
303258|NCT01890057|Drug|Sugammadex|The dose of sugammadex
303259|NCT01890031|Other|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
303260|NCT01890031|Other|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
303261|NCT01890018|Behavioral|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
303262|NCT01890018|Behavioral|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
303263|NCT01890018|Behavioral|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
303264|NCT01890005|Drug|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
303265|NCT01890005|Drug|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
303266|NCT01889992|Radiation|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short & long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
303267|NCT01889992|Procedure|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.~Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
303268|NCT01889992|Other|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
303269|NCT01889992|Drug|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels."
303270|NCT01889992|Procedure|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
303271|NCT01889992|Genetic|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
303272|NCT01889992|Other|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
303273|NCT01889979|Drug|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
303274|NCT01889979|Drug|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
303275|NCT01889966|Drug|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
303276|NCT01889953|Other|EUS-guided biliary drainage|"Based on the patient`s condition, the will receive:~Rendezvous technique~Direct transluminal access transesophageal technique~Direct transluminal access transduodenal technique~or direct transluminal access using transgastric approach"
303277|NCT01889940|Behavioral|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients & families are conducted to determine each party's needs and worries.~Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.~Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
303278|NCT01889927|Other|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
303311|NCT01889667|Drug|ORMD-0801 Dose # 2|Oral Insulin Formulation
303312|NCT01889667|Drug|Placebo|Oil Capsules
304759|NCT01878435|Other|Travel subsidy 2|
303279|NCT01889914|Drug|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
303280|NCT01889888|Other|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
303281|NCT01889875|Drug|"ALK Grazax 75,000 SQ-T Phleum pratense"|
303282|NCT01889875|Drug|"ALK AluTard 225 Phleum pratense"|
303283|NCT01889862|Drug|BMN165 20mg/day|BMN165 20mg/day self-administered daily
303284|NCT01889862|Drug|BMN165 40mg/day|BMN165 40mg/day self-administered daily
303285|NCT01889862|Drug|Placebo|Non-drug placebo, self-administered daily
303286|NCT01889849|Drug|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
303287|NCT01889849|Drug|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
303288|NCT01889836|Biological|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
303289|NCT01889836|Biological|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
303290|NCT01889823|Other|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
303291|NCT01889823|Other|Hyperoxia|Subjects will be breathing 100% oxygen
303292|NCT01889810|Dietary Supplement|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
303293|NCT01889797|Biological|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
303294|NCT01889797|Biological|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
303295|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
303296|NCT01889784|Device|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
303297|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
303298|NCT01889784|Device|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
303299|NCT01889771|Drug|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
303300|NCT01889758|Drug|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
303301|NCT01889758|Drug|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
303302|NCT01889758|Drug|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
303303|NCT01889745|Drug|HX-1171|Anti-oxidatant, Anti-inflamation
303304|NCT01889732|Device|ROTEM|
303305|NCT01889719|Biological|MVA-CMDR|injections of MVA-CMDR vaccine
303306|NCT01889680|Drug|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
303307|NCT01889680|Drug|LV|400 mg/m2 IV day 1 every 14 days until disease progression
303308|NCT01889680|Drug|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
303313|NCT01889654|Other|Venous blood sampling|
303314|NCT01889628|Dietary Supplement|Liquid-based Nutritional Formulae and liquid glucose|
303315|NCT01889615|Other|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
303316|NCT01889602|Drug|Topiramate|Topiramate: 100 mg, 150 mg or 200 mg, po, 1x
303317|NCT01889602|Drug|Lorazepam|Lorazepam: 2mg, po, 1x
303318|NCT01889602|Other|Placebo|
303319|NCT01889589|Other|Surveillance|
303320|NCT01889576|Dietary Supplement|Magnesium Oxide|
303321|NCT01889563|Other|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
303322|NCT01889550|Behavioral|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
303323|NCT01889550|Behavioral|Access to the website www.ouh.dk|Access to the usual information from the hospital website
303324|NCT01889537|Behavioral|Virtual Reality|The patient will receive virtual reality during a burn care procedure
303325|NCT01889524|Other|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
303326|NCT01889524|Other|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
303327|NCT01889524|Other|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
303328|NCT01889511|Behavioral|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
303329|NCT01889498|Drug|Acetazolamide|"Acetazolamide twice a day, at 12 hour intervals:~250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery~One tablet to take two hours before surgery~500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours."
303330|NCT01889472|Device|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
303331|NCT01889446|Dietary Supplement|Calcium propionate|
303332|NCT01889433|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
303333|NCT01889433|Drug|Pegasys|180 µg subcutaneously, once a week
303334|NCT01889420|Drug|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.~Cycles will span 28 days. Dosage schedules will be:~Everolimus daily for 28 days of a 28 day cycle;~Pomalidomide daily for 21 days of a 28 day cycle~Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
303335|NCT01889407|Drug|Idarubicin|8 mg/m2, iv drip on days 1-3
303336|NCT01889394|Procedure|secondary wound healing|secondary wound healing
303337|NCT01889394|Procedure|primary wound closure using a limberg flap|primary wound closure using a limberg flap
303338|NCT01889381|Drug|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
303339|NCT01889368|Dietary Supplement|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
303340|NCT01889368|Dietary Supplement|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
303341|NCT01889355|Device|AgaMatrix Blood Glucose Monitor|
303342|NCT01889342|Behavioral|Metacognitive therapy|
303343|NCT01889342|Behavioral|Cognitive behavioral therapy|
303344|NCT01889329|Dietary Supplement|RUTF-1|Made from local food ingredients
303345|NCT01889329|Dietary Supplement|RUTF-2|Made from local food ingredients
303346|NCT01889329|Dietary Supplement|Plumpynut|Commercially made from peanut paste
303347|NCT01889316|Device|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
303348|NCT01889316|Device|AN24|
303456|NCT01888497|Drug|Placebo|Oral, prior to bedtime on the night before performance testing
307766|NCT01855490|Drug|Exenatide|
303349|NCT01889303|Drug|DC|"Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.~chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles."
303350|NCT01889303|Drug|concurrent chemoradiotherapy with 5-FU/CF|"FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.~Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles."
303351|NCT01889303|Radiation|adjuvant radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
303352|NCT01889290|Drug|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
303353|NCT01889277|Drug|MT-3995-Low|
303354|NCT01889277|Drug|MT-3995-High|
303355|NCT01889277|Drug|Placebo|
303356|NCT01889264|Other|Observational|Observational, Translational non-treatment study
303357|NCT01889251|Drug|Ocriplasmin|
303358|NCT01889251|Drug|Sham injection|
303359|NCT01889238|Drug|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
303360|NCT01889212|Other|11C-erlotinib PET/CT|
303361|NCT01889199|Drug|Flutamide|Flutamide 125 mg orally each 28 day cycle for 6 cycles
303362|NCT01889199|Other|Placebo|Placebo orally each 28 day cycle for 6 cycles
303363|NCT01889186|Drug|ABT-199|Tablet
303364|NCT01889173|Drug|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
303365|NCT01889173|Drug|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
303366|NCT01889173|Drug|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
303367|NCT01889173|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
303368|NCT01889160|Drug|AZD4721 Solution|1-9 mg/mL liquid solution
303369|NCT01889160|Drug|AZD4721 Placebo|Liquid solution
303370|NCT01889160|Drug|AZD4721 Suspension|9 mg/g liquid suspension
303371|NCT01889147|Biological|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
303372|NCT01889147|Biological|Placebo|
303373|NCT01889134|Drug|Sedron (alendronate)|
303374|NCT01889134|Procedure|Parathyroidectomy|
303375|NCT01889121|Behavioral|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
303376|NCT01889108|Behavioral|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
303377|NCT01889095|Drug|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
303378|NCT01889095|Drug|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
303379|NCT01889082|Behavioral|Behavioral Weight Loss Intervention for Young Adults|
303380|NCT01889069|Drug|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
303381|NCT01889069|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
303382|NCT01889069|Drug|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
303383|NCT01889069|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
303384|NCT01889069|Drug|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
303385|NCT01889069|Drug|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
303386|NCT01889056|Drug|Erythropoietin (Epoetin beta)|
303387|NCT01889056|Drug|Placebo|0.9% sodium chloride solution
303388|NCT01889017|Other|patient questionnaire (tablet pc based)|
303389|NCT01889004|Drug|Dexmedetomidine|Escalating concentrations until loss of responsiveness
303390|NCT01889004|Drug|Propofol|Escalating concentrations until loss of responsiveness
303391|NCT01888991|Other|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
303392|NCT01888978|Drug|Gem-OX|
303393|NCT01888978|Drug|Gem-5FU|
303394|NCT01888978|Drug|Gem-Tax|
303395|NCT01888978|Drug|Modified FOLFOX-6|
303396|NCT01888978|Drug|Ox-Tax|
303397|NCT01888978|Drug|FOLFIRI|
303398|NCT01888978|Drug|Tax-Iri|
303399|NCT01888965|Drug|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.~If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
303400|NCT01888952|Drug|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
303401|NCT01888952|Drug|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
303402|NCT01888939|Other|Walking on a Treadmill|
303403|NCT01888939|Other|Sedendary Activities Only|
303404|NCT01888900|Drug|DUAL|Asunaprevir and Daclatsvir
303405|NCT01888900|Drug|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
303406|NCT01888887|Other|Cetaphil Daily Facial Cleanser|
303407|NCT01888874|Drug|GLPG0634|
303408|NCT01888874|Drug|Placebo|
303409|NCT01888861|Dietary Supplement|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
303410|NCT01888861|Drug|placebo|the patients in this arm were received 900mg placebo through NG tube.
303411|NCT01888848|Dietary Supplement|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
303412|NCT01888848|Dietary Supplement|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
303413|NCT01888835|Drug|Mirtazapine|
303414|NCT01888835|Drug|Placebo|
303415|NCT01888822|Drug|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
303416|NCT01888822|Drug|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
303417|NCT01888822|Drug|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
303418|NCT01888809|Behavioral|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
303419|NCT01888809|Behavioral|Screening and referral|
303420|NCT01888796|Drug|Linagliptin|
303421|NCT01888796|Drug|placebo|
303422|NCT01888783|Other|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
303423|NCT01888757|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
303424|NCT01888744|Drug|GnRH agonist|
303425|NCT01888744|Drug|GnRH antagonist|
303426|NCT01888744|Drug|hP-hMG|
303427|NCT01888744|Drug|Human chorionic gonadotropin|induction of final oocyte maturation
303428|NCT01888744|Drug|Progesterone|
303429|NCT01888731|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
303430|NCT01888718|Drug|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
303431|NCT01888679|Procedure|Head movement|Head movement in extension, flexion, right and left rotation
303432|NCT01888653|Behavioral|Attention Bias Modification (ABM)|The training protocol consisted of 160 trials per session with 120 angry-neutral and 40 neutral-neutral trials. Each participant was trained with an alternative set of faces to the one used in the assessment task (i.e. if measured with set A then trained with set B and vice-versa). In the ABM condition, training was contin- gent on the bias measured at pre-treatment. Specifically, for those showing a bias toward the threat, the target appeared at the neutral-face location in 100% of the threat-neutral trials, while for those showing a bias away from the threat, the target appeared at the threat-face location in 100% of the threat-neutral trials.
303433|NCT01888653|Behavioral|Attention control training (ACT)|In the ACT condition, threat- face location, probe location, and probe type were fully counter- balanced with no contingency between face valence and probe location, thus resembling the assessment task.
303434|NCT01888640|Device|TENS|"TENS Parameters: Active TENS and Placebo TENS~TENS Frequency - 2-125 Hz~TENS Pulse Width - 200 µs~TENS Intensity - Maximal tolerable intensity~Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.~Administration - Daily~TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.~Placebo TENS Unit Active TENS unit No TENS - Standard Care"
303435|NCT01888627|Other|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
303436|NCT01888588|Drug|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
303437|NCT01888575|Drug|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
303438|NCT01888562|Drug|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
303439|NCT01888549|Drug|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
303440|NCT01888549|Drug|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
303441|NCT01888549|Drug|placebo|
303442|NCT01888536|Drug|Limaprost|
303443|NCT01888536|Drug|Pregabalin|
303444|NCT01888536|Drug|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
303445|NCT01888536|Drug|Placebo(for Limaprost)|mimic Limaprost tablet
303446|NCT01888523|Behavioral|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
303447|NCT01888523|Behavioral|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
303448|NCT01888510|Procedure|computed tomography|Undergo conventional free breathing CT
303449|NCT01888510|Procedure|4-dimensional computed tomography|Undergo 4D CT
303450|NCT01888510|Procedure|computed tomography|Undergo ABC CT
303451|NCT01888510|Procedure|cone-beam computed tomography|Undergo ABC CBCT
303452|NCT01888510|Procedure|cone-beam computed tomography|Undergo free breathing CBCT
303453|NCT01888497|Drug|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
303454|NCT01888497|Drug|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
303455|NCT01888497|Drug|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
303457|NCT01888484|Biological|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
303458|NCT01888471|Procedure|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
303459|NCT01888471|Other|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
303460|NCT01888458|Drug|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
303461|NCT01888445|Drug|ASP1517|oral
303462|NCT01888445|Drug|darbepoetin alfa|iv
303463|NCT01888432|Drug|Everolimus + reduced tacrolimus|Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.
303464|NCT01888432|Drug|Standard tacrolimus|Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
303465|NCT01888419|Other|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
303466|NCT01888406|Behavioral|Guided Self-Help|
303467|NCT01888406|Behavioral|Pure Self-Help|
303468|NCT01888393|Drug|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
303469|NCT01888380|Procedure|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
303470|NCT01888380|Procedure|Conventional autopsy|
303471|NCT01888367|Drug|DFA-02 Antibiotic Gel|
303472|NCT01888367|Drug|DFA-02 Placebo Gel|
303473|NCT01888354|Drug|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
303474|NCT01888341|Drug|Isotretinoin|Isotretinoin Capsules,20 mg
303475|NCT01888328|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
303476|NCT01888315|Device|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
303477|NCT01888315|Device|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
303478|NCT01888315|Device|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
303479|NCT01888315|Device|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
303480|NCT01888302|Drug|Cisplatin|Given IV
303481|NCT01888302|Drug|Gemcitabine Hydrochloride|Given IV
303482|NCT01888302|Other|Quality-of-Life Assessment|Ancillary studies
303483|NCT01888302|Drug|Sirolimus|Given PO
303484|NCT01888289|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
303485|NCT01888276|Other|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~The test of Stroop that assesses selective attention~During the session 2:~The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~The task of the casino (Iowa Gambling Test)~The task of landing~The test of Stroop"
303486|NCT01888263|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
303487|NCT01888250|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
303488|NCT01888237|Drug|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
303489|NCT01888237|Drug|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
303490|NCT01888224|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
303491|NCT01888211|Dietary Supplement|Omega 3 fatty acid supplementation|2 grams Omacor daily
303492|NCT01888211|Dietary Supplement|Olive Oil|2 grams olive oil daily
303493|NCT01888198|Behavioral|(EORTC QLQ-C30) questionnaire|
303494|NCT01888198|Behavioral|EuroQol EQ-5D 7-item questionnaire|
303495|NCT01888172|Behavioral|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
303496|NCT01888172|Device|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
303497|NCT01888172|Behavioral|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
303498|NCT01888159|Procedure|Bilateral Salpingectomy|
303499|NCT01888159|Procedure|Tubal sterilization with bipolar energy|
303500|NCT01888146|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
303501|NCT01888133|Behavioral|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
303502|NCT01888133|Behavioral|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
303503|NCT01888120|Drug|Ziconotide|
303504|NCT01888107|Drug|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
303505|NCT01888107|Drug|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
303557|NCT01887704|Procedure|stenting|Stenting was implanted in both arms.
303506|NCT01888107|Drug|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
303507|NCT01888094|Other|Ultrasound-guided cannulation and examination|
303508|NCT01888081|Drug|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
303509|NCT01888081|Radiation|Ionizing Radiation|
303510|NCT01888055|Device|transcranial direct current stimulation|
303511|NCT01888055|Device|sham stimulation|
303512|NCT01888042|Drug|Everolimus|10 mg (1 tablet of 10 mg)
303513|NCT01888029|Device|transcranial direct current stimulation|
303514|NCT01888029|Device|sham stimulation|
303515|NCT01888016|Other|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
303516|NCT01888016|Other|standard physiotherapies treatment|"10 standard treatments in 2 weeks~Deltoid and infraspinatus muscles electrotherapy~Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day~Scar massage~Upper limb, cervical spine and scapula massages~Passive and assisted/active shoulder mobilization exercises~Scapula micro-mobilizations~Gleno-humeral decoaptation~Elbow, wrist and hand active mobilization~Proprioceptive exercise with and without the aid of the mirror"
303517|NCT01888003|Drug|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at −14 days and −7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
303518|NCT01888003|Drug|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at −14 days and −7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
303519|NCT01888003|Other|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb < 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
303520|NCT01887990|Drug|Ketamine|single dose IV 0.2 mg/kg ketamine
303521|NCT01887990|Drug|placebo|saline infusion
303522|NCT01887977|Other|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
303523|NCT01887964|Other|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
303524|NCT01887964|Other|Control flour|Wheat flour without resistant starch (type-4)
303525|NCT01887951|Drug|Penthrox Inhaler|
303526|NCT01887951|Drug|Tramadol Injection|
303527|NCT01887938|Biological|HGT-1110|Participants will receive IT injection of HGT-1110.
303528|NCT01887912|Biological|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
303529|NCT01887912|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
303530|NCT01887899|Device|transcranial direct current stimulation|
303531|NCT01887899|Device|sham stimulation|
303532|NCT01887886|Drug|erlotinib|150 mg orally daily
303533|NCT01887886|Drug|onartuzumab|15 mg/kg IV every 3 weeks
303534|NCT01887886|Drug|placebo|IV every 3 weeks
303535|NCT01887873|Device|Hyaluronan Thiomer i.o. implant|
303536|NCT01887860|Other|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
303537|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
303538|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
303539|NCT01887834|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|
303540|NCT01887834|Dietary Supplement|Kyodophilus Matching Placebo Capsules|
303541|NCT01887821|Drug|Chloroquine|
303542|NCT01887821|Drug|Dihydroartemisinin/Piperaquine|
303543|NCT01887808|Other|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
303544|NCT01887795|Drug|Erlotinib|
303545|NCT01887795|Drug|WBRT|
303546|NCT01887782|Device|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
303547|NCT01887782|Device|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
303548|NCT01887756|Device|Tele Rehabilitation|
303549|NCT01887743|Drug|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
303550|NCT01887730|Behavioral|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
303551|NCT01887730|Behavioral|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
303552|NCT01887730|Behavioral|Control|
303553|NCT01887717|Device|TheraSphere®|Intrahepatic treatment of advanced hepatocellular carcinoma
303554|NCT01887717|Drug|Sorafenib|Standard of care therapy for treatment of advanced hepatocellular carcinoma
303555|NCT01887704|Device|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
303556|NCT01887704|Procedure|conventional angioplasty|Conventional angioplasty was used in both arms.
303558|NCT01887704|Device|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
303559|NCT01887704|Drug|Aspirin|Aspirin will be administrated in participants in both arms.
303560|NCT01887704|Drug|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
303561|NCT01887704|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
303562|NCT01887704|Device|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
303563|NCT01887704|Device|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
303564|NCT01887704|Device|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
303565|NCT01887691|Drug|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
303566|NCT01887678|Drug|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
303567|NCT01887678|Drug|Placebo|Placebo is an injection of Saline
303568|NCT01887665|Behavioral|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
303569|NCT01887652|Other|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
303570|NCT01887652|Other|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
303571|NCT01887626|Drug|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
303572|NCT01887626|Drug|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
303573|NCT01887626|Drug|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
303574|NCT01887613|Drug|Regnite|oral
303575|NCT01887600|Drug|Roxadustat|Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
303576|NCT01887600|Drug|Placebo|Placebo was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with > 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
303577|NCT01887587|Drug|MLN9708|
303578|NCT01887587|Drug|Vincristine|
303579|NCT01887587|Drug|Doxorubicin|
303580|NCT01887587|Drug|Dexamethasone|
303581|NCT01887574|Other|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
303582|NCT01887561|Drug|dasatinib|
303583|NCT01887548|Other|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
303584|NCT01887535|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
303585|NCT01887535|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
303586|NCT01887535|Drug|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
303587|NCT01887535|Drug|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
303588|NCT01887535|Drug|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
303589|NCT01887535|Drug|Placebo|Matching placebo will be administered as an oral suspension formulation.
303590|NCT01887522|Drug|Vinblastine + Nilotinib|"Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.~Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
303591|NCT01887522|Drug|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
303592|NCT01887509|Device|Probe-based confocal laser endomicroscopy|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE~Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well.~After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
303627|NCT01887275|Drug|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
303628|NCT01887262|Device|BCM-guided fluid management|
303593|NCT01887509|Procedure|Rectoscopy|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Both healthy and tumor tissue will be examined."
303594|NCT01887509|Procedure|EUS|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
303595|NCT01887509|Procedure|Biopsy and resection|"Patients will undergo:~Conventional rectoscopy~pCLE exam following injection of fluorescein, fluorescent contrast agent~EUS : echoendoscopy~Biopsies for histopathology : location identical to those of pCLE~Tumor resection will be performed according to standard oncologic principles.~All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.~Biopsies will be harvested in both healthy and tumor tissue as well."
303596|NCT01887483|Dietary Supplement|Vetal Laban active|Dairy product with probiotic
303597|NCT01887483|Dietary Supplement|Placebo|Dairy product without probiotic
303598|NCT01887470|Drug|Full dose preparation|
303599|NCT01887470|Drug|Split dose preparation|
303600|NCT01887457|Drug|VFEND|voriconazole will be administered in iv form
303601|NCT01887444|Dietary Supplement|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
303602|NCT01887444|Other|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
303603|NCT01887431|Other|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
303604|NCT01887431|Other|Conventional therapy|3-month routine clinic visits
303605|NCT01887418|Drug|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
303606|NCT01887418|Drug|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
303607|NCT01887418|Drug|Delatestryl 200 mg IM Treatment C|Standard of care
303608|NCT01887405|Drug|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.~Valid for both Jext and Epipen:~Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
303609|NCT01887392|Other|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
303610|NCT01887379|Drug|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
303611|NCT01887366|Drug|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
303612|NCT01887366|Drug|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
303613|NCT01887366|Drug|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
303614|NCT01887353|Drug|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
303615|NCT01887353|Drug|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
303616|NCT01887340|Drug|Carboplatin|"- carboplatine: Dose (mg) = AUC x (GFR + 25)~GFR : glomérulaire filtration (ml/min)~AUC : area under curve (mg/ml x min)"
303617|NCT01887340|Drug|Etoposide|100 mg/m2 D1 to D5
303618|NCT01887340|Drug|Cisplatin|20 mg/m2 de D1 to D5
303619|NCT01887327|Procedure|Phototherapy|Phototherapy starts within 30 minutes before or after injection
303620|NCT01887327|Drug|Stannsoporfin|Stannsoporfin (3.0 or 4.5 mg/kg) administered by intramuscular (IM) injection (a shot in the muscle)
303621|NCT01887327|Drug|Placebo|Matching placebo administered by IM injection
303622|NCT01887314|Dietary Supplement|Standardized Ginger extract|
303623|NCT01887301|Drug|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
303624|NCT01887288|Drug|Capecitabine|650 mg/m^2 PO b.i.d.
303625|NCT01887288|Drug|Digoxin|0.25 mg once daily
303626|NCT01887275|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
303629|NCT01887262|Procedure|Fluid management based on the clinical information alone|
303630|NCT01887249|Drug|Clarithromycin|
303631|NCT01887249|Drug|metronidazole|
303632|NCT01887249|Drug|esomeprazole|
303633|NCT01887236|Behavioral|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
303634|NCT01887236|Behavioral|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
303635|NCT01887223|Procedure|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
303636|NCT01887223|Drug|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
303637|NCT01887210|Behavioral|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
303638|NCT01887210|Behavioral|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
303639|NCT01887197|Other|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
303640|NCT01887197|Drug|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
303641|NCT01887197|Drug|mannitol inhalation powder|mannitol inhalation powder
303642|NCT01887184|Drug|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranassaly
303643|NCT01887171|Drug|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
303644|NCT01887158|Drug|Polyethylene glycol|
303645|NCT01887158|Drug|Bisacodyl|
303646|NCT01887145|Procedure|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
303647|NCT01887145|Procedure|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
303648|NCT01887132|Drug|Donepezil|
303649|NCT01887132|Drug|Placebo|
303650|NCT01887119|Drug|Eplerenone|
303651|NCT01887119|Other|Placebo|Eplerenone-matched placebo
303652|NCT01887106|Drug|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
303653|NCT01887106|Drug|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
303654|NCT01887106|Drug|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
303655|NCT01887106|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
303656|NCT01887093|Behavioral|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
303657|NCT01887080|Other|Exercise|"This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
303658|NCT01887080|Device|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
303659|NCT01887080|Other|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
303660|NCT01887067|Procedure|Renal denervation therapy|
303661|NCT01887054|Device|Tower of Hanoi|
303662|NCT01887054|Other|Placebo group - non use of Tower of Hanoi|
303663|NCT01887041|Procedure|Stent|Endoscopically inserted biliary tract drainage
303664|NCT01887041|Procedure|Biliodigestive anastomosis|Biliodigestive anastomosis
303665|NCT01887028|Device|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
303666|NCT01887015|Device|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
303667|NCT01887002|Drug|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
303668|NCT01887002|Drug|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
303669|NCT01886989|Dietary Supplement|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
303670|NCT01886976|Biological|CART-138 cells|
303671|NCT01886963|Procedure|SPY - Unblinded use of SPY Elite|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
303672|NCT01886963|Procedure|Control - Blinded use of SPY Elite|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
303673|NCT01886937|Drug|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
303674|NCT01886937|Drug|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
303675|NCT01886924|Behavioral|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
303676|NCT01886924|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
303677|NCT01886911|Other|Attention Training Intervention Game|
303678|NCT01886911|Other|Prosocial Training Intervention Game|
303679|NCT01886911|Other|Control for Attention Intervention|
303680|NCT01886911|Other|Control for Prosocial Intervention|
303681|NCT01886898|Other|Infant formula|infant formula
303682|NCT01886898|Other|Breastfeeding|
303683|NCT01886885|Behavioral|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
303684|NCT01886872|Drug|Bendamustine Hydrochloride|Given IV
303685|NCT01886872|Drug|Ibrutinib|Given PO
303686|NCT01886872|Other|Laboratory Biomarker Analysis|Correlative studies
303687|NCT01886872|Other|Quality-of-Life Assessment|Ancillary studies
303688|NCT01886872|Biological|Rituximab|Given IV
303689|NCT01886859|Drug|Ibrutinib|Given PO
303690|NCT01886859|Drug|Lenalidomide|Given PO
303691|NCT01886820|Drug|[18F]NAV4694|
303692|NCT01886807|Device|TrueView PCD Video Laryngoscope|
303693|NCT01886794|Drug|Postmenopausal, topical vaginal cream|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
303694|NCT01886794|Drug|Placebo Comparator: Postmenopausal, topical placebo cream|Postmenopausal participants randomized to topical vaginal placebo for about one month's use prior to scheduled surgery.
303695|NCT01886781|Drug|Lactobacillus plantarum 299v|two capsules of 5 X 10 ^9 c.f.u each
303696|NCT01886781|Drug|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
303697|NCT01886781|Other|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
303698|NCT01886781|Other|Wash - out period|Wash - out period following treatment phase of eight weeks
303699|NCT01886768|Device|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
303700|NCT01886768|Device|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
303701|NCT01886755|Dietary Supplement|ORS rehydration solution|
303702|NCT01886755|Dietary Supplement|placebo|
303703|NCT01886742|Drug|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
303704|NCT01886742|Drug|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
303705|NCT01886729|Other|transcranial direct current stimulation (tDCS)|
303706|NCT01886716|Behavioral|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
303707|NCT01886716|Behavioral|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
303708|NCT01886716|Behavioral|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
303709|NCT01886703|Behavioral|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
303710|NCT01886690|Drug|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
303711|NCT01886690|Drug|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
303712|NCT01886677|Behavioral|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
303713|NCT01886677|Behavioral|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
303714|NCT01886664|Drug|sevoflurane|
303715|NCT01886664|Drug|Desflurane|
303716|NCT01886638|Drug|Abacavir|
303717|NCT01886625|Procedure|unilateral single-port VATS sympathicotomy|
303718|NCT01886612|Device|Duo-STIM neuromuscular electrical stimulator|
303719|NCT01886612|Device|AV Impulse System Model 6000|
303720|NCT01886599|Drug|Asunaprevir|
303721|NCT01886586|Behavioral|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
303722|NCT01886586|Behavioral|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
303723|NCT01886586|Other|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
303724|NCT01886573|Drug|Azacitidine|Given SC
303725|NCT01886573|Drug|Entinostat|Given PO
303726|NCT01886573|Other|Laboratory Biomarker Analysis|Correlative studies
303727|NCT01886573|Other|Pharmacological Study|Correlative studies
303728|NCT01886573|Procedure|Therapeutic Conventional Surgery|Undergo surgery
303729|NCT01886560|Drug|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
303730|NCT01886560|Drug|Placebo|Tablets placebo one PO per day for 12 weeks
303731|NCT01886547|Other|Prostate health screening|
303732|NCT01886534|Other|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
303733|NCT01886534|Behavioral|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
303734|NCT01886534|Other|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
303735|NCT01886534|Other|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
303736|NCT01886534|Other|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
303737|NCT01886521|Procedure|Lumbar drain|
303738|NCT01886521|Procedure|Ventricular drain|
303739|NCT01886508|Procedure|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
303740|NCT01886508|Procedure|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
303741|NCT01886495|Other|nutrition intervention|
303742|NCT01886482|Other|nutrition intervention|high protein diet
303743|NCT01886469|Drug|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
303744|NCT01886469|Drug|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
303745|NCT01886469|Drug|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
303746|NCT01886456|Device|Laser trabeculoplasty|
303747|NCT01886443|Drug|Antithrombin-III|
303748|NCT01886443|Drug|Infliximab|
303749|NCT01886443|Drug|Apotransferrin|
303750|NCT01886443|Drug|Human recombinant erythropoietin|
303751|NCT01886443|Drug|C1-Inhibitor|
303752|NCT01886443|Drug|Glutathione|
303753|NCT01886443|Drug|Alfa-tocopherol|
303754|NCT01886443|Drug|Melatonin|
303755|NCT01886443|Drug|Epoprostenol|
303756|NCT01886430|Other|Functional electrical stimulation|Functional electrical stimulation for 10 days
303757|NCT01886430|Other|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
303758|NCT01886404|Drug|Efavirenz|"HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.~Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.~Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well."
303797|NCT01886105|Other|Autologous Stem Cell Infusion|"Administered 14 days after Treatment infusion of Samarium-153 EDTMP."
303759|NCT01886391|Behavioral|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
303760|NCT01886378|Drug|UX007|
303761|NCT01886365|Device|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
303762|NCT01886365|Other|Conventional therapy with a fixed insulin dosing scheme|Routine care
303763|NCT01886352|Drug|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
303764|NCT01886352|Drug|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
303765|NCT01886352|Drug|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~Each subdiaphragmatic area 0.05 ml/kg~Dome of abdomen then settling onto bowel 0.05 ml/kg~Surgical dissection site 0.05 ml/kg~At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
303766|NCT01886339|Other|SNIF test (Sniff Nasal Inspiratory Force)|
303767|NCT01886326|Other|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
303768|NCT01886313|Drug|Civamide Nasal Spray|
303769|NCT01886313|Drug|Placebo|
303770|NCT01886287|Drug|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
303771|NCT01886274|Device|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
303772|NCT01886248|Drug|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
303773|NCT01886235|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
303774|NCT01886235|Drug|Fluorescein Sodium Injection|Given IV
303775|NCT01886235|Other|Laboratory Biomarker Analysis|Correlative studies
303776|NCT01886235|Procedure|Therapeutic Conventional Surgery|Undergo surgery
303777|NCT01886222|Other|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
303778|NCT01886222|Other|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
303779|NCT01886209|Drug|Prednisone|
303780|NCT01886209|Drug|VX-509|
303781|NCT01886209|Drug|Methylprednisolone|
303782|NCT01886196|Drug|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
303783|NCT01886196|Other|placebo|placebo designed to mimic experimental drug (ibuprofen)
303784|NCT01886196|Behavioral|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
303785|NCT01886196|Behavioral|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
303786|NCT01886183|Other|Virtual Reality Training|The participants of the study will be trained 8 balance games during 14 sessions
303787|NCT01886183|Other|Physical Therapy|Patients of the control group will be trained with balance exercises.
303788|NCT01886170|Other|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
303789|NCT01886157|Procedure|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
303790|NCT01886157|Procedure|Corticosteroid injection|Standard trigger finger corticosteroid injection.
303791|NCT01886144|Device|Knee OA Brace|
303792|NCT01886131|Other|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.~The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.~The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
303793|NCT01886118|Procedure|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
303794|NCT01886118|Other|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
303795|NCT01886118|Other|Conventional media culture|embryos are cultured in conventional media
303796|NCT01886105|Drug|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation (EBT) planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg."
303798|NCT01886105|Radiation|External Beam Radiotherapy|"The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.~After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the EBT portion of the treatment plan, as necessary."
303799|NCT01886092|Device|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
303800|NCT01886092|Device|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
303801|NCT01886092|Device|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
303802|NCT01886092|Device|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
303803|NCT01886079|Drug|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
303804|NCT01886079|Drug|Saline|0.4 mcg/kg/h, IV
303805|NCT01886066|Biological|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. One 25 mg vial of ICG will be reconstituted in 10 mL of aqueous solvent (2.5 mg/mL). The solution will be injected at the 3 and 9 o'clock positions of the cervical stroma. 0.5 mL is injected superficially (submucosa) and 0.5 mL is injected deep (~8mm) in the cervical stroma for a total injection volume of 2 mL.
303806|NCT01886053|Drug|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
303807|NCT01886053|Drug|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
303808|NCT01886053|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
303809|NCT01886027|Behavioral|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
303810|NCT01886027|Behavioral|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
303811|NCT01886014|Drug|Oxytocin|
303812|NCT01886014|Other|placebo|
303813|NCT01886001|Drug|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
303814|NCT01886001|Drug|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
303815|NCT01886001|Drug|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
303816|NCT01886001|Other|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
303817|NCT01885988|Drug|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
303818|NCT01885988|Drug|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
303819|NCT01885962|Behavioral|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
303820|NCT01885949|Drug|Tivozanib|Oral
303821|NCT01885949|Drug|Enzalutamide|oral
303822|NCT01885936|Drug|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
303823|NCT01885936|Drug|Placebo|Initially one capsule daily for one week, then one capsule BID per oral daily for the next 5 weeks. If the one capsule BID per oral is well tolerated, the dose will be increased to two capsules each morning/one capsule each evening for one week, followed by two capsules BID per oral for the remainder of the study.
303824|NCT01885923|Device|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
303825|NCT01885910|Drug|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
303826|NCT01885910|Drug|Aczone 5% gel|Aczone 5% gel twice daily
303827|NCT01885897|Biological|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
303828|NCT01885884|Behavioral|Embedded Supportive Care|
303829|NCT01885871|Device|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
303830|NCT01885858|Behavioral|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
303831|NCT01885858|Behavioral|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
303874|NCT01885429|Dietary Supplement|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
304004|NCT01884415|Biological|HBV vaccine|Patients receive vaccination according to the guidelines.
303832|NCT01885845|Device|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
303833|NCT01885845|Other|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.~After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
303834|NCT01885832|Biological|Autologous adipose tissue stromal vascular fraction|
303835|NCT01885819|Biological|Autologous stromal vascular fraction cells|
303836|NCT01885806|Device|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
303837|NCT01885806|Device|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10"
303838|NCT01885793|Device|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
303839|NCT01885780|Device|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
303840|NCT01885741|Device|IPBS|
303841|NCT01885728|Dietary Supplement|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
303842|NCT01885715|Drug|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.~During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
303843|NCT01885702|Biological|DC vaccination|DC vaccination
303844|NCT01885689|Drug|clofarabine|Given IV
303845|NCT01885689|Drug|melphalan|Given IV
303846|NCT01885689|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
303847|NCT01885689|Drug|tacrolimus|Given IV or PO
303848|NCT01885689|Drug|sirolimus|Given PO
303849|NCT01885689|Other|Pharmacological Study|Correlative studies
303850|NCT01885676|Device|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
303851|NCT01885676|Other|Saline Solution|Saline Solution mesotherapy micro injection
303852|NCT01885663|Procedure|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
303853|NCT01885650|Other|Airway Clearance Techniques|
303854|NCT01885637|Other|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
303855|NCT01885624|Biological|TAB08|monoclonal antibody
303856|NCT01885611|Other|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
303857|NCT01885611|Dietary Supplement|Virgin Coconut Oil|cold-processed VCO
303858|NCT01885598|Drug|Apixaban|
303859|NCT01885585|Drug|Apixaban|
303860|NCT01885572|Device|TiLOOP Bra|Titaniferously coated polypropylene mesh
303861|NCT01885559|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
303862|NCT01885559|Drug|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
303863|NCT01885559|Drug|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
303864|NCT01885546|Device|AgaMatrix Blood Glucose Monitor|
303865|NCT01885520|Dietary Supplement|fasting condition|eperisone SR tablet 75mg administrated under fasting
303866|NCT01885520|Dietary Supplement|fed condition|eperisone SR tablet 75mg administrated fed condition
303867|NCT01885507|Other|Pass recommendations on ventilation factors and extubation|"the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)~extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
303868|NCT01885481|Drug|Dexamethasone|epidural steroid injection using dexamethasone
303869|NCT01885481|Drug|Betamethasone|epidural steroid injection using betamethasone
303870|NCT01885455|Other|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
303871|NCT01885455|Other|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
303872|NCT01885442|Device|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
303873|NCT01885429|Dietary Supplement|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
303875|NCT01885429|Dietary Supplement|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
303876|NCT01885429|Dietary Supplement|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
303877|NCT01885429|Dietary Supplement|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
303878|NCT01885416|Other|consumption of test meal based on dairy products|
303879|NCT01885416|Other|consumption of high fat test meal without dairy products|
303880|NCT01885416|Other|consumption of high fat test meal with dairy products|
303881|NCT01885403|Device|non-invasive respiratory parameter measurements|
303882|NCT01885390|Device|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
303883|NCT01885377|Other|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
303884|NCT01885377|Other|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
303885|NCT01885364|Drug|Normal saline|intravenous injection with normal saline before injection of propofol
303886|NCT01885364|Drug|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
303887|NCT01885364|Drug|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
303888|NCT01885364|Drug|propofol|intravenous injection after pretreatment
303889|NCT01885351|Behavioral|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
303890|NCT01885351|Behavioral|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.~Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
303891|NCT01885338|Drug|N-acetylcysteine (NAC)|
303892|NCT01885338|Drug|Inactive placebo capsule|
303893|NCT01885325|Other|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
303894|NCT01885312|Behavioral|Adaptive Tailored Intervention|Adaptive
303895|NCT01885312|Behavioral|Consequence-based Intervention|Loss Framed
303896|NCT01885312|Behavioral|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
303897|NCT01885312|Other|Assessment only|EMA only
303898|NCT01885299|Radiation|SRS/SBRT|Intervention varies by condition being treated.
303899|NCT01885286|Procedure|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
303900|NCT01885273|Procedure|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
303901|NCT01885273|Procedure|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
303902|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
303903|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
303904|NCT01885260|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
303905|NCT01885234|Other|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
303906|NCT01885234|Other|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
303907|NCT01885221|Behavioral|Multimedia Support Intervention|
303908|NCT01885208|Drug|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
303909|NCT01885208|Drug|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
303910|NCT01885195|Drug|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
303911|NCT01885182|Drug|Oxycodone/Naloxone|
303912|NCT01885182|Drug|Oxycodone|
303958|NCT01884792|Other|Standing CGM|
308171|NCT01852435|Drug|R-CHOP-50|
303913|NCT01885169|Biological|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
303914|NCT01885156|Drug|Naftin 1% Cream|Topically applied once a day
303915|NCT01885156|Drug|Placebo Cream|Topically applied once a day
303916|NCT01885143|Radiation|Digital Breast Tomosynthesis|
303917|NCT01885130|Other|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
303918|NCT01885117|Biological|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
303919|NCT01885104|Drug|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
303920|NCT01885104|Drug|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
303921|NCT01885104|Drug|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
303922|NCT01885091|Other|Kinerase|
303923|NCT01885078|Drug|Baricitinib|Administered orally
303924|NCT01885078|Drug|Placebo|Administered orally
303925|NCT01885065|Other|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.~Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
303926|NCT01885052|Behavioral|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
303927|NCT01885052|Behavioral|Low Contact|
303928|NCT01885026|Behavioral|eScreen|Access to the eScreen platform offering assessment of alcohol and drug use, with automated feedback on problematic or non-problematic use. Follow-up over time based on user needs.
303929|NCT01885026|Behavioral|Assessment only of alcohol and drug use.|Assessment of alcohol and drug use at baseline and follow-up.
303930|NCT01885026|Behavioral|Internet-based treatment for depression or anxiety|Internet-based treatment for primary diagnoses of depression, panic anxiety or social phobia.
303931|NCT01885013|Drug|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
303932|NCT01885013|Drug|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
303933|NCT01885000|Drug|once-daily brimonidine tartrate 0.5% gel|
303934|NCT01885000|Drug|once-daily brimonidine tartrate vehicle gel|
303935|NCT01884987|Drug|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
303936|NCT01884974|Other|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
303937|NCT01884961|Other|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
303938|NCT01884948|Drug|Omegaven™|
303939|NCT01884935|Biological|Natalizumab|As specified in the treatment arm
303940|NCT01884922|Drug|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
303941|NCT01884922|Drug|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
303942|NCT01884909|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
303943|NCT01884909|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
303944|NCT01884896|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
303945|NCT01884896|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
303946|NCT01884883|Device|PROTEOR Internal unicompartmental knee brace|
303947|NCT01884870|Procedure|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
303948|NCT01884857|Drug|Metoprolol Succinate ER Tablets 50 mg|1* 50 mg tablet once a day
303949|NCT01884857|Drug|'TOPROL-XL®' ER Tablets 50 mg|1 * 50 mg tablet per day
303950|NCT01884844|Drug|Vitamin D3, Cholecalciferol|
303951|NCT01884844|Drug|Placebo|
303952|NCT01884831|Biological|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
303953|NCT01884818|Other|Manipulation vs. TNS thoracic pain|
303954|NCT01884805|Device|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
303955|NCT01884792|Other|Sitting OGTT|
303956|NCT01884792|Other|Standing OGTT|
303957|NCT01884792|Other|Sitting CGM|
303959|NCT01884740|Drug|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 m/m2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
303960|NCT01884727|Dietary Supplement|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
303961|NCT01884727|Dietary Supplement|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
303962|NCT01884714|Other|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
303963|NCT01884701|Device|ENABLER-P Catheter System|
303964|NCT01884688|Drug|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
303965|NCT01884675|Drug|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
303966|NCT01884675|Drug|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
303967|NCT01884662|Behavioral|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
303968|NCT01884662|Behavioral|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
303969|NCT01884636|Drug|isavuconazole|oral
303970|NCT01884636|Drug|methotrexate|oral
303971|NCT01884623|Drug|Cetuximab|
303972|NCT01884623|Drug|Methotrexate|
303973|NCT01884597|Drug|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
303974|NCT01884597|Drug|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
303975|NCT01884584|Drug|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
303976|NCT01884571|Drug|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
303977|NCT01884571|Drug|Methylprednisolone|125 mg, IV (in the vein) on day 1.
303978|NCT01884571|Drug|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
303979|NCT01884571|Drug|Tacrolimus|1-5 mg PO, twice a day (BID) days 2-180.
303980|NCT01884571|Drug|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
303981|NCT01884558|Drug|isavuconazole|oral
303982|NCT01884558|Drug|metformin|oral
303983|NCT01884545|Behavioral|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
303984|NCT01884545|Genetic|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
303985|NCT01884545|Behavioral|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
303986|NCT01884532|Device|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
303987|NCT01884519|Biological|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
303988|NCT01884506|Dietary Supplement|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
303989|NCT01884506|Dietary Supplement|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
303990|NCT01884493|Device|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
303991|NCT01884493|Device|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
303992|NCT01884467|Drug|Gentamicin|Comparison of Gentamicin versus placebo
303993|NCT01884467|Drug|Placebo|
303994|NCT01884454|Behavioral|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
303995|NCT01884441|Drug|Bendamustine|"Schedule:~Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
303996|NCT01884441|Drug|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
303997|NCT01884441|Drug|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
303998|NCT01884428|Drug|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
303999|NCT01884428|Drug|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
304000|NCT01884428|Drug|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
304001|NCT01884428|Drug|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
304002|NCT01884428|Drug|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
304003|NCT01884415|Biological|HBV vaccine|Patients receive a second cycle of vaccination
308172|NCT01852409|Drug|bevacizumab|
304005|NCT01884402|Drug|Peginterferon alfa-2a|Treatment as usual clinical practice
304006|NCT01884402|Drug|Ribavirin|Treatment as usual clinical practice
304007|NCT01884389|Other|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
304008|NCT01884376|Device|Neuromaix|
304009|NCT01884363|Other|Once ounce per day of walnuts|
304010|NCT01884350|Drug|Apixaban|
304011|NCT01884337|Drug|Apixaban|
304012|NCT01884324|Other|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
304013|NCT01884311|Biological|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
304014|NCT01884298|Drug|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
304015|NCT01884298|Drug|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
304016|NCT01884285|Drug|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
304017|NCT01884285|Drug|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
304018|NCT01884285|Drug|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
304019|NCT01884285|Drug|Part D1: AZD2014 combination with AZD8186|Dose & schedule finding of AZD8186 in combination with AZD2014
304020|NCT01884285|Drug|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
304021|NCT01884285|Drug|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
304022|NCT01884272|Drug|lesinurad 400 mg|
304023|NCT01884272|Drug|naproxen 250 mg|
304024|NCT01884272|Drug|indomethacin 25 mg|
304025|NCT01884259|Drug|Docetaxel|75 mg/m² on day 1 of 21-days cycle
304026|NCT01884259|Drug|Cisplatin|75 mg/m² on day 1 of 21-days cycle
304027|NCT01884259|Drug|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
304028|NCT01884259|Biological|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
304029|NCT01884259|Biological|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
304030|NCT01884259|Radiation|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
304031|NCT01884246|Behavioral|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
304032|NCT01884246|Other|Referral to primary care provider for CVD risk management|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
304033|NCT01884233|Behavioral|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
304034|NCT01884233|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
304035|NCT01884220|Other|There are no interventions in this study.|
304036|NCT01884207|Other|MRI|
304037|NCT01884168|Biological|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
304038|NCT01884155|Procedure|Allogeneic umbilical cord blood therapy|
304039|NCT01884142|Other|Aerobic Exercise Training|
304040|NCT01884116|Drug|NSAID patch|
304041|NCT01884116|Drug|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
304042|NCT01884116|Drug|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
304043|NCT01884116|Drug|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
304073|NCT01883830|Device|gaming therapy (Xbox)|
304074|NCT01883830|Device|Dynamic balance platform (Biodex)|
304075|NCT01883817|Drug|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
304044|NCT01884090|Behavioral|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
304045|NCT01884077|Device|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
304046|NCT01884077|Device|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
304047|NCT01884064|Device|rTMS|rTMS
304048|NCT01884064|Device|Sham rTMS|Sham rTMS
304049|NCT01884038|Drug|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.~The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
304050|NCT01884038|Drug|Placebo|
304051|NCT01884025|Behavioral|Get Moving and Get Well|Walking Class
304052|NCT01884025|Behavioral|Health and Humor Class|Class about the role of humor in health
304053|NCT01884012|Procedure|long term oxygen therapy|
304054|NCT01883999|Device|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
304055|NCT01883986|Behavioral|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
304056|NCT01883947|Procedure|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
304057|NCT01883947|Other|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
304058|NCT01883934|Other|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
304059|NCT01883934|Other|Control|
304060|NCT01883921|Other|Immunoglobulin Therapy|
304061|NCT01883908|Device|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
304062|NCT01883908|Other|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
304063|NCT01883895|Device|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
304064|NCT01883895|Other|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
304065|NCT01883895|Other|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
304066|NCT01883882|Behavioral|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
304067|NCT01883869|Drug|ticagrelor|
304068|NCT01883869|Drug|placebo|placebo
304069|NCT01883856|Device|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
304070|NCT01883856|Device|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
304071|NCT01883843|Device|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
304072|NCT01883843|Device|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
304076|NCT01883817|Drug|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
304077|NCT01883804|Drug|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
304078|NCT01883791|Behavioral|SBIRT|See above Arm description.
304079|NCT01883791|Behavioral|Health Education|See Arm Description.
304080|NCT01883765|Behavioral|Neurofeedback active|
304081|NCT01883765|Behavioral|Neurofeedback sham|
304082|NCT01883765|Behavioral|Metacognitive Training|
304083|NCT01883752|Procedure|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
304084|NCT01883739|Other|Parental Presence at Handover Rounds|
304085|NCT01883726|Device|Grayson's presurgical nasoalveolar molding|Grayson NAM
304086|NCT01883726|Device|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
304087|NCT01883713|Device|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
304088|NCT01883700|Other|Boiled Pasta|
304089|NCT01883700|Other|Boiled Chickpeas with Oil|
304090|NCT01883700|Other|Instant Mashed Potatoes|
304091|NCT01883700|Other|Instant Mashed Potatoes with Egg Whites|
304092|NCT01883687|Procedure|Septoplasty|
304093|NCT01883674|Other|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
304094|NCT01883661|Biological|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
304095|NCT01883648|Drug|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
304096|NCT01883648|Other|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
304097|NCT01883635|Behavioral|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
304098|NCT01883635|Behavioral|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
304099|NCT01883609|Biological|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
304100|NCT01883609|Biological|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
304101|NCT01883609|Biological|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
304102|NCT01883596|Drug|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
304103|NCT01883596|Drug|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
304104|NCT01883583|Device|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
304105|NCT01883570|Other|training in visual search strategy|
304106|NCT01883570|Other|access to a library of chest x-rays without search strategy|
304107|NCT01883544|Drug|ALXN1007|
304108|NCT01883531|Drug|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
304109|NCT01883531|Drug|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
304110|NCT01883518|Biological|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
304111|NCT01883505|Drug|Levodopa and carbidopa|Subcutaneous continuous administration
304112|NCT01883505|Drug|Placebo|Subcutaneous continuous administration
304113|NCT01883492|Device|Femoral Stem|JMDN classification/Class III device
304114|NCT01883492|Device|Acetabular Cup|JMDN classification: Class III device
304115|NCT01883492|Device|Acetabular Liner|JMDN classification: Class III device
304116|NCT01883479|Behavioral|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
304117|NCT01883479|Behavioral|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
304118|NCT01883466|Other|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
304119|NCT01883453|Device|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
304120|NCT01883453|Device|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
304121|NCT01883440|Drug|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
304122|NCT01883440|Drug|Saline+glucose|Placebo arm
304123|NCT01883427|Drug|Placebo|placebo containing saline+glucose
304124|NCT01883427|Drug|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
304125|NCT01883414|Device|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
304890|NCT01877330|Procedure|Interscalene block for shoulder arthroscopy|
304126|NCT01883401|Dietary Supplement|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
304127|NCT01883401|Dietary Supplement|Dietary fiber|4g or 8g dietary fiber blended in water
304128|NCT01883375|Behavioral|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
304129|NCT01883375|Behavioral|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
304130|NCT01883362|Drug|Midostaurin|Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
304131|NCT01883362|Other|Standard of Care|Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
304132|NCT01883349|Procedure|Kidney Transplant|Kidney Transplant Surgery
304133|NCT01883323|Drug|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
304134|NCT01883323|Drug|Fludarabine|i.v., 25mg/m2 per day for 5 days
304135|NCT01883323|Biological|Tumor-Infiltrating Lymphocytes|i.v., 1x10^10 - 1.6x10^11 cells
304136|NCT01883323|Biological|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
304137|NCT01883310|Device|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
304138|NCT01883310|Device|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
304139|NCT01883297|Biological|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10^7 TILs (with maximum 3x10^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10^8 TILs (with maximum 1x10^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10^8 TILs (with maximum 3x10^8 autologous dendritic cells)
304140|NCT01883297|Biological|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
304141|NCT01883297|Drug|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
304142|NCT01883284|Other|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
304143|NCT01883271|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
304144|NCT01883271|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
304145|NCT01883258|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
304146|NCT01883258|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
304147|NCT01883245|Device|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
304148|NCT01883245|Device|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
304149|NCT01883232|Device|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
304150|NCT01883232|Device|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
304151|NCT01883219|Drug|TKIs|Imatinib was given at a dose of 400mg/d or 600mg/d, dasatinib at a dose of 100mg/d or 140mg/d, and nilotinib at a dose of 400mg twice daily. If the patients had T315I mutations, ponatinib will be given. If the BCR/ABL levels increased or did not decrease after one month's use of TKI, donor lymphocyte infusion will be given and the TKI drugs will be modulated. If the patients experienced hematologic relapse, they will withdraw from the study.
304152|NCT01883193|Dietary Supplement|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
304225|NCT01882595|Other|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
304153|NCT01883180|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
304154|NCT01883167|Drug|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
304155|NCT01883167|Drug|Febuxostat 40 mg|Febuxostat 40 mg qd
304156|NCT01883167|Drug|placebo|placebo qd
304157|NCT01883141|Procedure|Electrophysiological Study|Subjects will receive pacing from one right ventricular lead and one left ventricular catheter/lead with multiple LV pacing spots
304158|NCT01883128|Device|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
304159|NCT01883128|Procedure|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
304160|NCT01883128|Procedure|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
304161|NCT01883102|Drug|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
304162|NCT01883102|Drug|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
304163|NCT01883089|Behavioral|Motivational Enhancement Therapy|
304164|NCT01883076|Biological|autologous cell-based delivery|"autologous cells (derived from self)"
304165|NCT01883063|Device|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
304166|NCT01883063|Device|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
304167|NCT01883050|Device|Self Monitoring Software Application|Computer Software application to track health progress after interventional surgery
304168|NCT01883037|Other|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
304169|NCT01883024|Other|A decision support software|
304170|NCT01883024|Other|Insulin Pump|
304171|NCT01883024|Other|Continuous glucose monitoring|
304172|NCT01883011|Drug|Piracetam|
304173|NCT01883011|Other|Placebo|
304174|NCT01882998|Behavioral|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
304175|NCT01882985|Drug|Docetaxel|Given IV
304176|NCT01882985|Dietary Supplement|Lycopene|Given PO
304177|NCT01882972|Behavioral|Exercise|
304178|NCT01882972|Behavioral|Meditation|
304179|NCT01882959|Other|Radiofrequncy Denervation|
304180|NCT01882946|Biological|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
304181|NCT01882933|Drug|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
304182|NCT01882933|Procedure|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
304183|NCT01882920|Drug|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) <2.5 l/min/m2, stroke volume index (SVI) < 35 SVI ml/m2 and stroke volume variation (SVV)> 15%. In the case of CI <2.5 l/min/m2 and SVI <35 ml/m2 with SVV < 15%, an infusion with dopamine was initiated.
304184|NCT01882920|Drug|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
304185|NCT01882907|Drug|vildagliptin|vildagliptin 50mg bid for 16 weeks
304186|NCT01882907|Drug|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
304187|NCT01882894|Device|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
304188|NCT01882894|Other|Faux orthosis|Foam cut out
304189|NCT01882881|Other|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
304190|NCT01882881|Other|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide ~33% of calories from fat. The SFA (~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (~9g).
304191|NCT01882881|Other|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide ~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing ~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
304226|NCT01882556|Drug|onabotulinumtoxinA|
304227|NCT01882556|Drug|Placebo|
304228|NCT01882543|Drug|AQX-1125|Synthetic SHIP1 activator
304229|NCT01882543|Drug|Placebo|Double blind placebo capsule
304230|NCT01882530|Drug|Paracetamol|
304192|NCT01882881|Other|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at ~34-35% and the SFA will match that of the Almond Diet at ~8-9%. The fiber content of this diet will be highest (~35g); cholesterol will remain ≤200 mg/day.
304193|NCT01882868|Drug|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL [25 mg/mL], 200 mg/8 mL [25 mg/mL]) for infusion; Route of administration: Intravenous
304194|NCT01882868|Drug|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
304195|NCT01882868|Drug|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
304196|NCT01882868|Drug|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
304197|NCT01882842|Procedure|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
304198|NCT01882842|Device|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
304199|NCT01882829|Drug|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
304200|NCT01882816|Radiation|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
304201|NCT01882816|Device|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
304202|NCT01882816|Drug|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
304203|NCT01882816|Other|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
304204|NCT01882803|Drug|Duvelisib|PI3K Inhibitor
304205|NCT01882777|Behavioral|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
304206|NCT01882764|Drug|HMPL-004|HMPL-004 at a strenth of 600 mg will be given orally three times per day with total daily dose of 1800 mg.
304207|NCT01882764|Drug|Placebo|Placebo will be given orally three times per day with total daily dose of 1800 mg.
304208|NCT01882751|Device|Conformis CR Total Knee Replacement|iTotal CR by Conformis
304209|NCT01882751|Device|Off the Shelf|A standard knee replacement not using ConforMIS' iFit technology
304210|NCT01882725|Device|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
304211|NCT01882712|Drug|CD07805/47 Gel 0.5%|
304212|NCT01882712|Drug|CD07805/47 Gel Placebo|
304213|NCT01882699|Device|Cereve Sleep System|cerebral hypothermia
304214|NCT01882686|Other|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
304215|NCT01882673|Behavioral|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
304216|NCT01882673|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
304217|NCT01882660|Drug|Decitabine|
304218|NCT01882647|Drug|000-0551 Lotion|
304219|NCT01882647|Drug|Vehicle Lotion|
304220|NCT01882634|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
304221|NCT01882621|Drug|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
304222|NCT01882621|Drug|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
304223|NCT01882608|Other|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
304224|NCT01882595|Other|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
304234|NCT01882517|Dietary Supplement|Yogurt that contains plant stanol esters|
304235|NCT01882517|Dietary Supplement|Placebo yogurt|
304236|NCT01882504|Drug|gevokizumab|
304237|NCT01882491|Drug|Placebo|Solution for subcutaneous injection
304238|NCT01882491|Drug|gevokizumab|Solution for subcutaneous injection
304239|NCT01882465|Device|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
304240|NCT01882465|Device|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
304241|NCT01882465|Device|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
304242|NCT01882452|Behavioral|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
304243|NCT01882452|Behavioral|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
304244|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
304245|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 6 months
304246|NCT01882439|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
304247|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
304248|NCT01882439|Other|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
304249|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 3 months
304250|NCT01882426|Other|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
304251|NCT01882426|Other|Usual Care|usual step care practice
304252|NCT01882413|Other|No intervention|No intervention
304253|NCT01882400|Drug|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
304254|NCT01882387|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
304255|NCT01882374|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
304256|NCT01882361|Drug|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
304257|NCT01882361|Drug|placebo comparator|this placebo has no specific pharmacological activity
304258|NCT01882348|Behavioral|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)—including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
304259|NCT01882335|Behavioral|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
304260|NCT01882322|Drug|Prograf|oral
304261|NCT01882322|Drug|Advagraf|oral
304262|NCT01882296|Drug|AGSPT_10|AGSPT 10mg for 7days administration
304263|NCT01882296|Drug|AGSPT_20|AGSPT 20mg for 7days administration
304264|NCT01882296|Drug|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
304265|NCT01882296|Drug|Pantoprazole_20|Pantoprazole 20mg for 7days administration
304266|NCT01882296|Drug|Pantoprazole_40|Pantoprazole 40mg for 7days administration
304267|NCT01882283|Dietary Supplement|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
304268|NCT01882283|Dietary Supplement|Placebo|
304269|NCT01882257|Device|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
304270|NCT01882257|Device|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
304271|NCT01882244|Behavioral|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
304328|NCT01881945|Other|Non-invasive physiological signal recording on healthy volunteer|
304393|NCT01881334|Biological|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
304272|NCT01882244|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
304273|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
304274|NCT01882218|Drug|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
304275|NCT01882218|Drug|Standard Treatment|Standard liver surgery.
304276|NCT01882205|Device|Virtual chromoendoscopy|
304277|NCT01882205|Procedure|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
304278|NCT01882192|Behavioral|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
304279|NCT01882179|Drug|Mineralocorticoid receptor antagonist potassium-canrenoate|
304280|NCT01882179|Drug|placebo|
304281|NCT01882166|Drug|fostimon|
304282|NCT01882166|Drug|puregon|
304283|NCT01882153|Behavioral|Pivotal Response Training (PRT)|The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, & Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.
304284|NCT01882153|Behavioral|PACE Therapy|The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.
304285|NCT01882153|Behavioral|PACE and PRT Hybrid|The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
304286|NCT01882140|Other|Electrical Stimulation by Capacitive Field|
304287|NCT01882140|Other|Electrical Stimulation by Capacitive Field Placebo Sham|
304288|NCT01882127|Drug|All-Trans Retinoid Acid(ATRA)|patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
304289|NCT01882127|Drug|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
304290|NCT01882101|Procedure|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
304291|NCT01882101|Procedure|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
304292|NCT01882088|Drug|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
304293|NCT01882075|Drug|Open loop|
304294|NCT01882075|Device|Closed-loop|
304295|NCT01882062|Drug|Triheptanoin 1g/kg/day|
304296|NCT01882049|Device|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
304297|NCT01882036|Procedure|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
304298|NCT01882036|Other|Hypocaloric diet|Hypocaloric liquid diet for 10 days
304299|NCT01882010|Procedure|blood draw|week -8
304300|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week -8
304301|NCT01882010|Procedure|blood draw|week -4
304302|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week -4
304303|NCT01882010|Procedure|blood draw|week 0
304304|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week 0
304305|NCT01882010|Procedure|MEG|week 0
304306|NCT01882010|Drug|sargramostim|"lyophilized 250 micrograms/vial~6 micrograms/kg daily subcutaneous injection~56 days"
304307|NCT01882010|Drug|placebo|saline solution daily subcutaneous injection 56 days
304308|NCT01882010|Procedure|blood draw|week +2
304309|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +2
304310|NCT01882010|Procedure|blood draw|week +4
304311|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +4
304312|NCT01882010|Procedure|blood draw|week +6
304313|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +6
304314|NCT01882010|Procedure|blood draw|week +8
304315|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +8
304316|NCT01882010|Procedure|MEG|week +12
304317|NCT01882010|Procedure|blood draw|week +12
304318|NCT01882010|Behavioral|physical exam and UPDRS part III assessment|week +12
304319|NCT01882010|Procedure|Motion Analysis|Week -4
304320|NCT01882010|Procedure|Motion Analysis|Week +8
304321|NCT01882010|Procedure|Motion Analysis|Week +12
304322|NCT01881997|Drug|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
304323|NCT01881997|Drug|Normal Saline|IM normal saline
304324|NCT01881984|Drug|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
304325|NCT01881971|Drug|Placebo|suger pill manufactured to mimic crestor pills
304326|NCT01881971|Drug|Rouvastatin calcium|
304329|NCT01881932|Device|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
304330|NCT01881932|Device|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
304331|NCT01881919|Dietary Supplement|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
304332|NCT01881919|Dietary Supplement|Control|Address: Fagron GmbH&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
304333|NCT01881906|Other|Usual care|
304334|NCT01881906|Other|Exercise|
304335|NCT01881893|Behavioral|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
304336|NCT01881880|Device|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
304337|NCT01881867|Biological|Glycosylated Recombinant Human Interleukin-7|Given SC
304338|NCT01881867|Other|Laboratory Biomarker Analysis|Correlative studies
304339|NCT01881841|Behavioral|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
304340|NCT01881828|Drug|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
304341|NCT01881828|Other|oral placebo|
304342|NCT01881815|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
304343|NCT01881789|Drug|Oprozomib|Subjects will receive Oprozomib extended release (ER) Tablets (hereafter referred to as oprozomib) administered orally, once daily on 1, 2, 8, 9, 15,16, 22 and 23 of 28-day cycles
304344|NCT01881789|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg on Days 1-21 of 28 day cycles
304345|NCT01881789|Drug|Dexamethasone|Subjects will receive dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28 day cycles
304346|NCT01881789|Drug|Cyclophosphamide|Subjects will receive cyclophophamide 300 mg/m2 on Days 1, 8 and 15 of 28 day cycles
304347|NCT01881776|Procedure|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.~For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
304348|NCT01881763|Drug|Ketamine|Ketamine 1-2 mgr/ kg IV
304349|NCT01881763|Drug|Methohexital|Methohexital 0.5-1mg/kg IV
304350|NCT01881750|Behavioral|Pivotal Response Training (PRT)|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
304351|NCT01881750|Behavioral|Parent Education Group (PEG)|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
304352|NCT01881737|Drug|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.~Week 1 and 2: 100 mg~Week 3 and 4: 200 mg~Week 5 and 6: 300 mg~Week 7 and 8: 400 mg~Week 9 -12: 500 mg~At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.~If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
304353|NCT01881724|Behavioral|Sleep education|
304354|NCT01881711|Device|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
304355|NCT01881711|Device|Imaging|Imaging of ventricle size
304356|NCT01881698|Other|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
304357|NCT01881659|Other|HPV screening|Women who signed informed consent will be screened with HPV testing.
304358|NCT01881646|Radiation|Positron emission tomography (PET) using [11C]PBR28|
304359|NCT01881633|Drug|ISU302|
304360|NCT01881633|Drug|Placebo|
304361|NCT01881620|Device|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
304388|NCT01881373|Other|CHL program|Multiple component environmentally focused program designed with community engagement.
304389|NCT01881360|Other|Gluten-free diet|A diet that is free of the gluten component
304390|NCT01881360|Other|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
304391|NCT01881347|Dietary Supplement|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
304392|NCT01881347|Dietary Supplement|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
304476|NCT01880671|Device|Migraine Medical Device|
309566|NCT01841554|Device|Cardioband|
304362|NCT01881607|Behavioral|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
304363|NCT01881594|Procedure|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
304364|NCT01881581|Biological|Saline Solution|Saline Solution is used as control in all arms.
304365|NCT01881581|Biological|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
304366|NCT01881581|Biological|M-GPE|M-GPE is used in Arm D,E,F,G and H
304367|NCT01881568|Drug|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
304368|NCT01881568|Drug|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
304369|NCT01881555|Procedure|invasive coronary angiography|
304370|NCT01881555|Procedure|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
304371|NCT01881516|Device|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
304372|NCT01881516|Device|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
304373|NCT01881503|Biological|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
304374|NCT01881490|Device|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)
304375|NCT01881477|Procedure|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.~The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.~Additionally, it promotes the adoption and sitting positions long and short legged and walk."
304376|NCT01881464|Device|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
304377|NCT01881464|Drug|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
304378|NCT01881451|Drug|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
304379|NCT01881451|Procedure|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
304380|NCT01881425|Procedure|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
304381|NCT01881425|Device|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
304382|NCT01881412|Drug|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
304383|NCT01881412|Other|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
304384|NCT01881399|Device|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
304385|NCT01881399|Other|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
304386|NCT01881399|Procedure|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
304387|NCT01881386|Device|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
304394|NCT01881321|Behavioral|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
304395|NCT01881308|Drug|TNF inhibitors|
304396|NCT01881308|Drug|Synthetic DMARD(s)|
304397|NCT01881308|Drug|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
304398|NCT01881295|Dietary Supplement|Placebo control|
304399|NCT01881295|Dietary Supplement|Low dose potassium gluconate|
304400|NCT01881295|Dietary Supplement|Medium dose potassium gluconate|
304401|NCT01881295|Dietary Supplement|High dose potassium gluconate|
304402|NCT01881295|Dietary Supplement|Low dose potato|
304403|NCT01881295|Dietary Supplement|Medium dose potato|
304404|NCT01881295|Dietary Supplement|High dose potato|
304405|NCT01881295|Dietary Supplement|High dose French fries|
304406|NCT01881295|Dietary Supplement|Basal diet control|
304407|NCT01881282|Drug|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
304408|NCT01881282|Drug|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
304409|NCT01881230|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
304410|NCT01881230|Drug|Carboplatin|Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
304411|NCT01881230|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Days 1 and 8 of each 21-day treatment cycle.
304412|NCT01881217|Drug|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
304413|NCT01881204|Dietary Supplement|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
304414|NCT01881204|Dietary Supplement|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
304415|NCT01881204|Dietary Supplement|Control|Cookies without Hesperidin or Calcilock added.
304416|NCT01881191|Other|MRI|
304417|NCT01881178|Dietary Supplement|NOPALEA|
304418|NCT01881165|Drug|Cranberry|
304419|NCT01881165|Drug|Placebo|
304420|NCT01881152|Other|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
304421|NCT01881152|Other|Usual care|Information on stroke usually delivered at the community level.
304422|NCT01881139|Behavioral|exercise training|
304423|NCT01881126|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
304424|NCT01881126|Drug|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
304425|NCT01881126|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
304426|NCT01881126|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
304427|NCT01881113|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
304428|NCT01881113|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
304429|NCT01881100|Other|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
304430|NCT01881100|Other|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
304431|NCT01881087|Drug|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
304432|NCT01881074|Drug|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
304433|NCT01881074|Drug|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
304434|NCT01881048|Dietary Supplement|Omega-3 fatty acid|Given PO
304435|NCT01881048|Drug|Celecoxib|Given PO
304436|NCT01881035|Procedure|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
304437|NCT01881022|Behavioral|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
304559|NCT01880047|Drug|Placebo|
304438|NCT01881009|Device|Hybrid Closed-loop System|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter, PID-IFB (proportional-integral-derivative based with insulin feedback) algorithm on an Android platform with remote monitoring.
304439|NCT01881009|Device|Sensor-augmented pump|Medtronic Revel insulin pump, Enlite 3 sensor, Minimed transmitter.
304440|NCT01880996|Other|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
304441|NCT01880970|Other|starter infant formula with pro and prebiotics|
304442|NCT01880970|Other|Placebo comparator|
304443|NCT01880957|Drug|Lithium|
304444|NCT01880957|Drug|Lamotrigine|
304445|NCT01880944|Other|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
304446|NCT01880931|Drug|Remifentanil|The effect site concentration of remifentanil
304447|NCT01880905|Procedure|Measure of uteroovarian ligament length during gynecological surgery|
304448|NCT01880892|Procedure|Cricopharyngeal myotomy|Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
304449|NCT01880892|Device|Restech's Dx-pH Probe|This is not an intervention, but a newer device that measure the pH of the nasopharynx and detects laryngopharyngeal reflux. We will perform 24 hour tests with this device to see if there is an increase in laryngopharyngeal reflux follow cricopharyngeal myotomy.
304450|NCT01880879|Device|helios stent|the group with helios stent implanted
304451|NCT01880866|Drug|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
304452|NCT01880853|Other|mammography|participants were screened by mammography alone every year
304453|NCT01880853|Other|ultrasound|participants were screened by ultrasound alone every year
304454|NCT01880853|Other|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
304455|NCT01880840|Drug|205.5 mcg of azelastine hydrochloride|nasal spray
304456|NCT01880840|Drug|137 mcg of azelastine hydrochloride|nasal spray
304457|NCT01880827|Procedure|Roux-en-Y|"Subjects in the intervention group will be divided into two consecutive surgical groups, and operated at the Department of Surgery at Turku University Hospital (Kiinamyllynkatu 4-8, Turku). During surgery, Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) is performed using standard laparoscopic techniques. In RYGB procedure large part of the ventricle, duodenum, and proximal jejunum (ad 1.5 meters from pylorus) is bypassed. New stomach pouch is anastomosed into the new proximal jejunum, and remaining larger portion of the stomach, duodenum, and jejunum are reattached to the distal part of the jejunum for the secretion of pancreatic, gastrointestinal, and biliary juice. In SG a notable amount of ventricle is removed to create a stomach pouch which effectively restricts the amount of food feasible to ingest. After the surgery, subjects are controlled in hospital ward for approximately three days."
304458|NCT01880827|Drug|GIP-infusion|Blood flow and volume during infusion
304459|NCT01880827|Drug|GLP-1|Blood flow and volume during infusion
304460|NCT01880827|Drug|MMS|Blood flow and volume after meal solution
304461|NCT01880827|Procedure|Sleeve gastrectomy|
304462|NCT01880814|Behavioral|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
304463|NCT01880814|Behavioral|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
304464|NCT01880775|Drug|Prilocaine|experimental
304465|NCT01880775|Drug|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
304466|NCT01880749|Drug|RAD001|
304467|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
304468|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
304469|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
304470|NCT01880723|Drug|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
304471|NCT01880723|Drug|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
304472|NCT01880710|Procedure|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
304473|NCT01880710|Procedure|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
304474|NCT01880697|Biological|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
304475|NCT01880671|Device|Inactive Migraine Medical Device|
304477|NCT01880658|Drug|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
304478|NCT01880645|Procedure|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
304479|NCT01880645|Procedure|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
304480|NCT01880645|Procedure|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
304481|NCT01880632|Drug|XELOX|"Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
304482|NCT01880619|Drug|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
304483|NCT01880619|Drug|Solifenacin|Patients in the arm will receive Solifenacin
304484|NCT01880619|Drug|Control|Patients in this are will receive placebo
304485|NCT01880606|Procedure|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
304486|NCT01880593|Drug|Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
304487|NCT01880593|Drug|Ketamine|
304488|NCT01880593|Drug|Placebo|Subjects in this arm take placebo pills at night for duration of the study.
304489|NCT01880567|Drug|Ibrutinib|Given PO
304490|NCT01880567|Other|Laboratory Biomarker Analysis|Correlative studies
304491|NCT01880567|Biological|Rituximab|Given IV
304492|NCT01880554|Device|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:~Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
304493|NCT01880541|Other|hypnosedation|hypnosedation
304494|NCT01880541|Other|general anesthésia|general anesthesia
304495|NCT01880528|Drug|lisinopril|Given PO
304496|NCT01880528|Drug|placebo|Given PO
304497|NCT01880515|Drug|Tetracycline|The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
304498|NCT01880502|Drug|Belviq 10mg|Belviq 10mg single dose administration
304499|NCT01880502|Drug|Belviq 20mg|Belviq 20mg single dose administration
304500|NCT01880502|Drug|Placebo|Placebo single dose administration
304501|NCT01880489|Behavioral|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
304502|NCT01880476|Other|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
304503|NCT01880463|Drug|Omega-3 fatty acids (fish oil)|
304504|NCT01880463|Dietary Supplement|Vitamin D3|
304505|NCT01880463|Dietary Supplement|Vitamin D3 placebo|
304506|NCT01880463|Drug|Fish oil placebo|
304507|NCT01880450|Behavioral|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
304508|NCT01880450|Behavioral|TEEN|Control condition the promote communication, decision-making skills etc.
304509|NCT01880437|Drug|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
304510|NCT01880437|Drug|vismodegib|Cohorts 1 and 2: 150 mg orally daily
304511|NCT01880424|Drug|Placebo|matching Placebo Capsules, Oral, once daily
304512|NCT01880424|Drug|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
304513|NCT01880411|Biological|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
304514|NCT01880398|Other|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
304515|NCT01880385|Biological|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
304516|NCT01880385|Drug|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
304517|NCT01880385|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
304560|NCT01880034|Other|Lipid Emulsion Survey|
304518|NCT01880385|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
304519|NCT01880385|Drug|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
304520|NCT01880385|Biological|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
304521|NCT01880372|Dietary Supplement|Alpha Lipoic Acid|Same as Arm description
304522|NCT01880359|Drug|Cisplatin|
304523|NCT01880359|Radiation|Radiotherapy|
304524|NCT01880359|Drug|Placebo|
304525|NCT01880359|Drug|Nimorazole|
304526|NCT01880346|Dietary Supplement|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
304527|NCT01880346|Dietary Supplement|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
304528|NCT01880333|Other|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
304529|NCT01880320|Drug|CD0271 0.3% / CD1579 2.5%|
304530|NCT01880320|Drug|CD0271 0.1% / CD1579 2.5%|
304531|NCT01880320|Drug|Topical Gel Vehicle|
304532|NCT01880307|Drug|Azathioprine|
304533|NCT01880307|Drug|Infliximab|
304534|NCT01880307|Drug|Prednisolon|
304535|NCT01880294|Drug|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
304536|NCT01880281|Other|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
304537|NCT01880268|Device|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
304538|NCT01880268|Behavioral|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
304539|NCT01880255|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
304540|NCT01880216|Drug|Bemiparin sodium|subcutaneous application daily for 7±2 days
304541|NCT01880216|Drug|Enoxaparin sodium|subcutaneous for 7±2 days
304542|NCT01880203|Procedure|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
304543|NCT01880190|Other|Ringer's Lactate|
304544|NCT01880190|Other|HES 130/0.4 and Ringer's Lactate|
304545|NCT01880151|Device|EEG|EEG recorded during a resting condition and during an episodic memory task condition
304546|NCT01880138|Other|watching animated cartoon before general anesthesia|
304547|NCT01880138|Other|not watching animated cartoon beofre general anaesthesia|
304548|NCT01880125|Drug|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
304549|NCT01880112|Drug|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
304550|NCT01880099|Drug|placebo|placebo compared to 8mg of galatamine
304551|NCT01880099|Drug|Galantamine 8mg|8mg of galatamine compared to placebo
304552|NCT01880099|Drug|Galantamine 16mg|16mg of galatamine compared to placebo
304553|NCT01880086|Drug|Clomiphene citrate|
304554|NCT01880086|Drug|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
304555|NCT01880073|Device|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
304556|NCT01880060|Behavioral|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; >20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
304557|NCT01880060|Behavioral|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
304558|NCT01880047|Drug|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (> 50,000 and increase by > 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (> 50,000 and > 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
304561|NCT01879969|Procedure|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
304562|NCT01879969|Procedure|computer assisted orthognathic planning and surgery of asymmetric patients|
304563|NCT01879956|Other|Craft Activities|There is no intervention method used to perform the task.
304564|NCT01879956|Behavioral|OGI Method|metacognitive approach to assess executive functions.
304565|NCT01879943|Device|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
304566|NCT01879943|Procedure|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
304567|NCT01879930|Drug|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
304568|NCT01879930|Drug|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland~Oral intake during study period (4 weeks) once in the morning and once in the evening~The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
304569|NCT01879917|Drug|Liraglutide|
304570|NCT01879917|Drug|Placebo|Saline
304571|NCT01879904|Procedure|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
304572|NCT01879891|Other|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
304573|NCT01879878|Dietary Supplement|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
304574|NCT01879878|Dietary Supplement|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
304575|NCT01879865|Other|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
304576|NCT01879865|Other|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
304577|NCT01879852|Behavioral|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
304578|NCT01879852|Behavioral|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
304579|NCT01879839|Dietary Supplement|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
304580|NCT01879826|Device|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
304581|NCT01879826|Device|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
304582|NCT01879813|Dietary Supplement|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
304583|NCT01879813|Dietary Supplement|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
304584|NCT01879800|Behavioral|Acceptance and Commitment Therapy plus Illness Management|
304585|NCT01879787|Other|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
304586|NCT01879774|Other|Neuropsychological and motoric tests|"Neuropsychological tests~Mini Mental Status Test~Dem-Tect~Rey-Osterrieth Complex Figure Test~Trailmaking Test~Beck Depression Inventory~d2-R (optional)~Motoric tests~modified UPDRS (Unified Parkinson Disease Rating Scale) Part III~Timed-up-and-go Test~Halstead Fingertapping Test~AIMS (Abnormal involuntary movement scale)~EEG (only in patients with hyponatremia)~MRI (only in patients with hyponatremia)"
304666|NCT01879098|Dietary Supplement|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
304667|NCT01879085|Drug|Docetaxel|75 mg/m2 IV over 60 minutes on day 8 every 21 days (1 cycle).
304761|NCT01878422|Drug|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
304587|NCT01879748|Drug|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:~cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~placebo (8 Japanese and 8 Caucasian subjects)"
304588|NCT01879748|Drug|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:~cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo~Each subject will then be randomly assigned to 1 of the following groups:~rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)~rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)~placebo (8 Japanese and 8 Caucasian subjects)"
304589|NCT01879735|Drug|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
304590|NCT01879735|Drug|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
304591|NCT01879722|Drug|TAK-063|TAK-063 tablets
304592|NCT01879722|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
304593|NCT01879709|Behavioral|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
304594|NCT01879709|Behavioral|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
304595|NCT01879709|Other|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group~Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
304596|NCT01879696|Device|ECSPRESS catheter with active vacuum|
304597|NCT01879683|Drug|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
304598|NCT01879670|Device|CircuLite Synergy left ventricular assist device|
304599|NCT01879657|Drug|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
304600|NCT01879644|Behavioral|NF|
304601|NCT01879644|Behavioral|SM|
304602|NCT01879644|Behavioral|PE|
304603|NCT01879644|Behavioral|SU|
304604|NCT01879631|Procedure|radial keratotomy|
304605|NCT01879618|Drug|Fragmin|variable dosing regimen
304606|NCT01879605|Drug|Docusate natrium and sorbitol|
304607|NCT01879605|Drug|Bisacodyl|
304608|NCT01879579|Other|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
304609|NCT01879566|Other|No intervention will be done. The study is observational|
304610|NCT01879553|Biological|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
304611|NCT01879540|Biological|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
304612|NCT01879527|Drug|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
304613|NCT01879527|Drug|Sugar pill|containing placebo
304614|NCT01879514|Drug|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
304615|NCT01879514|Drug|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
304616|NCT01879501|Behavioral|Low Vision Self-Management Program|The program has been describe above.
304617|NCT01879488|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
304618|NCT01879488|Device|Vibrating-mesh nebulizer|
304619|NCT01879488|Other|Gamma scintigraphy|
304620|NCT01879488|Other|Preoperative spirometry|
304621|NCT01879475|Device|032-11|Topical haemostat
304622|NCT01879475|Device|Floseal (R)|Topical haemostat
304623|NCT01879462|Drug|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
304624|NCT01879462|Drug|Placebo|Visually matching GSK2878175
304625|NCT01879423|Drug|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
304626|NCT01879423|Drug|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
304668|NCT01879085|Drug|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, Gem will be given over 67.5 minutes at 10 mg/m2/min.
304760|NCT01878422|Drug|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
304627|NCT01879410|Drug|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
304628|NCT01879410|Drug|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
304629|NCT01879410|Drug|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
304630|NCT01879410|Drug|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
304631|NCT01879397|Device|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam~ARFI based images of the carotid artery and plaque~Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
304632|NCT01879384|Device|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
304633|NCT01879371|Drug|Ibuprofen+caffeine FDC|oral dose
304634|NCT01879371|Drug|Ibuprofen (Nurofen Immedia®)|oral dose
304635|NCT01879371|Drug|Ibuprofen (Brufen®)|oral dose
304636|NCT01879358|Device|Drug-eluting stent|
304637|NCT01879345|Drug|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
304638|NCT01879345|Drug|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
304639|NCT01879345|Drug|Placebo|placebo tablets
304640|NCT01879332|Drug|Placebo|Matching placebo tablets for oral administration
304641|NCT01879332|Drug|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
304642|NCT01879332|Drug|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
304643|NCT01879319|Biological|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
304644|NCT01879319|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
304645|NCT01879293|Drug|Metformin|
304646|NCT01879293|Drug|placebo|
304647|NCT01879280|Procedure|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
304648|NCT01879280|Procedure|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
304649|NCT01879267|Behavioral|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
304650|NCT01879254|Device|Deep Brain Stimulation|
304651|NCT01879241|Drug|Rasagiline|
304652|NCT01879241|Drug|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
304653|NCT01879228|Drug|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
304654|NCT01879215|Procedure|Intramedullary nailing of the tibia|Standard care surgery
304655|NCT01879202|Drug|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
304656|NCT01879202|Drug|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
304657|NCT01879189|Behavioral|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
304658|NCT01879176|Device|CytoSorb|
304659|NCT01879163|Biological|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
304660|NCT01879163|Biological|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
304661|NCT01879150|Device|Cyclaplex bone anchor|Device implantation
304662|NCT01879111|Other|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
304663|NCT01879098|Dietary Supplement|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
304664|NCT01879098|Dietary Supplement|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
304665|NCT01879098|Dietary Supplement|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
304751|NCT01878474|Drug|Placebo|Age-effect in Caucasian men
304669|NCT01879085|Drug|Vorinostat|will be given orally at the specified dose levels (Table 2) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle).
304670|NCT01879085|Drug|Pegfilgrastim|Administered on day 9 subcutaneously at 6 mg.
304671|NCT01879059|Behavioral|Exercise|short period of inactivity (5 days) followed by a return to physical activity (1 day)
304672|NCT01879046|Procedure|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
304673|NCT01879033|Other|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
304674|NCT01879033|Other|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
304675|NCT01879020|Drug|TA-8995|Drug: TA-8995 1mg
304676|NCT01879020|Drug|TA-8995|Drug: TA-8995 2.5mg
304677|NCT01879020|Drug|TA-8995|Drug: TA-8995 5mg
304678|NCT01879020|Drug|TA-8995|Drug: TA-8995 10mg
304679|NCT01879020|Drug|TA-8995|Drug: TA-8995 25mg
304680|NCT01879020|Drug|Placebo|Placebo (TA-8995 1mg)
304681|NCT01879020|Drug|Placebo|Placebo (TA-8995 2.5mg)
304682|NCT01879020|Drug|Placebo|Placebo (TA-8995 5mg)
304683|NCT01879020|Drug|Placebo|Placebo (TA-8995 10mg)
304684|NCT01879020|Drug|Placebo|Placebo (TA-8995 25mg)
304685|NCT01879007|Drug|Factive® Tab / Factive IV|
304686|NCT01878994|Behavioral|Counselling group|
304687|NCT01878994|Behavioral|Nereu group|
304688|NCT01878968|Other|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
304689|NCT01878955|Genetic|AMH level difference between patient with PCOS and multicystic ovaries.|
304690|NCT01878942|Drug|Placebo|"Capsules containing mannitol looking identical to LSD~per os"
304691|NCT01878942|Drug|LSD|200µg per os, single dose
304692|NCT01878929|Drug|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
304693|NCT01878903|Other|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
304694|NCT01878890|Drug|Efavirenz|
304695|NCT01878864|Drug|Bupivacaine lozenge|
304696|NCT01878864|Drug|Lidocaine-adrenalin injection|
304697|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
304698|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
304699|NCT01878825|Biological|Fluviral™|1 dose administered intramuscularly in deltoid region of non-dominant arm.
304700|NCT01878812|Biological|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
304701|NCT01878799|Drug|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
304702|NCT01878786|Drug|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
304703|NCT01878786|Drug|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
304704|NCT01878786|Drug|Mycophenolate mofetil (MMF/MPA)|Control Drug
304705|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|"Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~--------------------------------------------------------------------------------"
304706|NCT01878747|Behavioral|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
304752|NCT01878474|Drug|Placebo|Gender-effect in Caucasian women
304753|NCT01878474|Drug|Placebo|Single ascending dose in Japanese men
304754|NCT01878461|Drug|Vehicle|
304755|NCT01878461|Drug|M518101|
304756|NCT01878448|Drug|Anlotinib|
304707|NCT01878734|Dietary Supplement|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
304708|NCT01878721|Radiation|PET/CT|positron emission tomography/computed tomography
304709|NCT01878708|Drug|PEG-L-asparaginase|
304710|NCT01878708|Drug|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
304711|NCT01878695|Drug|IV/oral n-acetylcysteine|
304712|NCT01878669|Drug|N-acetyl cysteine|
304713|NCT01878669|Drug|Saline|
304714|NCT01878656|Drug|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
304715|NCT01878656|Drug|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
304716|NCT01878643|Drug|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
304717|NCT01878643|Drug|Placebo|normal saline administered to patient via nebulization
304718|NCT01878630|Device|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:~weighing scale (Seca 861 with bluetooth, seca gmbh & co. kg.)~blood pressure device (UA767PBT with bluetooth, A&D Ltd.)~ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)~patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)~help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)~at center site:~- electronic patient record (eHealth connect 2.0, T-Systems International)"
304719|NCT01878630|Other|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
304720|NCT01878617|Radiation|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
304721|NCT01878617|Drug|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
304722|NCT01878617|Drug|Cisplatin|ROA: IV
304723|NCT01878617|Drug|Vincristine|ROA: IV
304724|NCT01878617|Drug|Vismodegib|ROA: Orally (PO)
304725|NCT01878617|Drug|Pemetrexed|ROA: IV
304726|NCT01878617|Drug|Gemcitabine|ROA: IV
304727|NCT01878617|Other|Aerobic Training|
304728|NCT01878617|Other|Neurocognitive Remediation|
304729|NCT01878604|Genetic|Gene analysis|Gene analysis
304730|NCT01878604|Other|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
304731|NCT01878604|Other|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
304732|NCT01878578|Drug|Eslicarbazepine acetate|Tablets containing ESL 600 mg
304733|NCT01878578|Drug|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
304734|NCT01878578|Drug|Placebo|Tablets containing matching placebo
304735|NCT01878565|Drug|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
304736|NCT01878565|Drug|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
304737|NCT01878539|Device|coagulometer|
304738|NCT01878539|Behavioral|training programme|
304739|NCT01878526|Drug|Alginic acid|Algycon 1 tab chew tid after meal
304740|NCT01878526|Drug|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
304741|NCT01878526|Drug|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
304742|NCT01878526|Drug|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
304743|NCT01878513|Drug|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
304744|NCT01878500|Device|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
304745|NCT01878487|Device|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~At baseline~After thrombus aspiration with a thrombus extraction catheter~After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
304746|NCT01878474|Drug|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
304747|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
304748|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
304749|NCT01878474|Drug|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
304750|NCT01878474|Drug|Placebo|Single ascending dose in Caucasian men
304757|NCT01878435|Other|SMS reminder|
304762|NCT01878422|Drug|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
304763|NCT01878422|Drug|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
304764|NCT01878396|Drug|Anti-B-RAF|
304765|NCT01878383|Device|Genexpert assay|
304766|NCT01878370|Other|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.~Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
304767|NCT01878370|Other|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.~Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
304768|NCT01878357|Drug|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
304769|NCT01878357|Drug|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
304770|NCT01878344|Drug|NAC|
304771|NCT01878344|Drug|Saline|
304772|NCT01878318|Drug|methotrexate|stable dose
304773|NCT01878318|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
304774|NCT01878305|Device|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
304775|NCT01878292|Drug|Placebo|Dose matched placebo tablets, once per day, oral administration.
304776|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
304777|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
304778|NCT01878279|Other|Underlying medical illness|
304779|NCT01878266|Radiation|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
304780|NCT01878266|Radiation|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
304781|NCT01878266|Radiation|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
304782|NCT01878253|Device|Sidus Stem-Free Total Shoulder Arthroplasty System|
304783|NCT01878240|Procedure|EVAR without coils embolization/ Coils embolization during EVAR|
304784|NCT01878227|Drug|Coenzyme A|Coenzyme A 400mg per day
304785|NCT01878227|Drug|Fenofibrate 200mg|Fenofibrate 200mg per day
304786|NCT01878214|Behavioral|Targeted messaging|6 targeted mailed messages and 6 booster text messages
304787|NCT01878214|Behavioral|Standard messaging|1 informational letter
304788|NCT01878201|Drug|Fimasartan|Fimasartan 30 mg
304789|NCT01878201|Drug|Valsartan|Valsartan 80 mg
304790|NCT01878188|Drug|BC-819/PEI|Intravesical instillation
304791|NCT01878188|Drug|BCG Vaccine|intravesical instillations
304792|NCT01878175|Behavioral|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
304793|NCT01878162|Other|Exercise|
304794|NCT01878136|Drug|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
304795|NCT01878123|Biological|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
304796|NCT01878123|Other|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
304797|NCT01878110|Behavioral|COMB|
304798|NCT01878097|Behavioral|Green Dot Bystander Intevention|Intervention allocated at the school level
304799|NCT01878097|Behavioral|Control|Awareness Education
304800|NCT01878084|Other|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
304801|NCT01878084|Other|empty extraction socket|Extraction socket will be left empty
304802|NCT01878058|Other|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
304803|NCT01878006|Drug|Morphine|
304804|NCT01878006|Drug|Placebo|
304805|NCT01877967|Dietary Supplement|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
304806|NCT01877967|Dietary Supplement|placebo|
304807|NCT01877954|Drug|Extra-fine hydrofluoroalkane beclometasone dipropionate|
304808|NCT01877954|Drug|Fluticasone propionate|
304809|NCT01877941|Device|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
304810|NCT01877941|Device|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
304811|NCT01877941|Device|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
304812|NCT01877928|Device|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
304813|NCT01877928|Device|standard CPAP|Standard of care postoperative treatment for OSA.
304814|NCT01877915|Drug|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
304815|NCT01877915|Drug|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
304816|NCT01877915|Other|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
304817|NCT01877889|Drug|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 [treatment period 2] or Sequence 2 [treatment period 1]).
304818|NCT01877889|Drug|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 [treatment period 1] or Sequence 2 [treatment period 2]).
304819|NCT01877863|Other|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
304820|NCT01877850|Procedure|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.~When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
304821|NCT01877837|Drug|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + [(0.4) x (ABW - IBW)]~b) Medications~i.) Alemtuzumab I. Hb S% must be < or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued >48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
304822|NCT01877837|Drug|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
304823|NCT01877837|Drug|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. *Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.~II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
304824|NCT01877837|Procedure|Stem Cells|Infusion of Hematopoietic Stem Cells
304825|NCT01877824|Other|Fast-track training|
304826|NCT01877811|Drug|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
304827|NCT01877798|Procedure|volume resuscitation, vasoactive drug|
304828|NCT01877785|Drug|MHAA4549A|Single-ascending dose of MHAA4549A
304829|NCT01877785|Drug|Placebo|Placebo to MHAA4549A
304830|NCT01877772|Procedure|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
304831|NCT01877772|Procedure|Control|The control group will undergo standard rotator cuff repair.
304832|NCT01877759|Biological|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow & umbilical cord , IN 6 divided doses , at interval of 1 week .
304833|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
304834|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.~Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
304835|NCT01877746|Other|No intervention|No intervention, only standard medical therapy
304836|NCT01877733|Other|Maximal strength training|
304837|NCT01877720|Device|noninvasive respiratory support with NAVA mode and PSV|
304838|NCT01877707|Other|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
304839|NCT01877694|Drug|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
304840|NCT01877694|Drug|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
304841|NCT01877681|Procedure|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
304842|NCT01877681|Procedure|Active comparator|Usual care as specified in the PU practice guideline
304843|NCT01877668|Drug|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
304844|NCT01877668|Drug|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
304845|NCT01877668|Drug|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
304846|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
304847|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
304848|NCT01877655|Biological|ASP0113|Intramuscular injection
304849|NCT01877655|Drug|Placebo|Intramuscular injection
304850|NCT01877642|Drug|Lorazepam 1 mg IM|Lorazepam 1 mg intramuscular
304851|NCT01877642|Drug|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg
304852|NCT01877642|Drug|Inhaled Placebo|Inhaler with no drug in it to mimic the ADASUVE inhaler
304853|NCT01877642|Drug|Placebo IM|intramuscular placebo to mimic lorazepam 1 mg IM
304854|NCT01877629|Drug|ACT-129968 500 mg tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
304855|NCT01877629|Drug|ACT-129968 250 mg capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
304856|NCT01877616|Other|diagnostic test|Polysomnography
304857|NCT01877616|Other|Diagnostic test|overnight polysomnography
304858|NCT01877590|Drug|alpha-lipoic acid|
304859|NCT01877577|Dietary Supplement|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
304860|NCT01877564|Drug|Metformin|
304861|NCT01877551|Drug|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
304862|NCT01877551|Other|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
304863|NCT01877538|Other|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand [11C]donepezil
304864|NCT01877525|Procedure|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
304865|NCT01877512|Drug|Change in daily dosage of Growth Hormone|
304866|NCT01877499|Other|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.~Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.~Precisely, the following 3 parameters will successively be increased towards a maximal target:~Treatment time (up to 4 hours per session);~Blood flow rate (up to 400 mL/min;~Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).~Maximal values for these parameters will be those achieved within pre-specified safety limits."
304867|NCT01877486|Procedure|Ablation|Pulmonary vein isolation following dofetilide
304868|NCT01877473|Procedure|Ablation|
304869|NCT01877460|Other|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
304870|NCT01877447|Device|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
304871|NCT01877434|Procedure|Reversed shoulder arthroplasty|
304872|NCT01877421|Drug|2 mg KSL-W|
304873|NCT01877421|Drug|4 mg KSL-W|
304874|NCT01877421|Drug|6 mg KSL-W|
304875|NCT01877421|Drug|10 mg KSL-W|
304876|NCT01877421|Drug|20 mg KSL-W|
304877|NCT01877421|Drug|30 mg KSL-W|
304878|NCT01877421|Drug|50 mg KSL-W|
304879|NCT01877421|Drug|75 mg KSL-W|
304880|NCT01877421|Drug|100 mg KSL-W|
304881|NCT01877421|Other|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
304882|NCT01877408|Procedure|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
304883|NCT01877408|Device|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
304884|NCT01877395|Biological|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
304885|NCT01877395|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
304886|NCT01877382|Drug|DS-3032|DS-3032b will be administered as an oral capsule. It will be supplied in 5 mg, 20 mg, 80 mg, and 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
304887|NCT01877356|Procedure|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
304888|NCT01877356|Procedure|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
304889|NCT01877343|Device|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
304891|NCT01877317|Device|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
304892|NCT01877304|Device|AKITA|
304893|NCT01877278|Device|Wearable pulsed electromagnetic fields|
304894|NCT01877265|Drug|LY2605541|
304895|NCT01877252|Procedure|Surgical revascularization|
304896|NCT01877252|Procedure|Endovascular revascularization|
304897|NCT01877252|Other|No vascular intervention|
304898|NCT01877239|Other|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
304899|NCT01877226|Drug|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
304900|NCT01877213|Behavioral|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
304901|NCT01877200|Other|No treatment given|Patients will fill out a questionnaire by interview.
304902|NCT01877187|Drug|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
304903|NCT01877174|Device|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
304904|NCT01877174|Procedure|transcarotid stenting|
304905|NCT01877161|Device|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
304906|NCT01877161|Device|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
304907|NCT01877161|Device|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
304908|NCT01877148|Device|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
304909|NCT01877148|Behavioral|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
304910|NCT01877122|Device|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
304911|NCT01877122|Device|Marlex® Mesh Implant|
304912|NCT01877096|Behavioral|Motivational Interviewing|A brief motivational interviewing session
304913|NCT01877096|Behavioral|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
304914|NCT01877083|Drug|Lenvatinib|Starting dose of 24 mg orally, once per day
304915|NCT01877070|Behavioral|assessments|
304916|NCT01877057|Dietary Supplement|Saturn|
304917|NCT01877044|Dietary Supplement|NAXUS|
304918|NCT01877044|Dietary Supplement|Placebo|
304919|NCT01877031|Device|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
304920|NCT01877031|Device|Ultrasound|Standard of Care - Ultrasound guided intervention
304921|NCT01877018|Behavioral|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
304922|NCT01877005|Drug|Ruxolitinib|
304923|NCT01876992|Drug|Metformin|
304924|NCT01876979|Device|IMF Screws|stainless steel screws placed in bone
304925|NCT01876979|Device|Erich Arch Bars|Surgical braces wired around teeth
304926|NCT01876966|Drug|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
304927|NCT01876966|Drug|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
304928|NCT01876966|Drug|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets [20/120 mg] at 0, 8, 24, 36, 48, and 60 hours)
304929|NCT01876953|Drug|cytarabine|Given IV
304930|NCT01876953|Drug|idarubicin|Given IV
304931|NCT01876953|Drug|dasatinib|Given PO
304932|NCT01876953|Other|laboratory biomarker analysis|Correlative studies
304933|NCT01876940|Device|air-Q, followed by fiberoptic intubation|
304934|NCT01876940|Device|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
304935|NCT01876927|Other|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
304936|NCT01876927|Other|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
304937|NCT01876901|Procedure|Delayed coloanal anastomosis (ACAD)|"Delayed coloanal anastomosis ACAD Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.~After surgical resection, the colon is exteriorized through the anus and attached to the buttock.~By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
304970|NCT01876615|Drug|Diclofenac|Depain tablet 25mg
304971|NCT01876615|Drug|YH4808+Diclofenac|
328399|NCT01694914|Procedure|corneal graft|
304938|NCT01876901|Procedure|ACAI Group (coloanal anastomosis Immediate)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.~In the absence of fistula, the patient will reoperation for stoma closure of its branch"
304939|NCT01876875|Dietary Supplement|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
304940|NCT01876875|Dietary Supplement|Usual diet|The patients of this group were randomized to continue their usual diet
304941|NCT01876862|Other|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
304942|NCT01876849|Drug|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
304943|NCT01876836|Device|i-gel|i-gel placed after induction
304944|NCT01876836|Device|C-LMA|placed after induction
304945|NCT01876823|Drug|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
304946|NCT01876823|Drug|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
304947|NCT01876810|Drug|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
304948|NCT01876810|Drug|Placebo|One lactose pill twice a day for two weeks.
304949|NCT01876797|Drug|ticagrelor/prasugrel|
304950|NCT01876784|Drug|Vandetanib (SAR390530)|"Pharmaceutical form: tablet~Route of administration: oral"
304951|NCT01876784|Drug|Placebo|"Pharmaceutical form: tablet~Route of administration: oral"
304952|NCT01876771|Drug|[177]Lu-DOTA-TATE|Peptide receptor radionuclide therapy (PPRT)
304953|NCT01876758|Behavioral|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
304954|NCT01876758|Behavioral|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
304955|NCT01876745|Drug|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
304956|NCT01876732|Drug|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
304957|NCT01876719|Drug|AR08|
304958|NCT01876719|Drug|Placebo|
304959|NCT01876706|Device|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
304960|NCT01876693|Procedure|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
304961|NCT01876680|Other|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
304962|NCT01876680|Other|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.~Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
304963|NCT01876667|Other|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
304964|NCT01876667|Other|Placebo|Usual Care
304965|NCT01876654|Device|TruMatch® patient specific cutting guide|
304966|NCT01876641|Drug|Vemurafenib + Cobimetinib, Decitabine|
304967|NCT01876628|Drug|Flucloxacillin and Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
304968|NCT01876628|Drug|Flucloxacillin and placebo|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
304969|NCT01876615|Drug|YH4808|experimental drug
329851|NCT01683175|Drug|cis-platinum|
304972|NCT01876602|Behavioral|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
304973|NCT01876589|Device|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
304974|NCT01876589|Device|Xience Prime|Drug eluting metallic stent
304975|NCT01876576|Other|Clear liquids|Clear liquids
304976|NCT01876576|Other|Low residue breakfast and lunch|Low residue
304977|NCT01876563|Dietary Supplement|vitamin D|one tab 4000 IU/day vitamin D
304978|NCT01876563|Dietary Supplement|placebo|one tab per day placebo
304979|NCT01876550|Drug|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
304980|NCT01876550|Drug|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
304981|NCT01876550|Drug|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
304982|NCT01876537|Device|Hardware wound healing|
304983|NCT01876537|Device|Usual Surgery|
304984|NCT01876524|Device|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
304985|NCT01876511|Drug|MK-3475|MK-3475 10 mg/kg every 14 days
304986|NCT01876511|Drug|MK-3475|MK-3475 200mg flat dose every 21 days
304987|NCT01876498|Procedure|Xiaflex surgery|Xiaflex surgery
304988|NCT01876485|Behavioral|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
304989|NCT01876485|Behavioral|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
304990|NCT01876472|Behavioral|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
304991|NCT01876459|Other|MRI|
304992|NCT01876459|Procedure|lumbar puncture|
304993|NCT01876459|Behavioral|neuropsychological tests|
304994|NCT01876446|Other|Laboratory Biomarker Analysis|Correlative studies
304995|NCT01876446|Drug|Pegylated Irinotecan|Given IV
304996|NCT01876446|Other|Pharmacological Study|Correlative studies
304997|NCT01876433|Drug|Mirabegron|
304998|NCT01876433|Drug|Placebo|
304999|NCT01876420|Device|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
305000|NCT01876407|Device|Low intensity laser for oral mucositis|
305001|NCT01876407|Device|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
305002|NCT01876394|Other|Coconut Oil|Shake with 50 g Coconut oil
305003|NCT01876394|Other|Canola Oil|Shake with 50 g Canola oil
305004|NCT01876394|Other|Grapeseed Oil|Shake with 50 g Grapeseed oil
305005|NCT01876394|Other|Chia Oil|Shake with 50 g Chia oil
305006|NCT01876394|Other|Butter|Shake with 50 g Butter
305007|NCT01876381|Drug|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
305008|NCT01876368|Drug|LCZ696|
305009|NCT01876368|Drug|Olmesartan|
305010|NCT01876368|Drug|Placebo of LCZ696|
305011|NCT01876368|Drug|Placebo of Olmesartan|
305012|NCT01876355|Drug|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
305013|NCT01876355|Drug|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
305014|NCT01876342|Procedure|open repair|2-0 sutures
305015|NCT01876342|Procedure|endoscopic TEP repair|mesh
305016|NCT01876316|Drug|Moxifloxacin|single oral administration of 400mg of moxifloxacin
305017|NCT01876316|Drug|Placebo|single oral administration of 400mg of placebo
305018|NCT01876303|Other|laboratory biomarker analysis|Correlative studies
305019|NCT01876303|Other|questionnaire administration|Ancillary studies
305020|NCT01876290|Drug|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
305021|NCT01876290|Drug|Placebo|Placebo
305022|NCT01876264|Procedure|Extended resection|
305023|NCT01876264|Procedure|Conventional resection|
305024|NCT01876251|Drug|PF-03084014|Tablet, 10 mg, twice a day
305025|NCT01876251|Drug|PF-03084014|Tablet, 50 mg, twice a day
305026|NCT01876251|Drug|PF-03084014|Tablet, 100 mg, twice a day
305027|NCT01876251|Drug|Docetaxel|Solution for IV infusion 75 mg/m^2, every 3 weeks
305028|NCT01876251|Drug|Docetaxel|Solution for IV infusion 100 mg/m^2, every 3 weeks
305029|NCT01876238|Other|T-PAT|
305030|NCT01876238|Other|Surveys|Pre-test and posttest surveys and questionnaires
305031|NCT01876225|Behavioral|Forced coughing during cervical punch biopsy|
305032|NCT01876212|Biological|DC vaccine|
305033|NCT01876212|Drug|Dasatinib|
305034|NCT01876199|Behavioral|intense follow up|
305035|NCT01876186|Drug|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
305036|NCT01876186|Drug|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
305037|NCT01876173|Behavioral|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
305038|NCT01876160|Other|Transcutaneous electrical nerve stimulation|
305039|NCT01876121|Drug|Celecoxib|oral
305040|NCT01876108|Drug|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
305041|NCT01876095|Procedure|Multidisciplinary medication review|"Consists of the following steps:~1. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.~2. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.~3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.~5. Execution of pharmaceutical care plan according to agreed schedule."
305042|NCT01876082|Drug|PAZOPANIB treatment|"Pazopanib~800 mg per day~oral administration~at least 1 hour before or 2 hours after a meal,~until disease progression or for 12 months maximum"
305043|NCT01876082|Drug|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
305044|NCT01876069|Device|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
305045|NCT01876069|Device|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
305046|NCT01876056|Behavioral|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
305047|NCT01876043|Drug|plitidepsin|
305048|NCT01876030|Device|FES|
305049|NCT01876017|Biological|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
305050|NCT01876004|Drug|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
305051|NCT01876004|Drug|Placebo|Prescribed Placebo IM (intramuscularly), single dose
305052|NCT01875991|Drug|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
305053|NCT01875991|Drug|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
305054|NCT01875978|Dietary Supplement|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
305055|NCT01875952|Drug|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
305056|NCT01875939|Drug|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
305057|NCT01875939|Drug|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
305058|NCT01875926|Biological|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
305059|NCT01875926|Biological|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
305060|NCT01875926|Biological|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
305061|NCT01875913|Behavioral|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
305062|NCT01875913|Behavioral|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
305063|NCT01875900|Other|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
305064|NCT01875900|Other|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
305065|NCT01875887|Procedure|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
305066|NCT01875874|Biological|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
305067|NCT01875861|Other|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
305068|NCT01875848|Drug|buprenorphine/naloxone|partial opioid agonist
305069|NCT01875848|Drug|opioid dose escalation|up to 25% increase in patient's current opioid dose
305070|NCT01875835|Device|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
305162|NCT01875094|Other|Self-Management / MTM using Health IT|
305071|NCT01875835|Device|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
305072|NCT01875822|Dietary Supplement|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
305073|NCT01875796|Behavioral|Cognitive-Behavioral Therapy|
305074|NCT01875796|Behavioral|Motivation Enhancement Therapy|
305075|NCT01875796|Behavioral|Integrated Cannabis and Anxiety Reduction Treatment|
305076|NCT01875796|Behavioral|False Safety Behavior Elimination Therapy|
305077|NCT01875783|Device|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
305078|NCT01875757|Drug|Vitamin D3|
305079|NCT01875757|Drug|Placebo|
305080|NCT01875744|Drug|Polyethylene glycol 4000|
305081|NCT01875731|Behavioral|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
305082|NCT01875731|Behavioral|Guideline|Strategy based on enforced guideline guided antibiotic use
305083|NCT01875718|Drug|UC1010|
305084|NCT01875718|Drug|Placebo|
305085|NCT01875705|Drug|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
305086|NCT01875705|Drug|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
305087|NCT01875679|Other|Comprehensive Surgical Coaching|
305088|NCT01875679|Other|Conventional Surgical Training|Surgical training as per participant's residency program
305089|NCT01875666|Drug|Trastuzumab|8 mg/kg IV, single dose
305090|NCT01875666|Drug|pertuzumab|840 mg IV single dose
305091|NCT01875666|Drug|lapatinib|1000 mg daily for 7 days
305092|NCT01875653|Biological|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
305093|NCT01875653|Biological|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
305094|NCT01875627|Dietary Supplement|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
305095|NCT01875627|Dietary Supplement|Carbohydrate and Konjac Noodles|
305096|NCT01875627|Dietary Supplement|Carbohydrate noodles|
305097|NCT01875601|Biological|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
305098|NCT01875601|Biological|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
305099|NCT01875575|Dietary Supplement|Placebo|
305100|NCT01875575|Dietary Supplement|Glucose 25g|
305101|NCT01875575|Dietary Supplement|Glucose 10g|
305102|NCT01875562|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
305103|NCT01875549|Device|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
305104|NCT01875549|Procedure|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
305105|NCT01875536|Device|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
305106|NCT01875536|Behavioral|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
305107|NCT01875523|Drug|Serelaxin|
305108|NCT01875510|Dietary Supplement|Fish-oil emulsions|"Fish -oil emulsions:~Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
305109|NCT01875510|Dietary Supplement|soybean-oil emulsion|soybean-oil emulsion
305110|NCT01875497|Dietary Supplement|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
305111|NCT01875471|Device|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
305112|NCT01875471|Device|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
305113|NCT01875445|Drug|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
305114|NCT01875445|Drug|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
305115|NCT01875419|Device|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.~Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
305116|NCT01875419|Behavioral|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
305117|NCT01875406|Other|diagnostic exercises|
305118|NCT01875393|Drug|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
305119|NCT01875380|Drug|Regorafenib|
305120|NCT01875367|Drug|Trastuzumab subcutaneous inyection vial|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
305386|NCT01873482|Behavioral|Movement to rhythm|Movement to rhythm
305121|NCT01875367|Device|Trastuzumab subcutaneous device administration|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
305122|NCT01875354|Dietary Supplement|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
305123|NCT01875354|Dietary Supplement|Placebo and Low Fat Eating Plan|
305124|NCT01875341|Device|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
305125|NCT01875341|Device|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
305126|NCT01875328|Other|Telemedicine|Post stroke follow up in home using telemedicine.
305127|NCT01875328|Other|Clinic|Post stroke clinic group follow up
305128|NCT01875315|Other|Diagnostic Cardiac Imaging|
305129|NCT01875289|Procedure|obturator nerve block|
305130|NCT01875263|Drug|Cloxacilin|2g/4 hours i.v., 5 days
305131|NCT01875263|Drug|Cloxacillin|2g/4h 14 days Standard therapy
305132|NCT01875263|Drug|Levofloxacin|500 mg v.o./24h, 9 days
305133|NCT01875250|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
305134|NCT01875250|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
305135|NCT01875250|Drug|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
305136|NCT01875237|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
305137|NCT01875237|Drug|Melphalan|140 mg/m2 by vein on Day -2.
305138|NCT01875237|Drug|Alemtuzumab|50 mg by vein on Day -1.
305139|NCT01875237|Procedure|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
305140|NCT01875237|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
305141|NCT01875237|Drug|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
305142|NCT01875237|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
305143|NCT01875237|Procedure|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
305144|NCT01875237|Drug|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade > 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
305145|NCT01875237|Drug|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
305146|NCT01875237|Behavioral|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
305147|NCT01875224|Drug|Belatacept|
305148|NCT01875224|Drug|Tacrolimus|Standard administration of tacrolimus
305149|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy with Splenectomy|
305150|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
305151|NCT01875185|Drug|Aspirin 81 mg|Aspirin 81 mg orally daily for 7 days
305152|NCT01875172|Drug|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
305153|NCT01875172|Drug|placebo|
305154|NCT01875172|Behavioral|smoking cessation counseling|
305155|NCT01875159|Drug|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
305156|NCT01875146|Other|4x4 min HIT|Conventional 4x4 min high-intensity interval training
305157|NCT01875146|Other|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
305158|NCT01875146|Other|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
305159|NCT01875146|Other|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
305160|NCT01875133|Other|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
305161|NCT01875107|Drug|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
329852|NCT01683175|Drug|Vinorelbine|
305163|NCT01875081|Biological|Livercellgram|"Livercellgram~Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃~Injection Method: Directly inject into liver through hepatic artery"
305164|NCT01875068|Behavioral|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
305165|NCT01875068|Behavioral|versus NPs and PAs who are not required to discuss patient referrals (control group).|
305166|NCT01875055|Device|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
305167|NCT01875055|Device|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
305168|NCT01875042|Device|TENS|Transcutaneous electrical nerve stimulation
305169|NCT01875042|Device|Sham TENS|Sham Transcutaneous electrical nerve stimulation
305170|NCT01875029|Device|sham-tDCS + back school|sham tDCS + back school
305171|NCT01875029|Device|real-tDCS + back school|real tDCS + back school
305172|NCT01875016|Procedure|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
305173|NCT01875003|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
305174|NCT01875003|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
305175|NCT01875003|Drug|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists [LABAs], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
305176|NCT01874990|Dietary Supplement|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
305177|NCT01874990|Dietary Supplement|low-salt diet|
305178|NCT01874977|Behavioral|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
305179|NCT01874977|Behavioral|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
305180|NCT01874977|Behavioral|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
305181|NCT01874964|Behavioral|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
305182|NCT01874964|Behavioral|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
305183|NCT01874951|Drug|Naltrexone|1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
305184|NCT01874951|Drug|Placebo|Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
305185|NCT01874938|Biological|LY2875358|Administered IV
305186|NCT01874899|Device|RestoreSensor Neurostimulation|
305187|NCT01874873|Drug|Anlotinib|
305188|NCT01874860|Drug|Doxycycline|Doxycycline capsule, 100 mg, taken twice daily
305189|NCT01874860|Drug|Hydrocortisone 1% cream|Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
305190|NCT01874860|Other|Sunscreen|Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
305191|NCT01874860|Other|Moisturizer|Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
305192|NCT01874860|Drug|Clindamycin|Recommended for daily use if rash returns (Topical cream)
305193|NCT01874860|Drug|Medrol-dose pack (Steroid)|Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
305194|NCT01874847|Dietary Supplement|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
305195|NCT01874847|Dietary Supplement|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
305196|NCT01874834|Other|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
305197|NCT01874821|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
305198|NCT01874821|Other|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
305199|NCT01874795|Device|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
305200|NCT01874795|Device|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
305201|NCT01874782|Device|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
305387|NCT01873469|Radiation|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
305388|NCT01873456|Other|multifactorial nutritional intervention|
305389|NCT01873443|Drug|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10~25mg/week Folic acid at least 5mg/week
305202|NCT01874769|Other|Blood collection|"5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.~10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen~5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
305203|NCT01874769|Other|Skin biopsies|"A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.~During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
305204|NCT01874756|Drug|LY500307 150mg|LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
305205|NCT01874756|Drug|LY500307 75mg|LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
305206|NCT01874756|Drug|Placebo|6 placebo capsules daily for 8 weeks
305207|NCT01874756|Drug|LY500307 25mg|LY500307 25mg daily dose (1 capsules of 25mg and 5 capsules of placebo) for 8 weeks
305208|NCT01874743|Drug|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
305209|NCT01874730|Other|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
305210|NCT01874730|Drug|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.~For the ERS Group:~GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
305211|NCT01874730|Other|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
305212|NCT01874717|Other|Conscious sedation for dental care|
305213|NCT01874717|Drug|midazolam|
305214|NCT01874704|Behavioral|Comparison of biomarkers of stress|
305215|NCT01874678|Drug|TS-1/Cisplatin|
305216|NCT01874665|Drug|Ponatinib|Ponatinib 45 mg, tablets, orally, once-daily.
305217|NCT01874652|Device|Light Weight Breast Implants|Light Weight Breast Implants
305218|NCT01874639|Device|standard bipolar coagulation|
305219|NCT01874639|Device|Aquamantys® probe for liver hemostasis|
305220|NCT01874626|Drug|Placebo|Placebo cream
305221|NCT01874626|Drug|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
305222|NCT01874613|Device|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
305223|NCT01874613|Device|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
305224|NCT01874600|Device|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
305225|NCT01874587|Radiation|adaptative radiotherapy|weekly replanning
305226|NCT01874574|Drug|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
305227|NCT01874574|Drug|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
305228|NCT01874561|Drug|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
305229|NCT01874561|Drug|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
305230|NCT01874561|Drug|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
305231|NCT01874535|Drug|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
305232|NCT01874522|Drug|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
305233|NCT01874522|Drug|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
305234|NCT01874509|Behavioral|Check Your Drinking|
305235|NCT01874509|Behavioral|Alcohol Help Centre|
305236|NCT01874496|Dietary Supplement|GDS, no meal|GDS, no meal
305237|NCT01874496|Dietary Supplement|GDS, meal|GDS, meal
305238|NCT01874496|Dietary Supplement|control, no meal|control, no meal
305239|NCT01874496|Dietary Supplement|control, meal|control, meal
305240|NCT01874483|Drug|Placebo|placebo
305241|NCT01874483|Drug|BI 187004|BI 187004, dose 2
305242|NCT01874483|Drug|BI 187004|BI 187004, dose 4
305243|NCT01874483|Drug|BI 187004|BI 187004, dose 5
305244|NCT01874483|Drug|BI 187004|BI 187004, dose 6
305245|NCT01874483|Drug|BI 187004|BI 187004, dose 7
305246|NCT01874483|Drug|BI 187004|BI 187004, dose 1
305247|NCT01874483|Drug|BI 187004|BI 187004, dose 3
305248|NCT01874470|Device|renal denervation|
305249|NCT01874470|Other|standard medication|
305250|NCT01874457|Biological|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
305251|NCT01874444|Device|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
305390|NCT01873430|Drug|Melatonin|
305391|NCT01873417|Drug|BG00012 (DMF)|
305392|NCT01873404|Drug|BG00010|As specified in the treatment arm
305252|NCT01874444|Device|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
305253|NCT01874444|Device|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
305254|NCT01874444|Device|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
305255|NCT01874431|Drug|Finerenone (BAY 94-8862)|
305256|NCT01874431|Drug|Placebo|
305257|NCT01874418|Other|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
305258|NCT01874392|Drug|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
305259|NCT01874392|Device|Artificial Pancreas (AP) device (APS©)|"Device includes:~OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.~Dexcom® G4® CGM System (CGM) from Dexcom® Corp~Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
305260|NCT01874379|Other|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
305261|NCT01874379|Other|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
305262|NCT01874379|Other|Standard of Care|Normal Procedures, no complementary medicine intervention.
305263|NCT01874366|Drug|P11187|"Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)~Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.~Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
305264|NCT01874366|Drug|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.~In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo~In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
305265|NCT01874353|Drug|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
305266|NCT01874353|Drug|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
305267|NCT01874340|Drug|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
305268|NCT01874340|Drug|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
305269|NCT01874327|Behavioral|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
305270|NCT01874327|Behavioral|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
305271|NCT01874314|Drug|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
305272|NCT01874314|Other|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
305273|NCT01874314|Drug|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
305274|NCT01874301|Other|High quantity probiotic|The intervention type is food product
305275|NCT01874301|Other|Low quantity probiotic|The intervention type is food product
305276|NCT01874301|Other|placebo|
305277|NCT01874288|Drug|0.5 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
305278|NCT01874288|Drug|1.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
305279|NCT01874288|Drug|2.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
305280|NCT01874288|Drug|4.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
305281|NCT01874288|Drug|6.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
305393|NCT01873404|Drug|Placebo|As specified in the treatment arm
305394|NCT01873391|Procedure|Diagnostic hysteroscopy|
305395|NCT01873378|Drug|Triptorelin 3.75 mg|
305805|NCT01870310|Procedure|Catheterised renal denervation|
305282|NCT01874288|Drug|8.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
305283|NCT01874288|Drug|10.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
305284|NCT01874288|Drug|50mg/m2 Rituximab|Pre-treatment with Rituximab will occur on Day 1 if patient's Rituximab level is <10 μg/mL; intended to bring their level above10 μg/mL.
305285|NCT01874275|Device|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.~Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
305286|NCT01874262|Device|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
305287|NCT01874262|Device|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
305288|NCT01874249|Other|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
305289|NCT01874249|Other|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
305290|NCT01874249|Other|Transient elastography|Transient elastography values greater than 8 kPa
305291|NCT01874236|Drug|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
305292|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
305293|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
305294|NCT01874197|Device|B-TEVAR device|Creation and implantation of the Branched Thorcoabdominal aortic anerysm device
305295|NCT01874184|Other|counseling intervention|Take part in weekly group counseling sessions
305296|NCT01874184|Behavioral|behavioral dietary intervention|Set goals for changing dietary habits
305297|NCT01874184|Behavioral|exercise intervention|Attend group exercise activities
305298|NCT01874184|Other|questionnaire administration|Ancillary studies
305299|NCT01874184|Other|laboratory biomarker analysis|Correlative studies
305300|NCT01874171|Drug|Cisplatin|
305301|NCT01874171|Drug|Cetuximab|
305302|NCT01874145|Drug|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
305303|NCT01874145|Drug|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
305304|NCT01874132|Behavioral|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
305305|NCT01874119|Drug|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
305306|NCT01874106|Other|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
305307|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
305308|NCT01874093|Device|The Ischemic Stroke System|SPG stimulation and standard of care
305309|NCT01874093|Device|Sham control|Sham stimulation and standard of care
305310|NCT01874080|Drug|Saxagliptin/Metformin|
305311|NCT01874067|Device|Arthritis glove|Isotoner three-quarter finger arthritis glove
305312|NCT01874054|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
305313|NCT01874054|Drug|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
305314|NCT01874041|Other|Massage|
305315|NCT01874041|Other|Occlusal splint|
305316|NCT01874028|Drug|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
305317|NCT01874015|Biological|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
305318|NCT01874015|Biological|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
305319|NCT01874002|Device|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
305320|NCT01873989|Drug|Testosterone replacement|
305321|NCT01873989|Other|Waitlist control|
305322|NCT01873950|Drug|Ranolazine|
305323|NCT01873950|Drug|Dofetilide|
305324|NCT01873950|Drug|Verapamil|
305325|NCT01873950|Drug|Quinidine sulfate|
305326|NCT01873950|Drug|Placebo|
305327|NCT01873937|Radiation|Red LED|Phototherapy with red LED on temporomandibular area
305328|NCT01873937|Radiation|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
305329|NCT01873937|Radiation|LASER|Phototherapy with LASER INFRARED on temporomandibular area
305396|NCT01873365|Other|Data collection|Case report forms (CRFs), logbooks and booklets.
305686|NCT01871220|Device|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
331718|NCT01668277|Drug|0.9% NaCl|
305330|NCT01873898|Device|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
305331|NCT01873885|Drug|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
305332|NCT01873885|Drug|Experimental: Single IV Infusion Vasomera (PB1046)|
305333|NCT01873872|Dietary Supplement|Theralac probiotic|
305334|NCT01873872|Dietary Supplement|Culturelle probiotic|
305335|NCT01873872|Other|placebo|
305336|NCT01873859|Drug|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
305337|NCT01873846|Device|Silicone Hydrogel Contact Lens|
305338|NCT01873833|Drug|capecitabine|Given PO
305339|NCT01873833|Drug|cyclophosphamide|Given PO
305340|NCT01873833|Drug|lapatinib ditosylate|Given PO
305341|NCT01873833|Biological|trastuzumab|Given IV
305342|NCT01873833|Other|laboratory biomarker analysis|Correlative studies
305343|NCT01873820|Dietary Supplement|Calcium ascorbate|
305344|NCT01873820|Dietary Supplement|Ascorbic acid|
305345|NCT01873807|Drug|IDA|Idarubicin: 15mg/m2/d: -8->-6d
305346|NCT01873807|Radiation|TBI|TBI: 4.5 Gy/d, -5d, -4d
305347|NCT01873807|Drug|CTX|CY:60mg/kg/d, -3d, -2d
305348|NCT01873807|Drug|VP-16|VP-16: 15mg/kg, -2d, -1d
305349|NCT01873794|Device|Bright white light|
305350|NCT01873794|Device|Dim red light|
305351|NCT01873781|Drug|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
305352|NCT01873768|Drug|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
305353|NCT01873768|Drug|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
305354|NCT01873755|Behavioral|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
305355|NCT01873742|Other|STIC feedback system|This condition includes the use of the STIC feedback system.
305356|NCT01873729|Drug|Naltrexone|Adults with ADHD
305357|NCT01873716|Drug|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
305358|NCT01873703|Drug|pracinostat|Histone deacetylase inhibitor (HDACi)
305359|NCT01873703|Drug|Placebo|Placebo
305360|NCT01873703|Drug|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
305361|NCT01873690|Drug|Ciprofloxacin|Once, 400 mg IV
305362|NCT01873690|Drug|Placebo|5% Dextrose in water
305363|NCT01873677|Drug|M518101|
305364|NCT01873677|Drug|Vehicle|
305365|NCT01873664|Behavioral|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
305366|NCT01873651|Device|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
305367|NCT01873638|Procedure|Cholecystectomy|
305368|NCT01873625|Biological|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
305369|NCT01873625|Biological|placebo|
305370|NCT01873612|Procedure|Hypoxic ventilatory response|
305371|NCT01873612|Procedure|Hypercapnic ventilatory response|
305372|NCT01873599|Behavioral|Positive Affect Journaling|
305373|NCT01873586|Procedure|Posterolateral Fusion|
305374|NCT01873573|Procedure|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
305375|NCT01873573|Other|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
305376|NCT01873573|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
305377|NCT01873547|Biological|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
305378|NCT01873547|Other|rehabilitation|Patients only receive rehabilitation of limb function.
305379|NCT01873534|Drug|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
305380|NCT01873521|Procedure|Non invasive ventilation|
305381|NCT01873508|Drug|RO4917523|Fast release MR capsule, single dose
305382|NCT01873508|Drug|RO4917523|Target release MR capsule, single dose
305383|NCT01873508|Drug|RO4917523|Slow release MR capsule, single dose
305384|NCT01873508|Drug|RO4917523|[13C]-labeled tracer dose i.v.
305385|NCT01873495|Drug|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.~Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
305397|NCT01873352|Procedure|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
305398|NCT01873352|Procedure|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
305399|NCT01873339|Drug|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
305400|NCT01873339|Drug|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
305401|NCT01873326|Drug|Paclitaxel|
305402|NCT01873326|Drug|Ifosfamide|
305403|NCT01873326|Drug|Cisplatin|
305404|NCT01873326|Drug|Mesna|
305405|NCT01873326|Drug|Bleomycin|
305406|NCT01873326|Drug|Etoposide|
305407|NCT01873313|Drug|Ropivacaine|
305408|NCT01873300|Procedure|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
305409|NCT01873274|Dietary Supplement|MK-7 containing capsule|
305410|NCT01873274|Dietary Supplement|basic yogurt enriched with MK-7|
305411|NCT01873274|Dietary Supplement|nutrient-enriched yogurt with MK-7|
305412|NCT01873248|Drug|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
305413|NCT01873222|Device|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI~Assessment by OFDI at a 8-month follow-up"
305414|NCT01873222|Device|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI~Assessment by OFDI at a 8-month follow-up"
305415|NCT01873196|Behavioral|Receive extra oil|
305416|NCT01873196|Behavioral|Receives behavior changed messages on CSB package|
305417|NCT01873183|Other|Goal directed fluid therapy|
305418|NCT01873170|Drug|levonorgestrel exposure|
305419|NCT01873170|Drug|DMPA exposure|
305420|NCT01873170|Drug|etonogestrel exposure|
305421|NCT01873170|Device|IUD insertion|
305422|NCT01873170|Device|subdermal contraceptive implant insertion|
305423|NCT01873157|Drug|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
305424|NCT01873157|Drug|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.~Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
305425|NCT01873144|Drug|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
305426|NCT01873144|Drug|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
305427|NCT01873144|Device|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
305428|NCT01873144|Drug|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
305429|NCT01873131|Drug|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
305430|NCT01873131|Device|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
305431|NCT01873118|Other|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
305432|NCT01873118|Other|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
305487|NCT01872715|Drug|Oracea|
305433|NCT01873118|Other|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
305434|NCT01873105|Other|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
305435|NCT01873079|Drug|Esomeprazole|
305436|NCT01873079|Other|Standard care|No PPI or other study medication given
305437|NCT01873066|Device|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
305438|NCT01873066|Device|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
305439|NCT01873053|Drug|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
305440|NCT01873053|Drug|Placebo|
305441|NCT01873040|Behavioral|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
305442|NCT01873040|Behavioral|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
305443|NCT01873027|Device|OFDI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
305444|NCT01873027|Device|IVUS|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI~Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
305445|NCT01873014|Drug|chinese herbs-I|two agent per day, twice a day
305446|NCT01873014|Drug|chinese herbs-II|two agent per day, twice a day
305447|NCT01873001|Drug|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
305448|NCT01873001|Drug|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
305449|NCT01872988|Drug|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
305450|NCT01872988|Drug|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
305451|NCT01872975|Radiation|regional nodal XRT|
305452|NCT01872975|Radiation|chestwall XRT|
305453|NCT01872975|Radiation|WBI|
305454|NCT01872962|Drug|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
305455|NCT01872962|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
305456|NCT01872936|Drug|Miravirsen|
305457|NCT01872936|Drug|Telaprevir|
305458|NCT01872936|Drug|Ribavirin|
305459|NCT01872923|Drug|Amphinex|Photosensitiser
305460|NCT01872923|Drug|Bleomycin|Anticancer agent
305461|NCT01872923|Device|Laser|Laser that emits red light at 652 nm.
305462|NCT01872910|Drug|Placebo|Administered orally
305463|NCT01872910|Drug|LY3023703|Administered orally
305464|NCT01872910|Drug|Celecoxib|Administered orally
305465|NCT01872897|Drug|Sodium Alginate Double Action Tablets|Four tablets as a single dose
305466|NCT01872897|Drug|Placebo|4 tablets as a single dose
305467|NCT01872884|Drug|Sevorane Remifentanil|Sevorane Remifentanil
305468|NCT01872884|Drug|Remifentanil|Remifentanil
305469|NCT01872871|Drug|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
305470|NCT01872871|Drug|Topical anaesthetic drop with placebo|
305471|NCT01872858|Drug|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
305472|NCT01872858|Drug|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
305473|NCT01872845|Drug|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
305474|NCT01872845|Drug|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
305475|NCT01872832|Drug|RDEA3170 and Placebo|
305476|NCT01872819|Other|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
305477|NCT01872819|Drug|chemotherapy|Patients receive 1 of 160 possible interventions
305478|NCT01872819|Biological|biological therapy|Patients receive 1 of 160 possible interventions
305479|NCT01872806|Radiation|a dialing smartphone will be placed on the chest and the ear|
305480|NCT01872780|Drug|Rosiglitazone|single oral administration of 4mg of rosiglitazone
305481|NCT01872780|Genetic|CYP2C8 genotype|CYP2C8*11.
305482|NCT01872754|Drug|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
305483|NCT01872754|Drug|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
305484|NCT01872741|Procedure|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
305485|NCT01872741|Procedure|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
305486|NCT01872728|Drug|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
305488|NCT01872702|Drug|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
305489|NCT01872689|Drug|Lebrikizumab|Lebrikizumab will be administered at a dose of 250 mg via SC injection once every 4 weeks.
305490|NCT01872689|Drug|Pirfenidone|Pirfenidone will be administered orally at a stable dose of 2403 mg per day or at MTD.
305491|NCT01872689|Drug|Placebo|Placebo matched to lebrikizumab will be administered via SC injection once every 4 weeks.
305492|NCT01872676|Other|Spine manipulation|
305493|NCT01872676|Other|Manipulation sham|
305494|NCT01872663|Procedure|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
305495|NCT01872663|Procedure|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
305496|NCT01872663|Procedure|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
305497|NCT01872663|Procedure|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
305498|NCT01872663|Procedure|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
305499|NCT01872663|Procedure|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
305500|NCT01872650|Device|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
305501|NCT01872637|Behavioral|Progressive Multi-Component Intervention|
305502|NCT01872637|Behavioral|Usual Care|
305503|NCT01872624|Procedure|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
305504|NCT01872611|Drug|Nepafenac Ophthalmic Suspension, 0.3%|
305505|NCT01872611|Other|Vehicle|Inactive ingredients used as placebo comparator
305506|NCT01872611|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
305507|NCT01872598|Drug|Masitinib|
305508|NCT01872598|Drug|Placebo|
305509|NCT01872585|Behavioral|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
305510|NCT01872572|Drug|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
305511|NCT01872572|Drug|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
305512|NCT01872572|Drug|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
305513|NCT01872572|Drug|Subcutaneous RB006 2.0 mg|"Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration~Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
305514|NCT01872572|Drug|Placebo|Placebo
305515|NCT01872559|Other|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
305516|NCT01872546|Drug|HUMIRA 40mg|
305517|NCT01872533|Other|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at ~ 15% O2 (ca. 2400 m elevation).
305518|NCT01872507|Other|Biofeedback training|usual treatment +12 biofeedback training
305519|NCT01872494|Other|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
305520|NCT01872494|Other|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
305521|NCT01872494|Drug|0.33% ropivacaine 250ml|
305522|NCT01872494|Drug|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
305523|NCT01872481|Device|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
305524|NCT01872481|Device|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
305525|NCT01872468|Behavioral|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
305557|NCT01872117|Other|Microwave therapy|Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
305526|NCT01872455|Dietary Supplement|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
305527|NCT01872455|Dietary Supplement|Usual diet|Usual diet of the patients
305528|NCT01872442|Drug|Dasatinib|"Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes > 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
305529|NCT01872442|Drug|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
305530|NCT01872416|Device|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
305531|NCT01872403|Drug|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
305532|NCT01872390|Other|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
305533|NCT01872390|Other|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
305534|NCT01872377|Radiation|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
305535|NCT01872351|Drug|Nutraceuticals|
305536|NCT01872338|Behavioral|Mindfulness-Based Cognitive Therapy for Suicide|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
305537|NCT01872338|Behavioral|Treatment as usual|VA standard care for suicide prevention
305538|NCT01872325|Behavioral|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
305539|NCT01872312|Device|treatment with valves (The Spiration® IBV Valve System)|treat BPF
305540|NCT01872286|Device|AKE-1|
305541|NCT01872286|Device|Pillcam SB2|
305542|NCT01872273|Other|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
305543|NCT01872260|Drug|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
305544|NCT01872260|Drug|Letrozole|Letrozole 2.5 mg/day
305545|NCT01872260|Drug|BYL719|BYL719 - 28 days cycle (continuous) for Arm 2; 3 and 4
305546|NCT01872234|Device|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
305547|NCT01872221|Procedure|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
305548|NCT01872208|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration.
305549|NCT01872195|Other|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
305550|NCT01872182|Drug|ALS-L1023|daily twice for 12 weeks
305551|NCT01872182|Drug|placebo|daily twice for 12 weeks
305552|NCT01872169|Other|Disordered eating screening questionnaire|
305553|NCT01872156|Other|Intervention GESTABAC|"Intervention based on the Clinician`s Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
305554|NCT01872156|Other|Control Group|The group control will act according to usual management.
305555|NCT01872143|Device|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
305556|NCT01872117|Other|Shortwave therapy|Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
305558|NCT01872104|Procedure|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
305559|NCT01872091|Other|cryotherapy by immersion|
305560|NCT01872091|Other|Control group|
305561|NCT01872078|Drug|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
305562|NCT01872078|Drug|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
305563|NCT01872065|Drug|ARC-520|
305564|NCT01872065|Drug|Placebo|
305565|NCT01872052|Device|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
305566|NCT01872039|Drug|Perdipine injection|IV
305567|NCT01872026|Drug|ASP7991|oral
305568|NCT01872013|Drug|ASP7991|oral
305569|NCT01872013|Drug|Placebo|oral
305570|NCT01872000|Procedure|Cataract surgery|
305571|NCT01871987|Drug|FK949E|oral
305572|NCT01871974|Drug|FK949E|oral
305573|NCT01871961|Drug|Methotrexate (Metoject® prefilled pen)|
305574|NCT01871948|Other|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
305575|NCT01871935|Drug|Remifentanil|Anaesthesia with remifentanil/propofol.
305576|NCT01871935|Drug|Sufentanil|Anaesthesia with sufentanil/propofol
305577|NCT01871922|Drug|Placebo|Saline
305578|NCT01871922|Drug|Atropine|Atropine
305579|NCT01871896|Device|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
305580|NCT01871883|Procedure|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
305581|NCT01871883|Procedure|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
305582|NCT01871870|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
305583|NCT01871857|Drug|Hypertonic saline and epinephrine|
305584|NCT01871857|Drug|Normal saline and epinephrine|
305585|NCT01871844|Drug|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
305586|NCT01871844|Drug|octreotide 50 mcg tid|
305587|NCT01871844|Drug|Placebo|
305588|NCT01871831|Device|6 blood glucose monitoring systems for self-testing|
305589|NCT01871818|Behavioral|Combined program|Combined program with physiotherapy, endurance training and resistance training
305590|NCT01871818|Behavioral|Physiotherapy in private practice|Physiotherapy in private practice
305591|NCT01871805|Drug|Alectinib|Participants will receive alectinib as described in the arm descriptions.
305592|NCT01871792|Drug|Pitavastatin|
305593|NCT01871792|Drug|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
305594|NCT01871779|Other|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
305595|NCT01871779|Other|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
305596|NCT01871766|Drug|Vincristine|"Dosage and route of administration:~< 1 year of age=0.025 mg/kg intravenously (IV)~> 1 year and < 3 years= 0.05 mg/kg IV~≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants."
305597|NCT01871766|Drug|Dactinomycin|"Dosage and route of administration:~< 1 year=0.025 mg/kg IV push~≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
305598|NCT01871766|Drug|Cyclophosphamide|"Dosage and route of administration:~During VAC chemotherapy:~< 3 years of age = 40 mg/kg IV~≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.~During maintenance for intermediate-risk participants:~oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)"
305599|NCT01871766|Procedure|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
305600|NCT01871766|Procedure|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
305601|NCT01871766|Drug|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
305602|NCT01871766|Drug|Sorafenib|Dosage and route of administration: 90 mg/m^2/dose twice daily.
305647|NCT01871532|Drug|Gonal-f®|
305648|NCT01871519|Device|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
305603|NCT01871766|Drug|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.~High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
305604|NCT01871766|Procedure|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
305605|NCT01871766|Drug|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m^2 IV (maximum dose 100 mg/day) daily x 5.
305606|NCT01871766|Drug|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m^2/day IV x 5 Age <1 year: treat with 50% doses calculated on a m^2 basis.
305607|NCT01871766|Drug|Etoposide|"Dosage and Route of Administration:~Age >1 year 100 mg/m^2/day IV x 5 Age < 1 year treat with 50% doses calculated on a m^2 basis"
305608|NCT01871766|Drug|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m^2/day IV.
305609|NCT01871766|Drug|Doxorubicin|"Dosage and route of Administration:~Age ≥1 year, 37.5 mg/m^2 IV over 1 hour x 2 days Age <1 year, 18.75 mg/m^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
305610|NCT01871766|Drug|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m^2 IV over 15-30 minutes Age <1 year, 187l.5 mg/m^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
305611|NCT01871766|Drug|^1^1C-methionine|Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
305612|NCT01871753|Other|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
305613|NCT01871740|Drug|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
305614|NCT01871740|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
305615|NCT01871727|Drug|E7777 9 mcg/kg|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
305616|NCT01871701|Drug|Escitalopram|Escitalopram
305617|NCT01871701|Drug|Quetiapine|Quetiapine
305618|NCT01871701|Drug|Moxifloxacin|Moxifloxacin
305619|NCT01871701|Other|Placebo|Placebo
305620|NCT01871688|Behavioral|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
305621|NCT01871675|Drug|IPI-145|
305622|NCT01871675|Drug|Rituximab|
305623|NCT01871675|Drug|Bendamustine|
305624|NCT01871662|Drug|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
305625|NCT01871662|Drug|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
305626|NCT01871662|Drug|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
305627|NCT01871649|Drug|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
305628|NCT01871649|Drug|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
305629|NCT01871636|Procedure|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
305630|NCT01871636|Procedure|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
305631|NCT01871636|Device|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
305632|NCT01871623|Procedure|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
305633|NCT01871623|Procedure|One-piece Le Fort I Osteotomy|conventional approach
305634|NCT01871610|Drug|[18F]AV-45 PET amyloid binding imaging|
305635|NCT01871597|Device|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
305636|NCT01871584|Device|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
305637|NCT01871571|Biological|bevacizumab|Given IV
305638|NCT01871571|Drug|oxaliplatin|Given IV
305639|NCT01871571|Drug|leucovorin calcium|Given IV
305640|NCT01871571|Drug|fluorouracil|Given IV
305641|NCT01871571|Other|laboratory biomarker analysis|Correlative studies
305642|NCT01871558|Drug|Vildagliptin|50 mg b.i.d
305643|NCT01871558|Drug|Metformin|metformin is to be kept unchanged
305644|NCT01871558|Drug|sulfonylurea (SU)|
305645|NCT01871558|Drug|Basal Insulin|
305646|NCT01871545|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
305649|NCT01871506|Behavioral|Standard Care (SC)|"Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.~3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.~Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
305650|NCT01871506|Behavioral|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.~Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.~Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
305651|NCT01871493|Drug|LY2605541|Administered subcutaneous (SQ)
305652|NCT01871493|Drug|Insulin Lispro|Administered SQ
305653|NCT01871480|Drug|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
305654|NCT01871480|Drug|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
305655|NCT01871467|Drug|Sargramostim|
305656|NCT01871454|Radiation|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
305657|NCT01871454|Drug|Pentoxifylline|pentoxifylline
305658|NCT01871441|Radiation|Total-body irradiation|Undergo TBI
305659|NCT01871441|Biological|Donor lymphocytes infusion (DLI)|Undergo DLI
305660|NCT01871441|Drug|Cyclophosphamide|Given IV
305661|NCT01871441|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
305662|NCT01871441|Drug|Tacrolimus|Given IV
305663|NCT01871441|Drug|Mycophenolate mofetil|Given IV
305664|NCT01871428|Drug|aleglitazar|150 mcg orally daily
305665|NCT01871428|Drug|placebo|matching aleglitazar placebo orally daily
305666|NCT01871415|Drug|aleglitazar|150 mcg orally daily
305667|NCT01871415|Drug|metformin|pre-existing background regimen and dose
305668|NCT01871415|Drug|placebo|matching aleglitazar placebo orally daily
305669|NCT01871402|Drug|000-0551 Lotion|
305670|NCT01871402|Drug|Vehicle Lotion|
305671|NCT01871376|Drug|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
305672|NCT01871363|Radiation|chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.~capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),~bevacizumab: at dose 5 mg/kg on days -1, 15, 31.~Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
305673|NCT01871350|Dietary Supplement|Daily intake for 10 weeks (+/- 2 weeks)|
305674|NCT01871337|Behavioral|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
305675|NCT01871324|Behavioral|Lifestyle counseling|group therapy
305676|NCT01871311|Drug|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly~Three dose levels for nilotinib:~Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID~Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
305677|NCT01871298|Other|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
305678|NCT01871285|Drug|Buprenorphine|
305679|NCT01871285|Drug|Placebo film|Matching placebo buccal film
305680|NCT01871285|Drug|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
305681|NCT01871285|Drug|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
305682|NCT01871285|Drug|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
305683|NCT01871272|Procedure|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
305684|NCT01871233|Drug|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
305685|NCT01871220|Device|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
344426|NCT01568398|Drug|TAK-438|
305687|NCT01871181|Procedure|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
305688|NCT01871181|Procedure|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
305689|NCT01871168|Procedure|TAP block|Infusion of 0.5-1% lidocaine
305690|NCT01871168|Procedure|Sham TAP block|Infusion of saline
305691|NCT01871155|Dietary Supplement|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal~1 serving is considered as food supplement"
305692|NCT01871142|Drug|Placebo|100 mL
305693|NCT01871142|Drug|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
305694|NCT01871142|Drug|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
305695|NCT01871129|Drug|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
305696|NCT01871129|Other|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
305697|NCT01871116|Behavioral|POWER-remote|Web-based weight loss program.
305698|NCT01871116|Behavioral|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
305699|NCT01871103|Procedure|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
305700|NCT01871090|Device|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
305701|NCT01871077|Drug|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
305702|NCT01871064|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
305703|NCT01871025|Other|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
305704|NCT01871025|Other|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
305705|NCT01870999|Drug|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
305706|NCT01870999|Drug|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
305707|NCT01870986|Biological|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
305708|NCT01870986|Biological|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
305709|NCT01870986|Biological|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
305710|NCT01870973|Procedure|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
305711|NCT01870973|Procedure|no root canal treatment, anesthesia, pain medications, and antibiotic|
305712|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in left side|
305713|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in right side|
305714|NCT01870947|Behavioral|Exercise on stationary recumbent exercise cycle|
305715|NCT01870947|Behavioral|Health Education|"Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)"
305716|NCT01870947|Behavioral|Questionnaires|
305717|NCT01870947|Procedure|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
305718|NCT01870947|Procedure|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
305719|NCT01870934|Device|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
305720|NCT01870921|Drug|Ticagrelor|90mg/tablet, 1 tablet bid
305721|NCT01870908|Drug|tacrolimus|
305722|NCT01870908|Drug|biological agents|
305723|NCT01870895|Drug|YM060|oral
305724|NCT01870895|Drug|Placebo|oral
305725|NCT01870882|Behavioral|Attentional retraining|
305726|NCT01870882|Behavioral|Control condition|
305727|NCT01870856|Device|Spectacles|Per participant's habitual prescription
305728|NCT01870856|Device|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
305729|NCT01870856|Device|Etafilcon A contact lenses|Hydrogel single vision contact lenses
305730|NCT01870843|Drug|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
305731|NCT01870830|Other|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
305732|NCT01870817|Dietary Supplement|Home jejunostomy feeding|
305733|NCT01870804|Drug|Rosuvastatin|
305734|NCT01870804|Drug|Atorvastatin|
305735|NCT01870791|Drug|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
305736|NCT01870778|Drug|RLX030|1 mg/mL solution in 6 mL vials
305737|NCT01870778|Drug|Placebo|Matching placebo solution to serelaxin
305738|NCT01870765|Device|non-invasive ventilation|non-invasive ventilation via face mask
305739|NCT01870765|Device|high-flow oxygen|high-flow oxygen via nasal cannula
305740|NCT01870765|Procedure|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
305741|NCT01870752|Radiation|Chemotherapy|
305742|NCT01870739|Drug|sacubitril/valsartan (LCZ696)|200 mg tablets
305743|NCT01870739|Drug|olmesartan|
305744|NCT01870739|Other|placebo to sacubitril/valsartan (LCZ696)|placebo
305745|NCT01870739|Other|placebo to olmesartan|placebo
305746|NCT01870739|Drug|Amlodipine (Optional)|If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
305747|NCT01870726|Drug|INC280|"Phase Ib: INC280 was given at the starting dose of 200mg capsules twice daily with escalation to higher strengths.~Phase II: INC280 was given at the dose of 400mg (tablets) twice daily."
305748|NCT01870726|Drug|Buparlisib|Buparlisib was given at the starting dose of 50mg once daily with escalation to higher strengths.
305749|NCT01870700|Drug|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
305750|NCT01870700|Drug|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
305751|NCT01870687|Drug|20mg VAC BNO 1095 FCT|
305752|NCT01870687|Drug|Placebo|
305753|NCT01870674|Drug|YH12852|
305754|NCT01870674|Drug|Prucalopride|
305755|NCT01870674|Drug|Placebo|
305756|NCT01870661|Device|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
305757|NCT01870661|Device|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
305758|NCT01870648|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
305759|NCT01870648|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
305760|NCT01870635|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
305761|NCT01870635|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
305762|NCT01870622|Procedure|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
305763|NCT01870622|Procedure|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
305764|NCT01870609|Drug|defactinib (VS-6063)|
305765|NCT01870609|Drug|Placebo|Sugar pill manufactured to mimic defactinib tablet
305766|NCT01870596|Drug|Cytarabine|Given IV
305767|NCT01870596|Drug|CHK1 Inhibitor SCH 900776|Given IV
305768|NCT01870596|Other|Laboratory Biomarker Analysis|Correlative studies
305769|NCT01870583|Drug|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
305770|NCT01870583|Drug|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
305771|NCT01870583|Drug|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
305772|NCT01870570|Other|Reference Glucose|
305773|NCT01870570|Other|Food Product A: Corn Flakes|
305774|NCT01870570|Other|Food Product B: Ginger Bread|
305775|NCT01870570|Other|Food Product C:Sandwiched Breakfast Biscuit|
305776|NCT01870570|Other|Food Product D: Crackers Nature|
305777|NCT01870570|Other|Food Product E: Breakfast Biscuit|
305778|NCT01870570|Other|Food Product F: White Bread|
305779|NCT01870544|Dietary Supplement|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
305780|NCT01870544|Dietary Supplement|Placebo|placebo will be administered daily for 44 days
305781|NCT01870518|Device|Bilateral GPi DBS|
305782|NCT01870518|Device|Bilateral STN DBS|
305783|NCT01870505|Drug|BYL719|
305784|NCT01870505|Drug|Letrozole|
305785|NCT01870505|Drug|Exemestane|
305786|NCT01870492|Drug|Activase|Patients treated with Activase
305787|NCT01870492|Device|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
305788|NCT01870479|Other|Live music|
305789|NCT01870479|Other|Taped music|
305790|NCT01870466|Drug|Cilostazol|cilostazol bid for 7 days
305791|NCT01870466|Drug|Simvastatin|simvastatin qd for 7 days
305792|NCT01870466|Drug|Rosuvastatin|rosuvastatin qd for 7 days
305793|NCT01870440|Drug|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
305794|NCT01870427|Drug|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
305795|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm
305796|NCT01870401|Device|Lutonix DCB|
305797|NCT01870401|Device|Uncoated PTA Catheter|
305798|NCT01870388|Drug|Baricitinib|Administered orally
305799|NCT01870362|Drug|Probiotic (Inersan)|
305800|NCT01870362|Drug|Placebo|
305801|NCT01870349|Procedure|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
305802|NCT01870336|Device|Combined treatment of medial knee osteoarthritis|
305803|NCT01870323|Behavioral|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
305804|NCT01870323|Behavioral|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
305806|NCT01870297|Drug|LY3025876|Administered SQ
305807|NCT01870297|Drug|Placebo|Administered SQ
305808|NCT01870297|Drug|Liraglutide|Administered SQ
305809|NCT01870284|Drug|Ixekizumab|Administered SC
305810|NCT01870284|Drug|Placebo|Administered SC
305811|NCT01870284|Drug|Adalimumab|Administered SC
305812|NCT01870271|Behavioral|Developmentally adapted cognitive processing therapy|
305813|NCT01870258|Other|ANN prediction of myocardial infarction|
305814|NCT01870245|Drug|ACHN-975|Intravenous multiple dose
305815|NCT01870245|Drug|placebo|Intravenous multiple dose
305816|NCT01870232|Procedure|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
305817|NCT01870219|Drug|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
305818|NCT01870219|Drug|Ketamine|ketamine was given to 1mg/kg ıv bolus
305819|NCT01870206|Biological|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
305820|NCT01870206|Biological|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
305821|NCT01870193|Dietary Supplement|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks~The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
305822|NCT01870180|Device|EyeBag|fabric bag of beads which can be heated in a microwave
305823|NCT01870180|Other|Placebo|
305824|NCT01870167|Drug|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
305825|NCT01870167|Dietary Supplement|Placebo|Placebo
305826|NCT01870154|Behavioral|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
305827|NCT01870141|Behavioral|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:~self-monitoring~problem solving~goal definition~cognitive restructuring~activation of personal and social resources"
305828|NCT01870128|Drug|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
305829|NCT01870128|Drug|Methotrexate|Methotrexate 15 to 25 mg PO per week
305830|NCT01870128|Drug|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
305831|NCT01870115|Dietary Supplement|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
305832|NCT01870115|Dietary Supplement|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
305833|NCT01870102|Drug|Pelubiprofen IR (Pelubiprofen 30mg) TID|
305834|NCT01870102|Drug|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
305835|NCT01870089|Device|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
305836|NCT01870076|Behavioral|Healing Touch|
305837|NCT01870076|Behavioral|Healing Touch, Sham|
305838|NCT01870076|Behavioral|Control, Presence|
305839|NCT01870050|Drug|Dapsone gel - verum|
305840|NCT01870037|Drug|Placebo (PBS-20% sucrose)|
305841|NCT01870037|Drug|hMaxi-K|Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
305842|NCT01870024|Drug|Clonazepam|clonazepam 0,015 mg/kg
305843|NCT01870024|Drug|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
305844|NCT01870024|Drug|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
305845|NCT01870024|Drug|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
305846|NCT01870011|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
305847|NCT01870011|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
305848|NCT01869985|Drug|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
305849|NCT01869959|Drug|LY2405319|Administered SC
305850|NCT01869959|Drug|Placebo|Administered SC
305851|NCT01869946|Drug|Ropivacaine|
305852|NCT01869933|Drug|OC-10X|
305853|NCT01869920|Behavioral|Intervention group|Education on breastfeeding
305854|NCT01869920|Behavioral|Usual care|Usual care
305855|NCT01869907|Drug|Minocycline|100 mg once daily by mouth during 14 days
305856|NCT01869907|Drug|placebo|once daily by mouth during 14 days
305857|NCT01869907|Drug|Amitriptyline|25mg once daily by mouth during 14 days
305858|NCT01869894|Procedure|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
305859|NCT01869894|Procedure|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
305860|NCT01869894|Procedure|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
305861|NCT01869881|Drug|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
305862|NCT01869881|Drug|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
305863|NCT01869855|Procedure|Subdural Drainage|
305864|NCT01869855|Procedure|Subperiosteal Drainage|
305865|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
305866|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
305867|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
305868|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
305869|NCT01869829|Drug|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:~fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin~All agents are given as standard of care."
305870|NCT01869803|Drug|gemtuzumab ozogamicin|Given IV
305871|NCT01869803|Other|laboratory biomarker analysis|Correlative studies
305872|NCT01869790|Other|Different fat types|Saturated, monounsaturated fats
305873|NCT01869777|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
305874|NCT01869764|Drug|omega-3 fatty acid|Given PO
305875|NCT01869764|Other|placebo|Given PO
305876|NCT01869764|Other|laboratory biomarker analysis|Correlative studies
305877|NCT01869751|Drug|Prucalopride|Treatment with prucalopride for slow-transit constipation
305878|NCT01869738|Device|MGuard Prime|
305879|NCT01869738|Device|(BMS/DES)|
305880|NCT01869725|Radiation|gallium Ga 68-edotreotide|Given IV
305881|NCT01869725|Procedure|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
305882|NCT01869725|Radiation|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
305883|NCT01869725|Procedure|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
305884|NCT01869725|Procedure|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
305885|NCT01869712|Other|Cupping therapy|
305886|NCT01869712|Other|Acupuncture|
305887|NCT01869699|Drug|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
305888|NCT01869699|Drug|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
305889|NCT01869686|Biological|Denosumab|60 mg
305890|NCT01869673|Device|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
305891|NCT01869673|Device|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
305892|NCT01869660|Behavioral|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
305893|NCT01869647|Radiation|Ultra low dose CT scan|Ultra low dose CT scan
305894|NCT01869647|Radiation|Regular CT or Low Dose CT scan|Regular CT or Low Dose CT scan
305895|NCT01869647|Radiation|No imaging|No imaging
305896|NCT01869634|Drug|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
305897|NCT01869621|Drug|Metformin|6 days treatment with metformin to steady-state
305898|NCT01869608|Procedure|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
305899|NCT01869582|Device|Fetoscope, Fetal heart rate|
305900|NCT01869582|Device|Upright Resuscitator, Resuscitation|
305901|NCT01869582|Device|Doppler, Fetal heart rate|
305902|NCT01869582|Device|Standard Resuscitator, Resuscitation|
305903|NCT01869569|Drug|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
305904|NCT01869569|Drug|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
305905|NCT01869556|Drug|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
305906|NCT01869556|Drug|Ergot|Ergot 0.25mg IV
305907|NCT01869556|Drug|Carboprost|Carboprost 0.25mg IM
306297|NCT01866540|Drug|FLUENZ|live attenuated influenza vaccine
305908|NCT01869543|Other|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
305909|NCT01869543|Other|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
305910|NCT01869517|Other|intrastromal corneal ring segments (Keraring) implantation|
305911|NCT01869517|Other|Intrastromal corneal continuous ring (Myoring) implantation|
305912|NCT01869504|Device|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
305913|NCT01869491|Drug|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
305914|NCT01869491|Drug|Matching placebo tablets|2 tablets four times daily
305915|NCT01869478|Drug|Intravenous Thrombolysis|
305916|NCT01869478|Device|Endovascular Arterial Reperfusion|
305917|NCT01869465|Other|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
305918|NCT01869465|Behavioral|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
305919|NCT01869452|Behavioral|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
305920|NCT01869439|Device|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
305921|NCT01869439|Device|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
305922|NCT01869439|Device|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
305923|NCT01869439|Device|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradient), mean, and the mode of the thermal wound bed can be measured.
305924|NCT01869426|Dietary Supplement|VSL#3 drops|
305925|NCT01869426|Dietary Supplement|VSL#3 drops placebo|
305926|NCT01869413|Drug|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
305927|NCT01869413|Drug|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
305928|NCT01869387|Device|Non-invasive ventilation|
305929|NCT01869374|Device|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
305930|NCT01869374|Biological|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
305931|NCT01869361|Drug|Indomethacin|Study drug
305932|NCT01869361|Drug|Placebo|Control drug
305933|NCT01869348|Behavioral|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
305934|NCT01869335|Device|radiography|
305935|NCT01869335|Device|MRI (magnetic resonance imaging)|
305936|NCT01869322|Device|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
305937|NCT01869322|Device|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
305938|NCT01869309|Drug|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
305939|NCT01869309|Drug|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
305940|NCT01869296|Procedure|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
305941|NCT01869296|Procedure|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
305942|NCT01869283|Other|Kinesiotherapy|
305943|NCT01869283|Other|Ultrasound|
305944|NCT01869283|Other|Diadynamic currents|
305945|NCT01869257|Device|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
306646|NCT01863823|Drug|Mouth washing|Two time washing mouth per day
305946|NCT01869257|Device|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
305947|NCT01869231|Dietary Supplement|olive oil|
305948|NCT01869231|Dietary Supplement|olive oil and chewing gum|
305949|NCT01869231|Dietary Supplement|chewing gum|
305950|NCT01869231|Dietary Supplement|water|
305951|NCT01869205|Device|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
305952|NCT01869192|Drug|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
305953|NCT01869192|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
305954|NCT01869192|Drug|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
305955|NCT01869192|Drug|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
305956|NCT01869192|Radiation|Radiation Therapy|Standard dosing, fields depending on clinical findings
305957|NCT01869179|Behavioral|Choir program|Attend weekly choir sessions for 12 months at the Senior Center. Choir sessions will last about 90 minutes each with a 20 minute break. Take part in 3 informal choir concerts.
305958|NCT01869166|Biological|CART-EGFR|
305959|NCT01869140|Device|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
305960|NCT01869127|Device|Shoes|A unisex canvas slip-on with a sturdy sole.
305961|NCT01869114|Drug|Sirolimus|Given PO
305962|NCT01869114|Drug|Azacitidine|Given IV
305963|NCT01869088|Drug|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery
305964|NCT01869088|Procedure|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
305965|NCT01869075|Other|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
305966|NCT01869062|Device|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
305967|NCT01869062|Device|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
305968|NCT01869036|Drug|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
305969|NCT01869036|Drug|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
305970|NCT01869023|Drug|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
305971|NCT01869023|Drug|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
305972|NCT01869010|Other|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
305973|NCT01868997|Drug|teprotumumab|
305974|NCT01868997|Drug|normal saline|
305975|NCT01868984|Drug|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
305976|NCT01868984|Procedure|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
305977|NCT01868971|Device|EndoRings|Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician`s evaluation
305978|NCT01868945|Dietary Supplement|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
305979|NCT01868945|Dietary Supplement|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
305980|NCT01868945|Dietary Supplement|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
305981|NCT01868945|Dietary Supplement|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
305982|NCT01868932|Other|hypertonic saline|inhaled nebulized 3%NaCl
305983|NCT01868932|Other|saline|inhaled nebulized 0.9% NaCl
305984|NCT01868919|Behavioral|Positive Parenting Program|Level 3 or 4 of Triple P
305985|NCT01868906|Drug|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
305986|NCT01868906|Procedure|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
305987|NCT01868906|Device|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
305988|NCT01868906|Procedure|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
305989|NCT01868906|Radiation|Radiotherapy|Standard radiation therapy
305990|NCT01868906|Drug|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
305991|NCT01868893|Drug|Obinutuzumab|
305992|NCT01868893|Drug|Chlorambucil|
344427|NCT01568385|Drug|TAK-438|
305993|NCT01868880|Drug|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
305994|NCT01868880|Drug|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
305995|NCT01868867|Behavioral|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
305996|NCT01868841|Drug|AdreView|10 millicurie of AdreView (123I-mIBG)
305997|NCT01868841|Other|Single Photon Emission Computed Tomography|
305998|NCT01868828|Drug|PAD|Induction Therapy of PAD for 4 cycles.
305999|NCT01868828|Drug|VCD|Induction Therapy of VCD for 4 cycles.
306000|NCT01868828|Other|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
306001|NCT01868802|Drug|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
306002|NCT01868802|Drug|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
306003|NCT01868789|Radiation|Weightbearing CT|
306004|NCT01868776|Drug|buffered lidocaine|
306005|NCT01868776|Drug|nonbuffered lidocaine|
306006|NCT01868763|Device|telemedical devices (weighing machine and step counter)|
306007|NCT01868763|Behavioral|care calls once per week for 12 weeks|
306008|NCT01868750|Dietary Supplement|Calcitriol|1.0ug twice daily for 7 days before surgery
306009|NCT01868750|Dietary Supplement|Control Pill|placebo pill taken twice daily for 7 days before surgery
306010|NCT01868737|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
306011|NCT01868737|Dietary Supplement|Placebo|MCT oil
306012|NCT01868711|Behavioral|Cognitive Behavior Therapy|"Fourteen sessions of cognitive behavior therapy for depression. The patient will be psycho educated about symptoms of depression. The patient will learn to use the following basic cognitive-behavioral techniques for the treatment of depression:~Constructing an 'Action Schedule', setting goals, doing 'Behavioral Experiments', and constructing a thought record, checking accuracy of thoughts, re framing thoughts when necessary and learn to engage in problem solving for particular situations."
306013|NCT01868698|Other|high-voltage electrical stimulation|
306014|NCT01868698|Other|Kinesiotherapy|
306015|NCT01868698|Other|shortwave diathermy|
306016|NCT01868685|Drug|BYM338|BYM338
306017|NCT01868685|Drug|Placebo|Placebo
306018|NCT01868672|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
306019|NCT01868659|Behavioral|Diagnostic checklist|Diagnostic checklist used before patient discharged
306020|NCT01868659|Behavioral|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
306021|NCT01868646|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type II diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
306022|NCT01868646|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type II diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
306023|NCT01868633|Drug|Dexamethasone|
306024|NCT01868633|Drug|Placebo|
306025|NCT01868620|Device|Iontophoretic CXL|
306026|NCT01868620|Device|Standard CXL|
306027|NCT01868594|Drug|Subetta|"Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
306028|NCT01868594|Drug|Placebo|"Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime)."
306029|NCT01868581|Drug|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
306030|NCT01868581|Drug|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
306031|NCT01868568|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin).
306032|NCT01868568|Drug|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
306033|NCT01868568|Drug|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
306034|NCT01868568|Drug|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
306035|NCT01868568|Drug|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
306036|NCT01868568|Drug|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
306037|NCT01868568|Drug|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
306038|NCT01868568|Drug|placebo|A single dose administered subcutaneously (s.c., under the skin).
306039|NCT01868555|Drug|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
306040|NCT01868555|Drug|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
306041|NCT01868555|Drug|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
306042|NCT01868555|Drug|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
306043|NCT01868542|Drug|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
306044|NCT01868529|Drug|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
306045|NCT01868529|Drug|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
306046|NCT01868516|Drug|dexmecamylamine|
306047|NCT01868516|Drug|Placebo|
306048|NCT01868503|Drug|lapatinib ditosylate|Given PO
306049|NCT01868503|Radiation|radiation therapy|Undergo radiation therapy
306050|NCT01868503|Other|laboratory biomarker analysis|Correlative studies
306051|NCT01868490|Drug|cytokine induced killer cells|at least 10*9 CIK cells, IV on day 0, 14, 28
306052|NCT01868477|Drug|Deferasirox DFX, DT|provided as dispersible tablets for oral use in 125 and 250, 500 mg
306053|NCT01868477|Drug|Erythropoietin alpha|
306054|NCT01868477|Drug|Deferasirox DFX, FCT|provided as film-coated tablet for oral use in 90, 180, 360 mg strengths
306055|NCT01868464|Biological|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10^6 cfu, 4x10^6 cfu, 8x10^6 cfu and 16x10^6 cfu, respectively.
306056|NCT01868451|Drug|Brentuximab vedotin (SGN-35)|
306057|NCT01868451|Drug|Doxorubicin HCL|
306058|NCT01868451|Drug|Vinblastine Sulfate|
306059|NCT01868451|Drug|Dacarbazine|
306060|NCT01868451|Radiation|Involved-Site Radiation Therapy (ISRT)|
306061|NCT01868451|Procedure|Interim PET|
306062|NCT01868451|Radiation|consolidation volume RT (CVRT)|
306063|NCT01868438|Drug|pyronaridine-artesunate granules|
306064|NCT01868438|Drug|Pyronaridine-artesunate tablets|
306065|NCT01868425|Drug|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane
306066|NCT01868425|Drug|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane plus placebos of intervention arm meds
306067|NCT01868412|Device|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
306068|NCT01868412|Device|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
306069|NCT01868386|Radiation|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
306070|NCT01868373|Biological|Microbiota Transplantation (FMT)|Active therapy
306071|NCT01868360|Drug|Subconjunctival aflibercept|subconjunctival aflibercept injection
306072|NCT01868360|Other|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
306073|NCT01868347|Other|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
306074|NCT01868347|Other|control|PEEP after pneumoperitoneum and trendelenburg
306075|NCT01868334|Behavioral|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
306076|NCT01868334|Behavioral|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
306077|NCT01868334|Behavioral|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
306078|NCT01868334|Behavioral|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
306079|NCT01868295|Behavioral|Sleeping with denture|Sleeping with denture at night
306118|NCT01867996|Drug|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
306161|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
306162|NCT01867671|Biological|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
306080|NCT01868282|Procedure|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
306081|NCT01868282|Procedure|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
306082|NCT01868282|Procedure|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
306083|NCT01868269|Drug|Dexamethasone acetate|"First step:~immunosuppressive treatment with dexamethasone"
306084|NCT01868269|Drug|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
306085|NCT01868269|Drug|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
306086|NCT01868256|Other|early discharge (<72 h)|
306087|NCT01868256|Other|Conventional discharge|
306088|NCT01868243|Drug|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
306089|NCT01868243|Drug|Warfarin|Warfarin adjusted-dose
306090|NCT01868230|Behavioral|Lifestyle Intervention|
306091|NCT01868191|Drug|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
306092|NCT01868191|Drug|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
306093|NCT01868178|Device|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
306094|NCT01868139|Device|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
306095|NCT01868126|Drug|DE-117 ophthalmic solution|
306096|NCT01868126|Drug|latanoprost ophthalmic solution|
306097|NCT01868126|Other|Placebo|
306098|NCT01868113|Drug|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
306099|NCT01868113|Other|Placebo|Placebo to be administered 12hourly
306100|NCT01868100|Other|self-completion questionnaire|
306101|NCT01868087|Dietary Supplement|Boost Plus®|
306102|NCT01868087|Dietary Supplement|Impact Advanced Recovery®|
306103|NCT01868074|Device|Insole|Custom-molded arch-supporting insole
306104|NCT01868061|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
306105|NCT01868061|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
306106|NCT01868048|Drug|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.~Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
306107|NCT01868048|Drug|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
306108|NCT01868035|Drug|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:~Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
306109|NCT01868022|Drug|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
306110|NCT01868022|Drug|paclitaxel|paclitaxel will be from commercial stock.
306111|NCT01868022|Drug|carboplatin|carboplatin will be from commercial stock.
306112|NCT01868022|Drug|docetaxel|docetaxel will be from commercial stock.
306113|NCT01868022|Drug|pemetrexed|pemetrexed will be from commercial stock
306114|NCT01868022|Drug|cisplatin|cisplatin will be from commercial stock
306115|NCT01868009|Device|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
306116|NCT01868009|Device|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
306117|NCT01867996|Drug|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
306119|NCT01867983|Behavioral|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:~Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
306120|NCT01867983|Behavioral|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
306121|NCT01867970|Device|Tool|"The It's LiFe! tool consists of three different elements:~the 3D accelerometer (Figure 7-8);~the application (app) on a Samsung Smartphone (Figure 6);~a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
306122|NCT01867970|Behavioral|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
306123|NCT01867957|Biological|Low-dose GC1109|50ug/dose
306124|NCT01867957|Biological|High-dose GC1109|100ug/dose
306125|NCT01867957|Biological|Low-dose Placebo|0.9% Saline 0.5 mL
306126|NCT01867957|Biological|High-dose Placebo|0.9% Saline 1.0 mL
306127|NCT01867944|Behavioral|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
306128|NCT01867944|Behavioral|Educational Control|Education on conventional treatment options for chronic constipation.
306129|NCT01867918|Procedure|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
306130|NCT01867918|Drug|Standard Chemotherapy|
306131|NCT01867892|Drug|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
306132|NCT01867892|Drug|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
306133|NCT01867879|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
306134|NCT01867879|Drug|Placebo|Placebo tablets, orally, single dose.
306135|NCT01867866|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
306136|NCT01867866|Drug|Trifluridine|35 mg/m2, orally, single dose
306137|NCT01867853|Device|PLR|passive leg raising test was done before and at the end of SBT
306138|NCT01867827|Other|Neurofeedback and Physical Exercise|
306139|NCT01867827|Other|Physical Exercise|
306140|NCT01867814|Procedure|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
306141|NCT01867775|Drug|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
306142|NCT01867762|Drug|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
306143|NCT01867762|Drug|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
306144|NCT01867749|Behavioral|Group Interpersonal Psychotherapy (IPT-G)|
306145|NCT01867749|Behavioral|Coping with Depression (CWD)|
306146|NCT01867736|Device|Passeo-18 Lux DRB|
306147|NCT01867736|Device|Standard PTA (POBA)|
306148|NCT01867723|Other|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
306149|NCT01867710|Drug|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
306150|NCT01867710|Drug|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
306151|NCT01867710|Drug|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
306152|NCT01867710|Drug|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
306153|NCT01867710|Drug|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
306154|NCT01867697|Drug|Cetuximab|
306155|NCT01867697|Drug|Irinotecan|
306156|NCT01867697|Drug|Oxaliplatin|
306157|NCT01867697|Drug|Folinic Acid|
306158|NCT01867697|Drug|Calcium Carbonate|
306159|NCT01867684|Other|Psychotherapy|
306160|NCT01867671|Biological|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
366013|NCT01404351|Device|PEAK PlasmaBlade|
306163|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
306164|NCT01867658|Device|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
306165|NCT01867645|Drug|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
306166|NCT01867645|Drug|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
306167|NCT01867632|Device|Acellular Dermal Matrix|
306168|NCT01867606|Biological|serum-derived bovine immunoglobulin protein isolate|Given PO
306169|NCT01867606|Other|placebo|Given PO
306170|NCT01867606|Other|laboratory biomarker analysis|Correlative studies
306171|NCT01867606|Other|quality-of-life assessment|Ancillary studies
306172|NCT01867606|Other|questionnaire administration|Ancillary studies
306173|NCT01867593|Device|C-11 methionine PET|
306174|NCT01867580|Device|V.A.C.Ulta with Prontosan instillation|NPWT with instillation of a wound cleanser (Prontosan® Wound Irrigation Solution)
306175|NCT01867580|Device|V.A.C.Ulta without instillation|NPWT only
306176|NCT01867567|Procedure|abdominal bandage|
306177|NCT01867554|Genetic|gene analysis|gene analysis
306178|NCT01867528|Procedure|Laparoscopic adhesiolysis|
306179|NCT01867528|Procedure|Open adhesiolysis|
306180|NCT01867515|Other|Acoustic distortion of speech|
306181|NCT01867502|Drug|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.~For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
306182|NCT01867502|Drug|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.~For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
306183|NCT01867489|Other|No intervention|
306184|NCT01867476|Other|Automated Adherence Monitoring System|
306185|NCT01867463|Biological|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
306186|NCT01867463|Biological|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
306187|NCT01867463|Biological|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
306188|NCT01867437|Drug|Placebo|Sterile solution (vehicle) for subcutaneous infusion
306189|NCT01867437|Drug|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
306190|NCT01867424|Drug|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
306191|NCT01867333|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
306192|NCT01867333|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
306193|NCT01867333|Biological|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
306194|NCT01867320|Drug|Raltegravir|
306195|NCT01867307|Drug|Empagliflozin|
306196|NCT01867307|Drug|BI 10773|open label
306197|NCT01867294|Drug|Doxycycline|Given PO
306198|NCT01867294|Procedure|Management of Therapy Complications|Moisturizer given topically
306199|NCT01867294|Other|Placebo|Given topically
306200|NCT01867294|Other|Questionnaire Administration|Ancillary studies
306201|NCT01867294|Drug|Spironolactone|Given topically
306202|NCT01867294|Drug|Sunscreen|Given topically
306203|NCT01867294|Drug|Therapeutic Hydrocortisone|Given topically
306204|NCT01867281|Drug|aspirin|
306205|NCT01867268|Drug|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
306206|NCT01867268|Other|prone positioning|prone positioning the patient for 10 days following the surgery
306207|NCT01867268|Other|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
306208|NCT01867255|Drug|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
306209|NCT01867242|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
306210|NCT01867242|Other|Snus|Winterchill or Robust flavors
306211|NCT01867229|Other|observational|standard of care fore patients with non metastatic breast cancer
306212|NCT01867216|Drug|Placebo|Administered orally as capsules
306213|NCT01867216|Drug|LY2922470|Administered orally as capsules
306214|NCT01867203|Other|Genotyping|DNA extraction from blood
368748|NCT01382017|Drug|Placebo|Placebo
306215|NCT01867190|Biological|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
306216|NCT01867177|Other|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
306217|NCT01867177|Other|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
306218|NCT01867177|Behavioral|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
306219|NCT01867164|Drug|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
306220|NCT01867164|Drug|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
306221|NCT01867151|Dietary Supplement|Gluten Free Diet|
306222|NCT01867151|Dietary Supplement|Normal Diet|
306223|NCT01867138|Drug|Cefazolin|
306224|NCT01867138|Drug|Vancomycin|
306225|NCT01867138|Drug|Amikacin|
306226|NCT01867125|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
306227|NCT01867125|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
306228|NCT01867112|Behavioral|Physical Activity|Physical activity either by individualized program or general guidelines
306229|NCT01867086|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
306230|NCT01867086|Drug|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
306231|NCT01867086|Drug|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
306232|NCT01867073|Other|Biomarker|
306233|NCT01867060|Device|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
306234|NCT01867060|Device|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
306235|NCT01867047|Drug|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
306236|NCT01867047|Drug|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:~benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
306237|NCT01867034|Other|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
306238|NCT01867034|Other|Bare Metal Stent|
306239|NCT01867021|Biological|Fluvirin(TIVf)|
306240|NCT01867021|Biological|Agriflu (TIV)|
306241|NCT01866995|Drug|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
306242|NCT01866995|Other|standard prostatostasis therapy|
306243|NCT01866982|Procedure|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
306244|NCT01866982|Procedure|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
306245|NCT01866969|Other|questionnaire administration|Ancillary studies
306246|NCT01866969|Procedure|quality-of-life assessment|Ancillary studies
306295|NCT01866553|Drug|Nilotinib|300 mg capsule BID oral use
306296|NCT01866553|Drug|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
306247|NCT01866943|Drug|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
306248|NCT01866943|Drug|Normal Saline Solution|
306249|NCT01866930|Biological|Pegylated Interferon Lambda-1a|
306250|NCT01866930|Drug|Daclatasvir (DCV)|
306251|NCT01866930|Drug|Ribasphere (RBV)|
306252|NCT01866917|Drug|Ropivacaine 0.5% 20cc injectate bilaterally|
306253|NCT01866891|Other|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
306254|NCT01866878|Device|equipment rehabilitation stereognosis|
306255|NCT01866878|Device|TENS|
306256|NCT01866839|Device|Graft Manipulation (CD34+ Selection)|
306257|NCT01866826|Drug|Rifaximin/ Placebo|subject will receive either three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily) or will receive three capsules of placebo by mouth twice daily.
306258|NCT01866813|Behavioral|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
306259|NCT01866800|Device|Renal Guard|Renal Guard
306260|NCT01866800|Drug|Conventional Treatment|Saline and N-acetylcysteine
306261|NCT01866774|Other|Fecal calprotectin level|
306262|NCT01866761|Procedure|Periodontal treatment|
306263|NCT01866748|Drug|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
306264|NCT01866748|Drug|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
306265|NCT01866748|Drug|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
306266|NCT01866748|Drug|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
306267|NCT01866735|Other|Standardized Rehabilitation Therapy|
306268|NCT01866722|Behavioral|Usual care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
306269|NCT01866722|Behavioral|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
306270|NCT01866722|Behavioral|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
306271|NCT01866709|Drug|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
306272|NCT01866709|Drug|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
306273|NCT01866696|Device|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:~Clinical examination~Radiological examination~Guided oral implants insertion~Immediate Prosthetic loading~Follow-up"
306274|NCT01866683|Behavioral|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
306275|NCT01866683|Behavioral|1 month waiting period|waiting or detraining period
306276|NCT01866670|Behavioral|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
306277|NCT01866670|Behavioral|relaxation therapy|Relaxation Therapy: deep breathing
306278|NCT01866657|Drug|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
306279|NCT01866657|Other|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
306280|NCT01866657|Other|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
306281|NCT01866657|Other|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
306282|NCT01866657|Drug|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
306283|NCT01866657|Biological|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
306284|NCT01866657|Drug|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
306285|NCT01866644|Drug|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
306286|NCT01866644|Drug|Saline|Bath saline transplanted liver
306287|NCT01866605|Drug|Midazolam|Intravenous midazolam 0.3 mg/kg
306288|NCT01866605|Drug|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
306289|NCT01866605|Device|Bair Hugger|Forced air warming
306290|NCT01866592|Drug|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
306291|NCT01866566|Biological|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
306292|NCT01866566|Biological|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
306293|NCT01866566|Biological|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
306294|NCT01866566|Biological|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
306298|NCT01866514|Procedure|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
306299|NCT01866514|Drug|2% preservative-free lidocaine|
306300|NCT01866514|Device|EZ-IO|
306301|NCT01866501|Procedure|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
306302|NCT01866501|Device|EZ-IO|
306303|NCT01866488|Drug|Misoprostol|
306304|NCT01866488|Other|Placebo|
306305|NCT01866475|Device|EZ-IO|To have an EZ-IO placed up to 48 hours
306306|NCT01866462|Other|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
306307|NCT01866449|Drug|Cabazitaxel|
306308|NCT01866436|Other|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
306309|NCT01866436|Other|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
306310|NCT01866423|Drug|orteronel|Given PO
306311|NCT01866423|Other|laboratory biomarker analysis|Correlative studies
306312|NCT01866410|Drug|Cabozantinib S-malate|Given PO
306313|NCT01866410|Drug|Erlotinib Hydrochloride|Given PO
306314|NCT01866410|Other|Laboratory Biomarker Analysis|Correlative studies
306315|NCT01866397|Other|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
306316|NCT01866384|Procedure|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
306317|NCT01866384|Other|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
306318|NCT01866371|Procedure|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
306319|NCT01866358|Procedure|Intraosseous infusion|Using intraosseous infusion for resustation in this group
306320|NCT01866358|Procedure|Umbilical vein infusion|Using umbilical vein infusion for resustation in this group
306321|NCT01866345|Procedure|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
306322|NCT01866345|Procedure|Conventional orthodontic treatment|Conventional orthodontic Procedure
306323|NCT01866332|Other|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
306324|NCT01866332|Device|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
306325|NCT01866319|Biological|Pembrolizumab|With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.
306326|NCT01866319|Biological|Ipilimumab|No change with Amendment 05.
306327|NCT01866306|Biological|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
306328|NCT01866306|Drug|LABA|Asthmatic participants were treated with LABA as part of their standard of care
306329|NCT01866293|Drug|Cabozantinib (XL184)|
306330|NCT01866280|Behavioral|Normal sleep|Normal sleep= sleep 2300-0700
306331|NCT01866280|Behavioral|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
306332|NCT01866280|Behavioral|Late sleep|Late sleep=sleep at 0230-1030 hours
306333|NCT01866280|Behavioral|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
306334|NCT01866267|Drug|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
306335|NCT01866254|Drug|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
306336|NCT01866254|Drug|Morphine|Injection of 200 mcg of intrathecal morphine
306337|NCT01866241|Drug|Misoprostol|Is a prostaglandin
306338|NCT01866228|Other|Consultation Recording|
306339|NCT01866215|Other|exercise|cycling at 100W during 60 min
306340|NCT01866215|Dietary Supplement|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
306341|NCT01866215|Dietary Supplement|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
306342|NCT01866189|Other|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
306343|NCT01866176|Device|Stabilizing Knee Brace|Brace with no valgus action
306344|NCT01866176|Device|Valgus Knee Brace|Valgus brace with traditional three point bending system
306345|NCT01866176|Device|New Knee Brace|Brace with new mechanism to decrease the knee loading.
306346|NCT01866163|Drug|LEO 90100|
306347|NCT01866163|Drug|Vehicle|
306348|NCT01866124|Other|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
306349|NCT01866111|Drug|YKP3089|
306350|NCT01866111|Drug|Placebo|
306351|NCT01866098|Drug|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
306352|NCT01866098|Drug|Placebo|
306353|NCT01866085|Procedure|AdVance® sling procedure|
306354|NCT01866085|Procedure|ARGUS Sling procedure|
306355|NCT01866059|Device|Calcium silicate cement|Calcium silicate cement
306356|NCT01866059|Device|Glass Ionomer Cement|Glass Ionomer Cement
306357|NCT01866059|Device|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
306358|NCT01866046|Behavioral|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
306359|NCT01866033|Drug|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
306360|NCT01866033|Drug|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
306361|NCT01866033|Drug|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
306362|NCT01866033|Drug|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
306363|NCT01866007|Drug|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
306364|NCT01866007|Drug|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
306365|NCT01866007|Drug|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
306366|NCT01866007|Drug|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
306367|NCT01865968|Biological|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
306368|NCT01865968|Biological|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
306369|NCT01865955|Procedure|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
306370|NCT01865955|Device|The spinal needle|
306371|NCT01865942|Procedure|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
306372|NCT01865942|Procedure|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
306373|NCT01865929|Device|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
306374|NCT01865929|Procedure|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
306375|NCT01865916|Drug|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
306376|NCT01865916|Drug|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
306377|NCT01865851|Device|Classic Face Mask and NuMask|
306378|NCT01865838|Device|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
306379|NCT01865825|Radiation|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.~We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
306380|NCT01865812|Drug|obeticholic acid (OCA)|All subjects will be treated with OCA (oral administration, 10 mg, once daily) for 8 weeks and should continue their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8 week Primary Treatment Phase of the study and the 4 week follow up period, during which time subjects do not take OCA, all eligible subjects will be offered the opportunity to enter an open label long term safety extension phase, during which they will receive 10 mg OCA daily for up to 2 years.
306381|NCT01865773|Procedure|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
306382|NCT01865760|Dietary Supplement|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
306383|NCT01865760|Dietary Supplement|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
306384|NCT01865760|Drug|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
306385|NCT01865747|Drug|Cabozantinib tablets|
306386|NCT01865747|Drug|Everolimus (Afinitor) tablets|
306387|NCT01865734|Other|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
306388|NCT01865734|Other|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
306389|NCT01865721|Drug|Entonox|Entonox will be used according to the allocated method
306390|NCT01865708|Drug|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
306391|NCT01865695|Drug|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
306392|NCT01865695|Other|Placebo|
306393|NCT01865669|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
306394|NCT01865656|Other|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
306395|NCT01865656|Other|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
306396|NCT01865656|Other|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
306397|NCT01865656|Other|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
306398|NCT01865656|Other|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
306399|NCT01865643|Device|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
306400|NCT01865630|Drug|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
306401|NCT01865617|Biological|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
306402|NCT01865617|Other|Laboratory Biomarker Analysis|Correlative studies
306403|NCT01865604|Device|Anodal tDCS|
306404|NCT01865604|Device|Cathodal tDCS|
306405|NCT01865604|Device|sham tDCS|
306406|NCT01865591|Device|Ultrasound-based Renal Denervation|
306407|NCT01865578|Device|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
306408|NCT01865578|Device|Sham Stimulation|no electrical stimulation
306409|NCT01865552|Biological|SB4|SC administration
306410|NCT01865552|Biological|EU sourced Enbrel|SC administration
306411|NCT01865552|Biological|US sourced Enbrel|SC administration
306412|NCT01865539|Device|Custom Foot Orthotic|Custom foot orthotic with custom design pads
306413|NCT01865539|Device|Sham Orthotic|Leather insert without the custom design pads
306414|NCT01865526|Dietary Supplement|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:~Do not add salt at table and for cooking;~Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;~Replace noodle or bread with special no-protein food;~The second course (meat, fish and eggs) are allowed once a day in the usual quantity;~4-5 servings/day of fruits or vegetables are suggested;~Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
306415|NCT01865526|Dietary Supplement|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
306416|NCT01865500|Drug|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
306417|NCT01865500|Drug|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
306418|NCT01865500|Drug|Metil prednisolone|
306419|NCT01865487|Biological|AERAS-456|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
306420|NCT01865487|Biological|Placebo|0.8 mL sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
306421|NCT01865474|Drug|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
306690|NCT01863550|Drug|Lenalidomide|Given PO
306422|NCT01865474|Drug|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
306423|NCT01865448|Dietary Supplement|Omega-3 DHA|Patients take daily 2 tablets of Docosahexaenoic Acid
306424|NCT01865448|Other|Placebo|Patients in control group take daily 2 placebo capsule
306425|NCT01865435|Genetic|cord blood sample|
306426|NCT01865422|Other|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
306427|NCT01865409|Behavioral|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
306428|NCT01865396|Behavioral|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
306429|NCT01865396|Behavioral|Standard oncologic care|Patients will receive standard oncologic care.
306430|NCT01865383|Behavioral|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
306431|NCT01865370|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
306432|NCT01865370|Dietary Supplement|Placebo|Placebo (34.5g/day)
306433|NCT01865357|Other|Brain MRI - Clinical and cognitive evaluation|"Clinical evaluation (EDSS, MSFC)~Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)~Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
306434|NCT01865357|Other|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
306435|NCT01865331|Drug|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
306436|NCT01865331|Drug|placebo|Administered subcutaneously (s.c., under the skin)
306437|NCT01865331|Drug|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
306438|NCT01865318|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin)
306439|NCT01865305|Drug|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
306440|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
306441|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
306442|NCT01865305|Drug|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
306443|NCT01865305|Drug|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
306444|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
306445|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
306446|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
306447|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
306448|NCT01865292|Drug|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
306449|NCT01865292|Drug|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
306450|NCT01865279|Drug|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
306451|NCT01865279|Drug|placebo|Ascending single doses - 5 dose levels
306452|NCT01865279|Drug|insulin degludec|A single dose corresponding to that of isophane human insulin
306453|NCT01865279|Drug|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
306454|NCT01865266|Drug|Ulinaststin for injection|
306455|NCT01865266|Drug|placebo|
306456|NCT01865253|Device|Renal Denervation|Renal Denervation
306457|NCT01865240|Device|Renal Denervation|Renal Denervation Catheter
306458|NCT01865227|Behavioral|Group Counseling|
306459|NCT01865201|Drug|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
306460|NCT01865201|Other|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
306461|NCT01865188|Drug|LCZ696|Experimental monotherapy doses
306462|NCT01865188|Drug|Amlodipine|Active comparator monotherapy doses
306463|NCT01865188|Drug|LCZ696 and amlodipine combination|Experimental combination doses
306464|NCT01865188|Drug|Placebo|Placebo comparator dose
306465|NCT01865175|Drug|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
306466|NCT01865175|Drug|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
306467|NCT01865162|Other|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
306468|NCT01865149|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
306469|NCT01865136|Other|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
306508|NCT01864785|Procedure|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
370000|NCT01371981|Drug|Etoposide|Given IV
306470|NCT01865123|Behavioral|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
306471|NCT01865123|Behavioral|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
306472|NCT01865123|Behavioral|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
306473|NCT01865110|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
306474|NCT01865110|Drug|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
306475|NCT01865110|Drug|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
306476|NCT01865110|Drug|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
306477|NCT01865097|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
306478|NCT01865097|Behavioral|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
306479|NCT01865084|Drug|Tadalafil|Administered orally
306480|NCT01865084|Drug|Placebo|
306481|NCT01865071|Procedure|loop ileostomi|
306482|NCT01865019|Device|mechanical ventilation|
306483|NCT01864993|Dietary Supplement|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
306484|NCT01864993|Dietary Supplement|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
306485|NCT01864980|Procedure|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
306486|NCT01864980|Procedure|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
306487|NCT01864954|Behavioral|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
306488|NCT01864941|Procedure|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
306489|NCT01864941|Device|Catheter venography with balloon venoplasty and balloon|
306490|NCT01864915|Drug|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
306491|NCT01864915|Procedure|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
306492|NCT01864902|Biological|CART33 cells|genetically modified lymphocyte therapy
306493|NCT01864902|Biological|anti-CD33 CART|
306494|NCT01864902|Biological|anti-CD33 CAR T cells|
306495|NCT01864889|Biological|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
306496|NCT01864876|Biological|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
306497|NCT01864876|Biological|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
306498|NCT01864876|Biological|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
306499|NCT01864863|Drug|HGP1206|One Bosentan 125 mg tablet
306500|NCT01864863|Drug|Traclear|Two Bosentan 62.5 mg tablets
306501|NCT01864850|Radiation|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
306502|NCT01864850|Radiation|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
306503|NCT01864824|Drug|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
306504|NCT01864824|Drug|Placebo|Placebo
306505|NCT01864811|Behavioral|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
306506|NCT01864811|Behavioral|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
306507|NCT01864798|Drug|Denosumab|
371947|NCT01357135|Drug|Sitagliptin|
306509|NCT01864785|Procedure|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
306510|NCT01864772|Drug|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)~Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
306511|NCT01864759|Biological|ICOVIR-5|
306512|NCT01864746|Drug|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
306513|NCT01864746|Drug|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
306514|NCT01864733|Other|Physical rehabilitation (exercise).|
306515|NCT01864720|Behavioral|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
306516|NCT01864720|Behavioral|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
306517|NCT01864707|Other|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
306518|NCT01864707|Other|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
306519|NCT01864707|Other|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
306520|NCT01864694|Behavioral|TLC-Diet|Participants receive diet intervention through an automated telephone system
306521|NCT01864694|Behavioral|WEB-Diet|Participants receive diet intervention through a web-based system
306522|NCT01864694|Other|Assessment-only control|Assessment-only control
306523|NCT01864681|Drug|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
306524|NCT01864681|Drug|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
306525|NCT01864655|Drug|saracatinib|oral drug given to experimental group
306526|NCT01864655|Drug|Placebo|Placebo given to placebo group
306527|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|
306528|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
306529|NCT01864629|Behavioral|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
306530|NCT01864616|Dietary Supplement|Vitamin D3|
306531|NCT01864603|Other|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
306532|NCT01864603|Other|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
306533|NCT01864603|Other|Targeted PrEP, Targeted testing, and Targeted care interventions|
306534|NCT01864603|Other|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
306535|NCT01864590|Device|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
306536|NCT01864590|Device|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
306537|NCT01864577|Other|Negative Pleural Suction at -20 cm H2O|
306538|NCT01864577|Other|Water seal|
306539|NCT01864564|Other|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-19.9 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
306540|NCT01864551|Drug|Lamotrigine|
306541|NCT01864551|Drug|Olanzapine|
306542|NCT01864538|Drug|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
306543|NCT01864525|Drug|Octanoic acid|
306544|NCT01864525|Drug|Inactive capsule|
306545|NCT01864499|Procedure|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
306546|NCT01864486|Device|Intelligent Retinal Implant System|
306547|NCT01864473|Other|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
306548|NCT01864460|Behavioral|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
306549|NCT01864447|Behavioral|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
306550|NCT01864434|Device|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
306551|NCT01864434|Device|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
306552|NCT01864408|Other|"Usual practice counseling"|
306553|NCT01864408|Other|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
306554|NCT01864395|Procedure|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
306555|NCT01864395|Procedure|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
306556|NCT01864395|Procedure|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
306557|NCT01864382|Other|Core stability|Core stability 5 days a week during 5 weeks
306558|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
306559|NCT01864369|Behavioral|eCounseling + Usual Care|"This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12."
306560|NCT01864356|Drug|NT100|
306561|NCT01864356|Drug|Placebo|
306562|NCT01864343|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
306563|NCT01864330|Device|Thealoz Duo®|Eye Drops
306564|NCT01864330|Device|Hyabak®|Eye Drops
306565|NCT01864330|Device|Hydrabak®|Eye Drops
306566|NCT01864317|Device|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
306567|NCT01864317|Other|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
306568|NCT01864317|Other|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
306569|NCT01864317|Other|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
306570|NCT01864317|Other|Humphrey Perimetry|Visual Field Testing
306571|NCT01864317|Other|Applanation Tonometry|Measurement of Intraocular Pressure
306572|NCT01864291|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
306573|NCT01864278|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
306574|NCT01864265|Drug|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
306575|NCT01864265|Drug|Placebo|Placebo will be administered according to the label of the biological
306576|NCT01864252|Other|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
306577|NCT01864252|Drug|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
306578|NCT01864252|Drug|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
306579|NCT01864239|Other|Medicines Advice Service|"The intervention consists of:~Telephone consultations with a pharmacist~Follow-up tailored written information~A medicine reminder chart"
306580|NCT01864226|Drug|RO5545965|Multiple ascending doses
306581|NCT01864226|Drug|placebo|Multiple ascending doses
306582|NCT01864213|Drug|Ametop cream|
306583|NCT01864200|Biological|Crotalidae polyvalent immune fab (ovine)|crotalidae antivenom
306584|NCT01864200|Biological|Placebo|Saline placebo
306585|NCT01864187|Drug|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
306586|NCT01864174|Drug|Metformin XR|
306587|NCT01864174|Drug|Metformin IR|
306588|NCT01864174|Drug|Placebo matching with Metformin XR|
306589|NCT01864174|Drug|Placebo matching with Metformin IR|
306590|NCT01864161|Drug|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
306591|NCT01864161|Drug|Liposomal iron|Sideral forte 30 mg/die
306592|NCT01864148|Drug|BIIB033|
306593|NCT01864148|Other|Placebo|
306594|NCT01864148|Drug|Avonex|
306595|NCT01864135|Device|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
306596|NCT01864135|Device|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
306597|NCT01864109|Drug|Cyclophosphamide|
306598|NCT01864109|Device|Doxorubicin|
306599|NCT01864109|Drug|Vincristine|
306600|NCT01864109|Drug|Ifosfamide|
306601|NCT01864109|Drug|Etoposide|
306602|NCT01864109|Procedure|Surgery|
371948|NCT01357135|Drug|Sulfonylurea|
306603|NCT01864109|Radiation|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
306604|NCT01864109|Drug|Temozolomide|
306605|NCT01864109|Drug|Irinotecan|
306606|NCT01864109|Drug|Mesna|Mesna 2,100 mg/m2 (or 70 mg/kg if < 10 yrs of age) administered intravenously in concordance with institutional pediatric administration guidelines.
306607|NCT01864109|Drug|Dexrazoxane|Dexrazoxane 375 mg/m2 intravenously over approximately 15-30 minutes and as clinically indicated. To be administered immediately prior to doxorubicin.
306608|NCT01864109|Drug|G-CSF|G-CSF-to be administered after the completion of appropriate chemotherapy cycles as per institutional guidelines.
306609|NCT01864096|Drug|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
306610|NCT01864096|Drug|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
306611|NCT01864083|Procedure|Positron Emission Tomography (PET)|
306612|NCT01864083|Drug|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
306613|NCT01864083|Procedure|Positron emission mammography (PEM) When available|
306614|NCT01864083|Procedure|MR|
306615|NCT01864070|Other|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
306616|NCT01864070|Drug|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.~Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
306617|NCT01864070|Other|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
306618|NCT01864057|Drug|thiamine hydrochloride 100 mg|
306619|NCT01864018|Drug|Cyclophosphamide|Given PO
306620|NCT01864018|Drug|Dexamethasone|Given PO
306621|NCT01864018|Drug|Ixazomib Citrate|Given PO
306622|NCT01864018|Other|Laboratory Biomarker Analysis|Correlative studies
306623|NCT01864018|Other|Pharmacological Study|Correlative studies
306624|NCT01864018|Other|Quality-of-Life Assessment|Ancillary studies
306625|NCT01864018|Other|Questionnaire Administration|Ancillary studies
306626|NCT01864005|Drug|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
306627|NCT01864005|Drug|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
306628|NCT01863966|Other|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
306629|NCT01863966|Procedure|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
306630|NCT01863953|Drug|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
306631|NCT01863953|Drug|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
306632|NCT01863953|Drug|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
306633|NCT01863953|Drug|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
306634|NCT01863940|Device|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
306635|NCT01863927|Other|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
306636|NCT01863914|Drug|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
306637|NCT01863901|Device|Treatment with Cryo-Touch III device|
306638|NCT01863888|Drug|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
306639|NCT01863888|Drug|cholestyramine|Pharmaceutical form:powder Route of administration: oral
306640|NCT01863888|Drug|charcoal|Pharmaceutical form:granule Route of administration: oral
306641|NCT01863862|Radiation|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.~Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.~Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
306642|NCT01863849|Biological|Fluval AB suspension for injection|Single intramuscular injection of Fluval AB and collect serum samples for immunogenicity
306643|NCT01863836|Procedure|Fluoroscopy|
306644|NCT01863836|Procedure|Radial EBUS-guided biopsy|
306645|NCT01863823|Drug|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
376019|NCT01325311|Other|Placebo|Given PO
306647|NCT01863810|Drug|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
306648|NCT01863810|Drug|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
306649|NCT01863810|Drug|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
306650|NCT01863810|Drug|Placebo of KW21052|Oral,once a day, for 8 weeks
306651|NCT01863810|Drug|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
306652|NCT01863797|Other|Early induction|
306653|NCT01863797|Other|Expectant mamagement|
306654|NCT01863784|Drug|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
306655|NCT01863771|Drug|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
306656|NCT01863771|Other|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
306657|NCT01863758|Biological|Human-cl rhFVIII|Human-cl rhFVIII was provided as a freeze-dried concentrate to be reconstituted in water for injection.
306658|NCT01863745|Drug|nilotinib|Nilotinib can be provided as 200 mg and 150 mg hard gelatin capsules. The starting dose of nilotinib should be the same as the last dose that was given in the parent nilotinib study. After this, the dose of nilotinib is based on the investigator's judgment.
306659|NCT01863732|Biological|Secukinumab|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
306660|NCT01863732|Other|Placebo (Pbo)|Group 1: secukinumab 75 mg plus placebo 150 mg or Group 2 secukinumab 150 mg plus placebo 75m dosed every four weeks Week 104E1 through Week 152. Starting on Week 156 (after unblinding), only secukinumab 75 mg or 150 mg were dosed. Secukinumab in PFS for s.c. self-administration Q4W
306661|NCT01863719|Drug|Colistin|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
306662|NCT01863719|Drug|Colistin|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
306663|NCT01863706|Drug|Misoprostol|400µg oral misoprostol
306664|NCT01863706|Drug|Oxytocin|20 IU Oxytocin
306665|NCT01863680|Drug|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent [%] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
306666|NCT01863680|Drug|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
306667|NCT01863680|Drug|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
306668|NCT01863680|Drug|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
306669|NCT01863667|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
306670|NCT01863667|Drug|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
306671|NCT01863667|Drug|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
306672|NCT01863667|Drug|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
306673|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Reference product
306674|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Test product
306675|NCT01863641|Drug|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
306676|NCT01863641|Drug|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
306677|NCT01863628|Other|aerobic exercise|
306678|NCT01863628|Other|psychoeducation|
306679|NCT01863615|Drug|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
306680|NCT01863615|Drug|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
306681|NCT01863602|Drug|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
306682|NCT01863589|Drug|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
306683|NCT01863576|Dietary Supplement|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
306684|NCT01863576|Dietary Supplement|Placebo Comparator|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
306685|NCT01863563|Device|QuickClot|1 application of treatment to each tonsil/adenoid removal area
306686|NCT01863550|Drug|Bortezomib|Given SC or IV
306687|NCT01863550|Drug|Carfilzomib|Given IV
306688|NCT01863550|Drug|Dexamethasone|Given PO
306689|NCT01863550|Other|Laboratory Biomarker Analysis|Optional correlative studies
306691|NCT01863550|Other|Quality-of-Life Assessment|Ancillary studies
306692|NCT01863537|Behavioral|Multimedia Connect|
306693|NCT01863537|Behavioral|Traditional Connect|
306694|NCT01863511|Drug|loop diuretic|
306695|NCT01863511|Drug|tolvaptan|
306696|NCT01863511|Procedure|ultrafiltration|
306697|NCT01863498|Other|Epidural|Patients will have an epidural for pain control
306698|NCT01863498|Other|PCA|Patients will have PCA for pain control
306699|NCT01863485|Drug|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
306700|NCT01863472|Device|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
306701|NCT01863472|Device|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
306702|NCT01863459|Drug|Lisdexamfetamine Dimesylate|
306703|NCT01863459|Drug|placebo|
306704|NCT01863446|Device|Lighting1|Ocular light exposure to a red wavelength light for one or two nights
306705|NCT01863446|Device|Lighting2|Ocular light exposure to a blue/green wavelength light for one night
306706|NCT01863446|Other|Lighting3|Ocular light exposure to a red wavelength light (Device 1) on night 1 and to a blue/green wavelength light (Device 2) for on night 2
306707|NCT01863433|Biological|Trivalent Influenza Vaccine|
306708|NCT01863420|Radiation|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
306709|NCT01863407|Drug|DAM|composed of dexamethasone, allantoin and metronidazole
306710|NCT01863407|Drug|Normal Saline|Normal Saline 250ml
306711|NCT01863394|Other|Screening by mothers|
306712|NCT01863394|Other|Active comparator: Screening by community health workers|
306713|NCT01863381|Device|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.~For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.~Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
306714|NCT01863381|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
306715|NCT01863368|Other|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
306716|NCT01863368|Other|Systane® ULTRA lubricant eyedrops|
306717|NCT01863368|Other|OPTIVE® lubricating eyedrops|
306718|NCT01863355|Drug|B0 group: bolus 0.6mcg/kg without background infusion|
306719|NCT01863355|Drug|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
306720|NCT01863355|Drug|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
306721|NCT01863342|Procedure|CSI score < 40|
306722|NCT01863342|Procedure|CSI score ≥ 40|
306723|NCT01863329|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
306724|NCT01863316|Device|I gel|
306725|NCT01863316|Device|LMA Supreme|
306726|NCT01863290|Other|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
306727|NCT01863277|Drug|Melatonin|
306728|NCT01863277|Drug|placebo|
306729|NCT01863264|Other|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
306730|NCT01863251|Drug|Atomoxetine|
306731|NCT01863238|Other|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
306732|NCT01863238|Drug|Ivacaftor Exposed|
306733|NCT01863225|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
306734|NCT01863225|Drug|Rosuvastatin|20 mg daily, 28-42 days
306735|NCT01863225|Drug|Atorvastatin|40 mg daily, 28-42 days
306736|NCT01863225|Drug|Rosuvastatin|40 mg daily, 28-42 days
306737|NCT01863225|Drug|Atorvastatin|80 mg daily, 28-42 days
306738|NCT01863212|Procedure|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
306739|NCT01863212|Behavioral|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
306740|NCT01863212|Other|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
306741|NCT01863199|Drug|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
306742|NCT01863199|Drug|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
306743|NCT01863199|Drug|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
306744|NCT01863186|Drug|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
306745|NCT01863186|Drug|Placebo|Lofexidine-matching sugar pills will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
376192|NCT01324063|Drug|amsacrine|
306746|NCT01863186|Drug|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
306747|NCT01863173|Drug|metoprolol|using B blocker in patient group
306748|NCT01863173|Drug|placebo|placebo to control group
306749|NCT01863160|Drug|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (0.1%)~Left arm, single treatment area - Placebo cream"
306750|NCT01863160|Drug|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).~The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.~Right arm, single treatment area - ZEP-3 (1.0%)~Left arm, single treatment area - Placebo cream"
306751|NCT01863147|Drug|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
306752|NCT01863134|Drug|Eptifibatide|
306753|NCT01863134|Drug|Placebo|
306754|NCT01863108|Biological|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
306755|NCT01863095|Behavioral|Personalized Feedback and Exercise|
306756|NCT01863082|Other|exercise|practice of physical exercise
306757|NCT01863069|Drug|Interferon beta 1a|
306758|NCT01863069|Drug|(IM) AVONEX®|
306759|NCT01863056|Other|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
306760|NCT01863043|Procedure|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
306761|NCT01863043|Procedure|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
306762|NCT01863030|Device|Phasix mesh implant|
306763|NCT01863017|Device|tDCS|
306764|NCT01863004|Drug|Bortezomib|
306765|NCT01862991|Other|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
306766|NCT01862991|Drug|Misoprostol|400 mcg buccal misoprostol 90 pre-op
306767|NCT01862991|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
306768|NCT01862991|Drug|Mifepristone|200 mcg Mifepristone orally
306769|NCT01862978|Drug|Heparin|
306770|NCT01862978|Drug|Nadroparin|
306771|NCT01862978|Drug|Placebo|
306772|NCT01862965|Drug|PredEver|Firstline treatment with prednisone and Everolimus
306773|NCT01862952|Other|starting of anti-epileptic drug treatment|
306774|NCT01862939|Drug|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
306775|NCT01862939|Drug|placebo|placebo to match part 2 DS-7309
306776|NCT01862926|Drug|Rituximab|
306777|NCT01862926|Drug|Cyclophosphamide|
306778|NCT01862913|Other|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
306779|NCT01862913|Other|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
306780|NCT01862900|Biological|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
306781|NCT01862887|Drug|PH-797804|Tablet, 24 mg, single dose
306782|NCT01862887|Drug|Moxifloxacin|Tablet, 400 mg, single dose
306783|NCT01862887|Drug|Placebo|Tablet, PH-797804 matched placebo, single dose
306784|NCT01862874|Biological|V501|Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant
306785|NCT01862874|Biological|Placebo|Formulated with AAHS adjuvant
306786|NCT01862835|Drug|Degarelix|
306787|NCT01862835|Drug|Testosterone|
306788|NCT01862835|Drug|Anastrozole|
306789|NCT01862835|Drug|Estrogen patch|
306790|NCT01862822|Other|upright position|
306791|NCT01862796|Behavioral|Underfeeding diet|Heart healthy diet with 35% reduced calories
306792|NCT01862796|Behavioral|Weight maintaining diet|Heart healthy weight-maintaining diet
306793|NCT01862718|Procedure|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
306794|NCT01862718|Procedure|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
306795|NCT01862705|Other|Thoracic spine manipulation|TSM thrust or non-thrust
306874|NCT01862003|Drug|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
307074|NCT01860508|Drug|pemetrexed /carboplatin|
306796|NCT01862692|Behavioral|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
306797|NCT01862692|Behavioral|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
306798|NCT01862679|Other|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
306799|NCT01862679|Procedure|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
306800|NCT01862653|Device|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
306801|NCT01862640|Drug|Brexpiprazole, OPC-34712|Once-daily, tablets
306802|NCT01862640|Drug|Placebo Oral Tablet|Once-daily, tablets
306803|NCT01862627|Procedure|Optical coherence tomography|
306804|NCT01862601|Device|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
306805|NCT01862562|Procedure|Open surgery|Conventional technique
306806|NCT01862562|Procedure|Laparoscopic surgery|New minimum invasive technique
306807|NCT01862549|Behavioral|Dialectical Behavior Therapy for children|
306808|NCT01862549|Behavioral|Treatment as Usual|
306809|NCT01862536|Drug|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
306810|NCT01862536|Drug|placebo|Daily use in double blind study.
306811|NCT01862523|Biological|Capsaicin|Thirty-three* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
306812|NCT01862523|Biological|diluent|diluent
306813|NCT01862497|Drug|Carvedilol vs. Prazosin|
306814|NCT01862484|Dietary Supplement|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
306815|NCT01862484|Dietary Supplement|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
306816|NCT01862471|Device|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
306817|NCT01862471|Device|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
306818|NCT01862458|Biological|tPA alone|
306819|NCT01862458|Biological|tPA plus dornase|
306820|NCT01862432|Other|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
306821|NCT01862419|Other|Alert|
306822|NCT01862406|Other|Label|Participants were presented with either a generic label or a brand-name label
306823|NCT01862393|Device|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
306824|NCT01862393|Device|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
306825|NCT01862393|Device|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
306826|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
306827|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
306828|NCT01862367|Drug|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
306829|NCT01862354|Procedure|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
306875|NCT01862003|Drug|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
306876|NCT01862003|Drug|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
306830|NCT01862354|Procedure|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
306831|NCT01862341|Dietary Supplement|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
306832|NCT01862328|Drug|MLN4924 and Docetaxel|"MLN4924 (IV) and Docetaxel (IV) in patients to determine maximum tolerated dose (MTD) on a 21-day cycle:~MLN4924 on Days 1,3,5 of each cycle~Docetaxel on Day 1 of each cycle~On Day 1 of each cycle, patients receive both agents"
306833|NCT01862328|Drug|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|"MLN4924 (IV) Paclitaxel (IV), and Carboplatin (IV) in patients to determine maximum tolerated dose (MTD) on a 21-day cycle:~MLN4924 on Days 1,3,5 of each cycle~Paclitaxel on Day 1 of each cycle~Carboplatin on Day 1 of each cycle~On Day 1 of each cycle, patients receive all 3 agents"
306834|NCT01862328|Drug|MLN4924 + Gemcitabine (Arm 3)|"MLN4924 (IV) and Gemcitabine (IV) in patients to determine maximum tolerated dose (MTD) on a 28-day cycle:~•MLN4924 and Gemcitabine on Days 1,8,15 of each cycle"
306835|NCT01862315|Drug|Floxuridine (FUDR)|
306836|NCT01862315|Drug|dexamethasone|
306837|NCT01862315|Drug|Gemcitabine|
306838|NCT01862315|Drug|Oxaliplatin|
306839|NCT01862315|Other|MRI|
306840|NCT01862315|Other|Research blood draws|These are optional
306841|NCT01862302|Drug|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
306842|NCT01862302|Drug|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
306843|NCT01862289|Other|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
306844|NCT01862263|Drug|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
306845|NCT01862263|Drug|Insulin|Long- acting human insulin analog indicated to improve glycemic control
306846|NCT01862263|Drug|Placebo|Matching placebo of vildagliptin
306847|NCT01862250|Drug|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~HR ≤70/min, sustained for ≥30 min after administration"
306848|NCT01862237|Other|Intervention|"blood collection~Completion of a pre-operative cardiac MRI.~Completion of a coronary angiography examination~Completion during the surgery d'une myocardial biopsy,~Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year~Completion of a cardiac MRI 1 year after surgery."
306849|NCT01862224|Drug|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
306850|NCT01862224|Drug|Placebo|Matching placebo once daily (Week 0 to Week 12).
306851|NCT01862224|Drug|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
306852|NCT01862211|Other|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
306853|NCT01862198|Device|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
306854|NCT01862185|Other|semi-quantitative procalcitonin|
306855|NCT01862172|Other|Additional MRI|
306856|NCT01862159|Procedure|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
306857|NCT01862146|Procedure|smoke expose|
306858|NCT01862133|Other|Patient preferences|Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
306859|NCT01862120|Drug|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
306860|NCT01862120|Drug|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
306861|NCT01862120|Drug|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
306862|NCT01862120|Drug|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
306863|NCT01862081|Drug|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
306864|NCT01862081|Drug|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
306865|NCT01862081|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
306866|NCT01862068|Other|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
306867|NCT01862068|Other|Blood sample|Blood sample will be performed at inclusion from all healthy patients
306868|NCT01862042|Other|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
306869|NCT01862029|Drug|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
306870|NCT01862016|Procedure|APRV|Pressure ventilation mode allowing early spontaneous breathing
306871|NCT01862016|Biological|arterial blood gas measurement each morning|
306872|NCT01862003|Drug|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
306873|NCT01862003|Drug|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
307269|NCT01858961|Drug|Pegylated Interferon|Once a week
306877|NCT01861990|Drug|Valproic Acid|All participants enrolled on valproic acid arm.
306878|NCT01861977|Behavioral|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
306879|NCT01861977|Behavioral|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
306880|NCT01861964|Dietary Supplement|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
306881|NCT01861964|Dietary Supplement|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
306882|NCT01861964|Dietary Supplement|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
306883|NCT01861951|Drug|Pazopanib|
306884|NCT01861951|Drug|Doxorubicin|
306885|NCT01861938|Biological|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
306886|NCT01861912|Device|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities
306887|NCT01861912|Drug|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
306888|NCT01861912|Drug|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
306889|NCT01861912|Drug|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
306890|NCT01861899|Device|SI-LOK|Sacro-iliac joint fusion
306891|NCT01861886|Device|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
306892|NCT01861873|Other|measuring liver function by 18-FDGal PET/CT|
306893|NCT01861860|Device|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
306894|NCT01861847|Drug|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
306895|NCT01861847|Drug|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
306896|NCT01861834|Drug|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.~Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
306897|NCT01861821|Device|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
306898|NCT01861821|Device|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
306899|NCT01861808|Other|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
306900|NCT01861795|Other|Preterm Neonates|Preterm Neonates
306901|NCT01861782|Other|Dead Sea Solar and Water Treatment|
306902|NCT01861782|Other|Sulfur Pool & Medicinal Mud|
306903|NCT01861769|Other|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
306904|NCT01861769|Other|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
306905|NCT01861756|Other|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
306906|NCT01861743|Other|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
306907|NCT01861743|Other|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
306908|NCT01861730|Biological|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
306909|NCT01861730|Biological|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
306910|NCT01861717|Drug|lanreotide|Somatuline Depot 90 mg deep subcutaneous injecton every 4 weeks X 3 doses
306911|NCT01861704|Device|Lyric|Extended wear hearing instrument
306912|NCT01861704|Device|Lyric2|Extended wear hearing instrument
306913|NCT01861691|Procedure|Open surgery|Conventional technique
306914|NCT01861691|Procedure|Laparoscopic surgery|New minimum invasive technique
306915|NCT01861678|Procedure|High tie of IMA|Conventional technique
306916|NCT01861678|Procedure|Low tie of IMA|Technique for preserving left colic arterial perfusion
306917|NCT01861665|Drug|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
306918|NCT01861665|Drug|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
306919|NCT01861652|Device|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
306920|NCT01861639|Device|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
306921|NCT01861639|Device|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
306922|NCT01861639|Device|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
306923|NCT01861639|Device|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2*-weighted echo-planar imaging sequence
306924|NCT01861639|Device|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
306925|NCT01861639|Device|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
306926|NCT01861626|Drug|V0057 - A mg|Single oral administration
306927|NCT01861626|Drug|Isotretinoin|Single oral administration
306928|NCT01861613|Biological|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
306929|NCT01861600|Other|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
306930|NCT01861600|Other|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
306931|NCT01861600|Other|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
306932|NCT01861600|Other|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
306933|NCT01861600|Other|Human Milk|Human Milk
306934|NCT01861587|Device|tDCS|20 minutes of either real or sham stimulation
306935|NCT01861574|Device|Real TMS 45 min|Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
306936|NCT01861574|Device|Sham TMS 45 min|Sham TMS 45 minutes after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
306937|NCT01861574|Device|Real TMS 4 Hours|Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
306938|NCT01861574|Device|Sham TMS 4 Hours|Sham TMS 4 hours after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
306939|NCT01861561|Drug|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
306940|NCT01861561|Drug|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:~the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
306941|NCT01861535|Drug|Imiquimod|
306942|NCT01861535|Procedure|Surgery|
306943|NCT01861522|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
306944|NCT01861522|Drug|Placebo|Two Placebo tablets will be taken orally twice a day
307270|NCT01858948|Drug|Omega|Omega-3 supplements
306945|NCT01861509|Drug|BP-C1|BP-C1, 0.05% solution for injection; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days
306946|NCT01861496|Drug|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
306947|NCT01861457|Other|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
306948|NCT01861457|Other|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
306949|NCT01861431|Behavioral|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
306950|NCT01861431|Behavioral|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
306951|NCT01861418|Other|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
306952|NCT01861418|Other|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
306953|NCT01861405|Behavioral|neuropsychological testing and quality of life assessments|
306954|NCT01861405|Radiation|Standard of Care WBRT or SRS|
306955|NCT01861405|Device|Functional magnetic resonance imaging|
306956|NCT01861392|Procedure|sensorio-motor training|
306957|NCT01861379|Procedure|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
306958|NCT01861366|Other|A one year multifaceted implementation strategy|
306959|NCT01861366|Other|A three hour lecture about the guidelines|
306960|NCT01861353|Other|Cranberry-lingonberry juice|
306961|NCT01861353|Other|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
306962|NCT01861340|Drug|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
306963|NCT01861327|Drug|CO2|carbon dioxide (CO2) as arterial contrast media
306964|NCT01861327|Drug|Iodine contrast media|Iodine as arterial contrast media
306965|NCT01861314|Drug|Bortezomib|Given SC
306966|NCT01861314|Drug|Decitabine|Given IV
306967|NCT01861314|Other|Laboratory Biomarker Analysis|Correlative studies
306968|NCT01861314|Other|Pharmacological Study|Correlative studies
306969|NCT01861314|Drug|Sorafenib Tosylate|Given PO
306970|NCT01861301|Other|Laboratory Biomarker Analysis|Correlative studies
306971|NCT01861301|Drug|Tivantinib|Given PO
306972|NCT01861275|Device|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
306973|NCT01861262|Device|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
306974|NCT01861249|Drug|SAR339658|"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
306975|NCT01861236|Drug|Firmagon® (degarelix)|Monthly subcutaneous injections
306976|NCT01861223|Drug|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
306977|NCT01861210|Behavioral|Couples Voluntary HIV Counseling and Testing|
306978|NCT01861210|Behavioral|Individual Counseling and Testing|
306979|NCT01861197|Drug|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
306980|NCT01861171|Dietary Supplement|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
306981|NCT01861158|Behavioral|Parenting Wisely|Computer-based, online, interactive parenting intervention
306982|NCT01861145|Device|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
306983|NCT01861145|Drug|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
306984|NCT01861119|Drug|Silicone gel Kelo-cort™;|
306985|NCT01861119|Drug|Onion extract gel Contractubex™|
306986|NCT01861106|Procedure|Allogeneic HSC|Stem cell transplant
306987|NCT01861106|Drug|Busulfan Test dose|0.8 mg/kg IV infusion over 2 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
307271|NCT01858948|Drug|Placebo|Similar in shape and color to Omega supplements
306988|NCT01861106|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg /m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
306989|NCT01861106|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing)
306990|NCT01861106|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
306991|NCT01861106|Procedure|Total Body Irradiation (TBI)|200 cGy Transplant Day -1
306992|NCT01861093|Biological|Cord Blood Units|Transplant
306993|NCT01861067|Procedure|LESS-TLH|
306994|NCT01861067|Procedure|LESS-LAVH|
306995|NCT01861054|Drug|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
306996|NCT01861041|Drug|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
306997|NCT01861041|Drug|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
306998|NCT01861015|Drug|Epinephrine|
306999|NCT01861015|Drug|Vasopressin|
307000|NCT01861002|Drug|Azacytidine|Dose assigned at study entry. Azacytidine will be given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
307001|NCT01861002|Drug|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
307002|NCT01861002|Drug|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
307003|NCT01860989|Drug|KAE609|KAE609 75mg single dose
307004|NCT01860989|Drug|KAE609|KAE609 150mg single dose
307005|NCT01860989|Drug|KAE609|KAE609 225mg single dose
307006|NCT01860989|Drug|KAE609|KAE609 300mg single dose
307007|NCT01860976|Drug|Abatacept|
307008|NCT01860976|Drug|Placebo|
307009|NCT01860963|Procedure|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
307010|NCT01860950|Device|anodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode electrode placed over the left DLPFC and the cathode electrode attached to the right shoulder
307011|NCT01860950|Device|cathodal tDCS|a single 20-minute session of transcranial direct current stimulation (tDCS) with the anode attached to the right shoulder and the cathode electrode placed over the left DLPFC.
307012|NCT01860950|Device|sham tDCS|Participants were provided pain education during 20 minutes of sham tDCS. For sham, the device was turned on for 30 seconds to temporarily mimic tingling and skin sensations of real tDCS and then ramped-down to 0mA for the duration of the 20-minute session
307013|NCT01860937|Procedure|leukapheresis or collection of PBMCs|
307014|NCT01860937|Drug|cyclophosphamide based chemotherapy regimens|
307015|NCT01860937|Biological|modified T cells|
307016|NCT01860924|Behavioral|exercise|vigorous intensity exercise
307017|NCT01860924|Behavioral|health education|education
307018|NCT01860911|Drug|Insulin|
307019|NCT01860911|Drug|NG-monomethyl-L-arginine|
307020|NCT01860898|Other|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
307021|NCT01860859|Procedure|Closure of the hysterotomy at the time of primary cesarean|
307022|NCT01860833|Drug|Ibuprofen|time of treatment 14 days
307023|NCT01860833|Drug|Celecoxib|time of treatment 14 days
307024|NCT01860833|Drug|Diclofenac|time of treatment 14 days
307025|NCT01860820|Device|Geko device|
307026|NCT01860807|Drug|Ibudilast|
307027|NCT01860807|Drug|Placebo|
307028|NCT01860794|Drug|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
307029|NCT01860781|Drug|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
307030|NCT01860755|Other|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
307031|NCT01860755|Other|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
307032|NCT01860742|Drug|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
307033|NCT01860742|Drug|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
307034|NCT01860729|Drug|Anacetrapib|
307035|NCT01860729|Drug|Placebo|
307036|NCT01860716|Drug|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
307037|NCT01860716|Drug|Placebo|
307038|NCT01860703|Drug|Deferiprone|Ferriprox 500 mg tablets
307039|NCT01860703|Drug|deferiprone matching placebo tablets|deferiprone matching placebo tablets
307040|NCT01860703|Drug|moxifloxacin|Active control
307041|NCT01860703|Drug|placebo|moxifloxacin-matching placebo
307042|NCT01860690|Drug|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
307043|NCT01860677|Device|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
307072|NCT01860521|Device|Pump for continuous epidural infusion.|Pump administering continuous epidural infusion for the maintenance of analgesia was used.
376193|NCT01324063|Drug|cytarabine|
307044|NCT01860664|Drug|hydrocortisone ophthalmic ointment 0.5%|"Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID~Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.~Study medication dosing details:~0.05 grams hydrocortisone per gram of combination product~each application equal to 1/20th of a gram~total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone~total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone~Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
307045|NCT01860664|Drug|placebo|Mineral oil and white petrolatum
307046|NCT01860651|Behavioral|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
307047|NCT01860638|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
307048|NCT01860638|Drug|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m^2 PO Q6W, with a cap of 200 mg per dose.
307049|NCT01860638|Drug|Placebo|Placebo will be administered via IV infusion, in a formulation matched to bevacizumab, Q2W after randomization.
307050|NCT01860638|Radiation|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
307051|NCT01860638|Drug|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m^2 per day for the first 5 days of Cycle 1, then 200 mg/m^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
307052|NCT01860638|Drug|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
307053|NCT01860625|Drug|Donepezil patch|
307054|NCT01860625|Drug|placebo|
307055|NCT01860612|Device|Artificial Iris (CustomFlex)|
307056|NCT01860599|Behavioral|Exercise|150 minutes of moderate exercise per week
307057|NCT01860599|Behavioral|Without exercise|Pre-study activity level (i.e. no exercise)
307058|NCT01860586|Drug|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
307059|NCT01860573|Drug|Amino acids|
307060|NCT01860560|Device|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
307061|NCT01860560|Device|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
307062|NCT01860547|Dietary Supplement|Bilberries|Frozen bilberries, 100 g/d
307063|NCT01860547|Dietary Supplement|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
307064|NCT01860547|Dietary Supplement|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
307065|NCT01860547|Dietary Supplement|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
307066|NCT01860534|Behavioral|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
307067|NCT01860521|Procedure|Programmed Intermittent Epidural Bolus|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
307068|NCT01860521|Procedure|Continuous Epidural Infusion|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
307069|NCT01860521|Procedure|Procedure of interruption of pregnancy|Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
307070|NCT01860521|Drug|Drug used for analgesia procedures|Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
307071|NCT01860521|Device|Pump for programmed intermittent bolus.|Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
307073|NCT01860521|Drug|Drug used for termination of pregnancy procedure.|Gemeprost pessaries.
307075|NCT01860495|Procedure|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
307076|NCT01860495|Procedure|G2|tradetional occlusive collagen membrane
307077|NCT01860482|Drug|Newrabell® Tablet 10mg|
307078|NCT01860469|Procedure|vancomycin-soaked mesh|
307079|NCT01860469|Procedure|plain mesh|
307080|NCT01860456|Drug|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
307081|NCT01860443|Other|Telepsychiatry collaborative program|"The intervention includes:~Online training for the health staff~Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression~Online supervision in a web platform by specialists~Telephone monitoring"
307082|NCT01860443|Other|Usual care|"Online training for the health staff~Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
307083|NCT01860417|Biological|Allogenic Mesenchymal Stromal Cells|
307084|NCT01860417|Drug|Mepivacaine|
307085|NCT01860404|Drug|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
307086|NCT01860404|Drug|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
307087|NCT01860391|Device|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
307088|NCT01860378|Other|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
307089|NCT01860378|Other|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
307090|NCT01860365|Other|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
307091|NCT01860365|Other|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
307092|NCT01860352|Dietary Supplement|Fish OIl|
307093|NCT01860326|Drug|Alisporivir|Capsules supplied as open labeled bulk medication in 10-unit blister packages
307094|NCT01860313|Behavioral|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
307095|NCT01860313|Behavioral|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
307096|NCT01860300|Drug|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
307097|NCT01860300|Drug|placebo|
307098|NCT01860287|Drug|Buprenorphine 0.2 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
307099|NCT01860287|Drug|Placebo|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
307100|NCT01860287|Drug|Buprenorphine 0.4 MG Sublingual Tablet|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
307101|NCT01860274|Device|Mesh|
307102|NCT01860274|Procedure|Control|
307103|NCT01860261|Behavioral|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
307104|NCT01860248|Drug|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
307105|NCT01860248|Drug|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
307106|NCT01860235|Drug|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
307107|NCT01860235|Drug|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
307108|NCT01860235|Drug|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
307109|NCT01860235|Drug|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
307110|NCT01860222|Procedure|SR|
307111|NCT01860222|Procedure|PLAT|
307112|NCT01860209|Procedure|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
307113|NCT01860196|Drug|Meditoxin|
307114|NCT01860196|Drug|Normal saline|
307115|NCT01860183|Drug|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
307272|NCT01858948|Drug|Quetiapine fumarate|Patients will be started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
307273|NCT01858935|Drug|ND-L02-s0201 Injection|Single IV infusion.
307274|NCT01858935|Drug|Placebo|Single IV infusion.
307325|NCT01858649|Drug|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
307116|NCT01860170|Drug|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
307117|NCT01860170|Drug|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
307118|NCT01860170|Drug|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.~Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.~Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
307119|NCT01860157|Device|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
307120|NCT01860157|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
307121|NCT01860144|Drug|Bevacizumab|
307122|NCT01860131|Behavioral|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
307123|NCT01860105|Drug|MDCO-157|intravenous administration
307124|NCT01860105|Drug|PLAVIX|oral administration
307125|NCT01860079|Procedure|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
307126|NCT01860066|Drug|QVA149|QVA149 via inhaler twice a day
307127|NCT01860066|Drug|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
307128|NCT01860053|Behavioral|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
307129|NCT01860040|Drug|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
307130|NCT01860040|Drug|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
307131|NCT01860040|Drug|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
307132|NCT01860014|Drug|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
307133|NCT01860014|Drug|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
307134|NCT01859988|Drug|Dupilumab|
307135|NCT01859988|Drug|Placebo|
307136|NCT01859962|Drug|PPI-668|
307137|NCT01859962|Drug|BI 207127 Dose 1|
307138|NCT01859962|Drug|BI 207127 Dose 2|
307139|NCT01859962|Drug|Faldaprevir|
307140|NCT01859962|Drug|Ribavirin|
307141|NCT01859962|Drug|BI 207127 Placebo|
307142|NCT01859949|Drug|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
307143|NCT01859936|Device|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
307144|NCT01859923|Drug|100 mg Delamanid|100 mg Delamanid BID for 6 months
307145|NCT01859923|Drug|50 mg Delamanid|50 mg Delamanid BID for 6 months
307146|NCT01859923|Drug|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 6 months
307147|NCT01859923|Drug|10 mg Delamanid Pediatric Formulation|Patients > 10 kg will receive DPF 10 mg BID for 6 months
307148|NCT01859923|Drug|5 mg Delamanid Pediatric Formulation|"Patients > 8 kg or ≤ 10 kg will receive DPF 5 mg BID for 6 months~Patients ≤ 8 kg will receive DPF 5 mg QD for 6 months"
307149|NCT01859923|Drug|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
307150|NCT01859910|Procedure|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
307151|NCT01859910|Procedure|routine preparation for cataract|
307152|NCT01859884|Behavioral|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
307153|NCT01859871|Behavioral|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
307154|NCT01859858|Dietary Supplement|curcumin|
307155|NCT01859858|Drug|Irinotecan|
307156|NCT01859845|Other|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
307157|NCT01859832|Other|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
307158|NCT01859819|Drug|Rituximab|
307159|NCT01859819|Drug|IT Cytarabine|
307160|NCT01859806|Procedure|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
307161|NCT01859806|Procedure|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
307162|NCT01859793|Drug|sitagliptin|100 mg pill, administered once/day orally
307163|NCT01859793|Drug|Placebo|Matching placebo in appearance given once/day orally
307164|NCT01859780|Other|Visual distractor|
307165|NCT01859767|Drug|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
307166|NCT01859754|Biological|Octagam 5%|Intravenous immunoglobulin 5%
307167|NCT01859754|Biological|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
307168|NCT01859741|Drug|OMP-59R5|OMP-59R5 administered intravenously
307169|NCT01859741|Drug|Etoposide|administered intravenously
307170|NCT01859741|Drug|Placebo|administered IV
307171|NCT01859741|Drug|Cisplatin or Carboplatin|administered intravenously
307172|NCT01859728|Drug|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
307173|NCT01859728|Drug|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
307174|NCT01859728|Drug|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.~Given in association with standard hydration and anti-emetics."
307175|NCT01859728|Drug|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.~Given in association with standard hydration and anti-emetics."
307176|NCT01859715|Drug|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
307177|NCT01859715|Drug|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
307178|NCT01859715|Drug|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
307179|NCT01859702|Drug|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
307180|NCT01859689|Radiation|brachytherapy|Undergo image-guided HDR brachytherapy
307181|NCT01859689|Radiation|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
307182|NCT01859689|Other|laboratory biomarker analysis|Correlative studies
307183|NCT01859650|Other|MR and CT imaging|
307184|NCT01859637|Biological|Filgrastim|Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
307185|NCT01859624|Drug|Albuterol|Albuterol 4 mg
307186|NCT01859611|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
307187|NCT01859585|Drug|Parecoxib|Parecoxib 40 mg intravenous
307188|NCT01859585|Drug|Ketorolac|Ketorolac 30 mg intravenous
307189|NCT01859559|Procedure|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
307190|NCT01859559|Procedure|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
307191|NCT01859546|Behavioral|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
307192|NCT01859533|Device|Neopuff|"Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).~Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
307329|NCT01858636|Device|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
307330|NCT01858623|Drug|Losartan/hydrochlorothiazide|
307331|NCT01858623|Drug|Losartan|
307193|NCT01859520|Procedure|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
307194|NCT01859507|Drug|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
307195|NCT01859494|Device|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
307196|NCT01859481|Drug|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
307197|NCT01859481|Drug|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
307198|NCT01859481|Drug|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
307199|NCT01859468|Dietary Supplement|Amorphous calcium carbonate|
307200|NCT01859468|Other|Placebo|
307201|NCT01859455|Drug|LGT209 50 mg|Active experimental drug
307202|NCT01859455|Drug|LGT209 300 mg|Active experimental drug
307203|NCT01859455|Drug|Placebo|Placebo comparator
307204|NCT01859455|Drug|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
307205|NCT01859442|Procedure|Structured responsive interval exercise training programme|
307206|NCT01859442|Other|Sham group|NO intervention in this group, only standard care (no exercise programme)
307207|NCT01859429|Other|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
307208|NCT01859416|Dietary Supplement|Oral nutritional supplement|
307209|NCT01859403|Genetic|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
307210|NCT01859390|Drug|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
307211|NCT01859390|Dietary Supplement|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
307212|NCT01859377|Drug|V0498 - A mg|Single oromucosal administration
307213|NCT01859377|Drug|Ibuprofen|Single oral administration
307214|NCT01859351|Drug|WX-037|
307215|NCT01859351|Drug|WX-554|
307216|NCT01859338|Radiation|cone-beam computed tomography|Undergo CBCT
307217|NCT01859338|Radiation|magnetic resonance imaging|Undergo MRI
307218|NCT01859338|Radiation|computed tomography|Undergo fan beam computed tomography
307219|NCT01859325|Biological|rVSV|Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene
307220|NCT01859325|Biological|IL-12 pDNA adjuvant|plasmid DNA containing human IL-12 gene
307221|NCT01859325|Biological|HIV-Mag pDNA|plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins
307222|NCT01859325|Drug|Placebo|
307223|NCT01859312|Drug|Hydrocortisone (Solucortef)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA). Total daily hydrocortisone dose was calculated based on the patient's estimated cortisol clearance. Rates were established to achieve peak and trough concentrations within the normal circadian cortisol range.
307224|NCT01859312|Device|Insulin pump (Medtronic)|Continuous subcutaneous hydrocortisone infusion (CSHI) via Medtronic insulin pump (MMT-722NA)
307275|NCT01858922|Drug|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 & Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 & 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of </=0.4mg/ml in NS on Day 1, 2 & 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
307326|NCT01858649|Drug|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
307327|NCT01858649|Drug|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
307225|NCT01859286|Other|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
307226|NCT01859273|Behavioral|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
307227|NCT01859260|Device|CPAP/autopap|
307228|NCT01859247|Device|rTMS|
307229|NCT01859234|Drug|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
307230|NCT01859221|Radiation|Stereotactic radiation|Stereotactic radiation
307231|NCT01859182|Drug|selumetinib|Given PO
307232|NCT01859182|Drug|Akt inhibitor MK2206|Given PO
307233|NCT01859182|Other|laboratory biomarker analysis|Correlative studies
307234|NCT01859182|Other|pharmacogenomic studies|Correlative studies
307235|NCT01859182|Procedure|quality-of-life assessment|Ancillary studies
307236|NCT01859169|Procedure|Photodynamic therapy|﻿Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
307237|NCT01859143|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
307238|NCT01859143|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
307239|NCT01859130|Device|Zimmer Persona Total Knee System|
307240|NCT01859117|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
307241|NCT01859117|Biological|10 x 10^6 cells|10 x 10^6 cells administered on Study Days 1 and 8
307242|NCT01859117|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
307243|NCT01859117|Biological|100 x 10^6 cells|100 x 10^6 cells administered on Study Days 1 and 8
307244|NCT01859104|Behavioral|Use of smartphone app|
307245|NCT01859091|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
307246|NCT01859078|Drug|Baricitinib|Administered orally
307247|NCT01859078|Drug|Digoxin|Administered orally
307248|NCT01859065|Behavioral|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
307249|NCT01859065|Behavioral|Routine|Routine anticipatory guidance (control)
307250|NCT01859052|Other|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
307251|NCT01859052|Other|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
307252|NCT01859052|Other|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
307253|NCT01859039|Biological|Administration of Live attenuated influenza vaccine|
307254|NCT01859026|Drug|MEK162|Treatment as outlined in study arms.
307255|NCT01859026|Drug|Erlotinib|Treatment as outlined in study arms.
307256|NCT01859013|Drug|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
307257|NCT01859013|Other|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
307258|NCT01859000|Other|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
307259|NCT01859000|Other|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
307260|NCT01858987|Procedure|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
307261|NCT01858987|Procedure|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
307262|NCT01858987|Device|Ligasure|
307263|NCT01858987|Other|vascular staple|
307264|NCT01858961|Drug|BI 201335|Once a day
307265|NCT01858961|Drug|ribavirin|Twice a day
307266|NCT01858961|Drug|BI 207127|Twice a day
307267|NCT01858961|Drug|Telaprevir|Three times a day
307268|NCT01858961|Drug|ribavirin|Twice a day
380911|NCT01286935|Drug|Safinamide|
307276|NCT01858922|Drug|DECA|"Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide*~*Mix together in NS at an etoposide concentration of </=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
307277|NCT01858909|Drug|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
307278|NCT01858896|Drug|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
307279|NCT01858896|Other|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
307280|NCT01858883|Drug|itacitinib|
307281|NCT01858883|Drug|Gemcitabine|
307282|NCT01858883|Drug|nab-paclitaxel|
307283|NCT01858883|Drug|filgrastim|
307284|NCT01858870|Drug|lacosamide|routine clinical practice
307285|NCT01858844|Other|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
307286|NCT01858831|Drug|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
307287|NCT01858831|Drug|Atovaquone|Atovaquone
307288|NCT01858805|Procedure|esophagectomy|
307289|NCT01858792|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
307290|NCT01858792|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
307291|NCT01858792|Other|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
307292|NCT01858779|Behavioral|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
307293|NCT01858779|Device|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
307294|NCT01858766|Drug|SOF|400 mg tablet administered orally once daily
307295|NCT01858766|Drug|VEL|Tablet administered orally once daily
307296|NCT01858766|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
307297|NCT01858753|Biological|Autologous fibroblasts|
307298|NCT01858753|Biological|placebo sterile saline|
307299|NCT01858740|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
307300|NCT01858740|Drug|Fludarabine Phosphate|Given IV
307301|NCT01858740|Other|Laboratory Biomarker Analysis|Correlative studies
307302|NCT01858740|Drug|Methotrexate|Given IV
307303|NCT01858740|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
307304|NCT01858740|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
307305|NCT01858740|Drug|Tacrolimus|Given IV or PO
307306|NCT01858740|Drug|Thiotepa|Given IV
307307|NCT01858740|Radiation|Total-Body Irradiation|Undergo TBI
307308|NCT01858727|Other|forced air warming group|30 minutes before the preoperative will use forced air warming
307309|NCT01858727|Other|control group|do not heating group
307310|NCT01858714|Behavioral|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
307311|NCT01858714|Behavioral|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
307312|NCT01858714|Behavioral|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
307313|NCT01858701|Device|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
307314|NCT01858701|Device|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
307315|NCT01858688|Device|Multiparametric MRI|an MRI of the prostate will be performed
307316|NCT01858688|Procedure|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
307317|NCT01858675|Other|Biomarkers, red blood cells and plasma assessment|
307318|NCT01858662|Procedure|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
307319|NCT01858662|Drug|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
307320|NCT01858662|Drug|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
307321|NCT01858662|Drug|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
307322|NCT01858662|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
307323|NCT01858662|Drug|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
307324|NCT01858649|Procedure|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
307328|NCT01858649|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
307332|NCT01858623|Drug|Hydrochlorothiazide|
307333|NCT01858610|Drug|Irbeasartan/hydrochlorothiazide|
307334|NCT01858610|Drug|Irbesartan|
307335|NCT01858610|Drug|Hydrochlorothiazide|
307336|NCT01858584|Drug|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.~dosage:~Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional~Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
307337|NCT01858584|Dietary Supplement|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
307338|NCT01858571|Drug|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.~Cycle A~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Etoposide (50 mg/m2/d)~Cycle B~Daily oral Thalidomide (at 3mg/kg)~Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)~Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
307339|NCT01858558|Biological|aMIL|Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
307340|NCT01858558|Drug|No aMIL|Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
307341|NCT01858545|Device|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
307342|NCT01858545|Device|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
307343|NCT01858532|Drug|Atrasentan|Film-coated tablet
307344|NCT01858532|Drug|Placebo|Film-coated tablet
307345|NCT01858506|Procedure|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
307346|NCT01858506|Procedure|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
307347|NCT01858493|Behavioral|Continence promotion group education workshop|Interactive group education workshop promoting continence
307348|NCT01858493|Behavioral|Sham health lecture|Interactive group education workshop about general health
307349|NCT01858480|Drug|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
307350|NCT01858480|Other|Placebo|Placebo dosage form designed to mock active.
307351|NCT01858467|Device|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
307352|NCT01858467|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
307353|NCT01858454|Procedure|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
307354|NCT01858454|Procedure|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere [Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.].
307355|NCT01858441|Drug|Abiraterone Acetate|
307356|NCT01858428|Device|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
307357|NCT01858428|Device|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
307358|NCT01858415|Device|TriPollar|
307359|NCT01858402|Drug|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
307360|NCT01858402|Drug|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
307361|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
307362|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
307363|NCT01858376|Dietary Supplement|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
307364|NCT01858363|Device|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
307365|NCT01858363|Device|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
307366|NCT01858350|Other|Active Music Therapy|
307367|NCT01858350|Other|Passive Music Therapy|
307368|NCT01858350|Other|Distraction Therapy|
307369|NCT01858337|Other|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
307370|NCT01858337|Other|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
307371|NCT01858337|Other|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
307763|NCT01855529|Drug|Ropivacaine in one arm and placebo (NaCl) in the other arm|
307372|NCT01858337|Other|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
307373|NCT01858324|Other|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
307374|NCT01858311|Dietary Supplement|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
307375|NCT01858311|Other|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
307376|NCT01858298|Other|Conservative treatment: pulpectomy and composite resin crown|
307377|NCT01858298|Other|Non-conservative treatment: Tooth extraction|
307378|NCT01858272|Drug|H5.020CMV.PDGF-b and limb compression bandage|
307379|NCT01858246|Device|Bonebridge|
307380|NCT01858246|Device|Bone Anchored Hearing Aid|
307381|NCT01858233|Behavioral|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
307382|NCT01858207|Procedure|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
307383|NCT01858207|Procedure|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
307384|NCT01858207|Drug|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
307385|NCT01858194|Device|Renal sympathetic denervation|"The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.~After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
307386|NCT01858194|Device|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
307387|NCT01858181|Biological|ocaratuzumab|
307388|NCT01858168|Drug|Olaparib|Tablets to be taken on an empty stomach twice a day.
307389|NCT01858168|Drug|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
307390|NCT01858168|Drug|Irinotecan|Administered via IV
307391|NCT01858155|Drug|Melatonin|
307392|NCT01858142|Behavioral|Parental presence decision tool|
307393|NCT01858142|Behavioral|Standard preparation|
307394|NCT01858129|Drug|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
307395|NCT01858129|Drug|placebo|
307396|NCT01858116|Drug|[68Ga]ABY-025|Intravenous injection followed by PET imaging
307397|NCT01858103|Drug|BMN 110|
307398|NCT01858090|Drug|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
307399|NCT01858090|Drug|Group Fentanyl|
307400|NCT01858090|Drug|Group sufentanil|
307401|NCT01858090|Drug|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to <100 mmHg, fluid loading and ephedrine (5 mg) were administered.
307402|NCT01858090|Drug|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
307403|NCT01858090|Drug|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
307404|NCT01858090|Drug|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
307405|NCT01858090|Drug|Diphenhydramine|for severe pruritus
307406|NCT01858090|Drug|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
307407|NCT01858090|Drug|Diclofenac sodium|as additional analgesic among cases in which VAS>3(Postoperatively)
307408|NCT01858077|Device|ABSORB BVS™|Bioresorbable scaffold
307409|NCT01858077|Device|XIENCE™|Drug eluting metallic stent
307410|NCT01858064|Drug|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
307411|NCT01858051|Dietary Supplement|Cholecalciferol|
307412|NCT01858051|Dietary Supplement|Placebo|
307413|NCT01858038|Device|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
307414|NCT01858025|Radiation|Pencil Beam scanning Radiation|
307415|NCT01858025|Drug|5-fluorouracil|
307416|NCT01858025|Drug|Mitomycin-C|
307417|NCT01858012|Behavioral|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks and have before and after alcohol cessation clinical and metabolic assessment and also patients with hepatitis C who have undergo therapy for hepatitis C may have repeat clinical and metabolic assessement
307418|NCT01857999|Drug|Losartan|
307419|NCT01857999|Drug|Placebo|
307420|NCT01857986|Device|AnapnoGuard 100 control unit|
307421|NCT01857973|Device|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
307422|NCT01857960|Behavioral|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
307423|NCT01857947|Other|AECOPD Mr proADM|
307424|NCT01857934|Drug|cyclophosphamide|Given intravenously (IV)
307425|NCT01857934|Drug|topotecan|Given IV
307426|NCT01857934|Biological|hu14.18K322A|Given IV
307427|NCT01857934|Procedure|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
307552|NCT01857076|Procedure|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
307764|NCT01855516|Drug|Heparin|
307428|NCT01857934|Procedure|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
307429|NCT01857934|Drug|cisplatin|Given IV
307430|NCT01857934|Drug|etoposide|Given IV
307431|NCT01857934|Drug|doxorubicin|Given IV
307432|NCT01857934|Drug|vincristine|Given IV
307433|NCT01857934|Drug|busulfan|Given IV
307434|NCT01857934|Drug|melphalan|Given IV
307435|NCT01857934|Biological|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
307436|NCT01857934|Biological|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
307437|NCT01857934|Radiation|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
307438|NCT01857934|Biological|GM-CSF|Given subcutaneously (SQ)
307439|NCT01857934|Biological|G-CSF|Given subcutaneously (SQ)
307440|NCT01857934|Drug|mesna|Given IV
307441|NCT01857934|Drug|levetiracetam|Given IV
307442|NCT01857934|Biological|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
307443|NCT01857934|Drug|Isotretinoin|Given orally (PO)
307444|NCT01857934|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
307445|NCT01857921|Drug|Pravastatin 20mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~Test group:~Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~Control group:~Pravastatin 20mg daily for 12 months after randomization"
307446|NCT01857921|Drug|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:~Test group:~Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization~Control group:~Pravastatin 20mg daily for 12 months after randomization"
307447|NCT01857895|Drug|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
307448|NCT01857882|Other|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.~Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities~Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system~Social worker (30 mins): values clarification exercise~Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
307449|NCT01857869|Biological|GSK257049 Dosage 1|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
307450|NCT01857869|Biological|GSK257049 Dosage 2|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
307451|NCT01857869|Procedure|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
307452|NCT01857856|Drug|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
307453|NCT01857843|Device|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
307454|NCT01857843|Device|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
307555|NCT01857063|Drug|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
307556|NCT01857037|Other|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
307455|NCT01857843|Drug|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~Pravastatin 20mg (mevalotin®, BMS)"
307456|NCT01857843|Drug|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.~Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.~Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)~Pravastatin 20mg (mevalotin®, BMS)"
307457|NCT01857830|Behavioral|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
307458|NCT01857830|Behavioral|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
307459|NCT01857817|Drug|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
307460|NCT01857817|Drug|Placebo|The placebo capsules will be prepared to match the active drug.
307461|NCT01857804|Drug|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
307462|NCT01857804|Drug|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
307463|NCT01857804|Drug|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
307464|NCT01857791|Behavioral|multidisciplinary, behavior modification|
307465|NCT01857765|Behavioral|Rehabilitation|Range of motion stretching exercises
307466|NCT01857765|Behavioral|Follow-up|Follow-up with surgeon's clinic
307467|NCT01857752|Drug|Temozolomide|
307468|NCT01857726|Drug|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
307469|NCT01857726|Drug|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
307470|NCT01857713|Device|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
307471|NCT01857700|Other|Compensation for transport cost|
307472|NCT01857700|Other|Compensation for lost wages|
307473|NCT01857700|Other|Compensation for transport cost and lost wages|
307474|NCT01857700|Other|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
307475|NCT01857661|Device|sound generator|hearing aid with an integrated sound generator
307476|NCT01857661|Device|hearing aids with only amplification|
307477|NCT01857648|Other|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
307478|NCT01857622|Drug|DU-176b 15mg|oral DU-176b 15mg once daily
307479|NCT01857622|Drug|DU-176b 30mg|oral DU-176b 30mg once daily
307480|NCT01857622|Drug|DU-176b 60mg|oral DU-176b 60mg once daily
307481|NCT01857609|Drug|Metformin|
307482|NCT01857609|Drug|Metformin and Pantoprazole|
307483|NCT01857609|Drug|Metformin and Rabeprazole|
307484|NCT01857596|Drug|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
307485|NCT01857583|Drug|15mg DU-176b|
307486|NCT01857583|Drug|30mg DU-176b|
307487|NCT01857583|Drug|Fondaparinux|
307488|NCT01857570|Radiation|Volume Computed Tomography of the wrist and carpus|
307489|NCT01857557|Other|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
307490|NCT01857544|Drug|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
307491|NCT01857531|Drug|Ganaxolone|"Pre-Quit Period:~Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.~Post-Quit Period:~Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
307492|NCT01857531|Drug|Nicotine Patch|"Pre-Quit Period:~Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.~Post-Quit Period:~Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
307493|NCT01857518|Other|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"Visit V1: Diagnostic and clinical assessments~Visit V2: psycho-behavioral assessment and neuroimaging~Visit V3: Diagnostic and clinical assessments~Visit V4: psycho-behavioral assessment and neuroimaging"
307494|NCT01857492|Device|tDCS|
307495|NCT01857492|Behavioral|Meditation|Both Active and SHAM groups will receive Meditation.
307496|NCT01857479|Drug|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
307553|NCT01857076|Other|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
307554|NCT01857063|Drug|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
307497|NCT01857479|Drug|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].~The first dose will be administered under direct supervision."
307498|NCT01857466|Procedure|Floseal|
307499|NCT01857466|Procedure|Bipolar coagulation|
307500|NCT01857453|Drug|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
307501|NCT01857453|Drug|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
307502|NCT01857453|Radiation|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
307503|NCT01857401|Other|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
307504|NCT01857388|Behavioral|ParentCorps|
307505|NCT01857375|Device|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
307506|NCT01857362|Drug|Nitisinone 20 mg|Nitisinone 20 mg capsules
307507|NCT01857362|Drug|Nitisinone 10 mg|Nitisinone 10 mg capsules
307508|NCT01857349|Other|Chlora Prep|Surgical Scrub skin preparation
307509|NCT01857349|Other|Dura Prep|Surgical Scrub skin preparation
307510|NCT01857336|Other|infusion of G-CSF mobilized peripheral harvest|
307511|NCT01857323|Drug|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
307512|NCT01857310|Dietary Supplement|5 mg folic acid and 30 mg elemental zinc|
307513|NCT01857310|Drug|Placebo Comparator: Placebo|
307514|NCT01857297|Biological|Enzira® vaccine|
307515|NCT01857284|Drug|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
307516|NCT01857284|Drug|Ursodeoxycholic Acid Capsules|250mg.tid.po
307517|NCT01857271|Drug|Erlotinib Hydrochloride|Given PO
307518|NCT01857271|Procedure|Therapeutic Conventional Surgery|Undergo thoracotomy
307519|NCT01857271|Other|Laboratory Biomarker Analysis|Correlative studies
307520|NCT01857258|Dietary Supplement|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
307521|NCT01857245|Other|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
307522|NCT01857232|Drug|Ondansetron|5HT3-antagonist
307523|NCT01857232|Drug|Placebo|Comparator
307524|NCT01857232|Drug|Dexamethasone|Corticosteroid
307525|NCT01857232|Drug|Fosaprepitant|NK1 antagonist
307526|NCT01857232|Drug|APD403 IV|Amisulpride IV 20 mg
307527|NCT01857232|Drug|APD403 oral|Amisulpride oral 10, 20 or 40 mg
307528|NCT01857219|Behavioral|Tai chi|
307529|NCT01857206|Biological|Mammalian cell based flu vaccine|
307530|NCT01857206|Biological|Egg based flu vaccine|
307531|NCT01857193|Drug|LEE011|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
307532|NCT01857193|Drug|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
307533|NCT01857193|Drug|Everolimus|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
307534|NCT01857180|Other|Curriculum|
307535|NCT01857167|Dietary Supplement|Fish Oil Supplementation|
307536|NCT01857167|Dietary Supplement|Flaxseed Oil Supplementation|
307537|NCT01857167|Dietary Supplement|placebo|
307538|NCT01857154|Dietary Supplement|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
307539|NCT01857154|Dietary Supplement|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.~Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
307540|NCT01857154|Dietary Supplement|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
307541|NCT01857141|Drug|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
307542|NCT01857141|Drug|normal saline|patients in the control groups received the equivalent volume of normal saline.
307543|NCT01857128|Device|Drawtex dressing|
307544|NCT01857128|Device|Negative Pressure Wound Therapy|
307545|NCT01857115|Drug|Carfilzomib|
307546|NCT01857115|Drug|Cyclophosphamide|
307547|NCT01857115|Drug|Dexamethasone|
307548|NCT01857102|Device|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
307549|NCT01857102|Device|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
307550|NCT01857089|Device|Orthotest CE|"Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.~Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.~Pressure measurement"
307551|NCT01857076|Procedure|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
307637|NCT01856387|Other|normal neutrophil-to Lymphocyte ratio|
307557|NCT01857024|Drug|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
307558|NCT01857011|Drug|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
307559|NCT01857011|Drug|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
307560|NCT01856998|Drug|Propofol|
307561|NCT01856998|Drug|Diprivan|
307562|NCT01856985|Drug|Misoprostol|
307563|NCT01856985|Drug|Mifepristone|
307564|NCT01856972|Procedure|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
307565|NCT01856972|Procedure|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
307566|NCT01856972|Other|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
307567|NCT01856959|Drug|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
307568|NCT01856959|Drug|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
307569|NCT01856959|Drug|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
307570|NCT01856946|Dietary Supplement|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
307571|NCT01856933|Drug|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
307572|NCT01856920|Biological|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
307573|NCT01856907|Drug|Sitagliptin-Metformin|Experimental -dipeptidyl peptidase-4 (DPP-4) inhibitor- oral medication
307574|NCT01856907|Drug|Metformin|Biguanide- insulin sensitizer
307575|NCT01856907|Drug|Placebo pill|Will evaluate effect of lifestyle and diet only
307576|NCT01856881|Drug|AMG 876|Ascending multiple doses of study drug administered SC
307577|NCT01856868|Drug|(-)-epicatechin|purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
307578|NCT01856855|Radiation|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
307579|NCT01856842|Procedure|Angiography and embolotherapy|
307580|NCT01856829|Dietary Supplement|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
307581|NCT01856829|Other|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
307582|NCT01856816|Other|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
307583|NCT01856816|Other|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
307584|NCT01856816|Other|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
307585|NCT01856803|Drug|anti thymoglobulin|
307586|NCT01856790|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
307587|NCT01856790|Drug|liraglutide|Liraglutide is a long-acting analog of human GLP-1 that works as a GLP-1 receptor agonist
307588|NCT01856777|Device|Semi-quantitative panel test|
307589|NCT01856777|Device|High sensitivity urine pregnancy test|
307590|NCT01856764|Drug|0.5% Roflumilast Cream|Roflumilast 0.5% cream
307591|NCT01856764|Drug|Vehicle Cream|Roflumilast formulation vehicle
307592|NCT01856738|Drug|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
307593|NCT01856738|Drug|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
307594|NCT01856725|Procedure|Hemodynamic measurements for CRT device programming|
307595|NCT01856725|Device|CRT device implant with MultiPoint Pacing|
307596|NCT01856712|Drug|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
307597|NCT01856686|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
307718|NCT01855854|Drug|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
307598|NCT01856686|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
307599|NCT01856673|Behavioral|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
307600|NCT01856673|Behavioral|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
307601|NCT01856673|Other|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
307602|NCT01856660|Behavioral|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to > 40 min per day, 5 times/week.
307603|NCT01856660|Behavioral|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
307604|NCT01856647|Procedure|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (~3 ml) will be obtained from the lower abdomen following local anesthesia.
307605|NCT01856634|Drug|100 mg Delamanid|100 mg Delamanid BID for 10 days
307606|NCT01856634|Drug|50 mg Delamanid|50 mg Delamanid BID for 10 days
307607|NCT01856634|Drug|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
307608|NCT01856634|Drug|10 mg Delamanid Pediatric Formulation|Patients > 10 kg will receive DPF 10 mg BID for 10 days
307609|NCT01856634|Drug|5 mg Delamanid Pediatric Formulation|"Patients > 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days~Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
307610|NCT01856634|Drug|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
307611|NCT01856621|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
307612|NCT01856621|Drug|Seretide Diskus|2 inhalations as a single dose
307613|NCT01856621|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
307614|NCT01856621|Drug|SF Easyhaler|2 inhalations as a single dose
307615|NCT01856595|Drug|PF-06291874|The dosing schedule is 5, 15, 50, 100 and 150 mg QD for 14 days for the first 5 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days and 30 mg QD for 28 days
307616|NCT01856595|Drug|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1- 5 and Part B cohort 1) or 28 days (Part B cohort 2).
307617|NCT01856582|Biological|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
307618|NCT01856569|Other|no intervention|in real life of drug,dosage,frequency and duration
307619|NCT01856556|Drug|NRX-1074|Single IV or PO administration
307620|NCT01856556|Drug|Placebo|Single IV or PO placebo administration
307621|NCT01856543|Other|Eucerin|
307622|NCT01856543|Other|Mometasone Furoate 0.1%|
307623|NCT01856530|Drug|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
307624|NCT01856530|Drug|Placebo|Matched placebo nasal spray
307625|NCT01856517|Drug|Clonidine|
307626|NCT01856517|Drug|Placebo|
307627|NCT01856491|Device|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
307628|NCT01856478|Drug|methotrexate|intravenous bolus injection, once weekly
307629|NCT01856478|Drug|afatinib|oral intake, once daily
307630|NCT01856452|Device|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
307631|NCT01856452|Device|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
307632|NCT01856439|Drug|ProSavin|Long term follow up of patients who received ProSavin in a previous study
307633|NCT01856426|Drug|EDP239|
307634|NCT01856426|Drug|Placebo|
307635|NCT01856413|Drug|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
307636|NCT01856387|Biological|high neutrophil to lymphocyte ratio|
307638|NCT01856374|Device|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
307639|NCT01856374|Device|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
307640|NCT01856374|Drug|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
307641|NCT01856374|Drug|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
307642|NCT01856361|Drug|Ramipril|Angiotensin Converting Enzyme Inhibitor
307643|NCT01856361|Drug|Placebo|Placebo pill that will match the treatment pill
307644|NCT01856348|Drug|Vitamin D|
307645|NCT01856335|Other|Patient Education|
307646|NCT01856335|Other|exercise: increase physical activity/goal setting|
307647|NCT01856322|Drug|Sulindac|one tablet 150mg twice daily
307648|NCT01856322|Drug|Placebo|One tablet twice daily
307649|NCT01856322|Other|Validate assays and shipping methods|
307650|NCT01856309|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
307651|NCT01856309|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
307652|NCT01856309|Drug|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
307653|NCT01856296|Procedure|Biopsy|
307654|NCT01856283|Drug|Nilotinib 300mg BID|Nilotinib
307655|NCT01856270|Drug|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
307656|NCT01856257|Biological|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
307657|NCT01856257|Biological|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
307658|NCT01856257|Drug|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
307659|NCT01856257|Biological|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
307660|NCT01856257|Drug|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
307661|NCT01856257|Drug|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
307662|NCT01856244|Behavioral|treadmill walking|
307663|NCT01856244|Device|Treadmill|
307664|NCT01856231|Behavioral|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
307665|NCT01856218|Drug|UX003|
307666|NCT01856205|Drug|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|"IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.~Placebo group received 0.9% saline intravenous at similar rate."
307667|NCT01856192|Drug|Cyclophosphamide|Given IV
307668|NCT01856192|Drug|Doxorubicin Hydrochloride|Given IV
307669|NCT01856192|Other|Laboratory Biomarker Analysis|Correlative studies
307670|NCT01856192|Drug|Lenalidomide|Given PO
307671|NCT01856192|Drug|Prednisone|Given PO
307672|NCT01856192|Biological|Rituximab|Given IV
307673|NCT01856192|Drug|Vincristine Sulfate|Given IV
307674|NCT01856179|Dietary Supplement|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
307675|NCT01856166|Device|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
307676|NCT01856166|Device|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
307677|NCT01856166|Drug|Levobupivacaine|
307678|NCT01856166|Drug|Sufentanil|
307679|NCT01856153|Dietary Supplement|Before meal|
307680|NCT01856153|Dietary Supplement|With Meal|
307681|NCT01856153|Dietary Supplement|After meal|
307682|NCT01856140|Biological|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
307762|NCT01855542|Other|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
307683|NCT01856127|Drug|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
307684|NCT01856127|Drug|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
307685|NCT01856114|Drug|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
307686|NCT01856114|Other|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
307687|NCT01856114|Behavioral|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
307688|NCT01856101|Drug|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
307689|NCT01856088|Device|Inspiron Stent|stent implantation
307690|NCT01856088|Device|Biomatrix Flex Stent|stent implantation
307691|NCT01856062|Drug|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
307692|NCT01856062|Drug|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
307693|NCT01856049|Other|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
307694|NCT01856036|Procedure|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
307695|NCT01856023|Drug|High Dose Interleukin-2|
307696|NCT01856023|Drug|Ipilimumab|
307697|NCT01856010|Other|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
307698|NCT01856010|Other|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
307699|NCT01855997|Drug|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
307700|NCT01855984|Dietary Supplement|Oral mixed tocotrienols|200mg per day
307701|NCT01855984|Dietary Supplement|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
307702|NCT01855971|Dietary Supplement|EGCG|Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.
307703|NCT01855971|Dietary Supplement|Placebo|Same capsules containing rice flour. No active treatment is given.
307704|NCT01855971|Other|Cognitive training|Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
307705|NCT01855958|Procedure|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
307706|NCT01855958|Procedure|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
307707|NCT01855945|Biological|Swine Influenza|Comparison of different dosages of vaccines
307708|NCT01855932|Behavioral|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
307709|NCT01855919|Drug|Duloxetine|Administered orally
307710|NCT01855919|Drug|Placebo|Administered orally
307711|NCT01855906|Procedure|Gap balanced surgical technique|Gap balanced surgical technique
307712|NCT01855906|Procedure|Measured resection|Measured resection surgical technique
307713|NCT01855893|Other|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
307714|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
307715|NCT01855880|Biological|AbGn-168H|
307716|NCT01855880|Biological|placebo|
307717|NCT01855867|Drug|Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
307719|NCT01855841|Drug|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
307720|NCT01855841|Drug|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
307721|NCT01855828|Drug|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
307722|NCT01855828|Drug|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).~For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
307723|NCT01855828|Drug|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
307724|NCT01855828|Drug|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
307725|NCT01855828|Drug|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
307726|NCT01855828|Drug|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
307727|NCT01855789|Drug|Tocilizumab (TCZ)|TCZ will be administered at a dose of 162 milligrams (mg) via SC injection weekly (if body weight is greater than or equal to [>/=] 100 kilograms [kg]) or every 2 weeks (if body weight was less than [<] 100 kg).
307728|NCT01855789|Drug|Methotrexate (MTX)|MTX will be administered at a stable dose (15 mg to 25 mg per week) orally.
307729|NCT01855789|Drug|Placebo (PBO)|PBO matching to MTX will be administered orally.
307730|NCT01855776|Device|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
307731|NCT01855776|Behavioral|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
307732|NCT01855776|Behavioral|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
307733|NCT01855776|Other|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
307734|NCT01855763|Drug|Metformin|
307735|NCT01855763|Drug|Insulin|
307736|NCT01855750|Drug|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
307737|NCT01855750|Drug|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
307738|NCT01855750|Drug|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
307739|NCT01855750|Drug|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
307740|NCT01855750|Drug|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
307741|NCT01855750|Drug|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
307742|NCT01855750|Drug|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
307743|NCT01855737|Drug|Warfarin|Prescribe warfarin to the patients who are needed.
307744|NCT01855724|Drug|Gemcitabine-Pazopanib|
307745|NCT01855711|Drug|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
307746|NCT01855698|Other|Observation|
307747|NCT01855685|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
307748|NCT01855672|Device|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
307749|NCT01855646|Other|Structured Sign Out Form|
307750|NCT01855633|Device|Traditional Theta burst stimulation (TBS)|
307751|NCT01855633|Device|Modified TBS rTMS|
307752|NCT01855633|Device|Sham rTMS|
307753|NCT01855607|Other|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
307754|NCT01855607|Other|placebo cream|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
307755|NCT01855594|Drug|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
307756|NCT01855594|Drug|Placebo|placebo tablet, 6 week course of oral administration
307757|NCT01855581|Drug|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
307758|NCT01855568|Procedure|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
307759|NCT01855568|Procedure|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
307760|NCT01855555|Drug|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
307761|NCT01855542|Other|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
307765|NCT01855503|Procedure|Core Biopsy|
307767|NCT01855477|Procedure|Histological biopsy procedure|
307768|NCT01855464|Procedure|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
307769|NCT01855464|Procedure|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
307770|NCT01855451|Drug|Cetuximab|
307771|NCT01855451|Radiation|RT (70 Gy in 35 fractions)|
307772|NCT01855451|Drug|Cisplatin|
307773|NCT01855438|Behavioral|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
307774|NCT01855425|Radiation|Radiation|Subjects to receive standard of care CT scan and additional Cone Beam CT scan.
307775|NCT01855412|Other|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
307776|NCT01855399|Behavioral|Peer Coaching|All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
307777|NCT01855399|Behavioral|Decision Aid|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
307778|NCT01855386|Other|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
307779|NCT01855386|Other|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
307780|NCT01855373|Dietary Supplement|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
307781|NCT01855373|Dietary Supplement|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
307782|NCT01855373|Dietary Supplement|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
307783|NCT01855373|Other|Placebo|Placebo: 2 capsules twice daily on an empty stomach
307784|NCT01855360|Drug|Tauroursodeoxycholic Acid and Doxycycline|
307785|NCT01855347|Device|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
307786|NCT01855334|Drug|Spironolactone|
307787|NCT01855334|Dietary Supplement|L-arginine|
307788|NCT01855334|Drug|Placebo|
307789|NCT01855321|Drug|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
307790|NCT01855321|Drug|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
307791|NCT01855308|Procedure|Single site robotic chole|Cholecystectomy
307792|NCT01855308|Device|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
307793|NCT01855295|Dietary Supplement|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
307794|NCT01855282|Behavioral|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
307795|NCT01855269|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
307796|NCT01855269|Dietary Supplement|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
307797|NCT01855269|Dietary Supplement|placebo sterile water|
307798|NCT01855256|Drug|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
307799|NCT01855256|Drug|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
307800|NCT01855243|Drug|regular insulin|
307801|NCT01855243|Drug|70/30 insulin|
307802|NCT01855243|Drug|Glargine|
307803|NCT01855243|Drug|glulisine|
307804|NCT01855230|Drug|ASM-024|ASM-024 b.i.d for 14 days
307805|NCT01855230|Drug|Placebo|Placebo b.i.d. for 14 days
307806|NCT01855217|Drug|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
307807|NCT01855217|Drug|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
307808|NCT01855217|Drug|Placebo|0,9% NaCl
307809|NCT01855204|Radiation|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
307810|NCT01855178|Device|Emfit Movement Monitor|Factory settings
307811|NCT01855165|Behavioral|Advice on DDIs|
307812|NCT01855152|Other|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
307813|NCT01855152|Other|Treatment as usual|Treatment delivered as usual in the care home
307814|NCT01855139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
307815|NCT01855126|Other|Blue light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver blue light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
307816|NCT01855126|Other|Red light|After a two week baseline collection period, half of the subjects will initially be given light masks that deliver red light through the closed eyelids, while subjects are sleeping. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that red light exposure will have no effect on the timing of the CBTmin.
307817|NCT01855100|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
307818|NCT01855074|Drug|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
307819|NCT01855061|Procedure|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
307820|NCT01855061|Procedure|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
307821|NCT01855061|Procedure|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
307822|NCT01855061|Procedure|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
307823|NCT01855048|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
307824|NCT01855048|Other|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
307825|NCT01855035|Other|prolonged ECG monitoring|10-day Holter ECG measurement
307826|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
307827|NCT01855022|Behavioral|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
307828|NCT01855009|Dietary Supplement|MannaBears|Subjects will be administered 4 MannaBears daily
307829|NCT01855009|Dietary Supplement|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
307830|NCT01855009|Dietary Supplement|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
307831|NCT01855009|Dietary Supplement|Vitamin D3|Subjects will be administered 800 IU vitamin D3
307832|NCT01854996|Drug|PF-05089771|450mg
307833|NCT01854996|Drug|PF-05089771|450mg
307834|NCT01854996|Drug|PF-05089771|450mg
307835|NCT01854970|Drug|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
307836|NCT01854957|Biological|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
307837|NCT01854944|Drug|Brexpiprazole 1mg to 4mg|
307838|NCT01854931|Behavioral|Tai Ji Quan|single aim intervention
307839|NCT01854918|Biological|Evolocumab|Administered by subcutaneous injection either every 2 weeks or once a month (patient preference) using a prefilled autoinjector pen
307840|NCT01854918|Drug|Standard of Care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
307841|NCT01854905|Other|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
307842|NCT01854892|Other|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
307843|NCT01854892|Other|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
307844|NCT01854892|Other|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
307845|NCT01854866|Other|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
307846|NCT01854853|Behavioral|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
307847|NCT01854853|Behavioral|Health Promotion|Health promotion intervention
307848|NCT01854827|Drug|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
307849|NCT01854814|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
307850|NCT01854814|Drug|Losartan|Maximum tolerated labeled dose of Losartan
307851|NCT01854801|Other|Individual medical Care|Individual medical care in occupational and environmental diseases centers
307852|NCT01854801|Other|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
307853|NCT01854788|Other|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
307854|NCT01854788|Other|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
307855|NCT01854788|Other|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
307856|NCT01854775|Drug|E/C/F/TAF|E/C/F/TAF tablets contain 150 mg of elvitegravir (EVG), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of tenofovir alafenamide (TAF; as 11.2 mg of TAF fumarate)
307857|NCT01854775|Drug|E/C/F/TAF (Low Dose)|90/90/120/6 mg STR administered orally
307858|NCT01854762|Drug|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
307859|NCT01854762|Drug|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
307860|NCT01854749|Drug|S1 combined with cisplatin|
307861|NCT01854736|Drug|Grazax|GRAZAX
307862|NCT01854736|Other|Placebo|Placebo
307863|NCT01854723|Drug|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
307864|NCT01854723|Drug|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
307865|NCT01854710|Drug|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
307866|NCT01854710|Drug|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
307867|NCT01854710|Drug|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
307868|NCT01854710|Drug|Oral placebo|Oral capsule identical in appearance to moxifloxacin
307869|NCT01854697|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
307870|NCT01854697|Drug|Ribavirin|Tablet
307871|NCT01854697|Drug|Telaprevir|Film-coated tablet
307872|NCT01854697|Drug|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
307873|NCT01854684|Drug|Temoporfin|Given IV
307874|NCT01854684|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
307875|NCT01854684|Drug|Photodynamic Therapy|Undergo intraoperative PDT
307876|NCT01854684|Other|Laboratory Biomarker Analysis|Correlative studies
307877|NCT01854684|Other|Pharmacological Study|Correlative studies
307878|NCT01854671|Other|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
307879|NCT01854658|Drug|GFF MDI (PT003)|GFF MDI administered as two puffs BID
307880|NCT01854658|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
307881|NCT01854658|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
307882|NCT01854658|Drug|Placebo|
307883|NCT01854645|Drug|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
307884|NCT01854645|Drug|GP MDI|GP MDI administered as two puffs BID
307885|NCT01854645|Drug|FF MDI|FF MDI administered as two puffs BID
307886|NCT01854645|Drug|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
307887|NCT01854645|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID
307888|NCT01854632|Biological|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
307889|NCT01854632|Biological|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
307890|NCT01854619|Device|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
307891|NCT01854619|Device|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
307892|NCT01854606|Drug|AEB071|a Protein Kinase C Inhibitor
307893|NCT01854606|Drug|Everolimus|mTOR inhibitor
307894|NCT01854593|Drug|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
307895|NCT01854593|Procedure|Vitrectomy|vitrectomy of 25 gauge system.
380912|NCT01286935|Drug|Placebo|
307896|NCT01854593|Device|Sham injection|Sham injection one day before vitrectomy
307897|NCT01854567|Biological|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
307898|NCT01854567|Biological|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
307899|NCT01854554|Radiation|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
307900|NCT01854554|Radiation|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
307901|NCT01854554|Behavioral|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
307902|NCT01854554|Behavioral|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
307903|NCT01854528|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
307904|NCT01854528|Drug|Ribavirin|Tablet
307905|NCT01854528|Drug|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
307906|NCT01854528|Drug|Telaprevir|Film-coated tablet
307907|NCT01854515|Drug|Budesonide|
307908|NCT01854515|Drug|Dexamethasone acetate|
307909|NCT01854502|Behavioral|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
307910|NCT01854502|Behavioral|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
307911|NCT01854489|Drug|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days [Phase 1 ]
307912|NCT01854489|Drug|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
307913|NCT01854489|Drug|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
307914|NCT01854476|Device|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
307915|NCT01854463|Drug|Vitamin D3|2000IU per day
307916|NCT01854463|Drug|placebo|elemental calcium 200mg per day per 24 weeks
307917|NCT01854450|Other|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).~Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
307918|NCT01854450|Other|control|usual obstetrical care
307919|NCT01854437|Drug|Mg Oxide|250 mg orally for 4 weeks
307920|NCT01854424|Other|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
307921|NCT01854411|Other|analgesic measure|ibuprofen and ketoprofen measured into breast milk
307922|NCT01854398|Device|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
307923|NCT01854398|Device|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
307924|NCT01854385|Drug|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
307925|NCT01854372|Drug|R-HCVAD and R-MC|
307926|NCT01854359|Drug|Idebenone|
307927|NCT01854346|Behavioral|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
307928|NCT01854333|Other|ADOS module 1-4 or ADI-R|
307929|NCT01854320|Behavioral|Acceptance-based treatment|
307930|NCT01854320|Behavioral|Standard behavioral treatment|
307931|NCT01854307|Procedure|Pneumoperitoneum and SVV/PPV|
307932|NCT01854294|Drug|GM604|GM604 treated group subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
307933|NCT01854294|Drug|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
307934|NCT01854268|Drug|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
307935|NCT01854255|Drug|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
307936|NCT01854242|Other|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
307937|NCT01854229|Device|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
307938|NCT01854216|Drug|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
307939|NCT01854216|Drug|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
307940|NCT01854216|Drug|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
307941|NCT01854203|Drug|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
307942|NCT01854203|Drug|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
307943|NCT01854190|Device|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
307944|NCT01854177|Drug|Aprepitant|
307945|NCT01854177|Drug|Placebo|
307946|NCT01854164|Dietary Supplement|HGE (hydrolyzed ginseng extract)|
307947|NCT01854164|Dietary Supplement|Placebo|
307948|NCT01854151|Other|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
307949|NCT01854138|Device|Prevena Incision Management System|Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty or Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
307950|NCT01854125|Biological|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
307951|NCT01854125|Biological|autologous bone marrow msenchymal stem cells transplantation|
307952|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 1.
307953|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 2.
307954|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m^2 x 21 days) with group 3.
307955|NCT01854086|Other|Questionnaires about compliance and persistence with bisphosphonates treatment|
307956|NCT01854073|Drug|Hyoscine butyl bromide|
307957|NCT01854073|Drug|Normal saline|
307958|NCT01854047|Drug|Dupilumab|Solution for injection, Subcutaneous injection
307959|NCT01854047|Drug|placebo|Solution for injection, Subcutaneous injection
307960|NCT01854047|Drug|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
307961|NCT01854047|Drug|Salbutamol/albuterol|Oral inhalation as needed
307962|NCT01854047|Drug|Levosalbutamol/levalbuterol|Oral inhalation as needed
307963|NCT01854034|Drug|AUY922|AUY922 administered intravenously once a week at 70mg/m2
307964|NCT01854021|Procedure|intravenous anesthesia|intravenous anesthesia
307965|NCT01854021|Procedure|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
307966|NCT01854021|Procedure|inhalational anesthesia|inhalational anesthesia
307967|NCT01854008|Other|rehabilitation more the urban circuit|"included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index"
307968|NCT01854008|Other|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
307969|NCT01853995|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
307970|NCT01853982|Drug|Ceftolozane/Tazobactam|
307971|NCT01853982|Drug|Piperacillin/Tazobactam|
307972|NCT01853969|Other|Typing assessment|
307973|NCT01853956|Drug|Alprazolam 0.25 mg|Reference product
307974|NCT01853956|Drug|Alprazolam 0.25 mg|Test product
307975|NCT01853930|Behavioral|Platform for Administering Eye-movement Control Training|The Platform for Administering Eye-movement Control Training (PAECT) meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
307976|NCT01853917|Other|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
307977|NCT01853904|Procedure|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
394134|NCT01185418|Drug|lactose|
307978|NCT01853904|Procedure|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
307979|NCT01853891|Other|dim light at night|
307980|NCT01853878|Biological|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
307981|NCT01853878|Biological|Placebo|Intramuscular administration
307982|NCT01853865|Other|Instruction in self-referral|
307983|NCT01853852|Drug|GR181413A/AT1001 solution|Powder for reconstitution
307984|NCT01853852|Drug|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
307985|NCT01853852|Other|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
307986|NCT01853852|Drug|Placebo capsule|Solution matched
307987|NCT01853826|Drug|afatinib|Patients will receive afatinib once daily
307988|NCT01853813|Drug|Bevacizumab and FOLFIRI|"The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.~After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.~Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity"
307989|NCT01853800|Drug|Rivaroxaban (Xarelto, BAY59-7939)|
307990|NCT01853787|Drug|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
307991|NCT01853787|Drug|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
307992|NCT01853774|Behavioral|Tailored navigation|
307993|NCT01853761|Device|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
307994|NCT01853761|Device|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
307995|NCT01853761|Device|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
307996|NCT01853761|Device|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
307997|NCT01853761|Device|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
307998|NCT01853761|Device|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
307999|NCT01853748|Drug|Trastuzumab|
308000|NCT01853748|Drug|Paclitaxel|
308001|NCT01853748|Drug|Trastuzumab emtansine|
308002|NCT01853722|Drug|DCN01|Three serial applications per periocular region.
308003|NCT01853722|Drug|Unisol|Three serial applications per periocular region.
308004|NCT01853709|Behavioral|Education|
308005|NCT01853709|Other|Fiber free diet|
308006|NCT01853709|Dietary Supplement|Adjuvants|
308007|NCT01853709|Drug|Polyethylene glycol (PEG)|
308008|NCT01853709|Drug|Bisacodyl|
308009|NCT01853696|Drug|loteprednol etabonate|
308010|NCT01853696|Drug|prednisolone acetate 1%|
308011|NCT01853683|Procedure|Conservative Management|
308012|NCT01853683|Procedure|Operative Management|
308013|NCT01853670|Radiation|concurrent chemo + IGRT|
308014|NCT01853670|Radiation|neoadjuvant chemo + IGRT|
308015|NCT01853657|Other|Virological monitoring|
308016|NCT01853644|Drug|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
308017|NCT01853631|Biological|CD19 CAR T Cells|"Group 1: CD19.CAR/28137ζ at 1×10^6 cells/m^2 and CD19.CAR/28ζ at 1×10^6 cells/m^2~Group 2: CD19.CAR/28137ζ at 5×10^6 cells/m^2 and CD19.CAR/28ζ at 5×10^6 cells/m^2~Group 3: CD19.CAR/28137ζ at 2×10^7 cells/m^2 and CD19.CAR/28ζ at 2×10^7 cells/m^2"
308018|NCT01853631|Drug|Fludarabine|3 daily doses of fludarabine (30 mg/m2) will be administered finishing at least 24 hours before T cell infusion.
308019|NCT01853631|Drug|Cyclophosphamide|3 daily doses of cyclophosphamide (500 mg/m2/day) will be administered finishing at least 24 hours before T cell infusion.
308020|NCT01853618|Drug|Tremelimumab|3.5 mg/kg or 10 mg /kg IV every 4 weeks times 6 doses and then every 12 weeks for 2 years
308021|NCT01853618|Procedure|RFA|Performed on Day 36
308022|NCT01853618|Procedure|TACE|Performed on Day 36 and may be repeated (as per standard of care) on months 3, 7, and 13, and q6 months thereafter (if indicated)
308023|NCT01853618|Procedure|Cryoablation|Performed on Day 36
308024|NCT01853605|Device|Anatomically shaped silicone gel-filled breast implants|Surgical implant
308025|NCT01853579|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
308026|NCT01853579|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.~Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
308210|NCT01852123|Device|High-sensitivity troponin I assay|
308027|NCT01853566|Drug|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
308028|NCT01853553|Drug|Spironolactone|Blood pressure medication.
308029|NCT01853553|Drug|Sugar pill|Placebo.
308030|NCT01853540|Drug|Sildenafil|
308031|NCT01853501|Procedure|Autologous fat grafting|ADSC ovary injection
308032|NCT01853488|Radiation|DXA|Osteodensitometry
308033|NCT01853488|Radiation|pQCT|Osteodensitometry
308034|NCT01853475|Drug|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
308035|NCT01853475|Drug|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
308036|NCT01853475|Drug|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
308037|NCT01853475|Drug|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
308038|NCT01853462|Other|PNF training|Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
308039|NCT01853462|Other|Balance training|Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
308040|NCT01853449|Drug|Fentanyl Citrate|
308041|NCT01853449|Other|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
308042|NCT01853449|Drug|Placebo|0.9% saline
308043|NCT01853436|Device|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
308044|NCT01853423|Drug|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
308045|NCT01853410|Device|gekoTM|
308046|NCT01853397|Device|Liposonix System (Model 2)|
308047|NCT01853384|Biological|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
308048|NCT01853384|Other|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
308049|NCT01853371|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
308050|NCT01853371|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
308051|NCT01853358|Biological|NK Cell infusion|"level 1: 1 x 10e6 NK cells /kg;~level 2: 5 x 10e6 NK cells /kg;~level 3: > 5.10e6 and ≤ 5.10e7 cellules NK/kg"
308052|NCT01853319|Drug|Regorafenib (Stivarga, BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
308053|NCT01853306|Drug|Veliparib|veliparib
308054|NCT01853293|Drug|Kudzu extract|
308055|NCT01853293|Drug|Placebo|
308056|NCT01853293|Behavioral|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
308057|NCT01853280|Drug|L-methylfolate|15mg/day L-methylfolate.
308058|NCT01853280|Drug|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
308059|NCT01853280|Drug|Placebo|15 mg matched placebo comparator, with open-label OROS-Methylphenidate
308060|NCT01853267|Procedure|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
308061|NCT01853267|Procedure|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
308062|NCT01853254|Drug|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
308063|NCT01853254|Drug|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing < 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
308064|NCT01853241|Procedure|Single Balloon|All patients in this group will undergo single balloon enteroscopy
308065|NCT01853241|Procedure|Spirus|All patients in this group will undergo Spirus Enteroscopy
308066|NCT01853228|Drug|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
308067|NCT01853228|Drug|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
397206|NCT01161537|Drug|Placebo|Tablet.
308068|NCT01853228|Drug|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
308069|NCT01853215|Device|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
308070|NCT01853202|Behavioral|Supervised aerobic exercise training|
308071|NCT01853189|Other|OMT + Usual Care|patients from this group received 6 sessions of OMT
308072|NCT01853189|Other|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
308073|NCT01853176|Drug|Liposomal Injection Bupivacaine (Exparel)|
308074|NCT01853176|Drug|Standard bupivicaine|
308075|NCT01853163|Procedure|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received Gadolinium-containing contrast agents in the past.
308076|NCT01853150|Device|rTMS Motor cortex|
308077|NCT01853150|Device|rTMS Supplementary motor area|
308078|NCT01853137|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
308079|NCT01853124|Drug|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
308080|NCT01853124|Drug|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
308081|NCT01853111|Biological|Interleukin-2|
308082|NCT01853098|Behavioral|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
308083|NCT01853085|Drug|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
308084|NCT01853072|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
308085|NCT01853072|Other|Nepafenac vehicle|Inactive ingredients used as placebo comparator
308086|NCT01853072|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
308087|NCT01853046|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
308088|NCT01853033|Biological|ABT-122|Injection
308089|NCT01853033|Biological|Placebo|Placebo Injection
308090|NCT01853020|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
308091|NCT01853020|Drug|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
308092|NCT01853007|Behavioral|COACH Program|
308093|NCT01852994|Drug|Testosterone replacement|Application quarterly of Testosterone Undecylate
308094|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
308095|NCT01852981|Behavioral|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
308096|NCT01852981|Behavioral|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
308097|NCT01852955|Drug|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
308098|NCT01852955|Drug|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
308099|NCT01852942|Drug|Losartan|We will start with 50 mg of losartan by mouth daily. We will increase the dosage to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
308100|NCT01852942|Drug|Placebo|one tablet by mouth daily
308173|NCT01852396|Procedure|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
405578|NCT01097096|Biological|CAD106|
308101|NCT01852929|Other|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
308102|NCT01852916|Device|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
308103|NCT01852916|Device|NHFOV|Nasal High Frequency Oscillatory Ventilation
308104|NCT01852903|Dietary Supplement|calcium ascorbate|
308105|NCT01852903|Dietary Supplement|ascorbic acid|
308106|NCT01852903|Other|placebo|
308107|NCT01852890|Drug|Ascorbate|Intravenous infusion of high-dose ascorbate
308108|NCT01852890|Drug|Gemcitabine|Intravenous chemotherapeutic
308109|NCT01852890|Radiation|Radiation therapy|
308110|NCT01852877|Behavioral|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
308111|NCT01852864|Drug|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
308112|NCT01852851|Behavioral|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
308113|NCT01852825|Biological|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
308114|NCT01852825|Other|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
308115|NCT01852825|Biological|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
308116|NCT01852812|Drug|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
308117|NCT01852812|Drug|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
308118|NCT01852799|Drug|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
308119|NCT01852786|Other|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
308120|NCT01852786|Other|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
308121|NCT01852773|Procedure|Open repair of thoracic aorta injury|open surgical management of aortic injury
308122|NCT01852773|Procedure|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
308123|NCT01852747|Procedure|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
308124|NCT01852734|Procedure|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)~26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
308125|NCT01852734|Procedure|embolizations|comparison between the two microspheres
308126|NCT01852721|Behavioral|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
308127|NCT01852721|Behavioral|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
308128|NCT01852695|Behavioral|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
308129|NCT01852682|Drug|PA21|
308130|NCT01852669|Procedure|Inversion|Patients inverted 30 degree head down in Trendelenburg position
308131|NCT01852669|Procedure|Shock Wave Lithotripsy|Shock wave lithotripsy
308132|NCT01852669|Drug|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
308209|NCT01852136|Device|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
405579|NCT01097096|Biological|CAD106|
308133|NCT01852656|Behavioral|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.~Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
308134|NCT01852656|Behavioral|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
308135|NCT01852656|Behavioral|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
308136|NCT01852643|Procedure|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
308137|NCT01852643|Procedure|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
308138|NCT01852630|Drug|cefepime + Albumin|cefepime + Albumin will be given for 2 days
308139|NCT01852630|Drug|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
308140|NCT01852617|Behavioral|Training in smoking cessation counseling|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
308141|NCT01852604|Drug|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
308142|NCT01852604|Drug|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
308143|NCT01852604|Drug|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
308144|NCT01852604|Drug|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
308145|NCT01852604|Drug|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
308146|NCT01852604|Biological|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
308147|NCT01852604|Other|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
308148|NCT01852591|Biological|PCV 13|
308149|NCT01852578|Drug|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
308150|NCT01852565|Drug|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
308151|NCT01852565|Drug|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
308152|NCT01852552|Device|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
308153|NCT01852552|Procedure|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
308154|NCT01852539|Drug|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
308155|NCT01852539|Drug|propofol|Propofol 2.0 mg/kg was administrated
308156|NCT01852539|Device|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
308157|NCT01852526|Device|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
308158|NCT01852526|Device|Active Comparator: Plif|monosegmental PLIF
308159|NCT01852513|Drug|QNASL|
308160|NCT01852513|Drug|Placebo nasal spray|
308161|NCT01852500|Other|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
308162|NCT01852500|Other|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
308163|NCT01852487|Dietary Supplement|400mg /day during 6 months|
308164|NCT01852474|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
308165|NCT01852461|Drug|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
308166|NCT01852461|Drug|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
308167|NCT01852448|Genetic|Blood or Saliva Sample Collection|A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
308168|NCT01852448|Other|Glucose -potentiated arginine (GPA) stimulation tests|Glucose -potentiated arginine (GPA) stimulation tests and mixed meal tolerance tests (MMTT) will be performed on two separate days in the outpatient setting.
308169|NCT01852435|Drug|R-CEOP-70|
308170|NCT01852435|Drug|R-CEOP-90|
308174|NCT01852383|Drug|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.~Adverse events: All adverse events and serious adverse events were documented.~The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.~Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
308175|NCT01852370|Biological|CD3/CD19 negative allogeneic hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
308176|NCT01852357|Other|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
308177|NCT01852357|Other|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
308178|NCT01852344|Drug|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
308179|NCT01852344|Drug|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
308180|NCT01852344|Behavioral|Easy Behavioral Task|Subjects do an easy version of the Letter E Task.
308181|NCT01852344|Behavioral|Hard Behavioral Task|Subjects do a hard version of the Letter E Task.
308182|NCT01852331|Drug|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
308183|NCT01852331|Drug|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
308184|NCT01852318|Drug|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
308185|NCT01852318|Drug|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
308186|NCT01852318|Drug|placebo|
308187|NCT01852305|Other|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI>30) or moderate sleep apnea (AHI>15 to <30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI>5 to <15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
308188|NCT01852305|Device|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
308189|NCT01852292|Drug|Buparlisib|Buparlisib comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
308190|NCT01852292|Drug|Buparlisib matching Placebo|Buparlisib matching placebo comes in gelatin capsules and is taken orally at a dose of 100 mg/day.
308191|NCT01852292|Drug|Paclitaxel|Paclitaxel is an intravenous infusion that is given once every week in 80 mg/m^2.
308192|NCT01852279|Device|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
308193|NCT01852279|Device|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
308194|NCT01852266|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
308195|NCT01852266|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
308196|NCT01852253|Procedure|2% chlorhexidine|
308197|NCT01852253|Procedure|0.12% chlorhexidine|
308198|NCT01852214|Drug|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
308199|NCT01852214|Drug|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
308200|NCT01852201|Device|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
308201|NCT01852188|Other|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
308202|NCT01852175|Drug|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
308203|NCT01852175|Drug|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
308204|NCT01852162|Drug|Dabigatran|Dabigatran 150mg
308205|NCT01852162|Drug|Placebo|Matching placebo tablets
308206|NCT01852149|Device|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
308207|NCT01852136|Device|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
308208|NCT01852136|Device|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
308211|NCT01852110|Drug|MK-7622|MK-7622 capsule
308212|NCT01852110|Drug|Placebo|Matching placebo to MK-7622 capsule
308213|NCT01852110|Drug|AChEI|"One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally"
308214|NCT01852097|Behavioral|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:~Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.~Give feedback to individuals on their questionnaire responses.~Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.~Provide advice on overcoming practical barriers.~Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.~Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
308215|NCT01852071|Genetic|Infusion of autologous EFS-ADA LV CD34+|Infusion of OTL-101 after reduced intensity conditioning
308216|NCT01852058|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
308217|NCT01852045|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
308218|NCT01852032|Radiation|Tomosynthesis Breast Scanning|The breast is positioned and compressed the same way it is in a conventional mammogram using a compression paddle device. The subject will be instructed to hold their breath and not move during the 7- second 3-D tomosynthesis acquisition. The affected breast is positioned with MLO compression. The radiation dose levels for each scan are equivalent to mammography
308219|NCT01852032|Radiation|Breast CT Scanning|"CT scanning will be performed before and after I.V. iodine contrast injection. The subject will lie prone on a large table (which is covered by a foam pad), and she will place the breast to be scanned in a small hole in that tabletop. The hole is surrounded by a soft neoprene hammock, which will allow the subject's entire upper torso to slump into the scan plane of the device. After positioning of the affected breast by a female mammography technologist, the subject will be instructed to hold their breath for 16 seconds and the pre-contrast scan will commence. There will be no breast compression. Other than the sound of the relatively noisy x-ray system in the room, the subject will not feel or sense any aspect of this scan."
308220|NCT01852019|Drug|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
308221|NCT01852019|Drug|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.~Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
308222|NCT01852006|Device|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
308223|NCT01851993|Drug|Ondansetron|
308224|NCT01851993|Drug|Placebo|0.9% saline
308225|NCT01851980|Other|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
308226|NCT01851980|Drug|Furosemide|40 mg and 120 mg
308227|NCT01851980|Drug|Placebo|0.9% saline
308228|NCT01851967|Other|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
308229|NCT01851954|Drug|Clarithromycin|IV clarithromycin infusion
308230|NCT01851941|Drug|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
308231|NCT01851915|Behavioral|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
308232|NCT01851915|Behavioral|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
308233|NCT01851876|Device|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
308234|NCT01851863|Drug|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
308235|NCT01851863|Drug|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
308236|NCT01851863|Drug|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
308237|NCT01851863|Drug|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
308238|NCT01851850|Drug|Opicapone|25mg or 50mg once per day
308239|NCT01851837|Other|Exercise time|Continuous training, Interval training
308240|NCT01851824|Drug|acenocoumarol|4 mg single oral doses on Days 1 and 23
308241|NCT01851824|Drug|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
308242|NCT01851798|Other|Home sleep test administered to all enrolled subjects|
308288|NCT01851473|Drug|acetazolamide|15 mg orally on days 2-5
308584|NCT01849055|Drug|LY3023703|Administered orally
308243|NCT01851785|Behavioral|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
308244|NCT01851772|Device|Treatment with Electronic Brachytherapy|
308245|NCT01851759|Drug|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
308246|NCT01851759|Drug|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.~1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
308247|NCT01851733|Device|MRI-guided Laser Heat Ablation (MLA)|
308248|NCT01851733|Drug|Doxorubicin|
308249|NCT01851733|Other|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:~before MLA (up to 3 days before)~2 weeks after MLA~4 weeks after MLA~every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
308250|NCT01851733|Device|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
308251|NCT01851720|Drug|Low dose fentanyl PCA|
308252|NCT01851720|Drug|Standard IV fentanyl bolus|
308253|NCT01851707|Drug|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
308254|NCT01851707|Drug|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
308255|NCT01851694|Drug|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
308256|NCT01851694|Drug|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
308257|NCT01851681|Drug|Amoxicillin|
308258|NCT01851655|Behavioral|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
308259|NCT01851642|Procedure|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
308260|NCT01851642|Procedure|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
308261|NCT01851642|Procedure|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
308262|NCT01851642|Drug|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
308263|NCT01851629|Behavioral|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
308264|NCT01851629|Other|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
308265|NCT01851616|Dietary Supplement|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
308266|NCT01851616|Dietary Supplement|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
308267|NCT01851603|Device|AVL-3288|Drug
308268|NCT01851603|Drug|Placebo|Identical diluent to that used for AVL-3288
308269|NCT01851590|Device|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
308270|NCT01851590|Drug|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
308271|NCT01851590|Drug|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
308272|NCT01851577|Behavioral|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
308273|NCT01851577|Behavioral|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
308274|NCT01851564|Device|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
308275|NCT01851564|Other|Standard Therapy|Standard Medical and Endoscopic Therapy
308276|NCT01851551|Drug|Vincristine Sulfate Liposome Injection plus rituximab|
308277|NCT01851538|Other|Observational study; no intervention.|
308278|NCT01851525|Device|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
308279|NCT01851512|Drug|T-R (Test-Reference drug)|
308280|NCT01851512|Drug|R-T (Reference-Test drug)|
308281|NCT01851499|Dietary Supplement|Ultramicronized PEA (Normast)|600 mg
308282|NCT01851486|Drug|Clonidine|Clonidine 0.15 mg
308283|NCT01851486|Drug|Naloxone|naloxone 0.15 mg/kg
308284|NCT01851486|Drug|placebo|
308285|NCT01851486|Other|saline|
308286|NCT01851473|Drug|cocaine|25 mg IV on days 1, 5, and 10
308287|NCT01851473|Drug|quinine|80 mg orally on days 7-10
308289|NCT01851460|Device|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer. After infiltration of the skin (for percutaneous approach) with a local anesthetic, the needle probe will be directed into the lesion. For all methods, the needle placement is confirmed to be within the lesion by ultrasound or other imaging modality as appropriate. After confirming needle placement, the lesion will be heated to a target temperature of >75 (Infinite)c for up to 15 minutes. The exposure time may be varied depending on the temperatures achieved. Depending on the size of the lesion to be ablated, multiple passes of the probe as well as multiple ablation cycles may be performed. Adequacy of ablation will be monitored by ultrasound throughout the procedure. Depending on the size of the lesions and the time required to complete the ablation, multiple lesions may be treated as staged procedures so as to improve safety.
308290|NCT01851408|Drug|sorafenib tosylate|Given orally
308291|NCT01851408|Drug|temsirolimus|Given IV
308292|NCT01851369|Drug|TRC 102|TRC102 has been shown to potentiate the activity of temozolomide by preventing BER and allowing cleavage of TRC102 bound DNA, which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co-administered with TMZ and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
308293|NCT01851343|Other|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
308294|NCT01851330|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
308295|NCT01851330|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
308296|NCT01851304|Dietary Supplement|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
308297|NCT01851304|Dietary Supplement|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
308298|NCT01851278|Drug|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
308299|NCT01851278|Drug|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
308300|NCT01851265|Drug|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
308301|NCT01851265|Other|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
308302|NCT01851265|Other|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
308303|NCT01851265|Other|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
308304|NCT01851252|Device|Methacetin (with Breath testing device)|The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
308305|NCT01851226|Procedure|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
308306|NCT01851200|Drug|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
308307|NCT01851187|Behavioral|antenatal psychological intervention|"emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
308308|NCT01851187|Behavioral|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
308309|NCT01851174|Drug|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m^2) IV over 30 minutes after nab-paclitaxel infusion
308310|NCT01851174|Drug|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m^2) IV over 30 minutes before Gemcitabine infusion
308311|NCT01851161|Procedure|computed tomography|Undergo conventional CT scan in both supine and prone positioning
308312|NCT01851161|Procedure|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
308313|NCT01851161|Radiation|radiation therapy|Undergo radiation therapy
308314|NCT01851148|Other|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
308315|NCT01851148|Other|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
308316|NCT01851148|Drug|triptans|administration of triptans drug treatment according to international guidelines
308317|NCT01851135|Other|Neuropsychological examination and quality of life measures|
308318|NCT01851122|Dietary Supplement|L-theanine capsule|L-theanine 250mg capsule
308362|NCT01850823|Drug|Mometasone nasal spray|
308363|NCT01850810|Other|Experimental Study Product|
308364|NCT01850810|Other|Control Study Product|
308365|NCT01850784|Dietary Supplement|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
308585|NCT01849055|Drug|Celecoxib|Administered orally
405580|NCT01097096|Biological|CAD106|
308319|NCT01851109|Behavioral|genetic counseling|"The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~Discuss how the results - positive or negative - affect cancer risk~Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc."
308320|NCT01851096|Drug|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
308321|NCT01851083|Biological|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
308322|NCT01851083|Other|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
308323|NCT01851070|Drug|Allogeneic Mesenchymal Precursor Cells|
308324|NCT01851070|Drug|Normal Saline|
308325|NCT01851057|Behavioral|STAR|Problem-solving and education intervention (8 total sessions)
308326|NCT01851057|Behavioral|Education Only|Education around epilepsy (8 total sessions)
308327|NCT01851044|Procedure|Platelet Rich Plasma|
308328|NCT01851044|Procedure|Whole Blood Injection|
308329|NCT01851044|Procedure|Saline Injection|
308330|NCT01851031|Procedure|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
308331|NCT01851018|Radiation|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
308332|NCT01851018|Radiation|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
308333|NCT01851005|Drug|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
308334|NCT01851005|Drug|Sevoflurane|Control Vol% to maintain BIS 40~45
308335|NCT01851005|Drug|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40~45 and changes of vital signs within 20%.
308336|NCT01851005|Drug|Normal saline|Use as placebo
308337|NCT01851005|Drug|Rocuronium|0.8 mg/kg for induction
308338|NCT01850992|Device|Active CPAP|Effective CPAP will be administered
308339|NCT01850992|Device|Sham CPAP|This is placebo CPAP
308340|NCT01850979|Drug|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
308341|NCT01850979|Drug|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
308342|NCT01850966|Drug|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
308343|NCT01850953|Drug|Varenicline|This is an approved smoking cessation medication.
308344|NCT01850953|Drug|Placebo|
308345|NCT01850940|Drug|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
308346|NCT01850940|Other|conventional thearpy|conventional therapy with salt limitation ,et al
308347|NCT01850927|Procedure|Remote ischaemic preconditioning|
308348|NCT01850927|Procedure|Control|
308349|NCT01850901|Procedure|Renal sympathetic denervation|
308350|NCT01850888|Drug|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
308351|NCT01850888|Drug|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
308352|NCT01850888|Drug|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000).
308353|NCT01850888|Procedure|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum > 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum >2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
308354|NCT01850875|Behavioral|Eye-Movement-Desensitization-Reprocessing|
308355|NCT01850862|Other|Collective group exercise program in patients with KOA|
308356|NCT01850862|Other|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
308357|NCT01850849|Drug|LEO 39652 cream|
308358|NCT01850849|Drug|cream vehicle|
308359|NCT01850836|Procedure|repetitive transcranial magnetic stimulation|
308360|NCT01850823|Drug|placebo|
308361|NCT01850823|Drug|Mometasone Nasal Spray|
308366|NCT01850784|Dietary Supplement|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
308367|NCT01850771|Procedure|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
308368|NCT01850771|Procedure|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
308369|NCT01850758|Procedure|Regenexx SD|stem cell treatment
308370|NCT01850758|Other|Exercise Therapy|exercise therapy control
308371|NCT01850745|Other|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
308372|NCT01850732|Other|Ultrasound of aorta|
308373|NCT01850719|Procedure|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
308374|NCT01850719|Other|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
308375|NCT01850680|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
308376|NCT01850680|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
308377|NCT01850680|Drug|methotrexate|Pharmaceutical form:capsule Route of administration: oral
308378|NCT01850680|Drug|folic acid|Pharmaceutical form:tablet Route of administration: oral
308379|NCT01850667|Radiation|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
308380|NCT01850654|Genetic|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
308381|NCT01850654|Genetic|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.~The following study participants will have free genetic testing:~CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors~CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter~CRC study participants diagnosed with CRC <50 years, regardless of tumor studies or family history~CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.~At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
308382|NCT01850654|Behavioral|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.~At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
308383|NCT01850654|Other|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
308384|NCT01850654|Behavioral|Questionnaire|
308385|NCT01850641|Drug|PA21|
308386|NCT01850628|Drug|Paclitaxel|
308387|NCT01850628|Biological|trastuzumab|
308388|NCT01850628|Biological|pertuzumab|
308389|NCT01850615|Drug|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
308390|NCT01850615|Drug|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
308391|NCT01850602|Drug|PA21|
308392|NCT01850602|Drug|Sevelamer hydrochloride|
308393|NCT01850589|Other|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:~Chantix (varenicline) GlaxoSmithKline,~Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
308394|NCT01850576|Behavioral|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
308395|NCT01850563|Other|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
308396|NCT01850550|Behavioral|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
308397|NCT01850537|Device|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
308398|NCT01850524|Drug|IXAZOMIB + Lenalidomide + Dexamethasone|"Patients will receive single oral dose of IXAZOMIB (4.0mg) on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days for the first 18 cycles or until progressive disease or unacceptable toxicity, whichever comes first.~After cycle 18 IXAZOMIB and Lenalidomide will be reduced and Dexamethasone will be discontinued."
308399|NCT01850524|Drug|Placebo + Lenalidomide + Dexamethasone|"Patients will receive single oral dose of Placebo on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days for the first 18 cycles or until progressive disease or unacceptable toxicity, whichever comes first.~After cycle 18 IXAZOMIB and Lenalidomide will be reduced and Dexamethasone will be discontinued."
308400|NCT01850511|Procedure|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
308401|NCT01850511|Drug|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
308402|NCT01850485|Device|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
308403|NCT01850446|Drug|Ergoferon|Safety and Efficacy
308404|NCT01850446|Drug|Oseltamivir|Safety and Efficacy
308405|NCT01850433|Behavioral|Internet based CBT for body dysmorphic disorder|
308406|NCT01850420|Drug|IMC-1|
308407|NCT01850407|Behavioral|Education Counseling|
308408|NCT01850394|Drug|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
308409|NCT01850394|Drug|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
308410|NCT01850381|Drug|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bacteriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
308411|NCT01850381|Drug|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
308412|NCT01850368|Radiation|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by >48 hours.~At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
308413|NCT01850355|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
308414|NCT01850342|Procedure|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
308415|NCT01850329|Other|computed-assisted information program|
308416|NCT01850316|Radiation|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
308417|NCT01850303|Drug|Pemetrexed|
308418|NCT01850303|Drug|Gemcitabine|
308419|NCT01850303|Drug|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
308420|NCT01850277|Drug|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
308421|NCT01850277|Procedure|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.~If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
308422|NCT01850277|Drug|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% >95%
308423|NCT01850277|Procedure|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
308424|NCT01850264|Device|Application of quadripolar / bipolar LV electrodes|
308425|NCT01850251|Dietary Supplement|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
308426|NCT01850251|Dietary Supplement|Standard nutritional supplement|High protein, high calorie nutritional supplement.
308427|NCT01850238|Biological|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
308428|NCT01850238|Other|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
308429|NCT01850225|Device|Auditory brainstem implant|
308430|NCT01850199|Other|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
308431|NCT01850199|Other|Usual management|Usual care will be provided, including face-to-face visits
308491|NCT01849783|Drug|cyclophosphamide|Given IV or PO
308492|NCT01849783|Drug|etoposide|Given IV
308493|NCT01849783|Drug|bortezomib|Given IV
308432|NCT01850186|Device|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
308433|NCT01850186|Drug|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
308434|NCT01850173|Device|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
308435|NCT01850160|Drug|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
308436|NCT01850160|Drug|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
308437|NCT01850160|Drug|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
308438|NCT01850147|Drug|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
308439|NCT01850134|Other|Experimental Study Product|
308440|NCT01850134|Other|Control Study Product|
308441|NCT01850121|Drug|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
308442|NCT01850108|Drug|Thymoglobulin|"Day 9 - 0.5 mg/kg IV before BMT~Days 8 & 7 - 2mg/kg IV before BMT"
308443|NCT01850108|Drug|Fludarabine|On Days -6 to -2 before BMT, 30 mg/m2/day IV
308444|NCT01850108|Drug|Cyclophosphamide (CTX)|Days 6 & 5 before BMT, 14.5 mg/kg IV; 50 mg/kg each day on 3rd & 4th day after BMT
308445|NCT01850108|Drug|Mesna|Days 3 & 4 after BMT: 40 mg/kg IV
308446|NCT01850108|Drug|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
308447|NCT01850108|Drug|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
308448|NCT01850108|Procedure|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
308449|NCT01850108|Radiation|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
308450|NCT01850095|Drug|treatment azelaic acid (azelan)|treatment for 6 months
308451|NCT01850095|Drug|dorspirenone/ethynil estradiol|
308452|NCT01850082|Procedure|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
308453|NCT01850056|Device|drug eluting balloon catheter (trade name: Orchid)|
308454|NCT01850056|Device|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
308455|NCT01850030|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
308456|NCT01850030|Drug|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
308457|NCT01850030|Drug|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
308458|NCT01850030|Drug|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
308459|NCT01850017|Drug|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
308460|NCT01850004|Drug|Dasatinib|
308461|NCT01849991|Biological|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.~The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
308462|NCT01849991|Biological|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
308463|NCT01849978|Behavioral|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
308464|NCT01849978|Behavioral|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
308494|NCT01849783|Drug|thalidomide|Given PO
308495|NCT01849783|Drug|melphalan|Given IV
308496|NCT01849783|Procedure|autologous stem cell transplant|
308497|NCT01849770|Drug|Mexiletine|
308498|NCT01849770|Drug|Placebo|
308499|NCT01849757|Other|prime crystalloid|used for priming the CPB circuit
308500|NCT01849757|Other|Human Albumin|Used as a constituent for priming the CPB circuit
308501|NCT01849757|Other|Voluven|Used as a constituent for priming the CPB circuit
308502|NCT01849744|Drug|VS-4718|
308465|NCT01849978|Behavioral|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
308466|NCT01849978|Behavioral|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
308467|NCT01849965|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
308468|NCT01849965|Drug|placebo vehicle gel|
308469|NCT01849965|Drug|Standard of Care gel, Aquasite|
308470|NCT01849939|Drug|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
308471|NCT01849926|Drug|Ibuprofen|
308472|NCT01849926|Drug|Mecillinam|
308473|NCT01849913|Other|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
308474|NCT01849913|Other|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
308475|NCT01849900|Other|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
308476|NCT01849900|Behavioral|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
308477|NCT01849887|Biological|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
308478|NCT01849887|Drug|Placebo|Placebo
308479|NCT01849874|Drug|MEK162, MEK inhibitor; oral|multiple dose, single schedule
308480|NCT01849874|Drug|Physician's choice chemotherapy|"Patients will receive one of the following chemotherapies as determined by the physician:~Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)"
308481|NCT01849861|Drug|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).~After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.~Variables considered in this study:~TSH and FT4~Questionnaire of Quality of life for older adults (WHOQOL-OLD)~Mini-Mental State Examination~Geriatric Depression Scale~Cardiopulmonary exercise testing - cardiopulmonary capacity"
308482|NCT01849848|Drug|SyB L-0501|The administration of SyB L-0501 at 90 mg/m^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
308483|NCT01849835|Procedure|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
308484|NCT01849835|Procedure|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
308485|NCT01849822|Device|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
308486|NCT01849809|Procedure|Gamma Ventral Capsulotomy|
308487|NCT01849796|Device|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
308488|NCT01849783|Drug|dexamethasone|Given PO
308489|NCT01849783|Drug|cisplatin|Given IV
308490|NCT01849783|Drug|doxorubicin|Given IV
308503|NCT01849731|Other|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
308504|NCT01849731|Other|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
308505|NCT01849705|Other|No intervention|
308506|NCT01849692|Drug|ESBA1008 solution|Intravitreal injection or infusion
308507|NCT01849692|Drug|Ranibizumab|Intravitreal injection
308508|NCT01849679|Other|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
308509|NCT01849666|Drug|phenprocoumon|6 mg oral single dose
308510|NCT01849666|Drug|vemurafenib|960 mg bid orally
308511|NCT01849640|Drug|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
308512|NCT01849627|Behavioral|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
308513|NCT01849627|Behavioral|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
308514|NCT01849614|Other|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
308515|NCT01849601|Device|percutaneous transluminal angioplasty balloon catheter|
308516|NCT01849588|Drug|Sorafenib|
308517|NCT01849575|Behavioral|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2─4 weeks a follow─up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.~CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
308518|NCT01849562|Drug|Sovaprevir|NS3/4A protease inhibitor
308519|NCT01849562|Drug|ACH-3102|NS5A inhibitor
308520|NCT01849562|Drug|RBV|
308521|NCT01849562|Drug|Placebo|
308522|NCT01849549|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
308523|NCT01849549|Other|MRI|Anatomical, diffusion, and/or functional MRI
308524|NCT01849536|Device|SENSIMED Triggerfish®|
308525|NCT01849523|Behavioral|Web-based information and support|
308526|NCT01849510|Radiation|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT & hfSRT
308527|NCT01849510|Radiation|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
308528|NCT01849497|Biological|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
308529|NCT01849497|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
308530|NCT01849484|Radiation|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
308531|NCT01849484|Radiation|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
308532|NCT01849471|Other|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
308533|NCT01849458|Device|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
308534|NCT01849445|Procedure|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
308535|NCT01849445|Other|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
308536|NCT01849419|Drug|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
308581|NCT01849068|Drug|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
308582|NCT01849068|Drug|Placebo|Placebo for 12 weeks
308583|NCT01849055|Drug|Placebo|Administered orally
308537|NCT01849419|Drug|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
308538|NCT01849419|Drug|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
308539|NCT01849406|Drug|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
308540|NCT01849406|Drug|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
308541|NCT01849393|Other|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
308542|NCT01849380|Drug|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
308543|NCT01849380|Drug|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
308544|NCT01849367|Device|Eldith Neuroconn tDCS device|
308545|NCT01849341|Drug|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
308546|NCT01849341|Drug|Roflumilast 500 mcg per day|
308547|NCT01849315|Behavioral|AKIDS II|Physically active intervention
308548|NCT01849302|Dietary Supplement|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
308549|NCT01849289|Drug|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
308550|NCT01849289|Drug|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
308551|NCT01849276|Drug|metformin hydrochloride|Given orally
308552|NCT01849276|Drug|cytarabine|Given IV
308553|NCT01849276|Other|laboratory biomarker analysis|Correlative studies
308554|NCT01849263|Drug|Ibrutinib|Given PO
308555|NCT01849263|Other|Laboratory Biomarker Analysis|Correlative studies
308556|NCT01849250|Drug|Docosahexaenoic Acid|Given PO
308557|NCT01849250|Other|Laboratory Biomarker Analysis|Correlative studies
308558|NCT01849250|Other|Placebo|Given PO
308559|NCT01849237|Genetic|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
308560|NCT01849237|Drug|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
308561|NCT01849224|Other|Pelvic and lower extremity exercise|
308562|NCT01849211|Drug|rocuronium|
308563|NCT01849198|Device|accelerometry m. trapezius and m. adductor pollicis|
308564|NCT01849185|Other|Food supplement|
308565|NCT01849172|Other|electroacupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
308566|NCT01849172|Other|sham electroacupuncture|"Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).~Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually."
308567|NCT01849159|Biological|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
308568|NCT01849159|Other|Reference therapy: 400 mL of 0.9% NaCl solution|
308569|NCT01849146|Drug|Adavosertib|Given PO
308570|NCT01849146|Radiation|Radiation Therapy|Undergo radiation therapy
308571|NCT01849146|Drug|Temozolomide|Given PO
308572|NCT01849133|Radiation|external fractionated radiotherapy|conventional external beam radiotherapy
308573|NCT01849133|Radiation|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
308574|NCT01849120|Device|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
308575|NCT01849107|Biological|Plasma citrulline|
308576|NCT01849094|Drug|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
308577|NCT01849094|Drug|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
308578|NCT01849094|Drug|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
308579|NCT01849081|Device|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
308580|NCT01849081|Behavioral|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
308586|NCT01849042|Drug|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
308587|NCT01849042|Drug|donepezil|
308588|NCT01849029|Behavioral|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
308589|NCT01849016|Drug|N-Acetylcysteine|
308590|NCT01849016|Drug|Placebo|
308591|NCT01849003|Drug|GS-6615|GS-6615 tablet(s) administered orally
308592|NCT01848990|Drug|Commercial Hylenex® recombinant (hyaluronidase human injection)|
308593|NCT01848990|Drug|Precommercial Hylenex recombinant (hyaluronidase human injection)|
308594|NCT01848990|Drug|Insulin lispro|
308595|NCT01848990|Drug|Insulin aspart|
308596|NCT01848990|Drug|Insulin glulisine|
308597|NCT01848977|Device|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
308598|NCT01848977|Device|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
308599|NCT01848964|Device|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.~Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)~After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.~Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.~Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
308600|NCT01848951|Drug|Epidural|
308601|NCT01848951|Drug|TAP Block|
308602|NCT01848938|Behavioral|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
308603|NCT01848925|Biological|SANGUINATE™|40 mg/mL intravenous infusion.
308604|NCT01848925|Drug|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
308605|NCT01848912|Device|Zephyr Biopatch Device|
308606|NCT01848899|Drug|Iodixanol|contrast media used during coronary angiography
308607|NCT01848899|Drug|Ioxaglate|contrast media used during coronary angiography
308608|NCT01848899|Drug|Bivalirudin|A direct thrombin inhibitor
308609|NCT01848886|Procedure|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
308610|NCT01848886|Procedure|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
308611|NCT01848886|Procedure|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
308612|NCT01848886|Procedure|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
308613|NCT01848873|Drug|Amlodipine|amlodipine 5mg daily
308614|NCT01848873|Drug|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
308615|NCT01848873|Drug|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
308616|NCT01848860|Procedure|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
308617|NCT01848860|Biological|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
308618|NCT01848847|Procedure|Hysteroscopy|
308619|NCT01848834|Biological|Pembrolizumab|IV infusion
308620|NCT01848821|Device|OASIS Ultra|Porcine derived intestinal submucosa
308621|NCT01848821|Device|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
308622|NCT01848808|Dietary Supplement|Wobenzym PS|
308623|NCT01848808|Dietary Supplement|Placebo|
308624|NCT01848795|Device|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
308625|NCT01848795|Device|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
308626|NCT01848782|Behavioral|interpretation of the abstract of the systematic review|
308627|NCT01848769|Drug|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
308628|NCT01848769|Drug|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
308629|NCT01848769|Drug|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
308630|NCT01848756|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
308631|NCT01848743|Drug|Tenofovir|
308632|NCT01848743|Drug|lamivudine|
308633|NCT01848730|Drug|CNV2197944|
308634|NCT01848730|Drug|Placebo|
308635|NCT01848717|Device|MINTLIFT®|
308636|NCT01848704|Behavioral|interpretation of the abstract|
308637|NCT01848691|Other|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
308638|NCT01848665|Drug|Indomethacin|
308639|NCT01848665|Drug|Placebo|
308640|NCT01848652|Drug|infusion of MYOCET|
308767|NCT01847651|Other|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
308641|NCT01848639|Drug|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
308642|NCT01848639|Drug|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
308643|NCT01848613|Drug|Vinorelbine|
308644|NCT01848600|Behavioral|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
308645|NCT01848587|Other|acupuncture|
308646|NCT01848587|Other|usual care|
308647|NCT01848574|Other|standardized multifaceted information procedure to improve patients' comprehension|
308648|NCT01848548|Procedure|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
308649|NCT01848535|Dietary Supplement|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
308650|NCT01848535|Dietary Supplement|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
308651|NCT01848509|Device|With teletransmission|Teletransmission of alerts
308652|NCT01848496|Procedure|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
308653|NCT01848483|Behavioral|AIDS EPC Package plus MI|"Motivational Interviewing: In MI session #1, the nurse will set the agenda & ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 & 4, the nurse will also introduce advance care planning.~EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic & conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation & coordination of care."
308654|NCT01848483|Other|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts ART, an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
308655|NCT01848470|Drug|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
308656|NCT01848470|Drug|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
308657|NCT01848470|Drug|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
308658|NCT01848470|Drug|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
308659|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
308660|NCT01848470|Drug|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
308661|NCT01848470|Drug|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
308662|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
308663|NCT01848457|Drug|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 & 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 & 2 of treatment Cycles 1 & 2 (Treatment Arms 1, 3) OR Cycles 3 & 4 (Treatment Arms 2, 4)
308664|NCT01848457|Drug|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
308665|NCT01848444|Other|Breastmilk|to measure levels of contaminants in human breastmilk samples
308666|NCT01848379|Procedure|ADT+FD|
308667|NCT01848379|Procedure|FD|
308668|NCT01848366|Device|Biowave Treatment|Twelve weekly treatments
308669|NCT01848353|Behavioral|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
308670|NCT01848340|Drug|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
308671|NCT01848340|Drug|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
308672|NCT01848340|Drug|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
308673|NCT01848327|Dietary Supplement|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
308674|NCT01848327|Dietary Supplement|Placebo|Placebo (40 gram packet orally once a day for 90 days)
308675|NCT01848314|Procedure|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
308676|NCT01848301|Device|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
308677|NCT01848301|Drug|Acetylcholine|Infusion in the coronary artery to study endothelial function
308678|NCT01848301|Procedure|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
308716|NCT01848002|Drug|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
308679|NCT01848288|Device|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
308680|NCT01848288|Device|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
308681|NCT01848275|Device|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
308682|NCT01848275|Device|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
308683|NCT01848262|Procedure|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
308684|NCT01848262|Procedure|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
308685|NCT01848236|Dietary Supplement|Vitamin D2|Ergocalciferol vitamin D2
308686|NCT01848236|Dietary Supplement|Vitamin D3|Cholecalciferol vitamin D2
308687|NCT01848210|Drug|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
308688|NCT01848210|Drug|Placebo|Coumarin + troxerutin placebo-matching tablets
308689|NCT01848197|Drug|paclitaxel|
308690|NCT01848184|Device|PARIETEX™ Composite Ventral Patch|PARIETEX™ Composite Ventral Patch for ventral hernia repair
308691|NCT01848171|Drug|L-thyroxine|
308692|NCT01848158|Device|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
308693|NCT01848158|Device|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
308694|NCT01848145|Drug|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of >= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE >= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
308695|NCT01848132|Drug|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
308696|NCT01848132|Drug|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
308697|NCT01848132|Drug|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
308698|NCT01848132|Drug|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
308699|NCT01848132|Drug|Prednisone|Prednisone: oral, 100 mg, days 1-5
308700|NCT01848132|Drug|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
308701|NCT01848119|Drug|Gabapentin|
308702|NCT01848119|Drug|lactose|
308703|NCT01848106|Drug|pegnivacogin/anivamersen|
308704|NCT01848106|Drug|Bivalirudin|
308705|NCT01848093|Other|sputum collection|collecting of spontaneous sputum from the patient
308706|NCT01848080|Behavioral|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
308707|NCT01848067|Drug|Alisertib|Given PO
308708|NCT01848067|Drug|Abiraterone acetate|Given PO
308709|NCT01848067|Drug|Prednisone|Given PO
308710|NCT01848054|Drug|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
308711|NCT01848054|Drug|Buprenorphine|Buprenorphine sublingual tablets
308712|NCT01848041|Drug|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
308713|NCT01848041|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
308714|NCT01848015|Other|detection of CTCs|
308715|NCT01848002|Drug|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
308877|NCT01846923|Biological|PCV13|
308717|NCT01847989|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
308718|NCT01847989|Drug|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
308719|NCT01847976|Drug|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
308720|NCT01847963|Drug|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
308721|NCT01847963|Drug|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
308722|NCT01847950|Dietary Supplement|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
308723|NCT01847950|Dietary Supplement|Maltodextrin|
308724|NCT01847924|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
308725|NCT01847924|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
308726|NCT01847911|Other|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
308727|NCT01847911|Other|instructor training|a pre-validated OSCE neonatal resuscitation program
308728|NCT01847898|Procedure|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
308729|NCT01847898|Procedure|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
308730|NCT01847885|Device|Smartpatch Peripheral Nerve Stimulation (PNS) System|"The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator)."
308731|NCT01847872|Drug|IPV IM Needle|
308732|NCT01847872|Drug|IPV ID Needle|
308733|NCT01847872|Drug|IPV IM Device|
308734|NCT01847872|Drug|IPV ID Device|
308735|NCT01847859|Procedure|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
308736|NCT01847833|Other|MRI scan|
308737|NCT01847820|Device|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
308738|NCT01847807|Drug|low dose Astragalus|
308739|NCT01847807|Drug|high dose astagalus|
308740|NCT01847794|Device|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
308741|NCT01847781|Biological|Prevenar13|
308742|NCT01847768|Biological|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
308743|NCT01847768|Procedure|Bronchoalveolar Lavage|
308744|NCT01847768|Drug|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
308745|NCT01847768|Procedure|Nasal Lavage|
308746|NCT01847768|Procedure|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
308747|NCT01847768|Procedure|Bronchial Brushings|
308748|NCT01847768|Procedure|Lung Mucosal Biopsy|
308749|NCT01847768|Procedure|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer & glycerol negative control.
308750|NCT01847768|Procedure|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
308751|NCT01847768|Procedure|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
308752|NCT01847768|Procedure|Spirometry|
308753|NCT01847755|Drug|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
308754|NCT01847742|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|
308755|NCT01847703|Procedure|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
308756|NCT01847703|Procedure|Abdominal surgery|Current gold standard
308757|NCT01847690|Drug|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
308758|NCT01847677|Drug|Bevacizumab|
308759|NCT01847677|Drug|Paclitaxel|
308760|NCT01847677|Drug|Carboplatin|
308761|NCT01847664|Drug|Rifamycin SV-MMX® 400 mg b.i.d.|
308762|NCT01847664|Drug|Rifamycin SV-MMX® 600 mg t.i.d.|
308763|NCT01847664|Drug|Rifamycin SV-MMX® Placebo|
308764|NCT01847651|Procedure|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
308765|NCT01847651|Drug|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
308766|NCT01847651|Other|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
308916|NCT01846520|Procedure|quality-of-life assessment|Ancillary studies
308768|NCT01847651|Other|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
308769|NCT01847651|Other|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
308770|NCT01847651|Other|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
308771|NCT01847651|Other|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
308772|NCT01847651|Other|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
308773|NCT01847638|Drug|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
308774|NCT01847638|Drug|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
308775|NCT01847625|Other|simulator|
308776|NCT01847612|Procedure|indocyanine green fluorescent cholangiography|
308777|NCT01847612|Drug|methylene blue|
308778|NCT01847599|Other|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
308779|NCT01847586|Procedure|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
308780|NCT01847586|Procedure|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
308781|NCT01847573|Drug|HT-100|May be administered in either fed or fasted state
308782|NCT01847534|Other|Supplemental PN|
308783|NCT01847534|Other|Standard Care|
308784|NCT01847521|Dietary Supplement|Luteolin, Quercetin and Rutin combined in a capsule|
308785|NCT01847508|Device|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
308786|NCT01847508|Device|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
308787|NCT01847495|Drug|Irinotecan|40mg/m2 x 3-5 days
308788|NCT01847495|Radiation|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
308789|NCT01847482|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
308790|NCT01847469|Behavioral|Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|
308791|NCT01847469|Drug|Zonisamide|
308792|NCT01847469|Drug|Placebo|
308793|NCT01847456|Drug|human insulin as nasal spray|
308794|NCT01847456|Drug|Placebo|
308795|NCT01847443|Drug|Nicotine (2 mg)|2 mg nicotine gum in two formulations
308796|NCT01847443|Drug|Nicotine (4 mg)|4 mg nicotine gum in two formulations
308797|NCT01847430|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
308798|NCT01847417|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
308799|NCT01847417|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
308800|NCT01847417|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
308801|NCT01847417|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
308802|NCT01847404|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
308803|NCT01847404|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
308804|NCT01847404|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
308805|NCT01847404|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
308806|NCT01847391|Drug|GS-6615|GS-6615 tablet(s) administered orally once daily
308807|NCT01847391|Drug|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
308808|NCT01847378|Procedure|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
308809|NCT01847365|Device|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
308810|NCT01847352|Drug|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
308811|NCT01847352|Other|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
308812|NCT01847339|Drug|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
308917|NCT01846520|Other|questionnaire administration|Ancillary studies
308813|NCT01847339|Other|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
308814|NCT01847326|Drug|carboplatin|Given IV
308815|NCT01847326|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
308816|NCT01847326|Drug|fluorouracil|Given IV
308817|NCT01847326|Drug|hydroxyurea|Given PO
308818|NCT01847326|Procedure|therapeutic conventional surgery|Undergo surgical resection
308819|NCT01847326|Radiation|radiation therapy|Undergo radiation therapy
308820|NCT01847326|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
308821|NCT01847326|Other|laboratory biomarker analysis|Correlative studies
308822|NCT01847313|Drug|Liraglutide|Daily administration of liraglutide for 6 months
308823|NCT01847300|Behavioral|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
308824|NCT01847274|Drug|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
308825|NCT01847274|Drug|placebo|
308826|NCT01847261|Dietary Supplement|Soy Dairy Protein Blend|
308827|NCT01847261|Dietary Supplement|Positive Control (Dairy Whey Protein)|
308828|NCT01847235|Drug|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
308829|NCT01847222|Biological|SANGUINATE™|PEG-bHb-CO
308830|NCT01847222|Drug|Normal Saline Solution|Placebo
308831|NCT01847209|Procedure|Video-Assisted Thoracic Surgery (VATS) wedge resection|
308832|NCT01847196|Device|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
308833|NCT01847183|Behavioral|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
308834|NCT01847170|Biological|Fecal Microbial Transplantation|
308835|NCT01847157|Device|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).~During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
308836|NCT01847157|Drug|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
308837|NCT01847157|Drug|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.~10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
308838|NCT01847157|Other|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.~Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
308839|NCT01847157|Device|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
308840|NCT01847144|Drug|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
308841|NCT01847144|Drug|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
308842|NCT01847131|Drug|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
308843|NCT01847131|Drug|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
308844|NCT01847118|Drug|Sevacizumab|
308845|NCT01847105|Other|RevitaLens|Multi-purpose disinfecting solution
308846|NCT01847105|Other|OptiFree PureMoist|Multi-purpose disinfecting solution
308847|NCT01847092|Drug|AZD1722|
308848|NCT01847092|Drug|Placebo|Placebo for AZD1722
308849|NCT01847079|Other|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
308850|NCT01847066|Device|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
308851|NCT01847066|Device|Erbium 2940 plus cosmetics|laser
308852|NCT01847053|Other|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
308853|NCT01847027|Drug|NutraStem|"Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.~Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress."
308918|NCT01846507|Drug|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
308854|NCT01847027|Drug|Placebo|Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
308855|NCT01847014|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
308856|NCT01847001|Drug|Propranolol|Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
308857|NCT01847001|Other|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
308858|NCT01847001|Drug|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
308859|NCT01847001|Drug|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
308860|NCT01847001|Drug|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
308861|NCT01847001|Drug|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
308862|NCT01847001|Drug|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
308863|NCT01847001|Drug|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
308864|NCT01847001|Procedure|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
308865|NCT01847001|Drug|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
308866|NCT01847001|Drug|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
308867|NCT01847001|Drug|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
308868|NCT01846988|Device|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
308869|NCT01846975|Drug|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
308870|NCT01846962|Drug|Budesonide|The administered dose of topical steroid was 400mcg or 800mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
308871|NCT01846962|Drug|Fluticasone|The administered dose of topical steroid was 440mcg or 880mcg/day (<150 cm or >150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
308872|NCT01846962|Behavioral|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
308873|NCT01846962|Drug|Oral Viscous Budesonide (OVB)|The administered dose of topical steroid was 1mg/day or 2mg/day (<150 cm or >150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
308874|NCT01846936|Procedure|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
308875|NCT01846936|Procedure|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
308876|NCT01846936|Procedure|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
308878|NCT01846910|Behavioral|Tooth Whitening|1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
308879|NCT01846910|Behavioral|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
308880|NCT01846871|Drug|Tivozanib|
308881|NCT01846845|Device|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
308882|NCT01846845|Device|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
308883|NCT01846832|Drug|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
308884|NCT01846832|Drug|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
308885|NCT01846832|Drug|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is < 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is > or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
308886|NCT01846806|Other|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
308887|NCT01846793|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
308888|NCT01846780|Procedure|PTA & stenting|PTA & stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
308889|NCT01846767|Other|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton & Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
308890|NCT01846741|Device|M106 VNS Therapy System|
308891|NCT01846728|Drug|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
308892|NCT01846715|Biological|Implantation of SRC|
308893|NCT01846702|Drug|Placebo|Given as a SC injection.
308894|NCT01846702|Drug|LY3084077|Given as a SC injection.
308895|NCT01846689|Drug|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
308896|NCT01846676|Behavioral|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
308897|NCT01846676|Other|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
308898|NCT01846663|Drug|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
308899|NCT01846663|Drug|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
308900|NCT01846650|Drug|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
308901|NCT01846650|Drug|XELODA|Single oral XELODA 2000mg qd
308902|NCT01846637|Procedure|laparoscopic sleeve gastrectomy|
308903|NCT01846624|Drug|Decitabine|Given IV
308904|NCT01846624|Drug|Midostaurin|Given PO
308905|NCT01846611|Drug|Trabectedin|1.1 mg/m^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
308906|NCT01846611|Drug|DOXIL|30 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
308907|NCT01846611|Drug|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
308908|NCT01846611|Drug|DOXIL|50 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
308909|NCT01846585|Behavioral|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
308910|NCT01846585|Behavioral|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
308911|NCT01846559|Biological|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
308912|NCT01846559|Drug|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
308913|NCT01846559|Drug|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
308914|NCT01846520|Other|educational intervention|Receive FCPCI home education sessions
308915|NCT01846520|Behavioral|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
405581|NCT01097096|Biological|CAD106|
308919|NCT01846481|Drug|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
308920|NCT01846481|Drug|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
308921|NCT01846481|Drug|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
308922|NCT01846481|Drug|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
308923|NCT01846468|Drug|LHW090|1 mg, 12.5 mg, 100 mg capsules
308924|NCT01846468|Drug|Placebo|Matching placebo capsules
308925|NCT01846455|Drug|2.0mg Buprenorphine/0.5mg Naloxone|Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
308926|NCT01846455|Drug|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
308927|NCT01846442|Drug|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
308928|NCT01846442|Drug|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
308929|NCT01846442|Drug|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
308930|NCT01846442|Drug|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
308931|NCT01846429|Drug|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
308932|NCT01846416|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
308933|NCT01846403|Device|Semi-quantitative urine pregnancy test|
308934|NCT01846390|Drug|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
308935|NCT01846390|Drug|Dexamethasone|40 mg D1 - D4
308936|NCT01846390|Drug|Cisplatin|75 mg/m2 D1
308937|NCT01846390|Drug|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
308938|NCT01846377|Behavioral|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
308939|NCT01846364|Dietary Supplement|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
308940|NCT01846338|Dietary Supplement|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
308941|NCT01846325|Dietary Supplement|vitamin E|
308942|NCT01846325|Dietary Supplement|DHA|
308943|NCT01846325|Other|placebo|
308944|NCT01846312|Other|No treatment given|The participants will not receive any treatment.
308945|NCT01846299|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
308946|NCT01846299|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
308947|NCT01846286|Behavioral|Questionnaires|Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
308948|NCT01846286|Other|Quantitative Sensory Testing|Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
308949|NCT01846273|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab
308950|NCT01846273|Drug|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
308951|NCT01846273|Drug|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
308952|NCT01846247|Other|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
308953|NCT01846247|Other|Standard care|
308954|NCT01846221|Drug|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
308955|NCT01846221|Drug|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
308956|NCT01846208|Drug|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
308957|NCT01846208|Drug|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
308958|NCT01846195|Device|CM 1500|
308959|NCT01846182|Drug|Duloxetine|serotonin norepinephrine reuptake inhibitor
308960|NCT01846182|Drug|Pregabalin|alpha-2-alpha subunit calcium channel ligand
308961|NCT01846182|Drug|Placebo|Placebo
308962|NCT01846169|Behavioral|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
308963|NCT01846156|Drug|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics & Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
308964|NCT01846143|Biological|pBCAR3-phosphopeptide|
308965|NCT01846143|Biological|pIRS2-phosphopeptide|
308966|NCT01846143|Biological|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
308967|NCT01846130|Dietary Supplement|Leucine|
308968|NCT01846130|Behavioral|Exercise|
308969|NCT01846130|Dietary Supplement|Whey protein|
308970|NCT01846117|Dietary Supplement|secoisolariciresinol diglucoside, vitamin D|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
308971|NCT01846104|Biological|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
308972|NCT01846091|Other|Laboratory Biomarker Analysis|Correlative studies
308973|NCT01846091|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
308974|NCT01846078|Device|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
308975|NCT01846039|Device|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
308976|NCT01846026|Drug|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
308977|NCT01846026|Drug|placebo|
308978|NCT01846013|Behavioral|Stand|Stand at least half of the workday at work.
308979|NCT01846013|Behavioral|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
308980|NCT01846013|Behavioral|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
308981|NCT01846000|Procedure|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
308982|NCT01845987|Drug|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
308983|NCT01845987|Drug|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
308984|NCT01845974|Device|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
308985|NCT01845974|Device|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
308986|NCT01845948|Behavioral|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
308987|NCT01845948|Behavioral|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
308988|NCT01845935|Device|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
308989|NCT01845922|Dietary Supplement|Low sodium diet|Low sodium diet
308990|NCT01845909|Other|ECG and survey screening|
308991|NCT01845896|Behavioral|Training|
308992|NCT01845883|Procedure|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
308993|NCT01845857|Behavioral|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
308994|NCT01845844|Drug|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
308995|NCT01845831|Drug|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
308996|NCT01845831|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
308997|NCT01845831|Drug|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
308998|NCT01845831|Drug|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
308999|NCT01845831|Drug|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
309000|NCT01845831|Drug|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
309001|NCT01845805|Drug|oral azacitidine|
309002|NCT01845805|Other|Observation|
309003|NCT01845805|Drug|First-line chemotherapy after recurrence|After disease recurrence, subjects on both Arm A and Arm B will start on a first-line chemotherapy (such as abraxane or gemcitabine).
309004|NCT01845792|Drug|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
309005|NCT01845792|Drug|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
309006|NCT01845779|Drug|DCF regimen|
309007|NCT01845766|Other|exercise rehabilitation|
309008|NCT01845753|Other|Observation|Observation
309043|NCT01845493|Dietary Supplement|Sulforaphane Homogenate|Active
309284|NCT01843725|Drug|aflibercept|Intravenous 6mg/kg every 3 weeks
309009|NCT01845740|Drug|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
309010|NCT01845740|Drug|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
309011|NCT01845727|Drug|Topical Amphotericin B at 3%|
309012|NCT01845714|Procedure|Corneal Cross Linking|
309013|NCT01845714|Procedure|Corneal Cross Linking combined with topoguided PRK|
309014|NCT01845701|Drug|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.~Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.~The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
309015|NCT01845701|Drug|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis[1-(7-chloro-4 quinolyl)-4- piperazinyl]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
309016|NCT01845701|Drug|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
309017|NCT01845688|Drug|Losartan Tablets & QingReMoShen Granule|
309018|NCT01845688|Drug|Losartan Tablets & Placebo Granule|
309019|NCT01845675|Drug|temozolomide or dacarbazine-based chemotherapy, endostatin|
309020|NCT01845662|Other|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
309021|NCT01845649|Drug|Estradiol Vaginal Gel|Daily for 14 days followed by 3 times per week for 10 weeks
309022|NCT01845649|Drug|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
309023|NCT01845636|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
309024|NCT01845636|Drug|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
309025|NCT01845623|Drug|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
309026|NCT01845623|Drug|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
309027|NCT01845623|Other|Placebo Concept 1|Placebo administered via the Concept 1 device.
309028|NCT01845623|Other|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
309029|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
309030|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
309031|NCT01845597|Procedure|MAKOplasty® medial UKA|A robot guided medical Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
309032|NCT01845584|Drug|NPB-01|
309033|NCT01845558|Drug|Wobenzym® plus|
309034|NCT01845558|Other|Placebo|
309035|NCT01845545|Other|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
309036|NCT01845532|Drug|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25~0.5% lidocaine, 0.125% bupivacaine)
309037|NCT01845532|Drug|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
309038|NCT01845519|Behavioral|Tailored Email|Participants will receive tailored emails.
309039|NCT01845519|Behavioral|Targeted Email|Participants will receive targeted emails.
309040|NCT01845506|Device|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
309041|NCT01845506|Device|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
309042|NCT01845493|Dietary Supplement|Alpha Sprout Homogenate|Alpha Sprout Homogenate
309044|NCT01845480|Behavioral|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
309045|NCT01845454|Device|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
309046|NCT01845441|Drug|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
309047|NCT01845441|Drug|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
309048|NCT01845441|Drug|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
309049|NCT01845428|Drug|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
309050|NCT01845415|Behavioral|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
309051|NCT01845415|Behavioral|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
309052|NCT01845402|Biological|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
309053|NCT01845389|Device|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
309054|NCT01845389|Device|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
309055|NCT01845376|Procedure|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
309056|NCT01845376|Procedure|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
309057|NCT01845376|Procedure|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
309058|NCT01845363|Drug|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC."
309059|NCT01845350|Other|M2 macrophage introduction|"Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~Intrathecal introduction of autologous M2 macrophages"
309060|NCT01845337|Drug|Teysuno|
309061|NCT01845337|Drug|Capecitabine|
309062|NCT01845311|Device|ReZolve2 Scaffold|
309063|NCT01845298|Drug|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
309064|NCT01845285|Device|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
309065|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
309066|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
309067|NCT01845259|Drug|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
309068|NCT01845259|Drug|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
309069|NCT01845246|Device|Prospective TDM Arm of colistin|
309070|NCT01845220|Drug|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
309071|NCT01845220|Drug|Placebo|80% acetone
309072|NCT01845194|Drug|Codeine|"Treatment period 2:~5 mg Codeine once"
309073|NCT01845194|Drug|Midazolam|"Treatment period 1:~0.2 mg Midazolam 3x~Treatment period 2:~1 mg Midazolam once"
309074|NCT01845194|Drug|Pravastatin|"Treatment period 2:~5 mg Pravastatin once"
309075|NCT01845194|Drug|Torsemide|"Treatment period 1:~2.5 mg Torsemide 3x~Treatment period 2:~0.25 mg Torsemide once"
309076|NCT01845194|Drug|Talinolol|"Treatment period 1:~50 mg Talinolol 3x~Treatment period 2:~2.5 mg Talinolol once"
309077|NCT01845194|Drug|Caffeine|"Treatment period 1:~50 mg Caffeine 3x"
309078|NCT01845194|Drug|Metoprolol|"Treatment period 1:~5 mg Metoprolol 3x"
309079|NCT01845181|Drug|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
309080|NCT01845181|Drug|Placebo|1 or 2 or 3 capsules of placebo.
405582|NCT01097096|Biological|CAD106|
309081|NCT01845168|Other|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
309082|NCT01845168|Device|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
309083|NCT01845168|Device|Computer-alert|
309084|NCT01845155|Behavioral|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.~For more details on the music therapy see Argstatter et al. 2012"
309085|NCT01845155|Behavioral|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
309086|NCT01845142|Drug|single administration of 100.000 I.U. vitamin D|
309087|NCT01845142|Drug|Placebo|
309088|NCT01845129|Device|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
309089|NCT01845129|Device|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
309090|NCT01845116|Drug|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
309091|NCT01845090|Drug|Lanthanum carbonate|the effect on serum FGF23
309092|NCT01845090|Drug|Calcium Carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
309093|NCT01845077|Drug|2x500 mg Metformin (Glumetza)|2 tablets
309094|NCT01845077|Drug|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
309095|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
309096|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
309097|NCT01845077|Drug|3x500 mg Metformin (Glumetza)|3 tablets
309098|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
309099|NCT01845077|Drug|2 x 500 mg Metformin (Glumetza)|2 tablets
309100|NCT01845077|Drug|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
309101|NCT01845077|Drug|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
309102|NCT01845064|Drug|DM199|
309103|NCT01845064|Drug|Placebo|
309104|NCT01845038|Drug|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of ~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
309105|NCT01845038|Drug|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of ~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
309106|NCT01845038|Drug|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
309107|NCT01845025|Drug|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
309108|NCT01845025|Drug|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
309109|NCT01845025|Drug|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
309110|NCT01845025|Drug|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
309111|NCT01845025|Drug|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
309112|NCT01845012|Other|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
309113|NCT01844999|Behavioral|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
309114|NCT01844999|Behavioral|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
309115|NCT01844986|Drug|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
309116|NCT01844973|Drug|M518101|Proper quantity twice a day
309117|NCT01844973|Drug|Vehicle|Proper quantity twice a day
309118|NCT01844960|Procedure|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
309119|NCT01844960|Procedure|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
309162|NCT01844609|Behavioral|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
309120|NCT01844947|Drug|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance >60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.~For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
309121|NCT01844947|Drug|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):~Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
309122|NCT01844934|Other|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
309123|NCT01844908|Procedure|Electroacupuncture|
309124|NCT01844895|Drug|Abatacept|
309125|NCT01844869|Drug|omacetaxine mepesuccinate|
309126|NCT01844856|Drug|Eravacycline|
309127|NCT01844856|Drug|Ertapenem|
309128|NCT01844856|Drug|Placebo|Administered IV to maintain the blind.
309129|NCT01844843|Device|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
309130|NCT01844830|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
309131|NCT01844830|Drug|Placebo|Inactive ingredients supplied in identical nasal sprayer
309132|NCT01844817|Drug|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
309133|NCT01844817|Drug|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
309134|NCT01844804|Biological|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
309135|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
309136|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
309137|NCT01844791|Drug|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
309138|NCT01844791|Drug|Platinum|Platinum is given as standard chemotherapy each cycle
309139|NCT01844791|Drug|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
309140|NCT01844778|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
309141|NCT01844778|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
309142|NCT01844778|Drug|Colistimethate|Colistimethate was administered via nebuliser.
309143|NCT01844765|Drug|nilotinib|Nilotinib supplied in 50mg, 150mg, and 200mg capsules. It was administered at 230mg/m2, twice daily for up to 66 cycles (1 cycle = 28 days). Dose administration was rounded to the nearest 50mg dose (to a maximum dose of 400mg).
309144|NCT01844752|Drug|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
309145|NCT01844752|Drug|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
309146|NCT01844752|Drug|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
309147|NCT01844739|Drug|NVN1000 4% Gel|Applied topically twice daily
309148|NCT01844739|Drug|Vehicle Gel|Applied topically twice daily
309149|NCT01844726|Drug|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
309150|NCT01844726|Drug|Placebo|Single injection of placebo (saline)
309151|NCT01844713|Behavioral|Workbook|Subjects will read a workbook about sun protection
309152|NCT01844700|Drug|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
309153|NCT01844700|Drug|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
309154|NCT01844687|Drug|CBD|Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
309155|NCT01844674|Drug|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast >/= 10 hours.
309156|NCT01844674|Drug|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
309157|NCT01844661|Biological|CELYVIR|
309158|NCT01844648|Drug|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
309159|NCT01844648|Drug|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
309160|NCT01844635|Drug|Thymoglobulin|
309161|NCT01844622|Other|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
309285|NCT01843725|Drug|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
309163|NCT01844609|Behavioral|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
309164|NCT01844596|Behavioral|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
309165|NCT01844596|Behavioral|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
309166|NCT01844583|Drug|Alisertib|Alisertib tablets
309167|NCT01844583|Drug|Esomeprazole|Esomeprazole capsules
309168|NCT01844583|Drug|Rifampin|Rifampin capsules
309169|NCT01844557|Other|Swallowing Exercises|Participants perform 3 swallowing exercises.
309170|NCT01844557|Behavioral|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
309171|NCT01844557|Behavioral|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
309172|NCT01844544|Other|inspection of medical records|
309173|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
309174|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
309175|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
309176|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
309177|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
309178|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
309179|NCT01844518|Biological|Abatacept|
309180|NCT01844505|Biological|Nivolumab|
309181|NCT01844505|Biological|Ipilimumab|
309182|NCT01844505|Biological|Placebo for Nivolumab|
309183|NCT01844505|Biological|Placebo for Ipilimumab|
309184|NCT01844492|Behavioral|The PARTNER Intervention|The PARTNER intervention (PAiring Re-engineered ICU Teams with Nurse-driven Emotional Support and Relationship-building) consists of: 1) institution of a clinical pathway for family support overseen by ICU staff nurses; 2) advanced communication skills training for ICU staff nurses; 3) a multifaceted strategy to support implementation of the clinical pathway for family support.
309185|NCT01844492|Other|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
309186|NCT01844479|Device|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
309187|NCT01844479|Other|Standard innersole|
309188|NCT01844466|Procedure|Physiotherapy and speech therapy|
309189|NCT01844453|Procedure|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
309190|NCT01844440|Procedure|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
309191|NCT01844427|Drug|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
309192|NCT01844427|Drug|Placebo|
309193|NCT01844414|Behavioral|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
309194|NCT01844414|Behavioral|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
309195|NCT01844414|Behavioral|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
309196|NCT01844401|Drug|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
309197|NCT01844401|Drug|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
309198|NCT01844388|Drug|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
309199|NCT01844388|Drug|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
309282|NCT01843738|Drug|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
309200|NCT01844375|Dietary Supplement|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
309201|NCT01844375|Other|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
309202|NCT01844362|Procedure|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
309203|NCT01844336|Device|PBASE system 1.1 + CT100 (active treatment)|
309204|NCT01844336|Device|PBASE system 1.1 + CT100 (placebo treatment)|
309205|NCT01844323|Other|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
309206|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
309207|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
309208|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
309209|NCT01844310|Drug|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
309210|NCT01844310|Drug|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
309211|NCT01844297|Drug|TDF+3TC+EFV|
309212|NCT01844284|Device|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
309213|NCT01844284|Device|Absorb™ BVS|Subjects receiving Absorb™ BVS
309214|NCT01844271|Device|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.~We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.~In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
309215|NCT01844258|Procedure|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
309216|NCT01844258|Procedure|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
309217|NCT01844245|Procedure|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
309218|NCT01844232|Drug|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
309219|NCT01844219|Procedure|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
309220|NCT01844206|Drug|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
309221|NCT01844206|Drug|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
309222|NCT01844193|Device|Compex Rehab|"Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment (Warm-up, Work, Relaxation, and Recovery) for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated."
309223|NCT01844180|Drug|ONO-2952|
309224|NCT01844180|Drug|ONO-2952 Matching Placebo|
309225|NCT01844167|Procedure|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
309226|NCT01844167|Procedure|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
309227|NCT01844141|Drug|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
309228|NCT01844141|Drug|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
309229|NCT01844128|Dietary Supplement|weight loss|
309230|NCT01844115|Drug|Placebo|
309231|NCT01844115|Drug|Vilazodone|Viibryd
309232|NCT01844102|Device|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
309233|NCT01844076|Drug|Phase I (Quinacrine)|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
309286|NCT01843699|Drug|Topiramate flexible dosage|
309234|NCT01844076|Drug|Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
309235|NCT01844063|Genetic|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
309236|NCT01844063|Genetic|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
309237|NCT01844063|Drug|Conventional treatment|"Received conventional treatment including:~A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
309238|NCT01844050|Drug|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
309239|NCT01844050|Drug|Placebo|
309240|NCT01844037|Device|OneShot Ablation System|Renal denervation
309241|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
309242|NCT01844011|Other|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
309243|NCT01843998|Drug|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
309244|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 6
309245|NCT01843972|Drug|BI 691751|oral solution
309246|NCT01843972|Drug|Placebo|placebo solution
309247|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 2
309248|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 5
309249|NCT01843972|Drug|BI 691751|1 tablet
309250|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 3
309251|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 4
309252|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 7
309253|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 1
309254|NCT01843933|Device|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
309255|NCT01843920|Drug|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
309256|NCT01843920|Drug|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
309257|NCT01843907|Behavioral|Empowerment|To give patients the necessary resources to take care of their own health
309258|NCT01843907|Other|Conversation with nurse|To find out, if the nurse, using her ....
309259|NCT01843894|Biological|RU-101|Recombinant human serum albumin
309260|NCT01843881|Drug|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
309261|NCT01843881|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
309262|NCT01843868|Drug|Standard anti-emetics in conjunction with R-CHOP|
309263|NCT01843855|Drug|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
309264|NCT01843855|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
309265|NCT01843842|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
309266|NCT01843842|Drug|Placebo|Safety and Efficiency of liquid dosage form
309267|NCT01843829|Drug|Oxaliplatin|
309268|NCT01843829|Drug|Capecitabine|
309269|NCT01843829|Drug|Carboplatin|
309270|NCT01843829|Drug|Paclitaxel|
309271|NCT01843829|Radiation|Radiotherapy|
309272|NCT01843829|Procedure|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
309273|NCT01843803|Other|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
309274|NCT01843803|Other|attention control|Patients will view a brief healthy living video on an iPad
309275|NCT01843790|Drug|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
309276|NCT01843790|Drug|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
309277|NCT01843777|Behavioral|Standard-of-Care|the standard of care in audiologic practice
309278|NCT01843777|Behavioral|Treatment|motivational interviewing
309279|NCT01843764|Device|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
309280|NCT01843751|Drug|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
309281|NCT01843738|Radiation|Radiation therapy|Per standard of care
309283|NCT01843725|Drug|capecitabine|escalation dose of capecitabine continuously
309287|NCT01843699|Drug|Placebo matching tablets|
309288|NCT01843699|Behavioral|4-session gambling cognitive restructuring|
309289|NCT01843686|Device|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
309290|NCT01843686|Other|Placebo Saline Gel and Usual and Customary Standard of Care|
309291|NCT01843673|Procedure|computed tomography|Undergo FBCT
309292|NCT01843673|Procedure|cone-beam computed tomography|Undergo dual CBCT
309293|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian kV OBI
309294|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
309295|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian MV OBI
309296|NCT01843673|Procedure|electronic portal imaging|Undergo EPID imaging
309297|NCT01843673|Radiation|image-guided adaptive radiation therapy|Undergo IGART
309298|NCT01843660|Drug|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
309299|NCT01843647|Drug|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
309300|NCT01843647|Drug|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine~/cisplatin regimen, until untolerable toxicity or disease progression."
309301|NCT01843634|Drug|ODSH|
309302|NCT01843621|Biological|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
309303|NCT01843608|Other|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
309304|NCT01843595|Behavioral|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
309305|NCT01843569|Biological|In Vitro maturation|
309306|NCT01843556|Drug|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
309307|NCT01843543|Other|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
309308|NCT01843530|Drug|Berinert|
309309|NCT01843530|Drug|Clemastin|
309310|NCT01843530|Drug|Cortisone acetate|
309311|NCT01843530|Drug|NaCl|
309312|NCT01843504|Biological|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
309313|NCT01843504|Other|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
309314|NCT01843491|Biological|Ad-PfCA|Vaccine
309315|NCT01843478|Other|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
309316|NCT01843478|Other|Usual Care|
309317|NCT01843465|Other|Maneuvers for documenting the disconnection|
309318|NCT01843452|Radiation|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.~Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).~Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
309319|NCT01843452|Biological|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
309320|NCT01843452|Drug|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
309321|NCT01843452|Drug|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
309322|NCT01843439|Dietary Supplement|Magnesium|
309323|NCT01843439|Behavioral|Education for asthma action plan|
309324|NCT01843439|Behavioral|hot-lines for acute exacerbation of asthma|
309325|NCT01843439|Behavioral|Inhaler technique training|
309376|NCT01843075|Drug|Placebo|Daily subcutaneous injection
309377|NCT01843062|Drug|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
309378|NCT01843062|Drug|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
309326|NCT01843426|Drug|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
309327|NCT01843413|Radiation|stereotactic radiosurgery|Undergo SRS
309328|NCT01843413|Procedure|quality-of-life assessment|Ancillary studies
309329|NCT01843413|Procedure|cognitive assessment|Ancillary studies
309330|NCT01843400|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients treated with Regorafenib under practical manner for colorectal cancer.
309331|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
309332|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
309333|NCT01843374|Drug|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
309334|NCT01843374|Drug|Placebo|Placebo is to be administered as an IV solution, followed by observation.
309335|NCT01843348|Drug|Everolimus|
309336|NCT01843348|Drug|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
309337|NCT01843348|Drug|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
309338|NCT01843348|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
309339|NCT01843348|Drug|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
309340|NCT01843348|Drug|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
309341|NCT01843348|Drug|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
309342|NCT01843322|Procedure|endoleak repair procedure (navigation technology )|
309343|NCT01843309|Drug|Spironolactone 100mg|
309344|NCT01843309|Drug|Spironolactone 200mg|
309345|NCT01843309|Drug|Placebo|
309346|NCT01843296|Drug|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
309347|NCT01843296|Procedure|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
309348|NCT01843296|Drug|Bupivacaine|
309349|NCT01843296|Drug|Fentanyl|
309350|NCT01843283|Behavioral|Daily Enhancement Meaningful Activity (DEMA)|
309351|NCT01843283|Behavioral|Information Support (IS)|
309352|NCT01843270|Device|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
309353|NCT01843270|Device|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
309354|NCT01843257|Other|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
309355|NCT01843257|Other|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
309356|NCT01843231|Device|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
309357|NCT01843231|Other|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
309358|NCT01843218|Other|Evaluation of erectile dysfunction|Register R / P and self-administered questionnaire IIEF-5
309359|NCT01843205|Drug|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
309360|NCT01843205|Drug|Placebo|The pharmacodynamic effects of placebo methamphetamine will be determined during placebo and buspirone maintenance.
309361|NCT01843192|Device|Endocutter|
309362|NCT01843179|Drug|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
309363|NCT01843179|Drug|Sulindac|Taken orally twice per day at home for 12 months
309364|NCT01843166|Drug|Premarin vaginal cream|2g at bedtime twice weekly
309365|NCT01843166|Drug|Placebo cream|2g at bedtime twice weekly
309366|NCT01843153|Drug|Ropivacaine|
309367|NCT01843127|Drug|Ranolazine|
309368|NCT01843127|Drug|Placebo|
309369|NCT01843127|Drug|Exenatide|
309370|NCT01843114|Device|FDOCT|Measurement of retinal blood velocities
309371|NCT01843114|Other|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
309372|NCT01843101|Device|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
309373|NCT01843088|Drug|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
309374|NCT01843088|Drug|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
309375|NCT01843075|Drug|Liraglutide|Daily subcutaneous injection
309379|NCT01843062|Drug|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
309380|NCT01843049|Radiation|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
309381|NCT01843049|Drug|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
309382|NCT01843036|Other|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
309383|NCT01843023|Drug|Extended Release Naltrexone|naltrexone for extended release injectable suspension
309384|NCT01843023|Behavioral|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
309385|NCT01843023|Drug|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
309386|NCT01843010|Drug|Parecoxib|Parecoxib 40mg will be intravenously infused.
309387|NCT01843010|Drug|Placebo|Normal saline 5ml will be intravenously infused.
309388|NCT01842997|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
309389|NCT01842984|Behavioral|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
309390|NCT01842971|Procedure|two stage hepatectomy|
309391|NCT01842958|Device|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
309392|NCT01842958|Device|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
309393|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
309394|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
309395|NCT01842932|Drug|Phloroglucin|Premedication of colonoscopy
309396|NCT01842932|Drug|Cimetropium bromide|Premedication of colonoscopy
309397|NCT01842932|Procedure|Colonoscopy|Diagnostic examination of colon
309398|NCT01842932|Drug|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
309399|NCT01842919|Other|Kinesthetics tests|
309400|NCT01842919|Other|Psychological questionnaires|
309401|NCT01842919|Other|structural Magnetic ResonanceImaging (MRI)|
309402|NCT01842906|Device|Theravent|nasal EPAP device
309403|NCT01842906|Device|Control|Sham device without EPAP
309404|NCT01842893|Drug|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
309405|NCT01842841|Drug|velaglucerase alfa|15-60 U/kg, EOW
309406|NCT01842828|Other|Standard care plus electronic cigarettes|
309407|NCT01842828|Behavioral|Standard care|
309408|NCT01842815|Device|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwante, non cosmetic, tattoos.
309409|NCT01842802|Device|Diode Laser|Diode Laser for treatment of subcutaneous fat
309410|NCT01842802|Device|YAG laser|YAG laser for treatment of subcutaneous fat
309411|NCT01842789|Device|Acessa Procedure|Acessa Procedure
309412|NCT01842750|Device|Endorectal Balloon insertion|
309413|NCT01842737|Procedure|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
309414|NCT01842737|Procedure|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
309415|NCT01842724|Procedure|Motec total wrist arthroplasty|
309416|NCT01842724|Procedure|Remotion total wrist arthroplasty|
309417|NCT01842698|Device|ultrasoundguided paravertebral catheter|
309418|NCT01842685|Procedure|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
309419|NCT01842672|Drug|Clofarabine|Dose Escalation of Clofarabine
309420|NCT01842672|Drug|Mitoxantrone|
309421|NCT01842659|Genetic|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
309422|NCT01842646|Drug|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
309423|NCT01842633|Drug|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
309424|NCT01842633|Drug|Ibuprofen|Caplets containing 200 mg of ibuprofen
309425|NCT01842633|Other|Placebo|Matching placebo caplets
309426|NCT01842620|Drug|Metformin|Oral antidiabetic agent
309427|NCT01842607|Biological|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
309428|NCT01842594|Drug|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .~Each treatment cycle is 28 days."
309429|NCT01842581|Drug|Rifaximin|Rifaximin will be administered per the dose and schedule specified in the arms.
309430|NCT01842581|Drug|Lactulose|Laculose will be administered per the schedule specified in the respective arm.
309431|NCT01842555|Other|Registry|Registry
309432|NCT01842542|Device|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.~3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
309433|NCT01842529|Biological|botulinum toxin injection|
309434|NCT01842529|Biological|0.9% normal saline injection|
309435|NCT01842529|Device|Implantable loop recorder|
309436|NCT01842516|Drug|LCB01-0371 800mg|LCB0-0371 800mg
309437|NCT01842516|Drug|LCB01-0371 1200mg|LCB01-0371 1200mg
309438|NCT01842516|Drug|Placebo|Placebo
309439|NCT01842503|Drug|GET 73|300 mg tid on 3 days cycle
309440|NCT01842503|Drug|inactive ingredients capsule|3 capsules tid on 3 days cycle
309441|NCT01842477|Procedure|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
309442|NCT01842464|Procedure|Anterior Sacro-Spinous|Anterior Sacro-Spinous
309443|NCT01842451|Drug|VX-135|
309444|NCT01842451|Drug|Daclatasvir|
309445|NCT01842438|Behavioral|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
309446|NCT01842412|Behavioral|exercise|one bout of exercise training
309447|NCT01842399|Dietary Supplement|Resveratrol|Dietary Supplement
309448|NCT01842399|Drug|Placebo|2x/day orally
309449|NCT01842386|Drug|Rituximab|Subjects will receive intravenous (IV) infusions of rituximab 1 gram on days 1 and 15, and subsequently if indicated up to once a month for 5 months ( 5 days for each visit) starting approximately on day 42. Subjects whose infections respond positively to the treatment but then relapse may be offered additional treatment.
309450|NCT01842373|Drug|LMX4|
309451|NCT01842373|Drug|BLT|
309452|NCT01842360|Biological|Placebo|The subjects will receive daily dose of placebo during 12 months
309453|NCT01842360|Biological|MV130|The subjects will receive daily dose of MV130 during 12 months
309454|NCT01842347|Other|Fecal microbiota|
309455|NCT01842334|Behavioral|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
309456|NCT01842334|Drug|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
309457|NCT01842321|Drug|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
309458|NCT01842308|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
309459|NCT01842308|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
309460|NCT01842308|Drug|Carfilzomib|Given IV
309461|NCT01842308|Other|Laboratory Biomarker Analysis|Correlative studies
309462|NCT01842308|Drug|Melphalan|Given IV
309463|NCT01842295|Other|Blood and sperm samples|Blood and sperm samples will be done in each visit
309464|NCT01842282|Drug|Amlexanox|
309465|NCT01842269|Drug|Mycophenolate Mofetil 500mg|
309466|NCT01842269|Drug|Mycophenolate Mofetil 250mg|
309563|NCT01841593|Drug|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
309564|NCT01841567|Device|Mepilex border post. op|
309467|NCT01842256|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),~oral intake, once in a period~over the period Ⅰ&Ⅱ(crossover)"
309468|NCT01842256|Drug|atorvastatin 40mg|"1 Tablet (atorvastatin 40mg),~oral intake, once in a period~over the period Ⅰ&Ⅱ(crossover)"
309469|NCT01842243|Procedure|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
309470|NCT01842243|Procedure|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
309471|NCT01842243|Device|Pacemaker|MR conditional Pacemaker implanted in all study patients
309472|NCT01842230|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~Atorvastatin 40mg: 1 tablet, oral, once daily, 2days~over the period I & II(cross-over)"
309473|NCT01842230|Drug|Telmisartan 80mg and S-amlodipine 5mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day~over the period I & II(cross-over)"
309474|NCT01842217|Procedure|FES-PET|
309475|NCT01842204|Device|Magnetic field therapy device|Therapy device for 1 week.
309476|NCT01842204|Device|Non magnetic field therapy device.|Non-active device for 1 week.
309477|NCT01842191|Dietary Supplement|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
309478|NCT01842191|Dietary Supplement|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
309479|NCT01842178|Procedure|scratching|"Endometrial Injury~Done between 18-24 days prior to embryo transfer cycle.~Using transfer catheter.~Introduction of the same to the uterine fundus.~Systematic scrapping of the four uterine walls, lengthwise.~Performed by a skilled doctor.~Subsequent ultrasound control."
309480|NCT01842165|Drug|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
309481|NCT01842139|Biological|basiliximab|Given IV
309482|NCT01842139|Biological|WT1 126-134 peptide vaccine|Given SC
309483|NCT01842139|Drug|Montanide ISA 51 VG|Given SC
309484|NCT01842139|Drug|poly ICLC|Given SC
309485|NCT01842139|Other|laboratory biomarker analysis|Correlative studies
309486|NCT01842126|Biological|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
309487|NCT01842126|Biological|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
309488|NCT01842126|Drug|Placebo IV|Ascending Doses intravenous (IV) of Placebo
309489|NCT01842126|Drug|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
309490|NCT01842113|Drug|Rifaximin|Rifaximin 550mg by mouth twice a day
309491|NCT01842113|Drug|Lactulose|Lactulose 30ml by mouth three times a day
309492|NCT01842113|Drug|Lactulose Placebo|Lactulose Placebo 30ml three times a day
309493|NCT01842113|Drug|Rifaximin Placebo|Rifaximin Placebo twice a day
309494|NCT01842100|Drug|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
309495|NCT01842100|Other|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
309496|NCT01842087|Other|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
309497|NCT01842087|Other|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
309498|NCT01842074|Drug|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
309499|NCT01842061|Behavioral|Active Living Program|
309500|NCT01842061|Behavioral|Education|
309501|NCT01842048|Other|Hyperthermia|
309502|NCT01842048|Radiation|External-beam radiotherapy|
309503|NCT01842035|Drug|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
309504|NCT01842022|Dietary Supplement|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
309505|NCT01842022|Dietary Supplement|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
309506|NCT01842022|Dietary Supplement|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
309507|NCT01842009|Device|High Definition transcranial Direct Current Stimulation|
309508|NCT01841996|Drug|ME1111 solution|Once a day for 28 days
309509|NCT01841996|Drug|Vehicle Solution|Once a day for 28 days
309510|NCT01841983|Other|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.~Overall intervention objectives:~Motivate individual staff members to engage in targeted health and safety behavior changes;~build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;~facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and~promote co-worker and supervisor support for targeted health and safety behaviors."
309511|NCT01841970|Device|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
309512|NCT01841957|Procedure|ISBCS|same-day cataract surgery
309513|NCT01841957|Procedure|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
309514|NCT01841944|Drug|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
309515|NCT01841944|Other|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
309565|NCT01841567|Device|Mepilex border post op|
309516|NCT01841931|Drug|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
309517|NCT01841918|Biological|Avian Flu Vaccine|
309518|NCT01841905|Other|Observational Study|Observational Study
309519|NCT01841892|Behavioral|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
309520|NCT01841879|Behavioral|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.~Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.~Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
309521|NCT01841879|Behavioral|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
309522|NCT01841866|Other|LMA removal|
309523|NCT01841853|Behavioral|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
309524|NCT01841840|Other|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
309525|NCT01841840|Other|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
309526|NCT01841827|Drug|Cilostazol|
309527|NCT01841827|Drug|Placebo|
309528|NCT01841814|Radiation|Bone densitometry.|
309529|NCT01841801|Device|Thermal Adhesive Patch|
309530|NCT01841801|Device|Marketed Thermal Adhesive Patch|
309531|NCT01841801|Device|Placebo Patch|
309532|NCT01841788|Device|Thermal Adhesion Patch|
309533|NCT01841788|Device|Marketed Thermal Adhesion Patch|
309534|NCT01841788|Device|Placebo Patch|
309535|NCT01841775|Drug|interferon α 2b + ribavirin|"interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks~ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
309536|NCT01841762|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
309537|NCT01841749|Procedure|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
309538|NCT01841736|Other|Laboratory Biomarker Analysis|Correlative studies
309539|NCT01841736|Drug|Pazopanib|Given PO
309540|NCT01841736|Drug|Pazopanib Hydrochloride|Given PO
309541|NCT01841736|Other|Placebo|Given PO
309542|NCT01841736|Other|Quality-of-Life Assessment|Ancillary studies
309543|NCT01841723|Drug|Ibrutinib|Given PO
309544|NCT01841697|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
309545|NCT01841697|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
309546|NCT01841697|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
309547|NCT01841697|Drug|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
309548|NCT01841697|Drug|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
309549|NCT01841697|Drug|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
309550|NCT01841684|Drug|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
309551|NCT01841684|Drug|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
309552|NCT01841671|Biological|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
309553|NCT01841671|Biological|bOPV|As indicated
309554|NCT01841671|Biological|mOPV type 2|Administered at 28 weeks of age to all study participants
309555|NCT01841671|Biological|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
309556|NCT01841658|Dietary Supplement|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
309557|NCT01841645|Dietary Supplement|CLA depletion-repletion|
309558|NCT01841632|Drug|MultiStem|
309559|NCT01841619|Drug|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in <25% subjects, the subjects will be re-treated by the standard protocol.
309560|NCT01841606|Drug|Ondansetron|4mg of IV ondansetron
309561|NCT01841606|Other|Normal saline|10mL of IV normal saline
309562|NCT01841593|Drug|Raltegravir|Isentress 400mg tablet taken twice daily
309567|NCT01841541|Behavioral|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
309568|NCT01841528|Other|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
309569|NCT01841528|Other|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
309570|NCT01841515|Drug|Desmopressin administration|
309571|NCT01841502|Drug|Paroxetine|paroxetine 20 mg once daily
309572|NCT01841502|Drug|telaprevir|telaprevir 1125 mg twice daily
309573|NCT01841489|Drug|Treatment A|1600 mg GS-9973 (Formulation 1)
309574|NCT01841489|Drug|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
309575|NCT01841489|Drug|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
309576|NCT01841489|Drug|Treatment D|1600 mg GS-9973 (Formulation 2)
309577|NCT01841489|Drug|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
309578|NCT01841489|Drug|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
309579|NCT01841489|Drug|Treatment G|1600 mg GS-9973 (Reference formulation)
309580|NCT01841489|Drug|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
309581|NCT01841489|Drug|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
309582|NCT01841489|Drug|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
309583|NCT01841476|Drug|POL6326|
309584|NCT01841463|Drug|P1446A-05|- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
309585|NCT01841463|Drug|Vemurafenib (Zelboraf®)|"In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.~In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle~Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
309586|NCT01841450|Device|iStent|Implantation of one iStent in conjunction with cataract surgery
309587|NCT01841450|Procedure|Cataract surgery|Cataract surgery alone
309588|NCT01841437|Device|iStent|
309589|NCT01841424|Behavioral|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
309590|NCT01841411|Drug|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
309591|NCT01841411|Drug|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
309592|NCT01841411|Drug|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
309593|NCT01841398|Behavioral|Multimedia Lifestyle Improvement|"Goal setting to improve diet, physical activity or smoking behaviours~Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
405583|NCT01097096|Biological|CAD106|
309594|NCT01841398|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
309595|NCT01841385|Other|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
309596|NCT01841372|Other|Second Life|Second Life is an online virtual reality environment.
309597|NCT01841372|Behavioral|Group Phone Conference Call|
309598|NCT01841359|Drug|Pramlintide|See description above (arm description).
309599|NCT01841346|Procedure|Procedure: PCI|
309600|NCT01841333|Drug|PF-04449913|100mg given orally
309601|NCT01841320|Other|Integrated methadone and antiretroviral therapy (iMART) clinic|
309602|NCT01841307|Drug|Cromolyn Sodium|
309603|NCT01841294|Drug|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
309604|NCT01841294|Drug|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
309605|NCT01841281|Drug|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
309606|NCT01841281|Drug|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
309607|NCT01841255|Device|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
309608|NCT01841255|Device|facemask|
309609|NCT01841242|Drug|alcoholic povidone iodine|
309610|NCT01841242|Drug|alcoholic chlorhexidine|
309611|NCT01841216|Device|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
309612|NCT01841177|Drug|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
309613|NCT01841164|Drug|Montelukast|
309614|NCT01841164|Drug|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
309615|NCT01841164|Other|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
309616|NCT01841151|Behavioral|SCP training|
309617|NCT01841151|Behavioral|Live Z-score training|
309618|NCT01841151|Behavioral|WM training|
309619|NCT01841125|Drug|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
309620|NCT01841125|Drug|Placebo|placebo 15mg, QD(once a day), Oral medication
309621|NCT01841112|Drug|BI 409306|tablet
309622|NCT01841112|Drug|BI 409306|tablet
309623|NCT01841112|Drug|BI 409306|tablet
309624|NCT01841112|Drug|BI 409306|tablet
309625|NCT01841112|Drug|placebo|placebo tablet
309626|NCT01841112|Drug|placebo|placebo tablet
309627|NCT01841112|Drug|BI 409306|tablet
309628|NCT01841099|Drug|Mesalamine|Mesalamine granules
309629|NCT01841099|Drug|Placebo granules|Provided by Ferring Pharma
309630|NCT01841086|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
309631|NCT01841086|Drug|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
309632|NCT01841073|Dietary Supplement|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
309633|NCT01841073|Dietary Supplement|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
309634|NCT01841073|Dietary Supplement|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
309635|NCT01841073|Dietary Supplement|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
309636|NCT01841073|Dietary Supplement|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
309637|NCT01841073|Dietary Supplement|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.~Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
309638|NCT01841060|Procedure|Radiofrequency|Radiofrequency
309639|NCT01841047|Radiation|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
309640|NCT01841034|Drug|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
309641|NCT01841021|Drug|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
309642|NCT01841008|Drug|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
309643|NCT01841008|Drug|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
309690|NCT01840579|Drug|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
309691|NCT01840579|Biological|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
309692|NCT01840579|Drug|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
309644|NCT01840995|Procedure|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
309645|NCT01840982|Dietary Supplement|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
309646|NCT01840982|Dietary Supplement|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
309647|NCT01840982|Dietary Supplement|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
309648|NCT01840982|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
309649|NCT01840956|Biological|HAVG|HAVG is implanted into patients' arm.
309650|NCT01840943|Drug|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
309651|NCT01840943|Drug|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
309652|NCT01840891|Behavioral|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
309653|NCT01840865|Device|brain stimulation|oscillating direct current brain stimulation
309654|NCT01840865|Device|no stimulation|sham Stimulation
309655|NCT01840839|Device|brain stimulation|
309656|NCT01840839|Device|Sham Stimulation|
309657|NCT01840826|Other|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
309658|NCT01840813|Drug|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
309659|NCT01840813|Drug|Normal saline|It is a placebo group
309660|NCT01840800|Drug|Ropivacaine|
309661|NCT01840800|Drug|placebo|
309662|NCT01840787|Device|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
309663|NCT01840787|Device|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
309664|NCT01840787|Device|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
309665|NCT01840774|Drug|Low-dose pain medication (Ketalar) and saline placebo|
309666|NCT01840761|Drug|herbal drug|
309667|NCT01840761|Drug|placebo|
309668|NCT01840735|Drug|GS-5737|
309669|NCT01840735|Drug|Placebo|
309670|NCT01840722|Other|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
309671|NCT01840709|Behavioral|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
309672|NCT01840696|Drug|Regadenoson|Vasodilator stress testing
309673|NCT01840683|Device|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
309674|NCT01840670|Drug|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
309675|NCT01840644|Other|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
309676|NCT01840631|Behavioral|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
309677|NCT01840618|Device|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
309678|NCT01840605|Drug|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
309679|NCT01840605|Drug|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
309680|NCT01840592|Drug|Sorafenib|
309681|NCT01840592|Drug|Doxorubicin|
309682|NCT01840579|Biological|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
309683|NCT01840579|Biological|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
309684|NCT01840579|Biological|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
309685|NCT01840579|Drug|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
309686|NCT01840579|Drug|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
309687|NCT01840579|Drug|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
309688|NCT01840579|Drug|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
309689|NCT01840579|Drug|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
310078|NCT01837446|Drug|Diphenhydramine|
309693|NCT01840579|Drug|G-CSF (pegfilgrastim) 3.6 mg|Administered as a subcutaneous injection on Day 4 of Cycle 1
309694|NCT01840566|Drug|Carmustine|
309695|NCT01840566|Drug|Etoposide|
309696|NCT01840566|Drug|Cytarabine|
309697|NCT01840566|Drug|Melphalan|
309698|NCT01840566|Biological|Pegfilgrastim|
309699|NCT01840566|Biological|19-28z T CELLS|
309700|NCT01840566|Procedure|Autologous Stem Cell Transplantation|
309701|NCT01840553|Drug|oral sodium phosphate tablets|
309702|NCT01840553|Drug|polyethylene glycol|
309703|NCT01840540|Drug|Arterial infusion of autologous mesenchymal stem cells|
309704|NCT01840501|Drug|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
309705|NCT01840501|Drug|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
309706|NCT01840501|Drug|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
309707|NCT01840501|Drug|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
309708|NCT01840488|Drug|Irosustat (BN83495)|"Three parts (A, B & C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.~Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
309709|NCT01840449|Drug|Somatuline Autogel® 60, 90 or 120 mg|
309710|NCT01840436|Device|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
309711|NCT01840436|Device|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
309712|NCT01840423|Drug|ODM-104|ODM-104
309713|NCT01840423|Drug|Placebo|Placebo
309714|NCT01840423|Drug|Entacapone|entacapone + levodopa/carbidopa
309715|NCT01840423|Drug|levodopa/carbidopa|entacapone + levodopa/carbidopa
309716|NCT01840410|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
309717|NCT01840410|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
309718|NCT01840384|Dietary Supplement|Multi-micronutrients|
309719|NCT01840384|Dietary Supplement|Maltodextrin and Lactose|
309720|NCT01840371|Drug|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure~IV bolus of 1 mg/kg for sedation induction,~Infusion of 60 mcg/min/kg for maintenance of sedation~Additional bolus dose of 10mg as needed for adequate sedation"
309721|NCT01840371|Drug|Experimental sedation|"Fentanyl~IV bolus of 1 µg/kg for sedation induction~Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol~IV bolus of 0.4 mg/kg for sedation induction~Infusion of 30 µg/min/kg for maintenance of sedation~Additional bolus dose of 10mg as needed for adequate depth of sedation"
309722|NCT01840358|Other|Observation of hypoglycemias frequency 3 days before and after pump initiation|
309723|NCT01840345|Drug|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
309724|NCT01840332|Drug|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is < 30 after 4 weeks the study continues up to 6 weeks.
309725|NCT01840306|Other|Biomarker Analysis|
309726|NCT01840267|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
309727|NCT01840254|Drug|dexmedetomidine|
309728|NCT01840254|Drug|normal saline|
309729|NCT01840241|Drug|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
309730|NCT01840241|Drug|normal saline|
309731|NCT01840228|Drug|Micronized progesterone suppository|
309732|NCT01840189|Other|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
309733|NCT01840189|Other|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.~This part of the study will take 2 months."
309734|NCT01840176|Procedure|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
309735|NCT01840163|Other|Static version of CanSORT tool|
309736|NCT01840163|Other|CanSORT Online Tool|
309737|NCT01840150|Procedure|breath test|Undergo NA-NOSE breath test
309738|NCT01840150|Other|laboratory biomarker analysis|Correlative studies
309739|NCT01840137|Other|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
309740|NCT01840137|Other|Exercise|Treadmill and muscle exercises.
309741|NCT01840124|Device|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
309742|NCT01840111|Behavioral|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
309743|NCT01840111|Behavioral|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
309744|NCT01840098|Dietary Supplement|low leucine content drink|
309745|NCT01840098|Dietary Supplement|high leucine content drink|
309746|NCT01840098|Dietary Supplement|low leucine + HMB drink|
309747|NCT01840098|Dietary Supplement|Control/carbohydrate|
309748|NCT01840098|Behavioral|36 hour fasting|
309749|NCT01840085|Drug|0.03% DSC127 topical gel|
309750|NCT01840072|Other|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
309751|NCT01840059|Device|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
309752|NCT01840046|Drug|Interleukin-2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5)."
309753|NCT01840033|Device|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
309754|NCT01840033|Device|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
309755|NCT01840020|Procedure|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
309756|NCT01840020|Procedure|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
309757|NCT01840007|Drug|Metformin Group|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
309758|NCT01839994|Radiation|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
309759|NCT01839994|Radiation|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
309760|NCT01839994|Drug|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
309761|NCT01839981|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
309762|NCT01839968|Other|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
309763|NCT01839955|Drug|erlotinib hydrochloride|"Dose Escalation Group:~Begins day 1: given 150mg daily, orally~Extension Group:~Begins Day 1: 150mg daily, orally"
309764|NCT01839955|Drug|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 [starting dose]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
309765|NCT01839955|Other|laboratory biomarker analysis|Correlative studies
309766|NCT01839955|Other|pharmacological study|Correlative studies
310079|NCT01837433|Drug|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
309767|NCT01839955|Drug|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
309768|NCT01839942|Procedure|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
309769|NCT01839942|Procedure|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
309770|NCT01839929|Drug|Prograf|oral
309771|NCT01839929|Drug|Advagraf|oral
309772|NCT01839916|Biological|therapeutic allogeneic lymphocytes|Given IV
309773|NCT01839916|Other|laboratory biomarker analysis|Correlative studies
309774|NCT01839903|Other|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
309775|NCT01839903|Other|Care as usual|Care as usual in the ED will be tracked
309776|NCT01839890|Device|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
309777|NCT01839890|Device|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
309778|NCT01839877|Drug|HIA DEBIRI + systemic FOLFOX|
309779|NCT01839864|Behavioral|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
309780|NCT01839851|Drug|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
309781|NCT01839851|Drug|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
309782|NCT01839838|Radiation|Proton Therapy|
309783|NCT01839825|Device|QuietCare|
309784|NCT01839812|Drug|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
309785|NCT01839799|Drug|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
309786|NCT01839799|Drug|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
309787|NCT01839799|Drug|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
309788|NCT01839799|Radiation|Chemoradiation|
309789|NCT01839773|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
309790|NCT01839773|Drug|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
309791|NCT01839747|Procedure|PET-MRI|Imaging
309792|NCT01839747|Procedure|PET-CT|Imaging
309793|NCT01839734|Drug|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
309794|NCT01839721|Drug|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
309795|NCT01839721|Other|placebo|
309796|NCT01839708|Behavioral|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
309797|NCT01839695|Device|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
309798|NCT01839669|Device|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
309799|NCT01839669|Procedure|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
309800|NCT01839669|Device|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
309801|NCT01839656|Drug|nusinersen|Administered by intrathecal (IT) injection
309802|NCT01839643|Drug|Meloxicam 2.4 g|2.4 g in Vaginal Ring
309803|NCT01839643|Drug|Meloxicam 3.0 g|3.0 g in Vaginal Ring
309804|NCT01839630|Drug|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
309805|NCT01839617|Dietary Supplement|Early parenteral nutrition|
309806|NCT01839617|Dietary Supplement|Late parenteral nutrition|
309807|NCT01839604|Drug|AZD9150|Intravenous infusion over 3 hours.
309808|NCT01839591|Device|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
309809|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Ci-Ca protocole for MultiFiltrate® CRRT machine :~4% trisodium citrate solution~Calcium chloride solution (100 mmol/L)~Dialysate flow rate: 35 ml/kg/h~Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3~Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.~Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.~Blood flow adapted to the acid-base status"
309810|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.~Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.~Standard dialysate for CRRT : Prismasol® K2 solution~Dialysate flow rate: 35 ml/kg/h~Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
309811|NCT01839565|Device|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
309812|NCT01839552|Drug|Fentanyl Citrate Nasal Spray (FCNS)|
309813|NCT01839539|Biological|dendritic and cytokine-induced killer cells|
310080|NCT01837433|Drug|Prednisone 6 weeks|Guidelines recommend
310081|NCT01837420|Drug|VB-201 80mg|
309814|NCT01839526|Drug|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
309815|NCT01839500|Drug|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
309816|NCT01839487|Drug|PEGPH20|PEGPH20 will be administered as per the dose and schedule specified in the respective arms.
309817|NCT01839487|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per the dose and schedule specified in the respective arms.
309818|NCT01839487|Drug|Gemcitabine|Gemcitabine will be administered as per the dose and schedule specified in the respective arms.
309819|NCT01839487|Drug|Dexamethasone|Dexamethasone will be administered as per the dose and schedule specified in the respective arms.
309820|NCT01839487|Drug|Enoxaparin|Enoxaparin will be administered as per the dose and schedule specified in the respective arms.
309821|NCT01839474|Device|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
309822|NCT01839448|Biological|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
309823|NCT01839435|Procedure|outpatient surgery|
309824|NCT01839422|Behavioral|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
309825|NCT01839422|Other|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
309826|NCT01839409|Behavioral|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
309827|NCT01839396|Device|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
309828|NCT01839383|Other|different dialysate calcium concentration|
309829|NCT01839370|Device|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
309830|NCT01839357|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
309831|NCT01839344|Dietary Supplement|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
309832|NCT01839344|Drug|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
309833|NCT01839344|Drug|placebo|An oral single dose of a solid, colored empty capsule.
309834|NCT01839331|Drug|Low Dose Ampion|4 mL Ampion
309835|NCT01839331|Drug|High Dose Ampion|10 mL Ampion 10mL
309836|NCT01839331|Drug|Placebo Low Dose 4 mL|4 mL Placebo
309837|NCT01839331|Drug|Placebo 10 mL|Placebo 10 mL
309838|NCT01839318|Device|Nelfilcon A contact lenses|
309839|NCT01839318|Device|Omafilcon A contact lenses|
309840|NCT01839318|Device|Etafilcon A contact lenses|
309841|NCT01839305|Other|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
309842|NCT01839292|Device|uncovered D-type stent insertion|
309843|NCT01839292|Device|double-layered ComVi stent insertion|
309844|NCT01839279|Drug|Tizanidine|
309845|NCT01839279|Drug|Placebo|
309846|NCT01839279|Drug|Moxifloxacin|
309847|NCT01839253|Drug|b-blocker(Atenolol)|
309848|NCT01839253|Drug|ACE inhibitor(Enapril)|
309849|NCT01839253|Other|control|
309850|NCT01839240|Drug|azacitidine|Given IV or SC
309851|NCT01839240|Drug|cytarabine|Given IV
309852|NCT01839240|Drug|mitoxantrone hydrochloride|Given IV
309853|NCT01839240|Other|laboratory biomarker analysis|Correlative studies
309854|NCT01839227|Other|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.~Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.~Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.~There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
309855|NCT01839214|Drug|VB-201 160mg|
309856|NCT01839214|Drug|Placebo|
309857|NCT01839201|Other|control|No psychological intervention
309858|NCT01839201|Other|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
309859|NCT01839201|Other|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
309860|NCT01839188|Biological|PR5I|Hexavalent PR5I vaccine (DTaP-HB-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Hepatitis B [HB; Recombinant DNA], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 2 and 6 months of age.
310082|NCT01837420|Drug|VB-201 160mg|
310083|NCT01837420|Drug|Placebo|
309861|NCT01839188|Biological|Pediacel®|Pentavalent Pediacel® vaccine (DTaP-IPV-Hib = Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed [DTaP], Inactivated Poliovirus [IPV], and Haemophilus influenzae type b [Hib] conjugate vaccine [adsorbed]) at 0.5 mL for IM injection (left upper thigh) at 4 months of age.
309862|NCT01839188|Biological|NeisVac-C®|Meningococcal group C (MCC) polysaccharide conjugate vaccine (adsorbed) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
309863|NCT01839188|Biological|RotaTeq®|Human-bovine rotavirus reassortants (live) vaccine 2 mL oral administration at 2, 4 and 6 months of age. RotaTeq® administered prior to any other vaccine administration to avoid having the infant participants spit up the RotaTeq® when crying.
309864|NCT01839188|Biological|Prevenar 13®|Pneumococcal polysaccharide conjugate vaccine [PCV; 13-valent, adsorbed]) at 0.5 mL for IM injection (right upper thigh) at 2 and 4 months of age.
309865|NCT01839175|Biological|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
309866|NCT01839175|Biological|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
309867|NCT01839175|Biological|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
309868|NCT01839175|Biological|RotaTeq|2 mL oral administration at 2, 3 and 4 months
309869|NCT01839175|Biological|Nimenrix|0.5 mL intramuscular injection at 12 months
309870|NCT01839175|Biological|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
309871|NCT01839162|Procedure|Coronary angiography|Diagnostic coronary angiography
309872|NCT01839162|Procedure|PCI|Percutaneous coronary intervention
309873|NCT01839162|Procedure|Right approach|Right transradial access
309874|NCT01839162|Procedure|Left approach|Left transradial access
309875|NCT01839149|Drug|TI-001|TI-001 is intranasal oxytocin
309876|NCT01839149|Drug|Placebo|
309877|NCT01839136|Procedure|Intrauterine transfer of gametes|
309878|NCT01839136|Procedure|Intrauterine transfer of embryos|
309879|NCT01839123|Device|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
309880|NCT01839123|Device|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
309881|NCT01839110|Drug|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
309882|NCT01839110|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
309883|NCT01839097|Drug|Belinostat|"Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:~Cohort 1: belinostat 1000 mg/m2 IV on Day 1~Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2~Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3~Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4~Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5"
309884|NCT01839097|Drug|CHOP|"Cyclophosphamide - 750 mg/m2 - IV - Day 1~Vincristine - 1.4 mg/m2 - IV - Day 1~Doxorubicin - 50mg/m2 - IV - Day 1~Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat."
309885|NCT01839084|Drug|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
309886|NCT01839084|Drug|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
309887|NCT01839071|Procedure|biopsy|
309888|NCT01839058|Other|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
309889|NCT01839032|Drug|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.~Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
309890|NCT01839019|Drug|ODM-102|Single dose escalation
309891|NCT01839019|Drug|Placebo for ODM-102|Single dose escalation
309892|NCT01839006|Procedure|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
309893|NCT01838993|Drug|Lidocaine inhalation|Lidocaine inhalation before intubation
309894|NCT01838993|Drug|Placebo|
309895|NCT01838980|Device|Motus GI Clean-Up Device|
309896|NCT01838967|Drug|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
309897|NCT01838967|Drug|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
309898|NCT01838967|Drug|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
309899|NCT01838967|Drug|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
309900|NCT01838967|Drug|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
309901|NCT01838967|Drug|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
309902|NCT01838954|Device|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
309903|NCT01838941|Drug|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~6 g/day in children < 30 kg, in 3 divided doses (2 g at meal time)~12 g/day in children > 30 kg, in 4 divided doses (3 g at meal time and bed time)."
309904|NCT01838928|Drug|Bupivacaine|
310084|NCT01837407|Procedure|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
309905|NCT01838915|Dietary Supplement|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.~Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
309906|NCT01838915|Dietary Supplement|Placebo|Maltodextrin, 20 g.
309907|NCT01838902|Drug|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
309908|NCT01838902|Drug|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
309909|NCT01838902|Drug|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
309910|NCT01838902|Drug|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
309911|NCT01838889|Behavioral|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
309912|NCT01838876|Drug|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/day (d); patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
309913|NCT01838876|Drug|Antidepressant Therapy (ADT)|ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its respective FDA approved package insert for each drug
309914|NCT01838863|Biological|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
309915|NCT01838863|Drug|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
309916|NCT01838850|Drug|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
309917|NCT01838850|Drug|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
309918|NCT01838824|Behavioral|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
309919|NCT01838811|Behavioral|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
309920|NCT01838798|Other|Baseline activities|Initial consent procedures and baseline data collection.
309921|NCT01838798|Other|Clinical interview with a psychologist|"Clinical interview with a psychologist.~This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:~An inventory of peritraumatic distress symptoms~A questionnaire on peritraumatic dissociative experiences~An assessment of related, potential impacts~The HADS questionnaire"
309922|NCT01838798|Other|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:~Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ~An assessment of psychological trauma~An assessment of potential impacts"
309923|NCT01838798|Other|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:~assess cognitive functions~evaluate clinical symptoms of depression~assess quality of life~assess symptoms of post traumatic stress"
309924|NCT01838785|Drug|18F-DTBZ AV-133|
309925|NCT01838772|Drug|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
309926|NCT01838733|Other|Observational study|
309927|NCT01838720|Procedure|zero ischemia laparoscopic RFA assisted TE|
309928|NCT01838720|Procedure|ischemia|conventional laparoscopic partial nephrectomy
309929|NCT01838707|Drug|0.125% Bupivacaine HCL @ 4-5 ml/h|
309930|NCT01838707|Drug|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
309931|NCT01838707|Drug|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
309932|NCT01838694|Biological|Ala-Cpn10|
309933|NCT01838694|Drug|Placebo|
309934|NCT01838681|Drug|Placebo|Once daily, tablets, orally
309935|NCT01838681|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
309936|NCT01838681|Drug|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
309937|NCT01838668|Drug|Placebo|Two placebo capsules orally BID
309938|NCT01838668|Drug|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
309939|NCT01838655|Drug|Nitisinone|Oral dose of 2mg daily for 12 months.
405587|NCT01097057|Drug|Etoposide|Given IV
309940|NCT01838642|Drug|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
309941|NCT01838616|Drug|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
309942|NCT01838616|Drug|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
309943|NCT01838603|Other|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
309944|NCT01838590|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
309945|NCT01838590|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
309946|NCT01838564|Other|Routine Data collection|"Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.~Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST."
309947|NCT01838564|Other|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
309948|NCT01838551|Drug|COR-003|
309949|NCT01838538|Drug|Bevacizumab|
309950|NCT01838538|Drug|TC:paclitaxel + carboplatin|
309951|NCT01838499|Biological|MEDI8968|SC injection at baseline, Week 4 and Week 8
309952|NCT01838499|Biological|Saline|SC injection at baseline, Week 4 and Week 8
309953|NCT01838486|Procedure|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
309954|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
309955|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
309956|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
309957|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
309958|NCT01838460|Drug|sublingual nicotine tablets|6 mg = 3 tablets
309959|NCT01838460|Other|Smokeless tobacco|Swedish type moist snuff
309960|NCT01838447|Dietary Supplement|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
309961|NCT01838434|Drug|lenalidomide|given PO
309962|NCT01838434|Drug|idelalisib|given PO
309963|NCT01838408|Other|Ez2go Complete|EZ2Go Complete
309964|NCT01838408|Other|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
309965|NCT01838395|Drug|Ara-C|IV
309966|NCT01838395|Drug|BL-8040|SC
309967|NCT01838382|Device|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
309968|NCT01838369|Drug|BI-505|
309969|NCT01838343|Other|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
309970|NCT01838330|Dietary Supplement|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
309971|NCT01838317|Drug|Pioglitazone|
309972|NCT01838304|Device|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
309973|NCT01838304|Device|Monitoring|Manual recording of drug doses determined by CRNA
309974|NCT01838278|Behavioral|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
309975|NCT01838265|Procedure|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
309976|NCT01838265|Procedure|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
309977|NCT01838265|Behavioral|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
309978|NCT01838265|Behavioral|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
309979|NCT01838265|Behavioral|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
309980|NCT01838265|Procedure|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
309981|NCT01838265|Procedure|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
309982|NCT01838265|Procedure|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
309983|NCT01838265|Procedure|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
309984|NCT01838252|Procedure|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
309985|NCT01838252|Procedure|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
309986|NCT01838239|Dietary Supplement|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
309987|NCT01838226|Behavioral|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
309988|NCT01838200|Biological|Bacillus Calmette-Guérin (BCG) vaccine|BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.
309989|NCT01838200|Drug|Ipilimumab|Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.
309990|NCT01838200|Drug|Isoniazid|Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
309991|NCT01838187|Radiation|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
309992|NCT01838174|Drug|ACTHAR Gel (ACTH)|15 days of daily injections
309993|NCT01838174|Drug|IV methylprednisolone (steroids)|3 days of intravenous methylprednisolone followed by 11 days of oral taper
309994|NCT01838161|Behavioral|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
309995|NCT01838161|Behavioral|Part III|•video educational
309996|NCT01838161|Behavioral|Part I|Parental Interviews
309997|NCT01838135|Device|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
309998|NCT01838109|Dietary Supplement|oral nutritional supplement|
309999|NCT01838096|Device|THA using 4th generation CoC|
310000|NCT01838083|Drug|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
310001|NCT01838057|Device|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
310002|NCT01838057|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
310003|NCT01838044|Drug|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
310004|NCT01838044|Drug|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.~All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
310005|NCT01838031|Other|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
310006|NCT01838005|Behavioral|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
310007|NCT01837992|Drug|Primaquine|
310008|NCT01837992|Drug|delayed primaquine|
310009|NCT01837979|Procedure|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
310010|NCT01837966|Other|Lavender oil|2 drops for aromatherapy
310011|NCT01837966|Other|Placebo|2 drops unscented mineral oil for aromatherapy
405697|NCT01096368|Drug|Etoposide|Given IV
310012|NCT01837953|Behavioral|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
310013|NCT01837953|Behavioral|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
310014|NCT01837940|Dietary Supplement|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
310015|NCT01837940|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
310016|NCT01837927|Drug|NVA237|Once daily for 52 weeks
310017|NCT01837927|Drug|Tiotropium Respimat®|Once daily for 52 weeks
310018|NCT01837914|Procedure|Maxillary expansion|
310019|NCT01837914|Procedure|Adenotonsillectomy|
310020|NCT01837901|Device|transcorneal electrostimulation|OkuStim is used to determine the phosphene threshold, and then to administer electrostimulation
310021|NCT01837888|Device|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
310022|NCT01837875|Behavioral|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
310023|NCT01837875|Behavioral|Mail-delivered arthritis kit|"The Arthritis Self-Management Tool Kit contains 1) a Self Test to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets."
310024|NCT01837875|Behavioral|Support group|"Interested participants will be referred to the Lupus: Listening and Learning Group, a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved."
310025|NCT01837875|Behavioral|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
310026|NCT01837862|Drug|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
310027|NCT01837862|Drug|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients < 12kg: 0.05 mg/kg; for patient > 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
310028|NCT01837862|Drug|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
310029|NCT01837862|Drug|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
310030|NCT01837862|Drug|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
310085|NCT01837394|Procedure|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
310340|NCT01835353|Drug|Prasugrel 100mg loading dose|
310031|NCT01837862|Drug|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
310032|NCT01837836|Behavioral|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
310033|NCT01837823|Drug|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
310034|NCT01837810|Drug|Ibuprofen|800mg every 8 hours as needed for pain
310035|NCT01837797|Drug|Placebo|Once daily, tablets, orally
310036|NCT01837797|Drug|Brexpiprazole 1 mg|once daily dose, tablets, orally
310037|NCT01837797|Drug|Brexpiprazole 3 mg|once daily dose, tablets, orally
310038|NCT01837784|Other|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
310039|NCT01837771|Device|Diaphragmatic stimulation|
310040|NCT01837745|Drug|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
310041|NCT01837745|Drug|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
310042|NCT01837745|Other|Follow up|"10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation~2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)~3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4~4 years (+/- 2 months) after randomization: a serum Tg/LT4~5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
310043|NCT01837732|Other|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
310044|NCT01837732|Other|Relational:|Relational: 10 mn verbal patient's centered exchanges
310045|NCT01837719|Drug|Atazanavir|300-mg capsule
310046|NCT01837719|Drug|Cobicistat|150-mg tablet
310047|NCT01837719|Drug|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
310048|NCT01837693|Procedure|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
310049|NCT01837680|Drug|Insulin|
310050|NCT01837667|Drug|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
310051|NCT01837667|Drug|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
310052|NCT01837654|Behavioral|Plantarflexion 2nd wave|At the beginning of the 2nd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
310053|NCT01837654|Behavioral|Plantarflexion - 3rd wave|At the beginning of the 3rd wave, patients will be asked to perform continuous plantar-flexion by pushing their tiptoes against the floor.
310054|NCT01837641|Biological|LY3002813-IV|Administered IV
310055|NCT01837641|Biological|LY3002183-SC|Administered SC
310056|NCT01837641|Drug|Placebo-IV|Administered IV
310057|NCT01837628|Drug|Lidocaine Gel|
310058|NCT01837628|Drug|Paraffin Oil|
310059|NCT01837615|Device|Photopill treatment|
310060|NCT01837602|Biological|cMet RNA CAR T cells|
310061|NCT01837589|Other|QCT|
310062|NCT01837589|Other|DXA|
310063|NCT01837576|Drug|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
310064|NCT01837550|Behavioral|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
310065|NCT01837550|Behavioral|Control group|The control group only had access to reading material.
310066|NCT01837524|Behavioral|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
310067|NCT01837524|Behavioral|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
310068|NCT01837511|Other|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
310069|NCT01837498|Drug|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
310070|NCT01837498|Drug|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
310071|NCT01837485|Drug|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
310072|NCT01837485|Drug|Placebo|Placebo pill was applied 3 times a day for 3 months
310073|NCT01837472|Drug|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
310074|NCT01837472|Drug|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
310075|NCT01837446|Drug|2% morphine solution|
310076|NCT01837446|Drug|Magnesium aluminum hydroxide|
310077|NCT01837446|Drug|2% viscous lidocaine|
310086|NCT01837394|Procedure|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
310087|NCT01837394|Drug|Paracetamol|
310088|NCT01837394|Drug|Morphine|5 mg as needed
310089|NCT01837394|Drug|Ondansetron|4 mg i.v. as needed in the PACU
310090|NCT01837394|Drug|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
310091|NCT01837381|Procedure|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol [absolute alcohol], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
310092|NCT01837368|Other|observational research|It is a observational research, no intervention are performed
310093|NCT01837355|Dietary Supplement|Lactobacillus rhamnosus|
310094|NCT01837355|Dietary Supplement|Placebo|
310095|NCT01837342|Procedure|Surgical reserction|
310096|NCT01837342|Other|Radiological percutaneous drainage and washing drainage|
310097|NCT01837329|Drug|Tetrathiomolybdate|"Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.~Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.~Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.~Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles."
310098|NCT01837316|Drug|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
310099|NCT01837316|Drug|Placebo|First strip: Inhalation powder of lactose
310100|NCT01837303|Procedure|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.~These slides will be processed so that they may be reviewed by a single board certified pathologist.~There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
310101|NCT01837290|Drug|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
310102|NCT01837290|Drug|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
310103|NCT01837290|Drug|saline infusion|Saline infusion to facilitate blinding
310104|NCT01837290|Drug|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
310105|NCT01837277|Drug|Use of Raltegravir-based regimens|Use of Raltegravir-based regimens: patients will receive a Raltegravir-based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
310106|NCT01837277|Drug|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
310107|NCT01837264|Device|Magellan®|
310108|NCT01837251|Drug|Carboplatin|
310109|NCT01837251|Drug|PLD|
310110|NCT01837251|Biological|Bevacizumab|
310111|NCT01837238|Dietary Supplement|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
310112|NCT01837238|Dietary Supplement|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
310113|NCT01837199|Drug|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
310114|NCT01837160|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
310115|NCT01837160|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
310116|NCT01837160|Procedure|Echocardiogram|Echocardiography.
310117|NCT01837160|Radiation|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
310118|NCT01837160|Procedure|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
310119|NCT01837147|Behavioral|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
310120|NCT01837147|Behavioral|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
310121|NCT01837134|Device|telemedical (TM) group|telemedical devices (weighing machine and step counter)
310122|NCT01837134|Behavioral|telemedical coaching (TMC) group|care calls once per week for 12 weeks
310123|NCT01837121|Other|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
310124|NCT01837108|Drug|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
310125|NCT01837108|Drug|Placebo|
310126|NCT01837095|Drug|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
310127|NCT01837082|Drug|ferric carboxymaltose|
310128|NCT01837082|Drug|Placebo|
310129|NCT01837069|Drug|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
310130|NCT01837069|Drug|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
310131|NCT01837069|Drug|Atorvastatin|80mg PO QD at preadmission testing
406290|NCT01092169|Other|No intervention|
310132|NCT01837069|Behavioral|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
310133|NCT01837043|Drug|Belatacept|
310134|NCT01837043|Drug|Calcineurin Inhibitor|
310135|NCT01837030|Dietary Supplement|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
310136|NCT01837030|Device|Capsule Endoscopy|GIVEN capsule
310137|NCT01837017|Behavioral|Home-based Exercise|This is a control group with no intervention
310138|NCT01837004|Behavioral|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
310139|NCT01836991|Procedure|surgery|
310140|NCT01836978|Other|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
310141|NCT01836965|Behavioral|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
310142|NCT01836939|Drug|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
310143|NCT01836939|Drug|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
310144|NCT01836926|Procedure|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum~Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.~laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description~intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
310145|NCT01836926|Device|laparoscopic intersphincteric resection|laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
310146|NCT01836900|Device|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
310147|NCT01836887|Dietary Supplement|Very low polyphenol fruit based drink (control)|
310148|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
310149|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
310150|NCT01836874|Drug|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
310151|NCT01836861|Drug|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
310152|NCT01836848|Procedure|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
310153|NCT01836835|Other|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
310154|NCT01836835|Other|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
310155|NCT01836822|Procedure|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
310156|NCT01836822|Procedure|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
310157|NCT01836822|Procedure|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
310158|NCT01836822|Procedure|Bronchoalveolar lavage (BAL)|
310159|NCT01836822|Procedure|Endobronchial forceps biopsy|
310160|NCT01836809|Drug|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
310161|NCT01836809|Drug|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
310162|NCT01836796|Dietary Supplement|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
310163|NCT01836796|Dietary Supplement|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
310164|NCT01836783|Other|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
310165|NCT01836783|Other|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
310166|NCT01836757|Drug|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
310167|NCT01836757|Drug|Placebo|
310168|NCT01836744|Device|Survival rate dental implant (OsseoSpeed™)|
310204|NCT01836471|Drug|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
310169|NCT01836731|Behavioral|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
310170|NCT01836731|Behavioral|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
310171|NCT01836705|Drug|SAR302503 (TG101348)|"Pharmaceutical form:capsule~Route of administration: oral"
310172|NCT01836705|Drug|Placebo SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
310173|NCT01836705|Drug|Panolosetron|"Pharmaceutical form:solution~Route of administration: intravenous"
310174|NCT01836692|Radiation|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
310175|NCT01836679|Drug|Chidamide|Given orally
310176|NCT01836679|Drug|Paclitaxel|Given IV
310177|NCT01836679|Drug|Carboplatin|Given IV
310178|NCT01836679|Drug|Placebo|Given orally
310179|NCT01836653|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310180|NCT01836653|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310181|NCT01836653|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310182|NCT01836653|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310183|NCT01836653|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310184|NCT01836653|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310185|NCT01836627|Other|Hyperinsufflation therapy|15 minutes twice a day of hyperinsufflation with Cough Assist® device
310186|NCT01836614|Drug|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
310187|NCT01836601|Behavioral|Family-centered nighttime communication bundle|
310188|NCT01836588|Procedure|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.~For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
310189|NCT01836575|Drug|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment [dexamethasone + vitamin B12 + folic acid, as per pemetrexed label] + Antiemetic therapy at investigator's discretion.
310190|NCT01836575|Drug|Carboplatin|Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle].
310191|NCT01836562|Biological|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
310192|NCT01836549|Drug|imetelstat sodium|Given IV
310193|NCT01836536|Drug|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
310194|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
310195|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
310196|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
310197|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
310198|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
310199|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
310200|NCT01836497|Device|SD01 ICD lead|
310201|NCT01836484|Diagnostic Test|Diffusion-weighted MRI|
310202|NCT01836484|Diagnostic Test|Fluorodeoxyglucose-18-PET/CT|
310203|NCT01836484|Diagnostic Test|Fluoro-ethyl-coline-PET/CT|
310249|NCT01836120|Drug|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d~1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
310205|NCT01836471|Drug|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
310206|NCT01836471|Drug|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
310207|NCT01836471|Drug|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
310208|NCT01836458|Drug|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
310209|NCT01836445|Behavioral|Keep It Up!|
310210|NCT01836445|Behavioral|HIV Knowledge Control|
310211|NCT01836432|Drug|FOLFIRINOX|FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours
310212|NCT01836432|Biological|Algenpantucel-L Immunotherapy|Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection
310213|NCT01836432|Radiation|5-FU Chemoradiation|5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
310214|NCT01836432|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
310215|NCT01836432|Drug|Capecitabine|Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation
310216|NCT01836432|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes
310217|NCT01836419|Procedure|classic LMA insertion|
310218|NCT01836406|Drug|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
310219|NCT01836393|Drug|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
310220|NCT01836380|Behavioral|Exercise Training|
310221|NCT01836367|Drug|Ingenol Mebutate 0.015%|Picato
310222|NCT01836354|Behavioral|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
310223|NCT01836341|Drug|Afatinib|
310224|NCT01836341|Drug|Cisplatin|
310225|NCT01836341|Drug|Carboplatin|
310226|NCT01836341|Drug|Pemetrexed|
310227|NCT01836341|Radiation|Radiation therapy|
310228|NCT01836328|Drug|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
310229|NCT01836328|Drug|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
310230|NCT01836315|Other|Observational Study|
310231|NCT01836302|Other|Observation|
310232|NCT01836289|Drug|High-dose Cyclophosphamide|
310233|NCT01836276|Drug|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
310234|NCT01836237|Device|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
310235|NCT01836224|Drug|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) >65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
310236|NCT01836224|Drug|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65
310237|NCT01836211|Other|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
310238|NCT01836211|Other|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
310239|NCT01836198|Drug|LY2409021|
310240|NCT01836198|Drug|Gemfibrozil|
310241|NCT01836198|Drug|Ketoconazole|
310242|NCT01836198|Drug|Clarithromycin|
310243|NCT01836185|Drug|Evacetrapib|
310244|NCT01836172|Drug|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
310245|NCT01836159|Other|iPad Intervention|"Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.~The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:~Popping a stationary balloon~Popping a moving balloon~Popping a pair of stationary balloons~Popping a pair of moving balloons~Stretching a balloon to pop~Balloon/Text distraction test"
310246|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
310247|NCT01836146|Device|EnligHTN™ Renal Artery Ablation Catheter|
310248|NCT01836133|Drug|Erlotinib 150 mg|
310250|NCT01836120|Drug|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
310251|NCT01836094|Drug|Methylene Blue (USP grade, 280mg oral)|
310252|NCT01836094|Drug|Placebo|oral, one time
310253|NCT01836081|Other|Volume expansion|
310254|NCT01836068|Drug|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
310255|NCT01836029|Drug|VTX-2337|TLR8 Agonist
310256|NCT01836029|Drug|Carboplatin|
310257|NCT01836029|Drug|Cisplatin|
310258|NCT01836029|Drug|5-fluorouracil|
310259|NCT01836029|Drug|Placebo|
310260|NCT01836016|Drug|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
310261|NCT01836016|Drug|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
310262|NCT01836016|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
310263|NCT01836016|Drug|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
310264|NCT01836016|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
310265|NCT01836016|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
310266|NCT01836016|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
310267|NCT01836016|Drug|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
310268|NCT01836003|Other|Tokafatso programmatic intervention|"Tokafatso programmatic intervention:~SMS-based platform for delivery of CD4 test results~Participatory educational session for clinic staff~Loan program for HIV and CD4 testing supplies~Facilitation of tracing of HAART-eligible pregnant women"
310269|NCT01835990|Device|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
310270|NCT01835990|Device|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
310271|NCT01835977|Device|Irreversible Electroporation (Nanoknife)|
310272|NCT01835964|Procedure|Glucose Variability Observation|On the morning of ~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
310273|NCT01835951|Other|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
310274|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
310275|NCT01835938|Drug|1- Erlotinib|"Erlotinib 50 mg tablet by mouth every day for 14 days,~Erlotinib 100 mg tablet by mouth every day for 14 days,~Erlotinib 150 mg tablet by mouth every day for 14 days,"
310276|NCT01835938|Drug|placebo|"Placebo 50 mg tablet by mouth every day for 14 days,~Placebo 100 mg tablet by mouth every day for 14 days,~Placebo 150 mg tablet by mouth every day for 14 days,"
310277|NCT01835925|Genetic|Tissue specimen|
310278|NCT01835912|Other|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
310279|NCT01835899|Drug|Placebo|Placebo to BI 1015550
310280|NCT01835899|Drug|BI 1015550|medium dose 1 powder for oral solution
310281|NCT01835899|Drug|BI 1015550|medium dose 2 powder for oral solution
310282|NCT01835899|Drug|BI1015550|low dose 2 powder for oral solution
310283|NCT01835899|Drug|BI 1015550|low dose 1 powder for oral solution
310284|NCT01835886|Other|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
310285|NCT01835873|Other|Lactated Ringer's|
310286|NCT01835873|Other|HES 130/0.42|Balanced colloid solution
310287|NCT01835860|Procedure|Prostate artery embolization|
310288|NCT01835847|Drug|Tipepidine Hibenzate|
310289|NCT01835834|Procedure|zirconia bridge restoration|
310290|NCT01835821|Device|prosthetic crowns|prosthetic crowns
310291|NCT01835808|Device|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
310292|NCT01835795|Device|Swiss DolorClast® CLASSIC applicator|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
411302|NCT01052649|Other|Blood sampling|
310293|NCT01835795|Device|Swiss DolorClast® CLASSIC placebo applicator|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 5 to 7 hertz frequency, 2 to 4 bar pressure
310294|NCT01835782|Drug|L-Serine|
310295|NCT01835756|Device|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
310296|NCT01835756|Device|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
310297|NCT01835743|Device|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
310298|NCT01835743|Device|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
310299|NCT01835730|Drug|PE0139 Injection|
310300|NCT01835730|Drug|Placebo|
310301|NCT01835704|Other|Radio-frequency dennervation of facet joint|
310302|NCT01835704|Other|Diagnostic nerve-blocks performed under direct x-ray vision|
310303|NCT01835691|Dietary Supplement|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
310304|NCT01835691|Dietary Supplement|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
310305|NCT01835678|Drug|Linagliptin|orally 5 mg/d for 4 weeks
310306|NCT01835678|Drug|Placebo|orally once a day for 4 weeks
310307|NCT01835665|Drug|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
310308|NCT01835652|Other|Active Exercise|
310309|NCT01835652|Other|Passive Exercise|
310310|NCT01835639|Dietary Supplement|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
310311|NCT01835626|Drug|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
310312|NCT01835626|Radiation|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
310313|NCT01835613|Other|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
310314|NCT01835600|Other|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
310315|NCT01835587|Drug|CC-486|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary Maximum Tolerated Dose (MTD) is identified.
310316|NCT01835574|Behavioral|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete >=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
310317|NCT01835561|Drug|Pomalidomide|Single oral dose of 4‐mg capsule
310318|NCT01835561|Drug|Pomalidomide|4-mg capsule
310319|NCT01835548|Drug|NT0102|NT0102 (methylphenidate polistirex [MPP] extended release [XR] ODT) was given once daily at a dose equivalent to 20-60 mg methylphenidate hydrochloride.
310320|NCT01835548|Drug|Placebo|Matching ODT placebo was given once daily.
310321|NCT01835535|Device|TIVUS|
310322|NCT01835509|Behavioral|Intervention, Camp plus reunions|
310323|NCT01835496|Drug|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
310324|NCT01835470|Drug|Abatacept|
310325|NCT01835457|Drug|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects.
310326|NCT01835457|Behavioral|Concentration/meditation|A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
310327|NCT01835444|Other|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
310328|NCT01835431|Drug|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
310329|NCT01835431|Drug|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
310330|NCT01835431|Drug|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
310331|NCT01835431|Drug|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
310332|NCT01835418|Drug|Amlodipine|crossover comparison of amlodipine vs lisinopril
310333|NCT01835405|Device|LiquiBand Flex|
310334|NCT01835405|Device|Dermabond Advanced|
310335|NCT01835405|Device|Sutures (Prolene)|
310336|NCT01835392|Procedure|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
310337|NCT01835392|Other|Control|Sham placement of blood pressure cuff without inflation
310338|NCT01835379|Device|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
310339|NCT01835379|Other|Standard|
310341|NCT01835353|Drug|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
310342|NCT01835340|Device|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
310343|NCT01835314|Drug|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
310344|NCT01835288|Drug|arsenic trioxide|Given IV
310345|NCT01835288|Other|laboratory biomarker analysis|Correlative studies
310346|NCT01835275|Behavioral|Enhanced Audio|
310347|NCT01835275|Behavioral|Audio|
310348|NCT01835262|Drug|Morphine|Morphine: 0.1 mg /kg given as IVP
310349|NCT01835262|Drug|Ketamine|Ketamine:0.3 mg/given as IVP
310350|NCT01835249|Other|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP <120 mmHg.
310351|NCT01835249|Other|Standard BP arm|Participants in the Standard BP arm have a goal of SBP <140 mmHg.
310352|NCT01835236|Drug|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.~- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
310353|NCT01835236|Drug|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.~- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
310354|NCT01835236|Drug|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
310355|NCT01835236|Drug|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion~then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
310356|NCT01835236|Drug|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
310357|NCT01835223|Other|Laboratory Biomarker Analysis|Correlative studies
310358|NCT01835223|Other|Pharmacological Study|Correlative studies
310359|NCT01835223|Drug|Tivozanib|Given PO
310360|NCT01835197|Drug|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
310361|NCT01835197|Drug|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
310362|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
310363|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
310364|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
310365|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
310366|NCT01835197|Drug|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
310367|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
310368|NCT01835197|Drug|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
310369|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
310370|NCT01835184|Drug|cabozantinib-s-malate|Given PO
310371|NCT01835184|Drug|vemurafenib|Given PO
310372|NCT01835184|Other|laboratory biomarker analysis|Correlative studies
310373|NCT01835184|Other|pharmacological study|Correlative studies
310374|NCT01835158|Drug|Cabozantinib S-malate|Given PO
310375|NCT01835158|Other|Laboratory Biomarker Analysis|Correlative studies
310376|NCT01835158|Drug|Sunitinib Malate|Given PO
310377|NCT01835145|Drug|Cabozantinib S-malate|Given PO
310378|NCT01835145|Drug|Dacarbazine|Given IV
310379|NCT01835145|Other|Laboratory Biomarker Analysis|Correlative studies
310380|NCT01835145|Drug|Temozolomide|Given PO
310381|NCT01835132|Device|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
310382|NCT01835119|Drug|gum|gum
310383|NCT01835106|Procedure|Epidural catheter is used postoperatively|
310384|NCT01835106|Procedure|Fascia iliaca compartment catheter is used postoperatively|
310385|NCT01835093|Drug|Tipepidine Hibenzate|
310386|NCT01835067|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
310387|NCT01835067|Drug|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
310388|NCT01835067|Drug|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
310389|NCT01835054|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
310390|NCT01835054|Genetic|DNA collection|Observational Study using Imaging and Biomarkers
310391|NCT01835054|Other|Echocardiography|Observational Study using Imaging and Biomarkers
310392|NCT01835054|Other|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
310393|NCT01835054|Other|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
310394|NCT01835054|Other|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
310395|NCT01835054|Other|Holter ECG|Observational Study using Imaging and Biomarkers
310396|NCT01835041|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
310397|NCT01835041|Drug|oxaliplatin|Given IV
310398|NCT01835041|Drug|leucovorin calcium|Given IV
310399|NCT01835041|Drug|irinotecan hydrochloride|Given IV
310400|NCT01835041|Drug|fluorouracil|Given IV
310401|NCT01835041|Other|laboratory biomarker analysis|Correlative studies
310402|NCT01835028|Other|Echocardiography|Observational Study using Imaging and Biomarkers
310403|NCT01835028|Other|Computed tomography|Observational Study using Imaging and Biomarkers
310404|NCT01835028|Other|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
310405|NCT01835028|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
310406|NCT01835028|Other|Stress echocardiography|Observational Study using Imaging and Biomarkers
310407|NCT01835015|Drug|CLG561|Administered by intravitreal injection, Day 1
310408|NCT01835002|Device|Electrostimulation|
310409|NCT01834989|Drug|Insulin-like growth factor I|
310410|NCT01834989|Drug|Placebo|
310411|NCT01834963|Drug|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha~Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks~Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
310412|NCT01834963|Drug|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)~Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks~Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
310413|NCT01834950|Other|Blood test|
310414|NCT01834937|Device|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
310415|NCT01834924|Other|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
310416|NCT01834911|Drug|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
310417|NCT01834898|Drug|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
310418|NCT01834885|Drug|QVA149|QVA149 via inhaler twice a day
310419|NCT01834885|Drug|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
310420|NCT01834872|Device|Amigo|
310421|NCT01834872|Device|Manual ablation|
310422|NCT01834859|Behavioral|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
310423|NCT01834859|Behavioral|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
310424|NCT01834846|Procedure|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
310425|NCT01834846|Procedure|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
310426|NCT01834833|Other|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
310427|NCT01834820|Drug|Epinephrine and Dexamethasone|
310428|NCT01834820|Drug|Hypertonic Saline|
310429|NCT01834820|Drug|Normal Saline|
310430|NCT01834794|Behavioral|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
310431|NCT01834781|Device|Pulsed electromagnetic fields|
310432|NCT01834781|Device|w/o pulsed electromagnetic fields|
310433|NCT01834768|Drug|Eplerenone|
310434|NCT01834755|Other|Evaluation of psychological phenotype|
310435|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
310436|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
310437|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
310438|NCT01834742|Drug|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
310439|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
310440|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
310441|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
310442|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
310443|NCT01834729|Drug|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
310444|NCT01834729|Other|Placebo|placebo capsule identical to the study drug
310445|NCT01834716|Behavioral|Aerobic vs. Non-Aerobic exercise|
310446|NCT01834703|Procedure|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
310447|NCT01834703|Procedure|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
310448|NCT01834664|Biological|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell [MNCs ]Per dose at the interval
310449|NCT01834651|Drug|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
310450|NCT01834638|Drug|ABT-126|capsule(s)
310451|NCT01834625|Diagnostic Test|PET scan|
310452|NCT01834612|Device|CM1500|blood volume monitor
310453|NCT01834599|Device|cerebral oximetry|tissue saturation measurement in pregnant women
310454|NCT01834586|Drug|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.~For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
310455|NCT01834573|Behavioral|physical exercise|10 weeks physical exercise; three times a week
310456|NCT01834547|Drug|Drugs use: methylphenidate|40 mg tablets
310457|NCT01834547|Drug|Drug use: modafinil|40 mg tablets
310458|NCT01834547|Drug|caffeine|400 mg
310459|NCT01834547|Drug|placebo|placebo
310460|NCT01834534|Behavioral|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
310461|NCT01834521|Other|Web-based screening and tailored support|
310462|NCT01834508|Drug|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
310463|NCT01834495|Device|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
310464|NCT01834495|Device|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
310465|NCT01834482|Dietary Supplement|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
310466|NCT01834482|Dietary Supplement|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
310467|NCT01834469|Drug|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
310468|NCT01834456|Other|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
310469|NCT01834443|Device|Direct current galvanic vestibular stimulation|
310470|NCT01834430|Dietary Supplement|enteral nutrition|
310471|NCT01834417|Device|TexiMat|
310472|NCT01834404|Drug|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
310473|NCT01834404|Drug|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
310474|NCT01834378|Behavioral|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
310475|NCT01834378|Behavioral|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
310476|NCT01834365|Other|Structured education|Formatted education about hypertension
310477|NCT01834365|Other|Checklist|
310478|NCT01834365|Other|Without structure education with checklist|
310479|NCT01834352|Drug|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
310480|NCT01834352|Drug|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
310481|NCT01834339|Biological|AlloDerm|
310482|NCT01834339|Biological|EVPOME|
310483|NCT01834326|Biological|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
310484|NCT01834326|Biological|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
310485|NCT01834300|Behavioral|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
310486|NCT01834300|Behavioral|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
310487|NCT01834287|Behavioral|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
310488|NCT01834287|Behavioral|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
310489|NCT01834274|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
310490|NCT01834274|Drug|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
310491|NCT01834274|Drug|Sitagliptin|Sitagliptin tablets
310492|NCT01834274|Drug|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
310493|NCT01834274|Drug|Metformin|Metformin tablets
310536|NCT01833910|Other|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
413922|NCT01031979|Drug|Placebo|Placebo
310494|NCT01834261|Drug|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
310495|NCT01834261|Drug|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
310496|NCT01834248|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
310497|NCT01834248|Drug|Decitabine|Given IV
310498|NCT01834248|Other|Laboratory Biomarker Analysis|Correlative studies
310499|NCT01834248|Drug|Poly ICLC|Given SC
310500|NCT01834235|Drug|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
310501|NCT01834235|Drug|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
310502|NCT01834235|Drug|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
310503|NCT01834222|Biological|Non-intervention|Non-intervention
310504|NCT01834209|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
310505|NCT01834209|Drug|Prednisone or prednisolone|5 mg tablet taken orally once daily
310506|NCT01834196|Device|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
310507|NCT01834183|Drug|Tivozanib|
310508|NCT01834183|Drug|Gemcitabine|
310509|NCT01834170|Drug|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.~The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
310510|NCT01834144|Other|Exercise Training|
310511|NCT01834131|Behavioral|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
310512|NCT01834118|Procedure|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
310513|NCT01834105|Drug|Liuwei Dihuang Pills|
310514|NCT01834092|Other|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
310515|NCT01834079|Biological|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
310516|NCT01834066|Biological|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
310517|NCT01834053|Biological|autologous Stem Cell|Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
310518|NCT01834040|Other|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
310519|NCT01834027|Behavioral|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
310520|NCT01834027|Behavioral|No music|In this group no music will be played in PACU
310521|NCT01834014|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310522|NCT01834014|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310523|NCT01834014|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310524|NCT01834014|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310525|NCT01834014|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310526|NCT01834014|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
310527|NCT01833988|Device|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
310528|NCT01833988|Other|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
310529|NCT01833975|Biological|Transplantation of Autologous stem cell [MNCs] .|Intra thecal transplantation of Autologous stem cell [MNCs],100millions per dose in 3 divided doses at interval of 10 days.
310530|NCT01833949|Procedure|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
310531|NCT01833949|Procedure|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
310532|NCT01833936|Device|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
310533|NCT01833936|Device|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
310534|NCT01833923|Drug|anlotinib|oral medicine.
310535|NCT01833910|Other|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
310537|NCT01833897|Drug|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
310538|NCT01833897|Drug|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
310539|NCT01833897|Drug|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
310540|NCT01833884|Other|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
310541|NCT01833871|Other|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
310542|NCT01833871|Other|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
310543|NCT01833858|Drug|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
310544|NCT01833858|Drug|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
310545|NCT01833845|Drug|Ribavirin|weight-based doses (1000 mg/day administered BID [twice daily] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects > 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
310546|NCT01833845|Drug|Hydroxychloroquine|subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
310547|NCT01833832|Drug|Cisplatin|Patients who are successfully debulked will then undergo hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
310548|NCT01833832|Procedure|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a Completeness of Cytoreduction Score (CC) of 0 or 1.
310549|NCT01833832|Drug|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
310550|NCT01833819|Drug|Dexmedetomidine and lidocaine|
310551|NCT01833819|Drug|Remifentanil|
310552|NCT01833806|Device|ExAblate MRgFUS|Focused Ultrasound Ablation
310553|NCT01833793|Drug|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
310554|NCT01833767|Drug|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
310555|NCT01833754|Drug|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
310556|NCT01833741|Drug|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
310557|NCT01833728|Drug|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.~In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
310558|NCT01833728|Drug|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
310559|NCT01833715|Drug|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
310560|NCT01833715|Drug|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
310561|NCT01833715|Drug|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
310562|NCT01833689|Dietary Supplement|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water~Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.~Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
310563|NCT01833676|Drug|Sevoflurane|
310564|NCT01833676|Drug|Desflurane|
310565|NCT01833663|Drug|Solifenacin Succinate Tablets|
310566|NCT01833663|Drug|Estrogen|
310567|NCT01833650|Dietary Supplement|thymus honey mouthwash|
310675|NCT01832701|Other|Placebo comparator|maltodextrine with caffeine
310676|NCT01832688|Other|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
310918|NCT01830686|Other|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
310568|NCT01833637|Other|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
310569|NCT01833624|Dietary Supplement|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
310570|NCT01833624|Dietary Supplement|Sondalis® HP|
310571|NCT01833611|Drug|Entecavir|entecavir 0.5mg qd
310572|NCT01833611|Drug|placebo|placebo qd
310573|NCT01833598|Procedure|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
310574|NCT01833598|Procedure|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
310575|NCT01833585|Biological|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
310576|NCT01833572|Drug|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
310577|NCT01833559|Dietary Supplement|Dietary control|
310578|NCT01833559|Drug|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
310579|NCT01833546|Drug|Evofosfamide|Evofosfamide infusion intravenously at an escalated dose of 240, 340 or 480 milligram per square meter (mg/m^2) on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
310580|NCT01833546|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Day 1, 8 and 15 of each 28-day treatment cycle until progressive disease, unacceptable toxicity or withdrawal.
310581|NCT01833533|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
310582|NCT01833533|Drug|Ribavirin|Capsule
310583|NCT01833533|Drug|Placebo for Ribavirin|Capsule
310584|NCT01833520|Drug|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.~Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
310585|NCT01833507|Behavioral|Self-Exercise|Behavioral Goal Setting
310586|NCT01833507|Behavioral|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
310587|NCT01833494|Drug|PA21|
310588|NCT01833481|Radiation|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
310589|NCT01833455|Drug|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
310590|NCT01833455|Drug|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
310591|NCT01833442|Behavioral|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
310592|NCT01833442|Behavioral|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
310593|NCT01833403|Other|Hyperinsulinemic-euglycemic clamp|"Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery~--------------------------------------------------------------------------------"
310594|NCT01833390|Drug|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
310595|NCT01833377|Dietary Supplement|caraway sample|
310596|NCT01833377|Dietary Supplement|placebo|
310597|NCT01833364|Procedure|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
310598|NCT01833351|Drug|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.~If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
310789|NCT01831583|Device|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
310599|NCT01833351|Drug|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.~Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
310600|NCT01833338|Device|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
310601|NCT01833325|Radiation|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
310602|NCT01833312|Device|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
310603|NCT01833312|Drug|Buspirone|anti-shivering treatment
310604|NCT01833312|Drug|Pethidine|anti-shivering treatment
310605|NCT01833299|Procedure|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.~Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
310606|NCT01833299|Procedure|TACE|
310607|NCT01833286|Procedure|TACE+RFA|TACE first, followed by RFA within 2 months
310608|NCT01833286|Procedure|re-resection|repeat hepatectomy for recurrent small HCC
310609|NCT01833273|Drug|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
310610|NCT01833260|Behavioral|Music|
310611|NCT01833234|Other|Interviews and questionnaires|
310612|NCT01833221|Drug|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
310613|NCT01833208|Other|Laboratory Biomarker Analysis|Correlative studies
310614|NCT01833208|Radiation|Radiation Therapy|Undergo single-fraction radiation therapy
310615|NCT01833182|Other|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
310616|NCT01833182|Other|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
310617|NCT01833169|Drug|BKM120|BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
310618|NCT01833156|Device|MoistureMeterD|measuring erythema size and the dielectric constant values
310619|NCT01833143|Drug|Bortezomib|
310620|NCT01833143|Drug|Acyclovir|
310621|NCT01833130|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
310622|NCT01833130|Drug|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
310623|NCT01833117|Other|FID 119515A|topical ocular drops
310624|NCT01833117|Other|Blink® Tears|topical ocular drops
310625|NCT01833104|Behavioral|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills & interoceptive body awareness. 2 exercises: Breathing Meditation & Body Scan.~PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, & other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation & Perspective Dyad.~AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
310626|NCT01833104|Behavioral|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
310627|NCT01833104|Behavioral|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
310919|NCT01830660|Drug|Hetrombopag Olamine Tablets|
310628|NCT01833091|Other|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand & arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
310629|NCT01833078|Drug|ghrelin|ghrelin administration subcutaneously for 7 days
310630|NCT01833065|Drug|Elobixibat 10 mg/day|Elobixibat 10 mg/day
310631|NCT01833065|Drug|Elobixibat 5 mg/day|Elobixibat 5 mg/day
310632|NCT01833065|Drug|Placebo|Placebo
310633|NCT01833052|Device|TAVI (Medtronic CoreValve)|
310634|NCT01833052|Device|Claret-Filter|
310635|NCT01833039|Drug|Ibrutinib|Ibrutinib
310636|NCT01833026|Device|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
310637|NCT01833026|Drug|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
310638|NCT01833013|Other|live birth date and quality of life assessment|
310639|NCT01833000|Device|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
310640|NCT01832987|Drug|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
310641|NCT01832974|Drug|IL-13-PE|IL-13-PE intravenous infusion
310642|NCT01832961|Device|flutter valve exercises|30 minutes of flutter exercises
310643|NCT01832961|Device|flutter-sham exercises|30 minutes of flutter-sham exercises
310644|NCT01832948|Drug|Endostar|
310645|NCT01832948|Drug|Oxaliplatin|
310646|NCT01832948|Drug|Folinic acid|
310647|NCT01832948|Drug|5-FU|
310648|NCT01832935|Drug|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
310649|NCT01832935|Drug|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
310650|NCT01832922|Drug|Bendamustine|
310651|NCT01832922|Drug|Rituximab|
310652|NCT01832909|Other|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
310653|NCT01832909|Other|Control Diet|Controlled diet without walnuts.
310654|NCT01832896|Drug|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
310655|NCT01832883|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
310656|NCT01832870|Drug|sipuleucel-T|
310657|NCT01832870|Drug|ipilimumab|
310658|NCT01832857|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
310659|NCT01832844|Procedure|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
310660|NCT01832844|Procedure|"Group  without scan "|
310661|NCT01832818|Device|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
310662|NCT01832805|Other|Theta burst stimulation.|In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
310663|NCT01832792|Other|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
310664|NCT01832792|Other|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
310665|NCT01832792|Other|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
310666|NCT01832779|Other|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
310667|NCT01832766|Drug|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
310668|NCT01832766|Other|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
310669|NCT01832753|Drug|Levothyroxine|
310670|NCT01832740|Device|brain stimulation|oscillating direct current brain stimulation
310671|NCT01832740|Device|SHAM|no stimulation
310672|NCT01832727|Drug|Oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 or on Days 1, 2, 8, and 9 of the 14-day treatment cycle.
310673|NCT01832727|Drug|Dexamethasone|Dexamethasone 20 mg will be taken on Days 1, 2, 8, and 9
310674|NCT01832701|Other|Coffee|coffee versus placebo
310677|NCT01832675|Drug|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
310678|NCT01832675|Drug|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
310679|NCT01832662|Other|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
310680|NCT01832662|Other|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
310681|NCT01832662|Other|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
310682|NCT01832649|Behavioral|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
310683|NCT01832649|Behavioral|Health education|Supervised groups 2 times per week during 8 weeks.
310684|NCT01832636|Dietary Supplement|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
310685|NCT01832623|Other|Exploration of Vitamin D roles|"Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound~Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
310686|NCT01832610|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
310687|NCT01832584|Dietary Supplement|RGC|
310688|NCT01832584|Dietary Supplement|Placebo|
310689|NCT01832571|Drug|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
310690|NCT01832558|Drug|Eplerenone|
310691|NCT01832558|Drug|Placebo|
310692|NCT01832545|Other|Aquatic Exercise|
310693|NCT01832545|Behavioral|Educational Program|Control Group
310694|NCT01832532|Drug|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
310695|NCT01832506|Drug|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
310696|NCT01832493|Device|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
310697|NCT01832480|Drug|MTZ 500 mg twice daily x 7 days|MTZ 500 mg twice daily x 7 days
310698|NCT01832480|Drug|MTZ 2 g|MTZ 2 g
310699|NCT01832467|Drug|cetuximab-containing chemotherapy|
310700|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
310701|NCT01832441|Other|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
310702|NCT01832428|Other|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
310703|NCT01832415|Drug|Bevacizumab|Observation of bevacizumab administration in first line ovarian cancer treatment
310704|NCT01832402|Drug|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
310705|NCT01832402|Drug|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
310706|NCT01832402|Other|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
310707|NCT01832402|Behavioral|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
310708|NCT01832402|Behavioral|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
310709|NCT01832389|Device|PiCCO|
310710|NCT01832376|Procedure|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
310711|NCT01832363|Drug|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
310790|NCT01831583|Device|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
310920|NCT01830660|Drug|placebo|
424414|NCT00956319|Drug|Zolpidem MR|oral
310712|NCT01832363|Other|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
310713|NCT01832350|Drug|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
310714|NCT01832337|Procedure|Limb remote ischemic preconditioning (LRIP)|Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
310715|NCT01832311|Drug|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
310716|NCT01832298|Drug|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
310717|NCT01832285|Drug|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
310718|NCT01832272|Procedure|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
310719|NCT01832259|Drug|Pazopanib|Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
310720|NCT01832259|Other|Placebo|Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
310721|NCT01832233|Procedure|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
310722|NCT01832207|Device|Transcutaneous electrical nerve stimulation|
310723|NCT01832207|Device|Placebo transcutaneous electrical nerve stimulation|
310724|NCT01832194|Drug|Botox|
310725|NCT01832168|Procedure|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
310726|NCT01832168|Other|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
310727|NCT01832168|Other|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
310728|NCT01832155|Behavioral|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
310729|NCT01832155|Behavioral|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
310730|NCT01832129|Drug|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
310731|NCT01832129|Drug|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
310732|NCT01832116|Drug|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
310733|NCT01832103|Drug|MK-7145|
310734|NCT01832090|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
310735|NCT01832077|Device|90 D|rural doctors exam eye fundus by 90 D
310736|NCT01832077|Device|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
310737|NCT01832064|Behavioral|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
310738|NCT01832051|Drug|89Zr-trastuzumab injection|
310739|NCT01832038|Drug|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg~Formulation: Tablet~Frequency: twice daily during the study period (until the date of approval)~At the completion of EP0008 [NCT01710657], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
310740|NCT01832025|Procedure|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
310741|NCT01832025|Procedure|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
310742|NCT01832012|Other|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
310743|NCT01832012|Other|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
310791|NCT01831570|Other|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
310792|NCT01831557|Other|Blood samples will be taken for gene sequencing|
310921|NCT01830634|Behavioral|Theraband with strengthening and stretching exercise|
310922|NCT01830621|Drug|BBI608|
310923|NCT01830621|Drug|Placebo|
310924|NCT01830621|Other|Best Supportive Care|
310744|NCT01831999|Behavioral|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
310745|NCT01831986|Dietary Supplement|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
310746|NCT01831986|Other|Placebo|Caps
310747|NCT01831973|Drug|Lipotecan|
310748|NCT01831960|Drug|cortexolone 17α-propionate|
310749|NCT01831947|Biological|Ranibizumab|
310750|NCT01831934|Biological|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
310751|NCT01831921|Behavioral|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
310752|NCT01831921|Behavioral|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
310753|NCT01831908|Other|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
310754|NCT01831895|Device|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
310755|NCT01831869|Drug|L-thyroxine|
310756|NCT01831856|Drug|1g of F373280|Oral administration, one capsule each evening with dinner.
310757|NCT01831856|Drug|Placebo|Oral administration, one capsule each evening with dinner.
310758|NCT01831843|Device|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
310759|NCT01831843|Device|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
310760|NCT01831843|Device|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
310761|NCT01831830|Behavioral|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
310762|NCT01831817|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
310763|NCT01831817|Drug|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
310764|NCT01831817|Drug|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
310765|NCT01831817|Drug|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
310766|NCT01831804|Drug|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
310767|NCT01831804|Drug|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
310768|NCT01831791|Drug|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
310769|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
310770|NCT01831765|Drug|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
310771|NCT01831765|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
310772|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
310773|NCT01831726|Drug|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
310774|NCT01831700|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
310775|NCT01831700|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
310776|NCT01831687|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
310777|NCT01831687|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
310778|NCT01831674|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
310779|NCT01831674|Drug|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
310780|NCT01831661|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
310781|NCT01831661|Drug|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
310782|NCT01831648|Other|Blood sample|
310783|NCT01831635|Other|Methodological pens|Randomisation of branded pen, non-branded pen and no pen
310784|NCT01831635|Other|Methodological compensation|Randomisation of a £10 monetary reimbursement for expenses on completion of the study
310785|NCT01831635|Other|Methodological trolley tokens|Trolley tokens to be randomly assigned to half of cases and General Practice controls.
310786|NCT01831622|Drug|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
310787|NCT01831622|Drug|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
310788|NCT01831596|Device|ciSNaP|
310793|NCT01831544|Device|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
310794|NCT01831531|Drug|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA >1.6 m2) p.o bid d1-28
310795|NCT01831531|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
310796|NCT01831518|Device|CRT Implant|
310797|NCT01831518|Device|Body Surface ECG Mapping|
310798|NCT01831505|Drug|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
310799|NCT01831492|Device|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
310800|NCT01831492|Device|cellulose|given for 14 weeks
310801|NCT01831479|Drug|Rosuvastatin|Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
310802|NCT01831479|Drug|Olmesartan|Single administration of olmesartan 40mg tablet QD for 7 consecutive days
310803|NCT01831479|Drug|Rosuvastatin and olmesartan|Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
310804|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
310805|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
310806|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
310807|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
310808|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
310809|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
310810|NCT01831453|Drug|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
310811|NCT01831453|Drug|placebo|soft gelatinous capsules filled with isopropylmyristate oil
310812|NCT01831440|Behavioral|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
310813|NCT01831440|Drug|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
310814|NCT01831427|Drug|GS-5745|GS-5745 administered by intravenous infusion or subcutaneous injection
310815|NCT01831427|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered by intravenous infusion
310816|NCT01831414|Other|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
310817|NCT01831414|Other|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
310818|NCT01831401|Procedure|Operating table position 0° head down (Horizontal)|
310819|NCT01831401|Procedure|Operating table position 7° head down.|
310820|NCT01831401|Procedure|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
310821|NCT01831401|Device|Standard straight acetabular component introducer without alignment guide.|
310822|NCT01831401|Device|Modified 35° acetabular component introducer.|
310823|NCT01831401|Device|Inclinometer-assisted acetabular component introducer.|
310824|NCT01831388|Other|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:~- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
310825|NCT01831388|Behavioral|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
310826|NCT01831375|Behavioral|Speak Up|Intervention group_treatment group
310827|NCT01831375|Behavioral|Get connected|Participants will learn to be connected with social resources in the community.
310828|NCT01831362|Behavioral|Mindfulness-Based Cognitive Therapy|
310829|NCT01831362|Behavioral|Focused Attention (FA)|
310830|NCT01831362|Behavioral|Open- Monitoring|
310831|NCT01831323|Dietary Supplement|VSL#3|VSL#3
310832|NCT01831323|Drug|Rifaximin|Rifaximin
310833|NCT01831323|Drug|Mesalazine|Mesalazine
310834|NCT01831323|Dietary Supplement|Psyllium|psyllium
310835|NCT01831310|Dietary Supplement|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
310836|NCT01831310|Dietary Supplement|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
310837|NCT01831310|Dietary Supplement|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
310915|NCT01830699|Drug|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
424415|NCT00956319|Drug|Estazolam|oral
310838|NCT01831310|Dietary Supplement|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
310839|NCT01831297|Device|measurement of blood pressure|measurement of pulse wave velocity
310840|NCT01831284|Procedure|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
310841|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
310842|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
310843|NCT01831258|Device|SensAwake On|
310844|NCT01831258|Device|SensAwake Off|
310845|NCT01831232|Drug|pravastatin sodium|Given PO
310846|NCT01831232|Drug|idarubicin|Given IV
310847|NCT01831232|Drug|cytarabine|Given IV
310848|NCT01831232|Other|laboratory biomarker analysis|Correlative studies
310849|NCT01831206|Procedure|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication."
310850|NCT01831193|Drug|Curcumin|
310851|NCT01831167|Other|dynamic light|
310852|NCT01831154|Drug|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
310853|NCT01831154|Drug|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
310854|NCT01831154|Drug|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
310855|NCT01831128|Device|ASV Treatment|
310856|NCT01831102|Other|none- observational study|
310857|NCT01831089|Drug|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion~paclitaxel: 6 mg/ml concentrate for solution for infusion~bevacizumab: 25 mg/ml concentrate for solution for infusion~Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
310858|NCT01831076|Drug|Exemestane|Given PO
310859|NCT01831076|Drug|Exemestane and tamoxifen|exemestane 25 mg po daily and tamoxifen 20 mg po daily given concurrently for 4 months prior to surgery
310860|NCT01831063|Behavioral|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
310861|NCT01831050|Biological|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
310862|NCT01831050|Biological|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
310863|NCT01831050|Biological|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
310864|NCT01831050|Biological|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
310865|NCT01831050|Biological|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
310866|NCT01831050|Biological|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India [SII]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
310867|NCT01831037|Other|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).
310868|NCT01831037|Other|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
310916|NCT01830686|Other|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
310917|NCT01830686|Other|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
310869|NCT01831024|Device|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
310870|NCT01831011|Drug|mildronate injection|
310871|NCT01831011|Drug|cinepazide maleate injection|
310872|NCT01831011|Drug|aspirin|
310873|NCT01830985|Drug|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
310874|NCT01830972|Drug|SA-ER 500 mg|oral tablets
310875|NCT01830972|Drug|SA-IR 500 mg|oral capsules
310876|NCT01830959|Drug|Roflumilast|Roflumilast
310877|NCT01830959|Drug|Placebo|Placebo one a day
310878|NCT01830946|Other|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
310879|NCT01830946|Other|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
310880|NCT01830946|Other|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
310881|NCT01830933|Other|BreastCARE|Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
310882|NCT01830920|Drug|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
310883|NCT01830920|Drug|Placebo|A normal saline solution identical in appearance to the active drug solution
310884|NCT01830907|Dietary Supplement|carbohydrates|
310885|NCT01830907|Dietary Supplement|vitamins|
310886|NCT01830894|Device|MRI|3 MRI on different times during the study for each arm.
310887|NCT01830881|Drug|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
310888|NCT01830881|Drug|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
310889|NCT01830881|Other|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
310890|NCT01830881|Drug|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
310891|NCT01830868|Drug|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
310892|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
310893|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
310894|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
310895|NCT01830855|Biological|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
310896|NCT01830855|Biological|Saline|0.5 mL dose of sterile normal saline for injection.
310897|NCT01830842|Drug|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
310898|NCT01830842|Drug|Placebo|nonsmokers will be measured following placebo administration
310899|NCT01830842|Other|satiety|smokers will be measured in a smoking satiated condition
310900|NCT01830842|Other|abstinence|smokers will be measured following 24-hours of smoking abstinence
310901|NCT01830829|Drug|Jalyn|study drug
310902|NCT01830829|Drug|Placebo|Placebo
310903|NCT01830816|Drug|Ixazomib|Ixazomib capsules
310904|NCT01830790|Drug|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
310905|NCT01830777|Drug|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
310906|NCT01830777|Drug|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
310907|NCT01830777|Drug|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
310908|NCT01830777|Drug|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
310909|NCT01830764|Drug|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
310910|NCT01830751|Other|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
310911|NCT01830738|Procedure|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
310912|NCT01830738|Procedure|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
310913|NCT01830712|Drug|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
310914|NCT01830699|Drug|Rilonacept|160 mg intra-bursal once
432099|NCT00900172|Drug|paclitaxel|
310925|NCT01830595|Drug|Recombinant Lactoferrin|
310926|NCT01830595|Drug|Placebo|
310927|NCT01830582|Procedure|Advanced MR Imaging|
310928|NCT01830569|Behavioral|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
310929|NCT01830569|Other|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
310930|NCT01830556|Drug|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
310931|NCT01830543|Drug|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
310932|NCT01830543|Drug|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
310933|NCT01830543|Drug|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
310934|NCT01830543|Drug|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
310935|NCT01830543|Drug|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
310936|NCT01830543|Drug|clopidogrel|One 75 mg tablet once daily for up to twelve months
310937|NCT01830543|Drug|prasugrel|One 10 mg tablet once daily for up to twelve months
310938|NCT01830543|Drug|ticagrelor|One 90 mg tablet twice daily for up to twelve months
310939|NCT01830530|Drug|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
310940|NCT01830530|Drug|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
310941|NCT01830530|Drug|placebo|two tablets daily in the morning
310942|NCT01830517|Drug|Amlodipine, Losartan|
310943|NCT01830504|Drug|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
310944|NCT01830491|Drug|Clopidogrel|
310945|NCT01830491|Drug|aspirin 100mg|
310946|NCT01830478|Drug|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
310947|NCT01830478|Drug|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
310948|NCT01830465|Drug|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
310949|NCT01830465|Drug|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
310950|NCT01830452|Procedure|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
310951|NCT01830439|Drug|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
310952|NCT01830439|Drug|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
310953|NCT01830400|Drug|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
310954|NCT01830387|Device|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
310955|NCT01830387|Other|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
310956|NCT01830361|Drug|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
310957|NCT01830348|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
310958|NCT01830348|Drug|placebo vehicle gel|
310959|NCT01830335|Drug|Indomethacin|
310960|NCT01830335|Drug|Placebo|
310961|NCT01830322|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
310962|NCT01830322|Drug|Gemcitabine|
310963|NCT01830322|Drug|Any non-gemcitabine chemotherapies or best supportive care|
311059|NCT01829477|Drug|TAK-875|TAK-875 50 mg tablets
310964|NCT01830309|Drug|CJ-12420 200mg|"Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition~Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition"
310965|NCT01830296|Drug|Remifentanil+morphine|Morphine, Remifentanil+Morphine
310966|NCT01830283|Biological|varicella vaccine|The providers would get varicella vaccine
310967|NCT01830270|Drug|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
310968|NCT01830270|Drug|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
310969|NCT01830270|Drug|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
310970|NCT01830270|Procedure|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
310971|NCT01830257|Other|sending message|Sending the suggestive short message
310972|NCT01830244|Drug|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
310973|NCT01830231|Drug|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
310974|NCT01830231|Drug|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~280 mg/m2 in patients aged >75 - ≤80 years or with PS 1 or prior pelvic radiation,~250 mg/m2 in patients aged >80 years."
310975|NCT01830218|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
310976|NCT01830205|Drug|Daclatasvir|
310977|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
310978|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
310979|NCT01830166|Radiation|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
310980|NCT01830153|Drug|RAD001|
310981|NCT01830140|Drug|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
310982|NCT01830140|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
310983|NCT01830127|Drug|Ribavirin|24 Weeks
310984|NCT01830127|Drug|BI 207127 high dose|24 Weeks
310985|NCT01830127|Drug|Faldaprevir|24 Weeks
310986|NCT01830127|Drug|Ribavirin|24 Weeks
310987|NCT01830127|Drug|BI 207127 low dose|24 Weeks
310988|NCT01830127|Drug|Faldaprevir|24 Weeks
310989|NCT01830114|Behavioral|Web app|The Checkup and Choices web application
310990|NCT01830101|Drug|TMZ plus concurrent re-irradiation|
310991|NCT01830101|Drug|Temozolomide|low-dose temozolomide daily for one year
310992|NCT01830088|Behavioral|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
310993|NCT01830088|Behavioral|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
310994|NCT01830075|Behavioral|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
310995|NCT01830062|Other|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
310996|NCT01830062|Other|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
310997|NCT01830049|Other|Take blood|
310998|NCT01830023|Device|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
310999|NCT01830010|Drug|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
311000|NCT01830010|Drug|Study Part 2: KRP203 lower dose|
311001|NCT01830010|Drug|Study Part 2: KRP203 higher dose|
311002|NCT01829997|Device|nanOss Bioactive 3D BVF|nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
311003|NCT01829984|Other|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient~Pre-teaching Evaluation: Caregiver~o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
311004|NCT01829984|Other|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient~Post-injection Evaluation: Caregiver~o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~Nurse Evaluation: Control~Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
311005|NCT01829971|Drug|MRX34|micro RNA therapy
311006|NCT01829958|Drug|rituximab|
311007|NCT01829958|Drug|prednisone|
311008|NCT01829958|Behavioral|Geriatric Assessment|
311009|NCT01829932|Dietary Supplement|Factor Altered Diet|
311010|NCT01829919|Drug|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
311011|NCT01829906|Behavioral|Multidisciplinary outpatient programme|
311012|NCT01829906|Behavioral|Inpatient lifestyle programme|
433914|NCT00888446|Biological|tgAAC09|
311013|NCT01829893|Drug|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
311014|NCT01829893|Drug|GL2701 capsule|oral medication with 240 mL water
311015|NCT01829867|Drug|sNN0031|
311016|NCT01829841|Drug|Famitinib|Famitinib 25 mg p.o. qd
311017|NCT01829841|Drug|Sunitinib|Sunitinib 50 mg p.o. qd
311018|NCT01829828|Behavioral|No intervention|This is an observational study with no investigational drug administered.
311019|NCT01829815|Behavioral|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
311020|NCT01829802|Drug|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
311021|NCT01829802|Drug|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
311022|NCT01829802|Drug|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
311023|NCT01829789|Behavioral|Group Community Reinforcement Training for Parents|
311024|NCT01829789|Behavioral|Individual Community Reinforcement Training for Parents|
311025|NCT01829776|Behavioral|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
311026|NCT01829763|Drug|injection botox|
311027|NCT01829750|Genetic|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group~(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
311028|NCT01829711|Drug|Moxetumomab pasudotox|
311029|NCT01829711|Drug|IV Bag Protectant for Moxetumomab pasudotox|
311030|NCT01829698|Drug|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
311031|NCT01829698|Drug|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
311032|NCT01829685|Drug|Entecavir, Adefovir|
311033|NCT01829672|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.~1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
311034|NCT01829659|Drug|Ticagrelor|
311035|NCT01829646|Other|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
311036|NCT01829646|Other|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
311037|NCT01829646|Other|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
311038|NCT01829633|Procedure|Physiotherapy|Shoulder physiotherapy with exercises
311039|NCT01829620|Behavioral|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
311040|NCT01829620|Behavioral|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, & 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.~Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
311041|NCT01829607|Other|Functional electrical stimulation of peripheral muscles|
311042|NCT01829594|Other|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
311043|NCT01829581|Other|no intervention, only descriptive data analysis|
311044|NCT01829568|Drug|Ibrutinib|Given PO
311045|NCT01829568|Other|Laboratory Biomarker Analysis|Correlative studies
311046|NCT01829568|Drug|Lenalidomide|Given PO
311047|NCT01829568|Other|Pharmacological Study|Correlative studies
311048|NCT01829568|Biological|Rituximab|Given IV
311049|NCT01829555|Behavioral|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
311050|NCT01829542|Dietary Supplement|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
311051|NCT01829542|Dietary Supplement|Control|Macro- and micro-nutrient matched control in water
311052|NCT01829529|Drug|Amoxicillin|Amoxicillin
311053|NCT01829516|Drug|Oxytocin|Intranasal oxytocin
311054|NCT01829516|Drug|Placebo|Intranasal placebo
311055|NCT01829503|Drug|decitabine and cytarabine|
311056|NCT01829503|Other|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
311057|NCT01829490|Biological|ChAdOx1 85A|Intramuscular injection
311058|NCT01829490|Biological|MVA85A|Intramuscular injection
311060|NCT01829477|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
311061|NCT01829477|Drug|Glimepiride|Glimepiride tablet.
311062|NCT01829464|Drug|Placebo|TAK-875 placebo-matching tablets
311063|NCT01829464|Drug|TAK-875|TAK-875 tablets
311064|NCT01829464|Drug|TAK-875|TAK-875 tablets
311065|NCT01829451|Other|Hyaluronic acid gel|"Hyaluronic acid gel is placed into the uterus after endometrial ablation~--------------------------------------------------------------------------------"
311066|NCT01829438|Behavioral|Listening to fast music|
311067|NCT01829438|Behavioral|Listening to preferred music|
311068|NCT01829438|Behavioral|Listening to slow music|
311069|NCT01829425|Drug|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
311070|NCT01829425|Behavioral|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
311071|NCT01829412|Other|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
311072|NCT01829399|Drug|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
311073|NCT01829399|Drug|Normal Saline|
311074|NCT01829386|Other|MRI scans with non heme iron levels|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.~Each MRI will take up to 1 hour to complete and will be done on day 3, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
311075|NCT01829373|Biological|vaccine 1650-G|
311076|NCT01829360|Behavioral|Treatment (interactive book reading, dialogic reading, shared book reading)|Children receive 2 rounds of treatment with interactive book reading. Each treatment teaches 30 words that the children do not know. Treatments vary in dose (the number of times the words is heard/taught in an individual book reading session: 4 vs. 6 vs. 9) and dose frequency (the number of times book reading sessions are repeated: 4 vs. 6. vs. 9). Across all dose x dose frequency combinations, children hear/are taught the 30 words 36 times, which has been shown to be the adequate overall intensity of the intervention.
311077|NCT01829347|Biological|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
311078|NCT01829347|Other|Standard of Care treatment|Standard of care treatment is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.) per AASLD/EASL Guidelines.
311079|NCT01829334|Other|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
311080|NCT01829334|Other|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
311081|NCT01829334|Other|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
311082|NCT01829334|Other|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
311083|NCT01829321|Drug|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
311084|NCT01829321|Drug|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
311085|NCT01829308|Behavioral|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
311086|NCT01829308|Behavioral|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
311087|NCT01829295|Drug|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg BID orally. After two weeks, the dose will be increased to 1.5 g BID.
311088|NCT01829295|Drug|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
311089|NCT01829295|Drug|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
311090|NCT01829282|Behavioral|Risk Reduction|
311091|NCT01829256|Behavioral|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
311092|NCT01829243|Drug|Milnacipran|
311093|NCT01829243|Drug|Placebo|
311094|NCT01829230|Device|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
311095|NCT01829217|Drug|Sunitinib|
311096|NCT01829191|Device|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
311097|NCT01829191|Device|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
311098|NCT01829178|Drug|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
311099|NCT01829178|Drug|Placebo|placebo tablets: 420 mg in 3 divided dose
311100|NCT01829178|Drug|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
311101|NCT01829165|Device|rTMS Treatment|MRI-compatible TMS stimulator
311102|NCT01829165|Device|Sham rTMS Treatment|
311103|NCT01829152|Device|CHM|
311104|NCT01829113|Drug|OGX-427|Three loading doses of 600mg OGX-427 will be administered intravenously (IV) during a 9 day period. Then 600mg IV OGX-427 will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive 600 mg IV OGX-427 plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
311105|NCT01829113|Drug|Placebo|Three loading doses of placebo will be administered intravenously (IV) during a 9 day period. Then placebo (IV) will be given weekly on Days 1, 8 and 15 of each 21 day cycle prior to the administration of pemetrexed (500mg/m^2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle for a maximum of four treatment cycles. Patients who respond to treatment or have stable disease will continue to receive placebo (IV) plus 500mg/m2 IV pemetrexed weekly until toxicity or disease progression.
311106|NCT01829100|Behavioral|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
311107|NCT01829087|Drug|Botox|
311108|NCT01829087|Drug|placebo|
311109|NCT01829048|Drug|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
311110|NCT01829048|Drug|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
311111|NCT01829048|Drug|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
311112|NCT01829048|Drug|Placebo|Placebo Q12h
311113|NCT01829035|Other|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.~Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~Anti-tumor drug:~Unapproved drug/embolization material from each regulatory agency should not be used.~To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
311114|NCT01829022|Procedure|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
311115|NCT01829009|Other|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.~Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
311116|NCT01828996|Device|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
311117|NCT01828996|Device|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
311118|NCT01828983|Behavioral|Telephone support groups|
311119|NCT01828983|Other|Education webinars|
311120|NCT01828970|Drug|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
311121|NCT01828957|Biological|Pneumostem®|
311122|NCT01828957|Other|Normal Saline|
311123|NCT01828944|Dietary Supplement|olive oil|
311124|NCT01828931|Behavioral|Lifestyle Intervention|A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
311125|NCT01828931|Other|Usual Care|Care as usual
311126|NCT01828918|Genetic|microRNAs|
311127|NCT01828905|Device|"CERAMENT™|BONE VOID FILLER"|ceramic bone void filler
311128|NCT01828905|Procedure|Autologous cancellous bone graft|autologous cancellous bone graft
311129|NCT01828892|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
311130|NCT01828892|Procedure|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
311131|NCT01828892|Drug|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
311212|NCT01828320|Behavioral|Psychoeducation|
311132|NCT01828892|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
311133|NCT01828879|Drug|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
311134|NCT01828866|Behavioral|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
311135|NCT01828866|Behavioral|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:~Functional analysis~Communication skills~Problem-solving skills~Sobriety sampling~Social networking~Refusal of substances~Reinforcing activities~Relapse management~Medication monitoring"
311136|NCT01828840|Drug|epidural morphine via PCEA|
311137|NCT01828840|Drug|epidural fentanyl via PCEA|
311138|NCT01828840|Drug|epidural methadone via PCEA|
311139|NCT01828840|Drug|intravenous morphine via PCA|
311140|NCT01828827|Drug|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
311141|NCT01828801|Device|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
311142|NCT01828788|Drug|Ropivacaine|
311143|NCT01828788|Drug|placebo|
311144|NCT01828775|Other|palliative care|Receive early PCI
311145|NCT01828775|Other|palliative care|Receive delayed PCI
311146|NCT01828775|Procedure|quality-of-life assessment|Ancillary studies
311147|NCT01828775|Other|survey administration|Ancillary studies
311148|NCT01828762|Biological|DC-TC+GM-CSF|
311149|NCT01828736|Biological|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
311150|NCT01828736|Drug|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
311151|NCT01828736|Drug|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
311152|NCT01828736|Drug|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
311153|NCT01828723|Biological|SVF|
311154|NCT01828710|Dietary Supplement|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
311155|NCT01828710|Dietary Supplement|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
311156|NCT01828710|Dietary Supplement|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
311157|NCT01828697|Drug|Low dose nadroparin|"Fixed low dose nadroparin:~< 100 kg: 2850 IU subcutaneously once-daily~100 kg and above: 3800 IU subcutaneously once-daily"
311158|NCT01828697|Drug|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:~< 50 kg: 3800 IU subcutaneously once-daily;~50 to < 70 kg: 5700 IU subcutaneously once-daily;~70 to < 100 kg: 7600 IU subcutaneously once-daily;~100 kg or above: 9500 IU subcutaneously once-daily."
311159|NCT01828697|Drug|Low dose enoxaparin|"Fixed low dose enoxaparin:~< 100 kg: 40 mg subcutaneously once-daily~100 kg and above: 60 mg subcutaneously once-daily"
311160|NCT01828697|Drug|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:~< 50 kg: 60 mg subcutaneously once-daily, or;~50 kg to < 70 kg: 80 mg subcutaneously once-daily, or;~70 kg to < 100 kg: 100 mg subcutaneously once-daily, or;~100 kg or above: 120 mg subcutaneously once-daily."
311161|NCT01828697|Drug|Low dose dalteparin|"Fixed low dose dalteparin:~< 100 kg: 5000 IU subcutaneously once-daily~100 kg and above: 7500 IU subcutaneously once-daily"
311162|NCT01828697|Drug|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:~< 50 kg: 7500 IU subcutaneously once-daily, or;~50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;~70 kg to < 100 kg: 12500 IU subcutaneously once-daily, or;~100 kg or above: 15000 IU subcutaneously once-daily."
311163|NCT01828697|Drug|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:~< 100 kg: 3500 IU subcutaneously once-daily~100 kg and above: 4500 IU subcutaneously once-daily"
311164|NCT01828697|Drug|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:~< 50 kg: 4500 IU subcutaneously once-daily, or;~50 kg to < 70 kg: 7000 IU subcutaneously once-daily, or;~70 kg to < 100 kg: 10000 IU subcutaneously once-daily, or;~100 kg or above: 12000 IU subcutaneously once-daily."
311165|NCT01828684|Other|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
311166|NCT01828684|Other|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
311167|NCT01828671|Other|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
311168|NCT01828671|Other|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
311169|NCT01828671|Other|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
311170|NCT01828671|Other|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
311171|NCT01828671|Other|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
311172|NCT01828658|Other|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
311173|NCT01828645|Dietary Supplement|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
311213|NCT01828307|Behavioral|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
311174|NCT01828632|Procedure|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
311175|NCT01828619|Procedure|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
311176|NCT01828606|Device|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
311177|NCT01828606|Device|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment~According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
311178|NCT01828593|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
311179|NCT01828593|Other|Placebo|Matching placebo
311180|NCT01828580|Device|active laparoscope positioner (AutoLap)|
311181|NCT01828567|Behavioral|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to Patient Aligned Care Team (PACT), and a follow-up call one month later to assess the progress of the prevention plan.
311182|NCT01828554|Drug|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.~Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.~Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
311183|NCT01828541|Behavioral|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
311184|NCT01828541|Other|Standard of Care|
311185|NCT01828528|Procedure|Sleeve gastrectomy|An intra-operative liver biopsy was performed in 20 patients
311186|NCT01828515|Drug|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
311187|NCT01828515|Drug|Placebo|
311188|NCT01828515|Drug|Hydrocortisone|Participants receive 160 mg x 4 days after vilazodone or placebo pre-treatment
311189|NCT01828502|Behavioral|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
311190|NCT01828502|Behavioral|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
311191|NCT01828489|Drug|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
311192|NCT01828489|Drug|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
311193|NCT01828476|Drug|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
311194|NCT01828476|Drug|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
311195|NCT01828476|Drug|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
311196|NCT01828463|Drug|Nitisinone|doses 1, 2, 4 & 8 mg plus no treatment arm
311197|NCT01828437|Drug|Pyridoxine plus prednisolone|
311198|NCT01828437|Drug|Prednisolone|
311199|NCT01828411|Device|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
311200|NCT01828411|Device|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
311201|NCT01828398|Device|real-tDCS + UE robot-assisted therapy|
311202|NCT01828398|Device|sham-tDCS + UE robot-assisted therapy|
311203|NCT01828385|Drug|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
311204|NCT01828385|Drug|Saline|Saline + rocuronium + sugammadex
311205|NCT01828372|Other|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
311206|NCT01828359|Drug|Amosartan® tab|comparison of different combination of anti-hypertension drug
311207|NCT01828359|Drug|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
311208|NCT01828346|Drug|Birinapant|"Dose escalation part: (Drug escalation dose levels)~Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)~Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)~Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)~Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR~Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
311209|NCT01828346|Drug|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
311210|NCT01828333|Other|No intervention|No intervention
311211|NCT01828320|Behavioral|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
311214|NCT01828307|Behavioral|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
311215|NCT01828307|Behavioral|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
311216|NCT01828294|Drug|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
311217|NCT01828281|Device|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
311218|NCT01828255|Device|SENSIMED Triggerfish®|
311219|NCT01828242|Behavioral|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
311220|NCT01828242|Other|Control group following conventional approach|Control group following conventional approach
311221|NCT01828229|Behavioral|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
311222|NCT01828229|Behavioral|inactivity|inactivity for 2 weeks
311223|NCT01828229|Behavioral|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
311224|NCT01828229|Behavioral|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
311225|NCT01828229|Behavioral|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
311226|NCT01828216|Device|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
311227|NCT01828216|Device|conventional polysomnography|conventional type I sleep study according to international guidelines
311228|NCT01828203|Drug|Minocycline|
311229|NCT01828203|Drug|Placebo|
311230|NCT01828203|Procedure|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
311231|NCT01828203|Procedure|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
311232|NCT01828190|Other|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
311233|NCT01828177|Drug|PDI-320|
311234|NCT01828177|Drug|PDI-320 Monad #1|
311235|NCT01828177|Drug|PDI-320 Monad #2|
311236|NCT01828177|Drug|Vehicle|
311237|NCT01828164|Device|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
311238|NCT01828164|Device|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
311239|NCT01828151|Device|Noninvasive ventilation mask|
311240|NCT01828138|Dietary Supplement|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
311241|NCT01828138|Dietary Supplement|Placebo|Placebo are given in 5 days
311242|NCT01828125|Procedure|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-[6,6-2H2] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-[6,6-2H2] glucose. A third catheter will be inserted for sampling. D-[6,6-2H2] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
311243|NCT01828125|Drug|Glucagon|
311244|NCT01828112|Drug|Ceritinib|Ceritinib is the investigational treatment and is referred to as the investigational study drug and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
311245|NCT01828112|Drug|pemetrexed|Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m2 every 21 days.
311246|NCT01828112|Drug|docetaxel|Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m2 every 21 days.
311247|NCT01828099|Drug|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule. Ceritinib (LDK378) was the investigational treatment and is referred to as the investigational study treatment/drug.
311248|NCT01828099|Drug|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m2 as an iv infusion on Day 1 of each 21-day cycle to patients randomized to the chemotherapy arm.
311249|NCT01828099|Drug|Cisplatin|Cisplatin was administered by IV at a dose of 75 mg/m2 every 21 days for up to 4 cycles.
311250|NCT01828099|Drug|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
311251|NCT01828086|Biological|CJM112|Monoclonal antibody
311252|NCT01828086|Biological|Secukinumab|Monoclonal antibody
311253|NCT01828086|Other|Placebo|Liquid for subcutaneous injection without active drug.
311254|NCT01828073|Drug|Raltegravir|No study-specific drugs were given to women or infants during this study. Women received RAL for clinical indications outside of the study.
311255|NCT01828060|Dietary Supplement|Jobelyn™|Sorghum bicolor leaf sheath extract
311256|NCT01828060|Dietary Supplement|Placebo|Placebo capsules
311257|NCT01828047|Device|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
311258|NCT01828034|Drug|Gemcitabine|
311259|NCT01828034|Drug|Cisplatin|
311260|NCT01828034|Drug|MEK162|
311261|NCT01828021|Biological|Margetuximab|Anti-HER2 monoclonal antibody
311262|NCT01827995|Other|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
311263|NCT01827995|Other|Routine assessment|Follow up in the clinic
311264|NCT01827982|Drug|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
311265|NCT01827982|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
311266|NCT01827982|Drug|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
311267|NCT01827982|Drug|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
311268|NCT01827982|Drug|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
311269|NCT01827982|Drug|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
311270|NCT01827982|Drug|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
311271|NCT01827982|Drug|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
311272|NCT01827982|Drug|Placebo|Matching placebo will be given as a single oral dose.
311273|NCT01827969|Procedure|ablathermy focused ultrasound|ablathermy focused ultrasound
311274|NCT01827956|Other|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
311275|NCT01827943|Drug|TORISEL|Temsirolimus
311276|NCT01827930|Drug|Imatinib Mesylate|Imatinib Mesylate LMC
311277|NCT01827917|Biological|rabies vaccine|Injection on day 0、7、21
311278|NCT01827904|Device|Transcranial ExAblate|
311279|NCT01827904|Device|Sham Transcranial ExAblate|
311280|NCT01827891|Procedure|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
311281|NCT01827878|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
311282|NCT01827878|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
311283|NCT01827865|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
311284|NCT01827865|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
311285|NCT01827839|Biological|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
311286|NCT01827826|Behavioral|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
311287|NCT01827813|Procedure|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
311288|NCT01827813|Procedure|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
311289|NCT01827813|Procedure|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
311324|NCT01827566|Other|gluten|
311325|NCT01827566|Other|gluten free flour|
311290|NCT01827800|Behavioral|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
311291|NCT01827787|Drug|Eribulin|
311292|NCT01827774|Device|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
311293|NCT01827761|Behavioral|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
311294|NCT01827748|Device|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
311295|NCT01827748|Device|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
311296|NCT01827735|Drug|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
311297|NCT01827722|Drug|Ozurdex|Intravitreal injection of Ozurdex
311298|NCT01827722|Drug|Ranibizumab|Intravitreal Injection of Ranibizumab
311299|NCT01827722|Drug|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
311300|NCT01827709|Other|A polymerase chain reaction -based hypoxia classifier|"Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.~These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET."
311301|NCT01827709|Other|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
311302|NCT01827709|Other|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
311303|NCT01827709|Other|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
311304|NCT01827709|Other|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
311305|NCT01827696|Dietary Supplement|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
311306|NCT01827683|Other|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
311307|NCT01827670|Drug|Stannous fluoride|Test dentifrice containing 0.454% SnF
311308|NCT01827670|Drug|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate [1000 parts per million (ppm) fluoride]
311309|NCT01827657|Drug|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
311310|NCT01827644|Drug|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
311311|NCT01827644|Drug|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
311312|NCT01827644|Drug|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
311313|NCT01827644|Drug|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
311314|NCT01827644|Drug|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
311315|NCT01827644|Drug|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
311316|NCT01827631|Drug|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
311317|NCT01827618|Drug|Rapamycin|
311318|NCT01827605|Other|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
311319|NCT01827605|Drug|BEAM|"BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~Patient collecting ≥6x106 CD34+ cells/kg use >4x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 4-6x106 CD34+ cells/kg use >2x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;~Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC > 1500/mmc"
311320|NCT01827592|Drug|Elobixibat 10 mg|Elobixibat 10 mg/day
311321|NCT01827592|Drug|Elobixibat 5 mg|Elobixibat 5 mg/day
311322|NCT01827592|Drug|Placebo|Placebo
311323|NCT01827579|Biological|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
311326|NCT01827553|Drug|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)
311327|NCT01827553|Radiation|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
311328|NCT01827553|Drug|Chemotherapy, gemcitabine|5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d
311329|NCT01827553|Drug|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
311330|NCT01827540|Drug|Cenicriviroc|
311331|NCT01827540|Drug|Dolutegravir|
311332|NCT01827540|Drug|Midazolam|
311333|NCT01827501|Device|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
311334|NCT01827475|Drug|Ibuprofen|single dose
311335|NCT01827475|Drug|Acetaminophen|single dose
311336|NCT01827475|Drug|Ibuprofen-acetaminophen combination|single dose
311337|NCT01827462|Biological|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
311338|NCT01827462|Biological|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
311339|NCT01827462|Biological|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
311340|NCT01827449|Device|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
311341|NCT01827436|Behavioral|Conventional physical therapy|
311342|NCT01827436|Behavioral|Asymmetrical gait training|
311343|NCT01827423|Device|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
311344|NCT01827410|Procedure|Ventral hernia repair|
311345|NCT01827397|Biological|EN41-UGR7C HIV vaccine|
311346|NCT01827397|Biological|NaCl|
311347|NCT01827384|Drug|Adavosertib|Given PO
311348|NCT01827384|Drug|Carboplatin|Given IV
311349|NCT01827384|Drug|Everolimus|Given PO
311350|NCT01827384|Drug|Temozolomide|Given PO
311351|NCT01827384|Drug|Trametinib|Given PO
311352|NCT01827384|Drug|Veliparib|Given PO
311353|NCT01827371|Biological|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
311354|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
311355|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
311356|NCT01827345|Dietary Supplement|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
311357|NCT01827332|Drug|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
311358|NCT01827332|Drug|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
311359|NCT01827306|Drug|Biofreeze|
311360|NCT01827293|Drug|Promethazine|
311361|NCT01827293|Drug|Lorazepam|
311362|NCT01827280|Drug|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
311363|NCT01827267|Drug|neratinib|
311364|NCT01827267|Drug|temsirolimus|
311365|NCT01827254|Other|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
311366|NCT01827241|Other|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
311367|NCT01827228|Other|Assays|May vary across sites
311368|NCT01827228|Other|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
311369|NCT01827228|Other|Social network and venue tracing|This is described in Arms 1 and 2
311370|NCT01827228|Other|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
311371|NCT01827228|Other|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
311372|NCT01827228|Behavioral|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
311373|NCT01827215|Behavioral|Virtual Patient Advocate (VPA)|Intervention participants will have access to the Virtual Patient Advocate (VPA) system for a period of 12 months. They will be encouraged to log on every two weeks or twice a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
311374|NCT01827202|Other|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
311375|NCT01827202|Drug|Aliskiren|
311376|NCT01827202|Drug|Candesartan|
311377|NCT01827189|Other|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
311378|NCT01827176|Other|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
311379|NCT01827163|Drug|Paclitaxel|
311380|NCT01827163|Drug|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
311381|NCT01827163|Drug|Lapatinib|
311382|NCT01827163|Drug|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
311383|NCT01827150|Drug|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
311384|NCT01827137|Biological|WT1 Analog Peptide Vaccine|
311385|NCT01827137|Biological|Sargramostim (GM-CSF)|
311386|NCT01827137|Drug|lenalidomide|Optional lenalidomide maintenance starting 3-months post auto SCT
311387|NCT01827124|Drug|Carbetocin|
311388|NCT01827124|Drug|oxytocin|
311389|NCT01827111|Drug|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
311390|NCT01827111|Drug|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
311391|NCT01827111|Behavioral|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
311392|NCT01827098|Procedure|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
311393|NCT01827085|Device|Conventional Macintosh laryngoscope|
311394|NCT01827085|Device|Stortz videolaryngoscope|
311395|NCT01827072|Drug|NPB-01|
311396|NCT01827059|Drug|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
311397|NCT01827059|Drug|Placebo|
311398|NCT01827046|Drug|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
311399|NCT01827033|Behavioral|meditation training|
311400|NCT01827020|Drug|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
311401|NCT01827020|Drug|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
311402|NCT01827020|Drug|Saline|12 mL saline (0.9% isotonic solution)
311403|NCT01827007|Other|Volume expansion with gelofusine|
311404|NCT01826994|Device|heart type fatty acid binding protein testing|
311405|NCT01826981|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
311406|NCT01826981|Drug|SOF|SOF 400 mg tablet administered orally once daily
311407|NCT01826981|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
311408|NCT01826981|Drug|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
311409|NCT01826981|Drug|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
311410|NCT01826981|Drug|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
311411|NCT01826968|Procedure|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
311412|NCT01826942|Device|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
311413|NCT01826942|Device|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
311414|NCT01826929|Other|Therapeutic education|
311415|NCT01826916|Drug|DX-88 (ecallantide)|solution for injection 10 mg/mL
311416|NCT01826890|Other|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
311417|NCT01826877|Biological|AdGMCAIX-transduced autologous dendritic cells|Given ID
311418|NCT01826877|Biological|therapeutic autologous dendritic cells|Given ID
311419|NCT01826877|Other|laboratory biomarker analysis|Correlative studies
311420|NCT01826864|Biological|sargramostim|Given SC
311421|NCT01826864|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
311422|NCT01826864|Other|laboratory biomarker analysis|Correlative studies
311423|NCT01826864|Other|hypertonic saline|Given SC
311424|NCT01826851|Drug|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
311425|NCT01826851|Drug|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."
311426|NCT01826838|Drug|Dasatinib|
311427|NCT01826825|Behavioral|Cognitive Screen|Cognitive Screen
311428|NCT01826825|Behavioral|Mini-Cog|Cognitive Screen
311429|NCT01826812|Other|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
311430|NCT01826812|Other|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
311431|NCT01826786|Drug|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
311432|NCT01826786|Drug|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
311433|NCT01826773|Drug|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
313031|NCT01814709|Drug|Rifampin|Oral doses of Rifampin
311434|NCT01826760|Other|Using training and testing groups to construct ANN based on laboratory tests|
311435|NCT01826747|Drug|crinone (progesterone 8%, vaginal application)|
311436|NCT01826721|Other|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
311437|NCT01826708|Biological|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
311438|NCT01826695|Other|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.~The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
311439|NCT01826695|Other|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
311440|NCT01826682|Other|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
311441|NCT01826682|Other|Medical treatment|Standard medical treatment without physiotherapy.
311442|NCT01826669|Procedure|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
311443|NCT01826656|Procedure|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
311444|NCT01826656|Radiation|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
311445|NCT01826656|Radiation|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
311446|NCT01826656|Radiation|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
311447|NCT01826630|Other|CLn BodyWash|Comparing two washes to determine change in bacterial load.
311448|NCT01826630|Other|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
311449|NCT01826604|Device|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
311450|NCT01826604|Other|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
311451|NCT01826591|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
311452|NCT01826591|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
311453|NCT01826591|Behavioral|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
311454|NCT01826578|Procedure|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
311455|NCT01826565|Procedure|Rotational technique|90 degree rotation
311456|NCT01826552|Device|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
311457|NCT01826552|Device|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
311458|NCT01826539|Procedure|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
311459|NCT01826526|Device|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.~The duration of TauroSept® administration in this trial will be 12 months."
311460|NCT01826513|Device|Standard AutoSet algorithm|An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
311461|NCT01826513|Device|Modified AutoSet algorithm|An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
311462|NCT01826500|Other|blood test|blood test
311463|NCT01826487|Drug|Ataluren|Ataluren PO 10-,10-,20-mg/kg for 48 weeks.
311464|NCT01826487|Drug|Placebo|Placebo PO 10-,10-,20-,mg/kg for 48 weeks.
311465|NCT01826474|Drug|PRO045, 0.15 mg/kg/week|Subcutaneous injection
311466|NCT01826474|Drug|PRO045, 1.0 mg/kg/week|Subcutaneous injection
311467|NCT01826474|Drug|PRO045, 3.0 mg/kg/week|Subcutaneous injection
311468|NCT01826474|Drug|PRO045, 6.0 mg/kg/week|Subcutaneous injection
311469|NCT01826474|Drug|PRO045, 9.0 mg/kg/week|Subcutaneous injection
311470|NCT01826474|Drug|PRO045, selected dose|Subcutaneous injection
311471|NCT01826461|Drug|PDI-192|
311472|NCT01826461|Drug|Vehicle|
311473|NCT01826448|Drug|PLX3397|
311474|NCT01826448|Drug|vemurafenib|
311511|NCT01826123|Device|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
311512|NCT01826110|Drug|[11C]PIB|Approximately 15 mCI [11C]PIB IV x1
311513|NCT01826097|Device|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
311514|NCT01826071|Other|Static Stretch|
311515|NCT01826071|Other|Active Elongation|
311516|NCT01826058|Radiation|Stereotactic body radiation therapy|
311475|NCT01826435|Behavioral|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
311476|NCT01826422|Dietary Supplement|EPA and DHA|Each capsule contains 225mg of DHA, 45mg of EPA, other omega 3 fatty acids 20mg.
311477|NCT01826422|Dietary Supplement|Placebo Comparator|Placebo capsules will contain gelatin and sunflower oil. Fatty acid composition is as follows: lauric (C12:0), 0.19%; myristic (C14:0), 0.29%; palmitic (C16:0), 7.59%; palmitoleic (C16:1), 0.25%; stearic (C18:0), 3.49%; oleic (C18:1), 31.08%; linolenic (C18:3), 1.13%; linoleic (C18:2), 55.64%; DHA 0.02%; arachidic (C20:0), 0.30% and arachidonic (C20:4), 0.01%.
311478|NCT01826409|Dietary Supplement|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
311479|NCT01826409|Dietary Supplement|Placebo|Placebo 2.7g/day for 4 weeks
311480|NCT01826396|Drug|Irinotecan|Comparison of standard and high dose irinotecan
311481|NCT01826383|Behavioral|Active-Video|This group will watch an active-video with pain management strategies for parents
311482|NCT01826383|Behavioral|Placebo Video|This group will watch a placebo-video describing immunization generally.
311483|NCT01826370|Drug|Linagliptin|tablet
311484|NCT01826331|Behavioral|Incentives for Participation|Participants will receive three smoking cessation programs
311485|NCT01826331|Behavioral|Incentives for Cessation|Participants will have access to a smoking cessation program
311486|NCT01826318|Behavioral|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
311487|NCT01826305|Procedure|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
311488|NCT01826305|Procedure|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
311489|NCT01826279|Dietary Supplement|Resveratrol|500mg 3 times daily for 1 month
311490|NCT01826279|Other|Placebo|1 placebo tablet 3 times daily for 1 month
311491|NCT01826266|Drug|PER977, Placebo|
311492|NCT01826253|Drug|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
311493|NCT01826240|Behavioral|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
311494|NCT01826227|Procedure|Positron Emission Tomography|
311495|NCT01826227|Radiation|18F-Fluoro-2-deoxy-D-lucose|
311496|NCT01826227|Procedure|Cytoreductive surgery|
311497|NCT01826214|Drug|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
311498|NCT01826201|Drug|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
311499|NCT01826201|Drug|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
311500|NCT01826188|Drug|THC 5mg/ml and CBS 50mg/ml|olive oil containing THC and CBD
311501|NCT01826188|Drug|Placebo|olive oil without cannabis
311502|NCT01826175|Drug|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
311503|NCT01826175|Drug|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
311504|NCT01826175|Device|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
311505|NCT01826162|Other|acetate or placebo infusion|
311506|NCT01826149|Drug|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
311507|NCT01826149|Drug|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
311508|NCT01826149|Drug|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
311509|NCT01826136|Device|Acapella device|
311510|NCT01826123|Device|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
311517|NCT01826045|Drug|Poly-gamma Glutamic Acid|
311518|NCT01826045|Drug|Placebo|
311519|NCT01826032|Device|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
311520|NCT01826032|Other|Standard care for OSA|sleep higiene and dietary counseling
311521|NCT01826019|Other|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
311522|NCT01826019|Other|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
311523|NCT01826006|Device|Excimer laser|
311524|NCT01826006|Device|Manual Thrombus Aspiration|
311525|NCT01825993|Drug|L-BUPIVACAINE ; MORPHINE|
311526|NCT01825993|Drug|MORPHINE|
311527|NCT01825980|Drug|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
311528|NCT01825980|Drug|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
311529|NCT01825980|Drug|Placebo|Placebo
311530|NCT01825967|Other|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
311531|NCT01825954|Device|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
311532|NCT01825941|Drug|metoclopramide|10 milligrams, administered intravenously over 15 minutes
311533|NCT01825941|Drug|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
311534|NCT01825941|Drug|placebo|
311535|NCT01825928|Drug|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
311536|NCT01825928|Drug|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
311537|NCT01825915|Procedure|Laparoscopic Hysterectomy|
311538|NCT01825915|Procedure|Laparoscopic Supracervical Hysterectomy|
311539|NCT01825902|Drug|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
311540|NCT01825902|Radiation|fludeoxyglucose F 18|Undergo 18F-FDG PET
311541|NCT01825902|Procedure|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
311542|NCT01825902|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
311543|NCT01825902|Other|laboratory biomarker analysis|Correlative studies
311544|NCT01825889|Drug|Evacetrapib|
311545|NCT01825876|Drug|Evacetrapib|Oral administration
311546|NCT01825876|Drug|Warfarin|Oral administration
311547|NCT01825863|Drug|Ropivacaine|
311548|NCT01825863|Drug|Saline 9%|
311549|NCT01825850|Drug|Gemigliptin|
311550|NCT01825850|Drug|Irbesartan|
311551|NCT01825837|Drug|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
311552|NCT01825837|Drug|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
311553|NCT01825837|Drug|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
311554|NCT01825837|Drug|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
311555|NCT01825824|Radiation|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
311556|NCT01825811|Biological|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10^6 cells mixed with fibrin-glue
311557|NCT01825811|Biological|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10^6 cells mixed with fibrin-glue
311558|NCT01825798|Drug|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
311559|NCT01825798|Drug|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
311560|NCT01825785|Drug|Romosozumab|Administered by subcutaneous injection
311561|NCT01825785|Drug|Placebo|Administered by subcutaneous injection
311562|NCT01825759|Drug|danshen dripping pill|
311694|NCT01824745|Procedure|standard follow-up care|Receive standard follow-up care
437605|NCT00861510|Drug|ON01910 Na|
311563|NCT01825746|Other|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
311564|NCT01825733|Drug|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
311565|NCT01825733|Drug|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
311566|NCT01825720|Drug|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
311567|NCT01825720|Drug|normal saline group|same rate of normal saline
311568|NCT01825707|Drug|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg (oral) on day1
311569|NCT01825694|Behavioral|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
311570|NCT01825681|Behavioral|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
311571|NCT01825668|Other|Plant Sterols|
311572|NCT01825668|Other|High cholesterol|
311573|NCT01825668|Other|Placebo|
311574|NCT01825655|Drug|Cetirizine|
311575|NCT01825655|Drug|Placebo or sugar pill|
311576|NCT01825642|Procedure|nerve-sparing radical prostatectomy|
311577|NCT01825642|Procedure|seminal vesicle-sparing radical prostatectomy|
311578|NCT01825629|Other|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.~Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.~Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
311579|NCT01825629|Other|Placebo|
311580|NCT01825616|Dietary Supplement|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
311581|NCT01825616|Other|Placebo|Mushroom powder without vitamin D2
311582|NCT01825603|Drug|ADH-1|Given IV
311583|NCT01825603|Drug|Cisplatin|Given IV
311584|NCT01825603|Drug|Gemcitabine Hydrochloride|Given IV
311585|NCT01825603|Other|Laboratory Biomarker Analysis|Correlative studies
311586|NCT01825590|Other|Dialysate and serum sodium concentration aligned|
311587|NCT01825577|Drug|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
311588|NCT01825551|Drug|Granulocyte Colony Stimulating Factor|
311589|NCT01825551|Drug|Placebo|
311590|NCT01825525|Device|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
311591|NCT01825512|Drug|Deferiprone|Deferiprone 80 mg/mL oral solution
311592|NCT01825512|Drug|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
311593|NCT01825499|Other|Registry|
311594|NCT01825486|Behavioral|accidental falls|
311595|NCT01825473|Drug|Erythromycin|
311596|NCT01825473|Device|Multi-channel intra-luminal impedance (MII) pH monitoring|
311597|NCT01825473|Drug|Placebo (D5W)|
311598|NCT01825460|Other|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
311599|NCT01825460|Other|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
311600|NCT01825447|Drug|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
311601|NCT01825447|Drug|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
311602|NCT01825447|Drug|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
311603|NCT01825434|Dietary Supplement|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
311604|NCT01825421|Other|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
311605|NCT01825408|Drug|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
311606|NCT01825408|Drug|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
311695|NCT01824745|Procedure|quality-of-life assessment|Ancillary studies
442746|NCT00822120|Drug|etoposide|
311607|NCT01825408|Drug|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
311608|NCT01825395|Drug|3, 4-Diaminopyridine|
311609|NCT01825382|Device|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
311610|NCT01825369|Drug|IV L-carnitine|See arm description
311611|NCT01825356|Procedure|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
311612|NCT01825356|Procedure|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
311613|NCT01825330|Device|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
311614|NCT01825330|Device|sham|
311615|NCT01825317|Device|NeuroAD|synchronized TMS+COGNITIVE TRAINING
311616|NCT01825317|Device|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
311617|NCT01825304|Device|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
311618|NCT01825291|Procedure|CPAP treatment|
311619|NCT01825278|Device|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
311620|NCT01825252|Behavioral|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
311621|NCT01825252|Behavioral|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
311622|NCT01825239|Other|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
311623|NCT01825226|Other|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
311624|NCT01825213|Device|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
311625|NCT01825200|Biological|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
311626|NCT01825200|Biological|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
311627|NCT01825187|Device|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
311628|NCT01825187|Device|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
311629|NCT01825187|Other|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
311630|NCT01825174|Behavioral|Ball games program|twice a week different ball games 90min
311631|NCT01825174|Behavioral|Nutrition counseling|9 units of 90min each of nutrition counseling
311632|NCT01825148|Other|radiolabeled Exendin|
311633|NCT01825135|Device|Neuromuscular electrical stimulation|
311634|NCT01825135|Device|sham stimulation|sham stimulation will be applied to the quadriceps
311635|NCT01825122|Drug|Nadolol|
311636|NCT01825122|Drug|Placebo|
311637|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
311638|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
311639|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
311640|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
311641|NCT01825083|Drug|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
311642|NCT01825083|Drug|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
311643|NCT01825070|Dietary Supplement|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
311644|NCT01825057|Behavioral|See One|
311645|NCT01825057|Behavioral|Do One|
311646|NCT01825057|Behavioral|Order One|
311647|NCT01825044|Drug|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
311648|NCT01825044|Drug|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
311649|NCT01825031|Drug|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
311650|NCT01825031|Drug|Fluconazole|100mg once daily for 12 weeks
311651|NCT01825031|Drug|Azithromycin|500mg once daily for 5 days
311652|NCT01825031|Drug|Albendazole|a single dose 400mg
311653|NCT01825031|Drug|Isoniazid|300mg taken immediately in combination with cotrimoxazole
311654|NCT01825031|Dietary Supplement|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
311696|NCT01824745|Other|questionnaire administration|Ancillary studies
311697|NCT01824706|Procedure|craniectomy|craniectomy
311655|NCT01825018|Behavioral|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
311656|NCT01825018|Behavioral|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
311657|NCT01824992|Drug|Yallaferon®|
311658|NCT01824979|Device|CPAP mask ( Pilairo)|
311659|NCT01824979|Procedure|Other CPAP mask|
311660|NCT01824940|Behavioral|Standard care|"Standard Care:~Exclusive breastfeeding promotion for all infants, birth to 6 months~Strengthened PMTCT (prevention of mother to child transmission of HIV) services~Strengthened Village Health Worker system"
311661|NCT01824940|Other|WASH|"WASH:~Standard care interventions~Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space~Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
311662|NCT01824940|Dietary Supplement|Infant and young child feeding|"IYCF:~Standard care interventions~Provide 20 g/d Nutributter from 6-18 months~Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
311663|NCT01824940|Other|WASH and Nutrition|"WASH AND IYCF interventions~Standard care interventions~All WASH interventions~All IYCF interventions"
311664|NCT01824927|Procedure|First eye (FE)|Phacoemulsification cataract extraction surgery
311665|NCT01824927|Procedure|Second eye (SE)|Phacoemulsification cataract extraction surgery
311666|NCT01824927|Drug|Steroids eye drops|Use steroids eye drops to decrease the pain.
311667|NCT01824914|Device|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
311668|NCT01824901|Drug|docetaxel|Given IV
311669|NCT01824901|Drug|AZD4547|Given PO
311670|NCT01824888|Drug|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
311671|NCT01824888|Drug|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
311672|NCT01824875|Drug|temozolomide|Given PO
311673|NCT01824875|Drug|capecitabine|Given PO
311674|NCT01824875|Other|laboratory biomarker analysis|Correlative studies
311675|NCT01824849|Procedure|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
311676|NCT01824849|Procedure|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
311677|NCT01824836|Drug|anastrozole|Given PO
311678|NCT01824836|Other|questionnaire administration|Ancillary studies
311679|NCT01824836|Other|laboratory biomarker analysis|Correlative studies
311680|NCT01824836|Other|pharmacogenomic studies|Correlative studies
311681|NCT01824823|Drug|afatinib|Given PO
311682|NCT01824823|Other|placebo|Given PO
311683|NCT01824810|Procedure|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
311684|NCT01824810|Procedure|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
311685|NCT01824810|Procedure|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
311686|NCT01824810|Procedure|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
311687|NCT01824771|Other|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
311688|NCT01824758|Drug|Lidocaine|Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg).
311689|NCT01824758|Drug|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
311690|NCT01824758|Drug|rocuronium|0.05 mg/kg rocuronium
311691|NCT01824758|Drug|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
311692|NCT01824745|Other|educational intervention|Receive the SCP-BCS template booklet
311693|NCT01824745|Other|counseling intervention|Receive counseling sessions with a patient navigator
442747|NCT00822120|Drug|prednisone|
311698|NCT01824693|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
311699|NCT01824693|Drug|Busulfan|Given IV
311700|NCT01824693|Drug|Cyclophosphamide|Given IV
311701|NCT01824693|Drug|Fludarabine Phosphate|Given IV
311702|NCT01824693|Other|Laboratory Biomarker Analysis|Correlative studies
311703|NCT01824693|Drug|Melphalan|Given IV
311704|NCT01824693|Drug|Mycophenolate Mofetil|Given IV or PO
311705|NCT01824693|Other|Pharmacological Study|Correlative studies
311706|NCT01824693|Drug|Tacrolimus|Given IV or PO
311707|NCT01824680|Behavioral|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
311708|NCT01824667|Dietary Supplement|B-GOS|
311709|NCT01824667|Dietary Supplement|Maltodextrin|
311710|NCT01824654|Other|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
311711|NCT01824654|Other|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
311712|NCT01824641|Device|Eliminate aspiration catheter|Eliminate aspiration catheter
311713|NCT01824641|Procedure|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
311714|NCT01824615|Drug|Sunitinib|37.5mg everyday from D1-D28
311715|NCT01824602|Drug|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
311716|NCT01824602|Drug|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
311717|NCT01824602|Drug|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
311718|NCT01824602|Drug|Placebo|Placebo sugar pills
311719|NCT01824589|Device|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
311720|NCT01824589|Device|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
311721|NCT01824576|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
311722|NCT01824563|Other|Observational study|
311723|NCT01824550|Other|home-based exercise training condition|Home based endurance exercise training
311724|NCT01824537|Biological|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Havrix).
311725|NCT01824537|Biological|Hepatitis A vaccine|Provided by GSK.
311726|NCT01824524|Drug|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
311727|NCT01824511|Behavioral|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
311728|NCT01824498|Other|Low Fat diet|Low fat diet = 20% fat
311729|NCT01824498|Other|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
311730|NCT01824498|Other|High Fat Diet|High Fat Diet = 40% fat
311731|NCT01824485|Drug|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
311732|NCT01824485|Drug|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
311733|NCT01824472|Device|CPAP|Treatment for sleep apnea
311734|NCT01824472|Behavioral|CBT|Treatment for insomnia
311735|NCT01824472|Device|sham CPAP|Placebo for sleep apnea
311736|NCT01824472|Behavioral|CC|Placebo (sham) for insomnia
311737|NCT01824459|Drug|S-1|S-1：40~60mg bid，d1~14 q3W
311738|NCT01824459|Drug|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
311739|NCT01824459|Drug|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
311740|NCT01824446|Drug|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
311741|NCT01824433|Drug|venlafaxine|venlafaxine 75-225mg qd
311742|NCT01824433|Drug|fluoxetine|fluoxetine 20-60mg qd
311743|NCT01824420|Drug|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
311744|NCT01824420|Drug|Detrusitol 4mg QD|Control group
311745|NCT01824407|Device|Electrohydraulic-generated shock wave|
311746|NCT01824407|Device|Sham device plus standard of care|
311747|NCT01824394|Device|nMARQ Navigation Catheters|
311748|NCT01824394|Device|NaviStar ThermoCool Catheters|
311749|NCT01824381|Procedure|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.~The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.~We will place a new membrane weekly to a maximum of 6 times."
311750|NCT01824381|Procedure|Obtaining and Cryopreservation of amniotic membrane|
311751|NCT01824381|Drug|amniotic membrane|
311814|NCT01823796|Other|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
311815|NCT01823796|Other|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
311752|NCT01824368|Procedure|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.~1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.~Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
311753|NCT01824355|Device|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
311754|NCT01824342|Biological|Denosumab|Administered by subcutaneous injection
311755|NCT01824329|Procedure|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
311756|NCT01824329|Procedure|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
311757|NCT01824303|Drug|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
311758|NCT01824303|Other|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
311759|NCT01824290|Drug|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
311760|NCT01824290|Drug|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
311761|NCT01824277|Other|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
311762|NCT01824264|Drug|LIK066|Experimental treatment doses
311763|NCT01824264|Drug|Sitagliptin|Active comparator treatment dose
311764|NCT01824264|Drug|Placebo|Placebo comparator dose
311765|NCT01824251|Drug|NPB-01|
311766|NCT01824238|Drug|Anacetrapib|
311767|NCT01824238|Drug|Placebo for anacetrapib|
311768|NCT01824225|Drug|Aflibercept|
311769|NCT01824199|Drug|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
311770|NCT01824186|Procedure|SILC|Underwent single-incision laparoscopic cholecystectomy
311771|NCT01824186|Procedure|LC|Underwent conventional 4-port laparoscopic cholecystectomy
311772|NCT01824173|Other|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
311773|NCT01824173|Other|Aerobic exercise|Moderate intensity for 45 minutes
311774|NCT01824160|Device|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
311775|NCT01824134|Other|Klean & Klear The Dandy Day Corp|
311776|NCT01824134|Other|The Skin Gel Herbal Answers, Inc|
311777|NCT01824121|Biological|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
311778|NCT01824108|Procedure|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
311779|NCT01824108|Procedure|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
311780|NCT01824095|Dietary Supplement|Dietary supplement|
311781|NCT01824082|Drug|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
311782|NCT01824069|Other|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
311816|NCT01823783|Other|Muscle biopsy|Muscle biopsy
311934|NCT01822899|Drug|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
313224|NCT01813188|Procedure|autologous bone graft|autologous bone graft
311783|NCT01824056|Drug|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
311784|NCT01824043|Drug|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
311785|NCT01824030|Device|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
311786|NCT01824030|Device|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
311787|NCT01824017|Other|Blood Draw|
311788|NCT01824004|Drug|S-1|
311789|NCT01823991|Drug|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
311790|NCT01823991|Other|Placebo|"Self administration of placebo for 3 months.~Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
311791|NCT01823991|Drug|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
311792|NCT01823978|Biological|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
311793|NCT01823965|Drug|ranibizumab|
311794|NCT01823939|Drug|iOWH032|"Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.~Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032."
311795|NCT01823926|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
311796|NCT01823926|Device|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
311797|NCT01823926|Device|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
311798|NCT01823913|Drug|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
311799|NCT01823913|Drug|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
311800|NCT01823900|Drug|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
311801|NCT01823900|Drug|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
311802|NCT01823887|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
311803|NCT01823874|Procedure|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
311804|NCT01823861|Behavioral|Mobile phone-based intervention|Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
311805|NCT01823848|Drug|Sodium phosphate enema|Rectally administered medication to treat constipation
311806|NCT01823848|Drug|Normal saline enema|Rectally administered medication to treat constipation
311807|NCT01823848|Drug|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
311808|NCT01823835|Drug|GDC-0810|GDC-0810 will be administered orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
311809|NCT01823835|Drug|LHRH Agonist|LHRH agonist will be administered once monthly until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
311810|NCT01823835|Drug|Palbociclib|Palbociclib will be administered orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
311811|NCT01823822|Dietary Supplement|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
311812|NCT01823822|Dietary Supplement|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
311813|NCT01823809|Device|adenosine stress Cardiac Magnetic Resonance Imaging|
314112|NCT01806571|Drug|Cytarabine|Given IV
311817|NCT01823770|Drug|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
311818|NCT01823770|Drug|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
311819|NCT01823757|Other|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
311820|NCT01823744|Dietary Supplement|micronutrient supplementation|
311821|NCT01823718|Biological|Injection of allogenic CTL EBV specific|
311822|NCT01823705|Device|Exilis Implantable Gastric Electrical Stimulation (GES)|
311823|NCT01823692|Other|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
311824|NCT01823679|Drug|Capecitabine|Given orally
311825|NCT01823653|Device|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
311826|NCT01823640|Other|placebo|
311827|NCT01823640|Other|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
311828|NCT01823627|Procedure|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
311829|NCT01823601|Behavioral|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
311830|NCT01823601|Behavioral|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
311831|NCT01823588|Behavioral|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.~Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
311832|NCT01823575|Device|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
311833|NCT01823575|Device|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
311834|NCT01823562|Drug|lyophilized black raspberry confection|Given PO
311835|NCT01823562|Other|laboratory biomarker analysis|Correlative studies
311836|NCT01823562|Dietary Supplement|dietary intervention|Follow a low polyphenol diet
311837|NCT01823562|Dietary Supplement|dietary intervention|Follow a low ellagitannin diet
311838|NCT01823562|Procedure|quality-of-life assessment|Ancillary studies
311839|NCT01823562|Other|questionnaire administration|Ancillary studies
311840|NCT01823549|Other|questionnaire administration|Ancillary studies
311841|NCT01823536|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
311842|NCT01823523|Drug|Cefazolin, Cephalexin, Clindamycin|
311843|NCT01823510|Drug|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
311844|NCT01823510|Drug|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
311845|NCT01823497|Drug|Morphine|Morphine will be used to control pain post-surgery.
311846|NCT01823484|Device|AN 69 ST hemofilter|
311847|NCT01823484|Device|AN 69 hemofilter|
311848|NCT01823471|Other|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
311849|NCT01823458|Behavioral|Lottery Insurance|
311850|NCT01823458|Behavioral|Standard Lottery|
311851|NCT01823445|Other|Xylitol disk|
311852|NCT01823406|Procedure|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
311853|NCT01823406|Procedure|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
311854|NCT01823393|Drug|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
311855|NCT01823393|Drug|NaCl|valvuloplasty is performed without heparin (placebo injection)
311856|NCT01823380|Procedure|Blood test|Blood test
311857|NCT01823367|Behavioral|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
311932|NCT01822912|Other|Heart Failure Usual Care|Subjects will receive standard of care.
311933|NCT01822899|Drug|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
314113|NCT01806571|Drug|Daunorubicin Hydrochloride|Given IV
311858|NCT01823354|Other|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
311859|NCT01823354|Other|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
311860|NCT01823354|Other|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
311861|NCT01823354|Other|Medical consultation|open questions
311862|NCT01823341|Device|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
311863|NCT01823328|Drug|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
311864|NCT01823328|Drug|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
311865|NCT01823315|Drug|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
311866|NCT01823315|Drug|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h)
311867|NCT01823315|Biological|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
311868|NCT01823302|Dietary Supplement|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
311869|NCT01823302|Other|nutritional counseling|nutritional counseling
311870|NCT01823289|Drug|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
311871|NCT01823276|Other|Tyrosine-Containing Bar|
311872|NCT01823276|Other|Placebo Bar|
311873|NCT01823263|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
311874|NCT01823263|Procedure|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
311875|NCT01823263|Procedure|Interference task|30-minute interference task
311876|NCT01823263|Behavioral|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
311877|NCT01823263|Behavioral|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
311878|NCT01823263|Behavioral|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
311879|NCT01823250|Behavioral|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
311880|NCT01823250|Behavioral|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
311881|NCT01823250|Behavioral|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
311882|NCT01823250|Behavioral|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
311883|NCT01823237|Device|Transcranial Magnetic Stimulation|
311884|NCT01823224|Drug|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
311885|NCT01823224|Drug|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
311886|NCT01823198|Biological|Aldesleukin|Given SC
311887|NCT01823198|Biological|Allogeneic CD56-positive CD3-negative Natural Killer Cells|Given IV
311888|NCT01823198|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplant
311889|NCT01823198|Drug|Busulfan|Given IV
311890|NCT01823198|Drug|Fludarabine Phosphate|Given IV
311891|NCT01823198|Other|Laboratory Biomarker Analysis|Correlative studies
311892|NCT01823198|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
311893|NCT01823198|Other|Pharmacological Study|Correlative studies
312148|NCT01821391|Drug|placebo c-PDT|Metvix placebo conventional photodynamic therapy
456842|NCT00718861|Drug|Placebo|
311894|NCT01823185|Drug|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
311895|NCT01823185|Drug|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
311896|NCT01823172|Procedure|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
311897|NCT01823159|Drug|retigabine|Single oral administration of a 400 mg tablet.
311898|NCT01823159|Drug|placebo|Single oral administration of a tablet
311899|NCT01823146|Drug|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
311900|NCT01823146|Drug|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
311901|NCT01823133|Drug|gemigliptin only|gemigliptin 50mg qd on day 1~7
311902|NCT01823133|Drug|rosuvastatin only|rosuvastatin 20mg qd on day 1~7
311903|NCT01823133|Drug|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1~7
311904|NCT01823120|Other|Supportive and interactive text messages|
311905|NCT01823107|Device|Meso BioMatrix Device|
311906|NCT01823081|Drug|Intravitreal injection of bevacizumab (Avastin)|
311907|NCT01823081|Drug|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
311908|NCT01823068|Drug|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
311909|NCT01823055|Procedure|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
311910|NCT01823042|Drug|azathioprine+enteral nutrition|
311911|NCT01823042|Drug|Azathioprine|
311912|NCT01823029|Drug|erythropoietin|
311913|NCT01823029|Drug|enteral nutrition.|
311914|NCT01823029|Drug|injection of iron|
311915|NCT01823016|Drug|Placebo|Placebo tablet, taken once daily
311916|NCT01823016|Drug|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
311917|NCT01823003|Radiation|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall > 1 cm, tumour size < 2 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
311918|NCT01823003|Radiation|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall > 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
311919|NCT01823003|Radiation|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall < 1 cm, tumour size < 5 cm and distance to main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
311920|NCT01823003|Radiation|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size < 5 cm and distance to the main bronchus < 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
311921|NCT01822977|Drug|omeprazole|
311922|NCT01822964|Device|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
311923|NCT01822964|Device|Placebo - current clinical practice, no cooling|
311924|NCT01822951|Drug|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
311925|NCT01822951|Drug|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
311926|NCT01822938|Other|incentive program for physical activity|
311927|NCT01822925|Drug|DA-9801 300mg|300 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
311928|NCT01822925|Drug|DA-9801 600mg|600 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
311929|NCT01822925|Drug|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
311930|NCT01822925|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
311931|NCT01822912|Other|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
456843|NCT00718861|Drug|Zoledronic acid|
311935|NCT01822899|Drug|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
311936|NCT01822899|Drug|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
311937|NCT01822886|Drug|Romidepsin + Gemcitabine|Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD
311938|NCT01822860|Drug|Chlorthalidone 12.5 mg|
311939|NCT01822860|Drug|Hydrochlorothiazide 25 mg|
311940|NCT01822860|Drug|Placebo|
311941|NCT01822821|Drug|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
311942|NCT01822821|Drug|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
311943|NCT01822808|Drug|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
311944|NCT01822808|Drug|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
311945|NCT01822795|Procedure|Lung volume reduction coïl treatment|
311946|NCT01822795|Other|Regular medical treatment|
311947|NCT01822782|Biological|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
311948|NCT01822769|Other|Cardiopulmonary rehabilitation|See Arm Description
311949|NCT01822769|Other|Standard of care|See Arm Description
311950|NCT01822756|Drug|ruxolitinib|
311951|NCT01822756|Drug|gemcitabine|Other names: Gemzar®
311952|NCT01822756|Drug|nab-paclitaxel|Other names: Abraxane®
311953|NCT01822756|Drug|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
311954|NCT01822743|Procedure|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
311955|NCT01822743|Procedure|sham comparator|
311956|NCT01822730|Drug|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
311957|NCT01822730|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
311958|NCT01822717|Behavioral|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
311959|NCT01822717|Behavioral|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
311960|NCT01822704|Device|Low intensity whole body vibration|
311961|NCT01822704|Device|High intensity whole body vibration|
311962|NCT01822704|Behavioral|Leg exercises|
311963|NCT01822691|Drug|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
311964|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
311965|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
311966|NCT01822678|Drug|Placebo|Placebo
311967|NCT01822665|Drug|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
311968|NCT01822665|Drug|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
311969|NCT01822665|Other|Placebo|Placebo tablets
311970|NCT01822652|Genetic|iC9-GD2 T Cells - frozen|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.~Subjects will receive one of the following dose levels (cells/m2):~Dose Level 1 = 1 x 10^7~Dose Level 2 = 1 x 10^8~Dose Level 3 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
311971|NCT01822652|Genetic|iC9-GD2 T Cells - fresh|"For subjects who will receive a fresh T cell product:~Dose Level 1 = 1 x 10^8~Dose Level 2 = 1.5 x 10^8~Dose Level 3 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
311972|NCT01822652|Drug|Cytoxan|Cyclophosphamide (500 mg/m2/day x 2 days, for patients <12 kg = 16.7 mg/kg/day x 2 days)
311973|NCT01822652|Drug|Fludara|Fludarabine (30 mg/m2/day x 3 days, for patients <12 kg = 1 mg/kg/day x 3 days)
311974|NCT01822652|Drug|Keytruda|Pembrolizumab (2 mg/kg on Day -1 and on Day 21).
311975|NCT01822652|Genetic|iC9-GD2 T cells|"For subjects who will receive a fresh T cell product:~Dose Level 1 = 1.5 x 10^8~Dose Level 2 = 2 x 10^8~Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
311976|NCT01822639|Drug|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
311977|NCT01822639|Drug|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
311978|NCT01822639|Drug|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
459895|NCT00696215|Drug|rasagiline|1mg
311979|NCT01822626|Behavioral|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
311980|NCT01822613|Drug|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
311981|NCT01822613|Drug|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
311982|NCT01822613|Drug|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
311983|NCT01822613|Drug|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
311984|NCT01822613|Drug|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
311985|NCT01822600|Drug|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels < 25 g/L.
311986|NCT01822600|Drug|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.~After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.~After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
311987|NCT01822587|Drug|Propranolol, 40 mg|
311988|NCT01822587|Drug|Propranolol, 80 mg|
311989|NCT01822587|Drug|Placebo|
311990|NCT01822574|Procedure|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
311991|NCT01822574|Procedure|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
311992|NCT01822574|Procedure|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
311993|NCT01822561|Drug|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
311994|NCT01822548|Drug|Vildagliptin|100 mg daily
311995|NCT01822548|Drug|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
311996|NCT01822548|Drug|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
311997|NCT01822535|Drug|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
311998|NCT01822522|Drug|Cabozantinib S-malate|Given PO
311999|NCT01822522|Other|Laboratory Biomarker Analysis|Correlative studies
312000|NCT01822522|Other|Pharmacological Study|Correlative studies
312001|NCT01822509|Biological|Ipilimumab|Given IV
312002|NCT01822509|Other|Laboratory Biomarker Analysis|Correlative studies
312003|NCT01822509|Biological|Nivolumab|Given IV
312004|NCT01822496|Radiation|Radiation Therapy|30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
312005|NCT01822496|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, AUC=6, IV, days 1 and 22."
312006|NCT01822496|Drug|Cisplatin|50 mg/m2, IV (intravenous), on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, cisplatin will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
312007|NCT01822496|Drug|Crizotinib|250 mg, orally, twice daily for four 3-week cycles (12 weeks in total)
312008|NCT01822496|Drug|Erlotinib|150 mg, orally, once daily for four 3-week cycles (12 weeks in total)
312009|NCT01822496|Drug|Etoposide|50 mg/m2, IV, on days 1 and 8 of two 4-week cycles concurrent with radiation therapy. For patients receiving either erlotinib or crizotinib, etoposide will begin 2 weeks after the completion of erlotinib or crizotinib, as applicable.
312010|NCT01822496|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. For patients receiving either erlotinib or crizotinib, carboplatin will begin 2 weeks after erlotinib or crizotinib, as applicable.~Consolidation: 4-6 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
312149|NCT01821378|Drug|Lurasidone|Lurasidone 20 mg once daily
312011|NCT01822483|Drug|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
312012|NCT01822483|Drug|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg*h ml-1.
312013|NCT01822457|Device|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
312014|NCT01822444|Other|Biomarker analysis|
312015|NCT01822431|Radiation|metaiodobenzylguanidine scintigraphy|
312016|NCT01822418|Drug|agomelatine|Augmentation of antipsychotic therapy with 25 to 50 mg agomelatine as a single oral dosage per day
312017|NCT01822405|Drug|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
312018|NCT01822405|Other|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
312019|NCT01822392|Behavioral|Online Parent Management Training (Interactive)|
312020|NCT01822392|Behavioral|Online Parent Management Training (Recorded)|
312021|NCT01822379|Procedure|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
312022|NCT01822366|Behavioral|Trauma-focused Cognitive Behavioral Therapy|
312023|NCT01822353|Dietary Supplement|Dietary supplement|Milk, egg or nut oral immunotherapy
312024|NCT01822340|Drug|HM10560A|Once weekly HM10560A
312025|NCT01822340|Drug|Genotropin|Once daily Genotropin
312026|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
312027|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
312028|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers earned independent of cocaine use
312029|NCT01822314|Drug|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
312030|NCT01822314|Drug|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
312031|NCT01822301|Procedure|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
312032|NCT01822288|Drug|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
312033|NCT01822288|Drug|Estradiol & medroxyprogesterone acetate|Estradiol & medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
312034|NCT01822275|Drug|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
312035|NCT01822275|Radiation|Radiation therapy|
312036|NCT01822262|Procedure|minimally invasive cholecystolithotomy with gallbladder reservation|
312037|NCT01822262|Procedure|laparoscopic cholecystectomy|
312038|NCT01822249|Drug|EPI-743|
312039|NCT01822249|Drug|Placebo|
312040|NCT01822236|Other|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
312041|NCT01822236|Other|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
312042|NCT01822223|Device|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a & 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.~Sub-groups 1-b & 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.~The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
312043|NCT01822210|Drug|Botox|injection by gastroscopy (100 Allergen units)
312044|NCT01822197|Device|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
312045|NCT01822171|Other|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
312046|NCT01822171|Other|Home medication if needed|Patient will be provided with medication to take home, when needed.
312047|NCT01822171|Other|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
312048|NCT01822158|Other|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
312049|NCT01822145|Device|ICD|
312050|NCT01822132|Drug|Extended release naltrexone|
312051|NCT01822132|Drug|Placebo|
312052|NCT01822119|Device|Baha Attract System|
312053|NCT01822106|Other|Placebo|
312054|NCT01822093|Biological|Cytovir-ADV|"A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results > 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.~This is a feasibility/pilot study and has no control group"
312055|NCT01822080|Drug|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
312056|NCT01822080|Drug|Placebo|Matching placebo once daily by mouth
312057|NCT01822041|Drug|ARN-509|Single oral dose of 240 mg ARN-509
312058|NCT01822028|Drug|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
312059|NCT01822028|Drug|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).~Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
312060|NCT01822015|Drug|Sirolimus|Given PO
312061|NCT01822015|Drug|Idarubicin|Given IV
312062|NCT01822015|Drug|Cytarabine|Given IV
312063|NCT01822002|Procedure|Canalith repositioning maneuver|
312064|NCT01821989|Dietary Supplement|Lactoferrin|dose of 100 mg/day
312065|NCT01821989|Dietary Supplement|Lactoferrin|dose of 150 mg/kg/ twice daily
312066|NCT01821989|Dietary Supplement|Placebo|in form of distilled water
312067|NCT01821976|Procedure|Ertl Procedure|
312068|NCT01821976|Procedure|Burgess Procedure|
312069|NCT01821963|Drug|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
312070|NCT01821963|Drug|Ribavirin|Starting dose: 1,000 mg by mouth daily.
312071|NCT01821963|Drug|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
312072|NCT01821950|Behavioral|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
312073|NCT01821937|Drug|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
312074|NCT01821937|Drug|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
312075|NCT01821911|Biological|Zagreb2-1-1|Injection on day 0、7、21
312076|NCT01821911|Biological|Essen|Injection on day 0、3、7、14、28
312077|NCT01821898|Drug|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
312078|NCT01821898|Other|Elimination diet|This group will receive an elimination diet
312079|NCT01821885|Behavioral|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
312080|NCT01821885|Behavioral|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
312081|NCT01821872|Drug|Administration of paracetamol|Administration of 1g intravenous paracetamol
312082|NCT01821859|Drug|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
312083|NCT01821859|Drug|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
312084|NCT01821846|Drug|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
312085|NCT01821833|Dietary Supplement|Omega-3 fatty acid|"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).~Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."
312086|NCT01821833|Dietary Supplement|Placebo|"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.~Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"
312087|NCT01821833|Drug|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
312088|NCT01821820|Other|Pistachios|
312089|NCT01821781|Drug|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
312090|NCT01821768|Procedure|Sentinel Lymph Node Biopsy|
312381|NCT01819701|Other|Placebo|
312091|NCT01821755|Behavioral|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
312092|NCT01821742|Other|Ultrasound cardiac output measurement|
312093|NCT01821729|Drug|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
312094|NCT01821729|Drug|Losartan|Taken orally every day during Phase I for all 8 cycles
312095|NCT01821729|Radiation|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
312096|NCT01821716|Biological|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
312097|NCT01821703|Drug|LY3045697|Administered as oral solution
312098|NCT01821703|Drug|Placebo|Administered as oral solution
312099|NCT01821703|Drug|Spironolactone|Administered as capsule
312100|NCT01821703|Drug|Placebo|Administered as capsule
312101|NCT01821690|Drug|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
312102|NCT01821690|Drug|Placebo|The placebo tablets taste and look identical to buspirone.
312103|NCT01821677|Drug|Low Dose Danazol|
312104|NCT01821677|Drug|Placebo|
312105|NCT01821664|Device|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
312106|NCT01821651|Device|HeartNavigator|Procedure with software
312107|NCT01821651|Device|EchoNav|Procedure with software
312108|NCT01821651|Other|Control-Group EN|Procedure without software
312109|NCT01821651|Other|Control-group HN|Procedure without software
312110|NCT01821625|Drug|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
312111|NCT01821612|Drug|oxaliplatin|IV
312112|NCT01821612|Drug|irinotecan|IV
312113|NCT01821612|Drug|leucovorin|IV
312114|NCT01821612|Drug|5-fluorouracil|IV
312115|NCT01821612|Drug|capecitabine|PO
312116|NCT01821612|Radiation|radiation|
312117|NCT01821612|Procedure|surgery|
312118|NCT01821612|Drug|gemcitabine|IV
312119|NCT01821599|Other|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
312120|NCT01821599|Other|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
312121|NCT01821586|Other|Modified ORS-1|
312122|NCT01821586|Other|Modified ORS-2 (ReSoMal)|
312123|NCT01821586|Other|Modified ORS-3 (Benefibre)|
312124|NCT01821573|Drug|botulinum toxin type A|"Experimental arm group:~150 Units in rectus femoris ( 3 ml and 3 points)~70 units in medial gastrocnemius (1.4 ml and 1 point)~70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~60 units in soleus ( 1.2 ml and 3 points)"
312125|NCT01821573|Drug|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:~3 ml of NaCl 0.9% in rectus femoris in 3 points~1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~1.2 ml of NaCl 0.9% in soleus in 3 points"
312126|NCT01821560|Drug|Baclofen|
312127|NCT01821560|Drug|placebo|
312128|NCT01821547|Drug|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
312129|NCT01821534|Other|No Intervention|No treatment (intervention) was administered.
312130|NCT01821521|Drug|AGSPT_L20|
312131|NCT01821521|Drug|Pantoloc 40mg|
312132|NCT01821508|Other|Clinical Treatment|metabolic surgery for diabetes and weight control
312133|NCT01821508|Procedure|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
312134|NCT01821495|Biological|DC-CIK|
312135|NCT01821495|Biological|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
312136|NCT01821482|Biological|Dendritic and Cytokine-induced Killer Cells|
312137|NCT01821469|Behavioral|psychoeducation|Bipolar disorders are educated to learn about their pathology
312138|NCT01821456|Drug|Antiinfectives|To analyze to efficacy of (novel) drug therapies
312139|NCT01821443|Other|Stereotactic radiosurgery (SRS)|"Dose & prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% [maximum=100%]), as defined by target delineation on the imaging studies.~The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
312140|NCT01821430|Drug|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
312141|NCT01821430|Drug|Placebo|Placebo group will follow the same titration as the pregabalin group
312142|NCT01821417|Device|Microtextured dental implant treatment|Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
312143|NCT01821417|Device|Dental implant treatment|Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
312144|NCT01821404|Drug|Atorvastatin|Capsules including 80 mg of atorvastatin
312145|NCT01821404|Drug|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
312146|NCT01821391|Drug|NDL-PDT|Metvix natural daylight photodynamic therapy
312147|NCT01821391|Drug|c-PDT|Metvix conventional photodynamic therapy
312150|NCT01821378|Drug|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
312151|NCT01821378|Drug|Placebo|Once Daily
312152|NCT01821352|Device|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
312153|NCT01821352|Device|Placebo Laser|Emits light that has no therapeutic effect
312154|NCT01821313|Other|Moderate exercise|
312155|NCT01821313|Other|High Intensity Interval Exercise|
312156|NCT01821287|Other|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
312157|NCT01821274|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
312158|NCT01821274|Drug|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
312159|NCT01821274|Drug|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
312160|NCT01821274|Drug|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
312161|NCT01821261|Device|Mouth Rinse 19668-012|20 ml of experimental mouth rinse 19668-012 for 30 seconds, twice daily
312162|NCT01821261|Drug|Mouth Rinse 500347078842|10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
312163|NCT01821261|Drug|Toothpaste 035000513007|Approximately one inch of toothpaste 035000513007, twice daily
312164|NCT01821248|Drug|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery~GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
312165|NCT01821235|Drug|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
312166|NCT01821235|Drug|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
312167|NCT01821235|Drug|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
312168|NCT01821235|Drug|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
312169|NCT01821222|Device|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.~Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
312170|NCT01821209|Procedure|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
312171|NCT01821196|Procedure|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
312172|NCT01821170|Drug|Methylphenidate|Patient will take treatment during two months
312173|NCT01821170|Device|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
312174|NCT01821170|Behavioral|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
312175|NCT01821170|Other|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
312176|NCT01821157|Procedure|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
312177|NCT01821157|Procedure|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
312178|NCT01821144|Behavioral|Salt reduction|Salt reduction
312179|NCT01821144|Other|Control|No salt awareness education
312180|NCT01821131|Other|muffin|
312181|NCT01821118|Biological|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
312182|NCT01821118|Other|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
312183|NCT01821105|Procedure|PET Scan|All patients will receive whole body PET scans (chest-abdomen-pelvis).
312184|NCT01821105|Procedure|CT Scan|All patients will receive CT scans of the abdomen and pelvis with contrast.
312185|NCT01821105|Radiation|fludeoxyglucose F 18|Given IV
312186|NCT01821105|Procedure|computer-aided detection/diagnosis|Undergo computer-aided detection/diagnosis during surgery
312187|NCT01821092|Procedure|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
312188|NCT01821092|Device|osseointegrated implant|Osseointegrated Implant Insertion
312189|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
459982|NCT00695409|Drug|etoposide|Given IV
312190|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
312191|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
312192|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
312193|NCT01821066|Drug|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
312194|NCT01821066|Drug|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
312195|NCT01821066|Drug|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
312196|NCT01821066|Drug|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
312197|NCT01821040|Drug|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
312198|NCT01821040|Drug|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
312199|NCT01821027|Drug|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
312200|NCT01821027|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
312201|NCT01821014|Other|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
312202|NCT01821014|Other|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
312203|NCT01821001|Drug|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
312204|NCT01820975|Dietary Supplement|High protein intake|
312205|NCT01820975|Other|Placebo comparator|No protein intake
312206|NCT01820962|Procedure|heparin|when not in use CVCs are locked with heparin
312207|NCT01820962|Procedure|concentrated citrate|when not in use the CVC is locked with concentrated citrate
312208|NCT01820936|Drug|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
312209|NCT01820936|Drug|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
312210|NCT01820936|Drug|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
312211|NCT01820936|Drug|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
312212|NCT01820936|Drug|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
312213|NCT01820923|Device|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
312214|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
312215|NCT01820923|Device|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
312216|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
312217|NCT01820910|Drug|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
312218|NCT01820897|Drug|Fosfomycin-Trometamol|
312219|NCT01820897|Drug|Sulfamethoxazole trimethoprim|
312220|NCT01820884|Procedure|TH|Total hysterectomy
312221|NCT01820884|Procedure|TH/BSO|Total hysterectomy and bilateral salpingo-oophorectomy
312222|NCT01820884|Procedure|BPLND|bilateral pelvic and para-aortic lymph node dissection
312223|NCT01820871|Other|Self-Management Using Smartphone Application for Type2 DM|
312224|NCT01820871|Other|self-management using booklet for management type 2 DM|
312225|NCT01820858|Drug|Paclitaxel|175 mg/m(2), intravenously (IV)
312226|NCT01820858|Drug|Paraplatin (Carboplatin Injection)|AUC=5, IV
312227|NCT01820858|Radiation|Pelvic Radiation|45-50 Gy
312228|NCT01820858|Radiation|Vaginal Brachytherapy 1|5 Gy, 3 times
312229|NCT01820858|Radiation|Vaginal brachytherapy 2|5 Gy, 2-4 times
312230|NCT01820832|Drug|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
312231|NCT01820806|Drug|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
312232|NCT01820793|Drug|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
312233|NCT01820780|Other|Natriuretic peptides levels to J7 and J14|
312234|NCT01820780|Other|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
312235|NCT01820780|Other|Phone calls in 6 months and 12 months|
312236|NCT01820780|Other|Natriuretic peptides levels at 6 months|
312237|NCT01820780|Other|Consultation with the general doctor or the cardiologist to J30 with blood results|
312382|NCT01819688|Procedure|laparoscopic liver resection|
312238|NCT01820767|Drug|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
312239|NCT01820767|Drug|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.~Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
312240|NCT01820767|Drug|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
312241|NCT01820754|Drug|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes~Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)~Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
312242|NCT01820754|Drug|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)~Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
312243|NCT01820728|Drug|DA-3801 Injection|
312244|NCT01820728|Drug|Gonal-F®|
312245|NCT01820715|Drug|600㎍ of DA-3030 Injection|
312246|NCT01820715|Drug|Placebo|
312247|NCT01820702|Other|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at ~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against ~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
312248|NCT01820689|Other|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
312249|NCT01820676|Device|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
312250|NCT01820663|Other|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
312251|NCT01820663|Other|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
312252|NCT01820650|Device|iTotal G2 CR Knee Replacement System|Total Knee replacement
312253|NCT01820637|Device|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
312254|NCT01820624|Drug|tretinoin|Given PO
312255|NCT01820624|Drug|lithium carbonate|Given PO
312256|NCT01820624|Other|laboratory biomarker analysis|Correlative studies
312257|NCT01820611|Device|Arcos Revision Stem System|Revision Hip System
312258|NCT01820598|Device|Multisite NMES training during 6 weeks|
312259|NCT01820585|Drug|Placebo|Tablets
312260|NCT01820585|Drug|ESL 400 mg|tablets
312261|NCT01820585|Drug|ESL 800 mg|tablets
312262|NCT01820585|Drug|ESL 1200 mg|tablets
312263|NCT01820572|Drug|Belatacept|
312264|NCT01820572|Drug|Tacrolimus|
312265|NCT01820572|Drug|Cyclosporine|
312266|NCT01820559|Drug|Placebo|Tablets
312267|NCT01820559|Drug|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
312268|NCT01820559|Drug|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
312269|NCT01820533|Other|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
312270|NCT01820520|Drug|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
312271|NCT01820507|Device|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
312272|NCT01820507|Device|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
312273|NCT01820494|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
312274|NCT01820481|Drug|WIN-901X dose level 1|100mg Bid, PO, 12weeks
312275|NCT01820481|Drug|WIN-901X dose level 2|200mg Bid, PO, 12weeks
312276|NCT01820481|Drug|WIN-901X dose level 3|300mg Bid, PO, 12weeks
312277|NCT01820481|Drug|Placebo|Bid, PO, 12weeks
312278|NCT01820468|Behavioral|Adapted critical time intervention team|
312279|NCT01820455|Drug|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
312280|NCT01820455|Drug|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
312281|NCT01820442|Drug|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
312383|NCT01819675|Device|Low frequency rTMS|
312384|NCT01819675|Device|High frequency rTMS|
312385|NCT01819675|Device|Sham rTMS|
459983|NCT00695409|Drug|melphalan|Given IV
312282|NCT01820442|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
312283|NCT01820416|Radiation|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
312284|NCT01820416|Other|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
312285|NCT01820403|Other|portion size kcal of box lunch|
312286|NCT01820377|Behavioral|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
312287|NCT01820364|Drug|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
312288|NCT01820351|Other|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
312289|NCT01820338|Behavioral|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
312290|NCT01820338|Behavioral|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
312291|NCT01820338|Other|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains & carbohydrates. Topics will also include use of vitamin & mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
312292|NCT01820325|Drug|Buparlisib|
312293|NCT01820325|Drug|Buparlisib placebo|Placebo + Carboplatin + Paclitaxel
312294|NCT01820325|Drug|Carboplatin|
312295|NCT01820325|Drug|Paclitaxel|
312296|NCT01820312|Radiation|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
312297|NCT01820299|Drug|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
312298|NCT01820299|Drug|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
312299|NCT01820286|Behavioral|Positive psychology intervention|
312300|NCT01820286|Behavioral|Recollection intervention|
312301|NCT01820260|Drug|Ingenol mebutate gel|
312302|NCT01820260|Drug|placebo|
312303|NCT01820247|Drug|enteral nutrition|
312304|NCT01820247|Drug|Tripterygium glycosides|
312305|NCT01820234|Other|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
312306|NCT01820234|Other|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
312307|NCT01820221|Procedure|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
312308|NCT01820208|Drug|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
312309|NCT01820208|Drug|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
312310|NCT01820195|Drug|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
312311|NCT01820195|Drug|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
312312|NCT01820195|Drug|Placebo group|The patients in this group will be received both oral placebo and IV placebo
312386|NCT01819662|Other|Enhanced standard management|Echocardiogram followed by letter to GP about results.
312313|NCT01820182|Device|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
312314|NCT01820169|Device|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
312315|NCT01820156|Device|Home Respiratory Polygraphy|
312316|NCT01820156|Device|Standard Polysomnography|
312317|NCT01820143|Drug|Ilaprazole|
312318|NCT01820143|Drug|Esomeprazole|
312319|NCT01820130|Device|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
312320|NCT01820117|Other|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
312321|NCT01820117|Other|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
312322|NCT01820117|Other|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
312323|NCT01820117|Other|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
312324|NCT01820117|Other|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
312325|NCT01820117|Other|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
312326|NCT01820117|Other|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
312327|NCT01820117|Other|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
312328|NCT01820117|Procedure|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
312329|NCT01820117|Other|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
312330|NCT01820104|Drug|lansoprazole, 30 mg per day for 6 days|
312331|NCT01820091|Drug|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
312332|NCT01820091|Drug|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
312333|NCT01820078|Drug|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
312334|NCT01820078|Other|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
312335|NCT01820065|Procedure|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
312336|NCT01820052|Drug|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
312337|NCT01820052|Drug|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
312338|NCT01820039|Other|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
312339|NCT01820026|Drug|Imipenem|second line therapy
312340|NCT01820026|Drug|Vancomycin|Second line therapy
312341|NCT01820026|Drug|azithromycin|Second line therapy
312342|NCT01820026|Drug|Cefotaxime|Standard antibiotic therapy
312343|NCT01820026|Drug|Amoxicillin|Standard therapy
312344|NCT01820013|Device|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
312345|NCT01820013|Device|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
312346|NCT01820000|Procedure|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
312347|NCT01819987|Behavioral|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
312427|NCT01819259|Drug|Placebo|
312428|NCT01819246|Procedure|Aphersis Treatment Arm|
312429|NCT01819246|Other|Control Arm|
312348|NCT01819987|Behavioral|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
312349|NCT01819974|Other|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
312350|NCT01819961|Drug|MCT/LCT and fish oil|
312351|NCT01819961|Drug|MCT/LCT|
312352|NCT01819948|Dietary Supplement|PhytoMed™|
312353|NCT01819935|Drug|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
312354|NCT01819935|Drug|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
312355|NCT01819922|Drug|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
312356|NCT01819922|Drug|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
312357|NCT01819909|Procedure|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
312358|NCT01819909|Procedure|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
312359|NCT01819896|Drug|Pacemaker and defibrillator|
312360|NCT01819870|Drug|Dilatrend SR capsule 32mg|"1 capsule, oral, once daily, 7days~over the period I&II(crossover)"
312361|NCT01819870|Drug|Dilatrend IR tablet 25mg|"1 tablet, oral, once daily, 7days~over the period I&II(crossover)"
312362|NCT01819857|Drug|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
312363|NCT01819857|Drug|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
312364|NCT01819857|Drug|Zofran 8 mg|intravenous administration of 8 mg ondansetron
312365|NCT01819844|Device|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose > 2 u/kg).
312366|NCT01819831|Radiation|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
312367|NCT01819831|Procedure|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
312368|NCT01819818|Drug|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
312369|NCT01819805|Drug|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
312370|NCT01819792|Other|Multiplex respiratory viral PCR|
312371|NCT01819779|Drug|Exforge tab. 10/160mg|
312372|NCT01819779|Drug|Lodivixx tab. 5/160mg|
312373|NCT01819753|Procedure|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
312374|NCT01819740|Other|"determine the levels of the HEM substance in seminal plasma"|
312375|NCT01819727|Drug|BMN 165|After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.
312376|NCT01819714|Other|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.~The impact of this multisensory strategy will be evaluated using a before-after design."
312377|NCT01819701|Dietary Supplement|LC-1000|L-carnitine 1000 mg /d
312378|NCT01819701|Dietary Supplement|LC-2000|L-carnitine: 2000 mg/d
312379|NCT01819701|Dietary Supplement|Q10-150|Coenzyme Q10: 150 mg/d
312380|NCT01819701|Dietary Supplement|Q10-300|Coenzyme Q10: 300 mg/d
312387|NCT01819662|Other|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
312388|NCT01819662|Other|Standard management|Usual care
312389|NCT01819649|Dietary Supplement|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
312390|NCT01819636|Other|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
312391|NCT01819623|Other|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
312392|NCT01819610|Drug|SPRIX|
312393|NCT01819597|Procedure|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
312394|NCT01819571|Drug|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
312395|NCT01819558|Biological|recwt1-A10+AS01B|
312396|NCT01819532|Procedure|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
312397|NCT01819532|Procedure|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
312398|NCT01819519|Behavioral|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q&A.
312399|NCT01819506|Behavioral|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
312400|NCT01819493|Behavioral|Lifestyle Intervention|Family-based group lifestyle intervention
312401|NCT01819493|Behavioral|Standard Family-Based intervention|Comparison intervention
312402|NCT01819480|Procedure|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
312403|NCT01819467|Device|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
312404|NCT01819454|Device|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
312405|NCT01819441|Drug|Azelnidipine|8mg or 16mg
312406|NCT01819441|Drug|Perindopril|4mg or 8mg
312407|NCT01819441|Drug|hydrochlorothiazide|12.5mg or 25mg
312408|NCT01819428|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
312409|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
312410|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
312411|NCT01819402|Drug|Pioglitazone vs Glimepiride|
312412|NCT01819389|Drug|Imatinib and Nilotinib|
312413|NCT01819376|Other|Facebook Status Update|
312414|NCT01819363|Procedure|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
312415|NCT01819350|Other|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
312416|NCT01819350|Other|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
312417|NCT01819324|Behavioral|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
312418|NCT01819324|Behavioral|Standardized Lifestyle Management|SLM material (every other week for 4 months)
312419|NCT01819311|Behavioral|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
312420|NCT01819311|Behavioral|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
312421|NCT01819285|Procedure|Immediate Orchiectomy or depot LHRH|
312422|NCT01819285|Procedure|Delayed Orchiectomy or depot LHRH|
312423|NCT01819272|Drug|Met DR|metformin delayed-release tablets
312424|NCT01819272|Drug|Met XR|metformin extended-release tablets
312425|NCT01819272|Drug|Placebo|placebo delayed-release tablets
312426|NCT01819259|Drug|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
312430|NCT01819233|Behavioral|Behavioral dietary intervention|Receive caloric restricted dietary intervention
312431|NCT01819233|Procedure|Therapeutic conventional surgery|Undergo definitive lumpectomy
312432|NCT01819233|Radiation|Radiation therapy|Undergo radiation therapy
312433|NCT01819233|Other|Counseling intervention|Receive dietary counseling
312434|NCT01819233|Procedure|Quality-of-life assessment|Ancillary studies
312435|NCT01819220|Drug|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.~Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
312436|NCT01819220|Drug|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
312437|NCT01819207|Other|blood test by thromboelastography|
312438|NCT01819194|Device|senofilcon A|
312439|NCT01819155|Biological|Adjuvanted seasonal trivalent inactivated influenza vaccine|
312440|NCT01819155|Biological|Seasonal trivalent inactivated influenza vaccine|
312441|NCT01819155|Biological|Saline (bacteriostatic 0.9% sodium chloride for injection)|
312442|NCT01819142|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
312443|NCT01819129|Drug|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
312444|NCT01819129|Drug|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
312445|NCT01819129|Drug|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
312446|NCT01819090|Device|Elysee 150 ventilator|
312447|NCT01819090|Device|Elysee 150 ventilator with a ventilation switch control|
312448|NCT01819077|Procedure|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
312449|NCT01819064|Drug|Atropine|intravenous atropine in low doses does not cause bradycardia
312450|NCT01819064|Drug|Atropine|IV dose at 5 mcg/kg
312451|NCT01819051|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
312452|NCT01819038|Procedure|continuous renal replacement therapy|
312453|NCT01819025|Behavioral|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
312454|NCT01819025|Behavioral|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
312455|NCT01819012|Drug|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
312456|NCT01819012|Drug|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
312457|NCT01819012|Drug|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
312458|NCT01818999|Drug|IXABEPILONE|injection
312459|NCT01818999|Radiation|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
312460|NCT01818986|Drug|Sipuleucel-T|
312461|NCT01818986|Radiation|Stereotactic Ablative Body Radiation|
312462|NCT01818973|Drug|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
312463|NCT01818973|Drug|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
312464|NCT01818973|Drug|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
312465|NCT01818973|Radiation|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
312466|NCT01818973|Procedure|surgery|Total Mesorectal Excision (TME)
312467|NCT01818960|Procedure|IRA-PCI|IRA only PCI at the time of Primary PCI
312468|NCT01818960|Procedure|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
312469|NCT01818934|Procedure|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
312470|NCT01818921|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
312471|NCT01818921|Drug|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
312472|NCT01818921|Drug|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
312473|NCT01818908|Drug|DA-EPOCH|DA-EPOCH regimen
312474|NCT01818882|Other|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
312475|NCT01818882|Device|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
312476|NCT01818869|Drug|AZD8848|Multiple doses inhaled IMP via a nebulizer
312477|NCT01818869|Drug|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
312478|NCT01818856|Drug|Ritonavir withdrawal, atazanavir 200 mg/12h|
312479|NCT01818856|Drug|Telaprevir interactions|
312480|NCT01818843|Other|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
312481|NCT01818804|Dietary Supplement|n-3PUFA|
312482|NCT01818804|Dietary Supplement|olive oil|
312681|NCT01817413|Procedure|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
312483|NCT01818791|Behavioral|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
312484|NCT01818791|Behavioral|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality—i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
312485|NCT01818778|Other|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
312486|NCT01818778|Other|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
312487|NCT01818765|Procedure|Trans-ventricular-septal placement of LV pacing lead|
312488|NCT01818765|Other|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
312489|NCT01818765|Other|Acute response assessment|Cardiac output monitoring
312490|NCT01818752|Drug|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
312491|NCT01818752|Drug|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
312492|NCT01818752|Drug|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
312493|NCT01818752|Drug|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
312494|NCT01818739|Procedure|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
312495|NCT01818739|Drug|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
312496|NCT01818739|Drug|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
312497|NCT01818739|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
312498|NCT01818726|Drug|ICL670|ICL670 was supplied in registered packages as 250mg or 500mg dispersible tablets.
312499|NCT01818726|Drug|Chelation|Main group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment (immunosupressant - Cyclosporine A) and received chelation with ICL670 (deferasirox).
312500|NCT01818726|Drug|No chelation|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload underwent treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
312501|NCT01818713|Drug|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
312502|NCT01818700|Drug|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
312503|NCT01818687|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
312504|NCT01818674|Behavioral|Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program)|A 6-month intervention program (sessions and educational materials) aims to increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement.
312505|NCT01818674|Behavioral|Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)|This basic program (6 month) aims to increase participants knowledge about diabetes self-management, but without structured social interaction programming. While group classroom setting is still used for delivery of the educational curriculum, the education program in group B have no group-based or team-building activities, group goal setting, and classroom program is lecture style with more limited class participation and interaction.
312506|NCT01818661|Drug|AV-1451|This is used to assess Tau burden in the brain.
312507|NCT01818648|Drug|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
312508|NCT01818648|Drug|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
312764|NCT01816828|Other|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
312765|NCT01816815|Drug|BAY1002670|
312766|NCT01816815|Drug|Placebo|
312509|NCT01818622|Device|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
312510|NCT01818622|Device|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
312511|NCT01818609|Behavioral|Step reduction|taking less than 1500 steps/d
312512|NCT01818596|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
312513|NCT01818583|Drug|Potassium chloride|
312514|NCT01818583|Drug|Glucose 50 MG/ML|
312515|NCT01818570|Drug|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
312516|NCT01818570|Drug|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
312517|NCT01818557|Behavioral|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
312518|NCT01818544|Drug|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
312519|NCT01818544|Drug|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
312520|NCT01818531|Drug|Adductor canal block|
312521|NCT01818531|Drug|Lumbar plexus block|
312522|NCT01818492|Biological|NI-0501|
312523|NCT01818479|Biological|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and TBI with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
312524|NCT01818479|Procedure|Stem cell transplant|
312525|NCT01818453|Behavioral|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
312526|NCT01818440|Other|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
312527|NCT01818440|Other|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
312528|NCT01818427|Biological|infusion of 2 units of plasma|infusion of 2 units of plasma
312529|NCT01818414|Drug|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D&E
312530|NCT01818414|Drug|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D&E
312531|NCT01818401|Device|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
312532|NCT01818401|Device|Matched patient cutting blocks MyKnee ® LBS|
312533|NCT01818388|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
312534|NCT01818375|Procedure|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
312535|NCT01818375|Other|Standard fluid therapy|
312536|NCT01818362|Biological|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
312537|NCT01818362|Biological|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
312538|NCT01818349|Other|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
312539|NCT01818349|Other|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
312540|NCT01818336|Drug|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
312541|NCT01818323|Other|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of T4-positive patient-derived T-cells contained within 1 mL.
312542|NCT01818310|Biological|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.~The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
312543|NCT01818310|Biological|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
312544|NCT01818310|Biological|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
312545|NCT01818310|Procedure|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
312546|NCT01818297|Device|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
312547|NCT01818284|Drug|Filgrastim|5 µg/kg in the morning daily for 4 days.
312548|NCT01818284|Drug|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
312549|NCT01818284|Procedure|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.~The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
312550|NCT01818271|Behavioral|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
314114|NCT01806571|Other|Laboratory Biomarker Analysis|Correlative studies
312551|NCT01818271|Behavioral|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:~Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.~Treadmill walking exercise program."
312552|NCT01818258|Drug|ZDV+3TC+LPV/r|
312553|NCT01818245|Drug|LY2605541|
312554|NCT01818232|Drug|[14C]-LX4211|
312555|NCT01818219|Procedure|Records of EADI derived parameters|
312556|NCT01818206|Other|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
312557|NCT01818180|Dietary Supplement|URELL|
312558|NCT01818180|Other|Placebo|
312559|NCT01818167|Drug|10% Benzoyl Peroxide Topical Body Wash|
312560|NCT01818167|Drug|Provodine Topical Cream|
312561|NCT01818154|Other|LED phototherapy|
312562|NCT01818154|Other|narrowband UVB phototherapy|
312563|NCT01818141|Drug|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
312564|NCT01818141|Drug|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
312565|NCT01818128|Device|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
312566|NCT01818128|Device|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
312567|NCT01818115|Device|Hydrus Implant|
312568|NCT01818115|Procedure|IOL placement|
312569|NCT01818102|Device|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
312570|NCT01818102|Device|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
312571|NCT01818089|Device|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
312572|NCT01818076|Drug|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
312573|NCT01818063|Drug|Paclitaxel|Given IV
312574|NCT01818063|Drug|Carboplatin|Given IV
312575|NCT01818063|Drug|Doxorubicin|Given IV
312576|NCT01818063|Drug|Cyclophosphamide|Given IV
312577|NCT01818063|Drug|Veliparib|Given PO
312578|NCT01818050|Other|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
312579|NCT01818037|Procedure|Cataract surgery|
312580|NCT01818024|Drug|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
312581|NCT01818024|Drug|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
312582|NCT01818024|Drug|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
312583|NCT01818024|Drug|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
312584|NCT01818024|Drug|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
312585|NCT01818024|Drug|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
312586|NCT01818024|Drug|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
312587|NCT01818024|Drug|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
312588|NCT01818011|Drug|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
312589|NCT01818011|Drug|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
312590|NCT01818011|Drug|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
312591|NCT01818011|Drug|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
312592|NCT01818011|Drug|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
312593|NCT01818011|Drug|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
312594|NCT01818011|Drug|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
312595|NCT01817998|Other|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
312596|NCT01817985|Drug|GS-5816|
312597|NCT01817972|Biological|Certolizumab pegol|Subcutaneous injection
312598|NCT01817972|Drug|Azathioprine|50mg tablets
312599|NCT01817959|Drug|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.
312600|NCT01817959|Drug|Placebo|Continuous infusion at a volume/rate matching active treatment.
312767|NCT01816802|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
312768|NCT01816789|Drug|rFSH|
312601|NCT01817946|Other|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
312602|NCT01817933|Behavioral|physical therapy|
312603|NCT01817920|Behavioral|integrated multidisciplinary fall prevention program|
312604|NCT01817907|Drug|Placebo pill|Subjects will receive a sugar pill during the placebo arm
312605|NCT01817907|Drug|Trazodone|Subjects will receive trazodone during one of their treatment arm studies
312606|NCT01817894|Drug|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
312607|NCT01817868|Other|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
312608|NCT01817855|Drug|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
312609|NCT01817855|Drug|Placebo to match|Multiple doses inhaled placebo via a nebulizer
312610|NCT01817842|Behavioral|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
312611|NCT01817842|Behavioral|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
312612|NCT01817842|Behavioral|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
312613|NCT01817829|Drug|paracetamol|500 mg oral tablet
312614|NCT01817829|Drug|placebo|
312615|NCT01817816|Procedure|Botox_A|
312616|NCT01817816|Procedure|Botox_B|
312617|NCT01817803|Drug|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
312618|NCT01817803|Drug|metolazone/no spironolactone|metolazone (add 2.5mg qod)
312619|NCT01817803|Drug|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
312620|NCT01817803|Drug|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
312621|NCT01817790|Drug|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
312622|NCT01817790|Drug|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
312623|NCT01817777|Drug|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
312624|NCT01817777|Drug|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
312625|NCT01817764|Drug|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
312626|NCT01817764|Drug|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
312627|NCT01817764|Drug|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
312628|NCT01817751|Drug|sorafenib tosylate|Given PO
312629|NCT01817751|Drug|valproic acid|Given PO
312630|NCT01817751|Drug|sildenafil citrate|Given PO
312631|NCT01817738|Biological|CV9104|Intradermal injection of CV9104
312632|NCT01817738|Biological|Placebo|Intradermal injection of placebo
312633|NCT01817725|Biological|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those <= 20 years old and 40μg in those > 20 years old.
312634|NCT01817712|Behavioral|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
312635|NCT01817712|Behavioral|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
312636|NCT01817699|Other|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.~Dose and interval will be adjusted according to hemoglobin level and its target."
312637|NCT01817699|Dietary Supplement|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
312638|NCT01817686|Other|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
312769|NCT01816789|Drug|buserelin|
313362|NCT01812174|Device|23mm mitral valve (On-X)|Heart mitral valve replacement surgery: 23mm Mitral
312639|NCT01817686|Other|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
312640|NCT01817686|Other|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
312641|NCT01817673|Dietary Supplement|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
312642|NCT01817673|Dietary Supplement|placebo|
312643|NCT01817660|Procedure|Open repair of popliteal artery|
312644|NCT01817660|Procedure|Endovascular repair of popliteal artery|
312645|NCT01817647|Procedure|Colorectal surgery|
312646|NCT01817634|Dietary Supplement|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
312647|NCT01817634|Dietary Supplement|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
312648|NCT01817634|Dietary Supplement|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
312649|NCT01817634|Dietary Supplement|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
312650|NCT01817621|Behavioral|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
312651|NCT01817621|Behavioral|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
312652|NCT01817595|Other|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
312653|NCT01817595|Other|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
312654|NCT01817582|Drug|Lotemax|Lotemax gel will be administered as per the dose and schedule specified in the arms.
312655|NCT01817582|Drug|Restasis|Restasis emulsion will be administered as per the dose and schedule specified in the arms.
312656|NCT01817582|Drug|Soothe® Lubricant Eye Drops|
312657|NCT01817556|Drug|Stillen Tab.|
312658|NCT01817556|Drug|Mucosta Tab.|
312659|NCT01817543|Device|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
312660|NCT01817530|Other|Elagolix placebo|oral coated tablet
312661|NCT01817530|Drug|Elagolix|oral coated tablet
312662|NCT01817530|Drug|0.5 mg estradiol / 0.1 mg norethindrone acetate|oral hard capsule
312663|NCT01817530|Drug|1 mg estradiol / 0.5 mg norethindrone acetate|oral hard capsule
312664|NCT01817530|Drug|E2/NETA placebo|oral hard capsule
312665|NCT01817517|Device|Medtronic Activa Deep Brain Stimulation System|
312666|NCT01817504|Procedure|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
312667|NCT01817504|Procedure|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.~In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
312668|NCT01817491|Other|American Heart Association Diet|
312669|NCT01817491|Other|Reduced Fat Vegan Diet|
312670|NCT01817478|Other|microbiologic sample|
312671|NCT01817465|Drug|Motilitone ®|
312672|NCT01817465|Drug|Pantoline®|
312673|NCT01817465|Drug|Motilitone® and Pantoline®|
312674|NCT01817452|Drug|Trastuzumab|
312675|NCT01817452|Drug|Pertuzumab|
312676|NCT01817452|Drug|Paclitaxel|
312677|NCT01817439|Drug|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
312678|NCT01817426|Drug|Infliximab|
312679|NCT01817426|Other|Placebo|
312680|NCT01817413|Procedure|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
312770|NCT01816776|Device|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
312682|NCT01817400|Other|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
312683|NCT01817400|Dietary Supplement|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
312684|NCT01817400|Drug|Aspirin|
312685|NCT01817400|Drug|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
312686|NCT01817387|Behavioral|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
312687|NCT01817387|Behavioral|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
312688|NCT01817374|Diagnostic Test|2D US grayscale plus quantitative VCEUS|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
312689|NCT01817348|Procedure|Lidocaine group|"Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle~Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
312690|NCT01817348|Other|Physiotherapy (PT)|- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
312691|NCT01817335|Procedure|psychosocial assessment and care|Participate in psycho-educational program
312692|NCT01817335|Other|educational intervention|Participate in psycho-educational program
312693|NCT01817335|Other|communication skills training|Participate in psycho-educational program
312694|NCT01817335|Other|questionnaire administration|Ancillary studies
312695|NCT01817322|Drug|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
312696|NCT01817322|Drug|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
312697|NCT01817322|Drug|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
312698|NCT01817309|Other|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
312699|NCT01817296|Procedure|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
312700|NCT01817283|Drug|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
312701|NCT01817283|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
312702|NCT01817283|Drug|placebo|Placebo pills produced the same as Triptolide wilfordii.
312703|NCT01817270|Biological|Live Attenuated Varicella Vaccine|
312704|NCT01817257|Drug|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
312705|NCT01817244|Other|care management|6-month care management
312706|NCT01817218|Drug|Platelet Rich Plasma|
312707|NCT01817218|Device|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).~The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
312708|NCT01817205|Procedure|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.~Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
312709|NCT01817192|Drug|Adjuvant Chemotherapy|
312710|NCT01817192|Other|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for stage I lung cancer
314115|NCT01806571|Drug|Nilotinib|Given PO
312711|NCT01817192|Other|Pervenio™ Lung RS Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of early stage non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as high-risk will be randomized to either adjuvant chemotherapy or observation.
312712|NCT01817179|Other|FES neuroprosthesis to dorsiflexors on affected leg|
312713|NCT01817166|Drug|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
312714|NCT01817166|Drug|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
312715|NCT01817166|Other|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
312716|NCT01817166|Biological|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
312717|NCT01817166|Biological|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
312718|NCT01817166|Biological|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
312719|NCT01817153|Drug|hydrocortison hemisuccinate|
312720|NCT01817153|Drug|placebo followed by hydrocortisone hemisuccinate|
312721|NCT01817114|Device|Auto Remote Ischemic Conditioning (AutoRIC) device|
312722|NCT01817101|Dietary Supplement|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
312723|NCT01817088|Procedure|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
312724|NCT01817088|Procedure|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
312725|NCT01817075|Drug|Chlorhexidine Gluconate|Given CGH cleansing
312726|NCT01817075|Other|Laboratory Biomarker Analysis|Correlative studies
312727|NCT01817075|Other|Questionnaire Administration|Ancillary studies
312728|NCT01817075|Procedure|Wound Care Management|Given control cleansing
312729|NCT01817049|Behavioral|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
312730|NCT01817049|Behavioral|placebo attention control|
312731|NCT01817036|Dietary Supplement|Placebo|placebo
312732|NCT01817036|Dietary Supplement|Vitamin D|400 IU vitamin D per pill
312733|NCT01817023|Radiation|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
312734|NCT01817023|Drug|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
312735|NCT01817010|Behavioral|Multi-Component Rehabilitation (CMC)|
312736|NCT01817010|Behavioral|Control (CON)|
312737|NCT01816997|Drug|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
312738|NCT01816997|Drug|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.~IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
312739|NCT01816997|Drug|Control|placebo
312740|NCT01816984|Drug|PI3K inhibitor BKM120|Given PO
312741|NCT01816984|Biological|cetuximab|Given IV
312742|NCT01816984|Other|laboratory biomarker analysis|Correlative studies
312743|NCT01816984|Other|questionnaire administration|Ancillary studies
312744|NCT01816971|Drug|dexamethasone|Given IV or PO
312745|NCT01816971|Drug|carfilzomib|Given IV
312746|NCT01816971|Drug|lenalidomide|Given PO
312747|NCT01816971|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
312748|NCT01816971|Other|laboratory biomarker analysis|Correlative studies
312749|NCT01816958|Other|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
312750|NCT01816945|Behavioral|MOMBA web-based application|Web-based, interactive, social network application.
312751|NCT01816932|Procedure|Home Visit|The intervention is the location of the insertion visit.
312752|NCT01816919|Other|collecting breath samples|
312753|NCT01816906|Device|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
312754|NCT01816906|Device|Footwear: MCP|One group of patients will receive footwear with MCP insoles
312755|NCT01816893|Other|Hypoglycemic hyperinsulinemic clamp|
312756|NCT01816893|Other|Euglycemic hyperinsulinemic clamp|
312757|NCT01816867|Device|Intramesh T1 implantation|
312758|NCT01816854|Device|Stenting|
312759|NCT01816841|Procedure|fluorescence imaging|Undergo DVFE
312760|NCT01816841|Procedure|biopsy|Undergo scalpel biopsy
312761|NCT01816841|Procedure|examination|Undergo COE
312762|NCT01816841|Procedure|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
312763|NCT01816828|Behavioral|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
463504|NCT00670358|Biological|rituximab|
312771|NCT01816776|Device|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
312772|NCT01816763|Behavioral|NRS pain one week|Eligible patients will be randomly assigned to complete a patient-reported 'NRS one week' on a tablet prior to making contact with a nursing staff vital signs screener.
312773|NCT01816763|Behavioral|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
312774|NCT01816763|Behavioral|DVPRS|Eligible patients will be randomly assigned to complete a patient-reported 'DVPRS' on a tablet prior to making contact with a nursing staff vital signs screener.
312775|NCT01816750|Device|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
312776|NCT01816698|Drug|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
312777|NCT01816698|Drug|Placebo|Placebo: 1 package once a day after meals, 12 weeks
312778|NCT01816685|Device|CPAP|
312779|NCT01816672|Device|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
312780|NCT01816672|Other|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
312781|NCT01816659|Drug|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
312782|NCT01816646|Drug|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
312783|NCT01816646|Drug|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
312784|NCT01816633|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
312785|NCT01816620|Drug|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.~For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.~All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
312786|NCT01816607|Procedure|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
312787|NCT01816594|Drug|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 was administered orally 100 mg/day.
312788|NCT01816594|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
312789|NCT01816594|Drug|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
312790|NCT01816594|Drug|BKM120 Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
312791|NCT01816581|Drug|Targin|
312792|NCT01816581|Drug|Oxynorm|
312793|NCT01816581|Drug|Morphine|
312794|NCT01816568|Procedure|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
312795|NCT01816568|Procedure|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
312796|NCT01816555|Dietary Supplement|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
312797|NCT01816542|Other|patch tests on healthy skin|Patches will be placed on healthy skin.
312798|NCT01816529|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
312799|NCT01816529|Drug|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
312800|NCT01816529|Drug|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
312801|NCT01816529|Drug|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
312802|NCT01816516|Behavioral|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).~The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
312803|NCT01816516|Behavioral|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
312804|NCT01816503|Drug|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
312805|NCT01816490|Drug|Intravenous Silibinin (iSIL)|
312842|NCT01816152|Other|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
312806|NCT01816477|Device|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
312807|NCT01816477|Drug|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
312808|NCT01816464|Biological|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.~The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
312809|NCT01816451|Other|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
312810|NCT01816425|Device|Thermoplastic partial denture|
312811|NCT01816425|Device|CoCr partial denture|
312812|NCT01816412|Device|MD02-LDCB Paclitaxel coated balloon catheter|
312813|NCT01816412|Procedure|Standard Uncoated Balloon Angioplasty Catheter|
312814|NCT01816399|Procedure|Routine coronary angiography|
312815|NCT01816386|Other|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
312816|NCT01816386|Other|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
312817|NCT01816373|Device|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
312818|NCT01816360|Other|Olfactory aromatherapy|Inhalation of essential oils.
312819|NCT01816360|Other|Yogatherapy|Yogatherapy respiratory exercises.
312820|NCT01816347|Procedure|Routine PCI|
312821|NCT01816334|Drug|methylprednisolone|
312822|NCT01816334|Drug|Ketoprofen|
312823|NCT01816334|Drug|Sodium Chloride|
312824|NCT01816321|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
312825|NCT01816321|Drug|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
312826|NCT01816321|Drug|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
312827|NCT01816321|Drug|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
312828|NCT01816295|Drug|Testosterone Solution|Administered topically to axillae.
312829|NCT01816295|Drug|Placebo Solution|Administered topically to axillae.
312830|NCT01816282|Drug|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
312831|NCT01816256|Procedure|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
312832|NCT01816243|Drug|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
312833|NCT01816243|Drug|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
312834|NCT01816230|Drug|NiCord®|
312835|NCT01816217|Device|Intubation with The McGrath Mac videolaryngoscope|
312836|NCT01816204|Behavioral|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
312837|NCT01816204|Behavioral|face-to-face individual therapy|weekly individual counseling as usual.
312838|NCT01816191|Drug|Diltiazem Hydrochloride Cream and Oral Diltiazem|
312839|NCT01816178|Behavioral|communication training|Participants were instructed in the use of a voices output communication aid.
312840|NCT01816165|Drug|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
312841|NCT01816165|Drug|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
314116|NCT01806571|Other|Pharmacological Study|Correlative studies
312843|NCT01816152|Other|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
312844|NCT01816139|Drug|WC3011|
312845|NCT01816139|Drug|Vehicle|
312846|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
312847|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
312848|NCT01816113|Biological|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
312849|NCT01816113|Biological|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
312850|NCT01816100|Other|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
312851|NCT01816100|Behavioral|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
312852|NCT01816087|Other|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
312853|NCT01816074|Drug|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
312854|NCT01816074|Behavioral|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
312855|NCT01816061|Behavioral|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
312856|NCT01816061|Behavioral|Control - COMPASS|Increased hours of patient-provider interactions Group.
312857|NCT01816048|Drug|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
312858|NCT01816048|Radiation|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
312859|NCT01816048|Procedure|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
312860|NCT01816048|Procedure|Computed Tomography|Undergo 18F NaF PET/CT scan
312861|NCT01816035|Other|Laboratory Biomarker Analysis|Correlative studies
312862|NCT01816035|Other|Pharmacological Study|Correlative studies
312863|NCT01816035|Biological|Trastuzumab Emtansine|Given IV
312864|NCT01816009|Other|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
312865|NCT01815996|Other|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
312866|NCT01815983|Other|Videolaryngoscopy review.|Review of video recordings.
312867|NCT01815970|Behavioral|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
312868|NCT01815957|Drug|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
312869|NCT01815944|Drug|0.75% Ropivacaine|
312870|NCT01815944|Drug|Normal saline|
312871|NCT01815944|Drug|Dextrose 5%|
312872|NCT01815918|Drug|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
312873|NCT01815918|Drug|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
312874|NCT01815905|Other|Mobile program for occupational and speech therapy|
312875|NCT01815905|Other|Traditional rehabilitation therapy|
312876|NCT01815892|Drug|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
312877|NCT01815892|Drug|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
312878|NCT01815866|Procedure|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
312879|NCT01815853|Radiation|Neoadjuvant Chemoradiotherapy|Radiotherapy (45Gy/25f) + 3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
312880|NCT01815853|Drug|Neoadjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
312881|NCT01815853|Procedure|R0 D2 Gastrectomy|
312882|NCT01815853|Drug|Adjuvant Chemotherapy|3 cycles of XELOX Chemotherapy (Capecitabine 1000mg/m2, d1-14 + Oxaliplatin 130mg/m2 d1; 21-days/cycle)
312883|NCT01815840|Drug|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
312884|NCT01815840|Drug|Placebo|Vismodegib placebo orally once daily
312885|NCT01815827|Drug|inclacumab|single intravenous doses
312886|NCT01815814|Other|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
312887|NCT01815801|Other|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
312888|NCT01815801|Other|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
312889|NCT01815788|Device|Use of a personal sound amplifying device = TeoFirst|
312926|NCT01815502|Diagnostic Test|Cardiac catheterization|All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.
312975|NCT01815164|Behavioral|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
312976|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
312890|NCT01815775|Other|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
312891|NCT01815762|Other|Active arm|"In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.~If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication."
312892|NCT01815749|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
312893|NCT01815749|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
312894|NCT01815749|Other|laboratory biomarker analysis|Correlative studies
312895|NCT01815736|Drug|E/C/F/TAF|Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered orally once daily
312896|NCT01815736|Drug|E/C/F/TDF|Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) (150/150/200/300 mg) FDC tablet administered orally once daily
312897|NCT01815736|Drug|EFV/FTC/TDF|Efavirenz (EFV)/FTC/TDF (600/200/300 mg) FDC tablet administered orally once daily
312898|NCT01815736|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
312899|NCT01815736|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
312900|NCT01815736|Drug|FTC/TDF|Emtricitabine (FTC)/TDF (200/300 mg) tablet administered orally once daily
312901|NCT01815736|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
312902|NCT01815723|Drug|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
312903|NCT01815723|Drug|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
312904|NCT01815723|Drug|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
312905|NCT01815723|Drug|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
312906|NCT01815710|Other|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
312907|NCT01815710|Other|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
312908|NCT01815697|Device|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
312909|NCT01815684|Drug|ASP3652|Oral
312910|NCT01815684|Drug|Placebo|Oral
312911|NCT01815671|Procedure|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
312912|NCT01815658|Device|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
312913|NCT01815645|Behavioral|ST+CM|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
312914|NCT01815645|Behavioral|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
312915|NCT01815632|Other|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
312916|NCT01815632|Other|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
312917|NCT01815619|Other|on-site specimen evaluation|The specimen will be evaluated on-site by a cytopathologist during the procedure to render a diagnosis
312918|NCT01815619|Other|off-site specimen evaluation|The specimen will be evaluated off-site by a cytopathologist
312919|NCT01815606|Procedure|biopsy with 19 gauge needle|biopsy with 19 gauge needle
312920|NCT01815606|Procedure|biopsy with 25 gauge needle|biopsy with 25 gauge needle
312921|NCT01815593|Device|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
312922|NCT01815580|Drug|Atripla or Stribild|Antiretroviral therapy
312923|NCT01815541|Drug|teicoplanin|
312924|NCT01815528|Drug|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:~10 µg on day 0~20 µg on day 3~50 µg on day 7~150 µg on day 10"
312925|NCT01815515|Drug|18F-DCFBC|"18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) [9-11 mCi (333-407 MBq)] of 18F-DCFBC will be injected into the IV line by slow IV push."
313029|NCT01814709|Drug|GDC-0032|Oral doses of GDC-0032
312927|NCT01815476|Radiation|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
312928|NCT01815450|Drug|BLI1100|BLI1100 topical cream
312929|NCT01815450|Drug|BLI1100 - modified formulation|BLI1100 topical cream
312930|NCT01815450|Drug|Placebo|Placebo topical cream
312931|NCT01815437|Dietary Supplement|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
312932|NCT01815437|Dietary Supplement|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
312933|NCT01815437|Dietary Supplement|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
312934|NCT01815437|Dietary Supplement|Mushroom Extract|Same quantity of mushroom extract in a capsule
312935|NCT01815424|Drug|placebo|placebo BID for 16 weeks and then re-randomized into active groups
312936|NCT01815424|Drug|CP-690,550|CP-690,550 5mg BID for 52 weeks
312937|NCT01815424|Drug|CP-690,550|CP-690,550 10mg BID for 52 weeks
312938|NCT01815411|Dietary Supplement|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
312939|NCT01815398|Behavioral|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
312940|NCT01815398|Behavioral|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
312941|NCT01815372|Procedure|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
312942|NCT01815372|Procedure|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
312943|NCT01815359|Procedure|Cytoreductive Surgery|Optimal Surgical Debulking
312944|NCT01815359|Drug|HIPEC with Mitomycin-C|
312945|NCT01815359|Drug|EPIC with FUDR and Leucovorin|
312946|NCT01815346|Procedure|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.~One group receives acupuncture 3 times a week for 4 weeks.~Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
312947|NCT01815346|Behavioral|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
312948|NCT01815346|Other|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
312949|NCT01815333|Drug|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
312950|NCT01815333|Procedure|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
312951|NCT01815320|Procedure|Contrast-enhanced ultrasound (CE-US)|
312952|NCT01815320|Device|SonoVue|
312953|NCT01815307|Drug|Gemcitabine|1000mg/m2, day 1 every 2 weeks
312954|NCT01815307|Drug|S-1|80mg/m2/day, day 1-28, every 6 weeks
312955|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
312956|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
312957|NCT01815281|Device|Foot Mechanical Stimulation (GONDOLA)|
312958|NCT01815268|Biological|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
312959|NCT01815268|Biological|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
312960|NCT01815268|Biological|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
312961|NCT01815268|Biological|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
312962|NCT01815255|Drug|tenofovir (TDF)|
312963|NCT01815242|Drug|nab-Paclitaxel|
312964|NCT01815242|Drug|Gemcitabine|
312965|NCT01815242|Drug|Carboplatin|
312966|NCT01815229|Procedure|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
312967|NCT01815216|Procedure|Bariatric surgery|Gastric bypass surgery
312968|NCT01815216|Behavioral|Brain activity in resting state|Measure of activity in brain networks during resting state
312969|NCT01815216|Behavioral|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
312970|NCT01815203|Drug|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
312971|NCT01815203|Drug|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
312972|NCT01815177|Device|Arthroscopic transosseous fixation|
312973|NCT01815177|Device|Suture anchors|
312974|NCT01815164|Behavioral|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
313030|NCT01814709|Drug|Itraconazole|Oral doses of Itraconazole
312977|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
312978|NCT01815125|Drug|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
312979|NCT01815125|Drug|PLacebo|placebo
312980|NCT01815112|Other|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
312981|NCT01815112|Other|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
312982|NCT01815099|Device|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
312983|NCT01815086|Biological|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
312984|NCT01815073|Biological|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
312985|NCT01815073|Biological|Live Attenuated Varicella Vaccine|
312986|NCT01815073|Biological|live attenuated JE vaccine|
312987|NCT01815047|Dietary Supplement|Vitamin D3 Supplementation|
312988|NCT01815021|Dietary Supplement|amorphous calcium carbonate|
312989|NCT01815021|Dietary Supplement|crystalline calcium supplements|
312990|NCT01815008|Drug|Clopidogrel|Clopidogrel 75 mg daily
312991|NCT01815008|Drug|Aspirin|Aspirin 81 mg daily
312992|NCT01814995|Behavioral|Nutrition/Physical Activity Intervention|Please see Arm description.
312993|NCT01814982|Drug|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
312994|NCT01814969|Radiation|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
312995|NCT01814969|Radiation|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
312996|NCT01814956|Drug|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
312997|NCT01814956|Drug|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
312998|NCT01814930|Behavioral|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
312999|NCT01814917|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
313000|NCT01814917|Drug|CBPB|
313001|NCT01814904|Drug|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
313002|NCT01814904|Drug|colestilan-M|BSAeq 6 g/day
313003|NCT01814904|Drug|colestilan-H|BSAeq 9 g/day
313004|NCT01814904|Drug|CBPB|
313005|NCT01814891|Other|Orange maize feeding|This group was fed orange maize.
313006|NCT01814891|Other|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
313007|NCT01814891|Other|Oil only|This group received a small amount of plain oil without vitamin A.
313008|NCT01814878|Drug|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl [75 mg]/acetaminophen [650 mg]) will be administered at 0, 12, 24 and 36 hours
313009|NCT01814878|Drug|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl [37.5 mg]/acetaminophen [325 mg]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
313010|NCT01814865|Drug|Abiraterone Acetate|1000 mg PO OD x 2 weeks
313011|NCT01814865|Drug|Prednisone|5 mg PO OD x 2 weeks
313012|NCT01814865|Drug|Aromatase Inhibitor|1 mg PO OD x 2 weeks
313013|NCT01814852|Device|Shockwave system|
313014|NCT01814852|Device|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
313015|NCT01814839|Drug|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
313016|NCT01814839|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
313017|NCT01814826|Drug|MLN4924 and azacitidine|"MLN4924 (IV) and azacitidine (IV) in AML patients to determine maximum tolerated dose (MTD) on a 28-day cycle:~Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles~MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles~Both agents given on Days 1, 3, and 5 of Cycle 1 and all subsequent cycles"
313018|NCT01814813|Biological|HSPPC-96|intradermal infusion
313019|NCT01814813|Drug|bevacizumab|intravenous
313020|NCT01814800|Biological|RI-002|Immune Globulin Intravenous (IGIV)
313021|NCT01814787|Other|CHICA Type 2 Diabetes Module|Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI > 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
313022|NCT01814774|Other|No Intervention|No treatment (intervention) was administered.
313023|NCT01814761|Drug|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
313024|NCT01814748|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
313025|NCT01814748|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
313026|NCT01814748|Drug|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
313027|NCT01814735|Other|Brown rice|
313028|NCT01814735|Other|White rice|
313032|NCT01814696|Device|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
313033|NCT01814683|Drug|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
313034|NCT01814683|Drug|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
313035|NCT01814683|Drug|Placebo|14 days placebo.
313036|NCT01814670|Biological|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
313037|NCT01814657|Drug|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
313038|NCT01814657|Drug|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
313039|NCT01814644|Behavioral|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
313040|NCT01814644|Behavioral|Standard Care|Individual assessment, lifestyle counseling
313041|NCT01814631|Other|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
313042|NCT01814631|Other|image quality and resolution|image quality and resolution will be viewed on the EU-me2
313043|NCT01814618|Drug|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
313044|NCT01814605|Procedure|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.~The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
313045|NCT01814605|Procedure|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
313046|NCT01814592|Procedure|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
313047|NCT01814592|Procedure|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
313048|NCT01814579|Device|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
313049|NCT01814579|Device|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
313050|NCT01814553|Drug|afatinib|Daily treatment starting 40 mg per day
313051|NCT01814553|Drug|loperamide|Follow cohort assignment and diarrhea management guidelines
313052|NCT01814540|Dietary Supplement|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
313053|NCT01814540|Dietary Supplement|Placebo Glucose Polymer|
313054|NCT01814527|Dietary Supplement|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
313055|NCT01814527|Drug|Placebo|5 capsules that are identical to the treatment.
313056|NCT01814514|Drug|Timolol-trusopt|
313057|NCT01814514|Drug|placebo|
313058|NCT01814501|Biological|panitumumab|Given IV
313059|NCT01814501|Drug|irinotecan hydrochloride|Given IV
313060|NCT01814501|Drug|fluorouracil|Given IV
313061|NCT01814501|Drug|leucovorin calcium|Given IV
313062|NCT01814488|Procedure|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.~The conditioning regimen in standard use is:~Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;~Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;~Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.~Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if <40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
313063|NCT01814475|Drug|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
313064|NCT01814475|Drug|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
313065|NCT01814462|Device|6 months CPAP|
313066|NCT01814449|Other|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
313067|NCT01814449|Drug|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
313068|NCT01814436|Device|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
313069|NCT01814423|Drug|Chloroquine-base 50 mg|
313070|NCT01814423|Drug|Chloroquine-base 70 mg|
463505|NCT00670358|Drug|cyclophosphamide|
313071|NCT01814410|Drug|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
313072|NCT01814410|Drug|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
313073|NCT01814410|Drug|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
313074|NCT01814397|Drug|Anastrozole|1 mg orally daily
313075|NCT01814397|Drug|exemestane|25 mg orally daily
313076|NCT01814397|Drug|letrozole|2.5 mg orally daily
313077|NCT01814384|Device|prosthesis GMK ® without the ancillary MyKnee ® LBS|
313078|NCT01814384|Device|Matched patient cutting blocks MyKnee ® LBS|
313079|NCT01814371|Drug|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
313080|NCT01814371|Other|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
313081|NCT01814371|Behavioral|Hygiene Protocol|"Follow key hygiene tips:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors, brushes, or deodorant.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
313082|NCT01814358|Dietary Supplement|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
313083|NCT01814358|Dietary Supplement|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
313084|NCT01814332|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
313085|NCT01814332|Drug|Placebo|Placebo compound treatment for comparison with IP
313086|NCT01814319|Drug|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
313087|NCT01814319|Drug|Placebo|Matching placebo oral twice daily
313088|NCT01814306|Device|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
313089|NCT01814306|Device|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
313090|NCT01814293|Device|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
313091|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
313092|NCT01814267|Other|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)~1 hospital consultation at inclusion time, week 0~then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.~1 hospital consultation to validate that the wound is well-healed"
313093|NCT01814267|Other|conventional|"conventional group: iterative diabetes physicians consultations at hospital~1 consultation at inclusion time, week 0~1 consultation 2 weeks after inclusion, week 2~1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period~1 consultation to validate that the wound is well-healed"
313094|NCT01814241|Drug|Open label peanut OIT|Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
313095|NCT01814228|Procedure|transcatheter ablation of ganglionated plexi in right atrium|
313096|NCT01814215|Behavioral|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
313097|NCT01814202|Other|PTM202|
313098|NCT01814202|Other|Placebo|
313099|NCT01814189|Drug|Sumatriptan+Promethazine (SPr)|
313100|NCT01814176|Device|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
313101|NCT01814163|Drug|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
313102|NCT01814137|Drug|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
313103|NCT01814137|Drug|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
313104|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
313105|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
313106|NCT01814124|Other|Manual therapy plus exercise|
313107|NCT01814124|Other|Advice and home exercise|
313108|NCT01814111|Procedure|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
313109|NCT01814098|Drug|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
314245|NCT01805440|Drug|Uridine|Uridine is the active treatment in this clinical trial.
313110|NCT01814085|Drug|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
313111|NCT01814072|Behavioral|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
313112|NCT01814072|Behavioral|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
313113|NCT01814072|Behavioral|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
313114|NCT01814072|Behavioral|Text Messages|Participants will receive regular text messages
313115|NCT01814072|Behavioral|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
313116|NCT01814072|Behavioral|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
313117|NCT01814059|Drug|sirolimus|
313118|NCT01814046|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
313119|NCT01814046|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
313120|NCT01814046|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
313121|NCT01814046|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
313122|NCT01814033|Other|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
313123|NCT01814033|Other|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
313124|NCT01814020|Drug|MOB015B|
313125|NCT01814007|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
313126|NCT01813994|Drug|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
313127|NCT01813994|Drug|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.~Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
313128|NCT01813981|Dietary Supplement|Low roast coffee|Instant coffee
313129|NCT01813981|Dietary Supplement|High roast coffee|Instant coffee
313130|NCT01813981|Dietary Supplement|Control (Caffeine dissolved in water)|Caffeine dissolved in water
313131|NCT01813968|Procedure|Ischemic postconditioning|
313132|NCT01813955|Drug|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
313133|NCT01813929|Drug|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
313134|NCT01813929|Drug|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
313135|NCT01813916|Other|proteomic analysis|
313136|NCT01813903|Behavioral|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
313137|NCT01813903|Behavioral|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
313138|NCT01813890|Drug|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
313139|NCT01813890|Drug|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
313140|NCT01813890|Drug|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
313141|NCT01813877|Radiation|FDOPA PET/CT|Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
313222|NCT01813201|Drug|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
314246|NCT01805440|Drug|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
313142|NCT01813864|Behavioral|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
313143|NCT01813851|Device|Exercise training in addition to nutritional support|
313144|NCT01813838|Drug|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
313145|NCT01813838|Drug|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
313146|NCT01813838|Drug|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.~In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.~In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
313147|NCT01813825|Other|Registry|
313148|NCT01813812|Drug|DA-6034|
313149|NCT01813812|Drug|Rebamipide 300mg|
313150|NCT01813799|Drug|DA-9801 300mg|300mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
313151|NCT01813799|Drug|DA-9801 600mg|600mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
313152|NCT01813799|Drug|DA-9801 900mg|900mg of DA-9801 tablet is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
313153|NCT01813799|Drug|Placebo|Placebo is assigned at week 0 point and is taken for 8 continuous weeks, 3 times a day.
313154|NCT01813786|Device|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
313155|NCT01813786|Device|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
313156|NCT01813786|Device|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
313157|NCT01813773|Drug|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
313158|NCT01813760|Device|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
313159|NCT01813747|Device|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
313160|NCT01813734|Drug|Ponatinib|28 day cycle
313161|NCT01813708|Behavioral|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
313162|NCT01813708|Behavioral|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
313163|NCT01813695|Procedure|Preemptive genotyping in medical record|
313164|NCT01813695|Procedure|Genotyping not included in electronic medical record|
313165|NCT01813682|Other|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
313166|NCT01813682|Other|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
313167|NCT01813669|Behavioral|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:~Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
313168|NCT01813656|Drug|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
313169|NCT01813656|Drug|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
313170|NCT01813643|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
313171|NCT01813643|Drug|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
313172|NCT01813630|Drug|DA-3002|
313173|NCT01813630|Drug|Genotropin®|
313174|NCT01813617|Drug|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
313175|NCT01813604|Biological|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
313176|NCT01813604|Biological|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
313177|NCT01813604|Biological|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
313223|NCT01813188|Procedure|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.~Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
313178|NCT01813604|Biological|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
313179|NCT01813604|Biological|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
313180|NCT01813591|Drug|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
313181|NCT01813578|Other|Exercise|Intensive aerobic and muscle endurance exercise
313182|NCT01813565|Drug|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
313183|NCT01813552|Drug|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
313184|NCT01813552|Drug|Omeprazole|40 mg delayed-release oral capsules, once daily
313185|NCT01813552|Drug|Ritonavir|100 mg oral tablets, once daily
313186|NCT01813539|Drug|ARGX-110|Outpatient intravenous infusion, in step-wise increments, every 3 weeks.
313187|NCT01813526|Other|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
313188|NCT01813513|Drug|IDX719|50 mg tablet for oral administration
313189|NCT01813513|Drug|Simeprevir|150 mg capsule for oral administration
313190|NCT01813500|Other|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
313191|NCT01813487|Drug|HBsAg vaccine with Entecavir|
313192|NCT01813474|Drug|olaparib|tablet oral
313193|NCT01813461|Drug|14C-labeled prodrug isavuconazonium sulfate|oral
313194|NCT01813448|Drug|Fidaxomicin|oral
313195|NCT01813448|Drug|Placebo|oral
313196|NCT01813435|Drug|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
313197|NCT01813435|Drug|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
313198|NCT01813435|Drug|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.~Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
313199|NCT01813422|Biological|Evolocumab|Administered by subcutaneous injection
313200|NCT01813422|Drug|Placebo|Administered by subcutaneous injection
313201|NCT01813396|Other|joint mobilization plus massage|
313202|NCT01813396|Other|joint mobilization/shoulder physical activity guide|
313203|NCT01813383|Other|There is not any intervention|
313204|NCT01813370|Other|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
313205|NCT01813357|Drug|Rosuvastatin|encapsulated tablet 20mg daily
313206|NCT01813357|Other|Placebo|Placebo arm included to maintain blinding
313207|NCT01813318|Drug|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
313208|NCT01813318|Drug|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
313209|NCT01813305|Drug|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
313210|NCT01813305|Drug|CSTC1 Matched vehicle|
313211|NCT01813279|Other|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
313212|NCT01813253|Drug|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
313213|NCT01813253|Drug|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
313214|NCT01813240|Drug|Minocycline|
313215|NCT01813240|Drug|placebo|
313216|NCT01813227|Drug|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
313217|NCT01813227|Drug|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
313218|NCT01813227|Drug|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
313219|NCT01813214|Drug|Vemurafenib|
313220|NCT01813214|Drug|Cobimetinib|
313221|NCT01813201|Drug|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
313225|NCT01813175|Other|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
313226|NCT01813175|Other|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
313227|NCT01813175|Other|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
313228|NCT01813162|Drug|Tenofovir 1% gel|
313229|NCT01813162|Drug|Vaginal product|
313230|NCT01813149|Drug|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
313231|NCT01813149|Other|punch biopsy|
313232|NCT01813136|Drug|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
313233|NCT01813136|Drug|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.~This sequential scheme will be maintained until the patient experiences on-treatment progression"
313234|NCT01813123|Behavioral|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
313235|NCT01813110|Drug|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
313236|NCT01813110|Drug|Placebo|olive oil
313237|NCT01813084|Drug|RV1729 single dose|Safety and tolerability of single escalating doses
313238|NCT01813084|Drug|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
313239|NCT01813084|Drug|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
313240|NCT01813084|Drug|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
313241|NCT01813071|Biological|WRSS1|
313242|NCT01813058|Drug|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:~placebo i.e. saline 0.9% (intravenous injection)~intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
313243|NCT01813058|Drug|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:~Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or~TXA as previously described."
313244|NCT01813045|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
313245|NCT01813045|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
313246|NCT01813045|Radiation|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
313247|NCT01813032|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
313248|NCT01813032|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
313249|NCT01813019|Drug|AFQ056|mGluR5 antagonist
313250|NCT01813019|Drug|Placebo|Matched placebo
313251|NCT01813006|Drug|Omega-3|
313252|NCT01813006|Drug|placebo|
313253|NCT01812993|Device|Non-invasive ventilatory treatment with auto-BPAP|
313254|NCT01812980|Biological|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
313255|NCT01812967|Dietary Supplement|Milk Fat|
313256|NCT01812967|Dietary Supplement|Milk Protein|
313257|NCT01812967|Dietary Supplement|Lactose|
313258|NCT01812967|Other|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
313259|NCT01812967|Dietary Supplement|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
313260|NCT01812954|Drug|Methotrexate|
313261|NCT01812954|Drug|Cyclosporins|
313262|NCT01812954|Drug|fumaric acid|
313263|NCT01812954|Drug|Acitretin|
313264|NCT01812954|Drug|Infliximab|
313265|NCT01812954|Drug|etanercept|
313266|NCT01812954|Drug|Adalimumab|
313267|NCT01812954|Drug|Ustekinumab|
313268|NCT01812941|Other|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
313269|NCT01812941|Other|healthy volunteers: blood collection|blood collected at designated time intervals
313270|NCT01812941|Other|Burn: blood collection|blood collected at designated time intervals
313271|NCT01812928|Drug|Diclofenac|
313272|NCT01812915|Device|Cylindrical-shape cuff ETT (Group C)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.
313273|NCT01812915|Device|Tapered-shape cuff ETT (Group T)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
313274|NCT01812902|Procedure|Radical Prostatectomy|
313275|NCT01812889|Drug|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
313276|NCT01812889|Drug|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
313441|NCT01811680|Device|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
313442|NCT01811667|Drug|Sirolimus|
313277|NCT01812863|Procedure|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.~If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
313278|NCT01812837|Device|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
313279|NCT01812837|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
313280|NCT01812837|Radiation|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
313281|NCT01812824|Behavioral|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
313282|NCT01812798|Other|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.~For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.~Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour~0.1 0.25 0.5 0.75~1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000~For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
313283|NCT01812772|Device|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
313284|NCT01812772|Device|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
313285|NCT01812759|Drug|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
313286|NCT01812759|Drug|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
313287|NCT01812759|Other|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
313288|NCT01812746|Drug|BIND-014|
313289|NCT01812720|Drug|carfilzomib|Given IV
313290|NCT01812720|Drug|dexamethasone|Given PO
313291|NCT01812720|Other|laboratory biomarker analysis|Correlative studies
313292|NCT01812707|Drug|Alirocumab|Two SC injections in the abdomen only
313293|NCT01812707|Drug|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only~Route of administration: subcutaneous injection (1 mL) in the abdomen"
313294|NCT01812707|Drug|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy~Route of administration: oral administration in the evening"
313295|NCT01812694|Behavioral|Controlling Gestational Weight Gain|Behavioral weight control
313296|NCT01812668|Drug|cabozantinib-s-malate|Given PO
313297|NCT01812668|Radiation|fluorine F 18 d-FMAU|Undergo 18F PET/FMAU PET scan
313298|NCT01812668|Procedure|positron emission tomography|Undergo 18F PET/FMAU PET scan
313299|NCT01812668|Other|pharmacological study|Correlative studies
313300|NCT01812668|Other|laboratory biomarker analysis|Correlative studies
313301|NCT01812655|Device|Virtual Reality|
313302|NCT01812655|Other|Passive Distraction|
313303|NCT01812642|Drug|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
313304|NCT01812642|Other|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
313305|NCT01812629|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
313306|NCT01812616|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
313307|NCT01812616|Drug|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs & Cosmetics (FD&C)certified color additives; FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
313308|NCT01812603|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
313309|NCT01812590|Behavioral|Exercise|
313310|NCT01812564|Biological|Platelet Poor Plasma (PPP)|
313311|NCT01812564|Biological|Platelet Rich Plasma (PRP)|
313312|NCT01812551|Drug|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
313313|NCT01812551|Drug|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
313314|NCT01812538|Drug|DIC075V|"Four single dose treatments:~Placebo (normal saline)~Moxifloxacin (positive control)~DIC075V 37.5 mg~DIC075V 75 mg~All subjects receive each of the 4 treatments."
313315|NCT01812525|Drug|NaCl 3%|NaCl 3%: 4ml QID
313316|NCT01812525|Other|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
313498|NCT01811277|Drug|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression~S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
313317|NCT01812512|Behavioral|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
313318|NCT01812486|Radiation|dose de escalation|
313319|NCT01812486|Radiation|standard dose|
313320|NCT01812473|Other|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
313321|NCT01812460|Other|Intervention-training-group|As descriped in Arm Description
313322|NCT01812447|Device|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
313323|NCT01812447|Other|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
313324|NCT01812434|Drug|Sildenafil|20mg three time daily for 28 days
313325|NCT01812434|Drug|Placebo|20 mg three times daily for 28 days
313326|NCT01812421|Other|Hypertension Health Education Protocol (HHEP)|
313327|NCT01812395|Device|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
313328|NCT01812395|Procedure|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
313329|NCT01812382|Drug|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
313330|NCT01812369|Drug|GEMCITABINE CISPLATINE|
313331|NCT01812369|Drug|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
313332|NCT01812356|Device|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
313333|NCT01812356|Device|Cryomaze procedure using Argon|Cryomaze procedure using Argon
313334|NCT01812343|Other|Exercise test|
313335|NCT01812330|Drug|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
313336|NCT01812330|Drug|Ticagrelor|90mg Bid
313337|NCT01812317|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
313338|NCT01812317|Procedure|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
313339|NCT01812304|Other|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
313340|NCT01812304|Other|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
313341|NCT01812291|Behavioral|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').~Includes:~Diabetes problem analysis/ definition~Diabetes problem solving intervention~Cognitive restructuring of diabetes problems~Activation of personal and social resources~Goal definition and agreement"
313342|NCT01812291|Behavioral|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).~Includes:~Functional explanatory model of depression~Cognitive restructuring of negative thoughts~Practice of alternative beneficial thoughts~Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
313343|NCT01812291|Behavioral|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
313344|NCT01812291|Behavioral|Standard Diabetes Education|"Standard diabetes education and professional care.~Includes:~Health care and specific topics (e. g. blood pressure)~Diabetes complications~Healthy and unhealthy foods, cooking recommendations and recipes~Foot care: exercises, care and control, injuries, and diabetic neuropathy~Sports, activities and exercise~Social aspects of living with diabetes"
313345|NCT01812278|Behavioral|ACT|
313346|NCT01812278|Behavioral|CBT|
313347|NCT01812265|Drug|PF-06305591|single Dose
313348|NCT01812265|Drug|PF-06305591|single Dose
313349|NCT01812265|Drug|Placebo|Single Dose
313350|NCT01812252|Drug|Azacitidine|Given IV or SC
313351|NCT01812252|Drug|Decitabine|Given IV or SC
313352|NCT01812252|Other|Quality-of-Life Assessment|Ancillary studies
313353|NCT01812239|Drug|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
313354|NCT01812239|Procedure|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
313355|NCT01812239|Drug|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
313356|NCT01812213|Drug|[18F]NAV4694|
313357|NCT01812200|Drug|Dabigatran, Ticagrelor, ASA|
313358|NCT01812200|Drug|Rivaroxaban, Ticagrelor, ASA|
313359|NCT01812200|Drug|Phenprocoumon, Ticagrelor, ASA|
313360|NCT01812187|Behavioral|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
313361|NCT01812174|Device|17mm aortic valve (On-X )|Heart aortic valve replacement surgery: 17mm Aortic
313363|NCT01812161|Other|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
313364|NCT01812161|Other|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of <5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
313365|NCT01812148|Procedure|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
313366|NCT01812135|Biological|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
313367|NCT01812122|Drug|Glimepiride|
313368|NCT01812122|Drug|Vildagliptin|
313369|NCT01812109|Device|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes ~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
313370|NCT01812096|Other|Subcutaneous bortezomib|
313371|NCT01812096|Other|Intravenous bortezomib|
313372|NCT01812070|Behavioral|ACT|
313373|NCT01812070|Behavioral|CBT|
313374|NCT01812057|Drug|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
313375|NCT01812057|Drug|Placebo|Sodium Chloride 0.9% -5 ml
313376|NCT01812044|Drug|subtenons anesthetic - preservative-free bupivacaine 0.75%|
313377|NCT01812044|Drug|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
313378|NCT01812044|Drug|topical control - 0.5 cc of Hypromellose 0.3% gel|
313379|NCT01812044|Drug|subtenons control - 0.5 cc of Normal Saline|
313380|NCT01812031|Other|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
313381|NCT01812018|Drug|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
313382|NCT01812018|Drug|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
313383|NCT01812018|Drug|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
313384|NCT01812005|Drug|alisertib|Given PO
313385|NCT01812005|Biological|rituximab|Given IV
313386|NCT01812005|Other|laboratory biomarker analysis|Laboratory correlative studies will be performed
313387|NCT01811992|Biological|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.~Radiation and chemotherapy will be administered as per standard of care."
313388|NCT01811979|Dietary Supplement|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
313389|NCT01811979|Dietary Supplement|Steril water|steril water plus topical anesthetics
313390|NCT01811966|Other|Volume|
313391|NCT01811966|Other|Control|
313392|NCT01811953|Drug|Empagliflozin|medium dose oral administration
313393|NCT01811953|Drug|Metformin|oral administration
313394|NCT01811953|Drug|Empagliflozin|low dose of Empagliflozin oral administration
313395|NCT01811953|Drug|Empagliflozin/Metformin|low dose of Empagliflozin
313396|NCT01811953|Drug|Metformin|oral administration
313397|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
313398|NCT01811953|Drug|Empagliflozin|medium dose oral administration
313399|NCT01811953|Drug|Metformin|oral administration
313400|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
313401|NCT01811940|Drug|Adderall-ER|MAS-ER 60mg/day
313402|NCT01811940|Drug|Topiramate|Topiramate 100 mg bid.
313403|NCT01811940|Other|Placebo|Placebo
313404|NCT01811927|Device|PRO-Kinetic Energy Stent|Bare-metal stent
313405|NCT01811914|Other|intraoperative TTE|
313406|NCT01811901|Other|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
313407|NCT01811888|Behavioral|Quantitative sensory testing (QST)|
313408|NCT01811875|Biological|Optivate 500IU|
313549|NCT01810913|Procedure|quality-of-life assessment|Ancillary studies
313550|NCT01810913|Radiation|intensity-modulated radiation therapy|Undergo IMRT
313409|NCT01811862|Procedure|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
313410|NCT01811862|Procedure|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
313411|NCT01811849|Drug|Insulin LISPRO|
313412|NCT01811849|Drug|Insulin LISPRO|
313413|NCT01811849|Drug|Insulin LISPRO|
313414|NCT01811836|Dietary Supplement|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
313415|NCT01811823|Biological|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~A/California/7/2009 (H1N1)pdm-like virus~A/Victoria/361/2011 (H3N2)-like virus~B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
313416|NCT01811810|Radiation|Radiation therapy (XRT)|
313417|NCT01811810|Other|Androgen Deprivation Therapy (ADT)|
313418|NCT01811810|Other|Chemotherapy|
313419|NCT01811797|Device|Low Intensity Shockwave by Renova|
313420|NCT01811797|Device|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
313421|NCT01811784|Behavioral|Ask people not to drink raw sap|
313422|NCT01811784|Behavioral|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
313423|NCT01811784|Other|No Intervention|
313424|NCT01811784|Other|No Intervention|
313425|NCT01811771|Biological|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
313426|NCT01811758|Behavioral|Culturally Specific CBT|
313427|NCT01811758|Behavioral|Standard CBT|
313428|NCT01811745|Behavioral|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
313429|NCT01811745|Behavioral|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
313430|NCT01811732|Drug|Delafloxacin|Delafloxacin
313431|NCT01811732|Drug|Vancomycin|Vancomycin
313432|NCT01811732|Drug|Aztreonam|Aztreonam
313433|NCT01811732|Drug|Placebo|Placebo
313434|NCT01811719|Behavioral|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
313435|NCT01811719|Behavioral|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
313436|NCT01811706|Drug|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
313437|NCT01811706|Drug|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
313438|NCT01811693|Drug|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
313439|NCT01811693|Drug|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
313440|NCT01811693|Drug|Glycerly Trinitrate|0.4 mg sublingual single metered spray
313551|NCT01810900|Device|Protescal|
313443|NCT01811654|Device|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
313444|NCT01811641|Other|season, dietary intake|
313445|NCT01811628|Behavioral|Questionnaire|Questionnaire completion taking about 10-15 minutes.
313446|NCT01811628|Behavioral|Interview|Audio-recorded interview that will last about 1 hour.
313447|NCT01811615|Other|alcohol-free experimental mouth rinse|
313448|NCT01811615|Other|alcohol-containing mouth rinsing|
313449|NCT01811602|Other|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
313450|NCT01811602|Other|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
313451|NCT01811589|Device|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
313452|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
313453|NCT01811576|Drug|TV-1106|
313454|NCT01811576|Drug|Recombinant human growth hormone|Subcutaneous once daily
313455|NCT01811563|Device|Zimmer|
313456|NCT01811563|Device|Stryker|
313457|NCT01811550|Other|Glycemic Control|
313458|NCT01811537|Device|Artificial Chordae|
313459|NCT01811511|Dietary Supplement|Chungkookjang|
313460|NCT01811511|Dietary Supplement|Placebo|
313461|NCT01811498|Drug|Bevacizumab|
313462|NCT01811485|Drug|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
313463|NCT01811485|Drug|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
313464|NCT01811485|Drug|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
313465|NCT01811472|Drug|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
313466|NCT01811472|Drug|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
313467|NCT01811459|Drug|Quetiapine|PO
313468|NCT01811459|Drug|Haloperidol|IV
313469|NCT01811459|Drug|Placebo|PO or IV
313470|NCT01811446|Device|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
313471|NCT01811420|Procedure|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
313472|NCT01811420|Procedure|Conventional method|Dental caries removal using rotatory instrument
313473|NCT01811407|Behavioral|Precommitment announcement|
313474|NCT01811407|Behavioral|Results announcement|
313475|NCT01811407|Behavioral|Walking program|
313476|NCT01811394|Radiation|protons|Treatment is performed using 16 x 4 GyE protons
313477|NCT01811394|Radiation|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
313478|NCT01811381|Drug|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
313479|NCT01811381|Behavioral|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
313480|NCT01811381|Behavioral|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.~Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
313481|NCT01811381|Dietary Supplement|Placebo|Subjects will take 4 capsules x BID of placebo
313482|NCT01811368|Biological|rituximab|Given IV
313483|NCT01811368|Biological|ibritumomab tiuxetan|Given IV
313484|NCT01811368|Biological|anti-thymocyte globulin|Given IV
313485|NCT01811368|Radiation|total nodal irradiation|Undergo TLI
313486|NCT01811368|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
313487|NCT01811368|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
313488|NCT01811368|Drug|cyclosporine|Given PO or IV
313489|NCT01811368|Drug|mycophenolate mofetil|Given PO or IV
313490|NCT01811355|Drug|Mexiletine|Sodium channel blocker
313491|NCT01811355|Drug|Placebo|Placebo
313492|NCT01811329|Dietary Supplement|Dairy fat|
313493|NCT01811329|Dietary Supplement|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
313494|NCT01811329|Dietary Supplement|Palm fat|
313495|NCT01811329|Dietary Supplement|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
313496|NCT01811316|Other|Probiotics|
313497|NCT01811303|Other|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose in 200 ml water if added 40 mg D-fagomine
313638|NCT01810315|Drug|TFV 1% gel|
313639|NCT01810315|Drug|Estradiol vaginal cream|
313499|NCT01811264|Behavioral|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
313500|NCT01811251|Drug|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
313501|NCT01811238|Drug|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
313502|NCT01811225|Drug|Low dose progesterone|"The low dose progesterone is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
313503|NCT01811225|Drug|High dose progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
313504|NCT01811212|Drug|Cabozantinib S-malate|Given PO
313505|NCT01811212|Other|Laboratory Biomarker Analysis|Correlative studies
313506|NCT01811186|Drug|Oxycodone/naloxone|Oxycodone/naloxone titration
313507|NCT01811173|Other|Nurse-physician comprehensive care|"Components of the intervention include:~Complete assessment of the patient's and family's needs conducted by the nurse.~Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.~Multimorbid care plan integrating all care aspects.~Action Plan for patients, supporting self management~Proactive monitoring according to the plan."
313508|NCT01811160|Drug|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
313509|NCT01811160|Drug|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
313510|NCT01811147|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
313511|NCT01811134|Device|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
313512|NCT01811134|Device|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
313513|NCT01811121|Drug|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
313514|NCT01811121|Drug|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
313515|NCT01811095|Other|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
313516|NCT01811082|Drug|Coenzyme A|Coenzyme A 400mg per day.
313517|NCT01811082|Drug|Pantethine|Pantethine 600mg per day.
313518|NCT01811069|Procedure|Head up|30˚ reverse trendelenburg body position
313519|NCT01811056|Drug|Mifepristone|Mifepristone use outside of the center
313520|NCT01811043|Behavioral|Guided Meditation|
313521|NCT01811043|Behavioral|Music|
313522|NCT01811043|Behavioral|Supportive Dialogue|
313523|NCT01811030|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
313524|NCT01811017|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
313525|NCT01811004|Device|miraDry|miraDry
313526|NCT01811004|Device|Nd:YAG Laser|Nd:YAG 1440 nm Laser
313527|NCT01811004|Device|Botox®|Botox®
313528|NCT01810991|Device|Nd:YAG Laser|Nd:YAG 1440nm Laser
313529|NCT01810978|Dietary Supplement|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
313530|NCT01810978|Dietary Supplement|Maltodextrin|same amount of maltodextrin per day will be given as placebo
313531|NCT01810965|Procedure|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
313532|NCT01810952|Drug|Glargine insulin|In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
313533|NCT01810952|Drug|Lispro insulin|In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
313534|NCT01810952|Drug|NPH Insulin|NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
313535|NCT01810939|Drug|Patiromer|
313536|NCT01810939|Drug|Placebo|
313537|NCT01810926|Biological|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
313538|NCT01810926|Drug|Rituximab|single infusion of200 mg/m2 on day -1
313539|NCT01810926|Drug|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
313540|NCT01810926|Drug|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
313541|NCT01810926|Drug|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
313542|NCT01810926|Drug|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
313543|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
313544|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
313545|NCT01810913|Drug|cisplatin|Given IV
313546|NCT01810913|Drug|docetaxel|Given IV
313547|NCT01810913|Biological|cetuximab|Given IV
313548|NCT01810913|Other|laboratory biomarker analysis|Correlative studies
313552|NCT01810887|Drug|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
313553|NCT01810887|Drug|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
313554|NCT01810874|Procedure|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
313555|NCT01810874|Procedure|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
313556|NCT01810861|Other|There is no intervention in this study|This is a non-interventional study.
313557|NCT01810848|Device|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
313558|NCT01810848|Other|Control|Control is puncture of the skin at the site of the knee.
313559|NCT01810809|Procedure|articular lavage with saline injection|Patients will receive articular lavage with saline injection
313560|NCT01810809|Drug|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
313561|NCT01810809|Drug|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
313562|NCT01810809|Drug|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
313563|NCT01810796|Drug|Ranolazine|Ranolazine versus placebo
313564|NCT01810783|Drug|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
313565|NCT01810770|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
313566|NCT01810757|Radiation|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
313567|NCT01810757|Radiation|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
313568|NCT01810744|Other|capillaroscopy|
313569|NCT01810744|Other|blood pressure measurement|
313570|NCT01810731|Biological|Quadrivalent Inactivated Influenza Vaccine (QIV)|
313571|NCT01810731|Biological|Inactivated Polio Vaccine|
313572|NCT01810731|Biological|Double Dose QIV|
313573|NCT01810718|Drug|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond >600 or <200mg/die The MTD will be used for phase II
313574|NCT01810705|Drug|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
313575|NCT01810692|Device|Group1:Spiriva® Respimat®|COPD patients using Respimat®
313576|NCT01810692|Device|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
313577|NCT01810679|Device|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
313578|NCT01810666|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
313579|NCT01810653|Drug|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
313580|NCT01810653|Drug|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
313581|NCT01810640|Procedure|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
313582|NCT01810627|Radiation|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
313583|NCT01810614|Other|ADPKD Diet|Diet specifically designed for people with ADPKD
313584|NCT01810601|Drug|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
313585|NCT01810588|Device|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
313586|NCT01810588|Drug|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
313587|NCT01810588|Drug|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
313687|NCT01809899|Behavioral|Consent as Usual|Routine informed consent procedures
313588|NCT01810588|Drug|anti-thymocyte globulin (rabbit)|Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
313589|NCT01810588|Drug|Rituximab|Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
313590|NCT01810588|Radiation|Total Body Irradiation|Patients at high risk of CNS relapse (e.g. ALL or Burkitt's lymphoma) or patients at high risk for graft rejection (i.e., donor-specific HLA antibodies, patients with severe aplastic anemia, or hemoglobinopathies) may receive 2 doses of TBI as part of the conditioning.
313591|NCT01810588|Drug|Mycophenolate Mofetil|Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
313592|NCT01810588|Drug|Tacrolimus|Administered 0.03/mg/kg/day intravenous continious infusion (CI) over 24 hours from 4pm Day -2 until engraftment or when subject is able to take orally, then tacrolimus approximately 0.09 mg/kg orally in 2 divided doses. Tacrolimus should be given at full dose to maintain levels of 5-15 ng/mL through Day 180, tapered by 20% every week thereafter. Infection, toxicity or other clinical circumstances may prompt earlier discontinuation or adjustment of doses. In the presence of Graft versus Host Disease, a clinical decision by the attending physician will determine if tacrolimus can be tapered or should be continued. Oral tacrolimus can be used when intravenous access for CI tacrolimus is unavailable.
313593|NCT01810575|Drug|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
313594|NCT01810575|Drug|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
313595|NCT01810575|Drug|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
313596|NCT01810562|Other|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.~Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.~Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.~Scrolling with spiked ball over the same area as brushing for two minutes evenly.~Firm pressure for two minutes evenly in the same area."
313597|NCT01810549|Drug|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
313598|NCT01810549|Drug|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
313599|NCT01810536|Device|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
313600|NCT01810536|Device|Venturi mask|
313601|NCT01810523|Behavioral|Narrative|Narrative form as described above.
313602|NCT01810523|Behavioral|Control|Blank piece of paper
313603|NCT01810510|Procedure|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
313604|NCT01810510|Procedure|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
313605|NCT01810497|Procedure|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
313606|NCT01810484|Device|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
313607|NCT01810484|Device|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
313608|NCT01810484|Device|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
313609|NCT01810471|Device|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
313610|NCT01810458|Device|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
313611|NCT01810458|Procedure|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
313612|NCT01810458|Procedure|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
313613|NCT01810458|Procedure|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
313614|NCT01810458|Other|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
313870|NCT01808495|Drug|Mitomycin C|
313615|NCT01810458|Procedure|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
313616|NCT01810458|Drug|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
313617|NCT01810458|Drug|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
313618|NCT01810458|Drug|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
313619|NCT01810458|Drug|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
313620|NCT01810458|Drug|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
313621|NCT01810458|Drug|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
313622|NCT01810458|Drug|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
313623|NCT01810432|Drug|Evacetrapib|Administered orally
313624|NCT01810432|Other|High-fat Meal|Administered orally, at breakfast.
313625|NCT01810419|Device|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
313626|NCT01810419|Device|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
313627|NCT01810406|Procedure|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
313628|NCT01810406|Procedure|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
313629|NCT01810393|Drug|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
313630|NCT01810380|Drug|Placebo|Once daily as tablets and capsules, orally
313631|NCT01810380|Drug|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
313632|NCT01810380|Drug|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
313633|NCT01810367|Drug|ABX Combined With Cisplatin|
313634|NCT01810367|Drug|Gemcitabine Combined With Cisplatin|
313635|NCT01810354|Drug|Cefazolin|
313636|NCT01810328|Other|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
313637|NCT01810328|Other|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
313640|NCT01810302|Drug|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
313641|NCT01810302|Drug|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
313642|NCT01810289|Behavioral|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level < 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.~This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
313643|NCT01810276|Other|Saline|400 mL of Saline will be given intravenously over 2 hours once
313644|NCT01810276|Other|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
313645|NCT01810263|Dietary Supplement|high protein supplement|Dietary Supplement: high protein supplement
313646|NCT01810250|Device|Endurant Stent Graft|
313647|NCT01810237|Drug|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
313648|NCT01810224|Procedure|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
313649|NCT01810211|Other|Horizontal Adduction Stretch and Pendulums|
313650|NCT01810211|Other|Modified Sleeper Stretch and Pendulum|
313651|NCT01810198|Procedure|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
313652|NCT01810198|Procedure|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
313653|NCT01810185|Drug|Low dose naltrexone|4.5 mg daily for 12 weeeks
313654|NCT01810185|Drug|Placebo|
313655|NCT01810172|Device|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
313656|NCT01810172|Device|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
313657|NCT01810159|Other|Integrated collaborative care|
313658|NCT01810159|Other|Education and Resources|
313659|NCT01810146|Other|Digestive functions investigations|
313660|NCT01810120|Biological|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
313661|NCT01810107|Procedure|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
313662|NCT01810094|Device|Fracture Fixation|Thoracolumbar Fracture Fixation
313663|NCT01810068|Procedure|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
313664|NCT01810068|Procedure|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
313665|NCT01810068|Procedure|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
313666|NCT01810068|Procedure|Diagnostic cystoscopy|Cysto-urethroscopy
313667|NCT01810042|Drug|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
313668|NCT01810029|Behavioral|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
313669|NCT01810016|Biological|Ipilimumab|Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
313670|NCT01810016|Biological|NY-ESO-1 Protein Vaccine|NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
313671|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
313672|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine with Poly-ICLC|NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.
313673|NCT01810003|Dietary Supplement|High DHA|10 week supplementation period
313674|NCT01810003|Dietary Supplement|High EPA|10 week supplementation period
313675|NCT01810003|Dietary Supplement|Placebo|10 week supplementation period
313676|NCT01809990|Behavioral|Internet-delivered Cognitive Behavior Therapy|
313677|NCT01809977|Procedure|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
313678|NCT01809977|Procedure|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
313679|NCT01809964|Biological|ANT-1401|
313680|NCT01809964|Biological|Vehicle|
313681|NCT01809938|Other|Black tea|300ml of tea without milk
313682|NCT01809938|Other|Tea with milk|250ml of black tea with 50ml of full fat milk
313683|NCT01809925|Dietary Supplement|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
313684|NCT01809925|Dietary Supplement|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
313685|NCT01809912|Drug|Recombinant human apolipoprotein(a) Kringle V|
313686|NCT01809899|Behavioral|Enhanced consent procedure|Enhanced consent entails a more detailed consent procedure
465879|NCT00654173|Drug|Atorvastatin|
313688|NCT01809886|Drug|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
313689|NCT01809886|Drug|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
313690|NCT01809873|Behavioral|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
313691|NCT01809860|Drug|isavuconazole|Oral
313692|NCT01809860|Drug|sirolimus|Oral
313693|NCT01809847|Drug|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
313694|NCT01809834|Device|Etafilcon A|
313695|NCT01809834|Device|Stenfilcon A|
313696|NCT01809821|Behavioral|Online Sleep Education|
313697|NCT01809808|Procedure|Surgery for acromegaly|(non-experimental) standard procedure
313698|NCT01809808|Drug|Medications for acromegaly|(non-experimental) standard procedure
313699|NCT01809808|Diagnostic Test|Total body magnetic resonance imaging|Subjects will undergo total body MRI with spectroscopy of the muscle and liver before and 3-6 months, 12 and 24 months after surgery or medical therapy for acromegaly.
313700|NCT01809808|Procedure|Adipose Tissue Biopsy|Subjects will undergo biopsy of subcutaneous adipose tissue before and 12 and 24 months after surgery or medical therapy for acromegaly.
313701|NCT01809795|Other|Blueberry Smoothie|
313702|NCT01809795|Other|Sham Smoothie|
313703|NCT01809769|Biological|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
313704|NCT01809769|Biological|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
313705|NCT01809769|Biological|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
313706|NCT01809756|Other|Caphosol|Caphosol 4 times a day
313707|NCT01809743|Drug|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
313708|NCT01809743|Drug|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
313709|NCT01809743|Drug|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
313710|NCT01809743|Drug|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
313711|NCT01809743|Drug|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
313712|NCT01809717|Other|Weight Lifting Exercises|
313713|NCT01809691|Drug|TAK-700|300 mg, PO, twice daily
313714|NCT01809691|Drug|Bicalutamide|50 mg, PO, q daily
313715|NCT01809678|Behavioral|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
313716|NCT01809678|Behavioral|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
313717|NCT01809678|Other|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
313718|NCT01809665|Device|ICD/CRT-P therapy|
313719|NCT01809665|Other|MRI|
313720|NCT01809652|Other|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
313721|NCT01809639|Drug|Progesterone|
313722|NCT01809639|Drug|Placebo|Standard placebo
313723|NCT01809626|Drug|Zolpidem|
313724|NCT01809626|Other|Placebo|
313725|NCT01809613|Procedure|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
313726|NCT01809600|Other|No intervention (observational study)|
313727|NCT01809587|Device|IQP-PO-101|
313728|NCT01809561|Procedure|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
313729|NCT01809548|Other|Early intervention group|solid food will be introduced between week 10 and 12
313730|NCT01809548|Other|Late intervention group|solid food is introduced between 16-18th week of gestation corrected for prematurity
313731|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
313732|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
313733|NCT01809522|Procedure|Posterior reconstruction of the rhabdosphincter|
313734|NCT01809509|Procedure|Endometrial biopsy|
313735|NCT01809496|Behavioral|Informational Counseling|
313736|NCT01809496|Behavioral|Patient Centered Counseling|
313737|NCT01809483|Device|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
313738|NCT01809483|Device|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
313739|NCT01809470|Behavioral|FIFA2013|Playing FIFA2013 for 1 hour
313740|NCT01809470|Behavioral|Call of Duty|Playing Call of Duty for 1 hour
313741|NCT01809470|Behavioral|Watching TV|Watching TV for 1 hour
313742|NCT01809457|Other|educational poster|educational poster for dental trauma
313743|NCT01809444|Drug|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
313744|NCT01809444|Drug|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
313745|NCT01809431|Behavioral|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
313746|NCT01809418|Device|keePAP|
313747|NCT01809392|Drug|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
313748|NCT01809379|Drug|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
313749|NCT01809366|Procedure|seminal plasma insemination|
313750|NCT01809353|Drug|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
313751|NCT01809353|Other|Placebo|Single matching intravenous dose
313752|NCT01809340|Drug|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
313753|NCT01809340|Drug|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
313754|NCT01809340|Drug|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
313755|NCT01809327|Drug|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
313756|NCT01809327|Drug|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
313757|NCT01809327|Drug|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
313758|NCT01809314|Drug|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
313759|NCT01809301|Drug|Niaspan|
313760|NCT01809301|Drug|TRIA-662|
313761|NCT01809275|Drug|QBECO|
313762|NCT01809275|Drug|Placebo|
313763|NCT01809262|Drug|single dose of 5 mcg|solution for inhalation
313764|NCT01809262|Drug|single dose of placebo|solution for inhalation
313765|NCT01809262|Drug|single dose of 40 mcg|solution for inhalation
313766|NCT01809262|Drug|single dose of 20 mcg|solution for inhalation
313767|NCT01809262|Drug|single dose of 2 mcg|solution for inhalation
313768|NCT01809262|Drug|single dose of 10 mcg|solution for inhalation
313769|NCT01809236|Biological|Conbercept|intravitreal injection of 0.5 mg Conbercept
313770|NCT01809223|Drug|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
313771|NCT01809223|Drug|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
313772|NCT01809223|Other|sham injection|sham intravitreal injection per month, fixed injection
313773|NCT01809210|Drug|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
313774|NCT01809210|Drug|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
313775|NCT01809210|Drug|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
313776|NCT01809210|Drug|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
313777|NCT01809210|Drug|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
313778|NCT01809197|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
313779|NCT01809197|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
313780|NCT01809197|Device|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
313781|NCT01809197|Device|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
313782|NCT01809184|Drug|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
313783|NCT01809184|Drug|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
313784|NCT01809184|Drug|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
313785|NCT01809171|Drug|Vitamin D3|ampoule
313786|NCT01809171|Drug|Placebo|ampoule
313787|NCT01809158|Drug|minocycline|
313788|NCT01809158|Drug|placebo|
313789|NCT01809145|Other|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
313790|NCT01809132|Drug|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
313791|NCT01809132|Drug|Pentoxifylline|Pentoxifylline, generic
313792|NCT01809132|Drug|Zinc Sulfate|Zinc Sulfate, nutritional supplement
313793|NCT01809132|Drug|Methylprednisolone|Methylprednisolone, corticosteroid
313794|NCT01809119|Procedure|Partial nephrectomy|
313795|NCT01809106|Drug|Morphine|60 mg /24 ore
313796|NCT01809106|Drug|Fentanyl|25 microg/h
313797|NCT01809106|Drug|Buprenorphine|35 microg/h
313798|NCT01809106|Drug|Oxycodone|40 mg /24 ore
313799|NCT01809093|Biological|Blood draw|3-4 tablespoons of blood will be drawn, one time.
313800|NCT01809067|Other|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
313801|NCT01809054|Drug|Arixtra|
313802|NCT01809054|Device|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
313803|NCT01809054|Drug|Aspirin|
313804|NCT01809041|Drug|Sevoflurane|
313805|NCT01809041|Drug|propofol|
313806|NCT01809041|Drug|remifentanil|
313807|NCT01809028|Procedure|EUS FNA with 2 passes|biopsy with 2 passes
313808|NCT01809028|Procedure|EUS FNA with 4 passes|biopsy with 4 passes
313809|NCT01809002|Biological|Processed Nerve Allograft (human)|
313810|NCT01809002|Device|Collagen Nerve Cuff|Bovine collagen based nerve cuff
313811|NCT01808989|Other|Exercise oxymetry|
313812|NCT01808976|Other|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
313813|NCT01808976|Behavioral|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
313814|NCT01808976|Behavioral|Basic health push app|This is an app that send daily tips for improving your mood.
313815|NCT01808950|Drug|0.06% Resiquimod Gel - A|single 60mg dose
313816|NCT01808950|Drug|0.06% Resiquimod Gel - B|single 100mg dose
313817|NCT01808950|Drug|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
313818|NCT01808937|Other|Morphea|
313819|NCT01808911|Drug|Steroid + cyclophosphamide|
313820|NCT01808911|Drug|Steroid + rituximab|
313821|NCT01808898|Procedure|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
313822|NCT01808885|Drug|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.~Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
313823|NCT01808885|Drug|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
313824|NCT01808859|Device|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
313825|NCT01808820|Biological|Dendritic Cell Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
313826|NCT01808820|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
313827|NCT01808820|Other|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
313828|NCT01808820|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
313829|NCT01808794|Device|Mucograft|Mucograft Collagen Matrix
313830|NCT01808794|Device|Dynamatrix|Dynamatrix
313831|NCT01808781|Other|Exercises plus walking program|"Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention."
314247|NCT01805414|Other|Modified Carbohydrate Breakfast|
313832|NCT01808781|Other|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
313833|NCT01808768|Drug|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
313834|NCT01808755|Dietary Supplement|D Mannose|1 gr. every 8 hours
313835|NCT01808755|Drug|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
313836|NCT01808742|Device|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
313837|NCT01808716|Device|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
313838|NCT01808703|Device|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
313839|NCT01808703|Procedure|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
313840|NCT01808690|Drug|Metformin|
313841|NCT01808690|Drug|Placebo|
313842|NCT01808677|Other|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
313843|NCT01808664|Behavioral|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.~During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
313844|NCT01808664|Behavioral|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
313845|NCT01808651|Drug|Fluoxetine|Administered orally
313846|NCT01808638|Drug|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
313847|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
313848|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.~Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
313849|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
313850|NCT01808612|Drug|Fluoxetine|
313851|NCT01808612|Drug|Placebo|
313852|NCT01808599|Drug|Chlorambucil|
313853|NCT01808599|Drug|Rituximab i.v.|
313854|NCT01808599|Drug|Rituximab s.c.|
313855|NCT01808586|Procedure|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
313856|NCT01808586|Procedure|Dexamethasone|4mg/mL
313857|NCT01808586|Procedure|Intramuscular Lidocaine|2%
313858|NCT01808586|Behavioral|Home Exercise|Standardized home exercise program
313859|NCT01808573|Drug|neratinib|
313860|NCT01808573|Drug|capecitabine|
313861|NCT01808573|Drug|lapatinib|
313862|NCT01808560|Device|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
313863|NCT01808560|Device|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
313864|NCT01808547|Drug|ISV-303|0.075% bromfenac in DuraSite dosed BID
313865|NCT01808547|Other|DuraSite Vehicle|DuraSite vehicle dosed BID
313866|NCT01808534|Drug|palifosfamide|Given IV
313867|NCT01808521|Drug|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
313868|NCT01808508|Device|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
313869|NCT01808508|Device|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
313871|NCT01808482|Drug|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
313872|NCT01808482|Drug|Part A: matching placebo|Matching placebo
313873|NCT01808482|Drug|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
313874|NCT01808482|Drug|Part B: matching placebo|Matching placebo
313875|NCT01808482|Drug|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
313876|NCT01808469|Biological|Monoclonal antibody|
313877|NCT01808456|Biological|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
313878|NCT01808456|Biological|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
313879|NCT01808443|Other|Cryotherapy|up to a maximum of four treatments every 21-28 days
313880|NCT01808443|Other|laser|up to a maximum of four treatments every 21-28 days
313881|NCT01808430|Procedure|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
313882|NCT01808417|Drug|Near Infrared Imaging|The intervention to be administered is the drug indocyanine green.
313883|NCT01808404|Behavioral|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
313884|NCT01808378|Drug|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
313885|NCT01808365|Procedure|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
313886|NCT01808365|Other|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
313887|NCT01808352|Drug|FTC/TDF|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
313888|NCT01808339|Drug|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
313889|NCT01808339|Drug|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
313890|NCT01808326|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
313891|NCT01808313|Drug|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
313892|NCT01808300|Drug|Pregabalin 300mg, Thioctic acid 600mg|"A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days~B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days~C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
313893|NCT01808287|Device|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
313894|NCT01808274|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
313895|NCT01808261|Drug|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
313896|NCT01808261|Drug|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
313897|NCT01808248|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
313898|NCT01808248|Drug|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
313899|NCT01808248|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
313900|NCT01808235|Behavioral|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
313901|NCT01808222|Drug|FACBC|Participants will receive a bolus of anti-[18F]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
313902|NCT01808209|Device|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
313903|NCT01808209|Device|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
313941|NCT01807897|Device|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
313942|NCT01807897|Behavioral|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
314248|NCT01805414|Other|Control Breakfast|
313904|NCT01808196|Drug|Losartan Potassium|The medication dosage for Losartan will change throughout this study slowly increasing to a larger amount. You will start the study drug at a low dose. It will be increased at Visit 3/Week 4, unless you have certain side effects. The dose of study drug will be increased depending on your weight and how well you tolerate each dose and will not exceed 100mg of study drug. It may be increased or decreased during the study if there are any side effects.
313905|NCT01808183|Device|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
313906|NCT01808170|Procedure|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
313907|NCT01808170|Procedure|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
313908|NCT01808157|Drug|CT327 ointment|
313909|NCT01808157|Drug|placebo|
313910|NCT01808144|Drug|lesinurad|Tablets, 400 mg once daily (QD)
313911|NCT01808144|Drug|lesinurad|Tablets, 200 mg QD
313912|NCT01808144|Drug|febuxostat|Tabletsm 80 mg QD
313913|NCT01808131|Drug|Lesinurad|Tablets, 200 mg QD
313914|NCT01808131|Drug|Lesinurad|Tablets, 400 mg QD
313915|NCT01808118|Biological|adalimumab|40 mg every other week
313916|NCT01808118|Biological|Placebo|every other week
313917|NCT01808105|Other|Control Formula|Feeding ad libitum
313918|NCT01808105|Other|Experimental Formula 1|Feeding ad libitum
313919|NCT01808105|Other|Experimental Formula 2|Feeding ad libitum
313920|NCT01808105|Other|Human Milk|Feeding ad libitum
313921|NCT01808092|Drug|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
313922|NCT01808092|Drug|meropenem (active comparator)|1000mg of Meropenem
313923|NCT01808079|Other|Laboratory Biomarker Analysis|Correlative studies
313924|NCT01808066|Device|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
313925|NCT01808053|Device|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
313926|NCT01808040|Drug|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
313927|NCT01808014|Drug|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
313928|NCT01807988|Behavioral|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
313929|NCT01807975|Other|Forced oscillation|
313930|NCT01807962|Drug|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine~bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
313931|NCT01807962|Drug|sterile saline|Placebo = 5ml of sterile saline solution
313932|NCT01807949|Drug|Placebo|Matching placebo tablet
313933|NCT01807949|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
313934|NCT01807949|Drug|Ivacaftor|Film-coated tablet
313935|NCT01807936|Procedure|Lymphadenectomy|
313936|NCT01807923|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
313937|NCT01807923|Drug|Ivacaftor|Film-coated tablet
313938|NCT01807923|Drug|Placebo|Matching placebo tablet
313939|NCT01807910|Drug|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
313940|NCT01807897|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
313943|NCT01807884|Procedure|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
313944|NCT01807884|Other|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
313945|NCT01807871|Drug|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
313946|NCT01807871|Drug|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
313947|NCT01807858|Dietary Supplement|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
313948|NCT01807858|Dietary Supplement|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
313949|NCT01807858|Other|Maltodextrin|Maltodextrin
313950|NCT01807858|Dietary Supplement|İnulin|900 mg inulin per day will be given
313951|NCT01807845|Dietary Supplement|enriched skimmilk with VD|enriched skimmilk with VD
313952|NCT01807845|Dietary Supplement|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
313953|NCT01807845|Dietary Supplement|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
313954|NCT01807832|Other|capsaicin challenge|
313955|NCT01807819|Other|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
313956|NCT01807806|Behavioral|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
313957|NCT01807793|Behavioral|Psychoeducation|
313958|NCT01807780|Biological|biological monitoring|
313959|NCT01807767|Drug|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).~Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.~Myfortic 360-720 mg BID"
313960|NCT01807767|Drug|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
313961|NCT01807754|Procedure|X-ray and ultrasound imaging scanning|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
313962|NCT01807754|Procedure|Photoacoustic imaging scans for breast cancer screening|The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
313963|NCT01807741|Drug|Asenapine|Available in 5 and 10 mg.
313964|NCT01807741|Drug|Placebo|
313965|NCT01807728|Other|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
313966|NCT01807728|Other|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
313967|NCT01807715|Other|survey|Survey before procedure to obtain demographic information and contraceptive information
313968|NCT01807702|Drug|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
313969|NCT01807676|Device|ET View Double Lumen Tube|
313970|NCT01807676|Device|conventional Double Lumen Tube|
313971|NCT01807663|Device|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
313972|NCT01807663|Device|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
313973|NCT01807650|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
313974|NCT01807650|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28
313975|NCT01807637|Device|transcranial direct current stim (tDCS)|During anodal tDCS, participants will receive 20 min at 2mA over motor cortex (with 30 seconds of ramp-up and ramp-down). During sham stimulation the stimulator is turned off.
313976|NCT01807624|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
313977|NCT01807611|Radiation|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
313978|NCT01807611|Drug|Fludarabine|Given IV.
313979|NCT01807611|Drug|Cyclophosphamide|Given IV.
313980|NCT01807611|Drug|Thiotepa|Given IV.
313981|NCT01807611|Drug|Melphalan|Given IV.
313982|NCT01807611|Biological|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
313983|NCT01807611|Biological|TC-NK Infusion|Participants receive infusions of TC-NK.
313984|NCT01807611|Biological|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.~Donors receive G-CSF subcutaneously during cell mobilization."
313985|NCT01807611|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
465880|NCT00654160|Drug|fluorouracil|
313986|NCT01807611|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
313987|NCT01807611|Drug|Mycophenolate mofetil|Given intravenously or orally.
313988|NCT01807598|Drug|Brentuximab vedotin|
313989|NCT01807585|Device|VenaSeal SCS|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
313990|NCT01807585|Device|ClosureFast Radiofrequency Ablation (RFA)|Radiofrequency thermal ablation of the GSV using the Covidien ClosureFast system.
313991|NCT01807585|Device|Roll-in (VenaSeal SCS)|Non-tumescent, non-thermal, non-sclerosant procedure that uses a proprietary medical adhesive delivered endovenously to close the vein.
313992|NCT01807559|Device|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
313993|NCT01807546|Drug|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
313994|NCT01807533|Behavioral|Family-centered intervention program|This program was in-hospital intervention, after-discharge intervention, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The 7-session after-discharge intervention consisted of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
313995|NCT01807533|Behavioral|Usual care intervention program|This program was in-hospital intervention, after-discharge consultation, and neonatal follow-up. Five sessions of in-hospital intervention emphasized in the parental involvements with modulation of the NICU, a teaching of child developmental skills, feeding support, massage, interactional activities, child developmental skills, parent support and education, and transition home preparation. The after-discharge service was provided 7-phone calls for the general health consultation.
313996|NCT01807520|Biological|Secukinumab|Study treatment was provided in pre-filled 1 mL syringes.
313997|NCT01807520|Biological|Placebo|Placebo was provided in pre-filled 1 mL syringes.
313998|NCT01807507|Device|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
313999|NCT01807494|Device|Total hip replacement components|All patients will receive the same implants
314000|NCT01807481|Drug|Mircera|Once Monthly Mircera
314001|NCT01807468|Procedure|haploidentical stem cell transplantation and NK cell therapy|
314002|NCT01807455|Device|Restylane Vital Lidocaine|
314003|NCT01807442|Other|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
314004|NCT01807429|Drug|Ketamine-midazolam|Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
314005|NCT01807429|Drug|Morphine|morphine 0.05 mg/kg
314006|NCT01807416|Procedure|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
314007|NCT01807403|Procedure|Deep brain stimulation|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
314008|NCT01807377|Drug|PF-05175157|200 mg tablet administered twice per day for 14 days
314009|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
314010|NCT01807377|Other|Placebo|Placebo administered twice per day for 14 days
314011|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
314012|NCT01807325|Procedure|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
314013|NCT01807312|Device|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
314014|NCT01807312|Device|Placebo|
314015|NCT01807299|Dietary Supplement|Omega 3|
314016|NCT01807299|Other|Physical Training|
314017|NCT01807286|Drug|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.~Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
314018|NCT01807286|Drug|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
314019|NCT01807286|Drug|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
314020|NCT01807286|Behavioral|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
314021|NCT01807273|Other|Walking test|
314067|NCT01806896|Drug|PF-02545920|"Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Treatment for 28 days."
314068|NCT01806896|Drug|Placebo|"- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
468325|NCT00637611|Drug|Fexofenadine HCl|
314022|NCT01807260|Procedure|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
314023|NCT01807247|Procedure|Intensive lower limbs muscles strengthening|
314024|NCT01807234|Drug|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
314025|NCT01807234|Drug|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
314026|NCT01807234|Drug|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
314027|NCT01807221|Drug|Finerenone (BAY94-8862)|
314028|NCT01807221|Drug|Placebo|
314029|NCT01807221|Drug|Inspra (eplerenone)|
314030|NCT01807208|Other|Educational Tool|"A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician."
314031|NCT01807195|Other|contrast medium usage|
314032|NCT01807182|Biological|Aldesleukin|Given IV
314033|NCT01807182|Drug|Cyclophosphamide|Given IV
314034|NCT01807182|Drug|Fludarabine Phosphate|Given IV
314035|NCT01807182|Other|Laboratory Biomarker Analysis|Correlative studies
314036|NCT01807182|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
314037|NCT01807169|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
314038|NCT01807156|Drug|Tivozanib|Oral medication given daily. No placebo.
314039|NCT01807143|Other|laboratory biomarker analysis|Correlative studies
314040|NCT01807130|Other|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
314041|NCT01807130|Other|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
314042|NCT01807117|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
314043|NCT01807117|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
314044|NCT01807117|Procedure|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
314045|NCT01807117|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
314046|NCT01807104|Procedure|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
314047|NCT01807104|Procedure|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
314048|NCT01807091|Drug|Chemotherapy|Receive outpatient induction chemotherapy
314049|NCT01807078|Drug|Ezetimibe|10 mg p.d. of ezetimibe
314050|NCT01807078|Dietary Supplement|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
314051|NCT01807065|Biological|sipuleucel-T|Given IV
314052|NCT01807065|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
314053|NCT01807065|Other|laboratory biomarker analysis|Correlative studies
314054|NCT01807052|Other|laboratory biomarker analysis|Correlative studies
314055|NCT01807039|Procedure|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
314056|NCT01807026|Drug|LY2886721|
314057|NCT01807026|Drug|Placebo|
314058|NCT01807013|Procedure|ultrasound, liver elastometry, minilaparoscopy|"conventional high-end ultrasound technique,~small access laparoscopy with fine laparoscopes~Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity."
314059|NCT01807000|Drug|Radiolabeled Prucalopride Succinate|A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
314060|NCT01806987|Behavioral|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
314061|NCT01806974|Other|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
314062|NCT01806948|Drug|Ramosetron|
314063|NCT01806935|Device|DC086|
314064|NCT01806935|Device|Placebo|
314065|NCT01806922|Behavioral|Yoga|
314066|NCT01806909|Biological|Ad4-H5-Vtn|
314069|NCT01806896|Drug|PF-02545920|"5mg dose~Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
314070|NCT01806896|Drug|Placebo|"Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days."
314071|NCT01806883|Behavioral|WII Rehabilitation|"30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects."
314072|NCT01806883|Behavioral|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
314073|NCT01806870|Dietary Supplement|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
314074|NCT01806857|Drug|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
314075|NCT01806857|Drug|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
314076|NCT01806831|Device|"Biocellulose Mask, Farhorm®"|
314077|NCT01806818|Drug|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
314078|NCT01806805|Drug|zonegran|
314079|NCT01806805|Drug|placebo|
314080|NCT01806792|Drug|risedronate combine|
314081|NCT01806792|Drug|Risedronate|
314082|NCT01806792|Drug|Placebo(for Risedronate)|
314083|NCT01806792|Drug|Placebo(for risedronate combine)|
314084|NCT01806779|Drug|Chantix|
314085|NCT01806779|Drug|Zyban|
314086|NCT01806779|Drug|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
314087|NCT01806766|Procedure|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
314088|NCT01806766|Procedure|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
314089|NCT01806753|Procedure|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.~First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.~When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).~If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
314090|NCT01806753|Procedure|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.~First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.~Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.~When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.~If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
314091|NCT01806740|Drug|Gadoterate meglumine|Gadoterate meglumine was administered at a dose of 0.1 mmol/kg (0.2 mL/kg) using a power injector, in an intravenous bolus at a rate of 3 mL/sec.
314092|NCT01806727|Behavioral|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
314093|NCT01806727|Behavioral|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
314094|NCT01806714|Other|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
314095|NCT01806714|Other|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
314096|NCT01806701|Behavioral|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
314097|NCT01806688|Other|snack|
314098|NCT01806675|Drug|18F-fludeoxyglucose (18F-FDG)|18F-FDG will be used as the radiotracer for a regular medical care PET/CT or PET/MRI scan
314099|NCT01806675|Drug|18F-FPPRGD2|18F-FPPRGD2 will be used as the radiotracer for a PET/CT or PET/MRI scan. Participants will be injected with less than 10 mCi of 18F-FPPRGD2.
314100|NCT01806662|Drug|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
314101|NCT01806662|Other|Placebo|Injection of placebo
314102|NCT01806649|Drug|BKM120|
314103|NCT01806636|Device|PneumRx Coil System|
314104|NCT01806623|Drug|Fluconazole|Single oral dose of 150mg Fluconazole
314105|NCT01806610|Drug|BPS804|Single dose BPS804 administration.
314106|NCT01806610|Drug|Placebo|Single dose placebo administration.
314107|NCT01806597|Biological|secukinumab 150 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
314108|NCT01806597|Biological|secukinumab 300 mg|Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
314109|NCT01806597|Biological|Placebo|Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
314110|NCT01806584|Biological|SRM003|One time implant (3 SRM003 pieces) on surgery day.
314111|NCT01806584|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
314117|NCT01806558|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
314118|NCT01806545|Biological|SRM003|One time implant (2 SRM003 pieces) on surgery day.
314119|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
314120|NCT01806519|Behavioral|Motor control intervention of head posture|"The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.~The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage"
314121|NCT01806506|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
314122|NCT01806506|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
314123|NCT01806480|Behavioral|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
314124|NCT01806454|Drug|calcium|
314125|NCT01806441|Other|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
314126|NCT01806441|Other|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
314127|NCT01806415|Drug|Fenobam|Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
314128|NCT01806415|Drug|Placebo|Oral administration of placebo or lactose 150 mg
314129|NCT01806376|Drug|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
314130|NCT01806363|Drug|Telmisartan 80mg|
314131|NCT01806363|Drug|Chlorthalidone 25mg|
314132|NCT01806350|Other|questionnaire administration|Ancillary studies
314133|NCT01806350|Procedure|standard follow-up care|Receive usual care
314134|NCT01806350|Other|educational intervention|Undergo PFMT
314135|NCT01806337|Drug|Alemtuzumab|Consolidation after CHOP induction
314136|NCT01806324|Drug|HL040XC|single dose
314137|NCT01806324|Drug|Losartan + Atorvastatin|Single dose
314138|NCT01806311|Drug|Candesartan32mg|
314139|NCT01806311|Drug|Amlodipine10mg|
314140|NCT01806298|Drug|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
314141|NCT01806272|Drug|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
314142|NCT01806272|Drug|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
314143|NCT01806259|Drug|Ketorolac 30 mg IV|
314144|NCT01806246|Behavioral|integrative rehabilitation program|
314145|NCT01806233|Procedure|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
314146|NCT01806233|Procedure|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
314147|NCT01806220|Procedure|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
314148|NCT01806220|Procedure|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
314149|NCT01806207|Device|Durolane injection|
314150|NCT01806207|Other|Saline injection|
314151|NCT01806194|Behavioral|Lifestyle Counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers
314152|NCT01806194|Behavioral|Educational Control Arm|16 mailings of diabetes educational materials but no regular contact with community health workers
314153|NCT01806181|Other|Exercise|
314154|NCT01806168|Device|rTMS|Magstim Super Rapid-2
314155|NCT01806142|Other|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
314156|NCT01806142|Other|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
314157|NCT01806129|Other|educational intervention|Undergo reproductive health program
314158|NCT01806129|Other|questionnaire administration|Ancillary studies
314159|NCT01806129|Procedure|quality-of-life assessment|Ancillary studies
314160|NCT01806116|Drug|decitabine|
314161|NCT01806103|Behavioral|Antimicrobial Stewardship Bundle|Guidelines, Education, Audit and Feedback
314162|NCT01806090|Drug|clopidogrel|Clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
314163|NCT01806090|Other|Placebo|Placebo for 7 days prior to the endoscopic procedure (Colonoscopy)
314164|NCT01806077|Drug|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
314165|NCT01806064|Drug|TRC105 and Axitinib|
314166|NCT01806064|Drug|Axitinib|
314167|NCT01806051|Drug|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
314168|NCT01806038|Other|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
314169|NCT01806038|Other|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
314170|NCT01806025|Other|no intervention|
314171|NCT01806012|Device|Sealing tissue with the Enseal device|
314172|NCT01806012|Procedure|Conventional supracervical hysterectomy|
314173|NCT01805999|Dietary Supplement|7 g Ispaghula|
314174|NCT01805999|Dietary Supplement|7 g placebo|
314175|NCT01805999|Dietary Supplement|3.5g Ispaghula + 3.5 g placebo|
314176|NCT01805973|Behavioral|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
314177|NCT01805960|Biological|Canakinumab|
314178|NCT01805960|Biological|Placebo|
314179|NCT01805947|Behavioral|Lifestyle Modification|Lifestyle Modification
314180|NCT01805934|Drug|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
314181|NCT01805934|Drug|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
314182|NCT01805921|Biological|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10^10 vp
314183|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10^8 pfu
314184|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10^10 vp
314185|NCT01805921|Biological|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10^9 vp
314186|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10^7 pfu
314187|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10^9 vp
314188|NCT01805908|Other|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
314189|NCT01805895|Drug|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
314190|NCT01805882|Drug|Sofosbuvir|
314191|NCT01805882|Drug|Ledipasvir|
314192|NCT01805882|Drug|GS-9669|
314193|NCT01805882|Drug|GS-9451|
314194|NCT01805856|Drug|PIPC piperacillin sodium|
314195|NCT01805856|Drug|CEZ, cefazolin sodium|
314196|NCT01805843|Other|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
314197|NCT01805830|Drug|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
314198|NCT01805830|Drug|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
314199|NCT01805817|Drug|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
314200|NCT01805817|Device|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
314201|NCT01805817|Device|levonorgestrel-releasing system|intrauterine device
314202|NCT01805804|Drug|placebo/valsartan|
314203|NCT01805791|Drug|HMPL-004 tablet|
314204|NCT01805791|Drug|Placebo|Placebo tablets will be used in the placebo arm of the study.
314205|NCT01805765|Drug|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
314206|NCT01805765|Drug|Placebo|Containing 2% of Qing'E pills
314207|NCT01805752|Other|Task-shifting to lower-cadre providers at PMTCT sites|
314208|NCT01805752|Other|POC CD4+ cell count testing|
314209|NCT01805752|Other|integrated mother-infant care|
314210|NCT01805752|Other|Prominent role for influential family members (male partners) in collaboration with CHWs|
314211|NCT01805726|Drug|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
314212|NCT01805726|Drug|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
314213|NCT01805726|Drug|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
314214|NCT01805700|Other|Caffeine enhanced energy drink|Comparison of different energy drinks
314215|NCT01805700|Other|Glucose drink|Glucose drink (containing 84mg glucose alone)
314216|NCT01805687|Drug|Zileuton extended release|
314217|NCT01805674|Dietary Supplement|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
314218|NCT01805661|Procedure|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
314219|NCT01805661|Procedure|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
314249|NCT01805401|Device|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
314220|NCT01805648|Drug|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10^9/L～100×10^9/L.
314221|NCT01805635|Other|No intervention|No intervention
314222|NCT01805622|Behavioral|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
314223|NCT01805609|Behavioral|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture & discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff & that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
314224|NCT01805609|Behavioral|questionnaires|
314225|NCT01805596|Drug|clopidogrel|
314226|NCT01805596|Drug|Ticagrelor|
314227|NCT01805583|Other|Acceptance and Commitment Therapy (ACT)|
314228|NCT01805583|Other|workplace intervention (WPI)|
314229|NCT01805570|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
314230|NCT01805570|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
314231|NCT01805557|Drug|R-DHAP|"Rituximab 375 mg/sqm iv day 0 or 1~Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~Dexamethasone 40 mg day 1-4~Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
314232|NCT01805557|Drug|BR-DHAP|"Rituximab 375 mg/sqm iv day 0 or 1~Bortezomib SC 1.5 mg/sqm day 1, day 4~Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion~Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3~Dexamethasone 40 mg day 1-4~Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)~Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
314233|NCT01805544|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
314234|NCT01805531|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
314235|NCT01805518|Dietary Supplement|Scelectium Tortuosum|"One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.~The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d."
314236|NCT01805505|Procedure|Transvaginal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound
314237|NCT01805505|Procedure|Transabdominal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
314238|NCT01805492|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
314239|NCT01805479|Other|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
314240|NCT01805479|Other|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
314241|NCT01805466|Device|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
314242|NCT01805466|Device|Conventional CPB|conventional miniature cardiopulmonary bypass technique
314243|NCT01805453|Drug|Losartan|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg*2/day until the halting for any reason
314244|NCT01805453|Drug|Placebo|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
314250|NCT01805388|Drug|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
314251|NCT01805388|Procedure|Control Non-Study Drug Group|Endodontic RTC with no study drug
314252|NCT01805375|Drug|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
314253|NCT01805362|Other|Randomization that determine the time of treatment|
314254|NCT01805349|Radiation|Hand X-rays|Hand X-rays to assess the digital arthrosis
314255|NCT01805336|Other|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
314256|NCT01805336|Other|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
314257|NCT01805336|Other|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
314258|NCT01805336|Other|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
314259|NCT01805336|Other|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
314260|NCT01805323|Drug|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
314261|NCT01805310|Other|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
314262|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
314263|NCT01805297|Drug|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
314264|NCT01805297|Other|Standard Vitrectomy|Surgical intervention
314265|NCT01805284|Drug|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
314266|NCT01805271|Drug|Everolimus|(5 or 10mg/day, i.e. 1 or 2 tablets/day)
314267|NCT01805271|Drug|Placebo|
314268|NCT01805258|Drug|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
314269|NCT01805258|Drug|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
314270|NCT01805245|Behavioral|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
314271|NCT01805232|Drug|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
314272|NCT01805232|Drug|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
314273|NCT01805219|Other|GPS and accelerometer recording (s) during exercises|
314274|NCT01805206|Other|Assessment of urinary iFABP|
314275|NCT01805206|Other|Administration of enteral feedings|
314276|NCT01805193|Other|Computed tomography myocardial perfusion imaging|
314277|NCT01805193|Other|Oxygen 15 labelled water positron emission tomography|
314278|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
314279|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
314280|NCT01805167|Other|Electrophysiological study of the interindividual variability of vocal performance|
314281|NCT01805154|Device|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
314282|NCT01805128|Other|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
314283|NCT01805128|Other|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
314284|NCT01805128|Other|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
314285|NCT01805115|Drug|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
314286|NCT01805115|Drug|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
314287|NCT01805115|Drug|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
314288|NCT01805115|Drug|Control|The control group was not given any cervical priming agents or placebo.
314289|NCT01805089|Drug|Melatonin 3 mg|Melatonin vs. Placebo
314290|NCT01805076|Procedure|Breast surgery|
314291|NCT01805076|Procedure|Magnetic resonance imaging|
314292|NCT01805076|Procedure|Mammography|
314293|NCT01805063|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
314294|NCT01805063|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
314295|NCT01805050|Procedure|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
314296|NCT01805037|Drug|brentuximab vedotin|Given IV
314297|NCT01805037|Biological|rituximab|Given IV
314298|NCT01805037|Other|laboratory biomarker analysis|Correlative studies
314299|NCT01805024|Drug|Omigapil|Cohort 1 0.02 mg/kg/day Cohort 2 0.08 mg/kg/day Cohort 3a 0.04 mg/kg/day Cohort 3b 0.06 mg/kg/day
314300|NCT01805011|Other|minimum 4 months of breastfeeding|
314301|NCT01804998|Procedure|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
314302|NCT01804998|Procedure|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
314303|NCT01804985|Drug|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
314304|NCT01804985|Drug|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
314305|NCT01804985|Drug|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
314306|NCT01804972|Other|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
314307|NCT01804972|Other|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
314308|NCT01804959|Dietary Supplement|Vivomixx probiotics|
314309|NCT01804946|Drug|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
314310|NCT01804946|Drug|Oseltamivir|Safety and Efficiency in treatment of Influenza
314311|NCT01804933|Drug|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
314312|NCT01804920|Dietary Supplement|D-serine|
314313|NCT01804920|Dietary Supplement|Placebo|
314314|NCT01804907|Behavioral|Cognitive Behavioral Therapy|
314315|NCT01804907|Behavioral|Behavioral Modification|
314316|NCT01804881|Behavioral|Lifestyle counseling|Six week program to address problematic eating
314317|NCT01804868|Other|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
314318|NCT01804868|Other|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
314319|NCT01804855|Behavioral|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
314320|NCT01804855|Device|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
314321|NCT01804842|Drug|Met DR|metformin delayed-release tablets
314322|NCT01804829|Biological|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
314323|NCT01804816|Procedure|Acupuncture|Standardized acupuncture administration for 10 sessions.
314324|NCT01804816|Other|No Intervention|No intervention during this period. This was a control period. Each subject acted as their own control.
314325|NCT01804803|Procedure|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|"Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS)."
314326|NCT01804803|Procedure|Use of regular glucometer|
314327|NCT01804790|Drug|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles: oxaliplatin: 85 mg/m² in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m² simultaneously in 2 hours at D1 during the irinotecan infusion 5-FU: 2400 mg/m² continuous infusion during 48 hours (1200 mg/m² at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800 mg/m² twice a day 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on ypTNM and center choice.
314328|NCT01804790|Radiation|Radiotherapy 50Gy|5 radiations per week of 2 Gy for 5 weeks
314329|NCT01804790|Drug|Capecitabine|1600 mg/m² (800 mg/m² twice daily) for 5 weeks
314330|NCT01804790|Procedure|TME surgery|
314658|NCT01802320|Other|Pharmacological Study|Correlative studies
314659|NCT01802307|Radiation|Brachytherapy|
314331|NCT01804790|Drug|mFolfox6 or capecitabine|oxaliplatine 85 mg/m² (day 1 of cycle; perfusion in 2h), folinic acid 400 mg/m² (day 1 of cycle perfusion in 2h), 5-FU (bolus 4OO mg/m² in 10 min and 2400 mg/m² perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500 mg/m²/day (Each cycle consists of 1250 mg/m² twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
314332|NCT01804777|Drug|Amiloride|"Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet."
314333|NCT01804777|Drug|HCTZ|"HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.~On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet"
314334|NCT01804738|Other|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
314335|NCT01804738|Other|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
314336|NCT01804712|Drug|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
314337|NCT01804686|Drug|PCI-32765 (Ibrutinib)|PCI-32765 (Ibrutinib) will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent PCI-32765 clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
314338|NCT01804673|Drug|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
314339|NCT01804660|Other|No study treatments administered|
314340|NCT01804647|Other|No study treatments administered - blood draws only|
314341|NCT01804634|Drug|Cyclophosphamide|preparative regimen
314342|NCT01804634|Drug|Fludarabine|
314343|NCT01804634|Radiation|low dose total body irradiation|
314344|NCT01804634|Drug|Melphalan|
314345|NCT01804634|Drug|Tacrolimus|
314346|NCT01804621|Behavioral|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
314347|NCT01804608|Other|Strength|
314348|NCT01804608|Other|Sensorimotor|
314349|NCT01804595|Other|Sunscreen|
314350|NCT01804595|Behavioral|Text-Message Reminders|
314351|NCT01804595|Other|Sunscreen and Text Message Reminders|
314352|NCT01804595|Behavioral|Education|
314353|NCT01804582|Other|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:~(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
314354|NCT01804569|Other|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
314355|NCT01804556|Procedure|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 ~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
314356|NCT01804543|Drug|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
314357|NCT01804530|Drug|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
314358|NCT01804504|Behavioral|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
314359|NCT01804491|Other|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
314360|NCT01804478|Behavioral|Mild pneumatic compression|
314361|NCT01804465|Drug|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.~SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
314362|NCT01804465|Drug|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
314363|NCT01804452|Other|Observational Study|
314364|NCT01804413|Drug|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
314365|NCT01804413|Drug|Regular insulin|0.1-0.15 units/kg
314366|NCT01804400|Drug|QAW039|
314367|NCT01804400|Drug|Montelukast|
314368|NCT01804400|Drug|Placebo|
314369|NCT01804387|Drug|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
314370|NCT01804387|Drug|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
314371|NCT01804374|Drug|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
314372|NCT01804374|Drug|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
314373|NCT01804361|Drug|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
314374|NCT01804361|Drug|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
314375|NCT01804348|Device|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
314376|NCT01804335|Drug|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
314377|NCT01804322|Other|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:~The cause and nature of the adverse event and/or drug interaction~The tolerability profile of each drug present in the schedule~The clinical manifestations associated with the current drug interactions~Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule~The reasons for and the potential benefits of the suggested treatment change~An encouragement to withdraw any potentially interfering or contraindicated drug"
314378|NCT01804322|Other|usual care|usual care according to the participating Epilepsy Centers
314379|NCT01804309|Procedure|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
314380|NCT01804296|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
314381|NCT01804283|Procedure|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult~Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
314382|NCT01804283|Procedure|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
314383|NCT01804283|Device|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
314384|NCT01804283|Device|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
314385|NCT01804270|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
314386|NCT01804257|Other|Digital Health Feedback System|The digital health offering passively collects and records medication-taking behavior and other habits of daily living
314387|NCT01804244|Drug|TMC278|1 25-mg tablet [27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
314388|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
314389|NCT01804218|Drug|Nadolol|
314390|NCT01804218|Drug|Placebo|
314391|NCT01804205|Drug|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
314392|NCT01804205|Drug|Placebo|100 ml of 0.9% physiological saline, for 10 min, and then continuous intravenous infusion of saline at a rate of 33 ml/h during the surgical procedure until the maximum of 3 h
314393|NCT01804192|Other|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
314394|NCT01804179|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
314395|NCT01804179|Other|Standard Intervention (SI) Educational Materials|"Screen for Life brochure"
314396|NCT01804179|Other|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
314397|NCT01804179|Other|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
314709|NCT01801891|Other|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
314398|NCT01804179|Other|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
314399|NCT01804166|Drug|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
314400|NCT01804166|Drug|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
314401|NCT01804153|Drug|Adipose-derived expanded stem cells|Intralesional application ASC
314402|NCT01804127|Drug|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
314403|NCT01804114|Procedure|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
314404|NCT01804114|Procedure|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
314405|NCT01804101|Other|Laboratory Biomarker Analysis|Correlative studies
314406|NCT01804101|Drug|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
314407|NCT01804088|Device|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
314408|NCT01804075|Drug|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
314409|NCT01804075|Drug|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
314410|NCT01804049|Drug|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
314411|NCT01804049|Drug|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
314412|NCT01804036|Drug|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
314413|NCT01804036|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
314414|NCT01804023|Other|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.~Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
314415|NCT01804010|Drug|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
314416|NCT01803997|Behavioral|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
314417|NCT01803984|Device|MRI|
314418|NCT01803984|Device|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
314419|NCT01803984|Other|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
314420|NCT01803971|Other|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
314421|NCT01803958|Radiation|partial breast irradiation|
314422|NCT01803958|Radiation|whole breast irradiation|
314423|NCT01803945|Drug|AVE8112|
314424|NCT01803945|Drug|Placebo|
314425|NCT01803932|Behavioral|Male-focused group violence prevention intervention|
314426|NCT01803919|Device|Silver Alloy-Coated Urinary Catheters|
314427|NCT01803919|Device|Conventional Urinary Catheter|
314428|NCT01803880|Device|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
314429|NCT01803880|Device|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
314430|NCT01803867|Drug|rHIgM22|Administered via IV infusion
314431|NCT01803841|Procedure|Transradial coronary angiography and intervention|
314432|NCT01803841|Procedure|Transfemoral coronary angiography and intervention|
314433|NCT01803828|Drug|Tadalafil|20 mg/die (1 capsule)
314434|NCT01803828|Drug|Placebo|Placebo 20 mg/die (1 capsule)
314435|NCT01803802|Behavioral|Expressive writing|Five sessions of 30 minutes of expressive writing
314436|NCT01803789|Device|Single Kirschner Wire|
314437|NCT01803789|Device|Double Kirschner Wire|
314438|NCT01803776|Behavioral|lifestyle counseling|Lifestyle intervention is based on Finnish exercise and nutrition recommendations. The children and their parents in the intervention group undergo intensive individual family-based exercise and diet intervention. They meet an exercise specialist and an authorized nutritionist, who give detailed and individualized instructions on health promoting physical activity and nutrition at months 0, 1.5, 3, 6, 12, 18, and 24 with a specific topic at each visit. After the 2-year intensive intervention period the intervention continues with yearly physical activity and dietary counseling sessions. Group-based exercise and cooking clubs are part of intervention.
314439|NCT01803763|Drug|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
314440|NCT01803763|Drug|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
314484|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
314710|NCT01801878|Biological|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
314711|NCT01801878|Biological|Normal saline|Normal saline inject to the half of irradiated breast
314441|NCT01803750|Behavioral|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
314442|NCT01803737|Behavioral|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
314443|NCT01803737|Behavioral|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
314444|NCT01803711|Drug|Desvenlafaxine|
314445|NCT01803711|Dietary Supplement|Omega 3 Fatty acids|
314446|NCT01803711|Drug|Placebo (for Omega 3 fatty acid supplement)|
314447|NCT01803698|Behavioral|Training in the use of IOM charts|
314448|NCT01803672|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
314449|NCT01803672|Behavioral|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
314450|NCT01803659|Dietary Supplement|b-carotene|
314451|NCT01803659|Dietary Supplement|retinyl palmitate|
314452|NCT01803659|Dietary Supplement|placebo|
314453|NCT01803646|Drug|AM-101|AM-101 gel for intratympanic injection
314454|NCT01803646|Drug|Placebo|Placebo gel for intratympanic injection
314455|NCT01803633|Other|Cheddar cheese|Tillamook medium cheddar cheese brand
314456|NCT01803633|Other|Vegan cheese|Daiya brand vegan cheese
314457|NCT01803607|Drug|odanacatib|odanacatib 50 mg oral tablet
314458|NCT01803607|Other|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
314459|NCT01803594|Dietary Supplement|Krill Oil|Neptune Krill Oil Gold
314460|NCT01803594|Dietary Supplement|Lutein|Jarrow Formulas
314461|NCT01803594|Dietary Supplement|Nicotinic acid|Natures Way
314462|NCT01803594|Dietary Supplement|Dairy phospholipids|PC700 manufactured by Fonterra
314463|NCT01803594|Other|Control|Control shake without dietary supplements
314464|NCT01803581|Other|X92001327|
314465|NCT01803581|Other|RID shampoo|
314466|NCT01803568|Other|Exercise|12 weeks of exercise; 4 times pr week
314467|NCT01803555|Drug|Budesonide/Formoterol SPIROMAX®|
314468|NCT01803555|Drug|SYMBICORT® TURBOHALER®|
314469|NCT01803542|Radiation|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
314470|NCT01803529|Other|heat-pack with massage|
314471|NCT01803529|Other|heat-pack only|
314472|NCT01803516|Behavioral|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
314473|NCT01803503|Drug|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
314474|NCT01803503|Drug|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
314475|NCT01803477|Drug|once daily for two consecutive days (Picato)|
314476|NCT01803464|Device|Low-magnitude vibration|Children will receive a daily low-magnitude vibration treatment.
314477|NCT01803464|Drug|Botox|Children who are candidates to receive Botox as part of their standard of care.
314478|NCT01803451|Drug|exendin-(9-39)|hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
314479|NCT01803451|Drug|exendin -(9-39)|2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
314480|NCT01803438|Device|cryoballoon ablation system|
314481|NCT01803438|Drug|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
314482|NCT01803425|Other|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
314483|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
314644|NCT01802372|Behavioral|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
314712|NCT01801865|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan
314485|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
314486|NCT01803399|Drug|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
314487|NCT01803399|Drug|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
314488|NCT01803399|Drug|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
314489|NCT01803399|Drug|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
314490|NCT01803386|Device|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
314491|NCT01803373|Drug|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
314492|NCT01803373|Drug|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
314493|NCT01803373|Drug|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
314494|NCT01803360|Drug|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
314495|NCT01803347|Drug|◦Drug: ASCs. + fibrin glue|Experimental group
314496|NCT01803347|Drug|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
314497|NCT01803334|Other|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
314498|NCT01803321|Drug|rilonacept (IL-1 Trap)|
314499|NCT01803321|Other|Placebo|
314500|NCT01803308|Drug|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
314501|NCT01803308|Drug|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
314502|NCT01803308|Drug|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
314503|NCT01803295|Device|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
314504|NCT01803295|Other|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
314505|NCT01803295|Device|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
314506|NCT01803282|Drug|Andecaliximab|Administered intravenously
314507|NCT01803282|Drug|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
314508|NCT01803282|Drug|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
314509|NCT01803282|Drug|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
314510|NCT01803282|Drug|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
314511|NCT01803282|Drug|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
314512|NCT01803282|Drug|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
314513|NCT01803282|Drug|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
314514|NCT01803282|Drug|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
314515|NCT01803282|Drug|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
314516|NCT01803282|Drug|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
314517|NCT01803269|Drug|topotecan hydrochloride|Given IV
314518|NCT01803269|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
314519|NCT01803243|Other|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
314520|NCT01803243|Other|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
314521|NCT01803243|Other|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
314522|NCT01803230|Dietary Supplement|creatine supplementation|creatine supplementation
314523|NCT01803230|Dietary Supplement|Placebo|
314524|NCT01803217|Other|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
314525|NCT01803204|Other|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
314526|NCT01803191|Drug|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
314527|NCT01803191|Drug|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
314528|NCT01803178|Dietary Supplement|Plant Sterols|
314529|NCT01803178|Dietary Supplement|Placebo Product|
314645|NCT01802372|Behavioral|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
314646|NCT01802359|Drug|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
314530|NCT01803165|Procedure|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
314531|NCT01803152|Biological|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
314532|NCT01803152|Biological|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
314533|NCT01803152|Drug|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
314534|NCT01803152|Drug|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
314535|NCT01803152|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
314536|NCT01803139|Device|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
314537|NCT01803113|Device|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
314538|NCT01803100|Other|No intervention|There is no intervention in this trial
314539|NCT01803087|Drug|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
314540|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
314541|NCT01803087|Drug|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
314542|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) (CTR)|
314543|NCT01803074|Drug|BMS-955176|BMS-955176
314544|NCT01803074|Drug|Placebo matching with BMS-955176|Placebo matching with BMS-955176
314545|NCT01803074|Drug|Atazanavir|Atazanavir
314546|NCT01803074|Drug|Ritonavir|Ritonavir
314547|NCT01803074|Drug|Tenofovir|Tenofovir
314548|NCT01803074|Drug|Emtricitabine|Emtricitabine
314549|NCT01803061|Behavioral|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
314550|NCT01803035|Drug|LTX-109 1 %|
314551|NCT01803035|Drug|LTX-109 2 %|
314552|NCT01803035|Drug|Placebo gel|
314553|NCT01803009|Behavioral|Patient views NCI CRC RAT|
314554|NCT01803009|Behavioral|View presentation regarding current chance of having an advanced adenoma|
314555|NCT01802996|Drug|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
314556|NCT01802970|Drug|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
314557|NCT01802957|Other|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
314558|NCT01802957|Other|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
314559|NCT01802957|Other|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
314560|NCT01802957|Other|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
314561|NCT01802957|Other|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
314647|NCT01802346|Dietary Supplement|dietary intervention|Consume a low-calorie diet
314648|NCT01802346|Procedure|nutritional support|Receive dietary advice
314649|NCT01802346|Other|laboratory biomarker analysis|Correlative studies
314650|NCT01802333|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
314562|NCT01802957|Other|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
314563|NCT01802957|Other|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
314564|NCT01802957|Other|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
314565|NCT01802944|Drug|Intranasal Insulin|
314566|NCT01802944|Drug|Placebos|
314567|NCT01802931|Drug|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
314568|NCT01802931|Drug|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
314569|NCT01802918|Drug|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
314570|NCT01802918|Drug|Placebo|Visually matching GSK2838232
314571|NCT01802918|Drug|Ritonavir|100mg tablets once daily for 12 days
314572|NCT01802905|Genetic|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
314573|NCT01802892|Drug|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
314574|NCT01802892|Drug|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
314575|NCT01802892|Drug|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
314576|NCT01802879|Drug|Panobinostat|single agent panobinostat starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications are at the discretion of the investigator based on guidance provided in the protocol and IB.
314577|NCT01802866|Drug|ACU-4429|Take orally once daily for 24 months
314578|NCT01802866|Drug|Placebo|Take orally once daily for 24 months
314579|NCT01802853|Drug|RO6811135|Single subcutaneous dose
314580|NCT01802853|Drug|RO6811135|Single intravenous dose
314581|NCT01802840|Dietary Supplement|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
314582|NCT01802814|Drug|SR-A + Epratuzumab|
314583|NCT01802814|Drug|SR-B + Epratuzumab|
314584|NCT01802801|Other|embryo development|intra- and inter-observator analysis
314585|NCT01802788|Device|St Jude Medical Portico replacement aortic valve|
314586|NCT01802788|Procedure|Transcatheter Aortic Valve Implant|
314587|NCT01802775|Drug|edoxaban|
314588|NCT01802775|Drug|Clopidogrel|75mg tablet
314589|NCT01802775|Drug|Aspirin|
314590|NCT01802762|Device|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
314591|NCT01802749|Drug|Bevacizumab|
314592|NCT01802749|Drug|Paclitaxel|
314593|NCT01802749|Drug|Carboplatin|
314594|NCT01802749|Drug|pegylated liposomal doxorubicin|
314595|NCT01802749|Drug|Gemcitabine|
314596|NCT01802736|Behavioral|Motivational intervention counselling plus SPP|
314597|NCT01802723|Drug|Drug: salmeterol xinafoate|
314598|NCT01802723|Drug|Drug: Placebo|
314599|NCT01802710|Behavioral|Psychological support|
314600|NCT01802710|Other|No intervention|
314601|NCT01802697|Drug|IdeS|
314602|NCT01802697|Drug|Placebo|
314603|NCT01802684|Biological|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
314604|NCT01802671|Other|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
314605|NCT01802671|Behavioral|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:~Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.~Cognitive restructuring techniques~Behavioural therapy and activity pacing~Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
314651|NCT01802333|Drug|Cytarabine|Given IV
314652|NCT01802333|Drug|Daunorubicin Hydrochloride|Given IV
314653|NCT01802333|Drug|Idarubicin|Given IV
314654|NCT01802333|Other|Laboratory Biomarker Analysis|Correlative studies
314655|NCT01802333|Drug|Vorinostat|Given PO
314606|NCT01802671|Behavioral|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
314607|NCT01802658|Drug|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
314608|NCT01802658|Drug|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
314609|NCT01802645|Drug|Cetuximab|
314610|NCT01802645|Drug|Bevacizumab|
314611|NCT01802645|Drug|Irinotecan|
314612|NCT01802645|Drug|Oxaliplatin|
314613|NCT01802645|Drug|5-FU|
314614|NCT01802645|Drug|Folinic Acid|
314615|NCT01802632|Drug|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
314616|NCT01802619|Other|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
314617|NCT01802619|Other|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
314618|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
314619|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks"
314620|NCT01802580|Behavioral|Internet Survey|
314621|NCT01802580|Drug|fluocinonide 0.05% ointment|
314622|NCT01802567|Device|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
314623|NCT01802554|Behavioral|Pleasant Events Program (PEP)|Behavioral Activation Therapy
314624|NCT01802554|Behavioral|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
314625|NCT01802541|Dietary Supplement|diacylglycerol oil|
314626|NCT01802541|Dietary Supplement|triacylglycerol oil|
314627|NCT01802515|Drug|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
314628|NCT01802515|Drug|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
314629|NCT01802515|Drug|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
314630|NCT01802502|Drug|Rifampicin intravenous|
314631|NCT01802502|Drug|Oral rifampicin|
314632|NCT01802489|Drug|Amiloride|
314633|NCT01802489|Drug|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
314634|NCT01802476|Drug|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
314635|NCT01802476|Drug|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
314636|NCT01802450|Drug|Dasatinib|
314637|NCT01802437|Drug|Fluoxetine|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increase in therapy (4 extra therapy sessions) or fluoxetine therapy. Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter. If no treatment response was observed by the sixth week, the dosage could be increased to 40 mg per day.
314638|NCT01802437|Behavioral|Increased Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores do not meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be further randomized to an increased dose of interpersonal psychotherapy (4 extra therapy sessions) or fluoxetine.
314639|NCT01802437|Behavioral|Continue to Receive Initial Dose of Interpersonal Psychotherapy|If Hamilton Rating Scale for Depression scores meet target reductions (20% reduction for 4-week decision point or 40% reduction for 8-week decision point), adolescents will be assigned to continue initial dose of interpersonal psychotherapy.
314640|NCT01802424|Behavioral|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
314641|NCT01802411|Drug|Liposome bupivacaine|
314642|NCT01802411|Drug|Placebo|
314643|NCT01802385|Drug|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
314656|NCT01802320|Drug|Akt Inhibitor MK2206|Given PO
314657|NCT01802320|Other|Laboratory Biomarker Analysis|Correlative studies
314660|NCT01802294|Behavioral|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.~Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.~The program is manualized in isiXhosa."
314661|NCT01802281|Procedure|Uterosacral ligament suspension|The USLS procedure used in this protocol is a modification of the technique described by Shull.
314662|NCT01802281|Procedure|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
314663|NCT01802268|Drug|Conversion from Tacrolimus to Sirolimus|
314664|NCT01802268|Drug|Maintenance on tacrolimus|
314665|NCT01802255|Drug|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
314666|NCT01802255|Drug|Midazolam|Intravenous sedation.
314667|NCT01802242|Radiation|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:~Arm 1: VMAT delivery with integrated VMAT boost (IB‐VMAT) GTV: 95Gy in 38fractions~Arm 2: HDR‐boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
314668|NCT01802242|Other|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI‐guided prostate biopsy at 3 years and PSA per standard practice
314669|NCT01802229|Procedure|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
314670|NCT01802229|Procedure|Fascial suture|The port-site hole is closed with simple suture of the fascia
314671|NCT01802216|Procedure|Scaling and root planing|non-surgical periodontal disease treatment
314672|NCT01802216|Drug|Minocycline|antibiotic microspheres
314673|NCT01802203|Device|truFreeze Spray Cryotherapy|spray cryotherapy
314674|NCT01802190|Genetic|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
314675|NCT01802177|Procedure|UVB excimer light|
314676|NCT01802164|Device|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
314677|NCT01802151|Dietary Supplement|B. subtilis R0179|B. subtilis R0179 for a period of 4 weeks. One capsule per day.
314678|NCT01802151|Dietary Supplement|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
314679|NCT01802138|Biological|Activated T lymphocyte|intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour.
314680|NCT01802125|Other|laboratory biomarker analysis|Correlative studies
314681|NCT01802112|Dietary Supplement|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
314682|NCT01802112|Other|placebo|15gr placebo
314683|NCT01802099|Other|Enteral nutrition|
314684|NCT01802099|Other|Parenteral nutrition|
314685|NCT01802086|Drug|Emla-cream|Topical anaesthetic
314686|NCT01802086|Drug|Miniderm cream|Topical
314687|NCT01802073|Drug|Oral Vancomycin|
314688|NCT01802047|Procedure|milk expression with electric pump|
314689|NCT01802021|Drug|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.~maximal for 6 months"
314690|NCT01802008|Procedure|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
314691|NCT01802008|Procedure|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
314692|NCT01801982|Other|non-interventional|non-interventional
314693|NCT01801969|Other|Rehabilitation service|"Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
314694|NCT01801956|Behavioral|physical activity|free membership of a sport club
314695|NCT01801956|Other|Motivational interview|Four motivational interviews by instructors of the local sport club
314696|NCT01801956|Other|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
314697|NCT01801943|Behavioral|Cognitive Remediation Therapy Group|30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week
314698|NCT01801943|Behavioral|Walking Intervention (WI) Group|60 min Walking Intervention + 30 min low interface reading 3x week
314699|NCT01801943|Behavioral|Combination Group|30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week
314700|NCT01801943|Behavioral|Healthy Living Group|60 Min Healthy Living class + 30 min low interface reading 3x week
314701|NCT01801930|Drug|OCV-103 and OCV-104|0.3 mg of each
314702|NCT01801930|Drug|OCV-103 and OCV-104|1 mg of each
314703|NCT01801930|Drug|OCV-103 and OCV-104|3 mg of each
314704|NCT01801930|Drug|OCV-103 and OCV-104|6 mg of each
314705|NCT01801917|Drug|Placebo|Matching placebo tablet for oral administration
314706|NCT01801917|Drug|BAF312|BAF312 in 4 dosage strengths in tablet form: 0.25 mg, 0.5 mg, 1 mg, 2 mg for oral administration
314707|NCT01801904|Drug|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
314708|NCT01801891|Device|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
314713|NCT01801852|Biological|NKT cells|
315264|NCT01797302|Dietary Supplement|Vitamin D3|Tablet form
314714|NCT01801826|Device|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
314715|NCT01801813|Other|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
314716|NCT01801800|Procedure|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
314717|NCT01801787|Device|tDCS|active vs. sham tDCS left hemisphere
314718|NCT01801774|Drug|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
314719|NCT01801774|Drug|Placebo|
314720|NCT01801748|Dietary Supplement|oral wheat challenge|
314721|NCT01801735|Drug|Meloxicam Test Capsules|
314722|NCT01801709|Genetic|intracerebral administration of AAVrh.10cuARSA|
314723|NCT01801696|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
314724|NCT01801696|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
314725|NCT01801683|Other|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
314726|NCT01801670|Procedure|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
314727|NCT01801670|Procedure|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
314728|NCT01801644|Drug|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
314729|NCT01801631|Other|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
314730|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
314731|NCT01801605|Procedure|rTMS|Active session with stimulation and placebo session with fictive stimulation
314732|NCT01801566|Procedure|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
314733|NCT01801553|Other|Spinal manipulation|"-In the intervention group :~True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:~If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.~-In the control group:~Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
314734|NCT01801553|Other|sham spinal manipulation|
314735|NCT01801553|Other|Usual medical care|
314736|NCT01801540|Dietary Supplement|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
314737|NCT01801527|Behavioral|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
314738|NCT01801514|Device|Computed Tomography scan|Routine Computed Tomography scan
314739|NCT01801475|Drug|Ondansetron|Pregnant & non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
314740|NCT01801462|Other|Simulation-based training|
314741|NCT01801449|Drug|Rilonacept|
314742|NCT01801436|Drug|Bortezomib|Bortezomib 1.3 mg per (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
314743|NCT01801423|Drug|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at ~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
314744|NCT01801410|Device|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
314745|NCT01801410|Drug|Misoprostol|25mcg every 2 hours for maximum of 12 doses
314746|NCT01801397|Drug|osteoanabolic therapy|
314747|NCT01801384|Behavioral|Voucher-based incentives|
315401|NCT01796197|Procedure|Mastectomy|
315402|NCT01796197|Radiation|Radiation Therapy|
314748|NCT01801371|Drug|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
314749|NCT01801358|Drug|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
314750|NCT01801358|Drug|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
314751|NCT01801345|Other|Fatigued|
314752|NCT01801345|Other|Rested|
314753|NCT01801332|Dietary Supplement|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
314754|NCT01801332|Dietary Supplement|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
314755|NCT01801319|Device|Libra Deep Brain Stimulation System|
314756|NCT01801306|Device|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
314757|NCT01801293|Drug|GS-5806|
314758|NCT01801280|Drug|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
314759|NCT01801280|Drug|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
314760|NCT01801280|Drug|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
314761|NCT01801267|Procedure|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
314762|NCT01801267|Procedure|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
314763|NCT01801254|Other|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
314764|NCT01801254|Other|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
314765|NCT01801228|Drug|Eplerenone|
314766|NCT01801202|Device|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
314767|NCT01801189|Drug|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
314768|NCT01801189|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
314769|NCT01801176|Other|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
314770|NCT01801163|Drug|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
314771|NCT01801163|Radiation|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
314772|NCT01801150|Device|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
314773|NCT01801137|Drug|Everolimus (Afinitor®)|
314774|NCT01801124|Drug|EXPAREL|single dose 266 mg of undiluted EXPAREL
314775|NCT01801111|Drug|Erlotinib|Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.
314776|NCT01801111|Drug|Alectinib|Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
314777|NCT01801072|Drug|Levetiracetam|Details covered in Arm Descriptions.
314778|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video and brochure
314779|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video
314780|NCT01801059|Other|questionnaire administration|Ancillary studies
314781|NCT01801046|Drug|mitoxantrone hydrochloride|Given IV
314782|NCT01801046|Drug|cytarabine|Given IV
314783|NCT01801046|Procedure|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
314784|NCT01801046|Other|laboratory biomarker analysis|Correlative studies
314785|NCT01801020|Other|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
314786|NCT01801020|Other|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
314787|NCT01801007|Device|Flow Re-Direction Endoluminal Device|
314788|NCT01800968|Drug|Liraglutide|Active Drug
314789|NCT01800968|Drug|Placebo|Placebo
314872|NCT01800370|Drug|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
314873|NCT01800370|Drug|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
314790|NCT01800955|Device|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
314791|NCT01800955|Other|sham placebo resistive capacitive diathermy treatment|"The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group"
314792|NCT01800942|Drug|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
314793|NCT01800929|Device|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
314794|NCT01800916|Device|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
314795|NCT01800916|Device|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
314796|NCT01800916|Device|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
314797|NCT01800916|Device|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
314798|NCT01800903|Device|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
314799|NCT01800903|Device|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
314800|NCT01800903|Device|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
314801|NCT01800890|Device|Coloplast A|Coloplast A is a newly developed 2-piece ostomy appliance
314802|NCT01800890|Device|Coloplast B|Coloplast B is a newly developed 2-piece ostomy appliance
314803|NCT01800890|Device|Coloplast C|Coloplast C is a newly developed 2-piece ostomy appliance
314804|NCT01800890|Device|SenSura Click|The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
314805|NCT01800877|Drug|Vasopressors|
314806|NCT01800864|Other|obesity|
314807|NCT01800851|Other|Energy expenditure evaluation in calorimetric chamber|
314808|NCT01800838|Drug|silicon phthalocyanine 4|Given topically
314809|NCT01800838|Drug|photodynamic therapy|Undergo PDT
314810|NCT01800838|Other|pharmacological study|Correlative studies
314811|NCT01800838|Other|laboratory biomarker analysis|Correlative studies
314812|NCT01800825|Drug|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
314813|NCT01800825|Drug|Placebo|This will be an identical placebo comparator made of starch.
314814|NCT01800812|Biological|Injections of OM-174|
314815|NCT01800799|Drug|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
314816|NCT01800799|Drug|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
314817|NCT01800786|Device|CPAP|
314818|NCT01800773|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
314819|NCT01800773|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
314820|NCT01800760|Dietary Supplement|Probiotics|Probiotics once a day for three weeks.
314821|NCT01800747|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
314822|NCT01800734|Other|Clamp-Mixed Meal Arm|"Standard clinical parameters will be assessed in all patients.~Metabolic tests:~A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).~B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump~This test will determine the time courses of:~1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
314823|NCT01800721|Behavioral|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
314824|NCT01800721|Behavioral|SNAP Control|Behavioral: SNAP control 7 group sessions
314825|NCT01800708|Drug|Triamcinolone acetonide|
314826|NCT01800708|Drug|Prednisolone syrup|
314827|NCT01800695|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
314828|NCT01800695|Drug|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
314829|NCT01800695|Radiation|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
314830|NCT01800682|Drug|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
314831|NCT01800669|Other|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
314832|NCT01800669|Other|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
314833|NCT01800656|Procedure|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
314834|NCT01800656|Procedure|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
314902|NCT01800188|Procedure|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
314903|NCT01800188|Procedure|Meal test|A 3 hour standardized liquid meal test without dialysis
314904|NCT01800175|Device|Punctum Plug|
314835|NCT01800643|Other|Analyze the pharmacokinetics of busulfan for transplantation|"Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target."
314836|NCT01800630|Drug|Gemcitabine HCl Oral Formulation|
314837|NCT01800617|Drug|Liothyronine, Sodium|
314838|NCT01800604|Behavioral|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
314839|NCT01800604|Behavioral|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
314840|NCT01800604|Behavioral|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
314841|NCT01800604|Behavioral|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
314842|NCT01800591|Behavioral|Financial incentive|
314843|NCT01800578|Device|monitor for depth of hypnosis|"evaluation of depth of hypnosis~--------------------------------------------------------------------------------"
314844|NCT01800565|Other|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
314845|NCT01800565|Other|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
314846|NCT01800552|Procedure|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
314847|NCT01800539|Behavioral|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
314848|NCT01800526|Drug|N-Acetylcysteine|Oral and Intravenous administration of NAC
314849|NCT01800513|Procedure|Endometrial Biopsy|
314850|NCT01800513|Procedure|Sham Procedure|
314851|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
314852|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using escalating product prices
314853|NCT01800500|Other|questionnaire administration|Ancillary studies
314854|NCT01800500|Other|quality-of-life assessment|Ancillary studies
314855|NCT01800500|Other|laboratory biomarker analysis|Correlative studies
314856|NCT01800500|Other|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
314857|NCT01800500|Other|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
314858|NCT01800487|Drug|silymarin|140 mg three times a day for 4 weeks
314859|NCT01800487|Drug|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
314860|NCT01800461|Other|OPC-Stroke|Occupational therapy coaching intervention
314861|NCT01800461|Other|Usual care|Usual community care
314862|NCT01800435|Drug|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
314863|NCT01800435|Drug|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
314864|NCT01800422|Drug|telapristone acetate|Given orally
314865|NCT01800422|Other|placebo|Given orally
314866|NCT01800422|Procedure|therapeutic conventional surgery|Undergo surgical resection
314867|NCT01800422|Other|laboratory biomarker analysis|Correlative studies
314868|NCT01800422|Other|questionnaire administration|Ancillary studies
314869|NCT01800409|Device|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
314870|NCT01800396|Dietary Supplement|Milk protein|
314871|NCT01800396|Dietary Supplement|Milk protein rich in phospholipids|
315030|NCT01799031|Procedure|management of therapy complications|Receive standard of care
314874|NCT01800370|Other|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.~Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds."
314875|NCT01800370|Procedure|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
314876|NCT01800370|Other|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
314877|NCT01800357|Drug|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
314878|NCT01800357|Drug|placebo|infusion of plabcebo once a day and for 14 days
314879|NCT01800357|Drug|aspirin|infusion of aspirin (100mg) once a day for days
314880|NCT01800344|Device|LMA|
314881|NCT01800344|Device|Ultra|Ultra
314882|NCT01800331|Behavioral|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
314883|NCT01800318|Device|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
314884|NCT01800318|Behavioral|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
314885|NCT01800318|Device|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
314886|NCT01800318|Behavioral|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
314887|NCT01800305|Drug|Pegylated rhEPO|
314888|NCT01800305|Drug|EPIAO®|
314889|NCT01800292|Drug|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
314890|NCT01800279|Other|Physiotherapy Protocol|"Kinesitherapy~Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.~Tongue in the palate for all applied exercises.~Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).~Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.~Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
314891|NCT01800279|Other|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):~Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).~Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).~Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
314892|NCT01800266|Behavioral|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
314893|NCT01800253|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
314894|NCT01800253|Procedure|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
314895|NCT01800253|Procedure|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
314896|NCT01800253|Procedure|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
314897|NCT01800253|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
314898|NCT01800240|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
314899|NCT01800227|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
314900|NCT01800201|Behavioral|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use the GlowCaps, a remote monitoring and reminder pill bottle; (2) will be assigned an engagement advisor from the study team; (3) asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence; and (5) will determine their preferences for Way to Health platform communication methods during the study.
314901|NCT01800188|Procedure|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
314905|NCT01800162|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
314906|NCT01800162|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
314907|NCT01800162|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
314908|NCT01800149|Procedure|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
314909|NCT01800136|Device|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
314910|NCT01800110|Dietary Supplement|pomegranate juice|
314911|NCT01800097|Drug|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
314912|NCT01800097|Drug|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
314913|NCT01800084|Device|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
314914|NCT01800071|Drug|MVA-EBNA1/LMP2 vaccine|
314915|NCT01800045|Drug|Pitolisant|1 capsule in the morning before breakfast
314916|NCT01800045|Drug|Placebo|1 capsule in the morning before breakfast
314917|NCT01800019|Drug|Nicotine Replacement Therapy (NRT)|
314918|NCT01800019|Drug|Varenicline|
314919|NCT01800019|Behavioral|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.~People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
314920|NCT01800006|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
314921|NCT01799993|Drug|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
314922|NCT01799993|Drug|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
314923|NCT01799954|Biological|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
314924|NCT01799954|Biological|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
314925|NCT01799954|Biological|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
314926|NCT01799954|Biological|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
314927|NCT01799954|Biological|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
314928|NCT01799954|Biological|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
314929|NCT01799941|Drug|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
314930|NCT01799902|Drug|Solifenacin|Oral
314931|NCT01799889|Drug|Entospletinib|Tablet administered orally
314932|NCT01799889|Drug|Entospletinib SDD|SDD tablet administered orally
314933|NCT01799876|Procedure|Autologous Cell|
314934|NCT01799876|Procedure|Standard microfracture arthroscopic surgery|
314935|NCT01799863|Drug|Ketorolac trometamol 0.45% with carboxymethylcellulose|
314936|NCT01799863|Drug|Preservative free artificial tear|
314937|NCT01799850|Drug|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
314938|NCT01799850|Drug|placebo|placebo assigned randomly, double blind
314939|NCT01799837|Drug|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
314940|NCT01799824|Biological|ANT-1403|
314941|NCT01799824|Biological|placebo|
314942|NCT01799798|Drug|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
314943|NCT01799785|Behavioral|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
314944|NCT01799785|Other|Usual Care|
314945|NCT01799772|Behavioral|Comprehensive Behavioral Intervention|"Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.~Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.~Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.~Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
314946|NCT01799772|Other|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
314947|NCT01799759|Behavioral|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
314948|NCT01799759|Other|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
314949|NCT01799733|Other|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
314950|NCT01799733|Other|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
314951|NCT01799720|Dietary Supplement|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
314952|NCT01799720|Dietary Supplement|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
314953|NCT01799720|Drug|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
314954|NCT01799707|Behavioral|vision restoration training|visual stimuli repetitively presented to stimulate areas of residual vision. The training consists of luminance increment stimuli similar to perimetry and the task isa simple detection task (pressing a key whenever a target stimulus was detected).
314955|NCT01799707|Behavioral|Discrimination Training|the stimulus is a line segment (bar) which is always presented within the central ±5° visual field in one of four possible random orientations: horizontal, vertical, oblique to the right or oblique to the left. If the patient has visual field defects in this central area, 80% of the stimuli are presented in the intact part of the training region. The task is to identify the orientation of the line segment and press, as fast as possible, one of 4 assigned buttons on the keyboard.
314956|NCT01799694|Drug|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
314957|NCT01799681|Behavioral|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
314958|NCT01799681|Behavioral|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
314959|NCT01799629|Drug|Glycerin suppositories|
314960|NCT01799616|Drug|Pamidronate|
314961|NCT01799616|Other|Placebo|
314962|NCT01799603|Drug|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
314963|NCT01799590|Drug|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
314964|NCT01799577|Procedure|Laparoscopic surgery|Two methods will be compare
314965|NCT01799564|Procedure|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
314966|NCT01799551|Behavioral|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
314967|NCT01799538|Drug|albuterol inhaler|2 puffs of Metered Dose inhaler for Bronchodilation
314968|NCT01799538|Drug|albuterol nebulizer|Albuterol administered by nebulization will produce a greater increase in FEV1.
314969|NCT01799538|Procedure|PFT|Breathing Test
314970|NCT01799525|Procedure|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
314971|NCT01799512|Device|experimental: real-time continuous glucose monitoring|
314972|NCT01799512|Device|Active comparator: blinded continuous glucose monitoring|
314973|NCT01799499|Device|TC-3 hydrogel|
314974|NCT01799499|Device|TC-3 hydrogel|
314975|NCT01799499|Device|TC-3 hydrogel|
314976|NCT01799486|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
314977|NCT01799486|Drug|Enecavir|0.5 mg monotherapy supplied in tablets.
314978|NCT01799486|Drug|Adefovir|10 mg monotherapy supplied in tablets.
314979|NCT01799460|Drug|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
314980|NCT01799460|Drug|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
314981|NCT01799447|Behavioral|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
314982|NCT01799434|Other|treadmill run|
315443|NCT01795937|Drug|Itraconazole|twice daily
314983|NCT01799382|Other|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
314984|NCT01799382|Device|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
314985|NCT01799369|Behavioral|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
314986|NCT01799356|Drug|Moxifloxacin|daily 400 mg moksifloksasin
314987|NCT01799356|Drug|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
314988|NCT01799356|Drug|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
314989|NCT01799343|Other|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
314990|NCT01799330|Procedure|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
314991|NCT01799317|Drug|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
314992|NCT01799304|Procedure|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
314993|NCT01799304|Procedure|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
314994|NCT01799304|Procedure|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
314995|NCT01799304|Procedure|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
314996|NCT01799291|Behavioral|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
314997|NCT01799278|Drug|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
314998|NCT01799265|Device|Somnetics Transcend Auto|
314999|NCT01799265|Device|Respironics REMstar Auto with C-Flex|
315000|NCT01799239|Device|Test product|The test product consists of an adhesive with a new top film
315001|NCT01799239|Device|SenSura|SenSura is the CE-marked and commercially available comparator product
315002|NCT01799226|Other|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
315003|NCT01799226|Other|Triclosan|this intervention will use Colgate Total which contains triclosan
315004|NCT01799213|Drug|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
315005|NCT01799213|Behavioral|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
315006|NCT01799187|Procedure|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
315007|NCT01799187|Procedure|apexification|apexification uses calcium hydroxide as root medication
315008|NCT01799174|Procedure|UVA-1 Phototherapy|
315009|NCT01799174|Procedure|Placebo|
315010|NCT01799161|Biological|gp96-Ig Vaccine|
315011|NCT01799161|Drug|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
315012|NCT01799161|Other|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
315013|NCT01799161|Procedure|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response [frequency of CD4+, FoxP3 (Treg), et al] in treated patients.
315014|NCT01799148|Other|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
315015|NCT01799135|Other|DCE-MRI scan|
315016|NCT01799135|Radiation|Stereotactic Body Radiation Therapy|
315017|NCT01799135|Other|4D-CT scan|
315018|NCT01799122|Device|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
315019|NCT01799109|Drug|Magnesium Sulfate & albuterol|
315020|NCT01799109|Drug|albuterol|
315021|NCT01799109|Drug|magnesium|
315022|NCT01799096|Dietary Supplement|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
315023|NCT01799096|Dietary Supplement|Aspartame|Intensely sweetened soft drink (no energy content)
315024|NCT01799083|Drug|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
315025|NCT01799083|Biological|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
315026|NCT01799057|Drug|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
315027|NCT01799057|Drug|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
315028|NCT01799044|Device|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
315029|NCT01799031|Other|internet-based intervention|Receive access to the WISE web-based educational intervention
315031|NCT01799031|Other|educational intervention|Receive access to the WISE web-based educational intervention
315032|NCT01799031|Other|questionnaire administration|Ancillary studies
315033|NCT01799031|Procedure|quality-of-life assessment|Ancillary studies
315034|NCT01799005|Dietary Supplement|Flavanol (410 mg)|
315035|NCT01799005|Dietary Supplement|Control (no flavanols)|
315036|NCT01798992|Drug|Carvedilol|
315037|NCT01798992|Drug|Metoprolol succinate|
315038|NCT01798992|Drug|Metoprolol succinate + doxazosin|
315039|NCT01798979|Drug|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
315040|NCT01798979|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
315041|NCT01798966|Device|SENSIMED Triggerfish|
315042|NCT01798940|Drug|Torrent's Pioglitazone|
315043|NCT01798927|Device|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
315044|NCT01798914|Drug|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
315045|NCT01798901|Drug|HDAC inhibitor AR-42|Given PO
315046|NCT01798901|Drug|decitabine|Given IV
315047|NCT01798901|Other|laboratory biomarker analysis|Correlative studies
315048|NCT01798901|Other|pharmacological study|Correlative studies
315049|NCT01798888|Procedure|Implantation of Deep Brain Stimulation|
315050|NCT01798875|Drug|oral metformin|
315051|NCT01798875|Drug|oral contraceptive|
315052|NCT01798862|Procedure|Endometrial injury by hysteroscopy or pipelle sampling|
315053|NCT01798862|Procedure|Proceed to COH directly|
315054|NCT01798849|Drug|MK-8892|
315055|NCT01798849|Drug|Placebo for MK-8892|
315056|NCT01798836|Procedure|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
315057|NCT01798836|Procedure|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
315058|NCT01798823|Procedure|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
315059|NCT01798810|Procedure|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
315060|NCT01798784|Behavioral|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
315061|NCT01798784|Behavioral|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
315062|NCT01798784|Behavioral|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
315063|NCT01798771|Procedure|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
315064|NCT01798771|Procedure|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
315065|NCT01798745|Drug|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
315066|NCT01798745|Other|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
315067|NCT01798732|Procedure|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
315068|NCT01798719|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
315069|NCT01798719|Behavioral|General Advice|Only general advice about diet
315070|NCT01798706|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
315071|NCT01798706|Drug|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning~Route of administration: Subcutaneous injection"
315072|NCT01798706|Drug|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
315073|NCT01798693|Dietary Supplement|Placebo (maltodextrin)|
315074|NCT01798693|Dietary Supplement|Multi-nutrient Blend|
315075|NCT01798680|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
315076|NCT01798680|Other|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
315077|NCT01798667|Drug|DA-8031|
315078|NCT01798667|Drug|Placebo|Placebo of DA-8031, undistinguishable
315079|NCT01798641|Device|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
315080|NCT01798628|Drug|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
315081|NCT01798628|Drug|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
315082|NCT01798628|Drug|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
315083|NCT01798602|Drug|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
315084|NCT01798602|Drug|Placebo|Identical placebo for rosuvastatin
315085|NCT01798589|Drug|Ethylenediamine dihydrochloride|1 allergen panel containing 2 allergen and 2 control patches
315086|NCT01798576|Drug|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
315087|NCT01798576|Drug|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
315088|NCT01798550|Drug|Enoxaparin|Twice daily dosing
315089|NCT01798537|Drug|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
315090|NCT01798511|Procedure|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
315091|NCT01798511|Other|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
315092|NCT01798498|Device|Princess® VOLUME|
315093|NCT01798485|Drug|Docetaxel|Docetaxel, 75 mg/m^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
315094|NCT01798485|Drug|Ganetespib|Ganetespib, 150 mg/m^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
315095|NCT01798472|Procedure|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
315096|NCT01798472|Procedure|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
315097|NCT01798472|Procedure|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
315098|NCT01798472|Procedure|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
315099|NCT01798459|Drug|Methylphenidate|
315100|NCT01798446|Drug|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
315101|NCT01798433|Device|One stent technique alone|One stent technique alone with drug-eluting stent
315102|NCT01798433|Device|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
315103|NCT01798433|Procedure|Provisional approach|Provisional approach with drung-eluting stents
315104|NCT01798433|Device|Elective 2-stent|Elective 2-stent with drug-eluting stents
315105|NCT01798407|Device|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
315106|NCT01798407|Other|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
315107|NCT01798394|Drug|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
315108|NCT01798394|Other|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
315109|NCT01798381|Dietary Supplement|Essential fatty acids|
315110|NCT01798368|Device|PBASE system 2.0|
315111|NCT01798355|Behavioral|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
315112|NCT01798355|Behavioral|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
315113|NCT01798342|Dietary Supplement|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
315114|NCT01798342|Dietary Supplement|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
315115|NCT01798329|Dietary Supplement|probiotic VSL#3|"VSL#3 is a probiotic that reduces:~urease faecal activity~faecal pH~inflammatory cytokine"
315116|NCT01798316|Drug|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
315117|NCT01798316|Drug|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
315118|NCT01798303|Drug|LY2940094|Administered orally
315119|NCT01798303|Drug|Placebo|Administered orally
315120|NCT01798290|Behavioral|narrative medicine: reading workshop|
315121|NCT01798290|Behavioral|critical reading|
315122|NCT01798277|Procedure|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
315123|NCT01798277|Drug|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
315124|NCT01798264|Drug|ITCA 650 (exenatide in DUROS)|
315125|NCT01798251|Drug|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
315126|NCT01798251|Drug|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
315127|NCT01798238|Drug|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
315128|NCT01798238|Drug|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
315129|NCT01798225|Drug|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
315130|NCT01798225|Drug|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
315131|NCT01798212|Procedure|endoscopic full thickness plication|
315132|NCT01798199|Other|The training by Verve System|
315133|NCT01798186|Drug|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
315134|NCT01798173|Biological|Serum, plasma and DNA samples|
315135|NCT01798173|Procedure|Radiological exploration by CT scan or MRI|
315136|NCT01798160|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
315137|NCT01798160|Procedure|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
315138|NCT01798147|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
315139|NCT01798147|Procedure|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
315140|NCT01798134|Device|TANDEM™|
315141|NCT01798121|Biological|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
315142|NCT01798121|Biological|Reference standard|Response of reference standard material compared to Aplisol@.
315143|NCT01798108|Radiation|Radium-223 dichloride (BAY88-8223)|- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
315144|NCT01798095|Biological|Aplisol@ PPD material|Determine equivalency of materials
315145|NCT01798095|Biological|Reference Standard|Reference standard material for comparison to newly produced materials.
315146|NCT01798082|Other|Pelvic organ prolapse decision aid|
315147|NCT01798069|Behavioral|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
315148|NCT01798069|Behavioral|reading medical publication workshops|
315149|NCT01798056|Biological|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
315150|NCT01798056|Drug|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
315151|NCT01798043|Other|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
315152|NCT01798043|Other|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
315153|NCT01798030|Other|Vitamin D|N/A, frozen specimen study
315154|NCT01798017|Drug|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
315155|NCT01798004|Drug|cyclophosphamide|Given IV
315156|NCT01798004|Drug|topotecan hydrochloride|Given IV
315157|NCT01798004|Drug|cisplatin|Given IV
315158|NCT01798004|Drug|etoposide|Given IV
315159|NCT01798004|Drug|vincristine sulfate|Given IV
315160|NCT01798004|Drug|doxorubicin hydrochloride|Given IV
315161|NCT01798004|Radiation|external beam radiation therapy|Undergo EBRT
315162|NCT01798004|Drug|busulfan|Given IV
315163|NCT01798004|Drug|melphalan|Given IV
315164|NCT01798004|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
315165|NCT01798004|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
315166|NCT01798004|Other|pharmacological study|Correlative studies
315167|NCT01798004|Other|laboratory biomarker analysis|Optional correlative studies
315168|NCT01798004|Biological|filgrastim|Given SC or IV
315169|NCT01798004|Drug|mesna|Given IV
315170|NCT01797991|Drug|Dexamethasone per os|
315171|NCT01797991|Drug|Matching placebo for dexamethasone IV|
315172|NCT01797991|Drug|Dexamethasone IV|
315173|NCT01797991|Drug|Matching placebo for dexamethasone per os|
315221|NCT01797653|Other|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
315174|NCT01797978|Drug|Intravenous methylene blue administration|Initial history taking and physical examination --> enrollment --> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
315175|NCT01797978|Drug|Placebo|
315176|NCT01797965|Drug|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
315177|NCT01797952|Drug|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
315178|NCT01797952|Other|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
315179|NCT01797926|Drug|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
315180|NCT01797926|Drug|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
315181|NCT01797926|Drug|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
315182|NCT01797926|Drug|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
315183|NCT01797913|Drug|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1&DAY8
315184|NCT01797900|Drug|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
315185|NCT01797900|Drug|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
315186|NCT01797900|Radiation|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
315187|NCT01797887|Behavioral|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
315188|NCT01797874|Drug|Pazopanib|Experimental
315189|NCT01797874|Drug|Placebo|placebo arm
315190|NCT01797861|Procedure|Half-dose photodynamic therapy (PDT)|"At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds."
315191|NCT01797861|Procedure|Micropulse laser (ML) treatment|"The following ML treatment settings will be used: a power of 1800 mW*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.~* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area."
315192|NCT01797848|Drug|Peginterferon alfa 2a|
315193|NCT01797848|Drug|Ribavirin|
315194|NCT01797848|Drug|Placebo matching Daclatasvir|
315195|NCT01797848|Drug|Daclatasvir|
315196|NCT01797835|Behavioral|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
315197|NCT01797835|Behavioral|usual care|Youth receive a brochure with information on AOD use.
315198|NCT01797822|Drug|dexamethasone, artificial tears|
315199|NCT01797809|Drug|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
315200|NCT01797796|Drug|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
315201|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
315202|NCT01797796|Drug|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
315203|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
315204|NCT01797783|Device|Nelfilcon A multifocal contact lens with comfort additive|
315205|NCT01797783|Device|Nelfilcon A multifocal contact lens|
315206|NCT01797770|Drug|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
315207|NCT01797770|Other|No Preparation|No laxatives or bowel preparation
315208|NCT01797757|Dietary Supplement|Fish oil enriched with EPA|
315209|NCT01797757|Dietary Supplement|MAG-EPA oil|
315210|NCT01797757|Drug|Orlistat|
315211|NCT01797744|Other|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
315212|NCT01797731|Device|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
315213|NCT01797731|Device|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
315214|NCT01797718|Drug|Testosterone|1mg/kg every 4 weeks for 6 months
315215|NCT01797718|Drug|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
315216|NCT01797705|Device|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
315217|NCT01797692|Other|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
315218|NCT01797679|Other|Strength Training|
315219|NCT01797679|Other|Aerobic Exercise|
315220|NCT01797666|Drug|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
315222|NCT01797653|Procedure|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
315223|NCT01797601|Drug|Human Insulin|160 U of insulin
315224|NCT01797601|Drug|Placebo|Insulin dilution medium without insulin
315225|NCT01797588|Procedure|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
315226|NCT01797588|Procedure|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
315227|NCT01797575|Drug|Aspirin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
315228|NCT01797575|Dietary Supplement|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
315229|NCT01797575|Drug|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
315230|NCT01797562|Drug|T.R.U.E. Test Panel 3.2|Surgical tape containing 12 polyester allergen patches.
315231|NCT01797536|Drug|Elbasvir|
315232|NCT01797523|Drug|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
315233|NCT01797523|Drug|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
315234|NCT01797523|Drug|Everolimus|10 mg by mouth once daily in a 28 day cycle.
315235|NCT01797510|Behavioral|Web Based Health Coaching|
315236|NCT01797497|Behavioral|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
315237|NCT01797484|Drug|Ranolazine|Improvement of myocardial microcirculation
315238|NCT01797471|Radiation|Lattice Extreme Ablative Dose (LEAD) Radiation Therapy|A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
315239|NCT01797458|Procedure|Hall Technique|"Technique:~Removal of dental plaque and rest of aliments from the cavity~Selection of the SSC~If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment~Dry the crown and fill with glass-ionomer luting cement~Place the crown over the tooth~Removal of cement excesses from the crown margins~The child should be asked to keep biting on the crown until the cement has set"
315240|NCT01797458|Procedure|Non-Restorative Caries Treatment|"Technique:~A high-speed bur should be used to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area~Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)~Show the cavity to patient/parents and give them tooth-brushing instructions~Tell to parents that good plaque control is the key for this treatment~The recall interval for these patients is every 3 months."
315241|NCT01797458|Procedure|Conventional Restoration|"Technique:~Local anesthesia should be used when needed~Perform complete caries removal and cavity preparation~Use a matrix band and a wedge to tightly hold the band against the tooth~Place the material (Compomer)~Check contacts and occlusion, and polish the restoration"
315242|NCT01797445|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
315243|NCT01797445|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
315244|NCT01797445|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
315245|NCT01797445|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
315246|NCT01797432|Drug|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
315247|NCT01797432|Device|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
315248|NCT01797419|Drug|GS-5806|Single dose, oral liquid, .5 mL/kg
315249|NCT01797419|Drug|Placebo|Single dose, oral liquid, .5 mL/kg
315250|NCT01797406|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
315251|NCT01797406|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
315252|NCT01797393|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
315253|NCT01797393|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
315254|NCT01797393|Other|" Air assisted water injection."|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
315255|NCT01797380|Drug|Placebo|Placebo daily for duration of double-blind portion of trial
315256|NCT01797380|Drug|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
315257|NCT01797354|Behavioral|Cognitive-behavioral therapy and hypnosis group|
315258|NCT01797354|Behavioral|Support group|
315259|NCT01797341|Drug|Tacrolimus|
315260|NCT01797341|Drug|Tacrolimus|
315261|NCT01797328|Procedure|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
315262|NCT01797328|Procedure|warm arm|To the best of ability avoid feeling cold during 6 weeks
315263|NCT01797315|Drug|Sirolimus|
315265|NCT01797289|Other|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
315266|NCT01797276|Drug|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
315267|NCT01797263|Other|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
315268|NCT01797263|Other|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
315269|NCT01797237|Device|PFNA|
315270|NCT01797237|Device|InterTAN|
315271|NCT01797211|Dietary Supplement|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
315272|NCT01797198|Drug|ASP3652|Oral
315273|NCT01797198|Drug|Gemfibrozil|Oral
315274|NCT01797198|Drug|Repaglinide|Oral
315275|NCT01797185|Drug|SPARC1104 modified dose regimen I|Subjects who exited study CLR_09_21
315276|NCT01797185|Drug|SPARC1104 modified dose regimen II|Subjects who received prior treatment regimen I
315277|NCT01797185|Drug|SPARC1104 modified dose regimen III|Subjects who received no prior treatment regimen
315278|NCT01797172|Procedure|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
315279|NCT01797172|Procedure|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
315280|NCT01797159|Radiation|Hippocampal-sparing Prophylactic Cranial Irradiation|Hippocampal-sparing Prophylactic Cranial Irradiation
315281|NCT01797146|Procedure|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.~Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.~Type and duration of urinary catheter use.~Indication of urinary catheter _________~Type and duration of central venous catheter use~Indication of urinary catheter _________~Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
315282|NCT01797133|Procedure|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
315283|NCT01797133|Procedure|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
315284|NCT01797120|Drug|Fulvestrant|"Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
315285|NCT01797120|Drug|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.~If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
315286|NCT01797120|Drug|Placebo|Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
315287|NCT01797107|Drug|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
315288|NCT01797094|Biological|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
315289|NCT01797094|Biological|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
315290|NCT01797081|Biological|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
315291|NCT01797081|Biological|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
315292|NCT01797081|Other|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
315293|NCT01797068|Behavioral|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
315294|NCT01797068|Other|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
315295|NCT01797055|Drug|Human apotransferrin|intravenous infusion
315296|NCT01797042|Behavioral|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
315297|NCT01797029|Biological|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
315298|NCT01797029|Biological|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
315299|NCT01797003|Other|High tibial osteotomy|
315300|NCT01796990|Behavioral|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.~The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
315301|NCT01796990|Behavioral|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
315302|NCT01796977|Device|OxyGenesys Dissolved Oxygen Dressing|
315303|NCT01796977|Device|Standard Gauze Dressing|
315304|NCT01796964|Drug|ESBA1008 solution|For intravitreal (IVT) injection
315305|NCT01796964|Drug|Aflibercept|For intravitreal (IVT) injection
315306|NCT01796951|Drug|Aspirin 325 mg daily|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
315307|NCT01796951|Drug|Celecoxib 200 mg BID|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
315308|NCT01796938|Drug|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
315309|NCT01796925|Device|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
315310|NCT01796912|Other|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
315311|NCT01796912|Other|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
315312|NCT01796899|Other|Brivaracetam 10 mg oral tablet|
315313|NCT01796899|Other|Brivaracetam 50 mg oral tablet|
315314|NCT01796899|Other|Brivaracetam 75 mg oral tablet|
315315|NCT01796899|Other|Brivaracetam 100 mg oral tablet|
315316|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
315317|NCT01796886|Other|pupillometry data|
315318|NCT01796860|Other|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
315319|NCT01796834|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
315320|NCT01796821|Drug|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application <1,500 mg gel per day."
315321|NCT01796821|Drug|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application <1,500 mg gel per day."
315322|NCT01796821|Drug|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.~Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.~Total application <1,500 mg gel per day."
315403|NCT01796171|Drug|Betalutin|Betalutin, 10 MBq/kg b.w. in escalated doses with 40 mg lilotomab pre-dosing
315404|NCT01796171|Drug|Betalutin|Betalutin, 15 MBq/kg b.w. in escalated doses without pre-dosing
315405|NCT01796171|Drug|Betalutin|Betalutin, 15 MBq/kg b.w. in escalated doses with rituximab pre-dosing
315406|NCT01796171|Drug|Betalutin|Betalutin, 15 MBq/kg b.w. in escalated doses with 100 mg/m2 lilotomab pre-dosing
315407|NCT01796171|Drug|Betalutin|Betalutin, 20 MBq/kg b.w. in escalated doses with 60 mg/m2 lilotomab pre-dosing
315323|NCT01796808|Procedure|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.~Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
315324|NCT01796808|Other|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.~Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot."
315325|NCT01796795|Drug|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
315326|NCT01796795|Drug|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
315327|NCT01796795|Drug|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
315328|NCT01796782|Drug|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
315329|NCT01796782|Drug|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
315330|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
315331|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
315332|NCT01796756|Other|Handover program|
315333|NCT01796730|Drug|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
315334|NCT01796730|Drug|Placebo|
315335|NCT01796717|Drug|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
315336|NCT01796717|Drug|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
315337|NCT01796678|Drug|Arginine|
315338|NCT01796678|Drug|Placebo|Saline or Sugar pill was given as placebo
315339|NCT01796665|Drug|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
315340|NCT01796665|Drug|Acanya Gel|
315341|NCT01796665|Drug|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
315342|NCT01796626|Device|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
315343|NCT01796613|Device|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
315344|NCT01796613|Device|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
315345|NCT01796600|Device|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
315346|NCT01796587|Device|LoFric Origo|
315347|NCT01796574|Dietary Supplement|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
315348|NCT01796561|Dietary Supplement|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
315349|NCT01796548|Drug|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
315350|NCT01796522|Drug|progesterone 200 mg / day vaginally|
315351|NCT01796522|Drug|nifedipine (60 mg / day orally)|
315352|NCT01796509|Other|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
315408|NCT01796171|Drug|Betalutin|Betalutin, 15 MBq/kg b.w. with 40mg lilotomab compared to Betalutin, 20 MBq/kg b.w. with 100 mg/m2 lilotomab
315444|NCT01795937|Drug|Atorvastatin|single dose
315445|NCT01795937|Drug|Faldaprevir|once daily
315353|NCT01796496|Other|Manipulative Therapy Techniques|"Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.~Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.~Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
315354|NCT01796496|Other|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
315355|NCT01796483|Device|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
315356|NCT01796483|Device|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
315357|NCT01796470|Drug|Entospletinib|Entospletinib tablets administered orally twice daily
315358|NCT01796470|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
315359|NCT01796444|Procedure|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
315360|NCT01796444|Procedure|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
315361|NCT01796444|Procedure|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
315362|NCT01796444|Procedure|Pathological Evaluation|H&E and IHC
315363|NCT01796444|Drug|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
315364|NCT01796444|Radiation|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
315365|NCT01796431|Drug|Eviplera®|
315366|NCT01796418|Drug|Beraprost sodium|
315367|NCT01796405|Drug|Clofarabine|
315368|NCT01796392|Device|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
315369|NCT01796392|Other|Optimal Medical Management|This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
315370|NCT01796379|Behavioral|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
315371|NCT01796379|Behavioral|Moderate Training|
315372|NCT01796366|Drug|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
315373|NCT01796366|Drug|placebo|S.c placebo administered in combination with insulin 338
315374|NCT01796366|Drug|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
315375|NCT01796366|Drug|placebo|Oral placebo administered in combination with s.c. insulin glargine
315376|NCT01796353|Other|sexual rehabilitation|exercise plus psycho-education
315377|NCT01796353|Other|Usual care|usual care
315378|NCT01796340|Behavioral|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
315379|NCT01796340|Behavioral|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
315380|NCT01796327|Drug|dacomitinib oral|Dacomitinib 45 mg oral tablet
315381|NCT01796327|Drug|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
315382|NCT01796314|Behavioral|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.~These collective sessions focus on :~Knowledge of the disease~Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia~Crisis situations. Prevention of caregiver's exhaustion~Assistive devices and care pathways.~Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
315383|NCT01796301|Drug|Romozosumab|Administered by subcutaneous injection once a month.
315384|NCT01796301|Drug|Teriparatide|Administered by subcutaneous injection once a day.
315385|NCT01796288|Radiation|simultaneous radiotherapy|
315386|NCT01796288|Drug|Erlotinib|
315387|NCT01796275|Behavioral|Core intervention program|
315388|NCT01796275|Behavioral|Booster session|
315389|NCT01796275|Behavioral|Control only (Tea gathering)|
315390|NCT01796262|Dietary Supplement|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
315391|NCT01796262|Dietary Supplement|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
315392|NCT01796236|Device|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
315393|NCT01796236|Device|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
315394|NCT01796223|Behavioral|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
315395|NCT01796223|Behavioral|Control|
315396|NCT01796197|Drug|Trastuzumab|
315397|NCT01796197|Drug|Pertuzumab|
315398|NCT01796197|Drug|Paclitaxel|
315399|NCT01796197|Drug|Doxorubicin|
315400|NCT01796197|Drug|Cyclophosphamide|
315409|NCT01796158|Behavioral|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
315410|NCT01796158|Behavioral|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
315411|NCT01796145|Other|Fibroscan|
315412|NCT01796132|Drug|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
315413|NCT01796119|Procedure|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
315414|NCT01796119|Procedure|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
315415|NCT01796106|Device|Icon|refer to instructions for use of Icon
315416|NCT01796106|Device|fluoride varnish|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish; Colgate Oral Pharmaceuticals, New York, NY, United States) to all study participants randomized to study arm 2 after the radiograph and visual exam. Topical fluoridation treatment will be provided is varnish (Duraphat) per manufacturer's instructions.
315417|NCT01796093|Drug|Digoxin and ivabradine|No more details
315418|NCT01796080|Other|Mueller manoeuvre|
315419|NCT01796080|Other|Inspiratory threshold|
315420|NCT01796080|Other|Expiratory apnoea|
315421|NCT01796080|Other|Steady state normal breathing|
315422|NCT01796067|Behavioral|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
315423|NCT01796067|Behavioral|Basic Health Education|This group will receive the comprehensive basic health education intervention.
315424|NCT01796067|Behavioral|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
315425|NCT01796067|Behavioral|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
315426|NCT01796054|Behavioral|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
315427|NCT01796054|Behavioral|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
315428|NCT01796041|Drug|Indocyanine Green|
315429|NCT01796028|Drug|METFORMIN|
315430|NCT01796028|Drug|Placebo|
315431|NCT01796028|Drug|TAXOTERE®|
315432|NCT01796015|Other|ONSD ultrasound|"Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).~For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.~At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.~As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned."
315433|NCT01796002|Drug|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
315434|NCT01796002|Drug|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
315435|NCT01795989|Device|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
315436|NCT01795976|Genetic|NY-ESO-1 T cells|
315437|NCT01795976|Drug|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
315438|NCT01795976|Drug|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
315439|NCT01795976|Biological|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
315440|NCT01795963|Behavioral|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
315441|NCT01795963|Behavioral|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
315442|NCT01795950|Drug|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
315446|NCT01795937|Drug|Rosuvastatin|single dose
315447|NCT01795937|Drug|Faldaprevir|once daily
315448|NCT01795924|Drug|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
315449|NCT01795911|Biological|Pegylated Interferon Lambda|
315450|NCT01795911|Drug|Ribasphere|
315451|NCT01795911|Drug|Daclatasvir|
315452|NCT01795898|Drug|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
315453|NCT01795885|Behavioral|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show."
315454|NCT01795872|Procedure|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
315455|NCT01795859|Drug|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
315456|NCT01795859|Drug|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
315457|NCT01795846|Other|Allergen specific immunotherapy and placebo injections|
315458|NCT01795833|Other|Short text messages|In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
315459|NCT01795820|Drug|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
315460|NCT01795820|Drug|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.~In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
315461|NCT01795794|Drug|omeprazole|
315462|NCT01795768|Drug|AZD 4547|
315463|NCT01795755|Behavioral|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
315464|NCT01795755|Behavioral|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
315465|NCT01795742|Device|Human-Powered Nebulizer|
315466|NCT01795729|Device|Stent|Coronary revascularization
315467|NCT01795729|Drug|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
315468|NCT01795716|Drug|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
315469|NCT01795716|Drug|Glivec|Single and multiple oral Glivec 400mg qd
315470|NCT01795703|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
315471|NCT01795703|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
315472|NCT01795677|Drug|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
315473|NCT01795664|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
315474|NCT01795664|Drug|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
315475|NCT01795664|Drug|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg~At visit 2 or visit 3 (cross-over design)"
315476|NCT01795664|Drug|Placebo of Test product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
315477|NCT01795664|Drug|Placebo of Reference product|"Single dose of 2 puffs~To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
315478|NCT01795651|Procedure|identification of take-home message of lecture|
315479|NCT01795638|Drug|Sodium chloride|
315480|NCT01795638|Drug|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
315481|NCT01795612|Other|physical activity|
315482|NCT01795599|Drug|Mifegyne ®|
315483|NCT01795599|Drug|Gymiso®|
315484|NCT01795586|Drug|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.~Level 1: 0.9 mg/m^2; Level 2: 1.1 mg/m^2; Level 3: 1.4 mg/m^2"
315485|NCT01795586|Drug|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
315486|NCT01795573|Biological|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
315487|NCT01795547|Drug|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
315488|NCT01795547|Drug|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
315489|NCT01795534|Dietary Supplement|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
315490|NCT01795534|Dietary Supplement|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
315491|NCT01795521|Radiation|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
315492|NCT01795508|Behavioral|PMTO|Parent Management Training, Oregon
315493|NCT01795508|Behavioral|TAU|Other kinds of family training
315494|NCT01795495|Drug|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
315495|NCT01795495|Drug|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
315496|NCT01795495|Drug|Remifentanil|
315497|NCT01795482|Device|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
315498|NCT01795469|Device|Zoex compression garment|5-strap compression of abdomen, thighs and legs
315499|NCT01795443|Other|Calibration|"Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.~The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range."
315500|NCT01795443|Other|Practice|"Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.~Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required."
315501|NCT01795443|Other|Measures - no vibration|"The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
315502|NCT01795443|Other|Measures - low vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
315503|NCT01795443|Other|Measures - high vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
315504|NCT01795430|Drug|etoposide|Given IV
315505|NCT01795430|Drug|ifosfamide|Given IV
315506|NCT01795430|Radiation|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
315507|NCT01795430|Drug|topotecan hydrochloride|Given IV
315508|NCT01795430|Drug|busulfan|Given IV
315509|NCT01795430|Drug|melphalan|Given IV
315510|NCT01795430|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
315511|NCT01795430|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
315512|NCT01795430|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
315513|NCT01795417|Device|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
315514|NCT01795417|Device|XP200 RF device|4 RF treatments of periorbital region on one side of the face
315515|NCT01795404|Behavioral|Inquiry Based Stress Reduction (IBSR)|
315650|NCT01794403|Behavioral|Memorial Anxiety Scale for Prostate Cancer patients|Memorial Anxiety Scale for Prostate Cancer patients quality of life questionnaire to be administered to study participants at protocol-defined intervals.
315988|NCT01791647|Drug|myoinositol 1500 mg|
315516|NCT01795378|Biological|donor natural killer cell infusion|"Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.~The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).~For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.~The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
315517|NCT01795365|Other|Active surveillance|
315518|NCT01795339|Drug|AZD3293|Oral solution
315519|NCT01795339|Drug|Placebo|Oral solution
315520|NCT01795313|Biological|HLA-A2 restricted synthetic tumor antigen|
315521|NCT01795313|Drug|Imiquimod|
315522|NCT01795313|Other|enzyme-linked immunosorbent assay|
315523|NCT01795313|Other|flow cytometry|
315524|NCT01795313|Other|immunohistochemistry staining method|
315525|NCT01795313|Other|laboratory biomarker analysis|
315526|NCT01795300|Radiation|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
315527|NCT01795300|Radiation|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.~The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
315528|NCT01795300|Radiation|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.~To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
315529|NCT01795300|Radiation|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
315530|NCT01795287|Procedure|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
315531|NCT01795287|Procedure|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
315532|NCT01795274|Radiation|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
315533|NCT01795248|Drug|Liraglutide|1.8 mg liraglutide
315534|NCT01795248|Drug|Placebo|Liraglutide without the GLP-1 analogue
315535|NCT01795235|Drug|Saline|Saline s.c.
315536|NCT01795235|Drug|Glucagon|Glucagon s.c.
315537|NCT01795235|Drug|Placebo|Sugar Pill
315538|NCT01795235|Drug|Atenolol|Beta-1 receptor antagonist
315539|NCT01795222|Drug|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
315540|NCT01795222|Drug|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
315541|NCT01795209|Drug|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg~Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
315542|NCT01795209|Device|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed~Stop criteria: V/A ≥20/20 and complete disappearance of macular edema~Retreatment: visual loss of 5 or more letter compared to previous visit"
315543|NCT01795209|Procedure|Rescue laser|"In the Lucentis group: performed if BCVA < 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6~In the standard of care group: performed if BCVA < 20/40 or CFT ≥ 350um from Month 3"
315544|NCT01795183|Drug|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
315699|NCT01794013|Behavioral|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
315700|NCT01794013|Behavioral|Routine care|routine care
315701|NCT01794000|Drug|Prasugrel|Administered orally
315702|NCT01794000|Drug|Placebo|Administered orally
315545|NCT01795170|Dietary Supplement|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) [23,24], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
315546|NCT01795170|Drug|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
315547|NCT01795157|Device|CCADSS|Questionnaire is transferred wireless to the physician's PC
315548|NCT01795157|Device|pen-paper|Questionnaire completed and transferred to the physician using standard methods
315549|NCT01795144|Drug|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
315550|NCT01795144|Drug|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
315551|NCT01795131|Dietary Supplement|Vitamin B12|
315552|NCT01795131|Dietary Supplement|Placebo|
315553|NCT01795092|Other|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
315554|NCT01795079|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
315555|NCT01795066|Device|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
315556|NCT01795053|Behavioral|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
315557|NCT01795053|Behavioral|Placebo open play session|
315558|NCT01795040|Dietary Supplement|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
315559|NCT01795027|Drug|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
315560|NCT01795027|Drug|S-1 single|16 courses S-1 single after d D2 resection
315561|NCT01795001|Other|No intervention|
315562|NCT01794988|Behavioral|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
315563|NCT01794988|Behavioral|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
315564|NCT01794988|Behavioral|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
315565|NCT01794988|Behavioral|NO TIVR|Control - no intervention
315566|NCT01794975|Drug|Ketamine|
315567|NCT01794975|Drug|Atomoxetine|
315568|NCT01794975|Other|Cold pressor test|
315569|NCT01794975|Drug|Placebo|
315570|NCT01794962|Other|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
315571|NCT01794962|Other|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
315572|NCT01794949|Device|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
315573|NCT01794936|Device|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
315574|NCT01794923|Drug|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
315575|NCT01794923|Drug|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
315576|NCT01794923|Drug|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
315577|NCT01794923|Drug|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
315578|NCT01794910|Other|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
315579|NCT01794897|Drug|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
315580|NCT01794897|Drug|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
315581|NCT01794884|Drug|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
315582|NCT01794884|Drug|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
315703|NCT01793987|Device|Coblation polypectomy|
315704|NCT01793961|Other|electroretinogram|
315705|NCT01793961|Other|contrast sensitivity tests|
315706|NCT01793948|Drug|metformin hydrochloride|Given PO
315707|NCT01793948|Other|placebo|Given PO
315583|NCT01794858|Other|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
315584|NCT01794845|Drug|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
315585|NCT01794845|Drug|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
315586|NCT01794845|Radiation|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
315587|NCT01794819|Device|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
315588|NCT01794806|Procedure|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
315589|NCT01794806|Procedure|Tooth extraction|Minimally traumatic single-rooted tooth extraction
315590|NCT01794793|Drug|Pasireotide|Administered subcutaneously in strengths 0.3mg, 0.6mg and 0.9mg. Doses to be taken BID or TID, dependent on parent study guidelines.
315591|NCT01794793|Drug|Cabergoline|Cabergoline tablet 0.5mg or 1.0mg taken by mouth once daily may be combined with subcutaneous formulation of pasireotide for Cushing's Disease or Acromegaly. Dose is dependent on parent study guidelines.
315592|NCT01794793|Drug|Pasireotide|Long Acting Release is administered by monthly injection. The strengths are 10mg, 20mg, 40mg and 60mg. All doses to be taken q28days. Strength is dependent on parent study guidelines.
315593|NCT01794780|Drug|LABA based treatment: indacaterol|LABA based treatment: indacaterol
315594|NCT01794780|Drug|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
315595|NCT01794780|Drug|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
315596|NCT01794780|Drug|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
315597|NCT01794780|Drug|theophylline based treatment|theophylline based treatment
315598|NCT01794780|Drug|Other treatment|"non-long-acting bronchodilators for COPD treatment, such treatments were classified as other treatments"
315599|NCT01794767|Drug|0,9% NaCl flush|Normal Saline solution
315600|NCT01794767|Drug|Heparin 50U/ml|Heparin solution
315601|NCT01794754|Other|Care as usual|
315602|NCT01794754|Other|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
315603|NCT01794741|Drug|Dymista Nasal Spray|
315604|NCT01794741|Drug|Fluticasone propionate nasal spray|
315605|NCT01794715|Procedure|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
315606|NCT01794702|Drug|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
315607|NCT01794702|Drug|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
315608|NCT01794702|Drug|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
315609|NCT01794702|Drug|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
315610|NCT01794689|Drug|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
315611|NCT01794689|Drug|Saline Placebo|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
315612|NCT01794689|Behavioral|Forced Awakenings|Participants will be awakened each hour during an 8 hour sleep opportunity period. One of the awakenings is for 60 minutes and randomly determined. The other 7 awakenings are for 20 minutes each, and are randomly scheduled to occur in either the first second or third tertile of each hour. The maximum total sleep time a participant will receive is 280 minutes.
315613|NCT01794689|Behavioral|Uninterrupted Sleep|Participants will receive an 8 hour period of undisturbed sleep
315614|NCT01794676|Genetic|Blood draw|Blood draw
315615|NCT01794663|Drug|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
315616|NCT01794663|Drug|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
315617|NCT01794650|Dietary Supplement|Meal composition|
315618|NCT01794624|Behavioral|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
315708|NCT01793948|Other|laboratory biomarker analysis|Correlative studies
315709|NCT01793935|Drug|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
315985|NCT01791673|Device|Ultrasound glaucoma treatment|Ultrasound glaucoma treatment with EYEOP1 device
315619|NCT01794624|Behavioral|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
315620|NCT01794611|Device|laryngoscopy|
315621|NCT01794598|Behavioral|Receiving educational material of depression care|The educational material provides patients about depression management
315622|NCT01794585|Behavioral|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
315623|NCT01794585|Behavioral|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
315624|NCT01794572|Drug|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
315625|NCT01794572|Biological|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
315626|NCT01794559|Device|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
315627|NCT01794546|Behavioral|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
315628|NCT01794533|Drug|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
315629|NCT01794533|Drug|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
315630|NCT01794520|Drug|Dexamethasone|Dexamethasone at defined dose and schedule for Venetoclax-Dexamethasone combination cohort.
315631|NCT01794520|Drug|ABT-199|ABT-199 dosed at cohort-defined dosing schedules
315632|NCT01794507|Drug|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
315633|NCT01794507|Drug|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
315634|NCT01794507|Drug|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
315635|NCT01794494|Procedure|Bypass surgery|Patients are treated with femoro-popliteal bypass
315636|NCT01794494|Procedure|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
315637|NCT01794481|Procedure|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.~There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
315638|NCT01794468|Other|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
315639|NCT01794455|Drug|Sertraline|50mg - 200mg daily
315640|NCT01794455|Drug|Candesartan|4mg - 32mg daily
315641|NCT01794429|Drug|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
315642|NCT01794429|Drug|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
315643|NCT01794416|Procedure|Thoracoscopic epicardial ablation|
315644|NCT01794416|Procedure|Endocardial catheter ablation|
315645|NCT01794416|Device|Implantable loop recorder|
315646|NCT01794403|Radiation|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
315647|NCT01794403|Radiation|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
315648|NCT01794403|Behavioral|Expanded Prostate Cancer Index Composite SF-12|The Expanded Prostate Cancer Index Composite SF-12 (EPIC-SF-12) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
315649|NCT01794403|Behavioral|International Prostate Symptom Score|International Prostate Symptom Score quality of life questionnaire to be administered to study participants at protocol-defined intervals.
315792|NCT01793090|Other|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
315793|NCT01793077|Drug|Depo-Eligard®|Subcutaneous
315651|NCT01794377|Behavioral|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:~30 sec at 120% of Vo2max,~1 min at 50% of Vo2max,~15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,~1 min at 50% of Vo2max.~The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
315652|NCT01794377|Behavioral|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).~Training three times per week for 5 months under supervision of an exercise physiologist.~Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).~Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
315653|NCT01794364|Drug|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
315654|NCT01794364|Other|placebo|Correspondingly, placebo doses will be administered as suspension.
315655|NCT01794351|Dietary Supplement|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
315656|NCT01794351|Other|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
315657|NCT01794338|Device|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
315658|NCT01794338|Device|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
315659|NCT01794325|Other|Trans-radial|Coronary angiography performed through trans-radial access
315660|NCT01794325|Other|Trans-femoral|Coronary angiography performed through trans-femoral access
315661|NCT01794312|Device|T4020|
315662|NCT01794312|Device|Vehicle|
315663|NCT01794299|Biological|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
315664|NCT01794286|Other|Provider bulletins|
315665|NCT01794286|Other|Trigger alerts|
315666|NCT01794273|Drug|ephedrine and phenylephrine|
315667|NCT01794260|Drug|Cream from Zingiber cassumunar Roxb. extract|
315668|NCT01794260|Drug|Placebo cream|
315669|NCT01794247|Drug|Magnesium sulfate|
315670|NCT01794247|Drug|Fentanyl|
315671|NCT01794247|Drug|Lidocaine|
315672|NCT01794221|Procedure|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
315673|NCT01794221|Procedure|stitches only|standard of care
315674|NCT01794208|Drug|FSH-GEX(TM)|
315675|NCT01794208|Drug|Gonal-f(R)|
315676|NCT01794195|Behavioral|Diffusion tensor imaging and fibres tracking|
315677|NCT01794182|Drug|RP-1127 (Glyburide for Injection)|Glyburide (5-chloro-N-(4-[N-(cyclohexylcarbamoyl) sulfamoyl]phenethyl)-2- methoxybenzamide) is an anti-diabetic medication in a class of medications known as sulfonylureas. RP-1127 is a formulation of glyburide designed for intravenous administration.
315678|NCT01794169|Drug|Azacitidine|
315679|NCT01794169|Drug|DA|
315680|NCT01794156|Behavioral|Cognitive behavior therapy|
315681|NCT01794156|Behavioral|Mindfulness-based stress reduction|
315682|NCT01794156|Behavioral|Inference-based therapy|
315683|NCT01794143|Drug|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
315684|NCT01794143|Drug|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
315685|NCT01794143|Drug|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
315686|NCT01794143|Drug|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
315687|NCT01794117|Drug|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If pustule formation persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4
315688|NCT01794104|Drug|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
315689|NCT01794091|Drug|Eplerenone|Eplerenone 25 mg daily for 6 months
315690|NCT01794091|Drug|Placebo|
315691|NCT01794078|Drug|Aminophylline 400 mg|Xanthine derivative
315692|NCT01794078|Drug|Ambrisentan 5 mg|Endothelin receptor antagonist
315693|NCT01794078|Other|Placebo|
315694|NCT01794052|Other|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.~The components of the interventions that we are developing are:~A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension~Treating patients as per a standard clinical guidelines~Giving health education to patients on lifestyle changes for better self-care~Optimizing the care pathways at the health facilities to enable better delivery of the intervention and~Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
315695|NCT01794039|Drug|Dexamethasone|Given PO
315696|NCT01794039|Drug|Lenalidomide|Given PO
315697|NCT01794039|Drug|Pomalidomide|Given PO
315698|NCT01794026|Procedure|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
315859|NCT01792674|Other|Off site simulation|
315710|NCT01793935|Drug|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
315711|NCT01793922|Procedure|PD|pneumodilation
315712|NCT01793922|Procedure|POEM|peroral endoscopic myotomy
315713|NCT01793909|Other|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
315714|NCT01793896|Behavioral|Control period|Analysis at recruitment and after a month without any intervention
315715|NCT01793896|Behavioral|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
315716|NCT01793896|Behavioral|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
315717|NCT01793896|Behavioral|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
315718|NCT01793883|Drug|40 mg Laninamivir Octanoate|
315719|NCT01793883|Drug|80 mg Laninamivir Octanoate|
315720|NCT01793883|Drug|Placebo|
315721|NCT01793870|Drug|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
315722|NCT01793870|Drug|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
315723|NCT01793870|Drug|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
315724|NCT01793857|Other|Data collection|Paper questionnaire
315725|NCT01793831|Procedure|FMT|Standard FMT
315726|NCT01793818|Biological|Tat Oyi|Three injections in the arm
315727|NCT01793792|Device|LVIS™ and LVIS™ Jr|The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
315728|NCT01793779|Procedure|cold water immersion|
315729|NCT01793779|Dietary Supplement|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
315730|NCT01793779|Dietary Supplement|Placebo|
315731|NCT01793766|Device|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
315732|NCT01793766|Device|Sham modulation|
315733|NCT01793753|Drug|Propofol|
315734|NCT01793740|Behavioral|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
315735|NCT01793727|Device|Glidescope videolaryngoscope|
315736|NCT01793701|Radiation|intensity modulated radiotherapy|"Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy).~This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial."
315737|NCT01793701|Procedure|Intracavitary brachytherapy|Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes
315738|NCT01793701|Drug|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
315739|NCT01793688|Drug|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).~Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
315740|NCT01793675|Procedure|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
315741|NCT01793662|Procedure|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
315742|NCT01793649|Drug|GS-5737|A single dose of GS-5737 in 2.8% saline
315743|NCT01793636|Drug|AZD2014|AZD2014 vs Everolimus
315744|NCT01793636|Drug|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
315745|NCT01793623|Other|atrial tissue|retrieval of discarded atrial tissue
315746|NCT01793610|Drug|Comparator-dose MDMA|Initial comparator-dose MDMA orally at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose MDMA.
315747|NCT01793610|Drug|Active Dose 1 MDMA|An initial dose of full-dose MDMA orally given at the start of each of two psychotherapy sessions and possibly followed a dose half the size of the initial dose of MDMA 1.5 to 2.5 hours later.
315748|NCT01793610|Drug|Active Dose 2 MDMA|
315749|NCT01793610|Behavioral|Psychotherapy|Psychotherapy conducted throughout main study
315750|NCT01793584|Procedure|Laparoscopic hysterectomy|LAVH, TLH
315751|NCT01793584|Procedure|Abdominal hysterectomy|TAH
315752|NCT01793571|Procedure|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
315753|NCT01793558|Procedure|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
315754|NCT01793519|Drug|Etanercept|Subcutaneous
315755|NCT01793519|Drug|Infliximab|Infusion
315756|NCT01793519|Drug|Adalimumab|Subcutaneous
315757|NCT01793519|Drug|Placebo|Matching Placebo
315758|NCT01793493|Other|Cognitive stimulation|"Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.~Meetings (each lasting about 2 hours) have a common structure:~body awakening (10 minutes)~cognitive stimulation (1 hour and a half) scheduled as follow:~temporospatial orientation~attentional abilities~one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)"
315759|NCT01793493|Other|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
315760|NCT01793480|Drug|Methadone|
315761|NCT01793454|Other|Fraction of inspired oxygen 40%|
315762|NCT01793454|Other|Fraction of inspired oxygen 80%|
315763|NCT01793441|Drug|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
315764|NCT01793441|Drug|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
315765|NCT01793428|Other|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
315766|NCT01793415|Drug|IodoCarb (r)|Powder, 3 grams daily for 28+-2 days
315767|NCT01793415|Other|Placebo|Non-iodinated activated charcoal 3 g daily for 28+-2 days
315768|NCT01793389|Procedure|Subepithelial connective tissue graft|
315769|NCT01793389|Procedure|Platelet Rich Fibrin|
315770|NCT01793363|Procedure|Tracheotomy|
315771|NCT01793350|Drug|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
315772|NCT01793337|Other|Exposure to cold environmental temperature (-20°C)|
315773|NCT01793311|Other|decaffeinated coffee|contains caffeine 0.5-2 mg
315774|NCT01793311|Other|regular dose coffee|contains 91.8 mg of caffeine
315775|NCT01793311|Other|high dose coffee|contains 144 mg of caffeine
315776|NCT01793298|Drug|ASM-024|Ascending doses of ASM-024
315777|NCT01793285|Drug|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.~This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
315778|NCT01793272|Other|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
315779|NCT01793259|Drug|methotrexate prefilled pen|
315780|NCT01793259|Drug|methotrexate prefilled syringe|
315781|NCT01793246|Device|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
315782|NCT01793233|Other|Laboratory Biomarker Analysis|Correlative studies
315783|NCT01793233|Other|Questionnaire Administration|Ancillary studies
315784|NCT01793220|Other|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
315785|NCT01793194|Other|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
315786|NCT01793155|Other|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
315787|NCT01793155|Other|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
315788|NCT01793142|Drug|Viviant|Viviant (Bazedoxifene) 20mg once daily
315789|NCT01793129|Device|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
315790|NCT01793129|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
315791|NCT01793090|Drug|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
315794|NCT01793064|Behavioral|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
315795|NCT01793064|Behavioral|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
315796|NCT01793051|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
315797|NCT01793051|Other|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
315798|NCT01793051|Behavioral|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
315799|NCT01793038|Drug|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
315800|NCT01793038|Drug|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
315801|NCT01793025|Biological|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
315802|NCT01792999|Device|Contrast-enhanced KBCT|Contrast-enhanced KBCT includes pre-contrast KBCT scan and post-contrast KBCT scan. After the pre contrast scan is completed, a bolus injection of a low osmolar, nonionic, iodinated 300mg of iodine per mL contrast agent, will be injected at a rate of approximately 2.0 mL/s, for a total injection time of approximately 30-60 seconds. 30-60 seconds after the contrast injection, the post-contrast scan will be acquired.
315803|NCT01792986|Behavioral|water-only 24-hour fasting once per week for 6 weeks|
315804|NCT01792947|Procedure|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
315805|NCT01792947|Behavioral|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
315806|NCT01792934|Drug|XELOX regimen according to standard procedures|
315807|NCT01792934|Drug|FOLFOX regimen according to standard procedures|
315808|NCT01792934|Procedure|Surgery|
315809|NCT01792934|Other|radiofrequency ablation (RFA)|
315810|NCT01792934|Other|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
315811|NCT01792934|Radiation|stereotactic body radiation therapy (SBRT)|
315812|NCT01792934|Drug|Bevacizumab|may be added to both regimens according to standard procedures
315813|NCT01792934|Procedure|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
315814|NCT01792921|Behavioral|COG - FUN|
315815|NCT01792908|Device|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
315816|NCT01792895|Procedure|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
315817|NCT01792895|Procedure|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
315818|NCT01792895|Procedure|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.~For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
315819|NCT01792856|Other|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
315820|NCT01792856|Other|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
315821|NCT01792843|Behavioral|data|"comparisons of clinical characteristics~comparisons of cognitive profiles~comparisons of grey matter density patterns~comparisons of EEG rhythms features"
315860|NCT01792661|Other|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
315861|NCT01792661|Other|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
315822|NCT01792830|Drug|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.~Patients without a history of diabetes and admission HbA1c < 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.~Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
315823|NCT01792830|Drug|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.~Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.~Patients with an HbA1c > 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
315824|NCT01792830|Drug|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
315825|NCT01792817|Device|GammaCore|Treatment with active gammacore vagus nerve stimulator
315826|NCT01792817|Device|Sham GammaCore device|Treatment with sham stimulator
315827|NCT01792804|Drug|Trimethoprim-Sulfamethoxazole|study drug 1
315828|NCT01792804|Drug|Clindamycin|study drug 2
315829|NCT01792804|Drug|Linezolid|study drug 3
315830|NCT01792804|Drug|Flucloxacillin|study drug 4
315831|NCT01792804|Drug|Cloxacillin|study drug 5
315832|NCT01792804|Drug|Vancomycin|study drug 6
315833|NCT01792804|Drug|Daptomycin|study drug 7
315834|NCT01792804|Drug|Cefazolin|study drug 8
315835|NCT01792791|Procedure|Tissue sample collection at the time of surgery|"Spanning surgery~A blood sample (32.5 ml)~joint aspirate (removal of synovial fluid) from both knees~urine sample~ORIF surgery~Joint aspirate (removal of synovial fluid) from both knees~A blood sample (32.5 ml)~Urine Sample~If patients only require one surgery, sample will be collected only once."
315836|NCT01792778|Device|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
315837|NCT01792778|Device|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
315838|NCT01792765|Other|Ultrasound guidance|Patient will have intraoperative ultrasound .
315839|NCT01792752|Behavioral|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
315840|NCT01792752|Behavioral|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
315841|NCT01792752|Behavioral|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
315842|NCT01792752|Behavioral|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
315843|NCT01792752|Behavioral|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
315844|NCT01792739|Drug|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
315845|NCT01792739|Drug|Placebo|"Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)"
315846|NCT01792726|Radiation|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
315847|NCT01792713|Drug|Sertaconazole 2% cream|
315848|NCT01792713|Drug|Placebo|
315849|NCT01792700|Drug|esomeprazole|
315850|NCT01792700|Drug|tripotassium dicitrate bismuthate|
315851|NCT01792700|Drug|metronidazole|
315852|NCT01792700|Drug|tetracycline|
315853|NCT01792700|Drug|moxifloxacin|
315854|NCT01792700|Drug|amoxicillin|
315855|NCT01792687|Drug|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
315856|NCT01792687|Drug|Abiraterone acetate|1,000 mg, oral, daily
315857|NCT01792687|Drug|Prednisone|5 mg, oral, daily
315858|NCT01792674|Other|In situ simulation|
315862|NCT01792661|Other|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
315863|NCT01792648|Other|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
315864|NCT01792648|Other|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
315865|NCT01792648|Other|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
315866|NCT01792635|Drug|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
315867|NCT01792635|Drug|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
315868|NCT01792622|Other|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
315869|NCT01792622|Other|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
315870|NCT01792609|Procedure|Maximum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
315871|NCT01792609|Procedure|Minimum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
315872|NCT01792596|Other|Pasta with protein|Pasta with Protein
315873|NCT01792596|Other|Pasta with Fiber|Pasta with Fiber
315874|NCT01792596|Other|Pasta|Pasta
315875|NCT01792583|Drug|Modafinil/armodafinil|
315876|NCT01792570|Drug|RPV + DRV/r|Switch to dual HAART
315877|NCT01792570|Drug|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
315878|NCT01792557|Drug|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
315879|NCT01792557|Procedure|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
315880|NCT01792557|Procedure|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
315881|NCT01792557|Procedure|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
315882|NCT01792544|Other|Statement|
315883|NCT01792544|Other|No Statement|
315884|NCT01792531|Behavioral|Parent training group|The More & Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More & Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
315885|NCT01792531|Behavioral|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
315886|NCT01792531|Behavioral|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
315887|NCT01792518|Drug|Placebo|
315888|NCT01792518|Drug|Linagliptin 5mg|
315889|NCT01792505|Biological|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
315890|NCT01792479|Drug|BIND-014|
315891|NCT01792466|Procedure|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
315892|NCT01792453|Other|Spring water|
315893|NCT01792414|Device|Sham TES|Neuroconn Eldith device
315894|NCT01792414|Device|Active TES|Neuroconn Eldith device
315895|NCT01792401|Drug|Probiotics|
315896|NCT01792401|Drug|Placebo|
315897|NCT01792388|Dietary Supplement|Vitamin D|Capsule Form
315898|NCT01792388|Dietary Supplement|Soya Bean oil|Capsule form
315899|NCT01792375|Procedure|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
315900|NCT01792375|Drug|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
315901|NCT01792362|Other|Weight loss diet|Control the patients diet to make them loosing weight
315902|NCT01792349|Behavioral|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
315903|NCT01792323|Drug|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
315943|NCT01791985|Drug|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).~AZD4547 will be given on an intermittent schedule of one week on / one week off.~*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
315989|NCT01791634|Procedure|proximal chevron osteotomy|
315904|NCT01792310|Drug|2-hydroxyoleic acid (2-OHOA/2OHOA)|"Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.~Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.~In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of 2-OHOA may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances."
315905|NCT01792297|Dietary Supplement|Bovine colostrum|
315906|NCT01792297|Dietary Supplement|Whey protein|
315907|NCT01792284|Drug|LY2605541|
315908|NCT01792284|Drug|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
315909|NCT01792271|Other|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
315910|NCT01792258|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
315911|NCT01792245|Device|Phototherapy|
315912|NCT01792232|Other|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
315913|NCT01792232|Other|Saline|Saline will be placed in the lung on day 1 of each triad
315914|NCT01792219|Other|Interprofessional collaboration in health care module|An educational module
315915|NCT01792206|Drug|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
315916|NCT01792206|Drug|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
315917|NCT01792180|Behavioral|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
315918|NCT01792167|Behavioral|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
315919|NCT01792115|Drug|Vitamin E 200 IU/d|Supplement-low dose
315920|NCT01792115|Drug|Vitamin E 400 IU/d|Supplement-intermediate dose
315921|NCT01792115|Drug|Vitamin E 800 IU/d|Supplement High Dose
315922|NCT01792115|Behavioral|Diet and Exercise|Diet and Exercise for all Arms of the study at baseline
315923|NCT01792102|Drug|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.~Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
315924|NCT01792089|Other|fat+protein meal|cream+ whey protein
315925|NCT01792089|Other|Fat + protein + 13C fructose meal|cream+ whey protein +13C fructose
315926|NCT01792089|Other|Fat+protein+13C fructose+glucose meal|Cream + whey protein + glucose:13C fructose mixture
315927|NCT01792089|Other|13C Fat + whey protein|cream labelled with 13C palmitate + whey protein
315928|NCT01792089|Other|13C Fat + whey protein + glucose+ glucose meal|cream labelled with 13C palmitate + whey protein + glucose:fructose mixture
315929|NCT01792063|Drug|Sevoflurane|
315930|NCT01792063|Drug|Sevoflurane|
315931|NCT01792050|Drug|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
315932|NCT01792050|Other|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
315933|NCT01792050|Drug|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
315934|NCT01792050|Drug|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
315935|NCT01792037|Drug|Etomidate|
315936|NCT01792037|Drug|Midazolam|
315937|NCT01792037|Drug|methylprednisolone|
315938|NCT01792024|Device|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
315939|NCT01792024|Procedure|magnetic resonance imaging|Undergo MR-guided LITT
315940|NCT01792011|Device|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
315941|NCT01791998|Procedure|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
315942|NCT01791998|Procedure|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
315944|NCT01791972|Drug|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
315986|NCT01791660|Device|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
315945|NCT01791972|Drug|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
315946|NCT01791959|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
315947|NCT01791959|Other|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
315948|NCT01791946|Procedure|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
315949|NCT01791946|Procedure|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
315950|NCT01791933|Drug|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
315951|NCT01791933|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
315952|NCT01791933|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10~20 acupoints 1-2times a week for more than 2 months
315953|NCT01791933|Procedure|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
315954|NCT01791920|Drug|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
315955|NCT01791920|Drug|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
315956|NCT01791907|Behavioral|Structured education in carbohydrate counting|
315957|NCT01791907|Behavioral|Structured education in healthy food choices and low glycemic index|
315958|NCT01791894|Drug|arsenic trioxide|Given IV
315959|NCT01791881|Drug|Hugeltox|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
315960|NCT01791881|Drug|Botulinum Toxin Type A(Botox®)|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
315961|NCT01791868|Drug|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
315962|NCT01791868|Drug|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
315963|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
315964|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
315965|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
315966|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
315967|NCT01791842|Drug|Tocilizumab|8 mg/kg/month
315968|NCT01791842|Drug|Placebo|
315969|NCT01791816|Drug|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.~If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
315970|NCT01791816|Drug|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
315971|NCT01791803|Behavioral|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
315972|NCT01791803|Drug|Nicotine|free one month supply after hospital discharge
315973|NCT01791790|Device|Stimulation|
315974|NCT01791790|Device|SHAM|no stimulation
315975|NCT01791777|Behavioral|SafeCare Coaching|This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
315976|NCT01791751|Drug|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
315977|NCT01791738|Procedure|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
315978|NCT01791725|Drug|ELND005|
315979|NCT01791725|Drug|Placebo|
315980|NCT01791712|Procedure|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
315981|NCT01791712|Procedure|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
315982|NCT01791699|Drug|Moxonidine|
315983|NCT01791699|Drug|Placebo|
315984|NCT01791686|Drug|CDX-1135|
315987|NCT01791647|Drug|metformin 1500 mg|
315990|NCT01791634|Procedure|proximal open wedge osteotomy with LPS system|
315991|NCT01791621|Other|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
315992|NCT01791608|Dietary Supplement|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
315993|NCT01791608|Dietary Supplement|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
315994|NCT01791608|Dietary Supplement|Milk without fortification without zinc|Milk without fortification
315995|NCT01791595|Drug|AZD3965|AZD3965 is available as 5, 10, 20 and 30mg capsules and patients took their dose orally once or twice every day of each 28 day cycle including a single dosing day at day-7 prior to Cycle 1 in Part 1 of the study. The RP2D for Part 2 of the study is 10mg BID. Patients can have up to 12 cycles of treatment if patient is benefitting.
315996|NCT01791556|Other|HIV-1 viral load testing|
315997|NCT01791543|Device|Intramural Needle Ablation Catheter|
315998|NCT01791517|Other|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
315999|NCT01791517|Other|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
316000|NCT01791517|Other|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
316001|NCT01791517|Other|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
316002|NCT01791504|Device|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
316003|NCT01791491|Drug|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
316004|NCT01791478|Drug|PI3K inhibitor BYL719|Given PO
316005|NCT01791478|Drug|letrozole|Given PO
316006|NCT01791478|Other|laboratory biomarker analysis|Correlative studies
316007|NCT01791478|Other|pharmacological studies|Correlative studies
316008|NCT01791465|Drug|extended-release exenatide|Single arm study - 2mg Bydureon every 7 days x 16 weeks
316009|NCT01791439|Other|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
316010|NCT01791439|Other|placebo|
316011|NCT01791426|Device|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
316012|NCT01791426|Device|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
316013|NCT01791413|Drug|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
316014|NCT01791400|Drug|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
316015|NCT01791400|Drug|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
316016|NCT01791387|Drug|Dovitinib|"Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions."
316017|NCT01791374|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
316018|NCT01791374|Drug|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
316019|NCT01791361|Other|Other|No intervention other than routine medical care
316020|NCT01791348|Other|d2 test of attention|
316021|NCT01791309|Drug|combination panitumumab and vemurafenib|Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
316022|NCT01791296|Drug|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
316054|NCT01791062|Device|HYTOP®|HYTOP® will be implanted once during surgery.
316055|NCT01791049|Drug|TD-1607|
316056|NCT01791049|Drug|Placebo|
316095|NCT01790672|Dietary Supplement|Alcoholized wine|Wine 13º or wine 8º
316096|NCT01790672|Dietary Supplement|De-alcoholized wine|Wine 0º
316023|NCT01791296|Other|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
316024|NCT01791283|Procedure|Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.|
316025|NCT01791270|Device|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.~First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).~The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.~We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.~Procedures:~- Respiratory Polygraphy~- Ambulatory Blood Pressure Monitoring~- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.~- ß1en subunit expression in peripheral blood leukocytes."
316026|NCT01791244|Drug|Rebif®|
316027|NCT01791231|Drug|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
316028|NCT01791218|Procedure|CABG, AVR or CABG+AVR and PVI|
316029|NCT01791218|Procedure|CABG, AVR or CABG+AVR|
316030|NCT01791192|Drug|FTY720|Fingolimod
316031|NCT01791192|Drug|Oral Corticosteroid|Oral Corticosteroid
316032|NCT01791179|Behavioral|Comprehensive substance abuse services|
316033|NCT01791166|Biological|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
316034|NCT01791153|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
316035|NCT01791153|Drug|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
316036|NCT01791153|Drug|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
316037|NCT01791153|Drug|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
316038|NCT01791153|Drug|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
316039|NCT01791153|Drug|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
316040|NCT01791127|Device|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
316041|NCT01791114|Other|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
316042|NCT01791114|Other|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
316043|NCT01791114|Other|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
316044|NCT01791114|Other|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
316045|NCT01791114|Other|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
316046|NCT01791114|Other|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
316047|NCT01791114|Other|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
316048|NCT01791101|Drug|Eltrombopag|
316049|NCT01791088|Drug|sirolimus|Given PO
316050|NCT01791088|Other|pharmacological study|Correlative studies
316051|NCT01791088|Other|laboratory biomarker analysis|Correlative studies
316052|NCT01791075|Device|Tan Endoglide|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
316053|NCT01791075|Device|Endosaver|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
316527|NCT01787214|Dietary Supplement|Control|Walnut free meals
316057|NCT01791036|Procedure|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
316058|NCT01791036|Procedure|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
316059|NCT01791023|Other|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
316060|NCT01791010|Other|Inspiratory muscle training|
316061|NCT01791010|Other|Training sham|Conducting fake training with the aim of blind the control group
316062|NCT01790997|Drug|DLBS1033|1 tablet of DLBS1033 490 mg thrice daily, after meal
316063|NCT01790997|Drug|Aspirin|1 tablet of aspirin 80 mg once daily, after meal
316064|NCT01790997|Drug|Clopidogrel|1 tablet of clopidogrel 75 mg once daily, after meal
316065|NCT01790984|Other|High sugar low starch diet|
316066|NCT01790984|Other|Low sugar high starch diet|
316067|NCT01790971|Drug|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
316068|NCT01790971|Drug|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
316069|NCT01790932|Drug|BKM120|
316070|NCT01790919|Behavioral|Cognitive therapy for depression|"Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.~Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory."
316071|NCT01790906|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
316072|NCT01790906|Other|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
316073|NCT01790893|Drug|aflibercept|
316074|NCT01790880|Behavioral|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
316075|NCT01790880|Behavioral|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
316076|NCT01790854|Drug|Prasugrel dose 5 mg/day|
316077|NCT01790854|Drug|Prasugrel dose 10 mg/day|
316078|NCT01790841|Device|Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego|
316079|NCT01790828|Drug|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
316080|NCT01790802|Device|2RT nanosecond laser|active laser therapy
316081|NCT01790789|Behavioral|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
316082|NCT01790789|Other|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
316083|NCT01790776|Radiation|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).~The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
316084|NCT01790776|Radiation|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
316085|NCT01790763|Device|Keramatrix|Dressing for second degree burn
316086|NCT01790763|Device|Mepilex|Dressing for second degree wound
316087|NCT01790750|Device|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
316088|NCT01790737|Drug|Cyclophosphamide|
316089|NCT01790737|Drug|Filgrastim|
316090|NCT01790724|Behavioral|Walking exercise|
316091|NCT01790711|Procedure|FMT through mid-gut|
316092|NCT01790685|Drug|dexamethasone implant|
316093|NCT01790672|Dietary Supplement|Ethanol|Vodka Absolut
316094|NCT01790672|Other|Water|Lemon-flavored water
316097|NCT01790659|Drug|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
316098|NCT01790659|Drug|Paromomycin|Paromomycin alone
316099|NCT01790646|Other|intubation|intubation using Glidescope videolaryngoscope
316100|NCT01790633|Other|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
316101|NCT01790633|Other|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
316102|NCT01790620|Other|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
316103|NCT01790620|Other|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
316104|NCT01790607|Drug|ONO-2745 /CNS 7056|
316105|NCT01790594|Biological|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
316106|NCT01790594|Drug|methylprednisolone|
316107|NCT01790594|Biological|Anti-thymocyte Globulin (Rabbit)|
316108|NCT01790594|Drug|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
316109|NCT01790594|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
316110|NCT01790581|Behavioral|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
316111|NCT01790581|Behavioral|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
316112|NCT01790568|Drug|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
316113|NCT01790568|Drug|Tacrolimus|
316114|NCT01790568|Drug|Methotrexate|
316115|NCT01790555|Drug|Namisol|
316116|NCT01790555|Drug|Diazepam/placebo|
316117|NCT01790542|Other|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
316118|NCT01790542|Other|Iron fortified cereal with fruit|
316119|NCT01790542|Other|Meat|
316120|NCT01790529|Procedure|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
316121|NCT01790529|Procedure|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
316122|NCT01790516|Drug|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
316123|NCT01790516|Drug|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
316124|NCT01790516|Radiation|Radiation|daily radiation for 7 weeks
316125|NCT01790503|Drug|PLX3397|
316126|NCT01790503|Radiation|Radiation Therapy|
316127|NCT01790503|Drug|Temozolomide|
316128|NCT01790490|Drug|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
316129|NCT01790490|Drug|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
316130|NCT01790490|Drug|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
316131|NCT01790477|Procedure|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
316132|NCT01790464|Drug|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
316133|NCT01790464|Drug|placebo|
316134|NCT01790451|Procedure|Irreversible Electroporation|
316135|NCT01790438|Drug|LY2605541|
316136|NCT01790438|Drug|Human Insulin NPH|
316137|NCT01790438|Drug|Oral Antihyperglycemic Medications (OAM)|
316138|NCT01790425|Procedure|to infuse water into colon to open the lumen for water infusion colonoscopy|
316139|NCT01790425|Procedure|Air colonoscopy|
316140|NCT01790412|Behavioral|Exercise group|Combined two land aerobic sessions and one aquatic activities session
316141|NCT01790399|Procedure|Excision of sentinel node(s)|Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
316142|NCT01790373|Behavioral|Suubi+Adherence|"Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.~Financial education and workshops on asset-building, future planning, and protection from risks~Mentorship from a young adult/near-peer~Family-based microenterprise development training~Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
316143|NCT01790373|Behavioral|Bolstered Standard of Care|"-Medical Event Monitoring System~Bolstered Standard of Care: Adherence Counseling Practices~-Four to six counseling sessions to review HIV, ART, resistance, and adherence.~Medical Standard of Care:~-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda~Psychosocial Standard of Care:~-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
316144|NCT01790360|Behavioral|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
316145|NCT01790360|Behavioral|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
316146|NCT01790347|Behavioral|Exercise group|"The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week."
316147|NCT01790334|Other|Ultrasonography|
316148|NCT01790321|Device|LSF-filtering device|LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 NTU turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
316149|NCT01790308|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
316150|NCT01790308|Drug|Liraglutide|CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
316151|NCT01790295|Drug|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
316152|NCT01790282|Drug|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
316153|NCT01790282|Drug|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
316154|NCT01790256|Device|Cereve Sleep System at 30 degrees C|
316155|NCT01790256|Device|Cereve Sleep System at 14-16 degrees C|
316156|NCT01790243|Device|Lutonix Drug Coated Balloon|
316157|NCT01790230|Device|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
316158|NCT01790204|Dietary Supplement|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
316194|NCT01789970|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
316159|NCT01790191|Behavioral|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
316160|NCT01790191|Behavioral|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
316161|NCT01790191|Behavioral|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
316162|NCT01790178|Procedure|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
316163|NCT01790165|Drug|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
316164|NCT01790152|Other|Assessment of Therapy Complications|Ancillary studies
316165|NCT01790152|Other|Laboratory Biomarker Analysis|Correlative studies
316166|NCT01790152|Other|Quality-of-Life Assessment|Ancillary studies
316167|NCT01790152|Other|Questionnaire Administration|Ancillary studies
316168|NCT01790139|Drug|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
316169|NCT01790126|Drug|ARN-509|
316170|NCT01790126|Drug|LHRH Agonist|
316171|NCT01790113|Device|Univers™|Control
316172|NCT01790113|Device|Eclipse™ Total Shoulder Replacement|Investigational
316173|NCT01790100|Drug|VX-135|12 weeks of VX-135
316174|NCT01790100|Drug|Ribavirin|12 weeks of ribavirin
316175|NCT01790087|Drug|ANX-188 Therapeutic Dose|
316176|NCT01790087|Drug|ANX-188 Supratherapeutic dose|
316177|NCT01790087|Drug|Saline|
316178|NCT01790087|Drug|Moxifloxacin|
316179|NCT01790074|Other|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
316180|NCT01790074|Other|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
316181|NCT01790061|Procedure|Standardized FMT|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut or whole colon
316182|NCT01790061|Drug|Traditional treatments|Medications
316183|NCT01790048|Dietary Supplement|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
316184|NCT01790048|Dietary Supplement|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.~Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
316185|NCT01790035|Drug|LGG|
316186|NCT01790035|Drug|Placebo|
316187|NCT01790022|Drug|Methylprednisolone|
316188|NCT01790009|Dietary Supplement|Flavanol rich drink|
316189|NCT01790009|Drug|Acetaminophen|2x500 mg Acetaminophen
316190|NCT01789996|Procedure|alternative six minute walk test|"Alternate instructions will be given Subjects will~walk as fast as they can in 6 minutes~walk as normally as they can in 6 minutes~walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
316191|NCT01789996|Procedure|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
316192|NCT01789983|Behavioral|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.~The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
316193|NCT01789983|Other|Collect Blood, GA and Other Survey Tools|"Geriatric Assessment (GA) (Version 5)~Functional Assessment of Cancer Therapy-General (FACT)~Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36~Outcome Expectations for Exercise (OEE) scale29~Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)~Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35~Visual Analog Scales (VAS)~Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
316195|NCT01789970|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
316196|NCT01789957|Drug|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
316197|NCT01789944|Behavioral|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
316198|NCT01789931|Device|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
316199|NCT01789918|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
316200|NCT01789905|Drug|Tigecycline (Tygacil)|Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
316201|NCT01789892|Drug|methylprednisolone|Given IV
316202|NCT01789892|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT scan
316203|NCT01789892|Procedure|positron emission tomography|Undergo FDG PET/CT scan
316204|NCT01789892|Procedure|computed tomography|Undergo FDG PET/CT scan
316205|NCT01789879|Drug|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
316206|NCT01789879|Drug|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
316207|NCT01789879|Drug|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
316208|NCT01789853|Behavioral|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
316209|NCT01789853|Behavioral|Conventional Physical Therapy|Regular physical therapy for 8 weeks
316210|NCT01789840|Device|Embosphere Microspheres|
316211|NCT01789840|Procedure|TURP|
316212|NCT01789827|Other|Laboratory Biomarker Analysis|Correlative studies
316213|NCT01789827|Procedure|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
316214|NCT01789827|Biological|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
316215|NCT01789814|Drug|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
316216|NCT01789814|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
316217|NCT01789801|Procedure|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
316218|NCT01789801|Procedure|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
316219|NCT01789788|Drug|Placebo|Matching placebo, multiple doses
316220|NCT01789788|Drug|RO6811135|multiple ascending doses
316221|NCT01789775|Drug|Drug: CD07805/47 gel|
316222|NCT01789775|Drug|CD07805/47 gel Placebo|
316223|NCT01789762|Biological|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
316224|NCT01789762|Biological|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
316225|NCT01789762|Biological|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
316226|NCT01789749|Other|Snare Tip Soft Coagulation|
316227|NCT01789749|Other|No Snare Tip Soft Coagulation|
316228|NCT01789736|Drug|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
316229|NCT01789736|Drug|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
316230|NCT01789736|Drug|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
316231|NCT01789723|Drug|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
316232|NCT01789723|Drug|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
316233|NCT01789710|Drug|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
316234|NCT01789710|Drug|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
316235|NCT01789710|Behavioral|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
316236|NCT01789697|Other|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
316237|NCT01789684|Other|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
316238|NCT01789671|Behavioral|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
316528|NCT01787188|Drug|Meloxicam Test Capsules|
316239|NCT01789658|Other|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
316240|NCT01789645|Other|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
316241|NCT01789645|Procedure|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
316242|NCT01789619|Drug|Extended release tacrolimus (Advagraf®)|
316243|NCT01789606|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
316244|NCT01789593|Other|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
316245|NCT01789580|Other|Gambling moderator|
316246|NCT01789567|Device|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
316247|NCT01789554|Other|MLS dispatch for bystander CPR|
316248|NCT01789528|Drug|CAZ-AVI|IV infusion
316249|NCT01789528|Drug|CXL|IV infusion
316250|NCT01789502|Device|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
316251|NCT01789502|Device|Plastic stents|Plastic stents were inserted by ERCP
316252|NCT01789489|Device|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
316253|NCT01789476|Drug|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
316254|NCT01789476|Drug|Placebo|Matching placebo administered using same dosing algorithm as the active arm
316255|NCT01789463|Other|Self rehabilitation|
316256|NCT01789463|Other|Self rehabilitation plus physiotherapy|
316257|NCT01789450|Procedure|Section of Periareolar Dermis in Breast Reduction.|
316258|NCT01789437|Device|Dexamethasone Intravitreal Implant (Ozuredex)|
316259|NCT01789411|Other|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
316260|NCT01789411|Device|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
316261|NCT01789411|Device|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
316262|NCT01789398|Drug|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
316263|NCT01789385|Drug|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
316264|NCT01789359|Other|Blueberry Juice|Dietary intervention
316265|NCT01789346|Device|532nm potassium titanyl phosphate (KTP) laser|
316266|NCT01789346|Device|595nm pulsed-dye laser (PDL)|
316267|NCT01789333|Device|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of Ultraviolet A (UVA) light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.~The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 milliwatts (mW)/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
316268|NCT01789333|Drug|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.~During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
316269|NCT01789320|Drug|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
316270|NCT01789307|Dietary Supplement|corn syrup solids|oral ingestion 50 grams, 2 doses
316271|NCT01789307|Dietary Supplement|sucrose|oral ingestion 50 grams, 2 doses
316272|NCT01789294|Drug|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
316273|NCT01789294|Behavioral|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
316274|NCT01789281|Drug|Everolimus|Everolimus will be provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. Everolimus can be provided as local commercial material or global supply where appropriate
316275|NCT01789281|Drug|Sandostatin LAR Depot|Patients receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol will be allowed to continue Sandostatin LAR Depot treatment. Sandostatin LAR Depot will continue to be provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections will be administered at the discretion of the treating physician.
316324|NCT01788865|Device|cSEMS(Covered self-expandable dual-layered metal stent) implant|
316529|NCT01787188|Drug|Meloxicam Test Capsules|
316276|NCT01789268|Device|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
316277|NCT01789255|Drug|vorinostat|Given PO
316278|NCT01789255|Drug|tacrolimus|Given IV or PO
316279|NCT01789255|Drug|cyclosporine|Given IV or PO
316280|NCT01789255|Drug|methotrexate|Given IV
316281|NCT01789255|Other|laboratory biomarker analysis|Correlative studies
316282|NCT01789255|Other|pharmacological study|Correlative studies
316283|NCT01789242|Drug|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
316284|NCT01789242|Drug|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with <VGPR after 4 cycles.
316285|NCT01789229|Other|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.~Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.~Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
316286|NCT01789229|Other|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
316287|NCT01789229|Other|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
316288|NCT01789229|Other|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
316289|NCT01789229|Other|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
316290|NCT01789229|Other|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
316291|NCT01789229|Other|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
316292|NCT01789216|Drug|NSAID|
316293|NCT01789216|Drug|Gabapentinoids|
316294|NCT01789216|Drug|placebo|
316295|NCT01789203|Drug|Ciprofloxacin|Patients will be randomized 2:1 active comparator, Cipro, to placebo comparator.
316296|NCT01789203|Drug|placebo|Patients will be randomized 2:1 placebo comparator to active comparator, Cipro.
316297|NCT01789177|Device|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
316298|NCT01789177|Other|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
316299|NCT01789151|Device|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
316300|NCT01789138|Behavioral|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
316301|NCT01789125|Drug|Nicotine Patch|
316302|NCT01789125|Behavioral|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
316303|NCT01789125|Behavioral|Education-Supportive Psychotherapy|
316304|NCT01789112|Other|Blood sample|Taking of blood sample
316305|NCT01789099|Biological|UV1 synthetic peptide vaccine and GM-CSF|
316306|NCT01789086|Drug|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
316307|NCT01789086|Drug|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
316308|NCT01789073|Dietary Supplement|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
316309|NCT01789060|Other|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
316310|NCT01789047|Drug|Topiramate|Topiramate as adjunct to amantadine
316311|NCT01789047|Drug|Placebo|Placebo control
316312|NCT01789047|Drug|Amantadine|Existing treatment for all participants
316313|NCT01789021|Device|4 blood glucose monitoring systems|
316314|NCT01789008|Other|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
316315|NCT01788982|Drug|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
316316|NCT01788982|Drug|Placebo|
316317|NCT01788969|Drug|Lexapro|Agent + training vs Placebo + training
316318|NCT01788969|Drug|Placebo|Agent + training vs Placebo + training
316319|NCT01788956|Device|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
316320|NCT01788956|Device|Co-Oximeter|
316321|NCT01788930|Device|CPAP|
316322|NCT01788917|Dietary Supplement|linseed oil|10 ml linseed oil per day over 10 weeks (without control oil)
316323|NCT01788878|Behavioral|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.~Medical data will be collected via the CRF."
316530|NCT01787188|Drug|Placebo Capsules|
316325|NCT01788839|Behavioral|surveys|A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 2 months.
316326|NCT01788839|Other|Blood draw|Those patients receiving chemotherapy who consent to the optional blood draw will provide blood at baseline (before start of chemotherapy), 12 months after baseline (+/-1 month) and 24 months after baseline (+/-2 months). All patients in the subset of the premenopausal cohort receiving tamoxifen only will have required blood draws at baseline (before they begin taking tamoxifen), at 6 months post-baseline/start of tamoxifen (+/- 2 weeks), 12 months post-start of tamoxifen (+/-1 month) and 24 months post-start of tamoxifen (+/-2 months). We will ask these participants for blood draws on day 1, 2, 3 or 4 of their menses at baseline and 6 months post-baseline/start of tamoxifen and during months 1 through 5 post-baseline/start of tamoxifen.
316327|NCT01788839|Device|Transvaginal ultrasounds|Transvaginal ultrasounds are used to determine the number of antral follicles in each ovary. They will be performed to evaluate both the number and size of antral follicles of premenopausal women on Tamoxifen as antral follicle count is a good predictor of ovarian reserve and response. All patients in the subset of the premenopausal cohort receiving tamoxifen only will also have required transvaginal ultrasounds at baseline (before they begin taking tamoxifen) and at 6 months post-start of tamoxifen (+/- 2 weeks).
316328|NCT01788826|Procedure|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
316329|NCT01788826|Procedure|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
316330|NCT01788813|Drug|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
316331|NCT01788813|Drug|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
316332|NCT01788800|Behavioral|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
316333|NCT01788787|Behavioral|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
316334|NCT01788787|Behavioral|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
316335|NCT01788787|Behavioral|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
316336|NCT01788787|Behavioral|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
316337|NCT01788774|Drug|Risperidone ISM 50 mg|
316338|NCT01788774|Drug|Risperidone ISM 75 mg|
316339|NCT01788774|Drug|Risperidone ISM 100 mg|
316340|NCT01788761|Dietary Supplement|Probiotic Supplemented Group|
316341|NCT01788761|Dietary Supplement|Control Group|
316342|NCT01788748|Device|bipolar radiofrequency and infrared|
316343|NCT01788748|Device|fractional bipolar radiofrequency|
316344|NCT01788722|Drug|Dienogest (Visanne, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
316345|NCT01788709|Other|preparation cleaning solution|
316346|NCT01788696|Radiation|Group A - Early Imaging|Total of 3 scans
316347|NCT01788696|Radiation|Group B - Delayed Imaging|Total of 2 scans
316348|NCT01788683|Procedure|Regenexx SD|stem cell treatment
316349|NCT01788683|Other|Exercise Therapy|exercise therapy control
316350|NCT01788670|Dietary Supplement|Ethanol|
316351|NCT01788670|Other|Water|
316352|NCT01788657|Behavioral|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
316353|NCT01788657|Behavioral|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
316381|NCT01788384|Drug|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
316382|NCT01788384|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
316666|NCT01786148|Behavioral|mobile phone application|
316354|NCT01788631|Drug|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
316355|NCT01788631|Drug|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
316356|NCT01788618|Other|Cognitive exams|"Psychopathological assessment (T0 and T3):~Scale of Spielberger~The self-administered questionnaire CES-D~Cognitive assessment(T0 and T3):~- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)~Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):~Self-assessment FACT-COG (T0,every months until T3)"
316357|NCT01788618|Other|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
316358|NCT01788618|Other|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
316359|NCT01788618|Other|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
316360|NCT01788605|Drug|ramosetron|
316361|NCT01788579|Behavioral|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
316362|NCT01788579|Behavioral|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
316363|NCT01788566|Drug|Necitumumab|Administered IV
316364|NCT01788566|Drug|Gemcitabine|Administered IV
316365|NCT01788566|Drug|Cisplatin|Administered IV
316366|NCT01788540|Drug|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
316367|NCT01788527|Device|CGM|Real Time Continuous Glucose Monitoring
316368|NCT01788514|Other|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
316369|NCT01788501|Drug|Tacrolimus|D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
316370|NCT01788501|Drug|Cyclosporine|D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
316371|NCT01788501|Drug|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
316372|NCT01788488|Other|Use of procalcitonin as biomarker to guide therapy|
316373|NCT01788475|Drug|Dexamethasone|Ozurdex (dexamethasone) 0.7mg steroid implant
316374|NCT01788462|Drug|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
316375|NCT01788436|Behavioral|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
316376|NCT01788436|Behavioral|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
316377|NCT01788423|Device|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
316378|NCT01788410|Procedure|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
316379|NCT01788410|Device|MRI Seednet Cryotherapy System (Galil Medical)|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
316380|NCT01788397|Behavioral|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
316424|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
316383|NCT01788384|Drug|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
316384|NCT01788371|Drug|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
316385|NCT01788371|Drug|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
316386|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
316387|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
316388|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
316389|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
316390|NCT01788345|Other|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
316391|NCT01788332|Drug|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
316392|NCT01788332|Other|Placebo|3 100mg tablets to be administered twice a day with approximately 240ml of water
316393|NCT01788319|Procedure|lasertrabeculoplasty|
316394|NCT01788306|Drug|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
316395|NCT01788293|Other|Intervention group|"Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.~This PVI cut-off value was chosen according to previous reports [Cannesson et al., 2008; Zimmermann et al., 2010].~During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation."
316396|NCT01788280|Drug|Fluciclitite , PET imaging, and Bevacizumab|[18F] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
316397|NCT01788267|Other|scan examination HR-pQCT|
316398|NCT01788254|Drug|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
316399|NCT01788254|Drug|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
316400|NCT01788254|Drug|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
316401|NCT01788254|Drug|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
316402|NCT01788254|Drug|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
316403|NCT01788228|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
316404|NCT01788215|Drug|doxycycline|200mg/day in divided doses of 100mg twice daily
316405|NCT01788215|Other|Sugar Pill|1 pill twice a day
316406|NCT01788189|Drug|Lenalidomide|
316407|NCT01788176|Drug|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
316408|NCT01788176|Drug|Placebo|one single intravenous infusion of 100ml of saline.
316409|NCT01788163|Genetic|EGFR mutation test|EGFR mutation being tested in tissue and blood
316410|NCT01788150|Device|Coronary Stenting|
316411|NCT01788137|Drug|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
316412|NCT01788137|Drug|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
316413|NCT01788111|Other|Low back exercises 1|Excentric / concentric extension type exercises
316414|NCT01788111|Other|Low back exercise 2|Traditional low back training
316415|NCT01788085|Device|Bravo pH monitoring procedure|Bravo pH monitoring procedure
316416|NCT01788072|Drug|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
316417|NCT01788072|Drug|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
316418|NCT01788059|Other|injection the mesenchymal stem cell in non union site|
316419|NCT01788046|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
316420|NCT01788046|Drug|Placebo|Administered intravenously (IV) three times per week.
316421|NCT01788033|Drug|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
316422|NCT01788033|Drug|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
316423|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide|
316425|NCT01788007|Drug|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
316426|NCT01788007|Drug|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
316427|NCT01788007|Drug|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
316428|NCT01787994|Genetic|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF‐T), given via intravenous infusion.|
316429|NCT01787955|Procedure|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
316430|NCT01787955|Procedure|conventional PPPD|
316431|NCT01787942|Device|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
316432|NCT01787929|Procedure|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
316433|NCT01787916|Drug|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
316434|NCT01787916|Drug|Placebos|placebo will be compared to liraglutide for 24 weeks in a cross-over design
316435|NCT01787903|Device|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
316436|NCT01787851|Drug|Triheptanoin oil|
316437|NCT01787838|Other|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.~The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
316438|NCT01787825|Device|PillCam SB2 capsule|Capsule Endoscopy system
316439|NCT01787825|Device|CapsoCam SV-1|Capsule endoscopy
316440|NCT01787799|Device|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
316441|NCT01787773|Device|Veniti Inferior Vena Cava Filter|
316442|NCT01787760|Device|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
316443|NCT01787760|Device|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
316444|NCT01787760|Device|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
316445|NCT01787747|Drug|AVP-786 Dose 1|
316446|NCT01787747|Drug|AVP-786 Dose 2|
316447|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 1|
316448|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 2|
316449|NCT01787747|Drug|AVP-786 Dose 2/Q Dose 2|
316450|NCT01787747|Drug|AVP-923|
316451|NCT01787721|Procedure|Ankle manipulation|
316452|NCT01787721|Other|Sham manipulation|
316453|NCT01787708|Procedure|Red light|
316454|NCT01787695|Procedure|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
316455|NCT01787682|Dietary Supplement|BOOST High Protein|
316456|NCT01787669|Drug|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
316457|NCT01787669|Drug|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
316458|NCT01787643|Other|Height-Adjustable Desk Intallation in Office|
316459|NCT01787630|Device|Hyaluronic acid|Injection in connection with ultrasound
316460|NCT01787617|Behavioral|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
316461|NCT01787617|Behavioral|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
316462|NCT01787604|Procedure|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
316463|NCT01787604|Procedure|Aortic Valve Reimplantation Procedure|David I
316464|NCT01787591|Other|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
316465|NCT01787591|Other|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
316466|NCT01787591|Other|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
316467|NCT01787591|Other|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
316468|NCT01787578|Drug|Sobetirome|50 mcg or 100 mcg once-daily oral
316469|NCT01787565|Other|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
316470|NCT01787565|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
316471|NCT01787552|Drug|LDE225|
316472|NCT01787552|Drug|INC424|
316473|NCT01787539|Drug|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.~Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
316474|NCT01787526|Drug|ferric carboxymaltose|1 g intravenously per infusion
316475|NCT01787526|Drug|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
316476|NCT01787513|Other|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
316477|NCT01787513|Other|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
316478|NCT01787500|Biological|Cetuximab|Given IV
316479|NCT01787500|Drug|Irinotecan Hydrochloride|Given IV
316480|NCT01787500|Other|Laboratory Biomarker Analysis|Correlative studies
316481|NCT01787500|Other|Pharmacological Study|Correlative studies
316482|NCT01787500|Drug|Vemurafenib|Given PO
316483|NCT01787487|Drug|Azacitidine|Given SC or IV
316484|NCT01787487|Other|Laboratory Biomarker Analysis|Correlative studies
316485|NCT01787487|Drug|Ruxolitinib Phosphate|Given PO
316486|NCT01787474|Drug|Cytarabine|Given IV
316487|NCT01787474|Biological|Filgrastim|Given SC
316488|NCT01787474|Biological|Filgrastim-sndz|Given SC
316489|NCT01787474|Drug|Fludarabine Phosphate|Given IV
316490|NCT01787474|Other|Laboratory Biomarker Analysis|Correlative studies
316491|NCT01787474|Biological|Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells|Given IV
316492|NCT01787461|Dietary Supplement|Imedeen|Two tablets per day for 6 months
316493|NCT01787461|Dietary Supplement|Placebo|Two tablets per day for 6 months
316494|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
316495|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
316496|NCT01787448|Drug|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
316497|NCT01787448|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
316498|NCT01787435|Drug|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy~No exposure to acid suppressing drugs during pregnancy"
316499|NCT01787422|Other|Traditional versus Telemedicine office visit|
316500|NCT01787409|Dietary Supplement|Cholecalciferol|Given PO
316501|NCT01787409|Other|Laboratory Biomarker Analysis|Correlative studies
316502|NCT01787396|Drug|Gemigliptin 50mg|
316503|NCT01787396|Drug|Placebo(Metformin)|
316504|NCT01787396|Drug|Metformin|
316505|NCT01787396|Drug|Placebo(Gemigliptin)|
316506|NCT01787383|Drug|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
316507|NCT01787383|Drug|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
316508|NCT01787357|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
316509|NCT01787357|Drug|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
316510|NCT01787357|Drug|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
316511|NCT01787344|Drug|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
316512|NCT01787344|Drug|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
316513|NCT01787331|Drug|Itraconazole|Given PO
316514|NCT01787331|Other|Laboratory Biomarker Analysis|Correlative studies
316515|NCT01787331|Other|Pharmacological Study|Correlative studies
316516|NCT01787318|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
316517|NCT01787318|Device|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
316518|NCT01787292|Behavioral|Coordination training|finger movement coordination training using sequenced finger movements of varying pressure.
316519|NCT01787292|Behavioral|Short Term exercise - supervised|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
316520|NCT01787292|Behavioral|Long Term Exercise|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
316521|NCT01787279|Drug|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
316522|NCT01787240|Drug|Escitalopram 10mg|
316523|NCT01787240|Drug|Placebo|
316524|NCT01787227|Device|xTAG RPP|
316525|NCT01787214|Dietary Supplement|Full dose|20% of daily energy needs supplied by walnuts
316526|NCT01787214|Dietary Supplement|Half dose|10% of daily energy needs supplied by walnuts
316531|NCT01787175|Other|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
316532|NCT01787162|Other|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
316533|NCT01787149|Drug|DMARDs|
316534|NCT01787136|Drug|Dextromethorphan|added on therapy
316535|NCT01787123|Drug|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
316536|NCT01787123|Drug|Normal Saline|14-day course of intravenous normal saline started within 4 days of ictus
316537|NCT01787110|Drug|Oxygen|see arm description
316538|NCT01787097|Drug|Symbicort®, Formoterol, Budesonide|Formeterol is Long acting beta 2-agonist (LABA) whereas Budesonide is inhaled corticosteroids (ICS).Patients will randomly receive one-off dose-administration of inhaled treatment (each medication will be taken as two puffs, all via a dry-powder inhaler device = Turbuhaler® to achieve the TOTAL doses).
316539|NCT01787084|Device|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
316540|NCT01787071|Other|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
316541|NCT01787058|Other|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
316542|NCT01787045|Other|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
316543|NCT01787045|Other|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
316544|NCT01787032|Drug|BI 113608|tablet
316545|NCT01787032|Drug|BI 113608|tablet
316546|NCT01787032|Drug|BI 113608|tablet
316547|NCT01787032|Drug|Ketoconazole|tablet
316548|NCT01787032|Drug|Voriconazole|tablet
316549|NCT01787019|Other|Oral feeding|
316550|NCT01787006|Drug|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
316551|NCT01787006|Drug|Cisplatin, 5-FU|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4~Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle"
316552|NCT01787006|Radiation|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
316553|NCT01786993|Device|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
316554|NCT01786993|Device|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
316555|NCT01786967|Drug|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
316556|NCT01786954|Device|Icare rebound tonometry|
316557|NCT01786954|Device|Tonopen applanation|
316558|NCT01786954|Device|Goldmann applanation|
316559|NCT01786941|Other|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
316560|NCT01786941|Other|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
316561|NCT01786928|Other|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
316562|NCT01786915|Drug|Bendavia 10mg|
316563|NCT01786915|Drug|Bendavia 50mg|
316564|NCT01786915|Drug|Placebo|
316565|NCT01786902|Drug|DA-3002|
316566|NCT01786889|Biological|blood and urine|Blood collection and urine collection after consent of the patient
316567|NCT01786889|Behavioral|Questionnaire|The patient complete the questionnaire alone at home
316568|NCT01786889|Behavioral|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
316569|NCT01786876|Drug|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
316570|NCT01786863|Procedure|Neuromuscular blockade|
316571|NCT01786850|Procedure|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
316572|NCT01786837|Device|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
316573|NCT01786824|Drug|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
316667|NCT01786135|Drug|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
316574|NCT01786824|Drug|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
316575|NCT01786824|Drug|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
316576|NCT01786824|Procedure|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
316577|NCT01786811|Behavioral|Training|"Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
316578|NCT01786798|Device|Transvaginal sonography|"Transvaginal sonography will be performed to:~measure the endometrial thickness~detect the endometrial pattern"
316579|NCT01786772|Other|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
316580|NCT01786772|Other|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
316581|NCT01786759|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
316582|NCT01786759|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
316583|NCT01786746|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
316584|NCT01786746|Behavioral|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
316585|NCT01786733|Behavioral|Behavioral Activation|
316586|NCT01786733|Behavioral|Supportive Therapy|
316587|NCT01786707|Biological|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
316588|NCT01786707|Other|Hyperbaric oxygen therapy|
316589|NCT01786707|Drug|Insulin|Insulin dose as per clinical management
316590|NCT01786707|Drug|Metformin|Metformin dose as tolerated
316591|NCT01786694|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
316592|NCT01786681|Procedure|Positive pressure|
316593|NCT01786668|Drug|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
316594|NCT01786668|Drug|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
316595|NCT01786668|Drug|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
316596|NCT01786668|Drug|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
316597|NCT01786655|Drug|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
316598|NCT01786655|Drug|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
316599|NCT01786655|Drug|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
316600|NCT01786655|Other|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
316601|NCT01786629|Drug|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
316602|NCT01786629|Drug|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
316603|NCT01786616|Drug|Formoterol|
316604|NCT01786603|Drug|Rasagiline|Rasagiline 2mg once a day for 12 months.
316605|NCT01786603|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
316606|NCT01786590|Procedure|EBUS-TBNA|Currently EBUS-TBNA is performed in patients with CT and/or PET positive lymph nodes in the mediastinum or hilum. In this study, all patients being considered for SBRT will undergo EBUS-TBNA for the lymph node staging prior to SBRT.
316607|NCT01786577|Other|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
316608|NCT01786577|Behavioral|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
316609|NCT01786551|Drug|Eplerenone|50 mg daily for 14 days
316668|NCT01786122|Other|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
316610|NCT01786538|Drug|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
316611|NCT01786538|Drug|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
316612|NCT01786525|Behavioral|House Calls|60-minute home based educational intervention which will be administered by a health educator
316613|NCT01786525|Behavioral|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
316614|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25-mg BID for 7 days
316615|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecardbil dose of 50-mg BID for 7 days.
316616|NCT01786512|Drug|Placebo|Placebo
316617|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25-mg BID for 20 weeks.
316618|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25 mg BID for 8 weeks followed by 50-mg BID for 12 weeks
316619|NCT01786499|Behavioral|Relaxation Response Training|
316620|NCT01786486|Device|Amplatzer Cardiac Plug|
316621|NCT01786473|Drug|Testogel 1%|
316622|NCT01786473|Drug|Placebo|
316623|NCT01786460|Other|Blood draw at Days 0, 7, 14, and 21|
316624|NCT01786434|Drug|Routine medication arm|50 micrograms of fentanyl given before the procedure
316625|NCT01786434|Drug|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
316626|NCT01786408|Device|TAP20-C|
316627|NCT01786408|Device|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
316628|NCT01786395|Drug|UF-021|
316629|NCT01786395|Drug|Placebo|
316630|NCT01786382|Drug|PPI-668|
316631|NCT01786382|Drug|Midazolam|
316632|NCT01786382|Drug|Omeprazole|
316633|NCT01786382|Drug|Telaprevir|
316634|NCT01786356|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
316635|NCT01786356|Other|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B&L MI60 in one eye
316636|NCT01786343|Drug|Decitabine|20 mg/m2 by vein daily for either 5 or 10 days.
316637|NCT01786330|Device|Procare abdominal binder|
316638|NCT01786330|Other|Standard of Care|
316639|NCT01786317|Device|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
316640|NCT01786304|Procedure|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
316641|NCT01786278|Radiation|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
316642|NCT01786278|Procedure|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
316643|NCT01786265|Drug|Abiraterone Acetate|Given PO
316644|NCT01786265|Drug|Bicalutamide|Given PO
316645|NCT01786265|Drug|Degarelix|Given via injection
316646|NCT01786265|Drug|Flutamide|Given PO
316647|NCT01786265|Drug|Goserelin Acetate|Given via injection
316648|NCT01786265|Drug|Leuprolide Acetate|Given via injection
316649|NCT01786265|Drug|Nilutamide|Given PO
316650|NCT01786265|Drug|Prednisone|
316651|NCT01786252|Drug|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
316652|NCT01786252|Drug|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
316653|NCT01786239|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
316654|NCT01786239|Drug|Omega-3 capsules|The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
316655|NCT01786239|Drug|Placebo|The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
316656|NCT01786226|Drug|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
316657|NCT01786226|Drug|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
316658|NCT01786200|Drug|Aspirin|
316659|NCT01786200|Drug|Ibuprofen|
316660|NCT01786187|Behavioral|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
316661|NCT01786187|Other|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
316662|NCT01786174|Drug|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
316663|NCT01786174|Other|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
316664|NCT01786161|Drug|Vancomycin continuous infusion|Vancomycin 24 hour intravenous continuous infusion
316665|NCT01786161|Drug|Vancomycin intermittent dosing interval|Vancomycin intravenous infusion at rate 1000mg/hr
316669|NCT01786122|Behavioral|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
316670|NCT01786109|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
316671|NCT01786109|Drug|Placebo|Placebo will match study drug; taken as one dose orally with water.
316672|NCT01786096|Drug|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
316673|NCT01786083|Behavioral|Application of Problem Solving Technique|
316674|NCT01786070|Drug|Budesonide|
316675|NCT01786070|Drug|placebo|
316676|NCT01786057|Procedure|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
316677|NCT01786057|Procedure|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
316678|NCT01786044|Behavioral|MasterMed|An online interactive educational program
316679|NCT01786044|Behavioral|Usual Care|
316680|NCT01786031|Other|metastasis biopsy|
316681|NCT01786018|Drug|Thiotepa|
316682|NCT01786018|Drug|Busulfan|
316683|NCT01786018|Drug|Fludarabin|
316684|NCT01786018|Procedure|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10^7 CD3 cells/kg recipient weight and cryopreserved.
316685|NCT01786018|Radiation|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
316686|NCT01786018|Drug|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
316687|NCT01786018|Drug|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.~If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.~See guidelines for PO to IV conversion below."
316688|NCT01786018|Drug|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
316689|NCT01786018|Drug|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
316690|NCT01786018|Procedure|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
316691|NCT01786005|Device|Transcranial magnetic stimulation|
316692|NCT01785992|Drug|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
316693|NCT01785979|Drug|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
316694|NCT01785979|Drug|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
316695|NCT01785966|Behavioral|Daily checklist and clinician prompting|"Interventions are:~Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.~Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
316696|NCT01785940|Procedure|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
316697|NCT01785927|Other|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
316698|NCT01785901|Other|without interventions|without interventions
316732|NCT01785602|Drug|Placebo|Capsules
317028|NCT01783353|Dietary Supplement|Corn starch pill|
316699|NCT01785875|Drug|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
316700|NCT01785862|Drug|Ibuprofen 25 mg|Lozenge, Oromucosal administration
316701|NCT01785862|Drug|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
316702|NCT01785849|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
316703|NCT01785849|Drug|Placebo|Administered intravenously (IV) three times per week.
316704|NCT01785836|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
316705|NCT01785836|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
316706|NCT01785836|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
316707|NCT01785836|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
316708|NCT01785823|Other|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
316709|NCT01785823|Other|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
316710|NCT01785823|Other|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
316711|NCT01785810|Drug|Maraviroc 300 mg|
316712|NCT01785797|Device|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
316713|NCT01785784|Drug|rhGM-CSF Gel|
316714|NCT01785771|Drug|ITCA 650 (exenatide in DUROS)|
316715|NCT01785758|Drug|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
316716|NCT01785745|Other|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
316717|NCT01785745|Other|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
316718|NCT01785732|Procedure|Renal Denervation|Sympathetic renal denervation via renal arteries
316719|NCT01785719|Behavioral|Commercial Weight Loss Program|Regardless of reproductive history, each participant will be provided with six months of the commercial weight loss program, Nutrisystem® D. Nutrisystem® D is a portion-controlled, low calorie, and low glycemic index meal delivery system that provides 1250-1500 kcal/day. It has been proven to help overweight adults achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, average weight loss is 1-2 lbs per week or 15-20% body weight by the end of six months. Nutrisystem® D offers a balanced meal plan that is consistent with the nutrition recommendations of the USDA Dietary Guidelines for Americans and American Diabetes Association. Each participant will be encouraged to take a daily multivitamin to help meet her micronutrient needs on the program.
316720|NCT01785693|Drug|levobupivacaine, clonidine|
316721|NCT01785680|Other|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
316722|NCT01785680|Other|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
316723|NCT01785641|Drug|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
316724|NCT01785641|Drug|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
316725|NCT01785641|Drug|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
316726|NCT01785641|Drug|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
316727|NCT01785628|Dietary Supplement|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
316728|NCT01785628|Dietary Supplement|Placebo Capsule|Placebo is dextrin composition.
316729|NCT01785615|Drug|Atorvastatin|80mg
316730|NCT01785615|Other|Placebo|80mg
316731|NCT01785602|Drug|QAW039|Capsules
316733|NCT01785589|Procedure|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
316734|NCT01785576|Behavioral|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
316735|NCT01785563|Device|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
316736|NCT01785550|Other|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
316737|NCT01785524|Drug|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
316738|NCT01785524|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
316739|NCT01785511|Radiation|UVA Radiation|UVA radiation exposure for 20 minutes
316740|NCT01785498|Behavioral|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
316741|NCT01785485|Other|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
316742|NCT01785472|Drug|LCZ696|LCZ696 200 mg tablet
316743|NCT01785472|Drug|Olmesartan|Olmesartan 20 mg capsule
316744|NCT01785472|Drug|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
316745|NCT01785472|Drug|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
316746|NCT01785459|Drug|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
316747|NCT01785459|Drug|Standard Care|10 mg Intravenous injection of Prochlorperazine
316748|NCT01785446|Drug|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
316749|NCT01785446|Drug|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
316750|NCT01785433|Drug|Tiotropium HFA BAI 4.5 mcg|
316751|NCT01785433|Drug|Tiotropium HFA BAI 9.0 mcg|
316752|NCT01785433|Drug|SPIRIVA® HandiHaler® 18 mcg/day|
316753|NCT01785433|Drug|Spiriva® Respimat® 5 mcg/day|
316754|NCT01785420|Drug|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
316755|NCT01785420|Drug|Placebo|A 90 minute intravenous infusion of saline as placebo
316756|NCT01785407|Dietary Supplement|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
316757|NCT01785394|Drug|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
316758|NCT01785381|Other|Added value of coordinator|Added value of coordinator
316759|NCT01785368|Other|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
316760|NCT01785368|Other|Baseline observation|During this period of the study, baseline data will be collected.
316761|NCT01785355|Other|Dental treatment|"The preliminary stage deals with:~assessment of the clinical state of the patient by completing a detailed dental and periodontal chart~education of the patient regarding correct oral hygiene habits;~Phase I Therapy:~plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)~evaluation of response to the treatment~Phase II Therapy - surgical phase:~extraction of hopeless teeth~evaluation of the surgical results.~Maintenance phase:~periodic reevaluation of plaque and calculus and of periodontal conditions."
316762|NCT01785342|Other|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
316763|NCT01785329|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
316764|NCT01785316|Procedure|IHP|
316765|NCT01785303|Behavioral|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
316805|NCT01785082|Drug|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
317152|NCT01782391|Device|Stimulation|
316766|NCT01785303|Procedure|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
316767|NCT01785290|Drug|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~aged ≥ 80 years~weight ≤ 50 kg~liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
316768|NCT01785290|Drug|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:~aged ≥ 80 years~weight ≤ 50 kg~liver failure~Patients with an adjusted dosage of study drug remain allocated to their original group.~In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
316769|NCT01785290|Drug|Placebo|Sodium Chloride 0.9%
316770|NCT01785264|Procedure|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
316771|NCT01785264|Procedure|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
316772|NCT01785264|Procedure|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.~All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
316773|NCT01785251|Device|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
316774|NCT01785238|Other|renal echography|renal echography to analyse the kidney
316775|NCT01785238|Other|Blood sampling|Blood sampling to analyse different parameters of renal function
316776|NCT01785238|Other|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
316777|NCT01785238|Other|Blood pressure measurement|
316778|NCT01785225|Device|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
316779|NCT01785212|Device|Stapler|stapler hepatectomy
316780|NCT01785212|Device|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
316781|NCT01785199|Procedure|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
316782|NCT01785186|Drug|SQ109|SQ109 300 mg
316783|NCT01785186|Drug|Rifampicin|Rifampicin 10 to 35 mg/kg
316784|NCT01785186|Drug|Moxifloxacin|Moxifloxacin 400mg
316785|NCT01785186|Drug|isoniazid|isoniazid 75 mg
316786|NCT01785186|Drug|pyrazinamide|pyrazinamide 400 mg
316787|NCT01785186|Drug|ethambutol|ethambutol 275 mg
316788|NCT01785186|Dietary Supplement|pyridoxine|pyridoxine 25 mg
316789|NCT01785173|Procedure|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
316790|NCT01785173|Procedure|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
316791|NCT01785160|Drug|Raltegravir|low dose oral administration
316792|NCT01785160|Drug|Raltegravir|low dose oral administration
316793|NCT01785160|Drug|Faldaprevir|medium dose oral administration
316794|NCT01785147|Drug|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
316795|NCT01785147|Drug|Placebo|
316796|NCT01785134|Procedure|Omentectomy|
316797|NCT01785134|Procedure|Gastric bypass operation|
316798|NCT01785121|Behavioral|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
316799|NCT01785121|Behavioral|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
316800|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg|
316801|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg X 2|
316802|NCT01785108|Drug|Vitamin D|
316803|NCT01785108|Drug|Ibuprofen|
316804|NCT01785095|Drug|FSH (Follicle Stimulating Hormone)|
316806|NCT01785056|Biological|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
316807|NCT01785043|Drug|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
316808|NCT01785043|Drug|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
316809|NCT01785030|Drug|50% Nitrous oxide|
316810|NCT01785004|Dietary Supplement|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
316811|NCT01785004|Drug|omega-3 fatty acids (fish oil)|
316812|NCT01784991|Drug|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
316813|NCT01784991|Drug|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
316814|NCT01784978|Drug|Sunitinib|50 mg pd
316815|NCT01784978|Drug|Everolimus|10 mg pd
316816|NCT01784965|Drug|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
316817|NCT01784965|Drug|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
316818|NCT01784952|Dietary Supplement|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
316819|NCT01784926|Procedure|Intraocular lens repositioning by scleral suturing|
316820|NCT01784926|Procedure|Intraocular lens exchange with retropupillary iris-claw lens|
316821|NCT01784913|Biological|UV1 synthetic peptide vaccine and GM-CSF|
316822|NCT01784900|Drug|Catumaxomab 100µg|
316823|NCT01784900|Drug|Catumaxomab 140µg|
316824|NCT01784887|Drug|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
316825|NCT01784874|Biological|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
316826|NCT01784874|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
316827|NCT01784861|Drug|X-82|
316828|NCT01784861|Drug|Everolimus|
316829|NCT01784861|Procedure|Blood draws for pharmacokinetic testing|
316830|NCT01784848|Procedure|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
316831|NCT01784848|Other|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
316832|NCT01784835|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
316833|NCT01784835|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
316834|NCT01784822|Device|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
316835|NCT01784809|Behavioral|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. ***To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:~http://ccnmtl.columbia.edu/projects/worth/presentation"
316836|NCT01784809|Behavioral|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
316837|NCT01784809|Behavioral|Wellness Promotion|
316838|NCT01784796|Behavioral|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
316839|NCT01784796|Behavioral|Health Education Program|8 week Health Education Program
316879|NCT01784419|Drug|ivacaftor|Prospective randomized double-blinded placebo controlled crossover study of the effects of ivacaftor in selected cystic fibrosis patients
316880|NCT01784406|Behavioral|Autonomy supportive counselling|
316881|NCT01784393|Radiation|chemoradiation|
316882|NCT01784380|Drug|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
317022|NCT01783431|Procedure|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
317023|NCT01783418|Behavioral|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
316840|NCT01784783|Behavioral|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.~Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
316841|NCT01784783|Behavioral|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
316842|NCT01784770|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
316843|NCT01784757|Drug|ODM-201 Tablet A|Tablet A formulation of ODM-201
316844|NCT01784757|Drug|ODM-201 Tablet B|Tablet B formulation of ODM-201
316845|NCT01784757|Drug|ODM-201 capsule formulation|Capsule formulation of ODM-201
316846|NCT01784744|Other|Hydroworx Pool at 98 degrees Fahrenheit|
316847|NCT01784744|Other|Hydroworx Pool at 102 degrees Fahrenheit|
316848|NCT01784731|Behavioral|Willingness to pay|
316849|NCT01784718|Drug|Buphenyl|
316850|NCT01784705|Device|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
316851|NCT01784705|Device|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
316852|NCT01784692|Dietary Supplement|Immulina|
316853|NCT01784666|Drug|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
316854|NCT01784666|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
316855|NCT01784653|Behavioral|iMET|Self-completed, computerized motivational enhancement therapy
316856|NCT01784653|Behavioral|MET|Clinician-delivered Motivational Enhancement Therapy
316857|NCT01784640|Drug|Hsp90 inhibitor AUY922|Given IV
316858|NCT01784640|Drug|pemetrexed disodium|Given IV
316859|NCT01784640|Other|pharmacological study|Correlative studies
316860|NCT01784640|Other|laboratory biomarker analysis|Correlative studies
316861|NCT01784627|Behavioral|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
316862|NCT01784614|Drug|LY2624803 - Solution|Administered orally as reconstituted solution
316863|NCT01784614|Drug|LY2624803 - Capsule|Administered orally as a capsule
316864|NCT01784614|Drug|Placebo - Solution|Administered orally as solution
316865|NCT01784614|Drug|Placebo - Capsule|Administered orally as a capsule
316866|NCT01784588|Device|Solyx Single Incision Sling System|Solyx Single Incision Sling System
316867|NCT01784588|Device|Obtryx II Sling System|Standard outside-in transobturator sling
316868|NCT01784575|Other|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
316869|NCT01784562|Drug|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
316870|NCT01784549|Drug|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
316871|NCT01784536|Drug|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
316872|NCT01784523|Drug|Hydroxychloroquine|
316873|NCT01784510|Procedure|distance of dissection of gastrocolic ligament from pylorus|
316874|NCT01784484|Other|No intervention|
316875|NCT01784471|Device|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
316876|NCT01784445|Drug|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
316877|NCT01784432|Device|Low-level laser therapy and training|
316878|NCT01784432|Other|Training|
316883|NCT01784367|Device|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
316884|NCT01784354|Other|Acupressure|
316885|NCT01784354|Other|Acupressure dilatation|
316886|NCT01784354|Behavioral|education|
316887|NCT01784328|Device|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
316888|NCT01784315|Drug|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
316889|NCT01784315|Drug|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
316890|NCT01784302|Dietary Supplement|Multivitamins|
316891|NCT01784302|Dietary Supplement|Sodium bicarbonate|
316892|NCT01784302|Drug|Maalox Plus extra|
316893|NCT01784302|Drug|Raltegravir 400 mg|
316894|NCT01784276|Behavioral|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
316895|NCT01784263|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
316896|NCT01784263|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
316897|NCT01784250|Drug|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
316898|NCT01784250|Drug|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
316899|NCT01784250|Drug|Placebo|Sugar pill manufactured to mimic a drug
316900|NCT01784237|Procedure|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
316901|NCT01784237|Procedure|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
316902|NCT01784224|Procedure|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
316903|NCT01784211|Drug|LY2605541|
316904|NCT01784211|Drug|Insulin Glargine|
316905|NCT01784198|Dietary Supplement|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
316906|NCT01784185|Procedure|virtual bronchoscopy guided transbronchial needle aspiration|
316907|NCT01784185|Procedure|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
316908|NCT01784172|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
316909|NCT01784172|Device|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
316910|NCT01784159|Drug|Aspirin|Aspirin administration for 7 days
317024|NCT01783392|Procedure|Transcutaneous Electrical Nerve Stimulation|
317025|NCT01783379|Drug|micafungin|100mg/day infusion in 1 hour
317026|NCT01783366|Device|TUBE EXCHANGER|
316911|NCT01784146|Other|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
316912|NCT01784146|Other|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the~nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
316913|NCT01784146|Other|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
316914|NCT01784133|Drug|omiganan|
316915|NCT01784133|Drug|placebo|
316916|NCT01784120|Drug|Doxorubicin/Genexol-PM|
316917|NCT01784107|Drug|Belotecan and Ifosfamide|
316918|NCT01784094|Device|StromaGlide|
316919|NCT01784081|Other|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
316920|NCT01784068|Drug|Nilotinib followed by treatment-free|Nilotinib will be used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
316921|NCT01784042|Drug|Placebo|placebo
316922|NCT01784042|Drug|Lovaza|
316923|NCT01784042|Other|Dietary energy restriction|
316924|NCT01784029|Drug|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
316925|NCT01784016|Radiation|[11C]-PHNO|[11C]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
316926|NCT01784003|Device|Powered ankle-foot prosthesis|
316927|NCT01783990|Drug|Hydroxyurea|Active and Passive groups both are on HU.
316928|NCT01783977|Biological|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
316929|NCT01783977|Biological|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10^8 PFU/ml; administered as 1 mL IM in participant's deltoid
316930|NCT01783977|Biological|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10^6 PFU/ml for a planned maximum dose of 1.1x10^7 PFU/ml; administered as 1 mL IM in participant's deltoid
316931|NCT01783977|Biological|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
316932|NCT01783977|Biological|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
316933|NCT01783977|Biological|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
316934|NCT01783964|Drug|[14C]-Elacytarabine|Single intravenous administration
316935|NCT01783951|Biological|DC-CIK|Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.
316936|NCT01783951|Drug|S-1|The dose of S-1 is determined according to the body surface area as follows: <1.25 m2, 40 mg; 1.25 to <1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.
316937|NCT01783951|Drug|Cisplatin|Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.
316938|NCT01783938|Biological|Nivolumab|
316939|NCT01783938|Biological|Ipilimumab|
316940|NCT01783925|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
316941|NCT01783912|Behavioral|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
316942|NCT01783912|Behavioral|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
316943|NCT01783912|Drug|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
316944|NCT01783912|Behavioral|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
316974|NCT01783704|Behavioral|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
316975|NCT01783691|Drug|NKTT120|
316945|NCT01783899|Device|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.~once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.~Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.~Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.~Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.~Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
316946|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
316947|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
316948|NCT01783886|Procedure|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
316949|NCT01783873|Other|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
316950|NCT01783860|Drug|Azithromycin|
316951|NCT01783860|Drug|Doxycycline|
316952|NCT01783847|Drug|Recombinant human erythropoietin (EPO)|4000 units per vial
316953|NCT01783847|Other|Observation|Just observation
316954|NCT01783847|Drug|Methyl prednisolone|250 mg every 6 hours for 3 days.
316955|NCT01783834|Drug|Gefitinib|compare progression free survivla rate and safety to both drugs
316956|NCT01783834|Drug|Pemetrexed|compare PFS rate, safety to both drugs
316957|NCT01783821|Drug|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
316958|NCT01783821|Drug|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
316959|NCT01783821|Drug|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
316960|NCT01783808|Other|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
316961|NCT01783795|Genetic|Genetic Analysis|
316962|NCT01783782|Behavioral|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
316963|NCT01783782|Drug|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
316964|NCT01783782|Drug|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
316965|NCT01783769|Behavioral|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
316966|NCT01783756|Drug|lapatinib ditosylate|Given PO
316967|NCT01783756|Drug|everolimus|Given PO
316968|NCT01783756|Drug|capecitabine|Given PO
316969|NCT01783756|Other|laboratory biomarker analysis|Correlative studies
316970|NCT01783743|Other|TT Training Program and TT Screening Card|The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
316971|NCT01783717|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
316972|NCT01783704|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
316973|NCT01783704|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
316976|NCT01783678|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
316977|NCT01783678|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
316978|NCT01783665|Other|aerobic exercise|
316979|NCT01783665|Other|home exercise program|
316980|NCT01783652|Behavioral|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
316981|NCT01783639|Procedure|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
316982|NCT01783626|Device|Evodial|
316983|NCT01783626|Device|Evodial+ Condition B1|
316984|NCT01783626|Device|Evodial+ Condition B2|
316985|NCT01783626|Device|Evodial+ Condition C|
316986|NCT01783613|Dietary Supplement|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
316987|NCT01783613|Dietary Supplement|Placebo: 50 mg/kg/day during 12 months|
316988|NCT01783600|Device|NanoCross .014 balloon catheter|
316989|NCT01783587|Drug|Afatinib|Taken orally once per day
316990|NCT01783587|Drug|Docetaxel|15 mg/m2, given intravenously once per week
316991|NCT01783587|Radiation|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
316992|NCT01783574|Drug|Testosterone|
316993|NCT01783574|Drug|Placebo|
316994|NCT01783561|Drug|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
316995|NCT01783548|Drug|BDP Nasal Aerosol|
316996|NCT01783548|Drug|Placebo|
316997|NCT01783535|Drug|vincristine|Given via minibag/gravity flow.
316998|NCT01783535|Drug|topotecan|Given IV over 30 minutes.
316999|NCT01783535|Drug|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is >2,000/µL on one occasion after the expected nadir.
317000|NCT01783535|Drug|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is >2,000/µL on one occasion after the expected nadir.
317001|NCT01783535|Drug|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
317002|NCT01783535|Other|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
317003|NCT01783535|Drug|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
317004|NCT01783535|Drug|cyclophosphamide|Given IV.
317005|NCT01783535|Drug|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
317006|NCT01783535|Drug|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
317007|NCT01783535|Procedure|enucleation|Eye removal due to advanced disease in Strata C and D participants.
317008|NCT01783535|Radiation|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
317009|NCT01783522|Drug|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
317010|NCT01783522|Other|quality-of-life assessment|Ancillary studies
317011|NCT01783522|Other|placebo|Given PO
317012|NCT01783496|Device|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
317013|NCT01783483|Device|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
317014|NCT01783483|Device|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
317015|NCT01783470|Drug|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
317016|NCT01783457|Other|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
317017|NCT01783457|Other|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.~Programme of sessions available upon request."
317018|NCT01783444|Drug|Capecitabine|Capecitabine, for oral use 1250 mg/m2 twice daily for 2 weeks followed by one week rest (3-week cycle). Capecitabine was locally supplied by the Investigator.
317019|NCT01783444|Drug|Exemestane|Exemestane tablets of 25 mg was taken orally once per day. Dose modifications in the management of adverse events were allowed.
317020|NCT01783444|Drug|Everolimus|Everolimus was centrally dispensed via IWRS. Everolimus was taken as oral tablets for oral use 10 mg (2 × 5 mg) daily.
317021|NCT01783431|Drug|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
317027|NCT01783353|Dietary Supplement|Zinc gluconate|
317029|NCT01783340|Drug|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
317030|NCT01783340|Drug|Placebo|Placebo capsules will be administered at each immunization
317031|NCT01783340|Biological|Immunization with falciparum|three inoculations with 5 infected mosquito bites
317032|NCT01783327|Behavioral|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
317033|NCT01783327|Behavioral|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
317034|NCT01783314|Procedure|MRI of liver|MRI of liver with intravenous gadoxetate disodium
317035|NCT01783301|Drug|FSH|
317036|NCT01783288|Other|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.~Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
317037|NCT01783288|Other|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured & collected in the supine (lying) and upright position for each participant.
317038|NCT01783288|Procedure|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
317039|NCT01783288|Other|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
317040|NCT01783275|Behavioral|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
317041|NCT01783262|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
317042|NCT01783262|Device|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
317043|NCT01783249|Other|Stationary Exercise cycling|Stationary exercise cycling
317044|NCT01783236|Drug|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
317045|NCT01783236|Drug|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
317046|NCT01783210|Behavioral|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
317047|NCT01783210|Behavioral|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.~30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
317048|NCT01783197|Drug|Paclitaxel|
317049|NCT01783197|Drug|Carboplatin|
317050|NCT01783197|Drug|Selumetinib|
317051|NCT01783197|Drug|Pemetrexed|
317052|NCT01783197|Drug|Cisplatin|
317053|NCT01783171|Drug|Akt Inhibitor MK2206|Given PO
317054|NCT01783171|Drug|Dinaciclib|Given IV
317055|NCT01783171|Other|Laboratory Biomarker Analysis|Correlative studies
317056|NCT01783171|Other|Pharmacological Study|Correlative studies
317057|NCT01783158|Procedure|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.~Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
317058|NCT01783132|Device|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
317059|NCT01783119|Dietary Supplement|Aloe Barbadensis Miller|
317060|NCT01783119|Dietary Supplement|placebo water|
317061|NCT01783106|Drug|Ciprofloxacin|experimental
317062|NCT01783106|Drug|Doxycycline|experimental
317063|NCT01783106|Drug|Hydroxychloroquine|oral
317064|NCT01783106|Drug|Budesonide|active comparator
317065|NCT01783093|Other|Data Collection|Collection of data from existing medical records
317066|NCT01783080|Behavioral|Behavioral Activation for return to work|See Arm Description
317067|NCT01783067|Other|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
317068|NCT01783067|Other|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
317069|NCT01783054|Procedure|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
317070|NCT01783054|Genetic|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
317071|NCT01783054|Drug|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
317072|NCT01783041|Drug|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
317073|NCT01783041|Drug|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
317074|NCT01783028|Behavioral|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
317075|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
317076|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
317077|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
317078|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
317079|NCT01783002|Radiation|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
317080|NCT01783002|Radiation|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
317081|NCT01783002|Radiation|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
317082|NCT01782989|Drug|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
317083|NCT01782989|Drug|Placebo|Placebo capsule daily for 24 months
317084|NCT01782976|Drug|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
317085|NCT01782976|Drug|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
317086|NCT01782976|Behavioral|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
317087|NCT01782963|Drug|Lenalidomide|
317088|NCT01782963|Drug|Bortezomib|
317089|NCT01782963|Drug|Dexamethasone|
317090|NCT01782950|Drug|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
317091|NCT01782937|Drug|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
317092|NCT01782924|Drug|KHK4827|
317093|NCT01782911|Dietary Supplement|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
317094|NCT01782911|Dietary Supplement|Placebo pills|The patients will take placebo for 40 days.
317095|NCT01782898|Drug|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
317096|NCT01782898|Drug|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
317097|NCT01782885|Procedure|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
317098|NCT01782885|Drug|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
317099|NCT01782872|Procedure|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous (IV): saline
317100|NCT01782872|Procedure|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
317101|NCT01782872|Procedure|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
317102|NCT01782872|Procedure|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
317103|NCT01782859|Drug|Prednisone|
317104|NCT01782859|Drug|Hydrocortisone|
317105|NCT01782859|Drug|Placebo (for Prednisone)|
317106|NCT01782846|Drug|Ixprim®|
317107|NCT01782846|Drug|Dafalgan-Codeine®|
317108|NCT01782833|Other|This is Non-interventional study|
317109|NCT01782807|Procedure|Salpingectomy or Fimbriectomy|
317110|NCT01782794|Other|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
317111|NCT01782781|Drug|ropivacaine, ketorelac and epinephrine|Active group
317112|NCT01782781|Drug|Placebo|Placebo group
317113|NCT01782768|Device|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
317114|NCT01782755|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
317115|NCT01782755|Other|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
317116|NCT01782742|Drug|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
317117|NCT01782742|Drug|Placebo|
317118|NCT01782729|Drug|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
317119|NCT01782690|Drug|erlotinib|Study participants will receive erlotinib according to Summary of Product Characteristics (SmPC)
317120|NCT01782690|Drug|gemcitabine|Study participants will receive gemcitabine according to Summary of Product Characteristics (SmPC)
317121|NCT01782677|Procedure|Bilateral Surgical Resection of Carotid Bodies|
317122|NCT01782664|Drug|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
317123|NCT01782664|Drug|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
317124|NCT01782664|Drug|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
317125|NCT01782664|Drug|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
317126|NCT01782651|Drug|Lapatinib plus capecitabine|Lapatinib plus capecitabine
317127|NCT01782638|Behavioral|deep brain stimulation|
317128|NCT01782625|Other|NO exercise at depth|Subjects will NOT exercise while at depth
317129|NCT01782625|Other|exercise at depth|Subjects will exercise while at depth
317130|NCT01782612|Procedure|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
317131|NCT01782612|Procedure|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
317132|NCT01782599|Other|Dual nicotine patch and electronic cigarette|
317133|NCT01782573|Drug|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
317134|NCT01782573|Drug|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
317135|NCT01782560|Drug|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
317136|NCT01782560|Drug|Placebo|
317137|NCT01782547|Behavioral|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
317138|NCT01782547|Other|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
317139|NCT01782521|Procedure|No primer|Primer not used when bonding orthodontic brackets
317140|NCT01782508|Drug|imatinib|a selectively inhibits the KIT protein tyrosine
317141|NCT01782508|Drug|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
317142|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
317143|NCT01782495|Drug|ombitasvir/paritaprevir/ritonavir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir
317144|NCT01782495|Drug|ribavirin|tablet
317145|NCT01782482|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
317146|NCT01782482|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
317147|NCT01782456|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
317148|NCT01782443|Drug|Ziv-aflibercept|
317149|NCT01782430|Procedure|- standard oxygenation|
317150|NCT01782417|Behavioral|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
317151|NCT01782404|Device|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
317153|NCT01782391|Device|SHAM|no stimulation
317154|NCT01782378|Device|Photomedex or Thor Photomedicine Helmet, with Near-Infrared Light-Emitting Diodes (LEDs), Sham Helmet is identical but has power output of 0.|"The LED helmet from Photomedex, Pennsylvania or Thor Photomedicine, Maryland will be used.~18 LED pods are in the helmet. Each LED pod: Pod size: 4.5 x 4.8 cm, 21.6 cm2 Power output: 665.3 mW Power density: 30.8 mW/cm2 20 NIR diodes, 830 nm"
317155|NCT01782378|Device|Intranasal LED device, Sham intranasal device appears identical but has power output of 0.|"Red and Near-infrared LED devices will be used.~Power output: 6.5 mW~Power density: 7.6 mW/cm2~Wavelength: 633 and 810 nm"
317156|NCT01782365|Device|SHAM stimulation|no stimulation
317157|NCT01782365|Device|0,75 Hz stimulation|
317158|NCT01782352|Drug|Omega-3 fatty acids (fish oil)|
317159|NCT01782352|Dietary Supplement|Vitamin D3|
317160|NCT01782352|Dietary Supplement|Vitamin D3 placebo|
317161|NCT01782352|Dietary Supplement|Fish oil placebo|
317162|NCT01782339|Drug|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
317163|NCT01782326|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
317164|NCT01782326|Drug|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
317165|NCT01782313|Drug|tivozanib|Given PO
317166|NCT01782313|Other|laboratory biomarker analysis|Correlative studies
317167|NCT01782300|Biological|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
317168|NCT01782300|Biological|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
317169|NCT01782287|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
317170|NCT01782287|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
317171|NCT01782274|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
317172|NCT01782274|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
317173|NCT01782261|Drug|Liraglutide|once daily subcutaneous injection
317174|NCT01782261|Drug|Saxagliptin|once daily tablet
317175|NCT01782248|Other|Questionnary and IRM|
317176|NCT01782235|Drug|Tocilizumab|
317177|NCT01782235|Drug|Placebo|
317178|NCT01782222|Drug|Rotigotine|"Rotigotine, transdermal patches:~10 cm^2 (2 mg / 24 hours); 20 cm^2 (4 mg / 24 hours); 30 cm^2 (6 mg / 24 hours); 40 cm^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
317179|NCT01782222|Other|Placebo|"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
317180|NCT01782196|Device|Enhanced one piece drainable pouch with Type A mouldable adhesive|
317181|NCT01782196|Device|Enhanced one piece drainable pouch with Type B mouldable adhesive|
317182|NCT01782183|Device|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
317183|NCT01782170|Drug|Iocide Oral Rinse|
317184|NCT01782170|Drug|Placebo|
317185|NCT01782144|Other|NutriSystem portion-controlled pre-packaged meals|
317186|NCT01782131|Drug|Posaconazole|
317187|NCT01782131|Drug|Voriconazole|
317188|NCT01782118|Dietary Supplement|Lactobacillus GG|
317189|NCT01782105|Behavioral|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
317190|NCT01782105|Behavioral|Control group|Evaluation of nutritional and physcial activity habits
317191|NCT01782092|Other|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
317192|NCT01782079|Dietary Supplement|L. brevis|
317193|NCT01782066|Biological|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
317194|NCT01782053|Behavioral|Picture warning|Warning contains picture proposed for each text statement by FDA
317195|NCT01782053|Behavioral|Control|
317196|NCT01782040|Other|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
317197|NCT01782027|Drug|3H-cholesterol bound to albumin|up to 100 uCi of [3H]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
317198|NCT01782014|Procedure|colonoscopy|colonoscopy using different methods of insufflation
317199|NCT01782001|Dietary Supplement|vitamin A|vitamin A with placebo
317200|NCT01782001|Dietary Supplement|vitamin A and zinc|combination of vitamin A and zinc supplements
317201|NCT01781988|Drug|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.~B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
317202|NCT01781975|Drug|Imatinib Mesylate|
317203|NCT01781975|Drug|Placebo (For imatinib mesylate)|
317204|NCT01781962|Other|No Treatment|No Treatment was given in this study.
317205|NCT01781949|Other|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
317206|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS <30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
317207|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
317208|NCT01781936|Drug|Fluocinolone Acetonide|
317209|NCT01781923|Behavioral|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
317210|NCT01781923|Behavioral|Small group social skills training|Meet once per week for duration of 40 weeks.
317211|NCT01781910|Dietary Supplement|Branched Chain Amino Acid drink supplement|
317212|NCT01781910|Dietary Supplement|Placebo|
317213|NCT01781897|Device|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
317214|NCT01781897|Drug|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
317215|NCT01781884|Drug|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
317216|NCT01781884|Drug|Placebo|
317217|NCT01781871|Biological|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
317218|NCT01781871|Biological|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
317219|NCT01781845|Procedure|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
317220|NCT01781832|Device|ARFI-Derived Shear Wave Velocities|An ultrasound based scan uses ARFI, an acoustic radiation force impulse to estimate shear wave velocities during scanning of the urinary bladder. The research ultrasound scan lasts about 10 to 15 minutes.
317221|NCT01781819|Procedure|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
317222|NCT01781806|Drug|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to <50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl <30 mL/min, Truvada will be discontinued.
317223|NCT01781793|Other|Room air|Humidified room air (21% oxygen) will be inspired
317224|NCT01781793|Other|Hyperoxia|60% oxygen will be inspired
317225|NCT01781780|Behavioral|General Nutrition Recommendations|
317226|NCT01781780|Behavioral|Breakfast Recommendation|
317227|NCT01781780|Behavioral|No Breakfast Recommendation|
317228|NCT01781754|Procedure|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
317229|NCT01781741|Combination Product|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
317230|NCT01781741|Other|quality-of-life assessment|Ancillary studies
317231|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 5 Gy x 5 (over 1-2 weeks)*
317232|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 6.6 Gy x 5 (over 1-2 weeks)*
317233|NCT01781715|Device|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
317234|NCT01781702|Drug|Pelubiprofen 30 mg|
317235|NCT01781702|Drug|Celebrex 200 mg|
317236|NCT01781689|Procedure|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
317237|NCT01781689|Other|Rehabilitation programs|include occupational therapy and physical therapy
317238|NCT01781663|Device|KAM2904 Face Cream|
317239|NCT01781663|Device|KAM3008 Body Lotion|
317240|NCT01781663|Other|petrolatum-based moisturizer|
317241|NCT01781650|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
317242|NCT01781650|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
317327|NCT01780922|Other|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
317328|NCT01780909|Drug|Paromomycin Sulfate Fasted State|
317243|NCT01781650|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
317244|NCT01781637|Drug|Omalizumab|subcutaneous injection
317245|NCT01781637|Drug|placebo|subcutaneous injection
317246|NCT01781624|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
317247|NCT01781611|Drug|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
317248|NCT01781611|Drug|81mg aspirin|half a tablet twice daily for 24 weeks
317249|NCT01781598|Device|Total knee arthroplasty (TKA) (Smith &Nephew®)|
317250|NCT01781585|Procedure|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
317251|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily on a continuous dosing schedule. LEE011 will be administered orally once daily for 21 days followed by a 1 week break (28-day cycle).
317252|NCT01781572|Drug|LEE011 and MEK162|Once the MTD(s)/RP2D have been determined for each tested dose schedule, the phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination.
317253|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily and LEE011 will be administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).
317254|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily and LEE011 will be administered once daily for 2 weeks followed by a 1 week break (21-day cycle).
317255|NCT01781559|Dietary Supplement|phenolic acid|phenolic acid
317256|NCT01781546|Procedure|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is >20mm or stent malapposition is suspected).
317257|NCT01781546|Procedure|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length >20mm or stent malapposition is suspected).
317258|NCT01781533|Procedure|algorithm|
317259|NCT01781520|Biological|DC-CIK Treatment|The DC-CIK cells were infused on days 15, 17, and 19 of 21-day cycles.
317260|NCT01781520|Drug|S1|The dose of S-1 is determined according to the body surface area as follows: <1.25 m2, 40 mg; 1.25-<1.5 m2, 50 mg; and >1.5 m2, 60 mg, given twice daily after meals for 14 days followed by a 7-day rest. Cycles is repeated every 21 days. Treatment is continued until disease progression, unacceptable toxic effects, or the withdrawal of consent.
317261|NCT01781520|Other|Best supportive care|Best supportive care
317262|NCT01781507|Drug|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
317263|NCT01781507|Drug|Placebo|This placebo ( sugar pill) will provide the negative control for this study
317264|NCT01781494|Procedure|Immobilization followed by protected range of motion|
317265|NCT01781494|Procedure|Immediate range of motion|
317266|NCT01781468|Drug|armodafinil 150 mg|given orally
317267|NCT01781468|Other|Placebo|given orally
317268|NCT01781468|Drug|armodafinil 250 mg|given orally
317269|NCT01781455|Drug|BBI503|
317270|NCT01781442|Drug|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.~Treatment will continue until disease progression or unacceptable toxicity.~The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
317271|NCT01781429|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
317272|NCT01781403|Drug|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
317273|NCT01781390|Biological|12.5 M Mesenchymal Precursor Cells (MPC)|MPCs
317274|NCT01781390|Other|Placebo|Placebo
317275|NCT01781390|Biological|25M Mesenchymal Precursor Cells (MPC)|MPC
317276|NCT01781377|Drug|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
317277|NCT01781377|Drug|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
317278|NCT01781377|Drug|PLACEBO|SALINE INFUSION
317279|NCT01781364|Behavioral|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
317280|NCT01781351|Other|Taping the ankle|
317281|NCT01781338|Other|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
317282|NCT01781325|Device|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
317283|NCT01781312|Dietary Supplement|ProTectis|
317284|NCT01781312|Dietary Supplement|Gastrus|
317285|NCT01781299|Device|AlloDerm RTU|
317286|NCT01781299|Device|SurgiMend PRS|
317287|NCT01781286|Behavioral|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
317288|NCT01781286|Behavioral|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
317329|NCT01780909|Drug|Paromomycin Sulfate Fed State|
317330|NCT01780909|Drug|Paromomycin Sulfate w/ domperidone|
317331|NCT01780909|Drug|Paromomycin Sulfate w/ loperamide HCl|
317332|NCT01780883|Drug|melatonin|
317333|NCT01780883|Drug|Placebo|Placebo tablets of Circadin®
317494|NCT01779479|Drug|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
317289|NCT01781273|Other|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
317290|NCT01781273|Other|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
317291|NCT01781247|Behavioral|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
317292|NCT01781247|Behavioral|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
317293|NCT01781234|Drug|Intranasal Insulin|
317294|NCT01781234|Drug|Placebo|
317295|NCT01781221|Device|Alpha-Bio's GRAFT Natural Bovine Bone|
317296|NCT01781221|Device|Bio-Oss xenograft|
317297|NCT01781208|Device|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
317298|NCT01781169|Dietary Supplement|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
317299|NCT01781143|Device|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
317300|NCT01781130|Procedure|Steroid injection|
317301|NCT01781117|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
317302|NCT01781117|Device|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
317303|NCT01781104|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
317304|NCT01781104|Drug|Placebo|Placebo delivered subcutaneously once daily for 14 days.
317305|NCT01781091|Device|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
317306|NCT01781091|Device|Conventionals Modes|
317307|NCT01781078|Radiation|MRI|The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
317308|NCT01781078|Device|ImageReady System implant|Pacemaker and lead(s) implant
317309|NCT01781065|Device|transcranial direct current stimulation|
317310|NCT01781052|Drug|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
317311|NCT01781039|Device|Hearing Aid fitting|Subjects with hfPTAs ranging from 0-55 dB HL will be recruitedwith 100 persons self-reporting difficulty HIN (> 50% of the time), and 100 persons reporting little difficulty HIN (< 50% of the time) will be randomly assigned to one of five groups (n = 200) based on enabled HA features using an online random assignment tool. Unaided HIQ and HIN assessments will be conducted in the sound field, and baseline DPOAE and CAP assessments will be measured. Subjects will be fit with binaural premium level receiver-in-the canal HAs (Phonak B90 or equivalent model at the start of the study) with 56 dB SPL gain receivers, using closed domes, and programmed to NAL-NL2 target gain, and randomly assigned to the groups.
317312|NCT01781026|Drug|Vemurafenib|Single arm trial
317313|NCT01781013|Other|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
317314|NCT01781000|Behavioral|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
317315|NCT01781000|Behavioral|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
317316|NCT01781000|Behavioral|Treatment as usual|standard treatment protocol of schizophrenia ward
317317|NCT01780987|Drug|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
317318|NCT01780987|Drug|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
317319|NCT01780987|Drug|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
317320|NCT01780974|Drug|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
317321|NCT01780974|Drug|Placebo|placebo capsules
317322|NCT01780948|Drug|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
317323|NCT01780948|Drug|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
317324|NCT01780935|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
317325|NCT01780922|Other|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
317326|NCT01780922|Other|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
317334|NCT01780870|Dietary Supplement|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
317335|NCT01780844|Drug|ASKP1240|intravenous infusion
317336|NCT01780844|Drug|Tacrolimus|intravenous or oral
317337|NCT01780844|Drug|Mycophenolate Mofetil (MMF)|intravenous or oral
317338|NCT01780844|Drug|Basiliximab|intravenous
317339|NCT01780844|Drug|Methylprednisone|Intravenous
317340|NCT01780844|Drug|Prednisone|Oral
317341|NCT01780831|Drug|Raltegravir|RAL will be given as oral granules for suspension. Dose may be modified after ongoing PK and safety analyses.
317342|NCT01780818|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
317343|NCT01780818|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
317344|NCT01780818|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
317345|NCT01780792|Other|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
317346|NCT01780779|Other|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.~The MR findings will not have any impact on the treatment."
317347|NCT01780753|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
317348|NCT01780740|Drug|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
317349|NCT01780740|Drug|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
317350|NCT01780727|Procedure|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
317351|NCT01780714|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
317352|NCT01780714|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
317353|NCT01780701|Procedure|Magnetic Resonance Spectroscopy Imaging with rectal probe|
317354|NCT01780688|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
317355|NCT01780688|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
317356|NCT01780675|Radiation|Radiation Prophylactic Cranial Irradiation|
317357|NCT01780675|Radiation|Radiation Hippocampal Avoidance PCI|
317358|NCT01780662|Drug|Brentuximab Vedotin|Given IV
317359|NCT01780662|Drug|Gemcitabine Hydrochloride|Given IV
317360|NCT01780649|Procedure|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
317361|NCT01780649|Procedure|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
317362|NCT01780636|Drug|botulinum toxin|
317363|NCT01780623|Device|Bright white light|
317364|NCT01780623|Device|Dim red light|
317365|NCT01780610|Drug|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
317366|NCT01780610|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
317367|NCT01780584|Drug|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
317368|NCT01780584|Drug|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
317369|NCT01780584|Drug|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
317370|NCT01780571|Procedure|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
317491|NCT01779505|Biological|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
317371|NCT01780558|Other|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
317372|NCT01780558|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
317373|NCT01780545|Drug|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.~Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
317374|NCT01780545|Drug|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.~For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
317375|NCT01780532|Procedure|Photoacoustic Imaging (PAI)|Standard of Care
317376|NCT01780519|Drug|lorazepam|single dose of 1 mg lorazepam
317377|NCT01780506|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
317378|NCT01780506|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
317379|NCT01780506|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
317380|NCT01780506|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
317381|NCT01780493|Procedure|The Direct Nipple Ureteroneocystostomy Technique|
317382|NCT01780480|Drug|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
317383|NCT01780480|Drug|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
317384|NCT01780480|Procedure|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
317385|NCT01780467|Behavioral|Role of dopamine|
317386|NCT01780454|Drug|MEDI-507|T-Cell Depleting Agent
317387|NCT01780454|Drug|Rituximab|B-Cell Depleting Agent
317388|NCT01780454|Radiation|Total Body Irradiation|Bone Marrow Depletion
317389|NCT01780454|Radiation|Thymic Irradiation|
317390|NCT01780428|Drug|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
317391|NCT01780428|Drug|Placebo|
317392|NCT01780415|Other|blastocoele aspiration|
317393|NCT01780402|Behavioral|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.~Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.~Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
317394|NCT01780389|Drug|Open-label flexibly dosed milnacipran|
317395|NCT01780376|Procedure|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
317396|NCT01780350|Device|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
317397|NCT01780337|Drug|Oxytocin|Intranasal dose of 20 IU oxytocin
317398|NCT01780337|Other|Saline|Intranasal dose of saline
317399|NCT01780324|Drug|Lidocaine|Intervention - intraurethral lidocaine
317400|NCT01780311|Drug|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
317401|NCT01780311|Procedure|Catheter Ablation|
317402|NCT01780285|Device|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
317403|NCT01780285|Device|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).~In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
317486|NCT01779544|Other|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
317492|NCT01779492|Drug|GL2907|once a day
317493|NCT01779492|Drug|Oxycontine CR 10mg|twice a day
317404|NCT01780272|Other|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
317405|NCT01780259|Drug|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
317406|NCT01780259|Drug|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
317407|NCT01780259|Drug|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
317408|NCT01780246|Drug|nusinersen|Administered by intrathecal (IT) injection
317409|NCT01780233|Drug|Fentanyl 400 µg sublingual spray|
317410|NCT01780233|Drug|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
317411|NCT01780233|Drug|Fentanyl citrate injection 100 µg intravenously|
317412|NCT01780233|Drug|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
317413|NCT01780220|Drug|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
317414|NCT01780207|Device|PFO Closure|
317415|NCT01780181|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
317416|NCT01780181|Drug|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
317417|NCT01780129|Drug|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
317418|NCT01780116|Behavioral|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
317419|NCT01780090|Other|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
317420|NCT01780077|Drug|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
317421|NCT01780077|Drug|Placebo|Multiple intradermal injections of placebo at incision sites
317422|NCT01780064|Behavioral|interviews with a psychologist|interviews with a psychologist
317423|NCT01780064|Behavioral|Questionnaires|Questionnaires
317424|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.~Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
317425|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.~Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
317426|NCT01780038|Behavioral|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
317427|NCT01780038|Behavioral|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
317428|NCT01780025|Behavioral|Auditory evoked potentials and audiometry|
317429|NCT01780025|Behavioral|Auditory evoked potentials|Different protocols for audiometry and auditory evoked potentials
317430|NCT01780012|Behavioral|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
317431|NCT01779999|Other|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
317432|NCT01779973|Behavioral|Remote Observed Dosing|
317433|NCT01779960|Other|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
317487|NCT01779544|Other|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
317434|NCT01779960|Other|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
317435|NCT01779947|Drug|Estradiol Vaginal Tablets 10 mcg|
317436|NCT01779947|Drug|placebo|
317437|NCT01779921|Drug|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
317438|NCT01779921|Drug|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
317439|NCT01779921|Drug|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
317440|NCT01779921|Drug|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
317441|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
317442|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
317443|NCT01779908|Dietary Supplement|Vitamin D|
317444|NCT01779908|Other|Placebo|
317445|NCT01779895|Dietary Supplement|Lactobacillus paracasei probiotic strain|
317446|NCT01779895|Dietary Supplement|Placebo|maltodextrin
317447|NCT01779882|Drug|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
317448|NCT01779882|Drug|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
317449|NCT01779869|Drug|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
317450|NCT01779856|Device|REVEAL Insertable Cardiac Monitor (ICM)|
317451|NCT01779843|Drug|Cytarabine|
317452|NCT01779843|Drug|Idarubicin|
317453|NCT01779843|Drug|Alisertib|
317454|NCT01779830|Drug|LY2624803 - Capsules|Administered orally as capsules.
317455|NCT01779830|Drug|Zolpidem - Tablets|Administered orally as tablets.
317456|NCT01779830|Drug|Placebo - Capsules|Administered orally as capsules.
317457|NCT01779830|Drug|Placebo - Tablets|Administered orally as tablets.
317458|NCT01779817|Behavioral|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
317459|NCT01779804|Procedure|OFAR|OFAR
317460|NCT01779791|Drug|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
317461|NCT01779765|Dietary Supplement|PHGG|
317462|NCT01779765|Dietary Supplement|Maltodextrin|
317463|NCT01779739|Procedure|Perineorrhaphy|Procedure to build up the vaginal opening
317464|NCT01779726|Radiation|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
317465|NCT01779726|Radiation|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
317466|NCT01779713|Genetic|Case-control transcriptomic study|No intervention
317467|NCT01779700|Drug|Fingolimod|0.5mg each day of 8 week cycle
317468|NCT01779700|Drug|placebo|1 tablet each day of 8 week cycle
317469|NCT01779687|Drug|raltegravir|Raltegravir 400 mg BID for 7 days
317470|NCT01779687|Drug|Atorvastatin|Atorvastatin 20 mg QD for 7 days
317471|NCT01779661|Other|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
317472|NCT01779661|Other|Infant Massage|Infant Massage
317473|NCT01779648|Device|DVT-3000|
317474|NCT01779648|Device|SCD Express|
317475|NCT01779635|Device|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
317476|NCT01779635|Device|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
317477|NCT01779622|Other|Mixed meal|Ingestion of mixed meal
317478|NCT01779609|Drug|Bosentan|
317479|NCT01779609|Drug|Placebo|
317480|NCT01779609|Behavioral|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
317481|NCT01779596|Drug|Bosentan|
317482|NCT01779596|Drug|Placebo|
317483|NCT01779570|Drug|Macrolide treatment|
317484|NCT01779557|Drug|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
317485|NCT01779557|Drug|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
317488|NCT01779518|Drug|Sofosbuvir|
317489|NCT01779518|Drug|Ribavirin|
317490|NCT01779518|Drug|Pegylated Interferon|
317840|NCT01776619|Drug|Placebo|14 day repeated BID doses
317495|NCT01779479|Drug|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
317496|NCT01779466|Drug|Desmopressin|
317497|NCT01779466|Drug|Placebo (not active)|
317498|NCT01779453|Drug|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
317499|NCT01779453|Drug|Placebo|Placebo once daily for 8 weeks
317500|NCT01779453|Drug|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
317501|NCT01779440|Behavioral|Electronic Decision Support System|
317502|NCT01779427|Behavioral|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
317503|NCT01779414|Other|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
317504|NCT01779401|Drug|Clopidogrel 75mg|
317505|NCT01779401|Drug|Clopidogrel 150mg|
317506|NCT01779401|Drug|Aspirin 100mg|
317507|NCT01779401|Drug|Cilostazol 100mg|
317508|NCT01779388|Procedure|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
317509|NCT01779375|Drug|Metformin|
317510|NCT01779375|Drug|Glargine|
317511|NCT01779362|Drug|Metformin|Titrated to 1000 mg BID
317512|NCT01779362|Drug|Liraglutide|Titrated to 1.8 mg/day
317513|NCT01779362|Drug|Glargine|Titrated to target fasting glucose <90 mg/dl
317514|NCT01779362|Drug|Placebo|Matching to metformin 1000 mg BI
317515|NCT01779349|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
317516|NCT01779336|Drug|PL225B|"Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~This 21 day administration will define a treatment cycle.~Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
317517|NCT01779323|Other|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
317518|NCT01779284|Drug|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
317519|NCT01779284|Drug|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
317520|NCT01779271|Drug|Pelubiprofen|
317521|NCT01779271|Drug|Loxoprofen|
317522|NCT01779258|Drug|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
317523|NCT01779258|Device|Atopiclair®|1 application in the morning, in the afternoon and in the evening
317524|NCT01779258|Drug|Locatop@|"During the Run-In period:~1 application in the morning and in the evening during a maximum of 21 days"
317525|NCT01779258|Drug|Locapred@|"During the 3 months study treatment:~1 application in the evening in case of flare "
317526|NCT01779245|Dietary Supplement|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
317527|NCT01779245|Dietary Supplement|Placebo|
317528|NCT01779232|Drug|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
317529|NCT01779232|Drug|placebo|administered daily like the active comparator
317530|NCT01779219|Device|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
317531|NCT01779219|Device|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
317532|NCT01779206|Drug|Epirubicin|
317533|NCT01779206|Drug|Cyclophosphamide|
317534|NCT01779206|Drug|Docetaxel|
317535|NCT01779206|Drug|Paclitaxel|
317536|NCT01779193|Dietary Supplement|lactic acid bacteria|oral lactobacillus capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
317537|NCT01779193|Dietary Supplement|cranberry|oral cranberry capsule, one pill daily
317538|NCT01779193|Dietary Supplement|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
317539|NCT01779167|Drug|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 & 27)
317540|NCT01779167|Drug|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 & 28). Lenalidomide will be initiated at a starting dose of 5 mg.
317541|NCT01779167|Drug|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
317542|NCT01779128|Procedure|PET-CT|
317543|NCT01779128|Procedure|MR-PET|
317544|NCT01779102|Biological|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
317545|NCT01779102|Biological|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
317546|NCT01779102|Biological|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
317841|NCT01776619|Drug|PF-06305591|14 day repeated 40mg BID doses
317547|NCT01779089|Drug|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
317548|NCT01779089|Drug|placebo|
317549|NCT01779076|Procedure|30% oxygen|
317550|NCT01779076|Procedure|100% oxygen|
317551|NCT01779063|Behavioral|web based multimedia intervention|cognitive therapy based web intervention
317552|NCT01779063|Other|educational booklet|patient education booklet
317553|NCT01779050|Drug|Doxorubicin|
317554|NCT01779050|Biological|Trastuzumab|
317555|NCT01779050|Drug|Cyclophosphamide|
317556|NCT01779050|Drug|Paclitaxel|
317557|NCT01779050|Drug|Epirubicin|
317558|NCT01779050|Drug|Docetaxel|
317559|NCT01779050|Drug|Carboplatin|
317560|NCT01779050|Drug|Fluorouracil|
317561|NCT01779024|Drug|Ghrelin|
317562|NCT01779024|Drug|Placebo|
317563|NCT01779024|Procedure|fMRI|
317564|NCT01779024|Drug|Alcohol|
317565|NCT01778998|Procedure|MICS-group|Micro incision cataract surgery is done
317566|NCT01778998|Procedure|SICS-group|small incision cataract surgery is done
317567|NCT01778998|Procedure|SICS pre-cut|Small incision cataract surgery with pre-cut is done
317568|NCT01778998|Procedure|SICS stab-incision|Small incision cataract surgery with stab-incision is done
317569|NCT01778985|Drug|Premarin|
317570|NCT01778985|Other|Placebo|
317571|NCT01778972|Other|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.~The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
317572|NCT01778972|Other|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
317573|NCT01778959|Device|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
317574|NCT01778959|Device|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
317575|NCT01778959|Device|standard OVD|use of a standard cohesive OVD during cataract surgery
317576|NCT01778959|Device|OVD|use of a highly cohesive OVD during cataract surgery
317577|NCT01778946|Drug|Low Dose Nicotine (7mg)|
317578|NCT01778946|Drug|Moderate Dose Nicotine (14mg)|
317579|NCT01778933|Drug|EC17|
317580|NCT01778920|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
317581|NCT01778907|Other|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
317582|NCT01778881|Other|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
317583|NCT01778881|Other|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
317584|NCT01778881|Other|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
317585|NCT01778881|Other|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
317586|NCT01778855|Other|IV t-PA and normothermia|
317587|NCT01778855|Device|IV-tPA and hypothermia|
317588|NCT01778842|Drug|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
317589|NCT01778842|Drug|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
317590|NCT01778829|Procedure|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
317591|NCT01778829|Procedure|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
317592|NCT01778803|Drug|defactinib|
317593|NCT01778803|Drug|Paclitaxel|
317594|NCT01778790|Device|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
317595|NCT01778777|Device|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
317596|NCT01778751|Behavioral|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
317597|NCT01778738|Procedure|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
317598|NCT01778738|Procedure|Sleeve gastrecomy|Vertical sleeve gastrectomy
317599|NCT01778738|Procedure|Bastric bypass|Gastric bypass surgery
317600|NCT01778712|Behavioral|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
317601|NCT01778699|Dietary Supplement|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.~The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
317602|NCT01778686|Drug|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
317603|NCT01778686|Other|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
317604|NCT01778686|Dietary Supplement|Acute tryptophan depletion|
317605|NCT01778673|Procedure|Cast immobilization|
317606|NCT01778660|Other|Type of Counselling (Mnemonic)|
317607|NCT01778660|Other|Standard|
317608|NCT01778647|Dietary Supplement|Stimulants plus Lovaza|Patients randomized to stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. Conners and CGI scales filled out by parents, teachers and evaluators on each visit
317609|NCT01778647|Drug|Stimulants plus placebo|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
317610|NCT01778634|Drug|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
317611|NCT01778634|Drug|Placebo|D5W
317612|NCT01778621|Device|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
317613|NCT01778556|Biological|Metreleptin|Recombinant analog of the human hormone, leptin
317614|NCT01778530|Drug|TRC105|Intravenous infusion.
317615|NCT01778517|Other|Group Psychotherapy|
317616|NCT01778517|Other|Cognitive behavior therapy based on self help|
317617|NCT01778465|Behavioral|Low salicylate diet|
317618|NCT01778452|Procedure|endometrial biopsy|endometrial biopsy
317619|NCT01778439|Drug|OMP-52M51|
317620|NCT01778413|Drug|ATRIPLA|
317621|NCT01778400|Procedure|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
317622|NCT01778400|Procedure|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
317623|NCT01778387|Procedure|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
317624|NCT01778374|Other|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
317625|NCT01778374|Other|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
317626|NCT01778348|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
317627|NCT01778348|Device|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
317628|NCT01778335|Procedure|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
317629|NCT01778322|Procedure|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
317630|NCT01778309|Dietary Supplement|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise"
317631|NCT01778296|Device|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
317632|NCT01778283|Biological|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
317633|NCT01778270|Device|Body Bioimpedance Sensor|
317634|NCT01778257|Dietary Supplement|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
317635|NCT01778257|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Mate extracts.
317636|NCT01778244|Drug|metformin|1000mg/day for 24 weeks
317637|NCT01778231|Dietary Supplement|Nutrof Total|Antioxidant and trace element supplement
317638|NCT01778231|Dietary Supplement|Placebo|
317639|NCT01778218|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
317640|NCT01778205|Other|Observational|
317641|NCT01778192|Drug|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
317642|NCT01778192|Drug|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
317643|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
317644|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
317645|NCT01778179|Drug|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2)treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.~Post-procedure phase (From week 2 up to Week 13 - Visit )~- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
317646|NCT01778179|Procedure|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
317647|NCT01778166|Drug|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
317648|NCT01778166|Drug|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
317842|NCT01776619|Drug|Placebo|14 day repeated BID doses
317649|NCT01778153|Behavioral|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
317650|NCT01778140|Other|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
317651|NCT01778140|Other|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
317652|NCT01778127|Behavioral|Activity Monitor|Measurement of physical activity.
317653|NCT01778127|Behavioral|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
317654|NCT01778127|Behavioral|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
317655|NCT01778114|Dietary Supplement|Vitamin D2 in orange juice|1000 IU dose
317656|NCT01778114|Dietary Supplement|Vitamin D3 in orange juice|1000 IU
317657|NCT01778114|Dietary Supplement|Vitamin D2|capsule, 1000 IU
317658|NCT01778114|Dietary Supplement|Vitamin D3|capsule, 1000 IU
317659|NCT01778114|Other|Placebo|Placebo
317660|NCT01778101|Drug|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
317661|NCT01778088|Drug|I-131-CLR1404 Injection|
317662|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
317663|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
317664|NCT01778062|Drug|Indacaterol|Indacaterol 150µg once daily oral inhalation
317665|NCT01778062|Drug|Control|Placebo once daily oral inhalation
317666|NCT01778049|Drug|BI 10773|Empagliflozin active
317667|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
317668|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
317669|NCT01778049|Drug|BI 10773|Empagliflozin active
317670|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
317671|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
317672|NCT01778049|Drug|BI 10773|Empagliflozin active
317673|NCT01778049|Drug|BI 10773|Empagliflozin active
317674|NCT01778049|Drug|BI 10773|Empagliflozin active
317675|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
317676|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
317677|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
317678|NCT01778049|Drug|BI 10773|Empagliflozin active
317679|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
317680|NCT01778023|Drug|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
317681|NCT01778010|Drug|Modafinil 0 mg|Modafinil (0 mg/day)
317682|NCT01778010|Drug|Modafinil 200 mg|Modafinil (200 mg/day)
317683|NCT01778010|Drug|Modafinil 400 mg|Modafinil (400 mg/day)
317684|NCT01778010|Drug|Cocaine 0 mg|Cocaine (0 mg/day)
317685|NCT01778010|Drug|Cocaine 12 mg|Cocaine (12 mg/day)
317686|NCT01778010|Drug|Cocaine 25 mg|Cocaine (25 mg/day)
317687|NCT01778010|Drug|Cocaine 50 mg|Cocaine (50 mg/day)
317688|NCT01777997|Drug|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|
317689|NCT01777945|Drug|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
317690|NCT01777945|Drug|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
317691|NCT01777919|Drug|Temozolomide|
317692|NCT01777919|Drug|Disulfiram|
317693|NCT01777919|Drug|Copper|
317694|NCT01777893|Behavioral|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
317695|NCT01777893|Behavioral|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
317696|NCT01777893|Behavioral|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
317697|NCT01777893|Behavioral|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
317698|NCT01777867|Procedure|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
317699|NCT01777867|Procedure|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
317786|NCT01777152|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
317787|NCT01777152|Drug|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
317788|NCT01777152|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
317700|NCT01777854|Drug|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
317701|NCT01777841|Other|Electronic Care plan delivery|
317702|NCT01777841|Other|Standard care|
317703|NCT01777815|Device|NeoChord DS1000 Artificial Chordae Delivery System|
317704|NCT01777802|Radiation|SBRT|
317705|NCT01777802|Radiation|IMRT|
317706|NCT01777802|Radiation|Brachytherapy|
317707|NCT01777776|Drug|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
317708|NCT01777776|Drug|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
317709|NCT01777763|Drug|Posaconazole 200 mg|
317710|NCT01777763|Drug|Posaconazole 300 mg|
317711|NCT01777750|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
317712|NCT01777737|Drug|Cotrimoxazole|24 weeks of treatment
317713|NCT01777737|Drug|Placebo|Identical capsules to cotrimoxazole
317714|NCT01777724|Behavioral|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
317715|NCT01777711|Behavioral|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
317716|NCT01777711|Behavioral|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
317717|NCT01777685|Drug|Sulpiride|
317718|NCT01777672|Behavioral|Dietary and oral hygiene recommendations|
317719|NCT01777672|Dietary Supplement|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
317720|NCT01777672|Device|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
317721|NCT01777672|Device|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
317722|NCT01777659|Device|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
317723|NCT01777646|Biological|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
317724|NCT01777633|Radiation|Palliative re-irradiation for progressive DIPG in children|
317725|NCT01777620|Biological|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
317726|NCT01777620|Drug|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
317727|NCT01777607|Device|IMPELLA® RP|
317728|NCT01777594|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
317729|NCT01777581|Drug|Milnacipran|
317730|NCT01777581|Drug|Placebo|
317731|NCT01777568|Drug|30% oxygen|Inspired oxygen will be maintained at 30%.
317732|NCT01777568|Drug|80% oxygen|Inspired oxygen will be maintained at 30%.
317733|NCT01777555|Drug|CVT-301|
317734|NCT01777555|Drug|Placebo|
317735|NCT01777542|Drug|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
317736|NCT01777542|Drug|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
317737|NCT01777529|Biological|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
317738|NCT01777503|Drug|prasugrel|prasugrel 5 mg o.d.
317739|NCT01777503|Drug|Clopidogrel|75 mg o.d.
317740|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number. The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
317789|NCT01777139|Drug|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
317741|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences - HI FIVES|In addition to the usual care activities outline in the Control arm, Caregivers in the HI-FIVES group will receive three individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. The calls will be tailored to the individual needs of Veteran-caregiver dyad. After the phone calls, caregivers will participate in four evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator and the PI and VA Caregiver Support Staff. The sessions will be targeted to address common needs of Veterans and their caregivers. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
317742|NCT01777477|Drug|Chloroquine|Addition of Chloroquine to Gemcitabine
317743|NCT01777477|Drug|Gemcitabine|
317744|NCT01777464|Biological|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
317745|NCT01777464|Biological|sham|sham solution
317746|NCT01777451|Other|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
317747|NCT01777412|Drug|Bevacizumab|
317748|NCT01777386|Procedure|preexpanded perforator flap surgery|
317749|NCT01777360|Device|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
317750|NCT01777347|Drug|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
317751|NCT01777347|Drug|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
317752|NCT01777334|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
317753|NCT01777334|Drug|Tiotropium 18 mcg|Inhalation Powder
317754|NCT01777321|Biological|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
317755|NCT01777308|Biological|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
317756|NCT01777295|Biological|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
317757|NCT01777295|Biological|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
317758|NCT01777295|Biological|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
317759|NCT01777282|Drug|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
317760|NCT01777282|Drug|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
317761|NCT01777282|Drug|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
317762|NCT01777282|Drug|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
317763|NCT01777282|Drug|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
317764|NCT01777282|Drug|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
317765|NCT01777269|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
317766|NCT01777269|Drug|Placebo|Take one capsule daily
317767|NCT01777256|Drug|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
317768|NCT01777256|Drug|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
317769|NCT01777256|Drug|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
317770|NCT01777256|Drug|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
317771|NCT01777256|Drug|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
317772|NCT01777243|Drug|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg [approximately equivalent to 0.1 mg/ kg]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
317773|NCT01777243|Drug|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
317774|NCT01777230|Procedure|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
317775|NCT01777230|Procedure|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
317776|NCT01777230|Procedure|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
317777|NCT01777217|Drug|Solifenacin succinate|IGRT with VESIcare
317778|NCT01777217|Drug|Placebo|IGRT with placebo
317779|NCT01777191|Drug|Ixekizumab Auto-Injector|Administered SC by auto-injector
317780|NCT01777191|Drug|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
317781|NCT01777178|Other|Low bicarbonate dialysis|
317782|NCT01777165|Drug|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
317783|NCT01777165|Drug|Placebo|Placebo infusion
317784|NCT01777152|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
317785|NCT01777152|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
317790|NCT01777126|Other|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
317791|NCT01777126|Other|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
317792|NCT01777113|Other|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
317793|NCT01777113|Other|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
317794|NCT01777113|Other|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
317795|NCT01777100|Drug|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
317796|NCT01777087|Other|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
317797|NCT01777074|Other|Data collection|Questionnaire, Vaccination book
317798|NCT01777061|Drug|[11C]Acetate|intravenous injection of an average of 40 mCi of [11C]Acetate
317799|NCT01777048|Dietary Supplement|Omega-3 Fatty Acids Supplementation|
317800|NCT01777048|Dietary Supplement|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
317801|NCT01777035|Other|early PT OT|"Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.~active assisted ROM in supine position.~treatment is advanced to bed mobility activities~sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~progression to transfer training, and finally pre-gait training and ambulation.~progression of activities dependent on patient tolerance and stability~therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged."
317802|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
317803|NCT01777009|Procedure|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
317804|NCT01776996|Drug|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
317805|NCT01776983|Device|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
317806|NCT01776970|Drug|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
317807|NCT01776957|Device|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
317808|NCT01776931|Dietary Supplement|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
317809|NCT01776892|Drug|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
317810|NCT01776892|Procedure|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
317837|NCT01776619|Drug|PF-06305591|14 day repeated 20mg BID doses
317838|NCT01776619|Drug|Placebo|14 day repeated BID doses
317839|NCT01776619|Drug|PF-06305591|14 day repeated 80mg BID doses
317811|NCT01776866|Procedure|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
317812|NCT01776853|Dietary Supplement|Glucose|
317813|NCT01776853|Dietary Supplement|Fructose|
317814|NCT01776853|Dietary Supplement|Fructans|
317815|NCT01776840|Drug|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
317816|NCT01776840|Drug|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
317817|NCT01776840|Drug|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
317818|NCT01776840|Drug|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
317819|NCT01776801|Other|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
317820|NCT01776788|Drug|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
317821|NCT01776788|Drug|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
317822|NCT01776775|Device|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
317823|NCT01776762|Dietary Supplement|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
317824|NCT01776749|Device|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
317825|NCT01776736|Device|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
317826|NCT01776723|Drug|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
317827|NCT01776710|Behavioral|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
317828|NCT01776697|Drug|pelubiprofen (30mg) tablet IR|
317829|NCT01776697|Drug|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
317830|NCT01776684|Drug|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
317831|NCT01776671|Drug|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
317832|NCT01776658|Drug|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
317833|NCT01776658|Drug|Placebo|Ocular topical administration of placebo for 10 consecutive days
317834|NCT01776645|Behavioral|Compassion Cultivation Training Course|
317835|NCT01776632|Behavioral|Physical activity|Promotoras led 6 free physical activity (PA) classes per week (2 walking groups, 2 cardio dance, and 2 strength training) at participating churches randomized to the intervention condition. Classes included prayer, warm-up, moderate-to-vigorous PA, cool-down, followed by discussion of a monthly health handout. Participants received copies of the handouts each month by mail, which promoted healthy PA habits. Promotoras conducted up to 5 motivational interviewing calls with each participant over the 2-year intervention using a guide to evaluate participants' PA engagement, barriers to being active, and solutions to those barriers. Promotoras advocated for changes to the social and built environments of the churches and surrounding neighborhoods in order to promote PA and healthy behaviors.
317836|NCT01776632|Behavioral|Cancer screening|Promotoras provided a 6-session group-based workshop series on cancer screening and prevention (breast, cervical, colorectal, and skin cancers) at participating churches randomized to the attention-control condition. Participants received informational handouts developed by American Cancer Society and the National Cancer Institute to reinforce learning in addition to lists of local cancer screening resources. Promotoras conducted up to 4 motivational interviewing calls with each participant over the 2-year intervention to encourage screening, help overcome barriers to screening, and provide support for goals.
317843|NCT01776619|Drug|PF-06305591|14 day repeated BID doses
317844|NCT01776619|Drug|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
317845|NCT01776606|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
317846|NCT01776606|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
317847|NCT01776567|Device|Everolimus eluting stents|
317848|NCT01776554|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
317849|NCT01776541|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
317850|NCT01776528|Biological|NGM282|
317851|NCT01776528|Biological|Placebo|
317852|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
317853|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
317854|NCT01776463|Drug|Z-360|
317855|NCT01776463|Drug|placebo|
317856|NCT01776450|Device|Endovascular AAA repair|
317857|NCT01776437|Drug|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
317858|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 2.5 mg twice daily, tablet
317859|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5.0 mg twice daily, tablet
317860|NCT01776424|Drug|Aspirin|Aspirin 100 mg once daily, tablet
317861|NCT01776424|Drug|Aspirin placebo|Placebo(1), matching Aspirin tablets
317862|NCT01776424|Drug|Rivaroxaban placebo|Placebo(2), matching Rivaroxaban tablets
317863|NCT01776424|Drug|Pantoprazole|Subjects who are not on a proton pump inhibitor (PPI) will also be randomized to pantoprazole or pantoprazole placebo
317864|NCT01776411|Drug|forodesine hydrochloride|
317865|NCT01776385|Other|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
317866|NCT01776385|Other|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
317867|NCT01776372|Device|Medela Thopaz Thoracic Drainage System|
317868|NCT01776372|Device|Atrium Express Dry Seal Chest Drain|
317869|NCT01776359|Dietary Supplement|High Protein|2.4g/kg of protein
317870|NCT01776359|Dietary Supplement|Low Protein|1.2g/kg of protein
317871|NCT01776333|Behavioral|video decision aid|
317872|NCT01776320|Drug|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
317873|NCT01776307|Drug|BBI608|BBI608 is administered at 500 mg po bid continuously.
317874|NCT01776307|Drug|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
317875|NCT01776307|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
317876|NCT01776307|Drug|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
317877|NCT01776281|Behavioral|Kangaroo Mother Care|
317878|NCT01776281|Behavioral|Standard Care|
317879|NCT01776268|Other|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
317880|NCT01776255|Behavioral|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
317881|NCT01776255|Behavioral|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
317882|NCT01776229|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
317883|NCT01776216|Other|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
317884|NCT01776216|Other|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
317885|NCT01776203|Drug|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
317886|NCT01776190|Device|UVA1 radiation treatment|
317887|NCT01776138|Other|Collect Blood and Survey Instruments|
317888|NCT01776125|Other|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
317889|NCT01776112|Other|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
317890|NCT01776112|Other|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
317891|NCT01776099|Dietary Supplement|Dietary supplement (4 arms, 2 active, 2 placebo)|
317892|NCT01776086|Behavioral|Neurological testing|
317893|NCT01776073|Behavioral|Patient Navigation|
317894|NCT01776060|Other|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
317895|NCT01776047|Drug|Exforge®|
317896|NCT01776047|Drug|G-0081|
317897|NCT01776034|Behavioral|SystemCHANGE Group Lifestyle counseling|
317898|NCT01776034|Behavioral|Phone Lifestyle Counseling|
317899|NCT01776021|Other|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
317900|NCT01776021|Other|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
317901|NCT01776008|Drug|Akt Inhibitor MK2206|Given PO
317902|NCT01776008|Drug|Anastrozole|Given PO
317903|NCT01776008|Drug|Goserelin Acetate|Given SC
317904|NCT01776008|Other|Laboratory Biomarker Analysis|Correlative studies
317905|NCT01776008|Procedure|Neoadjuvant Therapy|Given before standard-care surgery
317906|NCT01776008|Other|Pharmacological Study|Correlative studies
317907|NCT01776008|Procedure|Therapeutic Conventional Surgery|Undergo standard-care surgery
317908|NCT01775995|Behavioral|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.~Control participants will be offered the intervention after completing the study.~All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
317909|NCT01775995|Other|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
317910|NCT01775982|Other|Psychiatric evaluation|"This evaluation is carried out in several stages:~Assessment of cognitive functioning;~Interview with a relative;~Interview with caregivers;~Evaluation of the presence of delirium according to DSM-IV criteria;~Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;~Reports of adverse events.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
317911|NCT01775982|Other|Geriatric evaluation|"This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.~CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.~A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
317912|NCT01775969|Other|Text Message|A text message with instructions is sent to the patient
317913|NCT01775969|Other|Voicemail|A voicemail with instructions is sent to the patient
317914|NCT01775930|Drug|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
317915|NCT01775904|Drug|LY2886721 in a Capsule|Administered orally.
317916|NCT01775904|Drug|LY2886721 in an orally disintegrating tablet (ODT)|Administered orally.
317917|NCT01775891|Drug|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
317918|NCT01775891|Drug|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
317919|NCT01775878|Device|Telemonitoring Device|Telemonitoring device was installed in patients' homes
317920|NCT01775865|Drug|Salsalate|4 weeks of daily salsalate
317921|NCT01775865|Drug|Placebo (for salsalate)|4 week of daily placebo
317922|NCT01775852|Behavioral|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
317923|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
317924|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
317925|NCT01775826|Other|Measurement|Measured usual (day-to-day) behavior with body-worn sensors.
317926|NCT01775813|Drug|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
317927|NCT01775800|Other|Treatment modification|
317928|NCT01775787|Drug|Nicotine with Tobacco Flavor and Tobacco & Menthol Flavor|Subjects randomized to either Tobacco Flavor group for 7-10 days than crossed over to Tobacco & Menthol Flavor for 7-10 days or Tobacco & Menthol Flavor group for 7-10 days than crossed over to Tobacco Flavor for 7-10 days
317981|NCT01775371|Device|Patient controlled analgesia (PCA)|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
317929|NCT01775774|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
317930|NCT01775761|Drug|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
317931|NCT01775761|Drug|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
317932|NCT01775761|Drug|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
317933|NCT01775748|Other|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
317934|NCT01775748|Other|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
317935|NCT01775735|Device|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
317936|NCT01775722|Device|Pulsed Dye Laser|port wine stain
317937|NCT01775722|Device|Combined Bipolar Radiofrequency&Pulsed Dye Laser|Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
317938|NCT01775709|Device|PE tube with Duckbill Valve|PE tube with Duckbill Valve
317939|NCT01775670|Device|Off-the-shelf splint|Subjects will use an off-the-shelf splint
317940|NCT01775670|Device|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
317941|NCT01775657|Device|Thopaz (Digital drainage)|
317942|NCT01775657|Device|Pleur Evac (Analogue drainage)|
317943|NCT01775644|Drug|Bevacizumab|Administration of treatment will be as used in normal daily routine under local labeling.
317944|NCT01775631|Biological|Urelumab|
317945|NCT01775631|Biological|Rituximab|
317946|NCT01775618|Biological|BAY94-9027|Prophylaxis treatment 25-60 IU/kg at least 1x/week.
317947|NCT01775618|Biological|BAY94-9027|Prophylaxis treatment 25-60 IU/kg 2x/week for 12 weeks.
317948|NCT01775605|Drug|Synera|Synera Pain Patch
317949|NCT01775592|Drug|Arterakin (DHA-PPQ)|
317950|NCT01775579|Drug|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
317951|NCT01775553|Drug|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
317952|NCT01775540|Drug|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
317953|NCT01775540|Drug|Saline solution|Saline solution,1 drop used QID for 4 weeks
317954|NCT01775540|Drug|Maxidex|Eyedrop-1 drop QID for 4 weeks
317955|NCT01775527|Other|blood test|
317956|NCT01775501|Drug|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
317957|NCT01775501|Drug|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
317958|NCT01775501|Drug|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
317959|NCT01775501|Drug|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
317960|NCT01775488|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
317961|NCT01775475|Drug|cyclophosphamide|Given IV
317962|NCT01775475|Drug|doxorubicin hydrochloride|Given IV
317963|NCT01775475|Drug|vincristine sulfate|Given IV
317964|NCT01775475|Drug|prednisone|Given PO
317965|NCT01775475|Drug|lomustine|Given PO
317966|NCT01775475|Drug|etoposide|Given PO
317967|NCT01775475|Drug|cyclophosphamide|Given PO
317968|NCT01775475|Drug|procarbazine hydrochloride|Given PO
317969|NCT01775475|Other|laboratory biomarker analysis|Correlative studies
317970|NCT01775462|Drug|EDI200|3 or 10 mg/kg of EDI200
317971|NCT01775449|Behavioral|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
317972|NCT01775436|Behavioral|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.~Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.~Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
317973|NCT01775436|Behavioral|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.~Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
317974|NCT01775423|Drug|BBI608|
317975|NCT01775410|Device|Wolverine System to perform atherectomy|
317976|NCT01775397|Drug|Fidaxomicin|capsule
317977|NCT01775397|Drug|Vancomycin|capsule
317978|NCT01775397|Drug|Placebo|Capsule
317979|NCT01775384|Dietary Supplement|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
317980|NCT01775384|Dietary Supplement|Placebo|
317982|NCT01775371|Other|Usual Care|Usual opioid analgesia determined by the provider
317983|NCT01775358|Drug|ALRN-5281 0.015 mg/kg|
317984|NCT01775358|Drug|ALRN-5281 0.05 mg/kg|
317985|NCT01775358|Drug|ALRN-5281 0.15 mg/kg|
317986|NCT01775358|Drug|Placebo 0.015 mg/kg|
317987|NCT01775358|Drug|Placebo 0.05mg/kg|
317988|NCT01775358|Drug|Placebo 0.15mg/kg|
317989|NCT01775345|Procedure|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
317990|NCT01775345|Procedure|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
317991|NCT01775345|Procedure|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
317992|NCT01775345|Procedure|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
317993|NCT01775332|Other|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
317994|NCT01775319|Dietary Supplement|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
317995|NCT01775319|Dietary Supplement|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
317996|NCT01775319|Dietary Supplement|Placebo|
317997|NCT01775293|Device|Non-absorbable polypropylene mesh|"2 step procedures~first step is insertion of Non-absorbable polypropylene mesh under the facial skin~second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
317998|NCT01775280|Radiation|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
317999|NCT01775267|Procedure|Associating liver partition and portal vein ligation for staged hepatectomy|
318000|NCT01775267|Procedure|Portal vein embolization or ligation|
318001|NCT01775228|Behavioral|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
318002|NCT01775215|Radiation|Cardiac I123-MIBG Scintigraphy|
318003|NCT01775215|Other|Cardiac MRI|
318004|NCT01775215|Other|Stress and rest Echocardiogram|
318005|NCT01775215|Other|High Sensitivity Troponin I|
318006|NCT01775215|Other|Brain Natriuretic Peptide|
318007|NCT01775189|Drug|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
318008|NCT01775189|Drug|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
318009|NCT01775189|Drug|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
318010|NCT01775189|Drug|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
318011|NCT01775176|Drug|Metformin|
318012|NCT01775176|Behavioral|Exercise|
318013|NCT01775176|Behavioral|Dietary Restriction|
318014|NCT01775150|Other|health education|Health education via text messaging
318015|NCT01775137|Drug|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
318016|NCT01775124|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
318017|NCT01775111|Behavioral|Cognitive Training|
318018|NCT01775111|Behavioral|Strength Training|
318019|NCT01775111|Dietary Supplement|FortiFit|
318020|NCT01775098|Drug|allopurinol|No arms will not be change as the study as been closed.
318021|NCT01775085|Behavioral|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts & Sources of Meaning; 2) Identity, Cancer Survivorship, & Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present & Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity & Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, & Humor; and 8) Transitions: Reflections & Hopes for the Future.
318022|NCT01775085|Behavioral|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
318098|NCT01774448|Behavioral|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
318099|NCT01774435|Drug|EN3342|
318100|NCT01774422|Device|Extracorporeal CO2 removal device|
318023|NCT01775072|Genetic|molecular profiling of tumors|"Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies."
318024|NCT01775072|Genetic|Clinical Germline Analysis|"Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list)."
318025|NCT01775059|Device|Integrated sensor and infusion set.|
318026|NCT01775046|Device|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
318027|NCT01775033|Other|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
318028|NCT01775020|Dietary Supplement|L-arginine|
318029|NCT01775007|Device|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
318030|NCT01774994|Other|stable isotope infusion for measurement of metabolism|
318031|NCT01774981|Drug|Placebo|Administered IV
318032|NCT01774981|Drug|LY3016859|Administered IV
318033|NCT01774968|Drug|Human Regular U-500 Insulin|
318034|NCT01774942|Procedure|Procedure/Surgery|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
318035|NCT01774929|Drug|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
318036|NCT01774916|Genetic|blood samples|
318037|NCT01774903|Drug|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
318038|NCT01774877|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
318039|NCT01774877|Drug|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
318040|NCT01774864|Drug|DA-8159 (Udenafil)|
318041|NCT01774864|Drug|Placebo|
318042|NCT01774851|Drug|MM-111|MM-111 (IV)
318043|NCT01774851|Drug|Paclitaxel|Paclitaxel (IV)
318044|NCT01774851|Drug|Trastuzumab|Trastuzumab (IV)
318045|NCT01774838|Drug|Prasugrel|3 months treatment
318046|NCT01774838|Drug|Clopidogrel|3 months treatment
318047|NCT01774825|Dietary Supplement|IQP-CL-101|2 softgels twice a day
318048|NCT01774825|Other|Placebo|2 softgels twice a day
318049|NCT01774812|Dietary Supplement|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
318050|NCT01774812|Dietary Supplement|Ergocalciferol|50,000IU 1x per week for 6 weeks
318051|NCT01774799|Behavioral|Advance care planning intervention|
318052|NCT01774799|Other|Control group|
318053|NCT01774786|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
318054|NCT01774786|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
318055|NCT01774786|Drug|Cisplatin|Participants will receive cisplatin 80 mg/m^2 IV q3w for 6 cycles.
318056|NCT01774786|Drug|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
318057|NCT01774786|Drug|Placebo|Participants will receive pertuzumab placebo IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
318058|NCT01774786|Drug|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
318059|NCT01774773|Drug|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
318101|NCT01774409|Genetic|Blood and tumor samples|"Genetic: Establishment of the genetic and immunologic profile~Whole blood sampling :~1 tube for the constitutional DNA extraction;~3 tubes for ancillary studies and research.~Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.~With the established profile, recommendations will be given by a multidisciplinary molecular board."
318102|NCT01774396|Drug|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
318060|NCT01774773|Drug|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
318061|NCT01774773|Drug|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.~Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.~The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
318062|NCT01774760|Drug|18F-EF5|
318063|NCT01774760|Procedure|Pretreatment PET/CT-scan (performed two times)|
318064|NCT01774747|Drug|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
318065|NCT01774747|Drug|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
318066|NCT01774734|Other|Physical therapy|"Physical therapy~Provided by 2 experienced physiotherapist~Applied to every patients 3 times weekly"
318067|NCT01774734|Device|Neck Strength Exerciser (NSE)|"Neck strength exerciser use 10-20 minutes daily at home~Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
318068|NCT01774721|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
318069|NCT01774721|Drug|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
318070|NCT01774708|Device|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.~This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
318071|NCT01774695|Behavioral|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.~The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
318072|NCT01774682|Procedure|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
318073|NCT01774669|Device|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
318074|NCT01774669|Other|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
318075|NCT01774656|Drug|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
318076|NCT01774630|Drug|Nilotinib|300 mg/twice a day
318077|NCT01774617|Procedure|Comparison of different diagnostic tests|
318078|NCT01774604|Drug|Indomethacin|100 mg Indomethacin PR x 1
318079|NCT01774604|Drug|Placebo|
318080|NCT01774591|Drug|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
318081|NCT01774591|Drug|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
318082|NCT01774578|Drug|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
318083|NCT01774578|Biological|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
318084|NCT01774578|Drug|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
318085|NCT01774578|Drug|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
318086|NCT01774565|Device|Fully Automated Closed-Loop Insulin Delivery|
318087|NCT01774565|Device|Conventional insulin therapy|
318088|NCT01774552|Device|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
318089|NCT01774539|Other|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
318090|NCT01774526|Other|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
318091|NCT01774513|Device|Procore-Needle|
318092|NCT01774487|Drug|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
318093|NCT01774474|Drug|Bromfenac|
318094|NCT01774474|Drug|Dexamethasone|
318095|NCT01774474|Drug|Bevacizumab|
318096|NCT01774474|Drug|Triamcinolone Acetonide|
318097|NCT01774461|Other|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
318103|NCT01774396|Drug|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
318104|NCT01774370|Drug|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
318105|NCT01774344|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib, 40 mg tablets
318106|NCT01774344|Drug|Placebo|Placebo tablets matching in appearance
318107|NCT01774318|Other|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
318108|NCT01774305|Drug|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
318109|NCT01774305|Drug|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
318110|NCT01774292|Procedure|Endotracheal intubation with injection of liquid in the cuff|
318111|NCT01774279|Other|Tissue, blood and clinical data collection|
318112|NCT01774253|Drug|Vismodegib|
318113|NCT01774240|Other|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
318114|NCT01774227|Procedure|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
318115|NCT01774227|Procedure|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
318116|NCT01774214|Procedure|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
318117|NCT01774214|Procedure|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
318118|NCT01774201|Other|Breathing exercises|Breathing exercises with positive expiratory pressure.
318119|NCT01774162|Device|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
318120|NCT01774162|Device|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
318121|NCT01774149|Device|Few Touch Application|Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
318122|NCT01774149|Device|Diastat|Users get the Few Touch Application with Diastat module activated.
318123|NCT01774136|Behavioral|Enhanced HIV and MCH training for CHW|
318124|NCT01774110|Other|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
318125|NCT01774097|Biological|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
318126|NCT01774097|Biological|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
318127|NCT01774084|Dietary Supplement|Experimental: PreOp, NutriciaNordica AB|
318128|NCT01774084|Dietary Supplement|Placebo Comparator: Water|
318129|NCT01774071|Drug|89Zr- DFO-MSTP2109A|"If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~1-4 hours after the injection~24 hours after the injection (the next day, Day 2)~48-120 hours after the injection (on either Day 3, 4, or 5)~144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~At each time of your scheduled PET scan."
318130|NCT01774071|Drug|89Zr DFO-MSTP2109A|"If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (~ 3-7 days after injection).~No research blood work will be drawn in Group 2"
318131|NCT01774058|Drug|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
318132|NCT01774045|Drug|PDC-1421|
318133|NCT01774045|Drug|Placebo|
318134|NCT01774032|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
318135|NCT01774019|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
318136|NCT01774006|Other|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
318137|NCT01773993|Drug|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
318138|NCT01773980|Other|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
318139|NCT01773980|Other|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
318140|NCT01773967|Drug|LGG|LGG 10^10 cfu PO BID X 5 days
318141|NCT01773967|Drug|micro-crystalline cellulose|1 capsule PO bid x 5 days
318142|NCT01773954|Drug|Intravitreal Aflibercept Injection|Increased or decreased time between visits
318143|NCT01773928|Biological|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
318144|NCT01773928|Biological|VCIV manufactured with the current manufacturing process (VCIV current)|
318145|NCT01773928|Biological|Fluzone®, licensed trivalent influenza vaccine (TIV)|
318146|NCT01773902|Dietary Supplement|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
318147|NCT01773902|Dietary Supplement|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
318148|NCT01773902|Dietary Supplement|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
318149|NCT01773889|Drug|Denileukin Diftitox/SC Pegylated IFNα-2a|
318150|NCT01773876|Drug|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%~infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
318151|NCT01773876|Drug|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
318152|NCT01773850|Device|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
318153|NCT01773837|Drug|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
318154|NCT01773837|Drug|placebo|placebo (pill) p.o.
318155|NCT01773824|Behavioral|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
318156|NCT01773824|Behavioral|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
318157|NCT01773811|Behavioral|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
318158|NCT01773811|Behavioral|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
318159|NCT01773798|Drug|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
318160|NCT01773798|Drug|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
318161|NCT01773798|Drug|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
318162|NCT01773798|Drug|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
318163|NCT01773798|Drug|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
318164|NCT01773785|Drug|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
318165|NCT01773772|Drug|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those or = to 42 kg.
318166|NCT01773772|Drug|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
318167|NCT01773759|Behavioral|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
318168|NCT01773746|Other|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
318169|NCT01773707|Drug|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
318170|NCT01773707|Drug|Placebo|Saline given as 30 minute IV infusion
318171|NCT01773694|Behavioral|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.~On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
318208|NCT01773408|Drug|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m^2 IV infusion daily.
318616|NCT01769976|Other|Energy balance diet|
318172|NCT01773681|Drug|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.~After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
318173|NCT01773681|Device|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
318174|NCT01773681|Device|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
318175|NCT01773668|Device|Integrated sensor and infusion set.|
318176|NCT01773655|Other|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).~Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
318177|NCT01773642|Behavioral|Cognitive behavioral intervention to support pediatric HIV disclosure|
318178|NCT01773629|Other|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
318179|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
318180|NCT01773616|Drug|Oral prednisolone|
318181|NCT01773616|Drug|Rituximab|
318182|NCT01773616|Drug|Mycophenolate mofetil|
318183|NCT01773616|Drug|Methyl prednisolone|
318184|NCT01773603|Device|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
318185|NCT01773590|Other|Rhinovirus Infection|
318186|NCT01773564|Device|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
318187|NCT01773564|Device|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
318188|NCT01773551|Other|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
318189|NCT01773538|Drug|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
318190|NCT01773538|Dietary Supplement|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
318191|NCT01773538|Other|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
318192|NCT01773512|Drug|Rosuvastatin|All patients will be using rosuvastatin 40 mg
318193|NCT01773486|Drug|Hesperidin|Citrus polyphenol, hesperidin
318194|NCT01773486|Drug|Placebo|Placebo matching hesperidin
318195|NCT01773473|Drug|Insulin Lispro Mix25|Administered SC
318196|NCT01773473|Drug|Insulin Lispro Mix50|Administered SC
318197|NCT01773460|Drug|Everolimus|Everolimus is given beyond progress (comparison with placebo)
318198|NCT01773460|Drug|Everolimus-placebo|Everolimus-placebo
318199|NCT01773447|Procedure|Set-back suture|
318200|NCT01773447|Procedure|Vertical mattress suture|
318201|NCT01773434|Drug|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.~Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).~Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
318202|NCT01773421|Drug|E7820|"FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
318203|NCT01773421|Drug|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation,the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
318204|NCT01773408|Drug|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
318205|NCT01773408|Drug|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
318206|NCT01773408|Drug|Idarubicin|Idarubicin will be administered as per standard clinical practice.
318207|NCT01773408|Drug|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
318381|NCT01771991|Drug|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
318209|NCT01773395|Biological|GVAX|GVAX or placebo vaccination will begin between 30 to 45 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the GVAX arm will receive GVAX vaccine.
318210|NCT01773395|Biological|Placebo Vaccine|GVAX or placebo vaccination will begin between 30 to 45 days following participant's transplant, provided participant meets vaccination initiation criteria. Only participants in the placebo arm will receive placebo vaccine.
318211|NCT01773395|Procedure|Allogeneic Hematopoietic Stem Cell Transplant|Between 1-2 days after participant finishes the chemotherapy, the participant will receive the blood stem cell or marrow from their donor. This is given as a transfusion through a central intravenous line (IV usually placed in the chest or arm).
318212|NCT01773395|Drug|Busulfan|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
318213|NCT01773395|Drug|Fludarabine|In this study the condition regimen will include 2 chemotherapy drugs: busulfan (twice a day or four times a day for 5 days) and fludarabine (once daily for 4 days). Depending on participant's age, and other clinical factors, the transplant doctor will decide whether the participant will receive a higher or lower dose of busulfan.
318214|NCT01773395|Drug|Tacrolimus|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
318215|NCT01773395|Drug|Methotrexate|"Just prior to and immediately following the infusion of stem cells, the participant will receive medications to help prevent graft-versus-host disease (GVHD), a common complication of transplant where the donor's immune cells attack the recipient's body. The medications the participant will receive to prevent GVHD will include:~Tacrolimus- This will be taken orally twice daily start 3 days before the transplant, and will continue for about 6-9 months.~Methotrexate- This will be given a short intravenous infusion on days 1, 3, 6, and 11 after the transplant."
318216|NCT01773382|Behavioral|weight reduction|"Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)~Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.~Daily body weight measurement.~Record food diary"
318217|NCT01773369|Behavioral|Early leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therapist in the clinical setting.
318218|NCT01773369|Behavioral|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur ~3 months after recruitment.
318219|NCT01773369|Behavioral|Parent leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
318220|NCT01773356|Dietary Supplement|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
318221|NCT01773343|Procedure|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
318222|NCT01773330|Procedure|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
318223|NCT01773330|Dietary Supplement|Gatorade|The patient will be given Gatorade to drink at various times during the study.
318224|NCT01773330|Other|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
318225|NCT01773330|Other|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
318226|NCT01773330|Procedure|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
318227|NCT01773330|Procedure|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
318228|NCT01773317|Other|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
318229|NCT01773317|Other|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
318230|NCT01773304|Other|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
318231|NCT01773291|Other|acupuncture|acupuncture on GV26 and 12 Well points
318232|NCT01773291|Other|laser acupuncture|laser acupuncture on GV26 and 12 Well points
318233|NCT01773291|Other|control|sham laser acupuncture
318234|NCT01773278|Drug|Antioxidants|Patients will be prescribed the drug AquADEKS or DEKAs at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings.
318235|NCT01773278|Drug|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels > 100 mg/dl if possible
318236|NCT01773252|Device|Flow Detection System|
318237|NCT01773239|Behavioral|TARA computer-based exercises|
318382|NCT01771978|Drug|Placebo|Received 250 ml of a 5% dextrose solution as placebo
318238|NCT01773226|Device|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
318239|NCT01773213|Procedure|Ice-water-test|
318240|NCT01773187|Drug|Pacritinib|
318241|NCT01773187|Drug|Best Available Therapy|
318242|NCT01773174|Drug|dabigatran etexilate|age & weight adjusted equivalent of adult dose
318243|NCT01773161|Procedure|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
318244|NCT01773148|Device|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
318245|NCT01773135|Other|collection of blood sample and tocolysis adminstration|"investigators will abtain a blood sample from all patient to measure the serum level of ACTH.~all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.~After delivery, investigators devide the pateints into 2 groups (full term delivery & preterm delivery) and investigators compare between these 2 groups by level of hormone."
318246|NCT01773122|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
318247|NCT01773122|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
318248|NCT01773122|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
318249|NCT01773122|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
318250|NCT01773109|Drug|Etirinotecan pegol (NKTR-102)|Eligible patients will receive etirinotecan pegol at a dose of 145 mg/m2 iv every 3 weeks. One cycle will be defined as 3 weeks. Treatment will be administered on an outpatient basis.
318251|NCT01773096|Drug|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
318252|NCT01773096|Drug|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
318253|NCT01773083|Drug|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
318254|NCT01773083|Drug|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
318255|NCT01773070|Drug|ABT-450/ritonavir|ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.
318256|NCT01773070|Drug|ABT-333|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
318257|NCT01773070|Drug|ABT-267|Drug is not administered -- this study is follow-up for participants previously receiving the drug.
318258|NCT01773057|Other|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
318259|NCT01773044|Drug|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
318260|NCT01773044|Drug|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
318261|NCT01773044|Drug|Placebo (for alcalinized lidocaine)|
318262|NCT01773018|Drug|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
318263|NCT01773005|Drug|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
318264|NCT01773005|Drug|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
318265|NCT01772992|Behavioral|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
318266|NCT01772979|Drug|Trabectedin|
318267|NCT01772966|Procedure|Spinal manipulation|
318268|NCT01772953|Drug|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
318269|NCT01772940|Drug|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
318270|NCT01772940|Drug|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
318271|NCT01772940|Drug|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
318272|NCT01772940|Drug|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
318273|NCT01772927|Dietary Supplement|Parenteral Nutrition|Protein and energy intakes
318274|NCT01772901|Other|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
318275|NCT01772875|Procedure|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
318693|NCT01769378|Drug|Placebo|Administered SQ
318276|NCT01772862|Behavioral|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.~Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
318277|NCT01772849|Behavioral|Intervention group|"The intervention components includes (real time sequence):~An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.~Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
318278|NCT01772836|Drug|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
318279|NCT01772836|Drug|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
318280|NCT01772836|Drug|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
318281|NCT01772823|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
318282|NCT01772823|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
318283|NCT01772823|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
318284|NCT01772810|Drug|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
318285|NCT01772797|Drug|LDK378|LDK378 is a capsule to be taken daily by mouth.
318286|NCT01772797|Drug|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
318287|NCT01772784|Other|Phenolic acids|Phenolic acids
318288|NCT01772758|Drug|BH4 5mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 5 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
318289|NCT01772758|Drug|BH4 20mg|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects received an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
318290|NCT01772758|Dietary Supplement|Antioxidant Cocktail|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
318291|NCT01772745|Procedure|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
318292|NCT01772745|Procedure|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
318293|NCT01772732|Drug|Simotinib Hydrochloride|
318294|NCT01772719|Drug|Simvastatin and zoledronic acid|"Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
318295|NCT01772706|Procedure|low level laser therapy|
318296|NCT01772706|Procedure|placebo (laser low level energy nonfunctional)|
318297|NCT01772693|Device|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
318298|NCT01772693|Device|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
318299|NCT01772680|Dietary Supplement|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
318300|NCT01772667|Procedure|Inpatient Rehabilitation|"Rehabilitation program in Schoen Klinik Berchtesgadener Land"
318301|NCT01772654|Device|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.~This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
318302|NCT01772641|Other|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
318303|NCT01772641|Other|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
318304|NCT01772641|Other|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
318305|NCT01772641|Other|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
318306|NCT01772628|Behavioral|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
318307|NCT01772628|Behavioral|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
318308|NCT01772628|Behavioral|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
318309|NCT01772628|Behavioral|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
318310|NCT01772615|Drug|Ciprofloxacin|Antibiotic
318311|NCT01772615|Dietary Supplement|E. coli Nissle|Probiotic
318312|NCT01772589|Procedure|New saw blade|
318313|NCT01772589|Procedure|Reprocessed saw blade|
318314|NCT01772576|Device|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
318315|NCT01772563|Drug|volasertib|cycle in 21 days
318316|NCT01772563|Drug|itraconazole|over 18 days
318317|NCT01772550|Device|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
318318|NCT01772550|Device|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.~If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
318319|NCT01772537|Drug|Propofol|Intravenous anesthetic
318320|NCT01772537|Drug|isoflurane|
318321|NCT01772524|Biological|ALD403|
318322|NCT01772524|Drug|Placebo|
318323|NCT01772511|Behavioral|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
318324|NCT01772498|Behavioral|heart rate variability biofeedback|
318325|NCT01772485|Behavioral|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
318326|NCT01772485|Behavioral|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
318327|NCT01772472|Drug|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
318328|NCT01772472|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
318329|NCT01772446|Behavioral|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
318330|NCT01772433|Dietary Supplement|Olive oil|Phonophoresis with Olive oil for 10 day, daily
318331|NCT01772433|Drug|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
318332|NCT01772420|Drug|Eltrombopag Olamine|Given PO
318333|NCT01772420|Other|Laboratory Biomarker Analysis|Correlative studies
318334|NCT01772420|Drug|Lenalidomide|Given PO
318335|NCT01772394|Behavioral|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
318336|NCT01772394|Behavioral|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
318337|NCT01772381|Drug|Dexamethasone|Long acting corticosteroid
318383|NCT01771978|Drug|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
318384|NCT01771978|Drug|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
318421|NCT01771666|Drug|Isosulfan blue|"3 to 5 mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
318422|NCT01771666|Drug|99technetium-sulfur colloid radiolabel|
318338|NCT01772368|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
318339|NCT01772368|Drug|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
318340|NCT01772368|Drug|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
318341|NCT01772368|Drug|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
318342|NCT01772355|Device|semi automated core needle biopsy of orbital tumors|
318343|NCT01772342|Other|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
318344|NCT01772342|Other|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
318345|NCT01772329|Other|Cognitive Therapy|CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
318346|NCT01772329|Other|Routine Care|Routine Care. No Cognitive Therapy Intervention
318347|NCT01772316|Drug|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
318348|NCT01772303|Drug|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
318349|NCT01772290|Drug|fluconazole|Multiple oral doses
318350|NCT01772290|Drug|itraconazole|Multiple oral doses
318351|NCT01772290|Drug|rabeprazole|Multiple oral doses
318352|NCT01772290|Drug|vismodegib|Multiple oral doses
318353|NCT01772264|Drug|PF-05089771|titration from 150mg BID to 450mg BID
318354|NCT01772264|Drug|Placebo|matched placebo
318355|NCT01772251|Drug|Oshadi Icp|
318356|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
318357|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
318358|NCT01772225|Other|Data collection|Medical record abstraction form and patient survey questionnaire.
318359|NCT01772212|Drug|Terbinafine 250 mg|Test product
318360|NCT01772212|Drug|Terbinafine 250 mg|Reference product
318361|NCT01772199|Drug|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
318362|NCT01772199|Drug|Placebo|White to almost white, round tablets. Once daily orally.
318363|NCT01772186|Device|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
318364|NCT01772173|Other|Vessel measurements|Measurement of retinal vessels
318365|NCT01772160|Other|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
318366|NCT01772147|Drug|Umeclidinium bromide 62.5mcg|Inhalation powder
318367|NCT01772147|Drug|Umeclidinium bromide 125mcg|Inhalation powder
318368|NCT01772147|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
318369|NCT01772134|Drug|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
318370|NCT01772134|Drug|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
318371|NCT01772134|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
318372|NCT01772134|Drug|Placebo|Inhalation Powder, Placebo
318373|NCT01772108|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
318374|NCT01772082|Behavioral|Internet mediated walking program|
318375|NCT01772056|Drug|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
318376|NCT01772056|Drug|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
318377|NCT01772030|Other|Use of the Achieve catheter followed by ICE-guided mapping catheter|
318378|NCT01772017|Device|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
318379|NCT01772004|Drug|Avelumab|Avelumab will be administered in study location using a protocol-defined dose escalation scheme until confirmed progression, unacceptable toxicity, or if any criterion for withdrawal from the trial or investigational medicinal product occurs. After determination of the dose and regimen for Expansion Phase, avelumab will be administered to subjects divided into 4 primary cohorts: Non-small cell lung cancer (NSCLC) post platinum doublet, NSCLC first-line, gastric/gastroesophageal junction (GEJ) cancer and metastatic breast cancer (MBC); 8 secondary cohorts: Colorectal cancer (CRC), castrate-resistant prostate cancer (CRPC), melanoma, ovarian cancer, adrenocortical carcinoma (ACC) mesothelioma, urothelial carcinoma, and renal cell carcinoma (RCC); and 4 efficacy expansion cohorts: gastric and GEJ cancer (third line), ovarian cancer (second-line only), urothelial carcinoma, and head and neck squamous cell carcinoma (HNSCC).
318380|NCT01771991|Drug|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
318385|NCT01771978|Drug|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein~bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution~150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
318386|NCT01771965|Behavioral|CB Intervention|The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
318387|NCT01771952|Device|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
318388|NCT01771952|Other|Sham Treatment|A single needle stick without arthrocentesis or injection.
318389|NCT01771939|Procedure|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
318390|NCT01771939|Procedure|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
318391|NCT01771926|Other|potatoes|Daily intake of assigned treatment for 8 weeks
318392|NCT01771926|Other|other carbohydrate|Daily intake of assigned treatment for 8 weeks
318393|NCT01771913|Genetic|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
318394|NCT01771913|Genetic|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
318395|NCT01771900|Behavioral|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
318396|NCT01771900|Behavioral|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
318397|NCT01771887|Behavioral|education program|education program in 6 hours and monitoring phone every 15 days
318398|NCT01771874|Drug|MDMA|125 mg per os, single dose
318399|NCT01771874|Drug|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
318400|NCT01771874|Drug|Placebo|per os
318401|NCT01771861|Other|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
318402|NCT01771848|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
318403|NCT01771822|Drug|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
318404|NCT01771822|Drug|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
318405|NCT01771822|Drug|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
318406|NCT01771822|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
318407|NCT01771809|Drug|75mg SHP647 (PF-00547659)|75 mg sterile liquid injected subcutaneously every 4 weeks.
318408|NCT01771809|Drug|225mg SHP647 (PF-00547659)|225 mg sterile liquid injected subcutaneously every 4 weeks.
318409|NCT01771796|Behavioral|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
318410|NCT01771783|Drug|ACEI-ARB-RI|
318411|NCT01771783|Drug|ARB-RI-ACEI|
318412|NCT01771783|Drug|RI-ACEI-ARB|
318413|NCT01771731|Drug|Cannabis|
318414|NCT01771718|Device|MPTflex-multiphoton microscopy-based tomograph.|non-invasive optical biopsy
318415|NCT01771705|Other|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is <15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 80% the CNI daily dose will be increased by 15%.
318416|NCT01771692|Other|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
318417|NCT01771692|Other|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
318418|NCT01771679|Biological|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
318419|NCT01771666|Device|SPY Elite Imaging|A camera that is directed into the axillary cavity to try to capture an image of the tumor site labeled with Indocyanine green before and after excising sentinel nodes
318420|NCT01771666|Drug|Indocyanine Green|"started at 1mg /mL~If fluorescence is not detected with this dose, then it will be increased by 50%."
318515|NCT01770899|Drug|Montelukast|
318423|NCT01771640|Biological|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
318424|NCT01771627|Drug|varenicline|Given PO
318425|NCT01771627|Drug|nicotine patch|
318426|NCT01771614|Behavioral|Exercise|
318427|NCT01771614|Procedure|Hyperglycemia|
318428|NCT01771588|Dietary Supplement|Human milk fortifier|
318429|NCT01771575|Other|Placebo device|Placebo device
318430|NCT01771575|Device|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance & gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
318431|NCT01771536|Other|Decision Aid|
318432|NCT01771523|Procedure|Thyroidectomy|total thyroidectomy or lobectomy
318433|NCT01771523|Device|use of drain|drain will be used
318434|NCT01771497|Device|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
318435|NCT01771484|Device|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
318436|NCT01771471|Biological|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
318437|NCT01771471|Other|Placebo|0.9% w/v Sodium Chloride for Injection, USP
318438|NCT01771458|Drug|Targeted therapy based on molecular profiling : Imatinib|
318439|NCT01771458|Procedure|Tumor biopsy|
318440|NCT01771458|Drug|Standard Chemotherapy|
318441|NCT01771458|Drug|Targeted therapy based on molecular profiling : Everolimus|
318442|NCT01771458|Drug|Targeted therapy based on molecular profiling : Vemurafenib|
318443|NCT01771458|Drug|Targeted therapy based on molecular profiling : Sorafenib|
318444|NCT01771458|Drug|Targeted therapy based on molecular profiling : Erlotinib|
318445|NCT01771458|Drug|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
318446|NCT01771458|Drug|Targeted therapy based on molecular profiling : Dasatinib|
318447|NCT01771458|Drug|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
318448|NCT01771458|Drug|Targeted therapy based on molecular profiling : Abiraterone|
318449|NCT01771445|Drug|IL-1Ra|100mg, s.c, once only
318450|NCT01771445|Drug|Placebo|100mg, s.c., once only
318451|NCT01771432|Drug|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
318452|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
318453|NCT01771419|Device|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
318454|NCT01771419|Device|Cannulotome CT-25mm Cook Medical|
318455|NCT01771406|Drug|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
318456|NCT01771406|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
318457|NCT01771393|Device|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
318458|NCT01771393|Device|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
318459|NCT01771367|Biological|Fluad|
318460|NCT01771367|Biological|Agrippal|
318461|NCT01771367|Biological|Placebo|
318462|NCT01771354|Biological|Engerix B Vaccine|
318463|NCT01771354|Biological|Placebo|
318464|NCT01771341|Device|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
318465|NCT01771341|Device|MAQUET SERVOi ventilator|Pressure Support
318466|NCT01771328|Drug|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
318467|NCT01771328|Drug|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
318468|NCT01771315|Behavioral|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
318469|NCT01771302|Device|Bio-Oss|It is a bone substitute of bovine origin
318470|NCT01771302|Device|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
318471|NCT01771289|Drug|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
318472|NCT01771289|Radiation|Radiation|chemoradiation
318473|NCT01771276|Device|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
318474|NCT01771263|Device|iControl-RP|
318475|NCT01771250|Biological|Insulin Peglispro|Daily doses administered SC.
318476|NCT01771250|Biological|Insulin Glargine|Daily doses administered SC.
318477|NCT01771237|Behavioral|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
318478|NCT01771237|Behavioral|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
318479|NCT01771224|Dietary Supplement|Palmitoleic acid|Palmitoleic acid and 5-ASA
318516|NCT01770899|Drug|Placebo|Gelatin capsule given every 24 hours
318517|NCT01770886|Drug|UE2343|Oral capsule
318518|NCT01770886|Drug|Placebo|Oral capsule
318480|NCT01771211|Device|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
318481|NCT01771198|Drug|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
318482|NCT01771185|Procedure|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
318483|NCT01771185|Drug|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
318484|NCT01771159|Device|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor [bladder] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.~After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
318485|NCT01771146|Drug|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
318486|NCT01771133|Behavioral|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
318487|NCT01771120|Other|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
318488|NCT01771107|Drug|Brentuximab Vedotin|Given IV
318489|NCT01771107|Drug|Dacarbazine|Given IV
318490|NCT01771107|Drug|Doxorubicin Hydrochloride|Given IV
318491|NCT01771107|Other|Pharmacological Study|Correlative studies
318492|NCT01771107|Drug|Vinblastine|Given IV
318493|NCT01771094|Behavioral|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:~The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
318494|NCT01771081|Drug|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
318495|NCT01771068|Behavioral|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
318496|NCT01771055|Procedure|Galactose|Galactose dripped into the abdomen after surgery
318497|NCT01771055|Procedure|Standard surgical methods|
318498|NCT01771042|Other|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
318499|NCT01771003|Device|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
318500|NCT01770990|Behavioral|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
318501|NCT01770990|Behavioral|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
318502|NCT01770977|Device|Light-emitting diode therapy|
318503|NCT01770977|Device|Placebo light-emitting diode therapy|
318504|NCT01770964|Drug|Pregabalin|
318505|NCT01770964|Drug|placebo|
318506|NCT01770964|Behavioral|Training Type A|
318507|NCT01770964|Behavioral|Training Type B|
318508|NCT01770938|Device|Effective light-emitting diode therapy|
318509|NCT01770938|Device|Placebo light-emitting diode therapy|
318510|NCT01770925|Device|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.~CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.~If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
318511|NCT01770925|Device|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.~The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
318512|NCT01770925|Device|NIPPV|The NIPPV group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water).
318513|NCT01770912|Drug|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
318514|NCT01770912|Drug|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
318519|NCT01770873|Behavioral|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
318520|NCT01770860|Device|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
318521|NCT01770860|Device|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
318522|NCT01770860|Device|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
318523|NCT01770860|Device|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
318524|NCT01770821|Other|Dietary supplement and/or physical training|
318525|NCT01770808|Dietary Supplement|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
318526|NCT01770808|Dietary Supplement|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
318527|NCT01770808|Dietary Supplement|Placebo|Subjects swallowed 4 capsules/day for six weeks.
318528|NCT01770795|Drug|Genexol-PM/Gemcitabine|
318529|NCT01770782|Procedure|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
318530|NCT01770782|Other|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
318531|NCT01770769|Device|Hemi - arthroplasty|modular hemiarthroplasty
318532|NCT01770769|Device|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
318533|NCT01770756|Behavioral|Self-Care Training|
318534|NCT01770743|Biological|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
318535|NCT01770743|Biological|BioThrax|
318536|NCT01770730|Device|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
318537|NCT01770717|Other|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
318538|NCT01770691|Device|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
318539|NCT01770678|Other|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
318540|NCT01770652|Drug|Deferiprone|Oral iron chelator
318541|NCT01770639|Procedure|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
318542|NCT01770626|Other|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
318543|NCT01770613|Biological|Stem cells|Allogeneic mesenchymal stem cells
318544|NCT01770600|Other|placebo|placebo pill administered daily for 5 days
318545|NCT01770600|Drug|Riperidone|1 mg risperidone administered orally for 5 days
318546|NCT01770587|Behavioral|Behavioral Insomnia Treatment|
318547|NCT01770574|Device|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
318548|NCT01770574|Procedure|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
318549|NCT01770561|Device|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
318550|NCT01770548|Genetic|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
318551|NCT01770548|Genetic|DNA collection|DNA collection
318552|NCT01770548|Other|Auditory evoked potentials|auditory evoked potentials
318553|NCT01770509|Device|NMBM|Daily application of NMBM in addition to compression therapy
318554|NCT01770509|Other|Compression garments|Compression garments
318555|NCT01770496|Behavioral|Childhood vaccination reminder / recall notification|
318556|NCT01770483|Drug|nitazoxanide|nitazoxanide 500mg twice daily
318557|NCT01770483|Drug|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
318558|NCT01770483|Drug|Ribavirin|ribazole
318559|NCT01770470|Dietary Supplement|Chitosan|The product chitosan is contained in a chewing gum formulation
318560|NCT01770444|Other|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure~Prospective gating~Range: dedicated imaging (below carina to heart base)"
318561|NCT01770444|Other|Conventional cardiac CT protocol|"Conventional CCTA protocol~Retrospective gating with tube current modulation~Range: dedicated imaging (below carina to heart base)"
318562|NCT01770431|Drug|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
318608|NCT01770015|Procedure|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
318609|NCT01770015|Procedure|endotracheal aspiration|fungi and bacteria endotracheal aspiration
318610|NCT01770002|Procedure|Everted suture technique|
318611|NCT01770002|Procedure|Non-everted suture technique|
318612|NCT01769989|Procedure|Electrodermabrasion|
318613|NCT01769989|Procedure|Dermabrasion|
318614|NCT01769976|Other|Periodic fasting|
318615|NCT01769976|Other|Energy restriction|
318563|NCT01770418|Radiation|Radiation with Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional."
318564|NCT01770405|Device|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
318565|NCT01770392|Drug|Nintedanib|single dose administration
318566|NCT01770392|Drug|Rifampicin|single dose once daily for 7 days
318567|NCT01770392|Drug|Nintedanib|single dose administration
318568|NCT01770379|Biological|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
318569|NCT01770379|Biological|Placebo|
318570|NCT01770366|Device|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
318571|NCT01770366|Device|Usual Care|
318572|NCT01770353|Drug|Ferumoxytol|Ferumoxytol 5 mg/kg IV as a single bolus injection, given once.
318573|NCT01770353|Drug|MM-398|MM-398 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
318574|NCT01770340|Biological|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
318575|NCT01770340|Procedure|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
318576|NCT01770327|Behavioral|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
318577|NCT01770314|Behavioral|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
318578|NCT01770301|Drug|Paclitaxel|
318579|NCT01770301|Drug|Bevacizumab|
318580|NCT01770288|Other|Anaerobic wingate test|
318581|NCT01770249|Procedure|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
318582|NCT01770236|Drug|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
318583|NCT01770223|Drug|boceprevir|
318584|NCT01770223|Biological|PegIFN-2b|
318585|NCT01770223|Drug|RBV|
318586|NCT01770210|Drug|Patients on atorvastatin treatment|Statins Therapy
318587|NCT01770197|Drug|IV rt-PA|IV rt-PA treatment
318588|NCT01770184|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
318589|NCT01770171|Drug|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
318590|NCT01770171|Drug|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
318591|NCT01770145|Drug|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
318592|NCT01770145|Drug|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
318593|NCT01770145|Drug|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duration of the APOKYN Initiation Period and APOKYN Treatment Period.
318594|NCT01770132|Drug|porfimer sodium|Given IV
318595|NCT01770132|Procedure|endoscopic ultrasonography|Undergo EUS-PDT
318596|NCT01770132|Procedure|photodynamic therapy|Undergo EUS-PDT
318597|NCT01770132|Drug|gemcitabine hydrochloride|Given IV
318598|NCT01770119|Biological|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
318599|NCT01770106|Drug|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
318600|NCT01770106|Drug|Alendronate|Alendronate 70mg once weekly
318601|NCT01770093|Other|Questionnaire|
318602|NCT01770080|Drug|Euminz®|3 to 5 time topical use of study drug.
318603|NCT01770080|Drug|Placebo|3 to 5 time topical use of study drug.
318604|NCT01770067|Drug|CITA-RNPT|
318605|NCT01770054|Other|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
318606|NCT01770041|Other|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
318607|NCT01770015|Procedure|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
318617|NCT01769963|Other|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
318618|NCT01769950|Other|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
318619|NCT01769937|Drug|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
318620|NCT01769924|Other|Nephrectomy|Nephrectomy for the purposes of living kidney donation
318621|NCT01769911|Drug|carmustine|Given IV
318622|NCT01769911|Drug|cytarabine|Given IV
318623|NCT01769911|Drug|melphalan|Given IV
318624|NCT01769911|Drug|etoposide|Given IV
318625|NCT01769911|Drug|O6-benzylguanine|Given IV
318626|NCT01769911|Procedure|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
318627|NCT01769911|Procedure|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
318628|NCT01769911|Other|laboratory biomarker analysis|Correlative studies
318629|NCT01769898|Drug|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
318630|NCT01769898|Drug|Theophylline|Theophylline 0.1 Q12H
318631|NCT01769898|Drug|Placebo|Placebo for theophylline 0.1 Q12H
318632|NCT01769885|Drug|tivozanib|Given PO
318633|NCT01769885|Procedure|therapeutic conventional surgery|Undergo nephrectomy
318634|NCT01769872|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
318635|NCT01769846|Other|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 7 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 30 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position.
318636|NCT01769833|Drug|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
318637|NCT01769833|Drug|Nucleosides|
318638|NCT01769820|Drug|Dexamethasone|studies 1&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
318639|NCT01769820|Drug|placebo|
318640|NCT01769807|Device|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
318641|NCT01769794|Drug|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
318642|NCT01769794|Drug|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
318643|NCT01769794|Drug|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
318644|NCT01769781|Drug|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
318645|NCT01769781|Drug|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
318646|NCT01769768|Drug|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
318647|NCT01769768|Drug|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
318648|NCT01769768|Drug|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
318649|NCT01769755|Biological|PDA001|"Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart."
318650|NCT01769755|Drug|Vehicle Controlled Placebo|"Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.~Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart."
318651|NCT01769742|Behavioral|Early mobility bundle|
318652|NCT01769729|Behavioral|PEPP|
318653|NCT01769729|Behavioral|Care management|
318654|NCT01769716|Procedure|Umbilical cord blood transplantation|
318655|NCT01769703|Drug|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
318685|NCT01769443|Procedure|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
318686|NCT01769417|Drug|Placebo|Placebo
318687|NCT01769417|Drug|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
318688|NCT01769404|Biological|LY2605541|
318689|NCT01769404|Biological|Insulin Glargine|
318656|NCT01769690|Other|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.~Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
318657|NCT01769690|Other|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
318658|NCT01769677|Drug|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
318659|NCT01769664|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
318660|NCT01769664|Drug|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
318661|NCT01769664|Drug|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
318662|NCT01769651|Other|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
318663|NCT01769638|Drug|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
318664|NCT01769638|Drug|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
318665|NCT01769625|Drug|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
318666|NCT01769612|Other|No Intervention|
318667|NCT01769586|Drug|Diphenhydramine|
318668|NCT01769586|Drug|Midazolam|
318669|NCT01769573|Biological|RG-HRV16|A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
318670|NCT01769573|Drug|Placebo|The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
318671|NCT01769560|Behavioral|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
318672|NCT01769547|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
318673|NCT01769521|Device|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
318674|NCT01769508|Drug|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
318675|NCT01769508|Drug|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
318676|NCT01769508|Drug|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
318677|NCT01769508|Radiation|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
318678|NCT01769495|Other|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
318679|NCT01769482|Drug|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
318680|NCT01769482|Drug|placebo|
318681|NCT01769469|Drug|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
318682|NCT01769456|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
318683|NCT01769456|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
318684|NCT01769443|Drug|bortezomib|Bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
318690|NCT01769391|Drug|Necitumumab|Administered IV
318691|NCT01769391|Drug|Paclitaxel|Administered IV
318692|NCT01769391|Drug|Carboplatin|Administered IV
318694|NCT01769378|Drug|Dulaglutide|Administered SQ
318695|NCT01769378|Drug|Glimepiride|Administered PO
318696|NCT01769365|Drug|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
318697|NCT01769365|Drug|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
318698|NCT01769365|Drug|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
318699|NCT01769352|Drug|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
318700|NCT01769339|Drug|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
318701|NCT01769326|Other|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
318702|NCT01769326|Device|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
318703|NCT01769326|Other|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
318704|NCT01769326|Device|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
318705|NCT01769313|Device|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
318706|NCT01769313|Device|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
318707|NCT01769300|Behavioral|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
318708|NCT01769274|Drug|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
318709|NCT01769274|Drug|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
318710|NCT01769261|Other|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
318711|NCT01769261|Other|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
318712|NCT01769261|Other|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
318713|NCT01769248|Device|Fine needle aspiration|Fine needle aspiration
318714|NCT01769248|Device|Fine needle biopsy|FNB
318715|NCT01769235|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
318716|NCT01769235|Drug|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
318717|NCT01769235|Drug|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
318718|NCT01769222|Biological|Ipilimumab|Given intratumorally
318719|NCT01769222|Radiation|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
318720|NCT01769209|Drug|Bortezomib|Administered subcutaneously (SC) at 1.3 mg/m², on Days 1, 4, 8, and 11.
318721|NCT01769209|Drug|Doxorubicin hydrochloride (HCl)|Administered intravenously (IV) over 15 min at 60mg/m², on Day 1.
318722|NCT01769209|Drug|PEG-Asparaginase|Administered intravenously (IV) or intramuscularly (IM) 2500 U/m² (maximum 3750 U), on Days 5 and 22.
318723|NCT01769209|Drug|Vincristine sulfate|Administered by intravenous (IV) push at 1.5 mg/m² (maximum 2 mg), on Days 1, 8, 15, and 22.
318724|NCT01769209|Drug|Dexamethasone|Administered orally (PO) at 10 mg/m², daily on Days 1 to 14.
318725|NCT01769209|Drug|Cytarabine|Administered intrathecally (IT) at 100 mg, on Day 1
318726|NCT01769209|Drug|Methotrexate|Administered intrathecally (IT) at 15 mg, on Day 15.
318727|NCT01769196|Drug|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
318728|NCT01769196|Drug|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
318729|NCT01769183|Drug|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
318730|NCT01769170|Drug|Brincidofovir (CMX001)|
318731|NCT01769157|Drug|L-carnitine|
318732|NCT01769157|Drug|Placebo|
318733|NCT01769144|Device|Acticoat Absorbent|wound dressing
318734|NCT01769144|Device|BCT|wound dressing
318868|NCT01768208|Drug|Saxagliptin|
318735|NCT01769118|Drug|Caffeine|Caffeine will be given according to departmental protocol
318736|NCT01769105|Device|Lipiflow|Patients receive a single Lipiflow-treatment
318737|NCT01769105|Behavioral|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
318738|NCT01769092|Dietary Supplement|Fish Oil|The daily dose is divided; capsules are taken with meals for a period of 6 months.
318739|NCT01769092|Other|Safflower Oil|Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
318740|NCT01769079|Drug|Nitrate|Two arms: placebo and nitrate
318741|NCT01769079|Drug|Placebo|
318742|NCT01769066|Drug|Sequential Gefitinib With Pemetrexed/Platinum|
318743|NCT01769066|Drug|Pemetrexed/Platinum|
318744|NCT01769053|Other|Variable Ventilation|
318745|NCT01769040|Drug|Rifaximin|550 mg two times daily for 28 days
318746|NCT01769040|Drug|placebo|
318747|NCT01769027|Drug|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.~Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
318748|NCT01769027|Drug|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
318749|NCT01769027|Biological|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
318750|NCT01769001|Drug|PRX-102|Comparison of different doses of drug
318751|NCT01768988|Drug|Placebo|"Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~Paracetamol 1g/8h~Weak opioid (tramadol at maximal doses of 400 mg/24h)~Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
318752|NCT01768988|Drug|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~Paracetamol 1g/8h~Weak opioid (tramadol at maximal doses of 400 mg/24h)~Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
318753|NCT01768975|Drug|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
318754|NCT01768975|Other|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
318755|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel|Vaginal
318756|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|
318757|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|
318758|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel - Vaginal|
318759|NCT01768949|Device|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
318760|NCT01768923|Procedure|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score [SDAI] <3.3)
318761|NCT01768923|Procedure|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28<2.6) (minimal disease activity group)
318762|NCT01768910|Other|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
318763|NCT01768910|Other|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
318764|NCT01768910|Other|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
318765|NCT01768910|Other|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
318766|NCT01768897|Drug|CPI-613|Given IV
318767|NCT01768897|Drug|cytarabine|Given IV
318768|NCT01768897|Drug|mitoxantrone hydrochloride|Given IV
318769|NCT01768897|Other|laboratory biomarker analysis|Optional correlative studies
318770|NCT01768897|Other|pharmacological study|Correlative studies
318771|NCT01768884|Drug|Nitric Oxide|
318772|NCT01768884|Drug|Placebo|
318773|NCT01768858|Drug|Adalimumab|Adalimumab administered by subcutaneous injection, via pre-filled syringe or autoinjector pen
318774|NCT01768845|Genetic|umbilical cord blood (UCB)|Infusion will occur after preparative regimen in one or two UCB unit(s). If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis.
318775|NCT01768832|Behavioral|Treadmill|
318776|NCT01768832|Behavioral|Tango|
318777|NCT01768832|Behavioral|Stretching|
318778|NCT01768819|Behavioral|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
318779|NCT01768806|Behavioral|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
319035|NCT01767025|Drug|Oxytocin|
318780|NCT01768806|Behavioral|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
318781|NCT01768793|Behavioral|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
318782|NCT01768793|Behavioral|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
318783|NCT01768780|Device|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.~A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.~For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
318784|NCT01768767|Drug|Placebo|
318785|NCT01768767|Drug|Ketamine|
318786|NCT01768767|Drug|Ketamine/Lithium|
318787|NCT01768754|Behavioral|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
318788|NCT01768741|Procedure|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
318789|NCT01768741|Procedure|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
318790|NCT01768728|Procedure|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
318791|NCT01768728|Procedure|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
318792|NCT01768702|Biological|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
318793|NCT01768702|Biological|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
318794|NCT01768689|Behavioral|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
318795|NCT01768689|Behavioral|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
318796|NCT01768689|Behavioral|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
318797|NCT01768676|Drug|avanafil|100 mg
318798|NCT01768676|Drug|Placebo|
318799|NCT01768663|Drug|Lumacaftor|tablet, 200mg taken every 12 hours
318800|NCT01768663|Drug|Ivacaftor|tablet, 250mg taken every 12 hours
318801|NCT01768663|Drug|Ciprofloxacin|750 mg taken every 12 hours
318802|NCT01768663|Drug|Itraconazole|200mg taken once daily
318803|NCT01768663|Drug|Rifampin|600mg taken once daily
318804|NCT01768650|Behavioral|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
318805|NCT01768650|Behavioral|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
318806|NCT01768637|Drug|Aspirin|Aspirin 81 mg by mouth daily
318807|NCT01768637|Drug|Clopidogrel|Clopidogrel 75 mg by mouth once daily
318808|NCT01768624|Procedure|dialysis, kidney transplant|
318809|NCT01768598|Other|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
318810|NCT01768598|Other|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
318811|NCT01768598|Other|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
318812|NCT01768598|Other|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
318813|NCT01768585|Drug|Ivabradine|Please see description of Intervention Arm
318814|NCT01768585|Drug|Placebo|
318815|NCT01768572|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
318816|NCT01768572|Drug|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
318817|NCT01768572|Drug|hydroxychloroquine|Dispensed according to local practice.
318818|NCT01768572|Drug|methotrexate|Dispensed according to local practice.
318819|NCT01768572|Drug|sulfasalazine|Dispensed according to local practice.
318820|NCT01768572|Drug|leflunomide|Dispensed according to local practice.
318821|NCT01768572|Drug|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
318822|NCT01768572|Drug|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
318823|NCT01768559|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
318824|NCT01768559|Drug|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
318825|NCT01768559|Drug|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
318826|NCT01768559|Drug|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
318827|NCT01768559|Drug|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
318828|NCT01768546|Behavioral|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
318829|NCT01768546|Behavioral|Interactive tracking and problem solving web portal|
318830|NCT01768520|Drug|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|"morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~evening : 1 tab. of active Entelon 150mg"
318831|NCT01768520|Drug|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|"morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~evening : 1 tab. of placebo Entelon 150mg"
318832|NCT01768520|Drug|Placebo|"morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~evening : 1 tab. of placebo Entelon 150mg"
318833|NCT01768507|Dietary Supplement|Resveratrol|5 g (10 capsules) as single oral dose on day 1
318834|NCT01768481|Drug|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
318835|NCT01768481|Drug|sugar pill|placebo controlled arm receives similarly looking placebo.
318836|NCT01768468|Drug|LAYLA tablet|1 tablet twice a day
318837|NCT01768468|Drug|JOINS tablet|1 tablet at each time, 3 times a day
318838|NCT01768455|Drug|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
318839|NCT01768455|Drug|Glimepiride|Glimepiride 4mg (qd) on Day1
318840|NCT01768429|Behavioral|Fatty fish|
318841|NCT01768429|Behavioral|Lean Fish|
318842|NCT01768429|Behavioral|Alpha-linolenic acid|
318843|NCT01768429|Behavioral|Control|
318844|NCT01768390|Other|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
318845|NCT01768390|Other|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
318846|NCT01768377|Drug|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
318847|NCT01768377|Drug|Fentanyl|Fentanyl 2 microgram/Kg BW IV
318848|NCT01768377|Drug|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
318849|NCT01768364|Drug|Trimetoprim-Sulfa (Bactrim)|
318850|NCT01768364|Other|No antibiotics|
318851|NCT01768351|Drug|Paricalcitol|Zemplar cp 1 mcg/day per os
318852|NCT01768351|Drug|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
318853|NCT01768338|Drug|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
318854|NCT01768325|Device|EUS-TCB needle (QuickCore) standard of care|"The number of needle passes requiring to acquire adequate specimen were tallied.~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
318855|NCT01768325|Device|EUS-Guided biopsy needle (ProCore)|"The number of needle passes requiring to acquire adequate specimen were tallied.~Length of core tissue obtained~Diagnostic contribution of immunohistochemical staining~Rates of complications"
318856|NCT01768312|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
318857|NCT01768299|Drug|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
318858|NCT01768299|Drug|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
318859|NCT01768286|Drug|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
318860|NCT01768286|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
318861|NCT01768273|Drug|Midazolam|
318862|NCT01768273|Drug|PA-824|
318863|NCT01768260|Device|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
318864|NCT01768260|Drug|Aspirin|Standard drug therapy
318865|NCT01768247|Drug|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
318866|NCT01768234|Other|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
318867|NCT01768221|Behavioral|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.~The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.~In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
318869|NCT01768195|Drug|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.~In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
318870|NCT01768182|Dietary Supplement|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
318871|NCT01768182|Other|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
318872|NCT01768169|Dietary Supplement|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
318873|NCT01768156|Other|Experimental arm|"Serum samples are collected:~at time of diagnosis of recurrence (before 1st chemotherapy)~during each cycle of chemotherapy~after the end of chemotherapy~every 3 month until treatment failure (3-6 samples)~stop at the progression or after 18 months post chemotherapy"
318874|NCT01768143|Behavioral|unexperienced endoscopy nurses|
318875|NCT01768143|Behavioral|Experienced endoscopy nurses|
318876|NCT01768117|Biological|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
318877|NCT01768104|Procedure|ESTD|"A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).~Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.~Dissection was done along the margin of the tumor.~After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.~Endoclips were used to close the entry of the submucosal tunnel.~(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)"
318878|NCT01768104|Procedure|VATS|"General anesthesia with double lumen intubation.~Three to four cameras or working ports are placed over the chest wall.~After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.~The mass is exposed after the overlying muscle is split longitudinally.~The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.~The muscle layer is re-approximated and a chest tube is place through one of the ports.~(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
318879|NCT01768091|Procedure|POEM|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).~Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.~Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.~Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.~Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.~(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)"
318880|NCT01768091|Procedure|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.~(N Engl J Med 2011;364:1807-16.)"
318881|NCT01768078|Procedure|Intravitreal injection of Betamethasone + antibiotics|
318882|NCT01768078|Procedure|Intravitreal injection of antibiotics|
318883|NCT01768065|Device|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
318884|NCT01768065|Device|placebo sham|
318885|NCT01768052|Device|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
318886|NCT01768039|Drug|Vitamin D|
318887|NCT01768039|Drug|Placebo|
318888|NCT01768013|Drug|LEO 90105|Once daily for four weeks
318889|NCT01768000|Behavioral|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
318890|NCT01767987|Drug|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
318891|NCT01767987|Drug|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
318892|NCT01767961|Procedure|diagnostic imaging|Undergo MBS
318893|NCT01767961|Other|questionnaire administration|Correlative studies
318894|NCT01767961|Procedure|quality-of-life assessment|Correlative studies
318895|NCT01767948|Drug|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
318896|NCT01767935|Procedure|cryosurgery|Undergo cryosurgery
318897|NCT01767935|Radiation|radiation therapy|Undergo radiation therapy
318898|NCT01767935|Procedure|quality-of-life assessment|Ancillary studies
318899|NCT01767922|Dietary Supplement|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.~Each volunteer was seen for the 3 visits:~visit V1, so-called inclusion visit (D0),~visit V2 at 28 days, tolerance of +/- 3 days, (D28) and~visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
318900|NCT01767922|Dietary Supplement|Placebo - Excipient only|
318901|NCT01767909|Drug|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
319036|NCT01767025|Drug|Sea water|
318902|NCT01767909|Drug|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
318903|NCT01767896|Biological|ASP7374|subcutaneous (sc)
318904|NCT01767896|Biological|approved egg-derived TIV|subcutaneous (sc)
318905|NCT01767883|Other|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:~CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms~On-going mentoring and practice facilitation~Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference."
318906|NCT01767883|Other|Clinical Decision Support Only|"CKD decision support algorithms added to their Clinical Decision Support~System Academic detailing concerning the rationale for the algorithms"
318907|NCT01767870|Procedure|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
318908|NCT01767870|Procedure|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
318909|NCT01767857|Drug|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
318910|NCT01767857|Drug|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
318911|NCT01767844|Dietary Supplement|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
318912|NCT01767844|Dietary Supplement|Placebo|
318913|NCT01767831|Behavioral|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
318914|NCT01767805|Procedure|Standard incubator|
318915|NCT01767805|Procedure|Mini incubator|
318916|NCT01767805|Procedure|5% oxygen|
318917|NCT01767805|Procedure|20% oxygen|
318918|NCT01767792|Drug|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.~During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
318919|NCT01767766|Drug|TGR-1202|TGR-1202 Daily Oral Dose
318920|NCT01767753|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
318921|NCT01767740|Device|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
318922|NCT01767740|Device|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
318923|NCT01767727|Procedure|Soft tissue coverage|The dorsal homodigital island flaps are used for soft tissue coverage of multiple finger defects
318924|NCT01767714|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
318925|NCT01767714|Drug|Plerixafor|0.24 mg/kg/day subcutaneous injection
318926|NCT01767714|Drug|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
318927|NCT01767701|Drug|Raltegravir|400mg twice daily for 3 months
318928|NCT01767688|Drug|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
318929|NCT01767675|Procedure|Secondary Cytoreductive Surgery|
318930|NCT01767675|Drug|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
318931|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|5 cycles
318932|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|6 cycles
318933|NCT01767662|Procedure|manipulation|home programme
318934|NCT01767662|Procedure|No intervention|observation
318935|NCT01767649|Other|Caesarean|Collection of tissues and blood
318936|NCT01767649|Other|Vaginal delivery|Collection of tissues and blood
318937|NCT01767636|Drug|Pazopanib Hydrochloride|Given PO
318938|NCT01767623|Drug|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
318939|NCT01767610|Drug|micronized fenofibrate 160mg|
318940|NCT01767610|Drug|pitavastatin Ca 2mg|
318941|NCT01767610|Drug|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
318942|NCT01767597|Other|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
318943|NCT01767597|Other|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
318944|NCT01767584|Drug|Cephalexin 1g tablets|Reference product
318945|NCT01767584|Drug|Cephalexin 1g tablets|Test product
318946|NCT01767571|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
318947|NCT01767571|Drug|Cephalexin 250mg/5ml|Test product 10 ml
318948|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.~MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
318949|NCT01767545|Drug|Dexamethasone implant|
318950|NCT01767545|Drug|Bevacizumab|
318951|NCT01767532|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
318952|NCT01767532|Drug|Cephalexin 125 mg/5ml|Test product 20 ml
318953|NCT01767519|Biological|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
318954|NCT01767519|Drug|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
318955|NCT01767519|Drug|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
318956|NCT01767519|Drug|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
318957|NCT01767506|Other|Surveillance and treatment with azithromycin of newcomer and traveler families|The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
318958|NCT01767506|Other|Usual care|Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
318959|NCT01767493|Drug|[18F]Florbetapir and PET imaging|Subjects will have a baseline scan and second scan within 1 month following the baseline PET scan
318960|NCT01767480|Device|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
318961|NCT01767480|Behavioral|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
318962|NCT01767467|Biological|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
318963|NCT01767467|Drug|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
318964|NCT01767454|Drug|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
318965|NCT01767454|Drug|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
318966|NCT01767454|Drug|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
318967|NCT01767441|Procedure|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
318968|NCT01767441|Procedure|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
318969|NCT01767441|Procedure|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
318970|NCT01767441|Other|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
318971|NCT01767428|Drug|Paracetamol|500 mg immediate release paracetamol formulations
318972|NCT01767415|Drug|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
318973|NCT01767402|Biological|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
318974|NCT01767402|Biological|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
318975|NCT01767402|Biological|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
318976|NCT01767389|Other|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
318977|NCT01767389|Other|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
318978|NCT01767389|Other|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
318979|NCT01767376|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
318980|NCT01767376|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
319347|NCT01764737|Drug|VX15/2503|single dose intravenous administration
318981|NCT01767363|Other|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
318982|NCT01767363|Other|Alpha-blockers|Use of alpha-blockers over the study period.
318983|NCT01767350|Procedure|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
318984|NCT01767337|Device|FLUGEN 101.2 device|
318985|NCT01767324|Device|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
318986|NCT01767324|Device|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
318987|NCT01767324|Device|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
318988|NCT01767311|Drug|BAN2401 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
318989|NCT01767311|Drug|BAN2401 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
318990|NCT01767311|Drug|BAN2401 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion.
318991|NCT01767311|Drug|BAN2401 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as a 60 minute i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
318992|NCT01767311|Drug|BAN2401 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as a 60 minute i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
318993|NCT01767311|Drug|Placebo|biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
318994|NCT01767298|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
318995|NCT01767298|Drug|Valsartan|Valsartan alone
318996|NCT01767298|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
318997|NCT01767285|Drug|Etonogestrel implant|This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
318998|NCT01767272|Drug|fexofenadine|fexofenadine brand name
318999|NCT01767259|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
319000|NCT01767259|Drug|Valsartan|Valsartan alone
319001|NCT01767259|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
319002|NCT01767246|Other|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
319003|NCT01767246|Other|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
319004|NCT01767233|Procedure|ERCP and pancreatic stenting|
319005|NCT01767220|Procedure|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
319006|NCT01767220|Procedure|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
319007|NCT01767207|Other|mental disorders|mental disorders
319008|NCT01767207|Behavioral|screening for mental disorders|screening for mental disorders
319009|NCT01767194|Biological|Dinutuximab|Given IV
319010|NCT01767194|Drug|Irinotecan Hydrochloride|Given IV
319011|NCT01767194|Other|Laboratory Biomarker Analysis|Optional correlative studies
319012|NCT01767194|Biological|Sargramostim|Given SC or IV
319013|NCT01767194|Drug|Temozolomide|Given PO
319014|NCT01767194|Drug|Temsirolimus|Given IV
319015|NCT01767181|Other|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
319016|NCT01767181|Other|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
319017|NCT01767168|Other|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
319018|NCT01767155|Drug|AEZS-108 / zoptarelin doxorubicin|267 mg/m^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
319019|NCT01767155|Drug|doxorubicin|60 mg/m^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
319020|NCT01767142|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
319021|NCT01767129|Drug|AVP-923-45|One capsule twice daily for 14 days
319022|NCT01767129|Drug|Placebo|One capsule twice daily for 14 days
319023|NCT01767116|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
319024|NCT01767116|Drug|Ribavirin|Capsule
319025|NCT01767116|Drug|Placebo for ribavirin|Capsule
319026|NCT01767103|Drug|Ferriprox®|
319027|NCT01767090|Drug|ASP1707|Oral
319028|NCT01767090|Drug|Placebo|Oral
319029|NCT01767090|Drug|Leuprorelin acetate|subcutaneous
319030|NCT01767077|Dietary Supplement|Butter oil|Daily intake of 40 g butter oil
319031|NCT01767077|Dietary Supplement|Cream|Daily intake of 100 g cream (40%)
319032|NCT01767064|Other|Posted commitment letter|
319033|NCT01767038|Procedure|OCT Spectralis|
319034|NCT01767038|Procedure|microperimetry|
319037|NCT01767012|Device|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
319038|NCT01767012|Device|Polylens EC-Y10-PAL (uncoated)|
319039|NCT01766960|Other|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
319040|NCT01766960|Drug|Morphine|Five milligrams of intravenous morphine will be administered.
319041|NCT01766947|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
319042|NCT01766921|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
319043|NCT01766908|Other|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
319044|NCT01766895|Other|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
319045|NCT01766882|Behavioral|Lower sodium intervention|"1. Lower sodium intervention:~Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately >180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.~Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
319046|NCT01766882|Other|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
319047|NCT01766856|Other|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
319048|NCT01766843|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
319049|NCT01766843|Drug|Seretide Diskus|2 inhalations as a single dose
319050|NCT01766843|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
319051|NCT01766843|Drug|SF Easyhaler|2 inhalations as a single dose
319052|NCT01766830|Device|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
319053|NCT01766830|Device|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
319054|NCT01766830|Device|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
319055|NCT01766830|Device|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
319056|NCT01766830|Device|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
319057|NCT01766830|Device|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
319058|NCT01766830|Device|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
319059|NCT01766830|Device|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
319060|NCT01766830|Device|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
319061|NCT01766830|Device|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
319062|NCT01766817|Drug|BMS-986020|
319063|NCT01766817|Drug|Placebo matching with BMS-986020|
319064|NCT01766804|Dietary Supplement|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
319065|NCT01766804|Dietary Supplement|placebo|
319066|NCT01766791|Other|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM
319067|NCT01766791|Other|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - < 75 1RM
319068|NCT01766791|Other|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM and Protein Supplementation
319069|NCT01766791|Other|Control|control group, no intervention, maintenance of physical activity
319070|NCT01766778|Drug|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
319071|NCT01766778|Drug|Metformin|Metformin maximum tolerance dose
319072|NCT01766765|Procedure|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
319073|NCT01766765|Other|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
319074|NCT01766752|Device|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
319075|NCT01766739|Biological|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
319076|NCT01766713|Drug|Ezetimibe|
319077|NCT01766700|Behavioral|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
319078|NCT01766700|Behavioral|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
319079|NCT01766687|Dietary Supplement|Hydration|
319080|NCT01766674|Behavioral|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
319081|NCT01766661|Procedure|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
319082|NCT01766661|Procedure|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
319083|NCT01766661|Procedure|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
319084|NCT01766648|Device|Far Cortical locking screw fixation|Standard locking screw fixation
319085|NCT01766648|Device|Standard locking screw fixation|
319086|NCT01766622|Drug|[18F]-CP18|7mCi, IV (in the vein) at baseline
319087|NCT01766622|Procedure|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third [18F]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
319088|NCT01766609|Drug|Triamcinolone Acetonide|
319089|NCT01766596|Procedure|Optical Coherence Tomography|
319090|NCT01766583|Drug|CC-292 + lenalidomide|CC-292 + lenalidomide
319091|NCT01766570|Other|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
319092|NCT01766570|Other|Placebo|
319093|NCT01766557|Other|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
319094|NCT01766557|Other|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
319095|NCT01766544|Other|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
319096|NCT01766544|Other|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
319097|NCT01766531|Device|body bioelectrical impedance|
319098|NCT01766518|Drug|Mycophenolate mofetil|MY-REPT capsule 500~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
319099|NCT01766505|Drug|Candemore tablet|"Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure."
319100|NCT01766505|Drug|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
319101|NCT01766492|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
319102|NCT01766479|Radiation|CT colonography|
319103|NCT01766466|Drug|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
319248|NCT01765374|Device|ESAOTE MyLab60|US evaluation at different time points
319249|NCT01765374|Drug|Rituximab|
319104|NCT01766466|Drug|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion~Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
319105|NCT01766453|Behavioral|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
319106|NCT01766453|Behavioral|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
319107|NCT01766440|Drug|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
319108|NCT01766414|Drug|C1-esterase inhibitor|intravenously
319109|NCT01766414|Drug|Endotoxin|intravenously
319110|NCT01766401|Drug|Placebo|
319111|NCT01766401|Drug|Vilazadone|Viibryd
319112|NCT01766375|Drug|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
319113|NCT01766362|Procedure|PRPC using Pascal laser|
319114|NCT01766349|Behavioral|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
319115|NCT01766336|Drug|Group 1 ELND005|
319116|NCT01766336|Drug|Group 2 ELND005|
319117|NCT01766323|Drug|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
319118|NCT01766323|Drug|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
319119|NCT01766310|Drug|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
319120|NCT01766310|Drug|placebo|sugar tablet manufactured to mimic folic acid tablet
319121|NCT01766297|Radiation|Proton Radiotherapy|
319122|NCT01766284|Device|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
319123|NCT01766271|Behavioral|Health Coaching|biweekly health coaching for 5 months
319124|NCT01766271|Genetic|9p21|Genetic testing results of 9p21
319125|NCT01766271|Other|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
319126|NCT01766258|Drug|ODM-101 65mg Carbidopa|
319127|NCT01766258|Drug|ODM-101 105mg Carbidopa|
319128|NCT01766258|Drug|Stalevo|
319129|NCT01766245|Drug|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
319130|NCT01766219|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
319131|NCT01766206|Biological|MenACWY-CRM (Menveo)|One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
319132|NCT01766193|Procedure|vaginal delivery|
319133|NCT01766193|Procedure|forceps extraction|vaginal delivery by forceps extraction
319134|NCT01766193|Procedure|vacuum extraction|vaginal delivery by vacuum extraction
319135|NCT01766193|Procedure|cesarean section|
319136|NCT01766180|Drug|Fruitflow-II|150 mg/day for 3 months, orally
319137|NCT01766180|Drug|resVida|150 mg/day for 3 months, orally
319138|NCT01766167|Drug|MP-424|Low
319139|NCT01766167|Drug|MP-424|Middle
319140|NCT01766167|Drug|MP-424|High
319141|NCT01766167|Drug|MP-424|Multiple
319142|NCT01766154|Drug|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
319143|NCT01766141|Other|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
319144|NCT01766128|Drug|Zonisamide|The first arm will be treated by zonisamide and the second one will only receive placebo
319145|NCT01766115|Drug|Telaprevir|HCV Protease Inhibitor
319146|NCT01766102|Procedure|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
319147|NCT01766102|Procedure|Standard Mammography|There is not an added device associated with this arm.
319148|NCT01766089|Drug|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
319149|NCT01766089|Drug|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
319150|NCT01766076|Other|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
319151|NCT01766076|Drug|Placebo|PBMC collected for immune activation assays using flowcytometry
319152|NCT01766063|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
319153|NCT01766050|Drug|Caffeine|
319154|NCT01766050|Drug|Losartan|
319155|NCT01766050|Drug|Omeprazole|
319156|NCT01766050|Drug|Dextromethorphan|
319157|NCT01766050|Drug|Midazolam|
319158|NCT01766050|Biological|Belatacept|
319159|NCT01766037|Device|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
319160|NCT01766037|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
319161|NCT01766024|Drug|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
319162|NCT01766011|Other|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
319163|NCT01765998|Drug|Probiotic|Clinical evaluation according to the Crohn's activity scale
319164|NCT01765998|Drug|Placebo|
319296|NCT01764997|Drug|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
319348|NCT01764737|Drug|Placebo|single dose intravenous administration
319165|NCT01765985|Device|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
319166|NCT01765985|Device|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
319167|NCT01765972|Device|etafilcon A with Lacreon|contact lens with Lacreon
319168|NCT01765972|Device|etafilcon A with Lacreon with print|contact lens with Lacreon and cosmetic print
319169|NCT01765972|Device|etafilcon A with print|contact lens with print
319170|NCT01765972|Device|Spectacles (habitual)|Spectacles
319171|NCT01765959|Other|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
319172|NCT01765959|Other|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:~Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
319173|NCT01765946|Drug|Metformin|Metformin tablets 500 mg tris in die (tid)
319174|NCT01765946|Drug|placebo|
319175|NCT01765933|Dietary Supplement|DMAA|no placebo
319176|NCT01765920|Drug|Ergoferon|Safety and Efficacy of liquid dosage form
319177|NCT01765920|Drug|Placebo|Safety and Efficacy of liquid dosage form
319178|NCT01765907|Device|HIFU|
319179|NCT01765894|Other|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
319180|NCT01765881|Drug|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
319181|NCT01765881|Drug|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
319182|NCT01765868|Drug|Betrixaban|Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
319183|NCT01765855|Drug|Betrixaban single oral dose|
319184|NCT01765842|Biological|Rituximab|Only one cycle of rituximab will be administered in this arm.
319185|NCT01765829|Drug|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
319186|NCT01765829|Drug|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
319187|NCT01765816|Behavioral|high intensity interval training|
319188|NCT01765816|Behavioral|moderate intensity training|
319189|NCT01765803|Drug|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
319190|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing every 2 weeks~Intravenous injection"
319191|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing weekly~Intravenous injection"
319192|NCT01765777|Procedure|Osteopathic Manipulative Medicine|
319193|NCT01765777|Procedure|Phototherapy|
319194|NCT01765764|Drug|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
319195|NCT01765764|Drug|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
319196|NCT01765751|Procedure|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
319197|NCT01765738|Device|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
319198|NCT01765725|Behavioral|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
319199|NCT01765712|Procedure|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
319200|NCT01765712|Biological|Platelet Rich Plasma|
319201|NCT01765699|Device|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
319202|NCT01765686|Device|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
319203|NCT01765686|Device|Ligasure Small Jaw (Covidien, USA)|
319297|NCT01764984|Device|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
319204|NCT01765673|Device|Vibrotactile stimulation|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
319205|NCT01765660|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
319206|NCT01765660|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
319207|NCT01765647|Other|AGY|AGY is a natural health product produced in egg yolks
319208|NCT01765634|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) each week, four times for a cycle.
319209|NCT01765634|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
319210|NCT01765621|Other|DDI+ System and Pharmacogenetic Data|
319211|NCT01765608|Drug|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
319212|NCT01765608|Drug|Placebo|
319213|NCT01765608|Device|nCPAP|
319214|NCT01765595|Other|DDI+|
319215|NCT01765582|Drug|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
319216|NCT01765582|Drug|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
319217|NCT01765582|Drug|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
319218|NCT01765582|Drug|irinotecan|Participants will receive IV infusion of 165 mg/m^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
319219|NCT01765582|Drug|folinic acid|Participants will receive IV infusion of 200 mg/m^² (Arm A) or 400 mg/m^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m^2 in the maintenance therapy.
319220|NCT01765582|Drug|oxaliplatin|Participants will receive 85 mg/m^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
319221|NCT01765569|Drug|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
319222|NCT01765569|Drug|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
319223|NCT01765556|Drug|ketoconazole|multiple doses of ketoconazole in Period B and C
319224|NCT01765556|Drug|vemurafenib|single dose of vemurafenib in Period A and C
319225|NCT01765543|Drug|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
319226|NCT01765543|Drug|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
319227|NCT01765530|Device|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.~We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
319228|NCT01765517|Dietary Supplement|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
319229|NCT01765517|Dietary Supplement|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
319230|NCT01765491|Other|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
319231|NCT01765491|Other|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
319232|NCT01765478|Drug|HM71224 single ascending dose|
319233|NCT01765478|Drug|HM71224 food effect|
319234|NCT01765478|Drug|HM71224 Multiple ascending dose|
319235|NCT01765465|Drug|Rowachol|
319236|NCT01765465|Drug|Placebo|
319237|NCT01765452|Drug|Closone|75mg/100mg, 8weeks, PO
319238|NCT01765452|Drug|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
319239|NCT01765439|Dietary Supplement|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
319240|NCT01765426|Biological|TDV|TDV suspension for intradermal administration
319241|NCT01765426|Drug|Placebo|Phosphate buffered saline (PBS)
319242|NCT01765413|Biological|Varicella-zoster virus|
319243|NCT01765413|Biological|Yellow Fever Vaccine|
319244|NCT01765413|Biological|Placebo|
319245|NCT01765400|Drug|Prasugrel 10 mg daily x 2 weeks|
319246|NCT01765400|Drug|Clopidogrel 75 mg daily x 2 weeks|
319247|NCT01765387|Behavioral|Spa session|
319250|NCT01765348|Behavioral|Syntax treatment via sentence-combining method|"Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.~Treatments are conduced by school-speech therapist once two weeks for 8 sessions."
319251|NCT01765348|Behavioral|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
319252|NCT01765335|Device|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
319253|NCT01765322|Device|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
319254|NCT01765309|Procedure|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
319255|NCT01765296|Drug|CG100649|2 mg capsule
319256|NCT01765296|Drug|Celecoxib|200 mg capsule
319257|NCT01765296|Drug|Placebo|Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
319258|NCT01765283|Biological|HepaStem|
319259|NCT01765270|Drug|Saxagliptin|one 5-mg saxagliptin tablet daily
319260|NCT01765270|Drug|Placebo|5mg placebo tablet daily
319261|NCT01765257|Drug|AZILECT®|
319262|NCT01765257|Drug|Placebo|
319263|NCT01765244|Drug|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors embedded in a fibrin-agarose scaffold
319264|NCT01765244|Other|Amniotic membrane transplantation|Implantation of an amniotic membrane graft to cover the corneal scarring using the mixed graft/patch technique.
319265|NCT01765231|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
319266|NCT01765231|Drug|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
319267|NCT01765218|Drug|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
319268|NCT01765218|Drug|Placebo|A placebo identical in appearance to the active agent (topiramate)
319269|NCT01765205|Device|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
319270|NCT01765192|Drug|Roflumilast|Roflumilast was supplied in tablets.
319271|NCT01765192|Drug|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
319272|NCT01765192|Drug|Montelukast|Montelukast was supplied in tablets.
319273|NCT01765179|Drug|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
319274|NCT01765166|Behavioral|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
319275|NCT01765153|Behavioral|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
319276|NCT01765153|Behavioral|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
319277|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with Lambert Eaton myasthenia (LEM)
319278|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
319279|NCT01765114|Drug|PEG-Formulation|
319280|NCT01765101|Other|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
319281|NCT01765101|Other|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
319282|NCT01765088|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
319283|NCT01765088|Drug|α-IFN|3mIU (3million) D1，3，5
319284|NCT01765036|Drug|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
319285|NCT01765023|Drug|Period I : atorvastatin, Period II : atorvastatin and metformin|
319286|NCT01765023|Drug|Period I : metformin, Period II : atorvastatin and metformin|
319287|NCT01765010|Drug|Calcitriol|
319288|NCT01765010|Drug|Alfacalcidol|
319289|NCT01765010|Drug|Cholecalciferol|
319290|NCT01765010|Drug|Placebo|
319291|NCT01764997|Drug|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
319292|NCT01764997|Drug|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
319293|NCT01764997|Drug|Methotrexate|Dispensed according to local practice.
319294|NCT01764997|Drug|Placebo (for sarilumab)|
319295|NCT01764997|Drug|Placebo (for etanercept)|
319298|NCT01764971|Other|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
319299|NCT01764971|Other|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
319300|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
319301|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
319302|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
319303|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
319304|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
319305|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
319306|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
319307|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
319308|NCT01764932|Procedure|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
319309|NCT01764919|Radiation|[124I]FIAU|A single intravenous injection of 5 mCi[124I]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
319310|NCT01764906|Device|Novosis|
319311|NCT01764906|Procedure|Iliac crest bone graft|
319312|NCT01764893|Other|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
319313|NCT01764893|Other|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
319314|NCT01764880|Drug|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
319315|NCT01764867|Drug|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
319316|NCT01764867|Drug|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
319317|NCT01764867|Other|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
319318|NCT01764867|Other|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
319319|NCT01764867|Drug|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319320|NCT01764867|Drug|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319321|NCT01764867|Drug|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319322|NCT01764867|Drug|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319323|NCT01764867|Drug|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319324|NCT01764867|Drug|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319325|NCT01764867|Drug|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319326|NCT01764867|Drug|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319327|NCT01764867|Drug|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319328|NCT01764867|Drug|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319329|NCT01764867|Drug|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
319330|NCT01764854|Drug|AZD1722|doses between 5 and 90 mg may be administered based on tolerability
319331|NCT01764841|Drug|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
319332|NCT01764841|Drug|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
319333|NCT01764828|Drug|Refametinib (BAY86-9766)|
319334|NCT01764828|Drug|Gemcitabine|
319335|NCT01764815|Device|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
319336|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in enhanced standard care
319337|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in psychological intervention
319338|NCT01764789|Other|questionnaire administration|Ancillary studies
319339|NCT01764789|Procedure|quality-of-life assessment|Patients will participate in a quality life assessment.
319340|NCT01764789|Procedure|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
319341|NCT01764789|Behavioral|behavioral intervention|Participate in multi-component biobehavioral intervention
319342|NCT01764789|Other|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
319343|NCT01764789|Other|educational intervention|Participate in multi-component biobehavioral intervention
319344|NCT01764776|Drug|LDE225|LDE225
319345|NCT01764750|Drug|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
319346|NCT01764750|Drug|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
319349|NCT01764724|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
319350|NCT01764711|Drug|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
319351|NCT01764698|Behavioral|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
319352|NCT01764698|Behavioral|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
319353|NCT01764685|Drug|Topiramate|Max therapeutic dose of 150mg/day
319354|NCT01764685|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
319355|NCT01764685|Drug|Placebo|Placebo
319356|NCT01764672|Drug|Methylphenidate|Oral dose 40mg (2 x 20mg)
319357|NCT01764672|Other|Placebo|Oral intake of 2 placebo tablets
319358|NCT01764646|Radiation|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
319359|NCT01764646|Radiation|Volumetric modulated arc therapy|Highly conformational dose distribution
319360|NCT01764646|Radiation|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
319361|NCT01764633|Biological|Evolocumab|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
319362|NCT01764633|Drug|Placebo|Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
319363|NCT01764620|Other|Elastic taping applied with tension|
319364|NCT01764620|Other|Elastic taping applied without tension|
319365|NCT01764620|Other|Fatigue protocol|
319366|NCT01764607|Drug|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
319367|NCT01764594|Biological|CDP7657|"CDP7657 100 mg/ ml solution~30 mg/ kg initial dose~15 mg/ kg every other week~10 weeks"
319368|NCT01764594|Other|Placebo|Placebo comparator
319369|NCT01764581|Procedure|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
319370|NCT01764568|Behavioral|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz & Woodward 2007a; Moritz & Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8‐module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
319371|NCT01764568|Behavioral|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
319372|NCT01764555|Drug|acetaminophen 2 g|
319373|NCT01764542|Procedure|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
319374|NCT01764477|Drug|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)~PRI-724:~Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
319375|NCT01764464|Drug|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
319376|NCT01764464|Drug|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
319377|NCT01764451|Drug|Simvastatin|
319378|NCT01764438|Procedure|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
319379|NCT01764425|Drug|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
319380|NCT01764399|Behavioral|Care4U|
319381|NCT01764386|Drug|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
319382|NCT01764386|Behavioral|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
319383|NCT01764386|Behavioral|Usual Care|Usual Care is a self-directed lifestyle intervention program
319384|NCT01764373|Other|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
319385|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
319386|NCT01764347|Procedure|therapeutic conventional surgery|Undergo robotic radical prostatectomy
319387|NCT01764347|Procedure|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
319388|NCT01764347|Procedure|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
319389|NCT01764334|Device|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
319390|NCT01764308|Dietary Supplement|Omega-3|1200mg twice a day for 24 weeks
319391|NCT01764308|Dietary Supplement|Placebo|4 tablets twice a day for 24 weeks
319392|NCT01764295|Drug|DWJ1276|
319393|NCT01764295|Drug|Olmesartan|
319394|NCT01764295|Drug|Rosuvastatin|
319395|NCT01764295|Drug|Placebo|
319396|NCT01764282|Behavioral|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
319397|NCT01764269|Other|text message surveillance for fever|
319398|NCT01764256|Biological|P2-VP8 subunit rotavirus vaccine|P2-VP8 subunit rotavirus vaccine was made by inserting a codon optimized synthetic gene for the VP8 region of rotavirus VP4 fused to the P2 T-cell epitope of tetanus toxin into the Pj411 proprietary cloning vector developed by DNA 2.0, Menlo Park, CA. The vector carries a kanamycin resistance gene as a selection marker. The vector was transfected into the BL21 strain of E. coli. The fusion protein was purified from Isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced and physically lysed cultures using standard column chromatographic techniques employing Q-Sepharose and Butyl 650 as resins in addition to ultrafiltration and diafiltration.
319399|NCT01764256|Other|placebo|Sodium Chloride 0.9%, USP for Injection was used to dilute the active P2-VP8 vaccine to final dosing concentration and was used for the Placebo for the study.
319400|NCT01764243|Drug|MT-4666|low dose, high dose
319401|NCT01764243|Drug|Placebo|
319402|NCT01764230|Drug|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
319403|NCT01764204|Drug|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
319404|NCT01764191|Other|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
319405|NCT01764178|Drug|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
319406|NCT01764178|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
319407|NCT01764165|Other|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
319408|NCT01764165|Other|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
319409|NCT01764152|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
319410|NCT01764139|Procedure|Blood sampling|
319411|NCT01764126|Drug|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
319412|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
319413|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
319414|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
319415|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
319416|NCT01764113|Behavioral|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
319417|NCT01764113|Behavioral|Standard dietary counselling|
319418|NCT01764100|Genetic|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
319419|NCT01764087|Drug|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:~KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated~A treatment cycle in phase II will consist of 28 days, according to the following schedule:~KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
319420|NCT01764074|Behavioral|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
319421|NCT01764048|Drug|Fix protocol|Please see arm description
319422|NCT01764048|Drug|medications following demand protocol|Please see arm description
319423|NCT01764035|Behavioral|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
319424|NCT01764035|Behavioral|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
319425|NCT01764022|Drug|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
319426|NCT01764022|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
319427|NCT01764009|Biological|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
319428|NCT01763996|Drug|Febuxostat|Febuxostat capsules
319429|NCT01763996|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
319430|NCT01763983|Behavioral|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
319431|NCT01763983|Behavioral|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
319432|NCT01763970|Radiation|SBRT|800 delivered in 5 fractions every day to total dose of 4000
319433|NCT01763957|Behavioral|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
319434|NCT01763957|Behavioral|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
319435|NCT01763944|Behavioral|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
319436|NCT01763931|Drug|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
319437|NCT01763918|Biological|Evolocumab|Administered by subcutaneous injection
319438|NCT01763918|Drug|Placebo|Administered by subcutaneous injection
319439|NCT01763905|Biological|Evolocumab|Subcutaneous injection
319440|NCT01763905|Drug|Placebo to Evolocumab|Subcutaneous injection
319441|NCT01763905|Drug|Ezetimibe|Tablet for oral administration
319442|NCT01763905|Drug|Placebo to Ezetimibe|Tablet for oral administration
319443|NCT01763879|Other|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
319444|NCT01763879|Other|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
319445|NCT01763866|Biological|Evolocumab|Administered by subcutaneous injection
319446|NCT01763866|Drug|Ezetimibe|Administered orally once a day
319447|NCT01763866|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
319448|NCT01763866|Drug|Placebo to Ezetimibe|Administered orally once a day
319449|NCT01763866|Drug|Atorvastatin|Administered orally once a day
319450|NCT01763866|Drug|Rosuvastatin|Administered orally once a day
319451|NCT01763866|Drug|Simvastatin|Administered orally once a day
319452|NCT01763853|Drug|4% albumin|
319453|NCT01763840|Drug|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
319454|NCT01763827|Biological|Evolocumab|Administered by subcutaneous injection
319455|NCT01763827|Drug|Ezetimibe|Administered orally once a day
319456|NCT01763827|Biological|Placebo to Evolocumab|Administered by subcutaneous injection
319457|NCT01763827|Other|Placebo to Ezetimibe|Administered orally once daily
319458|NCT01763814|Procedure|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
319459|NCT01763814|Procedure|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
319460|NCT01763814|Procedure|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
319461|NCT01763801|Device|P-Max|tip placement in correspondence to the P-Max on the ECG
319462|NCT01763801|Device|P-Submax|tip placement in correspondence to the P-Submax on the ECG
319463|NCT01763788|Drug|Necitumumab|Administered IV
319464|NCT01763788|Drug|Gemcitabine|Administered IV
319465|NCT01763788|Drug|Cisplatin|Administered IV
319466|NCT01763775|Device|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
319467|NCT01763775|Device|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
319468|NCT01763762|Behavioral|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
319469|NCT01763762|Behavioral|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
319470|NCT01763762|Behavioral|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
319471|NCT01763749|Drug|Closone|Closone 75mg/100mg, 4weeks, PO
319472|NCT01763749|Drug|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
319473|NCT01763736|Behavioral|Music|playlist per patient preference
319474|NCT01763723|Device|IPL-home use device|A light based home use device for hair removal
319475|NCT01763710|Drug|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
319476|NCT01763710|Drug|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
319477|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
319478|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
319479|NCT01763697|Behavioral|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
319480|NCT01763697|Behavioral|Recorded meal|
319481|NCT01763684|Device|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
319482|NCT01763684|Procedure|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
319483|NCT01763671|Drug|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
319484|NCT01763671|Drug|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
319485|NCT01763671|Drug|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
319486|NCT01763658|Drug|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
319487|NCT01763658|Other|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
319488|NCT01763645|Drug|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
319489|NCT01763645|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
319490|NCT01763645|Drug|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
319491|NCT01763632|Device|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
319492|NCT01763619|Device|Freedom Cervical Disc|
319493|NCT01763606|Drug|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
319494|NCT01763606|Drug|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
319495|NCT01763580|Drug|Tacrolimus|Oral
319496|NCT01763580|Drug|Prednisolone|Oral
319497|NCT01763554|Drug|Lu-177 DOTA-TATE|The regimen used for therapy for patients treated under SAP was a standard dose of 5.55 GBq Lu-177 DOTA-TATE every 10-12 weeks for 4 treatments, then every 6 months as maintenance treatment.
319498|NCT01763541|Drug|leuprolide acetate|Given to both arms to induce hypogonadism
319499|NCT01763541|Drug|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
319500|NCT01763528|Other|nutrition intervention|high protein diet
320445|NCT01755754|Device|Female Condom|Female condom
319501|NCT01763515|Procedure|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
319502|NCT01763502|Other|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
319503|NCT01763502|Other|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
319504|NCT01763489|Behavioral|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
319505|NCT01763476|Procedure|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
319506|NCT01763476|Procedure|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
319507|NCT01763463|Drug|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
319508|NCT01763463|Drug|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
319509|NCT01763450|Drug|bevacizumab plus chemotherapy|"Bevacizumab:~7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
319510|NCT01763437|Drug|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
319511|NCT01763424|Drug|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
319512|NCT01763424|Drug|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
319513|NCT01763385|Drug|Erlotinib|
319514|NCT01763385|Radiation|concurrent brain radiotherapy|
319515|NCT01763385|Radiation|secondary brain radiotherapy|
319516|NCT01763346|Drug|Metformin|metformin 1000 mg bid
319517|NCT01763346|Device|gastric banding|LAP-BAND
319518|NCT01763333|Drug|BI 1026706 Placebo|Placebo to BI 1026706
319519|NCT01763333|Drug|BI 1026706|different dose formulations
319520|NCT01763320|Procedure|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
319521|NCT01763320|Drug|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
319522|NCT01763307|Drug|RECONVAL CREAM|
319523|NCT01763307|Drug|PLACEBO|
319524|NCT01763294|Device|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
319525|NCT01763294|Device|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
319526|NCT01763294|Device|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
319527|NCT01763294|Device|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
319528|NCT01763294|Device|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
319529|NCT01763281|Drug|CRH|
319530|NCT01763281|Drug|Placebo|
319531|NCT01763268|Biological|Trivivac vaccine|Trivalent MMR vaccine
319532|NCT01763255|Biological|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
319533|NCT01763242|Other|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
319534|NCT01763229|Procedure|transthoracic echocardiography|
319600|NCT01762787|Drug|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
319535|NCT01763216|Other|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
319536|NCT01763216|Other|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
319537|NCT01763203|Behavioral|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
319538|NCT01763203|Behavioral|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
319539|NCT01763190|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
319540|NCT01763177|Other|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
319541|NCT01763164|Drug|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
319542|NCT01763164|Drug|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
319543|NCT01763151|Device|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
319544|NCT01763151|Procedure|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
319545|NCT01763138|Behavioral|oral health education|oral health education in the form of a pictorial pamphlet.
319546|NCT01763138|Behavioral|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
319547|NCT01763125|Other|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
319548|NCT01763112|Device|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
319549|NCT01763099|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
319550|NCT01763099|Biological|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
319551|NCT01763086|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
319552|NCT01763060|Radiation|CT scan|
319553|NCT01763060|Behavioral|Cognitive function|
319554|NCT01763060|Radiation|MRI|
319555|NCT01763047|Device|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
319556|NCT01763047|Device|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
319557|NCT01763034|Procedure|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
319558|NCT01763021|Drug|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
319559|NCT01763021|Drug|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
319560|NCT01763008|Drug|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
319561|NCT01762995|Drug|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
319562|NCT01762995|Drug|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
319563|NCT01762995|Drug|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
319564|NCT01762982|Drug|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
319565|NCT01762982|Drug|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
319566|NCT01762982|Drug|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
319567|NCT01762982|Other|Empty Finn Chamber|Empty Finn Chamber
319568|NCT01762969|Other|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
319601|NCT01762787|Drug|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
319602|NCT01762774|Drug|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
320881|NCT01752205|Drug|Erlotinib|150mg/d,days 1-42,total 6 weeks
319569|NCT01762956|Other|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
319570|NCT01762943|Drug|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
319571|NCT01762943|Drug|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
319572|NCT01762943|Drug|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
319573|NCT01762930|Drug|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
319574|NCT01762904|Other|Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.
319575|NCT01762904|Other|Preparing skin's areas to be tested with two antiseptics and two controls|All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
319576|NCT01762891|Drug|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
319577|NCT01762891|Drug|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
319578|NCT01762891|Drug|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
319579|NCT01762891|Drug|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
319580|NCT01762878|Drug|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
319581|NCT01762878|Drug|Placebo|Dry powder for oral inhalation once daily using DIKUS device
319582|NCT01762852|Drug|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
319583|NCT01762852|Drug|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
319584|NCT01762839|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
319585|NCT01762839|Drug|Placebo|IV placebo will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
319586|NCT01762839|Drug|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a 400 mg moxifloxacin tablet and will not receive a placebo infusion.
319587|NCT01762826|Dietary Supplement|Myo-inositol|Dietary control plus Myo-inositol
319588|NCT01762826|Dietary Supplement|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
319589|NCT01762826|Dietary Supplement|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
319590|NCT01762826|Dietary Supplement|Placebo|Dietary control plus folic acid 400 mcg daily
319591|NCT01762813|Procedure|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
319592|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
319593|NCT01762800|Drug|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
319594|NCT01762800|Drug|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
319595|NCT01762800|Drug|tiotropium bromide placebo|Placebo, Once daily(morning)
319596|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
319597|NCT01762787|Drug|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
319598|NCT01762787|Drug|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
319599|NCT01762787|Drug|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
319603|NCT01762774|Drug|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
319604|NCT01762761|Drug|eltrombopag|TPO-R agonist
319605|NCT01762761|Drug|placebo|placebo
319606|NCT01762748|Drug|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
319607|NCT01762735|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
319608|NCT01762735|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
319609|NCT01762722|Device|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
319610|NCT01762709|Procedure|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
319611|NCT01762709|Procedure|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
319612|NCT01762709|Procedure|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
319613|NCT01762696|Behavioral|MET|Motivational Enhancement Therapy only
319614|NCT01762696|Behavioral|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
319615|NCT01762683|Other|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.~The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
319616|NCT01762670|Drug|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
319617|NCT01762670|Drug|Metronidazole|500 mg twice daily for 7 days
319618|NCT01762657|Drug|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
319619|NCT01762657|Drug|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
319620|NCT01762644|Drug|Oral Cyclosporine and Oral Omeprazole|
319621|NCT01762644|Drug|Oral Omeprazole|
319622|NCT01762618|Behavioral|Cognitive Behavioral Therapy Group|Therapy Groups
319623|NCT01762605|Other|Supportive Care|
319624|NCT01762605|Procedure|Cast|
319625|NCT01762592|Drug|Iodine (124I) Girentuximab|i.v.
319626|NCT01762579|Dietary Supplement|wheat flour|wheat flour is administered three times per day for 15 days
319627|NCT01762579|Dietary Supplement|Xylose|Xylose will be administered three times per day for 15 days
319628|NCT01762566|Dietary Supplement|wheat|wheat is administered blindly versus placebo in capsules once
319629|NCT01762566|Dietary Supplement|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
319630|NCT01762553|Behavioral|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
319631|NCT01762540|Drug|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
319632|NCT01762540|Drug|Calcium Supplement|Placebo
319633|NCT01762527|Radiation|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
319634|NCT01762514|Drug|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
319635|NCT01762514|Drug|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
319636|NCT01762501|Drug|Azilsartan|Azilsartan 20mg/day
319637|NCT01762501|Drug|Amlodipine|Amlodipine 5mg/day
319638|NCT01762488|Procedure|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
319639|NCT01762488|Procedure|Renal angiography|Renal angiography by femoral access
319640|NCT01762475|Drug|Sildenafil|
319641|NCT01762462|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
319642|NCT01762449|Other|Followup survey|
319643|NCT01762436|Drug|bisoprolol|
319644|NCT01762436|Drug|atenolol|
319645|NCT01762423|Device|Active Device (IVIVI SofPulse)|
319646|NCT01762423|Device|Sham Device|
319696|NCT01762046|Drug|Metformin|
319697|NCT01762046|Other|Oral Glucose Tolerance Test|
319698|NCT01762033|Drug|ASONEP|Intravenous infusion
319647|NCT01762410|Drug|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
319648|NCT01762397|Drug|PMK-S005|
319649|NCT01762384|Procedure|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
319650|NCT01762384|Procedure|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
319651|NCT01762384|Device|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
319652|NCT01762371|Other|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
319653|NCT01762358|Other|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
319654|NCT01762358|Other|Physiotherapy|Twelve times standardized Physiotherapy
319655|NCT01762345|Device|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter & Gamble
319656|NCT01762332|Drug|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
319657|NCT01762332|Drug|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
319658|NCT01762332|Other|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
319659|NCT01762319|Drug|Misoprostol|
319660|NCT01762319|Drug|Vitamin B6|
319661|NCT01762306|Drug|Diclofenac Potassium|
319662|NCT01762306|Drug|Folic Acid|
319663|NCT01762293|Drug|Famitinib|Famitinib 25 mg p.o. qd
319664|NCT01762293|Other|placebo|p.o. qd
319665|NCT01762280|Drug|Famitinib Malate Capsule|
319666|NCT01762267|Other|nutrition intervention|DASH diet control diet
319667|NCT01762254|Procedure|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
319668|NCT01762254|Procedure|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
319669|NCT01762241|Behavioral|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
319670|NCT01762228|Device|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
319671|NCT01762228|Dietary Supplement|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
319672|NCT01762215|Behavioral|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
319673|NCT01762202|Drug|Cyclophosphamide|
319674|NCT01762202|Drug|Fludarabine|
319675|NCT01762202|Drug|Ofatumumab|
319676|NCT01762189|Procedure|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
319677|NCT01762176|Procedure|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
319678|NCT01762176|Procedure|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
319679|NCT01762163|Drug|Qizhitongluo Capsule|
319680|NCT01762163|Drug|Naoxintong Capsule|
319681|NCT01762163|Drug|Aspirin Enteric-coated Tablets|
319682|NCT01762163|Behavioral|the routine recovery training|
319683|NCT01762163|Drug|placebo|
319684|NCT01762150|Drug|Sorafenib|Sorafenib 400mg BID by oral until progressed;
319685|NCT01762150|Drug|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30~60min on Day 1 and 8,for 4 cycles;
319686|NCT01762150|Drug|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
319687|NCT01762137|Procedure|Flow Diversion|Endovascular flow diverter placement
319688|NCT01762137|Procedure|Coiling|Endovascular coil placement
319689|NCT01762124|Device|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
319690|NCT01762085|Procedure|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
319691|NCT01762072|Dietary Supplement|Fish oil|
319692|NCT01762072|Dietary Supplement|vitaminB12|
319693|NCT01762059|Device|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
319694|NCT01762059|Other|Usual care|
319695|NCT01762046|Drug|Glipizide|
319699|NCT01762020|Device|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
319700|NCT01762020|Drug|Standard Preparation|standard creams
319701|NCT01761994|Drug|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
319702|NCT01761968|Drug|Givinostat|"Patients will continue at their last tolerable dose and treatment schedule of Givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.~If patients previously received Givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
319703|NCT01761955|Other|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
319704|NCT01761942|Dietary Supplement|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
319705|NCT01761929|Radiation|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
319706|NCT01761916|Drug|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
319707|NCT01761916|Drug|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
319708|NCT01761890|Behavioral|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
319709|NCT01761877|Drug|Sulindac|
319710|NCT01761864|Behavioral|academic detailing intervention|
319711|NCT01761838|Other|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
319712|NCT01761838|Other|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
319713|NCT01761838|Other|Low back pain participants without SMT|No treatment
319714|NCT01761825|Drug|ivabradine|
319715|NCT01761812|Other|MRI with gadofosveset and MR elastography|
319716|NCT01761799|Behavioral|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
319717|NCT01761786|Genetic|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with *1/*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (*2 or *3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
319718|NCT01761773|Drug|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
319719|NCT01761760|Behavioral|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
319720|NCT01761747|Drug|ponatinib|
319721|NCT01761734|Behavioral|text message|
319722|NCT01761708|Procedure|primary ventral hernia repair with mesh|
319723|NCT01761695|Other|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
319724|NCT01761682|Other|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
319725|NCT01761669|Drug|Vitamin D|
319726|NCT01761656|Drug|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
319727|NCT01761656|Drug|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
319728|NCT01761643|Device|SoC + iTab|Text messaging reminders to improve adherence to PrEP
319729|NCT01761617|Behavioral|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
320882|NCT01752205|Radiation|Radiation therapy|
319730|NCT01761617|Behavioral|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
319731|NCT01761604|Device|Nasal ganglion block for TN|
319732|NCT01761591|Device|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
319733|NCT01761591|Device|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
319734|NCT01761578|Device|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
319735|NCT01761565|Drug|Single dose of SUF NT 15 mcg|
319736|NCT01761565|Drug|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
319737|NCT01761552|Drug|Sugammadex Reversal|
319738|NCT01761552|Drug|Atropine/Neostigmine|
319739|NCT01761539|Other|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
319740|NCT01761539|Other|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
319741|NCT01761526|Drug|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
319742|NCT01761513|Drug|YH4808|"Group1~adminitration of YH4808 dose1, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose2, qd for 2weeks"
319743|NCT01761513|Drug|YH4808|"Group2~adminitration of YH4808 dose2, qd for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose1, bid for 2weeks"
319744|NCT01761513|Drug|YH4808|"Group3~adminitration of YH4808 dose2, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of Nexium tab 40mg, bid for 2weeks"
319745|NCT01761513|Drug|YH4808|"Group 4~adminitration of Nexium tab 40mg, bid for 2weeks~wash-out period for 3weeks between period1 and period2~adminitration of YH4808 dose2, bid for 2weeks"
319746|NCT01761500|Other|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
319747|NCT01761487|Device|Gentamicin and polymyxin E|
319748|NCT01761461|Drug|TS-1, oxaliplatin|
319749|NCT01761448|Device|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
319750|NCT01761448|Device|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
319751|NCT01761448|Device|Control group training without Guided Exercise system at home|
319752|NCT01761435|Biological|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :~A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.~B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.~The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
319753|NCT01761396|Behavioral|CBT|
319754|NCT01761396|Behavioral|UC|
319755|NCT01761383|Other|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
319756|NCT01761370|Procedure|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
319757|NCT01761370|Procedure|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
319758|NCT01761357|Other|answering to questionnaires of quality of live|
319759|NCT01761344|Other|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
319760|NCT01761331|Other|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.~Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
319761|NCT01761318|Drug|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
319826|NCT01760759|Behavioral|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
319911|NCT01760083|Device|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
319762|NCT01761318|Drug|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
319763|NCT01761305|Procedure|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
319764|NCT01761305|Behavioral|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
319765|NCT01761305|Other|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
319766|NCT01761292|Drug|Givinostat|
319767|NCT01761279|Procedure|High definition white light endoscopy|
319768|NCT01761266|Drug|Lenvatinib|12 mg (or 8 mg) once daily (QD) oral dosing.
319769|NCT01761266|Drug|Sorafenib|400 mg twice daily (BID) oral dosing.
319770|NCT01761240|Drug|MORAb-066|
319771|NCT01761227|Drug|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
319772|NCT01761227|Drug|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
319773|NCT01761214|Drug|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
319774|NCT01761214|Drug|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
319775|NCT01761201|Drug|Levofloxacin|Levofloxacin
319776|NCT01761201|Drug|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
319777|NCT01761188|Procedure|Ablation|electrophysiology substrate mapping is the critical difference between both groups
319778|NCT01761175|Procedure|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
319779|NCT01761175|Procedure|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
319780|NCT01761162|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
319781|NCT01761162|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
319782|NCT01761149|Drug|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
319783|NCT01761136|Biological|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
319784|NCT01761136|Biological|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
319785|NCT01761123|Biological|VXA-A1.1|
319786|NCT01761110|Behavioral|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
319787|NCT01761097|Device|Endocuff attachment|Endocuff
319788|NCT01761084|Behavioral|Exercise and behaviour change strategies|"cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day~postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)~perform muscle strengthening and balance training exercises ≥ 3 days a week~the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
319789|NCT01761071|Drug|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
319879|NCT01760330|Drug|Placebo|
319880|NCT01760317|Procedure|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
319912|NCT01760070|Device|Hybrid knife|Use Hybrid knife in ESD procedure
319913|NCT01760070|Device|IT knife|Use IT knife in ESD procedure.
320123|NCT01758302|Other|Vegetables|Participants are asked to taste test raw celery or radishes
319790|NCT01761071|Drug|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
319791|NCT01761045|Dietary Supplement|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
319792|NCT01761045|Dietary Supplement|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
319793|NCT01761045|Dietary Supplement|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
319794|NCT01761032|Device|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
319795|NCT01761019|Drug|Taclonex Topical Suspension|topical medication for psoriasis
319796|NCT01761006|Device|NIOX MINO®|
319797|NCT01760993|Drug|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
319798|NCT01760980|Drug|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
319799|NCT01760980|Drug|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
319800|NCT01760967|Drug|Dexmedetomidine|intervention to administer dexmedetomidine or not
319801|NCT01760954|Drug|Elagolix|Elagolix tablets administered orally
319802|NCT01760941|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
319803|NCT01760941|Other|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
319804|NCT01760941|Other|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
319805|NCT01760915|Other|NC100182 Hyperpolarized 3He|Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
319806|NCT01760902|Behavioral|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
319807|NCT01760889|Drug|SPD489 low dose range (40mg, 80mg, and 100mg)|"Capsule, dose titration,~40 mg capsule once-daily for 1 week; then~80 mg capsule once-daily for 4 weeks; then,~100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;~if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks"
319808|NCT01760889|Drug|SPD489 high dose range (120mg, 140mg and 160mg)|"Capsule, dose titration,~40 mg capsule once-daily for 1 week; then~80 mg capsule once daily for 1 week; then~120 mg capsule once-daily for 1 week, then,~140 mg capsule once-daily for 2 weeks, then~160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;~if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks"
319809|NCT01760889|Drug|Placebo|One capsule a day for 26 weeks
319810|NCT01760876|Device|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
319811|NCT01760863|Other|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
319812|NCT01760850|Other|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
319813|NCT01760850|Other|educational intervention|Engage in an educational information session for diabetes
319814|NCT01760850|Other|questionnaire administration|Ancillary studies
319815|NCT01760837|Other|Baked milk products to cow's milk allergic patients|
319816|NCT01760824|Drug|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
319817|NCT01760824|Drug|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
319818|NCT01760811|Drug|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
319819|NCT01760798|Drug|Teriparatide|
319820|NCT01760785|Drug|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
319821|NCT01760785|Drug|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
319822|NCT01760772|Drug|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
319823|NCT01760772|Drug|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
319824|NCT01760772|Other|saline|Constant infusion
319825|NCT01760759|Behavioral|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
319910|NCT01760096|Drug|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
321323|NCT01748838|Other|Mannitol|excipient blended with CTX-4430
319827|NCT01760746|Other|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.~On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .~Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
319828|NCT01760720|Behavioral|MMT CARE|
319829|NCT01760707|Behavioral|exercise training|
319830|NCT01760707|Behavioral|usual care|
319831|NCT01760694|Other|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
319832|NCT01760681|Device|H- Coil DTMS|20 daily deep rTMS treatments
319833|NCT01760681|Device|Sham|
319834|NCT01760655|Drug|Fludarabine phosphate|Given IV
319835|NCT01760655|Drug|Thiotepa|Given IV
319836|NCT01760655|Radiation|Total body irradiation|Undergo TBI
319837|NCT01760655|Biological|Therapeutic allogeneic lymphocytes|Undergo donor lymphocyte infusion
319838|NCT01760655|Drug|Cyclophosphamide|Given IV
319839|NCT01760655|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo allogeneic PBSCT
319840|NCT01760655|Procedure|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
319841|NCT01760655|Drug|Tacrolimus|Given IV
319842|NCT01760655|Drug|Mycophenolate mofetil|Given IV
319843|NCT01760642|Drug|Midazolam|Midazolam 3 mg IV
319844|NCT01760642|Drug|Ketoconazole|ketoconazole 400 mg PO
319845|NCT01760642|Drug|Rifampicin|Rifampicin 600 mg PO
319846|NCT01760629|Device|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
319847|NCT01760616|Drug|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
319848|NCT01760603|Procedure|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
319849|NCT01760590|Procedure|Manual Manipulation|A grade 5 thrust to the thoracic spine
319850|NCT01760590|Procedure|Mobilization|A grade 1-4 mobilization directed at thoracic spine
319851|NCT01760577|Drug|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
319852|NCT01760577|Drug|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
319853|NCT01760564|Drug|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
319854|NCT01760538|Behavioral|Exercise training|exercise training
319855|NCT01760538|Behavioral|usual care|received usual medical care after heart transplantation
319856|NCT01760525|Drug|CGM097|Patients treated with CGM097
319857|NCT01760512|Procedure|Gastric bypass|Gastric bypass
319858|NCT01760499|Drug|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
319859|NCT01760499|Procedure|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
319860|NCT01760486|Behavioral|Shape Up Rhode Island|
319861|NCT01760486|Behavioral|Shape Up Rhode Island + Professional Coach + Incentives|
319862|NCT01760486|Behavioral|Shape Up Rhode Island + Peer Coach + Incentives|
319863|NCT01760473|Drug|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
319864|NCT01760460|Drug|Anacetrapib|
319865|NCT01760460|Drug|Placebo for anacetrapib|
319866|NCT01760447|Drug|Sitagliptin + Metformin XR FDC|Sitagliptin + Metformin XR fixed-dose combination tablet (sitagliptin/metformin: 50/500 mg, 50/1000 mg) administered with a meal, preferably in the evening
319867|NCT01760447|Drug|Placebo to Sitagliptin + Metformin XR|Matching placebo to Sitagliptin + Metformin XR fixed-dose combination tablet administered with a meal, preferably in the evening
319868|NCT01760447|Drug|Metformin XR|Metformin XR tablet (500 mg, 1000 mg) administered with a meal, preferably in the evening
319869|NCT01760447|Drug|Placebo to metformin XR|Matching placebo to metformin XR tablet administered with a meal, preferably in the evening
319870|NCT01760447|Drug|Insulin glargine|The insulin regimen and dosing will be at the discretion of the investigator (based on locally accepted, national, or international guidelines for the indication and use of insulin glargine). When thresholds for rescue are met, participants who are not on background insulin will initiate insulin glargine.
319871|NCT01760447|Biological|Background insulin|Participants who enter the study on background insulin will continue on the same dose and formulation of insulin throughout the study. When thresholds for rescue are met, participants who have entered the study on background insulin will uptitrate their background insulin dose.
319872|NCT01760434|Other|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
319873|NCT01760421|Drug|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
319874|NCT01760408|Other|all patients on Home Parenteral Nutrition|
319875|NCT01760382|Device|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
319876|NCT01760343|Biological|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
319877|NCT01760343|Biological|CSL830|CSL830 is a formulation of Berinert.
319878|NCT01760330|Drug|IV acetaminophen|
319881|NCT01760304|Drug|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
319882|NCT01760304|Drug|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).~After 45 minutes , the above measurements will be repeated."
319883|NCT01760291|Device|WATCHMAN LAA Closure Technology|
319884|NCT01760278|Drug|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.~On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
319885|NCT01760252|Drug|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
319886|NCT01760239|Behavioral|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
319887|NCT01760226|Drug|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV~Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.~Day 5: cyclophosphamide will be given in a vein~Days 1-5: prednisone given by mouth twice a day~G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
319888|NCT01760226|Drug|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.~CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.~DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:~2+ extranodal sites~elevated LDH,~MYC rearrangement OR~bone or marrow disease.~ALL OTHERS receive IT MTX cycles 3-6."
319889|NCT01760226|Drug|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
319890|NCT01760226|Drug|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
319891|NCT01760226|Drug|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
319892|NCT01760226|Drug|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
319893|NCT01760226|Drug|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
319894|NCT01760226|Drug|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
319895|NCT01760226|Drug|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
319896|NCT01760213|Other|CBT delivered via Internet|
319897|NCT01760187|Drug|lomitapide|
319898|NCT01760174|Drug|Ropivacaine bolus in transversus abdominis plane catheter|"Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours."
319899|NCT01760174|Drug|Bupivacain-infusion in epidural catheter|"Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.~In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours"
319900|NCT01760161|Drug|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
319901|NCT01760161|Drug|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
319902|NCT01760148|Drug|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
319903|NCT01760135|Dietary Supplement|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
319904|NCT01760135|Dietary Supplement|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
319905|NCT01760122|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
319906|NCT01760122|Drug|Pegasys|sc, qw, 48 weeks.
319907|NCT01760109|Drug|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
319908|NCT01760096|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
319909|NCT01760096|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
319914|NCT01760057|Behavioral|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
319915|NCT01760057|Behavioral|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
319916|NCT01760044|Device|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
319917|NCT01760031|Other|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
319918|NCT01760018|Drug|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
319919|NCT01760018|Drug|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
319920|NCT01760005|Drug|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
319921|NCT01760005|Drug|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
319922|NCT01760005|Drug|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
319923|NCT01760005|Drug|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
319924|NCT01759992|Device|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
319925|NCT01759979|Procedure|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
319926|NCT01759979|Procedure|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
319927|NCT01759953|Other|Game|InsuOnline game, on the web, in the player´s own time and rhythm
319928|NCT01759953|Other|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
319929|NCT01759940|Drug|ropivacaine 0,375%|
319930|NCT01759940|Drug|ropivacaine 0,75%|
319931|NCT01759927|Behavioral|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
319932|NCT01759914|Drug|Potent topical steroid|
319933|NCT01759914|Drug|Superpotent topical steroid|
319934|NCT01759901|Procedure|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
319935|NCT01759888|Drug|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
319936|NCT01759875|Drug|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
319937|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
319938|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
319939|NCT01759862|Drug|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
319940|NCT01759862|Other|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
319941|NCT01759862|Drug|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
319942|NCT01759849|Other|Allergen|Allergen extract is administered by inhalation.
319943|NCT01759836|Drug|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
319944|NCT01759823|Biological|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
319945|NCT01759823|Other|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
319946|NCT01759823|Biological|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
319947|NCT01759810|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
319948|NCT01759810|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
319949|NCT01759797|Biological|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
319950|NCT01759784|Biological|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
319951|NCT01759771|Drug|Vitamin D3|4,000 IU of VD3 for at least one year
319952|NCT01759771|Drug|Placebo|Placebo for at least one year
319953|NCT01759758|Other|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
319954|NCT01759758|Other|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
319955|NCT01759732|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -4
319956|NCT01759732|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
319957|NCT01759732|Biological|anti-thymocyte globulin|
319958|NCT01759732|Biological|filgrastim|
319959|NCT01759732|Radiation|Total body irradiation|200 cGy per day on D-5 & -4
319960|NCT01759732|Procedure|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
319961|NCT01759719|Device|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
319962|NCT01759706|Behavioral|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
319963|NCT01759706|Procedure|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
319964|NCT01759706|Drug|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
319965|NCT01759706|Other|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
319966|NCT01759706|Drug|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
319967|NCT01759706|Drug|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
319968|NCT01759706|Behavioral|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
319969|NCT01759706|Drug|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
319970|NCT01759693|Procedure|Blood sampling|Blood sampling
319971|NCT01759680|Device|Vibrosphère device|Vertical Sinusoidal vibration
319972|NCT01759667|Other|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
319973|NCT01759654|Biological|AdimFlu-V|
319974|NCT01759641|Device|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
319975|NCT01759628|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
319976|NCT01759615|Other|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
319977|NCT01759615|Other|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
319978|NCT01759602|Drug|C1-esterase inhibitor (Cinryze)|
319979|NCT01759589|Drug|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
319980|NCT01759589|Drug|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
319981|NCT01759589|Drug|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
319982|NCT01759576|Drug|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
319983|NCT01759563|Device|nasopharyngeal targeted brain cooling|
319984|NCT01759537|Device|Ankylos dental endosseous implants-sub-crestal|Implants placed subcrestally
319985|NCT01759537|Device|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
319986|NCT01759524|Drug|Bupivacaine|
319987|NCT01759524|Drug|Lidocaine|
319988|NCT01759511|Drug|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
319989|NCT01759498|Dietary Supplement|HYDRO|
319990|NCT01759498|Dietary Supplement|ACTIVE|
319991|NCT01759498|Dietary Supplement|HYDRO 2|
319992|NCT01759485|Drug|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
319993|NCT01759485|Drug|placebo|
319994|NCT01759459|Drug|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
319995|NCT01759459|Drug|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
320029|NCT01759121|Radiation|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
319996|NCT01759459|Drug|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
319997|NCT01759446|Drug|Placebo taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
319998|NCT01759446|Drug|Generic H/A taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
319999|NCT01759446|Drug|Vycavert taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
320000|NCT01759446|Drug|Generic H/A plus i taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
320001|NCT01759446|Drug|Generic H/A plus p taken first|Snorted in both nostrils within 5 minutes; 48 hours washout between doses
320002|NCT01759420|Drug|Ondansetron|4mg of intravenous ondansetron
320003|NCT01759407|Drug|Ropivicaine|
320004|NCT01759407|Drug|Epinephrine|
320005|NCT01759394|Drug|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:~Fed, Fed, Fasted; or~Fed, Fasted, Fed; or~Fasted, Fed, Fed~During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.~During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.~Randomization Phase consists of three single-dose treatment periods:~Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
320006|NCT01759381|Device|Negative pressure wound therapy (NPWT)|
320007|NCT01759368|Device|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
320008|NCT01759355|Procedure|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
320009|NCT01759342|Behavioral|Aerobic exercise|
320010|NCT01759342|Behavioral|Resistance exercise|
320011|NCT01759342|Behavioral|Flexibility and postural exercise|
320012|NCT01759342|Behavioral|Balance exercise|
320013|NCT01759329|Dietary Supplement|test coffee|test coffee with higher alkyl pyridine content
320014|NCT01759329|Dietary Supplement|control coffee|control coffee with regular alkyl pyridine content
320015|NCT01759316|Other|heliox|heliox or oxygen is used in the two groups respectively
320016|NCT01759303|Drug|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
320017|NCT01759290|Device|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
320018|NCT01759277|Drug|Active comparator: Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve catheter and block under ultrasound guidance with the final position of catheter posterior to the femoral nerve and lateral to the femoral artery. Normal saline up to 10ml will be injected if necessary for hydro-dissection via the needle. The catheter will then be threaded 3-5cm past the needle tip and its location will be confirmed by a 30ml bolus of lidocaine 2% via the catheter under ultrasound visualization. The control group will receive a standardized general anesthetic with inhaled volatile anesthesia in nitrous oxide and oxygen or bupivacaine spinal anesthetic.
320019|NCT01759277|Drug|Experimental: Adductor Canal perineural local anesthetic infusion|The experimental group will receive an adductor canal catheter and block under ultrasound guidance with the final position of catheter between the femoral artery and nerve. Normal saline up to 10ml will be injected if necessary for hydro-dissection via the needle. The catheter will then be threaded 3-5cm past the needle tip and its location will be confirmed by a 30ml bolus of lidocaine 2% via the catheter under ultrasound visualization. The control group will receive a standardized general anesthetic with inhaled volatile anesthesia in nitrous oxide and oxygen or bupivacaine spinal anesthetic.
320020|NCT01759238|Drug|Capecitabine|825mg/m2 per os bid
320021|NCT01759238|Drug|Bevacizumab|7.5 mg/kg
320022|NCT01759238|Radiation|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
320023|NCT01759212|Biological|Allogeneic stem cells implantation|
320024|NCT01759199|Procedure|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
320025|NCT01759160|Procedure|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
320026|NCT01759160|Procedure|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
320027|NCT01759147|Procedure|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
320028|NCT01759134|Other|Post discharge formula|Babies will be given either materna sensitive or similac neosure
320077|NCT01758562|Device|Caphosol|
320030|NCT01759121|Radiation|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
320031|NCT01759108|Drug|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
320032|NCT01759095|Device|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
320033|NCT01759069|Procedure|Surgical treatment with microscope|
320034|NCT01759056|Drug|AVX 470|active comparator
320035|NCT01759056|Drug|Placebo|
320036|NCT01759043|Procedure|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
320037|NCT01759043|Procedure|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
320038|NCT01759030|Drug|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
320039|NCT01759004|Other|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
320040|NCT01758991|Device|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
320041|NCT01758978|Drug|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
320042|NCT01758965|Other|PPI|monotherapy of PPI
320043|NCT01758965|Other|H2RA and surgicel|combination therapy of H2RA and surgicel
320044|NCT01758913|Drug|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
320045|NCT01758900|Device|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
320046|NCT01758900|Device|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
320047|NCT01758874|Procedure|phlebotomy|repeated phlebotomy for 4 weeks
320048|NCT01758861|Drug|EPO group|
320049|NCT01758861|Drug|Placebo|
320050|NCT01758835|Other|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
320051|NCT01758835|Other|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
320052|NCT01758835|Other|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
320053|NCT01758822|Other|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
320054|NCT01758809|Procedure|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
320055|NCT01758809|Procedure|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
320056|NCT01758796|Procedure|Non-operative treatment|Below-the-knee cast for six weeks.
320057|NCT01758796|Procedure|Surgery|Open reduction and internal fixation with 1/3 semi-tubular plate and screws.
320058|NCT01758783|Drug|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
320059|NCT01758757|Procedure|Vitrectomy|
320060|NCT01758744|Drug|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
320061|NCT01758731|Drug|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
320062|NCT01758731|Drug|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
320063|NCT01758731|Radiation|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
320064|NCT01758718|Procedure|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
320065|NCT01758679|Biological|Licartin and CIK|Licartin and CIK
320066|NCT01758666|Drug|Methotrexate,Calcium folinate|
320067|NCT01758653|Other|No study intervention|There is no study-related intervention.
320068|NCT01758640|Drug|Warfarin|Low dose warfarin of 5mg or less per day
320069|NCT01758640|Drug|phenindione|Phenindione of 100mg or less per day
320070|NCT01758627|Drug|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
320071|NCT01758614|Procedure|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
320072|NCT01758614|Drug|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
320073|NCT01758614|Drug|Clopidogrel|
320074|NCT01758601|Other|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
320075|NCT01758601|Other|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
320076|NCT01758588|Drug|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
320078|NCT01758549|Other|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
320079|NCT01758549|Other|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
320080|NCT01758536|Drug|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
320081|NCT01758523|Drug|Dutasteride|
320082|NCT01758523|Drug|sugar pill|
320083|NCT01758510|Genetic|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10^6 cells/kg, 0.5 X 10^6 cells/kg, 1 X 10^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10^6 cells/kg dose cohort.
320084|NCT01758497|Procedure|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
320085|NCT01758497|Procedure|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
320086|NCT01758484|Other|palliative care|Undergo supportive care intervention
320087|NCT01758484|Other|questionnaire administration|Ancillary studies
320088|NCT01758484|Procedure|quality-of-life assessment|Ancillary studies
320089|NCT01758471|Drug|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
320090|NCT01758471|Drug|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
320091|NCT01758458|Biological|Aldesleukin|Given SC
320092|NCT01758458|Other|Laboratory Biomarker Analysis|Correlative studies
320093|NCT01758458|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
320094|NCT01758458|Radiation|Radiation Therapy|Undergo radiation therapy
320095|NCT01758458|Biological|Recombinant Interferon Beta|Given intralesionally
320096|NCT01758445|Radiation|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol & physician.
320097|NCT01758432|Combination Product|PRT064445/Apixaban|
320098|NCT01758432|Combination Product|Placebo/Apixaban|
320099|NCT01758432|Drug|Placebo|
320100|NCT01758419|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
320101|NCT01758406|Biological|Intracoronary injection|stem cell transplantation
320102|NCT01758406|Biological|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
320103|NCT01758393|Drug|Prednisone|
320104|NCT01758380|Drug|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
320105|NCT01758380|Drug|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
320106|NCT01758380|Drug|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
320107|NCT01758380|Drug|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
320108|NCT01758380|Drug|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
320109|NCT01758367|Drug|Deciatbine(DAC)|
320110|NCT01758354|Other|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
320111|NCT01758341|Procedure|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
320112|NCT01758341|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
320113|NCT01758341|Device|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
320114|NCT01758328|Drug|busulfan|
320115|NCT01758328|Drug|melphalan|
320116|NCT01758328|Drug|fludarabine|
320117|NCT01758328|Biological|anti-thymocyte globulin (ATG)|
320118|NCT01758328|Procedure|a T cell depleted stem cell transplant|
320119|NCT01758315|Other|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
320120|NCT01758302|Behavioral|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
320121|NCT01758302|Behavioral|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
320122|NCT01758302|Other|Cookies|Participants are asked to taste test chocolate chip cookies
320124|NCT01758302|Behavioral|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
320125|NCT01758263|Drug|Metoprolol|Metoprolol, oral administration
320126|NCT01758263|Drug|Nebivolol|Nebivolol, oral administration
320127|NCT01758250|Other|Acoustic Radiation Force Impulse (ARFI)|
320128|NCT01758250|Other|Laser Doppler Flowmetry (LDF)|
320129|NCT01758250|Other|Laser Doppler Perfusion Imaging (LDI)|
320130|NCT01758250|Other|Optical Coherence Tomography (OCT)|
320131|NCT01758250|Other|Orthogonal Polarization Spectral Imaging (OPSI)|
320132|NCT01758250|Other|Nail fold video capillaroscopy (NVC)|
320133|NCT01758237|Device|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
320134|NCT01758237|Procedure|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
320135|NCT01758224|Other|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
320136|NCT01758224|Other|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
320137|NCT01758211|Procedure|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
320138|NCT01758211|Procedure|conventional resection|conventional resection in AVM patients
320139|NCT01758198|Biological|Abatacept|
320140|NCT01758198|Drug|Placebo matching with Abatacept|
320141|NCT01758198|Drug|Methotrexate|
320142|NCT01758185|Biological|recombinant hepatitis b vaccine|0.5ml intramuscular
320143|NCT01758185|Biological|Aleph influenza vaccine|0.5ml intramuscular
320144|NCT01758172|Drug|6% hydroxyethyl starch 130/0.4|
320145|NCT01758172|Drug|Albumin|
320146|NCT01758159|Dietary Supplement|Iron supplementation|
320147|NCT01758159|Other|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
320148|NCT01758146|Drug|Tamoxifen|20 mg once daily for 5 years
320149|NCT01758146|Drug|Letrozole|Letroz, Femara, Letronat
320150|NCT01758133|Behavioral|Exposure to medical clown activities|
320151|NCT01758120|Drug|prednisone plus cyclophosphamide|"prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months);~supportive care,including ACE-I or ARBs and blood pressure control"
320152|NCT01758120|Drug|Prednisone alone|"prednisone alone: prednisone(0.5mg/kg/day*6 months);~supportive care,including ACE-I or ARBs and blood pressure control"
320153|NCT01758107|Other|Withdraw cyclosporine|
320154|NCT01758094|Drug|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
320155|NCT01758081|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
320156|NCT01758081|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
320157|NCT01758081|Dietary Supplement|Vitamin D3 placebo|
320158|NCT01758081|Dietary Supplement|fish oil placebo|
320159|NCT01758068|Procedure|Coconut Oil Application|Coconut oil - 4 ml
320160|NCT01758055|Biological|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
320161|NCT01758042|Procedure|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
320162|NCT01758029|Drug|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
320163|NCT01757990|Dietary Supplement|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
320164|NCT01757977|Device|double lumen endotracheal tube placement and use|
320165|NCT01757964|Biological|Bacteriotherapy|
320166|NCT01757951|Procedure|Unimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to unimalleolar fixation group and no fixation of the lateral side is performed.
320167|NCT01757951|Procedure|Bimalleolar fixation|Medial malleolus is fixed first and after that ankle mortise stability is assessed using external-rotation stress test. If talocrural joint is stable after fixation of medial malleolus, the patient is randomized to bimalleolar fixation group i.e. additional fixation of the lateral malleolus fracture is performed.
320168|NCT01757938|Procedure|Shang Ring Guided Circumcision|
320169|NCT01757938|Procedure|Forceps Guided Circumcision|
320170|NCT01757925|Behavioral|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
320171|NCT01757925|Other|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
320172|NCT01757912|Procedure|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
320203|NCT01757678|Procedure|cCTA (coronary computed tomography angiography)|Per the protocol, patients will have a coronary computed tomography angiography.
320173|NCT01757899|Drug|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
320174|NCT01757899|Drug|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
320175|NCT01757886|Other|Biomarkers to analyze both intracoronary thrombi as blood|
320176|NCT01757873|Drug|Z160|
320177|NCT01757873|Drug|Placebo|
320178|NCT01757860|Drug|CARD-024|Comparison of different dosages of drug
320179|NCT01757860|Other|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
320180|NCT01757847|Behavioral|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
320181|NCT01757847|Behavioral|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
320182|NCT01757834|Device|SWUS Elastography|
320183|NCT01757821|Device|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
320184|NCT01757821|Device|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
320185|NCT01757821|Device|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
320186|NCT01757808|Drug|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
320187|NCT01757808|Drug|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
320188|NCT01757795|Drug|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
320189|NCT01757795|Drug|Placebo|
320190|NCT01757782|Drug|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be <10% of previous value and SpO2 was not increasing >5 of previous value) and blood pressure remained stable
320191|NCT01757782|Drug|Placebo (distilled water)|
320192|NCT01757769|Drug|Silodosin|8 mg daily for 24 weeks
320193|NCT01757756|Drug|Pf-05175157|200-mg administered twice daily for 14 days
320194|NCT01757756|Drug|placebo|placebo administered twice daily for 14 days
320195|NCT01757756|Drug|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
320196|NCT01757717|Radiation|Ir-192 high dose rate (HDR)|Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
320197|NCT01757704|Procedure|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
320198|NCT01757704|Procedure|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
320199|NCT01757691|Drug|Fingolimod 0.5mg/daily|
320200|NCT01757691|Drug|Placebo|
320201|NCT01757678|Procedure|ICA (Invasive Coronary Angiography)|Per the protocol, patients will have an Invasive Coronary Angiography.
320202|NCT01757678|Procedure|FFR (Fractional Flow Reserve)|Per the protocol, patients will have a Fractional Flow Reserve procedure.
320293|NCT01756950|Biological|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
320204|NCT01757678|Other|FFRct Analysis (Fractional Flow Reserve Computed Tomography)|Per the protocol, patients will have a fractional flow reserve computed tomography.
320205|NCT01757665|Device|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
320206|NCT01757639|Biological|Ipilimumab|Given IV
320207|NCT01757639|Other|Laboratory Biomarker Analysis|Correlative studies
320208|NCT01757626|Biological|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 & 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m^2/day (day -4 to day 0), & at 500 mcg/m^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
320209|NCT01757626|Biological|Hu3F8 With GM-CSF|As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
320210|NCT01757613|Drug|AK 3012|cutaneous use twice a day
320211|NCT01757600|Other|Microperimetry|
320212|NCT01757587|Drug|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
320213|NCT01757587|Drug|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
320214|NCT01757574|Drug|Alemtuzumab infusion|
320215|NCT01757561|Procedure|propofol|use total intravenous anesthesia with propofol
320216|NCT01757561|Procedure|sevoflurane|use inhalation anesthesia with sevoflurane
320217|NCT01757548|Procedure|open operation|high ligation of spermatic vein by open operation
320218|NCT01757548|Procedure|microsurgery|high ligation of spermatic vein by microsurgery
320219|NCT01757535|Drug|300 mg Oral Azacitidine|Maintenance therapy
320220|NCT01757535|Drug|Placebo|
320221|NCT01757509|Other|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.~Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
320222|NCT01757496|Device|Cough Assist|
320223|NCT01757457|Drug|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
320224|NCT01757457|Drug|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
320225|NCT01757444|Device|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
320226|NCT01757444|Device|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
320227|NCT01757431|Drug|Eculizumab|
320228|NCT01757418|Drug|Immune Globulin Intravenous|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
320229|NCT01757418|Other|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
320230|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
320231|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
320232|NCT01757392|Biological|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
320233|NCT01757379|Dietary Supplement|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
320234|NCT01757379|Dietary Supplement|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
320235|NCT01757379|Dietary Supplement|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
320236|NCT01757379|Dietary Supplement|Inulin|15 g of inulin dissolved in 200 ml of water
320237|NCT01757366|Drug|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression~XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
320238|NCT01757366|Drug|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
320239|NCT01757353|Behavioral|BASICS motivational interview|
320240|NCT01757353|Behavioral|BASICS plus normative enhancement motivational interview|
320241|NCT01757353|Behavioral|Self-directed: Information only|
320242|NCT01757340|Behavioral|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
320294|NCT01756950|Biological|Placebo|administered as a single 2-hour intravenous infusion
320243|NCT01757340|Behavioral|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
320244|NCT01757327|Drug|Erismodegib|
320245|NCT01757327|Drug|Placebo|
320246|NCT01757314|Behavioral|ultrasound technique|instruction in the ultrasound technique
320247|NCT01757314|Other|palpation technique|placement of a line via palpation technique
320248|NCT01757301|Other|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
320249|NCT01757301|Other|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
320250|NCT01757288|Drug|NAB-PACLITAXEL|
320251|NCT01757288|Drug|PACLITAXEL|
320252|NCT01757275|Drug|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
320253|NCT01757275|Drug|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
320254|NCT01757275|Drug|Esomeprazole Mg|40 mg tablet once daily for 27 days
320255|NCT01757262|Drug|90 mg Ticagrelor|Morning and Evening dose for 5 days
320256|NCT01757262|Drug|75mg Clopidogrel|Morning dose for 5 days
320257|NCT01757249|Drug|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
320258|NCT01757236|Drug|VANCOMYCIN|
320259|NCT01757236|Drug|CEFTRIAXONE|
320260|NCT01757236|Drug|CLINDAMYCIN|
320261|NCT01757236|Drug|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
320262|NCT01757236|Drug|FLUOROQUINOLONE|
320263|NCT01757236|Drug|LINEZOLID|
320264|NCT01757236|Drug|RIFAMPIN|
320265|NCT01757223|Biological|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
320266|NCT01757223|Biological|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
320267|NCT01757197|Drug|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
320268|NCT01757184|Drug|SBC-102 [sebelipase alfa] (1 mg/kg)|
320269|NCT01757184|Drug|Placebo|
320270|NCT01757171|Drug|Cabazitaxel|20mg IV over 1 hour every 3 weeks
320271|NCT01757158|Radiation|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
320272|NCT01757145|Drug|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.~If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).~If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count >50,000/microliter will be reached again)."
320273|NCT01757132|Device|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
320274|NCT01757119|Drug|Tardyferon 80 mg|Oral administration (2 tablets)
320275|NCT01757106|Drug|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
320276|NCT01757106|Drug|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
320277|NCT01757093|Device|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
320278|NCT01757093|Device|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
320279|NCT01757080|Other|Cardiorespiratory performance assessment with ergospirometry test|
320280|NCT01757080|Other|Biochemical analysis|
320281|NCT01757067|Device|PVC ablation|This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
320282|NCT01757054|Dietary Supplement|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
320283|NCT01757015|Drug|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
320284|NCT01757015|Drug|Placebo to NVA237|Placebo to NVA237
320285|NCT01757002|Behavioral|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
320286|NCT01757002|Behavioral|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
320287|NCT01756989|Drug|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.~Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
320288|NCT01756976|Device|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
320289|NCT01756950|Biological|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
320290|NCT01756950|Biological|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
320291|NCT01756950|Biological|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
320292|NCT01756950|Biological|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
320443|NCT01755767|Drug|Placebo|Matching placebo tablets
320295|NCT01756937|Drug|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
320296|NCT01756937|Drug|Placebo|1 capsule once daily for 24 weeks
320297|NCT01756924|Drug|CEM-102|
320298|NCT01756924|Drug|IV or Oral standard of care antibiotics|
320299|NCT01756924|Drug|Rifampin|
320300|NCT01756911|Device|MFM|Implantation of the MFM
320301|NCT01756898|Drug|ASB17061|Oral administration of ASB17061 taken once daily for 28 consecutive days.
320302|NCT01756898|Drug|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
320303|NCT01756885|Drug|Varenicline|Varenicline was used in accordance with FDA approved labeling: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
320304|NCT01756885|Drug|Placebo|On Day 85, participants randomized to standard therapy will be given placebo pills (resembling the 1.0mg pills),
320305|NCT01756885|Behavioral|Smoking Cessation Counseling|"Behavioral Counseling (from Week 0 - Week 18)~The counseling protocol was based on PHS guidelines for smoking cessation treatment (Fiore et al., 2008), used in our past studies with cancer patients (Schnoll et al., 2010a) and in our ongoing cessation trial at NU (R01 DA025078). Counseling is included given its efficacy at helping smokers quit (Fiore et al., 2008) and to increase study retention. Counseling is provided to both treatment arms through Week 18 to equate for time and attention across arms and since this method was used in varenicline clinical trials (Gonzales et al., 2006) and in our extended therapy trial (Schnoll et al., 2010b). In-person counseling was selected for most sessions to ensure adequate monitoring of participant safety and adherence throughout the trial."
320306|NCT01756872|Procedure|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
320307|NCT01756859|Procedure|MRI Scan|
320308|NCT01756846|Other|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
320309|NCT01756846|Other|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
320310|NCT01756833|Drug|Doxycycline|100 mg po bid
320311|NCT01756833|Drug|Placebo|capsule identical to the doxycycline capsule
320312|NCT01756820|Procedure|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
320313|NCT01756820|Procedure|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
320314|NCT01756807|Device|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
320315|NCT01756794|Procedure|Liver transplantation|
320316|NCT01756781|Drug|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
320317|NCT01756781|Drug|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
320318|NCT01756781|Drug|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.~Treatment A includes a single 2 mg oral dose of midazolam alone."
320319|NCT01756781|Drug|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
320320|NCT01756768|Radiation|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of [14C]-PD-0332991.
320321|NCT01756755|Device|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
320322|NCT01756742|Other|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:~Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
320323|NCT01756742|Other|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
320324|NCT01756729|Device|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
320325|NCT01756716|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
320326|NCT01756716|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
320327|NCT01756716|Drug|Placebo|Placebo for 8 weeks
320328|NCT01756703|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
320329|NCT01756703|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
320330|NCT01756703|Drug|Placebo|Placebo for 8 weeks
320331|NCT01756664|Other|Sunscreen|
320332|NCT01756664|Other|Vaseline|
320333|NCT01756651|Drug|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
320334|NCT01756638|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
320335|NCT01756638|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
320336|NCT01756612|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
320337|NCT01756599|Biological|blood samples|
320338|NCT01756586|Drug|Dexamethasone|
320339|NCT01756586|Drug|Bupivacaine|Control
320340|NCT01756573|Drug|Dexamthsone|
320341|NCT01756573|Drug|Bupivacaine|
320342|NCT01756560|Drug|dexamethsone|
320343|NCT01756560|Drug|Bupivacaine|
320344|NCT01756547|Drug|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
320345|NCT01756547|Drug|Placebo|
320346|NCT01756534|Device|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
320347|NCT01756521|Drug|Moxifloxacin|
320348|NCT01756508|Drug|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
320349|NCT01756495|Drug|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
320350|NCT01756495|Drug|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
320351|NCT01756495|Drug|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
320352|NCT01756495|Drug|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
320353|NCT01756482|Drug|GS-5806|GS-5806, powder for oral solution
320354|NCT01756482|Drug|Placebo|
320355|NCT01756469|Behavioral|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
320356|NCT01756456|Drug|rhNGF 10 μg/ml|rhNGF 10 μg/ml : one drop 6 times a day (one 35 μl drop equals to 0.35 μg of rhNGF)
320357|NCT01756456|Drug|rhNGF 20 μg/ml|one drop 6 times a day (one 35 μl drop equals to 0.70 μg of rhNGF)
320358|NCT01756456|Other|vehicle|ophthalmic solution of the same composition as the test product without rhNGF
320359|NCT01756443|Drug|2% lidocaine/adrenaline and 0.5% bupivacaine|
320360|NCT01756430|Drug|Carvedilol SR 32mg, QD|"Carvedilol SR 32mg QD for 4 weeks~With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
320361|NCT01756430|Drug|Carvedilol SR 64mg, QD|"Carvedilol SR 64mg QD for 4 weeks~With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
320362|NCT01756430|Drug|Carvedilol IR 25mg, QD|"Carvedilol IR 25mg QD for 4 weeks~With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
320363|NCT01756430|Drug|Carvedilol IR 25mg, BID|"Carvedilol IR 25mg BID for 4 weeks~With the others investigation product placebo 2 capsules QD for 4 weeks."
320364|NCT01756417|Drug|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
320365|NCT01756417|Drug|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
320366|NCT01756404|Drug|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
320367|NCT01756404|Drug|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
320368|NCT01756378|Procedure|joint mobilization with movement|
320369|NCT01756378|Procedure|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
320370|NCT01756365|Procedure|surgical transplantation of CECA|
320371|NCT01756352|Drug|18F-FET|Radiotracer, surrogate marker for protein synthesis
320372|NCT01756339|Drug|Solithromycin|
320373|NCT01756339|Drug|Moxifloxacin|
320374|NCT01756339|Other|Placebo to match solithromycin|
320375|NCT01756326|Drug|PREOB® Implantation|
320376|NCT01756326|Procedure|Bone Autograft|
320377|NCT01756313|Procedure|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
320378|NCT01756300|Device|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
320379|NCT01756287|Other|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
320380|NCT01756274|Device|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
320381|NCT01756274|Device|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
320382|NCT01756274|Device|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
320444|NCT01755754|Combination Product|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
320383|NCT01756261|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
320384|NCT01756248|Drug|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
320385|NCT01756196|Drug|Spinal Steroid Injection|Steroid Injection
320386|NCT01756183|Drug|S-1 + Paclitaxel Chemotherapy|"Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.~Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1"
320387|NCT01756170|Drug|paclitaxel|
320388|NCT01756170|Drug|cisplatin|
320389|NCT01756170|Radiation|Radiotherapy|
320390|NCT01756157|Biological|CINRYZE with rHuPH20|
320391|NCT01756144|Device|rhBMP-2|
320392|NCT01756131|Drug|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
320393|NCT01756131|Other|Placebo to match injectable suspension|placebo
320394|NCT01756118|Drug|BEZ235|A minimum of 3 dose levels
320395|NCT01756105|Drug|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
320396|NCT01756105|Drug|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
320397|NCT01756092|Procedure|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
320398|NCT01756079|Drug|boceprevir|
320399|NCT01756079|Biological|PegIFN-2b|
320400|NCT01756079|Drug|RBV|
320401|NCT01756066|Behavioral|Different levels of cost sharing|
320402|NCT01756053|Drug|ABT-089|Selective neuronal nicotinic receptor agonist.
320403|NCT01756053|Drug|Placebo|Matched placebo capsules supplied by study drug supplier.
320404|NCT01756040|Drug|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
320405|NCT01756027|Device|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
320406|NCT01756027|Device|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
320407|NCT01756001|Device|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
320408|NCT01756001|Behavioral|Daily email, text message, or phone call reminders|
320409|NCT01756001|Behavioral|Paid for adherence|
320410|NCT01755988|Other|Educational website (in addition to usual care).|
320411|NCT01755988|Other|Website and interactive platform with telemonitoring.|
320412|NCT01755975|Drug|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
320413|NCT01755975|Drug|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
320414|NCT01755962|Other|Glycemic Load|
320415|NCT01755962|Other|Resistance Training|
320416|NCT01755949|Drug|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
320417|NCT01755949|Drug|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
320418|NCT01755936|Other|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
320419|NCT01755936|Other|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
320420|NCT01755936|Other|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
320421|NCT01755923|Drug|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
320422|NCT01755923|Drug|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
320423|NCT01755910|Other|Left thoracic paravertebral block|
320424|NCT01755910|Other|Right thoracic paravertebral block|
320425|NCT01755897|Procedure|radical hysterectomy + pelvic lymph node dissection|
320426|NCT01755897|Drug|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
320427|NCT01755897|Drug|Cisplatin|75 mg/m(2) IV on day 2 and 3
320428|NCT01755897|Drug|Cisplatin|35 mg/m(2) IV once a week
320429|NCT01755897|Radiation|Pelvic RT|IMRT
320430|NCT01755884|Dietary Supplement|Wheat oral immunotherapy|Cooked spaghetti
320431|NCT01755871|Drug|Fingolimod|0,5mg Fingolimod once a day
320432|NCT01755858|Drug|Bendavia|
320433|NCT01755858|Drug|Placebo|
320434|NCT01755845|Drug|paclitaxel|
320435|NCT01755845|Drug|cisplatin|
320436|NCT01755845|Radiation|radiotherapy|
320437|NCT01755832|Procedure|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
320438|NCT01755819|Device|Biocomposite interference screw|
320439|NCT01755819|Device|Extracortical ACL Tightrope fixation|
320440|NCT01755780|Other|Left interscalene block|
320441|NCT01755780|Other|Right interscalene block|
320442|NCT01755767|Drug|Tivantinib|Tivantinib tablets
320446|NCT01755741|Combination Product|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
320447|NCT01755741|Device|Condom|Male condom
320448|NCT01755728|Drug|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
320449|NCT01755728|Drug|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
320450|NCT01755728|Procedure|Closure of PDA|Open surgery for closure of PDA
320451|NCT01755715|Procedure|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
320452|NCT01755702|Drug|Placebo|Placebo
320453|NCT01755702|Drug|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
320454|NCT01755702|Drug|ibuprofen marketed formulation|ibuprofen marketed formulation
320455|NCT01755702|Drug|Paracetamol marketed formulation|Paracetamol marketed formulation
320456|NCT01755689|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
320457|NCT01755689|Biological|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
320458|NCT01755689|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
320459|NCT01755676|Drug|Orlistat 60 mg|1 tablet 3 times a day
320460|NCT01755676|Other|Placebo|1 tablet 3 times a day
320461|NCT01755663|Drug|Ivabradine and Metoprolol|
320462|NCT01755650|Radiation|18F FPM|
320463|NCT01755637|Drug|Albendazole|Albendazole tablets 400 mg
320464|NCT01755624|Device|NovoTTF-100A device|
320465|NCT01755624|Other|Best Standard of Care|
320466|NCT01755611|Drug|Minocycline 100mg|Test product
320467|NCT01755611|Drug|Minocycline 100mg|Reference product
320468|NCT01755598|Biological|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
320469|NCT01755598|Biological|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
320470|NCT01755572|Drug|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
320471|NCT01755572|Drug|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
320472|NCT01755559|Drug|Artesunate-amodiaquine|antimalarial ACT
320473|NCT01755559|Drug|Dihydroartemisinin-piperaquine|antimalarial ACT
320474|NCT01755559|Drug|Artemether-lumefantrine|antimalarial ACT
320475|NCT01755546|Drug|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
320476|NCT01755533|Other|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
320477|NCT01755533|Other|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
320478|NCT01755520|Drug|Ticagrelor|90mg twice daily dose
320479|NCT01755520|Drug|Aspirin|Aspirin 100mg once daily
320480|NCT01755520|Drug|Placebo - Ticagrelor|Placebo
320481|NCT01755520|Drug|Placebo - Aspirin|Placebo
320482|NCT01755507|Drug|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
320483|NCT01755507|Drug|Placebo|
320484|NCT01755494|Drug|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
320485|NCT01755494|Drug|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
320486|NCT01755494|Drug|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
320487|NCT01755494|Drug|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
320488|NCT01755494|Drug|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
320489|NCT01755481|Other|Probiotic|
320490|NCT01755481|Other|Whey protein concentrate|
320491|NCT01755468|Drug|Intermittent insulin therapy|
320492|NCT01755468|Drug|Continuous metformin|
320493|NCT01755455|Drug|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
320494|NCT01755455|Drug|Placebo|Matching placebo capsule
320495|NCT01755442|Other|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
320496|NCT01755442|Drug|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
320497|NCT01755416|Drug|Closed loop with sensor and Insulin|Subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
320498|NCT01755416|Drug|Closed loop with sensor, Insulin and Liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take a single injection of 1.2 mg of Liraglutide subcutaneously before dinner on Day 1.
320499|NCT01755403|Drug|Benznidazole|
320500|NCT01755390|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
320501|NCT01755377|Drug|Benznidazole|
320502|NCT01755364|Biological|AdimFlu-V|
320503|NCT01755338|Drug|Methylprednisolone|Methylprednisolone 15mg/kg
320504|NCT01755338|Drug|Placebo|Placebo
320505|NCT01755325|Drug|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.~imatinib,0.4g,qd"
320506|NCT01755325|Drug|placebo|
320507|NCT01755312|Device|Medication reminder|Medication reminder
320508|NCT01755299|Other|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
320509|NCT01755299|Other|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
320510|NCT01755299|Other|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
320511|NCT01755299|Other|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
320512|NCT01755286|Drug|OTO-201|Single intra-operative injection
320513|NCT01755286|Drug|Placebo|Single intratympanic injection
320514|NCT01755286|Drug|Sham|Simulated single intratympanic injection
320515|NCT01755273|Procedure|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
320516|NCT01755260|Other|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
320517|NCT01755247|Drug|Topical Gel Vehicle|
320518|NCT01755247|Drug|8% NVN1000 Topical Gel|
320519|NCT01755247|Drug|8% NVN1000 Topical Gel and moisturizer|
320520|NCT01755234|Drug|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
320521|NCT01755234|Drug|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
320522|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|All subjects will have a pH probe placed at their initial clinic visit and will have the probe removed 24 hours later. They will start on PPI medication (as per the standard of care) after probe removal. Subjects will have a follow up clinic visit 8-12 weeks after the initial visit. At the follow up visit, all subjects will have the option of a second probe placement to assess the effects of PPI therapy on reflux events.
320523|NCT01755208|Procedure|light-scattering spectroscopy|Undergo light-scattering spectroscopy
320524|NCT01755195|Drug|Cabozantinib|Cabozantinib inhibits multiple RTKs implicated in tumor growth, metastasis, and angiogenesis, and targets primarily MET and VEGFR2.
320525|NCT01755182|Drug|approved pharmacologic therapy|
320526|NCT01755182|Procedure|TAE|after randomization, and after 3 months
320527|NCT01755169|Drug|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
320528|NCT01755169|Drug|Placebo|
320529|NCT01755156|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
320530|NCT01755156|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
320531|NCT01755156|Drug|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
320532|NCT01755156|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
320533|NCT01755156|Drug|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
320534|NCT01755156|Drug|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
320535|NCT01755143|Other|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
320536|NCT01755143|Device|Pacemaker System|
320537|NCT01755130|Procedure|LOUIS-3D Imaging Procedure|LOUIS-3D imaging procedure either on the same day or within 10 days of a regular scheduled visit for a mammogram, ultrasound, magnetic resonance imaging (MRI) scan, or any other breast imaging procedure, between 1 and 7 days before scheduled biopsy. Results of the LOUIS-3D imaging scans compared with results of other imaging scan(s). Entire LOUIS-3D procedure should take about 30 minutes to complete.
320538|NCT01755117|Other|Sciatic, femoral, obturator nerve blocks|
320539|NCT01755117|Other|Sciatic nerve block, posterior lumbar plexus block|
320540|NCT01755104|Dietary Supplement|Stablor|
320541|NCT01755104|Dietary Supplement|Placebo|
320542|NCT01755091|Drug|Dronabinol|
320543|NCT01755091|Drug|Placebo (for Dronabinol)|
320544|NCT01755078|Drug|Sevelamer HCl|Non-metal phosphate binder
320545|NCT01755078|Drug|Calcium-based phosphate binder|
320546|NCT01755026|Drug|cefazolin|2 gram dose for pre-operative prophylaxis
320547|NCT01755026|Drug|cefazolin|4 gram dose for pre-operative prophylaxis
320548|NCT01755013|Procedure|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
320549|NCT01755000|Procedure|USCOM scan|
320550|NCT01755000|Procedure|Fluid Bolus|
320551|NCT01754987|Drug|Ascorbic Acid + Sorafenib|
320552|NCT01754987|Drug|Sorafenib|
320553|NCT01754974|Biological|Peginterferon Lambda-1a|
320554|NCT01754974|Drug|Ribavirin|
320555|NCT01754974|Biological|Peginterferon alfa-2a|
320556|NCT01754961|Drug|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
320557|NCT01754961|Drug|Placebo|Placebo given orally on Day 1
320558|NCT01754935|Drug|VX-509|50 mg oral tablet
320559|NCT01754935|Drug|VX-509 matching placebo|0 mg oral tablet
320560|NCT01754909|Drug|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
320561|NCT01754909|Drug|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
320562|NCT01754896|Other|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
320611|NCT01754597|Drug|Peptide Natriurétique de type B|Peptide Natriurétique de type B
320563|NCT01754896|Other|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
320564|NCT01754896|Other|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
320565|NCT01754896|Other|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
320566|NCT01754883|Drug|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
320567|NCT01754870|Drug|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
320568|NCT01754857|Drug|Bendamustine|Given IV
320569|NCT01754857|Drug|Rituximab|Given IV
320570|NCT01754857|Drug|Lenalidomide|Given PO
320571|NCT01754844|Drug|AZD7624|Single dose inhaled IMP via a nebulizer
320572|NCT01754844|Drug|Placebo to match|Single dose inhaled Placebo via a nebulizer
320573|NCT01754831|Device|Fluoride varnish|Topical application of fluoride varnish on present teeth
320574|NCT01754818|Drug|Bendavia 10mg|
320575|NCT01754818|Drug|Bendavia 50mg|
320576|NCT01754818|Drug|Bendavia 100mg|
320577|NCT01754818|Drug|Placebo|
320578|NCT01754805|Drug|peficitinib|oral
320579|NCT01754805|Drug|methotrexate|oral
320580|NCT01754792|Dietary Supplement|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
320581|NCT01754779|Drug|Placebo|Matching placebo for both aims.
320582|NCT01754779|Dietary Supplement|Citric Acid|
320583|NCT01754779|Dietary Supplement|Potassium Citrate|
320584|NCT01754779|Drug|Indapamide|Aim 2
320585|NCT01754766|Drug|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
320586|NCT01754766|Other|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
320587|NCT01754753|Other|Telephone Friendship groups|
320588|NCT01754740|Drug|Uréia|"The subjects were randomly divided into two groups:~1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
320589|NCT01754740|Drug|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
320590|NCT01754714|Drug|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
320591|NCT01754714|Drug|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
320592|NCT01754714|Drug|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
320593|NCT01754701|Dietary Supplement|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
320594|NCT01754701|Dietary Supplement|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
320595|NCT01754675|Behavioral|Soccer|Watching the soccer match at the time that the favorite team is playing
320596|NCT01754675|Behavioral|Movie|Watching a movie at the time that the favorite team is playing
320597|NCT01754662|Dietary Supplement|Soy protein|2 bars daily for 8 weeks.
320598|NCT01754662|Dietary Supplement|Isoflavones|2 bars daily for 8 weeks.
320599|NCT01754662|Dietary Supplement|Cocoa|2 bars daily for 8 weeks.
320600|NCT01754662|Dietary Supplement|Placebo|
320601|NCT01754649|Drug|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
320602|NCT01754636|Other|No intervention|
320603|NCT01754623|Drug|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
320604|NCT01754623|Drug|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
320605|NCT01754623|Drug|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
320606|NCT01754623|Radiation|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
320607|NCT01754623|Other|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
320608|NCT01754623|Procedure|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
320609|NCT01754623|Drug|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
320610|NCT01754610|Behavioral|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.~Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
320612|NCT01754571|Behavioral|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
320613|NCT01754558|Procedure|Ajust system|The use of Ajust system for stress incontinence
320614|NCT01754558|Procedure|TVT/TVT-O|sling surgery
320615|NCT01754545|Drug|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
320616|NCT01754545|Drug|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
320617|NCT01754532|Biological|Hair Sample|Analysis of hair cortisol levels
320618|NCT01754519|Procedure|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
320619|NCT01754519|Radiation|Radiation Therapy|Undergo SFRT
320620|NCT01754519|Other|Laboratory Biomarker Analysis|Correlative studies
320621|NCT01754519|Other|Quality-of-Life Assessment|Ancillary studies
320622|NCT01754506|Dietary Supplement|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
320623|NCT01754493|Drug|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
320624|NCT01754480|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
320625|NCT01754480|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
320626|NCT01754467|Behavioral|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
320627|NCT01754454|Biological|Human Umbilical Cord Derived MSC|1×10^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
320628|NCT01754415|Device|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
320629|NCT01754402|Drug|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
320630|NCT01754402|Drug|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
320631|NCT01754402|Drug|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
320632|NCT01754389|Drug|Tacrolimus|
320633|NCT01754389|Drug|Methotrexate|
320634|NCT01754389|Drug|Bortezomib|
320635|NCT01754389|Drug|Sirolimus|
320636|NCT01754376|Drug|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
320637|NCT01754376|Drug|Vemurafenib|Tablets given twice daily.
320638|NCT01754363|Device|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
320639|NCT01754350|Dietary Supplement|calorie-restricted ketogenic diet and transient fasting|"On day 1-3 and day 7-9, restriction of carbohydrates to < 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin."
320640|NCT01754350|Dietary Supplement|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
320641|NCT01754337|Other|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
320642|NCT01754324|Drug|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
320643|NCT01754298|Procedure|Retro-articular drilling|"Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.~Use a 0.045 K-wire for drilling.~Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
320644|NCT01754298|Procedure|Trans-articular drilling|"Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)~Use a 0.045 K-wire for drilling~A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
320645|NCT01754285|Drug|LF-PB and Placebo|
320646|NCT01754285|Drug|Placebo|
320647|NCT01754285|Drug|LF-PB|
320648|NCT01754259|Drug|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
320649|NCT01754259|Drug|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
320695|NCT01753843|Procedure|early cord clamping|early ( <20 seconds)
320650|NCT01754246|Device|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
320651|NCT01754233|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
320652|NCT01754220|Drug|Montelukast|Montelukast is a leukotriene receptor antagonist
320653|NCT01754207|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
320654|NCT01754207|Device|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
320655|NCT01754194|Procedure|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
320656|NCT01754194|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
320657|NCT01754181|Drug|Insulin|the intervention is applied only at the dose of insulin
320658|NCT01754155|Radiation|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
320659|NCT01754116|Drug|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
320660|NCT01754116|Drug|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
320661|NCT01754116|Drug|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
320662|NCT01754116|Drug|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
320663|NCT01754116|Drug|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
320664|NCT01754103|Other|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
320665|NCT01754090|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
320666|NCT01754090|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
320667|NCT01754090|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
320668|NCT01754077|Behavioral|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
320669|NCT01754077|Behavioral|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
320670|NCT01754077|Behavioral|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
320671|NCT01754064|Device|Cardiac Rhythm Management device|
320672|NCT01754051|Device|PC 400 coils|
320673|NCT01754012|Dietary Supplement|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
320674|NCT01753999|Device|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
320675|NCT01753999|Device|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
320676|NCT01753986|Behavioral|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
320677|NCT01753986|Behavioral|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
320678|NCT01753947|Other|Deliberate Practice|
320679|NCT01753921|Other|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
320680|NCT01753921|Other|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
320681|NCT01753921|Device|MRI|MRI study of the brain will be performed at t=3months.
320682|NCT01753908|Drug|Broccoli Sprout Extract|Given PO
320683|NCT01753908|Other|Laboratory Biomarker Analysis|Correlative studies
320684|NCT01753908|Other|Pharmacological Study|Urinary ITCs and metabolites measured
320685|NCT01753908|Other|Placebo|Given PO
320686|NCT01753882|Drug|Lexapro|Agent + training vs Placebo + training
320687|NCT01753882|Drug|Placebo|Agent + training vs Placebo + training
320688|NCT01753869|Procedure|Airways clearance and Hypertonic saline inhalation|
320689|NCT01753856|Drug|Teriparatide|Administered SC
320690|NCT01753856|Drug|Denosumab|Administered SC
320691|NCT01753856|Drug|Demeclocycline|Administered orally
320692|NCT01753856|Drug|Tetracycline|Administered orally
320693|NCT01753856|Drug|Calcium Supplement|Administered orally
320694|NCT01753856|Drug|Vitamin D|Administered orally
320696|NCT01753843|Procedure|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
320697|NCT01753830|Device|Durolane|
320698|NCT01753830|Device|PBS|
320699|NCT01753804|Other|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
320700|NCT01753791|Drug|80 mg PF-06473871|80 mg of PF-06473871 or placebo
320701|NCT01753791|Drug|160 mg PF-06473871|160 mg of PF-06473871 or placebo
320702|NCT01753791|Drug|320 mg PF-06473871|320 mg of PF-06473871 or placebo
320703|NCT01753791|Drug|480 mg PF-06473871|480 mg of PF-06473871 or placebo
320704|NCT01753778|Device|Cryo-Touch III Device|Treatment with Cryo-Touch III
320705|NCT01753765|Device|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
320706|NCT01753752|Drug|Chitosan- N- Acetylcysteine eye drops|
320707|NCT01753752|Drug|Placebo|
320708|NCT01753739|Drug|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
320709|NCT01753739|Drug|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
320710|NCT01753726|Other|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
320711|NCT01753726|Other|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
320712|NCT01753713|Drug|dovitinib|Given PO
320713|NCT01753713|Other|laboratory biomarker analysis|Correlative studies
320714|NCT01753700|Dietary Supplement|UHT treated milk|
320715|NCT01753687|Other|Ocular scattering of the tear film|
320716|NCT01753687|Other|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
320717|NCT01753687|Other|Measurement of tear film osmolarity|
320718|NCT01753674|Dietary Supplement|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
320719|NCT01753674|Dietary Supplement|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
320720|NCT01753661|Behavioral|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
320721|NCT01753661|Behavioral|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
320722|NCT01753661|Behavioral|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
320723|NCT01753648|Device|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
320724|NCT01753648|Other|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
320725|NCT01753648|Other|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
320726|NCT01753635|Device|supraglottic airway placement and use|
320727|NCT01753622|Behavioral|Exercise group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
320728|NCT01753609|Device|Tulip capsule|swallowing Tulip capsule for up to 29 days
320729|NCT01753596|Device|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
320730|NCT01753596|Other|Physiological Sodium Chloride solution (0,9%)|Placebo
320731|NCT01753583|Device|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
320732|NCT01753583|Other|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
320733|NCT01753570|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
320734|NCT01753570|Drug|RBV(24 weeks)|RBV: 600 - 1000mg/day based on body weight for 24 weeks
320735|NCT01753570|Drug|IFN beta(24 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 24 weeks
320736|NCT01753570|Drug|RBV(48 weeks)|RBV: 600 - 1000mg/day based on body weight for 48 weeks
320737|NCT01753570|Drug|IFN beta(48 weeks)|IFN beta: 600 MIU/day,6 days/week for initial 4 weeks following to 3 days/week for 48 weeks
320738|NCT01753557|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
320739|NCT01753557|Drug|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
320740|NCT01753557|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
320741|NCT01753531|Device|Flu Symptoms|
320742|NCT01753518|Device|Subcuticular suture|subcuticular Monocryl suture closure
320743|NCT01753518|Device|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
320744|NCT01753505|Other|64-slice Multidetector coronary CT angiography|
320745|NCT01753492|Device|Ologen|
320746|NCT01753479|Other|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
320747|NCT01753466|Dietary Supplement|Hydration|
320748|NCT01753453|Drug|Plerixafor|240mcg/kg, solution, subcutaneous injection
321691|NCT01746173|Procedure|Stem Cell Collection|
320749|NCT01753453|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
320750|NCT01753440|Procedure|Intramyocardial implantation of of a novel mesenchymal precursor cell type (iMP).|Intramyocardial implantation of a novel mesenchymal precursor cell type (iMP).
320751|NCT01753414|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
320752|NCT01753414|Procedure|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
320753|NCT01753401|Drug|Acthar|Acthar given SC (40 U daily or 80 U every other day) for Weeks 1-4 and tapered for Weeks 5-8
320754|NCT01753401|Drug|Placebo for Acthar|Placebo contains the same inactive ingredients as H.P. Acthar Gel with the API. Placebo is given SC for 6 months in equal volume as the Acthar comparator.
320755|NCT01753388|Device|Liberty Stent|
320756|NCT01753375|Dietary Supplement|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
320757|NCT01753375|Dietary Supplement|Placebo|Placebo to be given orally on weekly basis
320758|NCT01753362|Drug|liraglutide|
320759|NCT01753362|Drug|placebo|
320760|NCT01753349|Biological|Botulinum toxin type A|Investigators were free to prescribe any BoNT A preparation, including Dysport, Botox and Xeomin.
320761|NCT01753336|Biological|Botulinum toxin type A|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
320762|NCT01753323|Drug|KAF156|KAF156 was supplied as tablets for oral use.
320763|NCT01753310|Biological|Botulinum toxin type A|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
320764|NCT01753310|Drug|Placebo|Up to 2mL
320765|NCT01753297|Drug|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
320766|NCT01753271|Other|thoracic mobilization & shoulder mobilization & exercise|
320767|NCT01753271|Other|shoulder mobilization & exercise|
320768|NCT01753232|Device|DALI-adsorber|Recording of treatment data. No extra interventional treatment
320769|NCT01753232|Device|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
320770|NCT01753219|Procedure|Onstep|
320771|NCT01753219|Procedure|Lichtenstein|
320772|NCT01753193|Biological|Anifrolumab|Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
320773|NCT01753180|Biological|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
320774|NCT01753180|Drug|saline|Local intra-coronary administration of saline at or into the CTO
320775|NCT01753167|Drug|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
320776|NCT01753167|Drug|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
320777|NCT01753167|Drug|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
320778|NCT01753154|Drug|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
320779|NCT01753154|Drug|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
320780|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation|
320781|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
320782|NCT01753128|Drug|imipramine|
320783|NCT01753115|Biological|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
320784|NCT01753115|Drug|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
320785|NCT01753102|Drug|Estradiol|one tablet will be inserted daily for 14 days
320786|NCT01753089|Biological|WDVAX|
320787|NCT01753076|Drug|Ozanezumab|Ozanezumab injection solution
320788|NCT01753076|Drug|Placebo|Normal saline (0.9% sodium chloride) infusion
320789|NCT01753063|Behavioral|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
320790|NCT01753063|Behavioral|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
320791|NCT01753050|Device|Stroke volume monitoring|Pulse contour stroke volume monitoring
320792|NCT01753037|Dietary Supplement|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
320793|NCT01753037|Other|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
320794|NCT01753024|Dietary Supplement|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
320795|NCT01752998|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|
320796|NCT01752998|Behavioral|Health Education|
320797|NCT01752985|Drug|BMS-813160|
320798|NCT01752985|Drug|Placebo matching with BMS-813160|
320799|NCT01752972|Dietary Supplement|Spirulina|10 g/day orally for 12 weeks
320800|NCT01752959|Drug|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
320801|NCT01752959|Drug|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
320802|NCT01752933|Drug|SGI-110|SGI-110 will be administered by subcutaneously (SC) on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
320874|NCT01752270|Drug|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
320803|NCT01752920|Drug|Derazantinib|Subjects in this study will receive derazantinib orally at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg every other day (QOD) and will escalate until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
320804|NCT01752907|Other|General Education DVD|A general chemotherapy side effects education DVD
320805|NCT01752907|Other|Bone Pain Education DVD|
320806|NCT01752894|Device|Angio-guided PCI with EES or BES|Angio-guided intervention
320807|NCT01752894|Device|OCT-guided PCI with EES or BES|OCT-guided intervention
320808|NCT01752894|Device|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
320809|NCT01752894|Device|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
320810|NCT01752894|Drug|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (>6%) at 3months OCT follow up after stent implantation.
320811|NCT01752894|Drug|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
320812|NCT01752881|Biological|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013~Dosage: 0.5mL/per syringe~Administration route: Intramuscular Injection, once"
320813|NCT01752881|Biological|AdimFlu-S|
320814|NCT01752868|Dietary Supplement|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
320815|NCT01752855|Biological|New formulation adalimumab|New formulation adalimumab 40 mg every other week
320816|NCT01752842|Drug|Fenofibrate|
320817|NCT01752842|Drug|Placebo for fenofibrate|
320818|NCT01752816|Behavioral|exercise training|
320819|NCT01752803|Dietary Supplement|Probiotic|mix probiotic
320820|NCT01752803|Dietary Supplement|Placebo|placebo
320821|NCT01752790|Drug|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
320822|NCT01752790|Drug|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
320823|NCT01752777|Behavioral|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
320824|NCT01752777|Behavioral|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
320825|NCT01752764|Other|Test product: Salad with a high dosage fat|
320826|NCT01752764|Other|Control product: Salad with low dosage fat|
320827|NCT01752725|Device|BiCision®|
320828|NCT01752725|Device|Ultracision® Har-monic Scalpel(Ethicon)|
320829|NCT01752712|Drug|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
320830|NCT01752712|Drug|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
320831|NCT01752699|Drug|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
320832|NCT01752699|Drug|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
320833|NCT01752686|Drug|carboplatin|carboplatin as adjuvant chemotherapy
320834|NCT01752673|Other|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
320835|NCT01752673|Other|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
320836|NCT01752660|Behavioral|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
320837|NCT01752660|Behavioral|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
320838|NCT01752647|Procedure|Low dose computed tomography|Low dose computed tomography scan
320839|NCT01752634|Drug|Secukinumab (AIN457)|Secukinumab (AIN457)
320840|NCT01752634|Drug|Placebo|Placebo PFS for s.c. administration.
320841|NCT01752608|Behavioral|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
320875|NCT01752270|Drug|Diane-35 pretreatment|
320876|NCT01752257|Drug|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
320877|NCT01752244|Dietary Supplement|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
320878|NCT01752244|Dietary Supplement|Alfacalcidol|Alfacalcidol
320879|NCT01752218|Device|arcuate incision|
320880|NCT01752205|Drug|Paclitaxel|45mg/m2/w,total 6 weeks
320842|NCT01752595|Behavioral|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
320843|NCT01752595|Other|Preference Based Music Intervention|
320844|NCT01752582|Device|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
320845|NCT01752582|Device|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
320846|NCT01752569|Drug|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.~For phase I there were 4 potential dosing levels:~Level -1 - 50mg once daily (od) (50mg daily total)~Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)~Level 2 - 75mg bd (150mg daily total)~Level 3 - 100mg bd (200mg daily total)~Phase I has been completed and identified 75mg bd as the recommended phase II dose.~Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
320847|NCT01752556|Procedure|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
320848|NCT01752556|Procedure|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
320849|NCT01752543|Drug|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
320850|NCT01752543|Drug|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
320851|NCT01752530|Other|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
320852|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
320853|NCT01752517|Drug|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
320854|NCT01752504|Behavioral|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
320855|NCT01752491|Drug|Ascorbate|Intravenous infusion of high-dose ascorbate
320856|NCT01752491|Drug|Temozolomide|Oral chemotherapeutic
320857|NCT01752491|Radiation|Radiation therapy|External beam radiation therapy
320858|NCT01752465|Behavioral|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
320859|NCT01752465|Behavioral|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
320860|NCT01752439|Device|Anodal transcranial direct current stimulation|
320861|NCT01752439|Device|Sham transcranial direct current stimulation|
320862|NCT01752426|Other|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
320863|NCT01752426|Drug|PCI-32765|420 mg orally once daily.
320864|NCT01752413|Dietary Supplement|Ferrous gluconate 325mg|Participants with low ferritin (<30 micrograms/L (males) or <20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
320865|NCT01752413|Behavioral|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
320866|NCT01752400|Drug|AUY922|
320867|NCT01752361|Device|Motilis-3D transit|
320868|NCT01752348|Other|Endotoxin, US standard reference E.coli|
320869|NCT01752335|Other|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
320870|NCT01752322|Drug|Lidocaine 5% medicated plaster|
320871|NCT01752322|Drug|Placebo plaster|
320872|NCT01752283|Procedure|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
320873|NCT01752283|Procedure|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
321692|NCT01746173|Drug|Palifermin|
320883|NCT01752192|Device|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
320884|NCT01752179|Procedure|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.~Taping method include :~stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.~puts the base of tape over the contralateral of sacrum with no tension.~attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.~attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.~This is an origin to insertion application."
320885|NCT01752153|Drug|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
320886|NCT01752153|Drug|Silymarin (Legalon)|
320887|NCT01752140|Procedure|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
320888|NCT01752140|Procedure|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
320889|NCT01752127|Procedure|percutaneous coronary intervention using drug eluting stent|"1. Intracoronary stenting~The procedure could be conducted via brachial, radial or femoral approaches.~There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.~When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.~Direct stenting or bifurcation stenting is allowed.~Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
320890|NCT01752075|Drug|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
320891|NCT01752049|Drug|Topical timolol maleate|"Topical timolol maleate 0.5% drops~Applied twice daily for 12 weeks (84 days) or until disappearance of lesions~Study drops will be applied to 4 cutaneous telangiectasias per patient (timolol drops for 3 telangiectasia per patient and placebo drops to 1 telangiectasia per patient)."
320892|NCT01752049|Drug|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient.
320893|NCT01752036|Radiation|Stereotactic Radiotherapy (SRS)|600 cGy x 5 fractions
320894|NCT01752023|Drug|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
320895|NCT01752023|Drug|Cisplatin + Gemcitabine|Active Comparator
320896|NCT01752010|Other|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
320897|NCT01752010|Device|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
320898|NCT01752010|Device|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
320934|NCT01751750|Other|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
321693|NCT01746173|Drug|Gemcitabine|
320899|NCT01751997|Drug|Transplants from 8/8-matched Unrelated donors|"Myeloablative conditioning~Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)~Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)~Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~Reduced-intensity conditioning; older patients (age > 55 years) and/or patients with comorbidities~Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m^2)~Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)~Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)~ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)~GVHD prophylaxis~Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
320900|NCT01751997|Drug|Transplants from family-mismatched/haploidentical donors|"Reduced-intensity conditioning~Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)~Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m^2)~Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)~ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)~GVHD prophylaxis~Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)~Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
320901|NCT01751984|Drug|ETC-1002|Weeks 1-2, 60 mg/day; Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
320902|NCT01751984|Drug|Placebo|Placebo once daily for 8 weeks
320903|NCT01751971|Drug|Inspired oxygen (40%)|Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
320904|NCT01751971|Other|Sham|Medical air with 21% oxygen via venturi mask (15 L/min).
320905|NCT01751958|Radiation|Epidural steroid injection|Epidural steroid injection
320906|NCT01751945|Behavioral|EmONC package|"The EmONC package consists of:~Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.~Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.~Community mobilisation"
320907|NCT01751932|Device|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
320908|NCT01751919|Drug|Imatinib mesylate tablet 400 mg, 1 Tablet|
320909|NCT01751919|Drug|Glivec film-coated tablet 100 mg, 4 Tablets|
320910|NCT01751906|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm~Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.~The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.~Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
320911|NCT01751906|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).~Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm~Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition~For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices~To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
320912|NCT01751893|Drug|Henna|natural henna in the form of paste
320913|NCT01751893|Drug|Placebo|placebo
320914|NCT01751880|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
320915|NCT01751867|Drug|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
320916|NCT01751867|Drug|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
320917|NCT01751854|Drug|SSRI|SSRI alone or with training
320918|NCT01751854|Drug|Placebo|Placebo alone or with training
320919|NCT01751828|Drug|Sertraline|
320920|NCT01751815|Procedure|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
320921|NCT01751815|Procedure|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
320922|NCT01751802|Drug|Ecopipam|Antagonist of the dopamine D1 receptor
320923|NCT01751802|Drug|Placebo|Placebo for Ecopipam
320924|NCT01751789|Behavioral|Linkage|
320925|NCT01751789|Other|Treatment as Usual|
320926|NCT01751776|Drug|BI 655064 medium dose|Medium dose
320927|NCT01751776|Drug|BI 655064 high dose|High dose
320928|NCT01751776|Drug|BI 655064 high dose|High dose
320929|NCT01751776|Drug|Placebo|Placebo
320930|NCT01751776|Drug|BI 655064 low dose|Low dose
320931|NCT01751776|Drug|Placebo|Placebo
320932|NCT01751776|Drug|BI 655064 medium dose|Medium dose
320933|NCT01751763|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
321066|NCT01750814|Biological|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
321694|NCT01746173|Drug|Busulfan|
321695|NCT01746173|Drug|Melphalan|
320935|NCT01751737|Procedure|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
320936|NCT01751724|Drug|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
320937|NCT01751724|Other|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).~Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.~After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.~Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
320938|NCT01751698|Behavioral|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
320939|NCT01751698|Behavioral|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
320940|NCT01751685|Behavioral|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
320941|NCT01751685|Other|Control|monthly educational lectures on various topics
320942|NCT01751672|Behavioral|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
320943|NCT01751672|Behavioral|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
320944|NCT01751646|Dietary Supplement|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
320945|NCT01751646|Dietary Supplement|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
320946|NCT01751633|Procedure|Surgical|
320947|NCT01751633|Procedure|Conservative treatment|
320948|NCT01751620|Behavioral|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
320949|NCT01751620|Behavioral|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
320950|NCT01751594|Behavioral|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
320951|NCT01751594|Behavioral|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
320952|NCT01751581|Behavioral|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
320953|NCT01751581|Behavioral|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
320954|NCT01751568|Drug|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) twice daily.
320955|NCT01751555|Drug|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
320956|NCT01751542|Behavioral|Mindfulness + Residential Treatment|
320957|NCT01751542|Behavioral|Residential treatment alone|
320958|NCT01751529|Procedure|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
321696|NCT01746173|Procedure|Stem Cell Transplant|
320959|NCT01751529|Drug|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
320960|NCT01751503|Procedure|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
320961|NCT01751503|Procedure|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
320962|NCT01751490|Other|physiotherapy|physiotherapy
320963|NCT01751490|Procedure|shoulder stabilisation surgery|arthroscopic stabilisation surgery
320964|NCT01751464|Behavioral|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
320965|NCT01751451|Drug|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
320966|NCT01751451|Drug|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
320967|NCT01751451|Drug|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
320968|NCT01751438|Other|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
320969|NCT01751438|Other|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
320970|NCT01751438|Behavioral|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
320971|NCT01751438|Other|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
320972|NCT01751425|Drug|Dasatinib|Given PO
320973|NCT01751425|Drug|Imatinib Mesylate|Given PO
320974|NCT01751425|Drug|Nilotinib|Given PO
320975|NCT01751425|Drug|Ruxolitinib|Given PO
320976|NCT01751412|Radiation|Proton Radiation|
320977|NCT01751399|Drug|LY2605541|
320978|NCT01751386|Drug|Baclofen|
320979|NCT01751386|Other|Placebo|
320980|NCT01751373|Behavioral|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
320981|NCT01751373|Behavioral|Standard Therapy|
320982|NCT01751360|Drug|SYR-472|
320983|NCT01751347|Drug|Bupivacaine|Local anesthetics
320984|NCT01751347|Drug|Lidocaine|Local anesthetics
320985|NCT01751334|Device|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
320986|NCT01751334|Device|total knee arthroplasty|Fixed Total Knee Arthroplasty
320987|NCT01751321|Drug|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
320988|NCT01751308|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
320989|NCT01751295|Drug|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
320990|NCT01751282|Genetic|Stem Cell|
320991|NCT01751269|Drug|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
320992|NCT01751269|Drug|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
320993|NCT01751256|Device|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
320994|NCT01751243|Other|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
320995|NCT01751243|Other|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
321063|NCT01750840|Device|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
321064|NCT01750827|Drug|SB659032|single dose
321065|NCT01750814|Biological|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
320996|NCT01751230|Behavioral|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
320997|NCT01751217|Behavioral|Functional Family Tx|
320998|NCT01751217|Behavioral|Services as Usual|
320999|NCT01751204|Dietary Supplement|Calcium tablet|
321000|NCT01751204|Dietary Supplement|Calcium ion water (250mg)|
321001|NCT01751204|Dietary Supplement|Calcium ion water (125mg)|
321002|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
321003|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
321004|NCT01751165|Biological|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
321005|NCT01751152|Drug|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
321006|NCT01751152|Drug|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
321007|NCT01751139|Procedure|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
321008|NCT01751139|Other|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
321009|NCT01751126|Drug|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
321010|NCT01751126|Drug|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
321011|NCT01751113|Drug|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
321012|NCT01751113|Drug|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
321013|NCT01751113|Drug|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
321014|NCT01751100|Behavioral|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
321015|NCT01751100|Behavioral|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
321016|NCT01751087|Other|Mifepristone|oral mifepristone 200 mg on Day 1.
321017|NCT01751087|Drug|misoprostol|buccal misoprostol 400 mcg on Day 2
321018|NCT01751087|Device|Osmotic dilators|osmotic dilators on Day 1
321019|NCT01751087|Other|placebo|placebo for mifepristone, on day 1
321020|NCT01751087|Other|placebo|placebo for misoprostol, on day 2
321021|NCT01751074|Drug|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
321022|NCT01751074|Drug|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
321023|NCT01751061|Behavioral|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
321024|NCT01751061|Other|Usual care|usual ICU care
321025|NCT01751048|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
321026|NCT01751048|Biological|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
321027|NCT01751048|Biological|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
321028|NCT01751048|Drug|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
321029|NCT01751035|Behavioral|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
321030|NCT01751035|Behavioral|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
321031|NCT01751022|Device|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
321032|NCT01751009|Dietary Supplement|Vitamin A supplements|Sprinkles with Vitamin A
321033|NCT01751009|Dietary Supplement|Sprinkles without Vitamin A|Active comparator
321034|NCT01750996|Behavioral|Strongest Families|Behavioural intervention
321035|NCT01750983|Drug|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.~Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
321036|NCT01750983|Drug|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.~Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
321037|NCT01750970|Other|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
321038|NCT01750957|Drug|Placebo|orally daily, 12 weeks
321039|NCT01750957|Drug|RO4917523|Dose A orally daily, 12 weeks
321040|NCT01750957|Drug|RO4917523|Dose B orally daily, 12 weeks
321041|NCT01750944|Procedure|Ankle first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).~A 15 minute walking test (WT) is performed.~BBP-LR and BPA-LR are re-measured.~2 hours of rest.~BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.~WT is reperformed.~BBP-LR and BPT-LR are re-measured."
321042|NCT01750944|Procedure|Toe first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).~A 15 minute walking test (WT) is performed.~BBP-LR and BPT-LR are re-measured.~2 hours of rest.~BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.~WT is reperformed.~BBP-LR and BPA-LR are re-measured."
321043|NCT01750931|Drug|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH &amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
321044|NCT01750931|Drug|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
321045|NCT01750918|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
321046|NCT01750918|Drug|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
321047|NCT01750918|Drug|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
321048|NCT01750918|Drug|5-fluorouracil|5-fluorouracil-based chemotherapy
321049|NCT01750905|Drug|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
321050|NCT01750905|Drug|Placebo|Vehicle (D5W) SQ
321051|NCT01750892|Behavioral|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
321052|NCT01750892|Behavioral|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
321053|NCT01750892|Other|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
321054|NCT01750879|Drug|Peanut Flour|Peanut Flour
321055|NCT01750879|Drug|Oat Flour|Oat Flour
321056|NCT01750866|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
321057|NCT01750866|Drug|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
321058|NCT01750866|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
321059|NCT01750853|Drug|LY3045697|Administered orally
321060|NCT01750853|Drug|Placebo|Administered orally
321061|NCT01750840|Device|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
321062|NCT01750840|Device|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
321067|NCT01750801|Drug|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
321068|NCT01750801|Drug|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
321069|NCT01750788|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
321070|NCT01750775|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
321071|NCT01750775|Drug|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
321072|NCT01750762|Drug|Lenalidomide|
321073|NCT01750749|Biological|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
321074|NCT01750736|Other|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
321075|NCT01750736|Other|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
321076|NCT01750723|Drug|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
321077|NCT01750697|Drug|Rituximab|Participants will receive rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
321078|NCT01750684|Drug|AC105|
321079|NCT01750684|Other|Placebo|
321080|NCT01750645|Drug|Intradetrusor Injection of Type-A Botulinum Toxin|
321081|NCT01750645|Other|Other interventions analyzed according to protocol|"Placebo~Different dosage of Type-A Botulinum Toxin injected~Anticholinergic drugs"
321082|NCT01750632|Procedure|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
321083|NCT01750593|Procedure|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
321084|NCT01750580|Drug|Lirilumab|
321085|NCT01750580|Drug|Ipilimumab|
321086|NCT01750567|Drug|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
321087|NCT01750554|Other|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
321088|NCT01750541|Drug|Haloperidol|
321089|NCT01750541|Drug|Valproate|
321090|NCT01750515|Device|Acupuncture|
321091|NCT01750489|Device|non-invasive ventilation (NIV)|
321092|NCT01750476|Drug|Mirena|
321093|NCT01750476|Drug|Oral contraception|
321094|NCT01750476|Drug|Depo-Provera|
321095|NCT01750463|Other|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
321096|NCT01750463|Other|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
321097|NCT01750437|Drug|YH1885L(Revaprazan)|
321098|NCT01750437|Drug|Esomeprazole 20mg|
321099|NCT01750437|Drug|placebo|
321100|NCT01750424|Procedure|Autologous Fat Grafting|
321101|NCT01750424|Other|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
321102|NCT01750398|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
321103|NCT01750398|Drug|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
321104|NCT01750398|Drug|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
321105|NCT01750385|Drug|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
321106|NCT01750385|Drug|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
321107|NCT01750359|Drug|curcumin|500 mg/day for 6 week
321108|NCT01750346|Drug|Topical acetyl hexapeptide-8|
321109|NCT01750346|Drug|Placebo|
321697|NCT01746160|Drug|C1 Implant|Patients treated with dental implants.
321110|NCT01750320|Device|Koning Breast CT-guided Biopsy|The breast will be positioned and stabilized in the grid/compression device. Four KBCT scans will be taken to guide the vacuum-assisted biopsy procedure.
321111|NCT01750307|Dietary Supplement|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
321112|NCT01750307|Dietary Supplement|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
321113|NCT01750294|Drug|Chlorthalidone|
321114|NCT01750281|Drug|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
321115|NCT01750281|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
321116|NCT01750281|Drug|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
321117|NCT01750281|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
321118|NCT01750268|Behavioral|Medical Management Counseling|Brief alcohol and medication counseling
321119|NCT01750268|Drug|Topiramate|Experimental medication
321120|NCT01750268|Drug|Placebo|Placebo comparator
321121|NCT01750255|Other|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
321122|NCT01750255|Other|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
321123|NCT01750242|Device|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
321124|NCT01750229|Device|Sham|Frequency Setting - Sham
321125|NCT01750229|Device|1200 Hz|Frequency Setting - 1200 Hz
321126|NCT01750229|Device|3030 Hz|Frequency Setting - 3030 Hz
321127|NCT01750229|Device|5882 Hz|Frequency Setting - 5882 Hz
321128|NCT01750203|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
321129|NCT01750190|Drug|FG-4592|Oral
321130|NCT01750190|Drug|Placebo|Oral
321131|NCT01750177|Behavioral|Television Viewing before mealtime|
321132|NCT01750177|Behavioral|Video Game Playing|
321133|NCT01750177|Behavioral|Computer Use|
321134|NCT01750177|Behavioral|Sitting quietly|
321135|NCT01750151|Dietary Supplement|Glucose Beverage|
321136|NCT01750151|Behavioral|Video Game Playing|
321137|NCT01750151|Dietary Supplement|Control Beverage|
321138|NCT01750138|Drug|Glutamine|
321139|NCT01750138|Drug|Dextrose powder|
321140|NCT01750125|Device|measure ascending aortic blood flow with pulse wave Doppler|
321141|NCT01750112|Device|Macrolane VRF20|Injection treatment with Macrolane VRF20
321142|NCT01750099|Procedure|Combined Spinal-epidural|See arm description
321143|NCT01750099|Procedure|Continuous Lumbar epidural|See arm description
321144|NCT01750086|Drug|Teriparatide 40-mcg subcutaneous injection|
321145|NCT01750086|Drug|Denosumab Injection|One-time Denosumab injection
321146|NCT01750086|Drug|Alendronate Oral Tablet|weekly alendronate for 8 weeks
321147|NCT01750073|Drug|Cyclophosphamide|Given IV
321148|NCT01750073|Drug|Doxorubicin Hydrochloride|Given IV
321149|NCT01750073|Other|Laboratory Biomarker Analysis|Correlative studies
321150|NCT01750073|Drug|Paclitaxel|Given IV
321151|NCT01750073|Radiation|Radiation Therapy|Undergo RT
321152|NCT01750073|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
321153|NCT01750073|Biological|Trastuzumab|Given IV
321154|NCT01750060|Drug|Fentanyl|
321155|NCT01750060|Drug|Naltrexone|
321156|NCT01750034|Procedure|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
321157|NCT01750034|Procedure|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
321158|NCT01750021|Dietary Supplement|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
321159|NCT01750021|Dietary Supplement|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
321160|NCT01750008|Procedure|Global Fibroid Ablation|
321161|NCT01750008|Procedure|Myomectomy|
321162|NCT01749982|Other|Placebo|
321163|NCT01749982|Drug|Choline bitartrate|
321164|NCT01749982|Drug|Betaine|
321165|NCT01749982|Drug|Choline bitartrate + Betaine|
321166|NCT01749969|Drug|isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
321167|NCT01749969|Drug|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
321168|NCT01749969|Drug|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
321169|NCT01749956|Radiation|Radiation|
321170|NCT01749956|Drug|Aflibercept|
321171|NCT01749956|Procedure|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
321172|NCT01749956|Drug|FOLFOX6|
321173|NCT01749930|Drug|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
321174|NCT01749930|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening.
321175|NCT01749930|Drug|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
321176|NCT01749917|Other|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
321177|NCT01749917|Other|Control intervention|Active upper limb range of movement exercises for 15 minutes.
321178|NCT01749904|Drug|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
321179|NCT01749904|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
321180|NCT01749904|Drug|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
321181|NCT01749891|Drug|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
321182|NCT01749878|Drug|REGN1500|
321183|NCT01749878|Drug|placebo|
321184|NCT01749865|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
321185|NCT01749852|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
321186|NCT01749852|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
321187|NCT01749826|Drug|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
321188|NCT01749800|Device|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
321189|NCT01749800|Device|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
321190|NCT01749800|Device|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
321191|NCT01749787|Drug|PRTX-100 at 1.5 mcg/kg|
321192|NCT01749787|Drug|PRTX-100 at 3.0 mcg/kg|
321193|NCT01749787|Drug|PRTX-100 at 6.0 mcg/kg|
321194|NCT01749787|Drug|PRTX-100 at 12.0 mcg/kg|
321195|NCT01749787|Drug|PRTX-100 at 240 mcg|
321196|NCT01749787|Drug|Placebo|Placebo administered via infusion once per week for 5 weeks
321197|NCT01749787|Drug|PRTX-100 at 420 mcg|
321198|NCT01749774|Behavioral|Physical activity counseling|
321199|NCT01749761|Other|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
321200|NCT01749761|Other|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
321201|NCT01749748|Procedure|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
321202|NCT01749735|Device|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
321203|NCT01749735|Device|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
321204|NCT01749735|Device|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
321205|NCT01749722|Device|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
321206|NCT01749709|Behavioral|Music listening|
321207|NCT01749657|Device|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
321208|NCT01749618|Behavioral|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
321209|NCT01749605|Drug|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
321210|NCT01749605|Drug|ciprofloxacin 250 mg BID x 3 days|
321211|NCT01749592|Device|cochlear implant|Surgical implantation of a cochlear implant device
321212|NCT01749579|Drug|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
321213|NCT01749579|Drug|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
321214|NCT01749579|Drug|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
321215|NCT01749566|Drug|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
321216|NCT01749553|Other|Sleeper Stretch|Posterior shoulder stretch technique
321217|NCT01749540|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
321218|NCT01749527|Behavioral|minimal activity|Pad test with minimal activity
321219|NCT01749514|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
321220|NCT01749501|Drug|Rocuronium|0.6 mg/Kg once
321221|NCT01749501|Other|Placebo|Normal saline same amt as 0.6mg/kg of study drug
321222|NCT01749488|Other|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
321223|NCT01749475|Drug|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
321224|NCT01749475|Other|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
321225|NCT01749449|Other|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
321226|NCT01749436|Other|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
321227|NCT01749423|Biological|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
321228|NCT01749410|Biological|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
321229|NCT01749397|Drug|Floxuridine|Given IP
321230|NCT01749397|Other|Laboratory Biomarker Analysis|Correlative studies
321231|NCT01749397|Other|Pharmacological Study|Correlative studies
321232|NCT01749397|Drug|Veliparib|Given IV
321233|NCT01749384|Biological|Bevacizumab|Given IV
321234|NCT01749384|Other|Laboratory Biomarker Analysis|Correlative studies
321235|NCT01749384|Other|Pharmacological Study|Correlative studies
321236|NCT01749384|Drug|Tivantinib|Given PO
321237|NCT01749371|Drug|Vitamin E|1200 IU dl-alpha tocopheryl acetate after the initial excision surgery after admission (days 1-15 or days 16-30)
321238|NCT01749358|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
321239|NCT01749358|Behavioral|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
321240|NCT01749332|Other|Perihepatic Phlebotomy|
321241|NCT01749319|Drug|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
321242|NCT01749319|Drug|Intervenous baclofen|
321243|NCT01749306|Biological|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
321244|NCT01749306|Other|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
321245|NCT01749293|Procedure|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
321246|NCT01749293|Drug|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
321247|NCT01749293|Drug|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
321248|NCT01749293|Radiation|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
321249|NCT01749293|Drug|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
321250|NCT01749267|Procedure|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
321251|NCT01749241|Drug|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
321252|NCT01749241|Drug|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
321253|NCT01749228|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
321254|NCT01749228|Drug|Etodolac|500 mg tablet once a day
321255|NCT01749215|Drug|Topiramate|
321256|NCT01749215|Drug|placebo|
321257|NCT01749202|Dietary Supplement|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
321258|NCT01749202|Dietary Supplement|EPA softgels|3 x 500 mg softgel capsules/day
321259|NCT01749202|Other|Sunflower Oil Food|3 servings/day
321260|NCT01749202|Other|SDA soybean Oil Food|3 servings/day
321261|NCT01749189|Dietary Supplement|Blend|22 grams of protein/day
321262|NCT01749189|Dietary Supplement|Whey|22 grams of protein/day
321263|NCT01749189|Dietary Supplement|Placebo|22 grams of carbohydrate/day
321264|NCT01749176|Behavioral|SMS texting intervention|
321265|NCT01749176|Behavioral|Control-Usual Care|
321266|NCT01749163|Biological|Saline|
321267|NCT01749163|Biological|GIP|
321268|NCT01749163|Biological|GLP-1|
321269|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
321270|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
321271|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
321272|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
321273|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
321274|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
321275|NCT01749137|Drug|RM-493|
321276|NCT01749137|Drug|Placebo|
321320|NCT01748838|Drug|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
321321|NCT01748838|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
321322|NCT01748838|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
321277|NCT01749124|Device|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
321278|NCT01749111|Drug|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
321279|NCT01749111|Drug|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
321280|NCT01749098|Drug|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
321281|NCT01749098|Drug|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
321282|NCT01749098|Drug|Placebo|Placebo capsule orally administered on Days 1 - 5
321283|NCT01749098|Drug|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
321284|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
321285|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
321286|NCT01749072|Drug|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
321287|NCT01749072|Drug|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
321288|NCT01749046|Drug|Remegal|Remegal 1500 mg for 12 weeks
321289|NCT01749033|Other|Group 1 Classic|"Active Comparator: Group 1 classic~Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
321290|NCT01749033|Other|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA from the manufacturer.
321291|NCT01749033|Other|Group 3 ELLIA|Group 3 (ELLIA): Using the ELLIA technique
321292|NCT01749020|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
321293|NCT01749020|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
321294|NCT01748994|Drug|Pioglitazone|30mg per day for four months
321295|NCT01748994|Drug|Placebo|
321296|NCT01748981|Other|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
321297|NCT01748981|Other|As usual|Controls, not training
321298|NCT01748955|Drug|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
321299|NCT01748955|Drug|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
321300|NCT01748942|Drug|Dexamethasone|Given IV
321301|NCT01748942|Drug|Dexamethasone|Given PO
321302|NCT01748942|Other|Placebo|Given PO
321303|NCT01748942|Procedure|Quality-of-Life Assessment|Ancillary studies
321304|NCT01748942|Other|Questionnaire Administration|Ancillary studies
321305|NCT01748942|Procedure|Transoral Robotic Surgery|Undergo TORS
321306|NCT01748929|Drug|Albendazole|
321307|NCT01748929|Drug|Placebo|
321308|NCT01748916|Other|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
321309|NCT01748916|Other|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
321310|NCT01748916|Other|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
321311|NCT01748903|Device|Target 360°, 2D Coils, Nano Coils|
321312|NCT01748890|Device|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
321313|NCT01748877|Drug|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
321314|NCT01748877|Drug|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
321315|NCT01748864|Drug|Etarfolatide (EC20)|
321316|NCT01748851|Drug|XELOX|capecitabine 1000mg/m2 bid po D1-D14
321317|NCT01748851|Drug|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
321318|NCT01748838|Drug|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
321319|NCT01748838|Other|Mannitol|excipient blended with CTX-4430 in capsules
321324|NCT01748825|Drug|MK-1775 (AZD1775)|MK-1775 (AZD1775) is an inhibitor of Wee1-kinase.In preclinical models, MK-1775 selectively enhanced chemotherapy-induced death of cells deficient in p53 signaling.
321325|NCT01748812|Drug|Osteomalacia|
321326|NCT01748799|Drug|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
321327|NCT01748799|Drug|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
321328|NCT01748786|Behavioral|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
321329|NCT01748786|Other|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
321330|NCT01748773|Drug|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m^2 IV on Day 1 of Cycles 1-3.
321331|NCT01748773|Radiation|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
321332|NCT01748773|Drug|Capecitabine|Participants will receive capecitabine 850 mg/m^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
321333|NCT01748773|Drug|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
321334|NCT01748760|Behavioral|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
321335|NCT01748760|Other|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
321336|NCT01748747|Drug|Montanide ISA 51 VG|Given SC
321337|NCT01748747|Biological|MART-1 antigen|Given SC
321338|NCT01748747|Other|laboratory biomarker analysis|Correlative studies
321339|NCT01748747|Biological|Gag:267-274 peptide vaccine|Given SC
321340|NCT01748747|Drug|resiquimod|Applied topically
321341|NCT01748734|Procedure|quality-of-life assessment|Ancillary studies
321342|NCT01748734|Other|questionnaire administration|Ancillary studies
321343|NCT01748734|Other|counseling intervention|Undergo cognitive behavioral therapy
321344|NCT01748734|Behavioral|behavioral intervention|Undergo cognitive behavioral therapy
321345|NCT01748721|Biological|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
321346|NCT01748721|Other|pharmacological study|Correlative studies
321347|NCT01748721|Other|laboratory biomarker analysis|Optional correlative studies
321348|NCT01748708|Device|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
321349|NCT01748708|Device|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
321350|NCT01748695|Drug|V158866|
321351|NCT01748695|Drug|Placebo|
321352|NCT01748682|Other|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
321353|NCT01748669|Dietary Supplement|Garlic oil|Oral administration
321354|NCT01748656|Device|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
321355|NCT01748656|Device|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
321356|NCT01748643|Drug|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio > 0.9.
321357|NCT01748643|Drug|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is > 0.9.
321358|NCT01748630|Drug|dexmedetomidine|
321359|NCT01748630|Drug|Midazolam|
321360|NCT01748630|Drug|fentanyl|
321361|NCT01748617|Other|Controlled diet|1 week of controlled diet
321362|NCT01748604|Other|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
321363|NCT01748604|Device|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
321364|NCT01748604|Other|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
321365|NCT01748604|Device|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
321366|NCT01748578|Drug|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
321367|NCT01748578|Drug|EBI-005-1 Placebo|
321368|NCT01748552|Drug|Placebo|Administered orally as capsules
321369|NCT01748552|Drug|LY2922083|Administered orally as capsules
321370|NCT01748539|Drug|KHK4827|
321371|NCT01748539|Drug|Placebo|
321372|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
321373|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
321374|NCT01748513|Other|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
321375|NCT01748500|Drug|Pantoprazole|
321376|NCT01748487|Drug|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
321377|NCT01748474|Procedure|Supplemental oxygen via a mask|
321378|NCT01748461|Behavioral|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
321379|NCT01748461|Behavioral|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
321380|NCT01748448|Drug|Vitamin D|"prospective interventional randomized double blind placebo controlled trail~clinical setting (tertiary university hospital)~investigator driven, no pharmaceutical sponsor~cutaneous malignant melanoma patients~add- on study (placebo or vitamin D) on top of optimal standard care~1:1 inclusion ratio (placebo:Vitamin D)~randomisation after informed consent and screening"
321381|NCT01748448|Drug|arachides oleum raffinatum|
321382|NCT01748435|Drug|Qutenza|Single treatment with Qutenza
321383|NCT01748422|Drug|Qutenza|Transdermal patch
321384|NCT01748409|Other|Biopsies of peripheral autonomic nervous system|
321385|NCT01748409|Other|Autonomic dysfunction questionnaires|
321386|NCT01748409|Other|Electrophysiological tests|
321387|NCT01748396|Drug|Calcitriol|
321388|NCT01748396|Drug|Calcium Carbonate|
321389|NCT01748383|Procedure|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
321390|NCT01748383|Procedure|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
321391|NCT01748383|Procedure|stenting of IRA|The only stent implantation
321392|NCT01748370|Drug|Vitamin D supplementation in hypogonadal men|
321393|NCT01748370|Drug|Vitamin D supplementation in eugonadal men|
321394|NCT01748370|Drug|Placebo hypogonadal|
321395|NCT01748370|Drug|Placebo eugonadal|
321396|NCT01748344|Drug|Cetirizine|10mg tablets
321397|NCT01748344|Drug|High dose ONO-4053|Experimental
321398|NCT01748344|Drug|Low dose ONO-4053|Experimental
321399|NCT01748344|Drug|Placebo|None active
321400|NCT01748331|Other|Fluid restriction|Patients will be randomized to strict fluid restriction < 1 L/day versus moderate fluid restriction < 2.5 L/day
321401|NCT01748318|Drug|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
321402|NCT01748318|Drug|Bactrim DS|Bactrim DS
321403|NCT01748305|Behavioral|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
321404|NCT01748292|Drug|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
321405|NCT01748279|Drug|Atorvastatin|
321406|NCT01748279|Drug|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
321407|NCT01748279|Drug|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
321408|NCT01748266|Other|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
321409|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
321410|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
321411|NCT01748240|Drug|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
321412|NCT01748227|Behavioral|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
321413|NCT01748201|Procedure|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
321414|NCT01748188|Procedure|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
321415|NCT01748188|Procedure|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
321416|NCT01748188|Procedure|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
321417|NCT01748188|Procedure|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
321418|NCT01748188|Procedure|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
321419|NCT01748175|Drug|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
321420|NCT01748162|Drug|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
321421|NCT01748162|Drug|Prednisolone IF needed|
321458|NCT01747850|Behavioral|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
321508|NCT01747486|Biological|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
321509|NCT01747447|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
321510|NCT01747447|Dietary Supplement|Fish oil placebo|Fish oil placebo
321422|NCT01748149|Drug|Vemurafenib|"Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg twice a day (BID). Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.~Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery."
321423|NCT01748136|Device|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
321424|NCT01748123|Drug|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
321425|NCT01748123|Drug|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
321426|NCT01748110|Behavioral|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
321427|NCT01748110|Behavioral|TRIMM|text message intervention.
321428|NCT01748097|Drug|sodium bicarbonate 4.2%|
321429|NCT01748084|Drug|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
321430|NCT01748084|Drug|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
321431|NCT01748058|Behavioral|Exercise based on active video gaming|
321432|NCT01748045|Drug|inhaled nitric oxide|
321433|NCT01748045|Drug|Placebo Comparator - nitrogen gas|
321434|NCT01748032|Behavioral|Cognitive training|20 minutes/day for 5 sequential working days
321435|NCT01748019|Drug|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
321436|NCT01748006|Other|Standard of care therapy for severe decompensated heart failure|
321437|NCT01747993|Drug|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
321438|NCT01747993|Drug|Placebo|(1 tablet / day for 6 days)
321439|NCT01747980|Drug|PRX-112|Single dose level, four doses per cohort
321440|NCT01747967|Other|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
321441|NCT01747954|Other|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
321442|NCT01747954|Other|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
321443|NCT01747941|Drug|PF-06305591|single dose, solution
321444|NCT01747941|Drug|Placebo|matching placebo
321445|NCT01747941|Drug|PF-06305591|single dose, solution
321446|NCT01747941|Drug|Placebo|matching placebo
321447|NCT01747941|Drug|PF-06305591|single dose, solution
321448|NCT01747941|Drug|Placebo|matching placebo
321449|NCT01747928|Other|dual-chamber syringe|dual-chamber syringe for mock injection
321450|NCT01747915|Drug|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
321451|NCT01747915|Drug|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
321452|NCT01747915|Drug|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
321453|NCT01747902|Procedure|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
321454|NCT01747902|Procedure|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
321455|NCT01747889|Device|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.~On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
321456|NCT01747876|Drug|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
321457|NCT01747863|Other|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at </= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
321698|NCT01746147|Other|No intervention and study treatment|
321459|NCT01747850|Drug|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
321460|NCT01747850|Drug|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
321461|NCT01747837|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
321462|NCT01747811|Device|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
321463|NCT01747811|Device|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
321464|NCT01747798|Drug|auranofin|Given PO
321465|NCT01747798|Other|laboratory biomarker analysis|Correlative studies
321466|NCT01747785|Other|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
321467|NCT01747785|Other|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
321468|NCT01747785|Other|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
321469|NCT01747772|Device|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
321470|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|
321471|NCT01747746|Drug|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
321472|NCT01747746|Drug|Warfarin and Enoxaparin|Historical Control
321473|NCT01747733|Device|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
321474|NCT01747720|Dietary Supplement|Vitamin D3|Given orally
321475|NCT01747720|Dietary Supplement|Placebo|
321476|NCT01747707|Drug|Docetaxel|
321477|NCT01747707|Drug|Cisplatin|
321478|NCT01747707|Drug|S-1|
321479|NCT01747694|Behavioral|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
321480|NCT01747681|Procedure|Microfracture|
321481|NCT01747668|Dietary Supplement|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
321482|NCT01747668|Dietary Supplement|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
321483|NCT01747642|Dietary Supplement|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
321484|NCT01747642|Drug|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
321485|NCT01747629|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
321486|NCT01747629|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
321487|NCT01747616|Device|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
321488|NCT01747616|Other|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
321489|NCT01747603|Other|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
321490|NCT01747590|Drug|Zolpidem|
321491|NCT01747590|Drug|Alprazolam|
321492|NCT01747590|Drug|Caffeine|
321493|NCT01747590|Other|Placebo|
321494|NCT01747577|Drug|Solifenacin Succinate|Oral
321495|NCT01747577|Drug|Placebo|Oral
321496|NCT01747564|Drug|YM178 (mirabegron)|oral
321497|NCT01747551|Drug|Oxaliplatin|
321498|NCT01747551|Drug|Leucovorin|
321499|NCT01747551|Drug|Fluorouracil|
321500|NCT01747551|Drug|Ziv-aflibercept|
321501|NCT01747538|Drug|Placebo|Solution for subcutaneous injection
321502|NCT01747538|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
321503|NCT01747538|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
321504|NCT01747525|Device|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
321505|NCT01747512|Drug|C-PERT|Patients with thyroid and Head and Neck cancer
321506|NCT01747512|Drug|G-PERT|Patients with thyroid and Head and Neck cancer
321507|NCT01747499|Drug|Azacitidine|
321683|NCT01746199|Drug|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
321511|NCT01747447|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
321512|NCT01747447|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
321513|NCT01747408|Drug|Human Albumin|"25% human albumin given in four escalating doses:~Group 1: .625g/kg infused over 3hrs daily X 7day~Group 2: 1.25g/kg infused over 3hrs daily X 7day~Group 3: 1.875g/kg infused over 3hrs daily X 7day~Group 4: 2.5g/kg infused over 3hrs daily X 7day"
321514|NCT01747395|Other|Exercise training|The heart failure patients are subjected to differents protocols of physical training
321515|NCT01747382|Procedure|Renal denervation|
321516|NCT01747356|Device|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
321517|NCT01747343|Behavioral|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
321518|NCT01747330|Drug|Pancreatin|Doses of Pancreatin <2500 lipase u/kg/feed or <4000 lipase U/g fat/intake or <10000 lipase U/kg/day given orally are used
321519|NCT01747317|Device|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization——A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
321520|NCT01747304|Device|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
321521|NCT01747278|Drug|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
321522|NCT01747252|Dietary Supplement|RGC|
321523|NCT01747252|Dietary Supplement|RGC|
321524|NCT01747252|Dietary Supplement|Resveratrol|The equivalent of 150 mg resveratrol
321525|NCT01747239|Drug|Cabazitaxel|25 mg/m2 IV every three weeks
321526|NCT01747226|Other|Fluoride rinse|rinse with 15 ml for 1 minute
321527|NCT01747226|Other|Halita|rinsing with 15 ml for 1 minute
321528|NCT01747226|Other|Meridol Halitosis|rinsing with 15 ml for 1 minute
321529|NCT01747226|Other|Water|rinsing with 15ml for 1 minute
321530|NCT01747213|Drug|BNC|
321531|NCT01747213|Other|Placebo|Microcrystalline cellulose fiber
321532|NCT01747200|Procedure|Sham rTMS|
321533|NCT01747200|Procedure|Bilateral rTMS at same frequency and in phase|
321534|NCT01747200|Procedure|Bilateral rTMS at different frequencies|
321535|NCT01747200|Procedure|Bilateral rTMSat same frequency and out of phase|
321536|NCT01747200|Procedure|rTMS over TP8|
321537|NCT01747200|Procedure|rTMS over TP7|
321538|NCT01747174|Drug|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
321539|NCT01747174|Drug|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
321540|NCT01747174|Procedure|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
321541|NCT01747161|Drug|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
321542|NCT01747161|Drug|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
321543|NCT01747148|Drug|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
321544|NCT01747135|Drug|VTS-270|
321545|NCT01747122|Device|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
321546|NCT01747122|Device|Epidural|
321547|NCT01747109|Device|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
321548|NCT01747109|Procedure|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
321549|NCT01747096|Drug|68-Ga-DOTANOC|
321550|NCT01747083|Drug|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
321551|NCT01747070|Other|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
321552|NCT01747070|Other|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
321553|NCT01747070|Other|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
321554|NCT01747070|Other|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
321599|NCT01746784|Drug|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
321600|NCT01746784|Drug|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
321601|NCT01746771|Drug|HM781-36B(Poziotinib)|QD*2weeks/3weeks
321602|NCT01746771|Drug|Paclitaxel|175mg/m2
321603|NCT01746771|Drug|Trastuzumab|8mg/kg
321684|NCT01746173|Drug|Cyclophosphamide|
321685|NCT01746173|Drug|Doxorubicin|
321686|NCT01746173|Drug|Vincristine|
321687|NCT01746173|Drug|Etoposide|
321555|NCT01747057|Behavioral|Dynamic-parameters-guided fluid management|"● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation* and with sinus rhythm.~PPV >12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ [(PPmax+PPmin)/2] x100 (during 5 respiratory cycles)~SVV > 12% (15). SVV: Stroke volume variation~A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.~Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV < 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP>12).~● Non-preload responsive patients (defined as PPV or SVV < 12%) will resume the same protocol as responders when fluid response parameters are negative."
321556|NCT01747057|Behavioral|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (> 65mmHg) or CVP > 12mmHg. If CVP reaches > 12 mmHg and MAP remains < 65mmHg, norepinephrine should be started to reach MAP > 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output < 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
321557|NCT01747044|Drug|Milnacipran|100mg/day
321558|NCT01747044|Drug|Placebo|
321559|NCT01747031|Device|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization——A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
321560|NCT01747018|Biological|Platelet-rich Plasma|
321561|NCT01746992|Drug|Cyclophosphamide 750mg/m2|day 1 in both arms
321562|NCT01746992|Drug|Vincristine 1.4mg/m2|day 1
321563|NCT01746992|Drug|Doxorubicin 50mg/m2|day 1
321564|NCT01746992|Drug|prednisone 60mg/m2|day1-day5
321565|NCT01746992|Drug|ifosfamide 2000mg/m2|day 22-day 24
321566|NCT01746992|Drug|pirarubicin 50mg/m2|day 1
321567|NCT01746992|Drug|pirarubicin 25mg/m2|day 22
321568|NCT01746992|Drug|Etoposide phosphate 100mg/m2|day 22-day 24
321569|NCT01746992|Drug|methotrexate 1500mg/m2|day 43
321570|NCT01746979|Drug|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
321571|NCT01746979|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
321572|NCT01746979|Drug|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
321573|NCT01746940|Drug|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
321574|NCT01746940|Drug|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
321575|NCT01746940|Drug|Placebo Topical Solution|Placebo Topical Solution
321576|NCT01746927|Other|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
321577|NCT01746901|Drug|Placebo|Placebo solution + Placebo ALO-02 (intact)
321578|NCT01746901|Drug|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
321579|NCT01746901|Drug|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
321580|NCT01746901|Drug|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
321581|NCT01746901|Drug|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
321582|NCT01746901|Drug|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
321583|NCT01746875|Drug|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
321584|NCT01746875|Drug|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
321585|NCT01746862|Drug|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone [r-hGH]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
321586|NCT01746862|Drug|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
321587|NCT01746849|Biological|Palifermin|
321588|NCT01746849|Biological|Lupron|
321589|NCT01746849|Procedure|peripheral blood stem cell transplantation|
321590|NCT01746849|Radiation|Total-Body Irradiation (TBI)|
321591|NCT01746849|Drug|Thiotepa|
321592|NCT01746849|Drug|Cyclophosphamide|
321593|NCT01746849|Drug|Degarelix|
321594|NCT01746836|Other|Laboratory Biomarker Analysis|Blood draws.
321595|NCT01746836|Drug|Ponatinib Hydrochloride|Starting dose: 30 mg by mouth once a day.
321596|NCT01746836|Other|Quality-of-Life Assessment|Surveys completed.
321597|NCT01746823|Drug|Cyclosporins|
321598|NCT01746810|Radiation|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
321688|NCT01746173|Drug|Prednisone|
321689|NCT01746173|Drug|Filgrastim|
321604|NCT01746758|Behavioral|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
321605|NCT01746745|Drug|[^14C]-LY2940680|Administered as solution by mouth
321606|NCT01746732|Drug|Ortho-Cyclen|Oral administration
321607|NCT01746732|Drug|Evacetrapib|Oral administration
321608|NCT01746719|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
321609|NCT01746719|Drug|Etodolac|500 mg tablet once a day
321610|NCT01746706|Device|PET amyloid tracer (Florbetapir F18 AV45 F18|
321611|NCT01746693|Device|Dynamic Vessel Analyzer|retinal vessel diameter, retinal oxygen saturation
321612|NCT01746693|Other|Laser Doppler Velocimetry|retinal blood flow velocity, retinal blood flow
321613|NCT01746693|Device|7-Tesla MRI|High resolution functional and anatomical imaging of the visual pathway
321614|NCT01746693|Other|Pattern electroretinography|inner retinal function
321615|NCT01746693|Other|Fourier domain optical coherence tomography|Blood flow in retina.
321616|NCT01746680|Drug|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0~week4, 2mg for week4~week8, 3mg for week8~week24 with MTX ≤20mg/week
321617|NCT01746667|Behavioral|Exposure in vivo|
321618|NCT01746667|Behavioral|Virtual Reality Exposure Therapy|
321619|NCT01746654|Drug|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
321620|NCT01746654|Drug|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
321621|NCT01746654|Drug|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
321622|NCT01746654|Drug|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
321623|NCT01746641|Drug|Remifentanil|
321624|NCT01746641|Drug|Propofol|
321625|NCT01746628|Procedure|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
321626|NCT01746615|Device|Dynamic Vessel Analyzer|retinal vessel diameter & oxygen saturation
321627|NCT01746615|Other|Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)|retinal blood velocity
321628|NCT01746602|Drug|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
321629|NCT01746602|Drug|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
321630|NCT01746602|Device|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
321631|NCT01746602|Device|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
321632|NCT01746602|Device|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
321633|NCT01746589|Device|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
321634|NCT01746576|Other|Use of impedance threshold device during spontaneous ventilation|
321635|NCT01746563|Drug|Ranibizumab|Intravitreal injection
321636|NCT01746563|Procedure|Laser therapy|Laser therapy
321637|NCT01746550|Device|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
321638|NCT01746524|Device|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
321639|NCT01746511|Procedure|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
321640|NCT01746511|Drug|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
321641|NCT01746498|Procedure|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
321642|NCT01746498|Procedure|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
321643|NCT01746498|Procedure|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
321644|NCT01746485|Drug|UT-15C|
321645|NCT01746472|Behavioral|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
321646|NCT01746472|Behavioral|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
321647|NCT01746472|Behavioral|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
321648|NCT01746472|Behavioral|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
321649|NCT01746459|Other|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
321650|NCT01746459|Other|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
321651|NCT01746446|Other|Care team|Provides additional support to patients, family, and friends.
321681|NCT01746212|Device|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
321682|NCT01746199|Drug|cotrimoxazole daily prophylaxis|
321690|NCT01746173|Drug|Plerixafor|
321652|NCT01746433|Other|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.~The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.~The investigator then gives instructions on how to use the randomized device (correct hand placement).~The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
321653|NCT01746420|Drug|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
321654|NCT01746420|Drug|Placebo|sodium acetate buffer (0 mg rhPDGF-BB)
321655|NCT01746394|Behavioral|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
321656|NCT01746394|Behavioral|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
321657|NCT01746381|Device|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
321658|NCT01746368|Other|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
321659|NCT01746368|Other|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
321660|NCT01746355|Procedure|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
321661|NCT01746342|Device|Effective continuous positive airway pressure (CPAP)|
321662|NCT01746342|Device|Sham continuous positive airway pressure (CPAP)|
321663|NCT01746329|Other|Tea|Oral intake of tea containing 75 grams of glucose
321664|NCT01746329|Other|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
321665|NCT01746329|Other|Placebo|Oral intake of 75 grams of glucose in water
321666|NCT01746303|Dietary Supplement|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
321667|NCT01746303|Dietary Supplement|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
321668|NCT01746303|Other|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
321669|NCT01746303|Other|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
321670|NCT01746290|Other|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
321671|NCT01746277|Drug|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
321672|NCT01746277|Drug|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
321673|NCT01746264|Dietary Supplement|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
321674|NCT01746251|Drug|Afatinib|
321675|NCT01746238|Drug|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
321676|NCT01746238|Drug|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
321677|NCT01746238|Radiation|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
321678|NCT01746225|Drug|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
321679|NCT01746212|Procedure|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
321680|NCT01746212|Biological|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
321699|NCT01746121|Genetic|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
321700|NCT01746108|Biological|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
321701|NCT01746095|Drug|Vancomycin inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
321702|NCT01746095|Drug|Placebo inhalation powder|
321703|NCT01746082|Biological|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects >/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
321704|NCT01746069|Behavioral|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
321705|NCT01746069|Behavioral|health advice|routine clinical practice
321706|NCT01746056|Device|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
321707|NCT01746043|Drug|Armodafinil|150 mg by mouth once a day for 6 weeks.
321708|NCT01746043|Other|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
321709|NCT01746043|Drug|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
321710|NCT01746043|Behavioral|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
321711|NCT01746017|Drug|Placebo|Administered orally as capsules
321712|NCT01746017|Drug|LY2922470|Administered orally as capsules
321713|NCT01746004|Drug|[^14C]-LY2157299|[^14C]-LY2157299 monohydrate administered as oral solution
321714|NCT01745991|Device|CoSeal spray|
321715|NCT01745978|Procedure|Precut papillotomy|
321716|NCT01745965|Drug|T-DM1|
321717|NCT01745965|Drug|Trastuzumab|
321718|NCT01745952|Device|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
321719|NCT01745952|Device|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
321720|NCT01745952|Device|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
321721|NCT01745939|Other|Lumbar Manipulation|Manual therapy intervention
321722|NCT01745939|Other|Sham manipulation|Manual therapy intervention
321723|NCT01745926|Device|MECHANICAL CHEST COMPRESSION|
321724|NCT01745913|Device|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
321725|NCT01745913|Drug|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
321726|NCT01745913|Drug|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
321727|NCT01745913|Drug|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
321728|NCT01745913|Procedure|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of > 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
321729|NCT01745913|Procedure|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
321730|NCT01745887|Drug|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
321731|NCT01745861|Dietary Supplement|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
321732|NCT01745861|Dietary Supplement|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
321733|NCT01745848|Drug|Roflumilast|
321734|NCT01745835|Drug|2L Coolprep®|* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
321834|NCT01744977|Behavioral|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
321835|NCT01744964|Drug|Apomorphine|1.5 mg Apomorphine
321735|NCT01745835|Drug|1L Coolprep® and Bisacodyl|"Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)~* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g~Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) * composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
321736|NCT01745822|Drug|tenofovir disoproxil fumarate|administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
321737|NCT01745822|Drug|placebo|administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
321738|NCT01745809|Procedure|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
321739|NCT01745783|Other|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
321740|NCT01745783|Other|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
321741|NCT01745770|Drug|Mesalazine - TID 1000 mg|
321742|NCT01745770|Drug|Mesalazine - TID 2x 500 mg|
321743|NCT01745757|Drug|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
321744|NCT01745757|Drug|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
321745|NCT01745744|Other|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
321746|NCT01745731|Other|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
321747|NCT01745718|Other|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
321748|NCT01745705|Other|Cervical Spine Manipulation|
321749|NCT01745705|Other|Manual Contact|
321750|NCT01745692|Device|Mechanical thrombectomy|
321751|NCT01745692|Drug|Intravenous rtPA|All patients receive IV alteplase
321752|NCT01745679|Drug|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
321753|NCT01745666|Other|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
321754|NCT01745666|Other|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
321755|NCT01745653|Device|Low level laser therapy|
321756|NCT01745653|Procedure|sham procedure|
321757|NCT01745640|Drug|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
321758|NCT01745640|Drug|Dexamethasone|40mg (if patient <75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
321759|NCT01745627|Device|755nm Alex laser|
321760|NCT01745614|Drug|Nimesulide 100 mg tablets|Reference product
321761|NCT01745614|Drug|Nimesulide 100 mg tablets|Test product
321762|NCT01745601|Drug|escitalopram 10 mg|Reference product
321763|NCT01745601|Drug|escitalopram 10 mg|Test product
321764|NCT01745588|Drug|Pomalidomide|
321765|NCT01745588|Procedure|stem cell|
321766|NCT01745588|Drug|Dexamethasone|
321767|NCT01745588|Drug|Clarithromycin|
321768|NCT01745575|Drug|Alprazolam 2mg tablets|Reference product
321769|NCT01745575|Drug|Alprazolam 2 mg tablets|Test product
321770|NCT01745562|Drug|Alprazolam 0.5 mg|Reference product
321771|NCT01745562|Drug|Alprazolam 0.5 mg|Test product
321772|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
321773|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
321774|NCT01745536|Procedure|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
321775|NCT01745536|Procedure|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
321776|NCT01745523|Procedure|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
321777|NCT01745523|Procedure|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
321778|NCT01745510|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
321779|NCT01745510|Dietary Supplement|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
321780|NCT01745497|Drug|Ferrous sulfate|3mg/kg liquid
321781|NCT01745497|Drug|Placebo|Equivalent volume of liquid with similar color and taste.
321782|NCT01745484|Other|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
321783|NCT01745458|Drug|SB-659032|
321784|NCT01745458|Drug|Placebo|Matched placebo
322108|NCT01742884|Other|Thealoz|Instillation of 1 drop of Thealoz
321785|NCT01745445|Other|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
321786|NCT01745432|Device|ADBLOCK|Laparoscopic surgery
321787|NCT01745393|Behavioral|Clinic Quality Improvement + Behavioral Counseling|
321788|NCT01745393|Behavioral|Clinic Quality Improvement + Attention Control|
321789|NCT01745380|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
321790|NCT01745380|Drug|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
321791|NCT01745367|Drug|Tivozanib Hydrochloride|
321792|NCT01745367|Drug|paclitaxel|
321793|NCT01745354|Drug|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
321794|NCT01745354|Radiation|Local Radiation|
321795|NCT01745328|Drug|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
321796|NCT01745328|Drug|TCM|Subject is treated with TCM for 4 weeks.
321797|NCT01745328|Drug|LVX-AMX|treatment with placebo from 2 to 4 weeks.
321798|NCT01745315|Device|Advanced bipolar devices|
321799|NCT01745302|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
321800|NCT01745302|Drug|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
321801|NCT01745276|Device|Biphosfonate|External pins coated by biphosfonate.
321802|NCT01745276|Device|Hydroxylapatit|External pins coated by Hydroxylapatit.
321803|NCT01745263|Drug|Vitamin D3|2000 IU/d
321804|NCT01745263|Drug|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2~1 g/d"
321805|NCT01745263|Procedure|Strength Home Exercise|
321806|NCT01745263|Procedure|Flexibility Home Exercise|
321807|NCT01745250|Device|Emervel Lips|Lip treatment of both upper and lower lip
321808|NCT01745250|Device|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
321809|NCT01745224|Device|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
321810|NCT01745224|Device|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
321811|NCT01745211|Device|755nm Alexandrite Laser|755nm Alexandrite laser with modified and standard handpiece
321812|NCT01745172|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
321813|NCT01745159|Drug|tacrolimus|
321814|NCT01745146|Behavioral|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
321815|NCT01745146|Behavioral|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
321816|NCT01745133|Drug|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
321817|NCT01745133|Drug|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
321818|NCT01745133|Drug|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
321819|NCT01745120|Genetic|LentiGlobin BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin BB305 lentiviral vector.
321820|NCT01745107|Radiation|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
321821|NCT01745094|Drug|mirabegron|oral
321822|NCT01745094|Drug|solifenacin|oral
321823|NCT01745081|Drug|20% mannitol bolus administration|
321824|NCT01745081|Drug|Hypertonic saline 3% bolus administration|
321825|NCT01745068|Other|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
321826|NCT01745055|Drug|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
321827|NCT01745055|Drug|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
321828|NCT01745042|Other|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
321829|NCT01745029|Device|Motilis-3D-transit|
321830|NCT01745016|Dietary Supplement|Placebo|
321831|NCT01745016|Dietary Supplement|Beta-alanine|
321832|NCT01745003|Procedure|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes—anode and cathode. We will be using this device to investigate fibromyalgia.
321833|NCT01744990|Other|Oral food challenges to multiple nuts|
321836|NCT01744951|Behavioral|ADAPT|"ADAPT consists of the following modules/sessions:~Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
321837|NCT01744938|Procedure|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
321838|NCT01744925|Drug|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
321839|NCT01744925|Drug|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
321840|NCT01744912|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
321841|NCT01744912|Drug|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
321842|NCT01744899|Other|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
321843|NCT01744886|Procedure|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.~If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
321844|NCT01744873|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
321845|NCT01744873|Drug|Bisoprolol|10 mg tablet once a day
321846|NCT01744847|Device|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
321847|NCT01744821|Dietary Supplement|Arm A: Vitamin D3 Group|
321848|NCT01744821|Dietary Supplement|Placebo|
321849|NCT01744808|Drug|EB-1020 IR|Immediate release
321850|NCT01744808|Drug|EB-1020 SR1|sustained release
321851|NCT01744808|Drug|EB-1020 SR2|Sustained release
321852|NCT01744808|Drug|EB-1020 SR3|Sustained release
321853|NCT01744808|Other|Placebo|Placebo formulation
321854|NCT01744795|Other|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
321855|NCT01744782|Drug|RP103|Cysteamine Bitartrate Delayed-release Capsules (RP103) were administered twice daily, orally or via gastrostomy tube (G-tube), after a 2-hour fast. The starting dose was one-quarter of the RP103 targeted maintenance dose based on age, weight, and body surface area. The recommended targeted maintenance dose for children up to 6 years old was 1 gram/m²/day, in 2 divided doses given Q12H. The dose was gradually escalated, in 10% steps, based on monitoring of WBC cystine levels 30 minutes after the morning RP103 dose collected every 2 weeks, until the participant's WBC cystine level was <1 nmol ½ cystine/mg protein.
321856|NCT01744756|Drug|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
321857|NCT01744743|Procedure|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
321858|NCT01744730|Drug|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
321859|NCT01744717|Other|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.~The procedures to be studied are the following:~TURNING / POSITIONING (moving side to side or up or down in bed)~ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)~NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
321860|NCT01744704|Drug|rhNGF 0.5 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
321861|NCT01744704|Drug|rhNGF 5 µg/mL Sentinel|Part 0 represented a sentinel group.
321862|NCT01744704|Drug|rhNGF 20 µg/mL Sentinel|In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
321863|NCT01744704|Drug|rhNGF 20 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
321864|NCT01744704|Drug|rhNGF 60 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
321865|NCT01744704|Drug|rhNGF 180 µg/mL Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
321866|NCT01744704|Drug|rhNGF 20 µg/mL Part B|In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.
321933|NCT01744236|Drug|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
321867|NCT01744704|Drug|rhNGF 60 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
321868|NCT01744704|Drug|rhNGF 180 µg/mL Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
321869|NCT01744704|Drug|Placebo Part A|In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.
321870|NCT01744704|Drug|Placebo Part B|In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.
321871|NCT01744691|Drug|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
321872|NCT01744678|Behavioral|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
321873|NCT01744678|Behavioral|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
321874|NCT01744665|Drug|AMN107|Nilotinib will be provided by the sponsor as the study drug. Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
321875|NCT01744652|Drug|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.~Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
321876|NCT01744652|Drug|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.~Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
321877|NCT01744639|Behavioral|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
321878|NCT01744626|Drug|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
321879|NCT01744626|Drug|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
321880|NCT01744600|Behavioral|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
321881|NCT01744587|Other|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
321882|NCT01744587|Dietary Supplement|Placebo|Placebo qd (2# bid) for 3 years
321883|NCT01744574|Other|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
321884|NCT01744574|Drug|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
321885|NCT01744574|Other|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
321886|NCT01744561|Behavioral|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
321887|NCT01744548|Behavioral|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
321888|NCT01744535|Behavioral|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message."
321889|NCT01744535|Behavioral|Paper food diary|"The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity."
321890|NCT01744535|Behavioral|Online food diary|"The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity."
321891|NCT01744522|Procedure|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
321892|NCT01744509|Device|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
321931|NCT01744236|Drug|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
321932|NCT01744236|Drug|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
321893|NCT01744496|Drug|Rotigotine|Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
321894|NCT01744496|Drug|Placebo|Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
321895|NCT01744483|Device|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
321896|NCT01744483|Device|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
321897|NCT01744483|Device|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
321898|NCT01744470|Drug|Tacrolimus targeted half-dose|
321899|NCT01744470|Drug|Tacrolimus targeted plain dose|
321900|NCT01744457|Device|Measurement of tear film osmolarity with the TearLab® instrument|
321901|NCT01744457|Other|Schirmer I test|
321902|NCT01744457|Other|Tear break up time|
321903|NCT01744457|Device|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
321904|NCT01744457|Other|Ocular Surface Disease Index|
321905|NCT01744444|Drug|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
321906|NCT01744444|Drug|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
321907|NCT01744418|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
321908|NCT01744392|Behavioral|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
321909|NCT01744379|Drug|Lesinurad|
321910|NCT01744379|Drug|Placebo|
321911|NCT01744366|Drug|Degarelix|
321912|NCT01744366|Drug|Goserelin|
321913|NCT01744353|Drug|Dose level 1|Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
321914|NCT01744353|Drug|Dose level 2/MTD|Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
321915|NCT01744353|Drug|Dose level 3|Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
321916|NCT01744340|Drug|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter~Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
321917|NCT01744340|Drug|Colon- Closed as of May 2014|"Eribulin Mesylate:~1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
321918|NCT01744314|Drug|Indomethacin and Pantoprazole|
321919|NCT01744314|Drug|microcrystalline cellulose powder tablets|
321920|NCT01744301|Drug|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
321921|NCT01744288|Drug|Ticagrelor|Oral single loading dose 180ng
321922|NCT01744288|Drug|Clopidogrel|Oral single loading dose 600mg
321923|NCT01744288|Drug|ASA|81mg once daily from day -2 up to platelet transfusion
321924|NCT01744275|Dietary Supplement|Omega 3 fatty acids|
321925|NCT01744275|Dietary Supplement|corn oil|Placebo
321926|NCT01744262|Drug|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5~4 µg/mL and remifentanil effect site concentration 2~5 ng/mL.
321927|NCT01744262|Drug|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5~2.0 % and remifentanil effect site concentration 2~5 ng/mL.
321928|NCT01744249|Drug|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
321929|NCT01744249|Drug|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
321930|NCT01744249|Drug|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
321934|NCT01744236|Drug|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
321935|NCT01744236|Drug|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
321936|NCT01744236|Drug|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
321937|NCT01744236|Drug|L-NMMA|
321938|NCT01744223|Biological|BPX-501 dose 1|Subjects will receive 2x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
321939|NCT01744223|Drug|AP1903|Dimerizer drug administered by intravenous infusion in those subjects who develop GVHD after infusion of BPX-501 cells.
321940|NCT01744223|Biological|BPX-501 dose 2|Subjects will receive 5x10E5 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
321941|NCT01744223|Biological|BPX-501 dose 3|Subjects will receive 1x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
321942|NCT01744223|Biological|BPX-501 dose 4|Subjects will receive 3x10E6 donor T cells/kg genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene (BPX-501) after stem cell transplant.
321943|NCT01744223|Procedure|SCT|all subjects will receive an alpha beta depleted donor transplant as part of treatment
321944|NCT01744197|Drug|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
321945|NCT01744184|Drug|Entonox|Entonox arm
321946|NCT01744184|Drug|Midazolam|up to 5mg midazolam as appropriate
321947|NCT01744171|Biological|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
321948|NCT01744171|Other|Laboratory Biomarker Analysis|Correlative studies
321949|NCT01744158|Other|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:~differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)~measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording~measurement of severity of spasticity using the modified Ashworth score~description of presence of chorea or athetosis~classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)~classification of fine motor abilities using the manual ability classification system (MACS)~collection of demographic data and associated medical history"
321950|NCT01744145|Other|Interventional 40-60|This group will receive the intervention aged 40-60
321951|NCT01744145|Other|Interventional 60 and above|This group will receive the intervention aged 60 and above.
321952|NCT01744132|Behavioral|Aim 3: Contract|
321953|NCT01744119|Device|Vascutek Anaconda™ Stent Graft System|
321954|NCT01744106|Drug|pseudoephedrine hydrochloride 30 mg tablets|
321955|NCT01744106|Drug|Placebo tablets|
321956|NCT01744093|Drug|Doxycycline|100 mg twice daily (BID orally) x 6 months
321957|NCT01744093|Drug|Placebo (sugar pill)|100 mg twice daily (BID orally) x 6 months
321958|NCT01744080|Other|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
321959|NCT01744080|Other|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
321960|NCT01744067|Drug|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
321961|NCT01744067|Drug|Placebo|Placebo capsules 3 times a day (oral administration)
321962|NCT01744054|Device|PET/MR|
321963|NCT01744054|Device|PET/CT|
321964|NCT01744041|Behavioral|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
321965|NCT01744041|Other|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
321966|NCT01744028|Device|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
321967|NCT01744028|Other|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
321968|NCT01744015|Behavioral|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
322018|NCT01743651|Drug|arbaclofen|10 mg, 15 mg or 20 mg arbaclofen ER tablets administered orally 2 times per day
322019|NCT01743651|Drug|baclofen|20 mg, 30 mg or 40 mg baclofen administered orally 4 times per day
322020|NCT01743651|Drug|Placebo|arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
322021|NCT01743638|Procedure|MR-Guided Laser Ablation|
322022|NCT01743625|Drug|COV155|COV155 tablets
322023|NCT01743625|Drug|placebo|
322145|NCT01742624|Drug|Corticosteroid|oral
321969|NCT01744015|Other|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
321970|NCT01744002|Other|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
321971|NCT01744002|Other|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
321972|NCT01743989|Drug|Nilotinib|Nilotinib will be provided to patients for at least 24 or 36months. (depending if nilotinib re-initiation is necessary- nilotinib will be provided during nilotinib re-initiation phase)
321973|NCT01743976|Drug|Donepezil|donepezil 5 mg once daily for 6 weeks
321974|NCT01743976|Drug|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
321975|NCT01743963|Behavioral|Decision support|Clinical pharmacists mediated computerized decision support
321976|NCT01743963|Behavioral|Usual Care|clinicians typical apporach for GID monitering
321977|NCT01743950|Drug|Bevacizumab|10mg/kg every 2weeks.
321978|NCT01743950|Radiation|PRDR|daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions
321979|NCT01743937|Procedure|Coronary occlusion with balloon inflation|
321980|NCT01743924|Other|raw broccoli|To eat this plant material
321981|NCT01743911|Other|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
321982|NCT01743911|Drug|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
321983|NCT01743898|Drug|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
321984|NCT01743898|Other|no anticoagulation|
321985|NCT01743885|Drug|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
321986|NCT01743885|Drug|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
321987|NCT01743872|Procedure|iOCT|"Arterial access will performed by the operating surgeon. An aortic and infrainguinal angiogram using the standard method of intravenous iodinated contrast under digital subtraction fluoroscopy will be conducted in the usual manner according to the vascular surgeon. A 54 mm section of Superficial Femoral Artery will be chosen for study imaging. An intervention sheath or injection catheter will be placed just proximal to the area of interest. An 0.014 wire will be passed distal to the area of interest. The patient will then undergo OCT of this 54mm section with each of the three mediums below using a continuous flushing method through injection catheter. All OCT imaging will be collected at a rate of 25mm/sec. In the event of a subsequent procedure, OCT imaging will again be performed."
321988|NCT01743859|Drug|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
321989|NCT01743859|Drug|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
321990|NCT01743859|Other|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
321991|NCT01743833|Other|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
321992|NCT01743833|Other|Scapular High Velocity, Low Amplitude Thrust Maneuver|
321993|NCT01743820|Drug|dihydroartemisinin-piperaquine|
321994|NCT01743820|Drug|0.125 mg/kg Primaquine|
321995|NCT01743820|Drug|0.5 mg/kg Primaquine|
321996|NCT01743820|Drug|0.25 mg/kg Primaquine|
321997|NCT01743820|Drug|0.0625 mg/kg Primaquine|
321998|NCT01743807|Drug|GNKG168|GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.
321999|NCT01743794|Drug|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
322000|NCT01743794|Drug|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
322001|NCT01743781|Behavioral|video|view a 10-minute informational video about comprehensive eye examination
322002|NCT01743768|Drug|SB010|Treatment group (n=19), receiving the active drug substance.
322003|NCT01743768|Drug|Placebo|Treatment group (n=19), receiving placebo.
322004|NCT01743755|Drug|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
322005|NCT01743755|Drug|Placebo|Placebo tablet, once daily for four consecutive days
322006|NCT01743742|Drug|Vitamin E, Vitamin C|
322007|NCT01743729|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5.0%
322008|NCT01743729|Drug|Placebo|Placebo for Lifitegrast Ophthalmic Solution 5.0%
322009|NCT01743703|Other|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
322010|NCT01743690|Biological|Probiotic lactobacilli reuteri|
322011|NCT01743690|Drug|Nystatin|
322012|NCT01743690|Drug|fluocinolone|
322013|NCT01743677|Drug|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
322014|NCT01743677|Drug|Placebo|Single dose placebo tablets (5 tablets)
322015|NCT01743677|Drug|Moxifloxacin|Single dose Avelox 400 mg tablet
322016|NCT01743664|Behavioral|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
322017|NCT01743664|Behavioral|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
322104|NCT01742923|Behavioral|Complex tailored intervention|
322024|NCT01743612|Procedure|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
322025|NCT01743612|Procedure|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
322026|NCT01743586|Other|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
322027|NCT01743573|Other|yoga|
322028|NCT01743560|Drug|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
322029|NCT01743560|Drug|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer were to be treated with oral tablet RAD001 at a dose of 10mg daily and oral tablet exemestane 25mg daily. The study treatment for an individual patient was to begin on Study Day 1 and continue until the last patient enrolled completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
322030|NCT01743547|Other|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
322031|NCT01743521|Drug|TPV/PEG-IFN/RBV|"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.~Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg).~Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."
322032|NCT01743508|Procedure|Misoprostol treatment by midwife|Misoprostol treatment by midwife
322033|NCT01743495|Behavioral|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
322034|NCT01743482|Drug|Pazopanib|
322035|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
322036|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
322037|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
322038|NCT01743469|Drug|Tasquinimod|1 capsule: initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5 mg/day or decreasing to 0.25 mg/day after at least 2 weeks.
322039|NCT01743456|Other|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
322040|NCT01743443|Other|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
322041|NCT01743430|Other|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
322042|NCT01743417|Behavioral|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
322043|NCT01743404|Dietary Supplement|Inflaminat|
322044|NCT01743404|Drug|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
322045|NCT01743391|Procedure|Office-hysteroscopy with biopsy|
322046|NCT01743378|Procedure|TAP Block Ropivacaine 0,75 %|
322047|NCT01743378|Procedure|TAP Block Saline 0,9 %|
322048|NCT01743365|Drug|Cisplatin-5FU-Afatinib|
322049|NCT01743339|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
322050|NCT01743339|Behavioral|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
322051|NCT01743326|Procedure|Radio Frequency Denervation|
322052|NCT01743326|Procedure|Local Anesthesia|
322053|NCT01743300|Drug|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
322054|NCT01743300|Drug|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
322055|NCT01743300|Other|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
322056|NCT01743300|Other|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
322057|NCT01743287|Drug|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
322058|NCT01743287|Drug|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
322105|NCT01742923|Behavioral|Usual care|
322106|NCT01742910|Procedure|intraocular lens implantation|
322107|NCT01742897|Drug|TTS-fentanyl|
322059|NCT01743274|Procedure|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.~OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
322060|NCT01743261|Other|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
322061|NCT01743261|Other|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.~the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
322062|NCT01743235|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
322063|NCT01743235|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
322064|NCT01743235|Drug|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
322065|NCT01743222|Genetic|eASC|"First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.~Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
322066|NCT01743222|Drug|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node~Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
322067|NCT01743183|Device|Threshold|The load adjustment was done weekly by a single examiner.
322068|NCT01743170|Other|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
322069|NCT01743157|Drug|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, & 4)
322070|NCT01743144|Drug|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
322071|NCT01743144|Drug|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
322072|NCT01743131|Drug|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
322073|NCT01743131|Drug|placebo|
322074|NCT01743118|Drug|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
322075|NCT01743118|Drug|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
322076|NCT01743118|Drug|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
322077|NCT01743105|Procedure|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
322078|NCT01743105|Procedure|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
322079|NCT01743092|Behavioral|Webinar|Some clients will receive a webinar as part of their treatment.
322080|NCT01743092|Behavioral|Tutuorial workbook|A work book about their addiciton
322081|NCT01743079|Drug|Telbivudine|LdT 600mg QD
322082|NCT01743079|Drug|Lamivudine|LAM 100mg QD
322083|NCT01743066|Dietary Supplement|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
322084|NCT01743053|Device|Standard Care plus ReCell|
322085|NCT01743053|Other|Standard Care|
322086|NCT01743027|Drug|AL-4943A ophthalmic solution|
322087|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
322088|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.1%|
322089|NCT01743027|Drug|AL-4943A ophthalmic solution vehicle|
322090|NCT01743014|Drug|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
322091|NCT01743014|Drug|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
322092|NCT01743001|Drug|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
322093|NCT01743001|Drug|Placebo|Macitentan-matching placebo oral tablet once daily
322094|NCT01742988|Drug|fimepinostat|
322095|NCT01742988|Drug|Rituximab|
322096|NCT01742988|Drug|venetoclax|
322097|NCT01742988|Drug|Bendamustine|
322098|NCT01742975|Device|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
322099|NCT01742962|Procedure|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
322100|NCT01742949|Device|Heated humidification (ThermoSmart)|Heated Humidification (ThermoSmart) Turned On
322101|NCT01742949|Device|No Humidification|Heated Humidification (ThermoSmart) Turn Off
322102|NCT01742936|Device|CoaguChek|Hand held coagulation monitor.
322103|NCT01742936|Other|Hospital Laboratory|Coagulation testing done by hospital laboratory.
322109|NCT01742884|Other|Vehicle|1 drop of the vehicle will be instillated in the eye
322110|NCT01742845|Other|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
322111|NCT01742845|Other|landmark based superfical ropivacaine 4.75 mg/ml injection|
322112|NCT01742832|Drug|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
322113|NCT01742832|Drug|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
322114|NCT01742806|Device|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
322115|NCT01742793|Drug|lenalidomide (Revlimid) and romidepsin (Istodax)|
322116|NCT01742780|Procedure|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
322117|NCT01742767|Drug|Cisplatinum|
322118|NCT01742767|Drug|Pemetrexed|
322119|NCT01742754|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
322120|NCT01742741|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
322121|NCT01742715|Other|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.~Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
322122|NCT01742715|Other|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.~Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
322123|NCT01742715|Other|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
322124|NCT01742702|Drug|Nitroglycerin 0.25 mg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
322125|NCT01742702|Drug|Salbutamol 400 µg (single dose, no longer given since January 2017)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
322126|NCT01742702|Drug|L-arginine (10 min infusion, no longer given since January 2017)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
322127|NCT01742702|Dietary Supplement|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily, no longer given since 2012)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
322128|NCT01742702|Dietary Supplement|Small milk casein-derived polypeptides (12 weeks daily, recordings completed 2011)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed 2011).
322129|NCT01742702|Drug|Bisoprolol (5 mg daily for 3 weeks, recordings completed 2011)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed 2011).
322130|NCT01742689|Drug|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
322131|NCT01742689|Drug|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
322132|NCT01742689|Drug|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
322133|NCT01742676|Drug|ADVAGRAF|oral
322134|NCT01742676|Drug|PROGRAF|oral
322135|NCT01742663|Drug|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
322136|NCT01742663|Drug|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
322137|NCT01742663|Drug|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
322138|NCT01742650|Procedure|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
322139|NCT01742650|Procedure|TightRope|TightRope transfixation of syndesmosis
322140|NCT01742637|Drug|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
322141|NCT01742637|Drug|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
322142|NCT01742637|Drug|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
322143|NCT01742624|Drug|Advagraf|oral
322144|NCT01742624|Drug|Prograf|oral
322146|NCT01742624|Drug|Mycophenolate mofetil|oral
322147|NCT01742611|Drug|ASP1585|oral
322148|NCT01742598|Device|Portico Transapical Aortic Valve System|
322149|NCT01742585|Drug|ASP1585|oral
322150|NCT01742585|Drug|placebo|oral
322151|NCT01742572|Behavioral|Diet|Change in dietary intake
322152|NCT01742559|Procedure|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman & Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
322153|NCT01742559|Procedure|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
322154|NCT01742546|Device|Therapeutic ultrasound combine TENS|"Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.~The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius)."
322155|NCT01742533|Biological|human umbilical cord mesenchymal stem cells|
322156|NCT01742533|Biological|hUCMSCs and hCBMNCs|
322157|NCT01742533|Biological|human cord blood mononuclear cells|
322158|NCT01742533|Drug|Hormone Replacement Therapy|
322159|NCT01742520|Drug|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
322160|NCT01742520|Drug|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
322161|NCT01742507|Device|Resolute Integrity Stent|Resolute Integrity Stent
322162|NCT01742507|Device|Biomatrix stent|Biomatrix stent
322163|NCT01742494|Procedure|Water-jet POEM|Water-jet assisted POEM procedure was performed
322164|NCT01742494|Procedure|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
322165|NCT01742481|Behavioral|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
322166|NCT01742468|Dietary Supplement|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
322167|NCT01742468|Dietary Supplement|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
322168|NCT01742429|Drug|Proton pump inhibitor|
322169|NCT01742429|Drug|Bismuth subsalicylate|
322170|NCT01742429|Drug|Metronidazole|antibiotic
322171|NCT01742429|Drug|Tetracycline|antibiotic
322172|NCT01742429|Drug|Amoxicillin|antibiotic
322173|NCT01742429|Drug|Levofloxacin|antibiotic
322174|NCT01742416|Procedure|Ultrasound|Arterial cannulation facilitated by ultrasound.
322175|NCT01742416|Procedure|Palpation Method|Arterial cannulation by palpation method.
322176|NCT01742403|Radiation|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
322177|NCT01742390|Drug|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
322178|NCT01742390|Drug|risperidone or paliperidone|
322179|NCT01742377|Procedure|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
322180|NCT01742377|Procedure|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
322181|NCT01742377|Procedure|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
322182|NCT01742364|Device|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
322183|NCT01742364|Device|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
322184|NCT01742351|Behavioral|Guided internet-based cognitive behavior therapy|
322185|NCT01742338|Drug|Low Dose Corticosteroids|
322186|NCT01742338|Drug|High Dose Corticosteroids|
322187|NCT01742325|Behavioral|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
322188|NCT01742312|Radiation|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
322189|NCT01742312|Procedure|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
322190|NCT01742312|Other|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
322191|NCT01742299|Drug|STI571|STI571 (imatinib mesylate)
322192|NCT01742286|Drug|LDK378|LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via NG/G tube
322193|NCT01742273|Drug|Vitamin K1|Vitamin K1 to slow vascular calcification
322194|NCT01742260|Procedure|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
322195|NCT01742247|Other|Physiogel|Application of moisturizer on laser-treated area
322196|NCT01742247|Other|Moisturizer|Application of moisturizer on laser-treated area
322197|NCT01742234|Procedure|Organ Donation|People in this study will donate either a lung or kidney
322198|NCT01742221|Biological|HemaMax|single subcutaneous 12 microgram dose of HemaMax
322199|NCT01742221|Drug|Placebo|single subcutaneous dose
322200|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days. Pioneer Group participants were to have completed dosing prior to any study drug administration in Expansion Groups.
322201|NCT01742208|Drug|Placebo|Participants received placebo-matching sotagliflozin tablets once daily for 29 days.
322202|NCT01742208|Drug|Sotagliflozin|Participants received sotagliflozin once daily for 29 days; pioneer participants completed dosing prior to dosing any other study participants.
322203|NCT01742195|Procedure|Oral EBUS insertion|
322204|NCT01742195|Procedure|Nasal EBUS insertion|
322205|NCT01742182|Other|Light exposure|
322206|NCT01742169|Behavioral|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
322207|NCT01742143|Behavioral|The Integrated Cancer Care Access Network (ICCAN)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance."
322208|NCT01742143|Behavioral|Usual and Customary Group (U&C)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed."
322209|NCT01742130|Drug|sodium bicarbonate solution|
322210|NCT01742130|Drug|Isotonic saline|
322211|NCT01742117|Drug|Clopidogrel|Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.
322212|NCT01742117|Drug|Ticagrelor|Subjects will receive Ticagrelor, one 90 mg tablet twice per day by mouth.
322213|NCT01742117|Genetic|Retrospective Genotype testing|Mayo Clinic will use ABI TaqMan assay of three variants in the CYP2C10 gene: *2, *3 and *17
322214|NCT01742117|Genetic|Prospective Genotype testing|Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene: *2, *3 and *17
322215|NCT01742117|Other|Smartphone|Subjects will use their own iOS or Android smartphones to complete surveys and activities which will collect data on outcomes since their PCI, which can be compared to outcomes collected through study coordinator phone calls.
322216|NCT01742091|Drug|LY2541546 - SC|Administered SC
322217|NCT01742091|Drug|LY2541546 - IV|Administered IV
322218|NCT01742091|Drug|Placebo - SC|Administered SC
322219|NCT01742091|Drug|Placebo - IV|Administered IV
322220|NCT01742078|Drug|LY2541546 - IV|Administered IV
322221|NCT01742078|Drug|LY2541546 - SC|Administered SC
322222|NCT01742078|Drug|Placebo|Administered IV or SC
322223|NCT01742065|Other|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
322224|NCT01742052|Drug|MT-1303-Low|
322225|NCT01742052|Drug|MT-1303-Middle|
322226|NCT01742052|Drug|MT-1303-High|
322227|NCT01742052|Drug|Placebo|
322228|NCT01742026|Procedure|Aspergillus PCR technique|Aspergillus DNA PCR technique
322229|NCT01742026|Procedure|Aspergillus AGA technique|Aspergillus AGA technique
322230|NCT01742013|Drug|GCJBP Laennec Inj.|Test drug
322231|NCT01742013|Drug|Placebo|Comparator
322232|NCT01742000|Dietary Supplement|Karinat|
322233|NCT01742000|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
322234|NCT01741987|Other|Optive ®|instilation of 1 drop each eye 4 times per day
322235|NCT01741987|Other|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
322236|NCT01741974|Dietary Supplement|Karinat|
322237|NCT01741974|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
322238|NCT01741961|Procedure|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
322239|NCT01741948|Drug|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.~First appointment (before initiation of HCs):~Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.~3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:~Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).~FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
322396|NCT01740648|Drug|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
322240|NCT01741922|Drug|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
322241|NCT01741922|Drug|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
322242|NCT01741922|Drug|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
322243|NCT01741922|Drug|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
322244|NCT01741909|Behavioral|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
322245|NCT01741896|Procedure|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
322246|NCT01741883|Behavioral|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
322247|NCT01741883|Behavioral|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
322248|NCT01741870|Dietary Supplement|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
322249|NCT01741857|Biological|human umbilical cord derived MSC transplantation for SLE|
322250|NCT01741844|Drug|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
322251|NCT01741831|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
322252|NCT01741818|Other|Measuring IVC collapsibility index by bedside ultrasonography|
322253|NCT01741805|Other|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
322254|NCT01741792|Drug|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
322255|NCT01741779|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
322256|NCT01741779|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
322257|NCT01741779|Other|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
322258|NCT01741766|Other|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
322259|NCT01741753|Drug|BKM120|Orally, every morning
322260|NCT01741753|Drug|Abiraterone|Orally, 1000 mg, every morning
322261|NCT01741753|Drug|Prednisone|Orally, 5 mg, every morning
322262|NCT01741727|Drug|ABT-414|ABT-414 will be administered by intravenous infusion.
322263|NCT01741714|Other|Sham chiropractic manipulative therapy|Sham manipulation
322264|NCT01741714|Other|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
322265|NCT01741701|Drug|Oxaloacetate (OAA)|
322266|NCT01741701|Drug|Placebo|
322267|NCT01741688|Biological|Tocilizumab|Tocilizumab was administered according to the local label.
322268|NCT01741675|Behavioral|Questionnaire and monetary incentive|
322269|NCT01741675|Behavioral|Questionnaire only|
322270|NCT01741662|Other|neuropsychological evaluation|
322271|NCT01741649|Procedure|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
322272|NCT01741649|Procedure|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
322273|NCT01741636|Other|educational intervention|Undergo Survivorship Care Planning
322274|NCT01741636|Other|questionnaire administration|Ancillary studies
322275|NCT01741636|Procedure|quality-of-life assessment|Ancillary studies
322276|NCT01741623|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
322277|NCT01741623|Drug|Bisoprolol|10 mg tablet once a day
322278|NCT01741610|Biological|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
322279|NCT01741597|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
322280|NCT01741597|Other|pharmacological study|Correlative studies
322281|NCT01741597|Biological|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
322282|NCT01741584|Behavioral|stationary bike exercise|
322283|NCT01741584|Behavioral|aerobic|
322284|NCT01741571|Device|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.~Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
322285|NCT01741558|Drug|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
322286|NCT01741558|Drug|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
322287|NCT01741545|Biological|Pegylated-Interferon-lambda|
322288|NCT01741545|Drug|Ribavirin|
322289|NCT01741545|Drug|Daclatasvir|
322290|NCT01741532|Drug|Deferiprone oral solution|Deferiprone 80 mg/mL oral solution will be administered twice daily (b.i.d.) for 18 months. An initial dose of 5 mg/kg b.i.d. will be administered for 6 weeks. The dose will then be escalated to 10 mg/kg b.i.d. and finally to 15 mg/kg b.i.d.
322291|NCT01741532|Drug|Placebo|A deferiprone matching placebo oral solution will be given twice daily for 18 months.
322292|NCT01741519|Drug|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
322293|NCT01741519|Drug|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
322294|NCT01741506|Drug|Dalteparin (Fragmin®)|
322295|NCT01741493|Drug|ABT-494|Oral administration of ABT-494 capsules
322296|NCT01741493|Drug|Placebo|Oral administration of placebo capsules
322297|NCT01741493|Drug|Tofacitinib|Oral administration
322298|NCT01741480|Other|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system monitoring developed at Washington University.
322299|NCT01741480|Other|routine care|
322300|NCT01741467|Behavioral|RT-CGM|Dexcom Seven+
322301|NCT01741454|Drug|Tamsulosin|0.4 mg by mouth once per day.
322302|NCT01741454|Drug|Tolterodine ER|4 mg by mouth once a day.
322303|NCT01741441|Procedure|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
322304|NCT01741428|Behavioral|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
322305|NCT01741415|Behavioral|SIDI|
322306|NCT01741415|Behavioral|SC|
322307|NCT01741402|Device|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
322308|NCT01741402|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
322309|NCT01741389|Drug|"Melatonin (Circadin)"|
322310|NCT01741376|Drug|Progesterone|Progesterone 200 mg twice daily
322311|NCT01741376|Drug|Placebo|
322312|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
322313|NCT01741363|Other|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
322314|NCT01741363|Other|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
322315|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
322316|NCT01741363|Other|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
322317|NCT01741350|Behavioral|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
322318|NCT01741350|Behavioral|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
322319|NCT01741337|Procedure|Adaptive servo-ventilation post-operative treatment for 6 months|
322320|NCT01741324|Dietary Supplement|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
322321|NCT01741324|Dietary Supplement|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
322322|NCT01741324|Dietary Supplement|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
322323|NCT01741311|Behavioral|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
322324|NCT01741311|Behavioral|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
322325|NCT01741298|Behavioral|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
322326|NCT01741285|Drug|Beclomethasone (QVAR)|Small particle treatment
322327|NCT01741285|Drug|Beclomethasone (Clenil)|Course particle beclomethasone
322328|NCT01741285|Drug|Fluticasone|Course particle treatment
322329|NCT01741272|Procedure|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
322330|NCT01741272|Procedure|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
322331|NCT01741259|Drug|Meperidine|
322332|NCT01741233|Genetic|VitDgen|
322333|NCT01741207|Drug|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
322334|NCT01741194|Drug|AC-1204|AC-1204 taken once daily, by mouth
322335|NCT01741194|Drug|Placebo|Placebo taken once daily, by mouth
322336|NCT01741181|Drug|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
322337|NCT01741181|Drug|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
322338|NCT01741168|Other|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
322339|NCT01741168|Other|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
322340|NCT01741155|Drug|SPI-1620 & Docetaxel|"Single Arm & Randomized Part:~On Day 1, the patient will receive standard docetaxel premedication followed by SPI-1620 11 μg/m2 administered intravenously over one minute. Patients will receive docetaxel 10 (±2) minutes following the infusion of SPI-1620. Docetaxel dose is 75 mg/m2 infusion. Patients will continue to receive SPI-1620 plus docetaxel once every 3 weeks until disease progression or intolerable toxicity. Overall 27 patients will be enrolled in the Single Arm Part. If 6 or more responses are observed in this group then the Randomized Part will be initiated. About 100 patient in the experimental arm will receive SPI-1620 & Docetaxel"
322341|NCT01741155|Drug|Docetaxel|"Randomized Part-Control Arm (100 patient):~On Day 1 the patient will receive standard docetaxel premedication followed by docetaxel 75 mg/m2 by infusion over 1 hour. Patients will continue to receive docetaxel once every 3 weeks until disease progression or intolerable toxicity."
322342|NCT01741142|Drug|ABT-436|Subjects receiving ABT-436
322343|NCT01741142|Drug|Escitalopram|Subjects receiving escitalopram
322344|NCT01741142|Drug|Placebo|Subject receiving placebo
322345|NCT01741129|Device|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
322346|NCT01741129|Device|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
322347|NCT01741116|Drug|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
322348|NCT01741103|Drug|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
322349|NCT01741103|Drug|Placebo|Take one by mouth daily for 12 weeks
322350|NCT01741090|Biological|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
322351|NCT01741077|Dietary Supplement|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
322352|NCT01741051|Device|HEPA Filter|
322353|NCT01741038|Biological|AlloStim®|AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
322354|NCT01741038|Procedure|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
322355|NCT01741038|Other|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
322356|NCT01741025|Device|iFuse Implant System|Placement of iFuse implant system via surgery
322357|NCT01741025|Other|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
322358|NCT01741012|Drug|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
322359|NCT01740999|Procedure|silicone arthroplasty|silicone arthroplasty
322360|NCT01740999|Procedure|arthrodesis|arthrodesis
322361|NCT01740986|Drug|SA09012 Low dose|Tablet, b.i.d
322362|NCT01740986|Drug|SA09012 High dose|Tablet, b.i.d
322363|NCT01740986|Drug|Placebo|Tablet, b.i.d
322364|NCT01740960|Drug|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
322365|NCT01740960|Drug|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
322366|NCT01740947|Drug|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
322367|NCT01740934|Other|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
322368|NCT01740934|Other|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
322369|NCT01740921|Drug|Liraglutide|Administered once daily
322370|NCT01740921|Other|diet|reduction of caloric intake to promote weight loss
322371|NCT01740921|Drug|Aspirin|300mg of Aspirin per day
322372|NCT01740908|Other|Hyperbaric Oxygen Treatment|"Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.~All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days."
322373|NCT01740869|Other|Stem cells|
322374|NCT01740856|Other|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
322375|NCT01740856|Other|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
322376|NCT01740843|Device|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
322377|NCT01740830|Device|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
322378|NCT01740817|Drug|Intralipid 20%|30 ml/h for 48 h
322379|NCT01740817|Drug|Saline|30 ml/h for 48 h
322380|NCT01740791|Drug|GS-5816|3 days of monotherapy of GS-5816
322381|NCT01740765|Other|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
322382|NCT01740752|Behavioral|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
322383|NCT01740752|Behavioral|CBT|"weekly manualized higher dose of individual CBT"
322384|NCT01740726|Behavioral|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
322385|NCT01740726|Drug|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
322386|NCT01740713|Drug|Deferiprone, dose level 1|a solution at 80 mg/mL will be administered orally
322387|NCT01740713|Drug|Deferiprone, dose level 2|a solution at 80 mg/mL will be administered orally
322388|NCT01740713|Drug|Deferiprone, dose level 3|a solution at 80 mg/mL will be administered orally
322389|NCT01740700|Device|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
322390|NCT01740687|Device|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
322391|NCT01740687|Procedure|NovaSure|Nova Sure Endometrial Ablation
322392|NCT01740674|Other|Electronic data collection|
322393|NCT01740661|Other|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
322394|NCT01740661|Other|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
322395|NCT01740648|Drug|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
324124|NCT01727336|Drug|Dalantercept and axitinib|
322397|NCT01740648|Radiation|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
322398|NCT01740635|Device|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
322399|NCT01740622|Other|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
322400|NCT01740609|Drug|Placebo|Placebo
322401|NCT01740609|Biological|PF-06342674 Dose A|Single SC Dose
322402|NCT01740609|Biological|PF-06342674 Dose B|Single SC Dose
322403|NCT01740609|Biological|PF-06342674 Dose C|Single SC Dose
322404|NCT01740609|Biological|PF-06342674 Dose D|Single SC Dose
322405|NCT01740609|Biological|PF-06342674 Dose E|Single SC Dose
322406|NCT01740609|Biological|PF-06342674 Dose F|Single IV Dose
322407|NCT01740609|Biological|PF-06342674 Dose G|Single SC Dose
322408|NCT01740609|Biological|PF-06342674 Dose H|Single IV Dose
322409|NCT01740609|Biological|PF-06342674 Dose I|Single SC Dose
322410|NCT01740609|Biological|PF-06342674 Dose J|Single IV Dose
322411|NCT01740596|Device|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
322412|NCT01740583|Device|percutaneous annuloplasty|plication of the mitral valve annulus
322413|NCT01740570|Drug|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I."
322414|NCT01740557|Biological|Aldesleukin|Given IV
322415|NCT01740557|Biological|CXCR2-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
322416|NCT01740557|Drug|Cyclophosphamide|Given IV
322417|NCT01740557|Drug|Fludarabine Phosphate|Given IV
322418|NCT01740557|Other|Laboratory Biomarker Analysis|Correlative studies
322419|NCT01740557|Biological|NGFR-transduced Autologous T Lymphocytes|Given IV
322420|NCT01740557|Other|Quality-of-Life Assessment|Ancillary studies
322421|NCT01740544|Other|Cathodal tDCS|Cathodal tDCS applied over the right PPC
322422|NCT01740544|Other|Sham tDCS|Sham tDCS applied over the right PPC
322423|NCT01740531|Biological|S-303 Treated Red Blood Cells (RBCs)|
322424|NCT01740531|Biological|Conventional, untreated Red Blood Cells|
322425|NCT01740518|Drug|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
322426|NCT01740505|Behavioral|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
322427|NCT01740505|Behavioral|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
322428|NCT01740505|Behavioral|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
322429|NCT01740492|Drug|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
322430|NCT01740492|Drug|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
322431|NCT01740492|Other|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
322432|NCT01740479|Procedure|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
322433|NCT01740453|Drug|ropivacaine 2 mg/ml|single
322434|NCT01740440|Device|BMR Face|BMR Face used in accordance with manufacturer IFU
322435|NCT01740427|Drug|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
322436|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
322437|NCT01740427|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
322438|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
322481|NCT01740128|Other|Harness-supported multimodal balance training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
323088|NCT01735357|Dietary Supplement|Placebo - olive oil (BP specification)|
322439|NCT01740414|Drug|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
322440|NCT01740414|Drug|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
322441|NCT01740401|Drug|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
322442|NCT01740388|Drug|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
322443|NCT01740388|Drug|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
322444|NCT01740375|Procedure|esophagectomy|esophagectomy
322445|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
322446|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
322447|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
322448|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
322449|NCT01740336|Drug|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
322450|NCT01740336|Drug|Placebo|Placebo matching to GDC-0941
322451|NCT01740336|Drug|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
322452|NCT01740323|Drug|Placebo|daily placebo for 6 weeks
322453|NCT01740323|Drug|Curcumin|500 mg BID
322454|NCT01740310|Behavioral|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
322455|NCT01740297|Drug|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
322456|NCT01740297|Drug|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
322457|NCT01740284|Drug|Grazax + Aerius|
322458|NCT01740284|Drug|Grazax + placebo|
322459|NCT01740271|Drug|Epirubicin|
322460|NCT01740258|Radiation|Radiation Therapy|
322461|NCT01740258|Drug|Temozolomide|
322462|NCT01740258|Drug|Bevacizumab|
322463|NCT01740245|Device|Chlorhexidine vaginal suppositories|
322464|NCT01740245|Device|Polyhexamethylene biguanide vaginal suppositories|
322465|NCT01740232|Procedure|trephination|Artroscopic meniskal repair with trephination.
322466|NCT01740232|Procedure|Normal meniscal repair|Artroscopic meniskal repair without trephination.
322467|NCT01740219|Behavioral|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
322468|NCT01740219|Behavioral|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
322469|NCT01740206|Drug|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
322470|NCT01740206|Other|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
322471|NCT01740193|Procedure|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
322472|NCT01740193|Procedure|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
322473|NCT01740180|Other|Data entry|"This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.~These data are extracted from patient records by each participating center and collected in an e-CRF."
322474|NCT01740167|Behavioral|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
322475|NCT01740154|Procedure|transcranial magnetic stimulation|Undergo TMS
322476|NCT01740154|Procedure|electromyography|Undergo EMG
322477|NCT01740154|Other|survey administration|Ancillary studies
322478|NCT01740154|Drug|sunitinib malate|Given PO
322479|NCT01740141|Procedure|Plexus brachialis block|
322480|NCT01740128|Device|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
323089|NCT01735357|Dietary Supplement|DHA-rich triacylglycerol oil|
322482|NCT01740102|Procedure|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
322483|NCT01740089|Drug|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
322484|NCT01740089|Drug|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
322485|NCT01740089|Drug|Ribavirin|800-1400 mg/day orally
322486|NCT01740076|Other|soy nuts|
322487|NCT01740063|Drug|DAS181-F02 formulation|
322488|NCT01740063|Drug|DAS181-F04 formulation|
322489|NCT01740063|Drug|Placebo|
322490|NCT01740050|Dietary Supplement|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
322491|NCT01740050|Procedure|RYGB|
322492|NCT01740050|Procedure|LAGB|
322493|NCT01740037|Other|Specialized outpatient AF Clinic|
322494|NCT01740037|Other|Usual Care|
322495|NCT01740024|Biological|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
322496|NCT01740011|Procedure|Laparoscopic surgery|
322497|NCT01739998|Dietary Supplement|functional oil|
322498|NCT01739998|Dietary Supplement|Placebo|
322499|NCT01739985|Drug|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
322500|NCT01739985|Drug|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
322501|NCT01739972|Drug|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
322502|NCT01739972|Drug|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
322503|NCT01739933|Drug|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
322504|NCT01739933|Drug|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS2 study steering committee.
322505|NCT01739920|Other|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
322506|NCT01739920|Other|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
322507|NCT01739907|Other|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
322508|NCT01739894|Drug|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
322509|NCT01739881|Device|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
322510|NCT01739868|Other|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:~1 visit the first year (inclusion visit)~1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes~1 intermediary visit (in 3 years) or activated by the following conditions:~Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)~Normalization of the glycemia (fasting blood glucose < 1 g/l)"
322511|NCT01739855|Drug|Calciferol, calcium carbonate|
322512|NCT01739842|Dietary Supplement|Kudzu extract|
322513|NCT01739829|Device|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
322514|NCT01739829|Device|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
322515|NCT01739816|Behavioral|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.~The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.~As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
322516|NCT01739803|Behavioral|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
322517|NCT01739790|Drug|N-Acetylcysteine|1800 mg twice daily for 8 weeks
322518|NCT01739790|Drug|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
322519|NCT01739777|Biological|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
322520|NCT01739777|Other|Controls|Autologous Serum will administrated as placebo
322521|NCT01739764|Drug|Vemurafenib|Vemurafenib will be given based on the last dose of the antecedent study (minimum 480 mg orally BID).
322522|NCT01739751|Device|pedometers|portable device that estimate the number of steps walked daily
322523|NCT01739738|Device|Ureteral Stent|patients who need to receive stent as per standard of care
322524|NCT01739725|Device|Stent insertion|The patient will receive the helical stent
322525|NCT01739712|Behavioral|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
322526|NCT01739712|Behavioral|Fixed Sleep Duration|There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
322527|NCT01739699|Drug|Acetaminophen|
322528|NCT01739699|Drug|Placebo|
322529|NCT01739686|Other|CASA Intervention|"CASA Intervention~The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:~A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.~A social worker provides structured counseling targeting adjustment to illness and depression if present.~A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.~Most of the nurse and social worker visits are by phone."
322530|NCT01739673|Other|Ultraviolet-A and riboflavin|
322531|NCT01739660|Drug|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
322532|NCT01739647|Drug|AZD3293|Oral solution
322533|NCT01739647|Drug|Placebo|Oral solution
322534|NCT01739634|Drug|CASAD|CASAD is provided in 500mg capsules.
322535|NCT01739621|Drug|Proellex 12 mg|
322536|NCT01739621|Drug|Proellex 24 mg|
322537|NCT01739608|Other|Invitation to screening|Invitation to screening
322538|NCT01739595|Drug|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
322539|NCT01739595|Drug|Placebo|Oral capsule taken one time daily for 3 months
322540|NCT01739582|Drug|Androxal|
322541|NCT01739569|Other|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
322542|NCT01739556|Drug|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
322543|NCT01739543|Device|Hem-Avert|Application of Hem-Avert
322544|NCT01739530|Biological|Repaircell|allogenic differentiated adipocyte
322545|NCT01739517|Drug|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
322546|NCT01739504|Procedure|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
322547|NCT01739504|Biological|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.~AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.~Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
322548|NCT01739491|Drug|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
322549|NCT01739478|Other|Packing of abscess cavity|
322550|NCT01739478|Other|External dressing|Application of external dressing whilst abscess cavity heals
322551|NCT01739465|Procedure|Self expanding metallic stent (SEMS)|Self expanding metallic stent
322552|NCT01739465|Procedure|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
322553|NCT01739465|Procedure|Photodynamic therapy (PDT)|Photodynamic therapy
322554|NCT01739439|Drug|gemcitabine hydrochloride|Given IV
322555|NCT01739439|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
322556|NCT01739439|Radiation|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
322557|NCT01739439|Radiation|radiosurgery|Undergo radiosurgery boost
322558|NCT01739439|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
322559|NCT01739426|Device|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
322560|NCT01739413|Procedure|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
322561|NCT01739400|Drug|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
322562|NCT01739387|Device|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
322563|NCT01739374|Other|reduced mesh implants|mesh for pelvic floor reinforcement
322564|NCT01739361|Drug|Acetaminophen|
322565|NCT01739361|Drug|placebo|
322566|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
322567|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
322568|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
322569|NCT01739348|Drug|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
322570|NCT01739348|Drug|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
323090|NCT01735344|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
322571|NCT01739335|Drug|Mifepristone Oral Tablet [Korlym]|2 Mifepristone 300 MG Oral Tablets once daily (600mg total) for 7 days
322572|NCT01739335|Drug|Placebo Oral Tablet|2 Placebo Oral Tablets once daily for 7 days
322573|NCT01739322|Biological|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
322574|NCT01739309|Drug|Abemaciclib|Administered orally
322575|NCT01739296|Other|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
322576|NCT01739296|Other|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
322577|NCT01739283|Other|GIP|
322578|NCT01739283|Other|GLP-1|
322579|NCT01739283|Other|Saline|
322580|NCT01739270|Procedure|supraclavicular brachial plexus block|
322581|NCT01739257|Behavioral|Medical Lecture|
322582|NCT01739257|Behavioral|Dramatic Reading|
322583|NCT01739244|Drug|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
322584|NCT01739244|Drug|Placebo|Ocular topical administration of placebo for 14 consecutive days
322585|NCT01739231|Biological|ACE527|"3x10^9 cfu ACE527 vaccine strain. Comprised of three genetically attenuated and engineered strains of E. coli, with antigen profiles covering a wide range of ETEC surface colonization factor antigens (CFA/I, CFA/II [CS1, CS2, CS3] and CFA/IV [CS5, CS6]) and also expressing LTB, the inactive subunit of LT (ETEC heat labile toxin). The constituent strains of ACE527 were:~ACAM2025: a live, attenuated, CFA/I, LTB positive strain~ACAM2022: a live, attenuated, CS5, CS6, LTB positive strain, and~ACAM2027: a live, attenuated, CS1, CS2, CS3, LTB positive strain."
322586|NCT01739231|Biological|dmLT|A derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine (13). These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.
322587|NCT01739231|Biological|CeraVacx placebo|CeraVacx® is used to neutralize gastric acidity upon ingestion of vaccine. It was also used as the placebo in this study. CeraVacx® was prepared from the commercial product (Cera Products, Inc.); 9.5 grams were added to sterile water for each dose and mixed. Each dose contained 7 grams of rice syrup, 2 grams of sodium bicarbonate, and 0.5 grams of trisodium citrate.
322588|NCT01739231|Biological|H10407 challenge strain|Approximately 2 x 10^7 cfu of the fully virulent ETEC strain. Previously administered to 91 volunteers at this challenge dose by the CIR clinical team over the previous 4 years in conjunction with other Phase 1/2b trials.
322589|NCT01739218|Drug|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula ([participant's glomerular filtration rate + 25] multiplied by the target area under the concentration-time curve [AUC] of 5 milligrams per milliliter per minute [mg/mL/min]), as intravenous [IV] infusion over 30-60 minutes [min] every 3 weeks).
322590|NCT01739218|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared [mg/m^2] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
322591|NCT01739218|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram [mg/kg] as IV infusion over 30-90 min every 3 weeks.
322592|NCT01739205|Behavioral|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
322593|NCT01739192|Drug|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
322594|NCT01739179|Procedure|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
322595|NCT01739179|Procedure|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
322596|NCT01739166|Other|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.~During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
322597|NCT01739153|Other|Dietary intervention: CHEESE (High cheese intake)|
322598|NCT01739153|Other|Dietary intervention: MEAT (High Meat intake)|
322599|NCT01739153|Other|Dietary intervention: CARB (High Carbohydrate intake)|
322600|NCT01739140|Behavioral|Yoga|
322601|NCT01739127|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
322602|NCT01739127|Drug|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
322603|NCT01739114|Procedure|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
322604|NCT01739114|Procedure|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
322605|NCT01739101|Behavioral|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
322606|NCT01739088|Other|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
322607|NCT01739088|Other|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
322608|NCT01739062|Genetic|Genetic risk assessment|
322609|NCT01739049|Drug|Liraglutide|liraglutide
322610|NCT01739049|Behavioral|Diet and Exercise|diet and exercise
322611|NCT01739036|Biological|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
322612|NCT01739036|Biological|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
322613|NCT01739036|Biological|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
322614|NCT01739036|Biological|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
322615|NCT01739036|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
322616|NCT01739023|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
322617|NCT01738997|Device|Dilation 10 sec|
322618|NCT01738997|Device|Dilation 2 min|
322619|NCT01738984|Behavioral|MomZing Web Program|Online web platform that is accessed via a television connected to internet
322620|NCT01738984|Behavioral|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
322621|NCT01738971|Other|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
322622|NCT01738971|Other|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
322623|NCT01738958|Biological|L. retueri|two tablets a day for 6 weeks
322624|NCT01738958|Biological|Placebo|
322625|NCT01738945|Drug|Amlodipine|10 mg/day for 12 weeks
322626|NCT01738919|Procedure|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
322627|NCT01738919|Procedure|Operative treatment with extension block technique|Surgery with extension block technique. 6 weeks.
322628|NCT01738906|Other|Orange juice|
322629|NCT01738906|Other|maltodextrin|
322630|NCT01738906|Other|Vodka|
322631|NCT01738906|Other|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
322632|NCT01738906|Other|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
322633|NCT01738893|Drug|Gabapentin 300 mg|Test product
322634|NCT01738893|Drug|Gabapentin 300 mg|Reference product
322635|NCT01738880|Drug|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
322636|NCT01738880|Drug|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
322637|NCT01738867|Drug|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
322638|NCT01738867|Drug|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
322639|NCT01738867|Drug|Placebo|Matching placebo capsules to GSK1521498 or NTX
322640|NCT01738854|Procedure|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
322641|NCT01738841|Biological|Priorix-Tetra™|Single dose, subcutaneous injection
322642|NCT01738841|Other|Safety data collection|Recording of adverse events, using diary cards
322643|NCT01738815|Drug|Valproic Acid|500 mg orally, once daily for up to 30 days
322644|NCT01738802|Dietary Supplement|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
322645|NCT01738802|Drug|Placebo|This group will take a placebo.
322646|NCT01738763|Dietary Supplement|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
322647|NCT01738750|Other|Cost Information Included|
322648|NCT01738737|Device|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
322649|NCT01738737|Other|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
322650|NCT01738737|Device|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
322651|NCT01738724|Drug|Dienogest|Dienogest 2mg pills daily during 6 months
322652|NCT01738724|Drug|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
322653|NCT01738724|Drug|Desogestrel|Desogestrel 75mcg pills daily during six months
322654|NCT01738711|Behavioral|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
322655|NCT01738698|Drug|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
322656|NCT01738698|Drug|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
322657|NCT01738698|Drug|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
322658|NCT01738698|Drug|Placebo|Oral administration once-daily for 12 weeks
322659|NCT01738685|Behavioral|Behavioral Intervention.|
322660|NCT01738685|Other|Nutritional Education.|
322661|NCT01738672|Drug|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
322662|NCT01738659|Dietary Supplement|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
322663|NCT01738646|Drug|Vorinostat|
322664|NCT01738646|Drug|Bevacizumab|
322665|NCT01738633|Behavioral|nutritional counseling|
322666|NCT01738633|Behavioral|respirology counseling|
322667|NCT01738620|Behavioral|psychological counseling|
322668|NCT01738620|Behavioral|prevention of sleep disorders in ICU|
322669|NCT01738607|Dietary Supplement|Psyllium|
322670|NCT01738607|Dietary Supplement|Gum Arabic|Gum acacia dietary fiber
322671|NCT01738607|Dietary Supplement|carboxymethylcellulose|dietary fiber
322672|NCT01738607|Dietary Supplement|Placebo|
322673|NCT01738594|Drug|carfilzomib|Given IV
322674|NCT01738594|Drug|romidepsin|Given IV
322675|NCT01738594|Other|laboratory biomarker analysis|Correlative studies
322676|NCT01738581|Device|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
322677|NCT01738581|Behavioral|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
322678|NCT01738581|Behavioral|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
322679|NCT01738568|Behavioral|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at ~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
322680|NCT01738568|Behavioral|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
322681|NCT01738555|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
322682|NCT01738555|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
322683|NCT01738542|Drug|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
322684|NCT01738542|Drug|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
322685|NCT01738542|Drug|Statins|
322686|NCT01738542|Drug|Antihypertensive therapy|
322687|NCT01738529|Device|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
322688|NCT01738516|Procedure|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
322689|NCT01738516|Procedure|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
322690|NCT01738503|Drug|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and given on alternate sides of the participant's abdomen.
322691|NCT01738503|Drug|Subutex|Participants were inducted and stabilized over a 14-day period (study days -14 to -1) on SUBUTEX sublingual tablets. Tablets are placed under the tongue until dissolved.
322692|NCT01738490|Device|Bone anchored hearing implant|
322693|NCT01738477|Biological|Boostrix|Single dose intramuscular administration.
322694|NCT01738451|Drug|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
322695|NCT01738451|Drug|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
322696|NCT01738438|Drug|Cabozantinib|
322697|NCT01738425|Drug|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
322698|NCT01738425|Drug|GIC-1001 matching placebo|"Single ascending doses (SAD) [equivalent to active arm, 125 mg to 1000 mg]~Multiple ascending doses, TID over 7 successive days [equivalent to the active arm, 125 mg to 500 mg]"
322699|NCT01738412|Device|Neurokeeper stroke detector|Monitoring stroke patients
322700|NCT01738399|Dietary Supplement|Coffee|
322701|NCT01738399|Dietary Supplement|Placebo|
322702|NCT01738373|Drug|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
322703|NCT01738360|Drug|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.~The course of study is as follows :~Pre-inclusion between D-35 and D-15~Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.~A telephone contact between D32 and D34~A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
322704|NCT01738347|Drug|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
322705|NCT01738334|Behavioral|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
322706|NCT01738334|Behavioral|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
322707|NCT01738321|Other|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
322708|NCT01738308|Procedure|Healing Touch|"When enter PACU + usual standard of care.~The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
322709|NCT01738308|Procedure|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
322710|NCT01738295|Drug|Donepezil administration|
322711|NCT01738295|Drug|Placebo administration|
322712|NCT01738282|Drug|Baclofen|
322713|NCT01738282|Drug|Placebo (for baclofen)|
322714|NCT01738256|Behavioral|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
322715|NCT01738256|Behavioral|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
322716|NCT01738256|Behavioral|No intervention|No intervention
322717|NCT01738243|Drug|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
322718|NCT01738243|Drug|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
322719|NCT01738217|Procedure|Fluobeam|
322720|NCT01738191|Drug|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
322721|NCT01738191|Drug|Placebo|
322722|NCT01738178|Drug|Caffeine|
322723|NCT01738178|Drug|Placebo|
322764|NCT01737853|Drug|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
322765|NCT01737840|Drug|Pantoprazole|33 patients
322766|NCT01737840|Drug|Ranitidine|33 patients
323091|NCT01735344|Drug|Lisinopril|40 mg tablet once a day
322724|NCT01738152|Other|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
322725|NCT01738152|Behavioral|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
322726|NCT01738139|Drug|Imatinib Mesylate|Given PO
322727|NCT01738139|Biological|Ipilimumab|Given IV
322728|NCT01738113|Other|Open Kinetic Chain exercise|"Hamstrings strengthening exercise~Quadriceps strengthening exercise~Hamstrings stretch~Hip extensors and abductors strengthening~Calf-muscles stretching~Strength exercise of ankle dorsiflexors & plantar flexors"
322729|NCT01738113|Other|Closed kinetic chain exercise|"Foot sliding from sitting~Seated Toe Raises~Hamstrings and quadriceps co-contraction from sitting~Bridging exercise~Sitting-to-standing~Side-to side, forward and backwards weight shifting~Lunge exercise~Squatting exercise~Standing Toe Raises~Standing Hamstrings Stretch"
322730|NCT01738100|Drug|Ticagrelor|
322731|NCT01738100|Drug|Clopidogrel|
322732|NCT01738100|Drug|Morphine Sulfate|
322733|NCT01738100|Drug|Saline|
322734|NCT01738087|Drug|NEXThaler 100/6 mcg DPI|
322735|NCT01738087|Drug|Flixotide Accuhaler 500 mcg|Active comparator
322736|NCT01738087|Drug|NEXThaler 200/6 mcg DPI|
322737|NCT01738087|Drug|NEXThaler placebo|Placebo comparator
322738|NCT01738074|Biological|trivalent rotavirus genetic reassortment vaccine|
322739|NCT01738074|Biological|Placebo|
322740|NCT01738061|Behavioral|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
322741|NCT01738048|Procedure|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
322742|NCT01738035|Drug|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
322743|NCT01738035|Other|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
322744|NCT01738022|Other|Administration of gas mixtures|
322745|NCT01738009|Other|Induction of flow limitation|
322746|NCT01737996|Drug|BI 207127 + faldaprevir|fixed dose combination
322747|NCT01737983|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10^10 colony-forming units) for 6 months.
322748|NCT01737983|Dietary Supplement|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
322749|NCT01737957|Device|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
322750|NCT01737957|Device|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
322751|NCT01737944|Drug|Methotrexate (MTX)|Vibex MTX Device
322752|NCT01737931|Drug|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
322753|NCT01737931|Drug|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
322754|NCT01737918|Procedure|TOT|
322755|NCT01737918|Drug|solifenacin|
322756|NCT01737905|Drug|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
322757|NCT01737905|Drug|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
322758|NCT01737892|Drug|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
322759|NCT01737892|Drug|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
322760|NCT01737879|Drug|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
322761|NCT01737879|Drug|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
322762|NCT01737866|Drug|AMG 423|omecamtiv mecarbil
322763|NCT01737853|Drug|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
323092|NCT01735318|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
322767|NCT01737827|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
322768|NCT01737814|Drug|Saline|
322769|NCT01737814|Drug|MST-188|
322770|NCT01737801|Procedure|Lung function test|Lung function test.
322771|NCT01737788|Procedure|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
322772|NCT01737775|Procedure|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
322773|NCT01737762|Biological|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
322774|NCT01737762|Biological|Vehicle|
322775|NCT01737749|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
322776|NCT01737736|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
322777|NCT01737723|Device|Neurokeeper stroke detector|Monitoring stroke patients
322778|NCT01737710|Biological|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
322779|NCT01737710|Biological|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
322780|NCT01737697|Drug|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
322781|NCT01737697|Drug|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
322782|NCT01737697|Drug|Placebo (acute phase)|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
322783|NCT01737697|Drug|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
322784|NCT01737684|Drug|Vibegron|50 mg tablet, oral
322785|NCT01737671|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
322786|NCT01737671|Drug|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
322787|NCT01737671|Drug|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
322788|NCT01737658|Other|Exercise Program|Exercise Program for Obese Adolescents
322789|NCT01737632|Behavioral|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
322790|NCT01737632|Behavioral|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
322791|NCT01737619|Procedure|Computed Tomography|Undergo PET/CT
322792|NCT01737619|Drug|Indocyanine Green Solution|Given via superficial and deep cervical injection
322793|NCT01737619|Other|Laboratory Biomarker Analysis|Correlative studies
322794|NCT01737619|Procedure|Lymph Node Mapping|Undergo lymph node mapping
322795|NCT01737619|Procedure|Lymphadenectomy|Undergo full lymphadenectomy
322796|NCT01737619|Procedure|Positron Emission Tomography|Undergo PET/CT
322797|NCT01737606|Device|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
322798|NCT01737593|Drug|Acetaminophen|
322799|NCT01737580|Drug|resiquimod|
322800|NCT01737580|Drug|placebo gel|
322801|NCT01737567|Other|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
322802|NCT01737567|Other|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
322803|NCT01737554|Other|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
322804|NCT01737541|Drug|Fluoxetine|
322805|NCT01737541|Drug|Placebo|
322806|NCT01737528|Procedure|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
322807|NCT01737515|Other|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
322808|NCT01737502|Drug|Auranofin|Given PO
322809|NCT01737502|Drug|Sirolimus|Given PO
322810|NCT01737502|Other|Laboratory Biomarker Analysis|Correlative studies
322811|NCT01737502|Other|Pharmacological Study|Correlative studies
322812|NCT01737489|Behavioral|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
322856|NCT01737125|Radiation|Magnetic Resonance Imaging (MRI)|"spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences~MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
323093|NCT01735318|Drug|Lisinopril|40 mg tablet once a day
322813|NCT01737489|Behavioral|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
322814|NCT01737476|Procedure|Transcranial Magnetic Stimulation. PFC|
322815|NCT01737463|Procedure|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
322816|NCT01737450|Drug|BKM120|
322817|NCT01737437|Drug|group C|0.9% normal saline was applied to trachea and laryngoscope blade
322818|NCT01737437|Drug|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
322819|NCT01737437|Drug|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
322820|NCT01737437|Drug|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
322821|NCT01737424|Drug|LC28-0126|LC28-0126
322822|NCT01737424|Drug|Placebo|Placebo
322823|NCT01737411|Drug|solifenacin|
322824|NCT01737411|Procedure|cesa/vasa|surgical repair of USL
322825|NCT01737398|Drug|Inotersen|
322826|NCT01737398|Drug|Placebo|
322827|NCT01737385|Procedure|Measurement with O2C|Measurement of microcirculation using O2C light probes.
322828|NCT01737359|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
322829|NCT01737359|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
322830|NCT01737359|Drug|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
322831|NCT01737346|Drug|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
322832|NCT01737320|Drug|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:~Intervention group - antibiotic treatment stopped on day 7~Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
322833|NCT01737320|Drug|accepted prolonged antibiotic treatment|
322834|NCT01737307|Drug|Fluoride varnish|Fluoride Varnish (NaF 5%)
322835|NCT01737307|Other|Oral Hygiene|Oral hygiene followed.
322836|NCT01737307|Drug|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
322837|NCT01737294|Drug|Qutenza exposure|Cutaneous patch
322838|NCT01737281|Behavioral|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
322839|NCT01737281|Behavioral|Usual care|Usual smoking cessation care from VA clinical staff.
322840|NCT01737268|Drug|FK949E|Oral tablet
322841|NCT01737255|Other|Whole body MRI|Individuals will undergo whole body and brain MRI
322842|NCT01737255|Other|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
322843|NCT01737229|Device|Application of Biodentine™ (RD94), dentin substitute|
322844|NCT01737216|Drug|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
322845|NCT01737216|Drug|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
322846|NCT01737203|Drug|Viagra|50 mg tablet on Day 1 of each period
322847|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
322848|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
322849|NCT01737190|Other|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.~A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
322850|NCT01737177|Drug|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)~Bendamustine: 70 mg/m2 on day 2 and 3 every 28~Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course~Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8~CONSOLIDATION PHASE (courses 5-6)~Patients in CR and PR at the end of the induction phase~Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.~Rituximab: 375 mg/m2 on day 1 every 28 days~MAINTENANCE PHASE (courses 7-24)~Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)~- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
322851|NCT01737164|Behavioral|Aerobic Exercise|
322852|NCT01737151|Radiation|stereotactic body radiation therapy|Undergo SBRT
322853|NCT01737151|Radiation|four fraction split-course SBRT|four fraction split-course SBRT
322854|NCT01737138|Procedure|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
322855|NCT01737138|Drug|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
322950|NCT01736436|Procedure|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
322857|NCT01737112|Drug|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
322858|NCT01737099|Dietary Supplement|DHA-O|
322859|NCT01737099|Dietary Supplement|Fish oil|
322860|NCT01737099|Dietary Supplement|Placebo|
322861|NCT01737086|Dietary Supplement|Lactobacillus reuteri DSM 17938 and zinc sulphate|
322862|NCT01737086|Dietary Supplement|placebo|
322863|NCT01737073|Behavioral|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
322864|NCT01737073|Behavioral|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
322865|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tip and usual clinical care
322866|NCT01737060|Device|Reverse total shoulder arthroplasty|
322867|NCT01737034|Other|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
322868|NCT01737021|Other|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
322869|NCT01737008|Drug|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
322870|NCT01737008|Radiation|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
322871|NCT01737008|Drug|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
322872|NCT01736995|Behavioral|Functional Family Therapy|
322873|NCT01736995|Behavioral|Motivational Enhancement Tx/Cognitive Behavioral Tx|
322874|NCT01736995|Behavioral|Contingency Management|
322875|NCT01736982|Behavioral|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
322876|NCT01736982|Other|Standard of Care|Standard smoking cessation counseling
322877|NCT01736982|Other|Standard of Care|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)]
322878|NCT01736982|Other|Standard of Care|Breath sample monitoring
322879|NCT01736969|Device|RD047-023|Experimental hydrogel
322880|NCT01736969|Device|Predicate Device|
322881|NCT01736956|Procedure|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
322882|NCT01736943|Drug|Bortezomib|Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
322883|NCT01736943|Drug|Doxil|Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
322884|NCT01736930|Device|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
322885|NCT01736917|Drug|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
322886|NCT01736917|Drug|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
322887|NCT01736917|Drug|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
322888|NCT01736904|Drug|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
322889|NCT01736904|Drug|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
322890|NCT01736891|Drug|Rasagiline|Tablets, qd
322891|NCT01736891|Drug|Placebo|Tablets, qd
322892|NCT01736878|Drug|Sorafenib|
322893|NCT01736865|Drug|Cholecalciferol|
322894|NCT01736865|Drug|Placebo|
322895|NCT01736852|Device|CRB|Labor induction using the CRB and Pitocin
322896|NCT01736852|Drug|Pitocin|Labor induction using Pitocin alone
322897|NCT01736826|Biological|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
322898|NCT01736826|Biological|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 & 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
322899|NCT01736826|Biological|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
322900|NCT01736813|Drug|Maraviroc|Twelve patients with 300 mg/bid
322901|NCT01736800|Drug|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
322902|NCT01736800|Drug|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
322903|NCT01736787|Dietary Supplement|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
322904|NCT01736787|Dietary Supplement|Placebo|Placebo (1g/day)
322905|NCT01736774|Other|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
322906|NCT01736774|Other|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
322907|NCT01736761|Drug|Darunavir, Ritonavir and Rilpivirine|
322908|NCT01736748|Behavioral|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
322909|NCT01736748|Behavioral|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
322910|NCT01736735|Drug|CLP|
322911|NCT01736735|Drug|placebo|
322912|NCT01736722|Device|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
322913|NCT01736709|Biological|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
322914|NCT01736696|Drug|tofacitinib|5 mg BID For 13 days and once on Day 14
322915|NCT01736696|Drug|tofacitinib|10 mg BID for 13 days and once on Day 14*
322916|NCT01736696|Drug|tofacitinib|20 mg BID for 13 days and once on Day 14
322917|NCT01736696|Drug|tofacitinib|30 mg BID for 13 days and once on Day 14
322918|NCT01736696|Drug|tofacitinib|60 mg tablet once a day (QD) for 14 days
322919|NCT01736696|Drug|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
322920|NCT01736683|Drug|Sotatercept|Sotatercept is supplied as a lyophilized powder that is reconstituted using Water for Injection (WFI) and administered as a subcutaneous injection (SC) injection by the study staff at the clinical site.
322921|NCT01736670|Drug|Triamcinolone Acetonide spray|
322922|NCT01736670|Drug|Triamcinolone acetonide cream|
322923|NCT01736670|Drug|Alcohol spray|
322924|NCT01736657|Device|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
322925|NCT01736644|Device|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
322926|NCT01736644|Device|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
322927|NCT01736631|Behavioral|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark & Wells (Clark & Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
322928|NCT01736618|Device|S-ICD System|
322929|NCT01736605|Procedure|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
322930|NCT01736605|Procedure|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
322931|NCT01736592|Drug|SAR422459 administered in previous study TDU13583|No study drug given in LTS13588
322932|NCT01736579|Drug|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
322933|NCT01736566|Other|Family History + Whole Genome Sequencing|"Doctors and their patients receive a Genome Report and a Family History report.~There are two sections of the Genome Report:~The General Genome Report, which include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.~The Cardiac Risk Supplement, which contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.~Extension Phase: Experimental: Family History + Whole Genome Sequencing~*In the main study participants are randomized to either the Experimental or Other Arm, in the Extension phase of the study all participants are in the Experimental Arm."
322934|NCT01736566|Other|Family History Only|Doctors and their patients receive a Family History report.
322935|NCT01736540|Device|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2*, respectively).
322936|NCT01736527|Drug|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
322937|NCT01736514|Drug|febuxostat|oral
322938|NCT01736514|Drug|Allopurinol|oral
322939|NCT01736501|Other|Genetics education at baseline|
322940|NCT01736501|Other|Hypothetical genomic scenarios at follow-up|
322941|NCT01736488|Drug|Fimasartan|Fimasartan 60mg
322942|NCT01736488|Drug|Atenolol|Atenolol 50mg
322943|NCT01736475|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
322944|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
322945|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
322946|NCT01736475|Biological|PEGylated Recombinant Factor VIII|On-demand treatment
322947|NCT01736462|Drug|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
322948|NCT01736449|Drug|Bevacizumab|
322949|NCT01736436|Drug|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
322951|NCT01736436|Procedure|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
322952|NCT01736423|Drug|YM060|oral
322953|NCT01736410|Drug|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
322954|NCT01736397|Drug|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
322955|NCT01736397|Drug|Placebo|
322956|NCT01736384|Procedure|Gastric bypass or cholecystectomy|
322957|NCT01736371|Drug|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
322958|NCT01736371|Drug|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
322959|NCT01736371|Drug|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
322960|NCT01736358|Drug|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
322961|NCT01736358|Drug|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
322962|NCT01736345|Genetic|Genetic Providers|Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.
322963|NCT01736345|Other|Visual Aids|Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.
322964|NCT01736345|Other|Post-Disclosure Asessments|Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.
322965|NCT01736345|Other|In-person Clinical Follow-Up|Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner
322966|NCT01736345|Other|6 Month and 12 Month Assessments|At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
322967|NCT01736332|Drug|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
322968|NCT01736332|Other|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
322969|NCT01736280|Other|Standard of Care|Any evaluation or treatment under this protocol will be based on standard practice as related to the subjects's digestive disorder.These include but are not limited to biobehavioral interventions including bowel retraining, biofeedback, and other lifestyle interventions, all of which have been shown to be beneficial in the treatment of this type of chronic functional bowel disorder.
322970|NCT01736267|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
322971|NCT01736254|Drug|Evacetrapib|
322972|NCT01736254|Drug|Gemfibrozil|
322973|NCT01736241|Drug|LY3053102|
322974|NCT01736241|Drug|Placebo|
322975|NCT01736228|Device|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
322976|NCT01736215|Drug|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
322977|NCT01736202|Biological|fat orally|Oral ingestion of palm oil or canola oil at timepoint zero
322978|NCT01736189|Drug|Adalimumab|Pre-filled syringe, administered by subcutaneous injection
322979|NCT01736176|Drug|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
322980|NCT01736176|Procedure|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
322981|NCT01736176|Drug|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
322982|NCT01736163|Drug|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
322983|NCT01736163|Drug|131I|28 mCi or ≥ 1.036 GBq.
322984|NCT01736163|Other|Thyroid Hormone Withdrawal|Stop taking hormone therapy
322985|NCT01736150|Drug|Placebo|"Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.~If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
322986|NCT01736150|Drug|Sevelamer carbonate|"Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.~If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
323052|NCT01735643|Other|waiting|waiting for 12 weeks
323053|NCT01735630|Drug|ELND005|
323054|NCT01735630|Drug|Placebo|
323058|NCT01735591|Dietary Supplement|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
323094|NCT01735292|Device|Automatic Respiration Transfer System- Timer|
323095|NCT01735279|Drug|fish oil|
322987|NCT01736137|Other|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
322988|NCT01736124|Other|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
322989|NCT01736124|Other|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
322990|NCT01736111|Behavioral|one way text|
322991|NCT01736111|Behavioral|Personal feedback|
322992|NCT01736098|Other|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
322993|NCT01736085|Behavioral|Telephone counseling|Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
322994|NCT01736085|Behavioral|Voucher|"Subjects will receive a voucher for nicotine patches.~Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date."
322995|NCT01736085|Drug|Nicotine patches|Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
322996|NCT01736072|Procedure|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
322997|NCT01736072|Procedure|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
322998|NCT01736059|Drug|CD34+ bone marrow stem cells intravitreal|
322999|NCT01736046|Radiation|CT Enterography|"Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease."
323000|NCT01736033|Drug|Tamsulosin|1 tablet(0.2mg) orally q.d.
323001|NCT01736033|Drug|Finasteride|1 tablet(5mg) orally q.d.
323002|NCT01736033|Drug|Placebo|1 tablet(0.2mg) orally q.d.
323003|NCT01736020|Drug|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
323004|NCT01736020|Drug|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
323005|NCT01736020|Drug|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
323006|NCT01736020|Drug|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
323007|NCT01736020|Drug|Placebo|Placebo
323008|NCT01736007|Device|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
323009|NCT01736007|Device|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
323010|NCT01735994|Behavioral|Healthy Weight|Eating Disorder Prevention Program for Athletes
323011|NCT01735994|Other|Brochure|Brochure on the Female athlete triad
323012|NCT01735981|Other|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
323013|NCT01735981|Other|hand-held video game|hand-held video games
323014|NCT01735968|Drug|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
323015|NCT01735955|Drug|AMN107|AMN107 (nilotinib)
323016|NCT01735942|Drug|Ingenol mebutate|
323017|NCT01735942|Procedure|cryotherapy|
323018|NCT01735929|Procedure|Neck Liposuction and Ultrasound Treatment|
323019|NCT01735929|Procedure|Sham Treatment|
323055|NCT01735617|Drug|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
323056|NCT01735604|Biological|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
323057|NCT01735604|Other|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
323130|NCT01735006|Biological|HEV vaccine|3 doses at month 0,1 and 6
323020|NCT01735916|Device|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.~The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.~Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
323021|NCT01735916|Device|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
323022|NCT01735903|Procedure|Arm A - Non-Diabetic, Gait and Balance|"Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.~Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet."
323023|NCT01735890|Drug|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
323024|NCT01735877|Other|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
323025|NCT01735877|Other|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
323026|NCT01735864|Drug|Indirubin 200μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment containing 200 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
323027|NCT01735864|Drug|Indirubin 100 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 100 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
323028|NCT01735864|Drug|Indirubin 50 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 50 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
323029|NCT01735864|Drug|Indirubin 10 μg/g|"Dosage form: Ointment~Dose(s): Each gram of ointment contains 10 μg of indirubin~Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
323030|NCT01735851|Drug|Thoracic epidural analgesia|
323031|NCT01735851|Procedure|Bilateral Paravertebral block|
323032|NCT01735825|Device|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
323033|NCT01735825|Device|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
323034|NCT01735825|Device|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
323035|NCT01735812|Device|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
323036|NCT01735786|Device|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
323037|NCT01735747|Radiation|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
323038|NCT01735747|Drug|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
323039|NCT01735747|Drug|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
323040|NCT01735747|Drug|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
323041|NCT01735734|Device|Air cooling to CM site|
323042|NCT01735721|Procedure|Open Sinus Lift|"A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).~The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material."
323043|NCT01735708|Behavioral|HIVPASS|
323044|NCT01735708|Other|Health Education|
323045|NCT01735682|Device|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
323046|NCT01735682|Behavioral|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
323047|NCT01735682|Behavioral|Control|The control treatment involves exercises of the upper limbs.
323048|NCT01735669|Drug|Remifentanil|
323049|NCT01735669|Drug|Nitrous Oxide|
323050|NCT01735656|Device|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
323051|NCT01735643|Device|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
323059|NCT01735591|Dietary Supplement|Probiotic|Capsules with 3x10^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
323060|NCT01735539|Dietary Supplement|15g EAA bolus|Oral; in aqueous solution
323061|NCT01735539|Dietary Supplement|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
323062|NCT01735539|Dietary Supplement|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
323063|NCT01735513|Device|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
323064|NCT01735487|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
323065|NCT01735487|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
323066|NCT01735487|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
323067|NCT01735487|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
323068|NCT01735487|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
323069|NCT01735474|Other|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.~The manual technique includes:~stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
323070|NCT01735474|Other|Placebo|Usual care
323071|NCT01735461|Dietary Supplement|Calcium Carbonate|There is a regimen for dietary supplement intake that will be provided to study participants.
323072|NCT01735448|Other|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.~The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.~We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
323073|NCT01735448|Other|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
323074|NCT01735448|Other|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
323075|NCT01735435|Other|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
323076|NCT01735422|Drug|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
323077|NCT01735422|Drug|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
323078|NCT01735422|Drug|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
323079|NCT01735409|Drug|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
323080|NCT01735409|Drug|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
323081|NCT01735409|Drug|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
323082|NCT01735396|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
323083|NCT01735383|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
323084|NCT01735383|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
323085|NCT01735370|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
323086|NCT01735370|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
323087|NCT01735357|Dietary Supplement|EPA-rich triacylglycerol oil|
324125|NCT01727336|Drug|Placebo and axitinib|
323096|NCT01735266|Other|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
323097|NCT01735266|Other|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
323098|NCT01735253|Procedure|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
323099|NCT01735240|Drug|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
323100|NCT01735240|Drug|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
323101|NCT01735227|Drug|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
323102|NCT01735227|Drug|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
323103|NCT01735214|Drug|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
323104|NCT01735201|Drug|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
323105|NCT01735201|Drug|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
323106|NCT01735201|Drug|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
323107|NCT01735201|Drug|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
323108|NCT01735175|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
323109|NCT01735175|Drug|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
323110|NCT01735149|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
323111|NCT01735149|Dietary Supplement|Placebo|Placebo (34.5g/day)
323112|NCT01735136|Dietary Supplement|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
323113|NCT01735136|Dietary Supplement|Placebo|Placebo (10g/day)
323114|NCT01735123|Dietary Supplement|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
323115|NCT01735110|Procedure|transfemoral intervention (TFI)|
323116|NCT01735110|Procedure|Transradial intervention|
323117|NCT01735097|Dietary Supplement|Vitamin E|Vitamin E (200 mg, soft capsule)
323118|NCT01735097|Dietary Supplement|Nigella sativa|Nigella sativa (200 mg, soft capsule)
323119|NCT01735097|Dietary Supplement|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
323120|NCT01735084|Biological|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."
323121|NCT01735084|Biological|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
323122|NCT01735071|Drug|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
323123|NCT01735071|Drug|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.~Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.~Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.~From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
323124|NCT01735058|Drug|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
323125|NCT01735058|Drug|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
323126|NCT01735045|Device|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
323127|NCT01735045|Device|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
323128|NCT01735019|Drug|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
323129|NCT01735006|Biological|HPV Vaccine|3 doses at month 0,1 and 6
323131|NCT01734993|Drug|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
323132|NCT01734980|Procedure|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
323133|NCT01734967|Device|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:~The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.~nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).~Image data will be stored digitally for offline analysis."
323134|NCT01734967|Procedure|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
323135|NCT01734954|Procedure|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
323136|NCT01734954|Procedure|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
323137|NCT01734954|Drug|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
323138|NCT01734954|Device|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
323139|NCT01734954|Device|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
323140|NCT01734954|Drug|supplemental oxygen|supplemental oxygen during the block and/or during surgery
323141|NCT01734954|Drug|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
323142|NCT01734954|Drug|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
323143|NCT01734954|Procedure|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
323144|NCT01734941|Drug|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
323145|NCT01734941|Drug|Placebo|
323146|NCT01734928|Drug|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
323147|NCT01734928|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
323148|NCT01734928|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [>75 years old] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
323149|NCT01734915|Device|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
323150|NCT01734902|Drug|Hyoscine butylbromide|sugar coated tablets for oral administration
323151|NCT01734902|Drug|Hyoscine butylbromide|drops for oral administration
323152|NCT01734889|Drug|Nitisinone|Oral suspension
323153|NCT01734876|Behavioral|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
323154|NCT01734876|Behavioral|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
323155|NCT01734863|Radiation|External Beam Radiotherapy|
323156|NCT01734850|Drug|Busulfan|Intravenous busulfan
323157|NCT01734850|Biological|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
323158|NCT01734850|Biological|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
323159|NCT01734837|Device|DS-Ligature Clip|
323160|NCT01734824|Drug|Denosumab|sc RANKL-inhibitor
323161|NCT01734824|Drug|Teriparatide|daily subcutaneous injection of teriparatide
323162|NCT01734824|Drug|Placebo Denosumab|one subcutaneous injection denosumab placebo
323163|NCT01734824|Drug|Placebo Teriparatide|daily subcutaneous placebo injection
323164|NCT01734811|Biological|Biological vaccine|daily spray (2 puff of 100 µL) for six months
323165|NCT01734798|Radiation|Radiation|
323166|NCT01734798|Drug|gemcitabine and cisplatin|
323167|NCT01734798|Other|Radiotherapy and Drug|
323168|NCT01734785|Drug|Linagliptin|tablet
323169|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
323170|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
323171|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
323172|NCT01734785|Drug|Empaglifozin placebo + Linagliptin placebo|Matching Empaglifozin + Linagliptin low dose
323173|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
323174|NCT01734772|Drug|dabigatran etexilate|multiple doses of dabigatran
323175|NCT01734772|Drug|dabigatran etexilate|medium dose dabigatran
323176|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
323177|NCT01734772|Drug|ticagrelor|multiple doses of ticagrelor
323178|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
323179|NCT01734772|Drug|dabigatran etexilate|single dose of dabigatran
324126|NCT01727297|Device|REVEAL Implantable Cardiac Monitor|
323180|NCT01734759|Drug|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
323181|NCT01734746|Procedure|Tracerinjection|The intervention concerns the tracerinjection for detection of the sentinel node.
323182|NCT01734733|Other|NTCELL|
323183|NCT01734707|Dietary Supplement|Allicor|
323184|NCT01734707|Drug|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
323185|NCT01734694|Drug|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;~Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
323186|NCT01734694|Drug|Ceftaroline|"Dose based on package insert labeling~CrCL > 50 mL/min: 600 mg IV q12h~CrCL 31-50 mL/min: 400 mg q12h~CrCL 15-30 mL/min: 300 mg q12h~CrCL < 15mL/min: 200 mg q12h;"
323187|NCT01734694|Drug|Daptomycin|"Dose based on renal function and literature dosing recommendations~CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h~CrCL < 30 mL/min: 6 - 10 mg/kg IV q48h"
323188|NCT01734694|Drug|Linezolid|600 mg IV/PO q12h
323189|NCT01734681|Drug|G-202|
323190|NCT01734668|Device|In Vitro Diagnostic device to aid in diagnosis|
323191|NCT01734616|Behavioral|Old Exercise|
323192|NCT01734616|Dietary Supplement|Old Acute Cocoa|
323193|NCT01734616|Dietary Supplement|Old 7 Day Cocoa|
323194|NCT01734603|Procedure|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.~Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.~Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .~Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
323195|NCT01734603|Procedure|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)~Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.~Increase :~Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
323196|NCT01734590|Dietary Supplement|Carbohydrate based food mix 1|Carbohydrate based food
323197|NCT01734590|Dietary Supplement|Carbohydrate based food mix 2|Carbohydrate based food
323198|NCT01734590|Dietary Supplement|Control carbohydrate based food|Carbohydrate based food
323199|NCT01734577|Procedure|Dry needling|Sterile monofilament needles
323200|NCT01734577|Procedure|Sham needling|Applicator tubes from the sterile monofilament needles
323201|NCT01734564|Biological|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
323202|NCT01734564|Radiation|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
323203|NCT01734551|Drug|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is <0.1mg/kg/day, may discontinue."
323204|NCT01734551|Drug|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
323205|NCT01734538|Dietary Supplement|Omega-3 Complete|
323206|NCT01734538|Dietary Supplement|Placebo capsule|
323207|NCT01734525|Drug|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
323208|NCT01734512|Drug|Everolimus|Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.
323209|NCT01734499|Behavioral|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
323253|NCT01734174|Procedure|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
323254|NCT01734174|Procedure|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
323210|NCT01734499|Behavioral|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
323211|NCT01734499|Behavioral|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
323212|NCT01734486|Drug|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
323213|NCT01734486|Drug|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
323214|NCT01734473|Dietary Supplement|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
323215|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
323216|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
323217|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
323218|NCT01734473|Dietary Supplement|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
323219|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
323220|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
323221|NCT01734447|Drug|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
323222|NCT01734421|Other|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
323223|NCT01734421|Device|Cell phone Aplication for Smarth Phone|
323224|NCT01734408|Biological|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
323225|NCT01734408|Biological|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
323226|NCT01734408|Biological|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
323227|NCT01734408|Biological|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
323228|NCT01734408|Biological|0/0.5ml placebo|0/0.5ml placebo
323229|NCT01734395|Drug|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
323230|NCT01734382|Drug|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants less than [<] 30 kg) or 8 mg/kg (for participants </=30 kg) Q2W/Q3W/Q4W.
323231|NCT01734356|Other|Skin biopsies|
323232|NCT01734343|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
323233|NCT01734343|Device|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
323234|NCT01734330|Behavioral|Cognitive behavioral therapy in group|
323235|NCT01734330|Drug|Nicotine replacement|
323236|NCT01734317|Device|Mepilex Transfer Ag|A soft silicone wound contact layer.
323237|NCT01734304|Biological|DC vaccination for postremission therapy in AML|Vaccination with TLR7/8-matured DCs electroporated with mRNA encoding WT1, PRAME, and CMVpp65
323238|NCT01734291|Behavioral|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
323239|NCT01734278|Other|No intervention|This is a non-interventional study.
323240|NCT01734265|Drug|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
323241|NCT01734265|Drug|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
323242|NCT01734252|Drug|Argatroban|Start: Argatroban dose is 0.05 µg/kg/min (patients with hepatic impairment, after cardiac surgery) until maximum: 10 µg/kg/min
323243|NCT01734239|Biological|Pneumovax™ 23|Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
323244|NCT01734226|Dietary Supplement|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
323245|NCT01734226|Dietary Supplement|Placebo|Placebo (3.94g/day)
323246|NCT01734213|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
323247|NCT01734213|Dietary Supplement|Placebo|Placebo (1.5g/day)
323248|NCT01734200|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
323249|NCT01734200|Dietary Supplement|Placebo|Placebo (1.5g/day)
323250|NCT01734187|Dietary Supplement|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
323251|NCT01734187|Dietary Supplement|Placebo|Placebo (30g/day)
323252|NCT01734174|Procedure|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
323255|NCT01734161|Drug|Dexamethasone|8mg IV dexamethesone given
323256|NCT01734161|Drug|Placebo|Subjects randomized to placebo receive 50cc normal saline
323257|NCT01734148|Behavioral|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
323258|NCT01734135|Other|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
323259|NCT01734122|Other|Questionnaires / Observational Assessments|Includes QUEST, PDQ-39, FTM, and Neuropsych evaluation
323260|NCT01734109|Device|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
323261|NCT01734096|Other|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
323262|NCT01734096|Drug|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
323263|NCT01734083|Device|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
323264|NCT01734083|Behavioral|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
323265|NCT01734070|Other|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
323266|NCT01734057|Drug|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day)
323267|NCT01734057|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
323268|NCT01734044|Drug|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
323269|NCT01734044|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
323270|NCT01734005|Dietary Supplement|Red Ginseng|Red Ginseng (1.4g/day)
323271|NCT01734005|Dietary Supplement|Placebo|Placebo (1.4g/day)
323272|NCT01733992|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
323273|NCT01733992|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
323274|NCT01733992|Drug|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
323275|NCT01733992|Drug|Placebo|Placebo, single and multiple ascending dose
323276|NCT01733979|Dietary Supplement|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
323277|NCT01733979|Dietary Supplement|Placebo|Placebo (1g/day)
323278|NCT01733979|Dietary Supplement|Heme-Iron|Heme-Iron (1g/day)
323279|NCT01733979|Dietary Supplement|Organic Iron|Organic Iron (1g/day)
323280|NCT01733966|Drug|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
323281|NCT01733966|Drug|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
323282|NCT01733953|Drug|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
323283|NCT01733953|Drug|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
323284|NCT01733940|Device|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
323285|NCT01733940|Device|Application of a dressing without clorhexidine gluconate|
323286|NCT01733927|Device|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
323287|NCT01733914|Procedure|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
323288|NCT01733914|Other|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
323324|NCT01733732|Other|SYSTANE® Gel|
323325|NCT01733719|Procedure|ER plus RFA|
323326|NCT01733719|Procedure|ER plus APC|2 litres/minute, 70 watts
323372|NCT01733329|Drug|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
323373|NCT01733329|Drug|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
323374|NCT01733316|Drug|RP103|
323375|NCT01733316|Drug|Cystagon®|
324127|NCT01727284|Procedure|MR-guided cryoablation|
323289|NCT01733901|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
323290|NCT01733901|Procedure|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
323291|NCT01733888|Device|Office Bleaching with 35 % Hydrogen Peroxide|In this group before starting the procedure the teeth intended to be treated will be cleaned with pumice and after that cheek retractors will be placed and exposed lip surface will be covered with petroleum gel. Thereafter, teeth will be dried and gingival Barrier will be applied to both arches, slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds . Once the gingival barrier will be cured then homogeneous mixing of the powder and liquid will be done in powder pot, followed by application of thick layer of gel to all teeth undergoing treatment. The gel will be then left in place for 8 minutes and after that the gel will be removed using a surgical aspirator tip.
323292|NCT01733888|Device|Icon Infiltration|In this group after taking pre-operative photographs the fluorosed tooth will be isolated using rubber dam and the Resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. For this purpose, after rubber dam application tooth surface will be dried using cotton rolls and air syringe. Icon Etchant will be applied and left for 2 minutes followed by rinsing and air drying for 30 sec. After complete etching, Drying agent (99% ethanol), as supplied in the Icon kit. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds followed by cleaning of the surface with pumice and rubber polishing cup and rinsing with water for 30 sec. After application, patient will be instructed neither to eat nor brush their teeth for 45 minutes.
323293|NCT01733888|Device|Icon Infiltration twice|"In this group application of the resin infiltration shall be done similar to the procedure as explained for intervention Icon infiltration, but the resin infiltrant shall be applied twice."
323294|NCT01733888|Device|Bleaching+Icon Infiltration|"In this group vital bleaching will be done using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia), as explained in intervention bleaching; followed by wash over period of 20 days. After 20 days the patient will be recalled and on the day of appointment initially a new preoperative photograph shall be taken, then the fluorosed tooth will be isolated using rubber dam and the Resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions, similar to intervention Icon Infiltration. For this group a postoperative photograph shall be taken after the application of RI and then the circle of post-operative recall shall be counted from here, that is, 1week, 1 month and 6 months respectively."
323295|NCT01733875|Drug|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
323296|NCT01733875|Drug|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
323297|NCT01733875|Drug|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
323298|NCT01733875|Drug|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
323299|NCT01733875|Drug|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
323300|NCT01733875|Drug|Placebo|A single dose of placebo will be administered orally once a day.
323301|NCT01733875|Drug|CC-220|CC-220 4 mg will be administered orally once a day
323302|NCT01733875|Drug|CC-220|CC-220 6 mg will be administered orally once a day
323303|NCT01733875|Drug|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
323304|NCT01733862|Other|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:~Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
323305|NCT01733849|Other|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
323306|NCT01733849|Other|Data collection|Log books
323307|NCT01733836|Drug|Metformin|
323308|NCT01733836|Drug|placebo|
323309|NCT01733823|Radiation|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
323310|NCT01733810|Other|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
323311|NCT01733797|Device|Wooden spatula|Lollipop sticks placed between incisors
323312|NCT01733797|Device|Therabite|Hand held device placed in mouth that exercises the jaw
323313|NCT01733784|Other|Induced central apneas|
323314|NCT01733771|Other|CAM treatments|CAM treatments last 10-30 minutes
323315|NCT01733758|Drug|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
323316|NCT01733758|Drug|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
323317|NCT01733758|Drug|Placebo|Albiglutide matching placebo will be available as a pen injector
323318|NCT01733758|Drug|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
323319|NCT01733745|Other|SYSTANE® Lid Wipes|Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
323320|NCT01733745|Other|SYSTANE® BALANCE|Lubricant Eye Drops
323321|NCT01733745|Dietary Supplement|SYSTANE® Vitamins|
323322|NCT01733745|Other|Microfiber towels (as warm compresses, with or without saline eye drops)|
323323|NCT01733732|Other|SYSTANE® BALANCE Lubricant Eye Drops|
323327|NCT01733706|Device|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
323328|NCT01733706|Other|Standard counseling|standard counseling
323329|NCT01733693|Drug|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
323330|NCT01733693|Drug|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
323331|NCT01733680|Drug|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
323332|NCT01733680|Behavioral|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
323333|NCT01733667|Device|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
323334|NCT01733667|Device|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
323335|NCT01733654|Biological|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
323336|NCT01733602|Device|transcranial direct current stimulation|
323337|NCT01733589|Drug|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
323338|NCT01733589|Drug|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
323339|NCT01733589|Drug|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
323340|NCT01733589|Other|laboratory biomarker analysis|
323341|NCT01733589|Other|CT perfusion imaging|
323342|NCT01733576|Device|HD-tDCS|
323343|NCT01733563|Procedure|Soft drink consumption|
323344|NCT01733550|Device|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
323345|NCT01733550|Device|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
323346|NCT01733550|Device|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
323347|NCT01733537|Other|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
323348|NCT01733537|Behavioral|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
323349|NCT01733524|Behavioral|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
323350|NCT01733524|Behavioral|Picture of a fish|Participants will receive a picture of a betta fish.
323351|NCT01733485|Drug|Aspirin|500 mg/8 h for 5 days
323352|NCT01733485|Drug|Indomethacin|25 mg/8 h for 5 days
323353|NCT01733472|Drug|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
323354|NCT01733472|Drug|RA-arm|Intrathecal (i.e. spinal) anesthesia with isobaric bupivacaine 15 mg administered intrathecally at L4-L5.
323355|NCT01733459|Drug|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
323356|NCT01733459|Drug|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
323357|NCT01733459|Drug|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
323358|NCT01733459|Drug|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
323359|NCT01733446|Other|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
323360|NCT01733433|Procedure|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
323361|NCT01733420|Drug|Biodentine pulpotomy|
323362|NCT01733420|Drug|White MTA pulpotomy|
323363|NCT01733420|Drug|Tempophore pulpotomy|
323364|NCT01733407|Drug|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
323365|NCT01733407|Drug|placebo|400mg/kg/d divided TID for year 1 only.
323366|NCT01733394|Drug|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
323367|NCT01733394|Drug|lamotrigine|
323368|NCT01733355|Radiation|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
323369|NCT01733342|Device|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
323370|NCT01733342|Procedure|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
323371|NCT01733342|Device|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
323418|NCT01732900|Other|Morphology|Embryos selected for transfer will be based upon morphology alone.
323376|NCT01733303|Behavioral|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
323377|NCT01733290|Drug|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
323378|NCT01733290|Drug|Normal saline instillation|Normal saline instillation
323379|NCT01733277|Other|Magnetic Resonance Imaging (MRI)|All participants from both arms will be subjected to MRI
323380|NCT01733238|Drug|PNT2258|
323381|NCT01733212|Drug|Ginger|Ginger is an herb. The rhizome (underground stem) is used as a spice and also as a medicine. It can be used fresh, dried and powdered, or as a juice or oil. Two capsules (1g each) of dry powdered ginger are given, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
323382|NCT01733212|Drug|Placebo Oral Tablet|Two capsules (1g each) of placebo, one capsule a half-hour before induction of anesthesia and the second 2h after surgery.
323383|NCT01733199|Other|questionnaires|Summons of patients and filling questionnaire.
323384|NCT01733186|Biological|CARTISTEM®|
323385|NCT01733173|Procedure|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
323386|NCT01733147|Drug|Omega-3 free fatty acids|Baseline assessment: Measure waist and hip circumference, height, weight. Complete Gastroesophageal Reflux Questionnaire (GERQ). Blood draw for serum free fatty acid (FFA) profile. Clinical baseline blood draw: INR, LDL, AST and ALT. Single slice CT of abdomen. Endoscopy performed with biopsies, brushings, and mucosal impedance testing. Randomized to ω3 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects and reinforce compliance. Repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a blood draw as outlined at baseline, and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the GERQ.
323387|NCT01733147|Drug|Placebo|Baseline assessment: Measure waist and hip circumference, height, weight. Complete Gastroesophageal Reflux Questionnaire (GERQ). Blood draw for serum free fatty acid (FFA) profile. Clinical baseline blood draw: INR, LDL, AST and ALT. Single slice CT of abdomen. Endoscopy performed with biopsies, brushings, and mucosal impedance testing. Randomized to ω3 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects and reinforce compliance. Repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a blood draw as outlined at baseline, and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the GERQ.
323388|NCT01733134|Drug|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
323389|NCT01733134|Drug|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
323390|NCT01733121|Drug|NBI-98854|25 mg capsule
323391|NCT01733121|Drug|NBI-98854|50 mg capsule
323392|NCT01733121|Drug|Placebo|
323393|NCT01733108|Drug|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
323394|NCT01733108|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
323395|NCT01733095|Drug|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
323396|NCT01733069|Device|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
323397|NCT01733056|Biological|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
323398|NCT01733043|Drug|Dexmedetomidine|
323399|NCT01733043|Drug|Placebo|
323400|NCT01733030|Drug|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
323401|NCT01733030|Drug|Seromycin|
323402|NCT01733017|Behavioral|Sodium reduction|Teaching and skill building to reduce dietary sodium
323403|NCT01733017|Dietary Supplement|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
323404|NCT01733017|Dietary Supplement|rice bran oil capsules|placebo capsules
323405|NCT01733017|Behavioral|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
323406|NCT01733004|Drug|MM-141|
323407|NCT01732991|Device|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
323408|NCT01732978|Behavioral|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.~Listening tests:~Tests will be conducted playbacks with the father and mother separately, and with a staff"
323409|NCT01732965|Other|Phototherapy|
323410|NCT01732965|Other|Phototherapy and Photochemotherapy|
323411|NCT01732926|Drug|Idelalisib|150 mg tablet administered orally twice daily
323412|NCT01732926|Drug|Rituximab|375 mg/m^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
323413|NCT01732926|Drug|Bendamustine|90 mg/m^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
323414|NCT01732926|Drug|Placebo|Tablet administered orally twice daily
323415|NCT01732913|Drug|Placebo|Tablets administered orally twice daily
323416|NCT01732913|Drug|Rituximab|375 mg/m^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
323417|NCT01732913|Drug|Idelalisib|150 mg tablets administered orally twice daily
323419|NCT01732900|Other|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
323420|NCT01732887|Other|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,~General training applications~Memory training applications~Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
323421|NCT01732874|Drug|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
323422|NCT01732874|Drug|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
323423|NCT01732861|Drug|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
323424|NCT01732861|Drug|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
323425|NCT01732848|Drug|BMS-986094/INX-08189|
323426|NCT01732848|Drug|Placebo matching BMS-986094/INX-08189|
323427|NCT01732835|Device|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
323428|NCT01732822|Drug|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
323429|NCT01732822|Drug|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
323430|NCT01732809|Drug|group A|isovolumetric (0.02 mL) doses of 2 units of ABO injected on one side of the forehead and 2 units of ONA injected on the contralateral side
323431|NCT01732809|Drug|group B|Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.
323432|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
323433|NCT01732796|Drug|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
323434|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
323435|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
323436|NCT01732796|Drug|BI 201335 (Faldaprevir)|24 weeks of BI 201335
323437|NCT01732796|Drug|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
323438|NCT01732796|Drug|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
323439|NCT01732796|Drug|Faldaprevir (BI 201335)|24 weeks of 201335
323440|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
323441|NCT01732783|Other|Panitumumab + Chemotherapy|Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
323442|NCT01732770|Biological|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
323443|NCT01732770|Drug|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
323444|NCT01732770|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
323445|NCT01732770|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
323446|NCT01732757|Drug|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
323447|NCT01732757|Drug|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
323448|NCT01732757|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
323449|NCT01732744|Other|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
323450|NCT01732744|Other|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
323451|NCT01732744|Other|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
323452|NCT01732744|Other|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
323453|NCT01732731|Other|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
323454|NCT01732718|Drug|Atorvastatin|40 mg tablet by mouth daily for 6 weeks
323455|NCT01732718|Drug|Placebo|Matching placebo tablet by mouth daily for 6 weeks
323456|NCT01732705|Behavioral|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
323457|NCT01732692|Drug|MOVIPREP|MOVIPREP solution
323458|NCT01732679|Other|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
323459|NCT01732666|Drug|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
323460|NCT01732666|Drug|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
323461|NCT01732666|Drug|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
323462|NCT01732653|Other|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
323463|NCT01732653|Other|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
323464|NCT01732640|Drug|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
323465|NCT01732640|Drug|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
323466|NCT01732640|Drug|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
323467|NCT01732640|Drug|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
323468|NCT01732640|Radiation|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
323469|NCT01732627|Biological|MenACYW Conjugate Vaccine|0.5 mL, Intramuscular
323470|NCT01732627|Biological|Meningococcal Polysaccharide Vaccine Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous
323471|NCT01732614|Procedure|Topcon Endpoint Management laser|
323472|NCT01732601|Behavioral|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
323473|NCT01732601|Behavioral|Standard Care|Treatment at step-down facilities
323474|NCT01732588|Drug|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
323475|NCT01732588|Drug|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
323476|NCT01732588|Drug|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
323477|NCT01732575|Behavioral|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
323478|NCT01732562|Other|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
323479|NCT01732549|Drug|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
323480|NCT01732549|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
323481|NCT01732536|Drug|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
323482|NCT01732536|Procedure|Sham procedure|In-office bilateral sham procedure
323483|NCT01732536|Drug|Mometasone furoate nasal spray|Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
323484|NCT01732510|Drug|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
323485|NCT01732510|Drug|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
323486|NCT01732497|Device|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
323487|NCT01732484|Procedure|intraocular lens implantation|
323488|NCT01732471|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
323489|NCT01732458|Drug|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
323490|NCT01732458|Drug|Placebo to Aprepitant|
323491|NCT01732458|Drug|Ondansetron|Administered IV at a dose of 4 mg for participants >40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants <1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
323492|NCT01732458|Drug|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
323493|NCT01732445|Drug|ruxolitinib phosphate|Given PO
323494|NCT01732445|Drug|danazol|Given PO
323495|NCT01732445|Other|quality-of-life assessment|Ancillary studies
323496|NCT01732445|Other|questionnaire administration|Ancillary studies
323497|NCT01732419|Behavioral|Home-based training|Home-based exercise training for cardiac patients.
323498|NCT01732419|Behavioral|Centre-based training|Usual exercise training in an outpatient setting.
323499|NCT01732393|Drug|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
323500|NCT01732393|Drug|Placebo|
323501|NCT01732380|Drug|Raltitrexed|
323502|NCT01732380|Drug|Oxaliplatin|
323503|NCT01732380|Radiation|Radiotherapy|
323504|NCT01732367|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
323505|NCT01732367|Drug|Tenofovir|Tenofovir 300mg QD for 96 weeks
323506|NCT01732341|Device|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
323507|NCT01732341|Device|VISION balloon-expandable stent|"STEMI treatment with a VISION balloon-expandable stent~--------------------------------------------------------------------------------"
323508|NCT01732328|Dietary Supplement|Calcium plus vitamin D|
323509|NCT01732315|Behavioral|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
323510|NCT01732302|Other|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
323511|NCT01732289|Genetic|genes|Draw blood for genetic screening
323512|NCT01732276|Drug|gefitinib|
323513|NCT01732263|Drug|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
323514|NCT01732250|Drug|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
323515|NCT01732250|Drug|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
323516|NCT01732237|Drug|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
323517|NCT01732237|Drug|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
323518|NCT01732237|Drug|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
323519|NCT01732224|Drug|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
323520|NCT01732224|Drug|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
323521|NCT01732211|Biological|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
323522|NCT01732211|Other|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
323523|NCT01732198|Biological|NU300|
323524|NCT01732198|Biological|ActHIB|
323525|NCT01732198|Biological|Prevnar 13|
323526|NCT01732185|Genetic|Patient|Blood and histological samples will be done at day of the inclusion.
323527|NCT01732172|Other|Sperm sample|Sperm sample
323528|NCT01732159|Other|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
323529|NCT01732146|Drug|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
323530|NCT01732146|Drug|Placebo|
323531|NCT01732133|Device|Nexfin|
323532|NCT01732120|Procedure|Off-clamp partial nephrectomy|
323533|NCT01732107|Drug|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
323534|NCT01732094|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
323535|NCT01732094|Drug|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
323536|NCT01732094|Drug|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
323537|NCT01732068|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
323538|NCT01732068|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
323539|NCT01732068|Drug|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
323540|NCT01732055|Behavioral|Partner-Assisted Interpersonal Psychotherapy|
323541|NCT01732055|Other|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
323542|NCT01732029|Other|Normobaric hypoxia chamber|
323543|NCT01732016|Other|Normobaric hypoxia chamber|
323544|NCT01732003|Dietary Supplement|Omega-3 Complete|
323545|NCT01732003|Dietary Supplement|Placebo Pill|
323546|NCT01731990|Drug|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
323547|NCT01731990|Drug|Placebo|Matching placebo of Canakinumab
323584|NCT01731730|Drug|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
323548|NCT01731977|Behavioral|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
323549|NCT01731964|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
323550|NCT01731964|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
323551|NCT01731951|Drug|Imetelstat|Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
323552|NCT01731938|Biological|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
323553|NCT01731938|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
323554|NCT01731925|Drug|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
323555|NCT01731925|Drug|Placebo (for sunitinib)|
323556|NCT01731925|Drug|Sunitinib|Sunitinib 37.5 mg daily
323557|NCT01731912|Drug|Degarelix|Given SC
323558|NCT01731912|Radiation|External Beam Radiation Therapy|Undergo standard EBRT
323559|NCT01731912|Other|Laboratory Biomarker Analysis|Correlative studies
323560|NCT01731899|Drug|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
323561|NCT01731886|Procedure|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will undergo autologous peripheral blood stem cell transplantation on day 0.
323562|NCT01731886|Drug|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
323563|NCT01731886|Drug|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
323564|NCT01731886|Procedure|Stem cell collection|Peripheral stem cell collection will be performed at marrow recovery, usually when white blood cell (WBC) is >2500 x 109 cells/liter; platelet count is >20 x 103/mm3.
323565|NCT01731886|Drug|Melphalan|Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
323566|NCT01731886|Drug|G-CSF|Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
323567|NCT01731886|Drug|Cyclophosphamide|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously.
323568|NCT01731886|Drug|Mesna|Mesna will be provided with the cyclophosphamide.
323569|NCT01731860|Device|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
323570|NCT01731847|Procedure|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
323571|NCT01731834|Other|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
323572|NCT01731821|Procedure|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:~Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.~A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.~Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
323573|NCT01731808|Behavioral|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
323574|NCT01731795|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
323575|NCT01731782|Drug|bupivacaine|
323576|NCT01731782|Drug|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
323577|NCT01731769|Procedure|vacuum assisted closure in experimental arm|
323578|NCT01731769|Procedure|Axillary dissection|
323579|NCT01731756|Other|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
323580|NCT01731756|Drug|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
323581|NCT01731756|Other|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
323582|NCT01731743|Device|AT LISA tri 839MP|
323583|NCT01731730|Drug|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
323651|NCT01731158|Drug|TKI: Sutent, Nexavar or Votrient|TKI
323585|NCT01731730|Drug|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
323586|NCT01731717|Behavioral|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
323587|NCT01731717|Behavioral|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
323588|NCT01731717|Behavioral|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
323589|NCT01731717|Behavioral|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
323590|NCT01731717|Procedure|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
323591|NCT01731717|Behavioral|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
323592|NCT01731717|Other|Control group: treatment as usual|treatment as usual
323593|NCT01731704|Radiation|Stereotactic radiosurgery (SRS)|
323594|NCT01731704|Radiation|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
323595|NCT01731691|Biological|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
323596|NCT01731678|Procedure|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
323597|NCT01731652|Drug|TMX-101|
323598|NCT01731639|Other|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form > 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
323599|NCT01731613|Dietary Supplement|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
323600|NCT01731600|Drug|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
323601|NCT01731587|Other|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
323602|NCT01731587|Drug|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
323603|NCT01731574|Drug|dapivirine|
323604|NCT01731574|Drug|miconazole|
323605|NCT01731561|Drug|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
323606|NCT01731561|Drug|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
323607|NCT01731548|Radiation|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
323608|NCT01731522|Behavioral|EF condition|
323609|NCT01731509|Other|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
323610|NCT01731496|Other|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
323611|NCT01731496|Other|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
323612|NCT01731470|Biological|Liposomes|Intravesical instillation of liposomes.
323613|NCT01731457|Drug|etanercept|adding appropriate dose of etanercept to the perfusion fluid
323614|NCT01731444|Drug|Phenylephrine|
323615|NCT01731431|Other|Insulin|
323616|NCT01731431|Drug|Glyburide|
323617|NCT01731418|Behavioral|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, & Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
323789|NCT01729923|Drug|Celecoxib|Given PO
323618|NCT01731418|Other|Treatment-as-usual|"Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.~Regarding supportive counselling, the sessions included:~Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills"
323619|NCT01731392|Dietary Supplement|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
323620|NCT01731392|Dietary Supplement|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
323621|NCT01731392|Dietary Supplement|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
323622|NCT01731379|Procedure|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
323623|NCT01731366|Other|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
323624|NCT01731366|Other|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
323625|NCT01731340|Dietary Supplement|Calcium Citrate|750mg
323626|NCT01731340|Other|Low Dietary Calcium|450 mg
323627|NCT01731340|Other|High Dietary Calcium|1200 mg
323628|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
323629|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
323630|NCT01731314|Behavioral|Learning and Memory of Pain|
323631|NCT01731301|Drug|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
323632|NCT01731301|Drug|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
323633|NCT01731301|Drug|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
323634|NCT01731275|Drug|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
323635|NCT01731275|Drug|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
323636|NCT01731249|Biological|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
323637|NCT01731249|Biological|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
323638|NCT01731236|Dietary Supplement|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
323639|NCT01731236|Dietary Supplement|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
323640|NCT01731236|Drug|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
323641|NCT01731236|Drug|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
323642|NCT01731236|Drug|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
323643|NCT01731223|Behavioral|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
323644|NCT01731210|Device|implantation of the new LV lead: NANO system.|
323645|NCT01731197|Dietary Supplement|Dry-Blended Beverage|
323646|NCT01731184|Drug|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
323647|NCT01731171|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
323648|NCT01731171|Dietary Supplement|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
323649|NCT01731158|Drug|Avastin in combination with Roferon-A|
323650|NCT01731158|Drug|Afinitor|
323652|NCT01731145|Device|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
323653|NCT01731132|Drug|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
323654|NCT01731119|Drug|Latuda©|All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
323655|NCT01731093|Drug|AT-001|
323656|NCT01731093|Drug|Placebo|
323657|NCT01731067|Drug|Cocktail probe drugs|
323658|NCT01731041|Drug|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
323659|NCT01731041|Drug|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
323660|NCT01731028|Drug|Somatropin|Somatropin powder and solvent for solution for injection
323661|NCT01731015|Drug|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
323662|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the evening (PM) for 28 days
323663|NCT01731002|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD in the PM for 28 days
323664|NCT01731002|Drug|Latanoprost ophthalmic solution 0.005%|Administered to study eye, QD in the PM for 28 days
323665|NCT01730989|Dietary Supplement|Estromineral Serena Plus|
323666|NCT01730989|Dietary Supplement|Estromineral|
323667|NCT01730976|Dietary Supplement|Vitamin D 2,000 I.U.|
323668|NCT01730950|Biological|bevacizumab|Given IV
323669|NCT01730950|Radiation|intensity-modulated radiation therapy|Undergo IMRT
323670|NCT01730950|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
323671|NCT01730950|Radiation|proton beam radiation therapy|Undergo proton beam RT
323672|NCT01730937|Drug|sorafenib tosylate|Given PO
323673|NCT01730937|Radiation|stereotactic body radiation therapy|Undergo SBRT
323674|NCT01730924|Procedure|Pulmonary vein isolation using contact force sensing catheter|
323675|NCT01730911|Other|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
323676|NCT01730898|Other|Study product containing lutein|delivered in capsule form
323677|NCT01730898|Other|Study product containing lutein|delivered in capsule form
323678|NCT01730885|Other|Comparison of different Blood Glucose Meters|
323679|NCT01730872|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
323680|NCT01730872|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
323681|NCT01730859|Other|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.~Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
323682|NCT01730846|Drug|Doxazosin 4mg/day|4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
323683|NCT01730846|Drug|Placebo|Placebo
323684|NCT01730846|Drug|Doxazosin 8mg/day|8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
323685|NCT01730833|Biological|pertuzumab|Given IV
323686|NCT01730833|Biological|trastuzumab|Given IV
323687|NCT01730833|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
323688|NCT01730833|Other|laboratory biomarker analysis|Optional correlative studies
323689|NCT01730807|Device|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
323690|NCT01730794|Other|NAVA ventilation|Neurally adjusted ventilatory assist
323691|NCT01730794|Other|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
323692|NCT01730781|Radiation|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
323693|NCT01730768|Drug|AQW051|
323694|NCT01730768|Drug|Placebo|
323695|NCT01730755|Drug|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
323696|NCT01730742|Behavioral|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
323697|NCT01730742|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
323698|NCT01730742|Procedure|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
323699|NCT01730729|Drug|cabergoline|Given orally
323700|NCT01730716|Device|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
323701|NCT01730677|Drug|Lapatinib|lapatinib 1000mg, once daily
323702|NCT01730677|Drug|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
323703|NCT01730664|Drug|ertapenem|single dose of 2000mg ertapenem IV
323790|NCT01729923|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
323704|NCT01730651|Radiation|Tomotherapy|"IMRT boost of gross LNs~Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)~Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
323705|NCT01730638|Drug|• TF2 and 68 Ga-IMP-288|
323706|NCT01730625|Behavioral|Cognitive behavioral therapy for anxiety|
323707|NCT01730625|Behavioral|Attention Bias Modification Treatment|
323708|NCT01730612|Drug|TF2 - 68 Ga-IMP-288:|ImmunoTEP
323709|NCT01730599|Other|neurological exam|motor and cognitive functions
323710|NCT01730586|Drug|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
323711|NCT01730573|Procedure|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
323712|NCT01730573|Procedure|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
323713|NCT01730560|Other|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~two visits in pre-tests evaluation (V1 and V2),~one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~two visits after treatment (V4 at one week and V5 at one month)."
323714|NCT01730560|Other|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~two visits in pre-tests evaluation (V1 and V2),~one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~two visits after treatment (V4 at one week and V5 at one month)."
323715|NCT01730547|Biological|Autologous mesenchymal stem cells|
323716|NCT01730534|Drug|Dapagliflozin 10 mg|Oral dose (od)
323717|NCT01730534|Drug|Placebo tablet|Oral dose (od)
323718|NCT01730521|Behavioral|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
323719|NCT01730508|Drug|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
323720|NCT01730495|Drug|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
323721|NCT01730482|Drug|[14C] AT1001|150 mg of [14C] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
323722|NCT01730469|Drug|AT1001 150 mg|AT1001 150mg is available as a capsule
323723|NCT01730456|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
323724|NCT01730417|Drug|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
323725|NCT01730404|Drug|CHF6001 DPI|
323726|NCT01730404|Drug|Roflumilast|
323727|NCT01730404|Drug|Placebo|
323728|NCT01730391|Other|Data collection|Collection of demographic data and vaccination history
323729|NCT01730391|Other|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
323730|NCT01730378|Biological|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
323731|NCT01730378|Biological|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
323732|NCT01730365|Procedure|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
323733|NCT01730352|Drug|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
323734|NCT01730339|Drug|PF-06473871|Single dose administered by injection four different times
323735|NCT01730339|Drug|PF-06473871|Single dose administered by injection three different times
323736|NCT01730326|Drug|Paracetamol|1000 mg
323737|NCT01730326|Drug|Dexketoprofen|50 mg
323738|NCT01730313|Drug|Pyridoxine|
323739|NCT01730313|Drug|Sodium Valproate|
323740|NCT01730313|Drug|Phenytoin|
323741|NCT01730313|Drug|Placebo|
323742|NCT01730287|Drug|Control|The teeth in this group restored only by filling material,without liner application.
323743|NCT01730287|Drug|Calcium Hydroxide|Calcium Hydroxide paste applied.
323744|NCT01730287|Drug|Mineral Trioxide Aggregate(MTA)|MTA applied .
323745|NCT01730287|Drug|CEM cement|CEM cement applied .
323791|NCT01729923|Other|Laboratory Biomarker Analysis|Correlative studies
323792|NCT01729923|Other|Quality-of-Life Assessment|Ancillary studies
323793|NCT01729923|Radiation|Radiation Therapy|Undergo radiation therapy
323794|NCT01729923|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
323795|NCT01729923|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
323946|NCT01728766|Other|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at >37 weeks by and birth weight <2500 g
324128|NCT01727271|Drug|Tenofovir|
323746|NCT01730261|Behavioral|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
323747|NCT01730248|Drug|INC424|5 mg tablets administered orally twice daily
323748|NCT01730248|Drug|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
323749|NCT01730235|Other|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
323750|NCT01730222|Drug|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
323751|NCT01730222|Drug|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
323752|NCT01730222|Drug|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
323753|NCT01730222|Drug|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
323754|NCT01730209|Drug|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
323755|NCT01730209|Drug|Placebo|
323756|NCT01730196|Behavioral|Fit Body and Soul|
323757|NCT01730196|Behavioral|Wellness Education|
323758|NCT01730183|Other|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
323759|NCT01730157|Biological|ipilimumab|Given IV
323760|NCT01730157|Radiation|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
323761|NCT01730157|Other|laboratory biomarker analysis|Correlative studies
323762|NCT01730118|Biological|AdHER2/neu DC Vaccine|Autologous AdHER2 transduced dendritic cell vaccine manufactured under GMP conditions from cryopreserved patient monocytes here at the NIH CC DTM. Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8, 16 and 24 of the study.
323763|NCT01730066|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups"
323764|NCT01730053|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
323765|NCT01730053|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
323766|NCT01730053|Drug|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
323767|NCT01730053|Drug|Placebo|Placebo for alirocumab and ezetimibe.
323768|NCT01730040|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
323769|NCT01730040|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
323770|NCT01730040|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
323771|NCT01730040|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
323772|NCT01730040|Drug|Placebo|Placebo for alirocumab and ezetimibe.
323773|NCT01730027|Drug|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
323774|NCT01730027|Drug|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
323775|NCT01730027|Drug|montelukast|montelukast for 12 weeks
323776|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
323777|NCT01730014|Drug|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
323778|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
323779|NCT01730014|Drug|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
323780|NCT01730014|Drug|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
323781|NCT01730014|Drug|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
323782|NCT01730001|Procedure|Early Intubation|
323783|NCT01730001|Procedure|Late intubation|
323784|NCT01729988|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.~The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
323785|NCT01729949|Dietary Supplement|Active Treatment Beverage|Strawberry and Blackcurrent extract
323786|NCT01729949|Dietary Supplement|Placebo Treatment Beverage|without active components
323787|NCT01729936|Behavioral|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
323788|NCT01729923|Drug|Capecitabine|Given PO
323796|NCT01729910|Behavioral|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
323797|NCT01729910|Behavioral|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
323798|NCT01729897|Drug|Etomidate|
323799|NCT01729897|Drug|Fentanyl|
323800|NCT01729897|Drug|Propofol|
323801|NCT01729884|Biological|HER-2/neu peptide vaccine|Given ID
323802|NCT01729871|Drug|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
323803|NCT01729871|Drug|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
323804|NCT01729858|Device|Ceramic-Ceramic|"Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.~Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline."
323805|NCT01729858|Device|Metal-Ceramic|"Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.~Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline."
323806|NCT01729845|Drug|Cytarabine|Given IV
323807|NCT01729845|Drug|Decitabine|Given IV
323808|NCT01729845|Drug|Etoposide|Given IV
323809|NCT01729845|Other|Laboratory Biomarker Analysis|Correlative studies
323810|NCT01729845|Drug|Mitoxantrone Hydrochloride|Given IV
323811|NCT01729832|Procedure|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
323812|NCT01729832|Procedure|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
323813|NCT01729819|Drug|Tolterodine tartrate extended release capsules|
323814|NCT01729819|Drug|Desmopressin orally disintegrating tablets|
323815|NCT01729819|Drug|Placebo orally disintegrating tablets|
323816|NCT01729806|Biological|Ipilimumab|Given IV
323817|NCT01729806|Other|Laboratory Biomarker Analysis|Correlative studies
323818|NCT01729806|Biological|Rituximab|Given IV
323819|NCT01729793|Dietary Supplement|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
323820|NCT01729793|Other|Placebo|Capsule containing microcrystalline cellulose
323821|NCT01729780|Device|EEG-NF|
323822|NCT01729767|Drug|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
323823|NCT01729767|Drug|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
323824|NCT01729754|Drug|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
323825|NCT01729754|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
323826|NCT01729754|Drug|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
323827|NCT01729754|Drug|Etanercept Placebo|Matching placebo to etanercept administered SC
323828|NCT01729754|Drug|Etanercept 50 mg|Etanercept 50 mg administered SC
323829|NCT01729741|Procedure|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
323830|NCT01729728|Drug|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
323831|NCT01729715|Behavioral|Internet|
323832|NCT01729715|Behavioral|DVD|
323833|NCT01729702|Other|blood sample collection|
323834|NCT01729689|Other|counseling intervention|Undergo cognitive behavioral therapy
323835|NCT01729689|Other|questionnaire administration|Ancillary studies
323836|NCT01729689|Procedure|quality-of-life assessment|Ancillary studies
323837|NCT01729676|Drug|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
323838|NCT01729663|Biological|CSF470 vaccine, BCG, Molgramostim|
323839|NCT01729663|Drug|interferon alpha 2b|
323840|NCT01729650|Behavioral|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
323841|NCT01729598|Drug|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
323842|NCT01729598|Drug|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
323945|NCT01728779|Radiation|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
324051|NCT01728025|Drug|Ranolazine|
323843|NCT01729585|Procedure|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
323844|NCT01729572|Other|Tele-medicine monitoring of medication adherence|
323845|NCT01729559|Drug|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
323846|NCT01729559|Drug|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
323847|NCT01729546|Device|7 Blood glucose monitoring systems|
323848|NCT01729533|Other|ICSI|ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
323849|NCT01729533|Other|IMSI|Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei ([1] smooth, [2] symmetric, and [3] oval configuration) and [4] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies <4% of the nuclear area) are selected for injection.
323850|NCT01729520|Other|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for~Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
323851|NCT01729507|Other|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
323852|NCT01729507|Behavioral|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.~1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
323853|NCT01729494|Drug|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
323854|NCT01729494|Drug|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
323855|NCT01729494|Drug|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
323856|NCT01729494|Drug|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
323857|NCT01729494|Drug|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
323858|NCT01729494|Drug|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:~Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
323859|NCT01729481|Drug|Gemcitabine|1000 mg/m² iv weekly
323860|NCT01729481|Drug|Erlotinib|100mg, once per day
323861|NCT01729481|Drug|Oxaliplatin|85mg/m², q2weeks
323862|NCT01729481|Drug|Folinic Acid|400 mg/m², q2weeks
323863|NCT01729481|Drug|Irinotecan|180 mg/m², q2weeks
323864|NCT01729481|Drug|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
323865|NCT01729468|Drug|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
323866|NCT01729468|Drug|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
323867|NCT01729455|Biological|BENLYSTA|"As prescribed.~Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
324052|NCT01727986|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
323868|NCT01729455|Other|SLE treatment|"As prescribed.~At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
323869|NCT01729442|Other|Shear-wave ultrasound elastography (SWUE)|
323870|NCT01729429|Behavioral|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit~Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine~Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
323871|NCT01729429|Behavioral|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
323872|NCT01729416|Other|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.~We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.~On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
323873|NCT01729416|Other|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
323874|NCT01729403|Drug|aleglitazar|150 mcg orally daily, 16 weeks
323875|NCT01729403|Drug|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
323876|NCT01729403|Drug|placebo|orally daily, 16 weeks
323877|NCT01729390|Other|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
323878|NCT01729377|Other|Interview|
323879|NCT01729364|Drug|crystalloid|
323880|NCT01729364|Drug|colloid|
323881|NCT01729338|Drug|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles [10,12,14, etc.]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
323882|NCT01729338|Drug|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
323883|NCT01729338|Drug|Revlimid|"Lenalidomide (odd cycles [9,11,13, etc.]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.~Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
323884|NCT01729325|Behavioral|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
323885|NCT01729299|Drug|Exendin (9-39)|
323886|NCT01729299|Drug|acyl ghrelin|
323887|NCT01729299|Drug|saline|
323888|NCT01729286|Device|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
323889|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
323890|NCT01729273|Other|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
323891|NCT01729260|Drug|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
323892|NCT01729247|Device|NIOX MINO® Instrument (09-1100)|
323893|NCT01729234|Dietary Supplement|Nitrate|Dietary Supplement
323894|NCT01729234|Dietary Supplement|Placebo|Dietary Supplement
323895|NCT01729208|Device|Dual Focus Soft Contact Lens|
323896|NCT01729208|Device|Single Vision Soft Contact Lens|
323897|NCT01729195|Procedure|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
323898|NCT01729156|Drug|Metformin|1000 mg metformin twice daily in 3 months
323899|NCT01729156|Drug|Placebo|2 tablets twice daily in 3 months
324053|NCT01727973|Drug|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
323900|NCT01729143|Other|24-hour energy expenditure and substrate utilization|Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
323901|NCT01729130|Procedure|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
323902|NCT01729117|Other|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
323903|NCT01729117|Other|Standard Care|Standard Care only
323904|NCT01729104|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.~Phase II Starting Dose: MTD from Phase I."
323905|NCT01729104|Drug|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
323906|NCT01729104|Drug|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
323907|NCT01729091|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
323908|NCT01729091|Biological|Elotuzumab|Given IV
323909|NCT01729091|Other|Laboratory Biomarker Analysis|Correlative studies
323910|NCT01729091|Drug|Lenalidomide|Given PO
323911|NCT01729091|Drug|Melphalan|Given IV
323912|NCT01729091|Biological|Natural Killer Cell Therapy|Given IV
323913|NCT01729091|Biological|Umbilical Cord Blood-Derived Lymphocyte Therapy|Given IV
323914|NCT01729078|Dietary Supplement|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
323915|NCT01729065|Other|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
323916|NCT01729052|Device|Acupuncture|
323917|NCT01729039|Behavioral|standard balance rehabilitation|All subjects perform balance and gait exercises in addition to eye exercises and receive a written home exercise program (HEP) of balance and gait exercises to improve postural stability and mobility with progressively challenging tasks. Balance exercises include maintaining stability with vision and somatosensory cues altered, dynamic weight shifts and performing ankle, hip and step strategies. Gait activities include negotiating uneven terrains and obstacles, gait with head turns, varied speed, and unpredictable starts and stops. Walking for endurance is included in the HEP. Each participant receives a customized balance and gait HEP based on identified impairments and is progressed according to ability and level of assistance at home.
323918|NCT01729039|Behavioral|gaze stability|Vestibular adaptation and substitution exercises will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
323919|NCT01729039|Behavioral|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
323920|NCT01729026|Other|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
323921|NCT01729000|Other|Gloves|All staff must wear gloves for subjects that are in the experimental group.
323922|NCT01728987|Drug|cholecalciferol|as in arm description
323923|NCT01728987|Drug|placebo|capsule looking identical to the cholecalciferol capsule
323924|NCT01728974|Other|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
323925|NCT01728961|Drug|Artemether/Lumefantrine (AL)|
323926|NCT01728948|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
323927|NCT01728935|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
323928|NCT01728922|Dietary Supplement|5000IU vitamin D|Vigantol Oil
323929|NCT01728922|Dietary Supplement|10000IU vitamin D|Vigantol Oil
323930|NCT01728922|Other|Placebo|Placebo Oil
323931|NCT01728909|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
323932|NCT01728909|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
323933|NCT01728896|Other|Patient-controlled oral refeeding|
323934|NCT01728883|Device|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
323935|NCT01728870|Other|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
323936|NCT01728870|Other|Exclusive Enteral Nutrition (Modulen)|
323937|NCT01728857|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
323938|NCT01728818|Drug|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
323939|NCT01728818|Drug|Afatinib|40mg flat dose, po, once daily
323940|NCT01728818|Drug|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
323941|NCT01728805|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
323942|NCT01728805|Drug|Vorinostat|
323943|NCT01728792|Biological|TDV|TDV IM or SC injection
323944|NCT01728779|Drug|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
324122|NCT01727349|Other|HbA1c measurement|
323947|NCT01728766|Other|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at >37 weeks and birth weight >2800 g
323948|NCT01728753|Drug|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
323949|NCT01728753|Drug|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
323950|NCT01728753|Drug|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
323951|NCT01728753|Drug|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
323952|NCT01728740|Drug|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
323953|NCT01728740|Drug|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
323954|NCT01728740|Drug|Metformin|Metformin 500mg, oral, single dose
323955|NCT01728727|Other|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
323956|NCT01728727|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
323957|NCT01728701|Biological|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
323958|NCT01728701|Biological|Normal Saline (NS)|Normal saline
323959|NCT01728688|Other|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
323960|NCT01728688|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
323961|NCT01728675|Other|Exercise|Participants will perform two isokinetic eccentric exercise bouts
323962|NCT01728662|Procedure|ELVR Procedure|Lung Volume Reduction Procedure
323963|NCT01728649|Other|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermoguard XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 4 3cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
323964|NCT01728636|Drug|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
323965|NCT01728623|Drug|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
323966|NCT01728610|Dietary Supplement|Probiotic (Active high)|Higher dose of probiotic supplement
323967|NCT01728610|Dietary Supplement|Probiotic (Active low)|Lower dose of probiotic supplement
323968|NCT01728610|Dietary Supplement|Placebo|Placebo
323969|NCT01728584|Drug|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
323970|NCT01728584|Other|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.~Standard insufflation pressure - a starting pressure of 12 mmHg will be used.~Low insufflation pressure - a starting pressure of 8 mmHg will be used."
323971|NCT01728584|Drug|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
323972|NCT01728571|Dietary Supplement|Vitamin D|
323973|NCT01728571|Dietary Supplement|fish oil|
323974|NCT01728571|Dietary Supplement|Vitamin D placebo|
323975|NCT01728571|Dietary Supplement|Fish oil placebo|
323976|NCT01728558|Other|Early goal Directed Sedation|
323977|NCT01728558|Other|Standard care sedation|
323978|NCT01728532|Device|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
323979|NCT01728532|Device|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
323980|NCT01728519|Drug|AllerT SC|AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
323981|NCT01728519|Drug|AllerT ID|AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
323982|NCT01728519|Drug|Placebo SC|Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
323983|NCT01728519|Drug|Placebo ID|Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
323984|NCT01728506|Behavioral|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
323985|NCT01728480|Drug|entolimod|Given SC
323986|NCT01728480|Radiation|intensity-modulated radiation therapy|Undergo IMRT
323987|NCT01728480|Drug|cisplatin|Given IV
323988|NCT01728480|Other|pharmacological study|Correlative studies
323989|NCT01728480|Other|laboratory biomarker analysis|Correlative studies
323990|NCT01728467|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
323991|NCT01728467|Drug|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
323992|NCT01728454|Drug|Placebo|Placebo matching capsules, orally, once daily for 18 weeks.
323993|NCT01728454|Drug|Telapristone acetate|Telapristone acetate capsules, orally once daily for 18 weeks.
323994|NCT01728441|Device|Paclitaxel Eluting Stent|
323995|NCT01728441|Device|Paclitaxel Eluting Balloon|
323996|NCT01728415|Other|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
323997|NCT01728402|Procedure|blood draw, bone marrow procedure, or tissue biopsy|
323998|NCT01728389|Procedure|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
323999|NCT01728376|Drug|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
324000|NCT01728376|Drug|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
324001|NCT01728363|Drug|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
324002|NCT01728350|Behavioral|HOPE - Helping Others through Purpose and Engagement|
324003|NCT01728337|Drug|Dysport|Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
324004|NCT01728337|Drug|Xeomin|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
324005|NCT01728324|Drug|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
324006|NCT01728324|Drug|Ribavirin: 24-week treatment|24 weeks of active treatment
324007|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
324008|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
324009|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
324010|NCT01728324|Drug|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
324011|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
324012|NCT01728324|Drug|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
324013|NCT01728324|Drug|Faldaprevir: 16-week treatment|16 weeks of active treatment
324014|NCT01728324|Drug|Ribavirin: 16-week treatment|16 weeks of active treatment
324015|NCT01728324|Drug|RBV: 24-week treatment|24 weeks of active treatment
324016|NCT01728324|Drug|BI 207127: 16-week treatment|16 weeks of active treatment
324017|NCT01728311|Drug|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
324018|NCT01728298|Biological|SLITone ULTRA HDM immunotherapy|
324019|NCT01728285|Device|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
324020|NCT01728272|Drug|blood concentration of metoprolol|measure blood concentration of metoprolol
324021|NCT01728259|Drug|pomalidomide|Given PO
324022|NCT01728259|Drug|bortezomib|Given IV
324023|NCT01728259|Drug|dexamethasone|Given PO
324024|NCT01728259|Other|Laboratory Biomarker Analysis|Correlative studies
324025|NCT01728246|Drug|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
324026|NCT01728246|Drug|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
324027|NCT01728233|Drug|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
324028|NCT01728220|Drug|Inhaled NO|
324029|NCT01728220|Other|Placebo|Nitrogen gas
324030|NCT01728207|Drug|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
324031|NCT01728194|Drug|Escitalopram|20 mg target dose for 12 weeks
324032|NCT01728181|Drug|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
324033|NCT01728181|Drug|Erlotinib|150 mg/day for 28 day cycle. No rest period.
324034|NCT01728181|Other|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
324035|NCT01728155|Drug|chemotherapy|
324036|NCT01728142|Device|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
324037|NCT01728142|Other|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
324038|NCT01728129|Device|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
324039|NCT01728129|Other|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
324040|NCT01728116|Device|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
324041|NCT01728116|Procedure|Sham Procedure|Endoscopic evaluation but no device placement
324042|NCT01728103|Device|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
324043|NCT01728090|Other|hand sanitizer|alcohol-based, hydroalcoholic gel
324044|NCT01728077|Drug|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
324045|NCT01728064|Drug|Placebo|Placebo capsules
324046|NCT01728064|Drug|EPI-743 400 mg|
324047|NCT01728064|Drug|EPI-743 200 mg|
324048|NCT01728051|Drug|Melphalan|
324049|NCT01728051|Device|Percutaneous Hepatic Perfusion|
324050|NCT01728038|Behavioral|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
324054|NCT01727960|Behavioral|Education and posture correction|a lecture concerning the fine posture for health and exercises
324055|NCT01727947|Other|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied > 13% of nuclear area) in each sample will be assessed.
324056|NCT01727934|Drug|Miravirsen sodium|Subcutaneous injection
324057|NCT01727921|Device|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
324058|NCT01727921|Device|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
324059|NCT01727908|Other|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
324060|NCT01727895|Dietary Supplement|Beta-glucan (Glucan #300®)|
324061|NCT01727882|Behavioral|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
324062|NCT01727882|Behavioral|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
324063|NCT01727869|Drug|REGN1400|
324064|NCT01727869|Drug|Erlotinib|
324065|NCT01727869|Drug|Cetuximab|
324066|NCT01727856|Device|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
324067|NCT01727843|Drug|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
324068|NCT01727843|Other|placebo|applied topically to surgical site in OR.
324069|NCT01727830|Other|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
324070|NCT01727817|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
324071|NCT01727804|Other|Laser in caries prevention|
324072|NCT01727791|Drug|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
324073|NCT01727778|Biological|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
324074|NCT01727765|Other|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
324075|NCT01727752|Procedure|Decompression|
324076|NCT01727739|Device|Linvatec PLLA+TCP|Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
324077|NCT01727739|Device|Linvatec PLLA|Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
324078|NCT01727726|Drug|Brexpiprazole|tablet/capsule
324079|NCT01727726|Drug|Seroquel XR|tablet/capsule
324080|NCT01727726|Drug|Placebo|tablet/capsule
324081|NCT01727713|Drug|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
324082|NCT01727700|Drug|Aripiprazole|Once-daily, tablet
324083|NCT01727700|Drug|Placebo|
324084|NCT01727687|Behavioral|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
324085|NCT01727661|Behavioral|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
324086|NCT01727661|Behavioral|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.~single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
324087|NCT01727661|Behavioral|quality of life|assessing quality of life using short-forum 36 (questionnaire)
324088|NCT01727648|Behavioral|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
324089|NCT01727648|Behavioral|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
324090|NCT01727648|Behavioral|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
324123|NCT01727349|Other|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
324091|NCT01727648|Behavioral|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
324092|NCT01727635|Other|body-mind-spirit group therapy|8-session therapy
324093|NCT01727622|Drug|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
324094|NCT01727622|Other|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
324095|NCT01727622|Procedure|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
324096|NCT01727609|Dietary Supplement|Milk feed (breast milk or formula milk)|
324097|NCT01727596|Other|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
324098|NCT01727583|Dietary Supplement|meal intake|Intake of meals characterized by lipid composition
324099|NCT01727583|Dietary Supplement|Placebo|
324100|NCT01727570|Dietary Supplement|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
324101|NCT01727557|Procedure|regional anesthesia|Regional anesthesia will be compared to local anesthesia
324102|NCT01727557|Procedure|local anesthesia|Regional anesthesia will be compared to local anesthesia
324103|NCT01727544|Procedure|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
324104|NCT01727531|Drug|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
324105|NCT01727505|Device|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
324106|NCT01727505|Device|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.~In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.~Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).~During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.~During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
324107|NCT01727492|Drug|Antioxidantia|
324108|NCT01727479|Other|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
324109|NCT01727479|Other|Placebo|
324110|NCT01727466|Behavioral|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
324111|NCT01727453|Drug|warfarin|Warfarin in anticoagulant dose
324112|NCT01727453|Drug|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.~Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
324113|NCT01727427|Drug|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
324114|NCT01727414|Drug|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
324115|NCT01727414|Drug|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
324116|NCT01727401|Drug|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
324117|NCT01727388|Procedure|lateral decubitus|
324118|NCT01727388|Procedure|supine decubitus|
324119|NCT01727375|Other|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.~Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
324120|NCT01727362|Other|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
324121|NCT01727362|Other|Usual care|Patients of this group receive usual care only
324129|NCT01727271|Biological|Pegylated interferon alpha-2b|
324130|NCT01727258|Device|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
324131|NCT01727258|Drug|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
324132|NCT01727258|Drug|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
324133|NCT01727245|Other|Obese|gastric bypass
324134|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
324135|NCT01727206|Drug|Tocilizumab|
324136|NCT01727193|Drug|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
324137|NCT01727193|Drug|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
324138|NCT01727180|Other|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
324139|NCT01727167|Drug|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
324140|NCT01727167|Other|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
324141|NCT01727154|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
324142|NCT01727141|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
324143|NCT01727141|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
324144|NCT01727141|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
324145|NCT01727141|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
324146|NCT01727128|Drug|BKM120|
324147|NCT01727115|Other|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.~If the challenge is positive: The children continue the assigned formula~If the challenge is negative: A Follow up formula is given~(Nan pro2) if child > 6 months~(Nan pro1) if child < 6 months"
324148|NCT01727089|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
324149|NCT01727089|Biological|Bevacizumab|Given IV
324150|NCT01727089|Other|Laboratory Biomarker Analysis|Correlative studies
324151|NCT01727089|Other|Pharmacological Study|Correlative studies
324152|NCT01727076|Other|Laboratory Biomarker Analysis|Correlative studies
324153|NCT01727076|Other|Pharmacological Study|Correlative studies
324154|NCT01727076|Biological|Recombinant Human Interleukin-15|Given SC
324155|NCT01727063|Procedure|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
324156|NCT01727050|Device|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
324157|NCT01727050|Device|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
324158|NCT01727037|Procedure|Bronchoscopic intrabullous autologous blood instillation|
324159|NCT01727024|Drug|Tiotropium|Tiotropium via Respimat® device once a day
324160|NCT01727024|Drug|Indacaterol|Indacaterol via Breezhaler® device once a day
324161|NCT01727011|Radiation|IPAS|
324162|NCT01726998|Other|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
324163|NCT01726998|Other|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
324164|NCT01726985|Other|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'~Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:~NT-ProBNP reduction of > 23% from peak value during admission~Fluid Reduction of > 1.3L (orders for I/O q8h required)~Serum Sodium of > 135 mmol/L the day of planned discharge"
324165|NCT01726946|Drug|VX-135|12 weeks of VX-135
324166|NCT01726946|Drug|ribavirin|12 weeks of ribavirin
324167|NCT01726933|Drug|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
324168|NCT01726933|Drug|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
324169|NCT01726933|Drug|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
324170|NCT01726920|Drug|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
324171|NCT01726920|Drug|naratriptan|Tablets containing naratriptan 2,5 mg
324172|NCT01726920|Drug|naproxen|Tablets containing naproxen 500 mg
324173|NCT01726907|Device|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
324238|NCT01726426|Dietary Supplement|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
324174|NCT01726907|Device|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson & Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
324175|NCT01726894|Device|Irreversible Electroporation|
324176|NCT01726881|Device|Thermal stimulation|"Stimulation using a Thermal Sensory Analyzer:~2001, Maddock ltd., Israel."
324177|NCT01726881|Device|Mechanical stimulation|Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
324178|NCT01726881|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|A portable stimulator designed to Physical treatment of pain. TENS - Cedar rehab X2. Chattanooga group.USA.
324179|NCT01726868|Device|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
324180|NCT01726855|Procedure|vascularized finger dorsal fascial flap|
324181|NCT01726842|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
324182|NCT01726829|Device|MD-Logic Artificial Pancreas (MDLAP) system|
324183|NCT01726829|Procedure|sensor augmented pump therapy|
324184|NCT01726816|Drug|Probucol 250mg/day|Probucol 250mg + Placebo
324185|NCT01726816|Drug|Probucol 500mg/day|Probucol 500mg + Placebo
324186|NCT01726816|Drug|Placebo|Probucol matching placebo
324187|NCT01726803|Other|Early Physical Therapy with Usual Care|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
324188|NCT01726803|Other|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
324189|NCT01726777|Dietary Supplement|Control|Normal cheddar cheese
324190|NCT01726777|Dietary Supplement|Vitamin D|Vitamin D3 supplemented cheddar cheese
324191|NCT01726764|Other|St John's Wort|
324192|NCT01726764|Drug|Metformin|
324193|NCT01726751|Device|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
324194|NCT01726751|Device|Spinal cord nerve stimulation|
324195|NCT01726738|Drug|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
324196|NCT01726725|Drug|desflurane|
324197|NCT01726712|Other|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
324198|NCT01726686|Drug|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
324199|NCT01726686|Drug|Placebo|
324200|NCT01726673|Device|Transcranial Direct Current Stimulation (tDCS)|
324201|NCT01726673|Device|Placebo sham|
324202|NCT01726660|Device|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
324203|NCT01726634|Other|Elastic Tapping|
324204|NCT01726621|Device|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
324205|NCT01726608|Procedure|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
324206|NCT01726582|Drug|Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
324207|NCT01726582|Drug|standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
324208|NCT01726582|Drug|Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
324209|NCT01726582|Other|No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
324210|NCT01726582|Drug|Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
324211|NCT01726582|Radiation|Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
324212|NCT01726569|Behavioral|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
324213|NCT01726569|Other|traditional counseling|Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
324214|NCT01726556|Device|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
324215|NCT01726556|Device|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
324239|NCT01726413|Drug|GRC 17356|
324240|NCT01726413|Drug|Matching Placebo|
324216|NCT01726543|Procedure|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
324217|NCT01726543|Procedure|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
324218|NCT01726530|Drug|transdermal fentanyl patch (50 mcg/hour)|
324219|NCT01726530|Drug|Placebo|
324220|NCT01726517|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
324221|NCT01726517|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
324222|NCT01726504|Device|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
324223|NCT01726504|Device|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
324224|NCT01726478|Drug|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
324225|NCT01726478|Drug|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
324226|NCT01726465|Drug|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
324227|NCT01726465|Drug|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°−110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
324228|NCT01726452|Drug|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
324229|NCT01726452|Drug|Cisplatin / Oxaliplatin|Cisplatin, 60mg/m2 on day 1 of each cycle only (i.e. every 21 days). OR Oxaliplatin,130 mg/m2 on Day 1 of each cycle (i.e. every 21 days) The choice between administering Cisplatin or Oxaliplatin is at the discretion of the investigator.
324230|NCT01726452|Drug|5 Flourouracil/ Capecitabine|5-Flourouracil 200 mg/m2/day every day for 21 days OR Capecitabine 625 mg/m2 twice daily orally). The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator.
324231|NCT01726452|Radiation|(41.4 Gy/23 fractions)|Patient will receive 4.5 weeks of radiation therapy (41.4 Gy/23 fractions).
324232|NCT01726452|Drug|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine dose given per local standard practice. NACL infusion per local standard practice. Ondansetron dose given per local standard practice on Days 1, 8, 15, 22 and 29.
324233|NCT01726452|Drug|Carboplatin|Dose determined as per calculation, infused on Days 1, 8, 15, 22 and 29
324234|NCT01726452|Drug|Docetaxel|Docetaxel, 50 mg/m², day 1 of each cycle (i.e. every 14 days)
324235|NCT01726452|Drug|Oxaliplatin|85 mg/m², day 1 of each cycle (i.e. every 14 days)
324236|NCT01726452|Drug|Leucovorin|200 mg/m², day 1 of each cycle (i.e. every 14 days).
324237|NCT01726452|Drug|5-Fluorouracil|2600 mg/m² Day 1 of each cycle (i.e. every 14 days) Dexamethasone or equivalent, 8mg, twice daily, Day before, day of and day after OR administered as per standard practice
324241|NCT01726400|Drug|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
324242|NCT01726400|Drug|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
324243|NCT01726387|Behavioral|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
324244|NCT01726387|Behavioral|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
324245|NCT01726374|Drug|BEP(500)|"One cycle of BEP(500):~Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"
324246|NCT01726361|Behavioral|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
324247|NCT01726361|Behavioral|Treatment as usual|Other kinds of out of home placement
324248|NCT01726348|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
324249|NCT01726335|Drug|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
324250|NCT01726296|Other|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
324251|NCT01726296|Other|medical chart review|Complete patient medical chart audit
324252|NCT01726283|Device|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
324253|NCT01726283|Drug|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
324254|NCT01726270|Drug|tamsulosin|0.4 mg
324255|NCT01726257|Device|Nellix System|
324256|NCT01726244|Behavioral|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
324257|NCT01726205|Drug|Pregabalin and normal saline infusion, PRG|
324258|NCT01726205|Drug|Pregabalin and ropivacaine 02% infusion|
324259|NCT01726205|Drug|Placebo drug, normal saline infusion|
324260|NCT01726192|Procedure|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
324261|NCT01726192|Procedure|Placement of a femoral neurostimulating catheter|
324262|NCT01726179|Device|Icon infiltration|"Patients and their guardians will be instructed to use dental floss to remove dental biofilm in both proximal sites once a day and to brush teeth with fluorated toothpaste twice a day. Besides that, test lesion will be infiltrated with a low viscosity resin (Icon, DMG, Hamburg, Germany). The test lesions will be treated using Icon (DMG, Hamburg, Germany) following the instruction for use.~A sub-sample with children with indication for a composite restoration in at least one proximal surface will be selected for the analysis of dental anxiety and stress."
324263|NCT01726179|Device|control|"Patients and their guardians will be instructed to use dental floss to remove dental biofilm in both proximal sites once a day and to brush teeth with fluoridated toothpaste twice a day.~A sub-sample with children with indication for a composite restoration in at least one proximal surface will be selected for the analysis of dental anxiety and stress."
324264|NCT01726166|Procedure|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
324265|NCT01726166|Procedure|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
324266|NCT01726153|Behavioral|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
324267|NCT01726140|Procedure|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be >200, the patient will stop the treatment.
324268|NCT01726140|Procedure|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be >200, the patient will stop the treatment.
324269|NCT01726127|Other|Broccoli and Brussels Sprouts|
324270|NCT01726127|Dietary Supplement|Cruciferous Complete|
324271|NCT01726127|Other|Placebo|
324272|NCT01726114|Device|Non-invasive Optical Glucose Monitor™|Test device
324273|NCT01726114|Device|YSI blood glucose analyzer|Reference device
324274|NCT01726088|Drug|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
324275|NCT01726075|Drug|COLIRIOBCN070660|One drop per eye twice a day during 24 months
324276|NCT01726075|Drug|Placebo|One drop per eye twice a day during 24 months
324277|NCT01726075|Drug|Brimonidine|One drop per eye twice a day during 24 months
324278|NCT01726062|Behavioral|Motivational Interviewing plus Incentives|"Two hospital-based, face-to-face MI+ sessions~Two home-based MI+ sessions~Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
324279|NCT01726062|Behavioral|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
324280|NCT01726049|Drug|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
324281|NCT01726049|Drug|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
324282|NCT01726036|Device|Gomco Circumcision Clamp|Neonatal male circumcision utilizing the Gomco Circumcision Clamp
324283|NCT01726036|Device|Mogen Circumcision Clamp|Neonatal male circumcision utilizing the Mogen Circumcision Clamp
324284|NCT01726023|Drug|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
324285|NCT01726023|Drug|metronidazole|Metronidazole 500mg/100ml solution for infusion
324286|NCT01726023|Drug|Meropenem|Meropenem powder for solution for infusion 1000mg
324287|NCT01726010|Device|22-G Procore Needle|
324288|NCT01725997|Procedure|hook plate|Surgery with hook plate followed by physiotherapy
324289|NCT01725997|Other|Physiotherapy|Patients will be following a program specific for AC joint dislocations
324290|NCT01725958|Dietary Supplement|Nutritional supplement and protein shakes|
324291|NCT01725945|Behavioral|Dietary Approaches to Stop Hypertension dietary pattern|The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
324292|NCT01725932|Behavioral|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
324293|NCT01725919|Behavioral|CI therapy|constraint induced movement therapy
324294|NCT01725906|Drug|empirical therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus~Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
324295|NCT01725906|Drug|Genotypic resistance guided therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus~Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus~Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs~Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
324296|NCT01725880|Other|Observation|
324297|NCT01725867|Other|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
324298|NCT01725867|Device|oral appliance|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
324299|NCT01725854|Behavioral|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
324300|NCT01725828|Device|Ultrasound|Using the Ultrasound to determine the location of the CTM.
324301|NCT01725828|Other|External Palpation|Using External Palpation to identify cricothyoid membrane
324302|NCT01725815|Behavioral|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
324303|NCT01725802|Drug|levodopa and carbidopa solution for SC administration|
324304|NCT01725802|Drug|Placebo|
324305|NCT01725789|Drug|Ferinject®|"Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .~Note, Ferinject® should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight <50kg, administration of Ferinject® should be limited to 500mg at baseline . All patients with a serum ferritin value <15ng/mL and Hb<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(Study group: Ferinject®500mg, Control Group:Placebo)"
324343|NCT01725581|Procedure|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
324306|NCT01725789|Drug|normal saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
324307|NCT01725776|Drug|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
324308|NCT01725763|Other|Cardiac MRI|
324309|NCT01725750|Device|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
324310|NCT01725750|Device|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
324311|NCT01725737|Drug|GlyTI-M|
324312|NCT01725737|Drug|Placebo|Placebo Comparator: starch
324313|NCT01725724|Procedure|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
324314|NCT01725724|Procedure|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
324315|NCT01725711|Device|OPRA Implant System|
324316|NCT01725698|Drug|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
324317|NCT01725685|Drug|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
324318|NCT01725685|Drug|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
324319|NCT01725685|Drug|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
324320|NCT01725672|Drug|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324321|NCT01725672|Drug|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324322|NCT01725672|Drug|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324323|NCT01725672|Drug|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324324|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324325|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324326|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324327|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
324328|NCT01725659|Other|Motor Learning|training of the hemiplegic upper limb with motor learning
324329|NCT01725659|Other|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
324330|NCT01725659|Other|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
324331|NCT01725646|Drug|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
324332|NCT01725646|Drug|Placebo|Subjects in placebo group will take this drug
324333|NCT01725633|Behavioral|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
324334|NCT01725633|Behavioral|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
324335|NCT01725633|Other|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
324336|NCT01725633|Other|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
324337|NCT01725620|Drug|LBEC0101 (Etanercept 25mg)|
324338|NCT01725620|Drug|Enbrel (Etanercept 25mg)|
324339|NCT01725607|Drug|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
324340|NCT01725607|Procedure|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
324341|NCT01725594|Drug|CAT 2003|
324342|NCT01725594|Drug|Placebo|
324344|NCT01725568|Device|BioMonitor|Implantable cardiac monitor
324345|NCT01725555|Drug|Fasted treatment: AXL1717|
324346|NCT01725555|Drug|Fed treatment: AXL1717|
324347|NCT01725542|Drug|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
324348|NCT01725529|Drug|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
324349|NCT01725529|Drug|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms [μg] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
324350|NCT01725529|Drug|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is < 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
324351|NCT01725529|Drug|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
324352|NCT01725516|Procedure|Myofascial release technique|
324353|NCT01725503|Dietary Supplement|Creatine and Amino Acid supplement|
324354|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
324355|NCT01725490|Drug|Metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
324356|NCT01725490|Drug|Placebo|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
324357|NCT01725477|Drug|methylen blue &normal saline|Washing after dye injection
324358|NCT01725477|Drug|methylene blue|
324359|NCT01725477|Drug|metheylne blue with normal saline|
324360|NCT01725464|Device|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
324361|NCT01725451|Drug|Testosterone|Administered topically to axillae
324362|NCT01725451|Other|Deodorant Spray|Administered topically to axillae
324363|NCT01725451|Other|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
324364|NCT01725451|Other|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
324365|NCT01725438|Other|sample blood|
324366|NCT01725425|Other|Control|The control is designed to determine average mood.
324367|NCT01725425|Other|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
324368|NCT01725425|Other|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
324369|NCT01725425|Other|Mixed Portions|The purpose is to determine if a change in mood will occur.
324370|NCT01725412|Dietary Supplement|Thiamine 300mg PO once daily|
324371|NCT01725412|Dietary Supplement|placebo|
324372|NCT01725399|Other|Apple Juice|
324373|NCT01725399|Other|Water|
324374|NCT01725386|Drug|Capecitabine|Oral tablet(s) administered according to prescribing information
324375|NCT01725360|Drug|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
324376|NCT01725334|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
324377|NCT01725321|Other|Narrow band imaging|Colonoscopy with new narrow band imaging
324378|NCT01725308|Drug|FK949E|Taken by mouth (orally).
324379|NCT01725308|Drug|Placebo|Taken by mouth (orally).
324380|NCT01725295|Other|NST|A form of physical therapy
324381|NCT01725295|Other|Hydrotherapy|
324382|NCT01725282|Drug|quetiapine extended release (XR)|Extended release tablets
324383|NCT01725282|Drug|Placebo|matching tablets
324384|NCT01725269|Drug|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
324385|NCT01725256|Drug|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
324386|NCT01725243|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
324387|NCT01725230|Drug|Fostamatinib|100-mg tablet
324388|NCT01725230|Drug|Rosuvastatin|20-mg tablet
324389|NCT01725230|Drug|Simvastatin|40-mg tablet
324390|NCT01725217|Biological|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
324391|NCT01725204|Drug|Dasatinib + PegIFN|
324392|NCT01725191|Other|Laboratory Biomarker Analysis|Correlative studies
324393|NCT01725191|Other|Pharmacological Study|Correlative studies
324394|NCT01725191|Drug|Tivantinib|Given PO
324395|NCT01725178|Behavioral|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.~Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
324396|NCT01725165|Other|Clinical Observation|Undergo clinical observation
324397|NCT01725165|Radiation|External Beam Radiation Therapy|Undergo EBRT
324398|NCT01725165|Other|Laboratory Biomarker Analysis|Optional correlative studies
324399|NCT01725165|Other|Quality-of-Life Assessment|Ancillary studies
324400|NCT01725165|Procedure|Standard Follow-Up Care|Undergo standard maintenance therapy
324401|NCT01725165|Procedure|Therapeutic Conventional Surgery|Undergo surgery
324402|NCT01725152|Drug|Ganaxolone|oral suspension, given in 3 divided doses
324403|NCT01725152|Drug|Placebo|oral suspension, given in 3 divided doses
324404|NCT01725139|Drug|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
324405|NCT01725139|Drug|Placebo|Matching placebo will be available
324406|NCT01725126|Drug|GSK2890457|Provided as powder and capsule.
324407|NCT01725126|Drug|Metformin|"Tablet~Part A: Single doses on Day 1 and Day 42 orally~Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed~Part C: Subject continues usual metformin dose throughout study"
324408|NCT01725126|Drug|Placebo|Provided as powder and Capsule.
324409|NCT01725126|Drug|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg~Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
324410|NCT01725113|Drug|Calcitriol|3 times weekly
324411|NCT01725113|Drug|Paricalcitol|3 times weekly
324412|NCT01725100|Drug|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
324413|NCT01725100|Drug|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
324414|NCT01725087|Drug|Matching Placebo|
324415|NCT01725087|Drug|Low Dose GRT6005|
324416|NCT01725087|Drug|Medium Dose GRT6005|
324417|NCT01725087|Drug|High Dose GRT6005|
324418|NCT01725087|Drug|Tapentadol|
324419|NCT01725074|Behavioral|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~Biweekly/monthly telephone consultations or home visits~Identification of health or personal problems of the patient~Monitoring of medical parameters~Coordination of contact with health care providers if necessary~Support to the patient related to health status and environmental changes~Promote disease-self management through coaching~Counseling, that is focused on emotional support and active listening"
324420|NCT01725074|Behavioral|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
324421|NCT01725048|Drug|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
324422|NCT01725048|Drug|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
324423|NCT01725022|Other|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
324424|NCT01725009|Drug|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam|Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days
324425|NCT01724996|Other|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
324426|NCT01724983|Drug|ketamine|
324427|NCT01724983|Drug|fentanyl|
324428|NCT01724970|Device|ProSeal|Patients will be ventilated with PLMA
324429|NCT01724970|Device|Supreme LMA|Patients will be ventilated with SLMA
324430|NCT01724957|Procedure|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
324431|NCT01724944|Procedure|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
324432|NCT01724931|Drug|LD-aminopterin|
324433|NCT01724931|Drug|placebo|
324434|NCT01724918|Drug|Lacosamide|
324435|NCT01724905|Dietary Supplement|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
324436|NCT01724905|Dietary Supplement|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
324437|NCT01724892|Drug|Dexamethasone|
324438|NCT01724892|Drug|Loteprednol etabonate|
324439|NCT01724879|Drug|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
324440|NCT01724866|Drug|HM10460A (45 μg/kg)|Single-dose subcutaneous injection
324441|NCT01724866|Drug|HM10460A (135 μg/kg)|Single-dose subcutaneous injection
324442|NCT01724866|Drug|HM10460A (270 μg/kg)|Single-dose subcutaneous injection
324443|NCT01724866|Drug|Pegfilgrastim 6mg|Single-dose subcutaneous injection, per manufacturer's Prescribing Information
324567|NCT01723917|Dietary Supplement|PhytoSERM tablet|
324444|NCT01724853|Procedure|Surgery|Resection suspension interposition arthroplasty or Arthrodesis
324445|NCT01724853|Other|Conservative|Injection
324446|NCT01724840|Procedure|GraftJacket|Interposition with GraftJacket
324447|NCT01724840|Procedure|Tendon Interposition|Tendon Interposition with the FCR tendon
324448|NCT01724827|Device|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
324449|NCT01724827|Device|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
324450|NCT01724814|Drug|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
324451|NCT01724814|Drug|Placebo|Singe dose SC administration of Placebo
324452|NCT01724801|Radiation|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
324453|NCT01724801|Drug|Icotinib|administered orally at a dose of 125 mg 3 times daily
324454|NCT01724788|Drug|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
324455|NCT01724788|Drug|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
324456|NCT01724762|Other|Nursing Orientation|"Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information~Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
324457|NCT01724736|Drug|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
324458|NCT01724736|Drug|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
324459|NCT01724723|Drug|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
324460|NCT01724697|Other|BMSC transplantation|Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.
324461|NCT01724697|Other|conventional treatment & antivrial treatment|Participants will recieve conventional treatment and antivrial treatment.
324462|NCT01724684|Other|Telehealth program|
324463|NCT01724684|Other|Usual care|
324464|NCT01724658|Drug|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
324465|NCT01724658|Drug|placebo|placebo orally twice a week with progynova 1 mg oral daily
324466|NCT01724645|Dietary Supplement|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.~The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
324467|NCT01724645|Dietary Supplement|Control group|"Told to  eat as usal diets."
324468|NCT01724632|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
324469|NCT01724619|Drug|[F-18] fluorinated dihydrotestosterone (FDHT)|
324470|NCT01724606|Radiation|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
324471|NCT01724606|Drug|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
324472|NCT01724580|Drug|Baricitinib|Administered orally
324473|NCT01724567|Other|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
324474|NCT01724567|Other|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
324475|NCT01724554|Drug|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
324476|NCT01724528|Drug|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
324477|NCT01724528|Drug|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
324478|NCT01724515|Other|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
324479|NCT01724502|Behavioral|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
324480|NCT01724489|Drug|Growth hormone|
324481|NCT01724489|Drug|Placebo|
324482|NCT01724476|Drug|folate with B12|
324483|NCT01724476|Drug|placebo|
324484|NCT01724463|Other|Severe Sepsis Management Bundle|"Management Bundle includes:~Securing Intravenous Access~Obtaining Blood Culture~Antibiotic Administration~Goal Directed Fluid Bolus Therapy~Oxygen Administration~Measuring Serum Lactate Levels"
324485|NCT01724450|Drug|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
324486|NCT01724450|Drug|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
324568|NCT01723917|Dietary Supplement|placebo|
324487|NCT01724437|Device|catheter based pulmonary vein isolation|catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
324488|NCT01724424|Drug|Melatonin|20 mg oral single dose
324489|NCT01724424|Drug|Melatonin|30 mg oral single dose
324490|NCT01724424|Drug|Melatonin|50mg oral single dose
324491|NCT01724424|Drug|Melatonin|100mg oral single dose
324492|NCT01724411|Other|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
324493|NCT01724398|Other|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
324494|NCT01724398|Other|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
324495|NCT01724398|Other|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
324496|NCT01724398|Other|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
324497|NCT01724385|Drug|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
324498|NCT01724372|Drug|Antidepressant|
324499|NCT01724372|Drug|Antipsychotic|
324500|NCT01724359|Drug|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
324501|NCT01724346|Drug|Post-Chlorambucil Therapy Follow-up|Patients remain in this Arm for continued follow-up until PD, unacceptable toxicity, or other reason for treatment discontinuation. All patients in this Arm have completed Chlorambucil therapy. Patients who have progression will exit the study.
324502|NCT01724346|Drug|Ibrutinib|Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily.
324503|NCT01724346|Drug|Second-line Ibrutinib|Patients in this arm who were previously eligible to receive Second-line Ibrutinib will exit the study with option to roll-over to another long-term Ibrutinib study, if eligible.
324504|NCT01724346|Drug|Alternative Anticancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion.
324505|NCT01724346|Drug|Alternative Anti-cancer Treatment|Specific therapy and treatment regimen are at the Investigator's discretion. Patients originally randomized to Chlorambucil will exit the study. Patients originally randomized to Ibrutinib will continue on study.
324506|NCT01724320|Drug|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
324507|NCT01724307|Procedure|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
324508|NCT01724281|Other|No intervention, only follow up|
324509|NCT01724268|Drug|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
324510|NCT01724268|Drug|Anti TNF + Meth|
324511|NCT01724255|Other|questionnaire|
324512|NCT01724242|Drug|Vaginal DHEA|
324513|NCT01724242|Drug|Placebo|
324514|NCT01724229|Drug|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
324515|NCT01724216|Device|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
324516|NCT01724203|Dietary Supplement|Lactobacillus rhamnosus|
324517|NCT01724203|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
324518|NCT01724203|Dietary Supplement|Placebo|
324519|NCT01724190|Drug|Vitamin D|
324520|NCT01724190|Drug|Placebo|
324521|NCT01724177|Drug|Lenalidomide|25 mg of Lenalidomide administered orally once daily
324522|NCT01724164|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
324523|NCT01724164|Behavioral|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
324524|NCT01724164|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
324525|NCT01724164|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
324526|NCT01724164|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
324527|NCT01724138|Drug|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
324528|NCT01724125|Other|personal electronic medical record|
324529|NCT01724112|Drug|LY2940094|Administered orally
324530|NCT01724112|Drug|Placebo|Administered orally
324531|NCT01724099|Drug|Euiiyin-tang|Korean medicinal herbal drug
324532|NCT01724099|Drug|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
324533|NCT01724086|Drug|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
324534|NCT01724086|Drug|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
324535|NCT01724086|Drug|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
324569|NCT01723904|Drug|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
324570|NCT01723891|Drug|Surfolase capsule|
324536|NCT01724086|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
324537|NCT01724086|Drug|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
324538|NCT01724086|Drug|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
324539|NCT01724073|Dietary Supplement|Leafy vegetable-fish sauce|
324540|NCT01724073|Dietary Supplement|Leafy vegetable-fish/liver sauce|
324541|NCT01724073|Dietary Supplement|Misola|
324542|NCT01724047|Behavioral|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
324543|NCT01724047|Behavioral|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
324544|NCT01724034|Other|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
324545|NCT01724034|Other|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
324546|NCT01724034|Other|Pulmonary Interstitial Syndrome|"If lung ultrasound shows B pattern - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial."
324547|NCT01724034|Other|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
324548|NCT01724034|Other|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
324549|NCT01724034|Other|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
324550|NCT01724021|Drug|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
324551|NCT01724021|Drug|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
324552|NCT01724021|Drug|Bendamustine|Standard chemotherapy
324553|NCT01724021|Drug|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
324554|NCT01724021|Drug|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
324555|NCT01724021|Drug|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
324556|NCT01724021|Drug|Rituximab|1400 mg SC, Day 1 Cycles 5-8
324557|NCT01723995|Radiation|low-level laser on nipples|The LASER HAND WL device, manufactured by MM Optics.
324558|NCT01723982|Drug|Barusiban (FE 200440)|
324559|NCT01723982|Drug|Placebo Comparator|
324560|NCT01723969|Genetic|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
324561|NCT01723956|Procedure|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
324562|NCT01723956|Procedure|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
324563|NCT01723943|Other|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
324564|NCT01723943|Other|counseling intervention|Undergo Helping Her Heal educational counseling program
324565|NCT01723943|Other|educational intervention|Undergo Helping Her Heal educational counseling program
324566|NCT01723943|Other|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
324571|NCT01723891|Drug|HT-002-01|
324572|NCT01723852|Dietary Supplement|Vitamin D at 30 ug/day|
324573|NCT01723852|Dietary Supplement|Vitamin D at 10 ug/day|
324574|NCT01723839|Drug|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
324575|NCT01723826|Drug|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
324576|NCT01723813|Biological|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
324577|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
324578|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
324579|NCT01723800|Drug|PI3K inhibitor BKM120|Given PO
324580|NCT01723800|Drug|pemetrexed disodium|Given IV
324581|NCT01723800|Drug|carboplatin|Given IV
324582|NCT01723800|Other|laboratory biomarker analysis|Correlative studies
324583|NCT01723800|Other|pharmacological study|Correlative studies
324584|NCT01723800|Procedure|quality-of-life assessment|Ancillary studies
324585|NCT01723774|Drug|PD0332991|
324586|NCT01723774|Drug|Anastrozole|
324587|NCT01723774|Drug|Goserelin|
324588|NCT01723774|Procedure|Surgery (standard of care)|-Breast and axillary lymph node surgery
324589|NCT01723774|Procedure|Tumor biopsy|
324590|NCT01723748|Drug|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
324591|NCT01723735|Drug|Alirocumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
324592|NCT01723735|Drug|Ezetimibe|"Pharmaceutical form: overencapsulated tablet~Route of administration: oral"
324593|NCT01723735|Drug|Ezetimibe Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
324594|NCT01723735|Drug|Fenofibrate|"Pharmaceutical form: tablet~Route of administration: oral"
324595|NCT01723722|Drug|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
324596|NCT01723722|Drug|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
324597|NCT01723696|Dietary Supplement|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
324598|NCT01723696|Dietary Supplement|Placebo tablet+prenatal vitamin|
324599|NCT01723683|Drug|Surfactant|
324600|NCT01723670|Drug|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
324601|NCT01723670|Drug|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
324602|NCT01723670|Drug|Placebo|oral tablet,once a day for 24 months
324603|NCT01723657|Drug|Ara-C|"Intermediate dose during induction phase to remission.~High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
324604|NCT01723657|Other|Autologous peripheral blood stem cell transplantation.|"In patients with favorable cytogenetics with a Leukocyte index above 20.~Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
324605|NCT01723657|Other|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
324606|NCT01723657|Drug|G-CSF|"Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.~Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
324607|NCT01723657|Other|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
324608|NCT01723657|Other|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
324609|NCT01723644|Other|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
324610|NCT01723644|Other|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
324611|NCT01723631|Device|Trap Myelin Test|
324612|NCT01723618|Drug|CRD007|
324613|NCT01723605|Procedure|insitu repair|closure of the uterine incision while the uterus initu
324614|NCT01723605|Procedure|exteriorisation of the uterus|uterine closure while the uterus is exteriorised
324799|NCT01721967|Drug|Ranolazine|
324615|NCT01723592|Dietary Supplement|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
324616|NCT01723592|Dietary Supplement|Oral lactose placebo|Placebo
324617|NCT01723579|Drug|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
324618|NCT01723579|Drug|Estradiol (E2)|Daily release of 1.5 mg
324619|NCT01723553|Drug|C-11 PiB|One time intravenous administration of ~740 megabecquerel (MBq) of [N-methyl-C-11]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
324620|NCT01723540|Procedure|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
324621|NCT01723527|Drug|Methadone|Clinic-Based Methadone Maintenance Treatment
324622|NCT01723527|Drug|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
324623|NCT01723527|Behavioral|Employment-based drug abstinence reinforcement|
324624|NCT01723514|Drug|Erenumab|Administered by subcutaneous injection once a month
324625|NCT01723514|Drug|Placebo|Administered by subcutaneous injection once a month
324626|NCT01723501|Drug|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
324627|NCT01723501|Drug|sterile water|Sterile water wipes (placebo)
324628|NCT01723488|Radiation|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
324629|NCT01723475|Biological|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
324630|NCT01723475|Biological|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
324631|NCT01723436|Other|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
324632|NCT01723410|Behavioral|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
324633|NCT01723410|Other|Writing about places, objects|
324634|NCT01723397|Drug|Nasaleze Spray|Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
324635|NCT01723397|Other|Placebo spray|Subjects are treated with placebo nasal spray then challenged with allergen
324636|NCT01723397|Biological|Allergen|Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
324637|NCT01723384|Drug|Intermittent Oral Naltrexone|
324638|NCT01723384|Drug|Placebo|
324639|NCT01723371|Drug|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
324640|NCT01723358|Device|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
324641|NCT01723345|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
324642|NCT01723332|Behavioral|Educational|"The first interaction will happen at study enrolment and will be educational in nature.~Following the session, the nurse will follow up with the participant to discuss any questions."
324643|NCT01723332|Behavioral|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.~Following the session, the nurse will follow up with the participant to discuss any questions."
324644|NCT01723319|Device|HBLPADD coil deep TMS|20 daily deep TMS treatment
324645|NCT01723319|Device|Sham|inactive treatment
324646|NCT01723306|Genetic|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
324647|NCT01723293|Behavioral|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.~Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
324648|NCT01723280|Drug|Oxygen|During and 2 hrs after surgery
324649|NCT01723267|Other|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
324650|NCT01723267|Other|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
324651|NCT01723254|Biological|IGE-1|Intramuscular, multiple dose
324652|NCT01723254|Biological|IGE-2|Intramuscular, multiple dose
324653|NCT01723254|Biological|Saline|Saline (0.9% sodium chloride)
324654|NCT01723241|Drug|XAF5, concentration A|
324655|NCT01723241|Drug|XAF5, concentration B|
324656|NCT01723241|Drug|XAF5, concentration C|
324657|NCT01723241|Drug|Placebo|
324658|NCT01723228|Drug|Rasagiline|
324659|NCT01723228|Drug|Placebo|
324800|NCT01721954|Drug|FOLFOX6m|
324660|NCT01723215|Behavioral|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
324661|NCT01723215|Behavioral|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
324662|NCT01723215|Behavioral|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
324663|NCT01723202|Drug|dabrafenib|150 mg orally twice daily given orally
324664|NCT01723202|Drug|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
324665|NCT01723202|Other|Correlative Studies|"Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)~BRAF mutation studies in circulating plasma DNA (all study patients)~Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)~Assess predictors of response (Archival tumor block/unstained slides in all study patients)~Pharmacokinetic studies (First 10 pts enrolled on each arm)~Pharmacogenomics studies (All study patients)"
324666|NCT01723176|Procedure|Echocardiography|
324667|NCT01723163|Behavioral|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
324668|NCT01723163|Behavioral|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
324669|NCT01723150|Drug|Ciprofloxacin|
324670|NCT01723150|Drug|Ceftriaxone|
324671|NCT01723150|Drug|Trimethoprim/sulfamethoxazole|
324672|NCT01723150|Drug|Ertapenem|
324673|NCT01723124|Procedure|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
324674|NCT01723098|Behavioral|Exercise group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
324675|NCT01723072|Biological|Omalizumab|Humanized monoclonal antibody against human IgE
324676|NCT01723072|Drug|Placebo|Placebo to omalizumab
324677|NCT01723059|Drug|Standard Triple Therapy|for 10 days
324678|NCT01723059|Drug|Sequential Therapy|total 10 days
324679|NCT01723046|Device|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
324680|NCT01723020|Drug|AMG 232|Given an an oral tablet in escalating doses.
324681|NCT01723007|Other|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
324682|NCT01722994|Device|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
324683|NCT01722994|Device|Chromic Gut Sterile absorbable Suture (Ethicon)|
324684|NCT01722981|Procedure|Percutaneous tracheostomy|Three methods of percutaneous tracheostomy
324685|NCT01722968|Drug|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
324686|NCT01722968|Drug|Paclitaxel|80mg/m2 iv weekly
324687|NCT01722955|Other|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
324688|NCT01722955|Other|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
324689|NCT01722942|Procedure|ICD implantation|ventricular ICD implantation
324690|NCT01722942|Drug|amiodarone hydrochloride|
324691|NCT01722929|Device|Skin sensor|
324692|NCT01722916|Drug|Hyaluronidase|
324693|NCT01722877|Device|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
324694|NCT01722864|Drug|COV155|COV155 tablets
324695|NCT01722838|Behavioral|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
324696|NCT01722825|Drug|LY2157299|Administered orally.
324697|NCT01722812|Drug|Cromoglicate|Twice daily topical treatment for 14 days
324698|NCT01722812|Drug|Placebo|Twice daily topical treatment for 14 days
324699|NCT01722799|Device|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
324700|NCT01722799|Device|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
324701|NCT01722773|Device|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
324702|NCT01722760|Procedure|measurements|
324703|NCT01722747|Behavioral|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)|A 7-month intervention was conducted over one academic year & included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
324704|NCT01722734|Behavioral|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
324705|NCT01722708|Drug|Clindamycin|Oral clindamycin 300 Milligrams*2/Day for a week
324706|NCT01722708|Drug|Metronidazole|Oral metronidazole 500 Milligrams*2/Day for a week
324707|NCT01722695|Other|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).~The order of dialyzers used will be randomly assigned to the patient at randomization."
324708|NCT01722682|Biological|Human pancreatic islet transplantation|
324709|NCT01722669|Drug|isoquercetin or quercetin|Single dose PK/PD study
324710|NCT01722656|Drug|Aflibercept|
324711|NCT01722643|Behavioral|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
324712|NCT01722643|Behavioral|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment—quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
324713|NCT01722630|Drug|Dopamine|
324714|NCT01722617|Other|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
324715|NCT01722604|Drug|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
324716|NCT01722604|Drug|Azopt 1%|Azopt 1%, RLD
324717|NCT01722591|Device|Cardiapex device|Cardiapex percutaneous transapical access and closure system
324718|NCT01722578|Drug|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
324719|NCT01722578|Drug|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
324720|NCT01722565|Procedure|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
324721|NCT01722552|Behavioral|adherence feedback|
324722|NCT01722552|Behavioral|standard of care|
324723|NCT01722539|Drug|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
324724|NCT01722539|Drug|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
324725|NCT01722539|Drug|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
324726|NCT01722539|Drug|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
324727|NCT01722526|Drug|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
324728|NCT01722513|Drug|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
324729|NCT01722487|Drug|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
324730|NCT01722487|Drug|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
324731|NCT01722474|Device|ASI Device|
324732|NCT01722461|Device|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
324733|NCT01722461|Device|Sham treatment|Ulthera System delivering no ultrasound energy
324734|NCT01722448|Dietary Supplement|Choline|4 capsules with 480 mg choline per day
324735|NCT01722448|Dietary Supplement|Placebo|
324736|NCT01722435|Drug|Opiate Substitution Treatment|
324737|NCT01722422|Drug|oxygen and saline|
324738|NCT01722409|Drug|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
324739|NCT01722409|Drug|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
324740|NCT01722396|Dietary Supplement|Vitamin D|
324741|NCT01722370|Drug|Oxygen|
324742|NCT01722370|Drug|Medical air equivalent|
324743|NCT01722357|Behavioral|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
324744|NCT01722357|Behavioral|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
324801|NCT01721954|Device|SIR-Spheres microspheres|
324802|NCT01721941|Drug|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
324999|NCT01720537|Biological|Placebo|Single Intravenous Infusion
325353|NCT01717807|Other|C11-Erlotinib PET/CT|
324745|NCT01722344|Behavioral|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
324746|NCT01722344|Behavioral|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
324747|NCT01722331|Drug|Tildrakizumab 200 mg|Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
324748|NCT01722331|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg/mL PFS
324749|NCT01722331|Drug|Matching Placebo|Matching placebo to tildrakizumab PFS
324750|NCT01722318|Drug|Plecanatide|
324751|NCT01722318|Drug|Placebo|
324752|NCT01722305|Drug|Dexamethasone|Given PO
324753|NCT01722305|Other|Laboratory Biomarker Analysis|Optional correlative studies
324754|NCT01722305|Other|Pharmacological Study|Optional correlative studies
324755|NCT01722305|Drug|Pomalidomide|Given PO
324756|NCT01722292|Drug|LY2940680|Administered orally
324757|NCT01722292|Drug|Carboplatin|Administered IV
324758|NCT01722292|Drug|Etoposide|Administered IV
324759|NCT01722292|Drug|Placebo|Administered orally
324760|NCT01722279|Procedure|Bariatric surgery|
324761|NCT01722266|Drug|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.~Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
324762|NCT01722266|Drug|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.~Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
324763|NCT01722253|Procedure|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
324764|NCT01722240|Drug|Liraglutide 1.8mg|
324765|NCT01722240|Drug|Placebo|
324766|NCT01722227|Drug|Liraglutide|
324767|NCT01722227|Drug|Placebo|
324768|NCT01722214|Biological|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
324769|NCT01722214|Other|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
324770|NCT01722201|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
324771|NCT01722201|Drug|Risperidone|1 mg tablet once a day
324772|NCT01722175|Procedure|ALPPS surgery|
324773|NCT01722175|Procedure|PVO surgery|
324774|NCT01722162|Drug|Bevacizumab|
324775|NCT01722162|Drug|Capecitabine|
324776|NCT01722162|Drug|Levocetirizine|
324777|NCT01722149|Genetic|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
324778|NCT01722136|Behavioral|Low Dosage|Exercise dose of 8kcal/kg/week
324779|NCT01722136|Behavioral|High Dosage|Exercise dose of 14kcal/kg/week
324780|NCT01722123|Other|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
324781|NCT01722110|Drug|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
324782|NCT01722110|Drug|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
324783|NCT01722097|Drug|Rocuronium|
324784|NCT01722097|Drug|placebo|
324785|NCT01722084|Behavioral|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
324786|NCT01722071|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
324787|NCT01722071|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
324788|NCT01722058|Drug|Peptide application|
324789|NCT01722045|Drug|Intravitreal Aflibercept Injection (IAI)|
324790|NCT01722032|Other|Childhood Obesity|
324791|NCT01722019|Device|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
324792|NCT01722019|Device|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
324793|NCT01722006|Behavioral|Pairing condition|
324794|NCT01722006|Behavioral|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
324795|NCT01721993|Drug|T121|
324796|NCT01721993|Drug|Zoledronic acid|
324797|NCT01721980|Drug|GLPG0974|
324798|NCT01721980|Drug|Placebo|
324803|NCT01721941|Drug|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
324804|NCT01721941|Drug|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
324805|NCT01721941|Drug|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
324806|NCT01721928|Device|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
324807|NCT01721915|Drug|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
324808|NCT01721915|Drug|Placebo|
324809|NCT01721902|Device|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
324810|NCT01721902|Other|Carrier Solution|Intra-myocardial injection of carrier solution
324811|NCT01721889|Radiation|Radiostereometric Analysis|The radiostereometric (RSA) patient exam (flexion and extension RSA images) presents additional radiation exposure to the patient above standard of care (additional radiographs). Assuming 120kV, using three protocols (two loaded and one unloaded) per RSA exam results in a typical effective dose of approximately 2.04mSv per exam(single lumbar spine RSA at 120kV yields 0.68mSv,). HBI recommends using 140kV for lumbar spine RSA and has conducted simulations to estimate the effective dose using higher kV settings. 140kV reduces the effective dose from 0.68mSv per spine RSA to 0.2mSV, resulting in a total effective dose per RSA exam of 0.6mSv. In comparison, the estimated effective dose for a single standard lumbar spine x-ray is 1.2mSv. This additional radiation exposure is considered to be minimal risk in consideration of the number of planar x-rays the patient will undergo as part of standard care, as well as average background radiation received by humans per year (3.1mSv).
324812|NCT01721876|Drug|placebo|comparator
324813|NCT01721876|Drug|volasertib|'Investigational Medicinal Product
324814|NCT01721876|Drug|low dose cytarabine|background medication
324815|NCT01721876|Drug|low dose cytarabine|background medication
324816|NCT01721863|Other|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
324817|NCT01721850|Other|control formula|commercial stage 1 infant formula
324818|NCT01721850|Other|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
324819|NCT01721850|Other|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
324820|NCT01721824|Behavioral|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
324821|NCT01721811|Other|Hyperoxia|
324822|NCT01721811|Other|Glucose|
324823|NCT01721798|Device|Mirena levonorgestrel IUD|Intrauterine contraception system
324824|NCT01721798|Device|Copper T-380a IUD|intrauterine contraception system
324825|NCT01721785|Drug|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
324826|NCT01721772|Biological|BMS-936558 (Nivolumab)|
324827|NCT01721772|Biological|Placebo matching BMS-936558 (Nivolumab)|
324828|NCT01721772|Drug|Dacarbazine|
324829|NCT01721772|Drug|Placebo matching Dacarbazine|
324830|NCT01721759|Drug|Nivolumab|
324831|NCT01721746|Biological|BMS-936558|
324832|NCT01721746|Drug|Dacarbazine|
324833|NCT01721746|Drug|Carboplatin|
324834|NCT01721746|Drug|Paclitaxel|
324835|NCT01721733|Drug|Placebo|
324836|NCT01721733|Drug|EPI-743 15 mg/kg|
324837|NCT01721733|Drug|EPI-743 5 mg/kg|
324838|NCT01721707|Drug|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
324839|NCT01721707|Drug|Latanoprost|1 drop in each eye, 1x/day, at 9PM
324840|NCT01721694|Drug|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
324841|NCT01721694|Drug|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
324842|NCT01721681|Biological|FACTOR X|
324843|NCT01721668|Behavioral|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
324844|NCT01721668|Behavioral|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
324845|NCT01721655|Drug|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
324846|NCT01721655|Drug|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
324847|NCT01721642|Device|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
324848|NCT01721629|Procedure|Sudden wean of nasal CPAP|
324849|NCT01721629|Procedure|Gradual wean of nasal CPAP|
324850|NCT01721616|Drug|Azithromycin|
324851|NCT01721616|Drug|Cefazolin|
324852|NCT01721603|Drug|Dabrafenib|150 mg capsule by mouth twice daily
324853|NCT01721603|Procedure|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
324938|NCT01720875|Drug|Vorinostat Velcade Dexamethasone|
324854|NCT01721603|Drug|Trametinib|2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
324855|NCT01721590|Drug|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
324856|NCT01721590|Drug|placebo|3 capsules/time，3times/day for 1 year
324857|NCT01721577|Drug|AXL1717|IGF-1 receptor inhibitor
324858|NCT01721564|Drug|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
324859|NCT01721551|Other|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
324860|NCT01721538|Other|Weight reduction program|
324861|NCT01721538|Other|Lecture on healthy nutrition|
324862|NCT01721525|Drug|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
324863|NCT01721512|Other|Breastfeeding|
324864|NCT01721512|Other|Infant formula|
324865|NCT01721499|Behavioral|Nutritional Counseling|weekly group and individual skills training to improve self control and decrease stress.
324866|NCT01721499|Behavioral|Mindfulness Intervention|
324867|NCT01721486|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
324868|NCT01721486|Drug|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
324869|NCT01721473|Other|positron emission tomography scan|2-FA positron emission tomography scan
324870|NCT01721460|Drug|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
324871|NCT01721447|Drug|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
324872|NCT01721434|Drug|Levosimendan|
324873|NCT01721434|Drug|Placebo|Similar coloured placebo
324874|NCT01721421|Other|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
324875|NCT01721421|Other|Standard treatment time|
324876|NCT01721408|Drug|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
324877|NCT01721408|Drug|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
324878|NCT01721395|Dietary Supplement|Agave Syrup|
324879|NCT01721382|Drug|Sitagliptin|
324880|NCT01721343|Behavioral|telephone-based intervention|Undergo telephonic monitoring
324881|NCT01721343|Other|case management|Participate in an individualized conditioning program with an RCM
324882|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
324883|NCT01721343|Procedure|physical therapy|Participate in an individualized conditioning program with an RCM
324884|NCT01721343|Other|questionnaire administration|Ancillary studies
324885|NCT01721343|Procedure|quality-of-life assessment|Ancillary studies
324886|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care
324887|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care
324888|NCT01721343|Other|educational intervention|Participate in an individualized conditioning program with an RCM
324889|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM
324890|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM
324891|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
324892|NCT01721330|Drug|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
324893|NCT01721330|Drug|Placebo|Placebo twice a day for 6 weeks
324894|NCT01721317|Drug|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
324895|NCT01721317|Drug|Placebo|Matching placebo will be available
324896|NCT01721304|Other|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
324897|NCT01721291|Drug|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
324898|NCT01721239|Other|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
324939|NCT01720849|Drug|Fampyra|The will be given as per normal patient treatment plan
325000|NCT01720524|Drug|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
324899|NCT01721226|Device|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
324900|NCT01721226|Other|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
324901|NCT01721213|Drug|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
324902|NCT01721200|Other|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
324903|NCT01721200|Other|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
324904|NCT01721174|Procedure|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
324905|NCT01721174|Procedure|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
324906|NCT01721161|Biological|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
324907|NCT01721161|Drug|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
324908|NCT01721148|Drug|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
324909|NCT01721135|Drug|GSK2190915 100mg|Film coated oral tablet
324910|NCT01721135|Drug|GSK2190915 200mg|Film coated oral tablet
324911|NCT01721135|Drug|moxifloxacin 400mg|Film coated oral tablet
324912|NCT01721135|Drug|moxifloxacin placebo|Film coated oral tablet
324913|NCT01721135|Drug|GSK2190915 placebo|Film coated oral tablet
324914|NCT01721109|Drug|EVG/COBI/FTC/TDF|150/150/200/300 mg STR administered orally once daily with food
324915|NCT01721096|Device|XIENCE PRIME - Long Length (LL)|Long Length
324916|NCT01721096|Device|XIENCE PRIME - Core Size|Core Size
324917|NCT01721083|Procedure|Procedure: Z-track|Subject received immunization by z-track
324918|NCT01721083|Procedure|Procedure: Bunch|Subject receives immunization by bunch method.
324919|NCT01721070|Drug|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
324920|NCT01721070|Drug|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
324921|NCT01721057|Drug|Placebo|Administered orally
324922|NCT01721057|Drug|Baricitinib|Administered orally
324923|NCT01721057|Drug|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
324924|NCT01721044|Drug|Placebo|Administered orally
324925|NCT01721044|Drug|Baricitinib|Administered orally
324926|NCT01721044|Drug|cDMARD|Participants will continue to take background cDMARD therapy throughout study.
324927|NCT01721031|Procedure|DPNB|Patients receive DPNB 30min before extubation at the end of operation
324928|NCT01721031|Drug|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
324929|NCT01721018|Biological|HSV1716 Intra-pleural delivery|
324930|NCT01721005|Other|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
324931|NCT01720992|Other|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
324932|NCT01720966|Procedure|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
324933|NCT01720953|Other|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
324934|NCT01720940|Drug|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
324935|NCT01720940|Drug|intermittent vancomycin infusion|
324936|NCT01720901|Drug|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
324937|NCT01720888|Other|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
324940|NCT01720836|Biological|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
324941|NCT01720823|Device|home polysomnography (GETEMED)|
324942|NCT01720823|Device|standard polysomnography (BRAINNET II)|
324943|NCT01720797|Device|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
324944|NCT01720797|Drug|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
324945|NCT01720797|Other|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
324946|NCT01720784|Dietary Supplement|Alginate dietary fiber|
324947|NCT01720784|Dietary Supplement|Placebo|
324948|NCT01720771|Dietary Supplement|probiotic tablet|Intake of one probiotic lozenge tablet per day
324949|NCT01720771|Dietary Supplement|sugar pill|one tablet daily
324950|NCT01720732|Behavioral|Lifeline NET|Short Version of Narrative Exposure Therapy
324951|NCT01720719|Drug|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
324952|NCT01720719|Drug|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
324953|NCT01720706|Device|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.~This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
324954|NCT01720693|Procedure|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
324955|NCT01720680|Radiation|Low dose multislice CT thorax|"All patients will have 2 low dose multi-slice CT's at visit 2: one CT pre-dose and one CT 1 to 3 hours post-dose."
324956|NCT01720680|Device|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
324957|NCT01720667|Drug|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
324958|NCT01720667|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
324959|NCT01720654|Behavioral|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
324960|NCT01720641|Behavioral|Internet|Referral and user instructions for Peru section of www.inspot.org partner notification website
324961|NCT01720641|Behavioral|Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
324962|NCT01720641|Behavioral|Internet and Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
324963|NCT01720628|Other|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
324964|NCT01720615|Drug|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
324965|NCT01720615|Drug|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
324966|NCT01720602|Drug|vorinostat|Given PO
324967|NCT01720602|Drug|anastrozole|Given PO
324968|NCT01720602|Drug|letrozole|Given PO
324969|NCT01720602|Drug|exemestane|Given PO
324970|NCT01720602|Procedure|positron emission tomography|Correlative studies
324971|NCT01720602|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
324972|NCT01720602|Radiation|fludeoxyglucose F 18|Correlative studies
324973|NCT01720602|Other|laboratory biomarker analysis|Correlative studies
324974|NCT01720589|Dietary Supplement|Melt (test oil)|
324975|NCT01720589|Dietary Supplement|Corn oil (control)|
324976|NCT01720576|Drug|REGN1033 (SAR391786)|
324977|NCT01720576|Drug|Placebo|
324978|NCT01720563|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
324979|NCT01720563|Drug|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
324980|NCT01720563|Procedure|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
324981|NCT01720550|Drug|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
324982|NCT01720550|Drug|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
324983|NCT01720537|Biological|PF-05335810 Dose A|Single SC Injection
324984|NCT01720537|Biological|PF-05335810 Dose B|Single Subcutaneous Injection(s)
324985|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
324986|NCT01720537|Biological|PF-05335810 Dose B|Single Intravenous Infusion
324987|NCT01720537|Biological|Placebo|Single Intravenous Infusion
324988|NCT01720537|Biological|PF-04950615 Dose A|Single Subcutaneous Injection(s)
324989|NCT01720537|Biological|PF-04950615 Dose A|Single Intravenous Infusion
324990|NCT01720537|Biological|PF-05335810 Dose C|Single Subcutaneous Injection(s)
324991|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
324992|NCT01720537|Biological|PF-05335810 Dose C|Single Intravenous Infusion
324993|NCT01720537|Biological|Placebo|Single Intravenous Infusion
324994|NCT01720537|Biological|PF-04950615|Single Subcutaneous Injection(s)
324995|NCT01720537|Biological|PF-05335810 Dose D|Single Subcutaneous Injection(s)
324996|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
324997|NCT01720537|Biological|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
324998|NCT01720537|Biological|PF-05335810 Dose D|Single Intravenous Infusion
325001|NCT01720524|Drug|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
325002|NCT01720511|Dietary Supplement|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
325003|NCT01720511|Dietary Supplement|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
325004|NCT01720498|Drug|remifentanil|The effect site concentration of remifentanil
325005|NCT01720485|Drug|Desloratadine + Prednisolone|1 tablet 3 times a day
325006|NCT01720485|Drug|Dexchlorpheniramine + Betamethasone|1 tablet 3 times a day
325007|NCT01720472|Genetic|Biomarker studies|
325008|NCT01720459|Dietary Supplement|Micronized trans-resveratrol|
325009|NCT01720459|Dietary Supplement|Placebo|
325010|NCT01720446|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
325011|NCT01720446|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
325012|NCT01720446|Drug|placebo|Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
325013|NCT01720433|Procedure|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
325014|NCT01720420|Device|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
325015|NCT01720407|Drug|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
325016|NCT01720407|Drug|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
325017|NCT01720394|Device|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
325018|NCT01720394|Drug|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
325019|NCT01720342|Procedure|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
325020|NCT01720329|Dietary Supplement|Probiotics|Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
325021|NCT01720329|Other|probiotic placebo|Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
325022|NCT01720316|Drug|Glycine|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
325023|NCT01720316|Drug|placebo|
325024|NCT01720303|Drug|repaglinide|2 mg (tablets) before each main meal
325025|NCT01720303|Drug|isophane human insulin|Injection s.c. (under the skin) at bedtime
325026|NCT01720303|Drug|insulin|Injection s.c. (under the skin) twice daily
325027|NCT01720290|Drug|repaglinide|Dose individually adjusted
325028|NCT01720290|Drug|metformin|Dose individually adjusted
325029|NCT01720290|Drug|metformin|Dose at 1000 mg/day
325030|NCT01720277|Biological|HD Fluzone Vaccine|Nursing home residents over 65 years are allocated to receive high dose trivalent vaccine. Residents under 65 years are provided standard dose trivalent vaccine (TIV).
325031|NCT01720277|Biological|SD Fluzone Vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
325032|NCT01720264|Drug|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
325033|NCT01720251|Drug|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
325034|NCT01720251|Drug|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
325035|NCT01720251|Drug|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
325036|NCT01720238|Drug|Entecavir|0.5mg qd
325037|NCT01720238|Drug|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
325038|NCT01720225|Drug|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
325039|NCT01720225|Drug|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
325040|NCT01720212|Drug|YM178|oral
325041|NCT01720199|Other|Diario della Salute (DDS)|"DDS is composed by~tools for children and their parents on health and social and emotional well-being issues:~a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),~a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);~five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
325042|NCT01720186|Device|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
325043|NCT01720173|Biological|Dalantercept|Given SC
325044|NCT01720173|Other|Laboratory Biomarker Analysis|Correlative studies
325045|NCT01720160|Device|BAROSTIM NEO® System|Implant procedure
325046|NCT01720160|Other|Standard of care medical managment therapy for heart failure|Standard of care medical management therapy for heart failure (AHA/ACC guidelines), including drugs (determined by the patient's physician). Drug types include: Loop Diuretics, Thiazide Diuretics, Potassium-sparing Diuretics, Sequential Nephron Blockade, ACE Inhibitors, ARBs, ARNI, Aldosterone Antagonists, Beta Blockers and Hydralazine and Isosorbide Dinitrate.
325047|NCT01720147|Drug|Quercetin (dietary supplement)|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.~An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
325048|NCT01720121|Other|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
325049|NCT01720108|Drug|rivaroxaban and ASA|
325050|NCT01720095|Drug|Niaspan|
325051|NCT01720082|Procedure|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
325052|NCT01720082|Procedure|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
325053|NCT01720069|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
325054|NCT01720056|Drug|Verapamil|
325055|NCT01720056|Drug|Kenalog 10|
325056|NCT01720043|Drug|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
325057|NCT01720030|Drug|Levosimendan|Verum therapy
325058|NCT01720030|Drug|Conventional therapy|Placebo therapy to safeguard blinding
325059|NCT01720017|Other|Preclinical Manikin Training|During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.
325060|NCT01720017|Other|Inservice Training|Inservice training will include review of a product information handout and a video demonstration.
325061|NCT01720004|Other|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
325062|NCT01719991|Other|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.~Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
325063|NCT01719978|Drug|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
325064|NCT01719978|Procedure|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
325065|NCT01719978|Drug|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
325066|NCT01719978|Drug|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
325067|NCT01719965|Other|Interviews and Focus Group Discussions|
325068|NCT01719952|Drug|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.~pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
325069|NCT01719952|Drug|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
325070|NCT01719926|Drug|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
325071|NCT01719913|Other|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
325072|NCT01719913|Other|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
325073|NCT01719900|Dietary Supplement|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
325074|NCT01719900|Dietary Supplement|Control|Control biscuit with no yellow pea hull fibre.
325075|NCT01719887|Device|Conservative treatment|Conservative treatment with functional brace.
325076|NCT01719887|Procedure|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
325077|NCT01719887|Other|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
325078|NCT01719874|Biological|TCN-032|
325079|NCT01719874|Biological|Placebo (saline)|
325080|NCT01719861|Drug|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
325081|NCT01719848|Other|Measurements of parameters related with physical examinations for difficult airway prediction|
325082|NCT01719835|Drug|Cyclophosphamide|750mg/m2 IV every 21 days
325083|NCT01719835|Drug|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
325084|NCT01719835|Drug|Doxorubicin|50mg/m2 IV every 21 days
325085|NCT01719835|Drug|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
325086|NCT01719835|Drug|Prednisolone|100mg PO Days 1-5 every 21 days
325087|NCT01719835|Drug|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
325088|NCT01719835|Drug|Cisplatin|100mg/m2 IV Day 15 every 28 days
325089|NCT01719822|Device|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
325090|NCT01719796|Procedure|Regional analgesia infusion|
325091|NCT01719783|Biological|LAIV H5N2|2 doses provided intranasally
325092|NCT01719783|Other|Placebo|2 doses of placebo provided intranasally
325093|NCT01719770|Drug|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
325094|NCT01719770|Other|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
325095|NCT01719757|Drug|Oxycodone/Naloxone|Twice daily
325096|NCT01719744|Drug|ENMD-2076|
325097|NCT01719731|Behavioral|Education|This group will receive the psychoeducation
325098|NCT01719731|Behavioral|Non-Education|This group will not receive the psychoeducation
325099|NCT01719718|Procedure|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
325100|NCT01719718|Procedure|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
325101|NCT01719705|Drug|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
325102|NCT01719705|Drug|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
325103|NCT01719705|Drug|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
325104|NCT01719692|Drug|Rituximab|
325105|NCT01719679|Behavioral|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
325106|NCT01719666|Procedure|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
325107|NCT01719666|Procedure|conventional surgery|conventional surgery: MPFL reconstruction
325108|NCT01719653|Drug|MiraLAX|MiraLAX consumed as described in each arm.
325109|NCT01719653|Other|Gatorade|Gatorade consumed as described in each arm.
325110|NCT01719653|Drug|MoviPrep|MoviPrep consumed as described in each arm.
325111|NCT01719653|Drug|SUPREP|SUPREP consumed as described in each arm.
325112|NCT01719640|Drug|infusion of BMMSCs|infusion of BMMSCs
325113|NCT01719640|Drug|infusion BMMNCs|infusion of BMMNCs
325114|NCT01719640|Drug|insulin|intensive insulin care
325115|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 300mg
325116|NCT01719627|Drug|TVD 300/200 QD|TVD 300/200 QD during 7 days
325117|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 600mg
325118|NCT01719614|Drug|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
325119|NCT01719614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
325120|NCT01719601|Drug|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
325121|NCT01719588|Drug|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
325122|NCT01719575|Drug|Motilitone|
325123|NCT01719575|Drug|Placebo|
325124|NCT01719562|Procedure|Magnetic resonance imaging|Patients undergo MRI scans for left ventricular function, T1 myocardial signal, and aortic PWV at baseline, 3 months, and 24 months.
325125|NCT01719562|Other|Physical Activity|Tailored aerobic exercise program onsite and at home.
325126|NCT01719562|Other|Healthy Living|Healthy living presentations at a centralized meeting place and over the phone.
325127|NCT01719562|Device|Cardiopulmonary Exercise Testing (CPET)|Performed on the treadmill using the Bruce or Modified Bruce protocol based on current fitness level.
325128|NCT01719562|Other|Questionnaire Administration|A self-administered 13-item scale to assess fatigue in participants
325129|NCT01719549|Drug|Dovitinib|"Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule~Study drug: TKI258 capsule~Dose: 500mg p.o. qd~Every 3 weeks"
325130|NCT01719536|Drug|Icotinib|Icotinib: 125 mg is administered orally three times per day.
325131|NCT01719536|Drug|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
325132|NCT01719523|Drug|EPI-743|
325176|NCT01719120|Behavioral|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
325177|NCT01719107|Dietary Supplement|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
325178|NCT01719107|Dietary Supplement|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
325133|NCT01719510|Other|Samples|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.~For both groups:~one swab for GBS detection by real-time PCR~the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.~For all women included will be achieved in the delivery room:~To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.~A sampling of umbilical cord blood.~Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.~For mothers, the collection of 3-5 ml of milk when breastfeeding."
325134|NCT01719497|Drug|[C-11]OMAR|PET radioligand
325135|NCT01719458|Drug|(S,S)-[11C]MRB|PET radioligand
325136|NCT01719419|Drug|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
325137|NCT01719419|Drug|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
325138|NCT01719406|Behavioral|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
325139|NCT01719380|Drug|LGX818|
325140|NCT01719380|Drug|Cetuximab|
325141|NCT01719380|Drug|BYL719|
325142|NCT01719367|Drug|Atenolol|
325143|NCT01719354|Other|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
325144|NCT01719354|Other|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
325145|NCT01719328|Behavioral|Vinyasa yoga|
325146|NCT01719315|Other|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
325147|NCT01719302|Drug|Gemcitabine|1500 mg/m^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
325148|NCT01719302|Drug|Docetaxel|50 mg/m^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
325149|NCT01719302|Drug|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
325150|NCT01719289|Behavioral|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
325151|NCT01719276|Other|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
325152|NCT01719276|Other|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
325153|NCT01719263|Device|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
325154|NCT01719263|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
325155|NCT01719250|Drug|Buparlisib|Given PO
325156|NCT01719250|Other|Laboratory Biomarker Analysis|Correlative studies
325157|NCT01719250|Other|Questionnaire Administration|Ancillary studies
325158|NCT01719237|Drug|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
325159|NCT01719237|Drug|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
325160|NCT01719224|Procedure|elevated body position|45 degrees elevated upper body position
325161|NCT01719224|Procedure|supine body position|non-elevated upper body position
325162|NCT01719185|Drug|Phentermine and B12|
325163|NCT01719185|Drug|Phentermine|
325164|NCT01719172|Device|Veriset™ Hemostatic Patch|Topical Hemostat
325165|NCT01719159|Drug|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
325166|NCT01719146|Other|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
325167|NCT01719133|Drug|placebo|saline solution
325168|NCT01719133|Drug|Histamine|positive control
325169|NCT01719133|Drug|AllerT1|synthetic peptide T1
325170|NCT01719133|Drug|AllerT2|synthetic peptide T2
325171|NCT01719133|Drug|AllerT3|synthetic peptide T3
325172|NCT01719133|Drug|AllerT4|synthetic peptide T4
325173|NCT01719133|Drug|AllerT5|synthetic peptide T5
325174|NCT01719133|Drug|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
325175|NCT01719133|Drug|mix of AllerT4-T5|mix T4-T5
325179|NCT01719081|Procedure|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
325180|NCT01719055|Device|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
325181|NCT01719042|Drug|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
325182|NCT01719042|Dietary Supplement|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
325183|NCT01719029|Other|Low-Carbohydrate/Higher Fat Diet|
325184|NCT01719029|Other|High Carbohydrate/Low fat diet|
325185|NCT01719016|Procedure|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:~N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress~Lexiscan - stress agent for PET scan~Patients would also undergo Coronary catheterization including the following drug administration and device usage:~Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).~Adenosine - stress agent during catheterization, 140 ug/Kg/min"
325186|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
325187|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
325188|NCT01719003|Drug|Empagliflozin low dose qd|Empagliflozin low dose once daily
325189|NCT01719003|Drug|Empagliflozin high dose qd|Empagliflozin high dose once daily
325190|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
325191|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
325192|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
325193|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
325194|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
325195|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
325196|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
325197|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
325198|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
325199|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
325200|NCT01718977|Other|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
325201|NCT01718977|Other|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.~The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
325202|NCT01718964|Drug|Cortisol 20 mg|
325203|NCT01718964|Drug|Mannitol|Mannitol used as placebo
325204|NCT01718951|Drug|golimumab|golimumab
325205|NCT01718951|Drug|Pamidronate|pamidronate
325206|NCT01718938|Drug|velusetrag dose 1|
325207|NCT01718938|Drug|velusetrag dose 2|
325208|NCT01718938|Drug|velusetrag dose 3|
325209|NCT01718938|Drug|placebo|
325210|NCT01718912|Drug|metronidazole-nystatin oral rinse|
325211|NCT01718899|Biological|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
325212|NCT01718886|Device|Obalon Gastric Balloon|
325213|NCT01718873|Drug|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
325214|NCT01718873|Drug|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
325215|NCT01718873|Drug|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
325216|NCT01718873|Drug|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
325217|NCT01718873|Drug|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
325218|NCT01718860|Procedure|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
325219|NCT01718847|Drug|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
325220|NCT01718834|Biological|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
325221|NCT01718834|Biological|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
325222|NCT01718808|Drug|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
325223|NCT01718808|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
325224|NCT01718795|Device|Bag-valve mask or laryngeal tube ventilation|"Interventions are either Bag-valve mask (BVM) or Laryngeal tube (LT) ventilation during CPR"
325225|NCT01718782|Device|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
325226|NCT01718782|Device|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
325227|NCT01718769|Other|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
325228|NCT01718756|Drug|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
325229|NCT01718756|Drug|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
325230|NCT01718756|Drug|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
325231|NCT01718743|Drug|Ixazomib Citrate|Given PO
325232|NCT01718743|Drug|Lenalidomide|Given PO
325233|NCT01718743|Other|Questionnaire Administration|Ancillary studies
325234|NCT01718730|Device|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
325235|NCT01718730|Device|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
325236|NCT01718717|Other|Thoracic Epidural Analgesia (TEA)|
325237|NCT01718717|Other|TEA followed by Intravenous morphine|
325238|NCT01718704|Device|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
325239|NCT01718691|Drug|SyB L-0501|A dose of 90 mg/m^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
325240|NCT01718691|Drug|rituximab|A dose of 375 mg/m^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
325241|NCT01718678|Drug|Melatonin|it is kind of drug
325242|NCT01718678|Drug|Placebo|It is Placebo
325243|NCT01718652|Drug|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
325244|NCT01718652|Drug|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
325245|NCT01718639|Device|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
325246|NCT01718639|Device|IQP-LH-101 liquid|Oral medical device in the form of a liquid
325247|NCT01718639|Other|Placebo|
325248|NCT01718626|Drug|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
325249|NCT01718626|Drug|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
325250|NCT01718613|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
325251|NCT01718613|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
325252|NCT01718600|Behavioral|Neuropsychological testing|
325253|NCT01718587|Procedure|stem cell transplantation through interventional procedure|interventional procedure once
325254|NCT01718587|Drug|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
325255|NCT01718574|Other|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
325256|NCT01718561|Procedure|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
325257|NCT01718548|Dietary Supplement|Cordyceps Sinensis (CS) and Lingzhi|
325258|NCT01718548|Dietary Supplement|Tea and Flour|Placebo
325259|NCT01718535|Device|Spartan FRX CYP2C19 Test System|
325260|NCT01718522|Device|sensor augmented pump (SAP)|
325261|NCT01718509|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
325262|NCT01718509|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
325263|NCT01718496|Drug|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
325264|NCT01718496|Drug|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
325265|NCT01718483|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
325266|NCT01718483|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
325267|NCT01718470|Procedure|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
325268|NCT01718470|Procedure|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
325269|NCT01718457|Device|Endobarrier|
325270|NCT01718444|Drug|Progestin|
325271|NCT01718444|Drug|Clomiphene Citrate|
325272|NCT01718431|Other|test meal|
325273|NCT01718431|Other|reference meal|
325274|NCT01718418|Other|test meal|
325275|NCT01718418|Other|reference|
325276|NCT01718405|Other|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
325277|NCT01718405|Genetic|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
325278|NCT01718392|Behavioral|Training|
325279|NCT01718379|Drug|Lenalidomide|Lenalidomide:10 mg per day during 21 days
325280|NCT01718379|Drug|Epoetin beta|Epoetin beta: 60,000 Units/week.
325281|NCT01718366|Drug|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
325282|NCT01718353|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: Concentrate for solution for infusion Route of administration: Intravenous
325283|NCT01718353|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: Concentrate and solvent for solution for infusion Route of administration: Intravenous
325284|NCT01718353|Drug|Prednisone|Pharmaceutical form: Tablet Route of administration: Oral
325285|NCT01718340|Drug|Metformin|metformin tablet 500mg three time per day
325286|NCT01718327|Drug|Sunitinib|sunitinib dose :37.5mg/day
325287|NCT01718314|Drug|Sublingual Misoprostol|
325288|NCT01718314|Drug|Lidocaine pump spray|
325289|NCT01718314|Drug|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
325290|NCT01718314|Drug|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
325291|NCT01718301|Drug|boceprevir|
325292|NCT01718301|Drug|Ribavirin|
325293|NCT01718301|Drug|Peginterferon alfa-2a|
325294|NCT01718301|Drug|Peginterferon alfa-2b|
325295|NCT01718288|Drug|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).~For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.~The 4 groups:~1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment~B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment~A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment~2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
325296|NCT01718288|Drug|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.~correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
325297|NCT01718249|Other|Implantable neurostimulation system|
325298|NCT01718236|Drug|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
325299|NCT01718236|Drug|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
325300|NCT01718223|Drug|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
325301|NCT01718223|Procedure|therapeutic conventional surgery|Undergo surgical resection
325302|NCT01718223|Other|laboratory biomarker analysis|Correlative studies
325303|NCT01718223|Drug|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
325304|NCT01718210|Drug|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
325305|NCT01718210|Drug|CONTROL|group of controls treated with a standard IVF medium
325306|NCT01718184|Procedure|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
325307|NCT01718184|Procedure|Sulcoflex intraocular lens implantation|
325308|NCT01718158|Biological|Peginterferon Lambda-1a|
325309|NCT01718158|Biological|Peginterferon Alfa-2a|
325310|NCT01718158|Drug|Ribavirin|
325311|NCT01718158|Drug|Daclatasvir|
325312|NCT01718158|Drug|Telaprevir|
325313|NCT01718145|Drug|Daclatasvir|
325314|NCT01718145|Drug|Asunaprevir|
325315|NCT01718145|Drug|Ribavirin|
325316|NCT01718145|Biological|pegIFNα-2b|
325317|NCT01718145|Drug|Telaprevir|
325318|NCT01718119|Drug|r-hCG|r-hCG(250mcg) injection subcutaneously
325319|NCT01718106|Device|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
325320|NCT01718093|Drug|Sitagliptin|up to 50 mg twice a day
325321|NCT01718093|Drug|Metformin|up to 1000 mg twice a day
325322|NCT01718093|Drug|Sitagliptin + Metformin|up to 50/1000 mg twice a day
325323|NCT01718067|Device|VAKÜM system|15 minutes, twice a day.
325324|NCT01718067|Other|conventional manual ELTGOL technique|20 minutes twice a day
325325|NCT01718054|Dietary Supplement|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
325326|NCT01718054|Dietary Supplement|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
325327|NCT01718054|Drug|Chloroquine|
325328|NCT01718041|Drug|Experimental: VRS-317|Active treatment arm
325329|NCT01718028|Other|Propylene glycol 0.6% ocular emulsion|
325330|NCT01718028|Other|Sodium chloride 0.9% saline solution|
325331|NCT01718002|Behavioral|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
325332|NCT01717976|Behavioral|DISPO ED|primary care based nurse telephone support
325333|NCT01717963|Drug|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
325334|NCT01717963|Drug|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
325335|NCT01717950|Biological|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
325336|NCT01717950|Biological|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
325337|NCT01717937|Procedure|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
325338|NCT01717924|Procedure|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
325339|NCT01717924|Procedure|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
325340|NCT01717911|Drug|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
325341|NCT01717911|Drug|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
325342|NCT01717911|Drug|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
325343|NCT01717898|Drug|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
325344|NCT01717898|Drug|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
325345|NCT01717898|Drug|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
325346|NCT01717872|Device|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
325347|NCT01717859|Drug|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 > 3.2, dosage will be escalated to 8 mg/kg.
325348|NCT01717846|Drug|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
325349|NCT01717846|Other|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
325350|NCT01717833|Procedure|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
325351|NCT01717833|Procedure|Sham|Sham sessions of neuromuscular electrical stimulation
325352|NCT01717820|Dietary Supplement|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
325354|NCT01717794|Procedure|Thunderbeat technology|
325355|NCT01717794|Procedure|Standard bipolar electrosurgery|
325356|NCT01717781|Procedure|Thunderbeat technology|
325357|NCT01717781|Procedure|Standard bipolar electrosurgery|
325358|NCT01717768|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
325359|NCT01717755|Other|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
325360|NCT01717742|Drug|tPA|Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
325361|NCT01717742|Drug|DNase|Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
325362|NCT01717742|Other|Placebo|Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (>10 kg)
325363|NCT01717729|Procedure|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
325364|NCT01717729|Radiation|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
325365|NCT01717716|Dietary Supplement|water with Sucralose|
325366|NCT01717716|Dietary Supplement|water with HFCS|
325367|NCT01717716|Dietary Supplement|water with glucose|
325368|NCT01717716|Dietary Supplement|water with sucrose|
325369|NCT01717703|Dietary Supplement|Water|
325370|NCT01717703|Dietary Supplement|Fruit drink|
325371|NCT01717703|Dietary Supplement|Cola|
325372|NCT01717703|Dietary Supplement|1% chocolate milk|
325373|NCT01717690|Drug|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
325374|NCT01717677|Procedure|radical prostatectomy|
325375|NCT01717677|Radiation|percutaneous radiation therapy|
325376|NCT01717677|Radiation|permanent seed implantation|
325377|NCT01717677|Procedure|Active Surveillance|
325378|NCT01717664|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
325379|NCT01717638|Biological|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
325380|NCT01717638|Biological|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
325381|NCT01717625|Drug|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
325382|NCT01717612|Drug|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
325383|NCT01717612|Drug|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
325384|NCT01717599|Drug|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
325385|NCT01717599|Drug|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
325386|NCT01717586|Drug|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into three cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg or 40mg.
325387|NCT01717586|Drug|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
325388|NCT01717573|Procedure|Deferred stenting|
325389|NCT01717573|Procedure|Conventional treatment|
325390|NCT01717560|Other|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C~multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
325391|NCT01717547|Behavioral|Yoga-based treatment|
325392|NCT01717534|Dietary Supplement|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
325393|NCT01717508|Behavioral|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
325394|NCT01717482|Drug|Metformin|
325395|NCT01717482|Other|Placebo Comparator|Standard of Care Observation
325396|NCT01717469|Device|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
325397|NCT01717469|Device|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
325398|NCT01717456|Other|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
325399|NCT01717456|Dietary Supplement|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
325400|NCT01717456|Drug|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.~Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
325401|NCT01717456|Behavioral|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
325402|NCT01717456|Behavioral|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
325403|NCT01717456|Behavioral|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
325404|NCT01717456|Other|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
325405|NCT01717417|Device|miniscrew|
325406|NCT01717417|Device|TPA|
325407|NCT01717404|Drug|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
325408|NCT01717391|Drug|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
325409|NCT01717352|Behavioral|Weight Loss Education|
325410|NCT01717352|Behavioral|Sleep and Eating Routine|
325411|NCT01717339|Other|Sleep Study|
325412|NCT01717326|Drug|Grazoprevir|100 mg tablet orally QD
325413|NCT01717326|Drug|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
325414|NCT01717326|Drug|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
325415|NCT01717326|Drug|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
325416|NCT01717313|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
325417|NCT01717313|Drug|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
325418|NCT01717313|Drug|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
325419|NCT01717313|Drug|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
325420|NCT01717313|Drug|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
325421|NCT01717300|Drug|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
325422|NCT01717300|Drug|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
325423|NCT01717300|Drug|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
325424|NCT01717300|Drug|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
325425|NCT01717287|Drug|Raltegravir Film-coated Tablet|
325426|NCT01717287|Drug|Raltegravir Chewable Tablet|
325427|NCT01717287|Drug|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
325428|NCT01717274|Procedure|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
325429|NCT01717261|Radiation|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
325430|NCT01717248|Drug|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
325431|NCT01717235|Drug|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
325432|NCT01717222|Drug|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
325433|NCT01717222|Drug|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
325434|NCT01717209|Drug|Nitric Oxide|inhaled nitric oxide
325435|NCT01717209|Drug|Prostacyclin|inhaled prostacyclin
325436|NCT01717196|Other|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
325437|NCT01717183|Device|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
325438|NCT01717183|Device|Placebo URGO 310 3113 dressing|
325439|NCT01717170|Drug|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
325440|NCT01717157|Drug|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
325555|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
325441|NCT01717157|Drug|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
325442|NCT01717157|Drug|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
325443|NCT01717157|Drug|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
325444|NCT01717157|Drug|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
325445|NCT01717144|Behavioral|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
325446|NCT01717131|Procedure|Surgery for standard axillary node dissection|
325447|NCT01717131|Other|No axillary lymph node dissection|No surgery on axillary lymph node
325448|NCT01717118|Biological|Bivalent Vaccines|
325449|NCT01717118|Biological|Tetravalent Vaccine|
325450|NCT01717079|Procedure|Sham rTMS|120 pulses 0.2Hz
325451|NCT01717079|Procedure|rTMS|120 pulses 0.2Hz
325452|NCT01717066|Drug|the ginsenoside Rg3|
325453|NCT01717066|Drug|Placebo|
325454|NCT01717053|Drug|Abiraterone acetate|1000 mg orally once a day for 6 months.
325455|NCT01717053|Drug|Androgen deprivation|LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
325456|NCT01717053|Radiation|Radiation Therapy|Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
325457|NCT01717053|Drug|Prednisone|5 mg tablet once daily for 6 months.
325458|NCT01717040|Drug|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
325459|NCT01717040|Drug|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
325460|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
325461|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
325462|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
325463|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
325464|NCT01717014|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
325465|NCT01716975|Drug|EVP-6124|Arms 1, 2
325466|NCT01716975|Drug|Placebo|Arm 3
325467|NCT01716962|Other|Infusion of 6% tetrastarch for a total of 500 ml|
325468|NCT01716949|Radiation|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
325469|NCT01716949|Procedure|Hyperthermia|10 sessions, therapeutic time 60 min
325470|NCT01716949|Drug|5-Fluorouracil|250 mg/m^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
325471|NCT01716949|Drug|Capecitabine|1650 mg/m^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
325472|NCT01716949|Drug|Oxaliplatin|50 mg/m^2/d as 2-hour bolus infusion on d2, 9, 23, 30
325473|NCT01716923|Biological|S-303 Red Blood Cells (RBCs) - Test|
325474|NCT01716923|Biological|Conventional, untreated red blood cells (RBCs) - Control|
325475|NCT01716910|Dietary Supplement|Combination of Lactobacillus acidophilus NCFM and cellobiose|
325476|NCT01716897|Drug|E2609|
325477|NCT01716871|Device|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
325478|NCT01716871|Device|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
325479|NCT01716858|Dietary Supplement|Sulforaphane-rich Broccoli Sprout Extract|
325480|NCT01716832|Behavioral|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
325481|NCT01716819|Other|Urine sample|dosages on one spot and 24h collection
325482|NCT01716819|Other|Blood sample|dosages
325483|NCT01716819|Other|Assessment of sleep apnea syndrome|
325484|NCT01716819|Other|Electrocardiogram|
325485|NCT01716819|Other|Glucose tolerance test|
325486|NCT01716819|Other|Echocardiography|
325487|NCT01716819|Other|cardiac and abdominal magnetic resonance imaging|
325488|NCT01716819|Other|Ambulatory blood pressure monitoring|
325489|NCT01716819|Other|Echotracking|
325490|NCT01716819|Other|Pulse wave velocity|
325491|NCT01716819|Other|Composition of body mass by Dual x-ray absorptiometry|
325492|NCT01716806|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
325493|NCT01716806|Drug|bendamustine|70 mg/m2 by IV infusion on Days 1 and 2 of 3-week cycle
325494|NCT01716806|Drug|dacarbazine|375 mg/m2 every 3 weeks by IV infusion
325495|NCT01716806|Drug|nivolumab|3 mg/kg every 3 weeks by IV infusion
325496|NCT01716793|Drug|Ara-C|"Intermediate dose during induction phase to remission.~High-dose during consolidation phase in patients with favorable cytogenetics."
325675|NCT01715298|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
325497|NCT01716793|Other|Autologous transplantation|"In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~In patients with other cytogenetics without HLA-Identical sibling."
325498|NCT01716793|Other|Allogeneic HLA-identical sibling transplantation|"Patients without favorable or normal karyotype(and one course to CR).~Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
325499|NCT01716793|Other|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
325500|NCT01716780|Other|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
325501|NCT01716767|Other|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
325502|NCT01716767|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
325503|NCT01716754|Drug|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
325504|NCT01716754|Drug|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
325505|NCT01716754|Drug|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
325506|NCT01716741|Other|Enzyme analysis|
325507|NCT01716728|Other|enzyme analysis|
325508|NCT01716715|Drug|Cabozantinib S-malate|Given PO
325509|NCT01716715|Other|Laboratory Biomarker Analysis|Correlative studies
325510|NCT01716715|Drug|Paclitaxel|Given IV
325511|NCT01716702|Behavioral|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.~In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).~In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
325512|NCT01716689|Drug|oral cyclophosphamide|50mg daily
325513|NCT01716676|Other|Telemedicine CPAP monitoring (webpage and televisit)|
325514|NCT01716676|Other|Standard CPAP monitoring|
325515|NCT01716663|Device|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
325516|NCT01716637|Biological|Etanercept|
325517|NCT01716637|Dietary Supplement|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
325518|NCT01716624|Drug|Oxybutynin|standard oral therapy
325519|NCT01716624|Drug|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
325520|NCT01716611|Drug|Tolvaptan|15 - 60 mg/day for 28 days
325521|NCT01716611|Drug|placebo|
325522|NCT01716598|Device|IPS System|TLD Therapy will be achieved bronchoscopically.
325523|NCT01716585|Drug|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
325524|NCT01716585|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
325525|NCT01716585|Drug|Placebo for ABT-450/r/ABT-267|Tablet
325526|NCT01716585|Drug|Placebo for ABT-333|Tablet
325527|NCT01716585|Drug|Placebo for ribavirin|Capsule
325528|NCT01716572|Drug|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
325529|NCT01716572|Procedure|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
325530|NCT01716546|Drug|Pazopanib|
325531|NCT01716533|Procedure|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
325532|NCT01716533|Other|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
325533|NCT01716520|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
325534|NCT01716520|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
325535|NCT01716520|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
325536|NCT01716507|Procedure|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
325537|NCT01716481|Other|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
325538|NCT01716468|Other|Ketogenic Diet|modified ketogenic diet
325539|NCT01716455|Drug|SSP-004184|
325540|NCT01716442|Drug|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
325541|NCT01716442|Drug|Placebo|
325542|NCT01716429|Behavioral|Vegan diet|Vegan dietary approaches for weight loss
325543|NCT01716429|Behavioral|Low calorie diet|Reduced calorie diet for weight loss
325544|NCT01716416|Drug|Pazopanib|
325545|NCT01716416|Drug|Cetuximab|
325546|NCT01716403|Biological|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
325547|NCT01716390|Dietary Supplement|Drink that contains plant stanols|
325548|NCT01716390|Dietary Supplement|Placebo drink|
325549|NCT01716377|Drug|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
325550|NCT01716364|Biological|Anti-LeY- scFv-CD28-ζ vector,.|
325551|NCT01716351|Behavioral|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
325552|NCT01716338|Drug|Glyburide|
325553|NCT01716338|Drug|Placebo|
325554|NCT01716325|Other|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
325556|NCT01716312|Drug|Omalizumab|For each subject, treatment with omalizumab will start with a loading dose of 600 mg followed by a maintenance dose of 300 mg every 4 weeks. The study drug will be administered as a subcutaneous injection. On Week 0 and Week 16 the medication or placebo will be administered to subjects via 4 subcutaneous injections; the remaining weeks 2 injections will be administered.Subjects will be given written directions on dealing with adverse reactions. They will also receive an Epi-Pen before discharge and instructions on how to use it.
325557|NCT01716299|Other|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
325558|NCT01716299|Other|application of a confirmation test|use of rapid confirmation test
325559|NCT01716286|Dietary Supplement|low fat vs. essence yoghurt|
325560|NCT01716273|Other|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
325561|NCT01716273|Other|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
325562|NCT01716260|Drug|Chloroquine|
325563|NCT01716260|Drug|Primaquine|
325564|NCT01716247|Other|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
325565|NCT01716234|Drug|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
325566|NCT01716234|Drug|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
325567|NCT01716234|Drug|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
325568|NCT01716234|Drug|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
325569|NCT01716221|Drug|bupropion & Citalopram|
325570|NCT01716221|Drug|Bupropion & Placebo|
325571|NCT01716221|Drug|Placebo & Citalopram|
325572|NCT01716221|Drug|Placebo & Placebo|
325573|NCT01716208|Drug|Ofatumumab + Fresh Frozen Plasma|
325574|NCT01716195|Other|6 weeks of Radiotherapy|If tumor does not significantly shrink after initial chemotherapy
325575|NCT01716195|Other|5 weeks of Radiotherapy|If tumor shrinks after initial chemotherapy
325576|NCT01716169|Device|Helicoll|Helicoll Collagen I Wound Dressing
325577|NCT01716169|Device|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
325578|NCT01716156|Drug|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
325579|NCT01716156|Drug|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
325580|NCT01716143|Procedure|radiofrequency catheter ablation|
325581|NCT01716117|Device|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm while allowing blood in the aneurysm to clot. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
325582|NCT01716104|Drug|Afalaza|Safety and Efficacy
325583|NCT01716104|Drug|Placebo|Safety and Efficacy
325584|NCT01716091|Procedure|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
325585|NCT01716052|Drug|placebo|Lactulose
325586|NCT01716052|Drug|Ibuprofen|
325587|NCT01716039|Drug|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
325588|NCT01716039|Drug|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).~Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
325589|NCT01716039|Drug|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
325590|NCT01716026|Drug|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
325591|NCT01716013|Device|BondEase|topical skin adhesive
325592|NCT01716013|Procedure|CWCD|traditional closure methods of sutures, staples or adhesive strips
325593|NCT01716000|Other|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
325594|NCT01716000|Behavioral|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
325595|NCT01715987|Drug|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
325596|NCT01715987|Drug|Entecavir|0.5mg oral daily for two years.
325597|NCT01715974|Drug|G-CSF group|60 micrograms/day of G-CSF from the day of embryo transfer through the day of beta HCG test
325598|NCT01715974|Drug|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
325599|NCT01715961|Procedure|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
326063|NCT01712308|Other|Laboratory Biomarker Analysis|Correlative studies
325600|NCT01715948|Device|CROS hearing aid|Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
325601|NCT01715948|Device|Bone-anchored hearing device (BAHD)|All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
325602|NCT01715935|Drug|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
325603|NCT01715922|Drug|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
325604|NCT01715922|Drug|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
325605|NCT01715922|Procedure|lumbar punctures|lumbar punctures to control intracranial pressure
325606|NCT01715909|Drug|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams [mg]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for </= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
325607|NCT01715896|Biological|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
325608|NCT01715896|Biological|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
325609|NCT01715883|Drug|Sodium Nitrite|Same as the details in Arm Description.
325610|NCT01715870|Behavioral|Life style and food habits questionnaire|
325611|NCT01715844|Dietary Supplement|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
325612|NCT01715831|Drug|DMARDs|DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
325613|NCT01715831|Drug|Tocilizumab|Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
325614|NCT01715818|Drug|Placebo|matching aleglitazar placebo tablet orally daily
325615|NCT01715818|Drug|aleglitazar|150 mcg orally daily
325616|NCT01715805|Drug|Cariprazine|Cariprazine capsules 1.5 to 4.5 mg/day
325617|NCT01715805|Drug|Placebo|Dose-matched placebo capsule once per day
325618|NCT01715805|Drug|Antidepressant Therapy (ADT)|ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
325619|NCT01715792|Other|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
325620|NCT01715779|Drug|Eltrombopag|Eltrombopag exposure
325621|NCT01715753|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
325622|NCT01715753|Behavioral|Diet counseling and group education lessons|Individual and group diet counseling to achieve a >10% weight loss
325623|NCT01715740|Drug|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
325624|NCT01715740|Drug|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
325625|NCT01715714|Drug|Statin Recapture Therapy|Given 12h and 2h before CABG
325626|NCT01715714|Drug|Placebo|Given 12h and 2h before CABG.
325627|NCT01715701|Procedure|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
325628|NCT01715701|Procedure|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
325629|NCT01715701|Procedure|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
325630|NCT01715688|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
325631|NCT01715688|Drug|Saline|Administration of saline in the endotracheal tube cuff
325632|NCT01715675|Dietary Supplement|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
325633|NCT01715675|Dietary Supplement|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
325634|NCT01715662|Device|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
325635|NCT01715662|Device|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
325676|NCT01715285|Drug|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
325636|NCT01715649|Behavioral|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
325637|NCT01715636|Drug|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
325638|NCT01715623|Biological|a blood sample|Dosage of Ig
325639|NCT01715610|Drug|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
325640|NCT01715610|Drug|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
325641|NCT01715610|Drug|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
325642|NCT01715597|Drug|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
325643|NCT01715597|Drug|Normal saline|normal saline 500ml IV
325644|NCT01715584|Other|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
325645|NCT01715571|Device|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.~Men will record device use and intercourse attempts after device use in a diary."
325646|NCT01715532|Drug|Huachansu|
325647|NCT01715532|Other|TACE|
325648|NCT01715519|Drug|Treatment (Viibryd)|
325649|NCT01715506|Behavioral|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
325650|NCT01715493|Drug|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
325651|NCT01715493|Drug|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
325652|NCT01715480|Dietary Supplement|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
325653|NCT01715441|Drug|Sorafenib and irinotecan combination|
325654|NCT01715441|Drug|Sorafenib monotherapy|
325655|NCT01715441|Drug|Irinotecan monotherapy|
325656|NCT01715415|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
325657|NCT01715415|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
325658|NCT01715415|Drug|Placebo for ABT-450/r/ABT-267|Tablet
325659|NCT01715415|Drug|Placebo for ABT-333|Tablet
325660|NCT01715415|Drug|Placebo for ribavirin|Capsule
325661|NCT01715402|Procedure|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
325662|NCT01715389|Other|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
325663|NCT01715363|Drug|Oxaliplatin|
325664|NCT01715363|Drug|Folinic Acid|
325665|NCT01715363|Drug|Fluorouracile|
325666|NCT01715350|Drug|PM012|"The drug will be taken with water within 30 minutes after breakfast and supper.~650mg/1 tablet, PO, 12weeks"
325667|NCT01715350|Drug|Placebo|"The drug will be taken with water within 30 minutes after breakfast and supper.~650mg/1 tablet, PO, 12weeks"
325668|NCT01715337|Other|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
325669|NCT01715324|Drug|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
325670|NCT01715311|Drug|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
325671|NCT01715311|Drug|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
325672|NCT01715311|Drug|Tiotropium|Tiotropium capsules for inhalation once daily
325673|NCT01715311|Drug|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
325674|NCT01715298|Drug|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
325801|NCT01714310|Drug|Placebo|Initiated at end of study week 4 and continued to study week 12.
325677|NCT01715285|Drug|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
325678|NCT01715285|Other|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
325679|NCT01715285|Drug|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
325680|NCT01715285|Drug|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
325681|NCT01715272|Device|TF037|
325682|NCT01715272|Drug|Fleet enema|
325683|NCT01715259|Drug|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
325684|NCT01715259|Drug|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
325685|NCT01715246|Other|Infant Formula|
325686|NCT01715233|Drug|Docetaxel|Modified Docetaxel 40mg/m2 on Day 1
325687|NCT01715233|Drug|Leucovorin|Leucovorin 400mg/m2 on Day 1
325688|NCT01715233|Drug|Fluorouracil|Fluorouracil 400mg/m2 on Day 1 Fluorouracil 1000mg/m2/day on Days 1 and 2
325689|NCT01715233|Drug|Cisplatin|Cisplatin (or Carboplatin) 40mg/m2 on Day 3
325690|NCT01715220|Drug|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
325691|NCT01715207|Drug|Aliskiren|
325692|NCT01715207|Drug|Atenolol|
325693|NCT01715194|Device|Telemedicine intervention|Patients undergoing telemedicine intervention
325694|NCT01715181|Other|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
325695|NCT01715168|Drug|DOXIL/CAELYX|
325696|NCT01715168|Drug|ATI-0918|
325697|NCT01715142|Drug|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
325698|NCT01715142|Drug|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
325699|NCT01715129|Drug|Triptorelin Pamoate 11.25mg|
325700|NCT01715116|Device|Enhanced ICD programming|"VT monitor: > 166/min~fVT: > 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.~VF: > 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals~SVT/VT discrimination is turned on, high rate time out is OFF~SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min~SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min~T wave-oversensing and lead noise discrimination is turned on in all devices."
325701|NCT01715103|Procedure|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
325702|NCT01715090|Device|Web-based insulin titration|
325703|NCT01715077|Drug|Ipilimumab at 3 mg/kg dose|
325704|NCT01715064|Behavioral|Exercise|1 hour of moderate-intensity exercise
325705|NCT01715051|Drug|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
325706|NCT01715051|Behavioral|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
325707|NCT01715051|Drug|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
325708|NCT01715038|Dietary Supplement|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)~Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
325709|NCT01715038|Dietary Supplement|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement~Lipid-based nutrient supplement for infants and young children (LNS-Child)~Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
325710|NCT01715038|Dietary Supplement|MNP|"Dietary supplement: Micronutrient powder~Micronutrient powder for infants and young children (MNP)~The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
325711|NCT01715038|Dietary Supplement|IFA|"Dietary supplement: Iron and folic acid nutrient supplement~Iron-folic acid tablets for pregnant and lactating women~Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
325712|NCT01715025|Drug|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
325713|NCT01715012|Biological|ST266|ST266 is applied daily by spray to burn wound and skin graft donor site
325714|NCT01715012|Drug|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
326259|NCT01710852|Drug|Placebo|
325715|NCT01714999|Procedure|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
325716|NCT01714999|Procedure|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
325717|NCT01714986|Behavioral|Affect School|
325718|NCT01714986|Behavioral|Body Awareness Therapy|
325719|NCT01714973|Biological|ST266|Patients will receive ST266 spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ST266 and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
325720|NCT01714960|Drug|MRZ-99030 eye drops 5mg/mL|
325721|NCT01714960|Drug|MRZ-99030 eye drops 20mg/mL|
325722|NCT01714960|Drug|Placebo to MRZ-99030 eye drops|
325723|NCT01714947|Drug|[^14C]-alisertib|[^14C]-alisertib oral solution
325724|NCT01714947|Drug|alisertib|Alisertib enteric coated tablets
325725|NCT01714908|Other|Erlotinib w Concurrent Radiotherapy|
325726|NCT01714908|Other|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
325727|NCT01714895|Other|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
325728|NCT01714895|Other|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
325729|NCT01714882|Behavioral|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
325730|NCT01714882|Behavioral|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
325731|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
325732|NCT01714856|Drug|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
325733|NCT01714843|Drug|ASP0456|oral
325734|NCT01714843|Drug|placebo|oral
325735|NCT01714830|Device|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
325736|NCT01714830|Device|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
325737|NCT01714817|Biological|BMS-188667|
325738|NCT01714817|Drug|Mycophenolate mofetil|
325739|NCT01714817|Drug|Prednisone|
325740|NCT01714817|Biological|Placebo matching with BMS-188667|
325741|NCT01714804|Device|Accell Evo3 Prospective Use|
325742|NCT01714791|Other|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
325743|NCT01714791|Other|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:~Structural High Velocity Low Amplitude-techniques.~Muscle Energy Techniques.~General osteopathic mobilisations.~Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.~Fascia techniques.~Soft tissue- and connective tissue techniques.~Neurovisceral and neurolymphatic reflex techniques.~Fluidal techniques (lymphatic manipulative techniques,...).~Visceral manipulations.~Neurocranial and viscerocranial techniques."
325744|NCT01714778|Other|e-Cigarette|
325745|NCT01714765|Drug|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
325746|NCT01714765|Drug|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
325747|NCT01714752|Procedure|measure of left ventricular and diastolic pressure at exercise|
325748|NCT01714739|Drug|Lirilumab|Specified dose on specified days.
325749|NCT01714739|Drug|Nivolumab|Specified dose on specified days.
325750|NCT01714739|Drug|Ipilimumab|Specified dose on specified days.
325751|NCT01714726|Drug|MEDI2070|1 iv infusion on Week 0 and Week 4
325752|NCT01714726|Drug|placebo|1 iv infusion on Week 0 and Week 4
325753|NCT01714726|Drug|MEDI2070|1 sc injection of every 4 weeks for 100 weeks, starting at Week 12; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
325754|NCT01714713|Drug|EVP-6124|Arm 1, 2
325755|NCT01714700|Behavioral|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
325800|NCT01714310|Drug|lisdexamfetamine|Titration and open label treatment from baseline visit for 12 week study.
325962|NCT01713088|Other|YOT (usual services)|
325756|NCT01714700|Behavioral|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
325757|NCT01714687|Device|balloon sinus dilation|
325758|NCT01714687|Other|medical therapy|
325759|NCT01714674|Dietary Supplement|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
325760|NCT01714674|Dietary Supplement|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
325761|NCT01714661|Drug|EVP-6124|Arms 1, 2
325762|NCT01714661|Drug|Placebo|Arm 3
325763|NCT01714648|Drug|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
325764|NCT01714635|Device|Tecnis Multifocal Intraocular Lens|
325765|NCT01714635|Device|Monofocal Intraocular Lens|
325766|NCT01714622|Procedure|subtotal gastrectomy with gastroduodenostomy|
325767|NCT01714622|Procedure|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
325768|NCT01714622|Procedure|total gastrectomy with Rou-en-Y esophagojejunostomy|
325769|NCT01714609|Drug|Placebo|Placebo Comparator: Placebo
325770|NCT01714609|Drug|Sorafenib|Sorafenib, 400 mg twice daily
325771|NCT01714596|Other|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
325772|NCT01714570|Drug|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
325773|NCT01714570|Drug|Imipenem|0.5g q6h, 5-10 days
325774|NCT01714557|Drug|Piperacillin|4.0g q8h 3-5 days
325775|NCT01714557|Drug|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
325776|NCT01714544|Drug|Cloderm Cream|
325777|NCT01714531|Behavioral|Telephone-Based Goal Management Training|
325778|NCT01714531|Behavioral|Telephone-Based Attention-Control|
325779|NCT01714505|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
325780|NCT01714492|Device|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
325781|NCT01714479|Other|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
325782|NCT01714479|Other|Placebo|
325783|NCT01714466|Drug|NER1006|
325784|NCT01714466|Drug|MOVIPREP|
325785|NCT01714427|Drug|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
325786|NCT01714427|Drug|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
325787|NCT01714414|Drug|FZD|
325788|NCT01714414|Drug|3TC|
325789|NCT01714414|Drug|EFV|
325790|NCT01714414|Drug|AZT|
325791|NCT01714401|Drug|Salbutamol 2,5 mg|20 min nebulization of 2.5 mg of salbutamol
325792|NCT01714401|Drug|Salbutamol 5mg|20 min nebulization of 5 mg of salbutamol
325793|NCT01714388|Drug|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
325794|NCT01714375|Device|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
325795|NCT01714349|Procedure|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
325796|NCT01714336|Drug|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
325797|NCT01714336|Drug|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
325798|NCT01714323|Behavioral|Sustained Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free & Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
325799|NCT01714323|Behavioral|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
325802|NCT01714310|Drug|fluoxetine|Initiated at end of study week 4 and continued to study week 12.
325803|NCT01714297|Drug|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
325804|NCT01714284|Behavioral|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
325805|NCT01714284|Behavioral|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
325806|NCT01714271|Behavioral|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
325807|NCT01714271|Behavioral|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
325808|NCT01714258|Procedure|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
325809|NCT01714232|Device|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
325810|NCT01714232|Device|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
325811|NCT01714232|Device|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
325812|NCT01714232|Device|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
325813|NCT01714232|Device|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
325814|NCT01714219|Procedure|Posterior reconstruction|
325815|NCT01714206|Drug|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
325816|NCT01714206|Drug|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
325817|NCT01714206|Drug|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
325818|NCT01714193|Drug|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
325819|NCT01714193|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
325820|NCT01714167|Genetic|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
325821|NCT01714154|Drug|danoprevir|100 mg orally every 12 hours
325822|NCT01714154|Drug|ritonavir|100 mg orally every 12 hours
325823|NCT01714154|Drug|setrobuvir|200 mg orally every 12 hours
325824|NCT01714141|Behavioral|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
325825|NCT01714141|Behavioral|Asthma education active control|
325826|NCT01714128|Drug|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
325827|NCT01714115|Drug|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
325828|NCT01714102|Dietary Supplement|Placebo|Placebo manufactured to mimic resveratrol tablet
325829|NCT01714102|Dietary Supplement|Resveratrol|Resveratrol PO BID for 30 days
325830|NCT01714089|Drug|RNS60 125 ml|
325831|NCT01714089|Drug|RNS60 250 ml|
325832|NCT01714089|Drug|Interferon beta 1a|
325833|NCT01714076|Other|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
325834|NCT01714063|Device|Pressurized Metered-Dose Inhaler|Pressurized Metered-Dose Inhaler
325835|NCT01714050|Behavioral|Cognitive-Behavioral Therapy (CBT)|
325836|NCT01714050|Device|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
325837|NCT01714037|Drug|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
325838|NCT01714037|Drug|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
325839|NCT01714037|Drug|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
325840|NCT01714037|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
325841|NCT01714037|Drug|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
325963|NCT01713062|Device|Vitelene|THA
325964|NCT01713062|Device|XLPE|THA
325842|NCT01714024|Device|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
325843|NCT01714024|Device|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
325844|NCT01714011|Drug|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.~Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
325845|NCT01714011|Drug|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
325846|NCT01713998|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
325847|NCT01713985|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
325848|NCT01713985|Device|Thermage|Radiofrequency treatment focusing radiofrequency energy
325849|NCT01713972|Drug|dabrafenib|Given PO
325850|NCT01713972|Drug|pazopanib hydrochloride|Given PO
325851|NCT01713972|Other|Correlative studies|"Pharmacokinetic studies:~Blood draw for various time points:~Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12~Pharmacogenomic studies: Blood draw on Cycle 1 Day 1~Tumor genotyping: Archival tumor blocks or unstained slides~BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
325852|NCT01713959|Device|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
325853|NCT01713959|Device|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
325854|NCT01713946|Drug|RAD001|Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
325855|NCT01713946|Drug|Placebo|Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.
325856|NCT01713946|Drug|Antiepileptic drug (1 to 3 only)|no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin
325857|NCT01713946|Drug|open label RAD001 (only used for post-extension phase)|everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.
325858|NCT01713933|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
325859|NCT01713920|Drug|SEVIKAR|
325860|NCT01713907|Device|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
325861|NCT01713894|Other|Decision Aid|
325862|NCT01713894|Other|Standard|
325863|NCT01713868|Behavioral|Safe Sleep Nursery Education|Nursery-based program for safe sleep
325864|NCT01713868|Behavioral|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
325865|NCT01713868|Behavioral|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
325866|NCT01713868|Behavioral|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
325867|NCT01713855|Biological|Inactivated Trivalent Influenza vaccine|
325868|NCT01713842|Drug|TCZ|Tocilizumab at week 0, 4 and 8.
325869|NCT01713829|Other|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
325870|NCT01713829|Other|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
325871|NCT01713803|Drug|Buprenorphine and naloxone|
325872|NCT01713790|Device|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
325873|NCT01713790|Device|Exergame|training program over 10 weeks, three times a week.
325874|NCT01713790|Device|Leg press|training program over 10 weeks, three times a week.
325875|NCT01713777|Drug|"Lamotrigine Generic A"|
325876|NCT01713777|Drug|"Lamotrigine generic B"|
325877|NCT01713764|Behavioral|Low Carbohydrate Diet|
325878|NCT01713764|Behavioral|American Diabetes Association Diet|
325879|NCT01713764|Behavioral|Mindfulness and Positive Affect Skills|
325880|NCT01713751|Other|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
325881|NCT01713751|Other|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene [Prolene®]
325882|NCT01713738|Drug|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
325883|NCT01713725|Biological|Omalizumab|"Two injections will be administered the first two weeks~The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
326006|NCT01712776|Device|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
325884|NCT01713725|Biological|Placebo|"Two injections will be administered the first two weeks~The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
325885|NCT01713712|Behavioral|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
325886|NCT01713699|Procedure|lumbar puncture|
325887|NCT01713686|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
325888|NCT01713673|Drug|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
325889|NCT01713673|Drug|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
325890|NCT01713660|Device|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
325891|NCT01713647|Drug|Amlodipin, losartan, HCTZ|
325892|NCT01713634|Other|Preflight|4-d controlled diet sessions will occur twice before flight.
325893|NCT01713634|Other|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
325894|NCT01713621|Drug|OZ439|OZ439 is a novel synthetic trioxolane antimalarial agent
325895|NCT01713608|Drug|OZ439|OZ439 x mg once daily for 3 days with milk
325896|NCT01713595|Drug|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
325897|NCT01713582|Drug|OTX015/MK-8628|OTX015/MK-8628 10 mg, 20 mg, or 40 mg capsules administered orally
325898|NCT01713569|Device|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
325899|NCT01713556|Drug|Propranolol|
325900|NCT01713556|Other|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
325901|NCT01713556|Drug|placebo|
325902|NCT01713543|Other|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
325903|NCT01713530|Drug|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
325904|NCT01713530|Drug|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
325905|NCT01713530|Drug|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
325906|NCT01713517|Other|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
325907|NCT01713517|Device|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
325908|NCT01713504|Biological|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
325909|NCT01713478|Other|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
325910|NCT01713465|Other|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
325911|NCT01713452|Procedure|Purse string closure|"An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.~Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.~Diameter of the skin defect should then be measured.~A postoperative photo will then be taken."
325912|NCT01713452|Procedure|Primary closure|"An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.~Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (<1.5cm). No subcutaneous drains will be placed.~Length of the incision should be measured in centimeters.~A postoperative photo will then be taken."
325913|NCT01713439|Biological|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10^7/kg, 10^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10^4/kg and rising to 10^7/kg (10^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be <1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
325914|NCT01713426|Drug|Qutenza|Cutaneous patch
325915|NCT01713426|Drug|Pregabalin|Oral capsule
325916|NCT01713413|Device|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
325917|NCT01713413|Device|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
325918|NCT01713400|Drug|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
325919|NCT01713400|Drug|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
325920|NCT01713400|Drug|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
325921|NCT01713400|Drug|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
325922|NCT01713387|Drug|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
325923|NCT01713374|Procedure|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
325924|NCT01713374|Other|no intervention|control visit
325925|NCT01713374|Procedure|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
325926|NCT01713374|Procedure|Cold pressure test|A hand will be placed in ice-cold water.
325927|NCT01713361|Drug|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
325928|NCT01713361|Drug|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
325929|NCT01713361|Drug|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). [Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.]
325930|NCT01713348|Device|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
325931|NCT01713348|Device|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
325932|NCT01713322|Behavioral|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
325933|NCT01713322|Behavioral|No pain management education|Control - parents receive general information about childhood immunization.
325934|NCT01713309|Drug|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
325935|NCT01713296|Drug|Pazopanib|
325936|NCT01713283|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
325937|NCT01713283|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
325938|NCT01713270|Procedure|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
325939|NCT01713270|Drug|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
325940|NCT01713270|Procedure|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
325941|NCT01713257|Dietary Supplement|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
325942|NCT01713257|Dietary Supplement|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
325943|NCT01713244|Procedure|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
325944|NCT01713244|Procedure|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
325945|NCT01713231|Dietary Supplement|standard-dose vitamin D (400IU per day)|
325946|NCT01713231|Dietary Supplement|high-dose vitamin D (2000 IU per day)|
325947|NCT01713218|Drug|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
325948|NCT01713218|Drug|Vismodegib|150 mg capsule, oral, once daily
325949|NCT01713218|Procedure|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
325950|NCT01713179|Drug|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
325951|NCT01713166|Drug|plasmalyte solution|plasmalyte solution
325952|NCT01713166|Drug|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
325953|NCT01713153|Drug|Misoprostol|600 mcg misoprostol oral
325954|NCT01713153|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
325955|NCT01713140|Other|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
325956|NCT01713127|Drug|remifentanil infusion|
325957|NCT01713127|Drug|Placebo|
325958|NCT01713114|Other|Acute measures of satiety and food intake at next meal|
325959|NCT01713101|Drug|Early intravenous tranexamic acid administration|Initial history taking and physical examination --> enrollment --> 1g bolus over 10 minutes followed slow infusion over 8 hours.
325960|NCT01713101|Drug|placebo|
325961|NCT01713088|Other|Multisystemic therapy|
325965|NCT01713049|Drug|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
325966|NCT01713036|Drug|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) [14C] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries [mcgCi]) of [14C] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
325967|NCT01713023|Dietary Supplement|Glucose|The same described in Arm description
325968|NCT01713023|Dietary Supplement|Fructose|The same described in Arm description
325969|NCT01713010|Other|Predictive indexes of weaning from mechanical ventilation|
325970|NCT01712997|Drug|Iloprost|
325971|NCT01712997|Drug|Bosentan|
325972|NCT01712984|Biological|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
325973|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
325974|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
325975|NCT01712945|Drug|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
325976|NCT01712945|Drug|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
325977|NCT01712919|Radiation|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
325978|NCT01712919|Drug|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
325979|NCT01712919|Biological|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
325980|NCT01712906|Biological|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
325981|NCT01712906|Biological|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
325982|NCT01712906|Biological|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
325983|NCT01712906|Biological|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
325984|NCT01712906|Biological|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
325985|NCT01712893|Drug|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
325986|NCT01712880|Procedure|open debridement with modular exchange|
325987|NCT01712880|Procedure|one stage exchange|
325988|NCT01712867|Other|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
325989|NCT01712867|Other|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
325990|NCT01712854|Drug|Budesonide|budesonide 80 mcg
325991|NCT01712854|Drug|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
325992|NCT01712828|Drug|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
325993|NCT01712828|Drug|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
325994|NCT01712828|Drug|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
325995|NCT01712828|Drug|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
325996|NCT01712815|Other|laboratory biomarker analysis|Correlative studies
325997|NCT01712815|Other|pharmacological study|Correlative studies
325998|NCT01712815|Other|questionnaire administration|Ancillary studies
325999|NCT01712815|Radiation|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
326000|NCT01712815|Procedure|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
326001|NCT01712802|Other|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
326002|NCT01712802|Other|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
326003|NCT01712802|Other|Saline|work as control for Denture Adhesives: Cream and Powder
326004|NCT01712789|Drug|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
326005|NCT01712789|Drug|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
326007|NCT01712776|Device|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
326008|NCT01712763|Drug|degarelix|50 women will be treated with degarlix 80 mg, in only one administration covering three months
326009|NCT01712763|Drug|goserelin|50 women will be treated with decapeptyl 3.6 every month for three months
326010|NCT01712737|Other|Dietary intervention|
326011|NCT01712724|Other|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
326012|NCT01712711|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
326013|NCT01712685|Drug|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
326014|NCT01712685|Procedure|PET/CT|
326015|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Patient may continue to receive treatment until PD.
326016|NCT01712659|Drug|ruxolitinib|ruxolitinib 30-50 mg orally twice daily for 28 days. Patients may continue to receive treatment until PD or unacceptable toxicity
326017|NCT01712646|Drug|Intranasal Oxytocin|
326018|NCT01712620|Drug|Spironolactone|Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
326019|NCT01712620|Drug|Placebo|Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
326020|NCT01712607|Other|Preoperative Warm-Up training|Preoperative Warm-Up training
326021|NCT01712594|Device|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
326022|NCT01712581|Other|Magnetic Resonance Imaging|
326023|NCT01712568|Drug|Test Product (Ropinirole)|"one Tablet at 0 hour"
326024|NCT01712568|Drug|Reference Product (REQUIP )|"one Tablet at 0 hour"
326025|NCT01712555|Procedure|autologous fat grafting with PRP to anophthalmic orbits|
326026|NCT01712529|Behavioral|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
326027|NCT01712516|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
326028|NCT01712516|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
326029|NCT01712516|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
326030|NCT01712516|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
326031|NCT01712503|Device|Phacoemulsfication cataract surgery and intra-ocular lens implant|
326032|NCT01712490|Drug|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle.
326033|NCT01712490|Drug|doxorubicin|Doxorubicin: 25 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
326034|NCT01712490|Drug|bleomycin|Bleomycin: 10 units/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
326035|NCT01712490|Drug|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
326036|NCT01712490|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m^2 by IV infusion on Days 1 and 15 of each 28-day cycle.
326037|NCT01712477|Drug|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
326038|NCT01712477|Drug|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
326039|NCT01712464|Drug|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
326040|NCT01712451|Drug|salmeterol xinafoate, fluticasone propionate|LIPO-102
326041|NCT01712451|Drug|Placebo|Placebo
326042|NCT01712451|Drug|salmeterol xinafoate|Salmeterol
326043|NCT01712438|Biological|Human cl rhFVIII|
326044|NCT01712425|Biological|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
326045|NCT01712425|Biological|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
326046|NCT01712412|Drug|IW-9179|
326047|NCT01712412|Drug|Placebo|
326048|NCT01712399|Biological|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
326049|NCT01712386|Dietary Supplement|Beetroot|
326050|NCT01712386|Dietary Supplement|Beetroot placebo|
326051|NCT01712373|Drug|Ginseng|it is kind of drug
326052|NCT01712373|Drug|Placebo|it is placebo
326053|NCT01712360|Drug|NAFT500 (pediatric)|Applied to both feet and groin area
326054|NCT01712360|Drug|NAFT600 (pediatric)|Applied to both feet only
326055|NCT01712360|Drug|NAFT500 (adult)|Applied to both feet and groin area
326056|NCT01712360|Drug|NAFT600 (adult)|Applied to both feet
326057|NCT01712347|Drug|Bevacizumab|Bevacizumab will be administered as per approved label.
326058|NCT01712347|Drug|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
326059|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
326060|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
326061|NCT01712321|Drug|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
326062|NCT01712321|Drug|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
326064|NCT01712308|Biological|Sotatercept|Given SC
326065|NCT01712295|Drug|17% Salicylate with ethyl pyruvate|
326066|NCT01712295|Drug|Salicylates|
326067|NCT01712282|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
326068|NCT01712269|Procedure|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
326069|NCT01712256|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
326070|NCT01712243|Other|Light|
326071|NCT01712230|Drug|GnRH agonist|"Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
326072|NCT01712230|Behavioral|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
326073|NCT01712230|Drug|Placebo|Placebo
326074|NCT01712217|Drug|AT13387|HSP90 inhibitor
326075|NCT01712217|Drug|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
326076|NCT01712204|Drug|Placebo|Placebo Capsule BID for 16 Weeks
326077|NCT01712204|Drug|AC-201|AC-201 50mg Capsule BID for 16 Weeks
326078|NCT01712204|Drug|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
326079|NCT01712191|Device|NUsurface Meniscus Implant|
326080|NCT01712178|Biological|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
326081|NCT01712178|Biological|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
326082|NCT01712165|Dietary Supplement|ANMUM Materna|
326083|NCT01712165|Dietary Supplement|Control (milk powder)|
326084|NCT01712139|Drug|Irbesartan and Hydrochlorothiazide|
326085|NCT01712139|Drug|Avalide|
326086|NCT01712126|Drug|Irbesartan and Hydrochlorothiazide|
326087|NCT01712126|Drug|Avalide|
326088|NCT01712113|Drug|Irbesartan|
326089|NCT01712113|Drug|Avapro|
326090|NCT01712100|Drug|Irbesartan|
326091|NCT01712100|Drug|Avapro|
326092|NCT01712087|Device|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
326093|NCT01712074|Drug|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
326094|NCT01712074|Other|Placebo|Placebo QD
326095|NCT01712061|Drug|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
326096|NCT01712061|Drug|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
326097|NCT01712048|Procedure|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
326098|NCT01712048|Procedure|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
326099|NCT01712009|Drug|Naproxen|
326100|NCT01712009|Drug|Loratadine|
326101|NCT01712009|Biological|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
326102|NCT01712009|Drug|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
326103|NCT01711983|Device|GORE® Septal Occluder|The GORE® Septal Occluder consists of an implantable occluder and a catheter delivery system. The occluder is comprised of five platinum-filled nickel-titanium (Nitinol) wires which form a frame covered with expanded polytetrafluoroethylene (ePTFE). The ePTFE is treated with a hydrophilic coating to facilitate echocardiographic imaging of the occluder and surrounding tissue during implantation. When fully deployed, the occluder assumes a configuration to prevent shunting of blood between the right and left atria.
326104|NCT01711970|Drug|Paclitaxel|
326105|NCT01711957|Procedure|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
326106|NCT01711944|Behavioral|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
326107|NCT01711931|Device|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
326108|NCT01711931|Device|Implantation of everolimus-eluting stents|
326109|NCT01711931|Device|Implantation of biolimus-eluting stents|
326110|NCT01711918|Drug|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
326111|NCT01711905|Dietary Supplement|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
326112|NCT01711892|Behavioral|Soccer training|
326113|NCT01711879|Drug|Aflibercept|Details covered in arm description
326114|NCT01711866|Drug|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
326115|NCT01711853|Drug|Dabigatran Etexilate|Dabigatran Etexilate 75mg twice daily
326116|NCT01711827|Drug|Isavuconazole|oral
326117|NCT01711827|Drug|Prednisone|oral
326118|NCT01711814|Drug|peficitinib|oral
326119|NCT01711801|Drug|Placebo|Single ascending dose
326120|NCT01711801|Drug|RO5545965|Single ascending dose
326121|NCT01711801|Drug|RO5545965|Single dose, in fed and fasted state
326122|NCT01711788|Procedure|Intrabone infusion of umbilical cord blood stem cells|
326123|NCT01711775|Drug|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
326124|NCT01711762|Drug|GDC-0973|Single oral dose of [14C]-GDC-0973
326125|NCT01711749|Drug|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
326126|NCT01711749|Drug|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
326127|NCT01711736|Biological|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
326128|NCT01711736|Biological|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
326129|NCT01711723|Drug|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
326130|NCT01711710|Device|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.~Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
326131|NCT01711697|Radiation|stereotactic body radiation therapy|Undergo SBRT
326132|NCT01711697|Drug|carboplatin|
326133|NCT01711697|Drug|paclitaxel|
326134|NCT01711697|Radiation|radiation therapy|Undergo radiation therapy
326135|NCT01711684|Drug|Diphenylcyclopropenone (DPCP)|Topical application of study drug
326136|NCT01711671|Drug|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
326137|NCT01711671|Drug|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
326138|NCT01711671|Drug|Standard of Care|Current approved standard of care
326139|NCT01711658|Radiation|Intensity Modulated Radiation Therapy (IMRT)|70 Gy in 2 Gy fractions
326140|NCT01711658|Drug|Cisplatin|100 mg/m2 on days 8 and 29
326141|NCT01711658|Drug|placebo|1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 3 months
326142|NCT01711658|Drug|Lapatinib|1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 3 months
326143|NCT01711645|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
326144|NCT01711632|Drug|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
326145|NCT01711619|Device|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
326146|NCT01711619|Other|Optimized Medical Management|Optimized medical management
326147|NCT01711593|Biological|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
326148|NCT01711593|Procedure|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
326149|NCT01711580|Other|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
326150|NCT01711580|Other|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
326151|NCT01711580|Other|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
326152|NCT01711580|Other|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
326153|NCT01711580|Other|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
326154|NCT01711580|Other|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
326155|NCT01711580|Other|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
326156|NCT01711580|Other|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
326157|NCT01711567|Drug|tenofovir|tenofovir 300 mg qd
326158|NCT01711567|Drug|entecavir|entecavir 0.5 mg qd
326159|NCT01711554|Biological|Dinutuximab|Given IV
326160|NCT01711554|Drug|Isotretinoin|Given PO
326161|NCT01711554|Other|Laboratory Biomarker Analysis|Correlative studies
326162|NCT01711554|Drug|Lenalidomide|Given PO
326163|NCT01711554|Other|Pharmacological Study|Correlative studies
326164|NCT01711541|Drug|Carboplatin|Given IV
326165|NCT01711541|Drug|Cisplatin|Given IV
326166|NCT01711541|Drug|Fluorouracil|Given IV
326167|NCT01711541|Drug|Hydroxyurea|Given PO
326168|NCT01711541|Other|Laboratory Biomarker Analysis|Correlative studies
326169|NCT01711541|Drug|Paclitaxel|Given IV
326170|NCT01711541|Other|Placebo|Given PO
326171|NCT01711541|Radiation|Radiation Therapy|Undergo radiation therapy
326172|NCT01711541|Drug|Veliparib|Given PO
326173|NCT01711528|Drug|Bortezomib|Given SC
326174|NCT01711528|Drug|Dexamethasone|Given PO
326175|NCT01711528|Drug|Dinaciclib|Given IV
326176|NCT01711528|Other|Laboratory Biomarker Analysis|Correlative studies
326177|NCT01711515|Drug|Cisplatin|Given IV
326178|NCT01711515|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
326179|NCT01711515|Radiation|Internal Radiation Therapy|Undergo intracavitary brachytherapy
326180|NCT01711515|Biological|Ipilimumab|Given IV
326181|NCT01711515|Other|Laboratory Biomarker Analysis|Correlative studies
326182|NCT01711489|Drug|isavuconazole|oral
326183|NCT01711489|Drug|Mycophenolate mofetil|oral
326184|NCT01711476|Behavioral|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
326185|NCT01711476|Other|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
326186|NCT01711463|Drug|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
326187|NCT01711463|Drug|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
326188|NCT01711450|Procedure|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
326189|NCT01711450|Procedure|Control sham procedure|Injection of Normal saline into the paravertebral space
326190|NCT01711437|Device|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
326191|NCT01711437|Device|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
326192|NCT01711437|Device|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
326193|NCT01711437|Device|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
326194|NCT01711424|Drug|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
326195|NCT01711411|Device|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
326196|NCT01711398|Drug|Drug|
326197|NCT01711385|Behavioral|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
326198|NCT01711372|Device|Groundskeeper|A game created to be played on Sifteo Cubes to be used as a diagnostic aid for ADHD.
326199|NCT01711359|Drug|Baricitinib|Administered orally
326200|NCT01711359|Drug|Methotrexate|Administered orally
326201|NCT01711359|Drug|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
326202|NCT01711359|Drug|MTX Placebo|MTX placebo administered orally once weekly.
326203|NCT01711359|Drug|Folic Acid|Administered orally every day
326204|NCT01711346|Biological|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
326205|NCT01711346|Biological|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
326206|NCT01711333|Drug|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
326207|NCT01711320|Drug|Placebo|
326208|NCT01711320|Drug|Omeprazole|
326209|NCT01711307|Procedure|operative|
326210|NCT01711307|Procedure|non-operative|casting within 48 hrs
326211|NCT01711294|Device|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
326212|NCT01711294|Device|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
326213|NCT01711294|Device|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
326214|NCT01711281|Device|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
326215|NCT01711242|Drug|Capecitabine|
326216|NCT01711242|Drug|Oxaliplatin|
326217|NCT01711242|Radiation|Radiotherapy|
326218|NCT01711229|Drug|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
326219|NCT01711229|Drug|oral acetaminophen|oral acetaminophen will be given preoperatively
326220|NCT01711203|Other|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
326221|NCT01711203|Other|General Strengthening|General abdominal and lower quarter musculature strengthening
326222|NCT01711190|Procedure|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
326223|NCT01711177|Drug|placebo|Placebo
326224|NCT01711177|Drug|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
326225|NCT01711125|Drug|Baclofen 30mg/day|30mg/day 10 mg t.i.d
326226|NCT01711125|Drug|Baclofen 75mg/day|75mg/day 25 mg t.i.d
326227|NCT01711125|Drug|Placebo|Placebo 3 matched tabs/day
326228|NCT01711112|Drug|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
326229|NCT01711099|Device|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
326230|NCT01711086|Device|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
326231|NCT01711086|Device|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
326232|NCT01711073|Drug|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
326233|NCT01711060|Drug|oxytocin|
326234|NCT01711060|Procedure|balloon catheter|
326235|NCT01711047|Procedure|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
326236|NCT01711047|Procedure|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
326237|NCT01711034|Drug|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.~Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
326238|NCT01711021|Drug|d-Amphetamine Transdermal System|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
326239|NCT01711021|Drug|Placebo patch|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
326240|NCT01711008|Dietary Supplement|Cereal|
326241|NCT01711008|Dietary Supplement|No breakfast|
326242|NCT01710995|Drug|Zegerid|
326243|NCT01710995|Drug|Losec|
326244|NCT01710982|Drug|TZP-101|
326245|NCT01710982|Other|Placebo|
326246|NCT01710969|Behavioral|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
326247|NCT01710969|Behavioral|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
326248|NCT01710956|Radiation|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
326249|NCT01710943|Behavioral|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
326250|NCT01710930|Other|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :~In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.~Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.~Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
326251|NCT01710917|Drug|Targinact® (oxycodon/naloxon)|
326252|NCT01710904|Drug|Targinact® (oxycodone/naloxone)|
326253|NCT01710891|Procedure|CMAC videolaryngoscope|patients are intubated using the CMAC video laryngoscope
326254|NCT01710891|Procedure|Direct Laryngoscopy|Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
326255|NCT01710878|Device|Intergard Synergy Graft|
326256|NCT01710865|Other|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
326257|NCT01710865|Other|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
326258|NCT01710852|Drug|ISIS CRP Rx|
326260|NCT01710839|Drug|0.5mg Ranibizumab|intravitreal injections
326261|NCT01710839|Procedure|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
326262|NCT01710826|Biological|Genz-682452|Capsules for oral administration.
326263|NCT01710826|Biological|Placebo|Placebo capsules matching the Genz-682452 capsules.
326264|NCT01710813|Biological|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
326265|NCT01710800|Drug|Esomeprazole|
326266|NCT01710800|Drug|placebo|
326267|NCT01710787|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
326268|NCT01710787|Drug|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
326269|NCT01710787|Drug|Placebo|3 unilateral intranasal sprays per dose
326270|NCT01710774|Procedure|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
326271|NCT01710761|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
326272|NCT01710761|Dietary Supplement|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
326273|NCT01710748|Device|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
326274|NCT01710748|Device|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
326275|NCT01710735|Procedure|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
326276|NCT01710722|Drug|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
326277|NCT01710722|Drug|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
326278|NCT01710722|Drug|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
326279|NCT01710709|Drug|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
326280|NCT01710696|Drug|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
326281|NCT01710696|Drug|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
326282|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid
326283|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid.
326284|NCT01710670|Drug|Brivaracetam|"Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
326285|NCT01710670|Other|Ethanol|"Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
326286|NCT01710670|Other|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
326287|NCT01710670|Other|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
326288|NCT01710657|Drug|Lacosamide 50 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 50 mg~Route of Administration: Oral use"
326289|NCT01710657|Drug|Lacosamide 100 mg|"Active Substance: Lacosamide~Pharmaceutical Form: Film-coated tablet~Concentration: 100 mg~Route of Administration: Oral use"
326290|NCT01710657|Drug|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
326291|NCT01710644|Drug|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
326292|NCT01710644|Drug|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
326293|NCT01710631|Drug|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
326294|NCT01710631|Drug|placebo|placebo
326295|NCT01710605|Biological|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
326296|NCT01710592|Drug|Epirubicin|
326297|NCT01710592|Drug|Oxaliplatin|
326298|NCT01710592|Drug|Capecitabine|
326299|NCT01710592|Drug|Docetaxel|
326300|NCT01710579|Procedure|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
326301|NCT01710579|Procedure|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
326336|NCT01710332|Drug|Intravitreal Aflibercept Injection|"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).~GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."
326337|NCT01710319|Other|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
326302|NCT01710579|Procedure|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
326303|NCT01710566|Drug|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
326304|NCT01710566|Drug|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
326305|NCT01710553|Other|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
326306|NCT01710553|Other|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
326307|NCT01710540|Other|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
326308|NCT01710540|Other|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
326309|NCT01710527|Drug|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
326310|NCT01710527|Drug|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
326311|NCT01710514|Drug|FE 999913 vaginal tablet|
326312|NCT01710501|Drug|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
326313|NCT01710501|Biological|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
326314|NCT01710501|Drug|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
326315|NCT01710501|Drug|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
326316|NCT01710488|Drug|Levofloxacin 1 tablet 500 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
326317|NCT01710488|Drug|Prulifloxacin 1 tablet 600 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
326318|NCT01710462|Drug|Pantoprazole + Domperidone|
326319|NCT01710462|Drug|Pantozol®|
326320|NCT01710449|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
326321|NCT01710423|Behavioral|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.~The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.~The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
326322|NCT01710410|Device|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
326323|NCT01710410|Device|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
326324|NCT01710397|Other|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
326325|NCT01710384|Drug|betamethasone|
326326|NCT01710371|Drug|18F-AV-133|296 MBq (8 mCi)
326327|NCT01710371|Drug|10% Arginine Hydrochloride-R-Gene 10|
326328|NCT01710358|Drug|Adalimumab|Administered SC
326329|NCT01710358|Drug|Baricitinib|Administered orally
326330|NCT01710358|Drug|Methotrexate|Administered orally
326331|NCT01710358|Drug|Adalimumab Placebo|Adalimumab placebo administered SC.
326332|NCT01710358|Drug|Baricitinib Placebo|Baricitinib placebo administered orally.
326333|NCT01710345|Drug|Sufentanil NanoTab 20 mcg|
326334|NCT01710345|Drug|Sufentanil NanoTab 30 mcg|
326335|NCT01710345|Drug|Placebo NanoTab|
326338|NCT01710306|Behavioral|Nurse Care Manager (NCM)|Nurse care manager interventions with telephone implemented shared decision making protocol compared to outreach as usual OEF/OIF/OND outreach.
326339|NCT01710293|Behavioral|Communication of Patients Lost to Follow-up to Providers|"The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective."
326340|NCT01710280|Dietary Supplement|High-fat meal containing native palm olein|
326341|NCT01710280|Dietary Supplement|High-fat meal containing interesterified palm olein|
326342|NCT01710254|Drug|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
326343|NCT01710254|Drug|Gadobenate dimeglumine|Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.
326344|NCT01710228|Drug|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
326345|NCT01710215|Other|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).~Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
326346|NCT01710215|Other|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.~Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.~Centralized processes to promote guideline-based follow up."
326347|NCT01710202|Drug|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
326348|NCT01710189|Drug|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
326349|NCT01710176|Drug|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
326350|NCT01710176|Drug|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
326351|NCT01710176|Drug|trabectedin 1.3 mg/m2|
326352|NCT01710176|Drug|high-dose ifosfamide 14 g/m2, given in in 14 days|
326353|NCT01710176|Drug|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
326354|NCT01710176|Drug|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
326355|NCT01710163|Drug|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
326356|NCT01710163|Drug|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
326357|NCT01710150|Procedure|CTI ablation alone|
326358|NCT01710150|Procedure|CTI ablation and Pulmonary vein isolation (PVI)|
326359|NCT01710137|Drug|Varenicline|
326360|NCT01710137|Drug|Placebo|
326361|NCT01710137|Behavioral|Smoking Cessation Counseling|
326362|NCT01710124|Other|Financial incentives|
326363|NCT01710111|Device|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
326364|NCT01710098|Drug|Degarelix|subcutaneous injection
326365|NCT01710085|Device|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
326366|NCT01710072|Drug|aspirin|
326367|NCT01710059|Behavioral|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
326368|NCT01710059|Behavioral|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
326369|NCT01710059|Behavioral|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
326370|NCT01710059|Behavioral|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
326371|NCT01710046|Drug|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
326372|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
326373|NCT01710046|Drug|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
326374|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
326375|NCT01710033|Drug|Placebo|Placebo tables twice daily (BID) for 28 days
326376|NCT01710033|Drug|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
326377|NCT01710033|Drug|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
326378|NCT01710033|Drug|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
326379|NCT01710020|Drug|CP-690,550|CP-690,550 10 mg oral powder for constitution
326688|NCT01707901|Other|Placebo|Placebo
326380|NCT01710007|Drug|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
326381|NCT01710007|Drug|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
326382|NCT01709994|Drug|Aspirin|100 mg/day of aspirin
326383|NCT01709981|Drug|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
326384|NCT01709981|Drug|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
326385|NCT01709968|Drug|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
326386|NCT01709968|Drug|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
326387|NCT01709955|Dietary Supplement|Glucomannan|750 MG of Glucomannan in capsule form
326388|NCT01709955|Other|Placebo|750 mg of Cellulose powder in a capsule form
326389|NCT01709942|Drug|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
326390|NCT01709942|Drug|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were >300pg/ml
326391|NCT01709929|Drug|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
326392|NCT01709903|Drug|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
326393|NCT01709903|Drug|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
326394|NCT01709903|Drug|Placebo to QVA149|Placebo to QVA149 with SDDPI
326395|NCT01709903|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
326396|NCT01709890|Device|YO2(R) catheter|
326397|NCT01709877|Procedure|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
326398|NCT01709864|Drug|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
326399|NCT01709864|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
326400|NCT01709851|Device|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
326401|NCT01709851|Device|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
326402|NCT01709838|Drug|deferasirox|Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
326403|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
326404|NCT01709825|Dietary Supplement|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
326405|NCT01709825|Dietary Supplement|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
326406|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
326407|NCT01709812|Other|individualized patient support program|individualized patient support with compliance supporting tools
326408|NCT01709812|Other|Standard care|
326409|NCT01709799|Behavioral|Exercise|"Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:~(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.~Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data."
326410|NCT01709799|Behavioral|Exergames|"Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.~Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:~THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate~Polar Heart Rate monitors are used to measure THR and save resulting data."
326411|NCT01709799|Behavioral|Cognitive Training|"Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.~INSIGHT Assessments are done at baseline, the start of each training week and at week 28."
326412|NCT01709773|Procedure|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
326413|NCT01709760|Drug|Methotrexate|Methotrexate 15-25 mg/week
326414|NCT01709760|Drug|ENIA11|ENIA11 25 mg, sc twice weekly
326415|NCT01709760|Drug|Placebo|Placebo, sc twice weekly
326416|NCT01709747|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
326417|NCT01709747|Device|Programmable Implantable pump|"Device: Programmable Implantable pump~Programmable Implantable pump delivering intrathecal hydromorphone"
326418|NCT01709734|Drug|galeterone|
326419|NCT01709721|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
326420|NCT01709721|Device|Programmable Implantable pump|Programmable Implantable pump delivering intrathecal hydromorphone
326421|NCT01709708|Drug|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
326422|NCT01709708|Drug|Saline|Saline
326423|NCT01709695|Drug|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
326424|NCT01709695|Drug|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
326737|NCT01707381|Drug|Timolol maleate|Topical ophthalmic solution
326425|NCT01709682|Drug|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
326426|NCT01709682|Procedure|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
326427|NCT01709682|Procedure|ILR implantation|"The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events."
326428|NCT01709656|Biological|MSC|"human mesenchymal stem cells,1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.~a total of 24 weeks for follow up."
326429|NCT01709656|Drug|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
326430|NCT01709643|Dietary Supplement|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
326431|NCT01709643|Dietary Supplement|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
326432|NCT01709630|Drug|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
326433|NCT01709617|Dietary Supplement|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
326434|NCT01709604|Procedure|CVVH|Ultrafiltration at 35ml/h/Kg
326435|NCT01709604|Procedure|Standardized therapy regimens|"Standardized therapy regimens included the followings:~Remove all contaminated clothing~Gastric lavage~Receive activated charcoal as quickly as possible~Hemoperfusion with activated charcoal(160g)~Immunosuppression with methylprednisolone~Antioxidants (glutathione,1.2 gram iv twice a day)~Supportive care"
326436|NCT01709591|Behavioral|Prenatal education|
326437|NCT01709578|Drug|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
326438|NCT01709578|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
326439|NCT01709578|Drug|hydroxychloroquine|Dispensed according to the local practice.
326440|NCT01709578|Drug|methotrexate|Dispensed according to the local practice.
326441|NCT01709578|Drug|sulfasalazine|Dispensed according to the local practice.
326442|NCT01709578|Drug|leflunomide|Dispensed according to the local practice.
326443|NCT01709552|Behavioral|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
326444|NCT01709552|Behavioral|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
326445|NCT01709539|Procedure|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
326446|NCT01709526|Behavioral|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
326447|NCT01709513|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets.
326448|NCT01709513|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet.
326449|NCT01709513|Drug|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
326450|NCT01709513|Drug|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
326451|NCT01709500|Drug|LMT (atorvastatin, simvastatin, or rosuvastatin)|
326452|NCT01709500|Drug|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
326453|NCT01709500|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
326454|NCT01709487|Procedure|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
326455|NCT01709474|Drug|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
326456|NCT01709474|Drug|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
326457|NCT01709435|Drug|Cabozantinib S-malate|Given PO
326458|NCT01709435|Other|Laboratory Biomarker Analysis|Correlative studies
326459|NCT01709435|Other|Pharmacological Study|Correlative studies
326460|NCT01709422|Drug|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
326461|NCT01709422|Drug|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
326462|NCT01709422|Drug|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
326463|NCT01709409|Drug|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
326464|NCT01709409|Drug|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
326465|NCT01709396|Radiation|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
326466|NCT01709383|Device|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
326467|NCT01709383|Device|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
326468|NCT01709370|Drug|Letrozole, PD 0332991|
326469|NCT01709357|Other|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
326470|NCT01709357|Other|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
326471|NCT01709357|Other|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
326472|NCT01709357|Other|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
326473|NCT01709344|Behavioral|PS-OT|
326474|NCT01709344|Other|Usual care|Supportive and rehabilitation services available at DHMC
326475|NCT01709331|Drug|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
326476|NCT01709331|Drug|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
326477|NCT01709318|Drug|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
326478|NCT01709318|Drug|Etonogestrel (ENG)|Daily release of 75, 100, or 125 μg
326479|NCT01709318|Drug|Ethinyl estradiol (EE)|Daily release of 15 μg
326480|NCT01709318|Drug|Estradiol (E2)|Daily release of 300 μg
326481|NCT01709305|Drug|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
326482|NCT01709305|Drug|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
326483|NCT01709305|Drug|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
326484|NCT01709305|Drug|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
326485|NCT01709305|Drug|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
326486|NCT01709305|Drug|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
326487|NCT01709292|Drug|Vemurafenib (All Groups)|960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
326488|NCT01709292|Drug|Vemurafenib (Post Surgery) - Group A + C|"Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.~Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B."
326489|NCT01709292|Other|Post Surgery - Group B|Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
326490|NCT01709279|Biological|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
326491|NCT01709266|Dietary Supplement|Probiotics|
326492|NCT01709266|Dietary Supplement|Placebo|
326493|NCT01709253|Radiation|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
326494|NCT01709240|Device|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
326495|NCT01709227|Drug|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
326780|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
326496|NCT01709227|Procedure|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
326497|NCT01709214|Drug|Cebranopadol (GRT6005) Low-Dose Range|Capsules
326498|NCT01709214|Drug|Cebranopadol (GRT6005) High-Dose Range|Capsules
326499|NCT01709214|Drug|Placebo|Capsules that did not contain active substance but appeared identical to the cebranopadol and oxycodone CR capsules
326500|NCT01709214|Drug|Oxycodone CR|Capsules containing oxycodone CR 10 or 20 milligrams
326501|NCT01709201|Behavioral|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
326502|NCT01709188|Behavioral|Musical Dual Task Training|
326503|NCT01709188|Behavioral|Walking and Talking|
326504|NCT01709175|Behavioral|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
326505|NCT01709162|Biological|Ipilimumab|
326506|NCT01709162|Drug|Chemotherapy|
326507|NCT01709149|Drug|CK-2017357|CK-2017357 125 mg tablets twice daily
326508|NCT01709149|Other|Placebo tablets|Tablets
326509|NCT01709149|Drug|Riluzole|Tablets
326510|NCT01709136|Drug|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
326511|NCT01709123|Drug|chromium niacinate|200ug or 500ug supplementation in pill form
326512|NCT01709123|Drug|placebo|Placebo pill for chromium niacinate
326513|NCT01709110|Drug|Teriparatide|Administered SC
326514|NCT01709110|Drug|Risedronate|Administered orally
326515|NCT01709110|Drug|Placebo|"Teriparatide arm placebo administered orally.~Risedronate arm placebo administered SC."
326516|NCT01709110|Drug|Calcium|Administered orally
326517|NCT01709110|Drug|Vitamin D|Administered orally
326518|NCT01709084|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
326519|NCT01709084|Drug|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
326520|NCT01709084|Drug|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
326521|NCT01709084|Drug|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
326522|NCT01709071|Drug|IPV|
326523|NCT01709071|Drug|Low dose Sabin-IPV|
326524|NCT01709071|Drug|Low dose adjuvanted Sabin-IPV|
326525|NCT01709071|Drug|Middle dose Sabin-IPV|
326526|NCT01709071|Drug|Middle dose adjuvanted Sabin-IPV|
326527|NCT01709071|Drug|High dose Sabin-IPV|
326528|NCT01709071|Drug|High dose adjuvanted Sabin-IPV|
326529|NCT01709058|Drug|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
326530|NCT01709058|Other|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
326531|NCT01709045|Other|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
326532|NCT01709045|Radiation|Dual-Energy Computed Tomography (DECT)|
326533|NCT01709045|Other|Ultrasound|
326534|NCT01709045|Other|Transcranial doppler|
326535|NCT01709032|Drug|Deferasirox and deferiprone|
326536|NCT01709019|Biological|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
326537|NCT01709019|Biological|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
326538|NCT01709019|Biological|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
326539|NCT01709019|Biological|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
326540|NCT01709019|Biological|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
326541|NCT01709006|Radiation|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
326542|NCT01708993|Drug|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
326543|NCT01708993|Drug|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
326544|NCT01708993|Drug|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
326545|NCT01708993|Drug|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
326546|NCT01708980|Other|Six different strength training exercises|"Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.~The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for."
326547|NCT01708967|Procedure|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).~Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
326548|NCT01708954|Drug|Cabozantinib S-malate|Given PO
326549|NCT01708954|Drug|Erlotinib Hydrochloride|Given PO
326550|NCT01708954|Other|Laboratory Biomarker Analysis|Correlative studies
326551|NCT01708941|Biological|Ipilimumab|Given IV
326552|NCT01708941|Other|Laboratory Biomarker Analysis|Correlative studies
326553|NCT01708941|Biological|Recombinant Interferon Alfa-2b|Given IV or SC
326554|NCT01708928|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326555|NCT01708915|Drug|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
326556|NCT01708915|Drug|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
326557|NCT01708915|Drug|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
326558|NCT01708915|Drug|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
326559|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
326560|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
326561|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
326562|NCT01708902|Drug|Metformin 500mg|Metformin 500mg BID
326563|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
326564|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
326565|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
326566|NCT01708902|Drug|Metformin 1000mg|Metformin 1000mg BID
326567|NCT01708889|Biological|BMS-914143 (Peginterferon Lambda-1a)|
326568|NCT01708876|Drug|Artesunate-mefloquine|
326569|NCT01708876|Drug|Chloroquine|
326570|NCT01708876|Drug|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
326571|NCT01708850|Drug|Rivaroxaban|All specified in arm description. One arm study.
326572|NCT01708837|Drug|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
326573|NCT01708824|Behavioral|Dietary|"Dietary intervention to meet the target of~<5 servings of red/processed meat weekly; <2 servings would be processed meat~2 servings of refined grains daily"
326574|NCT01708824|Behavioral|Physical activity|"Physical activity intervention with the following targets:~General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);~Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
326575|NCT01708798|Drug|Eplerenone|
326576|NCT01708798|Drug|Placebo|
326577|NCT01708785|Behavioral|Single food Cue Exposure Treatment|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
326578|NCT01708785|Behavioral|Multiple food Cue Exposure Treatment|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
326579|NCT01708785|Behavioral|Partial Reinforcement - Enhanced Cue Exposure Treatment|Subjects will take random additional tastes of the food during cue exposure treatment.
326580|NCT01708785|Behavioral|Partial Reinforcement -Consistent Cue Exposure Treatment|Subjects will consistently take the same tastes of the food during cue exposure treatment.
326581|NCT01708733|Drug|KSY|Chinese herbal formula
326582|NCT01708720|Drug|IPV|
326583|NCT01708720|Drug|Sabin-IPV|
326584|NCT01708720|Drug|Adjuvanted Sabin-IPV|
326585|NCT01708707|Drug|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.~Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
326586|NCT01708707|Drug|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
326587|NCT01708694|Dietary Supplement|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
326896|NCT01706419|Dietary Supplement|Fortified rice cold extruded kernel|
326588|NCT01708694|Dietary Supplement|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
326589|NCT01708681|Dietary Supplement|Lean seafood|
326590|NCT01708681|Dietary Supplement|Meat, egg, milk|
326591|NCT01708668|Procedure|Epidural analgesia|
326592|NCT01708668|Procedure|Combined spinal-epidural analgesia|
326593|NCT01708668|Procedure|Continuous epidural infusion|
326594|NCT01708668|Procedure|Intermittent epidural bolus|
326595|NCT01708655|Other|Sweat Evaporimeter measurement|"The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.~intracutaneous injection of 0.2 ml of atropine~Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:~Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.~intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion~intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .~The procedure would take about 45 minutes."
326596|NCT01708642|Drug|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
326597|NCT01708642|Drug|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
326598|NCT01708629|Drug|210 mg brodalumab|210 mg brodalumab administered SC
326599|NCT01708629|Drug|140 mg brodalumab|140 mg brodalumab administered SC
326600|NCT01708629|Drug|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
326601|NCT01708629|Drug|placebo|placebo administered SC
326602|NCT01708616|Drug|RO5285119|multiple doses
326603|NCT01708616|Drug|RO5285119 placebo|multiple doses
326604|NCT01708616|Drug|risperidone|single dose
326605|NCT01708616|Drug|risperidone placebo|single dose
326606|NCT01708603|Drug|210 mg brodalumab|210 mg brodalumab administered SC
326607|NCT01708603|Drug|140 mg brodalumab|140 mg brodalumab administered SC
326608|NCT01708603|Drug|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
326609|NCT01708603|Drug|placebo|Placebo administered SC
326610|NCT01708590|Drug|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
326611|NCT01708590|Drug|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
326612|NCT01708590|Drug|placebo|Placebo administered subcutaneous (SC)
326613|NCT01708577|Device|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
326614|NCT01708564|Biological|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
326615|NCT01708551|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326616|NCT01708538|Drug|CXL|corneal crosslinking
326617|NCT01708525|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
326618|NCT01708525|Other|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
326619|NCT01708512|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326620|NCT01708499|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326621|NCT01708473|Drug|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
326622|NCT01708473|Drug|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
326623|NCT01708473|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326624|NCT01708460|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
326625|NCT01708447|Drug|L.M.X.4.® cream|A lidocaine topical anesthetic cream
326626|NCT01708447|Other|A placebo cream|Placebo cream containing no anesthetic properties.
326627|NCT01708447|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326628|NCT01708434|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
326629|NCT01708408|Genetic|Biomarker studies|
326630|NCT01708382|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326631|NCT01708369|Drug|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
326632|NCT01708369|Drug|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
326633|NCT01708369|Drug|Oseltamivir|Oseltamivir 150 mg orally
326634|NCT01708369|Drug|Aspirin|Aspirin 650 mg orally will be given
326635|NCT01708356|Behavioral|Cycling on a residential route|
326636|NCT01708343|Procedure|DIMMST|
326637|NCT01708330|Drug|Lidocaine|2% Lidocaine gel
326638|NCT01708330|Drug|Placebo gel|odorless, colorless gel will be used as a placebo
326639|NCT01708317|Behavioral|ACASI|Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
326640|NCT01708304|Behavioral|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
326641|NCT01708291|Behavioral|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
326642|NCT01708291|Behavioral|only pre and post evaluation measures|
326689|NCT01707888|Procedure|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
326779|NCT01707082|Drug|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
326643|NCT01708278|Drug|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week~Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin~Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
326644|NCT01708278|Other|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
326645|NCT01708265|Other|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
326646|NCT01708265|Procedure|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
326647|NCT01708252|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
326648|NCT01708239|Other|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
326649|NCT01708226|Behavioral|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
326650|NCT01708213|Device|Aline HA|Implantable dermal filler
326651|NCT01708200|Other|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
326652|NCT01708187|Biological|Clarix™1k graft|"Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.~Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue."
326653|NCT01708174|Drug|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
326654|NCT01708174|Drug|TMZ|Temozolomide capsules were obtained locally by the Investigator
326655|NCT01708161|Drug|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
326656|NCT01708161|Drug|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
326657|NCT01708148|Dietary Supplement|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
326658|NCT01708148|Other|Placebo|control group would receive a oral lactose placebo
326659|NCT01708135|Behavioral|Use of smartphone app|
326660|NCT01708122|Drug|Fentanyl|100 mcg in 1 mL intranasal spray
326661|NCT01708122|Drug|saline|Sodium Chloride 0.9% intranasal spray
326662|NCT01708109|Other|no measures taken to clear bile ductus|biliary calculus remain
326663|NCT01708109|Procedure|clearance of bile ductus|biliary calculus removed at surgery
326664|NCT01708096|Dietary Supplement|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
326665|NCT01708096|Dietary Supplement|Normal diet|normal diet 2 weeks before gastric by-pass
326666|NCT01708070|Behavioral|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
326667|NCT01708057|Drug|AZD8683|AZD8683 administered via inhalation
326668|NCT01708057|Drug|Placebo|Placebo administered via inhalation
326669|NCT01708057|Drug|Tiotropium|Tiotropium administered via inhalation
326670|NCT01708044|Drug|Pramlintide acetate|
326671|NCT01708044|Other|Placebo|Placebo Comparator
326672|NCT01708031|Other|physiological signals|
326673|NCT01708018|Procedure|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.~The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.~During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
326674|NCT01708005|Drug|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
326675|NCT01708005|Drug|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
326676|NCT01707992|Drug|Laquinimod|Laquinimod will be administered as per the dose and schedule specified in the respective arms.
326677|NCT01707992|Drug|Placebo|Placebo matching to laquinimod will be administered as per the schedule specified in the respective arms.
326678|NCT01707966|Drug|Orteronel|
326679|NCT01707966|Drug|Placebo|
326680|NCT01707953|Drug|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
326681|NCT01707953|Drug|Placebo|Placebo capsule to mimic midodrine
326682|NCT01707940|Drug|Ketoconazole|Ketoconazole 400 mg / day
326683|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
326684|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
326685|NCT01707914|Dietary Supplement|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
326686|NCT01707914|Dietary Supplement|placebo|
326687|NCT01707901|Drug|ONO-8539|Treatment
326690|NCT01707875|Other|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
326691|NCT01707849|Drug|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
326692|NCT01707849|Drug|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
326693|NCT01707823|Drug|acetylsalicylic acid|Given PO
326694|NCT01707823|Other|laboratory biomarker analysis|Correlative studies
326695|NCT01707810|Procedure|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
326696|NCT01707810|Procedure|conventional method|
326697|NCT01707771|Procedure|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
326698|NCT01707771|Behavioral|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
326699|NCT01707745|Procedure|Intravitreal Bevacizumab|
326700|NCT01707732|Drug|Enoxaparin|Administration of Enoxaparin
326701|NCT01707706|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
326702|NCT01707693|Behavioral|Lifestyle Physical Activity Intervention|Physical Activity Information given plus Behavioral counseling using motivational interviewing & follow-up
326703|NCT01707693|Behavioral|Information / Attention Comparison|Physical Activity information given & follow-up, no behavioral counseling
326704|NCT01707680|Other|SOC|Patient are given standard of care
326705|NCT01707667|Drug|prucalopride|One 2 mg tablet orally administered on Day 1
326706|NCT01707667|Drug|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
326707|NCT01707654|Device|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
326708|NCT01707641|Dietary Supplement|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
326709|NCT01707641|Other|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
326710|NCT01707628|Biological|influenza vaccination with influenza vaccine|
326711|NCT01707615|Drug|GSPE|GSPE 240 mg/day (120mg bid)
326712|NCT01707615|Other|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
326713|NCT01707602|Biological|INTANZA® 15|intradermal vaccination
326714|NCT01707602|Biological|Vaxigrip®|Intramuscular vaccination
326715|NCT01707602|Biological|INTANZA® 15 T|transcutaneous vaccination
326716|NCT01707589|Device|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
326717|NCT01707576|Behavioral|consultation 10 days later|new depression screening
326718|NCT01707563|Procedure|skin punch biopsy and molecular biology|
326719|NCT01707563|Other|fibroblast culture and molecular biology|
326720|NCT01707537|Biological|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
326721|NCT01707524|Procedure|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
326722|NCT01707498|Procedure|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
326723|NCT01707498|Procedure|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
326724|NCT01707485|Drug|amoxicillin|dosed 75-100 mg/kg/day (standardized dosing)
326725|NCT01707472|Biological|Simtuzumab|700 mg intravenously for a total of 12 infusions.
326726|NCT01707446|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
326727|NCT01707446|Other|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of < 75% from baseline is reached for > 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
326728|NCT01707433|Other|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
326729|NCT01707420|Drug|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
326730|NCT01707420|Drug|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
326731|NCT01707407|Drug|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
326732|NCT01707407|Drug|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
326733|NCT01707407|Drug|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
326734|NCT01707407|Drug|Carbamazepine|"100 mg Carbamazepine tablet administered orally once in the evening on Day 1~100 mg Carbamazepine tablet administered orally twice daily on Days 2-3~200 mg Carbamazepine tablet administered orally twice daily on Days 4-11"
326735|NCT01707394|Drug|Apixaban|
326736|NCT01707381|Drug|BOL-303259-X|Topical ophthalmic solution
326738|NCT01707368|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
326739|NCT01707355|Behavioral|intervention - poster|
326740|NCT01707342|Drug|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
326741|NCT01707329|Drug|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
326742|NCT01707329|Drug|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
326743|NCT01707316|Drug|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
326744|NCT01707316|Drug|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
326745|NCT01707316|Other|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
326746|NCT01707303|Other|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
326747|NCT01707303|Other|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
326748|NCT01707290|Drug|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
326749|NCT01707277|Other|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
326750|NCT01707277|Other|Usual care|Usual pahramacological treatment
326751|NCT01707264|Drug|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
326752|NCT01707251|Drug|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
326753|NCT01707251|Drug|Saline|Placebo control
326754|NCT01707238|Device|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
326755|NCT01707238|Device|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
326756|NCT01707225|Drug|Octreotide LAR Depot|The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
326757|NCT01707212|Behavioral|Pain management education|Education about pain management during infant immunization
326758|NCT01707212|Behavioral|No pain management education|Control - no education about pain management during infant immunization
326759|NCT01707199|Drug|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.~One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
326760|NCT01707173|Behavioral|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
326761|NCT01707173|Behavioral|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
326762|NCT01707160|Drug|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
326763|NCT01707160|Drug|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
326764|NCT01707147|Drug|Trajenta tablet|Linagliptin
326765|NCT01707134|Drug|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
326766|NCT01707134|Drug|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
326767|NCT01707134|Drug|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
326768|NCT01707108|Device|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
326769|NCT01707095|Other|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
326770|NCT01707095|Other|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
326771|NCT01707082|Drug|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
326772|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
326773|NCT01707082|Drug|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
326774|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
326775|NCT01707082|Drug|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
326776|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
326777|NCT01707082|Drug|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
326778|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
326781|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
326782|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
326783|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
326784|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
326785|NCT01707069|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
326786|NCT01707056|Other|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
326787|NCT01707056|Other|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
326788|NCT01707056|Other|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
326789|NCT01707056|Other|Water|Taking Synthroid with water for a period of 6 weeks.
326790|NCT01707043|Drug|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
326791|NCT01707030|Other|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
326792|NCT01707030|Other|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
326793|NCT01707017|Other|Strength training|
326794|NCT01707004|Drug|decitabine|Given IV
326795|NCT01707004|Drug|fludarabine phosphate|Given IV
326796|NCT01707004|Drug|busulfan|Given IV
326797|NCT01707004|Drug|cyclophosphamide|Given IV
326798|NCT01707004|Drug|tacrolimus|Given PO or IV
326799|NCT01707004|Drug|mycophenolate mofetil|Given PO
326800|NCT01707004|Biological|filgrastim|Given SC
326801|NCT01707004|Radiation|total-body irradiation|Undergo total-body irradiation
326802|NCT01707004|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
326803|NCT01707004|Other|laboratory biomarker analysis|Correlative studies
326804|NCT01706991|Device|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
326805|NCT01706978|Procedure|Bone Trephination|
326806|NCT01706978|Procedure|Soft Tissue Trephination|
326807|NCT01706965|Drug|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
326808|NCT01706965|Drug|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
326809|NCT01706952|Drug|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
326810|NCT01706952|Drug|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
326811|NCT01706939|Radiation|Reduced Dose Radiation|Reduced Dose Radiation (5600 cGy) dose radiotherapy
326812|NCT01706939|Radiation|Standard Dose Radiation|Standard Dose Radiation (7000 cGy) dose radiotherapy
326813|NCT01706939|Drug|Carboplatin|Day 1, every 21 days ( + 2 days)
326814|NCT01706926|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
326815|NCT01706926|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
326816|NCT01706926|Biological|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
326817|NCT01706926|Other|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
326818|NCT01706913|Other|Dermatology consult|
326819|NCT01706900|Other|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
326820|NCT01706900|Other|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
326821|NCT01706887|Other|Diet Amiloride|only arm of the trial
326822|NCT01706874|Other|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
326823|NCT01706861|Device|Celotres|Celotres following surgical removal of earlobe keloid.
326824|NCT01706848|Other|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
326825|NCT01706848|Other|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
326826|NCT01706835|Drug|aldoxorubicin|
326827|NCT01706822|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
326828|NCT01706809|Other|blood sampels from vena rectalis superior and vena cubiti|
326829|NCT01706796|Drug|PF-06273340|Oral solution, single dose, fasted
326830|NCT01706796|Drug|PF-06273340|Immediate Release Tablet, single dose, fasted
326831|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
326832|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
326833|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
326834|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
326835|NCT01706783|Drug|somapacitan|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 (somapacitan) in an escalating order
326836|NCT01706783|Drug|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
326837|NCT01706770|Device|enfilcon A|The Test device is a contact lens manufactured by CooperVision, Inc.
326838|NCT01706770|Device|galyfilcon A|The Control device is a contact lens manufactured by Johnson & Johnson Vision Care.
326839|NCT01706757|Device|go-cart|conducts exercises with the help of a go-cart
326840|NCT01706744|Other|Intermediate care unit|
326841|NCT01706744|Other|Local health care 1|
326842|NCT01706744|Other|Local health care 2|
326843|NCT01706731|Behavioral|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
326844|NCT01706731|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
326845|NCT01706718|Dietary Supplement|Bread|
326846|NCT01706705|Device|Intracavitary Applicator Placement|MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
326847|NCT01706705|Other|Computed Tomography (CT)|CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
326848|NCT01706705|Other|Magnetic Resonance Imaging (MRI)|MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
326849|NCT01706692|Biological|Adalimumab|all dosages, frequencies and durations prescribed
326850|NCT01706692|Biological|Etanercept|all dosages, frequencies and durations prescribed
326851|NCT01706692|Biological|Infliximab|all dosages, frequencies and durations prescribed
326852|NCT01706692|Biological|Ustekinumab|all dosages, frequencies and durations prescribed
326853|NCT01706692|Drug|Cyclosporine A|all dosages, frequencies and durations prescribed
326854|NCT01706692|Drug|Fumaric acids|all dosages, frequencies and durations prescribed
326855|NCT01706692|Drug|Methotrexate|all dosages, frequencies and durations prescribed
326856|NCT01706692|Drug|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
326857|NCT01706679|Drug|ATX-101 (10 mg/ml)|
326858|NCT01706679|Drug|ATX-101 (20 mg/ml)|
326859|NCT01706679|Drug|Moxifloxacin (400 mg)|
326860|NCT01706679|Drug|Placebo vehicle (PBS)|
326861|NCT01706666|Drug|bortezomib|Given SC
326862|NCT01706666|Drug|cyclophosphamide|Given PO
326863|NCT01706666|Drug|lenalidomide|Given PO
326864|NCT01706666|Other|laboratory biomarker analysis|Correlative studies
326865|NCT01706666|Drug|dexamethasone|Given PO
326866|NCT01706666|Procedure|quality-of-life assessment|Ancillary studies
326867|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
326868|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - medium|
326869|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
326870|NCT01706653|Dietary Supplement|Very low polyphenol fruit based drink (control)|
326871|NCT01706627|Drug|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
326872|NCT01706627|Drug|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
326873|NCT01706627|Drug|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
326874|NCT01706588|Drug|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
326875|NCT01706575|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
326876|NCT01706575|Drug|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
326877|NCT01706562|Drug|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
326878|NCT01706536|Drug|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
326879|NCT01706536|Drug|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
326880|NCT01706536|Drug|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
326881|NCT01706536|Drug|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
326882|NCT01706536|Drug|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
326883|NCT01706523|Drug|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
326884|NCT01706510|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
326885|NCT01706510|Drug|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
326886|NCT01706497|Device|Cerebral tissue oxygen saturation monitoring, blinded|
326887|NCT01706484|Drug|BNO 1016|comparison of different dosages of drug and placebo
326888|NCT01706471|Drug|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up >3 ng/mL. Steroid dose follows local protocol.
326889|NCT01706471|Drug|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
326890|NCT01706458|Biological|sipuleucel-T|Given IV
326891|NCT01706458|Biological|DNA Vaccine|Given ID
326892|NCT01706445|Other|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
326893|NCT01706432|Radiation|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
326894|NCT01706432|Other|laboratory biomarker analysis|Correlative studies
326895|NCT01706432|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
326897|NCT01706419|Dietary Supplement|fortified rice warm extruded kernel|
326898|NCT01706419|Dietary Supplement|fortiified rice hot extruded kernel|
326899|NCT01706406|Behavioral|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
326900|NCT01706393|Dietary Supplement|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
326901|NCT01706393|Dietary Supplement|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
326902|NCT01706380|Behavioral|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
326903|NCT01706380|Behavioral|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
326904|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
326905|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
326906|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
326907|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
326908|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
326909|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
326910|NCT01706354|Procedure|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
326911|NCT01706354|Procedure|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
326912|NCT01706341|Drug|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
326913|NCT01706341|Drug|acetate Ringer's solution containing no glucose|
326914|NCT01706341|Drug|acetate Ringer's solution containing 1% glucose|
326915|NCT01706328|Drug|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
326916|NCT01706328|Drug|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
326917|NCT01706328|Drug|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
326918|NCT01706328|Drug|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
326919|NCT01706328|Drug|Salbutamol as needed|Salbutamol inhalation powder
326920|NCT01706315|Drug|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
326921|NCT01706315|Drug|Placebo|Matching placebo will be available
326922|NCT01706302|Other|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD [recently re-named Clinical Practice Research Datalink (CPRD)], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
326923|NCT01706263|Drug|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
326924|NCT01706263|Drug|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
326925|NCT01706263|Drug|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
326926|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
326927|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
326928|NCT01706250|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
326929|NCT01706250|Other|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
326930|NCT01706250|Other|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
326931|NCT01706250|Other|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
326932|NCT01706237|Device|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
326933|NCT01706224|Procedure|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
326934|NCT01706224|Other|Data collection|Electronic Case Report Forms (eCRF)
326935|NCT01706224|Other|Data collection|Questionnaires, active questioning.
326936|NCT01706211|Drug|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
326937|NCT01706211|Drug|Placebo|
326938|NCT01706198|Drug|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
326939|NCT01706198|Drug|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
326940|NCT01706185|Other|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
326941|NCT01706172|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
326942|NCT01706172|Other|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
326943|NCT01706159|Drug|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
326944|NCT01706159|Drug|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
326945|NCT01706146|Drug|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
326946|NCT01706133|Other|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
326947|NCT01706120|Drug|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
326948|NCT01706120|Drug|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
326949|NCT01706120|Drug|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
326950|NCT01706094|Other|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.~This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
326951|NCT01706081|Procedure|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
326952|NCT01706081|Procedure|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
326953|NCT01706055|Biological|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
326954|NCT01706042|Other|legume meal|
326955|NCT01706042|Other|white bread|
326956|NCT01706016|Procedure|Thermic destruction of tissue by Laser using the Novilase device|
326957|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
326958|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
326959|NCT01705990|Biological|Ad35-GRIN (0.5mL)|(1x10^10 vp) Delivered intramuscularly by standard syringe and needle injection
326960|NCT01705977|Biological|Placebo plus standard therapy|Placebo plus standard therapy
326961|NCT01705977|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
326962|NCT01705977|Other|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
326963|NCT01705964|Drug|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
326964|NCT01705964|Other|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
326965|NCT01705951|Other|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
326966|NCT01705951|Biological|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
326967|NCT01705938|Drug|SP-333|
326968|NCT01705912|Other|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
326969|NCT01705912|Other|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
326970|NCT01705899|Drug|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
326971|NCT01705886|Procedure|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
326972|NCT01705886|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
326973|NCT01705886|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
326974|NCT01705886|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
326975|NCT01705886|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
326976|NCT01705860|Biological|Santyl|
326977|NCT01705847|Drug|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
326978|NCT01705821|Device|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
326979|NCT01705821|Procedure|Removal of pituitary tumor using modified curette|
326980|NCT01705808|Drug|Protein C concentrate|
326981|NCT01705795|Drug|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
326982|NCT01705795|Drug|Placebo|Nacl four times over four months
326983|NCT01705782|Biological|E. coli endotoxin, US standard|
326984|NCT01705769|Other|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
326985|NCT01705769|Other|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
326986|NCT01705769|Other|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
326987|NCT01705756|Drug|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
326988|NCT01705743|Drug|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
326989|NCT01705743|Drug|Sevoflurane|100% oxygen+ Sevoflurane
326990|NCT01705730|Drug|tocilizumab|Participants received tocilizumab monotherapy according to individualized physician-prescribed regimens.
326991|NCT01705691|Drug|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
326992|NCT01705691|Drug|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
326993|NCT01705691|Drug|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
326994|NCT01705691|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
326995|NCT01705678|Dietary Supplement|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
326996|NCT01705678|Dietary Supplement|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
326997|NCT01705652|Drug|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
326998|NCT01705639|Drug|Melatonin|All subjects receive the same dose of melatonin
326999|NCT01705600|Behavioral|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
327000|NCT01705587|Drug|teriparatide|20 microgram once-daily subcutaneous injection
327001|NCT01705574|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally with food once daily
327002|NCT01705574|Drug|ATV|300 mg capsule administered orally with food once daily
327003|NCT01705574|Drug|RTV|100 mg tablet administered orally with food once daily
327004|NCT01705574|Drug|FTC/TDF|200/300 mg tablet administered orally with food once daily
327005|NCT01705574|Drug|E/C/F/TDF Placebo|Tablet administered orally with food once daily
327006|NCT01705574|Drug|ATV Placebo|Tablet administered orally with food once daily
327007|NCT01705574|Drug|RTV Placebo|Capsule administered orally with food once daily
327008|NCT01705574|Drug|FTC/TDF Placebo|Tablet administered orally with food once daily
327009|NCT01705574|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally with food once daily
327010|NCT01705548|Radiation|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
327011|NCT01705535|Behavioral|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
327012|NCT01705535|Other|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
327013|NCT01705535|Behavioral|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
327014|NCT01705509|Drug|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
327015|NCT01705496|Radiation|[124I]FIAU|This is a single dose study of 5 mCi [124I]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after [124I]FIAU injection.
327016|NCT01705483|Drug|ASP9853|oral
327017|NCT01705483|Drug|Docetaxel|intravenous (IV)
327018|NCT01705483|Drug|Paclitaxel|Taxol
327019|NCT01705470|Drug|furosemide|
327020|NCT01705470|Drug|placebo normal saline|
327021|NCT01705457|Drug|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
327022|NCT01705457|Drug|placebo|
327023|NCT01705444|Device|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
327024|NCT01705431|Behavioral|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
327025|NCT01705405|Device|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
327026|NCT01705392|Drug|Bevacizumab|Bevacizumab 10 mg/kg q3w
327027|NCT01705392|Drug|Propranolol|Propranolol 80 mg x 1
327028|NCT01705392|Drug|Enalapril|Enalapril 5 mg x 1
327029|NCT01705392|Drug|Dacarbazine|dacarbazine 1000 mg/m2 q3w
327030|NCT01705379|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
327031|NCT01705366|Procedure|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
327032|NCT01705366|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
327033|NCT01705366|Procedure|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
327034|NCT01705366|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
327035|NCT01705366|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
327036|NCT01705366|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
327037|NCT01705340|Drug|Akt inhibitor MK2206|Given PO
327038|NCT01705340|Biological|trastuzumab|Given IV
327039|NCT01705340|Drug|lapatinib ditosylate|Given PO
327040|NCT01705340|Other|laboratory biomarker analysis|Optional correlative studies
327041|NCT01705314|Dietary Supplement|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
327042|NCT01705314|Dietary Supplement|placebo|7mls of placebo drops per week for 8 months.
327043|NCT01705301|Device|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
327044|NCT01705288|Procedure|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
327045|NCT01705288|Drug|intravenous narcotics|given for pain management after surgery per physician orders
327046|NCT01705288|Drug|standard anesthesia|inhalant or intravenous during surgery
327047|NCT01705288|Drug|regional anesthesia|given by spinal or epidural infusion
327048|NCT01705288|Drug|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
327049|NCT01705275|Drug|ONO-8539|ONO-8539
327050|NCT01705275|Other|Placebo|Identical to ONO-8539 tablet but without active ingedient
327051|NCT01705249|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
327052|NCT01705236|Other|longitudinal assessment|OTC assessments
327053|NCT01705223|Biological|DNA vaccine|4mg/dose, three doses at week 0,4,8
327054|NCT01705223|Biological|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
327055|NCT01705223|Biological|rTV boost|at week 16
327056|NCT01705223|Biological|rTV boost|at week 24
327057|NCT01705223|Biological|rTV boost|at week 32
327058|NCT01705197|Drug|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
327059|NCT01705184|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
327060|NCT01705184|Drug|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
327061|NCT01705184|Drug|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
327852|NCT01699386|Other|Control Study Formula|feed as lib
327062|NCT01705158|Drug|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
327063|NCT01705145|Drug|Ivacaftor|
327064|NCT01705119|Other|Standing|
327065|NCT01705106|Drug|capecitabine|Given PO
327066|NCT01705106|Drug|celecoxib|Given PO
327067|NCT01705106|Other|pharmacological study|Correlative studies
327068|NCT01705106|Other|laboratory biomarker analysis|Correlative studies
327069|NCT01705106|Other|pharmacogenomic studies|Correlative studies
327070|NCT01705093|Dietary Supplement|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
327071|NCT01705093|Dietary Supplement|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
327072|NCT01705080|Device|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
327073|NCT01705067|Device|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
327074|NCT01705041|Device|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
327075|NCT01705015|Behavioral|direct feedback about exercise|
327076|NCT01705015|Behavioral|PLacebo|UCFit plus encouraged exercise
327077|NCT01705002|Drug|Promitil|2 mg/kg dose IV
327078|NCT01705002|Drug|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
327079|NCT01705002|Drug|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
327080|NCT01704989|Procedure|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
327081|NCT01704989|Drug|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation.
327082|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
327083|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
327084|NCT01704963|Drug|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
327085|NCT01704937|Drug|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
327086|NCT01704924|Device|Prevena|Device will be applied at end of procedure over closed incision
327087|NCT01704924|Procedure|Standard of Care Dressing|Dressing applied as Standard of Care
327088|NCT01704911|Procedure|Transradial Coronary Intervention|
327089|NCT01704911|Procedure|Transfemoral Coronary Intervention|
327090|NCT01704911|Device|Coronary Stent System|Any kind of coronary stent system
327091|NCT01704898|Drug|Efavirenz 600 Test-Stocrin 600 Reference|
327092|NCT01704898|Drug|Stocrin 600 Reference-Efavirenz 600 Test|
327093|NCT01704885|Behavioral|Play Intervention|
327094|NCT01704885|Other|Questionnaires|
327095|NCT01704872|Drug|ch14.18/CHO|
327096|NCT01704859|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
327097|NCT01704859|Dietary Supplement|Fish oil placebo|Fish oil placebo
327098|NCT01704859|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
327099|NCT01704859|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
327100|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
327101|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
327102|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
327103|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
327104|NCT01704833|Behavioral|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
327105|NCT01704820|Procedure|Retroflexion in the right colon|
327106|NCT01704807|Device|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
327107|NCT01704807|Device|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
327108|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
327109|NCT01704794|Drug|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
327110|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
327111|NCT01704781|Drug|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
327112|NCT01704781|Drug|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
327113|NCT01704781|Drug|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
327114|NCT01704781|Drug|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
327115|NCT01704768|Behavioral|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
327116|NCT01704768|Behavioral|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
327117|NCT01704755|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
327118|NCT01704755|Drug|Ribavirin (RBV)|Capsule
327119|NCT01704729|Procedure|group1|Non-cycloplegic self-refraction +conventional glasses
327120|NCT01704729|Procedure|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
327121|NCT01704729|Procedure|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
327122|NCT01704729|Procedure|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
327123|NCT01704716|Drug|Vincristine|given during Rapid COJEC and modified N7 therapy
327124|NCT01704716|Drug|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
327125|NCT01704716|Drug|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
327126|NCT01704716|Drug|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
327127|NCT01704716|Drug|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
327128|NCT01704716|Drug|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
327129|NCT01704716|Drug|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
327130|NCT01704716|Drug|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
327131|NCT01704716|Drug|G-CSF|G-CSF is given during Induction Treatment
327132|NCT01704716|Drug|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
327133|NCT01704716|Drug|Melphalan|Melphalan is given during MAT treatment
327134|NCT01704703|Drug|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
327135|NCT01704703|Drug|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
327136|NCT01704690|Drug|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
327137|NCT01704690|Drug|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
327138|NCT01704690|Drug|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
327139|NCT01704677|Procedure|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
327140|NCT01704677|Behavioral|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
327141|NCT01704664|Dietary Supplement|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
327142|NCT01704664|Drug|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
327348|NCT01702974|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
327143|NCT01704664|Dietary Supplement|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
327144|NCT01704664|Drug|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
327145|NCT01704651|Drug|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
327146|NCT01704651|Drug|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
327147|NCT01704638|Drug|fluvoxamine|
327148|NCT01704638|Drug|Digoxin|
327149|NCT01704625|Procedure|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
327150|NCT01704625|Procedure|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
327151|NCT01704612|Drug|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
327152|NCT01704599|Drug|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
327153|NCT01704586|Radiation|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
327154|NCT01704586|Radiation|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
327155|NCT01704573|Drug|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-[18F]FA radioligand. The 2-[18F]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-[18F]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.~2-[18F]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-[18F]FA from the FDA."
327156|NCT01704560|Other|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
327157|NCT01704534|Drug|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
327158|NCT01704521|Drug|PegInterferon|
327159|NCT01704521|Drug|Ribavirin|
327160|NCT01704521|Drug|Telaprevir|
327161|NCT01704508|Drug|Artemether-lumefantrine|
327162|NCT01704508|Drug|Dihydroartemisinin-piperaquine|
327163|NCT01704495|Drug|AZD5069|AZD5069 oral capsules self-administered twice daily.
327164|NCT01704495|Drug|Placebo|Placebo oral capsules self-administered twice daily.
327165|NCT01704482|Drug|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
327166|NCT01704482|Drug|placebo|
327167|NCT01704469|Procedure|The local anesthetic injection|
327168|NCT01704456|Behavioral|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
327169|NCT01704456|Behavioral|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
327289|NCT01703481|Drug|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
327170|NCT01704443|Behavioral|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.~Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
327171|NCT01704443|Other|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
327172|NCT01704430|Dietary Supplement|Glutamine|Enteric L-Glutamine
327173|NCT01704430|Dietary Supplement|Maltodextrin|Enteric Maltodextrin
327174|NCT01704417|Drug|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
327175|NCT01704417|Drug|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
327176|NCT01704404|Drug|TD-4208|
327177|NCT01704404|Drug|Placebo|
327178|NCT01704378|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
327179|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
327180|NCT01704365|Biological|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
327181|NCT01704365|Biological|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
327182|NCT01704365|Biological|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
327183|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
327184|NCT01704365|Biological|Placebo|0.5mL IM Injection
327185|NCT01704352|Behavioral|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
327186|NCT01704339|Drug|QUTENZA|Single treatment with topical capsaicin 8%
327187|NCT01704313|Procedure|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
327188|NCT01704313|Procedure|Continuous|Continuous suturing technique used for the anastomosis
327189|NCT01704287|Biological|Pembrolizumab|IV infusion
327190|NCT01704287|Drug|Carboplatin|Carboplatin per institutional standard
327191|NCT01704287|Drug|Paclitaxel|Paclitaxel per institutional standard
327192|NCT01704287|Drug|Dacarbazine|Dacarbazine per institutional standard
327193|NCT01704287|Drug|Temozolomide|Temozolomide per institutional standard
327194|NCT01704274|Other|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
327195|NCT01704274|Other|High Dose GTN 0.057 mg/hr|High Dose GTN
327196|NCT01704274|Other|Placebo|Placebo
327197|NCT01704261|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
327198|NCT01704261|Drug|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
327199|NCT01704261|Drug|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
327200|NCT01704261|Drug|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
327201|NCT01704248|Device|Eye Drop Guide technique|"Wash the hands.~Shake and then uncap the bottle.~Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.~Then place the upper lip down to cover the whole orbital rim area.~Tilt the head back if seated or standing.~Insert the bottle in the device all the way. Hold the bottle gently.~Look upward.~Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~Close the eye 2-3 minutes.~For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
327202|NCT01704248|Behavioral|Routine self-instillation technique|"Wash the hands.~Shake and then uncap the bottle.~Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.~Lie down or tilt the head back if seated or standing.~Using the other hand, pull the lower lid down.~Hold the bottle over the eye and look up.~Squeeze the bottle one drop at a time until feel one drop instilled into the eye.~Close the eye 2-3 minutes.~For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
327203|NCT01704235|Other|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.~A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
327204|NCT01704209|Drug|Fibroblast Treatment|
327205|NCT01704209|Procedure|Vehicle|
327206|NCT01704196|Drug|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
327207|NCT01704196|Drug|Placebo|
327208|NCT01704170|Device|Kona Externally Focused Ultrasound Therapy|
327209|NCT01704157|Device|Cryo-Touch III|Study treatment at Day 0.
327210|NCT01704118|Device|I-gel|Supraglottic airway device
327211|NCT01704118|Device|ProSeal Laryngeal mask|Supraglottic airway device
327212|NCT01704105|Behavioral|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
327213|NCT01704105|Behavioral|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
327214|NCT01704105|Behavioral|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
327215|NCT01704105|Dietary Supplement|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
327216|NCT01704092|Drug|Dexmedetomidine|
327217|NCT01704079|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
327218|NCT01704079|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
327219|NCT01704066|Other|Training and education|
327220|NCT01704040|Drug|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
327221|NCT01704040|Drug|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
327222|NCT01704040|Drug|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
327223|NCT01704040|Drug|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
327224|NCT01704040|Other|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
327225|NCT01704027|Radiation|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :~Pelvis : 55,5 Gy (1,85 Gy/fr)~Seminal vesicles : 66 Gy (2,2 Gy/fr)~Prostate : 72 Gy (2,4 Gy/fr)"
327226|NCT01704027|Drug|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
327227|NCT01704001|Drug|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
327228|NCT01703988|Drug|Nusinersen|Single IT injection for each dose
327229|NCT01703975|Other|Training in pairs (Dyad training)|
327230|NCT01703949|Drug|Brentuximab Vedotin|Given IV
327231|NCT01703949|Other|Laboratory Biomarker Analysis|Correlative studies
327232|NCT01703949|Biological|Nivolumab|Given IV
327233|NCT01703936|Other|Agricultural and life skills training program|
327234|NCT01703923|Drug|FP01|
327235|NCT01703923|Drug|placebo|
327236|NCT01703910|Drug|Arm A chemotherapy|
327237|NCT01703910|Drug|arm B chemotherapy|
327238|NCT01703897|Device|Manometry and Impedance analysis|
327239|NCT01703884|Drug|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
327240|NCT01703858|Drug|BI 113608 PIB|powder for oral solution
327241|NCT01703858|Drug|BI 113608|conventional tablet formulation
327242|NCT01703858|Drug|BI 113608|conventional tablet formulation
327243|NCT01703858|Drug|BI 113608|conventional tablet formulation
327244|NCT01703858|Drug|pantoprazole 40 mg STADA|film-coated tablet
327245|NCT01703858|Drug|BI 113608|conventional tablet formulation
327246|NCT01703845|Drug|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
327247|NCT01703845|Drug|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
327248|NCT01703832|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
327249|NCT01703819|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
327250|NCT01703819|Other|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
327251|NCT01703793|Drug|Test Product 49778|
327252|NCT01703793|Drug|Test Product 10156|
327253|NCT01703793|Drug|Vehicle (placebo)|
327254|NCT01703767|Behavioral|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
327255|NCT01703754|Genetic|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
327256|NCT01703754|Drug|Palifosfamide|Small molecule chemotherapy, IV administration
327257|NCT01703741|Drug|Testosterone Gel (FE 999093)|
327258|NCT01703728|Other|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
327290|NCT01703468|Drug|Oxcarbazepine|
327291|NCT01703455|Drug|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
327259|NCT01703715|Device|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
327260|NCT01703702|Drug|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
327261|NCT01703689|Behavioral|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
327262|NCT01703689|Behavioral|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
327263|NCT01703663|Device|EPAP|
327264|NCT01703650|Drug|iopromide|"iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.~In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.~iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight[BW] <50kg) or 35 mL (50kg ≤BW <70kg) or 40 mL (70 kg≤BW <90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).~Injection rate is as follows; 6.0mL/sec if BW is <50kg, 7.0 mL/sec if BW is 50kg≤and <70kg, 8.0 mL/sec if BW is 70≤and<90kg and 9.0mL/sec if BW is 90kg≤."
327265|NCT01703650|Procedure|CT|"Perfusion CT will be performed by using a 320 channel MDCT~Patients are requested for fasting for at least 8 hours before CT scan.~Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.~Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.~During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.~ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
327266|NCT01703637|Drug|Sitagliptin|"before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy~before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
327267|NCT01703637|Drug|Vildagliptin|"before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy~before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
327268|NCT01703637|Drug|Saxagliptin|"before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy~before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
327269|NCT01703624|Drug|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
327270|NCT01703611|Other|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
327271|NCT01703611|Other|Usual Nutrition Care|Usual nutrition care in India
327272|NCT01703598|Device|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
327273|NCT01703598|Procedure|DBS surgery|Placement of DBS electrodes
327274|NCT01703572|Drug|OMP-52M51|
327275|NCT01703559|Drug|Phentolamine Mesylate Ophthalmic Solution 1.0%|Phentolamine mesylate (Nyxol) ophthalmic solution 1.0% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
327276|NCT01703559|Drug|Phentolamine Mesylate Ophthalmic Solution 0.5%|Phentolamine mesylate (Nyxol) ophthalmic solution 0.5% is a non-selective alpha-1 and alpha-2 adrenergic antagonist
327277|NCT01703559|Other|Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)|Placebo (vehicle) is a sterile, isotonic, buffered aqueous solution containing mannitol and sodium acetate
327278|NCT01703546|Procedure|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band & Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
327279|NCT01703533|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
327280|NCT01703533|Drug|Placebo|Strawberry flavored solution and Water for Injection
327281|NCT01703507|Drug|Ipilimumab|Given IV
327282|NCT01703507|Radiation|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
327283|NCT01703507|Radiation|Stereotactic Radiosurgery (SRS)|Undergo SRS
327284|NCT01703494|Biological|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
327285|NCT01703494|Biological|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
327286|NCT01703481|Drug|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
327287|NCT01703481|Drug|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
327288|NCT01703481|Drug|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
327292|NCT01703390|Drug|FOLFIRI + Cetuximab|
327293|NCT01703390|Drug|modifiedFOLFOX6 + Cetuximab|
327505|NCT01701986|Drug|Tacrolimus|Given IV then PO
327294|NCT01703364|Drug|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
327295|NCT01703351|Drug|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
327296|NCT01703351|Drug|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
327297|NCT01703325|Drug|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C~Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection~Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months~Group C: Controlled group"
327298|NCT01703312|Drug|QGE031|Drug administered by subcutaneous injection
327299|NCT01703312|Drug|omalizumab|Drug administered by subcutaneous injection
327300|NCT01703312|Drug|placebo|Drug administered by subcutaneous injection
327301|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
327302|NCT01703286|Drug|Linagliptin|given once daily for 28 days
327303|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
327304|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
327305|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
327306|NCT01703286|Drug|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
327307|NCT01703273|Behavioral|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
327308|NCT01703273|Behavioral|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
327309|NCT01703260|Drug|Roflumilast|Roflumilast dose
327310|NCT01703260|Drug|Pioglitazone|Pioglitazone dose
327311|NCT01703260|Drug|Placebo|Pioglitazone placebo-matching dose
327312|NCT01703260|Drug|Placebo|Roflumilast placebo-matching dose
327313|NCT01703247|Procedure|Pulmonary vein isolation|
327314|NCT01703247|Procedure|Ganglionated plexi ablation|
327315|NCT01703247|Procedure|Linear Lesion Ablation|
327316|NCT01703234|Drug|Ramipril|ramipril 10 mg/day during 3 months
327317|NCT01703221|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
327318|NCT01703221|Drug|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
327319|NCT01703221|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
327320|NCT01703221|Drug|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
327321|NCT01703208|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly
327322|NCT01703208|Drug|Placebo|Matching placebo to omarigliptin capsule or tablet administered orally once weekly
327323|NCT01703195|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
327324|NCT01703195|Procedure|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
327325|NCT01703169|Drug|Eltrombopag|Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
327326|NCT01703156|Procedure|Stress Test|
327327|NCT01703156|Procedure|No Stress Test|
327328|NCT01703143|Procedure|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
327329|NCT01703130|Procedure|Dose of of ropivacaine 0.75% used in block procedure|
327330|NCT01703117|Drug|Riluzole|24 subjects between the ages of 60-85 will receive study drug.
327331|NCT01703117|Drug|Placebo|24 subjects between the ages of 60-85 will receive placebo
327332|NCT01703104|Drug|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
327333|NCT01703104|Dietary Supplement|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
327334|NCT01703091|Drug|Ramucirumab|Administered IV
327335|NCT01703091|Drug|Placebo|Administered IV
327336|NCT01703091|Drug|Docetaxel|Administered IV
327337|NCT01703078|Drug|Ingenol once daily for two consecutive days|
327338|NCT01703065|Drug|Cabozantinib|Given orally once a day
327339|NCT01703052|Drug|CHF 6001 SD or placebo|Dry Powder Inhaler
327340|NCT01703052|Drug|CHF 6001 MD or placebo|Dry Powder Inhaler
327341|NCT01703039|Drug|Riluzole|
327342|NCT01703039|Drug|Sertraline|
327343|NCT01703039|Other|placebo|
327344|NCT01703000|Device|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
327345|NCT01702987|Dietary Supplement|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
327346|NCT01702987|Dietary Supplement|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
327347|NCT01702987|Drug|statin|statin was given for 1 month to 21 patients
327596|NCT01701323|Biological|Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion|Given IV
327349|NCT01702974|Drug|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
327350|NCT01702961|Drug|Melphalan|"Given on Day -1~Melphalan is administered according to the current SOP."
327351|NCT01702961|Drug|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
327352|NCT01702961|Drug|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
327353|NCT01702961|Drug|BCNU|BCNU 300 mg/m2 IV given on Day -6
327354|NCT01702961|Drug|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
327355|NCT01702961|Drug|Stem Cells|Stem cells given on Day 0
327356|NCT01702909|Drug|Interleukin-2|Interleukin-2
327357|NCT01702896|Drug|Interleukin-2|Interleukin-2
327358|NCT01702883|Other|Internet Survey|prompt to complete internet survey
327359|NCT01702870|Procedure|Magnetic Resonance Imaging|
327360|NCT01702857|Biological|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
327361|NCT01702857|Biological|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
327362|NCT01702857|Other|Phosphate buffered saline|
327363|NCT01702857|Biological|1 µg TDENV-PIV with Alum adjuvant|
327364|NCT01702857|Biological|1 µg TDENV-PIV with AS01E adjuvant|
327365|NCT01702844|Drug|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
327366|NCT01702831|Drug|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
327367|NCT01702831|Drug|Melphalan|"I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2"
327368|NCT01702831|Drug|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
327369|NCT01702805|Procedure|Liberal Cell Transfusion|
327370|NCT01702805|Procedure|Restricted red cell transfusion|
327371|NCT01702792|Biological|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
327372|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
327373|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
327374|NCT01702766|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
327375|NCT01702753|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
327376|NCT01702740|Drug|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
327377|NCT01702740|Drug|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
327378|NCT01702740|Drug|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
327379|NCT01702740|Drug|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
327380|NCT01702727|Device|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
327381|NCT01702727|Device|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
327382|NCT01702727|Device|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
327383|NCT01702714|Drug|RO5083945|multiple ascending doses
327384|NCT01702714|Drug|carboplatin|up to 6 cycles
327385|NCT01702714|Drug|cisplatin|up to 6 cycles
327386|NCT01702714|Drug|gemcitabine|up to 6 cycles
327387|NCT01702714|Drug|paclitaxel|up to 6 cycles
327388|NCT01702701|Drug|Montelukast|montelukast 10mg po pill q day for 12 weeks
327389|NCT01702701|Drug|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
327390|NCT01702688|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
327391|NCT01702688|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
327392|NCT01702675|Drug|ACH15 50 mg|ACH15 50mg capsule
327393|NCT01702675|Drug|ACH15 250 mg|ACH15 250mg capsule
327394|NCT01702675|Drug|ACH15 500mg|ACH15 500 mg capsule
327395|NCT01702675|Drug|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
327396|NCT01702675|Drug|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
327397|NCT01702675|Drug|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
327398|NCT01702675|Drug|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
327399|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
327400|NCT01702675|Drug|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
327401|NCT01702675|Drug|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
327402|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
327403|NCT01702662|Device|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
327597|NCT01701323|Drug|Cytarabine|Given IV
327598|NCT01701323|Drug|Filgrastim|Given SC or IV
327404|NCT01702649|Drug|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.~Single dose followed by multiple dose, three times a day."
327405|NCT01702649|Drug|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.~Single dose followed by multiple dose, three times a day."
327406|NCT01702636|Drug|Tranexamic Acid|
327407|NCT01702636|Drug|Placebo|
327408|NCT01702623|Drug|Oxcarbazepine|
327409|NCT01702610|Radiation|IMRT Technique|
327410|NCT01702610|Radiation|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
327411|NCT01702610|Radiation|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
327412|NCT01702610|Drug|Temozolomide and Accelerated Hypofractionation RT|
327413|NCT01702597|Device|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
327414|NCT01702597|Other|Physiotherapy|Patients will receive a standardized physical therapy.
327415|NCT01702584|Procedure|stent assisted embolization|stent assisted embolization and anti-thrombotic management
327416|NCT01702571|Drug|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
327417|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at de-escalating doses (starting from 750 mg/m^2) to determine the MTD.
327418|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
327419|NCT01702558|Drug|Trastuzumab emtansine (T-DM1)|Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
327420|NCT01702558|Drug|Capecitabine|Capecitabine will be administered at the MTD determined in Cohort 1.
327421|NCT01702532|Drug|Nicotine|Comparison of different dosage forms of nicotine
327422|NCT01702519|Drug|nicotine|nicotine transdermal patch
327423|NCT01702506|Drug|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
327424|NCT01702506|Drug|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
327425|NCT01702506|Drug|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
327426|NCT01702493|Drug|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
327427|NCT01702493|Drug|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
327428|NCT01702493|Drug|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
327429|NCT01702493|Drug|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
327430|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
327431|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
327432|NCT01702480|Drug|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
327433|NCT01702480|Drug|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
327434|NCT01702467|Drug|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
327435|NCT01702467|Drug|Placebo|Matching placebo capsules.
327436|NCT01702454|Biological|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
327437|NCT01702441|Drug|Subcutaneous AKB-9778|
327438|NCT01702428|Biological|Priorix|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
327439|NCT01702428|Biological|M-M-R II|Subjects receive 1 dose of MMR vaccine which is administered subcutaneously in the triceps region of the left arm.
327440|NCT01702428|Biological|Varivax|Subjects receive 1 dose of VV vaccine which is administered subcutaneously in the triceps region of the right arm.
327441|NCT01702428|Biological|Havrix|Subjects receive 1 dose of HAV vaccine which is administered intramuscularly in the anterolateral region of the right thigh.
327442|NCT01702428|Biological|Prevnar 13|US subjects receive 1 dose of PCV-13 vaccine which is administered intramuscularly in the anterolateral region of the left thigh.
327443|NCT01702415|Drug|Zoledronic acid|Single dose, intravenous solution 5mg
327444|NCT01702415|Drug|Placebo|
327445|NCT01702402|Behavioral|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.~Promote discussion and acceptance of post-partum family planning methods among key household members.~Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.~Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
327446|NCT01702402|Other|Comparison Group|A comparison area received standard government health services.
327447|NCT01702389|Drug|Remifentanil|
327448|NCT01702376|Drug|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
327449|NCT01702376|Drug|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
327450|NCT01702376|Drug|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
327451|NCT01702376|Drug|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
327452|NCT01702363|Drug|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
327453|NCT01702350|Drug|GSK2251052|Oral formulation of an an antibacterial
327454|NCT01702337|Other|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
327455|NCT01702324|Drug|DD-25|A topical DD-25 cream at 0.025% concentration.
327456|NCT01702311|Drug|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
327457|NCT01702298|Drug|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
327458|NCT01702298|Drug|Metformin|Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
327459|NCT01702285|Drug|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
327460|NCT01702272|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
327461|NCT01702259|Device|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
327462|NCT01702259|Device|Placebo device|Inactive Erchonia GLS.
327463|NCT01702246|Drug|Simvastatin|40 mg, orally, once daily for 3 months
327464|NCT01702233|Drug|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
327465|NCT01702233|Drug|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
327466|NCT01702233|Drug|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
327467|NCT01702220|Behavioral|CBT|6-12 sessions of CBT in person or over the phone
327468|NCT01702220|Other|ECC|6 biweekly sessions of ECC over the telephone
327469|NCT01702207|Drug|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
327470|NCT01702207|Drug|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
327471|NCT01702194|Drug|TD-1211 IV [C14]|
327472|NCT01702194|Drug|TD-1211 PO [C14]|
327473|NCT01702181|Drug|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
327474|NCT01702181|Drug|Tacrolimus|0.1% concentration of tacrolimus.
327475|NCT01702181|Drug|Placebo|
327476|NCT01702168|Other|Provider training: Cognitive Processing Therapy (CPT)|
327477|NCT01702155|Drug|DFP-10917|
327478|NCT01702129|Drug|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
327479|NCT01702116|Procedure|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
327480|NCT01702116|Procedure|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
327481|NCT01702103|Drug|Mometasone furoate|
327482|NCT01702090|Drug|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
327483|NCT01702077|Procedure|Neurofeedback|
327484|NCT01702077|Procedure|Sham feedback|
327485|NCT01702064|Drug|Nilotinib|"Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.~Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose."
327486|NCT01702064|Drug|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
327487|NCT01702038|Drug|Rituximab|1000 mg administered intravenously
327488|NCT01702025|Drug|Placebo|Yellow corn meal in gel capsules
327489|NCT01702025|Drug|Aminophylline|National Drug Code (NDC) 0143-1020-01
327490|NCT01702025|Drug|Methazolamide|NDC 0781-1072-01
327491|NCT01702025|Drug|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
327492|NCT01702012|Dietary Supplement|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
327493|NCT01702012|Behavioral|Group-Based Lifestyle Intervention|
327494|NCT01701999|Biological|rBV A/B|rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
327495|NCT01701986|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
327496|NCT01701986|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic BMT or PBSCT
327497|NCT01701986|Biological|Anti-Thymocyte Globulin|Given IV
327498|NCT01701986|Drug|Busulfan|Given IV
327499|NCT01701986|Drug|Clofarabine|Given IV
327500|NCT01701986|Drug|Gemcitabine Hydrochloride|Given IV
327501|NCT01701986|Drug|Mycophenolate Mofetil|Given IV then PO
327502|NCT01701986|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
327503|NCT01701986|Other|Pharmacological Study|Correlative studies
327504|NCT01701986|Biological|Rituximab|Given IV
327506|NCT01701973|Drug|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
327507|NCT01701973|Drug|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
327508|NCT01701973|Drug|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
327509|NCT01701973|Drug|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
327510|NCT01701973|Drug|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
327511|NCT01701947|Biological|Hemoleven|Replacement therapy
327512|NCT01701934|Drug|Roflumilast|500 mcg, oral, once daily for 6 months
327513|NCT01701934|Drug|Placebo|One placebo pill daily, for 6 months
327514|NCT01701921|Drug|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
327515|NCT01701921|Drug|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
327516|NCT01701921|Drug|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
327517|NCT01701882|Drug|tenofovir/emtricitabine/rilpivirine|
327518|NCT01701856|Drug|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
327519|NCT01701843|Drug|Cromoglicate|Twice daily topical treatment for 14 days
327520|NCT01701843|Drug|Placebo|Twice daily topical treatment for 14 days
327521|NCT01701817|Other|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
327522|NCT01701804|Drug|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
327523|NCT01701804|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
327524|NCT01701804|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10~20 acupoints once a week for 16 weeks.
327525|NCT01701804|Procedure|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
327526|NCT01701791|Other|Computerized Decision Support System|
327527|NCT01701778|Drug|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline"
327528|NCT01701778|Drug|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg"
327529|NCT01701778|Drug|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline"
327530|NCT01701778|Drug|sevoflurane|Induction and maintain anaesthesia
327531|NCT01701752|Biological|FP-01.1 + Placebo|
327532|NCT01701752|Biological|FP-01.1 + TIV|
327533|NCT01701752|Biological|FP-01.1-Adjuvant + Placebo|
327534|NCT01701752|Biological|FP-01.1-Adjuvant + TIV|
327535|NCT01701752|Biological|Adjuvant + TIV|
327536|NCT01701752|Biological|Placebo + TIV|
327537|NCT01701752|Biological|FP-01.1|
327538|NCT01701752|Biological|FP-01.1-Adjuvant|
327539|NCT01701752|Other|Placebo|
327540|NCT01701739|Drug|aleglitazar|Multiple doses of aleglitazar
327541|NCT01701739|Drug|digoxin|Single dose of digoxin
327542|NCT01701726|Other|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
327543|NCT01701726|Other|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
327544|NCT01701713|Device|DKI ED2011|
327545|NCT01701713|Device|Sham-TDCS|
327546|NCT01701700|Procedure|portable electronic magnifier|
327547|NCT01701700|Procedure|optical aids|
327548|NCT01701674|Drug|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
327549|NCT01701674|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging [MRI] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
327592|NCT01701362|Drug|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
327593|NCT01701349|Drug|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
327594|NCT01701349|Drug|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
327595|NCT01701336|Biological|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
327550|NCT01701674|Drug|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
327551|NCT01701674|Drug|Cyclophosphamide as Part of Lymphodepletion|
327552|NCT01701674|Drug|Fludarabine as Part of Lymphodepletion|
327553|NCT01701674|Drug|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
327554|NCT01701674|Biological|Adoptive Cell Therapy with TIL|
327555|NCT01701661|Procedure|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
327556|NCT01701661|Other|conservative treatment|Compression stockings class II
327557|NCT01701648|Other|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
327558|NCT01701635|Behavioral|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
327559|NCT01701635|Behavioral|usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
327560|NCT01701622|Drug|febuxostat|"If baseline allopurinol dose < 300 mg daily, will initiate febuxostat 40 mg daily.~If baseline allopurinol dose > 300 mg daily, will initiate febuxostat 80 mg daily.~Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
327561|NCT01701609|Behavioral|Cognitive Remediation Therapy|
327562|NCT01701596|Procedure|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
327563|NCT01701596|Procedure|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
327564|NCT01701583|Drug|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
327565|NCT01701570|Behavioral|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
327566|NCT01701570|Other|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
327567|NCT01701557|Other|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
327568|NCT01701557|Other|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
327569|NCT01701544|Device|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
327570|NCT01701531|Drug|RBCPF|
327571|NCT01701518|Drug|Ozurdex|biodegradable 0.7mg dexamethasone implant
327572|NCT01701505|Drug|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
327573|NCT01701505|Drug|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
327574|NCT01701505|Drug|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
327575|NCT01701492|Other|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
327576|NCT01701492|Other|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
327577|NCT01701479|Drug|ch14.18/CHO|
327578|NCT01701479|Drug|Aldesleukin|
327579|NCT01701479|Drug|Isotretinoin|
327580|NCT01701466|Other|Aveeno cream|Twice a day
327581|NCT01701466|Other|Flamazine cream|Twice a day, when there is dry desquamation
327582|NCT01701466|Other|NeoVIDERM cream|Three times a day
327583|NCT01701453|Drug|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
327584|NCT01701440|Device|Biofusionary Bebe|
327585|NCT01701414|Drug|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
327586|NCT01701414|Drug|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
327587|NCT01701401|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
327588|NCT01701401|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
327589|NCT01701388|Device|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
327590|NCT01701375|Drug|PD 0332991|• PD 0332991 will be given orally days 1,2,3
327591|NCT01701362|Drug|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
327599|NCT01701323|Drug|Fludarabine Phosphate|Given IV
327600|NCT01701310|Drug|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
327601|NCT01701310|Drug|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
327602|NCT01701297|Drug|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
327603|NCT01701297|Drug|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
327604|NCT01701297|Drug|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
327605|NCT01701284|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
327606|NCT01701271|Other|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
327607|NCT01701258|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride during the fMRI session only
327608|NCT01701258|Drug|Placebo|single-dose placebo capsule during the fMRI session only
327609|NCT01701245|Device|GammaCore|vagal stimulation
327610|NCT01701232|Biological|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
327611|NCT01701219|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
327612|NCT01701206|Behavioral|HIV knowledge Intervention|
327613|NCT01701193|Drug|Amino Acid|Dipeptide
327614|NCT01701193|Drug|Saline|Placebo Comparator
327615|NCT01701180|Drug|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
327616|NCT01701180|Drug|Placebo|
327617|NCT01701154|Other|respiratory muscle strength training|
327618|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
327619|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
327620|NCT01701128|Other|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
327621|NCT01701115|Procedure|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
327622|NCT01701115|Procedure|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:~Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
327623|NCT01701115|Drug|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
327624|NCT01701115|Drug|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
327625|NCT01701102|Procedure|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
327626|NCT01701102|Procedure|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
327627|NCT01701102|Procedure|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
327628|NCT01701102|Procedure|Mepivacaine|Mepivacaine 37.5 mg
327629|NCT01701089|Drug|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
327630|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for 14 days
327631|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for up to 17 days
327632|NCT01701076|Drug|Bendamustine|"Induction treatment phase (cycle 1-6):~Bendamustine 75 mg/m2 i.v day 1 and 2~Lenalidomide 25 mg p.o. day 1-21~Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22~Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia~Maintenance treatment phase (cycles 7-18):~Lenalidomide 25 mg p.o. day 1-21~Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
327633|NCT01701063|Drug|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
327634|NCT01701063|Drug|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
327635|NCT01701063|Drug|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
327636|NCT01701050|Other|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
327637|NCT01701037|Drug|dabrafenib|150 mg given PO
327638|NCT01701037|Drug|trametinib|2 mg given PO
327639|NCT01701037|Other|laboratory biomarker analysis|Correlative studies
327640|NCT01701024|Drug|ACYC|ACYC active, topically applied to the face for 12 weeks
327641|NCT01701024|Drug|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
327642|NCT01701011|Behavioral|Coping intervention|Positive reappraisal coping intervention
327643|NCT01700998|Drug|Magnesium|
327644|NCT01700998|Drug|Placebo|
327645|NCT01700985|Drug|122-0551|Applied twice daily for two weeks
327646|NCT01700985|Drug|Vehicle|Applied twice daily for two weeks
327647|NCT01700972|Procedure|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
327648|NCT01700959|Drug|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
327649|NCT01700959|Drug|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
327650|NCT01700946|Drug|dexamethasone|given intravenously or orally
327651|NCT01700946|Drug|vincristine sulfate|given intravenously
327652|NCT01700946|Biological|rituximab|given intravenously
327653|NCT01700946|Drug|clofarabine|given intravenously
327654|NCT01700946|Drug|cyclophosphamide|given intravenously
327655|NCT01700946|Drug|etoposide|given intravenously
327656|NCT01700946|Biological|aldesleukin|given subcutaneously
327657|NCT01700946|Drug|pegaspargase|given intravenously
327658|NCT01700946|Drug|methotrexate|given intrathecally or intravenously
327659|NCT01700946|Drug|mercaptopurine|given orally
327660|NCT01700946|Drug|cytarabine|given intrathecally or intravenously
327661|NCT01700946|Drug|mitoxantrone|given intravenously
327662|NCT01700946|Drug|teniposide|given intravenously
327663|NCT01700946|Drug|vinblastine|given intravenously
327664|NCT01700946|Biological|natural killer cell infusion|undergo allogeneic natural killer cell infusion
327665|NCT01700946|Other|laboratory biomarker analysis|correlative studies
327666|NCT01700946|Drug|therapeutic hydrocortisone|given intrathecally
327667|NCT01700946|Procedure|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
327668|NCT01700946|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
327669|NCT01700933|Other|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
327670|NCT01700933|Other|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:~5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
327671|NCT01700920|Procedure|bone marrow aspirate|
327672|NCT01700907|Drug|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
327673|NCT01700907|Drug|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
327674|NCT01700894|Behavioral|Walking Program + Motivational Interviewing Calls|
327675|NCT01700894|Behavioral|Walking Program + Automated Calls|
327676|NCT01700894|Behavioral|Walking Program|
327677|NCT01700881|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
327678|NCT01700881|Other|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
327679|NCT01700868|Other|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
327680|NCT01700868|Other|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
327681|NCT01700855|Procedure|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
327682|NCT01700855|Procedure|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
327683|NCT01700829|Drug|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
327684|NCT01700829|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
327685|NCT01700816|Device|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
327686|NCT01700816|Device|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
327687|NCT01700803|Drug|Povidone Iodine 10% vand cesarean section wound infections|
327688|NCT01700803|Drug|Povidone Iodine 7.5% vand cesarean section wound infections|
327689|NCT01700790|Drug|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
327690|NCT01700777|Other|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
327691|NCT01700751|Drug|brentuximab vedotin|
327692|NCT01700738|Procedure|gastric ring surgery|
327693|NCT01700738|Other|nutritional help|
327694|NCT01700725|Other|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
327695|NCT01700725|Drug|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
327696|NCT01700712|Dietary Supplement|Probiotic Lactobacilli reuteri|
327697|NCT01700712|Dietary Supplement|Placebo|
327698|NCT01700686|Other|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
327699|NCT01700673|Drug|Azacitidine|Azacitidine will be administered days 1-5 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
327700|NCT01700673|Biological|Sargramostim|Sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
327701|NCT01700647|Other|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
327702|NCT01700647|Other|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
327703|NCT01700621|Biological|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
327704|NCT01700621|Biological|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
327705|NCT01700608|Drug|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
327706|NCT01700595|Procedure|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
327707|NCT01700569|Drug|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
327708|NCT01700569|Drug|folinic acid at pharmacological dose is the escalated drug|
327709|NCT01700569|Radiation|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
327710|NCT01700556|Other|Case Manager|"The following support will be provided by a case manager:~At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.~Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.~Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
327711|NCT01700556|Other|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
327712|NCT01700556|Other|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
327713|NCT01700556|Other|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
327714|NCT01700543|Procedure|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
327715|NCT01700530|Drug|Statin|Statins (40mg/day)for 12 weeks
327716|NCT01700530|Other|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
327717|NCT01700530|Other|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
327718|NCT01700517|Other|Spinal anesthesia|spinal anesthesia
327719|NCT01700517|Other|Femoral nerve block|Femoral nerve block
327720|NCT01700517|Other|sciatic nerves block|sciatic nerves block
327721|NCT01700504|Drug|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
327722|NCT01700491|Drug|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
327723|NCT01700491|Drug|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
327724|NCT01700478|Drug|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
327725|NCT01700478|Drug|Vasopressin|Vasopressin was used in all patients during surgery.
327726|NCT01700439|Device|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
327846|NCT01699425|Device|Classical transobturator sling|Control group
327847|NCT01699412|Drug|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
327727|NCT01700426|Drug|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
327728|NCT01700426|Other|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
327729|NCT01700413|Drug|Idarubicin|
327730|NCT01700400|Drug|Everolimus|
327731|NCT01700400|Drug|Pemetrexed|
327732|NCT01700400|Drug|Carboplatin|
327733|NCT01700400|Drug|Bevacizumab|
327734|NCT01700387|Drug|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
327735|NCT01700387|Drug|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:~Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
327736|NCT01700387|Drug|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:~Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
327737|NCT01700348|Device|Airflosser|Use of Philips Airflosser
327738|NCT01700348|Device|Manual Floss|Active Comparator
327739|NCT01700335|Drug|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.~The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.~The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
327740|NCT01700322|Procedure|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
327741|NCT01700322|Drug|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
327742|NCT01700322|Drug|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
327743|NCT01700322|Drug|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
327744|NCT01700309|Behavioral|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
327745|NCT01700296|Behavioral|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:~10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)~Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
327746|NCT01700283|Behavioral|exercise education and walking program|12-week moderate intensity walking program
327747|NCT01700270|Drug|dovitinib (TKI258)|
327748|NCT01700270|Drug|fluvoxamine|perpetrator drug; 7 days of dosing
327749|NCT01700257|Radiation|CT scan & Early CDT Lung test|
327750|NCT01700257|Other|CT scan & Early CDT Lung test|
327751|NCT01700244|Device|Pacemaker implant|
327752|NCT01700231|Procedure|Liver resection|Liver resection of patient with neoplastic hepatic tumors
327753|NCT01700218|Other|telemonitoring|
327754|NCT01700218|Other|control|
327755|NCT01700205|Other|Type of Formula|infant formula
327756|NCT01700192|Biological|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
327757|NCT01700192|Biological|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
327758|NCT01700192|Drug|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
327759|NCT01700192|Drug|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
327760|NCT01700192|Drug|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
327761|NCT01700192|Drug|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
327762|NCT01700179|Drug|ACH-0143102|
327763|NCT01700179|Drug|Ribavirin|
327764|NCT01700166|Biological|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
327765|NCT01700153|Other|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
327766|NCT01700153|Other|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
327848|NCT01699412|Drug|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
327849|NCT01699399|Procedure|water immersion|
327767|NCT01700140|Drug|SyB D-0701|Study drug patches [Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
327768|NCT01700140|Drug|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
327769|NCT01700127|Other|Breastfeeding|breastfeeding encouraged versus withheld
327770|NCT01700114|Device|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
327771|NCT01700075|Drug|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
327772|NCT01700075|Dietary Supplement|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
327773|NCT01700062|Dietary Supplement|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
327774|NCT01700049|Drug|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
327775|NCT01700036|Drug|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
327776|NCT01700010|Drug|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.~Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
327777|NCT01699997|Drug|Oxytocin|Intranasal spray with 40 IU of OXT
327778|NCT01699997|Drug|Placebo|Intranasal spray with placebo solution
327779|NCT01699971|Procedure|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
327780|NCT01699971|Procedure|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
327781|NCT01699971|Procedure|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
327782|NCT01699958|Behavioral|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
327783|NCT01699945|Other|This is an observational study being conducted as a substudy of antoher trial.|
327784|NCT01699932|Drug|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet~Route of administration: oral"
327785|NCT01699919|Drug|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
327786|NCT01699906|Other|Diet regimen to induce weight loss|Diet regimen to induce weight loss
327787|NCT01699893|Other|unique arm|blood, nasal swab, skin biopsy, stool samples
327788|NCT01699867|Device|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
327789|NCT01699854|Drug|capsaicin patch (qutenza)|
327790|NCT01699854|Drug|Placebo|
327791|NCT01699828|Drug|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
327792|NCT01699828|Drug|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
327793|NCT01699815|Drug|Acetaminophen|
327794|NCT01699802|Other|Inhaled anaesthetic agent|
327795|NCT01699789|Other|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
327796|NCT01699789|Behavioral|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
327797|NCT01699789|Behavioral|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
327798|NCT01699776|Drug|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
327799|NCT01699776|Drug|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
327850|NCT01699399|Procedure|water exchange|
327851|NCT01699399|Procedure|air insufflation|
327800|NCT01699763|Device|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
327801|NCT01699763|Device|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
327802|NCT01699763|Device|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
327803|NCT01699750|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
327804|NCT01699750|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
327805|NCT01699750|Device|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
327806|NCT01699750|Device|BIOTRUE®|Contact lens care system, Phase 2
327807|NCT01699750|Device|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
327808|NCT01699750|Device|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
327809|NCT01699737|Drug|JTT-851|
327810|NCT01699737|Drug|Glimepiride|Encapsulated Glimepiride tablets
327811|NCT01699737|Drug|Placebo for Active|
327812|NCT01699737|Drug|Placebo for comparator|
327813|NCT01699724|Drug|JZoloft|50 mg tablet on Day 1 of each period
327814|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
327815|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
327816|NCT01699711|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
327817|NCT01699698|Other|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
327818|NCT01699685|Drug|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
327819|NCT01699685|Drug|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
327820|NCT01699685|Drug|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
327821|NCT01699672|Other|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
327822|NCT01699659|Other|allergen immunotherapy|allergy shots
327823|NCT01699646|Device|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
327824|NCT01699646|Procedure|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
327825|NCT01699620|Procedure|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
327826|NCT01699607|Drug|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
327827|NCT01699594|Drug|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
327828|NCT01699594|Drug|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
327829|NCT01699581|Dietary Supplement|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
327830|NCT01699568|Device|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
327831|NCT01699555|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
327832|NCT01699555|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
327833|NCT01699542|Device|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
327834|NCT01699542|Device|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
327835|NCT01699529|Device|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
327836|NCT01699503|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
327837|NCT01699490|Drug|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
327838|NCT01699490|Drug|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
327839|NCT01699477|Device|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
327840|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
327841|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
327842|NCT01699464|Drug|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
327843|NCT01699438|Drug|Mesalazine|2400 mg q.d. for 8 weeks
327844|NCT01699438|Drug|Placebo|3 tablets q.d. for 8 weeks
327845|NCT01699425|Device|Ajust sling|
327853|NCT01699386|Other|Experimental Study Formula|feed as lib
327854|NCT01699373|Procedure|Ultrasound scan|Pre-procedural ultrasound scan was performed
327855|NCT01699360|Drug|Cyclosporine A, Tacrolimus, Sirolimus|
327856|NCT01699347|Drug|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
327857|NCT01699334|Behavioral|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
327858|NCT01699334|Other|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
327859|NCT01699321|Behavioral|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
327860|NCT01699321|Other|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
327861|NCT01699308|Drug|Genotropin|
327862|NCT01699295|Behavioral|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
327863|NCT01699295|Behavioral|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
327864|NCT01699282|Behavioral|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
327865|NCT01699282|Behavioral|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
327866|NCT01699269|Other|peritumoral glial cell infiltration|
327867|NCT01699256|Behavioral|Guideline implementation as usual|Newsletters and Invitation to Meetings
327868|NCT01699256|Behavioral|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
327869|NCT01699230|Dietary Supplement|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
327870|NCT01699204|Dietary Supplement|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
327871|NCT01699204|Other|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
327872|NCT01699204|Other|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
327873|NCT01699191|Dietary Supplement|Probiotic|
327874|NCT01699191|Dietary Supplement|Placebo|
327875|NCT01699178|Drug|Oral testosterone undecanoate|Total daily dose of T = 200 mg T (as 316 mg TU) to 600 mg T (as 948 mg TU), taken as 100 mg to 300 mg T BID
327876|NCT01699178|Drug|Transdermal testosterone gel (AndroGel)|Total daily dose of T = 2.5 to 10 g of gel (25 mg to 100 mg T) QD
327877|NCT01699165|Device|Nasal filter|Active nasal filter
327878|NCT01699165|Device|Placebo nasal filter|Placebo nasal filter
327879|NCT01699152|Drug|TG02 citrate|TG02 citrate capsules
327880|NCT01699139|Device|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
327881|NCT01699139|Device|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
327882|NCT01699126|Device|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
327883|NCT01699126|Drug|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
327884|NCT01699113|Drug|YF476|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~YF476 100 mg; or~rabeprazole 20 mg; or~a combination of YF476 100 mg and rabeprazole 20 mg."
327885|NCT01699113|Drug|Rabeprazole|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:~YF476 100 mg; or~rabeprazole 20 mg; or~a combination of YF476 100 mg and rabeprazole 20 mg."
327886|NCT01699100|Other|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
327887|NCT01699087|Procedure|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
327888|NCT01699087|Device|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
327889|NCT01699074|Dietary Supplement|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
327890|NCT01699074|Dietary Supplement|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
327891|NCT01699074|Dietary Supplement|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
327892|NCT01699074|Dietary Supplement|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
327893|NCT01699074|Dietary Supplement|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
327894|NCT01699061|Drug|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
327895|NCT01699061|Drug|Placebo|Placebo tablet administered with a meal twice a day on Day 1
328020|NCT01697956|Drug|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
327896|NCT01699048|Procedure|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
327897|NCT01699048|Procedure|PCI|Multi-vessel PCI with DES
327898|NCT01699048|Procedure|CABG|Coronary artery bypass graft (CABG) treatment
327899|NCT01699022|Drug|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.~Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
327900|NCT01699009|Other|Plant based diet|
327901|NCT01699009|Other|an unrestricted diet|
327902|NCT01698996|Procedure|Packing vs No Packing|
327903|NCT01698970|Other|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
327904|NCT01698970|Other|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
327905|NCT01698957|Other|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
327906|NCT01698944|Drug|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
327907|NCT01698931|Drug|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
327908|NCT01698931|Drug|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
327909|NCT01698931|Drug|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
327910|NCT01698918|Drug|Everolimus|Everolimus will be self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously from study day 1 until progression of disease, unacceptable toxicity or withdrawal of consent. Everolimus should be taken at the same time every day. Everolimus tablets should be swallowed whole with a glass of water once daily, either consistently with food or consistently without food. Tablets should not be chewed or crushed.
327911|NCT01698918|Drug|Letrozole|1st line study treatment: Letrozole will be self administered as a daily dose of 2.5mg continuously from study day 1 until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day, consistently with or without food. Everolimus and letrozole tablets should be taken together.
327912|NCT01698918|Drug|Exemestane|2nd Line Study Treatment: If patients progress on everolimus + letrozole, patients will be offered everolimus + exemestane. Exemestane will be self administered as a daily dose of 25mg taken orally continuously until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day after a meal. Everolimus and exemestane tablets should be taken together.
327913|NCT01698918|Drug|Alcohol-free dexamethasone mouth rinse|At the onset of symptoms suggestive of stomatitis patients must contact the study site. Upon confirmation of stomatitis at the site, patients in countries where the alcohol-free 0.5mg/5ml dexamethasone oral solution is commercially available will be randomly assigned to take either dexamethasone 0.5 mg/5ml mouth rinse or the standard of care used to treat stomatitis at the patient's center. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day. Patients will be instructed to swish and expectorate the mouth rinse. Patients will also be instructed to fill out the Oral Stomatitis Daily Questionnaire (OSDQ) at home every day until the patient recovers. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day.Patients will be instructed to swish and expectorate the mouth rinse.
327914|NCT01698905|Drug|nilotinib|Nilotinib will be labeled as AMN107 and supplied as 150 mg and/or 200 mg hard gelatin capsule. Nilotinib will not be dosed by weight or body surface area. Nilotinib will be administered orally at 300 mg twice daily (BID) or 400 mg BID, at approximately 12 hour intervals, and must not be taken with food. The capsules should be swallowed whole with water. No food should be consumed for at least 2 hours before the dose is taken and no additional food should be consumed for at least one hour after the dose is taken. Patients who were previously treated with 400 mg BID, and required subsequent permanent dose reduction to 400 mg QD will be allowed to enter this study on the same dose, 400 mg once daily.
327915|NCT01698892|Drug|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
327916|NCT01698892|Drug|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
327917|NCT01698879|Drug|Mylotarg|"Cohort 1 (20 evaluable patients):~GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine (cytosine arabinoside): 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2 (20 evaluable patients):~G-CSF: 150 mcg/m^2, SC, days 0 to 7, to begin 12 to 18 hours before treatment with Gemtuzumab. GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1.~Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine (cytosine arabinoside): 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
327918|NCT01698866|Biological|Vaccin GenHevac B Pasteur|
327919|NCT01698840|Dietary Supplement|Vitamin D|
327920|NCT01698840|Dietary Supplement|Placebo|
327921|NCT01698827|Other|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
327922|NCT01698814|Drug|AL-4943A Ophthalmic Solution|
327923|NCT01698814|Drug|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
327924|NCT01698801|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
327925|NCT01698801|Drug|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
327926|NCT01698788|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
328021|NCT01697943|Procedure|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
327927|NCT01698775|Drug|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
327928|NCT01698775|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
327929|NCT01698775|Drug|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
327930|NCT01698775|Drug|Placebo to glipizide|Matching placebo to glipizide daily
327931|NCT01698775|Biological|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
327932|NCT01698762|Other|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
327933|NCT01698762|Other|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
327934|NCT01698762|Behavioral|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
327935|NCT01698749|Drug|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
327936|NCT01698736|Device|Membrane filtration|Membrane filtration (Polysulfone)
327937|NCT01698736|Device|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
327938|NCT01698723|Drug|Ribavirin|
327939|NCT01698723|Drug|Placebo|
327940|NCT01698710|Drug|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
327941|NCT01698697|Drug|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
327942|NCT01698684|Drug|Placebo|One dose 15 minutes before attempting intercourse
327943|NCT01698684|Drug|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
327944|NCT01698684|Drug|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
327945|NCT01698671|Device|InterGard Synergy Vascular Graft|
327946|NCT01698658|Other|ultrasound tomography|Undergo ultrasound tomography using SoftVue
327947|NCT01698658|Procedure|magnetic resonance imaging|Undergo MRI of the breast
327948|NCT01698645|Drug|PecFent® (fentanyl) nasal spray|
327949|NCT01698606|Behavioral|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
327950|NCT01698593|Drug|Bupivacaine 0.5%|
327951|NCT01698593|Drug|Bupivacaine 0.5% + Epinephrine (1:200,000)|
327952|NCT01698580|Other|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
327953|NCT01698580|Other|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
327954|NCT01698580|Other|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
327955|NCT01698580|Other|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
327956|NCT01698580|Other|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
328104|NCT01697319|Drug|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
327957|NCT01698567|Drug|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:~(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
327958|NCT01698567|Drug|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
327959|NCT01698554|Drug|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
327960|NCT01698554|Drug|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
327961|NCT01698554|Drug|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
327962|NCT01698554|Drug|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
327963|NCT01698541|Drug|Tacrolimus|Tested generic
327964|NCT01698541|Drug|Tacrolimus|Original formulation used as comparator
327965|NCT01698528|Device|Tablet Computer|
327966|NCT01698476|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
327967|NCT01698476|Drug|Placebo tablets|
327968|NCT01698463|Other|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.~Physician identifies that the patient is at risk of falls or fractures~Visit one: individualized exercise prescription by a physiotherapist.~Visit two: motivational interviewing (behavioural counselling) by kinesiologist~Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
327969|NCT01698450|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
327970|NCT01698437|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
327971|NCT01698398|Device|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
327972|NCT01698385|Other|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
327973|NCT01698372|Device|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
327974|NCT01698346|Biological|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
327975|NCT01698333|Drug|122-0551|Applied twice daily for 2 weeks
327976|NCT01698320|Drug|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
327977|NCT01698320|Drug|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
327978|NCT01698307|Other|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
327979|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
327980|NCT01698294|Other|Clinical Observation|Participants maintain usual diet and undergo clinical observation
327981|NCT01698294|Dietary Supplement|Flaxseed|Given PO
327982|NCT01698294|Other|Laboratory Biomarker Analysis|Correlative studies
327983|NCT01698294|Other|Questionnaire Administration|Ancillary studies
327984|NCT01698281|Drug|AEZS-108|"AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity."
327985|NCT01698281|Drug|SCCC|"commercially available SSCC (doses below the recommended package insert at the discretion of treating oncologist), on a 21-day cycle (although weekly administration is allowed; note: pegylated liposomal doxorubicin will be administered on a 28-day cycle).~Drugs considered acceptable as SSCC: paclitaxel; nab-paclitaxel; eribulin; pegylated liposomal doxorubicin (PLD); vinorelbine; gemcitabine; capecitabine.~Related to PLD: Per notification from EMA (dated 22-Nov-2011) no new patients should be started on treatment with Caelyx until further notice. Accordingly, this drug may be selected as SSCC treatment option only after such written notice is available."
327986|NCT01698281|Drug|Dexamethasone|Recommended prophylactic anti-emetic for AEZS-108: 8 mg dexamethasone.
327987|NCT01698268|Procedure|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
327988|NCT01698268|Procedure|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
327989|NCT01698255|Behavioral|ENGAGE|
327990|NCT01698255|Behavioral|Standard of Care Psychotherapy|
327991|NCT01698242|Behavioral|Enhanced Training|"PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.~Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up)."
327992|NCT01698242|Behavioral|Enhanced Education|"The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.~PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.~Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month."
327993|NCT01698229|Other|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
327994|NCT01698203|Drug|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
327995|NCT01698203|Drug|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
327996|NCT01698203|Drug|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
327997|NCT01698190|Procedure|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
327998|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
327999|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
328000|NCT01698164|Drug|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
328001|NCT01698164|Drug|Ximingting Tablet|Participants are given phytoestrogen.
328002|NCT01698164|Drug|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
328003|NCT01698138|Drug|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
328004|NCT01698138|Drug|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
328005|NCT01698125|Procedure|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
328006|NCT01698112|Dietary Supplement|Flaxseed High Dose|26 gram flaxseed intervention
328007|NCT01698112|Dietary Supplement|Flaxseed Low Dose|13 grams flaxseed
328008|NCT01698086|Other|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
328009|NCT01698073|Behavioral|mCOL|
328010|NCT01698073|Other|AS+|
328011|NCT01698060|Biological|ND1.1|
328012|NCT01698047|Behavioral|Resiliency Class|See Arm Description
328013|NCT01698047|Other|Case Management|See Case Management description
328014|NCT01698034|Behavioral|Volunteering|Weekly volunteering with elementary school children in after school programs
328015|NCT01698008|Other|Diabetes Doctor Mobile app|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
328016|NCT01697982|Behavioral|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
328017|NCT01697982|Behavioral|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
328018|NCT01697969|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
328019|NCT01697956|Drug|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
328022|NCT01697930|Drug|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of [18F] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the [18F] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
328023|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
328024|NCT01697904|Procedure|Titration of oxygen during newborn resuscitation in delivery room|
328025|NCT01697891|Device|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
328026|NCT01697878|Procedure|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
328027|NCT01697878|Procedure|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
328028|NCT01697865|Procedure|Transfer group|
328029|NCT01697865|Procedure|Control group|
328030|NCT01697852|Other|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
328031|NCT01697852|Other|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
328032|NCT01697826|Drug|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
328033|NCT01697826|Drug|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
328034|NCT01697800|Drug|Tadalafil|
328035|NCT01697800|Drug|Placebo|
328036|NCT01697787|Drug|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
328037|NCT01697787|Drug|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
328038|NCT01697761|Other|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
328039|NCT01697761|Other|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
328040|NCT01697748|Device|Silver-impregnated dressing|Silver-impregnated dressing placed over Cesarean wound after skin closure; the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
328041|NCT01697748|Device|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure; the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7.
328042|NCT01697735|Drug|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
328043|NCT01697735|Drug|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
328044|NCT01697722|Drug|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
328045|NCT01697722|Drug|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
328046|NCT01697709|Drug|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
328047|NCT01697709|Drug|Placebo|placebo capsules
328048|NCT01697696|Drug|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
328049|NCT01697696|Drug|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
328050|NCT01697696|Drug|Placebo|Placebo to match QAB149
328051|NCT01697683|Drug|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
328052|NCT01697683|Drug|Placebo|
328053|NCT01697670|Drug|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
328054|NCT01697657|Drug|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
328055|NCT01697657|Drug|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
328105|NCT01697306|Drug|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
328632|NCT01692782|Drug|SEP-225289|SEP-225289 4mg once daily
328056|NCT01697657|Drug|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
328057|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
328058|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
328059|NCT01697631|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
328060|NCT01697631|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
328061|NCT01697618|Drug|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
328062|NCT01697618|Drug|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
328063|NCT01697605|Drug|BGJ398|
328064|NCT01697592|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
328065|NCT01697592|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
328066|NCT01697579|Drug|Fosaprepitant|Administered intravenously (IV) as a single dose
328067|NCT01697579|Drug|Fosaprepitant Placebo|Administered IV as a single dose
328068|NCT01697579|Drug|Ondansetron|Administered IV according to local labeling and/or local standard of care
328069|NCT01697579|Drug|5-hydroxytryptamine 3 antagonist|Administered IV according to local labeling and/or local standard of care
328070|NCT01697566|Drug|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:~Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day~After week 4, participant continues to take 2 capsules of metformin 2 times each day.~Each capsule is 425 mg."
328071|NCT01697566|Other|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
328072|NCT01697566|Procedure|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
328073|NCT01697566|Behavioral|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
328074|NCT01697566|Behavioral|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
328075|NCT01697553|Other|home automation pack coupled to teleassistance service|
328076|NCT01697553|Other|Home without automation pack coupled to teleassistance service|
328077|NCT01697527|Biological|aldesleukin|Given SC
328078|NCT01697527|Drug|fludarabine phosphate|Given IV
328079|NCT01697527|Drug|cyclophosphamide|Given IV
328080|NCT01697527|Other|laboratory biomarker analysis|Correlative studies
328081|NCT01697527|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
328082|NCT01697527|Biological|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
328083|NCT01697527|Radiation|fludeoxyglucose F 18|Undergo PET scan using [18F] FDG tracer
328084|NCT01697527|Procedure|positron emission tomography|Undergo fludeoxyglucose F18 PET
328085|NCT01697514|Drug|LY2940680|Capsule administered orally.
328086|NCT01697514|Drug|LY2940680|Powder administered orally (may be sprinkled on soft food).
328087|NCT01697501|Other|Interleukin 28B testing|Blood sampling for IL28B genotyping
328088|NCT01697475|Behavioral|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
328089|NCT01697436|Drug|ribavirin [Copegus]|tablet under fed condition
328090|NCT01697436|Drug|ribavirin [Copegus]|tablet under fasted condition
328091|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fed condition
328092|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fasted condition
328093|NCT01697423|Drug|platelet-rich plasma|
328094|NCT01697423|Drug|durolane|
328095|NCT01697410|Drug|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
328096|NCT01697410|Drug|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
328097|NCT01697384|Drug|histrelin acetate|52 week implant
328098|NCT01697371|Radiation|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
328099|NCT01697371|Radiation|Proton Radiation|
328100|NCT01697358|Device|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
328101|NCT01697358|Drug|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
328102|NCT01697345|Drug|Testosterone|
328103|NCT01697332|Drug|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
328633|NCT01692782|Drug|SEP-225289|SEP-225289 8mg once daily
328106|NCT01697306|Drug|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
328107|NCT01697293|Drug|Cyclophosphamide|Given IV
328108|NCT01697293|Drug|Doxorubicin Hydrochloride|Given IV
328109|NCT01697293|Other|Laboratory Biomarker Analysis|Correlative studies
328110|NCT01697293|Drug|Paclitaxel|Given IV
328111|NCT01697293|Procedure|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
328112|NCT01697293|Drug|Triciribine Phosphate|Given IV
328113|NCT01697280|Behavioral|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:~Vaccines can save a child's life~Children who are immunized on time are less likely to become ill~Unimmunized children can become disabled for life~Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
328114|NCT01697280|Other|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
328115|NCT01697280|Other|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
328116|NCT01697267|Biological|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
328117|NCT01697267|Drug|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.~The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.~If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
328118|NCT01697241|Other|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
328119|NCT01697241|Other|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
328120|NCT01697228|Dietary Supplement|Vitamin D|
328121|NCT01697215|Other|AirWave|
328122|NCT01697189|Behavioral|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
328123|NCT01697150|Device|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
328124|NCT01697137|Behavioral|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
328125|NCT01697124|Behavioral|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
328126|NCT01697111|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
328127|NCT01697111|Drug|Placebo|One tablet (no active ingredient) / day and one tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day, for the first 24 weeks and the later 28 weeks, respectively
328128|NCT01697111|Drug|Dienogest|Dienogest 1mg twice a day (bid)
328129|NCT01697098|Drug|Dexamethasone 24 hours|
328130|NCT01697098|Drug|Dexamethasone 12|
328131|NCT01697085|Dietary Supplement|Sea buckthorn oil|
328132|NCT01697085|Dietary Supplement|Placebo oil|
328133|NCT01697072|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
328134|NCT01697072|Other|Placebo|Placebo
328135|NCT01697072|Drug|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
328136|NCT01697072|Drug|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
328137|NCT01697072|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine.
328138|NCT01697059|Drug|Piperacillin + Amoxicillin|
328238|NCT01696318|Behavioral|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
328239|NCT01696305|Device|Hyalobarrier|
328240|NCT01696305|Device|Guardix-SG|
328241|NCT01696279|Drug|Lanthanum Carbonate|Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.
328242|NCT01696279|Drug|Calcium Carbonate|Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
328139|NCT01697046|Drug|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.~Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
328140|NCT01697020|Drug|Mercaptopurine 20mg/ml oral suspension|50mg
328141|NCT01697020|Drug|Mercaptopurine 50mg tablet|50mg
328142|NCT01697007|Biological|HIVIS DNA vaccine|
328143|NCT01697007|Device|Zetajet|
328144|NCT01697007|Device|Derma Vax Electroporation|
328145|NCT01697007|Biological|Modified Vaccinia Ankara (MVA-CDMR)|
328146|NCT01696994|Other|Laboratory Biomarker Analysis|Correlative studies
328147|NCT01696994|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
328148|NCT01696994|Procedure|Ultrasonography|Undergo TVU
328149|NCT01696981|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
328150|NCT01696981|Procedure|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
328151|NCT01696968|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
328152|NCT01696968|Procedure|X-Ray Imaging|Undergo a chest x-ray
328153|NCT01696955|Biological|Cetuximab|Given IV
328154|NCT01696955|Other|Laboratory Biomarker Analysis|Correlative studies
328155|NCT01696955|Drug|Tivantinib|Given PO
328156|NCT01696942|Drug|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
328157|NCT01696942|Drug|Mesalamine|mesalamine 800 mg orally three times daily
328158|NCT01696929|Drug|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:~Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.~Type of Dosage Form:~Concentrate for solution for infusion.~Route of Administration:~Intravenous (i.v.) infusion."
328159|NCT01696916|Procedure|6-minute walking test|submaximum exercise test
328160|NCT01696903|Procedure|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
328161|NCT01696890|Device|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
328162|NCT01696890|Device|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
328163|NCT01696877|Drug|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
328164|NCT01696877|Drug|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
328165|NCT01696877|Drug|GVAX|GVAX is granulocytemacrophage -colony stimulating factor -secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
328166|NCT01696864|Device|Hand tutor rehabilitation device|A rehabilitation device for the hand
328167|NCT01696864|Device|Arm tutor rehabilitation device|A rehabilitation device for the arm
328168|NCT01696851|Other|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
328169|NCT01696838|Other|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
328170|NCT01696838|Other|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
328171|NCT01696825|Drug|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
328172|NCT01696825|Drug|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
328173|NCT01696825|Drug|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
328174|NCT01696812|Procedure|electrode position|
328175|NCT01696799|Drug|Econazole Nitrate|
328176|NCT01696799|Drug|placebo|
328177|NCT01696786|Procedure|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
328178|NCT01696773|Other|Tangerine tomato juice|Post-prandial feeding study
328179|NCT01696773|Other|Red tomato juice|Post-prandial feeding study
328180|NCT01696760|Drug|acetylsalicylic acid|325 mg twice a day
328181|NCT01696760|Drug|enoxaparin|40 mg once daily
328182|NCT01696760|Device|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
328183|NCT01696734|Drug|Domperidone|Given PO
328184|NCT01696734|Other|Questionnaire Administration|Ancillary studies
328185|NCT01696721|Other|No intervention|
328186|NCT01696708|Other|31-Phosphorus RMN Spectroscopy|
328187|NCT01696695|Drug|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
328188|NCT01696695|Drug|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
328189|NCT01696682|Procedure|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
328190|NCT01696682|Procedure|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
328191|NCT01696669|Drug|Chemotherapy|"Vincristine, 2 mg/m^2 IV bolus, day 1.~Doxorubicin: 75 mg/m^2 per cycle, or 25 mg/m^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~Cyclophosphamide: 2100 mg/m^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm^3/L.~Ifosfamide: 1800 mg/m^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~Gemcitabine: 1000 mg/m^2 IV, 90 minutes on day 1 and 8.~Docetaxel 100 mg/m^2, 2-3 hour infusion on day 8."
328192|NCT01696669|Procedure|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
328193|NCT01696669|Radiation|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
328194|NCT01696656|Drug|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
328195|NCT01696643|Drug|CB-5945|
328196|NCT01696643|Drug|Placebo|
328197|NCT01696630|Drug|Xenon|
328198|NCT01696630|Drug|Desflurane|
328199|NCT01696617|Drug|Aripiprazole 6-week group|
328200|NCT01696617|Drug|Aripiprazole 8-week group|
328201|NCT01696604|Drug|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
328202|NCT01696604|Drug|Placebo|Matching placebo capsules will be available.
328203|NCT01696591|Biological|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
328204|NCT01696578|Behavioral|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
328205|NCT01696565|Drug|PG2|Injectable
328206|NCT01696552|Procedure|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
328207|NCT01696552|Procedure|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
328208|NCT01696539|Behavioral|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
328209|NCT01696539|Other|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
328210|NCT01696526|Other|vitamin D fortified fish|fish containing vitamin D3
328211|NCT01696526|Other|conventional fish|fish containing low concentrations of vitamin D3
328212|NCT01696513|Procedure|Suction|
328213|NCT01696513|Procedure|Subcision|
328214|NCT01696500|Drug|Intravenous immunoglobulin|
328215|NCT01696487|Dietary Supplement|High oral Fructose challenge (150g per day for 28 days)|
328216|NCT01696474|Drug|Bortezomib|
328217|NCT01696461|Drug|Plerixafor|
328218|NCT01696448|Dietary Supplement|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
328219|NCT01696448|Other|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
328220|NCT01696435|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
328221|NCT01696435|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
328222|NCT01696435|Dietary Supplement|Fish oil placebo|Fish oil placebo
328223|NCT01696435|Dietary Supplement|Vitamin D placebo|Vitamin D placebo
328224|NCT01696422|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
328225|NCT01696422|Biological|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
328226|NCT01696422|Other|Placebo|Route:subcutaneous
328227|NCT01696409|Dietary Supplement|400 IU vitamin D3|Take 400 IU once/day for 2 months
328228|NCT01696409|Dietary Supplement|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
328229|NCT01696396|Drug|Abrilumab|Administered by subcutaneous injection.
328230|NCT01696396|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
328231|NCT01696383|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
328232|NCT01696370|Drug|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
328233|NCT01696370|Other|Placebo capsule|one capsule three times per day for 3 months
328234|NCT01696357|Device|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
328235|NCT01696344|Procedure|PVAI|
328236|NCT01696344|Procedure|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
328237|NCT01696331|Behavioral|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
328243|NCT01696266|Other|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
328244|NCT01696240|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
328245|NCT01696240|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
328246|NCT01696227|Drug|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
328247|NCT01696214|Drug|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
328248|NCT01696214|Drug|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
328249|NCT01696214|Drug|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
328250|NCT01696214|Drug|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
328251|NCT01696201|Behavioral|Exercise group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.~Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
328252|NCT01696188|Device|interscalene nerve catheter|
328253|NCT01696162|Other|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
328254|NCT01696162|Other|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
328255|NCT01696162|Other|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
328256|NCT01696149|Device|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
328257|NCT01696136|Device|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
328258|NCT01696123|Drug|MLC601|It was described
328259|NCT01696110|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
328260|NCT01696110|Drug|heparin|heparin monotherapy
328261|NCT01696110|Drug|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
328262|NCT01696097|Behavioral|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
328263|NCT01696084|Drug|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
328264|NCT01696084|Drug|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
328265|NCT01696071|Drug|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
328266|NCT01696071|Drug|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
328267|NCT01696058|Drug|Tiotropium|marketed product
328268|NCT01696058|Drug|Placebo matching Olodaterol|one dose
328269|NCT01696058|Drug|Tiotropium|marketed product
328270|NCT01696058|Drug|Olodaterol|one dose
328271|NCT01696045|Biological|Ipilimumab|
328272|NCT01696032|Drug|SGI-110|
328273|NCT01696032|Drug|Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)|Investigator may choose to treat with either topotecan, pegylated liposomal doxorubicin, or paclitaxel
328274|NCT01696032|Drug|Carboplatin|
328275|NCT01696019|Other|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
328276|NCT01696019|Other|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
328277|NCT01696019|Other|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
328278|NCT01696019|Other|Contact and testing only|
328279|NCT01695993|Device|Acupressure bands|Bilateral acupressure wrist bands
328634|NCT01692782|Drug|Placebo|Placebo once daily
328280|NCT01695993|Other|Expectancy-neutral handout|The expectancy neutral handout has neutral information regarding the acupressure bands
328281|NCT01695993|Behavioral|Expectancy-neutral MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
328282|NCT01695993|Other|Expectancy-enhancing handout|The expectancy enhancing handout has expectancy-enhancing information regarding the acupressure bands
328283|NCT01695993|Behavioral|Expectancy-enhancing MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. It also has expectancy-enhancing information regarding the acupressure bands.
328284|NCT01695980|Procedure|ETT with non modified retractor|adenotonsillectomy
328285|NCT01695980|Other|LMA with modified retractor|LMA with modified retractor
328286|NCT01695967|Procedure|turbinate cauterization|
328287|NCT01695954|Drug|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
328288|NCT01695954|Drug|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
328289|NCT01695954|Drug|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
328290|NCT01695954|Drug|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
328291|NCT01695941|Drug|Alisertib|Given PO
328292|NCT01695941|Drug|Bortezomib|Given SC
328293|NCT01695941|Other|Laboratory Biomarker Analysis|Correlative studies
328294|NCT01695941|Biological|Rituximab|Given IV
328295|NCT01695928|Device|Extracorporeal shockwave therapy|1000 impulses
328296|NCT01695928|Device|ESWT placebo|0 impulses, acoustic effect
328297|NCT01695915|Procedure|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
328298|NCT01695902|Drug|Levosert-20|
328299|NCT01695902|Drug|Mirena|
328300|NCT01695876|Drug|AMG 357|Oral administration available in varying dose strength.
328301|NCT01695876|Drug|Placebo|Matching placebo to AMG 357 containing no active drug
328302|NCT01695863|Drug|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
328303|NCT01695850|Drug|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
328304|NCT01695850|Drug|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
328305|NCT01695850|Drug|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
328306|NCT01695837|Behavioral|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
328307|NCT01695824|Device|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
328308|NCT01695824|Procedure|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
328309|NCT01695824|Drug|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group~All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
328310|NCT01695798|Biological|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.~There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
328311|NCT01695772|Drug|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
328312|NCT01695772|Drug|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
328313|NCT01695759|Drug|Epoetin alpha|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
328314|NCT01695759|Drug|Eprex|Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
328315|NCT01695746|Drug|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
328316|NCT01695733|Biological|trivalent influenza vaccine|
328392|NCT01694992|Other|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
328317|NCT01695720|Procedure|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam [the system itself] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
328318|NCT01695707|Drug|Pioglitazone|see Arm Description
328319|NCT01695707|Drug|Placebo (for pioglitazone)|see Arm Description
328320|NCT01695694|Behavioral|supporting positive and healthy relationships|
328321|NCT01695694|Behavioral|community support group|
328322|NCT01695681|Other|Gluten-free diet|Dietary advice by clinical dietitian
328323|NCT01695668|Drug|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
328324|NCT01695668|Drug|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
328325|NCT01695616|Drug|Placebo|
328326|NCT01695616|Drug|Active drug|
328327|NCT01695603|Device|Intellivent|
328328|NCT01695590|Drug|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
328329|NCT01695577|Other|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
328330|NCT01695577|Other|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
328331|NCT01695564|Device|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
328332|NCT01695564|Device|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
328333|NCT01695551|Other|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
328334|NCT01695538|Other|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
328335|NCT01695525|Other|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
328336|NCT01695473|Drug|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
328337|NCT01695460|Drug|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
328338|NCT01695460|Drug|Placebo|
328339|NCT01695447|Procedure|duct-to-mucosa|
328340|NCT01695447|Procedure|invagination|
328341|NCT01695447|Device|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
328342|NCT01695434|Other|MRI|All subjects will undergo a MRI.
328343|NCT01695421|Procedure|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
328344|NCT01695421|Procedure|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
328345|NCT01695421|Procedure|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
328393|NCT01694979|Other|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
328394|NCT01694979|Other|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
328395|NCT01694979|Other|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
328396|NCT01694966|Drug|Methylene Blue MMX®|
328397|NCT01694966|Drug|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
328836|NCT01691313|Drug|Placebo|single oral dose
328346|NCT01695421|Procedure|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
328347|NCT01695382|Behavioral|Navigation|As per Arm description
328348|NCT01695369|Device|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
328349|NCT01695369|Device|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
328350|NCT01695356|Drug|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
328351|NCT01695356|Drug|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
328352|NCT01695343|Biological|KB001-A|
328353|NCT01695343|Drug|Placebo Comparator|
328354|NCT01695330|Drug|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
328355|NCT01695317|Drug|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
328356|NCT01695304|Other|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
328357|NCT01695291|Drug|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
328358|NCT01695291|Other|Placebo|A placebo pill will be administered twice a day (BID) for 12 weeks.
328359|NCT01695278|Behavioral|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
328360|NCT01695265|Other|Exercie oronasal breathing (ONB)|10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using oronasal breathing (ONB)
328361|NCT01695265|Device|Exercie nasal breathing through the FB|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. 10 min at 50% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET using FeelBreathe device (FB)
328362|NCT01695252|Other|MEMOS|Patient informed clinical outcomes supervision
328363|NCT01695239|Drug|Ixekizumab|Administered SC
328364|NCT01695239|Drug|Placebo|Administered SC
328365|NCT01695239|Drug|Adalimumab|Administered SC
328366|NCT01695226|Drug|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
328367|NCT01695226|Drug|Placebo|pre-operative placebo twice daily for two to three weeks
328368|NCT01695213|Procedure|uncemented total hip arthroplasty|
328369|NCT01695200|Dietary Supplement|Omega-3 fatty acids|
328370|NCT01695187|Drug|NB-001 (0.3%)|Topical administration at least five times throughout the day
328371|NCT01695187|Drug|Placebo|
328372|NCT01695174|Drug|Xifaxan|
328373|NCT01695148|Dietary Supplement|β-Carotene Biofortified Maize Flour|
328374|NCT01695148|Dietary Supplement|White Maize Flour|
328375|NCT01695135|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
328376|NCT01695135|Drug|Placebo|Placebo (4 tablets) taken orally once daily
328377|NCT01695135|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
328378|NCT01695122|Drug|Valproic Acid|
328379|NCT01695109|Drug|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
328380|NCT01695109|Drug|Placebo|0.9% NaCl, 0.2 ml
328381|NCT01695096|Other|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
328382|NCT01695096|Other|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
328383|NCT01695070|Drug|Melatonin|4mg prolonged release melatonin oral tablets twice daily
328384|NCT01695057|Drug|vorinostat|Given PO
328385|NCT01695057|Procedure|therapeutic conventional surgery|Undergo surgery
328386|NCT01695057|Other|laboratory biomarker analysis|Correlative studies
328387|NCT01695044|Drug|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
328388|NCT01695031|Behavioral|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
328389|NCT01695031|Behavioral|Generic web-based education|Generic, web-based asthma education
328390|NCT01695005|Drug|LY3039478|Administered orally
328391|NCT01695005|Drug|Prednisone|Administered orally
328398|NCT01694927|Procedure|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
328400|NCT01694888|Other|lecture|Teaching documentation skill using lecture method
328401|NCT01694875|Device|APTIMA HPV Assay|In Vitro Diagnostics Assay
328402|NCT01694862|Procedure|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
328403|NCT01694849|Drug|GFT505 80mg|
328404|NCT01694849|Drug|GFT505 120mg|
328405|NCT01694849|Drug|Placebo|
328406|NCT01694836|Biological|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
328407|NCT01694823|Drug|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:~Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
328408|NCT01694810|Drug|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
328409|NCT01694810|Drug|4% NVN1000 Topical Gel|4% NVN 1000 4% Topical Gel applied once daily 4 weeks
328410|NCT01694810|Drug|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
328411|NCT01694810|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
328412|NCT01694797|Drug|Metoprolol Succinate|
328413|NCT01694784|Behavioral|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
328414|NCT01694784|Behavioral|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
328415|NCT01694784|Behavioral|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
328416|NCT01694784|Behavioral|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
328417|NCT01694771|Drug|Tiotropium|Marketed dose
328418|NCT01694771|Drug|Placebo matching Olodaterol|One dose
328419|NCT01694771|Drug|Olodaterol|One dose
328420|NCT01694771|Drug|Tiotropium|Marketed dose
328421|NCT01694732|Drug|Varenicline|
328422|NCT01694732|Drug|placebo|
328423|NCT01694719|Behavioral|Brief Behavioral Activation Treatment for Depression|
328424|NCT01694719|Behavioral|Cognitive Control Training|
328425|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
328426|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
328427|NCT01694706|Drug|omeprazole|medium dose of omeprazole
328428|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
328429|NCT01694693|Drug|Orencia|No Intervention
328430|NCT01694680|Dietary Supplement|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
328431|NCT01694680|Dietary Supplement|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
328432|NCT01694667|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
328433|NCT01694667|Other|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
328434|NCT01694641|Other|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
328435|NCT01694628|Behavioral|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
328436|NCT01694615|Procedure|Cryoprobe biopsy|
328437|NCT01694615|Procedure|Forceps Biopsy|
328438|NCT01694602|Biological|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
328439|NCT01694589|Drug|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
328837|NCT01691300|Other|ACT PET/CT|Old tracer but new indication
328440|NCT01694576|Drug|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
328441|NCT01694563|Device|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:~Coronary Artery Bypass Grafting (CABG)~Mitral valve repair or replacement~Aortic valve repair or replacement~Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
328442|NCT01694537|Drug|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
328443|NCT01694537|Drug|placebo|Placebo is made with same size and shape with study drug.
328444|NCT01694511|Procedure|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
328445|NCT01694511|Procedure|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
328446|NCT01694498|Drug|A: Desmopressin 25 µg|
328447|NCT01694498|Drug|B. Desmopressin 50 µg|
328448|NCT01694498|Drug|Placebo|
328449|NCT01694485|Biological|Abrilumab|Administered by subcutaneous injection.
328450|NCT01694485|Drug|Placebo|Placebo matching to abrilumab administered by subcutaneous injection
328451|NCT01694472|Biological|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
328452|NCT01694459|Drug|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
328453|NCT01694459|Drug|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
328454|NCT01694446|Other|Intraduodenal glucose or fructose|
328455|NCT01694433|Drug|Calcipotriene|1g daily BID
328456|NCT01694433|Drug|Placebo|1g daily BID
328457|NCT01694420|Drug|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
328458|NCT01694407|Drug|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
328459|NCT01694407|Drug|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
328460|NCT01694407|Drug|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
328461|NCT01694407|Drug|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
328462|NCT01694394|Device|Implantable Cardiac Monitor (Confirm ICM model 2102)|Patients who meet the study criteria will be implanted with a St. Jude Medical Confirm Implantable Cardiac Monitor (Confirm ICM) model 2102 or other St. Jude Medical ICM with the same capabilities.
328463|NCT01694355|Drug|Vitamin D|
328464|NCT01694316|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
328465|NCT01694303|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
328466|NCT01694290|Other|Chemical Cold Pack|
328467|NCT01694277|Drug|Masitinib|12 mg/kg/day
328468|NCT01694277|Drug|Sunitinib|50 mg/day
328469|NCT01694264|Drug|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
328470|NCT01694264|Drug|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
328471|NCT01694238|Procedure|Cruciate incision|
328472|NCT01694238|Procedure|Circular incision|
328473|NCT01694238|Other|Mesh enforced cruciate incision|
328474|NCT01694225|Other|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
328475|NCT01694212|Drug|Perioperative Diclofenac eye-drops administration|
328476|NCT01694212|Drug|placebo|
328477|NCT01694199|Device|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
328478|NCT01694199|Device|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
328479|NCT01694186|Drug|FAI insert|
328480|NCT01694186|Drug|Sham injection|
328481|NCT01694173|Other|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
328482|NCT01694173|Other|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
328483|NCT01694173|Other|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
328484|NCT01694173|Other|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
328485|NCT01694160|Drug|Paricalcitol|Zemplar (paricalcitol) 2ug daily, oral intake
328486|NCT01694147|Device|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
328838|NCT01691287|Behavioral|Michael Method|
328487|NCT01694134|Drug|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
328488|NCT01694134|Drug|Lidocaine|
328489|NCT01694121|Behavioral|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
328490|NCT01694121|Behavioral|Comparison|general health intervention for men, not inclusive of HIV or relationship health
328491|NCT01694108|Biological|BCG-vaccine (SSI)|
328492|NCT01694082|Behavioral|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
328493|NCT01694082|Behavioral|Brief brochure and assessment control|
328494|NCT01694069|Drug|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
328495|NCT01694056|Other|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
328496|NCT01694056|Other|Control diet|4 weeks high mixed protein diet (20 en%)
328497|NCT01694043|Other|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
328498|NCT01694043|Other|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
328499|NCT01694030|Other|Attachment security priming|
328500|NCT01694017|Drug|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
328501|NCT01694017|Drug|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
328502|NCT01694004|Drug|Benzocaine Infusion into Duodenum|
328503|NCT01693991|Behavioral|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
328504|NCT01693991|Behavioral|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
328505|NCT01693978|Behavioral|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, & Rothbaum, 2007)."
328506|NCT01693978|Behavioral|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
328507|NCT01693965|Other|sputum samples|
328508|NCT01693952|Biological|blood draw|
328509|NCT01693939|Device|FS200 Femtosecond Laser|
328510|NCT01693926|Behavioral|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
328511|NCT01693926|Behavioral|placebo|
328512|NCT01693913|Behavioral|cognitive behavioral exercise and nutrition over|
328513|NCT01693913|Behavioral|nutrition and exercise education|
328514|NCT01693900|Procedure|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
328515|NCT01693900|Procedure|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
328516|NCT01693874|Behavioral|MBSR|Mindfulness-Based Stress Reduction
328517|NCT01693874|Behavioral|control (health education)|health education
328552|NCT01693497|Behavioral|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
328630|NCT01692808|Drug|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
328518|NCT01693822|Drug|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.~Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
328519|NCT01693809|Drug|Caffeine|
328520|NCT01693796|Other|blood and urine samples ; Echography|
328521|NCT01693783|Biological|Ipilimumab|Given IV
328522|NCT01693783|Other|Laboratory Biomarker Analysis|Correlative studies
328523|NCT01693770|Procedure|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
328524|NCT01693718|Drug|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
328525|NCT01693718|Drug|5- Fluorouracil|"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.~Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."
328526|NCT01693718|Drug|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output > 100 cc/ hour.
328527|NCT01693705|Procedure|Tracheostomy|
328528|NCT01693692|Drug|TD-9855 Group 1|
328529|NCT01693692|Drug|TD-9855 Group 2|
328530|NCT01693692|Drug|Placebo|
328531|NCT01693679|Drug|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
328532|NCT01693666|Behavioral|Lifestyle intervention|"To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.~To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.~To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
328533|NCT01693653|Drug|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
328534|NCT01693640|Drug|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
328535|NCT01693627|Device|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
328536|NCT01693627|Device|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
328537|NCT01693627|Device|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
328538|NCT01693627|Device|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
328539|NCT01693614|Drug|Buparlisib|100 mg hard gelatin capsules administered orally, once daily in cycles of 28 days
328540|NCT01693601|Drug|Panobinostat|PO TIW QOW or PO TIW QW
328541|NCT01693601|Drug|Ruxolitinib|PO BID x 28 days
328542|NCT01693588|Other|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
328543|NCT01693575|Device|Pupil expansion with APX 100 device|Patients with small pupils (<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
328544|NCT01693562|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21, or 28 days.
328545|NCT01693549|Drug|Cabazitaxel|
328546|NCT01693536|Behavioral|Lifestyle counselling|as in Arm Description
328547|NCT01693523|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day).
328548|NCT01693523|Other|Placebo|Matching placebo capsules by mouth twice a day.
328549|NCT01693523|Behavioral|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
328550|NCT01693510|Behavioral|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
328551|NCT01693497|Behavioral|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
328627|NCT01692821|Drug|100% oxygen breathing|100% oxygen breathing - 30 minutes
328628|NCT01692821|Drug|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
328553|NCT01693484|Drug|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
328554|NCT01693458|Behavioral|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
328555|NCT01693445|Drug|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;~Oxaliplatin 85 mg/m²IV on day 1~Irinotecan 120 mg/m² IV on day 1~S-1 60 mg/m2/day PO on day 1-7~Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
328556|NCT01693432|Drug|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.~Docetaxel 60 mg/m²IV on day 1~S-1 80 mg/m2/day PO on day 1-14"
328557|NCT01693419|Drug|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.~Gemcitabine 1000 mg/m² IV on day 1, 8~Erlotinib 100 mg/day PO on day 1~S-1 60 mg/m²/day PO on day 1-14"
328558|NCT01693393|Drug|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
328559|NCT01693380|Biological|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:~From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.~9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
328560|NCT01693380|Biological|Control vaccine|"Schoolchildren from 6 to 8 years of age:~- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
328561|NCT01693367|Device|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
328562|NCT01693367|Device|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
328563|NCT01693354|Device|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
328564|NCT01693354|Device|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
328565|NCT01693341|Other|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
328566|NCT01693328|Drug|PecFent® (fentanyl) nasal spray|
328567|NCT01693315|Drug|AMA0076|
328568|NCT01693315|Drug|Placebo|
328569|NCT01693302|Other|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
328570|NCT01693289|Drug|metformin plus letrozole|
328571|NCT01693289|Procedure|ovarian drilling|
328572|NCT01693276|Drug|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.~Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
328573|NCT01693276|Drug|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
328574|NCT01693276|Radiation|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
328575|NCT01693263|Other|brachiocephalic fistula (BCF)|We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
328576|NCT01693250|Behavioral|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
328577|NCT01693250|Behavioral|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
328578|NCT01693237|Other|Group psychotherapy|20 sessions of systemic and narrative group therapy
328579|NCT01693237|Other|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
328580|NCT01693224|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
328581|NCT01693224|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
328582|NCT01693224|Device|Cepheid Xpert MTB/Rif assay|
328583|NCT01693211|Device|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
328584|NCT01693211|Device|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
328629|NCT01692821|Drug|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
328631|NCT01692808|Drug|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
328585|NCT01693198|Procedure|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
328586|NCT01693185|Drug|Remifentanil|continuous infusion 0.4 mcg/kg/min
328587|NCT01693185|Drug|Midazolam|bolus injection
328588|NCT01693185|Drug|Meperidine|bolus injection for 30 sec 1.0 mg/kg
328589|NCT01693185|Drug|placebo (for remifentanil)|normal saline mimic diluted remifentanil
328590|NCT01693185|Drug|placebo (for midazolam)|normal saline mimic to midazolam injection
328591|NCT01693185|Drug|placebo (for meperidine)|normal saline mimic meperidine injection
328592|NCT01693172|Behavioral|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
328593|NCT01693159|Device|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
328594|NCT01693159|Other|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
328595|NCT01693146|Device|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
328596|NCT01693146|Device|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
328597|NCT01693133|Other|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
328598|NCT01693133|Other|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
328599|NCT01693120|Device|Medtronic Phased RF Ablation System|Phased RF ablation
328600|NCT01693094|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
328601|NCT01693081|Drug|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
328602|NCT01693081|Drug|placebo|
328603|NCT01693068|Drug|Pimasertib|Subjects will receive pimasertib orally as monotherapy at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will continue until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first.
328604|NCT01693068|Drug|Dacarbazine|Subjects will receive dacarbazine intravenously at dose of 1000 milligram per square meter (mg/m^2) of body surface area every 3 weeks on Day 1 of each 21-days cycle until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever occurs first. Eligible subjects with documented tumor progression on dacarbazine will offer to switch to pimasertib treatment.
328605|NCT01693055|Device|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
328606|NCT01693042|Biological|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (> 3 months) infarct area
328607|NCT01693029|Drug|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
328608|NCT01693029|Drug|US-licensed epoetin alfa|Solution for subcutaneous injection.
328609|NCT01693016|Device|non-invasive measurement of Hb|
328610|NCT01693016|Procedure|taking blood samples|
328611|NCT01693003|Drug|Indacaterol|150 µg d.o. during the first 3 weeks
328612|NCT01693003|Drug|Tiotropium|150 µg d.o. during 3 weeks
328613|NCT01692990|Dietary Supplement|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
328614|NCT01692977|Other|neuropsychological assessment|
328615|NCT01692951|Other|serum sample|Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
328616|NCT01692925|Drug|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
328617|NCT01692925|Drug|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
328618|NCT01692912|Other|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28<2.6
328619|NCT01692886|Biological|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
328620|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
328621|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
328622|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
328623|NCT01692873|Procedure|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
328624|NCT01692860|Other|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
328625|NCT01692834|Drug|Sandimmune® Injection|
328626|NCT01692834|Drug|NeuroSTAT®|
328635|NCT01692769|Drug|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
328636|NCT01692769|Drug|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
328637|NCT01692756|Drug|Kenalog or placebo|
328638|NCT01692756|Drug|Kenalog then Placebo|
328639|NCT01692756|Drug|Kenalog|
328640|NCT01692756|Drug|Placebo|
328641|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
328642|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
328643|NCT01692730|Behavioral|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
328644|NCT01692730|Behavioral|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
328645|NCT01692717|Drug|Atorvastatin|10 mg
328646|NCT01692717|Drug|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
328647|NCT01692717|Drug|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
328648|NCT01692704|Drug|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
328649|NCT01692691|Drug|Dacarbazine|Dacarbazine IV - Day 1
328650|NCT01692691|Drug|Carmustine|Carmustine IV- Day 2
328651|NCT01692691|Drug|Neulasta|Neulasta SC - Day 3
328652|NCT01692678|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
328653|NCT01692678|Drug|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
328654|NCT01692652|Drug|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
328655|NCT01692652|Other|warm compress only group|
328656|NCT01692626|Drug|Pimecrolimus|Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.
328657|NCT01692626|Drug|Placebo|Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
328658|NCT01692587|Other|Protein restrictive diet|To begin a reduced protein diet
328659|NCT01692574|Behavioral|Behavior Modification for Weight Loss|
328660|NCT01692574|Behavioral|Alternative Approach to Weight Loss|
328661|NCT01692574|Behavioral|Cognitive-Behavior Therapy for Depression|
328662|NCT01692574|Behavioral|Depression Support and Education|
328663|NCT01692548|Other|Neurofeedback|
328664|NCT01692535|Procedure|Intubation|Intubation with one of the six videolaryngoscopes
328665|NCT01692522|Procedure|Intubation|visualized blind intubation
328666|NCT01692496|Drug|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
328667|NCT01692483|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
328668|NCT01692483|Drug|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
328669|NCT01692470|Drug|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
328670|NCT01692457|Drug|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
328671|NCT01692431|Dietary Supplement|EPA|High fat meal containing EPA
328672|NCT01692431|Dietary Supplement|DHA|High fat meal containing DHA
328673|NCT01692431|Dietary Supplement|Placebo|High fat meal containing negligible EPA/DHA content
328674|NCT01692418|Drug|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
328675|NCT01692418|Drug|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
328676|NCT01692405|Device|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
328677|NCT01692405|Procedure|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
328678|NCT01692379|Device|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
328679|NCT01692379|Other|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
328680|NCT01692366|Drug|SAR302503|"Pharmaceutical form:Capsule~Route of administration: oral"
328681|NCT01692353|Other|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
328682|NCT01692340|Other|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
328683|NCT01692327|Dietary Supplement|High fat meal|
328684|NCT01692314|Other|Resistance training|
328685|NCT01692301|Drug|LCZ696|200 mg tablet
328686|NCT01692301|Drug|Olmesartan|20 mg and 40 mg capsules
328687|NCT01692301|Drug|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
328688|NCT01692301|Drug|Olmesartan matching placebo|Olmesartan matching placebo capsule
328689|NCT01692301|Drug|amlodipine|amlodipine 2.5 mg or 5 mg tablets
328690|NCT01692301|Drug|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
328691|NCT01692288|Behavioral|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
328692|NCT01692275|Other|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
328693|NCT01692275|Other|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
328694|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
328695|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
328696|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
328697|NCT01692249|Other|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
328698|NCT01692223|Behavioral|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety & Depression Scale (HADS), revised Impact of Events Scale (IES-R), & a questionnaire about their health behaviors, to establish baseline distress levels & health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider & discuss resultant therapeutic & management recommendations for the participants & their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
328699|NCT01692210|Drug|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
328700|NCT01692197|Drug|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
328701|NCT01692197|Drug|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
328702|NCT01692197|Drug|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age <60 years) or Days 9 - 11 (age > 60 years).
328703|NCT01692197|Drug|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
328704|NCT01692184|Drug|50 mg AVL-292|
328705|NCT01692184|Drug|100 mg AVL-292|
328706|NCT01692184|Drug|200 mg AVL-292|
328707|NCT01692184|Drug|350 mg AVL-292|
328708|NCT01692184|Drug|Placebo capsules|
328709|NCT01692171|Drug|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
328710|NCT01692158|Drug|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
328711|NCT01692145|Drug|KCT-0809|
328712|NCT01692145|Drug|Placebo|
328713|NCT01692132|Drug|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
328714|NCT01692119|Behavioral|Regular, pharmacy based intervention|"Regular, pharmacy-based intervention conducted in cooperation with the treating physician:~Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.~Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician."
328715|NCT01692106|Procedure|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
328716|NCT01692093|Dietary Supplement|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
328717|NCT01692093|Dietary Supplement|Placebo|Placebo
328718|NCT01692080|Behavioral|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
328719|NCT01692041|Drug|ivy leaves dry extract|5 ml twice daily po
328720|NCT01692041|Drug|Placebo|5 ml per os twice daily
328721|NCT01692015|Other|Questionnaire on dietary history|
328722|NCT01692015|Other|Questionnaire on nosebleed severity|
328723|NCT01692015|Other|One week food diary generated by weighing foods|
328724|NCT01692015|Procedure|Blood tests for full blood count, albumin, and indices of nutritional status|
328725|NCT01692002|Dietary Supplement|Sodium propionate|Sodium propionate capsule or tablet
328726|NCT01692002|Dietary Supplement|Sodium Chloride|Placebo capsule or tablet
328727|NCT01692002|Procedure|Oral glucose tolerance test|
328728|NCT01692002|Procedure|Intravenous glucose tolerance test.|
328729|NCT01691989|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
328730|NCT01691989|Drug|placebo|oral doses once a day for 26 weeks
328731|NCT01691976|Drug|Oestrogen Patches|
328732|NCT01691976|Drug|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
328733|NCT01691963|Device|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.~The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.~Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.~The glottic view will be scored in both positions using the Cormack and Lehane classification system.~After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
328734|NCT01691937|Procedure|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
328735|NCT01691937|Procedure|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
328736|NCT01691937|Procedure|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
328737|NCT01691924|Drug|PBF-509|
328738|NCT01691924|Drug|Placebo|
328739|NCT01691911|Procedure|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
328740|NCT01691898|Drug|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Days 1, 8, 15 of first 21-Day cycle and on Day 1 of subsequent 21-day cycles for up to 8 cycles.
328741|NCT01691898|Drug|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
328742|NCT01691898|Drug|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycle.
328743|NCT01691898|Drug|Rituximab|RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycle.
328744|NCT01691885|Drug|Fluticasone Furoate|100mcg Once daily
328745|NCT01691885|Drug|Vilanterol|25mcg Once daily
328746|NCT01691872|Drug|Retigabine|Retigabine
328747|NCT01691859|Drug|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
328748|NCT01691846|Drug|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
328749|NCT01691846|Drug|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
328750|NCT01691833|Dietary Supplement|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
328751|NCT01691833|Dietary Supplement|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
328839|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, single, 1 day
328752|NCT01691820|Procedure|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
328753|NCT01691820|Procedure|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
328754|NCT01691820|Procedure|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
328755|NCT01691807|Drug|ofatumumab|treatment for NHL
328756|NCT01691807|Drug|bendamustine|treatment for NHL
328757|NCT01691794|Drug|Atazanavir|
328758|NCT01691794|Drug|Ritonavir|
328759|NCT01691781|Drug|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
328760|NCT01691768|Drug|1% tenofovir gel|"Participants will be randomized to receive 1% tenofovir gel through either:~Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm)."
328761|NCT01691755|Drug|Placebo|oral doses once a day for 26 weeks
328762|NCT01691755|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
328763|NCT01691742|Drug|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
328764|NCT01691742|Drug|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
328765|NCT01691742|Drug|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
328766|NCT01691729|Device|Ostomy accessory|Wearing each of the devices for 10 days each
328767|NCT01691716|Drug|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
328768|NCT01691716|Behavioral|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
328769|NCT01691703|Device|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
328770|NCT01691690|Drug|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
328771|NCT01691690|Drug|Normal Saline Flush|Saline placebo will be infused intraoperatively.
328772|NCT01691690|Drug|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
328773|NCT01691690|Drug|Sevoflurane|Sevoflurane for anesthesia induction.
328774|NCT01691690|Drug|Nitrous Oxide/Oxygen|Combination of NO2 & O2 for anesthesia induction.
328775|NCT01691690|Drug|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
328776|NCT01691690|Drug|Morphine|Morphine 0.1 mg/kg given prior to intubation.
328777|NCT01691690|Drug|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
328778|NCT01691690|Drug|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
328779|NCT01691677|Drug|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
328780|NCT01691677|Drug|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
328781|NCT01691664|Radiation|Only radiation therapy|Patients only radiation therapy after surgery
328782|NCT01691664|Other|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
328783|NCT01691651|Procedure|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
328784|NCT01691651|Drug|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
328785|NCT01691625|Other|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.~DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
328786|NCT01691625|Other|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.~Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
328787|NCT01691612|Biological|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
328788|NCT01691586|Device|Remote patient monitoring|Remote monitoring of ICD and heart failure data
328789|NCT01691586|Other|In-Clinic check-ups|Calender-based In-Clinic ICD check-up
328790|NCT01691560|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
328791|NCT01691560|Drug|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
328792|NCT01691560|Drug|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
328793|NCT01691560|Drug|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
328794|NCT01691547|Drug|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
328795|NCT01691547|Drug|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
328796|NCT01691547|Drug|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
328797|NCT01691547|Drug|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
328798|NCT01691534|Drug|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
328799|NCT01691534|Drug|PA-824 (PA)|PA-824 200mg Days 1-14
328800|NCT01691534|Drug|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
328801|NCT01691534|Drug|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
328802|NCT01691534|Drug|Rifafour|Rifafour e-275 mg dosed by weight
328803|NCT01691521|Drug|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
328804|NCT01691521|Drug|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
328805|NCT01691521|Drug|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
328806|NCT01691521|Drug|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
328807|NCT01691508|Drug|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
328808|NCT01691508|Drug|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
328809|NCT01691508|Drug|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
328810|NCT01691495|Drug|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
328811|NCT01691482|Drug|Albuterol/salbutamol|Albuterol/salbutamol (daily)
328812|NCT01691482|Drug|Ipratropium|Ipratropium (daily)
328813|NCT01691469|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
328814|NCT01691456|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
328815|NCT01691443|Procedure|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
328816|NCT01691430|Dietary Supplement|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
328817|NCT01691430|Dietary Supplement|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
328818|NCT01691417|Device|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
328819|NCT01691404|Dietary Supplement|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
328820|NCT01691404|Dietary Supplement|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
328821|NCT01691404|Dietary Supplement|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
328822|NCT01691391|Behavioral|(Early) Imaging of response with [18F-]-FDG PET-CT and kinase activity profiles|Patients will be treated with cetuximab or panitumumab. Two [18F-]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin and tumor biopsies for kinase activity profiles.
328823|NCT01691378|Other|Window to Hope|Psychotherapy - Group
328824|NCT01691378|Other|Waitlist Control|Members of the Waitlist Control arm continued to receive nonconstrained usual care from the Veterans Health Administration. Those initially allocated to the Waitlist Control arm were later provided with the opportunity to cross over and receive the WtoH Intervention after Time 2.
328825|NCT01691365|Dietary Supplement|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
328826|NCT01691365|Drug|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
328827|NCT01691352|Procedure|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
328828|NCT01691352|Procedure|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
328829|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
328830|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
328831|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
328832|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
328833|NCT01691326|Biological|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
328834|NCT01691326|Biological|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
328835|NCT01691313|Drug|Vanoxerine|single oral dose
328840|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, twice a day, 14 days
328841|NCT01691274|Drug|PF-04895162|Tablets, to be decided, twice a day, 14 days
328842|NCT01691274|Drug|Placebo|Tablets, twice a day, 14 days
328843|NCT01691261|Biological|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
328844|NCT01691248|Drug|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
328845|NCT01691248|Drug|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
328846|NCT01691235|Device|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
328847|NCT01691222|Device|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.~The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
328848|NCT01691209|Device|Phoenix (BAY81-2996)|Topical formulation applied to the skin
328849|NCT01691209|Drug|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
328850|NCT01691170|Other|Stretching Hamstring|
328851|NCT01691170|Other|Quadriceps Strengthening|
328852|NCT01691157|Other|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
328853|NCT01691157|Other|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
328854|NCT01691131|Other|Exercise training|Comparison of high intensity exercise training on land versus water.
328855|NCT01691118|Drug|Fimasartan|
328856|NCT01691118|Drug|Antihypertensive treatment|
328857|NCT01691105|Other|AD + Integrated Tobacco Order Set|"Physician will have access to:~NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
328858|NCT01691092|Drug|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
328859|NCT01691079|Drug|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
328860|NCT01691079|Drug|Placebo|Inhaled placebo administered before exercise.
328861|NCT01691066|Behavioral|Infant Toddler Years PRT|
328862|NCT01691053|Drug|Spironolactone|50mg once daily
328863|NCT01691053|Drug|Placebo|Placebo
328864|NCT01691040|Drug|NOX-H94|intravenous injection
328865|NCT01691040|Drug|Placebo solution|intravenous injection
328866|NCT01691027|Behavioral|Visuo-motor training|Participants will undergo training on three developed software modules on Samsung Galaxy Note Pro tablets to see their effect on low vision rehabilitation
328867|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
328868|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
328869|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
328870|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
328871|NCT01691001|Drug|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
328872|NCT01691001|Drug|normal saline|
328873|NCT01690988|Drug|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
328874|NCT01690988|Drug|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
328875|NCT01690988|Drug|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
328876|NCT01690975|Drug|Placebo|Placebo - single dose at start of each treatment period
328877|NCT01690975|Drug|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
328878|NCT01690975|Drug|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
328879|NCT01690962|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
328880|NCT01690962|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
328881|NCT01690949|Drug|PUR118|inhaled PUR118, BID
328882|NCT01690936|Dietary Supplement|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
328883|NCT01690923|Device|Nasal mask|Nasal mask (Mirage Activa, Micro, FX)
328884|NCT01690923|Device|Pillows mask|Nasal pillows mask (Swift FX)
328885|NCT01690910|Device|Rifton Gait Trainer|
328886|NCT01690910|Device|Front Wheeled Walker|
328887|NCT01690897|Behavioral|Mindfulness-based treatment|The mindfulness-based treatment for the MBCT group treatment consists of eight 2-hour long weekly sessions, based on a variety of empirically supported techniques, and integrates elements of education, mindfulness skills, and sex therapy. In addition, participants are also given handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and behavioural exercises between sessions.
328888|NCT01690897|Behavioral|Sex therapy, education, and support treatment|The sex therapy, education, and support group will consist of all of the same techniques and materials in the MBCT group except for the mindfulness components in group sessions and at-home practices.
328889|NCT01690884|Drug|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
328890|NCT01690871|Drug|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
328891|NCT01690858|Other|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
328892|NCT01690845|Device|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
328893|NCT01690832|Drug|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
328894|NCT01690832|Drug|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
328895|NCT01690819|Procedure|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
328896|NCT01690819|Procedure|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
328897|NCT01690780|Drug|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
328898|NCT01690780|Drug|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
328899|NCT01690767|Drug|2% lidocaine gel|Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
328900|NCT01690767|Drug|Health Care Lubricating Jelly|Non-medicinal lubrication gel
328901|NCT01690754|Other|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
328902|NCT01690741|Drug|Nerofe|Nerofe administered intravenously 3x/week
328903|NCT01690728|Behavioral|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
328904|NCT01690702|Drug|Epirubicin|
328905|NCT01690702|Drug|nab-Paclitaxel|
328906|NCT01690702|Drug|Cyclophosphamide|
328907|NCT01690702|Drug|Docetaxel|
328908|NCT01690689|Device|Implant surgery|surgery
328909|NCT01690676|Dietary Supplement|Epicatechin|
328910|NCT01690676|Dietary Supplement|Microcrystalline cellulose|
328911|NCT01690663|Drug|Bupivacaine 0.25%|
328912|NCT01690663|Drug|Dexamethasone|
328913|NCT01690663|Drug|normal saline|placebo
328914|NCT01690650|Drug|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
328915|NCT01690637|Drug|Oseltamivir phosphate suspension|
328916|NCT01690637|Drug|Placebo|
328917|NCT01690624|Drug|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
328918|NCT01690611|Procedure|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
328919|NCT01690611|Other|Visual Feedback|Real time feedback regarding body motion while walking.
328920|NCT01690598|Drug|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
328921|NCT01690598|Drug|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
328922|NCT01690585|Drug|Ferinject 1000 mg|
328923|NCT01690585|Drug|Sodium chlorure 0,9 %|
328924|NCT01690572|Device|Paclitaxel coated balloon catheter|Dilatation of the target lesion
328925|NCT01690572|Device|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
328926|NCT01690559|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
328927|NCT01690546|Drug|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
328928|NCT01690546|Drug|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
328929|NCT01690546|Drug|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
328930|NCT01690533|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
328931|NCT01690520|Drug|Cyclophosphamide|Given IV
328932|NCT01690520|Drug|Cyclosporine|Given IV or PO
328933|NCT01690520|Biological|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
328934|NCT01690520|Drug|Fludarabine Phosphate|Given IV
328935|NCT01690520|Drug|Mycophenolate Mofetil|Given IV or PO
328936|NCT01690520|Drug|Thiotepa|Given IV
328937|NCT01690520|Radiation|Total-Body Irradiation|Undergo high dose or middle intensity TBI
328938|NCT01690520|Procedure|Umbilical Cord Blood Transplantation|Undergo single-unit or double-unit unmanipulated umbilical cord blood transplant
328939|NCT01690507|Drug|Decitabine|20 mg/m²/day for 5 days
328940|NCT01690507|Drug|Cytarabine|
328941|NCT01690507|Drug|aclacinomycin|
328942|NCT01690507|Drug|Granulocyte colony-stimulating factor|
328943|NCT01690507|Other|HLA haploidentical mononuclear cells infusion|
328944|NCT01690494|Behavioral|PACT|Couple-based behavioral HIV/STI preventive intervention
328945|NCT01690494|Behavioral|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
328946|NCT01690468|Drug|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
328947|NCT01690468|Drug|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
328948|NCT01690442|Behavioral|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
328949|NCT01690442|Behavioral|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
328950|NCT01690429|Device|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
328951|NCT01690416|Procedure|Traditional palpation technique|
328952|NCT01690416|Procedure|Ultrasound DNTP|
328953|NCT01690403|Drug|rifapentine (M000473)|"Pharmaceutical form:tablet~Route of administration: oral"
328954|NCT01690403|Drug|EFZ EMT TDF|"Pharmaceutical form:tablet~Route of administration: oral"
328955|NCT01690390|Drug|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
328956|NCT01690390|Drug|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
328957|NCT01690377|Biological|PDC or myDC|PDC or myDC; first patient 0.3 * 10E6 PDC; second and third 1 * 10E6 PDC; fourth and fifth 3 * 10E6 PDC.
328958|NCT01690364|Other|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
328959|NCT01690364|Other|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
328960|NCT01690351|Drug|PF-05089771|Oral dispersion TS formulation- fasted
328961|NCT01690351|Drug|PF-05089771|Capsules TS formulation- fasted
328962|NCT01690338|Drug|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
328963|NCT01690338|Drug|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
328964|NCT01690338|Drug|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
328965|NCT01690325|Drug|Docetaxel|
328966|NCT01690325|Drug|Trastuzumab|
328967|NCT01690325|Drug|Bevacizumab|
328968|NCT01690325|Drug|Epirubicin|
328969|NCT01690325|Drug|Cyclophosphamid|
328970|NCT01690312|Dietary Supplement|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
328971|NCT01690312|Dietary Supplement|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
328972|NCT01690299|Drug|Apremilast|Apremilast 30 mg tablet orally BID
328973|NCT01690299|Drug|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
328974|NCT01690299|Drug|Placebo tablet|Placebo tablets BID
328975|NCT01690299|Drug|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
328976|NCT01690286|Drug|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
328977|NCT01690286|Drug|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
328978|NCT01690286|Drug|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
328979|NCT01690286|Drug|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
328980|NCT01690273|Other|mobility exercise|30 minutes, twice a week
328981|NCT01690273|Other|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
328982|NCT01690260|Drug|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
328983|NCT01690260|Procedure|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
328984|NCT01690247|Drug|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
328985|NCT01690247|Drug|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
328986|NCT01690234|Procedure|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
328987|NCT01690234|Procedure|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
328988|NCT01690221|Drug|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
328989|NCT01690221|Drug|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
328990|NCT01690208|Other|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.~These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
328991|NCT01690208|Other|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment & explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
328992|NCT01690195|Drug|ABT-126|See arm description
328993|NCT01690182|Dietary Supplement|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
328994|NCT01690182|Dietary Supplement|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
328995|NCT01690182|Dietary Supplement|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
328996|NCT01690169|Drug|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
328997|NCT01690169|Drug|placebo|A single dose of oral placebo administered.
328998|NCT01690143|Drug|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
328999|NCT01690143|Drug|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
329000|NCT01690130|Device|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
329001|NCT01690130|Device|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
329002|NCT01690117|Behavioral|GE-REACH-program|"The intervention program Resources to Enhance Alzheimer`s Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers"
329003|NCT01690104|Drug|Rifampicin|
329004|NCT01690104|Drug|Placebo|
329005|NCT01690091|Drug|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.~Titration:~500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
329006|NCT01690091|Drug|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
329007|NCT01690065|Drug|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy~4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).~Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
329008|NCT01690052|Drug|Cevimeline|"Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day."
329009|NCT01690052|Drug|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
329010|NCT01690039|Drug|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
329011|NCT01690026|Behavioral|Motivation interviewing based brief intervention|
329012|NCT01690026|Behavioral|Standard Intervention|
329013|NCT01690000|Drug|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
329014|NCT01689987|Drug|Cyclophosphamide|Given IV
329015|NCT01689987|Drug|Dexamethasone|Given PO
329016|NCT01689987|Drug|Hydroxychloroquine|Given PO
329017|NCT01689987|Other|Laboratory Biomarker Analysis|Correlative studies
329018|NCT01689987|Other|Pharmacological Study|Correlative studies
329019|NCT01689987|Drug|Sirolimus|Given PO
329020|NCT01689974|Drug|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
329021|NCT01689974|Radiation|Radiation Therapy|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
329022|NCT01689961|Behavioral|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
329023|NCT01689948|Behavioral|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
329024|NCT01689935|Drug|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
329025|NCT01689935|Device|Red light only|Red Light therapy
329026|NCT01689935|Device|Blue light only|Blue light only
329027|NCT01689922|Other|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
329028|NCT01689909|Drug|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
329029|NCT01689909|Drug|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
329030|NCT01689896|Drug|Testosterone Gel|
329031|NCT01689896|Drug|Placebo Gel|
329032|NCT01689883|Device|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
329033|NCT01689870|Drug|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
329034|NCT01689870|Drug|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
329035|NCT01689857|Device|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
329036|NCT01689857|Device|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
329037|NCT01689844|Behavioral|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
329038|NCT01689844|Behavioral|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
329039|NCT01689831|Biological|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
329040|NCT01689831|Biological|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
329041|NCT01689818|Other|exercise training|exercise training program which included aerobic exercise for 3 times per week.
329042|NCT01689792|Drug|MOVIPREP|
329043|NCT01689792|Drug|CitraFleet|
329044|NCT01689779|Drug|100,000 IU cholecalciferol|active drug
329045|NCT01689779|Drug|Placebo|comparator drug
329046|NCT01689766|Drug|Technetium Tc 99m EC20|
329047|NCT01689753|Device|TEGO connector®|
329048|NCT01689753|Drug|Trisodium citrate|
329049|NCT01689740|Drug|Active placebo dose MDMA|Initial dose of 25 mg MDMA administered orally at the start of each of two separate psychotherapy sessions scheduled three to five weeks apart possibly followed by a supplemental dose of 12.5 mg MDMA 1.5 to 2.5 hours later.
329050|NCT01689740|Drug|Full dose MDMA|Initial dose of 125 mg MDMA administered orally at the start of each of two psychotherapy sessions scheduled three to five weeks apart. In each case, it may be followed 1.5 to 2.5 hours later with 62.5 mg MDMA.
329051|NCT01689740|Drug|125 mg MDMA (open label)|Initial dose of MDMA administered orally at the start of each of two psychotherapy sessions, supplement administered 1.5 go 2.5 hours later.
329052|NCT01689740|Behavioral|Psychotherapy|Psychotherapy provided throughout course of main study
329053|NCT01689727|Drug|Technetium Tc 99m EC20|
329054|NCT01689714|Drug|Tc 99m EC20|
329055|NCT01689701|Dietary Supplement|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
329056|NCT01689701|Dietary Supplement|Placebo|Placebo(1.3g/d)
329057|NCT01689675|Behavioral|Computer based pain management|
329058|NCT01689662|Drug|Tc 99m EC20|
329059|NCT01689649|Drug|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
329060|NCT01689636|Drug|Tc 99m EC20|
329061|NCT01689623|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
329062|NCT01689623|Drug|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
329063|NCT01689623|Drug|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
329064|NCT01689597|Drug|Morphine|Comparison of different dosages of drug
329065|NCT01689597|Drug|Placebo|
329066|NCT01689584|Genetic|salivary kit|The saliva samples will be made of selected related (DNA).
329067|NCT01689571|Drug|CHF6001|
329068|NCT01689571|Drug|Placebo|
329069|NCT01689558|Drug|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
329276|NCT01687920|Drug|BAY94-8862 (1.25mg)|
329070|NCT01689545|Behavioral|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
329071|NCT01689545|Behavioral|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
329072|NCT01689545|Behavioral|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
329073|NCT01689545|Behavioral|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
329074|NCT01689532|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
329075|NCT01689532|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
329076|NCT01689532|Drug|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
329077|NCT01689519|Drug|Placebo|Placebo supplied as tablets
329078|NCT01689519|Drug|Vemurafenib|Vemurafenib supplied as tablets
329079|NCT01689519|Drug|Cobimetinib|Cobimetinib supplied as tablets
329080|NCT01689506|Drug|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
329081|NCT01689506|Drug|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
329082|NCT01689493|Behavioral|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
329083|NCT01689480|Other|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
329084|NCT01689467|Dietary Supplement|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
329085|NCT01689467|Dietary Supplement|Placebo|Placebo (1g/day)
329086|NCT01689441|Drug|Calcitriol|
329087|NCT01689441|Drug|Placebo|
329088|NCT01689402|Device|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.~Susceptibility weighted imaging (SWI)~Chemical Shift Imaging (CSI) multivoxel spectroscopi~Post contrast 3D box reconstruction"
329089|NCT01689376|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
329090|NCT01689363|Drug|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
329091|NCT01689363|Drug|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
329092|NCT01689363|Drug|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
329093|NCT01689350|Genetic|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
329094|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
329095|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
329096|NCT01689337|Drug|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
329097|NCT01689324|Biological|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
329098|NCT01689311|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
329099|NCT01689311|Drug|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
329100|NCT01689311|Drug|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
329101|NCT01689311|Drug|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
329102|NCT01689298|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
329103|NCT01689298|Drug|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
329104|NCT01689285|Drug|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
329105|NCT01689285|Drug|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
329106|NCT01689272|Procedure|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
329107|NCT01689259|Drug|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
329277|NCT01687920|Drug|BAY94-8862 (2.5mg)|
329108|NCT01689259|Drug|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
329109|NCT01689259|Drug|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
329110|NCT01689259|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
329111|NCT01689246|Drug|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
329112|NCT01689246|Drug|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
329113|NCT01689246|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
329114|NCT01689233|Drug|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
329115|NCT01689233|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
329116|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
329117|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
329118|NCT01689207|Drug|Avibactam (AVI)|PART A: AVI IV infusion
329119|NCT01689207|Drug|Aztreonam (ATM)|PART A: ATM IV infusion
329120|NCT01689207|Drug|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
329121|NCT01689207|Drug|Placebo|PART A, PART B, PART C: matching placebo IV infusions
329122|NCT01689194|Drug|genexolPM + cisplatin|
329123|NCT01689168|Behavioral|Counseling|Tobacco cessation counseling
329124|NCT01689168|Procedure|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
329125|NCT01689155|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
329126|NCT01689142|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
329127|NCT01689142|Drug|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
329128|NCT01689129|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
329129|NCT01689129|Drug|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
329130|NCT01689116|Drug|Bardoxolone Methyl 20mg|Oral
329131|NCT01689116|Drug|Bardoxolone Methyl 80mg|Oral
329132|NCT01689116|Drug|Bardoxolone Methyl Placebo|Oral
329133|NCT01689116|Drug|Moxifloxacin 400mg|Oral
329134|NCT01689116|Drug|Moxifloxacin Placebo|Oral
329135|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
329136|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
329137|NCT01689090|Other|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
329138|NCT01689090|Other|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
329139|NCT01689090|Other|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
329140|NCT01689077|Other|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
329141|NCT01689064|Procedure|Stamm Approach|
329142|NCT01689064|Procedure|Posterior Septectomy|
329143|NCT01689051|Other|human glucagon-like peptide 1 (7-36)amide|
329144|NCT01689051|Other|human glucagon-like peptide 1 (9-36)amide|
329145|NCT01689038|Drug|F17464|Single dose
329146|NCT01689025|Drug|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
329147|NCT01689025|Drug|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
329148|NCT01689012|Behavioral|Facial Exercise|
329149|NCT01688999|Drug|Cabozantinib|60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
329150|NCT01688973|Drug|Erlotinib Hydrochloride|150 mg (1 tablet) by mouth on days 1-28, once daily, until disease progression
329151|NCT01688973|Other|Laboratory Biomarker Analysis|Correlative studies
329152|NCT01688973|Drug|Tivantinib|360 mg (3 tablets) by mouth, Twice daily (720 mg total daily dose) on days 1-28, until disease progression
329153|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 1
329154|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 2
329155|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 3
329156|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 1
329157|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 2
329158|NCT01688947|Drug|V116517 50-mg tablets|Taken orally twice daily
329159|NCT01688947|Drug|V116517 30-mg tablets|Taken orally twice daily
329160|NCT01688947|Drug|Pregabalin capsules|1-2 capsules taken orally twice daily
329161|NCT01688947|Drug|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
329162|NCT01688934|Drug|V116517 50-mg tablets|Taken orally twice daily
329163|NCT01688934|Drug|V116517 30-mg tablets|Taken orally twice daily
329164|NCT01688934|Drug|Naproxen 500-mg capsules|Taken orally twice daily
329165|NCT01688934|Drug|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
329278|NCT01687920|Drug|BAY94-8862 (5mg)|
329279|NCT01687920|Drug|BAY94-8862 (7.5mg)|
329166|NCT01688921|Biological|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
329167|NCT01688921|Device|Needle-Syringe|
329168|NCT01688921|Device|Stratis needle-free injection device|
329169|NCT01688908|Procedure|Endoscopic Screening|"Upper G.I. endoscopic examination with Lugols Iodine in esophagus~Biopsy at the visually abnormal sites~Pathologic examination of all biopsy tissue specimens~Subsequent re-examination and further medical services among individuals who already have high-grade lesions found at screening.~Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of high grade upper G.I. lesions."
329170|NCT01688882|Drug|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
329171|NCT01688882|Drug|Placebo|Placebo will be used to control for normal variability in disease severity.
329172|NCT01688856|Device|Electrical stimulator|"The treatment period will be 13 weeks in duration, divided into two 6-week periods of actual treatment separated by 1 week to do mid-treatment assessments. Thus 12 weeks of actual treatment are provided over a 13 week period. Treatment consists of two components:~Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES groups but not for Cyclic NMES group during these sessions. To ensure that all 3 groups receive an equivalent dose of stimulation, the cyclic NMES group has slightly lengthened stimulated hand opening exercise sessions at home than the CCFES groups.)~Self-administered hand opening exercise performed 10 sessions per week at home using the device."
329173|NCT01688843|Device|INGEVITY lead|
329174|NCT01688830|Drug|Dabigatran|
329175|NCT01688830|Drug|BI 655075|
329176|NCT01688830|Drug|Placebo|
329177|NCT01688817|Other|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
329178|NCT01688817|Other|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
329179|NCT01688804|Behavioral|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
329180|NCT01688791|Drug|Vintafolide|
329181|NCT01688791|Drug|Carboplatin|
329182|NCT01688791|Drug|Paclitaxel|
329183|NCT01688778|Behavioral|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.~Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
329184|NCT01688739|Drug|Erenumab|Administered by subcutaneous injection or intravenous injection
329185|NCT01688739|Drug|Placebo|Administered by subcutaneous injection or intravenous injection
329186|NCT01688726|Other|SYSTANE® BALANCE eyedrops|
329187|NCT01688726|Other|Minims® Saline 0.9% eyedrops|
329188|NCT01688713|Drug|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
329189|NCT01688700|Drug|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).~Cisplatin: 75mg/m2,IV on days 1，22~paclitaxel: 90mg/m2, IV on days 1,8,22,29.~patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
329190|NCT01688687|Procedure|Endoscopic submucosal dissection|
329191|NCT01688674|Drug|10% dextrose|
329192|NCT01688648|Drug|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
329193|NCT01688648|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
329194|NCT01688635|Drug|LY2963016|Administered subcutaneously
329195|NCT01688635|Drug|US Approved Lantus|Administered subcutaneously
329196|NCT01688622|Behavioral|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
329197|NCT01688609|Drug|lapatinib ditosylate|Given PO
329198|NCT01688609|Drug|paclitaxel|Given IV
329199|NCT01688609|Biological|trastuzumab|Given IV
329200|NCT01688609|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
329201|NCT01688609|Other|pharmacological study|Correlative studies
329202|NCT01688609|Other|laboratory biomarker analysis|Correlative studies
329203|NCT01688596|Drug|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
329204|NCT01688583|Drug|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
329205|NCT01688570|Drug|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
329206|NCT01688570|Drug|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
329207|NCT01688570|Drug|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
329208|NCT01688557|Device|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
329209|NCT01688557|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
329210|NCT01688544|Drug|Ilaprazole|Ilaprazole 10 mg for 7 days
329211|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
329212|NCT01688531|Drug|CD0271 0.1%/CD1579 2.5% gel vehicle|one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months
329213|NCT01688518|Drug|Heated Lidocaine/Tetracaine Patch|
329214|NCT01688518|Drug|5% Lidocaine Patch|
329215|NCT01688492|Drug|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson & Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
329216|NCT01688479|Drug|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
329217|NCT01688479|Drug|Essex® cream (Schering-Plough), aqueous cream without parabens|
329218|NCT01688466|Drug|Pomalidomide|0.5 mg/day with and/or without Dose Escalation and 0.5 mg/day- 2.0 mg/day by mouth (PO) QD(every day) of each 28 day cycle
329219|NCT01688453|Behavioral|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
329220|NCT01688453|Behavioral|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.~The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.~The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
329221|NCT01688440|Other|#1 Respiratory Care Solution|Respiratory care solution.
329222|NCT01688427|Behavioral|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
329223|NCT01688427|Behavioral|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
329224|NCT01688414|Procedure|photoacoustic imaging|Undergo PAI
329225|NCT01688414|Procedure|fluorescence imaging|Undergo fluorescence imaging
329226|NCT01688414|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
329227|NCT01688401|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.~Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
329228|NCT01688388|Procedure|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
329229|NCT01688375|Drug|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
329230|NCT01688362|Biological|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
329231|NCT01688362|Drug|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
329280|NCT01687920|Drug|BAY94-8862 (10mg)|
329281|NCT01687907|Behavioral|Music|
329282|NCT01687894|Drug|Vasopressins|Vasopressins propofol vasopressins sevoflurane
329283|NCT01687894|Drug|Placebo|Placebo propofol & placebo sevoflurane
329284|NCT01687894|Drug|propofol|vasopressin propofol & placebo propofol
329285|NCT01687894|Drug|sevoflurane|vasopressins sevoflurane placebo sevoflurane
329286|NCT01687881|Other|Chiropractic|Chiropractic Spinal Manipulative Therapy
329232|NCT01688349|Other|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be~to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;~to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
329233|NCT01688336|Drug|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~Oxaliplatin (85 mg/m2)~Leucovorin (400mg/ m2)~Irinotecan (180 mg/m2)~5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
329234|NCT01688323|Other|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
329235|NCT01688310|Procedure|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
329236|NCT01688310|Procedure|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
329237|NCT01688297|Biological|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
329238|NCT01688297|Biological|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
329239|NCT01688284|Device|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
329240|NCT01688258|Procedure|Diagnostic swab|
329241|NCT01688245|Behavioral|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
329242|NCT01688245|Behavioral|SMS Assessments|Weekly post-weekend drinking outcome assessments
329243|NCT01688206|Biological|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
329244|NCT01688206|Biological|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram [mg] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
329245|NCT01688167|Behavioral|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
329246|NCT01688154|Dietary Supplement|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
329247|NCT01688154|Other|2 empty capsules|
329248|NCT01688141|Other|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
329249|NCT01688128|Device|Phase I U-SMART (4 wks)|Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
329250|NCT01688128|Other|Washout (2 wks)|2-weeks wash out period in both arms
329251|NCT01688128|Device|Phase II U-SMART (4 wks)|Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
329252|NCT01688115|Procedure|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
329253|NCT01688115|Other|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
329254|NCT01688102|Dietary Supplement|Oral Vitamin D3|50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
329255|NCT01688102|Radiation|Ultraviolet Light|16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
329256|NCT01688089|Drug|ODM103|
329257|NCT01688089|Drug|Placebo|
329258|NCT01688089|Drug|Entacapone|
329259|NCT01688089|Drug|Levodopa/carbidopa|
329260|NCT01688076|Procedure|Botulinum Toxin A|Forehead will be injected with Botox.
329261|NCT01688050|Device|Zenith® TX2® Low Profile Endovascular Graft|Zenith® TX2® Low Profile Endovascular Graft
329262|NCT01688037|Drug|NBI-98854|25 mg capsule
329263|NCT01688037|Drug|NBI-98854|50 mg capsule
329264|NCT01688037|Drug|Placebo|
329265|NCT01688024|Drug|Mitomycin C|
329266|NCT01688024|Drug|Normal saline|
329267|NCT01687998|Drug|Evacetrapib|Administered Orally
329268|NCT01687998|Drug|Placebo|Administered Orally
329269|NCT01687985|Drug|BLI801 laxative - low dose|BLI801 laxative - oral solution
329270|NCT01687985|Drug|BLI801 laxative - high dose|BLI801 laxative - oral solution
329271|NCT01687972|Combination Product|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
329272|NCT01687972|Combination Product|Absorbable sutures|placement of absorbable sutures at cesarean section
329273|NCT01687959|Other|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
329274|NCT01687933|Device|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
329275|NCT01687933|Other|usual care|Women in Control group did not use the glasses.
329287|NCT01687881|Other|Sham Chiropractic|Sham manipulation
329288|NCT01687868|Drug|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
329289|NCT01687855|Device|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
329290|NCT01687842|Other|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
329291|NCT01687803|Behavioral|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
329292|NCT01687803|Behavioral|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
329293|NCT01687790|Device|molecular breast imaging (Discovery)|
329294|NCT01687777|Biological|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
329295|NCT01687777|Biological|OrthADAPT|
329296|NCT01687764|Other|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
329297|NCT01687764|Other|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
329298|NCT01687764|Behavioral|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
329299|NCT01687764|Behavioral|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
329300|NCT01687751|Drug|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~The study drug will be started at a rate of 1.0 mL/hr.~The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
329301|NCT01687751|Drug|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.~The study drug will be started at a rate of 1.0 mL/hr.~The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
329302|NCT01687738|Other|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
329303|NCT01687738|Other|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
329304|NCT01687725|Device|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
329305|NCT01687712|Drug|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
329306|NCT01687712|Drug|Gonal-f® RFF|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
329307|NCT01687699|Drug|Spironolactone|
329308|NCT01687673|Drug|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
329309|NCT01687673|Drug|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
329310|NCT01687660|Other|acupuncture|apply acupuncture to prevent the migraine attack
329311|NCT01687647|Other|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
329312|NCT01687634|Behavioral|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
329313|NCT01687634|Behavioral|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
329367|NCT01687257|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
329368|NCT01687244|Drug|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
329369|NCT01687231|Other|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
329314|NCT01687621|Procedure|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
329315|NCT01687608|Biological|AskBio009|Single dose IV injection
329316|NCT01687595|Drug|HerpV and QS-21|HerpV (formerly AG-707 rh-Hsc70 Polyvalent Peptide Complex) in combination with adjuvant QS-21.
329317|NCT01687595|Drug|Placebo|phosphate buffered saline.
329318|NCT01687582|Drug|GLP-1 analog|GLP-1 analog treatment
329319|NCT01687569|Other|Control Cracker Snack|Base cracker snack
329320|NCT01687569|Other|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
329321|NCT01687569|Other|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
329322|NCT01687556|Other|topical EGCG application on acne|two times application of topical EGCG on acne lesion
329323|NCT01687543|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
329324|NCT01687543|Other|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
329325|NCT01687530|Procedure|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
329326|NCT01687517|Drug|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
329327|NCT01687491|Drug|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
329328|NCT01687491|Drug|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
329329|NCT01687478|Drug|Olanzapine|Administered Orally
329330|NCT01687478|Drug|Fluoxetine|Administered Orally
329331|NCT01687478|Drug|Placebo|Administered Orally
329332|NCT01687465|Procedure|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
329333|NCT01687465|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
329334|NCT01687452|Biological|Blood samples|
329335|NCT01687439|Drug|Endostar|7.5mg/m2, D1-14
329336|NCT01687439|Drug|Vinorelbine|25-30mg/m2, D1,8
329337|NCT01687439|Drug|Cisplatin|25 mg/m2, D1-3
329338|NCT01687439|Radiation|Radiotherapy|
329339|NCT01687426|Drug|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
329340|NCT01687426|Drug|Vehicle|1 drop in each eye daily four times a day for 14 days
329341|NCT01687413|Radiation|Intensity-modulated radiation therapy (IMRT)|
329342|NCT01687413|Drug|Cisplatin|
329343|NCT01687400|Drug|decitabine|
329344|NCT01687387|Drug|IPH2102 at 0.1 mg/kg|every 3 months
329345|NCT01687387|Drug|IPH2102 at 1 mg/kg|every 4 weeks
329346|NCT01687387|Drug|Placebo (normal saline solution)|every 4 weeks
329347|NCT01687374|Drug|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
329348|NCT01687374|Drug|Placebo|Saline injection daily for 8 weeks.
329349|NCT01687361|Dietary Supplement|branched-chain amino acids (BCAA) supplementation|
329350|NCT01687361|Drug|PLACEBO|
329351|NCT01687348|Drug|lidocaine aguettant|
329352|NCT01687335|Other|answering questionnare in differents time of the treatment|
329353|NCT01687309|Drug|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
329354|NCT01687309|Drug|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
329355|NCT01687309|Other|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
329356|NCT01687309|Other|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
329357|NCT01687296|Drug|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
329358|NCT01687296|Drug|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
329359|NCT01687296|Drug|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
329360|NCT01687296|Drug|placebo tablet|placebo soluble tablet, oral ,once daily
329361|NCT01687296|Drug|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
329362|NCT01687283|Drug|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
329363|NCT01687283|Drug|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
329364|NCT01687270|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
329365|NCT01687270|Drug|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
329366|NCT01687257|Drug|SOF|SOF 400 mg tablet administered orally once daily
329648|NCT01684891|Drug|RG1662|multiple doses of RG1662
329370|NCT01687218|Drug|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
329371|NCT01687218|Drug|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
329372|NCT01687218|Drug|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
329373|NCT01687205|Drug|1% Tenofovir Gel|
329374|NCT01687192|Biological|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
329375|NCT01687179|Drug|"Sirolimus and Hydroxychloroquine 200 mg"|"This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily."
329376|NCT01687179|Drug|"Sirolimus and Hydroxychloroquine 400 mg"|Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
329377|NCT01687166|Device|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
329378|NCT01687166|Device|FDA Approved Open-Irrigated Ablation Catheter|
329379|NCT01687140|Drug|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
329380|NCT01687140|Drug|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
329381|NCT01687127|Dietary Supplement|Folic acid|Supplement
329382|NCT01687127|Dietary Supplement|5-methyltetrahydrofolate, calcium salt|Supplement
329383|NCT01687114|Other|cranberry juice|27% cranberry juice
329384|NCT01687101|Drug|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
329385|NCT01687075|Device|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
329386|NCT01687062|Other|FeSO4|
329387|NCT01687062|Other|reduction of phytate|
329388|NCT01687062|Other|NaFeEDTA|
329389|NCT01687049|Drug|Red yeast rice|
329390|NCT01687036|Device|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
329391|NCT01686997|Procedure|Roux-en-Y Gastric Bypass|
329392|NCT01686984|Other|Altered breath|
329393|NCT01686958|Device|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
329394|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
329395|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
329396|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
329397|NCT01686945|Drug|placebo|Placebo semaglutide. For oral administration.
329398|NCT01686945|Drug|placebo|Placebo semaglutide with carrier. For oral administration.
329399|NCT01686932|Drug|Vildagliptin|vildagliptin 50mg BID for 8 weeks
329400|NCT01686932|Drug|Sitagliptin|sitagliptin 100mg QD for 8 weeks
329401|NCT01686919|Dietary Supplement|milk-free|milk-free diet during 8 preoperative weeks
329402|NCT01686906|Procedure|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
329403|NCT01686893|Device|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
329404|NCT01686893|Device|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
329405|NCT01686880|Device|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
329406|NCT01686867|Device|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.~The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
329407|NCT01686854|Behavioral|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
329408|NCT01686854|Other|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
329409|NCT01686841|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
329410|NCT01686828|Drug|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
329411|NCT01686828|Drug|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
329412|NCT01686828|Drug|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
329413|NCT01686828|Drug|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
329414|NCT01686828|Drug|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
329415|NCT01686802|Drug|oral morphine|
329416|NCT01686802|Drug|Ibuprofen|
329417|NCT01686789|Drug|Pegylated interferon alpha-2a|
329418|NCT01686776|Other|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
329419|NCT01686750|Behavioral|Integrated care centers|
329420|NCT01686737|Behavioral|Iyengar Yoga|"12 weeks of Iyengar yoga~2 weekly sessions of 60 minutes"
329421|NCT01686737|Behavioral|Walking|"12 weeks of walking~2 weekly sessions of 60 minutes"
329422|NCT01686724|Behavioral|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
329423|NCT01686724|Other|Business As Usual|
329424|NCT01686711|Drug|AD-4833 15 mg|
329425|NCT01686711|Drug|AD-4833 30 mg|
329426|NCT01686711|Drug|Placebo|
329427|NCT01686698|Dietary Supplement|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
329428|NCT01686698|Other|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
329429|NCT01686672|Behavioral|Web Intervention|Behavioral
329430|NCT01686659|Device|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin [SpHb] and Pleth Variability Index [PVI]) to the clinicians in the operating room
329431|NCT01686646|Drug|paracetamol + caffeine|paracetamol with caffeine
329432|NCT01686646|Drug|paracetamol|paracetamol
329433|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
329434|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
329435|NCT01686633|Drug|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
329436|NCT01686620|Drug|BIOD-123|
329437|NCT01686620|Drug|Lispro (Humalog)|
329438|NCT01686607|Drug|Parenteral micafungin application|Parenteral
329439|NCT01686607|Drug|Other parenteral antifungal drugs|Parenteral
329440|NCT01686594|Drug|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
329441|NCT01686581|Drug|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered according to physician prescription.
329442|NCT01686568|Drug|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
329443|NCT01686568|Drug|placebo|
329444|NCT01686555|Drug|ABT-199|Tablet
329445|NCT01686555|Other|Placebo|Tablet
329446|NCT01686542|Procedure|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
329447|NCT01686542|Procedure|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
329448|NCT01686529|Procedure|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
329449|NCT01686529|Drug|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
329450|NCT01686503|Drug|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
329451|NCT01686490|Behavioral|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
329452|NCT01686490|Behavioral|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
329453|NCT01686477|Other|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
329454|NCT01686477|Other|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
329455|NCT01686477|Other|Preterm Formula used when there is a shortfall in mother's own milk|
329456|NCT01686464|Drug|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
329457|NCT01686464|Device|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2~3.0 L / min for the same duration during all acupuncture sections.
329458|NCT01686451|Drug|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
329459|NCT01686451|Drug|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
329460|NCT01686438|Behavioral|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
329461|NCT01686425|Procedure|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
329462|NCT01686412|Device|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
329463|NCT01686399|Behavioral|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
329464|NCT01686386|Drug|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
329465|NCT01686386|Drug|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
329466|NCT01686386|Drug|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
329467|NCT01686373|Device|Activa Dose II Real tDCS|20 minutes of 1 milliamp active tDCS per treatment day (15 total sessions)
329468|NCT01686373|Device|Activa Dose II Sham tDCS|20 minutes of sham stimulation per treatment day (15 total sessions)
329469|NCT01686360|Behavioral|Decision Aid|
329470|NCT01686347|Drug|ropivacaine|
329471|NCT01686334|Biological|DC vaccine|Autologous WT1 mRNA-electroporated DCs
329472|NCT01686321|Drug|Bendamustine and subcutaneous rituximab|
329473|NCT01686308|Procedure|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
329474|NCT01686308|Procedure|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
329475|NCT01686295|Device|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
329476|NCT01686295|Device|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
329477|NCT01686282|Dietary Supplement|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
329478|NCT01686282|Dietary Supplement|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
329479|NCT01686269|Procedure|blood collecting|
329480|NCT01686256|Drug|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
329481|NCT01686243|Other|epidural needle placement with echogenic 17G Tuohy needles (Pajunk TuohySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G Tuohy needles (Pajunk TuohySono)
329482|NCT01686243|Other|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
329483|NCT01686230|Other|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
329484|NCT01686230|Drug|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.~We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.~Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
329485|NCT01686217|Drug|ASP015K ER|oral extended release (ER) at three dosing levels
329486|NCT01686217|Drug|ASP015K IR|oral immediate release (IR)
329487|NCT01686204|Other|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
329488|NCT01686204|Other|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
329489|NCT01686178|Behavioral|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
329490|NCT01686165|Drug|belinostat|Given IV
329491|NCT01686165|Biological|rituximab|Given IV
329492|NCT01686165|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
329493|NCT01686152|Drug|Imiquimod Cream, 3.75%|
329494|NCT01686152|Drug|Zyclara®|
329495|NCT01686152|Other|Vehicle of Test Product|
329496|NCT01686139|Biological|ABMD-MSC|10-20 x 10^6 cells/20mL
329497|NCT01686126|Drug|Levonorgestrel|Intrauterine device
329498|NCT01686126|Drug|Metformin|oral medication
329499|NCT01686113|Other|NEFA|
329500|NCT01686113|Other|Sucrose|
329501|NCT01686100|Procedure|No touch technique|The vein graft is harvested with its surronding tissues.
329502|NCT01686100|Procedure|Conventional technique|The vein graft is stripped from its surrounding tissues.
329503|NCT01686087|Behavioral|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
329504|NCT01686087|Procedure|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
329505|NCT01686061|Other|No intervention- only one time survey|
329506|NCT01686022|Other|Immunoblot|serum specific IgE binds to grass extract by immunoblot
329507|NCT01686009|Drug|Intra-nasal ketamine|
329508|NCT01685996|Drug|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
329509|NCT01685996|Drug|placebo|
329510|NCT01685983|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
329511|NCT01685983|Drug|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
329512|NCT01685970|Drug|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
329513|NCT01685970|Drug|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
329514|NCT01685957|Behavioral|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
329515|NCT01685957|Behavioral|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
329516|NCT01685957|Behavioral|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
329517|NCT01685944|Dietary Supplement|Live Pediococcus pentosaceus LP28|
329518|NCT01685944|Dietary Supplement|Heat-killed Pediococcus pentosaceus LP28|
329519|NCT01685944|Dietary Supplement|Placebo|
329520|NCT01685931|Drug|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
329521|NCT01685892|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab 100 milligrams (mg) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
329522|NCT01685892|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
329523|NCT01685879|Other|Rice|Rice portion containing 50 g total carbohydrate
329524|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
329525|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
329526|NCT01685879|Other|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
329527|NCT01685866|Device|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
329528|NCT01685853|Drug|Bisacodyl plus PEG-CS|"the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime~the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
329529|NCT01685853|Drug|PEG 4 litres split|"the day before colonoscopy: 2 litres of PEG~the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
329530|NCT01685840|Other|Usual Care|Usual Care
329531|NCT01685840|Device|Biomarker-guided care NT-proBNP|Device: NT-proBNP
329532|NCT01685827|Drug|Fexinidazole|
329533|NCT01685827|Drug|Nifurtimox|
329534|NCT01685827|Drug|Eflornithine|
329535|NCT01685814|Drug|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
329536|NCT01685814|Biological|autologous stem cell transplant|
329537|NCT01685814|Biological|allogeneic stem cell transplant|
329538|NCT01685801|Drug|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
329539|NCT01685801|Drug|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
329540|NCT01685788|Other|No intervention|
329541|NCT01685775|Procedure|Transvaginal/transumbilical|
329542|NCT01685775|Procedure|Needlescopic with 3 trocars|
329543|NCT01685762|Drug|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
329544|NCT01685723|Behavioral|Counseling group|Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.
329545|NCT01685723|Behavioral|General supporting|Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
329546|NCT01685710|Drug|GTN patch|
329547|NCT01685710|Drug|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
329548|NCT01685697|Procedure|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
329549|NCT01685697|Procedure|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
329550|NCT01685684|Drug|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
329551|NCT01685684|Drug|Placebo|Placebo, divided into 2 doses, q12h
329552|NCT01685671|Drug|NESP 60μg|Administrated NESP 60μg once subcutaneously
329553|NCT01685671|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
329554|NCT01685658|Drug|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
329555|NCT01685658|Drug|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
329556|NCT01685645|Device|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
329853|NCT01683162|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
329557|NCT01685632|Procedure|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
329558|NCT01685632|Procedure|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.~7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).~6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
329559|NCT01685606|Biological|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
329560|NCT01685593|Device|abdominal binder|
329561|NCT01685593|Other|no binder|
329562|NCT01685580|Device|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
329563|NCT01685567|Device|MICHI NPS+f|Cerebral protection with carotid flow reversal
329564|NCT01685554|Device|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
329565|NCT01685554|Device|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
329566|NCT01685541|Other|Maximum After Visit Summary Content|
329567|NCT01685541|Other|Intermediate After Visit Summary Content|
329568|NCT01685541|Other|Minimum After Visit Summary Content|
329569|NCT01685541|Other|Usual AVS|
329570|NCT01685528|Behavioral|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
329571|NCT01685515|Drug|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
329572|NCT01685515|Drug|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
329573|NCT01685502|Drug|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
329574|NCT01685489|Drug|Docetaxel, PSK®|
329575|NCT01685489|Drug|Docetaxel, Placebo|
329576|NCT01685476|Device|Echodia® hand-held equipment|
329577|NCT01685463|Device|Transcranial Magnetic Stimulation|Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.
329578|NCT01685463|Device|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
329579|NCT01685450|Device|Echodia® hand-held equipment|
329580|NCT01685437|Biological|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
329581|NCT01685424|Drug|Etoricoxib|As per routine clinical practice in the United Kingdom
329582|NCT01685411|Drug|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
329583|NCT01685411|Drug|Keppra|Day -8 (prior to transplant): Per institutional guidelines
329584|NCT01685411|Drug|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
329585|NCT01685411|Drug|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
329586|NCT01685411|Drug|Tacrolimus|All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
329587|NCT01685411|Drug|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (> or = 40 kg) or 15 mg/kg 3 times per day (< 40 kg) for up to 30 days unless no engraftment.
329588|NCT01685411|Biological|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
329589|NCT01685411|Biological|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is >2500 x 10^9/L or per institutional guidelines.
329590|NCT01685411|Biological|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
329591|NCT01685398|Drug|0.5% timolol maleate eye drop|
329592|NCT01685398|Drug|Normal saline|
329593|NCT01685385|Other|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
329594|NCT01685372|Biological|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
329595|NCT01685372|Biological|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
329596|NCT01685359|Drug|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
329646|NCT01684917|Behavioral|Metabolomic and Energy Intake Restriction|Metabolomic inquiry followed by a 12 week energy intake restriction
329647|NCT01684904|Radiation|Proton radiation|
329597|NCT01685346|Behavioral|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
329598|NCT01685333|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
329599|NCT01685320|Procedure|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
329600|NCT01685307|Dietary Supplement|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
329601|NCT01685294|Behavioral|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
329602|NCT01685281|Drug|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
329603|NCT01685281|Drug|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
329604|NCT01685268|Drug|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
329605|NCT01685268|Drug|abiraterone acetate|1000 mg PO daily.
329606|NCT01685268|Drug|Prednisone|5 mg PO twice daily.
329607|NCT01685255|Drug|Epacadostat|
329608|NCT01685255|Drug|tamoxifen|
329609|NCT01685242|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
329610|NCT01685242|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
329611|NCT01685229|Device|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
329612|NCT01685229|Drug|Medical Management|Subjects who select to continue on medical management rather than have a BSD procedure.
329613|NCT01685216|Biological|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
329614|NCT01685203|Drug|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
329615|NCT01685203|Drug|ABT-267|Tablet
329616|NCT01685203|Drug|Ribavirin (RBV)|Tablet
329617|NCT01685190|Radiation|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
329618|NCT01685190|Radiation|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
329619|NCT01685164|Other|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
329620|NCT01685151|Drug|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
329621|NCT01685151|Drug|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
329622|NCT01685151|Drug|Placebo|Placebo
329623|NCT01685138|Drug|LDK378|LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
329624|NCT01685125|Drug|abiraterone acetate|Given PO
329625|NCT01685125|Drug|dasatinib|Given PO
329626|NCT01685125|Drug|prednisone|Given PO
329627|NCT01685073|Drug|Zolpidem extended-release|nightly administration of zolpidem extended-release
329628|NCT01685073|Behavioral|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
329629|NCT01685060|Drug|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
329630|NCT01685034|Biological|"Allergy immunotherapy (allergy shots)"|
329631|NCT01685021|Drug|MOR00208 (formerly Xmab5574)|
329632|NCT01685008|Drug|MOR00208 (formerly Xmab 5574)|
329633|NCT01684995|Behavioral|Brief physician advice|Brief physician advice to quit smoking
329634|NCT01684995|Drug|nicotine patch|nicotine patch
329635|NCT01684995|Behavioral|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
329636|NCT01684982|Device|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
329637|NCT01684982|Device|sirolimus eluting stent|control arm of a comparison between drug eluting stents
329638|NCT01684969|Drug|Haloperidol|0.5 mg iv x one dose
329639|NCT01684969|Drug|Placebo|0.5 mg iv , one dose
329640|NCT01684956|Procedure|Intradermal injection|
329641|NCT01684956|Procedure|Subcutaneous injection|
329642|NCT01684943|Other|Multiplex pharmacokinetic profiling|
329643|NCT01684943|Other|Continuous insulin monitoring|
329644|NCT01684930|Drug|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
329645|NCT01684930|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
329649|NCT01684878|Drug|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
329650|NCT01684878|Drug|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
329651|NCT01684878|Drug|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
329652|NCT01684878|Drug|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
329653|NCT01684878|Drug|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
329654|NCT01684865|Drug|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
329655|NCT01684852|Other|Medical device, drug-like|
329656|NCT01684839|Device|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
329657|NCT01684826|Radiation|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
329658|NCT01684826|Radiation|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
329659|NCT01684813|Drug|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
329660|NCT01684813|Drug|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
329661|NCT01684800|Drug|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
329662|NCT01684800|Drug|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
329663|NCT01684800|Drug|C: Placebo|1 orally disintegrating tablet every night during study period
329664|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
329665|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
329666|NCT01684774|Drug|Bupivacaine|
329667|NCT01684761|Biological|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
329668|NCT01684761|Biological|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
329669|NCT01684748|Drug|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
329670|NCT01684722|Dietary Supplement|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
329671|NCT01684722|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
329672|NCT01684722|Dietary Supplement|Vitamin D placebo|Vitamin D3 placebo
329673|NCT01684722|Dietary Supplement|Fish oil placebo|Fish oil placebo
329674|NCT01684709|Behavioral|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
329675|NCT01684696|Behavioral|Virtual experience|
329676|NCT01684696|Behavioral|Videos|
329677|NCT01684683|Drug|Theophylline|Theophylline 0.1 bid
329678|NCT01684683|Drug|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
329679|NCT01684670|Behavioral|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
329680|NCT01684657|Drug|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
329681|NCT01684644|Behavioral|New Forest Parenting Programme|
329682|NCT01684644|Behavioral|Treatment as usual|
329683|NCT01684631|Device|Total Hip arthroplasty|
329684|NCT01684618|Procedure|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
329685|NCT01684605|Drug|NESP 60μg|Administrated NESP 60μg once intravenously
329686|NCT01684605|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
329687|NCT01684592|Behavioral|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
329688|NCT01684592|Behavioral|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by American College of Obstetricians and Gynecologists (ACOG) for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
329689|NCT01684579|Behavioral|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
329690|NCT01684579|Behavioral|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
329691|NCT01684579|Behavioral|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
329692|NCT01684566|Device|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
329693|NCT01684566|Other|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
329694|NCT01684553|Behavioral|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
329695|NCT01684553|Behavioral|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
329696|NCT01684540|Other|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
329697|NCT01684540|Drug|Sinupret forte|
329698|NCT01684527|Other|Respiratory secretions obtained|
329699|NCT01684514|Device|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
329700|NCT01684488|Behavioral|YRI|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
329701|NCT01684488|Other|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
329702|NCT01684475|Drug|CJH1 (CLR4001)|
329703|NCT01684462|Biological|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4~8h, commencing within 12 hours of stroke onset
329704|NCT01684462|Drug|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset
329705|NCT01684449|Drug|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).~Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.~Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
329706|NCT01684436|Device|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
329707|NCT01684423|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
329708|NCT01684423|Drug|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
329709|NCT01684423|Drug|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
329710|NCT01684410|Biological|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
329711|NCT01684410|Biological|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
329712|NCT01684410|Biological|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
329713|NCT01684397|Biological|Bevacizumab|Given IV
329714|NCT01684397|Other|Laboratory Biomarker Analysis|Correlative studies
329715|NCT01684397|Drug|Pazopanib Hydrochloride|Given PO
329716|NCT01684397|Other|Pharmacological Study|Correlative studies
329717|NCT01684384|Radiation|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
329766|NCT01684033|Device|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
329767|NCT01684020|Biological|ARTISS human fibrin sealant|
329854|NCT01683162|Drug|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
329718|NCT01684371|Other|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
329719|NCT01684358|Device|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
329720|NCT01684345|Drug|Placebo|Solution for subcutaneous injection
329721|NCT01684345|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
329722|NCT01684345|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
329723|NCT01684332|Other|Strawberry Jam|
329724|NCT01684319|Dietary Supplement|Formula milk free of cow's milk protein|
329725|NCT01684319|Dietary Supplement|Placebo|Infant formula milk
329726|NCT01684306|Drug|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
329727|NCT01684306|Drug|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
329728|NCT01684293|Behavioral|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
329729|NCT01684293|Behavioral|Psychoeducation/games|Psychoeducation/games
329730|NCT01684280|Genetic|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
329731|NCT01684267|Device|Robotic Gait Rehabilitation (RGR) Trainer|
329732|NCT01684241|Biological|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
329733|NCT01684215|Drug|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
329734|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
329735|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
329736|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
329737|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
329738|NCT01684202|Drug|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
329739|NCT01684189|Other|Patient registry|Patient registry without study intervention
329740|NCT01684176|Behavioral|Complex tailored intervention|
329741|NCT01684176|Behavioral|Usual care|
329742|NCT01684163|Drug|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
329743|NCT01684163|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
329744|NCT01684163|Drug|Placebo|Intravenous administration of normal saline into arm.
329745|NCT01684150|Drug|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
329746|NCT01684137|Dietary Supplement|Joalis Bambi Analerg|
329747|NCT01684137|Dietary Supplement|Joalis Bambi Bronchi|
329748|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
329749|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
329750|NCT01684124|Other|conservative O2 therapy|target lower O2 saturation
329751|NCT01684124|Other|standard care|
329752|NCT01684111|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
329753|NCT01684111|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
329754|NCT01684098|Drug|Tc 99m EC20|
329755|NCT01684085|Behavioral|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
329756|NCT01684085|Behavioral|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
329757|NCT01684085|Drug|Lorazepam|Lorazepam 1 mg
329758|NCT01684072|Biological|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
329759|NCT01684072|Biological|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
329760|NCT01684059|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
329761|NCT01684046|Device|Opti-Free® PureMoist® MPDS|
329762|NCT01684046|Device|RevitaLens MPDS|
329763|NCT01684046|Device|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
329764|NCT01684033|Device|Opti-Free® PureMoist® MPDS|
329765|NCT01684033|Device|Biotrue™ MPS|
329768|NCT01684007|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
329769|NCT01684007|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
329770|NCT01683994|Drug|Cabozantinib|Assigned dose given daily during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
329771|NCT01683994|Drug|Docetaxel|75mg/m^2 intravenous (IV) over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
329772|NCT01683994|Drug|Prednisone|5 mg by mouth (PO) twice a day during each 21 day cycle until disease progression or intolerable toxicity.
329773|NCT01683981|Drug|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
329774|NCT01683955|Drug|Transexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
329775|NCT01683955|Drug|Placebo|100mL 0.9% sterile saline
329776|NCT01683929|Other|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
329777|NCT01683929|Other|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.~The participants HR & BP will be monitored throughout the examination + 1 hour after.~In addition, the participants will be asked to complete a- 24 hr food questionnaire."
329778|NCT01683877|Procedure|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
329779|NCT01683877|Procedure|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
329780|NCT01683864|Drug|positive cytology with HIPEC|HIPEC with mytomycin and cisplatin
329781|NCT01683851|Device|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
329782|NCT01683838|Drug|Fampridine-SR|25mg bid (twice daily)
329783|NCT01683838|Drug|Placebo|Placebo
329784|NCT01683825|Drug|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
329785|NCT01683812|Device|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
329786|NCT01683799|Behavioral|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
329787|NCT01683786|Drug|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day
329788|NCT01683773|Biological|AERAS-402|Intramuscular needle injection 1x10^11 vp
329789|NCT01683773|Biological|MVA85A|Intradermal needle injection 1x10^8 pfu
329790|NCT01683760|Drug|Fluconazole|Prophylactic fluconazole administration in VLBW infants
329791|NCT01683747|Drug|Tranexamic Acid|
329792|NCT01683747|Drug|Control Intervention (Carrier fluid only)|
329793|NCT01683708|Dietary Supplement|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
329794|NCT01683695|Drug|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
329795|NCT01683695|Drug|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
329796|NCT01683682|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
329797|NCT01683682|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
329798|NCT01683682|Drug|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
329799|NCT01683669|Other|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
329800|NCT01683669|Other|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
329801|NCT01683656|Drug|niacin/laropiprant|
329802|NCT01683656|Drug|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
329803|NCT01683643|Behavioral|SBIRT|Screening, brief intervention, and referral to treatment.
329804|NCT01683643|Behavioral|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
329805|NCT01683617|Behavioral|Coping skills and relaxation training with new technologies|
329806|NCT01683617|Behavioral|Traditional coping skills and relaxation training|
329807|NCT01683604|Other|Observational study|
329848|NCT01683201|Procedure|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
329849|NCT01683188|Drug|vemurafenib + HD IL-2|
329808|NCT01683591|Procedure|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
329809|NCT01683578|Other|Variable Ventilation|
329810|NCT01683565|Drug|LCPUFA oil supplement|"2.5mL per day for 90 days~Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
329811|NCT01683565|Other|Canola Oil Placebo|2.5mL per day for 90 days
329812|NCT01683552|Drug|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
329813|NCT01683552|Drug|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
329814|NCT01683552|Drug|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
329815|NCT01683539|Behavioral|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
329816|NCT01683539|Behavioral|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
329817|NCT01683526|Procedure|Direct laryngoscopy|
329818|NCT01683526|Device|Video laryngoscopy (Glidescope)|
329819|NCT01683513|Drug|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
329820|NCT01683500|Device|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
329821|NCT01683487|Procedure|Observation|Observational study only, no intervention.
329822|NCT01683474|Device|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
329823|NCT01683461|Behavioral|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
329824|NCT01683461|Behavioral|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
329825|NCT01683435|Other|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
329826|NCT01683422|Radiation|Proton, Gemcitabine, Erlotinib, Capecitabine|"Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.~Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles."
329827|NCT01683422|Radiation|Proton Radiation|
329828|NCT01683409|Drug|Baricitinib|Administered orally
329829|NCT01683409|Drug|Placebo|Administered orally
329830|NCT01683396|Drug|Placebo|Solution for subcutaneous injection
329831|NCT01683396|Drug|gevokizumab|Solution for subcutaneous injection
329832|NCT01683383|Device|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
329833|NCT01683383|Other|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
329834|NCT01683357|Procedure|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
329835|NCT01683331|Drug|Insulin treatment for hyperglycemia|
329836|NCT01683318|Procedure|Thermal Pulsation therapy|
329837|NCT01683292|Drug|Inhaled VR040|
329838|NCT01683292|Drug|Placebo for VR040|Placebo arm
329839|NCT01683279|Biological|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
329840|NCT01683266|Drug|HOE901-U300 (Insulin glargine new formulation)|
329841|NCT01683266|Drug|Lantus (Insulin glargine)|
329842|NCT01683253|Drug|Levodopa/Carbidopa(200mg/50mg)|
329843|NCT01683253|Drug|Dopaminergic Agonists|Treated for at least 6 months after diagnosis of Parkinson's Disease.
329844|NCT01683240|Device|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
329845|NCT01683227|Behavioral|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
329846|NCT01683227|Behavioral|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
329847|NCT01683201|Procedure|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
329850|NCT01683175|Drug|Erlotinib|
329855|NCT01683162|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
329856|NCT01683149|Drug|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
329857|NCT01683149|Drug|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
329858|NCT01683136|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.~From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
329859|NCT01683110|Drug|cabozantinib|
329860|NCT01683097|Other|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
329861|NCT01683084|Drug|Telmisartan|
329862|NCT01683084|Drug|Placebo|
329863|NCT01683071|Drug|EXPAREL|EXPAREL 67 mg, 133 mg, or 266 mg
329864|NCT01683071|Drug|Placebo|Normal saline 20 mL
329865|NCT01683058|Drug|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
329866|NCT01683045|Device|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
329867|NCT01683032|Drug|MPH|a capsule containing 20 mg
329868|NCT01683019|Device|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
329869|NCT01683019|Device|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
329870|NCT01683006|Drug|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering."
329871|NCT01683006|Drug|Placebo|"Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
329872|NCT01682993|Other|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
329873|NCT01682993|Other|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
329874|NCT01682980|Other|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
329875|NCT01682980|Other|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
329876|NCT01682954|Behavioral|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
329877|NCT01682941|Dietary Supplement|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
329878|NCT01682941|Dietary Supplement|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
329879|NCT01682928|Drug|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~AFI (Baseline, day 3, 7 {or Discharge})~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs"
329880|NCT01682928|Other|Hydrotherapy|"Maternal BP (sitting)~Pulse Pressure~Pulse~Urine Specific Gravity BID~Fetal Heart Rate~Maternal Body Weight US Procedures~AC/EFW~Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})~o 1 hour +/- 30 minutes after submersion therapy~AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy~ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:~1 Liter Water PO over 2 hours~1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation~Strict I/O's~Vital signs~HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
329881|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
329882|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
329914|NCT01682733|Device|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
329883|NCT01682902|Drug|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
329884|NCT01682889|Dietary Supplement|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
329885|NCT01682889|Dietary Supplement|Placebo|NaCl 0.9% intravenously for 24h
329886|NCT01682876|Biological|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
329887|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
329888|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
329889|NCT01682863|Drug|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
329890|NCT01682863|Drug|Placebo|To mimic QAB149
329891|NCT01682850|Behavioral|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
329892|NCT01682850|Other|Usual Care|
329893|NCT01682837|Drug|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
329894|NCT01682837|Drug|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
329895|NCT01682837|Drug|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
329896|NCT01682837|Drug|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
329897|NCT01682824|Other|Nutritional Assessment|Complete dietary intake assessment
329898|NCT01682824|Other|Questionnaire Administration|Complete TFEQ-R18v2 questionnaire
329899|NCT01682824|Other|Questionnaire Administration|Complete EQ-EMA questionnaire
329900|NCT01682811|Drug|Levulan (5-aminolevulinic acid) uptake.|"8 adult subjects will be needed, two subjects for each incubation time point, and one each for negative and positive controls. Multiple lesions for each subject may be treated in order to provide better estimations of fluorescence levels.~Tumors will be incubated with Levulan under occlusion for 3, 6, or 24 hrs. A minimum of three tumors per group on the same subject will be incubated with Levulan or vehicle only for three hours. Tumors will then be excised in the normal manner. A minimum of three untreated control tumors will be excised. Thus there will be three groups of tumors excised per subject. Tumors will be sectioned vertically and checked for PpIX using fluorescence microscopy. Negative controls will now consist of untreated tumors and tumors incubated with vehicle only for 3 hours on the same subjects as the Levulan treated tumors. Positive controls will consist of intralesional injection of saline-dissolved ALA approximately one hour before excision."
329901|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy.|2-18 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 630 nm red light illumination. 630 nm light will be applied for varying periods of time in order to achieve a dose of 25, 50, or 100 J/cm2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
329902|NCT01682798|Dietary Supplement|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
329903|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
329904|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
329905|NCT01682772|Drug|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
329906|NCT01682759|Drug|Omarigliptin|
329907|NCT01682759|Drug|Placebo to Omarigliptin|
329908|NCT01682759|Drug|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
329909|NCT01682759|Drug|Glimepiride Placebo|
329910|NCT01682759|Drug|Metformin|Participants will continue on their stable dose (>=1500 mg/day) of open-label metformin throughout the trial.
329911|NCT01682759|Drug|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
329912|NCT01682746|Drug|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin~This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity & light precautions for a minimum of 30 days after the infusion.~Photodynamic Therapy (PDT)~After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
329913|NCT01682733|Drug|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
329915|NCT01682720|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
330002|NCT01682044|Genetic|western blotting|Correlative studies
329916|NCT01682720|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
329917|NCT01682720|Drug|Placebo to match SOF|Placebo to match SOF administered orally once daily
329918|NCT01682720|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
329919|NCT01682707|Procedure|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
329920|NCT01682707|Procedure|track light|
329921|NCT01682694|Dietary Supplement|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
329922|NCT01682694|Dietary Supplement|placebo|
329923|NCT01682681|Drug|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
329924|NCT01682668|Procedure|Bilateral subthalamic stimulation|
329925|NCT01682642|Drug|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
329926|NCT01682629|Other|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.~All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
329927|NCT01682629|Other|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
329928|NCT01682616|Drug|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
329929|NCT01682616|Drug|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
329930|NCT01682603|Drug|Botulinum toxin A|BoNT-A (BOTOX 300U)
329931|NCT01682590|Procedure|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).~In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.~In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output > 1000ml/24 hr or >2000ml/24hr with diuretics), RRT is not mandatory."
329932|NCT01682577|Drug|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
329933|NCT01682577|Drug|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
329934|NCT01682564|Drug|Candemore tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
329935|NCT01682564|Drug|Atacand tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg~dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
329936|NCT01682551|Drug|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
329937|NCT01682551|Drug|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
329938|NCT01682538|Drug|Nitisinone, capsule|
329939|NCT01682538|Drug|Nitisinone, suspension|
329940|NCT01682525|Other|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
329941|NCT01682512|Drug|BI 695500|
329942|NCT01682512|Drug|BI 695500|
329943|NCT01682512|Drug|Rituxan®|
329944|NCT01682512|Drug|Rituxan®|
329945|NCT01682512|Drug|MabThera®|
329946|NCT01682499|Drug|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
329947|NCT01682486|Device|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
329948|NCT01682486|Procedure|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
329949|NCT01682473|Drug|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
329950|NCT01682460|Drug|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
329951|NCT01682447|Other|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
329952|NCT01682434|Procedure|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
329953|NCT01682421|Drug|Weak steroid (Flurolon, Allergan)|
329954|NCT01682421|Drug|Potent steroid (Maxidex, Alcon)|
329955|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
329956|NCT01682408|Drug|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
329957|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
329958|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
329959|NCT01682408|Drug|Ranitidine|150 mg ranitidine
329960|NCT01682395|Procedure|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
329961|NCT01682395|Procedure|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
329962|NCT01682395|Procedure|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
329963|NCT01682369|Biological|TIV (Aggripal)|
329964|NCT01682369|Biological|ATIV (Fluad)|
329965|NCT01682356|Dietary Supplement|Beetroot Juice (BRJ)|double-blind placebo-controlled cross-over study
329966|NCT01682356|Dietary Supplement|placebo|double-blind placebo-controlled cross-over study
329967|NCT01682343|Dietary Supplement|Calcium|Milk-calcium supplement
329968|NCT01682317|Behavioral|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, < 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
329969|NCT01682291|Behavioral|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
329970|NCT01682291|Dietary Supplement|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
329971|NCT01682278|Device|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
329972|NCT01682265|Other|Stretta procedure|
329973|NCT01682265|Other|Sham procedure|No radiofrequency delivered
329974|NCT01682239|Other|RVAP|In this arm pacemaker leads will be placed in the RV apex.
329975|NCT01682239|Other|RVSP|In this arm pacemaker leads will be placed in the RV septum.
329976|NCT01682226|Device|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)~1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
329977|NCT01682226|Device|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3~1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood~1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
329978|NCT01682213|Drug|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
329979|NCT01682200|Drug|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
329980|NCT01682187|Drug|LY2157299|Administered orally
329981|NCT01682187|Drug|Lomustine|Administered orally
329982|NCT01682174|Other|Control Drink|
329983|NCT01682174|Other|Experimental Drink|
329984|NCT01682161|Drug|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
329985|NCT01682148|Biological|Botulinum toxin type A|
329986|NCT01682135|Biological|Ramucirumab|Administered IV.
329987|NCT01682109|Drug|Valacyclovir|
329988|NCT01682096|Radiation|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
329989|NCT01682096|Procedure|Exercise stress echocardiography|Limited by symptoms
329990|NCT01682083|Drug|Dabrafenib|Each capsule contained 50 mg or 75 mg of free base (present as the mesylate salt)
329991|NCT01682083|Drug|Trametinib|Each tablet contained 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
329992|NCT01682083|Drug|Placebos|The placebo capsules and tablets contained the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
329993|NCT01682070|Biological|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
329994|NCT01682070|Biological|Placebo|
329995|NCT01682057|Device|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
329996|NCT01682057|Device|ROX Anastomotic Coupler System (ACS)|
329997|NCT01682044|Biological|pegfilgrastim|Given SC
329998|NCT01682044|Biological|rituximab|Given IV
329999|NCT01682044|Other|flow cytometry|Correlative studies
330000|NCT01682044|Procedure|biopsy|Correlative studies
330001|NCT01682044|Other|immunohistochemistry staining method|Correlative studies
330003|NCT01682031|Dietary Supplement|selenomethionine|Given PO
330004|NCT01682031|Other|placebo|Given PO
330005|NCT01682031|Drug|cisplatin|Given IV
330006|NCT01682031|Radiation|radiation therapy|Undergo radiotherapy
330007|NCT01682031|Procedure|quality-of-life assessment|Ancillary studies
330008|NCT01682018|Device|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
330009|NCT01682005|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
330010|NCT01681992|Biological|Priorix|Subjects receive one dose of either minimum (Inv_MMR_Min) or medium (Inv_MMR_Med) potency lot at Day 0 and a dose of separate potency lot (Inv_MMR_Release) at Day 42, administered subcutaneously in the triceps region of the left arm.
330011|NCT01681992|Biological|M-M-R II|Subjects receive two doses of either Lot 1 or Lot 2, one at Day 0 and one at Day 42, administered subcutaneously in the triceps region of the left arm.
330012|NCT01681992|Biological|Varivax|Subjects receive one dose co-administered subcutaneously with the study vaccines (Priorix and M-M-R II), in the triceps region of right arm, at Day 0.
330013|NCT01681992|Biological|Havrix|Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the right thigh, at Day 0.
330014|NCT01681992|Biological|Prevnar 13|US Subjects receive one dose co-administered intramuscularly with the study vaccines (Priorix and M-M-R II), in the anterolateral region of the left thigh, at Day 0.
330015|NCT01681979|Drug|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
330016|NCT01681966|Drug|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
330017|NCT01681953|Drug|Lamazym|ERT, i.v. infusions weekly
330018|NCT01681953|Drug|Placebo|Infusions weekly
330019|NCT01681940|Drug|Lamazym|ERT, i.v. infusions weekly
330020|NCT01681901|Procedure|ultrasound imaging|Undergo ultrasound
330021|NCT01681888|Device|Sanger EMG Biofeedback Device|
330022|NCT01681875|Other|very low nicotine content cigarettes|
330023|NCT01681862|Behavioral|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
330024|NCT01681849|Drug|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
330025|NCT01681849|Drug|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
330026|NCT01681849|Other|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
330027|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrite|15Nitrogen(15N)-labeled sodium nitrite 20 mg once
330028|NCT01681836|Drug|15Nitrogen(15N)-labeled sodium nitrate|15Nitrogen(15N)-labeled sodium nitrate 1,000 mg once
330029|NCT01681823|Dietary Supplement|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
330030|NCT01681810|Drug|14Nitrogen Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times a day for 12 weeks
330031|NCT01681797|Device|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
330032|NCT01681771|Behavioral|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
330033|NCT01681771|Behavioral|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
330034|NCT01681758|Other|IV fluid according to PPV|intravenous fluids
330035|NCT01681758|Other|fluids according to standard care|
330036|NCT01681745|Device|Treatment with Cryo-Touch III|
330037|NCT01681732|Other|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
330038|NCT01681732|Other|Control Standard Care|This is the standard care arm
330039|NCT01681719|Device|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
330124|NCT01681121|Drug|ADX-N05|150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
330125|NCT01681121|Drug|Placebo|One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
331295|NCT01671878|Other|Test Food 1 (Cereal)|
330040|NCT01681719|Device|resistance & sham WBV|"used only resistance~For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.~For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
330041|NCT01681719|Device|WBV & resistance sham|"used really the WBV, but sham for resistance training~For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.~For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
330042|NCT01681693|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
330043|NCT01681680|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
330044|NCT01681667|Drug|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
330045|NCT01681654|Behavioral|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
330046|NCT01681654|Behavioral|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
330047|NCT01681641|Other|A psycho-social intervention|
330048|NCT01681628|Behavioral|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
330049|NCT01681615|Drug|Acetylsalicylate|1-2 drops
330050|NCT01681615|Drug|Isotonic NaCl|1 drop
330051|NCT01681602|Other|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
330052|NCT01681589|Device|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
330053|NCT01681589|Device|Control Group|This group will receive Sham TDCS
330054|NCT01681589|Other|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
330055|NCT01681576|Drug|Valsartan|Valsartan 320mg tablet once daily
330056|NCT01681576|Drug|LCZ696|LCZ696 400mg tablet once daily
330057|NCT01681563|Drug|Pentostatin|Lyophilized powder for intravenous administration.
330058|NCT01681563|Drug|Cyclophosphamide|IV
330059|NCT01681563|Drug|Ofatumumab|Liquid concentrate for solution for infusion.
330060|NCT01681550|Drug|Incretin-based therapy|
330061|NCT01681537|Drug|Lenalidomide|
330062|NCT01681537|Drug|Mitoxantrone|
330063|NCT01681537|Drug|Etoposide|
330064|NCT01681537|Drug|Cytarabine|
330065|NCT01681524|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
330066|NCT01681511|Device|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
330067|NCT01681511|Device|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®* silver alloy coating and BARD® hydrogel.
330068|NCT01681472|Drug|6R-MTHF 200 mg/m2|i.v. bolus injection
330069|NCT01681472|Drug|Levoleucovorin 200 mg/m2|i.v. bolus injection
330070|NCT01681472|Drug|6R-MTHF 60 mg/m2|i.v. bolus injection
330071|NCT01681472|Drug|Levoleucovorin 60 mg/m2|i.v. bolus injection
330072|NCT01681446|Drug|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscular injected 30 μg three times a week or 50 μg twice a week for 18 months
330073|NCT01681433|Drug|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
330074|NCT01681433|Drug|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
330075|NCT01681433|Drug|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
330076|NCT01681420|Behavioral|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
330077|NCT01681420|Behavioral|Blood Donation|Blood donation without HIV counseling
330078|NCT01681394|Dietary Supplement|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
330079|NCT01681394|Dietary Supplement|Chocolate cream|
330080|NCT01681381|Device|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
330126|NCT01681108|Behavioral|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
330160|NCT01680861|Drug|Everolimus|Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
330081|NCT01681381|Device|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
330082|NCT01681368|Drug|Birinapant (TL32711)|47mg/m^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
330083|NCT01681355|Other|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
330084|NCT01681329|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
330085|NCT01681329|Other|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
330086|NCT01681316|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
330087|NCT01681316|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
330088|NCT01681316|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
330089|NCT01681303|Drug|AST-120|
330090|NCT01681290|Drug|CBX129801|
330091|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
330092|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
330093|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
330094|NCT01681277|Drug|Placebo to BI 113608 PIB qd|powder for oral solution
330095|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
330096|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
330097|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
330098|NCT01681277|Drug|BI 113608 PIB qd|powder for oral solution
330099|NCT01681264|Drug|Morphine|
330100|NCT01681264|Drug|Guanfacine 1mg|
330101|NCT01681264|Drug|Guanfacine 2mg|
330102|NCT01681264|Drug|Placebo|
330103|NCT01681251|Other|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.~Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
330104|NCT01681251|Other|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
330105|NCT01681238|Procedure|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR <100 bpm, Hb> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
330106|NCT01681238|Procedure|Protocol group 1|The goal of this protocol is to ensure MAP> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP <8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
330107|NCT01681225|Other|Esophageal-pressure guided mechanical ventilation|
330108|NCT01681225|Other|High PEEP mechanical ventilation|
330109|NCT01681212|Drug|Ipilimumab|
330110|NCT01681212|Drug|Dacarbazine|
330111|NCT01681199|Drug|Fluvastatin extended release tablet|
330112|NCT01681186|Drug|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
330113|NCT01681186|Drug|LY2940680 Tablet (Test)|Administered orally as a tablet
330114|NCT01681186|Drug|Lansoprazole|Administered orally as a capsule
330115|NCT01681186|Drug|Placebo Capsule(s)|Administered orally as a capsule(s)
330116|NCT01681173|Dietary Supplement|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
330117|NCT01681173|Dietary Supplement|Placebo|200ml Placebo, BID, over 24 months
330118|NCT01681160|Other|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
330119|NCT01681160|Other|conventional therapy|patients receive ordinary treatment for diabetic foot
330120|NCT01681147|Behavioral|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
330121|NCT01681147|Behavioral|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
330122|NCT01681134|Drug|Advagraf®|oral
330123|NCT01681134|Drug|Prograf®|oral
330127|NCT01681095|Drug|Custodiol HTK|After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
330128|NCT01681095|Drug|Cold Blood Cardioplegia|After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
330129|NCT01681082|Behavioral|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
330130|NCT01681069|Dietary Supplement|IQP-VV-102|
330131|NCT01681069|Other|Placebo|
330132|NCT01681056|Behavioral|Autosuggestion for 30 days|
330133|NCT01681043|Behavioral|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~nurse nearby~no visits after 10 p.m.~decreased alarm sound in ventilator and monitor~decreased light intensity~no unnecessary conversations around the patient~medication should be limited to max 1-2 times in this time period~no unnecessary therapeutic or diagnostic procedures in this time period~earplugs and sleep masks"
330134|NCT01681030|Biological|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
330135|NCT01681030|Biological|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
330136|NCT01681030|Other|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
330137|NCT01681017|Behavioral|HBB/ENC Training and Equipment|See the detailed description section
330138|NCT01681017|Other|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
330139|NCT01681004|Device|iFuse Implant System|Placement of iFuse implant system via surgery
330140|NCT01681004|Other|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
330141|NCT01680991|Drug|Obinutuzumab|Multiple doses of obinutuzumab.
330142|NCT01680978|Drug|aleglitazar|150 mcg orally daily, 6 weeks
330143|NCT01680978|Drug|placebo|orally daily, 6 weeks
330144|NCT01680965|Drug|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.~Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
330145|NCT01680952|Drug|A) TEST|"Extended Release Tacrolimus (Advagraf®)~① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.~Sirolimus (Rapamune®):~After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
330146|NCT01680952|Drug|B) CONTROL|"Extended Release Tacrolimus (Advagraf®)~: Same as above.~Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
330147|NCT01680939|Drug|Morphine|0.2-0.5 mg/kg PO q4h
330148|NCT01680939|Drug|Ibuprofen|10mg/kg PO q6hrs
330149|NCT01680926|Dietary Supplement|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
330150|NCT01680913|Procedure|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
330151|NCT01680913|Procedure|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
330152|NCT01680913|Procedure|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
330153|NCT01680900|Drug|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
330154|NCT01680900|Drug|placebo capsules|placebo capsules matched to drug capsules.
330155|NCT01680887|Drug|Varenicline|
330156|NCT01680887|Drug|Placebo|
330157|NCT01680874|Dietary Supplement|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
330158|NCT01680874|Dietary Supplement|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
330159|NCT01680861|Drug|Tacrolimus|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
331296|NCT01671878|Other|Test Food 2 (Biscuit)|
330161|NCT01680861|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
330162|NCT01680861|Drug|Corticosteroids|Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
330163|NCT01680835|Device|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat
330164|NCT01680809|Device|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
330165|NCT01680809|Device|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
330166|NCT01680796|Drug|Dovitinib|"Dose Level 0: 200 mg daily~Dose Level 1: 300 mg daily~Dose Level 2: 300 mg daily~Dose Level 3: 400 mg daily~Dose Level 4: 500 mg daily"
330167|NCT01680796|Drug|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8~Dose Level 1: 1.3 mg/m2 IV on days 1 and 8~Dose Level 2: 1.6 mg/m2 IV on days 1 and 8~Dose Level 3: 1.6 mg/m2 IV on days 1 and 8~Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
330168|NCT01680796|Drug|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
330169|NCT01680783|Device|Non invasive ventilation using a helmet hyperbaric device|"Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.~If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay."
330170|NCT01680783|Other|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
330171|NCT01680757|Device|LARIAT Suture Delivery Device and Accessories|
330172|NCT01680744|Other|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
330173|NCT01680718|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
330174|NCT01680718|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
330175|NCT01680718|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
330176|NCT01680705|Other|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
330177|NCT01680692|Drug|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
330178|NCT01680692|Device|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
330179|NCT01680692|Device|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
330180|NCT01680679|Biological|Inactivated Trivalent Influenza Vaccine (TIV)|
330181|NCT01680679|Biological|Inactivated poliovirus vaccine (IPV), trivalent|
330182|NCT01680666|Procedure|central line placement|central line placement
330183|NCT01680666|Device|Ultrasound|Ultrasound guided central venous access
330184|NCT01680653|Drug|Mini-glucagon|Mini dose glucagon given for glucose <70 mg/dl at a dose of 1unit/year of age
330185|NCT01680653|Device|Remote monitoring|Provides real-time continuous glucose monitoring
330186|NCT01680653|Dietary Supplement|Carbohydrates|16 grams of carbohydrate
330187|NCT01680640|Dietary Supplement|Synbiotic|The synbiotic to be used is fructo-oligosachharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
330188|NCT01680640|Dietary Supplement|Maltodextrin|
330189|NCT01680627|Behavioral|CASI|
330190|NCT01680614|Behavioral|CASI|
330191|NCT01680601|Procedure|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
330192|NCT01680601|Procedure|Placebo|
330193|NCT01680588|Drug|[18F]NAV4694|
330194|NCT01680562|Other|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
330195|NCT01680549|Drug|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
330196|NCT01680536|Drug|maraviroc|
330197|NCT01680523|Procedure|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
330198|NCT01680523|Radiation|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
330199|NCT01680523|Radiation|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
330200|NCT01680510|Dietary Supplement|Alga Dunaliella Bardawil|
330201|NCT01680510|Other|Placebo (starch)|
330202|NCT01680497|Device|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
330203|NCT01680484|Dietary Supplement|Bitter chocolate|
330204|NCT01680484|Dietary Supplement|Orange juice|
330205|NCT01680471|Drug|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
330206|NCT01680471|Drug|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
330207|NCT01680471|Drug|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
330208|NCT01680458|Drug|Fluconazole|"Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended."
330209|NCT01680432|Dietary Supplement|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
330210|NCT01680432|Dietary Supplement|Regular Cheese|
330211|NCT01680419|Behavioral|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
330212|NCT01680419|Behavioral|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
330213|NCT01680406|Drug|Artemether-lumefantrine combination|
330214|NCT01680406|Drug|Primaquine|
330215|NCT01680406|Drug|Chloroquine|
330216|NCT01680393|Device|Sequential compression device|a sequential compression device will be applied to the legs
330217|NCT01680393|Other|TED stockings|TED stockings will be applied to the patients legs during surgery
330218|NCT01680367|Procedure|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
330219|NCT01680367|Procedure|wound care management|Receive native collagen wound dressing
330220|NCT01680367|Other|questionnaire administration|Ancillary studies
330221|NCT01680354|Procedure|ReLEx|
330222|NCT01680354|Procedure|LASIK|
330223|NCT01680341|Drug|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
330224|NCT01680341|Drug|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
330225|NCT01680328|Other|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
330226|NCT01680328|Drug|sodium chloride 0.9% solution|Solution for injection.
330227|NCT01680315|Behavioral|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
330228|NCT01680315|Behavioral|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
330229|NCT01680302|Behavioral|High intensity exercise|
330230|NCT01680302|Behavioral|Moderate intensity exercise|
330231|NCT01680302|Behavioral|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
330232|NCT01680289|Procedure|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
330233|NCT01680289|Procedure|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
330320|NCT01679587|Drug|Placebo|Single oral dose of matching placebo will be given in each treatment arm
330234|NCT01680276|Behavioral|PBS based staff training|"Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219"
330235|NCT01680276|Other|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
330236|NCT01680263|Device|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
330237|NCT01680263|Procedure|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
330238|NCT01680250|Drug|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
330239|NCT01680237|Behavioral|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
330240|NCT01680237|Behavioral|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
330241|NCT01680224|Behavioral|Healthy Weight|
330242|NCT01680224|Behavioral|Project Health|
330243|NCT01680224|Behavioral|Placebo Control|Participants will view a video on overweight and obesity
330244|NCT01680211|Dietary Supplement|Salacia bark extract|
330245|NCT01680211|Dietary Supplement|Salacia leaf extract|
330246|NCT01680211|Dietary Supplement|Sesame seed extract|
330247|NCT01680211|Behavioral|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
330248|NCT01680211|Other|Placebo|
330249|NCT01680198|Drug|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
330250|NCT01680198|Drug|placebo|
330251|NCT01680185|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
330252|NCT01680185|Drug|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
330253|NCT01680185|Other|Standard of care|all covered above
330254|NCT01680172|Drug|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
330255|NCT01680172|Drug|Placebo|Single dose of liquid placebo solution taken by mouth
330256|NCT01680159|Drug|TA-650|
330257|NCT01680146|Dietary Supplement|PRO+FAT|
330258|NCT01680146|Dietary Supplement|PRO|
330259|NCT01680133|Other|Hyperinsulinemic euglycemic clamp|
330260|NCT01680120|Procedure|Continuous spinal anaesthesia|"Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.~Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.~Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12)."
330261|NCT01680107|Drug|d-cycloserine|
330262|NCT01680107|Drug|placebo|
330263|NCT01680107|Behavioral|cognitive-behaviour therapy|
330264|NCT01680094|Drug|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
330265|NCT01680081|Other|Adenosine stress dynamic CT perfusion|
330266|NCT01680068|Procedure|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
330267|NCT01680042|Drug|Phenytoin paste|
330268|NCT01680042|Drug|Placebo|
330269|NCT01680029|Device|PBASE-system 2.0|
330270|NCT01680016|Biological|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
330271|NCT01680016|Biological|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
330272|NCT01680003|Drug|Hepar-P|
330273|NCT01680003|Drug|Placebo for Hepar-P|
330274|NCT01679990|Biological|PLX-PAD Low dose|
330275|NCT01679990|Biological|PLX-PAD high doses|
330276|NCT01679990|Biological|Double Placebo|
330277|NCT01679990|Biological|high dose +Placebo|
330278|NCT01679977|Device|Vibrational-proprioceptive Resistance Exercise Training|
330279|NCT01679977|Device|Neuromuscular Electrical Stimulation Training|
330280|NCT01679964|Drug|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
330281|NCT01679951|Drug|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
330282|NCT01679951|Drug|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
330283|NCT01679951|Drug|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
330284|NCT01679951|Drug|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
330285|NCT01679951|Drug|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
330321|NCT01679574|Drug|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
330322|NCT01679574|Drug|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
331332|NCT01671488|Drug|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
330286|NCT01679938|Behavioral|primary obesity prevention|"Training of child care providers.~Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.~Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.~Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
330287|NCT01679912|Other|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
330288|NCT01679899|Drug|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
330289|NCT01679899|Drug|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
330290|NCT01679886|Radiation|Rubidium PET|Rubidium PET
330291|NCT01679873|Other|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
330292|NCT01679860|Procedure|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:~CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).~HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest~Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
330293|NCT01679860|Drug|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:~CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
330294|NCT01679821|Other|A questionnaire and a clinical examination|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
330295|NCT01679795|Drug|Tibolone|
330296|NCT01679795|Drug|Placebo|
330297|NCT01679756|Procedure|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
330298|NCT01679743|Drug|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
330299|NCT01679743|Drug|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
330300|NCT01679717|Other|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
330301|NCT01679704|Dietary Supplement|Food products|
330302|NCT01679691|Other|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
330303|NCT01679678|Device|PolyHeal 2|PolyHeal is a sterile medical device
330304|NCT01679678|Device|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
330305|NCT01679665|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
330306|NCT01679665|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
330307|NCT01679652|Drug|Nebivolol|Tablet i blinded in capsula
330308|NCT01679652|Drug|placebo|
330309|NCT01679639|Drug|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
330310|NCT01679639|Drug|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
330311|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
330312|NCT01679613|Drug|Nintedanib|low dose oral administration
330313|NCT01679613|Drug|Ketoconazole|oral administration
330314|NCT01679613|Drug|Nintedanib|low dose oral administration
330315|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
330316|NCT01679613|Drug|Ketoconazole|oral administration
330317|NCT01679600|Device|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
330318|NCT01679600|Device|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
330319|NCT01679587|Drug|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
330323|NCT01679574|Drug|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
330324|NCT01679561|Drug|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
330325|NCT01679548|Procedure|Single-port LAVH|
330326|NCT01679548|Procedure|Three-port LAVH|
330327|NCT01679535|Behavioral|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
330328|NCT01679522|Procedure|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
330329|NCT01679522|Procedure|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
330330|NCT01679509|Procedure|Single-port laparoscopic adnexal surgery|
330331|NCT01679509|Procedure|Three-port laparoscopic adnexal surgery|
330332|NCT01679496|Other|Food items|Food items with different fatty acid composition
330333|NCT01679483|Drug|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
330334|NCT01679470|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
330335|NCT01679457|Behavioral|ACT-Focused ERP|
330336|NCT01679457|Behavioral|TAU-ERP|
330337|NCT01679444|Procedure|Magnetic Resonance Spectroscopy|
330338|NCT01679431|Diagnostic Test|Doppler-echocardiography|
330339|NCT01679431|Radiation|Computed tomography|
330340|NCT01679431|Other|Magnetic resonance imaging|
330341|NCT01679431|Biological|Fasting blood sample|
330342|NCT01679418|Device|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
330343|NCT01679418|Other|No-drain after surgery|After surgery, no drain was put
330344|NCT01679405|Drug|BIBW 2992|once daily per os
330345|NCT01679392|Drug|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
330346|NCT01679379|Procedure|Absorbable suture group|Skin is closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture]
330347|NCT01679379|Procedure|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
330348|NCT01679366|Drug|Placebo|1 tablet 2 times daily
330349|NCT01679366|Drug|Probiotics|1 tablet twice daily
330350|NCT01679353|Drug|caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
330351|NCT01679353|Drug|normal saline 0.5ml|
330352|NCT01679340|Drug|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
330353|NCT01679340|Drug|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
330354|NCT01679340|Drug|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
330355|NCT01679327|Drug|Oxaliplatin|
330356|NCT01679327|Drug|Xeloda|
330357|NCT01679327|Drug|Calcium folinate (CF)|
330358|NCT01679327|Drug|5-FU|
330359|NCT01679327|Drug|Bevacizumab|
330360|NCT01679314|Device|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
330361|NCT01679301|Device|Pulse Dose (Sleep Mode)|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
330362|NCT01679301|Device|Continuous Dose|SimplyGo Portable Oxygen Concentrator has two different modes of use 'Sleep Mode', or pulsed oxygen and continuous dose.
330363|NCT01679288|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
330364|NCT01679275|Other|measuring cerebral oxygenation|
330365|NCT01679262|Device|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
330366|NCT01679236|Behavioral|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
330367|NCT01679236|Behavioral|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
330368|NCT01679210|Behavioral|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
330369|NCT01679197|Drug|Metreleptin|
330370|NCT01679158|Device|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:~A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
330409|NCT01678924|Drug|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
331491|NCT01670110|Drug|Placebo|To be injected once per month
330371|NCT01679132|Device|BAROSTIM NEO System and Medical Management|"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers— non-Dihydropyridines; Calcium channel blockers— Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
330372|NCT01679119|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
330373|NCT01679119|Drug|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
330374|NCT01679119|Drug|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
330375|NCT01679119|Drug|Rituximab|Rituximab 375mg/m2 IV given day 1
330376|NCT01679119|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
330377|NCT01679119|Drug|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
330378|NCT01679106|Other|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
330379|NCT01679106|Other|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
330380|NCT01679093|Drug|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
330381|NCT01679093|Drug|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
330382|NCT01679093|Drug|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
330383|NCT01679080|Drug|Zoledronic acid|antiresorptive and calcium and vitamin D
330384|NCT01679080|Drug|Teriparatide|anabolic and calcium and vitamin D
330385|NCT01679080|Other|No active treatment|Calcium and vitamin D
330386|NCT01679067|Procedure|colonoscopy with endoscopic biopsies|
330387|NCT01679041|Drug|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
330388|NCT01679041|Drug|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
330389|NCT01679041|Drug|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
330390|NCT01679028|Drug|T89 Group A|150mg single dose on day 1
330391|NCT01679028|Drug|Placebo Group A|150mg single dose
330392|NCT01679028|Drug|Placebo Group B|300mg single dose
330393|NCT01679028|Drug|T89 Group B|300mg single dose
330394|NCT01679028|Drug|Placebo Group C|225mg bid
330395|NCT01679028|Drug|T89 Group C|225mg bid
330396|NCT01679002|Drug|BIA 2-093|
330397|NCT01679002|Drug|Oxcarbazepine|
330398|NCT01678976|Drug|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
330399|NCT01678976|Drug|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
330400|NCT01678963|Drug|Squalamine lactate|Ophthalmic solution 0.2%
330401|NCT01678963|Drug|Vehicle control|Ophthalmic solution vehicle control
330402|NCT01678937|Procedure|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
330403|NCT01678937|Procedure|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
330404|NCT01678937|Procedure|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
330405|NCT01678937|Procedure|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
330406|NCT01678937|Procedure|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
330407|NCT01678937|Procedure|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:~Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).~Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).~HLA microchimerism & HLA G"
330408|NCT01678924|Drug|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
331719|NCT01668264|Procedure|Echocardiograph|
330410|NCT01678911|Drug|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
330411|NCT01678898|Drug|PRX-102|
330412|NCT01678885|Behavioral|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
330413|NCT01678885|Other|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
330414|NCT01678885|Device|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
330415|NCT01678885|Behavioral|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
330416|NCT01678885|Device|Actical|The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
330417|NCT01678885|Device|Sensewear Armband|The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
330418|NCT01678872|Drug|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
330419|NCT01678846|Behavioral|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
330420|NCT01678820|Drug|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
330421|NCT01678820|Drug|Sitagliptin|Sitagliptin 100 mg tablet
330422|NCT01678820|Drug|Simvastatin|Simvastatin 40 mg tablet
330423|NCT01678820|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
330424|NCT01678820|Drug|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
330425|NCT01678820|Drug|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
330426|NCT01678820|Drug|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of >= 1500 mg for at least 12 weeks prior to randomization and during the study
330427|NCT01678820|Drug|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
330428|NCT01678807|Biological|MK-8237 6 DU|
330429|NCT01678807|Biological|MK-8237 12 DU|
330430|NCT01678807|Biological|Placebo|
330431|NCT01678794|Drug|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
330432|NCT01678794|Drug|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
330433|NCT01678755|Drug|ABT-126|ABT-126 Low Dose
330434|NCT01678755|Drug|ABT-126|ABT-126 High Dose
330435|NCT01678755|Drug|Placebo|Placebo
330436|NCT01678742|Dietary Supplement|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.~A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
330437|NCT01678742|Dietary Supplement|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
330438|NCT01678716|Behavioral|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
330439|NCT01678716|Dietary Supplement|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
330440|NCT01678716|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
330441|NCT01678703|Device|Laminaria, MedGyn Products, Inc. USA.|Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
330442|NCT01678703|Drug|Misoprostol|Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
330443|NCT01678690|Drug|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
331720|NCT01668264|Procedure|Magnetic Resonance Imaging (MRI)|
330444|NCT01678677|Biological|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330445|NCT01678677|Biological|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330446|NCT01678677|Biological|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330447|NCT01678677|Biological|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330448|NCT01678677|Biological|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330449|NCT01678677|Biological|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330450|NCT01678677|Biological|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330451|NCT01678677|Biological|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330452|NCT01678677|Drug|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
330453|NCT01678664|Drug|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
330454|NCT01678664|Device|embolization|2 sessions embolization with spheric particles
330455|NCT01678664|Drug|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
330456|NCT01678651|Procedure|Stimulation with human FSH|Human FSH
330457|NCT01678651|Procedure|Stimulation with recombinant FSH|Recombinant FSH
330458|NCT01678638|Procedure|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
330459|NCT01678638|Procedure|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed between 55-60 weeks post-menstrual age.
330460|NCT01678625|Device|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
330461|NCT01678612|Other|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
330462|NCT01678599|Drug|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients > 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
330463|NCT01678586|Other|Acupuncture|In true acupuncture the needles penetrate the skin.
330464|NCT01678586|Other|Sham Acupuncture|In sham acupuncture the needles do not penetrate the skin.
330465|NCT01678586|Drug|Gabapentin|Gabapentin is a commonly prescribed drug used to treat neuropathic pain.
330466|NCT01678586|Drug|Sham Gabapentin|Benadryl or diphenhydramine is used as a placebo as it could mimic some common side effects of gabapentin (i.e. sedation, drowsiness, lightheadedness)
330467|NCT01678573|Drug|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
330468|NCT01678573|Drug|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
330469|NCT01678573|Drug|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
330470|NCT01678560|Device|Monitoring every 3 months by face-to-face visits|
330471|NCT01678560|Device|Frequent remote monitoring|
330472|NCT01678547|Device|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
330473|NCT01678547|Device|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
330474|NCT01678547|Other|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
330475|NCT01678534|Drug|Allogenic mesenchymal stem cells from adipose tissue|
330476|NCT01678534|Drug|Placebo|
330477|NCT01678521|Procedure|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
330478|NCT01678495|Other|Sulfur hexafluoride + ultrasounds|
330479|NCT01678495|Drug|Recombinant tissue plasminogen activator|
330480|NCT01678482|Device|light based device for treatment of acne|
330481|NCT01678469|Other|blood sample|
330482|NCT01678443|Biological|indium In 111 anti-CD45 monoclonal antibody BC8|Given IV
330483|NCT01678443|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
330484|NCT01678443|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
330485|NCT01678430|Drug|Ofatumumab|
330486|NCT01678430|Drug|Chlorambucil|
330487|NCT01678430|Drug|Bendamustine|
330488|NCT01678417|Drug|131I-rituximab|
330489|NCT01678404|Drug|131I-rituximab|
330490|NCT01678391|Procedure|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
330575|NCT01677650|Drug|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
330491|NCT01678378|Behavioral|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
330492|NCT01678365|Drug|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
330493|NCT01678352|Biological|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
330494|NCT01678352|Drug|Imiquimod|Cohort 1 Cohort 2 Cohort 3
330495|NCT01678326|Procedure|EUS-Rendezvous or direct intervention|
330496|NCT01678326|Procedure|Advanced ERCP Biliary Access Techniques|
330497|NCT01678313|Drug|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
330498|NCT01678313|Drug|Doxazosin 4 mg every day (QD)|Control group
330499|NCT01678287|Drug|ASP1941|oral
330500|NCT01678287|Drug|Placebo|oral
330501|NCT01678235|Drug|Insulin glulisine|
330502|NCT01678235|Drug|Insulin aspart|
330503|NCT01678209|Other|fMRI scans|2 fMRI scans 6-8 weeks apart
330504|NCT01678209|Drug|Atomoxetine arm|Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
330505|NCT01678209|Drug|Methylphenidate arm|Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
330506|NCT01678196|Behavioral|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
330507|NCT01678196|Other|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
330508|NCT01678183|Behavioral|Monthly Financial Incentive|A cash payment.
330509|NCT01678183|Behavioral|Final Financial Incentive|One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
330510|NCT01678144|Device|Mitral valve repair using the Medtentia Annuloplasty Ring (MAR)|
330511|NCT01678131|Drug|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
330512|NCT01678131|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
330513|NCT01678131|Biological|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
330514|NCT01678131|Procedure|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
330515|NCT01678131|Drug|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
330516|NCT01678131|Procedure|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
330517|NCT01678118|Behavioral|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder & to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs & barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
330518|NCT01678105|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal
330519|NCT01678092|Biological|omalizumab|
330520|NCT01678079|Dietary Supplement|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
330521|NCT01678079|Dietary Supplement|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
330522|NCT01678066|Device|Bilateral cardiac output|
330523|NCT01678053|Drug|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
330524|NCT01678053|Drug|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
330525|NCT01678027|Drug|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
330526|NCT01678027|Drug|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
330527|NCT01678014|Procedure|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
330528|NCT01678014|Procedure|Capsulotomy|
330529|NCT01678001|Drug|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
330576|NCT01677624|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
330817|NCT01675570|Drug|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
330530|NCT01677988|Drug|Neo-adjuvant Chemotherapy|"Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.~Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)~Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.~Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
330531|NCT01677988|Radiation|Chemoradiation|"Chemoradiation may be administered at selected approved CTN sites.~Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.~Unresectable → Off study. Subsequent treatment per patient's primary MD.~Resectable → Continue to Registration #3 for Surgical Resection"
330532|NCT01677988|Procedure|Surgical Resection|"Meets criteria for resectable* →pancreaticoduodenectomy (POD)~At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
330533|NCT01677975|Procedure|FNA (fine needle aspiration)|
330534|NCT01677962|Biological|Poly-ICLC|
330535|NCT01677962|Biological|dendritic cell|
330536|NCT01677949|Drug|Clofarabine|Days 1-5: Clofarabine 30 mg/m^2 for 0-30 years of age or 20 mg/m^2 for > 30 years of age intravenously (IV) over 2 hours
330537|NCT01677949|Drug|Etoposide|Days 1-5: Etoposide 100mg/m^2 IV over 2 hours
330538|NCT01677949|Drug|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m^2 as a 30-60 minute infusion
330539|NCT01677949|Biological|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
330540|NCT01677936|Other|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
330541|NCT01677936|Other|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
330542|NCT01677923|Drug|Metformin|Metformin 500 mg BID for 12 months
330543|NCT01677910|Drug|Telotristat etiprate|Telotristat etiprate tablets.
330544|NCT01677910|Drug|Placebo-matching telotristat etiprate|Placebo-matching telotristat etiprate tablets.
330545|NCT01677897|Drug|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
330546|NCT01677884|Drug|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
330547|NCT01677884|Drug|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
330548|NCT01677884|Drug|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
330549|NCT01677871|Drug|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
330550|NCT01677871|Drug|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
330551|NCT01677871|Drug|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
330552|NCT01677871|Drug|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
330553|NCT01677858|Drug|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
330554|NCT01677858|Drug|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
330555|NCT01677845|Radiation|Radiation|"Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;~Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions."
330556|NCT01677806|Procedure|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
330557|NCT01677806|Other|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
330558|NCT01677780|Drug|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m^2) to 1800 mg/m^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
330559|NCT01677754|Drug|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
330560|NCT01677754|Drug|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
330561|NCT01677754|Drug|Donepezil|Stable dose as background medication
330562|NCT01677754|Drug|Memantine|Stable dose as background medication in combination with AChEIs
330563|NCT01677754|Drug|Rivastigmine|Stable dose as background medication
330564|NCT01677754|Drug|Galantamine|Stable dose as background medication
330565|NCT01677741|Drug|Dabrafenib|Dabrafenib is available as 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
330566|NCT01677715|Dietary Supplement|"Yili Mei Yi Tian active lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
330567|NCT01677715|Dietary Supplement|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
330568|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
330569|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
330570|NCT01677702|Dietary Supplement|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
330571|NCT01677689|Drug|Apomivir®|Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
330572|NCT01677689|Drug|Placebo|Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
330573|NCT01677676|Biological|FP-01.1|IM injection
330574|NCT01677676|Biological|FP-01.1-Adjuvant|IM injection
330577|NCT01677611|Drug|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
330578|NCT01677611|Drug|Placebo|
330579|NCT01677598|Drug|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
330580|NCT01677572|Drug|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
330581|NCT01677572|Drug|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 112 doses.
330582|NCT01677559|Drug|MLN8237|
330583|NCT01677559|Drug|nab-Paclitaxel|
330584|NCT01677546|Device|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
330585|NCT01677546|Device|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
330586|NCT01677533|Other|Data|The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
330587|NCT01677533|Other|Panel Management Support|PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
330588|NCT01677533|Other|Education|The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
330589|NCT01677507|Drug|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
330590|NCT01677468|Procedure|Intermediate embolization|TACE with substasis using gelfoam
330591|NCT01677468|Procedure|Complete embolization|TACE with complete embolization using gelfoam
330592|NCT01677455|Drug|ganetespib|Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
330593|NCT01677442|Procedure|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
330594|NCT01677442|Procedure|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
330595|NCT01677429|Device|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
330596|NCT01677429|Device|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
330597|NCT01677429|Behavioral|Cognitive Behavioral Therapy|For the treatment of panic disorder
330598|NCT01677403|Drug|Tobramycin|Nebulised 80mg twice daily
330599|NCT01677403|Drug|Saline|Nebulised 5mls 0.9% Saline twice daily
330600|NCT01677390|Drug|SGN-75|1-2 mg/kg IV every 21 days
330601|NCT01677390|Drug|everolimus|10 mg PO daily
330602|NCT01677377|Drug|Risperidone|Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
330603|NCT01677377|Drug|RBP-7000|RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
330604|NCT01677364|Drug|Oxytocin|Arm - Induction of labour
330605|NCT01677351|Drug|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
330606|NCT01677351|Drug|placebo|
330607|NCT01677338|Drug|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
330608|NCT01677338|Drug|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
330609|NCT01677325|Drug|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
330610|NCT01677312|Procedure|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
330874|NCT01675115|Drug|BNG-1|BNG-1 3 grams TID for 4 weeks
330875|NCT01675115|Drug|Aspirin|Aspirin 100 mg QD for 4 weeks
330611|NCT01677312|Procedure|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
330612|NCT01677299|Drug|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
330613|NCT01677299|Drug|EFB0026 (metformin immediate-release)|Active comparator
330614|NCT01677286|Drug|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
330615|NCT01677273|Dietary Supplement|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
330616|NCT01677273|Dietary Supplement|Intact casein|30 g protein/supplement, 4 supplements/visit
330617|NCT01677273|Dietary Supplement|Intact whey protein|30 g protein/supplement, 4 supplements/visit
330618|NCT01677260|Drug|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
330619|NCT01677260|Drug|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
330620|NCT01677247|Drug|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
330621|NCT01677247|Drug|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
330622|NCT01677221|Device|Acleara Acne Treatment System|
330623|NCT01677208|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
330624|NCT01677208|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
330625|NCT01677208|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
330626|NCT01677195|Drug|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
330627|NCT01677195|Drug|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
330628|NCT01677182|Drug|Ramelteon|Ramelteon tablets for sublingual administration
330629|NCT01677182|Drug|Placebo|Ramelteon placebo-matching tablets for sublingual administration
330630|NCT01677169|Dietary Supplement|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
330631|NCT01677169|Dietary Supplement|Placebo|
330632|NCT01677156|Diagnostic Test|CORUS CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
330633|NCT01677143|Drug|Bupivacaine 5mg/ml|5 ml in trocar area
330634|NCT01677104|Drug|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
330635|NCT01677104|Drug|Placebo|
330636|NCT01677091|Other|Cervical vibration|Vibration of neck muscles during 10 minutes
330637|NCT01677091|Other|Prism adaptation|Prism adaptation during 10 minutes
330638|NCT01677091|Other|Conventional rehabilitation|conventional rehabilitation
330639|NCT01677078|Device|Neuronavigation system|Neuronavigation
330640|NCT01677078|Device|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
330641|NCT01677065|Drug|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
330642|NCT01677065|Drug|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
330643|NCT01677039|Drug|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
330644|NCT01677039|Drug|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
330645|NCT01677039|Drug|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
330646|NCT01677013|Other|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
330647|NCT01676987|Drug|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
330648|NCT01676987|Drug|Budesonide|Delivered dry powder inhaler for 12 weeks.
330649|NCT01676961|Biological|romiplostim|Given SC
330650|NCT01676948|Drug|ACZ885|
330651|NCT01676948|Drug|Canakinumab|
330652|NCT01676948|Drug|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.~Canakinumab-naïve patients"
330653|NCT01676948|Drug|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
330654|NCT01676935|Drug|ABT-126|See arm description
330692|NCT01676636|Drug|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
330922|NCT01674738|Drug|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
330655|NCT01676909|Behavioral|Living Well|This study will involve a clinical trial of Living Well (LW), a 12-session, peer co-led, group intervention designed to help veterans with co-occurring Serious Mental Illnesses and Chronic Medical Conditions learn techniques for better health management and ways to live a healthier lifestyle. Key topics that will be discussed are medication side effects, how symptoms of mental illness may affect veterans' ability to manage their medical conditions, effects of substance use on medical and mental health functioning, learning ways to eat healthier and exercise, and how to communicate more effectively with care providers. There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
330656|NCT01676909|Behavioral|Medical Illness Education & Support Group|The comparison condition will be a general Medical Illness Education and Support (MIES) group that will discuss common challenges experienced by those living with a wide range of chronic illnesses and behavioral and lifestyle management techniques that may help veterans to better handle chronic medical conditions that also meets for 12 weeks.
330657|NCT01676896|Behavioral|Asthma in-school class|
330658|NCT01676896|Behavioral|Asthma Day Camp|
330659|NCT01676896|Behavioral|Health Promotion in-school class|
330660|NCT01676883|Device|Bioelectric impedance|removal of calluses and corns by pedicure
330661|NCT01676883|Device|Air displacement plethysmography|
330662|NCT01676870|Behavioral|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
330663|NCT01676870|Behavioral|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
330664|NCT01676870|Behavioral|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
330665|NCT01676844|Drug|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
330666|NCT01676844|Drug|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
330667|NCT01676831|Drug|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
330668|NCT01676831|Drug|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
330669|NCT01676818|Drug|eribulin mesylate|Given IV
330670|NCT01676792|Drug|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon & before bed time. Medication should be reapply after bathing or cleaning.
330671|NCT01676779|Biological|Dendritic cell therapy|Dendritic cell therapy IV and ID
330672|NCT01676753|Drug|Dinaciclib|"Given IV.~Dose Level = DL~DL1-12 mg/m2~DL2-18 mg/m2~DL3-25 mg/m2~DL4-33 mg/m2~DL5-50 mg/m2"
330673|NCT01676753|Drug|Pembrolizumab|Given 200mg IV.
330674|NCT01676740|Drug|Iron Supplement,|Pills to be swallowed
330675|NCT01676740|Drug|Placebo|Daily administration of active drug or placebo
330676|NCT01676727|Device|CoreValve aortic valve|Implantation of CoreValve aortic valve via direct aortic approach
330677|NCT01676714|Drug|Dovitinib|
330678|NCT01676701|Drug|Tabalumab Auto-Injector|Administered SC by auto-injector
330679|NCT01676701|Drug|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
330680|NCT01676675|Biological|7.5μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
330681|NCT01676675|Biological|15.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
330682|NCT01676675|Biological|30.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
330683|NCT01676675|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 21 days interval
330684|NCT01676662|Device|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
330685|NCT01676662|Device|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
330686|NCT01676649|Biological|Ipilimumab|3 mg/kg
330687|NCT01676649|Drug|Carboplatin|AUC = 6
330688|NCT01676649|Drug|Paclitaxel|175 mg/m2
330689|NCT01676636|Drug|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
330690|NCT01676636|Drug|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
330691|NCT01676636|Drug|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
330810|NCT01675635|Drug|OxyNorm Capsules|dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
330693|NCT01676623|Behavioral|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
330694|NCT01676623|Behavioral|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
330695|NCT01676623|Behavioral|Mass media campaign|Alive & Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
330696|NCT01676597|Drug|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
330697|NCT01676597|Drug|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
330698|NCT01676584|Drug|RO6811135|single ascending doses sc
330699|NCT01676584|Drug|placebo|single doses sc
330700|NCT01676571|Drug|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
330701|NCT01676558|Drug|131I-rituximab|
330702|NCT01676532|Other|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
330703|NCT01676519|Procedure|PCI|percutaneous coronary intervention
330704|NCT01676506|Drug|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
330705|NCT01676506|Procedure|Ranibizumab Injection|
330706|NCT01676493|Drug|Codeine|
330707|NCT01676480|Behavioral|Endurance training|12 weeks of endurance training 3 times per week
330708|NCT01676441|Drug|cellgram-spine|Mesenchymal stem cells transplantation
330709|NCT01676428|Radiation|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.~For lesions <5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
330710|NCT01676415|Drug|Prednisone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days~Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study"
330711|NCT01676415|Drug|Topical mometasone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily~If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead~Antihistamines if an appropriate history of atopy is obtained~Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study."
330712|NCT01676402|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
330713|NCT01676402|Biological|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
330714|NCT01676389|Other|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
330715|NCT01676389|Other|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
330716|NCT01676376|Device|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
330717|NCT01676376|Other|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
330718|NCT01676363|Drug|Diflunisal|Open-label diflunisal 500 mg twice daily for 4 weeks
330719|NCT01676350|Procedure|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
330720|NCT01676337|Other|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
330721|NCT01676311|Drug|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
330722|NCT01676311|Drug|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
330723|NCT01676298|Device|Spartan FRX CYP2C19 Test System|
330724|NCT01676285|Drug|Metoprolol succinate|
330725|NCT01676285|Drug|placebo|
330726|NCT01676259|Drug|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
330727|NCT01676259|Drug|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
330728|NCT01676246|Drug|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
330729|NCT01676246|Drug|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
330730|NCT01676246|Drug|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
330811|NCT01675635|Other|Morphine tablet|dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
330812|NCT01675622|Drug|Oxycodone|dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
330813|NCT01675622|Drug|Morphine|Morphine tablets 10mg and 20mg, oral every 4-6 hours
330814|NCT01675609|Drug|Placebo|1 drop in each eye daily for up to 35 days
330815|NCT01675609|Drug|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
330731|NCT01676246|Procedure|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
330732|NCT01676246|Procedure|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).~During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
330733|NCT01676233|Drug|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
330734|NCT01676233|Drug|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
330735|NCT01676220|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
330736|NCT01676220|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
330737|NCT01676207|Procedure|Coronary Angiography with collateral flow measurements|"Diagnostic coronary angiography and LV angiography~Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~Right and left IMA CFI during a 1-minute ostial vessel occlusion~Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~IMA angiography (left and right) during distal IMA and coronary occlusion."
330738|NCT01676207|Procedure|Coronary Angiography with collateral flow measurements|"Diagnostic coronary angiography and LV angiography~Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate~Right and left IMA CFI during a 1-minute ostial vessel occlusion~Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.~IMA angiography (left and right) during distal IMA and coronary occlusion."
330739|NCT01676194|Other|Intra-arterial administration of DC BeadsR|
330740|NCT01676181|Procedure|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
330741|NCT01676181|Procedure|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
330742|NCT01676129|Procedure|Nocipoint Therapy|
330743|NCT01676129|Procedure|Physical Therapy|
330744|NCT01676116|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
330745|NCT01676116|Drug|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
330746|NCT01676116|Drug|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
330747|NCT01676103|Dietary Supplement|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
330748|NCT01676103|Other|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
330749|NCT01676064|Drug|ringer lactate solution|
330750|NCT01676064|Other|restrictive fluid regime|
330751|NCT01676051|Other|Skin culture|Culture swab used to culture skin adjacent to incision
330752|NCT01676038|Procedure|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
330753|NCT01676038|Procedure|Conventional Total Knee Arthroplasty|Conventional technique.
330754|NCT01676025|Procedure|PRA|
330755|NCT01676025|Procedure|LA|
330756|NCT01675999|Other|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
330757|NCT01675999|Other|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
330758|NCT01675999|Other|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
330759|NCT01675986|Drug|hydroxyzine|75 mg
330760|NCT01675986|Drug|Pregabalin|150 mg
330761|NCT01675986|Drug|Lactose|4 g
330762|NCT01675973|Drug|RANEXA|500mg BID up to 1000mg BID
330763|NCT01675960|Drug|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
330764|NCT01675960|Drug|placebo|The placebo is a glycerin-based clear solution that is flavored similarly to the commercial product. The placebo will be given orally or through a gastrointestinal tube.
330816|NCT01675596|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
330765|NCT01675947|Drug|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
330766|NCT01675947|Drug|Lidocaine|Lidocaine 2%
330767|NCT01675934|Procedure|Retroflexion with the adult colonoscope.|
330768|NCT01675934|Procedure|Retroflexion with the pediatric colonoscope.|
330769|NCT01675921|Other|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
330770|NCT01675908|Procedure|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
330771|NCT01675908|Procedure|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
330772|NCT01675895|Drug|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
330773|NCT01675895|Drug|levobupivacaine Spinal anesthesia|spinal anesthesia
330774|NCT01675882|Biological|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
330775|NCT01675882|Biological|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
330776|NCT01675882|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
330777|NCT01675882|Biological|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
330778|NCT01675869|Behavioral|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
330779|NCT01675869|Behavioral|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
330780|NCT01675856|Other|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
330781|NCT01675856|Other|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
330782|NCT01675843|Procedure|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
330783|NCT01675830|Device|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
330784|NCT01675804|Other|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
330785|NCT01675804|Drug|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
330786|NCT01675804|Other|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
330787|NCT01675791|Biological|ALK tree AIT 0.5 DU|
330788|NCT01675791|Biological|ALK tree AIT 1 DU|
330789|NCT01675791|Biological|ALK tree AIT 2 DU|
330790|NCT01675791|Biological|ALK tree AIT 4 DU|
330791|NCT01675791|Biological|ALK tree AIT 7 DU|
330792|NCT01675791|Biological|ALK tree AIT 12 DU|
330793|NCT01675791|Biological|ALK tree AIT Placebo|
330794|NCT01675778|Drug|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
330795|NCT01675765|Biological|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
330796|NCT01675765|Biological|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
330797|NCT01675739|Behavioral|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
330798|NCT01675739|Drug|polyethylene glycol (PEG)|"No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.~SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS"
330799|NCT01675726|Other|questionary on quality of life|
330800|NCT01675713|Behavioral|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
330801|NCT01675700|Drug|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
330802|NCT01675687|Behavioral|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
330803|NCT01675674|Other|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
330804|NCT01675661|Drug|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
330805|NCT01675661|Drug|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
330806|NCT01675648|Drug|Lofexidine|
330807|NCT01675648|Drug|Diazepam|
330808|NCT01675648|Drug|Placebo for Lofexidine|
330809|NCT01675648|Drug|Placebo for Diazepam|
331333|NCT01671488|Drug|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
330818|NCT01675570|Drug|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
330819|NCT01675557|Dietary Supplement|Vitamin D3|a single oral dose of vitamin D3
330820|NCT01675557|Dietary Supplement|Vitamin D2|a single oral dose of vitamin D2
330821|NCT01675557|Dietary Supplement|Placebo|a single oral dose of placebo
330822|NCT01675544|Procedure|Electrocardiogram|EKG voltage changes between admission and discharge
330823|NCT01675544|Procedure|Six minute walk test|
330824|NCT01675531|Drug|Targin|Single arm for Targin
330825|NCT01675518|Drug|ASP7991|oral
330826|NCT01675518|Drug|Placebo|oral
330827|NCT01675492|Device|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
330828|NCT01675479|Device|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
330829|NCT01675466|Procedure|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
330830|NCT01675466|Procedure|General anaesthesia|
330831|NCT01675466|Device|Laparoscopic instruments|
330832|NCT01675453|Drug|7.2% NaCl plus 6% hydroxyethyl starch 200/0.5|
330833|NCT01675453|Drug|0.9% NaCl|
330834|NCT01675440|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
330835|NCT01675427|Other|Interleukin 28B testing|Blood sampling for ILB28 genotyping
330836|NCT01675414|Other|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
330837|NCT01675401|Other|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
330838|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
330839|NCT01675388|Other|Hypothermia|Hypothermia to 33.5 deg C
330840|NCT01675375|Device|Eye Shield|one application following refractive surgery
330841|NCT01675362|Drug|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
330842|NCT01675362|Drug|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
330843|NCT01675362|Drug|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
330844|NCT01675362|Drug|Placebo|They will receive placebo
330845|NCT01675349|Biological|Prick test Chenopodium album allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
330846|NCT01675310|Drug|medical nutrition therapy + metformin|
330847|NCT01675310|Behavioral|Medical nutrition therapy|medical nutrition therapy
330848|NCT01675297|Drug|Risedronate/Cholecalciferol combination|Risendronate/Cholecalciferol combination once a week
330849|NCT01675297|Drug|Risedronate|Risedronate once a week
330850|NCT01675284|Biological|AT-301|Inactivated H5N1 Influenza Virion Vaccine
330851|NCT01675271|Other|individual exercise|individual exercise and dietary prescription
330852|NCT01675271|Other|general exercise|general exercise counselling
330853|NCT01675258|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
330854|NCT01675245|Drug|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
330855|NCT01675232|Other|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
330856|NCT01675232|Other|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
330857|NCT01675219|Procedure|white light TUR-BT|traditional transurethral bladder tumor resection
330858|NCT01675219|Procedure|blue light TUR-BT|photodynamic transurethral bladder tumor resection
330859|NCT01675219|Drug|optimized MMC|six weekly optimized mitomycin-C instillations
330860|NCT01675219|Drug|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
330861|NCT01675206|Dietary Supplement|Vitamin K2 supplementation|
330862|NCT01675193|Behavioral|Disinvestment protocol|Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
330863|NCT01675180|Other|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
330864|NCT01675180|Other|Control|No intervention
330865|NCT01675167|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
330866|NCT01675167|Drug|Placebo|Matching Placebo Buccal Film twice daily
330867|NCT01675154|Drug|SLx-4090 placebo|
330868|NCT01675154|Drug|Orlistat Placebo|
330869|NCT01675154|Drug|Orlistat|
330870|NCT01675154|Drug|Slx-4090|
330871|NCT01675141|Drug|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
330872|NCT01675128|Drug|ISIS 183750|
330873|NCT01675128|Drug|Irinotecan|
330876|NCT01675089|Drug|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
330877|NCT01675076|Drug|Dabigatran|NOAC
330878|NCT01675076|Drug|Rivaroxaban|NOAC
330879|NCT01675076|Drug|Apixaban|NOAC
330880|NCT01675063|Device|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
330881|NCT01675050|Drug|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
330882|NCT01675050|Drug|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
330883|NCT01675037|Other|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
330884|NCT01675024|Drug|Rotigotine, Period 1|"Formulation: transdermal~Dosage: 2 mg / 24 hours once at Day 2~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
330885|NCT01675024|Drug|Rotigotine, Period 2|"Formulation: transdermal~Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12~Frequency: once every 24 hours~Duration: from Day 1 to Day 3"
330886|NCT01675011|Device|Embozene® Microspheres|
330887|NCT01675011|Device|Embosphere®|
330888|NCT01674985|Biological|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
330889|NCT01674972|Other|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
330890|NCT01674959|Radiation|concurrent chemoradiation|"postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
330891|NCT01674946|Other|saline|intraduodenal perfusion
330892|NCT01674946|Other|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
330893|NCT01674946|Other|oleanolic acid|intraduodenal perfusion
330894|NCT01674946|Dietary Supplement|oleic acid|intraduodenal perfusion
330895|NCT01674933|Drug|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
330896|NCT01674933|Behavioral|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
330897|NCT01674920|Behavioral|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
330898|NCT01674881|Other|Mindfulness-Based Cognitive Therapy|"MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).~Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD."
330899|NCT01674881|Other|Waitlist|Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
330900|NCT01674868|Drug|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
330901|NCT01674868|Drug|placebo|subjects will take one pill po daily for 90 days.
330902|NCT01674855|Drug|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
330903|NCT01674855|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
330904|NCT01674842|Radiation|Radiation Therapy|Once daily, Monday - Friday for six weeks
330905|NCT01674842|Drug|Cisplatin|Intravenously, once weekly for six weeks
330906|NCT01674829|Biological|MA09-hRPE|
330907|NCT01674816|Device|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
330908|NCT01674816|Device|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
330909|NCT01674803|Device|Orsiro|biodegradable polymer sirolimus eluting stent
330910|NCT01674803|Device|Synergy|biodegradable polymer everolimus eluting stent
330911|NCT01674803|Device|Resolute Integrity|durable polymer zotarolimus-eluting stent
330912|NCT01674790|Behavioral|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
330913|NCT01674790|Behavioral|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
330914|NCT01674790|Behavioral|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
330915|NCT01674790|Behavioral|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
330916|NCT01674777|Drug|ASP1941|oral
330917|NCT01674764|Procedure|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
330918|NCT01674764|Procedure|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
330919|NCT01674751|Other|Pre-ordering program|"During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time."
330920|NCT01674738|Drug|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
330921|NCT01674738|Drug|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
330923|NCT01674725|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
330924|NCT01674725|Drug|Ribavirin|Tablet
330925|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
330926|NCT01674712|Drug|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
330927|NCT01674712|Drug|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
330928|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
330929|NCT01674712|Drug|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
330930|NCT01674699|Device|EXCOR Pediatric|Ventricular Assist Device
330931|NCT01674686|Drug|Sarpogrelate|Sarpogrelate 100mg twice a day
330932|NCT01674686|Drug|Atorvastatin|Atorvastatin 80mg daily
330933|NCT01674647|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
330934|NCT01674647|Drug|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
330935|NCT01674634|Biological|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent [0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride])
330936|NCT01674621|Drug|BA058 Placebo|BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months
330937|NCT01674621|Drug|BA058 Transdermal (50 mcg)|BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months
330938|NCT01674621|Drug|BA058 Transdermal (100 mcg)|BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months
330939|NCT01674621|Drug|BA058 Transdermal (150 mcg)|BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months
330940|NCT01674621|Drug|BA058 Injection (80 mcg)|BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months
330941|NCT01674595|Biological|AVANZ olea|Immunotherapy Olea europaea
330942|NCT01674582|Other|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.~Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
330943|NCT01674569|Drug|X-82 oral|X-82 oral for 24 weeks or until unacceptable toxicity develops
330944|NCT01674569|Drug|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
330945|NCT01674556|Drug|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
330946|NCT01674543|Other|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
330947|NCT01674543|Other|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
330948|NCT01674543|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
330949|NCT01674530|Drug|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
330950|NCT01674530|Drug|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
330951|NCT01674530|Drug|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
330952|NCT01674517|Drug|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
330953|NCT01674504|Drug|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
330954|NCT01674491|Dietary Supplement|black soy peptide|black soy peptide: 4.5g/day for 8 weeks
330955|NCT01674478|Dietary Supplement|Microlipid with fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
330956|NCT01674478|Dietary Supplement|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
331090|NCT01673503|Device|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
331875|NCT01666951|Drug|LCP-Tacro tablets|Tacrolimus
330957|NCT01674465|Biological|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m^2 two-three hours prior to their standard of care biopsy
330958|NCT01674452|Behavioral|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
330959|NCT01674452|Behavioral|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
330960|NCT01674439|Procedure|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
330961|NCT01674439|Procedure|Without supplementation of ADRC|Standard fat graft preparation
330962|NCT01674426|Behavioral|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
330963|NCT01674413|Drug|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
330964|NCT01674413|Drug|Adalimumab PRN|"160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is < 167 mcg/gram of stool."
330965|NCT01674413|Drug|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
330966|NCT01674387|Device|acupuncture|30 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
330967|NCT01674387|Other|comprehensive treatment|Other 30 patients (the matched group) receive the comprehensive treatment, including traction and low-frequency therapy. Each treatment 15 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
330968|NCT01674387|Device|electro acupuncture|
330969|NCT01674387|Device|traction|
330970|NCT01674387|Device|low-frequency therapy.|
330971|NCT01674374|Other|placebo|Given PO
330972|NCT01674374|Procedure|quality-of-life assessment|Ancillary studies
330973|NCT01674374|Other|questionnaire administration|Ancillary studies
330974|NCT01674374|Drug|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
330975|NCT01674361|Drug|Bitopertin|Bitopertin once daily orally.
330976|NCT01674361|Drug|Placebo|Placebo matched to bitopertin once daily orally.
330977|NCT01674361|Drug|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
330978|NCT01674348|Drug|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
330979|NCT01674348|Drug|Placebo|Placebo
330980|NCT01674335|Behavioral|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
330981|NCT01674335|Behavioral|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).~This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
330982|NCT01674322|Drug|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
330983|NCT01674309|Drug|FOLFORINOX|INTRAVENOUS administration
330984|NCT01674283|Drug|Glucagon|
330985|NCT01674283|Drug|placebo|
330986|NCT01674270|Drug|Degarelix|
330987|NCT01674270|Drug|Casodex|
330988|NCT01674270|Drug|LHRH Agonist|
330989|NCT01674257|Other|USPIO (ferumoxytol)-enhanced MRI scan|Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.
330990|NCT01674257|Radiation|18f-Fluoride PET/CT scan|
330991|NCT01674257|Radiation|18F-Flurodeoxyglucose PET/CT scan|
330992|NCT01674244|Behavioral|Integrative Exercise|
330993|NCT01674244|Behavioral|Monitor Only Waitlist|
330994|NCT01674231|Other|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
330995|NCT01674231|Other|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
331876|NCT01666951|Drug|Prograf|Tacrolimus
330996|NCT01674218|Drug|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
330997|NCT01674218|Drug|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
330998|NCT01674218|Other|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
330999|NCT01674205|Biological|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
331000|NCT01674205|Biological|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
331001|NCT01674205|Biological|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
331002|NCT01674205|Biological|Vaccine placebo (Leibovitz-15 [L-15])|
331003|NCT01674205|Biological|Vaccine placebo (FluMist®)|
331004|NCT01674192|Drug|prucalopride|single dose of 2 mg prucalopride
331005|NCT01674166|Drug|prucalopride|single dose 0.03 mg/kg prucalopride open label
331006|NCT01674153|Procedure|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
331007|NCT01674140|Drug|anastrozole|Given orally
331008|NCT01674140|Drug|everolimus|Given PO
331009|NCT01674140|Drug|exemestane|Given orally
331010|NCT01674140|Drug|goserelin acetate|Given subcutaneously or intramuscularly
331011|NCT01674140|Drug|letrozole|Given orally
331012|NCT01674140|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
331013|NCT01674140|Drug|tamoxifen citrate|Given PO
331014|NCT01674140|Other|placebo|Given PO
331015|NCT01674127|Drug|Methyldopa|
331016|NCT01674127|Drug|Placebo|
331017|NCT01674114|Procedure|TAP block|
331018|NCT01674114|Procedure|control|
331019|NCT01674101|Other|Endurance|Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.
331020|NCT01674101|Other|Strengthening|Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.
331021|NCT01674101|Other|Stretching|Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.
331022|NCT01674101|Other|Home exercise program|All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
331023|NCT01674062|Drug|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
331024|NCT01674062|Drug|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
331025|NCT01674049|Dietary Supplement|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
331026|NCT01674049|Dietary Supplement|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
331027|NCT01674049|Other|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
331028|NCT01674036|Drug|Genz-682452|Capsules for oral administration.
331029|NCT01674036|Drug|Placebo|Placebo to Genz-682452
331030|NCT01674010|Drug|ELND005|
331031|NCT01674010|Drug|Lamotrigine|
331032|NCT01674010|Drug|Valproic acid|
331033|NCT01674010|Drug|Placebo|
331034|NCT01673997|Drug|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
331035|NCT01673984|Drug|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 & month 6 (+/- 7 days).
331036|NCT01673984|Drug|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
331037|NCT01673958|Other|Exercise|Comparison between stair descending and stair ascending training
331038|NCT01673945|Device|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
331039|NCT01673932|Biological|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
331040|NCT01673932|Procedure|surgery|
331041|NCT01673919|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
331091|NCT01673490|Drug|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
331334|NCT01671488|Radiation|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
331042|NCT01673906|Drug|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
331043|NCT01673893|Device|ClearWay™ Rx catheter|
331044|NCT01673880|Drug|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
331045|NCT01673867|Biological|Nivolumab|
331046|NCT01673867|Drug|Docetaxel|
331047|NCT01673854|Drug|Ipilimumab|
331048|NCT01673854|Biological|Vemurafenib|
331049|NCT01673841|Procedure|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
331050|NCT01673828|Drug|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
331051|NCT01673828|Drug|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
331052|NCT01673815|Other|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
331053|NCT01673802|Drug|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
331054|NCT01673789|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
331055|NCT01673776|Device|PulsioFlex® Monitoring|"goal directed therapy according to PulsioFlex® Monitoring- measurements~femoral catheter~extended perioperative monitoring~nutritional supplementation, (if necessary)"
331056|NCT01673763|Device|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
331057|NCT01673750|Other|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
331058|NCT01673737|Drug|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
331059|NCT01673737|Drug|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
331060|NCT01673724|Drug|pramipexole|pramipexole
331061|NCT01673724|Drug|Bromocriptine|bromocriptine
331062|NCT01673711|Drug|deuterated phenanthrene tetraol|Given PO
331063|NCT01673711|Drug|pharmacological study|Correlative studies
331064|NCT01673711|Drug|laboratory biomarker analysis|Correlative studies
331065|NCT01673698|Device|ReShape Duo balloon|
331066|NCT01673698|Other|Diet counseling|
331067|NCT01673698|Other|Exercise counseling|
331068|NCT01673685|Device|Portable Oxygen|
331069|NCT01673672|Biological|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
331070|NCT01673672|Biological|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
331071|NCT01673659|Drug|Mometasone furoate|
331072|NCT01673659|Drug|Nasonex Nasal Spray|
331073|NCT01673659|Drug|Placebo nasal spray|
331074|NCT01673646|Drug|Pasireotide LAR|Intramuscular administration of pasireotide LAR was repeated every month (1 month = 28 days) for 12 months in core phase. It was permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 > ULN. In the event of any problem with tolerability, it was permitted to reduce the next lower dosage level at any time.
331075|NCT01673620|Drug|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
331076|NCT01673620|Drug|Placebo|Matching placebo tablet administered once daily
331077|NCT01673607|Procedure|Biopsie liver|
331078|NCT01673594|Drug|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
331079|NCT01673594|Drug|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
331080|NCT01673581|Other|Survey|
331081|NCT01673568|Device|ETO garments|patients wearing abdominal binder for 7 days postoperatively
331082|NCT01673555|Drug|GSK1278863|GSK1278863
331083|NCT01673555|Drug|Placebo|Placebo
331084|NCT01673542|Drug|Lidocaine-Prilocaine 5%|
331085|NCT01673542|Drug|DEXERYL|
331086|NCT01673529|Drug|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
331087|NCT01673529|Drug|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
331088|NCT01673516|Procedure|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
331089|NCT01673516|Device|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
331092|NCT01673451|Drug|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
331093|NCT01673451|Drug|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
331094|NCT01673438|Drug|aldoxorubicin|
331095|NCT01673425|Drug|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
331096|NCT01673412|Other|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
331097|NCT01673399|Drug|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
331098|NCT01673399|Drug|placebo|
331099|NCT01673386|Drug|Tivozanib Hydrochloride|
331100|NCT01673386|Drug|Sunitinib|
331101|NCT01673373|Device|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
331102|NCT01673360|Device|Elevate PC|List of AMS prolapse products
331103|NCT01673360|Device|Mini Arc Pro|List of AMS Urinary Incontinence devices
331104|NCT01673360|Device|RetroArc|List of AMS Urinary Incontinence devices
331105|NCT01673347|Biological|Meniscal Allograft|Meniscal allograft
331106|NCT01673334|Device|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
331107|NCT01673321|Other|Dietary intervention|All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
331108|NCT01673308|Drug|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
331109|NCT01673295|Drug|RTX infusions|RTX + Standard of Care
331110|NCT01673295|Other|Standard of Care|Standard of Care only
331111|NCT01673282|Drug|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
331112|NCT01673269|Other|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
331113|NCT01673256|Device|SJM Confirm ICM|
331114|NCT01673243|Other|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
331115|NCT01673230|Procedure|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
331116|NCT01673217|Drug|decitabine|Given IV
331117|NCT01673217|Biological|NY-ESO-1 peptide vaccine|Given SC
331118|NCT01673217|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
331119|NCT01673217|Biological|sargramostim|Given SC
331120|NCT01673217|Biological|incomplete Freund's adjuvant|Given SC
331121|NCT01673217|Other|immunohistochemistry staining method|Correlative studies
331122|NCT01673217|Other|liquid chromatography|Correlative studies
331123|NCT01673217|Other|mass spectrometry|Correlative studies
331124|NCT01673217|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
331125|NCT01673217|Other|laboratory biomarker analysis|Correlative studies
331126|NCT01673217|Genetic|DNA methylation analysis|Correlative studies
331127|NCT01673217|Other|enzyme-linked immunosorbent assay|Correlative studies
331128|NCT01673204|Drug|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
331129|NCT01673204|Drug|Placebo|
331130|NCT01673191|Drug|Dexamethasone intravitreal implant|
331131|NCT01673191|Drug|Steroid plus NSAID eye drop combination therapy|
331132|NCT01673178|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
331133|NCT01673178|Drug|25 mg PF-05231023|25 mg IV once a week for 4 weeks
331134|NCT01673178|Drug|50 mg PF-05231023|50 mg IV once a week for 4 weeks
331135|NCT01673178|Drug|100 mg PF-05231023|100 mg IV once a week for 4 weeks
331136|NCT01673178|Drug|150 mg PF-05231023|150 mg IV once a week for 4 weeks
331137|NCT01673165|Other|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
331138|NCT01673165|Other|Specialized Formula|Infants will receive our standard of care - specialized formula
331139|NCT01673152|Dietary Supplement|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
331140|NCT01673152|Dietary Supplement|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
331141|NCT01673139|Behavioral|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
331142|NCT01673139|Behavioral|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
331143|NCT01673139|Behavioral|Control|Given information on recommendations for physical activity.
331144|NCT01673126|Device|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
331145|NCT01673126|Device|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
331146|NCT01673113|Device|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
331147|NCT01673100|Behavioral|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
331148|NCT01673087|Drug|Metyrapone|750 mcg, oral, administered twice, 3.5 hours apart
331149|NCT01673087|Drug|Dexamethasone|"Administered twice:~1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration."
331150|NCT01673087|Drug|Cortrosyn|250 mcg, IV, bolus, in the afternoon.
331151|NCT01673087|Drug|Corticorelin ovine triflutate|100 mcg, IV, over 30 seconds, in the afternoon.
331152|NCT01673074|Drug|(PDT) Photodynamic therapy|photosensitizer
331153|NCT01673061|Drug|Lidocaine|See associated Arm Description
331154|NCT01673061|Drug|Vapocoolant|See associated Arm Description
331155|NCT01673048|Procedure|3-Nail-ESIN in femoral shaft fractures|
331156|NCT01673035|Behavioral|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
331157|NCT01673035|Behavioral|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
331158|NCT01673022|Drug|IC Green|IC Green
331159|NCT01673009|Drug|Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
331160|NCT01672996|Drug|Ioforminol 160 mgI/mL|Given as s single administration to the subject
331161|NCT01672996|Drug|Ioforminol 200 mgI/mL|Given as a single administration to the subject
331162|NCT01672996|Drug|Iopamidol 300 mgI/mL|Given as a single administration to the subject
331163|NCT01672983|Drug|ABT-450/ritonavir, ABT-267|ABT-450 (tablet) dosed with ritonavir (capsule), and ABT-267 (tablet)
331164|NCT01672957|Drug|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
331165|NCT01672957|Drug|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
331166|NCT01672944|Other|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
331167|NCT01672944|Other|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
331168|NCT01672931|Other|Oocyte Measurement|
331169|NCT01672905|Other|laboratory biomarker analysis|
331170|NCT01672892|Radiation|Standard radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. Whole pelvis treated with a four-field technique (AP/PA/R lateral/L lateral) to 45 or 50.4 Gy at 1.8 Gy/fraction. The dose is prescribed to the isocenter which is defined as the intersection of the four beams and can be normalized to an isodose line between 97-100%. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
331171|NCT01672892|Radiation|intensity-modulated radiation therapy|Patients treated once a day, 5 days a week with a daily fraction size of 1.8 Gy. All targets treated simultaneously. The vaginal planning target volume (PTV) (ITV with 7.0 mm margin) and nodal PTV receives 45 Gy in 25 fractions or 50.4 Gy in 28 fractions. The decision to deliver 45 or 50.4 Gy is at the physician's discretion and must be reported at the time of enrollment.
331172|NCT01672879|Biological|Placebo|Placebo to match SIM intravenous infusion over 30 minutes every 2 weeks
331173|NCT01672879|Biological|SIM|Intravenous infusion over 30 minutes every 2 weeks
331174|NCT01672866|Biological|Placebo|Placebo to match SIM via subcutaneous injection every week
331175|NCT01672866|Biological|SIM|Subcutaneous injection every week
331176|NCT01672853|Biological|Simtuzumab|Subcutaneous injections weekly for a total of 96 injections
331177|NCT01672853|Biological|Placebo|Subcutaneous injections weekly for a total of 96 injections
331178|NCT01672840|Dietary Supplement|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
331179|NCT01672840|Dietary Supplement|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
331180|NCT01672827|Drug|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
331181|NCT01672814|Drug|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
331182|NCT01672814|Device|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
331183|NCT01672801|Drug|Placebo|oral administration
331184|NCT01672801|Drug|Nimodipine|oral administration
331185|NCT01672788|Drug|Empagliflozin|empagliflozin tablets and metformin tablet
331186|NCT01672788|Drug|Empagliflozin + Metformin|fixed dose combination tablet (low)
331187|NCT01672788|Drug|Metformin|empagliflozin tablets and metformin tablet
331188|NCT01672788|Drug|Metformin|empagliflozin tablet and metformin tablet
331189|NCT01672788|Drug|Empagliflozin + Metformin|fixed dose combination tablet (low)
331190|NCT01672788|Drug|Empagliflozin|empagliflozin tablet and metformin tablet
331191|NCT01672775|Drug|AGS-16C3F|intravenous (IV) infusion
331192|NCT01672762|Drug|ipragliflozin|oral
331193|NCT01672749|Device|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
331194|NCT01672749|Device|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
331195|NCT01672736|Drug|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
331196|NCT01672723|Drug|Naltrexone|
331197|NCT01672710|Drug|plain crystalline niacin, exercise, sauna|A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
331198|NCT01672697|Behavioral|Physical Therapy (PT) and Behavioral Therapy (BT)|"Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.~Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment."
331199|NCT01672684|Procedure|support group therapy|Complete at-home group video calling support sessions
331200|NCT01672684|Other|educational intervention|Receive an educational workbook journal
331201|NCT01672671|Drug|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
331202|NCT01672658|Device|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
331203|NCT01672658|Other|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
331204|NCT01672645|Biological|NIC7-001|Intramuscular, multiple dose
331205|NCT01672645|Biological|NIC7-003|Intramuscular, multiple dose
331206|NCT01672645|Biological|Saline|Saline (0.9% sodium chloride)
331207|NCT01672632|Other|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
331208|NCT01672619|Procedure|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
331209|NCT01672606|Drug|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
331210|NCT01672593|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
331211|NCT01672593|Drug|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
331212|NCT01672593|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
331213|NCT01672593|Procedure|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
331214|NCT01672580|Behavioral|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
331215|NCT01672580|Behavioral|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
331216|NCT01672580|Behavioral|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
331217|NCT01672580|Behavioral|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
331218|NCT01672567|Dietary Supplement|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
331219|NCT01672567|Dietary Supplement|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
331220|NCT01672567|Dietary Supplement|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
331221|NCT01672554|Drug|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
331253|NCT01672268|Other|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
331254|NCT01672255|Drug|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
331255|NCT01672255|Drug|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
331222|NCT01672541|Behavioral|Dating Matters Comprehensive Approach|"The Dating Matters Comprehensive Approach includes:~6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)"
331223|NCT01672541|Behavioral|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
331224|NCT01672528|Other|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
331225|NCT01672528|Other|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
331226|NCT01672515|Device|RIPC group|
331227|NCT01672515|Device|Control group|
331228|NCT01672502|Behavioral|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
331229|NCT01672502|Other|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
331230|NCT01672502|Other|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
331231|NCT01672476|Drug|Placebo|Placebo
331232|NCT01672476|Drug|Valsartan|Valsartan 80mg
331233|NCT01672476|Drug|Fimasartan|Fimasartan 30mg
331234|NCT01672463|Drug|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.~Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
331235|NCT01672450|Drug|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
331236|NCT01672437|Other|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
331237|NCT01672424|Other|Ice Chips|11 ounces of ice chips given to the laboring parturient
331238|NCT01672424|Other|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
331239|NCT01672398|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
331240|NCT01672385|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
331241|NCT01672372|Dietary Supplement|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
331242|NCT01672372|Dietary Supplement|Placebo Max Stress B|
331243|NCT01672359|Dietary Supplement|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
331244|NCT01672359|Dietary Supplement|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
331245|NCT01672359|Dietary Supplement|Placebo|
331246|NCT01672346|Procedure|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
331247|NCT01672333|Drug|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
331248|NCT01672307|Drug|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
331249|NCT01672307|Drug|Placebo|Placebo is applied twice daily to the other eyebrow.
331250|NCT01672294|Other|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
331251|NCT01672294|Other|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
331252|NCT01672281|Other|vibrox- vs. resistance training|Comparison between two exercise interventions
331294|NCT01671878|Other|Reference Glucose|
331256|NCT01672242|Device|HFNC|Graded high flow nasal cannula oxygen at 10, 20 , 30, and 40 liters per minute (LPM) to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
331257|NCT01672242|Device|CPAP|Graded contiuous positive airway pressure at 5, 10 , 15, and 20 cm H2O applied to each subject and end-expiratory lung volume measured by respiratory inductive plethysmography.
331258|NCT01672229|Drug|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
331259|NCT01672216|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
331260|NCT01672216|Device|EMG-biofeedback alone|
331261|NCT01672190|Other|Yoga Therapy Program|
331262|NCT01672177|Behavioral|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
331263|NCT01672151|Drug|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
331264|NCT01672138|Procedure|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum extended to the left atrial posterior wall
331265|NCT01672138|Procedure|scar homogenization|PVAI + RF energy will be delivered until all abnormal potentials in the low-voltage areas are eliminated.
331266|NCT01672138|Procedure|Non-PV triggers ablation|PVAI + Isolation of LA posterior wall + Catheter ablation of triggers originating from extra-PV sites
331267|NCT01672125|Other|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
331268|NCT01672112|Drug|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
331269|NCT01672112|Drug|Codeine|Oral Codeine 60mg 6hrly/prn
331270|NCT01672099|Dietary Supplement|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
331271|NCT01672099|Dietary Supplement|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
331272|NCT01672086|Device|Stelkast Surpass Acetabular System implant|
331273|NCT01672060|Behavioral|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
331274|NCT01672060|Behavioral|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
331275|NCT01672047|Drug|Vitamin D2|"25（OH）D level <12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month，~＞116.75nmol/L stopped."
331276|NCT01672034|Procedure|Laparoscopic gastric bypass surgery|
331277|NCT01672021|Procedure|PET/MRI|PET/MRI
331278|NCT01672008|Drug|NOX-100|
331279|NCT01671995|Procedure|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
331280|NCT01671995|Procedure|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
331281|NCT01671982|Other|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to <50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
331282|NCT01671969|Other|very low calorie diet|medically supervised diet
331283|NCT01671956|Biological|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
331284|NCT01671956|Biological|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
331285|NCT01671943|Device|Ice-Sense3TM|Ice-Sense Cryoprobe
331286|NCT01671917|Other|Educational and exercise program|"4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement~4 (twice a week) sessions of an exercise programme lasting 1 hour"
331287|NCT01671917|Other|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
331288|NCT01671904|Drug|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter [mg/m^2]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
331289|NCT01671904|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams [mg]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
331290|NCT01671904|Drug|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m^2) on Day 1 of Cycle 1 and 500 mg/m^2 administered on Day 1 of Cycles 2-6.
331291|NCT01671904|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
331292|NCT01671891|Radiation|radiation therapy|45-55Gy
331293|NCT01671891|Drug|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
331297|NCT01671852|Drug|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.~For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
331298|NCT01671852|Drug|Placebo|
331299|NCT01671839|Device|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
331300|NCT01671813|Drug|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
331301|NCT01671800|Drug|Botulinum Type B|
331302|NCT01671800|Drug|Placebo|
331303|NCT01671787|Drug|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
331304|NCT01671787|Drug|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
331305|NCT01671774|Drug|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
331306|NCT01671774|Drug|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
331307|NCT01671774|Drug|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
331308|NCT01671774|Drug|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
331309|NCT01671748|Device|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
331310|NCT01671748|Other|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
331311|NCT01671735|Other|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
331312|NCT01671722|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
331313|NCT01671709|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
331314|NCT01671696|Other|Cardiac MRI|Cardiac MRI
331315|NCT01671670|Other|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
331316|NCT01671670|Other|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
331317|NCT01671631|Other|Measurement of intracoronary pressure|
331318|NCT01671592|Biological|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
331319|NCT01671579|Procedure|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
331320|NCT01671579|Procedure|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
331321|NCT01671566|Behavioral|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
331322|NCT01671553|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
331323|NCT01671540|Device|intrapulmonary percussive ventilation|
331324|NCT01671540|Other|standard treatment|breathing control exercises
331325|NCT01671527|Procedure|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
331326|NCT01671514|Dietary Supplement|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
331327|NCT01671514|Other|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
331328|NCT01671501|Behavioral|Motivational Interviewing|
331329|NCT01671501|Behavioral|Email Feedback|
331330|NCT01671501|Other|Usual Care|
331331|NCT01671488|Biological|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
331335|NCT01671475|Device|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
331336|NCT01671462|Device|BD HPV assay on Viper LT|
331337|NCT01671449|Drug|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
331338|NCT01671449|Drug|Cisplatin|60 mg/m2/day Day 1
331339|NCT01671449|Drug|Oxaliplatin|130 mg/m2/day Day 1
331340|NCT01671436|Behavioral|Central Meditation and Imagery Therapy|
331341|NCT01671423|Drug|Prednisone|"See Prednisone arm description"
331342|NCT01671423|Drug|Placebo|"See Placebo arm description"
331343|NCT01671410|Drug|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
331344|NCT01671410|Drug|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
331345|NCT01671397|Behavioral|Diet and exercise counseling|Not needed
331346|NCT01671397|Behavioral|Diet, exercise, sleep hygiene counseling|None needed
331347|NCT01671384|Drug|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
331348|NCT01671384|Drug|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
331349|NCT01671371|Other|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
331350|NCT01671345|Behavioral|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
331351|NCT01671345|Behavioral|Control|Attention control
331352|NCT01671332|Drug|Docetaxel|IV over 60 minutes, 75 mg/m2
331353|NCT01671332|Drug|Suramin|IV over 30 minutes
331354|NCT01671332|Drug|Docetaxel|IV over 60 minutes. 56 mg/m2
331355|NCT01671319|Drug|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
331356|NCT01671293|Behavioral|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer & waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
331357|NCT01671293|Other|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
331358|NCT01671280|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.~The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
331359|NCT01671267|Behavioral|Strength training|
331360|NCT01671267|Behavioral|Ergonomic|
331361|NCT01671254|Dietary Supplement|FishOil|
331362|NCT01671254|Dietary Supplement|CBE75|
331363|NCT01671254|Dietary Supplement|CBE150|
331364|NCT01671254|Dietary Supplement|placebo|
331365|NCT01671241|Device|Polyethylene wrap|
331366|NCT01671241|Device|Polyethylene wrap|
331367|NCT01671228|Other|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
331368|NCT01671228|Other|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
331369|NCT01671228|Other|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
331370|NCT01671189|Other|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
331371|NCT01671176|Device|Wide diameter bone anchored implant|4.5 mm wide diameter bone anchored implant
331372|NCT01671163|Procedure|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
331373|NCT01671150|Drug|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
331374|NCT01671137|Other|Lactobacillus Rhamnosus Strain GG|Lactobacillus Rhamnosus Strain GG
331375|NCT01671124|Other|Soline capsule|
331376|NCT01671111|Drug|SSP-004184AQ|"Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)"
331377|NCT01671085|Drug|LY3015014|Administered SQ
331378|NCT01671085|Drug|Placebo|Administered SQ
331379|NCT01671072|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
331380|NCT01671072|Drug|Normal Saline|Sodium chloride 0.9%, 3.5ml
331381|NCT01671033|Behavioral|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
331382|NCT01671033|Behavioral|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
331383|NCT01671020|Drug|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
331384|NCT01671020|Drug|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
331385|NCT01670994|Biological|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
331386|NCT01670981|Biological|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
331387|NCT01670981|Other|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
331388|NCT01670955|Dietary Supplement|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
331389|NCT01670955|Drug|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
331390|NCT01670942|Other|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
331391|NCT01670929|Drug|Progesterone|
331392|NCT01670929|Other|Placebo|
331393|NCT01670916|Dietary Supplement|probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
331394|NCT01670890|Drug|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
331395|NCT01670890|Drug|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
331396|NCT01670877|Drug|Neratinib|
331397|NCT01670877|Drug|Fulvestrant|
331398|NCT01670877|Drug|Trastuzumab|
331399|NCT01670877|Procedure|Tumor biopsy|-Optional at baseline and disease progression
331400|NCT01670877|Procedure|Research blood sample|-Baseline, cycle 1 day 15, cycle 2 day 1, cycle 3 day 1, day 1 of each odd cycle, end of treatment (progression)
331401|NCT01670864|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
331402|NCT01670864|Behavioral|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
331403|NCT01670851|Device|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
331404|NCT01670825|Procedure|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
331405|NCT01670825|Drug|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
331406|NCT01670825|Drug|Local anethestic injection|
331407|NCT01670812|Drug|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
331408|NCT01670799|Drug|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
331409|NCT01670786|Procedure|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
331410|NCT01670773|Drug|CAT-1004|
331411|NCT01670773|Drug|Salsalate + DHA|
331412|NCT01670773|Drug|Placebo|
331533|NCT01669850|Device|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
331413|NCT01670760|Device|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
331414|NCT01670747|Radiation|Chest computed tomography|
331415|NCT01670734|Drug|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)~Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
331416|NCT01670721|Drug|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
331417|NCT01670721|Drug|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
331418|NCT01670721|Drug|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
331419|NCT01670721|Drug|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
331420|NCT01670708|Behavioral|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
331421|NCT01670708|Behavioral|Probation as Usual|Probation officer supervises following standard protocols.
331422|NCT01670682|Procedure|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
331423|NCT01670682|Procedure|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
331424|NCT01670682|Device|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
331425|NCT01670669|Drug|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
331426|NCT01670656|Drug|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
331427|NCT01670656|Drug|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
331428|NCT01670656|Drug|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
331429|NCT01670656|Drug|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
331430|NCT01670643|Behavioral|Video camera magnifier|reading with video camera magnifier
331431|NCT01670630|Procedure|Sheathed speculum examination|
331432|NCT01670630|Procedure|Standard speculum examination|
331433|NCT01670617|Other|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
331434|NCT01670604|Drug|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
331435|NCT01670604|Drug|Tetraspan, B. Braun, Melsungen, Germany|
331436|NCT01670591|Behavioral|PS - Prevention in School|
331437|NCT01670578|Biological|PRP|
331438|NCT01670578|Device|Hyaluronic acid|
331439|NCT01670565|Drug|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
331440|NCT01670552|Drug|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
331441|NCT01670552|Drug|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
331442|NCT01670539|Device|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
331443|NCT01670526|Drug|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
331444|NCT01670513|Drug|IDP-118 Low Strength|8 weeks
331445|NCT01670513|Drug|IDP-118 High Strength|8 weeks
331446|NCT01670500|Drug|Cisplatin|administered intravenously every 3 weeks for 4 doses
331447|NCT01670500|Drug|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
331448|NCT01670500|Drug|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
331449|NCT01670487|Device|Vapocoolant|Topical stream of 4 to 10 seconds duration to skin
331450|NCT01670487|Device|Sterile water|Topical intervention of sterile water stream 4 to 10 seconds to skin.
331451|NCT01670474|Drug|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
331452|NCT01670474|Drug|rt-PA|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
331488|NCT01670136|Drug|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
331534|NCT01669850|Procedure|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
331453|NCT01670461|Behavioral|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
331454|NCT01670461|Behavioral|Standard of Care (SOC) Control|"Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  … regarding advance directives … to honor each non-minor patient's wishes … to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record."
331455|NCT01670448|Procedure|PECBLOCK under echoguidance|Performance of block under echography
331456|NCT01670435|Drug|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
331457|NCT01670409|Radiation|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
331458|NCT01670409|Drug|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
331459|NCT01670370|Drug|R-GemOx|Rituximab Gemcitabine Oxaliplatin
331460|NCT01670357|Drug|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
331461|NCT01670357|Drug|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
331462|NCT01670357|Drug|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
331463|NCT01670344|Procedure|Treatment with investigational method (virtual implant positioning system)|
331464|NCT01670344|Procedure|Treatment with surgical standard of care|
331465|NCT01670331|Behavioral|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.~Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.~Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
331466|NCT01670318|Device|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
331467|NCT01670305|Procedure|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
331468|NCT01670305|Procedure|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
331469|NCT01670305|Procedure|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
331470|NCT01670305|Procedure|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
331471|NCT01670305|Procedure|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
331472|NCT01670292|Other|HVLA-SM|High Velocity Low Amplitude Spinal Manipulation
331473|NCT01670279|Drug|Brexpiprazole|up to 3mg oral dose once daily
331474|NCT01670279|Drug|Placebo|
331475|NCT01670266|Drug|ONO-9054|
331476|NCT01670266|Drug|Placebo|
331477|NCT01670253|Behavioral|Group 1|"6 hour fast from all solid foods and milk beverages~2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)~Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
331478|NCT01670240|Drug|Adalimumab|
331479|NCT01670240|Drug|Placebo|
331480|NCT01670227|Behavioral|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
331481|NCT01670214|Procedure|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
331482|NCT01670201|Device|Mepilex Transfer Ag|Silver dressing
331483|NCT01670188|Device|Pneumatic SCD - VenaFlow System (DJO Global)|
331484|NCT01670175|Drug|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
331485|NCT01670162|Drug|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
331486|NCT01670149|Drug|Rifaximin|Tablets
331487|NCT01670149|Drug|Placebo|Tablets
331489|NCT01670123|Behavioral|Personalized Real-Time Intervention for Stabilizing Mood|Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
331490|NCT01670110|Drug|Pasireotide LAR|Injectible, 60mg per month
331492|NCT01670097|Drug|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.~Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
331493|NCT01670097|Drug|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
331494|NCT01670097|Behavioral|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
331495|NCT01670097|Device|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
331496|NCT01670097|Other|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
331497|NCT01670084|Drug|nilotinib|Given PO
331498|NCT01670084|Biological|rituximab|Given IV
331499|NCT01670084|Drug|cyclophosphamide|Given IV
331500|NCT01670084|Drug|doxorubicin hydrochloride|Given IV
331501|NCT01670084|Drug|vincristine sulfate|Given IV
331502|NCT01670084|Drug|methotrexate|Given IV or IT
331503|NCT01670084|Drug|cytarabine|Given IV or IT
331504|NCT01670084|Drug|prednisone|Given PO
331505|NCT01670084|Drug|mesna|Given IV
331506|NCT01670084|Drug|dexamethasone|Given IV or PO
331507|NCT01670084|Drug|leucovorin calcium|Given IV
331508|NCT01670071|Drug|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
331509|NCT01670071|Drug|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
331510|NCT01670045|Drug|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
331511|NCT01670032|Drug|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
331512|NCT01670032|Drug|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
331513|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
331514|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
331515|NCT01670019|Drug|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
331516|NCT01670019|Drug|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
331517|NCT01669980|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)~Subjects < 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
331518|NCT01669980|Drug|IV Ceftriaxone and Vancomycin|"IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND~IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.~Optional Oral Switch:~PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h~PO clindamycin 13 mg/kg/dose~PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
331519|NCT01669967|Drug|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
331520|NCT01669967|Drug|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
331521|NCT01669941|Drug|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
331522|NCT01669941|Drug|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
331523|NCT01669941|Drug|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
331524|NCT01669928|Drug|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.~Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
331525|NCT01669915|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
331526|NCT01669915|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
331527|NCT01669915|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
331528|NCT01669915|Dietary Supplement|Fish oil placebo|Fish oil placebo
331529|NCT01669876|Dietary Supplement|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
331530|NCT01669876|Dietary Supplement|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
331531|NCT01669863|Device|ECMO|Use of veno-venous ECMO in non-intubated patients with ARDS
331532|NCT01669863|Procedure|ECMO in non-intubated patients|Use of veno-venous ECMO in non-intubated patients with ARDS
332222|NCT01664182|Other|Laboratory Biomarker Analysis|Correlative studies
331535|NCT01669837|Device|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
331536|NCT01669824|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
331537|NCT01669811|Drug|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
331538|NCT01669811|Drug|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
331539|NCT01669798|Drug|BIBF 1120|PO 200mg BID
331540|NCT01669785|Device|Group C|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
331541|NCT01669785|Device|Group A|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
331542|NCT01669785|Device|Group B|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
331543|NCT01669772|Drug|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
331544|NCT01669772|Drug|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
331545|NCT01669746|Biological|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
331546|NCT01669733|Other|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
331547|NCT01669733|Other|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
331548|NCT01669720|Drug|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
331549|NCT01669707|Drug|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
331550|NCT01669707|Drug|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
331551|NCT01669694|Other|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
331552|NCT01669668|Procedure|radiofrequency ablation|Undergo RFA
331553|NCT01669668|Procedure|laparoscopy|Undergo laparoscopic ultrasound
331554|NCT01669642|Drug|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
331555|NCT01669629|Device|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
331556|NCT01669629|Device|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
331557|NCT01669603|Dietary Supplement|Bifidobacterium lactis Bl-04|The study product will be a 2*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
331558|NCT01669603|Dietary Supplement|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
331559|NCT01669603|Biological|Rhinovirus|rhinovirus for experimental challenge
331560|NCT01669577|Procedure|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
331561|NCT01669564|Other|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.~Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
331562|NCT01669564|Other|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
331563|NCT01669538|Drug|Galantamine|
331564|NCT01669538|Drug|Placebo|
331565|NCT01669512|Biological|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
331566|NCT01669512|Biological|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
331567|NCT01669512|Biological|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
331568|NCT01669499|Drug|Dexamethasone acetate|
331569|NCT01669499|Drug|Placebo|
331570|NCT01669486|Other|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
331605|NCT01669200|Other|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
331606|NCT01669187|Other|Education brochure|
331925|NCT01666613|Drug|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
331571|NCT01669473|Other|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:~Medication Review: a consolidated list of the medications a patient is currently taking.~Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
331572|NCT01669460|Other|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
331573|NCT01669447|Biological|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.~To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.~Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
331574|NCT01669434|Drug|ACEI continuation|These chronic medications will be taken without interruption preoperatively.
331575|NCT01669434|Drug|ACEI omission|Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.
331576|NCT01669421|Drug|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
331577|NCT01669408|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
331578|NCT01669395|Other|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
331579|NCT01669395|Other|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
331580|NCT01669382|Device|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
331581|NCT01669369|Drug|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
331582|NCT01669369|Drug|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
331583|NCT01669356|Other|Parenteral supplement with enteral nutrition for patients after esophagectomy|
331584|NCT01669356|Other|Enteral Nutrition alone for patients after esophagectomy|
331585|NCT01669343|Drug|Letrozole|Active Comparator Arm receives 2.5 mg letrozole and Experimental Arm receives 5.0 mg letrozole
331586|NCT01669330|Procedure|Nissen fundoplication|Laparoscopic Nissen fundoplication
331587|NCT01669330|Procedure|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
331588|NCT01669317|Other|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
331589|NCT01669317|Other|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
331590|NCT01669304|Drug|Verapamil|
331591|NCT01669304|Drug|Sertraline|
331592|NCT01669291|Drug|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
331593|NCT01669291|Drug|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
331594|NCT01669291|Drug|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
331595|NCT01669278|Device|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
331596|NCT01669252|Drug|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
331597|NCT01669239|Drug|Liposomal Doxorubicin|"Six cycles of:~Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
331598|NCT01669226|Drug|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
331599|NCT01669226|Drug|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
331600|NCT01669213|Drug|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
331601|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
331602|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
331603|NCT01669213|Drug|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
331604|NCT01669200|Other|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
331753|NCT01667926|Drug|Ketamine|ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
331607|NCT01669187|Other|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
331608|NCT01669174|Drug|Placebo|
331609|NCT01669174|Drug|BYM338|BYM338
331610|NCT01669161|Device|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
331611|NCT01669161|Other|Rehab Only|Rehabilitation without device implant and VNS
331612|NCT01669148|Device|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
331613|NCT01669148|Device|Conventional|conventional (2D) imaging (standard mammography)
331614|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|
331615|NCT01669122|Drug|nicotine|4 mg nicotine lozenge experimental
331616|NCT01669109|Behavioral|Hatha yoga|
331617|NCT01669096|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
331618|NCT01669083|Drug|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
331619|NCT01669083|Drug|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
331620|NCT01669083|Drug|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
331621|NCT01669083|Drug|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
331622|NCT01669070|Drug|FF, 50 mcg|Novel dry powder inhaler
331623|NCT01669070|Drug|FF, 100 mcg|Novel dry powder inhaler
331624|NCT01669070|Drug|FF, 200 mcg|Novel dry powder inhaler
331625|NCT01669070|Drug|FF, 250 mcg|Intravenous
331626|NCT01669044|Drug|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
331627|NCT01669044|Drug|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
331628|NCT01669031|Other|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
331629|NCT01669018|Procedure|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
331630|NCT01669018|Procedure|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
331631|NCT01668992|Behavioral|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
331632|NCT01668979|Device|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
331633|NCT01668966|Drug|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
331634|NCT01668953|Other|Platelet Rich Plasma (PRP) Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations."
331635|NCT01668953|Other|Whole Blood Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations."
331636|NCT01668953|Other|Dry Needle Fenestration|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~A 22-gauge needle will then be placed into the tendon.~15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon."
331637|NCT01668953|Other|Sham Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected."
331688|NCT01668602|Other|Fast Treadmill Walking|Subjects will be trained while walking on a treadmill at speeds that were faster than their self-selected speed in fast treadmill walking
331721|NCT01668225|Procedure|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.~Taking the follicular fluid during the oocyte collection day"
331722|NCT01668212|Procedure|Doppler ultrasound|Doppler Ultrasound
331723|NCT01668199|Drug|TZP-101|
331754|NCT01667926|Drug|Placebo|
331638|NCT01668940|Other|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
331639|NCT01668940|Other|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
331640|NCT01668940|Other|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
331641|NCT01668927|Drug|Proton Pump Inhibitor|
331642|NCT01668927|Drug|Bismuth|
331643|NCT01668927|Drug|Metronidazole|
331644|NCT01668927|Drug|Tetracycline|
331645|NCT01668927|Drug|Furazolidone|
331646|NCT01668927|Drug|Amoxicillin|
331647|NCT01668914|Procedure|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
331648|NCT01668914|Radiation|99mTc-SC|Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
331649|NCT01668914|Device|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
331650|NCT01668914|Device|LSG|lymphoscintigraphy was performed 0.5~1.0 hour before surgery
331651|NCT01668914|Drug|Methylthioninium|Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
331652|NCT01668901|Drug|warfarin|anticoagulation
331653|NCT01668901|Drug|Aspirin|antiplatelet
331654|NCT01668875|Other|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
331655|NCT01668875|Other|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
331656|NCT01668862|Biological|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
331657|NCT01668862|Drug|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
331658|NCT01668849|Dietary Supplement|Grape extract|Grape extract self-administered by mouth daily for 35 days
331659|NCT01668849|Drug|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
331660|NCT01668836|Drug|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
331661|NCT01668836|Behavioral|Caloric restriction|Diet of 1000kcal per day for 30 days
331662|NCT01668823|Drug|HPPH|Given IV
331663|NCT01668823|Drug|photodynamic therapy|Undergo photodynamic therapy with HPPH
331664|NCT01668823|Procedure|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
331665|NCT01668797|Drug|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
331666|NCT01668797|Drug|Placebo|Placebo comparator for 52 weeks
331667|NCT01668784|Biological|Nivolumab|
331668|NCT01668784|Drug|Everolimus|
331669|NCT01668745|Biological|Early measles vaccine|
331670|NCT01668719|Drug|Bortezomib|Given SC or IV
331671|NCT01668719|Drug|Dexamethasone|Given PO or IV
331672|NCT01668719|Biological|Elotuzumab|Given IV
331673|NCT01668719|Other|Laboratory Biomarker Analysis|Correlative studies
331674|NCT01668719|Drug|Lenalidomide|Given PO
331675|NCT01668693|Other|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
331676|NCT01668693|Other|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
331677|NCT01668693|Other|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
331678|NCT01668680|Drug|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
331679|NCT01668667|Drug|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
331680|NCT01668667|Drug|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
331681|NCT01668667|Drug|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
331682|NCT01668667|Drug|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
331683|NCT01668654|Drug|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
331684|NCT01668641|Drug|GLPG0634|
331685|NCT01668641|Drug|Placebo|
331686|NCT01668615|Drug|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
331687|NCT01668602|Device|Functional electrical stimulation (FES)|Functional electrical stimulation (FES) Functional electrical stimulation (FES) is a technique that causes a muscle to contract through the use of an electrical current. The therapist applies an electrical current to either the skin over the nerve, or over the bulk of the muscle, and this will cause a muscle contraction. The FES is delivered to 2 muscle groups (dorsiflexor and plantarflexor) timed appropriately with the gait cycle.
331689|NCT01668563|Procedure|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
331690|NCT01668563|Procedure|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
331691|NCT01668550|Drug|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.~Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
331692|NCT01668537|Biological|LF formulation of IMVAMUNE®|
331693|NCT01668537|Biological|FD formulation of IMVAMUNE®|
331694|NCT01668524|Drug|ATS907|Single dose of each of three increasing concentrations
331695|NCT01668511|Biological|ABT-981|Injection
331696|NCT01668511|Biological|Placebo|Placebo Injection
331697|NCT01668498|Drug|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
331698|NCT01668498|Drug|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
331699|NCT01668485|Procedure|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg−1·min−1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
331700|NCT01668459|Drug|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
331701|NCT01668459|Other|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
331702|NCT01668446|Drug|Sildenafil|sildenafil tablets(50 mg) daily
331703|NCT01668446|Drug|estradiol valerat|
331704|NCT01668433|Drug|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
331705|NCT01668420|Other|thermal stimulation|hot and cold/warm and cool pads applying.
331706|NCT01668407|Device|Robot-Assisted Gait Training (RAGT)|Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
331707|NCT01668407|Procedure|Treadmill Gait Training (TT)|"Subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.~All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks."
331708|NCT01668394|Behavioral|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
331709|NCT01668394|Other|Control arm|Usual care. Teaching style: deductive.
331710|NCT01668381|Procedure|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
331711|NCT01668368|Other|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
331712|NCT01668355|Other|Patient Aligned Care Team (PACT)|A integrated healthcare model to coordinate and address physical health needs. The PACT model to be implemented here will be specially designed for individuals with serious mental illness.
331713|NCT01668342|Behavioral|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
331714|NCT01668316|Behavioral|Weight loss|"Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.~Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.~Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.~Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
331715|NCT01668303|Behavioral|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
331716|NCT01668303|Behavioral|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
331717|NCT01668277|Drug|7.2% NaCl|
331724|NCT01668186|Genetic|Next-generation panel|Molecular testing will be offered to participants whose mutations have not been found. Molecular testing will be done with a next-generation panel of 75 genes on a research basis. Genetic counselling services are available to participants.
331725|NCT01668186|Other|Consultation in Ophthalmology|Participants seen in consultation will have an OCT (optical coherence tomography) eye exam and FAF (fundus autofluorescence) photography.
331726|NCT01668173|Drug|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
331727|NCT01668160|Procedure|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
331728|NCT01668147|Drug|[11C] desmethyl-loperamide|IV administration of 10-14 mCi of [11C] desmethyl-loperamide with PET/CT imaging after control, ritonavir or efavirenz
331729|NCT01668134|Radiation|Stereotactic radiation|
331730|NCT01668121|Drug|Symbicort Turbohaler|
331731|NCT01668121|Drug|Budesonide/formoterol Easyhaler|
331732|NCT01668095|Other|Laboratory Biomarker Analysis|Correlative studies
331733|NCT01668082|Procedure|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
331734|NCT01668069|Drug|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
331735|NCT01668056|Drug|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
331736|NCT01668056|Procedure|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
331737|NCT01668056|Other|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
331738|NCT01668043|Drug|Antibody UB-421|UB-421 is administered by intravenous infusion
331739|NCT01668030|Drug|Enzymatic agent|Enzymatic agent
331740|NCT01668030|Drug|Bacitracin|
331741|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
331742|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
331743|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
331744|NCT01668017|Drug|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
331745|NCT01668017|Drug|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
331746|NCT01668004|Biological|Golimumab|GLM 50 mg subcutaneously once monthly.
331747|NCT01667978|Drug|Norethindrone acetate|
331748|NCT01667965|Behavioral|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
331749|NCT01667952|Genetic|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
331750|NCT01667952|Genetic|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
331751|NCT01667952|Other|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
331752|NCT01667939|Behavioral|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
331755|NCT01667913|Other|6 minutes walking test|
331756|NCT01667900|Drug|Dulaglutide|
331757|NCT01667900|Drug|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
331758|NCT01667874|Drug|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
331759|NCT01667848|Device|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
331760|NCT01667848|Device|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
331761|NCT01667835|Behavioral|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
331762|NCT01667822|Behavioral|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
331763|NCT01667822|Behavioral|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
331764|NCT01667809|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
331765|NCT01667809|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
331766|NCT01667796|Dietary Supplement|Vitamin D3|
331767|NCT01667783|Procedure|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
331768|NCT01667783|Behavioral|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
331769|NCT01667783|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
331770|NCT01667770|Procedure|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
331771|NCT01667744|Drug|Citalopram|10 mg/day
331772|NCT01667731|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
331773|NCT01667731|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
331774|NCT01667718|Drug|Bismuth|Bismuth 220mg b.i.d for 2 weeks
331775|NCT01667718|Drug|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
331776|NCT01667718|Drug|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
331777|NCT01667718|Drug|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
331778|NCT01667692|Drug|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.[1] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
331779|NCT01667692|Drug|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
331780|NCT01667679|Drug|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|
331781|NCT01667679|Drug|OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet|
331782|NCT01667666|Drug|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
331783|NCT01667653|Dietary Supplement|Probiotic|Probiotic capsule once daily
331784|NCT01667653|Dietary Supplement|Placebo|Placebo capsule once daily
331785|NCT01667640|Radiation|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
331786|NCT01667640|Radiation|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
332223|NCT01664182|Drug|Pazopanib|Given PO
331787|NCT01667627|Dietary Supplement|Bio-25|"Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.~Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus."
331788|NCT01667627|Other|Placebo|Identical placebo
331789|NCT01667614|Drug|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
331790|NCT01667601|Other|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
331791|NCT01667601|Behavioral|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
331792|NCT01667601|Behavioral|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
331793|NCT01667575|Drug|Esomeprazole|antisecretary drug of the quadruple therapy
331794|NCT01667575|Drug|Amoxicillin|antibiotic of the quadruple therapy
331795|NCT01667575|Drug|Clarithromycin|antibiotic of the quadruple therapy
331796|NCT01667575|Drug|Bismuth Potassium Citrate|one of a component of a quadruple therapy
331797|NCT01667575|Other|long duration (14 day)|
331798|NCT01667562|Drug|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
331799|NCT01667549|Other|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
331800|NCT01667536|Drug|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
331801|NCT01667523|Dietary Supplement|Capsaicin|1.5 mg capsaicin administered intraduodenally
331802|NCT01667523|Dietary Supplement|Cinnamaldehyde|70 mg per intervention administered intraduodenally
331803|NCT01667523|Dietary Supplement|Placebo|Physiological saline
331804|NCT01667510|Dietary Supplement|Cardio Mato|Soft gel capsule for oral use
331805|NCT01667510|Dietary Supplement|Placebo|Soft gel capsule without test material
331806|NCT01667497|Drug|Fampridine SR|
331807|NCT01667497|Drug|Placebo|
331808|NCT01667484|Drug|Adderall XR 5mg|
331809|NCT01667484|Drug|Adderall XR 10 mg|
331810|NCT01667484|Drug|Placebo|
331811|NCT01667471|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
331812|NCT01667445|Drug|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
331813|NCT01667445|Drug|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
331814|NCT01667432|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
331815|NCT01667419|Drug|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) were administered orally as per the schedule specified in the respective arm.
331816|NCT01667419|Drug|Placebo|Placebo matching to vemurafenib were administered orally as per the schedule specified in the respective arm.
331817|NCT01667406|Drug|kisspeptin|kisspeptin doses between 1.6 and 12.8 nmol/kg subcutaneously
331818|NCT01667393|Device|IDEV SUPERA Stent|
331819|NCT01667393|Device|Percutaneous Transluminal Angioplasty|
331820|NCT01667367|Drug|RG1662|Single oral dose
331821|NCT01667367|Drug|placebo|Single oral dose
331822|NCT01667354|Behavioral|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
331823|NCT01667341|Biological|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
331824|NCT01667341|Biological|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
331825|NCT01667341|Biological|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
331826|NCT01667328|Procedure|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
331827|NCT01667328|Procedure|Standard of care|Control group will receive standard of care with no massage therapy
331828|NCT01667315|Drug|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
331829|NCT01667302|Drug|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
331830|NCT01667289|Radiation|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
331831|NCT01667289|Drug|Concurrent chemoradiation|"Concurrent chemoradiation~Chemotherapy:~Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
331832|NCT01667263|Drug|All-trans retinoic acid|
331833|NCT01667263|Drug|Danazol|
331834|NCT01667250|Device|GammaCore Active Device|
331835|NCT01667250|Device|GammaCore Sham Device|
331867|NCT01666990|Drug|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
331868|NCT01666990|Drug|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
331869|NCT01666977|Drug|AMG 386|15mg/kg
331870|NCT01666977|Drug|AMG 386|30 mg/kg
331871|NCT01666977|Drug|AMG 386 Placebo|AMG 386 Placebo
331872|NCT01666977|Drug|Pemetrexed|Pemetrexed 500 mg/m2
331873|NCT01666977|Drug|Carboplatin|Carboplatin AUC 6
331874|NCT01666964|Other|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
331836|NCT01667237|Behavioral|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
331837|NCT01667224|Dietary Supplement|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
331838|NCT01667224|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Actiponin.
331839|NCT01667211|Drug|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
331840|NCT01667198|Procedure|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
331841|NCT01667198|Behavioral|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
331842|NCT01667172|Device|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
331843|NCT01667159|Behavioral|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
331844|NCT01667159|Behavioral|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
331845|NCT01667146|Other|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH > 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
331846|NCT01667146|Other|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
331847|NCT01667133|Drug|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
331848|NCT01667133|Drug|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
331849|NCT01667120|Drug|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
331850|NCT01667120|Drug|placebo|
331851|NCT01667107|Drug|Posaconazole|
331852|NCT01667107|Drug|Calogen®|
331853|NCT01667094|Drug|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
331854|NCT01667094|Drug|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
331855|NCT01667094|Drug|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
331856|NCT01667094|Drug|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
331857|NCT01667094|Drug|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
331858|NCT01667094|Drug|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
331859|NCT01667094|Drug|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
331860|NCT01667094|Drug|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
331861|NCT01667094|Drug|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
331862|NCT01667094|Drug|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
331863|NCT01667081|Drug|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
331864|NCT01667068|Other|Comprehensive non invasive cardiovascular examination|"Anamnesis with the participian~File recherche,Physical examination~Documentation of the carciovascular and antiretroviral medical therapy~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~Measuring of the arterial media thickness~Exercise Montreal Cognitive Assesment test~Exercise the Grooved Pegboard test~Blood collection~Questionnaire to quality of life and health economics"
331865|NCT01667029|Drug|Sulfasalazine|
331866|NCT01667029|Drug|placebo|
331877|NCT01666938|Other|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
331878|NCT01666938|Other|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
331879|NCT01666925|Biological|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu
331880|NCT01666925|Biological|Rabies vaccine|2 x 2.5IU Verorab
331881|NCT01666912|Drug|Contraceptive implant|
331882|NCT01666899|Procedure|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
331883|NCT01666886|Device|Mandibular Advancement Device (MAD)|
331884|NCT01666873|Procedure|patients that undergo a total knee prosthesis|
331885|NCT01666860|Procedure|Anterior Lumbar Interbody Fusion procedure|
331886|NCT01666847|Procedure|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
331887|NCT01666821|Other|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
331888|NCT01666808|Drug|FACBC|FACBC is given intravenously prior to PET scan
331889|NCT01666808|Radiation|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
331890|NCT01666782|Biological|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
331891|NCT01666782|Biological|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
331892|NCT01666769|Drug|Micafungin|4 mg/kg/day
331893|NCT01666769|Drug|Micafungin|8 mg/kg/day
331894|NCT01666769|Drug|Micafungin|Standard of care Dosing
331895|NCT01666756|Dietary Supplement|Chinese herbal formulation PHY906|Given PO
331896|NCT01666756|Drug|sorafenib tosylate|Given PO
331897|NCT01666756|Other|laboratory biomarker analysis|Correlative studies
331898|NCT01666756|Other|pharmacological study|Correlative studies
331899|NCT01666743|Drug|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
331900|NCT01666730|Drug|metformin hydrochloride|Given PO
331901|NCT01666730|Drug|oxaliplatin|Given IV
331902|NCT01666730|Drug|leucovorin calcium|Given IV
331903|NCT01666730|Drug|fluorouracil|Given IV
331904|NCT01666730|Other|laboratory biomarker analysis|Correlative studies
331905|NCT01666704|Drug|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
331906|NCT01666704|Drug|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
331907|NCT01666704|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
331908|NCT01666691|Drug|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
331909|NCT01666691|Drug|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
331910|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
331911|NCT01666678|Drug|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
331912|NCT01666678|Drug|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
331913|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
331914|NCT01666665|Drug|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
331915|NCT01666665|Drug|Sugar pill|Sugar pill up to 3 times per day for 12 months
331916|NCT01666652|Biological|4 µg TDENV-PIV with Alum adjuvant|
331917|NCT01666652|Biological|1 µg TDENV-PIV with AS03B1 adjuvant|
331918|NCT01666652|Other|Phosphate buffered saline|
331919|NCT01666652|Biological|1 µg TDENV-PIV with Alum adjuvant|
331920|NCT01666652|Biological|1 µg TDENV-PIV with AS01E1 adjuvant|
331921|NCT01666639|Behavioral|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
331922|NCT01666639|Behavioral|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
331923|NCT01666626|Procedure|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
331924|NCT01666613|Drug|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
331926|NCT01666613|Drug|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
331927|NCT01666613|Drug|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
331928|NCT01666600|Drug|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
331929|NCT01666600|Radiation|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
331930|NCT01666587|Dietary Supplement|Antioxidant|
331931|NCT01666587|Drug|Prostaglandin inhibitor (Ibuprophen)|
331932|NCT01666574|Other|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
331933|NCT01666574|Other|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
331934|NCT01666561|Other|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
331935|NCT01666561|Other|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
331936|NCT01666561|Other|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
331937|NCT01666535|Biological|Influenza vaccination|
331938|NCT01666522|Drug|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
331939|NCT01666522|Other|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
331940|NCT01666509|Device|Rossoseq™|
331941|NCT01666509|Device|Placebo|
331942|NCT01666496|Behavioral|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
331943|NCT01666496|Behavioral|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
331944|NCT01666483|Procedure|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
331945|NCT01666483|Procedure|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
331946|NCT01666470|Other|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
331947|NCT01666457|Other|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
331948|NCT01666444|Drug|pegylated liposomal doxorubicin (PLD)|
331949|NCT01666444|Drug|VTX-2337|TLR8 Agonist
331950|NCT01666444|Drug|Placebo|
331951|NCT01666431|Drug|Lapatinib|
331952|NCT01666418|Drug|Pazopanib/Paclitaxel|
331953|NCT01666405|Device|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
331954|NCT01666392|Dietary Supplement|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
331955|NCT01666392|Dietary Supplement|Placebo|Placebo
331956|NCT01666379|Drug|Fentanyl|
331957|NCT01666366|Procedure|Coronary artery bypass grafting|
331958|NCT01666353|Radiation|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
331959|NCT01666340|Other|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
331960|NCT01666340|Other|Exercise intervention|High intensity exercise
331961|NCT01666327|Drug|MT-1303|
331962|NCT01666314|Drug|Orteronel|Orteronel tablets
331963|NCT01666314|Drug|Orteronel Placebo|Orteronel placebo-matching tablets
331964|NCT01666314|Drug|Prednisone|Prednisone 5 mg
331965|NCT01666301|Drug|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
332013|NCT01665976|Drug|RO4927838|hard gelatin capsule, single dose
332014|NCT01665963|Device|TopClosure(c) System|
331966|NCT01666262|Biological|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
331967|NCT01666262|Other|Placebo:Stabilizer|5% sucrose
331968|NCT01666249|Biological|Immunoglobulin Anti-RhD|Participants will receive a single intramuscular administration of 300 mcg/2mL, correponding 1500 UI of Human Immunoglobulin Anti-RhD (Kamrho-D - Panamerican), up to 72 hours post exposition (child-birth).
331969|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.~After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
331970|NCT01666223|Drug|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
331971|NCT01666223|Drug|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
331972|NCT01666223|Other|saline|100 ml saline
331973|NCT01666223|Drug|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
331974|NCT01666210|Drug|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
331975|NCT01666210|Drug|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
331976|NCT01666197|Drug|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
331977|NCT01666197|Drug|placebo|placebo
331978|NCT01666171|Drug|metformin hydrochloride|
331979|NCT01666171|Other|clinical observation|
331980|NCT01666171|Other|diagnostic laboratory biomarker analysis|
331981|NCT01666171|Other|imaging biomarker analysis|
331982|NCT01666171|Other|medical chart review|
331983|NCT01666171|Procedure|digital mammography|
331984|NCT01666158|Behavioral|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
331985|NCT01666145|Device|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
331986|NCT01666132|Other|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
331987|NCT01666132|Other|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
331988|NCT01666132|Other|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
331989|NCT01666119|Drug|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
331990|NCT01666093|Procedure|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
331991|NCT01666080|Drug|Busulfan|0.4 mg/kg (0.5 mg/kg if <4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
331992|NCT01666080|Drug|Fludarabine|40 mg/m^2 intravenously (IV) over 1 hour on days -6 through -2.
331993|NCT01666080|Radiation|Total body irradiation|200 cGy on Day -1
331994|NCT01666080|Biological|Stem cell transplant|stem cell infusion on day 0
331995|NCT01666080|Drug|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
331996|NCT01666067|Drug|placebo|
331997|NCT01666067|Drug|vytorin|
331998|NCT01666067|Drug|simvastatin|
331999|NCT01666054|Other|PSV|Pressure Support Ventilation will be used until patient is extubated
332000|NCT01666054|Other|PAV|Proportional Assist Ventilation will be used until patient is extubated.
332001|NCT01666041|Drug|placebo|
332002|NCT01666041|Drug|fenofibrate/omega|
332003|NCT01666041|Drug|fenofibrate|
332004|NCT01666028|Device|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
332005|NCT01666028|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
332006|NCT01666015|Other|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.~The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
332007|NCT01666015|Other|Standard Care|This group will be under standard care without any EX intervention.
332008|NCT01666002|Device|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
332009|NCT01665989|Behavioral|Group Lifestyle Program|
332010|NCT01665989|Behavioral|Usual Care|Visits with a dietitian at nutrition services at MGH
332011|NCT01665976|Drug|RO4917838|film coated tablet, single dose
332012|NCT01665976|Drug|RO4917838|oral suspension, single dose
332015|NCT01665963|Device|Pressure Bandage|
332016|NCT01665950|Drug|Simvastatin|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
332017|NCT01665950|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
332018|NCT01665937|Drug|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.~During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
332019|NCT01665924|Drug|GLPG0634 100mg capsule once a day for 10 days|
332020|NCT01665911|Drug|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
332021|NCT01665911|Drug|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
332022|NCT01665911|Drug|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
332023|NCT01665911|Drug|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
332024|NCT01665911|Other|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
332025|NCT01665898|Procedure|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
332026|NCT01665898|Procedure|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
332027|NCT01665885|Device|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
332028|NCT01665885|Device|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
332029|NCT01665872|Behavioral|Cognitive-Behavioral Group Therapy|CBT Group
332030|NCT01665846|Drug|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
332031|NCT01665820|Device|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
332032|NCT01665807|Biological|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
332033|NCT01665807|Biological|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
332034|NCT01665794|Drug|Pomalidomide|Pomalidomide taken orally at assigned dose.
332035|NCT01665794|Drug|Carfilzomib|Carfilzomib given by intravenous (IV) infusion at assigned dose.
332036|NCT01665794|Drug|dexamethasone|Dexamethasone taken orally of given by IV infusion.
332037|NCT01665794|Drug|Daratumumab|Daratumumab given by intravenous (IV) infusion at assigned dose.
332038|NCT01665781|Drug|Erythropoietin|
332039|NCT01665768|Drug|Everolimus|The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL.
332040|NCT01665768|Biological|Rituximab|375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
332041|NCT01665755|Device|Upstroke Compression Defibrillation|
332042|NCT01665755|Device|Precompression Defibrillation|
332043|NCT01665742|Dietary Supplement|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks~AND~4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks~in conjunction with a weight management programme"
332044|NCT01665742|Dietary Supplement|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks~AND~4 x film-coated placebo tablets daily for 8 weeks~in conjunction with a weight management programme"
332045|NCT01665703|Procedure|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
332046|NCT01665690|Other|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
332047|NCT01665690|Behavioral|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
332048|NCT01665677|Drug|Atorvastatin calcium|40 mg PO daily
332049|NCT01665664|Other|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
332087|NCT01665352|Drug|Placebo|Administered orally once daily for 12 weeks.
332050|NCT01665651|Drug|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
332051|NCT01665651|Drug|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
332052|NCT01665651|Drug|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
332053|NCT01665651|Drug|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
332054|NCT01665638|Drug|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
332055|NCT01665638|Drug|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
332056|NCT01665638|Drug|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
332057|NCT01665638|Drug|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
332058|NCT01665625|Procedure|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
332059|NCT01665612|Device|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
332060|NCT01665599|Drug|Testosterone gel (FE 999303)|
332061|NCT01665586|Drug|dexmedetomidine|"Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water~dexmedetomidine 0.2~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration"
332062|NCT01665573|Drug|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
332063|NCT01665573|Drug|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
332064|NCT01665547|Drug|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
332065|NCT01665534|Behavioral|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
332066|NCT01665521|Other|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
332067|NCT01665508|Drug|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
332068|NCT01665495|Procedure|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return<30 ml.
332069|NCT01665482|Other|A 2000 kcal test meal|
332070|NCT01665482|Other|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
332071|NCT01665469|Dietary Supplement|Tomato extracted lycopene|
332072|NCT01665469|Dietary Supplement|Placebo|
332073|NCT01665430|Drug|Tocilizumab|Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.
332074|NCT01665417|Drug|Experimental|Icotinib: 125mg, oral administration, three times per day.
332075|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
332076|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
332077|NCT01665404|Drug|Fluvoxamine|Multiple doses of fluvoxamine
332078|NCT01665404|Drug|RO4917523|Single dose of RO4917523
332079|NCT01665391|Drug|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
332080|NCT01665391|Drug|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
332081|NCT01665391|Drug|Placebo|Placebo administered to match active treatment group
332082|NCT01665378|Dietary Supplement|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.~Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
332083|NCT01665378|Dietary Supplement|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
332084|NCT01665378|Dietary Supplement|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
332085|NCT01665365|Procedure|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
332086|NCT01665352|Drug|TTP054|Administered orally once daily for 12 weeks.
332088|NCT01665339|Other|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
332089|NCT01665339|Other|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
332090|NCT01665326|Other|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
332091|NCT01665274|Drug|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
332092|NCT01665274|Drug|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
332093|NCT01665274|Procedure|D2 resection|D2 resection
332094|NCT01665248|Other|18-F Sodium Fluoride Uptake in Positron emission tomography|
332095|NCT01665235|Drug|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
332096|NCT01665235|Drug|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
332097|NCT01665235|Drug|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
332098|NCT01665235|Drug|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
332099|NCT01665222|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
332100|NCT01665209|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
332101|NCT01665196|Drug|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
332102|NCT01665183|Drug|ADI-PEG 20|
332103|NCT01665170|Drug|Passiflora incarnata|3 x 1 tablet per day for 3 days
332104|NCT01665170|Drug|Placebo|3 x 1 ablet per day for 3 days
332105|NCT01665157|Dietary Supplement|Enimaclin®|"Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.~The duration of study is one day before colonoscopy."
332106|NCT01665157|Other|Self-controlled diet|Self-controlled low residue diet.
332107|NCT01665157|Drug|2L PEG-ELS|Normal volume of PEG-ELS
332108|NCT01665157|Drug|low volume 1.5L PEG-ELS|Low volume PEG-ELS
332109|NCT01665144|Drug|BAF312|0.25, 0.5, 1, and 2 mg film-coated tablets
332110|NCT01665144|Drug|Placebo|Film-coated tablets
332111|NCT01665131|Device|Cameron Health S-ICD SQ-RX|
332112|NCT01665118|Device|Trusculpt (Radio Frequency) Device|
332113|NCT01665105|Device|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
332114|NCT01665092|Drug|Levo-Carnitine|
332115|NCT01665092|Drug|placebo|
332116|NCT01665079|Drug|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 > 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
332117|NCT01665066|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
332118|NCT01665066|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
332119|NCT01665066|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
332120|NCT01665066|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
332121|NCT01665066|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
332122|NCT01665053|Device|PROMUS Element Plus|A drug eluting coronary stent system
332123|NCT01665053|Device|SYNERGY|A drug eluting coronary stent system
332124|NCT01665040|Device|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.~Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
332125|NCT01665027|Procedure|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
332126|NCT01665027|Procedure|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
332127|NCT01665014|Radiation|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
332178|NCT01664728|Drug|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
332179|NCT01664715|Behavioral|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
332128|NCT01665001|Other|Treatment strategy: induction, consolidation, HSCT, maintenance|"Patients <55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD <0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.~Patients >55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.~Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT."
332129|NCT01664988|Behavioral|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
332130|NCT01664988|Behavioral|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
332131|NCT01664988|Other|control (routine care)|received routine care of clinic or health center and use drugs if necessary
332132|NCT01664975|Drug|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
332133|NCT01664975|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
332134|NCT01664949|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
332135|NCT01664949|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
332136|NCT01664936|Radiation|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
332137|NCT01664923|Drug|Enzalutamide|160 mg, daily, by mouth.
332138|NCT01664923|Drug|Bicalutamide|50 mg, daily, by mouth
332139|NCT01664910|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BM transplant
332140|NCT01664910|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or BM transplant
332141|NCT01664910|Biological|Anti-Thymocyte Globulin|Given IV
332142|NCT01664910|Drug|Bendamustine Hydrochloride|Given IV
332143|NCT01664910|Drug|Fludarabine Phosphate|Given IV
332144|NCT01664910|Biological|Inotuzumab Ozogamicin|Given IV
332145|NCT01664910|Drug|Methotrexate|Given IV
332146|NCT01664910|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
332147|NCT01664910|Biological|Rituximab|Given IV
332148|NCT01664910|Drug|Tacrolimus|Given IV or PO
332149|NCT01664897|Drug|Erlotinib Hydrochloride|Given PO
332150|NCT01664897|Other|Laboratory Biomarker Analysis|Correlative studies
332151|NCT01664871|Device|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
332152|NCT01664858|Other|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
332153|NCT01664858|Other|SPECT|SPECT: Single Photon Emission Computed Tomography
332154|NCT01664858|Other|CT calcium score|CT calcium score
332155|NCT01664858|Other|CT coronary angiography|CT coronary angiography
332156|NCT01664858|Other|X-Ray coronary angiography|X-Ray coronary angiography
332157|NCT01664845|Drug|metformin|metformin 500mg tid
332158|NCT01664845|Drug|pegylated-IFN|pegasys 180 mcg qw
332159|NCT01664845|Drug|ribavirin|ribavirin 800-1200 mg qd according to BW
332160|NCT01664832|Device|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
332161|NCT01664819|Dietary Supplement|Antioxidant|
332162|NCT01664819|Dietary Supplement|Placebo|
332163|NCT01664806|Device|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
332164|NCT01664793|Behavioral|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
332165|NCT01664780|Device|ARFI imaging|
332166|NCT01664767|Other|Sulfur Thermal water|
332167|NCT01664767|Other|Placebo|
332168|NCT01664754|Drug|exemestane|Given PO
332169|NCT01664754|Drug|pemetrexed disodium|Given IV
332170|NCT01664754|Drug|carboplatin|Given IV
332171|NCT01664754|Other|laboratory biomarker analysis|Correlative studies
332172|NCT01664754|Other|pharmacological study|Correlative studies
332173|NCT01664754|Other|questionnaire administration|Ancillary studies
332174|NCT01664754|Procedure|quality-of-life assessment|Ancillary studies
332175|NCT01664741|Drug|Nicotine patch - transdermal|21 mg patch
332176|NCT01664741|Drug|placebo|
332177|NCT01664728|Drug|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
332221|NCT01664182|Biological|Bevacizumab|Given IV
332180|NCT01664715|Behavioral|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
332181|NCT01664715|Behavioral|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
332182|NCT01664702|Dietary Supplement|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
332183|NCT01664702|Dietary Supplement|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
332184|NCT01664689|Procedure|Microcoaxial Phacoemulsification|
332185|NCT01664676|Drug|Liraglutide|
332186|NCT01664676|Drug|Placebo-liraglutide|
332187|NCT01664663|Radiation|Standard radiochemotherapy to 68 Gy|
332188|NCT01664663|Radiation|Dose escalated radiochemotherapy up to 84 Gy|
332189|NCT01664650|Dietary Supplement|Genistein|
332190|NCT01664650|Dietary Supplement|Placebo|
332191|NCT01664637|Drug|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
332192|NCT01664637|Drug|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
332193|NCT01664624|Drug|Roflumilast|Roflumilast tablets
332194|NCT01664624|Drug|Alogliptin|Alogliptin tablets
332195|NCT01664624|Drug|Exenatide|Exenatide solution
332196|NCT01664624|Drug|Placebo to roflumilast|Placebo-matching roflumilast tablets
332197|NCT01664624|Drug|Placebo to alogliptin|Placebo-matching alogliptin tablets
332198|NCT01664611|Procedure|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
332199|NCT01664611|Procedure|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
332200|NCT01664598|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
332201|NCT01664585|Behavioral|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
332202|NCT01664585|Behavioral|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
332203|NCT01664559|Drug|Ketorolac|Ketorolac 30mg intramuscular injection, 1cc volume
332204|NCT01664559|Drug|Normal Saline|Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
332205|NCT01664546|Procedure|Trophectoderm biopsy|
332206|NCT01664533|Drug|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
332207|NCT01664520|Drug|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.~Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
332208|NCT01664507|Drug|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
332209|NCT01664507|Drug|low dose epinephrine|low dose epineprhine : 0.1mg/kg + 0.9% normal saline
332210|NCT01664494|Drug|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
332211|NCT01664273|Drug|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:~50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.~Injection volume will remain constant at 200 μL.~Once-only treatment and intra-individual dose escalation will therefore not occur."
332212|NCT01664260|Drug|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
332213|NCT01664260|Drug|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
332214|NCT01664247|Drug|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
332215|NCT01664247|Drug|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
332216|NCT01664247|Drug|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
332217|NCT01664234|Other|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
332218|NCT01664234|Other|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
332219|NCT01664221|Drug|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
332220|NCT01664195|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
332224|NCT01664182|Drug|Pazopanib Hydrochloride|Given PO
332225|NCT01664182|Other|Pharmacological Study|Correlative studies
332226|NCT01664182|Drug|Sorafenib|Given PO
332227|NCT01664182|Drug|Sorafenib Tosylate|Given PO
332228|NCT01664182|Drug|Sunitinib|Given PO
332229|NCT01664182|Drug|Sunitinib Malate|Given PO
332230|NCT01664182|Biological|Trebananib|Given IV
332231|NCT01664169|Other|laboratory biomarker analysis|
332232|NCT01664156|Drug|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
332233|NCT01664156|Drug|Placebo|
332234|NCT01664143|Drug|Placebo|Multiple doses of placebo
332235|NCT01664143|Drug|RO5508887|Multiple doses of RO5508887
332236|NCT01664130|Radiation|stereotactic body radiation therapy|Undergo SBRT
332237|NCT01664130|Procedure|quality-of-life assessment|Ancillary studies
332238|NCT01664130|Other|laboratory biomarker analysis|Correlative studies
332239|NCT01664104|Drug|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
332240|NCT01664091|Radiation|post-mastectomy radiation therapy (PMRT)|
332241|NCT01664091|Device|tissue expander (TE)|
332242|NCT01664091|Device|acellular dermal matrix (ADM)|
332243|NCT01664078|Device|Endovascular AAA repair with InCraft®|
332244|NCT01664065|Drug|200 mg Ceftaroline fosamil|1 h infusion
332245|NCT01664065|Drug|600 mg Ceftaroline fosamil|1 h infusion
332246|NCT01664052|Device|ESS505 (Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
332247|NCT01664052|Device|ESS305 (Essure, BAY1454032)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
332248|NCT01664052|Device|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
332249|NCT01664039|Drug|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
332250|NCT01664039|Drug|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
332251|NCT01664026|Behavioral|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
332252|NCT01664026|Behavioral|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
332253|NCT01664013|Drug|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
332254|NCT01664000|Drug|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
332255|NCT01663987|Drug|tiotropium bromide|18 mcg once a day (QD)
332256|NCT01663987|Drug|Placebo|once a day (QD)
332257|NCT01663961|Drug|YM178 OCAS|oral
332258|NCT01663961|Drug|Digoxin|oral
332259|NCT01663935|Drug|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
332260|NCT01663922|Drug|Boceprevir|Boceprevir as Victrelis(r) 200mg capsules
332261|NCT01663922|Drug|St John's Wort|Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
332262|NCT01663909|Behavioral|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
332263|NCT01663883|Other|Isometric exercise|use of a handgrip for 3x2 minutes
332264|NCT01663870|Behavioral|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
332265|NCT01663870|Behavioral|Focus Group Session|Focus group session taking 60-90 minutes.
332266|NCT01663870|Other|Website Session|10-15 minute session with the HealthATM website.
332267|NCT01663870|Behavioral|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
332268|NCT01663857|Drug|LY2228820|Administered Orally
332269|NCT01663857|Drug|Carboplatin|Administered IV
332270|NCT01663857|Drug|Placebo|Administered Orally
332271|NCT01663857|Drug|Gemcitabine|Administered IV
332272|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
334420|NCT01646775|Drug|epidural fentanyl|withold epidural fentanyl
332273|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
332274|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
332275|NCT01663844|Behavioral|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
332276|NCT01663831|Other|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
332277|NCT01663818|Device|Tack-It Endovascular Stapler|
332278|NCT01663805|Drug|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
332279|NCT01663792|Other|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
332280|NCT01663792|Other|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
332281|NCT01663792|Other|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
332282|NCT01663779|Procedure|Ultrasound guided radial artery catheterization.|Radial artery catheters will be placed with the assistance of bedside ultrasound.
332283|NCT01663779|Procedure|Blind insertion of radial artery catheterization|Radial artery catheters will be placed by the palpation technique only.
332284|NCT01663766|Drug|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
332285|NCT01663753|Device|18F-FDG-PET|
332286|NCT01663740|Drug|Valganciclovir|Participants will receive valganciclovir 900 milligrams (mg) orally once daily for up to a maximum of 200 days post-transplant.
332287|NCT01663727|Drug|Bevacizumab [Avastin]|Intravenous repeating dose
332288|NCT01663727|Drug|Paclitaxel|Intravenous repeating dose
332289|NCT01663727|Drug|Placebo|Intravenous repeating dose
332290|NCT01663714|Biological|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
332291|NCT01663701|Other|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
332292|NCT01663701|Other|Usual care|Patients are managed according to admitting doctors' orders
332293|NCT01663675|Genetic|karyotype|
332294|NCT01663662|Drug|Tolvaptan|
332295|NCT01663662|Drug|placebo|
332296|NCT01663649|Behavioral|Deprexis|web-based treatment program for depression
332297|NCT01663649|Behavioral|Wait-list|the wait-list group receives Deprexis after 6 month
332298|NCT01663636|Behavioral|SMS message reminding mothers to come for their scheduled vaccines|Reminder
332299|NCT01663623|Biological|Placebo|Placebo
332300|NCT01663623|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg
332301|NCT01663623|Drug|Azathioprine|Azathioprine
332302|NCT01663610|Behavioral|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
332303|NCT01663584|Procedure|Blood draw|
332304|NCT01663558|Drug|imiquimod|
332305|NCT01663558|Procedure|ablative|
332306|NCT01663532|Drug|Aripiprazole IM Depot|
332307|NCT01663532|Drug|Placebo|Matching Placebo
332308|NCT01663519|Other|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
332309|NCT01663519|Other|Prefabricated insoles|Prefabricated insoles
332310|NCT01663519|Other|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
332311|NCT01663493|Procedure|FNB|
332312|NCT01663467|Drug|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
332313|NCT01663467|Behavioral|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.~Ginexin-F 80mg tablet will be given twice a day for 6 months."
332314|NCT01663454|Behavioral|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
332315|NCT01663441|Drug|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
332316|NCT01663441|Drug|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
332317|NCT01663441|Drug|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
332318|NCT01663441|Drug|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
332319|NCT01663428|Other|Sup-ER Splint|
332320|NCT01663428|Other|Currently accepted treatment|
332321|NCT01663415|Drug|Enzalutamide|oral
332322|NCT01663402|Drug|Alirocumab|Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
332323|NCT01663402|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.
332324|NCT01663402|Drug|LMT|Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
332325|NCT01663389|Drug|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
332326|NCT01663389|Drug|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
332327|NCT01663376|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 ~3x10e8 cells
332328|NCT01663363|Device|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
332329|NCT01663337|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
332330|NCT01663337|Behavioral|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
332331|NCT01663324|Device|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.~Arms: single site rTMS"
332332|NCT01663324|Device|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS"
332333|NCT01663311|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
332334|NCT01663311|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
332335|NCT01663298|Procedure|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
332336|NCT01663285|Drug|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
332337|NCT01663272|Drug|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
332338|NCT01663272|Drug|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
332339|NCT01663259|Drug|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
332340|NCT01663259|Radiation|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
332341|NCT01663246|Procedure|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
332342|NCT01663233|Drug|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
332343|NCT01663233|Drug|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
332344|NCT01663233|Drug|Placebo|Matching placebo to LCZ696
332345|NCT01663194|Procedure|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
332346|NCT01663168|Drug|Rifabutin|
332347|NCT01663155|Device|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
332348|NCT01663116|Genetic|Stem cells|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15~second cohort: 2 million stem cells / kg administered at days 1, 8 and 15~third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
332349|NCT01663116|Genetic|Placebo|"first cohort: 20 ml administered at days 1, 8 and 15~second cohort: 40 ml administered at days 1, 8 and 15~third cohort: 80 ml administered at days 1, 8 and 15"
332350|NCT01663103|Drug|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
332351|NCT01663103|Drug|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
332352|NCT01663090|Drug|Ferumoxytol|
332353|NCT01663077|Drug|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
332354|NCT01663064|Device|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
332355|NCT01663051|Device|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
332356|NCT01663038|Drug|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
332357|NCT01663038|Drug|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
332358|NCT01663038|Drug|Aspirin|
332359|NCT01663025|Behavioral|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
332360|NCT01663012|Drug|Etirinotecan pegol|
332361|NCT01662999|Drug|Saxagliptin|
332362|NCT01662999|Drug|Dapagliflozin|
332363|NCT01662986|Drug|tiotropium bromide|18 mcg once a day (QD)
332364|NCT01662986|Drug|Placebo|Once a day (QD)
332365|NCT01662973|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1*10E6 UC-MSC/kg body weight for 12 weeks.
332366|NCT01662973|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
332367|NCT01662960|Behavioral|Mirror therapy|A home-based therapy involving mirrored visual feedback
332368|NCT01662960|Behavioral|Divider therapy|A home-based therapy involving removed visual feedback.
332369|NCT01662947|Device|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
332370|NCT01662947|Device|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
332371|NCT01662934|Device|I RUNE|
332372|NCT01662934|Device|sham|
332373|NCT01662921|Drug|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
332374|NCT01662921|Drug|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
332375|NCT01662921|Drug|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
332376|NCT01662908|Drug|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
332377|NCT01662908|Drug|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
332378|NCT01662908|Drug|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
332379|NCT01662895|Drug|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
332380|NCT01662895|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
332381|NCT01662882|Drug|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
332382|NCT01662869|Drug|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m^2) IV bolus and then 2400 mg/m^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
332383|NCT01662869|Drug|Folinic acid|Participants will receive folinic acid 400 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
332384|NCT01662869|Drug|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
332385|NCT01662869|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
332386|NCT01662869|Drug|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
332387|NCT01662856|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
332388|NCT01662856|Procedure|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
332389|NCT01662817|Behavioral|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
332390|NCT01662817|Behavioral|Control|PCP manages depression in the usual way for six months
332391|NCT01662804|Drug|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
332432|NCT01662440|Other|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
332605|NCT01660867|Drug|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
332392|NCT01662791|Drug|Rifaximin|All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
332393|NCT01662778|Drug|1.5 microns at 50mg|STAG generated monodisperse 1.5micron particles
332394|NCT01662778|Drug|6 microns at 50mg|STAG generated monodisperse 6 micron particles
332395|NCT01662778|Drug|Placebo Comparator|No drug just solvent
332396|NCT01662778|Drug|MDI FP|
332397|NCT01662765|Procedure|Surgery|modified umbilectomy
332398|NCT01662765|Other|conservative|this treatment will include conservative procedures under local anesthesia for patient comfort.
332399|NCT01662752|Drug|Indocyanine green|Please see arm description
332400|NCT01662739|Behavioral|Questionnaire|
332401|NCT01662726|Drug|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
332402|NCT01662713|Device|OFDI|Imaging of skin
332403|NCT01662700|Drug|Artesunate|
332404|NCT01662700|Drug|Chloroquine|
332405|NCT01662687|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
332406|NCT01662687|Drug|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.~Active Comparator arm:~Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).~Kytril tab. 1mg: administered twice a day by orally at Day 2~4."
332407|NCT01662674|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
332408|NCT01662674|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
332409|NCT01662661|Drug|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
332410|NCT01662661|Drug|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
332411|NCT01662648|Drug|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
332412|NCT01662622|Drug|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
332413|NCT01662609|Procedure|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
332414|NCT01662583|Other|Text Message|
332415|NCT01662583|Other|Written reminder|
332416|NCT01662570|Behavioral|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
332417|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
332418|NCT01662557|Behavioral|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
332419|NCT01662557|Other|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
332420|NCT01662544|Procedure|Oxygen delivery|
332421|NCT01662531|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
332422|NCT01662518|Device|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
332423|NCT01662505|Drug|Volasertib|Patient to receive volasertib
332424|NCT01662492|Biological|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
332425|NCT01662492|Biological|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
332426|NCT01662492|Drug|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
332427|NCT01662466|Drug|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
332428|NCT01662466|Dietary Supplement|DHEA|DHEA 25mg tid
332429|NCT01662466|Drug|Placebo|Carrier cream without added testosterone in the identical type of pump
332430|NCT01662440|Biological|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
332431|NCT01662440|Biological|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
332433|NCT01662427|Other|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
332434|NCT01662414|Dietary Supplement|Whey protein|1 sachect (10 g) 2times/ day
332435|NCT01662414|Dietary Supplement|Soy protein|1 sachect (10g) 2times/day
332436|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
332437|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
332438|NCT01662388|Device|Separation ring|Separation ring placed along with automatrix band
332439|NCT01662388|Device|automatrix band|band placed with a tightening device
332440|NCT01662375|Other|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
332441|NCT01662362|Device|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
332442|NCT01662349|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
332443|NCT01662336|Drug|Lopinavir / ritonavir|Prescribed according to the product monograph and physician's discretion.
332444|NCT01662336|Behavioral|Kaletra Adherence Support Assistance Program|A customized support network for patients treated with lopinavir / ritonavir that offers individual counseling with an HIV experienced nurse who assists patients with various aspects of their therapy including life-style changes, emotional stress, and adverse events, and may provide access to various healthcare professionals or may offer other types of support such as transportation, exercise, etc.
332445|NCT01662323|Behavioral|GP's treating HF according the dutch guidelines|
332446|NCT01662310|Drug|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
332447|NCT01662310|Drug|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
332448|NCT01662297|Drug|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
332449|NCT01662297|Drug|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
332450|NCT01662284|Drug|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
332451|NCT01662258|Device|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
332452|NCT01662232|Dietary Supplement|Green tea beverage|
332453|NCT01662232|Dietary Supplement|Green tea extract|
332454|NCT01662232|Dietary Supplement|EGCG|
332455|NCT01662232|Other|Placebo|
332456|NCT01662219|Other|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
332457|NCT01662206|Dietary Supplement|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
332458|NCT01662206|Dietary Supplement|Placebo|2 capsules daily containing 348.25 mg of potato starch
332459|NCT01662193|Dietary Supplement|vitamin D3 supplement|
332460|NCT01662193|Dietary Supplement|calcium supplement|
332461|NCT01662193|Dietary Supplement|vitamin D3 and calcium supplement|
332462|NCT01662193|Dietary Supplement|placebo|
332463|NCT01662180|Drug|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
332464|NCT01662167|Drug|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
332465|NCT01662167|Drug|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
332466|NCT01662154|Device|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
332467|NCT01662154|Device|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
332468|NCT01662128|Drug|Xeloda|Xeloda as Adjuvant Therapy
332469|NCT01662115|Drug|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
332470|NCT01662115|Other|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
332471|NCT01662102|Drug|Zevalin|Group A: Response consolidation with a single dose of 90Y-ibritumomab tiuxetan (Zevalin®) 0.4 mCi/Kg - Maximum dose: 32 mCi given with 2 doses of rituximab followed by observation for 24 months;
332472|NCT01662102|Drug|Rituximab|Group B: Response maintenance with 375 mg/m^2 of rituximab every 8 weeks for 24 months (12 infusions)
332473|NCT01662089|Drug|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
332474|NCT01662089|Drug|Placebo drug supplement|Placebo drug instead of Zinc supplement
332511|NCT01661764|Drug|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
332512|NCT01661764|Drug|Oleic Acid|Placebo
332475|NCT01662076|Other|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
332476|NCT01662063|Drug|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
332477|NCT01662050|Drug|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
332478|NCT01662037|Drug|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
332479|NCT01662024|Device|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
332480|NCT01662011|Device|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
332481|NCT01662011|Device|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
332482|NCT01661985|Drug|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
332483|NCT01661985|Drug|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
332484|NCT01661985|Drug|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
332485|NCT01661972|Drug|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle."
332486|NCT01661946|Drug|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
332487|NCT01661946|Drug|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
332488|NCT01661933|Biological|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
332489|NCT01661933|Biological|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
332490|NCT01661920|Other|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
332491|NCT01661920|Other|Control group|Those antibiotic duration treatments which are not modified by their doctors.
332492|NCT01661907|Procedure|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.5%-0.75% ropivacaine during surgery. Patient controlled epidural analgesia will be provided after surgery.
332493|NCT01661907|Procedure|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
332494|NCT01661894|Device|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
332495|NCT01661881|Drug|Rituximab|
332496|NCT01661881|Drug|Bendamustine|
332497|NCT01661881|Drug|Cytarabine|
332498|NCT01661868|Drug|Olaparib|Tablet formulation will be used.
332499|NCT01661855|Drug|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
332500|NCT01661855|Drug|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
332501|NCT01661842|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
332502|NCT01661842|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
332503|NCT01661816|Behavioral|interview|psychological, emotional, family and social parameters
332504|NCT01661790|Drug|Bevacizumab|Bevacizumab300mg&Cispltin30mg by intrapleural administration of each 2 week
332505|NCT01661790|Drug|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
332506|NCT01661777|Drug|Nasal steroid|
332507|NCT01661777|Procedure|Myringotomy tube placement|
332508|NCT01661777|Drug|Diuretic|
332509|NCT01661777|Drug|Antihistamine|
332510|NCT01661777|Behavioral|Low salt diet|
332513|NCT01661751|Biological|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
332514|NCT01661751|Biological|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
332515|NCT01661738|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2~6 years of age), early youth (7~15 years of age) and adult (16~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
332516|NCT01661725|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
332517|NCT01661712|Device|Transcutaneous electrical stimulation|Transcutaneous electrical stimulation (one night of electrical current titrated according to skin sensation)
332518|NCT01661712|Device|Sham stimulation|Sham stimulation for one night (no electrical stimulation)
332519|NCT01661686|Device|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
332520|NCT01661686|Device|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
332521|NCT01661673|Drug|EVP-0962|Arms: 1,2,3,4
332522|NCT01661673|Drug|Placebo|Arm 5
332523|NCT01661660|Other|observationnal|Observation during a physical exercise
332524|NCT01661647|Device|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
332525|NCT01661634|Drug|Ularitide|
332526|NCT01661634|Drug|Placebo|
332527|NCT01661621|Drug|Detrusitol 4 mg QD|Group 1
332528|NCT01661621|Drug|Doxazosin 4 mg QD|Group 2
332529|NCT01661608|Device|Using the EOS for gastric restriction|
332530|NCT01661595|Drug|Sildenafil|50 mg/day for 4 weeks
332531|NCT01661595|Drug|tadalafil|10 mg/day for 4 weeks.
332532|NCT01661595|Drug|Placebo|Placebo 1 capsule per day for four weeks.
332533|NCT01661582|Other|CT/PET Myocardial Perfusion Imaging using O-15 water|
332534|NCT01661582|Other|Coronary blood flow measured by doppler echocardiography|
332535|NCT01661569|Other|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
332536|NCT01661556|Drug|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
332537|NCT01661556|Drug|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
332538|NCT01661543|Dietary Supplement|Beans|90g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
332539|NCT01661543|Dietary Supplement|Control (rice)|90g of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group.
332540|NCT01661543|Dietary Supplement|Peas|90 grams of peas will be consumed 5 out of 7 days per week
332541|NCT01661530|Dietary Supplement|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
332542|NCT01661530|Dietary Supplement|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
332543|NCT01661517|Behavioral|Motivational interviewing and referral to treatment|
332544|NCT01661504|Behavioral|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
332545|NCT01661478|Other|Training on motivational interviewing|
332546|NCT01661452|Other|Referral to counseling services if desired|
332547|NCT01661439|Drug|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
332548|NCT01661426|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
332549|NCT01661426|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
332550|NCT01661400|Drug|Metronomic Cyclophosphamide|
332551|NCT01661400|Drug|Thalidomide|
332552|NCT01661361|Procedure|blood levels|
332553|NCT01661335|Drug|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
332602|NCT01660893|Drug|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
332603|NCT01660893|Drug|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
332604|NCT01660893|Drug|Placebo|3 unilateral intranasal sprays per dose
332554|NCT01661335|Drug|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
332555|NCT01661322|Drug|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
332556|NCT01661309|Dietary Supplement|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
332557|NCT01661309|Dietary Supplement|Methylcobalamin|Aimed at reducing plasma tHcy.
332558|NCT01661296|Other|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
332559|NCT01661296|Drug|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
332560|NCT01661283|Drug|everolimus|10 mg tablet once daily
332561|NCT01661283|Drug|bevacizumab|10 mg/kg dose every 14 days
332562|NCT01661270|Drug|Aflibercept|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
332563|NCT01661270|Drug|Placebo|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
332564|NCT01661257|Drug|Infliximab|
332565|NCT01661244|Drug|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
332566|NCT01661244|Drug|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
332567|NCT01661244|Drug|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
332568|NCT01661244|Drug|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
332569|NCT01661231|Device|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
332570|NCT01661205|Device|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
332571|NCT01661192|Drug|AAT( Alpha 1 Antitrypsin)|
332572|NCT01661179|Drug|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
332573|NCT01661166|Drug|Fesoterodine|4 mg
332574|NCT01661140|Drug|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
332575|NCT01661140|Drug|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
332576|NCT01661140|Drug|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
332577|NCT01661114|Drug|Gemcitabine|
332578|NCT01661114|Drug|5-FU|
332579|NCT01661114|Drug|Cisplatin|
332580|NCT01661101|Drug|Dabigatran|Dabigatran 110 mg taken twice daily
332581|NCT01661101|Drug|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
332582|NCT01661101|Drug|Omeprazole|Omeprazole 20 mg capsule taken once daily
332583|NCT01661101|Drug|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
332584|NCT01661088|Drug|FOLFIRINOX|"Starting dose levels as following:~Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
332585|NCT01661088|Radiation|Intensity-modulated radiotherapy (IMRT)|50.0Gy in 2.0Gy per fraction
332586|NCT01661088|Procedure|Surgical Exploration|Patients without metastatic disease will be offered surgical exploration.
332587|NCT01661062|Other|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
332588|NCT01660997|Drug|MLN9708|
332589|NCT01660997|Drug|Dexamethasone|
332590|NCT01660971|Drug|Dasatinib|Given PO
332591|NCT01660971|Drug|Erlotinib Hydrochloride|Given PO
332592|NCT01660971|Drug|Gemcitabine Hydrochloride|Given IV
332593|NCT01660958|Dietary Supplement|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
332594|NCT01660958|Behavioral|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
332595|NCT01660945|Drug|placebo|
332596|NCT01660945|Drug|vytorin|
332597|NCT01660932|Drug|placebo|
332598|NCT01660932|Drug|omega|
332599|NCT01660919|Drug|placebo|
332600|NCT01660919|Drug|rosuvastatin|
332601|NCT01660906|Drug|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
332606|NCT01660867|Drug|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
332607|NCT01660854|Biological|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
332608|NCT01660854|Drug|Malarone treatment|Three days: 4 tablets 250/100mg per day
332609|NCT01660841|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
332610|NCT01660828|Other|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
332611|NCT01660815|Drug|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
332612|NCT01660802|Drug|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
332613|NCT01660802|Other|Sham|Sham administered in the study eye on Day 1.
332614|NCT01660789|Behavioral|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
332615|NCT01660763|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
332616|NCT01660763|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
332617|NCT01660750|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
332618|NCT01660750|Drug|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
332619|NCT01660750|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
332620|NCT01660724|Procedure|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
332621|NCT01660724|Procedure|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
332622|NCT01660711|Drug|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
332623|NCT01660711|Drug|Leucovorin|400 mg/m2 by IV infusion over 2 hours
332624|NCT01660711|Drug|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
332625|NCT01660711|Drug|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
332626|NCT01660698|Dietary Supplement|Maltodextrin|maltodextrin powder
332627|NCT01660698|Dietary Supplement|Probiotic|probiotic blended in maltodextrin powder
332628|NCT01660685|Behavioral|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
332629|NCT01660685|Behavioral|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
332630|NCT01660685|Behavioral|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
332631|NCT01660685|Behavioral|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
332632|NCT01660672|Drug|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
332633|NCT01660659|Device|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
332634|NCT01660646|Behavioral|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
332635|NCT01660633|Drug|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
332636|NCT01660620|Drug|Betaxolol|
332637|NCT01660620|Drug|topical betaxolol|given topically
332638|NCT01660607|Biological|Conventional T cells (Tcon) and Regulatory T cells (Treg)|A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg
332639|NCT01660594|Other|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
332640|NCT01660581|Biological|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
332641|NCT01660581|Biological|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
332642|NCT01660542|Drug|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
332643|NCT01660529|Biological|hTERT|
332644|NCT01660503|Dietary Supplement|0 grams SCF|Given in snack foods (muffins and flavored beverage)
332645|NCT01660503|Dietary Supplement|10 grams SCF|Given in snack foods (muffins and flavored beverage)
332646|NCT01660503|Dietary Supplement|20 grams SCF|Given in snack foods (muffins and flavored beverage)
332647|NCT01660490|Procedure|ORIF|Open reduction internal fixation of the proximal femur
332648|NCT01660477|Drug|Isavuconazole|oral
332649|NCT01660477|Drug|Lopinavir/ritonavir|oral
332741|NCT01659827|Other|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
332742|NCT01659827|Other|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
332743|NCT01659827|Other|Saline|Injection of 1.25cc of Saline
332650|NCT01660464|Behavioral|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
332651|NCT01660451|Drug|Copanlisib (Aliqopa, BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).~Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.~Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
332652|NCT01660425|Behavioral|Enhancement with psychosocial intervention|
332653|NCT01660412|Drug|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40.
332654|NCT01660412|Drug|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
332655|NCT01660399|Drug|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
332656|NCT01660399|Drug|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
332657|NCT01660386|Drug|Sitagliptin|100mg po once
332658|NCT01660386|Drug|Saxagliptin|5mg po once
332659|NCT01660386|Drug|Glimepiride|2mg po once
332660|NCT01660386|Drug|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
332661|NCT01660373|Drug|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
332662|NCT01660373|Drug|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
332663|NCT01660360|Biological|Tanibirumab|
332664|NCT01660347|Biological|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
332665|NCT01660347|Biological|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
332666|NCT01660347|Procedure|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
332667|NCT01660334|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
332668|NCT01660321|Drug|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
332669|NCT01660295|Drug|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
332670|NCT01660295|Drug|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
332671|NCT01660295|Drug|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
332672|NCT01660295|Drug|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
332673|NCT01660256|Drug|OPC-12759|Instillation, 4 times/day for 4 weeks
332674|NCT01660256|Drug|Placebo|
332675|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
332676|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
332677|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
332678|NCT01660243|Drug|Placebo|Placebo (2capsules) once daily for 8 weeks
332679|NCT01660230|Biological|3K3A-APC, diluted in 0.9% sodium chloride in water|
332680|NCT01660230|Drug|0.9% NaCl in water|
332681|NCT01660217|Other|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
332682|NCT01660204|Other|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
332683|NCT01660191|Drug|Pitavastin 4mg|
332684|NCT01660191|Drug|Atorvastatin 20mg|
332685|NCT01660191|Drug|Rosuvastatin 5mg|
332686|NCT01660152|Other|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
332687|NCT01660152|Procedure|management of therapy complications|Receive VED
332688|NCT01660152|Procedure|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
332689|NCT01660126|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
332690|NCT01660126|Drug|Placebo|
332691|NCT01660100|Procedure|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
332692|NCT01660100|Procedure|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
332693|NCT01660087|Device|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
332694|NCT01660074|Other|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
332695|NCT01660048|Procedure|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
332696|NCT01660048|Procedure|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
332697|NCT01660022|Drug|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
332698|NCT01660022|Drug|Placebo|Placebo
332699|NCT01660022|Drug|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
332700|NCT01660022|Drug|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
332701|NCT01660022|Drug|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
332702|NCT01660022|Drug|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
332703|NCT01660022|Drug|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
332704|NCT01660009|Other|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
332705|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
332706|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
332707|NCT01659996|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
332708|NCT01659983|Procedure|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
332709|NCT01659957|Behavioral|Group Couples Counseling|
332710|NCT01659957|Behavioral|One-on-One Couples Counseling|
332711|NCT01659944|Drug|Eliglustat|Capsules for oral administration
332712|NCT01659944|Drug|Metoprolol|Tablets for oral administration
332713|NCT01659931|Drug|Montelukast|10 mg Tablet
332714|NCT01659931|Drug|Singulair|10 mg Tablet
332715|NCT01659918|Drug|Montelukast|
332716|NCT01659918|Drug|Singulair|
332717|NCT01659905|Drug|Montelukast|Chewable Tablet
332718|NCT01659905|Drug|Singulair|5 mg Chewable Tablet
332719|NCT01659892|Drug|Montelukast|5 mg Chewable Tablet
332720|NCT01659892|Drug|Singulair|5 mg Chewable Tablet
332721|NCT01659879|Behavioral|Multimedia information|
332722|NCT01659879|Behavioral|verbal information|
332723|NCT01659866|Drug|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
332724|NCT01659866|Drug|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
332725|NCT01659866|Drug|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
332726|NCT01659866|Drug|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
332727|NCT01659866|Drug|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
332728|NCT01659866|Drug|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
332729|NCT01659866|Drug|aztreonam|500 mg intramuscularly 2 hours before the procedure
332730|NCT01659866|Drug|imipenem|500 mg intramuscularly 2 hours before the procedure
332731|NCT01659866|Drug|ceftriaxone|2000 mg intravenously 1 hour before the procedure
332732|NCT01659866|Drug|gentamicin|2 mg/kg intravenously 1 hour before the procedure
332733|NCT01659866|Drug|amikacin|5 mg/kg intravenously 1 hour before the procedure
332734|NCT01659866|Drug|aztreonam|2000 mg intravenously 1 hour before the procedure
332735|NCT01659866|Drug|imipenem|1000 mg intravenously 1 hour before the procedure
332736|NCT01659853|Drug|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.~During each treatment period (baseline to Day 15):~CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
332737|NCT01659853|Drug|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
332738|NCT01659840|Radiation|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
332739|NCT01659840|Radiation|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
332740|NCT01659827|Other|Marcaine|Injection of 2cc of Marcaine
332744|NCT01659801|Device|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
332745|NCT01659788|Dietary Supplement|Coenzyme Q10 concomitant treatment|
332746|NCT01659788|Dietary Supplement|Placebo|
332747|NCT01659775|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
332748|NCT01659775|Drug|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
332749|NCT01659762|Biological|autologous mesenchymal stromal cell|
332750|NCT01659749|Behavioral|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
332751|NCT01659736|Device|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
332752|NCT01659723|Drug|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
332753|NCT01659697|Behavioral|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
332754|NCT01659684|Biological|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
332755|NCT01659671|Procedure|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
332756|NCT01659658|Drug|IXAZOMIB|IXAZOMIB capsules
332757|NCT01659658|Drug|Dexamethasone|Dexamethasone tablets
332758|NCT01659658|Drug|Melphalan|Melphalan tablets
332759|NCT01659658|Drug|Cyclophosphamide|Cyclophosphamide tablets
332760|NCT01659658|Drug|Thalidomide|Thalidomide capsules
332761|NCT01659658|Drug|Lenalidomide|Lenalidomide capsules
332762|NCT01659645|Drug|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
332763|NCT01659619|Drug|Erythromycin|125mg in normal saline single use infusion for 5 min.
332764|NCT01659606|Biological|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV x 5 doses
332765|NCT01659606|Drug|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
332766|NCT01659606|Drug|Cyclosporins|
332767|NCT01659606|Drug|Mycophenolate mofetil|
332768|NCT01659593|Other|procog|3 to 5 people group program
332769|NCT01659593|Other|Placebo|
332770|NCT01659580|Drug|T89 high dose|225mg bid
332771|NCT01659580|Drug|T89 Low dose|150mg bid
332772|NCT01659580|Drug|Sanqi+Bingpian|225 mg bid
332773|NCT01659580|Drug|Placebo|225mg bid
332774|NCT01659567|Drug|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
332775|NCT01659567|Drug|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
332776|NCT01659554|Drug|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
332777|NCT01659554|Drug|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
332778|NCT01659541|Device|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
332779|NCT01659541|Procedure|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
332780|NCT01659515|Drug|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
332781|NCT01659502|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
332782|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine."
332783|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:"
332784|NCT01659463|Other|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
332785|NCT01659463|Behavioral|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
332786|NCT01659450|Other|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
332787|NCT01659450|Other|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
332788|NCT01659450|Other|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
332789|NCT01659437|Drug|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
332790|NCT01659437|Drug|Streptomycin intramuscular injection|daily intramuscular drug injection
332791|NCT01659424|Radiation|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
332792|NCT01659411|Other|Observational|Yearly clinical visits
332793|NCT01659398|Device|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
332794|NCT01659372|Radiation|low level laser therapy|
332795|NCT01659372|Drug|Naproxen|
332796|NCT01659359|Device|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
332797|NCT01659359|Drug|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
332798|NCT01659346|Procedure|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
332799|NCT01659346|Drug|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
332800|NCT01659320|Drug|Minocycline|Minocycline 100 mg twice daily for 8 weeks
332801|NCT01659307|Drug|Aspirin 75mg|Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
332802|NCT01659307|Drug|Lactose powder|Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
332803|NCT01659307|Drug|Aspirin 1200mg|Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
332804|NCT01659294|Behavioral|Nurse Case Management|
332805|NCT01659294|Behavioral|standard diabetologist care|routine care by diabetologist & team
332806|NCT01659281|Drug|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
332807|NCT01659281|Drug|Artesunate|4 mg/kg/day for 3 days
332808|NCT01659281|Drug|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
332809|NCT01659281|Drug|Mefloquine|8 mg/kg daily for 3 days
332810|NCT01659268|Other|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.~The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
332811|NCT01659268|Other|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.~Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
332812|NCT01659255|Drug|ONO/GS-4059|ONO/GS-4059 capsule(s) once or twice daily (starting dose: 20 mg)
332813|NCT01659242|Drug|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose."
332814|NCT01659242|Drug|Leflunomide|"ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off"
332815|NCT01659203|Radiation|IG-IMPT|Daily, Monday-Friday for about 6 weeks
332816|NCT01659203|Radiation|IG IMRT|Daily, Monday-Friday for about 6 weeks
332817|NCT01659190|Other|Oiled-limestone liniment|
332818|NCT01659177|Drug|LY2140023|Administered orally
332819|NCT01659164|Behavioral|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
332820|NCT01659151|Drug|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
332821|NCT01659151|Procedure|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
332822|NCT01659151|Drug|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
332823|NCT01659151|Drug|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
332824|NCT01659138|Drug|SAR339658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
332825|NCT01659138|Other|Placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
332913|NCT01658501|Drug|Placebo (0.9% Sodium Chloride)|
332914|NCT01658501|Drug|Victoza®|
332915|NCT01658501|Other|Diet and Exercise|
332916|NCT01658501|Drug|Metformin|
332917|NCT01658501|Drug|Sulfonylurea|
332826|NCT01659125|Behavioral|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
332827|NCT01659112|Other|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
332828|NCT01659112|Other|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
332829|NCT01659099|Drug|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
332830|NCT01659099|Drug|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
332831|NCT01659099|Drug|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
332832|NCT01659099|Drug|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
332833|NCT01659099|Drug|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
332834|NCT01659099|Drug|Bleomycin|in ACBVP 10 mg from D1 to D5
332835|NCT01659099|Drug|Vindesin|in ACBVP 2 mg/m² from D1 to D5
332836|NCT01659099|Drug|Vincristine|in CHOP 1,4 mg/m² on D1
332837|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
332838|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
332839|NCT01659086|Biological|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
332840|NCT01659073|Procedure|Caloric Vestibular Stimulation|
332841|NCT01659060|Other|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
332842|NCT01659060|Other|Placebo Chocolate|Placebo intervention
332843|NCT01659047|Drug|GS-1101|150 mg taken twice daily by mouth
332844|NCT01659034|Drug|Thienopyridine for 3 months|
332845|NCT01659021|Drug|Idelalisib|150 mg tablets administered orally twice daily
332846|NCT01659021|Drug|Ofatumumab|Administered intravenously
332847|NCT01659008|Drug|Estradiol|
332848|NCT01659008|Drug|Lysteda|
332849|NCT01658995|Drug|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days
332850|NCT01658995|Drug|Placebo|Placebo, one capsule orally twice daily for 10 days
332851|NCT01658982|Other|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
332852|NCT01658956|Drug|GCSF administration on days 8 and 12 after chemotherapy|
332853|NCT01658943|Drug|Akt Inhibitor MK2206|Given PO
332854|NCT01658943|Drug|Fluorouracil|Given IV
332855|NCT01658943|Drug|Oxaliplatin|Given IV
332856|NCT01658943|Drug|Selumetinib|Given PO
332857|NCT01658930|Procedure|Radical Hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
332858|NCT01658930|Procedure|Simple hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
332859|NCT01658904|Drug|Carfilzomib|
332860|NCT01658904|Drug|Melphalan|
332861|NCT01658904|Drug|Filgrastim|
332862|NCT01658891|Drug|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
332863|NCT01658891|Drug|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
332864|NCT01658878|Biological|Nivolumab|
332865|NCT01658878|Drug|Sorafenib|
332866|NCT01658878|Drug|Ipilimumab|
332867|NCT01658878|Drug|Cabozantinib|
332868|NCT01658852|Drug|metronidazole|
332869|NCT01658852|Drug|Placebo|
332870|NCT01658839|Drug|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
332871|NCT01658826|Drug|AIC316|oral administration
332872|NCT01658826|Drug|Valacyclovir|oral administration
332873|NCT01658813|Drug|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
332874|NCT01658800|Biological|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
332875|NCT01658787|Device|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
332876|NCT01658774|Drug|Albendazole|Single 400mg dose
332877|NCT01658774|Dietary Supplement|Vitamin C|500 mg Vitamin C
332878|NCT01658761|Procedure|vitrectomy|Surgery
332918|NCT01658501|Drug|Metformin and Sulfonylurea|
332919|NCT01658488|Other|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
332920|NCT01658488|Other|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
332921|NCT01658462|Drug|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
336057|NCT01634113|Drug|tiotropium-bromide|IMP
332879|NCT01658748|Device|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
332880|NCT01658748|Device|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
332881|NCT01658735|Device|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
332882|NCT01658735|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
332883|NCT01658735|Device|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
332884|NCT01658722|Drug|Bapineuzumab|
332885|NCT01658696|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu heterologous prime-boost immunisation
332886|NCT01658696|Biological|Rabies vaccine|2 x 2.5IU Verorab
332887|NCT01658683|Behavioral|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
332888|NCT01658670|Behavioral|Enhanced Usual Care Group|The EUC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
332889|NCT01658670|Behavioral|HEART Camp (HC) Intervention Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive the cognitive-behavioral intervention (knowledge, attitudes, self-efficacy, behavioral self-management skills and social support) delivered using both group-based and individual-based strategies.
332890|NCT01658657|Drug|Hydrochlorothiazide|
332891|NCT01658657|Drug|Lisinopril|
332892|NCT01658657|Drug|Amlodipine|
332893|NCT01658657|Drug|metoprolol|
332894|NCT01658657|Drug|lisinopril/hydrochlorothiazide|This is a combination pill
332895|NCT01658644|Other|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
332896|NCT01658631|Device|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
332897|NCT01658618|Biological|HP802-247|
332898|NCT01658605|Drug|GSK1605786|500 mg twice daily administered orally
332899|NCT01658605|Other|Placebo|500 mg twice daily administered orally
332900|NCT01658592|Other|Deep brain stimulation|Stimulator setting is ON
332901|NCT01658592|Other|Placebo|Stimulator setting is OFF
332902|NCT01658579|Drug|HOE901-U300 (new formulation of insulin glargine)|
332903|NCT01658579|Drug|Lantus (insulin glargine)|
332904|NCT01658553|Drug|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
332905|NCT01658527|Drug|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.~Upon progression, patient may stay on study medication until the initiation of a new therapy"
332906|NCT01658527|Drug|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
332907|NCT01658514|Drug|Met DR|metformin delayed-release tablets
332908|NCT01658514|Drug|Met XR|metformin extended-release tablets
332909|NCT01658514|Drug|Placebo|
332910|NCT01658501|Drug|50 mg PB1023|
332911|NCT01658501|Drug|70 mg PB1023|
332912|NCT01658501|Drug|100 mg PB1023|
332922|NCT01658462|Drug|Nintedanib|"200 mg x 2 per os daily from D2*~*No Nintedanib on days when docetaxel is administered"
332923|NCT01658462|Drug|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
332924|NCT01658449|Other|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
332925|NCT01658449|Other|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
332926|NCT01658436|Drug|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
332927|NCT01658410|Drug|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
332928|NCT01658410|Drug|NaCl|NaCl, Route: intracoronary
332929|NCT01658397|Behavioral|Fasting|Ten day fast
332930|NCT01658358|Drug|Lapatinib|"dose level I, II 1000mg po daily~dose level III, IV 1250mg po daily"
332931|NCT01658358|Drug|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
332932|NCT01658332|Other|blood samples|3 tubes (15 ml)
332933|NCT01658319|Drug|fludarabine phosphate|Given IV
332934|NCT01658319|Drug|methoxyamine|Given IV
332935|NCT01658319|Other|laboratory biomarker analysis|Correlative studies
332936|NCT01658319|Other|pharmacological study|Correlative studies
332937|NCT01658319|Genetic|western blotting|Correlative studies
332938|NCT01658319|Other|mass spectrometry|Correlative studies
332939|NCT01658319|Genetic|DNA analysis|Correlative studies
332940|NCT01658306|Procedure|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
332941|NCT01658306|Procedure|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
332942|NCT01658293|Behavioral|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
332943|NCT01658293|Behavioral|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
332944|NCT01658280|Device|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
332945|NCT01658267|Other|nutritional supplement|2 servings per day
332946|NCT01658254|Other|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
332947|NCT01658241|Drug|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
332948|NCT01658228|Drug|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
332949|NCT01658228|Drug|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
332950|NCT01658228|Drug|Citalopram|Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
332951|NCT01658228|Drug|Venlafaxine|Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
332952|NCT01658215|Drug|V0116 transdermal patch (Test treatment )|
332953|NCT01658215|Drug|Nicotine transdermal patch (Reference treatment )|
332954|NCT01658202|Drug|V0116 transdermal patch (Test treatment )|
332955|NCT01658202|Drug|Nicotine transdermal patch (Reference Treatment )|
332956|NCT01658176|Drug|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
332957|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
332958|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
332959|NCT01658150|Drug|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
332960|NCT01658137|Other|Prudent Diet|This intervention lasts 2 weeks (14 days).
332961|NCT01658137|Other|Typical Western Diet|This intervention lasts 2 weeks (14 days).
332962|NCT01658124|Drug|Tranexamic Acid|
332963|NCT01658124|Drug|Placebo|
333039|NCT01657474|Other|Biweekly application of EpiFix plus standard of care|
333040|NCT01657461|Drug|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
332964|NCT01658111|Device|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).~The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
332965|NCT01658111|Procedure|Traditional physiotherapy|Active or passive exercises.
332966|NCT01658098|Behavioral|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
332967|NCT01658085|Device|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
332968|NCT01658085|Device|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
332969|NCT01658072|Procedure|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
332970|NCT01658072|Procedure|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
332971|NCT01658059|Other|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
332972|NCT01658059|Other|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
332973|NCT01658046|Other|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
332974|NCT01658046|Other|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
332975|NCT01658046|Other|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
332976|NCT01658033|Drug|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；~Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
332977|NCT01658020|Drug|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
332978|NCT01658020|Drug|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
332979|NCT01658007|Drug|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
332980|NCT01657994|Other|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
332981|NCT01657981|Drug|YM150|14C-labeled YM150, oral solution
332982|NCT01657955|Drug|Bendamustine Hydrochloride Injection|
332983|NCT01657955|Drug|Chlorambucil|
332984|NCT01657942|Device|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
332985|NCT01657929|Biological|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
332986|NCT01657929|Biological|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
332987|NCT01657929|Biological|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
332988|NCT01657929|Biological|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
332989|NCT01657903|Drug|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
332990|NCT01657903|Drug|Potassium nitrate|All study treatments contain 5% w/w KNO3.
332991|NCT01657890|Drug|isavuconazole|oral
332992|NCT01657877|Drug|Calcium sodium phosphosilicate|CSP high percentage weight by weight
332993|NCT01657877|Drug|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
332994|NCT01657877|Drug|Placebo|No CSP and no fluoride
332995|NCT01657864|Drug|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
332996|NCT01657851|Drug|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
332997|NCT01657851|Drug|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
332998|NCT01657851|Drug|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
332999|NCT01657838|Drug|Isavuconazole|oral
333000|NCT01657838|Drug|Ketoconazole|oral
333001|NCT01657825|Drug|Isavuconazole|oral
333002|NCT01657825|Drug|Warfarin|oral
333003|NCT01657812|Drug|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.~Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
333004|NCT01657799|Drug|Veliparib|Veliparib capsules for oral administration
333005|NCT01657799|Drug|Placebo|Placebo to veliparib capsules for oral administration
333006|NCT01657799|Radiation|Whole brain radiation therapy|30.0 grays (Gy) of WBRT given in 10 daily fractions of 3.0 Gy each, excluding weekends and holidays
336058|NCT01634113|Drug|tiotropium-bromide|IMP
333007|NCT01657786|Dietary Supplement|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
333008|NCT01657773|Other|Ultrasound examination and Colonoscopy examination|
333009|NCT01657760|Drug|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
333010|NCT01657747|Other|Whole body diffusion-weighted MRI|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.~During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.~During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines."
333011|NCT01657734|Other|MR imaging|MR imaging
333012|NCT01657721|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
333013|NCT01657708|Other|Shared Decision Making|
333014|NCT01657682|Drug|Crenolanib besylate|"Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.~Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy."
333015|NCT01657669|Drug|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
333016|NCT01657656|Dietary Supplement|Vitamin D|
333017|NCT01657643|Dietary Supplement|Probiotics|
333018|NCT01657643|Dietary Supplement|placebo|
333019|NCT01657630|Device|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
333020|NCT01657617|Radiation|Boost Stereotactic Body Radiation Therapy|"The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:~Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.~Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy."
333021|NCT01657604|Drug|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
333022|NCT01657604|Drug|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
333023|NCT01657591|Drug|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
333024|NCT01657591|Drug|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
333025|NCT01657578|Drug|Omeprazole|administration of Omeprazole
333026|NCT01657552|Drug|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
333027|NCT01657552|Drug|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
333028|NCT01657552|Drug|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
333029|NCT01657539|Dietary Supplement|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
333030|NCT01657539|Dietary Supplement|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
333031|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
333032|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
333033|NCT01657526|Biological|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
333034|NCT01657513|Drug|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.~The study subjects will receive treatment with one drug only -~infliximab or~adalimumab or~etanercept~The consulting dermatologist decides which drug to use according to official guidelines"
333035|NCT01657500|Other|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
333036|NCT01657500|Other|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
333037|NCT01657487|Drug|Fluticasone/Salmeterol high dose|
333038|NCT01657474|Other|Weekly application of EpiFix plus standard of care|
333041|NCT01657461|Device|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
333042|NCT01657448|Drug|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
333043|NCT01657448|Drug|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
333044|NCT01657435|Device|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
333045|NCT01657422|Behavioral|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
333046|NCT01657409|Drug|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
333047|NCT01657409|Drug|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
333048|NCT01657409|Drug|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
333049|NCT01657396|Procedure|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
333050|NCT01657396|Procedure|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
333051|NCT01657396|Procedure|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
333052|NCT01657383|Procedure|HPB Surgery|Hepatopancreatico Biliary Surgery
333053|NCT01657370|Drug|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
333054|NCT01657370|Drug|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration."
333055|NCT01657370|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
333056|NCT01657357|Other|Routine followup|questionnaires
333057|NCT01657331|Drug|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
333058|NCT01657331|Drug|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
333059|NCT01657331|Drug|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
333060|NCT01657318|Other|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
333061|NCT01657305|Drug|Oleogel-S10, non-adhesive wound dressing|1 cm or 100 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
333062|NCT01657305|Device|Non-adhesive wound dressing only|Soft silicone faced polyurethane foam dressing such as Mepilex® only every 3 to 4 days until 95% epithelialization of the wound or end of treatment at Day 28.
333063|NCT01657292|Drug|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
333064|NCT01657292|Device|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
333065|NCT01657279|Other|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome [i.e. from low (<10%) to high (>50%) expected risk death at 30 days].
333066|NCT01657266|Drug|PRO-155|Pre-medication (before surgery) and maintenance treatment.
333067|NCT01657266|Drug|Nevanac|Pre-medication (before surgery) and maintenance treatment.
333068|NCT01657253|Drug|PRO-148|Instill 1 drop in each eye four times a day, for 60 days
333069|NCT01657253|Drug|Systane|Instill 1 drop in each eye four times a day, for 60 days
333070|NCT01657240|Drug|PRO-118|instill one drop in each eye once a day for 21 days
333071|NCT01657240|Drug|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
333111|NCT01656928|Behavioral|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
333112|NCT01656902|Drug|NOVOCART® 3D plus|Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
336059|NCT01634113|Drug|placebo|placebo matching tiotropium
333072|NCT01657227|Behavioral|Intervention to patients|"Multifaceted intervention consisting of:~Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.~Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.~Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
333073|NCT01657227|Behavioral|Intervention to professionals|"Multifaceted intervention consisting of:~Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.~Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.~Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
333074|NCT01657227|Other|Usual care|Usual care for T2DM received in primary health care
333075|NCT01657214|Drug|SAR125844|"Pharmaceutical form:Concentrate for solution~Route of administration: intravenous"
333076|NCT01657201|Drug|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
333077|NCT01657201|Drug|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
333078|NCT01657188|Device|Cheyne-Stokes respiration by adaptive servoventilation|
333079|NCT01657175|Other|Supportive care|"The patients will be randomized to control or supportive care groups.~The control group will be given care as usual wich include clinical follow-ups at the surgical department.~The supportive care group get in addition to the clinical follow-ups a supportive care programme including:~Discharge information about surgery and life after surgery together with their relatives.~Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.~Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
333080|NCT01657162|Drug|Alendronate|Bisphosphonate
333081|NCT01657149|Procedure|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
333082|NCT01657149|Procedure|individual physiotherapy only|individual physiotherapy only
333083|NCT01657136|Drug|Ivabradine|comparison of different drugs
333084|NCT01657136|Drug|Beta blocker|comparison of different drugs
333085|NCT01657123|Other|ergometry|ergometry measurements
333086|NCT01657123|Other|ergometry|Ergometry measurements
333087|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
333088|NCT01657097|Drug|INCS|
333089|NCT01657097|Drug|Placebo|
333090|NCT01657084|Device|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
333091|NCT01657084|Device|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
333092|NCT01657071|Drug|YH14659|YH14659 capsule by oral
333093|NCT01657071|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
333094|NCT01657058|Dietary Supplement|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
333095|NCT01657058|Dietary Supplement|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
333096|NCT01657058|Dietary Supplement|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
333097|NCT01657058|Dietary Supplement|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
333098|NCT01657058|Dietary Supplement|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
333099|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
333100|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
333101|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
333102|NCT01657032|Dietary Supplement|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
333103|NCT01657032|Dietary Supplement|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
333104|NCT01657032|Dietary Supplement|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
333105|NCT01657019|Drug|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
333106|NCT01656980|Drug|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
333107|NCT01656980|Procedure|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
333108|NCT01656967|Device|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
333109|NCT01656967|Device|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
333110|NCT01656954|Procedure|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
333113|NCT01656902|Procedure|Microfracture|single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
333114|NCT01656889|Biological|HP-802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
333115|NCT01656889|Biological|Vehicle|(fibrinogen solution & thrombin solution without cells)
333116|NCT01656876|Behavioral|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
333117|NCT01656876|Other|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
333118|NCT01656876|Behavioral|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
333119|NCT01656863|Other|Questionnaire|
333120|NCT01656850|Other|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
333121|NCT01656850|Other|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
333122|NCT01656837|Behavioral|Comprehensive Community Treatment|
333123|NCT01656837|Behavioral|MST-BSF|
333124|NCT01656811|Drug|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
333125|NCT01656811|Drug|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
333126|NCT01656811|Drug|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
333127|NCT01656811|Drug|Placebo|Placebo 2 actuations QID
333128|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
333129|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
333130|NCT01656785|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
333131|NCT01656772|Device|Vdrive Lasso navigation|Remote robotic Lasso navigation
333132|NCT01656772|Procedure|Manual Lasso navigation|Manually maneuver a Lasso catheter
333133|NCT01656759|Drug|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
333134|NCT01656746|Procedure|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
333135|NCT01656733|Drug|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
333136|NCT01656733|Drug|Placebo Inhaler|Placebo inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper
333137|NCT01656720|Drug|1R, 2S-methoxamine hydrochloride|
333138|NCT01656720|Drug|Placebo|
333139|NCT01656707|Behavioral|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
333140|NCT01656707|Behavioral|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
333141|NCT01656694|Device|DePuy Sigma HP Partial Knee|
333142|NCT01656681|Dietary Supplement|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
333143|NCT01656681|Dietary Supplement|Placebo|Placebo tablet
333144|NCT01656668|Drug|BC1036|
333145|NCT01656642|Drug|Atezolizumab|Atezolizumab will be administered q3w or q2w.
333146|NCT01656642|Drug|Cobimetinib|Oral repeating dose
333147|NCT01656642|Drug|Vemurafenib|Oral repeating dose, depending on arm/cohort
333148|NCT01656629|Drug|Teriparatide|20 mcg subq daily for 3 months
333149|NCT01656629|Drug|Alendronate|70 mg weekly for 3 months
333150|NCT01656629|Dietary Supplement|calcium and vitamin D|
333151|NCT01656616|Drug|Cyanide antidote administration|
333152|NCT01656603|Biological|unlicensed CBU|infusion of unlicensed cord blood units
333153|NCT01656590|Other|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age & gender~500 cc Formula - Nutren Replete with Fiber overnight [8 hours] via gastrostomy tube~Conditioning Exercise once daily"
333154|NCT01656577|Drug|Pexacerfont|
333155|NCT01656551|Drug|Gemcitabine|
333156|NCT01656551|Drug|Pemetrexed|500 mg/m2 day 1 every 3 weeks
333157|NCT01656551|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks
333158|NCT01656538|Drug|Paclitaxel|
333159|NCT01656538|Drug|Reolysin|
333160|NCT01656525|Drug|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
333161|NCT01656525|Drug|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
333162|NCT01656525|Drug|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
333163|NCT01656525|Drug|Placebo|subcutaneous doses every 4 weeks for 24 weeks
333164|NCT01656512|Drug|zolendronic acid|"patients will receive calcium & vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of~Initial dose: (0.025) mg /kg~Subsequent doses ( 0.05) mg /kg.~Maximum dose of 4 mg."
333165|NCT01656512|Drug|calcium & vitamin D|patients will receive calcium & vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
333166|NCT01656499|Dietary Supplement|Arabinoxylanoligosaccharides|
333167|NCT01656499|Dietary Supplement|Maltodextrine|
333249|NCT01655953|Other|Control: high NaCl|7.7 mmol Na/kgBW/d
336060|NCT01634100|Drug|Probenecid|Probenecid
333168|NCT01656486|Radiation|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
333169|NCT01656473|Other|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
333170|NCT01656473|Other|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
333171|NCT01656460|Radiation|Stereotactic radiation Arm 1|"Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy"
333172|NCT01656460|Radiation|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
333173|NCT01656460|Radiation|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
333174|NCT01656460|Radiation|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
333175|NCT01656434|Drug|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
333176|NCT01656434|Drug|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
333177|NCT01656434|Other|Placebo|tablet
333178|NCT01656434|Drug|ethinylestradiol (EE)|EE 10 μg tablet
333179|NCT01656434|Drug|ferrous fumarate|ferrous fumarate 75 mg tablet
333180|NCT01656408|Drug|MK-8150|
333181|NCT01656408|Drug|Placebo for MK-8150|
333182|NCT01656395|Drug|MK-1029|MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
333183|NCT01656395|Drug|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
333184|NCT01656395|Drug|Placebo|Parts I-II: Participants will receive Placebo tablets QD
333185|NCT01656382|Drug|ABLC|
333186|NCT01656369|Procedure|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
333187|NCT01656369|Procedure|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
333188|NCT01656356|Biological|Avian Flu Vaccine|
333189|NCT01656356|Biological|Placebo|
333190|NCT01656343|Drug|Calcineurin inhibitors (CNI)|No Intervention
333191|NCT01656343|Drug|Belatacept|No Intervention
333192|NCT01656330|Drug|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
333193|NCT01656330|Drug|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
333194|NCT01656330|Drug|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
333195|NCT01656330|Drug|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
333196|NCT01656330|Other|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
333197|NCT01656317|Other|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.~The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
333198|NCT01656304|Biological|bevacizumab|Given IV
333199|NCT01656304|Other|laboratory biomarker analysis|Correlative studies
333200|NCT01656278|Procedure|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28>3.2 AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)"
333201|NCT01656278|Other|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28>3.2"
333202|NCT01656265|Drug|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
333203|NCT01656252|Drug|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.~One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
333204|NCT01656252|Drug|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
333205|NCT01656252|Drug|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.~Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.~Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.~Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
333206|NCT01656239|Drug|fedovapagon 1 mg|
333207|NCT01656239|Drug|fedovapagon 2 mg|
333208|NCT01656239|Drug|fedovapagon 4 mg|
333209|NCT01656239|Drug|Placebo ( sugar pill)|
333210|NCT01656226|Device|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
333211|NCT01656226|Other|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
333212|NCT01656213|Device|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
333213|NCT01656200|Biological|Live attenuated Japanese encephalitis vaccine SA14-14-2|Live attenuated Japanese encephalitis vaccine SA14-14-2
333214|NCT01656187|Drug|Memantine 10 mg capsule|"Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
333215|NCT01656187|Drug|Memantine-matched Placebo capsule|"Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."
333216|NCT01656174|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
333217|NCT01656161|Drug|Triptorelin embonate 22.5 mg|
333218|NCT01656148|Drug|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
333219|NCT01656135|Other|Blood drawing for immune monitoring and questionnaires|
333220|NCT01656122|Drug|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
333221|NCT01656122|Drug|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
333222|NCT01656109|Drug|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
333223|NCT01656096|Device|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
333224|NCT01656096|Other|Sham procedure|
333225|NCT01656070|Drug|oral cholecalciferol 1000000 UI (vitamin D3)|
333226|NCT01656070|Drug|Placebo|
333227|NCT01656057|Drug|Acetaminophen|Acetaminophen dissolved in 50 ml of water
333228|NCT01656057|Drug|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
333229|NCT01656057|Drug|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
333230|NCT01656057|Other|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
333231|NCT01656057|Other|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
333232|NCT01656044|Procedure|wound care management|Receive SSD
333233|NCT01656044|Procedure|wound care management|Receive NPT
333234|NCT01656031|Drug|clofarabine|
333235|NCT01656031|Drug|cytarabine|
333236|NCT01656018|Drug|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
333237|NCT01656005|Drug|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
333238|NCT01656005|Drug|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
333239|NCT01656005|Drug|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
333240|NCT01656005|Drug|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
333241|NCT01656005|Drug|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
333242|NCT01655992|Drug|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
333243|NCT01655992|Drug|S1 generic|40mg／m2 bid four weeks on two weeks off
333244|NCT01655979|Dietary Supplement|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
333245|NCT01655979|Other|Control|Bed rest without dietary supplement
333246|NCT01655966|Drug|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
333247|NCT01655966|Drug|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
333248|NCT01655953|Dietary Supplement|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
333250|NCT01655940|Device|Somanetics cerebral oximeter|Somanetics cerebral oximeter
333251|NCT01655940|Device|CASMED cerebral oximeter|CASMED cerebral oximeter
333252|NCT01655927|Drug|Tranexamic Acid|
333253|NCT01655927|Drug|Placebo: Saline|
333254|NCT01655914|Drug|Flumazenil|
333255|NCT01655901|Behavioral|Active video gaming|
333256|NCT01655901|Behavioral|Passive video gaming|
333257|NCT01655901|Behavioral|Resting|
333258|NCT01655888|Drug|Tremelimumab|Tremelimumab is administered as endovenous infusion
333259|NCT01655875|Drug|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
333260|NCT01655862|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
333261|NCT01655849|Drug|z160|
333262|NCT01655849|Drug|Placebo|
333263|NCT01655836|Radiation|Brachytherapy|Undergo high dose rate brachytherapy
333264|NCT01655836|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
333265|NCT01655836|Procedure|Quality-of-life assessment|Ancillary studies
333266|NCT01655836|Other|Questionnaire administration|Ancillary studies
333267|NCT01655823|Drug|Placebo|Sham treatment acting as control arm
333268|NCT01655823|Drug|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
333269|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
333270|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
333271|NCT01655810|Dietary Supplement|Calcium carbonate|500 mg orally twice daily
333272|NCT01655797|Behavioral|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
333273|NCT01655784|Procedure|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
333274|NCT01655784|Procedure|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
333275|NCT01655771|Drug|TD-1211 Dose 1|
333276|NCT01655771|Drug|TD-1211 Dose 2|
333277|NCT01655758|Drug|0.5% timolol|
333278|NCT01655758|Drug|timolol-dorzolamide fixed combination|
333279|NCT01655758|Drug|Latanoprost|
333280|NCT01655758|Drug|Travoprost|
333281|NCT01655758|Drug|Bimatoprost|
333282|NCT01655745|Procedure|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
333283|NCT01655732|Procedure|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
333284|NCT01655719|Drug|Pioglitazone|
333285|NCT01655706|Drug|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
333286|NCT01655706|Drug|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
333287|NCT01655693|Drug|Doxorubicin|
333288|NCT01655693|Drug|Doxorubicin|
333289|NCT01655693|Drug|Best Standard of Care|
333290|NCT01655680|Drug|ABT-126|ABT-126 Middle Dose
333291|NCT01655680|Drug|ABT-126|ABT-126 Low Dose
333292|NCT01655680|Drug|ABT-126|ABT-126 High Dose
333293|NCT01655680|Drug|Placebo|Placebo
333294|NCT01655654|Behavioral|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
333295|NCT01655654|Behavioral|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
333296|NCT01655654|Other|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
333297|NCT01655641|Drug|Tranexamic acid|"Drug: Tranexamic acid~1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.~Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
333298|NCT01655641|Other|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
333299|NCT01655628|Drug|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
333300|NCT01655628|Drug|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
333362|NCT01655134|Other|Capillary punction|
333363|NCT01655134|Other|Urine simples|
333365|NCT01655108|Drug|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
333416|NCT01654718|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
333301|NCT01655615|Behavioral|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
333302|NCT01655602|Procedure|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
333303|NCT01655602|Procedure|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
333304|NCT01655602|Procedure|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
333305|NCT01655576|Procedure|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
333306|NCT01655563|Drug|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
333307|NCT01655550|Other|Withhold oral contrast|The intervention is to withhold oral contrast
333308|NCT01655524|Drug|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
333309|NCT01655511|Drug|Tafamidis|240 mg, solution, single dose
333310|NCT01655511|Drug|Tafamidis|480 mg, solution, single dose
333311|NCT01655511|Drug|Tafamidis|TBD dose will be a single dose if < 720 mg or a loading dose followed by additional dose if > 720 mg.
333312|NCT01655498|Device|vaginal bowel control system (LivSure)|
333313|NCT01655485|Other|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
333314|NCT01655472|Device|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
333315|NCT01655472|Device|imaging follow up: Ultrasonographic examination|
333316|NCT01655459|Procedure|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
333317|NCT01655446|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
333318|NCT01655446|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
333319|NCT01655446|Behavioral|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
333320|NCT01655446|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
333321|NCT01655446|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
333322|NCT01655433|Device|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
333323|NCT01655433|Other|No Hypothermia Treatment|
333324|NCT01655420|Procedure|LASIK|Laser eye surgery
333325|NCT01655407|Drug|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
333364|NCT01655121|Dietary Supplement|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.~Each participant will receive nutritional counseling once month during six months."
333326|NCT01655407|Drug|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.~The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
333327|NCT01655381|Drug|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
333328|NCT01655368|Behavioral|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
333329|NCT01655368|Behavioral|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
333330|NCT01655316|Drug|Verapamil|
333331|NCT01655303|Drug|Propranolol|
333332|NCT01655303|Drug|Metoprolol|
333333|NCT01655303|Drug|Verapamil|
333334|NCT01655303|Drug|Diltiazem|
333335|NCT01655290|Other|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
333336|NCT01655277|Procedure|Ultrasound Guided Adductor Canal Block|
333337|NCT01655277|Procedure|Ultrasound Guided Femoral Nerve Block|
333338|NCT01655264|Behavioral|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
333339|NCT01655264|Behavioral|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
333340|NCT01655251|Behavioral|Intervention|
333341|NCT01655238|Other|BMI|Screening guideline to assess body mass index.
333342|NCT01655225|Drug|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
333343|NCT01655225|Drug|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
333344|NCT01655225|Drug|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
333345|NCT01655225|Drug|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
333346|NCT01655225|Drug|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
333347|NCT01655225|Drug|Abemaciclib|Administered orally
333348|NCT01655225|Drug|Letrozole|Administered orally
333349|NCT01655212|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
333350|NCT01655199|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
333351|NCT01655186|Drug|Bardoxolone Methyl|
333352|NCT01655186|Drug|Placebo|
333353|NCT01655173|Behavioral|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.~The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
333354|NCT01655173|Behavioral|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
333355|NCT01655160|Behavioral|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
333356|NCT01655160|Behavioral|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
333357|NCT01655160|Behavioral|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
333358|NCT01655160|Behavioral|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
333359|NCT01655147|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
333360|NCT01655147|Drug|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
333361|NCT01655134|Other|Blood simples|
333366|NCT01655108|Drug|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
333367|NCT01655095|Drug|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
333368|NCT01655095|Drug|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
333369|NCT01655095|Drug|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
333370|NCT01655095|Drug|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
333371|NCT01655095|Procedure|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
333372|NCT01655095|Procedure|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
333373|NCT01655082|Drug|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
333374|NCT01655082|Drug|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
333375|NCT01655069|Drug|Solifenacin succinate suspension|Oral suspension
333376|NCT01655056|Drug|YM150|oral
333377|NCT01655056|Drug|Placebo|oral
333378|NCT01655043|Drug|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
333379|NCT01655043|Drug|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
333380|NCT01655030|Dietary Supplement|creatine monohydrate|
333381|NCT01655030|Dietary Supplement|placebo|
333382|NCT01655017|Procedure|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
333383|NCT01655004|Drug|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
333384|NCT01654991|Behavioral|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
333385|NCT01654991|Behavioral|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
333386|NCT01654965|Other|Laboratory Biomarker Analysis|Correlative studies
333387|NCT01654965|Biological|Pegfilgrastim|Given SC
333388|NCT01654965|Other|Pharmacological Study|Correlative studies
333389|NCT01654965|Drug|Tivantinib|Given PO
333390|NCT01654965|Drug|Topotecan Hydrochloride|Given IV
333391|NCT01654939|Drug|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
333392|NCT01654926|Procedure|blood ultrafiltration|
333393|NCT01654913|Device|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :~at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),~with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),~with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
333394|NCT01654900|Other|No intervention in this study|
333395|NCT01654887|Other|Lung Ultrasound|Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
333396|NCT01654887|Radiation|Chest X-Ray|Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
333397|NCT01654874|Drug|99mTc-MIP-1404|
333398|NCT01654861|Drug|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose >90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
333399|NCT01654835|Other|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
333400|NCT01654835|Other|standard of care|A Low Blood Pressure condition as specified (SAP <80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
333401|NCT01654822|Drug|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
333402|NCT01654822|Drug|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
333403|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
333404|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
333405|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
333406|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
333407|NCT01654809|Biological|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
333408|NCT01654809|Biological|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
333409|NCT01654809|Biological|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
333410|NCT01654796|Device|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
333411|NCT01654796|Device|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
333412|NCT01654770|Device|video capsule endoscopy|
333413|NCT01654770|Device|double balloon enteroscopy|
333414|NCT01654731|Drug|Bezafibrate|
333415|NCT01654731|Drug|placebo|
333417|NCT01654718|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
333418|NCT01654705|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
333419|NCT01654705|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
333420|NCT01654692|Drug|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
333421|NCT01654679|Device|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
333422|NCT01654679|Other|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
333423|NCT01654666|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
333424|NCT01654666|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
333425|NCT01654666|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
333426|NCT01654653|Drug|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
333427|NCT01654653|Drug|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
333428|NCT01654640|Drug|Metformin|metformin 500mg p.o. bid for 24 weeks
333429|NCT01654640|Drug|Placebo (for metformin)|placebo 1T bid
333430|NCT01654627|Device|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
333431|NCT01654627|Device|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
333432|NCT01654601|Drug|DWCZP|Multiple dose
333433|NCT01654601|Drug|Clozaril|multiple-dose
333434|NCT01654575|Drug|Methotrexate|Methotrexate 25mg/week for 16 weeks
333435|NCT01654575|Drug|Placebo|Placebo tablets once a week for 16 weeks
333436|NCT01654562|Drug|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
333437|NCT01654549|Drug|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
333438|NCT01654536|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
333439|NCT01654536|Drug|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
333440|NCT01654523|Device|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
333441|NCT01654510|Behavioral|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
333442|NCT01654510|Other|Vocational Services as Usual|
333443|NCT01654497|Drug|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg"
333444|NCT01654484|Drug|DE-117|Ophthalmic Solution, QD, 28 Days
333445|NCT01654484|Drug|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
333446|NCT01654484|Drug|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
333447|NCT01654484|Drug|Placebo|Ophthalmic Solution, QD, 28 days
333448|NCT01654458|Behavioral|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
333449|NCT01654445|Drug|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
333450|NCT01654432|Other|Paravertebral Blocks (PVB)|
333451|NCT01654419|Device|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
333452|NCT01654419|Device|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
333453|NCT01654406|Device|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
333454|NCT01654406|Device|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
333455|NCT01654393|Other|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
333456|NCT01654380|Drug|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 units/milliliter (U/mL).
333457|NCT01654380|Other|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 milliliter (mL) glass vial.
333458|NCT01654367|Drug|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
333459|NCT01654354|Drug|NEOVIST 370 INJ.(Iopromide 768.86mg)|
333460|NCT01654354|Drug|Ultravist 370 INJ.(Iopromide 768.86mg)|
333461|NCT01654341|Behavioral|Exercise, dietary and educational program|
334088|NCT01649739|Drug|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
333462|NCT01654328|Drug|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
333463|NCT01654328|Drug|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
333464|NCT01654315|Device|Myomo Robotic Arm|"Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion."
333465|NCT01654315|Behavioral|RTP Standard Therapy|Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
333466|NCT01654302|Drug|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
333467|NCT01654302|Drug|Inactive patch|placebo patch applied once for 12 hours
333468|NCT01654289|Other|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
333469|NCT01654289|Other|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
333470|NCT01654276|Drug|Febuxostat|One 40 mg tablet once a day for 6 months
333471|NCT01654263|Biological|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
333472|NCT01654250|Drug|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
333473|NCT01654250|Drug|Placebo|Placebo
333474|NCT01654237|Other|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
333475|NCT01654224|Biological|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
333476|NCT01654224|Biological|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
333477|NCT01654211|Drug|danoprevir|single iv infusion
333478|NCT01654211|Drug|danoprevir|single oral dose
333479|NCT01654211|Drug|placebo|single iv infusion
333480|NCT01654211|Drug|ritonavir|oral doses
333481|NCT01654198|Radiation|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
333482|NCT01654185|Drug|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
333483|NCT01654185|Drug|Aromatase Inhibitor|1 tablet per day
333484|NCT01654172|Dietary Supplement|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is ~900mg
333485|NCT01654172|Dietary Supplement|Low Flavanol Cocoa|
333486|NCT01654159|Procedure|Monofocal IOL|Monofocal Intraocular lens will be implanted
333487|NCT01654159|Procedure|Multifocal IOL|Multifocal IOL will be implanted
333488|NCT01654159|Procedure|Toric IOL|Toric IOLS will be implanted
333489|NCT01654146|Drug|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
333490|NCT01654146|Drug|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
333491|NCT01654146|Drug|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
333492|NCT01654146|Drug|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
333493|NCT01654133|Device|Endovascular repair of thoracoabdominal aortic aneurysm (TAAA) using branched stent graft|Repair of thoracoabdominal aortic aneurysms
333494|NCT01654120|Drug|Liraglutide|SC, 1.8mg,QD, six months to one year
333495|NCT01654120|Drug|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
333496|NCT01654107|Behavioral|Persistence Targeted Smoking Cessation|"8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)"
333497|NCT01654107|Behavioral|Clearing The Air|8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
333498|NCT01654107|Drug|Nicotine lozenge|12-weeks 4mg nicotine lozenge
333499|NCT01654094|Device|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
333500|NCT01654094|Other|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
333501|NCT01654081|Drug|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
333502|NCT01654068|Radiation|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
333561|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
333503|NCT01654042|Other|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
333504|NCT01654029|Behavioral|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
333505|NCT01654016|Drug|Detralex|Detralex 500 mg twice daily for three month prior to surgery
333506|NCT01654003|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
333507|NCT01654003|Other|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
333508|NCT01653990|Drug|moxifloxacin|oral dose of 400mg moxifloxacin
333509|NCT01653990|Drug|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
333510|NCT01653977|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
333511|NCT01653977|Other|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).~The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
333512|NCT01653964|Diagnostic Test|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
333513|NCT01653951|Other|nurse-led care management or peer-led self management|
333514|NCT01653938|Behavioral|video decision aid|
333515|NCT01653925|Other|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
333516|NCT01653925|Drug|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
333517|NCT01653912|Drug|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
333518|NCT01653899|Drug|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
333519|NCT01653886|Other|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
333520|NCT01653886|Other|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
333521|NCT01653886|Other|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
333522|NCT01653860|Behavioral|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
333523|NCT01653860|Behavioral|Ordinary group treatment|group treatment 8 weeks (16 hours)
333524|NCT01653847|Drug|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
333613|NCT01653314|Drug|Glivec|
333525|NCT01653847|Drug|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is < 3 ng/mL, or reduced if the trough level is > 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
333526|NCT01653834|Procedure|Lymphocyte harvesting & reinfusion|Lymphocytes will be collected and stored approximately one week prior to initiating concurrent radiation therapy (RT) and temozolomide (TMZ). Two lymphocyte collections are allowed. After the patient has completed 6 weeks of RT/TMZ, all of the collected lymphocytes will be re-infused. After lymphocyte re-infusion, Heme-8 and absolute lymphocyte count (ALC) will be checked per standard of care. The absolute increase in ALC as the primary endpoint will be assessed 4 weeks after lymphocyte re-infusion.
333527|NCT01653821|Procedure|Carotid body excision|
333528|NCT01653808|Device|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
333529|NCT01653808|Procedure|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
333530|NCT01653808|Procedure|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
333531|NCT01653795|Device|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
333532|NCT01653795|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
333533|NCT01653782|Behavioral|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
333534|NCT01653782|Behavioral|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
333535|NCT01653782|Behavioral|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
333536|NCT01653756|Drug|IPI-145, a PI3K Inhibitor|Active drug
333537|NCT01653756|Drug|Placebo to match IPI-145|Comparator
333538|NCT01653743|Drug|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of >=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
333539|NCT01653743|Drug|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of >=18 mm; not more than 3 follicles each with a mean diameter of >=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
333540|NCT01653743|Drug|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
333541|NCT01653730|Device|Eclipse 3 portable oxygen concentrator|
333542|NCT01653730|Device|EverGo portable oxygen concentrator|
333543|NCT01653730|Device|iGo portable oxygen concentrator|
333544|NCT01653717|Procedure|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
333545|NCT01653717|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
333546|NCT01653717|Drug|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
333547|NCT01653717|Procedure|T-cell Infusion|Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
333548|NCT01653704|Behavioral|observational role|observational role in crisis scenario
333549|NCT01653704|Behavioral|active role|active role in managing crisis scenario
333550|NCT01653691|Procedure|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
333551|NCT01653691|Procedure|Sham|No treatment to one side of subject's scar.
333552|NCT01653678|Dietary Supplement|Vitamin D-3 (cholecalciferol), 2000 IU|
333553|NCT01653678|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
333554|NCT01653678|Dietary Supplement|Vitamin D placebo|
333555|NCT01653678|Drug|Fish oil placebo|
333556|NCT01653665|Drug|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
333557|NCT01653665|Drug|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
333558|NCT01653652|Dietary Supplement|Probiotic|
333559|NCT01653652|Dietary Supplement|Maltodextrin|
333560|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
333562|NCT01653626|Other|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
333563|NCT01653613|Genetic|DNA analysis|
333564|NCT01653613|Genetic|fluorescence in situ hybridization|
333565|NCT01653613|Genetic|gene expression analysis|
333566|NCT01653613|Genetic|microarray analysis|
333567|NCT01653613|Genetic|mutation analysis|
333568|NCT01653613|Genetic|polymorphism analysis|
333569|NCT01653613|Genetic|reverse transcriptase-polymerase chain reaction|
333570|NCT01653613|Other|laboratory biomarker analysis|
333571|NCT01653600|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
333572|NCT01653600|Device|LifeStent|same to SMART STENT
333573|NCT01653587|Device|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
333574|NCT01653574|Drug|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
333575|NCT01653561|Drug|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
333576|NCT01653548|Behavioral|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
333577|NCT01653548|Behavioral|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
333578|NCT01653548|Behavioral|Habituation|Participants will habituate to personally-relevant stressor.
333579|NCT01653535|Behavioral|Fast Track|First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
333580|NCT01653522|Drug|Triptan|
333581|NCT01653522|Drug|Doxycycline|
333582|NCT01653509|Device|Acyclovir patch|Patch containing acyclovir
333583|NCT01653509|Device|Placebo patch|Patch without acyclovir
333584|NCT01653496|Procedure|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
333585|NCT01653483|Drug|GSK573719|Novel Dry-Powder Inhaler
333586|NCT01653483|Drug|GSK573719matched-placebo|Novel Dry-Powder Inhaler
333587|NCT01653470|Drug|Paclitaxel|
333588|NCT01653470|Drug|5-Fluorouracil (5FU)|
333589|NCT01653470|Drug|Carboplatin|
333590|NCT01653470|Drug|Leucovorin|
333591|NCT01653470|Drug|Irinotecan|
333592|NCT01653470|Drug|Paclitaxel|
333593|NCT01653470|Drug|BMS-906024|
333594|NCT01653457|Drug|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:~1st week: 5 mg daily~2nd week: 10 mg daily~3rd week: 15 mg daily~From 4th week up to 24th week: 20 mg daily"
333595|NCT01653457|Drug|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
333596|NCT01653444|Drug|GC1119|biweekly, IV infusion
333597|NCT01653431|Device|Transcranial direct current stimulation|
333598|NCT01653418|Drug|Bortezomib|
333599|NCT01653418|Drug|Carmustine|
333600|NCT01653418|Drug|Etoposide|
333601|NCT01653418|Drug|Cytarabine|
333602|NCT01653418|Drug|Melphalan|
333603|NCT01653418|Procedure|Stem cell infusion|
333604|NCT01653405|Other|Multifaceted behavioral intervention|The intervention included access to a system to measure processes of care relevant to warfarin management, along with targeted audit and feedback.
333605|NCT01653392|Biological|Observational Intervention|This is an observational study, therefore no interventions are specified.
333606|NCT01653379|Drug|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
333607|NCT01653366|Behavioral|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
333608|NCT01653353|Behavioral|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
333609|NCT01653340|Device|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
333610|NCT01653327|Drug|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
333611|NCT01653327|Drug|Placebo|
333612|NCT01653314|Drug|Megavec|
333614|NCT01653301|Drug|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.~In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
333615|NCT01653301|Drug|XELOX RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;~Oxaliplatin: 130mg/m2, days 1, 19, 38~RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
333616|NCT01653288|Behavioral|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
333617|NCT01653275|Other|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
333618|NCT01653262|Drug|Brivaracetam|
333619|NCT01653249|Biological|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
333620|NCT01653236|Drug|Boceprevir|
333621|NCT01653236|Drug|Peginterferon alfa-2b|
333622|NCT01653236|Drug|ribavirin|
333623|NCT01653223|Drug|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.~In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
333624|NCT01653197|Behavioral|Control|No scratch off element
333625|NCT01653197|Behavioral|Curiosity|The recipient will be prompted to scratch off for answer to question.
333626|NCT01653197|Behavioral|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
333627|NCT01653184|Dietary Supplement|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
333628|NCT01653171|Drug|Water (Placebo)|Water 100 mL
333629|NCT01653171|Drug|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
333630|NCT01653171|Drug|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
333631|NCT01653171|Drug|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
333632|NCT01653158|Drug|CP-751,871|"CP-751,871 was given intravenously [IV] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.~Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
333633|NCT01653158|Drug|Docetaxel|Docetaxel up to 75 mg/m^2 was administered intravenously [IV] on Day 1 of each 3-week dosing cycle.
333634|NCT01653145|Other|Diet A|Dietary
333635|NCT01653145|Other|Diet B|Dietary
333636|NCT01653145|Other|Diet C|Dietary
333637|NCT01653132|Drug|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
333638|NCT01653132|Drug|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
333639|NCT01653119|Drug|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
333640|NCT01653106|Procedure|cryotherapy|Receive shaved ice
333641|NCT01653106|Other|questionnaire administration|Participate in PROMS
333642|NCT01653106|Other|pharmacological study|Correlative studies
333643|NCT01653093|Procedure|3-Tesla magnetic resonance imaging (3T MRI)|Undergo 3T MRI
333644|NCT01653093|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
333645|NCT01653093|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
333646|NCT01653093|Procedure|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
333647|NCT01653080|Procedure|dynamic contrast-enhanced MRI|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
333648|NCT01653067|Drug|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
333649|NCT01653054|Procedure|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
333650|NCT01653041|Drug|Everolimus|
333651|NCT01653028|Drug|Alisertib|Given PO
333652|NCT01653028|Other|Laboratory Biomarker Analysis|Correlative studies
333756|NCT01652196|Drug|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
333653|NCT01653015|Biological|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
333654|NCT01653015|Biological|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
333655|NCT01653002|Other|No intervention|
333656|NCT01652989|Behavioral|Weight loss maintenance intervention face-to-face|
333657|NCT01652989|Behavioral|Weight loss maintenance intervention delivered via DVD|
333658|NCT01652976|Drug|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
333659|NCT01652976|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
333660|NCT01652963|Other|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
333661|NCT01652950|Behavioral|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.~Level 1: <150 fitness points per month - equivalent to < 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month."
333662|NCT01652937|Drug|BIIB057|Oral
333663|NCT01652937|Drug|Placebo|Oral
333664|NCT01652924|Device|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
333665|NCT01652924|Device|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.~The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
333666|NCT01652911|Device|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
333667|NCT01652898|Drug|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
333668|NCT01652898|Drug|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
333669|NCT01652898|Drug|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
333670|NCT01652885|Drug|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
333671|NCT01652872|Biological|Darbepoetin alfa|Darbepoetin alfa was presented as single use prefilled syringes (PFS). Investigational product was administered SC Q4W for the duration of the treatment period.
333672|NCT01652872|Other|Placebo|Placebo was presented as single use PFS. Participants received a SC placebo injection in place of darbepoetin alfa therapy when the dose of study drug was withheld per the dosing algorithm for the duration of the treatment period.
333673|NCT01652859|Drug|Liposomal Amphotericin B|
333674|NCT01652859|Drug|AmBisome|
333675|NCT01652833|Other|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
333676|NCT01652820|Drug|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
333677|NCT01652820|Drug|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
333678|NCT01652807|Behavioral|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
333679|NCT01652794|Radiation|stereotactic body radiation therapy|Undergo SBRT
333680|NCT01652794|Drug|carboplatin|Given IV
333681|NCT01652794|Drug|gemcitabine hydrochloride|Given IV
333682|NCT01652794|Other|laboratory biomarker analysis|Optional correlative studies
333683|NCT01652794|Other|pharmacogenomic studies|Optional correlative studies
333684|NCT01652781|Drug|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
333685|NCT01652768|Other|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin & Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
333757|NCT01652196|Other|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
333758|NCT01652196|Procedure|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
334089|NCT01649726|Procedure|Apnea test - control|
334090|NCT01649726|Procedure|Apnea test - CPAP|
333686|NCT01652768|Other|Palliative Care Team|"Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).~Introduce the palliative care team concept.~Provide contact information for the palliative care team given~Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)~Offer community resources to patient and caregiver (Appendix B)~Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment~Provide supportive care"
333687|NCT01652768|Other|Educational Information Session for Patients and Caregivers|"Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.~Intervention (Length of time for class = 2 hours):~Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.~Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.~Provide supportive care."
333688|NCT01652768|Other|Contact every 2 weeks|"The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.~(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment~Provide resources/referrals for any needs identified during the social work follow-up assessment~Provide supportive care"
333689|NCT01652768|Other|Follow-up Surgical Visit Session|"The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Administer Symptom Assessment Tool~Provide pain and/or symptom management intervention~Provide supportive care"
333690|NCT01652768|Other|Medical and/or Radiation Oncology Appointment Session|"The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).~Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):~Administer Patient and Caregiver Follow-up Assessment~Re-assess pain and/or symptom management issues and /or intervention~Provide resources/referrals for any needs identified during the social work follow-up assessment~Provide supportive care."
333691|NCT01652742|Drug|BI 135585 XX|one single dose
333692|NCT01652729|Drug|Exenatide once weekly suspension|
333693|NCT01652729|Drug|Sitagliptin|
333694|NCT01652729|Drug|Placebo|Placebo oral capsule once daily
333695|NCT01652716|Drug|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
333696|NCT01652716|Drug|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
333697|NCT01652703|Biological|Evolocumab|Administered by subcutaneous injection
333698|NCT01652703|Other|Placebo|Administered by subcutaneous injection
333699|NCT01652690|Biological|Denosumab|This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
333700|NCT01652677|Procedure|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
333701|NCT01652664|Drug|Travoprost 0.004% PQ ophthalmic solution|
333702|NCT01652664|Drug|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to < 3 years of age received 0.25%
333703|NCT01652664|Drug|Travoprost Vehicle|Inactive ingredients used to maintain masking
333704|NCT01652651|Behavioral|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
333705|NCT01652638|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
333706|NCT01652625|Drug|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
333707|NCT01652625|Drug|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
333708|NCT01652612|Other|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
333709|NCT01652599|Drug|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
333710|NCT01652586|Drug|dexmedetomidine-remifentanil|
333711|NCT01652586|Drug|midazolam-remifentanil|
333712|NCT01652573|Drug|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
333713|NCT01652573|Drug|Saline Nasal Spray Placebo|
333714|NCT01652560|Drug|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
333715|NCT01652547|Drug|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
333843|NCT01651702|Device|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
333716|NCT01652547|Drug|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
333717|NCT01652534|Drug|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
333718|NCT01652534|Drug|Placebo|Sugar Pill
333719|NCT01652508|Other|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
333720|NCT01652508|Behavioral|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
333721|NCT01652495|Drug|methylprednisolone acetate|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
333722|NCT01652495|Drug|Triamcinolone Acetonide|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
333723|NCT01652482|Drug|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter [mg/m^2] administered as intravenous bolus and then 5-FU 2400 mg/m^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
333724|NCT01652482|Drug|Cetuximab|Cetuximab 400 mg/m^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
333725|NCT01652482|Drug|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter [mg/m^2] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
333726|NCT01652482|Drug|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m^2 [racemic form] or 200 mg/m^2 [L-isomer form] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
333727|NCT01652482|Drug|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
333728|NCT01652469|Drug|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
333729|NCT01652469|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
333730|NCT01652456|Other|Addiction support|one consultation with an addiction specialist
333731|NCT01652417|Drug|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
333732|NCT01652404|Behavioral|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
333733|NCT01652404|Behavioral|Conventional treatment|The antibiotics duration will be determined by treating physician.
333734|NCT01652391|Device|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
333735|NCT01652378|Drug|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
333736|NCT01652365|Behavioral|RDT Training and Subsidy Offered|
333737|NCT01652365|Behavioral|Information/Education Campaign|
333738|NCT01652339|Drug|Exforge tab. 10/160mg|
333739|NCT01652339|Drug|Lodivixx tab. 5/160mg|
333740|NCT01652326|Drug|Diazepam|
333741|NCT01652313|Drug|Rasagiline|1 mg/day, tablets for 7 days, orally
333742|NCT01652300|Behavioral|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
333743|NCT01652300|Behavioral|no education|women in the control group received no education
333744|NCT01652287|Drug|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
333745|NCT01652287|Other|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
333746|NCT01652261|Drug|ABVD + FDG-PET/CT Scan treatment adaptation|
333747|NCT01652261|Drug|BEACOPPesc|
333748|NCT01652248|Procedure|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
333749|NCT01652235|Device|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
333750|NCT01652222|Other|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
333751|NCT01652222|Other|Socio-educational training only|4 socio-educative training sessions during 8 weeks
333752|NCT01652209|Biological|Hearticellgram-AMI|
333753|NCT01652196|Biological|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
333754|NCT01652196|Drug|oxaliplatin|85 mg/m2 IV infused over 2 hours
333755|NCT01652196|Drug|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
333759|NCT01652196|Radiation|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
333760|NCT01652196|Procedure|PET (positron emission tomography)|Correlative studies
333761|NCT01652183|Drug|intravenous paracetamol|
333762|NCT01652183|Drug|Placebo|
333763|NCT01652157|Biological|ULTRESA|pancreatic enzyme replacement therapy
333764|NCT01652157|Biological|PANCREAZE|pancreatic enzyme replacement therapy
333765|NCT01652157|Biological|CREON|pancreatic enzyme replacement therapy
333766|NCT01652157|Biological|ZENPEP|pancreatic enzyme replacement therapy
333767|NCT01652157|Biological|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
333768|NCT01652157|Biological|PERTZYE|pancreatic enzyme replacement therapy
333769|NCT01652157|Other|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
333770|NCT01652144|Drug|AT7519M|
333771|NCT01652131|Other|Tetrastarch (130/0.4)|
333772|NCT01652118|Drug|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
333773|NCT01652118|Drug|Saline|
333774|NCT01652105|Dietary Supplement|Standard diet versus standard VLCD (Prodimed)|
333775|NCT01652092|Drug|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
333776|NCT01652092|Drug|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
333777|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
333778|NCT01652092|Biological|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10^8 nucleated cells/kg recipient weight.~Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be > 5.0 x 10^7 nucleated cells/kg."
333779|NCT01652092|Drug|Fludarabine phosphate 40 mg|40 mg/m^2 IV on days -5 through -2 (for children < 6 months and/or < 10 kg weight dose at 1.33 mg/kg)
333780|NCT01652092|Drug|Melphalan|140 mg/m^2 IV on day -3
333781|NCT01652092|Drug|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
333782|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
333783|NCT01652092|Drug|Fludarabine phosphate 30 mg|fludarabine 30 mg/m^2 IV on days -8 through -4
333784|NCT01652092|Drug|MESNA|administered as per the standard institutional protocol.
333785|NCT01652079|Drug|CRLX101|q 14 days
333786|NCT01652066|Dietary Supplement|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
333787|NCT01652066|Dietary Supplement|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
333788|NCT01652053|Device|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
333789|NCT01652040|Device|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
333790|NCT01652040|Drug|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
333791|NCT01652027|Drug|FVIII concentrate|usual treatment as directed by treating physician
333792|NCT01652014|Drug|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
333793|NCT01652014|Drug|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
333794|NCT01652014|Drug|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
333795|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
333796|NCT01652014|Procedure|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
333797|NCT01652014|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
333798|NCT01652014|Radiation|total-body irradiation|Undergo TBI
333799|NCT01652014|Drug|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
333800|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
333801|NCT01652014|Procedure|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
333802|NCT01652001|Drug|Malic Acid|Oral spray for application into the oral cavity
333803|NCT01652001|Other|Placebo|Oral spray for application into the oral cavity
333804|NCT01651988|Drug|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:~Procedures < 10 minutes~Ketamine-Propofol Combination KETOFOL 1:1~Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)~Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Ketamine-Propofol Combination KETOFOL 1:2~Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)~Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)~Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)~Procedures > 10 minutes~In addition to the initial bolus, an infusion was started:~KETOFOL 1:1~20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN~KETOFOL 1:2~20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN~Speed infusion:~0,03cc/kg/min"
334091|NCT01649713|Drug|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
333805|NCT01651975|Dietary Supplement|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
333806|NCT01651975|Dietary Supplement|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
333807|NCT01651962|Drug|Terbutaline|
333808|NCT01651962|Drug|Fentanyl|
333809|NCT01651962|Drug|0.9% NaCl|
333810|NCT01651949|Biological|9vHPV Vaccine|9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
333811|NCT01651936|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
333812|NCT01651936|Drug|Methotrexate|MTX dosed at the stable dose received upon study entry
333813|NCT01651936|Drug|Dose-match placebo|Dose-matched placebo dosed orally BID
333814|NCT01651923|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
333815|NCT01651884|Device|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
333816|NCT01651884|Device|Transcranial Direct Current Stimulation (Neuroconn)|
333817|NCT01651871|Drug|S-555739 Dose 1|
333818|NCT01651871|Drug|S-555739 Dose 2|
333819|NCT01651871|Drug|Cetirizine HCl Dose 1|
333820|NCT01651871|Drug|S-555739 placebo|
333821|NCT01651871|Drug|Cetirizine HCl placebo|
333822|NCT01651858|Drug|Nurigra Chewable tablet|1 tablet of 100mg, once a day
333823|NCT01651832|Behavioral|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
333824|NCT01651819|Procedure|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
333825|NCT01651806|Drug|Tranexamic Acid standard dose|Uniform 1 gram dosing
333826|NCT01651806|Drug|Females Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
333827|NCT01651806|Drug|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
333828|NCT01651806|Drug|Males Weighted Dose TA|Weighted dose--20mg/kg of the drug will be given
333829|NCT01651793|Other|Caffeinated cocoa|70 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
333830|NCT01651793|Other|Cocoa|21 mg caffeine, 179 mg theobromine, 499 mg flavanols, and 1 packet of Truvia sweetener
333831|NCT01651793|Other|Caffeine|473 ml brewed water containing 66 mg caffeine, caramel coloring and one packet Truvia sweetener
333832|NCT01651793|Other|Placebo|473 ml of brewed water, caramel coloring and one packet Truvia sweetener
333833|NCT01651780|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
333834|NCT01651780|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
333835|NCT01651767|Drug|Placebo|Form=suspension, route=oral.
333836|NCT01651767|Drug|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
333837|NCT01651754|Biological|Seasonal influenza vaccination|single dose of influenza vaccination
333838|NCT01651741|Dietary Supplement|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.~Seaweed:~Form: brown granule~Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~Duration: 4 weeks of treatment period~Duolac7S:~The probiotics, Duolac7S, consist of 7 bacteria.~Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.~Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (30 min after morning and evening meal)~Duration: 4 weeks of treatment period"
333839|NCT01651741|Dietary Supplement|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).~Seaweed:~Form: brown granule~Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)~Duration: 4 weeks of treatment period~Duolac7S-P:~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
333840|NCT01651728|Drug|Simvastatin|Tablet 20 mg once daily for 30 days
333841|NCT01651728|Drug|Placebo|daily for 30 days
333842|NCT01651715|Drug|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).~The investigational product will be taken for 7 days as follow:~Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.~Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
336061|NCT01634100|Drug|Rifampicin|Rifampicin
333844|NCT01651702|Device|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
333845|NCT01651676|Other|VQ11 validation|"Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug."
333846|NCT01651663|Drug|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
333847|NCT01651663|Other|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
333848|NCT01651663|Drug|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
333849|NCT01651663|Other|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
333850|NCT01651650|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
333851|NCT01651637|Drug|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
333852|NCT01651624|Other|Invitation to screening|
333853|NCT01651611|Behavioral|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
333854|NCT01651611|Behavioral|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
333855|NCT01651611|Behavioral|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
333856|NCT01651611|Behavioral|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
333857|NCT01651598|Drug|Placebo to BI 144807|multiple dose (bid)
333858|NCT01651598|Drug|BI 144807|multiple dose (bid, low to high dose)
333859|NCT01651585|Drug|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
333860|NCT01651572|Drug|Cisatracurium|"Cisatracurium (Nimbex):~initial dose: 0.2 mg/kg~maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
333861|NCT01651572|Drug|Rocuronium|"Rocuronium (Esmeron):~initial dose: 0.6 mg/kg~maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
333862|NCT01651546|Behavioral|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
333863|NCT01651533|Behavioral|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
333864|NCT01651533|Behavioral|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
333865|NCT01651520|Drug|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
333866|NCT01651494|Drug|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
333867|NCT01651494|Other|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
333868|NCT01651481|Drug|HCP1102|
333869|NCT01651481|Drug|Singulair and Xyzal|
333870|NCT01651468|Dietary Supplement|HEMOFIX|unique complex herbal mixture
333871|NCT01651442|Behavioral|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
333872|NCT01651442|Drug|Zolpidem|5mg or 10mg
333873|NCT01651442|Drug|Trazodone|50mg to 150mg
333874|NCT01651442|Behavioral|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
333875|NCT01651429|Behavioral|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
333876|NCT01651416|Drug|Artemether-lumefantrine combination|
333877|NCT01651416|Drug|Dihydroartemisinin Piperaquine combination|
333878|NCT01651416|Drug|Amodiaquine plus sulphadoxine-pyrimethamine combination|
333879|NCT01651403|Drug|Tenofovir DF|"Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg."
333880|NCT01651403|Drug|TDF Placebo|"Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
333881|NCT01651390|Device|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
333882|NCT01651390|Device|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
334373|NCT01647529|Drug|Ganciclovir|Treatment with topical ganciclovir ointment
333883|NCT01651377|Drug|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
333884|NCT01651377|Drug|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
333885|NCT01651364|Drug|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
333886|NCT01651364|Drug|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
333887|NCT01651351|Biological|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
333888|NCT01651351|Biological|Placebo: Human albumin 2.5%|Intravenous administration
333889|NCT01651338|Procedure|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
333890|NCT01651325|Drug|Isavuconazole|oral
333891|NCT01651325|Drug|dextromethorphan|oral
333892|NCT01651312|Drug|14C-labeled YM178|oral solution (1.85 MBq)
333893|NCT01651286|Procedure|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
333894|NCT01651286|Procedure|full face mask|using a standard full face mask during the induction of general anesthesia.
333895|NCT01651273|Drug|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
333896|NCT01651273|Drug|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
333897|NCT01651273|Drug|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
333898|NCT01651273|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
333899|NCT01651260|Other|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
333900|NCT01651247|Procedure|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
333901|NCT01651234|Drug|GCC-4401|"Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use~single dose~dosage~Cohort 1: 2.5-mg GCC-4401C~Cohort 2: 5.0-mg GCC-4401C~Cohort 3: 10-mg GCC-4401C~Cohort 4: 20-mg GCC-4401C~Cohort 5: 40-mg GCC-4401C~Cohort 6: 80-mg GCC-4401C"
333902|NCT01651234|Drug|GCC-4401C|"Capsule, identical in appearance to GCC-4401C, for oral use~single dose~dosage~Cohort 1: 2.5-mg matching placebo~Cohort 2: 5.0-mg matching placebo~Cohort 3: 10-mg matching placebo~Cohort 4: 20-mg matching placebo~Cohort 5: 40-mg matching placebo~Cohort 6: 80-mg matching placebo"
333903|NCT01651221|Other|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
333904|NCT01651208|Behavioral|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:~a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
333905|NCT01651208|Behavioral|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
333906|NCT01651195|Dietary Supplement|Probiotic|
333907|NCT01651195|Other|Placebo|
333908|NCT01651182|Drug|No tranexamic acid|Control
333909|NCT01651182|Drug|Tranexamic Acid|
333910|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
333911|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.~Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
333912|NCT01651156|Drug|Tolvaptan|oral taken
333913|NCT01651156|Drug|Placebo|
333914|NCT01651143|Drug|SAR100842|"Pharmaceutical form: tablets~Route of administration: oral"
333915|NCT01651143|Drug|Placebo (for SAR100842)|"Pharmaceutical form: tablets~Route of administration: oral"
333916|NCT01651130|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
333917|NCT01651117|Behavioral|Peer Mentoring|Patients will receive peer mentoring.
334177|NCT01649102|Device|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:~Palindroom~Hemoglide Bard"
333918|NCT01651104|Biological|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
333919|NCT01651091|Other|Meditation Awareness Training|Psychotherapy Intervention
333920|NCT01651091|Other|Treatment as usual|
333921|NCT01651065|Behavioral|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.~The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
333922|NCT01651065|Behavioral|Control|
333923|NCT01651052|Procedure|Heart Valve Surgery|Implant of an aortic valve, Model 11000
333924|NCT01651039|Drug|Panobinostat|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19.
333925|NCT01651039|Drug|Lenalidomide|Each cycle is 28 days. Lenalidomide will be given 25 mg: Days 1-21.
333926|NCT01651039|Drug|Dexamethasone|Each cycle is 28 days. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
333927|NCT01651000|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime.
333928|NCT01651000|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
333929|NCT01650974|Device|HFNOT|high flow nasal oxygen therapy
333930|NCT01650961|Drug|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
333931|NCT01650961|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
333932|NCT01650948|Device|RetnaGene AMD LDT|
333933|NCT01650935|Behavioral|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
333934|NCT01650922|Procedure|phlebotomy|
333935|NCT01650922|Procedure|biopsy|
333936|NCT01650896|Other|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
333937|NCT01650883|Dietary Supplement|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
333938|NCT01650883|Dietary Supplement|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
333939|NCT01650870|Drug|Crystalline Lactulose|
333940|NCT01650844|Other|School-Based Telemedicine Enhanced Asthma Management|
333941|NCT01650844|Other|Enhanced Usual Care|
333942|NCT01650831|Device|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
333943|NCT01650818|Other|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
333944|NCT01650818|Other|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
333945|NCT01650805|Drug|ponatinib|45 mg tablet, taken orally once daily
333946|NCT01650805|Drug|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
333947|NCT01650792|Drug|Aspirin|
333948|NCT01650779|Biological|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
333949|NCT01650753|Dietary Supplement|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10^10 cells/sachet)
333950|NCT01650753|Dietary Supplement|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
333951|NCT01650740|Drug|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
333952|NCT01650740|Drug|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
333953|NCT01650740|Other|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
333954|NCT01650727|Drug|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m^2 up to a maximum dose of 14 mg/m^2.
333955|NCT01650727|Biological|Rituximab|Rituximab 375 mg/m^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
333956|NCT01650714|Other|Full thickness gastric biopsy|
333957|NCT01650714|Procedure|Full thickness gastric biopsy|
333958|NCT01650701|Drug|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
333959|NCT01650701|Drug|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
333960|NCT01650701|Drug|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
333961|NCT01650701|Drug|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
333962|NCT01650701|Drug|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
334178|NCT01649089|Procedure|Conization|Undergo cone biopsy
334374|NCT01647516|Drug|RPC1063|
333963|NCT01650675|Behavioral|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
333964|NCT01650675|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
333965|NCT01650662|Drug|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
333966|NCT01650649|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
333967|NCT01650649|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
333968|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
333969|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
333970|NCT01650623|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
333971|NCT01650623|Behavioral|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
333972|NCT01650610|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
333973|NCT01650597|Drug|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
333974|NCT01650597|Drug|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
333975|NCT01650597|Drug|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
333976|NCT01650584|Drug|ISTA Tears|sterile ophthalmic solution
333977|NCT01650584|Drug|Systane|Sterile ophthalmic solution
333978|NCT01650558|Drug|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
333979|NCT01650558|Drug|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
333980|NCT01650545|Drug|Liposomal aerosol cyclosporine|inhaled form of immune suppression
333981|NCT01650545|Other|standard immune suppression, oral|"conventional drug~Conventrional oral immune suppression as standard of care thus consists of tacrolimus, mycophenolate mofetil prednisone and rapamycin"
333982|NCT01650532|Behavioral|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
333983|NCT01650532|Behavioral|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
333984|NCT01650519|Drug|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
333985|NCT01650519|Drug|IV ketorolac|30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) administered intravenously over no less than 15 seconds
333986|NCT01650506|Drug|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
333987|NCT01650506|Drug|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
333988|NCT01650493|Device|Clinpro 5000|Dentrifice containing 950ppm fluoride
333989|NCT01650493|Device|MI Paste Plus|Dentrifice containing 950ppm fluoride
333990|NCT01650493|Device|Tom's of Maine|Dentrifice that is fluoride free
333991|NCT01650480|Other|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
333992|NCT01650454|Other|2 night polysomnography|Polysomnography
333993|NCT01650454|Other|battery of neuropsychological tests|
333994|NCT01650454|Other|virtual reality test|
333995|NCT01650454|Other|subjective evaluation of sleep and somnolence|
334042|NCT01650129|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
333996|NCT01650441|Drug|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
333997|NCT01650441|Radiation|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.~The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
333998|NCT01650428|Biological|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
333999|NCT01650428|Drug|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
334000|NCT01650428|Drug|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
334001|NCT01650428|Drug|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
334002|NCT01650415|Drug|Erythropoietin|twice a week for 1 month
334003|NCT01650415|Drug|Placebo erythropoietin|twice a week for 1 month
334004|NCT01650402|Other|Anti-hypertensive therapy to SBP 130 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 130 mm Hg
334005|NCT01650402|Other|Anti-hypertensive therapy to SBP 145 mm Hg|Anti-hypertensive therapy to achieve 24 hour systolic blood pressure less than or equal to 145 mm Hg
334006|NCT01650389|Biological|MVA85A|
334007|NCT01650389|Biological|Candin|
334008|NCT01650389|Biological|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.~Infants who test positive by HIV PCR will not receive BCG vaccination."
334009|NCT01650376|Drug|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
334010|NCT01650376|Drug|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
334011|NCT01650376|Drug|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
334012|NCT01650363|Other|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
334013|NCT01650363|Drug|Homeopathic placebo medication|2-3 mm small spheric suger pils
334014|NCT01650350|Drug|Naltrexone|
334015|NCT01650337|Other|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
334016|NCT01650324|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
334017|NCT01650324|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
334018|NCT01650298|Other|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
334019|NCT01650285|Drug|Cabazitaxel|"Dose Level Day 1, 22, 43~5.0 mg/m2~10.0 mg/m2~15.0 mg/m2~20.0 mg/m2"
334020|NCT01650272|Drug|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
334021|NCT01650272|Drug|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
334022|NCT01650259|Drug|OAD|OAD except Trazenta tablets
334023|NCT01650259|Drug|Trazenta|Linagliptin
334024|NCT01650246|Drug|lesinurad|Tablets, 400 mg QD
334025|NCT01650233|Behavioral|Mindfulness-based stress reduction|
334026|NCT01650207|Procedure|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.~treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
334027|NCT01650207|Procedure|TENS|
334028|NCT01650207|Procedure|sham acupuncture|
334029|NCT01650194|Drug|enzalutamide|Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
334030|NCT01650194|Drug|abiraterone acetate|Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
334031|NCT01650194|Drug|prednisone|Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
334032|NCT01650181|Drug|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
334033|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
334034|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
334035|NCT01650181|Drug|Metformin|Patients with fatty liver treated with diet, exercise and metformin
334036|NCT01650155|Drug|BI 1005273 s.c.|injection
334037|NCT01650155|Drug|BI 105273 i.v. Placebo|infusion
334038|NCT01650155|Drug|BI 1005273 s.c. Placebo|injection
334039|NCT01650155|Drug|BI 1005273 i.v.|infusion
334040|NCT01650142|Other|No intervention|No intervention
334041|NCT01650129|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
334179|NCT01649089|Other|Quality-of-Life Assessment|Ancillary studies
334043|NCT01650090|Drug|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
334044|NCT01650051|Drug|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
334045|NCT01650051|Drug|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
334046|NCT01650038|Other|treatment with faecal transplantation (donor faeces)|faecal transplantation
334047|NCT01650038|Other|treatment with faecal transplantation (own faeces)|faecal transplantation
334048|NCT01650025|Dietary Supplement|VSL#3 active probiotic|
334049|NCT01650025|Other|VSL#3 placebo|
334050|NCT01650012|Drug|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
334051|NCT01650012|Drug|Placebo|Placebo
334052|NCT01649999|Drug|peficitinib|oral
334053|NCT01649999|Drug|Placebo|oral
334054|NCT01649986|Behavioral|Non-pharmacologic intervention|Diet and physical exercise
334055|NCT01649986|Drug|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
334056|NCT01649960|Drug|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
334057|NCT01649947|Drug|Paclitaxel|"Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv < 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~Diphenydramine 50 mg iv (or equivalent) < 1 hour prior to paclitaxel infusion~Ranitidine 50 mg iv < 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)"
334058|NCT01649947|Drug|Carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
334059|NCT01649947|Drug|Hydroxychloroquine|Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
334060|NCT01649947|Drug|Bevacizumab|"Cohort 1 only:~Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles."
334061|NCT01649934|Behavioral|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
334062|NCT01649934|Behavioral|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
334063|NCT01649921|Drug|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
334064|NCT01649921|Other|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
334065|NCT01649895|Drug|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
334066|NCT01649895|Drug|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
334067|NCT01649882|Procedure|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
334068|NCT01649869|Other|Placebo|Simple Syrup as 60-90% sucrose in purified water: given orally twice a day for 6 weeks
334069|NCT01649869|Drug|Valganciclovir|Valcyte (valganciclovir hydrochloride) 50 mg of valganciclovir free base per 1 mL, oral solution: given at 16.0 mg/kg, twice a day for 6 weeks.
334070|NCT01649856|Drug|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
334071|NCT01649856|Drug|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
334072|NCT01649856|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
334073|NCT01649843|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
334074|NCT01649830|Radiation|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
334075|NCT01649830|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
334076|NCT01649804|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
334077|NCT01649791|Drug|lenalidomide|Given orally
334078|NCT01649791|Other|laboratory biomarker analysis|Correlative study
334079|NCT01649791|Procedure|lymph node biopsy|Correlative study
334080|NCT01649791|Procedure|bone marrow aspiration|Correlative study
334081|NCT01649791|Other|pharmacological study|Correlative study
334082|NCT01649791|Other|flow cytometry|Correlative study
334083|NCT01649778|Drug|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
334084|NCT01649765|Drug|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
334085|NCT01649765|Other|placebo|Normal Saline 250 ml
334086|NCT01649752|Biological|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
334087|NCT01649752|Biological|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
334092|NCT01649700|Biological|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.
334093|NCT01649687|Biological|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells
334094|NCT01649674|Drug|polyethylene glycole (PEG) solution|
334095|NCT01649674|Drug|sodium picosulphate and magnesium citrate solution|
334096|NCT01649661|Behavioral|questionnaire|
334097|NCT01649648|Biological|Autologous cord blood|Baby's own umbilical cord blood
334098|NCT01649635|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
334099|NCT01649635|Drug|Prednisone|Pharmaceutical form: tablet Route of administration: oral
334100|NCT01649635|Drug|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
334101|NCT01649635|Drug|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
334102|NCT01649622|Drug|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
334103|NCT01649609|Drug|Tacrolimus|Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
334104|NCT01649609|Drug|Mycophenolate acid|Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
334105|NCT01649609|Drug|Sirolimus|mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
334106|NCT01649596|Device|Warming Gown|Forced air warming Gown and portable warming unit that follows patient from pre-operative through surgery and into post-operative recovery.
334107|NCT01649596|Other|Standard of care warming|The intervention is standard of care, placing warm blankets on the patient at time of pre operative preparation through the procedure and into recovery.
334108|NCT01649583|Device|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
334109|NCT01649570|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
334110|NCT01649557|Drug|OPC-34712|oral administered once daily
334111|NCT01649544|Device|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
334112|NCT01649544|Drug|Amiodarone|
334113|NCT01649531|Procedure|1 Implant|
334114|NCT01649531|Procedure|2 Implants|
334115|NCT01649505|Drug|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
334116|NCT01649505|Procedure|breast reconstruction|Undergo sharp dissection technique
334117|NCT01649505|Procedure|breast reconstruction|Undergo electrocoagulation dissection technique
334118|NCT01649492|Dietary Supplement|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
334119|NCT01649479|Biological|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
334120|NCT01649479|Biological|Thrombophilia bloodwork|"Bloodwork will be drawn up for:~antithrombin, protein C, protein S~Factor V Leiden polymorphisms (F5 1691A)~prothrombin 20210A gene polymorphism (F2 20210A)~JAK2 617F Mutation~Homocysteine~Factor VIII"
334121|NCT01649479|Other|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
334122|NCT01649466|Drug|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
334123|NCT01649466|Drug|Protaphane|Protaphane will be used as commercially available injection pens
334124|NCT01649453|Device|Pathwork® Tissue of Origin Test|
334125|NCT01649427|Drug|Prograf|Prograf® capsules were supplied as capsules of 0.5 mg, 1 mg and 1.5 mg dose strengths.
334126|NCT01649427|Drug|Tacrolimus Hexal|"Tacrolimus Hexal® capsules were supplied to the investigators at dose strengths of 0.5 mg,~1 mg and 1.5 mg."
334127|NCT01649401|Device|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
334128|NCT01649401|Device|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.~Manufacturer: PARI GmbH Germany"
334129|NCT01649388|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
334130|NCT01649375|Drug|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
334131|NCT01649375|Drug|Placebo|Placebo
334132|NCT01649375|Drug|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
334180|NCT01649089|Other|Questionnaire Administration|Ancillary studies
334181|NCT01649089|Procedure|Therapeutic Conventional Surgery|Undergo hysterectomy
334182|NCT01649089|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
334183|NCT01649050|Drug|BGG492|
334184|NCT01649050|Drug|Placebo|
334221|NCT01648712|Device|Balance surface, Carmeda heparin-coated surface|This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.
334375|NCT01647516|Drug|placebo|
334133|NCT01649362|Other|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.~The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
334134|NCT01649349|Device|two-piece nasogastric tube|one week period
334135|NCT01649336|Drug|MEK162, MEK inhibitor; oral|multiple dose, escalating
334136|NCT01649336|Drug|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
334137|NCT01649310|Other|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
334138|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
334139|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
334140|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
334141|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
334142|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
334143|NCT01649297|Drug|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
334144|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
334145|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
334146|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
334147|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
334148|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
334149|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
334150|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
334151|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
334152|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
334153|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
334154|NCT01649297|Drug|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
334155|NCT01649297|Drug|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
334156|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
334157|NCT01649297|Drug|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
334158|NCT01649284|Drug|afatinib|40, 30, and 20 mg film-coated tablets
334159|NCT01649271|Drug|Herceptin|3-weekly
334160|NCT01649271|Drug|afatinib|at MTD level
334161|NCT01649271|Drug|trastuzumab|3-weekly
334162|NCT01649271|Drug|Herceptin|weekly
334163|NCT01649271|Drug|afatinib|at MTD level
334164|NCT01649271|Drug|afatinib|escalating dose
334165|NCT01649258|Drug|granisetron transdermal system|Given granisetron transdermal system patch
334166|NCT01649258|Drug|fosaprepitant dimeglumine|Given IV
334167|NCT01649258|Other|laboratory biomarker analysis|Correlative studies
334168|NCT01649245|Drug|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
334169|NCT01649232|Device|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
334170|NCT01649219|Behavioral|Exercise|
334171|NCT01649206|Procedure|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
334172|NCT01649193|Other|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
334173|NCT01649180|Drug|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
334174|NCT01649154|Procedure|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
334175|NCT01649141|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
334176|NCT01649115|Other|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
334185|NCT01649037|Drug|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.[ No response defined as MAP < 10, or 4 hr Urine output < 200 ml] with maximum dose upto 3 mg/h."
334186|NCT01649037|Drug|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response [< 25% decrease in s.creatinine] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
334187|NCT01649024|Drug|Tremelimumab|Given IV
334188|NCT01649011|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
334189|NCT01649011|Behavioral|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
334190|NCT01648998|Drug|Fludrocortisone|single dose 500 mg, capsule
334191|NCT01648998|Drug|Placebo|
334192|NCT01648985|Other|Diabetes in stroke/TIA|Mostly no intervention. A small Group of the patients recieved Yoga
334193|NCT01648972|Drug|Gastrografin|
334194|NCT01648972|Drug|Placebo|
334195|NCT01648959|Other|EEG Recording|
334196|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
334197|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
334198|NCT01648933|Radiation|Rubidium PET|Myocardial Perfusion Imaging
334199|NCT01648920|Device|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
334200|NCT01648907|Other|Imaging exams|"Radiological examinations:~Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front~MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.~Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.~Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.~Biological tests :~Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.~Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.~Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
334201|NCT01648894|Procedure|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
334202|NCT01648894|Procedure|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
334203|NCT01648881|Radiation|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.~Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
334204|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
334205|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
334206|NCT01648855|Other|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
334207|NCT01648829|Drug|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
334208|NCT01648829|Drug|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
334209|NCT01648790|Drug|Prasugrel ODT1 - Tablet|Administered orally as tablet.
334210|NCT01648790|Drug|Prasugrel ODT2 - Tablet|Administered orally as tablet.
334211|NCT01648790|Drug|Prasugrel ODT2 - Suspension|Administered orally as suspension.
334212|NCT01648777|Device|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml~o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
334213|NCT01648777|Drug|placebo|"Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml~Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
334214|NCT01648764|Drug|LY2334737|Administered orally
334215|NCT01648751|Drug|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
334216|NCT01648751|Drug|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
334217|NCT01648738|Other|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
334218|NCT01648738|Other|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
334219|NCT01648725|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
334220|NCT01648725|Procedure|usual care|Standard care before induction of anesthesia
334295|NCT01648140|Drug|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
334376|NCT01647490|Procedure|Permanent Cardiac Pacemaker Implantation|
334222|NCT01648699|Drug|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
334223|NCT01648686|Procedure|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
334224|NCT01648660|Dietary Supplement|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
334225|NCT01648634|Drug|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is>60kg)
334226|NCT01648634|Drug|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is>60kg)
334227|NCT01648621|Behavioral|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
334228|NCT01648621|Behavioral|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
334229|NCT01648621|Behavioral|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
334230|NCT01648621|Behavioral|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
334231|NCT01648621|Behavioral|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.~Inclusion criteria for tele-home monitoring:~a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness [MRC] Class 4 & 5 or modified MRC [mMRC] 3 & 4) f. frequent ED visits (> 2) in last 12 months~5. 12 weeks of clinical stability with no ED visits."
334232|NCT01648621|Behavioral|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
334233|NCT01648621|Behavioral|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
334234|NCT01648621|Behavioral|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
334235|NCT01648621|Behavioral|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:~have had a recent exacerbation, but are now clinically stable;~symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;~have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and~have sufficient motivation to participate."
334236|NCT01648621|Behavioral|Smoking cessation|Referral to a smoking cessation program (as applicable)
334237|NCT01648621|Behavioral|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
334238|NCT01648621|Behavioral|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
334239|NCT01648608|Drug|Exemestane|Exemestane for neoadjuvant chemotherapy
334240|NCT01648595|Drug|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
334241|NCT01648582|Drug|Dulaglutide|Administered SC
334242|NCT01648582|Drug|Insulin glargine|Administered SC per dosing titration schedule
334243|NCT01648582|Drug|Metformin|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
334244|NCT01648582|Drug|Sulfonylureas|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
334245|NCT01648556|Other|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.~The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
334246|NCT01648543|Procedure|lumbar sympathetic ganglion block|
334247|NCT01648530|Other|No Treatment|No Treatment
334248|NCT01648517|Drug|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
334249|NCT01648517|Drug|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
334372|NCT01647542|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
334250|NCT01648504|Other|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
334251|NCT01648491|Procedure|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
334252|NCT01648491|Biological|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
334253|NCT01648478|Other|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:~A basal period (from T-30 to T0)~The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)~The infusion of glucose at variable rate (so as to maintain euglycemia)"
334254|NCT01648465|Drug|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
334255|NCT01648452|Biological|NT-501 CNTF-releasing implant|20 ng/day released into the eye
334256|NCT01648348|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
334257|NCT01648348|Biological|Bevacizumab|Given IV
334258|NCT01648348|Other|Laboratory Biomarker Analysis|Correlative studies
334259|NCT01648348|Other|Pharmacological Study|Correlative studies
334260|NCT01648348|Other|Quality-of-Life Assessment|Ancillary studies
334261|NCT01648335|Device|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
334262|NCT01648335|Device|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
334263|NCT01648322|Drug|F-627|subcutaneous injection given 1 per chemotherapy.
334264|NCT01648322|Drug|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
334265|NCT01648309|Other|Neuropsychological testing|This is an observational study
334266|NCT01648296|Drug|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
334267|NCT01648283|Drug|IV racemic methadone HCl|IV racemic Methadone HC1 6 mg
334268|NCT01648283|Drug|Oral racemic methadone HCl|oral d5-methadone HCl 11 mg
334269|NCT01648270|Drug|buprenorphine|"Session 1 Intravenous buprenorphine: 0.2 mg infused over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3intravenous buprenorphine 0.2 mg infused over 1 hr beginning 1 hr after starting cyclosporine.~Session 4 Sublingual buprenorphine: 2 mg"
334270|NCT01648270|Drug|Cyclosporine|Session 3 Cyclosporine (2.5mg/kg/hr infused over 2 hr) Subjects then take oral cyclosporine 4.5 mg/kg twice daily, until session 4, continue oral cyclosporine 4.5 mg/kg twice daily for 5 days
334271|NCT01648257|Drug|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
334272|NCT01648257|Drug|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
334273|NCT01648257|Drug|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
334274|NCT01648244|Other|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
334275|NCT01648231|Drug|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
334276|NCT01648231|Drug|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
334277|NCT01648231|Drug|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
334278|NCT01648218|Drug|Neutral protamine hagedorn (NPH) insulin|
334279|NCT01648218|Drug|Regular human insulin or Insulin Aspart|
334280|NCT01648218|Drug|Insulin glargine|
334281|NCT01648205|Drug|Placebo|Matching Placebo will be given
334282|NCT01648205|Drug|Ranolazine|Patients will receive ranolazine 1000mg bid or matching placebo
334283|NCT01648192|Drug|Losmapimod for single dose|Film coated white tablet
334284|NCT01648192|Drug|Losmapimod for repeat dose|Film coated white tablet
334285|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
334286|NCT01648179|Drug|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
334287|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
334288|NCT01648179|Drug|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
334289|NCT01648166|Other|Environmental sampling|Soil, water, blood, urine, hair and radon testing in homes in Appalachia
334290|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
334291|NCT01648153|Other|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
334292|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
334293|NCT01648140|Drug|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
334294|NCT01648140|Drug|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
334296|NCT01648140|Drug|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
334297|NCT01648140|Drug|Telaprevir|375 mg film-coated tablet
334298|NCT01648127|Drug|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
334299|NCT01648114|Other|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
334300|NCT01648101|Drug|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
334301|NCT01648101|Drug|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
334302|NCT01648101|Other|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
334303|NCT01648075|Dietary Supplement|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
334304|NCT01648062|Behavioral|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
334305|NCT01648049|Behavioral|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein & Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, & Dick, 1995).
334306|NCT01648049|Behavioral|Treatment as usual|Standard Care - Treatment as usual
334307|NCT01648036|Drug|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
334308|NCT01648036|Drug|Dalteparin|Dose 5000 IU, subcutaneous, daily
334309|NCT01648023|Device|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
334310|NCT01648023|Drug|Gem-Cis or Gem-Carbo|
334311|NCT01648010|Device|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
334312|NCT01648010|Device|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
334313|NCT01647997|Other|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
334314|NCT01647984|Dietary Supplement|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
334315|NCT01647984|Dietary Supplement|placebo|
334316|NCT01647971|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
334317|NCT01647958|Device|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication
334318|NCT01647945|Drug|Placebo|placebo pill
334319|NCT01647945|Drug|FK506 level < 2 ng/ml|FK506 goal trough blood level < 2 ng/ml
334320|NCT01647945|Drug|FK506 level 2-3 ng/ml|FK506 goal trough blood level 2-3 ng/ml
334321|NCT01647945|Drug|FK506 level 3-5 ng/ml|FK506 goal trough blood level 3-5 ng/ml
334322|NCT01647932|Drug|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; >50ml/min 25mg daily, 20-50ml/min 50mg daily amd <20ml/min 100mg daily.
334323|NCT01647932|Drug|Placebo|Placebo according to clearance of creatinine; >50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd <20ml/min 2 pills daily.
334324|NCT01647919|Dietary Supplement|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
334325|NCT01647919|Dietary Supplement|Placebo|4 capsules of placebo identical to cogniVida™ once a day
334326|NCT01647893|Drug|CTB-001|IV bolus or IV infusion
334327|NCT01647880|Drug|Verum arm receiving Gilenya®|
334328|NCT01647880|Drug|Active Comparator receiving Extavia®|
334329|NCT01647867|Other|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
334330|NCT01647854|Procedure|Teleconsultation|Teleconsultation in prehospital emergencies
334331|NCT01647828|Drug|OMP-59R5|OMP-59R5 administered intravenously
334332|NCT01647828|Drug|Gemcitabine|administered intravenously
334333|NCT01647828|Drug|Placebo|administered IV
334334|NCT01647828|Drug|Nab-Paclitaxel|administered intravenously
334335|NCT01647815|Procedure|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
334336|NCT01647802|Device|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
334337|NCT01647802|Device|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
334338|NCT01647802|Device|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
334339|NCT01647789|Drug|CFG920|
334340|NCT01647776|Other|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
334341|NCT01647776|Procedure|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors [levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression] as markers of risk of developing adenoma.
334342|NCT01647776|Other|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
334343|NCT01647763|Procedure|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.~In the area with the 3 largest knots a purse string suture will be placed."
334344|NCT01647763|Procedure|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
334345|NCT01647750|Drug|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
334346|NCT01647750|Drug|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
334347|NCT01647737|Dietary Supplement|MighTeaFlow|4-6 times daily
334348|NCT01647737|Dietary Supplement|Xylitol|4-6 times daily
334349|NCT01647711|Drug|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
334350|NCT01647698|Behavioral|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.~Adaptive refers to the increase in the number of items that the patient is required to remember."
334351|NCT01647698|Behavioral|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
334352|NCT01647698|Behavioral|No training|No training during the experiment.
334353|NCT01647685|Drug|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
334354|NCT01647685|Drug|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
334355|NCT01647685|Drug|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
334356|NCT01647672|Drug|Abraxane|Abraxane for neoadjuvant chemotherapy
334357|NCT01647659|Drug|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
334358|NCT01647659|Drug|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
334359|NCT01647646|Drug|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
334360|NCT01647633|Other|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
334361|NCT01647620|Drug|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
334362|NCT01647620|Drug|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
334363|NCT01647607|Behavioral|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
334364|NCT01647607|Behavioral|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
334365|NCT01647594|Behavioral|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
334366|NCT01647594|Behavioral|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
334367|NCT01647581|Device|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
334368|NCT01647581|Device|NO hemoclip placement|No hemoclip placement (placebo / sham)
334369|NCT01647555|Drug|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
334370|NCT01647555|Radiation|Radiotherapy|Curative dose: 66 to 70 Gy
334371|NCT01647542|Drug|TAK-875|TAK-875 tablets
334377|NCT01647477|Behavioral|interview|25 minutes of semi directive interview
334378|NCT01647477|Behavioral|questionnaires|questionnaires to answer at baseline 45 minutes
334379|NCT01647451|Drug|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
334380|NCT01647451|Drug|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
334381|NCT01647438|Behavioral|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
334382|NCT01647438|Other|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
334383|NCT01647425|Behavioral|physician assessment|"Socio-economic conditions and general features: educational level, professional status...~Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...~in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...~Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...~Assessment of current use of cannabis using the Cannabis Abuse Screening Test~Psychiatric assessment using the MINI 5.0"
334384|NCT01647412|Drug|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
334385|NCT01647412|Dietary Supplement|Nutraceutical Combination|
334386|NCT01647412|Other|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
334387|NCT01647412|Other|Placebo Growth Hormone|
334388|NCT01647347|Drug|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
334389|NCT01647347|Other|Water|
334390|NCT01647334|Radiation|Adaptive radiotherapy|
334391|NCT01647321|Behavioral|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
334392|NCT01647321|Behavioral|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
334393|NCT01647308|Drug|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
334394|NCT01647308|Drug|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
334395|NCT01647282|Drug|locally-applied minocycline HCl (1 mg)|
334396|NCT01647282|Procedure|scaling and root planing (Sc/RP)|
334397|NCT01647269|Procedure|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
334398|NCT01647256|Drug|Nikkomycin Z|Capsule, 500 mg, single-dose
334399|NCT01647243|Other|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
334400|NCT01647217|Drug|Terpinen-4-ol|Lid scrub once or twice per day for one month.
334401|NCT01647217|Other|Placebo|Lid scrub once or twice per day for one month
334402|NCT01647204|Other|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
334403|NCT01647191|Behavioral|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
334404|NCT01647191|Behavioral|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
334405|NCT01647178|Procedure|TORQ assisted sternal closure|
334406|NCT01647178|Procedure|Conventional closure|
334407|NCT01647165|Drug|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
334408|NCT01647165|Drug|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
334409|NCT01647165|Drug|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
334410|NCT01647152|Drug|Ustekinumab|
334411|NCT01646853|Radiation|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
334412|NCT01646853|Drug|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
334413|NCT01646840|Drug|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
334414|NCT01646840|Drug|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
334415|NCT01646827|Drug|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
334416|NCT01646814|Drug|PL2200|PL2200, containing 325 mg aspirin active ingredient
334417|NCT01646814|Drug|Aspirin tablets|325 mg aspirin tablets (USP)
334418|NCT01646801|Device|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
334419|NCT01646788|Device|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
334421|NCT01646762|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
334422|NCT01646762|Other|Laboratory Biomarker Analysis|Correlative studies
334423|NCT01646749|Dietary Supplement|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
334424|NCT01646736|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
334425|NCT01646736|Drug|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
334426|NCT01646736|Drug|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
334427|NCT01646723|Behavioral|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
334428|NCT01646710|Behavioral|Pretesting food based recommendations|
334429|NCT01646697|Other|cytology specimen collection procedure|Undergo cytopathologic sample collection
334430|NCT01646684|Drug|SOM230|
334431|NCT01646671|Drug|LCZ696|LCZ696 200 mg tablet once daily
334432|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
334433|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
334434|NCT01646645|Biological|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
334435|NCT01646632|Behavioral|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
334436|NCT01646632|Behavioral|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
334437|NCT01646619|Drug|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).~Diluent: Dextrose 5%."
334438|NCT01646619|Drug|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
334439|NCT01646606|Procedure|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
334440|NCT01646606|Procedure|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
334441|NCT01646593|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
334442|NCT01646580|Drug|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
334443|NCT01646567|Drug|SHP-141C|Topical Cream
334444|NCT01646567|Drug|Placebo to SHP-141C|Placebo Topical Cream
334445|NCT01646567|Drug|Betamethasone Valerate|Topical cream, 0.02%
334446|NCT01646567|Drug|Calcipotriol|Topical cream, 0.005%
334447|NCT01646554|Drug|Modified FOLFOX6|
334448|NCT01646554|Biological|Aflibercept|Targeted therapy
334449|NCT01646554|Procedure|Surgery|
334450|NCT01646528|Procedure|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
334451|NCT01646515|Drug|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.~Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
334452|NCT01646515|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
334453|NCT01646502|Biological|Esp protein|
334454|NCT01646502|Other|Standard wound care|
334455|NCT01646489|Drug|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
334456|NCT01646489|Drug|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
334457|NCT01646476|Device|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
334458|NCT01646476|Device|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
334459|NCT01646463|Behavioral|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
334460|NCT01646463|Behavioral|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
334461|NCT01646450|Drug|Icotinib|Icotinib: 125mg, oral administration, three times per day.
334462|NCT01646437|Drug|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
334463|NCT01646437|Drug|Aspirin|75 mg daily
334464|NCT01646437|Drug|Vitamin D|60,000 IU monthly
334465|NCT01646437|Drug|Matching Placebo|Matching Placebo
334466|NCT01646398|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
334467|NCT01646398|Biological|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
334468|NCT01646385|Drug|etanercept|use as per routine clinical practice
334469|NCT01646385|Drug|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
334470|NCT01646372|Other|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
334471|NCT01646372|Other|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
334472|NCT01646359|Device|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
334473|NCT01646359|Device|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
334474|NCT01646346|Radiation|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
334475|NCT01646333|Behavioral|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
334476|NCT01646333|Behavioral|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
334477|NCT01646320|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
334478|NCT01646320|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
334479|NCT01646320|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
334480|NCT01646320|Drug|Metformin immediate release (IR)|Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
334481|NCT01646307|Drug|Atorvastatin|
334482|NCT01646307|Drug|Rosuvastatin|
334483|NCT01646294|Drug|YM178 modified release (OCAS)|oral
334484|NCT01646294|Drug|YM178 immediate release (IR)|oral
334485|NCT01646281|Drug|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
334486|NCT01646281|Drug|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
334487|NCT01646268|Drug|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
334488|NCT01646268|Drug|Placebo Patch|"Transdermal Patch~Size:~10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo will receive matching placebo patches"
334489|NCT01646255|Drug|Rotigotine|"Transdermal Patch~Content:~4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
334490|NCT01646255|Drug|Placebo Patch|"Transdermal Patch~Size:~20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
334491|NCT01646255|Drug|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release [in combination with benserazide or carbidopa]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
334492|NCT01646242|Procedure|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
334493|NCT01646242|Procedure|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
334494|NCT01646229|Other|Polymyxin-B hemoperfusion|
334495|NCT01646229|Other|Control|
334496|NCT01646216|Behavioral|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
334497|NCT01646203|Biological|IMC-TR1|Administered intravenously
334498|NCT01646190|Dietary Supplement|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
334499|NCT01646190|Procedure|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
334500|NCT01646190|Behavioral|Fasting state after midnight|No preoperative glucose load
334501|NCT01646190|Behavioral|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
334502|NCT01646190|Behavioral|urinary catheter removal|at POD 1
334503|NCT01646190|Behavioral|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
334504|NCT01646190|Behavioral|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
334505|NCT01646190|Behavioral|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), >4h out of bed on POD1, >6h on POD2, complete at POD3
334506|NCT01646190|Other|Preanesthetic medication|Preanesthetic oral medication before surgery
334507|NCT01646177|Drug|Placebo|Administered SC
334508|NCT01646177|Drug|50 mg etanercept|Administered SC
334509|NCT01646177|Drug|80 mg ixekizumab|Administered SC
334510|NCT01646151|Drug|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
334511|NCT01646138|Biological|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
334512|NCT01646125|Drug|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
334513|NCT01646125|Drug|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
334514|NCT01646125|Drug|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
334515|NCT01646099|Behavioral|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
334516|NCT01646086|Behavioral|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
334517|NCT01646073|Biological|Adalimumab|adalimumab eow
334518|NCT01646073|Biological|placebo|placebo
334519|NCT01646060|Device|CM-1500|Blood Volume Monitor
334557|NCT01645774|Procedure|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
334558|NCT01645761|Drug|Endonase|PPI- based triple therapy with endonase
334520|NCT01646047|Dietary Supplement|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
334521|NCT01646047|Dietary Supplement|multi-component dietary supplement|placebo capsules
334522|NCT01646034|Drug|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
334523|NCT01646034|Drug|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
334524|NCT01646021|Drug|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
334525|NCT01646021|Drug|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
334526|NCT01646008|Other|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
334527|NCT01646008|Other|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
334528|NCT01645995|Dietary Supplement|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
334529|NCT01645995|Dietary Supplement|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
334530|NCT01645943|Procedure|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
334531|NCT01645930|Drug|Ixazomib|Ixazomib capsules
334532|NCT01645930|Drug|Lenalidomide|Lenalidomide capsules
334533|NCT01645930|Drug|Dexamethasone|Dexamethasone tablets
334534|NCT01645917|Device|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
334535|NCT01645904|Behavioral|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
334536|NCT01645904|Behavioral|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
334537|NCT01645904|Behavioral|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.~Group 3: Patients provide feedback regarding final version of My Family Garden website."
334538|NCT01645904|Behavioral|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
334539|NCT01645891|Device|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
334540|NCT01645891|Device|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
334541|NCT01645878|Behavioral|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
334542|NCT01645878|Behavioral|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
334543|NCT01645878|Behavioral|routin breast feeding education|
334544|NCT01645865|Behavioral|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
334545|NCT01645865|Behavioral|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
334546|NCT01645852|Dietary Supplement|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
334547|NCT01645839|Drug|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
334548|NCT01645826|Drug|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
334549|NCT01645826|Drug|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
334550|NCT01645800|Drug|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
334551|NCT01645800|Drug|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
334552|NCT01645787|Drug|4-aminopyridine|10 mg/twice daily
334553|NCT01645787|Drug|Placebo|Crossover study involving one trial with sugar pill (placebo)
334554|NCT01645774|Procedure|10s injections duration|10s injections duration
334555|NCT01645774|Procedure|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
334556|NCT01645774|Procedure|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
334652|NCT01644799|Drug|idelalisib|oral
334653|NCT01644799|Drug|lenalidomide|oral
334559|NCT01645748|Drug|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
334560|NCT01645748|Drug|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
334561|NCT01645748|Drug|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
334562|NCT01645735|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
334563|NCT01645735|Drug|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
334564|NCT01645722|Procedure|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
334565|NCT01645709|Drug|Verapamil|
334566|NCT01645709|Drug|Placebo|
334567|NCT01645696|Device|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
334568|NCT01645696|Device|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
334569|NCT01645696|Device|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
334570|NCT01645566|Behavioral|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
334571|NCT01645475|Drug|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
334572|NCT01645449|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
334573|NCT01645436|Other|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
334574|NCT01645423|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
334575|NCT01645410|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
334576|NCT01645384|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
334577|NCT01645358|Device|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
334578|NCT01645358|Device|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
334579|NCT01645345|Device|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
334580|NCT01645332|Drug|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
334581|NCT01645332|Drug|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
334582|NCT01645332|Other|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
334583|NCT01645306|Drug|Revacept|single intravenous injection
334584|NCT01645306|Drug|Placebo|single intravenous injection
334585|NCT01645293|Genetic|Genetically modified T cells # 1138|
334586|NCT01645280|Drug|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
334587|NCT01645280|Drug|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
334588|NCT01645280|Drug|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
334589|NCT01645280|Drug|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
334590|NCT01645280|Drug|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
334591|NCT01645267|Procedure|Hydroxyapatite|Use of artifical bonegraft material
334592|NCT01645254|Drug|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
334593|NCT01645241|Drug|gonadotropins plus GnRH antagonists|
334594|NCT01645241|Drug|ganirelix|
334595|NCT01645228|Radiation|coronary calcium score measurement|
334596|NCT01645228|Biological|high sensitivity C reactive protein measurement|
334597|NCT01645228|Procedure|ankle brachial index measurement|
334598|NCT01645215|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
334599|NCT01645202|Procedure|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
334600|NCT01645189|Biological|Hunterase|once weekly, 0.5mg/kg IV infusion
334601|NCT01645176|Drug|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
334602|NCT01645163|Behavioral|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
334603|NCT01645150|Behavioral|Progressive strength training|12 weeks of supervised progressive strength training
334604|NCT01645137|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
334605|NCT01645137|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
334606|NCT01645124|Drug|Hydroxyurea|
334607|NCT01645124|Procedure|Phlebotomy|
334608|NCT01645111|Drug|Clevidipine|
334609|NCT01645098|Drug|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
334610|NCT01645098|Drug|Dexmedetomidine|0.5 mcg/kg/hr IV
334611|NCT01645085|Drug|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
334612|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
334613|NCT01645085|Drug|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
334614|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
334615|NCT01645072|Other|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI <55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
334616|NCT01645072|Other|Control group|The ongoing anti epileptic drug treatment will be continued without change.
334617|NCT01645046|Drug|Coenzyme A|Coenzyme A 200mg per day.
334618|NCT01645046|Drug|Coenzyme A|Coenzyme A 400mg per day.
334619|NCT01645046|Drug|Placebo|Capsule without coenzyme A.
334620|NCT01645033|Other|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
334621|NCT01645033|Other|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:~Teaching about the treatment program~Teaching important ideas about sexual behaviors risks~Increasing knowledge about specific sexually transmitted diseases~Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
334622|NCT01644994|Combination Product|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
334623|NCT01644981|Other|blood sampling|blood sampling
334624|NCT01644968|Drug|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
334625|NCT01644968|Drug|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
334626|NCT01644968|Drug|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
334627|NCT01644968|Biological|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
334628|NCT01644968|Biological|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
334629|NCT01644968|Biological|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
334630|NCT01644968|Biological|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
334631|NCT01644955|Drug|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
334632|NCT01644955|Procedure|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
334633|NCT01644942|Other|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
334634|NCT01644929|Procedure|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
334635|NCT01644929|Procedure|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
334636|NCT01644929|Procedure|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
334637|NCT01644916|Procedure|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
334638|NCT01644916|Procedure|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
334639|NCT01644890|Drug|NK105|IV, Weekly
334640|NCT01644890|Drug|Paclitaxel|IV, Weekly
334641|NCT01644877|Drug|DAS181 dry powder, formulation F02|
334642|NCT01644877|Drug|Lactose Placebo|
334643|NCT01644864|Drug|0.375% ROPIVACAINE|
334644|NCT01644864|Drug|placebo|
334645|NCT01644851|Behavioral|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
334646|NCT01644838|Drug|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
334647|NCT01644838|Drug|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
334648|NCT01644825|Drug|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
334649|NCT01644825|Drug|pazopanib|orally, 800 mg orally daily
334650|NCT01644812|Behavioral|Aerobic exercise|
334651|NCT01644812|Behavioral|Stretching|
334654|NCT01644773|Drug|Crizotinib|"Starting dose level:~Initial Treatment Plan: 130 mg/m^2 per dose~Modified Treatment Plan per Amendment 1.0: 165 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day"
334655|NCT01644773|Drug|Dasatinib|"Starting dose level: 50 mg/m^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day"
334656|NCT01644760|Procedure|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
334657|NCT01644747|Device|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
334658|NCT01644734|Drug|Spiriva HandiHaler|
334659|NCT01644721|Biological|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
334660|NCT01644708|Behavioral|Self empowerment|"1. Group meeting, introducing the method and the assessment tools~Self-empowerment,~Handing over the journal,~Questionnaire about emotional states and motivations for losing weight and for change.~The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal."
334661|NCT01644695|Procedure|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
334662|NCT01644682|Other|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
334663|NCT01644682|Other|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
334664|NCT01644682|Other|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
334665|NCT01644669|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
334666|NCT01644656|Device|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
334667|NCT01644643|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
334668|NCT01644643|Drug|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
334669|NCT01644643|Drug|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
334670|NCT01644630|Procedure|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.~- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
334671|NCT01644630|Procedure|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
334672|NCT01644617|Drug|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
334673|NCT01644617|Drug|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
334674|NCT01644617|Drug|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
334675|NCT01644604|Device|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
334676|NCT01644591|Other|Quality-of-Life Assessment|Ancillary studies
334677|NCT01644591|Other|Questionnaire Administration|Ancillary studies
334678|NCT01644591|Radiation|Stereotactic Radiosurgery|Undergo SRS
334679|NCT01644578|Procedure|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
334680|NCT01644565|Biological|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
334681|NCT01644565|Biological|Recombinant fimbrial adhesin dscCfaE|
334682|NCT01644565|Biological|Modified E. coli heat labile enterotoxin LTR192G|
334683|NCT01644539|Dietary Supplement|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
334829|NCT01643590|Biological|JVS-100 30 mg dose injection|Intramyocardial Injection
336062|NCT01634100|Drug|Empagliflozin|BI Drug
334684|NCT01644539|Dietary Supplement|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
334685|NCT01644539|Dietary Supplement|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
334686|NCT01644526|Device|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
334687|NCT01644500|Drug|Dulaglutide|Administered SC
334688|NCT01644500|Drug|Glimepiride|Administered orally
334689|NCT01644500|Drug|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
334690|NCT01644500|Drug|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
334691|NCT01644487|Device|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
334692|NCT01644487|Device|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
334693|NCT01644474|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
334694|NCT01644474|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
334695|NCT01644474|Drug|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
334696|NCT01644474|Drug|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
334697|NCT01644461|Other|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
334698|NCT01644448|Other|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
334699|NCT01644448|Other|Standard Therapy|Topical Applications as directed by the investigator
334700|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
334701|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
334702|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
334703|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
334704|NCT01644422|Other|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
334705|NCT01644396|Biological|Adalimumab|
334706|NCT01644383|Behavioral|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
334707|NCT01644370|Drug|HAART|as per Thai HIV Treatment guidelines
334708|NCT01644357|Other|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
334709|NCT01644344|Other|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
334710|NCT01644344|Other|Xray|
334711|NCT01644331|Drug|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
334712|NCT01644331|Drug|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
334713|NCT01644292|Other|EPIC WheelS|EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
334714|NCT01644253|Biological|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
334715|NCT01644253|Biological|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses~Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
334716|NCT01644253|Biological|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months~Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
334717|NCT01644253|Biological|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
334718|NCT01644253|Biological|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
334719|NCT01644253|Biological|TRU-016 10-20 mg/kg + bendamustine|TRU-016 dosed 10 mg/kg for the first dose and then 20 mg/kg weekly for 2 cycles, followed by dosing every other week for an additional 4 cycles (cycle = 28 days). Bendamustine (90 mg/m2 on days 2 and 3 of cycle 1 and then days 1 and 2 of cycles 2 to 6) will be infused after completion of TRU-016. If a patient is benefiting with stable disease or better, then TRU-016 may continue to be dosed every 3 weeks after the first 6 cycles; bendamustine will not be dosed beyond 6 cycles.
334720|NCT01644240|Drug|TD-8954|Intravenous infusion
334721|NCT01644240|Drug|Placebo - saline|Intravenous infusion
334722|NCT01644214|Other|6 month follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
334723|NCT01644201|Dietary Supplement|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
334724|NCT01644201|Dietary Supplement|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
334725|NCT01644188|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
334726|NCT01644188|Drug|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
334727|NCT01644188|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
334728|NCT01644188|Drug|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
334729|NCT01644188|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
334730|NCT01644175|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
334731|NCT01644175|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
334732|NCT01644175|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
334733|NCT01644162|Device|iVAPS ventilation|3 months of ventilation on iVAPS mode
334734|NCT01644149|Device|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
334735|NCT01644149|Device|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
334736|NCT01644149|Biological|2011-2012 Fluzone trivalent inactivated influenza vaccine|
334737|NCT01644136|Procedure|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
334738|NCT01644136|Procedure|regional lymph node dissection|Undergo pelvic lymph node dissection
334739|NCT01644136|Device|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
334740|NCT01644110|Drug|INCB018424/CC-4047|For all patients the starting dose of ruxolitinib in this trial is 10mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.
334741|NCT01644097|Dietary Supplement|Lactobacillus plantarum strain 299v|Given PO
334742|NCT01644097|Dietary Supplement|Lactobacillus acidophilus probiotic|Given PO
334743|NCT01644097|Dietary Supplement|placebo|Given PO
334744|NCT01644097|Other|laboratory biomarker analysis|Correlative studies
334745|NCT01644097|Other|questionnaire administration|Ancillary studies
334746|NCT01644097|Procedure|quality-of-life assessment|Ancillary studies
334747|NCT01644097|Dietary Supplement|Bifidobacterium lactis probiotic supplement|Given PO
334748|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
334749|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
334750|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
334751|NCT01644071|Drug|cipralex|one time 10 mg, tablet
334752|NCT01644058|Procedure|Immediate loading|
334753|NCT01644045|Device|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
334754|NCT01644032|Other|Teleconsultation|Teleconsultation between paramedics and an EMS physician
334755|NCT01644019|Procedure|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
334756|NCT01644006|Procedure|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
334757|NCT01643993|Other|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
334758|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
334759|NCT01643980|Drug|Vaginal micronized progesterone|200 mg vaginal route per day
334760|NCT01643980|Device|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
334761|NCT01643967|Other|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
334762|NCT01643967|Other|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
334763|NCT01643954|Procedure|robotic radical prostatectomy|robotic assisted surgery
334764|NCT01643941|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
334868|NCT01643278|Other|Pharmacological Study|Correlative studies
334765|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
334766|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
334767|NCT01643941|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
334768|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
334769|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
334770|NCT01643941|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
334771|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
334772|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
334773|NCT01643941|Biological|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
334774|NCT01643941|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
334775|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
334776|NCT01643941|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
334777|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
334778|NCT01643941|Procedure|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
334779|NCT01643928|Biological|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion [IV] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
334780|NCT01643928|Biological|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
334781|NCT01643928|Biological|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
334782|NCT01643915|Behavioral|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
334783|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
334784|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
334785|NCT01643902|Drug|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
334786|NCT01643889|Drug|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
334787|NCT01643889|Drug|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
334788|NCT01643889|Drug|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
334789|NCT01643889|Drug|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
334790|NCT01643876|Behavioral|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
334791|NCT01643850|Drug|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
334792|NCT01643850|Drug|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
334793|NCT01643850|Drug|MCS110|Patients will receive the single dose of MCS110 (10mg/kg) on day 1
334794|NCT01643850|Drug|Placebo|Participants will receive a single dose of NaCl on day 1
334795|NCT01643837|Other|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
336063|NCT01634100|Drug|Empagliflozin|BI Drug
334796|NCT01643837|Other|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
334797|NCT01643824|Radiation|Proton Beam Therapy|"- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%~- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
334798|NCT01643811|Procedure|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
334799|NCT01643811|Procedure|Endoscopic submucosal dissection|endoscopic submucosal dissection
334800|NCT01643798|Procedure|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
334801|NCT01643798|Procedure|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
334802|NCT01643785|Drug|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
334803|NCT01643772|Drug|Oxycodone hydrochloride|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
334804|NCT01643759|Drug|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
334805|NCT01643746|Device|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
334806|NCT01643746|Device|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
334807|NCT01643733|Device|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
334808|NCT01643707|Behavioral|Evidence based guidelines and tools|Education, guidelines, tools
334809|NCT01643694|Behavioral|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
334810|NCT01643681|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
334811|NCT01643668|Drug|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
334812|NCT01643668|Drug|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
334813|NCT01643668|Procedure|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
334814|NCT01643655|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
334815|NCT01643642|Other|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
334816|NCT01643642|Other|Treatment As Usual|Other: Treatment As Usual
334817|NCT01643629|Biological|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
334818|NCT01643629|Other|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
334819|NCT01643616|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
334820|NCT01643616|Drug|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
334821|NCT01643616|Drug|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
334822|NCT01643616|Drug|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
334823|NCT01643616|Device|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
334824|NCT01643616|Device|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
334825|NCT01643603|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
334826|NCT01643603|Other|laboratory biomarker analysis|Correlative studies
334827|NCT01643590|Biological|JVS-100 15 mg dose Injection|Intramyocardial Injection
334828|NCT01643590|Biological|Placebo Injection|Intramyocardial Injection
336064|NCT01634100|Drug|Rifampicin|Rifampicin
334830|NCT01643577|Procedure|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
334831|NCT01643577|Procedure|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
334832|NCT01643538|Behavioral|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
334833|NCT01643538|Behavioral|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
334834|NCT01643538|Behavioral|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
334835|NCT01643538|Behavioral|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
334836|NCT01643525|Device|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
334837|NCT01643499|Drug|oxaliplatin|Given IV
334838|NCT01643499|Drug|irinotecan hydrochloride|Given IV
334839|NCT01643499|Drug|leucovorin calcium|Given IV
334840|NCT01643499|Drug|fluorouracil|Given IV
334841|NCT01643499|Other|laboratory biomarker analysis|Correlative studies
334842|NCT01643486|Other|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
334843|NCT01643486|Other|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
334844|NCT01643473|Behavioral|Adherence Intervention|Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
334845|NCT01643473|Other|Attention Control|Health education videos on topics unrelated to medication adherence, hypertension or type 2 diabetes
334846|NCT01643460|Procedure|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size & amount of fluid aspirated from the cyst.
334847|NCT01643447|Drug|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
334848|NCT01643447|Drug|Diammonium glycyrrhizinate|
334849|NCT01643434|Drug|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
334850|NCT01643434|Drug|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
334851|NCT01643421|Other|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
334852|NCT01643408|Drug|asparaginase Erwinia chrysanthemi|
334853|NCT01643395|Other|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
334854|NCT01643395|Other|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
334855|NCT01643382|Drug|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
334856|NCT01643382|Drug|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
334857|NCT01643369|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
334858|NCT01643369|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
334859|NCT01643369|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
334860|NCT01643356|Behavioral|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
334861|NCT01643330|Genetic|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10^13 DNase Resistant Particles (DRP) MYDICAR
334862|NCT01643330|Genetic|Placebo|Single intracoronary infusion
334863|NCT01643304|Behavioral|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
334864|NCT01643291|Procedure|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
334865|NCT01643278|Drug|Dasatinib|Given PO
334866|NCT01643278|Biological|Ipilimumab|Given IV
334867|NCT01643278|Other|Laboratory Biomarker Analysis|Correlative studies
334869|NCT01643265|Dietary Supplement|Whey Milk Protein|20 grams of Whey Milk Protein
334870|NCT01643265|Dietary Supplement|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
334871|NCT01643252|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
334872|NCT01643252|Drug|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
334873|NCT01643239|Other|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
334874|NCT01643239|Other|Hospital-based mCIT|the mCIT group with individualized intervention
334875|NCT01643239|Other|Hospital-based TR|OT or PT or therapist-based training
334876|NCT01643226|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
334877|NCT01643226|Drug|placebo solution|0.0% riboflavin ophthalmic solution
334878|NCT01643226|Device|KXL System|30 mW/cm2
334879|NCT01643213|Device|Non Boston Scientific SCS Trial Therapy|No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
334880|NCT01643213|Device|BSC approved SCS Trial Therapy w/ OMG|No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
334881|NCT01643187|Dietary Supplement|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
334882|NCT01643187|Dietary Supplement|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
334883|NCT01643161|Behavioral|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
334884|NCT01643161|Behavioral|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
334885|NCT01643135|Drug|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
334886|NCT01643135|Drug|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
334887|NCT01643122|Other|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
334888|NCT01643122|Other|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
334889|NCT01643109|Other|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
334890|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
334891|NCT01643096|Other|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
334892|NCT01643083|Drug|Rifaximin|Rifaximin 400mg tid for 2 wk
334893|NCT01643083|Drug|Placebo|Placebo for 2 week
334894|NCT01643070|Drug|Capecitabine, Oxaliplatin|Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.
334895|NCT01643070|Radiation|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
334896|NCT01643057|Device|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
334897|NCT01643044|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
334898|NCT01643044|Behavioral|Computer-delivered, brief intervention on alcohol use|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
334899|NCT01643031|Drug|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
334900|NCT01643031|Drug|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
334901|NCT01643018|Procedure|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
334902|NCT01643018|Procedure|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
334903|NCT01643005|Behavioral|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
334904|NCT01643005|Behavioral|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
334905|NCT01642979|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
334906|NCT01642979|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
334907|NCT01642979|Drug|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
334908|NCT01642966|Drug|Prasugrel|Prasugrel 10mg/day for 15 days
334909|NCT01642966|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
334910|NCT01642953|Dietary Supplement|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
334911|NCT01642940|Drug|Prasugrel|Prasugrel 10mg/day
334912|NCT01642940|Drug|Ticagrelor|Ticagrelor 90mg twice a day
334913|NCT01642914|Drug|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
334914|NCT01642914|Drug|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
334915|NCT01642914|Drug|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
334916|NCT01642901|Drug|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
334917|NCT01642901|Drug|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
334918|NCT01642888|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
334919|NCT01642888|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
334920|NCT01642875|Other|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
334921|NCT01642875|Other|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
334922|NCT01642862|Drug|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
334923|NCT01642849|Dietary Supplement|high protein diet|6 months on HP diet
334924|NCT01642849|Dietary Supplement|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
334925|NCT01642836|Behavioral|MMM|"a theory-based community team sports program designed specifically for overweight and obese children,~a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and~a primary care provider behavioral counseling intervention linked to the community and home interventions."
334926|NCT01642836|Behavioral|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:~notification of primary care providers about metabolic measures and blood pressure~state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
334927|NCT01642810|Behavioral|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
334928|NCT01642810|Other|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
334929|NCT01642797|Device|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
334930|NCT01642797|Device|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
334931|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
334932|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
334933|NCT01642771|Drug|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
334934|NCT01642771|Drug|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
334935|NCT01642758|Drug|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
334936|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
334937|NCT01642745|Drug|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
334938|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
334939|NCT01642732|Other|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.~Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).~Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.~Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.~Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
334940|NCT01642719|Behavioral|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
334941|NCT01642719|Behavioral|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
334942|NCT01642693|Radiation|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
334943|NCT01642693|Other|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
334944|NCT01642680|Other|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
334945|NCT01642680|Other|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
334946|NCT01642667|Drug|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
334947|NCT01642667|Drug|Placebo|
334948|NCT01642654|Other|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
334949|NCT01642654|Other|Educational lectures|Educational lectures
334950|NCT01642641|Procedure|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
334951|NCT01642641|Procedure|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
334952|NCT01642641|Procedure|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
334953|NCT01642628|Other|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
334954|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
334955|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
334956|NCT01642615|Drug|Placebo|Dexlansoprazole placebo-matching capsules
334957|NCT01642602|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
334958|NCT01642589|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
334959|NCT01642589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
334960|NCT01642576|Behavioral|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
334961|NCT01642563|Procedure|Platelet transfusion|One dose of pathogen reduced platelets
334962|NCT01642563|Procedure|Platelet transfusion|One dose of standard platelets
334963|NCT01642550|Drug|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
334964|NCT01642550|Drug|Placebo|
334965|NCT01642537|Device|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
334966|NCT01642524|Biological|hypertonic saline mixed Dextran|single dose administered intravenously
334967|NCT01642524|Biological|Saline solution|placebo - saline solution
334968|NCT01642511|Radiation|99mTc-labeled Sulfur Colloid|Control Group: Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5~1.0 mCi/0.5mL) in the tumor quadrant. Study Group: Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
334969|NCT01642511|Procedure|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
334970|NCT01642511|Drug|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
336065|NCT01634100|Drug|Probenecid|Probenecid
334971|NCT01642511|Device|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
334972|NCT01642511|Procedure|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
334973|NCT01642511|Procedure|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
334974|NCT01642498|Device|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
334975|NCT01642485|Drug|Moxifloxacin 400 mg fasted|"Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.~This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies."
334976|NCT01642485|Other|FDA breakfast|Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.
334977|NCT01642485|Other|Continental breakfast|High carbohydrate breakfast (>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.
334978|NCT01642485|Drug|Moxifloxacin 400 mg fed|Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
334979|NCT01642485|Procedure|Insulin Clamp|A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.
334980|NCT01642485|Drug|Placebo|Comparison of different meals effect on Moxifloxacin PK profile
334981|NCT01642472|Drug|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
334982|NCT01642459|Other|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
334983|NCT01642459|Other|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
334984|NCT01642446|Procedure|Precise hepatectomy|Precise hepatectomy
334985|NCT01642446|Other|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
334986|NCT01642433|Drug|Placebo|Placebo capsules, 3x daily
334987|NCT01642433|Drug|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
334988|NCT01642407|Drug|Sildenafil|Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
334989|NCT01642394|Behavioral|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.~Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
334990|NCT01642381|Behavioral|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
334991|NCT01642381|Behavioral|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
334992|NCT01642368|Other|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
334993|NCT01642355|Behavioral|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
334994|NCT01642355|Behavioral|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
334995|NCT01642342|Other|laboratory biomarker analysis|Correlative studies
334996|NCT01642342|Other|pharmacological study|Correlative studies
334997|NCT01642342|Biological|recombinant albumin fusion protein sEphB4-HSA|Given IV
334998|NCT01642316|Other|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
334999|NCT01642316|Other|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
335000|NCT01642303|Other|vodcasting|listening to downloaded vodcasting files
335001|NCT01642303|Other|no intervension|Listen to student book listening files
335002|NCT01642277|Drug|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
335003|NCT01642264|Behavioral|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
335004|NCT01642251|Drug|Cisplatin|Given IV
335005|NCT01642251|Drug|Etoposide|Given IV
335006|NCT01642251|Drug|Veliparib|Given PO
335007|NCT01642251|Drug|Placebo|placebo of Veliparib
335130|NCT01641354|Procedure|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
335008|NCT01642238|Drug|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
335009|NCT01642238|Drug|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
335010|NCT01642212|Drug|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
335011|NCT01642212|Drug|Placebo|
335012|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
335013|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
335014|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
335015|NCT01642186|Drug|everolimus|
335016|NCT01642186|Drug|letrozole plus leuprolide|
335017|NCT01642186|Drug|combination of everolimus, letrozole and leuprolide|
335018|NCT01642173|Device|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
335019|NCT01642160|Behavioral|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
335020|NCT01642160|Behavioral|Standard of care|participants will receive education from staff nurses as needed.
335021|NCT01642147|Device|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI－DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
335022|NCT01642147|Procedure|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
335023|NCT01642147|Procedure|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
335024|NCT01642147|Procedure|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
335025|NCT01642147|Procedure|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
335026|NCT01642134|Drug|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
335027|NCT01642121|Other|laboratory biomarker analysis|Correlative studies
335028|NCT01642108|Drug|Sitagliptin|50 mg once per day
335029|NCT01642095|Other|Laboratory Biomarker Analysis|Correlative studies
335030|NCT01642082|Biological|Dalantercept|Given SC
335031|NCT01642082|Other|Laboratory Biomarker Analysis|Correlative studies
335032|NCT01642069|Other|laboratory biomarker analysis|Correlative studies
335033|NCT01642056|Drug|EPI-743|This medication is used to treat disorders of energy metabolism such as mitochondrial diseases. It does not correct the inherited disorder of energy metabolism or mitochondrial diseases. EPI-743 is structurally related to Vitamin E and can be broadly classified as an antioxidant.
335034|NCT01642056|Drug|Placebo|
335035|NCT01642030|Drug|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
335036|NCT01642030|Drug|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
335037|NCT01642030|Drug|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
335131|NCT01641341|Drug|Bifidobacterium infantis|once a day for seven to eight weeks
335132|NCT01641341|Drug|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
335038|NCT01642017|Drug|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
335039|NCT01642004|Biological|Nivolumab|
335040|NCT01642004|Drug|Docetaxel|
335041|NCT01641991|Biological|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
335042|NCT01641991|Biological|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
335043|NCT01641965|Device|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 < 45 mmHg and improve symptoms.
335044|NCT01641952|Drug|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
335045|NCT01641939|Drug|Taxane|Standard taxane (docetaxel 75 mg/m^2 IV every 3 weeks or paclitaxel 80 mg/m^2) IV once a week according to investigator choice.
335046|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
335047|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
335048|NCT01641926|Biological|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
335049|NCT01641926|Biological|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
335050|NCT01641913|Other|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
335051|NCT01641900|Drug|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
335052|NCT01641900|Drug|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
335053|NCT01641887|Other|Decision Aid|Patients will use a decision aid administered on a computer.
335054|NCT01641874|Procedure|Exercise|Directional specific exercise
335055|NCT01641874|Procedure|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
335056|NCT01641861|Device|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
335057|NCT01641861|Procedure|Conventional method|caries removal by using rotary instrument.
335058|NCT01641848|Device|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
335059|NCT01641822|Drug|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
335060|NCT01641822|Drug|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
335061|NCT01641822|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
335062|NCT01641809|Drug|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
335063|NCT01641809|Drug|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
335064|NCT01641809|Drug|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
335065|NCT01641809|Drug|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
335066|NCT01641809|Drug|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
335067|NCT01641809|Drug|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
335068|NCT01641809|Drug|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
335069|NCT01641796|Drug|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
335070|NCT01641783|Drug|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
335071|NCT01641770|Other|Nutritional beverage 10003RF|2 sachets per day
335072|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
335073|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
335074|NCT01641757|Procedure|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
335075|NCT01641744|Behavioral|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
335076|NCT01641744|Behavioral|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
335133|NCT01641341|Drug|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
335134|NCT01641341|Drug|Placebo|Placebo capsule will not contain active treatment ingredients.
335077|NCT01641731|Other|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
335078|NCT01641718|Drug|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
335079|NCT01641718|Device|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
335080|NCT01641692|Drug|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
335081|NCT01641692|Procedure|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
335082|NCT01641692|Drug|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
335083|NCT01641666|Drug|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
335084|NCT01641666|Drug|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
335085|NCT01641666|Drug|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
335086|NCT01641653|Other|Normal saline|Normal saline 2cc. one dose prior to OR
335087|NCT01641653|Drug|Midazolam|1-2.5 mg
335088|NCT01641640|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
335089|NCT01641640|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
335090|NCT01641640|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
335091|NCT01641627|Procedure|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
335092|NCT01641614|Procedure|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
335093|NCT01641614|Procedure|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
335094|NCT01641601|Device|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
335095|NCT01641588|Behavioral|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
335096|NCT01641575|Drug|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
335097|NCT01641549|Procedure|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
335098|NCT01641549|Drug|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
335099|NCT01641536|Genetic|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
335100|NCT01641523|Device|CustomBone Service|customized hydroxyapatite cranial prosthesis
335101|NCT01641510|Drug|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
335102|NCT01641510|Drug|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
335103|NCT01641497|Radiation|3D conformational radiation|25 * 1.8 Gy in 5 weeks (=45 Gy)
335104|NCT01641497|Radiation|IMRT|25 * 1.8 Gy in 5 weeks (=45 Gy)
335105|NCT01641484|Procedure|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
335106|NCT01641471|Device|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
335107|NCT01641471|Device|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
335108|NCT01641458|Other|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G>A, c.1679T>G, HapB3/c.1129-5923C>G and c.2846A>T).
335135|NCT01641328|Behavioral|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
335109|NCT01641458|Other|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
335110|NCT01641445|Drug|Topiramate|Topiramate (200 mg daily)
335111|NCT01641445|Drug|Placebo|Non-active sugar pill
335112|NCT01641432|Behavioral|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).~Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
335113|NCT01641432|Behavioral|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
335114|NCT01641419|Drug|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
335115|NCT01641419|Drug|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
335116|NCT01641419|Drug|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
335117|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
335118|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
335119|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is >5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is <5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
335120|NCT01641393|Drug|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
335121|NCT01641393|Drug|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
335122|NCT01641380|Behavioral|Text Messaging Intervention|"Online enrollment in the Compliance for Life® (CFL) system through iReminder)~Welcome Message 24 hrs after enrollment~Appointment Reminder prior to 3 month injection cycles~Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder~6.Call for missed appointment or no reply to appointment reminder (or other text message)"
335123|NCT01641367|Drug|Darunavir|Participants were administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (taken with Ritonavir 100 mg twice a day [200 mg per day])
335124|NCT01641367|Drug|Etravirine|Patients were administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
335125|NCT01641367|Drug|Emtricitabine/tenofovir disoproxil fumarate|Patients were administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
335126|NCT01641367|Drug|Raltegravir|Participants were administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
335127|NCT01641367|Drug|Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r were the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC were the most frequent NRTI backbones. Cohort A did not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
335128|NCT01641367|Drug|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a participant received the same regimen that patients are getting in Cohorts B and C if that was the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there were no further drug options beyond the available study drugs).
335129|NCT01641367|Other|SOC adherence versus SOC+CPI adherence|"not participating in the adherence randomization; OR~randomized to SOC adherence; OR~randomized to SOC+CPI adherence."
336066|NCT01634100|Drug|Empagliflozin (BI 10773)|BI Drug
335136|NCT01641328|Behavioral|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
335137|NCT01641315|Biological|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.~Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.~Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
335138|NCT01641289|Drug|Paracetamol|>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate <50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
335139|NCT01641289|Drug|No Paracetamol|"No paracetamol + Intravenous Artesunate~If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
335140|NCT01641276|Device|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
335141|NCT01641263|Behavioral|Sleep Education|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
335142|NCT01641263|Behavioral|Cognitve Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
335143|NCT01641250|Drug|RO5429083|Multiple escalating doses
335144|NCT01641250|Drug|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
335145|NCT01641237|Drug|sodium fluoride|fluoride as sodium fluoride
335146|NCT01641237|Drug|no added fluoride in a silica base|no added fluoride
335147|NCT01641224|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
335148|NCT01641224|Device|Atractylodes|Atractylodes (~10-15g)
335149|NCT01641224|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
335150|NCT01641224|Device|Tangerine Peel|Tangerine Peel (~10g)
335151|NCT01641224|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
335152|NCT01641224|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
335153|NCT01641224|Drug|Radix curcumae|Radix curcumae (~10g)
335154|NCT01641224|Drug|Fingered citron|Fingered citron (~10g)
335155|NCT01641224|Drug|Tuckahoe|Tuckahoe (15g)
335156|NCT01641224|Drug|Placebo|Placebo is blindly given to patients.
335157|NCT01641211|Behavioral|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
335158|NCT01641211|Other|Nutrition video|Children in this group will watch a 2-minute nutrition video.
335159|NCT01641198|Device|Configuration 1|B placed at sites 2 and 5, SW placed at sites 1 and 4, SC placed at site 3
335160|NCT01641198|Device|Configuration 2|B placed at site 3, SW placed at sites 2 and 5, SC placed at sites 1 and 4
335161|NCT01641198|Device|Configuration 3|B placed at sites 1 and 4, SW placed at site 3, SC placed at sites 2 and 5
335162|NCT01641185|Procedure|radiation|radiation with protons or carbon ions
335163|NCT01641172|Procedure|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
335164|NCT01641172|Procedure|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
335165|NCT01641172|Procedure|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
335166|NCT01641172|Procedure|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
335167|NCT01641172|Dietary Supplement|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
335168|NCT01641172|Behavioral|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
335169|NCT01641172|Behavioral|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
335170|NCT01641159|Drug|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
335171|NCT01641159|Drug|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
335172|NCT01641146|Behavioral|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
335173|NCT01641146|Behavioral|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
335174|NCT01641133|Biological|Synflorix (3-Dose)|3 doses administered intramuscularly
335175|NCT01641133|Biological|Synflorix (2-Dose)|2 doses administered intramuscularly
335176|NCT01641133|Biological|Synflorix (Single Dose)|1 dose administered intramuscularly
335177|NCT01641133|Biological|Prevenar 13 (Single Dose)|1 dose administered intramuscularly
335178|NCT01641133|Biological|Prevenar 13 (2-Dose)|2 doses administered intramuscularly
335179|NCT01641120|Drug|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
335180|NCT01641107|Drug|Ponatinib|"Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
335181|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
335182|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
335183|NCT01641081|Drug|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
335184|NCT01641081|Drug|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
335185|NCT01641081|Drug|Placebo|Placebo in the Pressair for 14 days
335186|NCT01641068|Other|Cognitive Intervention|Participate in memory and thinking skills workshop
335187|NCT01641068|Other|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
335188|NCT01641068|Procedure|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
335189|NCT01641068|Other|Memory Intervention|Participate in memory and thinking skills workshop
335190|NCT01641068|Other|Quality-of-Life Assessment|Ancillary studies
335191|NCT01641068|Other|Questionnaire Administration|Ancillary studies
335192|NCT01641055|Dietary Supplement|Salmon protein hydrolysate|2.5g salmon protein hydrolysate per day for 8wk.
335193|NCT01641055|Dietary Supplement|Herring protein hydrolysate|2.5g herring protein hydrolysate per day for 8wk.
335194|NCT01641055|Dietary Supplement|Cod protein|2.5g cod protein per day for 8wk.
335195|NCT01641055|Dietary Supplement|Milk protein|2.5g milk protein per day for 8wk.
335196|NCT01641042|Biological|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
335197|NCT01641029|Other|No intervention|There is no intervention
335198|NCT01641016|Drug|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
335199|NCT01640990|Drug|Saline|30mins run-in period
335200|NCT01640990|Drug|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
335201|NCT01640990|Drug|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
335202|NCT01640977|Procedure|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
335203|NCT01640977|Procedure|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
335204|NCT01640964|Drug|Terlipressin acetate|IV bolus injection
335205|NCT01640964|Drug|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
335206|NCT01640951|Drug|AIN457 150 mg|(1 injection per dose) and placebo to Secukinumab 150 mg
335207|NCT01640951|Drug|AIN457 300 mg|Secukinumab 150 mg (2 injections per dose)
335208|NCT01640951|Drug|Placebo|
335209|NCT01640925|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
335210|NCT01640925|Other|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
335211|NCT01640912|Drug|RXI-109|Single intradermal injection of RXI-109 at incision sites
335212|NCT01640912|Drug|Placebo|Single intradermal injection of placebo at incision sites
335213|NCT01640899|Device|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
335214|NCT01640873|Drug|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
335215|NCT01640873|Drug|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
335216|NCT01640847|Drug|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
335217|NCT01640834|Drug|LY2409021|Administered orally
335218|NCT01640834|Drug|Placebo|Administered orally
335219|NCT01640834|Drug|Glucagon|Administered via intramuscular injection
335220|NCT01640821|Behavioral|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
335221|NCT01640808|Drug|NIK-333(peretinoin)|600mg (8 x 75mg tablets) orally, twice a day, continuously until recurrence of HCC, the patient's death, or termination or discontinuation of the entire study.
335222|NCT01640808|Drug|Placebo|600mg (8 x 75mg tablets) orally, twice a day, continuously until recurrence of HCC, the patient's death, or termination or discontinuation of the entire study.
335223|NCT01640782|Drug|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by~Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.~After 3 weeks from last infusion:~Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by~Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
335224|NCT01640782|Drug|Leucovorin, 5-Fluorouracil|"Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by~5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
335225|NCT01640769|Procedure|Image guided delivery of cardiac pacing leads.|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm).
335226|NCT01640769|Procedure|Standard delivery of cardiac pacing leads.|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
335227|NCT01640756|Device|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
335228|NCT01640743|Drug|Tacrolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
335229|NCT01640743|Drug|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
335230|NCT01640730|Drug|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
335231|NCT01640704|Behavioral|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
335232|NCT01640691|Biological|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine~Administration route: Intramuscular Injection~Dosing schedule: 2 injections - at Day 1 and Day 22 separately~Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
335233|NCT01640678|Procedure|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
335234|NCT01640678|Procedure|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
335235|NCT01640665|Drug|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
335236|NCT01640665|Drug|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
335237|NCT01640652|Biological|MenPF-1.|A new vaccine against meningococcal disease.
335238|NCT01640639|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
335239|NCT01640639|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
335312|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
335240|NCT01640626|Other|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
335241|NCT01640587|Drug|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
335242|NCT01640587|Drug|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
335243|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
335244|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
335245|NCT01640574|Drug|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
335246|NCT01640574|Drug|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
335247|NCT01640561|Behavioral|MISC|The Mediational Interventions for Sensitizing Caregivers
335248|NCT01640561|Behavioral|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by a non-governmental organization (NGO) operating in Uganda called Uganda Community Based Association for Child Welfare (UCOBAC) with support from UNICEF.
335249|NCT01640535|Drug|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
335250|NCT01640535|Drug|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
335251|NCT01640535|Drug|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
335252|NCT01640522|Other|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
335253|NCT01640522|Other|Enhanced usual Care|
335254|NCT01640509|Radiation|treated by synchrotron radiation|treated by synchrotron radiation
335255|NCT01640496|Drug|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
335256|NCT01640496|Other|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
335257|NCT01640483|Other|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
335258|NCT01640470|Device|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.~The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
335259|NCT01640470|Device|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
335260|NCT01640457|Drug|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
335261|NCT01640457|Device|NOVOCART® Disc basic|ADCT (Media with no active cell component)
335262|NCT01640444|Drug|FOLFIRI + bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
335263|NCT01640444|Drug|FOLFIRI + cetuximab|"Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly~FOLFIRI:~Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
335264|NCT01640431|Other|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
335265|NCT01640418|Device|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
335266|NCT01640405|Drug|modified FOLFOX6 + bevacizumab|"Bevacizumab 5 mg/kg iv, day 1, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by~5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 400 mg/m2 iv bolus, followed by~5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
335267|NCT01640405|Drug|FOLFOXIRI + Bevacizumab|"Bevacizumab 5 mg/kg iv, followed by~Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by~Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by~LV 400 mg/m2 iv administered over a period of 2 hours, followed by~5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
335268|NCT01640392|Behavioral|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
335392|NCT01639391|Procedure|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
335269|NCT01640379|Behavioral|Technology Enhanced Community Health Nursing|"Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)~Enhanced community health nursing visit on day 3-5, includes evidence-based STI/HIV prevention component (Sister to Sister Teen)"
335270|NCT01640366|Device|PICO|Single-use negative pressure wound therapy system
335271|NCT01640340|Drug|aprepitant|Given by mouth
335272|NCT01640340|Drug|palonosetron hydrochloride|Given IV(intervenous infusion)
335273|NCT01640340|Drug|ondansetron|Given PO
335274|NCT01640340|Drug|dexamethasone|Given PO
335275|NCT01640327|Biological|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
335276|NCT01640314|Biological|Cell derived subunit trivalent nonadjuvanted vaccine|A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
335277|NCT01640301|Biological|Aldesleukin|Given SC
335278|NCT01640301|Drug|Cyclophosphamide|Given IV
335279|NCT01640301|Drug|Fludarabine Phosphate|Given IV
335280|NCT01640301|Other|Laboratory Biomarker Analysis|Correlative studies
335281|NCT01640301|Biological|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
335282|NCT01640288|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
335283|NCT01640288|Other|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
335284|NCT01640275|Drug|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
335285|NCT01640275|Drug|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
335286|NCT01640262|Other|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
335287|NCT01640249|Drug|Placebo|Capsules administered orally
335288|NCT01640249|Drug|LY3006072|Capsules administered orally
335289|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
335290|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
335291|NCT01640210|Device|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.~Visit of inclusion:~This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.~Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.~Volume infused will be evaluated during a period of basal and bolus with a precision scale.~Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:~Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.~Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
335292|NCT01640197|Dietary Supplement|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
335293|NCT01640197|Other|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
335294|NCT01640184|Procedure|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
335295|NCT01640184|Drug|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
335296|NCT01640184|Procedure|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
335297|NCT01640171|Procedure|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
335298|NCT01640171|Drug|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
335299|NCT01640171|Drug|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
335300|NCT01640171|Drug|Acuvail|Anti-inflammatory drop given after treatment
335301|NCT01640171|Drug|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
335302|NCT01640158|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
335303|NCT01640158|Other|Commercially available computerized training|Commercially available computerized training, up to 65 hours
335304|NCT01640145|Dietary Supplement|Protein|Whey protein intake
335305|NCT01640145|Other|Exercise|Unilateral low intensity exercise
335306|NCT01640119|Dietary Supplement|Bicarbonate|bicarbonate administration
335307|NCT01640106|Dietary Supplement|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
335308|NCT01640106|Dietary Supplement|Placebo|Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
335309|NCT01640093|Drug|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
335310|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
335311|NCT01640093|Drug|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
335393|NCT01639378|Procedure|Renal Denervation|Symplicity Catheter System
335313|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
335314|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
335315|NCT01640080|Drug|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
335316|NCT01640067|Biological|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
335317|NCT01640054|Drug|Fostamatinib|Fostamatinib 100mg once daily
335318|NCT01640041|Device|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
335319|NCT01640015|Other|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
335320|NCT01640002|Drug|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
335321|NCT01640002|Drug|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
335322|NCT01639911|Drug|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
335323|NCT01639911|Drug|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
335324|NCT01639898|Drug|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
335325|NCT01639898|Drug|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
335326|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
335327|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
335328|NCT01639885|Biological|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
335329|NCT01639872|Drug|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
335330|NCT01639872|Drug|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
335331|NCT01639859|Other|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
335332|NCT01639846|Drug|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
335333|NCT01639846|Drug|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
335334|NCT01639833|Device|Veriset Hemostatic Patch|Topical hemostat
335335|NCT01639833|Device|TachoSil®|Topical Hemostat
335336|NCT01639820|Procedure|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
335337|NCT01639820|Procedure|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
335338|NCT01639807|Drug|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
335339|NCT01639807|Procedure|SLT|Selective Laser Trabeculoplasty
335340|NCT01639794|Drug|Vesitirim™ (Solifenacin)|Oral
335341|NCT01639781|Dietary Supplement|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
335342|NCT01639781|Dietary Supplement|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
335343|NCT01639768|Drug|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
335344|NCT01639755|Device|new texture shaped breast implants|breast implant surgery
335345|NCT01639742|Device|New texture round breast implants|Breast implant surgery
335346|NCT01639729|Drug|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
335347|NCT01639729|Drug|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
335348|NCT01639729|Drug|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
335349|NCT01639729|Drug|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
335350|NCT01639703|Drug|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
335351|NCT01639690|Genetic|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10^6 untransduced CD34+ cells per kg will be preserved for every patient.
335352|NCT01639677|Procedure|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
335353|NCT01639677|Procedure|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
335354|NCT01639664|Device|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
335394|NCT01639352|Biological|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
335395|NCT01639339|Biological|Placebo plus standard therapy|Placebo plus standard therapy
335355|NCT01639651|Other|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
335356|NCT01639651|Other|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
335357|NCT01639638|Drug|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
335358|NCT01639625|Drug|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
335359|NCT01639612|Biological|ALD-451|ALD-451 iv
335360|NCT01639599|Drug|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
335361|NCT01639599|Drug|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
335362|NCT01639599|Drug|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
335363|NCT01639586|Behavioral|respite platform|Impact of the respite platform patient care on health profit
335364|NCT01639586|Behavioral|Day care|Impact of the day care on health profit of patient
335365|NCT01639586|Behavioral|No access to a respite structure|Control group without access to a respite structure
335366|NCT01639573|Drug|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
335367|NCT01639560|Drug|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
335368|NCT01639560|Drug|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
335369|NCT01639547|Drug|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
335370|NCT01639521|Drug|cisplatin|Given IV
335371|NCT01639521|Drug|gemcitabine hydrochloride|Given IV
335372|NCT01639521|Drug|methotrexate|Given IV
335373|NCT01639521|Drug|vinblastine|Given IV
335374|NCT01639521|Drug|doxorubicin hydrochloride|Given IV
335375|NCT01639521|Biological|pegfilgrastim|Given SC
335376|NCT01639521|Other|laboratory biomarker analysis|Correlative studies
335377|NCT01639508|Drug|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
335378|NCT01639495|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
335379|NCT01639469|Behavioral|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
335380|NCT01639469|Behavioral|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
335381|NCT01639456|Biological|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
335382|NCT01639456|Biological|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
335383|NCT01639456|Device|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
335384|NCT01639456|Device|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
335385|NCT01639456|Drug|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
335386|NCT01639456|Drug|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
335387|NCT01639456|Drug|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
335388|NCT01639443|Other|Predictive no-show overbooking|"During intervention period, every Veteran scheduled for an endoscopy will be offered fast-track offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot."
335389|NCT01639430|Other|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.~Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
335390|NCT01639404|Procedure|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
335391|NCT01639404|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
335396|NCT01639339|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
335397|NCT01639339|Drug|Standard therapy|"The standard therapies allowed in this study are:~- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy~OR~- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
335398|NCT01639326|Drug|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
335399|NCT01639326|Drug|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
335400|NCT01639300|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
335401|NCT01639300|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
335402|NCT01639274|Other|COPD prevalence|Determine prevalence of COPD
335403|NCT01639261|Drug|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever >38,5 dose increase: 50µg/m² BSA three times/week
335404|NCT01639248|Drug|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
335405|NCT01639222|Drug|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
335406|NCT01639222|Other|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
335407|NCT01639209|Procedure|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
335408|NCT01639209|Procedure|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
335409|NCT01639196|Other|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
335410|NCT01639196|Other|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
335411|NCT01639183|Device|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
335412|NCT01639183|Other|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
335413|NCT01639170|Radiation|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.~All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.~The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
335414|NCT01639157|Drug|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
335415|NCT01639157|Drug|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
335416|NCT01639144|Biological|PRP and PPP|Autogenous PRP and PPP
335417|NCT01639131|Drug|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
335418|NCT01639131|Drug|Docetaxel|docetaxel 70mg/m2 on day 8 of each 21 day cycle
335419|NCT01639131|Drug|Filgrastim or Pegfilgrastim|filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle
335420|NCT01639105|Procedure|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
335421|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
335422|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
335423|NCT01639092|Drug|Entecavir|Entecavir 1 mg daily Oral
335424|NCT01639079|Behavioral|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
335425|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
335426|NCT01639066|Drug|Entecavir|Entecavir 1 mg daily Oral
335427|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
335428|NCT01639040|Drug|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
335429|NCT01639040|Drug|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
335430|NCT01639040|Other|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
335431|NCT01639027|Drug|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
335432|NCT01639027|Drug|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
335433|NCT01639014|Drug|F2695|75 mg OD in 2 capsules
335434|NCT01639014|Drug|placebo|2 capsules
335435|NCT01639001|Drug|Crizotinib|250 mg two times daily [BID], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
335436|NCT01639001|Drug|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
335559|NCT01638104|Drug|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
335560|NCT01638091|Behavioral|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
335750|NCT01636622|Drug|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
335437|NCT01639001|Drug|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
335438|NCT01638988|Drug|Metformin|"cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day~to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
335439|NCT01638988|Drug|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
335440|NCT01638975|Behavioral|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
335441|NCT01638962|Drug|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
335442|NCT01638962|Other|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
335443|NCT01638949|Behavioral|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
335444|NCT01638949|Biological|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
335445|NCT01638949|Genetic|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
335446|NCT01638949|Other|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
335447|NCT01638936|Drug|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
335448|NCT01638923|Drug|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
335449|NCT01638923|Drug|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
335450|NCT01638910|Drug|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
335451|NCT01638884|Behavioral|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
335452|NCT01638884|Other|Structural MRI|to compare differences between each populations
335453|NCT01638884|Other|Functional MRI|to compare differences between each populations
335454|NCT01638884|Other|Virtual reality / Memory assessment|to compare differences between each populations
335455|NCT01638871|Behavioral|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
335456|NCT01638858|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
335457|NCT01638845|Procedure|continuous perineural catheter|continuous perineural catheter
335458|NCT01638832|Device|Transient Elastography (FibroScan), Echosens, Paris, France|
335459|NCT01638832|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
335460|NCT01638819|Biological|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
335461|NCT01638819|Biological|Placebo|Saline
335462|NCT01638806|Procedure|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
335463|NCT01638793|Device|Microcap (Oridion, Needham, MA, USA)|
335464|NCT01638793|Device|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
335465|NCT01638780|Dietary Supplement|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
335466|NCT01638780|Dietary Supplement|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
335467|NCT01638767|Drug|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
335468|NCT01638767|Drug|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
335469|NCT01638754|Procedure|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
335470|NCT01638754|Procedure|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
335471|NCT01638741|Behavioral|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
335472|NCT01638715|Drug|Remicade|- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
336067|NCT01634087|Drug|Itacitinib|Itacitinib administered orally
335473|NCT01638715|Drug|Orencia|- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
335474|NCT01638715|Drug|Ro-Actemra|- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
335475|NCT01638715|Drug|Mabthera|"- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.~Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
335476|NCT01638702|Other|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
335477|NCT01638689|Drug|Escitalopram|20 mg p.o.
335478|NCT01638676|Drug|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
335479|NCT01638676|Drug|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
335480|NCT01638663|Drug|Tolvaptan|15 mg pr day for 1 day
335481|NCT01638663|Drug|Placebo|1 tablet Unikalk 1 pr day for 1 day
335482|NCT01638650|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
335483|NCT01638650|Drug|ritonavir|100 mg bid orally, Days 1-14
335484|NCT01638650|Drug|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
335485|NCT01638637|Device|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
335486|NCT01638624|Drug|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
335487|NCT01638624|Drug|Placebo|
335488|NCT01638611|Drug|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
335489|NCT01638611|Drug|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
335490|NCT01638598|Drug|matching placebo|matching placebo in each dose level
335491|NCT01638598|Drug|Test drug|BI 1021958
335492|NCT01638598|Drug|matching placebo|matching placebo in each dose level
335493|NCT01638598|Drug|Test drug|BI 1021958
335494|NCT01638598|Drug|Test drug|BI 1021958
335495|NCT01638598|Drug|Test drug|BI 1021958
335496|NCT01638598|Drug|Test drug|BI 1021958
335497|NCT01638598|Drug|matching placebo|matching placebo in each dose level
335498|NCT01638598|Drug|matching placebo|matching placebo in each dose level
335499|NCT01638598|Drug|matching placebo|matching placebo in each dose level
335500|NCT01638585|Drug|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
335501|NCT01638559|Drug|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
335502|NCT01638546|Other|Laboratory Biomarker Analysis|Correlative studies
335503|NCT01638546|Other|Placebo|Given PO
335504|NCT01638546|Drug|Temozolomide|Given PO
335505|NCT01638546|Drug|Veliparib|Given PO
335506|NCT01638533|Other|Pharmacological Study|Correlative studies
335507|NCT01638533|Drug|Romidepsin|Given IV
335508|NCT01638520|Drug|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
335509|NCT01638520|Drug|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
335510|NCT01638507|Device|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
335511|NCT01638494|Dietary Supplement|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
335512|NCT01638468|Device|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
335513|NCT01638455|Device|Noninvasive device|Noninvasive device
335514|NCT01638442|Drug|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
335515|NCT01638442|Drug|CHR-2797|"Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.~--------------------------------------------------------------------------------"
335516|NCT01638429|Drug|Neomycin|Neomycin: 500mg po bid for 10 days
335517|NCT01638429|Drug|Rifaximin|Rifaximin: 550mg po tid for 10 days
335518|NCT01638416|Other|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
335519|NCT01638403|Drug|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).~Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
335520|NCT01638403|Drug|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
335521|NCT01638403|Drug|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.~placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
335522|NCT01638390|Device|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
335523|NCT01638377|Drug|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
335524|NCT01638377|Drug|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
335525|NCT01638364|Drug|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
335526|NCT01638364|Drug|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
335527|NCT01638351|Behavioral|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
335528|NCT01638351|Behavioral|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
335529|NCT01638338|Behavioral|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
335530|NCT01638338|Behavioral|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
335531|NCT01638325|Drug|Insulin Lispro|Administered SC
335532|NCT01638325|Drug|BC106 insulin lispro|Administered SC
335533|NCT01638299|Device|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
335534|NCT01638273|Drug|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
335535|NCT01638273|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
335536|NCT01638260|Drug|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
335537|NCT01638260|Behavioral|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
335538|NCT01638247|Drug|Tamoxifen|25 mg daily.
335539|NCT01638247|Drug|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:~Goserelin (10.8 mg s.c. after randomisation and after three months) or~Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
335540|NCT01638247|Drug|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:~Goserelin (10.8 mg s.c. after randomisation and after three months) or~Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
335541|NCT01638234|Dietary Supplement|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
335542|NCT01638234|Dietary Supplement|Placebo|starch pill
335543|NCT01638208|Drug|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
335544|NCT01638195|Device|Focused Ultrasound|Focused Ultrasound
335545|NCT01638182|Dietary Supplement|Placebo|27 participants received for three months 1 placebo capsule per day
335546|NCT01638182|Dietary Supplement|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
335547|NCT01638182|Dietary Supplement|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
335548|NCT01638169|Device|adding a heel|walking with and without heels on the gaitrite system
335549|NCT01638143|Dietary Supplement|MenaQ7 M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
335550|NCT01638143|Dietary Supplement|Gnosis P-1000 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
335551|NCT01638143|Dietary Supplement|Gnosis M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):~MenaQ7 M-1500 capsule~Gnosis P-1000 capsule~Gnosis M-1500 capsule~Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
335552|NCT01638117|Other|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
335553|NCT01638117|Drug|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
335554|NCT01638117|Drug|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
335555|NCT01638117|Drug|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
335556|NCT01638117|Other|Saline|Saline, Daily for up to 21 days
335557|NCT01638117|Other|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
335558|NCT01638104|Drug|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
336068|NCT01634087|Drug|Placebo|Placebo administered orally
335561|NCT01638091|Behavioral|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
335562|NCT01638078|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
335563|NCT01638078|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
335564|NCT01638052|Drug|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
335565|NCT01638039|Other|Laboratory Tests|Stool, blood, urine and saliva samples
335566|NCT01638026|Drug|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
335567|NCT01638013|Drug|peficitinib|oral
335568|NCT01638000|Drug|Mirabegron|oral tablet
335569|NCT01638000|Drug|Solifenacin succinate|oral tablet
335570|NCT01637987|Procedure|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
335571|NCT01637987|Procedure|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
335572|NCT01637987|Procedure|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein & surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
335573|NCT01637974|Drug|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
335574|NCT01637961|Drug|Alisertib|Given PO
335575|NCT01637961|Other|Laboratory Biomarker Analysis|Correlative studies
335576|NCT01637948|Drug|Listerine mouthrinse|For six months
335577|NCT01637948|Drug|Chinese Medicine mouthrinse|six months
335578|NCT01637935|Drug|Pioglitazone|Pioglitazone tablets.
335579|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
335580|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
335581|NCT01637909|Drug|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
335582|NCT01637909|Dietary Supplement|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
335583|NCT01637909|Other|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
335584|NCT01637896|Device|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
335585|NCT01637896|Device|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
335586|NCT01637883|Drug|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
335587|NCT01637870|Device|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
335588|NCT01637857|Dietary Supplement|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
335589|NCT01637857|Dietary Supplement|oligoantigenic diet|oligoantigenic diet associated to life style counseling
335630|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
335662|NCT01637233|Drug|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
335590|NCT01637844|Drug|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
335591|NCT01637831|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
335592|NCT01637818|Procedure|Lichtenstein's operation|
335593|NCT01637818|Procedure|Mesh Plug Repair|
335594|NCT01637818|Drug|Opiate|Postoperative pain therapy
335595|NCT01637818|Drug|Paracetamol|Postoperative pain therapy
335596|NCT01637818|Drug|non-steroidal anti-inflammatory drug|Postoperative pain therapy
335597|NCT01637805|Biological|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
335598|NCT01637792|Other|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
335599|NCT01637792|Other|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
335600|NCT01637779|Behavioral|Fact sheet|fact sheet about pain management during immunization
335601|NCT01637766|Drug|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
335602|NCT01637753|Drug|Carmustine(BCNU)|Carmustine Sustained Release Implant
335603|NCT01637753|Procedure|Surgery|Routine tumor resection surgery
335604|NCT01637714|Drug|Multi-strain probiotics|"B. longum BORI: 1 x 109~B. bifidum BGN4: 1 x 109~B. lactis AD011: 1 x 109~B. infantis IBS007: 1 x 109~Lactobacillus acidophilus AD031: 1 x 109~three times a day, within 10 minutes after meal, per oral with water"
335605|NCT01637714|Drug|Placebo powder|"same taste, shape, dosage as experimental drug~three times a day, within 10 minutes after meal, per oral with water"
335606|NCT01637701|Procedure|PkEP|Plasmakinetic enucleation of the prostate
335607|NCT01637701|Procedure|B-TURP|Bipolar transurethral resection of the prostate
335608|NCT01637688|Dietary Supplement|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula (NAAF) and a commercial amino acid formula (AAF)
335609|NCT01637675|Drug|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
335610|NCT01637675|Drug|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
335611|NCT01637662|Drug|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
335612|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 12
335613|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 6
335614|NCT01637636|Drug|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
335615|NCT01637636|Drug|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
335616|NCT01637623|Drug|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
335617|NCT01637623|Drug|Allopurinol|Allopurinol 300 mg daily for 6 weeks
335618|NCT01637623|Drug|Placebo|Placebo capsule daily for 6 weeks
335619|NCT01637584|Drug|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
335620|NCT01637584|Drug|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
335621|NCT01637571|Drug|Dexilant|60mg of Dexilant QD for 12 weeks
335622|NCT01637571|Drug|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
335623|NCT01637558|Drug|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
335624|NCT01637558|Drug|Nevirapine|
335625|NCT01637558|Drug|Lopinavir/Ritonavir|
335626|NCT01637545|Drug|Ramosetron|"G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room~G3 - No medication but regular antiemetics injection if the patient want"
335627|NCT01637532|Drug|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.~Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
335628|NCT01637532|Drug|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
335629|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
335661|NCT01637233|Drug|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
338984|NCT01610388|Drug|1000mg IV GSK1322322J/placebo|1000mg IV
335631|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
335632|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
335633|NCT01637480|Other|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
335634|NCT01637467|Other|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
335635|NCT01637467|Other|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
335636|NCT01637454|Drug|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
335637|NCT01637454|Drug|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
335638|NCT01637441|Procedure|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
335639|NCT01637441|Procedure|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
335640|NCT01637428|Device|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
335641|NCT01637402|Drug|Abiraterone Acetate|"Standard dose: 1,000 mg, once daily, oral administration~Increased dose: 1,000 mg, twice daily, oral administration"
335642|NCT01637402|Drug|Prednisone|5 mg, twice daily, oral administration
335643|NCT01637389|Other|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
335644|NCT01637389|Other|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
335645|NCT01637376|Drug|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
335646|NCT01637363|Behavioral|Psychoeducation|6 x 2 hours of psychoeducation
335647|NCT01637350|Procedure|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
335648|NCT01637337|Procedure|laparoscopic pyelolithotomy|laparoscopy
335649|NCT01637337|Procedure|percutaneous nephrolithotomy|percutaneous nephrolithotomy
335650|NCT01637311|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
335651|NCT01637285|Biological|PF-04856883|Dose A
335652|NCT01637285|Biological|PF-04856883|Dose B
335653|NCT01637285|Biological|PF-04856883|Dose C
335654|NCT01637285|Biological|PF-04856883|Dose D
335655|NCT01637272|Drug|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 & 60 mg of pasireotide (as free base) & solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
335656|NCT01637259|Drug|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
335657|NCT01637259|Drug|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
335658|NCT01637259|Drug|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
335659|NCT01637246|Drug|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
335660|NCT01637233|Drug|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
335663|NCT01637220|Biological|Blood volume collected specifically for this study|"case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.~Control patients: 20 ml following neuromuscular blocking drug injection"
335664|NCT01637207|Other|Palpation|Group A: Palpation Group
335665|NCT01637207|Other|Ultrasound|Group B: Ultrasound Group
335666|NCT01637194|Drug|everolimus|Given PO
335667|NCT01637194|Biological|cetuximab|Given IV
335668|NCT01637194|Other|pharmacological study|Correlative studies
335669|NCT01637194|Other|laboratory biomarker analysis|Correlative studies
335670|NCT01637181|Procedure|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
335671|NCT01637168|Drug|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
335672|NCT01637168|Drug|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
335673|NCT01637155|Drug|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
335674|NCT01637142|Drug|LY2140023|Administered orally.
335675|NCT01637142|Drug|14C-LY2140023|Administered IV.
335676|NCT01637142|Drug|14C-LY404039|Administered IV.
335677|NCT01637129|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
335678|NCT01637129|Device|Sham Magnetic Stimulation|Sham Magnetic Stimulation
335679|NCT01637103|Behavioral|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
335680|NCT01637103|Behavioral|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
335681|NCT01637090|Drug|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
335682|NCT01637077|Drug|pregabalin|Given PO
335683|NCT01637077|Drug|placebo|Given PO
335684|NCT01637077|Other|questionnaire administration|Ancillary studies
335685|NCT01637064|Drug|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
335686|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
335687|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
335688|NCT01637038|Other|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
335689|NCT01637025|Device|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
335690|NCT01637025|Device|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
335691|NCT01637012|Procedure|Implantation|index angioplasty with ALEX stent implatation
335692|NCT01636999|Drug|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
335693|NCT01636986|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
335694|NCT01636986|Device|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
335695|NCT01636973|Procedure|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
335696|NCT01636960|Biological|PegIFN alfa-2b|
335697|NCT01636947|Drug|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
335698|NCT01636947|Drug|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
335699|NCT01636947|Drug|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
335700|NCT01636947|Drug|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
335701|NCT01636947|Drug|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
335702|NCT01636947|Drug|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
335703|NCT01636934|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
335704|NCT01636934|Other|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
335705|NCT01636934|Behavioral|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
335706|NCT01636908|Drug|Sunitinib|50 mg once daily, oral use, 14 days
335707|NCT01636908|Drug|Sorafenib|400 mg, twice daily, oral use, 14 days
335708|NCT01636908|Drug|Erlotinib|150 mg once daily, oral use, 14 days
335709|NCT01636908|Drug|Everolimus|10 mg once daily, oral use, 14 days
335710|NCT01636908|Drug|Lapatinib|1250 mg once daily, oral use, 14 days
335711|NCT01636908|Drug|Dasatinib|100 mg once daily, oral use, 14 days
335712|NCT01636908|Drug|Pazopanib|800 mg once daily, oral use, 14 days
335713|NCT01636908|Drug|Vemurafenib|960 mg twice daily, oral use, 15-21 days
335714|NCT01636908|Procedure|tumor biopsy|
335715|NCT01636908|Procedure|skin biopsy (optional)|
335716|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
335717|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
335718|NCT01636882|Biological|CVA21|
335719|NCT01636869|Drug|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.~Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
335720|NCT01636856|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
335721|NCT01636856|Behavioral|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
335722|NCT01636843|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
335723|NCT01636843|Drug|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
335724|NCT01636830|Device|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
335725|NCT01636817|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
335726|NCT01636817|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
335727|NCT01636804|Device|Quicksite|St. Jude Medical produced lead called Quicksite
335728|NCT01636804|Device|Quickflex|St. Jude Medical produced lead called Quickflex
335729|NCT01636791|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
335730|NCT01636791|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
335731|NCT01636778|Drug|SB-497115-GR|TPO receptor agonist to increase platelet count
335732|NCT01636765|Drug|No Intervention|No intervention.
335733|NCT01636752|Behavioral|Deprexis|Online self-help with and without e-mail-support
335734|NCT01636739|Biological|Oral Rotarix®|2 doses administered orally.
335735|NCT01636739|Other|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
335736|NCT01636726|Drug|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
335737|NCT01636713|Drug|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
335738|NCT01636713|Drug|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
335739|NCT01636713|Drug|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
335740|NCT01636700|Drug|Tramadol 2mg/kg|2mg/kg
335741|NCT01636700|Drug|Saline solution|saline solution- 1 dose
335742|NCT01636687|Drug|Placebo|2 injections of placebo to secukinumab 150mg per dose
335743|NCT01636687|Drug|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose were administered
335744|NCT01636687|Drug|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
335745|NCT01636674|Other|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
335746|NCT01636661|Device|tDCS|transcranial direct current stimulation- non-invasive brain stimulation
335747|NCT01636648|Device|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
335748|NCT01636635|Other|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
335749|NCT01636622|Drug|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
335751|NCT01636622|Drug|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
335752|NCT01636609|Drug|Azacitidine|Given IV or SC
335753|NCT01636609|Drug|Cytarabine|Given SC
335754|NCT01636609|Drug|Tosedostat|Given PO
335755|NCT01636596|Drug|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
335756|NCT01636583|Device|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
335757|NCT01636583|Device|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
335758|NCT01636583|Other|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
335759|NCT01636570|Drug|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
335760|NCT01636570|Drug|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
335761|NCT01636557|Drug|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
335762|NCT01636557|Drug|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
335763|NCT01636557|Drug|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
335764|NCT01636557|Drug|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
335765|NCT01636557|Drug|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
335766|NCT01636557|Drug|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
335767|NCT01636544|Procedure|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
335768|NCT01636531|Drug|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
335769|NCT01636531|Drug|gantenerumab|Lyophilized formulation (LyoF), single dose sc
335770|NCT01636518|Procedure|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
335771|NCT01636505|Drug|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
335772|NCT01636505|Drug|gnrh agonist (suprefact)|suprefact 5.5 ml
335773|NCT01636492|Drug|bitopertin|Single oral dose
335774|NCT01636492|Drug|placebo|Single oral dose
335775|NCT01636479|Drug|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
335776|NCT01636466|Drug|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
335777|NCT01636453|Device|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
335778|NCT01636440|Device|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
335779|NCT01636440|Device|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
335780|NCT01636414|Procedure|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
335781|NCT01636414|Procedure|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
335782|NCT01636414|Procedure|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
335783|NCT01636401|Drug|aclidinium bromide 400 μg|
335784|NCT01636401|Drug|aclidinium bromide placebo|
335785|NCT01636388|Biological|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
335786|NCT01636362|Device|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
335787|NCT01636349|Other|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
335788|NCT01636336|Other|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
335789|NCT01636336|Other|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
335790|NCT01636323|Other|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
335843|NCT01635920|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
335791|NCT01636310|Other|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
335792|NCT01636297|Behavioral|Forced exercise|Exercise on a stationary cycle that was controlled by a motor, to augment voluntary cycling rate by 35%. Intervention was administered 3 times per week for 8 weeks
335793|NCT01636297|Behavioral|Voluntary exercise|Exercise on a stationary cycle without motor assistance. Intervention was administered 3 times per week for 8 weeks
335794|NCT01636284|Biological|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
335795|NCT01636271|Drug|darapladib|darapladib enteric coated tablets 160 mg
335796|NCT01636271|Drug|placebo|placebo
335797|NCT01636258|Behavioral|Stress Management|Every other week
335798|NCT01636258|Behavioral|Diet|Every other week
335799|NCT01636258|Behavioral|Exercise|Every week
335800|NCT01636258|Behavioral|Culinary education|Every other week
335801|NCT01636245|Biological|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
335802|NCT01636245|Biological|placebo|placebo, two doses, 28 days interval
335803|NCT01636206|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: ~1 year
335804|NCT01636206|Drug|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: ~1 year
335805|NCT01636193|Biological|Oral Rotarix®|2 doses administered orally.
335806|NCT01636193|Other|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
335807|NCT01636180|Drug|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
335808|NCT01636180|Drug|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
335809|NCT01636167|Device|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
335810|NCT01636154|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
335811|NCT01636154|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
335812|NCT01636154|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
335813|NCT01636141|Drug|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
335814|NCT01636141|Drug|Placebo gel|
335815|NCT01636128|Drug|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
335816|NCT01636128|Drug|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
335817|NCT01636102|Biological|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
335818|NCT01636089|Drug|bicarbonates|sodium bicarbonates 1,4%
335819|NCT01636089|Drug|saline|sodium chloride 0,9%
335820|NCT01636076|Drug|QMF149|delivered via Concept1 device
335821|NCT01636076|Drug|Salmeterol|delivered via Accuhaler®
335822|NCT01636063|Drug|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
335823|NCT01636063|Drug|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
335824|NCT01636050|Other|squat exercise training|Intervention may include squat exercise for 8 weeks
335825|NCT01636037|Drug|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
335826|NCT01636024|Drug|AZD7594|Suspension inhaled via Spira nebuliser
335827|NCT01636024|Drug|Placebo to match|Matching placebo inhaled via Spira nebuliser
335828|NCT01636011|Other|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
335829|NCT01636011|Other|Light Touch sham|Light Touch sham
335830|NCT01635998|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
335831|NCT01635985|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
335832|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
335833|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
335834|NCT01635985|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
335835|NCT01635985|Drug|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
335836|NCT01635985|Drug|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
335837|NCT01635972|Drug|Isavuconazole|oral
335838|NCT01635972|Drug|bupropion hydrochloride|oral
335839|NCT01635946|Drug|Isavuconazole|oral
335840|NCT01635946|Drug|atorvastatin|oral
335841|NCT01635933|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
335842|NCT01635933|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
335844|NCT01635920|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
335845|NCT01635907|Drug|Dovitinib|
335846|NCT01635894|Behavioral|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
335847|NCT01635881|Device|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.~The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
335848|NCT01635855|Device|Belotero®|Hyaluronic acid dermal filler
335849|NCT01635829|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
335850|NCT01635829|Drug|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
335851|NCT01635829|Drug|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
335852|NCT01635816|Biological|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
335853|NCT01635816|Biological|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
335854|NCT01635816|Biological|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
335855|NCT01635816|Biological|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
335856|NCT01635803|Drug|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
335857|NCT01635803|Drug|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
335858|NCT01635790|Drug|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
335859|NCT01635790|Drug|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
335860|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 12 weeks
335861|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 8 weeks
335862|NCT01635764|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
335863|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
335864|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
335865|NCT01635751|Drug|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
335866|NCT01635738|Biological|LP GMNL-133 capsule|One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
335867|NCT01635738|Biological|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
335868|NCT01635738|Biological|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
335869|NCT01635738|Biological|Placebo|Placebo
335870|NCT01635712|Drug|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
335871|NCT01635686|Drug|DWP422 25mg|
335872|NCT01635686|Drug|ENBREL 25MG PFS INJ.|
335873|NCT01635673|Other|Exercise intervention|Whole body vibration exercise 3 times per week
335874|NCT01635660|Device|Intubation|Tracheal Intubation with the assigned video laryngoscope
335875|NCT01635647|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 1 x 10^8 pfu heterologous prime-boost immunisation
335876|NCT01635647|Biological|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
335877|NCT01635634|Other|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
335878|NCT01635621|Drug|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:~OKZ 120 mg every 2 weeks~OKZ 240 mg every 2 weeks~OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0~1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
335879|NCT01635621|Drug|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
335880|NCT01635608|Drug|Acetaminophen|administration of 500 mg paracetamol
335881|NCT01635608|Drug|Talinolol|administration of 50 mg talinolol
335882|NCT01635608|Drug|Amoxicillin|administration of 500 mg amoxicillin
335883|NCT01635608|Other|non-caloric water|administration of 240 ml water
335884|NCT01635608|Other|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
335885|NCT01635595|Procedure|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
335886|NCT01635595|Procedure|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
335887|NCT01635582|Other|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
335888|NCT01635582|Other|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
335889|NCT01635569|Behavioral|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
335890|NCT01635569|Other|Waitlist|Baseline and post-12 sessions
335891|NCT01635556|Behavioral|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
335892|NCT01635530|Drug|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
335893|NCT01635530|Drug|Ceftriaxone|2 g intravenous once a day, three weeks
335894|NCT01635504|Biological|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
335895|NCT01635439|Drug|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
335896|NCT01635439|Drug|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
335897|NCT01635426|Drug|Aspirin|Aspirin 75 mg daily for 2 months after meals
335898|NCT01635426|Drug|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
335899|NCT01635413|Behavioral|Exercise Intervention|Undergo strength training classes
335900|NCT01635413|Behavioral|Exercise Intervention|Undergo tai chi classes
335901|NCT01635413|Behavioral|Exercise Intervention|Undergo stretching and relaxation classes
335902|NCT01635413|Other|Laboratory Biomarker Analysis|Correlative studies
335903|NCT01635413|Other|Questionnaire Administration|Ancillary studies
335904|NCT01635413|Other|Survey Administration|Ancillary studies
335905|NCT01635400|Drug|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
335906|NCT01635387|Drug|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
335907|NCT01635374|Procedure|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
335908|NCT01635361|Other|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
335909|NCT01635348|Behavioral|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
335910|NCT01635348|Behavioral|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
335911|NCT01635335|Behavioral|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
335912|NCT01635322|Device|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
335913|NCT01635309|Other|Coronary CT Angiogram|pre-operative coronary CTA
335914|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
335915|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
335916|NCT01635296|Drug|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
335917|NCT01635296|Drug|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
335918|NCT01635283|Biological|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
335919|NCT01635283|Other|laboratory biomarker analysis|Correlative studies
335920|NCT01635270|Radiation|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
335921|NCT01635270|Radiation|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
335922|NCT01635257|Other|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
335923|NCT01635244|Device|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
335924|NCT01635231|Other|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
335925|NCT01635218|Drug|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
335967|NCT01634932|Other|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
335926|NCT01635218|Drug|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
335927|NCT01635218|Drug|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
335928|NCT01635205|Procedure|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
335929|NCT01635205|Procedure|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
335930|NCT01635192|Biological|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.~Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
335931|NCT01635192|Biological|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
335932|NCT01635179|Procedure|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
335933|NCT01635166|Device|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
335934|NCT01635153|Dietary Supplement|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
335935|NCT01635153|Dietary Supplement|Micronutrient|Dar-vite Multivitamin
335936|NCT01635140|Radiation|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
335937|NCT01635140|Radiation|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
335938|NCT01635127|Drug|Canakinumab|150mg s.c.
335939|NCT01635127|Drug|Placebo|Constituent of canakinumab
335940|NCT01635114|Dietary Supplement|resveratrol|150 mg resVida per day for 12 weeks
335941|NCT01635114|Dietary Supplement|Placebo|Placebo for 12 weeks
335942|NCT01635101|Drug|IV Acetaminophen|"7.5 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;~10 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;~12.5 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;~15 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours"
335943|NCT01635101|Other|Normal Saline as Placebo|
335944|NCT01635088|Drug|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
335945|NCT01635088|Device|KoKo Spirometry|
335946|NCT01635088|Drug|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
335947|NCT01635088|Device|Oscillometry|
335948|NCT01635075|Behavioral|Exercise|1-mile treadmill walk
335949|NCT01635075|Behavioral|passive control|20 min inactivity
335950|NCT01635062|Drug|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
335951|NCT01635062|Drug|Placebo|Subjects will receive placebo for 3 weeks.
335952|NCT01635036|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
335953|NCT01635023|Drug|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
335954|NCT01635023|Drug|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
335955|NCT01635023|Drug|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
335956|NCT01635023|Drug|AZD6244 Dosing Period 4|Treatment B
335957|NCT01635010|Procedure|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
335958|NCT01634971|Procedure|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
335959|NCT01634958|Biological|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
335960|NCT01634945|Drug|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
335961|NCT01634945|Dietary Supplement|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
335962|NCT01634945|Drug|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.~6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
335963|NCT01634945|Dietary Supplement|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
335964|NCT01634945|Other|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
335965|NCT01634932|Other|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
335966|NCT01634932|Other|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
335968|NCT01634919|Device|chronic hepatitis C|acoustic radiation force impulse ultrasonography
335969|NCT01634906|Drug|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
335970|NCT01634893|Drug|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.~Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.~Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
335971|NCT01634880|Drug|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.~Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
335972|NCT01634854|Drug|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
335973|NCT01634854|Drug|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.~Route of administration: intravenous"
335974|NCT01634841|Dietary Supplement|Walnuts|30 to 60g (1 to 2 oz) per day of walnuts
335975|NCT01634841|Other|habitual diet|Dietary information will be provided
335976|NCT01634815|Procedure|The Edge|measuring blood lactate
335977|NCT01634802|Other|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
335978|NCT01634802|Other|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
335979|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
335980|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
335981|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
335982|NCT01634789|Drug|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
335983|NCT01634776|Dietary Supplement|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
335984|NCT01634776|Dietary Supplement|corn oil|
335985|NCT01634763|Drug|LDK378|
335986|NCT01634750|Drug|ManNAc|Single dose
335987|NCT01634724|Drug|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
335988|NCT01634711|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
335989|NCT01634698|Dietary Supplement|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
335990|NCT01634685|Radiation|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
335991|NCT01634685|Drug|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
335992|NCT01634685|Drug|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
335993|NCT01634659|Device|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
335994|NCT01634659|Device|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
335995|NCT01634646|Dietary Supplement|Lyzme5|"Dietary Supplement (or placebo):~Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).~Week one:~A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;~Week two:~Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;~Week three through the end of the study:~Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
335996|NCT01634620|Device|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
335997|NCT01634594|Drug|Group R|
335998|NCT01634594|Drug|Group N|
335999|NCT01634594|Drug|Group D|
336000|NCT01634568|Drug|V81444|"Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo"
336001|NCT01634555|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
336002|NCT01634555|Drug|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
336003|NCT01634555|Drug|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
336004|NCT01634555|Drug|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
336005|NCT01634529|Drug|V158866|Single ascending oral doses of V158866 and Placebo
336006|NCT01634529|Drug|V158866|Multiple ascending oral doses of V158866 and Placebo
336007|NCT01634516|Behavioral|Dietary support|Face to face intervention plus subsequent telephone support
336008|NCT01634516|Behavioral|No dietary support|No face to face intervention or subsequent telephone support
336055|NCT01634126|Behavioral|1 FIT kit|Patient receives 1 FIT
336056|NCT01634126|Behavioral|2 FIT kit|Patient receives 2 FIT kits
336009|NCT01634503|Genetic|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
336010|NCT01634451|Other|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
336011|NCT01634451|Other|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
336012|NCT01634451|Device|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
336013|NCT01634438|Drug|unfractionated heparin|unfractionated heparin
336014|NCT01634425|Device|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
336015|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
336016|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
336017|NCT01634412|Drug|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
336018|NCT01634412|Drug|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
336019|NCT01634399|Drug|Torrent's Quetiapine Fumarate Tablets|
336020|NCT01634386|Drug|Torrent's Quetiapine Fumarate Tablets|
336021|NCT01634373|Drug|Torrent's Quetiapine Fumarate Tablets|
336022|NCT01634360|Drug|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
336023|NCT01634347|Drug|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
336024|NCT01634347|Drug|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
336025|NCT01634334|Behavioral|Real-Time Intervention|Lights and Sound Brief Coaching
336026|NCT01634334|Behavioral|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
336027|NCT01634321|Drug|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
336028|NCT01634308|Drug|Novosis(bongros/BMP-2)|
336029|NCT01634308|Drug|Bio-oss|
336030|NCT01634295|Drug|CKD-828 2.5/40mg|"Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~With the others investigation product placebo 4 tabs QD 2 weeks."
336031|NCT01634295|Drug|CKD-828 5/40mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~With the others investigation product placebo 4 tabs QD 2 weeks."
336032|NCT01634295|Drug|CKD-828 5/80mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~With the others investigation product placebo 4 tabs QD 6 weeks."
336033|NCT01634295|Drug|S-amlodipine 2.5mg|"S-amlodipine 2.5mg QD 4 weeks~With the others investigation product placebo 4 tabs QD 4 weeks."
336034|NCT01634295|Drug|S-amlodipine 5mg|"S-amlodipine 2.5mg QD 6weeks~With the others investigation product placebo 4 tabs QD 6 weeks."
336035|NCT01634282|Drug|OPC-262|Orally administered once daily
336036|NCT01634269|Device|MDT-2111 TAVI 23 mm|Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
336037|NCT01634256|Dietary Supplement|Placebo|Placebo(3.0g/day)
336038|NCT01634256|Dietary Supplement|Fermented turmeric|Fermented turmeric(3.0g/day)
336039|NCT01634243|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
336040|NCT01634230|Drug|OCR-002|daily dose: 10 g infused over 24 hours
336041|NCT01634217|Biological|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
336042|NCT01634204|Other|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.~Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
336043|NCT01634204|Other|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.~Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
336044|NCT01634191|Drug|Apremilast|One oral 30 mg dose of apremilast
336045|NCT01634178|Drug|Apremilast|One oral dose of 30 mg apremilast under fasted conditions
336046|NCT01634178|Drug|Apremilast|one oral dose of 30 mg apremilast after a high-fat meal
336047|NCT01634165|Drug|LY2963016|Administered subcutaneously
336048|NCT01634165|Drug|Lantus|Administered subcutaneously
336049|NCT01634152|Drug|Placebo|2 actuations once daily in the evening
336050|NCT01634152|Drug|Tiotropium low dose mcg|2 actuations once daily in the evening
336051|NCT01634152|Drug|Tiotropium high dose|2 actuations once daily in the evening
336052|NCT01634139|Drug|Tiotropium low dose QD|2 actuations once daily in the evening
336053|NCT01634139|Drug|Tiotropium high dose QD|2 actuations once daily in the evening
336054|NCT01634139|Drug|Placebo|2 actuations once daily in the evening
336069|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
336070|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
336071|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
336072|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
336073|NCT01634048|Dietary Supplement|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
336074|NCT01634022|Procedure|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (−) to GV24.5 (+).
336075|NCT01634009|Dietary Supplement|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
336076|NCT01633996|Procedure|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
336077|NCT01633983|Drug|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
336078|NCT01633983|Drug|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
336079|NCT01633970|Drug|5-FU|Participants will receive 5-FU 400 mg/m^2 IV q2w.
336080|NCT01633970|Drug|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
336081|NCT01633970|Drug|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
336082|NCT01633970|Drug|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
336083|NCT01633970|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV q2w.
336084|NCT01633970|Drug|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m^2 IV qw.
336085|NCT01633970|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV q2w.
336086|NCT01633970|Drug|Paclitaxel|Participants will receive paclitaxel 200 mg/m^2 IV q3w.
336087|NCT01633970|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV q3w.
336088|NCT01633957|Other|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
336089|NCT01633957|Other|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
336090|NCT01633944|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
336091|NCT01633944|Drug|Placebo|Matching Placebo Buccal Film twice daily
336092|NCT01633918|Behavioral|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
336093|NCT01633918|Behavioral|Usual health education|Usual health education lessons
336094|NCT01633892|Procedure|Fat Grafting|
336095|NCT01633879|Behavioral|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
336096|NCT01633879|Behavioral|health and success parent and school|Parenting education and school intervention
336097|NCT01633853|Drug|Vitamin D2|Treatment with Vit D2.
336098|NCT01633853|Drug|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
336099|NCT01633840|Other|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
336100|NCT01633840|Other|Elemental E028|Elemental E028 with no added food allergens
336101|NCT01633827|Drug|Placebo pill|Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
336102|NCT01633827|Drug|Sedative|Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
336103|NCT01633827|Other|Room air|Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies
336104|NCT01633827|Other|Oxygen|Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
336105|NCT01633814|Drug|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
336106|NCT01633814|Drug|Placebo|placebo patch.
336107|NCT01633801|Device|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
336108|NCT01633801|Device|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
336109|NCT01633788|Drug|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
336110|NCT01633788|Drug|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
336111|NCT01633788|Drug|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
336112|NCT01633788|Drug|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
336113|NCT01633775|Procedure|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
336152|NCT01633359|Drug|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
336436|NCT01631097|Drug|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
336114|NCT01633762|Drug|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
336115|NCT01633749|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
336116|NCT01633736|Other|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
336117|NCT01633723|Drug|DA-6886|"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"
336118|NCT01633723|Drug|Placebo of DA-6886|DA-6886 placebo
336119|NCT01633697|Behavioral|Breathing|Breathing techniques
336120|NCT01633697|Behavioral|Education alone|No special attention to breathing
336121|NCT01633658|Dietary Supplement|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
336122|NCT01633658|Dietary Supplement|25(OH)D|a single dose of 625 micrograms of 25(OH)D
336123|NCT01633645|Drug|Bortezomib|Velcade
336124|NCT01633645|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
336125|NCT01633645|Drug|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
336126|NCT01633632|Behavioral|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
336127|NCT01633632|Behavioral|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
336128|NCT01633593|Drug|Donepezil|5 mg PO a day, during 2 weeks
336129|NCT01633580|Drug|corifollitropin alfa|long acting FSH
336130|NCT01633567|Behavioral|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
336131|NCT01633567|Behavioral|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
336132|NCT01633541|Drug|AT-101|Patients will receive AT-101 40 mg orally two times a day.
336133|NCT01633541|Drug|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
336134|NCT01633541|Drug|Cisplatin|Cisplatin 100 mg/m2
336135|NCT01633541|Drug|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
336136|NCT01633528|Drug|Asprin|100 mg
336137|NCT01633528|Drug|placebo|100mg
336138|NCT01633515|Procedure|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.~Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
336139|NCT01633502|Device|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
336140|NCT01633502|Device|Impella CP|Control group treated with Impella CP for a minimum of 48 hrs.
336141|NCT01633476|Drug|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
336142|NCT01633450|Other|Zinc biofortified rice|1.12 mg zinc per meal
336143|NCT01633450|Other|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
336144|NCT01633437|Drug|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
336145|NCT01633437|Other|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
336146|NCT01633411|Device|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
336147|NCT01633411|Device|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
336148|NCT01633411|Device|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
336149|NCT01633398|Genetic|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
336150|NCT01633372|Drug|itacitinib|
336151|NCT01633359|Drug|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
336153|NCT01633333|Other|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
336154|NCT01633333|Other|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
336155|NCT01633307|Other|Education|Teaching program
336156|NCT01633294|Drug|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
336157|NCT01633281|Procedure|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
336158|NCT01633255|Drug|18F-Fluciclatide|
336159|NCT01633229|Procedure|Bone Marrow Stromal Cell Infusion|
336160|NCT01633216|Biological|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
336161|NCT01633216|Biological|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
336162|NCT01633216|Biological|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
336163|NCT01633216|Biological|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
336164|NCT01633216|Biological|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
336165|NCT01633203|Drug|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea."
336166|NCT01633177|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
336167|NCT01633177|Drug|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
336168|NCT01633177|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
336169|NCT01633177|Drug|Fish oil placebo|Fish oil placebo
336170|NCT01633164|Behavioral|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
336171|NCT01633164|Other|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
336172|NCT01633138|Behavioral|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
336173|NCT01633138|Behavioral|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
336174|NCT01633125|Other|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
336175|NCT01633112|Drug|fingolimod|capsule
336176|NCT01633112|Drug|glatiramer acetate|subcutaneous injection
336177|NCT01633099|Drug|Decitabine|"Number of Cycles: 4 cycles.~Dose and drug delivery(decitabine):~The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.~If bone marrow blast cells<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle.~If Grade 4 neutropenia（<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle)."
336178|NCT01633086|Drug|nitric oxide gel|"st gel: sodium nitrites,BID local use X 28 days~nd gel: maleic/ascorbic acids ,BID local use X 28 days"
336179|NCT01633086|Drug|placebo gel|placebo gel,BID local use X 28 days
336180|NCT01633073|Device|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
336181|NCT01633073|Device|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
336182|NCT01633060|Drug|Fulvestrant|Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
336183|NCT01633060|Drug|BKM120|BKM120 100 mg once daily
336184|NCT01633060|Drug|BKM120 matching placebo|BKM120 matching placebo, once daily
336185|NCT01633047|Other|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
336186|NCT01633047|Other|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
336187|NCT01633008|Behavioral|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
336188|NCT01632995|Drug|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
336189|NCT01632982|Behavioral|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
336190|NCT01632982|Behavioral|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
336191|NCT01632982|Behavioral|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
336192|NCT01632969|Behavioral|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
336193|NCT01632956|Behavioral|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
336194|NCT01632956|Behavioral|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
336195|NCT01632943|Device|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.~A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
336196|NCT01632930|Other|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
336197|NCT01632917|Drug|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
336198|NCT01632917|Drug|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
336199|NCT01632904|Drug|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
336200|NCT01632904|Drug|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
336201|NCT01632904|Drug|HU-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
336202|NCT01632904|Drug|Ruxolitinib-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.~When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
336203|NCT01632891|Drug|Lopinavir/ritonavir|Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
336204|NCT01632891|Drug|Emtricitabine/tenofovir disoproxil fumarate|Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
336205|NCT01632891|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz orally once daily.
336206|NCT01632891|Drug|Nevirapine|If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
336207|NCT01632891|Drug|Trimethoprim/sulfamethoxazole|Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
336208|NCT01632865|Device|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
336209|NCT01632852|Biological|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
336210|NCT01632826|Drug|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
336211|NCT01632800|Device|High pulsed magnetic fields|Magnetic fields will escalate in strength
336212|NCT01632787|Other|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
336213|NCT01632761|Dietary Supplement|Vitamin D3 .|
336214|NCT01632761|Drug|omega-3 fatty acids (fish oil)|
336215|NCT01632761|Dietary Supplement|Vitamin D3 placebo|
336216|NCT01632761|Dietary Supplement|Fish oil placebo|
336217|NCT01632748|Device|Neurotech Vital Device|5 minute treatment
336218|NCT01632748|Device|Modified Neurotech Vital Device|5 minute stimulation
341468|NCT01591317|Drug|Prasugrel|Tablets orally
336219|NCT01632735|Behavioral|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
336220|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)~Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
336221|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)~Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)~Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
336222|NCT01632709|Drug|Bupivacaine|one injection of 10ml of .25%
336223|NCT01632709|Drug|Placebo|Dry needling
336224|NCT01632696|Drug|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
336225|NCT01632683|Device|C-MAC|C-MAC arm
336226|NCT01632683|Device|Glidescope|Glidescope arm
336227|NCT01632670|Other|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
336228|NCT01632657|Drug|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
336229|NCT01632657|Drug|Placebo|Single injection saline 0.5ml subcutaneously in recovery
336230|NCT01632644|Other|Survey/Interview|Each group will be surveyed and interviewed.
336231|NCT01632618|Behavioral|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
336232|NCT01632618|Behavioral|Passive control intervention|Passive physical therapy approach to low back pain
336233|NCT01632605|Drug|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
336234|NCT01632592|Drug|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
336235|NCT01632592|Drug|Placebo|placebo given by injection 2mg subcutaneously daily
336236|NCT01632579|Drug|LY3023703|Administered orally
336237|NCT01632579|Drug|Placebo|Administered orally
336238|NCT01632579|Drug|Celecoxib|Administered orally
336239|NCT01632566|Drug|Placebo|Capsules administered orally
336240|NCT01632566|Drug|LY3031207|Administered orally
336241|NCT01632566|Drug|Celecoxib|Administered orally
336242|NCT01632566|Drug|Simvastatin|Administered orally
336243|NCT01632540|Drug|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
336244|NCT01632527|Drug|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
336245|NCT01632514|Drug|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
336246|NCT01632501|Device|Coronary stent - Tsunami|A coronary angioplasty was done
336247|NCT01632475|Biological|Pneumostem®|"A single intratracheal administration~Low Dose Group (3 patients): 1.0 x 10^7 cells/kg, High Dose Group (6 patients): 2 x 10^7 cells/kg~* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
336248|NCT01632462|Drug|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
336249|NCT01632449|Drug|Test product|Dimethyl Fumarate (BG00012)
336250|NCT01632449|Drug|Reference product|Dimethyl Fumarate (BG00012)
336251|NCT01632436|Drug|Pixantrone|Experimental Drug
336252|NCT01632423|Drug|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
336253|NCT01632397|Behavioral|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
336254|NCT01632397|Behavioral|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
336255|NCT01632384|Behavioral|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
336256|NCT01632371|Device|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
336257|NCT01632371|Device|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
336258|NCT01632358|Drug|TAP311 capsules|
336259|NCT01632358|Drug|Placebo|
336260|NCT01632345|Drug|Doravirine|Part I: Doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) depending upon randomization, taken orally every morning with or without food for at least 24 weeks. Part II: Selected dose of doravirine depending upon randomization (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet orally every morning with or without food for 96 weeks.
336261|NCT01632345|Drug|Efavirenz|Efavirenz 600 mg tablet orally at bedtime taken without food on an empty stomach for 96 weeks
336262|NCT01632345|Drug|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning for 96 weeks
336263|NCT01632345|Drug|Placebo for Doravirine|Placebo tablets matching doravirine
336264|NCT01632345|Drug|Placebo for Efavirenz|Placebo tablets matching efavirenz
336265|NCT01632332|Biological|HER-2/neu peptide vaccine|Given ID
336266|NCT01632332|Other|laboratory biomarker analysis|Correlative studies
336305|NCT01631994|Drug|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
336435|NCT01631110|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
336267|NCT01632319|Behavioral|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.~In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
336268|NCT01632319|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
336269|NCT01632306|Drug|LY2090314|LY2090314 administered IV
336270|NCT01632306|Drug|FOLFOX|FOLFOX administered IV
336271|NCT01632306|Drug|Gemcitabine|Gemcitabine administered IV
336272|NCT01632306|Drug|Nab-paclitaxel|Nab-paclitaxel administered IV
336273|NCT01632293|Behavioral|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
336274|NCT01632280|Device|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes—anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.~In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
336275|NCT01632241|Biological|Placebo plus standard therapy|Placebo plus standard therapy
336276|NCT01632241|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
336277|NCT01632241|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
336278|NCT01632228|Drug|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
336279|NCT01632228|Drug|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
336280|NCT01632228|Drug|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
336281|NCT01632215|Drug|Gabapentine|Gabapentine 600 mg 01 dose
336282|NCT01632215|Other|Sugar pill|Sugar pill 01 dose
336283|NCT01632202|Device|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
336284|NCT01632202|Device|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
336285|NCT01632189|Drug|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
336286|NCT01632176|Behavioral|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
336287|NCT01632163|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
336288|NCT01632163|Drug|Placebo|"Pharmaceutical form:solution~Route of administration: subcutaneous injection"
336289|NCT01632150|Biological|Elotuzumab|Powder for solution, 400-mg vials, for infusion
336290|NCT01632150|Biological|Thalidomide|50-mg capsules administered orally
336291|NCT01632150|Biological|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
336292|NCT01632150|Biological|Cyclophosphamide|50-mg tablets administered orally
336293|NCT01632137|Drug|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
336294|NCT01632137|Drug|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
336295|NCT01632124|Other|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
336296|NCT01632111|Other|Lung function measurement|Spirometry
336297|NCT01632085|Device|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.~Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
336298|NCT01632072|Dietary Supplement|Nutritional support|Nutritional support and counseling
336299|NCT01632046|Drug|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
336300|NCT01632020|Drug|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
336301|NCT01632020|Drug|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
336302|NCT01632007|Drug|SYR-472|
336303|NCT01632007|Drug|Alogliptin 25 mg|
336304|NCT01632007|Drug|Placebo|
336306|NCT01631981|Drug|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
336307|NCT01631981|Drug|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.~Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
336308|NCT01631968|Procedure|Cement without antibiotic.|
336309|NCT01631968|Procedure|Cement with erytromycin and colistin.|
336310|NCT01631955|Drug|Ciprobay|Ciprobay (250mg, bid, oral)
336311|NCT01631942|Drug|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.~Escalation to next dose level is based on a safety evaluation."
336312|NCT01631929|Other|One bag|Infusion of dextrose and electrolytes using one bag
336313|NCT01631929|Other|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
336314|NCT01631916|Drug|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
336315|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
336316|NCT01631903|Drug|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
336317|NCT01631903|Drug|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
336318|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
336319|NCT01631903|Drug|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
336320|NCT01631890|Procedure|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
336321|NCT01631890|Procedure|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
336322|NCT01631877|Drug|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
336323|NCT01631877|Other|placebo|injection placebo will be given for 5 days along with placebo tablets
336324|NCT01631864|Drug|LCZ696|LCZ696 was provided as 400 mg tablets.
336325|NCT01631864|Drug|amlodipine|amlodipine was provided as 5 mg tablets.
336326|NCT01631864|Drug|Placebo|Matching placebo to LCZ696 and amlodipine.
336327|NCT01631851|Behavioral|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
336328|NCT01631838|Dietary Supplement|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
336329|NCT01631838|Dietary Supplement|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
336330|NCT01631825|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
336331|NCT01631812|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
336332|NCT01631799|Device|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
336333|NCT01631799|Device|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
336334|NCT01631773|Genetic|microRNA|Biological samples will be taken from subjects w/ Nasal polyps & AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
336335|NCT01631760|Genetic|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
336336|NCT01631747|Behavioral|Lifestyle Intervention Group|Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
336337|NCT01631747|Behavioral|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
336338|NCT01631708|Procedure|Erythrocytapheresis|"To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.~An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to ~100 ug/L in accordance with current guidelines."
336433|NCT01631123|Other|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
336339|NCT01631708|Procedure|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
336340|NCT01631682|Drug|Propranolol|40mg single pill
336341|NCT01631682|Behavioral|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
336342|NCT01631682|Drug|Mifepristone|1800mg, 9 tablets
336343|NCT01631682|Drug|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
336344|NCT01631669|Drug|Celecoxib|200 mg Q 12 hours orally
336345|NCT01631656|Drug|Azelaic acid|15% gel on half the face, twice daily, 6 weeks
336346|NCT01631656|Device|Nd:Yag laser|Treatment with Nd:Yag laser , once at Week 2.
336347|NCT01631643|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
336348|NCT01631630|Drug|Pioglitazone|Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
336349|NCT01631630|Drug|Placebo|Placebo is an inactive tablet design to look exactly like pioglitazone
336350|NCT01631617|Drug|Trimethoprim/sulfamethoxazole (TMP/SMZ)|800/160 orally every 12 hours for 14 days
336351|NCT01631617|Drug|Cephalexin|500 mg orally every 8 hours for 14 days
336352|NCT01631617|Drug|Doxycycline|20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
336353|NCT01631617|Other|Sodium hypochlorite|6 % dilute bleach
336354|NCT01631617|Other|Placebo capsules|Capsule orally every 8 hours daily for 14 days
336355|NCT01631617|Other|Placebo Sodium hypochlorite|Three times a week for 14 days
336356|NCT01631604|Device|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
336357|NCT01631604|Drug|Muscle/nerve injection|Injection to muscle or nerve
336358|NCT01631604|Procedure|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
336359|NCT01631604|Other|Physical therapy treatment|
336360|NCT01631578|Procedure|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
336361|NCT01631565|Behavioral|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
336362|NCT01631565|Behavioral|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
336363|NCT01631565|Behavioral|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
336364|NCT01631552|Drug|IMMU-132|IMMU-132 is administered on days 1 & 8 of 3 week treatment cycles.
336365|NCT01631539|Device|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
336366|NCT01631539|Drug|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
336367|NCT01631539|Drug|5 FU|every 2 weeks IV
336368|NCT01631539|Drug|Irinotecan|every 4 weeks chemoembolization
336369|NCT01631526|Dietary Supplement|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
336370|NCT01631513|Drug|Nucynta ER|100 to 250 mg every 12 hours
336371|NCT01631500|Behavioral|Conventional treatment|Conventional treatment
336372|NCT01631500|Other|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
336373|NCT01631500|Other|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
336374|NCT01631487|Drug|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
336375|NCT01631487|Drug|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
336376|NCT01631487|Drug|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
336377|NCT01631487|Drug|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
336378|NCT01631474|Drug|CB-03-01|Topical cream, applied once a day
336379|NCT01631474|Drug|Vehicle|Topical cream, applied once or twice a day
336380|NCT01631474|Drug|CB-03-01|Topical cream, applied twice a day
336381|NCT01631448|Biological|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
336382|NCT01631435|Other|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
336383|NCT01631435|Device|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure~• Ileocolonoscopy with intubation of terminal ileum"
336384|NCT01631422|Drug|RO4602522|Single radiolabeled dose
336385|NCT01631409|Other|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
336386|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
336434|NCT01631123|Other|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
336387|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
336388|NCT01631409|Procedure|PCA|Percutaneous coronary angioplasty
336389|NCT01631409|Procedure|CABG|Coronary artery bypass grafting
336390|NCT01631409|Device|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
336391|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
336392|NCT01631396|Drug|Sugammadex vs. Neostigmine|"Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.~Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
336393|NCT01631383|Drug|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
336394|NCT01631383|Drug|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
336395|NCT01631370|Procedure|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
336396|NCT01631357|Biological|CIK cell|CIK cell injection
336397|NCT01631357|Drug|Gemcitabine Injection|Gemcitabine injection
336398|NCT01631357|Drug|Cisplatin injection|Cisplatin injection
336399|NCT01631344|Other|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
336400|NCT01631331|Drug|vismodegib|Given PO
336401|NCT01631331|Procedure|Mohs surgery|Undergo Mohs surgery
336402|NCT01631318|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo 3D contrast enhanced ultrasound imaging
336403|NCT01631305|Drug|Levothyroxine|3 mcg/kg/day
336404|NCT01631305|Other|Calcium magnesia|Placebo.
336405|NCT01631292|Dietary Supplement|600 IU Vitamin D3|Once daily
336406|NCT01631292|Dietary Supplement|2000 IU Vitamin D3|Once daily
336407|NCT01631292|Dietary Supplement|4000 IU Vitamin D3|Once daily
336408|NCT01631279|Drug|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
336409|NCT01631266|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
336410|NCT01631266|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
336411|NCT01631253|Procedure|Laparoscopic ovarian cyst enucleation|
336412|NCT01631227|Drug|Eprosartan|Eprosartan 450 mg
336413|NCT01631227|Drug|Eprosartan Mesylate|Eprosartan mesylate 600 mg
336414|NCT01631227|Drug|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
336415|NCT01631227|Drug|Placebo Eprosartan|Placebo Eprosartan
336416|NCT01631214|Biological|Romosozumab|Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.
336417|NCT01631214|Drug|Alendronate|Alendronate 70 mg tablet taken once a week
336418|NCT01631214|Drug|Placebo to Romosozumab|Administered by subcutaneous injection once a month during the double-blind treatment phase.
336419|NCT01631214|Drug|Placebo to Alendronate|Matching placebo tablet taken once a week during the double-blind treatment phase.
336420|NCT01631201|Drug|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
336421|NCT01631201|Drug|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
336422|NCT01631188|Procedure|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
336423|NCT01631188|Procedure|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
336424|NCT01631188|Device|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
336425|NCT01631175|Behavioral|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
336426|NCT01631162|Other|Breath sample in all patients|Breath sample will be collected by a special nylon bag
336427|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
336428|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
336429|NCT01631136|Drug|Cisplatin|75 mg/m²
336430|NCT01631136|Drug|Pemetrexed|500 mg/m²
336431|NCT01631136|Drug|Cisplatin|80 mg/m²
336432|NCT01631136|Drug|Gemcitabine|1250 mg/m²
336437|NCT01631084|Other|JADE|"Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.~Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate."
336438|NCT01631084|Other|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
336439|NCT01631071|Biological|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
336440|NCT01631058|Drug|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.~Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.~Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.~Corticosteroids: as clinical practice."
336441|NCT01631032|Drug|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
336442|NCT01631019|Behavioral|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
336443|NCT01631019|Behavioral|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
336444|NCT01631006|Device|CPAP|A low or high CPAP pressure is delivered for 20 minutes
336445|NCT01630993|Other|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
336446|NCT01630980|Other|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
336447|NCT01630967|Drug|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
336448|NCT01630954|Procedure|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
336449|NCT01630954|Procedure|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
336450|NCT01630941|Drug|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
336451|NCT01630928|Procedure|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
336452|NCT01630915|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
336453|NCT01630902|Drug|Torrent's Felodipine Extended-Release Tablets|
336454|NCT01630889|Drug|FG-4592|Subjects previously randomized to FG-4592 will receive study medication on the same dosing frequency assigned at the last dose of the previous FibroGen study.
336455|NCT01630876|Procedure|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
336456|NCT01630876|Procedure|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
336457|NCT01630863|Procedure|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
336458|NCT01630850|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
341552|NCT01590797|Drug|Placebo|Matching placebo once daily for 24 weeks
336459|NCT01630850|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
336460|NCT01630837|Other|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
336461|NCT01630824|Other|Structured education program|structured education program after kidney transplantation
336462|NCT01630811|Drug|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
336463|NCT01630811|Other|Placebo|Placebo will be given once daily for 7 days.
336464|NCT01630798|Drug|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
336465|NCT01630785|Device|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
336466|NCT01630772|Other|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
336467|NCT01630772|Other|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
336468|NCT01630759|Device|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
336469|NCT01630759|Other|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
336470|NCT01630746|Drug|TAK-438|
336471|NCT01630746|Drug|TAK-438|
336472|NCT01630733|Drug|Custirsen|Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
336473|NCT01630733|Drug|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
336474|NCT01630720|Dietary Supplement|vitamin C or vitamin D|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
336475|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
336476|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
336477|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
336478|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
336479|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
336480|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
336481|NCT01630681|Behavioral|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
336482|NCT01630668|Dietary Supplement|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
336483|NCT01630668|Dietary Supplement|One-a-Day placebo capsule|Once per day, 12 weeks
336484|NCT01630655|Drug|Torrent's Felodipine Extended-Release Tablets|
336485|NCT01630642|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
336486|NCT01630616|Drug|Odanacatib|single oral dose, tablets, 10 or 50 mg
336487|NCT01630616|Drug|Placebo|single oral dose, tablets
336488|NCT01630590|Drug|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
336489|NCT01630590|Drug|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
336490|NCT01630577|Other|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
336491|NCT01630564|Biological|Aldesleukin|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
336492|NCT01630564|Procedure|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
336493|NCT01630564|Biological|Umbilical Cord Blood-Derived Lymphocyte Therapy|Undergo ex-vivo-expanded umbilical cord blood progenitor cell donor T-cell infusion with aldesleukin
336494|NCT01630551|Dietary Supplement|Fishoil supplement|1 capsule per day
336495|NCT01630551|Dietary Supplement|Olive Oil|1 capsule per day
336496|NCT01630538|Drug|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
341878|NCT01588158|Drug|Vicodin|Vicodin 5/325 mg
336497|NCT01630525|Other|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
336498|NCT01630525|Other|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
336499|NCT01630525|Other|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
336500|NCT01630512|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
336501|NCT01630512|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
336502|NCT01630499|Behavioral|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
336503|NCT01630499|Behavioral|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
336504|NCT01630473|Procedure|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
336505|NCT01630473|Procedure|Conventional orthodontics|Conventional orthodontic treatment
336506|NCT01630434|Device|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
336507|NCT01630434|Device|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
336508|NCT01630408|Drug|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
336509|NCT01630395|Procedure|protective ventilation|low tidal volume and PEEP
336510|NCT01630395|Procedure|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
336511|NCT01630369|Drug|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
336512|NCT01630356|Behavioral|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
336513|NCT01630356|Device|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
336514|NCT01630356|Behavioral|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
336515|NCT01630356|Behavioral|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.~The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
336516|NCT01630343|Drug|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
336517|NCT01630343|Drug|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
336518|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
336519|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
336520|NCT01630317|Procedure|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
336521|NCT01630317|Procedure|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
336522|NCT01630304|Behavioral|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
336523|NCT01630291|Device|Electrode device|Lacrimal gland stimulation
336524|NCT01630278|Drug|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
336525|NCT01630278|Drug|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
336526|NCT01630265|Other|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
336527|NCT01630265|Other|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
336528|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
336529|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
336701|NCT01628965|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
336530|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
336531|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
336532|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
336533|NCT01630239|Procedure|Laser ablation|Laser ablation of hepatic tumors
336534|NCT01630226|Drug|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
336535|NCT01630213|Dietary Supplement|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
336536|NCT01630213|Dietary Supplement|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
336537|NCT01630200|Drug|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
336538|NCT01630200|Drug|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
336539|NCT01630187|Drug|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
336540|NCT01630187|Drug|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
336541|NCT01630161|Behavioral|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
336542|NCT01630161|Behavioral|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
336543|NCT01630148|Drug|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
336544|NCT01630135|Drug|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
336545|NCT01630135|Drug|Placebo|Placebo, intranasal, 2 weeks
336546|NCT01630109|Drug|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
336547|NCT01630109|Drug|Placebo|A placebo capsule made to look like the metoclopramide capsule.
336548|NCT01630096|Drug|Nu-Lytely|Bowl prep solution.
336549|NCT01630083|Drug|Epirubicin|50 mg/m2; d 1 q3w for max. 8 cycles
336550|NCT01630083|Drug|Oxaliplatin|130 mg/m2; d 1 q3w for max. 8 cycles
336551|NCT01630083|Drug|Capecitabine|625 mg/m2; p.o. d 1 - d 21 q3w twice daily for max. 8 cycles
336552|NCT01630083|Drug|Zolbetuximab 800/600 mg/m2|"800 mg/m2 loading dose on cycle 1.~600 mg/m2 every 3 weeks."
336553|NCT01630083|Drug|Zolbetuximab 1000 mg/m2|1000 mg/m2 every 3 weeks.
336554|NCT01630070|Device|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
336555|NCT01630057|Drug|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
336556|NCT01630057|Drug|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
336557|NCT01630044|Device|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
336558|NCT01630018|Drug|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
336559|NCT01630018|Drug|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
336560|NCT01630005|Behavioral|talk therapy|Psychotherapy
336561|NCT01629992|Other|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
336562|NCT01629979|Procedure|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.~Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
336563|NCT01629979|Radiation|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
336564|NCT01629966|Drug|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
336565|NCT01629966|Drug|Vilazodone|Vilazodone, 20mg, oral administration once per day.
336566|NCT01629966|Drug|Vilazodone|Vilazodone, 40mg, oral administration once per day.
336567|NCT01629953|Other|Group vocational intervention|Group based manualized vocational rehabilitation
336568|NCT01629953|Other|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
336569|NCT01629914|Behavioral|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
336570|NCT01629901|Device|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
336571|NCT01629888|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
336572|NCT01629888|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
336573|NCT01629875|Drug|Generic equivalent of Clostridium Botulinum A Toxin|
336574|NCT01629875|Drug|Botox (Clostridium Botulinum A Toxin)|
336575|NCT01629862|Device|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
336576|NCT01629862|Device|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
336577|NCT01629849|Drug|Placebo to BI 1021958 qd|tablet
336578|NCT01629849|Drug|BI 1021958 bid|tablets
336579|NCT01629849|Drug|Placebo to BI 1021958 bid|tablets
336580|NCT01629849|Drug|BI 1021958 qd|tablet
336581|NCT01629823|Device|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
336582|NCT01629810|Device|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
336583|NCT01629797|Behavioral|Educational script on Acne|An educational script on Acne will be presented by investigator
336584|NCT01629784|Behavioral|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
336585|NCT01629758|Biological|Denenicokin|
336586|NCT01629758|Biological|Nivolumab|
336587|NCT01629745|Genetic|gene expression analysis|
336588|NCT01629745|Other|flow cytometry|
336589|NCT01629745|Other|laboratory biomarker analysis|
336590|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
336591|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
336592|NCT01629732|Drug|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
336593|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
336594|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
336595|NCT01629732|Drug|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
336596|NCT01629732|Drug|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
336597|NCT01629706|Device|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
336598|NCT01629706|Device|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
336599|NCT01629706|Device|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
336600|NCT01629706|Device|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
336601|NCT01629706|Device|Habitual lens care|Lens care per habitual use
336602|NCT01629693|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
336603|NCT01629693|Device|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
336604|NCT01629680|Drug|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
336605|NCT01629680|Drug|Placebo|coated tablets identical in number and appearance as the study drug
336606|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
336607|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
336608|NCT01629667|Other|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
336609|NCT01629654|Behavioral|Health promotion program|"A 13 weeks organized program:~One group session about poststroke fatigue involving both patient and relatives~Two personal meetings, involving both patient and relatives~Three telephone meetings, involving only patient"
336610|NCT01629628|Drug|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
336611|NCT01629628|Drug|6 Mercaptopurine|"6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.~--------------------------------------------------------------------------------"
336612|NCT01629615|Drug|BKM120|BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
336613|NCT01629602|Procedure|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
336614|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
336615|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
336616|NCT01629576|Other|economic incentive|economic incentive for weight loss
336617|NCT01629576|Other|economic incentive|economic incentive for weight loss
336618|NCT01629563|Drug|PGL4001 5 mg|PGL4001 5 mg daily administration
336619|NCT01629563|Drug|PGL4001 10 mg|PGL4001 10mg daily administration
336620|NCT01629550|Procedure|skin disinfection prior catheter insertion|
336702|NCT01628952|Drug|Transversus Abdominis Plane|PIA coelioscopic
336703|NCT01628952|Drug|Curare|IAP coelioscopic
336704|NCT01628939|Other|MRI of the lumbar spine|standard protocol, approximately 30 minutes
336621|NCT01629537|Procedure|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
336622|NCT01629537|Procedure|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
336623|NCT01629511|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo stem cell transplant
336624|NCT01629511|Biological|Anti-Thymocyte Globulin|Given IV
336625|NCT01629511|Drug|Busulfan|Given IV
336626|NCT01629511|Drug|Clofarabine|Given IV
336627|NCT01629511|Biological|Filgrastim|Given SC
336628|NCT01629511|Drug|Gemcitabine|Given IV
336629|NCT01629511|Drug|Methotrexate|Given IV
336630|NCT01629511|Drug|Tacrolimus|Given PO
336631|NCT01629498|Radiation|Image Guided Radiation Therapy|Undergo image-guided IMRT
336632|NCT01629498|Radiation|Image Guided Radiation Therapy|Undergo image-guided IMPT
336633|NCT01629498|Radiation|Intensity-Modulated Radiation Therapy|Undergo image-guided IMRT
336634|NCT01629498|Radiation|Intensity-Modulated Radiation Therapy|Undergo image-guided IMPT
336635|NCT01629498|Other|Laboratory Biomarker Analysis|Optional correlative studies
336636|NCT01629498|Radiation|Photon Beam Radiation Therapy|Undergo image-guided IMRT
336637|NCT01629498|Radiation|Proton Beam Radiation Therapy|Undergo image-guided IMPT
336638|NCT01629498|Other|Questionnaire Administration|Ancillary studies
336639|NCT01629485|Behavioral|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
336640|NCT01629485|Behavioral|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
336641|NCT01629485|Behavioral|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
336642|NCT01629472|Behavioral|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
336643|NCT01629459|Behavioral|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
336644|NCT01629446|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
336645|NCT01629420|Drug|KLH-2109|
336646|NCT01629420|Drug|KLH-2109|
336647|NCT01629407|Other|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
336648|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
336649|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
336650|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
336651|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
336652|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)]
336653|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
336654|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
336655|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
336656|NCT01629381|Drug|Rivaroxaban|10 mg os once daily for 1 week
336657|NCT01629381|Drug|placebo|10 mg os once daily for 1 week
336658|NCT01629368|Drug|Carbamazepine|Multiple doses of carbamazepine
336659|NCT01629368|Drug|RO4917523|Single dose of RO4917523
336660|NCT01629342|Behavioral|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:~treadmill walking (5 minutes, 1 and 2km/h)~staircase walking (1 floor, normal pace)~cycling with fixed load (5 minutes)~standing up from sitting position and sitting down again (x5)~standing up from supine position~turning from left to right and back while lying in bed~raising outstretched arm 90° (x5, standing position)~eating (5 minutes, sitting position)~drinking a glass of water~sleeping (6 hours)"
336661|NCT01629329|Drug|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
336662|NCT01629329|Drug|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
336663|NCT01629316|Behavioral|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
336664|NCT01629316|Behavioral|Standard of care - control arm|The control arm is standard of care for each subject.
342560|NCT01582503|Drug|placebo|Subcutaneous repeating dose
336665|NCT01629303|Procedure|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.~Then all the stimulators are switched OFF (both first and second arms) for 15 days.~Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
336666|NCT01629290|Device|Enamel Pro|Varnish treatment containing 5% NaF
336667|NCT01629290|Device|Duraphat|Varnish treatment containing 5% NaF
336668|NCT01629290|Device|Vanish|Varnish treatment containing 5% NaF
336669|NCT01629290|Device|Placebo|Bland varnish containing no NaF
336670|NCT01629277|Device|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
336671|NCT01629277|Device|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
336672|NCT01629264|Device|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
336673|NCT01629264|Device|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
336674|NCT01629264|Other|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
336675|NCT01629251|Device|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
336676|NCT01629225|Drug|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
336677|NCT01629212|Drug|Tiropramide HCl 100mg|
336678|NCT01629212|Drug|Octylonium bromide 20mg|
336679|NCT01629199|Drug|rhEGF(recombinant human Epidermal Growth Factor)|
336680|NCT01629199|Drug|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
336681|NCT01629186|Other|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) <5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) <80 beats/min or oxygen saturation (SpO2) <85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
336682|NCT01629173|Procedure|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
336683|NCT01629173|Procedure|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
336684|NCT01629173|Procedure|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
336685|NCT01629173|Procedure|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
336686|NCT01629147|Dietary Supplement|Biogaia|5 drops containing Lactobacillus reuteri Protectis
336687|NCT01629147|Other|Placebo|5 drops
336688|NCT01629134|Device|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
336689|NCT01629121|Behavioral|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.~The proper way to fit the bicycle helmet was demonstrated."
336690|NCT01629082|Drug|Clofarabine|
336691|NCT01629082|Drug|Lenalidomide|
336692|NCT01629069|Behavioral|Mindfulness based Resilience Training|6 weekly group sessions
336693|NCT01629056|Procedure|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
336694|NCT01629056|Procedure|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
336695|NCT01629004|Other|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
336696|NCT01629004|Other|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
336697|NCT01628991|Behavioral|behavioural program|interventional behavioural program
336698|NCT01628991|Device|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
336699|NCT01628978|Other|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
336700|NCT01628978|Other|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
336705|NCT01628939|Other|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
336706|NCT01628926|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
336707|NCT01628926|Drug|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
336708|NCT01628926|Drug|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
336709|NCT01628913|Drug|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
336710|NCT01628913|Drug|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
336711|NCT01628900|Other|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
336712|NCT01628900|Other|Care management|Hospital vs home
336713|NCT01628887|Other|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
336714|NCT01628874|Device|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
336715|NCT01628874|Drug|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
336716|NCT01628874|Drug|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
336717|NCT01628861|Device|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
336718|NCT01628861|Behavioral|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
336719|NCT01628848|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
336720|NCT01628848|Drug|Placebo|Placebo transdermal patch
336721|NCT01628835|Behavioral|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
336722|NCT01628835|Behavioral|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
336723|NCT01628822|Behavioral|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
336724|NCT01628822|Behavioral|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
336725|NCT01628809|Behavioral|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
336726|NCT01628796|Other|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
336727|NCT01628783|Drug|escitalopram 10 mg|orally once daily
336728|NCT01628783|Drug|Placebo|once daily
336729|NCT01628770|Drug|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
336730|NCT01628770|Drug|Ferrous sulphate|200mg twice daily
336731|NCT01628731|Drug|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
336732|NCT01628731|Drug|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
336733|NCT01628718|Behavioral|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
336734|NCT01628718|Behavioral|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
336735|NCT01628705|Other|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat <7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
336736|NCT01628705|Dietary Supplement|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
336737|NCT01628692|Drug|Daclatasvir|Tablets, oral, 30 mg, once daily
336738|NCT01628692|Drug|Simeprevir|Capsule, oral, 150 mg, once daily
336739|NCT01628692|Drug|Ribavirin|Tablets, oral, 500-600 mg, twice daily
336740|NCT01628679|Behavioral|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
336741|NCT01628666|Drug|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
336742|NCT01628666|Drug|Conventional|Cefazolin preoperative
336743|NCT01628653|Device|U-SMART|4-weeks' training
336744|NCT01628640|Other|Laboratory Biomarker Analysis|Correlative studies
336745|NCT01628640|Other|Pharmacological Study|Correlative studies
336746|NCT01628640|Biological|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
336747|NCT01628627|Device|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly ~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
336748|NCT01628627|Device|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
336749|NCT01628614|Other|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
336750|NCT01628601|Drug|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
336751|NCT01628588|Drug|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
336752|NCT01628575|Procedure|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
336753|NCT01628562|Drug|Esmolol|Esmolol 50 mcg/kg/min
336754|NCT01628562|Drug|Remifentanil|Remifentanil 0.5 mcg/kg/min
336755|NCT01628549|Drug|50 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
336756|NCT01628549|Drug|Placebo|Dose-matched Placebo capsule administered as an oral capsule(s) once daily
336757|NCT01628549|Drug|100 mg P005672-HCl|P005672-HCl administered as an oral capsule(s) once daily
336758|NCT01628536|Dietary Supplement|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
336759|NCT01628523|Other|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
336760|NCT01628510|Device|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
336761|NCT01628510|Other|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
336762|NCT01628484|Other|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
336763|NCT01628484|Other|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
336764|NCT01628484|Other|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
336765|NCT01628471|Drug|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
336766|NCT01628458|Procedure|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
336767|NCT01628445|Drug|liraglutide|liraglutide titrated to 1.8 mg sc daily
336768|NCT01628445|Drug|placebo injection|placebo injected sc daily volume equal to active comparator
336769|NCT01628432|Procedure|conservative hysterectomy I|conservative hysterectomy for benign disease
336770|NCT01628432|Procedure|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
336771|NCT01628419|Behavioral|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.~Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
336772|NCT01628406|Procedure|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
336773|NCT01628393|Drug|RPC1063|oral, low dose, daily for 24 weeks
336774|NCT01628393|Drug|placebo|oral, 1 capsule, daily for 24 weeks
336775|NCT01628393|Drug|RPC1063|oral, high dose, daily for 24 weeks
336776|NCT01628380|Procedure|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).~HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
336777|NCT01628380|Procedure|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
336852|NCT01627756|Other|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
336778|NCT01628367|Procedure|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
336779|NCT01628367|Device|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
336780|NCT01628367|Biological|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
336781|NCT01628367|Biological|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
336782|NCT01628367|Biological|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
336783|NCT01628367|Drug|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
336784|NCT01628354|Drug|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of >5 letters or increase in retinal thickness of >100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
336785|NCT01628341|Drug|insulin|Patients will be asked to complete 2 self-assessment questionnaires
336786|NCT01628315|Device|MRI|Annual MRIs as part of participation in the ASA study.
336787|NCT01628302|Behavioral|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
336788|NCT01628289|Other|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
336789|NCT01628289|Other|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
336790|NCT01628276|Behavioral|Cog Rehab|Cognitive rehab for MS patients
336791|NCT01628263|Other|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
336792|NCT01628250|Procedure|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
336793|NCT01628250|Procedure|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
336794|NCT01628237|Device|comparison of spinal cord stimulation|
336795|NCT01628211|Procedure|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
336796|NCT01628211|Procedure|peritonectomy|for patients with PCI < 20
336797|NCT01628211|Drug|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI < 20
336798|NCT01628211|Drug|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI < 20
336799|NCT01628211|Drug|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI < 20
336800|NCT01628211|Drug|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI > 20
336801|NCT01628198|Device|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.~There are 2 devices that can be used---this is optional, based on physician preference:~Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California~or~Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
336802|NCT01628185|Procedure|Repositioning|pain assessment at baseline then following routine care repositioning in bed
336803|NCT01628172|Device|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
336804|NCT01628159|Device|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
336805|NCT01628146|Device|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
336806|NCT01628133|Procedure|ultrasound|sonographic evaluation of intestinal blood flow
336807|NCT01628120|Biological|Epoetin Hospira|Subcutaneous(SC) injection
336808|NCT01628107|Biological|Epoetin Hospira|Intravenous (IV) injection
336809|NCT01628094|Drug|RO5024048|
336810|NCT01628094|Drug|RO5190591|
336811|NCT01628094|Drug|RO5466731|
336812|NCT01628094|Drug|ribavirin [Copegus]|
336813|NCT01628094|Drug|ritonavir|
336814|NCT01628081|Dietary Supplement|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
336815|NCT01628081|Dietary Supplement|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups~Daily oral administration of:~Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).~Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
336816|NCT01628068|Device|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
336817|NCT01628055|Biological|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (~3-4 hours depending on weight).
336818|NCT01628055|Other|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).~It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.~The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
336819|NCT01628042|Drug|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
336820|NCT01628029|Device|Litebook|Either light therapy or placebo light over 30 minutes within 2 hours of waking for 14 days.
336821|NCT01628029|Drug|Melatonin|20 mg by mouth at bed time.
336822|NCT01628029|Drug|Methylphenidate|5 mg by mouth twice daily.
336823|NCT01628029|Drug|Placebo|One placebo capsule orally twice a day before 3 PM, and/or one placebo capsule at bedtime.
336824|NCT01628029|Behavioral|Counseling Sessions|Counseling session with a counselor lasting about 30 minutes, either in person or by phone on Days 8 and 15 only.
336825|NCT01628029|Behavioral|Questionnaires|Symptom and emotional well-being questionnaires completed on Days 1, 3, 8, 15, and 29.
336826|NCT01628029|Behavioral|Study Diaries|Completion of diaries at the end of each day of the 14-day study period, explaining how much light received from Litebook, and a pill diary about medication.
336827|NCT01628016|Behavioral|a word dot-probe task for training procedure|In the word dot-probe task for training procedure of attention bias modification, 90% of the targets appeared at the neutral word position and 10% at the sad word position.In the placebo condition, the targets appeared with equal probability in the sad (50%) and neutral (50%) word positions.All participants in ABM and placebo conditions received eight 12-min training sessions over a 2-week period.During each session, participants completed 216 word dot-probe trials.
336828|NCT01628003|Device|Brain MRI|Brain MRI
336829|NCT01628003|Device|MRI|Physical examination Neuropsychological testing Questionnaires
336830|NCT01627977|Other|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
336831|NCT01627951|Other|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
336832|NCT01627951|Other|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
336833|NCT01627951|Other|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
336834|NCT01627938|Drug|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
336835|NCT01627938|Drug|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
336836|NCT01627925|Device|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
336837|NCT01627912|Other|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink [white wine or red wine or 12.5% ethanol or water]/kg of individual, parallel with a standardized meal.
336838|NCT01627899|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
336839|NCT01627886|Drug|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
336840|NCT01627873|Drug|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
336841|NCT01627873|Drug|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
336842|NCT01627860|Drug|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
336843|NCT01627860|Drug|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
336844|NCT01627847|Drug|Ropinirole|
336845|NCT01627834|Drug|Ropinirole|
336846|NCT01627821|Device|Jarvik 2000 VAS|Jarvik 2000 LVAD
336847|NCT01627821|Device|HeartMate II|HeartMate II LVAD
336848|NCT01627795|Drug|Oshadi D and Oshadi R|anti cancer agents
336849|NCT01627782|Drug|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
336850|NCT01627782|Drug|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
336851|NCT01627756|Other|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
336853|NCT01627730|Other|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
336854|NCT01627717|Drug|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
336855|NCT01627717|Drug|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
336856|NCT01627704|Drug|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
336857|NCT01627691|Device|Lotus Valve System|"bioprosthetic bovine pericardial aortic valve~delivery system"
336858|NCT01627678|Drug|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
336859|NCT01627678|Drug|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
336860|NCT01627665|Drug|D->R->C+R|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
336861|NCT01627665|Drug|D->R->C+D|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
336862|NCT01627665|Drug|R->D->C+D|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
336863|NCT01627665|Drug|R->D->C+R|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
336864|NCT01627652|Other|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
336865|NCT01627639|Drug|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
336866|NCT01627639|Drug|Placebo|Placebo
336867|NCT01627626|Drug|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.~subjects were instructed to mouthwash with 10ml of solution for 1 minute."
336868|NCT01627626|Drug|saline|0.9% saline solution
336869|NCT01627613|Drug|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
336870|NCT01627613|Drug|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
336871|NCT01627587|Drug|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
336872|NCT01627587|Drug|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
336873|NCT01627587|Drug|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
336874|NCT01627587|Drug|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
336875|NCT01627587|Drug|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
336876|NCT01627574|Behavioral|Motivational Intervention|There are two, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, and at 3 month follow-up.
336877|NCT01627574|Behavioral|Didactic Educational Intervention|There are two, 45-60 minute didactic sessions designed to provide information and awareness for sexual health involving contraception and STI prevention. The first session occurs after enrollment in the study, the second at 3 month follow-up.
336878|NCT01627561|Biological|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6 in the HPV_2D and HPV_2D CO Groups 3 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0, Month 1 and Month 6 in the HPV_3D Group
336879|NCT01627561|Biological|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Day 0
336880|NCT01627561|Biological|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Month 6
336881|NCT01627548|Behavioral|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
336882|NCT01627535|Other|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
336883|NCT01627522|Procedure|TURP|Transurthral resection of prostate
336884|NCT01627483|Other|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
336885|NCT01627470|Device|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
336886|NCT01627457|Device|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
336887|NCT01627444|Procedure|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
336888|NCT01627431|Drug|Acetylsalicylic acid|100 mg once per day
336889|NCT01627431|Drug|Clopidogrel|75 mg once per day
336890|NCT01627418|Behavioral|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
336891|NCT01627418|Behavioral|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
336892|NCT01627392|Behavioral|Smoking abstinence|6 hour smoking abstinence
336893|NCT01627379|Drug|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
342977|NCT01579279|Drug|ABT-652 12 mg|12 mg capsules
336894|NCT01627379|Drug|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.~Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.~Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
336895|NCT01627366|Other|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
336896|NCT01627353|Procedure|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
336897|NCT01627353|Procedure|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.~The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
336898|NCT01627340|Biological|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
336899|NCT01627327|Drug|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
336900|NCT01627327|Drug|tiotropium bromide 18mcg|inhalation powder
336901|NCT01627314|Biological|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
336902|NCT01627314|Biological|Untreated CB|Cord Blood
336903|NCT01627301|Device|Device-Guided Breathing using the RESPeRATE device|15 minutes of device-guided breathing daily for 8 weeks
336904|NCT01627288|Radiation|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
336905|NCT01627275|Biological|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
336906|NCT01627262|Drug|Mesalamine|3x1000mg mesalamine granules per day
336907|NCT01627262|Drug|Placebo|3x1000mg placebo granules per day
336908|NCT01627249|Drug|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
336909|NCT01627249|Drug|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
336910|NCT01627249|Drug|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
336911|NCT01627236|Drug|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
336912|NCT01627223|Drug|Lamivudine|"Lamivudine 100 mg p.o. q.d.~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
336913|NCT01627223|Drug|Entecavir|"•Entecavir 0.5 mg p.o. q.d~This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
336914|NCT01627197|Procedure|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
336915|NCT01627184|Device|Dexcom G4 CGM System|
336916|NCT01627171|Drug|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
336917|NCT01627171|Drug|Polyethelene Glycol|280g reconstituted in 4 liters of water
336918|NCT01627171|Drug|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
336919|NCT01627158|Drug|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
336920|NCT01627158|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler
336921|NCT01627158|Drug|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
336922|NCT01627158|Drug|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
336923|NCT01627145|Drug|Solifenacin|Solifenacin 5 mg qd,
336924|NCT01627132|Drug|Dasatinib|100mg QD
336925|NCT01627106|Drug|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
336926|NCT01627106|Drug|Amiodarone|Administered IV as per product label
336927|NCT01627093|Other|Chart Review|Both retrospective and prospective patient charts reviewed to determine pretreatment characteristics, time to progression and overall survival of patients.
336928|NCT01627093|Behavioral|Questionnaires|Completion of 5 questionnaires before treatment begins, at each visit during treatment, and again at all follow-up visits. It should take about 30 minutes to complete the questionnaires each time.
336969|NCT01626872|Drug|Risperidone|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
336929|NCT01627080|Other|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
336930|NCT01627067|Drug|Everolimus|10 mg by mouth once daily.
336931|NCT01627067|Drug|Exemestane|25 mg by mouth once daily.
336932|NCT01627067|Drug|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
336933|NCT01627054|Drug|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
336934|NCT01627041|Drug|Cytarabine|Given IV
336935|NCT01627041|Drug|Daunorubicin Hydrochloride|Given IV
336936|NCT01627041|Drug|Decitabine|Given IV
336937|NCT01627041|Other|Laboratory Biomarker Analysis|Correlative studies
336938|NCT01627041|Other|Pharmacological Study|Correlative studies
336939|NCT01627028|Procedure|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
336940|NCT01627015|Other|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
336941|NCT01627015|Other|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
336942|NCT01627002|Biological|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
336943|NCT01627002|Other|Placebo|Subcutaneous
336944|NCT01626989|Device|BiPAP auto Advanced|Auto Servo Ventilation Device
336945|NCT01626989|Device|BiPAP auto SV4|Auto Servo Ventilation Device
336946|NCT01626976|Drug|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
336947|NCT01626976|Drug|Placebo|Solution, single dose
336948|NCT01626976|Drug|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
336949|NCT01626976|Drug|Placebo|suspension, single dose
336950|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
336951|NCT01626976|Drug|Placebo|suspension, single dose
336952|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
336953|NCT01626976|Drug|Placebo|suspension, single dose
336954|NCT01626976|Drug|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
336955|NCT01626976|Drug|Placebo|suspension, single dose
336956|NCT01626963|Procedure|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
336957|NCT01626963|Procedure|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
336958|NCT01626937|Other|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
336959|NCT01626937|Other|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
336960|NCT01626924|Drug|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
336961|NCT01626911|Procedure|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
336962|NCT01626911|Other|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
336963|NCT01626898|Behavioral|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
336964|NCT01626898|Behavioral|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
336965|NCT01626885|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for four weeks, then flexible dose of MP-214
336966|NCT01626872|Drug|MP-214 low dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
336967|NCT01626872|Drug|MP-214 middle dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
336968|NCT01626872|Drug|MP-214 high dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
337077|NCT01625936|Drug|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
336970|NCT01626859|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for twelve weeks.
336971|NCT01626859|Drug|MP-214 middle dose|Patients who meet eligibility criteria will be administered a once daily oral middle dose of MP-214 for twelve weeks.
336972|NCT01626859|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for twelve weeks.
336973|NCT01626833|Drug|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
336974|NCT01626833|Biological|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
336975|NCT01626820|Biological|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
336976|NCT01626807|Behavioral|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
336977|NCT01626794|Biological|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
336978|NCT01626794|Biological|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
336979|NCT01626794|Biological|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
336980|NCT01626781|Device|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
336981|NCT01626781|Other|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
336982|NCT01626755|Procedure|Sciatic name block|Ultrasound-guided sciatic nerve block.
336983|NCT01626742|Other|Ready to Drink Flavored Beverage|2 servings a day
336984|NCT01626742|Other|Ready to drink flavored beverage w/ AN 777|2 servings a day
336985|NCT01626729|Behavioral|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
336986|NCT01626729|Behavioral|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
336987|NCT01626729|Behavioral|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
336988|NCT01626729|Behavioral|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
336989|NCT01626729|Behavioral|No label control group|No label control group
336990|NCT01626716|Other|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
336991|NCT01626703|Other|Reminding call|
336992|NCT01626690|Device|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
336993|NCT01626690|Device|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
336994|NCT01626677|Biological|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
336995|NCT01626677|Procedure|Microfracture|Active control
336996|NCT01626664|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
336997|NCT01626664|Drug|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
336998|NCT01626664|Drug|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
336999|NCT01626664|Drug|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
337000|NCT01626651|Drug|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
337001|NCT01626651|Drug|Ketoconazole|Ketoconazole (400 mg [2 x 200 mg] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
337002|NCT01626638|Procedure|Confocal Micro Endoscopy|
337003|NCT01626625|Drug|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
337004|NCT01626625|Other|autograft taken from iliac crest|patient will be transplanted with autograft
337005|NCT01626612|Procedure|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
337006|NCT01626612|Procedure|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
337078|NCT01625936|Drug|Bevacizumab|
337079|NCT01625923|Drug|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD < 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
337531|NCT01622179|Procedure|sewed indirectly|The epitenon was repaired and sewed indirectly.
337007|NCT01626599|Device|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~is not implantable and no surgical procedure is required for a human subject to use the devices;~is not for use in supporting or sustaining a human life; and~is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
337008|NCT01626586|Behavioral|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
337009|NCT01626573|Drug|Itacitinib|
337010|NCT01626573|Drug|Itacitinib Placebo|
337011|NCT01626560|Drug|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
337012|NCT01626560|Drug|Vancomycin|Vancomycin 1g q12h 10 - 14 days
337013|NCT01626534|Drug|Clopidogrel|600mg loading dose then 75mg/day
337014|NCT01626534|Drug|trigagrelor|180 mg loading dose then 90 mg Twice a day
337015|NCT01626521|Other|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
337016|NCT01626495|Biological|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
337017|NCT01626482|Other|Kinesio Taping|"The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12."
337018|NCT01626482|Other|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
337019|NCT01626469|Drug|Captopril|25mg Captopril
337020|NCT01626469|Drug|placebo|placebo
337021|NCT01626456|Drug|ALKS 9072, Low|IM injection, given monthly
337022|NCT01626456|Drug|ALKS 9072, High|IM injection, given monthly
337023|NCT01626443|Dietary Supplement|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
337024|NCT01626443|Dietary Supplement|Folic acid|Folic acid (200 mcg); 2 x die
337025|NCT01626430|Dietary Supplement|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
337026|NCT01626430|Dietary Supplement|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
337027|NCT01626417|Device|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
337028|NCT01626391|Drug|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
337029|NCT01626391|Drug|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
337030|NCT01626378|Drug|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
337031|NCT01626378|Drug|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
337032|NCT01626365|Procedure|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
337033|NCT01626365|Procedure|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
337034|NCT01626352|Drug|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m^2 Days 1 and 2 of Cycles 1 through 6.
337035|NCT01626352|Drug|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
337036|NCT01626339|Drug|Intravitreal Ranibizumab|
337037|NCT01626339|Drug|Intravitreal bevacizumab|
337038|NCT01626326|Behavioral|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
337039|NCT01626313|Behavioral|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
337040|NCT01626287|Other|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
337041|NCT01626287|Other|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
337042|NCT01626274|Device|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
337043|NCT01626261|Device|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
337044|NCT01626222|Drug|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
337080|NCT01625910|Behavioral|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
337081|NCT01625897|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for four weeks, then flexible dose of MP-214
337045|NCT01626222|Drug|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
337046|NCT01626209|Drug|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
337047|NCT01626196|Other|No intervention|This was an observational study
337048|NCT01626183|Genetic|RNA analysis|
337049|NCT01626183|Genetic|proteomic profiling|
337050|NCT01626183|Other|laboratory biomarker analysis|
337051|NCT01626170|Other|laboratory biomarker analysis|Correlative studies
337052|NCT01626131|Behavioral|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (~60-75 min total per session) weekly for 8 consecutive weeks.~Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.~Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
337053|NCT01626131|Behavioral|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
337054|NCT01626118|Drug|Indomethacin|capsules, 40 mg, TID
337055|NCT01626118|Drug|Indomethacin|capsules, 40 mg, BID
337056|NCT01626118|Drug|Indomethacin|capsules, 20 mg, TID
337057|NCT01626118|Drug|Placebo|capsules
337058|NCT01626092|Drug|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
337059|NCT01626092|Drug|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,~-8, -7, -6, and -5."
337060|NCT01626092|Drug|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
337061|NCT01626092|Radiation|Total Body Irradiation with Marrow Boosting|"Dose to total body 200 cGy in single dose~Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
337062|NCT01626092|Biological|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
337063|NCT01626092|Drug|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
337064|NCT01626092|Drug|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
337065|NCT01626079|Device|MitraClip System|Percutaneous mitral valve repair using MitraClip System
337066|NCT01626066|Drug|LUM015|LUM015 assigned dose given once by IV push
337067|NCT01626053|Behavioral|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
337068|NCT01626053|Other|Control Group|no intervention
337069|NCT01626040|Drug|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
337070|NCT01626014|Behavioral|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
337071|NCT01626014|Behavioral|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
337072|NCT01626001|Procedure|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
337073|NCT01625988|Drug|LY2951742|Administered subcutaneously once every other week for 12 weeks
337074|NCT01625988|Drug|Placebo|Administered subcutaneously once every other week for 12 weeks
337075|NCT01625949|Procedure|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
337076|NCT01625949|Procedure|coronary dilatation and stenting|coronary dilatation and stenting
337082|NCT01625897|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for four weeks, then flexible dose of MP-214
337083|NCT01625897|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral dose of risperidone for two weeks, then flexible dose of risperidone
337084|NCT01625871|Drug|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
337085|NCT01625845|Drug|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
337086|NCT01625845|Other|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
337087|NCT01625845|Behavioral|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
337088|NCT01625832|Procedure|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
337089|NCT01625819|Behavioral|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
337090|NCT01625819|Behavioral|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
337091|NCT01625819|Behavioral|Health Education|32 1-hour bi-weekly group sessions of health education
337092|NCT01625806|Drug|RO4602522|Single oral dose
337093|NCT01625806|Drug|ketoconazole|Multiple oral doses
337094|NCT01625793|Drug|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
337095|NCT01625780|Procedure|3-layer block|"0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle."
337096|NCT01625780|Procedure|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
337097|NCT01625767|Behavioral|AAT experiment|Smokers and nonsmokers complete AAT experiment
337098|NCT01625754|Behavioral|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
337099|NCT01625741|Drug|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
337100|NCT01625715|Drug|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
337101|NCT01625702|Device|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).~Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.~Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
337102|NCT01625689|Biological|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
337103|NCT01625689|Biological|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
337104|NCT01625676|Other|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
337105|NCT01625676|Other|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
337106|NCT01625637|Behavioral|AAT-experiment|This AAT condition trains kids to avoid cigarettes
337107|NCT01625637|Behavioral|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
337108|NCT01625624|Other|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
337109|NCT01625624|Other|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
337110|NCT01625611|Drug|Naltrexone|Naltrexone 100 mg titrated over one week
337111|NCT01625598|Procedure|Photography of the retina|Every subject will undergo photography of the retina in both eyes
337112|NCT01625598|Procedure|Retinal photography|"Device~Subjects will have photography of both eyes"
337113|NCT01625572|Procedure|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
337114|NCT01625572|Procedure|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
337115|NCT01625559|Biological|MA09-hRPE|MA09-hRPE: 50,000 cells
337116|NCT01625546|Device|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
337191|NCT01625026|Drug|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
337117|NCT01625533|Procedure|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
337118|NCT01625533|Procedure|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
337119|NCT01625520|Drug|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
337120|NCT01625507|Behavioral|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
337121|NCT01625494|Drug|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
337122|NCT01625494|Drug|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
337123|NCT01625494|Drug|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
337124|NCT01625494|Drug|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
337125|NCT01625481|Device|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
337126|NCT01625468|Behavioral|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
337127|NCT01625455|Drug|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
337128|NCT01625455|Drug|Placebo|Placebo will be given orally for a total of 7 days.
337129|NCT01625442|Drug|Saffron tablet|Saffron tablets 100 mg
337130|NCT01625442|Drug|Barberry tablet|Barberry tablets 200 mg
337131|NCT01625442|Drug|Placebo|Placebo tablets received daily for 45 days
337132|NCT01625429|Drug|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
337133|NCT01625416|Behavioral|Stepped Care Management|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the 3-6 month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-6 months.
337134|NCT01625403|Drug|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
337135|NCT01625403|Drug|standard of care|standard of care for heart failure
337136|NCT01625390|Drug|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
337137|NCT01625390|Drug|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
337138|NCT01625390|Drug|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
337139|NCT01625377|Drug|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
337140|NCT01625377|Drug|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
337141|NCT01625377|Drug|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
337142|NCT01625377|Drug|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
337143|NCT01625377|Drug|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
337144|NCT01625364|Behavioral|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
337145|NCT01625364|Behavioral|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
337146|NCT01625351|Drug|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
337147|NCT01625351|Drug|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
337148|NCT01625351|Drug|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)~Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
337149|NCT01625351|Drug|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
337150|NCT01625351|Drug|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
337151|NCT01625351|Biological|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
337152|NCT01625351|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
337153|NCT01625338|Drug|SOF|SOF 400 mg tablet administered orally once daily
337154|NCT01625338|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
337155|NCT01625338|Drug|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
337156|NCT01625299|Dietary Supplement|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
337157|NCT01625299|Dietary Supplement|Placebo|Rice flour 1.0 g/kg/day
337192|NCT01625026|Drug|Placebo|Placebo to obeticholic acid
337158|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
337159|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
337160|NCT01625286|Drug|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
337161|NCT01625286|Drug|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
337162|NCT01625273|Other|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10^8 CFU per day from 28 days to 6 months of infant age
337163|NCT01625260|Biological|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
337164|NCT01625260|Drug|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
337165|NCT01625247|Procedure|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
337166|NCT01625234|Drug|X-396 (ensartinib)|Oral, ALK inhibitor
337167|NCT01625221|Device|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
337168|NCT01625208|Procedure|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
337169|NCT01625208|Procedure|Supraclavicular block|Standard supraclavicular brachial plexus block
337170|NCT01625195|Dietary Supplement|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
337171|NCT01625195|Dietary Supplement|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide
337172|NCT01625182|Drug|Fingolimod|Fingolimod 0.5 mg capsules
337173|NCT01625182|Drug|Placebo Comparator|Matching placebo capsules
337174|NCT01625169|Drug|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
337175|NCT01625156|Other|Laboratory Biomarker Analysis|Correlative studies
337176|NCT01625156|Other|Pharmacological Study|Correlative studies
337177|NCT01625156|Drug|Temsirolimus|Given IV
337178|NCT01625156|Drug|Tivantinib|Given PO
337179|NCT01625143|Other|laboratory biomarker analysis|Correlative studies
337180|NCT01625130|Dietary Supplement|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
337181|NCT01625130|Dietary Supplement|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
337182|NCT01625117|Behavioral|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
337183|NCT01625104|Other|Non Intervention|Business as usual
337184|NCT01625104|Other|Agressive Intervention Process Improvement Strategies|
337185|NCT01625091|Drug|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
337186|NCT01625091|Drug|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
337187|NCT01625078|Device|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
337188|NCT01625052|Device|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
337189|NCT01625039|Behavioral|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
337190|NCT01625039|Behavioral|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
337193|NCT01625013|Device|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
337194|NCT01625000|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for six weeks.
337195|NCT01625000|Drug|MP-214 middle dose|Patients who meet eligibility criteria will be administered a once daily oral middle dose of MP-214 for six weeks.
337196|NCT01625000|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for six weeks.
337197|NCT01625000|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral dose of risperidone for six weeks.
337198|NCT01625000|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
337199|NCT01624987|Behavioral|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
337200|NCT01624987|Other|Control group|The control group receives no intervention.
337201|NCT01624974|Drug|MK-1029|MK-1029 150 mg tablets taken QD
337202|NCT01624974|Drug|Placebo|Placebo tablets (matching the MK-1029 150 mg tablets) QD
337203|NCT01624974|Drug|Montelukast (ML)|ML 10 mg tablets QD
337204|NCT01624961|Biological|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
337205|NCT01624948|Drug|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
337206|NCT01624948|Drug|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
337207|NCT01624935|Behavioral|interpersonal psychotherapy|interpersonal psychotherapy
337208|NCT01624857|Drug|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
337209|NCT01624857|Drug|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
337210|NCT01624844|Other|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
337211|NCT01624818|Behavioral|Cardiac habilitation program|physical activity three weeks
337212|NCT01624805|Biological|Anti-Thymocyte Globulin|Given IV
337213|NCT01624805|Drug|Cyclosporine|Given PO
337214|NCT01624805|Biological|Filgrastim|Given SC
337215|NCT01624805|Drug|Methylprednisolone|Given IV or PO
337216|NCT01624805|Biological|Pegfilgrastim|Given SC
337217|NCT01624792|Dietary Supplement|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
337218|NCT01624792|Dietary Supplement|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
337219|NCT01624792|Dietary Supplement|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
337220|NCT01624779|Drug|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1&2
337221|NCT01624766|Biological|Anakinra|Given SC
337222|NCT01624766|Biological|Denosumab|Given SC
337223|NCT01624766|Drug|Everolimus|Given PO
337224|NCT01624753|Device|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
337225|NCT01624740|Device|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
337226|NCT01624740|Device|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
337227|NCT01624727|Dietary Supplement|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
337228|NCT01624714|Drug|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
337229|NCT01624714|Drug|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
337230|NCT01624701|Other|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
337231|NCT01624688|Procedure|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
337272|NCT01624350|Device|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
337273|NCT01624337|Drug|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
337232|NCT01624675|Drug|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
337233|NCT01624675|Drug|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
337234|NCT01624662|Drug|Fluticasone propionate|Delivered via Optinose Exhalation Delivery System
337235|NCT01624649|Drug|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
337236|NCT01624649|Drug|Atomoxetine|Form = tablet, route = oral;
337237|NCT01624636|Drug|Placebo|
337238|NCT01624636|Drug|LFG316|
337239|NCT01624636|Drug|LFG316|
337240|NCT01624610|Other|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
337241|NCT01624597|Behavioral|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
337242|NCT01624597|Behavioral|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
337243|NCT01624584|Behavioral|Experimental treatment|six sessions of child anxiety treatment
337244|NCT01624584|Behavioral|Traditional Treatment|six sessions of treatment consistent with current practice
337245|NCT01624571|Drug|LD02GIFRO|comparison of different dosages of drug
337246|NCT01624558|Device|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
337247|NCT01624545|Other|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
337248|NCT01624532|Biological|rPA vaccine containing alhydrogel 1.0 mL|rPA vaccine containing alhydrogel 1.0 mL
337249|NCT01624532|Drug|Normal Saline|Normal Saline 0.5mL
337250|NCT01624532|Biological|rPA vaccine containing alhydrogel 0.5 mL|rPA vaccine containing alhydrogel 0.5 mL
337251|NCT01624532|Biological|rPA vaccine containing alhydrogel 0.3 mL|rPA vaccine containing alhydrogel 0.3 mL
337252|NCT01624519|Procedure|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
337253|NCT01624493|Drug|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
337254|NCT01624493|Drug|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
337255|NCT01624493|Drug|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
337256|NCT01624493|Drug|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
337257|NCT01624493|Drug|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
337258|NCT01624480|Drug|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
337259|NCT01624467|Biological|Necitumumab|800 mg necitumumab, administered once per week IV
337260|NCT01624454|Other|Laxabon|4 l PEG solution split dose cleansing
337261|NCT01624454|Other|CitraFleet|Small volume osmotic bowelcleansing
337262|NCT01624441|Drug|Dinaciclib|Given IV
337263|NCT01624441|Drug|Epirubicin Hydrochloride|Given IV
337264|NCT01624441|Other|Laboratory Biomarker Analysis|Correlative studies
337265|NCT01624428|Drug|Varenicline|1 mg bid varenicline titrated over a 2 week period
337266|NCT01624428|Drug|Placebo|1 mg bid placebo titrated over a 2 week period
337267|NCT01624402|Behavioral|Education on Stroke and Depression (ESD)|"Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.~Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.~Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.~ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
337268|NCT01624402|Behavioral|Ecosystem Focused Therapy (EFT)|"EFT offers an action-oriented, new perspective about the subject's recovery;~It provides an adherence enhancement structure;~It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;~It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;~It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
337269|NCT01624389|Drug|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
337270|NCT01624376|Drug|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
337271|NCT01624376|Drug|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
337274|NCT01624337|Drug|placebo|
337275|NCT01624311|Other|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
337276|NCT01624311|Other|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
337277|NCT01624298|Behavioral|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
337278|NCT01624285|Drug|sorafenib tosylate|Given PO
337279|NCT01624285|Other|placebo|Given PO
337280|NCT01624285|Other|laboratory biomarker analysis|Correlative studies
337281|NCT01624272|Device|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
337282|NCT01624272|Other|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
337283|NCT01624259|Drug|LY2189265|Administered SC
337284|NCT01624259|Drug|Liraglutide|Administered SC
337285|NCT01624259|Drug|Metformin|
337286|NCT01624246|Drug|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil [600 mg] plus avibactam [600 mg]) infused over 60 (± 5) minutes.
337287|NCT01624233|Drug|80 mg ixekizumab|Administered SC
337288|NCT01624220|Radiation|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
337289|NCT01624220|Radiation|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
337290|NCT01624220|Procedure|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
337291|NCT01624220|Behavioral|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
337292|NCT01624207|Drug|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
337293|NCT01624207|Drug|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
337294|NCT01624194|Drug|Oxytocin nasal spray|24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.
337295|NCT01624194|Drug|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
337296|NCT01624168|Behavioral|Anxiety Management Education|written materials on management of anxiety for self-study
337297|NCT01624168|Behavioral|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
337298|NCT01624168|Behavioral|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
337299|NCT01624155|Behavioral|Education|EMR referral to teratogen and contraception counseling
337300|NCT01624142|Biological|Evolocumab|Evolocumab was administered by subcutaneous injection either once a month (QM) or once every two weeks (Q2W).
337301|NCT01624129|Drug|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
337302|NCT01624116|Drug|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
337303|NCT01624116|Other|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
337304|NCT01624116|Drug|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
337305|NCT01624116|Drug|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
337306|NCT01624116|Drug|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
337307|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
337308|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
337309|NCT01624090|Drug|Mithramycin|30 mcg/kg IV over 6 h once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
337310|NCT01624077|Biological|Regulatory T cells|Tregs will inject after liver transplantation
337311|NCT01624064|Drug|Enalapril|2.5-20 mg/day
337312|NCT01624064|Drug|Calcium Supplement|Calcium 2.5-20 mg/day
337313|NCT01624051|Other|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
337314|NCT01624051|Other|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
337532|NCT01622179|Procedure|sewed directly|The epitenon was unrepaired and sewed directly.
337315|NCT01624038|Drug|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.~Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
337316|NCT01624038|Drug|hydroxyurea, blood transfusion|Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
337317|NCT01624025|Other|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
337318|NCT01624012|Device|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
337319|NCT01624012|Device|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
337320|NCT01623986|Device|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
337321|NCT01623986|Device|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
337322|NCT01623973|Other|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
337323|NCT01623947|Dietary Supplement|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
337324|NCT01623947|Dietary Supplement|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
337325|NCT01623947|Dietary Supplement|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
337326|NCT01623921|Drug|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
337327|NCT01623921|Drug|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
337328|NCT01623921|Drug|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
337329|NCT01623921|Drug|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
337330|NCT01623908|Drug|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
337331|NCT01623869|Other|Laboratory Biomarker Analysis|Correlative studies
337332|NCT01623869|Biological|Trebananib|Given IV
337333|NCT01623856|Other|laboratory biomarker analysis|Correlative studies
337334|NCT01623843|Procedure|Arthroscopic Lavage|Lavage: inflammation debris caused from continual friction in the hip is washed out.
337335|NCT01623843|Procedure|Arthroscopic Osteochondroplasty|"Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming)."
337336|NCT01623830|Behavioral|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
337337|NCT01623817|Drug|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intraveous infusion during 2 or 3 hours.~Maintanance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
337338|NCT01623804|Device|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
337339|NCT01623804|Device|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
337340|NCT01623778|Drug|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
337341|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
337342|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
337343|NCT01623739|Procedure|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
337344|NCT01623726|Procedure|Transcranial Direct Current Stimulation (tDCS)|"Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA."
337345|NCT01623713|Drug|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
337346|NCT01623713|Drug|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
337347|NCT01623687|Device|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
337348|NCT01623687|Device|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
337349|NCT01623687|Device|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
337350|NCT01623687|Device|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson & Johnsson, USA).
337351|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
337352|NCT01623648|Other|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
337353|NCT01623648|Other|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
337354|NCT01623648|Other|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
337355|NCT01623635|Drug|Ropivacaine|"ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:~each subdiaphragmatic area 3.5 ml + 3.5ml~surgical dissection site 3 ml~diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections)."
337356|NCT01623635|Drug|placebo (normal saline)|"ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion~Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:~each subdiaphragmatic area 3.5 ml + 3.5ml~surgical dissection site 3 ml~diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.~At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections)."
337357|NCT01623622|Drug|HC-58|once or more / week
337358|NCT01623622|Drug|Placebo|once or more / week
337359|NCT01623609|Drug|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
337360|NCT01623609|Drug|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
337361|NCT01623596|Drug|Fingolimod|
337362|NCT01623596|Drug|Disease Modifying therapy|
337363|NCT01623583|Other|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:~The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch~Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
337364|NCT01623583|Other|Standard Needle Phobia Intervention|"The standard intervention will include the following components:~Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.~Basic training on relaxation breathing~Brief video of a patient overcoming needle phobia~Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
337365|NCT01623570|Drug|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
337366|NCT01623570|Drug|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
337367|NCT01623557|Biological|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
337368|NCT01623557|Biological|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
337369|NCT01623557|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
337370|NCT01623531|Drug|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
337371|NCT01623518|Biological|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;~5 x10^8 vp, 5 x10^9 vp, 2.5 x10^10 vp, 5 x10^10 vp"
337372|NCT01623505|Drug|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
337373|NCT01623505|Drug|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~*Off-label dosage approved by Health Canada via No Objection letter."
337374|NCT01623505|Drug|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
337375|NCT01623492|Other|Subjects with diagnosis of Eisenmenger Syndrome|"Antibiotic recommendation for SBE prophylaxis and influenza vaccine~Contraception counseling, and recommendations regarding avoidance of pregnancy~Documentation and prescription of the specific medications:~Oxygen~Diuretic~ASA, Anticoagulant~CCB, BB, ACEI, ARB~Iron Supplementation~Allopurinol~PAH specific therapy"
337376|NCT01623479|Drug|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
337377|NCT01623466|Drug|levonorgestrel|transdermal contraceptive delivery system
337378|NCT01623453|Biological|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
337379|NCT01623453|Biological|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
337380|NCT01623440|Combination Product|Placebo and fMRI|Pill form, participant dosed one time an hour before fMRI.
337381|NCT01623440|Combination Product|Naltrexone and fMRI|50 mg pill given one time, one hour before fMRI
337382|NCT01623427|Procedure|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
337383|NCT01623427|Procedure|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
337384|NCT01623401|Drug|TR-701 FA|TR-701 FA 200 mg once daily
337385|NCT01623388|Procedure|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
337386|NCT01623375|Drug|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
337387|NCT01623375|Drug|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
337388|NCT01623362|Other|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
337389|NCT01623362|Other|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
337390|NCT01623362|Other|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
337391|NCT01623349|Drug|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
337392|NCT01623349|Drug|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
337393|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
337394|NCT01623336|Drug|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
337395|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
337396|NCT01623323|Drug|Fluticasone Propionate|Fluticasone Propionate 400 μg
337397|NCT01623310|Drug|Fluticasone Propionate|Using Optinose Exhalation Delivery System
337398|NCT01623284|Drug|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
337399|NCT01623284|Drug|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of [18-F]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
337400|NCT01623271|Drug|Gabapentin|
337401|NCT01623232|Biological|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.~Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).~Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.~Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
337402|NCT01623232|Biological|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.~4. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
337430|NCT01622972|Drug|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
337459|NCT01622699|Other|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
337403|NCT01623219|Behavioral|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
337404|NCT01623206|Drug|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
337405|NCT01623193|Other|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
337406|NCT01623193|Procedure|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
337407|NCT01623180|Device|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
337408|NCT01623180|Device|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
337409|NCT01623167|Drug|hATG/CsA /eltrombopag -Cohort 1|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 6
337410|NCT01623167|Drug|hATG/CsA /eltrombopag Cohort 2|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months, eltrombopag (experimental) administered Day 14 to month 3
337411|NCT01623167|Drug|hATG/CsA /eltrombopag Cohort 3|hATG (standard of care) administered for 4 days, CsA (standard of care) administered starting day 1 for 6 months at higher dose, then reduced dose for 18 months, eltrombopag (experimental) administered Day 1 to month 6
337412|NCT01623154|Other|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
337413|NCT01623141|Procedure|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
337414|NCT01623128|Behavioral|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
337415|NCT01623115|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
337416|NCT01623115|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
337417|NCT01623115|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
337418|NCT01623102|Drug|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
337419|NCT01623102|Drug|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
337420|NCT01623063|Procedure|Hysteroscopy|hysteroscopy with guided biopsies
337421|NCT01623050|Device|SinuSys Dilation System|Sinuplasty
337422|NCT01623037|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
337423|NCT01623024|Drug|Vitamin D|20.000 UI/week for 96 weeks
337424|NCT01623024|Behavioral|Lifestyle counseling|Lifestyle counseling for 96 weeks
337425|NCT01623011|Procedure|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
337426|NCT01623011|Procedure|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
337427|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
337428|NCT01622998|Drug|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
337429|NCT01622998|Drug|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
337460|NCT01622686|Behavioral|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
342978|NCT01579279|Drug|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
337431|NCT01622959|Procedure|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%. Treatment failure is defined as VAPS>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
337432|NCT01622946|Drug|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
337433|NCT01622946|Drug|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
337434|NCT01622933|Biological|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
337435|NCT01622933|Biological|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
337436|NCT01622920|Other|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
337437|NCT01622881|Drug|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
337438|NCT01622881|Drug|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
337439|NCT01622868|Other|Laboratory Biomarker Analysis|Correlative studies
337440|NCT01622868|Drug|Lapatinib Ditosylate|Given PO
337441|NCT01622868|Radiation|Stereotactic Radiosurgery|Undergo SRS
337442|NCT01622868|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
337443|NCT01622855|Behavioral|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
337444|NCT01622829|Procedure|"Prescription for Activity and individual instructions"|"Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator)."
337445|NCT01622829|Other|"Prescription for Activity, without instructions"|"Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week."
337446|NCT01622829|Other|usual physiotherapy|physiotherapy, treatment as usual
337447|NCT01622803|Procedure|parallel stent|bilateral parallel stent insertion (right and left side)
337448|NCT01622803|Device|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
337449|NCT01622790|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
337450|NCT01622790|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
337451|NCT01622790|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
337452|NCT01622777|Drug|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
337453|NCT01622777|Drug|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
337454|NCT01622764|Radiation|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
337455|NCT01622725|Procedure|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
337456|NCT01622725|Procedure|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
337457|NCT01622712|Device|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
337458|NCT01622699|Device|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
337493|NCT01622439|Drug|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
337530|NCT01622192|Device|Florida Probe automated probe|Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
337461|NCT01622673|Drug|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours~Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
337462|NCT01622673|Drug|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
337463|NCT01622673|Drug|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)~Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
337464|NCT01622660|Drug|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
337465|NCT01622660|Drug|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
337466|NCT01622647|Other|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
337467|NCT01622634|Behavioral|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
337468|NCT01622634|Other|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
337469|NCT01622634|Other|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
337470|NCT01622621|Procedure|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
337471|NCT01622621|Radiation|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
337472|NCT01622608|Behavioral|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
337473|NCT01622569|Drug|Fluticasone Propionate|Delivered via Optinose Exhalation Delivery System
337474|NCT01622556|Drug|Fludarabine|35 mg/m2 IV/day x 5 days
337475|NCT01622556|Drug|Busulfan|.8 mg/kg IV Q6h x 8 doses
337476|NCT01622556|Drug|Thymoglobulin|1.5 mg/kg/day x 3 days
337477|NCT01622556|Radiation|Total Body Irradiation|150 cGy for 2 days
337478|NCT01622556|Biological|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
337479|NCT01622543|Drug|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
337480|NCT01622543|Drug|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
337481|NCT01622504|Drug|MVP005|2 mg single dose administered intranasally
337482|NCT01622504|Drug|MVP005|4 mg single dose administered intranasally
337483|NCT01622504|Drug|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
337484|NCT01622478|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
337485|NCT01622478|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
337486|NCT01622478|Procedure|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
337487|NCT01622478|Procedure|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
337488|NCT01622465|Behavioral|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
337489|NCT01622465|Behavioral|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
337490|NCT01622439|Drug|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
337491|NCT01622439|Drug|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
337492|NCT01622439|Drug|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
337529|NCT01622205|Other|Ordinary rehabilitation|Ordinary rehabilitation
337494|NCT01622439|Drug|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
337495|NCT01622439|Drug|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
337496|NCT01622426|Dietary Supplement|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
337497|NCT01622426|Dietary Supplement|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
337498|NCT01622413|Procedure|joimax TESSYS|Transforaminal Endoscopic Surgery System
337499|NCT01622413|Procedure|Microdiscectomy|Standard procedure for disc surgery
337500|NCT01622400|Other|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
337501|NCT01622387|Procedure|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
337502|NCT01622387|Procedure|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
337503|NCT01622374|Behavioral|Music|Ten minutes of music or silence were applied prior to dental procedures
337504|NCT01622361|Drug|Adriamycin+Cyclophosphamide>Docetaxel|"Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2~Route: by slow intravenous bolus~Schedule: every 3weeks for 4 cycle~Docetaxel 75mg/m2~Route: intravenous as per local practice~Schedule: every 3weeks for 4 cycle"
337505|NCT01622361|Drug|GnRHa with Tamoxifen|"Goserelin(GnRHa) 3.6mg~Route: subcutaneously under the abdominal skin~Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)~Tamoxifen 20mg/day~Route: Oral~Schedule: everyday"
337506|NCT01622348|Drug|IMO-3100 at 0.16 mg/kg|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
337507|NCT01622348|Drug|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
337508|NCT01622348|Drug|IMO-3100 at 0.32 mg/kg|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
337509|NCT01622335|Drug|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
337510|NCT01622335|Other|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
337511|NCT01622322|Drug|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
337512|NCT01622322|Other|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
337513|NCT01622309|Dietary Supplement|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
337514|NCT01622309|Other|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
337515|NCT01622296|Drug|Sodium bicarbonate|8.4% neutralizing solution
337516|NCT01622296|Drug|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
337517|NCT01622283|Drug|Levocetirizine|Levocetirizine
337518|NCT01622283|Drug|Cetirizine|Cetirizine
337519|NCT01622270|Other|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
337520|NCT01622257|Device|Cavitation US|The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm^2 adjustable, 60W with 20cm^2 active surface).
337521|NCT01622257|Drug|Metformin|Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
337522|NCT01622257|Other|Cavitation US + Metformin|Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
337523|NCT01622244|Other|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
337524|NCT01622244|Other|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
337525|NCT01622244|Behavioral|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
337526|NCT01622231|Drug|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
337527|NCT01622218|Behavioral|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
337528|NCT01622205|Other|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
337533|NCT01622166|Behavioral|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
337534|NCT01622153|Procedure|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
337535|NCT01622153|Procedure|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
337536|NCT01622127|Device|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
337537|NCT01622114|Other|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
337538|NCT01622101|Dietary Supplement|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by >7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
337539|NCT01622088|Drug|Dexpramipexole|Oral tablet 150 mg given twice daily up to 36 months
337540|NCT01622075|Device|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
337541|NCT01622075|Device|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
337542|NCT01622062|Biological|PVRV|0.1 mL, 4 site 'one week' (4-4-4-0-0) administered intradermally
337543|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 4 site 'one week' (4-4-4-0-0) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
337544|NCT01622062|Biological|PVRV and pERIG Favirab®|0.1 mL of vaccine administered intradermally in 2-site TRC (2-2-2-0-2) regimen, and pERIG Favirab® (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
337545|NCT01622049|Device|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
337546|NCT01622023|Procedure|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
337547|NCT01622010|Behavioral|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
337548|NCT01622010|Other|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
337549|NCT01622010|Device|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
337550|NCT01621997|Behavioral|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.~Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
337551|NCT01621984|Other|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
337552|NCT01621971|Drug|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
337553|NCT01621971|Drug|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
337554|NCT01621958|Behavioral|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
337555|NCT01621958|Behavioral|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
337556|NCT01621945|Biological|MenBvac|Blood test
337557|NCT01621932|Procedure|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
337558|NCT01621932|Procedure|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
337599|NCT01621477|Drug|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
342979|NCT01579279|Drug|Placebo|Placebo capsules
337559|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
337560|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.~Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.~Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
337561|NCT01621893|Procedure|Subchondroplasty|
337562|NCT01621880|Drug|bevacizumab|Patients receive bevacizumab 5mg/kg intravenously over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
337563|NCT01621880|Drug|Corticosteroid|Patients in the corticosteroid group were treated with intravenous pulsed-steroid therapy: methylprednisolone 500 mg daily intravenously for three consecutive days followed by oral prednisone 60 mg for five days and gradually tapered 15mg every 5 days. When the prednisone dose reached 30mg per day, it was tapered down more slowly (tapered 5mg every week), until a maintenance dose of 10mg per day was reached. The entire intervention lasted two months. At 2 months, prednisone was stopped.
337564|NCT01621867|Drug|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
337565|NCT01621867|Drug|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
337566|NCT01621854|Drug|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
337567|NCT01621828|Other|video|a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
337568|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
337569|NCT01621815|Behavioral|Video Game|Playing various video games: RPG, Race, FPS, Strategy
337570|NCT01621802|Biological|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
337571|NCT01621802|Biological|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
337572|NCT01621802|Biological|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
337573|NCT01621802|Biological|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
337574|NCT01621789|Other|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
337575|NCT01621776|Drug|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
337576|NCT01621776|Drug|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
337577|NCT01621776|Drug|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
337578|NCT01621763|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
337579|NCT01621750|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
337580|NCT01621737|Drug|Oxytocin|42 IU BID for six weeks
337581|NCT01621737|Drug|Oxytocin|84 IU BID for six weeks
337582|NCT01621737|Drug|Placebo|Vehicle placebo
337583|NCT01621724|Genetic|WT1 TCR-transduced T cells|"Two patient cohorts:~Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells~Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
337584|NCT01621711|Behavioral|Linkage patient activation intervention|"Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.~The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist."
337585|NCT01621698|Procedure|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
337586|NCT01621698|Procedure|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
337587|NCT01621685|Biological|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
337588|NCT01621672|Drug|Revlimid|10 mg/day in the morning same time each day
337589|NCT01621659|Behavioral|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
337590|NCT01621646|Other|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
337591|NCT01621633|Drug|LCZ696|
337592|NCT01621620|Drug|Yohimbine|
337593|NCT01621581|Genetic|Convection enhanced delivery/AAV2-GDNF|Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
337594|NCT01621568|Drug|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
337595|NCT01621542|Biological|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
337596|NCT01621503|Device|NT-530P|intraocular pressure and central corneal thickness measurement
337597|NCT01621490|Biological|Nivolumab|
337598|NCT01621490|Drug|Ipilimumab|
337600|NCT01621477|Drug|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
337601|NCT01621477|Drug|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
337602|NCT01621477|Drug|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
337603|NCT01621477|Drug|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
337604|NCT01621477|Drug|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
337605|NCT01621477|Biological|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
337606|NCT01621477|Drug|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
337607|NCT01621477|Drug|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
337608|NCT01621464|Device|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
337609|NCT01621451|Drug|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
337610|NCT01621451|Drug|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.~In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
337611|NCT01621425|Other|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
337612|NCT01621425|Other|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
337613|NCT01621425|Other|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
337614|NCT01621399|Drug|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
337615|NCT01621399|Drug|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
337616|NCT01621386|Drug|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
337617|NCT01621386|Drug|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
337618|NCT01621373|Drug|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
337619|NCT01621360|Procedure|Arthroscopic hip surgery|Hip arthroscopy
337620|NCT01621360|Other|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
337621|NCT01621334|Behavioral|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
337622|NCT01621334|Behavioral|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
337623|NCT01621321|Drug|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
337624|NCT01621321|Drug|Voriconazole|Voriconazole 200 mg BD for 4 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
337625|NCT01621308|Other|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
337626|NCT01621282|Other|Education|A 6-month interactive course on critical appraisal
337627|NCT01621282|Other|Conventional|Conventional method/no intervention
337628|NCT01621269|Drug|Fingolimod|
337629|NCT01621256|Drug|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
337630|NCT01621256|Drug|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
337631|NCT01621243|Drug|nab-paclitaxel|nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
337632|NCT01621243|Drug|gemcitabine|gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
337633|NCT01621243|Drug|placebo|Placebo will be dosed daily
337634|NCT01621243|Drug|Necuparanib|Necuparanib will be dosed daily
337635|NCT01621230|Drug|epidural 0.125% bupivacaine with fentanyl 2 mcg/cc infusion|"Randomization will occur when the woman reaches 8 cm cervical dilation. Group II will receive a 100mL cassette of fentanyl 10mcg/mL (to be infused at 10mL/hr). Group I will receive a 100mL epidural cassette of 0.125% bupivacaine with fentanyl 2mcg/mL to be infused at 10mL/hr. Both groups will have the same rate of epidural infusion such that the patient, nurse, obstetrician, and anesthesia providers will be blinded to the randomized treatment group.~The patient may request a 5mL bolus from the epidural infusion every 30 minutes if pain relief is inadequate. The study regimen will continue until spontaneous delivery of the infant or until which time operative vaginal delivery or cesarean delivery is planned."
337708|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
337745|NCT01620437|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
337636|NCT01621230|Drug|fentanyl 10 mcg/cc epidural infusion|"Randomization will occur when the woman reaches 8 cm cervical dilation. Group II will receive a 100mL cassette of fentanyl 10mcg/mL (to be infused at 10mL/hr). Group I will receive a 100mL epidural cassette of 0.125% bupivacaine with fentanyl 2mcg/mL to be infused at 10mL/hr.Both groups will have the same rate of epidural infusion such that the patient, nurse, obstetrician, and anesthesia providers will be blinded to the randomized treatment group.~The patient may request a 5mL bolus from the epidural infusion every 30 minutes if pain relief is inadequate. The study regimen will continue until spontaneous delivery of the infant or until which time operative vaginal delivery or cesarean delivery is planned."
337637|NCT01621217|Drug|Cetuximab|Will be given weekly intravenously during study treatment.
337638|NCT01621217|Drug|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
337639|NCT01621217|Drug|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
337640|NCT01621217|Radiation|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
337641|NCT01621204|Drug|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) 21 days before surgery. Dose may be adjusted based on subsequent platelet counts (minimum 25mg; maximum 75mg).
337642|NCT01621204|Drug|IVIG infusion|IVIG infusion (1-2 g/kg) given 7 (+/-2) days prior to surgery; with an additional infusion allowed within one week of achievement of surgical hemostasis, if needed
337643|NCT01621191|Drug|Duloxetine|Administered Orally
337644|NCT01621178|Drug|Dulaglutide|Administered SC
337645|NCT01621178|Drug|Insulin glargine|Administered SC
337646|NCT01621178|Drug|Insulin lispro|Administered SC
337647|NCT01621165|Drug|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
337648|NCT01621165|Drug|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
337649|NCT01621152|Other|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
337650|NCT01621152|Other|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
337651|NCT01621139|Procedure|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
337652|NCT01621126|Device|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
337653|NCT01621113|Drug|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
337654|NCT01621113|Drug|Placebo|Placebo tablet, twice daily, for 10 weeks.
337655|NCT01621100|Drug|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
337656|NCT01621087|Other|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
337657|NCT01621074|Dietary Supplement|Sodium bicarbonate|Ergogenic effect
337658|NCT01621074|Dietary Supplement|Placebo|Placebo effect
337659|NCT01621022|Drug|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
337660|NCT01621022|Drug|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
337661|NCT01621022|Drug|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
337662|NCT01621009|Drug|Active bupropion + counseling|"Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.~Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date."
337663|NCT01621009|Drug|Active bupropion, No counseling|"Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.~Counseling: No cessation counseling, only medication checks"
337664|NCT01621009|Drug|Placebo medication + counseling|"Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day."
337665|NCT01621009|Drug|Placebo medication, No counseling|"Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks"
337891|NCT01619319|Other|computer games|computer games that that consist of word puzzles
337666|NCT01620996|Behavioral|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
337667|NCT01620996|Behavioral|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:~FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism~These mediators/ingredients are delivered by the clinician using the following principles:~Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
337668|NCT01620996|Behavioral|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.~The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance~These stages are specific to different behaviours."
337669|NCT01620983|Behavioral|Pain Coping Skills Training|
337670|NCT01620983|Behavioral|Arthritis Education|
337671|NCT01620983|Other|Usual Care|
337672|NCT01620970|Drug|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
337673|NCT01620944|Drug|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
337674|NCT01620944|Drug|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
337675|NCT01620944|Drug|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
337676|NCT01620944|Drug|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
337677|NCT01620931|Drug|RO5469754|Single ascending doses, iv or sc
337678|NCT01620931|Drug|Placebo|Single doses, iv or sc
337679|NCT01620918|Procedure|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
337680|NCT01620918|Procedure|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
337681|NCT01620905|Procedure|Manipulation|Single level cervical spine joint manipulation
337682|NCT01620866|Other|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
337683|NCT01620840|Drug|Lacosamide 10mg/ml|intravenous administration up to 10 days
337684|NCT01620827|Other|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
337685|NCT01620827|Other|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
337686|NCT01620814|Drug|Dinoprostone|
337687|NCT01620814|Drug|misoprostol|
337688|NCT01620814|Drug|control|
337689|NCT01620801|Biological|AAV8-hFIX19|One-time IV vector administration.
337690|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
337691|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
337692|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
337693|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
337694|NCT01620775|Other|MRIs|Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
337695|NCT01620775|Other|Pain testing|There will be a 1-1.5 hour session including pain tolerance testing.
337696|NCT01620762|Drug|Cat-PAD|1 dose every 4 weeks
337697|NCT01620762|Drug|Placebo|1 dose every 4 weeks
337698|NCT01620749|Radiation|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
337699|NCT01620736|Drug|Raltegravir|Raltegravir 400 mg po bid
337700|NCT01620723|Other|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
337701|NCT01620723|Other|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
337702|NCT01620710|Radiation|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
337703|NCT01620710|Radiation|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
337704|NCT01620697|Procedure|Colorectal surgery|Colorectal surgery
337705|NCT01620684|Drug|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
337706|NCT01620684|Drug|placebo|placebo capsules
337707|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
337709|NCT01620658|Device|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
337710|NCT01620658|Device|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.~XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
337711|NCT01620658|Device|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
337712|NCT01620645|Radiation|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.~The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
337713|NCT01620632|Procedure|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
337714|NCT01620619|Other|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
337715|NCT01620619|Procedure|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
337716|NCT01620606|Behavioral|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy & Social Learning
337717|NCT01620606|Behavioral|Education and Support|Education about the GI system, nutrition and food safety
337718|NCT01620593|Drug|Placebo|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.
337719|NCT01620593|Drug|Metformin|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
337720|NCT01620580|Behavioral|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.~Week 3"
337721|NCT01620580|Behavioral|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills & adherence to renal diet and fluid restriction without discussing any intervention with the group.
337722|NCT01620567|Other|avocado|1 avocado/day for 6 months
337723|NCT01620567|Other|potato or chickpea|1 cup potatoes or chickpeas/day for 6 months
337724|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
337725|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
337726|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
337727|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
337728|NCT01620554|Drug|Placebo|1 capsule per week during 2 weeks
337729|NCT01620541|Procedure|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
337730|NCT01620541|Procedure|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
337731|NCT01620528|Drug|elagolix|oral tablet
337732|NCT01620528|Other|placebo|oral tablet
337733|NCT01620515|Drug|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
337734|NCT01620515|Drug|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
337735|NCT01620502|Dietary Supplement|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
337736|NCT01620489|Drug|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
337737|NCT01620489|Drug|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
337738|NCT01620476|Drug|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
337739|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
337740|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
337741|NCT01620476|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
337742|NCT01620463|Drug|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
337743|NCT01620463|Drug|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
337744|NCT01620450|Drug|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
337746|NCT01620424|Drug|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
337747|NCT01620424|Drug|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
337748|NCT01620411|Other|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
337749|NCT01620411|Procedure|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
337750|NCT01620398|Behavioral|BALANCE|
337751|NCT01620398|Behavioral|Control diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
337752|NCT01620385|Device|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
337753|NCT01620359|Device|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
337754|NCT01620346|Procedure|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
337755|NCT01620346|Procedure|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
337756|NCT01620333|Drug|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
337757|NCT01620333|Drug|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
337758|NCT01620320|Other|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
337759|NCT01620307|Drug|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
337760|NCT01620294|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
337761|NCT01620294|Procedure|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
337762|NCT01620281|Device|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
337763|NCT01620268|Drug|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
337764|NCT01620255|Drug|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
337765|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
337766|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
337767|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
337768|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
337769|NCT01620242|Drug|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
337770|NCT01620229|Drug|brentuximab vedotin|Given IV
337771|NCT01620229|Other|laboratory biomarker analysis|Correlative studies
337772|NCT01620229|Other|pharmacological study|Correlative studies
337773|NCT01620216|Other|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
337774|NCT01620216|Drug|Dasatinib|Given PO
337775|NCT01620216|Other|Laboratory Biomarker Analysis|Correlative studies
337776|NCT01620216|Drug|Nilotinib|Given PO
337777|NCT01620216|Other|Pharmacological Study|Correlative studies
337778|NCT01620216|Drug|Ponatinib Hydrochloride|Given PO
337779|NCT01620216|Drug|Sorafenib Tosylate|Given PO
337780|NCT01620216|Drug|Sunitinib Malate|Given PO
337781|NCT01620190|Other|Laboratory Biomarker Analysis|Correlative studies
337782|NCT01620190|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
337783|NCT01620177|Drug|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
337784|NCT01620177|Drug|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
337785|NCT01620164|Other|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
337786|NCT01620151|Procedure|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
337787|NCT01620138|Drug|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
337788|NCT01620138|Drug|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
337789|NCT01620125|Dietary Supplement|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
337790|NCT01620112|Drug|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
337791|NCT01620112|Drug|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
337792|NCT01620112|Drug|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
337793|NCT01620112|Drug|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
337794|NCT01620099|Drug|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
337795|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
337796|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
337797|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
337798|NCT01620086|Device|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
337799|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
337800|NCT01620073|Other|HIV counseling and testing|Male partner HIV counseling and testing
337801|NCT01620060|Drug|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
337802|NCT01620047|Drug|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
337803|NCT01620047|Drug|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
337804|NCT01620047|Drug|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
337805|NCT01620034|Radiation|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
337806|NCT01620008|Procedure|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
337807|NCT01619982|Drug|Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is > 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is > 8 hours in duration.
337808|NCT01619982|Drug|Cefazolin 30 mg/kg body weight|"Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery."
337809|NCT01619969|Drug|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
337810|NCT01619969|Drug|placebo|Capsules of identical appearance containing starch
337811|NCT01619956|Device|SLA dental implants|Dental implant with surface modification.
337812|NCT01619956|Procedure|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
337991|NCT01618474|Drug|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
337813|NCT01619956|Procedure|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
337814|NCT01619943|Other|no intervention|clinical follow up
337815|NCT01619943|Other|no intervention|no intervention
337816|NCT01619930|Behavioral|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
337817|NCT01619930|Behavioral|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
337818|NCT01619930|Behavioral|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
337819|NCT01619930|Behavioral|Behavioral activation without rationale|"A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week."
337820|NCT01619917|Device|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
337821|NCT01619904|Procedure|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
337822|NCT01619904|Procedure|Standard Therapy|Following standard protocol during peri-operative period
337823|NCT01619891|Dietary Supplement|Vitamin D|100mcg per day
337824|NCT01619878|Drug|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
337825|NCT01619865|Drug|68Ga-DOTATOC PET/C|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
337826|NCT01619852|Drug|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
337827|NCT01619852|Drug|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
337828|NCT01619839|Drug|NKTR-181|
337829|NCT01619839|Drug|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
337830|NCT01619826|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
337831|NCT01619826|Behavioral|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
337832|NCT01619813|Drug|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
337833|NCT01619813|Drug|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
337834|NCT01619800|Device|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:~HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
337835|NCT01619800|Device|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
337836|NCT01619774|Drug|GSK2118436|Starting dose 150 mg by mouth twice a day.
337837|NCT01619774|Drug|GSK1120212|2 mg by mouth daily.
337838|NCT01619761|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic umbilical cord blood transplant
337839|NCT01619761|Drug|Cyclophosphamide|Given IV
337840|NCT01619761|Drug|Fludarabine Phosphate|Given IV
337841|NCT01619761|Other|Laboratory Biomarker Analysis|Correlative studies
337842|NCT01619761|Drug|Lenalidomide|Given PO
337843|NCT01619761|Drug|Melphalan|Given IV
337844|NCT01619761|Drug|Mycophenolate Mofetil|Given IV or PO
337845|NCT01619761|Biological|Natural Killer Cell Therapy|Given IV
337846|NCT01619761|Biological|Rituximab|Given IV
337847|NCT01619761|Drug|Tacrolimus|Given IV or PO
337848|NCT01619761|Radiation|Total-Body Irradiation|Undergo TBI
337849|NCT01619761|Procedure|Umbilical Cord Blood Transplantation|Undergo allogeneic umbilical cord blood transplant
337850|NCT01619709|Other|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
337851|NCT01619696|Procedure|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
337992|NCT01618461|Behavioral|Drug indication icons|Icons illustrate the purpose of each medication
337993|NCT01618461|Behavioral|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
337852|NCT01619683|Drug|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
337853|NCT01619683|Drug|Placebo|1 placebo capsule per day, oral
337854|NCT01619670|Device|Apligraf|non adhesive layer
337855|NCT01619657|Drug|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
337856|NCT01619657|Drug|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
337857|NCT01619644|Drug|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
337858|NCT01619644|Drug|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
337859|NCT01619631|Behavioral|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
337860|NCT01619631|Behavioral|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
337861|NCT01619618|Genetic|mutation analysis|
337862|NCT01619618|Genetic|polymerase chain reaction|
337863|NCT01619618|Genetic|polymorphism analysis|
337864|NCT01619618|Other|laboratory biomarker analysis|
337865|NCT01619605|Procedure|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
337866|NCT01619592|Device|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
337867|NCT01619579|Device|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
337868|NCT01619566|Drug|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
337869|NCT01619540|Other|Valsalva maneuver|
337870|NCT01619527|Drug|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
337871|NCT01619527|Drug|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
337872|NCT01619488|Device|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.~Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
337873|NCT01619462|Biological|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
337874|NCT01619449|Procedure|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
337875|NCT01619436|Drug|Clonidine|bolus, clonidine 2 mg/kg IV
337876|NCT01619436|Drug|Ringer lactato|1 ML ringer lactato IV, as placebo
337877|NCT01619423|Drug|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
337878|NCT01619423|Drug|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
337879|NCT01619423|Drug|PledOx (10 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
337880|NCT01619423|Drug|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
337881|NCT01619410|Biological|Linezolid|Linezolid 600 mg every 12 hours for 7 days
337882|NCT01619410|Biological|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
337883|NCT01619397|Device|Test condom with new Xanthan gum condom coating|
337884|NCT01619384|Behavioral|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
337885|NCT01619371|Device|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
337886|NCT01619345|Drug|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
337887|NCT01619332|Drug|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
337888|NCT01619332|Drug|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
337889|NCT01619332|Drug|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
337890|NCT01619319|Other|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
337892|NCT01619280|Drug|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
337893|NCT01619254|Behavioral|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
337894|NCT01619241|Other|PET/CT|F-18 FLT PET/CT
337895|NCT01619228|Other|Vitamin B3 (Nicotinamide)|The assigned leg will be treated with a solution of Vitamin B3 (nicotinamide) in sterile water once a day for 14 consecutive days in an amount not to exceed 6 milligrams of Vitamin B3 (nicotinamide) per kilogram of body weight per day.
337896|NCT01619202|Behavioral|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
337897|NCT01619189|Biological|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
337898|NCT01619189|Procedure|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
337899|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
337900|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
337901|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
337902|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
337903|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
337904|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
337905|NCT01619176|Procedure|Acupuncture|"30 minutes acupuncture every other day for 3 months.~Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
337906|NCT01619163|Drug|Placebo|
337907|NCT01619163|Drug|Prednisolone|low dose, 7.5 mg/day
337908|NCT01619150|Drug|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
337909|NCT01619150|Drug|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
337910|NCT01619137|Drug|water and soap|water and soap for 6-8 hours per day.
337911|NCT01619137|Drug|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
337912|NCT01619111|Drug|standard chemo- or endocrine therapy|"standard chemo- or endocrine therapy:~Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
337913|NCT01619111|Drug|standard chemo- or endocrine therapy + Lapatinib|"Lapatinib~+ standard chemo- or endocrine therapy:~Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)~Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
337914|NCT01619098|Other|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
337915|NCT01619098|Other|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
337916|NCT01619085|Drug|BIBF 1120|BIBF 1120 Bis in die (twice a day)
337917|NCT01619072|Other|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
337918|NCT01619072|Other|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
337919|NCT01619059|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
337920|NCT01619059|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
337921|NCT01619059|Drug|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
337922|NCT01619059|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
337923|NCT01619046|Biological|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate < 10 mL/min
337924|NCT01619046|Biological|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
337925|NCT01619046|Biological|GreenGene™ F|"intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
337926|NCT01619046|Biological|GreenGene™ F|"intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
337927|NCT01619033|Drug|BF2.649|single dose 20 mg
337994|NCT01618448|Drug|Tolvaptan|Tolvaptan 15mg once daily
337995|NCT01618448|Drug|Placebo|Placebo
337996|NCT01618435|Biological|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
338589|NCT01613612|Procedure|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
337928|NCT01619020|Dietary Supplement|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
337929|NCT01619007|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
337930|NCT01619007|Drug|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
337931|NCT01618994|Procedure|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
337932|NCT01618981|Procedure|pace make active/inactive cross over|
337933|NCT01618968|Drug|MTX|"Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)~Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)~Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
337934|NCT01618955|Device|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
337935|NCT01618942|Device|pressure algometer|
337936|NCT01618929|Drug|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
337937|NCT01618916|Drug|LY3015014|Administered SC
337938|NCT01618916|Other|Placebo|Administered SC
337939|NCT01618903|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
337940|NCT01618903|Drug|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
337941|NCT01618890|Procedure|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.~In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.~In hemodynamic responders (HVPG second measurement< 12 mmHg or >20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
337942|NCT01618877|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
337943|NCT01618877|Other|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
337944|NCT01618864|Device|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
337945|NCT01618851|Radiation|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.~The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.~For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
337946|NCT01618838|Radiation|CyberKnife radiosurgery|"Treatment Planning:~Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the Planning Treatment Volume (PTV) and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
337947|NCT01618825|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
337948|NCT01618825|Drug|Lamotrigine|2 x 25 mg tablet once a day
337949|NCT01618812|Procedure|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
337950|NCT01618799|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
337951|NCT01618799|Drug|Lamotrigine|2 x 25 mg tablet once a day
337952|NCT01618786|Other|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
337953|NCT01618786|Other|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
337954|NCT01618773|Drug|0.1% adapalene / 2.5% benzoyl peroxide|topical application
337955|NCT01618760|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
337956|NCT01618760|Drug|Risperidone|1 mg tablet once a day
337957|NCT01618708|Device|Synvisc-One (hylan G-F 20)|6-mL IA injection
337958|NCT01618708|Device|Placebo|6 mL injection of phosphate buffered saline
342980|NCT01579279|Drug|Duloxetine|Duloxetine capsules
337959|NCT01618695|Drug|E2007|"Core study:4 mg group:~Week 0 Once daily; 2 mg/day,~Week 1 to Week 18 Once daily 4 mg/day:~8 mg group: Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day,~Week 3 to Week 18 Once daily 8 mg/day:~12 mg group: Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day Extension study 4 mg group: Week 19 to Week 22 Once daily perampanel 4 mg/day, Week 23 Once daily perampanel 6 mg/day, Week 24 Once daily perampanel 8 mg/day, Week 25 Once daily perampanel 10 mg/day,~Week 26 to Week 75 or more Once daily perampanel 12 mg/day:~8 mg group: Week 19 to Week 22 Once daily perampanel 8 mg/day, Week 23 Once daily perampanel 10 mg/day,~Week 24 to Week 75 or more Once daily perampanel 12 mg/day:~12 mg group: Week 19 to Week 75 or more Once daily perampanel 12 mg/day"
337960|NCT01618695|Drug|Placebo|"Core study:~Week 0 to Week 18 Once daily placebo, Week 19 to Week 22 Once daily placebo~Extension study~Week 19 to Week 22 Once daily placebo:~Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day"
337961|NCT01618669|Drug|Regadenoson|Administered as an intravenous (IV) bolus
337962|NCT01618669|Procedure|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
337963|NCT01618656|Drug|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
337964|NCT01618656|Drug|Placebo|Sugar pill
337965|NCT01618643|Procedure|Acetic acid chromoendoscopy|"Prospective observational pilot study.~We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.~We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
337966|NCT01618630|Dietary Supplement|EAA Supplementation + Exercise Training|Amino acids in drinks between meals for exercise training period.
337967|NCT01618630|Dietary Supplement|Placebo + Exercise Training|Placebo supplementation as drinks in between meals for exercise training period.
337968|NCT01618617|Dietary Supplement|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
337969|NCT01618617|Dietary Supplement|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
337970|NCT01618604|Procedure|Quantitative Sensory Testing|following the standardized protocol of DFNS
337971|NCT01618604|Procedure|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
337972|NCT01618604|Procedure|Repetition of four QST parameters|"warm detection threshold (WDT)~cold detection threshold (CDT)~mechanical detection threshold (MDT)~mechanical pain threshold (MPT)"
337973|NCT01618591|Drug|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
337974|NCT01618591|Drug|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
337975|NCT01618591|Drug|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
337976|NCT01618591|Drug|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
337977|NCT01618591|Drug|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
337978|NCT01618578|Procedure|rubber hand illusion|"There were three consecutive trials of the RHI:~one control trial: asynchronous condition (3 Min.)~two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
337979|NCT01618565|Procedure|Hands-On Training|one-time, 30 minute hands-on training
337980|NCT01618565|Procedure|Demonstration|30 minutes passive training
337981|NCT01618552|Behavioral|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
337982|NCT01618552|Other|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
337983|NCT01618539|Drug|propofol|varying intravenous dosages
337984|NCT01618526|Dietary Supplement|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
337985|NCT01618526|Dietary Supplement|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
337986|NCT01618513|Drug|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
337987|NCT01618487|Procedure|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
337988|NCT01618487|Procedure|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
337989|NCT01618487|Procedure|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
337990|NCT01618474|Drug|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
338023|NCT01618162|Drug|placebo|Injected subcutaneously (under the skin) once daily.
337997|NCT01618422|Other|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
337998|NCT01618422|Other|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
337999|NCT01618409|Behavioral|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
338000|NCT01618396|Drug|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
338001|NCT01618383|Other|colonoscopy or rectosigmoidoscopy|Usual procedure
338002|NCT01618370|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
338003|NCT01618357|Radiation|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
338004|NCT01618357|Procedure|Lumpectomy/Mastectomy|Resection of breast cancer.
338005|NCT01618331|Behavioral|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
338006|NCT01618331|Dietary Supplement|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
338007|NCT01618305|Drug|Lamivudine/zidovudine|"Participants received one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day from entry through delivery*.~* Participants may have received a locally supplied nucleoside reverse transcriptase inhibitor (NRTI) backbone in place of lamivudine/zidovudine with permission of the protocol team obtained prior to randomization."
338008|NCT01618305|Drug|Efavirenz|Participants received one 600 mg tablet of efavirenz each night from entry through delivery.
338009|NCT01618305|Drug|Raltegravir|Participants received one 400 mg raltegravir tablet twice a day from entry through delivery.
338010|NCT01618292|Procedure|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
338011|NCT01618266|Drug|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
338012|NCT01618253|Drug|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
338013|NCT01618253|Radiation|Conventional fractionation (2 Gy per day) external beam radiation therapy|"Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or >10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If >1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.~The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions >10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced."
338014|NCT01618240|Other|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
338015|NCT01618240|Other|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
338016|NCT01618227|Device|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
338017|NCT01618227|Procedure|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
338018|NCT01618214|Drug|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
338019|NCT01618188|Drug|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
338020|NCT01618188|Drug|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
338021|NCT01618175|Device|Home oxygen therapy|"Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration."
338022|NCT01618162|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
344086|NCT01570998|Other|Laboratory Biomarker Analysis|Correlative studies
338024|NCT01618149|Radiation|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
338025|NCT01618136|Drug|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
338026|NCT01618136|Drug|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
338027|NCT01618136|Drug|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
338028|NCT01618110|Device|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
338029|NCT01618110|Other|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
338030|NCT01618097|Behavioral|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
338031|NCT01618097|Behavioral|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
338032|NCT01618084|Device|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
338033|NCT01618071|Dietary Supplement|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
338034|NCT01618058|Drug|No Investigational Product|"This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants"
338035|NCT01618045|Dietary Supplement|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
338036|NCT01618032|Other|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
338037|NCT01618032|Other|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
338038|NCT01618032|Other|placebo|Manual contact during a period of time similar of teh other interventions
338039|NCT01618019|Dietary Supplement|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
338040|NCT01618019|Dietary Supplement|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
338041|NCT01618006|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
338042|NCT01618006|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
338043|NCT01618006|Drug|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
338044|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
338045|NCT01617967|Drug|Patisiran|Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks [Q3W]: Day 0 and Day 21) and an alternative premedication regimen.
338046|NCT01617954|Device|MammaPrint|All subjects
338047|NCT01617941|Drug|BGG492|
338048|NCT01617941|Drug|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
338049|NCT01617928|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
338050|NCT01617928|Drug|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
338051|NCT01617928|Drug|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
338052|NCT01617889|Other|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
338053|NCT01617889|Other|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
338054|NCT01617850|Other|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
338055|NCT01617850|Other|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
338056|NCT01617837|Device|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
338057|NCT01617837|Other|Placebo band|Comparison between groups 0-48 hours postoperatively
338058|NCT01617824|Drug|Linagliptin|Linagliptin 5 mg tablets for 4 days
338059|NCT01617824|Drug|Placebo|Placebo tablets for 4 days
338624|NCT01613326|Drug|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
338060|NCT01617811|Procedure|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.~Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).~Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
338061|NCT01617798|Drug|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
338062|NCT01617798|Drug|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
338063|NCT01617772|Drug|Atorvastatin|Atorvastatin 20 mg
338064|NCT01617772|Drug|L-Carnitine|1000mg L-carnitine
338065|NCT01617772|Drug|Placebo|Identically looking placebo
338066|NCT01617746|Drug|Ambrisentan|5mg od two weeks
338067|NCT01617746|Drug|Bosentan|62.5mg bd two weeks
338068|NCT01617746|Drug|Placebo|bd for two weeks
338069|NCT01617733|Drug|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
338070|NCT01617707|Drug|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
338071|NCT01617707|Drug|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
338072|NCT01617694|Drug|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
338073|NCT01617694|Drug|Normal Saline|
338074|NCT01617681|Drug|VAL489|Valsartan 3mg/kg oral solution
338075|NCT01617681|Drug|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
338076|NCT01617668|Drug|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
338077|NCT01617668|Drug|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2"
338078|NCT01617655|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
338079|NCT01617655|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
338080|NCT01617655|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
338081|NCT01617629|Biological|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X was every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).~Participants who received more than 3 doses of Cvac in CAN-003 continued with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)."
338082|NCT01617603|Other|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
338083|NCT01617590|Drug|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once 200-400mg per 3 weeks."
338084|NCT01617590|Drug|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.~Intravenous CTX was administrated once"
338085|NCT01617577|Drug|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
338086|NCT01617577|Drug|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
338087|NCT01617564|Drug|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
338088|NCT01617564|Other|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
338089|NCT01617551|Drug|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
338090|NCT01617538|Drug|atorvastatin|40mg per day,duration for 24 weeks
338091|NCT01617525|Other|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
338092|NCT01617512|Device|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
338093|NCT01617499|Behavioral|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
338094|NCT01617486|Behavioral|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
338095|NCT01617473|Procedure|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
338096|NCT01617460|Drug|Aripiprazole|Flexibly dose administered orally once daily
338097|NCT01617447|Drug|Placebo of Aripiprazole|administered orally once daily
338098|NCT01617447|Drug|Aripiprazole|Flexibly dose administered orally once daily
338099|NCT01617434|Drug|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
338100|NCT01617434|Drug|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
338101|NCT01617421|Behavioral|Yoga|This study used Hatha yoga (influenced by Integral, Iyengar, and Kripalu yoga) which includes postures (asanas), breathing techniques (pranayama) and meditation [9]. Biweekly, 60-minute, bilingual yoga classes were offered for 8 weeks at a yoga studio in Washington, DC. Classes were kept small (3-10 participants) to allow for pose modifications as needed for each participant. Participants were given instructions, bilingual manuals, and yoga equipment to encourage home practice. Participants were asked to keep journals to document the frequency and duration of home practice and their experience while on the study. After the last class, a yoga DVD and a list of local yoga studios were given to encourage continued practice.
338102|NCT01617369|Device|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
338103|NCT01617356|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
338104|NCT01617356|Other|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
338105|NCT01617343|Behavioral|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.~Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
338106|NCT01617330|Procedure|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
338107|NCT01617317|Drug|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
338108|NCT01617317|Drug|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
338109|NCT01617304|Other|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
338110|NCT01617291|Other|Induced therapeutic hypothermia|induced therapeutic hypothermia
338111|NCT01617278|Device|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
338112|NCT01617278|Device|HD Colon|High definition white light
338113|NCT01617278|Device|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
338114|NCT01617265|Procedure|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
338115|NCT01617265|Procedure|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
338116|NCT01617252|Device|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
338200|NCT01616563|Behavioral|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
338117|NCT01617239|Biological|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:~15 μg HA antigen of A/California/7/2009 (H1N1)-like virus~15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 μg HA antigen of B/Brisbane/60/2008-like virus~Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
338118|NCT01617226|Drug|Azacitidine|Azacitidine both arms; 75mg/m^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
338119|NCT01617226|Drug|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
338120|NCT01617213|Drug|Melphalan|200 mg/m2/IV
338121|NCT01617213|Drug|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
338122|NCT01617200|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
338123|NCT01617200|Drug|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
338124|NCT01617200|Drug|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
338125|NCT01617200|Drug|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
338126|NCT01617187|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
338127|NCT01617187|Drug|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
338128|NCT01617187|Drug|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
338129|NCT01617187|Drug|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
338130|NCT01617174|Behavioral|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
338131|NCT01617161|Radiation|Proton Beam Therapy|5 days per week up to 9 weeks
338132|NCT01617161|Radiation|Intensity Modulated Radiation Therapy|5 times per week up to 9 weeks
338133|NCT01617148|Drug|Aflibercept|Patients received 2 mg (0.05 mL) of intravitreal aflibercept injection administered monthly for the first 3 months, followed by 2 mg (0.05 mL) once every 2 months as per the drug label for the next 9 months.
338134|NCT01617135|Drug|CVT-301|
338135|NCT01617135|Drug|Placebo|
338136|NCT01617135|Drug|Sinemet (carbidopa/levodopa)|
338137|NCT01617135|Drug|CVT-301|
338138|NCT01617122|Biological|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
338139|NCT01617109|Dietary Supplement|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
338140|NCT01617109|Other|Placebo|administered as 5 pills daily or as 2 snack bars
338141|NCT01617096|Combination Product|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
338142|NCT01617096|Combination Product|Placebo Ring|Vaginal ring containing no drug substance
338143|NCT01617083|Drug|Azithromycin|Antibiotic used to treat infections
338144|NCT01617083|Drug|Placebo|Thickening compound with sugar and flavoring
338145|NCT01617070|Drug|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
338146|NCT01617070|Dietary Supplement|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
338147|NCT01617057|Drug|tiludronic acid|400 mg / day for 3 months
338148|NCT01617057|Drug|Placebo|400 mg / day for 3 month
338149|NCT01617044|Dietary Supplement|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
338150|NCT01617044|Dietary Supplement|Placebo|Placebo
338151|NCT01617005|Drug|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
338152|NCT01616992|Drug|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
338153|NCT01616979|Procedure|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
338154|NCT01616966|Drug|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
338155|NCT01616966|Drug|propofol|Maintenance of anesthesia with propofol
338156|NCT01616953|Biological|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
338157|NCT01616953|Procedure|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
338201|NCT01616550|Other|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
344123|NCT01570660|Drug|Pioglitazone|12 weeks of pioglitazone treatment
338158|NCT01616940|Behavioral|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:~Introduction and Assessment~HIV Transmission & Viral Life Cycle~Effective Communication and Self-Advocacy~Understanding Lab Values~HIV Medications~Drug Resistance & Adherence, and Understanding & Managing Side Effects~Disclosure and Stigma~Harm & Risk Reduction~Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:~Are any services needed?~Have referrals or appointments been made?~Does patient need accompaniment to a visit?~Connect patient with services as needed.~Appointment reminders.~Overall well-being?~Schedule next peer contact."
338159|NCT01616927|Drug|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
338160|NCT01616901|Procedure|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :~7 cm H2O continuous positive airway pressure~T piece~7 cmH2O of pressure support~0 cmH20 of pressure support~7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
338161|NCT01616888|Device|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
338162|NCT01616875|Drug|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
338163|NCT01616849|Drug|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.~Nimotuzumab 200mg/d, intravenous infusion every week"
338164|NCT01616836|Other|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
338165|NCT01616836|Other|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
338166|NCT01616836|Other|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
338167|NCT01616797|Behavioral|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
338168|NCT01616784|Other|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
338169|NCT01616784|Other|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
338170|NCT01616771|Device|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
338171|NCT01616771|Device|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
338172|NCT01616771|Device|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
338173|NCT01616758|Drug|GTx-024 9mg|
338174|NCT01616732|Drug|Testosterone|TU im
338175|NCT01616732|Drug|placebo|placebo im
338176|NCT01616719|Device|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
338177|NCT01616693|Dietary Supplement|Probiotic|A capsule that contains at least 1 x 10^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
338178|NCT01616693|Dietary Supplement|Zinc|Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
338179|NCT01616693|Dietary Supplement|Probiotic placebo|The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
338180|NCT01616693|Dietary Supplement|Zinc placebo|The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
338181|NCT01616693|Biological|Rotavirus vaccine|1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
338182|NCT01616693|Biological|Oral polio vaccine|A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
338183|NCT01616680|Drug|brentuximab vedotin|Given IV
338184|NCT01616680|Other|laboratory biomarker analysis|Correlative studies
338185|NCT01616680|Other|pharmacological study|Correlative studies
338186|NCT01616667|Procedure|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
338187|NCT01616654|Drug|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
338188|NCT01616654|Drug|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
338189|NCT01616654|Drug|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
338190|NCT01616654|Drug|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
338191|NCT01616654|Drug|Vehicle cream|Vehicle cream applied once daily
338192|NCT01616628|Behavioral|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
338193|NCT01616615|Drug|Aspirin|150 mg/day oral use
338194|NCT01616615|Drug|placebo|1 capsule / day oral use
338195|NCT01616602|Other|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
338196|NCT01616602|Other|Standard Position|The traditional left-lateral decubitus position
338197|NCT01616576|Device|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
338198|NCT01616576|Device|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
338199|NCT01616563|Behavioral|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
338489|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
338202|NCT01616550|Other|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
338203|NCT01616550|Other|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
338204|NCT01616550|Other|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
338205|NCT01616537|Other|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
338206|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
338207|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
338208|NCT01616524|Biological|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
338209|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
338210|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
338211|NCT01616524|Drug|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
338212|NCT01616524|Drug|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
338213|NCT01616485|Drug|TA-1790|2 TA-1790 100 mg capsules
338214|NCT01616485|Drug|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
338215|NCT01616485|Drug|Placebo|2 placebo capsules for TA-1790 100 mg capsules
338216|NCT01616485|Drug|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
338217|NCT01616472|Drug|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
338218|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
338219|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
338220|NCT01616459|Biological|Synflorix™|Intramuscular injection
338221|NCT01616459|Biological|Prevnar 13™|Intramuscular injection
338222|NCT01616459|Biological|Infanrix hexa™|Intramuscular injection
338223|NCT01616433|Behavioral|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
338224|NCT01616433|Behavioral|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
338225|NCT01616420|Other|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
338226|NCT01616407|Drug|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
338227|NCT01616407|Drug|Methylphenidate|40 mg per os, single dose
338228|NCT01616407|Drug|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
338229|NCT01616381|Drug|Sildenafil|PDE-5 Inhibitor
338230|NCT01616381|Drug|Placebo|Placebo for sildenafil 40mg x 3 daily
338231|NCT01616368|Behavioral|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
338232|NCT01616355|Other|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
338233|NCT01616342|Device|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
338234|NCT01616316|Procedure|subfascial flap|subfacial dissection to thyroid
338235|NCT01616316|Procedure|subplatysmal flap|subplatysmal approach to thyroid
338236|NCT01616303|Drug|carboplatin & paclitaxel|carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks [21 days]) plus paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks [21 days])
338237|NCT01616303|Biological|carboplatin & paclitaxel & oregovomab|carboplatin (AUC 6, administered intravenously in a single day for 6 cycles every three weeks [21 days]) plus paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks [21 days]) plus oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
338238|NCT01616290|Drug|PRT-201|0.03, 1, or 3 mg single adventitial administration
338239|NCT01616277|Biological|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
338240|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
338241|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
338242|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
338243|NCT01616277|Biological|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
338244|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
338245|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
338246|NCT01616277|Drug|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
338247|NCT01616277|Biological|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
338248|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
338249|NCT01616277|Biological|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
338250|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
338251|NCT01616277|Biological|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
338252|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
338253|NCT01616251|Other|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
338490|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
338254|NCT01616238|Drug|Chemotherapy|Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
338255|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
338256|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
338257|NCT01616225|Drug|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
338258|NCT01616212|Other|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
338259|NCT01616212|Other|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
338260|NCT01616212|Other|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
338261|NCT01616212|Other|Drug Education for adolescents|Drug Education for adolescents
338262|NCT01616199|Drug|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
338263|NCT01616199|Drug|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
338264|NCT01616186|Drug|Everolimus and sorafenib|"Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing~Everolimus and sorafenib are dosed continuously~(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
338265|NCT01616186|Drug|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing~(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
338266|NCT01616173|Drug|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
338267|NCT01616173|Drug|Dexamethasone|8mg/2mL
338268|NCT01616173|Drug|Saline|2mL
338269|NCT01616160|Drug|mometasone furoate|2 sprays/nostril BID
338270|NCT01616147|Behavioral|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
338271|NCT01616147|Behavioral|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
338272|NCT01616134|Other|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
338273|NCT01616134|Other|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
338274|NCT01616121|Other|Usual treatment of patients with developing acute heart failure|
338275|NCT01616121|Device|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
338276|NCT01616108|Drug|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
338277|NCT01616082|Behavioral|Low Calorie Diet (LCD)|A Diet History Questionnaire will be completed, and the subjects will have dietary counseling and be provided shakes. The low calorie diet will begin, to continue for a period of 8 weeks.
338278|NCT01616082|Drug|Phentermine|"Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.~Protection Against Risk:~Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.~Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
338279|NCT01616069|Drug|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
338280|NCT01616056|Biological|graft versus host disease prophylaxis/therapy|Wear bandage lenses
338281|NCT01616056|Other|questionnaire administration|Ancillary studies
338282|NCT01616056|Procedure|optical coherence tomography|Optional ancillary studies
338283|NCT01616043|Procedure|Glyaderm|acellular dermis
338284|NCT01616043|Procedure|STSG|autologous split skin only
338491|NCT01614418|Device|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
338625|NCT01613326|Drug|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
338285|NCT01616030|Other|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
338286|NCT01616004|Drug|N2O|
338287|NCT01616004|Drug|Air|sham comparator
338288|NCT01615991|Drug|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
338289|NCT01615978|Drug|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
338290|NCT01615978|Drug|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
338291|NCT01615978|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
338292|NCT01615965|Other|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
338293|NCT01615939|Drug|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
338294|NCT01615939|Drug|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
338295|NCT01615913|Drug|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
338296|NCT01615913|Drug|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
338297|NCT01615913|Drug|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
338298|NCT01615900|Other|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation~Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.~Stage 3: follow-up (2 years) according to the group:~Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year~Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year~Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations~Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
338299|NCT01615887|Drug|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
338300|NCT01615887|Drug|placebo|sugar pill
338301|NCT01615874|Drug|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
338302|NCT01615874|Drug|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
338303|NCT01615874|Drug|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
338304|NCT01615874|Drug|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
338305|NCT01615874|Drug|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age~OR~Montelukast chewable tablets 4 mg QD for children 5 years of age"
338306|NCT01615874|Drug|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
338307|NCT01615874|Drug|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
338308|NCT01615861|Procedure|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
338309|NCT01615861|Device|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
338310|NCT01615848|Other|mediterranean diet restricted calorie|1500 k/cal 30% fat
338311|NCT01615848|Other|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
338312|NCT01615848|Other|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
338313|NCT01615835|Other|EnSite NavX System|EnSite NavX system is a 3D Mapping system
338314|NCT01615822|Drug|OZ439 100mg|OZ439 100mg oral suspension, single dose
338315|NCT01615822|Drug|OZ439 400mg|OZ439 400mg oral suspension, single dose
338316|NCT01615822|Drug|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
338317|NCT01615822|Drug|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
338318|NCT01615822|Drug|Placebo|
338319|NCT01615809|Drug|﻿AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
338320|NCT01615796|Drug|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
338321|NCT01615796|Drug|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
338322|NCT01615783|Other|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
338323|NCT01615783|Other|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
338626|NCT01613326|Drug|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
344471|NCT01568073|Drug|Benserazide|DOPA decarboxylase inhibitor
338324|NCT01615770|Behavioral|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
338325|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
338326|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
338327|NCT01615744|Procedure|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
338328|NCT01615744|Procedure|Non-surgical management|Early active exercises and elevation to decrease swelling
338329|NCT01615731|Drug|Mifepristone|200mg Mifepristone orally
338330|NCT01615731|Other|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
338331|NCT01615731|Drug|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
338332|NCT01615731|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op
338333|NCT01615718|Procedure|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
338334|NCT01615718|Procedure|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
338335|NCT01615653|Procedure|EUS|EUS Guided Therapy
338336|NCT01615627|Drug|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
338337|NCT01615627|Drug|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
338338|NCT01615614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
338339|NCT01615614|Drug|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
338340|NCT01615601|Drug|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
338341|NCT01615601|Drug|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
338342|NCT01615601|Drug|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
338343|NCT01615601|Drug|Other antiretroviral medications|Given as per Canadian Product Monograph
338344|NCT01615588|Dietary Supplement|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
338345|NCT01615575|Procedure|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
338346|NCT01615575|Procedure|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
338347|NCT01615549|Procedure|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
338348|NCT01615536|Procedure|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
338349|NCT01615536|Procedure|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
338350|NCT01615523|Other|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
338351|NCT01615510|Drug|Tapentadol immediate release|100 mg, single administration
338352|NCT01615510|Drug|placebo|placebo, single administration
338353|NCT01615497|Behavioral|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
338354|NCT01615497|Behavioral|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
338355|NCT01615497|Behavioral|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
338356|NCT01615484|Procedure|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
338357|NCT01615484|Device|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
338358|NCT01615471|Behavioral|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
344518|NCT01567722|Other|flow cytometry|
338359|NCT01615458|Behavioral|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
338360|NCT01615445|Drug|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
338361|NCT01615445|Drug|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
338362|NCT01615432|Device|V-PAP III ventilator|
338363|NCT01615432|Device|Stellar 150 ventilator|
338364|NCT01615432|Device|BiPAP vision ventilator|
338365|NCT01615432|Device|V60 ventilator|
338366|NCT01615406|Drug|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
338367|NCT01615393|Drug|ribavirin [Copegus]|Single oral dose of 400 mg tablets
338368|NCT01615393|Drug|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
338369|NCT01615380|Behavioral|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
338370|NCT01615380|Behavioral|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
338371|NCT01615367|Other|Nutrition, Exercise, and Wellness (NEW) psychotherapy|NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
338372|NCT01615367|Drug|Typically consists of at least one FDA-approved mood stabilizer|Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
338373|NCT01615354|Drug|Aleglitazar|Multiple oral doses
338374|NCT01615354|Drug|Microgynon®|Multiple oral doses
338375|NCT01615354|Drug|Placebo|Multiple oral doses
338376|NCT01615328|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
338377|NCT01615328|Device|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
338378|NCT01615302|Procedure|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
338379|NCT01615302|Other|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.~For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
338380|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
338381|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
338382|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
338383|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
338384|NCT01615276|Device|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
338385|NCT01615276|Device|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
338386|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
338387|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
338388|NCT01615250|Biological|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
338389|NCT01615237|Behavioral|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
338390|NCT01615237|Behavioral|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
338627|NCT01613326|Drug|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
338628|NCT01613326|Drug|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
338391|NCT01615237|Behavioral|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
338392|NCT01615224|Drug|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
338393|NCT01615211|Drug|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
338394|NCT01615211|Drug|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
338395|NCT01615198|Drug|Olmesartan|10 mg, 20 mg, 40 mg capsules
338396|NCT01615198|Drug|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
338397|NCT01615198|Drug|LCZ696|100 mg, 200 mg tablets
338398|NCT01615185|Drug|full-dose amisulpride|amisulpride 800mg/d
338399|NCT01615172|Procedure|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
338400|NCT01615159|Behavioral|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
338401|NCT01615146|Other|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.~Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is < 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
338402|NCT01615120|Drug|GTx-758 125 mg|One 125 mg tablet once a day
338403|NCT01615120|Drug|GTx-758 250 mg|two 125 mg tablets once daily
338404|NCT01615107|Device|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
338405|NCT01615107|Drug|PITOCIN|: Oxytocin infusion alone (Standard Protocol
338406|NCT01615107|Other|double balloonand oxytocin|balloonand oxytocin
338407|NCT01615107|Other|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
338408|NCT01615107|Procedure|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
338409|NCT01615081|Other|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
338410|NCT01615055|Drug|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
338411|NCT01615055|Other|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
338412|NCT01615042|Drug|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
338413|NCT01615029|Drug|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
338414|NCT01615029|Drug|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
338415|NCT01615029|Drug|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
338416|NCT01615029|Drug|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously [injection of a substance into a vein]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index [BMI] less than [<] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
338417|NCT01615016|Other|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?~MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
338418|NCT01615003|Drug|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
338419|NCT01615003|Drug|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
338420|NCT01614990|Drug|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
338421|NCT01614990|Drug|Placebo|placebo (Powerade®) daily for 7 days.
338422|NCT01614977|Drug|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
344519|NCT01567722|Other|laboratory biomarker analysis|
338423|NCT01614964|Drug|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
338424|NCT01614964|Drug|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
338425|NCT01614951|Procedure|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
338426|NCT01614951|Drug|HTK Custodiol|Pulmoplegia before ECC.
338427|NCT01614951|Other|Standard ECC|ECC after standard procedure
338428|NCT01614938|Drug|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
338429|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
338430|NCT01614938|Drug|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
338431|NCT01614938|Radiation|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
338432|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
338433|NCT01614912|Drug|SM-13496|40 or 80 mg once daily orally
338434|NCT01614899|Drug|SM-13496 40mg|once daily orally
338435|NCT01614899|Drug|SM-13496 80mg|once daily orally
338436|NCT01614899|Drug|Placebo|once daily orally
338437|NCT01614886|Drug|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
338438|NCT01614886|Drug|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
338439|NCT01614873|Device|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
338440|NCT01614847|Drug|Artificial tears|At random, subjects will receive hypo-osmolar artificial tear or a control (normal saline).
338441|NCT01614821|Drug|PCI-32765|Taken orally, once daily in the morning
338442|NCT01614808|Other|laboratory biomarker analysis|Correlative studies
338443|NCT01614795|Biological|Cixutumumab|Given IV
338444|NCT01614795|Other|Laboratory Biomarker Analysis|Correlative studies
338445|NCT01614795|Drug|Temsirolimus|Given IV
338446|NCT01614782|Drug|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.~In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
338447|NCT01614782|Other|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
338448|NCT01614769|Drug|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
338449|NCT01614769|Drug|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
338450|NCT01614769|Drug|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
338451|NCT01614769|Procedure|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
338452|NCT01614756|Biological|BMS-981164|
338453|NCT01614756|Biological|Placebo matching with BMS-981164|
338454|NCT01614743|Drug|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
338455|NCT01614743|Drug|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
338456|NCT01614730|Device|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
338457|NCT01614730|Device|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
338458|NCT01614717|Device|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
338459|NCT01614691|Drug|SPARC1203|Active
338460|NCT01614691|Drug|Placebo|Placebo
338461|NCT01614678|Device|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
338462|NCT01614678|Device|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
338492|NCT01614405|Drug|Truvada and Kaletra|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
338629|NCT01613313|Drug|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
338463|NCT01614665|Drug|Tacrolimus|Participants receive an initial total daily dose of tacrolimus depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 2 doses in the morning and the evening. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus doses are taken orally twice a day in the morning and evening and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
338464|NCT01614665|Drug|Tacrolimus prolonged release|Participants receive an initial total daily dose of tacrolimus prolonged release depending on the type of organ transplant (heart = 0.075 mg/kg; liver/kidney = 0.3 mg/kg), to be given orally (or via nasogastric tube for liver transplant recipients) in 1 dose. The first dose is administered in the morning within days of skin closure (heart = 4 days; liver = 2 days; kidney = within 24 hours following reperfusion). Subsequent tacrolimus prolonged release doses are taken orally once a day in the morning and are adjusted on the basis of clinical evidence of efficacy, occurrence of adverse events and observing the recommended whole blood trough level ranges (day 1 through 21 = 10 to 20 ng/mL; day 22 through 365 = 5 to 15 ng/mL).
338465|NCT01614652|Device|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
338466|NCT01614639|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
338467|NCT01614613|Device|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
338468|NCT01614613|Device|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
338469|NCT01614613|Device|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
338470|NCT01614613|Device|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
338471|NCT01614613|Device|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
338472|NCT01614613|Device|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
338473|NCT01614600|Device|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
338474|NCT01614574|Biological|velaglucerase alfa|60 U/kg every other week intravenous infusion
338475|NCT01614535|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
338476|NCT01614522|Drug|ASLAN001|ASLAN001 500mg BID
338477|NCT01614509|Procedure|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
338478|NCT01614509|Procedure|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
338479|NCT01614496|Other|Algorithm for insulin administration|
338480|NCT01614483|Other|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
338481|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
338482|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
338483|NCT01614470|Drug|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
338484|NCT01614470|Drug|Placebo|oral use, administered twice a day (q12h)
338485|NCT01614457|Drug|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
338486|NCT01614457|Drug|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
338487|NCT01614444|Other|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
338488|NCT01614444|Other|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
338493|NCT01614392|Behavioral|High velocity low force Power Training|Lower Extremity high velocity power training performed at lower external resistance (40% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
338494|NCT01614392|Behavioral|Low velocity high force Power Training|Lower extremity low velocity power training performed at high external resistance (70% of the 1 repetition maximum muscle strength). Leg and knee extension exercises were performed twice per week (3 sets of each exercise consisting of 10 repetitions).
338495|NCT01614366|Drug|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
338496|NCT01614366|Drug|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
338497|NCT01614366|Drug|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
338498|NCT01614366|Drug|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
338499|NCT01614353|Other|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
338500|NCT01614353|Other|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
338501|NCT01614340|Behavioral|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
338502|NCT01614314|Other|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
338503|NCT01614314|Other|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
338504|NCT01614301|Drug|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.~Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
338505|NCT01614288|Procedure|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
338506|NCT01614288|Other|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
338507|NCT01614275|Behavioral|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
338508|NCT01614275|Behavioral|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
338509|NCT01614275|Behavioral|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
338510|NCT01614275|Behavioral|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
338511|NCT01614262|Other|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
338512|NCT01614249|Dietary Supplement|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
338513|NCT01614249|Dietary Supplement|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
338514|NCT01614236|Drug|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
338515|NCT01614236|Drug|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
338516|NCT01614223|Procedure|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
338517|NCT01614223|Drug|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
338518|NCT01614210|Drug|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
338519|NCT01614210|Procedure|Breast cancer surgery|Breast cancer surgery
338520|NCT01614197|Drug|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
338521|NCT01614197|Drug|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
338522|NCT01614197|Drug|Etoposide|For patients allergic to etoposide. 100 mg/m2 IV daily x 5 days on days 1-5.
338523|NCT01614197|Drug|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
338524|NCT01614197|Drug|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~Age 1 - 1.99 give 8 mg of methotrexate~Age 2 - 2.99 give10 mg of methotrexate~Age 3 - 8.99 give 12 mg of methotrexate~Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
338525|NCT01614197|Drug|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
338526|NCT01614197|Drug|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~Age 1 - 1.99 give 30 mg of Cytarabine~Age 2 - 2.99 give 50mg of Cytarabine~Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~16 mg for patients age 1-1.99~20 mg for patients age 2-2.99~24 mg for patients 3-8.99 years of age~30 mg for patients >9 years of age"
338527|NCT01614184|Drug|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
338528|NCT01614171|Biological|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
338529|NCT01614158|Device|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) [Schiefer 2008] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
338530|NCT01614158|Other|D-BCVA|D-BCVA using EDTRS chart
338531|NCT01614158|Other|RAPD|RAPD using swinging flashlight test
338532|NCT01614158|Device|IOP|IOP using applanation tonometer
338533|NCT01614158|Device|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
338534|NCT01614158|Other|Fundus photography|Optic disk morphology will be documented by fundus photography
338535|NCT01614132|Drug|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
338536|NCT01614132|Radiation|Radiotherapy|Radiotherapy of the partial brain
338537|NCT01614119|Other|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
338538|NCT01614106|Behavioral|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
338539|NCT01614093|Drug|Oxytocin|Single dose intranasal oxytocin (24 IU)
338540|NCT01614093|Drug|Placebo|Placebo- Sugar pill
338541|NCT01614067|Drug|GnRH antagonist|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
338542|NCT01614054|Other|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
338543|NCT01614041|Drug|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
338544|NCT01614041|Drug|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
338545|NCT01614028|Procedure|Total Hip Arthoplasty|
338586|NCT01613651|Other|intraoperative complication management/prevention|Undergo placement of pelvic drain
338587|NCT01613638|Other|meconium samples + maternal self-questionnaire|meconium samples + maternal self-questionnaire
338546|NCT01614015|Behavioral|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
338547|NCT01614015|Behavioral|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
338548|NCT01613989|Procedure|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
338549|NCT01613989|Procedure|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
338550|NCT01613976|Drug|Panobinostat|
338551|NCT01613963|Drug|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
338552|NCT01613950|Drug|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
338553|NCT01613950|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
338554|NCT01613937|Behavioral|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
338555|NCT01613924|Device|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
338556|NCT01613924|Device|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
338557|NCT01613898|Biological|Blood tests|Blood tests
338558|NCT01613885|Other|No Intervention|This study does not involve any intervention other than obtaining blood, urine, and stool samples.
338559|NCT01613872|Other|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
338560|NCT01613846|Drug|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
338561|NCT01613846|Drug|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
338562|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
338563|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
338564|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
338565|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
338566|NCT01613820|Drug|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
338567|NCT01613820|Drug|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
338568|NCT01613807|Drug|Insulin LISPRO|Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
338569|NCT01613807|Drug|Insulin, Long-Acting and Insulin LISPRO|Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
338570|NCT01613794|Drug|Rosuvastatin|20 mg od
338571|NCT01613781|Other|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
338572|NCT01613781|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
338573|NCT01613768|Drug|eribulin mesylate|Given IV
338574|NCT01613755|Drug|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
338575|NCT01613755|Drug|Metformin|Metformin 500 mg twice daily for four days
338576|NCT01613729|Drug|Rosuvastatin 5 mg|Rosuvastatin 5 mg
338577|NCT01613729|Drug|Rosuvastatin 10 mg|
338578|NCT01613716|Drug|Ozurdex|Ozurdex .7 mg injected into the treated eye
338579|NCT01613703|Drug|ONO-2952|1 mg to 200 mg QD at a single descending dose
338580|NCT01613690|Drug|NVA237|NVA237 is administered via a BREEZHALER device
338581|NCT01613677|Drug|BKM120|
338582|NCT01613664|Drug|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
338583|NCT01613664|Other|no tisseel|the surgeon does not applied tissucol during the surgery
338584|NCT01613651|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
338585|NCT01613651|Other|questionnaire administration|Ancillary studies
338588|NCT01613625|Procedure|Elastography|
338590|NCT01613612|Procedure|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
338591|NCT01613599|Drug|Rituximab|Participants received rituximab at the discretion of their treating physicians.
338592|NCT01613586|Drug|ASP3652|Oral
338593|NCT01613586|Drug|Placebo|Oral
338594|NCT01613573|Drug|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
338595|NCT01613573|Drug|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
338596|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
338597|NCT01613560|Drug|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
338598|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
338599|NCT01613547|Drug|Amoxicillin|80 mg/kg/day for 7 days
338600|NCT01613547|Drug|Placebo|7 days
338601|NCT01613534|Drug|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
338602|NCT01613534|Drug|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
338603|NCT01613521|Other|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
338604|NCT01613508|Procedure|Direct Anterior Approach|
338605|NCT01613508|Procedure|Mini-Posterior Approach|
338606|NCT01613495|Drug|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
338607|NCT01613495|Drug|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
338608|NCT01613482|Radiation|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
338609|NCT01613482|Drug|Trastuzumab|Weekly, 2mg/kg of corporal weight
338610|NCT01613482|Drug|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
338611|NCT01613469|Drug|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
338612|NCT01613456|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
338613|NCT01613456|Dietary Supplement|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.~2 capsules/day during 12 weeks"
338614|NCT01613430|Behavioral|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
338615|NCT01613430|Behavioral|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
338616|NCT01613417|Drug|gadoteridol|ProHance 0.1 mmol/kg
338617|NCT01613417|Drug|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
338618|NCT01613404|Other|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
338619|NCT01613378|Other|No intervention|No intervention administered in this study
338620|NCT01613365|Drug|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
338621|NCT01613365|Drug|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
338622|NCT01613352|Other|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
338623|NCT01613339|Other|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Example of exercises are weight-balancing in standing and relaxation exercises.
338630|NCT01613300|Drug|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
338631|NCT01613287|Device|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.~5 treatments performed over 5 to 8 consecutive days."
338632|NCT01613274|Other|gum chewing|gum chewing three times a day for up to 20 minutes
338633|NCT01613274|Other|no gum chewing|no gum chewing
338634|NCT01613261|Drug|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.~Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
338635|NCT01613248|Drug|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
338636|NCT01613248|Drug|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
338637|NCT01613248|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans or other medication not explicitly excluded."
338638|NCT01613235|Other|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
338639|NCT01613222|Device|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
338640|NCT01613209|Drug|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
338641|NCT01613209|Drug|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
338642|NCT01613196|Other|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion*, end of treatment and 6 months after completion of treatment in cases of persistent uptake~*except if already done in the last 15 days."
338643|NCT01613183|Drug|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
338644|NCT01613183|Other|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
338645|NCT01613170|Drug|Toviaz|Toviaz 4mg daily
338646|NCT01613170|Drug|Premarin|Premarin cream 1 g per vagina twice weekly
338647|NCT01613170|Drug|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
338648|NCT01613131|Drug|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
338649|NCT01613131|Drug|Estradiol|Topical, .06%, Applied once daily for 50 days.
338650|NCT01613131|Drug|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
338651|NCT01613118|Drug|RE-021 (Sparsentan)|Oral, once-daily
338652|NCT01613118|Drug|Irbesartan|Oral, once-daily
338653|NCT01613105|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
338654|NCT01613092|Drug|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
338655|NCT01613092|Drug|Cefazolin|Preoperative antibiotic
338656|NCT01613079|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
338657|NCT01613079|Drug|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
338658|NCT01613066|Procedure|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
338659|NCT01613053|Drug|Glivec|800 mg per day
338660|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 1
338661|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 11
338662|NCT01613040|Drug|RO4917838|Multiple daily low doses of RO4917838 for 10 days
338663|NCT01613040|Drug|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
338664|NCT01613040|Drug|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
338665|NCT01613027|Biological|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
338666|NCT01613014|Drug|ABT-436|Target dose - 400mg BID
338667|NCT01613014|Drug|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
338668|NCT01612988|Drug|BOMP|"Day-8 OMB prephase:~Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8~BOMP cycle 1 and 2 :~Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15~BOMP cycle 3 to 6 :~Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
338697|NCT01612728|Drug|Women with Arthralgia|
338669|NCT01612975|Drug|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
338670|NCT01612975|Drug|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
338671|NCT01612949|Other|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
338672|NCT01612936|Biological|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
338673|NCT01612936|Procedure|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
338674|NCT01612923|Other|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
338675|NCT01612910|Drug|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
338676|NCT01612910|Other|laboratory biomarker analysis|Correlative studies
338677|NCT01612897|Other|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
338678|NCT01612884|Drug|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
338679|NCT01612884|Drug|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
338680|NCT01612871|Drug|Tamoxifen, Letrozole , Anastrozole, Exemestane|"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :~Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"
338681|NCT01612858|Drug|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
338682|NCT01612858|Drug|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
338683|NCT01612845|Procedure|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
338684|NCT01612845|Biological|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
338685|NCT01612832|Drug|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
338686|NCT01612832|Other|Control|pain treatment as customary in the department
338687|NCT01612806|Device|PriMatrix|fetal bovine dermal scaffold
338688|NCT01612806|Device|PriMatrix Ag|fetal bovine dermal scaffold with Ag
338689|NCT01612806|Procedure|moist wound therapy|standard of care moist wound therapy
338690|NCT01612793|Device|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
338691|NCT01612780|Device|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
338692|NCT01612767|Device|PRO-Kinetic Energy Stent|Coronary artery stent implant
338693|NCT01612754|Behavioral|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
338694|NCT01612754|Behavioral|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
338695|NCT01612741|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
338696|NCT01612728|Other|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine & Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
338698|NCT01612715|Other|Segmental Allergen Challenge|segmental allergen challenge
338699|NCT01612702|Drug|Dexamethasone|Dexamethasone 10 mg intravenous administration
338700|NCT01612689|Device|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
338701|NCT01612676|Drug|FE 202158|
338702|NCT01612663|Device|Pain relief by Acupuncture needle at non-specific site|
338703|NCT01612663|Device|Acupuncture needle|
338704|NCT01612663|Device|Acupuncture needle|
338705|NCT01612663|Device|Acupuncture needle|
338706|NCT01612650|Device|tomosynthesis|2 incidences 3D numeric mammography
338707|NCT01612650|Device|2D mammography|2 incidences 2D analogic mammography
338708|NCT01612637|Behavioral|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
338709|NCT01612637|Behavioral|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
338710|NCT01612598|Other|counseling intervention|Undergo PCI
338711|NCT01612598|Procedure|quality-of-life assessment|Ancillary studies
338712|NCT01612598|Other|questionnaire administration|Ancillary studies
338713|NCT01612598|Other|educational intervention|Undergo PCI
338714|NCT01612546|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
338715|NCT01612546|Other|Laboratory biomarker analysis|Correlative studies
338716|NCT01612546|Other|Pharmacological studies|Correlative studies
338717|NCT01612520|Behavioral|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.~The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).~The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
338718|NCT01612507|Drug|600 mg Ceftaroline fosamil|1 h infusion
338719|NCT01612507|Drug|Placebo|1 h infusion
338720|NCT01612507|Drug|600 mg Ceftaroline fosamil|2 h infusion
338721|NCT01612507|Drug|Placebo|2 h infusion
338722|NCT01612494|Drug|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
338723|NCT01612494|Other|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
338724|NCT01612481|Procedure|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
338725|NCT01612481|Procedure|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
338726|NCT01612468|Drug|Liraglutide|1.8 mg/day subcutaneous
338727|NCT01612468|Drug|Placebo|1.8 mg/day subcutaneous
338728|NCT01612455|Behavioral|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
338729|NCT01612442|Behavioral|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
338730|NCT01612442|Behavioral|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
338731|NCT01612429|Dietary Supplement|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
338732|NCT01612416|Device|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
338733|NCT01612403|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
338734|NCT01612377|Drug|Prednisolone-Dipyridamole|Oral, QD
338735|NCT01612377|Drug|Prednisone|Oral QD Prednisone 5mg
338736|NCT01612377|Drug|prednisone|Oral, QD prednisone 7.5mg
338737|NCT01612364|Procedure|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
338738|NCT01612351|Drug|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
338739|NCT01612351|Drug|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
338740|NCT01612351|Drug|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
338741|NCT01612351|Drug|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
338742|NCT01612351|Drug|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
338743|NCT01612351|Radiation|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
338744|NCT01612351|Radiation|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
338745|NCT01612351|Procedure|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
338746|NCT01612338|Behavioral|Targeted|Targeted letter and booklet
338747|NCT01612338|Behavioral|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
338748|NCT01612325|Device|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
338749|NCT01612312|Procedure|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
338750|NCT01612312|Procedure|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
338751|NCT01612299|Drug|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 &2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.~Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml."
338752|NCT01612286|Drug|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle *4cycles
338753|NCT01612273|Drug|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
338754|NCT01612273|Drug|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
338755|NCT01612260|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
338756|NCT01612260|Drug|placebo Capsule|4 granules t.i.d. po for 12 weeks
338757|NCT01612247|Drug|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
338758|NCT01612234|Dietary Supplement|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
338759|NCT01612221|Drug|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
338760|NCT01612221|Other|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
338761|NCT01612208|Device|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
338762|NCT01612208|Device|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
338851|NCT01611571|Drug|placebo Risedronate|weekly placebo of Risedronic Acid
338852|NCT01611558|Biological|Ipilimumab|
338853|NCT01611545|Genetic|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
338857|NCT01611493|Device|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
338763|NCT01612195|Procedure|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
338764|NCT01612182|Other|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
338765|NCT01612169|Behavioral|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
338766|NCT01612169|Behavioral|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
338767|NCT01612156|Drug|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
338768|NCT01612156|Drug|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
338769|NCT01612143|Drug|setrobuvir|200 mg capsule formulation, single oral dose
338770|NCT01612143|Drug|setrobuvir|200 mg tablet formulation, single oral dose
338771|NCT01612130|Drug|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
338772|NCT01612130|Drug|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
338773|NCT01612104|Behavioral|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
338774|NCT01612091|Device|Monitoring Messenger|Monitoring Messenger prototype device
338775|NCT01612091|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
338776|NCT01612078|Drug|Droxidopa|200mg/tab 2tablets, po, three times a week
338777|NCT01612078|Drug|Placebo|200mg/tab, po, three times a week.
338778|NCT01612065|Drug|Misoprostol|200 ug
338779|NCT01612065|Drug|Misoprostol|Misoprostol vaginally, 400 ug
338780|NCT01612052|Drug|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
338781|NCT01612039|Drug|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
338782|NCT01612039|Drug|Placebo|Matching placebo tablets
338783|NCT01612026|Procedure|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
338784|NCT01612013|Drug|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
338785|NCT01612013|Drug|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
338786|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
338787|NCT01612013|Drug|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
338788|NCT01612013|Drug|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
338789|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
338790|NCT01612000|Biological|PanBlok|Intramuscular injection
338791|NCT01612000|Biological|rHA adjuvant|Intramuscular injection
338854|NCT01611506|Biological|Cetuximab|"Induction chemotherapy:~Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter~Followed by:~Cetuximab 250mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~3 cycles of Cetuximab 250mg/m2 weekly on day 1"
338897|NCT01611142|Biological|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
338792|NCT01611987|Other|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
338793|NCT01611987|Other|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
338794|NCT01611974|Drug|Maribavir|Tablet for oral administration
338795|NCT01611961|Drug|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
338796|NCT01611961|Drug|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
338797|NCT01611948|Drug|Aprepitant|125mg/day for 8 weeks
338798|NCT01611948|Drug|Placebo|125mg/d placebo pill for 8 weeks
338799|NCT01611948|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
338800|NCT01611935|Drug|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
338801|NCT01611922|Other|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
338802|NCT01611922|Device|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
338803|NCT01611909|Drug|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
338804|NCT01611896|Dietary Supplement|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
338805|NCT01611896|Other|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
338806|NCT01611883|Drug|Ezetimibe|10 mg oral dose once daily for 24 weeks
338807|NCT01611883|Drug|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
338808|NCT01611857|Drug|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
338809|NCT01611857|Drug|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m^2, 5-FU continuous IV 2400 mg/m^2 over 46 hours, leucovorin 400 mg/m^2 IV, and oxaliplatin 85 mg/m^2.
338810|NCT01611844|Device|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~1 intradermal injection of Tuberculin (5UI)~1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
338811|NCT01611844|Device|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:~1 intradermal injection of Tuberculin (5UI)~1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
338812|NCT01611831|Behavioral|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
338813|NCT01611831|Behavioral|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
338814|NCT01611818|Other|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
338815|NCT01611818|Other|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
338816|NCT01611818|Other|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
338817|NCT01611805|Drug|GSK1605786|Opaque Swedish orange body and cap.
338818|NCT01611805|Drug|GSK1605786 Placebo|Opaque Swedish orange body and cap.
338855|NCT01611506|Drug|Capecitabine|"Induction chemotherapy:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle~Postoperative treatment:~Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
338856|NCT01611506|Drug|Cisplatin|"Induction chemotherapy:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle~Followed by:~Cisplatin 30mg/m2 weekly on day 1 during chemoradiation~Postoperative treatment:~Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
339017|NCT01610076|Other|Code Status Video|"10 minute video about Code Status"
338819|NCT01611792|Other|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
338820|NCT01611792|Other|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
338821|NCT01611779|Device|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
338822|NCT01611766|Procedure|Secondary Cytoreductive Surgery|Complete Cytoreduction
338823|NCT01611766|Drug|Salvage Chemotherapy|6 cycles of postoperative chemotherapy
338824|NCT01611753|Other|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
338825|NCT01611740|Procedure|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :~the variability of the cardiac cycle duration ;~the variability of respiratory cycle amplitude and duration ;~and their relationships."
338826|NCT01611727|Drug|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
338827|NCT01611714|Other|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
338828|NCT01611714|Other|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
338829|NCT01611701|Procedure|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
338830|NCT01611701|Procedure|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.
338831|NCT01611688|Drug|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
338832|NCT01611688|Drug|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
338833|NCT01611688|Drug|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
338834|NCT01611675|Drug|Vemurafenib|take orally, twice daily
338835|NCT01611675|Drug|Leflunomide|take orally, once daily
338836|NCT01611662|Drug|gemcitabine hydrochloride|Given IV
338837|NCT01611662|Drug|cisplatin|Given IV
338838|NCT01611662|Procedure|therapeutic conventional surgery|Undergo radical cystectomy
338839|NCT01611662|Other|laboratory biomarker analysis|Correlative studies
338840|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils|4 months consumption
338841|NCT01611649|Dietary Supplement|Formula containing plant oils|4 months consumption
338842|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
338843|NCT01611623|Drug|SNX-5422|Tablets dose every other day; dose escalation based on safety
338844|NCT01611610|Other|Functional tests|"The ambulant patients will perform~MFM (20 items)~Hammersmith modified module - MHMFS~Timed tests (time to rise from the floor,...)~6 minute walk test~PedsQL - neuromuscular module"
338845|NCT01611610|Other|Functional tests|"The non-ambulant patients will perform:~MFM (20 items)~Hammersmith modified module - MHMFS~Upper Limb Functional Items~Egen Klassifikation 2 questionnaire - EK2~PedsQL questionnaire - neuromuscular module"
338846|NCT01611597|Other|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
338847|NCT01611584|Drug|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
338848|NCT01611571|Drug|Risedronate|weekly risedronate
338849|NCT01611571|Drug|Teriparatide|daily teriparatide
338850|NCT01611571|Drug|Placebo Teriparatide|daily placebo of teriparatide
338858|NCT01611493|Device|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
338859|NCT01611480|Drug|Imiquimod (topical use)|
338860|NCT01611467|Drug|CC-223|20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
338861|NCT01611467|Drug|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
338862|NCT01611454|Device|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
338863|NCT01611454|Device|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during fluoroscopy guided interventions.
338864|NCT01611428|Drug|Ipragliflozin|Oral and Intravenous (i.v.)
338865|NCT01611415|Drug|Ipragliflozin|Oral
338866|NCT01611415|Drug|Furosemide|Oral
338867|NCT01611389|Device|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
338868|NCT01611389|Device|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
338869|NCT01611376|Device|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
338870|NCT01611363|Drug|ASP1941|Oral
338871|NCT01611363|Drug|Placebo|Oral
338872|NCT01611350|Other|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
338873|NCT01611350|Other|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
338874|NCT01611350|Other|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
338875|NCT01611337|Other|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
338876|NCT01611324|Drug|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
338877|NCT01611324|Drug|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
338878|NCT01611311|Drug|BI 409306 BS|Medium dose film-coated tablet
338879|NCT01611311|Drug|BI 409306 BS|High dose film-coated tablet
338880|NCT01611311|Drug|Placebo|Film-coated tablet
338881|NCT01611298|Biological|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
338882|NCT01611259|Drug|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
338883|NCT01611246|Device|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
338884|NCT01611220|Behavioral|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
338885|NCT01611207|Device|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
338886|NCT01611207|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
338887|NCT01611194|Drug|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
338888|NCT01611194|Drug|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
338889|NCT01611181|Drug|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
338890|NCT01611181|Drug|Kräuterblut|40 mg iron, 20 ml twice daily.
338891|NCT01611181|Drug|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
338892|NCT01611168|Other|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
338893|NCT01611155|Drug|venlafaxine|Given PO
338894|NCT01611155|Drug|placebo|Given PO
338895|NCT01611155|Other|questionnaire administration|Ancillary studies
338896|NCT01611155|Other|quality-of-life assessment|Ancillary studies
338898|NCT01611129|Behavioral|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI & CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
338899|NCT01611116|Drug|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
338900|NCT01611116|Drug|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
338901|NCT01611103|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
338902|NCT01611090|Drug|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
338903|NCT01611090|Drug|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
338904|NCT01611090|Drug|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
338905|NCT01611090|Drug|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
338906|NCT01611077|Drug|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
338907|NCT01611077|Drug|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
338908|NCT01611077|Drug|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
338909|NCT01611064|Drug|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
338910|NCT01611064|Drug|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
338911|NCT01611051|Drug|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
338912|NCT01611051|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
338913|NCT01611051|Drug|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
338914|NCT01611038|Dietary Supplement|Methylselenocysteine|Methylselenocysteine capsule given daily
338915|NCT01611038|Dietary Supplement|Placebo|Placebo capsule given daily
338916|NCT01610999|Drug|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
338917|NCT01610986|Dietary Supplement|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
338918|NCT01610986|Dietary Supplement|Water|Only water intake during training
338919|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
338920|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
338921|NCT01610960|Device|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
338922|NCT01610960|Device|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
338923|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
338924|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
338925|NCT01610934|Drug|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
338926|NCT01610934|Drug|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
338927|NCT01610921|Other|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
338950|NCT01610687|Drug|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
339018|NCT01610063|Other|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
338928|NCT01610908|Other|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.~Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
338929|NCT01610908|Other|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
338930|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
338931|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.~Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.~Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
338932|NCT01610882|Device|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
338933|NCT01610882|Device|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
338934|NCT01610869|Drug|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
338935|NCT01610856|Drug|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
338936|NCT01610856|Drug|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
338937|NCT01610843|Other|Survey|Longitudinal surveys
338938|NCT01610817|Other|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
338939|NCT01610791|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
338940|NCT01610778|Dietary Supplement|Placebo|
338941|NCT01610778|Dietary Supplement|5-aminolevulinic acid phosphate|
338942|NCT01610765|Drug|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
338943|NCT01610765|Drug|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
338944|NCT01610752|Behavioral|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
338945|NCT01610739|Drug|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
338946|NCT01610726|Procedure|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
338947|NCT01610713|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
338948|NCT01610700|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
338949|NCT01610700|Drug|Placebo|Each actuation of placebo delivered the excipients only.
338981|NCT01610388|Drug|1500mg IV GSK1322322/placebo|1500mg IV
338982|NCT01610388|Drug|2000mg IV GSK1322322J/placebo|2000mg IV
338983|NCT01610388|Drug|3000mg IV GSK1322322J/placebo|3000mg IV
338951|NCT01610674|Other|Tailored improvement strategy|"A step-wise implementation model is applied:~1) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients."
338952|NCT01610661|Other|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
338953|NCT01610635|Other|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
338954|NCT01610622|Device|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.~No other interventions are made for the purpose of the study."
338955|NCT01610609|Behavioral|Population Health Management Intervention|"This intervention includes:~Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and~Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
338956|NCT01610596|Drug|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
338957|NCT01610596|Drug|Placebo|
338958|NCT01610570|Drug|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
338959|NCT01610557|Drug|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
338960|NCT01610557|Drug|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.~*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
338961|NCT01610544|Drug|3'-deoxy-3'-18F fluorothymidine (FLT)|
338962|NCT01610544|Other|PET/CT scan|
338963|NCT01610531|Other|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
338964|NCT01610518|Dietary Supplement|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
338965|NCT01610518|Dietary Supplement|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
338966|NCT01610492|Drug|belimumab|10mg/kg administered intravenously
338967|NCT01610479|Drug|TAS-114 + S-1|
338968|NCT01610466|Procedure|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
338969|NCT01610453|Procedure|ultrasound examination|transabdominal and transperineal ultrasound examinations
338970|NCT01610440|Biological|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
338971|NCT01610427|Procedure|Blood sample collection|Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
338972|NCT01610414|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
338973|NCT01610414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
338974|NCT01610401|Drug|Metformin|metformin 500 mg three times a day, for 3 days
338975|NCT01610401|Drug|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
338976|NCT01610401|Drug|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
338977|NCT01610388|Drug|500mg IV GSK1322322/placebo|500mg IV
338978|NCT01610388|Drug|1000mg oral GSK1322322/placebo|1000mg oral
338979|NCT01610388|Drug|1000mg IV GSK1322322/placebo|1000mg IV
338980|NCT01610388|Drug|1500mg oral GSK1322322/placebo dose|1500mg oral
338985|NCT01610375|Other|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
338986|NCT01610362|Biological|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
338987|NCT01610336|Drug|INC280|experimental
338988|NCT01610323|Other|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
338989|NCT01610323|Other|Standard Care|
338990|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
338991|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
338992|NCT01610297|Drug|ICL670|Oral dose of ICL670 at 10 mg/kg daily
338993|NCT01610284|Drug|BKM120 Matching placebo|BKM120 matching placebo, daily oral
338994|NCT01610284|Drug|Fulvestrant|Fulvestrant 500mg given intramuscularly at cycle 1 day 1, cycle 1 day 15 and at day 1 at each cycle thereafter
338995|NCT01610284|Drug|BKM120|BKM120 100mg, daily oral capsules
338996|NCT01610271|Device|Air Barrier System|ABS is a device that emits a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
338997|NCT01610258|Other|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.~The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
338998|NCT01610245|Drug|Nitazoxanide|
338999|NCT01610245|Drug|Oseltamivir|
339000|NCT01610245|Drug|Placebo Oral Tablet|
339001|NCT01610245|Drug|Placebo Oral Capsule|
339002|NCT01610232|Device|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
339003|NCT01610232|Other|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
339004|NCT01610219|Behavioral|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
339005|NCT01610219|Other|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
339006|NCT01610206|Drug|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
339007|NCT01610206|Drug|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
339008|NCT01610193|Procedure|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
339009|NCT01610180|Drug|Eltrombopag Olamine|"Initial dose : 50 mg/day for 14 days.~Next doses:~If platelet count <60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~If platelet count >60000/µL and ≤200000/µL same dose for the next 14 days.~If platelet count >200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~If platelet count >400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is <150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
339010|NCT01610167|Device|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
339011|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
339012|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
339013|NCT01610154|Drug|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
339014|NCT01610141|Other|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
339015|NCT01610141|Other|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
339016|NCT01610089|Other|stable isotope infusion|"Control subjects: [15N2-ureido] arginine (0.69 mg/kg); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of [15N2-ureido] arginine (0.69 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr).~Citrullinemia type 1 subjects,[15N2-ureido] arginine (4.14 mg/kg); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of [15N2-ureido] arginine (4.14 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr)."
339019|NCT01610050|Drug|LFA102|
339020|NCT01610037|Drug|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
339021|NCT01610037|Drug|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
339022|NCT01610037|Drug|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
339023|NCT01610024|Dietary Supplement|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
339024|NCT01610011|Dietary Supplement|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
339025|NCT01609998|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
339026|NCT01609998|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
339027|NCT01609972|Device|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
339028|NCT01609959|Drug|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
339029|NCT01609959|Drug|Valsartan|Valsartan 160 mg per day
339030|NCT01609946|Device|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
339031|NCT01609946|Procedure|Cytology (FNAB) or Surgery|
339032|NCT01609933|Drug|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
339033|NCT01609933|Drug|ABT-267|ABT-267 (tablets)
339034|NCT01609933|Drug|pegylated interferon alpha-2a (pegIFN)|pegIFN alpha-2a (syringe)
339035|NCT01609933|Drug|Ribavirin (RBV)|Ribavirin (tablets)
339036|NCT01609920|Drug|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
339037|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
339038|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
339039|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
339040|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
339041|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
339042|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
339043|NCT01609894|Dietary Supplement|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
339044|NCT01609894|Dietary Supplement|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
339045|NCT01609881|Drug|Acuvail|Dosing of drug 3 days prior to surgery
339046|NCT01609881|Other|Placebo|Artificial tears qid for 3 days preoperatively
339047|NCT01609868|Dietary Supplement|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
339048|NCT01609868|Dietary Supplement|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
339049|NCT01609855|Drug|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
339050|NCT01609855|Drug|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
339051|NCT01609842|Other|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
339052|NCT01609829|Procedure|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
339053|NCT01609816|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
339054|NCT01609803|Other|laboratory biomarker analysis|Correlative studies
339055|NCT01609790|Biological|Bevacizumab|Given IV
339056|NCT01609790|Other|Laboratory Biomarker Analysis|Correlative studies
339057|NCT01609790|Other|Pharmacological Study|Correlative studies
339058|NCT01609790|Other|Placebo|Given IV
339059|NCT01609790|Biological|Trebananib|Given IV
339060|NCT01609777|Procedure|SBAR|situation, background, assessment, recommendation
339061|NCT01609764|Behavioral|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
339062|NCT01609751|Dietary Supplement|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
339063|NCT01609738|Device|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
339064|NCT01609725|Device|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
339065|NCT01609725|Device|Oral prophylaxis|One session of supraginigval calculus removal
339066|NCT01609712|Procedure|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.~The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
339067|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
339068|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
339069|NCT01609673|Drug|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
339070|NCT01609660|Dietary Supplement|Saccharomyces boulardii|100mg daily for seven days prior to surgery
339071|NCT01609647|Drug|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
339072|NCT01609647|Drug|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
339073|NCT01609634|Other|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
339074|NCT01609634|Other|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
339075|NCT01609634|Other|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
339076|NCT01609621|Device|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
339077|NCT01609608|Procedure|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
339078|NCT01609595|Drug|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
339079|NCT01609582|Drug|TAK-875|TAK-875 tablets
339080|NCT01609582|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
339081|NCT01609556|Drug|IMGN853|Dose escalation study. Dosing on day 1 of every 21 day cycle.
339082|NCT01609543|Drug|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
339083|NCT01609530|Procedure|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
339084|NCT01609530|Procedure|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
339085|NCT01609517|Drug|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
339086|NCT01609504|Procedure|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
339087|NCT01609504|Procedure|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
339088|NCT01609491|Drug|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
339089|NCT01609491|Drug|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
339090|NCT01609478|Drug|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
339091|NCT01609478|Drug|placebo|placebo delivered via Concept 1 inhaler
339092|NCT01609478|Drug|mometasone furoate|via Twisthaler inhaler
339093|NCT01609452|Biological|Blisibimod|
339094|NCT01609452|Other|Placebo|
339095|NCT01609439|Drug|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
339096|NCT01609439|Drug|Placebo|Placebo
340464|NCT01598090|Drug|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
339097|NCT01609426|Genetic|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
339098|NCT01609413|Dietary Supplement|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
339099|NCT01609413|Dietary Supplement|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
339100|NCT01609387|Dietary Supplement|Fit For me|
339101|NCT01609387|Dietary Supplement|Davitamon|
339102|NCT01609374|Device|M6-C Artificial Cervical Disc|Total disc replacement
339103|NCT01609374|Device|Anterior plate system with corticocancellous allograft bone|Cervical fusion
339104|NCT01609361|Other|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
339105|NCT01609348|Drug|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
339106|NCT01609348|Drug|Venlafaxine|225 mg daily for 12 weeks
339107|NCT01609335|Drug|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
339108|NCT01609335|Drug|C-11 PiB|One time intravenous administration of 10-20 mCi
339109|NCT01609322|Behavioral|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
339110|NCT01609322|Behavioral|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
339111|NCT01609309|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
339112|NCT01609309|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.~The type of reconstruction will be selected according to the surgeon's experience."
339113|NCT01609296|Device|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
339114|NCT01609283|Biological|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:~Group 1: single intrathecal dose of 1 x 107 cells~Group 2: single intrathecal dose of 5 x 107 cells~Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells~Group 4: single intrathecal dose of 1 x 108 cells~Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
339115|NCT01609270|Device|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
339116|NCT01609257|Biological|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
339117|NCT01609257|Biological|Saline Comparator|2 doses IM 28 days apart
339118|NCT01609244|Device|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
339119|NCT01609244|Device|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
339120|NCT01609231|Drug|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
339121|NCT01609231|Drug|Irinotecan|Irinotecan 180 mg/m^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator, such as with dexamethasone or atropine will follow local, or country-specific standard of care.
339122|NCT01609231|Drug|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m^2 followed by weekly infusions of 250 mg/m^2. Pre-medication at the discretion of the investigator, such as with a histamine receptor antagonist or corticosteroid, will follow local, or country-specific standard of care.
339123|NCT01609218|Drug|LY2140023|80 mg tablet LY2140023 monohydrate, administered orally
339124|NCT01609218|Drug|Aqueous activated charcoal|75 g aqueous activated charcoal, mixed with water and administered orally
339125|NCT01609205|Biological|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
339126|NCT01609192|Drug|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
339127|NCT01609179|Drug|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
339128|NCT01609166|Drug|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
339129|NCT01609166|Drug|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
339130|NCT01609153|Drug|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
339131|NCT01609153|Drug|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
339132|NCT01609153|Drug|Olanzapine and Amisulpride|"Zyprexa:~Coated tablet 5-20 mg milligram(s) per day for 16 weeks~Amisulpride:~Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
339133|NCT01609140|Drug|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
339134|NCT01609140|Drug|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
339135|NCT01609140|Drug|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
339136|NCT01609140|Drug|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
339137|NCT01609140|Drug|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
339138|NCT01609140|Drug|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
339139|NCT01609127|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
339140|NCT01609127|Drug|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
339141|NCT01609127|Drug|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
339142|NCT01609101|Device|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
339143|NCT01609101|Device|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
339144|NCT01609101|Device|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
339145|NCT01609101|Device|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
339146|NCT01609101|Device|King Vision® videolaryngoscope|King Vision® videolaryngoscope
339147|NCT01609101|Device|Venner® videolaryngoscope|Venner® videolaryngoscope
339148|NCT01609101|Device|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
339149|NCT01609088|Dietary Supplement|Erythritol-containing beverage|Orange flavored beverage containing erythritol
339150|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
339151|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
339152|NCT01609049|Drug|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
339153|NCT01609049|Drug|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
339154|NCT01609023|Drug|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
339155|NCT01609010|Drug|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
339156|NCT01609010|Drug|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
339157|NCT01608984|Procedure|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
339158|NCT01608984|Procedure|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
339159|NCT01608984|Procedure|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
339160|NCT01608958|Drug|Oxytocin|10 IU oxytocin in 500 ml infusion
339161|NCT01608958|Drug|Oxytocin|10 IU oxytocin IM injection
339162|NCT01608945|Drug|Hydrocortisone sodium succinate|100mg/day
339163|NCT01608932|Procedure|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
339164|NCT01608919|Other|blood tests|thromboelastogram platelet mapping
339165|NCT01608906|Drug|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
339166|NCT01608906|Drug|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
339167|NCT01608893|Drug|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
339168|NCT01608893|Drug|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
339169|NCT01608880|Drug|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
339170|NCT01608880|Drug|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
339171|NCT01608867|Biological|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
339172|NCT01608854|Other|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
339173|NCT01608841|Drug|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
339174|NCT01608815|Biological|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
339175|NCT01608802|Other|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
340465|NCT01598077|Drug|LJM716|
339176|NCT01608802|Other|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
339177|NCT01608789|Device|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
339178|NCT01608776|Device|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
339179|NCT01608776|Other|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
339180|NCT01608763|Behavioral|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
339181|NCT01608750|Drug|Pantoprazol|40mg/day, oral, 28 days
339182|NCT01608750|Drug|Folic Acid|5 mg/day, oral, 28 days
339183|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
339184|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
339185|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
339186|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
339187|NCT01608737|Drug|BI 201335|BI 201335 once daily low dose for 24 weeks
339188|NCT01608724|Drug|Saxagliptin|oral, 5 mg once a day (Q.D.)
339189|NCT01608711|Biological|AGS-1C4D4|Intravenous Infusion
339190|NCT01608711|Biological|gemcitabine|Intravenous Infusion
339191|NCT01608698|Drug|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
339192|NCT01608698|Drug|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
339193|NCT01608672|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
339194|NCT01608659|Drug|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
339195|NCT01608646|Drug|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
339196|NCT01608633|Other|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
339197|NCT01608607|Other|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
339198|NCT01608594|Drug|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:~Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
339199|NCT01608594|Drug|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:~Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery~After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart~Dose continued 12 weeks later for 4 additional doses given 12 weeks apart~Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
339200|NCT01608581|Other|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
339201|NCT01608568|Device|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
339202|NCT01608555|Drug|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
339203|NCT01608542|Drug|Fostamatinib 100mg|oral tablet
339204|NCT01608542|Drug|Fostamatinib 200mg|oral tablet
339205|NCT01608529|Device|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
339206|NCT01608516|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
339207|NCT01608503|Procedure|lung deflation|lung was deflated during respiration cycle
339208|NCT01608503|Procedure|lung inflation|lung was inflated during respiratory cycle
339285|NCT01607853|Drug|Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
339209|NCT01608490|Device|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
339210|NCT01608464|Drug|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
339211|NCT01608464|Drug|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
339212|NCT01608451|Drug|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
339213|NCT01608451|Drug|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
339214|NCT01608438|Device|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
339215|NCT01608425|Procedure|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
339216|NCT01608412|Drug|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
339217|NCT01608412|Drug|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
339218|NCT01608399|Behavioral|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
339219|NCT01608386|Procedure|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
339220|NCT01608373|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
339221|NCT01608373|Drug|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
339222|NCT01608373|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
339223|NCT01608360|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
339224|NCT01608360|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
339225|NCT01608347|Drug|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
339226|NCT01608347|Drug|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
339227|NCT01608334|Drug|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
339228|NCT01608334|Drug|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
339229|NCT01608321|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
339230|NCT01608321|Device|Sham device|Placebo Device that simulates active rTMS treatment
339231|NCT01608308|Drug|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
339232|NCT01608308|Drug|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
339233|NCT01608295|Drug|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
339234|NCT01608295|Drug|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
339235|NCT01608282|Behavioral|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
339236|NCT01608269|Drug|Abacavir/Lamivudine|one tablet once a day
339237|NCT01608243|Biological|SLIT tablets of house dust mite allergen extracts|10 dosing days
339238|NCT01608243|Biological|Matching placebo|10 dosing days
339239|NCT01608217|Drug|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
339240|NCT01608217|Drug|Placebo|placebo (tablet) three times daily for a period of three weeks.
339241|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
339242|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
339243|NCT01608191|Behavioral|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
339244|NCT01608165|Procedure|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
339245|NCT01608165|Procedure|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
339517|NCT01605903|Drug|Acetaminophen|During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
339246|NCT01608165|Procedure|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
339247|NCT01608152|Behavioral|Needs Analysis|Focus group discussion lasting about 1½ hours. Several weeks after focus group, return visit to provide opinions on game development.
339248|NCT01608152|Behavioral|Video game|Instructions given at clinic visit on using video game through the internet. Participant asked to play game at home for 3 weeks.
339249|NCT01608152|Behavioral|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
339250|NCT01608139|Drug|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
339251|NCT01608139|Drug|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
339252|NCT01608139|Drug|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
339253|NCT01608126|Procedure|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.~The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
339254|NCT01608100|Device|ARCHITECT STAT High Sensitive Troponin I Assay|"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.~Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."
339255|NCT01608087|Drug|BI 695502|BI 695502 single i.v. infusion
339256|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
339257|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
339258|NCT01608074|Procedure|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :~Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
339259|NCT01608074|Other|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
339260|NCT01608061|Device|DBS-f on|deep brain stimulation of the fornix
339261|NCT01608061|Device|DBS-f off|deep brain stimulation of the fornix turned off
339262|NCT01608048|Device|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
339263|NCT01608035|Procedure|Sciatic catheter|presurgical sciatic catheter insertion
339264|NCT01608035|Procedure|Stump catheter|intraoperative placed stump catheter
339265|NCT01608022|Drug|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
339266|NCT01608009|Drug|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
339267|NCT01607996|Procedure|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
339268|NCT01607996|Drug|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
339269|NCT01607983|Drug|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
339270|NCT01607970|Drug|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
339271|NCT01607957|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
339272|NCT01607957|Drug|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
339273|NCT01607931|Behavioral|Exercise|1 hour of cycling at 50% of maximum power output
339274|NCT01607918|Drug|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
339275|NCT01607918|Drug|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
339276|NCT01607905|Drug|KPT-330|Subjects in this study will receive KPT-330 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
339277|NCT01607892|Drug|KPT-330|
339278|NCT01607879|Drug|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.~Take one packet twice daily for 3 months"
339279|NCT01607879|Other|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
339280|NCT01607866|Procedure|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
339281|NCT01607866|Procedure|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
339282|NCT01607853|Drug|Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)|Once daily application, 3 weeks
339283|NCT01607853|Drug|Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)|Once daily application, 3 weeks
339284|NCT01607853|Drug|Daivobet® gel applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
339286|NCT01607840|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
339287|NCT01607827|Procedure|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
339288|NCT01607827|Procedure|Polyp removal upon withdrawal only|"Endoscopic procedures:~All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.~The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
339289|NCT01607775|Device|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
339290|NCT01607775|Device|PMMA-cage|The in-house produced cervical cage will be implanted
339291|NCT01607762|Drug|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
339292|NCT01607762|Drug|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
339293|NCT01607762|Drug|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
339294|NCT01607762|Drug|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
339295|NCT01607762|Drug|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
339296|NCT01607749|Behavioral|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.~Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
339297|NCT01607749|Other|Usual Asthma Information for teachers|Common asthma information for teachers
339298|NCT01607736|Behavioral|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
339299|NCT01607723|Other|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
339300|NCT01607723|Other|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
339301|NCT01607697|Behavioral|Mindfulness Training|Mindfulness Training
339302|NCT01607684|Device|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
339303|NCT01607671|Drug|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
339304|NCT01607658|Drug|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
339305|NCT01607658|Drug|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
339306|NCT01607658|Drug|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
339307|NCT01607658|Drug|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
339308|NCT01607645|Drug|decitabine|Given IV
339309|NCT01607645|Drug|idarubicin|Given IV
339310|NCT01607645|Drug|cytarabine|Given IV
339311|NCT01607632|Behavioral|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
339312|NCT01607619|Dietary Supplement|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
339313|NCT01607593|Drug|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
339314|NCT01607580|Drug|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
339315|NCT01607554|Drug|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle~Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
340462|NCT01598090|Biological|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
339316|NCT01607541|Behavioral|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
339317|NCT01607541|Behavioral|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
339318|NCT01607528|Dietary Supplement|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
339319|NCT01607528|Dietary Supplement|Placebo|A similar looking and tasting powder with no active substances
339320|NCT01607515|Other|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
339321|NCT01607489|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,~1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
339322|NCT01607476|Drug|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
339323|NCT01607476|Drug|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
339324|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
339325|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
339326|NCT01607450|Drug|GLP-1 Low Dose|0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
339327|NCT01607450|Drug|GLP-1 Mid-Range Dose|1.5mmol/kg/min for 12 hours prior to PET study
339328|NCT01607450|Drug|GLP-1 High Dose|4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
339329|NCT01607450|Drug|Saline|Normal saline placebo infusion for 12 hours prior to PET study
339330|NCT01607424|Behavioral|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
339331|NCT01607411|Drug|Fluoride|Fluoride Toothpaste
339332|NCT01607411|Drug|Placebo|Fluoride free toothpaste
339333|NCT01607398|Drug|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
339334|NCT01607398|Drug|Placebo|Placebo inhalation, twice daily, from week0 -12.
339335|NCT01607385|Drug|GSK2330672|BID, repeat doses
339336|NCT01607385|Drug|Placebo|BID, repeat doses
339337|NCT01607385|Drug|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
339338|NCT01607372|Drug|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
339339|NCT01607372|Device|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
339340|NCT01607372|Other|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
339341|NCT01607346|Drug|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
339342|NCT01607333|Drug|Lamotrigine use|Lamotrigine prescription during the study period
339343|NCT01607320|Drug|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
339344|NCT01607320|Drug|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
339345|NCT01607307|Drug|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
339346|NCT01607307|Drug|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
339347|NCT01607294|Drug|ETC-1002|ETC-1002 Daily for 4 weeks
339348|NCT01607294|Drug|Placebo|Placebo Daily for 4 weeks
339349|NCT01607268|Procedure|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
339350|NCT01607255|Drug|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
339351|NCT01607255|Procedure|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
339352|NCT01607255|Procedure|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
340466|NCT01598064|Dietary Supplement|GK#10|GK#10, 1 pack tid
339353|NCT01607255|Procedure|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
339354|NCT01607242|Other|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
339355|NCT01607242|Other|Voice Handicap Index|Subjective Evaluation of Voice disorders
339356|NCT01607242|Other|Swallowing Assesment|Swallowing function questionnaire
339357|NCT01607229|Other|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
339358|NCT01607203|Drug|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
339359|NCT01607203|Drug|pregnyl|5000 IU SC
339360|NCT01607177|Behavioral|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
339361|NCT01607164|Behavioral|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
339362|NCT01607151|Other|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
339363|NCT01607151|Other|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
339364|NCT01607125|Drug|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
339365|NCT01607125|Drug|Placebo|capsules, orally, once daily for 13 to 14 days
339366|NCT01607112|Biological|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
339367|NCT01607099|Procedure|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
339368|NCT01607086|Drug|Cherry lamotrigine ODT|25mg, taken orally on one study visit
339369|NCT01607086|Drug|Cherry Placebo|Taken orally on one study visit
339370|NCT01607073|Drug|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.~Children will start on a 4 weeks titration period:~Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID~In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
339371|NCT01607060|Drug|Lactulone|Patients will receive lactulone to daily laxation
339372|NCT01607034|Drug|Dexpramipexole|150 mg single dose
339373|NCT01607008|Other|MRI imaging|"3 total MRI imaging studies:~pre standard radiation treatment~during standard radiation treatment~post standard radiation treatment"
339374|NCT01606995|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
339375|NCT01606982|Drug|MDV3100|oral
339376|NCT01606969|Drug|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
339377|NCT01606969|Drug|scalp infiltration solution|1:100000 epinephrine-containing 1% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
339378|NCT01606956|Procedure|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
339379|NCT01606956|Procedure|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
339380|NCT01606930|Behavioral|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
339381|NCT01606917|Other|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
339382|NCT01606904|Behavioral|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
339383|NCT01606891|Behavioral|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
339384|NCT01606878|Drug|Crizotinib|Given PO
339385|NCT01606878|Drug|Cyclophosphamide|Given IV
339386|NCT01606878|Drug|Dexrazoxane Hydrochloride|Given IV
339387|NCT01606878|Drug|Doxorubicin Hydrochloride|Given IV
339388|NCT01606878|Other|Laboratory Biomarker Analysis|Correlative studies
339389|NCT01606878|Other|Pharmacological Study|Correlative studies
339390|NCT01606878|Other|Questionnaire Administration|Ancillary studies
339391|NCT01606878|Drug|Topotecan Hydrochloride|Given IV
339392|NCT01606878|Drug|Vincristine Sulfate|Given IV
339393|NCT01606852|Drug|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
339394|NCT01606813|Other|Usual Care|Standard care
339395|NCT01606813|Behavioral|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
339396|NCT01606813|Behavioral|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
339397|NCT01606813|Behavioral|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
339398|NCT01606800|Drug|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
339399|NCT01606800|Drug|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
339400|NCT01606787|Drug|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
339401|NCT01606787|Other|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
339402|NCT01606774|Other|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
339403|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
339404|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
339405|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
339406|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
339407|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
339408|NCT01606748|Biological|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg~Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
339409|NCT01606748|Drug|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)~Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
339410|NCT01606748|Drug|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2~Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
339411|NCT01606735|Drug|IBI-10090|dexamethasone
339412|NCT01606722|Drug|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
339413|NCT01606709|Drug|GnRH agonist|GnRH agonist 1mg one dose
339414|NCT01606709|Drug|hCG|5,000 IU one dose
339415|NCT01606696|Behavioral|HIIT|Higher intensity interval training.
339416|NCT01606696|Behavioral|Standard intensity non-interval training|Standard intensity non-interval training.
339417|NCT01606683|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
339418|NCT01606683|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
339419|NCT01606683|Other|No intervention|
339420|NCT01606657|Procedure|Irrigation|The patient will receive irrigation as a part of their wound care
339421|NCT01606657|Other|No Irrigation|The patient will not receive irrigation as part of their wound care
339422|NCT01606644|Procedure|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
339423|NCT01606592|Behavioral|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
339424|NCT01606592|Behavioral|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
339425|NCT01606592|Other|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
339426|NCT01606579|Drug|PRI-724|PRI-724
339427|NCT01606579|Drug|PRI-724|PRI-724 in combination with dasatinib
339428|NCT01606579|Drug|PRI-724|PRI-724 in combination with low dose ara-C therapy
339429|NCT01606566|Drug|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
339430|NCT01606553|Device|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
339431|NCT01606553|Device|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
339681|NCT01604499|Behavioral|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
339432|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition."
339433|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery."
339434|NCT01606527|Drug|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
339435|NCT01606514|Behavioral|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
339436|NCT01606488|Drug|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
339437|NCT01606488|Other|no intervention|
339438|NCT01606475|Biological|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
339439|NCT01606462|Drug|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
339440|NCT01606449|Procedure|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.~Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
339441|NCT01606436|Drug|Pomaglumetad methionil|Administered orally.
339442|NCT01606436|Drug|Matching placebo|Administered orally.
339443|NCT01606436|Drug|Moxifloxacin|Administered orally.
339444|NCT01606423|Drug|Placebo|Administered orally, single dose
339445|NCT01606423|Drug|LY2409021|Administered orally, single dose
339446|NCT01606410|Other|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
339447|NCT01606397|Drug|Placebo|Administered orally (capsule)
339448|NCT01606397|Drug|LY2409021|Administered orally (capsule)
339449|NCT01606384|Drug|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
339450|NCT01606384|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
339451|NCT01606371|Drug|Placebo|Administered orally
339452|NCT01606371|Drug|LY2409021|Administered orally
339453|NCT01606358|Drug|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
339454|NCT01606345|Drug|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
339455|NCT01606332|Procedure|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
339456|NCT01606319|Drug|Acetaminophen|15 mg/kg every 6 hours as needed
339457|NCT01606319|Drug|Ibuprofen|9.4 mg/kg every 6 hours as needed
339458|NCT01606306|Drug|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
339459|NCT01606306|Drug|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
339460|NCT01606306|Drug|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
339461|NCT01606293|Behavioral|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
339462|NCT01606267|Other|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
339463|NCT01606254|Drug|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
339464|NCT01606241|Drug|Cyclophosphamide|Given PO
339465|NCT01606241|Other|Laboratory Biomarker Analysis|Correlative studies
339466|NCT01606241|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
339467|NCT01606228|Drug|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
339468|NCT01606215|Drug|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
339469|NCT01606215|Drug|Placebo|Placebo
339470|NCT01606202|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
339471|NCT01606202|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
339472|NCT01606189|Drug|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
339473|NCT01606189|Drug|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
339474|NCT01606189|Drug|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
339791|NCT01603485|Drug|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
339475|NCT01606176|Drug|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
339476|NCT01606176|Drug|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
339477|NCT01606163|Biological|GC1102|"Description: GC1102 IV bolus injection during 10~ 30 seconds.~Amount: group1-3ml, group2-5ml, group3-8ml~Subject number: group1-8, group2-8, group3-8~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
339478|NCT01606163|Other|JW normal saline|"Description: Normal saline IV bolus injection through 10~ 30 seconds.~Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~Subject number: 9~Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
339479|NCT01606150|Drug|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
339480|NCT01606150|Drug|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
339481|NCT01606137|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
339482|NCT01606124|Drug|defined green tea catechin extract|Given PO
339483|NCT01606124|Other|placebo|Given PO
339484|NCT01606124|Other|questionnaire administration|Ancillary studies
339485|NCT01606124|Other|laboratory biomarker analysis|Correlative studies
339486|NCT01606111|Drug|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
339487|NCT01606111|Drug|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
339488|NCT01606098|Procedure|Surgery of the primary tumour|Surgical resection of the colon tumour
339489|NCT01606098|Drug|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:~5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
339490|NCT01606085|Behavioral|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
339491|NCT01606085|Behavioral|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
339492|NCT01606072|Drug|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
339493|NCT01606059|Drug|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
339494|NCT01606059|Drug|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
339495|NCT01606046|Device|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
339496|NCT01606046|Drug|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
339497|NCT01606033|Other|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
339498|NCT01606033|Other|questionnaire|understanding of the implications of participating in a clinical trial
339499|NCT01606020|Other|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
339500|NCT01606020|Other|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
339501|NCT01606007|Drug|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
339502|NCT01606007|Drug|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
339503|NCT01606007|Drug|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
339504|NCT01606007|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
339505|NCT01606007|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
339506|NCT01605994|Drug|BMS-933043|
339507|NCT01605994|Drug|Placebo matching with BMS-933043|
339508|NCT01605994|Drug|Antacid Buffer Predose Solution|
339509|NCT01605981|Drug|AMN107|
339510|NCT01605968|Device|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
339511|NCT01605968|Device|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
339512|NCT01605942|Drug|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
339513|NCT01605942|Drug|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
339514|NCT01605929|Procedure|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
339515|NCT01605916|Drug|AZD6244|Tablet Oral bid
339516|NCT01605903|Drug|Ibuprofen|Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
339518|NCT01605890|Drug|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.~raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
339519|NCT01605877|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
339520|NCT01605864|Drug|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
339521|NCT01605851|Device|Closure, Foramen Ovale|
339522|NCT01605825|Drug|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
339523|NCT01605825|Drug|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
339524|NCT01605799|Behavioral|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
339525|NCT01605799|Behavioral|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
339526|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
339527|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.~The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
339528|NCT01605786|Other|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.~Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
339529|NCT01605773|Drug|repaglinide|Dose individually adjusted and conducted according to labeling
339530|NCT01605773|Drug|glyburide|Dose individually adjusted and conducted according to labeling
339531|NCT01605760|Drug|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
339532|NCT01605747|Dietary Supplement|Culturelle|one capsule 2x per day per feeding tube
339533|NCT01605747|Dietary Supplement|Placebo|one placebo 2x per day per feeding tube
339534|NCT01605734|Procedure|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
339535|NCT01605734|Drug|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
339536|NCT01605721|Device|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent~: XIENCE PRIMETM"
339537|NCT01605708|Drug|REGN846|Dose 1
339538|NCT01605682|Dietary Supplement|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
339539|NCT01605669|Other|Tranthoracic Echocardiogram|standard measurement
339540|NCT01605669|Device|Cardiac Ascultation Recordings with Electronic stethoscope|3M device
339541|NCT01605656|Behavioral|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
339542|NCT01605656|Behavioral|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.~The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
339543|NCT01605656|Behavioral|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.~Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
339544|NCT01605630|Behavioral|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
339545|NCT01605630|Behavioral|Control|standard of care
339546|NCT01605617|Drug|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
339547|NCT01605617|Drug|Placebo|PTNS + placebo for 12 weeks
339792|NCT01603485|Drug|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
339548|NCT01605617|Procedure|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
339549|NCT01605604|Behavioral|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
339550|NCT01605591|Procedure|the DLT bending to the right|bending the bronchial lumen of DLT 60~90 degrees in the same side with the tracheal lumen
339551|NCT01605591|Procedure|the DLT bending to the left|bending the bronchial lumen of DLT 60~90 degree opposed to the tracheal lumen
339552|NCT01605578|Procedure|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
339553|NCT01605565|Procedure|A nasal brushing|A nasal brushing in every nostril
339554|NCT01605552|Behavioral|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
339555|NCT01605552|Other|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
339556|NCT01605539|Drug|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
339557|NCT01605539|Drug|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
339558|NCT01605539|Drug|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
339559|NCT01605526|Drug|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
339560|NCT01605526|Drug|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
339561|NCT01605513|Drug|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
339562|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
339563|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
339564|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
339565|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
339566|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
339567|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
339568|NCT01605474|Other|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
339569|NCT01605474|Other|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
339570|NCT01605461|Drug|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
339571|NCT01605448|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
339572|NCT01605435|Drug|Ghrelin Group 1|The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
339573|NCT01605435|Drug|Ghrelin Group 2|The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
339574|NCT01605422|Other|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
339575|NCT01605409|Procedure|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR~Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.~Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
339798|NCT01603420|Other|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
339799|NCT01603394|Drug|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
339576|NCT01605409|Procedure|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.~Transportation:~Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.~Standard Post resuscitation Management:~After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.~If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
339577|NCT01605396|Drug|Ridaforolimus|Ridaforolimus 10 mg tablet, administered PO at a dose of 10 mg (triplet) or 30 mg (doublet) depending upon randomization, on Days 1-5, 8-12, 15-19, & 22-26 of 28-day cycle.
339578|NCT01605396|Drug|Dalotuzumab|Dalotuzumab administered 10 mg/kg IV weekly on Days 1, 8, 15, and 22 of 28-day cycle.
339579|NCT01605396|Drug|Exemestane|Exemestane 25 mg tablet administered PO QD.
339580|NCT01605383|Biological|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
339581|NCT01605383|Procedure|Standard treatment|Isolated core decompression
339582|NCT01605370|Drug|Nebivolol|Nebivolol 2.5 mg once daily
339583|NCT01605370|Drug|Metoprolol succinate|Metoprolol succinate 50 mg once daily
339584|NCT01605357|Drug|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
339585|NCT01605357|Drug|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium < 135 mmol/L) is to be corrected at the discretion of the provider.
339586|NCT01605344|Drug|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
339587|NCT01605344|Drug|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
339588|NCT01605331|Drug|sustained-release recombinant human GH (SR-rhGH)|
339589|NCT01605318|Drug|IMMU-130|This is a Phase I/II, open-label study of IMMU-130 administered in 21-day treatment cycles, once or twice weekly for 2 consecutive weeks followed by one week of rest to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
339590|NCT01605305|Drug|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
339591|NCT01605292|Procedure|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
339592|NCT01605292|Procedure|Palpation|Manual palpation for localizing radial artery for inserting needle.
339593|NCT01605279|Drug|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
339594|NCT01605279|Drug|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
339595|NCT01605253|Drug|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
339596|NCT01605253|Drug|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
339597|NCT01605240|Drug|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
339598|NCT01605240|Drug|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
339599|NCT01605227|Drug|cabozantinib|Tablets taken orally once-daily
339600|NCT01605227|Drug|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
339601|NCT01605201|Biological|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
339602|NCT01605162|Drug|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
339643|NCT01604876|Device|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
339603|NCT01605162|Drug|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.~For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
339604|NCT01605136|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
339605|NCT01605136|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
339606|NCT01605110|Drug|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
339607|NCT01605110|Drug|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
339608|NCT01605097|Radiation|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
339609|NCT01605084|Drug|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
339610|NCT01605084|Drug|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
339611|NCT01605084|Drug|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
339612|NCT01605084|Drug|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks~NRTI backbone are:~- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)~The following NRTI combinations are prohibited in this study:~Didanosine + Stavudine~Zidovudine + Stavudine~Lamivudine + Emtricitabine"
339613|NCT01605071|Drug|Estradiol|"1 week of transdermal estradiol (0.15mg)~1 week of transdermal placebo"
339614|NCT01605045|Other|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
339615|NCT01605045|Other|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
339616|NCT01605032|Drug|Busulfan|Given IV
339617|NCT01605032|Drug|Melphalan|Given IV
339618|NCT01605032|Drug|Bortezomib|Given IV
339619|NCT01605032|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
339620|NCT01605032|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
339621|NCT01605032|Other|Laboratory Biomarker Analysis|Correlative studies
339622|NCT01605032|Other|Pharmacological Study|Correlative studies
339623|NCT01605019|Device|CoSeal|3 - 8mls of Coseal
339624|NCT01605019|Device|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
339625|NCT01605006|Device|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
339626|NCT01604993|Other|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
339627|NCT01604993|Other|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
339628|NCT01604980|Dietary Supplement|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
339629|NCT01604954|Behavioral|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
339630|NCT01604954|Behavioral|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
339631|NCT01604954|Behavioral|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
339632|NCT01604941|Drug|SPD602|50 mg/kg/day orally twice daily for 24 weeks
339633|NCT01604928|Drug|YM178|Oral
339634|NCT01604928|Drug|tolterodine|Oral
339635|NCT01604928|Drug|Placebo|Oral
339636|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
339637|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
339638|NCT01604902|Other|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
339639|NCT01604889|Drug|Epacadostat|
339640|NCT01604889|Drug|Placebo|Placebo
339641|NCT01604889|Drug|ipilimumab|ipilimumab 3 mg/kg IV
339642|NCT01604889|Drug|ipilimumab|Doses to be determined following the completion of Phase I of the study
339680|NCT01604499|Behavioral|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
339644|NCT01604876|Device|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
339645|NCT01604863|Drug|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
339646|NCT01604863|Drug|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
339647|NCT01604863|Drug|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
339648|NCT01604850|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
339649|NCT01604850|Drug|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
339650|NCT01604850|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
339651|NCT01604850|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
339652|NCT01604824|Drug|alirocumab|Randomized, double-blind treatment period may be followed by open-label treatment with alirocumab for all patients if certain criteria are met.
339653|NCT01604824|Drug|placebo|
339654|NCT01604811|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
339655|NCT01604811|Drug|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
339656|NCT01604811|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
339657|NCT01604811|Drug|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
339658|NCT01604798|Other|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
339659|NCT01604785|Drug|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
339660|NCT01604785|Drug|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
339661|NCT01604772|Drug|Akt Inhibitor MK2206|Given PO
339662|NCT01604772|Other|Laboratory Biomarker Analysis|Correlative studies
339663|NCT01604759|Device|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
339664|NCT01604746|Biological|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
339665|NCT01604707|Other|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
339666|NCT01604694|Procedure|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
339667|NCT01604681|Dietary Supplement|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
339668|NCT01604681|Dietary Supplement|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
339669|NCT01604655|Procedure|Coronary CT Angiography|CCTA
339670|NCT01604655|Procedure|Stress Test|Stress Test
339671|NCT01604642|Other|blood tests and muscular biopsies|blood tests and muscular biopsies
339672|NCT01604629|Drug|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
339673|NCT01604629|Drug|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
339674|NCT01604590|Radiation|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
339675|NCT01604577|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
339676|NCT01604525|Behavioral|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
339677|NCT01604525|Behavioral|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
339678|NCT01604525|Other|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
339679|NCT01604512|Other|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
339800|NCT01603381|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
339682|NCT01604460|Procedure|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
339683|NCT01604460|Procedure|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
339684|NCT01604447|Procedure|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
339685|NCT01604447|Procedure|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
339686|NCT01604434|Procedure|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
339687|NCT01604434|Procedure|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
339688|NCT01604421|Procedure|Thermoregulation-standard care|Standard care without plastic bag. One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
339689|NCT01604421|Procedure|Thermoregulation with plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
339690|NCT01604408|Biological|LY2495655|Administered SC
339691|NCT01604408|Drug|Placebo|Administered SC
339692|NCT01604382|Drug|General Anesthesia|General Anesthesia as described above
339693|NCT01604382|Drug|Neuraxial anesthesia|Neuraxial anesthesia as described above
339694|NCT01604369|Procedure|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
339695|NCT01604356|Procedure|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device [Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
339696|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
339697|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
339698|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
339699|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
339700|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
339701|NCT01604330|Drug|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
339702|NCT01604330|Drug|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
339703|NCT01604317|Procedure|Resuscitation-torso plastic bag|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
339704|NCT01604317|Procedure|Resuscitation-partial-head plastic bag|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
339705|NCT01604304|Procedure|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
339706|NCT01604304|Procedure|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
339707|NCT01604278|Drug|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
339708|NCT01604278|Drug|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
339709|NCT01604265|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
339710|NCT01604265|Drug|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
339711|NCT01604239|Drug|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
339712|NCT01604213|Drug|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
339713|NCT01604213|Drug|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
339714|NCT01604200|Behavioral|focus group|key informant review
339715|NCT01604187|Drug|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
339716|NCT01604187|Drug|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
339717|NCT01604174|Other|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
339718|NCT01604174|Other|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
339719|NCT01604161|Drug|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
339720|NCT01604135|Device|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
339721|NCT01604122|Other|No drug|No drug.
339722|NCT01604122|Other|No drug|No drug.
339723|NCT01604109|Drug|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
339724|NCT01604109|Drug|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
339725|NCT01604096|Other|Multifaceted information campaign|"Following is the description of the multifaceted intervention:~brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)~posters (same distribution as brochures)~short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies~radio-spots transmitted in local radio stations~advertisements in local newspapers~banners on websites of local newspapers~newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists~training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
339726|NCT01604057|Drug|ZT-034 Low Dose Nasal Spray|Nasal Spray
339727|NCT01604057|Drug|ZT-034 Mid Dose Nasal Spray|Nasal Spray
339728|NCT01604057|Drug|ZT-034 High Dose Nasal Spray|Nasal Spray
339729|NCT01604057|Drug|Teriparatide|20 mcg subcutaneous daily
339730|NCT01604057|Drug|Placebo|Nasal Spray
339731|NCT01604044|Drug|Meropur 150 a day|one subcutaneous injection a day
339732|NCT01604044|Drug|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
339733|NCT01604031|Biological|B-CLL Vaccine|Patients will receive a fixed dose (2X10^7) of IL-2 secreting B-cells together with (2X10^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
339734|NCT01604031|Drug|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
339735|NCT01604005|Radiation|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
339736|NCT01603979|Biological|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
339737|NCT01603940|Drug|Benazepril|Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
339738|NCT01603940|Drug|Losartan|Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
339739|NCT01603927|Device|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
339740|NCT01603914|Device|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
339741|NCT01603901|Device|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
339742|NCT01603888|Other|no intervention|
339743|NCT01603875|Biological|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
339744|NCT01603862|Procedure|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
339745|NCT01603849|Radiation|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
339793|NCT01603459|Drug|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.~For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
339794|NCT01603446|Drug|L-Arginine|NOW® L-Arginine powder
339746|NCT01603836|Biological|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
339747|NCT01603784|Behavioral|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at ~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
339748|NCT01603784|Behavioral|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
339749|NCT01603784|Behavioral|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
339750|NCT01603784|Behavioral|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
339751|NCT01603771|Other|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
339752|NCT01603758|Drug|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
339753|NCT01603719|Dietary Supplement|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
339754|NCT01603563|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
339755|NCT01603563|Behavioral|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
339756|NCT01603550|Other|Sleep Deprivation|Sleep Deprivation
339757|NCT01603550|Other|Energy Restriction|Energy Restriction
339758|NCT01603524|Other|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:~Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.~Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.~Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).~Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
339759|NCT01603524|Behavioral|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
339760|NCT01603511|Device|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
339761|NCT01603498|Drug|Dexamethasone|Dexamethasone 8mg
339762|NCT01603498|Drug|Methylprednisolone|Methylprednisolone 40mg
339763|NCT01603407|Drug|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
339764|NCT01603407|Drug|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
339765|NCT01603407|Drug|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
339766|NCT01603810|Other|OCT|Optical coherence tomography of periocular basal cell carcinoma
339795|NCT01603433|Device|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
339796|NCT01603420|Drug|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
339797|NCT01603420|Drug|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
339767|NCT01603797|Behavioral|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
339768|NCT01603745|Drug|Zoely|1 pill every day
339769|NCT01603745|Drug|Yasmin|1 pill every day
339770|NCT01603706|Procedure|Echo guided implantation group|Lead placement according echo strain imaging result
339771|NCT01603693|Device|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
339772|NCT01603693|Device|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
339773|NCT01603680|Procedure|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
339774|NCT01603680|Procedure|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
339775|NCT01603667|Drug|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
339776|NCT01603667|Drug|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.~ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
339777|NCT01603654|Drug|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
339778|NCT01603654|Drug|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
339779|NCT01603641|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
339780|NCT01603628|Biological|botulinum toxin Type A|Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.
339781|NCT01603628|Drug|Normal Saline (Placebo)|Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.
339782|NCT01603615|Biological|Botulinum Toxin Type A|Participants received intramuscular injections of botulinum Toxin Type A in the upper and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.
339783|NCT01603602|Biological|botulinum toxin Type A|Intramuscular injections of botulinum toxin Type A into specified muscles of the upper limb on Day 1.
339784|NCT01603602|Drug|Normal Saline (Placebo)|Intramuscular injections of normal saline (placebo) into specified muscles of the upper limb on Day 1.
339785|NCT01603589|Procedure|Coronary artery bypass grafting with the use of minimal invasive extracorporeal circulation|We use a prototype AHEPA (modular type IV) circuit comprised of the standard and a standby accessory. Components of the standard circuit include: aortic cannula, three-stage venous cannula, coated tubing, a centrifugal pump, a new-generation membrane oxygenator with integrated arterial filter, a venous air removal device, a soft coated bag and pulmonary artery as well as aortic root vent. In addition, there is a standby hard-shell reservoir in parallel to the venous line, so as to convert the closed system to an open one. The standby component is bridged to the main circuit with an afferent line which is connected just before the VARD sending blood to the hard-shell reservoir and an efferent that re-directs it back to the VARD. A cell-saver device is added to the circuit for collecting shed blood and washing red blood cells for autotransfusion.
339786|NCT01603589|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
339787|NCT01603576|Device|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
339788|NCT01603485|Drug|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
339789|NCT01603485|Drug|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
339790|NCT01603485|Drug|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
339801|NCT01603368|Dietary Supplement|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
339802|NCT01603368|Dietary Supplement|Placebo|Oil drops without Lactobacillus reuteri
339803|NCT01603355|Drug|Tocilizumab|"Intravenous tocilizumab:~Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
339804|NCT01603342|Drug|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
339805|NCT01603342|Drug|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
339806|NCT01603329|Other|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:~Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.~Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.~When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
339807|NCT01603316|Behavioral|surveys|Each survey will take about 45 minutes.Surveys will include questions on medical treatment, health insurance, work-related information, overall health and well being, eating habits, and satisfaction/use of the food program provided. 3 and 6-month follow-up. All participants will be asked to complete the study contact form.
339808|NCT01603316|Behavioral|Focus groups|Prior to conducting the updated RCT design with the expanded cohort, we will conduct 4-6 focus groups (to saturation) with underserved breast cancer patients to optimally tailor the written materials and nutrition education sessions.
339809|NCT01603303|Behavioral|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
339810|NCT01603303|Other|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
339811|NCT01603303|Other|Luvena|Use vaginally 2 or 3 times a week.
339812|NCT01603303|Other|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
339813|NCT01603303|Other|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
339814|NCT01603303|Behavioral|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
339815|NCT01603303|Behavioral|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
339816|NCT01603277|Biological|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
339817|NCT01603277|Other|Placebo|Normal Saline
339818|NCT01603264|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
339819|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
339820|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
339821|NCT01603251|Drug|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
339822|NCT01603251|Drug|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
339823|NCT01603251|Drug|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
339824|NCT01603238|Drug|[14C]-LC15-0444|A single oral administration of [14C]-LC15-0444 50 mg, containing 4.9 MBq [14C]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
339825|NCT01603225|Procedure|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
339826|NCT01603212|Drug|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.~Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
339827|NCT01603212|Drug|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
339828|NCT01603212|Drug|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
339829|NCT01603199|Dietary Supplement|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
339830|NCT01603186|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
339831|NCT01603186|Drug|Quetiapine Fumarate|25 mg tablet once a day
339832|NCT01603173|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
339833|NCT01603173|Drug|Quetiapine Fumarate|25 mg tablet once a day
339885|NCT01602770|Drug|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
340467|NCT01598064|Drug|Placebo|Placebo 1 pack tid po
339834|NCT01603160|Behavioral|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.~A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
339835|NCT01603147|Biological|normal saline|saline 225 ml
339836|NCT01603147|Biological|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
339837|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
339838|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
339839|NCT01603121|Drug|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
339840|NCT01603108|Drug|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
339841|NCT01603108|Drug|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
339842|NCT01603082|Drug|Ticagrelor|180 mg loading dose
339843|NCT01603082|Drug|Clopidogrel|600 mg loading dose
339844|NCT01603069|Drug|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
339845|NCT01603069|Drug|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
339846|NCT01603069|Drug|Placebo|Placebo to AZD3241 BID
339847|NCT01603056|Biological|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
339848|NCT01603056|Biological|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
339849|NCT01603043|Drug|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
339850|NCT01603043|Drug|Sham injection|Mock injection administered as an empty hub without needle
339851|NCT01603030|Drug|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
339852|NCT01603030|Drug|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
339853|NCT01603017|Device|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
339854|NCT01603017|Device|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
339855|NCT01603004|Other|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
339856|NCT01602991|Procedure|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
339857|NCT01602991|Procedure|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
339858|NCT01602965|Procedure|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
339859|NCT01602965|Procedure|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
339860|NCT01602952|Drug|Radotinib|50mg, 100mg or 200mg Capsule BID
339861|NCT01602939|Drug|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.~Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
339862|NCT01602926|Procedure|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
339863|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
339864|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
339865|NCT01602913|Drug|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
339866|NCT01602913|Drug|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
339867|NCT01602913|Drug|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
339868|NCT01602900|Drug|GSK356278|Investigational Medicinal Product
339869|NCT01602900|Drug|Rolipram|Challenge Agent
339870|NCT01602887|Drug|PD-0332991|isethionate hard capsule, 125 mg, single dose
339871|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
339872|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
339873|NCT01602887|Drug|PD-0332991|oral solution, 50 mg, single dose
339874|NCT01602874|Drug|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
339875|NCT01602874|Drug|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
339876|NCT01602874|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
339877|NCT01602874|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
339878|NCT01602861|Drug|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.~In case of hyperkaliemia (>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
339879|NCT01602861|Drug|placebo|
339880|NCT01602848|Other|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
339881|NCT01602822|Drug|3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
339882|NCT01602822|Drug|Ritonavir, Atazanavir, Truvada|
339883|NCT01602796|Behavioral|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
339884|NCT01602783|Other|11C Acetate Imaging|Single scan
339886|NCT01602757|Drug|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
339887|NCT01602744|Other|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
339888|NCT01602731|Device|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
339889|NCT01602718|Other|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
339890|NCT01602705|Other|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
339891|NCT01602705|Other|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
339892|NCT01602705|Other|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
339893|NCT01602692|Drug|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
339894|NCT01602692|Drug|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
339895|NCT01602679|Drug|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
339896|NCT01602679|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
339897|NCT01602666|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
339898|NCT01602666|Drug|Carboplatin|Given IV
339899|NCT01602666|Drug|Etoposide|Given IV
339900|NCT01602666|Drug|Ifosfamide|Given IV
339901|NCT01602666|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
339902|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
339903|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
339904|NCT01602640|Drug|Morphine infusion|Conventional dose
339905|NCT01602640|Drug|Fentanyl and Midazolam infusion|Conventional dose
339906|NCT01602627|Drug|Hsp90 inhibitor AUY922|Given IV
339907|NCT01602627|Other|pharmacological study|Correlative studies
339908|NCT01602627|Other|laboratory biomarker analysis|Correlative studies
339909|NCT01602601|Drug|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
339910|NCT01602601|Drug|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
339911|NCT01602588|Drug|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
339912|NCT01602588|Radiation|Radiotherapy|Short Course radiotherapy
339913|NCT01602575|Behavioral|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
339914|NCT01602562|Drug|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
339915|NCT01602549|Drug|GSK962040 (25 mg tablet)|25 mg tablet
339916|NCT01602549|Drug|Placebo|matching placebo tablet
339917|NCT01602536|Behavioral|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
339918|NCT01602536|Behavioral|Twitter|Twitter quit-smoking group
339919|NCT01602523|Drug|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
339920|NCT01602523|Drug|Placebo|Placebo inhaler once daily 28 days
339921|NCT01602510|Drug|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
339922|NCT01602510|Drug|Placebo|Placebo
339923|NCT01602497|Device|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
339924|NCT01602497|Device|sham rTMS|Patients will undergo ten session of sham rTMS.
339925|NCT01602484|Device|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
339926|NCT01602484|Device|Bulk splint supplies|Applying splint by using the bulk splint supplies
339927|NCT01602471|Drug|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis > 69% will undergo an endarterectomy and will be imaged under PET/CT with [F-18]RGD-K5
339928|NCT01602458|Procedure|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
339980|NCT01602146|Other|ultramarathon running|"blood samples before and after ultramarathon~urinary samples before and after ultramarathon~voluntary ant electrically muscular forces measuring before and after ultramarathon~Broadband ultrasound Attenuation before and after ultramarathon"
340576|NCT01597362|Procedure|laparoscopy|Trocar access in laparoscopy
339929|NCT01602458|Procedure|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.~The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
339930|NCT01602419|Other|Patients using wilate as standard of care|Patients with von Willebrand Disease using wilate for a period of 2 years.
339931|NCT01602406|Drug|LJM716|LJM716
339932|NCT01602406|Drug|Trastuzumab|Trastuzumab
339933|NCT01602393|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
339934|NCT01602393|Drug|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
339935|NCT01602393|Drug|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
339936|NCT01602380|Drug|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
339937|NCT01602380|Drug|arimidex 1mg|oral tablet 1 daily
339938|NCT01602380|Drug|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
339939|NCT01602380|Drug|arimidex dummy|oral tablet 1 daily
339940|NCT01602367|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
339941|NCT01602367|Drug|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
339942|NCT01602367|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
339943|NCT01602367|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
339944|NCT01602341|Drug|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
339945|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
339946|NCT01602341|Drug|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
339947|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
339948|NCT01602328|Biological|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
339949|NCT01602328|Biological|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
339950|NCT01602315|Drug|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
339951|NCT01602315|Drug|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
339952|NCT01602315|Biological|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
339953|NCT01602315|Drug|BYL719 drink suspension|Oral alpha-specific PI3K inhibitor
339954|NCT01602302|Drug|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
339955|NCT01602289|Biological|LY2875358|Administered IV
339956|NCT01602289|Drug|Erlotinib|Administered orally
339957|NCT01602289|Drug|Gefitinib|Administered orally
339958|NCT01602276|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
339959|NCT01602263|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
339960|NCT01602250|Drug|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
339961|NCT01602250|Drug|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
339962|NCT01602224|Drug|Placebo|Administered IV
339963|NCT01602224|Drug|Dexamethasone|Administered orally
339964|NCT01602224|Drug|Bortezomib|Administered SQ
339965|NCT01602224|Biological|Tabalumab|Administered IV
339966|NCT01602211|Other|Internet-Based Intervention|Receive full access to INSPIRE
339967|NCT01602211|Other|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
339968|NCT01602211|Other|Medical Chart Review|Ancillary studies
339969|NCT01602211|Other|Quality-of-Life Assessment|Ancillary studies
339970|NCT01602211|Other|Questionnaire Administration|Ancillary studies
339971|NCT01602198|Drug|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
339972|NCT01602198|Drug|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
339973|NCT01602185|Drug|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
339974|NCT01602185|Drug|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
339975|NCT01602185|Drug|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
339976|NCT01602172|Behavioral|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
339977|NCT01602172|Other|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
339978|NCT01602159|Procedure|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
339979|NCT01602159|Procedure|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
340463|NCT01598090|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
339981|NCT01602133|Procedure|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
339982|NCT01602120|Drug|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
339983|NCT01602107|Other|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
339984|NCT01602081|Device|reinforce soft tissue|reinforce soft tissue
339985|NCT01602068|Drug|Dexamethasone Phosphate Ophthalmic|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
339986|NCT01602068|Drug|100 mM Sodium Citrate Buffer|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
339987|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
339988|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
339989|NCT01602029|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
339990|NCT01602029|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
339991|NCT01602029|Drug|Placebo|Placebo added to TAU
339992|NCT01602029|Drug|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
339993|NCT01602016|Drug|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
339994|NCT01602016|Drug|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
339995|NCT01602003|Drug|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
339996|NCT01602003|Drug|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
339997|NCT01602003|Drug|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
339998|NCT01601990|Drug|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
339999|NCT01601990|Drug|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
340000|NCT01601977|Device|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
340001|NCT01601977|Device|Usual care|Non-invasive ventilation with standard ventilator
340002|NCT01601951|Other|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
340003|NCT01601938|Dietary Supplement|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
340004|NCT01601938|Dietary Supplement|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
340005|NCT01601925|Other|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
340006|NCT01601912|Drug|Atomoxetine|40 mg, 1 application
340007|NCT01601912|Drug|Citalopram|20 mg, 1 application
340008|NCT01601899|Drug|Stavudine|30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg
340009|NCT01601899|Drug|Stavudine|20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg
340010|NCT01601899|Drug|Tenofovir|300 mg po QD
340011|NCT01601873|Device|PROPATEN|Heparin-bonded graft implantation for hemodialysis vascular access
340012|NCT01601873|Device|Standard Graft|non-heparin bonded conventional hemodialysis vascular access graft
340013|NCT01601860|Other|Use of non-pharmacological|Evaluation of maternal and perinatal outcomes associated with the use of non-pharmacological
340014|NCT01601847|Dietary Supplement|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
340015|NCT01601847|Drug|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
340016|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
340017|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
340330|NCT01599234|Drug|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
340018|NCT01601821|Drug|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
340019|NCT01601821|Drug|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
340020|NCT01601808|Drug|Placebo|Orally once a day, continuously throughout the study
340021|NCT01601808|Drug|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
340022|NCT01601795|Drug|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
340023|NCT01601795|Drug|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
340024|NCT01601782|Procedure|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
340025|NCT01601782|Device|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
340026|NCT01601769|Device|Vitom|Patients treated and diagnosed by vitom
340027|NCT01601769|Device|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.~Patients treated by colposcopy"
340028|NCT01601756|Device|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
340029|NCT01601756|Device|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
340030|NCT01601743|Behavioral|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
340031|NCT01601743|Behavioral|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
340032|NCT01601743|Behavioral|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
340033|NCT01601730|Drug|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
340034|NCT01601730|Drug|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
340035|NCT01601730|Drug|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
340036|NCT01601730|Drug|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
340037|NCT01601717|Drug|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
340038|NCT01601717|Drug|Placebo|Matching placebo pill administered once per day for 10 days.
340039|NCT01601704|Drug|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
340040|NCT01601704|Drug|PBO|Placebo. Administered in addition to the weight management program.
340041|NCT01601704|Behavioral|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
340042|NCT01601691|Device|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
340043|NCT01601678|Procedure|Peroral Endoscopic Myotomy (POEM)|After lavage, measure gastro-esophageal junction (GEJ) in cm from mouth piece. Determine entry point 12-14cm above GEJ at the lesser curvature site, inject 10ml coloured saline, create entry point. Advance endoscope into the submucosa, dissect the submucosal tunnel up to 2-3cm into the cardia. Dissect the submucosa close to the muscularis and check endoluminally for the direction of the lesser curvature, sufficient extension onto the cardia and mucosal integrity. After tunnel completion flush with gentamycin and saline. Start myotomy from proximally to distally starting 4-5cm below the mucosal entry site; the inner circular muscle layer should be fully dissected especially at the cardia for good symptomatic results. It is vital that the mucosa of the tubular esophagus remains intact. Extend myotomy at least 2cm onto the cardia. After completion check for mucosal integrity and opening of the distal esophageal sphincter. Close the entry point with clips from distal to proximal.
340044|NCT01601678|Procedure|Laparoscopic Heller Myotomy (LHM)|Use five trocar technique with patient in the French position as for laparoscopic anti-reflux procedures. Establish 12-15 mm Hg pneumoperitoneum. Use left paramedian trocar for camera, two lateral trocars for elevating liver and retraction of stomach and two trocars for dissection and suturing. Use of robotic surgery devices is allowed. Divide phrenoesophageal ligament starting on the right and mobilize distal esophagus on the lateral and anterior side. Identify and spare anterior vagal nerve. Perform myotomy by dividing both muscle-layers extending at least 6 cm above gastroesophageal junction and at least 2-3 cm inferiorly over stomach. Perform extent downwards after dividing epiphrenic fat pad overlying cardia. Measure myotomy length. Peroperative endoscopy check is advisable. Perform anterior fundoplication according to Dor. Only if necessary mobilize fundus of the stomach by dividing short gastric vessels. Suture fundus to both cut edges of myotomy, using non-resorbable material.
340045|NCT01601665|Device|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
340046|NCT01601665|Device|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
340047|NCT01601665|Device|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
340331|NCT01599221|Device|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
340048|NCT01601665|Device|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
340049|NCT01601665|Device|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
340050|NCT01601652|Drug|Omegaven|1 g/kg/d iv infusion over 24h
340051|NCT01601639|Device|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
340052|NCT01601639|Device|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
340053|NCT01601626|Drug|Standard-dose Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
340054|NCT01601626|Drug|Double-dose Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
340055|NCT01601626|Drug|Raltegravir|One 400 mg tablet orally twice daily from entry to Week 72.
340056|NCT01601626|Drug|Isoniazid|300 mg orally once daily from entry through Week 24.
340057|NCT01601626|Drug|Pyridoxine|25 mg orally once daily from entry to Week 24.
340058|NCT01601626|Drug|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
340059|NCT01601626|Drug|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
340060|NCT01601626|Drug|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
340061|NCT01601626|Drug|Rifampin|Weight-based dose; for weight < 45 kg: 450 mg orally once daily; for weight > 45 kg: 600 mg orally once daily, from entry to week 24.
340062|NCT01601613|Drug|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
340063|NCT01601613|Drug|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
340064|NCT01601600|Drug|BYM338|BYM338
340065|NCT01601600|Drug|Placebo|BYM338 Placebo
340066|NCT01601587|Other|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:~What is mental health?~Treatment options: orientation about individual and group based treatment modalities.~Former patients experience with their own treatment, self-help and participation.~How to influence and participate actively in the treatment and patient rights.~What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
340067|NCT01601574|Behavioral|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
340068|NCT01601574|Other|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
340069|NCT01601561|Drug|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.~Humulin R 5 mU/kg/min and a variable infusion of glucose."
340070|NCT01601548|Behavioral|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
340071|NCT01601535|Drug|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
340072|NCT01601535|Drug|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
340073|NCT01601535|Drug|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
340074|NCT01601522|Procedure|Peanut protein|500 mg
340075|NCT01601522|Procedure|Oat flour|500 mg Oat flour
340076|NCT01601509|Drug|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
340113|NCT01601184|Drug|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
340114|NCT01601158|Biological|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
340077|NCT01601509|Drug|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
340078|NCT01601496|Device|FUSION™ Vascular Graft|All subjects receive FUSION™ Vascular Graft at baseline implant procedure
340079|NCT01601483|Drug|MC-1101|1% Ophthalmic Solution TID
340080|NCT01601483|Drug|MC-1101 Vehicle|Ophthalmic solution, TID
340081|NCT01601470|Drug|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
340082|NCT01601470|Drug|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
340083|NCT01601457|Drug|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
340084|NCT01601457|Drug|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
340085|NCT01601444|Device|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
340086|NCT01601431|Device|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
340087|NCT01601431|Device|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
340088|NCT01601418|Drug|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
340089|NCT01601418|Drug|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
340090|NCT01601405|Drug|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
340091|NCT01601405|Drug|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
340092|NCT01601392|Procedure|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
340093|NCT01601392|Procedure|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
340094|NCT01601392|Procedure|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
340095|NCT01601366|Device|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
340096|NCT01601366|Drug|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
340097|NCT01601353|Device|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
340098|NCT01601340|Drug|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
340099|NCT01601340|Drug|Placebo|Placebo tablets, twice daily for 48 weeks
340100|NCT01601327|Drug|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
340101|NCT01601327|Drug|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
340102|NCT01601327|Drug|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
340103|NCT01601314|Drug|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
340104|NCT01601314|Other|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.~After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
340105|NCT01601301|Device|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
340106|NCT01601262|Device|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
340107|NCT01601249|Procedure|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
340108|NCT01601236|Drug|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups [8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)].
340109|NCT01601236|Drug|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
340110|NCT01601210|Drug|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
340111|NCT01601197|Behavioral|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
340112|NCT01601184|Drug|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
340306|NCT01599494|Drug|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
340115|NCT01601158|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
340116|NCT01601145|Dietary Supplement|consumption of lozenges|Each subject two lozenges a day for 6 weeks
340117|NCT01601132|Drug|theophylline|300mg (80mg/15ml elixir)
340118|NCT01601132|Drug|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
340119|NCT01601119|Drug|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
340120|NCT01601119|Other|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
340121|NCT01601106|Drug|liposomal prednisolone|Two weekly dosages with 150 mg.
340122|NCT01601106|Drug|Placebo|
340123|NCT01601093|Drug|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
340124|NCT01601093|Drug|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
340125|NCT01601093|Drug|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
340126|NCT01601067|Behavioral|Integrated Prolonged Exposure Therapy|Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
340127|NCT01601067|Behavioral|Seeking Safety|Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
340128|NCT01601054|Device|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
340129|NCT01601041|Other|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
340130|NCT01601028|Drug|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
340131|NCT01601028|Drug|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
340132|NCT01601015|Other|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
340133|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
340134|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
340135|NCT01601015|Other|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
340136|NCT01601002|Drug|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
340137|NCT01600989|Other|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
340138|NCT01600989|Other|blood sampling|Blood samples will be taken twice at a 7 day interval
340139|NCT01600976|Drug|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
340140|NCT01600963|Drug|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
340141|NCT01600963|Drug|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
340142|NCT01600963|Drug|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
340143|NCT01600963|Drug|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
340144|NCT01600950|Drug|LY2963016|Single 0.3 U/kg dose administered subcutaneously
340145|NCT01600950|Drug|Lantus|Single 0.3 U/kg dose administered subcutaneously
340146|NCT01600937|Behavioral|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
340147|NCT01600911|Other|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
340332|NCT01599208|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
340333|NCT01599195|Device|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
340148|NCT01600885|Drug|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
340149|NCT01600885|Drug|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
340150|NCT01600859|Drug|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg~E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg~According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
340151|NCT01600859|Drug|Placebo for E2609|"Placebo capsules~According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
340152|NCT01600820|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
340153|NCT01600820|Other|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
340154|NCT01600820|Other|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
340155|NCT01600807|Drug|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
340156|NCT01600807|Drug|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
340157|NCT01600781|Dietary Supplement|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
340158|NCT01600768|Drug|Beta-Lactams|infusion time: 30 mins or 1 hr
340159|NCT01600768|Drug|Beta-Lactams|infusion time 4 hrs
340160|NCT01600755|Biological|Autologous Muscle-Derived Cells (AMDC)|Cell Treatment
340161|NCT01600742|Drug|Vorinostat|"Run-in phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.~Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
340162|NCT01600742|Drug|Placebo|"Randomization phase:~WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.~Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
340163|NCT01600729|Drug|No Intervention|No intervention.
340164|NCT01600716|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
340165|NCT01600716|Drug|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
340166|NCT01600703|Drug|Sitagliptin|Sitagliptin, 100mg, oral, single dose
340167|NCT01600703|Drug|Placebo|Placebo, oral, single dose
340168|NCT01600690|Other|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
340169|NCT01600677|Device|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
340170|NCT01600677|Other|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
340171|NCT01600664|Behavioral|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
340172|NCT01600664|Behavioral|Convertible PC|Participants will be using the convertible PC without the interactive computer game
340173|NCT01600651|Other|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
340174|NCT01600651|Other|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
340175|NCT01600638|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
340176|NCT01600625|Drug|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
340177|NCT01600612|Drug|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
340178|NCT01600612|Drug|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
340179|NCT01600612|Drug|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
340180|NCT01600599|Drug|Tranexamic Acid|intravenous 1g and topical 1g
340181|NCT01600599|Drug|saline|100mls of topical saline
340182|NCT01600586|Device|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
340415|NCT01598480|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
340183|NCT01600573|Drug|pazopanib in combination with weekly topotecan|"Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
340184|NCT01600534|Behavioral|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
340185|NCT01600521|Drug|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
340186|NCT01600508|Other|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
340187|NCT01600495|Other|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
340188|NCT01600482|Device|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
340189|NCT01600469|Drug|DAOI-B|250-1500 mg/day, oral, for 24 weeks
340190|NCT01600469|Other|Placebo|placebo, oral, for 24 weeks
340191|NCT01600456|Behavioral|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
340192|NCT01600456|Other|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
340193|NCT01600443|Device|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
340194|NCT01600443|Device|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
340195|NCT01600443|Device|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
340196|NCT01600430|Dietary Supplement|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
340197|NCT01600430|Dietary Supplement|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
340198|NCT01600430|Dietary Supplement|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
340199|NCT01600404|Drug|antimuscarinic treatment|
340200|NCT01600391|Behavioral|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
340201|NCT01600391|Behavioral|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
340202|NCT01600391|Behavioral|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
340203|NCT01600365|Drug|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
340204|NCT01600365|Drug|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
340205|NCT01600339|Drug|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
340206|NCT01600326|Procedure|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
340207|NCT01600326|Drug|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.~The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.~Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.~Subjects will see their referring physician two weeks after treatment to begin physical therapy."
340208|NCT01600313|Dietary Supplement|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
340209|NCT01600300|Device|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
340210|NCT01600300|Device|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
340459|NCT01598103|Drug|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
340211|NCT01600287|Other|IAADS|"In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol."
340212|NCT01600287|Other|Manual propofol administration|"In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value."
340213|NCT01600274|Drug|Ethyinylestradiol Dienogest combination|"A: One tablet of Test B: One tablet of Reference~2 x 0.03 mg EE = 0.06 mg EE 2 x 2 mg DNG = 4 mg DNG"
340214|NCT01600248|Behavioral|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
340215|NCT01600235|Drug|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
340216|NCT01600222|Drug|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
340217|NCT01600196|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
340218|NCT01600183|Device|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
340219|NCT01600183|Procedure|cast|casting of the infant legs
340220|NCT01600170|Drug|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
340221|NCT01600170|Drug|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
340222|NCT01600157|Procedure|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
340223|NCT01600144|Other|digital mammography|data collection
340224|NCT01600131|Behavioral|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
340225|NCT01600131|Other|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
340226|NCT01600118|Device|Extracorporeal shockwave therapy|1000 impulses
340227|NCT01600118|Device|No extracorporeal shockwave|0 impulses, acoustic effect
340228|NCT01600105|Drug|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
340229|NCT01600092|Biological|RotaTeq™ experimental formulation|
340230|NCT01600092|Biological|RotaTeq™ existing formulation|
340231|NCT01600079|Biological|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
340232|NCT01600053|Drug|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
340233|NCT01600040|Radiation|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
340234|NCT01600027|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
340235|NCT01600027|Procedure|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
340236|NCT01600014|Drug|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
340237|NCT01600014|Drug|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
340238|NCT01600001|Drug|KWA-0711|
340239|NCT01600001|Drug|Placebo|
340240|NCT01599988|Dietary Supplement|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
340241|NCT01599988|Dietary Supplement|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
340242|NCT01599975|Drug|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
340243|NCT01599975|Drug|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
340244|NCT01599975|Drug|Matched placebo|2 tablets of matched placebo daily by mouth
340245|NCT01599962|Drug|Cinacalcet|single administration, 90mg
340246|NCT01599962|Drug|Placebo|single administration
340460|NCT01598103|Drug|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
340247|NCT01599949|Drug|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
340248|NCT01599936|Biological|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
340249|NCT01599923|Biological|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
340250|NCT01599910|Other|Scribes|Scribe
340251|NCT01599897|Biological|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
340252|NCT01599897|Biological|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
340253|NCT01599884|Drug|N-acetylcysteine|1800 mg twice daily for 8 weeks
340254|NCT01599884|Drug|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
340255|NCT01599871|Drug|theophylline|theophylline 100 mg, twice at day
340256|NCT01599871|Other|placebo|Placebo
340257|NCT01599858|Drug|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
340258|NCT01599858|Drug|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
340259|NCT01599832|Drug|pazopanib hydrochloride|Given PO
340260|NCT01599832|Other|laboratory biomarker analysis|Correlative studies
340261|NCT01599832|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
340262|NCT01599832|Other|pharmacogenomic studies|Correlative studies
340263|NCT01599819|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
340264|NCT01599819|Biological|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
340265|NCT01599806|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
340266|NCT01599806|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
340267|NCT01599806|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
340268|NCT01599806|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
340269|NCT01599793|Drug|cabozantinib|Given PO
340270|NCT01599793|Other|laboratory biomarker analysis|Correlative studies
340271|NCT01599793|Procedure|magnetic resonance imaging|Undergo MRI
340272|NCT01599767|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
340273|NCT01599754|Drug|Axitinib|Axitinib 5 mg twice daily
340274|NCT01599754|Drug|Placebo|Placebo twice daily
340275|NCT01599741|Radiation|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
340276|NCT01599741|Radiation|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
340277|NCT01599728|Drug|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min [15, 50 and 150 ng/min] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) [to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
340278|NCT01599715|Behavioral|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
340279|NCT01599715|Behavioral|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
340280|NCT01599702|Drug|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
340281|NCT01599689|Other|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.~To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
340282|NCT01599676|Dietary Supplement|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
340283|NCT01599676|Dietary Supplement|Non essential amino acid|Non essential amino acid supplementation
340307|NCT01599494|Drug|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
340284|NCT01599663|Other|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
340285|NCT01599650|Drug|Ranibizumab|
340286|NCT01599650|Procedure|Laser|laser photocoagulation
340287|NCT01599637|Drug|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
340288|NCT01599637|Drug|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
340289|NCT01599624|Behavioral|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
340290|NCT01599624|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad & Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
340291|NCT01599611|Procedure|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
340292|NCT01599598|Behavioral|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
340293|NCT01599598|Behavioral|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
340294|NCT01599585|Behavioral|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
340295|NCT01599572|Other|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
340296|NCT01599559|Other|observation|observation
340297|NCT01599559|Radiation|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
340298|NCT01599533|Other|blood samples|
340299|NCT01599520|Behavioral|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|"Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques."
340300|NCT01599520|Behavioral|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
340301|NCT01599507|Drug|FG-4592|TIW dosing, capsule
340302|NCT01599507|Drug|Placebo|TIW dosing, capsule
340303|NCT01599494|Drug|MK-8962|"MK-8962 is supplied in a ready-to-use prefilled syringe containing~100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962."
340304|NCT01599494|Drug|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
340305|NCT01599494|Drug|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
340308|NCT01599481|Behavioral|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
340309|NCT01599481|Behavioral|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
340310|NCT01599468|Drug|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
340311|NCT01599468|Drug|saline serum|The Placebo group received normal saline with the same volumes
340312|NCT01599416|Dietary Supplement|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
340313|NCT01599403|Procedure|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
340314|NCT01599403|Procedure|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
340315|NCT01599403|Procedure|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
340316|NCT01599390|Other|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.~Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
340317|NCT01599377|Drug|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
340318|NCT01599377|Drug|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
340319|NCT01599364|Drug|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
340320|NCT01599351|Radiation|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
340321|NCT01599338|Drug|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
340322|NCT01599325|Drug|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
340323|NCT01599312|Device|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
340324|NCT01599286|Drug|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
340325|NCT01599286|Drug|Placebo|
340326|NCT01599286|Drug|Standard of Care Treatment|
340327|NCT01599273|Drug|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
340328|NCT01599260|Other|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
340329|NCT01599234|Drug|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
340461|NCT01598090|Biological|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
340334|NCT01599169|Dietary Supplement|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
340335|NCT01599169|Dietary Supplement|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
340336|NCT01599156|Procedure|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
340337|NCT01599143|Behavioral|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
340338|NCT01599130|Drug|Entecavir|entecavir 0.5mg per day
340339|NCT01599130|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
340340|NCT01599117|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
340341|NCT01599117|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
340342|NCT01599104|Drug|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
340343|NCT01599104|Drug|Olmesartan|Olmesartan 20 mg capsule one daily
340344|NCT01599104|Drug|Placebo|Placebo to LCZ696 or Olmesartan
340345|NCT01599091|Other|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
340346|NCT01599078|Drug|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
340347|NCT01599078|Drug|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
340348|NCT01599065|Other|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
340349|NCT01599013|Drug|Vinflunine, Gemcitabine|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
340350|NCT01599013|Drug|Vinflunine, Carboplatin|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal~Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
340351|NCT01599000|Drug|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
340352|NCT01598987|Drug|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m^2/dose in combination wit Cyclosporine A or 2.0 mg/m^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
340353|NCT01598974|Procedure|Traditional Acupuncture|
340354|NCT01598974|Procedure|Laser Acupuncture|
340355|NCT01598961|Other|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
340356|NCT01598961|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
340357|NCT01598961|Other|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
340358|NCT01598948|Drug|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
340359|NCT01598935|Other|nutrition|protein-based food
340360|NCT01598922|Behavioral|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
340361|NCT01598909|Drug|Arnica|Application of Arnica ointment periorbitally
340362|NCT01598909|Drug|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
340363|NCT01598896|Drug|Dronabinol|Dronabinol titrated to 5 mg three times daily
340364|NCT01598896|Drug|Clonidine|Clonidine 0.1 mg twice daily
340365|NCT01598896|Drug|Placebo|One placebo capsule by mouth twice daily
340366|NCT01598883|Drug|Heparin|150 U/kg
340367|NCT01598883|Drug|ATryn|1000 IU
340368|NCT01598870|Other|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
340369|NCT01598857|Drug|Blisibimod|
340370|NCT01598857|Drug|Placebo|
340371|NCT01598844|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
340372|NCT01598831|Drug|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
340373|NCT01598831|Drug|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
340374|NCT01598805|Behavioral|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
340375|NCT01598792|Biological|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
340376|NCT01598766|Device|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
344520|NCT01567722|Other|medical chart review|
340377|NCT01598753|Drug|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.~Minimum accepted dose of 200mg per day"
340378|NCT01598753|Drug|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
340379|NCT01598753|Behavioral|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
340380|NCT01598753|Behavioral|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
340381|NCT01598740|Drug|CLP|Oral administration
340382|NCT01598740|Drug|Spironolactone|oral administration
340383|NCT01598727|Device|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
340384|NCT01598714|Device|Darco shoe|Darco shoe
340385|NCT01598714|Device|Podalux shoe|Podalux shoe
340386|NCT01598714|Device|Standard dressing shoe|Standard dressing shoe
340387|NCT01598701|Drug|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
340388|NCT01598701|Drug|Placebo|100 mL 0.9% Sodium Chloride
340389|NCT01598688|Other|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
340390|NCT01598688|Other|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.~For peripheral blood collection, venous access will be established with a small gauge needle.~The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
340391|NCT01598675|Other|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
340392|NCT01598675|Other|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
340393|NCT01598662|Device|Mirena (levonorgestrel-releasing intrauterine system)|The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
340394|NCT01598649|Dietary Supplement|Fabricated foods with lupin protein|- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
340395|NCT01598649|Dietary Supplement|Mannitol|- Placebo capsules containing mannitol (four capsules per day)
340396|NCT01598649|Dietary Supplement|Arginine|- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
340397|NCT01598649|Dietary Supplement|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
340398|NCT01598636|Procedure|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
340399|NCT01598623|Drug|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
340400|NCT01598623|Behavioral|Social Skills Training|three times a week for three weeks.
340401|NCT01598623|Behavioral|Placebo + Non Specific Counselling|
340402|NCT01598610|Device|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
340403|NCT01598584|Drug|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
340404|NCT01598584|Drug|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
340405|NCT01598571|Drug|Fostamatinib|Fostamatinib 50 mg tablet
340406|NCT01598571|Drug|Fostamatinib|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose
340407|NCT01598558|Drug|Cu-64 Rituximab|Up to 14 mCi, iv
340408|NCT01598545|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
340409|NCT01598532|Device|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
340410|NCT01598519|Behavioral|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.~indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
340411|NCT01598506|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
340412|NCT01598493|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
340413|NCT01598493|Drug|Flamazine|Silver sulfadiazine cream
340414|NCT01598480|Drug|Flamazine|Silver sulfadiazine cream
340416|NCT01598467|Procedure|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
340417|NCT01598454|Drug|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
340418|NCT01598441|Drug|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
340419|NCT01598441|Drug|distilled water|1-2 ml aerosolized distilled water inhalation per session
340420|NCT01598428|Procedure|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
340421|NCT01598415|Drug|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
340422|NCT01598415|Drug|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
340423|NCT01598402|Drug|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
340424|NCT01598389|Other|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
340425|NCT01598376|Procedure|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
340426|NCT01598376|Procedure|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
340427|NCT01598363|Drug|Digoxin|Oral, Day 1 and Day 10
340428|NCT01598363|Drug|Rosuvastatin|Oral, Day 1 and Day 10
340429|NCT01598350|Device|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
340430|NCT01598337|Drug|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
340431|NCT01598337|Drug|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
340432|NCT01598337|Drug|Clopidogrel|75 mg orally started 6-8hours before surgery
340433|NCT01598337|Drug|Prasugrel|10 mg daily as per instructions of investigators
340434|NCT01598311|Drug|CB-183,315|CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
340435|NCT01598311|Drug|Vancomycin|Vancomycin hydrochloride 125 mg capsule over-encapsulated in size 00 opaque hard gelatin capsule.
340436|NCT01598311|Drug|Placebo|Placebo size 00 opaque hard gelatin capsules.
340437|NCT01598298|Drug|duloxetine hydrochloride|Given PO
340438|NCT01598298|Other|placebo|Given PO
340439|NCT01598272|Dietary Supplement|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
340440|NCT01598272|Dietary Supplement|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
340441|NCT01598259|Drug|Melatonin|po 1 hour before bedtime
340442|NCT01598259|Other|placebo|po, 1 hour before bed
340443|NCT01598233|Device|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
340444|NCT01598220|Behavioral|Computer-assisted cognitive remediation therapy|"Comparison of two groups:~The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.~The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
340445|NCT01598220|Other|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
340446|NCT01598207|Drug|Marinol|5mg BID, orally for 1 month
340447|NCT01598207|Drug|Placebo|5mg BID, orally for 1 month
340448|NCT01598194|Device|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
340449|NCT01598181|Device|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
340450|NCT01598181|Device|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
340451|NCT01598168|Drug|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
340452|NCT01598155|Procedure|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~Scaling, planning and polishing coronary surface;~Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
340453|NCT01598155|Procedure|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):~Scaling, planning and polishing of coronary surface;~Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;~Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
340454|NCT01598142|Procedure|Team 1|experienced endoscopist with a experienced assistant
340455|NCT01598142|Procedure|Team 2|same experienced endoscopist with a new trained assistant
340456|NCT01598129|Genetic|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
340457|NCT01598116|Procedure|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
340458|NCT01598116|Procedure|Urine collection|Bagged urine collection
344521|NCT01567709|Drug|Alisertib|Given PO
340468|NCT01598051|Drug|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
340469|NCT01598038|Other|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
340470|NCT01598025|Radiation|total-body irradiation (TBI)|
340471|NCT01598025|Drug|thiotepa|
340472|NCT01598025|Drug|fludarabine phosphate|
340473|NCT01598025|Drug|melphalan|
340474|NCT01598025|Biological|anti-thymocyte globulin|
340475|NCT01598025|Procedure|allogeneic hematopoietic stem cell transplantation|
340476|NCT01598025|Biological|peripheral blood stem cell transplantation|
340477|NCT01598025|Other|laboratory biomarker analysis|
340478|NCT01598012|Drug|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
340479|NCT01598012|Drug|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
340480|NCT01597999|Radiation|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
340481|NCT01597986|Drug|isavuconazole|oral
340482|NCT01597986|Drug|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
340483|NCT01597973|Drug|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
340484|NCT01597973|Drug|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
340485|NCT01597960|Other|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
340486|NCT01597947|Drug|ACHN-975|Intravenous single dose
340487|NCT01597947|Drug|placebo|Intravenous single dose
340488|NCT01597934|Drug|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
340489|NCT01597934|Drug|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
340490|NCT01597908|Drug|Dabrafenib|dabrafenib 150 mg twice daily po
340491|NCT01597908|Drug|Vemurafenib|vemurafenib 960 mg twice daily po
340492|NCT01597908|Drug|Trametinib|trametinib 2 mg once daily po
340493|NCT01597895|Drug|Maraviroc|Maraviroc 150 mg BID x 5 days with food
340494|NCT01597895|Drug|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
340495|NCT01597895|Drug|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
340496|NCT01597869|Device|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
340497|NCT01597856|Behavioral|SBIRT|"SBIRT Therapy overview-~Therapist explains purpose of the therapy.~Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.~Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.~Discuss treatment needs, administer screening, provide feedback."
340498|NCT01597843|Other|Education|Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
340499|NCT01597830|Other|Mobility shoe|flat, specialized shoe
340500|NCT01597830|Other|control shoe|control shoe
340501|NCT01597817|Other|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
340502|NCT01597817|Other|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
340503|NCT01597804|Procedure|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
340504|NCT01597791|Device|Foley catheter|Foley catheter placement after CSE.
340505|NCT01597791|Other|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
340506|NCT01597778|Biological|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:~Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1~The GVHD prophylaxis regimen consists of:~Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
340507|NCT01597778|Biological|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:~Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.~The GVHD prophylaxis regimen consists of:~Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.~Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
340508|NCT01597765|Drug|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
340509|NCT01597765|Drug|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
340679|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
341329|NCT01592227|Drug|Experimental paracetamol formulation|Experimental paracetamol formulation
340510|NCT01597752|Biological|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
340511|NCT01597739|Drug|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
340512|NCT01597739|Drug|Placebo|Form=capsule; route=oral use; twice daily.
340513|NCT01597726|Drug|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D&E, repeated once 3 hours after the first dose if needed
340514|NCT01597726|Device|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D&E
340515|NCT01597713|Drug|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
340516|NCT01597713|Drug|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
340517|NCT01597713|Drug|placebo|Subjects will receive a single dose of oral placebo within each dose group
340518|NCT01597713|Drug|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
340519|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
340520|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
340521|NCT01597700|Drug|10mg Ezetimibe|1 tablet taken by mouth
340522|NCT01597700|Drug|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
340523|NCT01597687|Procedure|Blood collection|1 blood sample will be collected from each subject.
340524|NCT01597687|Other|Data collection|Quality of Life and HE questionnaires.
340525|NCT01597674|Drug|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.~Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
340526|NCT01597661|Drug|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
340527|NCT01597661|Drug|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
340528|NCT01597661|Other|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.~Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
340529|NCT01597648|Drug|Maraviroc|300 mg
340530|NCT01597648|Drug|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
340531|NCT01597648|Drug|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
340532|NCT01597635|Drug|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
340533|NCT01597635|Drug|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
340534|NCT01597635|Drug|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
340535|NCT01597635|Drug|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
340536|NCT01597635|Drug|Placebo (saline)|Administered intravenously to match intervention
340537|NCT01597622|Drug|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
340538|NCT01597609|Drug|sibutramine|10 mg, taken orally once per day for 12 weeks
340539|NCT01597609|Other|sibutramine placebo|taken orally once per day for 12 weeks
340540|NCT01597596|Biological|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
340541|NCT01597596|Biological|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
340542|NCT01597583|Behavioral|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
340543|NCT01597570|Device|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
340544|NCT01597557|Drug|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
340545|NCT01597557|Other|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
340577|NCT01597362|Procedure|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.~The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
340546|NCT01597544|Procedure|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
340547|NCT01597531|Drug|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
340548|NCT01597531|Drug|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
340549|NCT01597531|Drug|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
340550|NCT01597518|Drug|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
340551|NCT01597518|Drug|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
340552|NCT01597505|Drug|Surotomycin|250 mg Surotomycin over-encapsulated tablet administered orally, twice daily for a daily total dose of 500 mg, for 10 days
340553|NCT01597505|Drug|Vancomycin|125 mg Vancomycin over-encapsulated capsule administered orally, four times daily for a daily total dose of 500 mg, for 10 days
340554|NCT01597505|Drug|Placebo|Placebo for Surotomycin over-encapsulated tablet administered orally, twice daily for 10 days
340555|NCT01597492|Biological|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
340556|NCT01597492|Biological|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
340557|NCT01597479|Drug|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
340558|NCT01597466|Device|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
340559|NCT01597466|Procedure|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
340560|NCT01597453|Behavioral|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
340561|NCT01597440|Drug|N-carbamylglutamate|"Active NCG & Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.~This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
340562|NCT01597440|Other|Standard of Care|Standard of Care
340563|NCT01597427|Drug|Clonidine|Administration of 2 μg/kg of intravenous clonidine
340564|NCT01597427|Drug|Placebo|Injection of placebo solution.
340565|NCT01597414|Drug|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.~Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.~if T-DM1: 3.6 mg/kg IV, every 3 weeks."
340566|NCT01597414|Drug|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
340567|NCT01597401|Drug|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
340568|NCT01597401|Drug|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
340569|NCT01597401|Drug|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
340570|NCT01597401|Drug|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
340571|NCT01597401|Drug|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
340572|NCT01597388|Drug|AZD2014|Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
340573|NCT01597388|Drug|Fulvestrant|IM monthly after loading dose
340574|NCT01597375|Drug|Placebo Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
340575|NCT01597375|Drug|Prasugrel Oral Tablet|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
340578|NCT01597362|Procedure|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.~On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
340579|NCT01597362|Procedure|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
340580|NCT01597349|Drug|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
340581|NCT01597336|Procedure|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
340582|NCT01597336|Procedure|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
340583|NCT01597310|Drug|Warfarin|single doses at specified time periods
340584|NCT01597310|Drug|Dexpramipexole|multiple doses
340585|NCT01597297|Drug|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
340586|NCT01597297|Other|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
340587|NCT01597258|Drug|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
340588|NCT01597245|Drug|80 mg ixekizumab Dosing Regimen|Administered SC
340589|NCT01597245|Drug|50 mg etanercept|Administered SC
340590|NCT01597245|Drug|Placebo|Administered SC
340591|NCT01597232|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
340592|NCT01597232|Other|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
340593|NCT01597232|Other|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
340594|NCT01597219|Procedure|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
340595|NCT01597219|Procedure|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
340596|NCT01597206|Device|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
340597|NCT01597206|Other|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
340598|NCT01597193|Drug|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
340599|NCT01597193|Drug|anastrozole|1 mg/day
340600|NCT01597193|Drug|exemestane|The exemestane dose is 25mg daily.
340601|NCT01597193|Drug|fulvestrant|500 mg every 28 days
340602|NCT01597193|Drug|enzalutamide|160 mg (4 capsules) taken orally daily.
340603|NCT01597193|Drug|exemestane|The exemestane dose is 50 mg daily.
340604|NCT01597167|Dietary Supplement|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
340605|NCT01597154|Behavioral|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
340606|NCT01597141|Behavioral|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
340607|NCT01597141|Behavioral|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
340608|NCT01597128|Device|Flex HD|Flex HD mesh for hernia repair
340609|NCT01597128|Device|Strattice|Strattice mesh for hernia repair
340610|NCT01597115|Procedure|Duplex ultrasonography|
340611|NCT01597102|Other|No interventions|No intervention is planned in this study
340612|NCT01597076|Dietary Supplement|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas & Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
340613|NCT01597063|Device|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
340614|NCT01597050|Drug|R932333|R393233 6% (60 mg/g), bid
340615|NCT01597050|Drug|Placebo|Placebo, bid
340616|NCT01597037|Behavioral|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
340638|NCT01596894|Drug|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
340639|NCT01596894|Drug|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
340617|NCT01597024|Other|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
340618|NCT01597024|Other|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
340619|NCT01597011|Procedure|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
340620|NCT01597011|Procedure|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
340621|NCT01596998|Drug|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
340622|NCT01596998|Drug|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
340623|NCT01596998|Other|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
340624|NCT01596998|Other|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
340625|NCT01596985|Procedure|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
340626|NCT01596985|Procedure|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
340627|NCT01596972|Device|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
340628|NCT01596959|Procedure|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
340629|NCT01596959|Procedure|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
340630|NCT01596946|Behavioral|Contact tracing mode test at clinic|
340631|NCT01596946|Behavioral|Self-sampling at home - Sent Test Kit|
340632|NCT01596933|Dietary Supplement|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
340633|NCT01596933|Dietary Supplement|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
340634|NCT01596920|Other|Tissue|Allograft Tissue Cellular Repair Matrix
340635|NCT01596920|Other|Control|Non-adherent Dressing
340636|NCT01596907|Drug|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
340637|NCT01596907|Drug|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
341420|NCT01591655|Drug|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
340640|NCT01596868|Drug|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
340641|NCT01596868|Drug|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
340642|NCT01596855|Drug|FG-4592|TIW dosing, capsule
340643|NCT01596855|Drug|Epoetin Alfa|TIW
340644|NCT01596842|Drug|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
340645|NCT01596842|Other|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
340646|NCT01596842|Other|cholecalciferol|if baseline 25-hydroxyvitamin D levels are < 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
340647|NCT01596829|Dietary Supplement|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
340648|NCT01596829|Dietary Supplement|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
340649|NCT01596816|Radiation|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
340650|NCT01596816|Procedure|Fiducials placement|Placement of intra-prostatic markers for the tracking
340651|NCT01596816|Radiation|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
340652|NCT01596803|Procedure|Taking of blood|Taking venous blood samples to analyse oxidant stress
340653|NCT01596803|Dietary Supplement|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
340654|NCT01596803|Dietary Supplement|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
340655|NCT01596803|Dietary Supplement|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
340656|NCT01596790|Other|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
340657|NCT01596777|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
340658|NCT01596777|Drug|Loperamide placebo|200 ml apple juice
340659|NCT01596777|Drug|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
340660|NCT01596777|Drug|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
340661|NCT01596777|Drug|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
340662|NCT01596777|Drug|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
340663|NCT01596777|Device|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
340664|NCT01596777|Drug|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
340665|NCT01596764|Drug|Loperamide placebo|200 ml apple juice
340666|NCT01596764|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
340667|NCT01596764|Device|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
340668|NCT01596764|Drug|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
340669|NCT01596764|Drug|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
340670|NCT01596764|Drug|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
340671|NCT01596764|Drug|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
340672|NCT01596751|Drug|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
340673|NCT01596751|Drug|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
340674|NCT01596738|Drug|Tranexamic Acid|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction~Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
340675|NCT01596738|Drug|Saline|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction~Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
340676|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
340677|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
340678|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
340680|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
340681|NCT01596725|Biological|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
340682|NCT01596712|Drug|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
340683|NCT01596712|Drug|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
340684|NCT01596699|Drug|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
340685|NCT01596699|Drug|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
340686|NCT01596699|Drug|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
340687|NCT01596699|Drug|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
340688|NCT01596686|Drug|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
340689|NCT01596673|Drug|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
340690|NCT01596673|Drug|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
340691|NCT01596660|Drug|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
340692|NCT01596660|Drug|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
340693|NCT01596647|Drug|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
340694|NCT01596647|Drug|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
340695|NCT01596647|Drug|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
340696|NCT01596647|Drug|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
340697|NCT01596647|Drug|TKI258|dovitinib, 5 days on / 2 days off dose schedule
340698|NCT01596634|Other|questionnaire administration|Ancillary studies
340699|NCT01596634|Procedure|quality-of-life assessment|Ancillary studies
340700|NCT01596634|Other|laboratory biomarker analysis|Correlative studies
340701|NCT01596634|Dietary Supplement|bovine lactoferrin|Given PO
340702|NCT01596621|Drug|Bendamustine hydrochloride|Bendamustine will be supplied in 20-mL, amber, single-use vials containing 100 mg of bendamustine hydrochloride as a white to off-white lyophilized powder. The drug will be labeled as study drug with the study number and batch number. Patients will be administered bendamustine hydrochloride 120mg/m^2 as a 60-minute infusion, and not more than 120 minutes, on days 1 and 2 of each 21-day treatment cycle for 6 planned cycles or up to 8 total cycles. Dose reductions or modifications may be made as appropriate. Day 1 only of the 21-day cycle may be ±1 day. Day 2 dosing should begin 24 ±4 hours after the start of the day 1 dose.
340703|NCT01596608|Device|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal or vertex brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
340704|NCT01596582|Behavioral|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN ~3%) versus intermediate/high (~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, <20 years, 20+ years), daily alcohol intake (< 2 vs. >/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
340705|NCT01596569|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
340706|NCT01596569|Behavioral|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.~All participants receive weekly cognitive treatment sessions for 10 weeks."
340707|NCT01596556|Drug|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
340708|NCT01596556|Other|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
340709|NCT01596543|Other|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
340710|NCT01596530|Drug|Drug-AZD8931|Active drug for biological activity
340711|NCT01596530|Drug|Drug-Placebo|Placebo comparator for biological activity comparison
340712|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight <75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
341464|NCT01591330|Drug|LY2140023 Monohydrate (Reference)|80 mg tablet administered orally
340713|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
340714|NCT01596504|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).~Route of administration: subcutaneous"
340715|NCT01596504|Drug|Liraglutide|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
340716|NCT01596504|Drug|Insulin Glargine|Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
340717|NCT01596504|Drug|Metformin|If previously taken metformin to be continued at stable dose throughout the study
340718|NCT01596491|Procedure|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
340719|NCT01596478|Behavioral|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
340720|NCT01596478|Behavioral|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
340721|NCT01596478|Behavioral|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
340722|NCT01596465|Other|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
340723|NCT01596465|Other|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
340724|NCT01596426|Drug|Sancuso|granisetron transdermal system
340725|NCT01596426|Drug|IV granisetron|IV granisetron
340726|NCT01596413|Drug|Sancuso|granisetron transdermal system
340727|NCT01596413|Drug|IV granisetron|IV
340728|NCT01596400|Drug|granisetron transdermal system|patch
340729|NCT01596400|Drug|Granisetron IV|IV
340730|NCT01596387|Drug|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
340731|NCT01596335|Drug|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
340732|NCT01596335|Drug|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
340733|NCT01596309|Dietary Supplement|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
340734|NCT01596296|Device|Transcervical foley catheter|16 French foley catheter insertion
340735|NCT01596296|Drug|Dinoprostone 10mg|Dinoprostone vaginal insertion
340736|NCT01596283|Procedure|Standard fluid management|The patient will receive standard fluid management
340737|NCT01596283|Device|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
340738|NCT01596270|Drug|SAR245409|Pharmaceutical form: tablet Route of administration: oral
340739|NCT01596257|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
340740|NCT01596257|Device|CliniMACS|
340741|NCT01596244|Behavioral|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
340742|NCT01596231|Dietary Supplement|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
340743|NCT01596231|Dietary Supplement|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
340744|NCT01596218|Drug|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
340745|NCT01596205|Behavioral|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
340777|NCT01595945|Procedure|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
340746|NCT01596205|Behavioral|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.~In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
340747|NCT01596192|Other|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).~CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
340748|NCT01596179|Behavioral|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
340749|NCT01596179|Behavioral|Internet access|a netbook computer with internet access is provided to participants on the control arm.
340750|NCT01596166|Drug|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
340751|NCT01596166|Drug|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
340752|NCT01596153|Dietary Supplement|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
340753|NCT01596140|Drug|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
340754|NCT01596140|Drug|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
340755|NCT01596140|Drug|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
340756|NCT01596127|Drug|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.~Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
340757|NCT01596114|Other|Stopping treatment with TKI|stopping until loss of MMR
340758|NCT01596088|Drug|Dexrazoxane|
340759|NCT01596075|Drug|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
340760|NCT01596062|Drug|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
340761|NCT01596062|Drug|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
340762|NCT01596062|Drug|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
340763|NCT01596062|Drug|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
340764|NCT01596062|Drug|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
340765|NCT01596049|Device|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
340766|NCT01596036|Behavioral|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
340767|NCT01596036|Other|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
340768|NCT01596023|Device|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
340769|NCT01596010|Drug|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
340770|NCT01595997|Drug|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
340771|NCT01595984|Drug|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
340772|NCT01595984|Drug|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
340773|NCT01595971|Behavioral|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
340774|NCT01595971|Other|usual care|Received the usual care provided
340775|NCT01595958|Drug|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
340776|NCT01595958|Procedure|cardio-pulmonary resuscitation|usual care of cardiac arrest
340778|NCT01595945|Behavioral|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
340779|NCT01595932|Dietary Supplement|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children < 20kg: 4 drops;~children > 20kg and < 40kg: 8 drops;~children > 40kg: 1 tablet."
340780|NCT01595932|Dietary Supplement|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:~children < 20kg: 4 drops;~children > 20kg and < 40kg: 8 drops;~children > 40kg: 1 tablet."
340781|NCT01595919|Other|Nutritional Intervention|Ad libitum amounts of beverage at a meal
340782|NCT01595906|Procedure|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
340783|NCT01595893|Drug|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
340784|NCT01595893|Drug|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
340785|NCT01595880|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
340786|NCT01595880|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
340787|NCT01595867|Drug|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
340788|NCT01595867|Drug|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
340789|NCT01595867|Drug|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
340790|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
340791|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
340792|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
340793|NCT01595854|Drug|dabigatran etexilate|low dose dabigatran
340794|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
340795|NCT01595841|Drug|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
340796|NCT01595828|Drug|Pitavastatin|
340797|NCT01595815|Other|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
340798|NCT01595815|Other|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
340799|NCT01595802|Device|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.~In this intervention, patients are recorded using the Nautilus Neurowave device."
340800|NCT01595802|Device|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
340801|NCT01595789|Drug|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
340802|NCT01595789|Drug|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
340803|NCT01595776|Other|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
340804|NCT01595763|Other|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
340805|NCT01595750|Drug|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
340806|NCT01595750|Drug|Placebo|Placebo 500 mcg , 12 weeks of treatment
340807|NCT01595737|Drug|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
340808|NCT01595737|Drug|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
340809|NCT01595724|Drug|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
340810|NCT01595711|Device|Pain Monitor|Measurement of cutaneous conductance
340811|NCT01595698|Other|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
341465|NCT01591330|Drug|LY2140023 Monohydrate (Test - Low)|80 mg tablet administered orally
340812|NCT01595698|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
340813|NCT01595685|Drug|Telbivudine|Telbivudine 600 mg Daily Oral
340814|NCT01595685|Drug|Entecavir|Entecavir 0.5 mg Daily Oral
340815|NCT01595672|Device|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
340816|NCT01595672|Other|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
340817|NCT01595659|Behavioral|Passenger|Driving with risk accepting or risk averse passenger
340818|NCT01595646|Drug|Saline|Saline, administered intranasally twice per day for a 16 week duration
340819|NCT01595646|Drug|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
340820|NCT01595646|Drug|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
340821|NCT01595633|Drug|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
340822|NCT01595620|Other|Thermal|Thermal sensation/pain testing
340823|NCT01595620|Device|Electrical|Electrical sensation/pain testing
340824|NCT01595620|Other|Capsaicin|Intradermal Capsaicin
340825|NCT01595607|Other|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
340826|NCT01595594|Drug|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
340827|NCT01595594|Drug|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
340828|NCT01595581|Drug|Testosterone|8 weeks supraphysiologic dose testosterone enanthate
340829|NCT01595581|Drug|Saline|Placebo for 8 weeks
340830|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
340831|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
340832|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
340833|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
340834|NCT01595555|Behavioral|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
340835|NCT01595542|Behavioral|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:~Cover letter~Vaccine promotional flyer~Vaccine information sheets (one for adolescent vaccination and one for other vaccination)~Improved consent form~Note advertising a lottery for free movie tickets for returning the consent form~Self-addressed stamped envelope"
340836|NCT01595529|Drug|Cefixime|Cefixime 8 mg/kg/day orally, in 1 dose, with a maximum of 400 mg. Subjects originally receiving Cefdinir will receive Cefixime.
340837|NCT01595529|Drug|Cephalexin|Cephalexin 50mg/kg/day in 3 divided doses
340838|NCT01595529|Other|Placebo|Placebo to match the other four active treatments
340839|NCT01595529|Drug|Trimethoprim/Sulfamethoxazole|8 mg/kg/day of Trimethoprim-sulfamethoxazole (TMP-SMX) orally in 2 divided doses, with a maximum dose of 160 mg twice a day.
340840|NCT01595516|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
340841|NCT01595516|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
340842|NCT01595516|Drug|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
340843|NCT01595516|Other|Bradykinin|Bradykinin is infused into the brachial artery at doses of 12.5, 25.0 and 50.0 ng/100 mL of forearm tissue /min. BDK stimulates the endothelial cells to release tissue type plasminogen activator (t-PA). Blood flow in mL/100 mL tissue/min is also measured to BDK.
340844|NCT01595516|Other|Saline|Baseline or resting forearm blood flow is measured in response to saline for 5 minutes before each drug infusion. t-PA release in response to the saline is also measured.
340845|NCT01595516|Other|Vitamin C|The acute effects of into-arterial vitamin C on the ability of the endothelium to release t-PA was determined before and after the nebivolol and metoprolol intervention. After allowing sufficient time (~20 minutes) for FBF and plasma t-PA concentrations to return to baseline following the initial infusion of BDK, vitamin C (24 mg/min) was infused at a constant rate while the BDK dose-response curves were repeated. t-PA and FBF were measured.
340846|NCT01595503|Procedure|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
340847|NCT01595503|Procedure|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
344522|NCT01567709|Other|Laboratory Biomarker Analysis|Correlative studies
340848|NCT01595490|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
340849|NCT01595477|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
340850|NCT01595464|Behavioral|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
340851|NCT01595451|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
340852|NCT01595438|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
340853|NCT01595438|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
340854|NCT01595438|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
340855|NCT01595438|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
340856|NCT01595425|Drug|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
340857|NCT01595425|Drug|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
340858|NCT01595412|Procedure|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
340859|NCT01595412|Procedure|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
340860|NCT01595399|Drug|atropine|Atropine 0.02 mg/kg IV
340861|NCT01595399|Drug|Placebo|an equivalent volume of normal saline to atropine IV
340862|NCT01595386|Drug|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
340863|NCT01595386|Drug|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
340864|NCT01595373|Drug|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
340865|NCT01595373|Drug|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
340866|NCT01595360|Drug|Placebo|It is applied directly to the bleeding site after tooth extraction
340867|NCT01595360|Drug|TT-173|It is applied directly to the bleeding site after tooth extraction
340868|NCT01595347|Drug|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
340869|NCT01595347|Other|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
340870|NCT01595334|Drug|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (>4.5 mIU/ml) in the study arm
340871|NCT01595334|Drug|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
340872|NCT01595321|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
340873|NCT01595321|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Vaccine will be administered one day after cyclophosphamide (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
340874|NCT01595321|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first vaccine dose (Arm 2) or within 6-10 weeks of surgery (Arm 1).
340875|NCT01595321|Drug|FOLFIRINOX|FOLFIRINOX will be administered over 6 cycles starting at least 14 days after SBRT (Arms 1 and 2) and at least 28 days after the first vaccine (Arm 2).
340876|NCT01595308|Dietary Supplement|Pomegranate juice|Pomegranate juice
340877|NCT01595295|Other|non interventional|
340878|NCT01595282|Drug|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
340879|NCT01595282|Drug|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
340880|NCT01595269|Other|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
340881|NCT01595256|Behavioral|muscular strength|12-week moderate intensity walking program
340882|NCT01595243|Behavioral|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
340883|NCT01595230|Procedure|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
340884|NCT01595217|Device|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
340928|NCT01594827|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|"Oral trimethoprim/sulfamethoxazole (DS-160/800)~>45 kg: two DS tablets twice a day by mouth (320/1600)~25-45 kg: one DS tablet twice a day by mouth (160/800)"
340885|NCT01595204|Procedure|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
340886|NCT01595191|Other|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
340887|NCT01595191|Other|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
340888|NCT01595178|Behavioral|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
340889|NCT01595165|Procedure|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
340890|NCT01595165|Procedure|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
340891|NCT01595152|Drug|solifenacin succinate|8 mg once daily for 60 days
340892|NCT01595152|Drug|fesoterodine|8 mg, once daily for 60 dyas
340893|NCT01595087|Drug|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
340894|NCT01595074|Other|medical chart review|Correlative studies
340895|NCT01595074|Other|laboratory biomarker analysis|Correlative studies
340896|NCT01595061|Drug|Cisplatin|Given IV
340897|NCT01595061|Drug|Gemcitabine Hydrochloride|Given IV
340898|NCT01595061|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
340899|NCT01595061|Procedure|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
340900|NCT01595035|Behavioral|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
340901|NCT01595022|Drug|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
340902|NCT01595022|Drug|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
340903|NCT01595022|Drug|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
340904|NCT01595009|Drug|Everolimus (RAD001)|Everolimus was supplied as tablets of 5mg strength.
340905|NCT01594983|Drug|LCQ908|
340906|NCT01594983|Drug|Fenofibrate|Fenofibrate once daily 12 weeks
340907|NCT01594983|Drug|Fish Oil|Fish Oil once daily for 12 weeks
340908|NCT01594983|Drug|Placebo of LCQ908|Matching placebo of LCQ908
340909|NCT01594983|Drug|Placebo of fenofibrate|Matching placebo of fenofibrate
340910|NCT01594983|Drug|Placebo of fish oil|Matching placebo of fish oil capsule
340911|NCT01594970|Drug|Bimatoprost 0.01%|1 drop in the affected eye(s), administered in the evening for 12 weeks.
340912|NCT01594957|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
340913|NCT01594931|Drug|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1
340914|NCT01594918|Drug|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
340915|NCT01594918|Drug|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
340916|NCT01594918|Drug|Prednisone|5 mg PO BID
340917|NCT01594918|Drug|Pegfilgrastim|6 mg, SC, once every 21 days
340918|NCT01594905|Drug|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
340919|NCT01594892|Radiation|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
340920|NCT01594879|Device|MIrena(LNG-IUS), oral MPA|"General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.~General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
340921|NCT01594866|Drug|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
340922|NCT01594866|Drug|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
340923|NCT01594853|Behavioral|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
340924|NCT01594840|Device|Changing chat|Diapers with tips
340925|NCT01594827|Drug|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
340926|NCT01594827|Drug|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
340927|NCT01594827|Drug|Rifampin|"Oral Rifampin by mouth for 28 days~>45 kg: 600 mg by mouth daily~35-45 kg : 450 mg by mouth daily~25-34.9 kg: 300 mg by mouth daily"
340929|NCT01594827|Drug|Doxycycline|"If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline~>45 kg: 100 mg by mouth twice a day~35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day"
340930|NCT01594827|Drug|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
340931|NCT01594827|Drug|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
340932|NCT01594814|Procedure|RFA|radiofrequency ablation of slow pathway or accesory pathway
340933|NCT01594801|Device|InsuPad|Use of the InsuPad for at least 3 times a day.
340934|NCT01594775|Drug|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
340935|NCT01594775|Drug|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
340936|NCT01594762|Drug|Topical pexiganan cream 0.8%|14 days of treatment
340937|NCT01594762|Drug|Topical placebo cream|14 days of treatment
340938|NCT01594762|Other|Standard wound care|14 days of treatment
340939|NCT01594749|Drug|Fosaprepitant dimeglumine|
340940|NCT01594749|Drug|Fosaprepitant Placebo|
340941|NCT01594749|Drug|Dexamethasone|
340942|NCT01594749|Drug|Ondansetron|
340943|NCT01594749|Drug|Dexamethasone Placebo|
340944|NCT01594749|Drug|Ondansetron Placebo|
340945|NCT01594749|Drug|Rescue Therapy|
340946|NCT01594736|Drug|ORSIRO|due randomization ORSIRO will be implanted
340947|NCT01594736|Device|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
340948|NCT01594723|Drug|120 mg LY2784544|Administered orally
340949|NCT01594697|Drug|Metformin|
340950|NCT01594684|Device|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
340951|NCT01594684|Device|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
340952|NCT01594684|Device|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
340953|NCT01594684|Device|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
340954|NCT01594671|Drug|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
340955|NCT01594671|Drug|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
340956|NCT01594671|Other|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
340957|NCT01594658|Procedure|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
340958|NCT01594658|Procedure|conservative|This arm only has medical standard handling (healings performed by the nurse group)
340959|NCT01594645|Procedure|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
340960|NCT01594632|Drug|Jadelle|LNG containing subdermal contraceptive implant
340961|NCT01594632|Drug|Sino-implant (II)|LNG containing subdermal contraceptive implant
340962|NCT01594619|Drug|Naloxegol|Oral 25mg tablet
340963|NCT01594619|Drug|Diltiazem XR|Oral 240mg tablet
340964|NCT01594606|Behavioral|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
340965|NCT01594593|Behavioral|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
340966|NCT01594580|Other|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
340967|NCT01594580|Other|Non-impregnated scrubs|
340968|NCT01594567|Other|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
340969|NCT01594528|Other|pain tests|pain induction with pressure application or ischemia on the arm
340970|NCT01594515|Drug|BI 1015550|High dose powder for oral solution
340971|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
340972|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
340973|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
340974|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
340975|NCT01594515|Drug|Placebo|Solution for oral administration
340976|NCT01594515|Drug|BI 101550|High dose powder for oral solution
340977|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
340978|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
340979|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
340980|NCT01594502|Drug|Dutasteride|0.5 mg daily
340981|NCT01594502|Drug|Placebo|Placebo Comparator
340982|NCT01594489|Drug|Aminophylline|"200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration~Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
340983|NCT01594489|Drug|Hydration plus N-acetylcisteine|"Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure~N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
340984|NCT01594476|Drug|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
340985|NCT01594463|Other|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
340986|NCT01594463|Other|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
340987|NCT01594450|Biological|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
340988|NCT01594450|Procedure|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
340989|NCT01594437|Biological|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
340990|NCT01594437|Biological|Placebo|One or two doses administered by intravenous infusion.
340991|NCT01594424|Drug|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
340992|NCT01594424|Drug|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg [maximum 140 g per dose] on days 1 and 30).
340993|NCT01594411|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score (ASGES)
340994|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
340995|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
340996|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
340997|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
340998|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
340999|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
341000|NCT01594385|Biological|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~Two Seprafilm pieces between the liver and the anterior abdominal wall~Four pieces over the exposed bowel surfaces anteriorly~Two slightly staggered pieces of Seprafilm in each colic gutter~Two pieces in the pelvic area.~If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
341001|NCT01594372|Procedure|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
341002|NCT01594372|Procedure|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
341003|NCT01594359|Other|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
341004|NCT01594359|Other|BEAN|Placebo
341005|NCT01594346|Drug|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
341006|NCT01594346|Drug|Sugar Pill|
341007|NCT01594333|Drug|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
341008|NCT01594333|Drug|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
341009|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
341010|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
341011|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
341012|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
341013|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
341014|NCT01594320|Biological|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 & Day 21
341015|NCT01594294|Device|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
341016|NCT01594294|Device|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
341017|NCT01594294|Device|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
341018|NCT01594294|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
341019|NCT01594294|Device|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
341020|NCT01594281|Drug|Ranibizumab 0.5 mg|Pre-filled syringe for intravitreal injection
341021|NCT01594281|Procedure|Panretinal laser photocoagulation|PRP treatment following DRS guidelines
341022|NCT01594268|Drug|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
341023|NCT01594255|Drug|sotrastaurin|
341024|NCT01594255|Drug|sotrastaurin|
341025|NCT01594255|Drug|placebo to sotrastaurin|
341026|NCT01594255|Drug|Avelox|
341027|NCT01594242|Drug|Bortezomib|
341028|NCT01594229|Drug|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
341029|NCT01594229|Drug|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
341466|NCT01591330|Drug|LY2140023 Monohydrate (Test - Medium)|80 mg tablet administered orally
341030|NCT01594229|Drug|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
341031|NCT01594216|Drug|Ruxolitinib|
341032|NCT01594216|Drug|Exemestane|
341033|NCT01594203|Other|F18-FGD PET/CT|
341034|NCT01594190|Behavioral|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
341035|NCT01594190|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
341036|NCT01594177|Drug|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
341037|NCT01594177|Drug|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
341038|NCT01594177|Drug|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
341039|NCT01594177|Drug|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
341040|NCT01594177|Drug|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
341041|NCT01594164|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
341042|NCT01594164|Radiation|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
341043|NCT01594151|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
341044|NCT01594138|Other|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
341045|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
341046|NCT01594125|Drug|Nintedanib low dose|twice daily oral dosing
341047|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
341048|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
341049|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
341050|NCT01594099|Radiation|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
341051|NCT01594099|Drug|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
341052|NCT01594099|Drug|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.~Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).~Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
341053|NCT01594086|Dietary Supplement|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
341054|NCT01594060|Drug|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
341055|NCT01594060|Drug|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
341056|NCT01594047|Drug|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
341057|NCT01594047|Drug|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
341058|NCT01594034|Procedure|expired air|collection of expired air from ventilator
341059|NCT01594021|Drug|Gelatin 500 mL|intravenous administration
341060|NCT01594021|Drug|Gelatin 50 mL|intravenous administration
341061|NCT01594008|Other|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
341062|NCT01594008|Other|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
341063|NCT01594008|Other|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
341064|NCT01593995|Drug|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
341065|NCT01593982|Other|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
341066|NCT01593969|Dietary Supplement|RUTF/Flax Oil|Ready to Use Therapeutic Food
341067|NCT01593969|Dietary Supplement|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
341068|NCT01593969|Dietary Supplement|Standard RUTF|Standard formulation RUTF given according to National Guidelines
341069|NCT01593956|Behavioral|tDCS|
341070|NCT01593943|Behavioral|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
341071|NCT01593930|Other|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
341072|NCT01593930|Other|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
341073|NCT01593930|Other|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
341074|NCT01593930|Other|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
341075|NCT01593878|Other|TV|test taken with TV on
341076|NCT01593865|Procedure|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
341077|NCT01593865|Procedure|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
341078|NCT01593852|Radiation|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
341079|NCT01593852|Radiation|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
341080|NCT01593826|Drug|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
341081|NCT01593826|Drug|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
341082|NCT01593826|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
341083|NCT01593826|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
341084|NCT01593800|Dietary Supplement|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
341085|NCT01593787|Drug|LCZ696|100 mg, 200 mg, 400 mg tablets.
341086|NCT01593774|Drug|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
341087|NCT01593774|Drug|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
341088|NCT01593761|Drug|CG400549|960mg QD at fed state approx 1 hour after meal
341089|NCT01593748|Drug|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
341090|NCT01593748|Drug|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
341091|NCT01593735|Drug|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
341092|NCT01593735|Drug|Placebo|Placebo tablets, orally, once daily for 7 days
341093|NCT01593722|Drug|Diethylcarbamazine|single dose
341094|NCT01593722|Drug|Ivermectin|single dose
341095|NCT01593696|Biological|Anti-CD19- CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
341096|NCT01593683|Behavioral|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
341097|NCT01593670|Drug|Decitabine|administered intravenous (IV), 10 mg/m^2/day over 1 hour on days 1-5.
341098|NCT01593670|Drug|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
341099|NCT01593670|Biological|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
341100|NCT01593670|Other|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
341101|NCT01593657|Other|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
341102|NCT01593657|Other|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
341103|NCT01593657|Procedure|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
341104|NCT01593657|Procedure|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
341105|NCT01593644|Drug|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
341106|NCT01593631|Dietary Supplement|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
341107|NCT01593631|Dietary Supplement|Acid lactase|capsules containing 9000 FCC of acid lactase
341108|NCT01593631|Dietary Supplement|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
341109|NCT01593631|Dietary Supplement|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
341110|NCT01593631|Dietary Supplement|Placebo|Capsules containing di-calcium-phosphate
341111|NCT01593618|Behavioral|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
341112|NCT01593618|Other|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
341113|NCT01593605|Dietary Supplement|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
341114|NCT01593605|Dietary Supplement|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
341115|NCT01593605|Other|Placebo treatment|Placebo - one tablet taken twice a day by mouth
341209|NCT01593020|Drug|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
341116|NCT01593592|Dietary Supplement|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
341117|NCT01593592|Dietary Supplement|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
341118|NCT01593592|Drug|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
341119|NCT01593592|Drug|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
341120|NCT01593592|Drug|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
341121|NCT01593579|Behavioral|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine & standing heart rate & blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
341122|NCT01593579|Other|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
341123|NCT01593566|Drug|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
341124|NCT01593566|Drug|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
341125|NCT01593553|Other|ECG screening for atrial fibrillation using intermittent ECG recorder|ECG screening for atrial fibrillation with intermittent ECG recording (Zenicor device) for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
341126|NCT01593540|Device|metal-free interdental brush|one time per day
341127|NCT01593540|Device|metal-core interdental brush|one time per day
341128|NCT01593527|Drug|ACZ885|Canakinumab 150 mg s.c.
341129|NCT01593527|Drug|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
341130|NCT01593514|Biological|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
341131|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
341132|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
341133|NCT01593514|Biological|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
341134|NCT01593514|Biological|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
341135|NCT01593501|Dietary Supplement|vitamin D3|pharmaceutical grade D3
341136|NCT01593488|Drug|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
341137|NCT01593475|Radiation|Induction chemotherapy followed by CCRT|"Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy~Radiotherapy~- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
341138|NCT01593462|Procedure|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
341139|NCT01593462|Procedure|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
341204|NCT01593033|Dietary Supplement|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
341205|NCT01593033|Drug|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
341140|NCT01593462|Behavioral|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.~A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
341141|NCT01593449|Behavioral|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
341142|NCT01593436|Behavioral|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
341143|NCT01593423|Behavioral|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
341144|NCT01593423|Behavioral|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
341145|NCT01593423|Behavioral|a comparison group|No intervention.
341146|NCT01593410|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
341147|NCT01593410|Drug|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
341148|NCT01593397|Drug|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
341149|NCT01593371|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
341150|NCT01593371|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
341151|NCT01593345|Other|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
341152|NCT01593345|Other|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
341153|NCT01593332|Drug|Rituximab|two 500 mg rituximab infusions 2 weeks apart
341154|NCT01593332|Drug|Rituximab|500mg,two times with two weeks interval
341155|NCT01593319|Drug|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
341156|NCT01593319|Drug|Natrium chloride|Placebo injection of Natrium chloride solution
341157|NCT01593306|Drug|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
341158|NCT01593306|Drug|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
341159|NCT01593293|Drug|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
341160|NCT01593293|Drug|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
341161|NCT01593280|Device|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
341162|NCT01593280|Drug|intrathecal morphine|0.3 mg
341163|NCT01593267|Procedure|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
341164|NCT01593267|Procedure|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
341165|NCT01593254|Drug|Imatinib|
341166|NCT01593254|Drug|Dasatinib|
341167|NCT01593241|Drug|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
341168|NCT01593241|Radiation|Involved node RT|Involved node RT
341169|NCT01593228|Drug|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution~Route of administration: Intravenous"
341170|NCT01593228|Drug|Carboplatin|"Pharmaceutical form:Solution~Route of administration: Intravenous"
341171|NCT01593228|Drug|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution~Route of administration: Intravenous"
341172|NCT01593228|Drug|Gemcitabine|"Pharmaceutical form:Solution~Route of administration: Intravenous"
341173|NCT01593228|Drug|Irinotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
341174|NCT01593228|Drug|Paclitaxel|"Pharmaceutical form:Solution~Route of administration: Intravenous"
341175|NCT01593228|Drug|Topotecan|"Pharmaceutical form:Solution~Route of administration: Intravenous"
341176|NCT01593215|Drug|Yohimbine|Yohimbine capsule
341206|NCT01593020|Drug|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
341207|NCT01593020|Drug|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
341208|NCT01593020|Drug|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
344523|NCT01567709|Other|Pharmacological Study|Correlative studies
341177|NCT01593202|Behavioral|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
341178|NCT01593202|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
341179|NCT01593189|Behavioral|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
341180|NCT01593176|Procedure|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
341181|NCT01593163|Drug|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
341182|NCT01593163|Drug|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
341183|NCT01593150|Drug|Pradaxa|Pradaxa for 3 weeks prior to DC
341184|NCT01593150|Procedure|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
341185|NCT01593150|Other|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
341186|NCT01593137|Drug|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin >1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.~Patients will continue on metformin therapy as they were prescribed before enrolment."
341187|NCT01593137|Drug|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin >1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.~Patients will continue on metformin therapy as they were prescribed before enrolment."
341188|NCT01593124|Drug|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
341189|NCT01593124|Other|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
341190|NCT01593124|Drug|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
341191|NCT01593111|Other|Environmental Intervention|Home-based environmental intervention
341192|NCT01593085|Behavioral|interview with a doctor for evaluating suicide risk|"patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)~--------------------------------------------------------------------------------"
341193|NCT01593072|Drug|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV~The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
341194|NCT01593072|Other|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
341195|NCT01593046|Drug|GSK1265744 Oral|30mg tablet
341196|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
341197|NCT01593046|Drug|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
341198|NCT01593046|Drug|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
341199|NCT01593046|Drug|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
341200|NCT01593046|Drug|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
341201|NCT01593046|Drug|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
341202|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
341203|NCT01593033|Dietary Supplement|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months~1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
344524|NCT01567709|Drug|Vorinostat|Given PO
341210|NCT01593020|Drug|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
341211|NCT01593020|Drug|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
341212|NCT01593007|Other|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
341213|NCT01593007|Other|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
341214|NCT01592994|Behavioral|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
341215|NCT01592981|Drug|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
341216|NCT01592981|Drug|Cyclophosphamide|"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.~Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
341217|NCT01592981|Biological|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
341218|NCT01592981|Drug|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
341219|NCT01592968|Other|Cognitive Assessment|Ancillary studies
341220|NCT01592968|Other|Quality-of-Life Assessment|Ancillary studies
341221|NCT01592968|Radiation|Stereotactic Radiosurgery|Undergo SRS
341222|NCT01592968|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
341223|NCT01592955|Device|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
341224|NCT01592942|Device|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
341225|NCT01592942|Device|Progrip|self-gripping mesh
341226|NCT01592942|Device|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
341227|NCT01592929|Radiation|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
341228|NCT01592929|Other|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
341229|NCT01592929|Radiation|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
341230|NCT01592929|Radiation|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
341231|NCT01592929|Other|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
341232|NCT01592903|Genetic|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.~Sample digestion through controlled enzymes.~Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .~Culture of these cells.~Morphological and genetic characterization.~Assessment of pluripotent potential from isolated cells.~Analysis of the degree of functionality."
341233|NCT01592890|Drug|RO4917523|[14C]-labeled RO4917523, single oral dose
341234|NCT01592890|Drug|RO4917523|[13C]-labeled RO4917523, single intravenous tracer dose
341235|NCT01592864|Drug|Stannous Fluoride|dentifice
341236|NCT01592864|Drug|Sodium Monofluorophosphate|dentifrice
341237|NCT01592851|Drug|Stannous Fluoride|dentifrice containing stannous fluoride
341238|NCT01592851|Drug|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
341239|NCT01592838|Other|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
341240|NCT01592812|Device|electrical muscle stimulation|Duration of the stimulation 20 minutes
341241|NCT01592799|Procedure|Throat swab and/or nasopharyngeal swab|Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
341242|NCT01592799|Other|Data collection|Log Sheet will be used to collected data on a monthly basis for the following age groups: < 6 months; 6-23 months; 24-59 months; > 5 years.
341243|NCT01592786|Drug|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
341244|NCT01592773|Drug|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.~During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
341245|NCT01592760|Device|air-Q SP|air-Q SP placement for airway maintenance.
341246|NCT01592760|Device|air-Q|air-Q placement for airway maintenance.
341247|NCT01592760|Device|i-gel|i-gel placement for airway maintenance.
341248|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3-15mg/day; administered orally
341249|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Extended Release Dose ranging from 3mg every other day to 6mg/day; administered orally.
341250|NCT01592747|Drug|Placebo capsules|Once daily, oral administration.
341320|NCT01592253|Drug|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
341251|NCT01592734|Drug|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.~Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
341252|NCT01592734|Device|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children > 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.~Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
341253|NCT01592721|Biological|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
341254|NCT01592708|Other|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
341255|NCT01592695|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
341256|NCT01592695|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
341257|NCT01592695|Behavioral|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
341258|NCT01592695|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
341259|NCT01592695|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
341260|NCT01592695|Drug|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
341261|NCT01592695|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
341262|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
341263|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
341264|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
341265|NCT01592695|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
341266|NCT01592695|Behavioral|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
341267|NCT01592695|Behavioral|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
341268|NCT01592682|Behavioral|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
341269|NCT01592669|Procedure|passive leg raising|bilateral PLR was achieved by raising the legs of patient
341270|NCT01592656|Radiation|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
341271|NCT01592656|Other|Lung compliance measurement|At baseline
341272|NCT01592656|Device|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 > 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
341273|NCT01592643|Device|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
341274|NCT01592630|Drug|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
341275|NCT01592630|Drug|Saline|On-Q pumps containing saline to be attached to TAP catheters
341276|NCT01592617|Drug|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
341277|NCT01592604|Device|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
341278|NCT01592604|Device|Below knee walking cast|Below knee walking cast for 4 weeks
341279|NCT01592578|Procedure|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
341280|NCT01592578|Procedure|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
341321|NCT01592240|Drug|PBO|Placebo Q28d
341322|NCT01592240|Drug|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
341323|NCT01592240|Drug|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
341324|NCT01592240|Drug|PBO|Placebo, Q14d
341325|NCT01592240|Drug|PF-04950615|PF-04950615 50mg, Q14d
341326|NCT01592240|Drug|PF-04950615|PF-04950615 100 mg, Q14d
341327|NCT01592240|Drug|PF-04950615|PF-04950615 150mg, Q14d
341328|NCT01592227|Drug|Marketed paracetamol|Marketed paracetamol
341281|NCT01592565|Other|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
341282|NCT01592526|Other|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
341283|NCT01592526|Other|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
341284|NCT01592513|Device|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).~BIS values between 80-90 represent values corresponding to light/moderate sedation.~BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
341285|NCT01592500|Drug|MOD-4023|Once weekly subcutaneous injection
341286|NCT01592500|Drug|Somatropin|Once daily subcutaneous injection of Genotropin
341287|NCT01592448|Behavioral|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
341288|NCT01592422|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
341289|NCT01592422|Other|Best Supportive Care|Best Supportive Care in the absence of disease progression
341290|NCT01592409|Drug|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
341291|NCT01592409|Drug|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
341292|NCT01592396|Biological|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
341293|NCT01592383|Drug|erlotinib hydrochloride|Given PO
341294|NCT01592370|Biological|Nivolumab|Administered by intravenous (IV) infusion
341295|NCT01592370|Biological|Ipilimumab|Administered by IV infusion
341296|NCT01592370|Biological|Lirilumab|Administered by IV infusion
341297|NCT01592370|Biological|Daratumumab|Administered by IV infusion
341298|NCT01592370|Drug|Pomalidomide|Administered PO
341299|NCT01592370|Drug|Dexamethasone|Administered PO and by IV infusion
341300|NCT01592357|Behavioral|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
341301|NCT01592357|Behavioral|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
341302|NCT01592344|Device|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 100-250 µsec~Pulse Rate: 50-100 Hz~Intensity: 0-30mA Time Settings~Constant Stim: On~Total Time: 6 hour"
341303|NCT01592344|Device|StimRouter - Control|"The stimulation program settings for this arm are as follows:~Stim Settings~Waveform: Symmetric or Asymmetric~Phase Duration: 200 µsec~Pulse Rate: 1 Hz~Intensity: 0 mA Time Settings~Constant Stim: On~Total Time: 6 hour"
341304|NCT01592331|Drug|Placebo|Single oral dose
341305|NCT01592331|Drug|RO5508887|Single oral dose
341306|NCT01592318|Drug|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
341307|NCT01592318|Drug|danoprevir|Reference tablet, single oral dose
341308|NCT01592318|Drug|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
341309|NCT01592318|Drug|ritonavir|Reference tablet, single oral dose
341310|NCT01592305|Drug|atazanavir|multiple oral doses
341311|NCT01592305|Drug|danoprevir|multiple oral doses
341312|NCT01592305|Drug|ritonavir|multiple oral doses
341313|NCT01592305|Drug|tenofovir disoproxil fumarate|single oral doses
341314|NCT01592292|Drug|Rituximab|Rituximab as per physician's discretion.
341315|NCT01592292|Drug|Adalimumab|Adalimumab as per physician's discretion.
341316|NCT01592292|Drug|Etanercept|Etanercept as per physician's discretion.
341317|NCT01592292|Drug|Infliximab|Infliximab as per physician's discretion.
341318|NCT01592279|Drug|liraglutide|
341319|NCT01592279|Drug|Insulin injections|
344525|NCT01567683|Drug|Imiquimod (topical use)|
341330|NCT01592214|Other|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
341331|NCT01592214|Drug|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
341332|NCT01592214|Drug|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
341333|NCT01592201|Drug|Paliperdidone ER|Form = osmotic release oral system, route = oral
341334|NCT01592201|Drug|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
341335|NCT01592188|Behavioral|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
341336|NCT01592188|Behavioral|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
341337|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
341338|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
341339|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
341340|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
341341|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
341342|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
341343|NCT01592162|Drug|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
341344|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
341345|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
341346|NCT01592149|Other|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
341347|NCT01592136|Drug|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
341348|NCT01592123|Procedure|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
341349|NCT01592123|Behavioral|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score >5 is considered to be suggestive of significant sleep disturbance.
341350|NCT01592123|Behavioral|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
341351|NCT01592123|Behavioral|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
341352|NCT01592110|Drug|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
341353|NCT01592110|Other|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
341354|NCT01592110|Drug|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
341355|NCT01592110|Drug|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
341356|NCT01592071|Other|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
341357|NCT01592045|Biological|ch14.18 -NCI|25 mg/m^2/day IV for four consecutive days
341358|NCT01592045|Biological|ch14.18-UTC|17.5 mg/m^2/day IV for four consecutive days
341359|NCT01592045|Biological|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF will be administered SC at a dose of 250 mcg/m^2/day for 14 days during Courses 1, 3, and 5.
341467|NCT01591330|Drug|LY2140023 Monohydrate (Test - High)|80 mg tablet administered orally
341360|NCT01592045|Biological|Aldesleukin (IL-2)|Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m^2/day for the first week and at a dose of 4.5 MIU/m^2/day for the second week during Courses 2 and 4.
341361|NCT01592045|Drug|Isotretinoin|"Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:~If weight > 12 kg: 80 mg/m^2/dose twice daily (total daily dose is 160 mg/m^2/day, divided twice daily).~If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily)."
341362|NCT01592032|Drug|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
341363|NCT01592032|Drug|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
341364|NCT01592032|Drug|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
341365|NCT01592032|Drug|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
341366|NCT01592032|Drug|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
341367|NCT01592019|Drug|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
341368|NCT01592019|Device|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
341369|NCT01592019|Drug|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
341370|NCT01592019|Device|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
341371|NCT01592006|Drug|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
341372|NCT01592006|Drug|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
341373|NCT01592006|Drug|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
341374|NCT01591993|Procedure|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
341375|NCT01591993|Procedure|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
341376|NCT01591980|Drug|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
341377|NCT01591980|Drug|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
341378|NCT01591980|Drug|placebo|Identical placebo capsules will be administered in the same way.
341379|NCT01591967|Device|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
341380|NCT01591954|Device|Video Augmentation|Assessment of value of video-based navigation system
341381|NCT01591941|Other|Core-PAC|"Core position and control movement strategy (Core-PAC):~Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
341382|NCT01591915|Other|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
341383|NCT01591902|Drug|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
341384|NCT01591902|Drug|Placebo-Control|3.0 mL vials
341385|NCT01591889|Drug|Tinidazole|500 mg tablet
341386|NCT01591889|Drug|Tinidazole|500 mg tablet
341418|NCT01591668|Drug|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
341419|NCT01591655|Drug|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
341387|NCT01591876|Other|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
341388|NCT01591876|Other|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
341389|NCT01591863|Drug|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
341390|NCT01591850|Drug|RO5093151|Single oral dose
341391|NCT01591850|Drug|atazanavir|Multiple oral doses
341392|NCT01591850|Drug|ketoconazole|Multiple oral doses
341393|NCT01591850|Drug|rifampicin|Multiple oral doses
341394|NCT01591850|Drug|ritonavir|Multiple oral doses
341395|NCT01591837|Biological|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
341396|NCT01591824|Other|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas~general column.~lumbar muscles, and paraspinal muscles,~sacral decompression oscillatory~Opening by lateral vertebral lumbar rhythmic swing.~Balancing and pelvic decompression~Swing-lumbar vertebral rotation."
341397|NCT01591824|Other|column exercise group|"paraspinal muscle stretching exercises~postural correction~mobilization exercises thoracic and lumbar~Motor control exercises"
341398|NCT01591811|Radiation|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
341399|NCT01591811|Radiation|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
341400|NCT01591798|Procedure|Robotic surgery|Robotic assisted rectal resection
341401|NCT01591798|Procedure|Laparoscopic surgery|Laparoscopic assisted rectal resection
341402|NCT01591785|Drug|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
341403|NCT01591785|Drug|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
341404|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
341405|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
341406|NCT01591759|Drug|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
341407|NCT01591759|Drug|Placebo|Placebo arm of single-blind study
341408|NCT01591746|Drug|Botulinum Toxin Type A|
341409|NCT01591746|Drug|Placebo|5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
341410|NCT01591733|Drug|FOLFIRINOX|Up to Eight-14 day cycles
341411|NCT01591733|Drug|Capecitabine|Orally, for 10 days
341412|NCT01591733|Radiation|Short Course Radiation|Five or ten days
341413|NCT01591733|Procedure|Surgery|1-4 weeks after completion of capecitabine therapy
341414|NCT01591720|Behavioral|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
341415|NCT01591707|Behavioral|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
341416|NCT01591681|Device|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
341417|NCT01591668|Drug|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
341421|NCT01591629|Drug|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
341422|NCT01591629|Drug|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
341423|NCT01591629|Drug|Placebo|Placebo
341424|NCT01591616|Drug|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
341425|NCT01591603|Procedure|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
341426|NCT01591603|Procedure|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
341427|NCT01591590|Other|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
341428|NCT01591590|Other|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
341429|NCT01591590|Other|Blood samples (plasma preparation and CTC)|
341430|NCT01591577|Other|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
341431|NCT01591564|Behavioral|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
341432|NCT01591551|Drug|Natalizumab (Tysabri)|300 mg IV every 4 weeks
341433|NCT01591525|Behavioral|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
341434|NCT01591525|Behavioral|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
341435|NCT01591525|Behavioral|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
341436|NCT01591499|Device|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
341437|NCT01591499|Device|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
341438|NCT01591473|Drug|Poly I:Poly C12U 50 ug|Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
341439|NCT01591473|Drug|Poly I:Poly C12U 200 ug|Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
341440|NCT01591473|Drug|Poly I:Poly C12U 500 ug|Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
341441|NCT01591473|Drug|Poly I:Poly C12U 1250 ug|Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
341442|NCT01591473|Drug|Placebo|Placebo; 3 doses; nasal administration every 28 days
341443|NCT01591473|Drug|FluMist|FluMist 0.2 ml; 3 doses; nasal administration every 28 days
341444|NCT01591460|Drug|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
341445|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
341446|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
341447|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
341448|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
341449|NCT01591447|Drug|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
341450|NCT01591447|Drug|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
341451|NCT01591434|Device|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
341452|NCT01591434|Device|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
341453|NCT01591421|Drug|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
341454|NCT01591421|Drug|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
341455|NCT01591408|Device|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
341456|NCT01591395|Procedure|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
341457|NCT01591382|Drug|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
341458|NCT01591382|Drug|Placebo|Patients who received ketamine-matching placebo were given saline infusions
341459|NCT01591382|Drug|Hydromorphone PCA|Intravenous hydromorphone PCA
341460|NCT01591356|Drug|EphA2-targeting DOPC-encapsulated siRNA|Given IV
341461|NCT01591356|Other|Laboratory Biomarker Analysis|Correlative studies
341462|NCT01591356|Other|Pharmacological Study|Correlative studies
341463|NCT01591343|Biological|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).~Dose:~Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
341469|NCT01591304|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
341470|NCT01591291|Drug|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
341471|NCT01591291|Drug|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
341472|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
341473|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
341474|NCT01591265|Procedure|Extraction of upper and lower FPM teeth|Extraction of upper and lower FPM teeth
341475|NCT01591265|Procedure|Extraction of lower FPM tooth|Extraction of lower FPM tooth only
341476|NCT01591239|Behavioral|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
341477|NCT01591239|Behavioral|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
341478|NCT01591226|Dietary Supplement|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
341479|NCT01591226|Dietary Supplement|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
341480|NCT01591226|Dietary Supplement|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
341481|NCT01591226|Dietary Supplement|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
341482|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
341483|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
341484|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
341485|NCT01591187|Other|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
341486|NCT01591187|Other|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
341487|NCT01591187|Other|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
341488|NCT01591161|Drug|Mapracorat|1 drop of study medication into the study eye QID for 14 days
341489|NCT01591161|Drug|Placebo|1 drop of vehicle into the study eye QID for 14 days.
341490|NCT01591148|Drug|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
341491|NCT01591135|Drug|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
341492|NCT01591135|Drug|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
341493|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
341494|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
341495|NCT01591122|Drug|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
341496|NCT01591122|Drug|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
341497|NCT01591096|Drug|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
341498|NCT01591083|Drug|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score >=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score <6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
341499|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
341500|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
341501|NCT01591057|Dietary Supplement|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
341502|NCT01591057|Dietary Supplement|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
341960|NCT01587391|Drug|Placebo to BI 163538 XX|1 single dose per subject as oral solution
341503|NCT01591057|Dietary Supplement|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
341504|NCT01591044|Drug|Placebo|1 puff bid or 2 puffs bid
341505|NCT01591044|Drug|R940343 1mg|R343 1mg, 1 puff bid
341506|NCT01591044|Drug|R940343 2mg|R343 2mg, 2 puffs bid
341507|NCT01591031|Drug|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
341508|NCT01591031|Drug|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
341509|NCT01591018|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
341510|NCT01591018|Procedure|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
341511|NCT01591005|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
341512|NCT01591005|Procedure|endarterectomy|carotid endarterectomy
341513|NCT01591005|Procedure|carotid stenting|percutaneous transluminal angioplasty and stenting
341514|NCT01590992|Behavioral|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
341515|NCT01590992|Behavioral|Relaxation therapy|Progressive muscle relaxation (Jacobson)
341516|NCT01590979|Drug|Ranolazine|1000mg, two times a day, 12 hour intervals
341517|NCT01590979|Drug|Placebo|two times a day, 12 hour intervals
341518|NCT01590966|Drug|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
341519|NCT01590966|Drug|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
341520|NCT01590940|Procedure|Open inguinal hernia repair with mesh|
341521|NCT01590914|Procedure|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
341522|NCT01590914|Procedure|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
341523|NCT01590901|Drug|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
341524|NCT01590888|Drug|PBT2|250mg capsules administered orally once per day for 26 weeks
341525|NCT01590888|Drug|PBT2|100mg capsules administered orally once per day for 26 weeks
341526|NCT01590888|Drug|Placebo|Matching capsules administered orally once per day for 26 weeks
341527|NCT01590875|Drug|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
341528|NCT01590849|Drug|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:~Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).~Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).~Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
341529|NCT01590836|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
341530|NCT01590836|Drug|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
341531|NCT01590823|Drug|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
341532|NCT01590810|Drug|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
341533|NCT01590810|Drug|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
341534|NCT01590810|Drug|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
341535|NCT01590810|Drug|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
341536|NCT01590810|Drug|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
341537|NCT01590810|Drug|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
341538|NCT01590810|Drug|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
341539|NCT01590810|Drug|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
341540|NCT01590810|Drug|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
341541|NCT01590810|Drug|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
341542|NCT01590810|Drug|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
341543|NCT01590810|Drug|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
341544|NCT01590810|Drug|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
341545|NCT01590810|Drug|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
341546|NCT01590810|Drug|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
341547|NCT01590810|Drug|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
341548|NCT01590810|Drug|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
341549|NCT01590810|Drug|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
341550|NCT01590810|Drug|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
341551|NCT01590797|Drug|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
341553|NCT01590797|Biological|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
341554|NCT01590797|Drug|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
341555|NCT01590771|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
341556|NCT01590771|Drug|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
341557|NCT01590771|Drug|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
341558|NCT01590771|Drug|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
341559|NCT01590771|Drug|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
341560|NCT01590758|Drug|Topical pexiganan cream 0.8%|14 days of treatment
341561|NCT01590758|Drug|Topical placebo cream|14 days of treatment
341562|NCT01590758|Other|Standard wound care|14 days of treatment
341563|NCT01590745|Device|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
341564|NCT01590732|Drug|Carboplatin|Given IV
341565|NCT01590732|Drug|Etoposide|Given IV
341566|NCT01590732|Drug|Ifosfamide|Given IV
341567|NCT01590732|Drug|Romidepsin|Given IV
341568|NCT01590719|Drug|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
341569|NCT01590719|Drug|Onartuzumab (MetMAb)|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
341570|NCT01590719|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
341571|NCT01590719|Drug|Folinic acid|Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
341572|NCT01590719|Drug|Levofolinic acid|If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
341573|NCT01590719|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
341574|NCT01590693|Drug|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
341575|NCT01590680|Radiation|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
341576|NCT01590667|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
341577|NCT01590667|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
341578|NCT01590654|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
341579|NCT01590654|Drug|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
341580|NCT01590641|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
341581|NCT01590641|Drug|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
341582|NCT01590628|Drug|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
341583|NCT01590615|Drug|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
341584|NCT01590563|Device|IUD|Insertion of a spherical IUD, one year follow-up
341585|NCT01590550|Procedure|Use of citrate based dialysate|Use of heparin free citrate based dialysate
341586|NCT01590537|Drug|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
341587|NCT01590537|Device|Copper IUD|Copper device, inserted intrauterine
341588|NCT01590524|Behavioral|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
341589|NCT01590485|Other|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
341590|NCT01590485|Other|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
341591|NCT01590459|Drug|VX-509|50 mg oral tablet
341592|NCT01590459|Drug|VX-509 matching placebo|0 mg oral tablet
341593|NCT01590446|Drug|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
341594|NCT01590446|Drug|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
341691|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
341595|NCT01590433|Drug|Exenatide|Subjects will inject 5mcg of exenatide or identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
341596|NCT01590433|Drug|Placebo|Subjects will inject 5mcg of exenatide or identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
341597|NCT01590433|Behavioral|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects may or may not be asked to follow a reduced calorie diet in addition to receiving treatment.
341598|NCT01590420|Device|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
341599|NCT01590407|Drug|ALS-002200|ALS-002200
341600|NCT01590407|Drug|Placebo|Placebo
341601|NCT01590394|Device|Large plastic biliary stent|Stent placement for bile duct obstruction.
341602|NCT01590368|Device|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
341603|NCT01590368|Device|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
341604|NCT01590355|Radiation|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
341605|NCT01590355|Procedure|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
341606|NCT01590342|Drug|Diclofenac|Diclofenac 75 mg, two doses
341607|NCT01590342|Drug|Placebo|Placebo, two doses
341608|NCT01590329|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
341609|NCT01590316|Device|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
341610|NCT01590303|Drug|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
341611|NCT01590303|Drug|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
341612|NCT01590290|Other|financial compensation|financial monetary reimbursement
341613|NCT01590277|Drug|Ethanol|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil~active ethanol + placebo iomazenil~active ethanol + active iomazenil~placebo ethanol + active iomazenil"
341614|NCT01590277|Drug|Iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.~Potential Randomizations:~placebo ethanol + and placebo iomazenil~active ethanol + placebo iomazenil~active ethanol + active iomazenil~placebo ethanol + active iomazenil"
341615|NCT01590264|Device|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.~DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000~TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
341616|NCT01590251|Other|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
341617|NCT01590251|Behavioral|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
341618|NCT01590238|Biological|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
341619|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
341620|NCT01590225|Drug|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 24 weeks.
341621|NCT01590225|Drug|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 24 weeks.
341622|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
341623|NCT01590225|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 48 weeks.
341624|NCT01590225|Drug|Ribavirin|"Drug: Ribavirin~The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 48 weeks."
341625|NCT01590212|Other|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
341692|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
341626|NCT01590212|Other|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
341627|NCT01590199|Drug|RAD001|
341628|NCT01590199|Drug|SOM230|
341629|NCT01590173|Drug|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
341630|NCT01590173|Drug|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
341631|NCT01590160|Drug|Ganetespib|IV, Using dose from Phase I
341632|NCT01590147|Procedure|Yoga therapy|receive YST
341633|NCT01590147|Other|questionnaire administration|Ancillary studies
341634|NCT01590147|Procedure|quality-of-life assessment|Ancillary studies
341635|NCT01590147|Other|laboratory biomarker analysis|Correlative studies
341636|NCT01590147|Other|assessment of therapy complications|Ancillary studies
341637|NCT01590147|Procedure|management of therapy complications|Receive YST or CE
341638|NCT01590147|Other|educational intervention|Receive CE
341639|NCT01590134|Dietary Supplement|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
341640|NCT01590134|Drug|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
341641|NCT01590121|Other|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
341642|NCT01590121|Other|Questionnaire|Flight by aeroplane (previous)
341643|NCT01590108|Drug|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
341644|NCT01590108|Drug|Saline|Saline
341645|NCT01590095|Behavioral|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age."
341646|NCT01590095|Behavioral|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
341647|NCT01590095|Behavioral|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
341648|NCT01590095|Behavioral|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age.~Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.~Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
341649|NCT01590095|Behavioral|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.~Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
341650|NCT01590095|Behavioral|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation & Hand washing (Combined WASH) Plus the intervention described above for nutrition.
341651|NCT01590082|Drug|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
341652|NCT01590082|Drug|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
341653|NCT01590082|Drug|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
341654|NCT01590069|Biological|Aerosolized Aldesleukin|Breathe aerosolized aldesleukin
341655|NCT01590069|Other|Laboratory Biomarker Analysis|Optional correlative studies
341693|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
341961|NCT01587391|Drug|BI 163538 XX|1 single dose per subject as oral solution
341656|NCT01590056|Other|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:~listening to nonverbal affect bursts corresponding to emotions~applying a simple go-no-go auditory test"
341657|NCT01590043|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
341658|NCT01590030|Procedure|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
341659|NCT01590017|Drug|cisplatin|
341660|NCT01590017|Radiation|external beam radiation therapy|
341661|NCT01589991|Drug|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
341662|NCT01589978|Device|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
341663|NCT01589978|Drug|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
341664|NCT01589978|Drug|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.~Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)~Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)~Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses >100 mg may reduce ticagrelor effectiveness and should be avoided.~Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
341665|NCT01589965|Behavioral|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
341666|NCT01589952|Drug|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
341667|NCT01589926|Device|Bi-level positive airway pressure device|BiPAP initiated for at least 16 hours per day for a minimum of 48hrs.
341668|NCT01589926|Device|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
341669|NCT01589913|Behavioral|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:~Introduction to participants and online system~Knowledge regarding ICDs~Strategies for behavior change~Psychological models for anxiety and depression~Strategies to cope with avoidance, anxiety and depression~Resume, evaluation, resolution of open questions, goal setting, good bye"
341670|NCT01589861|Drug|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
341671|NCT01589835|Behavioral|Lifestyle changes|Green prescription with support from facilitator
341672|NCT01589822|Biological|EVICEL Fibrin Sealant|Intraoperative
341673|NCT01589809|Drug|nicotinamide|dose-escalation, 2-8 grams, oral
341674|NCT01589796|Procedure|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
341675|NCT01589783|Other|completion of a questionnaire|Completion of a questionnaire
341676|NCT01589783|Other|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
341677|NCT01589770|Other|cardiac Magnetic Resonance imaging|
341678|NCT01589757|Other|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
341679|NCT01589757|Other|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
341680|NCT01589744|Device|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
341681|NCT01589718|Drug|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
341682|NCT01589718|Drug|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
341683|NCT01589692|Procedure|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
341684|NCT01589692|Procedure|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
341685|NCT01589692|Procedure|Percutaneous Pinning|Pinning with any number of Kirschner wires
341686|NCT01589692|Procedure|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
341687|NCT01589679|Other|standard of care|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
341688|NCT01589679|Device|Metarsal Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
341689|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
341690|NCT01589666|Drug|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
341694|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
341695|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
341696|NCT01589640|Other|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
341697|NCT01589640|Other|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
341698|NCT01589640|Other|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
341699|NCT01589627|Device|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
341700|NCT01589614|Drug|PH-797804|Tablet, 6mg, single
341701|NCT01589614|Drug|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
341702|NCT01589601|Behavioral|Usual heart failure care|Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
341703|NCT01589601|Behavioral|Interdisciplinary palliative care|Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
341704|NCT01589588|Device|Open Hudson Mask|Mask type 1 oxygen
341705|NCT01589588|Device|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
341706|NCT01589588|Device|Mask 3|Mask type 3 oxygen
341707|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 oxygen
341708|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 placebo
341709|NCT01589562|Drug|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
341710|NCT01589562|Drug|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
341711|NCT01589549|Biological|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
341712|NCT01589536|Other|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
341713|NCT01589523|Drug|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
341714|NCT01589510|Drug|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
341715|NCT01589497|Drug|Rifampicin|Participants with body weight </= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight >50kg were administered one 600 mg tablet orally once daily.
341716|NCT01589497|Drug|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
341717|NCT01589497|Drug|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
341718|NCT01589497|Drug|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
341719|NCT01589497|Drug|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
341720|NCT01589484|Device|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
341721|NCT01589471|Drug|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
341722|NCT01589458|Drug|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
341723|NCT01589445|Drug|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
341724|NCT01589445|Drug|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
341725|NCT01589432|Drug|ABT-639|two 50 mg oral capsules
341726|NCT01589432|Drug|Placebo|2 placebo capsules
341727|NCT01589432|Drug|Lidocaine|3mg/kg infusion over 30 minutes
341728|NCT01589419|Drug|veliparib|see arm description
341729|NCT01589419|Drug|capecitabine|see arm description
341730|NCT01589419|Radiation|radiation|see arm description
341731|NCT01589393|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
341732|NCT01589393|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
341797|NCT01588795|Procedure|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
341800|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
341801|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
341733|NCT01589380|Drug|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.~Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
341734|NCT01589380|Drug|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
341735|NCT01589367|Drug|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
341736|NCT01589367|Drug|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
341737|NCT01589354|Procedure|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
341738|NCT01589354|Procedure|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
341739|NCT01589354|Device|Ultrasound guided technique|The block will be performed under U/S guidance
341740|NCT01589354|Drug|Ropivacaine|20ml of 0.375% Ropivacaine
341741|NCT01589354|Drug|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
341742|NCT01589341|Other|laboratory biomarker analysis|Correlative studies
341743|NCT01589328|Other|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:~(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
341744|NCT01589315|Device|focal ECT|FEAST, ECT, unidirectional stimulation
341745|NCT01589302|Drug|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
341746|NCT01589302|Other|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
341747|NCT01589302|Other|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
341748|NCT01589289|Device|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
341749|NCT01589289|Device|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
341750|NCT01589289|Device|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
341751|NCT01589289|Device|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
341752|NCT01589289|Device|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
341753|NCT01589263|Drug|onaBoNT-A + placebo|"200 U prostate injection once~Arms: ARM 1: onaBoNT-A + placebo"
341754|NCT01589263|Drug|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
341755|NCT01589237|Drug|LCQ908|
341756|NCT01589211|Behavioral|Brief advice|Brief advice of about 10 min accompanied by self-help material
341757|NCT01589211|Behavioral|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
341758|NCT01589211|Behavioral|Standard cessation course|Cessation course over 6 dates. Group setting.
341759|NCT01589185|Drug|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
341760|NCT01589185|Drug|Placebo|Placebo administered as a single intravenous infusion
341761|NCT01589159|Drug|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
341762|NCT01589159|Drug|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
341763|NCT01589146|Drug|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
341764|NCT01589120|Behavioral|Video decision aid|Video decision aid of the goals of care
341765|NCT01589107|Behavioral|video decision aid|video decision aid
341766|NCT01589094|Drug|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
341798|NCT01588795|Drug|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
341799|NCT01588782|Drug|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
341767|NCT01589081|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
341768|NCT01589081|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
341769|NCT01589068|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
341770|NCT01589068|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
341771|NCT01589055|Drug|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
341772|NCT01589029|Drug|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
341773|NCT01589003|Other|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
341774|NCT01589003|Other|High GI growing up milk|High glycaemic index growing up milk
341775|NCT01588990|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m^2) IV infusion on Day 1 of every 2 weeks cycle during alternative Phase A treatment or 130 mg/m^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
341776|NCT01588990|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle during Phase A treatment.
341777|NCT01588990|Drug|Bevacizumab|Participants will receive 7.5 mg/kg IV infusion on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
341778|NCT01588990|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m^2 or 50 mg total dose).
341779|NCT01588990|Drug|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m^2 IV on Day 1 followed by 2400 mg/m^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
341780|NCT01588990|Drug|Irinotecan|Participants will receive irinotecan 180 mg/m^2 IV on Day 1 every 2 weeks during Phase B treatment.
341781|NCT01588964|Procedure|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
341782|NCT01588951|Drug|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
341783|NCT01588951|Drug|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
341784|NCT01588925|Device|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
341785|NCT01588925|Drug|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
341786|NCT01588925|Drug|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
341787|NCT01588912|Drug|Telbivudine|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
341788|NCT01588912|Drug|Tenofovir|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
341789|NCT01588912|Drug|Entecavir|Maintain the entecavir through the study period
341790|NCT01588899|Device|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
341791|NCT01588873|Drug|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.~After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.~Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
341792|NCT01588847|Procedure|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
341793|NCT01588847|Procedure|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
341794|NCT01588834|Procedure|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
341795|NCT01588821|Drug|Cabozantinib|60 mg daily by mouth
341796|NCT01588808|Behavioral|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
341802|NCT01588769|Biological|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
341803|NCT01588756|Drug|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
341804|NCT01588756|Drug|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
341805|NCT01588743|Drug|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
341806|NCT01588730|Device|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
341807|NCT01588730|Procedure|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
341808|NCT01588717|Drug|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
341809|NCT01588704|Drug|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
341810|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
341811|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
341812|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
341813|NCT01588678|Drug|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
341814|NCT01588639|Drug|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
341815|NCT01588639|Drug|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
341816|NCT01588639|Drug|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
341817|NCT01588626|Drug|AZD6140|tablet
341818|NCT01588600|Other|Dietary Fiber|Fiber added to breakfast
341819|NCT01588587|Drug|Sitagliptin|The dosage, frequency and duration for each sitagliptin are variant.
341820|NCT01588587|Drug|Alogliptin|The dosage, frequency and duration for each alogliptin are variant.
341821|NCT01588587|Drug|Vildagliptin|The dosage, frequency and duration for each vildagliptin are variant.
341822|NCT01588574|Biological|MT10109|Botulinum toxin type A
341823|NCT01588574|Biological|BOTOX(Registered trade mark)|Botulinum toxin type A
341824|NCT01588561|Drug|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
341825|NCT01588561|Other|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
341826|NCT01588548|Drug|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
341827|NCT01588535|Drug|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
341828|NCT01588535|Drug|placebo|placebo solution, five drops in affected ear canal each hour as needed
341829|NCT01588522|Drug|compound 31543 Calcitriol|topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
341830|NCT01588509|Drug|Romosozumab|Administered by subcutaneous injection
341831|NCT01588496|Biological|Evolocumab|Administered by subcutaneous injection
341832|NCT01588496|Drug|Placebo|Administered by subcutaneous injection
341833|NCT01588470|Drug|pioglitazone|45 mg per day for 6 months
341834|NCT01588457|Drug|Lithium/Lithium Carbonate|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain LI of ≥0.5mEq/L.
341835|NCT01588457|Drug|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
341836|NCT01588457|Drug|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
341837|NCT01588457|Drug|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
341838|NCT01588444|Device|cortical FDBA|cortical mineralized freeze-dried bone allograft
341839|NCT01588444|Device|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
341840|NCT01588431|Drug|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
341841|NCT01588418|Drug|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
341842|NCT01588418|Drug|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
341843|NCT01588405|Drug|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
341844|NCT01588392|Behavioral|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
341845|NCT01588392|Behavioral|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
341846|NCT01588379|Behavioral|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
341847|NCT01588379|Behavioral|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
341848|NCT01588379|Other|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
341849|NCT01588366|Drug|Placebo|Administered orally
341850|NCT01588366|Drug|LY2409021|Administered orally
341851|NCT01588353|Drug|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
341852|NCT01588340|Procedure|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
341853|NCT01588340|Procedure|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
341854|NCT01588314|Drug|Gabapentin|gabapentin 100 mg capsules
341855|NCT01588314|Drug|placebo|compounded placebo capsules
341856|NCT01588301|Behavioral|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
341857|NCT01588301|Behavioral|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
341858|NCT01588288|Procedure|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
341859|NCT01588275|Device|mandibular repositioning appliance (MRA) (SomnoDent)|bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
341860|NCT01588275|Procedure|Continuous positive airway pressure (CPAP)|Proper CPAP-pressure will be set for each patient separately.
341861|NCT01588262|Other|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
341862|NCT01588249|Dietary Supplement|Pasteurized maple syrup|
341863|NCT01588249|Dietary Supplement|Placebo|
341864|NCT01588236|Drug|high dose KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
341865|NCT01588236|Drug|lower dose KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
341866|NCT01588236|Drug|Placebo|3 capsules of placebo tid (morning, midday, and evening)
341867|NCT01588223|Other|Lipid identification|The lipids are identified using Mass Spectrometry
341868|NCT01588210|Other|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
341869|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
341870|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.~All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
341871|NCT01588197|Behavioral|Attention/Distraction Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attend away from the thermal stimulus (for example, to the other side of the body). Vividly imagine they are somewhere else, or engage in a high-demanding mental task such as counting backward by 7's or completing math problems to distract from the experience
341872|NCT01588197|Behavioral|Stimulus Quality/Severity Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to perceive the stimulus as a neutral sensory experience rather than pain. Attempt to perceive the stimulus as low intensity rather than high intensity.
341873|NCT01588197|Behavioral|Control Strategy|One of three Cognitive Pain Inhibition Strategies. The Participant will be instructed to attempt to take control of their perception of the painful experience.
341874|NCT01588184|Drug|Bevacizumab|Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
341875|NCT01588171|Drug|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
341876|NCT01588171|Drug|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
341877|NCT01588158|Drug|Acetaminophen|325 mg
341879|NCT01588145|Drug|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
341880|NCT01588132|Drug|Anfibatide|"To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.~To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours."
341881|NCT01588093|Drug|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
341882|NCT01588093|Drug|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
341883|NCT01588080|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
341884|NCT01588080|Device|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
341885|NCT01588015|Biological|tetanus-CMV fusion peptide vaccine|Given SC
341886|NCT01588015|Other|laboratory biomarker analysis|Correlative studies
341887|NCT01588002|Drug|danoprevir|multiple oral doses
341888|NCT01588002|Drug|efavirenz|multiple oral doses
341889|NCT01588002|Drug|ritonavir|multiple oral doses
341890|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 1-12
341891|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 13-24
341892|NCT01587989|Drug|placebo|methotrexate placebo orally weekly, Weeks 13-24
341893|NCT01587989|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
341894|NCT01587963|Drug|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
341895|NCT01587963|Other|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
341896|NCT01587950|Drug|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
341897|NCT01587950|Drug|Placebo|Sterile Water
341898|NCT01587937|Other|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
341899|NCT01587924|Drug|GSK1278863|tablet
341900|NCT01587924|Drug|rhEPO|injection
341901|NCT01587911|Other|Whey|Preload containing complete whey protein.
341902|NCT01587911|Other|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
341903|NCT01587911|Other|Control|Preload control matched for energy to the other 5 preloads.
341904|NCT01587911|Other|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
341905|NCT01587911|Other|MPI|Preload containing whole milk protein.
341906|NCT01587911|Other|CPI|Preload containing sodium caseinate.
341907|NCT01587898|Drug|GSK1278863|Tablet
341908|NCT01587898|Other|Placebo|Tablet
341909|NCT01587885|Drug|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
341910|NCT01587885|Drug|Omeprazole 20 mg|Tablets, orally
341911|NCT01587872|Procedure|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
341912|NCT01587859|Procedure|laparoscopic surgery|Nissen fundoplication; Collis Gastroplasty.
341913|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
341914|NCT01587846|Dietary Supplement|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
341915|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
341959|NCT01587404|Device|THERMOCOOL® SMARTTOUCH™ Catheter (including Surround Flow)|Variable contact force as measured at the catheter tip within the left atrium
341916|NCT01587846|Dietary Supplement|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
341917|NCT01587833|Drug|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
341918|NCT01587820|Drug|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
341919|NCT01587820|Drug|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
341920|NCT01587807|Drug|GSK1995057|inhaled dose (volume based on cohort)
341921|NCT01587807|Procedure|bronchoalveolar lavage|BAL
341922|NCT01587807|Drug|LPS|50 μg
341923|NCT01587807|Drug|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
341924|NCT01587768|Drug|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides &amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
341925|NCT01587755|Other|TTOP|Patient is taken care of in an intensified, optimised manner
341926|NCT01587755|Other|non-TTOP|Standard medical care
341927|NCT01587742|Drug|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
341928|NCT01587729|Drug|Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants|TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
341929|NCT01587716|Drug|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
341930|NCT01587716|Other|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
341931|NCT01587716|Drug|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
341932|NCT01587716|Other|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
341933|NCT01587703|Drug|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
341934|NCT01587664|Device|NewBreez ILP|NewBreez ILP implantation
341935|NCT01587651|Drug|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
341936|NCT01587651|Drug|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
341937|NCT01587651|Drug|Ticagrelor Maintenance Dose|one 90mg film coated tablet
341938|NCT01587638|Drug|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
341939|NCT01587638|Drug|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
341940|NCT01587625|Drug|Oxytocin|
341941|NCT01587599|Behavioral|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
341942|NCT01587586|Biological|Pegasys|48 doses, solution, 48 weeks
341943|NCT01587586|Biological|P1101, 48 doses|48 doses, solution, 48 weeks
341944|NCT01587586|Biological|P1101, 24 doses|24 doses, solution, 48 weeks
341945|NCT01587586|Biological|P1101, 12 doses|12 doses, solution, 48 weeks
341946|NCT01587573|Other|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
341947|NCT01587560|Device|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
341948|NCT01587560|Device|TITAN, Ascension Orthopedics, Inc.|
341949|NCT01587534|Drug|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
341950|NCT01587508|Drug|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
341951|NCT01587508|Drug|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
341952|NCT01587508|Drug|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
341953|NCT01587495|Drug|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
341954|NCT01587482|Procedure|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
341955|NCT01587430|Drug|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
341956|NCT01587430|Drug|standard dose ARA-C|
341957|NCT01587417|Drug|Placebo to BI 187004 CL|1 single dose per subject as oral solution
341958|NCT01587417|Drug|BI 187004 CL|1 single dose per subject as oral solution
341962|NCT01587378|Drug|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
341963|NCT01587378|Drug|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
341964|NCT01587365|Biological|BMS-962476|
341965|NCT01587365|Biological|Placebo matching with BMS-962476|
341966|NCT01587352|Other|Laboratory Biomarker Analysis|Correlative studies
341967|NCT01587352|Drug|Vorinostat|Given PO
341968|NCT01587339|Drug|retigabine/ezogabine|oral - all doses
341969|NCT01587339|Drug|lacosamide|oral - all doses
341970|NCT01587339|Drug|zonisamide|oral - all doses
341971|NCT01587339|Drug|pregabalin|oral - all doses
341972|NCT01587339|Drug|eslicarbazepine|oral - all doses
341973|NCT01587326|Drug|Escitalopram|escitalopram 10 mg/d to 20 mg/d
341974|NCT01587313|Drug|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
341975|NCT01587287|Device|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
341976|NCT01587274|Drug|Naproxen|Naproxen 500mg twice/ day x 10 days
341977|NCT01587274|Drug|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
341978|NCT01587274|Drug|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
341979|NCT01587261|Drug|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
341980|NCT01587261|Drug|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
341981|NCT01587248|Device|Harmonic|Dissection with harmonic scalpel
341982|NCT01587248|Procedure|electrocautery|Dissection in modified radical mastectomy
341983|NCT01587235|Drug|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
341984|NCT01587235|Drug|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
341985|NCT01587222|Drug|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
341986|NCT01587222|Drug|Midodrine|"Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
341987|NCT01587222|Drug|Octreotide|"Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.~If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
341988|NCT01587196|Drug|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
341989|NCT01587183|Behavioral|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
341990|NCT01587183|Behavioral|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
341991|NCT01587183|Behavioral|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
341992|NCT01587157|Procedure|capnography|
341993|NCT01587144|Drug|Lucanthone|Lucanthone or Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks along with radiation and TMZ during the concomitant phase. In the maintenance phase, lucanthone/placebo will be administered along with TMZ on days 1-5 of a 28-day cycle for 6 cycles.
341994|NCT01587144|Drug|Temozolomide (TMZ)|TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment. Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the CTC nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.
341995|NCT01587144|Radiation|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
341996|NCT01587144|Drug|Placebo|Lucanthone or Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks along with radiation and TMZ during the concomitant phase. In the maintenance phase, lucanthone/placebo will be administered along with TMZ on days 1-5 of a 28-day cycle for 6 cycles.
341997|NCT01587131|Biological|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
341998|NCT01587118|Drug|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
341999|NCT01587105|Behavioral|Comprehensive Case Management Service|When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
342000|NCT01587092|Behavioral|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
342001|NCT01587092|Behavioral|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
342002|NCT01587079|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
342003|NCT01587079|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
342004|NCT01587079|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
342005|NCT01587079|Drug|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
342102|NCT01586312|Drug|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
342006|NCT01587066|Drug|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
342007|NCT01587066|Drug|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
342008|NCT01587053|Other|therapeutic education program|
342009|NCT01587040|Drug|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
342010|NCT01587040|Drug|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
342011|NCT01587027|Drug|Aminophylline|Aminophylline dosage form-tablet dosage-500mg
342012|NCT01587027|Drug|Methazolamide|Methazolamide dosage form-tablet dosage-250mg
342013|NCT01587027|Drug|Aminophylline and Methazolamide|Aminophylline 500mg orally and Methazolamide 250mg orally
342014|NCT01587001|Dietary Supplement|N-acetyl-cysteine|900mg three times daily for 8 weeks
342015|NCT01587001|Drug|Placebo|Matching placebo three times daily for 8 weeks.
342016|NCT01586988|Behavioral|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
342017|NCT01586975|Drug|Clopidogrel|Clopidogrel 75 mg QD
342018|NCT01586975|Drug|Aspirin 81 mg|Aspirin 81mg QD
342019|NCT01586975|Drug|Aspirin >300 mg|Aspirin >300 mg QD
342020|NCT01586962|Drug|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
342021|NCT01586949|Behavioral|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
342022|NCT01586936|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
342023|NCT01586923|Biological|RBC transfusion|RBC transfusion of different storage age
342024|NCT01586910|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
342025|NCT01586910|Procedure|Surgical Aortic Valve Replacement (SAVR)|
342026|NCT01586910|Device|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
342027|NCT01586897|Device|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
342028|NCT01586897|Other|Usual Care|
342029|NCT01586884|Procedure|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.~The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.~The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
342030|NCT01586858|Other|Observational|Observational study of subjects previously enrolled in the RAVE trial
342031|NCT01586845|Drug|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
342032|NCT01586845|Drug|tacrolimus|tacrolimus as per labeled dose
342033|NCT01586819|Drug|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
342034|NCT01586819|Procedure|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution [a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel [35% Trichloroacetic acid] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
342035|NCT01586806|Drug|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
342036|NCT01586806|Drug|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
342037|NCT01586806|Drug|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
342038|NCT01586793|Device|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
342039|NCT01586793|Device|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
342040|NCT01586780|Dietary Supplement|Protein drink|Test drink providing 9g protein
342041|NCT01586780|Dietary Supplement|Reference meal|Control meal
342042|NCT01586767|Radiation|Proton radiation therapy|Daily proton radiation therapy
342043|NCT01586767|Radiation|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
342044|NCT01586741|Procedure|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
342103|NCT01586299|Drug|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
342104|NCT01586299|Drug|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
344526|NCT01567670|Drug|Naloxone|2 mg x 1-2
342045|NCT01586728|Other|Air - oxygen|"his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)~nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
342046|NCT01586728|Other|Oxygen - Air|"nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.~his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
342047|NCT01586715|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
342048|NCT01586702|Behavioral|Patient centered structured support program|"Behavioural: Structured support program~Program with up to 8 outpatient appointments focusing on:~Measurement of risk factors~Assessment of medication intake~Monitoring of antithrombotic therapy~Joint agreement of an individual target plan~Target values for risk factors:~Blood pressure < 140/85 mmHg (<130/80 in diabetics), normal circadian profile~HbA1c <7.5%~Nicotine abstinence~LDL < 100mg/dl (< 70mg/dl in high risk patients)~Physical activity ≥ 30min >2 x / week~Targets for pharmaceutical treatment:~Platelet inhibitors for strokes / TIA of arterial etiology~Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis~Cumarins (INR 2-3) or new oral anticoagulants in AF patients~Statin treatment in patients with LDL >100mg/dl~Intervention strategies:~• According to Motivational Interviewing"
342049|NCT01586689|Behavioral|Oxford House|community-based recovery home for participants recovering from substance dependency
342050|NCT01586689|Behavioral|Safe Haven|professionally-staffed treatment facility
342051|NCT01586689|Behavioral|Usual aftercare|control group - participants may or may not seek treatment on their own
342052|NCT01586676|Behavioral|SAU|Supervision-as-usual
342053|NCT01586676|Behavioral|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
342054|NCT01586663|Device|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
342055|NCT01586663|Drug|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
342056|NCT01586650|Other|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
342057|NCT01586650|Other|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
342058|NCT01586637|Other|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
342059|NCT01586637|Other|Walking|The group walked twice a week during one hour.
342060|NCT01586624|Drug|Vandetanib, Selumetinib|"Dose escalation phase This phase consists of various cohorts, each investigating an increasing dose level of vandetanib and/or selumetinib. Vandetanib steady state dose levels investigated include 100, 200 or 300mg OD. Selumetinib dose levels are 25mg bd, 50mg bd and 75mg bd or 100 and 125mg OD.~All patients in this phase will take the study treatment as follows:~Cycle 1~Vandetanib higher (lead in) dose once daily (2 or 4 days) followed by vandetanib steady state dose once daily (10 or 12 days) followed by vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).~Cycle 1 is 42 days in length."
342061|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 2 onwards~Vandetanib steady state once daily in combination with selumetinib once/twice daily(28 days).~Cycle 2 and subsequent cycles are 28 days in length. From this phase, we will establish what the maximum tolerated dose (MTD) of the combination treatment is, which can safely be given to patients."
342062|NCT01586624|Drug|Vandetanib, Selumetinib|"Expansion cohort (patients with non small cell lung cancer).~All patients will receive the same dose of combination treatment (the MTD established during dose escalation phase). As follows:~All patients in the expansion cohort will take the study treatment in the same way as follows:~Cycle 1~Vandetanib higher dose (lead in) once daily (2 or 4 days) followed by vandetanib steady state dose once daily (10 or 12 days) followed by vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).~Cycle 1 is 42 days in length."
342063|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 2 onwards •o Vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).~o Cycle 2 and subsequent cycles are 28 days in length. Number of cycles: Patients will be allowed to receive 6 cycles of study treatment. If the patient is still benefiting clinically and experiencing no unacceptable toxicity, then the Investigator can make a request to the Sponsor for continuation of treatment."
342064|NCT01586611|Drug|5FU, leucovorin, oxaliplatin|Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
342065|NCT01586611|Drug|Gemcitabine|1000 mg/m2 IV weekly for 3 weeks then one week off
342066|NCT01586598|Behavioral|sensory retraining protocol|"within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day~one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day~three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
342067|NCT01586572|Drug|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
342068|NCT01586572|Drug|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
342105|NCT01586286|Drug|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
342106|NCT01586286|Drug|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
342107|NCT01586273|Device|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
344527|NCT01567670|Drug|naloxone placebo|h2o placebo spray
342069|NCT01586546|Behavioral|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
342070|NCT01586546|Other|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
342071|NCT01586546|Other|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
342072|NCT01586546|Behavioral|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
342073|NCT01586533|Drug|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine [5-ASA], 1.0g N-acetylcysteine [NAC]; 60ml)
342074|NCT01586533|Drug|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine [5-ASA], 60ml)
342075|NCT01586507|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
342076|NCT01586507|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
342077|NCT01586494|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
342078|NCT01586494|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
342079|NCT01586481|Device|SANIDIAB|off-loading shoe
342080|NCT01586481|Device|BAROUK|old shoe
342081|NCT01586468|Drug|WF10|0.5 mg/kg B.W.
342082|NCT01586468|Drug|NaCl Solution|NaCl Solution
342083|NCT01586455|Drug|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
342084|NCT01586442|Drug|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
342085|NCT01586442|Drug|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
342086|NCT01586429|Other|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
342087|NCT01586416|Behavioral|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
342088|NCT01586403|Biological|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10^6 TIL 1383I TCR transduced T cells per kg body weight.
342089|NCT01586403|Biological|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10^6 TIL 1383I TCR transduced T cells per kg body weight.
342090|NCT01586403|Biological|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10^7 TIL 1383I TCR transduced T cells per kg body weight.
342091|NCT01586403|Biological|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10^7 TIL 1383I TCR transduced T cells per kg body weight.
342092|NCT01586390|Other|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
342093|NCT01586390|Other|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
342094|NCT01586364|Drug|Ospemifene 60Mg Oral Tablet|
342095|NCT01586351|Device|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
342096|NCT01586338|Drug|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
342097|NCT01586325|Drug|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
342098|NCT01586325|Drug|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
342099|NCT01586325|Drug|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
342100|NCT01586325|Drug|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
342101|NCT01586312|Other|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
342108|NCT01586260|Drug|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
342109|NCT01586247|Dietary Supplement|Synbiotic|8g/day galacto-oligosaccharide + 10^9 CFU/day B.lactis
342110|NCT01586247|Dietary Supplement|Placebo|8g/day maltodextrin
342111|NCT01586247|Dietary Supplement|Prebiotic|8g/day galacto-oligosaccharide
342112|NCT01586247|Dietary Supplement|Probiotic|10^9 CFU/day B.lactis
342113|NCT01586234|Procedure|DSAEK with graft shaping and smoothing|"A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~The tissue on the underside of the cornea (endothelium) will be scraped away~The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea."
342114|NCT01586234|Procedure|Standard DSAEK|"A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~The tissue on the underside of the cornea (endothelium) will be scraped away~The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea."
342115|NCT01586221|Other|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
342116|NCT01586208|Drug|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
342117|NCT01586195|Drug|Vemurafenib|Vemurafenib 960 mg BID
342118|NCT01586182|Radiation|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
342119|NCT01586169|Drug|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
342120|NCT01586156|Drug|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
342121|NCT01586156|Drug|placebo|Placebo will be taken twice daily for 6 months
342122|NCT01586143|Drug|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
342123|NCT01586143|Drug|Placebo|
342124|NCT01586130|Other|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
342125|NCT01586117|Drug|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
342126|NCT01586104|Radiation|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
342127|NCT01586091|Drug|Levocetirizine Oral Tablet|
342128|NCT01586091|Drug|Fexofenadine 60 Mg Oral Tablet|
342129|NCT01586091|Drug|Placebo Oral Tablet|
342130|NCT01586065|Device|Continuous Glucose Monitor (CGM)|Use of CGM for 6 months
342131|NCT01586065|Other|Fingerstick BGs only|No CGM - fingerstick BGs only
342132|NCT01586052|Drug|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
342133|NCT01586039|Device|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
342134|NCT01586013|Drug|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
342135|NCT01586000|Drug|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
342136|NCT01586000|Drug|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
342137|NCT01586000|Drug|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
342138|NCT01585987|Biological|Ipilimumab|
342139|NCT01585987|Other|Best Supportive care (BSC)|
342140|NCT01585974|Other|No intervention|All dosage, frequency and duration for drugs will be under the decision of the treating physician
342141|NCT01585961|Device|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
342142|NCT01585935|Drug|SMOFLIPID|target dose: 3g/kg/d
342143|NCT01585935|Drug|INTRALIPID|target dose: 3g/kg/d
342144|NCT01585922|Procedure|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
342145|NCT01585922|Procedure|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
342146|NCT01585909|Procedure|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
342147|NCT01585896|Other|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, & Steketee, 2007).
342191|NCT01585610|Behavioral|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
342148|NCT01585883|Behavioral|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
342149|NCT01585870|Drug|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).~If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
342150|NCT01585870|Drug|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
342151|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.
342152|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
342153|NCT01585831|Drug|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
342154|NCT01585831|Drug|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
342155|NCT01585818|Other|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
342156|NCT01585818|Other|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
342157|NCT01585805|Drug|Cisplatin|Given IV
342158|NCT01585805|Drug|Gemcitabine|Given IV
342159|NCT01585805|Drug|Gemcitabine Hydrochloride|Given IV
342160|NCT01585805|Other|Laboratory Biomarker Analysis|Correlative studies
342161|NCT01585805|Drug|Veliparib|Given PO
342162|NCT01585792|Drug|TAK-875|
342163|NCT01585792|Drug|TAK-875|
342164|NCT01585792|Drug|Glimepiride|
342165|NCT01585792|Drug|Placebo|
342166|NCT01585779|Device|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
342167|NCT01585779|Device|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
342168|NCT01585766|Drug|MEDI-551 30 MG-IV|Participants received a fixed IV dose of 30 milligram (mg) MEDI-551 infused on Days 1 and 15.
342169|NCT01585766|Drug|MEDI-551 60 MG-SC|Participants received SC injection of 60 mg MEDI-551 on Day 1.
342170|NCT01585766|Drug|PLACEBO-IV-SC|Participants received either a fixed IV dose of placebo matching with MEDI- 551 on Days 1 and 15 or SC injection on Day 1
342171|NCT01585766|Drug|MEDI-551 100 MG-IV|Participants received a fixed IV dose of 100 mg MEDI-551 infused on Days 1 and 15.
342172|NCT01585766|Drug|MEDI-551 300 MG-SC|Participants received SC injection of 300 mg MEDI-551 on Day 1.
342173|NCT01585766|Drug|MEDI-551 600 MG-IV|Participants received a fixed IV dose of 600 mg MEDI-551 infused on Days 1 and 15.
342174|NCT01585753|Drug|NRTI + PI|tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
342175|NCT01585753|Drug|maraviroc + PI|maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
342176|NCT01585753|Drug|maraviroc + NRTI|maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
342177|NCT01585740|Drug|0.9% Normal Saline|Crystalloid fluid
342178|NCT01585740|Drug|Ringer's Lactate|Crystalloid fluid
342179|NCT01585727|Procedure|TME|Total mesorectal excision
342180|NCT01585727|Procedure|TME|Total mesorectal excision
342181|NCT01585727|Procedure|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
342182|NCT01585701|Biological|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
342183|NCT01585688|Drug|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
342184|NCT01585662|Procedure|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
342185|NCT01585649|Drug|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
342186|NCT01585636|Drug|SQ109|Single oral dose
342187|NCT01585623|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
342188|NCT01585623|Drug|omeprazol|"Pharmaceutical form:capsule~Route of administration: oral"
342189|NCT01585623|Drug|metoprolol|"Pharmaceutical form:tablet~Route of administration: oral"
342190|NCT01585623|Drug|midazolam|"Pharmaceutical form:solution~Route of administration: oral"
342225|NCT01585376|Other|laboratory biomarker analysis|
342302|NCT01584609|Device|Penumbra System with Separator 3D|The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
344912|NCT01564680|Drug|Paracetamol|IV paracetamol infusion
342192|NCT01585610|Behavioral|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
342193|NCT01585597|Device|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
342194|NCT01585584|Drug|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
342195|NCT01585558|Drug|Ospemifene (Dose 1)|
342196|NCT01585558|Drug|Ospemifene (Dose 2)|
342197|NCT01585558|Drug|Placebo|
342198|NCT01585519|Dietary Supplement|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. <1 portion per day) + 2 placebo capsules daily.~(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.~(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.~(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.~(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
342199|NCT01585506|Other|No treatment given|"Patients to complete the WHO-5 Well-being Index questionnaire"
342200|NCT01585506|Other|No treatment given|"Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
342201|NCT01585493|Other|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
342202|NCT01585493|Behavioral|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
342203|NCT01585493|Behavioral|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.~CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
342204|NCT01585480|Behavioral|Weight Gain Prevention Intervention|"Behavioral Approaches~Distribution of pedometers~Traffic light labeling in worksite cafeteria and vending machines~Informational & Persuasive Messages~Stair use prompts~Posters, pamphlets, table toppers~Website~Social Approaches~a. Identification and training of influential employees (Peer Helpers) to shape healthy norms~Environmental Changes~Traffic light labeling~1/2 portions at 1/2 price~Walking routes~Introduction of healthier foods~Rearrangement of foods in the cafeteria~Adjusting serving spoon size"
342205|NCT01585441|Drug|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
342206|NCT01585441|Drug|Placebo|Capsule with no active ingredients to mimic finasteride
342207|NCT01585428|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
342208|NCT01585428|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
342209|NCT01585428|Biological|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
342210|NCT01585428|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
342211|NCT01585415|Drug|Vemurafenib|Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
342212|NCT01585415|Biological|Young TIL|Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
342213|NCT01585415|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
342214|NCT01585415|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
342215|NCT01585415|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
342216|NCT01585402|Drug|Etidronate|Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
342217|NCT01585402|Device|MRI Scan|Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the highh degree of calcification is precluding that evaluation by CT.
342218|NCT01585389|Genetic|gene expression analysis|
342219|NCT01585389|Genetic|genetic linkage analysis|
342220|NCT01585389|Genetic|microarray analysis|
342221|NCT01585389|Other|immunohistochemistry staining method|
342222|NCT01585389|Other|laboratory biomarker analysis|
342223|NCT01585376|Genetic|mutation analysis|
342224|NCT01585376|Genetic|nucleic acid sequencing|
342226|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|"Cohort 1 will be divided into three sub-groups and will receive:~Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)~Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1~Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"
342227|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + polyICLC|"Cohort 2 will be divided into three sub-groups and will receive:~Group 2a: MELITAC 12.1 + polyICLC adjuvant~Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1~Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"
342228|NCT01585324|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
342229|NCT01585324|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
342230|NCT01585298|Drug|FTY720|
342231|NCT01585285|Procedure|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
342232|NCT01585285|Procedure|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
342233|NCT01585272|Drug|ENA713|
342234|NCT01585259|Drug|Anfibatide|Snake venom
342235|NCT01585259|Drug|Placebo|Saline
342236|NCT01585246|Drug|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
342237|NCT01585246|Drug|soybean oil soft gel|placebo (soybean oil soft gel)
342238|NCT01585233|Drug|ASKP1240|Intravenous
342239|NCT01585233|Drug|Placebo|Intravenous
342240|NCT01585220|Device|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
342241|NCT01585207|Drug|vigabatrin|3 tablets, bid for 8 weeks
342242|NCT01585194|Biological|Ipilimumab|Given IV
342243|NCT01585194|Other|Laboratory Biomarker Analysis|Correlative studies
342244|NCT01585194|Biological|Nivolumab|Given IV
342245|NCT01585181|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
342246|NCT01585181|Biological|Placebo|Approx 2 grams of lactose reconstituted in water
342247|NCT01585168|Drug|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
342248|NCT01585168|Drug|Placebo|Identically appearing sugar pill, given orally
342249|NCT01585155|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
342250|NCT01585142|Other|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
342251|NCT01585129|Drug|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
342252|NCT01585129|Drug|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
342253|NCT01585103|Device|Cytosponge - Brushing|"Patients with eosinophilic esophagitis will be enrolled. Undergoing clinically indicated endoscopy and biopsy either for initial diagnosis or for monitoring the activity of their disease.~Two hours prior to endoscopy in the patients will be asked to swallow the Cytosponge. Briefly, the capsule and bunched up string are swallowed with water.~The string is held without any tension to allow the capsule to move into the stomach. The patient holds onto the string for five minutes after ingestion to allow the capsule to dissolve in the proximal stomach, where a spherical mesh of 3 cm diameter is released.~The back of the throat is then sprayed with 1% lidocaine and the expanded mesh withdrawn by pulling on the string with the patient's head in an extended position.~Following this, the clinically indicated endoscopy will be performed. Prior to biopsies we will do a brushing of the esophagus."
342254|NCT01585090|Other|doing strengthening exercises of pelvic floor muscles|
342255|NCT01585077|Biological|P. vivax infected mosquito bites|All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
342256|NCT01585064|Other|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of < 2.4.
342257|NCT01585064|Other|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
342258|NCT01585064|Other|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
342259|NCT01585051|Drug|25(OH) vitamin D|300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
342260|NCT01585051|Drug|0.9 % NaCl|1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
342261|NCT01585038|Drug|Efavirenz|600mg orally every evening
342262|NCT01585038|Drug|Rilpivirine|25mg orally once daily
342301|NCT01584622|Device|CADence System|Non-invasive detection of > or equal to 50% stenosis in any of the major coronary arteries.
342263|NCT01585025|Drug|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
342264|NCT01585012|Device|Cervical cap (Focus Touch™ Conception System)|Cervical cap
342265|NCT01584999|Biological|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
342266|NCT01584986|Biological|ACP injections|Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
342267|NCT01584960|Behavioral|endurance training|2 years of home-based endurance training
342268|NCT01584947|Drug|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
342269|NCT01584947|Drug|Placebo|Placebo lozenge taken three times a day for two weeks
342270|NCT01584934|Drug|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
342271|NCT01584934|Drug|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
342272|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
342273|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
342274|NCT01584921|Drug|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
342275|NCT01584895|Behavioral|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
342276|NCT01584882|Behavioral|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
342277|NCT01584869|Device|capsule endoscopy|
342278|NCT01584843|Drug|GSK1358820|IM injection of Botulinum Toxin Type A
342279|NCT01584830|Drug|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
342280|NCT01584830|Drug|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
342281|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
342282|NCT01584804|Drug|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
342283|NCT01584804|Drug|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
342284|NCT01584791|Drug|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
342285|NCT01584791|Drug|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
342286|NCT01584778|Other|eosinophil cationic protein|Serum eosinophil cationic protein levels
342287|NCT01584765|Drug|Prescription drugs with known hepatotoxicity|14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
342288|NCT01584752|Procedure|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
342289|NCT01584739|Drug|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
342290|NCT01584739|Drug|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
342291|NCT01584726|Drug|Magnesium Sulfate|single dose of magnesium sulfate nebulization
342292|NCT01584713|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
342293|NCT01584700|Procedure|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
342294|NCT01584687|Biological|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
342295|NCT01584674|Device|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
342296|NCT01584661|Behavioral|Dietary recommendations|
342297|NCT01584648|Drug|dabrafenib|dabrafenib 150 mg twice daily
342298|NCT01584648|Drug|dabrafenib plus trametinib placebo|dabrafenib 150 mg twice daily and trametinib placebo
342299|NCT01584648|Drug|Trametinib|trametinib 2 mg once daily
342300|NCT01584635|Procedure|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
342303|NCT01584609|Device|Penumbra System alone|The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
342304|NCT01584596|Behavioral|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
342305|NCT01584596|Behavioral|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
342306|NCT01584570|Drug|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
342307|NCT01584557|Drug|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
342308|NCT01584557|Drug|placebo or sugar pill|sugar pill
342309|NCT01584544|Drug|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
342310|NCT01584544|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
342311|NCT01584544|Drug|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
342312|NCT01584544|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
342313|NCT01584544|Drug|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
342314|NCT01584531|Drug|rigosertib|"Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.~Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.~The patient will fill a diary indicating the day and time of drug intake."
342315|NCT01584518|Drug|Furosemide|Based on clinical standard per clinician
342316|NCT01584505|Drug|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
342317|NCT01584505|Drug|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
342318|NCT01584505|Drug|CHF1535 daily dose|CHF1535 daily dose for 14 days
342319|NCT01584492|Drug|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
342320|NCT01584492|Drug|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
342321|NCT01584492|Drug|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
342322|NCT01584492|Drug|Formoterol + Beclomethasone dipropionate|"Formoterol HFA pMDI 6 µg / actuation~Extrafine BDP HFA pMDI 50 µg/actuation"
342323|NCT01584492|Drug|Placebo (6 inhalations)|Matched placebo via pMDI
342324|NCT01584466|Drug|Paliperidone|"The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.~Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary."
342325|NCT01584453|Drug|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
342326|NCT01584453|Drug|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
342327|NCT01584440|Drug|AVP-923 (dextromethorphan/quinidine)|AVP-923 capsules administered twice a day over a 10-week period
342328|NCT01584440|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
342329|NCT01584427|Dietary Supplement|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
342330|NCT01584388|Drug|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
342331|NCT01584375|Other|Flat midline head position|"Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~--------------------------------------------------------------------------------"
342412|NCT01583686|Drug|Fludarabine|Days -5 to Day -1: Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
342332|NCT01584375|Other|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
342333|NCT01584362|Drug|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
342334|NCT01584362|Drug|placebo|single oral dose of placebo
342335|NCT01584362|Drug|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
342336|NCT01584362|Drug|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
342337|NCT01584362|Drug|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
342338|NCT01584362|Drug|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
342339|NCT01584362|Drug|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
342340|NCT01584336|Procedure|LATG|"After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy~The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).~The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.~After then, the operator performs the jejunojejunostomy."
342341|NCT01584323|Dietary Supplement|Pomgranate pills|"Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before~The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)"
342342|NCT01584323|Dietary Supplement|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
342343|NCT01584310|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
342344|NCT01584310|Other|No STAMP using|No intervention
342345|NCT01584297|Drug|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
342346|NCT01584284|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
342347|NCT01584271|Device|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil & Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
342348|NCT01584258|Procedure|Laproscopic Prostatectomy|
342349|NCT01584258|Radiation|Conventionally Fractionated Prostate Radiotherapy|Conventional fractionation delivered to a dose of 78 Gy in 2 Gy fractions.
342350|NCT01584258|Radiation|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
342351|NCT01584245|Other|Amino Acid formula|
342352|NCT01584232|Drug|LY2189265|
342353|NCT01584232|Drug|Insulin glargine|
342354|NCT01584232|Drug|Sulfonylureas (SU)|
342355|NCT01584232|Drug|Biguanide (BG)|
342356|NCT01584206|Drug|Ezetimibe|10mg ezetimibe/day, at least 4 months
342357|NCT01584193|Procedure|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
342358|NCT01584193|Procedure|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
342359|NCT01584180|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
342360|NCT01584180|Device|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
342361|NCT01584167|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
342362|NCT01584167|Device|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
342363|NCT01584154|Procedure|cryoablation|cryoablation with an 8mm-tip catheter
342364|NCT01584154|Procedure|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
342365|NCT01584115|Biological|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
342366|NCT01584115|Biological|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
342367|NCT01584102|Behavioral|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
342368|NCT01584102|Behavioral|group fitness classes only|15 weeks biweekly group fitness
342369|NCT01584076|Drug|Donepezil|"Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
342370|NCT01584076|Other|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
342411|NCT01583699|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
342981|NCT01579240|Other|Internet exercise program|12 voluntary weekly visits to website
342371|NCT01584063|Behavioral|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
342372|NCT01584050|Dietary Supplement|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
342373|NCT01584050|Dietary Supplement|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
342374|NCT01584050|Dietary Supplement|Placebo|frequency: once daily, duration: 12 weeks
342375|NCT01584024|Device|Resin infiltration|"Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062"
342376|NCT01584024|Device|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
342377|NCT01584011|Other|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
342378|NCT01584011|Other|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
342379|NCT01584011|Behavioral|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
342380|NCT01584011|Other|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
342381|NCT01583998|Behavioral|e-MBC|antidepressant treatment
342382|NCT01583985|Other|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
342383|NCT01583985|Other|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
342384|NCT01583972|Dietary Supplement|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
342385|NCT01583972|Dietary Supplement|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
342386|NCT01583959|Drug|Folic Acid|Folic acid tablets 5 mg
342387|NCT01583959|Drug|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
342388|NCT01583933|Device|Essix retainer|"The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake."
342389|NCT01583933|Device|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
342390|NCT01583920|Radiation|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
342391|NCT01583881|Procedure|renal denervation|Renal denervation
342392|NCT01583855|Procedure|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
342393|NCT01583855|Device|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
342394|NCT01583842|Radiation|124I-MIBG (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (no-carrier added) Administration & PET/CT scan 6 weeks later."
342395|NCT01583842|Radiation|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.~Optional 124I-MIBG (carrier added) Administration & PET/CT scan 6 weeks later."
342396|NCT01583829|Behavioral|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
342397|NCT01583829|Behavioral|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
342398|NCT01583829|Other|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
342399|NCT01583816|Drug|Resiquimod 0.03%|topical application
342400|NCT01583816|Drug|Resiquimod 0.01%|topical application
342401|NCT01583816|Drug|placebo|topical application
342402|NCT01583777|Drug|Belinostat|"On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.~After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days."
342403|NCT01583751|Procedure|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
342404|NCT01583738|Drug|V0251|single dose
342405|NCT01583738|Drug|placebo|single dose
342406|NCT01583725|Procedure|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
342407|NCT01583725|Behavioral|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
342408|NCT01583712|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
342409|NCT01583712|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
342410|NCT01583699|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
342413|NCT01583686|Biological|Anti-mesothelin chimeric T cell receptor (CAR) transduced peripheral blood lymphocytes (PBL)|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
342414|NCT01583686|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
342415|NCT01583686|Drug|Aldesleukin|Aldesleukin 72,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
342416|NCT01583673|Other|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
342417|NCT01583673|Other|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
342418|NCT01583660|Drug|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
342419|NCT01583660|Drug|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
342420|NCT01583647|Drug|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
342421|NCT01583647|Drug|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
342422|NCT01583634|Device|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
342423|NCT01583634|Device|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
342424|NCT01583621|Dietary Supplement|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
342425|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
342426|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
342427|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
342428|NCT01583543|Drug|Olaparib|400mg PO BID Continuous
342429|NCT01583530|Biological|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
342430|NCT01583530|Biological|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
342431|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
342432|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
342433|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
342434|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
342435|NCT01583517|Procedure|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
342436|NCT01583517|Procedure|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
342437|NCT01583517|Procedure|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
342438|NCT01583504|Procedure|Ultrasound guided injection of steroid and local anaesthetic|2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
342439|NCT01583504|Procedure|High volume saline injection|After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
342440|NCT01583504|Behavioral|exercise programme|a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
342441|NCT01583491|Procedure|autologous platlet rich fibrin|one dose immediate after surgery
342442|NCT01583491|Procedure|one side in control group|control group insert any things after surgery
342443|NCT01583478|Biological|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
342444|NCT01583465|Device|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
342445|NCT01583465|Device|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
342446|NCT01583452|Other|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
342478|NCT01583218|Drug|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.~Enoxaparin Placebo: Once daily, 6-14 days"
342479|NCT01583218|Drug|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.~Betrixaban Placebo: once daily, 35 days"
342447|NCT01583439|Drug|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
342448|NCT01583426|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
342449|NCT01583426|Drug|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
342450|NCT01583413|Procedure|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
342451|NCT01583400|Other|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
342452|NCT01583400|Other|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
342453|NCT01583387|Other|1-Increased water intake regimen|Arm 1-Intervention
342454|NCT01583387|Other|2-Non-modified water intake regimen|Arm 2-Control
342455|NCT01583374|Drug|Apremilast tablet 20 mg|Apremilast 20 mg was taken orally twice a day (BID)
342456|NCT01583374|Drug|Apremilast tablet 30 mg BID|Apremilast 30 mg was taken orally twice a day
342457|NCT01583374|Drug|Placebo|Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
342458|NCT01583361|Drug|Oxaliplatin+S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
342459|NCT01583361|Drug|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
342460|NCT01583348|Procedure|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
342461|NCT01583335|Behavioral|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
342462|NCT01583322|Drug|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
342463|NCT01583322|Drug|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).~Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.~The maximum time on monotherapy is 2 years."
342464|NCT01583309|Procedure|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
342465|NCT01583309|Procedure|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
342466|NCT01583296|Behavioral|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
342467|NCT01583296|Behavioral|CBT and HRVB|cognitive behavioral therapy and heart rate variability biofeedback
342468|NCT01583283|Drug|ACY-1215|Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
342469|NCT01583283|Drug|lenalidomide|Dosed on Days 1-21 of a 28 day cycle.
342470|NCT01583283|Drug|Dexamethasone|Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
342471|NCT01583270|Dietary Supplement|Arabinoxylan|Porridge rich in arabinoxylan
342472|NCT01583270|Dietary Supplement|Rye kernel|Porridge made of rye kernels
342473|NCT01583270|Dietary Supplement|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
342474|NCT01583270|Dietary Supplement|Semolina|Semoline porridge. control meal.
342475|NCT01583257|Behavioral|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
342476|NCT01583244|Drug|No Intervention (subjects were previously treated with Orencia®)|No Intervention
342477|NCT01583231|Other|Prewash|The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
342480|NCT01583205|Behavioral|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
342481|NCT01583192|Procedure|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
342482|NCT01583179|Drug|Buprenorphine|added to nerve block, 0.3mg one time peripheral block use
342483|NCT01583166|Drug|Bupivacaine|10ml 0.5% bupivacaine
342484|NCT01583166|Drug|Saline|10ml 0.9% sodium chloride
342485|NCT01583166|Drug|Epinephrine|1:200,000 epinephrine
342486|NCT01583153|Other|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
342487|NCT01583153|Other|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
342488|NCT01583140|Behavioral|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
342489|NCT01583140|Behavioral|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
342490|NCT01583127|Behavioral|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
342491|NCT01583114|Drug|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
342492|NCT01583114|Drug|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
342493|NCT01583101|Other|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
342494|NCT01583101|Other|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
342495|NCT01583088|Device|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
342496|NCT01583088|Device|sham phrenic nerve stimulation|sham phenic nerve stimulation
342497|NCT01583075|Procedure|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
342498|NCT01583075|Procedure|single ring pulmonary vein ablation|single ring pulmonary vein ablation
342499|NCT01583062|Drug|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
342500|NCT01583062|Drug|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
342501|NCT01583036|Drug|Digoxin Alone|Single administration of digoxin 0.25mg
342502|NCT01583036|Drug|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
342503|NCT01583023|Drug|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
342504|NCT01583023|Device|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
342505|NCT01583023|Other|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
342506|NCT01583023|Device|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
342507|NCT01583010|Device|ANV(R)|"Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group"
342508|NCT01582997|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
342509|NCT01582984|Other|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
342510|NCT01582971|Other|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
342511|NCT01582958|Procedure|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
342512|NCT01582958|Other|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
342513|NCT01582945|Drug|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
342559|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
342514|NCT01582932|Drug|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
342515|NCT01582919|Other|Neuroimaging|
342516|NCT01582893|Device|HCO1100|Dialysis
342517|NCT01582893|Device|P210H|Dialysis
342518|NCT01582880|Drug|Riboflavin|Used to treat donor cornea before implantation
342519|NCT01582867|Device|ARTIS hemodialysis system|"Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01"
342520|NCT01582854|Drug|Actovegin|Actovegin solution for infusion and Actovegin tablets
342521|NCT01582854|Drug|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
342522|NCT01582841|Procedure|MSI screening test|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
342523|NCT01582828|Procedure|Epicardial (surgical) ablation|"Pulmonary vein isolation with bipolar clamps and bipolar box lesion~Epicardial atrial appendage closure"
342524|NCT01582828|Procedure|Hybrid|"Epicardial (surgical) ablation~Pulmonary vein isolation with bipolar clamps and bipolar box lesion~Epicardial atrial appendage closure~Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
342525|NCT01582815|Drug|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
342526|NCT01582815|Drug|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
342527|NCT01582789|Device|enfilcon A|enfilcon A daily wear soft contact lens
342528|NCT01582789|Device|senofilcon A|senofilcon A daily wear soft contact lens
342529|NCT01582776|Drug|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
342530|NCT01582737|Drug|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
342531|NCT01582724|Procedure|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
342532|NCT01582711|Behavioral|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
342533|NCT01582711|Behavioral|SMS reminders|Short Message Service (SMS) text reminders
342534|NCT01582711|Drug|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
342535|NCT01582698|Biological|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
342536|NCT01582685|Behavioral|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
342537|NCT01582672|Drug|Standard Treatment|Standard treatment for Renal Cell Carcinoma
342538|NCT01582672|Biological|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
342539|NCT01582659|Other|Telephone counseling|2 planned telephone counseling sessions are conducted.
342540|NCT01582659|Other|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
342541|NCT01582646|Drug|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
342542|NCT01582633|Biological|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:~influenza A/California/7/2009 (H1N1)~influenza A/Perth/16/2009 (H3N2)~influenza B/Brisbane/60/2008 Single dose."
342543|NCT01582620|Procedure|Telestroke|remote videoconference consultations
342544|NCT01582607|Drug|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
342545|NCT01582607|Drug|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
342546|NCT01582607|Drug|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
342547|NCT01582607|Drug|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
342548|NCT01582607|Drug|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
342549|NCT01582607|Drug|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
342550|NCT01582581|Behavioral|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
342551|NCT01582581|Behavioral|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
342552|NCT01582568|Drug|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
342553|NCT01582555|Drug|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
342554|NCT01582555|Drug|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
342555|NCT01582542|Drug|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
342556|NCT01582516|Biological|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
342557|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
342558|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
342561|NCT01582490|Drug|Instillation - EXPAREL|Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
342562|NCT01582490|Drug|Infiltration - EXPAREL|IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
342563|NCT01582477|Drug|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
342564|NCT01582477|Drug|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
342565|NCT01582464|Behavioral|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.~To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), & a demographic & functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
342566|NCT01582451|Drug|LY2605541|
342567|NCT01582451|Drug|Insulin glargine|
342568|NCT01582438|Drug|Access program - sildenafil citrate, Viagra, Revatio|The recommended dose is 20 mg TID for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
342569|NCT01582425|Drug|Isavuconazole|oral
342570|NCT01582425|Drug|Methadone|oral
342571|NCT01582412|Drug|Isavuconazole|oral
342572|NCT01582412|Drug|digoxin|oral
342573|NCT01582399|Drug|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
342574|NCT01582373|Behavioral|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
342575|NCT01582347|Drug|RBP-6300|"Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).~Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate."
342576|NCT01582347|Drug|Subutex®/Suboxone®|"Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone."
342577|NCT01582347|Drug|Placebo for RBP-6300|"Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period."
342578|NCT01582347|Drug|Placebo for Subutex®/Suboxone®|Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
342579|NCT01582334|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
342580|NCT01582321|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
342581|NCT01582321|Drug|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
342582|NCT01582308|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
342583|NCT01582308|Drug|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
342584|NCT01582308|Drug|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
342585|NCT01582308|Drug|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
342586|NCT01582308|Drug|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
342587|NCT01582295|Drug|Cabozantinib|Starting dose 40 mg daily
342588|NCT01582282|Dietary Supplement|placebo|fiber-free placebo
342589|NCT01582282|Dietary Supplement|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
342590|NCT01582282|Dietary Supplement|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
342591|NCT01582269|Drug|LY2157299 monohydrate|Orally administered as tablets
342592|NCT01582269|Drug|Lomustine|Orally administered as capsules
342593|NCT01582269|Drug|Placebo|Orally administered as tablets
342594|NCT01582243|Drug|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
342595|NCT01582230|Drug|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
342848|NCT01580280|Other|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
342596|NCT01582230|Drug|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
342597|NCT01582204|Drug|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd & pelvis), 124I-cG250-PET/CT & Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan & 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, & pelvis with contrast after cycles 2, 3, 4 & 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline & week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, & serial blood sampling, following the lst inj of 124I-cG250.
342598|NCT01582191|Drug|Everolimus|Given PO
342599|NCT01582191|Other|Laboratory Biomarker Analysis|Optional correlative studies
342600|NCT01582191|Other|Pharmacological Study|Optional correlative studies
342601|NCT01582191|Drug|Vandetanib|Given PO
342602|NCT01582178|Procedure|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
342603|NCT01582178|Procedure|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
342604|NCT01582165|Drug|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
342605|NCT01582165|Drug|Placebo.|Placebo once daily vs rosuvastatin for 6 months
342606|NCT01582152|Drug|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
342607|NCT01582152|Drug|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
342608|NCT01582139|Device|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
342609|NCT01582126|Other|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
342610|NCT01582113|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
342611|NCT01582113|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
342612|NCT01582100|Device|Reletex|Neuromodulation device worn on the wrist
342613|NCT01582061|Drug|Pasireotide sub-cutaneous|Pasireotide sub-cutaneous was supplied in 1 ml ampoules containing 900 μg, 600 μg, or 300 μg pasireotide per 1 ml of solution and was administered BID. Starting dose was 900 μg and 600 μg for glucose impaired metabolism patients
342614|NCT01582048|Drug|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
342615|NCT01582035|Drug|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
342616|NCT01582035|Drug|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
342617|NCT01582035|Drug|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
342618|NCT01582035|Drug|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
342619|NCT01582035|Drug|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
342620|NCT01582035|Drug|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
342621|NCT01582035|Drug|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
342622|NCT01582022|Drug|Bupivacaine|local application for 5 minutes
342623|NCT01582022|Drug|normal saline|local application for 5 minutes
342624|NCT01582009|Drug|panobinostat|Given orally
342625|NCT01582009|Drug|everolimus|Given orally
342626|NCT01582009|Other|laboratory biomarker analysis|Correlative studies
342627|NCT01582009|Other|pharmacological study|Correlative studies
342628|NCT01582009|Other|liquid chromatography|Correlative studies
342629|NCT01582009|Other|mass spectrometry|Correlative studies
342630|NCT01582009|Other|enzyme-linked immunosorbent assay|Correlative studies
342631|NCT01582009|Other|immunohistochemistry staining method|Correlative studies
342632|NCT01581996|Drug|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
342633|NCT01581983|Behavioral|Internet Mindfulness Meditation|one hour session each week for six weeks
342634|NCT01581983|Behavioral|Individual Mindfulness Meditation|one hour session each week for six weeks
342635|NCT01581970|Drug|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
342636|NCT01581970|Drug|Cetuximab|The initial dose of cetuximab 400 mg/m^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m^2 intravenously (IV) over 60 minutes.
342637|NCT01581957|Other|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
342638|NCT01581957|Other|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
342639|NCT01581944|Drug|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
342640|NCT01581944|Drug|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
342641|NCT01581931|Drug|Linagliptin/metformin|FDC
342642|NCT01581931|Drug|Metformin|single tablet Metformin
342643|NCT01581931|Drug|Linagliptin|single tablet Linagliptin
342644|NCT01581918|Drug|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
342645|NCT01581905|Procedure|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
342646|NCT01581905|Procedure|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
342647|NCT01581892|Procedure|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
342648|NCT01581879|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
342649|NCT01581866|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
342650|NCT01581853|Drug|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
342651|NCT01581840|Drug|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
342652|NCT01581840|Drug|Panitumumab|3 or 6 mg/kg (according to dose level)
342653|NCT01581814|Drug|Metformin|500 mg of Metformin per 3/die
342654|NCT01581814|Drug|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
342655|NCT01581814|Drug|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
342656|NCT01581801|Procedure|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.~An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
342657|NCT01581801|Procedure|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
342658|NCT01581788|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
342659|NCT01581775|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
342660|NCT01581762|Procedure|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
342661|NCT01581749|Radiation|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
342662|NCT01581736|Drug|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
342663|NCT01581736|Other|Exercise|Single episode of exercise riding a stationary bike.
342664|NCT01581723|Device|Monopolar diathermy|monopolar diathermy
342665|NCT01581723|Device|Bipolar diathermy|bipolar diathermy
342666|NCT01581710|Drug|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
342667|NCT01581710|Drug|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
342668|NCT01581697|Dietary Supplement|Oat bran|
342669|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
342670|NCT01581684|Drug|Placebo|Solution for oral administration
342671|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
342672|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
342673|NCT01581684|Drug|BI 411034|High dose solution for oral administration
342674|NCT01581684|Drug|BI 411034|High dose solution for oral administration
342675|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
342676|NCT01581684|Drug|BI 411034|High dose solution for oral administration
342677|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
342678|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
342679|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
342680|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
342681|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
342682|NCT01581645|Device|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
342683|NCT01581632|Device|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
342684|NCT01581619|Radiation|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
342685|NCT01581593|Biological|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Duration - 12 months
342686|NCT01581580|Procedure|Deep Brain Stimulation|standard of care DBS surgery for patients with Parkinson's Disease, dystonia, and essential tremor
342687|NCT01581541|Drug|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
342688|NCT01581528|Genetic|gene expression analysis|
342689|NCT01581528|Other|cell culture procedure|
342690|NCT01581528|Other|flow cytometry|
342691|NCT01581528|Other|laboratory biomarker analysis|
342692|NCT01581528|Other|metabolic assessment|
342693|NCT01581515|Device|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
342694|NCT01581515|Device|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
342695|NCT01581502|Other|This is an observational study.|This is an observational, not intervention, study.
342696|NCT01581489|Procedure|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
342697|NCT01581476|Drug|Statin|10mg daily for a minimum period of 2 years
342698|NCT01581476|Drug|ACE inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
342699|NCT01581476|Drug|Placebo|Participants receive statin placebo and ACEI placebo
342700|NCT01581476|Drug|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
342701|NCT01581463|Drug|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
342702|NCT01581450|Drug|Nitrous Oxide|35%
342703|NCT01581450|Drug|Nitrous Oxide|50%
342704|NCT01581437|Procedure|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
342705|NCT01581411|Drug|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
342706|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
342707|NCT01581398|Drug|Pegasys|sc, qw, 24 weeks.
342708|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
342709|NCT01581398|Drug|Pegasys|sc, qw, 48 weeks.
342710|NCT01581372|Other|Pharmacist care|Pharmacist prescribing, education, drug management
342711|NCT01581359|Drug|Triptorelin acetate|"Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses~Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
342712|NCT01581346|Other|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
342713|NCT01581333|Drug|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
342714|NCT01581333|Drug|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:~The neutrophil count is above 500 million per mm3."
342715|NCT01581320|Drug|Test group|Once a month, administration of DP-R206 & placebo for 16 weeks
342716|NCT01581320|Drug|Reference group|Once a month, administration of Bonviva & placebo for 16 weeks
342717|NCT01581307|Drug|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
342718|NCT01581307|Device|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
342719|NCT01581281|Drug|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
342720|NCT01581281|Drug|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
342721|NCT01581281|Drug|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
342722|NCT01581242|Drug|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
342723|NCT01581242|Drug|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
342724|NCT01581242|Drug|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
342725|NCT01581229|Procedure|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
342726|NCT01581229|Procedure|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
342727|NCT01581216|Other|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
342728|NCT01581216|Other|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
342729|NCT01581216|Other|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
342730|NCT01581203|Drug|Asunaprevir (ASV)|
342731|NCT01581203|Drug|Daclatasvir (DCV)|
342732|NCT01581203|Drug|Pegylated-interferon alfa 2a (PegIFN)|
342733|NCT01581203|Drug|Ribavirin (RBV)|
342734|NCT01581190|Dietary Supplement|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
342735|NCT01581177|Drug|Albuterol DPI 25 mcg/inh|Albuterol DPI with 25 mcg Albuterol/inhalation
342736|NCT01581177|Drug|Albuterol DPI 90 mcg/inh|Albuterol DPI with 90 mcg Albuterol/inhalation
342737|NCT01581177|Drug|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
342738|NCT01581177|Drug|Albuterol MDI 90 mcg/inh|Albuterol MDI with 90 mcg Albtuerol/inhalation
342739|NCT01581164|Biological|Influenza vaccine|Influenza vaccine: Injection, post transplant
342740|NCT01581164|Biological|Varicella vaccine|Varicella vaccine: Injection, post transplant
342741|NCT01581151|Drug|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
342742|NCT01581151|Drug|Monthly Ranibizumab|30 days between treatments
342743|NCT01581138|Drug|VX-222|400 mg tablets twice daily for oral administration
342744|NCT01581138|Drug|telaprevir|1125 mg tablets twice daily for oral administration
342745|NCT01581138|Drug|ribavirin|1000 mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
342746|NCT01581125|Behavioral|Sleep:wake 1|Sleep and Wake durations for arm 1
342747|NCT01581125|Behavioral|Sleep:wake 2|Sleep and Wake durations for arm2
342748|NCT01581112|Biological|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
342749|NCT01581099|Procedure|Digestive Adaptations III surgery|
342750|NCT01581073|Drug|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
342751|NCT01581060|Drug|WX-554|Capsules of WX-554
342752|NCT01581034|Drug|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
342753|NCT01581034|Drug|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
342754|NCT01581021|Device|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
342755|NCT01581021|Device|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
342756|NCT01581008|Other|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
342757|NCT01581008|Behavioral|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
342758|NCT01580995|Drug|Valacyclovir|Valacyclovir 500 mg po bid
342759|NCT01580995|Drug|Placebo|Placebo tablet twice daily
342760|NCT01580969|Drug|Bevacizumab|Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15.
342761|NCT01580969|Drug|Minocycline|Minocycline will be given by mouth twice a day at the assigned dose level. Minocycline will be started on the day prior to radiation and continued until progression or intolerance.
342762|NCT01580969|Radiation|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
342763|NCT01580956|Other|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
342764|NCT01580956|Other|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
342765|NCT01580943|Drug|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
342766|NCT01580943|Drug|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
342767|NCT01580930|Behavioral|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
342768|NCT01580930|Behavioral|sedentary time reduction|participants provided with strategies to decrease sitting
342769|NCT01580930|Behavioral|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
342770|NCT01580904|Behavioral|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
342771|NCT01580891|Drug|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% applied topically once a day for 28 days.
342772|NCT01580891|Drug|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
342773|NCT01580891|Drug|Placebo topical cream|Placebo topical cream applied topically once a day for 28 days.
342774|NCT01580878|Drug|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
342775|NCT01580878|Drug|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
342776|NCT01580878|Drug|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
342777|NCT01580865|Drug|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|Patients were randomly assigned to receive regimen I or II: TAC plus prednisolone (TAC group) or MMF plus prednisolone (MMF group). TAC was started at a dosage of 0.1 mg/kg/day divided into 2 daily doses at 12-hour intervals, and the dosage was titrated to achieve trough blood concentrations of 6-10 ng/mL in the first and second month and then 4-8 ng/mL., thereafter. MMF was initiated at a dose of 500 mg twice daily (for patients > 50 Kg and Estimated Glomerular Filtration rate (eGFR) > 60 ml/min) for 2 weeks, and advanced to 750 mg twice daily in LN patients weighing less than 50 kg or 1,000 mg twice daily in LN patients weighing 50 kg or more. Patients received concomitant prednisone at a dose of 0.5-0.7 mg/kg/d (maximum 60 mg/day), with tapering by 5-10 mg/day every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage was maintained until the end of 24 weeks.
342778|NCT01580852|Procedure|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
342779|NCT01580852|Procedure|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
342780|NCT01580839|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
342781|NCT01580839|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
342782|NCT01580826|Other|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
342783|NCT01580813|Drug|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
342784|NCT01580813|Drug|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
342785|NCT01580787|Device|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
342786|NCT01580787|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
342787|NCT01580761|Behavioral|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
342788|NCT01580748|Drug|Roflumilast|500 microgram once daily for 16 weeks
342789|NCT01580735|Drug|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)~erlotinib: 150 mg qd"
342790|NCT01580722|Procedure|early reconstruction|patients underwent < 8 weeks reconstruction after injury
342791|NCT01580722|Procedure|delay reconstruction|patients underwent > 8 weeks reconstruction after injury
342792|NCT01580709|Procedure|Multiple brushings|Seven consecutive brush samples for cytology.
342793|NCT01580709|Procedure|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
342794|NCT01580696|Biological|E39 peptide (100mg)/GM-CSF vaccine|100mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose
342795|NCT01580696|Other|Non-vaccine clinically matched control group|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
342796|NCT01580696|Biological|E39 peptide (500mg)/GM-CSF vaccine|500mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose
342797|NCT01580696|Biological|E39 peptide (1000mg)/GM-CSF vaccine|1000mcg lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine at this dose
342798|NCT01580683|Drug|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
342799|NCT01580683|Other|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
342800|NCT01580670|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Week 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
342801|NCT01580657|Behavioral|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
342945|NCT01579500|Drug|normal saline|Subcutaneous injection of normal saline
342802|NCT01580657|Behavioral|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
342803|NCT01580657|Behavioral|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
342804|NCT01580657|Behavioral|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
342805|NCT01580657|Behavioral|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
342806|NCT01580657|Behavioral|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
342807|NCT01580644|Drug|GLPG0187 prodrug|
342808|NCT01580618|Drug|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
342809|NCT01580618|Drug|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
342810|NCT01580605|Drug|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
342811|NCT01580592|Drug|Omalizumab|150mg, s.c., every 4 weeks
342812|NCT01580592|Drug|Omalizumab|300mg, s.c., every 4 weeks
342813|NCT01580592|Drug|Placebo|Placebo, s.c., every 4 weeks
342814|NCT01580553|Drug|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
342815|NCT01580553|Drug|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
342816|NCT01580527|Procedure|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
342817|NCT01580527|Procedure|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
342818|NCT01580514|Drug|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
342819|NCT01580514|Drug|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.~Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
342820|NCT01580501|Drug|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
342821|NCT01580488|Drug|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
342822|NCT01580488|Drug|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
342823|NCT01580488|Drug|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
342824|NCT01580488|Drug|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
342825|NCT01580488|Drug|Daivonex® ointment|once daily application, 3 weeks
342826|NCT01580488|Drug|Daivonex® ointment vehicle|once daily application, 3 weeks
342827|NCT01580475|Other|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
342828|NCT01580462|Other|Observational study|"Study plan - data collecting:~Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
342829|NCT01580436|Procedure|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
342830|NCT01580423|Drug|aprepitant|125 mg capsule
342831|NCT01580423|Drug|placebo|capsule identical to aprepitant
342832|NCT01580410|Drug|mitomycin C|Given by HIPEC
342833|NCT01580410|Drug|oxaliplatin|Given by HIPEC
342834|NCT01580410|Procedure|therapeutic conventional surgery|Undergo surgery
342835|NCT01580410|Other|quality-of-life assessment|Ancillary studies
342836|NCT01580410|Drug|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
342837|NCT01580397|Drug|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
342838|NCT01580371|Drug|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
342839|NCT01580358|Drug|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
342840|NCT01580358|Drug|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
342841|NCT01580345|Dietary Supplement|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
342842|NCT01580345|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
342843|NCT01580319|Other|physical exercise|150 minutes per week
342844|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (A) for oral administration
342845|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (B) for oral administration
342846|NCT01580293|Biological|BAY94-9027|Intravenous infusion of BAY94-9027
342847|NCT01580280|Other|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
342849|NCT01580254|Drug|IOPIZE© Latanoprost eyedrops|patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
342850|NCT01580254|Drug|GALAXIA© Latanoprost eyedrops|patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
342851|NCT01580254|Drug|Latanoprost RATIOPHARM© latanoprost eyedrops|patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
342852|NCT01580228|Drug|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m^2 on Day 1, 10 mg/m^2 on Day 8, and 14 mg/m^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
342853|NCT01580228|Drug|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
342854|NCT01580215|Device|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
342855|NCT01580202|Drug|Entecavir|Entecavir 0.5mg daily per os
342856|NCT01580202|Drug|Lamivudine|lamivudine 100mg daily per os
342857|NCT01580189|Dietary Supplement|Whey protein|18g protein, immediately after training, 9 weeks
342858|NCT01580189|Dietary Supplement|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
342859|NCT01580189|Dietary Supplement|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
342860|NCT01580176|Device|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
342861|NCT01580163|Drug|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
342862|NCT01580163|Drug|Methadone|Oral Solution，1mg/ml
342863|NCT01580163|Drug|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
342864|NCT01580150|Other|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
342865|NCT01580150|Other|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
342866|NCT01580124|Procedure|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
342867|NCT01580124|Procedure|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
342868|NCT01580111|Biological|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
342869|NCT01580098|Other|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
342870|NCT01580098|Other|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
342871|NCT01580085|Other|polysomnography|full night supervised laboratory polysomnography
342872|NCT01580072|Other|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
342873|NCT01580072|Other|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
342874|NCT01580046|Drug|iodixanol|"coronary angiography, 32gI/100ml, 40～60 ml once injection~left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
342875|NCT01580046|Drug|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
342876|NCT01580033|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
342877|NCT01580033|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
342878|NCT01580033|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
342879|NCT01580033|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
342880|NCT01580020|Biological|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
342881|NCT01580020|Drug|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
342882|NCT01580007|Drug|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
342883|NCT01580007|Drug|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
342884|NCT01580007|Drug|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
342885|NCT01580007|Drug|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
342886|NCT01579994|Drug|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
342887|NCT01579981|Procedure|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
342976|NCT01579279|Drug|ABT-652 6 mg|6 mg capsules
342888|NCT01579968|Drug|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
342889|NCT01579955|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
342890|NCT01579929|Drug|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
342891|NCT01579916|Biological|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
342892|NCT01579916|Other|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
342893|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
342894|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
342895|NCT01579890|Drug|Diclofenac|diclofenac topical lotion
342896|NCT01579877|Dietary Supplement|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
342897|NCT01579877|Dietary Supplement|Placebo herbal extract granule|The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
342898|NCT01579864|Drug|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
342899|NCT01579864|Drug|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
342900|NCT01579851|Drug|Sugammadex|"sugammadex~4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~2 mg/kg : if there is at least two responses to Train of Four stimulations"
342901|NCT01579838|Drug|Eculizumab|PNH and or atypical TTP classical protocols
342902|NCT01579825|Other|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
342903|NCT01579812|Drug|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.~Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
342904|NCT01579799|Drug|L-lysine|Dose finding study for L-lysine
342905|NCT01579786|Procedure|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
342906|NCT01579760|Drug|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
342907|NCT01579760|Drug|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
342908|NCT01579747|Procedure|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
342909|NCT01579747|Procedure|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
342910|NCT01579734|Drug|Tamoxifen|1 tablet, 5 mg / day for 5 years
342911|NCT01579734|Drug|Placebo|1 tablet day for 5 years
342912|NCT01579721|Procedure|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
342913|NCT01579708|Behavioral|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
342914|NCT01579695|Drug|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
342915|NCT01579682|Behavioral|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
342916|NCT01579682|Behavioral|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
342917|NCT01579669|Behavioral|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
342918|NCT01579656|Dietary Supplement|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
342919|NCT01579656|Dietary Supplement|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
342920|NCT01579656|Dietary Supplement|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
342921|NCT01579656|Dietary Supplement|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
342922|NCT01579656|Dietary Supplement|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
342923|NCT01579643|Procedure|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|"The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.~The host cornea bed will be prepared with an excimer laser.~Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed."
342924|NCT01579643|Procedure|Penetrating Keratoplasty (KP)|"A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.~The donor cornea is then sutured where the patient's cornea was."
342925|NCT01579630|Drug|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
342926|NCT01579630|Drug|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
342927|NCT01579617|Behavioral|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
342928|NCT01579617|Behavioral|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
342929|NCT01579604|Procedure|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
342930|NCT01579591|Other|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
342931|NCT01579591|Other|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
342932|NCT01579578|Drug|AZD8931|40 mg, oral dose twice daily
342933|NCT01579578|Drug|Placebo|Placebo, oral dose twice daily
342934|NCT01579578|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
342935|NCT01579565|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
342936|NCT01579565|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
342937|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
342938|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
342939|NCT01579539|Drug|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
342940|NCT01579539|Drug|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
342941|NCT01579526|Drug|FP01|comparison of different dosages
342942|NCT01579513|Drug|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
342943|NCT01579513|Drug|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
342944|NCT01579500|Drug|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
342946|NCT01579487|Device|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
342947|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
342948|NCT01579474|Drug|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
342949|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
342950|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
342951|NCT01579461|Drug|mirabegron|oral
342952|NCT01579448|Biological|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
342953|NCT01579448|Biological|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.~Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
342954|NCT01579448|Other|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
342955|NCT01579435|Device|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
342956|NCT01579422|Behavioral|social cognitive training|social cognitive training, 8-10 sessions
342957|NCT01579409|Other|PNNS guidelines|Application of PNNS guidelines
342958|NCT01579396|Device|septeX|12 h septeX CVVH treatment after cardiac surgery
342959|NCT01579396|Other|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
342960|NCT01579383|Biological|ALD403|Single Dose IV infusion on Day 1
342961|NCT01579383|Biological|ALD403|Single Dose subcutaneous injection on Day 1
342962|NCT01579383|Biological|Sumatriptan|Single Dose subcutaneous injection on Day 1
342963|NCT01579370|Other|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
342964|NCT01579370|Other|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
342965|NCT01579370|Other|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
342966|NCT01579370|Other|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
342967|NCT01579357|Other|blood samples|"Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).~day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min"
342968|NCT01579344|Drug|Radioiodine therapy|Radioiodine therapy with NaI131
342969|NCT01579331|Device|DCT (PASCAL© Tonometer) IOP and OPA measurement|"Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.~Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve."
342970|NCT01579318|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
342971|NCT01579318|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulseswere administered to each tumor lesion at the approximate point of tavo injection.
342972|NCT01579305|Device|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
342973|NCT01579305|Device|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
342974|NCT01579292|Behavioral|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
342975|NCT01579292|Behavioral|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
342982|NCT01579227|Device|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
342983|NCT01579227|Dietary Supplement|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
342984|NCT01579227|Device|Tamoxifen Cream|Tamoxifen cream
342985|NCT01579227|Device|Placebo cream|Placebo cream
342986|NCT01579227|Dietary Supplement|placebo capsule|placebo capsule
342987|NCT01579214|Other|Cellular Phone Text Messages|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
342988|NCT01579201|Drug|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
342989|NCT01579188|Drug|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
342990|NCT01579188|Drug|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
342991|NCT01579175|Other|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
342992|NCT01579162|Device|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"
342993|NCT01579149|Drug|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
342994|NCT01579149|Drug|Placebo|Single subcutaneous (SC) dose of placebo
342995|NCT01579136|Behavioral|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
342996|NCT01579123|Procedure|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
342997|NCT01579123|Procedure|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
342998|NCT01579110|Drug|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
342999|NCT01579110|Drug|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
343000|NCT01579097|Other|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
343001|NCT01579097|Other|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
343002|NCT01579084|Drug|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
343003|NCT01579084|Drug|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
343004|NCT01579084|Drug|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
343005|NCT01579084|Drug|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
343006|NCT01579071|Procedure|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
343007|NCT01579058|Drug|bisoprolol|bisoprolol 5mg qd for 4 years
343008|NCT01579058|Drug|placebo|placebo for 4 years
343009|NCT01579045|Device|senofilcon A|bilateral daily use soft contact lens
343010|NCT01579045|Device|etafilcon A|bilateral daily use soft contact lens
343011|NCT01579045|Device|nelfilcon A|bilateral daily use soft contact lens
343012|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lens
343013|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lenses
343014|NCT01579019|Drug|RO5024048|1500 mg po bid, 24 or 26 weeks
343015|NCT01579019|Drug|RO5024048|1000 mg po bid, 24 or 26 weeks
343016|NCT01579019|Drug|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
343017|NCT01579019|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
343018|NCT01579019|Drug|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
343019|NCT01579019|Drug|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
343020|NCT01579006|Drug|Tocilizumab|
343021|NCT01578980|Device|Outpatient Control-to-Range|Subjects will spend two nights (~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
343022|NCT01578967|Drug|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
343023|NCT01578967|Drug|ABVD|"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."
343024|NCT01578954|Drug|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.~Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
343062|NCT01578655|Drug|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
343025|NCT01578941|Other|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
343026|NCT01578928|Drug|SOM230|
343027|NCT01578902|Radiation|Hypofractionated radiotherapy|35Gy/5 fractions/29 days
343028|NCT01578889|Biological|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
343029|NCT01578889|Biological|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
343030|NCT01578889|Biological|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10^8 plaque-forming units (PFUs) administered as 5x10^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
343031|NCT01578889|Biological|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
343032|NCT01578889|Device|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
343033|NCT01578876|Device|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
343034|NCT01578863|Other|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
343035|NCT01578850|Drug|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
343036|NCT01578850|Drug|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
343037|NCT01578837|Dietary Supplement|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
343038|NCT01578837|Dietary Supplement|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
343039|NCT01578824|Other|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
343040|NCT01578811|Drug|Placebo|Dosage
343041|NCT01578811|Drug|SK-MS10|Dosage
343042|NCT01578811|Drug|SK-MS10|Dosage
343043|NCT01578785|Drug|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
343044|NCT01578785|Drug|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
343045|NCT01578772|Drug|Telmisartan|80mg tablets po daily for 6 weeks
343046|NCT01578759|Procedure|Salpingectomy|Removal of the fallopian tubes
343047|NCT01578746|Procedure|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
343048|NCT01578746|Procedure|Anterior approach|The use of anterior approach in total hip arthroplasty
343049|NCT01578733|Dietary Supplement|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
343050|NCT01578720|Drug|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
343051|NCT01578707|Drug|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.~Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
343052|NCT01578707|Drug|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
343053|NCT01578694|Diagnostic Test|Magnetic Resonance Imaging (MRI)|T1 rho MRI is a modified pulse sequence from the standard T1 sequence used in the clinical MRI.
343054|NCT01578681|Procedure|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
343055|NCT01578681|Procedure|Stretching|Patient will be instructed to do muscle stretching of the thorax
343056|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
343057|NCT01578668|Drug|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
343058|NCT01578668|Drug|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
343059|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
343060|NCT01578655|Drug|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
343061|NCT01578655|Drug|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
343137|NCT01578109|Drug|Sorafenib Tosylate|Given PO
343063|NCT01578642|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:~an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
343064|NCT01578629|Other|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
343065|NCT01578629|Other|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
343066|NCT01578603|Dietary Supplement|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
343067|NCT01578603|Dietary Supplement|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
343068|NCT01578590|Dietary Supplement|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
343069|NCT01578577|Behavioral|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
343070|NCT01578577|Behavioral|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
343071|NCT01578564|Drug|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
343072|NCT01578551|Drug|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
343073|NCT01578551|Drug|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days~Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
343074|NCT01578551|Drug|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
343075|NCT01578551|Drug|Metformin|1000 mg twice daily with food.
343076|NCT01578538|Procedure|inguinal hernia repair|strangulated hernias will be repaired surgically
343077|NCT01578525|Other|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
343078|NCT01578512|Behavioral|Face-to-Face|Face-to-Face behavioral weight loss
343079|NCT01578512|Behavioral|Web-based|Web-based behavioral weight loss
343080|NCT01578512|Behavioral|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
343081|NCT01578499|Drug|Brentuximab Vedotin|Brentuximab vedotin intravenous injection.
343082|NCT01578499|Drug|Methotrexate|Methotrexate tablets.
343083|NCT01578499|Drug|Bexarotene|Bexarotene tablets.
343084|NCT01578486|Drug|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
343085|NCT01578473|Drug|Vitamin D2|oral softgel 2000 IU once daily 9 months
343086|NCT01578473|Drug|Vitamin E|"oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily~1 softgel of 200 IU daily 9 months"
343087|NCT01578473|Drug|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
343088|NCT01578460|Device|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
343089|NCT01578460|Device|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
343090|NCT01578447|Drug|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
343091|NCT01578447|Drug|Intramuscular DMPA|Intramuscular DMPA
343092|NCT01578434|Drug|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
343093|NCT01578434|Drug|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
343094|NCT01578434|Drug|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
343095|NCT01578421|Device|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
343096|NCT01578408|Procedure|Total Hip Arthroplasty|
343097|NCT01578408|Device|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
343098|NCT01578408|Device|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
343099|NCT01578395|Radiation|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
343100|NCT01578395|Radiation|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
343101|NCT01578395|Other|No radiation exposure|Subjects not undergoing any radiation exposure
343166|NCT01577914|Drug|Carvedilol|12.5mg tablet once a day
343167|NCT01577901|Other|Clearblue Advanced|Pregnancy test
343102|NCT01578369|Other|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
343103|NCT01578343|Drug|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)~Consolidation treatment for responders Patients not eligible for transplantation~Vorinostat maintenance up to 6 cycles~200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle~Delay of the start of the next cycle by up to 7 days will be acceptable.~If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation~High-dose chemotherapy followed by autologous stem cell transplantation"
343104|NCT01578330|Drug|Fingolimod|Fingolimod 0.5mg orally once a day without food.
343105|NCT01578317|Biological|H5N1 vaccine plus AS03 adjuvant|H5N1 influenza vaccine with AS03 at the 3.75 mcg dose level given 21 days apart.
343106|NCT01578317|Biological|H5N1 vaccine without adjuvant|H5N1 influenza vaccine non- adjuvanted form at the 3.75 mcg dose level given 21 days apart.
343107|NCT01578304|Drug|Imidafenacin|Tablet, 12 weeks twice daily
343108|NCT01578304|Drug|Fesoterodine|Tablet, 12 weeks once daily
343109|NCT01578291|Behavioral|Parental information|An informational brochure indicating the study details
343110|NCT01578291|Behavioral|Play therapy|Play therapy with a child life specialist
343111|NCT01578278|Drug|Bepotastine besilate formulation|Nasal Spray
343112|NCT01578278|Drug|Fluticasone propionate|Nasal Spray
343113|NCT01578278|Drug|Bepotastine besilate-fluticasone propionate|Nasal Spray
343114|NCT01578278|Drug|Placebo Comparator|Nasal Spray
343115|NCT01578265|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
343116|NCT01578265|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
343117|NCT01578252|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
343118|NCT01578252|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
343119|NCT01578239|Drug|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment will be given to the patients until the end of study for symptom control purpose, unless the patient progresses or dies.~In the active comparator arm, 60 mg Octreotide LAR treatment will be given to the patients every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies."
343120|NCT01578239|Drug|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity;
343121|NCT01578213|Drug|Imatinib mesylate|"Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg~Total dosage per day: 800 mg~Oral use"
343122|NCT01578200|Drug|Lanthanum Carbonate|
343123|NCT01578200|Drug|Calcium Carbonate|
343124|NCT01578187|Device|Hair2Go|Treatment with the device once under observation
343125|NCT01578174|Drug|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
343126|NCT01578174|Drug|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
343127|NCT01578161|Drug|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
343128|NCT01578161|Drug|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
343129|NCT01578148|Procedure|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
343130|NCT01578148|Procedure|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~TENS stimulation (45 minutes):~• Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~Other modalities of PT per the therapist's choice:~Infrared treatment on the pain areas (about 15 minutes)~Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~Exercise and training:~Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~Hot/cold pack to the pain area for about 15 minutes"
343131|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire at inclusion in registry
343132|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
343133|NCT01578122|Device|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.~Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
343134|NCT01578122|Device|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
343135|NCT01578109|Procedure|Bone Marrow Transplantation|Undergo BMT
343136|NCT01578109|Drug|Sorafenib|Given PO
343138|NCT01578096|Behavioral|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
343139|NCT01578070|Biological|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
343140|NCT01578070|Biological|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
343141|NCT01578070|Biological|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
343142|NCT01578070|Biological|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
343143|NCT01578070|Biological|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
343144|NCT01578057|Drug|tasimelteon|20mg, once
343145|NCT01578057|Drug|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
343146|NCT01578057|Other|Placebo tasimelteon|once
343147|NCT01578057|Drug|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
343148|NCT01578044|Behavioral|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.~Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.~Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
343149|NCT01578044|Other|Control|Usual care
343150|NCT01578031|Device|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
343151|NCT01578031|Other|Usual Care|Usual care.
343152|NCT01578018|Other|Measure DCAM levels in blood|Measure DCAM levels in blood
343153|NCT01578018|Other|DCAM levels in blood|DCAM levels in blood
343154|NCT01577992|Drug|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
343155|NCT01577992|Procedure|determination of objective and subjective pain threshold|Test without levodopa intake
343156|NCT01577979|Behavioral|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
343157|NCT01577979|Behavioral|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
343158|NCT01577966|Drug|Sulfasalazine|"Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety~Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA."
343159|NCT01577953|Drug|SB010|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.~Dose levels:~Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL)."
343160|NCT01577953|Drug|Placebo|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board."
343161|NCT01577940|Procedure|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
343162|NCT01577940|Procedure|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
343163|NCT01577927|Other|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
343164|NCT01577927|Behavioral|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.~Every two weeks, PT phones the patient for an educational reinforcement."
343165|NCT01577914|Drug|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
343168|NCT01577888|Device|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
343169|NCT01577875|Device|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
343170|NCT01577862|Drug|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
343171|NCT01577862|Drug|Rifampicin|600 mg every 12 hours intravenously
343172|NCT01577849|Drug|Vitamin D3|administration of Vitamin D3 24,000 IU
343173|NCT01577849|Drug|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
343174|NCT01577823|Device|Foley Catheter|
343175|NCT01577810|Device|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
343176|NCT01577797|Behavioral|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
343177|NCT01577784|Drug|Pazopanib|800 mg / day of pazopanib in monotherapy.
343178|NCT01577771|Biological|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
343179|NCT01577758|Drug|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
343180|NCT01577745|Biological|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
343181|NCT01577732|Biological|Infanrix-IPV+Hib™|Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
343182|NCT01577719|Behavioral|Multimedia Lifestyle Improvement|"Online Goal setting to improve diet, physical activity or smoking behaviours~regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.~Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
343183|NCT01577719|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
343184|NCT01577706|Drug|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
343185|NCT01577706|Drug|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
343186|NCT01577706|Other|Placebo|Placebo, gel-capsule, single-dose, 1-day
343187|NCT01577693|Drug|dutasteride|novel dutasteride
343188|NCT01577693|Drug|dutasteride|dutasteride soft gel capsule
343189|NCT01577680|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
343190|NCT01577680|Drug|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
343191|NCT01577667|Device|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
343192|NCT01577654|Drug|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
343193|NCT01577654|Drug|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +~Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
343194|NCT01577654|Drug|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
343195|NCT01577654|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
343196|NCT01577628|Drug|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
343197|NCT01577615|Behavioral|Patterned Experience|"The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.~Nonnutritive sucking will be offered to infants.~Blood work will be collected for inflammatory cytokines.~Saliva will be collected for genetic analysis~Saliva will be collected in 10 infant sub study for cortisol pre and post feedings~All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.~Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.~Follow up visits will occur at 2,6and 24 months corrected age."
343198|NCT01577602|Other|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
343199|NCT01577602|Other|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
343200|NCT01577602|Other|Combined intervention|Combines the printed medication list with the open ended question
343201|NCT01577589|Drug|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
343202|NCT01577589|Drug|Placebo in 50 ml infusion volume|IV infusion
343203|NCT01577589|Drug|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
343204|NCT01577589|Drug|Placebo in 250 ml infusion volume|IV infusion
343205|NCT01577589|Drug|600 mg ceftaroline in 100 ml infusion volume|IV infusion
343206|NCT01577589|Drug|Placebo in 100 ml infusion volume|IV infusion
343207|NCT01577550|Drug|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
343208|NCT01577550|Drug|Placebo, i.v.|Single i.v. administration of placebo
343209|NCT01577550|Drug|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
343210|NCT01577550|Drug|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
343211|NCT01577550|Drug|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
343212|NCT01577550|Drug|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
343213|NCT01577550|Drug|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
343214|NCT01577550|Drug|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
343215|NCT01577550|Drug|Placebo, s.c.|Single s.c. administration of placebo
343216|NCT01577550|Drug|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
343217|NCT01577537|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
343218|NCT01577537|Drug|Placebo|Vaginal gel, daily for 7 days
343348|NCT01576445|Procedure|medial parapatellar approach|medial parapatellar approach
343219|NCT01577524|Drug|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
343220|NCT01577524|Drug|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
343221|NCT01577511|Biological|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.~Follow-up: disease outcomes assessed at 24 months"
343222|NCT01577485|Dietary Supplement|Probiotics in an pastille|Test group
343223|NCT01577485|Dietary Supplement|Control pastille|Control group
343224|NCT01577472|Drug|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
343225|NCT01577472|Drug|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
343226|NCT01577472|Drug|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
343227|NCT01577472|Drug|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
343228|NCT01577459|Drug|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
343229|NCT01577459|Other|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
343230|NCT01577446|Procedure|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
343231|NCT01577420|Other|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
343232|NCT01577420|Other|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
343233|NCT01577407|Drug|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
343234|NCT01577394|Other|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades"
343235|NCT01577381|Biological|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
343236|NCT01577381|Biological|Placebo|Intravenous, 11 doses, 30 minute infusion
343237|NCT01577368|Drug|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
343238|NCT01577368|Drug|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
343239|NCT01577355|Radiation|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
343240|NCT01577342|Drug|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
343241|NCT01577329|Behavioral|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
343242|NCT01577316|Biological|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.~It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:~an A/California/7/2009 (H1N1)pdm09-like virus;~an A/Victoria/361/2011 (H3N2)-like virus;~a B/Wisconsin/1/2010-like virus."
343243|NCT01577303|Behavioral|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
343244|NCT01577303|Behavioral|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
343245|NCT01577303|Behavioral|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
343308|NCT01576718|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
343309|NCT01576705|Drug|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
343566|NCT01574859|Other|levothyroxine|titration of T4 according to biochemical values
343246|NCT01577303|Behavioral|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
343247|NCT01577303|Behavioral|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
343248|NCT01577303|Behavioral|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
343249|NCT01577290|Behavioral|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
343250|NCT01577290|Behavioral|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
343251|NCT01577238|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
343252|NCT01577238|Drug|Placebo|Vaginal gel, daily for 7 days
343253|NCT01577225|Device|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
343254|NCT01577225|Device|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
343255|NCT01577212|Radiation|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
343256|NCT01577199|Drug|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
343257|NCT01577199|Drug|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
343258|NCT01577186|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
343259|NCT01577173|Drug|MEHD7945A|1100 mg iv every 2 weeks
343260|NCT01577173|Drug|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
343261|NCT01577160|Drug|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
343262|NCT01577147|Other|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
343263|NCT01577134|Behavioral|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
343264|NCT01577134|Behavioral|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
343265|NCT01577134|Behavioral|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
343266|NCT01577121|Drug|indomethacin|50 mg / 6 hours during 5 days
343267|NCT01577121|Drug|placebo|50 mg / 6 hours during 5 days
343268|NCT01577108|Dietary Supplement|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
343269|NCT01577108|Dietary Supplement|Placebo|oral taking 2 capsules before sleeping per day for 14 days
343270|NCT01577095|Other|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
343271|NCT01577095|Drug|TZD|Rosiglitazone 8 mg single dose
343272|NCT01577082|Drug|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
343273|NCT01577082|Drug|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
343274|NCT01577056|Dietary Supplement|Fish oil capsule|4g Omega capsule for 12 weeks
343275|NCT01577056|Drug|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
343276|NCT01577043|Drug|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
343277|NCT01577043|Other|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
343278|NCT01577030|Dietary Supplement|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
343279|NCT01577030|Dietary Supplement|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
343280|NCT01577017|Drug|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
343281|NCT01577004|Dietary Supplement|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
343347|NCT01576445|Procedure|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
343567|NCT01574833|Device|pulsed electromagnetic field|PEMF treatment
343282|NCT01576978|Behavioral|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
343283|NCT01576965|Drug|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
343284|NCT01576952|Drug|ISV-303|Bromfenac in DuraSite
343285|NCT01576952|Other|DuraSite Vehicle|DuraSite Vehicle
343286|NCT01576939|Radiation|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to < 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
343287|NCT01576913|Other|Music listening|Listening to tempo music while cycling in an exercise test
343288|NCT01576900|Behavioral|SyBeMeP (Systemized Behavioural Modification education Program)|"Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
343289|NCT01576887|Drug|Bardoxolone Methyl 20 mg|Oral, once daily
343290|NCT01576887|Drug|Placebo|Oral, once daily
343291|NCT01576874|Drug|Oxytocin|40 IUs of oxytocin administered intranasally one time
343292|NCT01576874|Drug|placebo|placebo administered intranasally one time
343293|NCT01576861|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
343294|NCT01576848|Dietary Supplement|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
343295|NCT01576848|Dietary Supplement|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.~Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
343296|NCT01576822|Other|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.~High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).~Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
343297|NCT01576809|Drug|IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin|Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
343298|NCT01576796|Radiation|Radiotherapy|"No additional dose (patients negative F-miso)~Radiation therapy is conducted under standard conditions of conformal radiotherapy:~The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week~With additional dose (patients positive for F-miso)~The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
343299|NCT01576783|Drug|Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)|200 mg DHA+ 200 mg AA per day for 6 months
343300|NCT01576783|Dietary Supplement|Placebo|400 mg corn oil per day for 6 months
343301|NCT01576770|Device|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
343302|NCT01576770|Drug|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
343303|NCT01576731|Drug|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
343304|NCT01576731|Drug|Tenofovir, Emtricitabine, Raltegravir|Combination drug
343305|NCT01576718|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening."
343306|NCT01576718|Other|Placebo MDPI|Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
343307|NCT01576718|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
343568|NCT01574833|Device|sham|sham treatment
343310|NCT01576692|Biological|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:~Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy~Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)~Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m^2)/dose, over 4 hours daily~NK Cell dosage: minimum of 0.1 * 10^6 cells/kg; maximum of 400 * 10^6 CD45+ cells/kg, given once"
343311|NCT01576692|Drug|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:~cyclophosphamide: 400 mg/m^2 IV days 1-5~topotecan: 1.2 mg/m^2 IV days 1-5~temozolomide: 150 mg/m^2 PO at least 1 hour before irinotecan~irinotecan: 50 mg/m^2 IV over 1 hour daily for 5 days~carboplatin (AUC 8-dosing based on GFR), IV day 1 only~ifosfamide: 2 g/m2 IV days 1-3~etoposide: 100 mg/m2 days 1-3"
343312|NCT01576692|Other|Cytokines|"Cytokines may be given at the following dosages:~interleukin-2: 1 million units/m^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses~GM-CSF: 250 mcg/m^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC >2,000/mm^3"
343313|NCT01576692|Biological|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy & Procedure Manual.
343314|NCT01576692|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
343315|NCT01576679|Drug|Cathflo (Alteplase)|
343316|NCT01576679|Drug|Saline|
343317|NCT01576666|Drug|LDE225|
343318|NCT01576666|Drug|BKM120|
343319|NCT01576653|Other|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
343320|NCT01576640|Drug|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
343321|NCT01576640|Drug|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
343322|NCT01576640|Other|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
343323|NCT01576627|Dietary Supplement|zinc citrate|10 mg of zinc as either zinc citrate
343324|NCT01576627|Dietary Supplement|Zinc Gluconate|10 mg of zinc as either zinc gluconate
343325|NCT01576627|Dietary Supplement|Zinc oxide|10 mg of zinc as either zinc oxide
343326|NCT01576614|Behavioral|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
343327|NCT01576588|Drug|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
343328|NCT01576588|Drug|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
343329|NCT01576575|Drug|Buprenorphine|.2 mg IV or 2-4 mg sublingual
343330|NCT01576575|Drug|Rifampin|600 mg orally for 7 days
343331|NCT01576575|Other|grapefruit juice|8 oz at bedtime and 3oz in the morning.
343332|NCT01576575|Drug|Ketoconazole|400 mg orally for 3-4 days
343333|NCT01576549|Drug|LY2127399|Administered subcutaneously
343334|NCT01576523|Biological|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
343335|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
343336|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
343337|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
343338|NCT01576510|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
343339|NCT01576497|Procedure|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
343340|NCT01576497|Device|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
343341|NCT01576497|Device|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
343342|NCT01576484|Drug|REGN727 (SAR236553)|REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
343343|NCT01576471|Biological|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
343344|NCT01576471|Biological|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
343345|NCT01576458|Drug|ursodeoxycholic acid|450 mg/day for 14 days
343346|NCT01576458|Drug|Placebo|placebo
343349|NCT01576432|Behavioral|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
343350|NCT01576419|Drug|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
343351|NCT01576419|Drug|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
343352|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
343353|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
343354|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
343355|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
343356|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
343357|NCT01576393|Behavioral|Home-based Family Therapy|12 home-based family therapy sessions
343358|NCT01576393|Behavioral|office-based family therapy|12 office-based family therapy sessions
343359|NCT01576393|Behavioral|WHE|12 Women's Health Education Sessions
343360|NCT01576380|Drug|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
343361|NCT01576367|Biological|ACZ885|
343362|NCT01576354|Drug|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
343363|NCT01576354|Drug|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
343364|NCT01576341|Drug|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
343365|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
343366|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
343367|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
343368|NCT01576315|Drug|Itraconazole/voriconazole|The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
343369|NCT01576302|Behavioral|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
343370|NCT01576302|Behavioral|Muscle relaxation|Progressive passive muscle relaxation
343371|NCT01576289|Other|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
343372|NCT01576276|Radiation|Integrated MR-PET scan|Integrated MR-PET scan using [11C]diprenorphine
343373|NCT01576276|Drug|Ketorolac|3 administrations of ketorolac over course of study
343374|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
343375|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
343376|NCT01576250|Other|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
343377|NCT01576237|Other|blood donation|blood donation with preparative hemapheresis
343378|NCT01576224|Device|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
343379|NCT01576211|Genetic|DNA methylation analysis|
343380|NCT01576211|Genetic|RNA analysis|
343381|NCT01576211|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
343382|NCT01576211|Genetic|gene expression analysis|
343383|NCT01576211|Genetic|nucleic acid sequencing|
343384|NCT01576211|Genetic|polymorphism analysis|
343385|NCT01576211|Other|laboratory biomarker analysis|
343386|NCT01576198|Genetic|DNA analysis|
343387|NCT01576198|Genetic|nucleic acid amplification|
343388|NCT01576198|Other|diagnostic laboratory biomarker analysis|
343389|NCT01576198|Other|medical chart review|
343390|NCT01576185|Other|laboratory biomarker analysis|Correlative studies
343391|NCT01576185|Drug|quizartinib|Via gavage
343392|NCT01576185|Drug|sorafenib tosylate|Via gavage
343393|NCT01576172|Drug|Abiraterone Acetate|Given PO
343394|NCT01576172|Other|Laboratory Biomarker Analysis|Correlative studies
343395|NCT01576172|Drug|Prednisone|Given PO
343396|NCT01576172|Drug|Veliparib|Given PO
343397|NCT01576159|Other|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
343398|NCT01576159|Other|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
343569|NCT01574820|Drug|placebo tablet|placebo tablet for 6 months
343570|NCT01574820|Drug|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
343399|NCT01576159|Other|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
343400|NCT01576146|Drug|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
343401|NCT01576133|Behavioral|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
343402|NCT01576133|Behavioral|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
343403|NCT01576120|Other|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
343404|NCT01576120|Other|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.~In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
343405|NCT01576107|Other|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
343406|NCT01576107|Other|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
343407|NCT01576094|Drug|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
343408|NCT01576094|Drug|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
343409|NCT01576081|Device|HEPHAISTOS|HEPHAISTOS unloading orthotic
343410|NCT01576068|Other|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
343411|NCT01576055|Device|TIGRIS Vascular Stent|Implant
343412|NCT01576055|Device|BARD LifeStent|Implant
343413|NCT01576042|Drug|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
343414|NCT01576042|Drug|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
343415|NCT01576042|Device|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
343416|NCT01576029|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
343417|NCT01576029|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
343418|NCT01576016|Device|Accent MRI system|Patients implanted with an Accent MRI system will receive 30 minutes of magnetic scan imaging
343419|NCT01576016|Device|Accent MRI system|Patients implanted with an Accent MRI system will wait for one hour without receiving an MRI scan
343420|NCT01576003|Drug|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
343421|NCT01576003|Dietary Supplement|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
343422|NCT01575990|Behavioral|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.~Educational component~Values clarification exercise~Individualized decision making worksheet~The intervention or control condition is administered before the index visit with the patient's provider."
343423|NCT01575990|Behavioral|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
343424|NCT01575951|Radiation|MRI-DCE|"The treatment follows the standard practice including radiation dose and treatment volumes.~DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.~Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.~MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.~Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week."
343425|NCT01575938|Behavioral|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
343613|NCT01574482|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
343426|NCT01575938|Behavioral|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
343427|NCT01575925|Drug|4 mg Oral POM + 40 mg Oral DEX|
343428|NCT01575925|Drug|2 mg Oral POM + 40 mg Oral DEX|
343429|NCT01575912|Other|experimental pain tests|
343430|NCT01575899|Drug|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
343431|NCT01575899|Drug|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
343432|NCT01575886|Other|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
343433|NCT01575873|Drug|Denosumab|Administered by subcutaneous injection once every 6 months
343434|NCT01575873|Drug|Placebo for risendronate|Administered orally once a day
343435|NCT01575873|Drug|Risendronate|Administered orally once a day
343436|NCT01575873|Drug|Placebo for denosumab|Administered by subcutaneous injection once every 6 months
343437|NCT01575860|Drug|Lenalidomide|
343438|NCT01575834|Drug|Romosozumab|Administered by subcutaneous injection once a month (QM)
343439|NCT01575834|Drug|Placebo|Administered by subcutaneous injection once a month (QM)
343440|NCT01575834|Drug|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
343441|NCT01575821|Dietary Supplement|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
343442|NCT01575821|Dietary Supplement|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
343443|NCT01575821|Dietary Supplement|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
343444|NCT01575821|Dietary Supplement|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
343445|NCT01575808|Device|GP1101|Endovascular stent graft implantation
343446|NCT01575795|Drug|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
343447|NCT01575795|Drug|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
343448|NCT01575782|Drug|Chloroquine|Daily intake of Chloroquine during radiotherapy
343449|NCT01575769|Drug|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
343450|NCT01575756|Biological|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
343451|NCT01575756|Biological|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
343452|NCT01575743|Behavioral|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
343453|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
343454|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
343455|NCT01575730|Drug|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
343456|NCT01575717|Drug|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
343457|NCT01575717|Drug|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
343458|NCT01575704|Other|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
343459|NCT01575704|Other|Mental Training|Memorial/ mental training and relaxation, 5 times per week
343460|NCT01575678|Drug|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
343461|NCT01575678|Drug|Lactose|blinded capsule 1/day, oral use, for 4 weeks
343462|NCT01575665|Device|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
343463|NCT01575652|Other|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
343464|NCT01575652|Other|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
343465|NCT01575639|Drug|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
343563|NCT01574885|Device|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
343466|NCT01575626|Drug|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:~First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.~Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).~Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
343467|NCT01575613|Drug|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
343468|NCT01575613|Biological|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
343469|NCT01575613|Biological|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
343470|NCT01575613|Biological|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
343471|NCT01575600|Other|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
343472|NCT01575587|Drug|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
343473|NCT01575587|Drug|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
343474|NCT01575587|Drug|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
343475|NCT01575587|Drug|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
343476|NCT01575574|Drug|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
343477|NCT01575561|Drug|Lurasidone|Lurasidone 20-80 mg taken orally once daily
343478|NCT01575548|Drug|Pazopanib Hydrochloride|Given PO
343479|NCT01575548|Other|Pharmacological Study|Correlative studies
343480|NCT01575548|Other|Placebo|Given PO
343481|NCT01575548|Other|Quality-of-Life Assessment|Ancillary studies
343482|NCT01575548|Other|Questionnaire Administration|Ancillary studies
343483|NCT01575535|Genetic|gene expression analysis|
343484|NCT01575535|Other|flow cytometry|
343485|NCT01575535|Other|fluorescence activated cell sorting|
343486|NCT01575535|Other|laboratory biomarker analysis|
343487|NCT01575535|Other|medical chart review|
343488|NCT01575522|Other|Laboratory Biomarker Analysis|Correlative studies
343489|NCT01575522|Drug|Tivantinib|Given PO
343490|NCT01575509|Other|Berry product|Sugar infused dried lingonberry
343491|NCT01575509|Other|Bread product|Brown bread
343492|NCT01575509|Other|Bread product|Whole grain bread
343493|NCT01575509|Other|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
343494|NCT01575509|Other|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
343495|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
343496|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
343497|NCT01575483|Drug|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
343498|NCT01575470|Biological|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
343499|NCT01575457|Behavioral|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
343500|NCT01575418|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
343501|NCT01575418|Drug|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy)propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
343502|NCT01575418|Drug|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
343565|NCT01574872|Device|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
343503|NCT01575418|Radiation|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.~Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.~The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
343504|NCT01575405|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
343505|NCT01575405|Drug|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy) propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
343506|NCT01575405|Drug|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
343507|NCT01575366|Behavioral|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
343508|NCT01575353|Device|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
343509|NCT01575353|Device|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
343510|NCT01575340|Dietary Supplement|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
343511|NCT01575327|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
343512|NCT01575327|Device|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
343513|NCT01575314|Device|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
343514|NCT01575301|Drug|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
343515|NCT01575288|Drug|Placebo|100g maltose 1/day
343516|NCT01575288|Drug|High-dose trehalose|100g 1/day
343517|NCT01575275|Drug|aminolevulinic acid|Given PO
343518|NCT01575275|Procedure|therapeutic conventional surgery|Undergo surgery
343519|NCT01575262|Behavioral|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
343520|NCT01575262|Behavioral|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
343521|NCT01575236|Device|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
343522|NCT01575236|Device|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
343523|NCT01575223|Device|NeilMed sinus rinse|High volume saline irrigation
343524|NCT01575223|Device|Salinex|Low volume saline irrigation
343525|NCT01575197|Biological|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 & 10 weeks of age, 10 & 14 weeks of age, or 6, 10, & 14 weeks of age, depending on study arm assignment.
343564|NCT01574872|Device|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
343526|NCT01575184|Other|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
343527|NCT01575184|Other|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
343528|NCT01575171|Behavioral|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
343529|NCT01575158|Drug|Citalopram|
343530|NCT01575158|Drug|Clomipramine|
343531|NCT01575158|Drug|placebo|
343532|NCT01575145|Behavioral|Quitline facilitation intervention|brief quitline facilitation intervention
343533|NCT01575145|Behavioral|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
343534|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
343535|NCT01575119|Behavioral|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
343536|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
343537|NCT01575119|Behavioral|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
343538|NCT01575106|Device|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
343539|NCT01575093|Other|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
343540|NCT01575080|Device|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
343541|NCT01575054|Biological|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
343542|NCT01575054|Drug|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
343543|NCT01575041|Dietary Supplement|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
343544|NCT01575041|Drug|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
343545|NCT01575041|Drug|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
343546|NCT01575028|Drug|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
343547|NCT01575028|Drug|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
343548|NCT01575015|Device|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
343549|NCT01575015|Procedure|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
343550|NCT01575002|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
343551|NCT01574989|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
343552|NCT01574989|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35^2 electrodes.
343553|NCT01574976|Behavioral|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
343554|NCT01574937|Drug|Cabozantinib|28 day cycle
343555|NCT01574937|Drug|Abiraterone|28 day cycle
343556|NCT01574924|Other|No intervention.|There are no interventions in this observational study.
343557|NCT01574898|Drug|V0474 - A mg|Single oral administration
343558|NCT01574898|Drug|V0474 - B mg|Single oral administration
343559|NCT01574898|Drug|V0474 - C mg|Single oral administration
343560|NCT01574898|Drug|V0018 - B mg|Single oral administration
343561|NCT01574898|Drug|Niquitin® Fresh Mint 4 mg|Single oral administration
343562|NCT01574885|Device|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
343571|NCT01574807|Drug|3% mepivacaine/2% lidocaine with 1:100,000 epinephrine combo|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine compared to an injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
343572|NCT01574794|Other|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
343573|NCT01574794|Other|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
343574|NCT01574781|Procedure|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
343575|NCT01574781|Procedure|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
343576|NCT01574768|Procedure|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
343577|NCT01574742|Drug|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
343578|NCT01574729|Drug|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
343579|NCT01574729|Procedure|Surgery|Surgery plus post-surgery chemotherapy
343580|NCT01574716|Drug|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
343581|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
343582|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
343583|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
343584|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
343585|NCT01574716|Drug|Placebo|
343586|NCT01574703|Drug|placebo|All dosing to have taken place per study A3051123
343587|NCT01574703|Drug|varenicline tartrate|All dosing to have taken place per study A3051123
343588|NCT01574703|Drug|bupropion hydrochloride|All dosing to have taken place per study A3051123
343589|NCT01574703|Drug|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
343590|NCT01574690|Device|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
343591|NCT01574690|Procedure|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
343592|NCT01574690|Procedure|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
343593|NCT01574664|Device|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
343594|NCT01574651|Drug|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
343595|NCT01574651|Drug|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
343596|NCT01574651|Drug|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
343597|NCT01574651|Drug|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
343598|NCT01574651|Drug|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
343599|NCT01574651|Drug|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
343600|NCT01574638|Drug|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
343601|NCT01574612|Drug|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
343602|NCT01574599|Other|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
343603|NCT01574586|Device|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
343604|NCT01574573|Behavioral|Self support, group sessions|Self support,group sessions
343605|NCT01574560|Behavioral|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
343606|NCT01574560|Behavioral|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
343607|NCT01574534|Device|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
343608|NCT01574534|Device|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
343609|NCT01574508|Drug|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
343610|NCT01574508|Drug|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
343611|NCT01574495|Other|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
343612|NCT01574482|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
343614|NCT01574469|Other|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
343615|NCT01574469|Other|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
343616|NCT01574430|Procedure|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
343617|NCT01574417|Dietary Supplement|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
343618|NCT01574417|Dietary Supplement|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.~Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
343619|NCT01574404|Procedure|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
343620|NCT01574391|Device|Epidrum|Epidrum is used
343621|NCT01574378|Device|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
343622|NCT01574378|Device|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
343623|NCT01574365|Drug|RTA 402|
343624|NCT01574352|Behavioral|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
343625|NCT01574352|Behavioral|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
343626|NCT01574339|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.~The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative."
343627|NCT01574326|Drug|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
343628|NCT01574326|Drug|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
343629|NCT01574313|Procedure|stellate ganglion block|stellate ganglion block
343630|NCT01574313|Drug|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
343631|NCT01574313|Drug|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
343632|NCT01574313|Drug|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
343633|NCT01574300|Other|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
343634|NCT01574287|Drug|FACBC|Drug is give intravenously over 2 minutes at time of scan
343635|NCT01574274|Drug|SC-PEG|11 doses Intravenously over one hour
343636|NCT01574274|Drug|Oncaspar|16 doses Intravenously over one hour
343637|NCT01574261|Drug|Placebo|Placebo for four months
343638|NCT01574261|Drug|Inositol|Inositol 4g/die for four months
343639|NCT01574248|Drug|icatibant|Subcutaneous at time 0 and 6 hours
343640|NCT01574248|Other|Placebo|Subcutaneous at time 0 and 6 hours
343641|NCT01574235|Biological|Nivestim®|
343642|NCT01574222|Biological|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
343643|NCT01574196|Other|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
343644|NCT01574183|Drug|Vilazodone|up to 40 mg capsule daily
343645|NCT01574183|Drug|Placebo|up to 40 mg capsule daily
343646|NCT01574170|Other|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
343647|NCT01574157|Drug|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
343648|NCT01574157|Drug|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
343649|NCT01574144|Device|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
343650|NCT01574131|Drug|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
343651|NCT01574131|Drug|Sugar Pill|pill every day for 6 months
343652|NCT01574118|Behavioral|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
343653|NCT01574118|Behavioral|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
343654|NCT01574118|Behavioral|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
343655|NCT01574118|Behavioral|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
344913|NCT01564680|Drug|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
343656|NCT01574118|Behavioral|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
343657|NCT01574118|Behavioral|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
343658|NCT01574118|Behavioral|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
343659|NCT01574118|Behavioral|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
343660|NCT01574092|Drug|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
343661|NCT01574079|Other|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
343662|NCT01574079|Other|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
343663|NCT01574066|Procedure|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
343664|NCT01574040|Behavioral|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
343665|NCT01574040|Behavioral|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
343666|NCT01574040|Behavioral|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
343667|NCT01574040|Behavioral|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
343668|NCT01574027|Drug|Vitamin D3 (cholecalciferol)|One capsule per day for six months
343669|NCT01574027|Drug|Placebo|One capsule per day for six months
343670|NCT01574014|Behavioral|CBGT|Cognitive-behavioral group therapy
343671|NCT01574014|Drug|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
343672|NCT01574014|Drug|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
343673|NCT01574001|Behavioral|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
343674|NCT01574001|Behavioral|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
343675|NCT01574001|Behavioral|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
343676|NCT01573988|Other|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :~breakfast in one intake at 8:00~breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior~The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.~The administration order is determined by randomized allocation. The wash-out period is one to three weeks.~There are not diet or exercise interventions."
343677|NCT01573975|Drug|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
343678|NCT01573975|Drug|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
343679|NCT01573975|Drug|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
343680|NCT01573949|Drug|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
343681|NCT01573936|Other|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
343682|NCT01573923|Biological|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
343683|NCT01573923|Biological|Conventional therapy|Conventional therapy without cell therapy
343684|NCT01573910|Drug|Moxifloxacin ophthalmic solution, 0.5%|
343685|NCT01573910|Drug|Ofloxacin ophthalmic solution, 0.3%|
343686|NCT01573871|Other|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
343687|NCT01573858|Other|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
343688|NCT01573858|Other|Acupuncture treatment 2|Needles will be inserted to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
343689|NCT01573858|Other|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
343690|NCT01573858|Other|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
343691|NCT01573845|Behavioral|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:~A 22-lesson classroom curriculum~Homework activities that involve the family~Monthly parent newsletters~A food shopping and packing guide for parents~Food demonstrations~A poster contest~School wide announcements"
343692|NCT01573845|Behavioral|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:~A 22-lesson classroom curriculum~Homework activities that involve the family~Monthly parent newsletters~A food shopping and packing guide for parents~Food demonstrations~A poster contest~School wide announcements"
343693|NCT01573832|Other|integrated client care group|receives integrated client care for wound treatment
343694|NCT01573819|Drug|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
343695|NCT01573819|Drug|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
343696|NCT01573806|Drug|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
343697|NCT01573806|Drug|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
343698|NCT01573793|Behavioral|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
343699|NCT01573793|Behavioral|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
343700|NCT01573780|Drug|Smac mimetic TL32711|Given IV
343701|NCT01573780|Drug|gemcitabine hydrochloride|Given IV
343702|NCT01573780|Other|laboratory biomarker analysis|Correlative studies
343703|NCT01573780|Other|pharmacological study|Correlative studies
343704|NCT01573780|Procedure|biopsy|Optional correlative studies
343705|NCT01573767|Drug|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
343706|NCT01573767|Drug|Placebo|Placebo inhalation powder during treatment period
343707|NCT01573767|Drug|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
343708|NCT01573754|Drug|Hydroxychloroquine|100 mg by mouth twice weekly
343709|NCT01573754|Procedure|Phlebotomy|450 mL every 2 weeks
343710|NCT01573741|Drug|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
343711|NCT01573728|Behavioral|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
343712|NCT01573728|Behavioral|Public Health Exercise|At least 150 minutes at moderate intensity
343713|NCT01573715|Drug|NIMBEX|
343714|NCT01573715|Drug|NIMBEX|
343715|NCT01573715|Other|WITHOUT NIMBEX|
343716|NCT01573702|Procedure|Stereotactic Radiosurgery|21 Gy daily for 5 days
343717|NCT01573702|Drug|Erlotinib|150mg once daily
343718|NCT01573689|Behavioral|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
343719|NCT01573663|Drug|Ambroxol and Levodropropizine|Ambroxol HCl 30mg & Levodropropizine 60mg, PO, Single dose
343720|NCT01573663|Drug|Ambroxol|Ambroxol HCl 30mg, PO, single dose
343721|NCT01573663|Drug|Levodropropizine|Levodropropizine 60mg, PO, single dose
343722|NCT01573637|Drug|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
343723|NCT01573637|Drug|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
343724|NCT01573624|Drug|FF/GSK573719|100/15.6
343725|NCT01573624|Drug|FF/GSK573719|100/31.25
343726|NCT01573624|Drug|FF/GSK573719|100/62.5
343727|NCT01573624|Drug|FF/GSK573719|100/125
343728|NCT01573624|Drug|FF/GSK573719|100/250
343729|NCT01573624|Drug|FF|100
343730|NCT01573624|Drug|FF/VI|100/25
343731|NCT01573611|Dietary Supplement|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
343732|NCT01573611|Dietary Supplement|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
343733|NCT01573598|Drug|Placebo|Matching placebo given orally, once per day
343734|NCT01573598|Drug|Vilazodone|Vilazodone, 20 mg per day, oral administration
343735|NCT01573598|Drug|Vilazodone|Vilazodone, 40 mg once per day, oral administration
345484|NCT01560260|Other|Laboratory Biomarker Analysis|Correlative studies
343736|NCT01573585|Behavioral|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
343737|NCT01573585|Behavioral|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
343738|NCT01573572|Drug|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
343739|NCT01573546|Behavioral|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
343740|NCT01573546|Behavioral|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
343741|NCT01573546|Other|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
343742|NCT01573533|Biological|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
343743|NCT01573520|Other|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
343744|NCT01573507|Other|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
343745|NCT01573494|Other|Sampling of blood|7,5 ml of blood
343746|NCT01573481|Other|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
343747|NCT01573481|Other|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min).
343748|NCT01573468|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
343749|NCT01573468|Drug|Placebo|Placebo orally once on Day 1 of each cycle
343750|NCT01573468|Drug|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
343751|NCT01573442|Drug|testosterone|10.4 mg
343752|NCT01573442|Other|placebo|
343753|NCT01573429|Other|deuterated-Bisphenol A (d-BPA)|The primary endpoints are key pharmacokinetic measurements of d-BPA and d-BPA conjugates in blood and urine over 6 days after a single dose of oral and/or ethanol solution dermal application and/or a carboxymethylcellulose suspension dermal application of a dose of 100 micro g/kg bw of d-BPA.
343754|NCT01573416|Other|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
343755|NCT01573416|Other|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
343756|NCT01573403|Drug|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
343757|NCT01573403|Drug|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
343758|NCT01573403|Drug|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
343759|NCT01573377|Drug|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
343760|NCT01573377|Drug|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
343761|NCT01573351|Drug|Asunaprevir|
343762|NCT01573351|Drug|Daclatasvir|
343763|NCT01573351|Drug|Peg-interferon Alfa-2a|
343764|NCT01573351|Drug|Ribavirin|
343765|NCT01573338|Drug|Roniciclib (BAY 1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
343766|NCT01573338|Drug|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
343767|NCT01573338|Drug|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
343768|NCT01573338|Drug|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
343769|NCT01573312|Drug|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
343770|NCT01573312|Biological|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
343771|NCT01573299|Other|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
343772|NCT01573286|Drug|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
343773|NCT01573286|Drug|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.~Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
343774|NCT01573273|Drug|Oxytocin|intranasal administration, 40 IUs
343775|NCT01573273|Drug|Saline|intranasal administration, 40 IUs
343776|NCT01573260|Other|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
343777|NCT01573260|Other|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
343778|NCT01573247|Drug|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.~During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
343779|NCT01573234|Device|MySkin patch|Hydrogel and polyurethane film
343780|NCT01573234|Device|Gauze and Patch|Traditional Dressing
343781|NCT01573208|Device|Custom guides|Symbios custom guides for TKA
343782|NCT01573182|Biological|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
343783|NCT01573169|Drug|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
343784|NCT01573169|Other|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
343785|NCT01573156|Drug|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 & 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
343786|NCT01573143|Drug|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
343787|NCT01573143|Drug|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
343788|NCT01573130|Behavioral|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
343789|NCT01573117|Device|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
343790|NCT01573117|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
343791|NCT01573104|Other|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
343792|NCT01573104|Other|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
343793|NCT01573104|Other|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
343794|NCT01573091|Procedure|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
343795|NCT01573078|Behavioral|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
343796|NCT01573065|Behavioral|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
343797|NCT01573052|Drug|Chlordiazepoxide|25mg qid x 3 days then tapered over 3 days
343798|NCT01573052|Drug|Gabapentin|300mg qid x 3 days then tapered over 3 days
343799|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
343800|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
343801|NCT01573013|Dietary Supplement|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
345485|NCT01560260|Drug|Linsitinib|Given PO
343802|NCT01573013|Dietary Supplement|iron fortified biscuits|control biscuit on a daily basis for 8 months
343803|NCT01573000|Biological|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
343804|NCT01572987|Device|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
343805|NCT01572987|Device|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
343806|NCT01572961|Drug|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
343807|NCT01572961|Drug|Placebo|
343808|NCT01572948|Drug|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
343809|NCT01572948|Drug|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
343810|NCT01572922|Device|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
343811|NCT01572922|Device|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
343812|NCT01572922|Procedure|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
343813|NCT01572909|Drug|Bendavia (MTP-131)|0.05 mg/kg/hr
343814|NCT01572909|Drug|Placebo|Identically appearing placebo
343815|NCT01572896|Behavioral|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
343816|NCT01572896|Behavioral|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
343817|NCT01572857|Biological|urinary excretion of FLC immunoglobulin|"First phase :~Collection of four urine samples daily for 2 days:~Of the 24-hour urine~at 8 AM~at 12 AM~at 4 PM~On each of these urine samples, the following analysis will be performed:~Proteinuria~Albuminuria~Urinary FLC (Freelite ™)~Urine creatinine~Second phase:~Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
343818|NCT01572844|Device|Fractionated Carbon Dioxide (FCO2) Laser|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
343819|NCT01572844|Drug|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
343820|NCT01572831|Other|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (<12,000 and >4,000).
343821|NCT01572818|Procedure|phlebotomy|7 ml/kg without exceeding 500 mL
343822|NCT01572818|Behavioral|dietary and lifestyle counseling|dietary and lifestyle counseling
343823|NCT01572805|Drug|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
343824|NCT01572805|Drug|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
343825|NCT01572805|Drug|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
343826|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
343827|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
343828|NCT01572792|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
343829|NCT01572792|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
343830|NCT01572792|Drug|Placebo|Inhaled dose-matched placebo, twice per day
343970|NCT01571882|Other|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
343831|NCT01572779|Device|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
343832|NCT01572779|Device|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
343833|NCT01572766|Other|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
343834|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
343835|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
343836|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
343837|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
343838|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
343839|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
343840|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
343841|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
343842|NCT01572740|Drug|liraglutide|Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
343843|NCT01572740|Drug|placebo|Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
343844|NCT01572740|Drug|insulin|All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
343845|NCT01572727|Drug|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
343846|NCT01572727|Drug|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.~Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
343847|NCT01572727|Drug|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
343848|NCT01572714|Behavioral|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
343849|NCT01572714|Behavioral|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
343850|NCT01572714|Behavioral|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
343851|NCT01572701|Drug|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
343852|NCT01572688|Drug|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
343853|NCT01572675|Drug|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
343854|NCT01572675|Drug|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
343855|NCT01572662|Drug|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
343856|NCT01572662|Drug|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
343857|NCT01572662|Procedure|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
345486|NCT01560260|Other|Pharmacological Study|Correlative studies
343858|NCT01572662|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
343859|NCT01572662|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
343860|NCT01572662|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
343861|NCT01572649|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
343862|NCT01572649|Drug|Placebo|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
343863|NCT01572636|Drug|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
343864|NCT01572623|Drug|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
343865|NCT01572623|Drug|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
343866|NCT01572610|Drug|RTA 402|once a day, oral administration
343867|NCT01572597|Drug|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
343868|NCT01572597|Drug|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
343869|NCT01572558|Procedure|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
343870|NCT01572558|Drug|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
343871|NCT01572545|Drug|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
343872|NCT01572545|Drug|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
343873|NCT01572532|Other|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.~Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
343874|NCT01572519|Drug|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
343875|NCT01572519|Drug|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
343876|NCT01572519|Drug|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
343877|NCT01572519|Drug|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
343878|NCT01572519|Drug|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
343879|NCT01572506|Procedure|Biotin RBC survival|
343880|NCT01572506|Device|Sulpho-NHS-Biotin|
343881|NCT01572493|Biological|rh IL-15 (10 DAYS)|Continuous infusion of rhIL-15 IV for first 10 days of each cycle
343882|NCT01572493|Biological|rh IL-15 (5 DAYS)|Continuous infusion of rhIL-15 for first 5 days of each cycle
343883|NCT01572480|Drug|Carfilzomib|Carfilzomib (IV) 20-36 mg/m2 per dose on days 1, 2, 8, 9, 15, and 16 of each cycle based on arm; until disease progression or unacceptable toxicity.
343884|NCT01572480|Drug|Revlimid|Revlimid (PO) 25 mg/day, days 1 21 every 28 days of each cycle based on arm; until disease progression or unacceptable toxicity.
343885|NCT01572480|Drug|Dexamethasone|Dexamethasone (PO) 20 mg per dose on days 1, 2, 8, 9, 15, 16, 22, and 23 of each cycle based on arm; until disease progression or unacceptable toxicity.
343886|NCT01572467|Genetic|RNA analysis|
343887|NCT01572467|Genetic|gene expression analysis|
343888|NCT01572467|Genetic|mutation analysis|
343889|NCT01572467|Genetic|reverse transcriptase-polymerase chain reaction|
343890|NCT01572467|Other|laboratory biomarker analysis|
343891|NCT01572467|Other|medical chart review|
343892|NCT01572454|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
343893|NCT01572454|Drug|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
343894|NCT01572428|Procedure|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
343895|NCT01572428|Procedure|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
343896|NCT01572402|Other|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
343897|NCT01572402|Other|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
343898|NCT01572402|Other|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
343899|NCT01572389|Behavioral|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
343900|NCT01572389|Behavioral|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
343901|NCT01572376|Procedure|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
343902|NCT01572363|Drug|Sildenafil|50 mg once
343903|NCT01572350|Other|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
343904|NCT01572350|Drug|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
343905|NCT01572350|Drug|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
343906|NCT01572337|Procedure|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
343907|NCT01572337|Other|Standard care|
343908|NCT01572324|Drug|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
343909|NCT01572311|Behavioral|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
343910|NCT01572311|Behavioral|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
343911|NCT01572298|Device|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
343912|NCT01572298|Device|allograft with autograft|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
343913|NCT01572285|Procedure|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
343914|NCT01572285|Procedure|Sham|Sham procedure using a non-penetrating needle
343915|NCT01572259|Drug|Growth Hormone|
343916|NCT01572259|Other|interruption of the traitment with growth hormone|
343917|NCT01572246|Other|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
343918|NCT01572233|Behavioral|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection~The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
343919|NCT01572220|Other|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
343920|NCT01572207|Behavioral|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
343921|NCT01572207|Behavioral|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
343922|NCT01572194|Biological|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
343923|NCT01572181|Drug|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"IV fludarabine (30 mg/m²/day for 5 days)~IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)~Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
343924|NCT01572168|Other|Acupuncture|Eight session of weekly acupuncture
343925|NCT01572155|Procedure|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
343926|NCT01572155|Procedure|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
343927|NCT01572129|Drug|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
343928|NCT01572129|Drug|Placebo|Placebo in addition to the chronic daily dose of 75 mg
343929|NCT01572116|Drug|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
343930|NCT01572116|Drug|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
343931|NCT01572103|Dietary Supplement|Coffee|Administration of 4 cups of coffee per day for 1 month
343932|NCT01572103|Dietary Supplement|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
343933|NCT01572090|Behavioral|Lifestyle Changes|"Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.~Dietetic and physical activity counselling with a dietitian."
344048|NCT01571284|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous
343934|NCT01572090|Other|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
343935|NCT01572090|Procedure|Laparoscopic sleeve gastrectomy|The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
343936|NCT01572090|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
343937|NCT01572077|Radiation|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
343938|NCT01572064|Procedure|Blood sample|1 fasted blood sample taken for metabolomics
343939|NCT01572064|Other|MRI Scan|1 single visit for MRI and MRS
343940|NCT01572051|Behavioral|Educational Course|2 Educational courses
343941|NCT01572051|Behavioral|Phone Calls|Phone Calls
343942|NCT01572051|Behavioral|Printed Material|Printed Material
343943|NCT01572038|Drug|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
343944|NCT01572038|Drug|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
343945|NCT01572038|Drug|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
343946|NCT01572038|Drug|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
343947|NCT01572038|Drug|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
343948|NCT01572025|Drug|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
343949|NCT01572025|Drug|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol~: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
343950|NCT01572012|Drug|Ondansetron|Ondansetron solution 4 mg single administration
343951|NCT01572012|Drug|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
343952|NCT01572012|Drug|Zofran ODT|Zofran ODT (8 mg) single administration
343953|NCT01572012|Drug|Ondansetron solution|Ondansetron solution (4 mg) single administration
343954|NCT01571999|Drug|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
343955|NCT01571999|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
343956|NCT01571986|Procedure|Non-invasive ventilation|Non-invasive ventilation
343957|NCT01571973|Procedure|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
343958|NCT01571960|Biological|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
343959|NCT01571960|Biological|MVA/HIV62B (MVA62B) vaccine|1 x 10^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
343960|NCT01571960|Biological|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
343961|NCT01571960|Biological|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
343962|NCT01571947|Other|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
343963|NCT01571921|Dietary Supplement|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
343964|NCT01571908|Drug|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
343965|NCT01571908|Drug|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
343966|NCT01571908|Drug|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
343967|NCT01571908|Drug|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
343968|NCT01571895|Drug|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 [CXCL8; formerly interleukin (IL)-8] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
343969|NCT01571882|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
343971|NCT01571882|Other|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
343972|NCT01571869|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
343973|NCT01571869|Other|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
343974|NCT01571856|Drug|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
343975|NCT01571856|Other|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
343976|NCT01571843|Other|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
343977|NCT01571843|Other|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
343978|NCT01571817|Biological|Isolated Human Pancreatic Islets|
343979|NCT01571804|Drug|Placebo|to receive two identical placebo capsules 1 hr before surgery
343980|NCT01571804|Drug|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
343981|NCT01571804|Drug|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
343982|NCT01571791|Drug|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
343983|NCT01571791|Drug|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
343984|NCT01571778|Behavioral|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
343985|NCT01571765|Other|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
343986|NCT01571726|Drug|Fluciclatide|7mCi
343987|NCT01571700|Procedure|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension >5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
343988|NCT01571687|Dietary Supplement|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
343989|NCT01571687|Dietary Supplement|Placebo|Intake of 6 identically appearing tablets daily containing placebo
343990|NCT01571674|Procedure|Manipulation + Exercise Group|"First 2 sessions~High-velocity, low-amplitude manipulations to the thoracic spine.~Low-velocity mid to end-range mobilizations to the cervical spine.~Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
343991|NCT01571674|Procedure|Exercise Group|"First 2 sessions~◦ Active Range of Motion Exercises for the cervicothoracic spine~Final 6 sessions~◦ Evidence based shoulder girdle exercise program"
343992|NCT01571661|Drug|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
343993|NCT01571661|Other|Placebo|Placebo
343994|NCT01571648|Drug|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
343995|NCT01571635|Drug|Sotatercept 0.1mg/kg|
343996|NCT01571635|Drug|Sotatercept 0.3mg/kg|
343997|NCT01571635|Drug|Sotatercept 0.5mg/kg|
343998|NCT01571635|Drug|Sotatercept 0.75mg/kg|
343999|NCT01571635|Drug|Sotatercept 1.0mg/kg|
344000|NCT01571635|Drug|Sotatercept 1.5mg/kg|
344001|NCT01571635|Drug|SOTATERCEPT (ACE-011)|0.1 mg/kg to 0.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
344002|NCT01571622|Dietary Supplement|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
344003|NCT01571622|Dietary Supplement|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
344004|NCT01571609|Other|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.~HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes~Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.~Palmitate tracer:[9,10-3H]-palmitate 0,3 µCi/min. Duration 60 minutes."
344005|NCT01571596|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
344006|NCT01571583|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
344007|NCT01571583|Drug|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
344049|NCT01571284|Drug|FOLFIRI|irinotecan, 5-FU and leucovorin
344050|NCT01571271|Procedure|Laser Lithotripsy|Laser Lithotripsy
344051|NCT01571271|Procedure|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
344008|NCT01571583|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day [5 to 6 tablets] based on subject weight), twice daily regimen, for 48 weeks.
344009|NCT01571570|Drug|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
344010|NCT01571570|Drug|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
344011|NCT01571570|Drug|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
344012|NCT01571570|Drug|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
344013|NCT01571570|Drug|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
344014|NCT01571557|Drug|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
344015|NCT01571544|Device|Thermal suit|Thermal suit
344016|NCT01571544|Other|Conventional clothing|Conventional clothing
344017|NCT01571518|Drug|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
344018|NCT01571518|Drug|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
344019|NCT01571505|Biological|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
344020|NCT01571492|Procedure|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
344021|NCT01571492|Procedure|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
344022|NCT01571479|Procedure|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.~Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.~A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
344023|NCT01571466|Drug|Vaccination|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml~3 immunisations at week 0, 4 and 16"
344024|NCT01571466|Drug|Placebo|3 immunisations at week 0, 4 and 16
344025|NCT01571453|Drug|Vortioxetine (Lu AA21004)|10 mg/day
344026|NCT01571453|Drug|Venlafaxine extended release|150 mg/day
344027|NCT01571440|Dietary Supplement|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
344028|NCT01571440|Dietary Supplement|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
344029|NCT01571427|Behavioral|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
344030|NCT01571427|Behavioral|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device. Participants will be reassessed at the 3rd and 6th month after completion of the intervention.
344031|NCT01571414|Drug|PA-824|200-mg tablets once a day
344032|NCT01571414|Drug|Efavirenz (EFV)|600-mg tablets once a day
344033|NCT01571414|Drug|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
344034|NCT01571414|Drug|Rifampin (RIF)|300-mg capsules once a day
344035|NCT01571401|Behavioral|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
344036|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
344037|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
344038|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
344039|NCT01571362|Drug|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
344040|NCT01571362|Drug|Placebo|oral placebo, divided into symmetric doses and administered twice daily
344041|NCT01571323|Drug|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
344042|NCT01571323|Drug|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
344043|NCT01571323|Drug|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
344044|NCT01571310|Other|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
344045|NCT01571310|Other|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00~(YesB): The patients in YesB will eat all three mealswill consume three meals:"
344046|NCT01571297|Drug|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
344047|NCT01571297|Drug|Placebo|Placebo given subcutaneously for 35 days
344052|NCT01571258|Behavioral|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
344053|NCT01571232|Drug|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
344054|NCT01571232|Drug|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
344055|NCT01571219|Biological|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
344056|NCT01571206|Biological|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
344057|NCT01571167|Drug|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
344058|NCT01571167|Drug|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
344059|NCT01571167|Drug|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
344060|NCT01571141|Device|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
344061|NCT01571128|Other|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
344062|NCT01571128|Other|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
344063|NCT01571128|Drug|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
344064|NCT01571128|Behavioral|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
344065|NCT01571115|Behavioral|Physical Exercise|
344066|NCT01571102|Behavioral|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
344067|NCT01571102|Behavioral|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
344068|NCT01571089|Behavioral|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
344069|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
344070|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
344071|NCT01571076|Other|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
344072|NCT01571076|Other|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
344073|NCT01571063|Drug|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
344074|NCT01571063|Drug|Placebo|Placebo Tbl. p.o.
344075|NCT01571050|Drug|Purified water|Ingestion of 30 mL of purified water
344076|NCT01571050|Drug|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
344077|NCT01571050|Drug|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
344078|NCT01571050|Drug|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
344079|NCT01571050|Drug|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
344080|NCT01571037|Drug|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
344081|NCT01571037|Drug|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
344082|NCT01571024|Drug|BKM120|BKM120 40 mg, orally, once daily.
344083|NCT01571024|Drug|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
344084|NCT01571011|Behavioral|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
344085|NCT01570998|Radiation|Intraoperative Radiation Therapy|Undergo IORT
344087|NCT01570985|Drug|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
344088|NCT01570985|Drug|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
344089|NCT01570972|Behavioral|Group Cognitive Behavioral Therapy|weekly
344090|NCT01570972|Behavioral|Multifamily Group Psychoeducation|twice monthly
344091|NCT01570959|Drug|Quetiapine Fumarate|300 mg tablet
344092|NCT01570946|Behavioral|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
344093|NCT01570933|Device|NivNava|Non-invasive Nava ventilation mode on nasal cannula
344094|NCT01570933|Device|Cpap|nasal Cpap on nasal cannula
344095|NCT01570920|Behavioral|physical training|walking many times a week
344096|NCT01570907|Drug|Quetiapine Fumarate|25 mg tablet
344097|NCT01570894|Drug|Quetiapine Fumarate|25 mg tablet
344098|NCT01570868|Drug|Ponatinib|Starting dose: 45 mg by mouth once daily.
344099|NCT01570842|Other|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
344100|NCT01570842|Procedure|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
344101|NCT01570829|Drug|Dietressa|Safety and Efficacy of New Dosage Schedule
344102|NCT01570829|Drug|Placebo|Safety and Efficacy of New Dosage Schedule
344103|NCT01570816|Device|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
344104|NCT01570803|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
344105|NCT01570803|Device|Complete SE Stent|same to SMART CONTROL Stent
344106|NCT01570790|Drug|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
344107|NCT01570790|Drug|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
344108|NCT01570790|Drug|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
344109|NCT01570777|Procedure|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
344110|NCT01570777|Procedure|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
344111|NCT01570764|Drug|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
344112|NCT01570764|Drug|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
344113|NCT01570751|Drug|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
344114|NCT01570751|Drug|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
344115|NCT01570725|Behavioral|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.~Patients were exposed to the virtual environment for the entire length of the operation."
344116|NCT01570725|Behavioral|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
344117|NCT01570712|Other|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;~Support in the development and the maintenance of the housing;~Support in the diverse steps (administrative, judicial, financiers, etc.);~Support around addictions / alcohol;~Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)~to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
344118|NCT01570712|Other|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\or the restoring, but this by means of the existing devices"
344119|NCT01570699|Genetic|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
344120|NCT01570686|Drug|Aliskiren|Aliskiren 300 mg once daily
344121|NCT01570673|Behavioral|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
344122|NCT01570673|Behavioral|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
344124|NCT01570634|Drug|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
344125|NCT01570621|Procedure|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
344126|NCT01570608|Drug|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
344127|NCT01570608|Drug|Verteporfin|Verteporfin photodynamic therapy standard fluence
344128|NCT01570595|Behavioral|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
344129|NCT01570595|Behavioral|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
344130|NCT01570582|Drug|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
344131|NCT01570569|Drug|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
344132|NCT01570569|Drug|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
344133|NCT01570569|Drug|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
344134|NCT01570569|Drug|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.~Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
344135|NCT01570569|Drug|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
344136|NCT01570569|Drug|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
344137|NCT01570556|Other|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
344138|NCT01570530|Procedure|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
344139|NCT01570530|Procedure|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
344140|NCT01570517|Device|IASD System|Implantation of the DC Devices Inc. IASD System
344141|NCT01570504|Drug|Ivermectin|oral formulation
344142|NCT01570491|Other|ultrasound-guided spinal anesthesia|ultrasound-guided technique for block placement
344143|NCT01570491|Other|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
344144|NCT01570478|Drug|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
344145|NCT01570478|Drug|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
344146|NCT01570465|Other|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
344147|NCT01570452|Procedure|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
344148|NCT01570413|Procedure|No Pelvic Exam|Will not receive pelvic examination.
344149|NCT01570413|Procedure|Pelvic Examination|Pelvic examination will be performed.
344150|NCT01570400|Behavioral|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
344151|NCT01570400|Behavioral|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
344188|NCT01570179|Drug|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
344189|NCT01570179|Drug|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
344190|NCT01570179|Drug|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
344191|NCT01570179|Drug|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
345596|NCT01559311|Device|DDDR|Dual-chamber, rate-modulated pacemaker
344152|NCT01570400|Behavioral|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.~Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
344153|NCT01570387|Drug|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-28
344154|NCT01570387|Drug|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
344155|NCT01570374|Behavioral|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
344156|NCT01570361|Device|Catheter Ablation|Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
344157|NCT01570361|Drug|Drug Treatment|Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
344158|NCT01570348|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
344159|NCT01570348|Drug|Cyclophosphamide|Given IV
344160|NCT01570348|Drug|Fludarabine Phosphate|Given IV
344161|NCT01570348|Other|Laboratory Biomarker Analysis|Correlative studies
344162|NCT01570348|Drug|Mycophenolate Mofetil|Given PO
344163|NCT01570348|Drug|Mycophenolic Acid|Given PO
344164|NCT01570348|Other|Quality-of-Life Assessment|Ancillary studies
344165|NCT01570348|Drug|Tacrolimus|Given IV or PO
344166|NCT01570348|Radiation|Total-Body Irradiation|Undergo TBI
344167|NCT01570309|Drug|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
344168|NCT01570309|Other|Sugar pill|Oral capsule, once a week, 12 weeks
344169|NCT01570296|Drug|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
344170|NCT01570283|Biological|Multivirus-specific T cells Dose Level 1|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
344171|NCT01570283|Biological|Multivirus-specific T cells Dose Level 2|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
344172|NCT01570283|Biological|Multivirus-specific T cells Dose Level 3|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL"
344173|NCT01570270|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
344174|NCT01570257|Procedure|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
344175|NCT01570244|Drug|levonorgestrel|multiple doses
344176|NCT01570244|Drug|Ethinylestradiol|multiple doses
344177|NCT01570244|Drug|levonorgestrel|multiple doses
344178|NCT01570244|Drug|BI 201335|multiple doses
344179|NCT01570244|Drug|Ethinylestradiol|multiple doses
344180|NCT01570231|Device|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
344181|NCT01570218|Behavioral|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
344182|NCT01570205|Drug|XG-102|single intravenous infusion
344183|NCT01570192|Drug|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
344184|NCT01570192|Drug|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).~Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
344185|NCT01570192|Drug|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
344186|NCT01570192|Drug|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
344187|NCT01570192|Device|tobramycin nebulization|tobramycin nebulization 600mg/day
346291|NCT01553942|Radiation|Radiation|Daily, Monday-Friday
344192|NCT01570166|Procedure|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
344193|NCT01570166|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
344194|NCT01570140|Behavioral|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
344195|NCT01570127|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
344196|NCT01570127|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
344197|NCT01570127|Procedure|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
344198|NCT01570127|Other|Waiting|No interventions were applied to the patients in this group.
344199|NCT01570114|Device|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
344200|NCT01570101|Device|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
344201|NCT01570088|Dietary Supplement|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
344202|NCT01570088|Dietary Supplement|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
344203|NCT01570088|Other|Placebo|Placebo contains no folic acids
344204|NCT01570075|Procedure|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
344205|NCT01570075|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
344206|NCT01570062|Device|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
344207|NCT01570062|Device|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
344208|NCT01570049|Drug|Bendamustine|for injection
344209|NCT01570036|Drug|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
344210|NCT01570036|Drug|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
344211|NCT01570036|Drug|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
344212|NCT01570023|Behavioral|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
344213|NCT01570010|Other|new norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
344214|NCT01569997|Other|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
344215|NCT01569984|Radiation|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
344257|NCT01569633|Drug|placebo|The dose of sugar water is 1 ml per 8 hours.
344258|NCT01569620|Behavioral|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
344216|NCT01569971|Other|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
344217|NCT01569958|Other|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
344218|NCT01569958|Other|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
344219|NCT01569945|Drug|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
344220|NCT01569945|Drug|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
344221|NCT01569919|Biological|TroVax®|Dose of 1 x 10^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
344222|NCT01569919|Drug|Pemetrexed|500 mg/m^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
344223|NCT01569919|Drug|Cisplatin|75mg/m^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
344224|NCT01569919|Dietary Supplement|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
344225|NCT01569919|Dietary Supplement|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
344226|NCT01569919|Drug|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
344227|NCT01569906|Radiation|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
344228|NCT01569893|Other|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.~The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
344229|NCT01569841|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
344230|NCT01569841|Drug|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
344231|NCT01569828|Drug|LCZ696A|
344232|NCT01569828|Drug|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
344233|NCT01569815|Drug|LCZ696|LCZ696 400 mg once daily
344234|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
344235|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
344236|NCT01569776|Other|Amino Acid formula|Amino Acid baby formula
344237|NCT01569776|Other|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
344238|NCT01569763|Device|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
344239|NCT01569763|Device|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
344240|NCT01569750|Drug|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
344241|NCT01569750|Drug|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
344242|NCT01569750|Drug|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
344243|NCT01569750|Drug|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
344244|NCT01569750|Drug|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
344245|NCT01569737|Drug|ella|ella, single intake, tablet 30mg
344246|NCT01569724|Other|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
344247|NCT01569711|Procedure|Deep brain stimulation of nucleus accumbens|"Day0 : surgical placement of electrodes~M1 : stimulation of nucleus accumbens~M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
344248|NCT01569698|Procedure|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
344249|NCT01569685|Drug|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
344250|NCT01569685|Drug|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
344251|NCT01569672|Behavioral|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
344252|NCT01569672|Behavioral|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
344253|NCT01569659|Drug|Lurasidone|80 mg/day for up to 30 weeks
344254|NCT01569659|Drug|Lurasidone|Up to 240 mg/day for up to 30 weeks
344255|NCT01569633|Drug|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
344256|NCT01569633|Drug|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
344259|NCT01569620|Behavioral|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
344260|NCT01569620|Behavioral|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
344261|NCT01569607|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
344262|NCT01569607|Device|Sham stimulation|Sham stimulation
344263|NCT01569594|Device|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
344264|NCT01569581|Biological|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
344265|NCT01569581|Biological|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
344266|NCT01569581|Biological|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
344267|NCT01569581|Biological|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
344268|NCT01569568|Other|MRI scanning|1H MRS, DTI, FMRI
344269|NCT01569568|Behavioral|Cognitive testing|Behavioral testing
344270|NCT01569529|Behavioral|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
344271|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1mg, tid
344272|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
344273|NCT01569516|Drug|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
344274|NCT01569516|Drug|Placebo|0mg, tid
344275|NCT01569503|Device|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
344276|NCT01569490|Behavioral|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
344277|NCT01569490|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
344278|NCT01569477|Behavioral|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
344279|NCT01569477|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
344280|NCT01569464|Drug|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:~Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours~7 weeks (titration plus maintenance)"
344281|NCT01569464|Other|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.~Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.~7 weeks (titration plus maintenance)"
344282|NCT01569451|Drug|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
344283|NCT01569451|Drug|Glatiramer Acetate|20 mg injected subcutaneously daily
344284|NCT01569451|Other|Placebo|Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
344285|NCT01569438|Drug|Gefapixant|BID
344286|NCT01569438|Drug|Sugar Pill|Placebo
344287|NCT01569425|Other|Dietary intervention|High Calorie breakfast and high calorie dinner
344288|NCT01569412|Biological|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
344289|NCT01569399|Other|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
344290|NCT01569386|Behavioral|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
344291|NCT01569386|Behavioral|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
344292|NCT01569360|Device|Corset|the patients are assigned the use of a custome made corset during daytime
344293|NCT01569347|Other|Interviews|Interviews
344294|NCT01569347|Other|Blood sample|Blood sample
344295|NCT01569347|Other|Hair sample|Hair sample
344296|NCT01569334|Biological|blood samples|
344297|NCT01569321|Device|MRI|
344298|NCT01569321|Device|PET-CT scan|
344299|NCT01569321|Device|PEM scan with ClearPemSonic|
344300|NCT01569295|Drug|Idelalisib|Idelalisib 150 mg administered orally twice daily
344301|NCT01569295|Drug|Rituximab|Rituximab 375 mg/m^2 on Day 1, then 500 mg/m^2 every 28 days administered intravenously for a maximum of 6 infusions
344425|NCT01568411|Drug|TD-1211+ itraconazole|Period 2
344302|NCT01569295|Drug|Bendamustine|Bendamustine 70 mg/mg^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
344303|NCT01569295|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
344304|NCT01569282|Procedure|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
344305|NCT01569282|Procedure|Stent strategy|Biliary and/or enteral stents on demand
344306|NCT01569269|Behavioral|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation."
344307|NCT01569269|Behavioral|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
344308|NCT01569269|Behavioral|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
344309|NCT01569269|Other|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
344310|NCT01569256|Drug|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
344311|NCT01569243|Other|Text messages|"Participants will receive diabetic medical care as usual.~Participants will be given an ActiHealth pedometer to measure daily activity.~In addition, they will be enrolled to receive the study text messages."
344312|NCT01569243|Other|Usual care|"Participants will receive diabetic medical care as usual.~In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
344313|NCT01569230|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
344314|NCT01569230|Procedure|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
344315|NCT01569230|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
344316|NCT01569230|Other|Waiting|No interventions were applied to the patients in this group.
344317|NCT01569204|Drug|Etoposide|
344318|NCT01569204|Drug|Cyclophosphamide|
344319|NCT01569204|Drug|Doxorubicin|
344320|NCT01569204|Drug|Prednisone|
344321|NCT01569204|Drug|Procarbazine|
344322|NCT01569204|Drug|Dexamethasone|
344323|NCT01569204|Drug|Dacarbazine|
344324|NCT01569204|Drug|Brentuximab Vedotin|
344325|NCT01569191|Other|Artificial Tear Supplement|artificial tear supplement (Hypromellose)
344326|NCT01569191|Device|Cold compress|Cold compress bag fill with temperature retention gel placed over closed eyes Sold by http://www.visiondirect.co.uk/vision-direct/eye-gel-mask-blue
344327|NCT01569191|Drug|Anti-allergic Medication|1 drop on single occasion after exposure to grass pollen
344328|NCT01569178|Procedure|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
344329|NCT01569165|Procedure|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
344330|NCT01569152|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
344331|NCT01569152|Drug|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
344332|NCT01569152|Drug|Methotrexate|MTX dosed at the stable dose receive upon study entry
344333|NCT01569126|Drug|LY110140|Administered orally as capsules
344334|NCT01569126|Drug|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
344335|NCT01569113|Drug|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
344336|NCT01569113|Drug|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
344337|NCT01569087|Biological|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
344338|NCT01569087|Biological|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
344339|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
344340|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
344341|NCT01569074|Drug|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
344342|NCT01569074|Drug|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
344343|NCT01569074|Drug|Placebo|Placebo twice daily for 12 weeks
344344|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
344345|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
344346|NCT01569048|Drug|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
344347|NCT01569048|Drug|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
344348|NCT01569035|Drug|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
344349|NCT01569022|Device|CPAP|CPAP Treatment for 12 weeks
344350|NCT01569022|Device|MAD|MAD Treatment for 12 weeks
344351|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
344352|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
344353|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
344354|NCT01568983|Dietary Supplement|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
344355|NCT01568983|Dietary Supplement|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
344356|NCT01568983|Dietary Supplement|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
344357|NCT01568970|Behavioral|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
344358|NCT01568970|Behavioral|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
344359|NCT01568957|Behavioral|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
344360|NCT01568944|Drug|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
344361|NCT01568944|Procedure|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
344362|NCT01568931|Drug|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
344363|NCT01568931|Drug|Saline|intracoronary, saline, bolus 1 cc
344364|NCT01568918|Drug|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
344365|NCT01568918|Other|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
344366|NCT01568905|Other|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
344367|NCT01568905|Other|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
344368|NCT01568905|Other|High level nicotine cigarette|smoke the study cigarette exclusively for one week
344369|NCT01568892|Drug|Dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
344370|NCT01568892|Drug|Dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
344371|NCT01568879|Other|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
344372|NCT01568879|Other|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
344373|NCT01568866|Drug|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
344374|NCT01568866|Drug|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
344375|NCT01568866|Drug|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
344376|NCT01568853|Drug|Norepinephrine|Intravenously, 10 ug/min, 24 hours
344377|NCT01568853|Procedure|Open abdomen|IAH >=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
344378|NCT01568853|Other|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
344379|NCT01568853|Other|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
344380|NCT01568840|Other|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
344381|NCT01568840|Other|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
344382|NCT01568827|Dietary Supplement|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
344383|NCT01568814|Drug|Low volume PEG|low volume polyethylene glycol 2 liter one time
344384|NCT01568814|Drug|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
344385|NCT01568801|Behavioral|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
344386|NCT01568788|Biological|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
344387|NCT01568788|Biological|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
344388|NCT01568788|Biological|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
344389|NCT01568775|Drug|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
344390|NCT01568762|Drug|VAK694|Intravenous infusion
344391|NCT01568762|Drug|VAK694 placebo|Intravenous infusion
344392|NCT01568762|Drug|QAX576|Intravenous infusion
344393|NCT01568762|Drug|QAX576 placebo|Intravenous infusion
344394|NCT01568749|Drug|Paracetamol|Paracetamol
344395|NCT01568749|Drug|Paracetamol formulation 1|Paracetamol
344396|NCT01568749|Drug|Paracetamol Formulation 2|Paracetamol
344397|NCT01568749|Drug|Paracetamol formulation 3|Paracetamol
344398|NCT01568749|Drug|Paracetamol formulation 4|paracetamol
344399|NCT01568723|Genetic|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
344400|NCT01568684|Other|Citalopram|Treatment
344401|NCT01568645|Drug|Carvedilol|
344402|NCT01568645|Drug|Imatinib|
344403|NCT01568632|Drug|Imetelstat|
344404|NCT01568606|Device|Body Composition Analysis InBody Scale|"Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist."
344405|NCT01568593|Device|T2750|1 drop in each eye 3 to 6 times daily during 84 days
344406|NCT01568593|Device|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
344407|NCT01568580|Drug|GreenGene|Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus
344408|NCT01568567|Dietary Supplement|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
344409|NCT01568541|Drug|Regular toothpastes|One tooth brushing
344410|NCT01568541|Drug|Children's toothpastes|One tooth brushing
344411|NCT01568528|Drug|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
344412|NCT01568528|Drug|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
344413|NCT01568528|Other|Control|Participants who have no psychiatric diagnosis and will be controls for this project. These controls will NOT receive oxytocin or PBO. They will only receive psychiatric screening interview, MCCB Consensus Cogntive Battery assessment, urine drug screen, vision testing, and the three social cognition tasks.
344414|NCT01568515|Procedure|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention & control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
344415|NCT01568489|Drug|HL-009 Liposomal Gel|a semi-transparent red-color gel and is supplied as a laminated tube
344416|NCT01568476|Procedure|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
344417|NCT01568476|Procedure|Interneural|Sciatic nerve blockade at the site of bifurcation
344418|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
344419|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
344420|NCT01568450|Drug|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
344421|NCT01568437|Procedure|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
344422|NCT01568437|Other|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
344423|NCT01568424|Device|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
344424|NCT01568411|Drug|TD-1211|Period 1
344428|NCT01568372|Other|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
344429|NCT01568346|Other|MRI|Breast MRI
344430|NCT01568333|Drug|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
344431|NCT01568320|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
344432|NCT01568307|Drug|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
344433|NCT01568294|Drug|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
344434|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
344435|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
344436|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
344437|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
344438|NCT01568268|Drug|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
344439|NCT01568268|Drug|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
344440|NCT01568255|Drug|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
344441|NCT01568255|Drug|Placebo|placebo at 50,000IU for 8 weeks
344442|NCT01568242|Device|Phacoemlsification|Transurgical measurement of temperature
344443|NCT01568229|Drug|AMG 747|Three dose levels once-daily oral administration
344444|NCT01568229|Drug|Placebo|Once-daily oral administration
344445|NCT01568216|Drug|AMG 747|Three dose levels once-daily oral administration
344446|NCT01568216|Drug|Placebo|Once-daily oral administration
344447|NCT01568203|Drug|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
344448|NCT01568203|Drug|Placebo|Matching placebo control for AMG 579 at each dose level
344449|NCT01568190|Biological|AVANZ MITE|Immunotherapy Dermatophagoides mix
344450|NCT01568177|Behavioral|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
344451|NCT01568177|Other|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
344452|NCT01568177|Other|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
344453|NCT01568177|Other|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
344454|NCT01568177|Procedure|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
344455|NCT01568164|Device|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
344456|NCT01568151|Behavioral|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
344457|NCT01568151|Behavioral|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
344458|NCT01568138|Device|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
344459|NCT01568125|Drug|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
344460|NCT01568112|Drug|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
344461|NCT01568112|Drug|BG00012 placebo|Placebo matching BG00012
344462|NCT01568112|Drug|ASA|325 mg microcoated aspirin (ASA)
344463|NCT01568112|Drug|ASA placebo|Placebo matching aspirin
344464|NCT01568099|Biological|AFFITOPE® PD01A|s.c. injection
344465|NCT01568099|Other|Control|Untreated control
344466|NCT01568073|Drug|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
344467|NCT01568073|Drug|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
344468|NCT01568073|Drug|Placebo|200 mg
344469|NCT01568073|Drug|Levodopa|
344470|NCT01568073|Drug|Carbidopa|DOPA decarboxylase inhibitor
344472|NCT01568060|Other|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
344473|NCT01568047|Drug|Placebo|once-daily
344474|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
344475|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
344476|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
344477|NCT01568047|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
344478|NCT01568047|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
344479|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
344480|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
344481|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
344482|NCT01568034|Drug|Placebo|single-dose
344483|NCT01568034|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
344484|NCT01568034|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
344485|NCT01568021|Other|No Intervention|No intervention was administered in this study.
344486|NCT01568008|Drug|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
344487|NCT01567995|Drug|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
344488|NCT01567995|Drug|Vehicle (base cream)|Vehicle (base cream)
344489|NCT01567982|Device|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
344490|NCT01567969|Behavioral|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
344491|NCT01567969|Behavioral|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
344492|NCT01567956|Drug|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
344493|NCT01567956|Drug|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
344494|NCT01567943|Behavioral|Contingency Management|Behavioral reinforcement for alcohol abstinence
344495|NCT01567930|Drug|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
344496|NCT01567917|Procedure|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)~- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
344497|NCT01567904|Drug|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection"
344498|NCT01567891|Biological|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
344499|NCT01567865|Biological|Vaccine produced in existing facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the existing facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
344500|NCT01567865|Biological|Vaccine produced in new facility|Live attenuated Japanese encephalitis vaccine SA 14-14-2 (LJEVac) produced in the new facility by the Chengdu Institute of Biological Products (CDIBP), Chengdu, China
344501|NCT01567852|Drug|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
344502|NCT01567852|Drug|Methohexital|Methohexital (1.5mg/kg) will be given for induction
344503|NCT01567839|Procedure|Mandibular buccal Infiltration injection|
344504|NCT01567826|Drug|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.~Zocor, Lipitor [any dose] and Crestor [less than 40mg]"
344505|NCT01567826|Drug|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
344506|NCT01567800|Other|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
344507|NCT01567787|Radiation|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
344508|NCT01567787|Radiation|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
344509|NCT01567774|Drug|Atorvastatin|os, 20 mg, once per day, for 30 days
344510|NCT01567774|Drug|Rosuvastatin|os, 10 mg, once per day, for 30 days
344511|NCT01567748|Procedure|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
344512|NCT01567735|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
344513|NCT01567722|Genetic|DNA analysis|
344514|NCT01567722|Genetic|RNA analysis|
344515|NCT01567722|Genetic|gene expression analysis|
344516|NCT01567722|Genetic|polymorphism analysis|
344517|NCT01567722|Other|biologic sample preservation procedure|
344528|NCT01567657|Drug|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
344529|NCT01567657|Drug|Propofol|"50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.~< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved."
344530|NCT01567644|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
344531|NCT01567631|Procedure|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
344532|NCT01567631|Procedure|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
344533|NCT01567618|Drug|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;~Efficacy will be evaluated every three cycles."
344534|NCT01567618|Drug|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
344535|NCT01567605|Drug|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
344536|NCT01567605|Other|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
344537|NCT01567592|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
344538|NCT01567566|Other|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
344539|NCT01567553|Other|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :~baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
344540|NCT01567540|Drug|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
344541|NCT01567527|Drug|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
344542|NCT01567527|Drug|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
344543|NCT01567514|Procedure|Glass ionomer cement lining|Resin-modified glass ionomer lining
344544|NCT01567501|Drug|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
344545|NCT01567501|Drug|Levocetirizine Dihydrochloride|5 mg tablet once in a day
344546|NCT01567488|Drug|Everolimus|Everolimus 10mg/day
344547|NCT01567488|Drug|octreotide LAR|30 mg each 28 days
344548|NCT01567475|Drug|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
344549|NCT01567462|Device|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
344550|NCT01567462|Device|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
344551|NCT01567436|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
344552|NCT01567423|Drug|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
344553|NCT01567423|Drug|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:~tab/dose for children 5 to 14.9 kg (total 6 tabs)~tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
344554|NCT01567410|Other|e-learning|Braden scale and pressure ulcer classification
344555|NCT01567410|Other|traditional classroom training|Braden scale and pressure ulcer classification
344556|NCT01567384|Drug|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.~OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
344557|NCT01567371|Device|LiDCO rapid monitor|Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
344558|NCT01567358|Biological|Infliximab|100mg/vial
344559|NCT01567358|Biological|Infliximab|100mg/vial
344560|NCT01567345|Device|Implantable pump with continuous flow|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
344561|NCT01567345|Device|Implantable pump with programmable flow.|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
344562|NCT01567332|Device|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
344563|NCT01567332|Device|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).~6-week interval between two sessions."
344564|NCT01567319|Biological|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
344565|NCT01567319|Biological|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
344566|NCT01567319|Biological|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
344567|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
344568|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
344569|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
344570|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
344571|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
344572|NCT01567306|Biological|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
344573|NCT01567267|Behavioral|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
344574|NCT01567267|Behavioral|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
344575|NCT01567254|Behavioral|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
344576|NCT01567254|Behavioral|music ONLY|music. It will be equal in length to the auditory guided imagery disk
344577|NCT01567241|Other|clinical hypnosis or relaxation music|25 minute tape recording
344578|NCT01567228|Other|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
344579|NCT01567215|Procedure|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
344580|NCT01567215|Drug|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
344581|NCT01567215|Procedure|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
344582|NCT01567202|Procedure|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
344583|NCT01567202|Drug|Chemotherapy|Temozolomide(TMZ), 200mg·m^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
344584|NCT01567202|Radiation|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
344585|NCT01567202|Biological|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
344586|NCT01567202|Drug|blank placebo|Saline that has the same appearance with DC vaccine.
344587|NCT01567189|Behavioral|Cardiac rehabilitation|"Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.~Health education sessions and relaxation sessions: one per week.~Smoking and diet checking: as recommended by doctor."
344588|NCT01567189|Behavioral|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
344589|NCT01567176|Biological|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
344590|NCT01567163|Biological|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
346338|NCT01553578|Other|questionnaire administration|Ancillary studies
344591|NCT01567163|Drug|Docetaxel|docetaxel 75 milligrams/square meter (mg/m^2) intravenous infusion administered on Day 1 of each 3-week cycle
344592|NCT01567150|Device|Novel Dressing|Topical wound dressing
344593|NCT01567124|Drug|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
344594|NCT01567124|Drug|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
344595|NCT01567124|Drug|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
344596|NCT01567124|Drug|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
344597|NCT01567111|Procedure|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
344598|NCT01567098|Procedure|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
344599|NCT01567085|Drug|Eculizumab|
344600|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
344601|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
344602|NCT01567072|Drug|Placebo|Only placebo treatment instead of NSAID painkillers
344603|NCT01567059|Drug|tosedostat|Given PO
344604|NCT01567059|Drug|cytarabine|Given IV
344605|NCT01567059|Drug|decitabine|Given IV
344606|NCT01567046|Other|laboratory biomarker analysis|Correlative studies
344607|NCT01567033|Behavioral|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
344608|NCT01567020|Other|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
344609|NCT01567007|Behavioral|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
344610|NCT01567007|Behavioral|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
344611|NCT01567007|Behavioral|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
344612|NCT01566994|Behavioral|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
344613|NCT01566994|Behavioral|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
344614|NCT01566994|Behavioral|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
344615|NCT01566981|Procedure|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
344616|NCT01566968|Other|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
344617|NCT01566968|Other|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
344618|NCT01566968|Other|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
344619|NCT01566955|Procedure|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
344620|NCT01566942|Drug|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
344621|NCT01566942|Drug|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
344622|NCT01566929|Dietary Supplement|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
344623|NCT01566916|Procedure|Total Hip Arthroplasty|
344624|NCT01566890|Drug|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
344625|NCT01566890|Procedure|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
344626|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
344627|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
344628|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
344629|NCT01566877|Drug|AVI-7288|"Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
344630|NCT01566877|Other|Placebo|Normal Saline Solution (NSS)
344631|NCT01566864|Behavioral|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
344632|NCT01566864|Behavioral|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
344633|NCT01566864|Behavioral|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
344634|NCT01566851|Other|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
344635|NCT01566838|Drug|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
344636|NCT01566838|Drug|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.~Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.~The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
344637|NCT01566825|Drug|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
344638|NCT01566825|Drug|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
344639|NCT01566812|Behavioral|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
344640|NCT01566812|Behavioral|Usual care|Usual care applied in the hospital
344641|NCT01566799|Drug|Metformin|metformin 500 mg/day po for 24 weeks.
344642|NCT01566786|Drug|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
344643|NCT01566786|Drug|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
344644|NCT01566773|Drug|PT001 MDI|Administered as two puffs BID for 14 days
344645|NCT01566773|Drug|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
344646|NCT01566773|Drug|PT001 Placebo MDI|
344647|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
344648|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
344649|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
344650|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
344651|NCT01566760|Drug|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
344652|NCT01566747|Drug|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
344653|NCT01566734|Other|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
344654|NCT01566734|Other|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
344655|NCT01566721|Drug|Herceptin|Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
344656|NCT01566708|Behavioral|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
344657|NCT01566708|Behavioral|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
344658|NCT01566708|Behavioral|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
344659|NCT01566695|Drug|Oral Azacitidine|300mg daily, First 21 days of each 28-day cycle
344660|NCT01566695|Drug|Placebo|Placebo, First 21 days of each 28-day cycle
344661|NCT01566669|Drug|Parecoxib Sodium|Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
344662|NCT01566669|Drug|Normal saline|Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
344663|NCT01566656|Drug|total lymphoid irradiation and anti-thymocyte globulin|"TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.~ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.~Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.~GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"
344664|NCT01566643|Drug|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
344665|NCT01566643|Drug|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
344666|NCT01566643|Drug|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
344667|NCT01566630|Drug|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
344668|NCT01566630|Drug|RLX030|RLX030 1 mg/mL vials
344669|NCT01566617|Other|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
344670|NCT01566617|Other|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
344671|NCT01566604|Drug|NVA237|Delivered via a single dose dry powder inhaler
344672|NCT01566604|Drug|Placebo|Delivered via a single dose dry powder inhaler
344673|NCT01566591|Device|Deep TMS Treatment|24 TMS treatments over 6 weeks .
344674|NCT01566591|Device|Sham Treatment|24 TMS treatments over 6 weeks
344675|NCT01566578|Drug|Human recombinant epidermal growth factor|topical
344676|NCT01566578|Other|Placebo cream|Dermal cream without EGF
344677|NCT01566565|Drug|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
344678|NCT01566552|Drug|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
344679|NCT01566539|Drug|Intranasal Oxytocin (OT) 24 IU|Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
344680|NCT01566539|Drug|Intranasal Vasopressin (AVP)|Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
344681|NCT01566539|Drug|Intranasal Placebo|Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
344682|NCT01566539|Drug|Intranasal Vasopressin (AVP) 40 IU|Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
344683|NCT01566539|Drug|Lorazepam|Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
344684|NCT01566526|Drug|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
344773|NCT01565889|Drug|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
344685|NCT01566513|Behavioral|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
344686|NCT01566513|Behavioral|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
344687|NCT01566513|Behavioral|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
344688|NCT01566487|Drug|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
344689|NCT01566474|Drug|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
344690|NCT01566474|Drug|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
344691|NCT01566461|Device|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
344692|NCT01566461|Device|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
344693|NCT01566448|Drug|Ketamine|20mg/5ml swish and spit four times daily
344694|NCT01566435|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
344695|NCT01566435|Drug|Cisplatin|
344696|NCT01566435|Drug|Fluorouracil|
344697|NCT01566435|Radiation|Intensity modulated radiation therapy|
344698|NCT01566435|Drug|Cetuximab|
344699|NCT01566435|Procedure|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
344700|NCT01566422|Drug|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
344701|NCT01566409|Drug|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
344702|NCT01566409|Other|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
344703|NCT01566396|Device|A3F|A3F fractional RF treatments for facial wrinkles
344704|NCT01566383|Procedure|24-hr pH monitoring|"Visit 1~The following will be done:~A medical history including review of your current drugs;~Collection of demographic information;~A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;~24-hour pH testing will be done~Visit 2~You will return to the clinic 24 hours after the visit 1 and the following will occur:~The catheter will be removed from your nose; and~You will return the recording device"
344705|NCT01566370|Drug|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
344706|NCT01566370|Drug|Placebo|placebo
344707|NCT01566357|Other|Toothpaste|
344708|NCT01566357|Dietary Supplement|Milk|
344709|NCT01566357|Dietary Supplement|Fluoridated Milk|
344710|NCT01566357|Drug|Tooth Mousse|
344711|NCT01566357|Drug|MI Paste Plus|
344712|NCT01566357|Drug|Elmex Erosion Protection|
344713|NCT01566344|Other|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
344714|NCT01566331|Device|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
344715|NCT01566318|Behavioral|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
344716|NCT01566305|Dietary Supplement|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
344717|NCT01566305|Dietary Supplement|Buttermilk with added egg yolk|Buttermilk with added egg yolk
344718|NCT01566305|Dietary Supplement|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
344719|NCT01566305|Dietary Supplement|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
344720|NCT01566292|Drug|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
344721|NCT01566279|Drug|Everolimus|All patients will receive everolimus 10mg q.d.
344722|NCT01566266|Drug|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
344723|NCT01566266|Drug|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
344724|NCT01566253|Drug|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
344725|NCT01566253|Drug|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
344726|NCT01566240|Drug|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 160mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 & 36.
344727|NCT01566240|Drug|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, & 36.
344728|NCT01566240|Radiation|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
344729|NCT01566240|Drug|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
344730|NCT01566227|Other|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
344731|NCT01566214|Behavioral|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
344732|NCT01566201|Drug|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
344733|NCT01566201|Drug|placebo|water for injection
344734|NCT01566188|Dietary Supplement|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
344735|NCT01566188|Dietary Supplement|Placebo|6 months of supplementation with placebo
344736|NCT01566175|Device|Neovac coronary sinus reducer|reducer
344737|NCT01566162|Drug|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
344738|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
344739|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
344740|NCT01566136|Behavioral|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
344741|NCT01566123|Radiation|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
344742|NCT01566123|Radiation|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
344743|NCT01566110|Dietary Supplement|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
344744|NCT01566097|Device|Smoking Cessation Decision Aids|"The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.~The decision aids contained the followings, in proper Korean social and cultural context:~Information on the risk of continued smoking and benefits of cessation~Messages that address common misbeliefs regarding smoking cessation services and medications~Information on possible smoking cessation options, their efficacy, side effects, costs, etc.~The choices given in the decisions aid were:~Behavioral only~Nicotine replacement therapy~Bupropion~Varenicline"
344745|NCT01566084|Drug|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
344746|NCT01566084|Other|placebo|Placebo tablets are administered to maintain the low sodium condition.
344747|NCT01566071|Other|Assessment of drive abilities|
344748|NCT01566058|Device|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
344749|NCT01566058|Other|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
344750|NCT01566045|Procedure|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
344751|NCT01566045|Procedure|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
344752|NCT01566019|Procedure|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
344753|NCT01566006|Drug|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
344754|NCT01565993|Device|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
344755|NCT01565993|Device|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
344756|NCT01565980|Behavioral|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
344757|NCT01565980|Behavioral|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
344758|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
344759|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
344760|NCT01565928|Drug|MDV3100|4 x 40 mg capsules, orally, once per day
344761|NCT01565915|Device|Perlane-L|Perlane-L Injection in the midface
344762|NCT01565915|Other|Non-treatment|Non-treatment Arm
344763|NCT01565902|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
344764|NCT01565889|Drug|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
344765|NCT01565889|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
344766|NCT01565889|Drug|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
344767|NCT01565889|Drug|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
344768|NCT01565889|Drug|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
344769|NCT01565889|Drug|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
344770|NCT01565889|Drug|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
344771|NCT01565889|Drug|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
344772|NCT01565889|Drug|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
344774|NCT01565889|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
344775|NCT01565876|Device|"Minkal- Auxiliary device to alleviate backload"|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
344776|NCT01565863|Behavioral|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
344777|NCT01565850|Drug|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
344778|NCT01565850|Drug|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
344779|NCT01565850|Drug|COBI|COBI 150 mg tablet administered orally once daily
344780|NCT01565850|Drug|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
344781|NCT01565850|Drug|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
344782|NCT01565850|Drug|DRV Placebo|DRV placebo tablet administered orally once daily
344783|NCT01565850|Drug|COBI Placebo|COBI placebo tablet administered orally once daily
344784|NCT01565850|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
344785|NCT01565837|Drug|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
344786|NCT01565837|Radiation|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
344787|NCT01565824|Other|web-based support|
344788|NCT01565811|Procedure|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
344789|NCT01565798|Other|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
344790|NCT01565785|Behavioral|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
344791|NCT01565772|Radiation|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
344792|NCT01565772|Drug|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
344793|NCT01565772|Drug|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
344794|NCT01565759|Drug|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.~Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
344795|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
344796|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
344797|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
344798|NCT01565733|Drug|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
344799|NCT01565720|Drug|Isavuconazole|oral
344800|NCT01565720|Drug|Placebo|oral
344801|NCT01565720|Drug|Moxifloxacin|oral
344802|NCT01565707|Drug|Solifenacin Succinate Suspension|Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
344869|NCT01565083|Drug|Vinorelbine|A dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
344870|NCT01565070|Drug|Biofreeze|Use of Biofreeze ointment
344871|NCT01565070|Other|Placebo|Use of placebo ointment
344872|NCT01565057|Other|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
344803|NCT01565707|Drug|Placebo|Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
344804|NCT01565707|Behavioral|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
344805|NCT01565694|Drug|Solifenacin succinate|Oral suspension administered once a day via syringe.
344806|NCT01565681|Drug|ASP1240|infusion
344807|NCT01565681|Drug|Placebo|infusion
344808|NCT01565668|Drug|AC220|oral
344809|NCT01565655|Drug|peficitinib|oral
344810|NCT01565655|Drug|Placebo|oral
344811|NCT01565642|Behavioral|Goals of care decision support|Decision aid and care plan meeting
344812|NCT01565629|Behavioral|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
344813|NCT01565616|Drug|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Day -8 BU 3.2 mg/ kg/dose IV~Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV~Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV~Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV~Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV~Day -2 ATG 1.5mg/kg IV~Day -1 Rest~Day 0 Stem cell infusion~Graft Versus Host Disease (GVHD) Regimen~Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper~Day 0 Stem cell infusion~Day +1 Methotrexate 7.5 mg/m2 IV~Day +3 Methotrexate 7.5 mg/m2 IV~Day +6 Methotrexate 7.5 mg/m2 IV~Day+11 Methotrexate 7.5 mg/m2 IV"
344814|NCT01565590|Drug|Dexmedetomidine|0.2-1.5 mcg/kg/hr
344815|NCT01565590|Drug|propofol|5-80 mcg/kg/min
344816|NCT01565577|Biological|MenbVac|Blood test
344817|NCT01565564|Behavioral|Shared glycaemic control care within the local three-tier's antenatal care network|"Individualized dietary and physical activity consultation plus group diabetes education~Self blood glucose monitoring~Insulin therapy if indicated~Self blood glucose monitoring~Insulin therapy institutions if indicated;"
344818|NCT01565551|Other|N/A (Observational Study)|No Interventions: Observational Study
344819|NCT01565538|Drug|Erlotinib|150 mg Given orally
344820|NCT01565538|Drug|Pemetrexed|500mg/m2 Given IV
344821|NCT01565525|Behavioral|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
344822|NCT01565525|Behavioral|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
344823|NCT01565512|Drug|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
344824|NCT01565512|Drug|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
344825|NCT01565499|Drug|Nab-paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
344826|NCT01565486|Device|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
344827|NCT01565486|Device|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
344828|NCT01565460|Other|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
344829|NCT01565434|Other|CR1 impact|
344830|NCT01565408|Drug|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
344831|NCT01565408|Drug|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
344832|NCT01565395|Drug|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
344833|NCT01565395|Drug|placebo|Sterile preservative free 0.9% saline
344834|NCT01565382|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
344835|NCT01565369|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
344836|NCT01565356|Drug|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
344837|NCT01565343|Drug|florbetapir F 18|IV injection, 370MBq (10mCi)
344838|NCT01565330|Drug|florbetapir F 18|single dose IV injection
344910|NCT01564706|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
344911|NCT01564680|Other|placebo|normal saline
344839|NCT01565317|Other|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
344840|NCT01565304|Behavioral|POWER Through Choices|10-session group-based sexual education curriculum
344841|NCT01565291|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
344842|NCT01565278|Drug|Soybean oil (Standard treatment)|1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
344843|NCT01565278|Drug|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
344844|NCT01565265|Drug|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
344845|NCT01565265|Drug|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
344846|NCT01565252|Dietary Supplement|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
344847|NCT01565239|Device|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
344848|NCT01565213|Behavioral|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
344849|NCT01565213|Behavioral|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
344850|NCT01565213|Behavioral|CAU|Care as usual by the GPs
344851|NCT01565200|Drug|T-DM1|3.6 mg/kg iv every 3 weeks
344852|NCT01565200|Procedure|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
344853|NCT01565187|Behavioral|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
344854|NCT01565161|Behavioral|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:~In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.~Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.~Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
344855|NCT01565161|Behavioral|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.~Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
344856|NCT01565148|Drug|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
344857|NCT01565148|Drug|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
344858|NCT01565148|Drug|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
344859|NCT01565148|Drug|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
344860|NCT01565135|Behavioral|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:~Patient education regarding the importance of vaccination, including encouragement of vaccination for family members~Practice-based reminder/recall~Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
344861|NCT01565109|Drug|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
344862|NCT01565109|Radiation|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
344863|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
344864|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
344865|NCT01565096|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
344866|NCT01565096|Drug|Glimepiride|Glimepiride at individual dose
344867|NCT01565083|Drug|Pertuzumab|Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
344868|NCT01565083|Drug|Trastuzumab|Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
344873|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
344874|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
344875|NCT01565031|Procedure|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
344876|NCT01565018|Drug|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
344877|NCT01565018|Drug|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
344878|NCT01564992|Other|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
344879|NCT01564979|Drug|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
344880|NCT01564979|Drug|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
344881|NCT01564927|Device|Electroacupuncture to right LI4 and LI11 (ITO, EX-160)|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
344882|NCT01564927|Device|Sham Electroacupuncture to knee caps|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
344883|NCT01564927|Device|Sham electroacupuncture to LI4 and LI11|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
344884|NCT01564914|Drug|TRC105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
344885|NCT01564914|Drug|Bevacizumab|IV
344886|NCT01564888|Procedure|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
344887|NCT01564875|Drug|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
344888|NCT01564875|Drug|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
344889|NCT01564862|Drug|vortioxetine (Lu AA21004)|Lu AA21004 capsules
344890|NCT01564862|Drug|Duloxetine|Duloxetine capsules
344891|NCT01564862|Drug|Placebo|Placebo matching capsules
344892|NCT01564836|Behavioral|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
344893|NCT01564823|Drug|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
344894|NCT01564823|Drug|Metronidazole|Metronidazole 250 mg/8h 3 months
344895|NCT01564823|Drug|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
344896|NCT01564823|Drug|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
344897|NCT01564810|Drug|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
344898|NCT01564810|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
344899|NCT01564797|Behavioral|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
344900|NCT01564784|Drug|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
344901|NCT01564784|Drug|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m^2/day IV days 1-6 fludarabine30 mg/m^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
344902|NCT01564784|Drug|HIDAC (high dose cytarabine)|cytarabine 3 g/m^2 IV every 12 hours for up to 12 times
344903|NCT01564784|Drug|cytarabine and mitoxantrone|mitoxantrone 12 mg/m^2 IV days 1-3 cytarabine 200 mg/m^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
344904|NCT01564771|Other|Non Intervention|This Is A Non Interventional Study
344905|NCT01564758|Drug|Linezolid|"Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days~Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days~Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
344906|NCT01564745|Other|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
344907|NCT01564732|Device|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
344908|NCT01564732|Device|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
344909|NCT01564719|Behavioral|Holistic health|We conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
344914|NCT01564667|Behavioral|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
344915|NCT01564654|Device|iTotal KRS|Total Knee Replacement System
344916|NCT01564641|Device|iDuo G2|single comparator
344917|NCT01564628|Device|CADScor1|Acoustic recording
344918|NCT01564615|Device|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
344919|NCT01564615|Device|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
344920|NCT01564602|Device|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
344921|NCT01564576|Drug|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
344922|NCT01564563|Drug|standard therapy|Standard treatment of bleeding
344923|NCT01564563|Drug|placebo|Placebo
344924|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
344925|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
344926|NCT01564550|Drug|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
344927|NCT01564550|Drug|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
344928|NCT01564550|Other|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
344929|NCT01564550|Other|no diet|The subjects will ingest a non-restricted diet prior to the study day.
344930|NCT01564537|Drug|Ixazomib|Ixazomib capsules
344931|NCT01564537|Drug|Lenalidomide|Lenalidomide capsules
344932|NCT01564537|Drug|Dexamethasone|Dexamethasone tablets
344933|NCT01564537|Drug|Placebo|Ixazomib placebo-matching capsules
344934|NCT01564524|Procedure|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
344935|NCT01564511|Device|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
344936|NCT01564511|Other|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
344937|NCT01564498|Other|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
344938|NCT01564485|Procedure|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
344939|NCT01564485|Drug|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
344940|NCT01564472|Other|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
344941|NCT01564459|Drug|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
344942|NCT01564459|Drug|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
344943|NCT01564446|Other|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
344944|NCT01564433|Procedure|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
344945|NCT01564433|Procedure|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
345487|NCT01560247|Procedure|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
344946|NCT01564407|Drug|ICX‐RHY‐013|"Drug Dosing for Cohorts as follows:~Cohorts (N=4)~Safety Cohort 1:~Empty control no injection~Vehicle only (0.5 ml of HypoThermosol solution)~5 million cells / cm² , single administration at Day 0~5 million cells/ cm² , single administration at week 4~5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4~At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.~Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
344947|NCT01564394|Behavioral|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
344948|NCT01564394|Behavioral|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
344949|NCT01564381|Dietary Supplement|ResA|90mg of resveratrol conjugated with arginine.
344950|NCT01564381|Dietary Supplement|Resveratrol|90mg of resveratrol.
344951|NCT01564381|Dietary Supplement|Placebo|Made up of cellulose.
344952|NCT01564368|Procedure|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
344953|NCT01564355|Device|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
344954|NCT01564355|Drug|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
344955|NCT01564342|Procedure|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
344956|NCT01564329|Drug|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
344957|NCT01564303|Drug|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
344958|NCT01564290|Dietary Supplement|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
344959|NCT01564290|Drug|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
344960|NCT01564277|Drug|rasburicase|Given IV
344961|NCT01564277|Drug|allopurinol|Given PO
344962|NCT01564264|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
344963|NCT01564251|Drug|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
344964|NCT01564251|Drug|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m^2 and/or 500 mg/m^2.
344965|NCT01564238|Other|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
344966|NCT01564238|Other|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
344967|NCT01564225|Drug|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
344968|NCT01564212|Other|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
344969|NCT01564212|Other|laminar airflow with surgical drapes|
344970|NCT01564212|Other|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
344971|NCT01564212|Other|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
344972|NCT01564199|Drug|salmeterol / fluticasone propionate|100/1000 μg oral capsule
344973|NCT01564160|Dietary Supplement|Fish Oil|Source of omega-3 fatty acids.
344974|NCT01564160|Dietary Supplement|PCSO-524|Extract of Greenshell Mussel
344975|NCT01564147|Other|immediate therapeutic education|Access to the course of immediate therapeutic education
344976|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
344977|NCT01564134|Biological|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
344978|NCT01564121|Drug|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
344979|NCT01564108|Drug|Ranibizumab|Series of intravitreal injections of Ranibizumab
344980|NCT01564095|Drug|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
344981|NCT01564095|Drug|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
344982|NCT01564082|Device|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
347542|NCT01544179|Drug|Gefitinib|Investigational Drug
344983|NCT01564056|Drug|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.~(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
344984|NCT01564056|Drug|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:~i) 4 cycles of TC (docetaxel + cyclophosphamide)~Docetaxel 75 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~ii) 4 cycles of AC (doxorubicin + cyclophosphamide)~Doxorubicin 60 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~iii) 4 cycles of MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)~Myocet® 60 mg/m² IV infusion at hospital every 21 days~Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days~HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
344985|NCT01564043|Behavioral|website and pedometer|use of pedometer and website
344986|NCT01564030|Other|Empty|overnight fast
344987|NCT01564030|Other|Fluid|250mL apple juice
344988|NCT01564030|Other|Solid|breakfast
344989|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 1: 0.25 SPT"
344990|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 2: 0.5 SPT"
344991|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 3: 1 SPT"
344992|NCT01564017|Biological|Allergovac depot|"depot sterile suspension for subcutaneous injection~Increasing concentrations to reach the following maintenance doses:~Group 4: 2 SPT"
344993|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.~Increasing concentrations to reach the following maintenance doses:~Group 5: 4 SPT"
344994|NCT01564017|Biological|Allergovac depot|"Sterile suspension for subcutaneous injection.~Same number of administration as the active groups"
344995|NCT01564004|Other|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
344996|NCT01563991|Procedure|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
344997|NCT01563991|Procedure|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
344998|NCT01563978|Drug|fostamatinib|fostamatinib 100 mg twice daily
344999|NCT01563978|Drug|placebo|placebo
345000|NCT01563965|Dietary Supplement|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
345001|NCT01563965|Other|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
345002|NCT01563952|Device|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
345003|NCT01563952|Device|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
345004|NCT01563952|Device|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
345005|NCT01563952|Device|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
345006|NCT01563939|Drug|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.~Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
345007|NCT01563926|Drug|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
345008|NCT01563913|Drug|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
345009|NCT01563913|Drug|Placebo|Sugar Pill, taken for 1.5 years
345010|NCT01563900|Device|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
345011|NCT01563900|Device|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
345012|NCT01563887|Behavioral|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
345013|NCT01563887|Behavioral|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
345014|NCT01563861|Genetic|RNA analysis|
345015|NCT01563861|Genetic|gene expression analysis|
345016|NCT01563861|Other|immunohistochemistry staining method|
345017|NCT01563861|Other|laboratory biomarker analysis|
345056|NCT01563523|Drug|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
345173|NCT01562626|Drug|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
345174|NCT01562587|Drug|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
345018|NCT01563848|Procedure|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
345019|NCT01563848|Procedure|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
345020|NCT01563848|Procedure|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
345021|NCT01563835|Drug|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
345022|NCT01563835|Drug|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
345023|NCT01563822|Biological|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
345024|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
345025|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
345026|NCT01563783|Procedure|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
345027|NCT01563783|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
345028|NCT01563783|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
345029|NCT01563770|Dietary Supplement|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
345030|NCT01563770|Dietary Supplement|Placebo|3 placebo capsules, twice daily for four consecutive weeks
345031|NCT01563744|Procedure|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
345032|NCT01563744|Procedure|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
345033|NCT01563731|Drug|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
345034|NCT01563718|Drug|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
345035|NCT01563705|Procedure|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
345036|NCT01563705|Procedure|Manual dexterity assessment|Purdue pegboard test
345037|NCT01563653|Procedure|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
345038|NCT01563640|Other|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
345039|NCT01563640|Other|washing|normal washing of school uniforms, without permethrin insecticide impregnation
345040|NCT01563627|Other|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
345041|NCT01563627|Device|Magnetic Resonance Imaging|
345042|NCT01563614|Radiation|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
345043|NCT01563614|Drug|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
345044|NCT01563614|Drug|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
345045|NCT01563601|Drug|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
345046|NCT01563601|Drug|Carboplatin and Etoposide|"Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
345047|NCT01563588|Behavioral|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
345048|NCT01563575|Other|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
345049|NCT01563562|Drug|Bardoxolone Methyl|Oral, Single dose
345050|NCT01563536|Drug|ABT-267|Tablet
345051|NCT01563536|Drug|ABT-450|Tablet
345052|NCT01563536|Drug|ABT-333|Tablet
345053|NCT01563536|Drug|Ritonavir|Capsule
345054|NCT01563536|Drug|Ribavirin|Tablet
345055|NCT01563523|Drug|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
345057|NCT01563510|Procedure|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
345058|NCT01563510|Procedure|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
345059|NCT01563497|Drug|PF-05089771|Oral dispersion TS formulation- fasted
345060|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fasted
345061|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fed
345062|NCT01563471|Drug|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
345063|NCT01563471|Drug|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
345064|NCT01563458|Drug|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
345065|NCT01563458|Drug|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
345066|NCT01563458|Drug|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
345067|NCT01563445|Drug|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
345068|NCT01563445|Drug|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
345069|NCT01563432|Drug|Feburic®|80 mg*1 tablet
345070|NCT01563432|Drug|TMX-67|40 mg*2 tablets
345071|NCT01563419|Device|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan~Material: Polypropylene with polycarbonate lens"
345072|NCT01563406|Other|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
345073|NCT01563406|Other|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
345074|NCT01563406|Drug|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
345075|NCT01563406|Drug|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
345076|NCT01563393|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
345077|NCT01563393|Other|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
345078|NCT01563380|Biological|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
345079|NCT01563367|Drug|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
345080|NCT01563367|Drug|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
345081|NCT01563354|Drug|Pasireotide LAR|60 mg i.m. injected once every 28 days
345082|NCT01563354|Drug|Everolimus|10 mg p.o. daily
345083|NCT01563354|Drug|Pasireotide LAR + Everolimus|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
345084|NCT01563341|Device|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
345085|NCT01563328|Drug|DTG|50 mg q24h
345086|NCT01563328|Drug|BCV|800 mg q8h
345087|NCT01563328|Drug|TVR|750 mg q8h
345088|NCT01563302|Drug|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
345089|NCT01563289|Drug|Ibuprofen|3 times a day
345090|NCT01563289|Drug|Placebo|3 times a day
345091|NCT01563263|Biological|IC43|100 mcg
345092|NCT01563263|Drug|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
345167|NCT01562691|Procedure|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
345168|NCT01562678|Drug|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
347543|NCT01544179|Drug|Placebo|Matching placebo as comparator
345093|NCT01563250|Device|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
345094|NCT01563237|Device|MIDI Arrow|Implantation of MIDI Arrow
345095|NCT01563224|Drug|Baclofen 10mg|Baclofen 10mg single dose po
345096|NCT01563224|Drug|Baclofen 60mg|Baclofen 60mg single dose po
345097|NCT01563224|Drug|placebo|placebo
345098|NCT01563198|Behavioral|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
345099|NCT01563185|Drug|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
345100|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
345101|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
345102|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
345103|NCT01563172|Other|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
345104|NCT01563159|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
345105|NCT01563146|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
345106|NCT01563133|Procedure|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
345107|NCT01563133|Device|nCLE|needle-based Confocal Laser Endomicroscopy
345108|NCT01563120|Drug|metformin|metformin up to 2550mg per day.
345109|NCT01563120|Drug|glybenclamide|glybenclamide up to 20mg per day.
345110|NCT01563107|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
345111|NCT01563107|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
345112|NCT01563107|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
345113|NCT01563081|Drug|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
345114|NCT01563081|Drug|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
345115|NCT01563068|Drug|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
345116|NCT01563055|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
345117|NCT01563055|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
345118|NCT01563042|Drug|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
345119|NCT01563042|Drug|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
345120|NCT01563029|Drug|Fluticasone Furoate|current asthma medicine
345121|NCT01563029|Drug|Fluticasone Propionate|Fluticasone propionate
345122|NCT01563029|Drug|Placebo|placebo
345123|NCT01563016|Dietary Supplement|glucose drink|participants will receive a drink rich in glucose
345124|NCT01563003|Other|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
345125|NCT01563003|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
345126|NCT01562990|Drug|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
345127|NCT01562977|Drug|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
345169|NCT01562678|Drug|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
345170|NCT01562652|Device|AposTherapy (All Phases of Step-cycle {APOS} system, APOS—Medical and Sports Technologies Ltd. Herzliya, Israel)|
345171|NCT01562626|Drug|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
345172|NCT01562626|Drug|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
347544|NCT01544179|Drug|Pemetrexed|Chemotherapy (concomitant therapy)
345128|NCT01562964|Behavioral|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
345129|NCT01562964|Behavioral|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
345130|NCT01562951|Drug|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
345131|NCT01562951|Drug|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
345132|NCT01562938|Drug|Placebo|Placebo
345133|NCT01562938|Drug|MEDI-557|MEDI-557 low-dose
345134|NCT01562938|Drug|MEDI-557|MEDI-557 high-dose
345135|NCT01562925|Dietary Supplement|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
345136|NCT01562925|Dietary Supplement|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
345137|NCT01562925|Dietary Supplement|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
345138|NCT01562912|Device|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
345139|NCT01562912|Device|PVAC Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
345140|NCT01562899|Drug|MEK162|Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
345141|NCT01562899|Drug|AMG 479|Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
345142|NCT01562886|Drug|Rilpivirine|Rilpivirine 26mg
345143|NCT01562873|Drug|Ruxolitinib|
345144|NCT01562860|Procedure|Pronator Teres Release|Surgical release of median nerve compression
345145|NCT01562860|Procedure|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
345146|NCT01562860|Procedure|dual compression release|both procedures will be done on the same day
345147|NCT01562860|Procedure|median nerve release only|only the carpal tunnel compression is released
345148|NCT01562847|Drug|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
345149|NCT01562834|Drug|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
345150|NCT01562834|Drug|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
345151|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
345152|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
345153|NCT01562821|Drug|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
345154|NCT01562808|Drug|Aripiprazole|single oral administration of aripiprazole
345155|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
345156|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
345157|NCT01562795|Drug|corticosteroids|corticosteroids plus artificial tear substitute
345158|NCT01562795|Drug|artificial tear substitute|artificial tear substitute alone
345159|NCT01562782|Other|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
345160|NCT01562756|Other|HVLA-SM|High velocity, low amplitude spinal manipulation
345161|NCT01562743|Drug|SPM 962|Tansdermal patch
345162|NCT01562717|Drug|Ibuprofen|3 times a day
345163|NCT01562717|Drug|Placebo|3 times a day
345164|NCT01562704|Drug|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
345165|NCT01562691|Procedure|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
345166|NCT01562691|Procedure|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
345175|NCT01562587|Drug|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
345176|NCT01562574|Drug|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
345177|NCT01562574|Drug|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
345178|NCT01562561|Drug|repaglinide|2 mg at each main meal
345179|NCT01562561|Drug|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
345180|NCT01562548|Drug|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
345181|NCT01562548|Drug|Placebo|no active ingredient
345182|NCT01562535|Other|Pronation|"In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished."
345183|NCT01562535|Other|Supination|"The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain."
345184|NCT01562522|Other|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
345185|NCT01562509|Other|Implementation tools|"Professionals receive audit & feedback~Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.~Standardization of diagnostic and evaluative request forms and reports for clinicians.~Supporting material for standardizing the procedure for multidisciplinary meetings."
345186|NCT01562509|Other|Standard intervention|Standard intervention consists of audit&feedback
345187|NCT01562496|Behavioral|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
345188|NCT01562483|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
345189|NCT01562483|Drug|Placebo|Identical to the Namisol arm.
345190|NCT01562470|Other|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
345191|NCT01562457|Drug|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
345192|NCT01562444|Other|Blood draw|Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
345193|NCT01562431|Other|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
345194|NCT01562418|Behavioral|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
345195|NCT01562418|Behavioral|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
345196|NCT01562418|Behavioral|control group|general instructions no intervention
345197|NCT01562405|Drug|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
345198|NCT01562405|Drug|Lenalidomide|15 to 25 mg days 1-21, given orally
345199|NCT01562405|Drug|Dexamethasone|40 mg days 1,8,15,22; given orally
345200|NCT01562405|Drug|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
345201|NCT01562392|Dietary Supplement|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
345202|NCT01562392|Dietary Supplement|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
345203|NCT01562379|Dietary Supplement|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
345204|NCT01562379|Dietary Supplement|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
345205|NCT01562379|Dietary Supplement|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
345206|NCT01562379|Dietary Supplement|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
345207|NCT01562366|Device|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
345208|NCT01562366|Procedure|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
345209|NCT01562340|Other|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
345210|NCT01562340|Other|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
345211|NCT01562327|Drug|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
345212|NCT01562314|Drug|GWP42003|1 to 5 50 mg capsules taken BID
345213|NCT01562314|Drug|Placebo|1 to 5 matching capsules taken BID
345214|NCT01562301|Drug|Carboplatin|AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
345215|NCT01562301|Drug|Docetaxel|75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
345216|NCT01562301|Drug|Anvirzel|"Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.~Expansion Cohort Starting Dose: Maximum tolerated dose from"
345262|NCT01561976|Drug|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
345217|NCT01562301|Behavioral|Questionnaires|Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
345218|NCT01562288|Genetic|DNA analysis|
345219|NCT01562288|Genetic|gene expression analysis|
345220|NCT01562288|Genetic|polymerase chain reaction|
345221|NCT01562288|Other|enzyme-linked immunosorbent assay|
345222|NCT01562288|Other|laboratory biomarker analysis|
345223|NCT01562275|Drug|Ipatasertib|multiple doses
345224|NCT01562275|Drug|Cobimetinib|multiple doses
345225|NCT01562249|Other|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
345226|NCT01562249|Other|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
345227|NCT01562249|Other|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
345228|NCT01562223|Other|motexafin gadolinium|
345229|NCT01562210|Drug|Olaparib|"Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID."
345230|NCT01562210|Drug|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
345231|NCT01562210|Radiation|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
345232|NCT01562197|Drug|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
345233|NCT01562197|Drug|Axitinib plus Lomustine|Lomustine 90mg/m²
345234|NCT01562184|Device|Sham tDCS device|Sham tDCS
345235|NCT01562184|Device|Soterix tDCS device|Active tDCS
345236|NCT01562171|Other|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
345237|NCT01562171|Other|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
345238|NCT01562158|Procedure|standard therapy|Standard treatment of bleeding
345239|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
345240|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
345241|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
345242|NCT01562158|Drug|placebo|Placebo
345243|NCT01562145|Procedure|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
345244|NCT01562132|Drug|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
345245|NCT01562132|Drug|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
345246|NCT01562106|Procedure|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
345247|NCT01562093|Drug|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
345248|NCT01562093|Drug|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
345249|NCT01562080|Dietary Supplement|Armolipid Plus|one tablet per day during 12 weeks
345250|NCT01562080|Dietary Supplement|placebo|one tablet per day during 12 weeks
345251|NCT01562067|Device|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
345252|NCT01562041|Drug|Ranolazine|twice per day for 14 days
345253|NCT01562028|Drug|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
345254|NCT01562028|Drug|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
345255|NCT01562015|Drug|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
345256|NCT01562002|Procedure|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
345257|NCT01561989|Dietary Supplement|cholecalciferol|Given PO
345258|NCT01561989|Other|questionnaire administration|Ancillary studies
345259|NCT01561989|Biological|trivalent influenza vaccine|Given IM
345260|NCT01561976|Drug|Metformin hydrochloride prolonged release|1000mg in fasting state
345261|NCT01561976|Drug|metformin hydrochloride prolonged release|1000mg in fed state
345263|NCT01561963|Drug|Apremilast|"Each subject will receive the following 3 treatments in the same fixed sequence during the study (the study days are numbered sequentially across all 3 periods):~A single oral dose of 30 mg apremilast on Day 1 in Period 1;~A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3."
345264|NCT01561963|Drug|Rifampin|"A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;~Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3."
345265|NCT01561950|Drug|eptacog alfa (activated)|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
345266|NCT01561950|Drug|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
345267|NCT01561950|Drug|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
345268|NCT01561937|Drug|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
345269|NCT01561937|Drug|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
345270|NCT01561937|Drug|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
345271|NCT01561924|Drug|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
345272|NCT01561911|Drug|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
345273|NCT01561898|Drug|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
345274|NCT01561885|Other|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
345275|NCT01561859|Behavioral|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
345276|NCT01561859|Behavioral|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
345277|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
345278|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
345279|NCT01561833|Drug|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
345370|NCT01561131|Dietary Supplement|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
347545|NCT01544179|Drug|Cisplatin|Chemotherapy (concomitant therapy)
345280|NCT01561820|Behavioral|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5[HRmax-HRrest]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
345281|NCT01561807|Drug|VX-787|
345282|NCT01561807|Drug|Placebo|
345283|NCT01561794|Drug|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.~2) Hospital-acquired pneumonia (HAP): For the patient with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
345284|NCT01561781|Drug|Digoxin|Oral tablets 0.25mg, single dose
345285|NCT01561781|Drug|Vandetanib|Oral tablets, 300 mg, single dose
345286|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
345287|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
345288|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
345289|NCT01561768|Biological|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
345290|NCT01561768|Biological|cTIV|Preconfigured dose; intramuscular injection, deltoid
345291|NCT01561755|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
345292|NCT01561755|Drug|Placebo|Placebo - 2gr/kg over 2 days of saline
345293|NCT01561742|Drug|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
345294|NCT01561742|Drug|Placebo|EquivalentPlacebo will be given
345295|NCT01561729|Device|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
345296|NCT01561729|Radiation|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
345297|NCT01561716|Device|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
345298|NCT01561703|Drug|Antibiotic|One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
345299|NCT01561690|Drug|ARRY-502, CRTh2 antagonist; oral|multiple dose, single schedule
345300|NCT01561690|Drug|Placebo; oral|matching placebo
345301|NCT01561677|Device|Continuous Positive Airway pressure-RESPIRONICS|obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
345302|NCT01561677|Device|Sham Continuous Positive Airway pressure-RESPIRONICS|inefficient Continuous Positivie Airway pressure
345303|NCT01561664|Other|muscle and fat biopsy|muscle and fat biopsy
345304|NCT01561651|Other|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
345305|NCT01561638|Procedure|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
345306|NCT01561638|Procedure|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
345307|NCT01561638|Procedure|Sham|will receive puncture for 4 minutes
345308|NCT01561625|Other|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
345309|NCT01561612|Behavioral|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
345310|NCT01561599|Drug|BB3|Daily intravenous administration of 2mg/kg for 4 days
345311|NCT01561599|Drug|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
345312|NCT01561586|Drug|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
345371|NCT01561131|Dietary Supplement|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
345483|NCT01560273|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
345313|NCT01561586|Drug|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy~Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).~Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.~External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
345314|NCT01561573|Device|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
345315|NCT01561560|Device|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
345316|NCT01561560|Device|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
345317|NCT01561547|Behavioral|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
345318|NCT01561547|Dietary Supplement|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
345319|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
345320|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
345321|NCT01561521|Drug|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
345322|NCT01561508|Drug|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
345323|NCT01561508|Dietary Supplement|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
345324|NCT01561495|Radiation|Proton Therapy|
345325|NCT01561482|Drug|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
345326|NCT01561482|Drug|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
345327|NCT01561469|Drug|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
345328|NCT01561469|Drug|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
345329|NCT01561456|Drug|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
345330|NCT01561456|Drug|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
345331|NCT01561430|Drug|LY2886721|
345332|NCT01561430|Drug|Placebo|
345333|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
345334|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
345335|NCT01561404|Drug|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
345336|NCT01561391|Drug|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
345337|NCT01561391|Drug|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
345338|NCT01561391|Other|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
345339|NCT01561391|Drug|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
345340|NCT01561378|Drug|Aspart insulin|40 IU of aspart insulin will be administered intranasally using a mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
345341|NCT01561378|Drug|Placebo|200 microliters of normal saline will be administered per nostril using a mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
345342|NCT01561365|Behavioral|Ottawa ankle rules|Ottawa ankle rules implementation
345343|NCT01561352|Drug|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
345344|NCT01561326|Behavioral|Cognitive-affective barriers counseling|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
345345|NCT01561326|Behavioral|Cognitive-affective barriers counseling via brochure|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
345346|NCT01561326|Behavioral|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
345347|NCT01561313|Biological|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
345348|NCT01561300|Other|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
345349|NCT01561300|Other|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.~Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.~On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
345350|NCT01561287|Procedure|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
345351|NCT01561287|Procedure|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
345352|NCT01561274|Drug|2 ml bupivacaine|2 ml bupivacaine
345353|NCT01561274|Drug|1.5 ml bupivicaine.|1.5 ml bupivicaine.
345354|NCT01561261|Other|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
345355|NCT01561248|Drug|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
345356|NCT01561235|Other|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
345357|NCT01561222|Drug|Calcitriol|0.25 ug per day for one year
345358|NCT01561222|Drug|placebo|one pill per day
345359|NCT01561209|Drug|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
345360|NCT01561209|Drug|Placebo|"Placebo pill~1 before bedtime"
345361|NCT01561196|Procedure|arterial catheterisation|arterial catheterisation in Arterial Radialis
345362|NCT01561183|Procedure|Indirect pulp capping (IPC)|"Procedure: IPC~The IPC will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~incomplete removal of carious tissue from the cavity walls~indirect pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
345363|NCT01561183|Procedure|Direct pulp capping (DPC)|"Procedure: DPC~The DPC will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~complete removal of carious tissue from the cavity walls result in pulp exposure~preparation of clot-free pulpal mound~direct pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
345364|NCT01561183|Procedure|Miniature pulpotomy (MP)|"Procedure: MP~The MP will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~complete removal of carious tissue from the cavity walls result in pulp exposure~intentionally removal of pulp horn (≈1 mm)~preparation of clot-free pulpal mound~direct pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
345365|NCT01561183|Procedure|Full pulpotomy (FP)|"Procedure: FP~The FP will be performed as follow:~Anesthesia~isolation the tooth~access to the lesion~complete removal of carious tissue from the cavity walls result in pulp exposure~pulpotomy~preparation of clot-free pulpal mound~direct pulp capping with ≈2 mm layer calcium enriched mixture cement~permanent filling with sandwich technique"
345366|NCT01561170|Device|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
345367|NCT01561170|Device|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
345368|NCT01561131|Dietary Supplement|Whey protein|45g protein/d; Dosage 3x15g protein daily
345369|NCT01561131|Dietary Supplement|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
345372|NCT01561118|Other|Bicycle-Ergometer Training|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).~In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis."
345373|NCT01561105|Other|IMPACT|IMPACT is a collaborative care management program for late-life depression
345374|NCT01561092|Drug|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
345375|NCT01561092|Drug|Placebo|Tablets
345376|NCT01561079|Drug|Buprenorphine|Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
345377|NCT01561066|Procedure|Autologous platelet-rich fibrin glue (PRFG)|"Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.~PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
345378|NCT01561066|Drug|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
345379|NCT01561053|Biological|Albumin 5%|Therapeutic plasma exchange with human albumin 5%
345380|NCT01561053|Biological|Albumin 20%|Low volume plasma exchange with human albumin 5%
345381|NCT01561053|Biological|Immunoglobulin|Intravenous human immunoglobulin 5%
345382|NCT01561040|Dietary Supplement|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
345383|NCT01561027|Drug|CNV1014802|Administered as specified in treatment arm.
345384|NCT01561027|Drug|Placebo|Administered as specified in treatment arm
345385|NCT01561014|Drug|erlotinib hydrochloride|Given PO
345386|NCT01561014|Drug|oxaliplatin|Given IV
345387|NCT01561014|Drug|fluorouracil|Given IV
345388|NCT01561014|Radiation|radiation therapy|Undergo radiotherapy
345389|NCT01561014|Procedure|conventional surgery|Undergo surgical resection
345390|NCT01561014|Other|immunohistochemistry staining method|Correlative study
345391|NCT01561014|Procedure|positron emission tomography|Correlative study
345392|NCT01561014|Procedure|computed tomography|Correlative study
345393|NCT01561014|Procedure|laboratory biomarker analysis|Correlative study
345394|NCT01561014|Genetic|gene expression analysis|Correlative study
345395|NCT01561014|Radiation|fludeoxyglucose F 18|Undergo F18 PET and CT scan
345396|NCT01561001|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
345397|NCT01560988|Drug|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
345398|NCT01560988|Dietary Supplement|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
345399|NCT01560975|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
345400|NCT01560962|Drug|povidone iodine|
345401|NCT01560962|Drug|Povidone-Iodine|
345402|NCT01560962|Drug|Azithromycin|
345403|NCT01560962|Drug|tobramycin-dexmethasone|
345404|NCT01560949|Drug|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
345405|NCT01560949|Drug|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
345406|NCT01560949|Drug|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
345407|NCT01560949|Drug|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
345408|NCT01560949|Radiation|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
345409|NCT01560923|Biological|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
345410|NCT01560923|Biological|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
345411|NCT01560923|Other|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
345412|NCT01560897|Drug|Oral C13|Ingestion of C13 and follow up of the ureogenesis
345413|NCT01560884|Drug|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
345414|NCT01560884|Drug|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
345415|NCT01560884|Drug|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
345416|NCT01560884|Drug|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
345446|NCT01560572|Drug|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
345482|NCT01560286|Biological|BMN 165 (rAvPAL-PEG)|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
345417|NCT01560871|Behavioral|High-intensity IMT plus walking|"The IMT intensity will be set at 60% of PImax which will be adjusted weekly and nose clip will be used. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.~For the walking program, each participant will be given a pedometer and a heart rate monitor so he/she can track daily step counts and heart rate during the study. The walking program will consist of walking every day at an intensity of hard to somewhat hard on the Rating of Perceived Exertion (RPE) scale. Participants will begin walking at least 15 minutes twice a day for 7 days a week and eventually progress to 45-50 minutes a day by the end of the six weeks."
345418|NCT01560871|Behavioral|Low-intensity IMT plus walking|"The IMT training is about 15-20 minutes. Both groups will need to come in once a week for 15 to 20 minutes to probably readjust the IMT training intensity on the breathing device.~For the walking program, each participant will be given a pedometer and a heart rate monitor so he/she can track daily step counts and walking heart rate during the study. The walking program will consist of walking every day at an intensity of hard to somewhat hard on the Rating of Perceived Exertion (RPE) scale. Participants will begin walking at least 15 minutes twice a day for 7 days a week and eventually progress to 45-50 minutes a day by the end of the six weeks."
345419|NCT01560845|Procedure|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
345420|NCT01560845|Procedure|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
345421|NCT01560819|Drug|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
345422|NCT01560806|Other|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.~Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
345423|NCT01560793|Biological|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
345424|NCT01560780|Drug|Prasugrel|one 10 mg tablet by mouth daily
345425|NCT01560780|Drug|Placebo|placebo similar in appearance to prasugrel
345426|NCT01560767|Drug|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
345427|NCT01560767|Drug|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
345428|NCT01560754|Drug|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
345429|NCT01560741|Device|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
345430|NCT01560741|Device|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
345431|NCT01560728|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
345432|NCT01560715|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
345433|NCT01560702|Drug|Epinephrine|10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
345434|NCT01560702|Biological|Blood|5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
345435|NCT01560689|Drug|Budesonide/formoterol|800 µg/j twice a day, every day
345436|NCT01560689|Drug|Placebo|Twice a day, every day
345437|NCT01560676|Behavioral|HEALTH[e]TEEN|8 lessons over 6-8 weeks
345438|NCT01560676|Behavioral|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
345439|NCT01560663|Drug|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
345440|NCT01560650|Device|CRRT|Difference dose of CRRT
345441|NCT01560637|Drug|UT-15C (treprostinil diethanolamine)|UT-15C sustained release oral tablet for three times daily administration
345442|NCT01560624|Drug|Treprostinil Diolamine|Active
345443|NCT01560624|Drug|Placebo|Placebo
345444|NCT01560611|Device|Near infrared spectroscopy|
345445|NCT01560585|Drug|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
345447|NCT01560559|Procedure|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.~This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
345448|NCT01560546|Drug|Testosterone|50 mg/dose/day for 24 weeks
345449|NCT01560546|Drug|Placebo|placebo on the skin for 24 weeks
345450|NCT01560533|Behavioral|Interviews|Interviews will be done with patients
345451|NCT01560520|Behavioral|Physical activity|Observation only
345452|NCT01560507|Drug|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
345453|NCT01560507|Drug|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
345454|NCT01560507|Drug|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
345455|NCT01560494|Other|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
345456|NCT01560481|Drug|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
345457|NCT01560481|Drug|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
345458|NCT01560481|Drug|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
345459|NCT01560481|Drug|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
345460|NCT01560481|Drug|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
345461|NCT01560481|Drug|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
345462|NCT01560481|Drug|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
345463|NCT01560468|Drug|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
345464|NCT01560455|Device|single stent|single stent
345465|NCT01560455|Device|two stent|culotte
345466|NCT01560442|Drug|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
345467|NCT01560429|Procedure|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
345468|NCT01560429|Procedure|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
345469|NCT01560416|Drug|Fulvestrant|
345470|NCT01560416|Drug|Ganetespib|
345471|NCT01560403|Drug|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
345472|NCT01560390|Drug|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
345473|NCT01560390|Drug|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
345474|NCT01560377|Device|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
345475|NCT01560364|Other|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
345476|NCT01560351|Device|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
345477|NCT01560325|Drug|CKD-516 inj.|CKD-516: 3.3~13mg/m2/day
345478|NCT01560312|Device|Renal denervation (Symplicity® Catheter System™)|4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
345479|NCT01560299|Drug|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
345480|NCT01560299|Drug|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
345481|NCT01560299|Drug|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
345488|NCT01560234|Drug|AZD8848|Single dose, oral inhalation (nebuliser solution)
345489|NCT01560234|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
345490|NCT01560221|Behavioral|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
345491|NCT01560221|Drug|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
345492|NCT01560221|Drug|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
345493|NCT01560195|Drug|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
345494|NCT01560195|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
345495|NCT01560195|Drug|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
345496|NCT01560182|Genetic|OTL-200 Gene Therapy|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA
345497|NCT01560143|Drug|Tigecycline|100 mg IV as a single infusion over 30 minutes
345498|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
345499|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
345500|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
345501|NCT01560117|Drug|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
345502|NCT01560104|Drug|Veliparib|
345503|NCT01560104|Drug|Carboplatin|
345504|NCT01560104|Drug|paclitaxel|
345505|NCT01560104|Drug|placebo|
345506|NCT01560091|Drug|silodosin|8mg PO Qday
345507|NCT01560091|Procedure|Extra-corporeal shock wave lithotripsy|ESWL
345508|NCT01560091|Drug|Tamsulosin|Tamsulosin 0.4mg PO Qday
345509|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
345510|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
345511|NCT01560052|Drug|methylprednisolone|"Original Cohort:~Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines~Low Dose Cohort:~Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
345512|NCT01560052|Drug|Placebo|"Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
345513|NCT01560039|Device|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
345514|NCT01560039|Other|Neurofeedback|EEG neurofeedback based on the primary motor cortex
345515|NCT01560039|Other|Sham neurofeedback|Sham EEG neurofeedback
345516|NCT01560026|Procedure|surgery|endometrial cancer with or without oophorectomy
345517|NCT01560013|Drug|Naltrexone|Naltrexone, oral 50 mg per day.
345518|NCT01560000|Dietary Supplement|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
345519|NCT01559987|Other|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
345520|NCT01559987|Other|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
345521|NCT01559987|Other|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
345522|NCT01559974|Drug|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
345523|NCT01559974|Drug|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
345524|NCT01559961|Drug|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
345591|NCT01559337|Procedure|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
345592|NCT01559324|Device|ECT|Bifrontal ECT, low dosage
345593|NCT01559324|Device|ECT|Right unilateral electrode position, high dosage
345594|NCT01559311|Device|CRT-P OFF|CRT Pacemaker
345525|NCT01559948|Behavioral|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will complete 4 different exercises daily: one in supine, one in standing, one in quadruped, and one in a side-bridge position. The dosage for each exercise is 20 reps with an 8 second hold. In supine, the first exercise is the abdominal drawing-in maneuver. In standing, the first exercise is the abdominal drawing-in maneuver. In quadruped, the first exercise is alternating arm lifts. The final exercise is the side-bridge hold. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
345526|NCT01559948|Device|Sacroiliac joint belt|The belt should be worn low around the pelvis just above the greater trochanter and instructed to wear the belt during all waking hours of the first four weeks of the study. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
345527|NCT01559935|Drug|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
345528|NCT01559935|Drug|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
345529|NCT01559935|Drug|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
345530|NCT01559935|Drug|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
345531|NCT01559935|Drug|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
345532|NCT01559935|Drug|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
345533|NCT01559922|Drug|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
345534|NCT01559922|Device|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
345535|NCT01559909|Device|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
345536|NCT01559896|Dietary Supplement|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
345537|NCT01559883|Other|no intervention is being made|This is a Non-Interventional Study (NIS)
345538|NCT01559857|Drug|Pioglitazone|30mg once daily for 12 weeks
345539|NCT01559857|Drug|Sugar Pill|Placebo
345540|NCT01559844|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
345541|NCT01559844|Drug|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
345542|NCT01559831|Biological|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
345543|NCT01559818|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
345544|NCT01559805|Behavioral|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
345545|NCT01559805|Behavioral|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
345546|NCT01559753|Drug|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~Beta-Lactams:~Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~Ceftriaxone : 2 g OD during 3 days, then 1 g OD~Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
345547|NCT01559753|Drug|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~Ceftriaxone : 2 g OD during 3 days, then 1 g OD~Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
345548|NCT01559740|Drug|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
345549|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
345550|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
345551|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
345552|NCT01559701|Drug|PF-00345439|5-80 mg twice-a-day for 12 months
345553|NCT01559688|Behavioral|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
345554|NCT01559688|Behavioral|Waitlist|Fitness assessment or career counseling
345555|NCT01559675|Drug|Hydrocortisone High Dose|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
345595|NCT01559311|Device|CRT-P ON|CRT Pacemaker
345556|NCT01559675|Drug|Hydrocortisone Low Dose|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3 IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD 2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
345557|NCT01559662|Dietary Supplement|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
345558|NCT01559649|Behavioral|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
345559|NCT01559636|Biological|bivalent oral polio vaccine|vaccine given during immunization campaigns
345560|NCT01559623|Procedure|retrospective data analysis|retrospective data analysis
345561|NCT01559610|Other|Intervention Group|The patients were instructed by a nurse
345562|NCT01559597|Biological|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
345563|NCT01559584|Radiation|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
345564|NCT01559584|Drug|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
345565|NCT01559558|Procedure|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
345566|NCT01559545|Drug|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
345567|NCT01559545|Drug|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
345568|NCT01559545|Drug|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
345569|NCT01559519|Drug|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
345570|NCT01559506|Device|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
345571|NCT01559480|Drug|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
345572|NCT01559480|Drug|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
345573|NCT01559467|Other|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
345574|NCT01559467|Other|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
345575|NCT01559454|Drug|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
345576|NCT01559454|Drug|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
345577|NCT01559441|Dietary Supplement|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
345578|NCT01559441|Dietary Supplement|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
345579|NCT01559428|Dietary Supplement|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
345580|NCT01559428|Dietary Supplement|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
345581|NCT01559428|Dietary Supplement|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
345582|NCT01559415|Other|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
345583|NCT01559415|Other|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
345584|NCT01559402|Procedure|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
345585|NCT01559402|Procedure|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
345586|NCT01559402|Procedure|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
345587|NCT01559389|Drug|solifenacin succinate|5 mg daily up to 10 mg daily
345588|NCT01559363|Drug|KD019 (tesevatinib)|KD019 (tesevatinib) administered orally once daily in 7 different dosing schedules (cohorts).
345589|NCT01559350|Procedure|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
345590|NCT01559350|Procedure|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
345597|NCT01559298|Drug|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
345598|NCT01559298|Drug|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
345599|NCT01559285|Drug|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
345600|NCT01559285|Drug|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
345601|NCT01559285|Drug|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
345602|NCT01559272|Drug|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
345603|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
345604|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
345605|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
345606|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
345607|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
345608|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
345609|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
345610|NCT01559272|Drug|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
345611|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
345612|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
345613|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
345614|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
345615|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
345616|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
345617|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
345618|NCT01559259|Drug|Ibuprofen|Two caplets of ibuprofen 200 mg
345619|NCT01559259|Drug|Placebo|Two caplets of placebo
345620|NCT01559233|Device|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
345621|NCT01559220|Device|Deep Brain Stimulation|Implanted device
345622|NCT01559194|Behavioral|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
345623|NCT01559194|Behavioral|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
345624|NCT01559168|Device|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
345625|NCT01559142|Drug|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
345626|NCT01559142|Drug|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
345627|NCT01559129|Drug|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
345628|NCT01559129|Drug|Placebo|Matching placebo capsules taken orally once a day
345629|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
345630|NCT01559116|Drug|tiotropium|low dose
345631|NCT01559116|Drug|olodaterol|one dose only
345632|NCT01559116|Drug|tiotropium|high dose
345633|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
345634|NCT01559116|Drug|Placebo|placebo matching tiotropium+olodaterol FDC
345635|NCT01559116|Device|Respimat|Respimat inhaler
345636|NCT01559103|Biological|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
345637|NCT01559103|Biological|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
345638|NCT01559090|Drug|MEDI-546|Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
345639|NCT01559090|Drug|MEDI-546|Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
345640|NCT01559090|Drug|MEDI-546|Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
345641|NCT01559077|Drug|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
345642|NCT01559077|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
345643|NCT01559064|Device|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
345644|NCT01559051|Procedure|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
345645|NCT01559025|Drug|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
345646|NCT01559012|Drug|Clonidine|transdermal clonidine patch 5 mg q. 5 days
345647|NCT01558999|Drug|High concentration SI-614|1 drop in each eye 4 times a day
345648|NCT01558999|Drug|Low concentration SI-614|1 drop in each eye 4 times a day
345649|NCT01558999|Drug|Vehicle|1 drop in each eye 4 times a day
345650|NCT01558986|Procedure|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
345651|NCT01558986|Procedure|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
345652|NCT01558960|Drug|IVit Melphalan|IVit injections of Melphalan
345653|NCT01558947|Drug|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4~6 weeks after surgery.
345654|NCT01558947|Drug|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4~6 weeks after surgery.
345655|NCT01558934|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
345656|NCT01558921|Other|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
345657|NCT01558921|Other|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
345658|NCT01558908|Biological|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
345659|NCT01558895|Radiation|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
345660|NCT01558895|Other|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
345661|NCT01558882|Device|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
345662|NCT01558869|Drug|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
345663|NCT01558869|Drug|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
345664|NCT01558869|Drug|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
345665|NCT01558856|Procedure|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
345666|NCT01558856|Procedure|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
345667|NCT01558830|Drug|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
345668|NCT01558830|Drug|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
345669|NCT01558817|Behavioral|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
345670|NCT01558817|Behavioral|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
345671|NCT01558804|Other|Identifying group A strep carriers|At study entry and at 14 days: Standard culture for GAS and analysis of mRNA.
345672|NCT01558791|Other|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
345673|NCT01558778|Procedure|management of therapy complications|Undergo mechanical stimulation
345674|NCT01558778|Procedure|musculoskeletal complications management/prevention|Undergo mechanical stimulation
345675|NCT01558765|Other|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
347978|NCT01540812|Drug|Ara-C in induction-2|
345676|NCT01558752|Device|Total hip replacement with titanium shell and CORAIL stem|Patients that are randomized into Group 1 will receive a total hip replacement with the following components: CORAIL (impaction broach) titanium stem and a monoblock cup with ceramic on ceramic bearing (DELTA motion).
345677|NCT01558752|Device|Total hip replacement with Modular Titanium Femoral Stem|Patients that are randomized into Group 2 will receive a total hip replacement with the following components: the Trilock-Pinnacle system (titanium stem and titanium cup with polyethylene insert).
345678|NCT01558739|Drug|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
345679|NCT01558726|Behavioral|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
345680|NCT01558726|Behavioral|Usual Treatment|The usual treatment used for regular patients of CAPSad
345681|NCT01558713|Drug|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
345682|NCT01558713|Drug|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
345683|NCT01558713|Drug|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
345684|NCT01558713|Drug|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
345685|NCT01558713|Drug|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
345686|NCT01558713|Drug|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
345687|NCT01558700|Drug|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
345688|NCT01558700|Drug|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
345689|NCT01558687|Drug|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.~Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
345690|NCT01558687|Other|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
345691|NCT01558674|Drug|MK-7145|
345692|NCT01558674|Drug|Furosemide|
345693|NCT01558674|Drug|Torsemide|
345694|NCT01558661|Drug|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) > 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
345695|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
345696|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
345697|NCT01558635|Device|Cardioblate CryoFlex Surgical Ablation|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
345698|NCT01558635|Procedure|Mitral Valve surgery|Classic mitral valve surgery was performed
345699|NCT01558635|Device|Medtronic Reveal XT Insertable Cardiac Monitor|During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period
345700|NCT01558635|Procedure|MAZE III|Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
345701|NCT01558622|Drug|dexketoprofen trometamol|50mg intravenous infusion
345702|NCT01558622|Drug|tramadol hydrochloride|100mg intravenous infusion
345703|NCT01558622|Drug|pethidine hydrochloride|50mg intravenous infusion
345704|NCT01558622|Drug|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
345705|NCT01558622|Drug|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
345706|NCT01558622|Drug|vitamin c|500mg intravenous infusion
347979|NCT01540812|Drug|G-CSF in induction-2|
345707|NCT01558596|Procedure|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
345708|NCT01558596|Procedure|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
345709|NCT01558583|Other|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
345710|NCT01558583|Other|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
345711|NCT01558583|Other|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
345712|NCT01558570|Procedure|Blood Draw|One time blood draw
345713|NCT01558557|Other|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
345714|NCT01558544|Procedure|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
345715|NCT01558531|Device|DEB|paclitaxel-eluting balloon angioplasty
345716|NCT01558531|Device|POBA|conventional balloon angioplasty
345717|NCT01558505|Device|PEB|paclitaxel-eluting balloon angioplasty
345718|NCT01558505|Device|POBA|conventional balloon angioplasty
345719|NCT01558492|Drug|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
345720|NCT01558492|Drug|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
345721|NCT01558466|Drug|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
345722|NCT01558466|Drug|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
345723|NCT01558453|Drug|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.~NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
345724|NCT01558440|Dietary Supplement|Infant Formula|A diet that is being fed to the young infants.
345725|NCT01558440|Dietary Supplement|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
345726|NCT01558440|Dietary Supplement|Diluted F-100|300 ml of water is added to 1000 ml of f-100
345727|NCT01558427|Procedure|Surveillance|Active clinical surveillance
345728|NCT01558427|Procedure|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
345729|NCT01558414|Procedure|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
345730|NCT01558414|Procedure|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
345731|NCT01558414|Procedure|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
345732|NCT01558401|Other|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
345733|NCT01558388|Drug|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
345734|NCT01558388|Drug|Placebo|One vaginal tablet daily for 10 days.
345735|NCT01558375|Drug|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
345736|NCT01558375|Drug|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
345737|NCT01558362|Drug|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections.
345738|NCT01558336|Drug|praziquantel|praziquantel 40 mg/kg oral tablets
345739|NCT01558323|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
345740|NCT01558310|Drug|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
345843|NCT01557517|Drug|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
345967|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
345741|NCT01558310|Drug|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
345742|NCT01558297|Behavioral|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
345743|NCT01558297|Behavioral|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
345744|NCT01558297|Behavioral|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
345745|NCT01558284|Drug|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
345746|NCT01558284|Drug|Placebo|Placebo
345747|NCT01558271|Drug|LY2189265|
345748|NCT01558271|Drug|Placebo|
345749|NCT01558271|Drug|Liraglutide|
345750|NCT01558258|Behavioral|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
345751|NCT01558245|Drug|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
345752|NCT01558232|Device|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
345753|NCT01558219|Drug|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
345754|NCT01558206|Other|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
345755|NCT01558206|Other|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
345756|NCT01558193|Dietary Supplement|Placebo|"Placebo for DHA of identical appearance - based on olive oil~Placebo for vitamins/minerals of identical appearance"
345757|NCT01558193|Dietary Supplement|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
345758|NCT01558193|Dietary Supplement|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
345759|NCT01558193|Dietary Supplement|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
345760|NCT01558180|Behavioral|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
345761|NCT01558180|Behavioral|Usual Care|educational handouts on pediatric insomnia
345762|NCT01558167|Drug|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2~Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1~Lenalidomide:~Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28~Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28~Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28~Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28~Dose level 5: maximal tolerated dose"
345763|NCT01558154|Drug|Chinese herbs|Chinese herbs special for depression
345764|NCT01558154|Procedure|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
345765|NCT01558154|Other|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
345766|NCT01558154|Device|Transcranial magnetic stimulation|Give magnetic stimulation at head
345767|NCT01558141|Other|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
345768|NCT01558141|Other|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
345769|NCT01558128|Drug|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
345770|NCT01558128|Procedure|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
345771|NCT01558115|Drug|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1 (35 patients): Receive active drug for year 1 and year 2 of the study~Group #2 (17 patients): Receive placebo for year 1 and active drug for year 2 of the study"
345772|NCT01558115|Other|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.~The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.~Group # 1 (35 patients): Receive active drug for year 1 and year 2 of the study~Group #2 (17 patients): Receive placebo for year 1 and active drug for year 2 of the study"
345773|NCT01558089|Drug|etanercept|according to SmPC and clinical practice
345774|NCT01558089|Drug|methotrexate|according to SmPC and clinical practice
345775|NCT01558063|Drug|Ketamine|Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
345776|NCT01558063|Drug|Saline|Single infusion of saline given intravenously over 40 minutes.
345777|NCT01558063|Procedure|Magnetic Resonance Imaging (MRI)|90-minute scan during the 40-minute infusion.
345778|NCT01558050|Dietary Supplement|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
345779|NCT01558011|Drug|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
345780|NCT01557998|Behavioral|POC CD4 and Peer Case Management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
345781|NCT01557998|Drug|HCV+PWID|Deliver direct acting antiviral (DAA) regimens for HCV+PWID. We will treat both active and inactive confirmed HCV viremic PWID from either Medication Assisted Treatment (MAT) clinics in Nairobi, Mombasa, and Malindi, Kenya or Collaborating partners' sites/Drop-in Centers (DICs) in Mombasa and Mtwapa, Kenya with direct acting antiviral (DAA) regimens. The mode of treatment delivery will be Directly Observed Therapy (DOT) for 84 consecutive doses (one dose per day). All participants will receive pre, post and ongoing counseling as per study protocol.
345782|NCT01557998|Behavioral|Control - No intervention|
345783|NCT01557985|Drug|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
345784|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
345785|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
345786|NCT01557959|Drug|cisplatin|Given IV
345787|NCT01557959|Biological|pegfilgrastim|Given SC
345788|NCT01557959|Drug|erlotinib hydrochloride|Given PO
345789|NCT01557959|Other|laboratory biomarker analysis|Optional correlative study
345790|NCT01557959|Genetic|polymorphism analysis|Correlative study
345791|NCT01557959|Other|pharmacogenomic studies|Correlative study
345792|NCT01557959|Genetic|genetic linkage analysis|Correlative study
345793|NCT01557959|Drug|docetaxel|Given IV
345794|NCT01557946|Drug|citalopram|citalopram 20-40 mg daily
345795|NCT01557933|Other|No interventions will be used|No interventions will be used
345796|NCT01557920|Drug|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
345797|NCT01557920|Drug|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
345798|NCT01557907|Device|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
345799|NCT01557907|Device|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
345800|NCT01557894|Other|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
345801|NCT01557881|Device|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center [SCC] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
345802|NCT01557868|Device|hylan G-F 20|Three 2 cc injections at weekly intervals
345803|NCT01557868|Device|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
345804|NCT01557855|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
345805|NCT01557842|Drug|Drug Treatment|Class I and III antiarrhythmic drug treatment.
345806|NCT01557842|Device|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
345807|NCT01557829|Device|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
345808|NCT01557829|Device|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
345809|NCT01557816|Drug|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
345810|NCT01557816|Drug|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
345811|NCT01557790|Radiation|Proton Radiation Therapy|
345812|NCT01557777|Drug|Navitoclax|QD
345813|NCT01557764|Drug|lapatinib ditosylate|Given PO
345814|NCT01557764|Biological|trastuzumab|Given IV
345815|NCT01557751|Genetic|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
345816|NCT01557738|Dietary Supplement|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
345817|NCT01557738|Dietary Supplement|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
345818|NCT01557738|Dietary Supplement|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
345819|NCT01557738|Dietary Supplement|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
345844|NCT01557504|Drug|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metrformin XR 2000 mg).
345820|NCT01557712|Drug|ketamine venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~Intravenous injection on day 0 to 0.5 mg / kg of ketamine~D0 to D4: 75 mg of venlafaxine~D4 to D14: 150 mg per day of venlafaxine~D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
345821|NCT01557712|Drug|Venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~D0 to D4: 75 mg of venlafaxine~D4 to D14: 150 mg per day of venlafaxine~D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
345822|NCT01557699|Biological|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
345823|NCT01557699|Biological|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
345824|NCT01557699|Biological|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
345825|NCT01557686|Behavioral|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
345826|NCT01557673|Dietary Supplement|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
345827|NCT01557673|Dietary Supplement|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
345828|NCT01557660|Drug|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
345829|NCT01557647|Drug|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
345830|NCT01557647|Drug|Placebo|placebo inhalation solution
345831|NCT01557634|Procedure|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
345832|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
345833|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
345834|NCT01557621|Behavioral|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
345835|NCT01557608|Procedure|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
345836|NCT01557608|Procedure|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
345837|NCT01557595|Device|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
345838|NCT01557582|Device|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.~Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
345839|NCT01557569|Drug|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
345840|NCT01557569|Drug|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
345841|NCT01557543|Other|Cell Therapy|Intramyocardial Injection of BMSCs
345842|NCT01557517|Drug|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
345845|NCT01557504|Drug|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
345846|NCT01557504|Drug|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
345847|NCT01557504|Drug|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
345848|NCT01557491|Procedure|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
345849|NCT01557491|Procedure|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
345850|NCT01557478|Drug|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
345851|NCT01557478|Drug|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
345852|NCT01557452|Drug|Givinostat|oral suspension, 0,75 mg/Kg b.i.d. in fed conditions
345853|NCT01557439|Drug|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
345854|NCT01557426|Other|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
345855|NCT01557413|Procedure|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
345856|NCT01557413|Procedure|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
345857|NCT01557400|Drug|Ataluren|Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
345858|NCT01557387|Other|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
345859|NCT01557374|Drug|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
345860|NCT01557374|Drug|Decrease Tocilizumab, Abatacept|"The decrease pattern is established on 4 consecutive stages :~IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):~Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop~SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):~Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop~If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.~If DAS 28 > 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage~If DAS 28 > 3,2 : return to previous stage, (relapse according to European expert consensus)~In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study."
345861|NCT01557361|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
345862|NCT01557361|Other|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:~I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND~II. At least one of the following indications for RRT initiation:~Serum potassium ≥6.0 mmol/L, or~Serum bicarbonate ≤ 10 mmol/L, or~Evidence of severe respiratory failure, based on a PaO2/FiO2 <200 and bilateral infiltrates on the chest x-ray, or~By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
345863|NCT01557335|Drug|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
345864|NCT01557335|Drug|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
345865|NCT01557322|Biological|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
345866|NCT01557322|Drug|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
345867|NCT01557296|Dietary Supplement|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
345868|NCT01557296|Radiation|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
345869|NCT01557296|Other|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
345870|NCT01557296|Biological|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
345871|NCT01557283|Other|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
345872|NCT01557270|Drug|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
345873|NCT01557270|Drug|saline|ropivacaine + saline placebo, single shot perineural application
345874|NCT01557257|Drug|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
345875|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
345876|NCT01557257|Drug|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
345877|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
345878|NCT01557257|Drug|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
345879|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
345880|NCT01557244|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
345881|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
345882|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
345883|NCT01557244|Drug|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
345884|NCT01557244|Drug|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
345885|NCT01557244|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
345886|NCT01557244|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
345887|NCT01557218|Other|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
345888|NCT01557218|Other|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
345889|NCT01557218|Other|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
345890|NCT01557218|Other|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
345891|NCT01557218|Other|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
345892|NCT01557218|Other|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
345893|NCT01557218|Other|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
345894|NCT01557218|Other|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
345895|NCT01557192|Device|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
345896|NCT01557179|Device|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
345897|NCT01557179|Device|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
345898|NCT01557166|Drug|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
345899|NCT01557166|Drug|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
345900|NCT01557153|Drug|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
345901|NCT01557153|Drug|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
345902|NCT01557140|Drug|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
345903|NCT01557127|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
345904|NCT01557114|Drug|Ipilimumab|"Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.~Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy"
345905|NCT01557114|Radiation|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
345906|NCT01557101|Procedure|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
345907|NCT01557101|Procedure|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
345908|NCT01557088|Other|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
345909|NCT01557088|Procedure|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
345910|NCT01557075|Drug|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Atorvastatin 40 mg daily for 12 months after randomization"
345911|NCT01557075|Drug|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program~Pravastatin 20mg daily for 12 months after randomization"
345912|NCT01557062|Other|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
345913|NCT01557062|Other|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
345914|NCT01557062|Other|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
345915|NCT01557049|Other|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
345916|NCT01557049|Other|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
345917|NCT01557036|Device|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
345918|NCT01557023|Drug|barrier methods|
345919|NCT01557023|Drug|barrier methods|
345920|NCT01557010|Drug|DWP05195|Tablets, oral administration, 100mg
345921|NCT01557010|Drug|DWP05195|Tablets, oral administration, 200mg
345922|NCT01557010|Drug|DWP05195|Tablets, oral administration, 300mg
345923|NCT01557010|Drug|Control|Tablets, oral administration, Placebo
345924|NCT01556997|Drug|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
345925|NCT01556997|Drug|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
345926|NCT01556997|Drug|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
345927|NCT01556984|Other|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
345928|NCT01556971|Drug|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
345929|NCT01556971|Drug|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
345930|NCT01556945|Biological|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
345931|NCT01556945|Biological|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
345932|NCT01556945|Other|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
345933|NCT01556945|Other|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
345934|NCT01556932|Drug|ABH gel|Given topically
345935|NCT01556932|Other|placebo|Given topically
345936|NCT01556919|Procedure|Standard of care endoscopy|standard of care endoscopy
345937|NCT01556906|Drug|Lomitapide|Oral administration with escalating doses administered once daily
345938|NCT01556893|Device|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
345939|NCT01556880|Behavioral|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
345940|NCT01556867|Other|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
345965|NCT01556659|Drug|Absence of Acenocoumarol|Dual anti-platelet therapy without the addition of Acenocoumarol.
345966|NCT01556646|Drug|Tolvaptan|15 to 30mg qd titrated to sodium concentration
345941|NCT01556867|Other|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.~In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
345942|NCT01556841|Biological|TroVax®|"Pre-amendment 10:~Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.~Post-amendment 10:~Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
345943|NCT01556841|Biological|Placebo|"Pre-amendment 10:~Matched placebo will be administered as above.~Post-amendment 10:~TRI-70 onwards received TroVax only."
345944|NCT01556815|Procedure|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
345945|NCT01556815|Other|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.~Procedure: TACE~TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
345946|NCT01556802|Drug|Minocicline|Minocicline 100mg oral twice a day for 5 days
345947|NCT01556802|Drug|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
345948|NCT01556789|Biological|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
345949|NCT01556776|Drug|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
345950|NCT01556776|Drug|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
345951|NCT01556763|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
345952|NCT01556763|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
345953|NCT01556763|Drug|Placebo|Matching placebo was administered as one capsule per day for 21 days.
345954|NCT01556763|Drug|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole [10 to 30 mg/day], olanzapine [10 to 20 mg/day], paliperidone [3 to 12 mg/day], or risperidone [2 to 16 mg/day]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
345955|NCT01556737|Dietary Supplement|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
345956|NCT01556737|Dietary Supplement|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
345957|NCT01556724|Drug|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
345958|NCT01556698|Drug|NVN1000|
345959|NCT01556698|Drug|Vehicle|Placebo
345960|NCT01556685|Other|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
345961|NCT01556685|Other|Blood Sample|For evaluation of interferon-related Nab
345962|NCT01556685|Genetic|Blood Sample|genetic evaluation - predisposition to Nab generation
345963|NCT01556672|Drug|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
345964|NCT01556672|Device|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
345968|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
345969|NCT01556607|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
345970|NCT01556607|Drug|Placebo|
345971|NCT01556594|Drug|Nasal Glucagon 1 mg|
345972|NCT01556594|Drug|Nasal Glucagon 2 mg|
345973|NCT01556594|Drug|SC Glucagon|
345974|NCT01556594|Drug|Nasal Glucagon 3 mg|
345975|NCT01556581|Procedure|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
345976|NCT01556581|Procedure|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
345977|NCT01556568|Drug|MEK162|
345978|NCT01556542|Device|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
345979|NCT01556542|Device|nitinol stent implantation|nitinol stent implantation
345980|NCT01556529|Procedure|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
345981|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
345982|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
345983|NCT01556503|Device|VivaScope System|VivaScope System, Model#s 1500 and 2500
345984|NCT01556490|Device|TheraSphere|Yttrium 90 microspheres
345985|NCT01556477|Drug|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
345986|NCT01556477|Drug|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.~Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
345987|NCT01556464|Device|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
345988|NCT01556451|Biological|Zoster Vaccine Live|Zoster vaccine live
345989|NCT01556438|Biological|Tabalumab|Administered IV
345990|NCT01556438|Drug|Bortezomib IV|Administered IV
345991|NCT01556438|Drug|Bortezomib SC|Administered SC
345992|NCT01556438|Drug|Dexamethasone|Administered orally
345993|NCT01556425|Drug|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
345994|NCT01556425|Behavioral|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
345995|NCT01556425|Other|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
345996|NCT01556399|Other|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
345997|NCT01556373|Other|NA : non interventional study|NA : non interventional study
345998|NCT01556347|Drug|Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis|
345999|NCT01556334|Drug|Azithromycin|Azithromycin 1g po
346000|NCT01556334|Drug|Erythromycin|Erythromycin IV then PO
346001|NCT01556321|Dietary Supplement|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
346002|NCT01556321|Dietary Supplement|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
346003|NCT01556308|Procedure|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
346004|NCT01556282|Device|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
346005|NCT01556256|Other|Caregiver-Related Intervention or Procedure|Undergo TMV+P
346006|NCT01556256|Procedure|Music Therapy|Undergo TMV
346007|NCT01556256|Procedure|Music Therapy|Undergo TMV+P
346008|NCT01556256|Other|Quality-of-Life Assessment|Ancillary studies
346009|NCT01556256|Other|Questionnaire Administration|Ancillary studies
346010|NCT01556243|Procedure|therapeutic conventional surgery|
346011|NCT01556243|Radiation|whole breast irradiation|
346012|NCT01556230|Procedure|Surgical intervention for CNFA|(non-experimental) standard procedure
346013|NCT01556230|Radiation|Radiotherapy for CNFA|(non-experimental) standard procedure
346220|NCT01554488|Drug|Inhaled Fluticasone Propionate|Inhaled corticosteroid
346014|NCT01556217|Drug|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
346015|NCT01556217|Drug|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
346016|NCT01556204|Procedure|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
346017|NCT01556204|Procedure|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
346018|NCT01556191|Drug|Gefitinib|250 mg per day (oral)
346019|NCT01556191|Drug|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
346020|NCT01556191|Drug|Erlotinib|150 mg per day (oral)
346021|NCT01556165|Drug|rasagiline|1 mg/day, tablets, once daily, orally
346022|NCT01556165|Drug|placebo|tablets, once daily, orally
346023|NCT01556152|Drug|GRC 17536 (Medium Dose)|1 BD for 28 days
346024|NCT01556152|Drug|GRC 17536 (Low Dose)|1 BD for 28 Days
346025|NCT01556152|Drug|Placebo|Matching Placebo for 28 Days
346026|NCT01556139|Device|Spirotiger|"The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step."
346027|NCT01556126|Device|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
346028|NCT01556113|Other|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
346029|NCT01556100|Drug|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
346030|NCT01556087|Behavioral|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
346031|NCT01556087|Behavioral|Health Education|7 individual sessions with didactic health education information
346032|NCT01556074|Behavioral|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
346033|NCT01556061|Device|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
346034|NCT01556061|Device|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
346035|NCT01556048|Behavioral|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, & Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
346036|NCT01556035|Drug|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
346037|NCT01556022|Device|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
346038|NCT01556022|Device|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
346039|NCT01556009|Drug|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
346040|NCT01556009|Drug|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
346071|NCT01555697|Drug|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
346248|NCT01554254|Drug|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
346041|NCT01555996|Behavioral|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
346042|NCT01555996|Behavioral|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
346043|NCT01555983|Drug|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
346044|NCT01555970|Drug|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
346045|NCT01555970|Drug|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
346046|NCT01555957|Drug|intravenous lipid|intravenous given daily for 6 weeks
346047|NCT01555931|Drug|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
346048|NCT01555918|Drug|Isavuconazole|oral
346049|NCT01555918|Drug|Isavuconazole (IV)|intravenous (IV)
346050|NCT01555905|Device|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
346051|NCT01555892|Biological|LMP, BARF1 & EBNA1 specific CTLs: A|"Dose Level 1: 2 x 10^7 cells/ m2; 2 x 10^7 cells/m2~Dose Level 2: 2 x 10^7 cells/m2; 1 x 10^8 cells/m2~Dose Level 3: 1 x 10^8 cells/m2; 2 x 10^8 cells/m2"
346052|NCT01555892|Biological|LMP, BARF1 & EBNA1 specific CTLs : B|"Dose Level 1: 2 x 10^7 cells/ m2; 2 x 10^7 cells/m2~Dose Level 2: 2 x 10^7 cells/m2; 1 x 10^8 cells/m2~Dose Level 3: 1 x 10^8 cells/m2; 2 x 10^8 cells/m2"
346053|NCT01555879|Drug|Abatacept|As prescribed by a doctor for patient medical care.
346054|NCT01555866|Drug|isavuconazole|IV
346055|NCT01555853|Drug|Abraxane|
346056|NCT01555840|Device|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.~It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope"
346057|NCT01555827|Other|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:~Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)~Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)~Wide-field colour and autofluorescence imaging (Optomap)~Measure of intra-ocular pressure (pneumotonometer)~The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:~Age, gender~educational level~smoking~cardiovascular diseases, current medications~scores at neuropsychological tests"
346058|NCT01555814|Drug|Amisulpride|4-week open label amisulpride treatment
346059|NCT01555801|Device|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
346060|NCT01555801|Device|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
346061|NCT01555788|Device|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
346062|NCT01555775|Dietary Supplement|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
346063|NCT01555775|Dietary Supplement|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
346064|NCT01555749|Drug|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
346065|NCT01555749|Drug|placebo|One injection administered subcutaneously (s.c., under the skin)
346066|NCT01555736|Drug|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
346067|NCT01555710|Drug|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
346068|NCT01555710|Drug|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
346069|NCT01555710|Drug|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
346070|NCT01555710|Drug|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
346104|NCT01555385|Dietary Supplement|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
346221|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
346072|NCT01555697|Drug|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
346073|NCT01555684|Procedure|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
346074|NCT01555671|Drug|Placebo|Bag B (placebo group), containing 0.5mL of normal saline solution
346075|NCT01555671|Drug|Meperidine|25mg (0.5 ml ) meperidine injection intravenous
346076|NCT01555658|Drug|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
346077|NCT01555658|Drug|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200—250 s)
346078|NCT01555645|Behavioral|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
346079|NCT01555632|Drug|atorvastatin calcium|Given PO
346080|NCT01555632|Drug|placebo|Given PO
346081|NCT01555619|Device|CRT-D System|Implantation of a CRT-D System
346082|NCT01555606|Other|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
346083|NCT01555593|Device|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
346084|NCT01555580|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
346085|NCT01555567|Device|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
346086|NCT01555567|Other|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
346087|NCT01555554|Drug|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.~On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).~On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).~On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).~On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).~This will complete the course of propranolol."
346088|NCT01555554|Other|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.~On post operative days #1-13, patients will take one placebo pill (once daily by mouth).~This will complete the course of the placebo."
346089|NCT01555541|Drug|Ofatumumab|1000 mg IV days 0, 7, 14, 21
346090|NCT01555541|Drug|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
346091|NCT01555541|Drug|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
346092|NCT01555528|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
346093|NCT01555515|Procedure|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
346094|NCT01555515|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
346095|NCT01555489|Drug|Ascorbic Acid|3x per week
346096|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
346097|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
346098|NCT01555463|Drug|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
346099|NCT01555463|Drug|Vehicle foam|twice daily topical application
346100|NCT01555450|Other|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
346101|NCT01555424|Dietary Supplement|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
346102|NCT01555424|Dietary Supplement|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
346103|NCT01555398|Dietary Supplement|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
346105|NCT01555372|Device|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
346106|NCT01555372|Device|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
346107|NCT01555333|Drug|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
346108|NCT01555320|Drug|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
346109|NCT01555320|Drug|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
346110|NCT01555307|Other|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
346111|NCT01555307|Other|Typical group|Seven typical exercises, 10 times each, 3 times a day
346112|NCT01555281|Drug|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
346113|NCT01555281|Drug|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
346114|NCT01555281|Drug|Dexamethasone|40 mg (for patients <75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
346115|NCT01555268|Biological|trebananib|Given IV
346116|NCT01555268|Drug|cytarabine|Given SC
346117|NCT01555268|Other|laboratory biomarker analysis|Correlative studies
346118|NCT01555268|Other|pharmacological study|Correlative studies
346119|NCT01555242|Drug|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
346120|NCT01555229|Device|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
346121|NCT01555229|Device|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
346122|NCT01555216|Drug|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
346123|NCT01555216|Drug|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
346124|NCT01555203|Behavioral|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.~In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
346125|NCT01555190|Drug|myo-inositol 1500 gr|
346126|NCT01555190|Drug|myo-inositol 2000 gr + folic acid 200 mcg|
346127|NCT01555164|Drug|Ranolazine|Ranolazine tablet(s) administered orally
346128|NCT01555164|Drug|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
346129|NCT01555164|Drug|Metformin|Metformin tablet(s) administered orally once daily
346130|NCT01555164|Drug|Placebo to match metformin|Placebo to match metformin for the duration of the study
346131|NCT01555164|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
346132|NCT01555164|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
346133|NCT01555151|Drug|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
346134|NCT01555151|Device|Concept 1|A single dose dry powder inhaler (SDDPI)
346135|NCT01555151|Device|Twisthaler|A single dose dry powder inhaler (SDDPI)
346136|NCT01555138|Drug|Indacaterol|Indacaterol is delivered via a SDDPI.
346137|NCT01555138|Drug|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
346138|NCT01555125|Drug|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
346139|NCT01555125|Drug|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
346140|NCT01555125|Drug|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
346141|NCT01555112|Drug|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
346142|NCT01555099|Drug|AZD5423|oral inhaled
346143|NCT01555099|Drug|Budesonide|oral inhaled
346144|NCT01555099|Drug|Placebo|oral inhaled
346145|NCT01555086|Procedure|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
346146|NCT01555086|Procedure|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
346147|NCT01555073|Drug|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
346148|NCT01555073|Drug|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
346149|NCT01555073|Drug|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
346150|NCT01555073|Drug|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
346151|NCT01555060|Dietary Supplement|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
346152|NCT01555047|Procedure|IUI|intrauterine insemination
346153|NCT01555047|Procedure|IUI|intrauterine insemination
346154|NCT01555034|Behavioral|movement therapy|exercise, nutrition, movement therapy
346155|NCT01555034|Other|exercise plus nutrition|exercise, nutrition
346156|NCT01555021|Genetic|Genotyping assays|"Patients will provide blood samples at the beginning of the study. If the patient is in the AGT group (as opposed to the TAU group), their blood samples will be sent for genotyping immediately. AGT psychiatrists will be given the results of genotyping within 3-5 days in order to decide which antidepressants to use long-term and at what doses. Patients in the Treatment as Usual group will have their blood samples stored for future analysis. Both groups will provide saliva samples for GWAS analysis at a alter date; however, since the study was terminated early, GWAS testing for both groups and genotyping for the TAU group were not performed.~Patients will receive questionnaires to measure their mood, side effects, and symptoms.~Patients will be asked to participate in 3 follow-up phone calls (1 month, 3 months, and 6 months) to measure their mood."
346157|NCT01555008|Drug|LX4211|Subjects will receive LX4211 once daily for 7 days
346158|NCT01555008|Drug|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
346159|NCT01554995|Drug|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
346160|NCT01554995|Drug|Linezolid|Linezolid 600 mg (Cohort 9) none
346161|NCT01554982|Drug|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
346162|NCT01554969|Drug|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.~Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.~In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
346163|NCT01554956|Biological|Human Plasminogen|Eye Drops
346164|NCT01554943|Other|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
346165|NCT01554930|Drug|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
346166|NCT01554930|Drug|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
346167|NCT01554917|Drug|Iguratimod|taken orally, 2 tablets/day (bid)
346168|NCT01554904|Device|Facial-Flex|Oral exercise device
346169|NCT01554878|Procedure|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
346170|NCT01554865|Dietary Supplement|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
346171|NCT01554865|Behavioral|Conventional diet counseling|
346172|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
346173|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
346174|NCT01554852|Drug|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1 & 2, 8 & 9, 15 & 16 - carfilzomib 20*/36 mg/m2** IV (*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; **carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 & 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
346175|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
346176|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
346177|NCT01554852|Drug|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 & 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 & 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
346249|NCT01554241|Dietary Supplement|D3 2000 IU/day|2000 IU/day D3
346178|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
346179|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 & 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
346180|NCT01554852|Drug|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
346181|NCT01554839|Behavioral|"Family of Heroes"|One hour online educational tool
346182|NCT01554839|Behavioral|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
346183|NCT01554826|Biological|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
346184|NCT01554826|Biological|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
346185|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
346186|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
346187|NCT01554813|Biological|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
346188|NCT01554800|Drug|ACP-501|A single dose infusion
346189|NCT01554787|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
346190|NCT01554787|Other|Placebo|at a rate of 2.8g three times per day
346191|NCT01554761|Procedure|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
346192|NCT01554761|Device|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
346193|NCT01554748|Procedure|Total joint arthroplasty|
346194|NCT01554735|Behavioral|Exercise and diet|24 weeks of exercise and diet counselling
346195|NCT01554722|Procedure|Needle placement|In plane versus out of plane needle placement techniques
346196|NCT01554709|Device|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
346197|NCT01554696|Drug|peficitinib|oral
346198|NCT01554696|Drug|Placebo|oral
346199|NCT01554696|Drug|methotrexate|oral
346200|NCT01554683|Drug|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
346201|NCT01554670|Procedure|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
346202|NCT01554657|Other|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
346203|NCT01554657|Other|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
346204|NCT01554644|Device|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
346205|NCT01554644|Device|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
346206|NCT01554631|Drug|Acarbose (Glucobay ODT, BAYG5421)|
346207|NCT01554631|Drug|Acarbose (Glucobay, BAYG5421)|
346208|NCT01554618|Drug|Exenatide Once Weekly|2 mg exenatide once weekly
346209|NCT01554618|Drug|Placebo|Placebo
346210|NCT01554592|Drug|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
346211|NCT01554592|Drug|Statin therapy|Participants will continue on stable statin therapy.
346212|NCT01554579|Drug|Gefapixant|BID
346213|NCT01554579|Drug|Sugar Pill|Placebo
346214|NCT01554566|Dietary Supplement|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
346215|NCT01554553|Procedure|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
346216|NCT01554540|Drug|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
346217|NCT01554527|Procedure|CPAP treatment|6 months of treatment with PAP (CPAP or BPAP)
346218|NCT01554527|Other|No CPAP treatment|Children randomized to the comparison group will receive routine care
346219|NCT01554514|Biological|rituximab|rituximab intravenously 100 mg every week for four doses
346222|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
346223|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
346224|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
346225|NCT01554449|Procedure|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
346226|NCT01554449|Procedure|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
346227|NCT01554436|Behavioral|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.~The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
346228|NCT01554423|Other|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
346229|NCT01554423|Behavioral|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
346230|NCT01554423|Behavioral|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
346231|NCT01554410|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
346232|NCT01554410|Drug|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
346233|NCT01554410|Drug|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
346234|NCT01554397|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
346235|NCT01554397|Drug|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
346236|NCT01554384|Procedure|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
346237|NCT01554384|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
346238|NCT01554371|Drug|Eribulin in Combination w/ Cyclophosphamide|"Phase Ib Eribulin mesylate (mg/m2)~Level -1: 0.7 day 1, 8~Level 0 (start): 1.1 day 1, 8~Level 1: 1.4 day 1, 8~Cyclophosphamide (mg/ m2) Level -1: 600 day 1~Level 0: 600 day 1~Level 1: 600 day 1~Phase II The dose-expansion will enroll 40 patients with advanced breast cancer"
346239|NCT01554358|Behavioral|Lifestyle intervention|"The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) carbohydrate intake 55-65% of energy consumed, 4) fiber intake 20-30g per day, and 5) moderate or vigorous exercise for at least 30 min daily, seven days each week.~--------------------------------------------------------------------------------"
346240|NCT01554345|Drug|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
346241|NCT01554332|Device|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
346242|NCT01554319|Drug|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
346243|NCT01554319|Drug|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
346244|NCT01554293|Drug|Matching placebo|Matching Placebo, single dose
346245|NCT01554293|Drug|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
346246|NCT01554280|Device|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
346247|NCT01554267|Device|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
346250|NCT01554241|Dietary Supplement|D3 4000 IU/day|vitamin D3 4000 IU/day
346251|NCT01554241|Dietary Supplement|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
346252|NCT01554241|Dietary Supplement|vitamin D3 800 IU/day|vitamin D3 800 IU/day
346253|NCT01554228|Other|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
346254|NCT01554215|Behavioral|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
346255|NCT01554215|Behavioral|Mom Power Attentional Control Group|at home control, weekly mailings
346256|NCT01554202|Behavioral|assessment of memory|
346257|NCT01554202|Biological|circulating tPA dosage|
346258|NCT01554202|Genetic|ApoE4|
346259|NCT01554202|Other|Brain imaging examination MRI and PET examinations|
346260|NCT01554189|Drug|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
346261|NCT01554189|Drug|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
346262|NCT01554176|Drug|Filorexant|Filorexant, one 10 mg tablet, orally, once daily at bedtime
346263|NCT01554176|Drug|Placebo|Placebo, one tablet, orally, once daily at bedtime
346264|NCT01554163|Drug|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
346265|NCT01554163|Drug|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
346266|NCT01554150|Behavioral|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
346267|NCT01554137|Other|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
346268|NCT01554137|Other|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
346269|NCT01554124|Drug|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).~Treatment duration = 21 ± 7 days"
346270|NCT01554111|Drug|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
346271|NCT01554111|Drug|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
346272|NCT01554111|Drug|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
346273|NCT01554098|Procedure|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
346274|NCT01554098|Procedure|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
346275|NCT01554085|Drug|ALS-002158|ALS-002158
346276|NCT01554085|Drug|Placebo|placebo
346277|NCT01554072|Other|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
346278|NCT01554059|Drug|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
346279|NCT01554059|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly * 6 doses 3-4 weeks after radical resection
346280|NCT01554059|Drug|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
346281|NCT01554059|Radiation|Radiotherapy|2GY daily *20次
346282|NCT01554046|Drug|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.~Ages 6-12, up to 25Kg - 35mg maximum per day.~Ages 6-12, above 25Kg - 50mg maximum per day.~Ages 12-65, above 25Kg - 80mg maximum per day."
346283|NCT01554020|Dietary Supplement|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
346284|NCT01554020|Dietary Supplement|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
346285|NCT01554007|Other|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
346286|NCT01553981|Drug|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
346287|NCT01553981|Drug|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
346288|NCT01553968|Other|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
346289|NCT01553955|Procedure|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
346290|NCT01553942|Drug|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
346292|NCT01553942|Drug|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
346293|NCT01553942|Drug|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
346294|NCT01553942|Procedure|Surgery|Surgery to remove tumor
346295|NCT01553929|Other|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
346296|NCT01553929|Other|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
346297|NCT01553929|Other|control group|no physical training and no cognitive activity
346298|NCT01553916|Drug|Lithium Carbonate|
346299|NCT01553916|Radiation|Prophylactic cranial irradiation|
346300|NCT01553903|Drug|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
346301|NCT01553903|Drug|Exemestane|Exemestane 25mg/day during 5 years
346302|NCT01553903|Drug|Anastrozole|Anastrozole 1 mg/day during 5 years,
346303|NCT01553903|Drug|Letrozole|Letrozole 2.5 mg/day during 5 years,
346304|NCT01553890|Other|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
346305|NCT01553877|Dietary Supplement|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
346306|NCT01553877|Dietary Supplement|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
346307|NCT01553877|Dietary Supplement|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
346308|NCT01553851|Drug|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
346309|NCT01553838|Device|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
346310|NCT01553786|Drug|Lenalidomide|Lenalidomide
346311|NCT01553773|Drug|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
346312|NCT01553773|Drug|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
346313|NCT01553760|Procedure|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
346314|NCT01553760|Procedure|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
346315|NCT01553747|Drug|Eluxadoline|Oral tablets twice daily
346316|NCT01553747|Drug|Placebo|Oral tablets twice daily
346317|NCT01553721|Drug|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)~Phase IIb - Udenafil(BID)"
346318|NCT01553721|Drug|placebo|Phase IIa - placebo Phase IIb - placebo
346319|NCT01553708|Drug|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
346320|NCT01553708|Drug|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
346321|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
346322|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
346323|NCT01553682|Behavioral|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
346324|NCT01553682|Behavioral|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
346325|NCT01553669|Behavioral|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
346326|NCT01553656|Drug|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
346327|NCT01553656|Drug|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
346328|NCT01553643|Drug|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
346329|NCT01553643|Drug|placebo|at a rate of 3g two times per day
346330|NCT01553630|Procedure|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
346331|NCT01553630|Procedure|Surgery without bone graft|Plating of fracture without bone graft
346332|NCT01553617|Drug|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
346333|NCT01553617|Drug|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
346334|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the first postoperative day
346335|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
346336|NCT01553591|Drug|Eluxadoline|Oral tablets twice daily
346337|NCT01553591|Drug|Placebo|Oral tablets twice daily
346339|NCT01553578|Procedure|therapeutic touch|Receive healing touch therapy
346340|NCT01553578|Behavioral|management of therapy complications|Receive healing touch therapy
346341|NCT01553578|Behavioral|management of therapy complications|Receive guided imagery audiotapes
346342|NCT01553578|Procedure|standard follow-up care|Receive standard care
346343|NCT01553565|Procedure|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
346344|NCT01553539|Drug|therapeutic angiotensin-(1-7)|Given SC
346345|NCT01553539|Other|laboratory biomarker analysis|Correlative study
346346|NCT01553513|Other|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.~This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.~Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
346347|NCT01553513|Procedure|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
346348|NCT01553513|Procedure|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.~A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.~Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
346349|NCT01553513|Other|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.~ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
346350|NCT01553500|Dietary Supplement|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
346351|NCT01553500|Behavioral|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
346352|NCT01553487|Other|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
346353|NCT01553461|Drug|Cord Blood Transplant|
346354|NCT01553448|Genetic|gene expression analysis|
346355|NCT01553448|Genetic|protein expression analysis|
346356|NCT01553448|Other|enzyme-linked immunosorbent assay|
346357|NCT01553448|Other|immunohistochemistry staining method|
346358|NCT01553448|Other|laboratory biomarker analysis|
346359|NCT01553448|Other|medical chart review|
346360|NCT01553435|Drug|Dextromethorphan|The study medicines shall be administered via tube.
346361|NCT01553435|Drug|Placebo|The study medicines shall be administered via tube.
346362|NCT01553422|Other|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
346363|NCT01553422|Other|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
346364|NCT01553383|Device|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
346365|NCT01553370|Other|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
346366|NCT01553370|Other|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
346367|NCT01553357|Drug|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
346368|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
346369|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
346370|NCT01553318|Drug|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
346371|NCT01553318|Drug|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
346372|NCT01553305|Other|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
346373|NCT01553305|Other|Exercise programme|Supervised exercise programme
346374|NCT01553292|Device|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
346375|NCT01553292|Device|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
346376|NCT01553279|Biological|V419|Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate [meningococcal outer membrane protein complex], and Hepatitis B [recombinant] vaccine administered via 0.5 mL intramuscular injection.
346377|NCT01553279|Biological|PREVNAR 13®|Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).
346378|NCT01553279|Biological|MCC-TT|Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
346379|NCT01553279|Biological|MCC-CRM|Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
346380|NCT01553279|Biological|Hib-MCC|Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
346381|NCT01553279|Biological|MMR Vaccine|Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
346382|NCT01553266|Behavioral|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
346383|NCT01553240|Device|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
346384|NCT01553227|Device|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
346385|NCT01553214|Drug|Filgrastim|Donors shall receive G-CSF 480 mcg as a single 1.6-ml subcutaneous injection 12 to 24 hours prior to donation.
346386|NCT01553214|Drug|Dexamethasone|Donors shall ingest dexamethasone 8 mg (two 4-mg tablets) orally 12 hours prior to donation.
346387|NCT01553201|Drug|Botuninum toxin A|
346388|NCT01553201|Drug|Placebo|
346389|NCT01553188|Drug|AMG 386|AMG 386 dose will be calculated using the subjects actual body weight (Kg). Supplied in 240 mg v will be administered as an intravenous (IV) infusion using an intravenous infusion pump given over a 60-minute period.
346390|NCT01553188|Drug|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
346391|NCT01553188|Drug|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patients preference.
346392|NCT01553175|Genetic|DNA analysis|
346393|NCT01553175|Genetic|gene expression analysis|
346394|NCT01553175|Genetic|mutation analysis|
346395|NCT01553175|Genetic|protein expression analysis|
346396|NCT01553175|Other|immunohistochemistry staining method|
346397|NCT01553175|Other|laboratory biomarker analysis|
346398|NCT01553162|Genetic|DNA analysis|
346399|NCT01553162|Genetic|RNA analysis|
346400|NCT01553162|Genetic|gene expression analysis|
346401|NCT01553162|Other|laboratory biomarker analysis|
346402|NCT01553149|Drug|Lenalidomide|Given PO
346403|NCT01553149|Other|Pharmacological Study|Correlative studies
346404|NCT01553136|Drug|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
346405|NCT01553123|Drug|Ulipristal Acetate|once daily, oral
346406|NCT01553123|Drug|Iron|once daily, dried ferrous sulfate
346407|NCT01553097|Other|Neurocognitive impairment observation|None - observational
346408|NCT01553084|Drug|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
346409|NCT01553084|Drug|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
346410|NCT01553084|Drug|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
346454|NCT01552798|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
346455|NCT01552798|Drug|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
346456|NCT01552798|Drug|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
347980|NCT01540812|Drug|Dexamethasone in consolidation-1|
346411|NCT01553071|Drug|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.~Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
346412|NCT01553058|Drug|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
346413|NCT01553058|Drug|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
346414|NCT01553058|Other|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
346415|NCT01553032|Drug|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
346416|NCT01553032|Radiation|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
346417|NCT01553019|Radiation|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
346418|NCT01553019|Drug|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
346419|NCT01553006|Drug|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
346420|NCT01552993|Drug|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
346421|NCT01552993|Drug|sucrose|pacifier and sucrose
346422|NCT01552980|Drug|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;~Efficacy will be evaluated every three cycles."
346423|NCT01552967|Drug|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.~Efficacy will be evaluated every three cycles."
346424|NCT01552954|Behavioral|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
346425|NCT01552941|Device|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
346426|NCT01552928|Drug|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
346427|NCT01552928|Drug|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
346428|NCT01552928|Drug|Moxifloxacin|400 mg Moxifloxacin single oral dose
346429|NCT01552928|Drug|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
346430|NCT01552915|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
346431|NCT01552915|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
346432|NCT01552915|Drug|Placebo|Daily oral dosing in the AM for 8 weeks
346433|NCT01552902|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
346434|NCT01552902|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
346435|NCT01552902|Drug|Placebo|Daily oral dosing in the AM for 6 weeks
346436|NCT01552889|Behavioral|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
346437|NCT01552876|Device|etafilcon A|A daily wear contact lens
346438|NCT01552876|Device|nelfilcon A|A daily wear contact lens
346439|NCT01552876|Device|Filcon II 3|a daily disposable
346440|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
346441|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
346442|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
346443|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
346444|NCT01552863|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
346445|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
346446|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
346447|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
346448|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
346449|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
346450|NCT01552850|Drug|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
346451|NCT01552837|Drug|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
346452|NCT01552824|Procedure|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
346453|NCT01552824|Procedure|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
346457|NCT01552785|Device|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
346458|NCT01552772|Drug|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
346459|NCT01552759|Procedure|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
346460|NCT01552759|Behavioral|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
346461|NCT01552759|Behavioral|Test meal|Subjects are presented with an ad libitum buffet meal.
346462|NCT01552733|Device|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
346463|NCT01552733|Other|Standard of care|Rehabilitation Therapy
346464|NCT01552707|Biological|XCEL-MT-OSTEO-ALPHA|"Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion."
346465|NCT01552707|Procedure|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
346466|NCT01552694|Drug|Sitagliptin|Oral, 100 mg/day for 2 months
346467|NCT01552694|Drug|Placebo|oral, matching placebo daily for 2 months
346468|NCT01552681|Biological|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
346469|NCT01552681|Other|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
346470|NCT01552668|Drug|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
346471|NCT01552668|Drug|Placebo|Receive Placebo twice daily
346472|NCT01552655|Radiation|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
346473|NCT01552642|Behavioral|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
346474|NCT01552629|Drug|QGE031|
346475|NCT01552629|Drug|Placebo|
346476|NCT01552629|Drug|Cyclosporine A|
346477|NCT01552616|Procedure|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
346478|NCT01552603|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
346479|NCT01552590|Drug|Tolvaptan|
346480|NCT01552590|Drug|Placebo|
346481|NCT01552564|Procedure|Index of microvascular resistance|
346482|NCT01552564|Other|Cardiac magnetic resonance|
346483|NCT01552564|Other|Blood markers|
346484|NCT01552551|Behavioral|Assessment and education|PA Healthy Steps program
346485|NCT01552551|Behavioral|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
346486|NCT01552551|Behavioral|Healthy Steps in Motion|Group exercise program
346487|NCT01552538|Device|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
346488|NCT01552512|Dietary Supplement|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
346489|NCT01552512|Other|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
346490|NCT01552499|Other|Standard of care|
346491|NCT01552499|Other|Applications of EpiFix|
346492|NCT01552486|Other|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
346493|NCT01552486|Other|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
346494|NCT01552473|Behavioral|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
346495|NCT01552473|Behavioral|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
346496|NCT01552447|Other|EpiFix|Dehydrated placental tissue
346497|NCT01552447|Other|Compression Therapy|Compression bandaging
346498|NCT01552434|Biological|Bevacizumab|Given IV
346499|NCT01552434|Biological|Cetuximab|Given IV
346500|NCT01552434|Other|Laboratory Biomarker Analysis|Optional correlative studies
346501|NCT01552434|Other|Pharmacological Study|Optional correlative studies
346502|NCT01552434|Drug|Temsirolimus|Given IV
346503|NCT01552434|Drug|Valproic Acid|Given PO
346504|NCT01552421|Procedure|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
346505|NCT01552408|Drug|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
346506|NCT01552408|Procedure|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
346507|NCT01552369|Drug|Valganciclovir|Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
346508|NCT01552356|Other|Laboratory Biomarker Analysis|Correlative studies
346509|NCT01552356|Drug|Pazopanib Hydrochloride|Given PO
346510|NCT01552356|Other|Pharmacological Study|Correlative studies
346511|NCT01552343|Drug|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
346512|NCT01552343|Drug|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
346513|NCT01552330|Drug|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
346514|NCT01552330|Drug|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~- Dosage: 2 tablets~and~Pyronaridine-Artesunate:~- Dosage: 3 tablets"
346515|NCT01552317|Other|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
346516|NCT01552304|Other|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
346517|NCT01552304|Other|Control group|
346518|NCT01552291|Dietary Supplement|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
346519|NCT01552291|Drug|Placebo|30g oral maltodextrin / day for 5 days before surgery
346520|NCT01552252|Dietary Supplement|apple juice|unaltered(0% POs-Ca) commercially available apple juice
346521|NCT01552252|Dietary Supplement|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
346522|NCT01552252|Dietary Supplement|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
346523|NCT01552252|Dietary Supplement|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
346524|NCT01552252|Dietary Supplement|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
346525|NCT01552239|Radiation|IMRT/IGRT, Tumor resection, Brachytherapy|"All:~Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)~Tumor resection after 4-6 weeks~Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
346526|NCT01552226|Device|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
346527|NCT01552226|Device|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
346528|NCT01552213|Other|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
346529|NCT01552213|Other|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
346530|NCT01552200|Procedure|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
346531|NCT01552200|Procedure|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
346532|NCT01552187|Drug|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (<70kg) 48 to 72 hours before surgery till 1 months after surgery
346533|NCT01552187|Drug|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
346534|NCT01552148|Other|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
346535|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
346536|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
346537|NCT01552122|Drug|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
347981|NCT01540812|Drug|Vincristrine in consolidation-1|
346538|NCT01552122|Drug|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
346539|NCT01552122|Other|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
346540|NCT01552122|Dietary Supplement|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
346541|NCT01552122|Dietary Supplement|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
346542|NCT01552122|Other|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
346543|NCT01552096|Drug|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
346544|NCT01552083|Other|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
346545|NCT01552070|Behavioral|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
346546|NCT01552070|Other|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
346547|NCT01552057|Drug|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
346548|NCT01552057|Drug|Placebo|Placebo taken orally once every day for 15 weeks
346549|NCT01552044|Drug|Spironolactone|25mg tablet once a day for 1 month
346550|NCT01552044|Drug|Placebo|one tablet once a day for 1 month
346551|NCT01552018|Drug|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
346552|NCT01552018|Drug|Placebo|Placebo, 1 tablet per day for 3 months.
346553|NCT01552005|Drug|Saxagliptin|No Intervention
346554|NCT01551992|Procedure|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
346555|NCT01551979|Device|Repetitive Transcranial Magnetic Stimulation|"intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.~Sham participants will undergo the same procedures as those in the active rTMS group."
346556|NCT01551966|Device|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.~During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.~For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.~In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
346557|NCT01551953|Behavioral|Tai chi|12 week tai chi class
346558|NCT01551953|Behavioral|Mind-body breathing|12 week breathing class
346559|NCT01551953|Behavioral|Education|12 week education class
346560|NCT01551940|Drug|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
346561|NCT01551940|Drug|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
346562|NCT01551914|Device|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
346563|NCT01551914|Device|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
346564|NCT01551901|Device|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
346565|NCT01551888|Drug|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
346566|NCT01551888|Drug|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
346567|NCT01551862|Procedure|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
346568|NCT01551836|Drug|Paracetamol formulation 1|formulation 1
346569|NCT01551836|Drug|Paracetamol formulation 2|Formulation 2
346570|NCT01551823|Biological|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
346571|NCT01551823|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
346572|NCT01551810|Biological|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
346573|NCT01551810|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
346574|NCT01551797|Drug|Paracetamol 500 mg|Standard Paracetamol formulation
346575|NCT01551797|Drug|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
346576|NCT01551797|Drug|Paracetamol 750 mg|Paracetamol Sustained Release formulation
346577|NCT01551771|Drug|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
346578|NCT01551771|Drug|GW824575 matched-placebo|Placebo
346579|NCT01551758|Drug|FF/VI|FF/VI
346580|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:~Long acting bronchodilator therapy alone~ICS alone or in combination with a long acting bronchodilator~Triple maintenance therapy"
346581|NCT01551745|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
346582|NCT01551745|Drug|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
346583|NCT01551732|Behavioral|ACT|10 session manualized cognitive behavioral anger control therapy
346584|NCT01551732|Behavioral|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
346585|NCT01551719|Behavioral|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
346586|NCT01551706|Dietary Supplement|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
346587|NCT01551706|Other|Placebo|Placebo
346588|NCT01551693|Drug|STA-9090|
346589|NCT01551680|Radiation|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.~Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.~RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
346590|NCT01551667|Biological|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
346591|NCT01551667|Biological|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
346592|NCT01551654|Device|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
346593|NCT01551641|Other|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
346594|NCT01551641|Drug|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
346595|NCT01551641|Other|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
346596|NCT01551628|Drug|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
346597|NCT01551615|Drug|Metformin 1000 mg|2 x 500 mg oral tablets
346598|NCT01551615|Drug|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
346599|NCT01551602|Drug|AK159|transdermal administration of teriparatide acetate
346600|NCT01551602|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
346601|NCT01551602|Drug|Placebo|Multiple administration of placebo AK159
346602|NCT01551589|Radiation|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33~35F，once a day, 5 times per week.
346603|NCT01551589|Drug|docetaxel and cisplatin|Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
346604|NCT01551589|Radiation|Elective Nodal Irradiation (ENI)|The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
346605|NCT01551550|Procedure|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
346606|NCT01551550|Procedure|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
346607|NCT01551550|Procedure|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
346608|NCT01551537|Other|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
346609|NCT01551537|Other|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
346610|NCT01551524|Biological|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
346611|NCT01551511|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
346612|NCT01551511|Drug|Placebo|Identical step-up approach to the Namisol arm.
346613|NCT01551498|Dietary Supplement|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
346614|NCT01551498|Dietary Supplement|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
346615|NCT01551485|Drug|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
347982|NCT01540812|Drug|Metotrexato in consolidation-1|
346616|NCT01551485|Drug|Placebo|Pacebo tablet, blinded given on the first night after surgery
346617|NCT01551472|Device|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
346618|NCT01551459|Drug|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
346619|NCT01551459|Drug|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
346620|NCT01551446|Drug|Bardoxolone Methyl|Oral, once daily
346621|NCT01551433|Device|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
346622|NCT01551420|Device|Advanced upper limb prosthetic device IMU controlled|Advanced upper limb prosthetic IMU controlled
346623|NCT01551420|Device|Advanced upper limb prosthetic EMG-PR controlled|Advanced upper limb prosthetic EMG-PR controlled
346624|NCT01551407|Drug|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
346625|NCT01551394|Drug|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
346626|NCT01551394|Drug|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:~Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours~Gentamicin:~Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)~Cefotaxime:~Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
346627|NCT01551381|Drug|EV-077|twice daily oral administration
346628|NCT01551381|Drug|Placebo|twice daily oral administration
346629|NCT01551368|Drug|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
346630|NCT01551368|Drug|Placebo|Identical inactive tablets.
346631|NCT01551355|Behavioral|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
346632|NCT01551329|Drug|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
346633|NCT01551316|Drug|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
346634|NCT01551316|Drug|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
346635|NCT01551303|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
346636|NCT01551303|Drug|Placebo|Matched nasal spray placebo
346637|NCT01551290|Drug|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
346638|NCT01551290|Drug|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
346639|NCT01551277|Other|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
346640|NCT01551277|Other|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
346641|NCT01551264|Device|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
346642|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
346643|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
346644|NCT01551225|Drug|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
346645|NCT01551212|Drug|Everolimus|tablet containing 0.25mg, 0.5mg, 0.75mg or 1.0mg
346646|NCT01551212|Drug|Tacrolimus|capsule containing 0.5, 1.0, or 5.0mg
346647|NCT01551212|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids may have been used for the duration of the study according to the investigator`s discretion, but may not have been eliminated sooner than 6 months post-transplantation.
346648|NCT01551199|Behavioral|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
346649|NCT01551186|Dietary Supplement|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
346650|NCT01551173|Drug|Fluvastatin sodium|Fluvastatin sodium Extended Release Tablets 80mg
346651|NCT01551160|Other|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
346652|NCT01551147|Drug|ONO-6950|200 mg QD for 8 days
346653|NCT01551147|Drug|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
346654|NCT01551147|Drug|Montelukast|10 mg Montelukast QD for 8 days
346655|NCT01551134|Procedure|Fundoplication|Primary fundoplication
346656|NCT01551134|Procedure|Fundoplication|Primary fundoplication
346657|NCT01551121|Other|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
346658|NCT01551108|Behavioral|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
346659|NCT01551108|Behavioral|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
346660|NCT01551095|Device|PEGJ tube|The self-propelled PEGJ feeding tube
346661|NCT01551069|Drug|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet~Route of administration: oral"
346662|NCT01551069|Drug|Placebo|"Pharmaceutical form:tablet~Route of administration: oral"
346663|NCT01551056|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
346664|NCT01551056|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
346665|NCT01551043|Biological|CART-19|
346666|NCT01551030|Drug|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
346667|NCT01551004|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
346668|NCT01551004|Other|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
346669|NCT01550978|Device|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
346670|NCT01550965|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
346671|NCT01550939|Device|Ophthalmic Biometer|One complete biometry examination
346672|NCT01550926|Drug|120 mg orlistat|2 X60 mg capsule
346673|NCT01550926|Drug|60 mg orlistat|60 mg orlistat
346674|NCT01550926|Drug|orlistat experimental dose|experimental
346675|NCT01550913|Behavioral|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
346676|NCT01550913|Other|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
346677|NCT01550900|Drug|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
346678|NCT01550900|Other|Placebo|Placebo tablets by mouth 1 time a day.
346679|NCT01550887|Other|No intervention|No intervention will be performed on this study
346680|NCT01550874|Behavioral|Physical activity behavior-change counselling|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and (ii) get feedback about performance toward goals.
346681|NCT01550861|Procedure|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
346682|NCT01550861|Procedure|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
346683|NCT01550848|Drug|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
346684|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
346685|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
346686|NCT01550822|Other|HEALS|
346687|NCT01550809|Other|iBolus|Insulin bolus calculated from data obtained through CGM
346688|NCT01550809|Other|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
346689|NCT01550796|Behavioral|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
346690|NCT01550783|Other|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
346691|NCT01550783|Other|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
346692|NCT01550783|Other|Questionnaire Administration|Ancillary studies
346693|NCT01550783|Procedure|Screening Method|Undergo standard of care Pap test screening
346694|NCT01550783|Procedure|Screening Method|Undergo home-based HPV screening
346695|NCT01550770|Drug|propofol|peripheral IV of propofol at increasing dose levels
346696|NCT01550757|Behavioral|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
346697|NCT01550744|Drug|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
346698|NCT01550744|Drug|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
346699|NCT01550744|Drug|Placebo|Form = Injection, route = subcutaneous
346700|NCT01550731|Behavioral|PREPARE website|Advance care planning website and materials plus an advance directive.
346701|NCT01550731|Behavioral|Advance directive|The control group will only receive an advance directive.
346702|NCT01550718|Behavioral|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
346703|NCT01550718|Behavioral|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
346704|NCT01550705|Drug|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
346705|NCT01550666|Behavioral|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
346706|NCT01550653|Drug|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
346707|NCT01550653|Drug|Placebo|
346708|NCT01550640|Drug|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
346709|NCT01550627|Other|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
346710|NCT01550627|Other|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
346711|NCT01550614|Genetic|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
346712|NCT01550601|Device|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
346713|NCT01550588|Device|Device closure|PFO Amplatzer device closure
346714|NCT01550588|Drug|Standard medical treatment|Standard Medical management using anti-coagulant therapy
346715|NCT01550575|Device|Non Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc.
346716|NCT01550575|Device|Boston Scientific Systems|Spinal cord stimulation, RF, IDS etc
346717|NCT01550562|Device|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
346718|NCT01550549|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
346995|NCT01548469|Other|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
346719|NCT01550536|Behavioral|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
346720|NCT01550523|Drug|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
346721|NCT01550523|Device|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
346722|NCT01550510|Drug|Ascorbic Acid|3x a week for 9 weeks
346723|NCT01550510|Drug|Irinotecan|350mg/m2 once a week every 3 weeks
346724|NCT01550497|Other|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
346725|NCT01550484|Drug|18F-AV-133|222 MBq (6 mCi)
346726|NCT01550471|Drug|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
346727|NCT01550471|Drug|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
346728|NCT01550471|Drug|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
346729|NCT01550471|Drug|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
346730|NCT01550471|Drug|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
346731|NCT01550471|Drug|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
346732|NCT01550458|Drug|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
346733|NCT01550458|Other|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
346734|NCT01550445|Drug|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
346735|NCT01550432|Dietary Supplement|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
346736|NCT01550432|Dietary Supplement|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
346737|NCT01550432|Other|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
346738|NCT01550419|Drug|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
346739|NCT01550419|Drug|Placebo|The smell and shape of placebo are the same as atorvastatin
346740|NCT01550406|Device|Tachocomb|"A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
346741|NCT01550406|Device|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
346742|NCT01550393|Genetic|proteomic profiling|
346743|NCT01550393|Other|enzyme-linked immunosorbent assay|
346744|NCT01550393|Other|laboratory biomarker analysis|
346745|NCT01550393|Other|medical chart review|
346746|NCT01550380|Drug|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
346747|NCT01550367|Drug|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
346748|NCT01550367|Drug|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
346749|NCT01550354|Drug|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
346750|NCT01550354|Drug|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
346751|NCT01550354|Drug|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
346752|NCT01550341|Drug|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
346774|NCT01550172|Behavioral|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
346753|NCT01550315|Procedure|Pulsitile Arterial Tonometry (PAT) Protocol|"A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).~RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.~Continuous recording of pulsatile blood volume responses from both hands will be initiated.~After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
346754|NCT01550315|Device|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
346755|NCT01550315|Device|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
346756|NCT01550302|Procedure|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
346757|NCT01550302|Drug|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
346758|NCT01550289|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
346759|NCT01550289|Biological|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
346760|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
346761|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
346762|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
346763|NCT01550276|Other|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.~The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
346764|NCT01550250|Behavioral|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
346765|NCT01550250|Behavioral|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
346766|NCT01550237|Radiation|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
346767|NCT01550237|Radiation|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
346768|NCT01550224|Drug|Temozolomide|An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.
346769|NCT01550224|Drug|Vorinostat|A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
346770|NCT01550211|Device|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
346771|NCT01550198|Device|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
346772|NCT01550185|Drug|eltrombopag olamine|Given PO
346773|NCT01550185|Procedure|standard follow-up care|Receive standard care
346775|NCT01550172|Behavioral|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments."
346776|NCT01550146|Drug|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
346777|NCT01550146|Drug|Placebo|iv. Normal Saline 0.1 ml/kg
346778|NCT01550133|Behavioral|Learned: Non-nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
346779|NCT01550133|Behavioral|Learned: Nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
346780|NCT01550133|Behavioral|Learned: Nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
346781|NCT01550133|Behavioral|Not Learned: Non-nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
346782|NCT01550133|Behavioral|Not Learned: Nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
346783|NCT01550133|Behavioral|Not Learned: Non-Nutritive solid to Non-nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
346784|NCT01550133|Behavioral|Not Learned: Non-nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
346785|NCT01550133|Behavioral|Not Learned: Non-Nutritive solid to Non-Nutritive Solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
346786|NCT01550107|Drug|Allopurinol|300mg b.d for 24 weeks
346787|NCT01550107|Drug|Lactose tablets|matched placebo tablets b.d
346788|NCT01550081|Other|Rate of perceived exertion|Exercise intensity controlled by Borg scale
346789|NCT01550081|Other|Heart rate monitor|Exercise intensity controlled by heart rate monitors
346790|NCT01550068|Diagnostic Test|Echocardiography|
346791|NCT01550055|Drug|CMAB009 plus Irinotecan|Combined with irinotecan 180 mg/m2 every 2 weeks, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
346792|NCT01550055|Drug|Irinotecan-only and sequential-CMAB009|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, CMAB009 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
346793|NCT01550029|Behavioral|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
346794|NCT01550029|Behavioral|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
346795|NCT01550016|Other|Observation|Clinical follow-up and laboratory investigations.
346796|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range:~10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
346797|NCT01549990|Drug|Sevoflurane|maintenance of general anesthesia with sevoflurane
346798|NCT01549990|Drug|desflurane|maintenance of general anesthesia with desflurane
346799|NCT01549977|Drug|Febuxostat|Febuxostat tablets
346800|NCT01549977|Drug|Placebo|Febuxostat placebo-matching tablets
346801|NCT01549964|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
346802|NCT01549964|Drug|Sitagliptin|Sitagliptin tablets
346803|NCT01549964|Drug|Placebo|Placebo-matching tablets
346804|NCT01549951|Drug|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
346805|NCT01549938|Dietary Supplement|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
346806|NCT01549938|Dietary Supplement|Placebo|Microcellulose capsule identical in appearance to treatment
346807|NCT01549925|Other|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
346960|NCT01548703|Drug|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
346808|NCT01549925|Device|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
346809|NCT01549899|Behavioral|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education & hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
346810|NCT01549899|Behavioral|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
346811|NCT01549886|Drug|Zevalin Regimen|Day 1 - Rituximab 250 mg/m2 intravenous infusion. Day 8 - Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
346812|NCT01549886|Drug|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m2 intravenous infusion.~Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL."
346813|NCT01549873|Drug|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
346814|NCT01549873|Drug|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
346815|NCT01549860|Device|MIST Therapy|Non-contact low frequency ultrasound therapy
346816|NCT01549847|Drug|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
346817|NCT01549847|Drug|Placebo|Placebo PO BID
346818|NCT01549834|Drug|ABT-126|Low Dose
346819|NCT01549834|Drug|ABT-126|High Dose
346820|NCT01549834|Drug|placebo|Placebo
346821|NCT01549808|Other|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
346822|NCT01549808|Other|mobilization|sitting, standing and walking
346823|NCT01549795|Procedure|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
346824|NCT01549795|Radiation|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
346825|NCT01549795|Radiation|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
346826|NCT01549795|Drug|Capecitabine|Capecitabine - administered till liver transplantation
346827|NCT01549795|Procedure|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
346828|NCT01549782|Dietary Supplement|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
346829|NCT01549782|Dietary Supplement|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
346830|NCT01549769|Drug|Bardoxolone Methyl|Oral, once daily
346831|NCT01549756|Behavioral|bulletin board and teleophone depth interview|qualitative based research
346832|NCT01549743|Drug|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
346833|NCT01549743|Drug|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
346834|NCT01549743|Drug|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
346835|NCT01549730|Procedure|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
346836|NCT01549717|Device|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
346837|NCT01549704|Drug|Ropivacaine|"Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).~Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine."
346838|NCT01549704|Drug|Saline|please see intervention description for ropivacaine
346839|NCT01549691|Drug|Zopiclone|7.5 mg before sleep, the evening before surgery
346840|NCT01549691|Drug|Alprazolam|0.5 mg at awakening, the day of surgery
346841|NCT01549691|Drug|placebo|given night before surgery and at awakening, the day of surgery
346842|NCT01549678|Other|Total contact insole|EVA insole shaped on patient´s foot.
346843|NCT01549678|Other|placebo insole|EVA insole flat
346994|NCT01548482|Biological|Trebananib|Given IV
346844|NCT01549665|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
346845|NCT01549652|Drug|Ondansetron|Ondansetron 8 mg oral tablet
346846|NCT01549652|Drug|Placebo|Placebo to Match Ondansetron
346847|NCT01549652|Drug|Morphine|Sustained release oral morphine, beginning at 30 mg/d, titrated up by 15 mg/d every 2 days until adequate analgesia is achieved
346848|NCT01549652|Drug|Naloxone 0.4 mg/70 kg|Naloxone 0.4 mg/70 kg intravenous
346849|NCT01549652|Drug|Naloxone 0.8 mg/70 kg|Naloxone 0.8 mg/70 kg intravenous
346850|NCT01549626|Dietary Supplement|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
346851|NCT01549626|Dietary Supplement|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
346852|NCT01549626|Dietary Supplement|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
346853|NCT01549613|Drug|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
346854|NCT01549613|Drug|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
346855|NCT01549600|Dietary Supplement|psyllium|1 level tablespoon (~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
346856|NCT01549600|Dietary Supplement|Microcrystalline Cellulose|1 level tablespoon (~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
346857|NCT01549587|Drug|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
346858|NCT01549587|Device|toothbrush|brush thoroughly twice daily
346859|NCT01549587|Device|dental floss|floss the whole mouth once daily
346860|NCT01549587|Drug|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
346861|NCT01549587|Device|toothbrush|twice daily brush thoroughly for 2 minutes
346862|NCT01549587|Drug|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
346863|NCT01549587|Device|dental floss|floss the whole mouth once daily
346864|NCT01549574|Drug|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
346865|NCT01549574|Drug|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
346866|NCT01549561|Behavioral|Parent Training|16 weeks of parent training led by a trained group facilitator
346867|NCT01549561|Behavioral|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
346868|NCT01549548|Drug|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
346869|NCT01549535|Device|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
346870|NCT01549522|Behavioral|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
346871|NCT01549522|Behavioral|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
346872|NCT01549509|Biological|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
346873|NCT01549496|Drug|Amlodipine|amlodipine 2.5 mg QD
346874|NCT01549496|Drug|Diltiazem|diltiazem 120 mg qd
346875|NCT01549470|Biological|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
346876|NCT01549470|Biological|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
346877|NCT01549457|Other|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
346878|NCT01549444|Other|presence of maternal risk factor for hypertension|
346879|NCT01549431|Drug|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.~Standard 3+3 design~3 out of 4 weeks"
346880|NCT01549431|Drug|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.~Standard 3+3 design~Days 1/2, 8/9 and 15/16 every 4 weeks"
346881|NCT01549431|Drug|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
346882|NCT01549418|Drug|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
346883|NCT01549418|Drug|Placebo|
346884|NCT01549405|Other|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
346885|NCT01549392|Device|DECT|DECT at tumor progression and 3 months later
346886|NCT01549392|Device|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
346887|NCT01549379|Radiation|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
346888|NCT01549366|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
346889|NCT01549366|Device|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
346890|NCT01549353|Behavioral|gum chewing|
346891|NCT01549327|Other|Oncology Interactive Navigator|
346892|NCT01549327|Other|Routine Care|
346893|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
346894|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
346895|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
346896|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
346897|NCT01549288|Behavioral|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
346898|NCT01549288|Other|no dietetic input|continuation of anti-epileptic medication without any dietetic input
346899|NCT01549262|Device|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
346900|NCT01549262|Device|Observe embryo development|Observe embryo development in the traditional manner
346901|NCT01549249|Device|optical coherence tomography|spectral-domain optical coherence tomography
346902|NCT01549236|Drug|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:~- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
346903|NCT01549223|Drug|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
346904|NCT01549223|Drug|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
346905|NCT01549171|Drug|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
346906|NCT01549171|Other|normal saline|Supplement with vehicle only no Iloprost.
346907|NCT01549158|Drug|torasemide-PR|Single oral dose of torasemide PR 10 mg
346908|NCT01549158|Drug|Furosemide-IR|Single oral dose of furosemide IR 40 mg
346909|NCT01549158|Drug|torasemide-IR|Single oral dose of torasemide IR 10 mg
346910|NCT01549145|Device|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
346911|NCT01549119|Biological|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
346912|NCT01549119|Biological|Placebo|Comparison with experimental vaccine
346913|NCT01549106|Drug|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
346914|NCT01549106|Drug|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
346915|NCT01549093|Drug|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
346916|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
346917|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
346918|NCT01549080|Drug|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
346919|NCT01549054|Drug|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
346920|NCT01549054|Drug|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
346921|NCT01549054|Drug|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
346922|NCT01549054|Drug|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
346923|NCT01549041|Drug|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
346924|NCT01549041|Drug|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
346925|NCT01549028|Behavioral|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
346926|NCT01549015|Other|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
346927|NCT01549002|Drug|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
346928|NCT01549002|Drug|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
346929|NCT01548963|Procedure|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
346930|NCT01548950|Drug|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
346931|NCT01548937|Drug|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
346932|NCT01548924|Drug|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
346933|NCT01548924|Drug|Dovitinib + Paclitaxel|"Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.~Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.~Each cycle will last for 28 days."
346934|NCT01548911|Drug|gemtuzumab ozogamicin|Given IV
346935|NCT01548911|Other|laboratory biomarker analysis|Correlative studies
346936|NCT01548898|Device|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
346937|NCT01548885|Device|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
346938|NCT01548885|Device|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
346939|NCT01548885|Device|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
346940|NCT01548885|Device|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
346941|NCT01548885|Device|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
346942|NCT01548872|Drug|HTK solution|50 ml/kg bolus in 2 minutes
346943|NCT01548872|Drug|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
346944|NCT01548859|Drug|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
346945|NCT01548859|Drug|Sevoflurane|end tidal concentration of % 0,5-8
346946|NCT01548846|Radiation|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
346947|NCT01548833|Device|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
346948|NCT01548833|Device|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
346949|NCT01548833|Device|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
346950|NCT01548807|Drug|Everolimus (RAD001)|
346951|NCT01548794|Procedure|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
346952|NCT01548794|Procedure|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
346953|NCT01548794|Procedure|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
346954|NCT01548781|Behavioral|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
346955|NCT01548768|Drug|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.~The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
346956|NCT01548768|Drug|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
346957|NCT01548742|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
346958|NCT01548742|Behavioral|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
346959|NCT01548729|Procedure|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
347149|NCT01547182|Behavioral|Resistance Training|Lifting weights
346961|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
346962|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
346963|NCT01548690|Drug|Ornithine Phenylacetate|"Up to 36 patients will be enrolled into 2 groups [~18 with minimal renal dysfunction (Cohort 1) & ~18 w/ comprised renal function (Cohort 2)] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.~The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.~The remaining 12 patients (~6 Cohort 1 & ~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
346964|NCT01548677|Drug|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
346965|NCT01548664|Other|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
346966|NCT01548664|Other|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
346967|NCT01548651|Drug|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
346968|NCT01548651|Drug|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
346969|NCT01548638|Drug|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.~Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
346970|NCT01548612|Drug|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
346971|NCT01548612|Drug|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
346972|NCT01548599|Other|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
346973|NCT01548586|Device|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
346974|NCT01548573|Drug|Dexamethasone|Given PO
346975|NCT01548573|Procedure|Tandem autologous stem cell transplant|
346976|NCT01548573|Drug|Cisplatin|Given IV
346977|NCT01548573|Drug|Doxorubicin|Given IV
346978|NCT01548573|Drug|Cyclophosphamide|Given IV or PO
346979|NCT01548573|Drug|Etoposide|Given IV
346980|NCT01548573|Drug|Bortezomib|Given IV
346981|NCT01548573|Drug|Thalidomide|Given PO
346982|NCT01548573|Drug|Melphalan|Given IV
346983|NCT01548560|Drug|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
346984|NCT01548560|Drug|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
346985|NCT01548547|Other|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
346986|NCT01548534|Dietary Supplement|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
346987|NCT01548534|Dietary Supplement|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
346988|NCT01548521|Drug|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
346989|NCT01548508|Other|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
346990|NCT01548508|Other|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
346991|NCT01548482|Other|Laboratory Biomarker Analysis|Correlative studies
346992|NCT01548482|Other|Pharmacological Study|Correlative studies
346993|NCT01548482|Drug|Temsirolimus|Given IV
346996|NCT01548469|Other|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
346997|NCT01548456|Procedure|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
346998|NCT01548456|Procedure|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
346999|NCT01548443|Device|Medifoam H dressing|"Cover medifoam H on the wound for a week."
347000|NCT01548443|Device|Duoderm THIN dressing|"Cover Duoderm THIN on the wound for a week"
347001|NCT01548430|Drug|TTP4000|
347002|NCT01548430|Drug|Placebo|
347003|NCT01548417|Drug|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
347004|NCT01548417|Drug|Sugar Pill|600 mg/day, oral pill, 7 days
347005|NCT01548404|Drug|Placebo|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
347006|NCT01548404|Drug|Dupilumab|Subcutaneous injection altered between back of arms, abdomen and upper thighs.
347007|NCT01548391|Drug|HX-1171|20mg, 200mg, 500mg
347008|NCT01548378|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
347009|NCT01548378|Genetic|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
347010|NCT01548378|Genetic|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
347011|NCT01548378|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
347012|NCT01548365|Other|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.~If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.~If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
347013|NCT01548339|Procedure|Laparoscopic cholecystectomy|3 trocars laparoscopic cholecystectomy
347014|NCT01548326|Drug|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
347015|NCT01548326|Drug|placebo|one Placebo tablet orally per day for 10 days
347016|NCT01548287|Drug|AZD5213|AZD5213 doseA daily
347017|NCT01548287|Drug|AZD5213|AZD5213 doseB daily
347018|NCT01548287|Drug|AZD5213|AZD5213 doseC daily
347019|NCT01548287|Other|Placebo|Placebo tablet daily
347020|NCT01548274|Drug|Sarpogrelate|Sarpogrelate 300mg/day
347021|NCT01548261|Procedure|Donating oral mucosal cells|Donating oral mucosal cells
347022|NCT01548248|Drug|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
347023|NCT01548248|Drug|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
347024|NCT01548235|Drug|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
347025|NCT01548209|Drug|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
347026|NCT01548209|Drug|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
347027|NCT01548196|Procedure|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
347028|NCT01548183|Behavioral|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
347029|NCT01548170|Drug|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
347030|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
347031|NCT01548170|Drug|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
347032|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
347033|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
347034|NCT01548157|Drug|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
347035|NCT01548144|Drug|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.~Expansion Groups Starting Dose: MTD from Phase 1."
347036|NCT01548144|Drug|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1."
347037|NCT01548144|Drug|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.~Expansion Groups Starting Dose: MTD from Phase 1.~Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.~Expansion Group Starting Dose: MTD from Phase 1."
347038|NCT01548131|Behavioral|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
347039|NCT01548118|Biological|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
347191|NCT01546857|Drug|Placebo|Placebo
347040|NCT01548118|Biological|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
347041|NCT01548118|Biological|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
347042|NCT01548118|Biological|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
347043|NCT01548105|Other|Blood draw for the study participants|"These will include:~Procollagen 1-N propeptide levels (PINP)~Matrix metalloproteinase (MMP9)~Plasma Vitamin C levels"
347044|NCT01548092|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
347045|NCT01548079|Drug|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
347046|NCT01548066|Drug|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
347047|NCT01548066|Drug|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
347048|NCT01548053|Other|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
347049|NCT01548040|Device|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
347050|NCT01548040|Device|Quadriceps TENS|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
347051|NCT01548027|Procedure|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
347052|NCT01548027|Procedure|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
347053|NCT01548027|Other|No intervention|No intervention
347054|NCT01548014|Dietary Supplement|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
347055|NCT01548001|Drug|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
347056|NCT01548001|Drug|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
347057|NCT01547988|Other|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
347058|NCT01547962|Device|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
347059|NCT01547962|Other|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
347060|NCT01547949|Dietary Supplement|tart cultivar Montmorency cherry juice|
347061|NCT01547949|Dietary Supplement|placebo cherry fruit drink|
347062|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
347063|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
347064|NCT01547910|Dietary Supplement|Fish Oil|Fish oil given in supplementary dose
347065|NCT01547897|Drug|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
347066|NCT01547806|Drug|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
347067|NCT01547806|Drug|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
347068|NCT01547806|Procedure|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
347069|NCT01547780|Radiation|PET|
347070|NCT01547741|Drug|Doxorubicin|
347071|NCT01547741|Drug|Cyclophosphamide|
347072|NCT01547741|Drug|Docetaxel|
347073|NCT01547741|Drug|Paclitaxel|
347074|NCT01547728|Drug|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
347075|NCT01547715|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine
347076|NCT01547702|Behavioral|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:~Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology~Session 2: Help establish teacher's role; goal setting; introduce behaviour planning~Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals~Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship~Session 5: Help to use instructional interventions for ADHD~Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
347077|NCT01547689|Biological|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
347078|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
347079|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
347080|NCT01547650|Other|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
347081|NCT01547637|Procedure|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
347082|NCT01547637|Procedure|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
347083|NCT01547624|Other|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
347084|NCT01547611|Other|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
347085|NCT01547611|Other|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
347086|NCT01547598|Drug|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
347087|NCT01547598|Drug|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
347088|NCT01547598|Drug|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
347089|NCT01547585|Other|Standardized soy containing muffin|Standardized muffin containing two levels of soy
347090|NCT01547572|Procedure|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
347091|NCT01547572|Procedure|The control group will receive a leaflet only|The control group will receive a leaflet only
347092|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
347093|NCT01547559|Drug|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
347094|NCT01547559|Drug|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
347095|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
347096|NCT01547559|Drug|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
347097|NCT01547546|Drug|GDC-0084|Multiple doses
347098|NCT01547520|Drug|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
347099|NCT01547520|Drug|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
347100|NCT01547507|Device|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
347101|NCT01547494|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
347102|NCT01547494|Dietary Supplement|mixture of omega3 and vitamins|mixture of omega3 and vitamins
347103|NCT01547468|Procedure|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
347104|NCT01547468|Procedure|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
347105|NCT01547455|Drug|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
347106|NCT01547455|Drug|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
347107|NCT01547442|Device|Artisan Aphakia Intraocular Lens|Implantation of an intraocular lens
347108|NCT01547429|Device|Artisan Aphakia Intraocular Lens|Implantation of lens to correct refractive error in aphakic eye
347109|NCT01547416|Drug|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .~Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
347110|NCT01547416|Drug|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.~General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
347111|NCT01547390|Drug|Aspirin|
347112|NCT01547390|Drug|placebo|
347113|NCT01547377|Dietary Supplement|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
347114|NCT01547377|Other|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
347115|NCT01547364|Drug|Saline|Injection of 10 ml of normal saline into the caudal epidural space
347116|NCT01547364|Drug|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
347117|NCT01547351|Other|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
347118|NCT01547325|Drug|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
347119|NCT01547325|Drug|placebo hydrogel|placebo hydrogel
347120|NCT01547312|Drug|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
347121|NCT01547312|Procedure|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
347122|NCT01547312|Procedure|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
347123|NCT01547312|Procedure|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
347124|NCT01547312|Drug|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
347125|NCT01547312|Drug|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
347126|NCT01547312|Drug|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
347127|NCT01547312|Procedure|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
347128|NCT01547299|Drug|Enzalutamide|
347129|NCT01547299|Drug|Leuprolide|
347130|NCT01547299|Drug|Dutasteride|
347131|NCT01547286|Biological|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is < 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
347132|NCT01547286|Radiation|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
347133|NCT01547286|Drug|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
347134|NCT01547273|Procedure|bone graft inside socket only|bone graft inside socket only
347135|NCT01547273|Procedure|bone graft inside and outside socket|bone graft inside and outside socket
347136|NCT01547273|Procedure|no bone graft|no bone graft
347137|NCT01547260|Drug|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
347138|NCT01547260|Drug|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
347139|NCT01547247|Device|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
347140|NCT01547247|Procedure|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
347141|NCT01547221|Drug|clotrimazole|single application of 1%clotrimazole ear drop
347142|NCT01547221|Drug|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
347143|NCT01547208|Procedure|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
347144|NCT01547208|Procedure|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
347145|NCT01547195|Procedure|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.~Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
347146|NCT01547195|Procedure|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.~The training of walking will last 50 minutes, three times per week for 12 weeks.~At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
347147|NCT01547182|Behavioral|Caloric restriction|Caloric restriction
347148|NCT01547182|Behavioral|Aerobic Training|Walking
347150|NCT01547169|Drug|Placebo Comparator|saline, taken twice per day for a 3 week duration
347151|NCT01547169|Drug|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
347152|NCT01547169|Drug|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
347153|NCT01547156|Device|Intervention group|
347154|NCT01547143|Drug|IST and/or alloHCT|"1) Patients will be categorized by their initial serum ferritin level.~Mild ( ferritin<3,000 μg/L): close observation~Moderate (ferritin: 3,000-10,000 μg/L):~Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)~continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.~Severe (ferritin>10,000 μg/L):~initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)~continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.~2) AlloHCT for refractory or reactivated cases."
347155|NCT01547130|Drug|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
347156|NCT01547130|Drug|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
347157|NCT01547117|Radiation|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called carbon monoxide (CO) rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
347158|NCT01547117|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
347159|NCT01547117|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
347160|NCT01547117|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
347161|NCT01547104|Drug|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
347162|NCT01547104|Drug|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
347163|NCT01547091|Biological|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
347164|NCT01547091|Drug|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
347165|NCT01547091|Biological|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
347166|NCT01547078|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
347167|NCT01547078|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
347168|NCT01547052|Behavioral|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
347169|NCT01547052|Behavioral|Enhanced Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
347170|NCT01547026|Behavioral|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
347171|NCT01547000|Drug|placebo|Administered up to 8 weeks.
347172|NCT01547000|Drug|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
347173|NCT01546987|Drug|bicalutamide|Given orally
347174|NCT01546987|Drug|buserelin|Given subcutaneously or intramuscularly
347175|NCT01546987|Drug|flutamide|Given orally
347176|NCT01546987|Drug|goserelin acetate|Given subcutaneously or intramuscularly
347177|NCT01546987|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
347178|NCT01546987|Drug|orteronel|Given orally
347179|NCT01546987|Drug|triptorelin|Given subcutaneously or intramuscularly
347180|NCT01546974|Device|HME filter Twin Star 55, Drager Medical, Germany|
347181|NCT01546974|Device|Heated humidification|
347182|NCT01546961|Drug|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).~Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
347183|NCT01546948|Drug|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
347184|NCT01546948|Drug|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
347185|NCT01546935|Drug|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
347186|NCT01546922|Drug|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
347187|NCT01546909|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
347188|NCT01546896|Drug|buspirone+alprazolam|day 1~7: buspirone 10mg/d + alprazolam 0.5mg / day 8~28: buspirone 20mg/d + alprazolam 0.5mg / day 29~56: buspirone 20~30mg/d + alprazolam 0.5mg
347189|NCT01546896|Drug|alprazolam|0.5mg/d
347190|NCT01546883|Drug|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
347192|NCT01546857|Drug|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
347193|NCT01546844|Other|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
347194|NCT01546818|Biological|SAV001-H|A whole-killed HIV
347195|NCT01546805|Drug|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
347196|NCT01546805|Drug|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
347197|NCT01546792|Behavioral|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
347198|NCT01546779|Device|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
347199|NCT01546766|Device|Pupillometry testing.|
347200|NCT01546753|Drug|Walnut Protein Powder|Dosing begins with a one-day walnut oral desensitization protocol. Starting at 0.1 mg protein and increasing every thirty minutes until a maximum dose of 6 mg is reached or until allergic symptoms develop. After the initial escalation day, subjects will continue daily dosing with dosing build-every two weeks to a maximum dose of 1500mg walnut protein at 34 weeks. A daily maintenance dose (1500mg or the highest dose reached by 34 weeks) will be given for 4 weeks followed by 5 gram oral food challenges to walnut and the second tree nut (at 38 weeks), after which the study will be unblinded. Active treatment subjects will continue on maintenance dosing for up to a total of 298 weeks of therapy. Subjects reaching a qualifying specific IgE to walnut and the test tree nut at any early time point will receive a tolerance oral food challenge to the tree nuts on and 4 weeks off therapy. All subjects will have an oral food challenge on and off therapy at 142 weeks and at 298 weeks.
347201|NCT01546753|Drug|Oat Powder (placebo)|Subjects in the placebo group will undergo the same one-day desensitization protocol as the active treatment group, consuming a maximum dose of 6 mg of oat powder (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of oat powder, the dosing build-up will occur every two weeks through dose 24 (1500mg oat flour) at ~34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein double blind, placebo controlled OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment beginning with initial escalation day.
347202|NCT01546727|Behavioral|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
347203|NCT01546727|Behavioral|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
347204|NCT01546701|Drug|Buprenorphine|2 mg sublingual tablet
347205|NCT01546701|Drug|Morphine|0.1 mg/kg IV morphine
347206|NCT01546688|Drug|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
347207|NCT01546688|Drug|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
347208|NCT01546675|Other|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
347209|NCT01546662|Dietary Supplement|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
347210|NCT01546662|Dietary Supplement|Placebo|1/ 2 capsules, twice daily for 12 weeks
347211|NCT01546649|Drug|TAP-144-SR(6M)|
347212|NCT01546649|Drug|TAP-144-SR(3M)|
347213|NCT01546636|Other|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
347214|NCT01546636|Other|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
347215|NCT01546623|Drug|TAP-144-SR(6M)|
347216|NCT01546623|Drug|TAP-144-SR(3M)|
347217|NCT01546610|Other|insoles intervention|EVA insole with arch support and bar retrocapital
347218|NCT01546610|Other|placebo insole|EVA insole flat
347219|NCT01546597|Drug|Metformin|"Metformin 500 mg bid on Days 1-5~Metformin 850 mg bid on Days 6-10~Metformin 500 mg bid on Days 11-15~Metformin 850 mg bid on Days 16-20"
347220|NCT01546597|Drug|Ranolazine|"Ranolazine 1000 mg bid on Days 11-15~Ranolazine 1000 mg bid on Days 16-20"
347221|NCT01546571|Biological|POL-103A|POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
347222|NCT01546571|Biological|POL-103A without API|Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
347223|NCT01546558|Drug|Metformin|Metformin 1000 mg bid on Days 1-10
347224|NCT01546558|Drug|Ranolazine|Ranolazine 500 mg bid on Days 6-10
347225|NCT01546532|Drug|RLX030|RLX030 as intravenous infusion for 24 hours.
347226|NCT01546532|Drug|Placebo|Intravenous infusion of Placebo over 24 hours
347227|NCT01546519|Drug|Vismodegib|oral repeating dose of 150 mg once daily
347228|NCT01546506|Drug|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
347229|NCT01546493|Radiation|MRI|MRI scan. 3.0 Tesla MRI scans of both hips using Tip(T1-rho) and ultra-short echo time (UTE) sequences.
347230|NCT01546493|Radiation|qCT|Quantitative computed tomography(QCT) scans using a CT phantom
347231|NCT01546493|Other|Motion Analysis|3D motion analysis to assess hip function.
347232|NCT01546493|Radiation|PET-MRI|Positron emission tomography combined with magnetic resonance imaging (PET-MRI) is a technology that will help us examine bone and cartilage at the molecular level.
347434|NCT01544920|Biological|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
347233|NCT01546467|Behavioral|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
347234|NCT01546454|Drug|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
347235|NCT01546454|Drug|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
347236|NCT01546454|Drug|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
347237|NCT01546454|Drug|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
347238|NCT01546441|Behavioral|interprofessional assessment|assessment by interprofessional team
347239|NCT01546441|Behavioral|usual care|usual care in primary care clinic
347240|NCT01546428|Drug|INC280|
347241|NCT01546415|Drug|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
347242|NCT01546402|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
347243|NCT01546402|Procedure|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
347244|NCT01546389|Biological|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
347245|NCT01546389|Drug|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
347246|NCT01546376|Radiation|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
347247|NCT01546376|Other|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
347248|NCT01546363|Other|Blood draw|phlebotomy
347249|NCT01546350|Genetic|PGD|array CGH after blastocyst biopsy
347250|NCT01546350|Procedure|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
347251|NCT01546324|Procedure|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
347252|NCT01546311|Device|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
347253|NCT01546298|Other|Patch tests|Patch tests for allergic reaction
347254|NCT01546285|Device|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
347255|NCT01546272|Device|Insorb resorbable staples|Subcutanous suture using resorbable staples
347256|NCT01546272|Device|Monocryl resorbable wire|Subcutanous suture using resorbable wire
347257|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
347258|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
347259|NCT01546233|Behavioral|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
347260|NCT01546233|Behavioral|standard education|standard education before and after chemotherapy
347261|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
347262|NCT01546207|Procedure|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
347263|NCT01546194|Other|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
347264|NCT01546168|Device|esophageal deviation with IDE device|esophageal deviation during AF ablation
347265|NCT01546155|Radiation|PET imaging|Up to a 120 minute PET scan using [11C]diprenorphine as the radiotracer
347266|NCT01546142|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
347267|NCT01546142|Drug|Placebo|Phosphate buffered saline placebo for injection
347268|NCT01546129|Device|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
347269|NCT01546116|Drug|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
347270|NCT01546103|Dietary Supplement|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
347271|NCT01546103|Dietary Supplement|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
347272|NCT01546090|Drug|Alprazolam|preoperative administration of an orally 0.50 mg single dose
347273|NCT01546090|Drug|placebo|placebo capsules were filled with starch
347274|NCT01546077|Procedure|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
347275|NCT01546064|Device|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
347276|NCT01546064|Device|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
347277|NCT01546051|Drug|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
347278|NCT01546051|Drug|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
347279|NCT01546051|Drug|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
347280|NCT01546051|Drug|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
347281|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
347282|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
347283|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
347284|NCT01546038|Drug|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
347285|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
347286|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
347287|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
347288|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
347289|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
347290|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
347291|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
347292|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
347293|NCT01546025|Behavioral|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
347294|NCT01546025|Behavioral|Relaxation training|One hour training in relaxation techniques
347295|NCT01546012|Device|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
347296|NCT01546012|Device|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
347297|NCT01545999|Other|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.~Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
347298|NCT01545986|Behavioral|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
347299|NCT01545973|Other|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
347300|NCT01545960|Other|not applicable in this study|No actual interventions will be administered for this study.
347301|NCT01545947|Drug|CC-223, erlotinib|"Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotonib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
347302|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
347303|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.~Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
347304|NCT01545934|Behavioral|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
347305|NCT01545921|Other|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.~MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
347306|NCT01545908|Other|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
347307|NCT01545908|Other|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
347308|NCT01545882|Drug|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
347309|NCT01545869|Procedure|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
347310|NCT01545856|Drug|levodopa|levodopa use
347311|NCT01545843|Behavioral|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
347312|NCT01545843|Drug|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
347313|NCT01545830|Dietary Supplement|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
347314|NCT01545817|Drug|Pazopanib followed by everolimus|All patients received Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
347315|NCT01545804|Drug|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
347316|NCT01545791|Drug|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
347317|NCT01545778|Drug|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
347318|NCT01545778|Drug|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
347319|NCT01545765|Drug|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
347320|NCT01545752|Other|teaching by non-interactive CD|teaching book with non-interactive CD
347321|NCT01545752|Other|Interactive CD|Teaching book with interactive CD
347322|NCT01545739|Device|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
347323|NCT01545726|Drug|QAW039|QAW039 was supplied as capsules for oral administration.
347324|NCT01545726|Drug|Placebo|Placebo was supplied as capsules for oral administration.
347325|NCT01545700|Drug|Control-saline|Patients are randomized to receive saline 2 cc
347326|NCT01545700|Drug|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
347327|NCT01545700|Drug|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
347328|NCT01545700|Drug|Control saline|Patients are randomized to receive saline 2 cc
347329|NCT01545700|Drug|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
347330|NCT01545700|Drug|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
347331|NCT01545687|Dietary Supplement|Lactobacillus brevis CD2 lozenge|Dissolved orally
347332|NCT01545687|Other|placebo|Dissolved orally
347333|NCT01545674|Procedure|Blood Draw|Blood will be drawn from the mother and father
347334|NCT01545661|Procedure|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
347335|NCT01545661|Procedure|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
347336|NCT01545648|Drug|Denosumab|"Formulation of Dosage forms~The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.~Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year~Route of administration: subcutaneous injection"
347337|NCT01545635|Drug|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min~Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min~FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.~Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
347338|NCT01545635|Drug|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 <7mm and/or ExTEM CT>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
347339|NCT01545609|Other|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
347340|NCT01545596|Behavioral|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
347341|NCT01545583|Drug|LY3016859 intravenous|Administered intravenously
347342|NCT01545583|Drug|Placebo intravenous|Administered intravenously
347343|NCT01545583|Drug|LY3016859 subcutaneous|Administered subcutaneously
347344|NCT01545583|Drug|Placebo subcutaneous|Administered subcutaneously
347345|NCT01545570|Drug|GSK2376497|GSK2376497 Active Comparator
347346|NCT01545570|Drug|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
347347|NCT01545557|Device|Hyaluronic acid dermal filler gel|1 injection per indication and 1 touch-up injection if necessary
347348|NCT01545531|Drug|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration [13]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
347349|NCT01545518|Drug|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
347350|NCT01545505|Behavioral|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.~A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
347351|NCT01545479|Drug|captopril 25mg|renal blood oxygenation after captopril
347352|NCT01545466|Behavioral|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
347353|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
347354|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
347355|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
347356|NCT01545453|Drug|placebo|subcutaneous dose every 4 weeks
347357|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
347358|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
347359|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
347360|NCT01545440|Drug|placebo|subcutaneous dose every 4 weeks
347361|NCT01545427|Drug|Imatinib mesylate|200 mg bid for 6 months
347362|NCT01545427|Other|Placebo|Placebo coated to match appearance of Gleevec identically.
347363|NCT01545414|Behavioral|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
347364|NCT01545414|Behavioral|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
347365|NCT01545401|Other|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:~I. Phase 1: Formation and training of the CDM team~II. Phase 2: Distributions of the intervention tools~Global CV Risks Self-Management Booklets~CPG to aid clinical decision making~III. Phase 3: Facilitation and support to implement the intervention"
347366|NCT01545388|Drug|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
347367|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
347368|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
347369|NCT01545388|Drug|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
347370|NCT01545375|Biological|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
347371|NCT01545375|Biological|Placebo|4 doses administered intramuscularly
347372|NCT01545375|Biological|Prevnar 13®|4 doses administered intramuscularly
347373|NCT01545375|Biological|PedvaxHIB®|4 doses administered intramuscularly
347374|NCT01545362|Procedure|Total knee arthroplasty|Total knee arthroplasty
347375|NCT01545349|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
347376|NCT01545349|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
347377|NCT01545349|Biological|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
347378|NCT01545336|Drug|Anastrozole|1 mg tablet to be taken 1 time daily
347379|NCT01545336|Drug|Placebo|1 mg tablet to be taken 1 time daily
347380|NCT01545323|Genetic|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
347381|NCT01545310|Drug|SLV354|One dose of ABT-354
347382|NCT01545297|Drug|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
347383|NCT01545297|Drug|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
347384|NCT01545297|Drug|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
347385|NCT01545284|Drug|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
347386|NCT01545271|Drug|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours
347387|NCT01545271|Device|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment)
347388|NCT01545258|Other|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
347435|NCT01544920|Drug|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight <75 kilograms [kg]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
347983|NCT01540812|Drug|PEG-ASP in consolidation-1|
347389|NCT01545232|Biological|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
347390|NCT01545232|Biological|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
347391|NCT01545219|Dietary Supplement|Prebiotic|8g/day xylo-oligosaccharide
347392|NCT01545219|Dietary Supplement|Bi-07|10^9 CFU B. lactis / day
347393|NCT01545219|Dietary Supplement|Synbiotic|8g/day xylo-oligosaccharide + 10^9 CFU Bi-07
347394|NCT01545219|Dietary Supplement|Placebo|8g/day maltodextrin
347395|NCT01545193|Other|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
347396|NCT01545167|Genetic|blood sampling|blood samples obtained to extract biomarkers and dna for analysis, questionnaires
347397|NCT01545154|Device|Transperineal Ultrasound|
347398|NCT01545141|Drug|Chemokine modulatory regimen|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
347399|NCT01545089|Other|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
347400|NCT01545089|Other|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
347401|NCT01545076|Biological|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.2 g/kg body weight (low dose arm)"
347402|NCT01545076|Biological|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
347403|NCT01545076|Biological|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
347404|NCT01545076|Biological|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:~0.4 g/kg body weight (high dose arm)"
347405|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
347406|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
347407|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
347408|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
347409|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
347410|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
347411|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
347412|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
347413|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
347414|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
347415|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
347416|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
347417|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
347418|NCT01545037|Dietary Supplement|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®|Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
347419|NCT01545037|Other|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
347420|NCT01545024|Drug|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
347421|NCT01545011|Other|Inspiratory muscle training|Inspiratory muscle training
347422|NCT01544998|Drug|Nesiritide|10 ug/kg
347423|NCT01544998|Drug|Tadalafil|5 mg
347424|NCT01544998|Drug|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
347425|NCT01544998|Drug|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
347426|NCT01544985|Drug|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
347427|NCT01544985|Drug|placebo po|sterile water
347428|NCT01544972|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
347429|NCT01544972|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
347430|NCT01544959|Drug|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
347431|NCT01544959|Drug|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
347432|NCT01544946|Drug|88% sucrose po|88% sucrose solution (Syrup B.P.)
347433|NCT01544946|Drug|placebo po|sterile water
347436|NCT01544920|Drug|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
347437|NCT01544907|Device|Conventional PTA|Use of conventional balloon for angioplasty only
347438|NCT01544907|Device|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
347439|NCT01544894|Drug|Raloxifene|60 mg/d for one year
347440|NCT01544894|Drug|Strontium ranelate|2 g/d, for one year
347441|NCT01544881|Drug|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
347442|NCT01544881|Drug|Rapid Acting Analog|Subcutaneous Injection
347443|NCT01544868|Other|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
347444|NCT01544855|Dietary Supplement|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
347445|NCT01544842|Drug|0.1 % tacrolimus ointment|applied topically to oral mucosa
347446|NCT01544842|Drug|0.1 % triamcinolone paste|applied topically to oral mucosa
347447|NCT01544842|Drug|Orabase paste|applied topically to oral mucosa
347448|NCT01544829|Dietary Supplement|Theobromine|Single dose of theobromine
347449|NCT01544829|Dietary Supplement|Theobromine|Multiple doses of theobromine
347450|NCT01544829|Dietary Supplement|Placebo|Placebo capsules
347451|NCT01544816|Other|Snack Product|control food product
347452|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 1
347453|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 2
347454|NCT01544803|Behavioral|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
347455|NCT01544803|Behavioral|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
347456|NCT01544790|Procedure|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
347457|NCT01544777|Device|Study IOL|Aspheric IOL for correction of aphakia
347458|NCT01544777|Device|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
347459|NCT01544777|Device|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
347460|NCT01544764|Other|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
347461|NCT01544751|Drug|Low dose metformin|500 mg twice a day
347462|NCT01544751|Drug|Metformin|1000 mg twice a day
347463|NCT01544751|Drug|Atorvastatin|20 mg/day
347464|NCT01544738|Other|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
347465|NCT01544738|Other|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
347466|NCT01544725|Drug|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score~At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).~At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).~At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
347504|NCT01544426|Procedure|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
347505|NCT01544426|Procedure|Office hysteroscopy|Office hysteroscopy
347546|NCT01544166|Drug|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants <2 years of age.
347984|NCT01540812|Drug|Dexamethasone in consolidation-2|
347467|NCT01544725|Drug|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo~At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).~At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.~At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
347468|NCT01544712|Procedure|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
347469|NCT01544712|Procedure|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
347470|NCT01544699|Device|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
347471|NCT01544686|Device|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
347472|NCT01544673|Drug|linezolid|600 mg oral tablet twice daily for 4.5 days
347473|NCT01544673|Drug|Placebo|500 mg oral placebo twice daily for 4.5 days
347474|NCT01544647|Other|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
347475|NCT01544647|Other|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
347476|NCT01544634|Drug|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
347477|NCT01544634|Drug|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
347478|NCT01544634|Drug|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
347479|NCT01544634|Drug|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
347480|NCT01544621|Other|Smoking cessation|Smoking cessation
347481|NCT01544595|Drug|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
347482|NCT01544595|Drug|Placebo|Placebo
347483|NCT01544569|Genetic|DNA analysis|
347484|NCT01544569|Genetic|fluorescence in situ hybridization|
347485|NCT01544569|Genetic|gene expression analysis|
347486|NCT01544569|Genetic|gene mapping|
347487|NCT01544569|Genetic|microarray analysis|
347488|NCT01544569|Genetic|polymerase chain reaction|
347489|NCT01544569|Genetic|protein expression analysis|
347490|NCT01544569|Other|laboratory biomarker analysis|
347491|NCT01544569|Other|medical chart review|
347492|NCT01544530|Other|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
347493|NCT01544517|Drug|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
347494|NCT01544504|Drug|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
347495|NCT01544491|Drug|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
347496|NCT01544491|Drug|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
347497|NCT01544478|Biological|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
347498|NCT01544465|Behavioral|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
347499|NCT01544465|Behavioral|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
347500|NCT01544452|Procedure|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
347501|NCT01544452|Procedure|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
347502|NCT01544439|Procedure|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
347503|NCT01544439|Procedure|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
347541|NCT01544192|Drug|Antioxidant formula|2x1 tablet AOF
347506|NCT01544413|Procedure|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
347507|NCT01544387|Other|Bed Rest|"Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~Subjects may have limited bathroom privileges"
347508|NCT01544387|Other|Activity|"Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired."
347509|NCT01544374|Other|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
347510|NCT01544361|Other|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
347511|NCT01544361|Biological|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
347512|NCT01544361|Biological|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
347513|NCT01544361|Biological|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
347514|NCT01544361|Biological|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
347515|NCT01544348|Other|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
347516|NCT01544348|Biological|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
347517|NCT01544348|Biological|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
347518|NCT01544348|Biological|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
347519|NCT01544348|Biological|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
347520|NCT01544348|Biological|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
347521|NCT01544348|Biological|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
347522|NCT01544348|Biological|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
347523|NCT01544335|Other|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
347524|NCT01544322|Drug|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
347525|NCT01544309|Drug|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.~(When not reach the LDL-C level of target in the Japan Atherosclerosis Society [JAS] Guidelines [GL] after 3 months, had the atorvastatin [ATV] dose of 20 mg.)"
347526|NCT01544309|Drug|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.~(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin [RSV] dose of 10 mg.)"
347527|NCT01544296|Drug|KHK6188|
347528|NCT01544296|Drug|Placebo|
347529|NCT01544283|Drug|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
347530|NCT01544283|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
347531|NCT01544270|Dietary Supplement|Yogurt-like snacks|twice a day 120 g for four weeks
347532|NCT01544257|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
347533|NCT01544257|Procedure|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
347534|NCT01544244|Procedure|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
347535|NCT01544244|Procedure|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
347536|NCT01544231|Biological|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
347537|NCT01544205|Other|fMRI-based neurofeedback|5 sessions lasting one hour each
347538|NCT01544192|Drug|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
347539|NCT01544192|Drug|α−tocopherol|2x300 mg α−tocopherol
347540|NCT01544192|Drug|Placebo|control group did not receive oral neuroprotective agent
347547|NCT01544153|Behavioral|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
347548|NCT01544153|Behavioral|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
347549|NCT01544153|Behavioral|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
347550|NCT01544140|Drug|Midazolam|Oral syrup 7.5 mg, single dose
347551|NCT01544140|Drug|vandetanib|Oral tablets, 800 mg, single dose
347552|NCT01544127|Behavioral|MI-SI+TAU|MI-SI focuses on exploring and resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
347553|NCT01544127|Behavioral|MI-SI-R+TAU|MI-SI-R focuses on resolving ambivalence about living. It consists of 1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
347554|NCT01544127|Other|TAU Alone|Inpatient treatment includes medication management, case management, meals and a bed, milieu therapy consisting of creative and social activities, and a safety plan. Some families of veterans also received education to create a supportive home environment. As part of Veterans Health Administration (VHA) suicide prevention policy, the care of suicidal patients is also overseen by a local Suicide Prevention Coordinator and case managers.
347555|NCT01544114|Drug|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
347556|NCT01544114|Drug|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
347557|NCT01544114|Drug|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
347558|NCT01544101|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
347559|NCT01544101|Dietary Supplement|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
347560|NCT01544088|Behavioral|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
347561|NCT01544088|Behavioral|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
347562|NCT01544075|Behavioral|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
347563|NCT01544075|Behavioral|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
347564|NCT01544062|Drug|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
347565|NCT01544062|Drug|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
347566|NCT01544036|Drug|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
347567|NCT01544010|Behavioral|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
347568|NCT01544010|Behavioral|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
347569|NCT01544010|Behavioral|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
347570|NCT01544010|Behavioral|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
347571|NCT01544010|Behavioral|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
347572|NCT01543997|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
347573|NCT01543997|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
347574|NCT01543984|Other|Tailored Physical Activity|Tailored Physical Activity (3*50 min/week in 10 weeks)
347575|NCT01543984|Behavioral|Health Counselling|Health guidance (1,5h)
347576|NCT01543971|Drug|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
347577|NCT01543971|Drug|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
347578|NCT01543958|Drug|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
347579|NCT01543958|Device|Sevelamer carbonate|
347580|NCT01543945|Drug|Dexamethasone|4 mg iv before induction for high and extremely high risk
347581|NCT01543945|Drug|Ondansetron|4 mg iv before ended surgery 30 min
347582|NCT01543945|Drug|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
347583|NCT01543932|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
347584|NCT01543932|Drug|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
347669|NCT01543165|Drug|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
347585|NCT01543932|Drug|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
347586|NCT01543919|Drug|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
347587|NCT01543919|Drug|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
347588|NCT01543919|Drug|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
347589|NCT01543919|Drug|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
347590|NCT01543919|Drug|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
347591|NCT01543919|Drug|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
347592|NCT01543906|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
347593|NCT01543893|Behavioral|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
347594|NCT01543893|Behavioral|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.~Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
347595|NCT01543880|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
347596|NCT01543867|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
347597|NCT01543854|Drug|RLX030|Intravenous infusion of RLX030 over 20 hrs
347598|NCT01543854|Drug|Placebo|Intravenous infusion of placebo over 20 hours
347599|NCT01543828|Drug|indacaterol|delivered via single-dose dry-powder inhaler
347600|NCT01543828|Drug|placebo|delivered via single-dose dry-powder inhaler
347601|NCT01543815|Behavioral|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
347602|NCT01543815|Behavioral|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
347603|NCT01543815|Other|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
347604|NCT01543802|Drug|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
347605|NCT01543789|Procedure|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
347606|NCT01543789|Procedure|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
347607|NCT01543776|Drug|abiraterone acetate|Given PO
347608|NCT01543763|Drug|PZP115891, PCI-24781|"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19~PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
347609|NCT01543750|Drug|4-Aminopyridine|
347610|NCT01543750|Drug|Placebo|Placebo
347611|NCT01543737|Device|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
347612|NCT01543737|Device|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
347613|NCT01543724|Drug|Lithium|10mg/kg/day for 12 weeks
347614|NCT01543698|Drug|LGX818|
347615|NCT01543698|Drug|MEK162|
347616|NCT01543698|Drug|LEE011|
347617|NCT01543685|Drug|Indomethacin|40 mg TID capsules
347618|NCT01543685|Drug|Indomethacin|40 mg BID capsules
347619|NCT01543685|Drug|Indomethacin|20 mg TID capsules
347620|NCT01543685|Drug|Celecoxib|200 mg capsules
347621|NCT01543685|Drug|Placebo|Capsules
347622|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
347623|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
347624|NCT01543659|Drug|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11−100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
347625|NCT01543633|Drug|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
347626|NCT01543607|Device|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
347627|NCT01543581|Drug|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
347628|NCT01543581|Drug|Placebo|
347629|NCT01543568|Drug|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
347630|NCT01543555|Drug|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
347985|NCT01540812|Drug|ARA-C in consolidation-2|
347631|NCT01543555|Drug|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
347632|NCT01543542|Radiation|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
347633|NCT01543529|Drug|RO4917838|Single dose of RO4917838
347634|NCT01543529|Drug|Placebo to RO4917838|Single dose of placebo to RO4917838
347635|NCT01543529|Other|Alcohol|Standard alcoholic drink
347636|NCT01543490|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
347637|NCT01543490|Other|Vehicle|Placebo twice daily for 2 weeks
347638|NCT01543464|Drug|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
347639|NCT01543451|Drug|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
347640|NCT01543451|Drug|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
347641|NCT01543438|Other|Video Prescription (additional education)|receives video prescriptions
347642|NCT01543412|Drug|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
347643|NCT01543399|Drug|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
347644|NCT01543399|Drug|Placebo|patients of the placebo group will use placebo one a day for 30 days
347645|NCT01543386|Drug|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
347646|NCT01543373|Device|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
347647|NCT01543373|Device|Bare Metal Stent|Bare metal coronary stent
347648|NCT01543360|Procedure|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
347649|NCT01543360|Procedure|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
347650|NCT01543347|Drug|Temocillin|Antibiotic treatment
347651|NCT01543334|Biological|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
347652|NCT01543321|Drug|Tetrabenazine|"Treatment with tetrabenazine consists in:~5-week titration to a maximum dose of 200 mg / day~5 weeks at stable dose~2 weeks in wash-out~The treatment will be blinded for patients and investigators"
347653|NCT01543321|Drug|Placebo|"Treatment with placebo consists in:~5-week titration to a maximum dose of 200 mg / day~5 weeks at stable dose~2 weeks in wash-out~The treatment will be blinded for patients and investigators"
347654|NCT01543282|Device|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
347655|NCT01543269|Drug|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
347656|NCT01543269|Drug|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
347657|NCT01543256|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell.
347658|NCT01543256|Device|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
347659|NCT01543243|Device|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.~Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
347660|NCT01543243|Device|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.~Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
347661|NCT01543230|Device|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
347662|NCT01543217|Other|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
347663|NCT01543217|Other|Ususal care|Routine respiratory care.
347664|NCT01543204|Drug|Etanercept|Administered by subcutaneous injection
347665|NCT01543191|Drug|PUR118|low dose and high dose for 3 doses, BID
347666|NCT01543178|Drug|open-label rifaximin|550 mg three times a day (open-label)
347667|NCT01543178|Drug|double-blind placebo|3 times a day (double-blind)
347668|NCT01543178|Drug|double-blind rifaximin|550 mg three times a day (double-blind)
347670|NCT01543165|Drug|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
347671|NCT01543165|Drug|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
347672|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
347673|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
347674|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
347675|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
347676|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
347677|NCT01543139|Drug|Valproate+Cytidine-+Creatine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
347678|NCT01543139|Drug|Valproate+Cytidine-|Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day
347679|NCT01543139|Drug|Valproate|Valproate: Week0-8: 300mg/day
347680|NCT01543113|Other|sequencing|sequencing
347681|NCT01543100|Other|blood and bone marrow samples|"Specific tests of the study will be realized from :~Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.~Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.~In all cases, no additional sampling will be performed."
347682|NCT01543087|Procedure|blood sampling|Blood sample collection at different time points
347683|NCT01543087|Drug|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
347684|NCT01543074|Dietary Supplement|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
347685|NCT01543074|Dietary Supplement|Garlic oil|1 pill = 30 mg garlic oil/day
347686|NCT01543074|Drug|BSE|2 pills = 200 micromoles of Sulforaphane/day
347687|NCT01543074|Dietary Supplement|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
347688|NCT01543061|Device|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
347689|NCT01543061|Procedure|No treatment|One month of contact lens wear with no eye drop use
347690|NCT01543061|Device|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
347691|NCT01543048|Other|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
347692|NCT01543035|Drug|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
347693|NCT01543022|Device|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
347694|NCT01543022|Procedure|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
347695|NCT01543009|Other|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
347696|NCT01542983|Behavioral|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
347697|NCT01542983|Behavioral|treatment as usual|Standard treatment for fatigue and insomnia
347698|NCT01542970|Dietary Supplement|Placebo|Olive oil
347699|NCT01542970|Dietary Supplement|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
347700|NCT01542970|Dietary Supplement|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
347701|NCT01542970|Dietary Supplement|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
347702|NCT01542957|Behavioral|Combined Cognitive Behavioral and Dilemma-Focused Therapy|7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.
347703|NCT01542957|Behavioral|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
347704|NCT01542944|Drug|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
347705|NCT01542931|Drug|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
347706|NCT01542918|Drug|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.~Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)~Route of administration: Oral"
347798|NCT01542268|Drug|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
347707|NCT01542918|Drug|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial~Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)~Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
347708|NCT01542905|Dietary Supplement|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
347709|NCT01542905|Other|Placebo|Placebo Capsule (1g/day) for 8 Weeks
347710|NCT01542892|Other|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
347711|NCT01542892|Dietary Supplement|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
347712|NCT01542879|Procedure|WB-DW-MR scan|WB-DW-MR scans will be obtained on a 3T PET-MR system
347713|NCT01542879|Procedure|18-F-FDG PET scan|
347714|NCT01542879|Drug|Ferumoxytol|
347715|NCT01542879|Procedure|18-F-FDG PET/MR scan|
347716|NCT01542866|Other|Health Management Tool (HMT)|Mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
347717|NCT01542827|Other|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
347718|NCT01542827|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
347719|NCT01542814|Device|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
347720|NCT01542814|Device|2D FFDM|Standard of care screening mammogram.
347721|NCT01542801|Drug|Norfloxacin|Norfloxacin 400 mg per day
347722|NCT01542801|Drug|ciprofloxacin|Ciprofloxacin 750 mg per week
347723|NCT01542788|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
347724|NCT01542788|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
347725|NCT01542788|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
347726|NCT01542788|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
347727|NCT01542775|Behavioral|Aerobic Exercise Group|12 weeks Aerobic exercise
347728|NCT01542775|Behavioral|Control Group|maintaining usual activities
347729|NCT01542762|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
347730|NCT01542736|Drug|Carboplatin|Administered concurrently with craniospinal radiation.
347731|NCT01542736|Drug|Vincristine|Administered concurrently with craniospinal radiation.
347732|NCT01542736|Radiation|24 Gy|Craniospinal radiation.
347733|NCT01542723|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
347734|NCT01542710|Drug|Ganfort|Bimatoprost/Timolol fixed combination
347735|NCT01542710|Drug|Duotrav|Fixed combination of Travoprost and Timolol
347736|NCT01542697|Drug|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
347737|NCT01542684|Drug|Azacytidine|Starting dose: 40 mg/m^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
347738|NCT01542684|Drug|GM-CSF|250 mcg/m^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
347739|NCT01542671|Behavioral|Intervention|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months~Structured eating plan~Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.~Monthly Motivational phone calls with Lifestyle Counselor for the first year~4 informational DVDs over the two year period~Feedback on submitted food and exercise journals"
347740|NCT01542671|Behavioral|Control|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months~Structured eating plan~5 informational NIDDK mailings over the two year period"
347741|NCT01542645|Drug|Methadone|Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
347742|NCT01542645|Drug|Fentanyl|Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
347743|NCT01542632|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
347744|NCT01542632|Biological|TDV New Formulation|TDV New Formulation subcutaneous injection
347745|NCT01542632|Drug|Placebo|Placebo subcutaneous injection
347746|NCT01542632|Drug|New Formulation Placebo|New Formulation placebo subcutaneous injection
347747|NCT01542619|Biological|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
347748|NCT01542619|Biological|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
347749|NCT01542606|Device|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
347986|NCT01540812|Drug|PEG-ASP in consolidation-2|
347750|NCT01542593|Device|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.~Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
347751|NCT01542580|Device|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
347752|NCT01542580|Device|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
347753|NCT01542580|Device|Vanguard DA 360|Dual-articulation device, only cleared in EU
347754|NCT01542580|Device|Vanguard 360 TiNbN Femur with PS bearing|non-constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
347755|NCT01542580|Device|Vanguard 360 TiNbN Femur with PSC bearing|constrained tibial bearing, titanium niobium nitride coated Vanguard 360 femur
347756|NCT01542567|Drug|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
347757|NCT01542567|Drug|Placebo|Placebo suppositories
347758|NCT01542554|Other|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
347759|NCT01542554|Other|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
347760|NCT01542541|Drug|Rifaximin|550mg BID for 2 days
347761|NCT01542528|Behavioral|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
347762|NCT01542515|Procedure|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
347763|NCT01542502|Drug|Anakinra|Anakinra 100 mg daily subcutaneous injection
347764|NCT01542502|Drug|Placebo|Placebo daily subcutaneous injection
347765|NCT01542489|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
347766|NCT01542489|Drug|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
347767|NCT01542489|Drug|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
347768|NCT01542476|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
347769|NCT01542463|Drug|insulin detemir|Prescribed at the discretion of the physician
347770|NCT01542450|Drug|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
347771|NCT01542450|Drug|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
347772|NCT01542437|Drug|BIBW 2992|"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.~Not to be compared with any other drug."
347773|NCT01542424|Drug|biphasic insulin aspart 30|Prescribed at the discretion of the physician
347774|NCT01542424|Drug|insulin detemir|Prescribed at the discretion of the physician
347775|NCT01542398|Behavioral|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
347776|NCT01542385|Procedure|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
347777|NCT01542372|Drug|Medication augmentation|
347778|NCT01542372|Behavioral|CBT|
347779|NCT01542359|Other|Yogic practice|breathing, meditation, physical postures
347780|NCT01542359|Other|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
347781|NCT01542346|Procedure|subcutaneous adaption|
347782|NCT01542333|Genetic|gene expression analysis|
347783|NCT01542333|Genetic|proteomic profiling|
347784|NCT01542333|Genetic|reverse transcriptase-polymerase chain reaction|
347785|NCT01542333|Genetic|western blotting|
347786|NCT01542333|Other|immunohistochemistry staining method|
347787|NCT01542333|Other|laboratory biomarker analysis|
347788|NCT01542333|Procedure|spectroscopy|
347789|NCT01542320|Dietary Supplement|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
347790|NCT01542320|Other|Placebo|Solution without active Lactobacillus reuteri
347791|NCT01542307|Biological|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
347792|NCT01542307|Biological|Room air|Placebo
347793|NCT01542294|Drug|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
347794|NCT01542294|Drug|Oxaliplatin|130mg/m2 d1 repeated every 21 days
347795|NCT01542281|Dietary Supplement|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
347796|NCT01542281|Other|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
347797|NCT01542268|Drug|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
347987|NCT01540812|Drug|Dexamethasone in consolidation-3|
347799|NCT01542255|Drug|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
347800|NCT01542255|Drug|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
347801|NCT01542255|Drug|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
347802|NCT01542242|Drug|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
347803|NCT01542229|Behavioral|Prolonged Exposure for PTSD (PE) + Treatment as Usual (TAU)|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
347804|NCT01542229|Behavioral|Treatment As Usual (TAU)|Treatment as usual (TAU) will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
347805|NCT01542216|Behavioral|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
347806|NCT01542216|Behavioral|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
347807|NCT01542190|Drug|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
347808|NCT01542151|Other|Time of labor induction|Assigned time of labor induction - morning or evening
347809|NCT01542138|Drug|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
347810|NCT01542138|Drug|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
347811|NCT01542138|Drug|Placebo|Humectant placebo cream
347812|NCT01542125|Drug|Liposomal Lidocaine|4% Liposomal Lidocaine
347813|NCT01542125|Drug|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
347814|NCT01542112|Other|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.~The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
347815|NCT01542112|Other|No treatment|Patients in this arm receive the usual routine in the department.
347816|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
347817|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
347818|NCT01542086|Procedure|Myocardial SPECT|
347819|NCT01542086|Procedure|64-channel coronary CT angiography (CCTA)|
347820|NCT01542073|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
347821|NCT01542060|Drug|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
347822|NCT01542047|Drug|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
347823|NCT01542047|Drug|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
347824|NCT01542034|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
347825|NCT01542034|Drug|Placebo|Phosphate buffered saline placebo for injection
347826|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
347827|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
347828|NCT01542021|Drug|androgen deprivation therapy|
347829|NCT01542008|Behavioral|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
347830|NCT01542008|Behavioral|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
347831|NCT01541969|Device|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.~The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
347917|NCT01541189|Drug|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
347918|NCT01541176|Other|Absence of corticotherapy post-transplantation|No study treatment
347832|NCT01541969|Device|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
347833|NCT01541956|Drug|Metformin|500 mg twice daily
347834|NCT01541956|Drug|vildagliptin|Vildagliptin 50 mg twice daily
347835|NCT01541943|Drug|Atorvastatin|Once daily, administered orally, 8 week
347836|NCT01541943|Drug|Losartan|Once daily, administered orally, 8 week
347837|NCT01541943|Drug|Placebo|Once daily, administered orally, 8 week
347838|NCT01541943|Drug|HL-040XC|Once daily, administered orally, 8 week
347839|NCT01541930|Drug|GK567|Once or twice daily, for 14 days, up to 30 g per day
347840|NCT01541917|Behavioral|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
347841|NCT01541917|Behavioral|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
347842|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
347843|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
347844|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
347845|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
347846|NCT01541904|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
347847|NCT01541891|Drug|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
347848|NCT01541891|Drug|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
347849|NCT01541865|Device|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
347850|NCT01541852|Drug|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
347851|NCT01541852|Drug|Placebo|One tablet twice daily
347852|NCT01541839|Device|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
347853|NCT01541826|Dietary Supplement|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
347854|NCT01541826|Dietary Supplement|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
347855|NCT01541826|Dietary Supplement|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
347856|NCT01541774|Device|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
347857|NCT01541761|Behavioral|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
347858|NCT01541748|Other|Axis|Coloplast's Axis™ Allograft Dermis consists of solvent-dehydrated, gamma-irradiated, preserved human collagen. It is restricted to homologus use as a soft tissue graft for horizontal and vertical soft tissue augmentation of thickness and length.
347859|NCT01541735|Drug|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
347860|NCT01541735|Drug|placebo|Placebo 40 mg dose.
347861|NCT01541709|Drug|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
347862|NCT01541683|Other|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
347863|NCT01541683|Other|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
347864|NCT01541670|Drug|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
347919|NCT01541176|Drug|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :~D1 to D14 : 20 mg/day,~D15 to M1 : 15 mg/day,~M1 to M3 : 10 mg/day,~M3 to M12 : 5 mg/day."
347920|NCT01541150|Behavioral|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
347988|NCT01540812|Drug|Vincristine in consolidation-3|
347865|NCT01541657|Other|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
347866|NCT01541657|Other|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
347867|NCT01541657|Other|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
347868|NCT01541644|Device|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
347869|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
347870|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
347871|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
347872|NCT01541618|Other|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
347873|NCT01541605|Drug|methylphenidate|tablets for oral use
347874|NCT01541605|Drug|Placebo|tablets for oral use
347875|NCT01541592|Other|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of ~1 tablespoon per hour so that the total infusion time will be 6 hours.
347876|NCT01541579|Other|Cx601|120 million cells administered by intralesional injection.
347877|NCT01541579|Other|Saline solution|24 mL saline solution by intralesional injection
347878|NCT01541553|Procedure|Cryotherapy|"Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area"
347879|NCT01541553|Drug|Vehicle|Field treatment with vehicle gel once daily for 3 consecutive days.
347880|NCT01541553|Drug|Ingenol metabute|Field treatment with vehicle gel once daily for 3 consecutive days.
347881|NCT01541540|Behavioral|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
347882|NCT01541540|Behavioral|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
347883|NCT01541527|Biological|blood test|One blood test entering in the usual follow-up of the patient
347884|NCT01541501|Device|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
347885|NCT01541488|Drug|BI 1021958|tablet
347886|NCT01541488|Drug|BI 1021958|drinking solution / tablet
347887|NCT01541488|Drug|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
347888|NCT01541475|Drug|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
347889|NCT01541475|Drug|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
347890|NCT01541462|Other|Weaning|Decrease assistance provided by the ventilator
347891|NCT01541436|Device|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
347892|NCT01541410|Device|Vascutek Hybrid Graft|Single Group Assignment
347893|NCT01541397|Drug|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
347921|NCT01541137|Drug|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
347922|NCT01541137|Drug|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
347989|NCT01540812|Drug|Metotrexato in consolidation-3|
347990|NCT01540812|Drug|PEG-ASP in consolidation-3|
347894|NCT01541384|Device|Vitality GlowCaps|"The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.~Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval."
347895|NCT01541371|Drug|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
347896|NCT01541358|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
347897|NCT01541358|Procedure|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
347898|NCT01541345|Device|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
347899|NCT01541345|Drug|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
347900|NCT01541345|Procedure|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
347901|NCT01541332|Drug|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
347902|NCT01541332|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle."
347903|NCT01541332|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
347904|NCT01541293|Drug|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
347905|NCT01541293|Drug|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
347906|NCT01541280|Drug|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of >15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of >1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
347907|NCT01541280|Other|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of >grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.~If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
347908|NCT01541267|Drug|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
347909|NCT01541254|Device|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
347910|NCT01541228|Device|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.~Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
347911|NCT01541228|Procedure|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.~Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
347912|NCT01541215|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
347913|NCT01541215|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
347914|NCT01541215|Drug|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
347915|NCT01541202|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
347916|NCT01541202|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0ug/kg/day), followed by weekly 10 minutes i.v bolus (0ug/kg/day), from the 3rd week for 23 weeks
347977|NCT01540812|Drug|Fludarabine in induction-2|
347923|NCT01541137|Device|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
347924|NCT01541124|Drug|Opioid|10 mg/pill, po, each 6h, during 6m
347925|NCT01541111|Drug|Magnesiun|75mg pills; each 12h; 12wk
347926|NCT01541098|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
347927|NCT01541098|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
347928|NCT01541085|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
347929|NCT01541085|Drug|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
347930|NCT01541072|Drug|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
347931|NCT01541072|Drug|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils >= 0.5 G/L)
347932|NCT01541059|Drug|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
347933|NCT01541059|Drug|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
347934|NCT01541046|Biological|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
347935|NCT01541046|Biological|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
347936|NCT01541007|Drug|Cabazitaxel|25 mg/m2 every three weeks
347937|NCT01541007|Drug|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
347938|NCT01540994|Radiation|radiation therapy|Stereotactic Body Radiation Therapy
347939|NCT01540981|Device|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
347940|NCT01540981|Other|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
347941|NCT01540968|Behavioral|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
347942|NCT01540955|Behavioral|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
347943|NCT01540942|Dietary Supplement|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;[W=weight（Kg）；H=height（cm）；A=age（year）]
347944|NCT01540942|Other|surgery|bowel resection
347945|NCT01540916|Other|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
347946|NCT01540916|Other|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
347947|NCT01540903|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
347948|NCT01540903|Biological|Saline|Saline
347949|NCT01540877|Procedure|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
347950|NCT01540877|Procedure|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
347951|NCT01540877|Procedure|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
347952|NCT01540877|Procedure|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
347953|NCT01540864|Drug|HPP404|Administered orally once daily for 26 weeks
347954|NCT01540864|Drug|Placebo|Administered orally once daily for 26 weeks
347955|NCT01540851|Behavioral|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
347956|NCT01540851|Other|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
347957|NCT01540838|Drug|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
347958|NCT01540838|Drug|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
347959|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
347960|NCT01540825|Drug|BI 113608|High dose powder for oral solution
347961|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
347962|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
347963|NCT01540825|Drug|Placebo|Powder for oral solution
347964|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
347965|NCT01540825|Drug|BI 113608|High dose powder for oral solution
347966|NCT01540825|Drug|BI 113608|High dose powder for oral solution
347967|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
347968|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
347969|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
347970|NCT01540812|Drug|Vincristine in induction|
347971|NCT01540812|Drug|Daunorubicin in induction|
347972|NCT01540812|Drug|Prednisone in induction|
347973|NCT01540812|Drug|Metotrexato in induction|
347974|NCT01540812|Drug|Cytarabine in induction|
347975|NCT01540812|Drug|Hydrocortisone in induction|
347976|NCT01540812|Drug|Idarubicin in induction-2|
347991|NCT01540812|Procedure|allogeneic HSCT|
347992|NCT01540812|Procedure|Allo HSCT with reduced-intensity conditioning|
347993|NCT01540799|Device|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
347994|NCT01540786|Procedure|High resolution urodynamic assessment|
347995|NCT01540786|Procedure|Conventional urodynamic assessment|
347996|NCT01540773|Drug|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
347997|NCT01540773|Drug|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
347998|NCT01540760|Drug|MCAF5352A|Multiple ascending doses
347999|NCT01540760|Drug|Placebo|Matching MCAF5352A, multiple doses
348000|NCT01540747|Dietary Supplement|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
348001|NCT01540747|Dietary Supplement|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
348002|NCT01540734|Drug|Marketed paracetamol|Marketed formulation
348003|NCT01540734|Drug|Experimental paracetamol formulation|Experimental formulation
348004|NCT01540721|Drug|Marketed paracetamol|marketed formulation
348005|NCT01540721|Drug|Experimental paracetamol formulation|Experimental formulation
348006|NCT01540708|Drug|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
348007|NCT01540708|Drug|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
348008|NCT01540682|Drug|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
348009|NCT01540682|Drug|Cetuximab|~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
348010|NCT01540682|Radiation|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of ~70 Gy.
348011|NCT01540669|Dietary Supplement|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
348012|NCT01540669|Dietary Supplement|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
348013|NCT01540669|Dietary Supplement|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
348014|NCT01540669|Dietary Supplement|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
348015|NCT01540656|Device|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
348016|NCT01540643|Device|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
348017|NCT01540630|Drug|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
348018|NCT01540630|Drug|Placebo|Double-blind placebo comparator for 28 days.
348019|NCT01540604|Drug|CRD007|
348020|NCT01540591|Drug|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
348021|NCT01540591|Drug|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
348022|NCT01540578|Other|laboratory biomarker analysis|Correlative studies
348023|NCT01540565|Other|Laboratory Biomarker Analysis|Correlative studies
348024|NCT01540565|Drug|Veliparib|Given PO
348025|NCT01540552|Other|medical chart review|
348026|NCT01540552|Procedure|computed tomography|
348027|NCT01540552|Procedure|computer-aided detection/diagnosis|
348028|NCT01540539|Drug|REGN1154 or placebo|Participants will receive active drug or placebo
348029|NCT01540526|Drug|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
348030|NCT01540513|Drug|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging~Other Names:~PET imaging with I-124 NM404"
348031|NCT01540513|Drug|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
348032|NCT01540500|Drug|Tasimelteon|5.66 mg dose on Day 1 and Day 8
348033|NCT01540500|Drug|Fluvoxamine|50 mg Dose on Days 2-8
348034|NCT01540487|Drug|linagliptin/metformin(high dose)|patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
348377|NCT01537653|Drug|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
348035|NCT01540487|Drug|Linagliptin/metformin(low dose)|patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
348036|NCT01540474|Biological|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
348037|NCT01540474|Biological|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
348038|NCT01540474|Biological|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
348039|NCT01540461|Drug|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
348040|NCT01540448|Procedure|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
348041|NCT01540448|Procedure|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
348042|NCT01540448|Procedure|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
348043|NCT01540435|Drug|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
348044|NCT01540409|Drug|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
348045|NCT01540396|Behavioral|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
348046|NCT01540383|Behavioral|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, >=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
348047|NCT01540383|Behavioral|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
348048|NCT01540370|Other|No Treatment|No treatment
348049|NCT01540357|Behavioral|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
348050|NCT01540357|Behavioral|Treatment after waiting time|Treatment was performed after completion of the active arm.
348051|NCT01540344|Procedure|CRS|complete macroscopic cytoreduction (CC-0/1)
348052|NCT01540344|Drug|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
348053|NCT01540331|Device|"model 1000 PNT vacuum controller (the vacuum device for ocular suction)"|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
348054|NCT01540318|Procedure|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
348055|NCT01540305|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
348056|NCT01540305|Device|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
348057|NCT01540292|Biological|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
348058|NCT01540266|Procedure|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
348583|NCT01536197|Procedure|Gastric bypass|Roux-en-Y gastric bypass
348059|NCT01540266|Procedure|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
348060|NCT01540253|Drug|PI3K inhibitor BKM120|Given PO
348061|NCT01540253|Drug|docetaxel|Given IV
348062|NCT01540253|Other|pharmacological study|Correlative studies
348063|NCT01540253|Other|questionnaire administration|Ancillary studies
348064|NCT01540253|Other|laboratory biomarker analysis|Correlative studies
348065|NCT01540240|Drug|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
348066|NCT01540240|Drug|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
348067|NCT01540227|Drug|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)~Dose: 2.4 million units~Mode of Administration: intramuscular injection~Duration of Treatment: one dose~Health Canada approved indication: Yes"
348068|NCT01540214|Other|Pre- and postoperative evaluations|"At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).~At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).~At time of surgery: additional cystoscopy."
348069|NCT01540201|Other|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
348070|NCT01540201|Other|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
348071|NCT01540188|Behavioral|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.~Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
348072|NCT01540175|Other|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
348073|NCT01540136|Drug|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
348074|NCT01540136|Drug|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
348075|NCT01540123|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
348076|NCT01540123|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
348077|NCT01540110|Drug|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.~Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.~Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)~5.1.2 Cyclophosphamide~Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.~No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
348078|NCT01540084|Drug|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
348079|NCT01540071|Drug|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
348080|NCT01540058|Other|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).~CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
348081|NCT01540058|Other|No test Empiric strategy|Empiric strategy
348082|NCT01540032|Behavioral|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
348083|NCT01540032|Behavioral|Normal diet|Patients will eat their usual diet.
348084|NCT01540019|Drug|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
348085|NCT01540006|Other|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
348086|NCT01539980|Device|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith&Nephew, London, UK) are applied on the other half of the skin graft donor site
348087|NCT01539967|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~position of 4 trocars and insertion of a nasogastric tube~dissection and mobilization of the greater curvature of the stomach~preparation of the stomach for division~gastric partition~extraction of the gastric remnant~postoperative surveillance"
348088|NCT01539941|Behavioral|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
348089|NCT01539928|Other|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
348090|NCT01539915|Drug|BCT194|Topically applied BCT194 cream (0.5%)
348091|NCT01539902|Biological|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
348092|NCT01539902|Drug|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
348093|NCT01539889|Radiation|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
348094|NCT01539876|Procedure|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
348095|NCT01539863|Other|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
348096|NCT01539863|Other|Treatment as needed|Participants may never receive treatment, there is no upper limit
348097|NCT01539850|Device|OMS102|Subjects will receive implanted OMS102 System.
348098|NCT01539837|Drug|Deferiprone|20mg/kg/d or 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
348099|NCT01539837|Drug|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
348100|NCT01539824|Biological|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
348101|NCT01539824|Radiation|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
348102|NCT01539811|Procedure|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
348103|NCT01539811|Drug|Short course antibiotics|Short course (<2 weeks) of antibiotics will be prescribed
348104|NCT01539811|Drug|Long course antibiotics|Long course (>2 weeks) of antibiotics will be prescribed
348105|NCT01539798|Other|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
348106|NCT01539798|Other|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
348107|NCT01539785|Procedure|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
348108|NCT01539785|Procedure|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
348109|NCT01539759|Device|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
348110|NCT01539746|Procedure|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
348111|NCT01539746|Procedure|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
348112|NCT01539733|Drug|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
348113|NCT01539733|Drug|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
348114|NCT01539720|Drug|Ulipristal acetate|30 mg tablet
348115|NCT01539720|Device|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
348116|NCT01539707|Drug|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
348236|NCT01538836|Behavioral|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
348117|NCT01539681|Drug|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
348118|NCT01539655|Drug|vandetanib|Oral tablets, 300 mg, single dose
348119|NCT01539655|Drug|omeprazole|Oral capsules, 40 mg, multiple doses
348120|NCT01539655|Drug|ranitidine|Oral tables, 150 mg, multiple doses
348121|NCT01539642|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
348122|NCT01539642|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
348123|NCT01539629|Device|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
348124|NCT01539616|Drug|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
348125|NCT01539616|Drug|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
348126|NCT01539616|Drug|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
348127|NCT01539616|Drug|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
348128|NCT01539603|Device|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
348129|NCT01539603|Device|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
348130|NCT01539590|Drug|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
348131|NCT01539590|Drug|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
348132|NCT01539577|Drug|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
348133|NCT01539564|Drug|Minocycline HCl Microspheres|
348134|NCT01539551|Other|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
348135|NCT01539538|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
348136|NCT01539538|Drug|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
348137|NCT01539525|Behavioral|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
348138|NCT01539525|Other|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
348139|NCT01539512|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
348140|NCT01539512|Drug|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m^2, and 500 mg/m^2 thereafter
348141|NCT01539512|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
348142|NCT01539473|Drug|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
348143|NCT01539473|Drug|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
348144|NCT01539460|Procedure|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
348145|NCT01539447|Drug|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
348146|NCT01539447|Drug|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
348147|NCT01539434|Behavioral|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
348148|NCT01539434|Behavioral|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
348149|NCT01539421|Behavioral|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
348150|NCT01539408|Drug|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
348151|NCT01539408|Procedure|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
348152|NCT01539395|Other|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
348153|NCT01539382|Procedure|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow >2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
348154|NCT01539369|Other|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|"Participants were randomly assigned to one of two parallel arms:~Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided."
348155|NCT01539343|Drug|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
348156|NCT01539330|Drug|Voriconazole|"At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min~at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min~at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po"
348157|NCT01539330|Other|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
348158|NCT01539317|Drug|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
348159|NCT01539317|Drug|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
348160|NCT01539304|Drug|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
348161|NCT01539304|Drug|Placebo|Placebo dry syrup, b.i.d
348162|NCT01539291|Drug|Idelalisib|Idelalisib tablet(s) administered orally twice daily
348163|NCT01539278|Procedure|Adenotonsillectomy|Tonsils and adenoids are surgically removed
348164|NCT01539278|Other|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
348165|NCT01539265|Drug|silodosin|
348166|NCT01539265|Drug|silodosin|
348167|NCT01539265|Drug|placebo|
348168|NCT01539252|Procedure|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
348169|NCT01539252|Procedure|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
348170|NCT01539239|Device|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
348171|NCT01539239|Procedure|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
348172|NCT01539226|Combination Product|Placebo Vaginal Ring|Vaginal Ring containing 0.0 mg Dapivirine
348173|NCT01539226|Combination Product|Dapivirine Vaginal Ring, 25 mg|Dapivirine Vaginal Ring containing 25 mg of dapivirine
348174|NCT01539213|Drug|secukinumab (AIN457)|anti-IL-17 antibody
348175|NCT01539200|Dietary Supplement|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
348176|NCT01539200|Dietary Supplement|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
348177|NCT01539187|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
348178|NCT01539174|Biological|rituximab|Given IV
348179|NCT01539174|Drug|cyclophosphamide|Given IV
348180|NCT01539174|Drug|doxorubicin hydrochloride|Given IV
348181|NCT01539174|Drug|vincristine sulfate|Given IV
348182|NCT01539174|Drug|prednisone|Given PO
348183|NCT01539174|Other|laboratory biomarker analysis|Correlative studies
348184|NCT01539174|Other|pharmacological study|Correlative studies
348185|NCT01539161|Device|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
348186|NCT01539161|Procedure|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
348187|NCT01539135|Drug|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
348188|NCT01539122|Device|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
348189|NCT01539122|Device|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
348190|NCT01539109|Behavioral|Rehabilitation|Patients will receive training upon tasks of daily living. They will perform these exercises in our laboratory under the supervision of qualified personnel.
348191|NCT01539109|Procedure|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
348192|NCT01539109|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
348193|NCT01539096|Procedure|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
348194|NCT01539096|Behavioral|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
348237|NCT01538836|Behavioral|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
348238|NCT01538797|Drug|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
348195|NCT01539096|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
348196|NCT01539083|Drug|Thalidomide|Thalidomide 100 mg tablet, orally.
348197|NCT01539083|Drug|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m^2) solution for injection subcutaneously (SC).
348198|NCT01539083|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m^2 orally.
348199|NCT01539083|Drug|Dexamethasone|Dexamethasone 20 mg orally.
348200|NCT01539083|Drug|Prednisolone|Prednisolone 50 mg orally.
348201|NCT01539070|Behavioral|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.~There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
348202|NCT01539057|Drug|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.~Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.~Administration before surgery starts"
348203|NCT01539057|Drug|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
348204|NCT01539044|Drug|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
348205|NCT01539044|Drug|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
348206|NCT01539031|Drug|E2020|"Subjects in the Group-10 mg:~Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg"
348207|NCT01539031|Drug|E2020|"Subjects in the Group-23 mg:~Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg"
348208|NCT01539018|Drug|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
348209|NCT01539018|Drug|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
348210|NCT01538992|Device|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
348211|NCT01538979|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
348212|NCT01538979|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
348213|NCT01538979|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
348214|NCT01538966|Drug|Pegvisomant|
348215|NCT01538966|Drug|Octreotide LAR|
348216|NCT01538966|Drug|Lanreotide|
348217|NCT01538953|Other|handwashing|participants received weekly in-home handwashing promotion and soap as needed
348218|NCT01538953|Other|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
348219|NCT01538953|Other|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
348220|NCT01538940|Biological|Intradermal vaccine|15ug
348221|NCT01538940|Biological|Intramuscular vaccine|15ug
348222|NCT01538927|Drug|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
348223|NCT01538927|Drug|Suture|Black silk 000
348224|NCT01538914|Procedure|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
348225|NCT01538914|Procedure|PCA|Postoperative pain is controlled with intravenous PCA.
348226|NCT01538901|Other|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
348227|NCT01538901|Drug|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
348228|NCT01538888|Procedure|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
348229|NCT01538875|Drug|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
348230|NCT01538875|Drug|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
348231|NCT01538862|Drug|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
348232|NCT01538849|Drug|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
348233|NCT01538849|Drug|YH4808 A mg|1 tablet = YH4808 A mg
348234|NCT01538849|Drug|YH4808 B mg|1 tablet = YH4808 B mg
348235|NCT01538849|Drug|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
348239|NCT01538797|Drug|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
348240|NCT01538784|Drug|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:~Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth~Groups A & B were dosed alternately, at weekly intervals"
348241|NCT01538771|Drug|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
348242|NCT01538771|Drug|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
348243|NCT01538758|Other|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.~After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
348244|NCT01538758|Other|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
348245|NCT01538745|Drug|Ketamine|0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.
348246|NCT01538745|Drug|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
348247|NCT01538732|Drug|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
348248|NCT01538719|Drug|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
348249|NCT01538719|Other|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
348250|NCT01538706|Other|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
348251|NCT01538693|Drug|escitalopram oxalate|10 mg 4.5 hours prior to testing
348252|NCT01538693|Drug|Cyproheptadine|8mg 4.5 hours prior to testing
348253|NCT01538693|Drug|sugar pill|4.5 hour prior to testing
348254|NCT01538693|Other|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
348255|NCT01538680|Drug|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):~Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.~Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
348256|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
348257|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
348258|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
348259|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
348260|NCT01538654|Procedure|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
348261|NCT01538641|Drug|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
348262|NCT01538628|Device|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
348263|NCT01538615|Behavioral|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
348264|NCT01538589|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
348265|NCT01538576|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
348266|NCT01538563|Drug|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
348267|NCT01538550|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
348268|NCT01538550|Procedure|iFOBT|Biennial screening with iFOBT
348372|NCT01537679|Behavioral|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
348584|NCT01536197|Procedure|Gastric banding|Laparoscopic adjustable gastric banding
348269|NCT01538537|Drug|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
348270|NCT01538511|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
348271|NCT01538511|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
348272|NCT01538485|Drug|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
348273|NCT01538472|Drug|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
348274|NCT01538472|Drug|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
348275|NCT01538472|Drug|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.~1000 mg/m2 by vein on Days +1 and +8."
348276|NCT01538472|Drug|BCNU|300 mg/m2 by vein on Day -6.
348277|NCT01538472|Drug|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
348278|NCT01538472|Drug|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
348279|NCT01538472|Drug|Melphalan|140 mg/m2 by vein on Day -1.
348280|NCT01538472|Procedure|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
348281|NCT01538472|Drug|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
348282|NCT01538459|Drug|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
348283|NCT01538459|Drug|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
348284|NCT01538446|Drug|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
348285|NCT01538446|Drug|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
348286|NCT01538446|Device|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
348287|NCT01538420|Drug|GLPG0492|Oral solution
348288|NCT01538420|Drug|Placebo|Placebo oral solution
348289|NCT01538407|Other|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
348290|NCT01538394|Drug|Varenicline|
348291|NCT01538394|Drug|Nicotine patches|
348292|NCT01538394|Drug|Placebo (nicotine patches)|
348293|NCT01538381|Drug|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
348294|NCT01538381|Other|Observation|Observation
348295|NCT01538355|Other|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
348296|NCT01538355|Other|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
348297|NCT01538355|Other|Control diet|Patients stay on their regular diet.
348298|NCT01538342|Other|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
348299|NCT01538342|Other|2 biopsies|
348300|NCT01538342|Other|biopsy|1 biopsy ok healthy skin
348301|NCT01538329|Drug|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
348302|NCT01538329|Drug|placebo|200mg / day once daily in the morning and at noon - oral administration -
348303|NCT01538316|Dietary Supplement|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
348304|NCT01538316|Dietary Supplement|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
348305|NCT01538316|Dietary Supplement|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
348306|NCT01538277|Procedure|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
348307|NCT01538277|Other|Standard ablation procedure|Standard ablation procedure
348308|NCT01538251|Drug|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
348309|NCT01538251|Drug|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
348310|NCT01538238|Drug|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
348311|NCT01538225|Drug|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks"
348312|NCT01538225|Drug|Placebo|"Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks"
348373|NCT01537679|Behavioral|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
348313|NCT01538199|Device|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.~The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
348314|NCT01538199|Device|Sham device|The sham device does not emit near-infrared radiation.
348315|NCT01538173|Drug|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
348316|NCT01538173|Drug|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
348317|NCT01538160|Drug|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
348318|NCT01538108|Device|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
348319|NCT01538108|Procedure|Plain Balloon angioplasty (PBA)|PBA
348320|NCT01538095|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
348321|NCT01538095|Other|Laboratory Biomarker Analysis|Correlative studies
348322|NCT01538095|Other|Pharmacological Study|Correlative studies
348323|NCT01538095|Biological|Trebananib|Given IV
348324|NCT01538069|Other|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
348325|NCT01538069|Other|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
348326|NCT01538069|Other|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
348327|NCT01538056|Device|Fenestrated Endovascular Graft|Modified endovascular graft with fenestrations to allow for blood flow to vital visceral vessels such as the renal arteries and SMA (Superior Mesenteric Artery).
348328|NCT01538043|Other|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
348329|NCT01538017|Drug|Xiapex|Collagenase Clostridium Histolyticum
348330|NCT01538017|Procedure|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
348331|NCT01537991|Radiation|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
348332|NCT01537978|Other|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
348333|NCT01537965|Device|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:~elastography with Fibroscan®~ultrasound elastography in supersonic mode with Aixplorer®~ultrasound analysis of the surface liver with QRS software,~quantification of acoustic structure with Aplio XG,~elastography ARFI with Acuson S2000."
348334|NCT01537939|Behavioral|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
348335|NCT01537926|Drug|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
348336|NCT01537926|Drug|Placebo|sugar pill manufactured to minic NAC 600mg capsule
348337|NCT01537900|Drug|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
348338|NCT01537887|Drug|LY2484595|Administered orally once daily for 10 days.
348339|NCT01537887|Drug|Placebo|Administered orally once daily for 10 days.
348340|NCT01537887|Drug|Moxifloxacin|Single dose administered orally.
348341|NCT01537874|Behavioral|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
348342|NCT01537874|Behavioral|Usual best practices|Standard care delivered using informational materials
348343|NCT01537861|Drug|Filgrastim|
348344|NCT01537861|Drug|Bortezomib|
348345|NCT01537861|Drug|Carfilzomib|
348346|NCT01537861|Drug|Dexamethasone|
348347|NCT01537861|Drug|Cyclophosphamide|
348348|NCT01537861|Drug|Thalidomide|
348349|NCT01537861|Drug|Lenalidomide|
348350|NCT01537861|Drug|Pomalidomide|
348374|NCT01537666|Drug|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
348375|NCT01537666|Drug|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
348376|NCT01537653|Drug|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
348351|NCT01537848|Procedure|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
348352|NCT01537835|Other|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
348353|NCT01537822|Procedure|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
348354|NCT01537822|Procedure|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
348355|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
348356|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
348357|NCT01537796|Behavioral|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
348358|NCT01537796|Behavioral|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
348359|NCT01537796|Behavioral|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
348360|NCT01537783|Drug|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
348361|NCT01537783|Drug|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
348362|NCT01537770|Procedure|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
348363|NCT01537770|Procedure|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
348364|NCT01537757|Drug|MK-8931|Single dose, administered as oral capsules
348365|NCT01537744|Drug|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):~Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)~Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15~Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15~Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15~Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15~Level 4d MTD 8mg/m2 days 8, 15, and 22~Each cycle will last 28 days.~Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.~On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.~Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
348366|NCT01537731|Procedure|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
348367|NCT01537718|Device|REPLY 200|REPLY 200 pacemaker
348368|NCT01537705|Drug|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
348369|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
348370|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
348371|NCT01537692|Drug|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
348378|NCT01537640|Biological|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
348379|NCT01537640|Biological|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
348380|NCT01537627|Other|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.~Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
348381|NCT01537627|Other|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
348382|NCT01537614|Drug|COLIMYCINE inhalation|2 MILLION UI
348383|NCT01537614|Drug|COLIMYCINE injectable|2 MILLIONS UI
348384|NCT01537601|Procedure|Circumcision|Circumcision
348385|NCT01537601|Other|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
348386|NCT01537588|Other|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
348387|NCT01537588|Other|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
348388|NCT01537575|Biological|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
348389|NCT01537575|Biological|Saline solution|Placebo
348390|NCT01537562|Other|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
348391|NCT01537549|Drug|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
348392|NCT01537536|Drug|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
348393|NCT01537523|Procedure|community-care program|community nurse care, physiotherapy
348394|NCT01537510|Behavioral|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
348395|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
348396|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
348397|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
348398|NCT01537497|Drug|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
348399|NCT01537484|Procedure|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
348400|NCT01537471|Drug|Placebo|Placebo
348401|NCT01537471|Drug|Meclizine|Meclizine 12.5 mg
348402|NCT01537471|Drug|Meclizine|Meclizine 25 mg
348403|NCT01537458|Procedure|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
348404|NCT01537432|Drug|secukinumab|secukinumab
348405|NCT01537432|Drug|placebo|placebo comparator
348406|NCT01537419|Behavioral|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
348407|NCT01537419|Behavioral|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
348408|NCT01537406|Radiation|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
348409|NCT01537393|Biological|Cornea tissue transplant|Cornea tissue preserved 0 to 7 days
348410|NCT01537393|Biological|Cornea tissue transplant|Cornea tissue preserved 8 to 14 days.
348411|NCT01537380|Drug|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
348412|NCT01537367|Behavioral|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
348413|NCT01537367|Behavioral|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
348414|NCT01537367|Behavioral|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
348415|NCT01537354|Drug|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
348416|NCT01537354|Drug|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
348417|NCT01537341|Behavioral|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
348418|NCT01537341|Behavioral|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
348419|NCT01537328|Other|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
348420|NCT01537315|Drug|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
348421|NCT01537315|Other|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
348422|NCT01537302|Device|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
348423|NCT01537289|Device|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
348424|NCT01537289|Device|chest tube (28-French)|inserting chest tube to decompress pneumothorax
348425|NCT01537276|Procedure|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
348426|NCT01537263|Device|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
348427|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
348428|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
348429|NCT01537250|Drug|Nemonoxacin 3 tablets|oral form,once daily,7~10 days
348430|NCT01537224|Other|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
348431|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
348432|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
348433|NCT01537185|Other|Placebo|3 cohorts of normal saline injection
348434|NCT01537185|Biological|SPWCV+Alum 100 mcg|3 injections 28 days apart
348435|NCT01537185|Biological|SPWCV+Alum 600 mcg|3 injections 28 days apart
348436|NCT01537185|Biological|SPWCV+Alum 300 mcg|3 injections 28 days apart
348437|NCT01537172|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
348438|NCT01537172|Drug|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
348439|NCT01537159|Device|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
348440|NCT01537146|Drug|Ropivacaine|Bolus infusion via catheter/6H for 24H
348441|NCT01537146|Drug|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
348442|NCT01537133|Drug|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
348443|NCT01537133|Drug|Placebo|Dry Powder Inhaler: Placebo
348444|NCT01537120|Drug|Vildagliptin|
348445|NCT01537120|Drug|Placebo|
348446|NCT01537107|Drug|vismodegib|Given PO
348447|NCT01537107|Drug|sirolimus|Given PO
348448|NCT01537107|Procedure|positron emission tomography|Correlative studies
348449|NCT01537107|Procedure|computed tomography|Correlative studies
348450|NCT01537107|Other|pharmacological study|Correlative studies
348451|NCT01537107|Other|laboratory biomarker analysis|Correlative studies
348452|NCT01537107|Radiation|fludeoxyglucose F 18|Correlative studies
348453|NCT01537094|Dietary Supplement|Placebo|
348454|NCT01537094|Dietary Supplement|Vitamin C 250 mg once daily|
348455|NCT01537094|Dietary Supplement|Vitamin C 1,000 mg once daily|
348456|NCT01537081|Drug|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
348457|NCT01537081|Drug|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
348458|NCT01537081|Drug|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
348459|NCT01537068|Drug|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
348460|NCT01537068|Drug|Placebo|Matching placebo pills
348461|NCT01537055|Drug|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
348462|NCT01537055|Drug|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
348463|NCT01537042|Drug|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.~Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
348464|NCT01537042|Drug|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.~Up to 3 weeks of Titration,~2 weeks of Maintenance,~Up to 4 days of Taper Period."
348585|NCT01536197|Procedure|Sleeve gastrectomy|Sleeve gastrectomy surgery
348465|NCT01537029|Drug|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
348466|NCT01537029|Drug|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
348467|NCT01537016|Device|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
348468|NCT01537016|Device|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
348469|NCT01537003|Device|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
348470|NCT01537003|Device|Coban 2 layer|Compression bandage
348471|NCT01536977|Other|quality-of-life assessment|Ancillary studies
348472|NCT01536977|Other|questionnaire administration|Ancillary studies
348473|NCT01536977|Behavioral|management of therapy complications|Undergo BBT-I
348474|NCT01536977|Behavioral|cognitive assessment|Ancillary studies
348475|NCT01536977|Behavioral|educational intervention|Undergo BBT-I
348476|NCT01536964|Drug|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
348477|NCT01536964|Drug|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
348478|NCT01536951|Drug|LY3009104|administered orally
348479|NCT01536951|Drug|Placebo|Administered orally
348480|NCT01536951|Drug|moxifloxacin|Administered orally
348481|NCT01536938|Drug|LEO 90100|
348482|NCT01536938|Drug|Calcipotriol|
348483|NCT01536938|Drug|Betamethasone|
348484|NCT01536886|Drug|LEO 90100|
348485|NCT01536886|Drug|Betamethasone plus calcipotriol|
348486|NCT01536886|Drug|Ointment vehicle|
348487|NCT01536886|Drug|LEO 90100 vehicle|
348488|NCT01536873|Drug|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
348489|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
348490|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
348491|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
348492|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
348493|NCT01536847|Other|Dietary Intervention|300 mL of liquid food product
348494|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
348495|NCT01536834|Device|Medical Device|
348496|NCT01536808|Other|Cardiac RMI|Cardiac RMI
348497|NCT01536808|Other|Analysis telomere|Analysis telomere
348498|NCT01536808|Other|Stress test|Stress test
348499|NCT01536808|Other|echocardiography|echocardiography
348500|NCT01536795|Drug|WR279 396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
348501|NCT01536795|Drug|WR 279, 396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
348502|NCT01536782|Procedure|Bolus|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
348503|NCT01536782|Procedure|Gravity|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
348504|NCT01536782|Device|Pump|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).~Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
348505|NCT01536756|Other|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
348506|NCT01536756|Other|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
348507|NCT01536743|Drug|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.~PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
348581|NCT01536210|Drug|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
348508|NCT01536730|Behavioral|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
348509|NCT01536717|Drug|Articaine hydrochloride 2% solution|"4 ml/h periosteal wound infusion~duration of 72 h"
348510|NCT01536717|Drug|Sodium Chloride|Placebo Sodium chloride 0,9%
348511|NCT01536704|Drug|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
348512|NCT01536704|Drug|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
348513|NCT01536691|Drug|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
348514|NCT01536691|Drug|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
348515|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
348516|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
348517|NCT01536665|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
348518|NCT01536665|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
348519|NCT01536652|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
348520|NCT01536639|Drug|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
348521|NCT01536626|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
348522|NCT01536613|Drug|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
348523|NCT01536600|Drug|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
348524|NCT01536587|Drug|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
348525|NCT01536574|Drug|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
348526|NCT01536561|Biological|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
348527|NCT01536548|Procedure|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
348528|NCT01536548|Procedure|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
348529|NCT01536535|Drug|Mesalazine|Mesalazine (Pentasa) comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
348530|NCT01536535|Drug|IV Corticosteroid|Treatment with IV Corticosteroid
348531|NCT01536535|Drug|Oral Corticosteroids|Treatment with oral corticosteroids
348532|NCT01536535|Other|Additional Therapies|Anti-TNFα, Calcineurin inhibitor, Immunomodulator
348533|NCT01536535|Procedure|Colectomy|Colectomy
348534|NCT01536522|Dietary Supplement|Nutritional approach for asthma|participants will be provided a medium chain triglyceride supplement or placebo
348535|NCT01536522|Dietary Supplement|Low Caloric Shake|participants will be provided a low caloric dietary shake
348536|NCT01536522|Biological|whole lung allergen challenge|inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation
348537|NCT01536509|Behavioral|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
348538|NCT01536509|Behavioral|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
348539|NCT01536496|Biological|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
348540|NCT01536496|Biological|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
348582|NCT01536210|Drug|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
348541|NCT01536483|Drug|Butyrate enemas|"Seven enemas~Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)~The study remains blinded for the investigation team through the intervention of a clinical research nurse~According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention~Installation time and retention is setted at 15 minutes~Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C~Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
348542|NCT01536470|Other|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
348543|NCT01536470|Other|Ephedryne chorydrate|
348544|NCT01536444|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
348545|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
348546|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
348547|NCT01536431|Drug|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
348548|NCT01536418|Drug|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
348549|NCT01536418|Drug|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
348550|NCT01536405|Biological|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
348551|NCT01536405|Biological|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
348552|NCT01536392|Drug|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
348553|NCT01536392|Drug|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
348554|NCT01536392|Behavioral|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
348555|NCT01536392|Behavioral|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
348556|NCT01536379|Drug|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
348557|NCT01536379|Drug|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
348558|NCT01536366|Drug|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
348559|NCT01536366|Drug|Repaglinide|0.5 mg repaglinide (single-dose)
348560|NCT01536353|Drug|AGSAV301|tablet, q.d.
348561|NCT01536353|Drug|Exforge 10/160|Tablet, q.d.
348562|NCT01536314|Drug|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
348563|NCT01536314|Drug|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
348564|NCT01536301|Drug|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
348565|NCT01536301|Drug|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
348566|NCT01536288|Drug|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
348567|NCT01536288|Drug|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
348568|NCT01536275|Other|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
348569|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
348570|NCT01536262|Device|Respimat|Respimat inhaler
348571|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
348572|NCT01536262|Drug|Olodaterol|Olodaterol once daily inhalation
348573|NCT01536262|Device|Respimat|Respimat inhaler
348574|NCT01536262|Device|Respimat|Respimat inhaler
348575|NCT01536249|Drug|Dexpramipexole|Single Oral Dose
348576|NCT01536249|Drug|Cimetidine plus Dexpramipexole|Multiple Oral Doses
348577|NCT01536236|Device|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
348578|NCT01536236|Device|Placebo|Placebo
348579|NCT01536223|Drug|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
348580|NCT01536223|Drug|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .~And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
348586|NCT01536184|Behavioral|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
348587|NCT01536171|Other|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
348588|NCT01536158|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
348589|NCT01536158|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
348590|NCT01536145|Drug|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
348591|NCT01536132|Drug|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
348592|NCT01536132|Drug|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
348593|NCT01536119|Behavioral|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
348594|NCT01536106|Other|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
348595|NCT01536106|Other|Placebo control|Intracoronary infusion of autologous peripheral blood.
348596|NCT01536093|Other|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
348597|NCT01536093|Other|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
348598|NCT01536067|Biological|ofatumumab|Given IV
348599|NCT01536067|Drug|bortezomib|Given SC
348600|NCT01536067|Other|laboratory biomarker analysis|Correlative studies
348601|NCT01536054|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
348602|NCT01536054|Drug|sirolimus|Given PO
348603|NCT01536054|Other|laboratory biomarker analysis|Correlative studies
348604|NCT01536054|Biological|sargramostim|Given SC
348605|NCT01536041|Drug|ONO-6950|200 mg QD, single dose
348606|NCT01536041|Drug|ONO-6950|20 mg QD, single dose
348607|NCT01536041|Drug|Montelukast|10 mg Montelukast, QD single dose
348608|NCT01536041|Drug|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
348609|NCT01536028|Drug|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
348610|NCT01536028|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
348611|NCT01536028|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
348612|NCT01536028|Drug|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
348613|NCT01536015|Drug|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours~Dosage and Frequency: One patch every 24 hours~Duration: 10 weeks"
348614|NCT01536015|Drug|Placebo|"Frequency: One patch applied every 24 hours~Duration: 10 weeks"
348615|NCT01536002|Drug|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
348616|NCT01535989|Drug|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
348617|NCT01535989|Drug|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
348618|NCT01535976|Drug|Placebo|"Placebo Comparator: Placebo~.9 normal saline infusion"
348619|NCT01535976|Drug|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
348620|NCT01535950|Drug|LFG316|
348621|NCT01535950|Drug|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
348622|NCT01535937|Drug|Ketamine|0.5 mg/kg IV over 40 minutes
348623|NCT01535937|Drug|Midazolam|0.025 mg/kg IV over 40 minutes
348624|NCT01535924|Drug|gemcitabine hydrochloride|Given IV
348625|NCT01535924|Drug|bendamustine hydrochloride|Given IV
348626|NCT01535911|Other|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
348627|NCT01535898|Other|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
348744|NCT01534910|Drug|aged garlic extract|2400 mg a day
348628|NCT01535885|Biological|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
348629|NCT01535872|Dietary Supplement|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
348630|NCT01535859|Drug|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
348631|NCT01535859|Drug|Placebo|1 tablet daily for 8 days.
348632|NCT01535846|Behavioral|Conscious food tasting intervention|Six weekly 2-hour workshops
348633|NCT01535833|Procedure|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
348634|NCT01535820|Drug|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
348635|NCT01535820|Drug|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
348636|NCT01535807|Device|CorMatrix extra cellular matrix (ECM)|"Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.~No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
348637|NCT01535781|Drug|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
348638|NCT01535781|Drug|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
348639|NCT01535768|Drug|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
348640|NCT01535755|Device|protocol|In this group, the patients were weaned as the protocol.
348641|NCT01535755|Other|physician's orders|In this group, the patients were weaned as the clinicians' order.
348642|NCT01535742|Device|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
348643|NCT01535742|Device|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
348644|NCT01535742|Device|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
348645|NCT01535742|Device|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
348646|NCT01535716|Behavioral|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) & cardiac index (CI).~goals:~SVV < 11%~IC > 2,2 ml/min/m²~During the anesthesia"
348647|NCT01535716|Behavioral|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index~Diuresis > 0,5ml/kg/h~Blood pressure , PAM > 65 mmHg~Pulse pressure variation~CVP 8 to 12 cmH20~Visual aspect of the heart~Overload signs During the anesthesia"
348648|NCT01535690|Other|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
348649|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
348650|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
348651|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
348652|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
348653|NCT01535664|Other|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)~On drug Day-7 (visit 1) through Day 1 (visit 2)~Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)~On drug Day 15±2 days (visit 5)"
348654|NCT01535651|Behavioral|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
348655|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
348656|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
348657|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
348658|NCT01535625|Device|Momo stent|Patients with PCI
348740|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
348745|NCT01534910|Drug|placebo|placebo
348659|NCT01535612|Device|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
348660|NCT01535599|Drug|AL-60371, 0.3% Otic Suspension|
348661|NCT01535599|Other|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
348662|NCT01535586|Device|CPAP versus MAD|Cross over design
348663|NCT01535573|Drug|Citalopram|20 mg once per day for 9 weeks
348664|NCT01535573|Drug|Citalopram|40 mg per day for 9 weeks
348665|NCT01535573|Drug|Placebo|0 mg per day for 9 weeks
348666|NCT01535560|Drug|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
348667|NCT01535560|Drug|AL-60371 Vehicle|Inactive ingredients used as placebo
348668|NCT01535547|Drug|isavuconazole|oral
348669|NCT01535547|Drug|tacrolimus|oral
348670|NCT01535521|Device|Sleep Position Trainer (SPT)|
348671|NCT01535508|Drug|Liquid Vitamin D|300 IU/Kg/day not to exceed 10,000 IU/day.
348672|NCT01535495|Drug|Propranolol|Propranolol XL 120mg by mouth once daily
348673|NCT01535482|Behavioral|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
348674|NCT01535482|Behavioral|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
348675|NCT01535469|Drug|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
348676|NCT01535456|Procedure|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
348677|NCT01535443|Drug|Bromfenac|Drug: Bromfenac Other names: PRO-155
348678|NCT01535417|Drug|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
348679|NCT01535417|Drug|Celebrex|
348680|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
348681|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
348682|NCT01535391|Drug|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
348683|NCT01535365|Other|Heat|Application of heat pack to the back or neck sprain.
348684|NCT01535365|Other|Cold|Application of ice pack to the back or neck sprain.
348685|NCT01535352|Behavioral|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
348686|NCT01535352|Behavioral|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
348687|NCT01535326|Procedure|air insufflation|insufflate air during the insertion of colonoscopy
348688|NCT01535326|Procedure|water immersion|infuse water during insertion, aspirate water during withdrawal
348689|NCT01535326|Procedure|water exchange|infuse and remove water during insertion phase of colonoscopy
348690|NCT01535313|Device|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
348691|NCT01535300|Procedure|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
348692|NCT01535287|Drug|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
348693|NCT01535274|Other|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:~FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 30mmHg - beach chair position.~FIO2 100%, PETCO2 45mmHg - beach chair position.~FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
348741|NCT01534962|Drug|Placebo|Oral administration, BID; for a maximum of 112 days.
348742|NCT01534949|Biological|rituximab|375 mg/m2 by intravenous [IV] infusion
348743|NCT01534923|Behavioral|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
348694|NCT01535261|Drug|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
348695|NCT01535248|Other|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
348696|NCT01535235|Drug|Lisinopril|Lisinopril 20mg QD x 24 weeks
348697|NCT01535235|Drug|Placebo|Placebo QD x24wks
348698|NCT01535222|Drug|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
348699|NCT01535222|Drug|Placebo|Commercially available NaCl
348700|NCT01535209|Radiation|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
348701|NCT01535209|Radiation|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
348702|NCT01535196|Drug|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
348703|NCT01535183|Drug|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)~VCR 2㎎/㎡ d0 IV push~Etoposide 100㎎/㎡ d0-d2 IV over 1hr~Carboplatin 450㎎/㎡ d0 IV over 8hrs~Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
348704|NCT01535170|Dietary Supplement|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17].
348705|NCT01535157|Drug|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
348706|NCT01535144|Device|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
348707|NCT01535144|Device|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
348708|NCT01535131|Procedure|palatoplasty|procedure to close cleft palate
348709|NCT01535092|Drug|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
348710|NCT01535092|Drug|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
348711|NCT01535079|Drug|Placebo|Single administration
348712|NCT01535079|Drug|Ibuprofen 35 mg|Single administration
348713|NCT01535079|Drug|Ibuprofen 25 mg|Single administration
348714|NCT01535079|Drug|Ibuprofen 15 mg|Single administration
348715|NCT01535079|Drug|Strefen|Single administration
348716|NCT01535066|Procedure|acupuncture therapy|Receive acupuncture
348717|NCT01535066|Procedure|sham acupuncture|Receive sham acupuncture
348718|NCT01535053|Biological|Dactinomycin|Given IV
348719|NCT01535053|Drug|Leucovorin Calcium|Given PO
348720|NCT01535053|Drug|Methotrexate|Given IV and IM
348721|NCT01535053|Other|Quality-of-Life Assessment|Ancillary studies
348722|NCT01535040|Drug|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
348723|NCT01535040|Drug|placebo|Placebo by mouth through completion of 12 weeks.
348724|NCT01535027|Drug|teriparatide|teriparatide 20 ug/day, sc.
348725|NCT01535027|Drug|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
348726|NCT01535027|Drug|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
348727|NCT01535014|Drug|Dietressa|Comparison of different dosages (frequency) of drug
348728|NCT01535014|Drug|Placebo|"Placebo either (2 tablets 3 times daily) or~(1 tablet 6 times daily)"
348729|NCT01535001|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
348730|NCT01535001|Behavioral|Information|"Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.~Information will be given in a leaflet."
348731|NCT01535001|Drug|Paracetamol|1 g x 4/day
348732|NCT01535001|Drug|Burana|400 mg x 3/day for three weeks
348733|NCT01535001|Drug|Pantoprazole|20mg x 1/day for three weeks
348734|NCT01535001|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
348735|NCT01535001|Behavioral|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
348736|NCT01535001|Other|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
348737|NCT01534975|Diagnostic Test|contrast agent|we are randomizing patients to different contrast agents.
348738|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
348739|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
348746|NCT01534897|Drug|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
348747|NCT01534884|Biological|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
348748|NCT01534871|Behavioral|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
348749|NCT01534858|Device|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
348750|NCT01534845|Drug|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
348751|NCT01534832|Device|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
348752|NCT01534819|Device|EndoAnchor™|Use of the EndoAnchor™ in conjunction with endograft
348753|NCT01534819|Procedure|endovascular treament|implantation of a device inserted through an artery
348754|NCT01534806|Drug|Ketorolac|Ketorolac(0.5mg/kg) IV push
348755|NCT01534806|Drug|Placebo|Sodium Chloride 0.9% - 10 mL IV push
348756|NCT01534793|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
348757|NCT01534780|Procedure|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
348758|NCT01534780|Device|Protack|fixation of mesh with protack
348759|NCT01534780|Device|Securestrap|fixation of mesh with Securestrap
348760|NCT01534780|Device|Glubran|fixation of mesh with Glubran
348761|NCT01534754|Drug|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
348762|NCT01534754|Drug|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
348763|NCT01534754|Drug|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
348764|NCT01534754|Drug|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
348765|NCT01534741|Other|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
348766|NCT01534741|Device|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
348767|NCT01534715|Drug|IMGN529|
348768|NCT01534702|Drug|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (< 60 years vs. ≥ 60 years).~Medication:~Patients < 60 years:~idarubicin 7.5 mg/m2 iv, days 1 + 3~cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~idarubicine 6 mg/m2 iv, days 1 + 3~cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~level -1: 15 mg/m2 iv, days 1 to 5~level 1: 20 mg/m2 iv, days 1 to 5~level 2: 25 mg/m2 iv, days 1 to 5~level 3: 30 mg/m2 iv, days 1 to 5~level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
348769|NCT01534689|Device|Erchonia FX-405™ Laser|The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
348770|NCT01534676|Procedure|Transfusion|A routine medical procedure to transfuse packed red blood cells.
348771|NCT01534676|Biological|Blood|"Processing of RBC for transfusion include the following:~Fresh~Stored~Washed~Frozen (Cryopreserved)"
348772|NCT01534676|Procedure|Chelation therapy|(non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
348773|NCT01534663|Drug|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
348774|NCT01534663|Drug|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
348775|NCT01534637|Drug|aprepitant|Given PO
348776|NCT01534637|Drug|gemcitabine hydrochloride|Given IV
348777|NCT01534637|Drug|capecitabine|Given PO
348778|NCT01534637|Drug|fluorouracil|Given IV
348779|NCT01534637|Procedure|radiation therapy|Undergo radiation therapy
348780|NCT01534637|Other|questionnaire administration|Ancillary studies
348781|NCT01534637|Procedure|quality-of-life assessment|Ancillary studies
348782|NCT01534637|Procedure|nausea and vomiting therapy|Receive aprepitant
348783|NCT01534637|Procedure|management of therapy complications|Receive aprepitant
348784|NCT01534598|Drug|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown be feasible in an expansion cohort of the previous trial.
348821|NCT01534351|Drug|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
348822|NCT01534338|Behavioral|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
348785|NCT01534585|Drug|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.~Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
348786|NCT01534585|Radiation|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
348787|NCT01534585|Drug|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
348788|NCT01534585|Other|Quality of life|The EORTC QLQ-C30 and H&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
348789|NCT01534585|Genetic|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
348790|NCT01534572|Dietary Supplement|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
348791|NCT01534572|Dietary Supplement|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
348792|NCT01534559|Other|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
348793|NCT01534546|Drug|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
348794|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
348795|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
348796|NCT01534533|Dietary Supplement|Placebo|one gelatine capsule containing starch per day, for 12 months
348797|NCT01534533|Dietary Supplement|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
348798|NCT01534533|Dietary Supplement|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
348799|NCT01534533|Dietary Supplement|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
348800|NCT01534520|Drug|Lidocaine|Intravaginal insertion of 4mL 2% lidocaine gel
348801|NCT01534520|Drug|Placebo|KY Jelly
348802|NCT01534494|Drug|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
348803|NCT01534481|Biological|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
348804|NCT01534481|Dietary Supplement|Preterm Formula|Preterm Formula determined by center practice.
348805|NCT01534468|Biological|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
348806|NCT01534455|Drug|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
348807|NCT01534455|Drug|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
348808|NCT01534442|Drug|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
348809|NCT01534442|Drug|Placebo|
348810|NCT01534429|Procedure|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
348811|NCT01534416|Drug|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
348812|NCT01534416|Drug|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
348813|NCT01534403|Biological|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
348814|NCT01534390|Device|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
348815|NCT01534377|Behavioral|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
348816|NCT01534377|Behavioral|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
348817|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
348818|NCT01534351|Drug|Finasteride|Finasteride 5 mg oral tablet taken once daily.
348819|NCT01534351|Drug|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
348820|NCT01534351|Drug|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
349423|NCT01529814|Device|Implant with new abutment connection|New abutment connection implant system
348823|NCT01534338|Behavioral|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
348824|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
348825|NCT01534325|Device|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
348826|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.~The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.~The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.~The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
348827|NCT01534312|Drug|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
348828|NCT01534312|Drug|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
348829|NCT01534299|Device|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
348830|NCT01534286|Drug|Theramine|Theramine 2 capsules 3 times per day
348831|NCT01534286|Drug|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
348832|NCT01534273|Drug|LY2886721|Administered orally.
348833|NCT01534273|Drug|Placebo|Administered orally.
348834|NCT01534260|Drug|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
348835|NCT01534247|Drug|CAZ-AVI|Infusion
348836|NCT01534247|Drug|metronidazole|Infusion
348837|NCT01534247|Drug|CAZ-AVI + metronidazole|Infusion
348838|NCT01534234|Device|PARADYM RF SONR|SonR CRT Optimization
348839|NCT01534234|Device|PARADYM RF SONR|Echocardiography Optimization
348840|NCT01534221|Device|Biomatrix drug eluting stent|Biomatrix drug eluting stent
348841|NCT01534208|Drug|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
348842|NCT01534195|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
348843|NCT01534195|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
348844|NCT01534182|Drug|Fingolimod|0.5 mg orally once a day
348845|NCT01534182|Drug|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
348846|NCT01534182|Drug|Glatiramer acetate (GA)|20 mg subcutaneously once a day
348847|NCT01534169|Drug|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
348848|NCT01534143|Other|pharmacological study|Correlative studies
348849|NCT01534143|Drug|tacrolimus|Given IV
348850|NCT01534143|Drug|sirolimus|Given PO
348851|NCT01534143|Biological|anti-thymocyte globulin|Given IV
348852|NCT01534143|Drug|fludarabine phosphate|Given IV
348853|NCT01534143|Drug|busulfan|Given IV
348854|NCT01534143|Drug|bortezomib|Given IV
348855|NCT01534143|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
348856|NCT01534143|Other|laboratory biomarker analysis|Correlative studies
348857|NCT01534130|Device|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
348858|NCT01534130|Device|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
348859|NCT01534117|Biological|Platelets|1 unit of platelets
348860|NCT01534117|Drug|DDAVP|Desmopressin 0.3mcg/kg IV x 1
348943|NCT01533467|Device|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
351381|NCT01515319|Drug|0.9% saline|Identical volume to that of Y242
348861|NCT01534104|Procedure|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI & DSI, neurological/physical testing & brain MRI showing tumor &/or edema located in or near (<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), &/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately <48 hours before surgery*) fMRI to localize gray matter DTI, DSI & tractography to localize white matter, DSI & updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray &/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (<48 hours after surgery)
348862|NCT01534091|Behavioral|Pedometer with supervision|
348863|NCT01534091|Behavioral|Pedometer without supervision|
348864|NCT01534078|Drug|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
348865|NCT01534078|Drug|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
348866|NCT01534065|Device|Barricaid|Implanted intra-operatively during discectomy
348867|NCT01534052|Drug|Enzalutamide|Oral
348868|NCT01534039|Device|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
348869|NCT01534039|Device|FormaFlex|Hollister skin barrier for ostomy patients
348870|NCT01534026|Drug|Aspirin|Current dose
348871|NCT01534026|Other|withdrawal of aspirin|Stopping current dose of aspirin
348872|NCT01534013|Device|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
348873|NCT01534013|Device|Open loop|glucose sensor and pump
348874|NCT01534000|Procedure|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
348875|NCT01533987|Dietary Supplement|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
348876|NCT01533974|Other|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
348877|NCT01533974|Other|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
348878|NCT01533961|Drug|SCYX-7158|
348879|NCT01533961|Drug|Placebo|
348880|NCT01533948|Drug|axitinib|Given PO
348881|NCT01533948|Other|laboratory biomarker analysis|Correlative studies
348882|NCT01533935|Drug|Placebo|placebo matching tiotropium + olodaterol
348883|NCT01533935|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
348884|NCT01533935|Drug|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
348885|NCT01533935|Drug|Tiotropium|tiotropium
348886|NCT01533935|Drug|Olodaterol|Olodaterol 5 mcg once daily
348887|NCT01533935|Device|Respimat|Respimat inhaler
348888|NCT01533922|Drug|Placebo|placebo matching tiotropium + olodaterol FDC
348889|NCT01533922|Drug|Tiotropium|Tiotropium 5 mcg once daily
348890|NCT01533922|Drug|Olodaterol|Olodaterol 5 mcg once daily
348891|NCT01533922|Drug|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
348892|NCT01533922|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
348893|NCT01533922|Device|Respimat|Respimat inhaler
348894|NCT01533896|Behavioral|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
348895|NCT01533883|Device|Cardioband adjustable band|Cardioband is an adjustable sutureless annuloplasty band designed for mitral valve repair by a transfemoral approach. Cardioband is intended to remodel the annulus by deployment and fixation along the posterior annulus of the mitral valve, in order to correct mitral regurgitation. Adjustment can be performed on a beating heart, to optimize correction of mitral regurgitation.
348896|NCT01533870|Drug|NKTR-118|Oral 25 mg
348897|NCT01533870|Drug|Rifampin|Oral 600 mg
348898|NCT01533857|Dietary Supplement|hot water|Hot water and placebo capsule
348899|NCT01533857|Dietary Supplement|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
348900|NCT01533818|Drug|Amoxicillin|"80-100 mg/kg/day in 2 divided doses for 7 days~For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0"
348901|NCT01533818|Drug|Sugar Syrup|It will be given 2 times/day for 7 days
348902|NCT01533805|Other|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
348903|NCT01533805|Other|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
348904|NCT01533792|Procedure|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
348905|NCT01533792|Procedure|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
348906|NCT01533766|Drug|CombiflexOmega|intravenously over 5 days infusion
348907|NCT01533766|Drug|SmofKabiven|intravenously over 5 days infusion
349182|NCT01531647|Drug|raltegravir|400 mg q12h Days 1-4 and 18-21
349183|NCT01531647|Drug|ritonavir|100 mg q12h Days 8-21
348908|NCT01533753|Drug|Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
348909|NCT01533753|Drug|Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
348910|NCT01533740|Drug|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
348911|NCT01533727|Drug|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
348912|NCT01533727|Drug|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
348913|NCT01533714|Biological|Olokizumab|"Solution for injection with a concentration of Olokizumab of 100 mg/mL Subjects will receive CDP6038 at a dose of 120 mg every two weeks.~This study will continue until approval of the marketing application for the indication of RA in the subject's country or region or until further notice from UCB."
348914|NCT01533701|Other|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
348915|NCT01533688|Drug|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
348916|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
348917|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
348918|NCT01533675|Other|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
348919|NCT01533675|Other|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
348920|NCT01533662|Drug|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
348921|NCT01533662|Drug|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
348922|NCT01533649|Behavioral|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
348923|NCT01533649|Behavioral|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
348924|NCT01533623|Device|Mandibular Advancement Device|Nightly wearing time
348925|NCT01533610|Procedure|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
348926|NCT01533597|Drug|Solifenacin|Solifenacin (5mg, qd, oral)
348927|NCT01533597|Drug|Solifenacin plus Tamsulosin|Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
348928|NCT01533571|Procedure|Immediate implant placement with simultaneous bone grafting|"Flapless surgery is used for surgical implant installation.~Implant is placed in the cingulum position of adjacent teeth incisal edge.~After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.~Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .~Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
348929|NCT01533558|Drug|caspofungin|normal dosage for caspofungin, not adapted for the study
348930|NCT01533545|Drug|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
348931|NCT01533545|Drug|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
348932|NCT01533532|Drug|KLH-2109|
348933|NCT01533532|Drug|KLH-2109|
348934|NCT01533532|Drug|KLH-2109|
348935|NCT01533532|Drug|placebo|
348936|NCT01533519|Drug|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
348937|NCT01533506|Drug|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
348938|NCT01533493|Drug|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
348939|NCT01533493|Drug|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
348940|NCT01533493|Drug|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
348941|NCT01533480|Drug|Zirgan|0.15% ganciclovir gel(Zirgan)
348942|NCT01533480|Drug|genteal gel|0.3% Hypromellose gel
348944|NCT01533454|Other|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
348945|NCT01533441|Dietary Supplement|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
348946|NCT01533428|Drug|Capsaicin 8%|Capsaicin 8% transdermal delivery system
348947|NCT01533428|Drug|Placebo|Placebo Patch
348948|NCT01533415|Device|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of <1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
348949|NCT01533415|Device|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
348950|NCT01533402|Behavioral|therapist support|Weekly therapist support without CBT-interventions
348951|NCT01533402|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
348952|NCT01533389|Drug|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks~Arms: Placebo"
348953|NCT01533389|Drug|Placebo|dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks
348954|NCT01533376|Drug|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
348955|NCT01533376|Drug|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
348956|NCT01533363|Procedure|Stapled hemorrhoidopexy|
348957|NCT01533363|Procedure|Milligan Morgan|
348958|NCT01533337|Procedure|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
348959|NCT01533324|Drug|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
348960|NCT01533298|Drug|CombiflexOmega peri|intravenously over 3 days infusion
348961|NCT01533298|Drug|SmofKabiven peripheral|intravenously over 3 days infusion
348962|NCT01533285|Biological|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
348963|NCT01533285|Biological|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
348964|NCT01533272|Drug|Tenofovir, emtricitabine, maraviroc|experimental drug
348965|NCT01533272|Drug|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
348966|NCT01533259|Drug|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
348967|NCT01533246|Drug|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
348968|NCT01533246|Other|laboratory biomarker analysis|Correlative studies
348969|NCT01533233|Procedure|thoracoscopic lobectomy and mediastinal lymph node dissection|
348970|NCT01533220|Drug|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 03 days
348971|NCT01533220|Drug|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 03 days
348972|NCT01533207|Other|Clinical Observation|Patients followed clinically
348973|NCT01533207|Drug|Docetaxel|Given IV
348974|NCT01533207|Drug|Doxorubicin Hydrochloride|Given IV
348975|NCT01533207|Biological|Filgrastim|Given subcutaneously (SC)
348976|NCT01533207|Drug|Gemcitabine Hydrochloride|Given IV
348977|NCT01533207|Biological|Pegfilgrastim|Given SC
348978|NCT01533194|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
348979|NCT01533194|Biological|Wild-type Reovirus|Given IV
348980|NCT01533181|Other|Laboratory Biomarker Analysis|Correlative studies
348981|NCT01533181|Drug|Linsitinib|150 mg given orally (PO) twice a day (BID)
348982|NCT01533181|Other|Pharmacological Study|Correlative studies
348983|NCT01533181|Drug|Topotecan Hydrochloride|1.5 mg/m^2 intravenously (IV) or 2.3 mg/m^2 orally (PO)
348984|NCT01533168|Genetic|cytogenetic analysis|
348985|NCT01533168|Genetic|nucleic acid sequencing|
348986|NCT01533168|Other|diagnostic laboratory biomarker analysis|
348987|NCT01533168|Other|laboratory biomarker analysis|
348988|NCT01533168|Other|medical chart review|
348989|NCT01533155|Drug|Nektar 118|Oral 25 mg tablet
348990|NCT01533155|Drug|Quinidine|Oral 200 mg tablet
348991|NCT01533155|Drug|Quinidine placebo|Oral Tablet
348992|NCT01533155|Drug|Morphine|10 mg/ml, intravenously
348993|NCT01533142|Procedure|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::~sleeve gastrectomy or gastric bypass"
349862|NCT01526681|Procedure|Autologous Breast Reconstruction without Neurotization|
348994|NCT01533142|Procedure|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
348995|NCT01533129|Drug|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
348996|NCT01533129|Drug|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
348997|NCT01533116|Drug|BIA 9-1067|
348998|NCT01533116|Drug|Placebo|
348999|NCT01533116|Drug|levodopa/carbidopa|
349000|NCT01533116|Drug|levodopa/benserazide|
349001|NCT01533090|Drug|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
349002|NCT01533090|Drug|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
349003|NCT01533077|Drug|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
349004|NCT01533077|Drug|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
349005|NCT01533038|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
349006|NCT01533038|Procedure|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
349007|NCT01533025|Procedure|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
349008|NCT01533012|Procedure|Pressure difference|Peak inspiratory pressures difference between two lungs
349009|NCT01532999|Behavioral|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
349010|NCT01532999|Behavioral|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
349011|NCT01532986|Other|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
349012|NCT01532986|Other|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
349013|NCT01532973|Drug|Elbasvir|Elbasvir was administered orally by tablet(s)
349014|NCT01532973|Drug|Placebo|Dose-matched placebo tablets were administered orally.
349015|NCT01532960|Biological|poly-ICLC|poly-ICLC
349016|NCT01532960|Biological|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA & CTA derived breast cancer proteins.
349017|NCT01532960|Biological|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
349018|NCT01532947|Procedure|post placement|placement of an endocanalar post
349019|NCT01532934|Behavioral|motivational enhancement therapy|Four 45-minute MET sessions
349020|NCT01532934|Other|standard care|
349021|NCT01532921|Procedure|Tricuspid valve repair|
349022|NCT01532921|Procedure|Left-sided heart surgery|Tricuspid valve repair was with the study device was only warranted if concomitant left-sided heart surgery was planned
349023|NCT01532921|Device|Contour 3D Tricuspid Annuloplasty Ring|Contour 3D Tricuspid Annuloplasty procedure was used during the tricuspid valve repair
349024|NCT01532908|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
349025|NCT01532908|Drug|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
349026|NCT01532908|Drug|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
349027|NCT01532895|Drug|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
349028|NCT01532882|Drug|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
349029|NCT01532882|Drug|Placebo|tablet, PO, 1 per day during 28 days
349030|NCT01532869|Drug|Placebo|Subcutaneously weekly, Weeks 0-48
349031|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
349032|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
349033|NCT01532856|Drug|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
349034|NCT01532856|Drug|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
349035|NCT01532856|Drug|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
349036|NCT01532843|Drug|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
349037|NCT01532830|Device|n-VNS|
349038|NCT01532817|Device|AlphaCore|A single 90 second stimulation to the vagus nerve on the right side of the neck
349039|NCT01532804|Drug|bevacizumab, oxaliplatin and 5FU combination|"Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.~Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)"
349040|NCT01532804|Drug|Bevacizumab, oxaliplatin and raltitrexed combination|"Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.~Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min"
349041|NCT01532765|Procedure|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
349042|NCT01532765|Procedure|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
349043|NCT01532765|Procedure|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
349044|NCT01532739|Behavioral|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
349045|NCT01532726|Drug|ESL|ESL 400/800/1200 mg tablets once daily
349046|NCT01532713|Procedure|oxygen administration|nasal O2 5L/min via nasal cannula
349047|NCT01532700|Drug|Ofatumumab with GSK2110183|"GSK2110183 125mg OD continuously~Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
349048|NCT01532687|Drug|Gemcitabine Hydrochloride|Given IV
349049|NCT01532687|Other|Laboratory Biomarker Analysis|Correlative studies
349050|NCT01532687|Drug|Pazopanib Hydrochloride|Given PO
349051|NCT01532687|Other|Placebo|Given PO
349052|NCT01532674|Device|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:~The procedure is the same as in the control group~APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :~The photosensitive agent : Formulation Periowave Treatment Kit-2ml~Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.~Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.~All the periodontal pockets will be treated subgingivally~Elimination of the photosensitive by irrigation"
349053|NCT01532674|Procedure|scaling and root planing|"ROOT PLANNING PROCEDURE:~An unique operator ( independent from the explorer) will do the root planing for both the test and control group.~Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.~* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
349054|NCT01532661|Other|observational study|data collected by investigators
349055|NCT01532648|Drug|Budesonide MMX®|Oral tablet taken daily in the morning after breakfast.
349056|NCT01532648|Drug|Placebo|Matching budesonide MMX placebo oral tablet taken daily in the morning after breakfast.
349057|NCT01532648|Drug|5-ASA|"Acceptable oral 5-ASA medications to be received during the study include:~Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g"
349058|NCT01532635|Radiation|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
349059|NCT01532635|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
349060|NCT01532635|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
349061|NCT01532635|Drug|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
349062|NCT01532635|Drug|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
349063|NCT01532635|Biological|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
349064|NCT01532622|Dietary Supplement|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
349065|NCT01532622|Other|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
349066|NCT01532609|Behavioral|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
349067|NCT01532596|Behavioral|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
349068|NCT01532583|Other|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
349069|NCT01532570|Drug|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
349070|NCT01532544|Drug|Ilomedin and Integrilin|Continuous infusion
349071|NCT01532544|Drug|low molecular weight heparin.|
349072|NCT01532531|Device|"GEMORE Multi-Function Electrotherapy Stimulator"|"The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
349073|NCT01532518|Drug|Nepadutant|Nepadutant oral solution
349074|NCT01532466|Drug|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
349075|NCT01532453|Device|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
349076|NCT01532453|Other|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
349077|NCT01532414|Drug|Androxal|oral, capsules, taken one time daily, for 3 months
349078|NCT01532414|Drug|Placebo|Oral capsule taken one time daily for 3 months
349079|NCT01532401|Other|sodium chloride|sodium chloride 500mg
349080|NCT01532401|Other|Methylcellulose crystalline|Methylcellulose 37 ml
349081|NCT01532388|Behavioral|eScreen|Web based self-monitoring of problematic alcohol and drug use.
349082|NCT01532375|Dietary Supplement|Kochujang|Kochujang (32g/day) for 12weeks.
349083|NCT01532375|Dietary Supplement|placebo|placebo(32g/day) for 12weeks
349084|NCT01532362|Drug|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
349085|NCT01532349|Drug|Cholecalciferol|Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for > 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
349086|NCT01532336|Drug|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
349087|NCT01532336|Drug|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
349088|NCT01532323|Other|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
349089|NCT01532310|Drug|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
349090|NCT01532297|Device|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
349091|NCT01532297|Device|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
349092|NCT01532284|Other|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
349093|NCT01532258|Behavioral|Go! Foods for You without Weekly MA Support.|"Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week."
349094|NCT01532258|Behavioral|Go! Foods for You with Weekly MA Support.|"Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.~In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals."
349095|NCT01532245|Other|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
349096|NCT01532245|Other|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
349097|NCT01532245|Other|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
349184|NCT01531634|Behavioral|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
349185|NCT01531621|Other|Biomarker sampling|Blood samples every 8-12 weeks
352162|NCT01509300|Drug|cyclophosphamide|60 mg/kg IV on day-3 and -2
349098|NCT01532232|Drug|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
349099|NCT01532232|Drug|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
349100|NCT01532219|Behavioral|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
349101|NCT01532219|Behavioral|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
349102|NCT01532206|Other|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
349103|NCT01532193|Other|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
349104|NCT01532180|Device|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
349105|NCT01532154|Drug|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
349106|NCT01532141|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
349107|NCT01532141|Drug|Rasagiline|1 mg rasagiline (single-dose)
349108|NCT01532128|Drug|rasagiline|1 mg rasagiline (single-dose)
349109|NCT01532128|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
349110|NCT01532115|Drug|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
349111|NCT01532115|Drug|Placebo|single-dose
349112|NCT01532115|Drug|moxifloxacin|400 mg moxifloxacin (single-dose)
349113|NCT01532102|Drug|AP611074|
349114|NCT01532102|Drug|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
349115|NCT01532089|Biological|Bevacizumab|Given IV
349116|NCT01532089|Drug|Erlotinib|Given PO
349117|NCT01532089|Drug|Erlotinib Hydrochloride|Given PO
349118|NCT01532089|Other|Laboratory Biomarker Analysis|Correlative studies
349119|NCT01532076|Procedure|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
349120|NCT01532076|Procedure|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
349121|NCT01532063|Procedure|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
349122|NCT01532050|Device|Mandibular Advancement Device ( MAD)|
349123|NCT01532037|Other|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
349124|NCT01532037|Other|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
349125|NCT01532024|Other|Microdose of NAP|Delivery of NAP at microdose (<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
349126|NCT01532011|Drug|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
349127|NCT01532011|Drug|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
349128|NCT01531998|Drug|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
349129|NCT01531998|Drug|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.~Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
349130|NCT01531998|Drug|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.~Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
349131|NCT01531998|Drug|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.~Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
349132|NCT01531998|Behavioral|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
349133|NCT01531972|Drug|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
349134|NCT01531972|Drug|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
349135|NCT01531959|Drug|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
349136|NCT01531959|Drug|Placebo|Patients will be randomized to blinded placebo control
349137|NCT01531946|Procedure|MRI Scan|"Patients will have to spend additional 10min in the scanner.~Additional scan modalities used:~Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.~Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.~An overall 20min scan period."
349138|NCT01531933|Drug|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
349139|NCT01531933|Drug|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
349140|NCT01531920|Drug|alcohol + placebo|Part A alcohol + placebo
349141|NCT01531920|Drug|alcohol + perampanel|Part A: alcohol + perampanel
349142|NCT01531920|Drug|perampanel + alcohol|Part B: perampanel + alcohol
349143|NCT01531920|Drug|placebo + alcohol|Part B: placebo + alcohol
349144|NCT01531907|Other|Study visit procedures|"Anthropometric measurements to include:~Weight, height, and BMI.~Waist and hip circumference~Triceps skinfold thickness~Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
349145|NCT01531894|Drug|GSK2110183 (afuresertib)|Afuresertib is an oral, low nanomolar pan-AKT kinase inhibitor immediate release (IR) 50 mg or 75 mg tablets was to be taken orally with at least 200 mL of water, with or without food, in the morning.
349146|NCT01531868|Other|Video|Video of physician
349147|NCT01531868|Other|Video|Video of physician
349148|NCT01531868|Other|Video|Video of physician
349149|NCT01531868|Other|Video|Video of physician
349150|NCT01531868|Other|Video|Video of physician
349151|NCT01531868|Other|Video|Video of physician
349152|NCT01531855|Other|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
349153|NCT01531842|Procedure|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
349154|NCT01531829|Drug|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
349155|NCT01531829|Drug|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
349156|NCT01531816|Device|Early Rehabilitation intervention|"Passive mobility: cycle ergometer~Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
349157|NCT01531803|Drug|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).~The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
349158|NCT01531790|Drug|Carboplatin|d1, AUC 5, i.v.
349159|NCT01531790|Drug|Pemetrexed|d1, 500 mg/m2, i.v.
349160|NCT01531790|Drug|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
349161|NCT01531790|Drug|Centrum|1 tablet/day
349162|NCT01531777|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
349163|NCT01531777|Drug|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
349164|NCT01531764|Drug|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 & 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
349165|NCT01531751|Device|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
349166|NCT01531751|Drug|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
349167|NCT01531725|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
349168|NCT01531712|Drug|Gemcitabine|1000mg/m2 / / 40mg/m2
349169|NCT01531712|Radiation|Radiotherapy|50.4 Gy
349170|NCT01531712|Drug|Tarceva|100mg/day
349171|NCT01531712|Drug|Oxaliplatin|100mg/m2 (only in QT)
349172|NCT01531699|Drug|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
349173|NCT01531699|Other|saline control|single application for up to 6 hours
349174|NCT01531699|Drug|Comparator Product|single application for up to 6 hours
349175|NCT01531686|Procedure|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
349176|NCT01531673|Drug|VX-661|
349177|NCT01531673|Drug|Ivacaftor|
349178|NCT01531673|Drug|Placebo matched to VX-661|
349179|NCT01531673|Drug|Placebo matched to ivacaftor|
349180|NCT01531660|Behavioral|step-up jogging program|
349181|NCT01531647|Drug|danoprevir|100 mg q12h Days 8-21
349186|NCT01531595|Drug|Bevacizumab plus alternating Xelox/Xeliri|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
349187|NCT01531582|Drug|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
349188|NCT01531569|Other|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
349189|NCT01531543|Device|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
349190|NCT01531530|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
349191|NCT01531530|Other|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
349192|NCT01531517|Drug|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:~Assessment of the patient for inclusion/exclusion criteria~Informed consent process~Medical history of the patient~Blood withdrawn for investigation~Drainage of the ulcer if there is a collection~Revascularization as needed and indicated by APSV done at visit 0.~Swab from the ulcer for culture and micro-organism count: on detailed visits only.~Debridement as needed.~Dressing:~Inspection and assessment of the ulcer~Irrigation using 500 ml of saline or as required.~Drying of the ulcer (leave to dry)~Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer~Fix the dressing to the ulcer"
349193|NCT01531517|Drug|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:~Assessment of the patient for inclusion/exclusion criteria~Informed consent process~Medical history of the patient~Blood withdrawn for investigation~Drainage of the ulcer if there is a collection~Revascularization as needed and indicated by APSV done at visit 0.~Swab from the ulcer for culture and micro-organism count: on detailed visits only.~Debridement as needed.~Dressing:~Inspection and assessment of the ulcer~Irrigation using 500 ml of saline or as required.~Drying of the ulcer (leave to dry)~Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer~Fix the dressing to the ulcer"
349194|NCT01531504|Device|ViKY UP|laparoscopic-assisted hysterectomy procedure
349195|NCT01531491|Procedure|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
349196|NCT01531491|Procedure|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
349197|NCT01531478|Other|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.~After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
349198|NCT01531465|Other|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
349199|NCT01531465|Other|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
349200|NCT01531452|Drug|Oxaliplatin|130mg/m2 d1,repeated q21d
349201|NCT01531452|Drug|s1|80mg/m2/d, d1-14,repeated q21d
349202|NCT01531439|Drug|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
349203|NCT01531439|Drug|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
349204|NCT01531426|Device|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
349205|NCT01531413|Other|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
349206|NCT01531400|Other|self-selected music|Investigators played self-selected background music in the music group
349207|NCT01531387|Drug|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
349208|NCT01531374|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
349209|NCT01531361|Drug|Crizotinib|Given PO
349210|NCT01531361|Other|Laboratory Biomarker Analysis|Correlative studies
349211|NCT01531361|Other|Pharmacological Study|Correlative studies
349212|NCT01531361|Drug|Sorafenib Tosylate|Given PO
349213|NCT01531361|Drug|Vemurafenib|Given PO
349214|NCT01531348|Other|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
349215|NCT01531335|Dietary Supplement|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
349216|NCT01531335|Dietary Supplement|Standard care|25 kcal per kg of body weight
349333|NCT01530490|Drug|Cabergoline and Hydroxyethyl Starch|0.5mg
349217|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
349218|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
349219|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
349220|NCT01531309|Drug|AGO178|AGO178 is administered as a sublingual tablet.
349221|NCT01531283|Drug|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
349222|NCT01531283|Drug|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
349223|NCT01531283|Drug|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
349224|NCT01531283|Drug|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
349225|NCT01531244|Biological|dactinomycin|Given via ILI
349226|NCT01531244|Drug|melphalan|Given via ILI
349227|NCT01531244|Biological|Conditionally replicative adenovirus 3/5-delta|Given via ILI
349228|NCT01531218|Drug|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
349229|NCT01531218|Drug|Placebo|
349230|NCT01531205|Drug|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
349231|NCT01531205|Drug|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
349232|NCT01531205|Drug|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
349233|NCT01531205|Drug|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
349234|NCT01531205|Drug|Neoadjuvant Treatment - Cabazitaxel|"All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.~Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay."
349235|NCT01531192|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
349236|NCT01531192|Drug|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
349237|NCT01531179|Drug|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
349238|NCT01531179|Drug|Placebo|Placebo for 3 months
349239|NCT01531166|Drug|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
349240|NCT01531153|Drug|Galantamine|8mg or 16mg
349241|NCT01531153|Drug|Placebo|Placebo dose.
349242|NCT01531140|Drug|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
349243|NCT01531140|Drug|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
349244|NCT01531140|Drug|Sennosides|Sennosides 1tbl/8kg for 2 days
349245|NCT01531114|Drug|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
349246|NCT01531114|Drug|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
349247|NCT01531101|Behavioral|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
349248|NCT01531088|Behavioral|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
349249|NCT01531075|Biological|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
349250|NCT01531075|Biological|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
349251|NCT01531062|Drug|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
349252|NCT01531062|Dietary Supplement|black sticky rice|300 mg capsule bid, 56 days
349253|NCT01531049|Drug|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
349254|NCT01531049|Drug|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
349255|NCT01531049|Drug|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
349256|NCT01531049|Other|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
349334|NCT01530490|Drug|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
349257|NCT01531036|Device|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
349258|NCT01531010|Device|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.~In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
349259|NCT01530997|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
349260|NCT01530997|Drug|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
349261|NCT01530997|Procedure|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
349262|NCT01530984|Drug|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
349263|NCT01530984|Drug|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
349264|NCT01530971|Drug|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
349265|NCT01530958|Behavioral|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:~identify patients with CKD~notify PCPs of a patients' CKD status~provide PCP outreach with NKDEP guidelines and patient educational materials"
349266|NCT01530958|Behavioral|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
349267|NCT01530958|Behavioral|Usual care|"Primary care providers will manage their patients with CKD per usual care.~Patients will receive usual care."
349268|NCT01530919|Procedure|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
349269|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
349270|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
349271|NCT01530893|Dietary Supplement|Flavanone - supplement|acute single optimal dose
349272|NCT01530893|Other|Flavanone - food|acute single dose
349273|NCT01530893|Other|Flavanone - placebo|acute single dose (flavanone free)
349274|NCT01530893|Dietary Supplement|Isoflavone - supplement|acute single optimal dose
349275|NCT01530893|Other|Isoflavone - food|acute single optimal dose
349276|NCT01530893|Other|Isoflavone - placebo|acute single dose (isoflavone free)
349277|NCT01530893|Dietary Supplement|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
349278|NCT01530893|Dietary Supplement|Flavan-3-ol - supplement|acute single optimal dose
349279|NCT01530893|Other|Flavan-3-ol - food|acute single optimal dose
349280|NCT01530893|Other|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
349281|NCT01530893|Dietary Supplement|Anthocyanin - supplement|acute single optimal dose
349282|NCT01530893|Other|Anthocyanin - food|acute single optimal dose
349283|NCT01530893|Other|Anthocyanin - placebo|acute single dose (anthocyanin free)
349284|NCT01530880|Drug|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
349285|NCT01530880|Drug|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
349286|NCT01530841|Device|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
349287|NCT01530815|Drug|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
349288|NCT01530802|Procedure|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
349289|NCT01530776|Behavioral|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
349335|NCT01530477|Device|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
349290|NCT01530763|Drug|Ceftaroline fosamil|"Treatment Group 1:~Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Children < 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
349291|NCT01530763|Drug|Ceftriaxone|"Treatment group 2:~75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
349292|NCT01530763|Drug|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:~PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
349293|NCT01530737|Drug|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
349294|NCT01530737|Other|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
349295|NCT01530724|Other|low-fat diet|low-fat diet
349296|NCT01530724|Other|low-carb diet|low-carb diet
349297|NCT01530711|Drug|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase < 10 mmHg and the creatinine values decrease <25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
349298|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
349299|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
349300|NCT01530685|Dietary Supplement|Glycabiane|2 gelule per day for 4 months
349301|NCT01530685|Dietary Supplement|placebo|2 gelules per day for 4 months
349302|NCT01530672|Device|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
349303|NCT01530659|Drug|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
349304|NCT01530659|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure in the other eye.
349305|NCT01530646|Behavioral|Weight loss|-750kcal/d
349306|NCT01530646|Dietary Supplement|Soy|2 x 25g/d SPC
349307|NCT01530646|Dietary Supplement|Whey|2 x 25g/d WPI
349308|NCT01530620|Drug|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
349309|NCT01530620|Drug|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
349310|NCT01530607|Drug|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
349311|NCT01530607|Drug|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
349312|NCT01530594|Drug|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
349313|NCT01530594|Drug|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
349314|NCT01530594|Drug|Lenalidomide|Lenalidomide/Low dose Dex (LLD
349315|NCT01530581|Procedure|G-PB Transplant|G-PB Transplant
349316|NCT01530581|Procedure|G-BM Transplant|G-BM Transplant
349317|NCT01530568|Other|Xpert|This arm receives the GeneXpert test
349318|NCT01530568|Other|Smear|This arm receives smear microscopy
349319|NCT01530555|Drug|Rabbit ATG, Thymoglobuline (Genzyme)|"Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.~Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
349320|NCT01530542|Drug|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
349321|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
349322|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
349323|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
349324|NCT01530542|Drug|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
349325|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
349326|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
349327|NCT01530529|Drug|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
349328|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
349329|NCT01530516|Device|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
349330|NCT01530516|Device|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
349331|NCT01530503|Drug|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
349332|NCT01530503|Drug|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
349336|NCT01530477|Device|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
349337|NCT01530477|Device|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
349338|NCT01530464|Drug|Aminophylline|Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
349339|NCT01530464|Drug|Ambrisentan|Drug will be administered as a single dose of 5mg, followed by a 48h washout period
349340|NCT01530464|Drug|Aminophylline plus ambrisentan|Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
349341|NCT01530451|Drug|Desmopressin|120mg OD
349342|NCT01530451|Drug|Placebo|one tab OD
349343|NCT01530438|Other|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :~Imaging : fMRI at rest and anatomical MRI~Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
349344|NCT01530412|Other|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
349345|NCT01530399|Drug|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
349346|NCT01530399|Drug|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
349347|NCT01530399|Drug|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
349348|NCT01530399|Drug|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
349349|NCT01530399|Drug|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
349350|NCT01530399|Drug|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
349351|NCT01530386|Drug|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
349352|NCT01530373|Drug|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
349353|NCT01530373|Drug|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
349354|NCT01530360|Device|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
349355|NCT01530347|Device|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
349356|NCT01530334|Drug|Gefitinib 250mg|Gefitinib 250mg once daily
349357|NCT01530321|Other|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
349358|NCT01530321|Other|Light Massage|5 minutes of light pressure massage to the neck and upper back
349359|NCT01530308|Drug|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
349360|NCT01530308|Drug|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
349361|NCT01530295|Drug|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
349362|NCT01530282|Other|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
349363|NCT01530282|Other|Non invasive method|Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
349364|NCT01530269|Drug|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
349365|NCT01530256|Biological|ALD518|160 mg IV q 4 weeks for 4 doses
349366|NCT01530256|Biological|ALD518|320 mg IV q 4 weeks for 4 doses
349367|NCT01530256|Biological|ALD518|640 mg IV q 4 weeks for 2 doses
349368|NCT01530243|Drug|Placebo|same as tolterodine and terazosin dose
349369|NCT01530243|Drug|Terazosine|2 mg BID
349370|NCT01530243|Drug|Tolterodine|2 mg daily
349371|NCT01530243|Drug|Tolterodine + Terazosin|2mg daily and 2mg BID
349372|NCT01530230|Drug|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
349373|NCT01530217|Drug|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
349374|NCT01530204|Procedure|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
349375|NCT01530204|Behavioral|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
349376|NCT01530204|Other|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
349377|NCT01530178|Drug|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
349378|NCT01530178|Drug|Placebo Oral Tablet|
349421|NCT01529827|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
349422|NCT01529827|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
349379|NCT01530165|Behavioral|Life style counseling|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat <30 proportion of total energy, saturated fat <10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
349380|NCT01530152|Procedure|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.~The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
349381|NCT01530139|Behavioral|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
349382|NCT01530139|Behavioral|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
349383|NCT01530139|Behavioral|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
349384|NCT01530139|Behavioral|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
349385|NCT01530126|Biological|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
349386|NCT01530126|Biological|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
349387|NCT01530126|Biological|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
349388|NCT01530087|Device|CASTLE barrier|Prototype barrier to be used in place of current two piece device
349389|NCT01530074|Procedure|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
349390|NCT01530061|Other|Egg Breakfast|Egg, Toast and Jelly
349391|NCT01530061|Other|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
349392|NCT01530048|Drug|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
349393|NCT01530035|Other|physical training|training
349394|NCT01530022|Drug|Lacosamide (LCM)|"LCM 300 mg:~LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.~Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
349395|NCT01530022|Drug|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:~CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.~LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.~Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
349396|NCT01530009|Drug|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
349397|NCT01530009|Other|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
349398|NCT01529996|Procedure|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
349399|NCT01529983|Procedure|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
349400|NCT01529957|Drug|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
349401|NCT01529944|Drug|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
349402|NCT01529944|Drug|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
349403|NCT01529931|Device|Hair2Go|Hair2Go treatment once a month for 6 months
349404|NCT01529918|Other|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
349405|NCT01529892|Drug|A single oral 5 mg of duterium labeled methamphetamine|
349406|NCT01529879|Device|New Abutment Connection implant|New abutment connection implant
349407|NCT01529879|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
349408|NCT01529866|Device|New Abutment Connection implant|New abutment connection implant
349409|NCT01529866|Device|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
349410|NCT01529853|Drug|SAR156597|"Pharmaceutical form: solution~Route of administration: subcutaneous"
349411|NCT01529853|Drug|Placebo (for SAR156597)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
349412|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
349413|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
349414|NCT01529827|Drug|fludarabine phosphate|Given IV
349415|NCT01529827|Drug|melphalan|Given IV
349416|NCT01529827|Radiation|total-body irradiation|Undergo TBI
349417|NCT01529827|Drug|tacrolimus|Given IV or PO
349418|NCT01529827|Drug|mycophenolate mofetil|Given IV or PO
349419|NCT01529827|Drug|methotrexate|Given IV
349420|NCT01529827|Other|laboratory biomarker analysis|Correlative studies
349424|NCT01529814|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
349425|NCT01529801|Device|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
349426|NCT01529801|Device|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
349427|NCT01529801|Device|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
349428|NCT01529788|Drug|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
349429|NCT01529788|Drug|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
349430|NCT01529775|Device|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
349431|NCT01529775|Device|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
349432|NCT01529749|Drug|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --> oral, 600/200/245 mg, od Losartan --> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
349433|NCT01529749|Drug|EFV/FTC/TDF|600/200/245 mg, od, oral
349434|NCT01529749|Drug|FTC/TDF + MK-0518|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral
349435|NCT01529749|Drug|FTC/TDF+MK-0518+Losartan|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral Losartan --> -> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
349436|NCT01529736|Procedure|High torque insertion|Osseotite implant placed with high insertion torque forces
349437|NCT01529736|Procedure|Low torque insertion|Osseotite implant placed with low insertion torque forces
349438|NCT01529710|Drug|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
349439|NCT01529697|Behavioral|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
349440|NCT01529684|Drug|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
349441|NCT01529684|Drug|OSI-906|Part B: oral tablets OSI-906
349442|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
349443|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
349444|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
349445|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
349446|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension BID
349447|NCT01529658|Procedure|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.~When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
349448|NCT01529645|Biological|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
349449|NCT01529645|Biological|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
349450|NCT01529645|Biological|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
349451|NCT01529645|Biological|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
349452|NCT01529645|Other|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
349453|NCT01529632|Drug|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
349454|NCT01529632|Drug|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
349455|NCT01529632|Drug|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
349456|NCT01529632|Drug|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
349457|NCT01529619|Drug|Rivastigmine transdermal patch|
349458|NCT01529606|Other|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
349459|NCT01529606|Procedure|Plasma treatment|plasma treatment after preparation and for caries prevention
349460|NCT01529593|Drug|Temsirolimus|"Starting dose: 25 mg by vein weekly.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
349461|NCT01529593|Drug|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.~Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
349500|NCT01529385|Device|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
352163|NCT01509300|Drug|Tacrolimus|begin on 0
349462|NCT01529580|Behavioral|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:~One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
349463|NCT01529567|Behavioral|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
349464|NCT01529567|Behavioral|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
349465|NCT01529554|Drug|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
349466|NCT01529554|Drug|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
349467|NCT01529541|Drug|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
349468|NCT01529541|Drug|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
349469|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
349470|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
349471|NCT01529528|Drug|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
349472|NCT01529515|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
349473|NCT01529515|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
349474|NCT01529515|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
349475|NCT01529515|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
349476|NCT01529515|Drug|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
349477|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
349478|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
349479|NCT01529502|Drug|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
349480|NCT01529489|Other|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
349481|NCT01529489|Other|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
349482|NCT01529489|Other|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
349483|NCT01529489|Other|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
349484|NCT01529476|Drug|Levofloxacin|levofloxacin 500 mg,QD,7~10 days
349485|NCT01529476|Drug|Nemonoxacin|Nemonoxacin 500mg,QD,7~10 days
349486|NCT01529450|Drug|LDE225|800-mg (4 200-mg capsules/day) capsule
349487|NCT01529437|Drug|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
349488|NCT01529437|Drug|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
349489|NCT01529424|Drug|ISIS apoC-III Rx|Dose 1
349490|NCT01529424|Drug|ISIS apoC-III Rx|Dose 2
349491|NCT01529424|Drug|ISIS apoC-III Rx|Dose 3
349492|NCT01529424|Drug|Placebo|Dose 1
349493|NCT01529424|Drug|Placebo|Dose 2
349494|NCT01529424|Drug|Placebo|Dose 3
349495|NCT01529411|Drug|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min).
349496|NCT01529411|Other|Undefined (standard care)|All the current interventions used by each institution for the study disease.
349497|NCT01529398|Other|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
349498|NCT01529398|Other|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
349499|NCT01529398|Other|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
349501|NCT01529385|Device|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
349502|NCT01529372|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
349503|NCT01529359|Dietary Supplement|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
349504|NCT01529359|Dietary Supplement|Placebo|Placebo 2 gelules per days for 6 weeks
349505|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
349506|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
349507|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
349508|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
349509|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
349510|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
349511|NCT01529346|Drug|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
349512|NCT01529346|Other|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
349513|NCT01529346|Other|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
349514|NCT01529346|Other|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
349515|NCT01529333|Device|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
349516|NCT01529320|Drug|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
349517|NCT01529307|Drug|TAS266|TAS266 IV infusions given weekly
349518|NCT01529294|Drug|Iloperidone|
349519|NCT01529281|Dietary Supplement|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with ~300 ml of water.
349520|NCT01529281|Dietary Supplement|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with ~300 ml of water.
349521|NCT01529268|Drug|DR cysteamine bitartrate capsule|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
349522|NCT01529268|Other|DR cysteamine bitartrate placebo|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline~750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline~900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
349523|NCT01529255|Drug|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
349524|NCT01529255|Drug|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily~Stopping rules:~The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.~The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.~Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
349525|NCT01529242|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
349526|NCT01529242|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
349527|NCT01529229|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
349528|NCT01529229|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
349529|NCT01529216|Device|DIAMOND System|Electrical stimulation to the fundus
349530|NCT01529203|Drug|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
349531|NCT01529203|Device|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
349532|NCT01529190|Drug|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
349533|NCT01529190|Drug|Placebo|placebo
349534|NCT01529177|Drug|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
349535|NCT01529177|Drug|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
349536|NCT01529164|Drug|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
349537|NCT01529164|Drug|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
349538|NCT01529164|Drug|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
349539|NCT01529164|Drug|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
349540|NCT01529151|Other|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
349541|NCT01529151|Other|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
349542|NCT01529138|Drug|Axitinib|Combination treatment with temsirolimus and axitinib
349543|NCT01529138|Drug|Temsirolimus|Combination treatment with temsirolimus and axitinib
349544|NCT01529125|Drug|zidovudine, lamivudine, nevirapine|
349545|NCT01529112|Drug|Lenvatinib|
349546|NCT01529112|Drug|Lenvatinib matched placebo|
349547|NCT01529112|Drug|BSC|
349548|NCT01529099|Device|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
349549|NCT01529073|Drug|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
349550|NCT01529060|Drug|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
349551|NCT01529060|Drug|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
349552|NCT01529047|Behavioral|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
349553|NCT01529034|Drug|USL261|
349554|NCT01529008|Drug|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
349555|NCT01529008|Drug|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
349556|NCT01528995|Device|Medtronic Interstim II-3058|impulse generator
349557|NCT01528995|Procedure|Anal bulking injection|"Permacol injection:~four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
349558|NCT01528982|Behavioral|Mindfulness|Subjects receive mindfulness training
349559|NCT01528982|Behavioral|Cognition|Subject receive cognitive training
349560|NCT01528969|Dietary Supplement|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
349561|NCT01528969|Dietary Supplement|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
349562|NCT01528956|Genetic|DNA methylation analysis|
349563|NCT01528956|Genetic|RNA analysis|
349564|NCT01528956|Genetic|gene expression analysis|
349565|NCT01528956|Genetic|nucleic acid sequencing|
349566|NCT01528956|Genetic|polymorphism analysis|
349567|NCT01528943|Drug|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
349568|NCT01528943|Drug|Isotonic saline|same volume as the group that are allocated to prostacycline
349569|NCT01528930|Drug|Amikacin|500 mg, once daily for 2 years
349570|NCT01528891|Drug|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
349571|NCT01528891|Other|Placebo|
349572|NCT01528878|Radiation|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.~The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
349573|NCT01528865|Drug|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.~Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.~Subjects will be taking drug for 16 weeks."
349574|NCT01528865|Drug|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
349575|NCT01528852|Drug|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
349576|NCT01528852|Drug|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
349577|NCT01528852|Other|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
349578|NCT01528839|Drug|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
349579|NCT01528839|Drug|Placebo|
352164|NCT01509300|Drug|Mycophenolate mofetil|begin on 0
349580|NCT01528826|Drug|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
349581|NCT01528813|Device|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
349582|NCT01528813|Drug|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
349583|NCT01528800|Drug|Vitamin K1|10mg orally three times a week for 12 months
349584|NCT01528800|Drug|Microcrystalline Methylcellulose|10mg orally three times a week for 12 months
349585|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.01%|Administered to study eye, once daily (QD) in the morning (AM) for 7 days
349586|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.02%|Administered to study eye, QD AM for 7 days
349587|NCT01528787|Drug|AR-13324 Ophthalmic Solution 0.04%|Administered to study eye, QD AM for 7 days
349588|NCT01528787|Other|AR-13324 Ophthalmic Solution Vehicle|Administered to study eye, QD AM for 7 days
349589|NCT01528774|Other|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
349590|NCT01528761|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
349591|NCT01528761|Other|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
349592|NCT01528748|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
349593|NCT01528735|Drug|BI 207127 NA|one fix dose
349594|NCT01528735|Drug|peginterferon|per package insert
349595|NCT01528735|Drug|Ribavirin|per weight BID
349596|NCT01528735|Drug|Ribavirin|per weight BID
349597|NCT01528735|Drug|BI 207127 NA|one fix dose
349598|NCT01528735|Drug|BI 201335 NA|high dose
349599|NCT01528735|Drug|BI 201335 NA|low dose
349600|NCT01528735|Drug|peginterferon|per package insert
349601|NCT01528722|Drug|Bupivacaine|0.25% 20ml administered intraperitoneal
349602|NCT01528722|Other|Normal saline|sodium chloride 0.9% solution
349603|NCT01528709|Drug|Atorvastatin 80 mg daily|Atorvastatin 80 mg daily for 1 year
349604|NCT01528709|Drug|Atorvastatin 10 mg daily|Atorvastatin 10 mg daily for 1 year
349605|NCT01528696|Device|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.~All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
349606|NCT01528696|Device|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
349607|NCT01528683|Radiation|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
349608|NCT01528657|Other|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
349609|NCT01528657|Other|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
349610|NCT01528644|Dietary Supplement|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
349643|NCT01528436|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
349644|NCT01528436|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
349611|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
349612|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
349613|NCT01528644|Dietary Supplement|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
349614|NCT01528631|Other|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
349615|NCT01528631|Other|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
349616|NCT01528618|Drug|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
349617|NCT01528618|Drug|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
349618|NCT01528605|Dietary Supplement|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
349619|NCT01528605|Dietary Supplement|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
349620|NCT01528605|Dietary Supplement|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
349621|NCT01528605|Dietary Supplement|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
349622|NCT01528605|Dietary Supplement|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
349623|NCT01528605|Dietary Supplement|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
349624|NCT01528592|Drug|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
349625|NCT01528579|Other|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
349626|NCT01528579|Behavioral|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
349627|NCT01528579|Other|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
349628|NCT01528566|Behavioral|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
349629|NCT01528566|Behavioral|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
349630|NCT01528553|Device|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
349631|NCT01528553|Device|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
349632|NCT01528540|Drug|Placebo|This group will include placebo.
349633|NCT01528540|Drug|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
349634|NCT01528514|Dietary Supplement|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
349635|NCT01528514|Other|Placebo|Placebo in capsule form, 4 capsules 4 times/day
349636|NCT01528501|Drug|Panobinostat (LBH589)|
349637|NCT01528488|Other|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
349638|NCT01528488|Other|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
349639|NCT01528475|Behavioral|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
349640|NCT01528462|Other|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
349641|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
349642|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
349863|NCT01526668|Behavioral|Follow-up strategy|Comparison of different follow-up strategies
349645|NCT01528436|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
349646|NCT01528423|Procedure|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
349647|NCT01528410|Device|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
349648|NCT01528410|Procedure|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
349649|NCT01528397|Procedure|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
349650|NCT01528384|Drug|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
349651|NCT01528371|Drug|Midazolam|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~Investigators inject an additional sedative agent and the dental treatment is started."
349652|NCT01528371|Drug|Normal Saline Solution (NSS)|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.~Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.~Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.~10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.~Investigators inject an additional sedative agent and the dental treatment is started."
349653|NCT01528345|Drug|Dovitinib|Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
349654|NCT01528345|Drug|Fulvestrant|Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
349655|NCT01528345|Drug|Dovitinib Placebo|Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
349656|NCT01528332|Device|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
349657|NCT01528332|Device|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
349658|NCT01528319|Device|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
349659|NCT01528306|Biological|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
349660|NCT01528306|Other|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods~Larger wounds:~(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
349661|NCT01528293|Device|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
349662|NCT01528293|Other|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
349663|NCT01528280|Biological|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
349664|NCT01528280|Other|No Intervention|No Intervention
349665|NCT01528267|Other|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
349666|NCT01528267|Other|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
349667|NCT01528254|Drug|Placebo to vildagliptin|
349668|NCT01528254|Drug|vildagliptin|Patients will be instructed to take one tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
349669|NCT01528254|Drug|Metformin|Metformin should be taken in a twice daily (bid) regimen during or after meals at the same time as vildagliptin.
349670|NCT01528241|Drug|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
349737|NCT01527669|Drug|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
349864|NCT01526668|Behavioral|No contact after discharge|
349671|NCT01528228|Device|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
349672|NCT01528215|Device|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
349673|NCT01528215|Device|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
349674|NCT01528202|Dietary Supplement|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
349675|NCT01528202|Dietary Supplement|Fruit juice cordial|fruit flavoured juice concentrate
349676|NCT01528189|Other|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
349677|NCT01528189|Other|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
349678|NCT01528176|Drug|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
349679|NCT01528163|Drug|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
349680|NCT01528163|Drug|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
349681|NCT01528137|Biological|talactoferrin|Given PO
349682|NCT01528137|Other|laboratory biomarker analysis|Correlative studies
349683|NCT01528124|Drug|LY3025876|Given as a subcutaneous injection
349684|NCT01528124|Drug|Placebo|Given as a subcutaneous injection
349685|NCT01528111|Drug|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
349686|NCT01528111|Drug|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
349687|NCT01528111|Drug|LX7101 Vehicle|Subjects will receive vehicle
349688|NCT01528085|Drug|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
349689|NCT01528072|Device|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
349690|NCT01528059|Procedure|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
349691|NCT01528046|Drug|Vincristine|Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
349692|NCT01528046|Drug|Irinotecan|Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes
349693|NCT01528046|Drug|Temozolomide|Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5
349694|NCT01528046|Drug|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
349695|NCT01528033|Device|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.~VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.~Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
349696|NCT01528033|Other|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
349697|NCT01528020|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
349698|NCT01528020|Behavioral|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
349699|NCT01528007|Drug|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
349700|NCT01528007|Drug|Placebo|Placebo pill with no active ingredients.
349701|NCT01527994|Drug|Aprepitant|Aprepitant 125 mg oral tablets
349702|NCT01527994|Drug|Placebo pill|Placebo oral pill- inactive compound
349703|NCT01527981|Behavioral|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
349704|NCT01527968|Drug|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
349705|NCT01527968|Drug|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
349706|NCT01527968|Drug|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
349861|NCT01526681|Procedure|Autologous Breast Reconstruction with Neurotization|
349707|NCT01527955|Other|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
349708|NCT01527942|Drug|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
349709|NCT01527942|Drug|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
349710|NCT01527929|Drug|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
349711|NCT01527916|Drug|placebo|Placebo Comparator
349712|NCT01527916|Drug|donepezil|Active Comparator
349713|NCT01527916|Drug|ABT-126|low dose, middle dose, high dose
349714|NCT01527903|Drug|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
349715|NCT01527903|Drug|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
349716|NCT01527890|Drug|Fentanyl|intravenous patient-controlled analgesia
349717|NCT01527877|Drug|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.~• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
349718|NCT01527864|Drug|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
349719|NCT01527864|Drug|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
349720|NCT01527838|Biological|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
349721|NCT01527825|Biological|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~An A/California/7/2009 (H1N1)pdm-like virus~An A/Perth/16/2009 (H3N2)-like virus*~A B/Brisbane/60/2008-like virus * A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
349722|NCT01527825|Biological|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
349723|NCT01527812|Procedure|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
349724|NCT01527786|Drug|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
349725|NCT01527760|Drug|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
349726|NCT01527747|Drug|Saxagliptin|5 mg daily
349727|NCT01527734|Drug|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
349728|NCT01527734|Drug|placebo|1ml once or twice a day for 1 or 2 days.
349729|NCT01527721|Procedure|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
349730|NCT01527721|Procedure|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
349731|NCT01527708|Procedure|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
349732|NCT01527695|Drug|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
349733|NCT01527695|Drug|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
349734|NCT01527695|Drug|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
349735|NCT01527695|Drug|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
349736|NCT01527682|Drug|Latanoprost, Dorzolamide|"Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)~Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
352165|NCT01509300|Drug|Rituximab|375mg/m2 on day +21
349738|NCT01527669|Drug|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
349739|NCT01527656|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
349740|NCT01527643|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
349741|NCT01527630|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
349742|NCT01527617|Other|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
349743|NCT01527617|Other|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
349744|NCT01527604|Other|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
349745|NCT01527604|Other|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
349746|NCT01527591|Biological|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
349747|NCT01527565|Drug|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
349748|NCT01527552|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
349749|NCT01527539|Drug|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
349750|NCT01527513|Drug|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
349751|NCT01527513|Drug|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
349752|NCT01527500|Drug|LFG316|LFG316 5 mg/50 μL solution for IVT injection,
349753|NCT01527500|Drug|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
349754|NCT01527500|Drug|LFG316 Lower dose|LFG316 5 mg/50 μL solution for IVT Injection
349755|NCT01527487|Drug|Eribulin|1.4 mg/m2 IV (Days 1 & 8), given short (≤15 minute) IV infusion, per institutional standard
349756|NCT01527487|Drug|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
349757|NCT01527487|Drug|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
349758|NCT01527474|Drug|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
349759|NCT01527448|Drug|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
349760|NCT01527422|Drug|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
349761|NCT01527409|Behavioral|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).~Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.~Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.~The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.~Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
349762|NCT01527409|Behavioral|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.~Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
349763|NCT01527383|Biological|V212|V212 viral antigen for HZ
349764|NCT01527383|Biological|Placebo|Placebo comparator to V212 vaccine
349765|NCT01527370|Biological|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
349766|NCT01527357|Biological|Fibrocaps (PRO-0601)|Human fibrinogen and thrombin powder Single application during surgery
349767|NCT01527357|Device|Gelatin sponge|Single application during surgery
349768|NCT01527331|Behavioral|video decision aid|cpr video decision aid
349769|NCT01527318|Drug|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
349770|NCT01527305|Drug|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
349771|NCT01527292|Radiation|Stereotactic Radiation Therapy|SRT only
349772|NCT01527292|Radiation|SRT with Vertebral Augmentation Procedure|SRT with VAP
349773|NCT01527279|Drug|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
349774|NCT01527279|Drug|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
349775|NCT01527266|Dietary Supplement|Carbohydrate drink|sucrose beverage
349776|NCT01527266|Dietary Supplement|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
349777|NCT01527253|Other|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
349778|NCT01527240|Drug|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
349779|NCT01527240|Drug|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
349780|NCT01527227|Other|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
349781|NCT01527214|Radiation|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
349782|NCT01527201|Procedure|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
349783|NCT01527188|Biological|100IR|100IR sublingual tablet of
349784|NCT01527188|Biological|300IR|300IR sublingual tablets of
349785|NCT01527188|Biological|500IR|500IR sublingual tablet of
349786|NCT01527188|Other|Placebo|Placebo sublingual tablet of
349787|NCT01527175|Other|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
349788|NCT01527162|Device|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
349789|NCT01527162|Other|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
349790|NCT01527149|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
349791|NCT01527149|Drug|Cyclophosphamide|Given IV
349792|NCT01527149|Drug|Cytarabine|Given IV
349793|NCT01527149|Drug|Dexamethasone|Given IV or PO
349794|NCT01527149|Drug|Doxorubicin Hydrochloride|Given IV
349795|NCT01527149|Other|Laboratory Biomarker Analysis|Correlative studies
349796|NCT01527149|Drug|Methotrexate|Given IV
349797|NCT01527149|Biological|Ofatumumab|Given IV
349798|NCT01527149|Drug|Vincristine Sulfate|Given IV
349799|NCT01527136|Drug|entolimod|Given IM or SC
349800|NCT01527136|Other|pharmacological study|Correlative studies
349801|NCT01527136|Other|laboratory biomarker analysis|Correlative studies
349802|NCT01527123|Drug|GSK2585823|CLDM1%/BPO3%
349803|NCT01527110|Drug|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
349804|NCT01527097|Drug|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
349805|NCT01527097|Drug|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
349806|NCT01527084|Procedure|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
349807|NCT01527058|Drug|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
349808|NCT01527045|Drug|Atorvastatin Calcium|Given PO
349809|NCT01527045|Drug|Cyclosporine|Given PO
349810|NCT01527045|Drug|Fludarabine Phosphate|Given IV
349811|NCT01527045|Other|Laboratory Biomarker Analysis|Correlative studies
349812|NCT01527045|Drug|Mycophenolate Mofetil|Given PO or IV
349813|NCT01527045|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
349814|NCT01527045|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
349815|NCT01527045|Radiation|Total-Body Irradiation|Undergo TBI
349816|NCT01527032|Drug|melphalan, thalidomide and dexamethasone|
349817|NCT01527019|Drug|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
349818|NCT01527019|Drug|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
349819|NCT01527019|Drug|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
349820|NCT01527006|Drug|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
349821|NCT01526980|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
349822|NCT01526980|Drug|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
349823|NCT01526980|Drug|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
349824|NCT01526954|Device|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
349825|NCT01526941|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
349826|NCT01526941|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
349827|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib will be administered in escalating dosages in a period of 21-day cycles~Phase 2: Rociletinib will be administered daily"
349828|NCT01526915|Procedure|Bone curettage + PRF|Bone curettage and PRF insertion
349829|NCT01526915|Procedure|Bone curettage alone|Bone curettage without PRF insertion
349830|NCT01526902|Device|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
349831|NCT01526902|Device|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
349832|NCT01526889|Drug|LFG316|LFG316 administered intravitreally (IVT)
349833|NCT01526889|Drug|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
349834|NCT01526876|Drug|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
349835|NCT01526863|Dietary Supplement|HA egg|Daily dose of HA egg or placebo for 6 months
349836|NCT01526850|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
349837|NCT01526850|Drug|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
349838|NCT01526837|Drug|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
349839|NCT01526824|Dietary Supplement|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
349840|NCT01526811|Device|Endurant Stent graft|Endurant Stent graft implantation
349841|NCT01526798|Device|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
349842|NCT01526798|Device|Conventional high-flux dialyzer|
349843|NCT01526785|Drug|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
349844|NCT01526772|Procedure|Endoscopy|Transoral endoscopy versus transoral endoscopy
349845|NCT01526759|Dietary Supplement|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
349846|NCT01526759|Dietary Supplement|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
349847|NCT01526746|Drug|Tasimelteon|20mg capsule, once
349848|NCT01526746|Drug|Tasimelteon|20mg, once
349849|NCT01526733|Drug|Sham Injection|
349850|NCT01526733|Drug|Recombinant human hyaluronidase PH20|
349851|NCT01526733|Drug|Insulin aspart|
349852|NCT01526733|Drug|Insulin lispro|
349853|NCT01526707|Drug|inhaled steroid|inhaled budesonide for 7 days
349854|NCT01526694|Drug|Bendamustine|Bifunctional alkylating agent consisting of a purine and amino acid antagonist (a benzimidazole ring) and an alkylating nitrogen mustard moiety.
349855|NCT01526694|Drug|Thalidomide|Thalidomide can directly inhibit the growth and survival of myeloma cells, by oxidative damage to DNA mediated by free radicals. The drug can induce apoptosis even in drug resistant myeloma cells. Thalidomide modulates cell adhesion molecule expression, so it may interfere with the mutually stimulatory interactions between myeloma cells and the bone marrow microenvironment.
349856|NCT01526694|Drug|Dexamethasone|It's a corticosteroid.
349857|NCT01526681|Other|Processed Human Nerve Graft|Implantation of appropriate length of processed human nerve graft at the time of surgery
349858|NCT01526681|Other|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical control from established literature
349859|NCT01526681|Other|Autogenous Nerve Graft|Nerve gap reconstructions with autogenous nerve graft within the upper extremity
349860|NCT01526681|Device|Nerve Tube Conduit|Nerve gap reconstructions with nerve tube conduit within the upper extremity
349865|NCT01526655|Procedure|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
349866|NCT01526655|Procedure|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
349867|NCT01526642|Device|Non Invasive Ventilation|NIV during night
349868|NCT01526616|Drug|Metformin|Metformin 850 mg twice a day for six months
349869|NCT01526616|Drug|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
349870|NCT01526603|Drug|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
349871|NCT01526603|Biological|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
349872|NCT01526603|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) > 2000/μL for 3 consecutive days.
349873|NCT01526603|Radiation|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring >1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
349874|NCT01526603|Drug|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients >12 kg isotretinoin (accutane) should be administered at 160 mg/m^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
349875|NCT01526603|Drug|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
349876|NCT01526603|Drug|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
349877|NCT01526590|Drug|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
349878|NCT01526577|Drug|LC23-1306|LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
349879|NCT01526577|Drug|placebo|LC23-1306 placebo
349880|NCT01526577|Drug|Ticagrelor|Ticagrelor 90mg
349881|NCT01526564|Drug|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or >4 hours for 8 weeks
349882|NCT01526564|Drug|Placebo|3 t.i.d, two plates per time
349883|NCT01526551|Other|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
349884|NCT01526551|Other|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
349885|NCT01526538|Drug|d-cycloserine|50 mg d-cycloserine
349886|NCT01526538|Drug|sugar pill|placebo
349887|NCT01526525|Drug|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
349888|NCT01526525|Drug|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
349889|NCT01526525|Drug|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
349890|NCT01526525|Drug|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
349891|NCT01526525|Procedure|sedation|If the patient had sedation score >2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
349892|NCT01526525|Procedure|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
349893|NCT01526525|Drug|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
349894|NCT01526525|Drug|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
349895|NCT01526512|Drug|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
349896|NCT01526499|Drug|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
349897|NCT01526499|Drug|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
349898|NCT01526486|Procedure|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
349899|NCT01526486|Procedure|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
349900|NCT01526473|Biological|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
349901|NCT01526460|Drug|Atorvastatin|80 mg
349902|NCT01526460|Drug|Rosuvastatin|40 mg
349903|NCT01526460|Drug|Placebo|no statin loading dose
349904|NCT01526447|Procedure|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
349905|NCT01526447|Procedure|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
349906|NCT01526421|Other|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
349907|NCT01526408|Drug|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
349908|NCT01526408|Drug|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
349909|NCT01526395|Drug|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
349910|NCT01526382|Device|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
349911|NCT01526382|Procedure|central venous catheter|patients in this arm can receive central venous catheter
349912|NCT01526369|Drug|Trastuzumab|
349913|NCT01526369|Drug|Paclitaxel|
349914|NCT01526369|Drug|Lapatinib|
349915|NCT01526356|Drug|Placebo|Study cream is applied nightly to the affected areas on the face.
349916|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
349917|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
349918|NCT01526343|Device|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
349919|NCT01526330|Drug|YH14618|A mg/disc
349920|NCT01526330|Drug|YH14618|B mg/disc
349921|NCT01526330|Drug|YH14618|C mg/disc
349922|NCT01526330|Drug|Placebo|0mg/disc
349923|NCT01526317|Drug|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
349924|NCT01526304|Other|no intervention|No intervention, only observational study
349925|NCT01526278|Drug|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
349926|NCT01526265|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
349927|NCT01526265|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
349928|NCT01526265|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
349929|NCT01526265|Behavioral|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
349930|NCT01526265|Behavioral|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
349931|NCT01526239|Other|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
349932|NCT01526226|Device|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
349933|NCT01526226|Device|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
349934|NCT01526213|Drug|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
349935|NCT01526200|Procedure|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
349936|NCT01526174|Drug|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
349937|NCT01526161|Drug|inhaled fluticasone propionate|100 micrograms
349938|NCT01526161|Drug|salmeterol|50 m
349939|NCT01526161|Drug|Montelukast|Double blind double dummy
349940|NCT01526148|Drug|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels > 0.6mEq/L.
349941|NCT01526148|Drug|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
349942|NCT01526135|Drug|mFolfirinox|"mFolfirinox every 14 days, 12 cycles, 24 weeks.~mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.~Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.~5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
349943|NCT01526135|Drug|Gemcitabine|Gemcitabine 1000 mg/m² IV infusion over 30 minutes, weekly, during 3 weeks + 1 week of rest (= 1 cycle) repeated 6 times (i.e., 6 cycles) during 24 weeks
349944|NCT01526122|Drug|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg & Aspirin 100mg in 1 capsule), PO
349945|NCT01526122|Drug|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets & Aspirin 100mg 2 capsules, PO
349946|NCT01526109|Behavioral|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
349947|NCT01526109|Behavioral|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
349948|NCT01526109|Behavioral|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
349949|NCT01526096|Drug|G-CSF|G-CSF will be self-administered shot daily for 4 days pre-transplant. Up to 8 doses of G-CSF may be given. G-CSF will also be administered once daily under the skin beginning 5 days after your stem cell infusion until your white blood cell count is high enough
349950|NCT01526096|Drug|Plerixafor|Plerixafor (self-administered shot)prior to the beginning of the stem cell collection. Up to 4 doses of plerixafor may be given.
349951|NCT01526096|Procedure|Apheresis|Stem cell collection begins on day 5 and can last up to 3 days depending on the number collected.
349952|NCT01526096|Drug|Melphalan|Melphalan chemotherapy 100mg/m2 for 2 days after your admission into the hospital for your ASCT procedure.
349953|NCT01526096|Procedure|Stem cell re-infusion|Stem cells are thawed and reinfused back into the body via a catheter in the vein.
349954|NCT01526096|Drug|Basiliximab|Basiliximab (20mg) given by IV infusion (through the vein) 20-30 minutes the day after ASCT.
349955|NCT01526096|Device|CliniMACS CD25 microbeads and cell sorter|The stem cells collected during apheresis will be counted and treated with CD25 microbeads and processed by a special device called a CliniMACs machine which removes the regulatory T cells from you stem cell product.
349956|NCT01526083|Other|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
349957|NCT01526083|Other|Warfarin|"Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period~In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.~Duration: single dose"
349958|NCT01526070|Drug|Intravitreal injection of Aflibercept|
349959|NCT01526057|Biological|PF-05280586|1000 mg, IV on days 1 and 15
349960|NCT01526057|Biological|MabThera|1000 mg, IV on days 1 and 15
349961|NCT01526057|Biological|Rituxan|1000 mg, IV on days 1 and 15
349962|NCT01526044|Device|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
349963|NCT01526031|Procedure|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
349964|NCT01526031|Procedure|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
349965|NCT01526031|Procedure|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)~1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)~2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)~3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)~4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
349966|NCT01526031|Procedure|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.~transcutaneous electrical nerve stimulation (TENS) for 15 minutes~transcutaneous infrared thermotherapy (TDP) for 15 minutes~manual physical therapy for 15 minutes~simple home exercise program"
349967|NCT01526018|Behavioral|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
349968|NCT01526005|Drug|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
349969|NCT01526005|Drug|Transdermal Placebo Patch|1 patch per day; 8 weeks total
350001|NCT01525758|Drug|microcrystalline cellulose|identical number of tablets to active drug groups
349970|NCT01525992|Behavioral|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
349971|NCT01525992|Other|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
349972|NCT01525979|Behavioral|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
349973|NCT01525979|Behavioral|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
349974|NCT01525979|Behavioral|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
349975|NCT01525979|Behavioral|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
349976|NCT01525966|Drug|carboplatin|Given IV
349977|NCT01525966|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
349978|NCT01525966|Other|laboratory biomarker analysis|Correlative studies
349979|NCT01525953|Drug|Chemotherapy|Chemotherapy according to standard
349980|NCT01525953|Radiation|Radiotherapy|Radiotherapy according to local standard
349981|NCT01525940|Device|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
349982|NCT01525927|Drug|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
349983|NCT01525927|Radiation|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
349984|NCT01525927|Radiation|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
349985|NCT01525914|Drug|Dutasteride|dutasteride 0.5mg daily
349986|NCT01525901|Drug|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
349987|NCT01525901|Drug|Normal saline|Saline solution will be administered for three months subcutaneously.
349988|NCT01525888|Procedure|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
349989|NCT01525875|Drug|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).~Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
349990|NCT01525875|Drug|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
349991|NCT01525862|Device|Sinus Balloon Dilation Tool|transnasal sinus balloon dilation procedure
349992|NCT01525849|Device|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
349993|NCT01525849|Procedure|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
349994|NCT01525836|Drug|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 29th day)
349995|NCT01525836|Drug|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
349996|NCT01525823|Drug|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
349997|NCT01525823|Drug|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
349998|NCT01525810|Drug|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention [subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)]
349999|NCT01525771|Other|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.~Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)~Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days~Cisplatin 60mg/m2 IV (D1) every 21 days"
350000|NCT01525758|Drug|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
350002|NCT01525745|Radiation|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
350003|NCT01525745|Radiation|External Beam Radiation Therapy|10 consecutive days of standard radiation
350004|NCT01525732|Procedure|Per Oral Endoscopic Myotomy|
350005|NCT01525719|Drug|Everolimus|10 mg everolimus
350006|NCT01525706|Drug|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL [3mg/ml diluted in normal saline from original concentration of 6mg/mL] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
350007|NCT01525680|Other|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
350008|NCT01525680|Other|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
350009|NCT01525667|Biological|150M PLX-PAD|Single course, multiple IM injections
350010|NCT01525667|Biological|300M PLX-PAD|Single course, multiple IM injections
350011|NCT01525667|Biological|Placebo|Single course, multiple IM injections
350012|NCT01525654|Behavioral|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
350013|NCT01525641|Drug|Mirapex LA|Pramipexole Hydrochloride Hydrate
350014|NCT01525628|Drug|midazolam|CYP3A probe drug
350015|NCT01525628|Drug|BI 201335|HCV protease inhibitor
350016|NCT01525628|Drug|tenofovir|nucleoside analogue
350017|NCT01525628|Drug|caffeine|CYP1A2 probe drug
350018|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
350019|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
350020|NCT01525628|Drug|midazolam|CYP3A probe drug
350021|NCT01525628|Drug|caffeine|CYP1A2 probe drug
350022|NCT01525628|Drug|pegylated interferon|HCV treatment
350023|NCT01525628|Drug|BI 201335|HCV protease inhibitor
350024|NCT01525628|Drug|BI 201335|HCV protease inhibitor
350025|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
350026|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
350027|NCT01525628|Drug|BI 201335|HCV protease inhibitor
350028|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
350029|NCT01525628|Drug|ribavirin|HCV treatment
350030|NCT01525628|Drug|ribavirin|HCV treatment
350031|NCT01525628|Drug|ribavirin|HCV treatment
350032|NCT01525628|Drug|pegylated interferon|HCV treatment
350033|NCT01525628|Drug|ribavirin|HCV treatment
350034|NCT01525628|Drug|caffeine|CYP1A2 probe drug
350035|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
350036|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
350037|NCT01525628|Drug|midazolam|CYP3A probe drug
350038|NCT01525628|Drug|BI 201335|HCV protease inhibitor
350039|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
350040|NCT01525628|Drug|ribavirin|HCV treatment
350041|NCT01525615|Device|Respimat inhaler|Respimat inhaler
350042|NCT01525615|Drug|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
350043|NCT01525615|Drug|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
350044|NCT01525615|Device|Respimat inhaler|Respimat inhaler
350045|NCT01525615|Device|Respimat inhaler|Respimat inhaler
350046|NCT01525615|Drug|placebo to tiotropium+olodaterol|comparator
350047|NCT01525602|Drug|PLX3397|PLX3397 tablets, 200mg
350048|NCT01525602|Drug|Paclitaxel|Paclitaxel IV
350049|NCT01525589|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
350050|NCT01525576|Behavioral|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
350051|NCT01525550|Drug|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
350052|NCT01525537|Drug|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
350053|NCT01525537|Drug|sufentanil|sufentanil was given at standard practise
350054|NCT01525524|Device|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
350055|NCT01525511|Drug|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~Dosage: 2 tablets~DHA-PQP:~1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~Dosage: 3 tablets"
350056|NCT01525511|Drug|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.~Primaquine:~1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)~Dosage: 2 tablets~DHA-PQP:~1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg~Dosage: 3 tablets"
350057|NCT01525459|Procedure|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
350058|NCT01525459|Other|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
350059|NCT01525446|Radiation|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
350060|NCT01525433|Behavioral|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
350061|NCT01525433|Behavioral|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
350062|NCT01525420|Behavioral|Acceptance Therapy (ACT)|ACT
350063|NCT01525420|Other|Cognitive Behavioral Therapy (CBT)|CBT
350064|NCT01525407|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
350065|NCT01525407|Drug|Atorvastatin Calcium|Given PO
350066|NCT01525407|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
350067|NCT01525394|Drug|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
350068|NCT01525394|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
350069|NCT01525394|Drug|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
350070|NCT01525368|Behavioral|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
350071|NCT01525329|Drug|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting ~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
350072|NCT01525316|Dietary Supplement|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
350073|NCT01525316|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
350074|NCT01525303|Behavioral|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
350075|NCT01525290|Drug|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
350076|NCT01525290|Drug|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
350077|NCT01525264|Behavioral|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
350078|NCT01525264|Behavioral|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
350079|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 2.5 mg, Single-dose
350080|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 5 mg, Single-dose
350081|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 10 mg, Single-dose
350082|NCT01525225|Drug|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
350083|NCT01525225|Drug|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
350084|NCT01525225|Drug|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
350085|NCT01525225|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
350086|NCT01525225|Drug|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
350087|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
350088|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
350089|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
350090|NCT01525212|Drug|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
350091|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
350092|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
350093|NCT01525173|Drug|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
350094|NCT01525173|Drug|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
350095|NCT01525173|Drug|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
350096|NCT01525173|Drug|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
350097|NCT01525147|Biological|YHB1411-2: Level 2|IV infusion
350098|NCT01525147|Biological|YHB1411-2: Level 3|IV infusion
350099|NCT01525147|Biological|YHB1411-2: Level 4|IV infusion
350100|NCT01525147|Biological|YHB1411-2: Level 5|IV infusion
350101|NCT01525147|Biological|Placebo|IV infusion
350102|NCT01525147|Biological|YHB1411-2: level 1|IV infusion
350103|NCT01525134|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere"
350104|NCT01525134|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.~Manufacturer: Alere."
350105|NCT01525121|Other|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
350106|NCT01525108|Behavioral|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
350107|NCT01525108|Other|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
350108|NCT01525082|Drug|capecitabine|Given PO
350109|NCT01525082|Drug|temozolomide|Given PO
350110|NCT01525082|Biological|bevacizumab|Given IV
350111|NCT01525069|Drug|Floxuridine|
350112|NCT01525069|Drug|Dexamethasone|
350113|NCT01525069|Drug|Gemcitabine|
350114|NCT01525069|Drug|Oxaliplatin|
350115|NCT01525056|Radiation|ct and mri scans|ct and mri scan preradiation and postradiation
350116|NCT01525056|Radiation|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
350117|NCT01525056|Radiation|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
350118|NCT01525043|Drug|Naproxen|Naproxen 500mg BID for the first 2 weeks
350119|NCT01525043|Drug|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
350120|NCT01525043|Drug|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
350121|NCT01525043|Drug|Naproxen|500mg bid
350122|NCT01525043|Drug|Synera|Topical appication of single patch to elbow for 12hrs/day
350123|NCT01525043|Drug|Synera|Single patch applied to elbow for 4hrs/twice daily
350124|NCT01525017|Biological|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
350125|NCT01525004|Drug|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
350126|NCT01525004|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
350127|NCT01524991|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 & 8 (all cycles)
350128|NCT01524991|Drug|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
350129|NCT01524991|Drug|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
350130|NCT01524978|Drug|cetuximab|Escalating doses administered on Day 1 and then once weekly by intravenous infusion.
350131|NCT01524978|Drug|vemurafenib|Escalating doses given orally twice a day starting on Day 2
350132|NCT01524978|Drug|vemurafenib|960 mg vemurafenib orally twice a day until disease progression, unacceptable toxicity, or withdrawal of consent.
350133|NCT01524965|Procedure|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
350134|NCT01524965|Procedure|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.~Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
350135|NCT01524965|Device|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
350136|NCT01524952|Device|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
350137|NCT01524939|Drug|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
350138|NCT01524926|Drug|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
350139|NCT01524913|Drug|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
350140|NCT01524913|Drug|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
352347|NCT01508000|Biological|Bevacizumab|Targeted therapy
350141|NCT01524913|Drug|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
350142|NCT01524887|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
350143|NCT01524887|Biological|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
350144|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
350145|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
350146|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
350147|NCT01524861|Drug|Placebo|a placebo tablet bis in die for 12 months
350148|NCT01524861|Drug|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
350149|NCT01524861|Drug|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
350150|NCT01524848|Drug|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
350151|NCT01524809|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
350152|NCT01524809|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
350153|NCT01524796|Other|No intervention. Non-interventional study|No intervention. Non-interventional study
350154|NCT01524783|Drug|Everolimus|After randomization, patients will receive everolimus once daily until disease progression, intolerable toxicity, or consent withdrawal
350155|NCT01524783|Drug|Everolimus Placebo|After randomization, patients will receive everolimus placebo once daily until disease progression, intolerable toxicity, or consent withdrawal
350156|NCT01524770|Biological|Dulaglutide|Administered by subcutaneous (SC) injection
350157|NCT01524757|Drug|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
350158|NCT01524744|Drug|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
350159|NCT01524744|Drug|Adcortyl|triamcinolone acetonide 0.1% in orabase
350160|NCT01524731|Drug|Saline|Normal Saline
350161|NCT01524731|Drug|Dexamethasone|4 mg
350162|NCT01524731|Drug|Dexamethasone|8 mg
350163|NCT01524718|Radiation|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
350164|NCT01524705|Drug|"GLIPULIN: [insulin glargine, metformin, exenatide (GLP-1-agonist)]"|Glargine-injectable, variable, QD, 6 months Metformin-oral, up to 1000mg, BID, 6 months Exenatide-injectable, 5mcg, BID, 6 months
350165|NCT01524705|Drug|Insulin glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
350166|NCT01524692|Drug|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
350167|NCT01524679|Drug|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
350168|NCT01524653|Drug|Rosuvastatin|20 mg po od
350169|NCT01524653|Drug|Placebo|20 mg po od
350170|NCT01524640|Biological|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
350171|NCT01524640|Biological|Placebo|1.5 ml oral administration on day 0 and day 14
350172|NCT01524627|Drug|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
350173|NCT01524627|Drug|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
350174|NCT01524614|Procedure|nasal mask|nasal mask use instead of face mask
350175|NCT01524601|Drug|Rosuvastatin|20 mg rosuvastatin for 4 weeks
350176|NCT01524575|Drug|gemcitabine and oxaliplatin|Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
350177|NCT01524536|Drug|prednisone|Prednisoneis an adrenocortical steroid which is mainly used for antiinflammatory effects in different disorders of many organ systems. It causes profound and varied metabolic effects, modifies the immune response of the body to diverse stimuli, and is also used as replacement therapy for adrenocortical deficient patients.
350178|NCT01524510|Radiation|CT scan|low dose radiation scan without contrast without and with MRA
350179|NCT01524510|Device|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
350180|NCT01524497|Drug|Trazodone|75mg tablet/150 mg tablet
350181|NCT01524497|Drug|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
350182|NCT01524471|Procedure|Per Oral Endoscopic Myotomy|
350183|NCT01524458|Procedure|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
350184|NCT01524445|Other|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
350185|NCT01524432|Drug|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
350186|NCT01524432|Drug|Placebo|No drug loaded microcapsules socks
350187|NCT01524406|Drug|HPP593|Oral, twice a day.
350188|NCT01524406|Drug|Placebo|Oral, twice a day.
350189|NCT01524380|Drug|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
350190|NCT01524380|Drug|Placebo|twice a day, 10 weeks
350191|NCT01524367|Drug|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
350192|NCT01524367|Drug|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
350193|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
350194|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
350195|NCT01524341|Drug|KAE609|KAE609 was supplied as capsules for oral use.
350196|NCT01524315|Drug|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
350197|NCT01524315|Drug|Placebo|100 ml normal saline, intravenous, preoperative
350198|NCT01524302|Drug|Ceftaroline|600 mg Q12h
350199|NCT01524302|Drug|Levofloxacin|750 mg QD
350200|NCT01524289|Drug|Anacetrapib|One oral tablet, orally once daily for 52 weeks
350201|NCT01524289|Drug|Placebo|One oral tablet once daily for 52 weeks
350202|NCT01524250|Drug|corticosteroids|1250mg of oral prednisone daily for 3 days
350203|NCT01524250|Drug|corticosteroids|1000mg IV methylprednisolone daily for 3 days
350204|NCT01524237|Drug|LY2979165|Capsules administered orally
350205|NCT01524237|Drug|LY2140023|Tablets administered orally
350206|NCT01524237|Other|Placebo|Administered orally
350207|NCT01524237|Other|Ketamine|Administered intravenously (IV)
350208|NCT01524224|Drug|LY2495655|administered intravenously
350209|NCT01524211|Device|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
350210|NCT01524198|Drug|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
350211|NCT01524198|Drug|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
350212|NCT01524185|Behavioral|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
350213|NCT01524185|Behavioral|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
350214|NCT01524172|Behavioral|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
350215|NCT01524172|Behavioral|Standard Mental Health Treatment|Trauma and evidence informed therapy
350216|NCT01524159|Dietary Supplement|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
350217|NCT01524159|Dietary Supplement|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
350218|NCT01524146|Procedure|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.~• PDT involves three components:~Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.~Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis~Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.~Technique:~Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.~Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
350219|NCT01524133|Drug|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
350220|NCT01524133|Behavioral|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
350221|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
350222|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
350223|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
350224|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
350225|NCT01524094|Drug|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
350226|NCT01524094|Procedure|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
350227|NCT01524081|Drug|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.~- Cefuroxime in 100ml saline~- Metronidazole in 500ml saline"
350228|NCT01524081|Drug|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.~- 2x amoxicillin in 100ml saline~- Fluconazole in 500ml saline"
350229|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~- 100ml saline solution~- 500ml saline solution"
350230|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery~- 2x 100ml saline solution~- 500ml saline solution"
350231|NCT01524068|Drug|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
350232|NCT01524068|Drug|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
350233|NCT01524055|Device|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
350234|NCT01524055|Device|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
350235|NCT01524042|Procedure|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
350236|NCT01524016|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
350237|NCT01524003|Procedure|cryotherapy|cryotherapy treatment of the uterine cervix
350238|NCT01524003|Procedure|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
350239|NCT01523990|Drug|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
350240|NCT01523990|Drug|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
350241|NCT01523977|Drug|Everolimus|Orally, daily days 1-32 per assigned dose level
350242|NCT01523977|Drug|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
350243|NCT01523977|Drug|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
350244|NCT01523977|Drug|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
350245|NCT01523977|Drug|Doxorubicin|30 mg/m2 IV on days 4 and 5
350246|NCT01523977|Drug|Dexrazoxane|300 mg/m2 IV on days 4 and 5
350247|NCT01523964|Other|Testing with EIM|
350248|NCT01523938|Behavioral|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
350249|NCT01523925|Behavioral|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
350250|NCT01523925|Behavioral|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
350251|NCT01523925|Behavioral|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
350252|NCT01523925|Behavioral|Functional electrical stimulation|
350253|NCT01523912|Device|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
350254|NCT01523899|Device|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
350255|NCT01523899|Diagnostic Test|Standard culture|
350256|NCT01523886|Drug|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
350257|NCT01523886|Drug|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
350258|NCT01523860|Drug|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
350259|NCT01523847|Drug|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:~Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
350260|NCT01523834|Drug|Panobinostat|"Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).~Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted."
350261|NCT01523821|Drug|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]|Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia] at various levels over different days
350262|NCT01523808|Drug|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
350263|NCT01523795|Other|Motion-controlled video gaming|Play of motion-controlled video games for one hour
350264|NCT01523795|Other|Traditional video gaming|Participants played traditional video games for one hour
350265|NCT01523795|Other|Television watching|Participants watched television for one hour
350266|NCT01523782|Drug|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
350267|NCT01523769|Procedure|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
350268|NCT01523756|Device|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
350269|NCT01523756|Device|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
350270|NCT01523743|Device|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
350271|NCT01523743|Device|Standard care|The coated intermittent catheter normally used by subject
350272|NCT01523730|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
350273|NCT01523730|Device|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
350274|NCT01523704|Device|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
350275|NCT01523704|Device|BIOTRONIK Home Monitoring System with In-office Follow-up|
350276|NCT01523691|Behavioral|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
350277|NCT01523691|Behavioral|Control sleep|Regular amounts of sleep across study protocol
350278|NCT01523678|Drug|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
350279|NCT01523678|Drug|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
350280|NCT01523678|Drug|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
350281|NCT01523639|Drug|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks"
350282|NCT01523626|Other|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.~The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
350283|NCT01523626|Other|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.~Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
350284|NCT01523613|Device|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
350285|NCT01523613|Device|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
350313|NCT01523379|Drug|Placebo|NaCl i.v. two times a day, two days in an row
350314|NCT01523366|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
350286|NCT01523600|Behavioral|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
350287|NCT01523600|Behavioral|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
350288|NCT01523587|Drug|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
350289|NCT01523587|Drug|erlotinib|erlotinib taken once daily
350290|NCT01523574|Drug|Vitamin E|Vitamin E 400mg PO orally
350291|NCT01523574|Drug|Placebo|Placebo, given orally
350292|NCT01523561|Behavioral|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
350293|NCT01523548|Drug|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
350294|NCT01523535|Behavioral|repeated cycles of short sleep|- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
350295|NCT01523522|Other|Myoblast injection|Autologous myoblast injection in the anal sphincter
350296|NCT01523522|Procedure|saline solution injection|saline solution injection in anal sphincter
350297|NCT01523509|Device|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
350298|NCT01523496|Drug|Vitamin D control dose|18,000 IU per month
350299|NCT01523496|Drug|Vitamin D supplementation-|60,000 IU per month(medium dose) or 120,000 IU/month(high dose)
350300|NCT01523483|Drug|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
350301|NCT01523483|Drug|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
350302|NCT01523470|Device|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
350303|NCT01523457|Drug|Folfirinox|"Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~Leucovorin 400 mg/m2 IV over two hours~Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
350304|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
350305|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
350306|NCT01523431|Drug|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 *1/*1 or heterozygous UGT1A1*1/*28 or *1/*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1*28/*28, *6/*6 or *28/*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
350307|NCT01523431|Drug|5-fluorouracil|The 5-FU dosage will remain the standard.
350308|NCT01523431|Drug|Leucovorin|The LV dosage will remain the standard.
350309|NCT01523418|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) & 5 weeks (THR)
350310|NCT01523392|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
350311|NCT01523392|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
350312|NCT01523379|Drug|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
350315|NCT01523366|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
350316|NCT01523353|Behavioral|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
350317|NCT01523327|Other|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.~Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
350318|NCT01523314|Drug|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
350319|NCT01523314|Other|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
350320|NCT01523301|Drug|Rotigotine|"Transdermal Patch~Content:~2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)~For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period~For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
350321|NCT01523301|Drug|Placebo|"Transdermal Patch~Size:~10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2~Subjects randomized to placebo received matching placebo patches"
350322|NCT01523275|Drug|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
350323|NCT01523275|Other|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
350324|NCT01523262|Procedure|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
350325|NCT01523262|Procedure|Normal surgery, with sham intervention without inflating arm cuff|
350326|NCT01523249|Device|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
350327|NCT01523236|Drug|Mometasone furoate|50 mcg/actuation Nasal Spray
350328|NCT01523236|Drug|Nasonex®|50 mcg/actuation Nasal Spray
350329|NCT01523236|Drug|Placebo|Nasal Spray
350330|NCT01523223|Biological|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
350331|NCT01523210|Other|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
350332|NCT01523197|Device|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
350333|NCT01523184|Drug|Placebo Capsule|This is the placebo capsule
350334|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
350335|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
350336|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
350337|NCT01523171|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
350338|NCT01523158|Biological|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
350339|NCT01523145|Behavioral|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
350340|NCT01523145|Other|Control Group|usual follow-up Standard follow-up at the participating heart center
350341|NCT01523119|Drug|Ondansetron|Orally Disintegrating Tablets 8 mg
350342|NCT01523106|Drug|L-carnitine|dietary supplement
350343|NCT01523106|Other|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
350344|NCT01523093|Drug|Ondansetron|Orally Disintegrating Tablets 8mg
350345|NCT01523080|Drug|Acetaminophen|Extended release Gel tabs 650 mg
350346|NCT01523067|Drug|Vasomera (PB1046)|Single dose of Vasomera
350347|NCT01523067|Drug|0.9% Sodium Chloride|Placebo injection
350348|NCT01523054|Drug|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
350349|NCT01523054|Drug|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
350350|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
350351|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
350352|NCT01523041|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
350353|NCT01523028|Other|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~200 mL coffee or~200 mL coffee + 2 bread rolls + honey~200 mL coffee + 1 bread roll + peanut butter"
350354|NCT01523015|Other|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
350428|NCT01522508|Procedure|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
350429|NCT01522495|Device|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
350355|NCT01523015|Procedure|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
350356|NCT01523002|Drug|Metoprolol and Pyronaridine : artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of Pyramax as follows:~55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)~On Day 10, a 100 mg dose of metoprolol will be coadministered with Pyramax at the above dose.~On Days 98 - 100, subjects will receive Pyramax once daily at the same dose described above."
350357|NCT01523002|Drug|pyronaridine:artesunate|"In the first period, subjects will receive 3 days of Pyramax as follows:~55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)~≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate) followed by a 57 day follow-up period. In the second period, subjects will receive 3 days of Pyramax at the dose described above."
350358|NCT01522989|Drug|PD-0332991|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
350359|NCT01522989|Drug|5-FU|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
350360|NCT01522989|Drug|Oxaliplatin|"Stage 1:~PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10~Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:~Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3~In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
350361|NCT01522976|Drug|Azacitidine|Given SC or IV
350362|NCT01522976|Other|Laboratory Biomarker Analysis|Correlative studies
350363|NCT01522976|Drug|Lenalidomide|Given PO
350364|NCT01522976|Drug|Vorinostat|Given PO
350365|NCT01522963|Drug|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
350366|NCT01522950|Drug|Nebivolol|5 mg daily or 10 mg daily
350367|NCT01522950|Drug|atenolol|25 mg daily or 50 mg daily
350368|NCT01522950|Drug|placebo|one tablet daily
350369|NCT01522937|Radiation|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
350370|NCT01522924|Other|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
350371|NCT01522911|Device|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
350372|NCT01522898|Procedure|AV nodal ablation|Percutaneous catheter ablation of the AV node.
350373|NCT01522898|Drug|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
350374|NCT01522885|Device|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
350375|NCT01522885|Procedure|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
350376|NCT01522872|Drug|TH-302|
350377|NCT01522872|Drug|TH-302 and Dexamethasone|
350378|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
350379|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
350422|NCT01522560|Other|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
350423|NCT01522547|Drug|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
350424|NCT01522534|Drug|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
350425|NCT01522534|Drug|Morphine|Morphine alone with a placebo nerve block
350380|NCT01522859|Device|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
350381|NCT01522846|Drug|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
350382|NCT01522820|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
350383|NCT01522820|Other|Laboratory Biomarker Analysis|Correlative studies
350384|NCT01522820|Other|Pharmacological Study|Correlative studies
350385|NCT01522820|Drug|Sirolimus|Given PO or PEG
350386|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
350387|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
350388|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
350389|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
350390|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
350391|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
350392|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
350393|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
350394|NCT01522794|Drug|NOX-H94|single i.v. infusion
350395|NCT01522794|Drug|Placebo solution|single i.v. infusion
350396|NCT01522768|Drug|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
350397|NCT01522755|Device|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
350398|NCT01522729|Drug|Fentanyl|Single-dose of intrathecal fentanyl [25ug] Duration of fentanyl : 3.5 hours
350399|NCT01522729|Drug|Placebo comparator|placebo [NaCl]
350400|NCT01522716|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
350401|NCT01522703|Drug|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
350402|NCT01522703|Drug|Placebo|Alfalfa Sprouts
350403|NCT01522690|Other|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
350404|NCT01522677|Drug|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
350405|NCT01522664|Drug|DEDN6526A|Multiple ascending doses
350406|NCT01522651|Drug|Ranolazine|Ranolazine 750 mg tablet administered orally twice daily
350407|NCT01522651|Drug|Dronedarone low dose 1|Dronedarone 225 mg capsule administered orally twice daily
350408|NCT01522651|Drug|Dronedarone low dose 2|Dronedarone 150 mg capsule administered orally twice daily
350409|NCT01522651|Drug|Ranolazine placebo|Placebo to match ranolazine administered orally twice daily
350410|NCT01522651|Drug|Dronedarone placebo|Placebo to match dronedarone administered orally twice daily
350411|NCT01522625|Drug|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
350412|NCT01522625|Drug|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
350413|NCT01522612|Drug|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
350414|NCT01522612|Drug|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
350415|NCT01522612|Drug|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
350416|NCT01522599|Other|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
350417|NCT01522599|Other|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
350418|NCT01522586|Drug|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
350419|NCT01522586|Drug|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
350420|NCT01522573|Procedure|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
350421|NCT01522560|Other|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.~This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
350426|NCT01522521|Drug|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
350427|NCT01522521|Drug|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
350430|NCT01522495|Device|SPY Imaging|SPY Imaging to assess tissue perfusion
350431|NCT01522482|Dietary Supplement|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
350432|NCT01522482|Dietary Supplement|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.~The dose of fish oils was equivalent to two portions of oily fish."
350433|NCT01522482|Dietary Supplement|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
350434|NCT01522469|Drug|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
350435|NCT01522456|Drug|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
350436|NCT01522456|Drug|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
350437|NCT01522443|Drug|cabozantinib|Tablets taken orally once daily.
350438|NCT01522443|Drug|mitoxantrone|Given by IV once every 3 weeks.
350439|NCT01522443|Drug|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
350440|NCT01522430|Procedure|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
350441|NCT01522430|Procedure|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
350442|NCT01522417|Drug|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
350443|NCT01522417|Drug|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
350444|NCT01522417|Drug|Long Tirofiban|25 ug/kg i.v. bolus followed by a 0.15 ug/kg/min i.v. infusion for 12 to 18 hours post-PCI.
350445|NCT01522404|Drug|Atomoxetine|Subjects in this intervention will receive Atomoxetine up to 29 weeks, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
350446|NCT01522404|Drug|Placebo|Subjects in this intervention will receive inactive compound up to weeks 29 and will cross over to the other group
350447|NCT01522391|Drug|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
350448|NCT01522391|Drug|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
350449|NCT01522378|Drug|123 iodine metaiodobenzylguanidine|10 millicurie (mCi) (370 MBq)
350450|NCT01522365|Device|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
350451|NCT01522365|Device|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
350452|NCT01522352|Procedure|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
350453|NCT01522339|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
350454|NCT01522326|Drug|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
350455|NCT01522326|Drug|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
350456|NCT01522300|Other|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
350457|NCT01522300|Other|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
350458|NCT01522287|Behavioral|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
350459|NCT01522274|Behavioral|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
350460|NCT01522274|Behavioral|Health education|Videos
350461|NCT01522261|Other|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
350462|NCT01522261|Other|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
350463|NCT01522248|Biological|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
350464|NCT01522235|Drug|Double blinded IVIg|Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
350465|NCT01522235|Other|Double blinded Placebo|Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
350466|NCT01522235|Other|Single Blinded IVIg|This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
350548|NCT01521637|Procedure|Sham-treatment: no NMES|Sham comparator
350549|NCT01521624|Drug|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
350467|NCT01522222|Procedure|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
350468|NCT01522209|Procedure|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
350469|NCT01522209|Device|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
350470|NCT01522209|Radiation|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
350471|NCT01522209|Radiation|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
350472|NCT01522196|Drug|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
350473|NCT01522196|Other|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
350474|NCT01522157|Dietary Supplement|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
350475|NCT01522157|Dietary Supplement|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
350476|NCT01522157|Dietary Supplement|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
350477|NCT01522144|Behavioral|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
350478|NCT01522131|Procedure|bioresorbable membrane alonewill be used for regeneration of the periodontium(control)|bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
350479|NCT01522118|Device|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.~MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
350480|NCT01522105|Drug|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
350481|NCT01522092|Drug|escitalopram|5mg-20mg, tablet, od, 12 months
350482|NCT01522079|Procedure|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
350483|NCT01522066|Procedure|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
350484|NCT01522066|Procedure|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
350485|NCT01522053|Procedure|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
350486|NCT01522053|Procedure|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
350487|NCT01522040|Drug|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
350488|NCT01522040|Drug|Placebo|Simple saline drip, without active drug
350489|NCT01522027|Procedure|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
350490|NCT01522014|Device|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
350491|NCT01522014|Device|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
350492|NCT01522001|Behavioral|Shared Care model|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.~Dietary counseling with dietician~Exercise (1 hour, 2 timer pr week for 12 weeks)~Smoking cessation if smoker with educated smoking cessation instructor~Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse~Examination by the patient´s general practitioner 8-12 weeks after discharge."
350493|NCT01521988|Procedure|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
350494|NCT01521988|Procedure|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
350495|NCT01521975|Drug|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
350496|NCT01521962|Drug|Alogliptin|Alogliptin tablets
350497|NCT01521962|Drug|Insulin|Insulin injection
350498|NCT01521949|Drug|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
350499|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (lower dose)
350500|NCT01521936|Other|pharmacological study|Correlative studies
350501|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (higher dose)
350502|NCT01521936|Other|laboratory biomarker analysis|Correlative studies
350550|NCT01521611|Radiation|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
350503|NCT01521923|Biological|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.~On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).~CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.~The MTX treatment is to remain between 15-25 mg/week."
350504|NCT01521923|Biological|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.~The MTX treatment is to remain between 15-25 mg/week."
350505|NCT01521910|Dietary Supplement|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.~The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.~Supplementation of Calcium of 500mg/day.~Urine albumin losses >= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
350506|NCT01521910|Dietary Supplement|normal protein diet|"The patients pre-study diet during the whole study period~Patients were also seen by the same doctor during each visit for the whole study period."
350507|NCT01521897|Biological|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
350508|NCT01521884|Other|SC anti-TNF|SC anti-TNF
350509|NCT01521871|Procedure|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
350510|NCT01521871|Procedure|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
350511|NCT01521845|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
350512|NCT01521832|Drug|SEN0014196|5 mg single oral dose
350513|NCT01521832|Drug|SEN0014196|25 mg single oral dose
350514|NCT01521832|Drug|SEN0014196|75 mg single oral dose
350515|NCT01521832|Drug|SEN0014196|150 mg single oral dose
350516|NCT01521832|Drug|SEN0014196|300 mg single oral dose
350517|NCT01521832|Drug|SEN0014196|600 mg single oral dose
350518|NCT01521832|Drug|SEN0014196|300 mg single oral dose (females)
350519|NCT01521832|Drug|SEN0014196|100 mg multiple oral dose
350520|NCT01521832|Drug|SEN0014196|300 mg multiple oral dose
350521|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose
350522|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose (females)
350523|NCT01521819|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
350524|NCT01521819|Drug|Lucentis|Intravitreal injection of Lucentis as needed.
350525|NCT01521806|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to snack foods
350526|NCT01521793|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
350527|NCT01521780|Procedure|MRI|Participants undergo volumetric & diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
350528|NCT01521780|Procedure|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
350529|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
350530|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
350531|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of extended release capsules
350532|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
350533|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
350534|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
350535|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
350536|NCT01521728|Other|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
350537|NCT01521728|Other|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
350538|NCT01521728|Other|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
350539|NCT01521715|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
350540|NCT01521702|Drug|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
350541|NCT01521702|Procedure|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
350542|NCT01521689|Drug|Rituximab|Low doses of sub cutaneaous rituximab
350543|NCT01521676|Genetic|molecular alteration|research of molecular alteration
350544|NCT01521663|Drug|IPX159|
350545|NCT01521663|Drug|Placebo|
350546|NCT01521650|Dietary Supplement|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
350547|NCT01521637|Procedure|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
350551|NCT01521598|Drug|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
350552|NCT01521598|Drug|Placebo|This is the placebo. Patients will be randomized the placebo.
350553|NCT01521585|Drug|SEN0014196|50 mg oral once daily tablet
350554|NCT01521585|Drug|SEN0014196|200 mg oral once daily tablet
350555|NCT01521585|Drug|Placebo|oral once daily tablet
350556|NCT01521572|Drug|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
350557|NCT01521559|Procedure|Macular Laser Photocoagulation|
350558|NCT01521559|Drug|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
350559|NCT01521546|Drug|eplerenone|25mg tablet, once daily by mouth for 12 months
350560|NCT01521546|Drug|placebo|one tablet by mouth daily for 12 months
350561|NCT01521533|Drug|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):~3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX A12 in combination with VD):~Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
350562|NCT01521520|Drug|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
350563|NCT01521507|Device|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
350564|NCT01521507|Device|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
350565|NCT01521494|Drug|PA21|
350566|NCT01521494|Drug|PA21|
350567|NCT01521494|Drug|PA21|
350568|NCT01521494|Drug|PA21|
350569|NCT01521494|Drug|Placebo|
350570|NCT01521481|Other|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
350571|NCT01521481|Other|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
350572|NCT01521455|Drug|HCP0910|250/50, BID for 2 weeks
350573|NCT01521455|Drug|Seretide Diskus|250/50, BID for 2 weeks
350574|NCT01521442|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
350575|NCT01521442|Behavioral|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
350576|NCT01521416|Other|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.~All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
350577|NCT01521403|Drug|Metronidazole|3x500 mg/day for 10 days
350578|NCT01521403|Drug|Placebo|3x1 tablet per day for 10 days
350579|NCT01521390|Drug|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
350580|NCT01521390|Drug|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
350581|NCT01521390|Drug|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
350582|NCT01521390|Drug|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
350583|NCT01521390|Drug|Placebo|Placebo, no active ingredient
350584|NCT01521377|Drug|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
350585|NCT01521377|Drug|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
350586|NCT01521377|Drug|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
350587|NCT01521377|Drug|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
350588|NCT01521377|Drug|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
350589|NCT01521377|Drug|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
350590|NCT01521364|Drug|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
350591|NCT01521325|Drug|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
350592|NCT01521312|Drug|saxagliptin|5mg a day for 11-14 weeks
350593|NCT01521312|Other|placebo pill|one tablet a day for 11-14 weeks
350594|NCT01521299|Drug|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
350595|NCT01521286|Other|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
350596|NCT01521273|Other|Bean varieties|10 x 50 g/ arm
350597|NCT01521260|Procedure|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
350661|NCT01520701|Drug|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
350598|NCT01521260|Procedure|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
350599|NCT01521247|Other|Asthma Transition Program|Asthma Education.
350600|NCT01521234|Behavioral|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
350601|NCT01521221|Other|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
350602|NCT01521208|Device|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
350603|NCT01521208|Other|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
350604|NCT01521195|Device|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.~Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
350605|NCT01521182|Other|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
350606|NCT01521182|Other|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
350607|NCT01521169|Other|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
350608|NCT01521169|Other|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
350609|NCT01521169|Other|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
350610|NCT01521156|Other|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
350611|NCT01521156|Other|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
350612|NCT01521143|Biological|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
350613|NCT01521143|Biological|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.~Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
350614|NCT01521130|Drug|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
350615|NCT01521117|Drug|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
350616|NCT01521078|Behavioral|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
350617|NCT01521065|Device|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
350618|NCT01521052|Device|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
350619|NCT01521039|Procedure|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
350620|NCT01521026|Behavioral|Cognitive Training|12-week compensatory cognitive training in group format
350621|NCT01521013|Behavioral|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).~Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
350622|NCT01521013|Behavioral|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
350623|NCT01521000|Device|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
350624|NCT01520987|Drug|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
350625|NCT01520987|Drug|Placebo|once-daily
350626|NCT01520974|Other|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
350627|NCT01520974|Other|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
350628|NCT01520948|Behavioral|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
350629|NCT01520948|Behavioral|Behavioral control|Mirrored star drawing
350662|NCT01520688|Drug|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
350663|NCT01520688|Drug|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
350988|NCT01518153|Procedure|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
350630|NCT01520935|Other|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).~Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
350631|NCT01520922|Biological|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
350632|NCT01520922|Drug|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
350633|NCT01520909|Drug|Eltrombopag|Thrombopoietin receptor agonist
350634|NCT01520909|Drug|Placebo|Placebo with no active pharmaceutical ingredient
350635|NCT01520896|Drug|NKTR-118|Oral 25 mg
350636|NCT01520896|Drug|Ketoconazole|Oral 400 mg
350637|NCT01520870|Drug|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
350638|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
350639|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
350640|NCT01520844|Biological|blood sampling|blood sampling
350641|NCT01520831|Drug|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
350642|NCT01520831|Drug|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
350643|NCT01520831|Drug|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
350644|NCT01520831|Drug|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
350645|NCT01520818|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m^2 will receive BIAsp 50
350646|NCT01520818|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m^2 will receive BIAsp 70
350647|NCT01520818|Drug|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
350648|NCT01520805|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
350649|NCT01520792|Drug|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
350650|NCT01520766|Device|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
350651|NCT01520766|Device|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
350652|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
350653|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
350654|NCT01520753|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
350655|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
350656|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
350657|NCT01520727|Drug|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
350658|NCT01520727|Drug|Placebo|single-dose
350659|NCT01520714|Device|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
350660|NCT01520701|Device|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
350664|NCT01520688|Drug|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
350665|NCT01520688|Drug|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
350666|NCT01520688|Drug|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
350667|NCT01520688|Drug|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
350668|NCT01520675|Procedure|surgery|Drainage procedure
350669|NCT01520675|Procedure|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
350670|NCT01520662|Other|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
350671|NCT01520649|Drug|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
350672|NCT01520649|Drug|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
350673|NCT01520636|Procedure|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
350674|NCT01520636|Procedure|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
350675|NCT01520623|Other|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
350676|NCT01520584|Dietary Supplement|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
350677|NCT01520571|Procedure|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
350678|NCT01520571|Procedure|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
350679|NCT01520558|Biological|CNDO-109-AANK Cells|Single dose, infusion
350680|NCT01520545|Drug|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
350681|NCT01520545|Device|SynchroMed® II Programmable Pump|Intrathecal programmable pump
350682|NCT01520532|Other|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
350683|NCT01520519|Drug|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
350684|NCT01520519|Drug|PCI-32765|420 mg (3 * 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
350685|NCT01520506|Device|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
350686|NCT01520493|Other|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
350687|NCT01520467|Drug|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
350688|NCT01520467|Drug|Placebo|1 placebo tablet /day administered orally for 18 months.
350689|NCT01520454|Drug|Saline|IV saline at 0.83 mL/kg/hr for six hours
350690|NCT01520454|Drug|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
350691|NCT01520454|Dietary Supplement|Water|Water by mouth
350692|NCT01520454|Dietary Supplement|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
350693|NCT01520454|Drug|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
350694|NCT01520441|Drug|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
350695|NCT01520428|Behavioral|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
350696|NCT01520415|Drug|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
350697|NCT01520415|Drug|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
350698|NCT01520402|Drug|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
350699|NCT01520389|Drug|MM-151|MM-151
350700|NCT01520389|Drug|MM-151 + irinotecan|MM-151 + irinotecan
350701|NCT01520376|Behavioral|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
350702|NCT01520363|Drug|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
350703|NCT01520363|Drug|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
350704|NCT01520350|Drug|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
350705|NCT01520350|Drug|placebo|Placebo
350706|NCT01520337|Device|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
350707|NCT01520324|Device|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
350708|NCT01520311|Device|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
350709|NCT01520298|Drug|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
350710|NCT01520298|Drug|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
350711|NCT01520285|Drug|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
350712|NCT01520285|Drug|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
350713|NCT01520246|Genetic|gene expression analysis|
350714|NCT01520246|Other|laboratory biomarker analysis|
350715|NCT01520233|Genetic|RNA analysis|
350716|NCT01520233|Genetic|gene expression analysis|
350717|NCT01520233|Other|laboratory biomarker analysis|
350718|NCT01520220|Drug|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
350719|NCT01520207|Drug|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
350720|NCT01520207|Drug|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
350721|NCT01520194|Other|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
350722|NCT01520194|Other|medical records|medical chart review of patients assisted January 2009 to December 2010
350723|NCT01520181|Drug|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
350724|NCT01520142|Drug|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
350725|NCT01520142|Drug|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
350726|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
350727|NCT01520116|Drug|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
350728|NCT01520116|Drug|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
350729|NCT01520116|Drug|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
350730|NCT01520116|Drug|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
350731|NCT01520116|Drug|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
350732|NCT01520116|Drug|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
350733|NCT01520116|Drug|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
350734|NCT01520116|Drug|Timoptic|0.5%
350735|NCT01520103|Drug|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
350736|NCT01520103|Drug|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
350737|NCT01520077|Drug|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
350738|NCT01520051|Drug|Mepolizumab|3 monthly intravenous infusions of 750 mg
350739|NCT01520051|Drug|Placebo|3 monthly intravenous infusions with saline
350740|NCT01520038|Radiation|Proton therapy|
350741|NCT01520038|Radiation|IMRT|
350776|NCT01519765|Drug|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
350777|NCT01519752|Drug|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
350778|NCT01519752|Drug|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
350779|NCT01519752|Drug|Placebo|Placebo applied to affected area once a day for 28 days
350780|NCT01519739|Device|MediGuide™|MediGuide™ system will be used to guide CRT implants
350781|NCT01519726|Drug|Midazolam|
350742|NCT01520025|Radiation|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.~18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.~Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
350743|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
350744|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
350745|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
350746|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
350747|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
350748|NCT01519999|Behavioral|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
350749|NCT01519986|Dietary Supplement|Vitamin D3|Supplement of vitamin D3
350750|NCT01519986|Dietary Supplement|Placebo|Placebo
350751|NCT01519973|Radiation|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
350752|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
350753|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
350754|NCT01519947|Drug|Methoxy polyethylene glycol-epoetin beta|Participants received 50-250 mcg SC according to local label
350755|NCT01519921|Drug|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
350756|NCT01519908|Device|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
350757|NCT01519895|Behavioral|Telephone intervention|counseling and education support
350758|NCT01519882|Other|Placebo|"Placebo patches size equivalent to 4, 6 & 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
350759|NCT01519882|Other|Rotigotine|"Rotigotine patches of 4,6 & 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.~Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
350760|NCT01519869|Drug|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
350761|NCT01519856|Drug|piribedil (Clarium)|oral tablets, 50 mg
350762|NCT01519843|Device|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
350763|NCT01519843|Device|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
350764|NCT01519830|Drug|Iron carboxymaltose (Ferinject)|Intravenous iron
350765|NCT01519830|Drug|Placebo|0.9% NaCl solution
350766|NCT01519817|Biological|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
350767|NCT01519804|Drug|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
350768|NCT01519804|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
350769|NCT01519804|Drug|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
350770|NCT01519804|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
350771|NCT01519791|Biological|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
350772|NCT01519791|Other|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
350773|NCT01519791|Biological|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
350774|NCT01519778|Drug|TR701 FA|1 tablet 200 mg once daily
350775|NCT01519765|Drug|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
350826|NCT01519401|Drug|3 mg drospirenone and 30 µg ethinyl-estradiol|
350782|NCT01519713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
350783|NCT01519700|Drug|EP2006|Eligible patients will be teated with EP2006
350784|NCT01519700|Drug|Filgrastim|Eligible patients will be teated with Filgrastim
350785|NCT01519687|Drug|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
350786|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
350787|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
350788|NCT01519674|Drug|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
350789|NCT01519674|Drug|metformin|Subjects will continue on their pre-trial metformin treatment.
350790|NCT01519661|Drug|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
350791|NCT01519635|Drug|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
350792|NCT01519635|Drug|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
350793|NCT01519622|Other|Questionnaire|Questionnaire to be distributed among sick elderly in the community
350794|NCT01519609|Drug|bowel prep before endoscopy|bowel prep before colonoscopy
350795|NCT01519596|Procedure|quality-of-life assessment|Ancillary studies
350796|NCT01519596|Other|counseling intervention|Receive lifestyle-related counseling
350797|NCT01519596|Behavioral|exercise intervention|Undergo physical activity intervention
350798|NCT01519596|Other|educational intervention|Receive educational materials
350799|NCT01519596|Procedure|standard follow-up care|Undergo usual care
350800|NCT01519583|Behavioral|Basic Intervention|Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
350801|NCT01519583|Behavioral|Enhanced Pedometry|Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
350802|NCT01519583|Behavioral|Control Group|Maintain usual physical activity, and return for follow-up measures.
350803|NCT01519570|Other|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
350804|NCT01519557|Drug|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
350805|NCT01519557|Drug|Placebo|Placebo
350806|NCT01519544|Drug|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
350807|NCT01519544|Drug|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
350808|NCT01519531|Drug|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
350809|NCT01519531|Drug|VIA-3196|Oral, daily dosing for 14 days
350810|NCT01519518|Drug|unfractionated heparin|70 units/kg body weight intravenous
350811|NCT01519518|Drug|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
350812|NCT01519505|Behavioral|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
350813|NCT01519492|Drug|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
350814|NCT01519479|Other|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
350815|NCT01519479|Other|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
350816|NCT01519466|Device|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
350817|NCT01519466|Device|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
350818|NCT01519453|Behavioral|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
350819|NCT01519427|Drug|Akt inhibitor MK2206|Given PO
350820|NCT01519427|Drug|selumetinib|Given PO
350821|NCT01519427|Other|laboratory biomarker analysis|Correlative studies
350822|NCT01519414|Other|Laboratory Biomarker Analysis|Optional correlative studies
350823|NCT01519414|Other|Placebo|Given PO
350824|NCT01519414|Drug|Tivantinib|Given PO
350825|NCT01519401|Drug|3 mg drospirenone and 20 µg ethinyl-estradiol|
350827|NCT01519388|Other|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
350828|NCT01519388|Device|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
350829|NCT01519349|Biological|rAAV1.CMV.huFollistatin344|"First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)~Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)~Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
350830|NCT01519336|Drug|danoprevir|100 mg q12h
350831|NCT01519336|Drug|darunavir|600 mg q12h
350832|NCT01519336|Drug|ritonavir|100 mg q12h
350833|NCT01519323|Drug|vemurafenib|Cohort 1 (participants >=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants <45 kg): starting dose 480 mg
350834|NCT01519310|Other|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:~Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
350835|NCT01519297|Drug|Irbesartan|150mg orally for one dose
350836|NCT01519284|Drug|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
350837|NCT01519284|Drug|Entacapone|Entacapone 200 mg
350838|NCT01519284|Drug|Placebo|placebo (four times a day)
350839|NCT01519284|Drug|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
350840|NCT01519284|Drug|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
350841|NCT01519284|Drug|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
350842|NCT01519271|Drug|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
350843|NCT01519271|Drug|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
350844|NCT01519258|Other|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
350845|NCT01519258|Device|NAVA|Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
350846|NCT01519245|Drug|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
350847|NCT01519245|Drug|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
350848|NCT01519232|Radiation|Liver Irradiation|Patients already scheduled to undergo radiation treatment
350849|NCT01519219|Radiation|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
350850|NCT01519206|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
350851|NCT01519193|Behavioral|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
350852|NCT01519167|Drug|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
350853|NCT01519167|Drug|Midazolam|0.025 - 2 mg/kg IV
350854|NCT01519167|Drug|Fentanyl|0.5 - 3 mcg/kg IV
350855|NCT01519154|Drug|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
350856|NCT01519154|Drug|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
350857|NCT01519128|Drug|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
350858|NCT01519128|Drug|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
350859|NCT01519115|Other|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
350860|NCT01519115|Other|usual care|one physical therapy visit in hospital following ACF surgery
350861|NCT01519102|Device|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
350862|NCT01519089|Drug|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
350863|NCT01519089|Drug|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
350864|NCT01519076|Device|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
350865|NCT01519063|Drug|Naltrexone and memantine first|Naltrexone 50mg memantine 20mg
350866|NCT01519063|Drug|Naltrexone and Placebo first|Naltrexone 50 mg Placebo
350867|NCT01519050|Behavioral|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
350868|NCT01519037|Drug|calcimimetic agent (cinacalcet)|one dose of oral cinacalcet, 60mg
350869|NCT01519037|Drug|placebo|one dose of oral placebo
350870|NCT01519011|Drug|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
350871|NCT01519011|Drug|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
350872|NCT01518998|Drug|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
350873|NCT01518985|Drug|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
350874|NCT01518985|Drug|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
350875|NCT01518985|Other|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
350876|NCT01518972|Drug|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
350877|NCT01518972|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
350878|NCT01518959|Drug|Cholecalciferol|180.000 IU monthly
350879|NCT01518959|Drug|oleum neutralicum|Placebo comparator, 9 ml monthly
350880|NCT01518946|Drug|Midodrine HCl|dose at the subject's current dose level
350881|NCT01518946|Drug|Placebo|single dose of matching placebo
350882|NCT01518933|Drug|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
350883|NCT01518933|Drug|Saline|Placebo
350884|NCT01518920|Drug|PF-04958242|PF-04958242 0.35 mg oral solution
350885|NCT01518920|Drug|PF-04958242|PF-04958242 0.27 mg oral solution
350886|NCT01518920|Drug|Placebo|Placebo oral solution
350887|NCT01518907|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
350888|NCT01518894|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
350889|NCT01518894|Drug|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
350890|NCT01518894|Drug|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
350891|NCT01518894|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
350892|NCT01518881|Drug|TKM-100201|IV Infusion
350893|NCT01518881|Drug|Placebo|IV infusion
350894|NCT01518855|Drug|Nifedipine (Adalat, BAYA1040)|
350895|NCT01518855|Drug|Amlodipine (Norvasc)|
350896|NCT01518855|Drug|Diovan|
350897|NCT01518842|Biological|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
350898|NCT01518803|Dietary Supplement|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
350899|NCT01518803|Dietary Supplement|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
350900|NCT01518790|Drug|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
350901|NCT01518777|Other|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
350902|NCT01518764|Dietary Supplement|Red Wine Polyphenols 600mg/day|
350903|NCT01518764|Dietary Supplement|placebo|
350904|NCT01518738|Behavioral|breath attention training|4 week training
350905|NCT01518738|Behavioral|working memory attention training|4 week training
350906|NCT01518725|Dietary Supplement|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
350907|NCT01518725|Dietary Supplement|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
350908|NCT01518712|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
350943|NCT01518439|Device|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
351037|NCT01517802|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
350909|NCT01518712|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
350910|NCT01518699|Drug|Ha44|study drug at low, moderate and high dose single exposure
350911|NCT01518699|Drug|Ha44 Placebo|Ha44 Vehicle Gel without Ha44
350912|NCT01518699|Drug|Moxifloxacin Placebo|Moxifloxacin Placebo
350913|NCT01518699|Drug|Moxifloxacin|moxifloxacin 400mg
350914|NCT01518686|Device|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .~The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
350915|NCT01518673|Procedure|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
350916|NCT01518660|Behavioral|Training|Bi-weekly progressive resistance training
350917|NCT01518647|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
350918|NCT01518634|Drug|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
350919|NCT01518634|Drug|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
350920|NCT01518621|Radiation|Radiation|Whole brain radiation
350921|NCT01518621|Drug|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
350922|NCT01518608|Drug|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.~Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
350923|NCT01518595|Drug|bosentan|pts. will receive bosentan for 3 months
350924|NCT01518595|Drug|Placebo|pts. will receive placebo for 3 months
350925|NCT01518582|Device|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
350926|NCT01518569|Drug|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
350927|NCT01518569|Drug|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
350928|NCT01518556|Drug|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.~In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
350929|NCT01518530|Device|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
350930|NCT01518517|Drug|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
350931|NCT01518517|Drug|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
350932|NCT01518504|Other|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
350933|NCT01518504|Other|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
350934|NCT01518491|Drug|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
350935|NCT01518491|Other|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
350936|NCT01518478|Drug|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.~Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
350937|NCT01518465|Drug|dalteparin|Given SC
350938|NCT01518465|Drug|lenalidomide|Given PO
350939|NCT01518465|Drug|dexamethasone|Given PO
350940|NCT01518465|Other|laboratory biomarker analysis|Correlative studies
350941|NCT01518452|Behavioral|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
350942|NCT01518452|Behavioral|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
350944|NCT01518439|Device|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
350945|NCT01518439|Device|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
350946|NCT01518439|Device|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
350947|NCT01518439|Other|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
350948|NCT01518426|Device|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:~with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
350949|NCT01518413|Drug|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
350950|NCT01518413|Drug|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
350951|NCT01518387|Drug|Lanthanum Carbonate (BAY77-1931)|
350952|NCT01518374|Drug|Florbetapir F 18|370 MBq (10 mCi)
350953|NCT01518348|Biological|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
350954|NCT01518335|Procedure|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
350955|NCT01518335|Procedure|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
350956|NCT01518322|Device|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
350957|NCT01518309|Drug|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
350958|NCT01518296|Device|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
350959|NCT01518283|Drug|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
350960|NCT01518270|Other|No treatment|No treatment will be provided
350961|NCT01518257|Biological|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
350962|NCT01518257|Drug|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
350963|NCT01518244|Drug|Brinzolamide/timolol maleate fixed combination|
350964|NCT01518231|Procedure|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
350965|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
350966|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial);
350967|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
350968|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt.
350969|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
350970|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial)
350971|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
350972|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt
350973|NCT01518218|Behavioral|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
350974|NCT01518205|Device|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.~LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).~To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
350975|NCT01518192|Drug|doxycycline|100 mg bid; 15 days
350976|NCT01518192|Drug|cefuroxime axetil|500 mg bid; 15 days
350977|NCT01518179|Device|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
350978|NCT01518179|Other|Routine follow up and treatment|Control
350979|NCT01518166|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
350980|NCT01518166|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
350981|NCT01518166|Drug|atorvastatin|One single dose of 40 mg. Tablet
350982|NCT01518166|Drug|lisinopril|One single dose of 20 mg. Tablet
350983|NCT01518166|Drug|griseofulvin|One single dose of 500 mg. Tablet
350984|NCT01518166|Drug|digoxin|One single dose of 1 mg. Tablet
350985|NCT01518153|Drug|Fludarabine|40 mg/m^2 by vein on Day -6 to -3.
350986|NCT01518153|Drug|Melphalan|140 mg/m^2 by vein on Day -2.
350987|NCT01518153|Drug|Alemtuzumab|50 mg by vein on Day -1.
350989|NCT01518153|Drug|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
350990|NCT01518153|Drug|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
350991|NCT01518153|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
350992|NCT01518153|Procedure|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64.
350993|NCT01518153|Procedure|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64.
350994|NCT01518140|Device|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
350995|NCT01518140|Behavioral|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
350996|NCT01518127|Other|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
350997|NCT01518114|Behavioral|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
350998|NCT01518101|Drug|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
350999|NCT01518101|Drug|Liraglutide|1.2 mg once daily by commercially available injection pens
351000|NCT01518101|Drug|Metformin|1000 mg tablets twice daily
351001|NCT01518088|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to study foods
351002|NCT01518075|Other|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
351003|NCT01518075|Other|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
351004|NCT01518062|Drug|somatropin|4 IU/m^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
351005|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
351006|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface, the second year and finally 8 IU/m^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
351007|NCT01518062|Drug|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
351008|NCT01518036|Drug|somatropin|2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
351009|NCT01518036|Drug|somatropin|4.3 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
351010|NCT01518023|Other|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
351011|NCT01518010|Behavioral|Play game|Participants engage in non-game activity (establish baseline) 7 * 1 hr weekly; play single-player game 7 * 1 hr weekly; play multi-player game 7 * 1 hr weekly.
351012|NCT01517997|Procedure|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
351013|NCT01517997|Procedure|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
351014|NCT01517984|Drug|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
351015|NCT01517984|Drug|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
351016|NCT01517971|Other|laboratory biomarker analysis|Correlative studies
351017|NCT01517958|Other|Respiratory Distress Group|Diagnostic lung ultrasound.
351018|NCT01517958|Other|Control Group|Lung ultrasound
351038|NCT01517802|Drug|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
351039|NCT01517789|Device|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.~Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
351019|NCT01517945|Behavioral|AIM materials and assessments|Part 1 will be used to develop & refine the intervention & assessment materials with 10 participants. We will adapt two previously validated CBM tasks, attention modification & interpretation modification to create two novel AIM programs (designated AIM-Neutral & AIM-Meaning), each of which targets both attention & interpretation biases for fear of breast cancer recurrence. Participants will complete the assessment battery & 1 30-minute session of each version of the intervention (AIM-Neutral & AIM-Meaning) & will provide feedback about the recruitment procedures, stimuli, & assessments. Part 2 will be a proof-of-concept, small scale, single-blind, placebo-controlled RCT of AIM. One hundred eleven participants will be randomized to receive either AIM-Neutral (n=37), AIM-Meaning (n=37), or computer placebo (CP; n=37). The AIM & CP conditions will involve completion of 8 30-minute sessions Participants will be instructed to complete 2 sessions per week for a total of 4 weeks.
351020|NCT01517932|Drug|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
351021|NCT01517932|Drug|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.~Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.~Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
351022|NCT01517919|Behavioral|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.~PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
351023|NCT01517906|Behavioral|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
351024|NCT01517906|Behavioral|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
351025|NCT01517893|Drug|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
351026|NCT01517893|Drug|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
351027|NCT01517880|Drug|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
351028|NCT01517880|Drug|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
351029|NCT01517867|Behavioral|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
351030|NCT01517867|Behavioral|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
351031|NCT01517854|Drug|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
351032|NCT01517854|Drug|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
351033|NCT01517828|Drug|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
351034|NCT01517828|Drug|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.~One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
351035|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
351036|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:~in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.~in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
351040|NCT01517776|Drug|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
351041|NCT01517776|Drug|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
351042|NCT01517763|Device|Conventional CPAP Therapy|HC244 devices without Thermosmart or SensAwake
351043|NCT01517763|Device|Fixed pressure ICON™ without ThermoSmart™|Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
351044|NCT01517763|Device|Auto ICON™ with SensAwake™ and ThermoSmart™|APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
351045|NCT01517750|Device|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
351046|NCT01517750|Device|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
351047|NCT01517724|Drug|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
351048|NCT01517711|Drug|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
351049|NCT01517711|Drug|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
351050|NCT01517698|Drug|Placebo|placebo to RO4917523 orally once a day for 12 weeks
351051|NCT01517698|Drug|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
351052|NCT01517698|Drug|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
351053|NCT01517685|Dietary Supplement|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
351054|NCT01517685|Dietary Supplement|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
351055|NCT01517672|Behavioral|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
351056|NCT01517659|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
351057|NCT01517646|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
351058|NCT01517633|Device|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
351059|NCT01517620|Drug|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
351060|NCT01517607|Other|Mesalazine|Patient's treated with oral Mesalazine
351061|NCT01517568|Drug|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
351062|NCT01517555|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
351063|NCT01517555|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
351064|NCT01517555|Drug|paracetamol|One single dose of 1 g. Tablet
351065|NCT01517542|Other|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
351066|NCT01517503|Behavioral|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
351067|NCT01517503|Behavioral|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
351068|NCT01517490|Other|Insulin pump|Insulin pump therapy
351069|NCT01517490|Other|Multiple daily insulin injections|Multiple daily insulin injections
351070|NCT01517490|Procedure|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
351071|NCT01517490|Other|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
351072|NCT01517477|Device|iStent|Implantation of One iStent through a small temporal clear corneal incision.
351073|NCT01517477|Device|iStent|Implantation of Two iStents through a small temporal clear corneal incision
351074|NCT01517477|Device|iStent|Implantation of Three iStents through a small temporal clear corneal incision
351075|NCT01517464|Genetic|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
351076|NCT01517451|Radiation|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
351077|NCT01517451|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
351078|NCT01517438|Behavioral|agitation|agitation score after desflurane anesthesia
351079|NCT01517412|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
351080|NCT01517412|Device|Self-injector pen device (OptiClik®)|
351081|NCT01517412|Drug|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
351082|NCT01517399|Drug|tivantinib|three oral 120 mg tablets administered twice a day
351083|NCT01517399|Drug|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
351084|NCT01517399|Drug|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
351085|NCT01517399|Drug|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
351086|NCT01517399|Dietary Supplement|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
351087|NCT01517399|Drug|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
351088|NCT01517399|Drug|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
351089|NCT01517386|Procedure|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
351090|NCT01517373|Drug|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
351091|NCT01517373|Drug|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
351092|NCT01517373|Drug|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
351093|NCT01517373|Drug|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
351094|NCT01517373|Drug|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
351095|NCT01517360|Drug|Oxytocin|Oxytocin 40 IU, intranasal inhalation
351096|NCT01517360|Other|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
351097|NCT01517360|Behavioral|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
351098|NCT01517347|Drug|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
351099|NCT01517334|Drug|Minocycline HCl Microspheres|
351100|NCT01517321|Drug|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
351101|NCT01517321|Drug|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
351102|NCT01517308|Drug|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
351103|NCT01517295|Drug|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
351104|NCT01517282|Biological|MOR103|Anti-GM-CSF monoclonal antibody
351105|NCT01517282|Other|Placebo|Placebo to anti-GM-CSF monoclonal antibody
351106|NCT01517269|Behavioral|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
351107|NCT01517269|Behavioral|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
351108|NCT01517256|Behavioral|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
351109|NCT01517256|Other|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
351110|NCT01517243|Drug|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
351111|NCT01517243|Drug|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
351112|NCT01517230|Behavioral|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
351113|NCT01517217|Procedure|No girdle|No girdle is used for the first five postoperative days
351114|NCT01517217|Procedure|Girdle|Girdle the first five postoperative days
351115|NCT01517204|Device|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
351116|NCT01517204|Device|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
351117|NCT01517178|Device|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
351118|NCT01517178|Device|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
351119|NCT01517165|Drug|Pioglitazone|
351120|NCT01517165|Drug|Placebo|
351121|NCT01517100|Drug|Nabllone|CB Agonist
351122|NCT01517100|Drug|CP-945,598|Cannabinoid Receptor 1 antagonist
351123|NCT01517100|Procedure|Hypoglycemic Clamp|Assesses beta cell response
351124|NCT01517100|Drug|Euglycemic-Hyperinsulinemic Clamp|Measures insulin sensitivity
351125|NCT01517074|Drug|Sirolimus|Subconjunctival injection
351126|NCT01517035|Procedure|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
351429|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
351127|NCT01517022|Drug|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
351128|NCT01517009|Drug|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
351129|NCT01517009|Drug|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
351130|NCT01517009|Drug|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
351131|NCT01517009|Procedure|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
351132|NCT01516996|Drug|docetaxel and cisplatin|"The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.~CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
351133|NCT01516996|Radiation|IMRT|"IMRT is administered with chemotherapy from week 7 to week 13~GTV（primary tumor）：68-70Gy/35~38 F，once a day, 5 times per week~CTV（Clinical target）：56-66Gy/30~36f，once a day, 5 times per week~GTV-ln（positive neck region）：66-70Gy/33~36 F，once a day, 5 times per week~CTV-ln（negative neck region）：50-54Gy/28~30F, once a day, 5 times"
351134|NCT01516996|Biological|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13~14 weeks
351135|NCT01516983|Drug|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.~Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.~Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.~Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
351136|NCT01516983|Radiation|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
351137|NCT01516970|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
351138|NCT01516970|Drug|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
351139|NCT01516970|Drug|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
351140|NCT01516970|Drug|NRTIs|The NRTIs (including tenofovir/emtricitabine [Truvada], lamivudine/zidovudine [Combivir]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
351141|NCT01516970|Drug|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
351142|NCT01516957|Drug|AMG 827|140 mg AMG 827 SC (subcutaneous)
351143|NCT01516957|Drug|Placebo|Placebo SC (subcutaneous)
351144|NCT01516957|Drug|AMG 827|280 mg AMG 827 SC (subcutaneous)
351145|NCT01516957|Drug|AMG 827|210 mg AMG 827 SC (subcutaneous)
351146|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
351147|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
351148|NCT01516944|Drug|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
351149|NCT01516931|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
351150|NCT01516931|Behavioral|counseling|Placebo monthly by general counseling for 12 months.
351151|NCT01516918|Drug|VX-222|tablet, 400-mg twice daily
351152|NCT01516918|Drug|telaprevir|tablet, 1125-mg twice daily
351153|NCT01516918|Drug|ribavirin|tablet, 1000-mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
351154|NCT01516918|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
351155|NCT01516905|Drug|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
351156|NCT01516892|Biological|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
351157|NCT01516879|Biological|Evolocumab|Administered by subcutaneous injection once a month
351158|NCT01516879|Biological|Placebo|Administered by subcutaneous injection once a month
351159|NCT01516879|Drug|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
351160|NCT01516879|Drug|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
351161|NCT01516879|Other|Diet Only|Diet only, no lipid lowering background drug given
351162|NCT01516866|Procedure|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
351163|NCT01516853|Device|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
351164|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
351165|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
351166|NCT01516840|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
351167|NCT01516840|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
351168|NCT01516827|Behavioral|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
351169|NCT01516814|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
351170|NCT01516814|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
351171|NCT01516814|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
351172|NCT01516801|Other|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
351173|NCT01516788|Other|Phototesting|Single MED dose on Day 2
351174|NCT01516775|Other|clear fluid ingestion|drinking of clear fluid in preoperative period
351175|NCT01516762|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
351176|NCT01516749|Drug|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
351177|NCT01516736|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
351178|NCT01516736|Drug|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
351179|NCT01516723|Device|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
351180|NCT01516710|Procedure|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
351181|NCT01516710|Procedure|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
351182|NCT01516697|Procedure|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
351183|NCT01516697|Procedure|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
351184|NCT01516684|Drug|placebo administration|Given topically
351185|NCT01516684|Drug|EMLA|Given topically
351186|NCT01516684|Drug|propofol|Given IV
351187|NCT01516684|Drug|fentanyl citrate|Given IV
351188|NCT01516658|Device|Hydrogel coil|at least one Hydrogel coil have to use for embolization
351189|NCT01516658|Device|Bare platinum coil|only bare platinum coil have to use for embolization
351190|NCT01516645|Drug|KHK2898|injection
351191|NCT01516632|Behavioral|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
351192|NCT01516619|Drug|Romiplostim|"Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.~In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8."
351193|NCT01516606|Drug|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
351194|NCT01516593|Drug|Induction Phase|"dd -2 to 1: Methylprednisolone~dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine~dd 2, Rituximab~dd 7, Methotrexate~dd 14, Rituximab~dd 15, Etoposide~dd 21, Methotrexate~dd 29, Rituximab and Doxorubicin~dd 36, Rituximab and VCR~At the end of this induction phase, subsequent treatment will be performed according to the objective response:~pts in CR: consolidation phase followed by bulky site irradiation~pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation~pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
351195|NCT01516593|Drug|Consolidation Phase (on day +50)|"dd 1-2: cytarabine twice a day~dd 3 and 11: rituximab~dd 11-13: leukapheresis for PBPC collection."
351196|NCT01516593|Drug|Intensification phase|"One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.~CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);~AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
351197|NCT01516593|Drug|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
351198|NCT01516593|Radiation|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
351199|NCT01516580|Drug|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:~in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
351200|NCT01516580|Drug|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
351201|NCT01516567|Drug|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
351202|NCT01516554|Drug|Testosterone undecanoate|40 mg twice daily
351203|NCT01516554|Drug|placebo|twice daily
351204|NCT01516541|Other|Background care|Guidelines-based medical care
351205|NCT01516541|Drug|Placebo|Matching dalcetrapib placebo orally daily
351206|NCT01516541|Drug|dalcetrapib|600 mg orally daily
351207|NCT01516528|Procedure|Spirometry|Assessment of lung function by spirometry
351208|NCT01516515|Drug|Vehicle gel|placebo
351209|NCT01516515|Drug|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
351210|NCT01516502|Other|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
351211|NCT01516489|Behavioral|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
351212|NCT01516489|Behavioral|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
351213|NCT01516476|Drug|Placebo|Placebo for 12 weeks
351214|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
351215|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
351216|NCT01516476|Drug|liraglutide|liraglutide for 12 weeks
351217|NCT01516463|Drug|Collagenase Santyl|Applied topically (2 mm thickness once daily)
351218|NCT01516463|Biological|Bacitracin|Applied topically (2 mm thickness) once daily
351219|NCT01516450|Drug|GSK1550188 IV|Single IV dose of belimumab 200 mg
351220|NCT01516450|Drug|GSK1550188 SC|Single SC dose of belimumab 200mg
351221|NCT01516437|Procedure|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
351222|NCT01516437|Procedure|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
351223|NCT01516437|Procedure|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
351224|NCT01516424|Drug|Blonanserin|Blonanserin tablets: 8 - 24mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
351225|NCT01516424|Drug|Risperidone|Risperidone tablets: 2 - 6mg/day; twice daily after breakfast and dinner; in the meantime, the placebo and positive drug were taken in whole tablets. When the morning and evening doses could not be administered equally, the evening dose should be greater than the morning dose. The interval between 2 dose escalations should not be shorter than 3 days.
351226|NCT01516411|Behavioral|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
351227|NCT01516372|Drug|GEn 1200mg|1200 mg of Gen administered as a single dose
351228|NCT01516372|Drug|Gen 6000 mg|6000 mg of Gen administered as a single dose
351229|NCT01516372|Drug|GEn Placebo|Placebo to match GEn Tablets
351230|NCT01516372|Drug|Moxifloxacin Placebo|Placebo to match Moxifloxacin
351231|NCT01516372|Drug|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
351232|NCT01516346|Drug|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
351233|NCT01516346|Drug|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
351234|NCT01516346|Drug|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
351235|NCT01516333|Other|High GL 107|Three meals a day
351236|NCT01516333|Other|Medium GL 76|Three meals a day
351237|NCT01516333|Other|Medium GL 68|Three meals a day
351238|NCT01516333|Other|Low GL 48|Three meals a day
351239|NCT01516320|Procedure|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
351430|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
351240|NCT01516320|Procedure|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
351241|NCT01516320|Procedure|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
351242|NCT01516307|Biological|OPT-822/OPT-821(30 μg/100 μg)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
351243|NCT01516307|Biological|Phosphate Buffer Saline (PBS)|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
351244|NCT01516307|Drug|Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
351245|NCT01516294|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
351246|NCT01516268|Drug|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.~As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
351247|NCT01516255|Drug|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
351248|NCT01516255|Drug|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
351249|NCT01516255|Drug|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
351250|NCT01516255|Drug|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
351251|NCT01516255|Procedure|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
351252|NCT01516255|Procedure|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
351253|NCT01516242|Other|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
351254|NCT01516229|Drug|somatropin|Prescription of somatropin at the discretion of the physician
351255|NCT01516216|Drug|FOLFOX + bevacizumab|Given intravenously on Day 1 of every cycle
351256|NCT01516216|Dietary Supplement|Vitamin D|Standard Dose (400 IU once daily)
351257|NCT01516216|Dietary Supplement|Vitamin D|Higher Dose (8000 IU once daily for 2 weeks, followed by 4000 IU once daily)
351258|NCT01516203|Drug|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
351259|NCT01516203|Drug|Ethambutol, isoniazid, pyrazinamide, rifampin|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
351260|NCT01516190|Behavioral|Exercise|Supervised exercise sessions and independent exercise
351261|NCT01516190|Behavioral|Surgical preparation program|Book, tapes, CD
351262|NCT01516164|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
351263|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
351264|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
351265|NCT01516151|Dietary Supplement|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
351266|NCT01516151|Drug|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
351267|NCT01516151|Dietary Supplement|CaPre™|4 capsules of 1 g total per day for 8 weeks.
351268|NCT01516138|Drug|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
351269|NCT01516138|Drug|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
351270|NCT01516099|Other|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
351271|NCT01516099|Other|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
351272|NCT01516086|Drug|Fluticasone Propionate (FP)|FP Inhalation BID
351273|NCT01516073|Drug|Fluticasone Propionate|FP BID for 12 weeks
351274|NCT01516060|Drug|Efavirenz|400mg qd; 2 x 200mg
351275|NCT01516060|Drug|Efavirenz|600mg qd; 3 x 200mg qd
351276|NCT01516047|Drug|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
351277|NCT01516047|Drug|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
351278|NCT01516034|Device|Cupola Tattoo Removal device|Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
351279|NCT01516021|Dietary Supplement|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
351298|NCT01515917|Other|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
351280|NCT01516008|Drug|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
351281|NCT01516008|Drug|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
351282|NCT01516008|Drug|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
351283|NCT01515995|Drug|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour~Versus~15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
351284|NCT01515982|Behavioral|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
351285|NCT01515982|Behavioral|Control Group|All participants were asked not to commence any new exercise regimen.
351286|NCT01515969|Drug|Erlotinib hydrochloride|Given PO
351287|NCT01515969|Drug|Dovitinib lactate|Given PO
351288|NCT01515956|Drug|BMN 110|Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
351289|NCT01515943|Other|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
351290|NCT01515943|Procedure|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
351291|NCT01515943|Other|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
351292|NCT01515943|Procedure|Placebo yoked prism flippers|"Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and Accommodative Hopping Cards. Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:~Weeks 1-4: View the target through prism flippers~Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers~Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers"
351293|NCT01515930|Behavioral|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding monitoring diabetes care.
351294|NCT01515930|Behavioral|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding diabetes care.
351295|NCT01515930|Behavioral|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
351296|NCT01515917|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
351297|NCT01515917|Drug|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
351299|NCT01515917|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
351300|NCT01515904|Behavioral|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
351301|NCT01515891|Drug|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
351302|NCT01515878|Device|Hemocontrol|Blood Volume Tracking system using biofeedback
351303|NCT01515865|Drug|Midodrine HCl|dose at subject's current dose level
351304|NCT01515865|Drug|Placebo|single dose of matching placebo
351305|NCT01515852|Procedure|general anesthesia in stereotactic biopsy|stereotactic biopsy
351306|NCT01515852|Procedure|local anesthesia in stereotactic biopsy|stereotactic biopsy
351307|NCT01515839|Dietary Supplement|Multivitamin Supplement intervention|"We recommend the following protocol:~2 tablets of a high quality multivitamin BID~2 capsules of omega 3 fish oil BID for a total of 3 grams daily~3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg~Weight loss"
351308|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
351309|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
351310|NCT01515813|Drug|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
351311|NCT01515813|Drug|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
351312|NCT01515813|Drug|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
351313|NCT01515800|Behavioral|Text message reminder|Receive text message
351314|NCT01515787|Drug|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m^2 IV over 2 hours on day 1, leucovorin 400 mg/m^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m^2 bolus over 5-15 minutes then 2400 mg/m^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
351315|NCT01515787|Other|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
351316|NCT01515787|Procedure|surgery|low anterior resection with total mesorectal excision
351317|NCT01515787|Procedure|magnetic resonance imaging or endorectal ultrasound|
351318|NCT01515774|Drug|Mirapex ER|Change Requip or Mirapex to Mirapex ER
351319|NCT01515761|Procedure|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
351320|NCT01515761|Procedure|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
351321|NCT01515748|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
351322|NCT01515748|Drug|OXALIPLATIN (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
351323|NCT01515748|Drug|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + CDHP (Gemeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
351324|NCT01515722|Behavioral|Health education intervention (HEI)|"<Part 1> Understanding OAB~<Part 2> Behavioral/lifestyle modification~<Part 3> Bladder training~<Part 4> Understanding antimuscarinics"
351325|NCT01515696|Drug|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
351326|NCT01515696|Drug|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
351327|NCT01515683|Behavioral|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
351328|NCT01515683|Behavioral|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
351329|NCT01515683|Behavioral|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
351330|NCT01515683|Behavioral|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
351331|NCT01515657|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 3 days
351332|NCT01515657|Drug|Immediate-Release Aspirin Tablets|325 mg aspirin; once per day for 3 days
351333|NCT01515657|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 3 days
351334|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin I
351335|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin II
351336|NCT01515644|Other|Powder based infant formula|Powder based infant formula without Inulin
351337|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
351338|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
351339|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
351340|NCT01515592|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
351341|NCT01515579|Drug|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
351342|NCT01515579|Drug|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
351343|NCT01515566|Drug|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
351344|NCT01515566|Other|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
351345|NCT01515566|Other|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
351346|NCT01515566|Behavioral|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
351347|NCT01515553|Drug|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
351348|NCT01515540|Drug|lidocaine|5% lidoderm patch
351349|NCT01515540|Drug|placebo|placebo
351350|NCT01515527|Drug|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.~Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
351351|NCT01515527|Drug|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.~Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
351352|NCT01515527|Drug|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
351353|NCT01515501|Procedure|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
351354|NCT01515488|Other|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
351355|NCT01515488|Other|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
351356|NCT01515475|Procedure|Glasses|Glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction.
351357|NCT01515462|Genetic|OTL-103|OTL-103 is an autologous CD34+ cells collected from bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding Wiskott-Aldrich syndrome (WAS) protein
351358|NCT01515436|Other|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
351359|NCT01515436|Other|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
351360|NCT01515423|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
351361|NCT01515423|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
351362|NCT01515423|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
351363|NCT01515423|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
351364|NCT01515423|Drug|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
351365|NCT01515423|Drug|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
351366|NCT01515423|Drug|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
351367|NCT01515423|Drug|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
351368|NCT01515423|Drug|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
351369|NCT01515410|Drug|DM-1992|72.5mg carbidopa/230mg levodopa
351370|NCT01515410|Drug|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
351371|NCT01515397|Drug|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
351372|NCT01515397|Drug|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
351373|NCT01515384|Drug|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
351374|NCT01515371|Drug|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.~For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
351375|NCT01515371|Drug|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
351376|NCT01515358|Drug|Placebo|Administered orally
351377|NCT01515358|Drug|LY3000328|Administered orally
351378|NCT01515345|Drug|prasugrel or ticagrelor|prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
351379|NCT01515345|Drug|Clopidogrel|clopidogrel 75mg od for 12 month
351380|NCT01515319|Drug|Y242|Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 120 mg Y242 (Part A) Multiple ascending doses at weekly intervals, doses to be determined (Part B)
351382|NCT01515306|Biological|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
351383|NCT01515306|Drug|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
351384|NCT01515293|Procedure|Single Incision Laparoscopic Appendectomy|
351385|NCT01515293|Procedure|Conventional appendectomy|
351386|NCT01515254|Behavioral|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
351387|NCT01515241|Drug|CER-001|Weekly injection
351388|NCT01515228|Device|Xience Prime|everolimus-eluting stent implantation
351389|NCT01515228|Device|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
351390|NCT01515215|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
351391|NCT01515202|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
351392|NCT01515202|Drug|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
351393|NCT01515202|Drug|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
351394|NCT01515202|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
351395|NCT01515202|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
351396|NCT01515189|Biological|Ipilimumab|
351397|NCT01515176|Drug|Dinaciclib|Given IV
351398|NCT01515176|Other|Laboratory Biomarker Analysis|Correlative studies
351399|NCT01515176|Biological|Ofatumumab|Given IV
351400|NCT01515176|Other|Pharmacological Study|Correlative studies
351401|NCT01515163|Behavioral|Exercise training|Aerobic exercise training, two times a week
351402|NCT01515137|Drug|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
351403|NCT01515137|Drug|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
351404|NCT01515137|Drug|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
351405|NCT01515124|Behavioral|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
351406|NCT01515124|Behavioral|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
351407|NCT01515098|Dietary Supplement|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
351408|NCT01515098|Dietary Supplement|Dextrose Placebo|Placebo developed to closely match blueberry powder.
351409|NCT01515085|Procedure|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
351410|NCT01515072|Other|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
351411|NCT01515046|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)~Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
351412|NCT01515033|Other|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.~The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
351413|NCT01515020|Drug|vancomycin monotherapy|intravenous therapy by vancomycin
351414|NCT01515020|Drug|daptomycin monotherapy|intravenous therapy by daptomycin
351415|NCT01515007|Drug|Ciprofloxacin dispersion for inhalation|
351416|NCT01515007|Drug|Placebo|
351417|NCT01514994|Device|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
351418|NCT01514981|Drug|AMG 761|Single dose of AMG 761 on study day 1.
351419|NCT01514981|Drug|Placebo|Single dose of placebo on study day 1.
351420|NCT01514968|Drug|cyclosporine|Single oral dose
351421|NCT01514968|Drug|danoprevir|Single oral dose
351422|NCT01514968|Drug|ritonavir|Single oral dose
351423|NCT01514955|Radiation|Gold seeds insertion to detect movements at pelvis|
351424|NCT01514955|Radiation|Image guided MRI based RT (IMRT+Brachytherapy)|
351425|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
351426|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
351427|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
351428|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
351431|NCT01514929|Drug|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
351432|NCT01514929|Drug|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
351433|NCT01514929|Drug|Moxifloxacin|400mg oral pill given once
351434|NCT01514929|Drug|Placebo|Placebo oral pill given once
351435|NCT01514916|Device|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
351436|NCT01514903|Drug|HIP0908|SINGLE DOSE , CROSS OVER
351437|NCT01514903|Drug|viagra|single dose, cross over
351438|NCT01514877|Drug|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
351439|NCT01514864|Drug|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
351440|NCT01514851|Drug|Lanthanum carbonate (BAY77-1931)|
351441|NCT01514851|Drug|Calcium carbonate|
351442|NCT01514838|Drug|ASP1941|oral
351443|NCT01514838|Drug|acarbose|oral
351444|NCT01514838|Drug|Placebo|oral, used only during placebo run-in period
351445|NCT01514825|Drug|YM150|oral
351446|NCT01514825|Drug|Placebo|oral
351447|NCT01514812|Drug|YM150|oral - modified release formulation of YM150
351448|NCT01514812|Drug|placebo|oral
351449|NCT01514812|Drug|digoxin|oral
351450|NCT01514799|Procedure|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
351451|NCT01514786|Behavioral|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
351452|NCT01514760|Other|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
351453|NCT01514734|Drug|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
351454|NCT01514721|Drug|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
351455|NCT01514708|Biological|AdimFlu-S Influenza Vaccine|Suspension for injection
351456|NCT01514695|Drug|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
351457|NCT01514695|Drug|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
351458|NCT01514695|Other|Placebo|One dose of saline (2ml)
351459|NCT01514682|Drug|Anti-inflammatory Combination Therapy|"salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening~fluvastatin: target dose 40 mg/day, administered in a single evening dose~combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
351460|NCT01514682|Drug|Placebo|Non-medication pills; To be taken in morning and evening intervals.
351461|NCT01514656|Other|CPR Training using the Family and Friends CPR Anytime Video Self Instruction|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
351462|NCT01514656|Other|Implementation of a Hospital-based CPR Training Model|Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
351463|NCT01514656|Other|Follow-up prompting to encourage skill retention|Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
351464|NCT01514630|Drug|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
351465|NCT01514617|Procedure|Diffusion -and perfusion weighted MRI including iv contrast agent injection|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.~During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
351466|NCT01514578|Drug|TRV130A|Intravenous infusion of 1 hour duration
351467|NCT01514578|Drug|Dextrose in Water|Intravenous infusion of 1 hour duration
351468|NCT01514552|Other|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
351469|NCT01514552|Other|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
351470|NCT01514539|Other|cross-sectional|"Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity."
351510|NCT01514214|Device|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
351471|NCT01514526|Drug|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.~The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
351472|NCT01514513|Drug|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
351473|NCT01514513|Drug|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
351474|NCT01514500|Drug|somapacitan|Administered s.c. (subcutaneously, under the skin)
351475|NCT01514500|Drug|placebo (somapacitan)|Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
351476|NCT01514487|Drug|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
351477|NCT01514461|Drug|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
351478|NCT01514461|Drug|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
351479|NCT01514448|Drug|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
351480|NCT01514435|Device|Electroconvulsive therapy|treatment for major depression
351481|NCT01514435|Device|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.~It´s a neuroimaging technique."
351482|NCT01514422|Drug|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
351483|NCT01514409|Dietary Supplement|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.~5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
351484|NCT01514409|Dietary Supplement|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
351485|NCT01514396|Device|Surgiseal|surgical glue
351486|NCT01514383|Device|Cyanoacrylate (Octylseal )|surgical adhesive
351487|NCT01514370|Drug|IFN beta 1a 44 mcg TIW|Subjects received IFN beta 1a 44 microgram (mcg) subcutaneously TIW for 24 months.
351488|NCT01514370|Drug|Curcumin|Subjects received 500 milligram (mg) curcumin orally twice a day for 24 months.
351489|NCT01514370|Drug|Placebo|Subjects received placebo matched to curcumin orally twice a day for 24 months.
351490|NCT01514357|Drug|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
351491|NCT01514357|Drug|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
351492|NCT01514344|Drug|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
351493|NCT01514344|Biological|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
351494|NCT01514331|Other|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
351495|NCT01514331|Other|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
351496|NCT01514318|Device|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
351497|NCT01514292|Device|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
351498|NCT01514279|Behavioral|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
351499|NCT01514279|Behavioral|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.~It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
351500|NCT01514266|Drug|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
351501|NCT01514266|Drug|Placebo|
351502|NCT01514253|Drug|Glucose 25%|1 ml glucose 25%, once
351503|NCT01514253|Dietary Supplement|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
351504|NCT01514253|Other|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
351505|NCT01514240|Drug|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
351506|NCT01514240|Drug|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
351507|NCT01514227|Drug|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
351508|NCT01514227|Drug|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
351509|NCT01514214|Device|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
351511|NCT01514201|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
351512|NCT01514201|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
351513|NCT01514201|Other|Laboratory Biomarker Analysis|Optional correlative studies
351514|NCT01514201|Other|Pharmacological Study|Correlative studies
351515|NCT01514201|Drug|Temozolomide|Given PO
351516|NCT01514201|Drug|Veliparib|Given PO
351517|NCT01514188|Drug|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
351518|NCT01514188|Drug|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
351519|NCT01514175|Drug|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
351520|NCT01514175|Drug|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
351521|NCT01514162|Device|Trifecta valve|surgical replacement of aortic valve
351522|NCT01514149|Drug|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
351523|NCT01514149|Drug|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
351524|NCT01514136|Device|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
351525|NCT01514123|Drug|VGX-100|VGX-100 will be administered by IV infusion once every week
351526|NCT01514123|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
351527|NCT01514110|Drug|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
351528|NCT01514071|Behavioral|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
351529|NCT01514058|Procedure|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
351530|NCT01514058|Procedure|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
351531|NCT01514032|Procedure|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
351532|NCT01514032|Procedure|Retrograde intrarenal surgery|Retrograde intrarenal surgery
351533|NCT01514019|Drug|Acebutolol|Acebutolol
351534|NCT01514019|Drug|Placebo|Placebo capsule(Capsules filled up with lactose)
351535|NCT01513993|Procedure|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
351536|NCT01513980|Procedure|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.~The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
351537|NCT01513980|Procedure|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
351538|NCT01513967|Drug|RPh201, botanical drug product|SC administration at varying doses
351539|NCT01513967|Drug|Placebo|SC administration at varying doses
351540|NCT01513967|Drug|RPh201, botanical extract product|3-month treatment schedule, consisting of bi-weekly SC administration of the study drug followed by a follow up period 3 months post end of the last treatment day
351541|NCT01513967|Drug|Placebo|3-month treatment schedule, consisting of bi-weekly SC administration of the placebo followed by a follow up period 3 months post end of the last treatment day
351542|NCT01513941|Drug|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
351543|NCT01513941|Drug|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
351544|NCT01513941|Drug|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
351545|NCT01513928|Drug|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
351546|NCT01513928|Drug|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
351547|NCT01513928|Drug|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
351548|NCT01513915|Other|Group cognitive behavioral intervention|A Group cognitive behavioral intervention _based on parent training component of FRIENDS program_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
351614|NCT01513343|Behavioral|Parent and child groups focused on self-regulation of eating|
351615|NCT01513330|Device|SenSura Mio|Ostomy product - 1 piece closed bag
351549|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
351550|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
351551|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing <30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
351552|NCT01513863|Drug|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
351553|NCT01513863|Drug|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
351554|NCT01513863|Drug|Placebo|Placebo applied to affected area once a day for 70 days
351555|NCT01513850|Drug|Hepabulin IV|I.V.
351556|NCT01513824|Behavioral|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
351557|NCT01513811|Drug|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
351558|NCT01513811|Drug|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
351559|NCT01513811|Drug|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
351560|NCT01513798|Behavioral|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
351561|NCT01513798|Behavioral|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
351562|NCT01513785|Drug|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
351563|NCT01513785|Drug|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
351564|NCT01513772|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
351565|NCT01513772|Drug|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
351566|NCT01513759|Drug|recombinant tissue plasminogen activator|Participants will receive 24 mg of r-tPA delivered via the EkoSonic Endovascular Device.
351567|NCT01513759|Device|EKOS EkoSonic Endovascular System|24 mg of r-tPA will be delivered through the EkoSonic Endovascular System.
351568|NCT01513733|Drug|tasquinimod|tasquinimod 0.25 mg continuously
351569|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
351570|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
351571|NCT01513720|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
351572|NCT01513720|Drug|Lamictal®|Lamictal® 200 mg Tablets
351573|NCT01513694|Procedure|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.~They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.~Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
351574|NCT01513681|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
351575|NCT01513681|Drug|Lamictal®|Lamictal® 200 mg Tablets
351576|NCT01513668|Drug|Acetaminophen|Extended release Gel tabs 650 mg
351577|NCT01513655|Device|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
351578|NCT01513642|Behavioral|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
351579|NCT01513616|Other|Pulmonary rehabilitation|8-week program, 3 supervised session per week
351580|NCT01513616|Other|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
351581|NCT01513603|Drug|CLAG-M|IV times 5 days
351582|NCT01513603|Drug|CLAG-M|Chemotherapy
351583|NCT01513590|Drug|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
352006|NCT01510574|Drug|placebo|3 x placebo tablets resembling misoprostol taken orally
351584|NCT01513577|Other|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
351585|NCT01513577|Other|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
351586|NCT01513564|Drug|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
351587|NCT01513564|Drug|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
351588|NCT01513551|Biological|Pneumococcal Conjugate Vaccine (V114)|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
351589|NCT01513551|Biological|PNEUMOVAX® 23|23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose.
351590|NCT01513551|Biological|PREVNAR 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
351591|NCT01513538|Device|TherapyGuide|Use of TherapyGuide function to help programming the device
351592|NCT01513525|Drug|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
351593|NCT01513499|Drug|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
351594|NCT01513499|Drug|Placebo|Intranasal Placebo single-dose administration
351595|NCT01513486|Behavioral|immobilization|
351596|NCT01513473|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
351597|NCT01513473|Drug|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
351598|NCT01513473|Drug|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
351599|NCT01513460|Drug|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
351600|NCT01513460|Drug|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
351601|NCT01513460|Drug|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
351602|NCT01513460|Drug|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
351603|NCT01513447|Drug|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
351604|NCT01513434|Procedure|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
351605|NCT01513434|Procedure|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
351606|NCT01513434|Procedure|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
351607|NCT01513421|Procedure|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist"
351608|NCT01513408|Other|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
351609|NCT01513395|Behavioral|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
351610|NCT01513382|Procedure|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
351611|NCT01513369|Drug|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
351612|NCT01513369|Drug|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
351613|NCT01513356|Drug|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
351616|NCT01513330|Device|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
351617|NCT01513317|Drug|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
351618|NCT01513317|Drug|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
351619|NCT01513317|Drug|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
351620|NCT01513304|Procedure|Manual therapy|
351621|NCT01513291|Drug|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
351622|NCT01513291|Drug|Placebo|Placebo, 2 tablets, orally, once daily
351623|NCT01513278|Drug|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
351624|NCT01513278|Drug|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
351625|NCT01513265|Other|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
351626|NCT01513252|Behavioral|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
351627|NCT01513239|Biological|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
351628|NCT01513239|Biological|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
351629|NCT01513239|Biological|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
351630|NCT01513239|Drug|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
351631|NCT01513226|Other|Cycled light|lights on at daytime, lights off at nighttime
351632|NCT01513200|Drug|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
351633|NCT01513200|Drug|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
351634|NCT01513200|Drug|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
351635|NCT01513187|Drug|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.~Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
351636|NCT01513174|Drug|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
351637|NCT01513174|Drug|Gefitinib plus olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
351638|NCT01513161|Drug|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
351639|NCT01513161|Drug|Placebo|
351640|NCT01513148|Device|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
351641|NCT01513135|Biological|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
351642|NCT01513135|Biological|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
351643|NCT01513122|Drug|Lopinavir / ritonavir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily
351644|NCT01513122|Drug|2-3N(t)RTI|
351645|NCT01513122|Drug|raltegravir|raltegravir 400mg 1 tablet twice daily.
351646|NCT01513109|Biological|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
351647|NCT01513096|Drug|itopride|itopride, 10mg, twice per day, for 1 day
351648|NCT01513083|Drug|trastuzumab emtansine|Multiple intravenous doses
351649|NCT01513070|Drug|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
351650|NCT01513070|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
351651|NCT01513070|Drug|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
351652|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
351653|NCT01513070|Drug|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
351654|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
351655|NCT01513057|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
351656|NCT01513057|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
351657|NCT01513044|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
351658|NCT01513044|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
351659|NCT01513031|Other|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
351660|NCT01513018|Other|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
351661|NCT01513018|Other|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.~Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
351662|NCT01513005|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:~position of 4 trocars and insertion of a nasogastric tube~dissection and mobilization of the greater curvature of the stomach~preparation of the stomach for division~gastric partition~extraction of the gastric remnant~postoperative surveillance"
351663|NCT01512992|Procedure|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.~All patients in the intervention group receive:~Personalised care plan~Education on self-management~Access to a personalized online health folder~Access to Call center~Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).~Patients with LOW complexity additionally receive:~Daily videoconferences for the 1st week after discharge~Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.~Patients with HIGH complexity additionally receive:~Videoconferences for at least 1 month after discharge, scheduled on an individual basis.~Remote monitoring for respiratory parameters.~One monthly phone call from the call centre to promote and assess patient self-management."
351664|NCT01512979|Drug|metformin|1000 mg to 2000 mg per day
351665|NCT01512979|Drug|linagliptin|5 mg daily
351666|NCT01512979|Drug|metformin placebo|0 to 2 tablets daily
351667|NCT01512979|Drug|metformin placebo|4 tablets daily
351668|NCT01512966|Biological|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
351669|NCT01512953|Drug|Lansoprazole|Lansoprazole 30 mg once a day
351670|NCT01512940|Procedure|Laparoscopic Greater Curvature Plication|"The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.~Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope."
351671|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
351672|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
351673|NCT01512914|Drug|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
351674|NCT01512914|Drug|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
351675|NCT01512901|Drug|Betamethasone Microsphere (DE-102） Low Dose|
351676|NCT01512901|Drug|Betamethasone Microsphere (DE-102） High Dose|
351677|NCT01512901|Drug|Sham|
351678|NCT01512888|Genetic|CL20-i4-EF1α-hγc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
351679|NCT01512888|Drug|Busulfan|Given intravenously (IV).
351680|NCT01512888|Device|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
351681|NCT01512862|Drug|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
351682|NCT01512862|Drug|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
351683|NCT01512849|Drug|TA-7284 Low|Low
351684|NCT01512849|Drug|TA-7284 High|High
351715|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
351685|NCT01512836|Behavioral|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:~Formulation and implementation of care plans together with the patient~Monitoring of individual status and care plan effectuation~Overall coordination between health care providers~Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)~Regular telephone consultations and home visits~Promote disease-self management through coaching"
351686|NCT01512823|Behavioral|Education|"Interactive educational intervention:~4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)~Emailed notes from second session~Telephonic/email follow-up (reminders)~Didactic educational intervention:~- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills"
351687|NCT01512810|Procedure|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
351688|NCT01512797|Drug|Sitagliptin phosphate|100 mg/day orally
351689|NCT01512797|Other|Placebo|1 Placebo Pill per day
351690|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
351691|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).~Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:~first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.~Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:~Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
351692|NCT01512771|Other|CPAP|6 weeks of CPAP
351693|NCT01512758|Drug|Alisertib|Alisertib enteric-coated tablets
351694|NCT01512745|Drug|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
351695|NCT01512745|Drug|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
351696|NCT01512719|Procedure|POEM|Per Oral Endoscopic Myotomy for achalasia
351697|NCT01512706|Biological|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
351698|NCT01512706|Biological|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
351699|NCT01512706|Biological|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
351700|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
351701|NCT01512706|Biological|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
351702|NCT01512706|Biological|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
351703|NCT01512706|Biological|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
351704|NCT01512706|Biological|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
351705|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
351706|NCT01512706|Biological|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
351707|NCT01512706|Biological|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
351708|NCT01512706|Biological|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
351709|NCT01512706|Biological|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
351710|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
351711|NCT01512706|Biological|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
351712|NCT01512693|Drug|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
351713|NCT01512680|Behavioral|Education to Functional Insulin Therapy|"Intake of Continuous Glucose Monitor for 5 to 7 days~Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.~1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes~3 months after the training: Blood sampling, vital signs and data on diabetes~6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days~9 months after the training: Blood sampling, vital signs and data on diabetes~1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days~12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
351714|NCT01512667|Drug|MK-0822|A single oral dose (50 mg tablet) of MK-0822 will be administered on Day 1 after an overnight fast.
351716|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
351717|NCT01512641|Other|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
351718|NCT01512641|Other|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
351719|NCT01512628|Drug|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
351720|NCT01512615|Other|Complex Cardiac rehabilitation|Complex Cardiac Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
351721|NCT01512615|Other|Control group|Usual care, clinical control as provided by treating heart centre
351722|NCT01512602|Behavioral|DBT|16 weeks DBT treatment
351723|NCT01512602|Behavioral|CAMS|CAMS-informed psychotherapy
351724|NCT01512589|Radiation|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
351725|NCT01512589|Radiation|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
351726|NCT01512589|Behavioral|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
351727|NCT01512576|Other|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
351728|NCT01512576|Behavioral|relaxation|1 treatment session of 30 minutes
351729|NCT01512563|Device|Biliary stent|palliative treatment for malignant patients
351730|NCT01512550|Procedure|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
351731|NCT01512550|Procedure|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
351732|NCT01512550|Device|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
351733|NCT01512537|Radiation|Narrowband UVB|UVB 3 times a week
351734|NCT01512537|Dietary Supplement|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
351735|NCT01512524|Other|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
351736|NCT01512511|Procedure|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
351737|NCT01512485|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
351738|NCT01512472|Drug|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
351739|NCT01512459|Drug|Venlafaxine|Venlafaxine MR Capsules 150 mg
351740|NCT01512446|Drug|Alendronate|70 mg per week
351741|NCT01512446|Drug|Placebo|1 pill per week
351742|NCT01512433|Procedure|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
351743|NCT01512433|Procedure|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
351744|NCT01512407|Procedure|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
351745|NCT01512394|Procedure|standard bowel prep|standard bowel prep
351746|NCT01512394|Procedure|no bowel prep|no bowel prep
351747|NCT01512381|Device|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
351748|NCT01512381|Device|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
351749|NCT01512368|Other|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
351750|NCT01512355|Drug|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
351751|NCT01512355|Drug|placebo group|normal saline_02mcg/kg/hr
351752|NCT01512342|Behavioral|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
351753|NCT01512342|Behavioral|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
351754|NCT01512329|Behavioral|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
351755|NCT01512329|Behavioral|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
351756|NCT01512316|Drug|d-Cycloserine|250mg, one dose, 2hrs prior to fMRI
351757|NCT01512316|Drug|Lactose pill|one dose, 2hrs prior to fmri
351758|NCT01512316|Genetic|Saliva sample|Buccal cell material will be sampled from all participants on day3
351759|NCT01512316|Other|Functional neuroimaging (fMRI)|
352348|NCT01508000|Biological|Panitumumab|Targeted therapy
351760|NCT01512303|Behavioral|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
351761|NCT01512303|Behavioral|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
351762|NCT01512290|Other|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
351763|NCT01512277|Biological|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
351764|NCT01512264|Device|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
351765|NCT01512251|Drug|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)~Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid~Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid~Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid~Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid~Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid~Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
351766|NCT01512238|Other|Pharmaceutical care|Information about medicine, sideeffect, adherence
351767|NCT01512225|Drug|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 28 days
351768|NCT01512225|Drug|Placebo Tablet|placebo tablet 10 mg orally three times daily for 14 days
351769|NCT01512225|Drug|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 14 days
351770|NCT01512212|Procedure|biopsy|fnab
351771|NCT01512199|Drug|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
351772|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
351773|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
351774|NCT01512199|Drug|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
351775|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
351776|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
351777|NCT01512199|Drug|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
351778|NCT01512173|Drug|propranolol gel|Topical administration twice daily
351779|NCT01512173|Drug|Placebo|Topical administration twice daily
351780|NCT01512160|Drug|PF-04531083|2000 mg oral solution
351781|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
351782|NCT01512160|Drug|PF-04531083|1000 mg oral solution
351783|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
351784|NCT01512160|Drug|Ibuprofen|2 x 200 mg tablets
351785|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
351786|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
351787|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
351788|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.~After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:~Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.~After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.~Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
351789|NCT01512134|Device|Deep Brain Stimulation Device|Deep brain stimulation surgery
351790|NCT01512108|Drug|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
351791|NCT01512108|Drug|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
351792|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
351793|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
351794|NCT01512082|Device|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
351795|NCT01512082|Device|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
351796|NCT01512069|Behavioral|Web-based Health Planner on diet and exercise|"URL is closed~The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
351797|NCT01512069|Behavioral|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
351798|NCT01512056|Drug|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
351799|NCT01512043|Behavioral|Breathing control|Practice of device guided breathing control twice a day for four weeks.
351843|NCT01511692|Drug|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
351844|NCT01511692|Drug|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
351800|NCT01512017|Device|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
351801|NCT01512017|Device|Vaseline|External use
351802|NCT01512004|Drug|Propiverine Hydrochloride|drug of oral capsule
351803|NCT01512004|Drug|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
351804|NCT01511991|Drug|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
351805|NCT01511978|Drug|Continuous 3,4-DAP|Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
351806|NCT01511978|Drug|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
351807|NCT01511965|Other|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
351808|NCT01511952|Other|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
351809|NCT01511952|Other|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
351810|NCT01511939|Drug|Pennsaid|Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
351811|NCT01511913|Other|Non-Interventional|Non-Interventional
351812|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
351813|NCT01511900|Drug|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
351814|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
351815|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
351816|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
351817|NCT01511900|Drug|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
351818|NCT01511887|Drug|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
351819|NCT01511874|Drug|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
351820|NCT01511848|Drug|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).~Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.~Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.~Other Name: ICL670"
351821|NCT01511848|Drug|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
351822|NCT01511835|Dietary Supplement|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
351823|NCT01511835|Dietary Supplement|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
351824|NCT01511835|Drug|Folic Acid|Folic Acid 400mcg; 1 cp/die
351825|NCT01511822|Drug|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
351826|NCT01511822|Drug|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
351827|NCT01511822|Drug|placebo|
351828|NCT01511809|Drug|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
351829|NCT01511796|Other|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
351830|NCT01511783|Drug|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
351831|NCT01511783|Drug|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
351832|NCT01511770|Drug|Fluconazole|Fluconazole Tablets, 200 mg
351833|NCT01511770|Drug|Fluconazole|Fluconazole 200 mg tablets
351834|NCT01511757|Drug|Fluconazole|Fluconazole Tablets, 200 mg
351835|NCT01511757|Drug|Fluconazole|fluconazole 200 mg
351836|NCT01511744|Biological|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
351837|NCT01511731|Drug|Famotidine|Famotidine Tablets 40 mg
351838|NCT01511731|Drug|Pepcid|40mg tablets
351839|NCT01511718|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
351840|NCT01511718|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
351841|NCT01511705|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
351842|NCT01511705|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
351845|NCT01511692|Drug|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
351846|NCT01511692|Drug|glimepiride|Dose individually adjusted, administered orally for 4 weeks
351847|NCT01511666|Device|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
351848|NCT01511666|Other|Standard care|Standard care as per recent guidelines will be provided.
351849|NCT01511640|Drug|Pregabalin|pregabalin 2x daily for duration of study
351850|NCT01511640|Drug|Placebo|placebo 2x daily for duration of study
351851|NCT01511627|Drug|General Anesthesia + Spinal anesthesia combined|"All patients will receive a preoperative multimodal analgesic regime:~Tylenol® 975mg per os~Naproxen® 500 mg per os~Patients will receive a spinal anesthetic with:~Bupivacaine 0.5% 10 mg~Fentanyl 10ug~Epidural Morphine 150ug~After the spinal, a general anesthetic will be induced using:~Midazolam 1 - 2 mg intravenously~Fentanyl 1 - 2 ug/kg intravenously~Propofol 1-3 mg/kg intravenously~Rocuronium 0.3 - 0.9mg/kg intravenously~followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.~Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~Dexamethasone 4mg and Ondansetron 4mg intravenously~Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU)."
351852|NCT01511627|Drug|General Anesthesia (control group)|"All patients will receive a preoperative multimodal analgesic regime:~Tylenol® 975mg per os~Naproxen® 500 mg per os~Group I (General anesthetic) patients will receive a general anesthetic :~Midazolam 1 - 2 mg intravenously~Fentanyl 1 - 2 ug/kg intravenously~Propofol 1-3 mg/kg intravenously~Rocuronium 0.3 - 0.9mg/kg intravenously~followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.~Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.~Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.~Dexamethasone 4mg and Ondansetron 4mg intravenously~Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously~Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU)."
351853|NCT01511575|Genetic|RNA analysis|
351854|NCT01511575|Genetic|reverse transcriptase-polymerase chain reaction|
351855|NCT01511575|Other|laboratory biomarker analysis|
351856|NCT01511562|Drug|carmustine|Given IV
351857|NCT01511562|Drug|cytarabine|Given IV
351858|NCT01511562|Drug|etoposide|Given IV
351859|NCT01511562|Drug|thiotepa|Given IV
351860|NCT01511562|Procedure|stem cell transplant|
351861|NCT01511562|Drug|G-CSF|
351862|NCT01511549|Drug|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
351863|NCT01511549|Drug|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
351864|NCT01511536|Drug|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
351865|NCT01511536|Drug|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
351866|NCT01511536|Drug|Prednisone 5 mg|Route of administration: oral
351867|NCT01511523|Dietary Supplement|RGMA001|3 capsules administered BID once a day.
351868|NCT01511523|Dietary Supplement|Sugar Pill|Placebo
351869|NCT01511510|Drug|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
351870|NCT01511510|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
351871|NCT01511510|Drug|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
351872|NCT01511510|Drug|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
351873|NCT01511510|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
351874|NCT01511497|Biological|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
351875|NCT01511497|Other|Normal saline|Intravenous, normal saline
351876|NCT01511484|Behavioral|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
351877|NCT01511484|Behavioral|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.~Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.~Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
351878|NCT01511484|Behavioral|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
351879|NCT01511471|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
351880|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
351881|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
351882|NCT01511432|Drug|telaprevir formulation A|A single 1125-mg dose administered orally
351883|NCT01511432|Drug|telaprevir Formulation B|A single 1125-mg dose administered orally
351884|NCT01511432|Drug|telaprevir Formulation C|A single 1125-mg dose administered orally
351885|NCT01511432|Drug|telaprevir Formulation D|A single 1125-mg dose administered orally
351886|NCT01511419|Biological|LAIV H7N3|2 doses of vaccine
351887|NCT01511419|Biological|placebo|2 doses of placebo
351888|NCT01511406|Behavioral|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
351889|NCT01511393|Other|No treatment given|None. Non-interventional study.
351890|NCT01511380|Behavioral|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
351891|NCT01511380|Behavioral|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
351892|NCT01511367|Drug|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
351893|NCT01511367|Drug|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
351894|NCT01511367|Drug|Flixotide|50ug 2 puffs twice daily
351895|NCT01511341|Behavioral|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
351896|NCT01511328|Other|HPV testing|Testing for Human Papilloma Virus
351897|NCT01511315|Drug|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
351898|NCT01511302|Drug|RNS60|RNS60, 2ml, nebulized twice daily.
351899|NCT01511302|Drug|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
351900|NCT01511302|Drug|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
351901|NCT01511289|Drug|Imatinib|400mg/Tab, QD
351902|NCT01511289|Drug|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
351903|NCT01511276|Behavioral|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
351904|NCT01511276|Behavioral|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
351905|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
351906|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|"Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.~EGCG, 675 mg/day, oral, for one year."
351907|NCT01511250|Biological|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose). TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
351908|NCT01511250|Biological|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose).
351909|NCT01511237|Drug|Nevirapine, zidovudine, lamivudine|"Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~3TC syrup 2 mg/kg every 12 hours for four weeks."
351910|NCT01511211|Drug|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
351911|NCT01511211|Drug|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
351912|NCT01511198|Drug|liraglutide|Injected subcutaneously once daily
351913|NCT01511198|Drug|metformin|1000 mg twice daily, administered orally
351914|NCT01511185|Drug|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
351915|NCT01511185|Drug|placebo|A single dose administered subcutaneously in random order
351916|NCT01511172|Drug|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
351917|NCT01511172|Drug|metformin|1000 mg daily, administered orally
351918|NCT01511172|Drug|placebo|Metformin placebo administered orally. 1000 mg daily
351919|NCT01511172|Drug|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
351920|NCT01511172|Drug|glimepiride|Individually adjusted dose, administered orally
351921|NCT01511159|Drug|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
352349|NCT01508000|Procedure|Surgery|
351922|NCT01511159|Drug|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
351923|NCT01511159|Drug|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
351924|NCT01511159|Drug|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
351925|NCT01511159|Drug|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
351926|NCT01511159|Drug|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
351927|NCT01511159|Drug|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
351928|NCT01511146|Drug|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
351929|NCT01511146|Drug|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
351930|NCT01511133|Procedure|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
351931|NCT01511133|Procedure|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
351932|NCT01511120|Drug|Tetraspan|
351933|NCT01511120|Drug|acetated Ringer`s solution|
351934|NCT01511107|Drug|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
351935|NCT01511107|Drug|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5~Plus~Placebo Days 6-10"
351936|NCT01511094|Procedure|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
351937|NCT01511081|Radiation|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
351938|NCT01511081|Radiation|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
351939|NCT01511068|Drug|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
351940|NCT01511055|Drug|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
351941|NCT01511042|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
351942|NCT01511042|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
351943|NCT01511042|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
351944|NCT01511029|Drug|Dexpramipexole|300 mg - Oral Tablets
351945|NCT01511029|Drug|Dexpramipexole|600 mg Oral Tablets
351946|NCT01511029|Drug|Dexpramipexole Placebo|Placebo - Oral Tablet
351947|NCT01511029|Drug|Moxifloxacin|400 mg - Oral Tablet
351948|NCT01511016|Drug|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
351949|NCT01511016|Drug|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
351950|NCT01511003|Drug|Tacrolimus|oral
351951|NCT01510990|Drug|Gefitinib|gefitinib 250mg/day daily
351952|NCT01510977|Drug|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
351953|NCT01510977|Drug|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
351954|NCT01510964|Behavioral|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
351955|NCT01510964|Behavioral|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
351956|NCT01510951|Drug|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
351957|NCT01510938|Dietary Supplement|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
351958|NCT01510938|Dietary Supplement|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
351959|NCT01510912|Drug|Diclofenac|35 mg bid or tid Capsules
351960|NCT01510899|Drug|RO4917838|Single dose of RO4917838
351961|NCT01510899|Drug|RO4917838|Single dose of RO4917838
351962|NCT01510873|Other|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.~The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
351963|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|250 mg
351964|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|500 mg
351965|NCT01510847|Drug|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
351966|NCT01510834|Behavioral|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
351967|NCT01510821|Other|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
351968|NCT01510821|Other|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
351969|NCT01510808|Procedure|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
351970|NCT01510795|Drug|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
351971|NCT01510782|Drug|Placebo to BI 655064|intravenous infusion of escalating doses
351972|NCT01510782|Drug|Placebo to BI 655064|subcutaneous injection of escalating doses
351973|NCT01510782|Drug|BI 655064|intravenous infusion of escalating doses
351974|NCT01510782|Drug|BI 655064|subcutaneous injection of escalating doses
351975|NCT01510769|Drug|Lesinurad|Tablets, 400 mg once daily (QD)
351976|NCT01510769|Drug|Lesinurad|Tablets, 200 mg QD
351977|NCT01510769|Drug|Placebo|Tablets, Placebo QD
351978|NCT01510769|Drug|Febuxostat|80 mg
351979|NCT01510756|Drug|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
351980|NCT01510743|Procedure|Catheterization of subclavian vein|Catheterization of subclavian vein
351981|NCT01510743|Procedure|Catheterization of internal jugular vein|Catheterization of internal jugular vein
351982|NCT01510730|Drug|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
351983|NCT01510717|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
351984|NCT01510717|Device|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
351985|NCT01510704|Drug|APD421|IV
351986|NCT01510704|Drug|Placebo|IV
351987|NCT01510678|Behavioral|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F&Vs is perceived cost of these foods, information regarding lower-cost options for F&Vs will be included in the manual.
351988|NCT01510678|Behavioral|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
351989|NCT01510678|Behavioral|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
351990|NCT01510665|Dietary Supplement|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
351991|NCT01510665|Dietary Supplement|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
351992|NCT01510665|Behavioral|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
351993|NCT01510652|Procedure|BiP Group|Implantation of standard Left Ventricular (LV) lead
351994|NCT01510652|Device|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
351995|NCT01510639|Biological|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
351996|NCT01510626|Dietary Supplement|Food proteins|Food proteins
351997|NCT01510626|Drug|Omalizumab|Drug
351998|NCT01510613|Drug|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
351999|NCT01510600|Genetic|DNA analysis|
352000|NCT01510600|Genetic|polymerase chain reaction|
352001|NCT01510600|Other|laboratory biomarker analysis|
352002|NCT01510600|Other|medical chart review|
352003|NCT01510587|Behavioral|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
352004|NCT01510587|Behavioral|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
352005|NCT01510574|Drug|Misoprostol|3 x 200mcg tablets of oral misoprostol
352007|NCT01510561|Drug|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
352008|NCT01510561|Drug|90Y-hPAM4|
352009|NCT01510561|Drug|90Y-hPAM4 + gemcitabine|
352010|NCT01510548|Biological|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
352011|NCT01510535|Drug|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
352012|NCT01510535|Drug|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
352013|NCT01510535|Drug|LBSA0103|at third week LBSA0103(60mg) once in experimental group
352014|NCT01510522|Drug|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
352015|NCT01510522|Drug|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: > 1.700mg/day for 6 month"
352016|NCT01510509|Device|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
352017|NCT01510509|Device|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
352018|NCT01510496|Procedure|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
352019|NCT01510496|Procedure|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
352020|NCT01510496|Procedure|Thoracotomy .|Thoracotomy (non laparoscopic).
352021|NCT01510483|Behavioral|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
352022|NCT01510483|Behavioral|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
352023|NCT01510457|Drug|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
352024|NCT01510457|Drug|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
352025|NCT01510431|Drug|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
352026|NCT01510405|Other|Tissue Collection|Tissue sample collection
352027|NCT01510392|Device|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
352028|NCT01510379|Device|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
352029|NCT01510379|Drug|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
352030|NCT01510379|Drug|IV promethazine 25 mg q 6 hours prn|
352031|NCT01510379|Drug|Elixir promethazine 25 mg q 6 hours prn after discharge|
352032|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
352033|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
352034|NCT01510353|Device|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
352035|NCT01510340|Behavioral|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
352036|NCT01510327|Device|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
352037|NCT01510327|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
352038|NCT01510327|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
352039|NCT01510314|Biological|C-reactive protein and procalcitonin dosages|
352040|NCT01510301|Device|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;~Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;~Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
352057|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
352626|NCT01505881|Drug|warfarin 3mg|comparator warfarin
352041|NCT01510288|Drug|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
352042|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
352043|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
352044|NCT01510262|Behavioral|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.~Recruit/enroll in the intervention 500 subjects (50% women; African American focus).~After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:~A. The STI strengths-based prevention case management, or B. Standard care.~Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.~Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.~Conduct cost effectiveness analyses of intervention compared to the standard."
352045|NCT01510262|Behavioral|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
352046|NCT01510236|Behavioral|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
352047|NCT01510223|Dietary Supplement|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
352048|NCT01510223|Dietary Supplement|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
352049|NCT01510223|Dietary Supplement|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).~The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.~High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
352050|NCT01510223|Dietary Supplement|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
352051|NCT01510184|Drug|Zevalin (ibritumomab tiuxetan)|Day 1: Rituximab 250 mg/m2 intravenous infusion Days 7-9:Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg. In centers where biodistribution imaging is performed Day 1: Rituximab 250 mg/m2 intravenous infusion followed by In-111-Zevalin 185 MBq (5mCi), Days 3-4: Biodistribution imaging Days 7-9: Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg
352052|NCT01510171|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
352053|NCT01510171|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
352054|NCT01510158|Drug|Lesinurad|Tablets, 200 mg once daily (qd)
352055|NCT01510158|Drug|Lesinurad|Tablets, 400 mg qd
352056|NCT01510158|Drug|Placebo|Tablets, Placebo qd
352058|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
352059|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
352060|NCT01510145|Drug|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
352061|NCT01510132|Drug|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
352062|NCT01510119|Drug|Hydroxychloroquine|
352063|NCT01510119|Drug|RAD001|
352064|NCT01510093|Drug|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
352065|NCT01510080|Behavioral|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
352066|NCT01510080|Behavioral|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
352067|NCT01510041|Other|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
352068|NCT01510041|Other|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
352069|NCT01510028|Biological|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
352070|NCT01510015|Drug|Risperidone|variable dose
352071|NCT01510002|Procedure|Total thyroidectomy|Extracapsular total thyroidectomy
352072|NCT01510002|Procedure|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
352073|NCT01509976|Other|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
352074|NCT01509963|Other|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
352075|NCT01509950|Procedure|Staples|Staples for closure of cesarean section skin incision
352076|NCT01509950|Procedure|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
352077|NCT01509950|Procedure|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
352078|NCT01509937|Device|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
352079|NCT01509937|Device|Device|participants in control arm will not receive BCM measurement.
352080|NCT01509924|Other|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
352081|NCT01509911|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
352082|NCT01509911|Drug|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
352083|NCT01509898|Device|Water jet|use of water jet for a month
352084|NCT01509872|Behavioral|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
352085|NCT01509872|Behavioral|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
352086|NCT01509859|Device|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
352087|NCT01509859|Device|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith&Nephew INTERTAN proximal femur nail device"
352088|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^8 vp/mL Sf2aWC administered on Day 0
352089|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^9 vp/mL administered on Days 0, 28, and 56
352090|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^10 vp/mL administered on Days 0, 28, and 56
352091|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^11 administered on Days 0, 28, and 56
352092|NCT01509833|Drug|rFSH|Administration of rFSH for ovarian stimulation.
352093|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
352094|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
352095|NCT01509807|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
352096|NCT01509807|Drug|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
352097|NCT01509794|Other|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
352156|NCT01509313|Device|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
352098|NCT01509794|Other|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
352099|NCT01509781|Procedure|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
352100|NCT01509781|Procedure|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
352101|NCT01509755|Drug|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
352102|NCT01509755|Drug|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
352103|NCT01509755|Drug|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
352104|NCT01509742|Drug|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
352105|NCT01509742|Drug|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
352106|NCT01509729|Procedure|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
352107|NCT01509729|Procedure|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
352108|NCT01509703|Procedure|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
352109|NCT01509690|Other|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.~Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access [arteriovenous (AV) fistula or graft] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
352110|NCT01509677|Drug|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
352111|NCT01509677|Drug|Placebo|tablet, once daily, oral administration in the morning after breakfast
352112|NCT01509664|Behavioral|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
352113|NCT01509651|Drug|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
352114|NCT01509638|Drug|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
352115|NCT01509638|Drug|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
352116|NCT01509625|Drug|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
352117|NCT01509612|Drug|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
352118|NCT01509612|Drug|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
352119|NCT01509599|Procedure|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
352120|NCT01509599|Procedure|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
352121|NCT01509586|Drug|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
352157|NCT01509313|Device|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
352158|NCT01509300|Biological|anti-thymocyte globulin|On days -10 to -9
352159|NCT01509300|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
352160|NCT01509300|Radiation|Total body irradiation|2Gy D-6 to D-4
352161|NCT01509300|Drug|Fludarabine|30mg/M2 once daily IV on days -8 to -4
352122|NCT01509573|Behavioral|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
352123|NCT01509560|Drug|Everolimus|"Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.~Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16"
352124|NCT01509547|Drug|Varenicline|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
352125|NCT01509547|Drug|placebo|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
352126|NCT01509521|Drug|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
352127|NCT01509521|Drug|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
352128|NCT01509508|Drug|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
352129|NCT01509508|Other|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~WHO clinical stage 3 or 4 irrespective of CD4 count~MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
352130|NCT01509495|Device|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
352131|NCT01509482|Other|blood samples|blood samples to test for primary and secondary outcome measures
352132|NCT01509482|Other|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
352133|NCT01509469|Dietary Supplement|Casein|Ileal infusion of low dose casein (5 gram)
352134|NCT01509469|Dietary Supplement|Casein|Ileal infusion of high dose casein (15 gram)
352135|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
352136|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
352137|NCT01509469|Other|Saline|Ileal infusion with saline (180mL in total)
352138|NCT01509469|Dietary Supplement|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
352139|NCT01509456|Dietary Supplement|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
352140|NCT01509443|Other|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
352141|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
352142|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
352143|NCT01509417|Other|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
352144|NCT01509417|Other|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
352145|NCT01509404|Drug|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
352146|NCT01509404|Biological|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
352147|NCT01509404|Drug|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
352148|NCT01509391|Drug|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
352149|NCT01509365|Drug|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
352150|NCT01509365|Drug|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
352151|NCT01509352|Procedure|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
352152|NCT01509352|Procedure|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
352153|NCT01509339|Drug|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
352154|NCT01509326|Other|chiropractic treatment|12 sessions over 4 weeks
352155|NCT01509326|Device|Dr. Zaxx pillow|Daily use of an acupressure pillow
352166|NCT01509274|Biological|Plasma|3 ml plasma injected once into the plantar fascia
352167|NCT01509274|Biological|Saline|3 ml of saline injected once into the plantar fascia
352168|NCT01509274|Other|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
352169|NCT01509261|Drug|Ilaprazole|20mg/Tap, QD
352170|NCT01509261|Drug|Lansoprazole|30mg/Tap, QD
352171|NCT01509235|Procedure|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
352172|NCT01509222|Behavioral|Personalized nutrition counseling|
352173|NCT01509209|Drug|Pseudoephedrine / Levocetirizine|tablet, BID everyday
352174|NCT01509196|Drug|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
352175|NCT01509183|Device|Propeller Health System (formerly Asthmapolis System)|The Propeller (formerly Asthmapolis) system works through the provision of information to patients and their providers. With the Propeller (formerly Asthmapolis) device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller (formerly Asthmapolis) where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
352176|NCT01509157|Device|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
352177|NCT01509157|Procedure|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
352178|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
352179|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
352180|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
352181|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
352182|NCT01509144|Biological|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
352183|NCT01509131|Drug|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
352184|NCT01509131|Drug|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
352185|NCT01509105|Biological|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
352186|NCT01509092|Procedure|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
352187|NCT01509079|Drug|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
352188|NCT01509079|Drug|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
352189|NCT01509066|Other|Diet|Dietary approaches for PCOS
352190|NCT01509053|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014."
352191|NCT01509053|Drug|Oral aripiprazole|Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
352192|NCT01509040|Other|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.~Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.~Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.~Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
352193|NCT01509040|Device|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
352194|NCT01509040|Device|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.~Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
352195|NCT01509027|Behavioral|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
352196|NCT01509027|Behavioral|Standard care|standard care
352197|NCT01509027|Behavioral|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
352350|NCT01507974|Drug|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
352198|NCT01509014|Behavioral|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
352199|NCT01509001|Drug|Metformin|750 to 2500 mg/day, two times a day during 4 months
352200|NCT01509001|Drug|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
352201|NCT01508988|Drug|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
352202|NCT01508988|Drug|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
352203|NCT01508988|Drug|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
352204|NCT01508988|Drug|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
352205|NCT01508988|Drug|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
352206|NCT01508988|Drug|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
352207|NCT01508988|Drug|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
352208|NCT01508975|Other|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
352209|NCT01508949|Drug|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
352210|NCT01508949|Drug|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
352211|NCT01508936|Drug|Reslizumab|Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
352212|NCT01508936|Drug|Placebo|Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
352213|NCT01508923|Drug|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
352214|NCT01508923|Drug|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
352215|NCT01508910|Biological|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
352216|NCT01508910|Biological|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
352217|NCT01508910|Other|Standard of care|Standard of care for refractory angina
352218|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
352219|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
352220|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
352221|NCT01508884|Drug|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
352222|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
352223|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
352224|NCT01508884|Biological|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
352225|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
352226|NCT01508871|Other|Observational study, no intervention|No intervention
352227|NCT01508858|Drug|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
352228|NCT01508858|Drug|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
352229|NCT01508858|Drug|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
352230|NCT01508845|Dietary Supplement|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
352231|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
352232|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
352233|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
352234|NCT01508832|Drug|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
352235|NCT01508832|Drug|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
352236|NCT01508819|Other|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
352237|NCT01508806|Drug|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
352238|NCT01508793|Behavioral|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
352239|NCT01508780|Device|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
352240|NCT01508780|Device|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
352241|NCT01508767|Other|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
352242|NCT01508754|Procedure|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
352243|NCT01508741|Dietary Supplement|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
352244|NCT01508741|Dietary Supplement|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
352245|NCT01508728|Device|ORTHOSENS orthosis|with active vibration
352246|NCT01508728|Device|ORTHOSENS orthosis|with placebo vibration
352351|NCT01507974|Drug|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
352627|NCT01505868|Drug|Cabazitaxel|Given IV
352247|NCT01508715|Other|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
352248|NCT01508702|Drug|lesinurad|Tablets, 400 mg QD
352249|NCT01508702|Drug|Placebo|Tablets, Placebo QD
352250|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
352251|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
352252|NCT01508676|Drug|Pennsaid|
352253|NCT01508676|Drug|Placebo (2.3% DMSO solution)|
352254|NCT01508663|Device|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
352255|NCT01508663|Drug|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
352256|NCT01508650|Behavioral|Usual care|Usual care control group
352257|NCT01508650|Behavioral|Rehabilitation intervention|Multi-domain rehabilitation intervention
352258|NCT01508637|Other|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
352259|NCT01508637|Other|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
352260|NCT01508637|Drug|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
352261|NCT01508637|Drug|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
352262|NCT01508624|Other|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
352263|NCT01508624|Other|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
352264|NCT01508624|Behavioral|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
352265|NCT01508624|Behavioral|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
352266|NCT01508611|Other|30% silver diammine fluoride|"The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.~Anteroposterior toothbrushing technique will be explained to the children."
352267|NCT01508611|Behavioral|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
352268|NCT01508585|Behavioral|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
352269|NCT01508572|Drug|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
352270|NCT01508546|Procedure|axillary dissection|Conservative breast surgery with or without axillary dissection
352271|NCT01508494|Drug|Galantamine|16 mg galantamine daily P/O
352272|NCT01508494|Drug|placebo|placebo
352273|NCT01508468|Drug|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
352274|NCT01508468|Drug|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
352275|NCT01508455|Drug|Dexmedetomidine|
352276|NCT01508455|Drug|Midazolam|
352277|NCT01508455|Drug|Fentanyl|
352278|NCT01508455|Drug|Morphine|
352279|NCT01508429|Other|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
352280|NCT01508429|Drug|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
352281|NCT01508390|Radiation|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
352282|NCT01508377|Behavioral|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)~The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
352352|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
352283|NCT01508377|Behavioral|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).~The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.~First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.~Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
352284|NCT01508364|Drug|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
352285|NCT01508338|Dietary Supplement|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
352286|NCT01508338|Dietary Supplement|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
352287|NCT01508338|Dietary Supplement|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
352288|NCT01508338|Dietary Supplement|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
352289|NCT01508325|Drug|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was >=90 mmHg measured every 4 weeks.
352290|NCT01508325|Drug|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
352291|NCT01508312|Drug|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
352292|NCT01508312|Drug|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
352293|NCT01508299|Procedure|skin test|skin test with the Suspected raw food
352294|NCT01508286|Drug|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
352295|NCT01508286|Drug|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
352296|NCT01508286|Drug|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
352297|NCT01508273|Behavioral|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
352298|NCT01508273|Behavioral|Website|Website access given that allows participant to track exercise behavior and help to set goals.
352299|NCT01508273|Behavioral|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
352300|NCT01508273|Behavioral|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.~Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
352301|NCT01508273|Behavioral|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
352302|NCT01508260|Procedure|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
352303|NCT01508260|Drug|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
352304|NCT01508247|Biological|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
352305|NCT01508247|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
352306|NCT01508221|Drug|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
352307|NCT01508221|Dietary Supplement|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
352308|NCT01508208|Other|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
352309|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
352310|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
352311|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
352312|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
352313|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
352314|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
352315|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
352316|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
352317|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
352318|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
352319|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
352320|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
352321|NCT01508169|Device|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
352322|NCT01508156|Drug|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
352323|NCT01508156|Drug|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
352324|NCT01508143|Drug|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
352325|NCT01508143|Drug|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
352326|NCT01508117|Drug|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
352327|NCT01508117|Radiation|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
352328|NCT01508104|Drug|BEZ235|dose escalation 400mg- 1000mg per day
352329|NCT01508104|Drug|Everolimus|dose escalation 2.5 to 5 mg per day
352330|NCT01508091|Behavioral|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
352331|NCT01508091|Behavioral|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
352332|NCT01508065|Device|Glucometer CGM-305|The study procedure consists of three days trial. After each experimental day the results of blood glucose level reading from the non-invasive Glucometer CGM-305 will be compared to the reading from several devices, as following: Abbott Freestyle Libre, the hexokinase assay (YSI 2300 STAT Plus) from the venous and the laboratory blood measurements. First day of trial consists of 8-10 hours and is used to calibrate the non-invasive Glucometer CGM-305 for the specific patient. During the second and third days a fasting experiment is performed and consists of 4-6 hours.
352333|NCT01508052|Device|sequential compression device|applying sequential compression device during the surgery
352334|NCT01508052|Device|elastic stockings|applying elastic stockings during the surgery
352335|NCT01508039|Other|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).~A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
352336|NCT01508026|Drug|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
352337|NCT01508026|Drug|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
352338|NCT01508026|Drug|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
352339|NCT01508026|Drug|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
352340|NCT01508026|Drug|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
352341|NCT01508026|Drug|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
352342|NCT01508026|Drug|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
352343|NCT01508026|Drug|Placebo|Dose matched placebo, oral administration
352344|NCT01508013|Behavioral|Appearance-Focused Website Intervention|The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
352345|NCT01508013|Behavioral|Control Website|The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
352346|NCT01508000|Drug|FOLFOX6|5-FU, folinic acid, oxaliplatin
352353|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
352354|NCT01507974|Drug|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
352355|NCT01507974|Drug|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
352356|NCT01507948|Behavioral|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
352357|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
352358|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
352359|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
352360|NCT01507922|Drug|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
352361|NCT01507922|Drug|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
352362|NCT01507896|Biological|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
352363|NCT01507870|Procedure|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
352364|NCT01507857|Biological|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
352365|NCT01507857|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
352366|NCT01507844|Device|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
352367|NCT01507831|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
352368|NCT01507831|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
352369|NCT01507831|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
352370|NCT01507818|Device|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0>
352371|NCT01507818|Device|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
352372|NCT01507805|Device|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5—30 Hz，2．34—6．24 mA，30 min)for 5 consecutive days before surgery
352373|NCT01507805|Device|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5—30 Hz，2．34—6．24 mA，30 min)for 5 consecutive days before surgery
352374|NCT01507792|Drug|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
352375|NCT01507792|Drug|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
352376|NCT01507779|Biological|IVACFLU|IVACFLU is a whole virus vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge Alfpa Wassmann and inactivated with formaldehyde. It was formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose and filled in single dose vials.
352377|NCT01507779|Other|Placebo|Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
352378|NCT01507766|Drug|early enteral nutrition|The enteral nutrition was started within 48h after admission
352379|NCT01507766|Drug|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
352380|NCT01507753|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
352381|NCT01507753|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
352382|NCT01507753|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
352383|NCT01507740|Drug|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
352384|NCT01507740|Drug|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
352385|NCT01507740|Drug|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
352411|NCT01507467|Radiation|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
352628|NCT01505868|Drug|Carboplatin|Given IV
352386|NCT01507727|Drug|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
352387|NCT01507727|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
352388|NCT01507714|Procedure|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
352389|NCT01507701|Drug|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
352390|NCT01507688|Behavioral|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
352391|NCT01507662|Behavioral|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
352392|NCT01507649|Behavioral|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
352393|NCT01507636|Other|Occupational Therapy|Occupational therapy using a special arm function training.
352394|NCT01507636|Other|Physical therapy|Physical therapy for arm force training.
352395|NCT01507623|Device|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
352396|NCT01507610|Drug|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
352397|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
352398|NCT01507597|Drug|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
352399|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
352400|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.~Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
352401|NCT01507584|Device|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
352402|NCT01507571|Other|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:~a tape-recorded session with the patient using the DT question protocol~Transcription of the interview, which is then edited~A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
352403|NCT01507558|Procedure|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
352404|NCT01507545|Drug|MORAb-004|MORAb-004 8mg IV per kg once a week
352405|NCT01507545|Drug|Placebo|Placebo - normal saline IV once a week
352406|NCT01507532|Other|pharmacokinetic monitoring|pharmacokinetic monitoring
352407|NCT01507519|Device|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
352408|NCT01507506|Radiation|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
352409|NCT01507506|Radiation|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed~+~Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :~during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,~post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
352410|NCT01507480|Drug|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
352629|NCT01505868|Other|Laboratory Biomarker Analysis|Correlative studies
352412|NCT01507467|Radiation|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
352413|NCT01507454|Drug|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
352414|NCT01507441|Genetic|gene mapping|
352415|NCT01507441|Genetic|microarray analysis|
352416|NCT01507441|Genetic|mutation analysis|
352417|NCT01507441|Genetic|nucleic acid sequencing|
352418|NCT01507441|Other|laboratory biomarker analysis|
352419|NCT01507428|Drug|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
352420|NCT01507428|Drug|Carboplatin|Given IV
352421|NCT01507428|Procedure|Computed Tomography|Undergo FDG PET/CT
352422|NCT01507428|Procedure|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
352423|NCT01507428|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
352424|NCT01507428|Drug|Fludeoxyglucose F-18|Undergo FDG PET/CT
352425|NCT01507428|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
352426|NCT01507428|Other|Laboratory Biomarker Analysis|Correlative studies
352427|NCT01507428|Drug|Paclitaxel|Given IV
352428|NCT01507428|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
352429|NCT01507428|Procedure|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
352430|NCT01507402|Drug|REGN1033(SAR391786)|Administration method A
352431|NCT01507402|Drug|REGN1033(SAR391786)|Administration method B
352432|NCT01507402|Drug|Placebo|(inactive substance)
352433|NCT01507389|Drug|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
352434|NCT01507376|Drug|recombinant hCG|recombinant hCG(250 µg Ovitrell)
352435|NCT01507376|Drug|recombinant hCG|recombinant hCG(500 µg Ovitrell)
352436|NCT01507376|Drug|urinary hCG|10,000 IU urinary hCG
352437|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
352438|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
352439|NCT01507363|Drug|Placebo|Placebo tablets for 7 days, starting on the day of surgery
352440|NCT01507337|Drug|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
352441|NCT01507311|Drug|liraglutide|A single dose injected subcutaneously (under the skin)
352442|NCT01507311|Drug|placebo|A single dose injected subcutaneously (under the skin)
352443|NCT01507285|Drug|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
352444|NCT01507285|Drug|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
352445|NCT01507272|Drug|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
352446|NCT01507272|Drug|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
352447|NCT01507272|Drug|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
352448|NCT01507272|Drug|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
352449|NCT01507259|Other|cocoa|70% versus 34%
352450|NCT01507246|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
352451|NCT01507246|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
352452|NCT01507233|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
352453|NCT01507233|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
352454|NCT01507220|Drug|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
352455|NCT01507220|Drug|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed."
352456|NCT01507207|Procedure|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
352457|NCT01507194|Drug|Ondansetron|Single IV dose
352458|NCT01507194|Drug|Vestipitant|Single IV dose
352459|NCT01507181|Drug|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
352460|NCT01507181|Drug|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
352461|NCT01507168|Drug|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
352462|NCT01507168|Drug|RO5137382|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
352463|NCT01507155|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
352464|NCT01507116|Other|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
352465|NCT01507103|Biological|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
352466|NCT01507103|Drug|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
352467|NCT01507103|Other|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
352468|NCT01507090|Device|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
352469|NCT01507077|Drug|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
352470|NCT01507077|Drug|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
352471|NCT01507064|Drug|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
352472|NCT01507064|Procedure|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.~When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
352473|NCT01507051|Drug|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
352474|NCT01507051|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
352475|NCT01507051|Drug|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
352476|NCT01507051|Drug|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
352477|NCT01507038|Drug|YH14617|1mg once weekly
352478|NCT01507038|Drug|YH14617|1.6mg once weekly
352479|NCT01507038|Drug|YH14617|2mg once biweekly
352480|NCT01507038|Drug|Placebo|Once weekly
352481|NCT01507012|Dietary Supplement|Berry Polyphenols|
352482|NCT01507012|Dietary Supplement|Placebo|Placebo control containing sugar and artificial flavouring.
352483|NCT01506999|Biological|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
352484|NCT01506986|Drug|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
352485|NCT01506986|Drug|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
352486|NCT01506973|Drug|Hydroxychloroquine (HCQ)|
352487|NCT01506973|Drug|Gemcitabine|
352488|NCT01506960|Device|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
352489|NCT01506947|Drug|Paricalcitol|"Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:~[Paricalcitol (µg) = iPTH (pg/mL) / 80]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels."
352490|NCT01506947|Drug|Darbepoetin alfa|Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level < 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
352491|NCT01506934|Drug|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)~Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
352492|NCT01506921|Drug|Racemic ketamine|0.6 mg/kg
352493|NCT01506921|Drug|S-ketamine|0.3 mg/kg
352494|NCT01506908|Drug|oral nicotine|oral nicotine replacement product
352495|NCT01506908|Drug|Placebo|no active
352496|NCT01506895|Drug|darapladib|Experimental compound 160 mg dose
352497|NCT01506895|Drug|placebo|Placebo to match
352498|NCT01506882|Drug|Levetiracetam (LEV)|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: LEV 250 mg, LEV 500 mg~Frequency: Twice daily~Route of Administration: Oral use"
352499|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
352500|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
352540|NCT01506531|Procedure|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
352541|NCT01506531|Procedure|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
352542|NCT01506505|Drug|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
352625|NCT01505881|Drug|dabigatran etexilate high dose|active treatment (high)
352501|NCT01506843|Biological|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
352502|NCT01506830|Procedure|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
352503|NCT01506830|Procedure|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
352504|NCT01506817|Procedure|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
352505|NCT01506804|Other|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
352506|NCT01506791|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
352507|NCT01506778|Device|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
352508|NCT01506765|Drug|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
352509|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
352510|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
352511|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
352512|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
352513|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
352514|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
352515|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
352516|NCT01506726|Drug|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
352517|NCT01506726|Drug|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
352518|NCT01506713|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
352519|NCT01506700|Device|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
352520|NCT01506687|Behavioral|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
352521|NCT01506687|Behavioral|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
352522|NCT01506661|Drug|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
352523|NCT01506635|Drug|Timolol|
352524|NCT01506635|Drug|Placebo|artificial tear twice a day
352525|NCT01506622|Drug|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
352526|NCT01506622|Drug|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
352527|NCT01506622|Drug|Administration of saline|Saline will be administered to control group at the end of anesthesia.
352528|NCT01506609|Drug|Placebo|Placebo comparator for Veliparib days 1 through 7 of 21-day cycle (in combination with carboplatin and/or paclitaxel).
352529|NCT01506609|Drug|Veliparib|Days 1 through 7 of 28-day cycle (in combination with Temozolomide) or Days 1 through 7 of 21-day cycle (in combination with Carboplatin and Paclitaxel).
352530|NCT01506609|Drug|Carboplatin|Day 3 of 21-day cycle
352531|NCT01506609|Drug|Temozolomide|Days 1 through 5 of 28-day cycle (in combination with veliparib).
352532|NCT01506609|Drug|Paclitaxel|Day 3 of 21-day cycle.
352533|NCT01506596|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
352534|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10^3 plaque-forming unit [PFU] of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
352535|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
352536|NCT01506570|Biological|Placebo|One SC injection at Day 0 and Day 180 of placebo
352537|NCT01506557|Dietary Supplement|cholecalciferol|dose 800 IU/day for 6 month
352538|NCT01506557|Dietary Supplement|placebo|oil capsules
352539|NCT01506544|Drug|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
352543|NCT01506492|Behavioral|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
352544|NCT01506479|Behavioral|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
352545|NCT01506479|Behavioral|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
352546|NCT01506479|Behavioral|No Intervention|No-exercise control (i.e., usual care);
352547|NCT01506466|Other|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
352548|NCT01506453|Drug|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
352549|NCT01506453|Drug|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
352550|NCT01506440|Procedure|cognitive assessment|Given cognitive assessments
352551|NCT01506440|Procedure|quality-of-life assessment|Ancillary studies
352552|NCT01506427|Radiation|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
352553|NCT01506414|Drug|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
352554|NCT01506401|Device|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
352555|NCT01506401|Procedure|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure < or = 35cmH20; Prescribed PEEP/FiO2 chart
352556|NCT01506388|Device|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
352557|NCT01506388|Drug|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
352558|NCT01506388|Drug|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
352559|NCT01506375|Biological|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
352560|NCT01506375|Biological|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
352561|NCT01506362|Drug|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.~Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.~BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
352562|NCT01506349|Dietary Supplement|gluten|4 grams of gluten.
352563|NCT01506349|Dietary Supplement|Placebo|
352564|NCT01506336|Drug|masitinib|masitinib 12 mg/kg/day
352565|NCT01506336|Drug|sunitinib|sunitinib 50 mg/day
352566|NCT01506323|Behavioral|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
352567|NCT01506323|Behavioral|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
352568|NCT01506310|Behavioral|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
352569|NCT01506310|Other|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
352570|NCT01506310|Other|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.~Written recommendations for physical activity A brief written guide on behavior change"
352571|NCT01506284|Procedure|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.~LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
352572|NCT01506271|Drug|Relebactam 250 mg|Relebactam 250 mg IV every 6 hours for a minimum of 96 hours
352573|NCT01506271|Drug|Relebactam 125 mg|Relebactam 125 mg IV every 6 hours for a minimum of 96 hours
352574|NCT01506271|Drug|Imipenem/cilastatin|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
352575|NCT01506271|Drug|Matching placebo to relebactam|Placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
352576|NCT01506258|Procedure|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
352577|NCT01506258|Procedure|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
352622|NCT01505881|Drug|warfarin 5mg|comparator warfarin
352623|NCT01505881|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
352624|NCT01505881|Drug|warfarin 1mg|comparator warfarin
352578|NCT01506245|Behavioral|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
352579|NCT01506219|Procedure|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
352580|NCT01506193|Biological|PriorixTetra™|One dose administered subcutaneously
352581|NCT01506193|Biological|Meningitec|One dose administered intramuscularly
352582|NCT01506167|Drug|Bevacizumab|Bevacizumab was administered as part of standard first-line treatment
352583|NCT01506167|Drug|Capecitabine/Oxaliplatin|Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
352584|NCT01506167|Drug|Fluorouracil/Folinic Acid/Oxaliplatin|Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
352585|NCT01506167|Drug|Capecitabine|Capecitabine was administered along with bevacizumab as part of standard first-line treatment
352586|NCT01506167|Drug|Fluorouracil/Folinic Acid/Irinotecan|Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
352587|NCT01506167|Drug|Fluorouracil +/- Folinic Acid|Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
352588|NCT01506154|Drug|MRX-7EAT|Once daily application of a patch for 14 days
352589|NCT01506141|Drug|Idursulfase-IT|Participants will receive Idursulfase-IT once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD).
352590|NCT01506141|Drug|Elaprase|Participants will receive weekly IV infusions of commercially available Elaprase.
352591|NCT01506128|Other|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
352592|NCT01506115|Drug|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
352593|NCT01506102|Device|Thromboelastography|Thromboelastography during labor and after delivery
352594|NCT01506089|Other|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
352595|NCT01506076|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
352596|NCT01506063|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
352597|NCT01506050|Drug|Desloratadine|Desloratadine ODT 5 mg
352598|NCT01506037|Drug|Desloratadine|Desloratadine ODT 5 mg
352599|NCT01506024|Procedure|Total hip arthroplasty direct lateral approach|
352600|NCT01506024|Procedure|Total hip arthroplasty posterior approach|
352601|NCT01506024|Procedure|Total hip arthroplasty, anterior approach|
352602|NCT01506011|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
352603|NCT01505998|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
352604|NCT01505985|Dietary Supplement|Oral nutritional Supplement|Specialized nutritional supplement for seniors
352605|NCT01505985|Dietary Supplement|Placebo|placebo product with no specific nutrients
352606|NCT01505972|Other|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
352607|NCT01505972|Other|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
352608|NCT01505959|Device|CPAP treatment|Usual CPAP treatment
352609|NCT01505959|Device|CPAP treatment|CPAP treatment with telemedicine system
352610|NCT01505946|Other|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
352611|NCT01505933|Drug|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
352612|NCT01505933|Drug|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.~After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.~Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
352613|NCT01505920|Procedure|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
352614|NCT01505920|Procedure|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
352615|NCT01505907|Drug|CXB909|CXB909
352616|NCT01505894|Drug|BI 409306|High dose film-coated tablet
352617|NCT01505894|Drug|BI 409306|High dose film-coated tablet
352618|NCT01505894|Drug|BI 409306 Placebo|Placebo film-coated tablet
352619|NCT01505894|Drug|BI 409306|Low dose film-coated tablet
352620|NCT01505894|Drug|BI 409306|Medium dose film-coated tablet
352621|NCT01505881|Drug|dabigatran etexilate low dose|active treatment (low)
352630|NCT01505855|Drug|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
352631|NCT01505842|Procedure|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
352632|NCT01505842|Procedure|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
352633|NCT01505816|Device|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
352634|NCT01505803|Dietary Supplement|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
352635|NCT01505803|Dietary Supplement|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
352636|NCT01505803|Dietary Supplement|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
352637|NCT01505790|Drug|PRASUGREL|60 mg the first day then 10 mg per day during one month
352638|NCT01505790|Drug|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP <50%. No more than 3 * 600mg of clopidogrel will be authorized in this protocol.~Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
352639|NCT01505777|Drug|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
352640|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
352641|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
352642|NCT01505777|Drug|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
352643|NCT01505777|Drug|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
352644|NCT01505764|Drug|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
352645|NCT01505764|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
352646|NCT01505738|Other|bacterial samples|bacterial samples taken
352647|NCT01505712|Genetic|gene expression analysis|
352648|NCT01505712|Other|laboratory biomarker analysis|
352649|NCT01505699|Genetic|RNA analysis|
352650|NCT01505699|Genetic|cytogenetic analysis|
352651|NCT01505699|Genetic|microarray analysis|
352652|NCT01505699|Other|laboratory biomarker analysis|
352653|NCT01505686|Procedure|MRI scan|MRI scan with a 1,5 T MRI scanner
352654|NCT01505673|Drug|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
352655|NCT01505673|Drug|Saline|Placebo injection of 1.8mg saline once daily for 6-months
352656|NCT01505660|Behavioral|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at ~9 and 12 months after enrollment.
352657|NCT01505647|Biological|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
352658|NCT01505647|Biological|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
352659|NCT01505634|Drug|Relebactam 250 mg|Participants randomized to receive relebactam 250 mg will be administered a 250 mg dose of relebactam IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
352660|NCT01505634|Drug|Relebactam 125 mg|Participants randomized to receive relebactam 125 mg will be administered a 125 mg dose of relebactam IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
352661|NCT01505634|Drug|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
352662|NCT01505634|Drug|Placebo to relebactam|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
352663|NCT01505634|Drug|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
352664|NCT01505621|Other|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L[ring-13C6]phenylalanine
352665|NCT01505608|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
352666|NCT01505608|Drug|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
352667|NCT01505608|Drug|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
352668|NCT01505595|Other|Proprioceptive training|12 weeks
352669|NCT01505595|Other|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
352670|NCT01505582|Other|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
352671|NCT01505582|Other|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
352672|NCT01505569|Drug|Ifosfamide|"Arms A&B: 1.8 g/m^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen~Arm C: 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles"
352673|NCT01505569|Drug|Etoposide|"Arms A&B: 100 mg/m^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~Arm C: 400 mg/m^2 daily on days -4, -3, and -2 every 21 days~Arm D: Etoposide 8.3 mg/kg (or 250mg/m² if age >36 mos.) approx. hour 75 on days -5, -4, and -3"
352674|NCT01505569|Drug|Mesna|"Arms A&B: 1.8 g/m^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.~Arm C: 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles"
352675|NCT01505569|Biological|G-CSF|"Arms A&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (>) 1,000/mm^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3~Arm C: 10 μg/kg SQ daily beginning 6 hours after ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first.~Arm D: Beginning day +1 following hematopoietic cell reinfusion, patients receive filgrastim at a dose of 5mcg/kg SQ once daily (or 5mcg/Kg IV either daily or twice daily, per institutional preference)~Arm E: 5 micrograms/kg/dose beginning on Day 0 and continue per institutional preference"
352676|NCT01505569|Drug|Busulfan|Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6 Arm E: first dose of busulfan is dosed by mg/kg as appropriate for age and weight. Once the results of pharmacokinetic (PK) studies are known, subsequent daily doses are based upon those results,
352677|NCT01505569|Drug|Melphalan|Arm A: 50 mg/m^2 intravenously (IV) over 30 min on Days -4 and -5 Arm E:140 mg/m2 AT LEAST 24 hrs after last busulfan dose. Day: -1
352678|NCT01505569|Drug|Thiotepa|Arm A: 250 mg/m^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2 Arm D: Thiotepa 10 mg/kg (or 300mg/m² if age >36 mos.) approx. hour 72 on days -5, -4, and -3
352679|NCT01505569|Biological|Autologous stem cell infusion|"Arms A, B & C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.~Arm D: On day 0, peripheral blood hematopoietic progenitor cells (PHPCs) or bone marrow cells will be thawed and re-infused about 72 hours following completion of the last dose of chemotherapy.~Arm E: stem cells will be infused on Day 0 of Consolidation. Where the DMSO volume in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over 2 days to meet this standard."
352680|NCT01505569|Radiation|Radiation|"Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.~Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive spot irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose."
352681|NCT01505569|Drug|Carboplatin|Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days Arm D: as calculated from AUC of 7 approx. hour 0 on days -8, -7, and -6
352682|NCT01505569|Drug|Paclitaxel|Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
352683|NCT01505569|Procedure|Leukapheresis|Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
352684|NCT01505569|Drug|Anti-seizure prophylaxis|"Arm E: Lorazepam OR Levetaracetam~Lorazepam should be given 0.02-0.05 mg/kg/dose, given 30 minutes prior to each busulfan dose and then continuing every 6 hours, maximum dose: 2 mg.~Levetiracetam should be given 10 mg/kg/dose PO, administered BID, staring 12 hours prior to busulfan, maximum single dose: 1000mg."
352685|NCT01505569|Drug|Ursodiol|Arm E: 150 mg/m2/dose PO, administered BID, beginning on Day -7 and continuing a minimum of 28 days post-transplant, or until the end of Consolidation.
352686|NCT01505530|Drug|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
352687|NCT01505530|Drug|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
352688|NCT01505530|Drug|Standard of Care Chemotherapy|Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
352689|NCT01505504|Drug|mirtazapine|30 mg at bedtime
352690|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
352691|NCT01505491|Drug|BI695501|BI 695501 single s.c injection
352692|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
352693|NCT01505465|Drug|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
352694|NCT01505465|Drug|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
352695|NCT01505439|Drug|solifenacin|oral
352696|NCT01505426|Drug|ASP1941|oral
352697|NCT01505426|Drug|metformin|oral, concomitant use
352698|NCT01505426|Drug|Placebo|oral
352699|NCT01505413|Drug|Erlotinib|Erlotinib 100 mg po qd daily
352700|NCT01505413|Drug|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
352701|NCT01505413|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
352702|NCT01505387|Dietary Supplement|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
352703|NCT01505387|Dietary Supplement|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
352877|NCT01504074|Behavioral|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
352704|NCT01505374|Procedure|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
352705|NCT01505374|Procedure|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
352706|NCT01505361|Biological|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
352707|NCT01505361|Biological|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
352708|NCT01505348|Other|Overnight fast|Overnight fast from 21:00 h
352709|NCT01505335|Device|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
352710|NCT01505309|Device|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
352711|NCT01505296|Drug|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
352712|NCT01505296|Procedure|Catheter ablation|Complete PVI
352713|NCT01505283|Drug|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
352714|NCT01505283|Drug|Sufentanil|epidural administration of sufentanil 10 µg
352715|NCT01505283|Drug|lidocaine|epidural administration of lidocaine 50 mg
352716|NCT01505270|Other|Retrospective case study|Retrospective case study
352717|NCT01505257|Behavioral|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
352718|NCT01505244|Behavioral|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
352719|NCT01505231|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.
352720|NCT01505231|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
352721|NCT01505218|Drug|Propofol sedation by nurse anaesthestist|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.~Propofol sedation by nurse anaesthetists:"
352722|NCT01505218|Drug|Patient-controlled propofol sedation|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.~Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.~Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
352723|NCT01505192|Device|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
352724|NCT01505179|Drug|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
352725|NCT01505179|Drug|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
352726|NCT01505166|Biological|Vigil™ Vaccine|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
352727|NCT01505166|Drug|Placebo|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
352728|NCT01505153|Biological|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
352729|NCT01505140|Other|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
352730|NCT01505127|Drug|TAK-438|
352731|NCT01505127|Drug|Lansoprazole|
352732|NCT01505127|Drug|Amoxicillin|
352733|NCT01505127|Drug|Clarithromycin|
352734|NCT01505114|Drug|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
352735|NCT01505114|Drug|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
352736|NCT01505114|Drug|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
352737|NCT01505114|Other|Maraviroc placebo|Once daily from Week 0 through Week 48
352738|NCT01505114|Other|Emtricitabine placebo|Once daily from Week 0 through Week 48
352739|NCT01505114|Other|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
352740|NCT01505101|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
352741|NCT01505101|Behavioral|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
352742|NCT01505088|Drug|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
352743|NCT01505088|Drug|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
352744|NCT01505088|Drug|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
352745|NCT01505088|Drug|Placebo Eyedrops|Placebo Eyedrops
352746|NCT01505075|Radiation|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
352747|NCT01505062|Genetic|SAR421869|"Pharmaceutical form: prefilled syringes~Route of administration: subretinal injection"
352748|NCT01505049|Drug|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
352749|NCT01505036|Other|SMARTCARE service|U-Healthcare service
352750|NCT01505023|Dietary Supplement|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
352751|NCT01505023|Dietary Supplement|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
352752|NCT01505023|Dietary Supplement|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
352753|NCT01505010|Procedure|Renal denervation|Renal denervation in the intervention group
352754|NCT01504997|Device|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
352755|NCT01504984|Drug|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
352756|NCT01504984|Drug|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)
352757|NCT01504971|Other|symptom questionaire|GerdQ questionaire
352758|NCT01504971|Procedure|pH monitoring|24-hour pH monitoring
352759|NCT01504971|Procedure|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
352760|NCT01504971|Drug|rabeprazole|10mg, bid, p.o.
352761|NCT01504958|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).~Sham participants will receive the same study procedures as patients receiving active rTMS."
352762|NCT01504958|Behavioral|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).~A particular cognitive exercise will start 200msec after the termination of each TMS train.~Sham participants receive sham cognitive training that follows the same procedures as the active group."
352763|NCT01504945|Other|RBC transfusion|1 bag of packed red blood cells
352764|NCT01504945|Other|Normal saline infusion|500 mL of normal saline infusion
352765|NCT01504932|Drug|lyophilized black raspberry lozenge|ARM I: Patients will be instructed to begin LBR administration and continue daily for 6 months.
352766|NCT01504932|Other|survey administration|Patients will be asked to complete a baseline survey of family history of cancer and tobacco/alcohol and mouthwash usage, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) survey, and a Brief Fatigue Inventory (BFI) survey. They will then receive a logbook (specific for this trial)
352767|NCT01504932|Other|laboratory biomarker analysis|Patients will be asked to do blood, urine, and saliva sample and a buccal scrape. These biological samples will be evaluated for the presence of LBR components (as a measure of compliance) and assessment of LBR responsive genes, respectively.
352768|NCT01504932|Other|pharmacological study|Correlative studies
352769|NCT01504919|Behavioral|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
352770|NCT01504919|Behavioral|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
352771|NCT01504919|Behavioral|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
352772|NCT01504919|Drug|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
352773|NCT01504906|Drug|cyclosporine|Oral tablets, 600 mg , single dose
352774|NCT01504906|Drug|ticagrelor|Oral tablets, 180 mg, single dose
352775|NCT01504893|Procedure|protective ventilation|Low tidal volume, PEEP and recruitment maneuver
352776|NCT01504867|Drug|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
352777|NCT01504867|Drug|Lactose powder|Matching lactose powder filled capsules will be administered on days 1-7.
352778|NCT01504854|Drug|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
352779|NCT01504854|Drug|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
352780|NCT01504841|Drug|Etravirine (ETR)|ETR was administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children took the specified dose orally twice daily within 30 minutes following a meal. Dose was decided according to dosing tables in protocol.
352781|NCT01504828|Drug|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
352782|NCT01504815|Drug|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
352783|NCT01504815|Radiation|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
352784|NCT01504815|Radiation|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
352785|NCT01504789|Behavioral|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
352786|NCT01504789|Behavioral|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
352787|NCT01504789|Behavioral|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
352788|NCT01504789|Behavioral|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
352789|NCT01504776|Drug|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
352790|NCT01504776|Drug|Bortezomib|
352791|NCT01504763|Procedure|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
352792|NCT01504750|Procedure|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
352793|NCT01504737|Other|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
352794|NCT01504737|Other|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
352795|NCT01504724|Drug|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
352796|NCT01504711|Drug|fosaprepitant dimeglumine|Given IV
352797|NCT01504698|Procedure|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
352798|NCT01504698|Procedure|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
352799|NCT01504685|Procedure|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
352800|NCT01504685|Procedure|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.~To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
352801|NCT01504672|Other|Medication review|"In the intervention, the pharmacist will evaluate:~Is there an indication for the drug?~Has the drug desired effect?~Is the dose correct and dosing scheme correct?~Side effects, contraindications, inappropriate drugs~Interactions~Treatment time~Cost effectiveness~Adherence to recommendation list~Problems with handling the drugs (for example crushing of the tablets)~Untreated indication~Double medications~Administration of drugs"
352802|NCT01504659|Drug|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
352878|NCT01504061|Other|Mederma N&I|Topical gel applied three times a day for eight weeks.
352879|NCT01504061|Other|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
352803|NCT01504659|Drug|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
352804|NCT01504646|Dietary Supplement|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
352805|NCT01504646|Dietary Supplement|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
352806|NCT01504633|Dietary Supplement|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
352807|NCT01504620|Other|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
352808|NCT01504620|Drug|insulin infusion|i.v. infusion of insulin
352809|NCT01504607|Procedure|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
352810|NCT01504594|Procedure|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
352811|NCT01504581|Biological|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
352812|NCT01504581|Biological|HM10660A placebo|Single dose of HM10660A Placebo
352813|NCT01504581|Biological|Pegasys|Single dose of Pegasys 180ug
352814|NCT01504568|Other|Treatment|Adults: ≥40 kg:250mg every eight hours Children: <40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
352815|NCT01504542|Biological|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
352816|NCT01504542|Biological|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
352817|NCT01504542|Biological|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
352818|NCT01504516|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
352819|NCT01504516|Drug|Aricept|Aricept 10 mg Tablets
352820|NCT01504503|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
352821|NCT01504503|Drug|Aricept|Aricept 10 mg Tablets
352822|NCT01504490|Drug|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.~Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
352823|NCT01504477|Drug|Panitumumab and bortezomib|"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.~Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."
352824|NCT01504464|Biological|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
352825|NCT01504464|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
352826|NCT01504451|Device|ILR insertion|Insertion of implantable loop recorder
352827|NCT01504451|Procedure|AF ablation|AF ablation
352828|NCT01504438|Device|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
352829|NCT01504438|Device|STAR Total Ankle Replacement|STAR Total Ankle Replacement
352830|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
352831|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
352832|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
352833|NCT01504412|Drug|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
352834|NCT01504412|Drug|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
352835|NCT01504386|Procedure|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
352836|NCT01504386|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
352837|NCT01504373|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
352838|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
352839|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
352840|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
352841|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
352924|NCT01503684|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
352925|NCT01503671|Drug|Atorvastatin|Atorvastatin 40 mg/day
352842|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
352843|NCT01504334|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
352844|NCT01504334|Drug|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
352845|NCT01504321|Drug|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
352846|NCT01504321|Drug|Placebo|Encapsulated lactose powder
352847|NCT01504308|Device|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
352848|NCT01504308|Device|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
352849|NCT01504295|Drug|Metadoxine|Improve Liver Function and Reduce ALcohol Use
352850|NCT01504282|Drug|mitomycin-C|
352851|NCT01504282|Drug|Placebo|balanced salt solution (BSS)
352852|NCT01504256|Drug|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)~and 7 days after the last catumaxomab infusion~FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
352853|NCT01504256|Drug|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:~Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
352854|NCT01504204|Drug|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
352855|NCT01504204|Drug|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
352856|NCT01504191|Behavioral|Internet‐based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.~A psychologist will communicate with the participants through internal text‐messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
352857|NCT01504178|Drug|duloxetine|administration during 28 days
352858|NCT01504178|Drug|placebo of duloxetine|administration during 28 days
352859|NCT01504178|Drug|injection of apomorphine|injection performed at D28
352860|NCT01504178|Drug|injection of placebo of apomorphine|performed at D28
352861|NCT01504178|Drug|L-Dopa|performed at D28
352862|NCT01504178|Drug|injection of placebo of L-Dopa|performed at D28
352863|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
352864|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
352865|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
352866|NCT01504165|Drug|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
352867|NCT01504165|Drug|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide > 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
352868|NCT01504152|Behavioral|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
352869|NCT01504139|Drug|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
352870|NCT01504139|Drug|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
352871|NCT01504139|Drug|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
352872|NCT01504139|Drug|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
352873|NCT01504126|Drug|Chemotherapy|Undergo standard chemotherapy
352874|NCT01504126|Drug|Propranolol Hydrochloride|Given PO
352875|NCT01504126|Other|Quality-of-Life Assessment|Ancillary studies
352876|NCT01504126|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
352926|NCT01503658|Drug|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
352927|NCT01503632|Behavioral|Behavioral Intervention|Receive intervention program
352880|NCT01504048|Procedure|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
352881|NCT01504035|Device|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
352882|NCT01504035|Device|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
352883|NCT01504022|Other|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
352884|NCT01504009|Other|Muscle training|12 weeks of strength training 2-3 times/week
352885|NCT01503996|Behavioral|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
352886|NCT01503983|Drug|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
352887|NCT01503983|Drug|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
352888|NCT01503983|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
352889|NCT01503970|Device|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
352890|NCT01503957|Device|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
352891|NCT01503957|Device|Saline solution|Nasal spray, 2 sprays in each nostril
352892|NCT01503944|Drug|18F-AV-133|185 MBq
352893|NCT01503944|Drug|18F-AV-45|185-370 MBq
352894|NCT01503918|Drug|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
352895|NCT01503918|Drug|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
352896|NCT01503905|Drug|Docetaxel|75mg/m2, iv injection, day1, every 21 days
352897|NCT01503905|Drug|epirubicin|80mg/ m2, iv injection, day1, every 21 days
352898|NCT01503905|Drug|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
352899|NCT01503905|Procedure|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
352900|NCT01503905|Drug|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
352901|NCT01503905|Drug|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
352902|NCT01503905|Drug|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
352903|NCT01503905|Radiation|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
352904|NCT01503905|Drug|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
352905|NCT01503905|Drug|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
352906|NCT01503892|Dietary Supplement|Metanx|Metanx- one tablet twice daily for twelve months
352907|NCT01503892|Drug|Placebo|Placebo- one tablet twice daily for twelve months.
352908|NCT01503866|Drug|bardoxolone methyl|oral, single dose
352909|NCT01503840|Drug|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
352910|NCT01503840|Drug|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
352911|NCT01503827|Radiation|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
352912|NCT01503814|Other|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:~2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption~2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
352913|NCT01503801|Drug|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
352914|NCT01503801|Device|respiratory support|Routine respiratory support.
352915|NCT01503788|Drug|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
352916|NCT01503762|Other|Mirror therapy|mirror therapy
352917|NCT01503762|Other|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
352918|NCT01503749|Drug|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
352919|NCT01503749|Other|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
352920|NCT01503736|Drug|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
352921|NCT01503736|Drug|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
352922|NCT01503736|Drug|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
352923|NCT01503723|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
352928|NCT01503632|Behavioral|Compliance Monitoring|Correlative studies
352929|NCT01503632|Other|Laboratory Biomarker Analysis|Correlative studies
352930|NCT01503632|Drug|Mercaptopurine|Given orally
352931|NCT01503632|Other|Questionnaire Administration|Ancillary studies
352932|NCT01503632|Procedure|Standard Follow-Up Care|Receive usual standard of care
352933|NCT01503619|Other|laboratory biomarker analysis|Correlative studies
352934|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
352935|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
352936|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
352937|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
352938|NCT01503593|Device|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
352939|NCT01503580|Drug|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
352940|NCT01503567|Other|No treatment given|Subject will only fill out a questionaire
352941|NCT01503554|Behavioral|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.~Pharmacist will be available to patients should they have any medication-related questions post-discharge"
352942|NCT01503554|Behavioral|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
352943|NCT01503541|Genetic|DNA analysis|
352944|NCT01503541|Genetic|RNA analysis|
352945|NCT01503541|Genetic|gene expression analysis|
352946|NCT01503541|Genetic|mutation analysis|
352947|NCT01503541|Genetic|polymerase chain reaction|
352948|NCT01503541|Other|laboratory biomarker analysis|
352949|NCT01503528|Procedure|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
352950|NCT01503528|Procedure|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
352951|NCT01503515|Drug|Caspofungin Acetate|Given IV
352952|NCT01503515|Drug|Fluconazole|Given IV or PO
352953|NCT01503515|Other|Laboratory Biomarker Analysis|Optional correlative studies
352954|NCT01503515|Drug|Voriconazole|Given IV or PO
352955|NCT01503502|Drug|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
352956|NCT01503502|Drug|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
352957|NCT01503489|Drug|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
352958|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
352959|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
352960|NCT01503463|Procedure|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.~If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
352961|NCT01503450|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
352962|NCT01503437|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
352963|NCT01503424|Drug|Olanzapine|Olanzapine Tablets, 5 mg
352964|NCT01503398|Drug|Olanzapine|Olanzapine Tablets, 5 mg
352965|NCT01503385|Drug|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
352966|NCT01503372|Drug|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
352967|NCT01503372|Drug|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
352968|NCT01503359|Dietary Supplement|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.~Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
352969|NCT01503346|Drug|DaHuang GanTsao Tang|"Intervention group~2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;~each package was given to each patient four times a day (three time after meal and one time before sleep);~each patient received the usual medication of the hospice ward at the same time;~record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;~record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
352970|NCT01503333|Behavioral|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
352971|NCT01503320|Dietary Supplement|Enteral glutamine|Dosage of glutamine: 0.57g/kg, ~ 30g/day= 3sachets
352972|NCT01503320|Dietary Supplement|Placebo|Similar appearing nutritional supplement without glutamine.
352973|NCT01503281|Other|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
352974|NCT01503268|Device|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
352975|NCT01503268|Procedure|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
352976|NCT01503268|Procedure|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
352977|NCT01503255|Behavioral|cognitive behavioral group therapy|6 weekly 90-minute group sessions
352978|NCT01503255|Behavioral|health education group|6 weekly 90-minute group sessions
352979|NCT01503242|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
352980|NCT01503242|Drug|Cyclosporine|Given PO
352981|NCT01503242|Drug|Fludarabine Phosphate|Given IV
352982|NCT01503242|Drug|Mycophenolate Mofetil|Given IV or PO
352983|NCT01503242|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
352984|NCT01503242|Radiation|Total-Body Irradiation|Undergo TBI
352985|NCT01503242|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
352986|NCT01503229|Drug|Abiraterone Acetate|Given PO
352987|NCT01503229|Other|Laboratory Biomarker Analysis|Correlative studies
352988|NCT01503229|Other|Pharmacological Study|Correlative studies
352989|NCT01503229|Drug|Prednisone|Given PO
352990|NCT01503216|Dietary Supplement|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
352991|NCT01503216|Dietary Supplement|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
352992|NCT01503216|Dietary Supplement|Placebo|Placebo
352993|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
352994|NCT01503203|Other|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
352995|NCT01503203|Other|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
352996|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
352997|NCT01503203|Other|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
352998|NCT01503177|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
352999|NCT01503177|Other|laboratory biomarker analysis|Correlative studies
353000|NCT01503177|Procedure|single photon emission computed tomography|Correlative studies
353001|NCT01503177|Procedure|computed tomography|Correlative studies
353002|NCT01503164|Device|Positive Pressure Therapy (PAP)|Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
353003|NCT01503164|Behavioral|LifeStyle Counseling|Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
353004|NCT01503151|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
353005|NCT01503151|Behavioral|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
353006|NCT01503151|Behavioral|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
353007|NCT01503151|Behavioral|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
353008|NCT01503138|Behavioral|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
353009|NCT01503112|Other|No intervention, observational study|
353010|NCT01503086|Procedure|Cognitive Assessment|Ancillary studies
353011|NCT01503086|Other|Computer-Assisted Cognitive Training|Receive computer-assisted cognitive training
353012|NCT01503086|Procedure|Psychosocial Assessment and Care|Ancillary studies
353013|NCT01503086|Other|Quality-of-Life Assessment|Ancillary studies
353014|NCT01503086|Other|Questionnaire Administration|Ancillary studies
353015|NCT01503073|Device|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
353016|NCT01503060|Behavioral|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
353017|NCT01503060|Behavioral|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
353018|NCT01503060|Drug|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
353019|NCT01503060|Drug|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
353020|NCT01503060|Drug|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
354663|NCT01490801|Genetic|cytogenetic analysis|
353021|NCT01503060|Drug|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
353022|NCT01503047|Dietary Supplement|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
353023|NCT01503047|Dietary Supplement|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
353024|NCT01503021|Drug|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
353025|NCT01503021|Other|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
353026|NCT01503008|Device|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
353027|NCT01503008|Drug|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
353028|NCT01502995|Device|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
353029|NCT01502982|Drug|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
353030|NCT01502969|Biological|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
353031|NCT01502969|Biological|cell culture medium in absence of virus|Placebo
353032|NCT01502956|Device|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
353033|NCT01502956|Drug|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
353034|NCT01502943|Drug|Louxiangdan Tongxin granules|"TCM treatment:~Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
353035|NCT01502943|Drug|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
353036|NCT01502943|Drug|Chixiangshen Tongxin granules|"TCM treatment:~Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.~Usage:Once 100ml, twice per day after breakfast and supper."
353037|NCT01502943|Drug|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
353038|NCT01502943|Drug|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
353039|NCT01502930|Behavioral|IRT|Internet-based IRT with therapist support during 6 weeks
353040|NCT01502930|Behavioral|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
353041|NCT01502917|Radiation|Radioactive iodine-labeled monoclonal antibody 8H9|Prior to treatment, children will be pre-medicated with super-saturated potassium iodide (SSKI) & liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-8H9 into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-8H9. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations & PET/CT or PET/MRI scans of the brain & other organs. Clinical observations, intensive care unit monitoring, routine blood & interval imaging studies (MRI & PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
353042|NCT01502904|Device|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
353043|NCT01502904|Device|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
354664|NCT01490801|Genetic|in situ hybridization|
353044|NCT01502904|Drug|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
353045|NCT01502904|Drug|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
353046|NCT01502904|Drug|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
353047|NCT01502904|Drug|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
353048|NCT01502891|Other|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
353049|NCT01502878|Dietary Supplement|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
353050|NCT01502878|Dietary Supplement|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
353051|NCT01502878|Dietary Supplement|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
353052|NCT01502839|Other|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
353053|NCT01502826|Dietary Supplement|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
353054|NCT01502813|Drug|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
353055|NCT01502800|Drug|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
353056|NCT01502800|Drug|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
353057|NCT01502800|Drug|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
353058|NCT01502800|Drug|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)~You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.~The beginning dose level will be 390 mg/m2."
353059|NCT01502787|Drug|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
353060|NCT01502787|Drug|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
353061|NCT01502787|Procedure|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
353062|NCT01502787|Procedure|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
353063|NCT01502787|Procedure|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
353064|NCT01502787|Procedure|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
353065|NCT01502787|Drug|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
353066|NCT01502774|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
353067|NCT01502774|Drug|Placebo|One single intravenous bolus injection of Placebo
353068|NCT01502774|Procedure|Echocardiography|1 year after AMI
353069|NCT01502761|Drug|Magnesium Sulfate|Intra-arterial
353070|NCT01502748|Other|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
353071|NCT01502735|Biological|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
353072|NCT01502735|Biological|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
353073|NCT01502722|Behavioral|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
353074|NCT01502709|Device|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
353075|NCT01502709|Device|placebo|Matching placebo device
353076|NCT01502696|Biological|PEG IFN alfa-2b|3µg/kg weekly injections
353077|NCT01502683|Procedure|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
353078|NCT01502683|Procedure|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
353079|NCT01502683|Procedure|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
353080|NCT01502683|Procedure|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
353081|NCT01502670|Drug|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
353082|NCT01502657|Device|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
353083|NCT01502644|Drug|Oxycodone|Daily dosage up to 120 mg
353084|NCT01502644|Drug|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
353085|NCT01502644|Drug|Placebo|Placebo-matching oxycodone, placebo-matching morphine
353086|NCT01502631|Drug|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
353087|NCT01502631|Drug|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
353088|NCT01502618|Behavioral|Focus Group|N/A. Protocol is the focus group
353089|NCT01502605|Drug|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
353090|NCT01502592|Procedure|Cryoablation|"OncCore Biopsy (+ Cryo) Date*~Pre- and post- cryo MRI~Core biopsy x ≥3~Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.*"
353091|NCT01502592|Biological|Ipilimumab|"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date*~MRI~Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."
353092|NCT01502566|Behavioral|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
353093|NCT01502553|Device|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
353094|NCT01502527|Dietary Supplement|Femarelle|Twice daily oral treatment with Femarelle
353095|NCT01502514|Procedure|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
353096|NCT01502501|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
353097|NCT01502488|Procedure|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
353098|NCT01502449|Behavioral|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
353099|NCT01502449|Other|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
353100|NCT01502423|Biological|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
353101|NCT01502410|Drug|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
353102|NCT01502410|Other|pharmacological study|Optional correlative studies
353103|NCT01502410|Other|laboratory biomarker analysis|Optional correlative studies
353104|NCT01502384|Other|neurological examination|motor and cognitive functions
354665|NCT01490801|Genetic|mutation analysis|
353105|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
353106|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
353107|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
353108|NCT01502371|Drug|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
353109|NCT01502371|Drug|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
353110|NCT01502371|Drug|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
353111|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
353112|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
353113|NCT01502358|Biological|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
353114|NCT01502345|Biological|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
353115|NCT01502332|Other|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.
353116|NCT01502332|Other|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
353117|NCT01502319|Behavioral|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
353118|NCT01502306|Behavioral|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
353119|NCT01502306|Drug|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
353120|NCT01502306|Behavioral|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
353121|NCT01502293|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
353122|NCT01502293|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
353123|NCT01502280|Drug|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
353124|NCT01502280|Drug|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
353125|NCT01502267|Drug|High dose IVIG and B cell depleting agents|"IVIG(2g/kg two times on day 1, 30)~Rituximab(375mg/m2 on day 3)~Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
353126|NCT01502254|Other|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
353127|NCT01502241|Drug|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
353128|NCT01502241|Radiation|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
353129|NCT01502228|Drug|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
353130|NCT01502228|Drug|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
353131|NCT01502228|Procedure|Positron Emission Tomography|PET Scan
353132|NCT01502228|Drug|Sunitinib|
353133|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
353134|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
353135|NCT01502202|Drug|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
353136|NCT01502202|Drug|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
353137|NCT01502202|Drug|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
353138|NCT01502189|Other|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
353139|NCT01502163|Device|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
353140|NCT01502163|Device|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
353141|NCT01502150|Other|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
353142|NCT01502150|Other|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
353143|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
353144|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
353145|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
353146|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
353147|NCT01502098|Procedure|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
353148|NCT01502098|Other|Sling|Sling for 4 weeks
353149|NCT01502085|Drug|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
353150|NCT01502072|Drug|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
353151|NCT01502072|Drug|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
353152|NCT01502059|Other|Pilates|Pilates training - twice a week (one hour per class) during 90 days
353153|NCT01502046|Drug|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
353154|NCT01502046|Drug|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
353155|NCT01502033|Device|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
353156|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
353157|NCT01502020|Drug|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
353158|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
353159|NCT01502007|Other|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
353160|NCT01502007|Other|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
353161|NCT01501994|Other|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
353162|NCT01501994|Other|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
353192|NCT01501786|Drug|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
353252|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
353163|NCT01501994|Procedure|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
353164|NCT01501968|Drug|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
353165|NCT01501968|Drug|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
353166|NCT01501955|Device|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
353167|NCT01501955|Device|Stanmore|Stanmore hip prosthesis
353168|NCT01501942|Drug|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
353169|NCT01501942|Drug|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
353170|NCT01501929|Drug|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
353171|NCT01501929|Drug|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
353172|NCT01501929|Procedure|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
353173|NCT01501929|Procedure|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
353174|NCT01501929|Procedure|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
353175|NCT01501916|Dietary Supplement|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
353176|NCT01501916|Dietary Supplement|Placebo|daily intake of placebo
353177|NCT01501903|Procedure|Standard|FNA in a single plane
353178|NCT01501903|Procedure|Fanning|FNA in multiple planes
353179|NCT01501890|Drug|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
353180|NCT01501890|Drug|Placebo|0.9% NaCl
353181|NCT01501877|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
353182|NCT01501877|Behavioral|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
353183|NCT01501864|Behavioral|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
353184|NCT01501825|Device|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
353185|NCT01501825|Device|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
353186|NCT01501812|Behavioral|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
353187|NCT01501799|Drug|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
353188|NCT01501799|Drug|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
353189|NCT01501799|Drug|Placebo (Vehicle Gel)|Vehicle Gel
353190|NCT01501786|Drug|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
353191|NCT01501786|Drug|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
353193|NCT01501773|Biological|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
353194|NCT01501760|Drug|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
353195|NCT01501760|Drug|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
353196|NCT01501747|Drug|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
353197|NCT01501747|Drug|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
353198|NCT01501734|Device|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.~The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.~Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
353199|NCT01501721|Behavioral|Exercise|Home-based exercise program
353200|NCT01501721|Behavioral|Diet|Nutritional counseling aiming to reduce suggar intake
353201|NCT01501708|Drug|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.~All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.~In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
353202|NCT01501695|Drug|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
353203|NCT01501695|Drug|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.~Total duration:8 weeks."
353204|NCT01501695|Drug|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
353205|NCT01501669|Drug|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks~+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
353206|NCT01501643|Device|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
353207|NCT01501643|Device|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
353208|NCT01501630|Device|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
353209|NCT01501617|Biological|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
353210|NCT01501617|Device|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
353211|NCT01501604|Drug|BKM120|100 MG PO QD in cycles of 28 days
353212|NCT01501591|Drug|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
353213|NCT01501591|Other|Placebo|Matching placebo once on two different days, 72 hours apart.
353214|NCT01501591|Drug|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
353215|NCT01501565|Procedure|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
353216|NCT01501552|Other|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
353217|NCT01501552|Other|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
353218|NCT01501552|Other|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
353219|NCT01501539|Procedure|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
353220|NCT01501539|Procedure|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
353221|NCT01501513|Drug|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
353222|NCT01501513|Drug|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
353223|NCT01501513|Drug|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
353224|NCT01501500|Drug|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
353225|NCT01501500|Drug|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
354666|NCT01490801|Genetic|polymerase chain reaction|
353226|NCT01501487|Drug|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
353227|NCT01501487|Drug|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
353228|NCT01501487|Drug|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
353229|NCT01501487|Drug|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
353230|NCT01501487|Drug|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.~Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
353231|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).~Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
353232|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
353233|NCT01501487|Drug|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,~Followed by 4 cycles of AC or FEC:~AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles~In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
353234|NCT01501461|Procedure|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
353235|NCT01501448|Drug|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
353236|NCT01501448|Drug|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
353237|NCT01501435|Drug|CJ-30039|single dose
353238|NCT01501435|Drug|fenofibric acid|single dose
353239|NCT01501422|Drug|Estrogen patch|50 microgram estrogen patch weekly
353240|NCT01501422|Drug|Placebo|Placebo patch for 8 weeks
353241|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
353242|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
353243|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
353244|NCT01501396|Drug|Megestrol Acetate|
353245|NCT01501396|Drug|Mirtazapine|
353246|NCT01501383|Drug|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
353247|NCT01501383|Drug|Placebo|Matching placebo
353248|NCT01501383|Drug|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
353249|NCT01501370|Drug|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
353250|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
353251|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
353253|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
353254|NCT01501357|Behavioral|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
353255|NCT01501357|Behavioral|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
353256|NCT01501344|Dietary Supplement|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
353257|NCT01501331|Device|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
353258|NCT01501318|Behavioral|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
353259|NCT01501318|Behavioral|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
353260|NCT01501305|Dietary Supplement|Mineral solution|Rehydration mineral solution
353261|NCT01501305|Dietary Supplement|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
353262|NCT01501292|Other|Fixation and staining|Fixation and staining by MitiTracker Green FM
353263|NCT01501292|Other|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
353264|NCT01501279|Procedure|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
353265|NCT01501253|Drug|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
353266|NCT01501253|Drug|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
353267|NCT01501253|Drug|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
353268|NCT01501227|Device|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
353269|NCT01501227|Other|Conventional endotracheal tube|Sham Comparator
353270|NCT01501214|Drug|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
353271|NCT01501214|Drug|Normal saline|Normal saline given
353272|NCT01501201|Procedure|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
353273|NCT01501201|Drug|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
353274|NCT01501188|Other|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
353275|NCT01501188|Other|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
353276|NCT01501175|Other|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
353277|NCT01501162|Drug|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
353278|NCT01501162|Drug|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
353279|NCT01501149|Drug|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
353280|NCT01501149|Drug|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
353281|NCT01501136|Other|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
353282|NCT01501136|Other|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
353283|NCT01501136|Other|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
353284|NCT01501136|Other|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
353285|NCT01501136|Radiation|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
353286|NCT01501123|Drug|Haloperidol|5mg IM
353287|NCT01501123|Drug|Midazolam|IM midazolam
353288|NCT01501110|Drug|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
353289|NCT01501097|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
354667|NCT01490801|Genetic|western blotting|
353290|NCT01501084|Drug|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
353291|NCT01501084|Drug|Normal saline .2cc subcutaneous injection|sterile saline injection
353292|NCT01501071|Device|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
353293|NCT01501058|Behavioral|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
353294|NCT01501058|Behavioral|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
353295|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
353296|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
353297|NCT01501032|Device|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
353298|NCT01501019|Other|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.~Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.~Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
353299|NCT01500993|Drug|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
353300|NCT01500993|Drug|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cylce of 5-Fu based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
353301|NCT01500980|Biological|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
353302|NCT01500980|Drug|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
353303|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
353304|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
353305|NCT01500967|Other|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
353306|NCT01500967|Other|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
353307|NCT01500941|Dietary Supplement|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
353308|NCT01500941|Other|maltodextrin|sachets
353309|NCT01500928|Device|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
353310|NCT01500915|Drug|Ranibizumab|0,5mg intravitreal ranibizumab
353311|NCT01500902|Other|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
353312|NCT01500902|Other|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
353313|NCT01500889|Procedure|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
353314|NCT01500889|Procedure|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:~The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
353315|NCT01500889|Procedure|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
353316|NCT01500876|Radiation|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
353317|NCT01500863|Drug|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
353318|NCT01500863|Drug|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
353319|NCT01500863|Drug|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
353320|NCT01500863|Drug|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
353321|NCT01500863|Drug|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
353322|NCT01500863|Drug|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
353323|NCT01500850|Drug|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
353324|NCT01500850|Drug|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal"
353325|NCT01500850|Drug|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
353326|NCT01500850|Drug|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal"
353327|NCT01500837|Drug|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
353328|NCT01500837|Drug|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
353329|NCT01500824|Drug|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
353330|NCT01500811|Biological|cell injection|Intra articular injection of chondrocyte
353331|NCT01500798|Drug|20 mg bardoxolone methyl|20 mg, oral, once daily
353332|NCT01500798|Drug|Placebo|Oral, once daily
353333|NCT01500785|Drug|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
353334|NCT01500785|Drug|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
353335|NCT01500772|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
353336|NCT01500772|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
353337|NCT01500772|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
353338|NCT01500746|Procedure|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
353339|NCT01500746|Other|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
353340|NCT01500733|Drug|PCI 32765|420 mg daily
353341|NCT01500720|Drug|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
353342|NCT01500720|Drug|Topotecan|Topotecan 1.5 mg/m^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
353343|NCT01500707|Drug|SCH 900800|SCH 900800, one 20 mg tablet, orally
353344|NCT01500694|Drug|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
353345|NCT01500681|Procedure|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
353346|NCT01500668|Drug|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
353347|NCT01500668|Drug|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
353348|NCT01500655|Procedure|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
353349|NCT01500655|Procedure|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
353350|NCT01500642|Biological|Slit One|slit one sublingual immunotherapy 200 stu
353351|NCT01500642|Biological|Slit One|slit one vestibular immunotherapy 200 stu
353352|NCT01500642|Biological|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
353353|NCT01500629|Device|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
353354|NCT01500629|Device|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
353355|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
353356|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
353357|NCT01500603|Device|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
353358|NCT01500603|Device|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
353359|NCT01500590|Drug|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
353465|NCT01499927|Other|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
353360|NCT01500590|Drug|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
353361|NCT01500577|Drug|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
353362|NCT01500577|Drug|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
353363|NCT01500577|Other|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
353364|NCT01500564|Device|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
353365|NCT01500564|Device|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
353366|NCT01500551|Drug|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight for all subjects for all three index studies (A3921103, A3921104, and A3921165)~5 mg BID Dose Level:~Body Weight (Dose in tablet [mg BID] or solution [ml BID]) 5 ‑ < 7 kg (2 mg or 2 ml) 7 - < 10 kg (2.5 mg or 2.5 ml) 10 - <15 kg (3 mg or 3 ml) 15 - <25 kg (3.5 mg or 3.5 ml) 25 - <40 kg (4 mg or 4 ml) >=40 kg (5 mg or 5 ml)~Oral solution (1 mg/mL concentration) will be used for subjects weighing <40 kg. Oral tablets (5 mg) will be used for subjects weighing >=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.~Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
353367|NCT01500551|Drug|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
353368|NCT01500538|Drug|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
353369|NCT01500512|Other|Clinical Observation|Undergo observation
353370|NCT01500499|Genetic|gene expression analysis|
353371|NCT01500499|Genetic|gene rearrangement analysis|
353372|NCT01500499|Genetic|polymerase chain reaction|
353373|NCT01500499|Genetic|protein analysis|
353374|NCT01500499|Genetic|western blotting|
353375|NCT01500499|Other|laboratory biomarker analysis|
353376|NCT01500499|Other|mass spectrometry|
353377|NCT01500486|Device|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
353378|NCT01500473|Drug|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
353379|NCT01500434|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
353380|NCT01500434|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
353381|NCT01500434|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
353382|NCT01500421|Device|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
353383|NCT01500421|Device|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
353384|NCT01500421|Device|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
353385|NCT01500408|Drug|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
353386|NCT01500408|Drug|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
353387|NCT01500395|Procedure|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
353388|NCT01500382|Drug|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
353389|NCT01500382|Drug|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
353390|NCT01500382|Other|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
353391|NCT01500382|Other|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
353466|NCT01499914|Biological|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
353467|NCT01499901|Procedure|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
353392|NCT01500382|Drug|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
353393|NCT01500369|Other|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
353394|NCT01500369|Other|standard of care|Placebo Comparator
353395|NCT01500356|Behavioral|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
353396|NCT01500356|Behavioral|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
353397|NCT01500356|Behavioral|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
353398|NCT01500343|Drug|Saccharomyces boulardii|1 gram per day, during 3 months
353399|NCT01500330|Procedure|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
353400|NCT01500330|Procedure|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
353401|NCT01500317|Drug|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
353402|NCT01500317|Drug|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
353403|NCT01500317|Drug|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
353404|NCT01500304|Procedure|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
353405|NCT01500291|Other|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
353406|NCT01500278|Biological|Certolizumab Pegol (CZP)|"Active substance: an injectable volume of 1 ml solution for injection CZP~Pharmaceutical form: prefilled syringes CZP~Concentration: 200 mg/ml CZP~Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal."
353407|NCT01500278|Biological|Adalimumab (ADA)|"Active substance: an injectable volume of 0.8 ml solution for injection ADA~Pharmaceutical form: prefilled syringes ADA~Concentration: 40 mg/0.8 ml ADA~Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal."
353408|NCT01500278|Drug|Methotrexate (MTX)|"Active substance: Methotrexate~Pharmaceutical form: oral tablet~Concentration: 15-25 mg/week~Route of Administration: MTX orally"
353409|NCT01500265|Biological|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
353410|NCT01500252|Device|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
353411|NCT01500252|Device|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
353412|NCT01500226|Drug|Rolapitant|(4 X 50 mg capsule) 200 mg PO
353413|NCT01500226|Drug|Granisetron|2 mg PO
353414|NCT01500226|Drug|Dexamethasone|20 mg PO
353415|NCT01500226|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
353416|NCT01500213|Drug|Rolapitant|200 mg PO
353417|NCT01500213|Drug|Granisetron|10 mcg/kg IV
353418|NCT01500213|Drug|Dexamethasone|20 mg PO and 8 mg PO
353419|NCT01500213|Drug|Placebo|(4 X 0 mg capsules) o mg PO
353420|NCT01500200|Drug|ALKS 5461|Two active tablets, given daily
353421|NCT01500200|Drug|Placebo|Two placebo tablets, given daily
353422|NCT01500187|Device|Vanish Varnish|5% sodium fluoride varnish with tricalcium phosphate
353423|NCT01500187|Device|Pediagel|1.23% Acidulated Phosphate Fluoride Gel
353424|NCT01500174|Device|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
353425|NCT01500174|Device|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
353426|NCT01500161|Drug|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
353427|NCT01500161|Drug|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
353428|NCT01500161|Drug|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
353429|NCT01500161|Drug|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
353430|NCT01500161|Drug|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
353431|NCT01500161|Drug|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
353432|NCT01500161|Drug|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
353433|NCT01500148|Device|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
353434|NCT01500135|Drug|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
353435|NCT01500135|Drug|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
353436|NCT01500122|Drug|RhuDex|"Part 1:~Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose~The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
353437|NCT01500109|Drug|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
353438|NCT01500109|Drug|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
353439|NCT01500109|Drug|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
353440|NCT01500096|Drug|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
353441|NCT01500096|Dietary Supplement|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.~Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
353442|NCT01500083|Drug|Bendamustine at a dose of 100 mg/m2|Bendamustine will be administered intravenously over 30 minutes.
353443|NCT01500083|Drug|Bendamustine at a dose of 120 mg/m2|Bendamustine will be administered intravenous (i.v.) over 60 minutes.
353444|NCT01500070|Device|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
353445|NCT01500057|Device|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
353446|NCT01500057|Device|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
353447|NCT01500044|Procedure|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
353448|NCT01500044|Procedure|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
353449|NCT01500031|Device|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
353450|NCT01500018|Drug|TC-5214|Single oral dose of 2 mg
353451|NCT01500018|Drug|TC-5214 Placebo|Single oral dose
353452|NCT01500018|Drug|Ketamine|Single oral dose of 100 mg
353453|NCT01500018|Drug|Phentermine|Single oral dose of 45 mg
353454|NCT01500018|Drug|TC-5214|Single oral dose of 8 mg
353455|NCT01500018|Drug|TC-5214|Single oral dose of 16 mg
353456|NCT01500018|Drug|Phentermine|Single oral dose of 90 mg
353457|NCT01500005|Drug|Baby D3 drops|2000-4000 iu per day
353458|NCT01499992|Procedure|Standard physical therapy program PLUS aquatic physical therapy|2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
353459|NCT01499992|Other|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
353460|NCT01499979|Procedure|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
353461|NCT01499966|Procedure|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
353462|NCT01499953|Drug|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
353463|NCT01499953|Drug|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
353464|NCT01499940|Drug|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
353468|NCT01499901|Procedure|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
353469|NCT01499888|Procedure|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.~Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
353470|NCT01499888|Drug|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
353471|NCT01499888|Drug|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
353472|NCT01499875|Drug|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
353473|NCT01499862|Device|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
353474|NCT01499849|Drug|Rolapitant|(4 X 50 mg capsules) 200 mg PO
353475|NCT01499849|Drug|Granisetron|10 mcg/kg IV
353476|NCT01499849|Drug|dexamethasone|20 mg PO and 8 mg PO
353477|NCT01499849|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
353478|NCT01499836|Other|PVB|paravertebral block
353479|NCT01499810|Procedure|Bilateral radiofrequency sympathetic renal denervation|Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
353480|NCT01499797|Other|The CareWell programme|"The CareWell programme contains the following components:~multidisciplinary primary care teams~working with proactive care plans integrating cure, care and welfare~advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)~medication review~case-management~guidelines for consultation of in-hospital geriatric experts~guidelines for transfers from primary care to home-based facilities and hospital and back~practice guidelines for management of common geriatric conditions"
353481|NCT01499784|Behavioral|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
353482|NCT01499771|Drug|Atorvastatin|80 Mg tablets
353483|NCT01499758|Drug|Atorvastatin|80 Mg tablets
353484|NCT01499745|Behavioral|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
353485|NCT01499719|Behavioral|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
353486|NCT01499706|Behavioral|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
353487|NCT01499706|Behavioral|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
353488|NCT01499693|Drug|Magnesium Pantoprazole 20 mg|oral dose, twice a day
353489|NCT01499693|Drug|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
353490|NCT01499693|Drug|Placebo|"oral dose, once a day (night)~Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
353491|NCT01499667|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
353492|NCT01499667|Drug|Placebo|Matching placebo in capsules for oral administration once daily.
353493|NCT01499654|Drug|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
353494|NCT01499641|Drug|Methylprednisolone|Epidural methylprednisolone 40 mg or none
353495|NCT01499628|Behavioral|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
353496|NCT01499628|Behavioral|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
353497|NCT01499628|Behavioral|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
353498|NCT01499615|Device|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
353499|NCT01499602|Drug|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
353500|NCT01499602|Drug|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
353501|NCT01499589|Procedure|regional anesthesia|regional anesthesia procedure
353502|NCT01499576|Procedure|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
353503|NCT01499563|Drug|ITI-007|Capsules containing ITI-007 for 28 days
353504|NCT01499563|Drug|Placebo|Capsules containing inactive placebo for 28 days
353505|NCT01499563|Drug|Risperidone|Capsules containing risperidone for 28 days
353581|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
353582|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
353506|NCT01499550|Device|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
353507|NCT01499550|Other|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
353508|NCT01499537|Device|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
353509|NCT01499537|Device|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
353510|NCT01499498|Drug|Sildenafil and Boceprevir|25mg once/800mg three times a day
353511|NCT01499485|Drug|Acetazolamide|"Daily morning ABGA:~If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of acetazolamide 500 mg .~If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of acetazolamide 500 mg.~If actual bicarbonate <= 26 mmol/L: omit treatment that day."
353512|NCT01499485|Drug|Placebo|"Daily morning ABGA:~If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of placebo.~If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of placebo.~If actual bicarbonate <= 26 mmol/L: omit treatment that day."
353513|NCT01499472|Device|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
353514|NCT01499472|Device|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
353515|NCT01499472|Procedure|standard of care|regular care including debridement and bandaging.
353516|NCT01499459|Genetic|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
353517|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
353518|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
353519|NCT01499446|Drug|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
353520|NCT01499446|Drug|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
353521|NCT01499433|Drug|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
353522|NCT01499420|Biological|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
353523|NCT01499420|Biological|Placebo|Single intravenous doses of normal saline (0.9%)
353524|NCT01499407|Device|ClearWay RX catheter|
353525|NCT01499407|Drug|Abciximab|
353526|NCT01499368|Drug|Lafutidine|Lafutidine 20mg/day
353527|NCT01499368|Drug|Famotidine|Famotidine 40mg/day
353528|NCT01499368|Drug|Omeprazole|Omeprazole 20mg/day
353529|NCT01499355|Biological|BIIB023|
353530|NCT01499355|Biological|Placebo|
353531|NCT01499355|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
353532|NCT01499355|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
353533|NCT01499316|Procedure|High Flow oxygen|10 minute shigh flow oxygen
353534|NCT01499316|Procedure|Room Air|Room air breathing
353535|NCT01499303|Drug|Fostamatinib|Phase II Trial to evaluate the efficacy of 200mg fostamatinib
353536|NCT01499290|Drug|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
353537|NCT01499290|Drug|Metronidazole|500 mg of Metronidazole
353538|NCT01499290|Drug|Meropenem|1 gram of Meropenem
353539|NCT01499277|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
353540|NCT01499277|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
353541|NCT01499277|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
353542|NCT01499264|Device|MySkin patch|Hydrogel and polyurethane film
353543|NCT01499264|Device|Traditional Dressing|Gauze and Patch
353544|NCT01499251|Drug|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
353545|NCT01499251|Drug|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
353546|NCT01499251|Drug|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
353547|NCT01499238|Device|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
353548|NCT01499238|Device|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
353549|NCT01499225|Drug|YH14642 500mg Tab|YH14642 500mg per day(once a day)
353550|NCT01499225|Drug|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
353551|NCT01499225|Drug|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
353552|NCT01499225|Drug|INSADOL[Zea mays L. extract] 35mg Tab|"[Initiation dose : 4weeks after administraion] INSADOL[Zea mays L. extract] 210mg TAB per day~[Maintain dose : Between 4weeks and 8weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day~[Maintain dose : Between 8weeks and 12weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day"
353553|NCT01499225|Drug|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA[Doxycycline hyclate] Cap 40mg per day
353554|NCT01499225|Drug|Placebo|Placebo
353555|NCT01499212|Procedure|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
353556|NCT01499199|Drug|Dolutegravir|50mg Once Daily
353557|NCT01499186|Other|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
353558|NCT01499173|Behavioral|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
353559|NCT01499160|Drug|letrozole|Drug is are to be taken orally. 2.5 mg once daily
353560|NCT01499160|Drug|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
353561|NCT01499160|Drug|everolimus|Drug is to be taken orally. 5 mg once daily.
353562|NCT01499147|Drug|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
353563|NCT01499147|Drug|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl).
353564|NCT01499147|Drug|ATG|Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
353565|NCT01499134|Drug|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
353566|NCT01499134|Drug|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
353567|NCT01499121|Drug|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop > grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
353568|NCT01499108|Drug|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
353569|NCT01499095|Drug|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
353570|NCT01499095|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
353571|NCT01499082|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
353572|NCT01499082|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
353573|NCT01499069|Drug|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .~Duration; 3 or 6 months"
353574|NCT01499056|Biological|stem cell injection|intra articular inection of mesenchymal stem cell
353575|NCT01499043|Drug|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
353576|NCT01499017|Drug|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
353577|NCT01499017|Drug|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
353578|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
353579|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
353580|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
353665|NCT01498419|Drug|Pyrazinamide (Z)|
353583|NCT01499004|Drug|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
353584|NCT01498991|Device|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
353585|NCT01498978|Biological|ipilimumab|Given IV
353586|NCT01498978|Other|laboratory biomarker analysis|Correlative studies
353587|NCT01498952|Drug|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
353588|NCT01498952|Drug|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
353589|NCT01498939|Drug|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
353590|NCT01498926|Drug|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
353591|NCT01498926|Drug|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
353592|NCT01498913|Drug|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
353593|NCT01498900|Drug|repaglinide|Prescription according to the product labelling at the physicians' discretion
353594|NCT01498887|Drug|Fingolimod (FTY720)|Hard gelatin capsules containing 0.5 mg of fingolimod.
353595|NCT01498874|Drug|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
353596|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
353597|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
353598|NCT01498861|Drug|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
353599|NCT01498861|Drug|Dolutegravir|Dolutegravir is an experimental HIV drug
353600|NCT01498861|Drug|Placebo|Placebo is a tablet with no drug in it
353601|NCT01498848|Dietary Supplement|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
353602|NCT01498835|Drug|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).~Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
353603|NCT01498822|Drug|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
353604|NCT01498822|Drug|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
353605|NCT01498809|Drug|Midodrine|Single 10 mg dose
353606|NCT01498796|Drug|Ketorolac|
353607|NCT01498796|Drug|Normal Saline|
353608|NCT01498783|Drug|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
353609|NCT01498770|Drug|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
353610|NCT01498770|Drug|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
353611|NCT01498770|Drug|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
353612|NCT01498770|Drug|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
353613|NCT01498770|Drug|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
353614|NCT01498770|Drug|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
353615|NCT01498770|Drug|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
353616|NCT01498770|Drug|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
353617|NCT01498770|Drug|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
353618|NCT01498770|Drug|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
353619|NCT01498770|Drug|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
353620|NCT01498770|Drug|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
353621|NCT01498770|Drug|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
353622|NCT01498744|Drug|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
353623|NCT01498731|Behavioral|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
353624|NCT01498718|Biological|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
353625|NCT01498718|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
353626|NCT01498705|Other|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
354668|NCT01490801|Other|flow cytometry|
353627|NCT01498692|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
353628|NCT01498679|Drug|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
353629|NCT01498679|Drug|Placebo|Placebo administered once daily in the evening via a NDPI
353630|NCT01498666|Dietary Supplement|L. reuteri protectis|1 tablet once daily for 4 weeks
353631|NCT01498666|Dietary Supplement|Placebo tablet|1 tablet once daily for 4 weeks
353632|NCT01498653|Drug|GW685698/GW642444|ICS/LABA
353633|NCT01498653|Drug|CCI18781|ICS
353634|NCT01498640|Biological|Collagenase clostridium histolyticum|up to three 0.58 mg injections
353635|NCT01498627|Biological|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
353636|NCT01498627|Other|Data collection|PGRx information system
353637|NCT01498614|Behavioral|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
353638|NCT01498601|Other|Enhanced oral care protocol|"Changing mouth suction equipment every 24 hours~Mouth assessment every 2-4 hours~Cleansing mouth with toothbrush every 12 hours~Cleansing oral mucosa with oral rinse solution every 2-4 hours~Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~Suction mouth and throat as needed~Head of the bed elevated to a minimum of 30° during oral care"
353639|NCT01498588|Drug|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
353640|NCT01498588|Drug|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
353641|NCT01498588|Drug|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
353642|NCT01498588|Drug|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
353643|NCT01498575|Behavioral|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
353644|NCT01498562|Drug|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
353645|NCT01498562|Drug|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
353646|NCT01498549|Drug|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
353647|NCT01498549|Drug|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
353648|NCT01498536|Behavioral|aerobic exercise|3 times per week for 12-weeks
353649|NCT01498523|Other|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
353650|NCT01498523|Other|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
353651|NCT01498523|Other|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
353652|NCT01498523|Other|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
353653|NCT01498510|Behavioral|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
353654|NCT01498497|Drug|EUR-1100|
353655|NCT01498497|Drug|Placebo|
353656|NCT01498484|Biological|EBV-specific T cells|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
353657|NCT01498458|Drug|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~dose level I: 400 mg~dose level II: 600 mg~dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
353658|NCT01498445|Drug|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
353659|NCT01498445|Drug|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
353660|NCT01498445|Drug|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
353661|NCT01498432|Drug|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
353662|NCT01498432|Drug|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
353663|NCT01498419|Drug|Moxifloxacin (M)|
353664|NCT01498419|Drug|Pretomid (Pa)|
353666|NCT01498419|Drug|Rifafour|Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
353667|NCT01498406|Dietary Supplement|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
353668|NCT01498393|Device|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
353669|NCT01498380|Drug|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease < 20% or blood pressure decrease/increase < 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease >/= 20% or SBP/DBP/MAP decrease or increase >/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
353670|NCT01498367|Procedure|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
353671|NCT01498354|Procedure|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
353672|NCT01498354|Procedure|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
353673|NCT01498328|Drug|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
353674|NCT01498328|Drug|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
353675|NCT01498328|Drug|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
353676|NCT01498315|Other|Ultrasound examination|Ultrasound examination following hysterectomy
353677|NCT01498302|Other|diagnostic laboratory biomarker analysis|
353678|NCT01498302|Other|flow cytometry|
353679|NCT01498289|Drug|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, & leucovorin calcium.
353680|NCT01498289|Drug|docetaxel|30 mg/m^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
353681|NCT01498289|Drug|fluorouracil|400 mg/m^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
353682|NCT01498289|Drug|irinotecan hydrochloride|65 mg/m^2, IV over 90 minutes on Days 1 & 8 of every 21 day cycle.
353683|NCT01498289|Drug|leucovorin calcium|400 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
353684|NCT01498289|Drug|oxaliplatin|85 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
353685|NCT01498237|Device|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
353686|NCT01498237|Procedure|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
353687|NCT01498224|Device|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
353688|NCT01498224|Procedure|Sutures|
353689|NCT01498211|Procedure|Biopsy|3 mm punch biopsy of the skin at the distal leg.
353690|NCT01498198|Procedure|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
353691|NCT01498198|Other|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
353692|NCT01498185|Drug|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
353693|NCT01498185|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
353694|NCT01498172|Biological|MAGE-A3 ASCI|5 doses every 3 weeks
353695|NCT01498172|Biological|BCG|1 intravesical dose /week for 6 weeks
353696|NCT01498159|Behavioral|Pharmacist disease/medication management|
353697|NCT01498159|Behavioral|Pharmacist-patient encounters|
353698|NCT01498159|Behavioral|Pharmacist medication intensification and adherence support|
353699|NCT01498159|Behavioral|Pharmacist communication with primary care physicians|
353700|NCT01498159|Behavioral|Pharmacist documentation in electronic medical record|
353701|NCT01498159|Behavioral|Health promoter-patient encounters in-person or by phone|
353702|NCT01498159|Behavioral|Health promoter medication and lifestyle support|
353703|NCT01498159|Behavioral|Health promoter communication with pharmacists|
353780|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
353704|NCT01498133|Procedure|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
353705|NCT01498120|Drug|Rotigotine|"Optimal dose after titration period~0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)~1 patch /day"
353706|NCT01498107|Behavioral|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
353707|NCT01498094|Procedure|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
353708|NCT01498094|Other|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
353709|NCT01498081|Drug|AZD2115|AZD2115 administered via inhalation
353710|NCT01498081|Drug|Placebo|Placebo administered via inhalation
353711|NCT01498081|Drug|Indacaterol|Indacaterol administered via inhalation
353712|NCT01498081|Drug|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
353713|NCT01498068|Drug|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
353714|NCT01498068|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
353715|NCT01498068|Drug|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is < 75kg) or 1200mg (if participant's weight is >= 75kg) per day for 24 or 48 weeks.
353716|NCT01498029|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
353717|NCT01498029|Device|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
353718|NCT01498016|Drug|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
353719|NCT01498003|Drug|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
353720|NCT01498003|Drug|normal saline solution|same use as tirofiban
353721|NCT01497990|Drug|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
353722|NCT01497977|Drug|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
353723|NCT01497977|Drug|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
353724|NCT01497964|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
353725|NCT01497951|Other|Aminolaevulinic acid|Photodynamic therapy
353726|NCT01497951|Other|Methylcellulose Placebo|Methylcellulose
353727|NCT01497938|Device|Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Automatic suspension of insulin delivery when glucose is low.
353728|NCT01497938|Device|Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump|No Automatic suspension of insulin delivery when glucose is low.
353729|NCT01497925|Drug|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
353730|NCT01497912|Drug|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
353731|NCT01497912|Drug|Placebo|Placebo tablet once daily for 8 weeks
353732|NCT01497899|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
353733|NCT01497899|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
353734|NCT01497899|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
353735|NCT01497899|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
353736|NCT01497886|Behavioral|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
353737|NCT01497886|Behavioral|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
353738|NCT01497873|Drug|Topotecan|1.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
353739|NCT01497873|Drug|Belotecan|0.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
353740|NCT01497860|Drug|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
353741|NCT01497834|Drug|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
353742|NCT01497834|Drug|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
353743|NCT01497821|Drug|AMG 172|AMG 172 is an antibody drug conjugate
353744|NCT01497808|Drug|Ipilimumab|
353745|NCT01497808|Radiation|Stereotactic Body Radiation Therapy|
353868|NCT01496937|Drug|GLPG0974|
353746|NCT01497782|Other|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
353747|NCT01497769|Biological|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10^7 pfu and intradermal saline placebo
353748|NCT01497769|Biological|Intradermal MVA85A|Intradermal MVA85A 1 x 10^7 pfu and inhaled aerosol saline placebo
353749|NCT01497756|Device|CAPP use|Any abdominal pelvic pressure
353750|NCT01497743|Drug|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
353751|NCT01497730|Device|Total Knee Replacement|"Subjects will receive one of the following total knee implants:~PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
353752|NCT01497717|Drug|Adalimumab (Humira)|"Open label pilot trial.~The study includes 3 phases :~Open label treatment period of 24 weeks.~Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.~Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
353753|NCT01497704|Drug|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
353754|NCT01497691|Device|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
353755|NCT01497691|Device|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
353756|NCT01497691|Device|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
353757|NCT01497678|Device|Extracellular Matrix|Extracellular Matrix
353758|NCT01497665|Drug|GRN1005|650 mg/m2 IV every 3 weeks
353759|NCT01497652|Drug|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
353760|NCT01497652|Drug|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
353761|NCT01497639|Device|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
353762|NCT01497639|Device|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
353763|NCT01497626|Drug|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
353764|NCT01497613|Behavioral|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
353765|NCT01497613|Behavioral|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
353766|NCT01497600|Drug|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
353767|NCT01497600|Drug|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
353768|NCT01497587|Drug|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
353769|NCT01497574|Drug|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
353770|NCT01497574|Drug|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
353771|NCT01497561|Drug|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
353772|NCT01497561|Drug|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
353773|NCT01497548|Drug|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
353774|NCT01497548|Drug|Placebo|Placebo given on morning (0800) and noon (1200)daily
353775|NCT01497535|Drug|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
353776|NCT01497535|Drug|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
353777|NCT01497522|Drug|Vildagliptin|vildagliptin 50 mg twice daily
353778|NCT01497522|Drug|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
353779|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
354059|NCT01495338|Drug|AC-170 0.17%|1 drop in one eye at one timepoint
353781|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
353782|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
353783|NCT01497509|Drug|No epidural fentanyl or bupivacaine|
353784|NCT01497496|Drug|High Dose Methylprednisolone (HDMP)|1000 mg/m^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
353785|NCT01497496|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
353786|NCT01497496|Drug|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
353787|NCT01497483|Drug|Pravastatin alone|Pravastatin 40 mg with placebo.
353788|NCT01497483|Drug|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
353789|NCT01497470|Drug|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
353790|NCT01497457|Procedure|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
353791|NCT01497444|Drug|hypoxia-activated prodrug TH-302|
353792|NCT01497444|Drug|sorafenib tosylate|
353793|NCT01497431|Dietary Supplement|Selenium|Given PO
353794|NCT01497431|Other|Placebo|Given PO
353795|NCT01497431|Other|Laboratory Biomarker Analysis|Correlative studies
353796|NCT01497431|Other|Pharmacological Study|Correlative studies
353797|NCT01497431|Drug|Methylselenocysteine|Given PO
353798|NCT01497405|Behavioral|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
353799|NCT01497405|Biological|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
353800|NCT01497392|Drug|dovitinib lactate|Given PO
353801|NCT01497392|Drug|gemcitabine hydrochloride|Given IV
353802|NCT01497392|Drug|capecitabine|Given PO
353803|NCT01497392|Other|laboratory biomarker analysis|Correlative studies
353804|NCT01497392|Other|enzyme-linked immunosorbent assay|Correlative studies
353805|NCT01497392|Other|pharmacological study|Correlative studies
353806|NCT01497379|Procedure|surgical implantation of subretinal device|surgical implantation of subretinal device
353807|NCT01497379|Procedure|surgical implantation of subretinal device|intra-individual implant OFF
353808|NCT01497366|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
353809|NCT01497366|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
353810|NCT01497366|Drug|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~Dose of sofosbuvir+RBV group based on baseline weight: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg~Dose of PEG+RBV group: 800 mg"
353811|NCT01497353|Procedure|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
353812|NCT01497353|Procedure|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
353813|NCT01497340|Other|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
353814|NCT01497340|Other|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
353815|NCT01497327|Drug|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
353816|NCT01497327|Drug|PSI-7977|PSI-7977 400mg QD for seven days
353817|NCT01497314|Other|Low Lactose Infant Formula|Low Lactose Infant Formula
353818|NCT01497301|Behavioral|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
353819|NCT01497288|Drug|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
353820|NCT01497275|Drug|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
353821|NCT01497262|Drug|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
353822|NCT01497249|Dietary Supplement|A dietary fiber (FCHO)|15 g twice per day in beverage
353823|NCT01497249|Dietary Supplement|Placebo|Placebo drink
353824|NCT01497236|Dietary Supplement|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either~a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients~a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake~a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
353825|NCT01497223|Drug|MGCD290|1 Oral Dose Administration
353826|NCT01497210|Device|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
353827|NCT01497197|Drug|GONAL-f®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen.
353828|NCT01497197|Drug|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
353829|NCT01497197|Biological|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
353830|NCT01497184|Procedure|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
353831|NCT01497184|Genetic|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
353832|NCT01497171|Procedure|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
353833|NCT01497171|Procedure|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
353834|NCT01497158|Other|Self-help brochure|Self help brochure given at baseline visit.
353835|NCT01497158|Other|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
353836|NCT01497145|Drug|KRN321|
353837|NCT01497132|Drug|Vitamin D3|Oral drops 30000 IU weekly
353838|NCT01497132|Drug|Placebo|Matching placebo
353839|NCT01497119|Drug|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
353840|NCT01497119|Drug|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
353841|NCT01497119|Drug|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
353842|NCT01497106|Behavioral|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
353843|NCT01497106|Behavioral|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
353844|NCT01497093|Drug|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
353845|NCT01497093|Drug|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
353846|NCT01497093|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
353847|NCT01497067|Device|ACRYSOF CACHET Phakic Lens (L-series)|Intraocular lens for the treatment of moderate to high myopia
353848|NCT01497041|Drug|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
353849|NCT01497041|Drug|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
353850|NCT01497028|Procedure|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
353851|NCT01497015|Behavioral|memory training|10 1-hour sessions over 6-8 weeks
353852|NCT01497015|Behavioral|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
353853|NCT01497015|Behavioral|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
353854|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
353855|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (2 courses): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8.
353856|NCT01497002|Biological|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
353857|NCT01496989|Biological|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
353858|NCT01496989|Biological|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
353859|NCT01496989|Biological|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
353860|NCT01496989|Biological|Ad35-GRIN/ENV|(2x10^10vp) Delivered intramuscularly by standard needle injection
353861|NCT01496976|Drug|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
353862|NCT01496976|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
353863|NCT01496976|Drug|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
353864|NCT01496963|Other|Physician standard-of-care according to ESC/ERS Guidelines|Physician standard-of-care
353865|NCT01496950|Device|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
353866|NCT01496950|Device|Placebo|10Hz placebo rTMS delivered to the vertex
353867|NCT01496937|Drug|GLPG0974|
353869|NCT01496924|Other|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
353870|NCT01496911|Drug|Levocetirizine|a single oral dose of 5 mg
353871|NCT01496911|Drug|Hydroxyzine|a single oral dose of 50 mg
353872|NCT01496911|Drug|Placebo|a single oral dose
353873|NCT01496859|Device|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
353874|NCT01496846|Drug|IANB Articaine|IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
353875|NCT01496846|Drug|SUP Articaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
353876|NCT01496846|Drug|SUP Lidocaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
353877|NCT01496833|Device|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
353878|NCT01496820|Dietary Supplement|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
353879|NCT01496820|Dietary Supplement|Placebo|placebo 1500mg/day for 12weeks
353880|NCT01496807|Drug|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
353881|NCT01496807|Drug|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
353882|NCT01496781|Procedure|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
353883|NCT01496781|Procedure|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
353884|NCT01496768|Dietary Supplement|Leucine|7,2 g/day during 3 months
353885|NCT01496768|Dietary Supplement|Alanine|7,2 g/day during 3 months
353886|NCT01496755|Drug|Placebo|Single/multiple doses
353887|NCT01496755|Drug|RG7667|Single/multiple ascending doses
353888|NCT01496742|Drug|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
353889|NCT01496742|Drug|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
353890|NCT01496742|Drug|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
353891|NCT01496742|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
353892|NCT01496742|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
353893|NCT01496742|Drug|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
353894|NCT01496729|Procedure|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
353895|NCT01496729|Procedure|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
353896|NCT01496716|Procedure|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
353897|NCT01496703|Other|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
353898|NCT01496690|Drug|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
353899|NCT01496690|Drug|Pregabalin Placebo Capsules|Parallel to Active Comparator
353900|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
353901|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
353902|NCT01496664|Procedure|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
353903|NCT01496651|Procedure|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.~There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
353904|NCT01496651|Procedure|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
353905|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
353906|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
353907|NCT01496612|Drug|Buspirone|
353908|NCT01496573|Other|laboratory biomarker analysis|Correlative studies
353909|NCT01496547|Drug|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
353910|NCT01496534|Drug|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
353911|NCT01496534|Drug|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
353912|NCT01496521|Drug|Aspirin|100mg qd for 6 months.
353913|NCT01496521|Dietary Supplement|Tea Polyphenols|300mg bid for 6 months.
353914|NCT01496508|Device|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
353915|NCT01496495|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
353916|NCT01496482|Other|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
353917|NCT01496469|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
353918|NCT01496469|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
353919|NCT01496456|Device|Resin infiltration|Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
353920|NCT01496456|Behavioral|Caries management|Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
353921|NCT01496443|Drug|TAK-875 and Glimepiride|
353922|NCT01496430|Drug|Placebo|
353923|NCT01496430|Drug|Azilsartan medoxomil|
353924|NCT01496430|Drug|Azilsartan medoxomil|
353925|NCT01496417|Drug|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
353926|NCT01496404|Procedure|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
353927|NCT01496404|Procedure|Scalpel|Incising skin (epidermis and dermis) with scalpel.
353928|NCT01496378|Behavioral|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
353929|NCT01496365|Drug|DS-5565 tablet|5mg and 10mg tablets
353930|NCT01496365|Drug|pregabalin capsule|75mg and 150mg over-encapsulated
353931|NCT01496365|Drug|Placebo tablet|
353932|NCT01496365|Drug|placebo capsule|
353933|NCT01496352|Drug|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
353934|NCT01496352|Drug|Placebo|DFA-02 placebo
353935|NCT01496339|Biological|MenSCs transplantation|1×10^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
353936|NCT01496339|Drug|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
353937|NCT01496326|Drug|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
353938|NCT01496326|Drug|placebo|2 grams of placebo cream for 14 days
353939|NCT01496313|Drug|300mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment~Dosing with unblinded study treatment can continue until 24 months after patient was randomised.~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
353940|NCT01496313|Drug|150mg vandetanib|"Oral blinded tablets taken once daily.~At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg~Dosing with unblinded study treatment can continue until 24 months after patient was randomised~At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) [OR 300 reduced to 200mg/day if dose was increased at unblinding.] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
353941|NCT01496300|Procedure|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
353942|NCT01496300|Procedure|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
353943|NCT01496287|Device|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
353944|NCT01496274|Biological|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
353945|NCT01496261|Drug|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
353946|NCT01496261|Drug|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
353947|NCT01496248|Dietary Supplement|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
354060|NCT01495338|Drug|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
353948|NCT01496235|Dietary Supplement|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
353949|NCT01496235|Dietary Supplement|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
353950|NCT01496209|Biological|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
353951|NCT01496209|Biological|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
353952|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
353953|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
353954|NCT01496183|Drug|Olanzapine|Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
353955|NCT01496183|Drug|Placebo|Placebo capsule administered orally at bedtime for 14 days
353956|NCT01496170|Drug|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
353957|NCT01496170|Drug|Placebo|Placebo capsules, orally, once per day for 7 days
353958|NCT01496157|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) [9-11 mCi (333-407 MBq)] of 18F-DCFBC will be injected into the IV line by slow IV push.
353959|NCT01496144|Procedure|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
353960|NCT01496144|Procedure|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
353961|NCT01496131|Radiation|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
353962|NCT01496131|Drug|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
353963|NCT01496131|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
353964|NCT01496131|Drug|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
353965|NCT01496118|Drug|carfilzomib and panobinostat|"Cohort 1 (Dose Level 4): Carfilzomib Cycle 1: 20 mg/m2 IV D1, 2 / 45 mg/m2 IV D8, 9, 15, 16; Carfilzomib Cycle 2 to progression: 45 mg/m2 IV D 1, 2, 8, 9, 15, 16;~Panobinostat cycle 1: 30 mg D 1, 3, 5, 15, 17, 19; Panobinostat cycle 2 to progression: 30 mg D 1, 3, 5, 15, 17, 19~Cohort 2 (Dose Level 6): Carfilzomib Cycle 1: 20 mg/m2 IV D1, 2 / 56 mg/m2 IV D8, 9, 15, 16; Carfilzomib Cycle 2: 56 mg/m2 IV D 1, 2, 8, 9, 15, 16;~Panobinostat all cycles: 20 mg D 1, 3, 5, 15, 17, 19."
353966|NCT01496105|Drug|Lidocaine|
353967|NCT01496105|Drug|saline|
353968|NCT01496092|Drug|Keto Acid|12 tablets per day
353969|NCT01496066|Device|LAL (Light Adjustable Lens) and Light Deliver Device (LDD)|LAL implanted and adjusted with LDD
353970|NCT01496066|Device|Monofocal control IOL|Commercially available monofocal intraocular lens (IOL)
353971|NCT01496053|Dietary Supplement|AndoSan|AndoSan 30 ml x 2 for 21 days
353972|NCT01496053|Dietary Supplement|Sugar Extract|Sham comparator
353973|NCT01496040|Drug|rAAV2/4.hRPE65|"One injection in on eye~Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP~Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.~Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
353974|NCT01496001|Procedure|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
353975|NCT01496001|Other|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
353976|NCT01495988|Drug|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
353977|NCT01495988|Drug|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
353978|NCT01495988|Drug|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
353979|NCT01495975|Other|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
353980|NCT01495962|Drug|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
353981|NCT01495962|Drug|Placebo|Placebo (Normal Saline)
353982|NCT01495949|Drug|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
353983|NCT01495949|Drug|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
353984|NCT01495936|Procedure|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
354061|NCT01495338|Drug|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
353985|NCT01495936|Procedure|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
353986|NCT01495923|Procedure|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
353987|NCT01495923|Procedure|Sham epidural steroid injection|Injection of saline into the back muscles
353988|NCT01495923|Drug|Gabapentin|Titration of gabapentin to effect
353989|NCT01495923|Drug|Placebo gabapentin|Titration of placebo gabapentin
353990|NCT01495910|Drug|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
353991|NCT01495897|Device|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
353992|NCT01495897|Device|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
353993|NCT01495884|Drug|non-pegylated liposomal doxorubicon (Myocet™)|
353994|NCT01495884|Drug|Lapatinib (Tyverb™)|
353995|NCT01495871|Dietary Supplement|Amino Acids|15 grams amino acids two times per day for 6 weeks
353996|NCT01495871|Dietary Supplement|Placebo of inert compounds|Placebo two times per day for 6 weeks
353997|NCT01495871|Dietary Supplement|Valine|2.5 grams valine supplementation two times a day for 6 weeks
353998|NCT01495858|Drug|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
353999|NCT01495858|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
354000|NCT01495858|Drug|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
354001|NCT01495845|Other|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
354002|NCT01495832|Other|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
354003|NCT01495832|Other|Control Group|The control group will consume comparator foods for 12 weeks.
354004|NCT01495819|Drug|Saline|5cc's of saline give at least once.
354005|NCT01495819|Drug|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
354006|NCT01495806|Drug|Glucomannan|2 x 5g
354007|NCT01495806|Drug|placebo|glucose 5 g
354008|NCT01495793|Drug|Rotigotine|"Rotigotine transdermal patch:~Dose (size): 0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
354009|NCT01495780|Behavioral|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
354010|NCT01495767|Other|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
354011|NCT01495754|Other|coffee|Comparison of different amounts of coffee
354012|NCT01495728|Procedure|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
354013|NCT01495728|Procedure|Sham Manipulation|Mid and Upper Thoracic Spine
354014|NCT01495715|Drug|Idebenone|
354015|NCT01495715|Drug|Placebo|
354016|NCT01495702|Drug|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
354017|NCT01495702|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
354018|NCT01495702|Drug|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
354019|NCT01495689|Behavioral|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
354020|NCT01495689|Behavioral|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
354062|NCT01495338|Drug|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
354063|NCT01495325|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
354021|NCT01495676|Other|Radiation + cisplatin|"RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.~A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.~In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.~In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study."
354022|NCT01495676|Other|Radiation + cisplatin + gemcitabine|"Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.~Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.~Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection."
354023|NCT01495663|Drug|I-131-CLR1404|"Description:~Dosimetry: IV, 5 mCi, single dose, 6-day duration~Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
354024|NCT01495650|Behavioral|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
354025|NCT01495637|Drug|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
354026|NCT01495624|Other|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
354027|NCT01495624|Other|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
354028|NCT01495598|Drug|Pomalidomide|5 mg p.o. for 21 of 28 days
354029|NCT01495585|Drug|Lonafarnib|Commercially approved products used to test the research hypothesis
354030|NCT01495585|Other|Placebo|Placebo control
354031|NCT01495572|Drug|Fludarabine|25 mg/m^2 IV (in the vein) for 5 days (day -5 to -1)
354032|NCT01495572|Drug|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
354033|NCT01495572|Drug|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
354034|NCT01495572|Drug|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
354035|NCT01495546|Other|Early loading|Patients stepping down immediately after THA
354036|NCT01495546|Other|Late loading|Patients stepping down after three weeks of HTA
354037|NCT01495533|Device|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
354038|NCT01495533|Device|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
354039|NCT01495520|Drug|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
354040|NCT01495520|Drug|Placebo|os, pill, b.i.d., 30 days
354041|NCT01495507|Procedure|MPFL- Reconstruction|
354042|NCT01495494|Device|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
354043|NCT01495494|Device|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
354044|NCT01495481|Drug|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
354045|NCT01495481|Drug|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
354046|NCT01495468|Biological|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
354047|NCT01495442|Device|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
354048|NCT01495442|Device|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
354049|NCT01495429|Procedure|Central venous catheter|Placement of a peripherally inserted central venous catheter
354050|NCT01495429|Procedure|Central venous catheter|Placement of a centrally inserted central venous catheter
354051|NCT01495403|Drug|Hydroxychloroquine|daily dosing
354052|NCT01495377|Drug|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
354053|NCT01495377|Drug|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
354054|NCT01495377|Drug|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
354055|NCT01495377|Device|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
354056|NCT01495364|Biological|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
354057|NCT01495364|Other|placebo|matching placebo
354058|NCT01495351|Drug|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
354064|NCT01495325|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
354065|NCT01495312|Device|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
354066|NCT01495299|Device|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
354067|NCT01495286|Device|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
354068|NCT01495273|Procedure|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
354069|NCT01495273|Procedure|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
354070|NCT01495260|Drug|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
354071|NCT01495260|Drug|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
354072|NCT01495260|Drug|vitamin E|vitamin E, 150-300 mg daily for 2 months
354073|NCT01495247|Drug|BEZ235 + Paclitaxel|"Doses of oral BEZ235 (BID), supplied as 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.~The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.~BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts."
354074|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
354075|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
354076|NCT01495221|Drug|Alfilbercept|All patients will receive 2.0 mg intravitreal aflibercept injection.
354077|NCT01495208|Drug|Aflibercept|intravitreal aflibercept injection 2mg
354078|NCT01495195|Drug|High-dose donepezil|Donepezil titrated to 22.5 mg daily
354079|NCT01495195|Drug|Low-dose donepezil|Donepezil titrated to 10 mg daily
354080|NCT01495195|Drug|Selegiline|Transdermal selegiline, 6 mg daily
354081|NCT01495195|Drug|Placebo|microcrystalline cellulose
354082|NCT01495182|Other|Dietary fiber|A proprietary fiber will be given to subjects
354083|NCT01495169|Drug|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
354084|NCT01495156|Drug|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
354085|NCT01495156|Drug|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
354086|NCT01495143|Procedure|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
354087|NCT01495130|Procedure|ultrasound imaging|Undergo transrectal ultrasound
354088|NCT01495130|Procedure|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
354089|NCT01495117|Drug|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
354090|NCT01495117|Drug|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
354091|NCT01495104|Drug|RO4917838|Multiple doses
354092|NCT01495104|Drug|valproate|Multiple doses
354093|NCT01495078|Procedure|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.~Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
354094|NCT01495065|Drug|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
354095|NCT01495065|Drug|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
354096|NCT01495065|Drug|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
354097|NCT01495065|Drug|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
354098|NCT01495065|Drug|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
354190|NCT01494532|Drug|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
354099|NCT01495065|Drug|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
354100|NCT01495052|Dietary Supplement|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
354101|NCT01495039|Drug|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
354102|NCT01495026|Drug|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
354103|NCT01495026|Drug|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
354104|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
354105|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
354106|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
354107|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
354108|NCT01495026|Drug|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
354109|NCT01495026|Drug|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
354110|NCT01495026|Drug|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
354111|NCT01495013|Drug|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
354112|NCT01495013|Drug|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
354113|NCT01495013|Drug|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
354114|NCT01495013|Drug|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
354115|NCT01495013|Drug|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
354116|NCT01495013|Drug|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
354117|NCT01495013|Drug|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
354118|NCT01495013|Drug|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
354119|NCT01495013|Drug|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
354120|NCT01495013|Drug|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
354121|NCT01495013|Drug|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
354122|NCT01495013|Drug|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
354123|NCT01495013|Drug|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
354124|NCT01495013|Drug|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
354125|NCT01495000|Drug|denosumab|60mg subcutaneous injection, single dose
354126|NCT01495000|Drug|placebo|placebo subcutaneous injection, single dose
354127|NCT01494987|Drug|Ranolazine|Ranolazine tablet(s) administered orally
354128|NCT01494987|Drug|Placebo|Placebo to match ranolazine for the duration of the study
354129|NCT01494987|Drug|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
354130|NCT01494987|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
354131|NCT01494987|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
354132|NCT01494974|Device|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
354133|NCT01494974|Device|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
354134|NCT01494961|Behavioral|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
354135|NCT01494948|Other|allergen challenge|nasal challenges with antigen to which they are sensitive to
354136|NCT01494935|Behavioral|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
354137|NCT01494935|Behavioral|Control diet|Normal fat, normal fat diet
354138|NCT01494922|Drug|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
354139|NCT01494909|Dietary Supplement|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
354140|NCT01494883|Behavioral|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
354141|NCT01494870|Procedure|PCI|urgent PCI on admission
354142|NCT01494857|Drug|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
354143|NCT01494844|Device|Respiratory monitor patient interface.|Wear each interface for 20 minutes
354144|NCT01494831|Behavioral|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
354145|NCT01494818|Device|Hydrogen peroxide-based contact lens care system|
354146|NCT01494818|Device|PHMB-containing contact lens solution|
354147|NCT01494818|Device|Soft contact lenses|Contact lenses identical to habitual prescription worn per usual replacement regimen
354191|NCT01494532|Drug|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
354148|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
354149|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
354150|NCT01494805|Other|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
354151|NCT01494792|Device|In Vitro Diagnositc aid for diagnosis|
354152|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
354153|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
354154|NCT01494766|Dietary Supplement|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
354155|NCT01494753|Drug|T2345|One drop at 8.00pm.
354156|NCT01494753|Drug|Prostaglandin|One drop at 8.00pm.
354157|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
354158|NCT01494740|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
354159|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
354160|NCT01494727|Drug|CJ Amlodipine/Valsartan 10/160mg|single dose
354161|NCT01494727|Drug|Novartis Exforge 10/160mg|single dose
354162|NCT01494714|Drug|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
354163|NCT01494714|Drug|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
354164|NCT01494714|Drug|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
354165|NCT01494714|Drug|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
354166|NCT01494714|Drug|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
354167|NCT01494701|Drug|nusinersen|Administered by intrathecal (IT) injection
354168|NCT01494688|Drug|Paclitaxel|Paclitaxel, at a dose of 80 mg/m^2 will be administered QW for up to 12 weeks.
354169|NCT01494688|Drug|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
354170|NCT01494675|Other|procalcitonin measurement|"The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.~The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as  antibiotic discontinuation overruling"
354171|NCT01494662|Drug|HKI-272|240 mg orally, once daily
354172|NCT01494662|Procedure|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
354173|NCT01494662|Drug|Capecitabine|750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
354174|NCT01494662|Drug|HKI-272|160 mg orally, once daily
354175|NCT01494662|Drug|Ado-Trastuzumab Emtansine|3.6 mg/kg IV every 3 weeks
354176|NCT01494649|Drug|Test Toothpaste|0.454% stannous fluoride toothpaste
354177|NCT01494649|Drug|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
354178|NCT01494636|Drug|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
354179|NCT01494636|Drug|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
354180|NCT01494636|Drug|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
354181|NCT01494636|Drug|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
354182|NCT01494623|Device|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
354183|NCT01494610|Drug|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
354184|NCT01494610|Drug|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
354185|NCT01494597|Drug|isavuconazole|oral
354186|NCT01494597|Drug|cyclosporine|oral
354187|NCT01494584|Drug|ezogabine/retigabine|ezogabine dose escalation
354188|NCT01494558|Other|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
354189|NCT01494545|Device|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
354192|NCT01494519|Procedure|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
354193|NCT01494519|Procedure|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.~Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
354194|NCT01494506|Drug|MM-398|"Arm A: MM-398 120 mg/m2 IV Q3W~Arm C: MM-398 80mg/m2 IV Q2W"
354195|NCT01494506|Drug|5 Fluorouracil|"Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks"
354196|NCT01494506|Drug|Leucovorin|"Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks~Arm C: Leucovorin 400 mg/m2 IV every 2 weeks"
354197|NCT01494493|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
354198|NCT01494493|Procedure|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
354199|NCT01494480|Procedure|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
354200|NCT01494467|Drug|CD5024|CD5024 1% Cream, once daily
354201|NCT01494467|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
354202|NCT01494454|Device|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
354203|NCT01494454|Device|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
354204|NCT01494441|Procedure|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
354205|NCT01494441|Device|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
354206|NCT01494441|Device|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
354207|NCT01494428|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
354208|NCT01494428|Device|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
354209|NCT01494415|Drug|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
354210|NCT01494415|Drug|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
354211|NCT01494415|Radiation|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
354212|NCT01494402|Drug|D961S|Oral gelatine capsule
354213|NCT01494402|Drug|Esomeprazole|Oral HPMC capsule
354214|NCT01494402|Drug|Buffered acetylsalicylic acid|Tablet
354215|NCT01494363|Drug|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
354216|NCT01494363|Drug|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
354217|NCT01494363|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
354218|NCT01494363|Drug|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
354219|NCT01494350|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
354220|NCT01494337|Procedure|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
354221|NCT01494337|Procedure|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
354222|NCT01494324|Other|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
354223|NCT01494311|Drug|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
354224|NCT01494311|Drug|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
354225|NCT01494311|Drug|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
354226|NCT01494311|Drug|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
354227|NCT01494285|Drug|ARK-E021 5%|Topically applied once daily at bedtime
354228|NCT01494285|Drug|ARK-E021 10%|Topically applied once daily at bedtime
354229|NCT01494285|Drug|Placebo|Topically applied once daily at bedtime
354230|NCT01494259|Drug|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
354231|NCT01494259|Drug|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
354232|NCT01494246|Other|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
354233|NCT01494233|Drug|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
354234|NCT01494233|Drug|Placebo tablet|Matching placebo tablet administered orally
354235|NCT01494220|Device|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
354236|NCT01494207|Behavioral|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
354237|NCT01494194|Other|Air Structuring Protein|A novel food protein preparation
354238|NCT01494194|Other|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
354239|NCT01494168|Procedure|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
354240|NCT01494155|Drug|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
354241|NCT01494155|Drug|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
354242|NCT01494155|Radiation|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
354243|NCT01494116|Other|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
354244|NCT01494103|Biological|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
354245|NCT01494103|Drug|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
354246|NCT01494090|Drug|Rosuvastatin|5 or 20 mg per day during 6 months
354247|NCT01494090|Drug|Placebo|5 or 20 mg per day during 6 months
354248|NCT01494077|Other|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
354249|NCT01494051|Behavioral|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
354250|NCT01494038|Drug|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
354251|NCT01494038|Drug|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
354252|NCT01494025|Behavioral|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
354253|NCT01494012|Radiation|stereotactic body radiation therapy|Undergo SBRT
354254|NCT01494012|Procedure|positron emission tomography|Undergo FDG-PET/CT
354255|NCT01494012|Procedure|computed tomography|Undergo FDG-PET/CT
354256|NCT01494012|Other|questionnaire administration|Ancillary studies
354257|NCT01494012|Drug|fludeoxyglucose F 18|Undergo FDG-PET/CT
354258|NCT01493999|Drug|Clopidogrel reloading|Up to three times 600 mg clopidogrel
354259|NCT01493999|Drug|Prasugrel|60 mg prasugrel in patients with HPR
354260|NCT01493986|Drug|Ropivacaine|Dosage. Onset time
354261|NCT01493973|Drug|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
354262|NCT01493973|Drug|Placebo|Placebo
354263|NCT01493960|Drug|Cobitolimod|30 mg rectal dose at week 0 and 4
354264|NCT01493960|Drug|Placebo|Rectal dose at week 0 and 4
354265|NCT01493947|Drug|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
354266|NCT01493947|Drug|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
354267|NCT01493934|Drug|injection of 6-DIG|Unique injection dose of 92.5 MBq
354313|NCT01493661|Other|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
354268|NCT01493921|Drug|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
354269|NCT01493921|Drug|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
354270|NCT01493908|Drug|High price|Acetaminophen label as high price
354271|NCT01493908|Drug|Low price|Acetaminophen label as low price
354272|NCT01493908|Drug|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
354273|NCT01493908|Drug|No price|acetaminophen. No price - price issue not introduced to participants.
354274|NCT01493908|Drug|Free of charge|Acetaminophen. participants aware the product is free of charge
354275|NCT01493895|Device|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
354276|NCT01493895|Device|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.~All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.~Every treatment will consist of the following steps:~A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.~Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.~The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
354277|NCT01493882|Drug|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
354278|NCT01493882|Drug|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
354279|NCT01493882|Drug|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
354280|NCT01493882|Drug|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
354281|NCT01493869|Drug|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
354282|NCT01493856|Drug|Cresto|tablet, rosuvastatin 20mg
354283|NCT01493856|Drug|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
354284|NCT01493856|Drug|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
354285|NCT01493843|Drug|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
354286|NCT01493843|Drug|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
354287|NCT01493843|Drug|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
354288|NCT01493843|Drug|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
354289|NCT01493843|Drug|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
354290|NCT01493830|Genetic|fluorescence in situ hybridization|
354291|NCT01493830|Genetic|gene expression analysis|
354292|NCT01493830|Genetic|microarray analysis|
354293|NCT01493830|Genetic|mutation analysis|
354294|NCT01493830|Genetic|protein analysis|
354295|NCT01493830|Other|immunohistochemistry staining method|
354296|NCT01493830|Other|laboratory biomarker analysis|
354297|NCT01493830|Other|microscopy|
354298|NCT01493817|Other|laboratory biomarker analysis|Correlative studies
354299|NCT01493791|Drug|CDB-2914|
354300|NCT01493778|Drug|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
354301|NCT01493765|Other|Simulator training with expert scoring|Residents will be trained using surgical simulation
354302|NCT01493752|Dietary Supplement|beetroot juice|250mls daily beetroot juice
354303|NCT01493726|Drug|ALKS 9072, Low dose|IM injection, given monthly
354304|NCT01493726|Drug|ALKS 9072, Med dose|IM injection, given monthly
354305|NCT01493726|Drug|ALKS 9072, High dose|IM injection, given monthly
354306|NCT01493726|Drug|Placebo|Dosed matched placebo IM injection, given monthly
354307|NCT01493713|Other|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
354308|NCT01493700|Procedure|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
354309|NCT01493700|Procedure|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
354310|NCT01493687|Drug|CD5024|CD5024 1% Cream, once daily
354311|NCT01493687|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
354312|NCT01493674|Dietary Supplement|folic acid|two 5-mg tablets of folic acid
354314|NCT01493648|Drug|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
354315|NCT01493648|Drug|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
354316|NCT01493635|Other|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
354317|NCT01493635|Other|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
354318|NCT01493622|Drug|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
354319|NCT01493622|Drug|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
354320|NCT01493609|Behavioral|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
354321|NCT01493596|Drug|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
354322|NCT01493596|Drug|Placebo|An equal volume of water mixed with juice will be administered.
354323|NCT01493570|Drug|BI 409306|High dose film-coated tablet
354324|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
354325|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
354326|NCT01493570|Drug|BI 409306 Placebo|Film-coated tablet
354327|NCT01493570|Drug|BI 409306|Medium dose film-coated tablet
354328|NCT01493557|Drug|pantoprazole|40 mg q.a.m, p.o.
354329|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
354330|NCT01493557|Drug|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
354331|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
354332|NCT01493531|Drug|Lesinurad|Tablets, 200 mg QD
354333|NCT01493531|Drug|Lesinurad|Tablets, 400 mg QD
354334|NCT01493531|Drug|Placebo|Tablets, Placebo QD
354335|NCT01493531|Drug|Allopurinol|Tablets
354336|NCT01493518|Drug|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
354337|NCT01493505|Drug|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
354338|NCT01493505|Drug|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
354339|NCT01493505|Drug|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
354340|NCT01493505|Drug|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
354341|NCT01493479|Drug|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
354342|NCT01493479|Drug|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.~In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to <= 20% to enter the main treatment phase of the trial."
354343|NCT01493453|Genetic|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
354344|NCT01493440|Drug|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
354345|NCT01493427|Drug|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
354346|NCT01493414|Drug|INC424|All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.
354347|NCT01493401|Procedure|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
354348|NCT01493388|Drug|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
354349|NCT01493336|Drug|capecitabine RTD|single oral dose
354350|NCT01493336|Drug|capecitabine [Xeloda]|single oral dose
354351|NCT01493336|Drug|capecitabine [Xeloda]|standard treatment
354352|NCT01493323|Behavioral|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
354353|NCT01493323|Behavioral|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
354354|NCT01493323|Behavioral|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
354355|NCT01493323|Procedure|Cyber ball game|functional neuroimaging
354356|NCT01493323|Procedure|Iowa Gambling Task|functional neuroimaging
354357|NCT01493323|Procedure|Microcomputer|functional neuroimaging
354358|NCT01493323|Procedure|blood sample|blood sample
354359|NCT01493310|Drug|mifepristone|"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
354360|NCT01493310|Drug|placebo|Given orally
354361|NCT01493310|Drug|nab-paclitaxel|"Given by intravenous infusion (IV)~Dose of 80 mg/m2"
354362|NCT01493297|Other|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
354363|NCT01493284|Device|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
354364|NCT01493271|Drug|Placebo|Placebo to RO5093151
354365|NCT01493271|Drug|RO5093151|oral doses twice daily for up to 28 days
354397|NCT01492959|Drug|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
354398|NCT01492920|Dietary Supplement|Acetyl-L-Carnitine Hydrochloride|Given orally
354399|NCT01492920|Other|Placebo|Given orally
354400|NCT01492920|Other|Questionnaire Administration|Ancillary studies
354401|NCT01492920|Other|Quality-of-Life Assessment|Ancillary studies
354366|NCT01493258|Other|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
354367|NCT01493245|Drug|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
354368|NCT01493232|Other|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
354369|NCT01493206|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
354370|NCT01493193|Other|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
354371|NCT01493193|Other|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
354372|NCT01493193|Other|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
354373|NCT01493180|Drug|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension 2%
354374|NCT01493180|Drug|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution 0.1%
354375|NCT01493167|Other|limb casting/splinting|ankle and arm cast
354376|NCT01493154|Biological|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
354377|NCT01493154|Drug|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
354378|NCT01493115|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
354379|NCT01493115|Drug|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
354380|NCT01493102|Drug|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
354381|NCT01493102|Drug|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
354382|NCT01493089|Drug|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
354383|NCT01493089|Drug|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
354384|NCT01493076|Device|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
354385|NCT01493063|Other|Physiopathology|Samples of breastmilk and infant serum
354386|NCT01493050|Drug|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
354387|NCT01493050|Drug|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
354388|NCT01493037|Device|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
354389|NCT01493024|Drug|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times daily (tid) with meals.
354390|NCT01493024|Drug|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
354391|NCT01493011|Device|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
354392|NCT01492998|Other|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
354393|NCT01492985|Biological|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
354394|NCT01492985|Biological|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
354395|NCT01492972|Radiation|Radiation|"Consists of:~Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))~High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)~Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
354396|NCT01492972|Drug|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
354402|NCT01492907|Radiation|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
354403|NCT01492907|Procedure|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
354404|NCT01492894|Drug|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
354405|NCT01492894|Drug|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
354406|NCT01492881|Drug|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
354407|NCT01492881|Drug|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
354408|NCT01492881|Drug|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
354409|NCT01492855|Procedure|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
354410|NCT01492855|Behavioral|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
354411|NCT01492829|Behavioral|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
354412|NCT01492816|Behavioral|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
354413|NCT01492803|Dietary Supplement|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
354414|NCT01492803|Dietary Supplement|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
354415|NCT01492790|Procedure|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
354416|NCT01492790|Procedure|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
354417|NCT01492751|Behavioral|Quality of life assessment and Clinical evaluation|"quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.~Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment."
354418|NCT01492751|Procedure|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
354419|NCT01492751|Radiation|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
354420|NCT01492751|Radiation|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
354421|NCT01492738|Procedure|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
354571|NCT01491503|Drug|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
354422|NCT01492725|Device|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
354423|NCT01492725|Genetic|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
354424|NCT01492712|Drug|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
354425|NCT01492712|Drug|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
354426|NCT01492699|Drug|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
354427|NCT01492686|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
354428|NCT01492686|Drug|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
354429|NCT01492686|Drug|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
354430|NCT01492673|Drug|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
354431|NCT01492660|Device|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
354432|NCT01492660|Device|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
354433|NCT01492647|Drug|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
354434|NCT01492647|Drug|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
354435|NCT01492647|Drug|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
354436|NCT01492634|Other|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).~The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.~Prescription steps will be calculated weekly for all study patients. TAFO < -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO > 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
354437|NCT01492621|Drug|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
354438|NCT01492608|Drug|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
354439|NCT01492582|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
354440|NCT01492582|Other|laboratory biomarker analysis|Correlative studies
354441|NCT01492582|Other|survey administration|Ancillary studies
354442|NCT01492582|Other|medical chart review|Ancillary studies
354443|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS at sham point
354444|NCT01492569|Other|questionnaire administration|Ancillary studies
354445|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS
354446|NCT01492556|Drug|Etoposide|Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
354447|NCT01492543|Drug|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
354448|NCT01492530|Behavioral|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
354449|NCT01492530|Behavioral|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
354450|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
354572|NCT01491503|Drug|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
354451|NCT01492517|Other|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
354452|NCT01492517|Other|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
354453|NCT01492517|Other|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
354454|NCT01492504|Drug|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention [(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)]
354455|NCT01492491|Device|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
354456|NCT01492465|Drug|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
354457|NCT01492452|Other|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
354458|NCT01492439|Behavioral|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
354459|NCT01492439|Behavioral|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
354460|NCT01492426|Drug|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
354461|NCT01492426|Drug|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
354462|NCT01492426|Drug|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
354463|NCT01492426|Drug|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
354464|NCT01492413|Behavioral|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
354465|NCT01492400|Drug|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
354466|NCT01492400|Drug|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
354467|NCT01492387|Other|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
354468|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
354469|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
354470|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
354471|NCT01492374|Drug|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
354472|NCT01492361|Drug|AMR101|Parallel Assignment
354473|NCT01492361|Drug|Placebo|Parallel Assignment
354474|NCT01492348|Behavioral|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:~Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.~Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, & primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.~Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.~Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
354475|NCT01492348|Behavioral|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
354476|NCT01492335|Behavioral|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
354477|NCT01492335|Behavioral|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
354478|NCT01492322|Radiation|TRODAT|Smoker will receive a TRODAT injection
354479|NCT01492309|Device|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
354480|NCT01492309|Device|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
354481|NCT01492296|Procedure|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
354482|NCT01492296|Procedure|conventional fasting|patients were evaluated after fasting for 8 hours
354483|NCT01492283|Other|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
354484|NCT01492283|Other|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
354485|NCT01492270|Procedure|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
354486|NCT01492270|Procedure|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
354487|NCT01492270|Procedure|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
354488|NCT01492270|Procedure|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
354489|NCT01492257|Other|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
354490|NCT01492218|Drug|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
354491|NCT01492205|Drug|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
354492|NCT01492192|Drug|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.~The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
354493|NCT01492179|Drug|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
354494|NCT01492179|Drug|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
354495|NCT01492179|Drug|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
354496|NCT01492166|Drug|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
354497|NCT01492153|Drug|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
354498|NCT01492153|Drug|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
354499|NCT01492153|Drug|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
354500|NCT01492140|Procedure|Subdermal Injection|Injection of dermal filler
354501|NCT01492140|Device|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
354502|NCT01492127|Biological|Blood test|Blood test
354503|NCT01492114|Dietary Supplement|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
354504|NCT01492114|Dietary Supplement|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
354505|NCT01492101|Drug|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90 minute intravenous (IV) infusion on day 1 of each treatment cycle.
354506|NCT01492101|Drug|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin ixabepilone vinorelbine gemcitabine paclitaxel docetaxel or nab-paclitaxel"
354507|NCT01492088|Drug|Brentuximab vedotin|Brentuximab vedotin IV infusion
354508|NCT01492075|Drug|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
354509|NCT01492062|Device|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
354510|NCT01492049|Behavioral|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
354511|NCT01492049|Behavioral|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
354512|NCT01492049|Behavioral|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
354513|NCT01492036|Other|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
354573|NCT01491503|Drug|Montelukast & levocetirizine|Montelukast sodium 10mg & levocetirizine dihydrochloride 5mg PO. Single dose.
354574|NCT01491490|Drug|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
354514|NCT01492036|Behavioral|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.~Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
354515|NCT01492023|Behavioral|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
354516|NCT01492010|Dietary Supplement|whey protein|25 g whey protein
354517|NCT01492010|Dietary Supplement|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
354518|NCT01492010|Dietary Supplement|whey protein supplemeted with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
354519|NCT01491997|Behavioral|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
354520|NCT01491997|Behavioral|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
354521|NCT01491984|Device|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
354522|NCT01491984|Device|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
354523|NCT01491971|Drug|Degarelix|
354524|NCT01491958|Drug|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.~Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
354525|NCT01491958|Drug|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
354526|NCT01491958|Drug|methotrexate|Day +1, +3, and +6 and +11
354527|NCT01491945|Device|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:~bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
354528|NCT01491932|Drug|AFQ056|AFQ056 will be supplied as oral capsules.
354529|NCT01491919|Drug|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
354530|NCT01491906|Behavioral|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
354531|NCT01491893|Biological|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)|Recombinant nonpathogenic polio-rhinovirus chimera (PVSRIPO)
354532|NCT01491880|Behavioral|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
354533|NCT01491880|Behavioral|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
354534|NCT01491867|Drug|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
354535|NCT01491854|Other|Bloodsampling|Bloodsampling
354536|NCT01491841|Drug|Bendamustine + Rituximab + Pixantrone|Dose escalation of pixantrone (55mg/m2, 85mg/m2 and 115mg/m2) in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
354537|NCT01491841|Drug|Pegfilgrastim|6mg administered on Day 2 of each 21 day cycle
354538|NCT01491828|Device|Kai Strap|Medical device component that vibrates on a subject's neck.
354539|NCT01491815|Drug|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
354540|NCT01491815|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
354541|NCT01491815|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
354542|NCT01491815|Biological|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.~Methotrexate: 25mg/week"
354575|NCT01491490|Drug|Placebo|Capsules taken once a day for 6 weeks
354669|NCT01490801|Other|immunohistochemistry staining method|
354543|NCT01491802|Drug|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
354544|NCT01491802|Drug|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
354545|NCT01491789|Device|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
354546|NCT01491763|Drug|Imatinib|600 mg p.o. from day 1 until consolidation
354547|NCT01491750|Behavioral|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
354548|NCT01491750|Behavioral|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
354549|NCT01491737|Drug|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
354550|NCT01491737|Drug|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
354551|NCT01491737|Drug|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
354552|NCT01491737|Drug|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
354553|NCT01491711|Drug|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
354554|NCT01491711|Drug|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
354555|NCT01491698|Procedure|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
354556|NCT01491698|Procedure|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
354557|NCT01491672|Drug|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
354558|NCT01491659|Dietary Supplement|Idoform Plus|orally once daily
354559|NCT01491659|Dietary Supplement|Placebo|orally once daily
354560|NCT01491633|Drug|Dasatinib|140 mg orally, daily in 28 day cycles
354561|NCT01491620|Device|532 nm KTP laser|Two laser treatment sessions, 6 weeks apart.
354562|NCT01491607|Biological|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
354563|NCT01491594|Drug|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
354564|NCT01491581|Dietary Supplement|food bar|milk based food bar enriched with micronutrients
354565|NCT01491568|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
354566|NCT01491542|Device|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
354567|NCT01491542|Device|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
354568|NCT01491529|Drug|AFQ056|"AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.~Patients will be randomized in two groups by amantadine status.~Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.~Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
354569|NCT01491529|Drug|Placebo|Placebo for AFQ056 will be supplied as oral tablets.
354570|NCT01491516|Device|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
354576|NCT01491477|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
354577|NCT01491477|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
354578|NCT01491464|Device|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
354579|NCT01491464|Device|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
354580|NCT01491451|Device|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
354581|NCT01491451|Device|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
354582|NCT01491438|Procedure|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.~Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
354583|NCT01491438|Procedure|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
354584|NCT01491425|Device|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
354585|NCT01491425|Device|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
354586|NCT01491399|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
354587|NCT01491399|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
354588|NCT01491386|Device|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
354589|NCT01491386|Device|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
354590|NCT01491373|Device|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
354591|NCT01491373|Device|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
354592|NCT01491360|Procedure|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
354593|NCT01491321|Procedure|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~1st week : SC 0.2cc/day, 2days/week~2nd week : SC 0.4cc/day, 2days/week~3rd week : SC 0.8cc/day, 2days/week"
354594|NCT01491321|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
354595|NCT01491321|Procedure|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~1st week : SC 0.2cc/day, 2days/week~2nd week : SC 0.4cc/day, 2days/week~3rd week : SC 0.8cc/day, 2days/week"
354596|NCT01491308|Other|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
354597|NCT01491295|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
354598|NCT01491295|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
354599|NCT01491282|Other|Enabling and disabling VNS|No intervention
354600|NCT01491269|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
354601|NCT01491256|Drug|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
354602|NCT01491256|Drug|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
354603|NCT01491243|Drug|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
354604|NCT01491243|Drug|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
354605|NCT01491217|Drug|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
354606|NCT01491204|Drug|Paclitaxel+HM30181|oral, 3times for 4weeks
354607|NCT01491191|Dietary Supplement|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
354608|NCT01491191|Dietary Supplement|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
354609|NCT01491178|Drug|Prazaxa|Dabigatran etexilate
354610|NCT01491165|Procedure|stem cell transplantation through interventional procedures|one time interventional procedures
354611|NCT01491152|Device|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
354612|NCT01491139|Drug|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
354613|NCT01491139|Drug|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
354614|NCT01491139|Radiation|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
354615|NCT01491113|Drug|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
354616|NCT01491113|Drug|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
354617|NCT01491100|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
354618|NCT01491087|Biological|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
354619|NCT01491074|Drug|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
354620|NCT01491074|Drug|NaCl 0.9% 100 ml|Placebo
354621|NCT01491061|Drug|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
354622|NCT01491061|Drug|Placebo|os, two doses 12 hours apart prior to PCI
354623|NCT01491048|Procedure|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
354624|NCT01491048|Procedure|No physiotherapy after THA|No physiotherapy after THA
354625|NCT01491035|Drug|Vortioxetine|5 mg tablets for 14 days; orally; once daily
354626|NCT01491035|Drug|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
354627|NCT01491035|Drug|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
354628|NCT01491035|Drug|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
354629|NCT01491022|Drug|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
354630|NCT01491022|Drug|placebo first, then Ampyra|placebo
354631|NCT01491009|Drug|Remifentanil|IV infusion
354632|NCT01491009|Drug|Midazolam|IV infusion
354633|NCT01490996|Drug|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
354634|NCT01490996|Drug|Chemotherapy only|Standard care chemotherapy
354635|NCT01490983|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
354636|NCT01490983|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
354637|NCT01490970|Other|Database|Database
354638|NCT01490957|Other|Database|Database
354639|NCT01490944|Drug|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks~Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
354640|NCT01490944|Drug|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
354641|NCT01490931|Drug|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
354642|NCT01490918|Drug|Acarbose|The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively
354643|NCT01490905|Other|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
354644|NCT01490905|Drug|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
354645|NCT01490905|Drug|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
354646|NCT01490892|Drug|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
354647|NCT01490879|Drug|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
354648|NCT01490879|Drug|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
354649|NCT01490879|Drug|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
354650|NCT01490879|Drug|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
354651|NCT01490866|Drug|Axitinib|5-mg tablets PO BID
354652|NCT01490866|Drug|Bevacizumab|5 mg/kg Days 1 and 15; IV
354653|NCT01490866|Drug|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
354654|NCT01490866|Drug|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
354655|NCT01490866|Drug|Leucovorin|400 mg/m2 Days 1 and 15; IV
354656|NCT01490866|Drug|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
354657|NCT01490853|Drug|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
354658|NCT01490840|Other|Physical exercise|Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
354659|NCT01490814|Procedure|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
354660|NCT01490814|Procedure|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
354661|NCT01490801|Genetic|DNA analysis|
354662|NCT01490801|Genetic|RNA analysis|
354670|NCT01490801|Other|medical chart review|
354671|NCT01490788|Drug|Treatment A|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
354672|NCT01490788|Drug|Treatment B|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
354673|NCT01490788|Drug|Treatment C|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
354674|NCT01490775|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
354675|NCT01490775|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
354676|NCT01490762|Drug|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
354677|NCT01490762|Drug|Regular Human Insulin|Subcutaneous injection
354678|NCT01490749|Drug|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
354679|NCT01490749|Drug|XELOX|Patients will receive two cycles of XELOX.
354680|NCT01490749|Drug|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
354681|NCT01490749|Radiation|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
354682|NCT01490736|Drug|Lemuteporfin|lemuteporfin topical solution, 1%
354683|NCT01490723|Drug|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
354684|NCT01490723|Drug|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
354685|NCT01490723|Procedure|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
354686|NCT01490723|Drug|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
354687|NCT01490723|Drug|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
354688|NCT01490723|Drug|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
354689|NCT01490723|Drug|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
354690|NCT01490723|Drug|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.~For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
354691|NCT01490723|Drug|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
354692|NCT01490723|Drug|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
354693|NCT01490723|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
354694|NCT01490723|Procedure|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
354695|NCT01490710|Other|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
354696|NCT01490710|Other|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
354697|NCT01490697|Drug|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
354698|NCT01490697|Drug|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
354699|NCT01490697|Drug|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
354700|NCT01490697|Drug|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
354701|NCT01490671|Drug|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
354702|NCT01490671|Drug|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
354703|NCT01490658|Drug|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
354704|NCT01490658|Drug|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
354705|NCT01490658|Drug|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
354706|NCT01490632|Drug|Placebo|Administered orally
354707|NCT01490632|Drug|Baricitinib|Administered orally
354708|NCT01490619|Behavioral|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
354709|NCT01490619|Other|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
354710|NCT01490606|Other|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
354711|NCT01490606|Other|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
354712|NCT01490593|Behavioral|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
354713|NCT01490580|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
354714|NCT01490580|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
354715|NCT01490567|Drug|Donepezil|5 mg/day
354716|NCT01490567|Drug|placebo|placebo 5mg/d
354717|NCT01490554|Procedure|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
354718|NCT01490515|Procedure|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
354719|NCT01490515|Other|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
354720|NCT01490502|Drug|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
354721|NCT01490489|Other|blood sample and doppler Ultrasound of uterine arteries|"36 ml of blood samples (serum and plasma) will be collected~After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
354722|NCT01490476|Drug|RAD001|10 mg per os / day or 05mg per os / day with 12 month
354723|NCT01490450|Biological|Placebo matching BMS-945429|Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
354724|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
354725|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
354726|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
354727|NCT01490437|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
354728|NCT01490437|Drug|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
354729|NCT01490437|Drug|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
354730|NCT01490437|Drug|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
354731|NCT01490411|Drug|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
354732|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
354733|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
354734|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
354735|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
354736|NCT01490398|Drug|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
354737|NCT01490385|Device|LED Phototherapy|
354738|NCT01490359|Behavioral|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
354739|NCT01490359|Behavioral|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
354740|NCT01490346|Drug|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
354741|NCT01490333|Dietary Supplement|Vitamin D3|The vitamin D3 will be taken daily.
354742|NCT01490320|Behavioral|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
355456|NCT01484496|Biological|Belimumab 200 mg SC|Belimumab 200 mg SC
354743|NCT01490320|Behavioral|Play Nicely Program|Multimedia program available at www.playnicely.org.
354744|NCT01490320|Other|Control Group|Standard care in primary care clinic.
354745|NCT01490307|Behavioral|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
354746|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
354747|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
354748|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
354749|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
354750|NCT01490281|Behavioral|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
354751|NCT01490281|Behavioral|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
354752|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
354753|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
354754|NCT01490255|Drug|Ranolazine|os, 750 mg, twice per day, for 15 days
354755|NCT01490255|Drug|Amlodipine|os, 10 mg, once daily, 15 days
354756|NCT01490229|Drug|Ezetimibe|os, 10 mg, once daily, 1 year
354757|NCT01490229|Drug|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
354758|NCT01490216|Drug|lisdexamfetamine|20mg q.d. to 70mg b.i.d
354759|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
354760|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
354761|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
354762|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
354763|NCT01490190|Drug|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
354764|NCT01490177|Drug|Food proteins|Oral ingestion of Food proteins
354765|NCT01490151|Device|TTR controller (Medtronic)|Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
354766|NCT01490125|Drug|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
354767|NCT01490125|Drug|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
354768|NCT01490125|Drug|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
354769|NCT01490125|Drug|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
354770|NCT01490125|Drug|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
354771|NCT01490112|Drug|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
354772|NCT01490099|Drug|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
354773|NCT01490086|Drug|RP5063|daily
354774|NCT01490086|Drug|placebo|daily
354775|NCT01490086|Drug|RP5063|daily
354776|NCT01490086|Drug|RP5063|daily
354777|NCT01490086|Drug|aripiprazole|daily
354778|NCT01490073|Drug|Insertion of nitroglycerin ointment|Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion
354779|NCT01490073|Drug|Insertion of placebo ointment|Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
354780|NCT01490060|Drug|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
354781|NCT01490060|Drug|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
354782|NCT01490060|Drug|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
354783|NCT01490060|Drug|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
354784|NCT01490060|Drug|Doxorubicin|25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
354785|NCT01490060|Drug|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
354786|NCT01490060|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m^2).
354787|NCT01490060|Drug|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
354788|NCT01490047|Drug|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
354789|NCT01490047|Drug|Liposomal doxorubicin|Infusion over 60 minutes
354790|NCT01490047|Drug|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
354791|NCT01490047|Drug|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
354792|NCT01490034|Behavioral|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
354793|NCT01490034|Behavioral|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
354794|NCT01490034|Behavioral|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
354795|NCT01490034|Behavioral|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
354796|NCT01490021|Procedure|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
354797|NCT01490021|Procedure|rTMS/Placebo TBS|rTMS/Placebo TBS
354798|NCT01490008|Drug|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
354799|NCT01490008|Other|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
354800|NCT01489995|Drug|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
354801|NCT01489995|Drug|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
354802|NCT01489995|Drug|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
354803|NCT01489995|Drug|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
354804|NCT01489995|Drug|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
354805|NCT01489982|Device|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
354806|NCT01489982|Behavioral|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
354807|NCT01489982|Drug|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
354808|NCT01489982|Device|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
354809|NCT01489969|Drug|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
354810|NCT01489956|Biological|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
354811|NCT01489956|Biological|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
354812|NCT01489956|Biological|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
354813|NCT01489943|Drug|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
354814|NCT01489943|Drug|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
354815|NCT01489943|Drug|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
354816|NCT01489943|Drug|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
354817|NCT01489943|Drug|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
354818|NCT01489930|Behavioral|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
354819|NCT01489930|Behavioral|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for ~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
354820|NCT01489930|Behavioral|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
356984|NCT01473394|Drug|Vilazodone|Vilazodone was supplied as tablets.
354821|NCT01489917|Other|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
354822|NCT01489904|Biological|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
354823|NCT01489891|Drug|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
354824|NCT01489891|Drug|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
354825|NCT01489865|Drug|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
354826|NCT01489852|Drug|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
354827|NCT01489839|Other|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
354828|NCT01489826|Drug|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
354829|NCT01489826|Other|Cremophor|Drug vehicle.
354830|NCT01489813|Drug|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
354831|NCT01489813|Drug|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
354832|NCT01489800|Behavioral|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
354833|NCT01489787|Procedure|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
354834|NCT01489787|Procedure|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
354835|NCT01489787|Procedure|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient"
354836|NCT01489774|Drug|Placebo|single and multiple dose
354837|NCT01489774|Drug|CJ-12406|single and multiple dose
354838|NCT01489761|Device|percutaneous coronary intervention|drug eluting stent implantation
354839|NCT01489722|Drug|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
354840|NCT01489709|Drug|Vesicare|oral
354841|NCT01489696|Drug|mirabegron|oral
354842|NCT01489696|Drug|tamsulosin|oral
354843|NCT01489683|Drug|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
354844|NCT01489683|Drug|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
354845|NCT01489670|Drug|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
354846|NCT01489644|Drug|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
354847|NCT01489644|Drug|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
354848|NCT01489644|Drug|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
354849|NCT01489631|Drug|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
354850|NCT01489631|Drug|marcaine|bupivacaine 0,125%
354851|NCT01489631|Drug|sufentanil|sufentanil 1mcg/ml
354852|NCT01489631|Drug|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
354853|NCT01489618|Biological|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
354854|NCT01489618|Biological|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
354855|NCT01489605|Device|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
354856|NCT01489605|Device|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
354857|NCT01489592|Drug|curcuma longa|oral administration of 6 grams of curcumin
354858|NCT01489579|Behavioral|Telephone Counseling for Tobacco Cessation|"The patients in the Brief, Structured, Telephone (BST) counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
354859|NCT01489579|Behavioral|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
354860|NCT01489566|Drug|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
354861|NCT01489566|Drug|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
354862|NCT01489540|Device|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
354863|NCT01489527|Biological|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
354864|NCT01489527|Other|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
354865|NCT01489514|Other|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:~Histamine control purchased from Greer.~Saline control purchased from Greer.~Standard Peanut Extract purchased from Greer.~Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A & T.~Sterile extract prepared from roasted & blanched but untreated peanuts. This is prepared by North Carolina A & T.~Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A & T. This is not classified as a drug and is~Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.~Sterile extracts containing peanuts that have been treated with alcalase"
354866|NCT01489501|Procedure|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
354867|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter [mg/mL], i.e. 16 mL) under fasting conditions
354868|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
354869|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
354870|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
354871|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
354872|NCT01489462|Behavioral|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
354873|NCT01489462|Behavioral|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
354874|NCT01489462|Behavioral|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
354875|NCT01489449|Device|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
354876|NCT01489449|Device|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
354877|NCT01489436|Procedure|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
354878|NCT01489436|Procedure|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
354879|NCT01489423|Genetic|RNA analysis|
354880|NCT01489423|Genetic|in situ hybridization|
354881|NCT01489423|Genetic|polymerase chain reaction|
354882|NCT01489423|Other|enzyme-linked immunosorbent assay|
354883|NCT01489423|Other|flow cytometry|
354884|NCT01489423|Other|immunohistochemistry staining method|
354885|NCT01489423|Other|laboratory biomarker analysis|
354886|NCT01489410|Drug|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
354887|NCT01489410|Drug|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
354888|NCT01489397|Device|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
354889|NCT01489371|Other|Laboratory Biomarker Analysis|Correlative studies
354890|NCT01489371|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
354891|NCT01489371|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
354892|NCT01489358|Biological|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
354893|NCT01489345|Drug|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
354894|NCT01489345|Drug|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
354895|NCT01489332|Drug|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).~Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
354896|NCT01489319|Drug|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
354897|NCT01489319|Drug|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
354898|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
354899|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
354900|NCT01489267|Other|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10`7 cells).
354901|NCT01489254|Drug|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
354902|NCT01489254|Drug|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
354903|NCT01489254|Drug|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
354904|NCT01489241|Procedure|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
354905|NCT01489228|Drug|E1224|100 mg tablets
354906|NCT01489228|Drug|Benznidazole|100mg tablets
354907|NCT01489228|Drug|Placebo|tablets
354908|NCT01489215|Behavioral|"presence"|"constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying."
354909|NCT01489215|Behavioral|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
354910|NCT01489202|Device|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
354911|NCT01489202|Device|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
354912|NCT01489189|Other|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
354913|NCT01489189|Drug|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
354914|NCT01489189|Other|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
354915|NCT01489176|Drug|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
354916|NCT01489163|Behavioral|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
354917|NCT01489137|Drug|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
354918|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
354919|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
354920|NCT01489124|Drug|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
357309|NCT01471080|Procedure|RFA|using RFA to treat cavernous hemangiomas
354921|NCT01489111|Drug|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
354922|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
354923|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
354924|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
354925|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
354926|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
354927|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
354928|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
354929|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
354930|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
354931|NCT01489046|Drug|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
354932|NCT01489046|Drug|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
354933|NCT01489046|Drug|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
354934|NCT01489046|Drug|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
354935|NCT01489046|Drug|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
354936|NCT01489046|Drug|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
354937|NCT01489046|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
354938|NCT01489033|Biological|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
354939|NCT01489020|Biological|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
354940|NCT01489020|Biological|Subcutaneous depot placebo|Increasing doses of subcutaneous depot placebo in three different scales
354941|NCT01488994|Biological|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
354942|NCT01488981|Other|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
354943|NCT01488981|Device|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
354944|NCT01488968|Radiation|Standard Radiation Treatment|39 radiation treatments
354945|NCT01488968|Radiation|Hypofractionated radiation treatment|25 radiation treatments
354946|NCT01488955|Drug|Ibuprofen|400 mg oral once a day from day 0 for 3 days
354947|NCT01488955|Drug|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
354948|NCT01488942|Other|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
354949|NCT01488929|Drug|TC-5619|
354950|NCT01488929|Drug|Placebo|
354951|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
354952|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
354953|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
354954|NCT01488890|Biological|Yellow Fever|0.5 mL, Subcutaneous
354955|NCT01488877|Drug|PF-03882845|3 mg tablet once daily
354956|NCT01488877|Drug|PF-03882845|up to 10 mg tablet once daily
354957|NCT01488877|Drug|PF-03882845|up to 30 mg once daily
354958|NCT01488877|Drug|Spironolactone|spironolactone 25 mg once daily
354959|NCT01488877|Other|placebo|placebo once daily
354960|NCT01488864|Behavioral|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.~During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.~The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
354961|NCT01488838|Drug|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
354962|NCT01488838|Radiation|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
354963|NCT01488825|Behavioral|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
354964|NCT01488799|Behavioral|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
354965|NCT01488786|Device|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
354966|NCT01488773|Drug|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
354967|NCT01488773|Drug|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
354968|NCT01488747|Dietary Supplement|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
354969|NCT01488747|Dietary Supplement|Coromega Nectar|660 mg EPA, 436 mg DHA
354970|NCT01488747|Dietary Supplement|Barleans Swirl|660 mg EPA, 660 mg DHA
354971|NCT01488747|Dietary Supplement|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
354972|NCT01488734|Dietary Supplement|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
354973|NCT01488734|Dietary Supplement|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
354974|NCT01488734|Dietary Supplement|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
354975|NCT01488734|Dietary Supplement|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
354976|NCT01488734|Drug|Placebo|Placebo for the fortified mushroom arms
354977|NCT01488708|Drug|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies is not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
354978|NCT01488708|Drug|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
354979|NCT01488695|Device|GlideScope Groove|GlideScope Groove
354980|NCT01488695|Device|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
354981|NCT01488682|Procedure|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
354982|NCT01488682|Procedure|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
354983|NCT01488669|Procedure|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
354984|NCT01488669|Procedure|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
354985|NCT01488656|Dietary Supplement|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
354986|NCT01488656|Dietary Supplement|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
354987|NCT01488630|Other|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
354988|NCT01488604|Device|Polymeric Nasal Spray|Experimental nasal spray
354989|NCT01488604|Device|Sham Nasal Spray|Sham nasal spray
354990|NCT01488578|Drug|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
354991|NCT01488565|Drug|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
354992|NCT01488552|Drug|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
354993|NCT01488552|Drug|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
354994|NCT01488552|Drug|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;~Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
354995|NCT01488552|Genetic|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
354996|NCT01488552|Drug|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
354997|NCT01488552|Drug|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
354998|NCT01488539|Behavioral|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
354999|NCT01488539|Behavioral|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
355000|NCT01488526|Drug|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
355001|NCT01488513|Drug|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
355002|NCT01488500|Other|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
355003|NCT01488487|Drug|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
355004|NCT01488487|Drug|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
355005|NCT01488474|Procedure|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
355006|NCT01488461|Genetic|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
355007|NCT01488448|Drug|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
355008|NCT01488448|Drug|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
355009|NCT01488435|Dietary Supplement|Cow's milk|Powdered whole cow's milk
355010|NCT01488435|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
355011|NCT01488422|Behavioral|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
355012|NCT01488409|Drug|Acipimox|250 mg by mouth (PO) three times daily
355013|NCT01488409|Drug|Placebo|0 mg by mouth (PO) three times daily
355014|NCT01488396|Drug|0.05%cyclosporin eye drop|use twice daily for 6 months
355015|NCT01488383|Drug|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
355016|NCT01488383|Drug|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
355017|NCT01488370|Device|Endotracheal intubation|Endotracheal intubation
355018|NCT01488344|Drug|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
355019|NCT01488318|Drug|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
355020|NCT01488318|Drug|Dasatinib|Dasatinib 150 mg po
355021|NCT01488305|Dietary Supplement|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
355022|NCT01488305|Other|AAMA project activities (HFP and IYCF BCC)|This is the existing AAMA program
355023|NCT01488292|Behavioral|RECAP social skills and reading program|weekly individual and group sessions
355024|NCT01488279|Drug|Dexamethasone 2.5 mg and Sitagliptin 100 mg|Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days
355025|NCT01488279|Drug|Dexamethasone 2.5 mg and placebo tablet|Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days
355026|NCT01488266|Drug|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
355273|NCT01486030|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
355027|NCT01488266|Drug|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
355028|NCT01488253|Drug|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
355029|NCT01488253|Drug|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
355030|NCT01488240|Procedure|pulsed dye laser|laser energy
355031|NCT01488227|Dietary Supplement|Vitamin D|4000 IU of Vitamin D daily for 6 months
355032|NCT01488227|Dietary Supplement|Placebo|Acts as a control for the Vitamin D intervention
355033|NCT01488214|Other|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
355034|NCT01488201|Drug|Placebo|
355035|NCT01488201|Drug|KHK4827|
355036|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
355037|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
355038|NCT01488175|Procedure|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
355039|NCT01488175|Procedure|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
355040|NCT01488136|Drug|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
355041|NCT01488136|Drug|Placebo|Lactose Ph capsules (Placebo)
355042|NCT01488123|Behavioral|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
355043|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
355044|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
355045|NCT01488097|Drug|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase.
355046|NCT01488084|Procedure|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
355047|NCT01488084|Procedure|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
355048|NCT01488071|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
355049|NCT01488071|Drug|Agomelatine|encapsulated tablets, daily, orally
355050|NCT01488058|Other|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
355051|NCT01488058|Other|Waitlist Control|Waitlist will receive iCBT at week 11
355052|NCT01488045|Drug|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
355053|NCT01488045|Drug|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
355054|NCT01488045|Drug|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
355055|NCT01488019|Drug|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
355056|NCT01488019|Drug|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
355057|NCT01488006|Device|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
355058|NCT01487993|Drug|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
355059|NCT01487993|Behavioral|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
355060|NCT01487980|Procedure|Cord clamping|Early vs Delayed
355061|NCT01487967|Other|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
355062|NCT01487954|Dietary Supplement|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
355063|NCT01487954|Dietary Supplement|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
355064|NCT01487954|Radiation|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
355100|NCT01487590|Other|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
355274|NCT01486017|Drug|ASP015K|oral
357565|NCT01469039|Drug|Placebo|Placebo for IM injection, given monthly
355065|NCT01487928|Dietary Supplement|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
355066|NCT01487915|Drug|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
355067|NCT01487915|Drug|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
355068|NCT01487902|Drug|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
355069|NCT01487902|Drug|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
355070|NCT01487889|Other|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
355071|NCT01487876|Biological|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
355072|NCT01487876|Other|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
355073|NCT01487863|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
355074|NCT01487863|Drug|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
355075|NCT01487850|Biological|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
355076|NCT01487837|Drug|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
355077|NCT01487811|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
355078|NCT01487798|Drug|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
355079|NCT01487798|Drug|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
355080|NCT01487785|Drug|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
355081|NCT01487759|Dietary Supplement|Oligofructose enriched inulin|
355082|NCT01487759|Dietary Supplement|Maltodextrin|
355083|NCT01487733|Genetic|gene expression analysis|
355084|NCT01487733|Genetic|in situ hybridization|
355085|NCT01487733|Other|immunohistochemistry staining method|
355086|NCT01487733|Other|laboratory biomarker analysis|
355087|NCT01487720|Drug|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
355088|NCT01487707|Behavioral|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
355089|NCT01487707|Behavioral|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
355090|NCT01487707|Behavioral|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
355091|NCT01487694|Drug|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
355092|NCT01487694|Drug|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
355093|NCT01487668|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
355094|NCT01487642|Device|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
355095|NCT01487642|Device|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
355096|NCT01487642|Device|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
355097|NCT01487642|Device|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
355098|NCT01487629|Drug|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
355099|NCT01487629|Drug|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
355101|NCT01487590|Other|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
355102|NCT01487577|Drug|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
355103|NCT01487564|Drug|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
355104|NCT01487551|Drug|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
355105|NCT01487538|Behavioral|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
355106|NCT01487538|Behavioral|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
355107|NCT01487538|Behavioral|Discussion Boards|forum to exchange information and experiences
355108|NCT01487538|Behavioral|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
355109|NCT01487525|Device|Double leg press with partial blood flow restriction|double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
355110|NCT01487525|Other|Double leg press without partial blood flow restriction|double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
355111|NCT01487512|Drug|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
355112|NCT01487512|Drug|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
355113|NCT01487512|Drug|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
355114|NCT01487512|Drug|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
355115|NCT01487499|Drug|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
355116|NCT01487486|Drug|IVF Antagonist Protocol|"Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.~Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle >14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection~hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
355117|NCT01487473|Behavioral|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
355118|NCT01487460|Drug|TAP311|
355119|NCT01487447|Other|Customized sound|treatment with customized sound therapy
355120|NCT01487447|Other|Regular Masker|treatment with white noise
355121|NCT01487434|Behavioral|Check & Connect|Structured mentoring and case management
355122|NCT01487421|Drug|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
355123|NCT01487421|Drug|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
355124|NCT01487408|Drug|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
355125|NCT01487395|Drug|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
355126|NCT01487395|Drug|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
355127|NCT01487382|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
355128|NCT01487369|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
355129|NCT01487356|Other|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
355130|NCT01487343|Behavioral|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
355131|NCT01487330|Device|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
355132|NCT01487317|Drug|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity < 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity < 10, the active treatment will be stopped
355133|NCT01487317|Drug|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity < 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity < 10, the placebo treatment will be stopped
355134|NCT01487304|Drug|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
355135|NCT01487278|Drug|misprostol|600 mcg misoprostol oral
355136|NCT01487278|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
355242|NCT01486420|Procedure|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
355137|NCT01487265|Drug|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
355138|NCT01487252|Behavioral|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
355139|NCT01487239|Drug|[14C]-GDC-0980|100 uCi of [14C]-GDC-0980 in total dose of 10 mg GDC-0980
355140|NCT01487226|Drug|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks * 6 cycles
355141|NCT01487226|Drug|Cisplatin 50mg/m2|"Cisplatin 50mg/m2~Repeat every 3 weeks * 6 cycles"
355142|NCT01487213|Other|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
355143|NCT01487200|Drug|FX006|single intra-articular injection
355144|NCT01487200|Drug|commercially available triamcinolone acetonide|single intra-articular injection
355145|NCT01487187|Procedure|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
355146|NCT01487187|Procedure|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
355147|NCT01487174|Drug|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
355148|NCT01487174|Drug|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
355149|NCT01487161|Drug|FX006|Single 3 mL intra-articular injection
355150|NCT01487161|Drug|TCA IR|Single 1 mL intra-articular injection
355151|NCT01487135|Drug|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
355152|NCT01487135|Drug|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
355153|NCT01487135|Drug|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
355154|NCT01487122|Radiation|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
355155|NCT01487122|Radiation|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
355156|NCT01487122|Procedure|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
355157|NCT01487109|Drug|CTP-499|600 mg tablet twice daily
355158|NCT01487109|Drug|Placebo|Matching placebo tablet
355159|NCT01487096|Drug|Teriflunomide|"film-coated tablet~oral administration"
355160|NCT01487096|Drug|Placebo (placebo for teriflunomide)|"film-coated tablet~oral administration"
355161|NCT01487083|Drug|Pomaglumetad methionil|Administered orally
355162|NCT01487070|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
355163|NCT01487044|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
355164|NCT01487031|Other|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
355165|NCT01487031|Other|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
355166|NCT01487018|Procedure|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
355167|NCT01487018|Procedure|Traditional Surgery|To compare with the experamental group.
355168|NCT01486992|Drug|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
355169|NCT01486979|Drug|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
355170|NCT01486979|Drug|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
355171|NCT01486966|Drug|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
355172|NCT01486966|Drug|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
355173|NCT01486966|Drug|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
355243|NCT01486420|Procedure|Open surgery|Open A1-pulley release
355174|NCT01486966|Drug|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
355175|NCT01486966|Drug|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
355176|NCT01486953|Drug|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
355177|NCT01486953|Drug|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
355178|NCT01486940|Drug|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
355179|NCT01486940|Drug|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
355180|NCT01486940|Drug|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
355181|NCT01486940|Drug|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
355182|NCT01486927|Biological|rVIII-SingleChain|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
355183|NCT01486927|Biological|Octocog alfa|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
355184|NCT01486914|Drug|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
355185|NCT01486901|Drug|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
355186|NCT01486888|Drug|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
355187|NCT01486875|Drug|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
355188|NCT01486862|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
355189|NCT01486849|Drug|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
355190|NCT01486849|Drug|Placebo|Matching placebo tablets BID for 21 days
355191|NCT01486849|Drug|Riluzole 50 MG|
355192|NCT01486823|Drug|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
355193|NCT01486823|Drug|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
355194|NCT01486810|Drug|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
355195|NCT01486810|Behavioral|medication management|All participants will receive medication management counseling and individual therapy using a structured compliance enhancement manual designed for pharmacotherapy trials in subjects with substance use disorders.
355196|NCT01486797|Drug|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):~3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.~Expansion Group (NOX-A12 in combination with BR):~Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
355197|NCT01486784|Drug|TL32711|
355198|NCT01486771|Drug|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.~Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.~Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.~All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
355199|NCT01486758|Drug|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
355200|NCT01486758|Drug|Placebo|
355201|NCT01486732|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
355202|NCT01486732|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
355203|NCT01486732|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
355204|NCT01486719|Procedure|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
355205|NCT01486706|Drug|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
355206|NCT01486706|Drug|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
355207|NCT01486706|Drug|Placebo drugs|will titrate medications similar to the active drug group
355208|NCT01486680|Procedure|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
355209|NCT01486680|Procedure|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
355210|NCT01486667|Drug|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
355211|NCT01486667|Drug|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
355212|NCT01486654|Device|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
355213|NCT01486654|Device|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
355214|NCT01486654|Device|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
355215|NCT01486641|Procedure|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
355216|NCT01486628|Drug|ND0612|levodopa and carbidopa solution for subcutaneous administration
355217|NCT01486628|Drug|Placebo|Saline solution for SC continuous administration
355218|NCT01486615|Drug|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
355219|NCT01486615|Drug|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
355220|NCT01486615|Drug|(alprax) alprazolam|0.5 mg alprazolam
355221|NCT01486615|Drug|placebo|similar looking placebo tablet
355222|NCT01486602|Drug|carboplatin|IV
355223|NCT01486602|Drug|paclitaxel|IV
355224|NCT01486602|Radiation|radiation therapy|Defined per the protocol
355225|NCT01486576|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
355226|NCT01486576|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
355227|NCT01486563|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
355228|NCT01486563|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
355229|NCT01486550|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
355230|NCT01486550|Drug|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
355231|NCT01486511|Procedure|Liver resection|Hepatectomy including both minor and major.
355232|NCT01486511|Radiation|Computed Tomography|Computed Tomography +/- pulmonary angiography
355233|NCT01486485|Drug|heparinized saline priming group|
355234|NCT01486485|Drug|nafamostat infusion after heparinized saline priming|
355235|NCT01486472|Drug|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
355236|NCT01486459|Drug|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
355237|NCT01486446|Drug|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
355238|NCT01486446|Drug|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
355239|NCT01486433|Drug|Simvastatin|40 mg (1 tablet) simvastatin once a day
355240|NCT01486433|Drug|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
355241|NCT01486433|Drug|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
355244|NCT01486394|Other|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
355245|NCT01486381|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
355246|NCT01486368|Drug|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
355247|NCT01486355|Biological|Measles vaccine|Edmonston-Zagreb measles vaccine
355248|NCT01486342|Radiation|PET-CT scan|"PET-CT imaging with [18F]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.~A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
355249|NCT01486329|Biological|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
355250|NCT01486329|Biological|Placebo|Drink solution
355251|NCT01486316|Device|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
355252|NCT01486316|Other|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
355253|NCT01486303|Procedure|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
355254|NCT01486290|Behavioral|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
355255|NCT01486277|Drug|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
355256|NCT01486264|Biological|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
355257|NCT01486251|Drug|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.~One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
355258|NCT01486238|Drug|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
355259|NCT01486225|Device|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
355260|NCT01486225|Other|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
355261|NCT01486199|Other|Absorptive clearance scan|Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
355262|NCT01486186|Drug|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
355263|NCT01486186|Drug|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
355264|NCT01486147|Behavioral|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
355265|NCT01486147|Behavioral|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
355266|NCT01486134|Procedure|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
355267|NCT01486121|Other|Therapy strategy|Sedation & mechanical ventilation
355268|NCT01486108|Procedure|dorsal column stimulator|test different settings of stimulation
355269|NCT01486095|Device|AXXESS + Biomatrix Biolimus Eluting stent|NAP
355270|NCT01486095|Device|Culotte technique with Xience V or Xience Prime stents|NAP
355271|NCT01486082|Other|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
355272|NCT01486043|Drug|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
355275|NCT01486004|Drug|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
355276|NCT01486004|Drug|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
355277|NCT01485991|Drug|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
355278|NCT01485991|Drug|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
355279|NCT01485978|Drug|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
355280|NCT01485978|Drug|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
355281|NCT01485978|Drug|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
355282|NCT01485965|Drug|SEN0014196|100 mg, immediate release tablets, once daily administration
355283|NCT01485952|Drug|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
355284|NCT01485952|Drug|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
355285|NCT01485952|Drug|Placebo|Once daily administration (immediate release capsule)
355286|NCT01485939|Other|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
355287|NCT01485939|Other|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
355288|NCT01485926|Drug|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
355289|NCT01485926|Drug|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
355290|NCT01485913|Other|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
355291|NCT01485900|Drug|SAR407899A|"Pharmaceutical form:capsule~Route of administration: oral"
355292|NCT01485887|Drug|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
355293|NCT01485874|Drug|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
355294|NCT01485874|Drug|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid~Phase II: MTD orally, bid, day 2 of 28-day cycle"
355295|NCT01485861|Drug|Abiraterone|Orally once daily
355296|NCT01485861|Drug|Apitolisib|Orally once daily
355297|NCT01485861|Drug|Ipatasertib|Orally once daily
355298|NCT01485861|Drug|Placebo|Orally once daily
355299|NCT01485861|Drug|Prednisone|Orally bid
355300|NCT01485861|Drug|Prednisolone|Orally bid
355301|NCT01485848|Drug|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
355302|NCT01485848|Drug|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
355303|NCT01485835|Drug|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
355304|NCT01485835|Drug|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
355305|NCT01485835|Drug|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
355306|NCT01485822|Procedure|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
355307|NCT01485822|Drug|Travoprost 0.004% ophthalmic solution|
355308|NCT01485809|Drug|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
355309|NCT01485796|Biological|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
355310|NCT01485796|Biological|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
355311|NCT01485770|Drug|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
355312|NCT01485770|Drug|Placebo|Placebo to match ADX-N05 to be taken for 2 consecutive weeks during 4 week study treatment period
355484|NCT01484197|Drug|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
355313|NCT01485757|Drug|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
355314|NCT01485744|Drug|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
355315|NCT01485731|Drug|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
355316|NCT01485731|Drug|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
355317|NCT01485731|Radiation|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
355318|NCT01485731|Radiation|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
355319|NCT01485731|Procedure|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
355320|NCT01485731|Procedure|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
355321|NCT01485731|Procedure|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
355322|NCT01485731|Procedure|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
355323|NCT01485731|Procedure|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
355324|NCT01485731|Procedure|Proctoscopy|Optional. Pre-Treatment
355325|NCT01485731|Procedure|Cytoscopy|Optional. Pre-Treatment
355326|NCT01485731|Procedure|Renal Ultrasound|Optional. Pre-Treatment
355327|NCT01485731|Procedure|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
355328|NCT01485731|Procedure|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
355329|NCT01485718|Dietary Supplement|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
355330|NCT01485718|Dietary Supplement|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
355331|NCT01485705|Other|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
355332|NCT01485692|Drug|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
355333|NCT01485692|Drug|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
355334|NCT01485692|Drug|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
355335|NCT01485692|Drug|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
355336|NCT01485679|Other|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
355337|NCT01485666|Other|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
355338|NCT01485653|Drug|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
355339|NCT01485640|Drug|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
355340|NCT01485627|Behavioral|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
355341|NCT01485614|Drug|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
355342|NCT01485614|Drug|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
355343|NCT01485614|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
355344|NCT01485614|Drug|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
355485|NCT01484197|Drug|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
355345|NCT01485614|Drug|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin in both Phase A and Phase B. Participants in the placebo arm who require glycemic rescue will receive metformin in Phase A. Participants in the placebo arm who have switched to metformin in Phase B and require glycemic rescue will receive sitagliptin.
355346|NCT01485614|Biological|Glycemic Rescue 2|Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
355347|NCT01485601|Biological|MT10109|Single dose intramuscular injection MT10109 vs Botox®
355348|NCT01485588|Drug|hI-con1™|Phase 1: 20µl, 50µl, or 100µl per injection (in the eye) on Day 1 only
355349|NCT01485575|Procedure|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
355350|NCT01485562|Drug|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
355351|NCT01485562|Other|placebo|4 tablets, administered sublingually if the woman experiences a PPH
355352|NCT01485536|Drug|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
355353|NCT01485523|Other|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
355354|NCT01485510|Behavioral|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
355355|NCT01485510|Behavioral|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
355356|NCT01485497|Device|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
355357|NCT01485484|Device|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
355358|NCT01485471|Device|Diffuse optical spectroscopy imaging|ear exam imaging
355359|NCT01485458|Procedure|Early surgery|Surgery within 24 hours after admission
355360|NCT01485458|Procedure|Delayed surgery|Surgery more than 2 weeks after injury
355361|NCT01485445|Drug|Fluticasone Furoate (200mcg unit strength)|inhalation powder
355362|NCT01485445|Drug|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
355363|NCT01485432|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
355364|NCT01485406|Biological|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
355365|NCT01485406|Biological|Synflorix™|1 dose administered intramuscularly
355366|NCT01485393|Drug|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
355367|NCT01485393|Drug|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
355368|NCT01485380|Drug|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
355369|NCT01485367|Drug|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand & extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand & extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right & left forearms.
355370|NCT01485354|Device|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
355371|NCT01485341|Dietary Supplement|gluten|gluten is administered once a day at 10g/day for 15 days
355372|NCT01485341|Dietary Supplement|rice starch|rice starch is administered once a day at 10 g/day for 15 days
355373|NCT01485328|Drug|AMARGOL®|per oral solution, 40 mL single dose
355374|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
355375|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
355376|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution~Route of administration: intravenous"
355377|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution~Route of administration: subcutaneous"
355378|NCT01485276|Procedure|DBS Surgery|
355379|NCT01485237|Other|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
355418|NCT01484834|Behavioral|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
355380|NCT01485224|Drug|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.~Treatment will be continued until one of the following criteria is met:~8 additional weeks of treatment after the achievement of complete response~16 additional weeks of treatment after the achievement of partial response~24 weeks of treatment completed without response~unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
355381|NCT01485211|Drug|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
355382|NCT01485198|Procedure|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
355383|NCT01485198|Drug|Acetaminophen|Acetaminophen (750mg orally TID) administration
355384|NCT01485185|Drug|Gabapentin lower dose|Repeat, oral dose
355385|NCT01485185|Drug|Donepezil|Repeat, oral dose
355386|NCT01485185|Other|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
355387|NCT01485185|Other|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
355388|NCT01485185|Drug|Gabapentin higher dose|Repeat, oral dose
355389|NCT01485172|Drug|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
355390|NCT01485172|Drug|placebo monotherapy|placebo as monotherapy in Parkinson's disease
355391|NCT01485159|Procedure|Spirometry|assessment of lung function by spirometry
355392|NCT01485146|Drug|ETC-1002|escalating doses
355393|NCT01485120|Device|BP monitoring using two methods|BP readings from participant using invasive radial arterial line, Non-invasive cuff with SuperSTAT NIBP algorithm, and Non-invasive cuff with Classic NIBP algorithm.
355394|NCT01485107|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
355395|NCT01485094|Drug|GRT6010|Oral solution given once daily.
355396|NCT01485094|Drug|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
355397|NCT01485094|Drug|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.~Capsules twice daily on Days 1 to 7. Solution once daily."
355398|NCT01485081|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
355399|NCT01485068|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
355400|NCT01485055|Drug|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.~Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
355401|NCT01485042|Drug|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
355402|NCT01485029|Procedure|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
355403|NCT01485003|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
355404|NCT01484990|Drug|Levodopa-Carbidopa|Intestinal Gel
355405|NCT01484977|Drug|Lacosamide|"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.~Maximum duration of study drug administration is approximately 23 weeks."
355406|NCT01484964|Drug|ASP015K|oral
355407|NCT01484951|Drug|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
355408|NCT01484938|Device|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
355409|NCT01484912|Drug|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
355410|NCT01484912|Drug|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
355411|NCT01484886|Other|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
355412|NCT01484886|Other|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
355413|NCT01484873|Drug|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
355414|NCT01484860|Drug|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
355415|NCT01484847|Drug|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
355416|NCT01484834|Behavioral|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.~Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
355417|NCT01484834|Behavioral|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
355419|NCT01484834|Other|Control Company|No intervention was applied for the participants of this group
355420|NCT01484821|Device|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
355421|NCT01484795|Device|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
355422|NCT01484795|Device|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
355423|NCT01484782|Behavioral|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
355424|NCT01484756|Dietary Supplement|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
355425|NCT01484756|Dietary Supplement|Placebo|calcium carbonate 500 mg
355426|NCT01484743|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
355427|NCT01484730|Device|Multi-Spectral & Laser Speckle Imaging|Changes in skin tissue and blood flow.
355428|NCT01484717|Behavioral|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
355429|NCT01484717|Drug|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)].
355430|NCT01484717|Behavioral|Telephone counseling|Participants receive brief twice weekly telephone counseling.
355431|NCT01484691|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
355432|NCT01484665|Other|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
355433|NCT01484652|Drug|COV795|2 tablets taken every 12 hours
355434|NCT01484652|Drug|Placebo|2 tablets taken every 12 hours
355435|NCT01484639|Other|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
355436|NCT01484639|Other|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
355437|NCT01484626|Drug|Bendamustine|The first group of three patients to enter the study will receive a 25 mg/m^2 dose of bendamustine. If this dose is found to be safe, the next three patients will receive 50 mg/m^2. Using a modified Fibonacci dose-escalation design, the dose will continue to increase at a rate of 25 mg/m^2 until the highest safe dose of bendamustine is found. The maximum dose will be 125 mg/m^2. Bendamustine and bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
355438|NCT01484613|Device|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
355439|NCT01484600|Drug|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
355440|NCT01484600|Drug|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
355441|NCT01484587|Drug|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
355442|NCT01484587|Drug|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
355443|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
355444|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
355445|NCT01484561|Drug|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
355446|NCT01484561|Drug|Placebo|Placebo BID orally, approximately 72 days
355447|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
355448|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
355449|NCT01484548|Biological|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
355450|NCT01484535|Procedure|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
355451|NCT01484535|Procedure|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
355452|NCT01484522|Biological|FluMist|Administered at the manufacture's recommended dose
355453|NCT01484522|Biological|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
355454|NCT01484522|Biological|Fluzone|Vaccine administered at manufacturer's recommended dose
355455|NCT01484496|Biological|Placebo|Placebo
355457|NCT01484496|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
355458|NCT01484470|Biological|StemEx|"For patients allocated to StemEx® arm:~Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase~Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase~Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.~Day 1: StemEx® transplantation.~Day 2 to 3 years: Post transplant follow-up."
355459|NCT01484457|Device|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose < 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.~Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.~After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
355460|NCT01484431|Drug|Tadalafil- Tablet or Oral suspension|Tadalafil Tablets administered orally. Tadalafil Oral suspension: An aqueous, ready-to-use suspension for oral administration.
355461|NCT01484418|Behavioral|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
355462|NCT01484418|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
355463|NCT01484405|Procedure|posterior approach|Surgical approach for Total Hip Arthroplasty
355464|NCT01484405|Procedure|anterolateral approach|anterolateral surgical approach
355465|NCT01484379|Procedure|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
355466|NCT01484366|Procedure|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
355467|NCT01484366|Procedure|plating|Surgical plating of both bonforearm fractures
355468|NCT01484353|Behavioral|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
355469|NCT01484340|Drug|Nicotine|"The nicotine patch be given in three phases:~2 weeks of patches at enrollment~6 weeks of patches at two-week follow-up visit~2 weeks of patches at two-month follow-up visit~This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
355470|NCT01484340|Behavioral|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.~Visit schedule:~Baseline~2-week follow-up (Quit Day)~1-month follow-up~2-month follow-up~3-month follow-up~6-month follow-up~Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.~Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
355471|NCT01484327|Drug|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
355472|NCT01484314|Drug|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
355473|NCT01484288|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
355474|NCT01484275|Drug|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
355475|NCT01484275|Drug|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
355476|NCT01484262|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
355477|NCT01484262|Drug|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
355478|NCT01484249|Device|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
355479|NCT01484223|Behavioral|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
355480|NCT01484210|Drug|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
355481|NCT01484197|Drug|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
355482|NCT01484197|Drug|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
355483|NCT01484197|Drug|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
355647|NCT01483027|Device|TheraSphere|yttrium 90 microspheres
355486|NCT01484184|Drug|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
355487|NCT01484171|Drug|idarubicin|idarubicin 10-12 mg/m2 for three days
355488|NCT01484171|Biological|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
355489|NCT01484145|Drug|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
355490|NCT01484132|Procedure|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
355491|NCT01484119|Drug|ACT-129968|daily tablets
355492|NCT01484119|Drug|Placebo|matching placebo tablets and capsules
355493|NCT01484119|Drug|Cetirizine|daily capsules
355494|NCT01484106|Other|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
355495|NCT01484106|Other|Standard of Care|Standard of Care
355496|NCT01484093|Other|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
355497|NCT01484080|Drug|BIBF + Paclitaxel|"Priming Period:~Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.~One week washout is planned before starting the treatment phase.~Treatment Phase:~Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
355498|NCT01484080|Drug|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
355499|NCT01484067|Device|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
355500|NCT01484054|Device|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
355501|NCT01484054|Device|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
355502|NCT01484041|Drug|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
355503|NCT01484041|Drug|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
355504|NCT01484028|Device|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
355505|NCT01484028|Device|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
355506|NCT01484028|Device|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
355507|NCT01484015|Drug|cefepime hydrochloride|Given IV
355508|NCT01484002|Device|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
355509|NCT01483989|Other|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
355510|NCT01483976|Other|Oral medical nutritional supplement|orally over a three hour period
355511|NCT01483976|Other|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
355512|NCT01483963|Biological|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
355513|NCT01483963|Biological|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
355514|NCT01483963|Biological|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
355515|NCT01483963|Biological|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
355516|NCT01483963|Other|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
355517|NCT01483937|Device|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
355518|NCT01483937|Other|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
355519|NCT01483924|Drug|Apo805K1|Sequential parallel dose escalation.
355520|NCT01483911|Biological|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
355521|NCT01483911|Biological|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
355522|NCT01483898|Biological|Ixmyelocel-T|On Day 14, 20 intramuscular injections of ixmyelocel-T on pre-identified index leg.
355523|NCT01483898|Other|Placebo|On Day 14, 20 intramuscular injections of vehicle control on pre-identified index leg.
355524|NCT01483885|Device|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
355525|NCT01483885|Device|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
355648|NCT01483014|Drug|imatinib mesylate|
357692|NCT01468077|Drug|Tocilizumab|8 mg/kg infusion
355526|NCT01483885|Procedure|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
355527|NCT01483872|Drug|NAC/Tigecycline/Heparin combination lock solution|
355528|NCT01483872|Drug|Standard anticoagulant (Heparin or Citrate)|
355529|NCT01483859|Other|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
355530|NCT01483846|Drug|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
355531|NCT01483846|Drug|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
355532|NCT01483833|Drug|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
355533|NCT01483833|Drug|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
355534|NCT01483820|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
355535|NCT01483807|Behavioral|Sound Production Treatment - Blocked|Sound Production Treatment is a treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Blocked entailed practicing all treatment targets blocked by target. SPT-Random entailed practicing all treatment targets in a non predictable, random order.
355536|NCT01483807|Behavioral|Sound Production Treatment - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice. SPT-Random entailed practicing treatment targets in a non predictable order. SPT-Blocked entailed practicing treatment targets blocked by target.
355537|NCT01483781|Drug|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
355538|NCT01483781|Drug|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
355539|NCT01483768|Procedure|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
355540|NCT01483755|Procedure|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
355541|NCT01483755|Procedure|Percutaneaous intervention|Conventional primary percutaneaous intervention
355542|NCT01483742|Drug|RO5024048|1000 mg orally bid, 24 weeks
355543|NCT01483742|Drug|danoprevir|100 mg orally bid, 24 weeks
355544|NCT01483742|Drug|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
355545|NCT01483742|Drug|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
355546|NCT01483742|Drug|ritonavir|100 mg orally bid, 24 weeks
355547|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
355548|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
355549|NCT01483729|Drug|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
355550|NCT01483729|Drug|ritonavir|Test Formulation 1, single oral dose
355551|NCT01483729|Drug|ritonavir|Test Formulation 2, single oral dose
355552|NCT01483729|Drug|ritonavir|Reference Formulation, single oral dose
355553|NCT01483716|Behavioral|Rehabilitation|
355554|NCT01483703|Device|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
355555|NCT01483690|Drug|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
355556|NCT01483690|Drug|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
355557|NCT01483690|Drug|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
355558|NCT01483690|Drug|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
355559|NCT01483690|Drug|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
355560|NCT01483690|Drug|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
355561|NCT01483690|Drug|Methotrexate|"Given intrathecally to all patients the dose defined by age below.~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age~CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
355562|NCT01483677|Other|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
355563|NCT01483677|Other|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
355564|NCT01483651|Drug|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
355565|NCT01483651|Drug|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
355566|NCT01483638|Drug|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
355567|NCT01483638|Drug|placebo|will be administered orally with the same schedule of axitinib
355568|NCT01483625|Drug|tiotropium|18mcg
355569|NCT01483625|Drug|Placebo|placebo
356295|NCT01478347|Biological|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
355570|NCT01483612|Behavioral|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.~The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
355571|NCT01483599|Drug|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
355572|NCT01483599|Drug|CNTO 1959 (15 mg)|SC injections
355573|NCT01483599|Drug|CNTO 1959 (50 mg)|SC injections
355574|NCT01483599|Drug|CNTO 1959 (100 mg)|SC injections
355575|NCT01483599|Drug|CNTO 1959 (200 mg)|SC injections
355576|NCT01483599|Drug|Adalimumab|SC injections
355577|NCT01483599|Drug|Placebo|SC injections
355578|NCT01483586|Drug|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
355579|NCT01483586|Drug|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
355580|NCT01483573|Other|neural mobilization|stretch the nerve
355581|NCT01483573|Other|straight leg raise|stretch the hamstring
355582|NCT01483560|Drug|Metformin|3 years treatment duration
355583|NCT01483560|Drug|Placebo|3 years duration
355584|NCT01483547|Device|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
355585|NCT01483534|Device|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
355586|NCT01483521|Other|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
355587|NCT01483508|Other|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomer] and procyanidins [dimers to decamers]
355588|NCT01483508|Other|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins [dimers to decamers]
355589|NCT01483508|Other|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomers]
355590|NCT01483495|Device|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
355591|NCT01483482|Procedure|Conservative Treatment|Simple Sling
355592|NCT01483482|Procedure|Surgical treatment|Superior Locking plate
355593|NCT01483469|Drug|RO4917523|orally daily, 14 days
355594|NCT01483469|Drug|RO5011232|[11C]-RO5011232 intravenously
355595|NCT01483456|Other|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:~Identification of patient's fall risk,~Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),~Get up workshop and morbidity and mortality conferences related to fall cases"
355596|NCT01483443|Procedure|Oophrectomy|Both oophrectomy
355597|NCT01483430|Drug|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
355598|NCT01483430|Drug|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
355599|NCT01483430|Drug|Placebo|1 capsule/day (starch), Duration: 8 weeks
355600|NCT01483417|Procedure|Single incision Laparoscopic hysterectomy|SILS port
355601|NCT01483417|Procedure|Conventional laparoscopic hysterectomy|3-4 conventional ports
355602|NCT01483404|Procedure|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
355603|NCT01483391|Behavioral|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
355604|NCT01483391|Behavioral|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
355605|NCT01483378|Other|Choosing to receive the vaccine|
355606|NCT01483365|Drug|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
355607|NCT01483352|Device|Accu-Chek DiaPort|
355608|NCT01483339|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
355609|NCT01483339|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
355610|NCT01483300|Drug|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
355611|NCT01483300|Drug|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
355612|NCT01483287|Dietary Supplement|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.~No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
355613|NCT01483274|Biological|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
355614|NCT01483261|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
356636|NCT01475825|Drug|Placebo|Placebo vehicle for subcutaneous injection.
355615|NCT01483248|Biological|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.~MenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks."
355616|NCT01483248|Drug|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
355617|NCT01483235|Behavioral|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
355618|NCT01483235|Behavioral|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
355619|NCT01483222|Device|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
355620|NCT01483222|Device|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
355621|NCT01483209|Drug|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
355622|NCT01483196|Procedure|ultrasound imaging|Undergo TCD
355623|NCT01483196|Other|questionnaire administration|Complete neurocognitive questionnaires
355624|NCT01483196|Procedure|assessment of therapy complications|Undergo TCD
355625|NCT01483196|Procedure|quality-of-life assessment|Ancillary studies
355626|NCT01483196|Procedure|magnetic resonance imaging|Undergo MRI
355627|NCT01483183|Drug|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target~Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
355628|NCT01483183|Drug|Placebo|Placebo dose, 10-minute constant rate IV infusion
355629|NCT01483170|Drug|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
355630|NCT01483170|Drug|Placebo|Placebo fexinidazole
355631|NCT01483157|Other|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
355632|NCT01483157|Other|high intensity resistance training|twelve weeks of resistance training twice a week
355633|NCT01483144|Drug|Eflornithine plus Sulindac|Eflornithine [250 mg tablet, three tablets (750 mg) orally once a day] and Sulindac [150 mg tablet, one tablet orally once a day] for 24 months
355634|NCT01483144|Drug|Eflornithine and Placebo|Eflornithine [250 mg, three tablets (750 mg) orally once a day] and Placebo [one tablet orally once a day] for 24 months
355635|NCT01483144|Drug|Sulindac and Placebo|Sulindac [150 mg tablet, one tablet orally once a day] and Placebo [three tablets orally once a day] for 24 months
355636|NCT01483131|Other|Exercise training|12 weeks of resistance training twice a week.
355637|NCT01483131|Other|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
355638|NCT01483118|Drug|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
355639|NCT01483118|Dietary Supplement|Placebo|Placebo capsules containing ground cereal.
355640|NCT01483105|Behavioral|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
355641|NCT01483092|Dietary Supplement|inulin|20g/day for 4 weeks
355642|NCT01483092|Dietary Supplement|maltodextrin|20g/day for 4 weeks
355643|NCT01483066|Device|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
355644|NCT01483053|Drug|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
355645|NCT01483053|Drug|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
355646|NCT01483040|Device|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
355649|NCT01483001|Drug|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
355650|NCT01482975|Other|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
355651|NCT01482975|Other|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
355652|NCT01482962|Drug|Alisertib|Alisertib enteric coated tablets
355653|NCT01482962|Drug|Pralatrexate|Pralatrexate IV infusion
355654|NCT01482962|Drug|Gemcitabine|Gemcitabine IV infusion
355655|NCT01482962|Drug|Romidepsin|Romidepsin IV infusion
355656|NCT01482949|Drug|AGS-003|Autologous Dendritic Cell Immunotherapy
355657|NCT01482936|Drug|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
355658|NCT01482923|Behavioral|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
355659|NCT01482923|Behavioral|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
355660|NCT01482910|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
355661|NCT01482910|Drug|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
355662|NCT01482897|Drug|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
355663|NCT01482897|Drug|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
355664|NCT01482897|Drug|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
355665|NCT01482884|Drug|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
355666|NCT01482884|Drug|placebo|2 sc injections of every 2 weeks for 12 weeks.
355667|NCT01482871|Drug|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
355668|NCT01482871|Drug|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
355669|NCT01482871|Drug|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
355670|NCT01482871|Drug|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
355671|NCT01482858|Dietary Supplement|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
355672|NCT01482858|Other|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
355673|NCT01482845|Drug|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
355674|NCT01482845|Drug|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
355675|NCT01482832|Behavioral|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
355676|NCT01482819|Device|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
355677|NCT01482819|Device|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
355678|NCT01482819|Device|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
355679|NCT01482819|Device|polymacon|contact lenses worn bilaterally for 8-12 hours
355680|NCT01482819|Other|spectacles|habitual spectacles owned by subject, non-specific manufacturer
355681|NCT01482806|Behavioral|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants~These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
358583|NCT01461733|Drug|Placebo|placebo delivered blinded
355682|NCT01482806|Behavioral|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.~This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.~Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
355683|NCT01482793|Procedure|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
355684|NCT01482780|Device|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
355685|NCT01482767|Drug|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
355686|NCT01482767|Drug|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
355687|NCT01482767|Drug|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
355688|NCT01482754|Drug|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
355689|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
355690|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
355691|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
355692|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
355693|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
355725|NCT01482442|Drug|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
355829|NCT01481714|Drug|Sodium picosulphate, magnesium oxid and citric acid|"A sachet mixed with 250 mL of water at 18:00 pm~A sachet mixed with 250 mL of water at 21:00 pm~A minimum of 4 litres of fluid were recommended throughout the preparation"
356637|NCT01475825|Drug|mipomersen sodium 70 mg|Subcutaneous mipomersen 70 mg thrice weekly
355694|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
355695|NCT01482728|Drug|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
355696|NCT01482728|Drug|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
355697|NCT01482715|Drug|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
355698|NCT01482702|Behavioral|weight loss intervention|Behavioral weight loss intervention
355699|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
355700|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
355701|NCT01482689|Dietary Supplement|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
355702|NCT01482689|Dietary Supplement|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
355703|NCT01482663|Behavioral|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology."
355704|NCT01482650|Device|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
355705|NCT01482637|Other|CAS|All clients will be asked to complete the CAS instrument.
355706|NCT01482624|Device|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
355707|NCT01482624|Procedure|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
355708|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
355709|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
355710|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
355711|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
355712|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
355713|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
355714|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
355715|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
355716|NCT01482598|Device|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
355717|NCT01482585|Other|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
355718|NCT01482572|Procedure|biopsy|percutaneous lung biopsy and aspiration
355719|NCT01482559|Drug|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
355720|NCT01482559|Drug|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
355721|NCT01482468|Drug|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
355722|NCT01482468|Drug|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
355723|NCT01482455|Other|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
355724|NCT01482455|Other|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
355794|NCT01482000|Other|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
355726|NCT01482442|Drug|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
355727|NCT01482429|Other|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
355728|NCT01482416|Drug|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
355729|NCT01482416|Drug|Placebo|Placebo group will use placebo once/day during 30 days
355730|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
355731|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
355732|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 24 weeks
355733|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 48 weeks
355734|NCT01482403|Drug|boceprevir|800 mg three times a day for 24 weeks
355735|NCT01482403|Drug|boceprevir|800 mg three times a day for 48 weeks
355736|NCT01482403|Drug|mericitabine|1000 mg twice daily for 24 weeks
355737|NCT01482403|Drug|mericitabine placebo|mericitabine placebo
355738|NCT01482403|Drug|boceprevir placebo|boceprevir placebo
355739|NCT01482403|Drug|boceprevir|800 mg three times a day for 44 weeks
355740|NCT01482390|Drug|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than [<] 75 kg) or 1200 mg (for participants weighing greater than or equal to [>=] 75 kg) orally for 24 or 48 weeks.
355741|NCT01482390|Drug|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
355742|NCT01482390|Drug|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
355743|NCT01482390|Drug|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
355744|NCT01482390|Drug|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
355745|NCT01482377|Drug|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
355746|NCT01482377|Drug|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m^2 for the first infusion, followed by doses of 250 mg/m^2 for subsequent infusions.
355747|NCT01482377|Drug|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
355748|NCT01482377|Drug|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
355749|NCT01482364|Device|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
355750|NCT01482364|Device|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
355751|NCT01482351|Behavioral|CPAP adherence intervention|Critical factors were (1) OSA education, treatment expectations, and ways to minimize barriers and facilitate CPAP use; (2) promotion of a positive initial CPAP experience; (3) motivational interviewing to reinforce participants' health-related goals and CPAP self-efficacy; (4) anticipatory guidance and follow-up of common CPAP problems; and (5) social support by a study partner. Trained project staff provided the intervention by phone and face to face for a total of 12-14 hours over the 1 year project.
355752|NCT01482351|Behavioral|Attention control intervention|This intervention, provided by phone and face to face by project staff, provided equal time and attention. Critical factors were (1) education about OSA and risks, (2) education about memory, and other health topics of interest to the participants; (3) motivational interviewing to reinforce participants' health-related goals; (4) building rapport, and (5) social support by a study partner.
355753|NCT01482338|Drug|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
355754|NCT01482338|Drug|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
355755|NCT01482325|Device|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
355756|NCT01482312|Device|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
355757|NCT01482312|Device|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
355758|NCT01482312|Other|Glasses|Glasses per habitual prescription
355759|NCT01482299|Drug|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
355760|NCT01482286|Drug|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
355795|NCT01482000|Other|usual care|The control group will get the usual care with some additional tests for the study.
355796|NCT01481987|Procedure|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
355911|NCT01481116|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
358996|NCT01458444|Device|Non invasive ventilation (VNI)|BIPAP® vision
355761|NCT01482286|Behavioral|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
355762|NCT01482286|Behavioral|Exercise Training|"For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).~The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch."
355763|NCT01482273|Procedure|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
355764|NCT01482273|Procedure|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
355765|NCT01482260|Procedure|Biopsy|Biopsy
355766|NCT01482247|Dietary Supplement|L-Arginine|Dietary Supplement
355767|NCT01482247|Dietary Supplement|Placebo Supplement|Dietary Supplement
355768|NCT01482234|Behavioral|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
355769|NCT01482221|Drug|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
355770|NCT01482221|Drug|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
355771|NCT01482221|Drug|Placebo|0.9 sodium chloride [normal saline] solution for injection by iv infusion
355772|NCT01482195|Genetic|Recombinant Adeno-Associated Virus|Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus
355773|NCT01482169|Drug|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
355774|NCT01482156|Drug|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
355775|NCT01482143|Drug|AFQ056|
355776|NCT01482130|Behavioral|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
355777|NCT01482130|Behavioral|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:~Weight bearing activities (walking, jogging or strength training)~30 - 60 minutes, 3 - 5 times each week~A total of 2 - 3 hours each week should be achieved"
355778|NCT01482117|Drug|Clopidogrel|single oral administration of 300mg of clopidogrel
355779|NCT01482117|Drug|Cilostazol|single oral administration of 100mg cilostazol
355780|NCT01482117|Drug|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
355781|NCT01482104|Drug|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
355782|NCT01482104|Drug|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
355783|NCT01482091|Drug|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
355784|NCT01482091|Drug|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
355785|NCT01482065|Device|CPAP (ResMed S9 autoset CPAP)|A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
355786|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
355787|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
355788|NCT01482039|Procedure|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
355789|NCT01482039|Procedure|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
355790|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
355791|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
355792|NCT01482013|Drug|HPP854|Oral, once a day for 28 days.
355793|NCT01482013|Drug|Placebo|Oral, once a day for 28 days.
355912|NCT01481116|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
355797|NCT01481974|Drug|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.~Treatment phase activities include:~• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
355798|NCT01481961|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
355799|NCT01481948|Behavioral|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
355800|NCT01481935|Other|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
355801|NCT01481935|Other|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
355802|NCT01481922|Device|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
355803|NCT01481922|Device|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
355804|NCT01481909|Drug|Rupatadin|20 mg, 28 days over 60 days
355805|NCT01481896|Device|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
355806|NCT01481883|Drug|Raloxifene Hydrochloride|120mg daily - 1 capsule daily for 12 week trial
355807|NCT01481883|Drug|Placebo|1 capsule daily for 12 week trial
355808|NCT01481870|Drug|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
355809|NCT01481870|Drug|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
355810|NCT01481857|Other|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
355811|NCT01481857|Other|Segmental trunk exercise|Segmental trunk exercise
355812|NCT01481844|Drug|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
355813|NCT01481844|Drug|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
355814|NCT01481831|Drug|Palonosetron Hydrochloride|0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
355815|NCT01481831|Drug|Palonosetron Hydrochloride|0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
355816|NCT01481818|Drug|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
355817|NCT01481779|Drug|Glargine|Administered by SC injection via a pen device.
355818|NCT01481779|Drug|LY2605541|Administered by SC injection with a pen device.
355819|NCT01481779|Drug|Insulin Lispro|Administered by SC injection with a pen device.
355820|NCT01481766|Dietary Supplement|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
355821|NCT01481766|Dietary Supplement|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
355822|NCT01481766|Behavioral|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
355823|NCT01481753|Procedure|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
355824|NCT01481753|Procedure|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
355825|NCT01481740|Drug|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
355826|NCT01481740|Drug|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
355827|NCT01481727|Device|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (>18mmHg) for at least six hours, nocturnal ventilation.
355828|NCT01481727|Device|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
356163|NCT01479348|Diagnostic Test|PET/CT|One prior CT and 3 sequential whole body PET
355830|NCT01481714|Drug|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
355831|NCT01481701|Drug|Oxaliplatin|85 mg/m² / 14days
355832|NCT01481701|Drug|oxaliplatin|oxaliplatin
355833|NCT01481688|Other|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
355834|NCT01481688|Other|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
355835|NCT01481662|Device|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
355836|NCT01481623|Other|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
355837|NCT01481623|Other|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
355838|NCT01481610|Drug|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
355839|NCT01481610|Drug|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
355840|NCT01481597|Drug|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
355841|NCT01481597|Drug|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
355842|NCT01481597|Drug|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
355843|NCT01481597|Drug|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
355844|NCT01481597|Drug|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
355845|NCT01481584|Dietary Supplement|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
355846|NCT01481584|Dietary Supplement|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
355847|NCT01481571|Device|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
355848|NCT01481558|Device|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
355849|NCT01481545|Radiation|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
355850|NCT01481545|Drug|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
355851|NCT01481545|Drug|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
355852|NCT01481545|Drug|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
355853|NCT01481545|Drug|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
355854|NCT01481545|Drug|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
355855|NCT01481532|Drug|Crotoxin|Intra patient dose escalation
355856|NCT01481519|Drug|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
355857|NCT01481519|Drug|Artificial Tears|artificial tears 1 drop, 4 times per day
355858|NCT01481506|Procedure|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
355859|NCT01481493|Biological|BT061|subcutaneous administration of the monoclonal antibody BT061
355860|NCT01481493|Biological|Placebo|subcutaneous injection of placebo
355861|NCT01481480|Procedure|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
355862|NCT01481480|Procedure|Arthroscopic repair|Arthroscopic repair
355863|NCT01481467|Behavioral|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
355864|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
355865|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
355866|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
355867|NCT01481454|Biological|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
355868|NCT01481441|Drug|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
355907|NCT01481142|Device|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
355908|NCT01481129|Drug|Akt Inhibitor MK2206|Given PO
355909|NCT01481129|Other|Laboratory Biomarker Analysis|Correlative studies
355869|NCT01481428|Behavioral|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
355870|NCT01481428|Behavioral|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
355871|NCT01481402|Drug|Liothyronine|Liothyronine 40 microgram per day
355872|NCT01481402|Drug|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
355873|NCT01481389|Dietary Supplement|Theobromine|200 ml drink with added theobromine (no cocoa added)
355874|NCT01481389|Dietary Supplement|Cocoa|200 ml drink with cocoa (no theobromine added)
355875|NCT01481389|Dietary Supplement|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
355876|NCT01481389|Dietary Supplement|Placebo|200 ml drink (no added theobromine or cocoa)
355877|NCT01481363|Behavioral|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
355878|NCT01481363|Behavioral|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
355879|NCT01481350|Drug|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
355880|NCT01481337|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
355881|NCT01481311|Device|medical Body Composition Analyzer seca 514/515|Current of 100 µA
355882|NCT01481311|Procedure|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
355883|NCT01481272|Drug|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
355884|NCT01481272|Drug|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
355885|NCT01481272|Drug|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients >/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
355886|NCT01481272|Drug|Mesna|300mg/m2 or 200mg/m2 (patients >/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients >/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
355887|NCT01481272|Drug|Cytarabine|2g/m2 or 0,5-1g/m2 (patients >/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
355888|NCT01481272|Drug|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
355889|NCT01481272|Drug|Leukovorin|15mg, po 24 hours after methotrexate it
355890|NCT01481272|Drug|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC>1.0x109/l
355891|NCT01481259|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
355892|NCT01481259|Other|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
355893|NCT01481246|Behavioral|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
355894|NCT01481233|Drug|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
355895|NCT01481220|Drug|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
355896|NCT01481194|Drug|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
355897|NCT01481194|Drug|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
355898|NCT01481194|Drug|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
355899|NCT01481194|Drug|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
355900|NCT01481194|Drug|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
355901|NCT01481181|Dietary Supplement|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
355902|NCT01481168|Device|Pacemaker implantation (Medtronic)|DDD+/-R pacing
355903|NCT01481168|Device|Pacemaker implantation (Medtronic)|ODO pacing
355904|NCT01481168|Device|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
355905|NCT01481155|Procedure|ablative CO2 laser therapy|CO2 laser therapy
355906|NCT01481155|Procedure|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
355910|NCT01481129|Other|Pharmacological Study|Correlative studies
356164|NCT01479296|Biological|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
355913|NCT01481116|Drug|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
355914|NCT01481103|Procedure|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
355915|NCT01481090|Procedure|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
355916|NCT01481077|Drug|Latanoprost-PPDS|Sustained release for 12 weeks
355917|NCT01481064|Behavioral|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
355918|NCT01481051|Drug|Latanoprost-PPDS|Sustained delivery for 12 weeks
355919|NCT01481025|Drug|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months~1 tablet, 80+450mg/tablet, once a day for 3-6 months"
355920|NCT01481025|Drug|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months~1 caps, 80mg/caps, once a day for 3-6 months"
355921|NCT01481025|Drug|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
355922|NCT01480986|Drug|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m^2，ivgtt，90min，D1 Cisplatin 50 mg/m^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
355923|NCT01480973|Radiation|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
355924|NCT01480960|Other|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
355925|NCT01480947|Drug|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
355926|NCT01480921|Behavioral|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:~5-10 min warm-up~30 min aerobic interval training (walking or stationary bicycle)~10 min cool-down~Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
355927|NCT01480921|Behavioral|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:~5-10 min of warm-up~30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers~10 min of cool down~Exercise will be tracked by the participant in exercise log books."
355928|NCT01480908|Procedure|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
355929|NCT01480908|Procedure|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
355930|NCT01480908|Procedure|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
355931|NCT01480908|Procedure|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
355932|NCT01480895|Behavioral|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
355933|NCT01480882|Procedure|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
355934|NCT01480882|Device|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
355935|NCT01480869|Drug|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
355936|NCT01480869|Drug|calcium and cholecalciferol|"Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:~100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level < 10 ng/mL~100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level < 20 ng/mL~100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level < 30 ng/mL"
355937|NCT01480856|Procedure|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
355938|NCT01480856|Procedure|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
355939|NCT01480843|Drug|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
355940|NCT01480830|Device|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
355941|NCT01480817|Drug|Sorafenib|Sorafenib 400mg po bid
356165|NCT01479296|Biological|rAd5 env A|Given intramuscularly
356166|NCT01479296|Biological|rAd5 env B|Given intramuscularly
356167|NCT01479296|Biological|rAd5 env C|Given intramuscularly
356168|NCT01479296|Biological|rAd5 gag-pol|Given intramuscularly
355942|NCT01480817|Procedure|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
355943|NCT01480804|Other|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
355944|NCT01480791|Drug|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
355945|NCT01480791|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
355946|NCT01480778|Drug|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
355947|NCT01480778|Drug|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
355948|NCT01480765|Drug|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
355949|NCT01480765|Drug|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
355950|NCT01480765|Drug|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
355951|NCT01480765|Drug|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
355952|NCT01480752|Drug|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
355953|NCT01480752|Drug|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
355954|NCT01480752|Drug|no injection|inject nothing after inferior alveolar injection and before root canal therapy
355955|NCT01480739|Drug|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
355956|NCT01480739|Drug|100 mg Placebo|Twice daily for 7 days
355957|NCT01480726|Procedure|Surgery|
355958|NCT01480713|Drug|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
355959|NCT01480713|Drug|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
355960|NCT01480700|Other|Nutritional study|subjects consume 2 eggs per day during 4 months
355961|NCT01480687|Dietary Supplement|DHA-EPA|1800 mg/day
355962|NCT01480687|Drug|Ciprofibrate|100 mg/day
355963|NCT01480674|Drug|Trastuzumab|
355964|NCT01480661|Drug|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
355965|NCT01480661|Drug|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
355966|NCT01480661|Radiation|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
355967|NCT01480648|Drug|BI 144807 Placebo|Placebo that represents BI drug
355968|NCT01480648|Drug|BI 144807|single dose (low to high dose)
355969|NCT01480622|Drug|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
355970|NCT01480609|Drug|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
355971|NCT01480596|Biological|Belimumab|10mg/kg IV infusion
355972|NCT01480596|Other|Placebo|placebo IV infusion
355973|NCT01480583|Drug|GRN1005|550 mg/m2 IV every 3 weeks
355974|NCT01480583|Drug|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
355975|NCT01480583|Drug|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
355976|NCT01480557|Procedure|liquefaction|Cataract extraction surgery type
355977|NCT01480557|Procedure|Torsional ip|A type cataract surgery using torsional ip technology
355978|NCT01480544|Other|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
355979|NCT01480544|Other|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
355980|NCT01480531|Drug|Clevidipine|"Clevidipine administration begins in the ER or ICU~Clevidipine is again administered post op when blood pressure control is required.~Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:~Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.~Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.~Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.~As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
355981|NCT01480518|Genetic|DNA analysis|
355982|NCT01480518|Genetic|comparative genomic hybridization|
355983|NCT01480518|Genetic|gene expression analysis|
355984|NCT01480518|Genetic|mutation analysis|
355985|NCT01480518|Genetic|polymerase chain reaction|
355986|NCT01480518|Genetic|polymorphic microsatellite marker analysis|
355987|NCT01480518|Other|laboratory biomarker analysis|
356169|NCT01479296|Biological|Placebo Vaccine|Given intramuscularly
356331|NCT01478048|Biological|Elotuzumab|Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 & 2: Days 1, 8 & 15; Cycles 3-8: Days 1 & 11; Cycle 9+: Days 1 & 15); Until subject meets criteria for discontinuation of study drug
356449|NCT01477281|Drug|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
355988|NCT01480505|Procedure|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.~Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
355989|NCT01480492|Drug|Telbivudine|600mg,1/d,one year
355990|NCT01480479|Drug|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.~Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
355991|NCT01480479|Drug|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
355992|NCT01480479|Drug|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
355993|NCT01480466|Other|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
355994|NCT01480453|Device|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
355995|NCT01480440|Device|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
355996|NCT01480414|Biological|4times injection|bone marrow derived mono nuclear stem cell
355997|NCT01480414|Biological|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
355998|NCT01480401|Other|low-sodium diet (1500 mg daily)|
355999|NCT01480388|Drug|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
356000|NCT01480388|Drug|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
356001|NCT01480388|Drug|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
356002|NCT01480388|Drug|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
356003|NCT01480388|Drug|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
356004|NCT01480375|Device|Smartbx™ system.|The SmartBx™ system semi-automated downloads the biopsy cores from the biopsy needle onto a designated cassette which integrates into the routine pathology lab processing. The core is downloaded in an oriented and straightened fashion while preserving core fragments in its original locations relative to the needle notch.
356005|NCT01480362|Device|Negative Pressure Wound Therapy|"Used therapy systems:~KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
356006|NCT01480362|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
356007|NCT01480336|Drug|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
356008|NCT01480336|Drug|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
356009|NCT01480323|Drug|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
356010|NCT01480323|Drug|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
356011|NCT01480310|Drug|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
356012|NCT01480310|Drug|Placebo|may receive up to 3 subcutaneous doses of placebo
356013|NCT01480297|Drug|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
356014|NCT01480284|Drug|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
356015|NCT01480284|Drug|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
356016|NCT01480271|Drug|2 ng GSK2445053|2ng GSK2445053 administered intranasally
356017|NCT01480271|Drug|20ng GSK2445053|20ng GSK2445053 administered intranasally
356018|NCT01480271|Drug|100ng GSK2445053|100ng GSK2445053 administered intranasally
356019|NCT01480271|Drug|200ng GSK2445053|200ng GSK2445053 administered intranasally
356020|NCT01480271|Drug|400ng GSK2445053|400ng GSK2445053 administered intranasally
356021|NCT01480271|Drug|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
356022|NCT01480271|Drug|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
356023|NCT01480271|Drug|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
356024|NCT01480271|Drug|Placebo|Placebo administered intranasally
356025|NCT01480258|Biological|PR5I|DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis [acellular, component], hepatitis B [recombinant DNA], polio virus [inactivated], and Haemophilus influenza type b conjugate vaccine [adsorbed]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.
356026|NCT01480258|Biological|Rotavirus vaccine|Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)
356027|NCT01480258|Biological|Prevenar 13™|Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.
356208|NCT01478997|Dietary Supplement|Placebo Capsules|Carboxy Methyl Cellulose
356209|NCT01478984|Procedure|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
356028|NCT01480258|Biological|INFANRIX™ hexa|Combined Diphtheria-Tetanus-acellular Pertussis [DTaP], Hepatitis B [HepB], Poliovirus [IPV] and Haemophilus influenzae type b [Hib] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
356029|NCT01480245|Drug|GSK2402968|6mg/kg/week
356030|NCT01480232|Drug|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
356031|NCT01480232|Drug|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
356032|NCT01480232|Drug|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
356033|NCT01480232|Drug|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
356034|NCT01480232|Behavioral|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
356035|NCT01480219|Drug|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
356036|NCT01480219|Other|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
356037|NCT01480206|Other|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
356038|NCT01480193|Other|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
356039|NCT01480193|Other|Integrative Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions, 5 Acupuncture Sessions, and Group-Based 8 week Mindfulness Based Stress Reduction Provided synergistically through an integrative medicine paradigm
356040|NCT01480180|Drug|turoctocog alfa pegol|Administered i.v.
356041|NCT01480167|Device|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
356042|NCT01480167|Other|Non-operative Management|Conservative Care
356043|NCT01480154|Drug|Akt Inhibitor MK2206|Given PO
356044|NCT01480154|Drug|Hydroxychloroquine|Given PO
356045|NCT01480141|Drug|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
356046|NCT01480128|Procedure|Single-port|Single-port laparoscopic colon resection
356047|NCT01480128|Procedure|Multi-port|Multi-port laparoscopic colon resection
356048|NCT01480115|Other|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
356049|NCT01480102|Drug|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
356050|NCT01480102|Other|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
356051|NCT01480089|Drug|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
356052|NCT01480089|Drug|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
356053|NCT01480076|Drug|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
356054|NCT01480063|Drug|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
356055|NCT01480050|Drug|temozolomide|standard of care drug
356056|NCT01480050|Other|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
356057|NCT01480050|Other|pharmacological study|
356058|NCT01480050|Drug|Mibefradil|
356059|NCT01480011|Drug|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
356060|NCT01479998|Other|standard care|standard care plus nicotine replacement therapy
356061|NCT01479998|Other|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
356062|NCT01479985|Other|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
356063|NCT01479972|Biological|VPM1002|Tuberculosis vaccine
356064|NCT01479972|Biological|BCG|commercially available live vaccine BCG
356065|NCT01479959|Device|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
356066|NCT01479946|Drug|Electrochemotherapy|bleomycin together with electroporation
356067|NCT01479933|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
356068|NCT01479933|Dietary Supplement|Placebo|Inactive placebo
356069|NCT01479933|Dietary Supplement|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
356070|NCT01479920|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
356210|NCT01478984|Procedure|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
356332|NCT01478048|Drug|Bortezomib|Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
356071|NCT01479920|Procedure|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
356072|NCT01479920|Procedure|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
356073|NCT01479907|Dietary Supplement|Synbiotics|12 gr in 250 cc of water once daily X 15 days
356074|NCT01479907|Dietary Supplement|Placebo|12 gr in 250 cc of water once daily X 15 days
356075|NCT01479881|Drug|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
356076|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
356077|NCT01479881|Drug|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
356078|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
356079|NCT01479868|Drug|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
356080|NCT01479868|Drug|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
356081|NCT01479868|Drug|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
356082|NCT01479842|Drug|BTK inhibitor PCI-32765|Given PO
356083|NCT01479842|Biological|rituximab|Given IV
356084|NCT01479842|Drug|bendamustine hydrochloride|Given IV
356085|NCT01479842|Other|pharmacogenomic studies|Correlative studies
356086|NCT01479842|Other|pharmacological study|Correlative studies
356087|NCT01479842|Other|laboratory biomarker analysis|Correlative studies
356088|NCT01479829|Drug|ESC + CBX|Escitalopram (ESC) 10 mg twice day given orally twice a day plus Celecoxib (CBX) 200 mg twice daily.
356089|NCT01479829|Drug|ESC + PBO.|• Escitalopram (ESC) 10 mg twice per day plus Placebo (PBO)administered twice daily.
356090|NCT01479829|Drug|ESC+CBX|• Escitalopram 10 mg given twice day plus Celecoxib 200 mg twice daily.
356091|NCT01479803|Procedure|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
356092|NCT01479790|Device|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
356093|NCT01479777|Device|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
356094|NCT01479764|Drug|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
356095|NCT01479764|Drug|Neostigmine|neostigmine, per usual practice
356096|NCT01479764|Drug|Glycopyrrolate|glycopyrrolate per usual practice
356097|NCT01479751|Drug|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
356098|NCT01479751|Drug|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
356099|NCT01479751|Drug|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
356100|NCT01479738|Procedure|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
356101|NCT01479725|Procedure|HBOT|HBOT
356102|NCT01479712|Procedure|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
356103|NCT01479699|Dietary Supplement|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
356104|NCT01479686|Procedure|iMRI|3.0TiMRI guided resection in adults with glioma
356105|NCT01479686|Procedure|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
356106|NCT01479673|Dietary Supplement|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
356107|NCT01479660|Other|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
356108|NCT01479660|Drug|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
356109|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
356110|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
356111|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
356112|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
356113|NCT01479647|Drug|PH-797804|Tablet, 24 mg, single dose
356114|NCT01479634|Drug|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
356115|NCT01479634|Drug|Study-Provided ART|"Study provided drugs:~Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate [TDF] and emtricitabine [FTC]) PLUS~Efavirenz [EFV]"
356247|NCT01478685|Drug|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2
356408|NCT01477580|Biological|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356116|NCT01479621|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
356117|NCT01479621|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
356118|NCT01479621|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
356119|NCT01479621|Drug|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
356120|NCT01479608|Procedure|Liver transplantation and liver resection|
356121|NCT01479595|Drug|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
356122|NCT01479595|Drug|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
356123|NCT01479582|Drug|Access to unlicensed cord blood units|
356124|NCT01479569|Procedure|Pericardiocentesis|
356125|NCT01479556|Drug|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
356126|NCT01479556|Drug|Placebo|150mg BID p.o.
356127|NCT01479543|Other|Probiotic CNCM I-4034|Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
356128|NCT01479543|Other|Probiotic CNCM I-4035|9x10E9 cfu (colony forming unit) per day during 28 days.
356129|NCT01479543|Other|Probiotic CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
356130|NCT01479543|Other|Probiotics CNCM I-4035 and CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
356131|NCT01479543|Other|Placebo|Placebo capsule for 28 days.
356132|NCT01479530|Drug|Placebo|Once daily; tablet; orally; 16 weeks
356133|NCT01479530|Drug|Azilect®|1 mg daily; tablet; orally; 16 weeks
356134|NCT01479517|Drug|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
356135|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
356136|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
356137|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
356138|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
356139|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
356140|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy~concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
356141|NCT01479491|Other|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
356142|NCT01479478|Drug|Placebo|One placebo capsule daily.
356143|NCT01479478|Dietary Supplement|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
356144|NCT01479465|Biological|Simtuzumab|SIM administered via intravenous infusion over 30 minutes
356145|NCT01479465|Drug|Placebo to match SIM|Placebo to match SIM administered via intravenous infusion over 30 minutes
356146|NCT01479465|Drug|Leucovorin|l-Leucovorin 200 mg/m^2 or dl-leucovorin 400 mg/m^2 administered via intravenous infusion over 2 hours
356147|NCT01479465|Drug|Irinotecan|Irinotecan 180 mg/m^2 administered via intravenous infusion over 90 minutes
356148|NCT01479465|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 administered via intravenous bolus and 2400 mg/m^2 via intravenous infusion over 46 hours
356149|NCT01479452|Procedure|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
356150|NCT01479452|Other|Usual care|Non-surgical obesity treatment
356151|NCT01479439|Drug|Losartan|Form: suspension, tablet. Dosage & frequency: age 6-16 = 0.7mg/kg once daily; age >16 = 50mg once daily. Duration: 6 months
356152|NCT01479426|Dietary Supplement|EFLA400|EFLA400(960mg/day)for 12 weeks
356153|NCT01479426|Dietary Supplement|Placebo|Placebo(960mg/day) for 12 weeks
356154|NCT01479387|Drug|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
356155|NCT01479374|Drug|AL-4943A ophthalmic solution|
356156|NCT01479374|Drug|AL-4943A vehicle|Inactive ingredients used as placebo
356157|NCT01479374|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
356158|NCT01479361|Drug|Atovaquone 750 mg twice daily|
356159|NCT01479361|Drug|Atovaquone 1500 mg twice daily|
356160|NCT01479348|Drug|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|18FdCyd radiotracer
356161|NCT01479348|Drug|Tetrahydrouridine (IV)|Total dose of THU = 350 mg/m2, IV
356162|NCT01479348|Drug|Tetrahydrouridine (oral)|Total dose of THU is 3000 mg, oral
356170|NCT01479283|Drug|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
356171|NCT01479283|Drug|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.~Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.~Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
356172|NCT01479270|Drug|TAP Block|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
356173|NCT01479257|Behavioral|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
356174|NCT01479257|Device|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
356175|NCT01479257|Device|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
356176|NCT01479244|Biological|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
356177|NCT01479244|Biological|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
356178|NCT01479231|Drug|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
356179|NCT01479218|Device|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
356180|NCT01479192|Drug|Fenretinide|100mg (2cps/day) for 5 years
356181|NCT01479192|Other|Placebo|2 cpr/day of matched placebo for 5 years
356182|NCT01479179|Drug|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
356183|NCT01479179|Drug|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.~Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
356184|NCT01479153|Procedure|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
356185|NCT01479127|Drug|ABT-SLV187|
356186|NCT01479127|Drug|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
356187|NCT01479127|Device|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
356188|NCT01479127|Device|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
356189|NCT01479127|Device|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
356190|NCT01479114|Drug|rh-GCSF|10 ug/kg/day intravenously for 3 days
356191|NCT01479101|Other|MammaPrint 70-gene expression profile|
356192|NCT01479101|Other|BluePrint 80 gene expression profile|
356193|NCT01479088|Drug|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value <180 pg/mL as tolerated by the patient
356194|NCT01479075|Drug|intransal insulin|4x 40mU intranasal insulin
356195|NCT01479075|Drug|Placebo|
356196|NCT01479075|Device|taVNS|
356197|NCT01479075|Device|sham stimulation|
356198|NCT01479062|Behavioral|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
356199|NCT01479062|Behavioral|Usual Care|Placebo Control
356200|NCT01479049|Drug|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
356201|NCT01479049|Drug|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
356202|NCT01479036|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
356203|NCT01479036|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
356204|NCT01479023|Drug|64Cu-DOTA-U3-1287|
356205|NCT01479023|Drug|U3-1287 (unlabeled)|
356206|NCT01479010|Drug|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
356207|NCT01478997|Dietary Supplement|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
356211|NCT01478971|Drug|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous [IV] or subcutaneous [SC]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of <11 g/dL.
356212|NCT01478971|Drug|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at <11 g/dL.
356213|NCT01478958|Dietary Supplement|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
356214|NCT01478958|Dietary Supplement|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
356215|NCT01478958|Dietary Supplement|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
356216|NCT01478945|Device|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.~Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.~Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
356217|NCT01478932|Behavioral|diaphragmatic breathing retraining|Experimental group participates in an 8-week breathing retraining intervention that requires 30 minutes a day. Control group receives an 8-week health promotion attention control condition.
356218|NCT01478893|Biological|SEL-068|Sub-cutaneous injection, multiple dose
356219|NCT01478893|Biological|Saline|Sub-cutaneous injection, multiple dose
356220|NCT01478880|Procedure|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
356221|NCT01478880|Procedure|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
356222|NCT01478867|Other|Detection of gluten in feces|Detection of Gluten in Feces
356223|NCT01478854|Radiation|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
356224|NCT01478854|Drug|Chemotherapy|Temozolomide
356225|NCT01478841|Drug|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
356226|NCT01478841|Drug|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
356227|NCT01478828|Drug|Lovastatin|oral qd varying dose escalations/de-escalations
356228|NCT01478815|Behavioral|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
356229|NCT01478815|Other|Standard Care|Standard Care
356230|NCT01478802|Device|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
356231|NCT01478802|Device|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
356232|NCT01478789|Dietary Supplement|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
356233|NCT01478789|Dietary Supplement|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
356234|NCT01478789|Dietary Supplement|placebo|100g/d yogurt with no added plant sterol
356235|NCT01478776|Dietary Supplement|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
356236|NCT01478776|Dietary Supplement|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
356237|NCT01478750|Dietary Supplement|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
356238|NCT01478750|Procedure|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
356239|NCT01478737|Drug|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
356240|NCT01478737|Procedure|Vitrectomy|Vitrectomy only
356241|NCT01478724|Dietary Supplement|Milk proteins fraction|capsules, one per day, 24 months
356242|NCT01478711|Other|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
356243|NCT01478698|Drug|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
356244|NCT01478698|Drug|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
356245|NCT01478685|Drug|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
356246|NCT01478685|Drug|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
358997|NCT01458444|Device|Non invasive ventilation|OPTIFLOW system
356248|NCT01478672|Procedure|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
356249|NCT01478659|Dietary Supplement|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
356250|NCT01478659|Dietary Supplement|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
356251|NCT01478646|Other|conventional breathing therapy|duration: 60 minutes.
356252|NCT01478646|Other|reflectory breathing therapy|duration: 60 minutes.
356253|NCT01478633|Drug|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
356254|NCT01478620|Drug|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
356255|NCT01478607|Drug|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
356256|NCT01478594|Drug|Tivozanib|Capsules for oral administration
356257|NCT01478594|Drug|Bevacizumab|Solution for intravenous infusion
356258|NCT01478594|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
356259|NCT01478581|Drug|PCI-32765|
356260|NCT01478581|Drug|Dexamethasone|
356261|NCT01478568|Drug|mirabegron|oral
356262|NCT01478568|Drug|desipramine|oral
356263|NCT01478555|Drug|ISV 101|Bromfenac in DuraSite
356264|NCT01478542|Drug|Conventional Vincristine|
356265|NCT01478542|Drug|Liposomal Vincristine|
356266|NCT01478542|Drug|Ricover-scheme rituximab|
356267|NCT01478542|Drug|optimised rituximab-schedule|
356268|NCT01478529|Drug|mirabegron OCAS|oral administration
356269|NCT01478529|Drug|mirabegron|iv administration
356270|NCT01478516|Procedure|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
356271|NCT01478503|Drug|mirabegron OCAS|oral
356272|NCT01478503|Drug|Placebo|oral
356273|NCT01478490|Drug|mirabegron|oral
356274|NCT01478490|Drug|metoprolol|oral
356275|NCT01478477|Dietary Supplement|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
356276|NCT01478477|Other|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
356277|NCT01478477|Other|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
356278|NCT01478477|Other|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
356279|NCT01478477|Procedure|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
356280|NCT01478477|Procedure|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
356281|NCT01478464|Other|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
356282|NCT01478451|Behavioral|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
356283|NCT01478451|Other|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
356284|NCT01478438|Device|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
356285|NCT01478425|Device|Lipidic Microemulsion|Topical nasal, twice a day
356286|NCT01478425|Device|Saline|Topical Nasal, twice a day
356287|NCT01478412|Other|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
356288|NCT01478399|Drug|PB1023 Injection|90 mg Dose
356289|NCT01478386|Other|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
356290|NCT01478386|Device|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
356291|NCT01478386|Device|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
356292|NCT01478373|Drug|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
356293|NCT01478360|Drug|AIN457 (secukinumab)|Secukinumab intravenous injection
356294|NCT01478360|Drug|Placebo|Placebo intravenous injection
356296|NCT01478334|Behavioral|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.~Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
356297|NCT01478334|Behavioral|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.~Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
356298|NCT01478321|Drug|Temozolomide|Given PO
356299|NCT01478321|Radiation|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
356300|NCT01478321|Biological|bevacizumab|Given IV
356301|NCT01478321|Other|questionnaire administration|Ancillary studies
356302|NCT01478308|Drug|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
356303|NCT01478308|Drug|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
356304|NCT01478308|Drug|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
356305|NCT01478295|Behavioral|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
356306|NCT01478295|Other|Control Group/Usual Care:|"Control Group/Usual Care:~Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
356307|NCT01478282|Drug|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
356308|NCT01478282|Drug|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
356309|NCT01478256|Drug|Erythromycin|Topical erythromycin ointment twice a day
356310|NCT01478256|Drug|Besifloxocin|Topical Besifloxocin twice a day
356311|NCT01478230|Drug|Nicotine|Nicotine 5 mg Inhaler
356312|NCT01478230|Drug|Nicotine|Nicotine 10 mg Inhaler
356313|NCT01478178|Drug|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
356314|NCT01478165|Drug|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
356315|NCT01478165|Drug|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
356316|NCT01478152|Other|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
356317|NCT01478139|Procedure|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
356318|NCT01478139|Procedure|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
356319|NCT01478126|Drug|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
356320|NCT01478126|Drug|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2*weight/24. Infusion starts in operating room and ends next day after the surgery.
356321|NCT01478113|Drug|Amphetamine/dextroamphetamine|The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
356322|NCT01478113|Drug|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
356323|NCT01478113|Behavioral|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
356324|NCT01478087|Device|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
356325|NCT01478074|Drug|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC > 1000
356326|NCT01478074|Drug|Cytarabine|2 g/m2 daily from day -6 through -2
356327|NCT01478074|Drug|Fludarabine|30 mg/m2 daily from day -6 through -2
356328|NCT01478074|Biological|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10^6 cells/Kg
356329|NCT01478074|Biological|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
356330|NCT01478061|Device|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
356333|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
356334|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 8 mg; (Cycles 1& 2: Days 1, 8, 15; Cycles 3-8: Days 1 &11; Cycles 9+; Days 1 & 15); Until subject meets criteria for discontinuation of study drug
356335|NCT01478048|Drug|Dexamethasone|Solution; IV; 8 mg; (Cycles 1& 2: Days 1, 8, 15; Cycles 3-8: Days 1 &11; Cycles 9+; Days 1 & 15); Until subject meets criteria for discontinuation of study drug
356336|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
356337|NCT01478035|Drug|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
356338|NCT01478035|Drug|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
356339|NCT01478022|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
356340|NCT01478022|Drug|Ibuprofen|Ibuprofen 200 mg daily, capsules
356341|NCT01478022|Other|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
356342|NCT01478009|Dietary Supplement|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
356343|NCT01478009|Dietary Supplement|Placebo|Placebo (3.0g/day) for 12 weeks
356344|NCT01477996|Procedure|27-gauge|27-gauge needle for IVT
356345|NCT01477996|Procedure|30-gauge|30-gauge needle for IVT
356346|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
356347|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
356348|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
356349|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
356350|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
356351|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
356352|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
356353|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
356354|NCT01477957|Procedure|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
356355|NCT01477931|Drug|Bupropion extended release|300mg once a daily, PO, 8weeks
356356|NCT01477905|Device|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
356357|NCT01477905|Device|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
356358|NCT01477892|Drug|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
356359|NCT01477879|Other|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
356360|NCT01477879|Other|placebo (versabase gel only)|versabase gel only
356361|NCT01477866|Dietary Supplement|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
356362|NCT01477866|Other|conventional therapy|conventional therapy for colon-rectal cancer
356363|NCT01477853|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally daily
356364|NCT01477853|Drug|Atorvastatin|Atorvastatin 80 mg tablet orally daily
356365|NCT01477853|Other|Placebo to sitagliptin|Placebo to sitagliptin tablet orally daily
356366|NCT01477853|Other|Placebo to atorvastatin|Placebo to atorvastatin tablet orally daily.
356367|NCT01477853|Drug|Metformin (open-label)|Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
356368|NCT01477853|Drug|Glimepiride (open-label)|Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
356369|NCT01477853|Drug|Glimepiride (double-blind)|Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
356370|NCT01477853|Drug|Placebo to glimepiride|Phase B: placebo to glimepiride tablet orally daily.
356371|NCT01477840|Drug|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
356372|NCT01477827|Other|None - observational study|
356373|NCT01477814|Behavioral|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
356409|NCT01477580|Biological|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356374|NCT01477814|Behavioral|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
356375|NCT01477814|Behavioral|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
356376|NCT01477801|Drug|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months"
356377|NCT01477801|Drug|PLACEBO|Standard guideline based therapy plus placebo
356378|NCT01477775|Drug|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
356379|NCT01477775|Drug|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
356380|NCT01477762|Drug|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
356381|NCT01477762|Drug|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
356382|NCT01477749|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
356383|NCT01477736|Drug|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
356384|NCT01477736|Drug|Botulinum toxin A|300 U intradetrusor injection
356385|NCT01477723|Other|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
356386|NCT01477710|Procedure|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
356387|NCT01477710|Procedure|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
356388|NCT01477710|Procedure|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
356389|NCT01477697|Dietary Supplement|Omega-3|50 mg/kg per day of omega-3 fatty acids
356390|NCT01477697|Dietary Supplement|Placebo|50 mg/kg per day of placebo equivalent
356391|NCT01477632|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
356392|NCT01477632|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
356393|NCT01477632|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
356394|NCT01477619|Drug|Tasimelteon|20mg single dose on Day 1
356395|NCT01477606|Drug|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year."
356396|NCT01477606|Drug|Cytarabine|"Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
356397|NCT01477606|Drug|Daunorubicin|"Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
356398|NCT01477593|Procedure|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
356399|NCT01477593|Procedure|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
356400|NCT01477593|Procedure|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
356401|NCT01477580|Biological|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356402|NCT01477580|Biological|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356403|NCT01477580|Biological|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
356404|NCT01477580|Biological|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356405|NCT01477580|Biological|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356406|NCT01477580|Biological|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
356407|NCT01477580|Biological|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
356448|NCT01477294|Drug|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
356410|NCT01477580|Biological|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356411|NCT01477580|Biological|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356412|NCT01477580|Biological|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
356413|NCT01477580|Biological|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
356414|NCT01477567|Drug|LY3009385|
356415|NCT01477567|Drug|Placebo|
356416|NCT01477554|Other|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
356417|NCT01477541|Other|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
356418|NCT01477502|Other|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
356419|NCT01477502|Other|standard treatment without homeopathy|participants receive standard UTI prophylaxis
356420|NCT01477489|Drug|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
356421|NCT01477489|Radiation|Standard radiation treatment|Limited to 60 Gy.
356422|NCT01477476|Drug|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
356423|NCT01477476|Other|Placebo Comparator|A placebo will be given to 7 subjects.
356424|NCT01477463|Drug|Vitamin D3|4,000 IU oral vitamin D3
356425|NCT01477463|Drug|placebo and vitamin D|
356426|NCT01477450|Device|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
356427|NCT01477450|Device|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
356428|NCT01477437|Other|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
356429|NCT01477424|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
356430|NCT01477424|Drug|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
356431|NCT01477411|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
356432|NCT01477411|Drug|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
356433|NCT01477398|Device|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
356434|NCT01477385|Procedure|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
356435|NCT01477385|Procedure|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
356436|NCT01477385|Procedure|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
356437|NCT01477385|Procedure|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
356438|NCT01477385|Procedure|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
356439|NCT01477372|Behavioral|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
356440|NCT01477346|Other|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
356441|NCT01477346|Other|Standard care|Continuing standard General Practitioner led care.
356442|NCT01477333|Drug|UT-15C SR|Initiated at 0.125 mg BID, titrated as clinically indicated.
356443|NCT01477333|Drug|Tyvaso Inhalation Solution|Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
356444|NCT01477320|Drug|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
356445|NCT01477320|Other|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
356446|NCT01477307|Other|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
356447|NCT01477294|Drug|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
356450|NCT01477281|Drug|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
356451|NCT01477268|Drug|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
356452|NCT01477255|Behavioral|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
356453|NCT01477242|Drug|Ondansetron|2mg (5mL) in < 15 kg and 4mg (10mL) in 15kg to 30kg
356454|NCT01477216|Other|ELSA 1-9|Measuring GI and II values for Finnish foods
356455|NCT01477203|Drug|Escitalopram|2-4 weeks, 5-10mg, max 20mg
356456|NCT01477190|Drug|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
356457|NCT01477190|Drug|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
356458|NCT01477177|Device|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
356459|NCT01477164|Behavioral|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at ~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
356460|NCT01477164|Behavioral|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
356461|NCT01477164|Behavioral|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
356462|NCT01477151|Drug|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.~No IV drug infusions will be permitted until after protamine administration."
356463|NCT01477138|Procedure|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
356464|NCT01477125|Behavioral|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
356465|NCT01477112|Dietary Supplement|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
356466|NCT01477112|Dietary Supplement|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
356467|NCT01477099|Device|Toothbrushing with a manual brush|Toothbrushing with a manual brush
356468|NCT01477073|Drug|FSH-GEX™|
356469|NCT01477073|Drug|Drug: Comparator 1|
356470|NCT01477073|Drug|Drug: Comparator 2|
356471|NCT01477073|Drug|Drug: Placebo|
356472|NCT01477073|Drug|FSH-GEX|
356473|NCT01477073|Drug|Placebo|
356474|NCT01477060|Drug|Lapatinib|1250 mg/ die, os
356475|NCT01477060|Drug|Metformin|1500 mg/die, os
356476|NCT01477034|Dietary Supplement|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
356477|NCT01477021|Drug|cyclophosphamide|Given IV
356478|NCT01477021|Biological|NY-ESO-1-specific T cells|Given IV
356479|NCT01477021|Other|laboratory biomarker analysis|Correlative studies
356480|NCT01477008|Device|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
356481|NCT01477008|Procedure|Marrow Stimulation|Microfracture or Subchondral Drilling
356482|NCT01476982|Device|ClearView Scan|Assessment with ClearView device
356483|NCT01476969|Device|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
356484|NCT01476956|Other|Observational study|RA patients on standard DMARD therapy
356485|NCT01476930|Procedure|cupping and serkangabin syrup|wet cupping serkangabin syrup
356486|NCT01476930|Drug|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
356487|NCT01476917|Device|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
356488|NCT01476904|Drug|Placebo|0 mcg/inhalation, 2 inhalations QID
356489|NCT01476904|Drug|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
356490|NCT01476904|Drug|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
356491|NCT01476891|Other|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
356492|NCT01476891|Other|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
356493|NCT01476878|Device|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
356494|NCT01476839|Biological|basiliximab|Given IV
356495|NCT01476839|Drug|carmustine|Given IV
356496|NCT01476839|Drug|etoposide|Given IV
356497|NCT01476839|Drug|cytarabine|Given IV
356498|NCT01476839|Drug|melphalan|Given IV
356499|NCT01476839|Other|pharmacological study|Correlative studies
356500|NCT01476839|Other|laboratory biomarker analysis|Correlative studies
356501|NCT01476839|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic progenitor cell infusion
356502|NCT01476839|Biological|yttrium Y 90-labeled basiliximab|Given IV
356503|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
356504|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
356505|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
356506|NCT01476813|Drug|Comparator|comparison of different dosages of drug versus comparator
356507|NCT01476800|Drug|YM178 OCAS|oral
356508|NCT01476800|Drug|Ketoconazole|oral
356509|NCT01476787|Drug|Rituximab|375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
356510|NCT01476787|Drug|Lenalidomide|20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
356511|NCT01476787|Drug|Rituximab-CHOP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
356512|NCT01476787|Drug|Rituximab-CVP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
356513|NCT01476787|Drug|Rituximab-Bendamustine|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
356514|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
356515|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
356516|NCT01476761|Device|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
356517|NCT01476748|Device|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
356518|NCT01476735|Other|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
356519|NCT01476722|Device|OPTI-FREE PureMoist multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
356520|NCT01476696|Drug|Prasugrel|Administered orally
356521|NCT01476683|Drug|Racecadotril|Film-coated tablet
356522|NCT01476683|Drug|Racecadotril|Racecadotril Powder Blend
356523|NCT01476683|Drug|Racecadotril|Marketed Capsule
356524|NCT01476683|Drug|Racecadotril|Marketed Film-coated Tablet
356525|NCT01476670|Other|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
356526|NCT01476657|Drug|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
356527|NCT01476644|Other|Clinical evaluation|Biomicroscopy (look at front of eye), ophthalmoscopy (look at back of eye), visual acuity, visual fields, intraocular pressure, spectral domain optical coherence tomography, Pelli-Robson and the Spaeth-Richman Contrast Sensitivity tests
356528|NCT01476644|Other|Performance based measures|Compressed Assessment of Ability Related to Vision (CAARV) items include: 1) computerized motion detection; 2) recognizing facial expressions; 3) reading street signs; and 4) finding objects in a room
356529|NCT01476644|Other|Subjective measures of vision-related quality of life|National Eye Institute Visual Functioning Questionnaire 25 (NEI-VFQ-25) includes a series of questions pertaining to vision or feelings about a vision condition and the Modified Glaucoma Symptom Scale (MGSS) includes a series of questions pertaining to eye comfort.
356530|NCT01476631|Behavioral|Walking|"7 days prior to baseline participants must wear a blinded pedometer~At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
356531|NCT01476618|Other|No Intervention|No Intervention
356532|NCT01476605|Procedure|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
356533|NCT01476605|Procedure|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
356534|NCT01476605|Procedure|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
356535|NCT01476592|Dietary Supplement|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
356536|NCT01476579|Device|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
356574|NCT01476332|Drug|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
356575|NCT01476319|Other|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
356537|NCT01476566|Behavioral|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
356538|NCT01476553|Procedure|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.~Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
356539|NCT01476540|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
356540|NCT01476527|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
356541|NCT01476514|Other|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
356542|NCT01476501|Drug|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
356543|NCT01476488|Drug|tacrolimus|
356544|NCT01476475|Drug|Insulin glargine /lixisenatide Fixed Ratio Combination|FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
356545|NCT01476475|Drug|Insulin glargine|Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
356546|NCT01476475|Drug|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
356547|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
356548|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
356549|NCT01476436|Other|Low carbohydrate dietary advice|Dietary advice
356550|NCT01476436|Other|Continue usual diet|Dietary advice
356551|NCT01476423|Drug|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
356552|NCT01476410|Drug|brentuximab vedotin|Given IV
356553|NCT01476410|Drug|doxorubicin hydrochloride|Given IV
356554|NCT01476410|Drug|vinblastine|Given IV
356555|NCT01476410|Drug|dacarbazine|Given IV
356556|NCT01476410|Procedure|quality-of-life assessment|Ancillary studies
356557|NCT01476410|Genetic|DNA analysis|Optional correlative studies
356558|NCT01476410|Genetic|RNA analysis|Optional correlative studies
356559|NCT01476410|Radiation|fludeoxyglucose F 18|Correlative studies
356560|NCT01476410|Procedure|positron emission tomography|Correlative studies
356561|NCT01476410|Other|laboratory biomarker analysis|Optional correlative studies
356562|NCT01476410|Other|immunohistochemistry staining method|Optional correlative studies
356563|NCT01476410|Genetic|polymorphism analysis|Optional correlative studies
356564|NCT01476397|Other|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
356565|NCT01476397|Other|Test infant formula|partially hydrolyzed whey formula with probiotic
356566|NCT01476384|Dietary Supplement|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
356567|NCT01476384|Dietary Supplement|Placebo|250 ml water
356568|NCT01476371|Behavioral|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here & Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
356569|NCT01476358|Dietary Supplement|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth~Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
356570|NCT01476345|Drug|LY2963016|Administered subcutaneously
356571|NCT01476345|Drug|Lantus|Administered subcutaneously
356572|NCT01476332|Drug|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
356573|NCT01476332|Drug|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
356635|NCT01475825|Drug|mipomersen sodium 200 mg|Subcutaneous mipomersen 200 mg once weekly
356576|NCT01476306|Other|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
356577|NCT01476306|Other|Usual care|Patients in this group will receive care as they usually do with the physician.
356578|NCT01476280|Drug|palonosetron|0.075mg immediately before induction of anesthesia
356579|NCT01476280|Drug|Ramosetron|0.3mg immediately before induction of anesthesia
356580|NCT01476267|Drug|dalcetrapib|Single oral radiolabeled dose
356581|NCT01476241|Procedure|PEG tube placement|Percutaneous endoscopic gastrostomy
356582|NCT01476228|Device|EEG recording|EEG recording
356583|NCT01476215|Drug|Paracetamol fast dissolution suspension|
356584|NCT01476215|Drug|Paracetamol medium dissolution suspension|
356585|NCT01476215|Drug|Paracetamol slow dissolution suspension|
356586|NCT01476215|Drug|Paracetamol|
356587|NCT01476202|Drug|nicotine|nicotine in the form of a mouth strip, lozenge and gum
356588|NCT01476189|Drug|Experimental paracetamol formulation|experimental
356589|NCT01476189|Drug|Marketed paracetamol|Marketed paracetamol
356590|NCT01476189|Drug|Higher dose marketed paracetamol|Higher dose marketed paracetamol
356591|NCT01476176|Drug|Experimental paracetamol|experimental paracetamol with caffeine
356592|NCT01476176|Drug|Paracetamol marketed formulation|marketed formulation containing caffeine
356593|NCT01476163|Drug|migalastat HCl|150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
356594|NCT01476137|Drug|GSK1120212|MEK inhibitor
356595|NCT01476137|Drug|GSK2110183|AKT inhibitor
356596|NCT01476124|Drug|morphine Placebo|Morphine Placebo
356597|NCT01476124|Drug|GEn 600 mg|Gabapentin enacarbil 600 mg
356598|NCT01476124|Drug|Morphine|morphine extended release 60 mg
356599|NCT01476124|Drug|GEn Placebo|Gabapentin enacarbil placebo
356600|NCT01476098|Drug|Placebo|SB-705498 placebo
356601|NCT01476098|Drug|SB-705498|400 or 600mg oral SB-705498
356602|NCT01476085|Radiation|ML10|[18F]ML10 radioligand apoptosis biomarker
356603|NCT01476072|Other|MRI scan|MRI scan only, methodology study with no other intervention
356604|NCT01476059|Other|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
356605|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
356606|NCT01476046|Drug|GSK1995057 single dose|Single intravenous dose
356607|NCT01476046|Drug|Placebo|Single intravenous dose
356608|NCT01476033|Dietary Supplement|nutraceutical group|6 capsules of supplement or placebo for 8wk
356609|NCT01476007|Drug|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
356610|NCT01476007|Drug|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
356611|NCT01475994|Other|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
356612|NCT01475994|Other|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
356613|NCT01475981|Drug|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
356614|NCT01475968|Other|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
356615|NCT01475968|Other|Filtered Air|Filtered Air
356616|NCT01475955|Drug|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
356617|NCT01475955|Drug|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
356618|NCT01475955|Drug|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
356619|NCT01475955|Drug|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
356620|NCT01475955|Drug|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
356621|NCT01475955|Device|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
356622|NCT01475942|Dietary Supplement|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
356623|NCT01475929|Dietary Supplement|Probiotic supplement|A single strain probiotic supplement given at two doses
356624|NCT01475916|Behavioral|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
356625|NCT01475903|Procedure|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
356626|NCT01475890|Dietary Supplement|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
356627|NCT01475890|Dietary Supplement|Placebo|Once a day for 12 months.
356628|NCT01475877|Drug|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
356629|NCT01475864|Procedure|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
356630|NCT01475851|Drug|GSK548470 300 mg tablet|Blue tablets containing 300 mg of tenofovir disoproxil fumarate
356631|NCT01475838|Drug|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
356632|NCT01475838|Drug|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
356633|NCT01475838|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
356634|NCT01475838|Drug|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
360332|NCT01448369|Device|Blephasteam|10 minute treatment twice daily
356638|NCT01475812|Other|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
356639|NCT01475799|Device|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
356640|NCT01475786|Biological|Low Dose: 16 mg VM202|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)~Day 14 - 32 injections / calf:~• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
356641|NCT01475786|Biological|High Dose: 32 mg VM202|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:~Day 0~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)~Day 14~• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
356642|NCT01475786|Other|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
356643|NCT01475760|Other|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
356644|NCT01475760|Other|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:~Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).~If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
356645|NCT01475734|Biological|albiglutide|subcutaneous injection
356646|NCT01475734|Biological|placebo|subcutaneous injection
356647|NCT01475721|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
356648|NCT01475721|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
356649|NCT01475721|Drug|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
356650|NCT01475721|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
356651|NCT01475721|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
356652|NCT01475721|Drug|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
356653|NCT01475708|Drug|Doxycycline|100 mg PO bid, 14 days
356654|NCT01475695|Drug|14C GSK2251052|1500 mg iv dose GSK2251052
356655|NCT01475669|Biological|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
356656|NCT01475669|Biological|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
356657|NCT01475656|Drug|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
356658|NCT01475643|Drug|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
356659|NCT01475643|Drug|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
356660|NCT01475630|Procedure|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
356661|NCT01475630|Procedure|control|relaxation
356662|NCT01475617|Dietary Supplement|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
356663|NCT01475617|Dietary Supplement|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
356664|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
356665|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
356666|NCT01475617|Dietary Supplement|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
356667|NCT01475617|Dietary Supplement|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
356668|NCT01475604|Device|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
356669|NCT01475604|Device|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
356670|NCT01475591|Behavioral|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
356671|NCT01475578|Drug|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
356672|NCT01475578|Drug|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
356673|NCT01475552|Drug|Abciximab|Patients, who showed PRU >270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
356674|NCT01475552|Drug|control|"Patients,who showed PRU >270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.~Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
356675|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
356676|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
356677|NCT01475539|Biological|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
356678|NCT01475526|Other|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
356679|NCT01475513|Drug|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
356680|NCT01475500|Procedure|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
356681|NCT01475500|Procedure|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
356682|NCT01475500|Radiation|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
356683|NCT01475500|Other|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
356684|NCT01475500|Procedure|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
356685|NCT01475500|Procedure|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
356686|NCT01475500|Procedure|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
356687|NCT01475500|Procedure|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
356688|NCT01475500|Procedure|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
356689|NCT01475500|Procedure|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
356690|NCT01475487|Procedure|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
356691|NCT01475474|Device|Renew Insert|The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.
356692|NCT01475461|Drug|Placebo|double-dummy placebo tablets administered once-daily for 84-days
356693|NCT01475461|Drug|PF-04937319 - 3mg|PF-04937319 3mg administered as tablets once-daily for 84-days
356694|NCT01475461|Drug|PF-04937319 - 20mg|PF-04937319 20mg administered as tablets once-daily for 84-days
356695|NCT01475461|Drug|PF-04937319 - 50mg|PF-04937319 50mg administered as tablets once-daily for 84-days
356696|NCT01475461|Drug|PF-04937319 - 100mg|PF-04937319 100mg administered as tablets once-daily for 84-days
356697|NCT01475461|Drug|Sitagliptin - 100mg|Sitagliptin 100mg administered as tablets once-daily for 84-days
356698|NCT01475448|Other|Long distance training|Long distance training during four months, 3 times per week
356699|NCT01475448|Other|Walking training|Walking training during four months, three times per week
356700|NCT01475435|Procedure|non- surgical periodontal treatment|scaling and root planning
356701|NCT01475435|Procedure|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
356702|NCT01475422|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
356703|NCT01475422|Behavioral|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
356704|NCT01475409|Biological|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
356705|NCT01475396|Behavioral|exercise|
356706|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
356707|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
356708|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
356709|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
356710|NCT01475370|Drug|OCV-501|"Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.~After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
356785|NCT01474785|Drug|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
356711|NCT01475357|Other|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
356712|NCT01475357|Other|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
356713|NCT01475344|Drug|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
356714|NCT01475344|Drug|Placebo|"intravenous infusion over 5 min/vial:~Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
356715|NCT01475331|Drug|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
356716|NCT01475331|Drug|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
356717|NCT01475331|Drug|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
356718|NCT01475318|Drug|mifepristone|200 mg mifepristone on day 1
356719|NCT01475318|Drug|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
356720|NCT01475318|Drug|Misoprostol|misoprostol 800mcg PV on day 3
356721|NCT01475305|Drug|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
356722|NCT01475305|Drug|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
356723|NCT01475292|Drug|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
356724|NCT01475292|Drug|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
356725|NCT01475292|Drug|Placebo|Placebo administered via a nebuliser once daily for 14 days
356726|NCT01475279|Drug|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
356727|NCT01475266|Drug|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
356728|NCT01475266|Drug|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
356729|NCT01475253|Drug|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
356730|NCT01475253|Other|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
356731|NCT01475253|Procedure|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
356732|NCT01475227|Drug|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
356733|NCT01475227|Drug|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
356734|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
356735|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
356736|NCT01475214|Other|Inactive placebo capsule|microcrystalline cellulose
356737|NCT01475201|Behavioral|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
356738|NCT01475201|Behavioral|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
356739|NCT01475188|Drug|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
356740|NCT01475188|Other|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
356741|NCT01475175|Device|CRT pacing at rest and during exercise|CRT pacing with aCRT settings and BiV pacing with nominal programming at rest and during submaximal exercise
356742|NCT01475162|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
356743|NCT01475149|Other|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
356744|NCT01475136|Drug|LY2140023|Administered orally
356745|NCT01475123|Drug|Nicorandil|15mg per day
356746|NCT01475110|Drug|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
356747|NCT01475097|Drug|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
356748|NCT01475097|Drug|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
356749|NCT01475084|Device|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.~Forceps biopsy will be performed on usual way."
356750|NCT01475071|Drug|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
356751|NCT01475071|Drug|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
356752|NCT01475058|Biological|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
356753|NCT01475032|Drug|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
356754|NCT01475032|Drug|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
356755|NCT01475032|Drug|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
356756|NCT01475019|Drug|Orlistat|Tablet, 120 mg, three times daily, for six months
356757|NCT01475019|Drug|Sibutramine|Tablet, 10 mg, once daily, for six months
356758|NCT01475019|Behavioral|Diet and physical exercise|Hypocaloric diet and regular physical exercise
356759|NCT01475006|Drug|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
356760|NCT01474993|Drug|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing ~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to ~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:~Subjects with body weight less than 101 lbs will receive ~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)~Subjects with body weight 101 lbs to 199 lbs will receive ~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)~Subjects with bidy weight > 199 lbs will receive ~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
356761|NCT01474993|Drug|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
356762|NCT01474967|Drug|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
356763|NCT01474967|Drug|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
356764|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
356765|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
356766|NCT01474941|Drug|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
356767|NCT01474928|Behavioral|patient role played community video|Group two viewed the patient role played community video
356768|NCT01474928|Behavioral|both videos group|Group three viewed both the knowledge and community videos
356769|NCT01474928|Behavioral|Pamphlet group|Group four read an educational pamphlet only
356770|NCT01474928|Behavioral|physician-led knowledge video|Group one viewed a physician-led knowledge video
356771|NCT01474928|Behavioral|Community video group|Group two viewed the patient role played community video
356772|NCT01474928|Behavioral|knowledge video|Group one viewed a physician-led knowledge video
356773|NCT01474915|Drug|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
356774|NCT01474915|Drug|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
356775|NCT01474915|Drug|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
356776|NCT01474915|Drug|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
356777|NCT01474902|Drug|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
356778|NCT01474889|Device|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
356779|NCT01474863|Drug|High Dose Citrulline|Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
356780|NCT01474863|Drug|Placebo|D5W IV fluids at isovolumetric rate (about 15ml/hr)
356781|NCT01474863|Drug|Low Dose Citrulline|Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
356782|NCT01474850|Procedure|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
356783|NCT01474837|Behavioral|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
356784|NCT01474798|Drug|RA-18C3|"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.~For subjects weighing > 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."
356786|NCT01474785|Other|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
356787|NCT01474785|Procedure|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
356788|NCT01474772|Drug|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
356789|NCT01474772|Other|placebo|matching placebo capsules given in 3 divided doses
356790|NCT01474759|Behavioral|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
356791|NCT01474759|Behavioral|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
356792|NCT01474759|Other|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
356793|NCT01474759|Behavioral|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
356794|NCT01474746|Drug|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
356795|NCT01474746|Drug|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
356796|NCT01474733|Other|educational intervention|series of lectures and workshops on health literacy
356797|NCT01474720|Drug|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
356798|NCT01474707|Behavioral|Group one|Group 1 will view the knowledge-based video only
356799|NCT01474707|Behavioral|Group two|Group two will view the motivational video only
356800|NCT01474707|Behavioral|Group three|Group three will view both knowledge-based and motivational videos
356801|NCT01474707|Behavioral|Group four|Group four will view the printed educational pamphlet and will not view either video
356802|NCT01474694|Other|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
356803|NCT01474681|Biological|HSC835|
356804|NCT01474668|Drug|GDC-0941|Single oral dose\n \n\n\n\n
356805|NCT01474655|Procedure|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
356806|NCT01474642|Drug|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
356807|NCT01474642|Drug|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
356808|NCT01474629|Dietary Supplement|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
356809|NCT01474629|Dietary Supplement|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
356810|NCT01474616|Other|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
356811|NCT01474603|Dietary Supplement|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
356812|NCT01474590|Drug|Epiduo/Tactuo|topical to the face, once daily in the evening
356813|NCT01474590|Other|vehicle gel|topical to the face, once daily in the evening
356814|NCT01474590|Drug|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
356815|NCT01474590|Drug|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
356816|NCT01474577|Other|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
356842|NCT01474382|Drug|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
356843|NCT01474382|Other|Sham injection|No drug administered, simulation of injection used in same manner as drug
356985|NCT01473381|Drug|Vilazodone|Vilazodone was supplied as film-coated tablets.
356817|NCT01474564|Other|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
356818|NCT01474551|Drug|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
356819|NCT01474538|Drug|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
356820|NCT01474538|Drug|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
356821|NCT01474525|Device|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.~Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
356822|NCT01474512|Drug|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
356823|NCT01474512|Drug|Placebo|Administered SC
356824|NCT01474499|Drug|Glycerine|
356825|NCT01474499|Drug|Docusate sodium and sorbitol rectal solution|
356826|NCT01474486|Drug|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
356827|NCT01474473|Device|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.~CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days"
356828|NCT01474473|Device|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.~Placebo is applied on the wound for 10 minutes every 3 to 4 days"
356829|NCT01474460|Dietary Supplement|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
356830|NCT01474447|Behavioral|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
356831|NCT01474434|Drug|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
356832|NCT01474434|Drug|Placebo|matching placebo tablets
356833|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
356834|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
356835|NCT01474421|Drug|Placebo|Patients will receive placebo once daily orally for 28 days.
356836|NCT01474408|Behavioral|interval training day 1|
356837|NCT01474408|Behavioral|Moderate exercise day 2|
356838|NCT01474408|Behavioral|Control day 3|
356839|NCT01474395|Drug|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
356840|NCT01474395|Drug|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
356841|NCT01474395|Behavioral|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
356844|NCT01474369|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
356845|NCT01474369|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
356846|NCT01474369|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
356847|NCT01474356|Other|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
356848|NCT01474343|Genetic|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
356849|NCT01474330|Drug|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
356850|NCT01474330|Drug|Placebo|Placebo capsule
356851|NCT01474317|Device|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
356852|NCT01474304|Drug|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
356853|NCT01474291|Biological|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
356854|NCT01474278|Drug|Placebo|Single dose
356855|NCT01474278|Drug|RO5028442|Single dose
356856|NCT01474265|Drug|Varenicline|0.5-2 mg per day, oral use
356857|NCT01474265|Drug|Placebo|1-2 tablets per day, oral use
356858|NCT01474265|Drug|Nicorette TX|10-15 mg per day, transdermal use (patches)
356859|NCT01474252|Drug|RSI|"All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg"
356860|NCT01474239|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
356861|NCT01474239|Drug|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
356862|NCT01474226|Dietary Supplement|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
356863|NCT01474226|Dietary Supplement|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
356864|NCT01474213|Drug|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
356865|NCT01474213|Drug|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
356866|NCT01474200|Device|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
356867|NCT01474200|Drug|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
356868|NCT01474187|Drug|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
356869|NCT01474187|Drug|Capecitabine|625mg/m2,bid,d1-5,qw
356870|NCT01474187|Radiation|Radiotherapy|50Gy for whole pelvis
356871|NCT01474174|Biological|trivalent influenza vaccine|Given IM
356872|NCT01474174|Other|laboratory biomarker analysis|Correlative studies
356873|NCT01474161|Drug|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
356874|NCT01474161|Drug|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
356875|NCT01474161|Drug|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
356876|NCT01474161|Drug|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
356877|NCT01474161|Drug|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
356878|NCT01474161|Drug|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
356879|NCT01474148|Device|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
356880|NCT01474135|Drug|0.25% AR-12286 / 0.004% travoprost|
356881|NCT01474135|Drug|0.5% AR-12286, 0.004% travoprost|
356882|NCT01474135|Drug|0.004% Travoprost|
356883|NCT01474122|Drug|Macitentan 3 mg|Macitentan 3-mg tablet once daily
356884|NCT01474122|Drug|Macitentan 10 mg|Macitentan 10-mg tablet once daily
356885|NCT01474122|Drug|Placebo|Placebo tablet matching macitentan tablet, once daily
356886|NCT01474109|Drug|macitentan 3mg|macitentan 3mg tablet once daily
356887|NCT01474109|Drug|macitentan 10mg|macitentan 10mg tablet once daily
356888|NCT01474109|Drug|placebo|matching placebo once daily
356889|NCT01474096|Other|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
356890|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
356891|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
356892|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
356893|NCT01474083|Drug|Placebo|Dose-matched placebo. Oral administration.
356894|NCT01474070|Device|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
356895|NCT01474057|Behavioral|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
356896|NCT01474057|Other|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
356897|NCT01474044|Drug|Gastropylor Complex Capsules|3 pills, three times a day, after meal
356898|NCT01474044|Other|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
356899|NCT01474031|Other|biomechanics|"Time interval: pre-op - 3m - 6m - 12m~Assessment of all subjects:~XR with magnification marker~Biodex force measurement in flexion and extension and mid flexion (with EMG if possible)~Gait analysis with surface EMG and trunk markers:~Unipodal standing: 3 trials Right and 3 trials Left on FP~Level walking: 3 trials Right and 3 trials Left on FP~Chair rise: 3 trials, both legs on FP~Stair ascent: 3 trials Right and 3 trials Left on first FP~Stair descent: 3 trials Right and 3 trials Left on first FP~Squat: 3 trials, both legs on FP~Bipodal squat: 3 trials Right and 3 trials Left on FP~Functional scores (HHS, UCLA, HOOS, SF-36)~Assessment of final 5 subjects per group:~CT pre and post at 6w (pre: pelvis-knee and post: hip)~MRI pre and 1 y post~Accelerometer 1 week"
356900|NCT01474018|Drug|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
356901|NCT01474005|Device|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
356902|NCT01473992|Device|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
356903|NCT01473992|Device|Otto Bock Genium|Study knee.
356904|NCT01473979|Procedure|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.~Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
356905|NCT01473966|Dietary Supplement|coffee|patients will receive a cup of coffee at room temperature orally twice daily
356906|NCT01473966|Dietary Supplement|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
356907|NCT01473953|Drug|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
356908|NCT01473953|Drug|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
356909|NCT01473940|Biological|ipilimumab|Given IV
356910|NCT01473940|Drug|gemcitabine hydrochloride|Given IV
356911|NCT01473940|Other|laboratory biomarker analysis|Correlative studies
356912|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
356913|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
356914|NCT01473914|Dietary Supplement|Low dose: supplemental zinc, selenium and vitamin E|"ZINC 25mg (AS ZINC SULFATE)~SELENIUM 50 mcg (AS SODIUM SELENITE)~VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
356915|NCT01473914|Dietary Supplement|Standard renal vitamin: B and C renal vitamin|"BIOTIN 300 MCG~D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~FOLIC ACID 1 MG~NIACINAMIDE 20 MG~VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~VITAMIN B12(CYANOCOBALAMIN) 6 MCG~VITAMIN B2 (RIBOFLAVIN) 1.7 MG~VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~VITAMIN C (ASCORBIC ACID) 100 MG~INERT FILLER (CORNSTARCH)"
356916|NCT01473914|Dietary Supplement|Medium dose: supplemental zinc, selenium and vitamin E|"ZINC 50 mg (AS ZINC SULFATE)~SELENIUM 75 mcg (AS SODIUM SELENITE)~VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
356978|NCT01473433|Other|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
356979|NCT01473420|Biological|Epoetin Hospira|Variable dose
356980|NCT01473420|Biological|Epogen Amgen|Variable dose
356981|NCT01473407|Biological|Epoetin Hospira|Variable dose
356917|NCT01473901|Drug|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
356918|NCT01473901|Drug|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
356919|NCT01473888|Drug|T89(Dantonic)|capsule, 225mg B.I.D.
356920|NCT01473875|Drug|SBC-102|SBC-102 is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with LAL Deficiency.
356921|NCT01473836|Drug|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
356922|NCT01473836|Drug|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
356923|NCT01473823|Dietary Supplement|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
356924|NCT01473810|Biological|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
356925|NCT01473810|Biological|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
356926|NCT01473810|Biological|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
356927|NCT01473810|Biological|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
356928|NCT01473797|Drug|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
356929|NCT01473784|Procedure|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
356930|NCT01473784|Procedure|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
356931|NCT01473771|Behavioral|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
356932|NCT01473758|Drug|Roflumilast|500 µg tablet, od, oral administration in the morning after breakfast
356933|NCT01473758|Drug|Placebo|tablet, od, oral administration in the morning after breakfast
356934|NCT01473745|Procedure|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
356935|NCT01473745|Procedure|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
356936|NCT01473732|Drug|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml.
356937|NCT01473732|Drug|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml.
356938|NCT01473732|Drug|Mycophenolic acid|Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Used in both arms. Used for one year.
356939|NCT01473719|Behavioral|motivational intervention|7-session individual motivationally-based intervention
356940|NCT01473719|Behavioral|health education|7 individual sessions focusing on health education
356941|NCT01473706|Other|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
356942|NCT01473693|Other|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes."
356943|NCT01473693|Other|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.~MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.~Demographic / Medical Data: Administration time: 5 minutes"
356944|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
356982|NCT01473407|Biological|Epogen (Amgen)|Variable dose
356983|NCT01473394|Drug|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
356945|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
356946|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
356947|NCT01473667|Procedure|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
356948|NCT01473667|Procedure|Local site infiltration|Local site infiltration using 2% lidocaine
356949|NCT01473654|Behavioral|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
356950|NCT01473628|Drug|Rituximab|"375 mg/m^2 by vein every week for four consecutive weeks during the radiation treatment.~Maintenance: 375 mg/m2 by vein every 3 months for a total of 2 years."
356951|NCT01473628|Radiation|Radiation|Total dose of 24 to 30 Gy over 12 to 15 treatments.
356952|NCT01473615|Behavioral|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
356953|NCT01473602|Drug|Teriparatide|Administered by SC injection
356954|NCT01473602|Drug|Placebo|Administered by SC injection
356955|NCT01473602|Dietary Supplement|Calcium supplementation|Administered orally
356956|NCT01473602|Dietary Supplement|Vitamin D supplementation|Administered orally
356957|NCT01473589|Drug|Teriparatide|Administered by SC injection
356958|NCT01473589|Drug|Placebo|Administered by SC injection
356959|NCT01473589|Dietary Supplement|Calcium supplementation|Administered orally
356960|NCT01473589|Dietary Supplement|Vitamin D supplementation|Administered orally
356961|NCT01473576|Dietary Supplement|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
356962|NCT01473576|Dietary Supplement|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
356963|NCT01473563|Drug|Pemetrexed|Administered intravenously
356964|NCT01473550|Behavioral|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
356965|NCT01473537|Drug|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
356966|NCT01473524|Drug|Obeticholic Acid (OCA)|
356967|NCT01473524|Drug|Placebo|
356968|NCT01473511|Behavioral|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
356969|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
356970|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.~In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
356971|NCT01473485|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
356972|NCT01473472|Drug|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
356973|NCT01473472|Drug|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
356974|NCT01473459|Procedure|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
356975|NCT01473459|Procedure|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
356976|NCT01473446|Procedure|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.~Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV <10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding >1000ml. By fall in blood pressure and SVV <10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
356977|NCT01473433|Procedure|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
356986|NCT01473381|Drug|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
356987|NCT01473381|Drug|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
356988|NCT01473381|Drug|Citalopram|Citalopram was supplied as encapsulated tablets.
356989|NCT01473368|Dietary Supplement|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
356990|NCT01473368|Drug|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
356991|NCT01473355|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
356992|NCT01473342|Behavioral|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors & their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting & participation. During the 9th week (Week 17), participants complete one final survey & accelerometer wear.
356993|NCT01473329|Other|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
356994|NCT01473316|Drug|GDC-0980|Single oral dose
356995|NCT01473316|Drug|Ketoconazole|Repeating Oral Dose
356996|NCT01473303|Biological|ganitumab|Given IV
356997|NCT01473303|Drug|fluorouracil|Given IV
356998|NCT01473303|Drug|irinotecan hydrochloride|Given IV
356999|NCT01473303|Drug|leucovorin calcium|Given IV
357000|NCT01473303|Drug|oxaliplatin|Given IV
357001|NCT01473303|Other|placebo|Given IV
357002|NCT01473303|Other|questionnaire administration|Completed on paper
357003|NCT01473290|Dietary Supplement|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
357004|NCT01473290|Other|placebo|Given PO
357005|NCT01473277|Drug|BT-A (Dysport 500U), Triamcinolone acetonide|"All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment."
357006|NCT01473264|Drug|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
357007|NCT01473264|Drug|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
357008|NCT01473264|Drug|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
357009|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
357010|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
357011|NCT01473251|Drug|Lucentis|0.5 mg monthly for 4 months
357012|NCT01473238|Other|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
357013|NCT01473225|Other|Calorie information|Nutrition label featuring calorie information will be provided.
357014|NCT01473225|Other|No calorie information|No nutrition label will be provided in this condition.
357015|NCT01473199|Device|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
357016|NCT01473173|Drug|CJ-12420|
357017|NCT01473173|Drug|Esomeprazole 40mg|
357018|NCT01473160|Device|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
357019|NCT01473160|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
357020|NCT01473147|Drug|Exenatide|Exenatide 5 microgram bid sc.
357021|NCT01473147|Drug|Normal saline|Normal saline 2 u bid sc.
357022|NCT01473121|Other|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
357023|NCT01473108|Drug|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
357024|NCT01473108|Drug|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
357025|NCT01473108|Drug|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
357026|NCT01473108|Drug|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
357027|NCT01473095|Drug|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
357028|NCT01473082|Device|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
357029|NCT01473082|Device|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
357030|NCT01473069|Drug|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
357031|NCT01473069|Drug|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
357032|NCT01473056|Drug|JTK-853|Tablets, twice a day for 3 days
357033|NCT01473056|Drug|Dose 2 JTK-853|Tablets, twice a day for 3 days
357034|NCT01473056|Drug|Dose 3 JTK-853|Tablets, three times a day for 3 days
357035|NCT01473056|Drug|Dose 4 JTK-853|Tablets, twice a day for 3 days
357036|NCT01473056|Drug|Placebo|Tablets, twice a day or three times a day for 3 days
357037|NCT01473043|Drug|Axitinib|5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
357038|NCT01473017|Behavioral|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
357039|NCT01473004|Device|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
357040|NCT01472991|Drug|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
357041|NCT01472991|Drug|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
357042|NCT01472991|Drug|Placebo|Placebo capsules will be taken once daily for 4 weeks
357043|NCT01472978|Drug|metronidazole|Metronidazole, 500 mg three times a for 10 days
357044|NCT01472965|Drug|ethanol|70% ethanol catheter lock therapy
357045|NCT01472965|Drug|heparin-saline placebo|heparin-saline placebo catheter lock therapy
357046|NCT01472939|Drug|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
357047|NCT01472939|Drug|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
357048|NCT01472939|Drug|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
357049|NCT01472939|Drug|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
357050|NCT01472926|Drug|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
357051|NCT01472926|Drug|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
357052|NCT01472913|Drug|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
357053|NCT01472913|Drug|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
357054|NCT01472900|Device|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
357055|NCT01472900|Drug|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
357056|NCT01472887|Drug|SAR3419|"Pharmaceutical form:concentrate for solution for infusion~Route of administration: intravenous"
357057|NCT01472874|Drug|Once a day Trientine|Trientine at a dosage of ~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
357058|NCT01472861|Procedure|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
357059|NCT01472861|Other|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
357060|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
357061|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
357062|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
357063|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
357064|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
357065|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
357066|NCT01472835|Drug|Midazolam|Used for anxiolysis
357067|NCT01472835|Drug|Fentanyl|Used for analgesia and as a sedative
357068|NCT01472822|Dietary Supplement|Omija extract.|Omija extract 1.2g/day for 12weeks
357069|NCT01472822|Dietary Supplement|Placebo|Placebo 1.2g/day for 12weeks
357070|NCT01472809|Drug|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
357071|NCT01472809|Drug|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
357072|NCT01472796|Dietary Supplement|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
357073|NCT01472796|Drug|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
357074|NCT01472783|Drug|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
357075|NCT01472770|Drug|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
357076|NCT01472757|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
357077|NCT01472757|Drug|Placebo|Placebo delivered via a new dry powder inhaler
357078|NCT01472744|Behavioral|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
357079|NCT01472744|Behavioral|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
357080|NCT01472744|Behavioral|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
357081|NCT01472744|Behavioral|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
357082|NCT01472731|Other|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
357083|NCT01472731|Drug|GC1008|5 mg/kg intravenous use
357084|NCT01472718|Device|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
357085|NCT01472718|Device|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
357086|NCT01472692|Drug|Febuxostat|80mg PO daily for 8 weeks
357087|NCT01472666|Dietary Supplement|High content of MC-SFA|12 weeks dietary intervention
357088|NCT01472666|Dietary Supplement|Whey|12 weeks dietary intervention
357089|NCT01472666|Dietary Supplement|Low content of MC-SFA|12 weeks dietary intervention
357090|NCT01472666|Dietary Supplement|Casein|12 weeks dietary intervention
357091|NCT01472653|Drug|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
357092|NCT01472653|Radiation|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
357093|NCT01472653|Drug|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
357094|NCT01472640|Drug|liraglutide|1.8 mg sc QOD
357095|NCT01472640|Drug|placebo|1 U sc QOD
357096|NCT01472627|Procedure|Blood draws|Blood draws
357097|NCT01472614|Drug|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
357098|NCT01472588|Behavioral|DPP lifestyle intervention-Community Health Coach (CHWs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
357099|NCT01472588|Behavioral|DPP Lifestyle intervention--health professionals/(PHCs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
357100|NCT01472588|Other|Self Help|Public education/information booklet on weight management.
357101|NCT01472562|Drug|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.~Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
357102|NCT01472562|Biological|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.~Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
357103|NCT01472549|Drug|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
357104|NCT01472549|Drug|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
357105|NCT01472536|Behavioral|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
357106|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
357107|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
357108|NCT01472497|Drug|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
357109|NCT01472484|Other|586/8x87 white|2 x 50 g
357110|NCT01472484|Other|586/8x87 brown|2 x 50 g
357111|NCT01472484|Other|BAT 881|2 x 50 g
357112|NCT01472484|Other|586/8|2 x 50 g
357113|NCT01472458|Behavioral|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
357114|NCT01472445|Drug|Vitamin D|
357115|NCT01472432|Drug|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
357116|NCT01472432|Drug|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
357117|NCT01472406|Device|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
357118|NCT01472406|Device|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
357119|NCT01472406|Device|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
357120|NCT01472406|Device|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
357308|NCT01471093|Drug|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
357121|NCT01472406|Device|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
357122|NCT01472393|Dietary Supplement|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
357123|NCT01472393|Dietary Supplement|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
357124|NCT01472380|Drug|efavirenz|600 mg
357125|NCT01472380|Drug|fenofibric acid 105 mg|fenofibric acid 105 mg
357126|NCT01472367|Drug|Metformin|Metformin oral tablets twice daily. Participants on a metformin daily dose of 1000, 1250, or 1275 mg at screening will be switched to a metformin daily dose of 1000 mg (500 mg twice a day); 1500, 1700, or 1750 mg will be switched to a metformin daily dose of 1700 mg (850 mg twice a day); 2000 mg or more will be switched to a metformin daily dose of 2000 mg (1000 mg twice a day).
357127|NCT01472367|Drug|Sitagliptin + Metformin FDC|Sitagliptin + metformin FDC oral tablet 50/500, 50/850, or 50/1000 mg dosed twice daily.
357128|NCT01472367|Drug|Placebo to Metformin|Matching placebo to metformin administered twice daily.
357129|NCT01472367|Drug|Placebo to Sitagliptin + Metformin FDC|Matching placebo to sitagliptin + metformin FDC oral tablet administered twice daily.
357130|NCT01472367|Biological|Insulin|Participants who enter the study on background insulin will continue on the same dose and formulation of insulin throughout the study. If rescue therapy is necessary, participants who are not on background insulin will intiate insulin and those that entered the study on insulin will uptitrate their background insulin dose.
357131|NCT01472367|Biological|Insulin glargine|Participants who are not on background insulin therapy during the base study may initiate insulin glargine during the extension period if their fasting fingerstick glucose is >130 mg/dL and their fasting state A1C is greater than 7.5%.
357132|NCT01472354|Behavioral|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
357133|NCT01472328|Procedure|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
357134|NCT01472328|Procedure|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
357135|NCT01472315|Drug|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
357136|NCT01472315|Drug|Placebo|Placebo pills were taken in same way as active comparator
357137|NCT01472302|Device|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
357138|NCT01472302|Device|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
357139|NCT01472289|Other|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
357140|NCT01472276|Behavioral|Web-based program|Provided with the web-based program
357141|NCT01472263|Drug|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
357142|NCT01472263|Drug|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
357143|NCT01472250|Drug|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:~Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
357144|NCT01472237|Other|Nutritional intervention|Modification of diet
357145|NCT01472211|Device|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
357146|NCT01472211|Device|placebo filter|filter purifies water
357147|NCT01472211|Other|disinfection tablets|government promoted tablets disinfect water
357148|NCT01472198|Drug|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
357149|NCT01472198|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
357150|NCT01472198|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
357151|NCT01472185|Drug|Ranolazine|Ranolazine tablets administered orally twice daily.
357152|NCT01472185|Drug|Placebo|Placebo to match ranolazine administered orally twice daily.
357153|NCT01472185|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
357154|NCT01472185|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
357155|NCT01472172|Device|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
357156|NCT01472159|Behavioral|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
357157|NCT01472146|Drug|Zo-Nantax|"Experimental:~AC,Docetaxel,Trastuzumab,Zolendronate~Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles~Drug: Docetaxel~Docetaxel 100 mg/m2 every 21 days for 4 cycles.~Drug: Trastuzumab~Trastuzumab 8mg/kg [loading dose] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.~Drug: zolendronic acid~Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
357158|NCT01472133|Other|Recording of 12 lead ECG|Recording of 12 lead ECG
357159|NCT01472133|Other|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
357160|NCT01472133|Other|Recording of chest wall movement|Recording of chest wall movement
357161|NCT01472133|Other|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
357162|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
357163|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
357164|NCT01472081|Biological|Nivolumab|
357165|NCT01472081|Biological|Pazopanib|
357166|NCT01472081|Drug|Sunitinib|
357167|NCT01472081|Biological|Ipilimumab|
357168|NCT01472068|Device|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
357169|NCT01472055|Drug|Fludarabine|"Fludarabine 40 mg/m^2 once a day intravenous administration over 30 min~Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~Population pharmacokinetics analysis~Comparative analysis of population pharmacokinetics in pediatric and adult patients~Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
357170|NCT01472042|Other|Banyan Biomarkers|Biomarkers to detect specific proteins.
357171|NCT01472029|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:~Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle~Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle~Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle~Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle~5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"
357172|NCT01472029|Drug|Post-operative treatment trastuzumab mono therapy|"Trastuzumab mono therapy for 9 cycles:~Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"
357173|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
357174|NCT01472016|Drug|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
357175|NCT01472016|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
357176|NCT01472016|Drug|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
357177|NCT01472016|Drug|erlotinib|Erlotinib will be taken orally daily.
357178|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
357179|NCT01472003|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
357180|NCT01472003|Drug|ABT-806i|ABT-806i will be administered by intravenous infusion.
357181|NCT01471990|Drug|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
357182|NCT01471990|Drug|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
357183|NCT01471977|Other|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
357184|NCT01471964|Drug|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
357185|NCT01471951|Other|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
357186|NCT01471925|Drug|Nexium®|
357187|NCT01471925|Drug|Esomeprazol (40mg) + Sdium Bicarbonate (721mg)|
357188|NCT01471912|Procedure|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
357189|NCT01471899|Drug|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
357190|NCT01471899|Drug|Naproxen|2 tablets every 8 hours for 4 days
357191|NCT01471886|Drug|Ketorolac Tromethamine|Every 8 hours for 4 days.
357192|NCT01471886|Drug|Naproxen|Every 8 hours for 4 days.
357193|NCT01471873|Procedure|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:~Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
357194|NCT01471860|Device|BAROSTIM NEO System|
357195|NCT01471860|Drug|Medical Management|
357266|NCT01471496|Procedure|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
357304|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
357305|NCT01471119|Biological|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
357306|NCT01471106|Drug|Dasatinib|"Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day."
357196|NCT01471847|Drug|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
357197|NCT01471847|Drug|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
357198|NCT01471834|Device|BAROSTIM NEO System|
357199|NCT01471834|Drug|Medical Management|
357200|NCT01471821|Drug|antiretroviral treatment|antiretroviral treatment
357201|NCT01471808|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
357202|NCT01471808|Drug|CSII, Metformin, Pioglitazone|CSII for 2~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
357203|NCT01471808|Drug|CSII, Sitagliptin|CSII for 2~4 weeks combined with sitagliptin 100mg/d for 3 months
357204|NCT01471782|Biological|Blinatumomab|Administered by continuous intravenous infusion
357205|NCT01471769|Behavioral|Pain management video|6-minute video
357206|NCT01471769|Behavioral|Falls Prevention Video|6-minute video
357207|NCT01471756|Procedure|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
357208|NCT01471743|Dietary Supplement|Impact Advance Recovery (R)|
357209|NCT01471743|Dietary Supplement|Ensure Plus (R)|
357210|NCT01471730|Drug|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 [mm] − MCF [mm]) * body weight [kg] / 140 [m] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
357211|NCT01471730|Drug|Saline solution|Normal saline will be administered to control patients.
357212|NCT01471730|Drug|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds [M1] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
357213|NCT01471717|Drug|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
357214|NCT01471717|Drug|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
357215|NCT01471717|Drug|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
357216|NCT01471717|Drug|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
357217|NCT01471717|Drug|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
357218|NCT01471717|Drug|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
357219|NCT01471704|Drug|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
357220|NCT01471704|Drug|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
357221|NCT01471704|Drug|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
357222|NCT01471691|Drug|ranibizumab 0.5mg|Standard dose
357223|NCT01471691|Drug|ranibizumab 1.0mg|High dose
357224|NCT01471678|Drug|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
357225|NCT01471678|Drug|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
357226|NCT01471678|Drug|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
357227|NCT01471665|Drug|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
357228|NCT01471665|Drug|Placebo|Placebo will be administered once daily for up to 16 days.
357229|NCT01471548|Drug|TKI258|
357302|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
357307|NCT01471093|Drug|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
357230|NCT01471431|Other|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).~During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia <100 for >15 seconds or oxygen saturation by pulse oximetry <85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
357231|NCT01471418|Drug|PET/CT with 18-FDG|FDG uptake
357232|NCT01471379|Drug|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
357233|NCT01471379|Drug|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
357234|NCT01471379|Drug|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
357235|NCT01471379|Drug|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
357236|NCT01471366|Dietary Supplement|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
357237|NCT01471366|Dietary Supplement|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
357238|NCT01471366|Dietary Supplement|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
357239|NCT01471366|Dietary Supplement|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
357240|NCT01471353|Drug|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
357241|NCT01471340|Drug|Mometasone Furoate/Formoterol MDI 100/5 mcg|two inhalations BID
357242|NCT01471340|Drug|Mometasone Furoate/Formoterol MDI 200/5 mcg|two inhalations BID
357243|NCT01471340|Drug|Mometasone Furoate MDI 100 mcg|two inhalations BID
357244|NCT01471340|Drug|Mometasone Furoate MDI 200 mcg|two inhalations BID
357245|NCT01471340|Drug|Albuterol 90 mcg /salbutamol 100 mcg HFA MDI|use as needed for asthma symptoms
357246|NCT01471340|Drug|Prednisone/prednisolone|Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
357247|NCT01471652|Drug|Nutraceutical supplements|"CoEnzyme Q10: oral gel capsule bid~Acetyl L-carnitine: oral capsule bid~Alpha Lipoic Acid: oral tablet qd~Docosahexaenoic acid: oral gel capsule bid"
357248|NCT01471652|Drug|Placebo|"Capsule form to imitate the following nutraceuticals:~Placebo 1: oral gel capsule bid~Placebo 2: oral capsule bid~Placebo 3: oral tablet qd~Placebo 4: oral gel capsule bid"
357249|NCT01471639|Drug|intranasal ketorolac|15 mg
357250|NCT01471626|Device|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
357251|NCT01471613|Procedure|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
357252|NCT01471613|Drug|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
357253|NCT01471613|Biological|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
357254|NCT01471613|Other|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
357255|NCT01471600|Procedure|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
357256|NCT01471574|Drug|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
357257|NCT01471574|Drug|Ribavirin|Tablets; oral; for patients weighing <75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing >75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
357258|NCT01471574|Drug|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
357259|NCT01471535|Drug|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
357260|NCT01471522|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
357261|NCT01471522|Procedure|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
357262|NCT01471522|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
357263|NCT01471522|Behavioral|Lifestyle|diet, physical activity, smoking cessation
357264|NCT01471522|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
357265|NCT01471509|Other|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
357303|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
357267|NCT01471483|Behavioral|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
357268|NCT01471483|Other|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
357269|NCT01471470|Drug|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
357270|NCT01471457|Drug|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
357271|NCT01471444|Drug|Fludarabine|"Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.~Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3."
357272|NCT01471444|Drug|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
357273|NCT01471444|Drug|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
357274|NCT01471444|Drug|Thymoglobulin|"Both groups who receive a graft from an unrelated donor:~0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete."
357275|NCT01471444|Procedure|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
357276|NCT01471444|Drug|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
357277|NCT01471444|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
357278|NCT01471392|Device|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
357279|NCT01471327|Biological|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
357280|NCT01471327|Other|Placebo|Saline IV, single dose at Day 1
357281|NCT01471314|Behavioral|Headache day versus non-headache day|
357282|NCT01471288|Drug|Carum Cravi|40mg/kg of body weight
357283|NCT01471288|Drug|Placebo|Placebo
357284|NCT01471275|Drug|Metformin|250 mg or 500mg three times a day
357285|NCT01471275|Drug|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
357286|NCT01471262|Procedure|Right hepatectomy|Right liver resection
357287|NCT01471262|Procedure|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
357288|NCT01471236|Device|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).~The implant will be inserted gently in a pressed fit manner."
357289|NCT01471236|Procedure|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator`s final decision. Related treatments during the procedure should be recorded.~Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
357290|NCT01471210|Drug|Urelumab (BMS-663513)|
357291|NCT01471197|Biological|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
357292|NCT01471197|Biological|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
357293|NCT01471184|Device|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
357294|NCT01471184|Device|Placebo|Placebo Eye Drops/Nasal Spray
357295|NCT01471171|Drug|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
357296|NCT01471171|Drug|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
357297|NCT01471158|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
357298|NCT01471158|Drug|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
357299|NCT01471145|Drug|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
357300|NCT01471132|Drug|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
357301|NCT01471132|Drug|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
357310|NCT01471080|Procedure|hepatectomy|using hepatectomy to treat cavernous hemangiomas
357311|NCT01471067|Drug|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
357312|NCT01471067|Drug|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
357313|NCT01471067|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
357314|NCT01471067|Drug|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
357315|NCT01471067|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
357316|NCT01471067|Drug|Rituximab|375 mg/m^2 by vein on Day -10 for B cell malignancy.
357317|NCT01471067|Drug|ATG|"1.25 mg/Kg by vein on Day -4.~1.75 mg/Kg by vein on Day -3."
357318|NCT01471067|Drug|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
357319|NCT01471067|Drug|Clofarabine|30 mg/m^2 IV Day -7 to Day -4;
357320|NCT01471067|Radiation|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
357321|NCT01471054|Drug|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:~i.The study eye must have shown initial favorable response to prior Ozurdex implant (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]) ii. Interval since last Ozurdex implant should be > 4 and < 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
357322|NCT01471054|Drug|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
357323|NCT01471041|Device|Venous Window Needle Guide|Subcutaneous, extravascular needle guide made of medical-grade titanium
357324|NCT01471028|Biological|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
357325|NCT01471028|Other|Standard of care (Control)|Control receives standard medical treatment.
357326|NCT01471015|Drug|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
357327|NCT01471015|Drug|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
357328|NCT01471015|Drug|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
357329|NCT01471002|Device|Galil Medical patented 17G Cryoablation Needles|
357330|NCT01470989|Drug|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
357331|NCT01470976|Other|Goal-directed Resuscitation Therapy (GDT)|"A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.~The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.~When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.~The final step will be red blood transfusion to reach a hematocrit higher than 28%."
357332|NCT01470976|Other|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
357333|NCT01470963|Other|Implementation of referral template|Implementation of referral template at the GP office
357334|NCT01470950|Procedure|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
357335|NCT01470937|Drug|Acarbose|acarbose 100 mg PO once daily
357336|NCT01470937|Drug|Placebo|acarbose placebo
357337|NCT01470911|Drug|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.~Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
357338|NCT01470911|Drug|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
357410|NCT01470313|Drug|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
357411|NCT01470313|Drug|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
357563|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
357339|NCT01470898|Device|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
357340|NCT01470859|Drug|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
357341|NCT01470859|Drug|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
357342|NCT01470846|Procedure|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
357343|NCT01470846|Procedure|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
357344|NCT01470833|Procedure|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:~Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.~Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.~Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
357345|NCT01470820|Other|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
357346|NCT01470807|Device|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
357347|NCT01470794|Biological|Toca 511 vector|All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.
357348|NCT01470794|Drug|Toca FC|
357349|NCT01470781|Behavioral|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
357350|NCT01470781|Behavioral|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
357351|NCT01470768|Other|Amino Acid-based Formula with high DHA and ARA|
357352|NCT01470768|Other|Amino Acid-based Formula with lower DHA and ARA|
357353|NCT01470755|Drug|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
357354|NCT01470755|Drug|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
357355|NCT01470755|Drug|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
357356|NCT01470755|Drug|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
357357|NCT01470742|Drug|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
357358|NCT01470742|Drug|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
357359|NCT01470729|Other|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
357360|NCT01470716|Drug|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
357361|NCT01470703|Device|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure <25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level <25 cm H2O and low pressure level ≥10 cm H2O
357487|NCT01469572|Drug|Pasireotide|Pasireotide is given as an injection.
357564|NCT01469039|Drug|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
357362|NCT01470703|Other|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 <80% for >6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
357363|NCT01470690|Drug|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
357364|NCT01470690|Drug|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
357365|NCT01470677|Drug|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
357366|NCT01470664|Drug|FST-100|FST-100
357367|NCT01470664|Drug|FST-100 (Component #1)|FST-100 (Component #1)
357368|NCT01470664|Drug|FST-100 Vehicle|FST-100 Vehicle
357369|NCT01470651|Drug|Armodafinil|50mg - 250mg pills, taken each morning, for 14 weeks
357370|NCT01470651|Drug|Sugar Pill|Inactive pill, matched to look like active medication
357371|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
357372|NCT01470612|Drug|CP-690,550|5 mg tablets, BID, for at least 12 months
357373|NCT01470612|Drug|CP-690,550|10 mg tablets, BID, for at least 12 months
357374|NCT01470599|Drug|CP-690,550|ORAL TABLET, TWICE DAILY
357375|NCT01470599|Drug|CP-690,550|ORAL TABLETS, TWICE DAILY
357376|NCT01470586|Procedure|Surgery for colorectal cancer|Surgical resection of colorectal cancer
357377|NCT01470573|Procedure|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
357378|NCT01470560|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
357379|NCT01470560|Behavioral|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
357380|NCT01470534|Dietary Supplement|carbohydrate drink|carbohydrate drink
357381|NCT01470534|Procedure|Muscle biopsy|Open muscle biopsy
357382|NCT01470534|Procedure|Blood sampling|Venopuncture
357383|NCT01470534|Dietary Supplement|Placebo|
357384|NCT01470521|Biological|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
357385|NCT01470521|Biological|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
357386|NCT01470508|Behavioral|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
357387|NCT01470508|Behavioral|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
357388|NCT01470495|Other|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
357389|NCT01470495|Other|RFA|treat Recurrent HCC with RFA
357390|NCT01470482|Procedure|No use of tourniquet|Tourniquet is not applied i 25 pts
357391|NCT01470482|Procedure|Tourniquet|Use of tourniquet
357392|NCT01470469|Drug|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
357393|NCT01470469|Drug|Placebo|Once-daily oral dosing in the evening for 12 weeks.
357394|NCT01470456|Drug|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
357395|NCT01470456|Drug|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
357396|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
357397|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
357398|NCT01470417|Drug|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
357399|NCT01470417|Drug|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
357400|NCT01470391|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
357401|NCT01470391|Procedure|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
357402|NCT01470378|Procedure|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
357403|NCT01470365|Procedure|quality-of-life assessment|Ancillary studies
357404|NCT01470365|Radiation|intensity-modulated radiation therapy|Undergo IMRT
357405|NCT01470365|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
357406|NCT01470352|Drug|Doluxetine|30 mg/d
357407|NCT01470352|Drug|Placebo|suger pill 30mg/d
357408|NCT01470339|Drug|duloxetine|duloxetine 60mg once a day for 5 weeks
357409|NCT01470326|Drug|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
357412|NCT01470300|Other|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit & vegetables, decreased fat, added plain water).
357413|NCT01470287|Biological|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
357414|NCT01470248|Drug|Arsenic Trioxide|Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
357415|NCT01470222|Other|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
357416|NCT01470209|Drug|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
357417|NCT01470209|Drug|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
357418|NCT01470196|Drug|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
357419|NCT01470196|Drug|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
357420|NCT01470196|Drug|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
357421|NCT01470170|Drug|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
357422|NCT01470170|Drug|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
357423|NCT01470170|Device|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
357424|NCT01470170|Drug|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
357425|NCT01470157|Drug|Ketamine|5mg/kg as oral suspension
357426|NCT01470157|Drug|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
357427|NCT01470144|Drug|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
357428|NCT01470131|Drug|Masitinib|Masitinib 6 mg/kg/day
357429|NCT01470131|Drug|Placebo|Matching placebo
357430|NCT01470131|Drug|Bortezomib|Standard therapy (cycles of bortezomib)
357431|NCT01470131|Drug|Dexamethasone|Standard therapy (cycles of dexamethasone)
357432|NCT01470118|Drug|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
357433|NCT01470118|Drug|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
357434|NCT01470118|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
357435|NCT01470105|Other|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.~At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
357436|NCT01470092|Drug|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
357437|NCT01470053|Drug|mometasone furoate plus azelastine HCl|
357438|NCT01470053|Drug|mometasone furoate|
357439|NCT01470053|Drug|azelastine HCl|
357440|NCT01470040|Drug|discontinuation of aspirin therapy|discontinuation of aspirin therapy
357441|NCT01470040|Drug|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
357442|NCT01470027|Drug|N-acetylcysteine|900mg NAC effervescent tablets
357443|NCT01470027|Drug|Placebo|effervescent tablets
357444|NCT01470001|Drug|solifenacin|patient will receive solifenacin 5mg daily or placebo daily
357445|NCT01469988|Drug|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
357446|NCT01469975|Drug|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
357447|NCT01469975|Drug|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
357448|NCT01469975|Drug|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data."
357449|NCT01469949|Other|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
357450|NCT01469936|Dietary Supplement|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~First Week of intervention : 1/2 stick per day~Second to 5th Week : 1 stick per day"
357451|NCT01469936|Dietary Supplement|PLACEBO|"Duration : 5 weeks +/- 1 week.~Dosage:~First Week : 1/2 stick per day~Second to 5th Week : 1 stick per day"
357452|NCT01469923|Drug|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
357453|NCT01469923|Drug|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
357454|NCT01469910|Drug|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
357455|NCT01469910|Drug|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
357456|NCT01469884|Drug|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
357457|NCT01469884|Drug|Cyclosporine|Trough level should be between 100 and 200ng/ml.
357458|NCT01469884|Drug|Tacrolimus|Trough level should be between 5 and 10ng/ml.
357459|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
357460|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
357461|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
357462|NCT01469858|Device|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
357463|NCT01469845|Device|3% hypertonic saline|4 ml dose to be administered every 6 hours
357464|NCT01469832|Biological|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
357465|NCT01469819|Drug|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
357466|NCT01469806|Device|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
357467|NCT01469793|Drug|DMOT4039A|DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
357468|NCT01469767|Drug|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
357469|NCT01469741|Behavioral|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
357470|NCT01469728|Procedure|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
357471|NCT01469728|Procedure|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
357472|NCT01469715|Device|GBP CGM|Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active & one mock device simultaneously during hyperglycemic & hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 & 4: Subjects will return to the research center approximately 24 & 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 & 5.
357473|NCT01469702|Drug|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
357474|NCT01469702|Drug|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
357475|NCT01469702|Drug|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
357476|NCT01469689|Other|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
357477|NCT01469689|Other|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
357478|NCT01469676|Device|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
357479|NCT01469650|Dietary Supplement|cholecalciferal|400 IU/day
357480|NCT01469650|Dietary Supplement|cholecalciferol|800 IU/day D3
357481|NCT01469637|Drug|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
357482|NCT01469637|Drug|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
357483|NCT01469624|Drug|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
357484|NCT01469611|Biological|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
357485|NCT01469598|Drug|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
357486|NCT01469585|Drug|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
357488|NCT01469572|Procedure|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
357489|NCT01469572|Drug|Everolimus|Given orally every day for the duration of the study
357490|NCT01469559|Drug|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
357491|NCT01469559|Drug|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
357492|NCT01469546|Drug|Axitinib (AG-013736)|The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST [Response Evaluation Criteria In Solid Tumors] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
357493|NCT01469533|Other|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
357494|NCT01469533|Other|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
357495|NCT01469520|Drug|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
357496|NCT01469520|Drug|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
357497|NCT01469520|Drug|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
357498|NCT01469507|Device|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
357499|NCT01469507|Drug|Hyaluronan|3 weekly injections
357500|NCT01469494|Procedure|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
357501|NCT01469494|Procedure|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.~The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
357502|NCT01469481|Drug|PF-04991532|a single oral dose of [14C]PF-04991532 (450 mg/100 uCi suspension)
357503|NCT01469468|Drug|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
357504|NCT01469468|Drug|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
357505|NCT01469455|Drug|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.~DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
357506|NCT01469442|Procedure|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
357507|NCT01469429|Other|placebo|Receive lozenge placebo PO
357508|NCT01469429|Other|laboratory biomarker analysis|Correlative studies
357509|NCT01469429|Other|questionnaire administration|Ancillary studies
357510|NCT01469429|Drug|chemoprevention|Receive LBR lozenge PO
357511|NCT01469429|Drug|chemoprevention|Receive LBR Saliva Substitute PO
357512|NCT01469429|Other|placebo|Receive Saliva Substitute placebo PO
357513|NCT01469416|Drug|Rosuvastatin|Rosuvastatin 20 mg PO x 1
357514|NCT01469416|Drug|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
357561|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
357562|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
357515|NCT01469403|Behavioral|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
357516|NCT01469377|Drug|Placebo|Placebo was supplied in capsules
357517|NCT01469377|Drug|Cariprazine|Cariprazine was supplied in capsules.
357518|NCT01469364|Drug|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
357519|NCT01469364|Procedure|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
357520|NCT01469351|Drug|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
357521|NCT01469351|Drug|non-active study drug|placebo
357522|NCT01469338|Drug|cabazitaxel|Given IV
357523|NCT01469338|Drug|prednisone|Given PO
357524|NCT01469338|Drug|octreotide pamoate|Given IM
357525|NCT01469338|Other|questionnaire administration|Ancillary studies
357526|NCT01469338|Drug|octreotide acetate|Given SC
357527|NCT01469325|Other|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
357528|NCT01469325|Other|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
357529|NCT01469312|Other|modified pasta|50 grams carbohydrate as a single breakfast meal
357530|NCT01469286|Device|TEA|Electroacupuncture at ST36
357531|NCT01469286|Device|Sham-TEA|Electroacupuncture at sham-points
357532|NCT01469273|Drug|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
357533|NCT01469260|Other|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
357534|NCT01469247|Radiation|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
357535|NCT01469234|Drug|loratadine|loratadine, one 10 mg tablet, orally
357536|NCT01469234|Drug|fexofenadine|fexofenadine, one 180 mg tablet, orally
357537|NCT01469234|Drug|placebo to loratadine|one tablet, orally
357538|NCT01469234|Drug|placebo to fexofenadine|one tablet, orally
357539|NCT01469221|Drug|Apaziquone|6 weekly multi-instillation of Apaziquone 4 mg in 40 mL
357540|NCT01469221|Drug|Placebo|6 weekly multi-instillation of matching placebo in 40mL
357541|NCT01469182|Biological|SCH 39641|Rapidly dissolving tablet sublingually once daily
357542|NCT01469182|Drug|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
357543|NCT01469169|Drug|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
357544|NCT01469156|Drug|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
357545|NCT01469143|Drug|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
357546|NCT01469143|Drug|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
357547|NCT01469130|Drug|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
357548|NCT01469117|Other|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
357549|NCT01469104|Other|3 day fast|Subjects will fast for 72 hours
357550|NCT01469104|Other|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
357551|NCT01469091|Behavioral|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
357552|NCT01469078|Drug|Monofer®|Single Bolus Injections
357553|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
357554|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
357555|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
357556|NCT01469065|Drug|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
357557|NCT01469065|Drug|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
357558|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
357559|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
357560|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
357566|NCT01469026|Radiation|PET/CT or Conventional diagnostics including CT|"Radiation:~PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.~CT. iv.contrast medium (Ultravist 370 mg I/ml)."
357567|NCT01469013|Drug|Placebo|
357568|NCT01469013|Drug|Baricitinib|
357569|NCT01469013|Drug|Baricitinib|
357570|NCT01469013|Drug|Baricitinib|
357571|NCT01469013|Drug|Methotrexate|Administered orally as background therapy
357572|NCT01469000|Drug|Gefitinib|250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
357573|NCT01469000|Drug|Pemetrexed|500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
357574|NCT01468987|Drug|LY2605541|
357575|NCT01468987|Drug|Insulin Glargine|
357576|NCT01468987|Drug|Insulin Lispro|
357577|NCT01468974|Device|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
357578|NCT01468961|Behavioral|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
357579|NCT01468948|Drug|Octanoic Acid|
357580|NCT01468922|Drug|Pazopanib|VEGFR inhibitor
357581|NCT01468922|Drug|ARQ 197|MET inhibitor
357582|NCT01468909|Other|Laboratory Biomarker Analysis|Correlative studies
357583|NCT01468909|Drug|Paclitaxel|Given IV
357584|NCT01468909|Drug|Pazopanib Hydrochloride|Given PO
357585|NCT01468909|Other|Placebo|Given PO
357586|NCT01468896|Biological|Cetuximab|Given IV
357587|NCT01468896|Other|Laboratory Biomarker Analysis|Correlative studies
357588|NCT01468896|Biological|Recombinant Interleukin-12|Given SC
357589|NCT01468883|Procedure|M|Modified radical mastectomy
357590|NCT01468883|Radiation|X|Excisional biopsy plus radiation
357591|NCT01468844|Drug|Minocycline|
357592|NCT01468831|Drug|Minocycline|
357593|NCT01468818|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
357594|NCT01468818|Drug|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
357595|NCT01468818|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
357596|NCT01468805|Procedure|Cockroach mitigation/extermination|
357597|NCT01468779|Dietary Supplement|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
357598|NCT01468779|Dietary Supplement|Sugar pill|
357599|NCT01468766|Other|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
357600|NCT01468766|Other|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
357601|NCT01468753|Procedure|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
357602|NCT01468740|Drug|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
357603|NCT01468740|Drug|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
357604|NCT01468740|Drug|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
357605|NCT01468740|Drug|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine~Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
357606|NCT01468740|Drug|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
357647|NCT01468402|Procedure|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
357607|NCT01468740|Drug|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
357608|NCT01468740|Drug|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
357609|NCT01468740|Drug|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
357610|NCT01468740|Drug|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.~Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation~Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
357611|NCT01468727|Dietary Supplement|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
357612|NCT01468727|Dietary Supplement|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
357613|NCT01468714|Drug|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
357614|NCT01468688|Drug|STI571|
357615|NCT01468688|Drug|BKM120|BKM120 combination therapy
357616|NCT01468675|Other|Intervention|risk assessment survey; decision support for providers for prevention based on risk
357617|NCT01468649|Device|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
357618|NCT01468636|Drug|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
357619|NCT01468636|Drug|Placebo|200mg BID x 8 weeks
357620|NCT01468623|Other|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
357621|NCT01468623|Other|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
357622|NCT01468610|Drug|desvenlafaxine|50-100 mg daily for 8 weeks
357623|NCT01468584|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
357624|NCT01468584|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
357625|NCT01468584|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
357626|NCT01468571|Drug|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
357627|NCT01468571|Drug|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.~So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
357628|NCT01468558|Drug|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
357629|NCT01468558|Drug|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
357630|NCT01468558|Drug|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
357631|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
357632|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
357633|NCT01468532|Drug|docetaxel|Given IV
357634|NCT01468532|Drug|pasireotide|Given IM
357635|NCT01468532|Drug|prednisone|Given PO
357636|NCT01468519|Drug|Insulin|Insulin via continuous subcutaneous insulin infusion
357637|NCT01468519|Drug|Insulin|insulin via multiple daily injections
357638|NCT01468480|Drug|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
357639|NCT01468480|Drug|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
357640|NCT01468480|Drug|MultiCal|application of Multical in forth group as a pulp dressing agent
357641|NCT01468480|Drug|Dycal|application of Dycal in first group as a pulp dressing agent
357642|NCT01468467|Drug|AC220|Oral Liquid
357643|NCT01468454|Drug|18 F-DOPA|one time injection of 0.08 - 0.16 mCurie/kg of 18F-DOPA
357644|NCT01468441|Drug|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
357645|NCT01468441|Drug|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
357646|NCT01468415|Drug|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
357648|NCT01468389|Drug|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
358236|NCT01464242|Drug|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
357649|NCT01468389|Drug|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
357650|NCT01468376|Dietary Supplement|GLU-01|14 day dosing
357651|NCT01468376|Dietary Supplement|GLU-02|14 day dosing
357652|NCT01468376|Dietary Supplement|GLU-03|14 day dosing
357653|NCT01468376|Dietary Supplement|GLU-04|14 day dosing
357654|NCT01468376|Dietary Supplement|GLU-05|14 day dosing
357655|NCT01468376|Dietary Supplement|GLU-06|14 day dosing
357656|NCT01468363|Device|Dry weight adjustment|Dry weight adjustment according to BCM results
357657|NCT01468350|Drug|dalfampridine-ER 10mg|
357658|NCT01468350|Other|Placebo|
357659|NCT01468337|Drug|Interferon gamma-1b|"Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg~Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.~Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.~Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.~If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes)."
357660|NCT01468324|Drug|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
357661|NCT01468311|Procedure|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
357662|NCT01468311|Drug|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
357663|NCT01468311|Radiation|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
357664|NCT01468311|Radiation|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
357665|NCT01468298|Other|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
357666|NCT01468298|Other|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
357667|NCT01468285|Drug|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
357668|NCT01468285|Other|placebo|placebo tablets b.i.d., six weeks treatment
357669|NCT01468272|Drug|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
357670|NCT01468272|Drug|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
357671|NCT01468259|Drug|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
357672|NCT01468233|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
357673|NCT01468233|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
357674|NCT01468220|Other|Endurance training|Endurance training three times per week over six weeks
357675|NCT01468207|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
357676|NCT01468207|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
357677|NCT01468194|Other|Breathing procedure 1|inhalation during one step, exhalation during the next step
357678|NCT01468194|Other|Breathing procedure 2|inhalation and exhalation during one step
357679|NCT01468181|Drug|LY2189265|
357680|NCT01468181|Drug|Sulfonylureas (SU)|SU is a pre-study prescribed dose and is not being provided as part of the trial.
357681|NCT01468181|Drug|Biguanides (BG)|Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
357682|NCT01468181|Drug|alpha-glucosidase inhibitor (a-GI)|a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
357683|NCT01468181|Drug|Thiazolidinedione (TZD)|TZD is a pre-study prescribed dose and is not being provided as part of the trial.
357684|NCT01468181|Drug|Glinides|Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
357685|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
357686|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
357687|NCT01468168|Drug|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
357688|NCT01468155|Drug|dabigatran|30 days pre ablation and 90 days post ablation
357689|NCT01468129|Other|Cell Saver|
357690|NCT01468103|Procedure|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
357691|NCT01468103|Procedure|Laser Iridotomy|alternative choice to surgical iridectomy
357693|NCT01468064|Genetic|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
357694|NCT01468064|Genetic|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
357695|NCT01468064|Genetic|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
357696|NCT01468051|Biological|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
357697|NCT01468051|Biological|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
357698|NCT01468038|Drug|Trazodone|active trazodone and sentra pm-like placebo
357699|NCT01468038|Other|Sentra PM|Active Sentra PM and trazodone-like placebo
357700|NCT01468038|Drug|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
357701|NCT01468038|Drug|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
357702|NCT01468025|Drug|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
357703|NCT01468025|Other|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
357704|NCT01468025|Drug|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
357705|NCT01468012|Drug|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
357706|NCT01468012|Drug|Placebo|matched placebo for LCE condition dosed twice daily
357707|NCT01467999|Drug|Guanfacine|Guanfacine, 4mg given once daily
357708|NCT01467986|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
357709|NCT01467986|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
357710|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
357711|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
357712|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
357713|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
357714|NCT01467947|Biological|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
357715|NCT01467921|Drug|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
357716|NCT01467908|Device|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
357717|NCT01467882|Drug|Triptorelin|Powder and solution for solution for injection
357718|NCT01467856|Procedure|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP > 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
357719|NCT01467843|Behavioral|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
357720|NCT01467843|Behavioral|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
357721|NCT01467830|Procedure|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
357805|NCT01467193|Other|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
357722|NCT01467817|Behavioral|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
357723|NCT01467817|Behavioral|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
357724|NCT01467804|Drug|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
357725|NCT01467804|Drug|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
357726|NCT01467791|Other|Observation|Observe patients
357727|NCT01467778|Device|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
357728|NCT01467778|Device|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
357729|NCT01467765|Other|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
357730|NCT01467752|Procedure|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
357731|NCT01467739|Device|Ambu ® aScope®|
357732|NCT01467739|Device|a conventional reusable fiberscope|
357733|NCT01467726|Drug|Velusetrag|Capsules
357734|NCT01467726|Drug|Velusetrag|Capsules
357735|NCT01467726|Drug|Placebo|Capsules
357736|NCT01467713|Drug|Ramelteon SL|Ramelteon sublingual (SL) tablets
357737|NCT01467713|Drug|Placebo|Ramelteon sublingual (SL) placebo-matching tablets
357738|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets
357739|NCT01467700|Drug|Placebo|Ramelteon placebo-matching tablets
357740|NCT01467687|Drug|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
357741|NCT01467661|Drug|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
357742|NCT01467648|Drug|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
357743|NCT01467648|Drug|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
357744|NCT01467635|Device|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
357745|NCT01467622|Procedure|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
357746|NCT01467596|Device|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
357747|NCT01467583|Drug|Fondaparinux|2.5 mg every 48 hours
357748|NCT01467570|Dietary Supplement|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
357749|NCT01467570|Dietary Supplement|ESPGHAN ORS|"Volume of the solution calculated by weight:~fast oral rehydration in 3-4 hours by mouth~ORS given for ongoing losses until diarrhea stops (maintenance phase)"
357750|NCT01467557|Device|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
357751|NCT01467557|Device|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
357752|NCT01467544|Other|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
357753|NCT01467531|Drug|Dolutegravir|50mg q 24h
357754|NCT01467531|Drug|Rlipivirine|25mg q24h
357755|NCT01467531|Drug|GSK1265744|30mg q24h
357756|NCT01467518|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
357757|NCT01467518|Drug|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
357758|NCT01467505|Drug|Telaprevir|Tablet
357759|NCT01467505|Drug|Ribavirin|Tablet
357760|NCT01467505|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
357761|NCT01467505|Drug|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
357762|NCT01467492|Drug|Telaprevir|Tablet
357763|NCT01467492|Drug|Ribavirin|Tablet
357764|NCT01467492|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
357765|NCT01467479|Drug|Telaprevir|Tablet
357766|NCT01467479|Drug|Ribavirin|Tablet
357767|NCT01467479|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
357806|NCT01467180|Device|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
357768|NCT01467479|Drug|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
357769|NCT01467466|Drug|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
357770|NCT01467466|Drug|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
357771|NCT01467466|Drug|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
357772|NCT01467466|Drug|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
357773|NCT01467453|Device|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
357774|NCT01467440|Device|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
357775|NCT01467427|Drug|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
357776|NCT01467414|Drug|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
357777|NCT01467401|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
357778|NCT01467401|Drug|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
357779|NCT01467388|Procedure|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
357780|NCT01467375|Drug|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
357781|NCT01467362|Drug|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
357782|NCT01467362|Drug|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
357783|NCT01467362|Drug|desonide 0.1% cream|cream, once a day (in the evening) during flares
357784|NCT01467362|Other|Foaming gel|for the washing and cleaning
357785|NCT01467336|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
357786|NCT01467323|Drug|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
357787|NCT01467323|Drug|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
357788|NCT01467310|Drug|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
357789|NCT01467297|Drug|ceftidoren|ceftidoren 200 mg bid for 5 days
357790|NCT01467297|Drug|levofloxacin|levofloxacin 500 mg once daily for 7 days
357791|NCT01467284|Behavioral|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
357792|NCT01467284|Behavioral|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
357793|NCT01467258|Drug|Amantadine|Single dose
357794|NCT01467245|Procedure|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
357795|NCT01467245|Procedure|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
357796|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
357797|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
357798|NCT01467219|Procedure|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
357799|NCT01467219|Procedure|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
357800|NCT01467219|Procedure|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
357801|NCT01467219|Radiation|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
357802|NCT01467206|Behavioral|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
357803|NCT01467206|Behavioral|Standard care|Standard care as it is given to all stoke patients after stroke
357804|NCT01467193|Dietary Supplement|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
357807|NCT01467180|Device|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
357808|NCT01467141|Drug|insulin aspart|Injected s.c. (under the skin) three times a day
357809|NCT01467141|Drug|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
357810|NCT01467141|Drug|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
357811|NCT01467128|Other|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
357812|NCT01467128|Other|No Intervention|Normal hospital pharmaceutical care
357813|NCT01467115|Radiation|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
357814|NCT01467115|Drug|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
357815|NCT01467115|Biological|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
357816|NCT01467115|Drug|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
357817|NCT01467115|Drug|Erythropoetin|Subcutaneous or intravenous
357818|NCT01467115|Drug|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
357819|NCT01467115|Drug|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
357820|NCT01467115|Drug|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
357821|NCT01467089|Other|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
357822|NCT01467076|Drug|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
357823|NCT01467076|Drug|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
357824|NCT01467063|Dietary Supplement|Glutamine|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
357897|NCT01466478|Drug|Diprosone® ointment|once daily application, 4 weeks
357898|NCT01466465|Drug|Cholecalciferol|given orally, once daily, before grass pollen season
358237|NCT01464229|Drug|Iloperidone|Iloperidone 1-8 mg for 4 weeks
357825|NCT01467063|Dietary Supplement|Placebo|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
357826|NCT01467050|Other|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.~Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
357827|NCT01467050|Other|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
357828|NCT01467037|Other|No intervention done|Not applicable because no intervention was done.
357829|NCT01467024|Other|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
357830|NCT01467011|Drug|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
357831|NCT01466998|Other|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
357832|NCT01466998|Other|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
357833|NCT01466985|Drug|Doravirine|Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
357834|NCT01466985|Drug|Placebo|Placebo tablets once daily for 7 days.
357835|NCT01466972|Drug|Pazopanib|Oral, 800mg tablet daily per cycle
357836|NCT01466959|Other|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
357837|NCT01466959|Other|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
357838|NCT01466946|Behavioral|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin & Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
357839|NCT01466933|Behavioral|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
357840|NCT01466933|Behavioral|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
357841|NCT01466907|Other|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
357842|NCT01466907|Other|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
357843|NCT01466894|Biological|IMM 124-E|Tablets orally twice a day for 24 weeks
357844|NCT01466894|Biological|Placebo|Tablets orally twice daily for 24 weeks
357845|NCT01466881|Drug|Alisertib|Given PO
357846|NCT01466881|Other|Laboratory Biomarker Analysis|Correlative studies
357847|NCT01466881|Other|Pharmacological Study|Correlative studies
357848|NCT01466868|Drug|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.~The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
357849|NCT01466855|Drug|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
357850|NCT01466842|Procedure|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
357851|NCT01466829|Drug|Parathyroid hormone|100 microgram daily. S.c
357852|NCT01466829|Drug|Placebo|Placebo; saline injection.
357853|NCT01466816|Dietary Supplement|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
357854|NCT01466803|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
357855|NCT01466803|Drug|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
357856|NCT01466790|Drug|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
357857|NCT01466790|Drug|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
357858|NCT01466790|Drug|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
357859|NCT01466777|Procedure|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
357860|NCT01466777|Procedure|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
357861|NCT01466764|Drug|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
357862|NCT01466764|Other|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
357863|NCT01466751|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
357864|NCT01466738|Biological|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
357865|NCT01466738|Biological|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
357866|NCT01466725|Drug|CC-930|
357867|NCT01466725|Drug|Placebo|Placebo
357868|NCT01466712|Drug|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
357869|NCT01466712|Drug|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
357870|NCT01466686|Radiation|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide.
357871|NCT01466686|Drug|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
357872|NCT01466673|Drug|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
357873|NCT01466673|Drug|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
357874|NCT01466660|Drug|Afatinib|afatinib once daily
357875|NCT01466660|Drug|gefitinib|Gefitinib once daily
357876|NCT01466647|Drug|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
357877|NCT01466634|Procedure|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
357878|NCT01466608|Drug|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
357879|NCT01466595|Drug|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
357880|NCT01466569|Drug|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
357881|NCT01466569|Drug|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
357882|NCT01466556|Other|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
357883|NCT01466543|Drug|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
357884|NCT01466543|Drug|Placebo|Placebo
357885|NCT01466530|Drug|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
357886|NCT01466530|Drug|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
357887|NCT01466517|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
357888|NCT01466517|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
357889|NCT01466504|Procedure|skin punch biopsy|Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.
357890|NCT01466491|Drug|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
357891|NCT01466478|Drug|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
357892|NCT01466478|Drug|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
357893|NCT01466478|Drug|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
357894|NCT01466478|Drug|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
357895|NCT01466478|Drug|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
357896|NCT01466478|Drug|Daivonex® ointment|once daily application, 4 weeks
357899|NCT01466465|Other|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
357900|NCT01466452|Drug|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
357901|NCT01466452|Drug|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
357902|NCT01466452|Drug|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
357903|NCT01466439|Procedure|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
357904|NCT01466439|Procedure|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
357905|NCT01466413|Device|Tropoelastin|"Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43."
357906|NCT01466387|Biological|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
357907|NCT01466387|Biological|Yellow Fever Vaccine|One dose of yellow fever vaccine.
357908|NCT01466387|Biological|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
357909|NCT01466387|Biological|Rabies Vaccine|Three doses of Rabies vaccine.
357910|NCT01466387|Biological|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
357911|NCT01466374|Drug|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
357912|NCT01466374|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
357913|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
357914|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
357915|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
357916|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
357917|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
357918|NCT01466361|Drug|Nicotine lower dose|lower dose nicotine lozenge
357919|NCT01466361|Drug|Nicotine higher dose|higher dose nicotine lozenge
357920|NCT01466361|Drug|Placebo|placebo
357921|NCT01466348|Drug|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
357922|NCT01466348|Drug|Paracetamol|Paracetamol 1000 mg
357923|NCT01466335|Drug|Ronacaleret (100mg tablet)|100mg tablet
357924|NCT01466335|Drug|Placebo|matching placebo tablet
357925|NCT01466322|Drug|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
357926|NCT01466309|Device|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
357927|NCT01466296|Device|Chaotic Perturbation|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session."
357928|NCT01466296|Device|Dummy not active shoes|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session."
357929|NCT01466296|Device|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
357930|NCT01466283|Genetic|DNA methylation analysis|
357931|NCT01466283|Genetic|fluorescence in situ hybridization|
357932|NCT01466283|Genetic|gene expression analysis|
357933|NCT01466283|Genetic|reverse transcriptase-polymerase chain reaction|
357934|NCT01466283|Other|laboratory biomarker analysis|
357935|NCT01466270|Drug|donepezil hydrochloride|Given PO
357936|NCT01466270|Drug|Placebo|Given PO
357937|NCT01466257|Biological|cetuximab|
357938|NCT01466257|Drug|cisplatin|
357939|NCT01466257|Genetic|DNA analysis|
357940|NCT01466257|Genetic|gene expression analysis|
357941|NCT01466257|Genetic|mutation analysis|
357942|NCT01466257|Other|laboratory biomarker analysis|
357943|NCT01466244|Biological|cetuximab|
357944|NCT01466244|Drug|cisplatin|
357945|NCT01466244|Genetic|gene expression analysis|
357946|NCT01466244|Genetic|microarray analysis|
357947|NCT01466244|Other|immunohistochemistry staining method|
357948|NCT01466244|Other|laboratory biomarker analysis|
357949|NCT01466231|Drug|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
358185|NCT01464515|Device|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
357950|NCT01466205|Drug|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
357951|NCT01466205|Drug|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
357952|NCT01466192|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
357953|NCT01466192|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
357954|NCT01466192|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
357955|NCT01466179|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
357956|NCT01466166|Biological|Pegloticase|Pegloticase 8 mg intravenous every 2 weeks
357957|NCT01466153|Drug|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m^2 on Day 2 of Cycle 1 and then at 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycles
357958|NCT01466153|Drug|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
357959|NCT01466153|Drug|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
357960|NCT01466140|Other|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
357961|NCT01466127|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
357962|NCT01466127|Drug|Placebo|Matched nasal spray placebo
357963|NCT01466114|Drug|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
357964|NCT01466114|Other|Placebo|4 capsules PO QD
357965|NCT01466114|Drug|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
357966|NCT01466114|Other|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
357967|NCT01466101|Drug|Placebo administration|Administration of placebo
357968|NCT01466101|Drug|Pregabalin administration|Administration of pregabalin
357969|NCT01466088|Drug|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
357970|NCT01466088|Drug|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
357971|NCT01466075|Device|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
357972|NCT01466062|Drug|Palivizumab|
357973|NCT01466036|Drug|Cabozantinib|60 mg QD orally in cycles of 28 days
357974|NCT01466010|Procedure|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
357975|NCT01465997|Drug|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
357976|NCT01465997|Drug|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
357977|NCT01465984|Drug|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
357978|NCT01465958|Biological|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
357979|NCT01465958|Biological|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
357980|NCT01465945|Procedure|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
357981|NCT01465945|Procedure|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
357982|NCT01465932|Other|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
357983|NCT01465932|Other|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
357984|NCT01465919|Drug|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
357985|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
357986|NCT01465906|Drug|tulobuterol|patch, 2mg, qN, 3 months
357987|NCT01465906|Drug|Tiotropium Bromide|18ug, inhale, qD, 3 months
357988|NCT01465906|Drug|tiotropium bromide|18ug, inhale, qD, 3 months
357989|NCT01465893|Drug|Vitamin D|vitamin D ,50000 unit /week
357990|NCT01465893|Drug|Vitamin D withheld|do not receive anything
357991|NCT01465880|Other|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
358186|NCT01464515|Device|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
358187|NCT01464502|Procedure|Standard CRT Implant|
357992|NCT01465867|Dietary Supplement|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
357993|NCT01465867|Other|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
357994|NCT01465867|Other|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
357995|NCT01465867|Other|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
357996|NCT01465841|Device|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
357997|NCT01465828|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
357998|NCT01465828|Drug|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
357999|NCT01465815|Drug|erlotinib hydrochloride|Given PO
358000|NCT01465815|Drug|linsitinib|Given PO
358001|NCT01465815|Drug|placebo|Given PO
358002|NCT01465815|Radiation|radiation therapy|Undergo radiation therapy
358003|NCT01465815|Procedure|therapeutic conventional surgery|Undergo planned surgery
358004|NCT01465815|Other|laboratory biomarker analysis|Correlative studies
358005|NCT01465802|Drug|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
358006|NCT01465802|Drug|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
358007|NCT01465802|Drug|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
358008|NCT01465802|Drug|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
358009|NCT01465802|Drug|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
358010|NCT01465776|Other|laboratory biomarker analysis|Correlative studies
358011|NCT01465776|Other|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
358012|NCT01465763|Drug|tofacitinib|10 mg oral BID
358013|NCT01465763|Drug|Placebo|Plabebo oral BID
358014|NCT01465737|Other|Histologic types|evaluate survival among different histologic types
358015|NCT01465724|Procedure|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
358016|NCT01465711|Procedure|All abdominal surgical procedures|Laparotomy, Laparoscopy
358017|NCT01465711|Procedure|Intubation|Ventilatory support
358018|NCT01465711|Radiation|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
358019|NCT01465698|Behavioral|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.~The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
358020|NCT01465698|Behavioral|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
358021|NCT01465698|Behavioral|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
358022|NCT01465698|Other|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
358023|NCT01465685|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
358024|NCT01465685|Drug|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
358025|NCT01465685|Drug|Placebo|capsules identical to MDMA or methylphenidate
358026|NCT01465659|Drug|temozolomide|Given PO
358027|NCT01465659|Drug|pazopanib hydrochloride|Given PO
358028|NCT01465646|Drug|levothyroxine|
358029|NCT01465646|Drug|levothyroxine|
358030|NCT01465633|Drug|levothyroxine|
358031|NCT01465633|Drug|levothyroxine|
358032|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
358033|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
358034|NCT01465607|Behavioral|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
358035|NCT01465607|Behavioral|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
358036|NCT01465594|Procedure|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
358037|NCT01465594|Procedure|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
358038|NCT01465581|Procedure|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
358039|NCT01465568|Drug|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
358040|NCT01465568|Drug|bisphosphonates|continue present bisphosphonate treatment
358041|NCT01465555|Behavioral|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
358042|NCT01465529|Drug|OligoG CF-5/20|6% OligoG CF-5/20 in water
358043|NCT01465529|Drug|Saline|0.9% NaCl in water
358044|NCT01465516|Drug|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).~Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
358045|NCT01465503|Drug|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
358046|NCT01465503|Drug|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
358047|NCT01465490|Behavioral|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
358048|NCT01465477|Biological|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
358049|NCT01465477|Biological|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
358050|NCT01465464|Drug|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
358051|NCT01465464|Drug|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
358052|NCT01465451|Procedure|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
358053|NCT01465451|Drug|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.~5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
358054|NCT01465438|Drug|Adalimumab|Adalimumab 40 mg every other week
358055|NCT01465412|Drug|Preladenant|After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
358056|NCT01465399|Biological|Plasma Rich in Growth Factors PRGF-Endoret|
358057|NCT01465399|Procedure|Conventional closure of the lesion|
358058|NCT01465386|Drug|bortezomib|Given SC
358059|NCT01465373|Drug|Endometrin|100 mg per vagina TID
358060|NCT01465373|Drug|Progesterone in Oil|50 mg IM injection daily
358061|NCT01465347|Drug|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
358062|NCT01465334|Drug|Ofatumumab|
358063|NCT01465334|Drug|High-Dose Methylprednisolone|
358064|NCT01465334|Drug|Alemtuzumab|
358065|NCT01465308|Dietary Supplement|Honey mouthwash|The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
358066|NCT01465308|Other|Normal Saline|Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
358067|NCT01465295|Device|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
358068|NCT01465282|Drug|CT327 0.05%|0.05% CT327 (w/w) ointment
358069|NCT01465282|Drug|CT327 0.1%|0.1% CT327 (w/w) ointment
358070|NCT01465282|Drug|CT327 0.5%|0.5% CT327 (w/w) ointment
358071|NCT01465282|Drug|Placebo|Placebo
358233|NCT01464255|Device|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
358072|NCT01465269|Behavioral|Group Interactive Structured Treatment|GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.
358073|NCT01465269|Behavioral|Alternative Intervention|Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.
358074|NCT01465256|Drug|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
358075|NCT01465243|Drug|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
358076|NCT01465230|Drug|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
358077|NCT01465217|Behavioral|text message medication reminders|daily medication reminders for one month
358078|NCT01465204|Behavioral|Total Sanitation and Sanitation Marketing|"Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment."
358079|NCT01465204|Behavioral|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
358080|NCT01465191|Drug|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
358081|NCT01465178|Dietary Supplement|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
358082|NCT01465178|Dietary Supplement|Placebo|matching placebo
358083|NCT01465152|Drug|metformin|Adminstered orally during the three main meals for 24 weeks
358084|NCT01465152|Drug|repaglinide|Administered orally before the three main meals for 24 weeks
358085|NCT01465139|Drug|CDX-301|"CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days"
358086|NCT01465113|Drug|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
358087|NCT01465113|Drug|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
358088|NCT01465113|Drug|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
358089|NCT01465113|Procedure|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
358090|NCT01465113|Drug|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
358091|NCT01465100|Radiation|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
358092|NCT01465100|Procedure|Hepatocyte Transplant|"Transplantation of hepatocytes into the liver will be through the portal vein, either accessed transhepatically, or by umbilical vein. After cell transplantation, measures will be taken to provide chronic access to the portal venous circulation system. If chronic access is achieved, patients will be seen in the PCTRC once a week to assess the site.~Hepatocytes from more than one donor may be required to provide sufficient numbers of cells for transplantation to correct the disease process and to optimize Phe tolerance. Hepatocytes will be infused until the goal number of hepatocytes is infused. If viable hepatocytes remain after the goal number has been infused, the remaining cells will also be infused, as tolerated by the patient."
358093|NCT01465100|Drug|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
358094|NCT01465100|Other|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases, EKG, chest x-ray, and abdominal ultrasound to assess blood flow to the blood vessels in the liver. A liver biopsy may be performed if, in the clinical judgment of the investigators, the subject shows clinical signs of liver failure, or is at increased risk for liver fibrosis.
358095|NCT01465100|Behavioral|Neuro-psychological Assessment|Subjects will undergo a repeat neuropsychological assessment at 6, 12 and 24 months post-transplant (Visits 4 and 6 and the End of Study Visit) which will be compared to results obtained pre-transplant to determine whether an improvement in assessment scoring is associated with the transplant procedure.
358096|NCT01465100|Diagnostic Test|Whole body Phe oxidation testing|Patient will again be asked to not eat or drink for at least four hours prior to testing. Isotopic monitoring of whole body Phe oxidation will be performed pre-transplant and at every follow-up visit following the final hepatocyte infusion. An additional Phe oxidation test may also be completed in the event of suspected graft rejection.
358097|NCT01465100|Procedure|Liver Biopsy|Liver biopsies will be performed at 3 and 12 months post-transplant to assess for the presence of donor hepatocytes, and may be completed in the event of suspected graft rejection.
358098|NCT01465087|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
358099|NCT01465074|Drug|Nicotine polacrilex|4 mg
358100|NCT01465074|Drug|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
358101|NCT01465061|Behavioral|Online support group|Joining online support group
358102|NCT01465048|Biological|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
358103|NCT01465048|Biological|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
358104|NCT01465048|Biological|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
358105|NCT01465035|Biological|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
358106|NCT01465035|Biological|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
358107|NCT01465022|Drug|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
358108|NCT01465022|Drug|Progestin-only pill|.35 mg norethindrone once a day orally
358109|NCT01465009|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
358110|NCT01465009|Drug|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
358111|NCT01465009|Drug|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
358112|NCT01464996|Procedure|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
358113|NCT01464996|Procedure|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
358114|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
358115|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
358116|NCT01464983|Drug|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
358117|NCT01464983|Drug|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
358118|NCT01464983|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
358119|NCT01464970|Procedure|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
358120|NCT01464970|Procedure|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
358121|NCT01464970|Procedure|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
358122|NCT01464970|Procedure|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
358123|NCT01464957|Behavioral|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
358124|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
358125|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
358126|NCT01464944|Drug|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
358127|NCT01464944|Drug|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
358128|NCT01464944|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
358129|NCT01464931|Drug|Denosumab|Adminstered by subcutaneous injection
358130|NCT01464918|Device|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
358131|NCT01464905|Biological|NU100|0.25 mg SQ, every other day for 12 months
358132|NCT01464905|Biological|Placebo|1 mL SQ, every other day for 4 months
358133|NCT01464905|Biological|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
358134|NCT01464892|Behavioral|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
358234|NCT01464242|Drug|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
358235|NCT01464242|Drug|Placebo|Placebo 400mg orally 3 times a day for 20 days
358135|NCT01464892|Behavioral|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
358136|NCT01464879|Drug|Testosterone Gel (FE 999303)|
358137|NCT01464866|Other|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
358138|NCT01464866|Other|Hospital food|Typical hospital food given daily at meals
358139|NCT01464853|Other|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
358140|NCT01464853|Other|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
358141|NCT01464840|Drug|Azithromycin|500 mg intravenous infused over 1 hour
358142|NCT01464827|Drug|ABT-450|ABT-450 tablets
358143|NCT01464827|Drug|ABT-333|ABT-333 tablets
358144|NCT01464827|Drug|ABT-267|ABT-267 tablets
358145|NCT01464827|Drug|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
358146|NCT01464827|Drug|Ritonavir|Ritonavir capsules
358147|NCT01464814|Dietary Supplement|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
358148|NCT01464814|Dietary Supplement|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
358149|NCT01464801|Dietary Supplement|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
358150|NCT01464801|Dietary Supplement|Placebo|Tablet Placebo 3 times daily for 6 months
358151|NCT01464788|Drug|Low Dose Argatroban|100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
358152|NCT01464788|Drug|High Dose Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
358153|NCT01464788|Drug|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
358154|NCT01464775|Other|NBI|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
358155|NCT01464775|Other|White light|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
358156|NCT01464762|Drug|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
358157|NCT01464749|Behavioral|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
358158|NCT01464749|Behavioral|usual care|no specific rehabilitation
358159|NCT01464736|Other|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
358160|NCT01464723|Drug|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
358161|NCT01464697|Drug|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
358162|NCT01464697|Drug|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
358163|NCT01464671|Drug|Bivalirudin|Anticoagulation during percutaneous coronary intervention
358164|NCT01464671|Drug|Heparin|Anticoagulation during percutaneous coronary intervention
358165|NCT01464658|Procedure|panniculectomy|surgery
358166|NCT01464645|Device|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
358167|NCT01464632|Device|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
358168|NCT01464619|Other|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
358169|NCT01464619|Other|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
358170|NCT01464606|Drug|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
358171|NCT01464606|Drug|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
358172|NCT01464606|Drug|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
358173|NCT01464606|Drug|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
358174|NCT01464606|Drug|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
358175|NCT01464593|Drug|Lyso-Thermosensitive Liposomal Doxorubicin|Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
358176|NCT01464593|Other|5% Dextrose Solution|Single 30 minute intravenous infusion
358177|NCT01464593|Drug|ThermoDox|ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
358178|NCT01464567|Procedure|"T Tube Spontaneous Breathing Trial"|"T Tube ventilation for 30 minutes"
358179|NCT01464567|Procedure|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
358180|NCT01464554|Behavioral|Usual care|alcohol and drug education
358181|NCT01464554|Behavioral|Project Free Talk|motivational interviewing alcohol and drug program
358182|NCT01464541|Procedure|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
358183|NCT01464541|Procedure|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
358184|NCT01464528|Drug|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
358188|NCT01464502|Procedure|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
358189|NCT01464489|Drug|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.~Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
358190|NCT01464489|Drug|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
358191|NCT01464476|Drug|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
358192|NCT01464476|Drug|Placebo|Dose-matched placebo. Once daily, oral administration
358193|NCT01464463|Behavioral|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
358194|NCT01464463|Behavioral|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
358195|NCT01464463|Behavioral|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.~Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
358196|NCT01464450|Drug|Rivaroxaban|Single 20 mg-dose
358197|NCT01464437|Drug|AMG 151|Drug: AMG 151 50 mg BID
358198|NCT01464437|Drug|Placebo|Placebo
358199|NCT01464437|Drug|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
358200|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg BID
358201|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg BID
358202|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg QD
358203|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg QD
358204|NCT01464437|Drug|AMG 151|Drug: AMG 151 400 mg QD
358205|NCT01464424|Drug|Travoprost 0.004% ophthalmic solution|
358206|NCT01464424|Drug|Bimatoprost 0.01% ophthalmic solution|
358207|NCT01464398|Behavioral|Stress reduction|8 weekly sessions
358208|NCT01464398|Behavioral|Stress reduction with Health education|8 weekly sessions
358209|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
358210|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237 mL
358211|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
358212|NCT01464372|Device|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
358213|NCT01464372|Device|Sham Nerve Stimulation Device|Use of the sham device
358214|NCT01464359|Drug|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
358215|NCT01464359|Drug|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m^2 intravenously over 1 hour.
358216|NCT01464359|Radiation|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
358217|NCT01464359|Drug|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
358218|NCT01464359|Drug|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
358219|NCT01464359|Drug|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if <12 kg) intravenously every 6 hours
358220|NCT01464359|Biological|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
358221|NCT01464359|Biological|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m^2 every other day for a total of 6 doses.~Second Course of IL-2 (day +60):~Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
358222|NCT01464346|Device|Enlite Sensor|This is the Enlite sensor (all subjects)
358223|NCT01464320|Drug|ABT-614|Active
358224|NCT01464320|Drug|Placebo Comparator|Placebo
358225|NCT01464307|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
358226|NCT01464307|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
358227|NCT01464294|Device|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
358228|NCT01464294|Device|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
358229|NCT01464281|Drug|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
358230|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
358231|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
358232|NCT01464255|Device|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
358238|NCT01464229|Drug|Placebo|Placebo
358239|NCT01464203|Other|CT coronary angiography|"CT coronary angiography:~This allows two distinct assessments of the coronary arteries to be made:~coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.~contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
358240|NCT01464203|Other|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
358241|NCT01464190|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
358242|NCT01464190|Drug|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
358243|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization"
358244|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:~Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.~Planning tumor volume (PTV) equals GTV plus 3mm margin.~The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.~RT to begin in a maximum of 2 weeks after randomization."
358245|NCT01464164|Drug|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
358246|NCT01464164|Drug|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:~Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
358247|NCT01464138|Drug|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
358248|NCT01464125|Drug|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
358249|NCT01464125|Drug|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
358250|NCT01464112|Drug|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
358251|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
358252|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
358253|NCT01464086|Other|whole body MRI|whole body MRI at inclusion, one and two years
358254|NCT01464073|Behavioral|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
358255|NCT01464073|Behavioral|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
358256|NCT01464073|Behavioral|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
358257|NCT01464073|Dietary Supplement|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
358258|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
358259|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
358260|NCT01464034|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
358261|NCT01464034|Drug|Pomalidomide|PO daily on Days 1-21, every 28 Days
358262|NCT01464034|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
358263|NCT01464008|Drug|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
358264|NCT01463982|Drug|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine~Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5~HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5~Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
358265|NCT01463956|Drug|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
358266|NCT01463956|Biological|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
358267|NCT01463956|Drug|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: <65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; >105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
358268|NCT01463943|Other|Probiotic|
358269|NCT01463943|Other|Probiotic|
358270|NCT01463943|Other|Probiotic|
358271|NCT01463930|Behavioral|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
358272|NCT01463930|Behavioral|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
358273|NCT01463917|Drug|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
358274|NCT01463917|Drug|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
358275|NCT01463904|Procedure|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
358276|NCT01463891|Drug|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
358277|NCT01463878|Dietary Supplement|Glycerna|Diabetes specific formula
358278|NCT01463878|Dietary Supplement|Jevity - Control Diet|Control Diet
358279|NCT01463865|Drug|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
358280|NCT01463865|Drug|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
358281|NCT01463852|Drug|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
358282|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
358283|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
358284|NCT01463813|Dietary Supplement|Placebo|Inactive placebo
358285|NCT01463800|Behavioral|Structured exercise training|12 weeks low level ambulatory structured exercise training
358286|NCT01463787|Procedure|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
358287|NCT01463787|Procedure|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
358288|NCT01463774|Drug|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
358289|NCT01463774|Drug|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
358290|NCT01463774|Drug|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
358291|NCT01463761|Device|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
358292|NCT01463748|Other|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
358293|NCT01463748|Other|Placebo|starch
358294|NCT01463735|Dietary Supplement|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
358295|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
358296|NCT01463709|Device|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.~NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
358297|NCT01463696|Drug|MK-8242|10 mg, 100 mg and 150 mg capsules
358298|NCT01463683|Biological|2XP HEPTAVAX™-II SC|
358299|NCT01463683|Biological|1XP HEPTAVAX™-II SC|
358300|NCT01463683|Biological|2XP HEPTAVAX™-II IM|
358301|NCT01463670|Drug|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
358302|NCT01463657|Device|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
358330|NCT01463397|Drug|placebo|"Pharmaceutical form:capsule~Route of administration: oral"
358331|NCT01463384|Drug|Minocycline|50mg, twice daily for 6 months.
358303|NCT01463657|Device|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
358304|NCT01463644|Drug|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
358305|NCT01463644|Drug|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
358306|NCT01463631|Drug|LY3007113|Administered orally
358307|NCT01463605|Drug|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
358308|NCT01463592|Biological|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
358309|NCT01463592|Drug|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
358310|NCT01463592|Biological|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
358311|NCT01463579|Other|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.~At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
358312|NCT01463579|Other|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
358313|NCT01463566|Device|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
358314|NCT01463553|Procedure|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
358315|NCT01463540|Device|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
358316|NCT01463540|Device|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
358317|NCT01463527|Device|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
358318|NCT01463514|Procedure|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
358319|NCT01463514|Procedure|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
358320|NCT01463501|Other|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
358321|NCT01463501|Other|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
358322|NCT01463488|Drug|SAR113945|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
358323|NCT01463488|Drug|placebo|"Pharmaceutical form:Injection~Route of administration: Intra-articular"
358324|NCT01463475|Procedure|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
358325|NCT01463449|Procedure|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
358326|NCT01463436|Dietary Supplement|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
358327|NCT01463436|Dietary Supplement|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
358328|NCT01463423|Radiation|Individualized Stereotactic Ablative Radiotherapy (iSABR)|Standard of Care describing dosing here
358329|NCT01463397|Drug|SAR292833|"Pharmaceutical form: capsule~Route of administration: oral"
358332|NCT01463371|Drug|Azithromycin|250 mg three times a week during three months
358333|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
358334|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
358335|NCT01463345|Other|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 7.5 g/dl. Blood products should be given to maintain Hgb levels >7.5 g/dl.
358336|NCT01463345|Other|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 9.0 g/dl. Blood products should be given to maintain Hgb levels > 9.0 g/dl.
358337|NCT01463332|Drug|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
358338|NCT01463332|Drug|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
358339|NCT01463332|Drug|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
358340|NCT01463319|Other|air insufflation|air insufflation during insertion phase colonoscopy
358341|NCT01463319|Other|warm water irrigation|warm water irrigation during insertion phase colonoscopy
358342|NCT01463306|Drug|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects <4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
358343|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
358344|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
358345|NCT01463293|Dietary Supplement|Placebo|Capsule containing no probiotic once a day
358346|NCT01463280|Drug|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
358347|NCT01463267|Device|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
358348|NCT01463267|Behavioral|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
358349|NCT01463241|Behavioral|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills [Belief Repair, Action, Solving Problems, Incentives, and Calming]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
358350|NCT01463228|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
358351|NCT01463228|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
358352|NCT01463215|Drug|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
358353|NCT01463202|Drug|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
358354|NCT01463202|Drug|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
358355|NCT01463189|Behavioral|painACTION: Arthritis|"Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs."
358356|NCT01463176|Behavioral|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
358357|NCT01463163|Drug|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
358358|NCT01463163|Drug|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
358359|NCT01463150|Drug|Clopidogrel|Clopidogrel 150mg per day for 15 days
358360|NCT01463150|Drug|Prasugrel|Prasugrel 5mg per day for 15 days
358361|NCT01463137|Behavioral|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
358410|NCT01462877|Drug|fenofibrate|Fenofibrate Capsule 200mg qd orally
358362|NCT01463124|Behavioral|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
358363|NCT01463124|Behavioral|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
358364|NCT01463111|Drug|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
358365|NCT01463111|Drug|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
358366|NCT01463111|Drug|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
358367|NCT01463098|Drug|E2006 1.0 mg|1.0 mg, or placebo
358368|NCT01463098|Drug|E2006 2.5 mg|2.5 mg or placebo
358369|NCT01463098|Drug|E2006 5.0 mg|5.0 mg or placebo
358370|NCT01463098|Drug|E2006 10.0 mg|10.0 mg or placebo
358371|NCT01463098|Drug|E2006 25.0 mg|25.0 mg or placebo
358372|NCT01463098|Drug|E2006 50.0 mg|50.0 mg or placebo
358373|NCT01463098|Drug|E2006 100 mg|100mg or placebo
358374|NCT01463098|Drug|E2006 200 mg|200 mg or placebo
358375|NCT01463098|Drug|zolpidem 10 mg|10 mg
358376|NCT01463098|Drug|zolpidem - matched placebo|Part B only
358377|NCT01463098|Drug|E2006 - matched placebo|(Part A and Part B)
358378|NCT01463085|Other|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
358379|NCT01463072|Other|Laboratory Biomarker Analysis|Correlative studies
358380|NCT01463072|Drug|Nab-paclitaxel|Given IV
358381|NCT01463072|Other|Questionnaire Administration|Ancillary studies
358382|NCT01463059|Biological|Placebo|Placebo solution for injection, administered as subcutaneous injections
358383|NCT01463059|Biological|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
358384|NCT01463059|Biological|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
358385|NCT01463059|Biological|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
358386|NCT01463046|Drug|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8~Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5~Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
358387|NCT01463046|Drug|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.~Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.~Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
358388|NCT01463046|Drug|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.~Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.~Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
358389|NCT01463033|Drug|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
358390|NCT01463020|Behavioral|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
358391|NCT01463020|Other|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
358392|NCT01463007|Radiation|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
358393|NCT01463007|Other|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
358394|NCT01462994|Other|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
358395|NCT01462968|Device|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
358396|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
358397|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
358398|NCT01462942|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
358399|NCT01462942|Drug|Placebo|Inhaled dose-matched placebo, twice per day
358400|NCT01462942|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
358401|NCT01462929|Drug|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
358402|NCT01462929|Drug|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
358403|NCT01462929|Drug|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
358404|NCT01462916|Dietary Supplement|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control [I/C] and control to intervention [C/I] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
358405|NCT01462903|Biological|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
358406|NCT01462890|Biological|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
358407|NCT01462890|Drug|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
358408|NCT01462890|Drug|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
358409|NCT01462890|Other|specialized pathology review (Germany only)|before randomization
358411|NCT01462864|Behavioral|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
358412|NCT01462851|Drug|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
358413|NCT01462851|Drug|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
358414|NCT01462851|Drug|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
358415|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
358416|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
358417|NCT01462838|Biological|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
358418|NCT01462825|Dietary Supplement|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
358419|NCT01462825|Dietary Supplement|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
358420|NCT01462812|Drug|Sumatriptan|Sumatriptan 20mg
358421|NCT01462812|Drug|Placebo|Matching placebo
358422|NCT01462799|Behavioral|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
358423|NCT01462799|Behavioral|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
358424|NCT01462786|Drug|ATX-101|2 mg/cm2 ATX-101
358425|NCT01462773|Drug|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
358426|NCT01462773|Drug|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
358427|NCT01462760|Device|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
358428|NCT01462760|Device|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
358429|NCT01462747|Device|KULIST|Twice daily dosing for 8 weeks
358430|NCT01462734|Procedure|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
358431|NCT01462721|Device|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
358432|NCT01462708|Drug|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not >10% of 10 mCi limit)of [18F]MK-9470, followed by PET imaging.
358433|NCT01462695|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
358434|NCT01462695|Other|Pharmacological Study|Correlative studies
358435|NCT01462695|Drug|Sunitinib Malate|Given PO
358436|NCT01462669|Drug|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
358437|NCT01462669|Drug|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
358438|NCT01462669|Drug|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
358439|NCT01462669|Drug|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
358440|NCT01462656|Drug|Non-EZG containing AED polytherapy|AED polytherapy without EZG
358441|NCT01462656|Drug|EZG containing AED polytherapy|AED polytherapy including EZG
358442|NCT01462656|Drug|Non-EZG AED monotherapy|AED monotherapy without EZG
358443|NCT01462656|Drug|EZG AED monotherapy|Any off-label use of EZG as monotherapy
358444|NCT01462643|Drug|LAS41004|once daily, topical ointment, 100 microgram per day
358445|NCT01462630|Drug|pazopanib hydrochloride|Given PO
358446|NCT01462630|Other|laboratory biomarker analysis|Correlative studies
358447|NCT01462630|Procedure|positron emission tomography|Correlative studies
358448|NCT01462630|Procedure|computed tomography|Correlative studies
358449|NCT01462630|Radiation|fludeoxyglucose F 18|Correlative studies
358450|NCT01462617|Drug|GSK2269557|Study Drug
358451|NCT01462617|Drug|GSK2269557 matching placebo|Study Drug
358452|NCT01462604|Other|non-drug intervention educational programme|educational programme
358453|NCT01462591|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
358454|NCT01462578|Drug|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
358455|NCT01462565|Drug|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
358456|NCT01462565|Drug|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
358457|NCT01462552|Drug|Lapatanib|Prescription of lapatinib (Tykerb)
358458|NCT01462513|Biological|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
358459|NCT01462513|Biological|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
358460|NCT01462500|Drug|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
358461|NCT01462487|Drug|Treatment with zanamivir|Subjects treated with zanamivir
358462|NCT01462474|Drug|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
358463|NCT01462474|Drug|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
358464|NCT01462474|Radiation|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
358465|NCT01462448|Procedure|Blood Draw|Single blood draw of 30 ml
358466|NCT01462435|Drug|Diclofenac Test (lower dose)|Capsules
358467|NCT01462435|Drug|Diclofenac Test (upper dose)|Capsules
358468|NCT01462435|Drug|Celecoxib|200 mg Capsules
358469|NCT01462435|Drug|Placebo|Capsules
358470|NCT01462422|Drug|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
358471|NCT01462422|Drug|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
358472|NCT01462409|Device|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
358473|NCT01462409|Device|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
358474|NCT01462409|Device|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
358475|NCT01462396|Device|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
358476|NCT01462370|Drug|Etoricoxib|Etoricoxib 120 mg tablet given orally for one dose.
358477|NCT01462370|Drug|Ibuprofen|Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
358478|NCT01462370|Drug|Placebo to etoricoxib|Placebo to etoricoxib, one tablet.
358479|NCT01462370|Drug|Placebo to ibuprofen|Placebo to ibuprofen, up to four 3-capsule doses.
358480|NCT01462370|Drug|Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg|Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
358481|NCT01462357|Biological|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6.
358482|NCT01462357|Biological|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gardasil 2 dose Group) or at Day 0, Month 2 and Month 6 (Gardasil 3 dose Group), respectively.
358483|NCT01462357|Drug|Placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
358484|NCT01462344|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
358485|NCT01462344|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
358486|NCT01462344|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
358487|NCT01462344|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
358488|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
358489|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
358490|NCT01462331|Other|Sucrose|12g/dose, three times a day
358491|NCT01462318|Drug|Midazolam|5 mg
358492|NCT01462318|Other|Caffeine|200 mg
358493|NCT01462318|Drug|S-warfarin|10 mg
358494|NCT01462318|Other|Vitamin K|10 mg
358495|NCT01462318|Drug|Omeprazole|40 mg
358496|NCT01462318|Drug|Dextromethorphan|30 mg
358497|NCT01462318|Biological|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
358498|NCT01462305|Device|goLITE|goLITE at 30 minutes per day, within 30 minutes of waking in the morning
358499|NCT01462305|Device|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
358500|NCT01462292|Drug|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
358501|NCT01462292|Drug|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
358502|NCT01462292|Drug|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
358503|NCT01462292|Drug|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
358504|NCT01462279|Drug|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
358505|NCT01462266|Drug|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
358506|NCT01462266|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
358507|NCT01462266|Biological|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
358508|NCT01462266|Drug|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
358509|NCT01462253|Drug|Clofarabine, Cyclophosphamide|The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
358510|NCT01462240|Device|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
358511|NCT01462227|Drug|Naltrexone High Dose|Naltrexone 100mg for two administrations.
358512|NCT01462227|Drug|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
358513|NCT01462214|Drug|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
358514|NCT01462201|Device|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
358515|NCT01462188|Procedure|Immediate stenting|Primary coronary stenting
358516|NCT01462188|Procedure|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
358517|NCT01462175|Drug|RO5503781|
358518|NCT01462162|Drug|Tocilizumab|
358519|NCT01462149|Drug|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
358520|NCT01462149|Drug|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
358521|NCT01462136|Drug|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
358522|NCT01462123|Other|endoscopic assessment of colonic polyps|
358523|NCT01462097|Behavioral|Aerobic exercise training|12 months of aerobic exercise
358524|NCT01462097|Behavioral|Health Education|12 months of health education sessions
358525|NCT01462084|Device|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
358526|NCT01462084|Device|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
358527|NCT01462058|Dietary Supplement|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
358528|NCT01462058|Drug|Placebo|Placebo, daily, 12 weeks
358529|NCT01462045|Behavioral|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
358530|NCT01462032|Behavioral|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
358531|NCT01462032|Behavioral|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
358532|NCT01462019|Device|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.~The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
358533|NCT01462006|Drug|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
358534|NCT01462006|Other|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
358535|NCT01461993|Biological|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
358536|NCT01461993|Biological|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
358537|NCT01461993|Biological|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
358538|NCT01461980|Biological|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
358539|NCT01461980|Biological|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
358540|NCT01461980|Biological|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
358541|NCT01461967|Drug|Placebo|Single ascending doses
358542|NCT01461967|Drug|RO5508887|Single ascending doses
358543|NCT01461967|Drug|RO5508887|Single doses
358544|NCT01461954|Drug|FST-100|FST-100
358545|NCT01461954|Drug|FST-100 Vehicle|FST-100 Vehicle
358546|NCT01461941|Drug|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
358547|NCT01461941|Drug|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
358548|NCT01461928|Drug|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
358549|NCT01461928|Drug|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
358550|NCT01461915|Drug|Abraxane ( Nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes. Given weekly for 3 weeks followed by one week of rest.
358551|NCT01461915|Drug|Abraxane ( Nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes. Nab-paclitaxel to be given weekly for 3 weeks followed by one week of rest.
358581|NCT01461746|Radiation|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
358552|NCT01461915|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 over 30 minutes to be administered after the completion of Abraxane administration. Gemcitabine will be given weekly for 3 weeks followed by one week of rest.
358553|NCT01461915|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 administered IV over 30 minutes (after the nab-paclitaxel IV administration is complete). Gemcitabine to be administered weekly for 3 weeks followed by one week of rest.
358554|NCT01461915|Drug|ODSH ( 2-O, 3-O Desulfated Heparin)|"ODSH IV bolus at 4 mg/kg to be administered in 5 minutes immediately after completion of gemcitabine administration.~ODSH 48-h IV continuous infusion at 0.375 mg/kg/h should be started immediately after the ODSH IV bolus has been administered."
358555|NCT01461915|Drug|ODSH ( 2-O, 3-O Desulfated Heparin)|"ODSH IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration.~ODSH 48-h IV continuous infusion at 0.375 mg/kg/h should be started immediately after the ODSH IV bolus has been administered."
358556|NCT01461915|Drug|Abraxane ( nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes will be given weekly for 3 weeks followed by one week of rest.
358557|NCT01461915|Drug|Gemcitabine|Gemcitabine to be administered IV at 1000 mg/m2 over 30 minutes given weekly for 3 weeks followed by one week of rest
358558|NCT01461889|Other|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
358559|NCT01461889|Other|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
358560|NCT01461876|Drug|antiretroviral therapy|Standard of care antiretroviral therapy
358561|NCT01461863|Dietary Supplement|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
358562|NCT01461863|Dietary Supplement|multivitamin|Standard multivitamin
358563|NCT01461850|Drug|Neoadjuvant chemotherapy + Interval Debulking Surgery|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
358564|NCT01461850|Procedure|Primary Debulking Surgery + Adjuvant Chemotherapy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
358565|NCT01461837|Drug|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
358566|NCT01461824|Drug|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
358567|NCT01461811|Device|Nelfilcon A toric contact lenses (with comfort additives)|
358568|NCT01461811|Device|Nelfilcon A toric contact lenses|
358569|NCT01461798|Dietary Supplement|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
358570|NCT01461798|Dietary Supplement|Placebo Yogurt|Yogurt without the active principle
358571|NCT01461798|Dietary Supplement|yogurt|yogurt without plant stanols
358572|NCT01461785|Biological|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).~The lipograft of Group A will be enriched with 3ml of autologous PRP"
358573|NCT01461785|Procedure|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
358574|NCT01461772|Radiation|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
358575|NCT01461772|Drug|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
358576|NCT01461772|Drug|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
358577|NCT01461759|Drug|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
358578|NCT01461759|Drug|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
358579|NCT01461746|Drug|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
358580|NCT01461746|Drug|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
358582|NCT01461733|Drug|amiodarone|standard dose amiodarone
358584|NCT01461720|Other|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
358585|NCT01461720|Biological|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
358586|NCT01461707|Behavioral|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
358587|NCT01461707|Behavioral|Activity monitor|Participants will receive an activity monitor
358588|NCT01461694|Device|Intense Pulsed Light (IPL)|Half Face Treated with IPL
358589|NCT01461694|Device|Alexandrite Laser|Half face treated with Alexandrite Laser
358590|NCT01461681|Procedure|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
358591|NCT01461668|Drug|Retapamulin|Two times a day for 5 days
358592|NCT01461668|Drug|Placebo|Two times a day for 5 days
358593|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
358594|NCT01461655|Drug|marketed topical NSAID|once daily application, 4 weeks
358595|NCT01461655|Drug|vehicle gel|once daily application, 4 weeks
358596|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
358597|NCT01461642|Other|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
358598|NCT01461616|Drug|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
358599|NCT01461616|Drug|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
358600|NCT01461616|Drug|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
358601|NCT01461603|Dietary Supplement|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
358602|NCT01461603|Dietary Supplement|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
358603|NCT01461590|Other|Whole blood|30mls/kg transfused over fours hours
358604|NCT01461590|Other|Whole blood|20mls/kg transfused over four hours
358605|NCT01461577|Drug|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
358606|NCT01461564|Procedure|Colonoscopy|Screening colonoscopy
358607|NCT01461551|Drug|Sevoflurane|anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
358608|NCT01461551|Drug|Propofol|anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
358609|NCT01461551|Drug|combine of sevoflurane and propofol|anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
358610|NCT01461538|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
358611|NCT01461538|Drug|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
358612|NCT01461538|Drug|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
358613|NCT01461525|Procedure|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
358614|NCT01461525|Procedure|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
358615|NCT01461512|Drug|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
358616|NCT01461512|Drug|Placebo administration|NaCl isotonic
358617|NCT01461499|Drug|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
358618|NCT01461499|Drug|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
358619|NCT01461486|Device|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
358620|NCT01461486|Device|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
358621|NCT01461473|Device|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
358622|NCT01461473|Device|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
358623|NCT01461460|Drug|TR-701 FA 1200 mg|6 tablet of T-701 FA
358624|NCT01461460|Drug|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
358625|NCT01461460|Drug|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
358626|NCT01461460|Drug|Placebo|6 placebo tablets
358627|NCT01461447|Biological|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
358628|NCT01461434|Device|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
360333|NCT01448369|Device|EyeGiene|10 minute treatment, twice daily
358629|NCT01461421|Behavioral|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
358630|NCT01461421|Behavioral|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
358631|NCT01461421|Behavioral|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
358632|NCT01461421|Behavioral|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
358633|NCT01461408|Behavioral|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect—their hairdressers—will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.~The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
358634|NCT01461382|Other|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
358635|NCT01461382|Other|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
358636|NCT01461369|Drug|Diclofenac|35 mg bid Capsules
358637|NCT01461369|Drug|Diclofenac|35 mg tid Capsules
358638|NCT01461369|Drug|Placebo|Capsules
358639|NCT01461356|Procedure|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
358640|NCT01461356|Procedure|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
358641|NCT01461343|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
358642|NCT01461330|Other|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat~Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
358643|NCT01461330|Other|ADA diet|Adoption of ADA diet.
358644|NCT01461317|Drug|Etrolizumab|Participants will receive etrolizumab at a dose of 100 mg.
358645|NCT01461304|Drug|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours; subjects who experience cardiomyopathy may receive doses up to 4 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
358646|NCT01461291|Device|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
358647|NCT01461291|Procedure|Cataract surgery|Cataract surgery alone
358648|NCT01461278|Device|iStent supra|Cataract surgery and implantation of one iStent supra
358649|NCT01461278|Procedure|Cataract surgery|Cataract surgery alone
358650|NCT01461265|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
358651|NCT01461252|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
358652|NCT01461252|Procedure|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
358653|NCT01461239|Procedure|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
358654|NCT01461239|Procedure|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
358655|NCT01461239|Procedure|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
358656|NCT01461226|Behavioral|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
358657|NCT01461226|Behavioral|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
358658|NCT01461213|Drug|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
358659|NCT01461200|Other|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
358660|NCT01461187|Other|exercise during pregnancy|supervised aerobic physical exercises twice a week.
358661|NCT01461174|Drug|Modafinil|200 mg tablet, single dose
358662|NCT01461174|Drug|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
358663|NCT01461174|Drug|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
358664|NCT01461161|Drug|bardoxolone methyl|oral, single dose
358665|NCT01461148|Biological|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
358666|NCT01461109|Drug|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
358667|NCT01461096|Biological|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
358668|NCT01461096|Biological|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
358669|NCT01461096|Biological|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
358670|NCT01461083|Drug|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of [18F]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not >10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
358671|NCT01461057|Drug|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
358672|NCT01461057|Drug|Cisplatin|80 mg/m2 on Day 1 of each cycle
358673|NCT01461057|Drug|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
358674|NCT01461057|Drug|Pertuzumab|840 mg once every three weeks
358675|NCT01461057|Drug|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
358676|NCT01461031|Drug|nefopam|nefopam infusion for postoperative 24 hours
358677|NCT01461031|Drug|normal saline (control)|normal saline infusion for postoperative 24 hours
358678|NCT01461018|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
358679|NCT01461005|Device|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
358680|NCT01460992|Procedure|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
358681|NCT01460979|Drug|Temsirolimus|25mg weekly intravenous until progression
358682|NCT01460966|Procedure|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
358683|NCT01460966|Procedure|Thrombus aspiration catheter|Thrombus aspiration catheter only
358684|NCT01460953|Behavioral|health literacy training video|participants will watch a training video
358685|NCT01460940|Drug|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
358686|NCT01460940|Drug|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
358687|NCT01460927|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
358688|NCT01460901|Biological|GD2 CAR modified Tri-virus specific cytotoxic t-cells|This is a feasibility study to assess safety of an infusion of chimeric-antigen receptor gene modified allogeneic virus specific T lymphocytes after reduced intensity allogeneic stem cell transplant. Three patients were treated and safety was evaluated. Patients received a single infusion of 2x10e6/m2 donor derived, GD2 CAR modified, tri-virus specific CTL performed 30-120 days after allogeneic stem cell transplantation
358689|NCT01460888|Drug|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
358690|NCT01460888|Radiation|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
358691|NCT01460875|Biological|recombinant interferon alfa-2b|Given SC
358692|NCT01460875|Other|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
358693|NCT01460836|Drug|Tobramycin solution for inhalation|
358694|NCT01460836|Drug|Aztreonam lysine for inhalation|
358695|NCT01460823|Procedure|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
358696|NCT01460810|Other|1000CsK Silicon Oil Tamponade|Details covered in arm description
358697|NCT01460797|Other|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
358698|NCT01460771|Device|TDCS (Transcranial Direct-current Stimulation)|active TDCS
358699|NCT01460771|Device|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
358700|NCT01460758|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
358701|NCT01460758|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
358702|NCT01460758|Device|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
358703|NCT01460732|Device|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
358704|NCT01460719|Biological|V212|V212 viral antigen for HZ
358705|NCT01460706|Drug|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
358706|NCT01460693|Drug|Imatinib|Oral Imatinib 100mg daily
358707|NCT01460693|Drug|Dasatinib|Oral Dasatinib 100mg daily
358708|NCT01460667|Drug|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
358709|NCT01460667|Drug|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
358710|NCT01460654|Drug|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
358711|NCT01460654|Drug|Alendronate|Alendronate (Fosamax) 70mg every week.
358712|NCT01460654|Drug|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
358713|NCT01460654|Drug|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
358714|NCT01460628|Drug|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
358715|NCT01460615|Drug|Hydrocortisone|
358716|NCT01460602|Drug|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:~(VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~(VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
358717|NCT01460589|Procedure|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
358718|NCT01460563|Drug|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
358719|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
358720|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
358721|NCT01460550|Procedure|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
358722|NCT01460550|Procedure|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
358723|NCT01460537|Drug|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
358724|NCT01460537|Drug|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
358725|NCT01460537|Drug|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
358726|NCT01460537|Drug|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
358727|NCT01460537|Drug|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
358728|NCT01460511|Drug|E004 (Epinephrine Inhalation Aerosol) HFA-MDI|E004 (Epinephrine Inhalation Aerosol) HFA-MDI, 125 mcg/inhalation, 2 inhalations QID
358729|NCT01460511|Drug|Placebo-HFA|Placebo-HFA, 0 mcg/inhalation, 2 inhalations QID
358730|NCT01460498|Drug|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
358731|NCT01460498|Drug|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
358732|NCT01460498|Drug|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
358733|NCT01460472|Biological|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
358734|NCT01460472|Other|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
358735|NCT01460459|Behavioral|a specific frequency of SMBG|"Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly"
358736|NCT01460446|Device|Aviva Expert blood glucose meter|
358737|NCT01460446|Device|Aviva Nano blood glucose meter|
358738|NCT01460433|Procedure|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
358739|NCT01460420|Drug|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
358740|NCT01460420|Drug|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.~Maintenance therapy and dose reduction pre-specified."
358741|NCT01460407|Drug|LY2216684|Administered orally
358742|NCT01460407|Drug|Clarithromycin|Administered orally
358743|NCT01460381|Drug|LY2216684|
358744|NCT01460381|Drug|Quinidine|
358745|NCT01460368|Drug|LY2409021|Administered orally
358746|NCT01460368|Drug|Placebo|Administered orally
358747|NCT01460368|Drug|Moxifloxacin|Administered orally
358748|NCT01460355|Drug|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
358749|NCT01460355|Drug|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
358750|NCT01460342|Drug|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
358751|NCT01460342|Drug|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
358752|NCT01460329|Device|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
358753|NCT01460316|Biological|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
358754|NCT01460303|Device|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
358755|NCT01460303|Device|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
358756|NCT01460290|Drug|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
358757|NCT01460277|Procedure|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
358758|NCT01460277|Procedure|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
358759|NCT01460251|Drug|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
358760|NCT01460225|Drug|lubiprostone|24 micrograms twice daily for 1 week
358761|NCT01460212|Drug|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
358762|NCT01460212|Behavioral|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
358763|NCT01460199|Drug|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"
358764|NCT01460199|Drug|placebo|tablets
358765|NCT01460186|Other|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
358766|NCT01460173|Other|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
358767|NCT01460160|Drug|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
358768|NCT01460147|Other|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
358769|NCT01460134|Drug|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.~The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
358770|NCT01460134|Drug|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
358771|NCT01460134|Drug|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
358772|NCT01460121|Device|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
358773|NCT01460121|Device|Placebo|
358774|NCT01460108|Device|AeriSeal System|20 mL
358775|NCT01460095|Other|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
358816|NCT01459770|Other|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
358817|NCT01459770|Other|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
358998|NCT01458431|Drug|Levobupivacaine|continuous levobupivacaine subfascial infusion
358776|NCT01460069|Drug|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
358777|NCT01460069|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
358778|NCT01460043|Drug|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
358779|NCT01460043|Drug|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
358780|NCT01460030|Drug|Cinacalcet HCl|Oral administration
358781|NCT01460017|Procedure|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
358782|NCT01460017|Procedure|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
358783|NCT01460004|Device|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
358784|NCT01459991|Other|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
358785|NCT01459991|Other|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
358786|NCT01459978|Other|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:~Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).~Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
358787|NCT01459965|Procedure|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
358788|NCT01459965|Procedure|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
358789|NCT01459952|Dietary Supplement|Rose hip Liquid|Rose hip Liquid, 20 ml BID
358790|NCT01459939|Dietary Supplement|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
358791|NCT01459939|Dietary Supplement|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
358792|NCT01459926|Drug|TD-1211|once daily
358793|NCT01459926|Drug|TD-1211|Once daily
358794|NCT01459926|Drug|TD-1211|Once daily
358795|NCT01459926|Drug|Placebo|Once daily
358796|NCT01459913|Drug|Telaprevir|Tablet
358797|NCT01459913|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
358798|NCT01459913|Drug|Ribavirin|Tablet
358799|NCT01459900|Procedure|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
358800|NCT01459900|Procedure|Renal angiography|Renal angiography by femoral access.
358801|NCT01459887|Drug|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
358802|NCT01459887|Drug|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
358803|NCT01459874|Behavioral|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
358804|NCT01459861|Procedure|Canal Block and Capsular Injection|Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
358805|NCT01459861|Procedure|Femoral Nerve Block with Tibial Nerve Block|Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
358806|NCT01459848|Behavioral|block play|30 minutes of block play
358807|NCT01459848|Behavioral|baby dvd|30 minutes of dvd viewing
358808|NCT01459835|Behavioral|media diet|advice and tips and tools for healthy non violent TV viewing
358809|NCT01459835|Behavioral|nutritional intervention|advice on healthy eating
358810|NCT01459809|Drug|GLIMEPIRIDE|"Pharmaceutical form: oral~Route of administration: oral"
358811|NCT01459809|Drug|METFORMIN|"Pharmaceutical form: oral~Route of administration: oral"
358812|NCT01459796|Drug|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
358813|NCT01459796|Drug|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
358814|NCT01459796|Drug|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
358815|NCT01459783|Behavioral|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
358892|NCT01459172|Other|limonene containing massage oil|daily massage application to the breast for 4 weeks
358999|NCT01458431|Drug|NaCl|continuous NaCl subfascial infusion
358818|NCT01459757|Other|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
358819|NCT01459744|Behavioral|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.~Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.~Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
358820|NCT01459744|Other|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
358821|NCT01459718|Drug|Deferasirox|20-40 mg/kg/day orally, once daily
358822|NCT01459718|Drug|Deferoxamine (DFO)|40 mg/kg/day subcutaneous (sc) infusion, 3-4 days per week
358823|NCT01459705|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
358824|NCT01459705|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
358825|NCT01459705|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
358826|NCT01459692|Other|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
358827|NCT01459679|Device|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
358828|NCT01459679|Device|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
358829|NCT01459679|Device|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
358830|NCT01459679|Drug|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
358831|NCT01459666|Drug|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
358832|NCT01459666|Drug|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
358833|NCT01459640|Drug|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
358834|NCT01459640|Biological|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
358835|NCT01459627|Other|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
358836|NCT01459627|Other|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
358837|NCT01459614|Drug|Gemcitabine|IV at 10mg/m2/min (50 minutes for 500mg/m2) on Days 4 and 11
358838|NCT01459614|Drug|Taxotere|IV on Days 4 and 11
358839|NCT01459614|Drug|Xeloda|orally, twice a day Days 1-14
358840|NCT01459614|Drug|Cisplatin|IV Days 4 and 11
358841|NCT01459601|Drug|Cabergoline|0,5mg per week
358842|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
358843|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
358844|NCT01459588|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
358845|NCT01459588|Drug|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
358846|NCT01459562|Drug|NI-0501|
358847|NCT01459562|Drug|Placebo|
358848|NCT01459549|Procedure|Roux-en-Y choledochojejunostomy|Roux-en-Y choledochojejunostomy must be operated
358849|NCT01459523|Procedure|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
358850|NCT01459523|Procedure|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
358851|NCT01459523|Procedure|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
358852|NCT01459523|Procedure|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
358853|NCT01459510|Behavioral|Play Nicely Program|Multi media educational intervention
358854|NCT01459497|Radiation|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
358855|NCT01459497|Radiation|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
358888|NCT01459211|Drug|Lenalidomide & Dexamethasone|"Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:~Oral Dexamethasone (20mg daily, days 1-4),~Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity"
358889|NCT01459198|Biological|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10^5 or 10^6 plaque-forming units (PFU), depending on study arm.
358856|NCT01459484|Drug|Mifamurtide arm|"PRE SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN~Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)~All the product are used as commercial formulation"
358857|NCT01459484|Other|3 drugs arm|"High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen~PRE-SUGERY TREATMENT:~Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)~POST SURGERY TREATMENT:~Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2~Total lenght 34 weeks~All the product are used as commercial formulation"
358858|NCT01459471|Procedure|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
358859|NCT01459458|Behavioral|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:~Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.~Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.~Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
358860|NCT01459445|Drug|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
358861|NCT01459432|Other|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
358862|NCT01459419|Drug|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
358863|NCT01459419|Drug|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
358864|NCT01459406|Dietary Supplement|Glucose|500 ml water drink containing 40g glucose
358865|NCT01459406|Dietary Supplement|Fructose|500 ml water drink containing 40g fructose
358866|NCT01459406|Dietary Supplement|Fructan|500 ml water drink containing 40g fructan
358867|NCT01459406|Dietary Supplement|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
358868|NCT01459393|Drug|5-ALA Photodynamic Therapy|
358869|NCT01459393|Drug|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
358870|NCT01459380|Biological|Bevacizumab|Given IV
358871|NCT01459380|Drug|Carboplatin|Given IV
358872|NCT01459380|Other|Laboratory Biomarker Analysis|Correlative studies
358873|NCT01459380|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
358874|NCT01459380|Drug|Veliparib|Given PO
358875|NCT01459367|Drug|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
358876|NCT01459367|Drug|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
358877|NCT01459367|Drug|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.~In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
358878|NCT01459328|Radiation|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day~Injected Leucovorin 20 mg/m2/day for 5 days"
358879|NCT01459328|Radiation|Radiotherapy|"Conventional long course chemo-radiation:~Radiation 50Gy in 25 daily fractions over 5 weeks~Bolus 5 Fluorouracil 350mg/m2/d for 5 days~Injected Leucovorin 20mg in both the first and last (5th) week of radiation~Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
358880|NCT01459315|Drug|dolutegravir|Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
358881|NCT01459289|Other|leaflet|
358882|NCT01459289|Other|counseling and leaflet|
358883|NCT01459276|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
358884|NCT01459276|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
358885|NCT01459263|Device|ClariVein|Using the ClariVein device, the GSV will be occluded.
358886|NCT01459250|Drug|AGO178C|
358887|NCT01459237|Drug|Acthrel|Ovine Corticorelin
358890|NCT01459198|Biological|Placebo vaccine|Given intranasally once at a baseline study visit
358891|NCT01459185|Drug|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
358893|NCT01459159|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
358894|NCT01459146|Drug|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
358895|NCT01459146|Drug|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
358896|NCT01459146|Drug|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
358897|NCT01459133|Drug|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
358898|NCT01459120|Other|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
358899|NCT01459120|Other|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
358900|NCT01459107|Procedure|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
358901|NCT01459107|Drug|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
358902|NCT01459094|Drug|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
358903|NCT01459094|Drug|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
358904|NCT01459081|Drug|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
358905|NCT01459081|Drug|Placebo|inhaled by mouth, twice daily, for 5 days
358906|NCT01459068|Behavioral|Common Elements Treatment Approach|"CETA components include:~Engagement (encouraging participation)~Psychoeducation (introduction)~Anxiety Management Strategies (relaxation)~Behavioral Activation (getting active)~Cognitive Coping/Restructuring (thinking in a different way, part I and part II)~Imaginal Gradual Exposure (talking about difficult memories)~In Vivo Exposure (Live exposure)~Suicide/Homicide/Danger Assessment and Planning (safety)~Screening and Brief Intervention for Alcohol (alcohol intervention)"
358907|NCT01459029|Drug|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
358908|NCT01459016|Other|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
358909|NCT01459016|Other|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
358910|NCT01459003|Other|beauty care|beauty care performed before each chemo cycle
358911|NCT01458990|Drug|Omeprazole|20mg PO BID for 20 days
358912|NCT01458977|Drug|Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
358913|NCT01458977|Drug|Placebo|Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
358914|NCT01458964|Drug|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
358915|NCT01458951|Drug|tofacitinib|10 mg oral BID
358916|NCT01458951|Drug|Placebo|Placebo oral BID
358917|NCT01458938|Other|treatment plan|Data Collection Study
358918|NCT01458925|Device|The P1 Check-Cap capsule|The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
358919|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
358920|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
358921|NCT01458912|Drug|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
358922|NCT01458912|Drug|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
358923|NCT01458899|Drug|TC-5214|Oral tablets, single 4mg dose
358924|NCT01458886|Drug|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
358925|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
358926|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
358927|NCT01458886|Drug|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
358928|NCT01458873|Drug|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
358929|NCT01458873|Drug|diluted sodium bicarbonate 2.1%|50ml
358930|NCT01458873|Drug|normal saline|50ml
358931|NCT01458847|Drug|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
358932|NCT01458847|Drug|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
358933|NCT01458847|Drug|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
358966|NCT01458600|Drug|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
358967|NCT01458600|Drug|Methimazole|T Methimazole 5 mg 3x2 for 18 months
358968|NCT01458600|Drug|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
358969|NCT01458600|Drug|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
358934|NCT01458834|Behavioral|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
358935|NCT01458834|Behavioral|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
358936|NCT01458821|Behavioral|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
358937|NCT01458808|Other|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
358938|NCT01458808|Other|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
358939|NCT01458795|Procedure|Endovenous laser ablation|
358940|NCT01458782|Procedure|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
358941|NCT01458769|Drug|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
358942|NCT01458769|Drug|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
358943|NCT01458769|Drug|C-10297|C-10297 200 mg, oral, single dose
358944|NCT01458769|Drug|C-10299|C-10299 200 mg, oral, single dose
358945|NCT01458769|Drug|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
358946|NCT01458769|Drug|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
358947|NCT01458769|Drug|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
358948|NCT01458769|Drug|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
358949|NCT01458743|Drug|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
358950|NCT01458743|Drug|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
358951|NCT01458730|Drug|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
358952|NCT01458717|Drug|Neoadjuvant chemoradiation|"Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~4 weeks rest, re-evaluation for resectability~operation~start maintenance chemotherapy within 4~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
358953|NCT01458717|Procedure|Upfront surgery|"Operation at time of diagnosis~Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡~start maintenance chemotherapy within 4~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
358954|NCT01458704|Other|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
358955|NCT01458691|Procedure|Steroid injection into the glenohumeral joint|"Group: Steroid~Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)~The number of injections : only once during the study period~Injection site : glenohumeral joint~Material : 25-gauze spinal needle~The intra-articular injections were performed using ultrasonographic guidance."
358956|NCT01458691|Procedure|Allogeneic PRP injection into the glenohumeral joint|"Group: Allogeneic PRP~Total volume of injection drugs: 4ml~The number of injections : only once during the study period~Injection site : glenohumeral joint~Material : 25-gauze spinal needle~The intra-articular injections were performed using ultrasonographic guidance."
358957|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
358958|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
358959|NCT01458665|Procedure|Conventional arthroscopic rotator cuff repair|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
358960|NCT01458665|Procedure|Arthroscopic rotator cuff repair with PRP|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~After tying sutures of the medial row, PRP gels were applied on the repair site.~The lateral row was secured using suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
358961|NCT01458652|Drug|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
358962|NCT01458639|Drug|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
358963|NCT01458639|Drug|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
358964|NCT01458626|Drug|mirtazapine|mirtazapine 30mg QD
358965|NCT01458626|Drug|paroxetine 20mg QD|paroxetine 20mg QD
358970|NCT01458600|Drug|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
358971|NCT01458587|Drug|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
358972|NCT01458587|Drug|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
358973|NCT01458574|Drug|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
358974|NCT01458574|Drug|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
358975|NCT01458574|Drug|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
358976|NCT01458561|Device|BioFoam Surgical Matrix|Surgical adjunct to control bleeding in open liver surgery
358977|NCT01458561|Device|Gelfoam Plus|Surgical adjunct in control of bleeding in open liver surgery
358978|NCT01458548|Drug|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
358979|NCT01458548|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
358980|NCT01458535|Drug|ABT-450|tablets
358981|NCT01458535|Drug|ABT-267|tablets
358982|NCT01458535|Drug|ribavirin|tablets
358983|NCT01458535|Drug|ritonavir|capsules
358984|NCT01458522|Drug|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
358985|NCT01458522|Drug|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered: the subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period; the subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period; the subject experiences an AE that precludes further use of the first study drug.~If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
358986|NCT01458509|Behavioral|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
358987|NCT01458509|Behavioral|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
358988|NCT01458509|Behavioral|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
358989|NCT01458509|Behavioral|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
358990|NCT01458496|Behavioral|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
358991|NCT01458483|Device|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
358992|NCT01458470|Drug|Memantine|oral tablet, 1 BID, 24 weeks
358993|NCT01458470|Other|Placebo|oral tablet, 1 BID, 24 weeks
358994|NCT01458457|Other|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
358995|NCT01458457|Other|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
359000|NCT01458418|Drug|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
359001|NCT01458418|Other|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
359002|NCT01458418|Drug|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
359003|NCT01458405|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, blinded, intracoronary infusion of 25 Million cardiosphere-derived cells
359004|NCT01458405|Drug|Placebo|Single, blinded, intracoronary infusion of a placebo solution
359005|NCT01458392|Biological|Dalantercept|Subcutaneous dose of dalantercept once every 3 weeks.
359006|NCT01458366|Drug|Bendamustine|"Phase 1: Given via IV at the following dose levels:~Level 1: 70 mg/m2~Level -1: 50 mg/m2~Level 2: 90 mg/m2~Level 3: 120 mg/m2~Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
359007|NCT01458366|Drug|Ofatumumab|"Phase II~Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3~Cycles 2 and 3: 1000 mg via IV on Day 1"
359008|NCT01458366|Drug|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
359009|NCT01458366|Drug|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
359010|NCT01458366|Procedure|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
359011|NCT01458366|Procedure|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
359012|NCT01458366|Genetic|Stem Cell Transplant (STC)|"For potential transplant candidates:~Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee~Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
359013|NCT01458353|Procedure|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
359014|NCT01458353|Procedure|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
359015|NCT01458340|Drug|TD-9855|Once daily
359016|NCT01458340|Drug|TD-9855|Once daily
359017|NCT01458340|Drug|Placebo|Once daily
359018|NCT01458327|Drug|3,4-methylenedioxymethamphetmine (MDMA)|125 mg MDMA followed by 62.5 mg 1.5 to 2.5 hours later
359019|NCT01458327|Behavioral|Psychotherapy|Psychotherapy in combination with MDMA
359020|NCT01458314|Other|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
359021|NCT01458314|Other|Rehabilitation without NIV|Training in patients without NIV adoption
359022|NCT01458301|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
359023|NCT01458301|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
359024|NCT01458301|Drug|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
359025|NCT01458301|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
359026|NCT01458301|Drug|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
359027|NCT01458288|Drug|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
359028|NCT01458275|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
359029|NCT01458275|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
359030|NCT01458275|Drug|Placebo|Placebo - one actuation per nostril
359031|NCT01458262|Other|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
359032|NCT01458249|Drug|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
359033|NCT01458236|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
359034|NCT01458236|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
359035|NCT01458223|Drug|Antibiotic|Ancef or Vancomycin
359036|NCT01458223|Drug|Antibiotic|Ancef or Vancomycin
359037|NCT01458210|Drug|Ortho-Cyclen|Administered orally
359038|NCT01458210|Biological|Dulaglutide|Administered subcutaneously
359039|NCT01458197|Drug|Tarafenacin 0.2 mg|Capsule, qd, 12 weeks
359040|NCT01458197|Drug|Placebo|Capsule, qd, 12 weeks
359041|NCT01458197|Drug|Tarafenacin 0.4 mg|Capsule, qd, 12 weeks
359042|NCT01458184|Behavioral|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
359043|NCT01458171|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
359044|NCT01458145|Behavioral|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
359045|NCT01458119|Drug|migalastat hydrochloride|Oral capsule QOD
360334|NCT01448369|Device|Hot compresses|10 minute treatment, twice daily
359046|NCT01458106|Drug|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
359047|NCT01458106|Drug|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
359048|NCT01458093|Other|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
359049|NCT01458080|Drug|eltrombopag|eltrombopag
359050|NCT01458067|Drug|GSK2636771|Oral capsules
359051|NCT01458054|Drug|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
359052|NCT01458054|Drug|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
359053|NCT01458041|Drug|Iloprost (Ilomedin, BAYQ6256)|Prescription and treatment of Iloprost will be decided by physicians
359054|NCT01458028|Drug|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
359055|NCT01458028|Drug|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
359056|NCT01458015|Drug|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
359057|NCT01458002|Other|Tailored Internet Communication with Relational Agent|"The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site."
359058|NCT01458002|Other|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
359059|NCT01457989|Drug|retigabine/ezogabine|dose range up to 1200 mg/day
359060|NCT01457950|Drug|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
359061|NCT01457950|Drug|placebo|double-blind phase: placebo subcutaneous injection, single dose
359062|NCT01457950|Drug|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
359063|NCT01457937|Drug|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)~or~PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
359064|NCT01457924|Drug|Ofatumumab 3mg|3mg of investigational product
359065|NCT01457924|Drug|Ofatumumab 30mg|30mg of investigational product
359066|NCT01457924|Drug|Ofatumumab 60mg|60mg of investigational product
359067|NCT01457924|Drug|Placebo|Placebo
359068|NCT01457911|Drug|Glimepiride and Metformin hydrochloride combination (HOE490)|Pharmaceutical form:tablet Route of administration: oral
359069|NCT01457911|Drug|Glimepiride (HOE490)|Pharmaceutical form:tablet Route of administration: oral
359070|NCT01457898|Device|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
359071|NCT01457885|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV dose level: 40 mg/m2/day x 5 days~Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
359072|NCT01457885|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
359073|NCT01457872|Behavioral|Strength-based case management|Strength-based case management
359074|NCT01457872|Behavioral|Control condition - referral only|Referral only
359075|NCT01457859|Drug|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
359076|NCT01457859|Other|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
359077|NCT01457846|Drug|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
359078|NCT01457846|Drug|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
359079|NCT01457833|Device|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
359080|NCT01457833|Device|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
359081|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
359082|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
359083|NCT01457820|Drug|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
359084|NCT01457807|Drug|AZD3241 ER formulation 1|Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
359085|NCT01457807|Drug|Placebo|Placebo will be administered with the same intervention scheme as intervention 1 and 2
359086|NCT01457807|Drug|AZD3241 Alternative titration scheme with formulation 1 or 2|50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
359087|NCT01457794|Other|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
360371|NCT01448044|Drug|Pegylated-interferon alfa 2a|
359088|NCT01457781|Drug|Nitric Oxide|0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
359089|NCT01457781|Other|Placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%)
359090|NCT01457781|Drug|Nitric Oxide|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
359091|NCT01457742|Device|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
359092|NCT01457742|Device|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
359093|NCT01457729|Behavioral|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
359094|NCT01457716|Drug|Budesonide|Single inhalation
359095|NCT01457716|Drug|Formoterol|Single inhalation
359096|NCT01457716|Device|Easyhaler|Inhaler device
359097|NCT01457716|Device|Turbohaler Forte|Inhaler device
359098|NCT01457703|Drug|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
359099|NCT01457703|Drug|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
359100|NCT01457703|Drug|Recombinant LH|Used to stimulate ovarian function in women.
359101|NCT01457703|Drug|Letrozole|An aromatase inhibitor.
359102|NCT01457690|Drug|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
359103|NCT01457690|Drug|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
359104|NCT01457690|Drug|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
359105|NCT01457677|Drug|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
359106|NCT01457677|Drug|RO4995819|5 mg oral once daily for 6 weeks
359107|NCT01457677|Drug|RO4995819|15 mg oral once daily for 6 weeks
359108|NCT01457677|Drug|RO4995819|30 mg oral once daily for 6 weeks
359109|NCT01457664|Drug|Placebo|Placebo to RO4995819 once daily for 14 days
359110|NCT01457664|Drug|RO4995819|RO4995819 doses once daily for 14 days
359111|NCT01457651|Procedure|Alveolar recruitment|"Four approaches:~CPAP 40 cm H2O~Peak pressure 40 cm H2O~PEEP 15 cm H2O for 300 sec~no intervention (controls)"
359112|NCT01457638|Procedure|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
359113|NCT01457638|Procedure|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
359114|NCT01457612|Dietary Supplement|Strawberry|20g twice per day (BID) in beverage
359115|NCT01457612|Dietary Supplement|Placebo1|Placebo Beverage 1 without fiber
359116|NCT01457612|Dietary Supplement|Placebo2|Placebo Beverage 2 with Fiber
359117|NCT01457599|Procedure|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
359118|NCT01457586|Biological|Blood transfusion|Blood transfusion in perioperative period.
359119|NCT01457586|Biological|No blood transfusion|No transfusion in the perioperative period.
359120|NCT01457573|Drug|Tamsulosin|Alpha blocker used to in the treatment of urinary difficulties related to enlarged prostate or symptomatic benign prostatic hypertrophy. All men will receive Tamsulosin (Flomax®) 0.4 mg, 1 tab, per morning with Solifenacin (Vesicare®).
359121|NCT01457573|Drug|Solifenacin|Antispasmodic/anticholinergic used to treat overactive bladder. All men will receive Solifenacin (Vesicare®) 5 mg, 1 tab, per morning with Tamsulosin.
359122|NCT01457560|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
359123|NCT01457560|Biological|OPV|One dose administered orally
359124|NCT01457547|Biological|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
359125|NCT01457547|Biological|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
359126|NCT01457521|Drug|Ibuprofen|Ibuprofen
359127|NCT01457508|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
359128|NCT01457508|Biological|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
359129|NCT01457508|Biological|Hib (Hiberix™)|Three doses administered intramuscularly
359130|NCT01457495|Biological|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
359131|NCT01457495|Biological|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
359132|NCT01457495|Biological|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
359133|NCT01457482|Other|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
359134|NCT01457482|Other|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
359135|NCT01457469|Other|questionnaire administration|Ancillary studies
359136|NCT01457469|Procedure|quality-of-life assessment|Ancillary studies
359137|NCT01457469|Other|counseling intervention|Undergo counseling session
359138|NCT01457469|Other|internet-based intervention|Receive enhanced quitline intervention
359139|NCT01457469|Behavioral|telephone-based intervention|Receive enhanced quitline intervention
359140|NCT01457469|Other|educational intervention|Receive usual care plus
359141|NCT01457469|Drug|nicotine replacement therapy|Receive nicotine replacement patches
359142|NCT01457469|Other|educational intervention|Receive enhanced quitline intervention
359143|NCT01457430|Drug|Icatibant|30 mg subcutaneous dose of Icatibant
359176|NCT01457066|Behavioral|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
359240|NCT01456520|Drug|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
359241|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
360372|NCT01448044|Drug|Ribavirin|
359144|NCT01457417|Drug|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
359145|NCT01457404|Behavioral|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
359146|NCT01457404|Behavioral|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
359147|NCT01457391|Behavioral|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
359148|NCT01457391|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
359149|NCT01457391|Behavioral|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
359150|NCT01457352|Drug|SPARC0921|
359151|NCT01457352|Drug|Placebo0921|
359152|NCT01457339|Drug|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
359153|NCT01457339|Drug|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
359154|NCT01457300|Other|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
359155|NCT01457274|Other|Sedation depth|"The intervention is the depth of sedation targeted in this study.~Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.~It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (<60) than those in the light sedation group (BIS 70-80)."
359156|NCT01457261|Drug|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
359157|NCT01457248|Device|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
359158|NCT01457248|Device|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
359159|NCT01457235|Other|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
359160|NCT01457222|Behavioral|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
359161|NCT01457222|Behavioral|Music relaxation|Music relaxation 10 minutes daily
359162|NCT01457209|Other|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.~Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
359163|NCT01457196|Diagnostic Test|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
359164|NCT01457183|Device|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
359165|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
359166|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
359167|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
359168|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
359169|NCT01457144|Drug|RiBVD|"Every cycle:~Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
359170|NCT01457131|Drug|Fludarabine|50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
359171|NCT01457131|Drug|Cyclophosphamide|60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
359172|NCT01457131|Other|IL-12 &amp; Anti-NY ESO1 TCR PBL|10(7) cells to 3 X 10(10) cells
359173|NCT01457118|Drug|NKTR-102|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. Patients who previously received a dose of NKTR-102 < 145 mg/m2 will continue at the lower dose on this study.
359174|NCT01457105|Device|Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)|Metal stents placement in the main biliary duct during ERC
359175|NCT01457092|Device|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
359239|NCT01456520|Drug|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
359177|NCT01457053|Drug|Loop diuretics (furosemide, torsemide, bumetanide)|"Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety."
359178|NCT01457053|Other|Ultrafiltration|"Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.~Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety."
359179|NCT01457040|Drug|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
359180|NCT01457040|Drug|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10~-6d; AraC: 1g/m2/d, -10d~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
359181|NCT01457027|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
359182|NCT01457014|Device|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
359183|NCT01457014|Device|Continuous positive airway pressure|continuous positive airway pressure
359184|NCT01457014|Device|servo ventilation manual|servo ventilation titrated in manual mode
359185|NCT01457001|Drug|25-OH-D vitamin|
359186|NCT01456975|Procedure|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
359187|NCT01456949|Device|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
359188|NCT01456936|Drug|Placebo|Triple dummy placebo for each treatment arm
359189|NCT01456936|Drug|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
359190|NCT01456936|Drug|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
359191|NCT01456936|Drug|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
359192|NCT01456923|Other|Treatment with chemotherapy|
359193|NCT01456923|Other|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
359194|NCT01456923|Procedure|surgery|
359195|NCT01456910|Behavioral|Resistance Training Program|Frequency, volume, repetitions, load, interval
359196|NCT01456897|Drug|OPC-34712|orally administered once daily
359197|NCT01456884|Behavioral|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
359198|NCT01456884|Behavioral|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
359199|NCT01456871|Procedure|Guided insertion of electrodes|Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.
359200|NCT01456871|Procedure|Electromyographic (EMG) recording|EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).
359201|NCT01456858|Other|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
359202|NCT01456858|Other|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
359203|NCT01456819|Biological|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
359204|NCT01456819|Biological|Mononuclear cells|Intramuscular administration into the ischemic limb
359205|NCT01456806|Other|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
359206|NCT01456793|Behavioral|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
359207|NCT01456780|Drug|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
359208|NCT01456780|Drug|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
359209|NCT01456780|Drug|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
359242|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
359210|NCT01456767|Dietary Supplement|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
359211|NCT01456754|Dietary Supplement|low feeding frequency (3x)|3 meals a day
359212|NCT01456754|Dietary Supplement|High feeding frequency (14x)|14 meals a day
359213|NCT01456741|Procedure|EBNA with ROSE|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation~B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
359214|NCT01456741|Procedure|standard EBNA|"The patients in this arm will undergo:~A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.~B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed~C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
359215|NCT01456728|Dietary Supplement|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.~L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
359216|NCT01456728|Dietary Supplement|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
359217|NCT01456715|Biological|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
359218|NCT01456715|Biological|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
359219|NCT01456702|Procedure|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
359220|NCT01456689|Drug|LGH447|
359221|NCT01456689|Drug|midazolam|
359222|NCT01456676|Drug|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
359223|NCT01456663|Drug|AFQ056|
359224|NCT01456650|Drug|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:~Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
359225|NCT01456637|Behavioral|CBT for insomnia|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
359226|NCT01456624|Drug|Megace|800mg
359227|NCT01456624|Drug|DW-ES(B)|625mg
359228|NCT01456611|Drug|Diclofenac|Diclofenac Sodium Gel 1%
359229|NCT01456611|Drug|Placebo|Placebo Topical Gel
359230|NCT01456598|Procedure|Laparoscopic gastrectomy|"After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.~The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection~After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.~As the reconstruction, one of the techniques like Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
359231|NCT01456598|Procedure|Open gastrectomy|"After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.~The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection~After lymph node dissection, one of the techniques likes Billroth I, Billroth II and Roux en Y and so on is applied and there is no limitation on use of appliance."
359232|NCT01456585|Other|Gemcitabine|
359233|NCT01456585|Drug|CP-870,893|
359234|NCT01456572|Dietary Supplement|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
359235|NCT01456572|Dietary Supplement|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
359236|NCT01456559|Other|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.~Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
359237|NCT01456546|Drug|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
359238|NCT01456546|Drug|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
359243|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
359244|NCT01456494|Other|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
359245|NCT01456494|Other|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
359246|NCT01456481|Drug|midodrine hydrochloride|Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
359247|NCT01456481|Drug|matching placebo|The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
359248|NCT01456468|Drug|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
359249|NCT01456442|Device|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
359250|NCT01456442|Device|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
359251|NCT01456429|Procedure|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
359252|NCT01456403|Other|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
359253|NCT01456390|Device|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
359254|NCT01456377|Drug|predinose oral|1 mg for kg for 3 wekees
359255|NCT01456377|Drug|placebo group|use a oral placebo
359256|NCT01456364|Drug|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
359257|NCT01456364|Drug|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
359258|NCT01456351|Drug|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
359259|NCT01456351|Drug|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
359260|NCT01456338|Behavioral|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
359261|NCT01456338|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
359262|NCT01456325|Drug|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
359263|NCT01456325|Drug|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
359264|NCT01456325|Drug|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
359265|NCT01456312|Drug|Peginterferon alfa-2a|Duration and combination
359266|NCT01456312|Drug|Entecavir|combination
359267|NCT01456299|Drug|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
359268|NCT01456299|Drug|Control|The control group, which received an infusion of normal saline
359269|NCT01456299|Drug|Remifentanil 2|"Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml."
359270|NCT01456286|Drug|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
359271|NCT01456273|Procedure|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
359272|NCT01456273|Procedure|Therapeutic Encounter|"Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo."
359273|NCT01456260|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
359274|NCT01456260|Drug|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
359275|NCT01456260|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
359276|NCT01456260|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
359277|NCT01456260|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
359278|NCT01456260|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
359279|NCT01456247|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
359280|NCT01456247|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
359281|NCT01456247|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
359282|NCT01456247|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
359283|NCT01456247|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
359284|NCT01456247|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
359285|NCT01456234|Drug|Oseltamivir|Oseltamivir 75 mg BID
359286|NCT01456221|Dietary Supplement|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
359287|NCT01456221|Dietary Supplement|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
359288|NCT01456208|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
359289|NCT01456208|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
359290|NCT01456208|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
359291|NCT01456195|Drug|Placebo|Fasiglifam placebo-matching tablets
359292|NCT01456195|Drug|Fasiglifam|Fasiglifam tablets
359293|NCT01456182|Drug|AFX-2|Dose level 1
359294|NCT01456182|Drug|AFX-2|Dose level 2
359295|NCT01456182|Drug|AFX-2|Dose level 3
359296|NCT01456182|Drug|AFX-2|Dose level 4
359297|NCT01456182|Drug|AFX-2|Dose level 5
359298|NCT01456169|Drug|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
359299|NCT01456169|Drug|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
359300|NCT01456156|Radiation|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
359301|NCT01456143|Device|High Resolution Microendoscopy (HRME)|High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.
359302|NCT01456143|Other|Proflavine hemisulfate|0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
359303|NCT01456130|Drug|Alogliptin|Alogliptin tablets
359304|NCT01456130|Drug|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
359305|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
359306|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
359307|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
359308|NCT01456117|Drug|Placebo|Pioglitazone matching placebo once daily for up to 14 days.
359309|NCT01456104|Biological|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
359310|NCT01456091|Behavioral|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
359311|NCT01456078|Drug|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
359312|NCT01456065|Biological|Procure|The IMP (Investigational Medical Product) consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
359313|NCT01456065|Biological|Procure|The IMP consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
359314|NCT01456052|Drug|Telotristat Etiprate|500 mg telotristat etiprate (LX1606) administered orally.
359315|NCT01456052|Drug|Placebo|Matching placebo administered orally.
359316|NCT01456039|Drug|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
359317|NCT01456026|Dietary Supplement|Glycated beta-lactoglobulins.|oral, 20 g, single administration
359318|NCT01456026|Dietary Supplement|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
359319|NCT01456013|Device|RenalGuard Therapy|Induced Diuresis with matched replacement
359320|NCT01456013|Drug|Standard Therapy|Standard of care for patients at risk of CIN
359321|NCT01456000|Device|EAS-AC (HeartLight)|Pulmonary vien isolation
359322|NCT01456000|Procedure|Control Arm Ablation|Treatment with standard ablation.
359494|NCT01454596|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
359323|NCT01455974|Other|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
359324|NCT01455948|Device|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
359325|NCT01455948|Procedure|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
359326|NCT01455935|Drug|Anti-platelets and statin|
359327|NCT01455935|Drug|alteplase|"Full dose Intravenous thrombolysis~0.9 mg/kg~Maximum dose is 90 mg~10% of the dose will be given over one minute~90% of the dose will be infused over 1 hour~Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~Neuro checks every 5 minutes during the infusion~Neuro checks every hour after the infusion for 24 hours"
359328|NCT01455935|Procedure|intra arterial intervention|"Intra arterial Activase (Maximum dose of 22 mg)~MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~PENUMBRA device (no standard time frame for how long the procedure takes)"
359329|NCT01455922|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
359330|NCT01455922|Drug|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
359331|NCT01455909|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
359332|NCT01455909|Drug|sitagliptin|sitagliptin oral 100 mg/day
359333|NCT01455896|Drug|ITCA 650|ITCA 650
359334|NCT01455896|Other|ITCA placebo|ITCA placebo
359335|NCT01455883|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
359336|NCT01455883|Drug|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
359337|NCT01455870|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
359338|NCT01455870|Drug|sitagliptin|oral sitagliptin 100 mg/day
359339|NCT01455857|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
359340|NCT01455857|Other|ITCA placebo|Formulation in DUROS (no exenatide)
359341|NCT01455844|Drug|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
359342|NCT01455844|Other|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
359343|NCT01455844|Drug|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
359344|NCT01455831|Drug|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
359345|NCT01455831|Drug|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
359346|NCT01455805|Device|Minuteman Fusion Implant|The Minuteman™ interspinous interlaminar fusion device consists of a central threaded portion that has a two-part wing plate hinged near its proximal end, with spikes on the extended distal end of the wing plate, and a multi-spiked end cap plate that is located at the distal end of the device and is retained and tightened in place with a locking hex nut. Compression between the spiked wing plate and the spiked end cap plate serves to fix the spinous processes in place and to facilitate fusion, together with bone graft fusion material placed within the device. The threaded external body has been designed to provide ease of distraction and insertion via a minimally invasive surgical procedure.
359347|NCT01455805|Procedure|surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis
359348|NCT01455792|Procedure|Biopsies using image fusion|MRI and soft image fusion guided biopsy
359349|NCT01455792|Procedure|Gold standard biopsy|Gold standard TRUS biopsy
359350|NCT01455779|Device|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.~The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
359351|NCT01455753|Other|Functional Proximity|Using each employee's building entry/exit swipe card data, we test whether functional proximity—the likelihood that the employee walks by the clinic for reasons other than vaccination—predicts whether the employee gets vaccinated at the clinic.
359352|NCT01455753|Other|Base Proximity|We also test whether base proximity—the inverse of walking distance from the employee's desk to the clinic—predicts vaccination probability.
359353|NCT01455740|Behavioral|Provider Visit Incentive (PVI)|"All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits."
359354|NCT01455740|Behavioral|Incentive Choice (IC)|"All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits."
360727|NCT01445223|Drug|Lopinavir ritonavir|400mg BD 100mg BD
359355|NCT01455727|Other|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
359356|NCT01455727|Other|Usual care|Control patients received usual care directed by their physician.
359357|NCT01455701|Drug|Tocilizumab|Tocilizumab will be administered as indicated in the arm description.
359358|NCT01455688|Drug|early HAART|Initiation of HAART within 5 days of ICU admission
359359|NCT01455688|Drug|Late HAART|Initiation of HAART after ICU discharge
359360|NCT01455675|Drug|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
359361|NCT01455675|Drug|Placebo|Placebo, 70 ml gargling solution, once daily
359362|NCT01455649|Drug|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
359363|NCT01455649|Drug|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
359364|NCT01455636|Other|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
359365|NCT01455636|Dietary Supplement|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
359366|NCT01455636|Other|No hand sanitizer|"All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.~No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed"
359367|NCT01455636|Dietary Supplement|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
359368|NCT01455597|Drug|Estradiol Vaginal Gel|Estradiol vaginal gel containing 0.017 mg estradiol per gram, 3X weekly for 40 weeks
359369|NCT01455584|Drug|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
359370|NCT01455571|Drug|HM781-36B|Q1DX14/2W for 3W HM781-36B
359371|NCT01455558|Drug|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state~Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state~Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
359372|NCT01455532|Drug|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
359373|NCT01455532|Drug|Gemcitabine|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
359374|NCT01455532|Drug|Carboplatin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
359375|NCT01455532|Drug|Placlitaxel|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
359376|NCT01455532|Drug|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
359377|NCT01455519|Drug|Hydromorphone ER|Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
359378|NCT01455519|Drug|Sugar pill|Sugar pill
359379|NCT01455506|Drug|Decitabine plus Fludarabine and Busulfan|"Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient >20% above ideal body weight~Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.~Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.~Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.~Hematopoietic cells will be infused on day 0."
359380|NCT01455493|Drug|GDC-0980|Oral daily dose
359381|NCT01455480|Drug|RPh201, botanical drug product|topical
359382|NCT01455467|Device|One iStent|Implantation of one iStent in conjunction with cataract surgery
359383|NCT01455467|Device|Two iStent|Implantation of two iStent in conjunction with cataract surgery
359384|NCT01455441|Other|Training and liraglutide|
359385|NCT01455441|Other|Training and placebo|
359386|NCT01455428|Drug|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
359387|NCT01455428|Drug|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
359388|NCT01455415|Drug|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
359389|NCT01455415|Drug|placebo|matching placebo 3 time a day
359390|NCT01455389|Drug|DOTAP:Chol-TUSC2|Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.
359391|NCT01455389|Drug|Erlotinib|Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.
359392|NCT01455389|Drug|Dexamethasone|8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-TUSC2 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).
359393|NCT01455389|Drug|Diphenhydramine|50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol TUSC2
359394|NCT01455376|Drug|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
360728|NCT01445223|Drug|Atazanavir ritonavir|300mg QD 100mg QD
359395|NCT01455363|Procedure|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
359396|NCT01455363|Other|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
359397|NCT01455363|Other|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
359398|NCT01455350|Procedure|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
359399|NCT01455350|Drug|lidocaine|10 weeks of daily topical 5% lidocaine application
359400|NCT01455337|Drug|pentoxifylline|400mg tid
359401|NCT01455337|Drug|Prednisolone|40mg qd
359402|NCT01455324|Device|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
359403|NCT01455311|Procedure|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
359404|NCT01455311|Procedure|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
359405|NCT01455298|Other|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
359406|NCT01455285|Device|transcutaneous electrical nerve stimulation|
359407|NCT01455272|Procedure|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
359408|NCT01455259|Biological|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
359409|NCT01455246|Drug|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
359410|NCT01455246|Drug|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
359411|NCT01455233|Drug|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
359412|NCT01455233|Drug|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
359413|NCT01455220|Drug|Tysabri ® (Natalizumab)|IV, monthly
359414|NCT01455207|Behavioral|Neuropsychological testing|assessment of memory, executive functions and ataxia
359415|NCT01455207|Biological|blood draw|hepatic markers, red blood markers and vitamin markers
359416|NCT01455207|Genetic|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
359417|NCT01455207|Other|Brain imaging examination|MRI, DTI and PET examinations
359418|NCT01455194|Drug|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
359419|NCT01455181|Drug|NPSP558|50, 75, 100 μg
359420|NCT01455155|Other|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
359421|NCT01455155|Other|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
359422|NCT01455142|Drug|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
359423|NCT01455129|Drug|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
359424|NCT01455129|Drug|placebo|placebo, once daily, inhaled by HandiHaler
359425|NCT01455116|Procedure|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
359426|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response
359427|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response
359428|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
359429|NCT01455090|Drug|BMS-650032|
359430|NCT01455090|Drug|BMS-790052|
359431|NCT01455090|Drug|BMS-791325|
359432|NCT01455090|Drug|Ribavirin|
359433|NCT01455064|Device|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
359434|NCT01455051|Drug|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
359435|NCT01455025|Drug|Plerixafor granulocyte-colony stimulating factor|"Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.~Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5"
359436|NCT01455012|Drug|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
359437|NCT01455012|Drug|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
359438|NCT01454999|Behavioral|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
359439|NCT01454986|Drug|ALXN1007|Single dose, IV
359440|NCT01454986|Other|Placebo|Single dose, IV
359441|NCT01454960|Behavioral|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
359442|NCT01454960|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
359443|NCT01454960|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
359444|NCT01454947|Behavioral|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
359445|NCT01454947|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
359446|NCT01454947|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
359447|NCT01454934|Drug|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
359448|NCT01454934|Drug|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
359449|NCT01454921|Behavioral|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
359450|NCT01454908|Device|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
359451|NCT01454895|Behavioral|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
359452|NCT01454895|Behavioral|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
359453|NCT01454895|Behavioral|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
359454|NCT01454882|Behavioral|Effects of Clothing|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
359455|NCT01454882|Behavioral|Effects of Temperature|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
359456|NCT01454882|Behavioral|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
359457|NCT01454882|Behavioral|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
359458|NCT01454882|Behavioral|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
359459|NCT01454869|Drug|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
359460|NCT01454869|Drug|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
359461|NCT01454843|Procedure|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
359462|NCT01454843|Procedure|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
359463|NCT01454830|Behavioral|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
359464|NCT01454830|Other|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
359465|NCT01454817|Behavioral|Quality of life|Improving Quality of Life
359466|NCT01454804|Drug|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
359467|NCT01454804|Drug|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
359468|NCT01454804|Drug|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.~Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.~Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
359469|NCT01454804|Drug|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
359470|NCT01454791|Drug|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
359471|NCT01454791|Other|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
359472|NCT01454778|Drug|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3~Paclitaxel Dosage:~Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon* Popliteal: 1.8 mg/inflation of balloon* Tibial: 1.4 mg/inflation of balloon*~not to exceed 10mg total dose"
359473|NCT01454765|Other|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
359474|NCT01454752|Drug|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
359475|NCT01454752|Other|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
359476|NCT01454739|Drug|rFVIIIFc|Administered as specified in the treatment arm.
359477|NCT01454726|Other|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
359478|NCT01454726|Other|drug|the Western medical treatment alone.
359479|NCT01454700|Device|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
359480|NCT01454700|Other|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
359481|NCT01454687|Procedure|Grafting of Autologous Cultured Revertant Keratinocytes|Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas
359482|NCT01454674|Other|2, 5 & 10 Vegetable doses|2,5 & 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers & tomatoes consumed for 3 week intervals
359483|NCT01454661|Dietary Supplement|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
359484|NCT01454661|Dietary Supplement|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
359485|NCT01454661|Dietary Supplement|Placebo|Microcrystalline cellulose is used as placebo.
359486|NCT01454635|Drug|Sertraline|dosage,frequency and duration
359487|NCT01454622|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
359488|NCT01454622|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
359489|NCT01454609|Drug|0.9% Normal saline|Saline
359490|NCT01454609|Drug|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
359491|NCT01454609|Device|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours~Clonidine - 0.5 - 1 microgram/ kg"
359492|NCT01454596|Biological|Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL|Day 0: Cells will be infused intravenously over 20-30 minutes. Patients will receive two cell doses, 2 hours apart.
359493|NCT01454596|Drug|Aldesleukin|Aldeskeukin 72,000 IU /kg intravenous (IV) or 720,000 IU /kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
360729|NCT01445223|Drug|Efavirenz|600mg QD
359495|NCT01454596|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hr.
359496|NCT01454583|Drug|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
359497|NCT01454583|Drug|ACE-I/ARB|
359498|NCT01454583|Drug|No RAS-inhibition|
359499|NCT01454557|Other|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
359500|NCT01454544|Biological|AIT Tablet|1 tablet per day in 12 months
359501|NCT01454531|Drug|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
359502|NCT01454518|Procedure|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
359503|NCT01454518|Procedure|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
359504|NCT01454505|Drug|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
359505|NCT01454505|Other|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
359506|NCT01454479|Drug|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
359507|NCT01454466|Procedure|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
359508|NCT01454453|Drug|Patients- dose titration|dose titration (patients) - 4-10 weeks
359509|NCT01454440|Drug|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure) vs placebo.
359510|NCT01454414|Other|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
359511|NCT01454401|Device|LeucoPatch treatment|weekly
359512|NCT01454388|Other|breakfast|
359513|NCT01454375|Behavioral|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
359514|NCT01454362|Drug|Nicotine|Inhalation of nicotine.
359515|NCT01454349|Drug|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
359516|NCT01454349|Drug|Placebo|Single intraprostatic injection of matching placebo
359517|NCT01454336|Biological|Cell injection|MSCs introduced into portal vein
359518|NCT01454323|Other|Bone marrow mononuclear cells|Intracoronary infusion of autologous bone marrow-derived mononuclear cells
359519|NCT01454310|Device|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
359520|NCT01454310|Device|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
359521|NCT01454284|Drug|Glargine|
359522|NCT01454284|Drug|LY2605541|
359523|NCT01454284|Drug|Insulin Lispro|
359524|NCT01454271|Procedure|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
359525|NCT01454245|Drug|JNJ-39439335|Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
359526|NCT01454245|Drug|JNJ-39439335|"Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.~or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods."
359527|NCT01454232|Other|stools sampling|stools sampling at baseline, 1, 3 and 12 months
359528|NCT01454232|Other|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
359529|NCT01454219|Other|Bakery and confectionary products|Control product: Glucose solution, Test products: 11 bakery and confectionary products
359530|NCT01454206|Behavioral|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
359531|NCT01454180|Drug|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
359577|NCT01454024|Device|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
359578|NCT01454024|Device|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
359618|NCT01453712|Radiation|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
359532|NCT01454180|Drug|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.~Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.~Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily~FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.~FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
359533|NCT01454154|Drug|Glyburide|RP-1127 (Glyburide for Injection) delivered as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
359534|NCT01454154|Drug|Placebo|Placebo delivered as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
359535|NCT01454141|Other|Cognitive Control Training|Three sessions of CCT.
359536|NCT01454141|Other|Peripheral Vision Task|Three sessions of PVT.
359537|NCT01454128|Behavioral|exercise|36 session supervised exercise intervention
359538|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
359539|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
359540|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
359541|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
359542|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
359543|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
359544|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
359545|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
359546|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
359547|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
359548|NCT01454115|Drug|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
359549|NCT01454115|Drug|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
359550|NCT01454102|Biological|Nivolumab|
359551|NCT01454102|Drug|Gemcitabine|
359552|NCT01454102|Drug|Cisplatin|
359553|NCT01454102|Drug|Pemetrexed|
359554|NCT01454102|Drug|Paclitaxel|
359555|NCT01454102|Drug|Carboplatin|
359556|NCT01454102|Drug|Bevacizumab|
359557|NCT01454102|Drug|Erlotinib|
359558|NCT01454102|Biological|Ipilimumab|
359559|NCT01454089|Drug|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
359560|NCT01454089|Drug|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
359561|NCT01454089|Drug|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
359562|NCT01454089|Drug|Gemcitabine|Patients will receive gemcitabine (1000 mg/m^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
359563|NCT01454089|Drug|Cisplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
359564|NCT01454089|Drug|Carboplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
359565|NCT01454076|Drug|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
359566|NCT01454076|Drug|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
359567|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
359568|NCT01454076|Drug|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
359569|NCT01454076|Drug|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
359570|NCT01454076|Drug|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
359571|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
359572|NCT01454063|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
359573|NCT01454063|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
359574|NCT01454037|Procedure|Prostate cryotherapy|cryoablate the prostate
359575|NCT01454037|Procedure|Radical prostatectomy|Remove prostate
359576|NCT01454037|Procedure|Radiation|Radiate prostate
359579|NCT01454011|Drug|Testosteron 250mg injection|The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
359580|NCT01454011|Drug|Testosterone 50mg transdermal application|Application of testosterone 50mg transdermal gel in every night
359581|NCT01453998|Biological|Infanrix hexa™|Single dose, licensed formulation, intramuscular into right thigh
359582|NCT01453998|Biological|Prevenar 13®|Single co-administered dose, intramuscular into left thigh
359583|NCT01453998|Biological|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
359584|NCT01453985|Procedure|Full-Thickness-Gastroplication|
359585|NCT01453972|Behavioral|Long distanse moderate training|Moderate exercise
359586|NCT01453972|Behavioral|Long interval training|High-intensity exercise, long duration
359587|NCT01453972|Behavioral|Short interval training|High intensity exercise, short duration
359588|NCT01453959|Drug|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
359589|NCT01453959|Other|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
359590|NCT01453946|Drug|Entocort|Entocort capsules, taken orally, 6 mg daily.
359591|NCT01453933|Drug|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
359592|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
359593|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
359594|NCT01453907|Drug|"ETI-204, Anthim"|intravenously, single dose
359595|NCT01453907|Drug|placebo|intravenously, single dose
359596|NCT01453894|Behavioral|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
359597|NCT01453881|Device|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
359598|NCT01453881|Device|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
359599|NCT01453868|Other|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
359600|NCT01453868|Other|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
359601|NCT01453855|Drug|Travoprost ophthalmic solution, 0.003%|
359602|NCT01453855|Drug|Travoprost ophthalmic solution, 0.004%|
359603|NCT01453842|Dietary Supplement|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
359604|NCT01453842|Dietary Supplement|Olive oil|Carrot and olive oil and 1½ g of paracetamol
359605|NCT01453842|Dietary Supplement|Carrot|Carrot and 1½ g of paracetamol
359606|NCT01453829|Procedure|Harvesting and Isolation of Stem Cells|This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be implanted into the Internal Carotid Artery and intravenously.
359607|NCT01453816|Procedure|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
359608|NCT01453803|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
359609|NCT01453790|Behavioral|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
359610|NCT01453790|Behavioral|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
359611|NCT01453777|Procedure|harvesting and implantation of adipose derived stem cells|Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.
359612|NCT01453764|Procedure|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
359613|NCT01453751|Procedure|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
359614|NCT01453738|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
359615|NCT01453738|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
359616|NCT01453725|Biological|Golimumab|Golimumab 50 mg SC injection every 4 weeks
359617|NCT01453725|Biological|Placebo|Placebo SC injection every 4 weeks
359619|NCT01453712|Radiation|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
359620|NCT01453686|Drug|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
359621|NCT01453686|Drug|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
359622|NCT01453660|Other|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
359623|NCT01453660|Other|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, & urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure & heart rate, including orthostatics & Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, & urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
359624|NCT01453647|Other|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
359625|NCT01453634|Drug|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
359626|NCT01453634|Drug|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
359627|NCT01453621|Other|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
359628|NCT01453608|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
359629|NCT01453608|Drug|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
359630|NCT01453595|Drug|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
359631|NCT01453582|Drug|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
359632|NCT01453582|Drug|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
359633|NCT01453569|Drug|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
359634|NCT01453569|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
359635|NCT01453569|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
359636|NCT01453556|Procedure|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
359637|NCT01453543|Other|deep transverse friction massage|For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.
359638|NCT01453530|Drug|Sugammadex|A single dose of sugammadex 2 mg/kg iv
359639|NCT01453530|Drug|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
359640|NCT01453530|Other|Placebo|Placebo
359641|NCT01453517|Behavioral|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
359642|NCT01453504|Drug|DHAP|Dexamethasone, Cytarabine, Cisplatin
359643|NCT01453504|Drug|Everolimus|
359644|NCT01453491|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
359645|NCT01453478|Drug|GSK1325756|CXCR2 antagonist
359646|NCT01453465|Other|Laboratory Biomarker Analysis|Correlative studies
359647|NCT01453452|Behavioral|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be < 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
359648|NCT01453452|Behavioral|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
359702|NCT01453075|Drug|Placebo|Matching placebo twice daily
359649|NCT01453452|Other|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
359650|NCT01453452|Procedure|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
359651|NCT01453439|Behavioral|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
359652|NCT01453439|Behavioral|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
359653|NCT01453426|Drug|BG00012 Dose 1|
359654|NCT01453426|Drug|BG00012 Dose 2|
359655|NCT01453413|Other|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
359656|NCT01453400|Drug|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
359657|NCT01453400|Drug|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
359658|NCT01453400|Drug|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
359659|NCT01453387|Drug|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
359660|NCT01453387|Drug|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
359661|NCT01453374|Drug|VIVITROL 380mg|380 mg IM injection given once monthly
359662|NCT01453361|Biological|Vigil™ Vaccine|
359663|NCT01453348|Biological|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
359664|NCT01453348|Biological|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 & 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
359665|NCT01453348|Biological|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
359666|NCT01453348|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
359667|NCT01453309|Procedure|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
359668|NCT01453309|Procedure|No Cell Saver|Cell Saver will not be available during surgery
359669|NCT01453296|Drug|GW642444|GW642444 25 μg; Novel dry powder inhaler
359670|NCT01453296|Drug|Placebo|Matching placebo; Novel dry powder inhaler
359671|NCT01453283|Drug|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
359672|NCT01453270|Device|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
359673|NCT01453270|Other|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
359674|NCT01453257|Drug|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:~K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
359675|NCT01453231|Procedure|thighplasty|Plastic surgery of thigh
359676|NCT01453218|Drug|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
359677|NCT01453205|Drug|MEDI-551 2 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
359678|NCT01453205|Drug|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
359679|NCT01453205|Drug|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min [800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
359680|NCT01453205|Drug|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
359681|NCT01453205|Procedure|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
359703|NCT01453062|Drug|Arzerra|Treatment with Arzerra
359682|NCT01453205|Drug|MEDI-551 4 mg/kg|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
359683|NCT01453192|Drug|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
359684|NCT01453179|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
359685|NCT01453179|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
359686|NCT01453166|Other|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
359687|NCT01453166|Other|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
359688|NCT01453166|Other|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
359689|NCT01453153|Drug|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
359690|NCT01453153|Drug|PEGPH20|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
359691|NCT01453153|Drug|Placebo|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
359692|NCT01453140|Drug|Cyclophospahmide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are >40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.~One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
359693|NCT01453140|Drug|Low dose IL-2, Cyclophosphamide and Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.~IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
359694|NCT01453140|Drug|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.~The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
359695|NCT01453127|Drug|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
359696|NCT01453127|Device|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
359697|NCT01453114|Behavioral|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
359698|NCT01453101|Drug|Fludarabine monophosphate, melphalan, Bortezomib|"Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
359699|NCT01453088|Drug|Melphalan|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.~Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.~Dosing will be based on body surface area calculated using actual body weight~Stem cell infusion:~Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.~Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
359700|NCT01453088|Drug|Bortezomib|"Bortezomib:~Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
359701|NCT01453075|Drug|Valacyclovir|Valacyclovir 1.5 mg po bid
359704|NCT01453049|Drug|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
359705|NCT01453049|Drug|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
359706|NCT01453036|Procedure|23S rRNA point mutation test of Helicobacter pylori|mutation test group>> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group >> no intervention
359707|NCT01453036|Procedure|UBT test & Gastroenterology with biopsy c silver stain|UBT test & Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group >> intervention
359708|NCT01453023|Drug|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
359709|NCT01453023|Drug|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
359710|NCT01453010|Other|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.~Participants are closely monitored at least once a week by a saebo-trained therapist."
359711|NCT01452997|Drug|NSAI treatment|Ibuprofen 5% gel
359712|NCT01452997|Drug|Steroid treatment|Steroid intervention with 0.05% w/w clobetasone butyrate.
359713|NCT01452958|Biological|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
359714|NCT01452958|Biological|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
359715|NCT01452932|Other|Physiotherapy|"The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.~The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.~Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.~The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them."
359716|NCT01452932|Other|Yoga|"The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.~The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.~No instruments were needed for this intervention."
359717|NCT01452919|Drug|LY2140023|Administered orally
359718|NCT01452919|Drug|Placebo|Administered orally
359719|NCT01452906|Drug|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
359720|NCT01452906|Drug|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
359721|NCT01452906|Drug|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
359722|NCT01452893|Procedure|Spiroergometry|"At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.~At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP)."
359723|NCT01452880|Drug|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
359724|NCT01452880|Drug|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
359725|NCT01452867|Device|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
359726|NCT01452867|Device|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
359727|NCT01452867|Device|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
359728|NCT01452841|Other|Grapefruit|1.5 Rio Red Grapefruit consumed daily for 6 weeks
359729|NCT01452841|Other|Control|Participants followed a diet low in bioactive rich fruits and vegetables and avoided citrus for six weeks
359730|NCT01452828|Drug|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
359731|NCT01452828|Drug|TR-701 FA|Two separate infusions of 200 mg
359732|NCT01452828|Drug|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
359733|NCT01452815|Drug|Placebo|Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
359734|NCT01452815|Drug|10mg TZP-102|One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
359735|NCT01452815|Drug|20mg TZP-102|Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
359736|NCT01452802|Device|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
359737|NCT01452802|Drug|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
359738|NCT01452789|Drug|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
359739|NCT01452789|Drug|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
359740|NCT01452776|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
359741|NCT01452776|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
359742|NCT01452763|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
359743|NCT01452763|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
359744|NCT01452763|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
359745|NCT01452763|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
359746|NCT01452763|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
359747|NCT01452763|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
359748|NCT01452750|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
359749|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
359750|NCT01452750|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
359751|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
359752|NCT01452750|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
359753|NCT01452750|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
359754|NCT01452737|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Golytely the day prior to procedure.
359755|NCT01452737|Drug|2L Golytely/bisacodyl|Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
359756|NCT01452724|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
359757|NCT01452724|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
359758|NCT01452724|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
359759|NCT01452724|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
359760|NCT01452711|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
359761|NCT01452711|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
359762|NCT01452711|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
359763|NCT01452711|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
359764|NCT01452698|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
359765|NCT01452698|Drug|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
359766|NCT01452698|Drug|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
359767|NCT01452698|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
359768|NCT01452685|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
359769|NCT01452685|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
359770|NCT01452685|Drug|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
359771|NCT01452685|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
359772|NCT01452685|Drug|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
359773|NCT01452672|Radiation|Radiotherapy|RT 40 Gy in 15 fractions
359774|NCT01452672|Radiation|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
359775|NCT01452659|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
359776|NCT01452659|Drug|TAK-385|TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
359777|NCT01452659|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
359778|NCT01452659|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
359779|NCT01452646|Other|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
359780|NCT01452633|Drug|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
359781|NCT01452633|Drug|Saline will be injected at the study port site prior to incision|Injection will precede incision
359782|NCT01452633|Drug|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
359783|NCT01452633|Drug|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
359784|NCT01452607|Drug|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
359785|NCT01452607|Drug|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
359786|NCT01452594|Drug|Diphenylcyclopropenone|Topical administration
359787|NCT01452594|Drug|Placebo|Placebo
359788|NCT01452581|Other|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
359789|NCT01452581|Drug|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
359790|NCT01452568|Drug|Aspirin|150mg/daily for three months, starting day after surgery
361443|NCT01439945|Drug|magnesium oxide|Given PO
359791|NCT01452568|Drug|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
359792|NCT01452555|Behavioral|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
359793|NCT01452542|Drug|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
359794|NCT01452542|Drug|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
359795|NCT01452529|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
359796|NCT01452529|Drug|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
359797|NCT01452516|Device|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
359798|NCT01452516|Device|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
359799|NCT01452503|Device|Path Women's Condom|comparison between 3 types of female condoms
359800|NCT01452503|Device|FC2 female condom|comparison between 3 types of female condoms
359801|NCT01452503|Device|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
359802|NCT01452490|Device|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
359803|NCT01452477|Drug|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
359804|NCT01452477|Drug|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
359805|NCT01452464|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
359806|NCT01452451|Drug|HM11260C|1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
359807|NCT01452451|Drug|Placebo|Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
359808|NCT01452438|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
359809|NCT01452425|Device|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
359810|NCT01452425|Device|INVOS assessment|Near Infraread spectroscopy, non invasive
359811|NCT01452425|Device|EMG assessment|Electromyography, non invasive
359812|NCT01452412|Drug|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
359813|NCT01452412|Drug|Placebo|To be taken on the same schedule as the active arm
359814|NCT01452399|Procedure|Shave margins|Partial mastectomy with shave margins.
359815|NCT01452399|Procedure|No Shave Margins|Partial mastectomy without shave margins.
359816|NCT01452373|Drug|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
359817|NCT01452373|Drug|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
359818|NCT01452347|Drug|warfarin 1mg|comparator warfarin
359819|NCT01452347|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
359820|NCT01452347|Drug|dabigatran etexilate low dose|active treatment (low)
359821|NCT01452347|Drug|warfarin 5mg|comparator warfarin
359822|NCT01452347|Drug|dabigatran etexilate high dose|active treatment (high)
359823|NCT01452347|Drug|warfarin 3mg|comparator warfarin
359824|NCT01452334|Biological|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
359825|NCT01452321|Procedure|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex"
359826|NCT01452308|Biological|Simtuzumab|
359827|NCT01452295|Drug|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
359828|NCT01452269|Behavioral|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.~Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).~The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
359829|NCT01452256|Drug|Desflurane|4-6 Vol %
359830|NCT01452256|Drug|Propofol|TIVA to achieve BIS value of 40-60
359831|NCT01452243|Drug|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
359832|NCT01452230|Behavioral|Supervised physical activity|Supervised physical activity
359833|NCT01452217|Drug|Secretin|Secretin 1 IU/kg over 3 min
359834|NCT01452204|Other|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
359869|NCT01451866|Other|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
359835|NCT01452191|Behavioral|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
359836|NCT01452191|Behavioral|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
359837|NCT01452152|Drug|clopidogrel|clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
359838|NCT01452152|Drug|prasugrel|Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
359839|NCT01452139|Genetic|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19*2 & ABCB1 3435 TT)
359840|NCT01452139|Drug|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
359841|NCT01452126|Drug|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
359842|NCT01452113|Drug|Vildagliptin|one 50 mg tablet per os
359843|NCT01452100|Drug|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
359844|NCT01452100|Other|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
359845|NCT01452087|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
359846|NCT01452074|Other|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
359847|NCT01452074|Other|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
359848|NCT01452035|Other|Exercise|single session of exercise
359849|NCT01452022|Device|Inductigraft|Synthetic bone graft
359850|NCT01452009|Drug|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
359851|NCT01452009|Drug|TRAVATAN®|TRAVATAN® administered one drop once daily
359852|NCT01451996|Drug|Claritin|Subject will be given 10mg Claritin tablet.
359853|NCT01451970|Other|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
359854|NCT01451957|Other|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)]
359855|NCT01451957|Other|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
359856|NCT01451957|Other|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
359857|NCT01451944|Behavioral|education|home asthma case management and education
359858|NCT01451931|Other|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
359859|NCT01451931|Radiation|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
359860|NCT01451931|Other|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
359861|NCT01451918|Drug|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
359862|NCT01451905|Drug|Liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
359863|NCT01451905|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
359864|NCT01451892|Other|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
359865|NCT01451892|Other|patient education|overweight individuals participating in a patient education program
359866|NCT01451879|Drug|Rituximab|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
359867|NCT01451879|Drug|Miglustat|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
359868|NCT01451866|Other|resistance training|hypertrophic resistance training
360007|NCT01450813|Drug|Saline 0.06 ml/kg|IV Infusion x1 prior to laryngoscopy
359870|NCT01451853|Drug|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy~Arms: Low Dose~Other Names:~200 mg Ebselen"
359871|NCT01451853|Drug|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
359872|NCT01451853|Drug|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
359873|NCT01451853|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
359874|NCT01451840|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
359875|NCT01451840|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
359876|NCT01451827|Drug|Tolvaptan MR|50/80 mg capsules
359877|NCT01451827|Drug|Tolvaptan IR|60/30 mg capsules
359878|NCT01451827|Drug|Placebo|tablet
359879|NCT01451814|Behavioral|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
359880|NCT01451814|Drug|Nicotine polacrilex|8 weeks of nicotine patch
359881|NCT01451814|Behavioral|Relaxation training|Instructions in progressive muscle relaxation
359882|NCT01451814|Behavioral|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
359883|NCT01451801|Biological|Twinrix|"A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.~Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin."
359884|NCT01451788|Device|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
359885|NCT01451775|Drug|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
359886|NCT01451775|Drug|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
359887|NCT01451775|Drug|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
359888|NCT01451762|Drug|.9 normal saline|.9 normal saline administered before surgery.
359889|NCT01451762|Drug|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
359890|NCT01451762|Drug|50 mg diphenhydramine IV|50 mg diphenhydramine administered IV before surgery
359891|NCT01451749|Drug|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.~Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
359892|NCT01451749|Drug|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.~Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
359893|NCT01451736|Drug|paliperidone palmitate|long-acting injectable
359894|NCT01451736|Drug|risperidone|oral
359895|NCT01451723|Drug|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
359896|NCT01451723|Other|Placebo|Matching placebo capsules
359897|NCT01451710|Drug|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
359898|NCT01451697|Behavioral|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
359899|NCT01451697|Behavioral|Control (Placebo)|The control condition will involve relaxation training.
359900|NCT01451658|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
359901|NCT01451645|Drug|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
359902|NCT01451645|Drug|placebo|daily placebo dosing for 16 weeks
359903|NCT01451645|Drug|allopurinol|background therapy
359904|NCT01451632|Drug|MM-121|escalating doses MM-121 IV QW
359905|NCT01451632|Drug|Irinotecan|180 mg/m2 IV Q2W
359906|NCT01451632|Drug|Cetuximab|escalating doses cetuximab IV QW
359907|NCT01451619|Drug|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
359908|NCT01451619|Drug|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
359909|NCT01451606|Drug|Duloxetine|30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
359910|NCT01451606|Drug|Placebo|To serve as placebo for duloxetine. Administration schedule same as for active drug.
359911|NCT01451593|Drug|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
359912|NCT01451593|Drug|Placebo|placebo identical in appearance to active IMP (phenytoin)
359913|NCT01451580|Drug|Lipo-Dox|
359914|NCT01451567|Behavioral|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
359915|NCT01451554|Behavioral|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
359916|NCT01451554|Behavioral|Usual Care|self-help booklets
359917|NCT01451541|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
361444|NCT01439945|Other|placebo|Given PO
359918|NCT01451541|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
359919|NCT01451541|Drug|Placebo|Placebo - one dose per nostril
359920|NCT01451528|Biological|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
359921|NCT01451515|Drug|Prednisone|Given orally (PO).
359922|NCT01451515|Drug|Vincristine|Given intravenously (IV).
359923|NCT01451515|Drug|Daunorubicin|Given IV.
359924|NCT01451515|Drug|PEG-asparaginase|Given intramuscularly (IM) or IV.
359925|NCT01451515|Drug|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
359926|NCT01451515|Drug|Doxorubicin|Given IV.
359927|NCT01451515|Drug|Cyclophosphamide|Given IV.
359928|NCT01451515|Drug|Cytarabine|Given IV or IT.
359929|NCT01451515|Drug|Thioguanine|Given PO.
359930|NCT01451515|Drug|Clofarabine|Given IV.
359931|NCT01451515|Drug|Methotrexate|Given IV or IT.
359932|NCT01451515|Drug|Mercaptopurine|Given PO.
359933|NCT01451515|Drug|Dexamethasone|Given PO or IV.
359934|NCT01451515|Drug|Hydrocortisone|Given IT.
359935|NCT01451515|Drug|Etoposide|Given IV.
359936|NCT01451502|Biological|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
359937|NCT01451489|Drug|FK506|FK506:0.05-0.1mg/kg/d
359938|NCT01451489|Drug|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
359939|NCT01451450|Drug|QGE031|QGE031 liquid for subcutaneous injection.
359940|NCT01451450|Drug|Placebo|Placebo liquid for subcutaneous injection.
359941|NCT01451437|Drug|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
359942|NCT01451424|Drug|Proellex|vaginal suppository, daily, for 12 weeks
359943|NCT01451411|Drug|Conivaptan hydrochloride|Intravenous
359944|NCT01451411|Drug|Placebo|Intravenous
359945|NCT01451398|Drug|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
359946|NCT01451398|Drug|Technosphere Powder|Placebo Comparator
359947|NCT01451385|Drug|COV795|2 tablets COV795 taken every 12 hours
359948|NCT01451359|Device|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
359949|NCT01451346|Dietary Supplement|B. Infantis 35624|One sachet daily for 12 weeks
359950|NCT01451333|Drug|Efavirenz|600mg qd; 3 x 200mg qd
359951|NCT01451333|Drug|Efavirenz|400mg qd; 2 x 200mg
359952|NCT01451320|Drug|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
359953|NCT01451320|Drug|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
359954|NCT01451320|Drug|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
359955|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
359956|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
359957|NCT01451294|Drug|Administration of phenylephrine|Phenylephrine: 50-100µg
359958|NCT01451294|Drug|Administration of ephedrine|Ephedrine: 5- 10 mg
359959|NCT01451268|Drug|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
359960|NCT01451268|Drug|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
359961|NCT01451242|Other|no intervention is made|no intervention is made
359962|NCT01451229|Drug|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
359963|NCT01451203|Drug|Placebo|Subcutaneous (SC)
359964|NCT01451203|Drug|CZP|SC
359965|NCT01451203|Drug|methotrexate (MTX)|oral
359966|NCT01451190|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
359967|NCT01451177|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
359968|NCT01451164|Drug|OPC-34712|orally administered once daily
359969|NCT01451164|Drug|OPC-34712|orally administered once daily
359970|NCT01451164|Drug|OPC-34712|orally administered once daily
359971|NCT01451164|Drug|Placebo|orally administered once daily
360008|NCT01450813|Drug|Rocuronium 0.2 mg/kg|IV Infusion x1 prior to laryngoscopy
360009|NCT01450813|Drug|Rocuronium 0.4 mg/kg|IV Infusion x1 prior to laryngoscopy
360010|NCT01450813|Drug|Rocuronium 0.6 mg/kg|IV Infusion x1 prior to laryngoscopy
359972|NCT01451151|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
359973|NCT01451138|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
359974|NCT01451125|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
359975|NCT01451112|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
359976|NCT01451099|Biological|Autologous cultured dermal cells|A piece of occipital scalp is taken from the subject. The dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
359977|NCT01451086|Biological|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
359978|NCT01451086|Biological|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
359979|NCT01451073|Biological|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
359980|NCT01451060|Drug|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
359981|NCT01451060|Drug|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
359982|NCT01451047|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
359983|NCT01451034|Procedure|WHYX cancer group|WHYX cancer diagnosed by pathologic report
359984|NCT01451021|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
359985|NCT01451008|Device|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
359986|NCT01450995|Drug|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
359987|NCT01450995|Drug|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
359988|NCT01450982|Drug|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
359989|NCT01450956|Drug|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
359990|NCT01450956|Other|Control|Patients will receive only oxygen and air through oxygenator
359991|NCT01450943|Device|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
359992|NCT01450943|Procedure|debridement, irrigation|debridement, irrigation
359993|NCT01450943|Device|Dermagraft|Dermagraft per company protocol
359994|NCT01450943|Device|Oasis|Oasis per company protocol
359995|NCT01450930|Drug|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
359996|NCT01450930|Drug|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
359997|NCT01450904|Procedure|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
359998|NCT01450904|Procedure|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
359999|NCT01450904|Procedure|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
360000|NCT01450878|Drug|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
360001|NCT01450865|Drug|flupirtine|Potassium channel opener (SNEPCO)
360002|NCT01450852|Behavioral|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
360003|NCT01450839|Drug|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
360004|NCT01450839|Drug|Placebo|Matching Placebo tablets and tape
360005|NCT01450826|Drug|aprepitant|On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
360006|NCT01450826|Drug|ondansetron|On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
360011|NCT01450800|Drug|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
360012|NCT01450800|Drug|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
360013|NCT01450774|Drug|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
360014|NCT01450774|Drug|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
360015|NCT01450761|Biological|Ipilimumab|
360016|NCT01450761|Biological|Placebo matching Ipilimumab|
360017|NCT01450761|Drug|Etoposide|
360018|NCT01450761|Drug|Cisplatin|
360019|NCT01450761|Drug|Carboplatin|
360020|NCT01450748|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
360021|NCT01450748|Drug|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
360022|NCT01450735|Device|MANOS CTR™|The MANOS device is a carpal tunnel blade used to release the transverse carpal ligament in order to provide relief for Carpal Tunnel Syndrome.
360023|NCT01450722|Procedure|bypass surgery, stent placement|bypass surgery, stent placement
360024|NCT01450722|Procedure|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
360025|NCT01450709|Dietary Supplement|Kibow Biotics|6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
360026|NCT01450696|Drug|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
360027|NCT01450696|Drug|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
360028|NCT01450696|Drug|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
360029|NCT01450683|Drug|Itraconazole|"600 mg/day oral (PO)~IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
360030|NCT01450670|Dietary Supplement|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
360031|NCT01450657|Dietary Supplement|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 & 4, three capsules three times daily (270 CFU's). Months 5 & 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 & 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
360032|NCT01450644|Other|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
360033|NCT01450631|Device|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
360034|NCT01450631|Device|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
360035|NCT01450605|Drug|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
360036|NCT01450592|Other|No drug|Diabetic Population
360037|NCT01450592|Other|No drug|Non-Diabetic Population
360038|NCT01450579|Biological|ASP7373|Intermuscular administration
360039|NCT01450579|Biological|Placebo|Intramuscular administration
360040|NCT01450566|Drug|Lidocaine|Use of lidocaine
360041|NCT01450566|Drug|Saline|Saline
360042|NCT01450514|Drug|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
360043|NCT01450514|Drug|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
360044|NCT01450488|Drug|masitinib|masitinib 3 mg/kg/day
360045|NCT01450488|Drug|masitinib|masitinib 6 mg/kg/day
360210|NCT01449357|Drug|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
360046|NCT01450475|Procedure|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
360047|NCT01450462|Dietary Supplement|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
360048|NCT01450462|Dietary Supplement|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
360049|NCT01450449|Radiation|Radiotherapy|25 Gy in 5 daily fractions over 1 week
360050|NCT01450449|Radiation|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
360051|NCT01450436|Other|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.~After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
360052|NCT01450423|Behavioral|Physical activity|Participation in a 10-week supervised cardio exercise program two-three times a week. Each training session consists of 10 minutes of warm-up, 20 minutes treadmill run/walk and 30 minutes cycling. Heart rate (HR) is monitored during each session. Week 1-5: at least 15 minutes above 75% of HRmax in each session. Week 6-10: at least one session above 75% HRmax.
360053|NCT01450410|Drug|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
360054|NCT01450410|Drug|Placebo|Placebo treatment will last for 12 weeks.
360055|NCT01450397|Biological|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
360056|NCT01450384|Drug|sorafenib tosylate|Given PO
360057|NCT01450384|Drug|pemetrexed disodium|Given IV
360058|NCT01450384|Other|laboratory biomarker analysis|Correlative studies
360059|NCT01450384|Procedure|biopsy|Optional correlative studies
360060|NCT01450371|Device|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
360061|NCT01450371|Device|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
360062|NCT01450358|Other|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
360063|NCT01450345|Drug|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
360064|NCT01450332|Device|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
360065|NCT01450319|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) every 2 weeks until disease progression, death, or consent withdrawal.
360066|NCT01450306|Drug|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
360067|NCT01450306|Behavioral|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
360068|NCT01450306|Drug|Placebo|Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
360069|NCT01450293|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|1x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
360070|NCT01450293|Biological|AdCH63 ME-TRAP, MVA ME-TRAP|5x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
360071|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0
360072|NCT01450280|Biological|ChAd63 CS, MVA CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
360073|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0
360074|NCT01450280|Biological|ChAd63, MVA CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
360075|NCT01450267|Drug|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
360076|NCT01450267|Drug|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
360077|NCT01450254|Device|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
360078|NCT01450254|Other|Control|No intervention will be prescribed to the control group during participation in the study.
360079|NCT01450241|Other|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
360080|NCT01450241|Other|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
360081|NCT01450228|Drug|KI1001|Prolonged release melatonin 2mg
360082|NCT01450228|Drug|Placebo KI1001|Placebo KI1001 tablets
360083|NCT01450215|Drug|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
360084|NCT01450202|Other|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
360085|NCT01450202|Other|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
360211|NCT01449344|Drug|Rituximab|Rituximab 375mg/m² IV , day 1
360086|NCT01450189|Behavioral|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
360087|NCT01450189|Behavioral|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
360088|NCT01450189|Drug|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
360089|NCT01450189|Drug|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
360090|NCT01450176|Drug|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
360091|NCT01450176|Drug|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
360092|NCT01450163|Drug|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
360093|NCT01450163|Drug|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
360094|NCT01450150|Device|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
360095|NCT01450150|Device|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
360096|NCT01450137|Drug|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
360097|NCT01450137|Drug|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
360098|NCT01450124|Drug|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
360099|NCT01450111|Drug|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
360100|NCT01450111|Drug|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
360101|NCT01450111|Drug|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
360102|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
360103|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
360104|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
360105|NCT01450098|Drug|LY2484595 Reference Formulation (RF)|Administered orally
360106|NCT01450098|Drug|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
360107|NCT01450085|Other|GeneXpert|Point of care GeneXpert
360108|NCT01450085|Other|LED Microscopy|Point of care LED Microscopy
360109|NCT01450072|Device|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
360110|NCT01450072|Other|Control arm|Venography and sham angioplasty
360111|NCT01450046|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
360112|NCT01450033|Behavioral|Peer Mentoring|Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
360113|NCT01450033|Behavioral|e-Communication with mentor|Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
360114|NCT01450020|Other|educational intervention|Receive ACS material
360115|NCT01450020|Other|questionnaire administration|Ancillary studies
360116|NCT01450020|Other|counseling intervention|Undergo PN session
360117|NCT01450020|Other|survey administration|Ancillary studies
360118|NCT01450020|Procedure|quality-of-life assessment|Ancillary studies
360119|NCT01450007|Drug|Ropivacaine|25 ml ropivacaine 0.5%
360120|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (perineural)
360121|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
360122|NCT01450007|Drug|Normal saline|5 ml normal saline (intravenous)
360123|NCT01450007|Drug|Normal saline|0.8 ml normal saline (perineural)
360124|NCT01449994|Device|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
360160|NCT01449695|Behavioral|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
360208|NCT01449383|Dietary Supplement|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
362165|NCT01434472|Drug|Mycophenolate Mofetil|Given PO
360125|NCT01449981|Behavioral|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
360126|NCT01449981|Behavioral|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
360127|NCT01449968|Other|home visit|home visit of UMG
360128|NCT01449968|Other|telephone management|telephone management of the situation reported by the patient's GP
360129|NCT01449955|Drug|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study."
360130|NCT01449955|Drug|Placebo|Inactive
360131|NCT01449942|Biological|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
360132|NCT01449942|Other|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.~The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
360133|NCT01449929|Drug|dolutegravir 50 mg OAD|1 x 50 mg tablet OAD
360134|NCT01449929|Drug|darunavir 800mg OAD|2 x 400mg tablets OAD
360135|NCT01449929|Drug|ritonavir 100mg OAD|1 x 100mg tablet OAD
360136|NCT01449916|Other|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
360137|NCT01449890|Behavioral|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
360138|NCT01449877|Drug|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
360139|NCT01449864|Radiation|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
360140|NCT01449838|Drug|Colistimethate sodium|active
360141|NCT01449838|Drug|Saline|placebo
360142|NCT01449825|Drug|Pazopanib use|Treatment with pazopanib
360143|NCT01449825|Drug|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
360144|NCT01449812|Biological|Infanrix+Hib™|Intramuscular, one dose
360145|NCT01449812|Biological|Poliorix™|Intramuscular, one dose
360146|NCT01449799|Drug|GSK961081 800 microgram dose|To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
360147|NCT01449799|Drug|Fluticasone Propionate 500 microgram dose|To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
360148|NCT01449799|Drug|GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately|To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
360149|NCT01449799|Drug|GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
360150|NCT01449786|Drug|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
360151|NCT01449786|Drug|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
360152|NCT01449786|Other|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
360153|NCT01449773|Dietary Supplement|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
360154|NCT01449773|Dietary Supplement|Placebo|5 capsules/day containing corn and soybean oil
360155|NCT01449760|Other|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
360156|NCT01449760|Other|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
360157|NCT01449747|Drug|Sitagliptin|Sitagliptin (100mg, per oral) once a day.
360158|NCT01449721|Drug|Intravenous fluid|0.9% Sodium chloride intravenous fluid
360159|NCT01449708|Drug|TIVA NoNarc|"patients in both groups receive antiemetic prophylaxis~patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively~postop management in both groups is similar in both groups"
360209|NCT01449370|Drug|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
360161|NCT01449695|Behavioral|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
360162|NCT01449695|Behavioral|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
360163|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
360164|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
360165|NCT01449656|Device|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
360166|NCT01449656|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
360167|NCT01449643|Device|Threshold|
360168|NCT01449643|Device|Sham Threshold|
360169|NCT01449630|Drug|LY3031207|Administered orally
360170|NCT01449630|Drug|Placebo|Administered orally
360171|NCT01449630|Drug|Celecoxib|Administered orally
360172|NCT01449617|Drug|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.~Aspirin will be given at the dose of 100-325mg/day."
360173|NCT01449604|Radiation|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
360174|NCT01449604|Radiation|stereotactic radiosurgery|Radio surgery 12 Gy
360175|NCT01449591|Drug|BFH772 1% ointment|
360176|NCT01449591|Drug|Vehicle ointment|
360177|NCT01449591|Drug|Noritate® 1% cream|
360178|NCT01449578|Drug|Dexpramipexole|Oral Tablet at varying doses
360179|NCT01449578|Drug|Dexpramipexole Placebo|Oral tablet at varying doses
360180|NCT01449565|Drug|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
360181|NCT01449565|Drug|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
360182|NCT01449552|Drug|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
360183|NCT01449552|Procedure|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
360184|NCT01449552|Other|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
360185|NCT01449552|Other|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
360186|NCT01449539|Drug|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
360187|NCT01449526|Device|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
360188|NCT01449526|Device|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
360189|NCT01449513|Drug|Ingenol mebutate|0.05% Ingenol mebutate Gel once daily for 2 consecutive days
360190|NCT01449513|Drug|Placebo Gel|Gel vehicle of PEP005
360191|NCT01449500|Dietary Supplement|L. reuteri|Chewable tablet, one tablet/day for 28 days
360192|NCT01449500|Dietary Supplement|Placebo|Chewable tablet, one tablet per day for 28 days
360193|NCT01449487|Drug|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
360194|NCT01449487|Drug|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
360195|NCT01449474|Device|Patient matched instruments|The patients undergo TKA with using patient matched instruments
360196|NCT01449474|Device|Jig based instruments|The patients undergo TKA with using jig based instruments
360197|NCT01449461|Drug|Brigatinib|Brigatinib tablets and capsules
360198|NCT01449448|Drug|Ketorolac|Subacromial injection
360199|NCT01449448|Drug|Triamcinolone|Subacromial Injection
360200|NCT01449435|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
360201|NCT01449422|Device|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
360202|NCT01449422|Device|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
360203|NCT01449409|Other|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
360204|NCT01449396|Other|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
360205|NCT01449396|Procedure|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
360206|NCT01449396|Procedure|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
360207|NCT01449383|Dietary Supplement|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
360212|NCT01449344|Drug|High dose Ara-C|Ara-C 2000 mg/m² (patients >65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
360213|NCT01449344|Drug|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
360214|NCT01449344|Drug|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
360215|NCT01449318|Device|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
360216|NCT01449305|Device|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
360217|NCT01449292|Device|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
360218|NCT01449292|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
360219|NCT01449279|Drug|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
360220|NCT01449279|Radiation|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
360221|NCT01449266|Drug|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
360222|NCT01449253|Drug|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
360223|NCT01449253|Drug|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
360224|NCT01449240|Other|No treatment|
360225|NCT01449214|Procedure|Ultrasound|Ultrasound-guided technique
360226|NCT01449214|Procedure|Landmarking|Landmark-guided technique
360227|NCT01449201|Drug|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
360228|NCT01449188|Drug|ondansetron|FDA approved drug used to treat nausea and vomiting
360229|NCT01449188|Drug|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
360230|NCT01449188|Other|saline|USP saline IV solution used as placebo for ondansetron IV.
360231|NCT01449162|Drug|Masitinib|6 mg/kg/day
360232|NCT01449162|Drug|Placebo|
360233|NCT01449149|Radiation|Proton Therapy|
360234|NCT01449136|Other|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
360235|NCT01449123|Drug|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
360236|NCT01449110|Dietary Supplement|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:~capsule/day of placebo (350 mg maltodextrin) for 6 months~capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
360237|NCT01449110|Dietary Supplement|Placebo in secondary prevention|"12 months follow-up:~capsule/day (350 mg maltodextrin) for 6 months~capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
360238|NCT01449110|Dietary Supplement|Grape extract in primary prevention (PP)|"12 months follow-up:~capsule/day (350 mg grape extract) for 6 months~capsules/day (350 mg + 350 mg grape extract) for 6 months"
360239|NCT01449110|Dietary Supplement|Grape extract in SP|"12 months follow-up:~capsule/day (350 mg grape extract) for 6 months~capsules/day (350 mg + 350 mg grape extract) for 6 months"
360240|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
360241|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.~12 months follow-up:~capsule/day (350 mg resveratrol-enriched grape extract) for 6 months~capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
360242|NCT01449097|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
360243|NCT01449097|Procedure|The femoral nerve block|US-guided femoral nerve block with ropivacaine
360244|NCT01449097|Procedure|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
360245|NCT01449084|Procedure|immediate stent removal|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE"
360331|NCT01448382|Device|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
360246|NCT01449084|Other|Leaving the stent in place|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.~THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE"
360247|NCT01449071|Biological|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
360248|NCT01449071|Biological|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
360249|NCT01449071|Biological|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
360250|NCT01449071|Biological|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
360251|NCT01449071|Biological|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
360252|NCT01449058|Drug|BYL719|taken orally
360253|NCT01449058|Drug|MEK162|taken orally
360254|NCT01449045|Drug|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
360255|NCT01449045|Drug|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
360256|NCT01449032|Biological|MSC|No of cells after culture expansion
360257|NCT01449032|Biological|Saline|3 cc saline
360258|NCT01449019|Drug|exendin(9-39)amide|intravenous infusion of exendin(9-39)
360259|NCT01449019|Drug|saline|intravenous infusion of saline
360260|NCT01449019|Other|duodenal meal|duodenal perfusion of a meal
360261|NCT01449019|Other|duodenal saline|duodenal perfusion of saline
360262|NCT01449006|Drug|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
360263|NCT01448993|Drug|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
360264|NCT01448993|Drug|Placebo|
360265|NCT01448980|Procedure|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
360266|NCT01448980|Procedure|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
360267|NCT01448954|Drug|ADC3680B oral|Once daily for 28 days
360268|NCT01448954|Drug|Placebo oral|Once daily for 28 days
360269|NCT01448941|Procedure|Temporary extraarticular plate fixation|Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
360270|NCT01448941|Procedure|Primary arthrodesis|Primary arthrodesis
360271|NCT01448941|Procedure|Primary arthrodesis TMT 2 and 3|Primary arthrodesis TMT 2 and 3 when instability is present
360272|NCT01448928|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
360273|NCT01448902|Drug|OC000459|OC000459 200mg bid for 8 days
360274|NCT01448902|Drug|Placebo|Placebo bid for 8 days
360275|NCT01448889|Drug|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
360276|NCT01448889|Drug|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
360277|NCT01448863|Other|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.~The frozen media culture is analyzed for the metabolomic profile."
360278|NCT01448850|Biological|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
360279|NCT01448850|Other|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
360280|NCT01448837|Drug|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
360281|NCT01448837|Drug|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
360282|NCT01448824|Drug|LY2484595|Administered orally
360283|NCT01448824|Drug|Placebo|Administered orally
360284|NCT01448824|Drug|Ketoconazole|Administered orally
360285|NCT01448811|Device|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI＞40, titrate up propofol dosage, AAI＜25, titrated down propofol dosage.
360286|NCT01448811|Procedure|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
360287|NCT01448798|Procedure|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
360288|NCT01448798|Procedure|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
360289|NCT01448785|Device|abiliti system implant|Subjects will receive implanted abiliti System.
360290|NCT01448785|Device|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
360291|NCT01448772|Drug|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
360292|NCT01448772|Drug|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
360293|NCT01448759|Other|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
360294|NCT01448746|Drug|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
360295|NCT01448733|Drug|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
360296|NCT01448720|Drug|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
360297|NCT01448707|Drug|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
360298|NCT01448707|Drug|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
360299|NCT01448694|Other|No treatment|No treatment, only collecting observational data.
360300|NCT01448681|Other|No Interventions|
360301|NCT01448642|Drug|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
360302|NCT01448642|Drug|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
360303|NCT01448629|Device|Standard Care|"Participants are using their own product and this procedure is called Standard Care.~Standard Care are the participants own products and may consist of several manufacturer and brand names."
360304|NCT01448629|Device|River|River is a new developed product with Coloplast as manufacturer
360305|NCT01448616|Drug|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
360306|NCT01448616|Drug|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.~The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects — negative or positive — on study endpoints."
360307|NCT01448616|Drug|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
360308|NCT01448616|Drug|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
360309|NCT01448603|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
360310|NCT01448603|Biological|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
360311|NCT01448564|Other|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
360312|NCT01448564|Other|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
360313|NCT01448551|Behavioral|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
360314|NCT01448538|Drug|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
360315|NCT01448525|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
360316|NCT01448525|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
360317|NCT01448512|Behavioral|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
360318|NCT01448512|Other|Usual Care|4 time matched sessions focused on health education
360319|NCT01448499|Drug|Clozapine|escalating dose of clozapine up to 900 mg/day
360320|NCT01448499|Drug|Amisulpride|escalating dose of amisulpride up to 800 mg/day
360321|NCT01448499|Drug|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
360322|NCT01448486|Drug|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
360323|NCT01448473|Other|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
360324|NCT01448473|Other|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
360325|NCT01448447|Device|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
360326|NCT01448447|Device|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
360327|NCT01448434|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
360328|NCT01448434|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
360329|NCT01448421|Device|SMT Embolic Deflection Device|The SMT Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
360330|NCT01448395|Drug|[14C]NXL104|500mg/100mL intravenous solution
360335|NCT01448356|Procedure|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:~25°C and 45% humidity;~25°C and 65% humidity;~30°C and 45% humidity;~30°C and 65% humidity~After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
360336|NCT01448343|Device|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
360337|NCT01448330|Drug|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
360338|NCT01448317|Drug|Alirocumab (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
360339|NCT01448317|Drug|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: subcutaneous"
360340|NCT01448317|Drug|Placebo (Solution)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
360341|NCT01448317|Drug|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation~Route of administration: Subcutaneous"
360342|NCT01448304|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
360343|NCT01448291|Drug|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
360344|NCT01448278|Procedure|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
360345|NCT01448278|Procedure|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
360346|NCT01448265|Procedure|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
360347|NCT01448252|Biological|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
360348|NCT01448252|Biological|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
360349|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
360350|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
360351|NCT01448213|Drug|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
360352|NCT01448213|Drug|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
360353|NCT01448200|Drug|PPI-668|capsules
360354|NCT01448200|Drug|Placebo|capsules
360355|NCT01448174|Drug|Atorvastatin|"Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:~atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or~placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks."
360356|NCT01448148|Other|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
360357|NCT01448148|Other|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
360358|NCT01448135|Other|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
360359|NCT01448135|Other|Osmolite 1.2|High protein enteral formula
360360|NCT01448122|Other|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
360361|NCT01448109|Drug|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
360362|NCT01448109|Drug|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
360363|NCT01448096|Drug|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
360364|NCT01448096|Procedure|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
360365|NCT01448083|Other|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
360366|NCT01448070|Drug|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
360367|NCT01448057|Drug|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
360368|NCT01448057|Drug|Paracetamol (500 mg) tablets|Paracetamol (500 mg) tablets
360369|NCT01448044|Drug|BMS-790052 (NS5A Replication Complex Inhibitor)|
360370|NCT01448044|Drug|Placebo matching BMS-790052|
360373|NCT01448031|Drug|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
360374|NCT01448031|Drug|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
360375|NCT01448018|Drug|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
360376|NCT01448018|Procedure|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
360377|NCT01448005|Device|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
360378|NCT01447992|Device|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
360379|NCT01447979|Device|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
360380|NCT01447966|Behavioral|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
360381|NCT01447953|Other|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
360382|NCT01447953|Other|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
360383|NCT01447940|Device|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
360384|NCT01447927|Drug|metformin hydrochloride|Given PO QD and BID
360385|NCT01447927|Other|placebo|Given PO QD and BID
360386|NCT01447914|Drug|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
360387|NCT01447914|Other|Diagnostic laboratory biomarker analysis|Correlative studies
360388|NCT01447914|Other|Questionnaire administration|Ancillary studies
360389|NCT01447914|Procedure|Quality-of-life assessment|Ancillary studies
360390|NCT01447888|Drug|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
360391|NCT01447888|Other|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
360392|NCT01447875|Other|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
360393|NCT01447875|Drug|propofol or mexmedetomidine|
360394|NCT01447862|Drug|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
360395|NCT01447862|Drug|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
360396|NCT01447849|Drug|lubiprostone|24mcg twice a day (BID) 1 week
360397|NCT01447849|Drug|placebo|Placebo pills twice a day for one week.
360398|NCT01447810|Other|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
360399|NCT01447797|Drug|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
360400|NCT01447784|Biological|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
360401|NCT01447784|Biological|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
360402|NCT01447771|Behavioral|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
360403|NCT01447758|Drug|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
360404|NCT01447758|Drug|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
360405|NCT01447732|Drug|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
360406|NCT01447719|Drug|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
360407|NCT01447706|Drug|MM-121|MM-121 (SAR256212) (IV)
360408|NCT01447706|Drug|Paclitaxel|Standard dosing Paclitaxel (IV)
360409|NCT01447693|Procedure|application of ointment (olive-omega 3 ointment)|
360410|NCT01447667|Procedure|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
360411|NCT01447654|Drug|Losartan|100 mg for 12 months.
360412|NCT01447654|Drug|Placebo|100 mg for 12 months.
360413|NCT01447641|Other|Polysomnography|Overnight physiological recording of sleep
360414|NCT01447641|Other|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
360415|NCT01447628|Drug|Saline|intravenous, no active drug
360416|NCT01447628|Drug|Ferinject or CosmoFer|Intravenous, 1000 mg iron
360417|NCT01447615|Behavioral|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
360418|NCT01447615|Behavioral|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
360419|NCT01447615|Other|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
360420|NCT01447602|Behavioral|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
360421|NCT01447589|Drug|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
360422|NCT01447589|Radiation|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
360423|NCT01447576|Drug|ADT|Once daily dosing during the duration of the study.
360424|NCT01447576|Drug|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
360425|NCT01447563|Drug|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
360426|NCT01447563|Drug|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
360427|NCT01447550|Drug|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
360428|NCT01447537|Other|Exercise + relaxation|Exercise + relaxation
360429|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
360430|NCT01447524|Behavioral|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
360431|NCT01447511|Drug|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
360432|NCT01447511|Drug|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
360433|NCT01447511|Drug|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
360434|NCT01447498|Other|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:~screening and risk assessment~control group~All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.~Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.~Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.~points: Age: < 60: 0; 60-69: 1; 70-79: 2; >=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___"
360435|NCT01447485|Drug|Valsartan (VAL489)|
360436|NCT01447472|Drug|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
360437|NCT01447459|Behavioral|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
360438|NCT01447446|Drug|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
360439|NCT01447446|Drug|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
360440|NCT01447446|Drug|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
360441|NCT01447446|Drug|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
360442|NCT01447446|Drug|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
360443|NCT01447433|Drug|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
360444|NCT01447433|Behavioral|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
360445|NCT01447420|Drug|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
360446|NCT01447420|Drug|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
360447|NCT01447407|Biological|NDV-3 vaccine with alum administered IM|One dose administered IM
360448|NCT01447407|Biological|NDV-3 vaccine without alum administered IM|One dose administered IM
360449|NCT01447407|Biological|Placebo administered ID|One dose saline placebo administered ID
360450|NCT01447407|Biological|NDV-3 vaccine without alum administered ID|One dose administered ID
360451|NCT01447394|Biological|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
360452|NCT01447394|Biological|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
360453|NCT01447394|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
360454|NCT01447368|Drug|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
360455|NCT01447368|Procedure|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
360456|NCT01447355|Drug|cholecalciferol|Given PO
360457|NCT01447342|Device|Cryo-Touch II|Percutaneous treatment with the device
360458|NCT01447329|Other|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
360459|NCT01447329|Drug|Standard Treatment|
360460|NCT01447316|Other|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
360461|NCT01447303|Other|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
360462|NCT01447277|Procedure|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
360463|NCT01447277|Procedure|Femoral Block only|Performing a preoperative sciatic nerve block only
360464|NCT01447264|Procedure|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
360465|NCT01447264|Procedure|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
360466|NCT01447251|Behavioral|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS <4.5, moderate risk as PreDx DRS ≥4.5 and <8.0, and high risk as PreDx DRS ≥8.0.
360467|NCT01447238|Device|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.~The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
360468|NCT01447225|Drug|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
360469|NCT01447225|Drug|Carboplatin|administered at AUC 6
360470|NCT01447225|Drug|Pemetrexed|administered IV at 500 mg/m2
360471|NCT01447225|Drug|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
360472|NCT01447225|Drug|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
360473|NCT01447212|Drug|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
360474|NCT01447212|Drug|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
360475|NCT01447212|Drug|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
360476|NCT01447212|Drug|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
360477|NCT01447199|Behavioral|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
360478|NCT01447186|Behavioral|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
360479|NCT01447186|Behavioral|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
360480|NCT01447186|Behavioral|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
360481|NCT01447173|Drug|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
360482|NCT01447160|Drug|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
360483|NCT01447147|Drug|Placebo|Placebo capsules once daily
360484|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
360485|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
360486|NCT01447121|Device|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
362166|NCT01434472|Other|Pharmacological Study|Correlative studies
360487|NCT01447108|Device|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|"All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.~The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping."
360488|NCT01447095|Drug|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
360489|NCT01447095|Drug|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
360490|NCT01447095|Drug|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
360491|NCT01447069|Drug|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains <100 bpm
360492|NCT01447056|Biological|LMP specific T cells|"Three dose levels will be evaluated:~Dose Level 1: 2×10^7 cells/m2; Dose Level 2: 1×10^8 cells/m2; Dose Level 3: 2×10^8 cells/m2~If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
360493|NCT01447043|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
360494|NCT01447017|Drug|DPK-060|DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
360495|NCT01447017|Drug|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
360496|NCT01446991|Drug|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
360497|NCT01446991|Drug|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
360498|NCT01446978|Biological|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
360499|NCT01446978|Biological|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
360500|NCT01446965|Device|wearable defibrillator|LifeVest wearable defibrillator
360501|NCT01446952|Drug|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
360502|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
360503|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
360504|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
360505|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
360506|NCT01446926|Biological|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
360507|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
360508|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
360509|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
360510|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
360511|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
360512|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
360513|NCT01446913|Device|Standard CPAP Intervention|
360514|NCT01446913|Behavioral|Enhanced CPAP Intervention|
360515|NCT01446900|Drug|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
360516|NCT01446900|Drug|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
360517|NCT01446887|Other|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
360518|NCT01446874|Drug|0.12% chlorhexidine solution|Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
360519|NCT01446848|Dietary Supplement|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
360520|NCT01446835|Device|nelfilcon A contact lens with print|Investigational spherical contact lens
360521|NCT01446835|Device|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
360522|NCT01446822|Device|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
360523|NCT01446822|Device|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
360524|NCT01446809|Drug|Doxorubicin Hydrochloride|Given IV
360525|NCT01446809|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
360526|NCT01446809|Drug|Ifosfamide|Given IV
360527|NCT01446809|Other|Laboratory Biomarker Analysis|Correlative studies
360528|NCT01446809|Drug|Pazopanib Hydrochloride|Given PO
360529|NCT01446809|Other|Pharmacological Study|Correlative studies
360530|NCT01446809|Other|Placebo|Given PO
360531|NCT01446809|Procedure|Therapeutic Conventional Surgery|Undergo surgery
360532|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
360533|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
360534|NCT01446783|Drug|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
360535|NCT01446783|Drug|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
360536|NCT01446770|Device|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
360537|NCT01446757|Procedure|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
360538|NCT01446757|Procedure|control group|No intervention
360539|NCT01446744|Radiation|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
360540|NCT01446744|Radiation|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:~Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions~Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions~Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions~Liver: 20 Gy in 5 fractions if standard institutional practice"
360541|NCT01446731|Biological|mRNA transfected dendritic cell|"Autologues monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.~5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
360542|NCT01446731|Drug|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
360543|NCT01446718|Biological|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
360544|NCT01446705|Other|Active Health Information Exchange|Patients selected to share data between the VA & external healthcare agencies.
360545|NCT01446705|Other|Non-Active Health Information exchange|Patients not selecting to share data
360546|NCT01446679|Drug|atrovastatin|oral
360547|NCT01446653|Behavioral|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
360548|NCT01446653|Behavioral|Video|Video arm will provide information via documentary video
360549|NCT01446653|Behavioral|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
360550|NCT01446640|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10^6 MSCs per kg; intrathecal administration of up to 1x10^6 MSCs per kg.
360551|NCT01446627|Other|There is no intervention for this study|None, no intervention made.
360552|NCT01446614|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
360553|NCT01446601|Device|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
360554|NCT01446588|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
360555|NCT01446562|Biological|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
360556|NCT01446549|Other|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
360557|NCT01446549|Procedure|Deep Brain Stimulation|Deep Brain Stimulation implantation
360558|NCT01446536|Other|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
360559|NCT01446523|Drug|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
360560|NCT01446523|Drug|Lactulose|Syrup 30 ml BD for 12 weeks
360561|NCT01446510|Other|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
360562|NCT01446497|Drug|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
360563|NCT01446497|Drug|Timolol|Twice per day, 1 drop at each time
360564|NCT01446484|Biological|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
360565|NCT01446484|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
360566|NCT01446484|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
360567|NCT01446484|Drug|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
360568|NCT01446484|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
360569|NCT01446484|Drug|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
360570|NCT01446484|Drug|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
360571|NCT01446484|Procedure|Kidney transplantation|Living related kidney transplantation
360572|NCT01446458|Drug|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
360573|NCT01446458|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
360574|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
360575|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
360576|NCT01446419|Device|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
360577|NCT01446419|Device|Sham Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
360578|NCT01446406|Device|MONARCA|Monitoring affective symptoms entered by the patient every day.
360579|NCT01446406|Device|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
360580|NCT01446341|Procedure|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
360581|NCT01446341|Procedure|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
360582|NCT01446328|Drug|Amisulpride|Tablets, dose range 50-1200 mg/ day
360583|NCT01446328|Drug|Aripiprazole|Tablets, dose range 5-30 mg/ day
360584|NCT01446328|Drug|Olanzapine|Tablets, dose range 2.5-20 mg/ day
360585|NCT01446315|Behavioral|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
360586|NCT01446315|Behavioral|Asthma APGAR tools|Usual care
360587|NCT01446302|Dietary Supplement|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
360588|NCT01446289|Biological|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
360589|NCT01446289|Biological|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
360590|NCT01446276|Dietary Supplement|Resveratrol|500 mg 3 times daily for six month
360591|NCT01446276|Other|Placebo|1 placebo tablet 3 times daily for six month
360592|NCT01446263|Procedure|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
360593|NCT01446250|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
360594|NCT01446250|Drug|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
360595|NCT01446250|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
360596|NCT01446250|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
360597|NCT01446237|Other|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
360598|NCT01446224|Drug|Pazopanib|Patients treated with pazopanib
360599|NCT01446224|Drug|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
360600|NCT01446211|Drug|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
360601|NCT01446211|Drug|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .~Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
360602|NCT01446185|Device|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
360603|NCT01446159|Drug|MEDI-573|Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
360604|NCT01446159|Drug|Aromatase Inhibitor|Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
360605|NCT01446146|Behavioral|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
360606|NCT01446146|Behavioral|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
360607|NCT01446133|Drug|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
360608|NCT01446133|Drug|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
360609|NCT01446120|Drug|NPH-Insulin Injection|
360610|NCT01446120|Drug|Insulin loaded Orally Dissolved Films (insulin-ODF|
360611|NCT01446107|Other|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
360612|NCT01446107|Other|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
360613|NCT01446107|Other|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
360614|NCT01446107|Other|placebo control|application of water onto tooth surface every year
360615|NCT01446094|Drug|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
360616|NCT01446081|Behavioral|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
360617|NCT01446068|Dietary Supplement|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
360618|NCT01446055|Device|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
360619|NCT01446055|Device|Ficoll conventional cell processing method|Comparison of different cell processing methods
360620|NCT01446042|Drug|Testosterone|Intranasal testosterone
360621|NCT01446042|Drug|Testosterone|Intranasal testosterone
360622|NCT01446029|Device|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
360623|NCT01446016|Drug|Taxane|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
360624|NCT01446016|Drug|Docetaxel|Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks
360625|NCT01446016|Drug|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
360626|NCT01446016|Drug|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
360627|NCT01446003|Drug|MK-8457|10 x 10-mg capsule BID for 10 days
360628|NCT01446003|Drug|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
360629|NCT01445990|Device|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
360630|NCT01445964|Drug|Atenolol|Atenolol oral administration
360631|NCT01445964|Drug|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
360632|NCT01445964|Drug|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
360633|NCT01445951|Drug|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
360634|NCT01445951|Drug|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
360635|NCT01445951|Drug|Insulin Aspart in combination with a basal insulin|Injectable insulin
360636|NCT01445938|Drug|SAR97276A|"Pharmaceutical form:solution for injection~Route of administration: intramuscular"
360637|NCT01445938|Drug|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet~Route of administration: oral"
360638|NCT01445925|Procedure|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
360639|NCT01445925|Procedure|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
360640|NCT01445925|Drug|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
360641|NCT01445899|Drug|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
360642|NCT01445899|Drug|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
360643|NCT01445899|Drug|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
360644|NCT01445886|Drug|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
360645|NCT01445886|Drug|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
360646|NCT01445873|Drug|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
360647|NCT01445860|Drug|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
360648|NCT01445847|Drug|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
360649|NCT01445847|Other|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
360650|NCT01445821|Biological|Peripheral Blood Stem Cells|Mobilized leukapheresis product
360651|NCT01445821|Drug|Cyclophosphamide|An alkylating agent which causes prevention of cell division by forming adducts with DNA
360652|NCT01445821|Drug|Mesna|Medication used to decrease the risk of hemorrhagic cystitis prophylaxis
360653|NCT01445821|Drug|rATG|A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells
360654|NCT01445821|Drug|Methylprednisolone|Steroid
360655|NCT01445821|Drug|Filgrastim|Granulocyte-colony stimulating factor (G-CSF); a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
360656|NCT01445821|Drug|Fludarabine|Purine analog which inhibits DNA synthesis or repair
360657|NCT01445808|Behavioral|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
360658|NCT01445808|Behavioral|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
360659|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
360660|NCT01445795|Drug|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
360661|NCT01445795|Drug|Placebo QD Fasted|Placebo capsule QD fasted x7 days
360662|NCT01445795|Drug|100 mg INX-08189 QD|100 mg INX-08189 capsule QD x 7 days
360663|NCT01445795|Drug|Placebo QD|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
360664|NCT01445795|Drug|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
360665|NCT01445795|Drug|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
360666|NCT01445795|Drug|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
360667|NCT01445795|Drug|Placebo BID Fasted|Placebo BID fasted x7 days
360668|NCT01445795|Drug|ribavirin|
360669|NCT01445782|Drug|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
360670|NCT01445782|Drug|Placebo|Multiple dose, oral inhalation (nebuliser solution)
360671|NCT01445769|Drug|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 & 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10^9/L at wk 12 or ≥ 150 x 10^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets <100 x 10^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level < 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
360672|NCT01445756|Drug|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
360673|NCT01445756|Drug|Placebo|Placebo; no topical lidocaine administered
360674|NCT01445743|Biological|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
360675|NCT01445730|Dietary Supplement|Fructose|fructose drink 75 g/day per day while consuming a self-selected ad libitum diet
360676|NCT01445730|Dietary Supplement|Fructose|3 month fructose diet 75 g/day while consuming isocaloric diet
360677|NCT01445704|Dietary Supplement|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
360678|NCT01445704|Dietary Supplement|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
360679|NCT01445691|Drug|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
360680|NCT01445678|Drug|CXA-201 and metronidazole|CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
360681|NCT01445678|Drug|Meropenem|Meropenem IV infusion (1000mg q8h) for 4-14 days
360682|NCT01445652|Device|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
360683|NCT01445652|Other|Spectacles|Spectacles per current prescription
360684|NCT01445639|Drug|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
360685|NCT01445639|Drug|Normal saline|as placebo
360686|NCT01445626|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
360687|NCT01445613|Device|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
360688|NCT01445600|Drug|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
360726|NCT01445236|Other|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
360689|NCT01445587|Drug|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
360690|NCT01445587|Drug|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
360691|NCT01445587|Drug|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
360692|NCT01445587|Drug|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
360693|NCT01445561|Drug|Interleukin-2 (100,00 IU/m(2) SQ)|100,000 International Units/m2 SQ daily for 5 days
360694|NCT01445548|Drug|Sirolimus|
360695|NCT01445535|Biological|Rituximab|Rituximab will be given with siplizumab and EPOCH (combo chemo) every 21 days
360696|NCT01445535|Drug|EPOCH|EPOCH (combo chemo)will be given with siplizumab and rituximab every 21 days
360697|NCT01445535|Biological|Siplizumab|Siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
360698|NCT01445522|Drug|ABT-888|
360699|NCT01445522|Drug|Cyclophosphamide|
360700|NCT01445509|Drug|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
360701|NCT01445509|Drug|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
360702|NCT01445444|Behavioral|Habit Reversal Training|"8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).~The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.~components:~Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.~Session 2. implement habit reversal, including awareness training, competing response training, and social support.~Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
360703|NCT01445431|Other|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
360704|NCT01445431|Other|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
360705|NCT01445418|Drug|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
360706|NCT01445405|Drug|Bortezomib (Velcade, PS-341)|
360707|NCT01445405|Drug|Cetuximab|
360708|NCT01445405|Drug|Cisplatin|
360709|NCT01445405|Procedure|Radiation Therapy|
360710|NCT01445392|Biological|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 &amp; 5 of a 21 day cycle for 2 cycles
360711|NCT01445392|Drug|Pemetrexed|500 mg/m^2 on day 1 of each 21 day cycle until disease progression
360712|NCT01445392|Drug|Cisplatin|75 mg/m^2 on day 1 of each 21 day cycle until disease progression
360713|NCT01445392|Biological|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
360714|NCT01445379|Drug|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
360715|NCT01445366|Device|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
360716|NCT01445366|Device|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
360717|NCT01445340|Drug|Romidepsin (FR901228)|
360718|NCT01445301|Drug|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
360719|NCT01445301|Drug|CLDM 1% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
360720|NCT01445275|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
360721|NCT01445275|Other|Medical Chart Review|Ancillary study
360722|NCT01445275|Other|Study of Socioeconomic and Demographic Variables|Ancillary studies
360723|NCT01445262|Drug|Levocetirizine|
360724|NCT01445249|Procedure|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
360725|NCT01445249|Procedure|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
360730|NCT01445210|Procedure|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
360731|NCT01445210|Procedure|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
360732|NCT01445197|Biological|Biostate|200 IU/kg administered daily
360733|NCT01445171|Device|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
360734|NCT01445132|Drug|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
360735|NCT01445119|Drug|Enzastaurin (LY317615)|
360736|NCT01445119|Drug|Carboplatin|
360737|NCT01445106|Drug|Nelfinavir|
360738|NCT01445106|Drug|Nelfinavir Mesylate|
360739|NCT01445080|Other|Laboratory Biomarker Analysis|Correlative studies
360740|NCT01445080|Other|Pharmacological Study|Correlative studies
360741|NCT01445080|Drug|Sorafenib Tosylate|Given orally
360742|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
360743|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
360744|NCT01445054|Drug|111Indium CHX-A|111Indium CHX-A will be administered intravenously over a 10-15 minute period using an intravenous catheter
360745|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
360746|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
360747|NCT01445028|Drug|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
360748|NCT01445015|Behavioral|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
360749|NCT01445015|Other|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
360750|NCT01445002|Biological|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
360751|NCT01445002|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
360752|NCT01445002|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
360753|NCT01445002|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
360754|NCT01444989|Other|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
360755|NCT01444989|Other|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
360756|NCT01444976|Drug|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
360757|NCT01444976|Behavioral|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
360758|NCT01444976|Drug|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
360759|NCT01444924|Drug|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
360760|NCT01444924|Drug|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
360761|NCT01444911|Device|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
360762|NCT01444911|Device|Vaginal Dilator|Still vaginal dilator with lubricant.
360763|NCT01444898|Drug|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
360764|NCT01444885|Drug|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
360765|NCT01444872|Drug|TRV120027|IV infusion
360766|NCT01444872|Drug|Normal Saline|IV infusion
360767|NCT01444859|Dietary Supplement|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
360768|NCT01444859|Dietary Supplement|Placebo|Daily placebo for 10 weeks
360769|NCT01444846|Drug|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
360770|NCT01444846|Drug|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
360771|NCT01444846|Drug|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
360772|NCT01444846|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
360773|NCT01444833|Drug|Candesartan|32 mg per day duration 6 months
360774|NCT01444820|Radiation|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
360816|NCT01444482|Biological|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
360817|NCT01444469|Drug|Zithromax|250mg * 2 capsules once daily for three days
360775|NCT01444820|Radiation|conventional|"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.~The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.~For patients with T3b, the whole SV is to be treated to 7600 cGy."
360776|NCT01444807|Drug|sorafenib|sorafenib 400 mg bid
360777|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
360778|NCT01444781|Biological|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
360779|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
360780|NCT01444768|Other|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
360781|NCT01444742|Drug|Clofarabine|"Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)"
360782|NCT01444742|Drug|Cytarabine|"Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)"
360783|NCT01444729|Drug|Xiapex|Xiapex administration will follow SMPC
360784|NCT01444729|Procedure|surgery|Non-pharmacological treatment
360785|NCT01444716|Biological|Ofatumumab|Given IV
360786|NCT01444703|Other|licorice solution|licorice (0.5 g)
360787|NCT01444703|Other|sugar solution|sugar (5 g).
360788|NCT01444690|Drug|Dimiracetam|Capsules for oral administration twice daily
360789|NCT01444690|Drug|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
360790|NCT01444677|Drug|MB12066|MB12066 300mg
360791|NCT01444677|Drug|MB12066|MB12066 400mg
360792|NCT01444677|Drug|MB12066|MB12066 100mg
360793|NCT01444677|Drug|MB12066|MB12066 200mg
360794|NCT01444677|Drug|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
360795|NCT01444664|Procedure|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
360796|NCT01444651|Drug|Tadalafil|20 mg Tadalafil taken once a day for 3 months
360797|NCT01444651|Drug|Placebo|Placebo tablet taken by mouth once a day for 3 months
360798|NCT01444638|Device|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
360799|NCT01444625|Other|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
360800|NCT01444625|Other|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
360801|NCT01444612|Drug|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
360802|NCT01444612|Drug|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
360803|NCT01444612|Drug|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
360804|NCT01444612|Drug|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
360805|NCT01444586|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
360806|NCT01444573|Device|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
360807|NCT01444547|Drug|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
360808|NCT01444534|Device|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
360809|NCT01444534|Device|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
360810|NCT01444521|Drug|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles."
360811|NCT01444508|Drug|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
360812|NCT01444508|Drug|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
360813|NCT01444495|Radiation|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
360814|NCT01444495|Procedure|Surgery|Total mesorectal excision of rectal cancer
360815|NCT01444482|Biological|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
360818|NCT01444469|Drug|Placebo|Lactose powder
360819|NCT01444443|Device|Closed-loop control|Blood glucose controlled by algorithm
360820|NCT01444443|Other|Open-loop control|Blood glucose controlled by patient
360821|NCT01444430|Drug|Symbicort pMDI|Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
360822|NCT01444430|Drug|budesonide pMDI|Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
360823|NCT01444417|Drug|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10^9/L and ≤ 200 x 10^9/L.
360824|NCT01444417|Drug|Placebo|Matching placebo administered by subcutaneous injection
360825|NCT01444404|Drug|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
360826|NCT01444391|Device|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
360827|NCT01444378|Device|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
360828|NCT01444365|Drug|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
360829|NCT01444365|Drug|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
360830|NCT01444352|Biological|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
360831|NCT01444352|Biological|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
360832|NCT01444352|Biological|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
360833|NCT01444352|Biological|Placebo|0.5 mL, Intramuscular
360834|NCT01444339|Biological|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
360835|NCT01444339|Biological|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
360836|NCT01444339|Biological|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
360837|NCT01444339|Biological|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
360838|NCT01444339|Biological|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
360839|NCT01444339|Biological|Placebo|0.5 mL, intramuscular
360840|NCT01444326|Other|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.~During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
360841|NCT01444313|Device|narafilcon A contact lens|Soft contact lenses with UV protection
360842|NCT01444313|Device|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
360843|NCT01444300|Drug|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
360844|NCT01444300|Drug|Placebo|placebo pill, bid for 12 weeks
360845|NCT01444287|Device|narafilcon B|test product
360846|NCT01444287|Device|Polymacon|marketed product
360847|NCT01444287|Device|Lotrafilcon A|marketed product
360848|NCT01444287|Other|Spectacles|None - subject used own spectacles
360849|NCT01444274|Device|Obalon Gastric Balloon(s)|One or two balloons administered per patient
360850|NCT01444261|Dietary Supplement|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
360851|NCT01444261|Other|control|No dietary supplements
360852|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg once daily
360853|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg bid
360854|NCT01444235|Drug|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
360855|NCT01444235|Drug|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
360856|NCT01444209|Radiation|Iodine Implants|Interstitial Radioactive Iodine Implants
360857|NCT01444196|Drug|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
360858|NCT01444183|Behavioral|Progressive muscle relaxation|"Subjects practice a progressive muscle relaxation exercise for 15 minutes every AM and 5 minutes every PM~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
360859|NCT01444183|Behavioral|Sham exercise|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.~Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
360860|NCT01444170|Dietary Supplement|dicreatinol sulfate|nutritional supplement
360861|NCT01444170|Drug|placebo sugar pill|
360905|NCT01443819|Other|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).~Please note: There will be another PT evaluation at the end of 6 weeks."
361102|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
360862|NCT01444157|Other|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
360863|NCT01444144|Other|Fracture union|Retrospective records review post-operatively until fracture resolved.
360864|NCT01444131|Drug|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
360865|NCT01444131|Drug|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
360866|NCT01444118|Biological|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
360867|NCT01444105|Device|iStent|Implantation of two iStent devices
360868|NCT01444105|Other|SLT|Laser treatment
360869|NCT01444092|Drug|Entocort|Entocort capsules, oral
360870|NCT01444066|Procedure|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
360871|NCT01444053|Device|No Intervention|No Intervention
360872|NCT01444040|Device|iStent inject|Implantation of two iStent inject devices
360873|NCT01444040|Drug|Travoprost|Travoprost drops
360874|NCT01444027|Behavioral|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
360875|NCT01444014|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
360876|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
360877|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
360878|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
360879|NCT01443988|Device|iStent|Implantation of two iStent devices
360880|NCT01443988|Drug|Travoprost|Travoprost drops
360881|NCT01443975|Procedure|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
360882|NCT01443962|Other|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
360883|NCT01443962|Other|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
360884|NCT01443936|Biological|Ad4-H5-VTN vaccination-tonsillar route|
360885|NCT01443936|Biological|Ad4-H5-vaccination-oral route|
360886|NCT01443923|Drug|Boceprevir|
360887|NCT01443923|Drug|Peg-Interferon-alfa 2B|
360888|NCT01443923|Drug|Ribavirin|
360889|NCT01443897|Dietary Supplement|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
360890|NCT01443897|Dietary Supplement|placebo capsule|0 IU vitamin D2
360891|NCT01443897|Other|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
360892|NCT01443897|Other|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
360893|NCT01443897|Other|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
360894|NCT01443884|Dietary Supplement|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
360895|NCT01443884|Dietary Supplement|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
360896|NCT01443871|Other|Aromatherapy|Subject will assigned inhale aromatherapy
360897|NCT01443871|Other|Pure water|Subject will assigned inhale Pure water
360898|NCT01443858|Drug|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
360899|NCT01443858|Drug|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
360900|NCT01443858|Drug|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
360901|NCT01443845|Drug|Roflumilast|Roflumilast 500 µg, oral administration, once per day
360902|NCT01443845|Drug|Placebo|Dose-matched placebo, oral administration, once per day.
360903|NCT01443832|Dietary Supplement|Fe57 and Fe58-FeSO4 stable isotopes|[57Fe] and [58Fe]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
360904|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.~The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
360978|NCT01443169|Drug|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360906|NCT01443819|Other|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
360907|NCT01443806|Drug|Oseltamivir|75 mg, one time
360908|NCT01443780|Dietary Supplement|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
360909|NCT01443754|Procedure|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:~use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;~minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
360910|NCT01443754|Procedure|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.~Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
360911|NCT01443741|Other|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
360912|NCT01443728|Drug|Experimental: Vitamin D3 100,000 IU|Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
360913|NCT01443728|Drug|Active Comparator: Vitamin D3 12,000 IU|Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
360914|NCT01443715|Behavioral|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
360915|NCT01443715|Behavioral|Treatment as Usual|Standard treatment in the community
360916|NCT01443702|Drug|Lapis Judaicus|2 g capsule per day.
360917|NCT01443702|Drug|Placebo|2 g capsule per day.
360918|NCT01443689|Biological|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
360919|NCT01443689|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
360920|NCT01443689|Drug|Conventional therapy|Participants will be given conventional therapy only.
360921|NCT01443676|Drug|Bevacizumab|Bevacizumab will be added to radiotherapy
360922|NCT01443676|Radiation|Radiation therapy|Radiation therapy
360923|NCT01443663|Biological|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
360924|NCT01443650|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
360925|NCT01443624|Drug|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
360926|NCT01443585|Device|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
360927|NCT01443572|Drug|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
360928|NCT01443572|Drug|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
360929|NCT01443559|Genetic|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
360930|NCT01443559|Genetic|homogenic cornea|homogenic corneas were sterilised by radiation
360931|NCT01443546|Drug|HCG|hCG Trigger
360932|NCT01443546|Drug|Lupron Trigger|leuprolide acetate 2 mg SQ
360933|NCT01443546|Drug|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
360934|NCT01443533|Behavioral|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
360935|NCT01443520|Drug|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
360936|NCT01443520|Drug|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
360937|NCT01443520|Drug|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
360938|NCT01443507|Other|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
360939|NCT01443494|Other|NE|norepinephine
360940|NCT01443481|Drug|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
360941|NCT01443455|Behavioral|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
360979|NCT01443169|Drug|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360980|NCT01443169|Drug|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
360942|NCT01443455|Behavioral|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
360943|NCT01443455|Behavioral|delayed entry control|"Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.~--------------------------------------------------------------------------------"
360944|NCT01443442|Drug|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
360945|NCT01443442|Drug|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
360946|NCT01443429|Drug|beraprost sodium(BPS)|
360947|NCT01443416|Biological|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
360948|NCT01443416|Biological|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
360949|NCT01443403|Drug|Placebo|Matching placebo tablets administered orally once a day.
360950|NCT01443403|Drug|Naldemedine|Naldemedine tablets administered orally once a day.
360951|NCT01443377|Biological|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
360952|NCT01443364|Biological|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
360953|NCT01443338|Drug|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
360954|NCT01443338|Drug|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
360955|NCT01443325|Drug|lidocaine patch|1 patch for 12 hours within each 24 hours period
360956|NCT01443312|Genetic|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
360957|NCT01443273|Other|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
360958|NCT01443260|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
360959|NCT01443247|Drug|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
360960|NCT01443234|Other|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
360961|NCT01443234|Other|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
360962|NCT01443221|Drug|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
360963|NCT01443221|Drug|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
360964|NCT01443208|Drug|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
360965|NCT01443208|Drug|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
360966|NCT01443208|Drug|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
360967|NCT01443195|Drug|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:~Before starting iron supplementation (maximum one week before).~At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).~Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
360968|NCT01443182|Behavioral|STAIR|Skills Training in Affective and Interpersonal Regulation
360969|NCT01443182|Behavioral|MPE|Modified prolonged exposure (MPE)
360970|NCT01443182|Behavioral|EMDR|Eye movement desensitization and reprocessing
360971|NCT01443169|Drug|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360972|NCT01443169|Drug|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360973|NCT01443169|Drug|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360974|NCT01443169|Drug|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
360975|NCT01443169|Drug|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
360976|NCT01443169|Drug|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360977|NCT01443169|Drug|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
360981|NCT01443169|Drug|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360982|NCT01443169|Drug|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360983|NCT01443169|Drug|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
360984|NCT01443169|Drug|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360985|NCT01443169|Drug|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
360986|NCT01443169|Drug|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
360987|NCT01443169|Drug|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360988|NCT01443169|Drug|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360989|NCT01443169|Drug|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
360990|NCT01443169|Drug|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
360991|NCT01443143|Other|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
360992|NCT01443143|Dietary Supplement|Usual Diet|"During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study."
360993|NCT01443130|Drug|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
360994|NCT01443130|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
360995|NCT01443117|Biological|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
360996|NCT01443117|Biological|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
360997|NCT01443117|Biological|Placebo Vaccine|Administered as a 0.5 mL IM dose
360998|NCT01443104|Device|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
360999|NCT01443104|Device|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
361000|NCT01443091|Other|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
361001|NCT01443091|Other|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
361002|NCT01443078|Drug|pemetrexed|
361003|NCT01443078|Drug|cisplatin|
361004|NCT01443078|Drug|Carboplatin|
361005|NCT01443078|Drug|Gemcitabine Hydrochloride|
361006|NCT01443078|Drug|Vinorelbine Tartrate|
361007|NCT01443078|Drug|Docetaxel|
361008|NCT01443065|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
361009|NCT01443065|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
361010|NCT01443065|Drug|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
361011|NCT01443065|Drug|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
361012|NCT01443065|Drug|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
361013|NCT01443052|Other|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
361014|NCT01443039|Drug|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
361015|NCT01443026|Drug|Lycopene 30mg|Lycopene 30 mg.
361016|NCT01443026|Drug|Placebo|Placebo
361017|NCT01443013|Other|Renal Transplant|urinary sample at month 3, 6 and 12
361018|NCT01442987|Drug|Irbesartan/Atorvastatin A|once daily, P.O. 8week
361019|NCT01442987|Drug|Irbesartan|once daily, P.O. 8week
361020|NCT01442987|Drug|Atorvastatin A|once daily, P.O. 8week
361021|NCT01442987|Drug|Placebo|once daily, P.O. 8week
361022|NCT01442987|Drug|Irbesartan/Atorvastatin B|once daily, P.O. 8week
361023|NCT01442987|Drug|Atorvastatin B|once daily, P.O. 8week
361101|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
361024|NCT01442974|Drug|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
361025|NCT01442961|Procedure|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
361026|NCT01442961|Procedure|vaginal : vaginal hysterectomy|Vaginal hysterectomy
361027|NCT01442935|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
361028|NCT01442935|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
361029|NCT01442935|Drug|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
361030|NCT01442935|Drug|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
361031|NCT01442935|Drug|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
361032|NCT01442935|Drug|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
361033|NCT01442935|Drug|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
361034|NCT01442922|Other|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
361035|NCT01442922|Other|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
361036|NCT01442909|Drug|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
361037|NCT01442883|Device|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
361038|NCT01442870|Drug|Metformin|Metformin
361039|NCT01442857|Radiation|MRI|High resolution MRI of the brachial plexus
361040|NCT01442844|Device|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
361041|NCT01442831|Drug|Human ADME|Oral single dose
361042|NCT01442818|Drug|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
361043|NCT01442818|Drug|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
361044|NCT01442805|Behavioral|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
361045|NCT01442805|Behavioral|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
361046|NCT01442792|Drug|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
361047|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
361048|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
361049|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
361050|NCT01442779|Drug|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
361051|NCT01442766|Drug|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
361052|NCT01442766|Drug|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
361053|NCT01442753|Behavioral|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
361054|NCT01442740|Procedure|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
361055|NCT01442727|Drug|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
361056|NCT01442727|Drug|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
361057|NCT01442714|Drug|Azacitidine|Azacitidine is a chemical analogue of the cytosine nucleoside used in DNA and RNA. Azacitidine is thought to induce antineoplastic activity via two mechanisms; inhibition of DNA methyltransferase at low doses, causing hypomethylation of DNA, and direct cytotoxicity in abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA at high doses, resulting in cell death
361058|NCT01442714|Drug|Lenalidomide|Lenalidomide has been used to successfully treat both inflammatory disorders and cancers. In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulatory role. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity.
361059|NCT01442701|Other|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
361060|NCT01442688|Drug|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
361061|NCT01442688|Drug|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
361062|NCT01442675|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
361063|NCT01442662|Drug|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
361064|NCT01442649|Drug|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
361065|NCT01442649|Drug|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
361066|NCT01442649|Drug|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
361067|NCT01442649|Drug|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
361068|NCT01442649|Drug|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
361069|NCT01442649|Drug|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
361070|NCT01442636|Device|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
361071|NCT01442623|Other|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.~Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
361072|NCT01442610|Drug|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
361073|NCT01442610|Drug|Placebo|Placebo 1tablet once daily for 8 weeks
361074|NCT01442597|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
361075|NCT01442597|Behavioral|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
361076|NCT01442597|Behavioral|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
361077|NCT01442584|Procedure|ovarian transplantation|ovarian transplantation
361078|NCT01442571|Device|Hyaluronic Acid Injection|
361079|NCT01442571|Drug|Saline Injection|
361080|NCT01442558|Drug|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
361081|NCT01442545|Drug|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
361082|NCT01442532|Drug|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
361083|NCT01442532|Drug|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
361084|NCT01442532|Drug|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
361085|NCT01442532|Drug|Placebo|Form=tablet, route=oral use, for 14 days
361086|NCT01442532|Drug|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
361087|NCT01442519|Biological|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
361088|NCT01442519|Drug|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
361089|NCT01442506|Other|biopsies|taking biopsies
361090|NCT01442506|Other|biopsy|biopsy
361091|NCT01442493|Other|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
361092|NCT01442493|Other|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
361093|NCT01442480|Dietary Supplement|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
361094|NCT01442480|Dietary Supplement|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
361095|NCT01442454|Other|chronic pancreatitis|No intervention, subjects followed through surgery
361096|NCT01442428|Drug|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
361097|NCT01442428|Drug|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
361098|NCT01442428|Drug|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
361099|NCT01442428|Drug|Placebo|Atorvastatin placebo
361100|NCT01442415|Behavioral|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
361103|NCT01442376|Drug|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
361104|NCT01442376|Drug|Placebo to Ondansetron|
361105|NCT01442376|Drug|Placebo to Ondansetron|
361106|NCT01442376|Drug|Placebo to Palonosetron|
361107|NCT01442363|Drug|BLI-1300 low dose|topical ointment
361108|NCT01442363|Drug|BLI-1300 high dose|topical ointment
361109|NCT01442363|Drug|placebo|topical ointment
361110|NCT01442337|Drug|ASP8597|one time IV dose
361111|NCT01442337|Drug|Placebo|one time IV dose
361112|NCT01442324|Procedure|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
361113|NCT01442311|Other|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
361114|NCT01442311|Other|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
361115|NCT01442298|Procedure|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
361116|NCT01442298|Procedure|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
361117|NCT01442285|Behavioral|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
361118|NCT01442272|Drug|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
361119|NCT01442272|Drug|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
361120|NCT01442272|Drug|Habitual medication|Habitual medication
361121|NCT01442259|Drug|AFQ056|
361122|NCT01442246|Drug|Leuprorelin Acetate|Leuprorelin Acetate 45mg, one injection every 6 months for 24 months
361123|NCT01442233|Procedure|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
361124|NCT01442233|Procedure|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
361125|NCT01442207|Procedure|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
361126|NCT01442207|Procedure|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:~Standard management for placenta previa.~Hospital admission for vaginal bleeding/hemorrhage~Antenatal corticosteroids > 24w0d of gestation~Tocolytic therapy per physician's discretion~Magnesium sulfate for neuroprotection~Fetal Heart Rate Monitoring~Avoidance of digital examinations of the cervix~Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM > 34 wks, worsening maternal or fetal condition )~Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
361127|NCT01442194|Drug|other disease-modifying therapy|
361128|NCT01442194|Drug|Fingolimod|
361129|NCT01442181|Procedure|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
361130|NCT01442181|Other|Medical therapy|Patients are treated with rhythm and rate control medications.
361131|NCT01442168|Drug|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
361132|NCT01442168|Drug|atovaquone/proquanil|malanil according to label
361133|NCT01442155|Drug|Capecitabine|Administered according to the Summary of Product Characteristics.
361134|NCT01442155|Biological|Oxaliplatin|Administered according to the Summary of Product Characteristics.
361135|NCT01442142|Behavioral|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
361136|NCT01442142|Behavioral|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
361137|NCT01442142|Behavioral|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
361138|NCT01442129|Biological|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
361139|NCT01442129|Biological|Control Solution|Injection of control solution during the LVAD implantation.
361140|NCT01442116|Procedure|stress echocardiography|safety and efficacy of stress echocardiography
361141|NCT01442103|Device|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
361142|NCT01442090|Drug|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
361143|NCT01442090|Drug|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
361181|NCT01441856|Procedure|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
361144|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
361145|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
361146|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
361147|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
361148|NCT01442064|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
361149|NCT01442051|Procedure|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB < 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB <7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
361150|NCT01442038|Drug|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
361151|NCT01442038|Drug|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.~Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
361152|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
361153|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
361154|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
361155|NCT01442012|Other|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
361156|NCT01441999|Device|Less rigid rod|Titanium rod with semi rigid end
361157|NCT01441999|Device|Rigid Rod|Rigid Titanium rods
361158|NCT01441986|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
361159|NCT01441986|Drug|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
361160|NCT01441986|Drug|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
361161|NCT01441986|Drug|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
361162|NCT01441973|Biological|Elotuzumab (BMS-901608; HuLuc63)|
361163|NCT01441960|Drug|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
361164|NCT01441960|Drug|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
361165|NCT01441947|Drug|Cabozantinib|Part of combination arm
361166|NCT01441947|Drug|Fulvestrant|part of combination arm
361167|NCT01441934|Drug|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
361168|NCT01441934|Drug|Sugar pills|placebo t.i.d.
361169|NCT01441921|Dietary Supplement|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
361170|NCT01441921|Other|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.~Total duration of intervention and follow-up is nine months."
361171|NCT01441908|Drug|Pravastatin|40mg or 80mg dose 28 days for 6 month period
361172|NCT01441882|Drug|Dasatinib|Given PO
361173|NCT01441882|Other|Laboratory Biomarker Analysis|Correlative studies
361174|NCT01441882|Other|Pharmacological Study|Correlative studies
361175|NCT01441869|Drug|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
361176|NCT01441869|Drug|Diabex|Extended release oral tablets, 1000 mg, single dose
361177|NCT01441869|Drug|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
361178|NCT01441869|Drug|Diabex|Extended release oral tablets, 500 mg, single dose
361179|NCT01441869|Drug|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
361180|NCT01441856|Procedure|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
361182|NCT01441843|Drug|Lorazepam|Once 1mg <75kg body weight, 1.5mg 75kg and >75kg body weight, IV, before surgery
361183|NCT01441843|Drug|NaCl 0.9% (Sodium Chloride)|Once 1ml <75kg body weight, 1.5ml 75kg or >75kg body weight, IV, before surgery
361184|NCT01441830|Device|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
361185|NCT01441817|Procedure|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
361186|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
361187|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
361188|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
361189|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
361190|NCT01441791|Procedure|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
361191|NCT01441778|Drug|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
361192|NCT01441778|Drug|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
361193|NCT01441765|Drug|CT-011|CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
361194|NCT01441765|Biological|DC/RCC fusion vaccine|Vaccination once per cycle on Day 8 of treatment cycles 2-4
361195|NCT01441752|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
361196|NCT01441752|Drug|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
361197|NCT01441700|Procedure|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
361198|NCT01441687|Other|laboratory biomarker analysis|Correlative studies
361199|NCT01441687|Procedure|transrectal prostate biopsy|Undergo prostate biopsy
361200|NCT01441674|Behavioral|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
361201|NCT01441648|Other|contact lens wear|tinted contact lens wear
361202|NCT01441635|Other|Placebo|Placebo
361203|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 1
361204|NCT01441635|Other|Placebo|Placebo
361205|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 2
361206|NCT01441635|Drug|Elagolix Dose 1 plus estradiol/norethindrone acetate|Elagolix Dose 1 plus estradiol/norethindrone acetate
361207|NCT01441635|Other|Placebo|Placebo
361208|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 3
361209|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 4
361210|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 5
361211|NCT01441635|Drug|Elagolix Dose 2 plus estradiol|Elagolix Dose 2 plus estradiol
361212|NCT01441635|Drug|Elagolix Dose 2 plus cyclical progesterone|Elagolix Dose 2 plus cyclical progesterone
361213|NCT01441622|Device|AL539 (SRETT)|recording data with AL539 (SRETT)
361214|NCT01441596|Drug|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
361215|NCT01441596|Drug|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
361216|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
361217|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
361218|NCT01441583|Device|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
361219|NCT01441583|Device|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
361220|NCT01441570|Drug|Nebivolol|Subject will take nebivolol daily for 12 weeks.
361221|NCT01441570|Drug|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
361222|NCT01441557|Drug|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
361223|NCT01441544|Behavioral|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
361224|NCT01441531|Drug|gabapentin 600 mg po|Given one hour before surgery
361225|NCT01441531|Drug|Placebo pill given one hour before surgery|Placebo pill given
361226|NCT01441518|Other|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
361227|NCT01441518|Other|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.~The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.~All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
361228|NCT01441505|Drug|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
361229|NCT01441505|Drug|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
361230|NCT01441492|Procedure|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
361231|NCT01441492|Procedure|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
361232|NCT01441479|Device|In Vitro Diagnostic Device aid in diagnosing|
361233|NCT01441466|Other|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
361234|NCT01441453|Procedure|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
361235|NCT01441440|Drug|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
361236|NCT01441440|Drug|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
361237|NCT01441440|Drug|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
361238|NCT01441427|Drug|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
361239|NCT01441427|Drug|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
361240|NCT01441427|Drug|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
361241|NCT01441427|Drug|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
361242|NCT01441427|Drug|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
361243|NCT01441414|Biological|PF-04856884|15 mg/kg/week intravenously [IV] until toxicity or disease progression
361244|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
361245|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
361246|NCT01441401|Drug|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
361247|NCT01441388|Drug|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
361248|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
361249|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
361250|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
361251|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
361252|NCT01441388|Drug|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
361253|NCT01441388|Drug|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
361254|NCT01441362|Procedure|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
361255|NCT01441362|Procedure|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
361256|NCT01441349|Drug|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy~Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8.~Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 & 8~Every 21 days"
361257|NCT01441349|Drug|IP chemotherapy plus simvastatin|"Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8~Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1& 8.~Every 21days.~Simvastatin 40 mg per day orally D1of cycle 1"
361258|NCT01441336|Procedure|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
361259|NCT01441323|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
361260|NCT01441323|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
361261|NCT01441310|Procedure|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
361262|NCT01441297|Drug|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
361263|NCT01441284|Drug|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
361264|NCT01441284|Drug|placebo|placebo
361265|NCT01441271|Procedure|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution [GoLytely®; Braintree Laboratories] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes [500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days] via a Malecot catheter [24 French] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole [500mg q8 hours] for 10 days.
361266|NCT01441271|Procedure|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
361267|NCT01441258|Behavioral|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
361268|NCT01441258|Behavioral|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
361269|NCT01441258|Behavioral|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
361270|NCT01441245|Drug|furosemide infusion|Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
361271|NCT01441232|Drug|LX4211|400 mg of LX4211 administered as two 200 mg tablets
361272|NCT01441232|Drug|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
361273|NCT01441219|Device|Colon 2|Ingest one colon 2 capsule
361274|NCT01441206|Drug|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)~Cohort 1:~Dosing will be as follows:~GA at birth < 32 weeks - PNA < 14 days: 10 mg/kg QD GA at birth < 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA < 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
361275|NCT01441193|Biological|HIV-1 Tat/delta-V2 Env combined vaccine|
361276|NCT01441193|Biological|HIV-1 delta-V2 Env vaccine|
361277|NCT01441193|Biological|HIV-1 Tat vaccine 7.5 microg|
361278|NCT01441193|Biological|HIV-1 Tat vaccine 30 microg|
361279|NCT01441180|Drug|GS7977|drug intervention
361280|NCT01441180|Drug|RBV|drug intervention
361281|NCT01441167|Biological|PfSPZ|
361282|NCT01441128|Drug|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
361283|NCT01441128|Drug|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
361284|NCT01441115|Procedure|Radiation Therapy|
361285|NCT01441115|Drug|ECI301|
361286|NCT01441102|Drug|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
361287|NCT01441076|Drug|Anakinra|Anakinra/Kineret[registered] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
361288|NCT01441063|Drug|Zidovudine|Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)
361289|NCT01441063|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks
361290|NCT01441063|Drug|Valganciclovir (VGC)|Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
361291|NCT01441037|Drug|Danazol|Danazol, 800 mg daily by mouth for 2 years
361292|NCT01441024|Drug|DAS181|20 mg per day of DAS181-FO3 for 5 days
361293|NCT01441024|Other|Placebo|20 mg per day of Lactose for 5 days
361294|NCT01441011|Behavioral|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
361295|NCT01441011|Behavioral|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
361296|NCT01440998|Drug|Carboplatin|Given IV
361297|NCT01440998|Drug|Dasatinib|Given PO
361298|NCT01440998|Other|Laboratory Biomarker Analysis|Correlative studies
361299|NCT01440998|Drug|Paclitaxel|Given IV
361300|NCT01440985|Drug|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
361301|NCT01440985|Drug|Nicotine|Nicotine gum 4 mg, Lot number GC962A
361302|NCT01440985|Drug|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
361303|NCT01440972|Other|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
361304|NCT01440972|Other|low intensity resistance training|low intensity resistance training without partial blood flow restriction
361305|NCT01440959|Drug|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
361306|NCT01440946|Drug|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
361307|NCT01440946|Drug|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
361308|NCT01440933|Drug|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
361309|NCT01440933|Drug|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
361310|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
361311|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
361312|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
361313|NCT01440907|Other|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
361314|NCT01440894|Device|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.~DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
361315|NCT01440881|Drug|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
361316|NCT01440881|Drug|Placebo|infuses at 0.01MCG/KG/min for 48 hours
361317|NCT01440868|Procedure|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher & Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm ).
361318|NCT01440855|Other|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
361319|NCT01440855|Other|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
361320|NCT01440842|Other|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
361321|NCT01440842|Other|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
361322|NCT01440829|Drug|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
361323|NCT01440816|Biological|Tavokinogene Telseplasmid (tavo)|Patients received intratumoral injection(s) of tavo.
361324|NCT01440816|Device|OncoSec Medical System (OMS)|Electroporation via OMS was performed immediately following intratumoral injection of tavo. A sterile applicator containing 6 stainless steel electrodes arranged in a circle were placed around the tumor. The applicator was connected to the OMS power supply and six pulses were administered to each tumor lesion at the approximate point of tavo injection.
361325|NCT01440803|Drug|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
361326|NCT01440803|Drug|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
361327|NCT01440790|Dietary Supplement|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
361328|NCT01440790|Dietary Supplement|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
361329|NCT01440790|Dietary Supplement|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
361330|NCT01440790|Dietary Supplement|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
361331|NCT01440777|Behavioral|Go! to Sleep|"The online program provides various tools for the delivery of the intervention including:~Daily articles~Daily activities to help get the sleep you need~Daily sleep improvement recommendations~Audio recorded relaxation exercises~Daily e-mails from your program coach~Personal progress charts~An online sleep log and daily sleep score"
361332|NCT01440764|Drug|Furosemide|
361333|NCT01440764|Drug|Saline|
361334|NCT01440751|Device|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
361400|NCT01440257|Drug|Placebo|Placebo capsules once daily
361401|NCT01440257|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
362235|NCT01433913|Drug|metformin hydrochloride|Given PO
361335|NCT01440751|Drug|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
361336|NCT01440738|Behavioral|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
361337|NCT01440725|Biological|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
361338|NCT01440725|Procedure|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
361339|NCT01440712|Drug|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
361340|NCT01440712|Drug|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
361341|NCT01440699|Biological|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
361342|NCT01440686|Drug|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
361343|NCT01440686|Drug|Placebo|Tablets, oral administrations
361344|NCT01440673|Drug|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
361345|NCT01440647|Procedure|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
361346|NCT01440647|Procedure|Extubation to CPAP|After extubation infants were placed on CPAP
361347|NCT01440634|Other|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
361348|NCT01440621|Drug|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
361349|NCT01440621|Drug|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
361350|NCT01440608|Drug|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
361351|NCT01440608|Drug|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
361352|NCT01440608|Dietary Supplement|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
361353|NCT01440595|Drug|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
361354|NCT01440595|Drug|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
361355|NCT01440595|Drug|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
361356|NCT01440595|Drug|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
361357|NCT01440582|Drug|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.~Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.~Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.~Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
361358|NCT01440582|Drug|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 1.3 mg/m^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
361359|NCT01440582|Drug|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.~Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
361360|NCT01440582|Drug|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.~Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.~Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
361361|NCT01440582|Behavioral|Symptom Questionnaire|Completed on day 1 of each cycle.
361362|NCT01440569|Drug|COBI|150 mg tablet administered orally with food once daily
361363|NCT01440569|Drug|DRV|800 mg (2 x 400 mg tablets) administered orally with food once daily
361364|NCT01440569|Drug|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
361365|NCT01440543|Procedure|Water immersion insertion AND CO2 insufflation|"room temperature water infused by water pump into the colon just to facilitate scope insertion~CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection"
361366|NCT01440543|Procedure|Water immersion insertion|"room temperature water infused by water pump into the colon just to facilitate scope insertion~standard room air insufflation during colonoscope withdrawal and mucosal inspection"
361367|NCT01440543|Procedure|CO2 insufflation|- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
361442|NCT01439958|Drug|Inhalation|Twice daily inhalation for a maximum of three years.
361368|NCT01440530|Behavioral|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
361369|NCT01440530|Other|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
361370|NCT01440517|Drug|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
361371|NCT01440504|Other|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
361372|NCT01440491|Other|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
361373|NCT01440478|Drug|LY2140023|Administered orally
361374|NCT01440478|Drug|Ammonium chloride|Administered orally
361375|NCT01440478|Drug|Sodium bicarbonate|Administered orally
361376|NCT01440452|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
361377|NCT01440452|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
361378|NCT01440452|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
361379|NCT01440452|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
361380|NCT01440439|Drug|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
361381|NCT01440439|Drug|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
361382|NCT01440426|Procedure|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
361383|NCT01440426|Device|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
361384|NCT01440413|Biological|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.~Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
361385|NCT01440400|Procedure|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
361386|NCT01440387|Biological|FLULAVAL® QUADRIVALENT|Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
361387|NCT01440374|Drug|eltrombopag|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
361388|NCT01440374|Drug|placebo|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
361389|NCT01440361|Drug|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
361390|NCT01440361|Drug|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
361391|NCT01440348|Procedure|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
361392|NCT01440335|Drug|Oral R,R'-Fenoterol|
361393|NCT01440335|Drug|Oral Racemic Fenoterol|
361394|NCT01440322|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
361395|NCT01440322|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
361396|NCT01440309|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
361397|NCT01440309|Drug|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
361398|NCT01440283|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
361399|NCT01440270|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy"
362236|NCT01433913|Other|placebo|Given PO
361402|NCT01440244|Procedure|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
361403|NCT01440231|Drug|Placebo|Matching placebo administered by subcutaneous injection, once weekly
361404|NCT01440231|Drug|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
361405|NCT01440231|Drug|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
361406|NCT01440231|Drug|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
361407|NCT01440231|Drug|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
361408|NCT01440205|Behavioral|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
361409|NCT01440205|Behavioral|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
361410|NCT01440205|Behavioral|Control|No check box element
361411|NCT01440192|Biological|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 & 8
361412|NCT01440179|Drug|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
361413|NCT01440166|Drug|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
361414|NCT01440166|Other|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
361415|NCT01440153|Other|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
361416|NCT01440153|Other|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
361417|NCT01440140|Other|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
361418|NCT01440140|Other|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
361419|NCT01440127|Drug|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
361420|NCT01440114|Drug|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
361421|NCT01440114|Drug|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
361422|NCT01440101|Drug|Natalizumab (BG00002)|
361423|NCT01440101|Drug|Placebo|
361424|NCT01440088|Drug|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.~Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
361425|NCT01440088|Drug|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.~Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.~Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
361426|NCT01440075|Other|Cardiac evaluation|"complete cardiac evaluation with :~Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
361427|NCT01440062|Drug|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
361428|NCT01440062|Drug|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
361429|NCT01440049|Other|Prospective Observational|this is an observational study non interventional
361430|NCT01440036|Procedure|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
361431|NCT01440023|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
361432|NCT01440023|Behavioral|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
361433|NCT01440023|Behavioral|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
361434|NCT01440010|Radiation|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
361435|NCT01439997|Drug|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
361436|NCT01439984|Drug|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
361437|NCT01439971|Biological|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
361438|NCT01439971|Biological|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
361439|NCT01439971|Biological|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
361440|NCT01439971|Biological|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
361441|NCT01439971|Biological|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
361445|NCT01439932|Device|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people [Andrew 1987]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). [Linda et al 2007]"
361446|NCT01439919|Drug|SSR411298|"Form: tablet~Route: oral administration with food"
361447|NCT01439919|Drug|Placebo (for SSR411298)|"Form: tablet~Route: oral administration with food"
361448|NCT01439906|Procedure|Surgical correction of the deformity|"Three different surgical techniques are used:~lumbar fusion vs thoraco-lumbar fusion~iliac fixation vs fixation to the sacrum~posterior + interbody fusion vs posterior interbody fusion"
361449|NCT01439893|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
361450|NCT01439893|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
361451|NCT01439880|Biological|Evolocumab|Administered by subcutaneous injection
361452|NCT01439880|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
361453|NCT01439867|Drug|Cinacalcet hydrochloride|Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
361454|NCT01439867|Drug|Standard of Care|Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
361455|NCT01439854|Drug|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
361456|NCT01439854|Drug|Placebo|Patients are treated with placebo
361457|NCT01439841|Dietary Supplement|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
361458|NCT01439841|Dietary Supplement|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
361459|NCT01439828|Drug|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
361460|NCT01439815|Drug|Fluticasone Propionate Nasal Spray|50 mcg QD
361461|NCT01439815|Drug|Saline Nasal Spray|two sprays in each nostril once daily
361462|NCT01439802|Device|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
361463|NCT01439789|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
361464|NCT01439789|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
361465|NCT01439776|Dietary Supplement|Vit D|800IU/day
361466|NCT01439750|Drug|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
361467|NCT01439750|Drug|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
361468|NCT01439750|Drug|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
361469|NCT01439724|Device|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
361470|NCT01439724|Device|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
361471|NCT01439711|Drug|letrozole|
361472|NCT01439711|Procedure|MRI|
361473|NCT01439711|Procedure|conventional surgery|
361474|NCT01439698|Device|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
361475|NCT01439672|Dietary Supplement|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to ~100mg/dl at 1100.
361476|NCT01439659|Behavioral|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
361477|NCT01439659|Dietary Supplement|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
361478|NCT01439646|Other|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
361479|NCT01439633|Device|MGH OFDI marking|Imaging of esophagus with OFDI system
361715|NCT01437826|Drug|placebo|placebo had an identical appearance as intervention
361480|NCT01439620|Device|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
361481|NCT01439607|Other|Bone marrow and blood sampling|Bone marrow and blood sampling
361482|NCT01439594|Device|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
361483|NCT01439581|Device|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
361484|NCT01439581|Device|Non-Mapping System|Standard ICU bed with no mapping system
361485|NCT01439568|Drug|LY2510924|Administered subcutaneous injection
361486|NCT01439568|Drug|Carboplatin|Administered intravenously
361487|NCT01439568|Drug|Etoposide|Administered intravenously
361488|NCT01439555|Drug|Simvastatin|Simvastatin, 40 mg per day orally
361489|NCT01439555|Drug|L-Arginine|L-Arginine, 2 Gm four times per day orally;
361490|NCT01439555|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin 20 mg/kg/day orally
361491|NCT01439542|Radiation|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
361492|NCT01439542|Drug|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
361493|NCT01439529|Other|Device programming: nominal|CRT device is programmed to nominal values
361494|NCT01439529|Other|Programming optimization by QRS|CRT device is programmed by QRS optimization
361495|NCT01439516|Behavioral|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
361496|NCT01439503|Behavioral|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
361497|NCT01439490|Other|FES-PET|Patients undergo FES-PET prior to obtaining histology
361498|NCT01439464|Device|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
361499|NCT01439464|Device|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
361500|NCT01439451|Procedure|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
361501|NCT01439438|Drug|Topiramate coated tablet|Test formulation
361502|NCT01439438|Drug|Topamax® coated tablet|Reference formulation
361503|NCT01439425|Behavioral|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
361504|NCT01439412|Procedure|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.~In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.~The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
361505|NCT01439412|Other|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
361506|NCT01439399|Drug|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
361507|NCT01439399|Drug|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
361508|NCT01439399|Drug|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
361509|NCT01439399|Drug|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
361510|NCT01439386|Procedure|Catheter ablation|PVAI with or without CTI ablation
361511|NCT01439386|Procedure|Catheter ablation|CTI ablation only
361512|NCT01439373|Drug|GSK2336805|Active Investigational Drug
361513|NCT01439373|Drug|Pegylated interferon alfa-2a|Standard of Care drug
361514|NCT01439373|Drug|Ribavirin|Standard of Care drug
361515|NCT01439373|Drug|GSK2336805 Matching Placebo|Placebo of Investigational Drug
361516|NCT01439360|Biological|Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A|Intramuscular injection
361517|NCT01439360|Biological|Havrix Junior|Intramuscular injection administered to subjects aged 12 months or older
361518|NCT01439360|Biological|Prevenar 13|Intramuscular injection administered to subjects less than 12 months of age
361519|NCT01439360|Biological|Varivax/ProVarivax|Intramuscular injection administered to subjects more than 12 months of age
361520|NCT01439360|Biological|Varilrix|Subcutaneous injection administered to subjects more than 12 months of age
361521|NCT01439347|Drug|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m2 (without any dose cap) as an IV infusion over 60 minutes
361522|NCT01439347|Drug|Vincristine Sulfate Injection (VSI)|1.4 mg/m2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes
361523|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
361872|NCT01436513|Drug|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
361524|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
361525|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
361526|NCT01439321|Biological|Eltrombopag|Switched to Eltrombopag
361527|NCT01439321|Biological|Romiplostim|Switched to Romiplostim
361528|NCT01439308|Drug|Placebo|SB-705498 placebo
361529|NCT01439308|Drug|SB-705498|12mg intranasal SB-705498
361530|NCT01439282|Drug|eribulin mesylate|Cohort I & II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
361531|NCT01439282|Drug|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
361532|NCT01439269|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
361533|NCT01439256|Behavioral|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
361534|NCT01439256|Other|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
361535|NCT01439243|Drug|Donepezil|10 mg Tablet
361536|NCT01439243|Drug|Aricept®|10 mg Tablet
361537|NCT01439230|Drug|Donepezil|10 mg Tablet
361538|NCT01439230|Drug|Aricept®|10 mg Tablet
361539|NCT01439204|Biological|Abatacept (BMS-188667)|Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
361540|NCT01439191|Drug|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
361541|NCT01439191|Drug|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
361542|NCT01439178|Drug|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
361543|NCT01439165|Biological|Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|0.5 mL, Intramuscular
361544|NCT01439165|Biological|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
361545|NCT01439152|Drug|BAY94-9343|BAY94-9343 will be administered intravenously in this study. The starting dose for this first-in-man study is 0.15 mg/kg administered as a 1 hour infusion every 21 days.
361546|NCT01439152|Drug|BAY94-9343 (Expansion)|BAY94-9343 will be administered intravenously in this study. The dose for this expansion cohort is 5.5mg/kg administered as a 1 hour infusion every 21 days
361547|NCT01439152|Drug|BAY94-9343 (1.8 mg/kg)|BAY94-9343 will be administered intravenously in this study. The dose for this cohort is 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
361548|NCT01439152|Drug|BAY94-9343 (2.2 mg/kg)|BAY94-9343 will be administered intravenously in this study. The dose for this cohort is 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
361549|NCT01439126|Drug|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
361550|NCT01439126|Drug|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
361551|NCT01439113|Procedure|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
361552|NCT01439100|Drug|Oxycodone/Naloxone Prolonged Release tablets|
361553|NCT01439100|Drug|Placebo|Dummy tablet
361554|NCT01439087|Device|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
361555|NCT01439074|Device|Mepilex Ag|Dressing
361556|NCT01439074|Drug|Silver Sulphadiazine Ag cream|A cream used on burnt areas.
361557|NCT01439061|Device|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
361558|NCT01439035|Device|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
361559|NCT01439022|Behavioral|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
361560|NCT01439022|Behavioral|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
361561|NCT01439009|Drug|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
361562|NCT01439009|Drug|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
361563|NCT01438996|Biological|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
361564|NCT01438970|Device|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
361565|NCT01438957|Drug|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
361566|NCT01438957|Drug|Placebo|
361567|NCT01438944|Drug|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
361568|NCT01438931|Drug|DA-9501|Dexmedetomidine hydrochloride variable dose
361569|NCT01438931|Drug|placebo|
361570|NCT01438918|Drug|SD-6010|200 mg tablets once a day for 2 years
361571|NCT01438918|Drug|SD-6010|50 mg tablets once a day for 2 years
361572|NCT01438918|Drug|Placebo|Placebo tablets once a day for 2 years
362237|NCT01433913|Other|laboratory biomarker analysis|Correlative studies
361573|NCT01438905|Other|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
361574|NCT01438905|Other|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
361575|NCT01438892|Drug|tDMARDs|Traditional DMARDs for RA
361576|NCT01438892|Drug|biodmards|Biologic DMARDs
361577|NCT01438866|Other|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
361578|NCT01438866|Other|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
361579|NCT01438853|Biological|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
361580|NCT01438853|Drug|Placebo|Single intravenous dose of saline control
361581|NCT01438840|Drug|Avatrombopag|
361582|NCT01438840|Drug|Placebo|
361583|NCT01438840|Drug|Standard of care|"Permitted ITP concomitant background therapies are as follows:~Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport [P-gp] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
361584|NCT01438827|Drug|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
361585|NCT01438827|Drug|Placebo|Suspension for Injection, Every 6 weeks for one year
361586|NCT01438814|Drug|metformin placebo|metformin placebo tablets 500mg
361587|NCT01438814|Drug|linagliptin placebo|linagliptin placebo tablets 5mg
361588|NCT01438814|Drug|metformin|metformin tablets 500mg
361589|NCT01438814|Drug|metformin|metformin tablets 500 mg
361590|NCT01438814|Drug|linagliptin|linagliptin tablets 5mg
361591|NCT01438801|Drug|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS <0).
361592|NCT01438788|Other|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
361593|NCT01438775|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
361594|NCT01438762|Behavioral|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
361595|NCT01438762|Other|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.~In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
361596|NCT01438749|Drug|Placebo|Single dose
361597|NCT01438749|Drug|RO4917838|Single doses (3 dose levels)
361598|NCT01438749|Drug|diazepam|Single dose
361599|NCT01438736|Drug|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
361600|NCT01438736|Drug|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
361601|NCT01438723|Drug|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
361602|NCT01438723|Drug|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
361603|NCT01438710|Drug|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
361604|NCT01438710|Drug|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
361605|NCT01438697|Behavioral|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
361606|NCT01438697|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
361607|NCT01438684|Drug|RPh201|400 microliter s.c. twice a week for 3 months
361608|NCT01438684|Drug|Saline|400 microliter Saline solution s.c. twice a week for 3 months
361609|NCT01438671|Procedure|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
361610|NCT01438671|Procedure|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
361611|NCT01438645|Device|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
361612|NCT01438632|Device|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
361613|NCT01438606|Biological|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
361614|NCT01438606|Biological|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
361615|NCT01438593|Procedure|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
361616|NCT01438580|Drug|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
361617|NCT01438580|Drug|aspirin|100mg aspirin was administrated every day
361618|NCT01438567|Drug|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
361619|NCT01438567|Drug|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
361620|NCT01438554|Drug|Pazopanib|
361621|NCT01438554|Drug|GSK1120212|
361622|NCT01438541|Device|Window|Dressing
361623|NCT01438528|Device|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
361624|NCT01438515|Drug|Rifampin|600mg po once daily x 7 days
361625|NCT01438515|Drug|Doxycycline|100mg po twice daily x 7 days
361626|NCT01438515|Other|2% mupirocin ointment|~ 1cm applied to the anterior nares twice daily for 7 days
361627|NCT01438515|Other|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
361628|NCT01438502|Drug|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
361629|NCT01438489|Biological|Anifrolumab 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
361630|NCT01438489|Biological|Anifrolumab 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
361631|NCT01438489|Other|Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
361632|NCT01438476|Procedure|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
361633|NCT01438476|Procedure|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
361634|NCT01438476|Behavioral|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
361635|NCT01438476|Behavioral|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
361636|NCT01438463|Biological|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
361637|NCT01438463|Biological|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
361638|NCT01438463|Biological|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
361639|NCT01438463|Biological|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
361640|NCT01438463|Biological|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
361641|NCT01438450|Drug|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.~Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
361642|NCT01438450|Other|Supportive|No specific therapy will be given
361643|NCT01438437|Procedure|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
361644|NCT01438437|Procedure|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
361645|NCT01438424|Drug|Entecavir|Tablets, Oral, 1.0 mg, once daily
361646|NCT01438424|Drug|Lamivudine|Oral, 100 mg, daily
361647|NCT01438411|Drug|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
361648|NCT01438398|Procedure|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
361649|NCT01438398|Procedure|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
361650|NCT01438385|Procedure|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
361651|NCT01438372|Drug|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
361652|NCT01438372|Drug|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
361653|NCT01438359|Drug|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
361654|NCT01438359|Drug|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
361655|NCT01438359|Drug|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
361656|NCT01438346|Behavioral|Substance Abuse Education|10 weeks of usual care for substance abuse.
361657|NCT01438346|Behavioral|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
361658|NCT01438333|Dietary Supplement|lactobacillus brevis tablets|5 tablets a day for 6 weeks
361659|NCT01438333|Dietary Supplement|PLACEBO|5 tablets a day for 6 weeks
361660|NCT01438320|Dietary Supplement|Quercetin|Bioflavonoid
361661|NCT01438307|Drug|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
361662|NCT01438307|Drug|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
361663|NCT01438294|Other|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
361664|NCT01438294|Other|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
361665|NCT01438281|Drug|SYL1001|SYL1001 eye drops. topical administration
361666|NCT01438242|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
361667|NCT01438229|Device|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
361668|NCT01438203|Procedure|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
361669|NCT01438203|Procedure|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
361670|NCT01438190|Drug|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
361671|NCT01438190|Drug|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
361672|NCT01438177|Drug|Velcade|
361673|NCT01438177|Drug|Cyclophosphamide|
361674|NCT01438177|Drug|Chloroquine|
361716|NCT01437813|Drug|Glimepiride/extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
361675|NCT01438151|Drug|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
361676|NCT01438138|Other|diagnostic laboratory biomarker analysis|Correlative studies
361677|NCT01438125|Other|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
361678|NCT01438125|Other|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
361679|NCT01438112|Biological|CG0070 adenovirus vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
361680|NCT01438112|Other|Control Arm: Quadruple Choice|"Quadruple Choice Treatment Options:~I. Mitomycin C II. Interferon III. Valrubicin IV. Gemcitabine"
361681|NCT01438086|Drug|mecasermin|Intracoronary bolus
361682|NCT01438086|Drug|mecasermin|Intracoronary bolus
361683|NCT01438086|Drug|0.9% sodium chloride injection|Intracoronary bolus
361684|NCT01438073|Drug|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
361685|NCT01438073|Drug|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
361686|NCT01438060|Drug|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
361687|NCT01438060|Drug|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
361688|NCT01438034|Drug|kisspeptin 112-121|0.24 nmol/kg
361689|NCT01438034|Drug|GnRH|75 ng/kg
361690|NCT01438021|Other|pharmacological study|Correlative studies
361691|NCT01438021|Drug|methotrexate|Given intraventricularly
361692|NCT01438008|Drug|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
361693|NCT01438008|Drug|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
361694|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
361695|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
361696|NCT01437995|Drug|Fluticasone Diskus|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
361697|NCT01437982|Drug|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
361698|NCT01437982|Drug|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
361699|NCT01437969|Genetic|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
361700|NCT01437943|Drug|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
361701|NCT01437943|Drug|Placebo|Take 1 tablet (0 mg) daily for 180 days.
361702|NCT01437930|Dietary Supplement|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder~linseed oil (20g/d)(PPM, Magdeburg)~echium oil (20g/d) (HARKE Nutrition)~microalgae powder(12g/d)(HARKE Nutrition)"
361703|NCT01437917|Other|20% amylose bread|20% amylose bread
361704|NCT01437917|Dietary Supplement|10% amylose bread|10% amylose bread
361705|NCT01437917|Dietary Supplement|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
361706|NCT01437904|Procedure|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
361707|NCT01437904|Procedure|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
361708|NCT01437878|Drug|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
361709|NCT01437878|Drug|Placebo|matching placebo
361710|NCT01437865|Drug|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
361711|NCT01437852|Biological|StrataGraft Skin Tissue|
361712|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
361713|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
361714|NCT01437826|Drug|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
362299|NCT01433445|Drug|ruxolitinib|Given twice daily in 28-day cycles.
361717|NCT01437800|Drug|Glimepiride/extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
361718|NCT01437787|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
361719|NCT01437787|Drug|Placebo|"Pharmaceutical form:capsule~Route of administration: oral"
361720|NCT01437774|Device|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
361721|NCT01437761|Device|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
361722|NCT01437748|Drug|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
361723|NCT01437748|Drug|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
361724|NCT01437735|Drug|QAW039|QAW039 po
361725|NCT01437735|Drug|Comparator leukotriene receptor antagonist (LRTA)|leukotriene receptor antagonist (LRTA)
361726|NCT01437735|Drug|Placebo|Placebo
361727|NCT01437722|Drug|1% SPL7013 Gel|vaginal gel
361728|NCT01437722|Drug|3% SPL7013 Gel|vaginal gel
361729|NCT01437722|Drug|placebo gel|vaginal gel
361730|NCT01437709|Biological|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
361731|NCT01437709|Other|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 & 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
361732|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
361733|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
361734|NCT01437696|Other|placebo|No liquid cholecalciferol will be added to the food.
361735|NCT01437670|Drug|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
361736|NCT01437657|Drug|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
361737|NCT01437657|Drug|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
361738|NCT01437657|Drug|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
361739|NCT01437644|Drug|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.~The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
361740|NCT01437631|Procedure|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
361741|NCT01437618|Drug|FOLFOXIRI plus bevacizumab|"BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
361742|NCT01437605|Drug|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
361743|NCT01437605|Drug|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
361744|NCT01437592|Drug|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
361745|NCT01437579|Procedure|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
361746|NCT01437579|Procedure|cystoscopy|cystoscopy under general anesthesia
361747|NCT01437566|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
361748|NCT01437566|Drug|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
361749|NCT01437566|Drug|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
361750|NCT01437566|Drug|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
361751|NCT01437566|Drug|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
361752|NCT01437553|Device|iMAP|IVUS and iMAP analysis for acute coronary syndromes
361753|NCT01437540|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
361754|NCT01437540|Drug|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
361755|NCT01437527|Behavioral|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
361756|NCT01437527|Behavioral|therapy as usual|Body image therapy as usual
361757|NCT01437514|Radiation|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
361758|NCT01437501|Drug|Broccoli Sprout Extract Beverage|Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
361759|NCT01437501|Drug|placebo beverage|100 mL of dilute pineapple and lime juice daily for 84 days.
361760|NCT01437488|Drug|Cabazitaxel|"Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days~Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion~Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
361761|NCT01437488|Drug|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
361762|NCT01437488|Procedure|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
361763|NCT01437488|Biological|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
361764|NCT01437475|Biological|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
361765|NCT01437462|Drug|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
361766|NCT01437462|Drug|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
361767|NCT01437449|Drug|Docetaxel|30 mg/m2 iv
361768|NCT01437449|Drug|Cisplatin|30 mg/m2 iv
361769|NCT01437449|Drug|Cetuximab|C1: 400 mg/m2, thereafter 250 iv
361770|NCT01437449|Drug|Carboplatin|AUC 2 iv
361771|NCT01437436|Procedure|ventilation tube|ventilation tube insertion
361772|NCT01437423|Biological|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
361773|NCT01437410|Procedure|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
361774|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
361775|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
361776|NCT01437397|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
361777|NCT01437397|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
361778|NCT01437397|Drug|Placebo|Inhaled dose-matched placebo, twice per day
361779|NCT01437384|Drug|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
361780|NCT01437371|Drug|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
361781|NCT01437358|Other|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
361782|NCT01437319|Device|lotrafilcon A|To be used during run-in phase only.
361783|NCT01437319|Device|comfilcon A|To be assigned at randomization at phase 2 only.
361784|NCT01437319|Device|balafilcon A|To be assigned at randomization during phase 2 only.
361785|NCT01437319|Other|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
361786|NCT01437306|Drug|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
361787|NCT01437293|Drug|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
361788|NCT01437280|Biological|CGTG-102|"VP=virus particle~Dose Level 1: 3x10^10 VP/injection~Dose Level 2: 1x10^11 VP/injection~Dose Level 3: 3x10^11 VP/injection~Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).~Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.~The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.~Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
361789|NCT01437267|Biological|Vi-CRM197 vaccine|
361790|NCT01437267|Biological|Pneumococcal conjugate vaccine|
361791|NCT01437267|Biological|Vi Polysaccharide (PS) vaccine|
361792|NCT01437254|Drug|CPERT|Single 340 MBq CPERT scan in first 10 subjects
361793|NCT01437254|Drug|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
361794|NCT01437228|Drug|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
361795|NCT01437228|Drug|placebo|NO İNTERVENTİON
361796|NCT01437215|Device|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
361797|NCT01437189|Drug|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
361798|NCT01437176|Device|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
361799|NCT01437176|Device|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
361800|NCT01437163|Device|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
361801|NCT01437163|Device|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
361802|NCT01437150|Device|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
361803|NCT01437150|Procedure|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
361804|NCT01437137|Device|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
361805|NCT01437137|Device|i-gel™|Insertion of I-gel
361806|NCT01437111|Drug|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
361807|NCT01437098|Device|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
361808|NCT01437072|Other|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
361809|NCT01437059|Drug|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
361810|NCT01437059|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
361811|NCT01437046|Drug|Doxazosin|Doxazosin 16mg/day
361812|NCT01437046|Drug|Placebo|
361813|NCT01437020|Drug|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
361814|NCT01437020|Drug|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
361815|NCT01437007|Drug|TKM-080301|
361816|NCT01436994|Procedure|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
361817|NCT01436994|Procedure|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.~Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.~Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
361818|NCT01436994|Drug|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
361819|NCT01436994|Drug|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
361820|NCT01436994|Drug|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
361821|NCT01436981|Procedure|CABG|Preparation of artery mammaria interna
361822|NCT01436968|Biological|ProstAtak®(AdV-tk) + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of AdV-tk injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~The second injection will be 0-3 days before initiation of radiation therapy.~The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
361823|NCT01436968|Biological|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:~The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.~The second injection will be 0-3 days before initiation of radiation therapy.~The third injection will be 15-22 days after the 2nd injection.~The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.~Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
361824|NCT01436955|Drug|Placebo|multiple oral doses
361825|NCT01436955|Drug|RG1662|Cohorts receiving multiple oral doses
361826|NCT01436942|Behavioral|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.~A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.~Dose: 12 weeks. Three times a week, 60 minutes."
361827|NCT01436929|Drug|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
361828|NCT01436929|Drug|Placebo|Placebo 1tab bid
361829|NCT01436916|Drug|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
361830|NCT01436916|Drug|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
361831|NCT01436903|Device|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
361832|NCT01436890|Drug|Revamilast|Tablet. Low dose, Once daily for 12 weeks
361833|NCT01436890|Drug|Revamilast|Medium dose, Once daily for 12 weeks
361834|NCT01436890|Drug|Revamilast|High dose, Once daily for 12 weeks
361835|NCT01436890|Drug|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
361836|NCT01436877|Device|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
361837|NCT01436864|Biological|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
361838|NCT01436851|Biological|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
361839|NCT01436838|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
361840|NCT01436825|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
361841|NCT01436812|Procedure|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
361842|NCT01436812|Procedure|positive end expiratory pressure|PEEP 0 cmH2O
361843|NCT01436799|Drug|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
361844|NCT01436799|Drug|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
361845|NCT01436799|Drug|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
361846|NCT01436799|Drug|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
361847|NCT01436786|Other|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
361848|NCT01436747|Drug|Paricalcitol|2 micrograms daily, peroral, 24 weeks
361849|NCT01436747|Drug|Placebo|2 micrograms daily, peroral, 24 weeks
361850|NCT01436734|Other|Fasting glycemia|no intervention
361851|NCT01436734|Other|Hypoglycemia|Insulin induced hypoglycemia
361852|NCT01436721|Device|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
361853|NCT01436695|Device|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
361854|NCT01436656|Drug|LGX818|
361855|NCT01436643|Drug|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
361856|NCT01436643|Drug|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
361857|NCT01436643|Drug|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
361858|NCT01436643|Drug|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
361859|NCT01436630|Other|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
361860|NCT01436617|Other|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
361861|NCT01436604|Other|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.~After establishing a good quality ECG synchronization, the following sequences are carried out successively:~Sequences locating anatomical~T2 black blood (such as ESF)~rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex~T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
361862|NCT01436578|Drug|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
361863|NCT01436565|Drug|MM-121 (SAR256212)|"Pharmaceutical form:solution~Route of administration: Intravenous"
361864|NCT01436565|Drug|SAR245408|"Pharmaceutical form:tablet~Route of administration: oral"
361865|NCT01436539|Drug|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
361866|NCT01436539|Drug|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
361867|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
361868|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
361869|NCT01436513|Drug|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
361870|NCT01436513|Drug|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
361871|NCT01436513|Drug|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
361873|NCT01436500|Drug|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
361874|NCT01436500|Drug|Placebo|Sterile water with 5% Dextrose
361875|NCT01436487|Biological|MultiStem|single infusion 1-2 days following ischemic stroke
361876|NCT01436487|Biological|Placebo|single infusion 1-2 days following ischemic stroke
361877|NCT01436474|Drug|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
361878|NCT01436474|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
361879|NCT01436448|Drug|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
361880|NCT01436435|Device|Jetstream Atherectomy System|Atherectomy
361881|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
361882|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
361883|NCT01436422|Biological|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
361884|NCT01436409|Other|echography|echography during labor
361885|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
361886|NCT01436396|Biological|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
361887|NCT01436396|Biological|Measles, mumps, and rubella (MMR) vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
361888|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
361889|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
361890|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
361891|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
361892|NCT01436396|Biological|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
361893|NCT01436396|Biological|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
361894|NCT01436396|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
361895|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
361896|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
361897|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months and 25 to 26 months
361898|NCT01436383|Other|Hypoxic exposure|Hypoxic exposure
361899|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
361900|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
361901|NCT01436357|Biological|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose, intramuscularly on day 0.
361902|NCT01436357|Biological|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10^8 plaque forming units (pfu) intramuscularly on day 56.
361903|NCT01436357|Other|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
361904|NCT01436331|Other|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
361975|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
362063|NCT01435226|Drug|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
361905|NCT01436331|Behavioral|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
361906|NCT01436305|Drug|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
361907|NCT01436305|Drug|MMF|"All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.~Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily."
361908|NCT01436305|Biological|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication[s])
361909|NCT01436305|Drug|Short-term Tac|Short-term (3 months)
361910|NCT01436305|Drug|tacrolimus|maintenance
361911|NCT01436305|Biological|Belatacept|maintenance
361912|NCT01436305|Drug|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
361913|NCT01436292|Drug|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:~≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; < 10 gr/L: 150 g of 5% HAS."
361914|NCT01436279|Drug|Mifepristone|200 mg po 20-24 hours prior to the procedure
361915|NCT01436279|Device|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
361916|NCT01436266|Drug|Misoprostol|400 mcg buccally 2 hours prior to procedure
361917|NCT01436266|Other|Folic acid|2mg buccally 2 hours prior to procedure
361918|NCT01436253|Behavioral|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
361919|NCT01436253|Drug|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
361920|NCT01436240|Behavioral|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
361921|NCT01436227|Drug|Pazopanib|800 mg by mouth once daily for up to six, four week cycles.
361922|NCT01436214|Drug|APC-100|Daily oral, dose escalation, 28-day cycle(s)
361923|NCT01436201|Drug|Digoxin|Administered orally
361924|NCT01436201|Biological|Dulaglutide|Administered as subcutaneous injection
361925|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
361926|NCT01436188|Procedure|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
361927|NCT01436188|Procedure|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
361928|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
361929|NCT01436188|Procedure|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
361930|NCT01436175|Drug|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
361931|NCT01436162|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
361932|NCT01436162|Drug|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
361933|NCT01436149|Drug|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
361934|NCT01436149|Drug|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
361935|NCT01436136|Other|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
361976|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
361936|NCT01436136|Other|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
361937|NCT01436123|Other|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
361938|NCT01436123|Device|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
361939|NCT01436110|Drug|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
361940|NCT01436110|Drug|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
361941|NCT01436110|Drug|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
361942|NCT01436097|Behavioral|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
361943|NCT01436097|Behavioral|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
361944|NCT01436097|Behavioral|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
361945|NCT01436097|Behavioral|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
361946|NCT01436084|Drug|SB1518|400 mg taken orally, once daily without regard of food, 28 day cycle.
361947|NCT01436071|Drug|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
361948|NCT01436071|Drug|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
361949|NCT01436058|Biological|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
361950|NCT01436045|Drug|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
361951|NCT01436045|Drug|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
361952|NCT01436032|Drug|N1539|IV
361953|NCT01436032|Drug|N1539|IV
361954|NCT01436032|Drug|N1539|IV
361955|NCT01436032|Drug|Ketorolac Tromethamine|IV
361956|NCT01436032|Drug|Placebo|IV
361957|NCT01435993|Drug|GSK1223249|Intravenous infusion
361958|NCT01435993|Other|Saline placebo|placebo intravenous infusion
361959|NCT01435980|Procedure|Gastric Bypass|basal treatment and Gastric Bypass
361960|NCT01435980|Drug|Exenatide|basal treatment and Exenatide
361961|NCT01435967|Other|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
361962|NCT01435954|Drug|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
361963|NCT01435954|Drug|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
361964|NCT01435941|Drug|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
361965|NCT01435941|Drug|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
361966|NCT01435928|Drug|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
361967|NCT01435928|Drug|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
361968|NCT01435915|Drug|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period."
361969|NCT01435902|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
361970|NCT01435902|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
361971|NCT01435876|Procedure|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
361972|NCT01435876|Procedure|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
361973|NCT01435876|Procedure|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
361974|NCT01435876|Procedure|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
362061|NCT01435226|Drug|placebo to match tegobuvir|tegobuvir placebo BID
361977|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
361978|NCT01435850|Procedure|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
361979|NCT01435837|Drug|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
361980|NCT01435837|Drug|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
361981|NCT01435837|Drug|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
361982|NCT01435837|Drug|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
361983|NCT01435824|Drug|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
361984|NCT01435824|Drug|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
361985|NCT01435811|Biological|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
361986|NCT01435798|Drug|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
361987|NCT01435772|Biological|BMN 701|GILT-tagged recombinant human GAA
361988|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
361989|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
361990|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
361991|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
361992|NCT01435759|Drug|Antidepressant + Placebo|oral, once daily for 8 weeks
361993|NCT01435746|Behavioral|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
361994|NCT01435720|Biological|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
361995|NCT01435720|Biological|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
361996|NCT01435720|Biological|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
361997|NCT01435720|Biological|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
361998|NCT01435707|Other|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
361999|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
362000|NCT01435707|Other|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
362001|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
362002|NCT01435694|Behavioral|Lokomat (Hocoma, Switzerland)|
362003|NCT01435694|Behavioral|Conventional Therapy|
362004|NCT01435668|Behavioral|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
362005|NCT01435668|Behavioral|Simple written advice|Patients receive an information leaflet.
362006|NCT01435655|Drug|tafamidis|tafamidis meglumine 20 mg QD
362007|NCT01435642|Other|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
362008|NCT01435629|Drug|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
362009|NCT01435616|Drug|Glargine|
362010|NCT01435616|Drug|LY2605541|
362011|NCT01435603|Behavioral|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
362012|NCT01435603|Behavioral|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
362013|NCT01435590|Procedure|Curette v/s endocervical brush|
362014|NCT01435577|Drug|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
362015|NCT01435577|Drug|Matching Placebo|Maximum 12 administrations over 48 hours
362016|NCT01435564|Behavioral|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
362017|NCT01435564|Behavioral|pedometer only|Participants in this group will receive only a pedometer.
362018|NCT01435551|Other|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
362019|NCT01435538|Behavioral|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
362020|NCT01435512|Behavioral|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
362062|NCT01435226|Drug|placebo to match RBV|Ribovirin placebo BID
362021|NCT01435499|Biological|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
362022|NCT01435499|Drug|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
362023|NCT01435486|Drug|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
362024|NCT01435486|Drug|Normal saline|Placebo with an equivalent volume of normal saline.
362025|NCT01435473|Procedure|Cardiac Surgery|
362026|NCT01435460|Drug|Loteprednol etabonate 0.2%|1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
362027|NCT01435460|Drug|Olopatadine 0.1%|1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
362028|NCT01435447|Drug|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
362029|NCT01435434|Device|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
362030|NCT01435408|Other|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
362031|NCT01435408|Other|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
362032|NCT01435408|Other|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
362033|NCT01435395|Drug|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
362034|NCT01435382|Biological|PF-04950615 (RN316)|Dose A - single-dose intravenous infusion
362035|NCT01435382|Biological|PF-04950615 (RN316)|Dose B - single-dose subcutaneous injection
362036|NCT01435382|Biological|PF-04950615 (RN316)|Dose C - single-dose subcutaneous injection
362037|NCT01435382|Biological|PF-04950615 (RN316)|Dose D - single-dose subcutaneous injection
362038|NCT01435369|Drug|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
362039|NCT01435356|Biological|recMAGE-A3 + AS15 ASCI|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
362040|NCT01435356|Biological|Placebo|5 doses were administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
362041|NCT01435343|Drug|fludarabine|30 mg/m2/day intravenously on days 1 to 4
362042|NCT01435343|Drug|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
362043|NCT01435343|Drug|cytarabine|2 g/m2/day intravenously on days 1 to 4
362044|NCT01435343|Drug|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
362045|NCT01435343|Drug|plerixafor|intravenously from days 1 to 4
362046|NCT01435330|Drug|BVS857|
362047|NCT01435330|Drug|Placebo|
362048|NCT01435317|Device|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
362049|NCT01435304|Device|method of returning residual CPB blood ( Hemobag®)|The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
362050|NCT01435291|Drug|Advagraf Capsule|"Other Names:~FK506E~MR4~tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
362051|NCT01435291|Drug|Prograf Capsule|"Other Names:~FK506E~MR4~tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
362052|NCT01435278|Device|Glucosanol|2 tablets taken 3 times a day.
362053|NCT01435265|Behavioral|Standard nurse education|Standard-of-care education from a dermatology nurse on the proper use of adalimumab
362054|NCT01435265|Behavioral|Additional nurse education|Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
362055|NCT01435252|Drug|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
362056|NCT01435239|Device|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
362057|NCT01435239|Device|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
362058|NCT01435226|Drug|GS-5885|"Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD"
362059|NCT01435226|Drug|GS-9451|"Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD"
362060|NCT01435226|Drug|tegobuvir|tegobuvir 30 mg BID
362064|NCT01435213|Drug|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
362065|NCT01435213|Drug|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
362066|NCT01435213|Drug|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
362067|NCT01435213|Other|Cold pressor test|30-45 min cold pressor test of the foot
362068|NCT01435213|Drug|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
362069|NCT01435213|Drug|Placebo|A single dose of placebo (capsules) administered orally
362070|NCT01435200|Drug|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
362071|NCT01435174|Drug|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
362072|NCT01435174|Procedure|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
362073|NCT01435174|Procedure|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
362074|NCT01435161|Drug|Nifedipine,|Nifedipine 30-60mg/day
362075|NCT01435161|Drug|Telmisartan|Telmisartan 80-160mg/day
362076|NCT01435148|Procedure|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
362077|NCT01435135|Biological|ALVAC-HIV|1 mL per injection containing 10^6 CCID50/dose administered
362078|NCT01435135|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
362079|NCT01435135|Biological|ALVAC-HIV Placebo|1 ml per injection
362080|NCT01435135|Biological|AIDSVAX B/E Placebo|1 ml per injection
362081|NCT01435122|Drug|Axitinib|Axitinib Administration as outlined in Arm description
362082|NCT01435109|Behavioral|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
362083|NCT01435109|Behavioral|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
362084|NCT01435109|Behavioral|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
362085|NCT01435096|Drug|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
362086|NCT01435083|Drug|Desmopressin|120 µg, oral lyophilisate, sublingual use
362087|NCT01435070|Procedure|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.~A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
362088|NCT01435070|Procedure|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
362089|NCT01435057|Procedure|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
362090|NCT01435044|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
362091|NCT01435044|Drug|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
362092|NCT01435044|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
362093|NCT01435044|Drug|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
362094|NCT01435044|Drug|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
362095|NCT01435031|Device|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:~XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent~HT PROGRESS and/or HT PILOT guide wires in recanalization~MINI-TREK Coronary Dilatation Catheter in predilatation"
362096|NCT01435018|Drug|Etoposide (ET)|"Beginning on day one of the chemotherapy cycle, ET was given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there was no Grade ≥ 2 toxicity attributable to ET after the first cycle, the dose was escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there was no Grade ≥ 2 toxicity attributable to ET, the dose was escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.~Treatment with ET was continued for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
362097|NCT01435018|Drug|Bleomycin and Vincristine (BV)|"BV was administered on day one of each chemotherapy cycle.~Vincristine sulfate was administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion was followed by bleomycin as detailed below.~Bleomycin sulfate was administered at a dose of 15 units/m^2 over 10 minutes every 3 weeks.~Treatment with BV was continued for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the protocol CMC, had determined that alternative therapy is required, whichever occurs first."
362161|NCT01434472|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
362098|NCT01435018|Drug|Paclitaxel (PTX)|Paclitaxel was administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m^2 body surface area (BSA) every 3 weeks.
362099|NCT01435018|Drug|Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)|"The following ART regimens were used:~EFV/FTC/TDF (Atripla®) 200 mg/300 mg/600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada®) orally once daily at bedtime plus EFV (Stocrin®) 600 mg orally once daily at bedtime or~FTC/TDF 200 mg/300 mg (Truvada®) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or~FTC/TDF 200 mg/300 mg (Truvada®) orally once daily plus PI/r at standard dosing or~FTC/TDF 200 mg/300 mg (Truvada®) orally once daily plus integrase inhibitor at standard dosing"
362100|NCT01435005|Other|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
362101|NCT01435005|Other|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
362102|NCT01434966|Other|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
362103|NCT01434966|Other|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
362104|NCT01434966|Other|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
362105|NCT01434953|Behavioral|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
362106|NCT01434953|Behavioral|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
362107|NCT01434940|Other|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
362108|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
362109|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
362110|NCT01434914|Drug|octenisept®|Cutaneous solution
362111|NCT01434914|Drug|Placebo|Cutaneous use
362112|NCT01434901|Drug|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
362113|NCT01434901|Drug|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
362114|NCT01434901|Drug|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
362115|NCT01434901|Drug|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
362116|NCT01434888|Drug|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
362117|NCT01434888|Drug|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
362118|NCT01434888|Drug|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
362119|NCT01434862|Drug|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
362120|NCT01434862|Device|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
362121|NCT01434862|Drug|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
362122|NCT01434849|Drug|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
362123|NCT01434849|Drug|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
362124|NCT01434836|Other|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
362125|NCT01434836|Other|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
362162|NCT01434472|Drug|Cyclosporine|Given PO
362163|NCT01434472|Drug|Fludarabine Phosphate|Given IV
362164|NCT01434472|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
362126|NCT01434823|Other|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.~For the Intensivist Sleep and Work sub-study:~Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
362127|NCT01434810|Device|Filtered-sunlight phototherapy|Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.
362128|NCT01434810|Device|Conventional phototherapy|Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
362129|NCT01434745|Drug|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5 mg/kg/day
362130|NCT01434745|Dietary Supplement|Lactose|Lactose will be administered in a capsule formula.
362131|NCT01434732|Procedure|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
362132|NCT01434732|Procedure|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
362133|NCT01434706|Other|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
362134|NCT01434693|Biological|Trichuris suis ova|single dose
362135|NCT01434693|Other|Placebo|
362136|NCT01434680|Biological|MenC-CRM LIQ|One dose of MenC-CRM vaccine, liquid formulation
362137|NCT01434680|Biological|MenC-CRM ROS|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.
362138|NCT01434680|Biological|MenC-CRM EMV|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
362139|NCT01434667|Behavioral|APOE genotype and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
362140|NCT01434667|Behavioral|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
362141|NCT01434641|Other|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
362142|NCT01434628|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
362143|NCT01434615|Device|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
362144|NCT01434615|Other|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
362145|NCT01434602|Drug|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; dose escalation from 5mg to 10 mg daily
362146|NCT01434602|Drug|sorafenib|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; dose escalation from 400 mg bid, 7 days on and 7 days off to 800 mg bid
362147|NCT01434589|Behavioral|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
362148|NCT01434576|Biological|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
362149|NCT01434576|Biological|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
362150|NCT01434576|Drug|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
362151|NCT01434550|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
362152|NCT01434550|Radiation|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess~Necrosis/apoptosis~Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)~1. Aposense-PET imaging"
362153|NCT01434524|Drug|LIVACT|LIVACT contains 13.0 g of free amino acids
362154|NCT01434511|Biological|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
362155|NCT01434498|Drug|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
362156|NCT01434498|Drug|GS-9451 tablet|GS-9451 tablet, 200 mg QD
362157|NCT01434498|Drug|tegobuvir capsule|tegobuvir capsule, 30 mg BID
362158|NCT01434498|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
362159|NCT01434498|Drug|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
362160|NCT01434498|Device|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
362167|NCT01434472|Biological|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
362168|NCT01434472|Radiation|Total-Body Irradiation|Undergo TBI
362169|NCT01434472|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
362170|NCT01434472|Drug|Fludarabine|Given IV
362171|NCT01434459|Drug|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
362172|NCT01434446|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
362173|NCT01434420|Genetic|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
362174|NCT01434407|Other|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
362175|NCT01434394|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
362176|NCT01434381|Biological|Pfs25-EPA/Alhydrogel|
362177|NCT01434355|Other|Laboratory Biomarker Analysis|Correlative studies
362178|NCT01434355|Other|Questionnaire Administration|Ancillary studies
362179|NCT01434342|Drug|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, & 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
362180|NCT01434329|Genetic|DNA methylation analysis|
362181|NCT01434329|Genetic|gene expression analysis|
362182|NCT01434329|Genetic|microarray analysis|
362183|NCT01434329|Other|laboratory biomarker analysis|
362184|NCT01434329|Other|medical chart review|
362185|NCT01434316|Drug|Dinaciclib|Given IV
362186|NCT01434316|Drug|Veliparib|Given PO
362187|NCT01434303|Drug|Entinostat|Given PO
362188|NCT01434303|Other|Laboratory Biomarker Analysis|Correlative studies
362189|NCT01434303|Drug|Lapatinib Ditosylate|Given PO
362190|NCT01434303|Biological|Trastuzumab|Given IV
362191|NCT01434290|Radiation|36.25 Gy IMRT|36.25 Gy in 5 fractions of 7.5 Gy twice a week over 15-17 days. A minimum of 72 hours and a maximum of 96 hours will separate each treatment. IMRT or similar techniques that use inverse treatment planning or protons are required.
362192|NCT01434290|Radiation|51.6 Gy IMRT|51.6 Gy in 12 fractions of 4.3 Gy 5 days a week over 16-18 days. IMRT or similar techniques that use inverse treatment planning or protons are required.
362193|NCT01434277|Other|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
362194|NCT01434264|Procedure|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
362195|NCT01434251|Other|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
362196|NCT01434238|Other|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
362197|NCT01434225|Drug|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
362198|NCT01434212|Drug|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.~Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
362199|NCT01434199|Procedure|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
362200|NCT01434186|Drug|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
362201|NCT01434186|Drug|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
362202|NCT01434186|Drug|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
362203|NCT01434186|Drug|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
362204|NCT01434173|Drug|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
362205|NCT01434173|Drug|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
362238|NCT01433900|Drug|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
362206|NCT01434160|Drug|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
362207|NCT01434147|Drug|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
362208|NCT01434134|Drug|Metoprolol|Tablet, target dose 100 mg once daily
362209|NCT01434134|Drug|Placebo|Tablet, target dose 100 mg once daily
362210|NCT01434134|Drug|Candesartan|Tablet, target dose 32 mg once daily
362211|NCT01434134|Drug|Placebo|Tablet, 32 mg once daily
362212|NCT01434121|Drug|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
362213|NCT01434121|Drug|Placebo|
362214|NCT01434108|Drug|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
362215|NCT01434095|Procedure|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
362216|NCT01434082|Behavioral|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
362217|NCT01434069|Drug|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
362218|NCT01434069|Drug|FOLFIRI Infusion|Standard therapy of FOLFIRI
362219|NCT01434030|Behavioral|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
362220|NCT01434017|Drug|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
362221|NCT01434017|Drug|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
362222|NCT01434017|Drug|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
362223|NCT01434004|Behavioral|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.~Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
362224|NCT01433991|Drug|E7050 plus lenvatinib|Dose escalation will begin at low doses of both E7050 and lenvatinib, then gradually increase in future cohorts until a recommended combination dose is identified. This recommended dose will be used to treat patients with Glioblastoma and Melanoma in later groups in this study.
362225|NCT01433991|Drug|lenvatinib plus E7050|The recommended dose for the combination of E7050 plus lenvatinib determined from the Dose escalation phase will be given to subjects to confirm it as the MTD. This recommended dose will be used to treat patients with Glioblastoma and Melanoma in later groups in this study.
362226|NCT01433991|Drug|E7050 plus lenvatinib or lenvatinib alone plus E7050 add-on therapy|Phase 2 Cohort 1 Arm A: E7050 will be taken once daily for 28 day cycles starting C1D1 in combination with lenvatinib at Recommended phase 2 (RP2) dose Arm B: E7050 at RP2 dose will be added on to single agent lenvatinib at time of disease progression.
362227|NCT01433991|Drug|E7050 plus lenvatinib|"Phase 2 Cohort 2:~Arm C: E7050 will be taken once daily for 28 day cycles starting C1D1 in combination with lenvatinib at Recommended phase 2 (RP2) dose"
362228|NCT01433991|Drug|E7050|Phase 2 Cohort 2: Arm D: E7050 will be taken alone at 400 mg daily for 28 day cycles.
362229|NCT01433978|Drug|Eltrombopag|
362230|NCT01433978|Drug|Avatrombopag|
362231|NCT01433978|Drug|Standard of care|"Permitted ITP concomitant background therapies are as follows:~Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;~Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;~Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport [P-gp] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.~At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.~Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
362232|NCT01433965|Drug|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
362233|NCT01433952|Dietary Supplement|Thiamine|Vitamin B1
362234|NCT01433952|Dietary Supplement|Placebo|Placebo
362239|NCT01433900|Drug|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
362240|NCT01433887|Drug|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
362241|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
362242|NCT01433887|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
362243|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
362244|NCT01433874|Procedure|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
362245|NCT01433874|Procedure|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
362246|NCT01433874|Procedure|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
362247|NCT01433874|Procedure|Control group|Co2 was removed by passive exsufflation through the port site.
362248|NCT01433861|Procedure|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
362249|NCT01433835|Drug|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
362250|NCT01433835|Other|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
362251|NCT01433770|Drug|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
362252|NCT01433757|Drug|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
362253|NCT01433757|Drug|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
362254|NCT01433744|Procedure|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
362255|NCT01433731|Drug|placebo for SHAPE (SHP-141)|topical gelled solution
362256|NCT01433731|Drug|SHAPE (SHP-141) 0.1% BID|topical gelled solution
362257|NCT01433731|Drug|SHAPE (SHP-141) 0.5% BID|topical gelled solution
362258|NCT01433731|Drug|SHAPE (SHP-141) 1.0% BID|topical gelled solution
362259|NCT01433718|Procedure|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
362260|NCT01433705|Other|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
362261|NCT01433705|Other|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
362262|NCT01433705|Other|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
362263|NCT01433705|Drug|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
362264|NCT01433692|Behavioral|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
362265|NCT01433679|Behavioral|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
362266|NCT01433666|Drug|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
362267|NCT01433666|Drug|Placebo|Acute intervention: single administration, capsulated form.
362268|NCT01433666|Drug|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
362269|NCT01433653|Behavioral|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
362270|NCT01433627|Other|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
362271|NCT01433627|Other|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.~Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
362272|NCT01433627|Other|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
362273|NCT01433627|Other|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
362274|NCT01433627|Other|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.~Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
362275|NCT01433627|Other|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
362276|NCT01433614|Drug|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
362277|NCT01433614|Drug|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
362278|NCT01433614|Drug|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
362279|NCT01433601|Behavioral|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
362280|NCT01433588|Device|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
362281|NCT01433588|Other|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
362282|NCT01433575|Drug|RO4917838|10 mg single oral dose
362283|NCT01433575|Drug|RO4917838|20 mg single oral dose
362284|NCT01433562|Drug|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
362285|NCT01433562|Drug|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
362286|NCT01433549|Device|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
362287|NCT01433549|Device|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
362288|NCT01433523|Drug|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
362289|NCT01433523|Drug|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
362290|NCT01433523|Drug|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
362291|NCT01433510|Drug|Grazax|1 tablet/day - pre and co-seasonal
362292|NCT01433497|Drug|Masitinib|
362293|NCT01433497|Drug|Placebo|
362294|NCT01433484|Behavioral|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
362295|NCT01433484|Behavioral|Maintenance of Weight Loss--Experimental|
362296|NCT01433471|Drug|Trichuris suis ova|2,500 eggs by mouth every two weeks for 12 weeks
362297|NCT01433458|Drug|RLX030A|RLX030 is administered as a continuous 24 hour infusion
362298|NCT01433445|Drug|panobinostat|Given 3 times a week, every other week in 28-day cycles.
362300|NCT01433432|Drug|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
362301|NCT01433419|Drug|TAK-875|
362302|NCT01433419|Drug|TAK-875|
362303|NCT01433406|Drug|TAK-875|
362304|NCT01433406|Drug|TAK-875|
362305|NCT01433393|Drug|TAK-875|
362306|NCT01433393|Drug|TAK-875|
362307|NCT01433393|Drug|Placebo|
362308|NCT01433380|Drug|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
362309|NCT01433380|Drug|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
362310|NCT01433367|Device|CerPass® Total Disc Replacement|Single level cervical disc disease
362311|NCT01433354|Drug|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
362312|NCT01433328|Drug|Lidocaine|Lidocaine
362313|NCT01433328|Drug|Placebo|Placebo
362314|NCT01433315|Behavioral|sleep restriction|restricted sleep
362315|NCT01433302|Procedure|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
362316|NCT01433289|Drug|Polyphenon E|There will be three treatment arms, each consisting of 8 participants. Two participants in each study arm will be randomized to receive placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding arm will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each arm is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
362317|NCT01433276|Drug|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
362318|NCT01433276|Drug|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
362319|NCT01433263|Drug|BYM338 active drug|
362320|NCT01433263|Drug|Placebo|
362321|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
362322|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
362323|NCT01433237|Genetic|RNA analysis|
362324|NCT01433237|Genetic|gene expression analysis|
362325|NCT01433237|Other|laboratory biomarker analysis|
362326|NCT01433224|Genetic|DNA methylation analysis|
362327|NCT01433224|Genetic|RNA analysis|
362328|NCT01433224|Genetic|mutation analysis|
362329|NCT01433224|Genetic|nucleic acid sequencing|
362330|NCT01433224|Genetic|polymerase chain reaction|
362331|NCT01433224|Genetic|polymorphism analysis|
362332|NCT01433224|Other|laboratory biomarker analysis|
362333|NCT01433224|Other|medical chart review|
362334|NCT01433198|Other|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
362335|NCT01433185|Other|Text message|Text messages sent to women before and after delivery
362336|NCT01433172|Biological|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
362337|NCT01433172|Biological|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10^6 irradiated H1944 tumor cells, 7.5 X 10^6 irradiated H2122 cells, and containing 15 X 10^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
362338|NCT01433172|Biological|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.~Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
362339|NCT01433159|Drug|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
362340|NCT01433159|Drug|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
362341|NCT01433133|Biological|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
362342|NCT01433120|Dietary Supplement|Lactobacillus paracasei ssp paracasei F19|10^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
362343|NCT01433120|Dietary Supplement|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
362344|NCT01433120|Dietary Supplement|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
362345|NCT01433107|Drug|Terbinafine|1% single application
362346|NCT01433107|Drug|Terbinafine Placebo|single application
362347|NCT01433094|Behavioral|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
362348|NCT01433094|Behavioral|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
362349|NCT01433081|Drug|Placebo infusion of .9 normal saline|administration of .9 normal saline
362350|NCT01433081|Drug|administration of magnesium sulfate|administration of magnesium sulfate
362351|NCT01433068|Device|NBTXR3|One intratumor implantation by injection
362352|NCT01433055|Drug|Minocycline|"Minocycline Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
362353|NCT01433055|Drug|Placebo|"Placebo Dosing:~Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
362354|NCT01433042|Device|capsule endoscopy|capsule endoscopy procedure
362355|NCT01433029|Other|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
362356|NCT01433029|Other|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
362357|NCT01433016|Drug|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
362358|NCT01433003|Procedure|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
362359|NCT01432990|Device|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
362360|NCT01432990|Other|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
362361|NCT01432977|Drug|paracetamol /droperidol|
362362|NCT01432977|Drug|paracetamol / ondansetron|
362363|NCT01432964|Procedure|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
362364|NCT01432951|Drug|Enzastaurin|Administered orally
362365|NCT01432938|Biological|dulaglutide|Administered subcutaneously
362366|NCT01432938|Drug|Warfarin|Administered orally
362367|NCT01432925|Procedure|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
362368|NCT01432912|Behavioral|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
362369|NCT01432886|Drug|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
362370|NCT01432873|Drug|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
362371|NCT01432873|Drug|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
362398|NCT01432600|Drug|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
362470|NCT01432028|Drug|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
362471|NCT01432028|Drug|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
362727|NCT01430130|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
362372|NCT01432860|Behavioral|In-person counseling|The design is a 3 [in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care] X 7 [baseline, 4, 8, 12, 16, 20, and 24 month follow-up] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
362373|NCT01432860|Behavioral|Workbook|Participants will read a workbook and perform skills training exercises.
362374|NCT01432860|Behavioral|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
362375|NCT01432834|Other|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH & Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
362376|NCT01432834|Other|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
362377|NCT01432821|Other|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg~Route of administration: Subcutaneous~Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.~Two injections will be made by visiting during visits 2 and 3.~The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:~Sequence A during visit 2 followed by sequence B during visit 3~or sequence B during visit 2"
362378|NCT01432795|Device|Gliding aids for medical compression stockings|"Each subject tests devices:~3 gliding aids for stockings with closed tips~3 gliding aids for stockings with open tips~2 stocking butlers using~3 medical compression stockings with open tip, compression class 3 (36-46mmHg)~3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)~2 superimposed compression stockings class 1 (18 - 21 mmHg)"
362379|NCT01432782|Drug|Placebo|Saline 4 ml
362380|NCT01432782|Drug|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
362381|NCT01432769|Dietary Supplement|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
362382|NCT01432756|Behavioral|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
362383|NCT01432743|Procedure|NavX Fusion|Using NavX Fusion to guide catheter ablation
362384|NCT01432743|Procedure|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
362385|NCT01432730|Drug|Gefapixant|Oral tablets, BID
362386|NCT01432730|Drug|Placebo|Oral tablets, BID
362387|NCT01432717|Biological|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
362388|NCT01432717|Other|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
362389|NCT01432704|Drug|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
362390|NCT01432691|Procedure|Hemi (hemialloplastik)|THA vs hemi
362391|NCT01432665|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
362392|NCT01432665|Drug|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
362393|NCT01432665|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
362394|NCT01432639|Other|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
362395|NCT01432626|Drug|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
362396|NCT01432613|Procedure|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
362397|NCT01432600|Drug|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
362399|NCT01432600|Drug|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
362400|NCT01432587|Drug|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
362401|NCT01432574|Biological|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
362402|NCT01432561|Drug|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 & 4 which must occur within a 14 day period.
362403|NCT01432548|Procedure|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
362404|NCT01432535|Drug|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
362405|NCT01432522|Drug|Epinephrine|"Intranasal epinephrine 5 mg /spray~Intramuscular epinephrine 0.3 mg~Intranasal saline spray"
362406|NCT01432509|Other|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :~Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and < 1,26 g/l) or fasting blood glucose ≥ 1 g/l and < 1,10 g/l with HbA1c ≥ 6,5%.~First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).~Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.~End of study phone call"
362407|NCT01432496|Drug|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
362408|NCT01432496|Drug|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
362409|NCT01432483|Drug|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
362410|NCT01432470|Drug|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
362411|NCT01432470|Drug|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
362412|NCT01432457|Drug|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
362413|NCT01432457|Drug|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
362414|NCT01432457|Drug|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
362415|NCT01432444|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
362416|NCT01432431|Procedure|spiritual therapy|Undergo palliative spiritual care
362417|NCT01432431|Other|questionnaire administration|Ancillary studies
362418|NCT01432431|Other|survey administration|Ancillary studies
362419|NCT01432431|Other|counseling intervention|Undergo palliative spiritual care
362420|NCT01432431|Other|psychosocial support for caregiver|Undergo palliative spiritual care
362421|NCT01432431|Procedure|psychosocial assessment and care|Undergo palliative spiritual care
362422|NCT01432418|Other|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
362423|NCT01432405|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
362424|NCT01432405|Drug|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
362425|NCT01432379|Biological|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
362426|NCT01432366|Other|SC anti-TNF|Subcutaneous (SC) anti-TNF
362427|NCT01432353|Drug|DFRF4539A|multiple ascending doses
362428|NCT01432340|Biological|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
362429|NCT01432327|Device|SenseWear display|"Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.~The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals."
362430|NCT01432327|Device|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
362431|NCT01432327|Device|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
362432|NCT01432327|Behavioral|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
362678|NCT01430442|Drug|BMS-927711|Capsule, Oral, 25mg, One time, One dose
362433|NCT01432314|Other|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.~C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).~D. Dose:~i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
362434|NCT01432314|Other|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.~C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
362435|NCT01432301|Drug|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
362436|NCT01432275|Device|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
362437|NCT01432275|Device|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
362438|NCT01432275|Device|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
362439|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
362440|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
362441|NCT01432249|Drug|Enbrel group|will be decided by treating physicians
362442|NCT01432236|Drug|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
362443|NCT01432236|Drug|placebo|placebo capsules twice a day for 14 weeks
362444|NCT01432223|Drug|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
362445|NCT01432210|Other|Post-prandial Feeding Study|
362446|NCT01432197|Other|ADL intervention|1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
362447|NCT01432184|Procedure|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
362448|NCT01432171|Drug|Lacosamide|Given PO
362449|NCT01432171|Other|Placebo|Given PO
362450|NCT01432158|Biological|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
362451|NCT01432158|Biological|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
362452|NCT01432145|Drug|6-Mercaptopurine|6-Mercaptopurine (6MP) 55mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. One cycle is 28 days. Treatment is given continuously until disease progression.
362453|NCT01432145|Drug|Methotrexate|Methotrexate (MTX) 15 mg/m2 taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously until disease progression.
362454|NCT01432132|Behavioral|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
362455|NCT01432132|Behavioral|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
362456|NCT01432119|Device|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
362457|NCT01432119|Drug|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
362458|NCT01432119|Drug|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
362459|NCT01432119|Procedure|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
362460|NCT01432106|Drug|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of < 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.~(However, all non-study medication will be manipulated, initially.)"
362461|NCT01432093|Other|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
362462|NCT01432093|Other|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
362463|NCT01432080|Drug|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
362464|NCT01432080|Drug|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
362465|NCT01432080|Drug|Montelukast|Montelukast 10 mg PO qhs for 3 months
362466|NCT01432080|Drug|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
362467|NCT01432067|Other|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
362468|NCT01432067|Other|Classic physical activities|Daily physical activities based on a standard guide
362469|NCT01432041|Behavioral|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
362679|NCT01430442|Drug|BMS-927711|Capsule, Oral, 75mg, One time, One dose
362472|NCT01432015|Drug|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
362473|NCT01432015|Drug|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
362474|NCT01432015|Other|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
362475|NCT01432015|Other|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
362476|NCT01431989|Drug|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
362477|NCT01431989|Drug|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
362478|NCT01431976|Drug|Lamictal|No comparison
362479|NCT01431963|Drug|Lamictal|No comparison.
362480|NCT01431950|Drug|fluticasone furoate|Inhaled corticosteroid
362481|NCT01431950|Drug|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
362482|NCT01431937|Drug|GSK2018682|Active Drug
362483|NCT01431937|Drug|Placebo|Placebo
362484|NCT01431924|Drug|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
362485|NCT01431924|Drug|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
362486|NCT01431911|Drug|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
362487|NCT01431911|Drug|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
362488|NCT01431898|Drug|GS-9669 tablets|
362489|NCT01431898|Drug|Placebo to Match GS-9669 tablet|
362490|NCT01431885|Procedure|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
362491|NCT01431885|Procedure|Cervical change|Diagnosis will be made by digital examination of cervical change
362492|NCT01431859|Biological|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
362493|NCT01431859|Other|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
362494|NCT01431846|Behavioral|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
362495|NCT01431833|Drug|TR-701 FA|Oral single dose 200 mg
362496|NCT01431820|Drug|Luliconazole Solution, 10%|Topical
362497|NCT01431820|Drug|Vehicle Solution|Topical
362498|NCT01431807|Drug|SYR-472|oral, for up to 52 weeks.
362499|NCT01431794|Drug|LDE225-600mg|"Phase I: oral LDE225 (Sonidegib), 600mg daily.~Phase II Arm A: LDE225 at the recommended phase 2 dose on Days 1, 8 and 15. Cycles repeated every 28 days."
362500|NCT01431794|Drug|Gemcitabine|Four cycles of Gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days.
362501|NCT01431794|Drug|nab-paclitaxel|Four cycles of nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days.
362502|NCT01431794|Drug|LDE225-400mg|Phase I: oral LDE225 (Sonidegib), 400mg daily.
362503|NCT01431794|Drug|LDE225-800mg|Phase I: oral LDE225 (Sonidegib), 800mg daily.
362504|NCT01431781|Drug|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.~Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
362505|NCT01431781|Other|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
362506|NCT01431768|Device|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
362507|NCT01431755|Device|Restylane SubQ|Treatment with up to 2 ml of the product
362508|NCT01431755|Device|Restylane SubQ Lidocaine|Treatment with up to 2 ml of the product
362509|NCT01431742|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
362510|NCT01431729|Other|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
362511|NCT01431716|Drug|EFI/ACT-385781A|
362512|NCT01431690|Drug|warfarin|A single 25 mg dose of warfarin
362513|NCT01431690|Drug|omefas|4 x 1 g capsule dose of Epanova®
362514|NCT01431690|Drug|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
362515|NCT01431677|Procedure|Muscle Biopsy|
362516|NCT01431664|Drug|multikinase inhibitor AT9283|
362517|NCT01431664|Other|laboratory biomarker analysis|
362518|NCT01431664|Other|pharmacological study|
362519|NCT01431651|Dietary Supplement|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
362680|NCT01430442|Drug|BMS-927711|Capsule, Oral, 150mg, One time, One dose
362520|NCT01431638|Drug|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
362521|NCT01431625|Other|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:~.- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.~- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
362522|NCT01431612|Drug|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
362523|NCT01431612|Drug|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
362524|NCT01431612|Drug|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
362525|NCT01431599|Radiation|short-course radiation|33Gy/10 fractions
362526|NCT01431586|Drug|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
362527|NCT01431573|Behavioral|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
362528|NCT01431573|Device|light box|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
362529|NCT01431573|Drug|Lithium|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
362530|NCT01431560|Device|fixation of the ankle fracture (Solco )|fixation with metallic implant
362531|NCT01431560|Device|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
362532|NCT01431547|Drug|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m^2, and escalated for successive cohorts of participants until MTD is found
362533|NCT01431547|Drug|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
362534|NCT01431547|Drug|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
362535|NCT01431534|Drug|Ridaforolimus|Oral administration of 10 mg enteric-coated tablets at doses of 22 mg/m^2, 28 mg/m^2, or 33 mg/m^2 based on body surface area (BSA), once daily for 5 consecutive days each week in consecutive 28-day cycles.
362536|NCT01431521|Drug|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
362537|NCT01431521|Drug|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
362538|NCT01431521|Drug|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
362539|NCT01431521|Drug|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
362540|NCT01431508|Drug|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
362541|NCT01431495|Drug|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
362542|NCT01431495|Drug|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
362543|NCT01431469|Dietary Supplement|Cow's milk|Powdered Whole Cow's Milk
362544|NCT01431469|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
362545|NCT01431456|Drug|Dabigatran|Dabigatran
362546|NCT01431456|Drug|Rivaroxaban|Rivaroxaban
362547|NCT01431456|Drug|Nadroparin|Nadroparin
362548|NCT01431443|Other|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
362549|NCT01431443|Other|Placebo Chocolate|Placebo intervention
362550|NCT01431430|Drug|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
362551|NCT01431430|Drug|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
362552|NCT01431404|Biological|Etanercept (Enbrel)|prefilled syringe, SC
362553|NCT01431404|Biological|HD203|HD203, prefilled syringe, SC injection
362554|NCT01431391|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
362555|NCT01431391|Drug|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
362556|NCT01431365|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
362557|NCT01431365|Behavioral|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
362681|NCT01430442|Drug|BMS-927711|Capsule, Oral, 300mg, One time, One dose
362558|NCT01431352|Drug|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
362559|NCT01431352|Drug|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
362560|NCT01431339|Drug|IV Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
362561|NCT01431339|Drug|Vancomycin/Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
362562|NCT01431326|Drug|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
362563|NCT01431313|Drug|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
362564|NCT01431300|Drug|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
362565|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
362566|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
362567|NCT01431287|Drug|tiotropium|low dose or high dose
362568|NCT01431287|Drug|tiotropium|low dose or high dose
362569|NCT01431287|Drug|olodaterol|one dose only
362570|NCT01431287|Device|Respimat|Respimat inhaler
362571|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
362572|NCT01431274|Drug|tiotropium|low dose
362573|NCT01431274|Drug|olodaterol|one dose only
362574|NCT01431274|Drug|tiotropium|high dose
362575|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
362576|NCT01431274|Device|Respimat|Respimat inhaler
362577|NCT01431261|Other|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
362578|NCT01431261|Behavioral|Pain management|Educational sessions in pain management 4 times
362579|NCT01431235|Behavioral|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
362580|NCT01431222|Device|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
362581|NCT01431209|Other|Laboratory Biomarker Analysis|Correlative studies
362582|NCT01431209|Drug|Ruxolitinib Phosphate|Given PO
362583|NCT01431196|Biological|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
362584|NCT01431183|Behavioral|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
362585|NCT01431170|Drug|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
362586|NCT01431170|Drug|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
362587|NCT01431157|Procedure|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
362588|NCT01431157|Other|No nasal oxygen|Patients will have no intervention for sleep apnea
362589|NCT01431144|Procedure|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
362590|NCT01431144|Procedure|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
362591|NCT01431131|Procedure|Intrasocket graft|Intrasocket mineralized cancellous allograft
362592|NCT01431131|Procedure|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
362593|NCT01431118|Other|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
362594|NCT01431118|Other|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
362595|NCT01431105|Drug|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
362596|NCT01431092|Drug|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
362597|NCT01431092|Drug|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
362598|NCT01431079|Behavioral|HPV vaccine acceptability|One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
362599|NCT01431066|Device|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
362600|NCT01431066|Device|ActiPatch PRFE Device|Actipatch PRFE device
362601|NCT01431053|Drug|aspirin|Aspirin 50mg po daily
362602|NCT01431053|Drug|Exemestane|Exemestane 25mg po daily
362603|NCT01431040|Other|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
362604|NCT01431040|Other|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
362605|NCT01431014|Drug|"Dexamethasonelow-dose"|5mg
362606|NCT01431014|Drug|"Dexamethasonehigh-dose"|15 mg
362607|NCT01431001|Device|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
362608|NCT01430975|Drug|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
362609|NCT01430975|Drug|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
362682|NCT01430442|Drug|BMS-927711|Capsule, Oral, 600mg, One time, One dose
362610|NCT01430949|Procedure|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
362611|NCT01430923|Drug|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
362612|NCT01430923|Drug|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
362613|NCT01430910|Drug|CAZ104|IV infusion
362614|NCT01430910|Drug|Avibactam|IV infusion
362615|NCT01430910|Drug|Ceftazidime|IV infusion
362616|NCT01430884|Other|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
362617|NCT01430858|Device|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
362618|NCT01430858|Other|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion & strain gauge readings will be captured.~Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion & strain gauge readings will be captured.~Power Plate Pro5 Two amplitude settings will be tested, described as low & high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion & strain gauge readings will be captured."
362619|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
362620|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
362621|NCT01430806|Drug|Dronedarone arm|PO Dronedarone 400 mg BID
362622|NCT01430806|Drug|Dronedarone|Dronedarone PO 400 MG BID
362623|NCT01430793|Drug|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
362624|NCT01430793|Drug|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
362625|NCT01430793|Drug|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
362626|NCT01430793|Drug|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
362627|NCT01430780|Drug|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
362628|NCT01430780|Drug|control group|placebo
362629|NCT01430754|Drug|tasimelteon|20 mg tasimelteon capsules, daily
362630|NCT01430754|Drug|Placebo|Placebo capsules, daily
362631|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
362632|NCT01430741|Other|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
362633|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
362634|NCT01430741|Other|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
362635|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
362636|NCT01430715|Other|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, > 5th % to < 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
362683|NCT01430442|Drug|Sumatriptan|Capsule, Oral, 100mg, One time, One dose
362684|NCT01430429|Drug|NI-0801|
362685|NCT01430416|Drug|AEB071|
362637|NCT01430702|Device|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
362638|NCT01430689|Biological|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once~Household and Woman/Infant surveillance~Home visits weekly until the infant is born and reaches 6 months of age~If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
362639|NCT01430689|Biological|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once~Household and Woman/Infant surveillance~Home visits weekly until the infant is born and reaches 6 months of age~If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
362640|NCT01430676|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
362641|NCT01430650|Drug|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
362642|NCT01430650|Drug|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
362643|NCT01430637|Genetic|DNA analysis|
362644|NCT01430637|Genetic|RNA analysis|
362645|NCT01430637|Genetic|gene expression analysis|
362646|NCT01430637|Genetic|mutation analysis|
362647|NCT01430637|Genetic|nucleic acid sequencing|
362648|NCT01430637|Genetic|polymerase chain reaction|
362649|NCT01430637|Other|laboratory biomarker analysis|
362650|NCT01430637|Other|pharmacogenomic studies|
362651|NCT01430624|Behavioral|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
362652|NCT01430624|Behavioral|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
362653|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
362654|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
362655|NCT01430598|Procedure|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
362656|NCT01430598|Other|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
362657|NCT01430585|Drug|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
362658|NCT01430585|Drug|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
362659|NCT01430585|Drug|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
362660|NCT01430572|Drug|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
362661|NCT01430572|Drug|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.~Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
362662|NCT01430559|Drug|Meloxicam|7.5mg x2 once a day for 12 weeks
362663|NCT01430559|Drug|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
362664|NCT01430533|Drug|azelaic acid pre foam formulation|
362665|NCT01430533|Drug|Vehicle pre foam formulation|
362666|NCT01430533|Drug|Water|
362667|NCT01430520|Drug|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
362668|NCT01430520|Drug|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
362669|NCT01430507|Drug|Revamilast|Tablet, Low dose, Once daily for 12 weeks
362670|NCT01430507|Drug|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
362671|NCT01430507|Drug|Revamilast|Tablet, High dose, Once daily for 12 weeks
362672|NCT01430507|Drug|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
362673|NCT01430481|Dietary Supplement|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
362674|NCT01430468|Procedure|Glenoid Positioning System|Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
362675|NCT01430455|Drug|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
362676|NCT01430442|Drug|Placebo matching BMS-927711|Capsule, Oral, 0mg, One time, One dose
362677|NCT01430442|Drug|BMS-927711|Capsule, Oral, 10mg, One time, One dose
362686|NCT01430403|Biological|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
362687|NCT01430403|Drug|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
362688|NCT01430403|Biological|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
362689|NCT01430403|Biological|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
362690|NCT01430390|Biological|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
362691|NCT01430390|Drug|Cyclophosphamide-based chemotherapy|Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
362692|NCT01430377|Procedure|SB predilatation|Initial SB [predilatation.
362693|NCT01430377|Procedure|No SB predilatation|Without SB predilatation
362694|NCT01430364|Device|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
362695|NCT01430364|Device|BIOSS Lim|
362696|NCT01430364|Device|CarloS|
362697|NCT01430351|Drug|Mefloquine|Given PO
362698|NCT01430351|Drug|Memantine Hydrochloride|Given PO
362699|NCT01430351|Drug|Metformin Hydrochloride|Given PO
362700|NCT01430351|Drug|Temozolomide|Given PO
362701|NCT01430325|Drug|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
362702|NCT01430325|Drug|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
362703|NCT01430312|Drug|azelaic acid pre-foam formulation|
362704|NCT01430312|Drug|Vehicle pre-foam formulation|
362705|NCT01430312|Drug|Water|
362706|NCT01430312|Drug|Sodium lauryl sulfate|
362707|NCT01430299|Device|Demineralized Bone Matrix|Accell Evo3 in posteriolateral fusion (prospective cohort)
362708|NCT01430299|Device|rh-BMP2|rh-BMP2 in posterolateral fusion (retrospective cohort)
362709|NCT01430286|Behavioral|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
362710|NCT01430286|Behavioral|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
362711|NCT01430260|Drug|Ciclesonide|200 ㎍ once daily
362712|NCT01430260|Drug|Levocetirizine|5mg once daily
362713|NCT01430260|Drug|Ciclesonide & Levocetirizine|"Omnaris (ciclesonide) 200 ㎍ once daily~Levocetirizine 5mg once daily"
362714|NCT01430247|Other|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
362715|NCT01430234|Drug|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
362716|NCT01430221|Behavioral|Mindfulness-based Personalized Health Planning|
362717|NCT01430221|Other|Structured & Guided Education|
362718|NCT01430208|Procedure|resectoscopy|hysteroscopy for myomas G0 and/or polyps
362719|NCT01430195|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
362720|NCT01430195|Procedure|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
362721|NCT01430182|Drug|Methadone|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
362722|NCT01430182|Drug|Morphine|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
362723|NCT01430169|Biological|AA4500|Two injections of AA4500 0.58 mg 24 hours apart
362724|NCT01430156|Drug|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
362725|NCT01430156|Drug|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
362726|NCT01430143|Behavioral|Exercise|Daily exercise for 12 weeks.
364114|NCT01419509|Genetic|polymerase chain reaction|
362728|NCT01430117|Biological|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
362729|NCT01430104|Drug|Teriparatide|Administered subcutaneously during the Treatment Period
362730|NCT01430104|Drug|Aspara-CA 600 mg|Administered orally throughout the study
362731|NCT01430104|Drug|Alfarol 1.0 µg|Administered orally throughout the study
362732|NCT01430091|Drug|Prasugrel (clinical formulation)|Administered orally
362733|NCT01430091|Drug|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
362734|NCT01430078|Drug|ASP015K|oral tablet
362735|NCT01430078|Drug|ASP015K|solution via oral capsule
362736|NCT01430065|Drug|ASP015K|oral
362737|NCT01430065|Drug|Tacrolimus|oral
362738|NCT01430052|Drug|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
362739|NCT01430052|Drug|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
362740|NCT01430039|Procedure|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
362741|NCT01430039|Procedure|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
362742|NCT01430013|Drug|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
362743|NCT01430000|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
362744|NCT01429987|Drug|plecanatide|Subjects receive experimental study drug for 12 weeks.
362745|NCT01429987|Other|Placebo|Subjects receive experimental study drug for 12 weeks.
362746|NCT01429974|Other|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.~The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
362747|NCT01429961|Drug|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1~14
362748|NCT01429935|Drug|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
362749|NCT01429935|Drug|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
362750|NCT01429935|Other|placebo|capsules contain starch
362751|NCT01429909|Device|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2*.
362752|NCT01429896|Other|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
362753|NCT01429870|Drug|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
362754|NCT01429844|Drug|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
362755|NCT01429844|Drug|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
362756|NCT01429831|Drug|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
362757|NCT01429818|Drug|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
362758|NCT01429818|Drug|Metformin|1000 mg tablets once daily for eight weeks
362759|NCT01429805|Device|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
362760|NCT01429792|Drug|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
362761|NCT01429792|Drug|ribavirin [Copegus]|standard treatment, orally daily
362762|NCT01429779|Drug|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
362763|NCT01429766|Other|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed~st visit Within one day of the date of simulation~nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
362764|NCT01429753|Other|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
362765|NCT01429753|Device|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
362766|NCT01429740|Drug|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
362767|NCT01429740|Drug|Placebo|Placebo oral solution or capsules
362836|NCT01429116|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
362768|NCT01429714|Device|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
362769|NCT01429714|Device|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
362770|NCT01429701|Drug|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
362771|NCT01429701|Drug|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
362772|NCT01429688|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
362773|NCT01429675|Drug|bonviva|150mg Ibandronate once a month
362774|NCT01429662|Behavioral|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
362775|NCT01429662|Behavioral|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
362776|NCT01429649|Procedure|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
362777|NCT01429636|Behavioral|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
362778|NCT01429636|Behavioral|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
362779|NCT01429623|Drug|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
362780|NCT01429623|Drug|Placebo|Placebo comparator
362781|NCT01429610|Drug|Rituximab+mVPDL|"Induction:~Dauno 90 mg/m2/d by civ (d1-3)~Vinc 2 mg iv (d1, 8)~Pred 60 mg/m2/d po (d1-14)~for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~Rituximab 375mg/m2/d (d8)~Consolidation A (cycle1)~D 45 mg/m2/day by continuous iv (d1, 2)~V 2 mg iv (d1, 8)~P 60 mg/m2/day po (d1-14)~for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~Rituximab 375mg/m2/d (d8)~Consolidation B (cycles2&4)~Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~Eto 150 mg/m2/d iv over 3 hr (d1-4)~Rituximab 375mg/m2/d d8~Consolidation C (cycles 3&5)~Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~Rituximab 375mg/m2/d (d8&22)~Maintenance (for 2 years)~- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~Consider alloHCT"
362782|NCT01429584|Drug|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
362783|NCT01429584|Drug|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
362784|NCT01429571|Other|No intervention|No intervention
362785|NCT01429545|Drug|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
362786|NCT01429545|Drug|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
362787|NCT01429532|Procedure|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
362788|NCT01429519|Drug|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
362789|NCT01429506|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
362790|NCT01429506|Drug|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
362791|NCT01429493|Radiation|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
362792|NCT01429493|Radiation|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
362793|NCT01429493|Radiation|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
362794|NCT01429480|Procedure|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
362795|NCT01429480|Procedure|Preoperative Ultrasound Guided Posterior TAP Block|
362796|NCT01429480|Drug|Patient controlled analgesia|
362797|NCT01429467|Device|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
362798|NCT01429454|Drug|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
362799|NCT01429454|Drug|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
362800|NCT01429441|Drug|Ocriplasmin|0.125 mg single intravitreal injection
362801|NCT01429441|Other|Sham injection|Sham injection
362876|NCT01428817|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
362802|NCT01429428|Other|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
362803|NCT01429428|Other|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
362804|NCT01429415|Drug|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
362805|NCT01429415|Drug|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
362806|NCT01429402|Drug|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
362807|NCT01429402|Drug|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
362808|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
362809|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
362810|NCT01429376|Other|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
362811|NCT01429376|Other|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).~Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.~Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
362812|NCT01429376|Other|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.~All questionnaires were completed on the day of initial pulmonary function tests and three months later."
362813|NCT01429376|Other|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
362814|NCT01429363|Procedure|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
362815|NCT01429350|Drug|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
362816|NCT01429350|Device|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
362817|NCT01429337|Drug|Midostaurin|Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on day 1.
362818|NCT01429298|Drug|Hydromorphone|2 mg IV hydromorphone over to 2-3 minutes
362819|NCT01429298|Drug|Usual care|Attending administers IV opioid of his choosing
362820|NCT01429285|Drug|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
362821|NCT01429285|Drug|Usual care|Attending administers any IV opioid in any dose he chooses
362822|NCT01429272|Drug|Minocycline|100 mg po bid for 6 weeks
362823|NCT01429272|Drug|Aspirin|81 mg po bid for 6 weeks
362824|NCT01429272|Drug|placebo|placebo for minocycline and/or aspirin
362825|NCT01429259|Drug|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
362826|NCT01429246|Dietary Supplement|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
362827|NCT01429246|Dietary Supplement|Salt Substitute|Estimated 30 grams per day per household member
362828|NCT01429194|Procedure|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
362829|NCT01429181|Drug|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
362830|NCT01429168|Drug|Etoricoxib|One 60-mg tablet orally daily
362831|NCT01429168|Drug|Placebo for etoricoxib|One 60-mg tablet orally daily
362832|NCT01429155|Genetic|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
362833|NCT01429142|Behavioral|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
362834|NCT01429142|Behavioral|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:~-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.~Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
362835|NCT01429129|Drug|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
363022|NCT01427881|Drug|fludarabine phosphate|Given IV
362837|NCT01429090|Procedure|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
362838|NCT01429090|Drug|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
362839|NCT01429090|Drug|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
362840|NCT01429090|Procedure|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
362841|NCT01429090|Procedure|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
362842|NCT01429090|Procedure|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
362843|NCT01429077|Drug|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
362844|NCT01429077|Drug|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
362845|NCT01429064|Drug|ODM-201|ODM-201 administered orally daily
362846|NCT01429051|Drug|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
362847|NCT01429051|Drug|Placebo|Matching intranasal placebo spray
362848|NCT01429038|Biological|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
362849|NCT01429025|Biological|rituximab|IV
362850|NCT01429025|Drug|bendamustine|IV
362851|NCT01429025|Drug|lenalidomide|PO
362852|NCT01429012|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
362853|NCT01429012|Other|Culture medium without MSC.|2 ml of culture medium.
362854|NCT01428999|Dietary Supplement|probiotics|probiotics 1 pack (2g) bid for three weeks
362855|NCT01428986|Drug|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
362856|NCT01428973|Drug|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
362857|NCT01428973|Drug|Sirolimus|Tablets. 6 mg loading dose on day −3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
362858|NCT01428960|Dietary Supplement|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
362859|NCT01428947|Procedure|Arterial approach|Randomization to right radial or femoral approach
362860|NCT01428921|Behavioral|Theory based education and brief motivation interview|"Standard education programme as described above,~Plus~Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration~Follow-up phone call would be arranged within 1 week after using CPAP.~Video, slides and booklets would be used as education media."
362861|NCT01428908|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
362862|NCT01428908|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
362863|NCT01428908|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
362864|NCT01428908|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
362865|NCT01428895|Procedure|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
362866|NCT01428895|Other|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
362867|NCT01428882|Drug|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
362868|NCT01428882|Drug|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
362869|NCT01428843|Drug|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
362870|NCT01428843|Drug|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
362871|NCT01428830|Procedure|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
362872|NCT01428830|Procedure|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
362873|NCT01428817|Drug|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
362874|NCT01428817|Drug|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
362875|NCT01428817|Drug|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
363023|NCT01427881|Drug|busulfan|Given IV
362877|NCT01428817|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
362878|NCT01428804|Device|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
362879|NCT01428791|Behavioral|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:~• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
362880|NCT01428791|Behavioral|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health & health behavior change for 6 - 12 months, including:~• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
362881|NCT01428739|Device|MRS|Procedure
362882|NCT01428726|Drug|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
362883|NCT01428713|Drug|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
362884|NCT01428713|Drug|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
362885|NCT01428687|Behavioral|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
362886|NCT01428687|Behavioral|No change in sleep|This group is taught to maintain their current sleep habits.
362887|NCT01428674|Other|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
362888|NCT01428674|Other|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
362889|NCT01428661|Drug|tasimelteon|20 mg once daily
362890|NCT01428661|Drug|placebo|once daily
362891|NCT01428648|Behavioral|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
362892|NCT01428635|Drug|Eltrombopag Olamine|Given PO
362893|NCT01428622|Device|Respimat|aqueous and ethanolic solution
362894|NCT01428622|Device|Respimat|aqueous and ethanolic solution
362895|NCT01428622|Device|Respimat|aqueous and ethanolic solution
362896|NCT01428622|Device|Respimat|aqueous and ethanolic solution
362897|NCT01428622|Device|Respimat|aqueous and ethanolic solution
362898|NCT01428622|Device|Respimat|aqueous and ethanolic solution
362899|NCT01428622|Device|Respimat|aqueous and ethanolic solution
362900|NCT01428622|Drug|Olodaterol|aqueous solution
362901|NCT01428622|Drug|Olodaterol|aqueous solution
362902|NCT01428622|Drug|Olodaterol|aqueous solution
362903|NCT01428622|Drug|Olodaterol|aqueous solution
362904|NCT01428622|Drug|Olodaterol|aqueous solution
362905|NCT01428622|Drug|Olodaterol|aqueous solution
362906|NCT01428622|Drug|Olodaterol|aqueous solution
362907|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
362908|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
362909|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
362910|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
362911|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
362912|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
362913|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
362914|NCT01428622|Drug|BI54903|ethanolic solution
362915|NCT01428622|Drug|BI54903|ethanolic solution
362916|NCT01428622|Drug|BI54903|ethanolic solution
362917|NCT01428622|Drug|BI54903|ethanolic solution
362918|NCT01428622|Drug|BI54903|ethanolic solution
362919|NCT01428622|Drug|BI54903|ethanolic solution
362920|NCT01428622|Drug|BI54903|ethanolic solution
362921|NCT01428609|Procedure|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
362922|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ lower dose (10^8 TU) at weeks 0, 8 and 16.
362923|NCT01428596|Biological|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
362924|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ higher dose (10^9 TU) at weeks 0, 8 and 16.
362925|NCT01428583|Drug|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
362926|NCT01428570|Device|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
363024|NCT01427881|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
363025|NCT01427868|Drug|LB80380 maleate salt|183 mg (150 mg as a free base)
362927|NCT01428544|Drug|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
362928|NCT01428531|Drug|Fondaparinux Sodium|
362929|NCT01428518|Drug|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
362930|NCT01428505|Radiation|[18F]PBR111|radioligand to assess binding to TSPO
362931|NCT01428492|Drug|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
362932|NCT01428492|Drug|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
362933|NCT01428492|Drug|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
362934|NCT01428479|Drug|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
362935|NCT01428479|Drug|Placebo|Placebo solution will be administered intravenously.
362936|NCT01428466|Drug|GSK2585823|CLDM1%/BPO3%
362937|NCT01428466|Drug|Benzoyl peroxide 3%|Benzoyl peroxide 3%
362938|NCT01428466|Drug|Benzoyl peroxide 5%|Benzoyl peroxide 5%
362939|NCT01428466|Other|Vehicle|placebo
362940|NCT01428453|Drug|250mg rilapladib|Experimental Drug
362941|NCT01428453|Drug|placebo|Placebo comparator
362942|NCT01428440|Radiation|18FML10|apoptosis imaging radio ligand
362943|NCT01428427|Drug|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
362944|NCT01428427|Drug|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
362945|NCT01428414|Drug|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
362946|NCT01428414|Drug|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
362947|NCT01428414|Drug|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
362948|NCT01428414|Drug|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
362949|NCT01428401|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
362950|NCT01428401|Other|Placebo|at a rate of 3 g three times per day
362951|NCT01428388|Drug|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
362952|NCT01428388|Drug|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
362953|NCT01428375|Drug|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
362954|NCT01428375|Other|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
362955|NCT01428362|Drug|VI-1121|
362956|NCT01428362|Drug|Placebo|
362957|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
362958|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
362959|NCT01428336|Procedure|1 ug ACTH stimulation test|1 ug cortrosyn dose
362960|NCT01428336|Procedure|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
362961|NCT01428336|Procedure|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
362962|NCT01428336|Procedure|Insulin tolerance test|subjects will undergo an insulin tolerance test
362963|NCT01428323|Device|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
362964|NCT01428310|Dietary Supplement|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
362965|NCT01428310|Dietary Supplement|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
362966|NCT01428297|Drug|BPR277 ointment (controlled application)|
362967|NCT01428297|Drug|Placebo (Vehicle)|
362968|NCT01428297|Drug|BPR277 ointment|
362969|NCT01428297|Drug|Placebo (Vehicle)|
362970|NCT01428297|Drug|BPR277|
362971|NCT01428297|Drug|Placebo (Vehicle)|
362972|NCT01428284|Drug|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
362973|NCT01428271|Other|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
362974|NCT01428258|Other|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
363026|NCT01427868|Drug|LB80380 free base|150 mg
363027|NCT01427855|Other|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
362975|NCT01428258|Other|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
362976|NCT01428245|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
362977|NCT01428245|Drug|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
362978|NCT01428232|Other|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
362979|NCT01428232|Other|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
362980|NCT01428219|Drug|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
362981|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
362982|NCT01428193|Drug|Flutamide|Subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day.
362983|NCT01428193|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
362984|NCT01428193|Drug|estrace|0.5-1 mg once a day for seven days
362985|NCT01428180|Drug|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
362986|NCT01428180|Procedure|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
362987|NCT01428180|Drug|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
362988|NCT01428154|Drug|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
362989|NCT01428141|Drug|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
362990|NCT01428128|Drug|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
362991|NCT01428089|Drug|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
362992|NCT01428089|Drug|Placebo|Placebo
362993|NCT01428076|Drug|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
362994|NCT01428063|Drug|Daclatasvir|
362995|NCT01428063|Drug|Asunaprevir|
362996|NCT01428063|Drug|Pegylated interferon alfa-2a|
362997|NCT01428063|Drug|Ribavirin|
362998|NCT01428050|Drug|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
362999|NCT01428050|Drug|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
363000|NCT01428037|Drug|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
363001|NCT01428037|Drug|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
363002|NCT01428024|Device|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
363003|NCT01428024|Device|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and optional at week 12.
363004|NCT01427998|Dietary Supplement|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
363005|NCT01427998|Other|placebo|placebo
363006|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg~Mivacurium 200µg/kg immediately followed by~Fentanyl 2µg/kg"
363007|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg~Fentanyl 2µg/kg, repeat max. two times~Mivacurium 200µg/kg"
363008|NCT01427972|Drug|LY2623091|Administered orally
363009|NCT01427972|Drug|Eplerenone|Administered orally
363010|NCT01427946|Drug|IPI-504|
363011|NCT01427946|Drug|Everolimus|
363012|NCT01427933|Biological|Ramucirumab (IMC-1121B)|Administered intravenously
363013|NCT01427933|Drug|Eribulin|Administered intravenously
363014|NCT01427920|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
363015|NCT01427907|Drug|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
363016|NCT01427907|Drug|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
363017|NCT01427894|Other|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
363018|NCT01427881|Drug|cyclophosphamide|Given IV
363019|NCT01427881|Drug|cyclosporine|Given IV
363020|NCT01427881|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
363021|NCT01427881|Radiation|total-body irradiation|Undergo TBI
363028|NCT01427855|Other|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
363029|NCT01427855|Other|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
363030|NCT01427855|Other|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
363031|NCT01427855|Other|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
363032|NCT01427855|Other|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
363033|NCT01427842|Drug|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
363034|NCT01427829|Behavioral|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
363035|NCT01427816|Drug|KCT-0809|
363036|NCT01427816|Drug|KCT-0809|
363037|NCT01427816|Drug|Placebo|
363038|NCT01427803|Drug|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
363039|NCT01427764|Device|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.~The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
363040|NCT01427751|Drug|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
363041|NCT01427751|Biological|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
363042|NCT01427738|Drug|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
363043|NCT01427738|Drug|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
363044|NCT01427699|Drug|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
363045|NCT01427686|Drug|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
363046|NCT01427686|Drug|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
363047|NCT01427673|Procedure|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
363048|NCT01427660|Behavioral|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
363049|NCT01427660|Behavioral|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
363050|NCT01427647|Procedure|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
363051|NCT01427634|Behavioral|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
363052|NCT01427634|Other|Usual Care|Receive usual care as provided by the VAD clinical team.
363053|NCT01427621|Procedure|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
363054|NCT01427608|Drug|Sertraline + Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
363144|NCT01426880|Drug|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
363055|NCT01427608|Drug|Sertraline + Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
363056|NCT01427595|Drug|Metformin|500-2000 mg PO BID (X12 weeks)
363057|NCT01427595|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)
363058|NCT01427595|Drug|estrace|oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
363059|NCT01427582|Drug|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
363060|NCT01427569|Drug|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
363061|NCT01427569|Other|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
363062|NCT01427543|Behavioral|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
363063|NCT01427530|Device|Deep Brain Stimulation|Deep Brain Stimulation
363064|NCT01427517|Drug|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
363065|NCT01427504|Drug|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
363066|NCT01427491|Device|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
363067|NCT01427491|Device|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
363068|NCT01427478|Drug|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
363069|NCT01427478|Drug|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
363070|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Consult
363071|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Control - Standard of Care
363072|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Newsletter
363073|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Parent Letter
363074|NCT01427426|Dietary Supplement|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
363075|NCT01427426|Other|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
363076|NCT01427400|Drug|Botulinum Toxin-A|100 Units diluted in 25cc saline
363077|NCT01427400|Drug|Saline|Dispensed in a 25cc syringe
363078|NCT01427387|Drug|ASP0456|oral
363079|NCT01427387|Drug|Placebo|oral
363080|NCT01427348|Procedure|with assistant|head extension by an assistant during direct laryngoscopy
363081|NCT01427348|Procedure|without assistant|without head extension by an assistant during direct laryngoscopy
363082|NCT01427335|Drug|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.~Intravenous infusion was performed within 30 minutes"
363083|NCT01427335|Drug|0.9 % saline|0.9 % saline intravenous infusion
363084|NCT01427322|Drug|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
363085|NCT01427322|Radiation|Radiation therapy|Standard radiation therapy
363086|NCT01427309|Biological|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
363087|NCT01427309|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
363088|NCT01427296|Drug|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
363089|NCT01427296|Drug|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
363090|NCT01427283|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
363091|NCT01427283|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
363092|NCT01427283|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
363093|NCT01427270|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
363094|NCT01427270|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
363095|NCT01427270|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
363096|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation A
363097|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
363098|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
363099|NCT01427244|Drug|trastuzumab|monoclonal antibody
363100|NCT01427231|Dietary Supplement|glucose|The effect of a glucose solution on cognitive performance will be measured.
363101|NCT01427231|Dietary Supplement|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
363102|NCT01427231|Dietary Supplement|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
363181|NCT01426516|Device|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
363182|NCT01426490|Dietary Supplement|Vitamin C|Vitamin C, 100 mg/d
363183|NCT01426490|Dietary Supplement|Vitamin B6|Vitamin B6, 50mg/d
363184|NCT01426490|Dietary Supplement|Folic acid|Folic acid 400 microgram/d
363185|NCT01426490|Dietary Supplement|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
363103|NCT01427218|Other|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
363104|NCT01427218|Behavioral|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
363105|NCT01427218|Behavioral|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
363106|NCT01427218|Other|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
363107|NCT01427205|Drug|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
363108|NCT01427205|Drug|OSI-906|150 mg by mouth twice a day.
363109|NCT01427205|Other|Placebo|Placebo taken by mouth twice daily.
363110|NCT01427192|Drug|acetazolamide|250 mg bid
363111|NCT01427192|Other|Supplemental oxygen|Oxygen deliverded by nasal cannula
363112|NCT01427192|Procedure|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
363113|NCT01427192|Other|Room air|Room air applied via sham oxygen concentrator
363114|NCT01427192|Drug|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
363115|NCT01427166|Other|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
363116|NCT01427153|Procedure|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
363117|NCT01427153|Procedure|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
363118|NCT01427140|Other|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
363119|NCT01427140|Other|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
363120|NCT01427127|Drug|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
363121|NCT01427114|Drug|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
363122|NCT01427088|Device|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
363123|NCT01427075|Procedure|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
363124|NCT01427062|Other|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
363125|NCT01427062|Other|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
363126|NCT01427049|Device|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
363127|NCT01427036|Procedure|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
363128|NCT01427036|Procedure|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.~Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.~Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
363129|NCT01427023|Device|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
363130|NCT01427010|Radiation|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography ([18F]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
363131|NCT01426984|Drug|methylphenidate|a capsule containing 20 mg
363132|NCT01426971|Drug|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
363133|NCT01426971|Drug|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
363134|NCT01426958|Drug|afatinib|standard therapeutic dose
363135|NCT01426958|Drug|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
363136|NCT01426958|Drug|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
363137|NCT01426945|Genetic|protein expression analysis|
363138|NCT01426945|Other|immunohistochemistry staining method|
363139|NCT01426945|Other|laboratory biomarker analysis|
363140|NCT01426932|Other|Video recording of Head Impulse Test|Video recording of Head Impulse Test
363141|NCT01426919|Other|Head CT scan and blood draw within 12 hours of injury|
363142|NCT01426906|Drug|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
363143|NCT01426906|Drug|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
363145|NCT01426880|Drug|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
363146|NCT01426867|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
363147|NCT01426867|Drug|Brinzolamide ophthalmic suspension, 1%|
363148|NCT01426867|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
363149|NCT01426854|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
363150|NCT01426854|Other|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
363151|NCT01426841|Radiation|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
363152|NCT01426828|Biological|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
363153|NCT01426815|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
363154|NCT01426815|Drug|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
363155|NCT01426802|Drug|vildagliptin|Drug 50mg vildagliptin bid
363156|NCT01426789|Drug|Placebo|Matching placebo to secukinumab I.V.
363157|NCT01426789|Drug|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
363158|NCT01426776|Procedure|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
363159|NCT01426763|Biological|CINRYZE with rHuPH20|
363160|NCT01426750|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
363161|NCT01426737|Drug|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
363162|NCT01426724|Drug|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
363163|NCT01426698|Procedure|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
363164|NCT01426672|Other|Monovision Correction (with the help of glasses or contact lenses)|
363165|NCT01426659|Behavioral|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
363166|NCT01426646|Drug|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
363167|NCT01426646|Drug|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles~S-1: 40mg/m2 orally twice daily (days 1-14)~Cisplatin: 60mg/m2 IV on day 1"
363168|NCT01426633|Drug|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
363169|NCT01426620|Dietary Supplement|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
363170|NCT01426607|Device|AMO|
363171|NCT01426581|Behavioral|Teach-To-Goal|"Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)"
363172|NCT01426581|Behavioral|Brief Intervention|Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
363173|NCT01426568|Behavioral|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
363174|NCT01426555|Other|FES-Rowing|FES- Rowing Exercise
363175|NCT01426555|Drug|Zoledronic acid|5 mg IV single dose
363176|NCT01426542|Drug|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
363177|NCT01426542|Other|No medication, but routine heart surgery|No medication, but routine heart surgery
363178|NCT01426529|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
363179|NCT01426529|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
363180|NCT01426529|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
363308|NCT01425632|Drug|Placebo|Placebo
363186|NCT01426464|Drug|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
363187|NCT01426451|Other|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
363188|NCT01426451|Other|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
363189|NCT01426438|Drug|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
363190|NCT01426438|Drug|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
363191|NCT01426438|Drug|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
363192|NCT01426425|Device|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
363193|NCT01426412|Drug|LY3015014 IV|Administered IV over 30-90 minutes
363194|NCT01426412|Drug|Placebo IV|Administered IV only over 30-90 minutes
363195|NCT01426412|Drug|LY3015014 SC|Administered SC
363196|NCT01426412|Drug|Placebo SC|Administered SC
363197|NCT01426399|Drug|LC15-0444|LC15-0444 50mg qd (8 days once daily)
363198|NCT01426399|Drug|Metformin|Metformin 1000 mg bid (8 days twice daily)
363199|NCT01426399|Drug|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
363200|NCT01426386|Drug|FE 999049|
363201|NCT01426386|Drug|Gonal - F|
363202|NCT01426373|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
363203|NCT01426360|Other|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
363204|NCT01426360|Other|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
363205|NCT01426347|Drug|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
363206|NCT01426347|Drug|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
363207|NCT01426334|Drug|dasatinib|Given PO
363208|NCT01426334|Other|diagnostic laboratory biomarker analysis|Correlative studies
363209|NCT01426334|Other|pharmacological study|Correlative studies
363210|NCT01426334|Drug|cyclosporine|Given PO
363211|NCT01426321|Other|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
363212|NCT01426295|Device|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)~The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.~Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.~The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0."
363213|NCT01426295|Drug|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.~Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
363214|NCT01426282|Other|no intervention|no intervention
363215|NCT01426282|Other|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
363216|NCT01426269|Drug|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads), oral, one capsule daily in the morning
363217|NCT01426269|Drug|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
363218|NCT01426269|Drug|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
363219|NCT01426256|Dietary Supplement|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
363220|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
363221|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
363222|NCT01426217|Device|Passive Bundle PSI (Problem Solving Innovations) Medical HubScrub, PSI Medical DocIt|Implementation of passive bundle which includes HubScrub and DocIt device into the operating room environment.
363223|NCT01426191|Drug|xinzhijun|"durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)~1.5-3.0g,iv,bid or tid for 5-12 days;~Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days"
363224|NCT01426178|Device|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.~They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
363225|NCT01426165|Drug|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
364115|NCT01419509|Other|laboratory biomarker analysis|
363226|NCT01426139|Device|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
363227|NCT01426126|Drug|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
363228|NCT01426113|Drug|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
363229|NCT01426113|Drug|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
363230|NCT01426113|Drug|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
363231|NCT01426100|Drug|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
363232|NCT01426100|Drug|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
363233|NCT01426100|Drug|Telmisartan 80mg|Telmisartan 80mg monotherapy
363234|NCT01426087|Drug|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
363235|NCT01426087|Procedure|endoscopic therapy|gastroscope plus EIS/EVL/HI
363236|NCT01426074|Drug|Bevacizumab 5 mg/kg|Intravenously every two weeks
363237|NCT01426061|Other|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
363238|NCT01426061|Other|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
363239|NCT01426061|Other|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
363240|NCT01426048|Other|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
363241|NCT01426035|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
363242|NCT01426022|Other|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
363243|NCT01426022|Behavioral|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
363244|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 25 ug|EP-101 (25 ug ) Dose 1 administered once daily for 7 days
363245|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 50 ug|EP-101 (50 ug ) administered once daily for 7 days
363246|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 100 ug|EP-101 (100ug) administered once daily for 7 days
363247|NCT01426009|Drug|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
363248|NCT01426009|Drug|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
363249|NCT01426009|Drug|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
363250|NCT01426009|Drug|EP-101 via nebulizer (eFlow®) 200 ug|EP-101 (200) ug administered once daily for 7 days
363251|NCT01425996|Drug|Lipotecan® (TLC388)|"Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT~Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT~Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT~Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)~Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
363252|NCT01425983|Dietary Supplement|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks"
363253|NCT01425983|Other|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks"
363254|NCT01425970|Drug|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
363255|NCT01425970|Drug|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
363256|NCT01425970|Drug|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
363257|NCT01425970|Drug|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
363258|NCT01425970|Biological|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
363259|NCT01425970|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
363260|NCT01425970|Drug|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
363261|NCT01425970|Drug|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
363262|NCT01425957|Procedure|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).~Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
363263|NCT01425931|Procedure|Heart Lung machine|measurement of microcirculation with O2C device
363309|NCT01425619|Biological|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
363310|NCT01425619|Drug|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
363311|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
364116|NCT01419496|Genetic|protein expression analysis|
363264|NCT01425918|Behavioral|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
363265|NCT01425918|Behavioral|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
363266|NCT01425905|Other|The Blues Program|
363267|NCT01425905|Other|Hey Durham|
363268|NCT01425879|Drug|Akt Inhibitor MK2206|Given PO
363269|NCT01425879|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
363270|NCT01425879|Other|Pharmacological Study|Correlative studies
363271|NCT01425866|Behavioral|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
363272|NCT01425853|Drug|Chondroitin/Glucosamine (Droglican)|Experimental
363273|NCT01425853|Drug|Celecoxib|Active comparator
363274|NCT01425840|Drug|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
363275|NCT01425827|Drug|duloxetine HCL|60 mg/day duloxetine for 16 weeks
363276|NCT01425827|Drug|placebo|similar looking tablets to the active agent for 16 weeks
363277|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
363278|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
363279|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
363280|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
363281|NCT01425814|Drug|Reference|Dry powder inhalation (capsule),single dose
363282|NCT01425814|Drug|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
363283|NCT01425801|Drug|LAS100977 0.313 μg|Dry powder inhalation, once-daily, single-dose
363284|NCT01425801|Drug|LAS100977 0.625 μg|Dry powder inhalation, once-daily, single-dose
363285|NCT01425801|Drug|LAS100977 1.25 μg|Dry powder inhalation, once-daily, single-dose
363286|NCT01425801|Drug|LAS100977 2.5 μg|Dry powder inhalation, once-daily, single-dose
363287|NCT01425801|Drug|Salbutamol 400 μg|Pressurized inhalation suspension, once-daily, single-dose
363288|NCT01425801|Drug|Salbutamol placebo|Pressurized inhalation, once-daily
363289|NCT01425801|Drug|LAS100977 placebo|Dry powder inhalation, once-daily
363290|NCT01425788|Biological|Osiris Phleum pratense|
363291|NCT01425788|Biological|Osiris Phleum pratense|
363292|NCT01425788|Biological|Osiris Phleum pratense|
363293|NCT01425775|Drug|vitamin D 25(OH)D|2000IU/day for 12 months
363294|NCT01425775|Other|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
363295|NCT01425762|Other|Drug Dose|100 versus 200 mcg IT morphine
363296|NCT01425749|Biological|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
363297|NCT01425736|Drug|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
363298|NCT01425736|Drug|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
363299|NCT01425723|Biological|rFIXFc|Administered as specified in the treatment arm.
363300|NCT01425697|Other|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
363301|NCT01425697|Other|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
363302|NCT01425658|Drug|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
363303|NCT01425658|Drug|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
363304|NCT01425658|Drug|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
363305|NCT01425645|Other|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
363306|NCT01425632|Drug|TAU-284|TAU-284 Low
363307|NCT01425632|Drug|TAU-284|TAU-284 High
363312|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
363313|NCT01425606|Other|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
363314|NCT01425580|Drug|liraglutide|1.8 mg s.c. (QD)
363315|NCT01425580|Drug|glimepiride|4 mg p.o. (QD)
363316|NCT01425580|Drug|Metformin|500 mg p.o. (BID)
363317|NCT01425567|Drug|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
363318|NCT01425554|Other|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
363319|NCT01425554|Other|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
363320|NCT01425554|Other|Air-plethysmography of the neck|Air-plethysmography of the neck
363321|NCT01425554|Other|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
363322|NCT01425541|Drug|estrace|0.5-1 mg once a day PO for 7 days
363323|NCT01425541|Drug|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
363324|NCT01425528|Drug|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
363325|NCT01425515|Behavioral|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
363326|NCT01425502|Behavioral|DQIP Intervention|"The DQIP intervention comprises of:~Educational outreach~Information technology application~Financial incentives"
363327|NCT01425476|Drug|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
363328|NCT01425476|Drug|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
363329|NCT01425476|Drug|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
363330|NCT01425463|Drug|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
363331|NCT01425463|Drug|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).~Administered orally with water."
363332|NCT01425463|Other|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
363333|NCT01425463|Other|Placebo to Polyferose|Administered orally with water.
363334|NCT01425450|Drug|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
363335|NCT01425450|Drug|HF1020 placebo|Single dose: HF1020 placebo capsule
363336|NCT01425424|Other|Vitamin D supplementation|Vitamin D
363337|NCT01425411|Drug|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
363338|NCT01425398|Drug|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
363339|NCT01425398|Drug|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
363340|NCT01425385|Other|Near infrared spectroscopy monitoring|This is an observational study without interventions
363341|NCT01425385|Other|Autoregulation monitoring|There are no interventions in this observational study
363342|NCT01425359|Drug|Ranolazine|
363343|NCT01425359|Drug|Ranolazine placebo|
363344|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
363345|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
363346|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
363347|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
363348|NCT01425320|Drug|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
363349|NCT01425320|Drug|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
363350|NCT01425307|Drug|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
363351|NCT01425281|Device|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
363352|NCT01425281|Device|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
363353|NCT01425268|Device|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
363354|NCT01425268|Procedure|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
363355|NCT01425242|Drug|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
363430|NCT01424657|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography
363356|NCT01425242|Drug|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
363357|NCT01425229|Drug|Bosentan|"Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
363358|NCT01425216|Drug|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
363359|NCT01425203|Drug|Boceprevir|boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
363360|NCT01425203|Drug|Placebo|boceprevir-matched placebo four 200-mg capsules PO TID.
363361|NCT01425203|Biological|peginterferon alfa-2b|peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
363362|NCT01425203|Drug|Ribavirin|ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
363363|NCT01425190|Drug|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
363364|NCT01425177|Procedure|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
363365|NCT01425164|Drug|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
363366|NCT01425164|Drug|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
363367|NCT01425151|Device|i-Gel|Oropharyngeal leak pressure Insertion success
363368|NCT01425151|Device|ProSeal|Oropharyngeal leak pressure Insertion success
363369|NCT01425125|Drug|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
363370|NCT01425112|Procedure|Phacoemulsification|Surgery for complications of trabeculectomy
363371|NCT01425099|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
363372|NCT01425099|Drug|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
363373|NCT01425086|Device|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
363374|NCT01425073|Other|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
363375|NCT01425060|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
363376|NCT01425060|Other|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
363377|NCT01425034|Other|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
363378|NCT01425034|Other|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
363379|NCT01425008|Drug|MLN2480|Dose Escalation Phase: patients will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Patients may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the patient discontinues for any other reason. If it is determined that a patient would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Patients will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the patient discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a patient would derive benefit from continued therapy beyond 12 months.
363380|NCT01424982|Drug|Cyclophosphamide|Given IV
363381|NCT01424982|Drug|Cytarabine|Given IV
363382|NCT01424982|Drug|Dexamethasone|Given IV or PO
363383|NCT01424982|Drug|Doxorubicin|Given IV
363384|NCT01424982|Drug|Doxorubicin Hydrochloride|Given IV
363385|NCT01424982|Other|Laboratory Biomarker Analysis|Correlative studies
363386|NCT01424982|Drug|Methotrexate|Given IV
363387|NCT01424982|Drug|Ponatinib|Given PO
363388|NCT01424982|Drug|Ponatinib Hydrochloride|Given PO
363389|NCT01424982|Drug|Prednisone|Given PO
363390|NCT01424982|Biological|Rituximab|Given IV
363391|NCT01424982|Drug|Vincristine|Given IV
363392|NCT01424982|Drug|Vincristine Sulfate|Given IV
363393|NCT01424956|Device|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
363394|NCT01424943|Behavioral|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
363395|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
363396|NCT01424930|Drug|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
363397|NCT01424930|Drug|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
363431|NCT01424657|Procedure|MRCP|magnetic resonance cholangiopancreatography
363432|NCT01424644|Biological|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
363398|NCT01424904|Dietary Supplement|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.~Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
363399|NCT01424891|Drug|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
363400|NCT01424891|Drug|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
363401|NCT01424891|Drug|Placebo|treatment with placebo over 8 weeks
363402|NCT01424865|Genetic|fluorescence in situ hybridization|
363403|NCT01424865|Other|immunohistochemistry staining method|
363404|NCT01424865|Other|immunologic technique|
363405|NCT01424865|Other|laboratory biomarker analysis|
363406|NCT01424852|Dietary Supplement|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
363407|NCT01424839|Radiation|craniospinal irradiation|"Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)~Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)~Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
363408|NCT01424839|Drug|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
363409|NCT01424839|Radiation|ventricular irradiation|"Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)~Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles~Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
363410|NCT01424839|Drug|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
363411|NCT01424839|Drug|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
363412|NCT01424839|Radiation|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
363413|NCT01424826|Drug|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
363414|NCT01424826|Drug|Rifampicin|< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days > 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
363415|NCT01424826|Drug|Raltegravir|800 mg bd for 4 days
363416|NCT01424813|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
363417|NCT01424813|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
363418|NCT01424800|Device|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
363419|NCT01424774|Drug|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
363420|NCT01424761|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
363421|NCT01424761|Other|Placebo|Placebo :starch
363422|NCT01424748|Dietary Supplement|Tahitian Noni Juice|noni fruit juice
363423|NCT01424748|Dietary Supplement|Placebo|Placebo juice
363424|NCT01424735|Drug|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
363425|NCT01424722|Device|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
363426|NCT01424709|Drug|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
363427|NCT01424709|Drug|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
363428|NCT01424670|Drug|Delamanid + OBR|The assigned doses of delamanid were administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
363429|NCT01424670|Drug|Placebo + OBR|Matching placebo was administered with an OBR. The selection and administration of the OBR were based on WHO's guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country.
363433|NCT01424644|Biological|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.~Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
363434|NCT01424631|Procedure|single incision laparoscopic appendectomy|
363435|NCT01424631|Procedure|conventional laparoscopic appendectomy|
363436|NCT01424618|Drug|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
363437|NCT01424618|Drug|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
363438|NCT01424605|Procedure|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
363439|NCT01424592|Device|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
363440|NCT01424579|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
363441|NCT01424579|Other|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
363442|NCT01424579|Other|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
363443|NCT01424566|Drug|Nabiximols|
363444|NCT01424566|Drug|Placebo (GA-0034)|
363445|NCT01424553|Other|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
363446|NCT01424540|Drug|GSK2336805 150mg|Single Dose
363447|NCT01424540|Other|Placebo|Single Dose
363448|NCT01424514|Drug|SB-705498|12mg intra nasal
363449|NCT01424514|Drug|Placebo|Placebo intra nasal
363450|NCT01424501|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|Intramuscular injection, 2 doses
363451|NCT01424501|Biological|Placebo|Intramuscular injection, 2 doses
363452|NCT01424488|Drug|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
363453|NCT01424488|Drug|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
363454|NCT01424475|Genetic|Healthy|Healthy Volunteers
363455|NCT01424475|Genetic|PKD Patients|PKS Patients
363456|NCT01424462|Drug|A|Single dose treatment IR formulation
363457|NCT01424462|Drug|B|Low Extended release single dose
363458|NCT01424462|Drug|C|Medium extended release formulation
363459|NCT01424462|Drug|D|High extended release rate single dose
363460|NCT01424449|Radiation|[11C]PHNO|examine the effects of [11C]PHNO mass carry-over and displaceable binding
363461|NCT01424449|Drug|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
363462|NCT01424436|Biological|GSK933776|1mg/kg dose group
363463|NCT01424436|Biological|GSK933776|3mg/kg dose group
363464|NCT01424436|Biological|GSK933776|6mg/kg dose group
363465|NCT01424423|Drug|Placebo|Placebo
363466|NCT01424423|Drug|GSK1223249|I.V. Infusion
363467|NCT01424397|Drug|SB-705498|12mg intranasal
363468|NCT01424397|Drug|FP|200ug intranasal
363469|NCT01424397|Drug|placebo|placebo intranasal
363470|NCT01424384|Drug|Citalopram|Neurophysiological testing.
363471|NCT01424384|Drug|GSK424887|Neurophysiological testing
363472|NCT01424384|Drug|Plactebo To Match|Neurophysiological testing
363473|NCT01424358|Other|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
363474|NCT01424345|Drug|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
363475|NCT01424345|Drug|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
363476|NCT01424332|Drug|Darexaban|oral
363477|NCT01424332|Drug|Acetyl Salicylic Acid (ASA)|oral
363478|NCT01424319|Drug|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
363479|NCT01424319|Drug|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
363480|NCT01424319|Drug|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
363481|NCT01424306|Other|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
363482|NCT01424306|Other|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
363483|NCT01424306|Other|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
363484|NCT01424293|Device|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
363485|NCT01424293|Device|The SPY® Intraoperative Imaging System|
363486|NCT01424280|Drug|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
363487|NCT01424280|Drug|Placebo|Single dose of matching placebo tablets
363488|NCT01424267|Device|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
363489|NCT01424254|Device|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
363490|NCT01424254|Procedure|Push-Enteroscopy|currently recommended standard
363491|NCT01424241|Drug|Sandostatin LAR|This will be a open label dose escalation study of Sandostatin LAR 10 Mg, 20Mg, 30 Mg up to 40 mg if necessary.
363492|NCT01424228|Drug|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
363493|NCT01424228|Drug|prucalopride|"Prucalopride 2 mg daily before breakfast~1 mg for subjects >65 years; in case of insufficient response 2 mg at week 2 or week 4"
363494|NCT01424215|Drug|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
363495|NCT01424202|Device|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.~On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.~The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
363496|NCT01424189|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
363497|NCT01424189|Device|AcrySof® ReSTOR® Multifocal IOL Model SA60D3|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
363498|NCT01424176|Drug|Dexpramipexole (dose 1)|
363499|NCT01424176|Drug|Dexpramipexole (dose 2)|
363500|NCT01424163|Drug|Single dose reduced|Treatment 1 (Part A)
363501|NCT01424163|Drug|Single dose standard|Treatment 2 (Part A)
363502|NCT01424163|Drug|Multiple Dose|Treatment 3 (Part A)
363503|NCT01424163|Drug|Multiple Dose|Part B
363504|NCT01424150|Other|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
363505|NCT01424150|Other|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
363506|NCT01424137|Device|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
363507|NCT01424137|Device|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
363508|NCT01424137|Device|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
363509|NCT01424124|Drug|YHD001 dose level 1|Tablet, three times daily / 8 weeks
363510|NCT01424124|Drug|YHD001 dose level 2|Tablet, three times daily / 8 weeks
363511|NCT01424124|Drug|Singulair|Tablet, one times daily / 8 weeks
363512|NCT01424124|Drug|Placebo|Tablet, one times daily / 7 days
363513|NCT01424111|Drug|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
363514|NCT01424111|Other|Healthy Control|No Treatment
363515|NCT01424098|Behavioral|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
363516|NCT01424072|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
363517|NCT01424072|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
363518|NCT01424059|Other|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
363519|NCT01424046|Drug|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
364109|NCT01419535|Drug|Mifepristone|Mifepristone 50mg tablet by mouth every six hours for nine days.
363520|NCT01424046|Drug|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
363521|NCT01424033|Drug|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
363522|NCT01424020|Other|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
363523|NCT01424007|Behavioral|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
363524|NCT01423994|Procedure|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.~Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.~Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.~Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
363525|NCT01423994|Procedure|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate <50 bpm, High Heart Rate >165 bpm, and Pause > 3 seconds.
363526|NCT01423968|Biological|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
363527|NCT01423968|Other|saline|
363528|NCT01423955|Drug|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
363529|NCT01423955|Drug|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
363530|NCT01423929|Drug|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
363531|NCT01423929|Device|Room air|Fitting of Oxymask TM
363532|NCT01423916|Drug|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
363533|NCT01423916|Drug|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
363534|NCT01423916|Drug|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
363535|NCT01423916|Drug|Placebo|OPC-34712 placebo
363536|NCT01423903|Drug|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
363537|NCT01423890|Genetic|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
363538|NCT01423864|Drug|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
363539|NCT01423864|Drug|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 > FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
363540|NCT01423851|Drug|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
363541|NCT01423838|Drug|Solifenacin|5 mg, oral, once in a day
363542|NCT01423838|Drug|Oxybutynin|5 mg, oral, three times in a day
363543|NCT01423825|Biological|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
363544|NCT01423825|Biological|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
363545|NCT01423825|Other|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
363546|NCT01423812|Drug|Twice-daily Darunavir and ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
363547|NCT01423812|Drug|Once-daily Darunavir and ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
363548|NCT01423799|Dietary Supplement|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
363549|NCT01423799|Dietary Supplement|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
363550|NCT01423786|Dietary Supplement|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
363551|NCT01423773|Device|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
363552|NCT01423773|Device|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
363553|NCT01423773|Device|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
363554|NCT01423760|Biological|Tecemotide|Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
363555|NCT01423760|Other|No intervention|Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
363556|NCT01423747|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
363557|NCT01423747|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
363604|NCT01423409|Device|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
363558|NCT01423747|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
363559|NCT01423747|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
363560|NCT01423747|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
363561|NCT01423747|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
363562|NCT01423747|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
363563|NCT01423734|Other|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.~During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
363564|NCT01423721|Drug|Bromihexine hydrochloride syrup|syrup
363565|NCT01423721|Drug|Bromihexine hydrochloride granules|granules
363566|NCT01423708|Drug|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of >5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels <5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
363567|NCT01423695|Drug|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
363568|NCT01423682|Behavioral|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
363569|NCT01423656|Drug|LEO 29102|
363570|NCT01423656|Drug|Placebo|Placebo Comparator: LEO 29102 vehicle
363571|NCT01423630|Dietary Supplement|Probiotics and fruit fibre|probiotics and fruit fibre
363572|NCT01423617|Dietary Supplement|Zenoctil|3 tablets 2 times daily
363573|NCT01423617|Other|Placebo|3 tablets 2 times daily
363574|NCT01423604|Drug|Capecitabine|Capecitabine starting dose - 2000 mg/m^2 (1000 mg/m^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
363575|NCT01423604|Drug|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
363576|NCT01423604|Drug|Placebo|Placebo matching ruxolitinib
363577|NCT01423591|Drug|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
363578|NCT01423591|Drug|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
363579|NCT01423578|Behavioral|Hatha Yoga (HY)|3 Sessions of yoga instruction
363580|NCT01423578|Behavioral|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
363581|NCT01423578|Behavioral|Smoking Cessation Counseling|4 smoking cessation counseling visits.
363582|NCT01423565|Device|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
363583|NCT01423539|Drug|bendamustine|Intravenous repeating dose\n
363584|NCT01423539|Drug|navitoclax|Oral repeating dose\n
363585|NCT01423539|Drug|rituximab|Intravenous repeating dose\n
363586|NCT01423526|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
363587|NCT01423526|Drug|Placebo|Placebo tablets, oral administration, single administrations
363588|NCT01423513|Other|Fibular Taping|Tape with be applied with tension.
363589|NCT01423513|Other|Sham Taping|Tape will be applied without tension
363590|NCT01423500|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
363591|NCT01423500|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
363592|NCT01423500|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
363593|NCT01423500|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
363594|NCT01423500|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
363595|NCT01423500|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
363596|NCT01423500|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
363597|NCT01423487|Drug|Metformin|0.5g bid 26 weeks
363598|NCT01423487|Other|Starch tablets|0.5g bid 26 weeks
363599|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
363600|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
363601|NCT01423448|Other|bulletin board|An asynchronous online bulletin board for people with experience of depression
363602|NCT01423435|Drug|TRK-100STP|oral
363603|NCT01423409|Device|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
363605|NCT01423396|Other|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
363606|NCT01423396|Other|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
363607|NCT01423370|Drug|YHD1023|5g oral once daily
363608|NCT01423370|Drug|YHD1023|5g oral twice a day
363609|NCT01423370|Drug|YHD1023|10g oral once daily
363610|NCT01423370|Drug|Cialis|5mg oral once daily
363611|NCT01423370|Drug|Placebo|Oral
363612|NCT01423357|Other|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
363613|NCT01423318|Drug|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
363614|NCT01423318|Drug|placebo|single dose subcutaneously
363615|NCT01423305|Drug|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
363616|NCT01423305|Drug|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
363617|NCT01423292|Procedure|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
363618|NCT01423292|Drug|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
363619|NCT01423292|Drug|Placebo|placebo
363620|NCT01423266|Procedure|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
363621|NCT01423253|Drug|Lurasidone|Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
363622|NCT01423240|Drug|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
363623|NCT01423240|Drug|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
363624|NCT01423240|Drug|Placebo|Placebo once daily orally in the evening
363625|NCT01423227|Behavioral|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
363626|NCT01423227|Behavioral|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
363627|NCT01423214|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
363628|NCT01423214|Procedure|Laparoscopic surgery|Conventional laparoscopic procedures
363629|NCT01423188|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
363630|NCT01423188|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
363631|NCT01423175|Drug|Clofarabine, ara-C|
363632|NCT01423175|Drug|FLAMSA|
363633|NCT01423162|Other|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
363634|NCT01423162|Other|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
363635|NCT01423149|Drug|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
363636|NCT01423136|Device|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
363637|NCT01423123|Drug|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
363638|NCT01423123|Biological|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
363639|NCT01423123|Drug|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
363640|NCT01423110|Biological|BYM338|
363641|NCT01423110|Biological|Placebo|
363642|NCT01423084|Biological|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.~A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
363643|NCT01423058|Drug|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.~In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
363644|NCT01423032|Drug|bendamustine|100 mg/m² iv, day 1+2, q4w
363645|NCT01423032|Drug|Fludarabine|25 mg/m² iv, days 1-5, q4w
363646|NCT01423019|Dietary Supplement|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
363647|NCT01423019|Dietary Supplement|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
363648|NCT01423019|Other|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
363649|NCT01423006|Procedure|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
363650|NCT01422993|Other|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
363651|NCT01422980|Other|1- Test dairy product containing specific ingredients|
363652|NCT01422980|Other|2- Control dairy product without specific ingredients|
363653|NCT01422967|Behavioral|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
363654|NCT01422954|Drug|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
363655|NCT01422954|Drug|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
363656|NCT01422954|Biological|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
363657|NCT01422954|Biological|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
363658|NCT01422954|Drug|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
363659|NCT01422941|Device|CAVU Attune Device|The CAVU Attune device is used with LAGB.
363660|NCT01422928|Procedure|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.~Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:~GV.14~LI.11 (bilateral)~SP.6 (bilateral)~SP.10 (bilateral)~ST.36 (bilateral)~Additional points may be added based on the symptom concerns reported."
363661|NCT01422915|Drug|Colestipol|2 grams morning and bedtime for 90 days.
363662|NCT01422902|Other|Plasticity-based Cognitive Training|
363663|NCT01422902|Other|Non-plasticity-based Training|Computer games
363664|NCT01422889|Device|ION™ Coronary Stent System|This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
363665|NCT01422876|Drug|high dose FDC|once daily
363666|NCT01422876|Drug|BI 10773 high dose|once daily
363667|NCT01422876|Drug|high dose FDC placebo|once daily
363668|NCT01422876|Drug|low dose FDC placebo|once daily
363669|NCT01422876|Drug|high dose FDC placebo|once daily
363670|NCT01422876|Drug|high dose FDC placebo|once daily
363671|NCT01422876|Drug|low dose FDC placebo|once daily
363672|NCT01422876|Drug|low dose FDC placebo|once daily
363673|NCT01422876|Drug|high dose BI 10773 placebo|once daily
363674|NCT01422876|Drug|low dose FDC|once daily
363675|NCT01422876|Drug|high dose FDC placebo|once daily
363676|NCT01422876|Drug|BI 10773 low dose|low dose once daily
363677|NCT01422876|Drug|high dose BI 10773 placebo|once daily
363678|NCT01422876|Drug|high dose BI 10773 placebo|once daily
363679|NCT01422876|Drug|linagliptin|once daily
363680|NCT01422876|Drug|low dose FDC placebo|once daily
363681|NCT01422876|Drug|linagliptin placebo|once daily
363682|NCT01422876|Drug|BI 10773 low dose placebo|once daily
363683|NCT01422876|Drug|linagliptin placebo|once daily
363684|NCT01422876|Drug|low dose BI 10773 placebo|once daily
363685|NCT01422876|Drug|linagliptin placebo|once daily
363686|NCT01422876|Drug|high dose BI 10773 placebo|once daily
363687|NCT01422876|Drug|BI 10773 low dose placebo|once daily
363688|NCT01422876|Drug|low dose BI 10773 placebo|once daily
363689|NCT01422876|Drug|linagliptin placebo|once daily
363690|NCT01422863|Behavioral|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
363691|NCT01422850|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
363692|NCT01422811|Behavioral|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:~Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;~Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
363693|NCT01422811|Other|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
364117|NCT01419496|Other|flow cytometry|
363694|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
363695|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
363696|NCT01422772|Biological|VM202RY|0.5mg intramuscular injection
363697|NCT01422772|Biological|VM202RY|1mg intramuscular injection
363698|NCT01422772|Biological|VM202RY|2mg intramuscular injection
363699|NCT01422759|Drug|Spironolactone|50-100 mg PO BID (X 12 weeks)
363700|NCT01422746|Drug|Metformin|500-1000 mg PO BID (X12 weeks)
363701|NCT01422733|Drug|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
363702|NCT01422733|Drug|dexamethasone|1 mg PO twice
363703|NCT01422733|Drug|Cosyntropin|250 micrograms IV twice
363704|NCT01422733|Drug|rhCG|25 mcg IV twice
363705|NCT01422720|Drug|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
363706|NCT01422707|Drug|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
363707|NCT01422681|Device|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).~Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
363708|NCT01422668|Other|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
363709|NCT01422642|Device|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
363710|NCT01422642|Device|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
363711|NCT01422629|Device|Ultrasonic ablation device|High Intensity focused ultrasound treatment
363712|NCT01422616|Drug|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus [maximum bolus dose of 9mg] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
363713|NCT01422616|Drug|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
363714|NCT01422616|Other|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
363715|NCT01422616|Other|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
363716|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
363717|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
363718|NCT01422590|Drug|Sitagliptin|Single oral administration of sitagliptin 100 mg
363719|NCT01422590|Drug|Mitiglinide|Single oral administration of mitiglinide 10 mg
363720|NCT01422590|Drug|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
363721|NCT01422577|Device|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
363722|NCT01422577|Device|White light Endoscopy|White light Endoscopy
363723|NCT01422564|Device|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
363724|NCT01422564|Device|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
363725|NCT01422551|Behavioral|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
363726|NCT01422551|Behavioral|a psycho-educational control|a single-day psycho-educational seminar
363727|NCT01422538|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
363728|NCT01422538|Drug|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
363729|NCT01422538|Other|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
363730|NCT01422525|Procedure|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
363731|NCT01422512|Biological|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
363867|NCT01421433|Drug|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
363732|NCT01422499|Drug|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
363733|NCT01422486|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
363734|NCT01422473|Device|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
363735|NCT01422460|Biological|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)~intra articular injection 2ml~Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
363736|NCT01422447|Other|regular intervention|the subjects in the control group live in the used model
363737|NCT01422447|Other|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
363738|NCT01422434|Drug|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
363739|NCT01422434|Drug|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
363740|NCT01422434|Drug|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
363741|NCT01422421|Other|intensive control|use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
363742|NCT01422421|Other|standard control|use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
363743|NCT01422408|Drug|Fluocinonide Cream|Given topically
363744|NCT01422408|Procedure|Management of Therapy Complications|Receive fluocinonide cream
363745|NCT01422408|Other|Questionnaire Administration|Ancillary studies
363746|NCT01422395|Procedure|Freezing|Vitrification
363747|NCT01422382|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
363748|NCT01422382|Drug|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
363749|NCT01422369|Drug|Pitavastatin (NK-104)|Pitavastatin (NK-104) 4mg once daily (QD)
363750|NCT01422369|Drug|Darunavir/Ritonavir (Prezista)|Darunavir/Ritonavir (Prezista) 800 mg/100 mg
363751|NCT01422343|Procedure|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
363752|NCT01422330|Drug|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
363753|NCT01422317|Drug|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
363754|NCT01422317|Drug|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
363755|NCT01422304|Drug|Sugammadex|Sugammadex 4 mg/kg intravenously
363756|NCT01422304|Drug|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
363757|NCT01422304|Drug|Placebo to neostigmine|Normal saline (NaCl 0.9%)
363758|NCT01422304|Drug|Placebo to sugammadex|Normal saline (NaCl 0.9%)
363759|NCT01422291|Drug|paracetamol|1 gr
363760|NCT01422291|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
363761|NCT01422291|Drug|Dexketoprofen|50 mg
363762|NCT01422291|Drug|Paracetamole|1 gr
363763|NCT01422278|Other|Rehabilitation|Three weeks of rehabilitation in Hospital.
363764|NCT01422252|Device|Vigi'Fall®|Precocious fall detection device
363765|NCT01422239|Behavioral|Tailored treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
363766|NCT01422239|Behavioral|Standard Treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
363767|NCT01422226|Drug|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
363768|NCT01422226|Other|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
363769|NCT01422213|Drug|Placebo|capsules; daily; orally
363770|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
363771|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
363772|NCT01422200|Biological|2011-2012 seasonal flu vaccine|The 2011-2012 seasonal flu vaccine will be given by subcutaneous injection.
363773|NCT01422200|Biological|2011-2012 seasonal flu vaccine|the 2011-2012 seasonal flu vaccine will be given by intramuscular injection
363774|NCT01422187|Drug|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
363775|NCT01422174|Procedure|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
363776|NCT01422161|Drug|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study."
363777|NCT01422161|Drug|Placebo|The control group will receive a placebo injection.
363778|NCT01422148|Drug|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
363779|NCT01422148|Drug|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
363868|NCT01421407|Device|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
364111|NCT01419522|Other|Gait Training Method|Treadmill training at constant velocity
363780|NCT01422135|Drug|AG200-15|A transdermal contraceptive delivery system for levonorgestrel (LNG) and ethinyl estradiol (EE). . A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
363781|NCT01422122|Drug|Vitamin D3|4000 mg per day, one tablespoon syrup per day
363782|NCT01422122|Drug|Placebo|one table spoon Syrup per day
363783|NCT01422109|Drug|YH14659|YH14659 capsule by oral
363784|NCT01422109|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
363785|NCT01422096|Drug|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if > 37.5 kg im once
363786|NCT01422083|Procedure|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
363787|NCT01422018|Drug|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
363788|NCT01422005|Other|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
363789|NCT01422005|Other|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
363790|NCT01421992|Drug|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
363791|NCT01421992|Drug|Placebo|one tablet placebo per day during 3 weeks
363792|NCT01421979|Dietary Supplement|Energy Drink, Taurine, Caffeine|
363793|NCT01421966|Biological|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
363794|NCT01421966|Biological|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
363795|NCT01421953|Device|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
363796|NCT01421940|Drug|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
363797|NCT01421940|Drug|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
363798|NCT01421927|Drug|Lenalidomide|"Start between Day+100 and Day+120 post-transplant~- Initial dose: 5 mg/day every day~In the absence of thrombocytopenia < 75000/mm3 or neutropenia < 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.~- Duration~until persistent stringent complete response for 3 months~or progression defined by IMWG criteria12~or unacceptable toxicity~or one year after transplant"
363799|NCT01421914|Other|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
363800|NCT01421901|Drug|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
363801|NCT01421901|Procedure|appendectomy|
363802|NCT01421875|Genetic|DNA methylation analysis|
363803|NCT01421875|Genetic|RNA analysis|
363804|NCT01421875|Genetic|gene expression analysis|
363805|NCT01421875|Genetic|microarray analysis|
363806|NCT01421875|Genetic|nucleic acid sequencing|
363807|NCT01421875|Other|laboratory biomarker analysis|
363808|NCT01421862|Genetic|DNA methylation analysis|
363809|NCT01421862|Genetic|RNA analysis|
363810|NCT01421862|Genetic|gene expression analysis|
363811|NCT01421862|Genetic|microarray analysis|
363812|NCT01421862|Genetic|mutation analysis|
363813|NCT01421862|Genetic|nucleic acid sequencing|
363814|NCT01421862|Other|laboratory biomarker analysis|
363815|NCT01421849|Procedure|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.~Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.~The total duration of the study will be 12 to 18 months."
363816|NCT01421836|Procedure|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
363817|NCT01421836|Procedure|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
363818|NCT01421823|Drug|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
363819|NCT01421823|Drug|Placebo|2 weeks local treatment with placebo ointment
363820|NCT01421810|Drug|Dexamethasone|1 mg PO
363821|NCT01421810|Drug|rhCG|25 mcg IV
363822|NCT01421797|Drug|Dexamethasone|1 mg PO
363823|NCT01421797|Drug|Cortrosyn|single IV bolus of 0.25 mg will be administered
363824|NCT01421784|Other|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
363825|NCT01421771|Drug|Antihypertensive Agents|"Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.~ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator"
363826|NCT01421771|Other|Dry weight Challenge|Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
363827|NCT01421771|Dietary Supplement|Extend dialysis treatment time and re-challenge estimated dry weight|Extend dialysis treatment time and re-challenge estimated dry weight
363828|NCT01421758|Behavioral|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
363829|NCT01421758|Behavioral|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
363830|NCT01421745|Other|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
363831|NCT01421719|Drug|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
363832|NCT01421706|Drug|Sibutramine-clopidogrel|Sibutramine-clopidogrel
363833|NCT01421706|Drug|sibutramine-Clarithromycin|sibutramine-Clarithromycin
363834|NCT01421693|Drug|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days~14 years and older - 2g once daily for 7 days~Intravenous infusion. Vials of crystalline powder."
363835|NCT01421693|Drug|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
363836|NCT01421680|Dietary Supplement|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
363837|NCT01421667|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
363838|NCT01421667|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion
363839|NCT01421654|Device|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
363840|NCT01421654|Device|S9 Elite|S9 Elite Flow Generator
363841|NCT01421641|Drug|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
363842|NCT01421641|Drug|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
363843|NCT01421628|Other|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
363844|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
363845|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
363846|NCT01421589|Drug|Growth hormone treatment|Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
363847|NCT01421576|Dietary Supplement|High fat meal|offer high fat-meal in the morning before drug intake.
363848|NCT01421563|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
363849|NCT01421550|Procedure|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
363850|NCT01421550|Procedure|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
363851|NCT01421524|Drug|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are > 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
363852|NCT01421524|Drug|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
363853|NCT01421524|Drug|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
363854|NCT01421524|Drug|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
363855|NCT01421511|Drug|TR-701 FA|"TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion~TR-701 FA Tablets, 200 mg, orally once daily"
363856|NCT01421511|Drug|Linezolid|"Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~Linezolid Tablets, 600 mg, orally every 12 hours"
363857|NCT01421498|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
363858|NCT01421498|Drug|Placebo|Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
363859|NCT01421485|Behavioral|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
363860|NCT01421485|Behavioral|Treatment as Usual|Treatment in community, case management
363861|NCT01421472|Drug|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
363862|NCT01421472|Drug|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
363863|NCT01421459|Drug|LY2963016|Administered subcutaneously
363864|NCT01421459|Drug|Lantus|Administered subcutaneously
363865|NCT01421459|Drug|OAMs|Administered orally
363866|NCT01421433|Drug|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
364112|NCT01419509|Genetic|DNA methylation analysis|
363869|NCT01421368|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
363870|NCT01421368|Drug|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
363871|NCT01421368|Drug|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
363872|NCT01421355|Drug|Atazanavir|The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
363873|NCT01421342|Drug|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
363874|NCT01421342|Drug|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.~And~Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
363875|NCT01421342|Drug|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.~And~Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
363876|NCT01421316|Radiation|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
363877|NCT01421303|Drug|Enbrel|Enbrel
363878|NCT01421290|Procedure|Surgery|Knee surgery
363879|NCT01421290|Other|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
363880|NCT01421277|Drug|Statin Therapy|Investigator's choice of any statin.
363881|NCT01421264|Drug|Gabapentin|300mg capsules by mouth
363882|NCT01421238|Behavioral|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
363883|NCT01421225|Device|Closed-loop Insulin Pump therapy|Subjects insulin doses were adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.
363884|NCT01421225|Device|Standard Insulin Pump Therapy|Subjects insulin doses followed their usual home routine.
363885|NCT01421212|Biological|Hepatitis B Immune Globulin (Boca HBVIg)|"Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).~Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study."
363886|NCT01421199|Procedure|Myringotomy|tube placement for children with multiple ear infections
363887|NCT01421186|Drug|MOR03087 phase 1 dose escalation|"Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.~In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1."
363888|NCT01421186|Drug|MOR03087|MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
363889|NCT01421186|Drug|Dexamethasone|Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
363890|NCT01421186|Drug|Pomalidomide|Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
363891|NCT01421186|Drug|Lenalidomide|Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
363892|NCT01421173|Drug|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
363893|NCT01421173|Drug|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
363894|NCT01421173|Drug|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.~Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
363895|NCT01421173|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
363896|NCT01421173|Procedure|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
363897|NCT01421173|Drug|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
363898|NCT01421173|Drug|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
363899|NCT01421173|Drug|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
363900|NCT01421173|Drug|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
363901|NCT01421160|Drug|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
363902|NCT01421147|Drug|LY2963016|Administered subcutaneously
363903|NCT01421147|Drug|Lantus|Administered subcutaneously
363904|NCT01421147|Drug|Insulin Lispro|Administered subcutaneously
363905|NCT01421134|Drug|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
363906|NCT01421134|Drug|Placebo|Placebo
363907|NCT01421121|Biological|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
363908|NCT01421121|Biological|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
363909|NCT01421121|Biological|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
363910|NCT01421121|Biological|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
363911|NCT01421121|Biological|Placebo|0.5ml placebo, two doses, 28 days interval
363912|NCT01421108|Behavioral|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
363913|NCT01421108|Behavioral|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.~The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
363914|NCT01421095|Drug|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
363915|NCT01421082|Device|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
363916|NCT01421069|Drug|etanercept|"Subjects aged <18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).~Subjects aged greater than or equal to 18 years or >62 kg will receive etanercept SC at a dose of 50 mg QW."
363917|NCT01421056|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
363918|NCT01421056|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
363919|NCT01421056|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
363920|NCT01421043|Drug|triazolam liquid oral drops|0.25 mg single dose oral drops
363921|NCT01421043|Drug|triazolam tablets|0.25 mg single oral dose
363922|NCT01421030|Procedure|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
363923|NCT01421017|Radiation|Radiation|
363924|NCT01421017|Drug|Imiquimod|
363925|NCT01421017|Drug|Cyclophosphamide|
363926|NCT01421004|Drug|TKI258|
363927|NCT01420978|Procedure|CSF Diversion|CSF drainage
363928|NCT01420965|Drug|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
363929|NCT01420965|Other|Sipuleucel-T (Provenge)|Vaccine
363930|NCT01420965|Drug|Cyclophosphamide|Low dose- Immune Enhancer
363931|NCT01420952|Drug|[11C]LY2428703|
363932|NCT01420926|Drug|Bortezomib|Given SC
363933|NCT01420926|Drug|Decitabine|Given IV
363934|NCT01420926|Other|Laboratory Biomarker Analysis|Correlative studies
363935|NCT01420926|Other|Pharmacological Study|Correlative studies
363936|NCT01420926|Other|Quality-of-Life Assessment|Ancillary studies
363937|NCT01420926|Other|Questionnaire Administration|Ancillary studies
363938|NCT01420913|Drug|Pregabalin|Pregabalin 300mg a day
363939|NCT01420900|Device|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
363940|NCT01420900|Device|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
363941|NCT01420887|Procedure|Continuous Passive Motion|Continuous passive motion.
363942|NCT01420887|Procedure|Physical Therapy|Physical therapy.
363943|NCT01420874|Drug|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
363944|NCT01420874|Biological|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
363945|NCT01420861|Drug|GTx-758|two GTx 758 tablets per day
363946|NCT01420848|Other|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
363947|NCT01420848|Other|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
364061|NCT01419938|Device|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
363948|NCT01420835|Other|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
363949|NCT01420835|Other|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
363950|NCT01420822|Drug|Fluticasone|Collection of safety data
363951|NCT01420796|Other|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.~This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
363952|NCT01420796|Other|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
363953|NCT01420796|Other|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
363954|NCT01420783|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
363955|NCT01420770|Drug|SAR302503|"Pharmaceutical form:capsule~Route of administration: oral"
363956|NCT01420757|Procedure|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
363957|NCT01420744|Drug|BT086|"BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.~Infusion rate:~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period."
363958|NCT01420744|Drug|1% Human Albumin infusion|"1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)"
363959|NCT01420718|Drug|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
363960|NCT01420718|Drug|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
363961|NCT01420692|Drug|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
363962|NCT01420692|Drug|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
363963|NCT01420679|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met."
363964|NCT01420666|Drug|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
363965|NCT01420666|Drug|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
363966|NCT01420666|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
363967|NCT01420666|Drug|Placebo|placebo, three tablets four times a day, orally, with food
363968|NCT01420653|Drug|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
363969|NCT01420653|Drug|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
363970|NCT01420653|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
363971|NCT01420653|Drug|Placebo|placebo, three tablets four times a day, with food for 48 hours
363972|NCT01420640|Behavioral|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
363973|NCT01420640|Behavioral|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
363974|NCT01420640|Behavioral|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
363975|NCT01420640|Behavioral|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
363976|NCT01420640|Behavioral|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
363977|NCT01420627|Biological|EZN-2279|weekly administration of EZN-2279 via IM injection
363978|NCT01420627|Biological|Adagen|
363979|NCT01420614|Procedure|Femoral approach|diagnostic and interventional procedures by femoral artery access
363980|NCT01420614|Procedure|Radial approach|diagnostic and interventional procedures by radial artery access
364062|NCT01419938|Device|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
364063|NCT01419925|Biological|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
364110|NCT01419535|Drug|Placebo|Placebo (matching mifepristone 50mg tablet) by mouth every six hours for nine days.
363981|NCT01420575|Behavioral|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
363982|NCT01420575|Behavioral|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
363983|NCT01420562|Procedure|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
363984|NCT01420549|Drug|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.
363985|NCT01420549|Drug|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.
363986|NCT01420536|Procedure|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.~Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
363987|NCT01420523|Drug|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
363988|NCT01420510|Drug|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
363989|NCT01420510|Drug|Placebo vaginal gel|Application of a placebo vaginal gel
363990|NCT01420497|Drug|intra-articular infiltration|intra articular infiltration
363991|NCT01420497|Drug|epidural infiltration|epidural infiltration
363992|NCT01420484|Other|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
363993|NCT01420471|Drug|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
363994|NCT01420471|Other|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
363995|NCT01420458|Drug|Experimental|Bioequivalence of two drug formulations
363996|NCT01420445|Drug|YHD001 dose level 1|three times daily / 7 days
363997|NCT01420445|Drug|YHD001 dose level 2|three times daily / 7 days
363998|NCT01420445|Drug|Pelargonium sidoides extract|6-9mL three times daily / 7 days
363999|NCT01420445|Drug|placebo|three times daily / 7 days
364000|NCT01420432|Biological|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
364001|NCT01420419|Other|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
364002|NCT01420419|Other|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
364003|NCT01420406|Other|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
364004|NCT01420406|Other|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
364005|NCT01420406|Other|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
364006|NCT01420406|Other|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
364007|NCT01420393|Procedure|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
364008|NCT01420393|Other|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
364009|NCT01420367|Drug|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
364010|NCT01420341|Drug|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
364011|NCT01420341|Drug|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
364012|NCT01420328|Drug|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin
364013|NCT01420302|Procedure|Nurse directed insulin titration|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
364014|NCT01420302|Procedure|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
364015|NCT01420289|Device|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
364016|NCT01420289|Behavioral|Excercise|Treadmill walking 45 minutes once daily
364017|NCT01420263|Procedure|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
364064|NCT01419925|Biological|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
364018|NCT01420263|Procedure|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
364019|NCT01420250|Drug|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:~Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
364020|NCT01420250|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
364021|NCT01420250|Drug|Anti-Androgen Therapy: Bicalutamide|"Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)~Will continue once daily until the final day of IMRT"
364022|NCT01420250|Genetic|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)~Will continue for 24 months after IMRT~Total administered duration and agent used must be documented on the case report form"
364023|NCT01420237|Device|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
364024|NCT01420224|Other|Commercial airline flight|Normal scheduled passenger flight
364025|NCT01420211|Drug|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
364026|NCT01420211|Device|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
364027|NCT01420198|Behavioral|Lifestyle intervention|Increased physical activity and improved food habits
364028|NCT01420185|Genetic|RNA analysis|
364029|NCT01420185|Genetic|gene expression analysis|
364030|NCT01420185|Genetic|microarray analysis|
364031|NCT01420185|Genetic|reverse transcriptase-polymerase chain reaction|
364032|NCT01420185|Other|laboratory biomarker analysis|
364033|NCT01420172|Other|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
364034|NCT01420159|Drug|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
364035|NCT01420146|Drug|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
364036|NCT01420133|Other|Regimen|regimen normal in salt and sugar
364037|NCT01420133|Other|Standard regimen|with diet low in salt and sugar
364038|NCT01420094|Drug|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.
364039|NCT01420094|Drug|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
364040|NCT01420094|Drug|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
364041|NCT01420081|Drug|PF-05212384|154mg IV weekly
364042|NCT01420081|Drug|PF-05212384|154mg IV weekly
364043|NCT01420081|Drug|PF-05212384|154mg IV weekly
364044|NCT01420068|Drug|SPP100|
364045|NCT01420055|Drug|fingolimod|
364046|NCT01420042|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
364047|NCT01420042|Drug|Placebo|Lemon flavoured cordial and Water for Injection
364048|NCT01420016|Other|Prioritized Clinical Decision Support|Eighteen primary care clinics were blocked on size and on patient characteristics. Each clinic was randomly assigned to one of 2 study arms. All consenting PCPs were allocated to the study arm that their clinic was assigned to and the estimated 400 eligible adults with 10-year CVR >= 10% under the care of each consenting physician were allocated to the same treatment arm as their PCP.
364049|NCT01420003|Procedure|Bone Marrow Aspiration|3 per study
364050|NCT01420003|Procedure|Tonsil Biopsy|Optional upon completion of study
364051|NCT01419990|Drug|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
364052|NCT01419990|Drug|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
364053|NCT01419990|Drug|Placebo|Placebo oral capsules, qd, 10 days
364054|NCT01419977|Drug|Placebo|Normal saline solution, administered by nursing staff once daily
364055|NCT01419977|Drug|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
364056|NCT01419964|Drug|Group 01|ACH24
364057|NCT01419964|Drug|Group 02|Placebo
364058|NCT01419951|Behavioral|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
364059|NCT01419951|Other|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
364060|NCT01419951|Behavioral|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
364108|NCT01419548|Drug|Paclitaxel|
364113|NCT01419509|Genetic|microarray analysis|
364065|NCT01419925|Biological|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
364066|NCT01419925|Biological|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
364067|NCT01419912|Dietary Supplement|soy milk|
364068|NCT01419912|Dietary Supplement|cow's milk|
364069|NCT01419899|Behavioral|Brief motivational intervention|A 20-30 minute motivational based discussion
364070|NCT01419873|Drug|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
364071|NCT01419860|Procedure|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
364072|NCT01419847|Drug|Ciclopirox|
364073|NCT01419847|Drug|Placebo|
364074|NCT01419834|Biological|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over ~30 minutes
364075|NCT01419821|Drug|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
364076|NCT01419821|Other|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
364077|NCT01419808|Procedure|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
364078|NCT01419808|Procedure|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
364079|NCT01419795|Drug|lenalidomide|Given PO
364080|NCT01419795|Biological|rituximab|Given IV
364081|NCT01419795|Other|pharmacological study|Correlative studies
364082|NCT01419795|Other|laboratory biomarker analysis|Correlative studies
364083|NCT01419782|Other|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
364084|NCT01419769|Device|AXIOS Stent & Delivery System|"The AXIOS Stent & Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.~Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.~Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal."
364085|NCT01419756|Device|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
364086|NCT01419730|Drug|Vitamin D3|Vitamin D3 50,000 IU
364087|NCT01419730|Behavioral|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
364088|NCT01419717|Drug|Denosumab|Administered by subcutaneous injection every 4 weeks (Q4W)
364089|NCT01419704|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
364090|NCT01419691|Drug|auranofin|6 mg twice a day for a total of 12 mg total daily dose
364091|NCT01419678|Other|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
364092|NCT01419665|Biological|GP2013|Type: Biological/Vaccine
364093|NCT01419665|Biological|rituximab|Type: Biological/Vaccine
364094|NCT01419652|Other|hold hypoglycemic meds|continue versus hold hypoglycemic medications
364095|NCT01419639|Drug|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
364096|NCT01419613|Behavioral|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
364097|NCT01419613|Behavioral|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
364098|NCT01419600|Drug|AZD8683|Single Dose Inhaled IMP via Turbuhaler
364099|NCT01419600|Drug|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
364100|NCT01419587|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
364101|NCT01419561|Drug|Zidovudine|Zidovudine 600 mg will be administered orally 4 times a day or i.v. at 300 mg every 6 hours for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
364102|NCT01419561|Drug|Liposomal Doxorubicin|Liposomal doxorubicin (20 mg/m2) will be administered i.v. over 1 hour at day 1 of each cycle
364103|NCT01419561|Drug|Valganiclovir|Valganciclovir (900mg) will be administered orally twice/day or Ganciclovir (5 mg/kg) will be administered i.v. over 1 hour for 14 days for cycle 1 and for 7 days (up to additional 7 days if ongoing symptoms) for following cycles.
364104|NCT01419561|Drug|Rituximab|"Rituximab (375 mg/m2) will be admnistered i.v. at 50 mg/hr up to 100 mg/hr at day 1 of the first cycle and at 100mg/hr up to 400 mg~/hr at day 1 of following cycles."
364105|NCT01419561|Other|Standard Therapies|
364106|NCT01419548|Drug|ABT-888|
364107|NCT01419548|Drug|Carboplatin|
364118|NCT01419496|Other|laboratory biomarker analysis|
364119|NCT01419483|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
364120|NCT01419470|Drug|dapoxetine|"multiple dosing~12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine"
364121|NCT01419457|Drug|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
364122|NCT01419457|Drug|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
364123|NCT01419457|Drug|Favipiravir|800 mg Single Dose
364124|NCT01419444|Behavioral|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
364125|NCT01419431|Procedure|Laparoscopic resection|Inflammatory response in laparoscopic surgery
364126|NCT01419405|Drug|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
364127|NCT01419405|Drug|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
364128|NCT01419405|Drug|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
364129|NCT01419392|Drug|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
364130|NCT01419392|Drug|matching placebo|orally, 4 times per day for 21 days
364131|NCT01419366|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
364132|NCT01419353|Drug|estradiol valerate|2 mg P.O / day for 1-6 days.
364133|NCT01419340|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
364134|NCT01419327|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
364135|NCT01419314|Device|Splinting application to the lower extremities|Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
364136|NCT01419314|Device|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
364137|NCT01419301|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
364138|NCT01419288|Other|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
364139|NCT01419275|Drug|Xenon contrast agent|
364140|NCT01419275|Device|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
364141|NCT01419262|Drug|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
364142|NCT01419262|Drug|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
364143|NCT01419249|Other|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
364144|NCT01419236|Drug|Testosterone Solution 2%|Administered topically
364145|NCT01419236|Drug|Placebo Solution|Administered topically
364146|NCT01419210|Other|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
364147|NCT01419210|Other|Educational Presentations|Attend a two-hour presentation each week for four weeks
364148|NCT01419210|Other|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
364149|NCT01419210|Other|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
364150|NCT01419197|Drug|Trastuzumab emtansine|The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change > 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
364151|NCT01419197|Drug|Treatment of physician's choice|"The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.~Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.~The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information."
364152|NCT01419184|Drug|Daptomycin|
364153|NCT01419184|Drug|Vancomycin|
364154|NCT01419171|Device|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
364218|NCT01418495|Other|Cytology Specimen Collection Procedure|Correlative studies
364219|NCT01418495|Other|Pharmacological Study|Correlative studies
364220|NCT01418482|Device|Mepilex Border Ag|a silver dressing
364155|NCT01419145|Other|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
364156|NCT01419145|Other|Standard care|Standard cancer care
364157|NCT01419132|Drug|Furosemide|125-250 mg furosemide bid
364158|NCT01419132|Drug|Furosemide|125-250 mf furosemide bid
364159|NCT01419119|Drug|Cholecalciferol|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
364160|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
364161|NCT01419119|Drug|Cholecalciferol|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
364162|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
364163|NCT01419106|Device|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
364164|NCT01419093|Other|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on [feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
364165|NCT01419067|Procedure|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
364166|NCT01419067|Device|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
364167|NCT01419067|Drug|^1^8F-fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
364168|NCT01419067|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
364169|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =>90 mL/min)
364170|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr <30 mL/min)
364171|NCT01419015|Device|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
364172|NCT01419002|Radiation|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
364173|NCT01419002|Procedure|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
364174|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
364175|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
364176|NCT01418976|Behavioral|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
364177|NCT01418963|Drug|RO5285119|single and multiple ascending oral doses
364178|NCT01418963|Drug|placebo|single and multiple oral doses
364179|NCT01418950|Other|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
364180|NCT01418937|Biological|CervarixTM (GSK580299)|Three intramuscular injections
364181|NCT01418911|Other|questionnaire|questionnaire only
364182|NCT01418898|Other|Dietary Intervention|Nutrient fortified oat beverage
364183|NCT01418872|Other|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.~The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.~Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.~Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
364221|NCT01418469|Dietary Supplement|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
364184|NCT01418820|Device|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
364185|NCT01418820|Device|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
364186|NCT01418807|Procedure|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
364187|NCT01418807|Procedure|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
364188|NCT01418794|Device|High dose rapamycin stent|Concentration of rapamycin is 2.5%
364189|NCT01418794|Device|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
364190|NCT01418768|Other|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
364191|NCT01418755|Biological|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
364192|NCT01418742|Drug|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
364193|NCT01418742|Drug|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
364194|NCT01418729|Drug|Pravastatin|"Treatment:~Patients will be randomized in two groups, A and B:~Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
364195|NCT01418716|Other|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
364196|NCT01418716|Other|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
364197|NCT01418703|Device|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
364198|NCT01418703|Device|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
364199|NCT01418677|Drug|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
364200|NCT01418677|Drug|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
364201|NCT01418677|Drug|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
364202|NCT01418664|Dietary Supplement|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
364203|NCT01418651|Drug|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
364204|NCT01418625|Drug|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
364205|NCT01418612|Drug|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
364206|NCT01418599|Drug|Torrent's Alfuzosin Extended Release Tablet|
364207|NCT01418586|Drug|Torrent's Alfuzosin Extended Release Tablet|
364208|NCT01418573|Other|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
364209|NCT01418573|Other|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
364210|NCT01418573|Other|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
364211|NCT01418560|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
364212|NCT01418547|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
364213|NCT01418534|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
364214|NCT01418521|Drug|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
364215|NCT01418521|Drug|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
364216|NCT01418508|Behavioral|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
364217|NCT01418508|Behavioral|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
364378|NCT01417104|Drug|Aliskiren|150 mg/300mg
364222|NCT01418469|Dietary Supplement|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
364223|NCT01418469|Dietary Supplement|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
364224|NCT01418469|Dietary Supplement|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
364225|NCT01418456|Drug|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
364226|NCT01418443|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
364227|NCT01418430|Drug|CHOP-daclizumab|
364228|NCT01418417|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
364229|NCT01418404|Other|Noxious TS|hot, cold alternately, noxious TS in study A
364230|NCT01418404|Other|Innocuous TS|warm, cool alternately, Innocuious TS in study A
364231|NCT01418404|Other|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
364232|NCT01418404|Other|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
364233|NCT01418404|Other|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
364234|NCT01418404|Other|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
364235|NCT01418391|Procedure|Transversus Abdominis Plane block|"TAP BLOCK:~dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12~18 hours upon to the regional anesthetics choose"
364236|NCT01418378|Device|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
364237|NCT01418378|Device|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
364238|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
364239|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
364240|NCT01418352|Drug|aripiprazole 52.5 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
364241|NCT01418352|Drug|Matching Placebo|Matching Placebo once-weekly for 8 weeks
364242|NCT01418352|Drug|Aripiprazole 77.5 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
364243|NCT01418352|Drug|Aripiprazole 110 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
364244|NCT01418339|Drug|aripiprazole|Flexible dose of once-weekly aripiprazole tablets
364245|NCT01418339|Drug|Placebo|Dose of matching placebo tablets for 8 weeks
364246|NCT01418300|Drug|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
364247|NCT01418274|Drug|danoprevir|oral doses of danoprevir
364248|NCT01418274|Drug|escitalopram|oral doses of escitalopram
364249|NCT01418274|Drug|ritonavir|oral doses of ritonavir
364250|NCT01418261|Device|Renal denervation (Symplicity Catheter System)|
364251|NCT01418261|Diagnostic Test|Renal angiogram|
364252|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
364253|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
364254|NCT01418235|Biological|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
364255|NCT01418235|Biological|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6~Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
364256|NCT01418222|Drug|5-FU|Intravenous repeating dose
364257|NCT01418222|Drug|FOLFOX regimen|Intravenous repeating dose
364258|NCT01418222|Drug|Placebo|Intravenous repeating dose
364259|NCT01418222|Drug|bevacizumab [Avastin]|Intravenous repeating dose
364260|NCT01418222|Drug|leucovorin|Intravenous repeating dose
364261|NCT01418222|Drug|onartuzumab [MetMAb]|Intravenous repeating dose
364262|NCT01418209|Drug|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
364297|NCT01417936|Drug|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
364298|NCT01417923|Drug|vitamin D|P.O.4000 units Vit D per day for 6 weeks
364299|NCT01417897|Drug|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
364263|NCT01418209|Drug|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
364264|NCT01418209|Drug|Placebo|The placebo is an inactive pill that looks like the active medication.
364265|NCT01418183|Procedure|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
364266|NCT01418183|Procedure|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
364267|NCT01418183|Procedure|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
364268|NCT01418170|Other|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
364269|NCT01418157|Drug|Acetazolamide|125 mg twice daily until 4380 meters altitude
364270|NCT01418157|Drug|Placebo|Twice daily
364271|NCT01418144|Procedure|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
364272|NCT01418144|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
364273|NCT01418131|Drug|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
364274|NCT01418131|Drug|Placebo|Placebo
364275|NCT01418118|Drug|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
364276|NCT01418118|Drug|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
364277|NCT01418118|Drug|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
364278|NCT01418118|Drug|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
364279|NCT01418105|Procedure|Videofluroscopic swallow study (VFSS)|Barium, radiation
364280|NCT01418105|Procedure|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
364281|NCT01418105|Procedure|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
364282|NCT01418092|Drug|ALKS 37|Capsules for oral administration
364283|NCT01418092|Drug|Placebo|Capsules for oral administration
364284|NCT01418079|Device|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
364285|NCT01418066|Drug|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
364286|NCT01418066|Drug|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
364287|NCT01418053|Drug|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
364288|NCT01418053|Drug|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
364289|NCT01418027|Other|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
364290|NCT01418027|Other|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
364291|NCT01418001|Drug|Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination|"Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.~Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first ."
364292|NCT01417988|Drug|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
364293|NCT01417988|Drug|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
364294|NCT01417975|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
364295|NCT01417975|Behavioral|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
364296|NCT01417949|Other|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
364300|NCT01417897|Drug|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
364301|NCT01417897|Drug|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
364302|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
364303|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
364304|NCT01417845|Behavioral|High Intensity Exercise Training|"High intensity resistance and aerobic training~Resistance training is performed 2 days per week for 3 months~Aerobic training is performed on the same days as resistance training and 1 additional day per week."
364305|NCT01417845|Behavioral|Moderate Intensity Exercise Training|"Moderate intensity resistance and aerobic training~Resistance training is performed on 2 days per week for 3 months.~Aerobic training is performed on the same days as resistance training and 1 additional day per week."
364306|NCT01417832|Drug|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
364307|NCT01417832|Drug|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
364308|NCT01417819|Other|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
364309|NCT01417806|Drug|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
364310|NCT01417793|Behavioral|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
364311|NCT01417780|Drug|AB103 0.25 mg/kg|Active
364312|NCT01417780|Drug|AB103 0.5 mg/kg|Active
364313|NCT01417780|Drug|NaCl 0.9%|Placebo
364314|NCT01417767|Drug|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
364315|NCT01417767|Drug|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
364316|NCT01417754|Drug|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
364317|NCT01417741|Device|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
364318|NCT01417715|Device|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
364319|NCT01417702|Device|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
364320|NCT01417689|Other|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
364321|NCT01417676|Radiation|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
364322|NCT01417663|Drug|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
364323|NCT01417663|Behavioral|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
364324|NCT01417650|Radiation|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
364325|NCT01417650|Radiation|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
364326|NCT01417637|Radiation|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
364327|NCT01417637|Radiation|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
364328|NCT01417624|Other|CMR Guidance in terms of guiding LV lead implantation|"Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.~The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only."
364329|NCT01417611|Procedure|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
364330|NCT01417598|Other|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
364331|NCT01417598|Other|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
364332|NCT01417585|Behavioral|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
364333|NCT01417585|Behavioral|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
364334|NCT01417572|Drug|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
364335|NCT01417546|Drug|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
364336|NCT01417507|Procedure|cognitive assessment|Undergo neurocognitive assessment
364337|NCT01417507|Procedure|magnetic resonance imaging|Undergo MRI
364338|NCT01417507|Other|laboratory biomarker analysis|Correlative studies
364339|NCT01417507|Other|questionnaire administration|Ancillary studies
364340|NCT01417507|Procedure|quality-of-life assessment|Ancillary studies
364341|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
364342|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
364343|NCT01417481|Dietary Supplement|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
364344|NCT01417481|Dietary Supplement|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
364345|NCT01417468|Behavioral|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
364346|NCT01417468|Behavioral|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
364347|NCT01417442|Genetic|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
364348|NCT01417429|Drug|Galantamine|8mg/a day or placebo
364349|NCT01417429|Drug|IV Nicotine|1.0 mg/70 kg of nicotine against saline
364350|NCT01417403|Drug|hydroxychloroquine|Given PO
364351|NCT01417403|Radiation|radiation therapy|Undergo radiotherapy
364352|NCT01417390|Drug|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
364353|NCT01417390|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
364354|NCT01417377|Drug|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
364355|NCT01417364|Drug|Testosterone enanthate|100 mg. IM weekly throughout study
364356|NCT01417364|Drug|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
364357|NCT01417364|Drug|Placebo|Injected IM weekly throughout study
364358|NCT01417351|Dietary Supplement|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
364359|NCT01417351|Dietary Supplement|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
364360|NCT01417312|Dietary Supplement|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
364361|NCT01417312|Dietary Supplement|Placebo|Daily intake of placebo capsules for 3 months
364362|NCT01417299|Dietary Supplement|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
364363|NCT01417299|Dietary Supplement|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
364364|NCT01417286|Radiation|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
364365|NCT01417273|Dietary Supplement|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
364366|NCT01417273|Drug|Drug: placebo|1 cap placebo/day for 12 month
364367|NCT01417247|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
364368|NCT01417234|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
364369|NCT01417221|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
364370|NCT01417208|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
364371|NCT01417195|Drug|Bravelle|
364372|NCT01417195|Drug|Menopur|
364373|NCT01417182|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
364374|NCT01417169|Drug|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting <50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
364375|NCT01417156|Drug|Nintedanib|150 mg bid
364376|NCT01417156|Drug|Pirfenidoneone|Existing treatment
364377|NCT01417143|Drug|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
364379|NCT01417104|Drug|Placebo|150mg/300mg
364380|NCT01417091|Drug|BPS804|
364381|NCT01417078|Drug|Diazepam|single-dose; dosage in mg, based on patient body weight
364382|NCT01417065|Drug|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
364383|NCT01417052|Drug|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
364384|NCT01417052|Drug|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
364385|NCT01417052|Drug|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
364386|NCT01417052|Drug|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
364387|NCT01417052|Drug|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
364388|NCT01417052|Drug|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
364389|NCT01417052|Drug|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
364390|NCT01417052|Drug|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
364391|NCT01417052|Drug|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
364392|NCT01417052|Drug|Placebo|Matching placebo dosing in capsule form
364393|NCT01417026|Drug|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
364394|NCT01417013|Other|Systane Ultra|Lubricant Eye Drops
364395|NCT01417013|Other|Optive|Lubricant eye drops
364396|NCT01417000|Biological|GVAX Pancreas|
364397|NCT01417000|Biological|CRS-207|
364398|NCT01417000|Drug|Cyclophosphamide|
364399|NCT01416987|Drug|Pergoveris®|Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.
364400|NCT01416974|Drug|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
364401|NCT01416974|Biological|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
364402|NCT01416961|Radiation|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
364403|NCT01416961|Drug|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
364404|NCT01416961|Drug|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
364405|NCT01416948|Drug|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
364406|NCT01416948|Drug|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
364407|NCT01416948|Drug|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
364408|NCT01416935|Other|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
364409|NCT01416909|Other|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
364410|NCT01416909|Other|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
364411|NCT01416909|Other|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
364412|NCT01416896|Procedure|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
364413|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
364414|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
364415|NCT01416896|Procedure|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
364416|NCT01416883|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
364417|NCT01416870|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
364418|NCT01416870|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
364419|NCT01416857|Other|RDDT|
364516|NCT01416051|Dietary Supplement|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
364420|NCT01416844|Biological|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
364421|NCT01416831|Other|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
364422|NCT01416831|Drug|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
364423|NCT01416818|Drug|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
364424|NCT01416818|Drug|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
364425|NCT01416818|Drug|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
364426|NCT01416805|Behavioral|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
364427|NCT01416805|Behavioral|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
364428|NCT01416792|Procedure|Centrifugation|
364429|NCT01416792|Procedure|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
364430|NCT01416779|Behavioral|Writing Intervention|Finding Balance Writing Intervention
364431|NCT01416766|Other|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
364432|NCT01416753|Device|UCR|BVM-based regulation of ultrafiltration and conductivity
364433|NCT01416753|Device|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
364434|NCT01416740|Procedure|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
364435|NCT01416740|Drug|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
364436|NCT01416727|Other|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
364437|NCT01416727|Other|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
364438|NCT01416701|Dietary Supplement|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
364439|NCT01416701|Dietary Supplement|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
364440|NCT01416688|Procedure|assessment of therapy complications|Will be given by questionnaire
364441|NCT01416688|Procedure|psychosocial assessment and care|Will be given by questionnaire
364442|NCT01416688|Procedure|quality-of-life assessment|Will be given by questionnaire
364443|NCT01416662|Drug|gemcitabine hydrochloride|
364444|NCT01416649|Drug|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
364445|NCT01416636|Drug|Treprostinil sodium|
364446|NCT01416623|Drug|henatinib|Henatinib Maleate Tablets
364517|NCT01416051|Other|Placebo|100% milk fat
364447|NCT01416597|Biological|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
364448|NCT01416584|Behavioral|methadone contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
364449|NCT01416584|Behavioral|Methadone & Abstinence Contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
364450|NCT01416571|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
364451|NCT01416558|Drug|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks~Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
364452|NCT01416545|Behavioral|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
364453|NCT01416545|Behavioral|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
364454|NCT01416519|Procedure|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
364455|NCT01416519|Procedure|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
364456|NCT01416506|Other|No Drug|It's a surveillance
364457|NCT01416493|Drug|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
364458|NCT01416480|Drug|Theobromine 300mg|Capsule, b.i.d.
364459|NCT01416480|Drug|Levodropropizine 10mg|Syrup, t.i.d.
364460|NCT01416441|Drug|aripiprazole|Open-label Once-weekly formulation of aripiprazole as a flexible-dose regimen
364461|NCT01416428|Drug|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
364462|NCT01416415|Other|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
364463|NCT01416415|Other|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
364464|NCT01416402|Drug|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
364465|NCT01416402|Drug|Febuxostat|80 mg once daily orally for 5 weeks
364466|NCT01416402|Drug|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
364467|NCT01416389|Drug|LY2523355|Administered intravenously as a one hour infusion
364468|NCT01416389|Drug|ixabepilone|Administered intravenously
364469|NCT01416389|Drug|pegfilgrastim|Administered intravenously
364470|NCT01416389|Drug|filgrastim|Administered intravenously
364471|NCT01416376|Drug|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
364472|NCT01416376|Drug|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
364473|NCT01416363|Drug|Firategrast immediate release tablet|Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
364474|NCT01416363|Drug|Firategrast modified release tablet|Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
364475|NCT01416363|Drug|Firategrast gastro-retentive solution|Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
364476|NCT01416350|Drug|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
364477|NCT01416350|Drug|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
364478|NCT01416350|Drug|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
364479|NCT01416337|Drug|GSK1120212|2 mg single dose tablet on Day 1 of study
364480|NCT01416337|Drug|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
364481|NCT01416324|Drug|placebo|Vehicle used to dilute the powder for oral administration.
364482|NCT01416324|Drug|0.1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
364483|NCT01416324|Drug|0.3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
364484|NCT01416324|Drug|1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
364485|NCT01416324|Drug|3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
364486|NCT01416324|Drug|10 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
364487|NCT01416324|Drug|30 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
364488|NCT01416324|Drug|60 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
364489|NCT01416311|Drug|Eltrombopag|
364490|NCT01416298|Other|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and > 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching >10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after >10% is achieved is acceptable and now will be put into standard clinical practice.
364491|NCT01416272|Device|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
364492|NCT01416259|Drug|Withdraw treatment|
364493|NCT01416246|Procedure|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is < or = to 50 and/or age > 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
364494|NCT01416233|Procedure|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
364495|NCT01416220|Drug|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
364496|NCT01416220|Drug|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.~Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
364497|NCT01416207|Drug|Avonex|4 weekly injections of Avonex (IM)
364498|NCT01416194|Drug|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
364499|NCT01416194|Drug|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
364500|NCT01416194|Drug|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
364501|NCT01416181|Drug|natalizumab|Administered as specified in the treatment arm
364502|NCT01416181|Drug|Placebo|Matched placebo in part 1
364503|NCT01416168|Other|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
364504|NCT01416155|Drug|natalizumab|
364505|NCT01416142|Device|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
364506|NCT01416142|Device|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
364507|NCT01416129|Device|Standard of care socket|Amputees' preferred socket.
364508|NCT01416129|Device|Prosthetic brimless socket|Study socket
364509|NCT01416116|Drug|QUTENZA|topical
364510|NCT01416116|Drug|Lidocaine|topical
364511|NCT01416116|Drug|Tramadol|oral
364512|NCT01416103|Other|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
364513|NCT01416103|Other|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
364514|NCT01416077|Other|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised~Crystalloid infusion (2,5 ml/kg/t) throughout surgery~3 ml/kg Volulyte (artifical colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase > 10% is observed. A new dose is given if SV decreases more than 10% from the last value.~If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI > 2,5.~If despite CI > 2,5 Mean Arterial Pressure <65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
364515|NCT01416064|Drug|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
364518|NCT01416038|Biological|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
364519|NCT01416038|Drug|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
364520|NCT01416025|Drug|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
364521|NCT01416012|Behavioral|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
364522|NCT01416012|Behavioral|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
364523|NCT01416012|Behavioral|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
364524|NCT01416012|Behavioral|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
364525|NCT01415986|Drug|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
364526|NCT01415986|Device|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
364527|NCT01415973|Dietary Supplement|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
364528|NCT01415973|Dietary Supplement|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
364529|NCT01415960|Drug|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
364530|NCT01415947|Device|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
364531|NCT01415934|Other|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
364532|NCT01415921|Drug|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
364533|NCT01415908|Device|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
364534|NCT01415908|Other|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
364535|NCT01415895|Drug|ATNC05 - a study drug capsule|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
364536|NCT01415895|Drug|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
364537|NCT01415882|Drug|Cyclophosphamide|Given PO
364538|NCT01415882|Drug|Dexamethasone|Given PO
364539|NCT01415882|Drug|Ixazomib Citrate|Given PO
364540|NCT01415882|Other|Laboratory Biomarker Analysis|Correlative studies
364541|NCT01415856|Device|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
364542|NCT01415856|Device|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
364543|NCT01415830|Biological|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
364544|NCT01415830|Biological|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
364545|NCT01415817|Other|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
364546|NCT01415804|Device|endoprosthesis|Thoracic aortic stentgraft
364547|NCT01415791|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
364548|NCT01415778|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
364549|NCT01415778|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
364550|NCT01415765|Drug|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
364551|NCT01415765|Drug|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
364552|NCT01415765|Drug|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
364553|NCT01415765|Drug|Vincristine|CIV on days 1-4 of every 21 day cycle
364554|NCT01415765|Drug|Cyclophosphamide|IV on day 5 of each 21 day cycle
364555|NCT01415765|Drug|Doxorubicin|CIV on days 1-4 of each 21 day cycle
364556|NCT01415765|Drug|Rituximab|IV on day 1 of each 21 day cycle
364557|NCT01415765|Drug|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
364558|NCT01415752|Biological|rituximab|Given IV
364559|NCT01415752|Drug|bendamustine hydrochloride|Given IV
364560|NCT01415752|Drug|bortezomib|Given IV or SC
364561|NCT01415752|Drug|lenalidomide|Given PO
364562|NCT01415739|Other|laboratory biomarker analysis|Correlative studies
364563|NCT01415726|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 ~ 7 hrs.
364564|NCT01415713|Drug|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
364565|NCT01415700|Device|Functional electrical stimulator|The stimulator is surgically implanted
364566|NCT01415700|Device|feet orthosis|feet orthosis specifically mold
364567|NCT01415687|Drug|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
364568|NCT01415687|Drug|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
364569|NCT01415674|Drug|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
364570|NCT01415661|Other|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
364571|NCT01415648|Other|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
364572|NCT01415648|Other|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
364573|NCT01415635|Dietary Supplement|Nutritional intervention using|"The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)."
364574|NCT01415622|Device|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
364575|NCT01415622|Procedure|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
364576|NCT01415596|Drug|salbutamol|
364577|NCT01415596|Drug|Placebo|
364578|NCT01415583|Drug|Dexamethasone|0.5mg/kg (max dose 20mg)
364579|NCT01415557|Other|Non-Fortified Control Product|Non-Fortified Control Beverage
364580|NCT01415557|Other|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
364581|NCT01415531|Drug|Nebivolol|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
364582|NCT01415531|Drug|Placebo|Dose-match placebo
364583|NCT01415518|Drug|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
364584|NCT01415518|Drug|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
364585|NCT01415518|Drug|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
364586|NCT01415505|Drug|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
364587|NCT01415492|Behavioral|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
364588|NCT01415492|Behavioral|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
364589|NCT01415479|Behavioral|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
364590|NCT01415479|Behavioral|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
364591|NCT01415479|Behavioral|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
364592|NCT01415466|Drug|Cresto|tablet, 20mg
364593|NCT01415466|Drug|Olmetec|tablet, 40mg
364594|NCT01415466|Drug|Cresto, Olmetec|tablet, 20mg and 40mg
364595|NCT01415453|Procedure|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
364637|NCT01415076|Procedure|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
364596|NCT01415440|Drug|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
364597|NCT01415440|Drug|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
364598|NCT01415427|Drug|BMN 110 - Weekly|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo."
364599|NCT01415427|Drug|BMN 110 - Every Other Week|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo."
364600|NCT01415414|Drug|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
364601|NCT01415401|Drug|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
364602|NCT01415388|Dietary Supplement|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
364603|NCT01415375|Behavioral|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
364604|NCT01415375|Behavioral|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
364605|NCT01415362|Device|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
364606|NCT01415349|Drug|SSP-002358|1 mg, oral, once
364607|NCT01415349|Drug|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
364608|NCT01415336|Drug|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
364609|NCT01415336|Drug|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
364610|NCT01415297|Drug|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
364611|NCT01415284|Drug|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
364612|NCT01415271|Other|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
364613|NCT01415245|Device|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
364614|NCT01415232|Device|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
364615|NCT01415219|Other|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
364616|NCT01415206|Behavioral|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
364617|NCT01415206|Behavioral|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
364618|NCT01415193|Procedure|Selective Tibial Nerve block|Use of selective pain block.
364619|NCT01415193|Procedure|Sciatic Nerve Block|Use of Sciatic Nerve Block
364620|NCT01415154|Device|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
364621|NCT01415141|Drug|Peginterferon alfa-2a|180ug subcutaneously, weekly
364622|NCT01415141|Drug|Ribavirin|"Administered orally twice a day as follows:~weight < 75kg - 1000mg weight ≥ 75kg - 1200mg"
364623|NCT01415141|Drug|telaprevir|750mg every 8 hours, orally
364624|NCT01415128|Drug|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
364625|NCT01415128|Drug|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
364626|NCT01415128|Drug|Desipramine|Single dose of Desipramine (50 mg) for 1 day
364627|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 1: 50 ug
364628|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
364629|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
364630|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
364631|NCT01415102|Drug|Placebo|Inhaled
364632|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
364633|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
364634|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
364635|NCT01415102|Drug|Placebo|Inhaled
364636|NCT01415089|Behavioral|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
364638|NCT01415063|Procedure|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
364639|NCT01415063|Procedure|TACE-RFA|TACE first, then RFA within 2 weeks
364640|NCT01415050|Device|Whole body vibration|15 times WBV
364641|NCT01415037|Procedure|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
364642|NCT01415024|Procedure|second LV lead in CRT|second LV lead in CRT
364643|NCT01415011|Drug|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
364644|NCT01414998|Behavioral|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:~use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.~use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
364645|NCT01414998|Behavioral|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:~use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.~smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.~One week later participants will complete the other arm."
364646|NCT01414985|Biological|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
364647|NCT01414972|Drug|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
364648|NCT01414972|Drug|placebo|1 cap placebo/day for 3 month
364649|NCT01414946|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
364650|NCT01414946|Other|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient`s measured resting energy expenditure.
364651|NCT01414933|Other|Biopsy|Breast metastases biopsy
364652|NCT01414920|Drug|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
364653|NCT01414920|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
364654|NCT01414920|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
364655|NCT01414920|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
364656|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
364657|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
364658|NCT01414907|Behavioral|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
364659|NCT01414894|Other|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
364660|NCT01414894|Other|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
364661|NCT01414881|Drug|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
364662|NCT01414881|Drug|Placebo|Placebo administered subcutaneously (SC) once weekly
364663|NCT01414868|Drug|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
364664|NCT01414855|Drug|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
364665|NCT01414855|Drug|cyclophosphamide|750 mg/m^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
364666|NCT01414855|Drug|doxorubicin|50 mg/m^2 IV, Day 1 of each 21-cycle, 6 cycles.
364667|NCT01414855|Drug|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
364668|NCT01414855|Drug|vincristine|1.4 mg/m^2 IV, Day 1 of each 21-day cycle, 6 cycles.
364669|NCT01414842|Device|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
364670|NCT01414842|Device|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
364671|NCT01414829|Procedure|Gastroscopy|The reason for gastroscopy will be not related to the study
364672|NCT01414816|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
364673|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
364674|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg per day
364675|NCT01414790|Procedure|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
364676|NCT01414777|Drug|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
364677|NCT01414777|Drug|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
364763|NCT01414101|Drug|ISIS CRP Rx or Placebo|
364678|NCT01414764|Other|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
364679|NCT01414764|Drug|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.~First injection at approximately 10 days post-operatively~Second Injection at approximately 21 days post-operatively"
364680|NCT01414751|Behavioral|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
364681|NCT01414751|Behavioral|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
364682|NCT01414738|Radiation|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
364683|NCT01414725|Other|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al [2009]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
364684|NCT01414725|Other|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
364685|NCT01414725|Other|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
364686|NCT01414712|Other|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
364687|NCT01414699|Behavioral|Variety|These conditions will have snack served with an increase of fruit variety.
364688|NCT01414699|Behavioral|Non-Variety|These conditions will receive a snack without a variety of fruit.
364689|NCT01414686|Other|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.~Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
364690|NCT01414673|Drug|HCG|5000 IU
364691|NCT01414660|Procedure|transplantation|transplantation of islet, kidney or liver
364692|NCT01414647|Dietary Supplement|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
364693|NCT01414647|Dietary Supplement|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
364694|NCT01414647|Other|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
364695|NCT01414634|Biological|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
364696|NCT01414621|Other|atrial tissue sample|atrial tissue sample from CABG patient
364697|NCT01414608|Drug|Carboplatin|Given IV
364698|NCT01414608|Drug|Cisplatin|Given IV
364699|NCT01414608|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
364700|NCT01414608|Radiation|Internal Radiation Therapy|Undergo brachytherapy
364701|NCT01414608|Drug|Paclitaxel|Given IV
364702|NCT01414608|Other|Quality-of-Life Assessment|Ancillary studies
364703|NCT01414595|Genetic|DNA analysis|
364704|NCT01414595|Genetic|DNA methylation analysis|
364705|NCT01414595|Genetic|RNA analysis|
364706|NCT01414595|Genetic|gene expression analysis|
364707|NCT01414595|Genetic|polymorphism analysis|
364708|NCT01414595|Other|laboratory biomarker analysis|
364709|NCT01414595|Other|medical chart review|
364710|NCT01414582|Device|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
364711|NCT01414582|Other|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
364712|NCT01414569|Drug|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
364713|NCT01414556|Other|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
364714|NCT01414556|Other|saline|
364715|NCT01414543|Other|Information Sheet|Providing the Participant with information regarding the aim of the experiment
364716|NCT01414543|Other|Consent|Providing a consent form for participants. The participant is aware of his or her rights
364717|NCT01414543|Other|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
364718|NCT01414543|Other|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
364719|NCT01414530|Drug|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
364720|NCT01414530|Drug|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
364721|NCT01414517|Dietary Supplement|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
364722|NCT01414517|Dietary Supplement|Maltodextrin|a non-prebiotic carbohydrate
364723|NCT01414504|Biological|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
364724|NCT01414504|Biological|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
364725|NCT01414504|Biological|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
364726|NCT01414504|Biological|Control|control, 0.1mL Pneumovax at 3-5yrs
364727|NCT01414478|Other|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
364728|NCT01414465|Drug|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
364729|NCT01414439|Behavioral|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
364730|NCT01414426|Drug|vandetanib|Given PO
364731|NCT01414426|Other|placebo|Given PO
364732|NCT01414426|Other|immunohistochemistry staining method|Correlative studies
364733|NCT01414426|Other|laboratory biomarker analysis|Correlative studies
364734|NCT01414426|Procedure|biopsy|Correlative studies
364735|NCT01414426|Other|pharmacological study|Correlative studies
364736|NCT01414413|Other|Home assessment and initiation of ART|Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
364737|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
364738|NCT01414400|Other|Blood draw for culture|Blood will be drawn and sent for culture.
364739|NCT01414387|Procedure|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.~The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
364740|NCT01414387|Procedure|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
364741|NCT01414374|Drug|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
364742|NCT01414374|Drug|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
364743|NCT01414348|Behavioral|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
364744|NCT01414348|Behavioral|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
364745|NCT01414335|Dietary Supplement|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
364746|NCT01414335|Other|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
364747|NCT01414296|Drug|PSMA ADC|PSMA ADC administered IV
364748|NCT01414283|Drug|PSMA ADC|PSMA ADC administered IV
364749|NCT01414257|Drug|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
364750|NCT01414244|Drug|Glutamine|Drug
364751|NCT01414231|Drug|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
364752|NCT01414218|Behavioral|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
364753|NCT01414205|Drug|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
364754|NCT01414205|Drug|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
364755|NCT01414166|Drug|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
364756|NCT01414166|Drug|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
364757|NCT01414153|Drug|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
364758|NCT01414153|Drug|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
364759|NCT01414153|Drug|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
364760|NCT01414153|Drug|sham injection|administered monthly for 4 months
364761|NCT01414140|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
364762|NCT01414114|Drug|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
364764|NCT01414088|Other|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
364765|NCT01414088|Other|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
364766|NCT01414088|Other|glucose 5%|infusion, 23 ml/kg, during 50 minutes
364767|NCT01414075|Drug|FG-4592|Tiered, weight-based dosing with or without oral or intravenous iron supplementation
364768|NCT01414062|Behavioral|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
364769|NCT01414062|Behavioral|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the NYC-based not-for-profit, God's Love We Deliver
364770|NCT01414049|Procedure|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
364771|NCT01414049|Procedure|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
364772|NCT01414036|Other|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
364773|NCT01414036|Behavioral|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
364774|NCT01414023|Behavioral|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
364775|NCT01414023|Behavioral|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
364776|NCT01414010|Dietary Supplement|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
364777|NCT01414010|Dietary Supplement|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
364778|NCT01414010|Drug|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
364779|NCT01413984|Behavioral|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
364780|NCT01413958|Drug|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
364781|NCT01413958|Drug|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
364782|NCT01413958|Drug|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
364783|NCT01413932|Drug|HT-2157|QD oral dosing
364784|NCT01413932|Drug|Placebo|QD oral dosing
364785|NCT01413906|Drug|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
364786|NCT01413893|Drug|linifanib|QD daily
364787|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
364788|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
364789|NCT01413854|Drug|sugar pill|One tablet two times daily during four weeks
364790|NCT01413854|Drug|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
364791|NCT01413841|Drug|Nasal oxygen|3 l oxygen
364792|NCT01413841|Drug|Regular nasal air|3 l nasal air
364793|NCT01413828|Drug|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
364794|NCT01413828|Drug|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
364795|NCT01413815|Dietary Supplement|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
364796|NCT01413815|Other|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
364797|NCT01413802|Procedure|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
364798|NCT01413789|Drug|Dermatix|1 application of Dermatix
364799|NCT01413789|Drug|Kelocote|1 application of Kelocote
364800|NCT01413789|Drug|BAP scar gel|1 application of BAP scar gel
364801|NCT01413789|Drug|Alhydran|1 application of Alhydran
364802|NCT01413789|Drug|Bap Scar Care T|1 application of BAP Scar Care T
364803|NCT01413789|Drug|Bap Scar Care S|1 Application of Bap Scar Care S
364804|NCT01413789|Drug|Mepiform|1 application of Mepiform
364805|NCT01413789|Drug|Scar Ban Elastic|1 application of Scar Ban Elastic
364806|NCT01413776|Dietary Supplement|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
364807|NCT01413763|Drug|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
364808|NCT01413763|Drug|Placebo cream|placebo cream applied daily for 2 weeks
364809|NCT01413750|Drug|Paclitaxel|Given IV
364810|NCT01413750|Drug|Carboplatin|Given IV
364811|NCT01413750|Drug|Vorinostat|Given PO
364812|NCT01413750|Other|Placebo|Given PO
364813|NCT01413750|Other|Laboratory Biomarker Analysis|Correlative studies
364814|NCT01413711|Drug|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
364815|NCT01413685|Other|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
364816|NCT01413672|Device|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
364817|NCT01413659|Biological|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
364818|NCT01413646|Dietary Supplement|Walnut Supplementation|Eight weeks of walnut supplementation
364819|NCT01413646|Dietary Supplement|No walnut supplementation|Eight weeks without walnut supplementation
364820|NCT01413633|Procedure|cholecystectomy|single incision laparoscopic cholecystectomy
364821|NCT01413620|Drug|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
364822|NCT01413607|Device|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
364823|NCT01413607|Device|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
364824|NCT01413594|Behavioral|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
364825|NCT01413581|Drug|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
364826|NCT01413581|Drug|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
364827|NCT01413568|Drug|POL6326|
364828|NCT01413568|Procedure|Leukapheresis|
364829|NCT01413568|Procedure|PBSC Transplant|
364830|NCT01413555|Other|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
364831|NCT01413542|Drug|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
364832|NCT01413542|Drug|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
364833|NCT01413542|Drug|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
364834|NCT01413542|Drug|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
364835|NCT01413542|Drug|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
364836|NCT01413542|Drug|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
364837|NCT01413529|Behavioral|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
364838|NCT01413529|Behavioral|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
364839|NCT01413516|Behavioral|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
364840|NCT01413516|Drug|Placebo|Sugar pill without any active medication
364841|NCT01413516|Drug|Varenicline|Varenicline (an approved medication for smoking cessation)
364842|NCT01413503|Radiation|131I-MIBG|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
364843|NCT01413490|Drug|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
364844|NCT01413477|Drug|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
364845|NCT01413451|Drug|Amatuximab (MORab-009)|
364846|NCT01413438|Procedure|Craniotomy|
364847|NCT01413412|Procedure|Ventral hernia repair using full thickness skin graft|25 patients
364848|NCT01413412|Procedure|Ventral hernia repair using mesh|25 patients
364849|NCT01413399|Drug|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
364850|NCT01413386|Device|biliary stent|palliative treatment for malignant patients
364851|NCT01413373|Radiation|cone beam computed tomography|A preoperative CBCT is performed for all patients in this study for medical reason
364852|NCT01413373|Radiation|computer tomography|One cone beam computer tomography examination before surgery
364853|NCT01413360|Drug|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
364854|NCT01413347|Procedure|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
364855|NCT01413347|Procedure|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
364856|NCT01413295|Drug|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
364857|NCT01413295|Other|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
364858|NCT01413282|Radiation|Cardiac CT|Calcium scan and CT coronary angiography
364859|NCT01413269|Radiation|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.~the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
364860|NCT01413243|Drug|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
364861|NCT01413230|Drug|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
364862|NCT01413204|Drug|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
364863|NCT01413204|Drug|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
364864|NCT01413204|Drug|Placebo|The patients will receive Placebo orally for 24 weeks.
364865|NCT01413191|Biological|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
364866|NCT01413191|Other|Laboratory biomarker analysis|Correlative studies
364867|NCT01413178|Drug|Busulfan|Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
364868|NCT01413178|Drug|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
364869|NCT01413178|Other|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
364870|NCT01413178|Drug|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
364871|NCT01413178|Drug|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
364872|NCT01413178|Procedure|Stem cell transplant|Stem cell infusion on Day 0.
364873|NCT01413152|Biological|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
364874|NCT01413139|Device|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
364875|NCT01413126|Dietary Supplement|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
364876|NCT01413113|Drug|pazopanib hydrochloride|Given PO
364877|NCT01413113|Radiation|iodine I 131|Given IM
364878|NCT01413100|Biological|Anti-Thymocyte Globulin|Given IV
364879|NCT01413100|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
364880|NCT01413100|Drug|Cyclophosphamide|Given IV
364881|NCT01413100|Biological|Filgrastim|Given SC
364882|NCT01413100|Other|Laboratory Biomarker Analysis|Correlative studies
364883|NCT01413100|Drug|Mycophenolate Mofetil|Given PO
364884|NCT01413100|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
364885|NCT01413100|Drug|Plerixafor|Given SC
364886|NCT01413100|Other|Quality-of-Life Assessment|Ancillary studies
364887|NCT01413100|Other|Questionnaire Administration|Ancillary studies
364888|NCT01413087|Biological|Biological/Vaccine: BC-819|"Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.~After randomization patients will receive 6 weekly IV infusions of gemcitabine at a dose of 1000mg/m2 + 7 intratumoral injections of BC-819 (8 mg or 12 mg according to allocations by randomization)"
364889|NCT01413074|Other|Peritoneal Dialysis treatment|PD treatment
364890|NCT01413074|Other|Hemodialysis treatment|HD treatment
364891|NCT01413061|Procedure|Subtalar Arthrodesis|
364892|NCT01413048|Drug|Carvedilol 25mg|Tablet, q.d.
364893|NCT01413048|Drug|AGSCT101 12.5mg|Tablet, q.d.
364894|NCT01413035|Biological|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
364895|NCT01413022|Drug|Oxaliplatin|
364896|NCT01413022|Drug|Irinotecan|
364897|NCT01413022|Drug|Leucovorin|
364898|NCT01413022|Drug|Fluorouracil|
364899|NCT01413022|Other|laboratory biomarker analysis|Correlative studies
364900|NCT01413022|Other|flow cytometry|Correlative studies
364901|NCT01413022|Other|immunohistochemistry staining method|Correlative studies
364902|NCT01413022|Other|pharmacological study|Correlative studies
364903|NCT01413022|Drug|PF-04136309|
364904|NCT01412996|Procedure|surgery|single ACCESS laparoscopic cholecystectomy
364905|NCT01412996|Other|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
364906|NCT01412983|Device|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
364907|NCT01412983|Device|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
364908|NCT01412970|Other|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
364909|NCT01412957|Other|Best Supportive Care (BSC)|BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
364910|NCT01412957|Drug|Panitumumab|Administered intravenously
364911|NCT01412944|Drug|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
364912|NCT01412944|Drug|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
364913|NCT01412918|Device|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
364914|NCT01412892|Drug|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
364915|NCT01412879|Biological|rituximab|Given IV
364916|NCT01412879|Drug|bendamustine hydrochloride|Given IV
364917|NCT01412879|Drug|cyclophosphamide|Given IV
364918|NCT01412879|Drug|cytarabine|Given IV
364919|NCT01412879|Drug|dexamethasone|Given PO or IV
364920|NCT01412879|Drug|doxorubicin hydrochloride|Given IV
364921|NCT01412879|Drug|leucovorin calcium|Given PO or IV
364922|NCT01412879|Drug|methotrexate|Given IV
364923|NCT01412879|Drug|vincristine sulfate|Given IV
364924|NCT01412866|Behavioral|EDSS with CO feedback and health checklist|Web-based electronic decision support system with CO feedback and health-checklist
364925|NCT01412866|Behavioral|EDSS with health checklist feedback alon|Web-based electronic decision support system (EDSS) with health-checklist feedback alone (without CO feedback)
364926|NCT01412853|Other|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
364927|NCT01412840|Other|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
364928|NCT01412840|Other|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
364929|NCT01412827|Radiation|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.~Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
364930|NCT01412814|Device|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
364931|NCT01412814|Other|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
364932|NCT01412801|Biological|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
364933|NCT01412788|Procedure|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
364934|NCT01412788|Procedure|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
364935|NCT01412775|Behavioral|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.~The study includes three weekly sessions, Each session will be 90 minutes in duration."
364936|NCT01412762|Behavioral|patient interviews|The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
364937|NCT01412762|Behavioral|CITSAV survey|Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
364938|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
364939|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
364940|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
364941|NCT01412736|Drug|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
364942|NCT01412723|Other|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
364943|NCT01412723|Other|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
364944|NCT01412710|Drug|Cholecalciferol|4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.
364945|NCT01412697|Behavioral|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
364946|NCT01412684|Procedure|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
364947|NCT01412671|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
364948|NCT01412658|Dietary Supplement|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
364949|NCT01412658|Dietary Supplement|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily."
364950|NCT01412645|Dietary Supplement|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months"
364951|NCT01412632|Drug|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
364952|NCT01412606|Procedure|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
364953|NCT01412593|Biological|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
364954|NCT01412580|Other|observational follow-up|observational follow-up
364955|NCT01412567|Drug|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
364956|NCT01412567|Drug|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
364957|NCT01412541|Procedure|Standard Uncoated Angioplasty Balloon|Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
364958|NCT01412541|Device|Moxy Drug Coated Balloon|Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
364959|NCT01412528|Other|Allergen extracts|
364960|NCT01412515|Drug|everolimus|everolimus per os 10mg per day
364961|NCT01412502|Other|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
364962|NCT01412489|Device|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
364963|NCT01412463|Device|stent placement|"pre-dilation of the study lesion is mandatory~stent placement with 1 Protégé Everflex+ stent~only 1 stent is allowed within the study protocol~post-dilation may be performed but is not mandatory"
364964|NCT01412450|Device|nitinol stent|implantation of one Protégé EverFlex stent
364965|NCT01412437|Dietary Supplement|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
364966|NCT01412437|Drug|sapropterin dihydrochloride|20 mg/kg for 4 months
364967|NCT01412437|Drug|sapropterin dihydrochloride|
364968|NCT01412424|Drug|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
364969|NCT01412411|Behavioral|Nutritionl Education|to assess the change in behaviour
364970|NCT01412411|Dietary Supplement|Oral Iron Supplementation along with Nturition Eductaion|
364971|NCT01412411|Dietary Supplement|Multiple micronutrient fortification plus Nutrition Education|
364972|NCT01412398|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CAPD who have received Fosrenol for hyperphosphatemia
364973|NCT01412385|Biological|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
364974|NCT01412385|Biological|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
364975|NCT01412385|Biological|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
364976|NCT01412372|Drug|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
364977|NCT01412372|Drug|Placebo|This is an inactive pill
364978|NCT01412359|Drug|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
364979|NCT01412346|Other|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
364980|NCT01412333|Drug|Interferon beta-1a|
364981|NCT01412333|Drug|Ocrelizumab-matching placebo|
364982|NCT01412333|Drug|Ocrelizumab|
364983|NCT01412333|Drug|Interferon beta-1a-matching placebo|
364984|NCT01412320|Other|Cocoa|dissolved in water twice daily
364985|NCT01412320|Other|Cocoa|dissolved in water twice daily
364986|NCT01412307|Drug|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
364987|NCT01412307|Drug|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
364988|NCT01412307|Other|Bio-specimen Retention|Samples with DNA and without DNA
365102|NCT01411293|Other|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
365103|NCT01411293|Other|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
364989|NCT01412294|Drug|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
364990|NCT01412281|Biological|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
364991|NCT01412281|Biological|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
364992|NCT01412242|Other|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
364993|NCT01412229|Drug|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
364994|NCT01412229|Drug|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
364995|NCT01412229|Drug|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
364996|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
364997|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|
364998|NCT01412203|Behavioral|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
364999|NCT01412190|Device|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
365000|NCT01412190|Other|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
365001|NCT01412177|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
365002|NCT01412177|Drug|Placebo|Single intratympanic injection of placebo
365003|NCT01412164|Device|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
365004|NCT01412151|Drug|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
365005|NCT01412138|Other|genetic analysis|"To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.~In vitro culture conditions for cell proliferation.~To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.~Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
365006|NCT01412125|Other|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
365007|NCT01412125|Other|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
365008|NCT01412099|Behavioral|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
365009|NCT01412099|Behavioral|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
365010|NCT01412086|Drug|No Intervention|No Intervention.
365011|NCT01412073|Drug|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
365012|NCT01412073|Drug|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby & the placenta
365013|NCT01412060|Drug|Placebo|Placebo was supplied in capsules.
365014|NCT01412060|Drug|Cariprazine|Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
365015|NCT01412034|Drug|CER-001|Biweekly infusion
365016|NCT01412008|Drug|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
365017|NCT01411995|Drug|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to Intrauterine device insertion
365018|NCT01411995|Drug|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to intrauterine device insertion
365019|NCT01411969|Drug|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
365104|NCT01411280|Drug|methylphenidate|Ritalin 10mg, Ritalin 20mg
365105|NCT01411267|Drug|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
365232|NCT01410331|Biological|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
365020|NCT01411956|Other|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
365021|NCT01411956|Other|Placebo video|The control group watched a 25-minute patient education video on depression.
365022|NCT01411930|Drug|Intramuscular olanzapine, aripiprazole|"1st clamp: single intramuscular 10.0 mg dose of olanzapine~2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
365023|NCT01411930|Drug|Intramuscular aripiprazole, olanzapine|"1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
365024|NCT01411917|Procedure|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
365025|NCT01411904|Device|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
365026|NCT01411891|Device|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
365027|NCT01411878|Behavioral|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
365028|NCT01411878|Behavioral|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
365029|NCT01411865|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
365030|NCT01411865|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
365031|NCT01411852|Drug|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
365032|NCT01411852|Drug|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
365033|NCT01411839|Behavioral|Cognitive-Behavioral Therapy (CBT-AD)|CBT-AD is a therapy program intervention that uses one-on-one and face-to-face patient-therapist sessions.
365034|NCT01411826|Behavioral|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
365035|NCT01411826|Behavioral|Information Only|Information from CDC website on colon cancer screening.
365036|NCT01411800|Drug|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
365037|NCT01411800|Drug|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
365038|NCT01411787|Behavioral|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
365039|NCT01411774|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
365158|NCT01410916|Drug|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
365357|NCT01409200|Drug|Antiandrogen Therapy|Given per standard of care
365040|NCT01411774|Drug|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
365041|NCT01411774|Drug|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
365042|NCT01411761|Dietary Supplement|Reflor|5 million unit/day, first 15 day of life
365043|NCT01411761|Other|serum physiologic|1 cc added to one feeding in a day
365044|NCT01411748|Dietary Supplement|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
365045|NCT01411748|Drug|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
365046|NCT01411735|Drug|Enalapril|2.5mg titrated up to 10mg twice daily
365047|NCT01411735|Drug|placebo|2.5mg titrated up to 10mg twice daily.
365048|NCT01411722|Device|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
365049|NCT01411709|Drug|Vitano|two 200mg tablets per day for 14 days
365050|NCT01411696|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
365051|NCT01411683|Device|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
365052|NCT01411670|Drug|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
365053|NCT01411670|Drug|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
365054|NCT01411670|Drug|Placebo comparator|Standard treatment
365055|NCT01411657|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
365056|NCT01411631|Dietary Supplement|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
365057|NCT01411618|Other|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
365058|NCT01411605|Behavioral|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
365059|NCT01411592|Other|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
365060|NCT01411592|Other|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
365061|NCT01411566|Behavioral|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
365062|NCT01411566|Behavioral|regular treatment|regular treatment
365063|NCT01411553|Other|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
365064|NCT01411540|Dietary Supplement|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
365065|NCT01411514|Drug|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
365066|NCT01411514|Drug|Placebo|Placebo tablets. They will be administered during 25 days
365067|NCT01411501|Other|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).~Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.~Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
365068|NCT01411501|Drug|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
365069|NCT01411488|Device|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
365070|NCT01411475|Other|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
365071|NCT01411462|Device|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
365072|NCT01411449|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
365073|NCT01411436|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
365074|NCT01411423|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
365075|NCT01411410|Drug|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles~The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)~Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
365076|NCT01411410|Drug|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
365077|NCT01411397|Other|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
365078|NCT01411397|Other|mesh repair|mesh repair of strangulated hernia without resection
365079|NCT01411384|Procedure|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
365080|NCT01411384|Device|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
365081|NCT01411371|Procedure|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
365082|NCT01411371|Drug|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
365083|NCT01411358|Biological|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
365084|NCT01411358|Biological|elderly aged over 60|one dose of 0.5mL AdimFlu-S
365085|NCT01411345|Radiation|Standard Salvage Radiation Treatment (SSRT)|A total dose of 68 Gy will be delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
365086|NCT01411345|Radiation|Mapped Tumor Salvage RT (MTSRT)|Dose escalation to the Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
365087|NCT01411345|Behavioral|Expanded Prostate Cancer Index Composite-SF12|Expanded Prostate Cancer Index Composite-Sf12 (EPIC SF12) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
365088|NCT01411345|Behavioral|Memory Anxiety Scale for Prostate Cancer patients|Memory Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
365089|NCT01411345|Behavioral|International Prostate Symptom Score (IPSS)|International Prostate Symptom Score (IPSS) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
365090|NCT01411332|Radiation|SIMRT|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
365091|NCT01411332|Radiation|HTIMRT|Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
365092|NCT01411332|Behavioral|EPIC SF-12 Questionnaire|Expanded Prostate Cancer Index Composite-Short Form 12 (SF12) (EPICSF-SF12) quality of life questionnaire prior to, during and post radiation therapy per protocol.
365093|NCT01411332|Behavioral|MAX-PC Questionnaire|Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) questionnaire prior to, during and post radiation therapy per protocol.
365094|NCT01411332|Behavioral|IPSS Questionnaire|International Prostate Symptom Score (IPSS) questionnaire prior to, during and post radiation therapy per protocol.
365095|NCT01411319|Radiation|Lattice Extreme Ablative Dose Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
365096|NCT01411319|Radiation|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
365097|NCT01411319|Behavioral|EPIC SF-12 Questionnaire|Expanded Prostate Cancer Index Composite-Short Form 12 (EPIC-SF12) quality of life questionnaire at various time points per study protocol.
365098|NCT01411319|Behavioral|MAX-PC Questionnaire|Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire at various time points per study protocol.
365099|NCT01411319|Behavioral|IPSS Questionnaire|International Prostate Symptom Score (IPSS) quality of life questionnaire at various time points per study protocol.
365100|NCT01411306|Other|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
365101|NCT01411306|Procedure|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
365358|NCT01409200|Drug|Axitinib|Given PO
365106|NCT01411267|Drug|Cytarabine|"1000 mg/m2/day IV given every 12 hours on days 1 through 5.~IT cytarabine given intrathecally to patients with AML on day 0 of course 1 and 2. Dose defined by age~30 mg for patients age 1-1.99 years of age~50 mg for patients age 2-2.99 years of age~70 mg for patients >3 years of age"
365107|NCT01411267|Drug|Etoposide|150 mg/m2/day IV on days 1 through 5.
365108|NCT01411267|Drug|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
365109|NCT01411254|Drug|Betamethasone Microsphere (DE-102） Low Dose|
365110|NCT01411254|Drug|Betamethasone Microsphere (DE-102） High Dose|
365111|NCT01411254|Drug|Sham|
365112|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
365113|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
365114|NCT01411241|Biological|Placebo|0.5 mL, subcutaneous
365115|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
365116|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
365117|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
365118|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
365119|NCT01411241|Biological|Placebo|0.5 mL, subcutaneously
365120|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
365121|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
365122|NCT01411228|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
365123|NCT01411215|Drug|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
365124|NCT01411202|Drug|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
365125|NCT01411202|Other|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
365126|NCT01411189|Drug|Menthol|20 mL NPO-11 in prefilled syringe
365127|NCT01411176|Drug|Menthol|20 mL NPO-11 in a prefilled plastic syringe
365128|NCT01411176|Drug|Placebo|The placebo is included same additives as active comparator.
365129|NCT01411163|Drug|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
365130|NCT01411150|Drug|Creatine Monohydrate|Up to 30 grams daily creatine monohydrate
365131|NCT01411137|Drug|IPX066|"Subjects were converted from their current treatment to IPX066 over a 6-week period.~Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"
365132|NCT01411124|Drug|gabapentin enacarbil|600 mg investigational compound
365133|NCT01411124|Drug|diphenhydramine|50 mg active comparator
365134|NCT01411124|Drug|placebo|placebo
365135|NCT01411111|Drug|Rosuvastatin 10 mg|days 1-14
365136|NCT01411111|Drug|GSK2190915 30mg|1x30mg tablet, days 8-14
365137|NCT01411111|Drug|GSK2190915 100mg|1x100mg tablet, days 8-14
365138|NCT01411098|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
365139|NCT01411098|Radiation|intensity-modulated radiation therapy|Undergo IMRT
365140|NCT01411098|Drug|cisplatin|Given IV
365141|NCT01411098|Drug|etoposide|Given IV
365142|NCT01411085|Drug|Risperidone + Desipramine|
365143|NCT01411072|Drug|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
365144|NCT01411072|Drug|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
365145|NCT01411059|Behavioral|yoga|yoga classes 2 times per week for 32 weeks
365146|NCT01411046|Diagnostic Test|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
365147|NCT01411020|Procedure|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
365148|NCT01410968|Drug|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
365149|NCT01410955|Dietary Supplement|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
365150|NCT01410955|Dietary Supplement|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
365151|NCT01410942|Other|Placebo|Capsules by mouth twice daily.
365152|NCT01410942|Drug|Methylphenidate|Starting dose 5 mg by mouth twice daily.
365153|NCT01410942|Behavioral|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
365154|NCT01410942|Other|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
365155|NCT01410942|Other|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
365156|NCT01410942|Other|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
365157|NCT01410929|Procedure|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
365437|NCT01408641|Drug|Placebo|Placebo capsules without topiramate
365159|NCT01410903|Device|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
365160|NCT01410890|Biological|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
365161|NCT01410864|Device|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
365162|NCT01410864|Other|Control|Devices or drugs used to seal the dura (other than DuraSeal)
365163|NCT01410851|Other|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
365164|NCT01410838|Other|Broth|200 mL of sodium chloride containing broth, consumed three times per day
365165|NCT01410838|Other|Broth|200 mL of MSG containing broth consumed three times per day
365166|NCT01410825|Biological|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
365167|NCT01410812|Behavioral|Control|Receive weekly emails asking participants about their exercise and receive cash.
365168|NCT01410812|Behavioral|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
365169|NCT01410812|Behavioral|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
365170|NCT01410799|Drug|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
365171|NCT01410786|Procedure|Conventional Instrumentation|Standard Oxford surgical instruments
365172|NCT01410786|Procedure|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
365173|NCT01410773|Device|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
365174|NCT01410760|Other|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
365175|NCT01410747|Drug|Tacrolimus|oral
365176|NCT01410734|Drug|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
365177|NCT01410721|Behavioral|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
365178|NCT01410721|Behavioral|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
365179|NCT01410708|Drug|Dasatinib|
365180|NCT01410695|Drug|masitinib 3 mg|
365181|NCT01410695|Drug|masitinib 6.0 mg|
365182|NCT01410695|Drug|methotrexate|
365183|NCT01410695|Drug|Placebo (methotrexate)|
365184|NCT01410695|Drug|Placebo (masitinib)|
365185|NCT01410682|Other|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
365186|NCT01410682|Other|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
365187|NCT01410669|Behavioral|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).~In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
365188|NCT01410656|Behavioral|Telephone Implementation Intention|Telephone implementation intention counseling
365189|NCT01410656|Behavioral|Self-completed implementation intention|Self-administered implementation intention intervention
365190|NCT01410643|Other|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
365191|NCT01410630|Diagnostic Test|FLT-PET/CT|Standard of Care
365192|NCT01410630|Diagnostic Test|FDG-PET/CT|Standard of Care
365193|NCT01410630|Drug|FLT|5 mCi IV
365194|NCT01410617|Procedure|hemodialysis|3 sessions hemodialysis before CABG
365195|NCT01410604|Drug|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
365196|NCT01410604|Drug|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
365197|NCT01410591|Device|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
365198|NCT01410591|Device|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
365199|NCT01410565|Drug|Apaziquone|Apaziquone 4 mg in 40 mL diluent
365200|NCT01410565|Drug|Placebo|Placebo for Double Blind Phase
365201|NCT01410552|Device|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
365202|NCT01410539|Device|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
365203|NCT01410539|Drug|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
365204|NCT01410513|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
365205|NCT01410500|Drug|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
365206|NCT01410474|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
365207|NCT01410461|Device|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
365208|NCT01410461|Device|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
365209|NCT01410448|Drug|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
365210|NCT01410448|Drug|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
365211|NCT01410448|Drug|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
365212|NCT01410448|Drug|Steroids|Steroids were administered according to local clinical practice.
365213|NCT01410435|Drug|Monofer|Infusion according to current HB level
365214|NCT01410409|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
365215|NCT01410409|Drug|Paracetamol|1 g x 4/day
365216|NCT01410409|Drug|Burana|400 mg x 3/day for three weeks
365217|NCT01410409|Drug|Pantoprazol|20mg x 1/day for three weeks
365218|NCT01410409|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
365219|NCT01410409|Behavioral|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
365220|NCT01410409|Procedure|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
365221|NCT01410409|Other|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes."
365222|NCT01410383|Drug|Placebo|Tablets taken daily
365223|NCT01410383|Drug|Eprotirome|Tablets taken daily
365224|NCT01410383|Drug|Eprotirome|Tablets taken daily
365225|NCT01410370|Radiation|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
365226|NCT01410370|Drug|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
365227|NCT01410357|Behavioral|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
365228|NCT01410344|Drug|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:~Days -6 to -2: Flu (30 mg/m^2/day, total dose of 150 mg/m^2)~Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m^2 IV, respectively)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
365229|NCT01410344|Drug|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m^2, Melphalan total dose: less than or equal to 150 mg/m^2. Recommended regimen:~Days -5 to -2: Flu (30mg/m^2/day, total dose of 120 mg/m^2)~Day -1: Mel (140mg/m^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
365230|NCT01410344|Drug|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:~Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively)~Days -5 to -2: Flu (30 mg/m^2/day, total dose of 120 mg/m^2)~Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.~Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
365231|NCT01410344|Drug|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:~Days -7 to -4: TBI (total dose of 1200-1420 cGy)~Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)~Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
365233|NCT01410331|Biological|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
365234|NCT01410331|Biological|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
365235|NCT01410331|Biological|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
365236|NCT01410292|Other|GI and fiber meals|meals with different fiber content and glycemic index
365237|NCT01410292|Other|meals|four different meal regarding GI and fiber content
365238|NCT01410279|Other|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
365239|NCT01410266|Other|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
365240|NCT01410253|Other|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
365241|NCT01410253|Other|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
365242|NCT01410253|Other|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
365243|NCT01410253|Other|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
365244|NCT01410240|Procedure|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
365245|NCT01410240|Drug|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.~+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
365246|NCT01410227|Biological|Recombinant von Willebrand factor (rVWF)|Intravenous administration
365247|NCT01410227|Drug|Placebo|Syringe supplied with physiologic saline solution for infusion
365248|NCT01410227|Biological|Recombinant factor VIIII (rFVIII)|Intravenous administration
365249|NCT01410214|Drug|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
365250|NCT01410214|Drug|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
365251|NCT01410201|Drug|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
365252|NCT01410188|Drug|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
365253|NCT01410188|Drug|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
365254|NCT01410188|Drug|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
365255|NCT01410175|Device|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
365256|NCT01410162|Drug|Tacrolimus|tacrolimus extended release capsules vs Prograf
365257|NCT01410149|Other|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
365258|NCT01410149|Other|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
365259|NCT01410149|Other|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
365260|NCT01410136|Procedure|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
365261|NCT01410123|Other|Integrated Stepped Care (ISC)|"At risk drinking:~Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy~Alcohol abuse/dependence:~Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare~Moderate Alcohol + Liver Disease:~Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy."
365262|NCT01410123|Other|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
365263|NCT01410110|Behavioral|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
365264|NCT01410110|Behavioral|Work Therapy|20 hours per week of work therapy
365265|NCT01410097|Behavioral|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
365266|NCT01410097|Behavioral|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
365267|NCT01410084|Dietary Supplement|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
365268|NCT01410084|Dietary Supplement|Vitamin E|400 IU vitamin E once monthly for 5 months
365269|NCT01410058|Dietary Supplement|Moringa oleifera|leaf powder, 1.85g once daily, hard gelatin capsules
365270|NCT01410058|Drug|Efavirenz 600mg|Efavirenz 600mg based regimen
365271|NCT01410058|Drug|Nevirapine 200Mg Oral Tablet|Nevirapine 200mg based regimen
365272|NCT01410045|Procedure|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
365273|NCT01410032|Procedure|Plate fixation|Reconstruction plate
365274|NCT01410032|Procedure|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
365275|NCT01410019|Other|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
365276|NCT01409993|Drug|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
365277|NCT01409993|Drug|Placebo|Matching placebo three times a day for three months
365278|NCT01409993|Diagnostic Test|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
365279|NCT01409993|Diagnostic Test|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
365280|NCT01409928|Device|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
365281|NCT01409915|Drug|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
365282|NCT01409915|Drug|Saline -- placebo comparator|subcutaneous injection
365283|NCT01409889|Behavioral|Diabetes Prevention Program|
365284|NCT01409889|Behavioral|Healthy Living Program|
365285|NCT01409876|Radiation|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
365286|NCT01409863|Procedure|laser and standard diamond fraise dermabrasion|standard dermabrasion, CO2 laser resurfacing
365287|NCT01409850|Device|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
365288|NCT01409850|Device|Soft splint|
365289|NCT01409837|Drug|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
365290|NCT01409824|Other|CDSS|Clinical Decision Support System
365291|NCT01409811|Drug|zoledronic acid|Given IV
365292|NCT01409811|Other|laboratory biomarker analysis|Correlative studies
365293|NCT01409811|Procedure|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
365294|NCT01409772|Drug|Ethanol Lock|Ethanol Lock
365295|NCT01409759|Procedure|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
365296|NCT01409733|Device|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
365297|NCT01409720|Other|exercise|tailored isometric physical exercise
365298|NCT01409707|Behavioral|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
365299|NCT01409707|Behavioral|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
365300|NCT01409707|Behavioral|Healthy lifestyles sessions|
365301|NCT01409694|Drug|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
365302|NCT01409694|Drug|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
365303|NCT01409694|Drug|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
365304|NCT01409668|Dietary Supplement|L. Amylovorus|L. Amylovorus
365305|NCT01409668|Dietary Supplement|L. Fermentum|L. Fermentum
365306|NCT01409655|Behavioral|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
365307|NCT01409642|Behavioral|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
365308|NCT01409642|Behavioral|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
365309|NCT01409642|Behavioral|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
365310|NCT01409629|Behavioral|Computer game|Participants will play a computer game
365311|NCT01409616|Drug|darexaban|oral
365312|NCT01409616|Drug|darexaban (double dose)|oral
365313|NCT01409616|Drug|Acetyl Salicylic Acid|oral
365314|NCT01409616|Drug|clopidogrel|oral
365315|NCT01409603|Drug|darexaban|oral
365316|NCT01409603|Drug|Naproxen|oral
365317|NCT01409590|Behavioral|Exercise program|Homogenous exercise program in local fitness centers
365795|NCT01405950|Drug|Zanaflex Capsules|0.05 mg/kg
365318|NCT01409590|Behavioral|Diet|Weigh loss diet program prescribed by a professional nutritionist
365319|NCT01409564|Drug|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
365320|NCT01409564|Drug|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
365321|NCT01409551|Procedure|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
365322|NCT01409551|Procedure|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
365323|NCT01409538|Other|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
365324|NCT01409538|Other|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
365325|NCT01409512|Procedure|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
365326|NCT01409499|Procedure|hepatic resection|palliative hepatectomy followed by sorafenib
365327|NCT01409499|Procedure|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
365328|NCT01409499|Drug|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
365329|NCT01409486|Other|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
365330|NCT01409473|Radiation|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
365331|NCT01409460|Procedure|Oburator Nerve block|Use of selective pain block.
365332|NCT01409460|Procedure|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
365333|NCT01409447|Device|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
365334|NCT01409434|Drug|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
365335|NCT01409421|Behavioral|motivational interviewing|counseling intervention
365336|NCT01409421|Behavioral|three phone calls to remind patients to take their eye drops|reminder phone calls
365337|NCT01409408|Drug|Aliskiren|300 mg of aliskiren daily for 8 weeks.
365338|NCT01409408|Drug|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
365339|NCT01409395|Drug|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
365340|NCT01409395|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
365341|NCT01409382|Behavioral|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
365342|NCT01409369|Drug|RO4995819|single oral dose
365343|NCT01409369|Drug|activated charcoal|orally 3 times daily, Days 1-7
365344|NCT01409356|Behavioral|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
365345|NCT01409343|Drug|TrasGEX™|
365346|NCT01409330|Dietary Supplement|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
365347|NCT01409317|Device|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
365348|NCT01409317|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
365349|NCT01409304|Device|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
365350|NCT01409278|Procedure|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
365351|NCT01409278|Procedure|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
365352|NCT01409278|Procedure|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
365353|NCT01409239|Drug|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
365354|NCT01409239|Drug|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
365355|NCT01409226|Device|3.0-T MRI|Participants undergo MRI prior to biopsy.
365356|NCT01409226|Procedure|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
365359|NCT01409200|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
365360|NCT01409200|Procedure|Regional Lymph Node Dissection|Undergo pelvic lymph node dissection
365361|NCT01409187|Drug|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
365362|NCT01409187|Drug|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
365363|NCT01409187|Drug|Interleukin-2 (Aldesleukin)|9 million IU/m^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
365364|NCT01409174|Drug|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.~Phase II dose: Maximum tolerated dose (MTD) from Phase I."
365365|NCT01409174|Drug|Temozolomide|200 mg/m^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
365366|NCT01409174|Drug|Cisplatin|25 mg/m^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
365367|NCT01409174|Drug|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
365368|NCT01409174|Drug|Interleukin-2|9 million IU/m^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
365369|NCT01409161|Drug|Arsenic Trioxide|Given IV
365370|NCT01409161|Drug|Gemtuzumab Ozogamicin|Given IV
365371|NCT01409161|Other|Laboratory Biomarker Analysis|Correlative studies
365372|NCT01409161|Drug|Tretinoin|Given PO
365373|NCT01409148|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
365374|NCT01409135|Drug|AGS-22M6E|IV Infusion
365375|NCT01409135|Drug|ASG-22CE|IV Infusion
365376|NCT01409122|Drug|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
365377|NCT01409122|Drug|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
365378|NCT01409122|Drug|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
365379|NCT01409122|Drug|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
365380|NCT01409122|Drug|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
365381|NCT01409096|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
365382|NCT01409096|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
365383|NCT01409083|Device|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
365384|NCT01409044|Other|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
365385|NCT01409031|Drug|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
365386|NCT01409031|Other|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
365387|NCT01409018|Drug|Itraconazole|pharmacokinetics
365388|NCT01409005|Drug|Gemcitabine and UFTE chemotherapy|"Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15~UFTE : 200mg/m2 PO q 8 hr, Days 1~21~Interval: every 4 weeks"
365389|NCT01408992|Procedure|Audiometry|Standard hearing test performed by audiologists
365390|NCT01408992|Other|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
365391|NCT01408979|Drug|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
365392|NCT01408979|Drug|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
365393|NCT01408966|Dietary Supplement|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
365394|NCT01408966|Dietary Supplement|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
365395|NCT01408953|Biological|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.~A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
365396|NCT01408927|Other|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
365397|NCT01408927|Other|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
365398|NCT01408927|Other|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
365485|NCT01408290|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
365486|NCT01408277|Biological|Santyl|2 mm Santyl applied once daily
365487|NCT01408277|Procedure|Control|Standard Care
365399|NCT01408914|Drug|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
365400|NCT01408901|Behavioral|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
365401|NCT01408901|Other|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
365402|NCT01408901|Drug|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M^2 subcutaneously three times weekly for two weeks.
365403|NCT01408888|Biological|LY2189265|Administered subcutaneously
365404|NCT01408888|Drug|Sitagliptin|Administered orally
365405|NCT01408875|Device|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
365406|NCT01408862|Other|venous puncture|Blood for in vitro studies will be drawn
365407|NCT01408849|Drug|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
365408|NCT01408849|Drug|Omeprazole|Standard therapy
365409|NCT01408836|Procedure|Plasma exchange|Plasma exchange
365410|NCT01408836|Drug|Intravenous methyl prednisolone|Intravenous methyl prednisolone
365411|NCT01408836|Drug|Methyl prednisolone|methyl prednisolone
365412|NCT01408810|Drug|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
365413|NCT01408797|Procedure|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
365414|NCT01408797|Drug|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
365415|NCT01408797|Procedure|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
365416|NCT01408758|Other|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
365417|NCT01408758|Other|No VCRT, only physician counseling at visits|No intervention
365418|NCT01408745|Device|Sternumfix|sternotomy closure with Sternumfix
365419|NCT01408745|Procedure|steel wire|sternotomy closure with steel wire
365420|NCT01408732|Drug|Sclerotherapy|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
365421|NCT01408732|Other|Standard Treatment|Normal standard of care followed by Drug interevention
365422|NCT01408719|Dietary Supplement|Control|Minimal beta-glucan
365423|NCT01408719|Dietary Supplement|3g LMW beta-glucan|3grams beta-glucan
365424|NCT01408719|Dietary Supplement|5g LMW beta-glucan|5 grams beta-glucan
365425|NCT01408719|Dietary Supplement|3g HMW beta-glucan|3 grams of high molecular weight beta-glucan
365426|NCT01408706|Device|Miller Air tip|Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
365427|NCT01408706|Device|Radiadyne Immobilizer|Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
365428|NCT01408693|Procedure|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
365429|NCT01408693|Procedure|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
365430|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
365431|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
365432|NCT01408680|Dietary Supplement|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
365433|NCT01408667|Drug|TRC150094|50 mg Tablets once a day
365434|NCT01408667|Other|Placebo|Tablets once daily
365435|NCT01408654|Behavioral|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
365436|NCT01408641|Drug|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
365438|NCT01408628|Behavioral|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of < 7.0% using an established treat-to-target algorithm."
365439|NCT01408615|Drug|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
365440|NCT01408602|Drug|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
365441|NCT01408602|Drug|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
365442|NCT01408602|Drug|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
365443|NCT01408589|Drug|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
365444|NCT01408576|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
365445|NCT01408576|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
365446|NCT01408563|Drug|Fludarabine|30 mg/m2/day IV x 6 days
365447|NCT01408563|Drug|Melphalan|100 mg/m2/day IV x 1 day
365448|NCT01408563|Radiation|Total Body Radiation|200 cGy on Day 0
365449|NCT01408563|Biological|Cord Blood|2 cord blood units IV
365450|NCT01408550|Drug|NPB-01|Intravenous immunoglobulin
365451|NCT01408550|Drug|Placebo|Physiological saline
365452|NCT01408537|Biological|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
365453|NCT01408524|Drug|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
365454|NCT01408524|Drug|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
365455|NCT01408511|Drug|Mapracorat|Application of the investigational product on the affected skin areas
365456|NCT01408498|Drug|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
365457|NCT01408485|Device|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~IBI 1500T9 V1.43 RF Generator"
365458|NCT01408472|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
365459|NCT01408459|Dietary Supplement|Tomato Product|Motivational Telephone Counseling weekly
365460|NCT01408459|Dietary Supplement|Control|No Motivational telephone Counseling
365461|NCT01408446|Drug|Menthol|Capsule 48mg three times a day after meals 8 weeks
365462|NCT01408446|Drug|Placebo|Capsule 48mg three times a day after meals 8 weeks
365463|NCT01408433|Other|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
365464|NCT01408433|Other|Double embryo transfer|two (2) embryo transfer of untested embryos
365465|NCT01408420|Procedure|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP > 60 mmHg during extracorporeal circulation is used.
365466|NCT01408407|Other|Aveeno cream|Apply cream on irradiated area twice a day
365467|NCT01408407|Other|Alkagin paste|Apply Alkagin paste three times a day.
365468|NCT01408394|Drug|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
365469|NCT01408394|Drug|90 mg controlled release form|This is the 90 mg controlled release form
365470|NCT01408394|Drug|180 mg controlled release form|This is the 180 mg controlled release capsule
365471|NCT01408381|Other|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
365472|NCT01408368|Procedure|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
365473|NCT01408368|Procedure|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
365474|NCT01408355|Drug|PF-06273588|Intravenous, 50 microgram, single dose
365475|NCT01408355|Drug|PF-06273588|Oral solution, 50 microgram, single dose
365476|NCT01408342|Drug|Alemtuzumab and Rituximab|"Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3~Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25~Cyclosporine 3 mg/kg starting day 21"
365477|NCT01408329|Device|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
365478|NCT01408316|Drug|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
365479|NCT01408303|Drug|Olive oil, 4g|Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
365480|NCT01408303|Drug|omega-3-carboxylic acids, 2g|Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
365481|NCT01408303|Drug|omega-3-carboxylic acids, 4g|Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
365482|NCT01408290|Biological|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
365483|NCT01408290|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
365484|NCT01408290|Biological|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
365488|NCT01408264|Device|Conventional 0.035 guidewire|0.035 guidewire
365489|NCT01408264|Device|Olympus Visiglide 0.025 guidewire|0.025 guidewire
365490|NCT01408238|Biological|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
365491|NCT01408225|Procedure|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
365492|NCT01408212|Procedure|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.~Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22~Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
365493|NCT01408199|Drug|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
365494|NCT01408186|Drug|Rabeprazole|Rabeprazole 20 mg daily
365495|NCT01408186|Drug|Famotidine|Famotidine 40mg daily
365496|NCT01408173|Drug|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
365497|NCT01408160|Drug|Cytarabine|Given IV
365498|NCT01408160|Biological|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
365499|NCT01408160|Other|Laboratory Biomarker Analysis|Correlative studies
365500|NCT01408160|Other|Pharmacological Study|Correlative studies
365501|NCT01408147|Behavioral|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
365502|NCT01408134|Other|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
365503|NCT01408121|Other|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
365504|NCT01408108|Procedure|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
365505|NCT01408108|Procedure|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.~In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
365506|NCT01408095|Drug|LY2608204|Administered orally
365507|NCT01408095|Drug|Glimepiride|Administered orally
365508|NCT01408082|Drug|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
365509|NCT01408082|Drug|Azasite|Azasite twice daily for 2 weeks
365510|NCT01408082|Drug|Dexamethasone|Dexamethasone twice daily for 2 weeks
365511|NCT01408082|Other|Vehicle|Vehicle twice daily for 2 weeks
365512|NCT01408069|Drug|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
365513|NCT01408069|Drug|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
365514|NCT01408056|Drug|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:~4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day~8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
365515|NCT01408056|Drug|Mupirocin 2% Ointment|Topical application twice per day for 60 days
365516|NCT01408043|Drug|plerixafor|Given SC
365517|NCT01408043|Biological|filgrastim|Given SC
365518|NCT01408043|Drug|etoposide|Given IV
365519|NCT01408043|Procedure|leukapheresis|Undergo apheresis
365520|NCT01408030|Drug|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
365521|NCT01408030|Drug|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
365522|NCT01408030|Drug|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
365523|NCT01408030|Drug|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
365524|NCT01408004|Drug|Pazopanib|Tablet 800mg qd til progression
365525|NCT01408004|Drug|Everolimus|tablet 10 mg qd til progression
365526|NCT01408004|Drug|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
365527|NCT01408004|Drug|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
365528|NCT01408004|Drug|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
365529|NCT01408004|Drug|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
365581|NCT01407679|Drug|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
365582|NCT01407666|Procedure|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
365796|NCT01405950|Drug|Zanaflex Capsules|0.075 mg/kg
365530|NCT01407991|Other|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
365531|NCT01407991|Other|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
365532|NCT01407978|Biological|Vaccination with Fluval P monovalent influenza vaccine|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
365533|NCT01407978|Biological|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
365534|NCT01407978|Biological|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
365535|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
365536|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
365537|NCT01407952|Device|HydroCoil Embolic System|HydroCoil Embolic System
365538|NCT01407952|Device|Control (bare platinum coils)|bare platinum coils
365539|NCT01407926|Other|Nurse-Led Mental Health Promotion Intervention|The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
365540|NCT01407913|Procedure|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
365541|NCT01407900|Drug|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
365542|NCT01407900|Drug|5% Dextrose in Water|four hour infusion IV
365543|NCT01407887|Drug|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
365544|NCT01407874|Drug|Placebo|Oral dose administered daily for 84 days.
365545|NCT01407874|Drug|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
365546|NCT01407874|Drug|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
365547|NCT01407861|Other|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
365548|NCT01407861|Other|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
365549|NCT01407848|Drug|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
365550|NCT01407848|Drug|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
365551|NCT01407835|Biological|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
365552|NCT01407822|Drug|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
365553|NCT01407822|Drug|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
365554|NCT01407809|Device|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
365555|NCT01407796|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|
365556|NCT01407796|Drug|[18F](+/-)NOS|
365557|NCT01407783|Behavioral|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
365558|NCT01407770|Genetic|DNA analysis|Genetic
365559|NCT01407770|Genetic|gene expression analysis|Genetic
365560|NCT01407770|Other|enzyme-linked immunosorbent assay|Genetic
365561|NCT01407770|Other|flow cytometry|Genetic
365562|NCT01407770|Other|laboratory biomarker analysis|Genetic
365563|NCT01407770|Other|questionnaire administration|Genetic
365564|NCT01407770|Procedure|adjuvant therapy|Genetic
365565|NCT01407770|Procedure|assessment of therapy complications|Genetic
365566|NCT01407770|Procedure|quality-of-life assessment|Genetic
365567|NCT01407770|Radiation|3-dimensional conformal radiation therapy|Genetic
365568|NCT01407770|Radiation|breast irradiation|Genetic
365569|NCT01407770|Radiation|external beam radiation therapy|Genetic
365570|NCT01407770|Radiation|hypofractionated radiation therapy|Genetic
365571|NCT01407770|Radiation|intensity-modulated radiation therapy|Genetic
365572|NCT01407770|Radiation|whole breast irradiation|Genetic
365573|NCT01407757|Genetic|DNA analysis|
365574|NCT01407757|Genetic|gene expression analysis|
365575|NCT01407757|Other|laboratory biomarker analysis|
365576|NCT01407757|Other|pharmacogenomic studies|
365577|NCT01407744|Other|laboratory biomarker analysis|Correlative studies
365578|NCT01407731|Genetic|protein expression analysis|
365579|NCT01407731|Genetic|western blotting|
365580|NCT01407731|Other|laboratory biomarker analysis|
365583|NCT01407653|Procedure|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
365584|NCT01407653|Procedure|Usual care|Classical care
365585|NCT01407640|Procedure|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
365586|NCT01407627|Dietary Supplement|Fructose|"Subjects will be randomized to one of 2 sequences:~Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
365587|NCT01407614|Procedure|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
365588|NCT01407601|Dietary Supplement|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
365589|NCT01407588|Procedure|Magnetic navigation|Ablation with use of the magnetic navigation system
365590|NCT01407588|Procedure|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
365591|NCT01407575|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
365592|NCT01407575|Drug|Placebo|matched placebo
365593|NCT01407562|Drug|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
365594|NCT01407562|Drug|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
365595|NCT01407562|Drug|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
365596|NCT01407549|Behavioral|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
365597|NCT01407536|Device|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
365598|NCT01407523|Drug|Levetiracetam|"Formulation: concentrate for solution for infusion~Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~Frequency: twice daily"
365599|NCT01407510|Drug|Mapracorat|Application of the investigational product on the affected skin areas
365600|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
365601|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
365602|NCT01407497|Biological|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
365603|NCT01407497|Biological|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
365604|NCT01407484|Drug|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
365605|NCT01407484|Drug|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
365606|NCT01407471|Drug|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
365607|NCT01407471|Drug|Clobetasol + Placebo|One application 6 days a week during 4 weeks
365608|NCT01407471|Drug|Placebo + Spironolactone|One application 6 days a week during 7 weeks
365609|NCT01407471|Drug|Placebo + Placebo|One application 6 days a week during 7 weeks
365610|NCT01407458|Other|Upper Limb Exercises|Upper limb exercises
365611|NCT01407458|Other|Normal physical exercises|Exercises usually done by children in physical education classes
365612|NCT01407445|Drug|Placebo|1 tablet/ oral/ 3 times a day for 90 days
365613|NCT01407445|Drug|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
365614|NCT01407432|Drug|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
365615|NCT01407432|Drug|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
365616|NCT01407419|Other|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.~Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
365617|NCT01407419|Other|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
365618|NCT01407406|Drug|BIIB023 - low dose IV Dose|
365619|NCT01407406|Drug|BIIB023 - high dose IV Dose|
365620|NCT01407393|Device|Glucosanol|2 tablets 3x daily for 12 weeks
365621|NCT01407393|Device|Placebo|2 tablets 3x daily for 12 weeks
365622|NCT01407380|Drug|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
365623|NCT01407354|Device|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
365624|NCT01407354|Other|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
365625|NCT01407341|Procedure|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
365626|NCT01407341|Procedure|bone graft|Receive beta tricalcium-phosphate bone graft
365627|NCT01407341|Procedure|quality-of-life assessment|Ancillary studies
365628|NCT01407341|Other|questionnaire administration|Ancillary studies
365629|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.~An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.~This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
365630|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.~Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.~This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
365631|NCT01407302|Other|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
365632|NCT01407289|Drug|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
365633|NCT01407276|Drug|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
365634|NCT01407263|Procedure|Lymph node template|Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence.
365635|NCT01407263|Procedure|Transverse versus vertical closure|Transverse versus vertical closure of the port site incision
365636|NCT01407263|Drug|antibiotic prophylaxis|One vs. three days of antibiotic prophylaxis at catheter removal
365637|NCT01407237|Drug|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
365638|NCT01407224|Behavioral|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
365639|NCT01407211|Dietary Supplement|vitamin A|"25000 IU/day vitamin A 6 months~1 Cap/Day~1 cap placebo/day for 6 month"
365640|NCT01407198|Drug|Nilotinib|Orally, daily 200 - 400 mg BID
365641|NCT01407198|Radiation|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
365642|NCT01407185|Other|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
365643|NCT01407133|Device|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
365644|NCT01407133|Device|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
365645|NCT01407120|Behavioral|New Beginnings Program|A preventive intervention for divorced families.
365646|NCT01407107|Drug|nitroglycerin|0.2mg/hr nitroglycerin transdermal patch daily
365647|NCT01407094|Drug|Sertraline|50-200mg/day
365648|NCT01407094|Drug|Placebo|1-4 pills per day
365649|NCT01407094|Drug|BupropionXL|150-450 mg/day
365650|NCT01407081|Behavioral|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
365651|NCT01407068|Biological|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
365652|NCT01407055|Behavioral|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
365653|NCT01407055|Behavioral|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
365654|NCT01407042|Procedure|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
365655|NCT01407016|Drug|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
365656|NCT01407003|Drug|LIK066|Participants will receive a single or multiple doses of LIK066
365657|NCT01407003|Drug|Placebo|Participants will receive a single or multiple doses of a matching placebo
365658|NCT01406977|Drug|BPS804|
365659|NCT01406964|Other|CAT test|A CAT test is performed in order to diagnose tubal factor causes
365660|NCT01406964|Other|Histerosalpingography|A Histerosalpingography is performed.
365661|NCT01406938|Drug|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
365662|NCT01406938|Drug|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
365663|NCT01406925|Drug|Placebo control|Placebo cream
365664|NCT01406925|Drug|NRL001 cream|Cream for single-dose intra-anal application
365665|NCT01406912|Other|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
365666|NCT01406912|Other|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
365667|NCT01406899|Behavioral|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
365668|NCT01406886|Behavioral|Eating rate|
365669|NCT01406873|Drug|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
365670|NCT01406873|Drug|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
365671|NCT01406860|Drug|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
365672|NCT01406860|Drug|Metoclopramide + diphenhydramine|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses + Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
365673|NCT01406847|Other|Spinal Manipulation|High velocity low amplitude joint-biased intervention
365674|NCT01406847|Other|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
365675|NCT01406847|Other|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
365676|NCT01406834|Behavioral|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
365677|NCT01406821|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
365678|NCT01406821|Procedure|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
365679|NCT01406808|Behavioral|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
365680|NCT01406795|Device|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
365681|NCT01406782|Biological|rituximab|
365682|NCT01406782|Genetic|DNA analysis|
365683|NCT01406782|Genetic|gene expression analysis|
365684|NCT01406782|Genetic|polymerase chain reaction|
365685|NCT01406782|Other|laboratory biomarker analysis|
365686|NCT01406769|Procedure|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
365687|NCT01406769|Procedure|Lymphadenectomy|Undergo lymphadenectomy
365688|NCT01406769|Procedure|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
365689|NCT01406743|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
365690|NCT01406730|Other|exercise|16 week of periodized progressive running exercise 2-4 times/week
365691|NCT01406717|Drug|SPIL1033, Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
365692|NCT01406704|Drug|Rosiglitazone|Rosiglitazone (8 mg/day)
365693|NCT01406704|Drug|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
365694|NCT01406704|Drug|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
365695|NCT01406691|Device|Flashes|three hours of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during three hours immediately prior to desired waketime
365696|NCT01406678|Procedure|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
365697|NCT01406678|Procedure|Control|Coronary artery bypass surgery without remote ischemic preconditioning protocol
365698|NCT01406678|Drug|isoflurane+sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
365699|NCT01406652|Procedure|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
365744|NCT01406366|Behavioral|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
365797|NCT01405950|Drug|Zanaflex Capsules|0.1 mg/kg
366014|NCT01404351|Procedure|Scalpel and Traditional Electrosurgery|
365700|NCT01406639|Drug|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
365701|NCT01406626|Behavioral|Health Navigator|Health navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
365702|NCT01406613|Other|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
365703|NCT01406600|Drug|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24~48 hours from optimal ovarian stimulation status.
365704|NCT01406587|Drug|PP4001|50 mg, 1 dose every 12 hours x 4 doses
365705|NCT01406587|Drug|PP4001|100 mg, 1 dose every 12 hours x 4 doses
365706|NCT01406587|Drug|PP4001|200 mg, 1 dose every 12 hours x 4 doses
365707|NCT01406587|Drug|Placebo|Placebo, 1 dose every 12 hours x 4 doses
365708|NCT01406574|Drug|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
365709|NCT01406574|Drug|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
365710|NCT01406561|Drug|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
365711|NCT01406561|Drug|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
365712|NCT01406548|Drug|BPS804|
365713|NCT01406548|Drug|Placebo|
365714|NCT01406548|Drug|BPS804|
365715|NCT01406548|Drug|Placebo|
365716|NCT01406548|Drug|BPS804|
365717|NCT01406548|Drug|Placebo|
365718|NCT01406535|Drug|Vardenafil|5 mg vardenafil per os twice daily
365719|NCT01406535|Other|Placebo|5 mg placebo per os twice daily
365720|NCT01406522|Drug|Oral tacrine|Tacrine, 160 mg per day, four times daily
365721|NCT01406522|Drug|Oral placebo|Microcrystalline cellulose
365722|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
365723|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
365724|NCT01406496|Drug|insulin|Three different timings of insulin delivered by a pump
365725|NCT01406483|Other|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
365726|NCT01406470|Drug|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
365727|NCT01406444|Drug|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
365728|NCT01406444|Drug|Risedronate|Risedronate 35mg PO one time weekly
365729|NCT01406444|Drug|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
365730|NCT01406431|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
365731|NCT01406431|Drug|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
365732|NCT01406418|Biological|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
365733|NCT01406418|Biological|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
365734|NCT01406418|Biological|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
365735|NCT01406418|Biological|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
365736|NCT01406418|Biological|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
365737|NCT01406418|Biological|Placebo|Administered as a single 2-hour intravenous infusion
365738|NCT01406405|Procedure|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
365739|NCT01406392|Drug|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
365740|NCT01406392|Drug|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
365741|NCT01406379|Procedure|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
365742|NCT01406379|Procedure|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
365743|NCT01406366|Behavioral|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
365792|NCT01405963|Drug|AMG 157 Matching Placebo|Matching placebo administered as multiple IV doses in subjects with mild atopic asthma
365793|NCT01405963|Drug|AMG 157|One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.
365745|NCT01406353|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
365746|NCT01406340|Drug|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
365747|NCT01406327|Drug|Ambrisentan|Ambrisentan
365748|NCT01406314|Drug|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
365749|NCT01406301|Drug|fondaparinux|fondaparinux
365750|NCT01406288|Other|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
365751|NCT01406275|Drug|Amoxicillin and clavulanate|
365752|NCT01406262|Biological|Albiglutide|once weekly subcutaneous injection
365753|NCT01406262|Drug|Moxifloxacin|oral tablet
365754|NCT01406249|Drug|SP|"Drug: S-1:~S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
365755|NCT01406249|Drug|XP|"Drug: Capecitabine:~Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin:~Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
365756|NCT01406236|Procedure|Transradial PCI|Transradial PCI
365757|NCT01406236|Procedure|Transfemoral PCI|Transfemoral PCI
365758|NCT01406223|Drug|Varenicline|
365759|NCT01406223|Drug|Bupropion|
365760|NCT01406223|Drug|Nicotine patches|
365761|NCT01406223|Other|Placebo varenicline|
365762|NCT01406223|Other|Placebo bupropion|
365763|NCT01406223|Other|Placebo patch|
365764|NCT01406197|Drug|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
365765|NCT01406197|Drug|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
365766|NCT01406197|Drug|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
365767|NCT01406184|Other|Durham Connects|The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
365768|NCT01406171|Drug|Isavuconazole|oral
365769|NCT01406171|Drug|Midazolam|Oral
365770|NCT01406158|Drug|Solifenacin Succinate Formulation A|oral suspension
365771|NCT01406158|Drug|Solifenacin Succinate Formulation B|oral suspension
365772|NCT01406158|Drug|Solifenacin Succinate|oral tablet
365773|NCT01406145|Drug|ASP0777|oral tablet
365774|NCT01406145|Drug|Placebo|oral tablet
365775|NCT01406132|Drug|ASP015K|oral
365776|NCT01406119|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
365777|NCT01406106|Dietary Supplement|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
365778|NCT01406080|Drug|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
365779|NCT01406080|Drug|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
365780|NCT01406067|Behavioral|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
365781|NCT01406067|Behavioral|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
365782|NCT01406054|Other|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
365783|NCT01406041|Biological|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
365784|NCT01406028|Behavioral|Phone calls|Phone calls to offer emotional support
365785|NCT01406015|Drug|Spironolactone|50 mg once daily for 6 weeks.
365786|NCT01406015|Drug|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
365787|NCT01406002|Drug|darexaban|oral
365788|NCT01406002|Drug|Rifampicin|oral
365789|NCT01405989|Drug|darexaban|oral
365790|NCT01405989|Drug|ketoconazole|oral
365791|NCT01405976|Device|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
365794|NCT01405950|Drug|Zanaflex Capsules|0.025 mg/kg
365798|NCT01405937|Drug|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
365799|NCT01405937|Biological|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
365800|NCT01405937|Drug|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
365801|NCT01405924|Drug|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
365802|NCT01405924|Drug|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
365803|NCT01405924|Drug|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
365804|NCT01405924|Drug|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
365805|NCT01405911|Drug|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
365806|NCT01405911|Drug|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
365807|NCT01405911|Drug|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
365808|NCT01405911|Drug|Placebo for Sitagliptin 50 mg|1 tablet orally once daily for 8 weeks
365809|NCT01405898|Dietary Supplement|beetroot juice|Beetroot juice 4 weeks 250ml daily
365810|NCT01405898|Dietary Supplement|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
365811|NCT01405885|Biological|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
365812|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
365813|NCT01405885|Biological|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
365814|NCT01405885|Biological|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
365815|NCT01405885|Biological|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
365816|NCT01405885|Biological|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
365817|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
365818|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
365819|NCT01405885|Biological|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
365820|NCT01405885|Biological|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
365821|NCT01405872|Other|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
365822|NCT01405846|Drug|Gefitinib|250mg od for 6 months
365823|NCT01405833|Drug|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
365824|NCT01405833|Drug|Placebo|Single dose IV matched placebo
365825|NCT01405820|Drug|natalizumab IV|natalizumab for IV Infusion
365826|NCT01405820|Drug|natalizumab SC|natalizumab for Subcutaneous Injection
365827|NCT01405820|Drug|IV Placebo|Intravenous placebo to natalizumab
365828|NCT01405820|Drug|SC Placebo|Subcutaneous placebo to natalizumab
365829|NCT01405807|Drug|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
365830|NCT01405794|Drug|32ppm Silver Particle|Oral silver dose of 32ppm
365831|NCT01405794|Drug|Placebo|Sterile Water No Silver
365832|NCT01405768|Drug|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
365833|NCT01405768|Drug|Non-buffered lidocaine|
365834|NCT01405755|Behavioral|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
365835|NCT01405742|Drug|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
365836|NCT01405716|Behavioral|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
365837|NCT01405716|Behavioral|Health Education|8-week health education program
365838|NCT01405703|Other|xrays|xrays from 2 week postop to 5 year postop
365839|NCT01405677|Biological|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
365840|NCT01405677|Biological|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
365841|NCT01405677|Biological|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
365842|NCT01405664|Other|Weight-Bearing as Tolerated|WBAT immediately after surgery
365843|NCT01405651|Drug|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
365844|NCT01405651|Drug|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
365845|NCT01405638|Behavioral|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
365846|NCT01405638|Behavioral|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
365847|NCT01405625|Other|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
365848|NCT01405625|Other|AAAAI standard of care written action plan|
365849|NCT01405612|Drug|Midazolam|Single oral administration on Day 1 or Day 5
365850|NCT01405612|Drug|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
365851|NCT01405599|Drug|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
365852|NCT01405586|Drug|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
365853|NCT01405586|Drug|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
365854|NCT01405586|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
365855|NCT01405573|Other|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
365856|NCT01405573|Drug|sorafenib|400 mg twice a day
365857|NCT01405560|Drug|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
365858|NCT01405560|Biological|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
365859|NCT01405560|Drug|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
365860|NCT01405521|Biological|Vaccine placebo (excipients only)|single oral dose,
365861|NCT01405521|Biological|Ty21a|3 oral doses, alternate days
365862|NCT01405521|Biological|M10ZH09 vaccine|single oral dose
365863|NCT01405508|Drug|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
365864|NCT01405508|Drug|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
365865|NCT01405508|Drug|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
365866|NCT01405508|Other|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
365867|NCT01405495|Procedure|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
365868|NCT01405482|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
365869|NCT01405482|Other|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
365870|NCT01405469|Other|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
365871|NCT01405456|Drug|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
365872|NCT01405456|Other|placebo and lifestyle|placebo pill daily and lifestyle counseling
365873|NCT01405430|Biological|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.~Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
365874|NCT01405417|Procedure|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
365875|NCT01405404|Behavioral|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
365876|NCT01405404|Other|Parent Training|12-session group on parenting skills and child behavior management
365877|NCT01405391|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
365878|NCT01405378|Device|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:~Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:~Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
365879|NCT01405365|Drug|Metronidazole|Metronidazole 400mg TID for 10 days
365880|NCT01405365|Drug|Placebo|Placebo pill TID for 10 days
365881|NCT01405365|Procedure|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
365882|NCT01405352|Dietary Supplement|Vitamin A|"25000 IU/day vitamin A 4 months~1 Cap/Day~1 cap placebo/day for 4 month"
365883|NCT01405339|Device|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
365884|NCT01405339|Device|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
365885|NCT01405326|Biological|adalimumab|40mg sc. every two weeks for six months
365886|NCT01405313|Device|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
365887|NCT01405313|Device|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
365888|NCT01405300|Dietary Supplement|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver ~1200 kcal.
365889|NCT01405300|Dietary Supplement|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver ~1200 kcal.
365890|NCT01405287|Device|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
365891|NCT01405274|Other|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
365892|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
365893|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
365894|NCT01405261|Drug|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
365895|NCT01405261|Drug|oral placebo|Subjects will be randomised to receive a single dose of placebo.
365896|NCT01405248|Drug|Butylphthalide|20 mg/time per os three times a day. 180days
365897|NCT01405248|Drug|Placebo|20 mg/time per os three times a day. 180days
365898|NCT01405235|Drug|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
365899|NCT01405235|Drug|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
365900|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
365901|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
365902|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
365903|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
365904|NCT01405183|Other|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
365905|NCT01405170|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
365906|NCT01405170|Drug|methylprednisolone|tablets 32 mg single dose
365907|NCT01405157|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
365908|NCT01405157|Drug|methylprednisolone|tablets 16 mg single dose
365909|NCT01405144|Drug|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
365910|NCT01405144|Procedure|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
365911|NCT01405131|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
365912|NCT01405131|Drug|methylprednisolone|tablets 32 mg single dose
365913|NCT01405118|Drug|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
365914|NCT01405092|Device|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
365915|NCT01405092|Device|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
365916|NCT01405079|Drug|Gefitinib|Gefitinib 250 mg/day oral daily
365917|NCT01405079|Drug|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
365918|NCT01405066|Behavioral|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
365919|NCT01405066|Behavioral|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
365920|NCT01405053|Drug|Rufinamide|Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
365921|NCT01405053|Drug|Any other approved Antiepileptic Drug|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
365922|NCT01405027|Procedure|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
365923|NCT01405027|Other|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
365924|NCT01405014|Behavioral|Hold Me Tight|Relationship enhancement group
365925|NCT01404988|Behavioral|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
365926|NCT01404988|Behavioral|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
365927|NCT01404988|Other|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
365928|NCT01404975|Other|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.~Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.~Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
365966|NCT01404689|Drug|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
366015|NCT01404338|Drug|Halobetasol 0.05% ointment|
366016|NCT01404338|Drug|Placebo Ointment|
365929|NCT01404962|Biological|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
365930|NCT01404949|Drug|Tretinoin and Arsenic Trioxide|See Detailed Description
365931|NCT01404936|Drug|Interferon-2A|4 (x106 IU/m^2) subcutaneously on days 1-4.
365932|NCT01404936|Drug|Adriamycin|25 mg/m^2 by vein on day 4.
365933|NCT01404936|Drug|Bleomycin|10 mg/m^2 by vein on day 4.
365934|NCT01404936|Drug|Velban|6 mg/m^2 by vein on day 4.
365935|NCT01404936|Drug|Dacarbazine|375 mg/m^2 by vein on day 4.
365936|NCT01404923|Drug|anti spasmodic agents|best standard of care prescriptions
365937|NCT01404923|Drug|alverine citrate, simeticone|on-demand therapy
365938|NCT01404910|Device|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
365939|NCT01404897|Other|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
365940|NCT01404897|Other|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
365941|NCT01404897|Other|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
365942|NCT01404884|Procedure|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
365943|NCT01404871|Drug|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily
365944|NCT01404871|Drug|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including >8 weeks at max dose 50mg daily
365945|NCT01404871|Drug|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including >8weeks at 120mg daily
365946|NCT01404858|Behavioral|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
365947|NCT01404845|Dietary Supplement|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
365948|NCT01404845|Dietary Supplement|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
365949|NCT01404832|Drug|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
365950|NCT01404819|Drug|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
365951|NCT01404819|Drug|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
365952|NCT01404806|Drug|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
365953|NCT01404793|Drug|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
365954|NCT01404780|Device|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
365955|NCT01404780|Device|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
365956|NCT01404767|Drug|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
365957|NCT01404767|Drug|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
365958|NCT01404754|Drug|Lactose (inactive placebo)|Placebo in an equivalent weight to MDMA will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
365959|NCT01404754|Drug|3,4-methylenedioxymethamphetamine|125 mg MDMA will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 62.5 mg may be administered 1.5 to 2.5 hours later.
365960|NCT01404741|Procedure|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
365961|NCT01404741|Procedure|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
365962|NCT01404715|Drug|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
365963|NCT01404715|Drug|Imatinib|A single oral dose of 600 mg of imatinib
365964|NCT01404702|Drug|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
365965|NCT01404702|Biological|Aldesleukin|"Dose Level 1: 3 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle~Dose Level 2: 6 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
366012|NCT01404364|Drug|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
365967|NCT01404689|Other|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
365968|NCT01404676|Drug|Add Vildagliptin|Adding Vildagliptin 50 mg bid to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
365969|NCT01404676|Drug|Add Glimepiride|Adding Glimepiride 2mg to patients with type 2 diabetes mellitus being treated with metformin 500-1000mg bid per day who had hemoglobin A1c of 7.0-10.0%
365970|NCT01404663|Biological|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
365971|NCT01404650|Drug|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
365972|NCT01404637|Drug|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
365973|NCT01404637|Drug|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
365974|NCT01404611|Drug|DF289|Ear drops
365975|NCT01404611|Drug|DF277|Ear drops
365976|NCT01404611|Drug|DF289 plus DF277|Ear drops
365977|NCT01404598|Drug|naproxcinod 750 bid|naproxcinod 750 bid
365978|NCT01404598|Drug|naproxcinod 3000 mg od|naproxcinod 3000 mg od
365979|NCT01404598|Drug|naproxen 500 mg bid|naproxen 500 mg bid
365980|NCT01404585|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
365981|NCT01404585|Drug|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
365982|NCT01404585|Drug|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
365983|NCT01404572|Drug|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
365984|NCT01404572|Drug|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
365985|NCT01404572|Drug|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
365986|NCT01404559|Device|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
365987|NCT01404559|Device|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
365988|NCT01404559|Device|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
365989|NCT01404546|Other|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
365990|NCT01404546|Other|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
365991|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg Ferrous sulfate
365992|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg ferrous sulfate
365993|NCT01404533|Dietary Supplement|Ferrous sulfate|6 mg ferrous sulfate
365994|NCT01404520|Other|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
365995|NCT01404507|Drug|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
365996|NCT01404507|Device|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
365997|NCT01404507|Other|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
365998|NCT01404481|Device|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
365999|NCT01404468|Device|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
366000|NCT01404468|Other|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
366001|NCT01404468|Device|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
366002|NCT01404455|Other|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
366003|NCT01404442|Drug|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
366004|NCT01404442|Drug|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
366005|NCT01404442|Drug|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
366006|NCT01404429|Drug|Methotrexate|Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
366007|NCT01404403|Device|Rapid System|
366008|NCT01404390|Drug|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
366009|NCT01404390|Drug|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
366010|NCT01404377|Procedure|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
366011|NCT01404364|Drug|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
366017|NCT01404325|Drug|standard therapy|centre specific CNI-based triple drug immunosuppression
366018|NCT01404325|Drug|Everolimus|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
366019|NCT01404312|Drug|Rifapentine (RPT)|"RPT dosing was be based on participants' weight:~Participants who weighed 30 kg to less than 35 kg received 300 mg once daily (administered as two 150-mg tablets).~Participants who weighed 35 kg to less than 45 kg received 450 mg once daily (administered as three 150-mg tablets).~Participants who weighed greater than 45 kg received 600 mg once daily (administered as four 150-mg tablets)."
366020|NCT01404312|Drug|Isoniazid (INH)|Participants received one 300-mg tablet or three 100-mg tablets of INH once daily.
366021|NCT01404312|Dietary Supplement|Pyridoxine (Vitamin B6)|"Participants received 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.~Participants who received 25 mg of pyridoxine took one 25-mg tablet once daily with INH.~Participants who received 50 mg of pyridoxine took two 25-mg tablets once daily with INH."
366022|NCT01404299|Dietary Supplement|Nutritional Supplementation|- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
366023|NCT01404299|Other|Control|- No intervention, except monthly home visits
366024|NCT01404286|Behavioral|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
366025|NCT01404273|Behavioral|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
366026|NCT01404260|Drug|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
366027|NCT01404260|Drug|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
366028|NCT01404247|Other|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
366029|NCT01404247|Procedure|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
366030|NCT01404234|Drug|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
366031|NCT01404208|Drug|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
366032|NCT01404208|Drug|Placebo|Sugar pill
366033|NCT01404195|Dietary Supplement|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
366034|NCT01404182|Biological|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
366035|NCT01404169|Drug|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
366036|NCT01404169|Drug|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
366037|NCT01404156|Drug|(Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel|"NEOADJUVANT CHEMOTHERAPY (OPTION of CHEMO REGIMEN 1 or 2)~1) FLOT - Four x 14 day cycles FLOT preoperatively and 4 cycles postoperatively (within 4-10 weeks after surgery): 5-Fluorouracil 2600 mg/m², day 1 IV every 14 days Leucovorin 200 mg/m², day 1, IV., every 14 days Oxaliplatin 85 mg/m², day 1, IV, every 14 days Docetaxel 50mg/m2, day 1, IV, every 14 days~2) ECF / ECX - Three x 21-day cycles ECF preoperatively and 3 cycles postoperatively (within 4-10 weeks after surgery): Epirubicin (50 mg/m²,mg per square meter of body-surface area) by intravenous bolus on day 1 IV Cisplatin: 60 mg/m², mg per square meter intravenously with hydration on day 1 IV 5-Fluorouracil: 200 mg/m², mg per square meter daily for 21 days by continuous IV infusion 5-FU may be substituted with Capecitabine (Xeloda) 625mg/m2, PO BID (ECX)"
366038|NCT01404156|Other|Carboplatin paclitaxel plus concurrent radiotherapy|"5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:~paclitaxel: 50 mg / m2 IV over 1 hour~carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion~Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.~1. Dose specifications:~Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.~Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment ."
366039|NCT01404143|Procedure|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
366040|NCT01404143|Procedure|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
366041|NCT01404130|Drug|Isotretinoin|0.5-1mg/kg daily for 4-6 months
366042|NCT01404117|Drug|Laquinimod 0.6|Laquinimod 0.6 capsule
366043|NCT01404117|Drug|Laquinimod 1.2|Placebo
366044|NCT01404117|Other|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
366045|NCT01404104|Drug|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
366046|NCT01404091|Drug|LY2940094|Administered orally
366047|NCT01404078|Drug|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
366048|NCT01404078|Drug|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
366049|NCT01404065|Procedure|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
366050|NCT01404052|Device|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
366051|NCT01404039|Behavioral|Motor Learning|Subject will have to draw a set of shapes and words during 20 minutes.
366052|NCT01404039|Behavioral|Somatosensory Learning|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
366053|NCT01404039|Behavioral|Observational Task|Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
366054|NCT01404039|Behavioral|Mental Imagery|Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
366055|NCT01404039|Device|transcranial direct current stimulation|Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
366056|NCT01404026|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
366057|NCT01404013|Drug|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
366058|NCT01404013|Drug|Montelukast|Montelukast 10mg ,every night, for 8 weeks
366059|NCT01404013|Drug|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
366060|NCT01404000|Drug|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
366061|NCT01403987|Behavioral|Residency Program Teaching|The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
366062|NCT01403987|Behavioral|Lecture|During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
366063|NCT01403987|Other|Pocket Card Reference|A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
366064|NCT01403987|Behavioral|Pager|"The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure."
366065|NCT01403974|Drug|BI 836845|Intravenous infusion once every week
366066|NCT01403948|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
366067|NCT01403922|Drug|TC-5214|Tablet oral bid days 1 to 7
366068|NCT01403922|Drug|TC-5214|Tablet oral bid days 8 to 14
366069|NCT01403909|Device|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
366070|NCT01403909|Procedure|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
366071|NCT01403896|Drug|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
366181|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
366072|NCT01403896|Drug|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
366073|NCT01403883|Behavioral|Standard Care|Psychological & enterostomal therapy clinics on demand only
366074|NCT01403883|Behavioral|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
366075|NCT01403870|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
366076|NCT01403857|Other|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
366077|NCT01403857|Other|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
366078|NCT01403844|Other|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
366079|NCT01403844|Other|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
366080|NCT01403844|Other|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
366081|NCT01403844|Other|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
366082|NCT01403831|Other|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
366083|NCT01403818|Drug|ASP1941|oral
366084|NCT01403818|Drug|Mitiglinide calcium hydrate|oral
366085|NCT01403805|Biological|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
366086|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
366087|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
366088|NCT01403805|Other|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
366089|NCT01403792|Drug|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
366090|NCT01403779|Radiation|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
366091|NCT01403740|Drug|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
366092|NCT01403714|Procedure|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
366093|NCT01403701|Behavioral|Physical therapy|pelvic floor physical therapy
366094|NCT01403688|Procedure|RPFNA|"Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).~Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment~Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding"
366095|NCT01403675|Procedure|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
366096|NCT01403662|Drug|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
366097|NCT01403649|Behavioral|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
366098|NCT01403649|Other|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
366099|NCT01403636|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
366100|NCT01403623|Procedure|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
366182|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 5 for 84 days
366183|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 6 for 84 days
366101|NCT01403623|Procedure|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
366102|NCT01403610|Drug|TH-302 preoperative|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
366103|NCT01403610|Drug|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
366104|NCT01403610|Drug|TH-302 (escalating) with bevacizumab 10mg/kg|Combination of 10mg/m2 of bevacizumab with an escalating dose of TH-302 from 240 to 670 mg/m2
366105|NCT01403597|Device|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
366106|NCT01403571|Dietary Supplement|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
366107|NCT01403571|Dietary Supplement|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
366108|NCT01403558|Behavioral|Cognitive behavioral therapy with motivational interwiewing|CBT combined With MI
366109|NCT01403545|Drug|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
366110|NCT01403545|Other|Placebo|5% glucose infusion over 120 minutes
366111|NCT01403532|Drug|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
366112|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
366113|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
366114|NCT01403506|Drug|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
366115|NCT01403493|Behavioral|Patient education|
366116|NCT01403467|Device|Continuous positive airway pressure|CPAP 8 cmH2O
366117|NCT01403454|Behavioral|Interactive Health Communication Application|web-based application
366118|NCT01403441|Device|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
366119|NCT01403428|Other|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
366120|NCT01403415|Drug|Dexamethasone|Given PO or IV
366121|NCT01403415|Other|Laboratory Biomarker Analysis|Correlative studies
366122|NCT01403415|Drug|Methotrexate|Given IT
366123|NCT01403415|Drug|Mitoxantrone Hydrochloride|Given IV
366124|NCT01403415|Drug|Pegaspargase|Given IV
366125|NCT01403415|Other|Pharmacological Study|Correlative studies
366126|NCT01403415|Drug|Temsirolimus|Given IV
366127|NCT01403415|Drug|Vincristine Sulfate|Given IV
366128|NCT01403389|Drug|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
366129|NCT01403389|Drug|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
366130|NCT01403376|Drug|teriflunomide|"Film-coated tablet~Oral administration"
366131|NCT01403376|Drug|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
366132|NCT01403376|Biological|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012~One administration by intramuscular or intradermal route as per product specification"
366133|NCT01403363|Drug|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
366134|NCT01403350|Device|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
366135|NCT01403337|Other|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
366136|NCT01403337|Other|Control|A Blood Pressure cuff inflated to 40-50 mmHg
366137|NCT01403324|Drug|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
366138|NCT01403311|Drug|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
366139|NCT01403298|Behavioral|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
366140|NCT01403298|Other|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
366141|NCT01403285|Drug|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
366142|NCT01403285|Biological|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
366143|NCT01403285|Biological|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
366144|NCT01403285|Drug|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
366145|NCT01403272|Device|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
366146|NCT01403259|Drug|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
366147|NCT01403246|Drug|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
366148|NCT01403233|Dietary Supplement|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
366149|NCT01403233|Dietary Supplement|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
366150|NCT01403233|Dietary Supplement|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
366151|NCT01403220|Procedure|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
366152|NCT01403220|Procedure|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
366153|NCT01403207|Other|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
366154|NCT01403194|Device|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
366155|NCT01403181|Drug|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.~Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
366156|NCT01403168|Other|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.~The conventional analgesic treatments will be administered in the 15 days following the enrollment."
366157|NCT01403168|Other|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
366158|NCT01403155|Biological|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
366159|NCT01403129|Procedure|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
366160|NCT01403129|Procedure|Optical Coherence Tomography (OCT) Exam|OCT exam of both eyes. Exam will be performed once, duration is 10. I utes per eye.
366161|NCT01403116|Drug|Oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
366162|NCT01403116|Drug|topical testosterone gel|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
366163|NCT01403103|Dietary Supplement|cholecalciferol|Given PO
366164|NCT01403103|Procedure|biopsy|Correlative studies
366165|NCT01403103|Genetic|protein expression analysis|Correlative studies
366166|NCT01403103|Other|enzyme-linked immunosorbent assay|Correlative studies
366167|NCT01403103|Other|laboratory biomarker analysis|Correlative studies
366168|NCT01403103|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
366169|NCT01403090|Device|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
366170|NCT01403077|Device|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
366171|NCT01403064|Biological|ALD518|IV
366172|NCT01403064|Drug|0.9% saline|IV Infusion
366173|NCT01403051|Drug|EFV/FTC/TDF|FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
366174|NCT01403051|Drug|Calcium Carbonate|Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
366175|NCT01403051|Drug|Vitamin D3|One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
366176|NCT01403051|Drug|Placebo for calcium carbonate|A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
366177|NCT01403051|Drug|Placebo for vitamin D3|A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
366178|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 1 for 84 days
366179|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 2 for 84 days
366180|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 3 for 84 days
366581|NCT01399723|Drug|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
366184|NCT01403038|Drug|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
366185|NCT01403025|Drug|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
366186|NCT01403012|Other|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)~Laboratory measurements:~Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
366187|NCT01402999|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
366188|NCT01402986|Other|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
366189|NCT01402986|Biological|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
366190|NCT01402986|Other|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
366191|NCT01402986|Biological|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
366192|NCT01402973|Other|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
366193|NCT01402960|Device|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.~For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.~For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.~For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
366194|NCT01402947|Drug|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
366195|NCT01402947|Drug|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
366196|NCT01402934|Procedure|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
366197|NCT01402921|Device|V0322 BC|"Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).~The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)~3 months duration daily treatment"
366198|NCT01402908|Drug|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
366199|NCT01402908|Other|Placebo|Lactose lyophilized powder
366200|NCT01402895|Other|Exercise|Transversus abdominus exercise
366201|NCT01402895|Other|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
366202|NCT01402882|Drug|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
366203|NCT01402869|Drug|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
366204|NCT01402869|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
366205|NCT01402856|Other|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long & utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, & interactive games simulating distracted driving.
366206|NCT01402843|Drug|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
366207|NCT01402830|Other|Visual analogue scales (EVAs)|This scale measures the pain intensity.
366208|NCT01402817|Drug|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
366209|NCT01402791|Other|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
366210|NCT01402765|Device|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
366211|NCT01402765|Device|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
366212|NCT01402752|Biological|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
366213|NCT01402739|Other|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
366214|NCT01402739|Other|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
366215|NCT01402726|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
366216|NCT01402713|Biological|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
366217|NCT01402713|Biological|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
366218|NCT01402700|Device|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
366219|NCT01402674|Drug|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
366220|NCT01402648|Dietary Supplement|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
366221|NCT01402648|Dietary Supplement|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
366222|NCT01402635|Device|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
366223|NCT01402622|Drug|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
366224|NCT01402609|Device|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
366225|NCT01402609|Device|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
366226|NCT01402596|Drug|Midazolam|0,4 mg per kg - intranasal midazolam - once
366227|NCT01402596|Drug|Chloral Hydrate|50 mg per kg, rectal
366228|NCT01402583|Drug|PEG IFN/Ribavirin|PEG IFN/Ribavirin
366229|NCT01402570|Dietary Supplement|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
366230|NCT01402557|Behavioral|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
366231|NCT01402557|Behavioral|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
366232|NCT01402557|Behavioral|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
366233|NCT01402544|Drug|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
366234|NCT01402531|Drug|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
366235|NCT01402518|Procedure|Per-oral enodscopic myotomy|
366236|NCT01402505|Procedure|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
366237|NCT01402492|Drug|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
366238|NCT01402492|Drug|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
366239|NCT01402479|Drug|Ramipril|ramipril 2.5mg twice a day
366240|NCT01402466|Behavioral|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
366241|NCT01402466|Behavioral|Project Bridge|Arm 2
366242|NCT01402453|Behavioral|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
366315|NCT01402011|Procedure|25% dextrose in shoulder entheses|injections of 1 mL of 25% dextrose and .1% lidocaine solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
366392|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
366243|NCT01402453|Behavioral|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
366244|NCT01402440|Drug|AEB071|
366245|NCT01402427|Drug|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
366246|NCT01402427|Drug|Placebo|Intraarterial administration of 10 mL saline.
366247|NCT01402414|Radiation|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
366248|NCT01402414|Radiation|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
366249|NCT01402414|Radiation|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
366250|NCT01402401|Drug|AUY922 + Trastuzumab|
366251|NCT01402388|Behavioral|Group lifestyle programme|
366252|NCT01402375|Drug|Hydrocodone (first trial)|Patients will take 1 dose of Hydrocodone 5mg / Acetaminophen 500mg every 4 hours as needed for pain
366253|NCT01402375|Drug|Codeine (first trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
366254|NCT01402375|Drug|Oxycodone (for second trial)|Patients will take 1 dose of Oxycodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain
366255|NCT01402375|Drug|Codeine (for second trial)|Patients will take 1 dose of Codeine 30 mg / Acetaminophen 300 mg every 4 hours as needed for pain
366256|NCT01402375|Drug|Oxycodone (third trial)|Patients will take 1 dose of Oxycodone 5mg / Acetaminophen 325 mg every 4 hours as needed for pain
366257|NCT01402375|Drug|Hydrocodone (third trial)|Patients will take 1 dose of Hydrocodone 5 mg / Acetaminophen 325 mg every 4 hours as needed for pain.
366258|NCT01402336|Drug|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
366259|NCT01402336|Drug|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
366260|NCT01402323|Other|time point of tooth extraction|
366261|NCT01402310|Other|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
366262|NCT01402297|Drug|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
366263|NCT01402284|Drug|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
366264|NCT01402284|Drug|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
366265|NCT01402284|Drug|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
366266|NCT01402284|Drug|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
366267|NCT01402284|Drug|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
366268|NCT01402271|Drug|carboplatin|
366269|NCT01402271|Drug|paclitaxel|
366270|NCT01402271|Drug|pazopanib hydrochloride|
366271|NCT01402271|Other|laboratory biomarker analysis|
366272|NCT01402271|Other|pharmacological study|
366273|NCT01402258|Behavioral|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
366274|NCT01402245|Biological|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
366275|NCT01402245|Biological|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
366276|NCT01402219|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
366277|NCT01402219|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
366316|NCT01402011|Procedure|.1% lidocaine in shoulder entheses|injections of 1 mL of .1% lidocaine 'ssolution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
366278|NCT01402206|Behavioral|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention)."
366279|NCT01402193|Drug|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
366280|NCT01402193|Drug|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
366281|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
366282|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
366283|NCT01402180|Biological|Nimotuzumab|
366284|NCT01402180|Radiation|Radiation therapy|
366285|NCT01402180|Radiation|radiation therapy|
366286|NCT01402180|Drug|chemotherapy|
366287|NCT01402180|Drug|chemotherapy|
366288|NCT01402167|Procedure|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
366289|NCT01402167|Procedure|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
366290|NCT01402154|Biological|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
366291|NCT01402154|Biological|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
366292|NCT01402141|Dietary Supplement|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
366293|NCT01402141|Dietary Supplement|Placebo|Placebo(35g/day) for 12 weeks
366294|NCT01402128|Dietary Supplement|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
366295|NCT01402128|Dietary Supplement|Placebo|Placebo for 12 weeks
366296|NCT01402115|Dietary Supplement|Polycan|polycan 150 mg/d for 12 weeks
366297|NCT01402115|Dietary Supplement|Placebo|Placebo 150mg/d for 12 weeks
366298|NCT01402102|Dietary Supplement|Aged garlic powder|Aged garlic powder(6.0g/day)
366299|NCT01402102|Dietary Supplement|Placebo powder|Placebo powder(6.0g/day)
366300|NCT01402089|Drug|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
366301|NCT01402089|Drug|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
366302|NCT01402089|Drug|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
366303|NCT01402089|Drug|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
366304|NCT01402076|Drug|Tasimelteon|20mg daily dosing, Days 4-20
366305|NCT01402076|Drug|Rosiglitazone|4mg, single dose, Days 3 and 20
366306|NCT01402076|Drug|Midazolam|10mg, single dose, Days 1 and 18
366307|NCT01402063|Drug|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
366308|NCT01402063|Drug|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
366309|NCT01402050|Drug|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
366310|NCT01402050|Device|FOLEY BALLOON|INDUCTION OF LABOR
366311|NCT01402037|Drug|Glucose|Glucose 20% intravenous
366312|NCT01402037|Device|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
366313|NCT01402024|Drug|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and~The patient with weight category of 41-65 kg in study group will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
366314|NCT01402024|Drug|Placebo|"Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
366623|NCT01399398|Procedure|Arterial Line|
366317|NCT01402011|Procedure|.1% lidocaine subcu. above shouldr enth.|injections of 1 mL of .1% lidocaine solution subcutaneously, above the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic, above the insertion of the teres minor and the triceps on the scapula.
366318|NCT01401985|Drug|TD-1211|Capsules once daily
366319|NCT01401959|Drug|Eribulin|1.4 mg/m^2 IV Days 1 and 8, every 21 days for six cycles
366320|NCT01401959|Drug|Trastuzumab|6 mg/kg IV Day 1 every 21 days
366321|NCT01401946|Drug|soy isoflavones|
366322|NCT01401946|Drug|Placebo|
366323|NCT01401933|Drug|Linifanib|QD on Days 1 and 13
366324|NCT01401933|Drug|Rifampin|QD on Days 5-16
366325|NCT01401920|Other|leg elevation|bilateral passive leg elevation for 30 seconds
366326|NCT01401920|Other|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
366327|NCT01401920|Other|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
366328|NCT01401920|Other|control group|supine position without passive leg elevation or trendelenburg position
366329|NCT01401907|Other|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
366330|NCT01401868|Drug|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.~Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
366331|NCT01401842|Other|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
366332|NCT01401842|Other|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
366333|NCT01401829|Behavioral|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
366334|NCT01401829|Behavioral|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
366335|NCT01401829|Behavioral|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
366336|NCT01401816|Other|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
366337|NCT01401803|Drug|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
366338|NCT01401790|Device|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for~Automatic download of blood glucose levels~Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team~Changes in treatment plan by the diabetes professionals~E mail exchanges between families and health care professionals~Reinforcement of teaching program"
366339|NCT01401790|Other|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
366340|NCT01401764|Other|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
366341|NCT01401751|Device|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
366342|NCT01401725|Behavioral|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
366343|NCT01401725|Behavioral|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
366344|NCT01401725|Other|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
366345|NCT01401712|Procedure|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
366346|NCT01401712|Procedure|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
366347|NCT01401699|Device|Optical Frequency Domain Imaging (OFDI)|Optical Frequency Domain (OFDI) imaging of esophagus
366348|NCT01401673|Drug|Indantadol|Titration
366391|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
366624|NCT01399398|Procedure|Venous Line|
366349|NCT01401660|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
366350|NCT01401647|Drug|amiodarone|300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
366351|NCT01401647|Drug|Lidocaine|120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
366352|NCT01401647|Other|Normal saline|6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
366353|NCT01401634|Other|Oral water|2 Liters of water given orally
366354|NCT01401634|Other|Intravenous normal saline|2 Liters Intravenous normal saline
366355|NCT01401621|Behavioral|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
366356|NCT01401621|Behavioral|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
366357|NCT01401621|Behavioral|Control|No scratch-off element
366358|NCT01401608|Device|RF Ablation|Ablation of arrhythmogenic ventricular tissue
366359|NCT01401595|Drug|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
366360|NCT01401582|Other|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
366361|NCT01401569|Behavioral|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
366362|NCT01401556|Other|case management|
366363|NCT01401556|Other|Multifaceted quality improvement intervention|
366364|NCT01401543|Drug|LY2452473|Administered orally
366365|NCT01401543|Drug|Tadalafil|Administered orally
366366|NCT01401543|Drug|LY900010|Administered orally
366367|NCT01401530|Biological|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
366368|NCT01401517|Drug|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
366369|NCT01401504|Drug|ASP3026|oral
366370|NCT01401491|Drug|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
366371|NCT01401491|Drug|clozapine plus placebo|clozapine 300 mg/day plus placebo
366372|NCT01401465|Drug|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
366373|NCT01401465|Drug|mometasone|200 mcg mometasone aqueous nasal spray once daily
366374|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
366375|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
366376|NCT01401413|Drug|ramelteon|8 mg nightly for 30 nights
366377|NCT01401413|Drug|placebo|placebo control i pill nightly for 30 nights
366378|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
366379|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
366380|NCT01401361|Device|Treatment Arm|The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
366381|NCT01401335|Behavioral|Questionnaires|questionnaires at entry, month 4, 8 and 12
366382|NCT01401322|Drug|Lenalidomide|50 mg; po
366383|NCT01401296|Behavioral|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
366384|NCT01401296|Behavioral|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
366385|NCT01401283|Device|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
366386|NCT01401270|Behavioral|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
366387|NCT01401257|Drug|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
366388|NCT01401257|Drug|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
366389|NCT01401257|Drug|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
366390|NCT01401257|Other|Placebo|Liquid,5 ml, twice a day, 12-month treatment
366393|NCT01401231|Behavioral|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
366394|NCT01401231|Other|Usual care|Continued usual care (could include referral for medication or psychotherapy)
366395|NCT01401218|Other|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.~potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
366396|NCT01401205|Other|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
366397|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
366398|NCT01401192|Drug|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 & cisplatin 70mg/m2 D1 every 3 weeks
366399|NCT01401192|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 & cisplatin 70mg/m2 every 3 weeks
366400|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
366401|NCT01401179|Drug|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
366402|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
366403|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
366404|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
366405|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
366406|NCT01401153|Other|Skipping lunch|Just water.
366407|NCT01401140|Drug|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
366408|NCT01401140|Drug|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
366409|NCT01401114|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
366410|NCT01401101|Other|PCM|Care Manager (CM) intervention
366411|NCT01401101|Other|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
366412|NCT01401088|Device|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
366413|NCT01401075|Drug|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
366414|NCT01401075|Drug|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
366415|NCT01401062|Drug|Fresolimumab|
366416|NCT01401062|Radiation|Radiation Therapy|
366417|NCT01401049|Drug|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
366418|NCT01401049|Drug|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
366419|NCT01401036|Device|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
366420|NCT01401036|Procedure|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
366421|NCT01401023|Drug|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
366422|NCT01401010|Drug|Doripenem|500 mg every 8 hours
366423|NCT01401010|Drug|doripenem|1000 mg every 8 hours
366424|NCT01400997|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
366425|NCT01400984|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
366426|NCT01400958|Drug|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
366427|NCT01400958|Drug|Placebo|Placebo x 42 days; THEN, No More Placebo
366428|NCT01400945|Drug|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
366429|NCT01400932|Drug|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
366430|NCT01400932|Drug|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
366431|NCT01400919|Device|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
366432|NCT01400906|Drug|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
366433|NCT01400906|Drug|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
366434|NCT01400906|Drug|lactose powder|lactose powder in dry powder device : placebo comparator
366435|NCT01400893|Device|SCD|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
366436|NCT01400867|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)~Subjects < 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
366437|NCT01400867|Drug|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)~Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
366438|NCT01400867|Drug|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.~Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
366439|NCT01400854|Drug|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
366440|NCT01400841|Device|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
366441|NCT01400828|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
366442|NCT01400828|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
366443|NCT01400828|Drug|Placebo|(encapsulated) Tablets QD/14 days
366444|NCT01400815|Drug|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
366445|NCT01400815|Drug|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
366446|NCT01400802|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
366447|NCT01400789|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
366448|NCT01400776|Drug|WC3011 Vaginal Gel|WC3011 Vaginal Gel administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
366449|NCT01400776|Drug|Vehicle|Vehicle Vaginal Gel administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
366450|NCT01400763|Dietary Supplement|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
366451|NCT01400763|Dietary Supplement|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
366452|NCT01400763|Dietary Supplement|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
366453|NCT01400763|Dietary Supplement|Placebo beverage|Placebo beverage
366454|NCT01400750|Drug|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
366455|NCT01400750|Drug|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
366456|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
366457|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
366458|NCT01400724|Dietary Supplement|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
366459|NCT01400711|Other|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
366460|NCT01400711|Other|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
366461|NCT01400698|Drug|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
366462|NCT01400698|Drug|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
366463|NCT01400698|Other|Observation only|Subjects were only observed.
366464|NCT01400685|Drug|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
366465|NCT01400685|Drug|Bendamustine|90 mg/m^2 IV days 1-2 of each cycle for 6 cycles
366466|NCT01400685|Drug|Rituximab|375 mg/m^2 IV day 1 (cycle 1), 500 mg/m^2 day 1 (cycles 2-6)
366467|NCT01400672|Biological|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
366468|NCT01400672|Drug|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
366579|NCT01399736|Procedure|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
366469|NCT01400672|Radiation|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
366470|NCT01400659|Procedure|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
366471|NCT01400659|Procedure|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
366472|NCT01400646|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
366473|NCT01400646|Drug|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
366474|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
366475|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
366476|NCT01400646|Drug|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
366477|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
366478|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
366479|NCT01400633|Drug|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
366480|NCT01400620|Drug|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
366481|NCT01400607|Biological|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
366482|NCT01400607|Other|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
366483|NCT01400594|Drug|HTU-520 Patch|Terbinafine hydrochloride patch
366484|NCT01400594|Other|Placebo Patch|Treatment with Placebo Patch
366485|NCT01400581|Behavioral|Collaborative Care Intervention|See description of Intervention arm
366486|NCT01400568|Drug|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
366487|NCT01400568|Drug|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
366488|NCT01400555|Drug|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
366489|NCT01400555|Drug|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
366490|NCT01400555|Drug|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
366491|NCT01400555|Drug|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
366492|NCT01400542|Device|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
366493|NCT01400542|Device|No treatment|no treatment
366494|NCT01400516|Drug|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
366495|NCT01400516|Drug|calcium citrate|1000 mg of calcium citrate
366496|NCT01400516|Drug|Vitamin D|800 IU of Vitamin D
366497|NCT01400516|Drug|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
366498|NCT01400503|Drug|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
366499|NCT01400490|Dietary Supplement|EPA-DHA Study|6 weeks of dietary supplementation
366500|NCT01400477|Drug|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
366501|NCT01400477|Other|Placebo|Placebo Comparator
366502|NCT01400464|Drug|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
366503|NCT01400451|Drug|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
366504|NCT01400451|Drug|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
366505|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
366506|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
366507|NCT01400425|Drug|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose
366508|NCT01400412|Drug|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
366509|NCT01400412|Drug|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
366510|NCT01400412|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
366511|NCT01400412|Drug|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
366512|NCT01400412|Drug|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
366513|NCT01400412|Drug|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
366514|NCT01400412|Drug|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
366515|NCT01400386|Other|Coffee bioavailability trial|Coffee bioavailability trial
366516|NCT01400373|Device|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
366517|NCT01400360|Other|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
366518|NCT01400334|Radiation|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine [HED, 20 mCi (740 MBq)] to quantify sympathetic nerve function, b) 13N-ammonia [NH3, 20 mCi (740 MBq)] for regional perfusion, and c) 18F-2-deoxyglucose [FDG; 6.5 mCi (241 MBq)] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
366519|NCT01400308|Drug|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
366520|NCT01400308|Device|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.~Prontoderm® is a Class III medical device"
366521|NCT01400282|Device|High frequency spinal cord stimulation|
366522|NCT01400269|Behavioral|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
366523|NCT01400256|Drug|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
366524|NCT01400243|Drug|Nicotine|Nicotine patch 7mg
366525|NCT01400243|Drug|Placebo Patch|Placebo patch
366526|NCT01400230|Procedure|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
366527|NCT01400217|Drug|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
366528|NCT01400217|Drug|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
366529|NCT01400191|Drug|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
366530|NCT01400165|Drug|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
366531|NCT01400165|Drug|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
366532|NCT01400165|Drug|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
366533|NCT01400165|Procedure|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
366534|NCT01400152|Device|Additional active warming|Chemical heat pad applied to the upper torso
366535|NCT01400139|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
366536|NCT01400113|Drug|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
366537|NCT01400113|Drug|Placebo|Placebo Sublingual Tablet, single-dose
366538|NCT01400100|Drug|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
366539|NCT01400100|Drug|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
366540|NCT01400087|Device|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
366541|NCT01400074|Drug|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
366542|NCT01400048|Dietary Supplement|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
366543|NCT01400048|Dietary Supplement|Placebo control|60mg Ascorbic acid
366544|NCT01400022|Other|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
366545|NCT01400022|Other|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
366546|NCT01400009|Drug|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
366547|NCT01400009|Drug|Placebo|Standard Placebo made of Lactose 100 mg
366548|NCT01399996|Dietary Supplement|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
366549|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
366550|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
366551|NCT01399996|Dietary Supplement|A capsule containing the probiotic|A capsule taken daily will provide between 10x^y9 and 10x^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
366552|NCT01399970|Other|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
366553|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
366554|NCT01399918|Drug|everolimus and bevacizumab|Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
366555|NCT01399905|Drug|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
366556|NCT01399892|Dietary Supplement|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
366557|NCT01399879|Other|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
366558|NCT01399866|Drug|D-cycloserine|2 single weekly doses, 50 mg capsule
366559|NCT01399866|Drug|Placebo|
366560|NCT01399853|Biological|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
366561|NCT01399853|Biological|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
366562|NCT01399853|Biological|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
366563|NCT01399853|Biological|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
366564|NCT01399853|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
366565|NCT01399840|Drug|BMN 673|Oral capsule with multiple dosage forms given once daily
366566|NCT01399827|Drug|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
366567|NCT01399827|Drug|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
366568|NCT01399814|Behavioral|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000~1500ml crystalloid was administered on the days following operation
366569|NCT01399814|Behavioral|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000~2500ml crystalloid was administered on the days following operation
366570|NCT01399801|Procedure|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
366571|NCT01399801|Procedure|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
366572|NCT01399788|Drug|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
366573|NCT01399788|Drug|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
366574|NCT01399775|Procedure|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
366575|NCT01399775|Procedure|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
366576|NCT01399762|Device|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
366577|NCT01399749|Other|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
366578|NCT01399736|Procedure|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
366580|NCT01399723|Drug|Amoxicillin|Oral 45mg/kg 12 hourly
366582|NCT01399710|Procedure|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
366583|NCT01399710|Procedure|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
366584|NCT01399710|Device|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
366585|NCT01399697|Drug|methotrexate|orally, Week 1 - 16
366586|NCT01399697|Drug|methotrexate|orally, Week 17-28
366587|NCT01399697|Drug|placebo|methotrexate placebo orally, Week 17-28
366588|NCT01399697|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 28 weeks
366589|NCT01399684|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m^2) intravenous (IV) bolus and then 2400 mg/m^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
366590|NCT01399684|Drug|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
366591|NCT01399684|Drug|Folinic acid|Participants will receive folinic acid 400 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
366592|NCT01399684|Drug|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
366593|NCT01399684|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
366594|NCT01399684|Drug|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
366595|NCT01399671|Other|vestibular stimulation|vestibular stimulation
366596|NCT01399658|Procedure|Image-guided brachytherapy|MRI-guided application of brachytherapy
366597|NCT01399645|Drug|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.~Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
366598|NCT01399632|Behavioral|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
366599|NCT01399632|Behavioral|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
366600|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
366601|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
366602|NCT01399619|Drug|BI201335|BI201335 for 12w
366603|NCT01399619|Drug|BI201335 24W|BI201335 for 24w
366604|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
366605|NCT01399619|Drug|Bi 201335|BI 201335 for 24 w
366606|NCT01399606|Drug|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
366607|NCT01399593|Drug|Eculizumab|
366608|NCT01399580|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
366609|NCT01399580|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
366610|NCT01399567|Behavioral|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
366611|NCT01399554|Behavioral|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
366612|NCT01399515|Drug|Valproic Acid|One 500mg tablet by mouth daily
366613|NCT01399502|Behavioral|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
366614|NCT01399489|Behavioral|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
366615|NCT01399476|Procedure|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
366616|NCT01399476|Procedure|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
366617|NCT01399463|Device|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
366618|NCT01399463|Device|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
366619|NCT01399450|Drug|paliperidone|paliperidone augmenting on ongoing medication
366620|NCT01399424|Drug|CP|Immunization
366621|NCT01399398|Procedure|Brain Scan-PET|
366622|NCT01399398|Procedure|Brain Scan-MRI|
366625|NCT01399398|Procedure|Blood Sampling|
366626|NCT01399372|Biological|rituximab|Given IV
366627|NCT01399372|Drug|cytarabine|Given IV
366628|NCT01399372|Drug|methotrexate|Given IV
366629|NCT01399372|Drug|procarbazine hydrochloride|Given PO
366630|NCT01399372|Drug|vincristine sulfate|Given IV
366631|NCT01399372|Radiation|whole-brain radiation therapy|Undergo radiotherapy
366632|NCT01399359|Behavioral|Counseling session|
366633|NCT01399359|Other|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
366634|NCT01399359|Other|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
366635|NCT01399359|Other|online questionnaire|
366636|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
366637|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
366638|NCT01399333|Dietary Supplement|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
366639|NCT01399333|Dietary Supplement|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
366640|NCT01399333|Dietary Supplement|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
366641|NCT01399320|Procedure|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
366642|NCT01399307|Procedure|Liposuction|Elective Liposuction
366643|NCT01399268|Drug|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
366644|NCT01399268|Drug|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
366645|NCT01399255|Biological|Insulin lispro|Dosage form- Subcutaneous Injection
366646|NCT01399242|Drug|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
366647|NCT01399216|Dietary Supplement|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
366648|NCT01399216|Dietary Supplement|Placebo|for 8 weeks
366649|NCT01399190|Biological|Bevacizumab|Bevacizumab administered according to prescribing information and normal clinical practice.
366650|NCT01399190|Biological|Capecitabine|Capecitabine administered according to prescribing information and normal clinical practice.
366651|NCT01399190|Drug|Oxaliplatin|Capecitabine administered according to prescribing information and normal clinical practice.
366652|NCT01399164|Other|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
366653|NCT01399151|Dietary Supplement|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
366654|NCT01399151|Dietary Supplement|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
366655|NCT01399151|Dietary Supplement|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
366656|NCT01399138|Dietary Supplement|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
366657|NCT01399125|Drug|Rivastigmine Patch|Once-daily target patch size 10 cm²
366658|NCT01399125|Drug|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
366659|NCT01399125|Drug|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
366660|NCT01399125|Drug|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
366661|NCT01399112|Behavioral|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
366662|NCT01399099|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
366663|NCT01399086|Drug|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
366664|NCT01399073|Behavioral|virtual reality setup|testing for neglect in a virtual reality setup
366665|NCT01399073|Behavioral|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
366666|NCT01399073|Other|c-mri|structural and functional (resting state) imaging
366667|NCT01399047|Drug|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
366696|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
366697|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
366668|NCT01399047|Drug|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
366669|NCT01399021|Other|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
366670|NCT01399021|Other|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
366671|NCT01399008|Drug|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
366672|NCT01399008|Drug|Allopurinol|Allopurinol 300 mg as active comparator
366673|NCT01399008|Drug|Colchicine|0.6 mg colchicine daily as flare prophylaxis
366674|NCT01399008|Drug|Placebo|Placebo
366675|NCT01398995|Other|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
366676|NCT01398982|Drug|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
366677|NCT01398982|Drug|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
366678|NCT01398969|Procedure|Fresh Human Biotherapy|Patients will receive fresh fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
366679|NCT01398969|Procedure|Frozen-and-Thawed Human Biotherapy|Patients will receive frozen-and-thawed fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
366680|NCT01398956|Drug|Levetiracetam|"formulation: tablet or dry syrup~strength: 250 mg tablet, 500 mg tablet, dry syrup 50%~dosage: Sb ≥16 years and ≥4 and <16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and <16 years (<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day~frequency: twice daily"
366681|NCT01398943|Drug|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
366682|NCT01398943|Dietary Supplement|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
366683|NCT01398930|Other|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
366684|NCT01398917|Procedure|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
366685|NCT01398917|Procedure|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
366686|NCT01398891|Other|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
366687|NCT01398878|Behavioral|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
366688|NCT01398865|Procedure|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).~MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
366689|NCT01398852|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
366690|NCT01398852|Device|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
366691|NCT01398839|Device|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
366692|NCT01398839|Drug|Riboflavin|Both treatment and sham groups will receive riboflavin
366693|NCT01398787|Device|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
366694|NCT01398787|Device|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
366695|NCT01398761|Other|Signout tool|Electronic signout tool
366698|NCT01398748|Drug|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
366699|NCT01398722|Other|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
366700|NCT01398722|Other|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
366701|NCT01398709|Other|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
366702|NCT01398709|Other|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
366703|NCT01398696|Procedure|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
366704|NCT01398696|Procedure|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
366705|NCT01398670|Biological|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50~The drugs would be administered subcutaneously"
366706|NCT01398670|Biological|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50~The drugs would be administered subcutaneously"
366707|NCT01398657|Drug|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
366708|NCT01398644|Other|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
366709|NCT01398618|Drug|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
366710|NCT01398605|Other|Exercise training|Different dose of exercise training
366711|NCT01398592|Drug|Vildagliptin|50mg vildagliptin bid
366712|NCT01398592|Drug|Sitagliptin|100mg sitagliptin po qd
366713|NCT01398579|Procedure|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
366714|NCT01398566|Behavioral|SuperBetter play|average 10 min of game play per day for 6 week period
366715|NCT01398553|Device|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
366716|NCT01398553|Other|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
366717|NCT01398540|Biological|IXIARO|2 immunizations (0,5ml) with a 28 day interval
366718|NCT01398527|Other|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
366719|NCT01398514|Drug|Escitalopram|Escitalopram 10mg/day or matched pill placebo
366720|NCT01398501|Drug|Sorafenib|Oral, 200 to 400 mg QD or BID
366721|NCT01398488|Behavioral|Patient education|Patient education by health care professional compared to education via tablet PC
366722|NCT01398475|Drug|LY3009104|Administered orally
366723|NCT01398462|Drug|CWP232291|IV Infusion
366724|NCT01398449|Radiation|Elective nodal irradiation (ENI)|
366725|NCT01398449|Other|Adjuvant chemotherapy only|
366726|NCT01398436|Procedure|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
366727|NCT01398423|Drug|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
366728|NCT01398423|Drug|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
366729|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
366730|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
366731|NCT01398384|Drug|Nitric Oxide|MI size at 48-72 hours
366732|NCT01398384|Drug|MI size at 48-72 hours|Placebo gas
366733|NCT01398371|Drug|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
366734|NCT01398371|Drug|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
366735|NCT01398358|Behavioral|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.~The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
366736|NCT01398358|Behavioral|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.~For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.~Teachers are trained in classroom management strategies."
366737|NCT01398345|Behavioral|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
366738|NCT01398332|Device|Stent graft (EXCLUDER)|Endovascular repair
366739|NCT01398319|Behavioral|Group Brief Alcohol Intervention|Intervention includes identifying reasons for joining the military, roadblocks to successful completion of training, information about alcohol, two anonymous self-assessments, information on quantity-based alcohol consumption in order to reduce the risk of incidents.
366740|NCT01398306|Other|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
366741|NCT01398293|Drug|danoprevir|100 mg single dose orally
366742|NCT01398293|Drug|danoprevir|400 mg single dose orally
366743|NCT01398293|Drug|danoprevir placebo|single oral dose
366744|NCT01398293|Drug|moxifloxacin|400 mg single dose orally
366745|NCT01398293|Drug|moxifloxacin placebo|single oral dose
366746|NCT01398293|Drug|ritonavir|100 mg single dose orally
366747|NCT01398293|Drug|ritonavir placebo|single oral dose
366748|NCT01398280|Drug|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
366749|NCT01398280|Drug|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
366750|NCT01398267|Drug|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
366751|NCT01398267|Drug|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
366752|NCT01398267|Drug|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
366753|NCT01398254|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
366754|NCT01398241|Drug|RO5267683|Multiple ascending doses
366755|NCT01398241|Drug|placebo|Multiple ascending doses
366756|NCT01398228|Behavioral|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
366757|NCT01398215|Procedure|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
366758|NCT01398202|Dietary Supplement|vitamin D3|20 micrograms per day for 10 weeks
366759|NCT01398202|Dietary Supplement|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
366760|NCT01398202|Dietary Supplement|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
366761|NCT01398202|Dietary Supplement|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
366762|NCT01398189|Drug|clozapine|C-11 clozapine
366763|NCT01398176|Dietary Supplement|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
366764|NCT01398176|Dietary Supplement|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
366765|NCT01398163|Other|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
366766|NCT01398163|Other|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
366767|NCT01398150|Dietary Supplement|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
366768|NCT01398150|Dietary Supplement|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
366769|NCT01398124|Biological|Cyclin B1 Peptide|vaccine
366770|NCT01398111|Drug|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
366771|NCT01398111|Drug|Glycopyrrolate|glycopyrrolate pMDI
366772|NCT01398111|Drug|Formoterol|formoterol pMDI
366773|NCT01398111|Drug|Placebo|placebo pMDI
366774|NCT01398098|Drug|Sodium phosphate|32 tablets
366775|NCT01398085|Radiation|I131 1.1 GBq|Radio-iodine
366776|NCT01398072|Drug|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
366777|NCT01398072|Drug|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
366778|NCT01398072|Drug|Doxycycline|An oral dose of 100 mg once daily.
366779|NCT01398072|Drug|Placebo|Oral dose of one table once daily.
366780|NCT01398059|Other|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
366781|NCT01398059|Other|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
366782|NCT01398059|Other|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
366783|NCT01398046|Drug|Dasatinib|dasatinib (100mg) PO x1
366784|NCT01398046|Drug|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
366785|NCT01398046|Drug|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
366786|NCT01398033|Device|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
366787|NCT01398033|Device|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
366788|NCT01398020|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
366789|NCT01398020|Drug|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
366790|NCT01398007|Procedure|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
366791|NCT01397994|Drug|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
366792|NCT01397994|Drug|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
366793|NCT01397981|Behavioral|Gait retraining|Changing the kinematics of walking
366794|NCT01397968|Drug|YKP3089|Capsule, dose to be titrated Tablet, dose to be titrated
366795|NCT01397968|Drug|Placebo|Placebo capsule Placebo tablet
366796|NCT01397955|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
366797|NCT01397942|Other|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
366798|NCT01397929|Drug|BAL101553|Intravenous administration
366799|NCT01397890|Drug|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
366800|NCT01397890|Drug|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
366801|NCT01397877|Drug|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
366802|NCT01397864|Drug|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
366803|NCT01397851|Device|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
366804|NCT01397838|Drug|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
366805|NCT01397825|Drug|Alisertib (MLN8237)|Alisertib (MLN8237) enteric coated tablet (ECT).
366806|NCT01397825|Drug|Rituximab|Rituximab IV infusion.
366807|NCT01397825|Drug|Vincristine|Vincristine IV Infusion.
366808|NCT01397812|Device|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
366809|NCT01397812|Device|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
366810|NCT01397799|Drug|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
366811|NCT01397786|Drug|OPC-34712|"Phase A: 1-2 mgs/day by mouth, max of 4 wks.~Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
366812|NCT01397734|Drug|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
366813|NCT01397708|Biological|INXN-2001|"approximately 1.0 x 1012 viral particles (vp) per injection~one intratumoral injection of INXN-2001 per study cycle~maximum of 6 study cycles"
366814|NCT01397708|Drug|INXN-1001|"4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)~7 oral daily doses of INXN-1001 per study cycle~maximum of 6 study cycles~1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
366815|NCT01397695|Drug|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
366816|NCT01397682|Other|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
366817|NCT01397669|Procedure|Colon biopsy, lymph node biopsy, lumbar puncture|Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
366818|NCT01397656|Procedure|CPR using 30:2 ratio|Participants will begin performing CPR using a ratio of 30 compressions to 2 ventilations. Participants will then cross over to the other intervention and use continuous compressions.
366819|NCT01397656|Procedure|CPR using continuous compressions|Participants will begin performing CPR using continuous chest compressions. Participants will then cross-over to the other intervention arm and perform CPR using a ratio of 30 compressions to 2 ventilations.
366820|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
366821|NCT01397643|Other|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
366822|NCT01397630|Drug|Oxytocin|Accelerated Oxytocin Titration
366823|NCT01397617|Device|NobelActive Internal implant|Dental implant
366824|NCT01397617|Device|NobelActive External implant|Dental implant
366825|NCT01397617|Device|NobelReplace Tapered Groovy implant|Dental implant
366826|NCT01397604|Drug|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
366827|NCT01397604|Drug|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
366828|NCT01397604|Other|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
366829|NCT01397591|Biological|Ofatumumab|Given intravenously
366830|NCT01397591|Drug|Bortezomib|Given intravenously
366831|NCT01397578|Drug|MABT5102A|Repeating subcutaneous injection
366832|NCT01397578|Drug|MABT5102A|Repeating intravenous infusion
366833|NCT01397578|Drug|placebo|Repeating subcutaneous injection
366834|NCT01397578|Drug|placebo|Repeating intravenous infusion
366835|NCT01397565|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
366836|NCT01397565|Procedure|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
366837|NCT01397552|Drug|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
366838|NCT01397552|Drug|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
366839|NCT01397539|Drug|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
366840|NCT01397539|Other|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
366841|NCT01397513|Drug|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
366842|NCT01397500|Drug|Genotropin|Genotropin administered sc once a day by patient or caregiver.
366843|NCT01397500|Drug|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
366844|NCT01397487|Procedure|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
366845|NCT01397474|Other|PPTFM|Peripheral Perfusion Targeted Fluid Management
366846|NCT01397461|Drug|ozenoxacin placebo|cream
366847|NCT01397461|Drug|retapamulin 1% ointment|ointment
366848|NCT01397461|Drug|ozenoxacin 1% cream|1% cream
366849|NCT01397448|Drug|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
366850|NCT01397448|Drug|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
366851|NCT01397448|Drug|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
366852|NCT01397422|Drug|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
366853|NCT01397409|Drug|AGN-150998|AGN-150998 Intravitreal injection.
366854|NCT01397409|Drug|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
366855|NCT01397409|Other|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
366856|NCT01397396|Procedure|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
366857|NCT01397370|Drug|GLPG0492|Oral solution
366858|NCT01397370|Drug|Placebo|Oral solution
366859|NCT01397357|Other|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
366860|NCT01397331|Drug|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
366861|NCT01397331|Drug|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
366862|NCT01397305|Drug|[6R] 5,10-methylenetetrahydrofolate|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
366863|NCT01397305|Drug|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
366864|NCT01397279|Biological|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
366865|NCT01397279|Biological|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
366866|NCT01397266|Procedure|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
366867|NCT01397266|Procedure|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
366868|NCT01397253|Other|Automated communication tools|"Automated communication tools will include:~PCP notification of patient admission and location~Data on medications begun on admission~Automated alerts on changes in patient status and location while the patient is hospitalized~Links to the EMR and to hospital physician contact information on all email alerts~Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP~Automatic reporting to PCPs of test results pending at discharge~Electronic delivery of final discharge summaries"
366869|NCT01397240|Drug|Albis Tab|2 Tab, twice a day, 12 weeks
366870|NCT01397240|Drug|Placebo|2 Tab, twice a day, 12 weeks
366871|NCT01397227|Biological|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
366872|NCT01397227|Biological|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
366873|NCT01397227|Biological|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
366874|NCT01397214|Drug|Megace F|Megace F oral suspension
366875|NCT01397214|Drug|Megace OS|Megace oral suspension
366876|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
366877|NCT01397201|Drug|BI 54903|2 puffs b.i.d. BI54903 medium range via Respimat inhaler
366878|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo BI54903
366879|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
366880|NCT01397201|Drug|Fluticasone|2 puffs b.i.d. 110mcg Fluticasone propionate HFA MDI
366881|NCT01397201|Drug|BI 54903|2 puffs BI54903 via Respimat inhaler
366882|NCT01397201|Drug|BI 54903|2 puffs b.i.d. BI54903 via Respimat inhaler
366883|NCT01397201|Drug|Placebo|2 puffs placebo BI54903 via Respimat inhaler
366884|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
366885|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
366886|NCT01397188|Device|PiCCO|transpulmonary thermodilution technique
366887|NCT01397188|Other|sham, no intervention|no intervention
366888|NCT01397175|Device|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
366889|NCT01397175|Device|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
366987|NCT01396278|Drug|Placebo|2 puffs BID placebo matching BI54903 Respimat
366890|NCT01397175|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
366891|NCT01397162|Drug|Fluticasone propionate|2 puffs b.i.d. via HFA MDI matching placebo inhaler
366892|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
366893|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
366894|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
366895|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
366896|NCT01397162|Drug|Placebo|2 puffs b.i.d. via placebo Respimat inhaler
366897|NCT01397162|Drug|Placebo|2 puffs b.i.d. via placebo Respimat inhaler
366898|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
366899|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
366900|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
366901|NCT01397149|Drug|Placebo|Dosage form, frequency and duration exactly as experimental arm.
366902|NCT01397149|Drug|Eltrombopag|"Phase I:~Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to > 400,000/µl).~Phase II:~Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
366903|NCT01397123|Other|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
366904|NCT01397110|Other|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
366905|NCT01397097|Drug|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
366906|NCT01397097|Drug|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
366907|NCT01397084|Drug|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
366908|NCT01397071|Other|Avocado|Fresh Avocado
366909|NCT01397045|Other|VATS|Video-assisted lung segmentectomy
366910|NCT01397045|Procedure|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
366911|NCT01397032|Behavioral|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
366912|NCT01397032|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
366913|NCT01397019|Drug|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
366914|NCT01397006|Drug|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
366915|NCT01396993|Procedure|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
366916|NCT01396993|Procedure|Breast Surgery|Breast conserving therapy without defect correction
366917|NCT01396967|Device|surgery|cataract surgery
366918|NCT01396941|Behavioral|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
366919|NCT01396928|Procedure|Colonic reservoir|Type of reservoir to be performed
366920|NCT01396915|Dietary Supplement|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
366921|NCT01396902|Behavioral|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
366922|NCT01396902|Behavioral|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
366923|NCT01396889|Drug|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
366924|NCT01396889|Drug|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
366925|NCT01396876|Behavioral|clown|a distraction technique is performed by a clown during venipuncture
366926|NCT01396863|Procedure|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.~During the second examination the patient will receive treatment with low flux hemodialysis.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
366988|NCT01396278|Drug|Fluticasone propionate|2 puffs BID 88 mcg Fluticasone propionate HFA MDI
366927|NCT01396863|Procedure|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.~During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.~MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
366928|NCT01396837|Device|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
366929|NCT01396824|Other|No intervention|No intervention
366930|NCT01396811|Drug|33525|Daily for 14 days
366931|NCT01396811|Drug|Placebo|Daily for 14 days
366932|NCT01396785|Drug|33525|Daily for 14 days
366933|NCT01396785|Drug|Placebo|Daily for 14 days
366934|NCT01396772|Behavioral|PREPARE education program|"PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity."
366935|NCT01396772|Other|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
366936|NCT01396759|Procedure|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
366937|NCT01396759|Procedure|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
366938|NCT01396759|Procedure|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
366939|NCT01396733|Drug|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
366940|NCT01396720|Drug|fluvoxamine|Fluvoxamine 100mg daily, 7 days
366941|NCT01396720|Drug|citalopharm|Citalopharm 20mg daily, 7 days
366942|NCT01396707|Drug|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression~Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks~Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~Oxaliplatin 130 mg/m2 i.v. on day 1"
366943|NCT01396694|Other|Questionnaire|Questionnaire
366944|NCT01396681|Drug|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
366945|NCT01396668|Drug|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
366946|NCT01396655|Drug|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
366947|NCT01396642|Other|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
366948|NCT01396629|Procedure|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
366949|NCT01396616|Device|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
366950|NCT01396590|Drug|Perampanel|6 x 2 mg perampanel once per day
366951|NCT01396590|Drug|Perampanel|12 mg perampanel once per day
366952|NCT01396577|Drug|perampanel|3 x 2 mg perampanel once per day
366953|NCT01396577|Drug|perampanel|6 mg perampanel once per day
366954|NCT01396564|Drug|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
366955|NCT01396564|Drug|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
366956|NCT01396551|Device|Implantation of anchored Beacon transponder in the lung|Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
366989|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
366957|NCT01396525|Device|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
366958|NCT01396512|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
366959|NCT01396512|Biological|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
366960|NCT01396499|Drug|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
366961|NCT01396486|Drug|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
366962|NCT01396486|Drug|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
366963|NCT01396473|Behavioral|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
366964|NCT01396460|Other|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
366965|NCT01396447|Drug|Placebo|Placebo was supplied in capsules.
366966|NCT01396447|Drug|Cariprazine|Cariprazine was supplied in capsules.
366967|NCT01396434|Biological|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
366968|NCT01396421|Drug|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
366969|NCT01396421|Drug|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
366970|NCT01396421|Drug|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
366971|NCT01396421|Drug|Placebo|Placebo, once daily, for six weeks
366972|NCT01396408|Drug|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
366973|NCT01396408|Drug|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
366974|NCT01396395|Drug|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
366975|NCT01396395|Drug|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
366976|NCT01396382|Radiation|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
366977|NCT01396369|Drug|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
366978|NCT01396369|Drug|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
366979|NCT01396356|Procedure|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
366980|NCT01396330|Behavioral|stress|3 professional safe drive training courses each lasting 30 minutes
366981|NCT01396317|Drug|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
366982|NCT01396304|Device|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
366983|NCT01396304|Device|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
366984|NCT01396291|Drug|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
366985|NCT01396291|Drug|placebo|asenapine-matched placebo, sublingual tablets, BID
366986|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
366990|NCT01396278|Drug|Fluticasone propionate|2 puffs BID 220 mcg Fluticasone propionate HFA MDI
366991|NCT01396278|Drug|Placebo|2 puffs BID placebo matching BI54903 Respimat
366992|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
366993|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
366994|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
366995|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
366996|NCT01396265|Drug|Afatinib|single dose
366997|NCT01396265|Drug|Afatinib|single dose
366998|NCT01396265|Drug|Rifampicin|multiple doses
366999|NCT01396252|Drug|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
367000|NCT01396252|Drug|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
367001|NCT01396252|Drug|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
367002|NCT01396252|Drug|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
367003|NCT01396252|Drug|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
367004|NCT01396239|Drug|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
367005|NCT01396239|Other|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
367006|NCT01396226|Drug|AZD2927|A single dose of AZD2927 administered as an iv infusion
367007|NCT01396226|Drug|Placebo|A single dose of placebo administered as an iv infusion
367008|NCT01396213|Drug|Larazotide Acetate|gelatin capsule
367009|NCT01396213|Drug|placebo|gelatin capsule
367010|NCT01396200|Drug|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
367011|NCT01396200|Drug|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
367012|NCT01396187|Drug|PF-05231023|5 mg IV twice a week for 4 weeks
367013|NCT01396187|Drug|PF-05231023|25 mg IV twice a week for 4 weeks
367014|NCT01396187|Drug|PF-05231023|100 mg IV twice a week for 4 weeks
367015|NCT01396187|Drug|PF-05231023|200 mg IV twice a week for 4 weeks
367016|NCT01396187|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
367017|NCT01396174|Behavioral|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
367018|NCT01396174|Behavioral|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
367019|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
367020|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
367021|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
367022|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
367023|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
367024|NCT01396148|Drug|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
367025|NCT01396148|Drug|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
367026|NCT01396135|Drug|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
367027|NCT01396135|Drug|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
367028|NCT01396135|Drug|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
367029|NCT01396135|Drug|Placebo|Single dose of placebo given as a matching number of oral tablets
367030|NCT01396135|Drug|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
367031|NCT01396135|Drug|Placebo|Multiple doses of placebo given as a matching number of oral tablets
367032|NCT01396122|Procedure|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
367033|NCT01396109|Procedure|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
367034|NCT01396109|Procedure|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
367035|NCT01396083|Drug|Ranibizumab|
367036|NCT01396083|Drug|Dexamethasone implant and sham injections|
367037|NCT01396070|Drug|Brentuximab vedotin|"1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).~Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10."
367038|NCT01396057|Drug|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
367039|NCT01396057|Other|Dexamethasone Implant|Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
367040|NCT01396057|Other|Sham injection|Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
367041|NCT01396044|Other|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
367042|NCT01396044|Other|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
367043|NCT01396031|Behavioral|Physical Therapy|Standard of care
367044|NCT01396005|Drug|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
367045|NCT01396005|Drug|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
367046|NCT01396005|Drug|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
367047|NCT01395992|Drug|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
367048|NCT01395992|Drug|asenapine|asenapine 10 mg tablet, SL BID for 182 days
367049|NCT01395979|Behavioral|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
367050|NCT01395979|Behavioral|Supportive Psychotherapy|Eight weekly sessions
367051|NCT01395979|Behavioral|Sexual Risk Reduction Intervention|Two weekly sessions.
367052|NCT01395966|Drug|DF289|Ear drops
367053|NCT01395966|Drug|DF277|Ear drops
367054|NCT01395966|Drug|DF289 plus DF277|Ear drops
367055|NCT01395953|Drug|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
367056|NCT01395953|Drug|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
367057|NCT01395940|Drug|KLH-2109|
367058|NCT01395940|Drug|KLH-2109|
367059|NCT01395927|Drug|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
367060|NCT01395927|Drug|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
367061|NCT01395914|Drug|Anamorelin HCl|
367062|NCT01395914|Drug|Placebo|
367063|NCT01395901|Drug|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
367064|NCT01395901|Drug|Ondansetron|"Single dose Ondansetron IV:~0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for >40 kg;~13 years to less than 17 years dose: 4 mg"
367065|NCT01395901|Drug|Placebo to Ondansetron|
367066|NCT01395901|Drug|Placebo to Palonosetron|
367067|NCT01395888|Drug|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
367068|NCT01395888|Drug|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
367069|NCT01395875|Drug|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
367070|NCT01395875|Drug|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium [IPR]).
367071|NCT01395862|Drug|Salmeterol and Fluticasone|
367072|NCT01395849|Drug|Salmeterol and Fluticasone|
367073|NCT01395823|Dietary Supplement|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
367074|NCT01395823|Other|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
367075|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
367076|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
367077|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
367078|NCT01395797|Drug|PIO|0, 15, and 45 mg per day.
367079|NCT01395797|Drug|Placebo|Placebo
367080|NCT01395784|Drug|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
367081|NCT01395771|Behavioral|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
367082|NCT01395758|Drug|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
367083|NCT01395758|Drug|Pemetrexed, docetaxel or gemcitabine|Investigator's choice of a single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to the approved label.
367322|NCT01393639|Drug|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
367084|NCT01395745|Drug|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
367085|NCT01395745|Drug|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
367086|NCT01395732|Drug|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
367087|NCT01395719|Other|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
367088|NCT01395706|Procedure|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.~A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.~10 mg (5mg/ml)per injection are applicated"
367089|NCT01395693|Device|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
367090|NCT01395667|Other|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
367091|NCT01395654|Drug|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
367092|NCT01395641|Drug|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
367093|NCT01395628|Drug|in vitro sensitivity-directed chemotherapy|
367094|NCT01395628|Other|cell proliferation assay|
367095|NCT01395628|Other|fluorescence activated cell sorting|
367096|NCT01395628|Other|laboratory biomarker analysis|
367097|NCT01395628|Other|microscopy|
367098|NCT01395602|Drug|Cabergoline|cabergoline 0.5 mg twice weekly
367099|NCT01395602|Other|placebo|1 pill twice weekly
367100|NCT01395589|Drug|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
367101|NCT01395576|Device|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
367102|NCT01395563|Behavioral|strength training|strength training, high intensity, twice up to 3 times per week
367103|NCT01395537|Drug|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
367104|NCT01395537|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
367105|NCT01395537|Drug|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
367106|NCT01395524|Drug|NKTR-118|12.5 mg oral tablet once daily
367107|NCT01395524|Drug|NKTR-118|25 mg oral tablet once daily
367108|NCT01395524|Drug|Placebo|Oral tablet intake once daily
367109|NCT01395511|Device|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 * 40 (mm) / SJ 0.18 * 50 (mm) L-type needles were used for the study.~Made from stainless steel needle SEIRIN JAPAN"
367110|NCT01395498|Other|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
367111|NCT01395485|Drug|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
367112|NCT01395472|Behavioral|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
367113|NCT01395472|Behavioral|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
367114|NCT01395459|Behavioral|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
367115|NCT01395459|Behavioral|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
367116|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
367117|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
367118|NCT01395433|Drug|Escitalopram|1 x 20 mg, single dose
367119|NCT01395420|Drug|CAZ104|IV Infusion
367120|NCT01395420|Drug|CAZ104|IV Infusion
367121|NCT01395407|Radiation|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).~Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)~Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)~21 18 15~23 20 17~25 22 19"
367122|NCT01395394|Drug|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
367123|NCT01395394|Other|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
367124|NCT01395381|Drug|Placebo|placebo given once
367125|NCT01395381|Drug|Albendazole|single dose albendazole given at the time of enrollment
367126|NCT01395355|Behavioral|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
367127|NCT01395355|Behavioral|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
367158|NCT01395043|Drug|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
367159|NCT01395030|Diagnostic Test|Computed Tomography|Undergo FCH PET/CT
367160|NCT01395030|Drug|18F-fluoromethylcholine|Undergo FCH PET/CT
367128|NCT01395342|Other|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.~Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.~The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.~After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
367129|NCT01395329|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
367130|NCT01395329|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
367131|NCT01395329|Drug|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
367132|NCT01395329|Other|Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)|The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.
367133|NCT01395329|Other|FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
367134|NCT01395329|Other|FBF response to Acetylcholine|The FBF response to the endothelium-dependent vasodilator ACh (4, 8 and 16 ug/100 mL tissue/min) at baseline and at 12 weeks.
367135|NCT01395329|Other|FBF response to Sodium Nitroprusside|The FBF response to the endothelium independent vasodilator NTP (1,2 and 4 ug/100 mL tissue/min) at baseline and at 12 weeks.
367136|NCT01395329|Other|FBF response to BQ-123+BQ-788+ACh|The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
367137|NCT01395316|Drug|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
367138|NCT01395290|Drug|cholecalciferol|20.000 IU per week, oral
367139|NCT01395277|Dietary Supplement|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
367140|NCT01395277|Dietary Supplement|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
367141|NCT01395251|Drug|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
367142|NCT01395238|Behavioral|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
367143|NCT01395199|Drug|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
367144|NCT01395186|Procedure|varicocelectomy|varicocelectomy for painful varicocele
367145|NCT01395173|Procedure|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
367146|NCT01395173|Procedure|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
367147|NCT01395147|Drug|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
367148|NCT01395134|Device|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
367149|NCT01395121|Drug|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
367150|NCT01395108|Drug|Nemonoxacin|oral once daily
367151|NCT01395095|Other|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
367152|NCT01395095|Other|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
367153|NCT01395095|Other|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
367154|NCT01395069|Drug|Nepafenac 0.1%|1 drop QID for 1 month
367155|NCT01395069|Drug|Ketorolac 0.5%|1 drop QID for 1 month
367156|NCT01395069|Other|Placebo (sterile saline drops)|1 drop QID for 1 month
367157|NCT01395043|Procedure|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
367161|NCT01395030|Diagnostic Test|Positron Emission Tomography|Undergo FCH PET/CT
367323|NCT01393639|Drug|prednisone|5 mg capsule once daily for 8 weeks
367162|NCT01395017|Drug|dasatinib|GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
367163|NCT01395017|Drug|Placebo|Matching Placebo
367164|NCT01395004|Drug|GSK2110183|GSK2110183 was orally administered at 125 mg once daily.
367165|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
367166|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
367167|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
367168|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
367169|NCT01394978|Other|Control|Standard surgical techniques including staples and sutures.
367170|NCT01394978|Device|ProGEL Pleural Air Leak Sealant|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG).
367171|NCT01394965|Procedure|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
367172|NCT01394952|Drug|Dulaglutide|Administered subcutaneously
367173|NCT01394952|Drug|Placebo|Administered subcutaneously
367174|NCT01394939|Biological|JX-594|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
367175|NCT01394939|Drug|Irinotecan|180 mg/m2 IV every 2 weeks.
367176|NCT01394926|Drug|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
367177|NCT01394913|Drug|Reumatocept (etanercept)|50mg each week for 30 weeks
367178|NCT01394913|Drug|Enbrel (etanercept)|50mg each week for 30 weeks
367179|NCT01394900|Behavioral|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
367180|NCT01394900|Behavioral|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
367181|NCT01394887|Drug|Metformin|850 mg of metformin twice daily over 12 weeks
367182|NCT01394887|Drug|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
367183|NCT01394874|Behavioral|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
367184|NCT01394861|Device|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
367185|NCT01394848|Device|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
367186|NCT01394848|Device|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
367187|NCT01394848|Drug|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
367188|NCT01394848|Drug|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
367189|NCT01394835|Drug|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
367190|NCT01394835|Drug|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
367191|NCT01394835|Drug|AAT|Inhalation twice daily' 160mg
367192|NCT01394809|Behavioral|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
367193|NCT01394796|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
367194|NCT01394796|Drug|Placebo|No active treatment is given.
367195|NCT01394783|Device|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
367196|NCT01394783|Device|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
367197|NCT01394770|Drug|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
367198|NCT01394757|Drug|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
367199|NCT01394731|Drug|Acetaminophen|
367200|NCT01394731|Drug|Meperidine|
367201|NCT01394718|Drug|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
367202|NCT01394718|Other|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
367203|NCT01394705|Device|BodyMedia|Accelerometer
367204|NCT01394692|Procedure|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
367205|NCT01394692|Procedure|standard microsurgery|microsurgical tumor resection
367206|NCT01394679|Drug|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
367207|NCT01394679|Drug|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
367208|NCT01394653|Drug|YM060|oral, with water
367209|NCT01394640|Biological|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
367210|NCT01394627|Drug|Eplerenone|100mg x 2
367211|NCT01394627|Drug|Placebo|
367212|NCT01394614|Biological|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
367213|NCT01394588|Device|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
367214|NCT01394575|Radiation|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
367215|NCT01394562|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
367216|NCT01394562|Other|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
367217|NCT01394536|Device|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
367218|NCT01394536|Device|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
367219|NCT01394523|Drug|Bupivacaine|0.25% or 0.5%
367220|NCT01394510|Drug|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
367221|NCT01394497|Drug|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco‑regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross‑clamping.
367222|NCT01394484|Other|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
367223|NCT01394484|Dietary Supplement|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
367224|NCT01394471|Drug|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
367225|NCT01394458|Other|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
367226|NCT01394458|Drug|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
367227|NCT01394445|Drug|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
367228|NCT01394445|Drug|Placebo|"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"
367229|NCT01394432|Procedure|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
367230|NCT01394419|Drug|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
367231|NCT01394419|Drug|Saline|Equal volume of normal saline
367232|NCT01394406|Drug|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
367233|NCT01394406|Drug|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
367234|NCT01394393|Behavioral|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, & Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
367235|NCT01394393|Behavioral|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive—behavioral treatment approach described by Cooper and colleagues (Cooper & Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
367320|NCT01393639|Drug|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
367236|NCT01394393|Dietary Supplement|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
367237|NCT01394380|Other|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
367238|NCT01394367|Other|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
367239|NCT01394354|Drug|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.~The dose level of Vorinostat will be escalated in each new cohort:~if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
367240|NCT01394354|Drug|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
367241|NCT01394354|Drug|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
367242|NCT01394354|Drug|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
367243|NCT01394341|Drug|Liraglutide|Daily sc. injection, individual dosage
367244|NCT01394289|Biological|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.~Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
367245|NCT01394263|Drug|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
367246|NCT01394263|Drug|Zoladex goserelin implant|goserelin implant injection.
367247|NCT01394250|Device|Buzzy|Cold, Vibrational Device
367248|NCT01394250|Drug|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
367249|NCT01394237|Other|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
367250|NCT01394224|Drug|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
367251|NCT01394224|Drug|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
367252|NCT01394211|Drug|anastrozole|Given PO
367253|NCT01394211|Drug|pazopanib hydrochloride|Given PO
367254|NCT01394211|Procedure|therapeutic conventional surgery|Undergo definitive surgery
367255|NCT01394185|Drug|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
367256|NCT01394185|Drug|Placebo|Participants receive placebo
367257|NCT01394185|Drug|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
367258|NCT01394159|Procedure|22G ProCore biopsy needle|Tissue will be acquired with the 22G Procore biopsy needle and the sample will be compared to the sample obtained with the 22G standard FNA needle.
367259|NCT01394159|Procedure|22G standard FNA needle|Tissue will be acquired with the 22G standard FNA biopsy needle and the sample will be compared to the sample obtained with the 22G ProCore biopsy needle.
367260|NCT01394146|Other|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
367261|NCT01394133|Drug|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
367262|NCT01394120|Drug|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen~Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX~TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX~TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI~TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine~TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent~TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
367263|NCT01394120|Drug|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
367264|NCT01394094|Behavioral|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
367265|NCT01394081|Other|Enhanced Engagement and Enrollment (EEE)|Consists of motivational interviewing, educational outreach, and patient navigation.
367266|NCT01394081|Other|Administrative Outreach (AO)|Consists of giving information about enrolling for VA medical care or scheduling an appointment
367267|NCT01394055|Drug|RM-131|100 μg subcutaneously once
367268|NCT01394055|Drug|Placebo|Matching placebo volume subcutaneously once
367269|NCT01394042|Device|Proxiscan device|All patients will be imaged with the device
367270|NCT01394029|Drug|deferasirox|
367271|NCT01394016|Drug|LY2835219|Administered orally, daily for 28-day cycles for two planned cycles. For Part G only in addition to LY2835219 as above, fulvestrant is administered as specified in the label. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
367272|NCT01394016|Drug|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks as specified in the label in Part G only.
367273|NCT01394003|Drug|LY2584702|administered orally
367274|NCT01393990|Drug|LY2228820|Administered orally
367275|NCT01393977|Procedure|rehabilitation of limb function|only receive rehabilitation of limb function
367321|NCT01393639|Drug|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
367276|NCT01393977|Procedure|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
367277|NCT01393964|Drug|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
367278|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
367279|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 & 22 (cycle 1); days 8 &22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
367280|NCT01393964|Drug|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
367281|NCT01393964|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
367282|NCT01393951|Biological|ASP7374|subcutaneous and intramuscular
367283|NCT01393938|Other|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
367284|NCT01393925|Drug|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
367285|NCT01393912|Drug|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
367286|NCT01393899|Drug|Placebo|oral tablets twice daily
367287|NCT01393899|Drug|CP-690,550|oral tablets twice daily
367288|NCT01393899|Drug|CP-690,550|oral tablets twice daily
367289|NCT01393886|Procedure|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
367290|NCT01393834|Procedure|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
367291|NCT01393834|Procedure|Milking of the cord|Milking of the cord 4 times in 10 seconds
367292|NCT01393821|Drug|menadione topical lotion|Given topically
367293|NCT01393821|Other|placebo|Given topically
367294|NCT01393821|Other|questionnaire administration|Ancillary studies
367295|NCT01393821|Procedure|management of therapy complications|Given menadione topical lotion
367296|NCT01393808|Drug|Paricalcitol|1-month Paricalcitol 2mcg/day
367297|NCT01393808|Other|placebo|1-month Placebo Treatment
367298|NCT01393795|Drug|Qutenza|8% patch
367299|NCT01393795|Drug|Tegaderm|No active drug
367300|NCT01393782|Drug|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
367301|NCT01393769|Drug|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
367302|NCT01393756|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
367303|NCT01393743|Drug|Perampanel|
367304|NCT01393743|Drug|Placebo comparator|
367305|NCT01393730|Drug|Abiraterone acetate|
367306|NCT01393730|Drug|Dutasteride|
367307|NCT01393730|Drug|Prednisone|
367308|NCT01393717|Drug|brentuximab vedotin|Given IV
367309|NCT01393704|Drug|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
367310|NCT01393691|Behavioral|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
367311|NCT01393691|Behavioral|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
367312|NCT01393678|Drug|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
367313|NCT01393678|Drug|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg & garlic oil 50mg ............. 1cap
367314|NCT01393665|Drug|PENNEL capsule|"hard capsule DDB 25mg & GO 50mg in cap .......... 1 capsule~1 or 2 capsule, T.I.D"
367315|NCT01393665|Drug|Placebo|Placebo
367316|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
367317|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
367318|NCT01393652|Drug|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
367319|NCT01393639|Drug|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
367324|NCT01393639|Other|prednisone|10 mg capsule once daily for 8 weeks
367325|NCT01393639|Other|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
367326|NCT01393626|Drug|Placebo|oral tablets twice daily
367327|NCT01393626|Drug|CP-690,550|oral tablets twice daily
367328|NCT01393626|Drug|CP-690,550|oral tablets twice daily
367329|NCT01393613|Drug|OPC-34712|Higher dose tablet, once daily, for six weeks,
367330|NCT01393613|Drug|OPC-34712|Middle dose tablet, once daily, for six weeks
367331|NCT01393613|Drug|OPC-34712|Lower dose tablet, once daily, for six weeks
367332|NCT01393613|Drug|Placebo|Placebo, once daily, for six weeks
367333|NCT01393600|Drug|NBI-98854|12.5 mg powder in bottle once daily for 14 days
367334|NCT01393600|Drug|NBI-98854|50 mg powder in bottle once daily for 14 days
367335|NCT01393600|Drug|Placebo|Solution containing no active substance
367336|NCT01393587|Procedure|Taking blood samples|
367337|NCT01393574|Drug|Melatonin|3 mg for body weight <40kg, 6 mg for body weight >40kg, once a day 30-60 minutes before sleep
367338|NCT01393574|Drug|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
367339|NCT01393561|Drug|Group 1|Brompheniramine + phenylephrine
367340|NCT01393561|Drug|Group 2|Placebo
367341|NCT01393548|Drug|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.~OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
367342|NCT01393548|Drug|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
367343|NCT01393522|Drug|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then will taper down.
367344|NCT01393522|Drug|Placebo|Tablet will be titrated 1 tablet once a day increased per protocol to 2 tablets twice a day, with a starting dose of 12.5mg per day to 50 mg twice a day
367345|NCT01393509|Drug|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
367346|NCT01393496|Other|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
367347|NCT01393496|Other|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
367348|NCT01393483|Other|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
367349|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
367350|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
367351|NCT01393470|Procedure|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
367352|NCT01393457|Drug|levodopa/carbidopa|800/200 mg/d
367353|NCT01393457|Drug|Ropinirole 2 mg/d|2 mg/d
367354|NCT01393457|Drug|Placebo|sugar pill
367355|NCT01393457|Drug|Ropinirole 4 mg/d|4 mg/d
367356|NCT01393444|Device|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
367357|NCT01393418|Other|Cardiac Surgery|
367358|NCT01393405|Drug|Methotrexate|"Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
367359|NCT01393392|Behavioral|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
367360|NCT01393392|Behavioral|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
367361|NCT01393366|Other|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
367362|NCT01393366|Other|Usual Practice|None, only usual practice.
367363|NCT01393353|Other|Cognitive Training|
367364|NCT01393353|Other|computer game|
367365|NCT01393340|Drug|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.~Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
367366|NCT01393340|Drug|Placebo|Placebo
367367|NCT01393327|Behavioral|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
367368|NCT01393314|Device|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
367563|NCT01391624|Drug|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
367369|NCT01393301|Behavioral|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
367370|NCT01393301|Behavioral|Control|Enhanced standard smoking cessation treatment and NRT.
367371|NCT01393288|Drug|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
367372|NCT01393288|Drug|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
367373|NCT01393288|Drug|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
367374|NCT01393275|Other|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
367375|NCT01393275|Other|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week~15 minutes warm up, 30 minutes strength endurance training - once a week"
367376|NCT01393223|Drug|LP-08 80mg|Intravesical instillation of 80mg LP08
367377|NCT01393223|Drug|Normal saline|Intravesical instillation of normal saline
367378|NCT01393223|Drug|LP-08 20mg|Intravesical instillation of 20mg LP08
367379|NCT01393210|Dietary Supplement|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
367380|NCT01393210|Other|low-calorie diet|low-calorie diet only for 12 weeks.
367381|NCT01393197|Other|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
367382|NCT01393184|Drug|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
367383|NCT01393171|Device|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
367384|NCT01393171|Procedure|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
367385|NCT01393171|Procedure|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
367386|NCT01393158|Drug|Apremilast|30 mg by mouth twice daily for a total of 124 weeks.
367387|NCT01393145|Drug|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
367388|NCT01393145|Drug|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
367389|NCT01393132|Drug|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
367390|NCT01393132|Drug|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
367391|NCT01393119|Drug|GTx-758|
367392|NCT01393119|Drug|GTx-758|
367393|NCT01393119|Drug|GTx-758|
367394|NCT01393119|Drug|GTx-758|
367395|NCT01393106|Drug|Idelalisib|Idelalisib tablets administered orally
367396|NCT01393093|Procedure|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
367397|NCT01393080|Drug|Nimotuzumab and TP regimen|"TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.~Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
367398|NCT01393080|Drug|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
367399|NCT01393067|Device|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
367400|NCT01393067|Device|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
367401|NCT01393054|Drug|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
367402|NCT01393041|Device|Angio-Seal VIP|Vascular Closure Device
367403|NCT01393028|Other|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
367404|NCT01393028|Other|Standard care|Standard care according to international guidelines
367405|NCT01393015|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
367406|NCT01393015|Device|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
367407|NCT01392989|Drug|CIK cells|Standard of care
367408|NCT01392989|Drug|Cyclosporine|5 mg/kg, po
367409|NCT01392989|Drug|Mycophenolate Mofetil|15 mg/kg, oral
367410|NCT01392989|Drug|Thymoglobulin|7.5 mg/kg, IV
367411|NCT01392989|Radiation|Total Lymphoid Irradiation (TLI)|
367412|NCT01392976|Drug|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
367413|NCT01392976|Drug|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
367414|NCT01392963|Drug|botulinum toxin type A neurotoxin complex|29-40 U injection
367415|NCT01392963|Drug|Placebo|29-40 U 0.9% NaCl injection
367416|NCT01392950|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
367564|NCT01391624|Drug|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
367565|NCT01391611|Drug|Pazopanib|800 mg; PO
367417|NCT01392950|Device|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
367418|NCT01392937|Device|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
367419|NCT01392937|Device|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
367420|NCT01392924|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
367421|NCT01392911|Drug|Rifampicin|High dose rifampicin
367422|NCT01392898|Drug|liraglutide|liraglutide 1.8 mg q.d.
367423|NCT01392898|Drug|Insulin|insulin dosed according titration scheme
367424|NCT01392872|Other|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
367425|NCT01392859|Drug|levocetirizine|5mg liquid or capsule, daily, five days
367426|NCT01392859|Other|placebo|placebo will be given in liquid or capsule form to match levocetirizine, for five days
367427|NCT01392833|Drug|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
367428|NCT01392833|Drug|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
367429|NCT01392833|Drug|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
367430|NCT01392820|Drug|TC-5214|Tablet, Oral, twice daily
367431|NCT01392820|Drug|Placebo|Tablet, Oral, twice daily
367432|NCT01392807|Drug|NKTR-118|25 mg Oral tablets, single dose
367433|NCT01392794|Drug|YM060|oral, without water
367434|NCT01392768|Drug|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
367435|NCT01392768|Drug|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
367436|NCT01392755|Drug|danoprevir|oral doses of danoprevir
367437|NCT01392755|Drug|omeprazole|oral doses of omeprazole
367438|NCT01392755|Drug|ranitidine|oral dose of ranitidine
367439|NCT01392755|Drug|ritonavir|oral doses of ritonavir
367440|NCT01392716|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
367441|NCT01392703|Drug|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
367442|NCT01392703|Drug|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
367443|NCT01392703|Drug|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
367444|NCT01392690|Behavioral|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
367445|NCT01392677|Drug|dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
367446|NCT01392677|Drug|placebo|matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
367447|NCT01392638|Other|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
367448|NCT01392638|Drug|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
367449|NCT01392625|Biological|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
367450|NCT01392625|Biological|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:~Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
367451|NCT01392612|Drug|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
367452|NCT01392599|Procedure|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
367453|NCT01392586|Procedure|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
367454|NCT01392586|Other|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
367455|NCT01392573|Drug|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
367456|NCT01392573|Drug|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
367457|NCT01392560|Drug|BI 10773|Oral once daily
367458|NCT01392547|Drug|vatreptacog alfa (activated)|1-3 doses per bleeding episode
367459|NCT01392547|Drug|eptacog alfa (activated)|1-3 doses per bleeding episode
367460|NCT01392534|Drug|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
367461|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
367462|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
367463|NCT01392495|Drug|Imatinib|200 mg or 400 mg qd
367464|NCT01392469|Drug|Imatinib|
367465|NCT01392456|Procedure|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
367466|NCT01392443|Drug|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength was 5 mg/tablet INC424 phosphate (free base equivalent).
367467|NCT01392430|Other|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
367468|NCT01392391|Procedure|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.~Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
367469|NCT01392391|Procedure|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
367470|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367471|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367472|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
367473|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367474|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367475|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
367476|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367477|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367478|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
367479|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367480|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367481|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
367482|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367483|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
367484|NCT01392352|Drug|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
367485|NCT01392339|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
367486|NCT01392326|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
367487|NCT01392326|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
367488|NCT01392326|Drug|Placebo Comparator|Placebo Comparator
367489|NCT01392313|Dietary Supplement|Carnitine|Carnitine Ingestion
367490|NCT01392313|Dietary Supplement|Placebo|Carnitine placebo
367491|NCT01392300|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
367492|NCT01392300|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
367493|NCT01392287|Drug|Memantine|"Dosing Form: Tablet~Dosage: 5mg, 10 mg~Description:~Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.~Memantine HCl Dosing Schedule:~5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
367494|NCT01392235|Drug|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
367742|NCT01390402|Drug|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
367975|NCT01388738|Drug|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
367495|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues~Perceptions of thyroid cancer and disease status~Sources of information used in papillary microcarcinoma treatment decision-making~Treatment decision-making processes and influential factors~Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~Views about how to improve acceptability of active surveillance as a disease management option"
367496|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues:~Perceptions of thyroid cancer and disease status~Sources of information used in papillary microcarcinoma treatment decision-making~Treatment decision-making processes and influential factors~Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)~Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)~Views about how to improve acceptability of active surveillance as a disease management option"
367497|NCT01392209|Other|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
367498|NCT01392196|Procedure|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
367499|NCT01392183|Drug|Pazopanib|800 mg by mouth daily in 4 week study cycle.
367500|NCT01392183|Drug|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
367501|NCT01392183|Behavioral|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
367502|NCT01392183|Drug|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
367503|NCT01392170|Drug|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
367504|NCT01392157|Device|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
367505|NCT01392157|Device|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
367506|NCT01392157|Device|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
367507|NCT01392157|Device|LNG-IUS|100 women will receive an LNG-IUS
367508|NCT01392144|Procedure|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
367509|NCT01392144|Behavioral|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
367510|NCT01392131|Dietary Supplement|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
367511|NCT01392131|Other|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
367512|NCT01392105|Drug|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
367513|NCT01392105|Drug|Control group|No additional treatment of mesenchymal stem cells
367514|NCT01392079|Drug|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
367515|NCT01392066|Behavioral|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.~The questionnaire is administered at baseline and 5- and 12-months follow up."
367516|NCT01392053|Other|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
367517|NCT01392027|Procedure|Blood Draw|Blood draw for research specimens only
367518|NCT01392014|Drug|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
367519|NCT01392014|Drug|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
367520|NCT01391988|Procedure|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
367521|NCT01391988|Procedure|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
367522|NCT01391975|Procedure|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
367523|NCT01391962|Drug|Cediranib|Cediranib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
367524|NCT01391962|Drug|Sunitinib|Sunitinib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
367743|NCT01390402|Procedure|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
367744|NCT01390402|Drug|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
367525|NCT01391949|Behavioral|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
367526|NCT01391949|Behavioral|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
367527|NCT01391936|Procedure|Tension Band Wiring|AO technique of TBW for fixation of fracture.
367528|NCT01391936|Procedure|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
367529|NCT01391923|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
367530|NCT01391897|Behavioral|psychotherapy|"multimodal complex psychotherapy"
367531|NCT01391871|Device|OCT|Optical coherence tomography
367532|NCT01391871|Device|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
367533|NCT01391858|Drug|lyrica|150mg of pregabalin/placebo
367534|NCT01391845|Drug|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
367535|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
367536|NCT01391845|Drug|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
367537|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
367538|NCT01391832|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
367539|NCT01391832|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
367540|NCT01391832|Device|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
367541|NCT01391819|Other|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
367542|NCT01391819|Procedure|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
367543|NCT01391793|Drug|Placebo|Twice daily for 3 days
367544|NCT01391793|Drug|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
367545|NCT01391767|Device|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
367546|NCT01391754|Behavioral|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
367547|NCT01391754|Other|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
367548|NCT01391754|Behavioral|Services As Usual|Home based services not using the SafeCare model
367549|NCT01391754|Other|Uncoached|No in vivo coached quality control or fidelity monitoring
367550|NCT01391741|Other|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
367551|NCT01391741|Other|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
367552|NCT01391728|Behavioral|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
367553|NCT01391715|Drug|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
367554|NCT01391715|Drug|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
367555|NCT01391689|Dietary Supplement|diindolylmethane|Given PO
367556|NCT01391689|Dietary Supplement|placebo|Given PO
367557|NCT01391676|Procedure|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
367558|NCT01391663|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
367559|NCT01391663|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
367560|NCT01391663|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
367561|NCT01391650|Procedure|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
367562|NCT01391637|Biological|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
367566|NCT01391598|Drug|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
367567|NCT01391598|Drug|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
367568|NCT01391585|Other|Text Message prompts|In this single armed intervention, patients will receive text message prompts
367569|NCT01391572|Radiation|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
367570|NCT01391572|Radiation|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
367571|NCT01391572|Drug|cisplatin|
367572|NCT01391572|Drug|fluorouracil|
367573|NCT01391559|Drug|arformoterol|15 mcg administered via nebulizer
367574|NCT01391559|Drug|salmeterol|50 mcg delivered vis Diskus
367575|NCT01391546|Biological|ZOSTAVAX|1 dose 0.65 mL
367576|NCT01391533|Drug|SAR125844|"Pharmaceutical form:solution~Route of administration: intravenous"
367577|NCT01391520|Drug|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
367578|NCT01391520|Drug|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
367579|NCT01391507|Drug|0.9 % sodium chloride|Monthly intravenous injection for 6 months
367580|NCT01391507|Drug|COR-1|Monthly intravenous injection for 6 months
367581|NCT01391507|Drug|Standard therapy for heart failure|All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
367582|NCT01391494|Biological|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
367583|NCT01391494|Biological|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
367584|NCT01391494|Biological|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
367585|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
367586|NCT01391494|Biological|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
367587|NCT01391494|Biological|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
367588|NCT01391494|Biological|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
367589|NCT01391494|Biological|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
367590|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
367591|NCT01391494|Biological|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
367592|NCT01391494|Biological|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
367593|NCT01391494|Biological|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
367594|NCT01391494|Biological|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
367595|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
367596|NCT01391494|Biological|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
367597|NCT01391481|Drug|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
367598|NCT01391481|Drug|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
367599|NCT01391468|Dietary Supplement|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
367600|NCT01391468|Dietary Supplement|Cornstarch|placebo will be given in 6 months
367601|NCT01391455|Procedure|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
367602|NCT01391442|Biological|blood and urine samples|58 ml of blood 120 ml of urine
367603|NCT01391442|Genetic|blood sample|11 ml of blood
367604|NCT01391442|Other|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
367605|NCT01391442|Other|Stanislas ancillary study : MRI examination with GRICS technique|
367606|NCT01391429|Behavioral|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
367607|NCT01391403|Drug|Artemisinin|400 mg/day
367608|NCT01391403|Other|Placebo|400mg/day
367609|NCT01391390|Drug|Melatonin|10mg/day, 12-week treatment
367610|NCT01391390|Drug|Placebo|10mg/day, 12-week treatment for TD
367611|NCT01391377|Drug|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
367612|NCT01391377|Drug|Sugar pill|Placebo
367745|NCT01390402|Drug|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
367976|NCT01388738|Drug|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
367613|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :~On Day 1 of the first course of chemotherapy~On Day 1 of the second course of chemotherapy~Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~At the end of chemotherapy"
367614|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:~On Day 1 of the first course of chemotherapy~On Day 1 of the second course of chemotherapy~Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy~At the end of chemotherapy"
367615|NCT01391338|Drug|ASP3652|Oral
367616|NCT01391338|Drug|Placebo|Oral
367617|NCT01391325|Drug|Allopurinol|Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
367618|NCT01391312|Biological|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
367619|NCT01391312|Drug|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
367620|NCT01391299|Biological|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
367621|NCT01391299|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
367622|NCT01391286|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
367623|NCT01391286|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
367624|NCT01391273|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
367625|NCT01391273|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
367626|NCT01391260|Other|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
367627|NCT01391234|Radiation|STAT RT planning and delivery workflow|"Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.~Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.~Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
367628|NCT01391221|Drug|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
367629|NCT01391208|Drug|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
367630|NCT01391195|Device|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
367631|NCT01391182|Other|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
367632|NCT01391182|Other|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
367633|NCT01391169|Other|seromuscular flap enforcement|seromuscular flap enforcement
367634|NCT01391156|Drug|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
367635|NCT01391156|Drug|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
367636|NCT01391143|Biological|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.~Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
367637|NCT01391130|Drug|LY2510924|Administered subcutaneously
367638|NCT01391130|Drug|Sunitinib|Administered orally
367639|NCT01391117|Drug|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
367640|NCT01391117|Drug|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
367641|NCT01391117|Drug|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
367642|NCT01391117|Drug|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
367643|NCT01391117|Drug|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
367644|NCT01391117|Drug|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
367645|NCT01391117|Drug|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
367646|NCT01391117|Drug|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
367647|NCT01391117|Drug|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
367648|NCT01391117|Drug|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
367649|NCT01391104|Drug|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
367650|NCT01391104|Drug|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
367651|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
367652|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
367653|NCT01391078|Device|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
367654|NCT01391078|Device|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
367655|NCT01391065|Radiation|MR PET Guided Brachytherapy|
367656|NCT01391052|Drug|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
367657|NCT01391052|Other|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
367658|NCT01391039|Drug|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
367659|NCT01391026|Behavioral|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
367660|NCT01391013|Drug|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
367661|NCT01391013|Drug|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
367662|NCT01391013|Drug|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
367663|NCT01391000|Procedure|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
367664|NCT01391000|Procedure|TENS|"Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.~Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA."
367665|NCT01390961|Drug|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
367666|NCT01390948|Drug|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
367667|NCT01390948|Radiation|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
367668|NCT01390948|Drug|Temozolomide (TMZ)|75 milligrams per square meter (mg/m^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m^2/day) x 12 cycles, 1st cycle 150 mg/m^2/days 1-5, escalated to 200 mg/m^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
367669|NCT01390935|Other|guideline adherence|guideline adherence of physician
367670|NCT01390922|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
367671|NCT01390909|Drug|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
367672|NCT01390896|Drug|Fondaparinux Sodium|
367673|NCT01390883|Drug|Fondaparinux Sodium|
367674|NCT01390870|Drug|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
367675|NCT01390857|Drug|Valaciclovir|
367676|NCT01390844|Drug|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
367677|NCT01390844|Drug|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
367678|NCT01390844|Drug|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
367679|NCT01390844|Drug|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
367680|NCT01390844|Drug|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
367681|NCT01390831|Device|THERMOCOOL® Catheter|Catheter-based renal denervation
367682|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
367683|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
367684|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
367685|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
367686|NCT01390805|Drug|Valaciclovir Hydrochloride.|
367687|NCT01390792|Drug|Zanamivir hydrate|
367688|NCT01390779|Device|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
367689|NCT01390766|Drug|Azathioprine|
367690|NCT01390753|Dietary Supplement|Human donor milk|
368046|NCT01388088|Drug|Placebo|twice a day
367691|NCT01390727|Device|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
367692|NCT01390727|Other|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
367693|NCT01390714|Drug|E3710|"Arm A:~E3710 40 mg→RPZ 10 mg→E3710 20 mg~RPZ 10 mg→E3710 20 mg→E3710 40 mg~E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
367694|NCT01390714|Drug|E3710|"Arm B:~E3710 40 mg→E3710 80 mg→EPZ 40 mg~E3710 80 mg→EPZ 40 mg →E3710 40 mg~EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
367695|NCT01390701|Device|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
367696|NCT01390701|Drug|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
367697|NCT01390662|Dietary Supplement|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
367698|NCT01390662|Dietary Supplement|placebo|one tablet of sugar pill pr. day, for 24 weeks.
367699|NCT01390649|Biological|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
367700|NCT01390623|Drug|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.~The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
367701|NCT01390597|Genetic|DNA analysis|
367702|NCT01390597|Genetic|cytogenetic analysis|
367703|NCT01390597|Genetic|gene mapping|
367704|NCT01390597|Genetic|mutation analysis|
367705|NCT01390597|Genetic|polymerase chain reaction|
367706|NCT01390597|Other|laboratory biomarker analysis|
367707|NCT01390584|Drug|ABVD Induction|Step 1 Induction (Arm I) - ABVD Treatment : (Cycle Length: 28 days)
367708|NCT01390584|Drug|Escalated BEACOPP|Escalated BEACOPP (Cycle Length: 21 days)
367709|NCT01390584|Drug|Standard BEACOPP|Standard BEACOPP (Cycle Length: 21 days)
367710|NCT01390584|Diagnostic Test|PET|fludeoxyglucose F 18 Imaging exam
367711|NCT01390584|Radiation|INRT|selective external radiation therapy
367712|NCT01390571|Drug|olaparib|
367713|NCT01390571|Drug|temozolomide|
367714|NCT01390571|Genetic|gene expression analysis|
367715|NCT01390571|Genetic|protein expression analysis|
367716|NCT01390571|Other|laboratory biomarker analysis|
367717|NCT01390571|Other|pharmacological study|
367718|NCT01390571|Procedure|diffusion-weighted magnetic resonance imaging|
367719|NCT01390571|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
367720|NCT01390571|Procedure|therapeutic conventional surgery|
367721|NCT01390558|Procedure|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
367722|NCT01390545|Drug|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
367723|NCT01390532|Device|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (>85% PHR).~Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
367724|NCT01390519|Other|everolimis|
367725|NCT01390506|Drug|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
367726|NCT01390506|Drug|Placebo|0,9% sodium chloride is administered intravenously
367727|NCT01390493|Behavioral|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
367728|NCT01390480|Drug|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
367729|NCT01390467|Drug|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
367730|NCT01390454|Procedure|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
367731|NCT01390454|Procedure|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
367732|NCT01390454|Procedure|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
367733|NCT01390441|Biological|MK-8808|MK-8808 500 mg/m^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
367734|NCT01390441|Biological|MabThera® (rituximab)|MabThera® 500 mg/m^2 or 1000 mg administered by IV on Day 1 and Day 15
367735|NCT01390441|Drug|Methotrexate|Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
367736|NCT01390441|Biological|Rituxan® (rituximab)|Rituxan® 1000 mg administered by IV on Day 1 and Day 15
367737|NCT01390441|Drug|Methylprednisolone|Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
367738|NCT01390441|Drug|Acetaminophen|Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
367739|NCT01390441|Drug|Loratadine|Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
367740|NCT01390428|Drug|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
367741|NCT01390402|Drug|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
367746|NCT01390402|Procedure|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
367747|NCT01390402|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
367748|NCT01390402|Drug|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
367749|NCT01390402|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
367750|NCT01390389|Drug|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.~CoQ10 dosing guidelines:~Visit 1 (baseline) start at 400mg once a day for two weeks~Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks~The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
367751|NCT01390376|Drug|DAAOI-1|DAAOI-1 1g
367752|NCT01390376|Drug|DAAOI-1|DAAOI-1 2g
367753|NCT01390376|Drug|placebo|starch pill
367754|NCT01390363|Other|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
367755|NCT01390363|Other|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
367756|NCT01390350|Drug|Canakinumab|150mg subcutaneous injections on day 0
367757|NCT01390350|Drug|Placebo|150mg subcutaneous injections on day 0
367758|NCT01390337|Drug|AC220|Oral Liquid
367759|NCT01390337|Drug|daunorubicin|Intravenous Infusion
367760|NCT01390337|Drug|cytarabine|Intravenous Infusion
367761|NCT01390324|Drug|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
367762|NCT01390324|Drug|Naratriptan|Tablets containing naratriptan 2,5 mg
367763|NCT01390324|Drug|Naproxen|Tablets containing naproxen 500 mg
367764|NCT01390311|Drug|Azacitidine|
367765|NCT01390311|Drug|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
367766|NCT01390311|Biological|Donor Leukocyte Infusion (DLI)|
367767|NCT01390298|Other|Observational|Observational study only
367768|NCT01390285|Device|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
367769|NCT01390285|Device|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
367770|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
367771|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
367772|NCT01390272|Behavioral|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
367773|NCT01390272|Behavioral|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
367774|NCT01390259|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
367775|NCT01390259|Device|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
367776|NCT01390246|Drug|Bupropion SR|Bupropion SR 150 mg tablet
367777|NCT01390246|Behavioral|Smoking Cessation Counseling|35-min counseling by trained research nurse
367778|NCT01390246|Drug|Placebo|Matching Bupropion SR placebo tablet
367779|NCT01390233|Drug|Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel in the vagina.
367780|NCT01390233|Device|Urinary Balloon Catheter|Pre-induction cervical ripening using a urinary balloon catheter device.
367781|NCT01390233|Other|Combined Urinary Catheter & Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel injected through a urinary balloon catheter placed in the lower uterine segment.
367782|NCT01390220|Drug|USL261|
367783|NCT01390220|Drug|Placebo|
367938|NCT01389063|Drug|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
367784|NCT01390207|Other|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:~• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
367785|NCT01390181|Drug|Cozaar|Angiotensin II Receptor Blocker
367786|NCT01390168|Behavioral|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
367787|NCT01390168|Behavioral|Waitlist|active waitlist
367788|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
367789|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
367790|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
367791|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
367792|NCT01390142|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
367793|NCT01390142|Procedure|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
367794|NCT01390142|Procedure|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
367795|NCT01390129|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
367796|NCT01390129|Procedure|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
367797|NCT01390116|Dietary Supplement|Aged garlic extract|2 aged garlic extract capsules taken twice daily
367798|NCT01390116|Dietary Supplement|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
367799|NCT01390103|Other|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
367800|NCT01390077|Drug|Nitisinone|Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
367801|NCT01390064|Biological|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
367802|NCT01390051|Drug|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
367803|NCT01390051|Drug|tinzaparin|Dose 4,500 IE daily
367804|NCT01390038|Device|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
367805|NCT01390025|Biological|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
367806|NCT01390025|Biological|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
367807|NCT01390012|Drug|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
367808|NCT01390012|Drug|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
367809|NCT01389999|Other|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
367810|NCT01389986|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
367811|NCT01389973|Drug|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
367812|NCT01389973|Drug|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
367813|NCT01389973|Drug|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
367814|NCT01389973|Drug|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
367815|NCT01389934|Drug|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
367816|NCT01389934|Drug|Placebo|Women of this group be infused saline 2 ml / h for 48h.
367817|NCT01389921|Other|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
367818|NCT01389908|Drug|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
367939|NCT01389050|Radiation|Intensity-Modulated Radiotherapy|Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
367819|NCT01389895|Drug|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
367820|NCT01389895|Drug|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
367821|NCT01389882|Procedure|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
367822|NCT01389869|Biological|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
367823|NCT01389869|Biological|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
367824|NCT01389869|Biological|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
367825|NCT01389869|Biological|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
367826|NCT01389856|Drug|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
367827|NCT01389856|Drug|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
367828|NCT01389830|Behavioral|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
367829|NCT01389817|Device|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
367830|NCT01389791|Drug|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
367831|NCT01389791|Drug|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
367832|NCT01389791|Drug|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
367833|NCT01389778|Drug|Metformin ER|Metformin ER 1500 mg for 12 weeks
367834|NCT01389778|Drug|Metformin|
367835|NCT01389765|Drug|LY2216684|Administered orally
367836|NCT01389752|Drug|LY2216684|Administered orally
367837|NCT01389752|Drug|Activated Charcoal|Administered orally
367838|NCT01389739|Other|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
367839|NCT01389726|Behavioral|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
367840|NCT01389726|Behavioral|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
367841|NCT01389726|Behavioral|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader & 1 peer leader over the course of 11 weeks.
367842|NCT01389713|Drug|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
367843|NCT01389713|Drug|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
367844|NCT01389700|Drug|SAR279356|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
367845|NCT01389700|Drug|placebo|"Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion"
367846|NCT01389687|Biological|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
367847|NCT01389674|Procedure|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.~Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
367848|NCT01389661|Biological|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
367849|NCT01389648|Other|Pre Operative|Pre operative chest physiotherapy treatment
367850|NCT01389622|Other|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
367851|NCT01389622|Other|acupuncture|random points + digital pressure
367852|NCT01389609|Drug|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
367853|NCT01389609|Drug|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
367854|NCT01389609|Drug|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
367855|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
367856|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
367857|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
367858|NCT01389583|Drug|AUY922|70 mg/m2 60-min i.v. infusion weekly
367859|NCT01389570|Procedure|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
367860|NCT01389557|Drug|Dihydroartemisinin-piperaquine with primaquine|"P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.~P. vivax: DHP (3 days) + primaquine (14 days)"
367861|NCT01389544|Drug|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
367862|NCT01389544|Drug|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
367863|NCT01389544|Drug|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
367864|NCT01389531|Procedure|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
367865|NCT01389518|Drug|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
367866|NCT01389518|Drug|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
367867|NCT01389505|Procedure|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
367868|NCT01389505|Procedure|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
367869|NCT01389492|Other|frozen meat cutlets meal|250 g of meat cutlets
367870|NCT01389492|Other|meat meals|250 g of meat meal for 4 days
367871|NCT01389479|Biological|Fluviral™|Intramuscular, single dose
367872|NCT01389479|Biological|Fluzone®|Intramuscular, single dose
367873|NCT01389466|Biological|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
367874|NCT01389466|Biological|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
367875|NCT01389453|Procedure|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7—14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
367876|NCT01389440|Drug|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
367877|NCT01389427|Drug|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367878|NCT01389427|Drug|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367879|NCT01389427|Drug|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367880|NCT01389427|Drug|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367881|NCT01389427|Drug|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367882|NCT01389427|Drug|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
368047|NCT01388075|Drug|Rifampicin|oral, 450 mg/day , 7 days
367883|NCT01389427|Drug|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367884|NCT01389427|Drug|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367885|NCT01389427|Drug|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367886|NCT01389427|Drug|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367887|NCT01389427|Drug|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367888|NCT01389427|Drug|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
367889|NCT01389414|Drug|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
367890|NCT01389414|Drug|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
367891|NCT01389401|Drug|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
367892|NCT01389388|Drug|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
367893|NCT01389375|Device|FemoSeal®|Closure device for femoral artery access closure
367894|NCT01389375|Device|ExoSeal®|Closure device for femoral artery access closure
367895|NCT01389375|Other|Manual compression|Conventional manual compression
367896|NCT01389362|Drug|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
367897|NCT01389362|Drug|Placebo comparator|2 sachets to be taken daily
367898|NCT01389349|Other|Acupuncture|Battlefield acupuncture protocol
367899|NCT01389349|Other|Sham Control|Sham control acupuncture
367900|NCT01389323|Drug|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
367901|NCT01389323|Drug|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
367902|NCT01389323|Drug|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
367903|NCT01389297|Behavioral|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
367904|NCT01389297|Behavioral|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
367905|NCT01389284|Drug|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
367906|NCT01389284|Drug|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
367907|NCT01389284|Drug|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
367908|NCT01389284|Drug|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
367909|NCT01389271|Drug|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
367910|NCT01389258|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
367911|NCT01389245|Device|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
367912|NCT01389232|Device|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
367913|NCT01389219|Other|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron & vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
367914|NCT01389206|Drug|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi|observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
367915|NCT01389193|Drug|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
367916|NCT01389193|Drug|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
367940|NCT01389050|Radiation|Daily Cone Beam CT|Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
367941|NCT01389037|Behavioral|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
368080|NCT01387737|Drug|TA-7284-High|TA-7284-High
368081|NCT01387724|Genetic|RNA analysis|
368082|NCT01387724|Genetic|polymerase chain reaction|
367917|NCT01389180|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
367918|NCT01389180|Behavioral|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
367919|NCT01389180|Behavioral|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
367920|NCT01389167|Drug|Vivitrol|An extended release naltrexone formulation for intramuscular injection
367921|NCT01389167|Drug|Naltrexone (oral)|Naltrexone 50 mg pills, daily
367922|NCT01389167|Behavioral|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
367923|NCT01389167|Behavioral|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
367924|NCT01389154|Procedure|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
367925|NCT01389128|Other|Non-pharmacological resources|"A sequence of non-pharmacological resources were applied to the patient by the researcher according to uterine cervical dilation, as follows:~Pelvic mobility on the exercise ball oriented and accompanied by the researcher for 40 minutes;~Lumbosacral massage for a period of 40 minutes, when dilation was between 5 and 6 cm. During the procedure, the woman in labor was allowed to freely choose the most comfortable position; and,~Warm shower with the water flow directed to the lower-back of the woman in labor, for 40 minutes, when uterine cervical dilation was equal to or higher than 7cm."
367926|NCT01389128|Other|Routine care|Routine care of the institution performed by the staff, without the presence of the researcher that included offering a balanced meal, continuous support with the presence of a partner or family throughout labor, use of oxytocin when prescribed by the staff, use of drug analgesia when requested by the patient.
367927|NCT01389102|Drug|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
367928|NCT01389102|Drug|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
367929|NCT01389102|Drug|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
367930|NCT01389102|Drug|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
367931|NCT01389102|Drug|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
367932|NCT01389102|Drug|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
367933|NCT01389089|Other|ice gel pack|ice gel pack combined with elevation
367934|NCT01389089|Other|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
367935|NCT01389089|Device|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
367936|NCT01389076|Drug|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
367937|NCT01389076|Drug|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
368083|NCT01387724|Genetic|protein expression analysis|
367942|NCT01389037|Behavioral|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
367943|NCT01389024|Drug|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an absolute neutrophil count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
367944|NCT01389024|Drug|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
367945|NCT01388998|Other|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
367946|NCT01388985|Biological|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
367947|NCT01388959|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
367948|NCT01388946|Drug|Ropivacaine 0.75|
367949|NCT01388946|Drug|Normal saline|
367950|NCT01388933|Drug|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
367951|NCT01388933|Drug|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
367952|NCT01388920|Drug|Tesamorelin|
367953|NCT01388907|Other|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
367954|NCT01388907|Device|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
367955|NCT01388881|Other|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
367956|NCT01388868|Other|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
367957|NCT01388868|Other|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
367958|NCT01388868|Other|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
367959|NCT01388855|Drug|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
367960|NCT01388855|Drug|Placebo|Pills made to look like vitamin D but have no medication in them
367961|NCT01388842|Drug|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
367962|NCT01388842|Drug|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
367963|NCT01388829|Drug|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
367964|NCT01388829|Drug|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
367965|NCT01388816|Drug|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
367966|NCT01388790|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
367967|NCT01388790|Drug|Cisplatin|Cisplatin 60 mg/m^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
367968|NCT01388790|Drug|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
367969|NCT01388777|Device|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
367970|NCT01388777|Procedure|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
367971|NCT01388777|Procedure|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
367972|NCT01388764|Drug|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
367973|NCT01388751|Procedure|night splinting|splint finger at night for 4 weeks
367974|NCT01388738|Drug|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg*3 times per day) per os
367977|NCT01388712|Dietary Supplement|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10^8CFU).
367978|NCT01388712|Dietary Supplement|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
367979|NCT01388673|Procedure|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
367980|NCT01388660|Drug|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I & II Day 1 (crossover manner)
367981|NCT01388660|Drug|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I & II Day 1 (crossover manner)
367982|NCT01388647|Drug|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
367983|NCT01388647|Drug|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
367984|NCT01388647|Drug|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
367985|NCT01388621|Drug|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
367986|NCT01388621|Drug|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
367987|NCT01388621|Drug|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
367988|NCT01388621|Drug|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
367989|NCT01388621|Drug|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
367990|NCT01388621|Drug|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
367991|NCT01388595|Drug|FLUTICASONE PROPRIONATE|1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
367992|NCT01388595|Drug|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
367993|NCT01388595|Drug|PLACEBO|4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported & QP release tested in UK : DHP Clinical supplies, Powys, UK
367994|NCT01388582|Device|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
367995|NCT01388582|Device|Implanon|60 mcg/day contraceptive implant
367996|NCT01388582|Drug|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
367997|NCT01388582|Device|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
367998|NCT01388582|Device|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
367999|NCT01388569|Other|flow cytometry|
368000|NCT01388569|Other|immunologic technique|
368001|NCT01388569|Other|laboratory biomarker analysis|
368002|NCT01388556|Behavioral|Tango dancing|Twice weekly tango dance classes
368003|NCT01388543|Drug|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
368004|NCT01388530|Device|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
368005|NCT01388517|Drug|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
368006|NCT01388517|Drug|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
368007|NCT01388517|Drug|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
368008|NCT01388504|Drug|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
368009|NCT01388504|Other|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
368010|NCT01388491|Drug|desogestrel/ethinyl estradiol and ethinyl estradiol|
368011|NCT01388491|Drug|desogestrel/ethinyl estradiol|
368012|NCT01388478|Drug|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with Dr. Burns prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
368013|NCT01388465|Behavioral|Mobile phone text messaging|Daily assessment followed by feedback
368084|NCT01387724|Genetic|proteomic profiling|
368085|NCT01387724|Genetic|western blotting|
368014|NCT01388452|Device|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
368015|NCT01388439|Drug|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants < 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants > 38 weeks PMA. Dosing in infants < 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants > 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants > 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
368016|NCT01388426|Device|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
368017|NCT01388413|Drug|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
368018|NCT01388400|Other|conventional occupational therapy|upper limb exercises
368019|NCT01388400|Device|video capture virtual reality|virtual reality delivered uppe limb exercises
368020|NCT01388387|Other|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
368021|NCT01388374|Other|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
368022|NCT01388361|Drug|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
368023|NCT01388361|Drug|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
368024|NCT01388361|Drug|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
368025|NCT01388348|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
368026|NCT01388335|Drug|warfarin|Administered orally
368027|NCT01388335|Drug|enzastaurin|Administered orally
368028|NCT01388322|Drug|Enoxaparin|40 mg (4000 IU) women <80 kg at the time of randomization or 60 mg (6000 IU) women> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
368029|NCT01388270|Device|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
368030|NCT01388257|Procedure|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
368031|NCT01388257|Procedure|Simple seton drain removal|Patients are simply followed after seton drain removal.
368032|NCT01388244|Other|Screening|Screening by risk factor assessment (FRAX) followed by DXA
368033|NCT01388244|Other|Control|Observation by use of register data
368034|NCT01388231|Behavioral|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
368035|NCT01388231|Behavioral|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
368036|NCT01388205|Behavioral|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
368037|NCT01388179|Device|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
368038|NCT01388166|Procedure|Education|Education
368039|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
368040|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
368041|NCT01388153|Drug|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
368042|NCT01388114|Device|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
368043|NCT01388101|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
368044|NCT01388088|Drug|Spironolactone|25 mg twice a day
368045|NCT01388088|Drug|Amiloride|5 mg twice a day
368048|NCT01388062|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
368049|NCT01388049|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
368050|NCT01388036|Drug|esmolol|consecutive infusions of esmolol and normal saline (placebo)
368051|NCT01388023|Dietary Supplement|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
368052|NCT01388010|Other|1-Fermented Probiotic Dairy Product (test)|
368053|NCT01388010|Other|2-Milk-based non-fermented dairy product(control)|
368054|NCT01387997|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
368055|NCT01387958|Drug|LCQ908|
368056|NCT01387958|Drug|Placebo|
368057|NCT01387945|Behavioral|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
368058|NCT01387932|Device|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
368059|NCT01387932|Procedure|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
368060|NCT01387919|Behavioral|Prolonged fasting|48 hours of fasting
368061|NCT01387906|Drug|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
368062|NCT01387893|Behavioral|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
368063|NCT01387880|Drug|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.~Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
368064|NCT01387880|Drug|Everolimus|1.66 mg per day up to 7½ mg per day
368065|NCT01387867|Procedure|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
368066|NCT01387867|Procedure|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
368067|NCT01387867|Procedure|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
368068|NCT01387841|Behavioral|yoga|Postures,relaxation techniques
368069|NCT01387841|Behavioral|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
368070|NCT01387828|Procedure|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
368071|NCT01387828|Procedure|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
368072|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
368073|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
368074|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
368075|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
368076|NCT01387763|Drug|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
368077|NCT01387750|Other|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
368078|NCT01387750|Other|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
368079|NCT01387737|Drug|TA-7284-Low|TA-7284-Low
368086|NCT01387724|Other|enzyme-linked immunosorbent assay|
368087|NCT01387724|Other|immunohistochemistry staining method|
368088|NCT01387724|Other|laboratory biomarker analysis|
368089|NCT01387724|Other|liquid chromatography|
368090|NCT01387724|Other|mass spectrometry|
368091|NCT01387711|Drug|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
368092|NCT01387672|Drug|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
368093|NCT01387672|Other|Placebo|Placebo ointment
368094|NCT01387659|Procedure|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
368095|NCT01387646|Behavioral|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
368096|NCT01387633|Other|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
368097|NCT01387633|Other|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
368098|NCT01387620|Drug|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
368099|NCT01387607|Drug|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
368100|NCT01387607|Drug|placebo|Placebo, twice daily
368101|NCT01387594|Procedure|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
368102|NCT01387594|Drug|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
368103|NCT01387568|Drug|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg−1.h−1. and were continued up to 6 hours postoperatively
368104|NCT01387568|Drug|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg−1.h−1,and were continued up to 6 hours postoperatively
368105|NCT01387555|Biological|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
368106|NCT01387555|Other|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
368107|NCT01387542|Drug|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
368108|NCT01387516|Behavioral|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
368109|NCT01387516|Behavioral|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
368110|NCT01387516|Behavioral|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
368111|NCT01387516|Behavioral|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
368112|NCT01387503|Procedure|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
368113|NCT01387490|Behavioral|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
368749|NCT01382017|Drug|Carbamazepine|Carbamazepine 600 mg
368114|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
368115|NCT01387477|Drug|Lactate|Infusion of 66 mmol of lactate
368116|NCT01387477|Drug|Glucose|Infusion of 33 mmol of glucose
368117|NCT01387464|Drug|ISV-303|0.075% bromfenac in DuraSite dosed QD
368118|NCT01387464|Drug|Bromday™|0.09% bromfenac dosed QD
368119|NCT01387425|Drug|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
368120|NCT01387425|Drug|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
368121|NCT01387399|Procedure|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
368122|NCT01387373|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
368123|NCT01387360|Device|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.~The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
368124|NCT01387347|Drug|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
368125|NCT01387347|Drug|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
368126|NCT01387334|Behavioral|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
368127|NCT01387321|Drug|BYL719|
368128|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
368129|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 3, single dose
368130|NCT01387308|Drug|Fostamatinib|Oral tablets, 100 mg, single dose
368131|NCT01387308|Drug|Fostamatinib|Oral tablets, 150 mg, single dose
368132|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
368133|NCT01387295|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
368134|NCT01387282|Drug|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
368135|NCT01387282|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
368136|NCT01387269|Drug|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
368137|NCT01387269|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
368138|NCT01387256|Drug|medical abortion|pregnancy termination with drugs
368139|NCT01387243|Drug|Orlistat|60 mg
368140|NCT01387230|Drug|GSK573719|62.5 mcg
368141|NCT01387230|Drug|GSK573719|125mcg
368142|NCT01387230|Other|Placebo|Placebo
368143|NCT01387217|Drug|GSK2018682|GSK2018682
368144|NCT01387217|Drug|Placebo|Matched Placebo
368145|NCT01387204|Drug|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
368146|NCT01387191|Drug|Epoprostenol|
368147|NCT01387178|Drug|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
368148|NCT01387178|Drug|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
368149|NCT01387165|Drug|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
368150|NCT01387139|Drug|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
368151|NCT01387139|Drug|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
368152|NCT01387126|Dietary Supplement|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
368153|NCT01387113|Other|Computed tomography perfusion imaging|As per standard of care at CPMC
368154|NCT01387100|Behavioral|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
368155|NCT01387087|Drug|ASP015K|oral
368156|NCT01387087|Drug|Placebo|oral
368157|NCT01387074|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
368158|NCT01387061|Procedure|hepatic resection|surgical resection of the liver for multiple HCC
368159|NCT01387048|Drug|skinoren|gel 15%, twice daily, 36 weeks
368160|NCT01387048|Drug|differin|0.1% gel, once daily in the evening
368161|NCT01387048|Drug|skinoren|12 weeks treatment, the following 24 months only observation
368162|NCT01387022|Drug|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
368163|NCT01386996|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
368164|NCT01386996|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
368165|NCT01386983|Drug|5ARI|Dutasteride or Finasteride
368166|NCT01386983|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
368167|NCT01386970|Drug|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
368168|NCT01386931|Procedure|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
368169|NCT01386931|Procedure|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
368170|NCT01386918|Device|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
368171|NCT01386905|Device|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
368172|NCT01386892|Other|No intervention|There is no intervention for this study
368173|NCT01386879|Drug|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
368174|NCT01386866|Drug|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of [14C]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
368175|NCT01386853|Drug|Pitavastatin|2 mg QD
368176|NCT01386853|Drug|Atorvastatin|10 mg QD
368177|NCT01386840|Other|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.~Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
368178|NCT01386827|Biological|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml > 2 years later
368179|NCT01386827|Biological|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml > 2 years later
368180|NCT01386827|Biological|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
368181|NCT01386827|Biological|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
368182|NCT01386788|Other|There is no intervention planned (observational)|No intervention foreseen
368183|NCT01386762|Other|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
368184|NCT01386749|Procedure|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
368185|NCT01386736|Drug|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
368186|NCT01386736|Drug|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
368187|NCT01386723|Drug|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
368188|NCT01386710|Drug|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
368189|NCT01386710|Drug|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier~Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment~If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
368190|NCT01386671|Drug|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
368191|NCT01386671|Drug|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
368192|NCT01386658|Drug|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
368193|NCT01386645|Other|low glycemic index diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index <35) for 4 weeks with all food provided by the Human Nutrition Lab
368194|NCT01386645|Other|high glycemic index diet plus placebo|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
368195|NCT01386645|Drug|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
368241|NCT01386281|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
368196|NCT01386632|Drug|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
368197|NCT01386632|Drug|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
368198|NCT01386619|Biological|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing >1 10e7 NK cells/kg bodyweight (BW) and < 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
368199|NCT01386606|Drug|Androxal (enclomiphene citrate)|"capsule oral~1X a day 6 weeks"
368200|NCT01386606|Drug|Testosterone|"topical gel~1X a day 6 weeks"
368201|NCT01386593|Drug|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
368202|NCT01386593|Drug|"Basel Cocktail"|
368203|NCT01386593|Drug|Basel cocktail + Rifampicin|
368204|NCT01386580|Drug|2B3-101|IV every 21 days
368205|NCT01386580|Drug|Trastuzumab|IV every 21 days
368206|NCT01386580|Drug|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
368207|NCT01386580|Drug|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
368208|NCT01386567|Drug|Androxal (enclomiphene citrate)|"capsules oral 1x a day~1 year"
368209|NCT01386567|Drug|Testim (topical testosterone)|"topical~1 tube~1x a day~1 year"
368210|NCT01386554|Drug|Repository Corticotropin Injection|Acthar given SC for 6 months
368211|NCT01386554|Drug|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.~Placebo given SC for 6 months (80 U two times a week)."
368212|NCT01386541|Drug|BYK324677|capsules, administered orally
368213|NCT01386528|Drug|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
368214|NCT01386502|Biological|p53: 264-272 peptide|
368215|NCT01386502|Drug|CT-011|
368216|NCT01386489|Biological|VRC-HIVDNA016-00-VP|
368217|NCT01386489|Biological|VRC-HIVADV014-00-VP|
368218|NCT01386411|Genetic|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
368219|NCT01386398|Drug|bortezomib|
368220|NCT01386398|Drug|vorinostat|
368221|NCT01386398|Other|laboratory biomarker analysis|
368222|NCT01386385|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
368223|NCT01386385|Drug|Carboplatin|Given IV
368224|NCT01386385|Other|Laboratory Biomarker Analysis|Correlative studies
368225|NCT01386385|Drug|Paclitaxel|Given IV
368226|NCT01386385|Other|Placebo|Given PO
368227|NCT01386385|Drug|Veliparib|Given PO
368228|NCT01386372|Drug|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
368229|NCT01386372|Other|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
368230|NCT01386359|Drug|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
368231|NCT01386346|Drug|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
368232|NCT01386346|Drug|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
368233|NCT01386346|Drug|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
368234|NCT01386346|Drug|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
368235|NCT01386333|Drug|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
368236|NCT01386333|Drug|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
368237|NCT01386320|Procedure|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
368238|NCT01386320|Procedure|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
368239|NCT01386294|Drug|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
368240|NCT01386294|Drug|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
368833|NCT01381419|Drug|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
368242|NCT01386268|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
368243|NCT01386255|Drug|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
368244|NCT01386255|Drug|placebo|placebo. No other names
368245|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
368246|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
368247|NCT01386242|Other|Saline Injection|Saline Injection, 1mL, im,three times per week
368248|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
368249|NCT01386229|Drug|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
368250|NCT01386229|Drug|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
368251|NCT01386216|Device|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
368252|NCT01386190|Other|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
368253|NCT01386177|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
368254|NCT01386177|Drug|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.~1 day (-16h) before MDMA: 8 mg doxazosin per os."
368255|NCT01386177|Drug|placebo|capsules identical to MDMA or doxazosin
368256|NCT01386164|Biological|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
368257|NCT01386164|Biological|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
368258|NCT01386151|Drug|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
368259|NCT01386151|Drug|Saline placebo|Normal (0.9%) saline will be used as a placebo.
368260|NCT01386138|Behavioral|Psycho-education|Receive RBT education and peer-support in a group format.
368261|NCT01386138|Behavioral|Experimental|Receive RBT education and a pro-active counseling method
368262|NCT01386125|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
368263|NCT01386125|Drug|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
368264|NCT01386112|Drug|EUR-1100|Active oral medication
368265|NCT01386112|Drug|placebo|matching placebo
368266|NCT01386099|Drug|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
368267|NCT01386099|Drug|Placebo|Placebo twice a day for 12 weeks.
368268|NCT01386086|Drug|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
368269|NCT01386073|Drug|FreshKote|Three times a day for three months
368270|NCT01386073|Drug|Systane|three times a day for three months
368271|NCT01386060|Other|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
368272|NCT01386047|Other|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
368273|NCT01386034|Drug|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-[1-13C]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
368274|NCT01386008|Device|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
368275|NCT01386008|Device|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
368276|NCT01385995|Device|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
368277|NCT01385995|Device|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
368278|NCT01385982|Other|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
368279|NCT01385969|Device|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
368835|NCT01381406|Drug|TIO|Patients receiving tiotropium bromide at index within the study period.
368280|NCT01385969|Device|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
368281|NCT01385969|Device|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
368282|NCT01385956|Drug|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
368283|NCT01385956|Drug|Gemcitabine|Fixed dose: 1000mg/m^2 weekly x3 then 1 week off
368284|NCT01385930|Behavioral|Lifestyle counseling|Lifestyle counseling
368285|NCT01385891|Drug|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
368286|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
368287|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
368288|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
368289|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
368290|NCT01385865|Dietary Supplement|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
368291|NCT01385865|Dietary Supplement|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
368292|NCT01385852|Procedure|microcoaxial phacoemulsification|conventional longitudinal ultrasound
368293|NCT01385839|Procedure|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
368294|NCT01385839|Procedure|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
368295|NCT01385826|Drug|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
368296|NCT01385826|Drug|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
368297|NCT01385800|Biological|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
368298|NCT01385800|Biological|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
368299|NCT01385774|Procedure|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
368300|NCT01385774|Other|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
368301|NCT01385761|Device|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
368302|NCT01385761|Device|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
368303|NCT01385748|Drug|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
368304|NCT01385748|Drug|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
368305|NCT01385748|Drug|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
368306|NCT01385735|Drug|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
368307|NCT01385735|Drug|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
368308|NCT01385696|Device|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
368309|NCT01385696|Device|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
368310|NCT01385683|Drug|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
368311|NCT01385683|Drug|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
368312|NCT01385670|Device|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
368313|NCT01385657|Drug|REGN668 (SAR231893)|Dose 1 or placebo
368314|NCT01385657|Drug|REGN668 (SAR231893)|Dose 2 or placebo
368344|NCT01385358|Procedure|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
368315|NCT01385644|Other|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
368316|NCT01385631|Drug|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
368317|NCT01385631|Drug|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
368318|NCT01385592|Drug|AFQ056|
368319|NCT01385592|Drug|Placebo|
368320|NCT01385579|Other|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
368321|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
368322|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
368323|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
368324|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
368325|NCT01385566|Biological|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
368326|NCT01385566|Biological|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
368327|NCT01385553|Behavioral|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
368328|NCT01385553|Behavioral|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
368329|NCT01385540|Behavioral|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
368330|NCT01385527|Behavioral|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
368331|NCT01385527|Drug|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
368332|NCT01385501|Other|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
368333|NCT01385488|Behavioral|self-monitor arm volume|bioelectrical impedance
368334|NCT01385475|Behavioral|RT|8 week RT Intervention
368335|NCT01385449|Procedure|interscalene catheter|interscalene catheter
368336|NCT01385449|Procedure|interscalene block|interscalene block
368337|NCT01385423|Drug|Preparative Regimen|Fludarabine 25 mg/m^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (*if < 4 months from prior transplant, omit day -4 dose)
368338|NCT01385423|Biological|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
368339|NCT01385410|Behavioral|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
368340|NCT01385397|Other|Preceptorship and virtual community|
368341|NCT01385384|Device|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.~The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.~Sites that provide the optimal response (greater region and magnitude) are noted.~Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
368342|NCT01385371|Biological|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
368343|NCT01385371|Biological|Placebo for SCH 697243|One dissolving tablet sublingually once daily
368345|NCT01385358|Procedure|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
368346|NCT01385345|Drug|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
368347|NCT01385332|Procedure|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
368348|NCT01385332|Procedure|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
368349|NCT01385319|Device|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
368350|NCT01385319|Device|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:~Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.~Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.~Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
368351|NCT01385306|Device|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
368352|NCT01385293|Drug|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
368353|NCT01385280|Biological|therapeutic estradiol|Given orally (PO)
368354|NCT01385280|Drug|exemestane|Given PO
368355|NCT01385280|Other|laboratory biomarker analysis|Correlative studies
368356|NCT01385280|Other|enzyme-linked immunosorbent assay|Correlative studies
368357|NCT01385267|Procedure|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
368358|NCT01385241|Behavioral|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
368359|NCT01385228|Drug|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
368360|NCT01385228|Drug|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
368361|NCT01385228|Drug|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
368362|NCT01385228|Drug|Prednisone|5mg Prednisone given twice daily days 1-21.
368363|NCT01385228|Drug|Pegfilgrastim|
368364|NCT01385215|Drug|Fluzone|0.5 ml/15 micrograms
368365|NCT01385215|Drug|Fluzone|0.5 ml/60 micrograms
368366|NCT01385202|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
368367|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
368368|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
368369|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
368370|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
368371|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
368372|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
368373|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
368374|NCT01385176|Device|Vagal Nerve Stimulation|Patients randomized to therapy arm with receive right vagal nerve stimulation. Patients randomized to control arm will not receive right vagal nerve stimulation for the first 6-months post-implant, after which they will also receive therapy.
368375|NCT01385163|Behavioral|Treatment as usual|Standard psychosocial counseling
368376|NCT01385163|Behavioral|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
368377|NCT01385163|Behavioral|Cognitive Processing Therapy|group 12 session intervention
368378|NCT01385150|Genetic|mutation analysis|
368379|NCT01385150|Genetic|protein analysis|
368380|NCT01385150|Other|laboratory biomarker analysis|
368381|NCT01385150|Other|liquid chromatography|
368382|NCT01385150|Other|mass spectrometry|
368383|NCT01385137|Dietary Supplement|omega-3 fatty acid|Given orally
368384|NCT01385137|Other|placebo|Given orally
368385|NCT01385124|Drug|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
368746|NCT01382030|Drug|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
368386|NCT01385111|Procedure|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
368387|NCT01385111|Procedure|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
368388|NCT01385098|Dietary Supplement|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
368389|NCT01385072|Biological|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.~Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
368390|NCT01385059|Drug|axitinib|Given PO
368391|NCT01385059|Procedure|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
368392|NCT01385059|Other|enzyme-linked immunosorbent assay|Correlative studies
368393|NCT01385059|Other|laboratory biomarker analysis|Correlative studies
368394|NCT01385046|Behavioral|Project Fit|physical activity and nutrition education
368395|NCT01385033|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
368396|NCT01385020|Drug|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
368397|NCT01385007|Behavioral|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
368398|NCT01384994|Drug|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
368399|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
368400|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
368401|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
368402|NCT01384994|Drug|Panitumumab|6 mg/kg BW every 2 weeks
368403|NCT01384994|Drug|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
368404|NCT01384994|Drug|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
368405|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
368406|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
368407|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
368408|NCT01384981|Procedure|pulmonary rehabilitation|
368409|NCT01384968|Dietary Supplement|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
368410|NCT01384942|Behavioral|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
368411|NCT01384942|Behavioral|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
368412|NCT01384916|Behavioral|Yoga|2x weekly
368413|NCT01384916|Behavioral|Healthy Living Workshop|2x weekly
368414|NCT01384903|Drug|KW-3357|Intravenous infusion once a day
368415|NCT01384903|Drug|Plasma-derived antithrombin|Intravenous infusion once a day
368416|NCT01384890|Radiation|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
368417|NCT01384890|Radiation|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
368418|NCT01384877|Drug|Lidocaine|10mg/kg by subcutaneous infusion over 5.5 hours
368419|NCT01384877|Drug|Placebo (D5W)|Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
368420|NCT01384864|Drug|proflavine|2-6 ml of 0.01% proflavine
368421|NCT01384851|Drug|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
368422|NCT01384851|Drug|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
368423|NCT01384851|Drug|Refresh Contacts|One drop both eyes four times daily for two weeks
368424|NCT01384838|Behavioral|Counseling|Nutritional, lifestyle and sports counseling
368425|NCT01384838|Behavioral|physical activity|counseling and controlled physical activity
368426|NCT01384812|Drug|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
368427|NCT01384812|Drug|isoton sodium chloride|intravenous injection for 25 min
368428|NCT01384799|Drug|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
368429|NCT01384799|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
368430|NCT01384799|Radiation|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
368431|NCT01384773|Other|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
368538|NCT01383876|Behavioral|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
368432|NCT01384773|Device|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
368433|NCT01384760|Behavioral|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
368434|NCT01384760|Behavioral|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
368435|NCT01384747|Drug|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
368436|NCT01384747|Drug|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
368437|NCT01384734|Drug|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
368438|NCT01384734|Drug|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
368439|NCT01384734|Drug|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
368440|NCT01384734|Drug|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
368441|NCT01384734|Drug|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
368442|NCT01384734|Drug|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
368443|NCT01384734|Drug|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
368444|NCT01384734|Drug|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
368445|NCT01384708|Drug|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
368446|NCT01384695|Drug|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
368447|NCT01384695|Drug|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
368448|NCT01384682|Drug|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
368449|NCT01384656|Drug|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
368450|NCT01384643|Drug|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
368451|NCT01384630|Drug|RA-18C3|200 mg subcutaneous injection
368452|NCT01384617|Procedure|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
368453|NCT01384617|Procedure|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
368454|NCT01384591|Drug|N-acetylcysteine|50 mg/kg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
368455|NCT01384591|Drug|Losartan|25mg/dose. 3 total doses: 1 dose on day 1, 2 doses on day 2.
368456|NCT01384591|Drug|Placebo losartan|Placebo losartan 3 total doses: 1 dose on day 1, 2 doses on day 2.
368457|NCT01384591|Drug|Placebo N-acetylcysteine|Placebo N-acetylcysteine 3 total doses: 1 dose on day 1, 2 doses on day 2.
368458|NCT01384578|Drug|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
368459|NCT01384578|Drug|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
368460|NCT01384565|Drug|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)~G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).~Arms: G-CSF+EPO Drug: Placebo~Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
368461|NCT01384565|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
368462|NCT01384552|Other|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
368463|NCT01384552|Other|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
368464|NCT01384539|Drug|Cholecalciferol|
368465|NCT01384539|Drug|Calcitriol|
368466|NCT01384513|Drug|Fludarabine|Given IV
368467|NCT01384513|Drug|Busulfan|Given IV
368468|NCT01384513|Radiation|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
368469|NCT01384513|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
368470|NCT01384513|Drug|Cyclophosphamide (CY)|Given IV
368471|NCT01384513|Drug|Tacrolimus|Given IV or PO
368472|NCT01384513|Drug|Mycophenolate mofetil|Given IV
368473|NCT01384513|Device|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
368474|NCT01384513|Procedure|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
368475|NCT01384500|Other|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
368476|NCT01384474|Other|Diffusion of a surgical safety checklist|"Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;~A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:~First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;~Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication~Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms"
368477|NCT01384448|Procedure|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
368478|NCT01384448|Procedure|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
368479|NCT01384435|Drug|KPS-0373|
368480|NCT01384435|Drug|KPS-0373|
368481|NCT01384435|Drug|KPS-0373|
368482|NCT01384435|Drug|KPS-0373|
368483|NCT01384435|Drug|Placebo|
368484|NCT01384422|Drug|GLPG0634|
368485|NCT01384409|Drug|KW-3357|Intravenous infusion once a day
368486|NCT01384396|Drug|KW-3357|Intravenous infusion once a day
368487|NCT01384383|Drug|GS-5885|GS-5885 30 mg tablet administered orally once daily
368488|NCT01384383|Drug|GS-9451|GS-9451 200 mg tablet administered orally once daily
368489|NCT01384383|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
368490|NCT01384383|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
368491|NCT01384344|Other|observational|Observation during a physical exercise
368492|NCT01384331|Drug|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules~21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms~21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days~21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
368493|NCT01384318|Other|Manometer|Measuring cuff pressure
368494|NCT01384292|Drug|NKTR-118|12.5 mg oral tablet once daily
368495|NCT01384292|Drug|NKTR-118|25 mg oral tablet once daily
368496|NCT01384292|Drug|Placebo|Oral treatment
368497|NCT01384279|Drug|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
368498|NCT01384253|Other|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
368499|NCT01384253|Biological|trastuzumab|4 mg/kg.
368500|NCT01384240|Drug|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
368501|NCT01384227|Drug|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
368502|NCT01384214|Biological|botulinum toxin Type A|750 U at Visit 1
368503|NCT01384188|Drug|ONO-5334|150 mg for 5 days administered in the morning or in the evening
368504|NCT01384188|Drug|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
368505|NCT01384175|Procedure|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
368506|NCT01384175|Procedure|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
368507|NCT01384175|Procedure|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
368508|NCT01384162|Drug|sNN0029|ICV infusion
368509|NCT01384149|Device|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
368510|NCT01384149|Device|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
368511|NCT01384110|Dietary Supplement|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
368512|NCT01384084|Procedure|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
368513|NCT01384084|Procedure|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
368514|NCT01384071|Device|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
368515|NCT01384071|Device|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
368516|NCT01384058|Drug|ezetimibe|ezetimibe 10 mg per day for six weeks
368517|NCT01384058|Drug|simvastatin|Simvastatin 20 mg per day for six weeks
368518|NCT01384058|Drug|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
368519|NCT01384045|Other|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
368520|NCT01384032|Dietary Supplement|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
368521|NCT01384032|Dietary Supplement|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
368522|NCT01384032|Dietary Supplement|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
368523|NCT01384019|Device|distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))|The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
368524|NCT01384019|Procedure|c-PCI|conventional PCI without Guard wire
368525|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
368526|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
368527|NCT01383980|Dietary Supplement|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
368528|NCT01383967|Drug|LY2979165|Administered orally
368529|NCT01383967|Drug|placebo|Administered orally
368530|NCT01383954|Drug|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
368531|NCT01383941|Drug|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
368532|NCT01383928|Drug|Ixazomib|Ixazomib capsules
368533|NCT01383928|Drug|Lenalidomide|Lenalidomide capsules
368534|NCT01383928|Drug|Dexamethasone|Dexamethasone Tablets
368535|NCT01383902|Other|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
368536|NCT01383889|Other|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
368537|NCT01383876|Behavioral|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
368539|NCT01383850|Other|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
368540|NCT01383850|Other|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
368541|NCT01383837|Behavioral|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
368542|NCT01383837|Behavioral|Health Promotion|Health Promotion Intervention
368543|NCT01383824|Device|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
368544|NCT01383811|Other|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
368545|NCT01383811|Other|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
368546|NCT01383798|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
368547|NCT01383798|Dietary Supplement|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
368548|NCT01383785|Other|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.~Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
368549|NCT01383785|Other|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.~Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
368550|NCT01383785|Other|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.~Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
368551|NCT01383772|Procedure|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
368552|NCT01383759|Drug|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:~1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks. Long Term Follow Up will cease when all patients on study have fulfilled the requirements for at least five follow up appointments."
368553|NCT01383746|Device|Yttrium microsphere injection|Radiation therapy
368554|NCT01383733|Drug|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
368555|NCT01383720|Device|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
368556|NCT01383707|Drug|5-Fluorouracil (5-FU)|Participants will receive 5-FU 400 mg per meter-squared (mg/m^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m^2, continuous infusion over 46 hours up to 12 cycles.
368557|NCT01383707|Drug|Bevacizumab|Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
368558|NCT01383707|Drug|Levofolinic acid|Participants will receive levofolinic acid 200 mg/m^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
368559|NCT01383707|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
368560|NCT01383694|Drug|Piperine|
368561|NCT01383681|Other|No treatment|There was no treatment in this study.
368562|NCT01383668|Drug|sirolimus|Given PO
368563|NCT01383668|Drug|gold sodium thiomalate|Given IM
368564|NCT01383668|Other|pharmacological study|Correlative studies
368565|NCT01383668|Genetic|RNA analysis|Correlative studies
368566|NCT01383668|Genetic|polymerase chain reaction|Correlative studies
368567|NCT01383655|Drug|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
368568|NCT01383655|Drug|Placebo|NaCl
368569|NCT01383642|Other|No intervention, observational study|
368570|NCT01383629|Behavioral|Counselling|Preoperative counselling
368571|NCT01383616|Device|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
368572|NCT01383603|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
368573|NCT01383590|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
368574|NCT01383577|Procedure|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
368575|NCT01383577|Procedure|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
368576|NCT01383564|Procedure|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
368577|NCT01383564|Procedure|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
368578|NCT01383551|Behavioral|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
368579|NCT01383538|Drug|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.~Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.~Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.~5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.~IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
368580|NCT01383525|Device|Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
368581|NCT01383512|Device|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
368582|NCT01383512|Other|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
368583|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
368584|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
368585|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
368586|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
368587|NCT01383486|Drug|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
368588|NCT01383486|Drug|Advil|Commercially available Advil; oral caplet upon incidence of pain
368589|NCT01383460|Drug|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
368590|NCT01383460|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
368591|NCT01383447|Drug|entinostat|Given PO
368592|NCT01383447|Drug|imatinib mesylate|Given PO
368593|NCT01383447|Other|laboratory biomarker analysis|Correlative studies
368594|NCT01383447|Other|pharmacological study|Correlative studies
368595|NCT01383447|Genetic|western blotting|Correlative studies
368596|NCT01383447|Other|immunohistochemistry staining method|Correlative studies
368597|NCT01383447|Other|flow cytometry|Correlative studies
368598|NCT01383447|Genetic|polymerase chain reaction|Correlative studies
368599|NCT01383447|Other|high performance liquid chromatography|Correlative studies
368600|NCT01383447|Other|mass spectrometry|Correlative studies
368601|NCT01383434|Procedure|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
368602|NCT01383408|Other|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
368603|NCT01383395|Drug|simvastatin/cilostazol|
368604|NCT01383356|Drug|Metformin Single Tablet|Metformin medium doseTablet
368605|NCT01383356|Drug|Linagliptin/Metformin Combo|Fixed dose combination
368606|NCT01383356|Drug|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
368607|NCT01383343|Biological|Bevacizumab|Given IV
368608|NCT01383343|Drug|Fluorouracil|Given IV
368609|NCT01383343|Drug|Irinotecan Hydrochloride|Given IV
368610|NCT01383343|Drug|Leucovorin Calcium|Given IV
368611|NCT01383343|Drug|Sorafenib Tosylate|Given PO
368612|NCT01383330|Drug|megace|800mg
368613|NCT01383330|Drug|DW-ES(A)|625mg
368614|NCT01383330|Drug|DW-ES(B)|625mg
368615|NCT01383317|Device|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
368616|NCT01383317|Device|Sham RIPC|Disposable sterile thigh tourniquet
368617|NCT01383278|Behavioral|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
368618|NCT01383278|Behavioral|Screening and resource provision|Screening and resource provision
368619|NCT01383265|Procedure|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
368620|NCT01383265|Procedure|Water method|Control method will use plain water with water method for screening colonoscopy
368621|NCT01383252|Procedure|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
368622|NCT01383252|Procedure|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
368702|NCT01382498|Drug|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
368623|NCT01383239|Other|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
368624|NCT01383239|Other|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
368625|NCT01383226|Procedure|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
368626|NCT01383213|Other|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
368627|NCT01383213|Other|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
368628|NCT01383200|Drug|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
368629|NCT01383200|Drug|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
368630|NCT01383187|Procedure|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
368631|NCT01383187|Procedure|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
368632|NCT01383174|Behavioral|Peer Support Program|"Work with a trained counselor who is a breast cancer survivor~Meet 8 times in-person over the 8 week program with the counselor~Counselor helps participant develop a personalized support program to help her improve her quality of life~Receives information on breast cancer, its treatments, and stress management"
368633|NCT01383161|Drug|Curcumin|Six Theracurmin capsules (containing 30 mg of curcumin each) per day for 18 months.
368634|NCT01383161|Other|Placebo|Six capsules per day for 18 months.
368635|NCT01383148|Biological|TG4010|"TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling."
368636|NCT01383148|Drug|placebo|"Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~First line therapy: as in Arm 1~Maintenance therapy: as in Arm 1"
368637|NCT01383135|Drug|FPPRGD2|radiopharmaceutical administered for imaging, up to 14 mCi i.v.
368638|NCT01383122|Device|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
368639|NCT01383122|Device|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
368640|NCT01383109|Drug|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
368641|NCT01383096|Drug|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
368642|NCT01383096|Drug|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
368643|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
368644|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
368645|NCT01383070|Behavioral|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
368646|NCT01383057|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
368647|NCT01383044|Procedure|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
368648|NCT01383044|Drug|carvedilol|carvedilol 6.25mg-12.5 mg per day
368649|NCT01383031|Procedure|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
368650|NCT01383031|Procedure|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
368651|NCT01383018|Device|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
368652|NCT01382979|Behavioral|AlcoholEdu for College|Online course for college freshmen.
368653|NCT01382953|Device|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
368654|NCT01382940|Drug|rituximab|1000 mg in 250 mL intravenous infusion
368655|NCT01382940|Drug|methotrexate|10 to 25 mg/week (oral or parenteral)
368656|NCT01382940|Drug|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
368657|NCT01382940|Drug|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
368658|NCT01382940|Drug|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
368659|NCT01382914|Other|chlorhexidine 0.12%|twice daily, 10 ml, topical
368660|NCT01382901|Drug|Ferric Carboxymaltose (FCM)|
368661|NCT01382901|Drug|Placebo|
368747|NCT01382017|Drug|Lacosamide|Lacosamide 200 or 400 mg
368662|NCT01382888|Drug|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
368663|NCT01382888|Drug|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
368664|NCT01382875|Other|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
368665|NCT01382862|Other|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
368666|NCT01382823|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
368667|NCT01382810|Drug|Altaire Gel forming solution|Three times a day for two months
368668|NCT01382810|Drug|Refresh Tears|Three times a day for two months
368669|NCT01382797|Drug|ALKS 37|Capsules for oral administration
368670|NCT01382797|Drug|Placebo|Capsules for oral administration
368671|NCT01382771|Drug|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
368672|NCT01382771|Drug|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
368673|NCT01382745|Drug|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
368674|NCT01382745|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
368675|NCT01382732|Drug|Carbetocin|Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
368676|NCT01382732|Drug|Oxytocin|Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
368677|NCT01382719|Drug|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.~Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.~Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
368678|NCT01382706|Drug|docetaxel|Given IV
368679|NCT01382706|Drug|lapatinib ditosylate|Given PO
368680|NCT01382706|Other|immunohistochemistry staining method|Correlative studies
368681|NCT01382706|Genetic|fluorescence in situ hybridization|Correlative studies
368682|NCT01382706|Other|laboratory biomarker analysis|Correlative studies
368683|NCT01382693|Behavioral|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
368684|NCT01382693|Behavioral|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
368685|NCT01382680|Device|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
368686|NCT01382654|Drug|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
368687|NCT01382654|Drug|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
368688|NCT01382654|Drug|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
368689|NCT01382654|Drug|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
368690|NCT01382654|Drug|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
368691|NCT01382641|Device|Hoya AF-1 IOL|The patients will be assessed for three months
368692|NCT01382641|Device|Revital vision|The patients will be assessed for three months.
368693|NCT01382602|Biological|AMDC-USR|AMDC-USR Treatment
368694|NCT01382602|Biological|Placebo|Placebo treatment
368695|NCT01382589|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
368696|NCT01382589|Device|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
368697|NCT01382550|Drug|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.~According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.~The occurrence of surgery, trauma, prolonged immobilization (>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
368698|NCT01382537|Device|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
368699|NCT01382537|Device|InterX 5000|Placebo treatment
368700|NCT01382511|Drug|Simvastatine|80 mg
368701|NCT01382498|Drug|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
368703|NCT01382485|Other|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
368704|NCT01382485|Other|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
368705|NCT01382472|Drug|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
368706|NCT01382472|Drug|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
368707|NCT01382446|Drug|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
368708|NCT01382446|Other|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
368709|NCT01382433|Procedure|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
368710|NCT01382433|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
368711|NCT01382433|Behavioral|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
368712|NCT01382420|Procedure|surgery|adrenalectomy
368713|NCT01382407|Drug|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
368714|NCT01382368|Drug|Sildenafil|Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
368715|NCT01382342|Drug|Rasagiline|1 mg daily
368716|NCT01382342|Drug|Placebo|1 mg daily
368717|NCT01382329|Biological|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
368718|NCT01382316|Behavioral|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
368719|NCT01382316|Behavioral|Usual care|Group format, six weekly education sessions about alcohol and drugs
368720|NCT01382303|Drug|Pentoxifylline|Pentoxifylline 400mg three times a day
368721|NCT01382303|Drug|Placebo|placebo tablet three times a day
368722|NCT01382290|Procedure|MRI|
368723|NCT01382277|Drug|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
368724|NCT01382264|Other|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
368725|NCT01382238|Drug|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
368726|NCT01382238|Drug|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
368727|NCT01382225|Drug|Sodium Hyaluronate Ophthalmic Solution, 0.18%|
368728|NCT01382225|Other|Vehicle|Inactive ingredients used as run-in and placebo comparator
368729|NCT01382212|Drug|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
368730|NCT01382199|Drug|Lactoferrin|
368731|NCT01382160|Biological|adalimumab|40 mg every two weeks, by subcutaneous way
368732|NCT01382147|Drug|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
368733|NCT01382134|Drug|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
368734|NCT01382134|Drug|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
368735|NCT01382121|Behavioral|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
368736|NCT01382121|Behavioral|Control|watching a video unrelated to the fitness test and self-efficacy
368737|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
368738|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
368739|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
368740|NCT01382095|Biological|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
368741|NCT01382069|Drug|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
368742|NCT01382069|Drug|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
368743|NCT01382056|Other|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
368744|NCT01382056|Other|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
368745|NCT01382056|Other|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
368750|NCT01382004|Drug|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
368751|NCT01382004|Drug|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.~Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
368752|NCT01381991|Device|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
368753|NCT01381965|Procedure|Vitreous surgery for macular hole|Vitreous surgery for macular hole
368754|NCT01381952|Radiation|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
368755|NCT01381952|Radiation|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
368756|NCT01381926|Drug|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
368757|NCT01381926|Drug|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
368758|NCT01381900|Drug|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
368759|NCT01381900|Drug|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
368760|NCT01381900|Drug|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
368761|NCT01381900|Drug|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
368762|NCT01381900|Drug|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
368763|NCT01381887|Drug|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
368764|NCT01381887|Drug|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
368765|NCT01381887|Drug|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
368766|NCT01381887|Drug|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
368767|NCT01381874|Drug|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
368768|NCT01381874|Drug|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
368769|NCT01381874|Drug|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
368770|NCT01381861|Biological|Carotuximab (TRC105)|Carotuximab (TRC105) 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
368771|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients <8 weeks CA.
368772|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients >=8 weeks CA.
368773|NCT01381835|Drug|TMC435|150 mg capsule once daily for 7 days
368774|NCT01381822|Drug|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
368775|NCT01381809|Drug|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
368776|NCT01381809|Drug|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
368777|NCT01381796|Drug|NP101|comparison of NP101 with minor patch modifications
368778|NCT01381796|Drug|sumatriptan succinate|tablet, 100 mg
368779|NCT01381783|Procedure|Phacoemulsification|Phacoemulsification under topical anesthesia
368780|NCT01381770|Biological|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
368834|NCT01381419|Drug|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
368781|NCT01381744|Biological|Flagellin/F1/V|Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
368782|NCT01381744|Other|Placebo|Phosphate buffered saline (PBS) used as diluent and placebo.
368783|NCT01381731|Drug|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
368784|NCT01381731|Drug|placebo|opthalmic solution 2 drops in each eye QID
368785|NCT01381718|Drug|modafinil|Given PO
368786|NCT01381718|Other|placebo|Given PO
368787|NCT01381705|Biological|rituximab|
368788|NCT01381705|Genetic|DNA analysis|
368789|NCT01381705|Genetic|gene expression analysis|
368790|NCT01381705|Genetic|polymorphism analysis|
368791|NCT01381705|Other|laboratory biomarker analysis|
368792|NCT01381705|Other|medical chart review|
368793|NCT01381692|Drug|Bortezomib|Given IV or SC
368794|NCT01381692|Drug|Dexamethasone|Given PO
368795|NCT01381692|Other|Laboratory Biomarker Analysis|Correlative studies
368796|NCT01381692|Other|Quality-of-Life Assessment|Ancillary studies
368797|NCT01381692|Biological|Rituximab|Given IV
368798|NCT01381692|Drug|Temsirolimus|Given IV
368799|NCT01381679|Drug|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
368800|NCT01381666|Drug|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
368801|NCT01381666|Drug|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
368802|NCT01381653|Other|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
368803|NCT01381640|Drug|Marketed paracetamol|marketed formulation
368804|NCT01381640|Drug|Experimental paracetamol formulation|Experimental formulation
368805|NCT01381627|Drug|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
368806|NCT01381627|Drug|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
368807|NCT01381614|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
368808|NCT01381601|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
368809|NCT01381588|Other|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
368810|NCT01381575|Biological|GSK Biologicals' HPV vaccine 580299|Subjects will receive 2 or 3 doses of HPV vaccine administered intramuscularly
368811|NCT01381562|Drug|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
368812|NCT01381562|Drug|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
368813|NCT01381562|Other|Placebo|saline placebo
368814|NCT01381549|Drug|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
368815|NCT01381549|Drug|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
368816|NCT01381549|Other|Placebo|saline placebo
368817|NCT01381536|Drug|GSK1550188 1mg/kg or 10mg/kg|IV one shot
368818|NCT01381523|Drug|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
368819|NCT01381523|Drug|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
368820|NCT01381510|Drug|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
368821|NCT01381497|Drug|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
368822|NCT01381497|Drug|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
368823|NCT01381484|Drug|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
368824|NCT01381471|Drug|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
368825|NCT01381458|Drug|FSC|fluticasone propionate / salmeterol xinofoate combination
368826|NCT01381458|Drug|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
368827|NCT01381445|Drug|GW870086 0.2%|White to slightly coloured opaque cream
368828|NCT01381445|Drug|GW870086 2%|White to slightly coloured opaque cream
368829|NCT01381445|Drug|Clobetasol Propionate|White cream
368830|NCT01381445|Drug|Placebo|White to slightly coloured opaque cream
368831|NCT01381432|Drug|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
368832|NCT01381419|Drug|GSK1144814|Single dose.
368836|NCT01381406|Drug|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
368837|NCT01381393|Drug|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
368838|NCT01381380|Procedure|Manual therapy|Manual therapy, once a week for 8 weeks
368839|NCT01381367|Biological|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
368840|NCT01381367|Drug|Normal Saline|normal saline, 0.5ml given subcutaneously
368841|NCT01381354|Other|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
368842|NCT01381354|Device|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
368843|NCT01381354|Other|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
368844|NCT01381354|Dietary Supplement|Omega 3 fatty acids|4 grams daily by mouth.
368845|NCT01381354|Dietary Supplement|Full Spectrum vitamin|Two capsules daily.
368846|NCT01381354|Dietary Supplement|Essential - hydroxytyrosol|Two capsules twice daily.
368847|NCT01381354|Dietary Supplement|Maltodextrin fiber supplement|One scoop daily.
368848|NCT01381354|Dietary Supplement|Mineral boost (magnesium)|Two capsules daily
368849|NCT01381354|Dietary Supplement|Niacinamide|500 mg daily
368850|NCT01381354|Dietary Supplement|Methyl B12|Methyl B12 1000 mcg daily
368851|NCT01381354|Dietary Supplement|Taurine|one gram daily
368852|NCT01381354|Dietary Supplement|creatine|one teaspoon daily
368853|NCT01381354|Dietary Supplement|thiamine|100 mg daily
368854|NCT01381354|Dietary Supplement|riboflavin|200 mg daily
368855|NCT01381354|Dietary Supplement|N acetylcysteine|1 gram daily
368856|NCT01381354|Dietary Supplement|alpha lipoic acid|300 mg twice daily
368857|NCT01381354|Dietary Supplement|L acetyl carnitine|500 mg twice daily
368858|NCT01381354|Dietary Supplement|methyl folate|1000 mcg one pill four times a week
368859|NCT01381354|Dietary Supplement|coenzyme Q|100 mg daily
368860|NCT01381354|Behavioral|meditation|meditation 15 minutes daily
368861|NCT01381354|Behavioral|self massage|self massage of hands, feet, ears 15 minutes daily
368862|NCT01381354|Behavioral|learning|completing puzzles or learning 15 minutes daily
368863|NCT01381354|Dietary Supplement|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
368864|NCT01381341|Drug|linifanib|QD on Day 1 of Periods 1 and 2
368865|NCT01381315|Procedure|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur <3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
368866|NCT01381315|Procedure|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative—that the lymphedema rate is <0.13 for subjects undergoing ALND—if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
368867|NCT01381289|Drug|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
368868|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
368869|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
368870|NCT01381276|Other|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
368871|NCT01381263|Behavioral|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
368872|NCT01381263|Other|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
368873|NCT01381250|Behavioral|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
368874|NCT01381237|Behavioral|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
368875|NCT01381224|Other|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
368876|NCT01381211|Drug|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
368877|NCT01381211|Drug|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
368878|NCT01381198|Procedure|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
368879|NCT01381185|Drug|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
368880|NCT01381172|Device|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
368881|NCT01381172|Other|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
368882|NCT01381159|Behavioral|Motivational Communication|Brief MC sessions focused on medication adherence within 4-6 week period
368883|NCT01381159|Behavioral|Control|Standard medical care
368884|NCT01381146|Behavioral|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
368885|NCT01381146|Behavioral|TAU|have access to other jail programs and services
368886|NCT01381133|Behavioral|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
368887|NCT01381133|Behavioral|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
368888|NCT01381133|Behavioral|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
368889|NCT01381120|Drug|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
368890|NCT01381120|Drug|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
368891|NCT01381107|Drug|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
368892|NCT01381107|Drug|Placebo|Sublingual administration once daily for 7 consecutive days.
368893|NCT01381094|Drug|AKB-6548|oral dose administered once daily for 42 days
368894|NCT01381094|Drug|Placebo|oral placebo administered once daily for 42 days
368895|NCT01381081|Biological|platelet-rich plasma|a single intra-articular injection
368896|NCT01381081|Drug|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
368897|NCT01381068|Device|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
368898|NCT01381055|Drug|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
368899|NCT01381055|Drug|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
368900|NCT01381016|Drug|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
368901|NCT01381016|Drug|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
368902|NCT01381016|Drug|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
368903|NCT01381003|Genetic|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
368904|NCT01380990|Genetic|EF1αS-ADA lentiviral vector transduced patient Cd34+ cells|EF1αS-ADA lentiviral vector transduced patient Cd34+ cells will be infused in a volume of ~10-20 mls/kg intravenously over 30-45 minutes.
368905|NCT01380977|Behavioral|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
368906|NCT01380951|Drug|telbivudine|telbivudine 600mg/d 96 weeks
368907|NCT01380938|Drug|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight < or > 75 kg for 24 weeks (Arm A).~Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).~These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
368908|NCT01380912|Drug|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
368909|NCT01380899|Procedure|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
368910|NCT01380886|Other|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
368911|NCT01380886|Other|Infant formula powder|powdered infant formula to be fed ad libitum
368912|NCT01380873|Drug|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
368913|NCT01380873|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
368914|NCT01380873|Drug|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
368915|NCT01380860|Procedure|Colostomy with mesh implantation|Colostomy with mesh implantation
368916|NCT01380860|Procedure|Simple colostomy|Colostomy with no mesh implantation.
368917|NCT01380847|Genetic|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
368918|NCT01380834|Drug|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
368919|NCT01380834|Drug|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
368920|NCT01380821|Radiation|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
368921|NCT01380808|Drug|capecitabine and pseudomonas aeruginosa combination|capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
368922|NCT01380795|Biological|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
368923|NCT01380782|Drug|BIBF 1120|200 mg BID oral for 28 day cycle
368924|NCT01380769|Drug|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
368925|NCT01380769|Other|Best Supportive Care|best supportive care
368926|NCT01380756|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
368927|NCT01380756|Drug|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
368928|NCT01380743|Drug|duvoglustat|Single oral dose
368929|NCT01380743|Drug|rhGAA|Single intravenous infusion
368930|NCT01380730|Biological|Evolocumab|Administered by subcutaneous injection
368931|NCT01380730|Other|Placebo to Evolocumab|Administered by subcutaneous injection
368932|NCT01380717|Drug|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
368933|NCT01380717|Drug|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
368934|NCT01380704|Drug|ABT-436|QD Days 1-7
368935|NCT01380704|Drug|Matching Placebo|QD Days 1-7
368936|NCT01380691|Drug|LY2216684|Administered orally
368937|NCT01380691|Drug|Placebo-matching LY2216684|Administered orally
368938|NCT01380691|Drug|Placebo-matching alcoholic beverage|Administered orally
368939|NCT01380691|Drug|Alcoholic beverage|Administered orally
368940|NCT01380678|Drug|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
368941|NCT01380678|Drug|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
368942|NCT01380665|Device|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
368943|NCT01380652|Procedure|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
368944|NCT01380639|Other|whole body vibration training|performing squats for 3x3 minutes while using vibration platform three times a week
368945|NCT01380626|Procedure|exercise training|strength and endurance training, 5 time per week.
368946|NCT01380613|Behavioral|Workshop|10 session intervention
368947|NCT01380613|Behavioral|Workshop control|1 session intervention on standard HIV/STD information
368948|NCT01380600|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10^6 pfu/kg, 1x10^7 pfu/kg, 3x10^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
368949|NCT01380561|Drug|asimadoline|10mg [14]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
368950|NCT01380548|Dietary Supplement|Placebo|Placebo; once/day; for 12 weeks
368951|NCT01380548|Dietary Supplement|Iron alone|Iron (3 mg); once/day; for 12 weeks
368952|NCT01380548|Dietary Supplement|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
368953|NCT01380548|Dietary Supplement|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
368954|NCT01380548|Dietary Supplement|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
368955|NCT01380535|Drug|ECP Methoxsalen|Methoxsalen delivered by ECP
368956|NCT01380535|Drug|Standard of Care|Tapered prednisone with cyclosporine or tacrolimus via oral administration, consistent with local institutional practice (corticosteroids and cyclosporine A/tacrolimus)
368957|NCT01380522|Drug|Metronidazole|Capsules, single-dose, fed
368958|NCT01380522|Drug|Flagyl|Capsules, single-dose, fed
368959|NCT01380509|Drug|Metronidazole|Capsules, single-dose, fasting
368960|NCT01380509|Drug|Flagyl|Capsules, single-dose, fasting
368961|NCT01380496|Drug|doxycycline monohydrate|tablet, 100 mg, single, oral dose
368962|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
369093|NCT01379378|Device|Artificial urinary sphincter|Standard of care
368963|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
368964|NCT01380483|Drug|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
368965|NCT01380483|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
368966|NCT01380457|Drug|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
368967|NCT01380457|Drug|Marinol|Capsules, 10 mg, single-dose, fasting conditions
368968|NCT01380444|Procedure|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
368969|NCT01380444|Procedure|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
368970|NCT01380431|Drug|Lisinopril|Tablets, 40 mg, single oral dose
368971|NCT01380431|Drug|lisinopril|Tablets, 40 mg, single, oral dose
368972|NCT01380431|Drug|Lisinopril|50% of subjects received the Par formulated product.
368973|NCT01380405|Behavioral|education intervention|"Individual or collective education interventions about the correct use of inhalers.~session in the management of inhalers in the collective or individual programmed.~Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
368974|NCT01380379|Behavioral|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
368975|NCT01380366|Drug|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
368976|NCT01380366|Procedure|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
368977|NCT01380366|Procedure|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
368978|NCT01380366|Other|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
368979|NCT01380366|Other|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
368980|NCT01380366|Other|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
368981|NCT01380353|Drug|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner [B].
368982|NCT01380340|Other|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
368983|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
368984|NCT01380327|Other|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume [w/v]) was achieved.
368985|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
368986|NCT01380314|Drug|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
368987|NCT01380314|Drug|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
368988|NCT01380301|Drug|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
368989|NCT01380301|Drug|Miltefosine alone|short course (half)
368990|NCT01380288|Drug|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
368991|NCT01380275|Drug|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
368992|NCT01380275|Drug|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
368993|NCT01380249|Drug|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
368994|NCT01380236|Drug|ASM8|
368995|NCT01380223|Drug|placebo|I.V. infusion of placebo for 8 hr
368996|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
368997|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
368998|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
368999|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
369000|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
369001|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
369002|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
369003|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
369004|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
369005|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
369006|NCT01380197|Drug|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
369007|NCT01380197|Drug|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.~Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
369008|NCT01380184|Drug|ridaforolimus|4 enteric-coated tablets, each containing 10 mg ridaforolimus, orally (total daily dose: 40 mg)
369009|NCT01380158|Device|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
369010|NCT01380145|Biological|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
369011|NCT01380132|Procedure|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
369012|NCT01380119|Biological|V7|experimental arm
369013|NCT01380119|Other|placebo|placebo pill
369014|NCT01380106|Drug|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
369015|NCT01380106|Drug|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
369016|NCT01380093|Drug|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
369017|NCT01380093|Drug|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
369018|NCT01380093|Drug|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
369019|NCT01380080|Drug|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
369020|NCT01380080|Drug|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
369021|NCT01380080|Drug|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
369022|NCT01380080|Drug|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
369023|NCT01380080|Drug|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
369024|NCT01380080|Drug|Isoniazid|INH 300 mg orally once daily
369025|NCT01380054|Behavioral|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
369094|NCT01379378|Device|InVance Sling|Standard of care
369026|NCT01380028|Drug|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
369027|NCT01380028|Drug|placebo|placebo
369028|NCT01380015|Other|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
369029|NCT01380015|Other|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
369030|NCT01379989|Drug|Carboplatin|Carboplatin AUC 5
369031|NCT01379989|Drug|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
369032|NCT01379989|Drug|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
369033|NCT01379976|Drug|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
369034|NCT01379976|Drug|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).~Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
369035|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
369036|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
369037|NCT01379937|Biological|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
369038|NCT01379937|Biological|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
369039|NCT01379924|Behavioral|Modules|
369040|NCT01379924|Other|No intervention|
369041|NCT01379924|Other|No intervention|
369042|NCT01379911|Other|Yogurt|
369043|NCT01379898|Drug|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
369044|NCT01379898|Drug|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
369045|NCT01379885|Behavioral|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
369046|NCT01379885|Behavioral|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
369047|NCT01379872|Other|Non-Interventional Study|This is a non-interventional study
369048|NCT01379846|Biological|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
369049|NCT01379846|Biological|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
369050|NCT01379820|Device|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
369051|NCT01379807|Drug|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
369052|NCT01379781|Behavioral|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
369053|NCT01379768|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
369054|NCT01379768|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
369055|NCT01379768|Device|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
369056|NCT01379742|Device|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
369057|NCT01379742|Device|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
369058|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
369059|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
369095|NCT01379378|Device|AdVance Sling|Standard of care
369096|NCT01379378|Device|Virtue Sling|Standard of care
369097|NCT01379378|Drug|Contigen|2.5-10 cc
369098|NCT01379365|Device|Cryo-Touch III|Percutaneous treatment with the device
369355|NCT01377233|Drug|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
369422|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
369060|NCT01379716|Other|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
369061|NCT01379690|Other|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
369062|NCT01379677|Drug|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
369063|NCT01379677|Drug|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
369064|NCT01379664|Drug|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
369065|NCT01379664|Drug|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
369066|NCT01379651|Other|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
369067|NCT01379625|Drug|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
369068|NCT01379612|Other|Ultrasonic Elastography|Non-invasive
369069|NCT01379599|Behavioral|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
369070|NCT01379586|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
369071|NCT01379586|Drug|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
369072|NCT01379573|Drug|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
369073|NCT01379560|Drug|unoprostone isopropyl|"unoprostone isopropyl (2 drops)~placebo (2 drops)"
369074|NCT01379560|Drug|unoprostone isopropyl|"unoprostone isopropyl (3 drops)~placebo (3 drops)"
369075|NCT01379547|Behavioral|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
369076|NCT01379547|Behavioral|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
369077|NCT01379534|Drug|TKI258|
369078|NCT01379521|Drug|everolimus|
369079|NCT01379521|Drug|everolimus placebo|
369080|NCT01379508|Drug|telbivudine|600 mg film-coated tablets taken as 600 mg once daily
369081|NCT01379508|Drug|tenofovir disoproxil fumarate|300 mg tablets taken as 300 mg once daily
369082|NCT01379495|Behavioral|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
369083|NCT01379482|Drug|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.~Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.~Neo-adjuvant chemotherapy:~Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)~Hyperthermic intraoperative chemotherapy:~Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)~Early postoperative chemotherapy:~5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
369084|NCT01379469|Drug|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated, and the placebo group will receive encapsulated tablets without CBZ.
369085|NCT01379469|Drug|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
369086|NCT01379456|Procedure|physiotherapy|exercises, 20 sessions over 10 weeks
369087|NCT01379443|Other|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
369088|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intramuscularly
369089|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intradermal
369090|NCT01379417|Dietary Supplement|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
369091|NCT01379404|Device|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
369092|NCT01379391|Drug|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.~Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
369099|NCT01379339|Drug|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
369100|NCT01379339|Drug|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
369101|NCT01379339|Drug|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
369102|NCT01379339|Drug|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
369103|NCT01379339|Drug|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
369104|NCT01379326|Drug|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
369105|NCT01379313|Procedure|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
369106|NCT01379313|Procedure|1:1 ratio|I:E ratio of 1:1 is applied.
369107|NCT01379313|Procedure|2:1 group|Inverse I:E ratio of 2:1 is applied.
369108|NCT01379313|Procedure|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
369109|NCT01379300|Drug|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
369110|NCT01379300|Drug|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
369111|NCT01379287|Drug|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
369112|NCT01379274|Drug|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.~Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
369113|NCT01379261|Procedure|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
369114|NCT01379248|Device|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
369115|NCT01379235|Other|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
369116|NCT01379222|Device|Endurant Stent Graft System|The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
369117|NCT01379209|Drug|RGI-2001|A single administration of RGI-2001 on Day 0 post AHSCT.
369118|NCT01379209|Drug|Calcineurin Inhibitors|GVHD prophylaxis according to institutional guidelines. Subjects could have received any number/combinations of treatments.
369119|NCT01379209|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|According to institutional guidelines.
369120|NCT01379209|Drug|Conditioning Regimen|Myeloablative preparative treatment according to institutional guidelines. Subjects could have received any number/combinations of treatments.
369121|NCT01379209|Procedure|Allogeneic Bone Marrow Transplantation|According to institutional guidelines
369122|NCT01379209|Drug|Methotrexate|
369123|NCT01379209|Drug|Mofetil Mycophenolate|
369124|NCT01379209|Drug|sirolimus|Administered for GVHD prophylaxis as per institutional guidelines
369125|NCT01379196|Drug|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
369126|NCT01379183|Drug|Erythromycin|200 mg suspension
369127|NCT01379183|Drug|Placebo|200 mg suspension
369128|NCT01379183|Procedure|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
369129|NCT01379183|Other|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
369130|NCT01379170|Drug|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
369131|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
369132|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
369133|NCT01379144|Drug|latanoprost 75 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
369134|NCT01379144|Drug|latanoprost 100 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
369135|NCT01379144|Drug|latanoprost 125 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
369136|NCT01379144|Drug|latanoprost 50 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).~Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
369137|NCT01379105|Other|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
369138|NCT01379105|Other|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
369139|NCT01379092|Device|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
369140|NCT01379092|Device|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
369141|NCT01379079|Drug|Acetylsalicylic acid|aspirin intake at bedtime
369142|NCT01379079|Drug|Acetylsalicylic acid lysinate|aspirin intake on awakening
369143|NCT01379040|Other|Cystic Fibrosis patients|
369144|NCT01379027|Behavioral|Pure self-help Internet CBT for depression|Internet, CBT, Depression
369145|NCT01379027|Behavioral|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
369146|NCT01379027|Behavioral|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
369147|NCT01379014|Behavioral|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
369148|NCT01379014|Other|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
369149|NCT01379001|Drug|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
369150|NCT01379001|Drug|Placebo|IM or PO placebo
369151|NCT01379001|Drug|Donepezil|donepezil 5mg PO x 1
369152|NCT01378988|Drug|Dexmedetomidine|For sedation according to protocol
369153|NCT01378975|Drug|Vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
369154|NCT01378962|Drug|erlotinib|150 mg orally once a day for 12 months
369155|NCT01378949|Drug|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
369156|NCT01378949|Drug|Morphine|Morphine 1 mg/cc
369157|NCT01378936|Behavioral|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
369158|NCT01378936|Behavioral|Motivational Interview only|45 minute Motivational Interview session
369159|NCT01378923|Behavioral|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
369160|NCT01378923|Behavioral|TAU|have access to standard jail programs and services
369161|NCT01378910|Drug|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
369195|NCT01378650|Drug|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
369196|NCT01378650|Drug|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
369162|NCT01378897|Device|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
369163|NCT01378884|Drug|Domperidone|Patient to receive treatment with Domperidone
369164|NCT01378871|Drug|IMTOX-25|This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mls contains 2.5 mg IMTOX-25 15 mg/m²/cycle IV; The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7.
369165|NCT01378871|Other|IMTOX-25|Imtox-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.
369166|NCT01378858|Behavioral|Varenicline treatment as usual or directly observed therapy|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
369167|NCT01378845|Drug|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
369168|NCT01378845|Drug|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
369169|NCT01378832|Procedure|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
369170|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
369171|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
369172|NCT01378806|Behavioral|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
369173|NCT01378793|Behavioral|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
369174|NCT01378793|Behavioral|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
369175|NCT01378780|Behavioral|Educational intervention for diet and physical activity|The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
369176|NCT01378780|Behavioral|Educational message on skin cancer awareness|Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
369177|NCT01378767|Dietary Supplement|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
369178|NCT01378754|Drug|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
369179|NCT01378754|Drug|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
369180|NCT01378754|Drug|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
369181|NCT01378741|Drug|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
369182|NCT01378741|Drug|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
369183|NCT01378715|Drug|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
369184|NCT01378702|Drug|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
369185|NCT01378689|Other|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
369186|NCT01378676|Drug|Placebo (Part A)|Placebo tablets once daily for 14 days (Part A)
369187|NCT01378676|Drug|CK-2017357 (Part A)|One 125 mg CK-2017357 tablet once daily for 14 days (Part A)
369188|NCT01378676|Drug|CK-2017357 (Part A)|Two 125 mg CK-2017357 tablets once daily for 14 days (Part A)
369189|NCT01378676|Drug|CK-2017357 (Part A)|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A)
369190|NCT01378676|Drug|Riluzole 50 MG (Part B)|One 50 mg tablet once daily for 14 days (Part B)
369191|NCT01378676|Drug|Placebo (Part B)|Placebo tablets once daily for 14 days (Part B)
369192|NCT01378676|Drug|CK-2017357 (Part B)|One 125 mg tablet once daily for 14 days (Part B)
369193|NCT01378676|Drug|CK-2017357 (Part B)|Two 125 mg tablets once daily for 14 days (Part B)
369194|NCT01378676|Drug|CK-2017357 (Part B)|Three 125 mg tablets once daily for 14 days (Part B)
369423|NCT01376557|Drug|Placebo|Subjects will receive placebo once daily.
369197|NCT01378637|Device|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
369198|NCT01378624|Other|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.~The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
369199|NCT01378611|Device|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
369200|NCT01378598|Other|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
369201|NCT01378585|Drug|DLBS1033|3 x 490 mg DLBS1033 daily
369202|NCT01378585|Drug|Placebo|3 x 1 tablet daily
369203|NCT01378559|Other|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
369204|NCT01378546|Drug|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
369205|NCT01378533|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d*8cycles
369206|NCT01378520|Drug|ketoconazole|600 mg capsule oral once
369207|NCT01378520|Drug|inert powder|oral once
369208|NCT01378507|Behavioral|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
369209|NCT01378481|Drug|Vorinostat|Given PO
369210|NCT01378481|Radiation|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
369211|NCT01378481|Other|Laboratory Biomarker Analysis|Correlative studies
369212|NCT01378481|Other|Pharmacological Study|Correlative studies
369213|NCT01378481|Procedure|Therapeutic Conventional Surgery|Undergo neurosurgery
369214|NCT01378468|Other|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
369215|NCT01378455|Other|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
369216|NCT01378455|Other|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
369217|NCT01378442|Other|fitness training program|"Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.~Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.~Control:The control group will not receive fitness training program but maintain the usual life style."
369218|NCT01378429|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
369219|NCT01378429|Drug|Placebo|Placebo
369220|NCT01378416|Drug|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m^2 of decitabine.
369221|NCT01378390|Drug|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
369222|NCT01378390|Drug|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgery standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
369223|NCT01378377|Drug|Pimasertib|Pimasertib will be administered in fasted state at a dose of 45 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
369224|NCT01378377|Drug|Pimasertib|Pimasertib will be administered in fasted state at a dose of 75 mg once daily orally on Days 1 to 15. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
369225|NCT01378377|Drug|Temsirolimus|Temsirolimus will be administered at a dose of 12.5 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
369349|NCT01377285|Drug|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
369226|NCT01378377|Drug|Temsirolimus|Temsirolimus will be administered at a dose of 25 mg as intravenous infusion over a 30-60 minute period once a week within 10 minutes after administration of pimasertib on Days 1, 8 and 15 in successive 21-day cycles. Treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent.
369227|NCT01378364|Drug|AbGn-168H|single very low dose of AbGn-168H i.v.
369228|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H i.v.
369229|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
369230|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
369231|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
369232|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
369233|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H i.v.
369234|NCT01378364|Drug|AbGn-168H|single high dose of AbGn-168H i.v.
369235|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H s.c.
369236|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
369237|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
369238|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H s.c.
369239|NCT01378351|Other|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
369240|NCT01378325|Drug|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
369241|NCT01378325|Drug|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
369242|NCT01378312|Biological|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
369243|NCT01378312|Biological|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
369244|NCT01378299|Drug|Testosterone Cypionate|"Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61."
369245|NCT01378286|Drug|ARTESUNATE + AMODIAQUINE|"Pharmaceutical form:~Route of administration:"
369246|NCT01378286|Drug|Chloroquine|Pharmaceutical form:tablet Route of administration: oral
369247|NCT01378273|Drug|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
369248|NCT01378273|Other|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
369249|NCT01378247|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
369250|NCT01378234|Behavioral|Enhanced Discharge Planning Program transitional care|"Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:~Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs~Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment~Supporting caregivers to reduce stress and burden"
369251|NCT01378208|Behavioral|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|"Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.~DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)~28 days of dietary monitoring~28 days measurement by pedometer DAY 1, DAY 28 & DAY 56: Test 1~Oral glucose tolerance test with stable isotopes~Fat and muscle biopsies DAY 2, DAY 29 & DAY 57: Test 2~DXA scanning~Resting Metabolic Rate Measurement~VO2max test on bicycle~Cognitive testing~MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 & DAY 48: Test 3~Actiheart for 3 days~72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION~Fasting from 7am - 9pm~28 days of dietary monitoring~28 days measurement by pedometer"
369252|NCT01378195|Behavioral|CBT-based program for dementia caregivers|Participants will receive a CBT-based program [Cognitive Behavioral Therapy], containing videos, workbook, and website.
369253|NCT01378195|Behavioral|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
369254|NCT01378182|Genetic|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
369255|NCT01378156|Biological|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
369256|NCT01378143|Drug|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
369257|NCT01378117|Drug|Sitagliptin|Sitagliptin 50-100mg po once daily
369258|NCT01378117|Drug|glargine|glargine once daily
369259|NCT01378117|Drug|lispro|lispro before meals
369260|NCT01378104|Drug|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
369261|NCT01378104|Drug|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
369262|NCT01378091|Drug|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
369263|NCT01378091|Drug|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
369264|NCT01378091|Drug|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."
369265|NCT01378078|Device|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
369266|NCT01378078|Device|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
369267|NCT01378065|Device|Restorelle Direct Fix A&P|Restorelle Direct Fix A&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
369268|NCT01378039|Drug|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
369269|NCT01377987|Drug|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
369270|NCT01377987|Drug|Placebo|4 mg/kg, once daily before bed, for 7 days
369271|NCT01377974|Drug|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
369272|NCT01377974|Drug|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
369273|NCT01377961|Drug|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
369274|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
369275|NCT01377961|Other|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
369276|NCT01377961|Other|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
369277|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
369278|NCT01377961|Other|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
369279|NCT01377948|Behavioral|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
369280|NCT01377922|Drug|Amifampridine Phosphate|Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
369281|NCT01377922|Drug|Placebo|Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
369282|NCT01377909|Drug|statin|daily statin orally for 48 weeks
369283|NCT01377883|Other|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.~Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.~Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
369284|NCT01377883|Behavioral|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
369285|NCT01377870|Biological|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
369286|NCT01377870|Biological|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
369287|NCT01377857|Behavioral|Monetary Incentive|$1, $5, or $10 incentive
369288|NCT01377857|Behavioral|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
369289|NCT01377857|Behavioral|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
369290|NCT01377844|Drug|EGT0001442|
369291|NCT01377844|Drug|Placebo|
369292|NCT01377818|Procedure|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
369350|NCT01377259|Other|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
369293|NCT01377818|Procedure|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
369294|NCT01377818|Procedure|Both|both types of intervention
369295|NCT01377792|Drug|Hypertonic saline|comparison of different dosages of drug
369296|NCT01377779|Drug|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
369297|NCT01377779|Drug|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
369298|NCT01377753|Device|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
369299|NCT01377740|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
369300|NCT01377675|Other|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
369301|NCT01377662|Drug|OND-PR002 and MPh-IR|"Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR"
369302|NCT01377662|Other|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
369303|NCT01377636|Drug|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
369304|NCT01377623|Drug|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
369305|NCT01377623|Drug|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
369306|NCT01377610|Drug|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
369307|NCT01377610|Drug|Buprenorphine|Following detoxification with buprenorphine [8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
369308|NCT01377610|Drug|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
369309|NCT01377597|Drug|ranibizumab|
369310|NCT01377584|Behavioral|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
369311|NCT01377584|Behavioral|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
369312|NCT01377584|Device|Continuous positive airway pressure (CPAP)|CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
369313|NCT01377584|Other|No intervention|No intervention will be received.
369314|NCT01377571|Biological|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
369315|NCT01377558|Other|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices~week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week~week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week~week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
369316|NCT01377558|Other|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)~week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week~week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
369351|NCT01377246|Drug|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
369352|NCT01377246|Other|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
369353|NCT01377233|Drug|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
369354|NCT01377233|Drug|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
369421|NCT01376557|Drug|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
369317|NCT01377558|Other|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week~week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week~week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
369318|NCT01377545|Procedure|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
369319|NCT01377545|Procedure|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
369320|NCT01377532|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions. A radiation safety officer will instruct the patient, family, and caretakers about specific UCSF radiation safety guidelines for both hospitalization and discharge.
369321|NCT01377519|Procedure|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
369322|NCT01377519|Procedure|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
369323|NCT01377506|Behavioral|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
369324|NCT01377506|Behavioral|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
369325|NCT01377493|Dietary Supplement|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
369326|NCT01377480|Drug|Posaconazole|POS 40 mg/mL oral suspension
369327|NCT01377480|Drug|Placebo for posaconazole|Placebo oral suspension
369328|NCT01377480|Drug|Benznidazole|BNZ 100 mg oral tablet
369329|NCT01377467|Drug|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
369330|NCT01377441|Drug|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
369331|NCT01377441|Drug|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
369332|NCT01377428|Drug|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
369333|NCT01377428|Drug|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
369334|NCT01377415|Drug|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
369335|NCT01377389|Drug|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
369336|NCT01377389|Drug|Leuprolide|7.5 mg intramuscular once a month for 8 months
369337|NCT01377389|Drug|Goserelin|3.6 mg subcutaneous once a month for 8 months
369338|NCT01377389|Drug|Degarelix|80 mg subcutaneous once a month for 8 months
369339|NCT01377376|Drug|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
369340|NCT01377376|Drug|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
369341|NCT01377350|Device|"Pneumedicares monitoring system."|50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
369342|NCT01377350|Device|"Pneumedicares monitoring system"|Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
369343|NCT01377337|Drug|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.~Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
369344|NCT01377324|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with ~200MBq 18F-FES
369345|NCT01377311|Procedure|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
369346|NCT01377298|Drug|Pazopanib|200mg/tablet, 800mg/day PO.
369347|NCT01377285|Drug|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
369348|NCT01377285|Drug|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
369356|NCT01377233|Drug|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
369357|NCT01377233|Drug|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
369358|NCT01377220|Drug|11C-Choline|11C-Choline : 6MBq/kg on direct intravenous on one minute.
369359|NCT01377207|Procedure|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
369360|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
369361|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
369362|NCT01377194|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
369363|NCT01377168|Drug|oral naltrexone|
369364|NCT01377168|Drug|Placebo pill|
369365|NCT01377155|Drug|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
369366|NCT01377142|Device|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
369367|NCT01377142|Device|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
369368|NCT01377129|Procedure|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
369369|NCT01377129|Procedure|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
369370|NCT01377103|Drug|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
369371|NCT01377103|Drug|Placebo|
369372|NCT01377077|Procedure|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
369373|NCT01377077|Procedure|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
369374|NCT01377064|Behavioral|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
369375|NCT01377064|Other|Standard Care Group|No intervention, the group will be followed under their standard medical care.
369376|NCT01377051|Drug|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
369377|NCT01377051|Drug|Placebo|Dry powered, same to study drug, only one inhalation
369378|NCT01377038|Other|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
369379|NCT01377025|Drug|Placebo|two tablets in the morning and two in the evening.
369380|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
369381|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
369382|NCT01377012|Biological|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
369383|NCT01377012|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
369384|NCT01376999|Drug|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
369385|NCT01376986|Behavioral|physical, psychological and social activation|
369386|NCT01376960|Procedure|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
369387|NCT01376934|Procedure|procedure hysteroscopy|office hysteroscopy with gas or saline solution
369388|NCT01376921|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
369389|NCT01376908|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
369390|NCT01376908|Other|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
369391|NCT01376895|Behavioral|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
369392|NCT01376895|Behavioral|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
369393|NCT01376882|Dietary Supplement|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
369394|NCT01376882|Dietary Supplement|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
369395|NCT01376882|Dietary Supplement|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
369396|NCT01376882|Dietary Supplement|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
369397|NCT01376869|Dietary Supplement|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
369398|NCT01376869|Other|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
369399|NCT01376817|Drug|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
369400|NCT01376817|Drug|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
369401|NCT01376804|Drug|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
369402|NCT01376778|Drug|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
369403|NCT01376778|Other|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
369404|NCT01376765|Drug|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
369405|NCT01376765|Other|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
369406|NCT01376765|Biological|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
369407|NCT01376752|Procedure|Maximal cytoreductive surgery|Maximal cytoreductive surgery
369408|NCT01376752|Drug|HIPEC|HIPEC: Hyperthermic Intra-PEritoneal Chemotherapy. Administration of cisplatin at 75mg/m²
369409|NCT01376739|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
369410|NCT01376726|Biological|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
369411|NCT01376726|Biological|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.~Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
369412|NCT01376713|Biological|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
369413|NCT01376713|Biological|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.~Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
369414|NCT01376700|Biological|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
369415|NCT01376596|Behavioral|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
369416|NCT01376596|Behavioral|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
369417|NCT01376570|Behavioral|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. When participants have urines with opiates or cocaine, the value of the voucher is reset. The vouchers are part of the intervention, they are not participant compensation.
369418|NCT01376570|Behavioral|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
369419|NCT01376557|Drug|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
369420|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
369424|NCT01376544|Device|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
369425|NCT01376531|Procedure|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
369426|NCT01376518|Procedure|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
369427|NCT01376505|Biological|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
369428|NCT01376505|Biological|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
369429|NCT01376492|Other|Functioning assessment|The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
369430|NCT01376492|Other|Quality of sleep assessment|The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
369431|NCT01376479|Biological|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
369432|NCT01376479|Biological|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
369433|NCT01376479|Biological|Placebo|Phosphate Buffered Saline (PBS)
369434|NCT01376466|Other|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
369435|NCT01376453|Drug|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
369436|NCT01376453|Drug|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m^2 daily through a catheter in a large vein continuously until the last day of radiation.
369437|NCT01376453|Radiation|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
369438|NCT01376440|Other|household water treatment|household water treatment with 1.25% sodium hypochlorite
369439|NCT01376427|Drug|Dexamethasone|Dexamethasone
369440|NCT01376427|Drug|Methotrexate|Methotrexate
369441|NCT01376427|Drug|Vincristine|Vincristine
369442|NCT01376414|Other|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
369443|NCT01376401|Drug|Bendamustine|
369444|NCT01376401|Drug|Velcade|
369445|NCT01376401|Drug|Prednisone|
369446|NCT01376388|Drug|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
369447|NCT01376375|Procedure|Acupuncture|
369448|NCT01376362|Drug|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
369449|NCT01376349|Drug|prasterone|Applied vaginally
369450|NCT01376349|Other|placebo|Applied vaginally
369451|NCT01376336|Device|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
369452|NCT01376323|Drug|GSK256073 1mg|GSK256073 1mg capsule
369453|NCT01376323|Drug|GSK256073 5mg|GSK256073 5mg capsule
369454|NCT01376323|Drug|GSK256073 10mg|GSK256073 10mg capsule
369455|NCT01376323|Drug|GSK256073 25mg|GSK256073 25mg capsule
369456|NCT01376323|Drug|Placebo|placebo capsule
369457|NCT01376323|Drug|Sitagliptin 100mg|Sitagliptin 100mg capsule
369458|NCT01376310|Drug|GSK1120212|up to 2 mg/day
369459|NCT01376310|Drug|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
369460|NCT01376310|Drug|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
369461|NCT01376310|Drug|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
369462|NCT01376310|Drug|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
369463|NCT01376310|Drug|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
369464|NCT01376310|Drug|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
369465|NCT01376310|Drug|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
369466|NCT01376297|Drug|Netupitant and Palonosetron|
369467|NCT01376297|Drug|Aprepitant|
369468|NCT01376297|Drug|Palonosetron|
369469|NCT01376297|Drug|Dexamethasone|
369470|NCT01376284|Drug|Dutasteride|Collection of safety data
369471|NCT01376271|Drug|Paroxetine|
369472|NCT01376258|Drug|5ARI|dutasteride or finasteride
369473|NCT01376245|Drug|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
369474|NCT01376245|Drug|Placebo|matching placebo
369475|NCT01376232|Drug|GSK1278863|GSk1278863 100mg
369476|NCT01376232|Drug|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
369477|NCT01376232|Drug|Gemfibrozil|600 mg Gemfibrozil
369478|NCT01376219|Other|asthma control test|results of asthma control testing collected
369479|NCT01376206|Drug|Fluticasone|Collection of safety data
369480|NCT01376193|Drug|Naratriptan|Collection of safety data
369481|NCT01376180|Drug|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
369482|NCT01376167|Drug|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
369483|NCT01376167|Drug|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
369484|NCT01376167|Drug|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
369485|NCT01376167|Drug|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
369486|NCT01376167|Drug|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
369487|NCT01376167|Drug|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
369488|NCT01376167|Drug|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
369489|NCT01376167|Drug|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
369490|NCT01376167|Drug|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
369491|NCT01376167|Drug|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
369492|NCT01376167|Drug|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
369493|NCT01376154|Drug|Lamivudine|
369494|NCT01376141|Drug|Sumatriptan|
369495|NCT01376128|Drug|Paroxetine|
369496|NCT01376115|Drug|Nelarabine|
369497|NCT01376102|Drug|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
369498|NCT01376089|Drug|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
369499|NCT01376089|Drug|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
369500|NCT01376076|Drug|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
369501|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
369502|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
369503|NCT01376063|Drug|FG-4592|"FG-4592 on days 3,5,7,9~Rosiglitazone maleate on days 1 and 9"
369504|NCT01376050|Device|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
369505|NCT01376050|Device|Placebo Laser|Placebo Laser has no therapeutic output emitted.
369506|NCT01376037|Device|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
369507|NCT01376037|Device|inactive placebo laser device|non-therapeutic light application
369508|NCT01376011|Dietary Supplement|quercetin/placebo|Quercetin 500mg once per day versus placebo
369509|NCT01375998|Drug|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
369510|NCT01375985|Drug|AVI-7100|Single intravenous administration
369511|NCT01375985|Drug|Placebo|Single intravenous administration
369512|NCT01375972|Drug|S-1 plus cisplatin|S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks
369513|NCT01375972|Drug|Gemcitabine plus Cisplatin|Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks
369514|NCT01375959|Dietary Supplement|resveratrol|resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
369515|NCT01375959|Drug|Placebo|3 placebo capsules orally twice a day for 6 weeks
369516|NCT01375946|Drug|AG200-15|There will be three treatment periods. Subjects will be randomly assigned to one of the five conditions for the treatment period. The subject will be exposed daily to the condition assigned while wearing the patch. The study patch will be worn for a 7 day treatment period, followed by a 7 day washout period. The total duration of the study is 6 weeks.
369517|NCT01375933|Biological|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
369518|NCT01375920|Drug|Metyrapone|500 milligrams to be taken twice a day orally
369519|NCT01375920|Drug|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
369520|NCT01375907|Drug|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
369521|NCT01375894|Device|"imitation assessment using the 5-dt data glove."|measuring the speed of the hand during imitation
369522|NCT01375881|Drug|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
369523|NCT01375868|Biological|Silgard|vaccination with tetravalent antiviral vaccine
369524|NCT01375855|Procedure|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
369525|NCT01375842|Drug|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure </= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
369526|NCT01375829|Drug|Ixabepilone|Given IV
369527|NCT01375829|Other|Pharmacological Study|Correlative studies
369528|NCT01375829|Drug|Temsirolimus|Given IV
369529|NCT01375816|Drug|FOLFIRI 1-Bevacizumab|
369530|NCT01375816|Drug|fluorouracil|
369531|NCT01375816|Drug|irinotecan hydrochloride|
369532|NCT01375816|Drug|leucovorin calcium|
369533|NCT01375816|Drug|liposome-encapsulated irinotecan hydrochloride PEP02|
369534|NCT01375816|Drug|Bevacizumab|
369535|NCT01375803|Dietary Supplement|Novel dietary fiber|oral consumption in beverage
369536|NCT01375803|Dietary Supplement|Novel dietary fiber|Oral consumption in beverage
369537|NCT01375803|Other|Placebo|Oral consumption in beverage
369538|NCT01375790|Device|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
369539|NCT01375790|Other|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
369540|NCT01375777|Biological|Evolocumab|Administered by subcutaneous injection
369541|NCT01375777|Drug|Ezetimibe|Administered orally once a day
369542|NCT01375777|Other|Placebo to Evolocumab|Administered by subcutaneous injection
369543|NCT01375764|Biological|Evolocumab|Administered by subcutaneous injection
369544|NCT01375764|Drug|Ezetimibe|Administered orally once a day
369545|NCT01375764|Other|Placebo to Evolocumab|Administered by subcutaneous injection
369546|NCT01375751|Biological|Evolocumab|Administered by subcutaneous injection
369547|NCT01375751|Biological|Placebo|d by subcutaneous injection
369548|NCT01375738|Procedure|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30~40cm from the new gastric-jejunal junction.
369549|NCT01375738|Procedure|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
369550|NCT01375712|Dietary Supplement|Fermented milk containing Lactobacillus casei strain Shirota|A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of Lactobacillus casei strain Shirota.
369551|NCT01375712|Dietary Supplement|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
369552|NCT01375699|Drug|Doxorubicin|As prescribed by treating provider.
369553|NCT01375699|Drug|Sildenafil|Given PO, by mouth
369554|NCT01375673|Other|Exercise|Walking Strength Training Bicycling
369555|NCT01375660|Drug|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
369556|NCT01375660|Drug|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
369557|NCT01375647|Biological|IPV|Administered per protocol
369558|NCT01375647|Biological|Rotarix|Administered per protocol
369559|NCT01375634|Drug|Midazolam|2 mg intravenous over 2 minutes For patients >60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
369560|NCT01375608|Drug|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
369561|NCT01375582|Drug|B & L Soothe Lubricant Eye Drops|Eye Drop
369562|NCT01375582|Drug|Liposic EDO|Eye Drop
369563|NCT01375582|Drug|OcuFresh Eye Wash|Saline drop
369564|NCT01375569|Drug|TRC105|
369565|NCT01375556|Drug|Ethanol|
369566|NCT01375504|Behavioral|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
369567|NCT01375504|Behavioral|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
369568|NCT01375491|Drug|Doxycycline|generic doxycycline 100mg twice daily
369569|NCT01375491|Other|Placebo|Placebo comparator to doxycycline
369570|NCT01375465|Device|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
369571|NCT01375452|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
369572|NCT01375439|Other|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
369573|NCT01375426|Drug|Oral amoxicillin|
369574|NCT01375413|Behavioral|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
369575|NCT01375400|Drug|Aspirin|Administration of 300 mg of aspirin, per os.
369576|NCT01375400|Biological|blood sample|2 blood samples will be performed
369577|NCT01375387|Drug|Lacosamide|100 mg oral tablet, single dose
369578|NCT01375387|Drug|Lacosamide|Lacosamide 2 X 100 mg tablet
369579|NCT01375387|Drug|Lacosamide|Lacosamide 4 X 100mg tablet
369580|NCT01375387|Other|Placebo 3|Placebo - 3 tablets
369581|NCT01375387|Other|Placebo 4|Placebo - 4 tablets
369582|NCT01375387|Other|Placebo 2|Placebo - 2 tablets
369583|NCT01375374|Drug|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
369713|NCT01374217|Drug|Lenalidomide|Lenalidomide will be administered as it was prior to study entry.
369584|NCT01375374|Drug|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
369585|NCT01375361|Drug|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
369586|NCT01375361|Drug|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
369587|NCT01375348|Drug|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
369588|NCT01375335|Drug|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
369589|NCT01375322|Drug|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
369590|NCT01375322|Drug|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
369591|NCT01375309|Dietary Supplement|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5*10to9th bacteria per day
369592|NCT01375309|Dietary Supplement|Placebo contains dextrin|0.5 of dextrin
369593|NCT01375296|Device|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
369594|NCT01375296|Other|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
369595|NCT01375270|Procedure|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
369596|NCT01375270|Procedure|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
369597|NCT01375257|Drug|Oral treatment with antibiotics for endocarditis|
369598|NCT01375257|Drug|Guideline treatment with parenteral antibiotics|
369599|NCT01375244|Drug|Lisinopril|Tablets, 10 mg, single dose
369600|NCT01375244|Drug|Zestril|Tablets, 10 mg, single dose
369601|NCT01375231|Procedure|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
369602|NCT01375231|Procedure|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
369603|NCT01375218|Other|Pavlik Brace|Pavlik Brace
369604|NCT01375218|Other|Plastizote Brace|Plastizote Brace
369605|NCT01375205|Other|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
369606|NCT01375205|Other|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
369607|NCT01375179|Drug|KRP203|
369608|NCT01375179|Drug|Placebo matching KRP203|
369609|NCT01375153|Drug|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
369610|NCT01375153|Drug|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
369611|NCT01375140|Drug|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
369612|NCT01375140|Drug|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
369613|NCT01375140|Drug|Prednisone|"Prednisone will be added for patients who have not responded after 3 cycles of therapy.~30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."
369614|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
369615|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
369616|NCT01375114|Drug|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
369617|NCT01375114|Dietary Supplement|Placebo|Placebo by mouth twice daily for 4 weeks.
369618|NCT01375114|Behavioral|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
369619|NCT01375101|Drug|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
369620|NCT01375101|Drug|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
369621|NCT01375088|Drug|propolis|15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
369622|NCT01375075|Drug|LY2484595|Administered orally
369623|NCT01375075|Drug|Placebo|Administered orally
369624|NCT01375075|Drug|Atorvastatin|Administered orally
369625|NCT01375062|Other|analyse and proliferate the cells|"Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.~Digestion of the biopsies through controlled enzymes~Replication of the cells~Selection undifferentiated cells~Expansion of the purification cells population~Characterization of the cell population~Assessment of pluripotent and germinal cell potential.~Possible maturation of the cells."
369626|NCT01375049|Drug|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
369627|NCT01375023|Radiation|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
369628|NCT01375023|Biological|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
369629|NCT01375010|Drug|Vitamin D3|2000 mg QD
369630|NCT01375010|Other|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
369631|NCT01375010|Drug|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
370001|NCT01371981|Other|Laboratory Biomarker Analysis|Correlative studies
369632|NCT01374997|Other|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
369633|NCT01374984|Biological|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
369634|NCT01374971|Drug|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
369635|NCT01374971|Procedure|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
369636|NCT01374945|Device|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
369637|NCT01374932|Device|CPAP|Continuous positive airways pressure (CPAP)
369638|NCT01374919|Drug|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
369639|NCT01374906|Drug|pasireotide LAR|Pasireotide long-acting was administered as an intra-muscular depot intragluteal injection once every 28 days (±2 days). Patients were administered pasireotide long-acting 10 mg or 30 mg for four months, followed by either continuation of the starting dose, or dose up-titration (if mUFC was still >1.5xULN unless titration was precluded by safety reasons).
369640|NCT01374906|Drug|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
369641|NCT01374906|Drug|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
369642|NCT01374893|Behavioral|Exercise|The intervention group will perform the multi-session per day training program
369643|NCT01374893|Behavioral|Control|Usual care
369644|NCT01374854|Biological|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
369645|NCT01374854|Drug|traditional therapy|exogenous insulin injection daily
369646|NCT01374841|Drug|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
369647|NCT01374841|Other|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
369648|NCT01374828|Drug|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
369649|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
369650|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
369651|NCT01374802|Drug|Darunavir|400 mg tablet for oral administration
369652|NCT01374802|Drug|Ritonavir|tablet for oral administration
369653|NCT01374802|Drug|BI 201335|
369654|NCT01374789|Drug|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
369655|NCT01374789|Drug|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
369656|NCT01374776|Drug|Double blind, randomized, placebo controlled inter|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
369657|NCT01374763|Drug|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
369658|NCT01374763|Drug|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
369659|NCT01374750|Drug|Sirolimus|Sirolimus
369660|NCT01374750|Drug|m-TOR inhibitor free|calcineurin inhibitors
369661|NCT01374737|Drug|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
369662|NCT01374724|Behavioral|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
369663|NCT01374724|Behavioral|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
369664|NCT01374724|Behavioral|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
369665|NCT01374724|Behavioral|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
369666|NCT01374711|Drug|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
369667|NCT01374711|Drug|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
369668|NCT01374711|Other|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
369669|NCT01374698|Drug|Aspirin|Aspirin 325 mg
369670|NCT01374672|Other|laboratory biomarker analysis|Correlative studies
369671|NCT01374646|Behavioral|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
369672|NCT01374633|Drug|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
369673|NCT01374620|Drug|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~40~60~70~75~80~85~90"
370002|NCT01371981|Drug|Mitoxantrone Hydrochloride|Given IV
369674|NCT01374620|Drug|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
369675|NCT01374620|Drug|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle~1 cycle = 28 days"
369676|NCT01374620|Biological|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
369677|NCT01374581|Drug|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~Weight in kg Number of tablet per dose Age 5 to < 15 kg 1 tablet per dose 15 to < 25 kg 2 tablets per dose 25 to < 35 kg 3 tablets per dose"
369678|NCT01374581|Drug|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to < 9kg):1 tablet (25 mg/675mg) for 3 days~1 to 5 years (= 9 kg to < 18 kg)1 tablet(25mg/67,5mg)for 3 days"
369679|NCT01374581|Drug|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;~Quinine:~9 to < 11 kg: ½ tablets 12 to < 19 kg: 1 tablets per dose 20 to < 27 kg: 1½ tablets per dose 28 to < 35 kg: 2 tablets per dose~Clindamycin syrup:~10 mg/kg twice daily"
369680|NCT01374568|Drug|sitagliptin|sitagliptin 100mg daily
369681|NCT01374568|Other|Placebo|1 pill daily
369682|NCT01374542|Procedure|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
369683|NCT01374516|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
369684|NCT01374516|Biological|Placebo: (NaCl) 0.9% solution|0.5 mL, Subcutaneous
369685|NCT01374503|Biological|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
369686|NCT01374503|Biological|Placebo|single or multiple i.v. administration
369687|NCT01374490|Drug|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
369688|NCT01374464|Other|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:~High Volume, High Concentration = 15mls of 0.75% levobupivicaine~High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
369689|NCT01374451|Drug|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
369690|NCT01374451|Drug|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
369691|NCT01374438|Drug|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
369692|NCT01374438|Drug|Placebo|Placebo capsules given once daily for 90 days
369693|NCT01374425|Drug|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m^2) by IV bolus and subsequent 2400 mg/m^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
369694|NCT01374425|Drug|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
369695|NCT01374425|Drug|Irinotecan|Irinotecan 180 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
369696|NCT01374425|Drug|Leucovorin|Leucovorin 400 mg/m^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
369697|NCT01374425|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
369698|NCT01374425|Drug|Capecitabine|Capecitabine 850 or 1000 mg/m^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
369699|NCT01374399|Behavioral|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
369700|NCT01374386|Behavioral|Exergaming|Participants will have access to Exergaming equipment (video games that require physical activity)
369701|NCT01374373|Biological|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
369702|NCT01374321|Drug|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
369703|NCT01374321|Drug|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
369704|NCT01374308|Biological|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
369705|NCT01374308|Drug|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
369706|NCT01374295|Other|video|watch a 3 minute video
369707|NCT01374295|Other|standard education|Receives standard verbal education from healthcare provider
369708|NCT01374282|Drug|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
369709|NCT01374269|Other|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
369710|NCT01374269|Drug|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
369711|NCT01374230|Procedure|Total knee arthroplasty|Primary total knee arthroplasty surgery for the treatment of osteoarthritis.
369712|NCT01374217|Drug|Tadalafil|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
369714|NCT01374217|Drug|Dexamethasone|Dexamethasone will be administered as it was prior to study entry.
369715|NCT01374217|Drug|Clarithromycin|Clarithromycin will be administered as it was prior to study entry.
369716|NCT01374191|Drug|onabotulinum toxin type-A|1 injection of Btx-A
369717|NCT01374191|Other|placebo|1 injection of saline solution
369718|NCT01374191|Drug|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
369719|NCT01374178|Drug|LY2963016|Administered subcutaneously
369720|NCT01374178|Drug|Lantus|Administered subcutaneously
369721|NCT01374152|Other|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
369722|NCT01374139|Drug|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
369723|NCT01374139|Drug|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
369724|NCT01374126|Drug|Artesunate|Artesunate alone
369725|NCT01374126|Drug|Azithromycin + Artesunate|Combination of azithromycin + artesunate
369726|NCT01374113|Drug|50mg safinamide|50 mg safinamide on Day 1
369727|NCT01374100|Behavioral|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
369728|NCT01374100|Behavioral|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
369729|NCT01374087|Drug|Triptorelin 22.5 mg|Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
369730|NCT01374087|Radiation|Brachytherapy|Brachytherapy: Low or high dose rate.
369731|NCT01374061|Device|Classical intubation|Classical intubation
369732|NCT01374061|Device|GLIDESCOPE|GLIDESCOPE intubation
369733|NCT01374035|Other|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
369734|NCT01374022|Other|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
369735|NCT01374022|Other|ARDSNet Strategy|Conventional mechanical ventilation strategy.
369736|NCT01373996|Device|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|"The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.~A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System."
369737|NCT01373983|Drug|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
369738|NCT01373970|Drug|Placebo|Placebo, one tablet daily for 12 weeks
369739|NCT01373970|Drug|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
369740|NCT01373931|Drug|LY2216684|Administered orally
369741|NCT01373931|Drug|Ortho Cyclen|35 micrograms (mcg) ethinyl estradiol and 250 mcg norgestimate administered orally
369742|NCT01373931|Drug|Placebo|Administered orally
369743|NCT01373918|Drug|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
369744|NCT01373918|Drug|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
369745|NCT01373905|Procedure|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
369746|NCT01373905|Procedure|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
369747|NCT01373892|Procedure|Bariatric surgery|
369748|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
369749|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
369750|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
369751|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
369752|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
369753|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
369754|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
369755|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
369836|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
369756|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
369757|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
369758|NCT01373853|Procedure|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
369759|NCT01373853|Procedure|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
369760|NCT01373827|Device|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
369761|NCT01373801|Device|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
369762|NCT01373801|Device|Control|Standard packing gauze roll bandage.
369763|NCT01373775|Other|Patient charts reviewing|Reviewing chart and identifying risk factors
369764|NCT01373762|Behavioral|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
369765|NCT01373749|Drug|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
369766|NCT01373749|Drug|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
369767|NCT01373736|Drug|123I-meta-iodobenzylguanidine|
369768|NCT01373723|Other|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
369769|NCT01373710|Drug|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
369770|NCT01373697|Drug|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
369771|NCT01373697|Drug|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
369772|NCT01373684|Drug|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
369773|NCT01373684|Drug|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
369774|NCT01373671|Device|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
369775|NCT01373658|Device|Yinyi stent|subjects with Yinyi stent implantation
369776|NCT01373645|Device|Yinyi stent|subjects with Yinyi stent implantation
369777|NCT01373632|Device|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
369778|NCT01373632|Device|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
369779|NCT01373619|Drug|Ivabradine|ivabradine titrated to 7.5 mg BID
369780|NCT01373606|Drug|Terlipressin|
369781|NCT01373593|Drug|lidocaine|
369782|NCT01373593|Drug|Placebo|
369783|NCT01373580|Device|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
369784|NCT01373567|Drug|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
369785|NCT01373554|Drug|Placebo|30mig/bid or 60mg/bid P.O
369786|NCT01373554|Drug|Oltipraz|30mig/bid or 60mg/bid P.O
369787|NCT01373541|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
369788|NCT01373541|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
369789|NCT01373528|Drug|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
369790|NCT01373515|Biological|DCP-001|4 bi-weekly vaccinations
369791|NCT01373502|Device|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
369792|NCT01373502|Device|Taxus Liberté Stent|Taxus Liberté Coronary Stent
369793|NCT01373489|Behavioral|Technology-Assisted Case Management|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time. Medications are titrated under supervision of a primary care and endocrinology physicians
369837|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
369838|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
369794|NCT01373476|Drug|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
369795|NCT01373476|Drug|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
369796|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
369797|NCT01373463|Drug|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
369798|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
369799|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
369800|NCT01373463|Drug|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
369801|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
369802|NCT01373463|Procedure|Lobectomy|Surgery
369803|NCT01373463|Procedure|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
369804|NCT01373450|Drug|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
369805|NCT01373450|Drug|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
369806|NCT01373450|Drug|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
369807|NCT01373450|Drug|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
369808|NCT01373450|Drug|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
369809|NCT01373437|Device|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
369810|NCT01373411|Drug|ticagrelor|ticagrelor 90 mg BID for 90 days
369811|NCT01373411|Drug|Placebo|Placebo 1 pill BID for 90 days
369812|NCT01373398|Drug|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
369813|NCT01373372|Drug|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
369814|NCT01373359|Drug|Misoprostol|400 µg sublingual misoprostol
369815|NCT01373359|Drug|Oxytocin|10 IU IM
369816|NCT01373346|Procedure|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
369817|NCT01373333|Drug|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
369818|NCT01373320|Behavioral|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.~For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
369819|NCT01373307|Behavioral|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
369820|NCT01373294|Drug|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
369821|NCT01373294|Drug|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
369822|NCT01373281|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
369823|NCT01373281|Biological|Placebo: Sodium chloride (NaCl) 0.9%|0.5 mL, Subcutaneous
369824|NCT01373255|Procedure|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
369825|NCT01373242|Drug|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
369826|NCT01373229|Drug|Lenalidomide + Plerixafor (+ Rituximab)|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.~Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.~Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.~Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:~Cohort 1: 0.24 mg/kg~Cohort 2: 0.32 mg/kg~Cohort 3: 0.42 mg/kg~Cohort 4: 0.54 mg/kg~Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.~Subjects will then continue single agent lenalidomide until disease progression."
369827|NCT01373216|Drug|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
369828|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-II|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-II was published in 1993. BSID-II provides normative data from two scales - Mental Development Index (MDI), and Psychomotor Development Index (PDI).
369829|NCT01373177|Diagnostic Test|Bayley Scales of Infant Development-III|Individually administered test, designed to evaluate the developmental functioning of infants and small children, between 1 and 42 months of age. The purpose of the test is to identify infants and children with developmental delay. BSID-III was released in 2006. BSID-III provides normative data from five scales - Cognitive, Language, Motor, Social-Emotional, and Adaptive.
369830|NCT01373164|Drug|Galunisertib|Administered orally
369831|NCT01373164|Drug|Gemcitabine|Administered intravenously
369832|NCT01373164|Drug|Placebo|Administered orally
369833|NCT01373151|Drug|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
369834|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
369835|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
370003|NCT01371981|Other|Pharmacological Study|Correlative studies
369839|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
369840|NCT01373151|Drug|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
369841|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
369842|NCT01373151|Drug|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
369843|NCT01373151|Drug|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
369844|NCT01373138|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
369845|NCT01373112|Procedure|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
369846|NCT01373112|Procedure|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
369847|NCT01373099|Procedure|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
369848|NCT01373099|Procedure|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
369849|NCT01373086|Drug|LFF269|
369850|NCT01373086|Drug|Eplerenone|
369851|NCT01373086|Drug|Placebo|
369852|NCT01373073|Other|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
369853|NCT01373073|Other|Control human milk fortifier|Control human milk fortifier to be added to human milk
369854|NCT01373060|Drug|ASP1941|oral
369855|NCT01373060|Drug|Placebo|oral
369856|NCT01373047|Biological|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
369857|NCT01373034|Dietary Supplement|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
369858|NCT01373034|Dietary Supplement|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
369859|NCT01373021|Drug|Fentanyl|Fentanyl 2500mcg+NS50ml
369860|NCT01373021|Drug|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
369861|NCT01373008|Drug|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
369862|NCT01372995|Drug|Enteral Vitamin D3 50,000 IU|Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
369863|NCT01372995|Drug|Enteral Vitamin D3 100,000IU|Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)
369864|NCT01372995|Other|Inactive substance|Inactive substance given enterally for 5 days.
369865|NCT01372982|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
369866|NCT01372969|Drug|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
369867|NCT01372943|Biological|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
369868|NCT01372930|Drug|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
369869|NCT01372930|Drug|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
369870|NCT01372904|Drug|Dexamethasone Phosphate|"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.~The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."
369871|NCT01372878|Device|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
369926|NCT01372462|Device|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
369872|NCT01372878|Procedure|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.~Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
369873|NCT01372865|Drug|Mometasone furoate|
369874|NCT01372865|Drug|Mometasone furoate|
369875|NCT01372839|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
369876|NCT01372839|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
369877|NCT01372826|Drug|NKTR118 Group1|Oral dose, 25 mg
369878|NCT01372826|Drug|NKTR118 Group 2|Oral dose, 25 mg
369879|NCT01372826|Drug|NKTR118 Group3|Oral dose, 25 mg
369880|NCT01372826|Drug|NKTR118|Oral dose, 25 mg
369881|NCT01372813|Drug|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
369882|NCT01372787|Procedure|Assessment of Therapy Complications|Ancillary studies
369883|NCT01372787|Other|Medical Chart Review|Ancillary studies
369884|NCT01372787|Other|Quality-of-Life Assessment|Ancillary studies
369885|NCT01372787|Other|Questionnaire Administration|Ancillary studies
369886|NCT01372774|Radiation|stereotactic radiosurgery|Undergo RT
369887|NCT01372774|Radiation|whole-brain radiation therapy|Undergo radiotherapy (RT)
369888|NCT01372761|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
369889|NCT01372761|Drug|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
369890|NCT01372748|Other|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
369891|NCT01372748|Other|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
369892|NCT01372735|Radiation|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
369893|NCT01372735|Radiation|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
369894|NCT01372722|Device|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
369895|NCT01372722|Device|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
369896|NCT01372709|Device|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
369897|NCT01372696|Other|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
369898|NCT01372683|Other|Dietary Intervention|Comparison of oat based breakfast cereals
369899|NCT01372670|Drug|Hydroxyzine|"Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:~15-29 Kg 10 mg TID 30-44 Kg 20 mg TID~≥ 45 Kg 30 mg TID"
369900|NCT01372670|Drug|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
369901|NCT01372670|Other|Placebo|Placebo given 3 times per day
369902|NCT01372657|Other|biometry calculation|
369903|NCT01372644|Drug|SOM 230 / Pasireotide|
369904|NCT01372631|Device|miniature spectral imaging system|Use of miniature spectral imaging system
369905|NCT01372631|Device|Bench-top optical spectrometer|Use of bench-top optical spectrometer
369906|NCT01372631|Device|High resolution microendoscope|Use of high resolution microendoscope
369907|NCT01372618|Drug|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
369908|NCT01372605|Other|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
369909|NCT01372605|Other|Enhanced Usual Care|
369910|NCT01372592|Procedure|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
369911|NCT01372579|Drug|eribulin mesylate|Given IV
369912|NCT01372579|Drug|carboplatin|Given IV
369913|NCT01372579|Procedure|biopsy|Correlative studies
369914|NCT01372566|Device|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
369915|NCT01372566|Other|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
369916|NCT01372540|Drug|Carfilzomib|Given IV
369917|NCT01372540|Drug|Filanesib|Given IV
369918|NCT01372540|Other|Laboratory Biomarker Analysis|Correlative studies
369919|NCT01372527|Other|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
369920|NCT01372501|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
369921|NCT01372488|Procedure|Suture self removal|Suture self removal
369922|NCT01372488|Procedure|Suture removal by family doctor or clinic|As above
369923|NCT01372475|Device|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
369924|NCT01372475|Procedure|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
369925|NCT01372462|Device|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
369927|NCT01372462|Device|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
369928|NCT01372449|Drug|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but <60 kg, and 6 mg for subjects weighing ≥ 20 kg but < 40kg.
369929|NCT01372449|Drug|Placebo|
369930|NCT01372423|Drug|Lubiprostone|24 mcg capsules
369931|NCT01372423|Drug|Placebo|24 mcg capsules
369932|NCT01372410|Drug|GSK573719|125 mcg once daily
369933|NCT01372410|Drug|GSK573719|62.5 mcg once daily
369934|NCT01372410|Drug|GSK573719|31.25 mcg once daily
369935|NCT01372410|Drug|GSK573719|15.6 mcg once daily
369936|NCT01372410|Drug|GSK573719|31.25 mcg twice daily
369937|NCT01372410|Drug|GSK573719|15.6 mcg twice daily
369938|NCT01372410|Drug|Tiotropium|18 mcg once daily
369939|NCT01372410|Drug|Placebo|once or twice daily
369940|NCT01372384|Drug|erlotinib [Tarceva]|150 mg orally daily
369941|NCT01372371|Biological|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
369942|NCT01372371|Biological|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
369943|NCT01372371|Biological|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
369944|NCT01372358|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
369945|NCT01372345|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
369946|NCT01372306|Drug|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
369947|NCT01372293|Drug|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
369948|NCT01372280|Drug|Reminyl|Galantamine Hydrobromide Tablets 4 mg
369949|NCT01372267|Behavioral|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
369950|NCT01372267|Behavioral|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
369951|NCT01372254|Behavioral|Standard Treatment|Participants will receive a standard, individual smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 5, 90-minute group sessions over an 4-5 week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BAD-AS condition.
369952|NCT01372254|Behavioral|BAD-AS|BAD-AS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 5, 90-minute individual sessions over a 4-5 week period.
369953|NCT01372254|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
369954|NCT01372241|Behavioral|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
369955|NCT01372228|Biological|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
369956|NCT01372202|Drug|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
369957|NCT01372202|Drug|Cisplatin|"Paclitaxel and cisplatin:~Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.~Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.~Cisplatin and 5-fluorouracil:~5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.~Cisplatin 75 mg/m² days 1, 29."
369958|NCT01372202|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
369959|NCT01372202|Drug|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:~Oxaliplatin 85 mg/m2 days 1, 15, 29.~5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)~Cisplatin and 5-fluorouracil:~5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.~Cisplatin 75 mg/m² days 1, 29."
369960|NCT01372202|Radiation|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
369961|NCT01372202|Procedure|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
369962|NCT01372176|Other|Early Goal-Directed Nutrition|"Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).~Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.~Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
369963|NCT01372176|Other|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
369964|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
369965|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
369966|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
369999|NCT01371981|Drug|Daunorubicin Hydrochloride|Given IV
369967|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
369968|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
369969|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
369970|NCT01372163|Drug|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
369971|NCT01372150|Drug|desvenlafaxine succinate sustained release|Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
369972|NCT01372150|Drug|fluoxetine|Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
369973|NCT01372150|Drug|placebo|Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
369974|NCT01372137|Drug|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
369975|NCT01372137|Other|Glucose 5%|Placebo
369976|NCT01372124|Drug|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
369977|NCT01372111|Drug|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
369978|NCT01372111|Radiation|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
369979|NCT01372098|Behavioral|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
369980|NCT01372085|Drug|LY2584702 Reference Formulation|Administered orally
369981|NCT01372085|Drug|LY2584702 Test Formulation|Administered orally
369982|NCT01372085|Drug|Placebo|Administered orally
369983|NCT01372072|Device|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
369984|NCT01372059|Other|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
369985|NCT01372059|Other|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
369986|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
369987|NCT01372046|Behavioral|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
369988|NCT01372046|Behavioral|Training|memorandums, staff meetings
369989|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
369990|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
369991|NCT01372020|Other|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
369992|NCT01372007|Drug|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
369993|NCT01372007|Drug|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
369994|NCT01371994|Drug|solifenacin succinate|oral
369995|NCT01371994|Drug|Placebo|oral
369996|NCT01371981|Drug|Asparaginase|Given IM
369997|NCT01371981|Drug|Bortezomib|Given IV
369998|NCT01371981|Drug|Cytarabine|Given IT or IV
370004|NCT01371981|Other|Quality-of-Life Assessment|Ancillary studies
370005|NCT01371981|Other|Questionnaire Administration|Ancillary studies
370006|NCT01371981|Drug|Sorafenib Tosylate|Given PO
370007|NCT01371968|Drug|alfentanil|Alfentanil is administered intravenously at the end of surgery.
370008|NCT01371877|Drug|Vitamin D3|Vitamin D 4000 IU per day for 3 months
370009|NCT01371877|Drug|Vitamin D3|Vitamin D 600 IU per day
370010|NCT01371851|Drug|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
370011|NCT01371838|Drug|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
370012|NCT01371838|Drug|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
370013|NCT01371825|Drug|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase enzyme. The investigational medicinal product is an enzyme replacement therapy intended for treatment of participants with LAL Deficiency. Dosing occurred qw for up to 5 years.
370014|NCT01371812|Drug|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
370015|NCT01371812|Drug|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
370016|NCT01371799|Drug|Drug|Placebo
370017|NCT01371799|Drug|Drug|4mg and 8mg Study drug
370018|NCT01371786|Drug|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
370019|NCT01371786|Drug|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
370020|NCT01371773|Procedure|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
370021|NCT01371760|Procedure|Venous PTA|PTA of the internal jugular and/or azygous vein
370022|NCT01371760|Other|Catheter Venography|The patients will undergo catheter venography but not PTA
370023|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
370024|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
370025|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
370026|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
370027|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
370028|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
370029|NCT01371747|Drug|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
370030|NCT01371747|Drug|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
370031|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
370032|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
370033|NCT01371734|Drug|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
370034|NCT01371721|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
370035|NCT01371708|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
370036|NCT01371682|Drug|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
370037|NCT01371656|Drug|levofloxacin|Given PO or IV
370038|NCT01371643|Drug|Octreotide LAR|
370039|NCT01371643|Procedure|transsphenoidal surgery|
370040|NCT01371630|Biological|Blinatumomab|Given CIVI
370041|NCT01371630|Drug|Cyclophosphamide|Given IV
370042|NCT01371630|Drug|Cytarabine|Given IT and IV
370043|NCT01371630|Biological|Inotuzumab Ozogamicin|Given IV
370044|NCT01371630|Other|Laboratory Biomarker Analysis|Correlative studies
370045|NCT01371630|Drug|Mercaptopurine|Given PO
370046|NCT01371630|Drug|Methotrexate|Given IT, IV, and PO
370047|NCT01371630|Drug|Prednisone|Given PO
370048|NCT01371630|Biological|Rituximab|Given IV
370049|NCT01371630|Drug|Vincristine Sulfate|Given IV
370050|NCT01371617|Drug|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
370051|NCT01371604|Drug|IDX184|IDX184 50 mg tablet administered orally
370052|NCT01371604|Biological|Peginterferon alfa-2a (Peg-IFN)|Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
370053|NCT01371604|Drug|Ribavirin (RBV)|Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
370054|NCT01371604|Drug|Placebo|Matching placebo to IDX184 50 mg tablet administered orally
370055|NCT01371591|Device|Pill Cam, clinical evaluation|The Pill Cam, VCE, will be used for clinical decisions. VCE will be read by site PI or co-PI and by site GI doctor.
370056|NCT01371591|Device|Pill Cam, archived|VCE will not be used for clinical decisions. VCE video will be archived and read at a later date.
370057|NCT01371578|Drug|GS-5885 tablet|30 mg active tablet
370058|NCT01371578|Drug|GS-9451 tablet|two active 100 mg tablets
370059|NCT01371578|Biological|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
370060|NCT01371578|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
370061|NCT01371565|Drug|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
370062|NCT01371552|Device|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
370063|NCT01371552|Device|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
370064|NCT01371552|Device|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
370065|NCT01371539|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
370066|NCT01371539|Device|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
370067|NCT01371526|Drug|depot tetracosactide|1mg, 3x weekly by sc injection
370068|NCT01371513|Other|continuous screening|practice patterns for screening prostate cancer
370069|NCT01371487|Drug|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
370070|NCT01371474|Drug|Paroxetine|
370071|NCT01371461|Drug|Paroxetine|
370072|NCT01371448|Drug|Paroxetine|
370073|NCT01371435|Drug|Paroxetine|
370074|NCT01371422|Other|Paravertebral Block (PVB)|"The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).~In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level."
370075|NCT01371422|Other|Saline|Ultrasonography and local infiltration of saline will only be performed
370076|NCT01371409|Other|continuous theta burst stimulation|80% active motor threshold, 600 pulses
370077|NCT01371396|Other|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
370078|NCT01371396|Other|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
370079|NCT01371383|Dietary Supplement|Omega-3 fatty acids|1.6~2.8 gram/day (5 capsules)
370080|NCT01371383|Dietary Supplement|placebo|5 gram/day (5 capsules)
370081|NCT01371370|Other|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
370082|NCT01371370|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
370083|NCT01371370|Other|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
370084|NCT01371357|Drug|TEST 1|2.4 g/day of guanidinoacetic acid
370085|NCT01371357|Drug|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
370086|NCT01371357|Drug|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
370087|NCT01371357|Drug|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
370088|NCT01371344|Drug|Tacrolimus granules|oral
370089|NCT01371344|Drug|Tacrolimus capsules|oral
370090|NCT01371331|Drug|Tacrolimus granules|oral
370091|NCT01371318|Other|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
370092|NCT01371305|Drug|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
370093|NCT01371305|Drug|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
370094|NCT01371292|Behavioral|Transformational Teaching|Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.
370095|NCT01371292|Behavioral|Standard Educational Practices|Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
370096|NCT01371279|Device|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
370097|NCT01371266|Dietary Supplement|Honey|60.7 grams orally daily times 14 days
370098|NCT01371266|Dietary Supplement|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
370099|NCT01371266|Dietary Supplement|CHO (sugar)|50 grams daily orally times 14 days
370100|NCT01371253|Other|Nintendo wii balance training|
370101|NCT01371253|Other|EVA-soles|
370188|NCT01370642|Drug|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
371558|NCT01359982|Drug|RRx-001|Dose Level 4 (33 mg/m2)
370102|NCT01371240|Drug|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
370103|NCT01371227|Drug|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
370104|NCT01371214|Behavioral|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
370105|NCT01371201|Drug|Sunitinib|sunitinib 37.5 mg per day
370106|NCT01371201|Drug|Placebo|Placebo 37.5 mg per day
370107|NCT01371175|Biological|DNA.HIVA|0.5mg DNA.HIVA or placebo
370108|NCT01371175|Biological|MVA.HIVA|5x10^6 pfu MVA or placebo
370109|NCT01371175|Biological|MVA.HIVA|5x10^7 pfu MVA or placebo
370110|NCT01371175|Biological|MVA.HIVA|2.5x10^8 pfu MVA or placebo
370111|NCT01371162|Drug|RO5428029|Multiple ascending doses
370112|NCT01371162|Drug|placebo|multiple doses
370113|NCT01371149|Other|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
370114|NCT01371136|Procedure|curricular training|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
370115|NCT01371110|Drug|Ketamine|Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
370116|NCT01371110|Drug|Midazolam|Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
370117|NCT01371097|Other|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
370118|NCT01371084|Behavioral|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
370119|NCT01371084|Behavioral|Pedal@Work|Worksite wellness program.
370120|NCT01371058|Drug|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
370121|NCT01371058|Drug|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
370122|NCT01371058|Drug|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
370123|NCT01371045|Other|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
370124|NCT01371032|Device|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
370125|NCT01371032|Device|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
370126|NCT01371006|Drug|low dose|efavirenz single dosing once daily
370127|NCT01371006|Drug|normal dose|efavirenz once daily
370128|NCT01371006|Drug|low dose|Efavirenz single dosing once daily
370129|NCT01370967|Other|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
370130|NCT01370967|Other|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
370131|NCT01370967|Other|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
370132|NCT01370954|Other|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
370133|NCT01370941|Dietary Supplement|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
370134|NCT01370941|Dietary Supplement|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
370135|NCT01370928|Device|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
370136|NCT01370928|Device|Standard colonoscope|Screening colonoscopy
370137|NCT01370915|Drug|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
370138|NCT01370915|Drug|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
370139|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
370140|NCT01370902|Drug|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
370141|NCT01370902|Drug|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
370142|NCT01370902|Drug|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
370189|NCT01370642|Biological|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
370143|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
370144|NCT01370902|Drug|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
370145|NCT01370889|Drug|resveratrol|Given PO
370146|NCT01370889|Other|laboratory biomarker analysis|Correlative studies
370147|NCT01370876|Drug|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
370148|NCT01370863|Drug|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
370149|NCT01370863|Drug|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
370150|NCT01370837|Other|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
370151|NCT01370837|Other|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
370152|NCT01370824|Procedure|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
370153|NCT01370824|Procedure|Surgical excision|"Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds."
370154|NCT01370811|Drug|OC oral solution treatment A|
370155|NCT01370811|Drug|OC oral solution treatment B|
370156|NCT01370811|Drug|OC oral solution treatment C|
370157|NCT01370811|Drug|OC oral solution treatment D|Placebo
370158|NCT01370798|Drug|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
370159|NCT01370798|Drug|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
370160|NCT01370798|Procedure|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
370161|NCT01370798|Radiation|Wrist X ray|Wrist X ray to follow the degree of bone maturation
370162|NCT01370798|Procedure|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
370163|NCT01370772|Drug|Rituximab|"Cycle 1 Rituximab : 375 mg/m² i.v on day 1~Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
370164|NCT01370772|Drug|Rituximab|"Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15~Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
370165|NCT01370772|Drug|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
370166|NCT01370772|Drug|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
370167|NCT01370759|Other|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
370168|NCT01370733|Device|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
370169|NCT01370733|Device|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
370170|NCT01370720|Dietary Supplement|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
370171|NCT01370720|Other|Placebo|tablets, 2tablets/day, 12 weeks
370172|NCT01370707|Drug|Metformin|1000~1500mg/day, 24weeks
370173|NCT01370707|Drug|CJ-30001/CJ-30002|0.6/1500mg~0.9/1500mg/day, 24weeks
370174|NCT01370694|Drug|MK-8808|
370175|NCT01370694|Drug|cyclophosphamide|
370176|NCT01370694|Drug|vincristine|
370177|NCT01370694|Drug|prednisolone|
370178|NCT01370681|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001|
370179|NCT01370681|Drug|Period I : CJ30001, Period II : HKB0701 and SLM0807|
370180|NCT01370668|Behavioral|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
370181|NCT01370668|Behavioral|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
370182|NCT01370668|Behavioral|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
370183|NCT01370655|Drug|MK-7145|
370184|NCT01370655|Drug|Hydrochlorothiazide (HCTZ)|
370185|NCT01370655|Drug|Placebo to MK-7145|
370186|NCT01370655|Drug|Placebo to HCTZ|
370187|NCT01370642|Drug|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
370190|NCT01370642|Drug|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
370191|NCT01370629|Drug|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
370192|NCT01370616|Drug|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
370193|NCT01370616|Drug|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
370194|NCT01370616|Drug|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
370195|NCT01370616|Drug|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
370196|NCT01370603|Drug|Atorvastatin|40 mg tablet administered orally once daily
370197|NCT01370603|Drug|Ezetimibe|10 mg tablet administered orally once daily
370198|NCT01370603|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
370199|NCT01370603|Drug|Placebo to atorvastatin|Administered orally once daily
370200|NCT01370603|Drug|Placebo to ezetimibe|Administered orally once daily
370201|NCT01370603|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
370202|NCT01370590|Drug|Atorvastatin|20 mg tablet administered orally once daily
370203|NCT01370590|Drug|Ezetimibe|10 mg tablet administered orally once daily
370204|NCT01370590|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
370205|NCT01370590|Drug|Placebo to atorvastatin|Administered orally once daily
370206|NCT01370590|Drug|Placebo to ezetimibe|Administered orally once daily
370207|NCT01370590|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
370208|NCT01370564|Drug|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
370209|NCT01370551|Drug|Gynoflor|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
370210|NCT01370538|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
370211|NCT01370525|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
370212|NCT01370512|Drug|Droxidopa|100 mg t.i.d. for 2 days; then 200 mg t.i.d. for another 2 days
370213|NCT01370512|Drug|Pyridostigmine Bromide|180 mg daily for 4 days
370214|NCT01370499|Drug|LY2216684|
370215|NCT01370499|Drug|SSRI|Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.
370216|NCT01370486|Drug|melatonin|melatonin cp 2 mg 1x/d for 1 month
370217|NCT01370486|Drug|placebo|placebo cp 1x/d for 1 month
370218|NCT01370460|Drug|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
370219|NCT01370460|Drug|Placebo|100mL 0.9% sterile saline
370220|NCT01370447|Drug|EPI-743|EPI-743 is administered as a dose escalation from 50 mg bid to 100 mg tid
370221|NCT01370434|Drug|PAD combination|"Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11~Doxorubicin 9 mg/m2/d iv on D 1-4~Dexamethasone 40mg/d po or iv on D1-4, 8-11"
370222|NCT01370408|Drug|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
370223|NCT01370408|Drug|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
370224|NCT01370408|Drug|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
370225|NCT01370369|Drug|Testosterone gel (FE 99903)|
370226|NCT01370356|Drug|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
370227|NCT01370356|Drug|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
370228|NCT01370343|Drug|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
370229|NCT01370343|Drug|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
370230|NCT01370330|Drug|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present over 120 minutes.
370231|NCT01370317|Drug|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
370232|NCT01370317|Drug|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
370233|NCT01370304|Other|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
370234|NCT01370304|Other|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
370235|NCT01370304|Other|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region~Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
370236|NCT01370291|Other|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
370295|NCT01369862|Biological|Placebo|SPGNH buffer
370296|NCT01369849|Drug|Akt Inhibitor MK2206|Given PO
370237|NCT01370291|Other|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
370238|NCT01370291|Other|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
370239|NCT01370278|Other|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
370240|NCT01370278|Other|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
370241|NCT01370265|Drug|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
370242|NCT01370265|Drug|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
370243|NCT01370265|Drug|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
370244|NCT01370239|Biological|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
370245|NCT01370226|Behavioral|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
370246|NCT01370226|Behavioral|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
370247|NCT01370213|Drug|Preparative Regimen|"Preparative Regimen:~1) fludarabine 40 mg/m^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
370248|NCT01370213|Biological|NK Cells|CD3^- CD19^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
370249|NCT01370213|Drug|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
370250|NCT01370213|Biological|Anti-thymocyte globulin|rabbit anti-thymocyte globulin will be administered on day -5 (0.5 mg/kg) and day -4 (2.5 mg/kg) pretransplant per institutional guidelines
370251|NCT01370213|Biological|Donor TCR α/β-depleted Cells|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10^6/kg) on day 0
370252|NCT01370200|Procedure|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
370253|NCT01370187|Drug|Montelukast|Montelukast 4mg daily for 2 months
370254|NCT01370174|Other|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
370255|NCT01370161|Procedure|TIPS treatment|"A 8 mm Fluency stent will be used. The aim will be to reduce the portal pressure gradient (PPG) below to 12 mm Hg or 25-75% of baseline.~Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of large portosystemic collaterals feeding the varices.~After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted."
370256|NCT01370161|Drug|Medical treatment|"Patients will receive vasoactive drugs up to 5 days; then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg, the dose of propranolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm, or 25% reduction of basal heart rate or up to the maximum tolerated dose of propranolol.~The second elective session of endoscopic band ligation will be performed within the first 7-14 days after the initial endoscopic treatment. The following sessions will be performed at 14 +/- 3 days intervals until variceal eradication. Once eradication is achieved, endoscopic monitoring will be performed every 6 months. If varices reappear, new band ligation will be performed."
370257|NCT01370148|Drug|conivaptan hydrochloride|Intravenous
370258|NCT01370135|Drug|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
370259|NCT01370122|Other|Survey|
370260|NCT01370096|Drug|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
370297|NCT01369849|Drug|Bendamustine Hydrochloride|Given IV
370298|NCT01369849|Other|Laboratory Biomarker Analysis|Correlative studies
370299|NCT01369849|Biological|Rituximab|Given IV
370300|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 20 mg capsule
370261|NCT01370096|Drug|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
370262|NCT01370083|Behavioral|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
370263|NCT01370083|Behavioral|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
370264|NCT01370070|Drug|MK-2206|200mg weekly repeated q 28 days
370265|NCT01370057|Device|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
370266|NCT01370044|Drug|Carbogen|3 minutes administration of carbogen
370267|NCT01370044|Drug|Placebo|3 minutes administration of oxygen
370268|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
370269|NCT01370031|Drug|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
370270|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
370271|NCT01370031|Drug|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
370272|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose used will depend on the patient's body weight. For example, a patient weighing 150 pounds would be infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients will be admitted to hospital for infusion. The I.V. infusion will be approximately 1 teaspoon/minute. Patients will receive weekly infusions of Zemaira® for 8 or 12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood will be collected (IRB approval #R04-003). The blood sample will be used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
370273|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose used was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of Zemaira® for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
370274|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of Zemaira® for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
370275|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The alpha-1-Proteinase Inhibitor dose used was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
370276|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
370277|NCT01370005|Drug|BI 10773|BI 10773 high dose once daily
370278|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
370279|NCT01370005|Drug|BI 10773|BI 10773 low dose once daily
370280|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
370281|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
370282|NCT01369979|Procedure|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
370283|NCT01369927|Biological|Shigella Sonnei O-SPC/rBRU|
370284|NCT01369901|Behavioral|A functional exercise program|
370285|NCT01369901|Behavioral|A stretching exercise program|
370286|NCT01369888|Drug|Cyclophosphamide|60 mg/m^2, intravenous (IV) (in the vein) x 2 days
370287|NCT01369888|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
370288|NCT01369888|Biological|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
370289|NCT01369888|Drug|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
370290|NCT01369875|Drug|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
370291|NCT01369875|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
370292|NCT01369875|Biological|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
370293|NCT01369875|Biological|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
370294|NCT01369862|Biological|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
370301|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 40 mg capsule.
370302|NCT01369836|Drug|Placebo|A single oral dose of matched placebo.
370303|NCT01369797|Other|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
370304|NCT01369771|Drug|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
370305|NCT01369758|Device|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
370306|NCT01369745|Drug|Prednisolone|Prednisolone 2.7 mg daily
370307|NCT01369745|Drug|dipyridamole|dipyridamole 360 mg daily
370308|NCT01369745|Drug|Prednisone|Prednisone 5 mg daily
370309|NCT01369745|Drug|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
370310|NCT01369745|Other|placebo|
370311|NCT01369732|Drug|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
370312|NCT01369732|Drug|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
370313|NCT01369719|Drug|osveral|receive 20 mg/kg daily orally
370314|NCT01369719|Drug|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
370315|NCT01369706|Device|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
370316|NCT01369693|Procedure|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
370317|NCT01369680|Drug|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
370318|NCT01369667|Dietary Supplement|Vitamin D3|
370319|NCT01369667|Other|Placebo|
370320|NCT01369654|Behavioral|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
370321|NCT01369641|Procedure|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
370322|NCT01369641|Drug|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
370323|NCT01369641|Other|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
370324|NCT01369641|Drug|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
370325|NCT01369628|Drug|Atacicept|"Regimen 1: Atacicept 25 mg weekly for 12 weeks~Regimen 2: Atacicept 75 mg weekly for 12 weeks~Regimen 3: Atacicept 150 mg weekly for 12 weeks"
370326|NCT01369615|Drug|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
370327|NCT01369602|Drug|PF-04991532|single dose 300-mg
370328|NCT01369602|Drug|PF-04991532|single dose 300-mg
370329|NCT01369602|Drug|PF-04991532|single dose 300-mg
370330|NCT01369602|Drug|PF-04991532|single dose 300-mg
370331|NCT01369589|Drug|P-552|P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
370332|NCT01369589|Drug|Placebo|Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
370333|NCT01369576|Drug|Placebo|3.75-7.5mg 14 doses 4 weeks
370334|NCT01369576|Drug|Zopiclone|3.75-7.5mg 14 doses 4 weeks
370335|NCT01369550|Other|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
370336|NCT01369550|Other|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
370337|NCT01369550|Other|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
370338|NCT01369511|Drug|LY2495655|Administered subcutaneously
370339|NCT01369511|Drug|Placebo|Administered subcutaneously
370340|NCT01369498|Drug|Simtuzumab|Simtuzumab 200 mg or 700 mg administered intravenously over approximately 30 minutes every 2 weeks
370341|NCT01369498|Drug|Ruxolitinib|In stage 2, participants will be on a stable dose of ruxolitinib and will continue their treatment in combination with simtuzumab
370342|NCT01369485|Device|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
370343|NCT01369485|Device|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
370344|NCT01369472|Drug|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
370375|NCT01369290|Other|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
370410|NCT01369095|Drug|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
370345|NCT01369459|Behavioral|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
370346|NCT01369446|Device|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
370347|NCT01369433|Drug|Tivozanib + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
370348|NCT01369433|Drug|Tivozanib + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
370349|NCT01369433|Drug|Tivozanib|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
370350|NCT01369433|Drug|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
370351|NCT01369433|Drug|Tivozanib + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
370352|NCT01369433|Drug|Tivo|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
370353|NCT01369420|Device|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
370354|NCT01369407|Other|No Intervention|Not an interventional study
370355|NCT01369394|Other|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
370356|NCT01369381|Procedure|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
370357|NCT01369368|Drug|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
370358|NCT01369355|Drug|Placebo SC|Placebo will be administered subcutaneously.
370359|NCT01369355|Drug|Placebo IV|Placebo will be administered as a single Intravenous infusion at week 0.
370360|NCT01369355|Drug|Ustekinumab 90 mg SC q8w|Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
370361|NCT01369355|Drug|Ustekinumab 130 mg IV|Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
370362|NCT01369355|Drug|Ustekinumab 90 mg SC q12w|Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
370363|NCT01369342|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
370364|NCT01369342|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
370365|NCT01369342|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
370366|NCT01369329|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
370367|NCT01369329|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
370368|NCT01369329|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
370369|NCT01369316|Procedure|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
370370|NCT01369316|Procedure|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
370371|NCT01369303|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
370372|NCT01369290|Drug|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
370373|NCT01369290|Drug|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
370374|NCT01369290|Drug|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
370376|NCT01369290|Drug|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
370377|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
370378|NCT01369277|Drug|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
370379|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
370380|NCT01369264|Device|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
370381|NCT01369264|Device|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
370382|NCT01369251|Behavioral|Hygiene|
370383|NCT01369251|Procedure|Usual alcohol care|
370384|NCT01369238|Device|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2~3days/wk, for 1 month
370385|NCT01369238|Drug|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
370386|NCT01369225|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
370387|NCT01369225|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
370388|NCT01369225|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
370389|NCT01369225|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
370390|NCT01369225|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
370391|NCT01369212|Drug|Tenofovir|300 mg daily for 192 weeks (4 years)
370392|NCT01369212|Drug|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
370393|NCT01369199|Drug|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
370394|NCT01369186|Drug|Morphine|i.v. bolus injection
370395|NCT01369186|Drug|Placebo|i.v. bolus injection
370396|NCT01369173|Other|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
370397|NCT01369160|Behavioral|Quality of Life measures|measuring QOL with different therapies
370398|NCT01369147|Drug|Parenteral nutrition energy dose at 0.6 x measured REE|Participants will be provided a total daily calorie (kcal) intake from parenteral nutrition (PN), dextrose-containing IV fluids (> 500 mL/day), propofol/clevidipine, and any enteral feedings at 0.6 x baseline metabolic energy expenditure (MEE). Total energy dosing based on real-time REE measurements will be adjusted during the ICU stay. The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL) or clevidipine (2 kcal/mL), and any dextrose-containing IV fluid orders exceeding 500 mL/day. Participants will receive a maximum of 28 days of the double blind study energy dose and will be transitioned from PN to enteral feeds as soon as tolerated and clinically indicated.
370399|NCT01369147|Drug|Parenteral nutrition energy dose at 1.0 x measured REE|Participants will be provided a total daily calorie (kcal) intake from parenteral nutrition (PN), dextrose-containing IV fluids (> 500 mL/day), propofol/clevidipine, and any enteral feedings at 1.0 x baseline metabolic energy expenditure (MEE). Total energy dosing based on real-time REE measurements will be adjusted during the ICU stay. The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL) or clevidipine (2 kcal/mL), and any dextrose-containing IV fluid orders exceeding 500 mL/day. Participants will receive a maximum of 28 days of the double blind study energy dose and will be transitioned from PN to enteral feeds as soon as tolerated and clinically indicated.
370400|NCT01369147|Drug|Parenteral nutrition energy dose at 1.3 X measured REE|Participants will be provided a total daily calorie (kcal) intake from parenteral nutrition (PN), dextrose-containing IV fluids (> 500 mL/day), propofol/clevidipine, and any enteral feedings at 1.3 x baseline metabolic energy expenditure (MEE). Total energy dosing based on real-time REE measurements will be adjusted during the ICU stay. The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL) or clevidipine (2 kcal/mL), and any dextrose-containing IV fluid orders exceeding 500 mL/day. Participants will receive a maximum of 28 days of the double blind study energy dose and will be transitioned from PN to enteral feeds as soon as tolerated and clinically indicated.
370401|NCT01369134|Device|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
370402|NCT01369121|Drug|XERECEPT|BID dosing, subcutaneous for 1 year
370403|NCT01369108|Device|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
370404|NCT01369108|Device|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
370405|NCT01369095|Drug|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C&D)
370406|NCT01369095|Drug|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C&D)
370407|NCT01369095|Drug|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B&C)
370408|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
370409|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
370411|NCT01369095|Drug|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
370412|NCT01369082|Drug|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
370413|NCT01369069|Drug|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
370414|NCT01369069|Drug|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
370415|NCT01369056|Behavioral|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
370416|NCT01369043|Dietary Supplement|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
370417|NCT01369030|Other|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
370418|NCT01369017|Drug|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
370419|NCT01369017|Drug|Placebo|Injection of NS
370420|NCT01369004|Behavioral|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
370421|NCT01368991|Device|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
370422|NCT01368991|Procedure|Conventional closure|conventional closure, no kryptonite applied
370423|NCT01368978|Device|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
370424|NCT01368965|Device|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
370425|NCT01368952|Device|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
370426|NCT01368926|Drug|RO4917523|single oral doses
370427|NCT01368926|Drug|RO4917523|multiple oral doses
370428|NCT01368926|Drug|placebo|oral doses
370429|NCT01368900|Device|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
370430|NCT01368887|Drug|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
370431|NCT01368887|Other|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
370432|NCT01368887|Drug|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
370433|NCT01368887|Drug|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
370434|NCT01368874|Device|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
370435|NCT01368848|Drug|Bevacizumab|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging~-> further 3 cycles BCD Q3W -> Bevacizumab Q3W until progression"
370436|NCT01368848|Drug|Cisplatin|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging~-> further 3 cycles BCD Q3W"
370437|NCT01368848|Drug|Docetaxel|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging~-> further 3 cycles BCD Q3W"
370438|NCT01368835|Device|Ulthera treatment|treatment of cheeks and upper neck area of face
370439|NCT01368809|Drug|Saline|2 ml at induction 1-2 ml boluses as needed
370440|NCT01368809|Drug|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
370441|NCT01368796|Biological|Agriflu|0.5mL dose IM vaccination
370442|NCT01368796|Biological|Fluad|0.5mL dose of vaccine given IM
370443|NCT01368796|Biological|Intanza|0.5mL dose vaccine given IM
370444|NCT01368796|Biological|Vaxigrip|0.5mL dose vaccine given IM
370445|NCT01368783|Drug|atazanavir|400 mg/day for 2 days
370446|NCT01368783|Drug|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
370447|NCT01368783|Drug|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
370448|NCT01368783|Drug|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
370449|NCT01368770|Other|Coronary CTA|Coronary CTA using standard protocols
370450|NCT01368770|Other|Stress MPI SPECT|Stress MPI using standard protocols
370728|NCT01366534|Biological|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
370451|NCT01368757|Drug|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients~The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.~Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
370452|NCT01368744|Device|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Groups: OSNA Breast Cancer System"
370453|NCT01368731|Procedure|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
370454|NCT01368718|Procedure|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
370455|NCT01368705|Dietary Supplement|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
370456|NCT01368705|Dietary Supplement|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
370457|NCT01368705|Dietary Supplement|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
370458|NCT01368692|Procedure|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
370459|NCT01368692|Procedure|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
370460|NCT01368679|Procedure|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
370461|NCT01368666|Device|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
370462|NCT01368653|Behavioral|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
370463|NCT01368653|Behavioral|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
370464|NCT01368653|Drug|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
370465|NCT01368627|Device|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
370466|NCT01368614|Device|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
370467|NCT01368614|Device|Respironics OnmiLab BiPAP S mode|Currently cleared Non-Invasive Ventilation (NIV) therapy modality
370468|NCT01368614|Device|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
370469|NCT01368601|Procedure|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
370470|NCT01368588|Radiation|radiation therapy|Undergo RT using IMRT or 3D-CRT
370471|NCT01368588|Radiation|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
370472|NCT01368575|Procedure|CABG|CABG
370473|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
370474|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
370475|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
370476|NCT01368575|Procedure|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
370477|NCT01368562|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the arm.
370478|NCT01368549|Other|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
370479|NCT01368536|Drug|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
370480|NCT01368536|Drug|Amlodipine|Amlodipine 5 mg and 10 mg capsule
370481|NCT01368536|Drug|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
370482|NCT01368536|Drug|Placebo of Valturna Tablet|Matching placebo of valturna tablet
370483|NCT01368536|Drug|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
370484|NCT01368523|Drug|nilotinib|
370485|NCT01368510|Behavioral|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
370486|NCT01368510|Behavioral|Waitlist|Minimal contact waitlist weekly for 4 weeks
370770|NCT01366261|Device|rigid thoracoscopy|thoracoscopy with rigid instrument
370487|NCT01368497|Drug|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
370488|NCT01368484|Dietary Supplement|Sunflower oil|1500 mg sunflower/day for 10 weeks
370489|NCT01368484|Dietary Supplement|Docosahexanoic acid|1500mg/day for 10 weeks
370490|NCT01368471|Device|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
370491|NCT01368471|Device|Control BMS or DES|Control BMS or DES
370492|NCT01368458|Other|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
370493|NCT01368445|Drug|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM & PM)
370494|NCT01368445|Drug|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
370495|NCT01368445|Drug|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM)
370496|NCT01368432|Drug|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
370497|NCT01368432|Drug|Placebo|Sugar pill placebo
370498|NCT01368419|Drug|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
370499|NCT01368419|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
370500|NCT01368406|Behavioral|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
370501|NCT01368393|Procedure|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
370502|NCT01368393|Procedure|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
370503|NCT01368380|Behavioral|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
370504|NCT01368367|Other|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
370505|NCT01368354|Behavioral|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
370506|NCT01368341|Drug|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
370507|NCT01368341|Drug|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
370508|NCT01368341|Drug|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
370509|NCT01368328|Dietary Supplement|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
370510|NCT01368315|Drug|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
370511|NCT01368315|Drug|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
370512|NCT01368315|Drug|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
370513|NCT01368315|Drug|No intervention|No intervention to one out of four test fields marked on the patient's back.
370514|NCT01368302|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
370515|NCT01368289|Procedure|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
370516|NCT01368276|Biological|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
370517|NCT01368276|Drug|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
370518|NCT01368263|Drug|goserelin acetate|Given SC
370519|NCT01368263|Drug|letrozole|Given PO
370520|NCT01368263|Drug|anastrozole|Given PO
370521|NCT01368263|Drug|chemotherapy|Standard chemotherapy
370522|NCT01368263|Procedure|Surgery|
370523|NCT01368250|Procedure|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
370729|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
370524|NCT01368237|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
370525|NCT01368224|Dietary Supplement|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|"1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.~Oral route."
370526|NCT01368211|Biological|2-4-day-old Mirasol-treated Platelets Transfusion|"2-4-day-old Mirasol-treated Platelets Units with:~Platelet yield between 2.4x10e11 and 4.5x10e11~Plasma carryover of >32%~Cell count > 800x103/µL"
370527|NCT01368211|Biological|2-4-day-old Untreated Platelets Transfusion|"2-4-day-old Untreated Platelets Units with:~Platelet yield between 2.4x10e11 and 4.5x10e11~Plasma carryover of >32%~Cell count > 800x103/µL"
370528|NCT01368198|Other|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
370529|NCT01368198|Other|OPTIVE™|One instillation of the eye drop in each eye
370530|NCT01368172|Behavioral|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
370531|NCT01368159|Device|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
370532|NCT01368146|Device|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
370533|NCT01368146|Device|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
370534|NCT01368146|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
370535|NCT01368120|Device|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
370536|NCT01368120|Device|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
370537|NCT01368120|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
370538|NCT01368107|Drug|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
370539|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
370540|NCT01368107|Drug|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
370541|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
370542|NCT01368094|Procedure|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
370543|NCT01368094|Procedure|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
370544|NCT01368081|Drug|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
370545|NCT01368081|Drug|BI 10773|BI 10773 low dose tablet once daily
370546|NCT01368081|Drug|Placebo (low dose)|Placebo tablets once daily
370547|NCT01368081|Drug|BI 10773|BI 10773 high dose tablet once daily
370548|NCT01368081|Drug|Placebo (high dose)|Placebo tablets once daily
370549|NCT01368068|Drug|Tibolone|2.5mg/oral/daily
370550|NCT01368068|Drug|Escitalopram|10mg/oral/daily
370551|NCT01368068|Drug|Natvia|serving size: 0.09g per tablet
370552|NCT01368055|Radiation|70 Gy/CGE|Low Risk
370553|NCT01368055|Radiation|72.5 Gy/CGE|Intermediate Risk
370554|NCT01368029|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
370555|NCT01368029|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
370556|NCT01368016|Drug|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
370557|NCT01368016|Drug|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
370558|NCT01368003|Drug|STA9090|200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
370559|NCT01368003|Drug|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
370560|NCT01367990|Drug|Norepinephrine|"The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments)."
370561|NCT01367964|Drug|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
370730|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
370771|NCT01366235|Drug|chloroquine phosphate 1000 mg|1000 mg, 1day
370562|NCT01367951|Procedure|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws~Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.~Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.~Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
370563|NCT01367938|Device|OMNI Apex Ultracongruent Knee Device|
370564|NCT01367925|Device|Stryker Triathlon® CS Tibial Insert|
370565|NCT01367925|Device|Stryker Triathlon® PS Tibial Insert|
370566|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
370567|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
370568|NCT01367886|Drug|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
370569|NCT01367873|Drug|Placebo|Oral, matching number of placebo capsule(s) with active arm
370570|NCT01367873|Drug|VIA-3196|Oral, capsule(s)
370571|NCT01367860|Procedure|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
370572|NCT01367860|Procedure|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
370573|NCT01367847|Behavioral|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon & Forehand) for parents of 3 to 8 y.o. children with externalizing problems
370574|NCT01367847|Behavioral|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
370575|NCT01367834|Drug|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
370576|NCT01367808|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
370577|NCT01367808|Drug|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
370578|NCT01367808|Drug|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
370579|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
370580|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
370581|NCT01367769|Other|No intervention|There will be no intervention in this study.
370582|NCT01367756|Drug|RO4995819|multiple oral doses, Days 10-16
370583|NCT01367756|Drug|citalopram|multiple oral doses, Days 1-16
370584|NCT01367756|Drug|placebo|multiple oral doses, Days 10-16
370585|NCT01367743|Drug|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
370586|NCT01367743|Drug|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
370587|NCT01367717|Dietary Supplement|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
370588|NCT01367717|Dietary Supplement|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
370589|NCT01367704|Behavioral|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
370590|NCT01367691|Device|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
370591|NCT01367678|Device|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
370592|NCT01367678|Device|i-Gel extraglottic airway device|Directly measured mucosal pressures
370593|NCT01367665|Drug|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
370594|NCT01367652|Drug|Letrozole|2.5 mg tablet
370595|NCT01367652|Drug|Letrozole|2.5 mg Tablet
370655|NCT01367223|Dietary Supplement|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
371559|NCT01359982|Drug|RRx-001|Dose Level 5 (55.0 mg/m2)
370596|NCT01367639|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
370597|NCT01367626|Drug|letrozole|2.5 mg tablet
370598|NCT01367626|Drug|letrozole|2.5 mg tablet
370599|NCT01367613|Drug|SC Methylnaltrexone|
370600|NCT01367600|Drug|SC Methylnaltrexone (MNTX)|
370601|NCT01367587|Drug|IV Methylnaltrexone|
370602|NCT01367574|Drug|SC MNTX|Dose 1
370603|NCT01367574|Drug|SC MNTX|Dose 2
370604|NCT01367574|Drug|SC MNTX|Dose 3
370605|NCT01367561|Drug|Naloxone|
370606|NCT01367561|Drug|IV Methylnaltrexone (MNTX)|
370607|NCT01367561|Drug|Placebo|
370608|NCT01367548|Drug|IV Methylnaltrexone (MNTX)|
370609|NCT01367548|Drug|Placebo|
370610|NCT01367535|Drug|SC Methylnaltrexone (MNTX)|
370611|NCT01367535|Drug|IV Methylnaltrexone (MNTX)|
370612|NCT01367535|Drug|Oral Paroxetine|
370613|NCT01367535|Drug|SC Placebo|
370614|NCT01367522|Drug|SC Methylnaltrexone (MNTX)|
370615|NCT01367509|Drug|Methylnaltrexone (MNTX)|
370616|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 1
370617|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 2
370618|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 3
370619|NCT01367496|Drug|IV Methylnaltrexone (MNTX)|
370620|NCT01367483|Drug|IV methylnaltrexone (MNTX)|
370621|NCT01367470|Dietary Supplement|VSL#3 probiotic preparation|VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
370622|NCT01367470|Other|Placebo VSL#3|Placebo VSL#3 is a base of corn starch containing no active ingredient.
370623|NCT01367457|Other|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
370624|NCT01367444|Drug|SAR422459|Pharmaceutical form: sterile solution Route of administration: subretinal injection
370625|NCT01367431|Dietary Supplement|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
370626|NCT01367418|Drug|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
370627|NCT01367418|Drug|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
370628|NCT01367405|Procedure|Surgical decompression|Surgical decompression within 24 hour postinjury
370629|NCT01367405|Procedure|Conservative treatment|Usual conservative treatment without surgery
370630|NCT01367392|Device|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
370631|NCT01367379|Procedure|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
370632|NCT01367379|Other|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2~4 times/month)
370633|NCT01367366|Procedure|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
370634|NCT01367353|Procedure|surgery or debulking surgery|surgery or debulking surgery
370635|NCT01367340|Behavioral|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
370636|NCT01367340|Behavioral|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
370637|NCT01367327|Behavioral|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
370638|NCT01367327|Behavioral|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
370639|NCT01367314|Drug|NVC-422|Dermal Gel applied 3 times per day for 7 days
370640|NCT01367301|Drug|paclitaxel|Given IV
370641|NCT01367301|Drug|carboplatin|Given IV
370642|NCT01367301|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
370643|NCT01367301|Radiation|brachytherapy|Undergo HDR brachytherapy
370644|NCT01367301|Radiation|intensity-modulated radiation therapy|Undergo IMRT
370645|NCT01367301|Other|laboratory biomarker analysis|Correlative studies
370646|NCT01367288|Drug|Zometa + Neoadjuvant therapy|4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
370647|NCT01367288|Drug|Neoadjuvant therapy|4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
370648|NCT01367275|Drug|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
370649|NCT01367275|Drug|Irinotecan|180 mg/m^2 by vein on Day 1 of a 14 day cycle.
370650|NCT01367262|Drug|LY2886721|Administered orally
370651|NCT01367249|Drug|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
370652|NCT01367249|Drug|Placebo|Sterile ophthalmic solution
370653|NCT01367236|Drug|standard care|"atazanavir 300 mg daily~ritonavir 100 mg daily~tenofovir 245 mg daily*~emtricitabine 200 mg daily*"
370654|NCT01367236|Drug|novel treatment|"darunavir 800 mg daily~ritonavir 100 mg daily~lamivudine 300 mg daily** and abacavir 600mgs daily**~maraviroc 150 mg once daily"
370656|NCT01367223|Dietary Supplement|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
370657|NCT01367210|Drug|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
370658|NCT01367210|Drug|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
370659|NCT01367197|Behavioral|exercise training|group based exercise training
370660|NCT01367158|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
370661|NCT01367158|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
370662|NCT01367158|Biological|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
370663|NCT01367145|Drug|OMACOR|4 capsules OMACOR 1g per day
370664|NCT01367145|Drug|Placebo|4 capsules placebo per day
370665|NCT01367132|Procedure|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
370666|NCT01367119|Drug|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
370667|NCT01367119|Drug|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
370668|NCT01367106|Procedure|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
370669|NCT01367080|Drug|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
370670|NCT01367080|Drug|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
370671|NCT01367054|Drug|Metformin|500 mg tablet
370672|NCT01367054|Drug|Glifage|500 mg tablet
370673|NCT01367041|Procedure|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
370674|NCT01367028|Drug|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
370675|NCT01367028|Drug|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
370676|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
370677|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
370678|NCT01367015|Other|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
370679|NCT01367015|Other|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
370680|NCT01367002|Drug|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
370681|NCT01367002|Drug|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
370682|NCT01366989|Device|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
370683|NCT01366976|Drug|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
370684|NCT01366963|Behavioral|Seated Measurements|"The following measurements will take place in a seated position:~Ruff 1 & 7 (visual search and attention processes) Trails A & B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
370685|NCT01366963|Behavioral|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)~Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
370686|NCT01366963|Behavioral|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
370687|NCT01366950|Behavioral|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
370688|NCT01366924|Dietary Supplement|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
370689|NCT01366924|Other|Endurance exercise|60 minute endurance exercise session
370690|NCT01366898|Drug|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
370691|NCT01366885|Drug|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
370692|NCT01366859|Dietary Supplement|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
370727|NCT01366547|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
370693|NCT01366859|Dietary Supplement|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
370694|NCT01366846|Other|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
370695|NCT01366833|Radiation|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
370696|NCT01366833|Procedure|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
370697|NCT01366820|Drug|NNZ-2566|"Solution for intravenous infusion.~Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
370698|NCT01366820|Drug|Placebo|Sodium Chloride 0.9% Injection
370699|NCT01366794|Other|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
370700|NCT01366781|Other|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
370701|NCT01366768|Other|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
370702|NCT01366768|Other|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
370703|NCT01366729|Device|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
370704|NCT01366729|Device|Cane walking|All walking activities must take place with cane from waking until sleeping
370705|NCT01366716|Behavioral|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
370706|NCT01366716|Behavioral|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
370707|NCT01366703|Device|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
370708|NCT01366690|Behavioral|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
370709|NCT01366677|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
370710|NCT01366664|Drug|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
370711|NCT01366664|Drug|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days)
370712|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age.
370713|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.
370714|NCT01366638|Drug|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
370715|NCT01366638|Drug|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
370716|NCT01366638|Drug|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
370717|NCT01366625|Device|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
370718|NCT01366612|Drug|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1"
370719|NCT01366612|Drug|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.~rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
370720|NCT01366599|Drug|HEC or MEC|Any HEC or MEC, including aprepitant
370721|NCT01366573|Drug|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
370722|NCT01366573|Other|Placebo|Placebo
370723|NCT01366560|Drug|Active|GSK962040 125mg
370724|NCT01366560|Drug|Placebo|Matching Placebo
370725|NCT01366547|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
370726|NCT01366547|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
370731|NCT01366534|Other|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
370732|NCT01366521|Biological|Mepolizumab|Monoclonal antibody
370733|NCT01366508|Other|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
370734|NCT01366508|Other|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
370735|NCT01366495|Behavioral|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
370736|NCT01366482|Device|Cotavance Drug-Eluting Balloon|Treatment with a paclitaxel-coated angioplasty balloon (without preceding plaque excision)
370737|NCT01366482|Device|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision with a SilverHawk or TurboHawk plaque excision device followed by treatment with a paclitaxel-coated angioplasty balloon
370738|NCT01366482|Device|TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
370739|NCT01366456|Device|Moxibustion|Comparison of different kinds of moxibustion
370740|NCT01366443|Procedure|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
370741|NCT01366443|Procedure|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
370742|NCT01366443|Procedure|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
370743|NCT01366430|Procedure|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
370744|NCT01366430|Procedure|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
370745|NCT01366430|Procedure|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
370746|NCT01366417|Drug|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
370747|NCT01366417|Drug|70% isopropyl alcohol|Curity Alcohol Prep Pads
370748|NCT01366391|Drug|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
370749|NCT01366378|Drug|methylnaltrexone|
370750|NCT01366365|Drug|methylnaltrexone|
370751|NCT01366365|Drug|placebo|
370752|NCT01366352|Drug|MNTX tablet (Formulation 1)|
370753|NCT01366352|Drug|MNTX tablet (Formulation 2)|
370754|NCT01366339|Drug|Oral methylnaltrexone|
370755|NCT01366339|Drug|Oral placebo|
370756|NCT01366326|Drug|Methylnaltrexone bromide|Subcutaneous MNTX
370757|NCT01366313|Drug|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
370758|NCT01366313|Drug|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
370759|NCT01366313|Drug|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
370760|NCT01366300|Drug|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
370761|NCT01366300|Other|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
370762|NCT01366300|Drug|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
370763|NCT01366300|Procedure|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
370764|NCT01366287|Drug|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
370765|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
370766|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
370767|NCT01366274|Other|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
370768|NCT01366274|Other|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
370769|NCT01366261|Device|semirigid thoracoscopy|thoracoscopy with semirigid instrument
371560|NCT01359982|Drug|RRx-001|Dose Level 6 (83 mg/m2)
370772|NCT01366222|Dietary Supplement|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
370773|NCT01366209|Drug|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
370774|NCT01366209|Drug|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
370775|NCT01366196|Drug|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
370776|NCT01366196|Drug|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
370777|NCT01366183|Procedure|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
370778|NCT01366183|Drug|Carboplatin|Undergo chemotherapy
370779|NCT01366183|Biological|Filgrastim|Undergo chemotherapy
370780|NCT01366183|Drug|Paclitaxel|Undergo chemotherapy
370781|NCT01366183|Other|Pharmacological Study|Correlative studies
370782|NCT01366183|Other|Quality-of-Life Assessment|Ancillary studies
370783|NCT01366183|Other|Questionnaire Administration|Ancillary studies
370784|NCT01366170|Genetic|microarray analysis|
370785|NCT01366170|Genetic|protein expression analysis|
370786|NCT01366170|Genetic|western blotting|
370787|NCT01366170|Other|flow cytometry|
370788|NCT01366170|Other|immunohistochemistry staining method|
370789|NCT01366170|Other|laboratory biomarker analysis|
370790|NCT01366170|Other|mass spectrometry|
370791|NCT01366157|Genetic|microarray analysis|
370792|NCT01366157|Genetic|protein expression analysis|
370793|NCT01366157|Other|immunohistochemistry staining method|
370794|NCT01366157|Other|laboratory biomarker analysis|
370795|NCT01366144|Drug|Carboplatin|Given IV
370796|NCT01366144|Other|Laboratory Biomarker Analysis|Correlative studies
370797|NCT01366144|Drug|Paclitaxel|Given IV
370798|NCT01366144|Other|Pharmacological Study|Correlative studies
370799|NCT01366144|Drug|Veliparib|Given PO
370800|NCT01366131|Drug|MEGF0444A|Intravenous repeating dose
370801|NCT01366131|Drug|bevacizumab|Intravenous repeating dose
370802|NCT01366131|Drug|carboplatin|Intravenous repeating dose
370803|NCT01366131|Drug|paclitaxel|Intravenous repeating dose
370804|NCT01366131|Drug|placebo|Intravenous repeating dose
370805|NCT01366118|Drug|Therapeutic target tailored chemotherapy|"All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.~Ch combination schema was customized based on:~Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.~When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen"
370806|NCT01366105|Device|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
370807|NCT01366092|Drug|Interleukin-2|Daily subcutaneous IL-2 (1 x 10^6 IU/m^2/day) for self-administration for 12 weeks followed by 4-week hiatus
370808|NCT01366079|Procedure|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
370809|NCT01366079|Procedure|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
370810|NCT01366066|Device|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
370811|NCT01366014|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
370812|NCT01366014|Drug|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
370813|NCT01366014|Drug|Placebo; oral|matching placebo
370814|NCT01366001|Drug|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
370815|NCT01366001|Drug|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
370816|NCT01366001|Drug|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
370817|NCT01365962|Genetic|gene expression analysis|
370818|NCT01365962|Other|immunohistochemistry staining method|
370819|NCT01365962|Other|laboratory biomarker analysis|
370820|NCT01365962|Other|mass spectrometry|
370821|NCT01365949|Genetic|microarray analysis|
370822|NCT01365949|Genetic|protein analysis|
370823|NCT01365949|Other|immunohistochemistry staining method|
370824|NCT01365949|Other|laboratory biomarker analysis|
370825|NCT01365936|Drug|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
370826|NCT01365936|Drug|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
370827|NCT01365923|Drug|remifentanil|remifentanil effect site-TCI 2-4ng/ml
370828|NCT01365923|Drug|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
370829|NCT01365910|Drug|linifanib|Given PO
370830|NCT01365897|Drug|Modafinil|Modafinil 200mg
370831|NCT01365871|Procedure|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
371949|NCT01357135|Drug|Antihyperglycemic Medication|
370832|NCT01365858|Other|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
370833|NCT01365845|Radiation|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
370834|NCT01365845|Radiation|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
370835|NCT01365832|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
370836|NCT01365819|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
370837|NCT01365819|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
370838|NCT01365793|Drug|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
370839|NCT01365793|Drug|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
370840|NCT01365793|Drug|0.45% saline intravenous fluid|0.45% saline fluid
370841|NCT01365793|Drug|0.9% saline Intravenous fluid|0.9% saline fluid
370842|NCT01365780|Procedure|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
370843|NCT01365754|Procedure|standard|fusion
370844|NCT01365754|Procedure|new|dynamic stabilization
370845|NCT01365741|Other|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
370846|NCT01365728|Procedure|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
370847|NCT01365715|Procedure|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
370848|NCT01365715|Procedure|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
370849|NCT01365676|Drug|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
370850|NCT01365676|Drug|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
370851|NCT01365663|Drug|SPC4955|3 Weekly SC injections
370852|NCT01365663|Drug|SPC4955|3 Weekly SC injections
370853|NCT01365663|Drug|SPC4955|3 Weekly SC injections
370854|NCT01365663|Drug|SPC4955|3 Weekly SC injections
370855|NCT01365663|Drug|SPC4955|3 Weekly SC injections
370856|NCT01365663|Drug|Saline 0.9%|3 Weekly SC injections
370857|NCT01365650|Drug|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
370858|NCT01365650|Drug|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
370859|NCT01365650|Drug|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
370860|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
370861|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
370862|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
370863|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
370864|NCT01365624|Drug|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
370865|NCT01365611|Drug|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
370866|NCT01365611|Drug|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
370867|NCT01365598|Drug|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
370868|NCT01365585|Drug|sildenafil citrate|Sildenafil citrate, 20mg oral tablets, taken at least three times daily
370869|NCT01365572|Device|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
370870|NCT01365559|Drug|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
370907|NCT01365247|Behavioral|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
370871|NCT01365559|Drug|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.~Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.~Maintenance regimen maybe administered if patient does not progress while on study."
370872|NCT01365546|Biological|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
370873|NCT01365533|Drug|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
370874|NCT01365533|Drug|Placebo|Placebo, one tablet once daily, orally
370875|NCT01365520|Drug|turoctocog alfa|A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
370876|NCT01365507|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
370877|NCT01365494|Biological|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
370878|NCT01365481|Drug|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
370879|NCT01365481|Drug|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
370880|NCT01365481|Drug|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
370881|NCT01365468|Drug|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
370882|NCT01365455|Drug|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
370883|NCT01365455|Drug|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
370884|NCT01365429|Device|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
370885|NCT01365403|Drug|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
370886|NCT01365403|Drug|carbamazepine|multiple oral doses, Days 1-24 of study period 2
370887|NCT01365390|Other|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to < 6 years) or since birth (for subjects aged < 1 year) will be recorded in the electronic case report form.
370888|NCT01365390|Other|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
370889|NCT01365377|Other|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
370890|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
370891|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
370892|NCT01365351|Other|Growth hormone|Drug given by prescription
370893|NCT01365338|Drug|Placebo|oral solution, single dose
370894|NCT01365338|Drug|PF-04958242|oral solution, single dose; 0.075mg
370895|NCT01365338|Drug|PF-04958242|oral solution, single dose; 0.15mg
370896|NCT01365325|Other|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
370897|NCT01365325|Other|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
370898|NCT01365312|Drug|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
370899|NCT01365312|Drug|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
370900|NCT01365286|Drug|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
370901|NCT01365286|Drug|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
370902|NCT01365273|Device|Mepitel One|Dressing
370903|NCT01365260|Device|MM-II|Single intraarticular (knee) injection of MM-II
370904|NCT01365260|Device|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
370905|NCT01365247|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
370906|NCT01365247|Behavioral|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
370908|NCT01365234|Device|Pacing Lead|Implant and follow up of Model 20066 lead
370909|NCT01365221|Drug|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
370910|NCT01365221|Drug|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
370911|NCT01365208|Drug|Chemotherapy|platinum-based chemotherapy
370912|NCT01365195|Drug|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
370913|NCT01365195|Drug|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
370914|NCT01365195|Drug|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
370915|NCT01365182|Behavioral|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
370916|NCT01365182|Behavioral|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
370917|NCT01365169|Behavioral|Exercise Intervention|Participate in walking and/or strengthening program
370918|NCT01365169|Other|Health Telemonitoring|Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
370919|NCT01365169|Other|Health Telemonitoring|Use accelerometers, blood pressure monitor, weight scale, and smart phone
370920|NCT01365169|Other|Health Telemonitoring|Use smart phone
370921|NCT01365169|Other|Health Telemonitoring|Use CO monitor and smart phone
370922|NCT01365169|Other|Health Telemonitoring|Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
370923|NCT01365169|Other|Quality-of-Life Assessment|Ancillary studies
370924|NCT01365169|Other|Questionnaire Administration|Ancillary studies
370925|NCT01365156|Procedure|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
370926|NCT01365156|Radiation|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
370927|NCT01365143|Procedure|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
370928|NCT01365143|Procedure|Open Radical Prostatectomy|Open radical prostatectomy
370929|NCT01365130|Drug|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
370930|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder [one 20 U, two 20 U and one 40 U cartridges)
370931|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder [one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)])
370932|NCT01365104|Drug|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
370933|NCT01365091|Drug|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
370934|NCT01365091|Drug|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
370935|NCT01365091|Drug|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
370936|NCT01365091|Drug|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
370937|NCT01365091|Drug|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
370938|NCT01365078|Dietary Supplement|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
370939|NCT01365078|Dietary Supplement|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
370940|NCT01365065|Drug|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
370941|NCT01365052|Drug|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
370942|NCT01365052|Drug|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
370943|NCT01365039|Device|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
370944|NCT01365039|Device|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
370945|NCT01365026|Behavioral|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
370946|NCT01365013|Behavioral|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
370947|NCT01365013|Behavioral|Control group|Standard advice for lifestyle change
370948|NCT01365000|Drug|NKTR118 Formulation 1|Oral dose, 25 mg
370949|NCT01365000|Drug|NKTR118 Formulation 2|Oral dose, 25 mg
370950|NCT01365000|Drug|NKTR118 Formulation 3|Oral dose, 25 mg
370951|NCT01365000|Drug|NKTR118 Formulation 1a|Oral dose, 25 mg
370952|NCT01365000|Drug|NKTR118 Formulation 3a|Oral dose, 25 mg
370953|NCT01364987|Drug|ASP015K|oral
370954|NCT01364987|Drug|Mycophenolate Mofetil|oral
370955|NCT01364974|Drug|ASP015K|oral
370956|NCT01364974|Drug|Placebo|oral
370957|NCT01364961|Dietary Supplement|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
370958|NCT01364948|Other|Coconut oil application|Four ml coconut oil application twice daily for first week
370959|NCT01364948|Other|No oil application|Oil application was not done
370960|NCT01364922|Drug|hydrocodone/acetaminophen extended release|
370961|NCT01364922|Drug|Placebo|
371036|NCT01364402|Drug|Saline 0.9%|normal saline intravenously
370962|NCT01364909|Other|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.~According to level of sedation and stability they may also perform sitting exercises"
370963|NCT01364909|Other|Usual practice|These patients will not receive exercise early in their intensive care admission
370964|NCT01364896|Procedure|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~Anal cytology testing"
370965|NCT01364883|Biological|Vaccination Schedule One|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
370966|NCT01364883|Biological|Vaccination Schedule Two|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
370967|NCT01364883|Biological|Vaccination Schedule Three|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
370968|NCT01364883|Biological|Vaccination Schedule Four|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
370969|NCT01364883|Biological|Vaccination Schedule Five|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
370970|NCT01364883|Biological|Vaccination Schedule Six|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
370971|NCT01364883|Biological|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
370972|NCT01364870|Device|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
370973|NCT01364870|Device|Active TENS|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
370974|NCT01364857|Genetic|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
370975|NCT01364844|Drug|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
370976|NCT01364831|Behavioral|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
370977|NCT01364805|Drug|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
370978|NCT01364805|Drug|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
370979|NCT01364792|Drug|Valaciclovir|4 times 2 grams valaciclovir per day, administrated orally, for seven days.
370980|NCT01364740|Device|PMP-300E|Data collected from Level 3 device
370981|NCT01364740|Device|In-lab PSG|Data collected from Type I In-Lab Polysomnography
370982|NCT01364727|Drug|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
370983|NCT01364701|Drug|Sildenafil 100 mg|4 tablets for on demand use
370984|NCT01364701|Drug|Tadalafil 20 mg|4 tablets on demand
370985|NCT01364701|Drug|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
370986|NCT01364688|Drug|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
370987|NCT01364688|Drug|no drug|no drug
370988|NCT01364675|Drug|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
370989|NCT01364675|Drug|Placebo tablet|Identical Placebo Tablet
370990|NCT01364662|Drug|SPN-810|administered orally
370991|NCT01364662|Drug|Placebo|administered orally
370992|NCT01364649|Drug|Vortioxetine|Vortioxetine tablets
370993|NCT01364649|Drug|Escitalopram|Escitalopram tablets
370994|NCT01364649|Drug|Placebo|Vortioxetine Placebo-matching capsules
370995|NCT01364623|Drug|Low dose testosterone nasal gel, single dose|Low dose testosterone nasal gel, single dose
370996|NCT01364623|Drug|Medium dose testosterone nasal gel, single dose|Medium dose testosterone nasal gel, single dose
370997|NCT01364623|Drug|High dose testosterone nasal gel, single dose|High dose testosterone nasal gel, single dose
370998|NCT01364623|Drug|Medium dose testosterone nasal gel, multiple dose|Medium dose testosterone nasal gel, multiple dose
370999|NCT01364610|Device|Bravo|Bravo pH Monitoring System sited manometrically.
371037|NCT01364389|Drug|AIN457|3 mg/kg
371038|NCT01364389|Drug|ACZ885|3 mg/kg
371039|NCT01364389|Drug|Prednisone|20 mg
371000|NCT01364610|Device|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
371001|NCT01364597|Drug|Brivaracetam (BRV)|The max BRV dose will be 5.0 mg/kg/day,not to exceed a dose of 200 mg/day for subjects with body weight >40kg. Subjects may receive oral solution or oral tablets. The LTFU subjects will start dosing in N01266 on the individualized BRV dose they were receiving at the completion of the core study. Subjects must be able to tolerate the min BRV dose specified in the core study to be eligible for entry into the Evaluation Period of N01266. Dose can be adjusted as considered necessary by the Investigator and required by the subject's medical condition. All subjects who prematurely discontinue the study should complete an EDV and have their BRV dose down titrated by a maximum of half the dose every week for a maximum of 4 weeks until a dose of 1 mg/kg/day (50 mg/day for subjects with body weights >50kg) is reached.
371002|NCT01364584|Drug|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
371003|NCT01364584|Drug|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
371004|NCT01364571|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
371005|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
371006|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
371007|NCT01364571|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
371008|NCT01364571|Procedure|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
371009|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
371010|NCT01364571|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
371011|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
371012|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
371013|NCT01364571|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
371014|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
371015|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
371016|NCT01364558|Drug|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
371017|NCT01364558|Drug|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
371018|NCT01364545|Dietary Supplement|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
371019|NCT01364545|Dietary Supplement|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
371020|NCT01364532|Procedure|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
371021|NCT01364532|Procedure|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
371022|NCT01364519|Drug|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
371023|NCT01364519|Drug|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
371024|NCT01364506|Other|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
371025|NCT01364493|Drug|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
371026|NCT01364480|Device|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
371027|NCT01364467|Drug|Placebo|Children aged 7-11 years old will receive placebo 200 mg three times a day (TID), while children older than 12 will receive Placebo 400 mg TID.
371028|NCT01364467|Drug|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
371029|NCT01364454|Other|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
371030|NCT01364441|Drug|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
371031|NCT01364441|Drug|Placebo|Placebo dosed in the same manner as ONO-2952
371032|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
371033|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.~Dose was individually adjusted."
371034|NCT01364415|Drug|Pasireotide LAR|
371035|NCT01364402|Drug|Epoetin beta|50,000U intravenously
371040|NCT01364389|Drug|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
371041|NCT01364376|Drug|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:~oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles~SOX:~oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
371042|NCT01364363|Procedure|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
371043|NCT01364350|Other|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
371044|NCT01364337|Other|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
371045|NCT01364337|Other|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
371046|NCT01364324|Drug|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
371047|NCT01364311|Dietary Supplement|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.~Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
371048|NCT01364298|Drug|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram [mg] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
371049|NCT01364298|Drug|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
371050|NCT01364259|Drug|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
371051|NCT01364259|Procedure|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
371052|NCT01364246|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
371053|NCT01364233|Device|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
371054|NCT01364220|Drug|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
371055|NCT01364220|Other|Placebo tablet|Placebo tablet, once daily, for 14 days
371056|NCT01364207|Other|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
371057|NCT01364207|Other|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
371058|NCT01364194|Drug|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
371059|NCT01364194|Drug|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
371060|NCT01364181|Drug|Udenafil|Udenafil 50mg qd po
371061|NCT01364155|Drug|LIM-0705|
371062|NCT01364155|Drug|Placebo capsules|
371063|NCT01364142|Procedure|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
371064|NCT01364129|Procedure|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
371065|NCT01364103|Other|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
371066|NCT01364090|Drug|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
371067|NCT01364090|Drug|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
371068|NCT01364077|Drug|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
371069|NCT01364077|Drug|Placebo|Matched placebo
371070|NCT01364064|Drug|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
371071|NCT01364051|Drug|Cediranib|Given PO
371072|NCT01364051|Drug|Cediranib Maleate|Given PO
371073|NCT01364051|Other|Laboratory Biomarker Analysis|Correlative studies
371074|NCT01364051|Other|Pharmacological Study|Correlative studies
371075|NCT01364051|Drug|Selumetinib|Given PO
371076|NCT01364051|Drug|Selumetinib Sulfate|Given PO
371077|NCT01364025|Procedure|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
371078|NCT01364012|Drug|Bevacizumab|Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
371079|NCT01364012|Drug|Carboplatin|Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
371080|NCT01364012|Drug|Paclitaxel|Paclitaxel will be administered at 175 milligrams per square meter (mg/m^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
371081|NCT01364012|Drug|Placebo|Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
371082|NCT01363999|Drug|atorvastatin|single dose of atorvastatin on day 1
371083|NCT01363999|Drug|dalcetrapib|single dose of dalcetrapib on day 1
371084|NCT01363986|Drug|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
371085|NCT01363973|Device|VITALSTIM transcutaneous electrical stimulation|
371086|NCT01363947|Drug|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
371087|NCT01363934|Drug|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.~Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
371088|NCT01363934|Drug|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
371089|NCT01363921|Device|HCO 1100|Dialysis treatment with HCO1100
371090|NCT01363908|Drug|SPD602|
371091|NCT01363895|Procedure|Percutaneous closure of LAA|Percutaneous closure of LAA
371092|NCT01363895|Procedure|Catheter ablation of AF|Catheter ablation of AF
371093|NCT01363882|Other|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
371094|NCT01363882|Other|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
371095|NCT01363869|Dietary Supplement|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 2 grams per day."
371096|NCT01363869|Dietary Supplement|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 4 grams per day."
371097|NCT01363869|Dietary Supplement|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.~Total dosage is 6 grams per day."
371098|NCT01363843|Drug|FOLFOX6|FOLFOX6
371099|NCT01363843|Radiation|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
371100|NCT01363843|Procedure|Surgery|
371101|NCT01363830|Behavioral|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
371102|NCT01363830|Behavioral|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
371103|NCT01363817|Drug|BMS-906024|
371104|NCT01363817|Drug|Dexamethasone|
371105|NCT01363804|Drug|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
371106|NCT01363791|Other|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
371107|NCT01363778|Drug|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
371108|NCT01363765|Other|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
371109|NCT01363765|Other|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
371110|NCT01363752|Drug|Advagraf|oral
371111|NCT01363752|Drug|Mycophenolate Mofetil|oral
371112|NCT01363752|Drug|Sirolimus|oral
371113|NCT01363752|Drug|Corticosteroids|i.v. and oral
371114|NCT01363713|Drug|DE-114 ophthalmic solution|
371115|NCT01363700|Drug|DE-114 ophthalmic solution|
371116|NCT01363700|Drug|Placebo ophthalmic solution|
371117|NCT01363700|Drug|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
371118|NCT01363687|Device|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
371119|NCT01363674|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
371120|NCT01363661|Drug|Coruno|Molsidomine 16 mg tablet, per os, once a day
371121|NCT01363661|Drug|Placebo|Placebo (16 mg tablet, per os; once-daily)
371122|NCT01363648|Drug|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
371123|NCT01363648|Drug|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
371124|NCT01363609|Drug|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
371125|NCT01363609|Drug|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration < 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
371126|NCT01363609|Drug|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
371351|NCT01361828|Procedure|Electrophysiology|Visual Evoked Potential and Elctroretinogram
371127|NCT01363596|Other|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
371128|NCT01363583|Drug|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
371129|NCT01363583|Drug|normal saline|0.5-1.5 ml/hour during 4 days
371130|NCT01363570|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
371131|NCT01363557|Other|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
371132|NCT01363557|Drug|Gefitinib (IRESSA)|250 mg/day
371133|NCT01363544|Other|Neurofeedback|30 sessions of theta/beta neurofeedback within 10 weeks.
371134|NCT01363544|Behavioral|Exercise|30 sessions of individual sports training during 10 weeks.
371135|NCT01363544|Drug|methylphenidate|The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
371136|NCT01363531|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
371137|NCT01363505|Device|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
371138|NCT01363492|Biological|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
371139|NCT01363479|Drug|Oral palonosetron|
371140|NCT01363479|Drug|I.V. palonosetron|
371141|NCT01363479|Drug|Dexamethasone|
371142|NCT01363466|Procedure|hysterectomy|
371143|NCT01363440|Drug|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
371144|NCT01363440|Procedure|Macular Laser Photocoagulation|Laser therapy
371145|NCT01363414|Drug|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
371146|NCT01363414|Drug|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
371147|NCT01363401|Biological|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
371148|NCT01363401|Other|Control group|No treatment of HYNR-CS inj
371149|NCT01363388|Drug|Placebo|BID for 84 days
371150|NCT01363388|Drug|CCX168|BID for 84 days
371151|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
371152|NCT01363375|Procedure|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
371153|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
371154|NCT01363362|Procedure|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
371155|NCT01363349|Drug|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
371156|NCT01363349|Drug|Risperidone|
371157|NCT01363336|Drug|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
371158|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 1
371159|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 2
371160|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 3
371161|NCT01363323|Drug|Placebo|
371162|NCT01363323|Drug|Moxifloxacin|
371163|NCT01363310|Drug|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
371164|NCT01363310|Drug|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
371165|NCT01363297|Drug|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2."
371166|NCT01363284|Drug|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
371167|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
371168|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
371169|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
371170|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
371171|NCT01363258|Behavioral|Care-resistant mouth care (MOUTh)|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
371172|NCT01363258|Procedure|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
371173|NCT01363245|Behavioral|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
371174|NCT01363245|Behavioral|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
371175|NCT01363232|Drug|BKM120 + MEK162|
371176|NCT01363206|Biological|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
371221|NCT01362946|Behavioral|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
371177|NCT01363206|Biological|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
371178|NCT01363193|Drug|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.~Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = [9270 x weight (kg)] / [6680+216 x BMI] Female = [9270 x weight (kg)] / [8780+244 x BMI]"
371179|NCT01363180|Behavioral|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
371180|NCT01363180|Other|No stress condition|
371181|NCT01363167|Dietary Supplement|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
371182|NCT01363154|Other|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
371183|NCT01363154|Other|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
371184|NCT01363154|Other|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
371185|NCT01363141|Other|Regular AGE Diet|Regular AGE Diet
371186|NCT01363141|Other|Low AGE Diet|One year reduction in dietary AGE intake.
371187|NCT01363128|Drug|Cyclophosphamide|Given IV
371188|NCT01363128|Drug|Cytarabine|Given IV
371189|NCT01363128|Drug|Dexamethasone|Given IV or PO
371190|NCT01363128|Drug|Doxorubicin Hydrochloride|Given IV
371191|NCT01363128|Other|Laboratory Biomarker Analysis|Correlative studies
371192|NCT01363128|Drug|Methotrexate|Given IV
371193|NCT01363128|Biological|Ofatumumab|Given IV
371194|NCT01363128|Drug|Vincristine Sulfate|Given IV
371195|NCT01363115|Dietary Supplement|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
371196|NCT01363115|Dietary Supplement|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
371197|NCT01363115|Behavioral|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
371198|NCT01363102|Procedure|SOMS|Apply a number to mobilization goal for patient
371199|NCT01363089|Drug|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
371200|NCT01363089|Drug|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
371201|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing <50 kg.
371202|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
371203|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
371204|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
371205|NCT01363050|Drug|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
371206|NCT01363037|Drug|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
371207|NCT01363037|Drug|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
371208|NCT01363037|Other|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
371209|NCT01363037|Drug|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
371210|NCT01363024|Drug|MFGR1877S|Intravenous escalating dose
371211|NCT01363011|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
371212|NCT01363011|Drug|COBI|COBI 150 mg tablet administered with food orally once daily
371213|NCT01363011|Drug|ATV|ATV 300 mg tablet administered orally once daily
371214|NCT01363011|Drug|DRV|DRV 800 mg tablet administered orally once daily
371215|NCT01363011|Drug|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
371216|NCT01362998|Drug|Preservative free morphine|3mg given epidurally during the Cesarean section.
371217|NCT01362998|Drug|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
371218|NCT01362959|Drug|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
371219|NCT01362959|Other|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
371220|NCT01362946|Behavioral|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
371222|NCT01362933|Procedure|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
371223|NCT01362907|Device|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
371224|NCT01362907|Device|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
371225|NCT01362894|Device|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
371226|NCT01362894|Device|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
371227|NCT01362868|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
371228|NCT01362829|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
371229|NCT01362803|Drug|AZD6244|AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
371230|NCT01362790|Drug|Pentostatin|Regimen A: Cycle 1: 4 mg/m^2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m^2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m^2 or 2 mg/m^2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m^2 on days 1 and 5 of 25 day cycle
371231|NCT01362790|Drug|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
371232|NCT01362790|Biological|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: Cycle 1: 35mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles Regimen B: Cycle 1: 35mcg/kg days 18, 20 and 22 Cycles 2-4: (Days 6, 8 and 10), for a maximum of six treatment cycles
371233|NCT01362790|Biological|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:~Cycle 1: Cycle 1:35mcg/kg or 25 mcg/kg days 10, 12 and 14 Cycles 2-4: Days 2, 4 and 6, for a maximum of six treatment cycles"
371234|NCT01362777|Behavioral|In-patient rehabilitation|"Individualized exercise training (IET):~Duration : 24 sessions during 4 weeks~IET session (2h) contains:~15' start warming up muscles~30' muscle strengthening exercise for arms and abdominal muscles~45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.~15' stretching~15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.~Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
371235|NCT01362777|Behavioral|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :~Physiological mechanisms of apneas/hypopneas~Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)~Beneficials effects of CPAP and/or advanced mandibular orthosis~Description of sleep stages and physiological roles of sleep~Known effects of exercise on sleep and metabolism~Importance of good nutritional status and sleep hygiene on quality of life~How to apply theses lessons of rehabilitation in daily life"
371236|NCT01362764|Drug|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
371237|NCT01362764|Drug|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
371238|NCT01362764|Drug|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
371239|NCT01362751|Other|No intervention|This study is an observational cohort study > no interventions
371240|NCT01362738|Procedure|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
371241|NCT01362738|Procedure|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
371242|NCT01362725|Device|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
371243|NCT01362712|Radiation|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
371244|NCT01362699|Drug|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
371245|NCT01362699|Drug|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
371246|NCT01362686|Drug|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
371247|NCT01362686|Drug|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
371248|NCT01362686|Drug|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
371249|NCT01362673|Drug|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
371250|NCT01362673|Drug|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
371251|NCT01362673|Drug|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
371252|NCT01362673|Drug|Placebo|Oral single dose as matching placebo
371253|NCT01362673|Drug|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
371254|NCT01362673|Drug|Placebo|Oral multiple doses as matching placebo for 12 days
371553|NCT01360021|Drug|Symbicort|Actuation counter pressured metered dose inhaler
371255|NCT01362660|Other|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
371256|NCT01362647|Procedure|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
371257|NCT01362647|Procedure|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
371258|NCT01362634|Behavioral|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
371259|NCT01362634|Behavioral|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
371260|NCT01362608|Drug|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
371261|NCT01362608|Drug|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
371262|NCT01362595|Drug|leucine|"Dosage of leucine will be dependent on body surface area (BSA):~leucine 700 mg/m2/dose by mouth three times a day"
371263|NCT01362582|Drug|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
371264|NCT01362556|Drug|Sodium bicarbonate|"Administration of a calculated amount of sodium bicarbonate 8% [SB] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].~Formula: SB [ml] = -BE * kg * 0.1"
371265|NCT01362556|Drug|Sodium Chloride|"Administration of a calculated amount of sodium chloride 0.9% [SC] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].~Formula: SC [ml] = -BE * kg * 0.1"
371266|NCT01362543|Other|Cognitive behavioural therapy (stress management)|Following a manual
371267|NCT01362543|Other|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
371268|NCT01362530|Drug|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
371269|NCT01362530|Drug|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
371270|NCT01362530|Drug|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
371271|NCT01362530|Drug|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
371272|NCT01362530|Drug|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
371273|NCT01362530|Drug|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
371274|NCT01362530|Drug|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
371275|NCT01362530|Drug|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
371276|NCT01362517|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at 2, 3 and 4 months of age"
371277|NCT01362491|Drug|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
371278|NCT01362491|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
371279|NCT01362491|Drug|Placebo|Single-dose of placebo
371280|NCT01362465|Procedure|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
371281|NCT01362452|Genetic|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
371282|NCT01362452|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0.
371283|NCT01362439|Drug|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
371284|NCT01362426|Drug|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
371285|NCT01362400|Drug|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
371286|NCT01362400|Drug|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle~75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
371287|NCT01362387|Other|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
371288|NCT01362374|Drug|5-FU|5-FU at a dose level of 400 mg/m^2 as intravenous (IV) injection followed by a dose of 2400 mg/m^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
371289|NCT01362374|Drug|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
372992|NCT01349010|Drug|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
371290|NCT01362374|Drug|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
371291|NCT01362374|Drug|Ipatasertib|Ipatasertib will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
371292|NCT01362374|Drug|Leucovorin|Leucovorin at a dose level of 400 mg/m^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
371293|NCT01362374|Drug|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
371294|NCT01362374|Drug|Paclitaxel|Paclitaxel at a dose of 90 mg/m^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
371295|NCT01362361|Drug|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
371296|NCT01362361|Drug|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
371297|NCT01362348|Drug|pazopanib eye drops|10 mg/mL (1 drop) four times daily
371298|NCT01362322|Biological|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
371299|NCT01362322|Biological|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
371300|NCT01362309|Drug|d-cycloserine.|50 mg administered on two occasions.
371301|NCT01362296|Drug|GSK1120212|Oral once daily
371302|NCT01362296|Drug|docetaxel|IV once every 3 weeks
371303|NCT01362283|Other|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
371304|NCT01362270|Device|Acupuncture Therapy|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
371305|NCT01362257|Drug|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
371306|NCT01362257|Drug|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
371307|NCT01362244|Drug|Mepolizumab|750 mg of mepolizumab by IV infusion
371308|NCT01362244|Drug|Placebo|Placebo by IV infusion
371309|NCT01362244|Drug|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
371310|NCT01362231|Drug|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
371311|NCT01362218|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
371312|NCT01362218|Drug|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
371313|NCT01362205|Drug|Dexmedetomidine|
371314|NCT01362205|Drug|Placebos|Inactive placebo (normal saline)
371315|NCT01362192|Device|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:~Spot Size: 5 mm~Fluence: 13-15 J/cm2~Pulse Duration: 40 ms~Epidermal contact-cooling: 5° Celsius"
371316|NCT01362153|Drug|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
371317|NCT01362153|Drug|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
371318|NCT01362140|Drug|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
371319|NCT01362140|Drug|Placebo|Administered by subcutaneous injection every 3 weeks
371320|NCT01362127|Drug|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
371321|NCT01362127|Radiation|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
371322|NCT01362114|Drug|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
371323|NCT01362114|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
371324|NCT01362101|Behavioral|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
371325|NCT01362075|Procedure|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
371326|NCT01362075|Procedure|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
371327|NCT01362062|Drug|Tocilizumab|
371328|NCT01362049|Other|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
371347|NCT01361867|Device|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
371348|NCT01361854|Device|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
371349|NCT01361841|Drug|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
371329|NCT01362049|Other|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
371330|NCT01362036|Drug|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
371331|NCT01362023|Behavioral|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:~Classroom practice by HPA to highlight healthy lifestyle habits~Teaching practice by HPA using books designed to include the nutritional objectives~Parental activities included with their children~In each of 12 activities (1 h/activity), the classroom practice consisted of three components:~Experimental development of activities regarding each healthy lifestyle habit~Assessment of activity performed in classroom~An activity developed for use at home"
371332|NCT01362010|Drug|Topical Minocycline Foam FXFM244|Topically applied once a day.
371333|NCT01361997|Biological|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
371334|NCT01361997|Biological|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
371335|NCT01361984|Drug|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is ~9 minutes
371336|NCT01361984|Drug|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
371337|NCT01361971|Procedure|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
371338|NCT01361958|Drug|NOMAC|
371339|NCT01361945|Drug|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
371340|NCT01361932|Other|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
371341|NCT01361919|Procedure|Feedback During CPR Training and Testing|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool."
371342|NCT01361919|Procedure|No Feedback Group|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
371343|NCT01361919|Procedure|Feedback during CPR Training Not Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
371344|NCT01361906|Behavioral|Sensomotoric training|"The intervention will be given once a week (2h per occasion) for twelve weeks.~Each occasion is planned to have the following structure:~10 min initial conversation about how participants are feeling today and how it felt after the last time.~70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today."
371345|NCT01361893|Other|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
371346|NCT01361880|Behavioral|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
371350|NCT01361841|Drug|travoprost, latanoprost and bimatoprost|one drop once a day for life
371352|NCT01361815|Device|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
371353|NCT01361802|Drug|Ambroxol Spray|low dose Ambroxol Spray
371354|NCT01361802|Drug|Ambroxol Spray|medium dose Ambroxol Spray
371355|NCT01361802|Drug|Ambroxol Spray|high dose Ambroxol Spray
371356|NCT01361802|Drug|Placebo Spray|Placebo Spray
371357|NCT01361789|Drug|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.~After retraction of parecoxib from the market:~Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
371358|NCT01361789|Drug|Dexamethasone|8 mg IV
371359|NCT01361789|Drug|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
371360|NCT01361776|Biological|FSME-immune|0.5 ml im as scheduled in the 4 arms
371361|NCT01361763|Drug|Dabigatran|110 mg twice daily
371362|NCT01361763|Drug|Antiplatelets|100mg once a day
371363|NCT01361750|Procedure|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
371364|NCT01361724|Behavioral|Physical therapy|Physical therapy program for people with PD--one on one with a PT
371365|NCT01361724|Behavioral|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
371366|NCT01361724|Behavioral|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
371367|NCT01361711|Biological|alemtuzumab|Given SC
371368|NCT01361711|Biological|ofatumumab|Given IV
371369|NCT01361711|Procedure|biopsy|Correlative studies
371370|NCT01361698|Behavioral|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
371371|NCT01361659|Procedure|shockwave treatment|9 treatments in 3 months
371372|NCT01361646|Drug|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
371373|NCT01361633|Drug|d-cycloserine|single oral administration of 250 mg d-cycloserine
371374|NCT01361633|Drug|Sugar Pill|Single oral administration 250 mg Sugar Pill
371375|NCT01361620|Drug|aspirin|aspirin 81mg, 7-10 days
371376|NCT01361607|Drug|Nabiximols|
371377|NCT01361607|Drug|Placebo (GA-0034)|
371378|NCT01361594|Other|Regular insulin (intensive treatment)|Titration of the IV insulin rate for glucose goal 100-140 mg/dL
371379|NCT01361594|Other|Regular Insulin (conventional treatment)|Titration of the IV insulin rate for glucose goal 141-180 mg/dl
371380|NCT01361568|Drug|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
371381|NCT01361568|Drug|Placebo|Single i.v. dose administered preoperatively
371382|NCT01361568|Drug|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
371383|NCT01361568|Drug|Placebo|Single i.v. dose administered postoperatively for pain
371384|NCT01361555|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
371385|NCT01361555|Drug|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
371386|NCT01361555|Drug|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
371387|NCT01361555|Drug|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
371388|NCT01361542|Drug|anti TNF alpha agent|Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
371389|NCT01361542|Drug|Anti TNF alpha therapy|Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
371390|NCT01361529|Drug|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
371391|NCT01361516|Other|Anaesthesia and Lithotripsy|The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
371392|NCT01361464|Drug|Tipifarnib|Given PO
371393|NCT01361464|Other|Laboratory Biomarker Analysis|Correlative studies
371394|NCT01361438|Other|Total therapy approach|Total therapy approach
371395|NCT01361425|Drug|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
371396|NCT01361425|Drug|placebo|placebo 500mg 8/8h, orally
371397|NCT01361412|Biological|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
371398|NCT01361412|Biological|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
371399|NCT01361399|Drug|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
371400|NCT01361399|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
371401|NCT01361399|Drug|Lidocain|Single oral application of Lidocain (as lozenge)
371402|NCT01361399|Drug|Placebo|Single oral application of Placebo (as lozenge)
371403|NCT01361373|Drug|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
371404|NCT01361373|Drug|placebo|placebo for 2 weeks
371405|NCT01361347|Dietary Supplement|milk|milk for milk allergic children (1:25 dilution, whole milk)
371406|NCT01361334|Drug|Pazopanib|800 mg QD p.o.
371407|NCT01361308|Drug|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
371408|NCT01361308|Drug|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
371409|NCT01361295|Procedure|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
371410|NCT01361295|Procedure|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
371510|NCT01360398|Procedure|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
371411|NCT01361269|Drug|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
371412|NCT01361256|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
371413|NCT01361256|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
371414|NCT01361243|Behavioral|NOURISH+|6 week face-to-face parent intervention.
371415|NCT01361243|Behavioral|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
371416|NCT01361230|Device|"Sedation Trial Monitor is the name of the device used."|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
371417|NCT01361217|Drug|Fluoxetine, Lovastatin, Omeprazole, caffeine, midazolam, dextromethorphan|"1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.~On study day 1 and study day 18, 100mg caffeine, 2mg midazolam, 30mg dextromethorphan and 20mg omeprazole (enteric coated formulation) orally with 250mL of water.~On study day 3 and study day 20 20mg of lovastatin with 250mL of water."
371418|NCT01361204|Dietary Supplement|Theanine|Taking 4 tablets of theanine two times daily for 16 days
371419|NCT01361191|Drug|R-MEGACHOP|"If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT~If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5~R-IFE: 2 cycles every 21 days:~IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.~ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
371420|NCT01361178|Drug|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
371421|NCT01361152|Device|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
371422|NCT01361152|Device|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
371423|NCT01361126|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
371424|NCT01361113|Drug|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
371425|NCT01361100|Device|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
371426|NCT01361087|Other|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
371427|NCT01361074|Behavioral|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
371428|NCT01361074|Behavioral|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
371429|NCT01361048|Drug|oral metronidazole|2 gm oral once
371430|NCT01361048|Drug|neo penotran forte|neo penotran forte intravaginal twice a day for 7 days
371431|NCT01361048|Drug|neo penotran forte once a day|neo penotran forte intravaginally once a day for 7 days
371432|NCT01361035|Other|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
371433|NCT01361022|Drug|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
371434|NCT01361022|Drug|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
371435|NCT01361009|Drug|pramipexole|as prescibed by the investigator
371554|NCT01360021|Drug|Budesonide|Actuation counter pressured metered dose inhaler
371436|NCT01360996|Drug|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
371437|NCT01360970|Biological|hepatitis A vaccine ( HAVRIX or EPAXAL)|1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval
371438|NCT01360957|Dietary Supplement|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
371439|NCT01360944|Drug|LAS41004|once daily, topical, 100 microgram
371440|NCT01360944|Drug|reference|once daily, 100 microgram
371441|NCT01360918|Device|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
371442|NCT01360918|Other|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
371443|NCT01360866|Drug|OPC-34712|Tablet
371444|NCT01360866|Drug|Escitalopram|Tablet
371445|NCT01360866|Drug|Fluoxetine|Capsule
371446|NCT01360866|Drug|Paroxetine CR|Controlled-release tablets
371447|NCT01360866|Drug|Sertraline|Tablets
371448|NCT01360866|Drug|Duloxetine|Delayed-release capsules
371449|NCT01360866|Drug|Venlafaxine XR|Extended-release capsules
371450|NCT01360853|Drug|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
371451|NCT01360853|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
371452|NCT01360853|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
371453|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent [%] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
371454|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
371455|NCT01360840|Other|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
371456|NCT01360840|Other|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
371457|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
371458|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
371459|NCT01360814|Procedure|quality-of-life assessment|Ancillary studies
371460|NCT01360814|Behavioral|telephone-based intervention|Receive multidisciplinary structured intervention
371461|NCT01360814|Other|questionnaire administration|Ancillary studies
371462|NCT01360814|Other|counseling intervention|Receive multidisciplinary structured intervention
371463|NCT01360814|Behavioral|exercise intervention|Receive multidisciplinary structured intervention
371464|NCT01360814|Other|educational intervention|Receive multidisciplinary structured intervention
371465|NCT01360814|Behavioral|telephone-based intervention|Receive standard care
371466|NCT01360814|Procedure|standard follow-up care|Receive standard care
371467|NCT01360788|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
371468|NCT01360775|Behavioral|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
371469|NCT01360762|Drug|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
371470|NCT01360749|Drug|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
371471|NCT01360749|Drug|Placebo|Placebo dose: 2 g for 10 cm2.
371472|NCT01360736|Behavioral|Safety Planning - Military (SAFE MIL)|The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
371473|NCT01360710|Drug|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
371474|NCT01360710|Drug|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
371511|NCT01360398|Other|Data collection|Patient interview, diary cards review and questionnaires completion
371512|NCT01360398|Other|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
371513|NCT01360372|Drug|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
371514|NCT01360372|Drug|Saline injection|Saline 0.4 to 0.8 ml injection
371555|NCT01359982|Drug|RRx-001|Dose level 1 (10 mg/m2)
371556|NCT01359982|Drug|RRx-001|Dose Level 2 (16.7 mg/m2)
371557|NCT01359982|Drug|RRx-001|Dose Level 3 (24.6 mg/m2)
371475|NCT01360697|Other|JADE|"The nurse will complete the CA using standardized protocol including blood & urine tests, eye & feet examination.~Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.~Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications & healthy lifestyles, perform self blood glucose monitoring as appropriate.~At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight & blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.~After the FU visit, the patients will see the nurse or HCA again to clarify any issues & concerns, reinforce compliance & record any changes in medications.~After each FU visit, the HCA will generate summary reports to be given to patients & doctors to promote sharing of information."
371476|NCT01360697|Other|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
371477|NCT01360671|Drug|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
371478|NCT01360658|Drug|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
371479|NCT01360645|Drug|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
371480|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
371481|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
371482|NCT01360632|Drug|OPC-34712 + ADT|Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
371483|NCT01360632|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
371484|NCT01360632|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
371485|NCT01360606|Radiation|Stereotactic Body Radiation Therapy|"SBRT:~Patients will receive one of the following radiation regimens:~50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
371486|NCT01360593|Drug|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:~Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
371487|NCT01360593|Drug|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:~Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
371488|NCT01360593|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:~12 Gy x 3 fractions (36 Gy total) This will be given every other day."
371489|NCT01360567|Dietary Supplement|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
371490|NCT01360567|Dietary Supplement|Placebo|500 mg . one capsule of placebo, 3 times per day
371491|NCT01360554|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
371492|NCT01360554|Drug|Active Comparator (erlotinib)|Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
371493|NCT01360554|Drug|Placebo erlotinib|placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
371494|NCT01360554|Drug|Placebo PF00299804|placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
371495|NCT01360541|Procedure|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
371496|NCT01360541|Other|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
371497|NCT01360476|Dietary Supplement|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
371498|NCT01360476|Dietary Supplement|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
371499|NCT01360463|Behavioral|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
371500|NCT01360463|Behavioral|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
371501|NCT01360450|Drug|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between < 9.
371502|NCT01360450|Drug|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
371503|NCT01360437|Drug|Prasugrel|Prasugrel 10mg/day
371504|NCT01360437|Drug|Ticagrelor|Ticagrelor 90mg twice a day
371505|NCT01360424|Drug|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
371506|NCT01360398|Procedure|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
371507|NCT01360398|Procedure|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
371508|NCT01360398|Procedure|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
371509|NCT01360398|Procedure|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
371515|NCT01360359|Other|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education~Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.~Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
371516|NCT01360359|Other|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education~Stage 2: trunk muscle conditioning exercises~Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
371517|NCT01360346|Procedure|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
371518|NCT01360346|Procedure|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
371519|NCT01360333|Other|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
371520|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks~150mg EGCG two times daily (p.o.) over the course of three years.~Colonoscopy after 3 years"
371521|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG~Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks~Placebo two times daily (p.o.) over the course of three years~Colonoscopy after 3 years"
371522|NCT01360281|Other|Neuromuscular Electrical Stimulation|
371523|NCT01360281|Other|ECR|Resisted exercises
371524|NCT01360242|Procedure|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
371525|NCT01360242|Procedure|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
371526|NCT01360229|Procedure|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
371527|NCT01360229|Other|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
371528|NCT01360216|Behavioral|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
371529|NCT01360203|Other|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
371530|NCT01360190|Drug|fluoxetine|fluoxetine 20 mg. daily
371531|NCT01360177|Procedure|124 PET/CT imaging|Standard of Care
371532|NCT01360177|Drug|Na134I|25 to 150 mCi
371533|NCT01360177|Drug|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
371534|NCT01360177|Drug|Tri-iodothyronine|20 mg/day x 2
371535|NCT01360164|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
371536|NCT01360151|Drug|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
371537|NCT01360138|Procedure|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
371538|NCT01360125|Genetic|proteomic profiling|
371539|NCT01360125|Other|flow cytometry|
371540|NCT01360125|Other|laboratory biomarker analysis|
371541|NCT01360086|Biological|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
371542|NCT01360086|Drug|cisplatin|Cisplatine (50mg/m²)
371543|NCT01360086|Drug|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
371544|NCT01360086|Drug|leucovorin calcium|
371545|NCT01360086|Procedure|adjuvant therapy|
371546|NCT01360086|Procedure|neoadjuvant therapy|
371547|NCT01360086|Procedure|quality-of-life assessment|
371548|NCT01360086|Procedure|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
371549|NCT01360060|Drug|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
371550|NCT01360034|Drug|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
371551|NCT01360034|Drug|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
371552|NCT01360021|Drug|Symbicort|Breath actuated metered dose inhaler
371561|NCT01359969|Drug|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
371562|NCT01359956|Drug|Dacarbazine|900 mg / m2 every 3 weeks
371563|NCT01359956|Drug|Fotemustine|100 mg / m2 every 3 weeks
371564|NCT01359956|Drug|Interferon Alfa-2b|5 M units every 3 weeks
371565|NCT01359943|Biological|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
371566|NCT01359943|Drug|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
371567|NCT01359930|Other|placebo|matching placebo
371568|NCT01359930|Drug|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
371569|NCT01359904|Other|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
371570|NCT01359878|Drug|Fibrinogen Concentrate|2 gram intra venous
371571|NCT01359878|Drug|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
371572|NCT01359865|Procedure|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at <0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
371573|NCT01359852|Drug|[11C] JNJ-42491293|Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
371574|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
371575|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|"Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
371576|NCT01359852|Drug|[11C] JNJ-42491293|Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
371577|NCT01359839|Behavioral|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
371578|NCT01359826|Drug|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
371579|NCT01359813|Drug|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
371580|NCT01359787|Drug|Mapracorat|Daily topical application
371581|NCT01359787|Drug|Vehicle without active|Daily topical application
371582|NCT01359774|Other|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
371583|NCT01359774|Other|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
371584|NCT01359761|Behavioral|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
371585|NCT01359748|Device|Reference sphygmomanometer|* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
371586|NCT01359748|Device|Sphygmomanometer under test|Electronic Oscillometric method.
371587|NCT01359735|Biological|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
371588|NCT01359735|Biological|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
371589|NCT01359722|Drug|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
371590|NCT01359722|Drug|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
371591|NCT01359709|Drug|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
371592|NCT01359696|Drug|GDC-0425|Oral escalating dose
371593|NCT01359696|Drug|gemcitabine|Intravenous repeating dose
371594|NCT01359683|Device|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
371595|NCT01359670|Drug|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
371596|NCT01359670|Drug|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
371597|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
371598|NCT01359657|Biological|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
371599|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
371600|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
371601|NCT01359657|Biological|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
371731|NCT01358825|Procedure|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
371602|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
371603|NCT01359644|Drug|PSI-7977|Tablets, oral, 400 mg, once daily
371604|NCT01359644|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily
371605|NCT01359644|Drug|Ribavirin|Tablets, oral, 200 mg
371606|NCT01359618|Drug|TC-5214|Single dose, oral tablets
371607|NCT01359618|Other|Placebo comparator|Single dose, oral tablets
371608|NCT01359618|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
371609|NCT01359618|Other|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
371610|NCT01359605|Drug|varespladib methyl|500 mg oral suspension
371611|NCT01359592|Biological|rituximab|
371612|NCT01359592|Drug|cyclophosphamide|
371613|NCT01359592|Drug|doxorubicin hydrochloride|
371614|NCT01359592|Drug|prednisone|
371615|NCT01359592|Drug|vincristine sulfate|
371616|NCT01359592|Other|R-CHOP regimen|
371617|NCT01359592|Other|laboratory biomarker analysis|
371618|NCT01359592|Radiation|fludeoxyglucose F 18|
371619|NCT01359592|Radiation|selective external radiation therapy|
371620|NCT01359592|Radiation|yttrium Y 90 ibritumomab tiuxetan|
371621|NCT01359579|Drug|varespladib methyl|Single oral 500 mg dose
371622|NCT01359566|Drug|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
371623|NCT01359566|Drug|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
371624|NCT01359566|Drug|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
371625|NCT01359566|Drug|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
371626|NCT01359553|Other|Intra-articular ultrasound imaging of knee joint during arthroscopy|
371627|NCT01359553|Other|Non-invasive ultrasound imaging of knee|
371628|NCT01359553|Other|Quantitative MRI imaging of knee|
371629|NCT01359553|Other|Contrast-enhanced CT imaging of knee|
371630|NCT01359540|Device|OMNI Apex Modular™ Hip Device|
371631|NCT01359540|Device|OMNI Apex ARC™ Hip Device|
371632|NCT01359527|Device|Hip Resurfacing|
371633|NCT01359527|Device|Total Hip Arthroplasty|
371634|NCT01359514|Drug|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
371635|NCT01359514|Drug|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
371636|NCT01359501|Drug|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
371637|NCT01359501|Drug|Placebo|Start to take the powder of Placebo 3g*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
371638|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
371639|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
371640|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
371641|NCT01359488|Drug|VRS-317|VRS-317 Single dose
371642|NCT01359488|Drug|VRS-317|VRS-317 Single dose
371643|NCT01359475|Procedure|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
371644|NCT01359462|Drug|tolvaptan|"Drug: tolvaptan~tablet, 15mg, Qd, for 7 days."
371645|NCT01359449|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
371646|NCT01359449|Biological|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
371647|NCT01359436|Device|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
371648|NCT01359423|Drug|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
371649|NCT01359423|Drug|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
371650|NCT01359410|Device|Mesh reinforced staple line (SEAMGUARD)|Reinforce the pancreatic transaction with SEAMGUARD®
371651|NCT01359410|Device|Stapled without mesh reinforcement (PER-STRIPS DRY)|Stapled without mesh reinforcement (PERI-STRIPS DRY®)
371652|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
371653|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
371654|NCT01359345|Drug|gadollinum|use of on injection gadollinum Iv for imaging
371655|NCT01359332|Procedure|Moderate hypothermia|procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
371656|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
371821|NCT01358201|Drug|Cytosine arabinoside|
371657|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
371658|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
371659|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
371660|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
371661|NCT01359280|Behavioral|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
371662|NCT01359280|Behavioral|General Health Counseling|5 sessions of health improvement counseling
371663|NCT01359280|Behavioral|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
371664|NCT01359267|Drug|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
371665|NCT01359254|Drug|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
371666|NCT01359254|Drug|Fludarabine|Fludarabine is given through the vein daily for 5 days.
371667|NCT01359254|Drug|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
371668|NCT01359254|Drug|Busulfan|Busulfan is given daily for 4 days.
371669|NCT01359254|Drug|Total Body Irradiation (TBI)|TBI is given twice on the last day.
371670|NCT01359241|Procedure|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
371671|NCT01359241|Drug|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
371672|NCT01359228|Drug|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
371673|NCT01359228|Drug|Placebo|Placebo 1 tablet three times a day for 14 days.
371674|NCT01359202|Biological|rfVIIa|80ug/kg IV bolus
371675|NCT01359202|Other|Standard saline solution|Saline
371676|NCT01359189|Device|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
371677|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
371678|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
371679|NCT01359150|Drug|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
371680|NCT01359150|Drug|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
371681|NCT01359137|Behavioral|Probation as usual|Routine probation with do deferred jail condition.
371682|NCT01359137|Behavioral|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
371683|NCT01359137|Behavioral|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
371684|NCT01359124|Behavioral|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
371685|NCT01359124|Behavioral|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
371686|NCT01359124|Behavioral|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
371687|NCT01359111|Device|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
371688|NCT01359098|Drug|Ciprodex Otic Suspension|4 gtt b.i.d. for 7 days.
371689|NCT01359098|Drug|Ciprodexa Otic Foam|0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
371690|NCT01359085|Drug|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
371691|NCT01359085|Procedure|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
371822|NCT01358175|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
371692|NCT01359072|Other|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
371693|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
371694|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
371695|NCT01359046|Device|silver SPC|subject randomized to receive silver alloy impregnated catheter
371696|NCT01359046|Device|standard SPC|subject randomized to receive standard catheter
371697|NCT01359020|Drug|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
371698|NCT01359007|Drug|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
371699|NCT01358981|Drug|LY2881835|Administered orally
371700|NCT01358981|Drug|Placebo|Administered orally
371701|NCT01358968|Drug|LY2603618|Administered intravenously as a 1-hour infusion.
371702|NCT01358968|Drug|Desipramine|Administered orally
371703|NCT01358968|Drug|Pemetrexed|Administered intravenously as a 10-minute infusion.
371704|NCT01358968|Drug|Gemcitabine|Administered intravenously as a 30-minute infusion.
371705|NCT01358955|Other|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
371706|NCT01358955|Other|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
371707|NCT01358929|Drug|Placebo|Placebo to RO6807952
371708|NCT01358929|Drug|RO6807952|Escalating subcutaneous dose
371709|NCT01358916|Other|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
371710|NCT01358903|Drug|RO5429083|Cohorts receiving multiple escalating doses iv
371711|NCT01358903|Drug|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
371712|NCT01358890|Other|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
371713|NCT01358890|Other|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
371714|NCT01358877|Drug|5-Fluorouracil|5-Fluorouracil will be administered as per the schedule specified in the respective arm.
371715|NCT01358877|Drug|Carboplatin|Carboplatin will be administered as per the schedule specified in the respective arm.
371716|NCT01358877|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per the schedule specified in the respective arm.
371717|NCT01358877|Drug|Docetaxel|Docetaxel will be administered as per the schedule specified in the respective arm.
371718|NCT01358877|Drug|Doxorubicin|Doxorubicin will be administered as per the schedule specified in the respective arm.
371719|NCT01358877|Drug|Epirubicin|Epirubicin will be administered as per the schedule specified in the respective arm.
371720|NCT01358877|Drug|Paclitaxel|Paclitaxel will be administered as per the schedule specified in the respective arm.
371721|NCT01358877|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm.
371722|NCT01358877|Drug|Placebo|Placebo will be administered as per the schedule specified in the respective arm.
371723|NCT01358877|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm.
371724|NCT01358864|Drug|BI 201335|BI 201335 once a day (QD) for 24 weeks
371725|NCT01358864|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
371726|NCT01358864|Drug|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
371727|NCT01358864|Drug|Placebo|Placebo to BI201335 for 24 weeks
371728|NCT01358851|Procedure|Cryotherapy|1-2 times during the treatment time
371729|NCT01358851|Drug|LAS41005|once daily
371730|NCT01358838|Device|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.~Half of the scar, or one of two comparable scars, will receive no treatment at all."
371823|NCT01358175|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
371732|NCT01358812|Drug|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
371733|NCT01358799|Device|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
371734|NCT01358786|Procedure|quilting suture|"quilting sutures and drains~quilting sutures but no drains"
371735|NCT01358773|Other|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
371736|NCT01358760|Drug|Placebo|Placebo vaginal suppository
371737|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
371738|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
371739|NCT01358747|Drug|BEACOPPesc|
371740|NCT01358747|Drug|BEACOPPesc - ABVD - PET2|
371741|NCT01358734|Drug|Azacitidine|Azacitidine at 75 mg/m^2/day subcutaneous on Days 1-7
371742|NCT01358734|Drug|Lenalidomide|Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
371743|NCT01358734|Other|Best Supportive Care (BSC)|"The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support"
371744|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
371745|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
371746|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
371747|NCT01358708|Drug|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
371748|NCT01358708|Drug|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
371749|NCT01358695|Biological|ANT-1207|The interventions differ by dose of investigational product applied.
371750|NCT01358695|Biological|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
371751|NCT01358695|Biological|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
371752|NCT01358669|Drug|Denosumab|60mg denosumab by injection as a single dose
371753|NCT01358669|Other|Placebo|Placebo by injection as a single dose
371754|NCT01358656|Procedure|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith & Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
371755|NCT01358656|Procedure|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
371756|NCT01358643|Other|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.~Thirty OEF/OIF veterans with BMI > 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
371757|NCT01358617|Other|diagnostic laboratory biomarker analysis|Correlative studies
371758|NCT01358604|Genetic|polymerase chain reaction|
371759|NCT01358604|Genetic|protein expression analysis|
371760|NCT01358604|Genetic|western blotting|
371761|NCT01358604|Other|flow cytometry|
371762|NCT01358604|Other|immunohistochemistry staining method|
371763|NCT01358604|Other|laboratory biomarker analysis|
371764|NCT01358591|Dietary Supplement|High calcium milk|High calcium milk (9 mg/kgBM)
371765|NCT01358591|Dietary Supplement|Control|Regular Milk
371766|NCT01358578|Drug|Placebo|Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
371767|NCT01358578|Drug|secukinumab (AIN457)|secukinumab (AIN457) 150mg or 300mg subcutaneous
371768|NCT01358578|Drug|etanercept|etanercept 50mg subcutaneous
371769|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
371770|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
371824|NCT01358175|Drug|Placebo|Placebo
371771|NCT01358552|Other|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
371772|NCT01358539|Behavioral|Pain education|Patients receiving pain education
371773|NCT01358526|Drug|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
371774|NCT01358526|Drug|Placebo|Placebo tablets to match OXN taken orally every 12 hours
371775|NCT01358500|Drug|Fentanyl|Intravenous infusion using STANPUMP
371776|NCT01358487|Behavioral|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
371777|NCT01358487|Behavioral|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
371778|NCT01358461|Biological|Blood sampling|Blood sampling
371779|NCT01358461|Other|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
371780|NCT01358448|Behavioral|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
371781|NCT01358448|Behavioral|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
371782|NCT01358435|Biological|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
371783|NCT01358435|Biological|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
371784|NCT01358409|Drug|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
371785|NCT01358396|Other|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
371786|NCT01358383|Drug|naproxen|250mg, oral dose
371787|NCT01358383|Drug|esomeprazole|20mg, oral dose
371788|NCT01358357|Drug|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
371789|NCT01358357|Drug|Placebo|20-80 mg flexible dose
371790|NCT01358344|Drug|Pantoprazole|40 mg delayed‑release tablet administered orally in the morning of Days 1-7
371791|NCT01358344|Drug|SCH 530348 (high percentage)|2.5 mg tablet containing ~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
371792|NCT01358344|Drug|SCH 530348 (standard percentage)|2.5 mg tablet containing ~23% API as free base (STANDARD) administered orally on the morning of Day 5
371793|NCT01358331|Drug|MK-8353|
371794|NCT01358318|Other|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
371795|NCT01358305|Other|Protein Blend|Single intake of approximately 20 grams of total protein
371796|NCT01358292|Procedure|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
371797|NCT01358292|Procedure|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
371798|NCT01358279|Procedure|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
371799|NCT01358266|Drug|DE-109 44 ug|Low dose
371800|NCT01358266|Drug|DE-109 440 ug|Medium dose
371801|NCT01358266|Drug|DE-109 880 ug|High dose
371802|NCT01358253|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
371803|NCT01358253|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
371804|NCT01358253|Drug|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
371805|NCT01358253|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
371806|NCT01358253|Drug|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
371807|NCT01358253|Drug|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
371808|NCT01358253|Drug|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).~Maintenance:375 mg/m2 IV in 6th month and 12th month."
371809|NCT01358253|Drug|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
371810|NCT01358253|Drug|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
371811|NCT01358253|Drug|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
371812|NCT01358240|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
371813|NCT01358240|Drug|Vehicle Foam|Vehicle Foam applied once a day for 4 week
371814|NCT01358240|Drug|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
371815|NCT01358240|Other|Placebo Cream|Placebo cream applied once a day for 4 weeks
371816|NCT01358227|Drug|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
371817|NCT01358214|Behavioral|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
371818|NCT01358201|Drug|vINCRISTINE|
371819|NCT01358201|Drug|Dexamethasone|
371820|NCT01358201|Drug|Methotrexate|
371825|NCT01358162|Other|Placebo|Placebo given orally, daily for 14 consecutive days
371826|NCT01358162|Drug|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
371827|NCT01358149|Other|cocoa-based food|single intake of cocoa-based food
371828|NCT01358149|Other|cocoa-based food|Single intake of cocoa-based food
371829|NCT01358110|Other|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
371830|NCT01358110|Other|Care as usual|Standard care as usual which may or may not include palliative care consultation
371831|NCT01358084|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
371832|NCT01358084|Drug|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
371833|NCT01358084|Other|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
371834|NCT01358071|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60 minutes intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
371835|NCT01358071|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
371836|NCT01358071|Drug|Doxorubicin|60 mg/m² iv every 3 weeks for a maximum of 8 cycles
371837|NCT01358058|Radiation|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
371838|NCT01358045|Drug|Diclofenac|Application on the lesion 2 times a day 8 weeks.
371839|NCT01358045|Drug|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
371840|NCT01358045|Drug|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
371841|NCT01358032|Behavioral|an in-home cognitive behavioral program|The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) & 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
371842|NCT01358019|Drug|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
371843|NCT01358006|Drug|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
371844|NCT01358006|Drug|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
371845|NCT01357993|Drug|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
371846|NCT01357980|Biological|Botulinum toxin type A|750 U intra detrusor injection on Day 1 (single dose)
371847|NCT01357980|Drug|Placebo|Intra detrusor injection on Day 1 (single dose)
371848|NCT01357967|Drug|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
371849|NCT01357967|Drug|Seroquel XR adjunctive|"Quetiapine group:~seroquel XR 50mg Day 1 --> 50mg Day 2 --> 150mg Day 3 --> 150mg Day 4 --> adjustment usually at hs but can be daytime"
371850|NCT01357954|Other|Regular physiotherapy|The child's regular physiotherapy
371851|NCT01357954|Other|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
371852|NCT01357915|Procedure|Blood sampling|"Blood samples will be collected at 2 time points:~At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.~At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
371853|NCT01357915|Biological|GSK149203A|GSK Biologicals' Recombinant CMV glycoprotein B Vaccine, Intramuscular injection, 3 doses
371854|NCT01357902|Drug|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
371855|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
371856|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
371857|NCT01357876|Other|Metformin|withdrawral
371858|NCT01357863|Drug|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
371859|NCT01357850|Drug|GSK716155|GSK716155
371860|NCT01357850|Drug|Placebo|Placebo
371861|NCT01357837|Drug|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
371862|NCT01357837|Drug|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
371863|NCT01357837|Drug|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
371864|NCT01357837|Drug|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
371865|NCT01357824|Procedure|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
371950|NCT01357122|Device|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
371866|NCT01357811|Drug|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
371867|NCT01357811|Drug|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
371868|NCT01357798|Drug|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
371869|NCT01357798|Drug|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
371870|NCT01357785|Procedure|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
371871|NCT01357772|Drug|Tamoxifen|at daily dose of 5 mg for a total treatment time of 3 years
371872|NCT01357772|Drug|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
371873|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
371874|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
371875|NCT01357746|Procedure|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
371876|NCT01357733|Other|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
371877|NCT01357720|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
371878|NCT01357720|Biological|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:~diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), inactive pertussis bacteria (>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen~One dose of Quinvaxem given at Weeks 6, 10 and 14"
371879|NCT01357707|Genetic|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
371880|NCT01357694|Behavioral|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
371881|NCT01357681|Drug|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
371882|NCT01357681|Drug|Placebo|Placebo
371883|NCT01357655|Drug|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
371884|NCT01357655|Drug|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
371885|NCT01357642|Drug|Epinephrine inhalation aerosol|Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
371886|NCT01357642|Drug|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine
371887|NCT01357642|Drug|epinephrine inhalation aerosol|epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
371888|NCT01357616|Drug|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
371889|NCT01357616|Drug|Brinzolamide 1% ophthalmic suspension|
371890|NCT01357616|Drug|Timolol 0.5% ophthalmic solution|
371891|NCT01357603|Biological|Glargine|dosage form: Subcutaneous injection
371892|NCT01357590|Device|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
371893|NCT01357577|Behavioral|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
371894|NCT01357564|Other|Tailored Activity Program|The interventionist, an occupational therapist, meets with the caregiver and introduces the intervention goals. The OT provides and reviews written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed is The 36 Hour Day. The OT interviews the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT also observes interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale.
371895|NCT01357564|Other|Attention Control|Caregivers in this group received bi-weekly telephone contact by a trained healthcare professional. In each session, caregivers were provided information about dementia and strategies for disease management. Each telephone contact began with a brief overview the session purpose, followed by a description of key facts, and concluded with a question and answer period. The attention control group intervention was delivered by a member of the research team who is knowledgeable about dementia and has had prior experience working with family caregivers.
371896|NCT01357551|Behavioral|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
371897|NCT01357538|Drug|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
371898|NCT01357538|Drug|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
371899|NCT01357525|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)"
371900|NCT01357512|Device|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
371945|NCT01357148|Drug|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
371901|NCT01357499|Device|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
371902|NCT01357499|Device|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
371903|NCT01357486|Drug|sorafenib|patients receiving sorafenib 400 mg - twice a day
371904|NCT01357486|Drug|Pravastatin|patients receiving pravastatin 40 mg - once a day
371905|NCT01357486|Drug|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
371906|NCT01357486|Other|patients receiving best supportive care|palliative management
371907|NCT01357460|Device|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
371908|NCT01357447|Drug|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
371909|NCT01357447|Drug|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
371910|NCT01357434|Behavioral|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
371911|NCT01357421|Drug|TT301|Single iv dose of TT301
371912|NCT01357421|Drug|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
371913|NCT01357395|Drug|Amuvatinib|Amuvatinib 300 mg PO TID
371914|NCT01357382|Other|Low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
371915|NCT01357369|Procedure|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
371916|NCT01357356|Drug|SER120 (750 ng/day)|
371917|NCT01357356|Drug|SER120 (1000 ng/day)|SER120 (1000 ng/day)
371918|NCT01357356|Drug|SER120 (1500 ng/day)|
371919|NCT01357356|Drug|Placebo|
371920|NCT01357343|Other|Chiropractic|Spinal manipulation and active and passive therapy.
371921|NCT01357343|Other|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
371922|NCT01357330|Drug|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
371923|NCT01357330|Drug|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
371924|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
371925|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
371926|NCT01357317|Drug|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
371927|NCT01357304|Behavioral|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
371928|NCT01357291|Behavioral|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
371929|NCT01357291|Behavioral|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
371930|NCT01357278|Procedure|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.~Patient education will be offered every eight week."
371931|NCT01357265|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
371932|NCT01357252|Drug|vildagliptin|
371933|NCT01357252|Drug|Placebo|
371934|NCT01357239|Drug|AFQ056|
371935|NCT01357239|Drug|Placebo|
371936|NCT01357213|Drug|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
371937|NCT01357213|Other|Placebo|Normal saline 100 ml
371938|NCT01357200|Other|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
371939|NCT01357187|Other|Scheduled removal of posterior instrumentation with AmnioFix|
371940|NCT01357187|Other|Scheduled removal of posterior instrumentation without AmnioFix|
371941|NCT01357161|Drug|MK-1775|MK-1775 capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
371942|NCT01357161|Drug|Placebo|placebo to MK-1775, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
371943|NCT01357161|Drug|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
371944|NCT01357161|Drug|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
371946|NCT01357135|Drug|Metformin|
371951|NCT01357122|Procedure|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
371952|NCT01357109|Drug|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
371953|NCT01357109|Drug|Placebo|Matched placebo bid
371954|NCT01357096|Behavioral|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
371955|NCT01357096|Other|Traditional group|CAD education fryers
371956|NCT01357070|Dietary Supplement|Brocco-sprout homogenate|Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
371957|NCT01357070|Dietary Supplement|Alfalfa sprout homogenate|Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
371958|NCT01357044|Dietary Supplement|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
371959|NCT01357044|Dietary Supplement|Placebo|Tablets, two in the morning and two in the evening
371960|NCT01357031|Drug|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
371961|NCT01357031|Drug|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
371962|NCT01357031|Drug|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
371963|NCT01357005|Other|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
371964|NCT01356992|Drug|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
371965|NCT01356979|Procedure|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
371966|NCT01356966|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
371967|NCT01356966|Drug|Placebo|2 placebo pills PO BID for12 weeks
371968|NCT01356966|Dietary Supplement|Folate|Folate 1 mg daily for 12 weeks
371969|NCT01356953|Other|Aerobic exercise|Intensity of aerobic exercise
371970|NCT01356940|Drug|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
371971|NCT01356940|Drug|placebo|identical placebo tablet administered bid for four weeks
371972|NCT01356927|Drug|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
371973|NCT01356927|Drug|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
371974|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
371975|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
371976|NCT01356914|Drug|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
371977|NCT01356914|Drug|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
371978|NCT01356888|Device|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
371979|NCT01356888|Device|Percutaneous Coronary Intervention (Orsiro DES)|stenting
371980|NCT01356875|Drug|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
371981|NCT01356875|Drug|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
371982|NCT01356862|Drug|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
371983|NCT01356862|Drug|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
371984|NCT01356849|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
371985|NCT01356849|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
371986|NCT01356823|Biological|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
371987|NCT01356823|Biological|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
371988|NCT01356823|Biological|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
371989|NCT01356823|Biological|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
371990|NCT01356810|Other|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
371991|NCT01356810|Other|Standard Care|Delirium management by the attending physician's preferences.
371992|NCT01356797|Drug|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
371993|NCT01356797|Drug|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
371994|NCT01356784|Other|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
371995|NCT01356784|Behavioral|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
371996|NCT01356784|Behavioral|Health counselling|Health guidance (1,5h)
372041|NCT01356355|Drug|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
372042|NCT01356355|Drug|Placebo|One capsule twice a day daily till ureteral stent in situ
372043|NCT01356355|Drug|Tolterodine|One capsule twice a day daily till ureteral stent in situ
371997|NCT01356771|Other|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.~Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.~The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.~Each survey will ask the participant about:~Current and past skin cancer screening practices~Current and past sun protection practices~Attitudes about skin cancer and sun protection~Knowledge of melanoma"
371998|NCT01356758|Drug|biological treatment|patients treated with anti-psoriatic biological agents
371999|NCT01356745|Drug|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
372000|NCT01356745|Drug|medical air|inhalation gas for inhalation use
372001|NCT01356732|Drug|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
372002|NCT01356693|Drug|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
372003|NCT01356693|Drug|Placebo|Placebo with mimicking characteristics of experimental drug
372004|NCT01356680|Drug|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
372005|NCT01356680|Drug|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
372006|NCT01356680|Radiation|30Gy IF-RT (Involved-Field Radiotherapy)|
372007|NCT01356680|Radiation|30Gy IN-RT (Involved-Node Radiotherapy)|
372008|NCT01356667|Behavioral|DARTNA|3-hour protocol provided 2x/week over 12 weeks
372009|NCT01356667|Behavioral|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
372010|NCT01356654|Device|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
372011|NCT01356654|Device|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
372012|NCT01356641|Drug|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
372013|NCT01356641|Procedure|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
372014|NCT01356628|Drug|PD-0332991|PD-0332991, 125mg, 3 cycles
372015|NCT01356615|Drug|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
372016|NCT01356615|Drug|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
372017|NCT01356602|Drug|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
372018|NCT01356602|Drug|Canakinumab lyophilized powder|Canakinumab lyophilized powder
372019|NCT01356602|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide
372020|NCT01356602|Drug|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
372021|NCT01356563|Behavioral|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
372022|NCT01356550|Drug|RO4917838|single oral dose
372023|NCT01356524|Drug|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
372024|NCT01356511|Drug|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
372025|NCT01356511|Drug|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
372026|NCT01356498|Biological|pegloticase|8 mg intravenous infusion
372027|NCT01356485|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
372028|NCT01356485|Drug|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
372029|NCT01356472|Drug|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
372030|NCT01356459|Device|Mepilex Border Dressing|Soft silicone self adherent dressing
372031|NCT01356446|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
372032|NCT01356433|Drug|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
372033|NCT01356433|Drug|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
372034|NCT01356420|Dietary Supplement|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
372035|NCT01356407|Drug|PICOPREP|
372036|NCT01356407|Drug|PEG-ELS|
372037|NCT01356394|Other|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
372038|NCT01356381|Drug|Vildagliptin|Dosage 50mg b.i.d.
372039|NCT01356381|Drug|Placebo|50mg bid
372040|NCT01356368|Drug|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
372044|NCT01356342|Biological|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months~<3 years;0.25 mL per injection2 injections at 4 weeks apart~3~<9 years;0.5 mL per injection2 injections at 4 weeks apart~9~<18 years;0.5 mL per injection1 injections"
372045|NCT01356329|Drug|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)~). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
372046|NCT01356316|Biological|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
372047|NCT01356303|Drug|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.~Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
372048|NCT01356290|Drug|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
372049|NCT01356290|Drug|Thalidomide|3mg/kg, oral, daily, 1 year
372050|NCT01356290|Drug|Celecoxib|50-400mg, oral bid, daily, 1 year
372051|NCT01356290|Drug|Fenofibric acid|90mg/m2, oral, daily, 1 year
372052|NCT01356290|Drug|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
372053|NCT01356290|Drug|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
372054|NCT01356290|Drug|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
372055|NCT01356290|Drug|Cytarabine|16-30mg, intrathecal, twice weekly for two weeks out of every four weeks, alternating with intrathecal etoposide phosphate, 1 year
372056|NCT01356277|Behavioral|Action-focused problem-solving|"Adherence Support Team (patient, parent, Coach)~standardized education on immunosuppressive medications~identification of adherence barriers~'Action-Focused Problem-Solving' to address barriers selected as most important by the patient"
372057|NCT01356277|Device|Electronic pillbox monitoring, dose reminders, and feedback|"Electronic adherence monitoring with feedback of past 3 months of electronic monitoring data at 3-month intervals~text message, email, or visual cue dose reminders"
372058|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
372059|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
372060|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
372061|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
372062|NCT01356238|Other|MRC media|Culture media
372063|NCT01356238|Other|Sydney IVF media|Culture media
372064|NCT01356225|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
372065|NCT01356225|Drug|Placebo|IN placebo
372066|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
372067|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
372068|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
372069|NCT01356199|Dietary Supplement|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
372070|NCT01356199|Dietary Supplement|PLACEBO|PLACEBO. 6 per day for 8 months.
372071|NCT01356186|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
372072|NCT01356173|Drug|GDC-0349|Oral escalating dose
372073|NCT01356160|Drug|GS-5885|tablet, 30 mg QD
372074|NCT01356160|Drug|GS-9451|tablet, 200 mg QD
372075|NCT01356160|Biological|peginterferon alfa-2a|(solution for injection) 180 µg/week
372076|NCT01356160|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
372077|NCT01356160|Drug|GS-9451 Placebo|Placebo to match GS-9451 QD
372078|NCT01356147|Drug|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
372079|NCT01356147|Drug|Placebo|No therapy will be given to placebo arm
372080|NCT01356121|Drug|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
372081|NCT01356121|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
372151|NCT01355497|Drug|placebo|subject will receive placebo for the duration of the trial
372082|NCT01356108|Device|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
372083|NCT01356095|Other|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
372084|NCT01356095|Other|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
372085|NCT01356082|Device|CNAP|Non-invasive blood pressure monitor
372086|NCT01356069|Other|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.~SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
372087|NCT01356069|Other|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
372088|NCT01356056|Device|Kinesia HomeView|Quantifies motor symptom severity in the home
372089|NCT01356043|Drug|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
372090|NCT01356043|Drug|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
372091|NCT01356030|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
372092|NCT01356030|Procedure|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
372093|NCT01356017|Drug|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
372094|NCT01356017|Drug|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
372095|NCT01356004|Drug|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
372096|NCT01356004|Drug|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
372097|NCT01355991|Drug|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
372098|NCT01355991|Drug|Salmeterol|50mcg inhalation twice daily for two weeks
372099|NCT01355978|Device|Noninvasive Open Ventilation System|Noninvasive ventilation system
372100|NCT01355965|Biological|Autologous T cells|
372101|NCT01355952|Dietary Supplement|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
372102|NCT01355939|Procedure|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
372103|NCT01355926|Other|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
372104|NCT01355926|Other|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
372105|NCT01355900|Procedure|Total knee arthroplasty performed under tourniquet|Comparison of the different tourniquet tactics.
372106|NCT01355874|Drug|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
372107|NCT01355874|Drug|Placebo|Placebo ointment BID for 14 days during double blind.
372108|NCT01355874|Drug|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
372109|NCT01355861|Behavioral|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
372110|NCT01355848|Behavioral|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
372111|NCT01355835|Device|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
372112|NCT01355822|Drug|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
372113|NCT01355822|Drug|Placebo control|orally, twice daily
372114|NCT01355809|Drug|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
372115|NCT01355809|Drug|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
372116|NCT01355809|Drug|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
372117|NCT01355796|Drug|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
372118|NCT01355796|Drug|Hypertonic saline|4 ml of 7 % saline aerosolized twice a day for 2 weeks
372119|NCT01355783|Drug|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
372120|NCT01355757|Device|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
372121|NCT01355757|Drug|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
372122|NCT01355718|Drug|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
372123|NCT01355705|Drug|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
372124|NCT01355705|Drug|Lenalidomide|15 mg daily by mouth
372125|NCT01355705|Drug|Dexamethasone|40 mg weekly by mouth
372126|NCT01355705|Drug|Aspirin|81 or 325 mg daily by mouth
372127|NCT01355705|Drug|Pegfilgrastim|6 mg subcutaneous on Day 2
372128|NCT01355692|Device|Nd: YLF laser treatment|grid selective retinal treatment
372129|NCT01355679|Device|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
372130|NCT01355666|Device|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.~Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
372131|NCT01355653|Device|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
372132|NCT01355653|Device|marketed heatwrap|heatwrap, topical, one time application, 8 hour duration
372133|NCT01355640|Other|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
372134|NCT01355640|Other|non-nutritive sucking|"Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry."
372135|NCT01355627|Procedure|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
372136|NCT01355627|Procedure|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.~In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
372137|NCT01355614|Drug|QAX576|
372138|NCT01355614|Drug|Infliximab|
372139|NCT01355601|Other|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
372140|NCT01355601|Other|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
372141|NCT01355588|Drug|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
372142|NCT01355588|Drug|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
372143|NCT01355588|Drug|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
372144|NCT01355588|Drug|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
372145|NCT01355575|Drug|Rifaximin|Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
372146|NCT01355562|Drug|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
372147|NCT01355549|Biological|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
372148|NCT01355523|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
372149|NCT01355523|Drug|Placebo|6 mg oral placebo daily 1 hour before bedtime
372150|NCT01355497|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the duration of the trial.
372152|NCT01355484|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
372153|NCT01355484|Drug|placebo|subject will receive placebo for the duration of the trial
372154|NCT01355471|Drug|CD07805/47 Gel|applied topically once daily
372155|NCT01355471|Drug|Placebo|applied topically once daily
372156|NCT01355458|Drug|CD07805/47 gel|applied topically once daily
372157|NCT01355458|Drug|Placebo|applied topically once daily
372158|NCT01355445|Drug|Vincristine, Irinotecan|"D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
372159|NCT01355445|Drug|Vincristine, Irinotecan, Temozolomide|"D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind)~D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~D1 to D5: Irinotecan 50 mg/m²/d, IV~cycle / 21 days"
372160|NCT01355432|Other|Observation|There is no intervention, this is an observational study.
372161|NCT01355406|Device|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
372162|NCT01355393|Biological|HER-2/neu peptide vaccine|Given ID
372163|NCT01355393|Biological|sargramostim|Given ID
372164|NCT01355393|Drug|rintatolimod|Given ID
372165|NCT01355380|Drug|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
372166|NCT01355367|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
372167|NCT01355354|Drug|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
372168|NCT01355354|Drug|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
372169|NCT01355341|Drug|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
372170|NCT01355328|Procedure|laser and radiofrequency|different laser and radiofrequency with different fluences
372171|NCT01355302|Drug|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
372172|NCT01355302|Drug|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
372173|NCT01355302|Drug|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
372174|NCT01355289|Drug|Avatrombopag|
372175|NCT01355289|Drug|Placebo|
372176|NCT01355289|Drug|Pegylated interferon (PEG-IFN)|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor.
372177|NCT01355289|Drug|Telaprevir|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
372178|NCT01355289|Drug|Ribavirin|Participants in Treatment Periods A2, B2, and B3 are to receive antiviral treatment PEG-IFN, ribavirin, or telaprevir. Provided by the sponsor
372179|NCT01355276|Drug|Cinitapride|cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
372180|NCT01355276|Drug|domperidone|10 mg for each dose ,30 mg/daily, for 4 weeks
372181|NCT01355263|Drug|iron and vitamin a|
372182|NCT01355224|Genetic|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
372183|NCT01355224|Behavioral|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
372184|NCT01355198|Dietary Supplement|Cysteine (as n-acetylcysteine) and glycine|Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
372185|NCT01355198|Dietary Supplement|Cysteine/glycine|Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
372186|NCT01355172|Biological|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
372187|NCT01355159|Drug|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
372188|NCT01355159|Drug|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
372189|NCT01355133|Biological|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
372190|NCT01355120|Drug|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
372191|NCT01355094|Device|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
372253|NCT01354483|Biological|Methylprednisolone|30mg/kg i.v. methylprednisolone
372254|NCT01354483|Drug|Lithium Carbonate Tablet|6 weeks
372255|NCT01354470|Drug|Modafinil|600 mg Modafinil capsule
372256|NCT01354457|Drug|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
372257|NCT01354444|Drug|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
372258|NCT01354444|Drug|Placebo|a pill that will look like the active drug but will not contain any carvedilol
372192|NCT01355094|Device|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.~Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
372193|NCT01355081|Drug|Vortioxetine|Vortioxetine tablets
372194|NCT01355081|Drug|Placebo|Vortioxetine placebo
372195|NCT01355068|Drug|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
372196|NCT01355068|Drug|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
372197|NCT01355029|Behavioral|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
372198|NCT01355016|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
372199|NCT01354990|Drug|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
372200|NCT01354977|Drug|Resveratrol|1,000mg twice daily for 28 days
372201|NCT01354964|Drug|Vitamin D|Weekly oral vitamin D drops, weight-based calculated dosage, taken on the same day each week for 4 months.
372202|NCT01354964|Drug|Placebo|
372203|NCT01354951|Other|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
372204|NCT01354938|Drug|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
372205|NCT01354925|Drug|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
372206|NCT01354925|Drug|Standard of care|Standard of care during Ramadan according to physicians decision
372207|NCT01354886|Drug|FSH-GEX™|
372208|NCT01354886|Drug|Comparator 1|
372209|NCT01354886|Drug|Comparator 2|
372210|NCT01354886|Drug|Placebo|
372211|NCT01354860|Other|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.~Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.~We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
372212|NCT01354860|Other|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.~Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
372213|NCT01354847|Device|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
372214|NCT01354834|Drug|hMG|Patients with a condition
372215|NCT01354821|Procedure|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
372216|NCT01354821|Procedure|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
372217|NCT01354808|Drug|Dual Anti-Platelet Therapy (DAPT)|"Loading: aspirin 300mg + clopidogrel 600mg~Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month"
372218|NCT01354808|Drug|Triple Anti-Platelet Therapy (TAPT)|"Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg~Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month"
372219|NCT01354795|Procedure|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
372220|NCT01354795|Procedure|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
372221|NCT01354782|Drug|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.~Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
372222|NCT01354769|Device|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
372345|NCT01353768|Other|retrospective chart review|retrospective chart review
372223|NCT01354743|Drug|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region~Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.~Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
372224|NCT01354743|Device|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
372225|NCT01354717|Drug|Brand Carac|treatment of actinic keratosis
372226|NCT01354717|Drug|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
372227|NCT01354717|Other|Placebo cream|treatment of actinic keratosis
372228|NCT01354704|Drug|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
372229|NCT01354691|Drug|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
372230|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
372231|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
372232|NCT01354665|Biological|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
372233|NCT01354652|Drug|entecavir, lamivudine|"entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.~lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
372234|NCT01354626|Other|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
372235|NCT01354626|Other|low-protein|The control group will get a diet which is according to healthy eating guidelines.
372236|NCT01354613|Drug|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
372237|NCT01354613|Drug|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
372238|NCT01354600|Other|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of ~120 minutes/day or no daily exercise (sedentary)
372239|NCT01354587|Drug|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
372240|NCT01354574|Other|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
372241|NCT01354574|Other|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
372242|NCT01354561|Procedure|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
372243|NCT01354548|Device|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
372244|NCT01354535|Procedure|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
372245|NCT01354535|Procedure|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
372246|NCT01354522|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
372247|NCT01354522|Drug|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
372248|NCT01354496|Drug|LY2409021 Reference Form|Administered orally
372249|NCT01354496|Drug|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
372250|NCT01354496|Drug|LY2409021 Test-High Formulation (high particle size)|Administered orally
372251|NCT01354496|Drug|LY2409021 Test-Low Formulation (low particle size)|Administered orally
372252|NCT01354483|Biological|Umbilical Cord Blood Mononuclear Cell|
372259|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
372260|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
372261|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
372262|NCT01354418|Drug|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
372263|NCT01354418|Drug|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
372264|NCT01354405|Drug|Lanreotide|120 mg every 28 days intramuscular
372265|NCT01354392|Drug|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
372266|NCT01354379|Biological|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
372267|NCT01354379|Biological|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
372268|NCT01354366|Other|Infant formula|
372269|NCT01354353|Drug|LY2140023|Administered orally
372270|NCT01354353|Drug|Aripiprazole|Administered orally
372271|NCT01354340|Dietary Supplement|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
372272|NCT01354340|Dietary Supplement|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
372273|NCT01354340|Other|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
372274|NCT01354327|Dietary Supplement|Limicol|3 tablets / day during 4 months
372275|NCT01354327|Dietary Supplement|Placebo|3 tablets / day during 4 months
372276|NCT01354314|Drug|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
372277|NCT01354314|Drug|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
372278|NCT01354314|Drug|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
372279|NCT01354314|Drug|Placebo|One capsule in the morning, three capsules in the evening
372280|NCT01354301|Drug|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
372281|NCT01354301|Drug|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
372282|NCT01354301|Drug|Basiliximabe|days 0 and 4, according to the package insert instructions.
372283|NCT01354301|Drug|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
372284|NCT01354301|Drug|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
372285|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
372286|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
372287|NCT01354288|Other|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
372288|NCT01354275|Other|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
372289|NCT01354275|Other|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
372290|NCT01354262|Dietary Supplement|Vitamin D|600 IU daily oral supplementation
372291|NCT01354262|Dietary Supplement|Vitamin D|50,000 IU supplementation bi-monthly
372292|NCT01354249|Dietary Supplement|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
372293|NCT01354223|Device|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
372294|NCT01354223|Device|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
372295|NCT01354210|Behavioral|SMS Text Message Reminder|Daily
372296|NCT01354184|Drug|CRD007|
372297|NCT01354184|Drug|CRD007 matching placebo|
372298|NCT01354171|Device|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
372299|NCT01354158|Drug|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
372300|NCT01354145|Drug|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
372301|NCT01354145|Drug|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
372302|NCT01354132|Drug|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
372303|NCT01354132|Drug|Placebo|Placebo tablets are placed in water or juice in the AM and PM
372304|NCT01354119|Procedure|Aortic stent-graft|Early intervention with aortic stent-graft
372305|NCT01354106|Device|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
372306|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
372307|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
372343|NCT01353794|Drug|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
372308|NCT01354080|Other|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
372309|NCT01354080|Other|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
372310|NCT01354067|Behavioral|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
372311|NCT01354067|Behavioral|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
372312|NCT01354054|Procedure|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
372313|NCT01354054|Procedure|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
372314|NCT01354054|Procedure|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
372315|NCT01354041|Behavioral|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
372316|NCT01354028|Other|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
372317|NCT01354015|Device|DRMS|USE OF TEXT MESSAGING SYSTEM
372318|NCT01353976|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
372319|NCT01353976|Other|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
372320|NCT01353963|Drug|desvenlafaxine succinate|50 mg tablet once daily
372321|NCT01353937|Drug|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
372322|NCT01353924|Biological|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
372323|NCT01353924|Biological|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
372324|NCT01353911|Drug|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
372325|NCT01353911|Drug|Boceprevir|Four 200 mg capsules orally three times daily.
372326|NCT01353911|Drug|Placebo for Grazoprevir|Orally once daily in AM.
372327|NCT01353911|Drug|Placebo for Boceprevir|Four capsules orally three times daily.
372328|NCT01353911|Drug|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
372329|NCT01353911|Drug|Ribavirin|300 mg to 700 mg orally twice daily.
372330|NCT01353898|Drug|MK-1972|MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
372331|NCT01353898|Drug|Placebo to MK-1972|Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
372332|NCT01353872|Dietary Supplement|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
372333|NCT01353872|Dietary Supplement|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
372334|NCT01353859|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for a total of 6 infusions
372335|NCT01353859|Drug|methotrexate|10-25 mg orally weekly
372336|NCT01353846|Other|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
372337|NCT01353846|Drug|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
372338|NCT01353833|Drug|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
372339|NCT01353820|Dietary Supplement|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( >10E8 to <5.10E9 cfu/ml of L. delbruckii lactis )
372340|NCT01353820|Dietary Supplement|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
372341|NCT01353807|Dietary Supplement|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
372342|NCT01353807|Dietary Supplement|Olive oil|4 1-g gelatine capsules with virgin olive oil
372344|NCT01353781|Drug|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
372346|NCT01353755|Drug|Grass pollen specific immunotherapy|"Strength 1 (0.78μg/mL)~Strength 2 (6.25μg/mL)~Strength 3 (50μg/mL)~Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
372347|NCT01353755|Drug|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
372348|NCT01353742|Drug|Lamivudine|100mg tablet
372349|NCT01353742|Drug|Adefovir dipivoxil|10mg tablet
372350|NCT01353742|Drug|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
372351|NCT01353729|Drug|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
372352|NCT01353729|Drug|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
372353|NCT01353729|Drug|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
372354|NCT01353729|Drug|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
372355|NCT01353716|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
372356|NCT01353703|Biological|Infanrix hexa™|Intramuscular, three doses
372357|NCT01353690|Biological|AMDC|Cell Treatment
372358|NCT01353664|Drug|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
372359|NCT01353651|Device|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
372360|NCT01353651|Device|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
372361|NCT01353638|Drug|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
372362|NCT01353625|Drug|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).~Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
372363|NCT01353599|Drug|Mometasone furoate|220mcg once daily, for eight weeks
372364|NCT01353586|Device|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
372365|NCT01353573|Radiation|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
372366|NCT01353573|Radiation|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
372367|NCT01353534|Biological|A/H5N1 Antigen|A/H5N1 Antigen
372368|NCT01353534|Drug|Vaccine Enhancement Patch|Vaccine Enhancement Patch
372369|NCT01353521|Procedure|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
372370|NCT01353508|Drug|LCZ696|200 mg and 400 mg tablets
372371|NCT01353508|Drug|Valsartan|160 mg tablets
372372|NCT01353495|Device|APM Graft (BIOTAPE XMTM)|Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.
372373|NCT01353482|Drug|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
372374|NCT01353482|Drug|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
372375|NCT01353482|Drug|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
372376|NCT01353482|Drug|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
372377|NCT01353469|Drug|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
372378|NCT01353469|Drug|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension~Route of administration: Subcutaneous"
372379|NCT01353456|Drug|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
372380|NCT01353456|Drug|Normal Saline|Same volume as dexmedetomidine given
372381|NCT01353443|Procedure|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
372990|NCT01349036|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
372382|NCT01353417|Other|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
372383|NCT01353404|Drug|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
372384|NCT01353404|Drug|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
372385|NCT01353404|Drug|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
372386|NCT01353404|Drug|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
372387|NCT01353404|Drug|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
372388|NCT01353404|Drug|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
372389|NCT01353391|Drug|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
372390|NCT01353391|Drug|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
372391|NCT01353378|Drug|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
372392|NCT01353352|Other|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
372393|NCT01353339|Drug|Levofloxacin|500mg, PO, once daily for 3 months
372394|NCT01353326|Device|Cormet|Cementless hip resurfacing system
372395|NCT01353326|Device|Conserve|Cemented hip resurfacing system
372396|NCT01353313|Drug|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
372397|NCT01353313|Drug|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:~4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then~1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
372398|NCT01353300|Genetic|DNA analysis|
372399|NCT01353300|Genetic|cytogenetic analysis|
372400|NCT01353300|Genetic|gene expression analysis|
372401|NCT01353300|Genetic|gene rearrangement analysis|
372402|NCT01353300|Genetic|mutation analysis|
372403|NCT01353300|Genetic|polymerase chain reaction|
372404|NCT01353300|Genetic|polymorphism analysis|
372405|NCT01353300|Other|laboratory biomarker analysis|
372406|NCT01353300|Other|medical chart review|
372407|NCT01353274|Drug|Micamlo|Telmisartan plus Amlodipine T40/A5
372408|NCT01353248|Drug|GS-5885|tablet, 30 mg QD
372409|NCT01353248|Drug|Tegobuvir|capsule, 30 mg BID
372410|NCT01353248|Drug|GS-9451|tablet, 200 mg QD
372411|NCT01353248|Drug|ribavirin tablet|(weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
372412|NCT01353248|Drug|GS-5885|tablet, 90 mg QD
372413|NCT01353235|Drug|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
372414|NCT01353235|Drug|usual care|no drug administered
372415|NCT01353222|Biological|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
372416|NCT01353222|Other|Standard of Care|Observation only until documentation of disease recurrence.
372417|NCT01353209|Drug|Letrozole|2.5 mg daily for twelve months
372418|NCT01353209|Drug|Placebo|sugar pill given daily for twelve months
372419|NCT01353183|Procedure|colonoscopy or rectosigmoidoscopy|Usual procedure
372420|NCT01353170|Other|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
372421|NCT01353144|Drug|aspirin|aspirin, 100 mg, qd x 8 weeks
372422|NCT01353118|Biological|gastric bypass|Optimise glucose control within 3 months before operation
372423|NCT01353105|Procedure|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
372424|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
372425|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):~30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
372426|NCT01353079|Biological|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
372427|NCT01353079|Biological|Placebo|Placebo: Glycero-COCAs sublingual
372428|NCT01353066|Drug|Intensive Medical Treatment|
372429|NCT01353066|Other|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
372430|NCT01353040|Drug|AVI-6003|Single intravenous administration
372431|NCT01353040|Drug|Placebo|Single intravenous administration
372432|NCT01353027|Drug|Placebo|Normal saline
372433|NCT01353027|Drug|AVI-6002|Single intravenous administration
372993|NCT01349010|Drug|Placebo|1 tablet bid. p.o for 8 weeks
372434|NCT01353014|Other|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
372435|NCT01353014|Other|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
372436|NCT01353001|Behavioral|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
372437|NCT01353001|Behavioral|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
372438|NCT01353001|Behavioral|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
372439|NCT01352988|Drug|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
372440|NCT01352962|Drug|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
372441|NCT01352962|Drug|Carboplatin|AUC 5** IVPB over 30 min x 1
372442|NCT01352962|Drug|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
372443|NCT01352923|Other|blood test|preparation of blood platelets
372444|NCT01352910|Device|rTMS|120 pulses 0.2 Hz
372445|NCT01352910|Device|Sham rTMS|120 pulses 0.2 Hz
372446|NCT01352884|Drug|AMP-224|Escalating doses of AMP-224
372447|NCT01352884|Drug|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
372448|NCT01352871|Behavioral|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
372449|NCT01352871|Drug|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
372450|NCT01352858|Drug|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
372451|NCT01352858|Drug|Arthroscopy & saline irrigation alone|
372452|NCT01352845|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
372453|NCT01352845|Other|Placebo|0.5 mL dose, given at 0, 2 and 6 months
372454|NCT01352832|Other|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
372455|NCT01352832|Other|Usual Care|Usual Care
372456|NCT01352806|Procedure|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
372457|NCT01352793|Biological|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
372458|NCT01352793|Biological|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
372459|NCT01352780|Behavioral|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.~Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client`s perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
372460|NCT01352767|Device|InsuPad|Heating pad
372461|NCT01352741|Drug|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
372462|NCT01352741|Drug|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
372463|NCT01352741|Drug|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
372464|NCT01352728|Drug|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
372465|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
372466|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
372467|NCT01352715|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
372588|NCT01351805|Drug|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
372468|NCT01352715|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
372469|NCT01352715|Drug|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
372470|NCT01352715|Drug|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
372471|NCT01352715|Drug|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
372472|NCT01352715|Drug|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
372473|NCT01352715|Drug|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
372474|NCT01352715|Drug|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
372475|NCT01352702|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
372476|NCT01352702|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
372477|NCT01352689|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
372478|NCT01352689|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
372479|NCT01352663|Biological|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
372480|NCT01352663|Biological|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
372481|NCT01352650|Drug|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg, cohort 2 will receive plerixafor at a dose of 540 mcg/kg and cohort 3 will receive plerixafor at a dose of 810 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
372482|NCT01352650|Drug|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
372483|NCT01352637|Drug|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
372484|NCT01352637|Drug|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
372485|NCT01352637|Drug|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
372486|NCT01352637|Drug|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
372487|NCT01352624|Behavioral|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
372488|NCT01352611|Drug|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
372489|NCT01352598|Radiation|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
372490|NCT01352585|Drug|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
372491|NCT01352572|Drug|antidepressant response|Antidepressants administration for 6 weeks under therapeutic dose responders
372492|NCT01352572|Drug|antidepressant non-response|Antidepressants administration for 6 weeks under therapeutic dose nonresponders
372493|NCT01352559|Drug|responders|Antidepressants administration for 6 weeks under therapeutic dose
372494|NCT01352559|Drug|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
372495|NCT01352546|Biological|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
372496|NCT01352533|Procedure|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
372497|NCT01352533|Procedure|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
372498|NCT01352533|Procedure|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
372499|NCT01352520|Drug|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
372500|NCT01352507|Drug|Tadalafil|Administered Orally
372501|NCT01352507|Drug|Sildenafil|Administered Orally
372502|NCT01352494|Drug|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
372503|NCT01352494|Drug|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
372504|NCT01352481|Other|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
372505|NCT01352468|Other|Multifaceted cognitive training|Four computerized training tasks
372506|NCT01352455|Procedure|Hemodialysis|5 days per week hemodialysis
372507|NCT01352442|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
372508|NCT01352429|Radiation|Proton Therapy|
372509|NCT01352429|Radiation|IMRT|
372510|NCT01352416|Drug|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
372589|NCT01351805|Dietary Supplement|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
372590|NCT01351805|Other|placebo pill|placebo
372511|NCT01352416|Drug|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
372512|NCT01352403|Procedure|gastric bypass|
372513|NCT01352403|Behavioral|intensive life style intervention|
372514|NCT01352390|Behavioral|Planning Prompt|A prompt to have their child their health test reminder mailing to color
372515|NCT01352390|Behavioral|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
372516|NCT01352364|Other|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
372517|NCT01352351|Behavioral|Breastfeeding promotion intervention|"Breastfeeding counseling during monthly microcredit meetings~Weekly cell phone messages about breastfeeding"
372518|NCT01352338|Drug|Lenalidomide, endoxan, prednisone|dose-finding
372519|NCT01352338|Drug|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
372520|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
372521|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
372522|NCT01352312|Drug|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
372523|NCT01352312|Drug|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
372524|NCT01352312|Drug|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
372525|NCT01352299|Device|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
372526|NCT01352299|Device|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
372527|NCT01352299|Device|Miller|Laryngoscopy performed with Miller Laryngoscope
372528|NCT01352299|Device|TrueView|Laryngoscopy performed with TrueView laryngoscope
372529|NCT01352286|Genetic|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.~Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
372530|NCT01352273|Drug|MEK162 + RAF265|
372531|NCT01352247|Procedure|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
372532|NCT01352247|Procedure|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
372533|NCT01352234|Drug|Acetylsalicylic Acid 160 mg|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
372534|NCT01352234|Drug|Acetylsalicylic Acid 80 mg|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
372535|NCT01352221|Drug|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
372536|NCT01352221|Drug|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
372537|NCT01352208|Drug|ASP9521|oral
372538|NCT01352195|Behavioral|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
372539|NCT01352182|Drug|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
372540|NCT01352143|Drug|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
372541|NCT01352143|Drug|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
372542|NCT01352130|Drug|Ondansetron|Intravenous Ondansetron 8 mgs
372543|NCT01352130|Drug|Granisetron|Intravenous Granisetron 1 mgs
372544|NCT01352117|Drug|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
372545|NCT01352117|Drug|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
372585|NCT01351831|Other|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
372686|NCT01351012|Other|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
372546|NCT01352104|Behavioral|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
372547|NCT01352091|Drug|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
372548|NCT01352091|Drug|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
372549|NCT01352065|Drug|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
372550|NCT01352065|Drug|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
372551|NCT01352065|Drug|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
372552|NCT01352052|Other|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
372553|NCT01352039|Biological|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
372554|NCT01352039|Biological|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
372555|NCT01352026|Drug|Metformin|
372556|NCT01352013|Dietary Supplement|Omega-3 (oil)|5ml daily with breakfast for 56 days.
372557|NCT01352013|Dietary Supplement|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
372558|NCT01352000|Behavioral|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
372559|NCT01351961|Biological|blood sampling|take a sample of blood, 46 ml
372560|NCT01351961|Procedure|brain MRI and TEP cerebral|magnetic resonance imaging
372561|NCT01351961|Other|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
372562|NCT01351961|Other|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
372563|NCT01351961|Procedure|Vascular explorations|Pulse wave velocity, VWF, IMT
372564|NCT01351961|Biological|Urine sample|
372565|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
372566|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
372567|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
372568|NCT01351948|Biological|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
372569|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 112. IM injections
372570|NCT01351935|Drug|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
372571|NCT01351922|Other|No treatment given|Patients will fill out a questionaire by interview.
372572|NCT01351909|Drug|Cyclophosphamide|Given PO
372573|NCT01351909|Other|Laboratory Biomarker Analysis|Correlative studies
372574|NCT01351909|Drug|Veliparib|Given PO
372575|NCT01351896|Other|Laboratory Biomarker Analysis|Correlative studies
372576|NCT01351896|Drug|Lenalidomide|Given PO
372577|NCT01351896|Other|Pharmacological Study|Correlative studies
372578|NCT01351896|Biological|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
372579|NCT01351883|Dietary Supplement|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
372580|NCT01351870|Radiation|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week~Cranio-spinal axis:~23.4 Gy in 13 fractions of 1.8 Gy~Posterior fossa:~30.6 Gy in 17 fractions of 1.8 Gy"
372581|NCT01351870|Radiation|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week~Craniospinal axis:~36 Gy in 36 fractions of 1 Gy~Posterior fossa:~24 Gy in 24 fractions of 1 Gy~Tumour Bed:~8 Gy in 8 fractions of 1 Gy"
372582|NCT01351857|Other|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
372583|NCT01351844|Behavioral|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
372584|NCT01351844|Behavioral|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
372586|NCT01351831|Other|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
372587|NCT01351818|Drug|Growth Hormone|
372591|NCT01351792|Drug|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
372592|NCT01351792|Drug|Symbicort® Turbohaler® 200/6 μg/actuation|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
372593|NCT01351766|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
372594|NCT01351753|Drug|Metformin|
372595|NCT01351753|Drug|Orlistat|
372596|NCT01351753|Drug|Topiramate|
372597|NCT01351753|Drug|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
372598|NCT01351740|Drug|atazanavir|switch to unboosted atazanavir 400 mg daily
372599|NCT01351740|Drug|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
372600|NCT01351714|Procedure|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
372601|NCT01351688|Drug|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
372602|NCT01351675|Drug|Placebo|Oral, once daily
372603|NCT01351675|Drug|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
372604|NCT01351662|Behavioral|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
372605|NCT01351649|Behavioral|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
372606|NCT01351636|Drug|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
372607|NCT01351636|Drug|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
372608|NCT01351623|Drug|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
372609|NCT01351610|Biological|PTA + Infusion of MSC_Apceth|percutaneous transluminal angioplasty followed by infusion of MSC_Apceth
372610|NCT01351610|Procedure|PTA|percutaneous transluminal angioplasty only
372611|NCT01351597|Drug|docetaxel/ oxaliplatin|"docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks~oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
372612|NCT01351558|Other|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
372613|NCT01351558|Other|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
372614|NCT01351558|Other|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
372615|NCT01351545|Drug|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
372616|NCT01351532|Behavioral|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
372617|NCT01351532|Behavioral|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
372618|NCT01351519|Drug|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
372619|NCT01351493|Drug|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
372620|NCT01351493|Drug|placebo|placebo Gel, once or twice per day, 12weeks
372621|NCT01351480|Biological|abatacept|Abatacept administered SC weekly at 125 mg dose
372687|NCT01351012|Other|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
372759|NCT01350427|Dietary Supplement|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
372622|NCT01351454|Behavioral|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
372623|NCT01351454|Behavioral|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
372624|NCT01351441|Behavioral|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
372625|NCT01351441|Other|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
372626|NCT01351441|Other|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
372627|NCT01351441|Behavioral|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
372628|NCT01351428|Drug|Nifedipine|30-60 mg, twice daily
372629|NCT01351415|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
372630|NCT01351415|Drug|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m^2) on Day 1 every 21 days.
372631|NCT01351415|Drug|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
372632|NCT01351415|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV over 10 minutes on Day 1 every 21 days.
372633|NCT01351402|Procedure|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
372634|NCT01351389|Behavioral|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
372635|NCT01351389|Behavioral|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
372636|NCT01351376|Device|Low Level Laser Therapy|Placebo LLL combined with CDT
372637|NCT01351376|Device|Low Level Laser|Active LLL combined with CDT
372638|NCT01351363|Device|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
372639|NCT01351363|Device|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
372640|NCT01351350|Drug|MLN0128|MLN0128 capsules
372641|NCT01351350|Drug|paclitaxel|paclitaxel intravenous infusion
372642|NCT01351350|Drug|trastuzumab|trastuzumab intravenous infusion
372643|NCT01351337|Procedure|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
372644|NCT01351324|Dietary Supplement|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
372645|NCT01351311|Other|Exercise|Resistance Training exercise with swiss ball
372646|NCT01351311|Other|Drug treatment|Drug treatment
372647|NCT01351298|Drug|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
372648|NCT01351298|Drug|0.05% xylometazoline hydrochloride|Decongestant
372649|NCT01351298|Drug|Isotonic normal saline|Placebo
372650|NCT01351285|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
372688|NCT01351012|Other|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
372689|NCT01351012|Other|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
372690|NCT01350999|Drug|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
372691|NCT01350999|Drug|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
372651|NCT01351272|Drug|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
372652|NCT01351259|Device|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
372653|NCT01351246|Behavioral|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, & Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
372654|NCT01351233|Procedure|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
372655|NCT01351220|Behavioral|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
372656|NCT01351220|Behavioral|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
372657|NCT01351207|Other|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
372658|NCT01351194|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
372659|NCT01351194|Procedure|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
372660|NCT01351181|Behavioral|Leaflet|Advice Leaflet
372661|NCT01351181|Behavioral|Exercise Advice|Leaflet
372662|NCT01351181|Behavioral|Normal Care|Normal Care
372663|NCT01351168|Drug|Levodopa|CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
372664|NCT01351168|Drug|Zolpidem first dose|Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
372665|NCT01351168|Drug|Zolpidem second dose|Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
372666|NCT01351168|Drug|sugar pill|a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
372667|NCT01351155|Device|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
372668|NCT01351142|Other|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
372669|NCT01351129|Drug|Formulation 1|150-mg immediate release tablet (single dose)
372670|NCT01351129|Drug|Formulation 2|150-mg modified release capsule, short duration (single dose)
372671|NCT01351129|Drug|Formulation 3|150-mg modified release capsule, long duration (single dose)
372672|NCT01351116|Radiation|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
372673|NCT01351116|Radiation|EBR|EBR of 20 Gy in 5 daily fractions over one week
372674|NCT01351103|Drug|LGK974|
372675|NCT01351103|Biological|PDR001|
372676|NCT01351090|Drug|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
372677|NCT01351090|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
372678|NCT01351090|Drug|Placebo|Intranasal
372679|NCT01351077|Other|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
372680|NCT01351064|Other|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
372681|NCT01351038|Drug|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
372682|NCT01351025|Drug|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
372683|NCT01351025|Drug|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
372684|NCT01351025|Drug|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
372685|NCT01351012|Other|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
372692|NCT01350986|Behavioral|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, & Lehmkuhl, 2006)."
372693|NCT01350986|Behavioral|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
372694|NCT01350973|Drug|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
372695|NCT01350973|Drug|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
372696|NCT01350960|Drug|SPC5001|3 weekly SC injections
372697|NCT01350960|Drug|Saline 0.9%|3 weekly SC injections
372698|NCT01350960|Drug|SPC5001|3 weekly SC injections
372699|NCT01350960|Drug|SPC5001|3 weekly SC injections
372700|NCT01350960|Drug|SPC5001|3 weekly SC injections
372701|NCT01350960|Drug|SPC5001|3 weekly SC injections
372702|NCT01350947|Drug|5-Azacitidine|"Administered on Days 1-7 of each Cycle.~Subcutaneous administration:~To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.~The 5-azacitidine suspension is administered subcutaneously.~Intravenous Administration:~5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
372703|NCT01350934|Drug|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
372704|NCT01350934|Drug|Calcitriol|0.25 μg once daily orally
372705|NCT01350934|Dietary Supplement|Calcium 500 mg|one 500 mg tablet once daily
372706|NCT01350921|Drug|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
372707|NCT01350921|Drug|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
372708|NCT01350908|Other|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
372709|NCT01350882|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
372710|NCT01350882|Drug|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
372711|NCT01350869|Device|Xience|Patients with Xience
372712|NCT01350856|Drug|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
372713|NCT01350856|Drug|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
372714|NCT01350843|Dietary Supplement|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
372715|NCT01350830|Procedure|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
372716|NCT01350830|Procedure|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
372717|NCT01350817|Drug|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
372718|NCT01350817|Drug|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
372719|NCT01350804|Biological|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
372720|NCT01350804|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
372721|NCT01350804|Biological|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
372722|NCT01350765|Behavioral|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
372723|NCT01350765|Behavioral|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
372758|NCT01350440|Biological|IVIG|Intravenous Immune Globulin
372724|NCT01350752|Behavioral|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
372725|NCT01350752|Behavioral|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
372726|NCT01350752|Behavioral|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
372727|NCT01350739|Procedure|intraumbilical incision|vertical, intraumbilical incision
372728|NCT01350739|Procedure|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
372729|NCT01350713|Drug|povidone iodine|one local application of 10% povidone iodine ointment
372730|NCT01350700|Other|Scars assessment & QOL|Scar assessment and quality of life questionnaires
372731|NCT01350674|Procedure|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
372732|NCT01350635|Biological|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
372733|NCT01350622|Drug|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
372734|NCT01350622|Drug|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
372735|NCT01350609|Drug|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
372736|NCT01350609|Drug|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
372737|NCT01350596|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
372738|NCT01350596|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
372739|NCT01350583|Drug|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
372740|NCT01350570|Other|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
372741|NCT01350570|Other|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
372742|NCT01350570|Other|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
372743|NCT01350570|Drug|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
372744|NCT01350557|Other|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
372745|NCT01350557|Other|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
372746|NCT01350544|Behavioral|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
372747|NCT01350531|Behavioral|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
372748|NCT01350531|Behavioral|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
372749|NCT01350518|Dietary Supplement|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.~Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
372750|NCT01350518|Dietary Supplement|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
372751|NCT01350505|Behavioral|White light exposure|~200 lux of broad spectrum white light
372752|NCT01350505|Behavioral|Dim white light exposure|~28 lux of broad spectrum white light
372753|NCT01350505|Behavioral|Very dim white light exposure|<0.5 lux of broad spectrum white light
372754|NCT01350505|Behavioral|Dim orange light exposure|~28 lux of orange light
372755|NCT01350492|Behavioral|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
372756|NCT01350453|Behavioral|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
372757|NCT01350453|Behavioral|Standard Care|Participants will receive their usual care from their NHS provider.
372760|NCT01350427|Dietary Supplement|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
372761|NCT01350427|Dietary Supplement|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
372762|NCT01350414|Device|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
372763|NCT01350401|Genetic|Autologous genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion of NY-ESO-1ᶜ²⁵⁹T
372764|NCT01350388|Drug|Febuxostat|80 mg/day of febuxostat for 24 weeks
372765|NCT01350388|Drug|Placebo|1 placebo tablet per day for 24 weeks
372766|NCT01350375|Drug|Botox|
372767|NCT01350375|Drug|Saline|
372768|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
372769|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
372770|NCT01350362|Drug|tideglusib|500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
372771|NCT01350362|Drug|Placebo|Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
372772|NCT01350349|Behavioral|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
372773|NCT01350349|Behavioral|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
372774|NCT01350336|Device|Alair System|Treatment of airways with the Alair System
372775|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
372776|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
372777|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
372778|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)
372779|NCT01350310|Procedure|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
372780|NCT01350310|Procedure|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
372781|NCT01350310|Procedure|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
372782|NCT01350297|Procedure|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
372783|NCT01350284|Dietary Supplement|Cinnamon|acute oral administration of 3 g cinnamon
372784|NCT01350284|Dietary Supplement|Placebo control|3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
372785|NCT01350271|Drug|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
372786|NCT01350271|Drug|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
372787|NCT01350271|Drug|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
372788|NCT01350258|Drug|Fludarabine|Part of the conditioning regimen
372789|NCT01350258|Drug|Thiotepa|Part of the conditioning regimen
372790|NCT01350258|Radiation|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
372791|NCT01350258|Biological|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
372792|NCT01350258|Drug|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
372793|NCT01350258|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
372794|NCT01350245|Radiation|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
372795|NCT01350245|Biological|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
372796|NCT01350245|Drug|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
372797|NCT01350245|Drug|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
372798|NCT01350245|Drug|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
372799|NCT01350245|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
372800|NCT01350232|Drug|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
372869|NCT01349842|Biological|Blood sampling|20ml of patient peripherical blood will be collected
372801|NCT01350232|Drug|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
372802|NCT01350232|Device|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.~The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
372803|NCT01350232|Radiation|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
372804|NCT01350232|Drug|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
372805|NCT01350232|Drug|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
372806|NCT01350232|Drug|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
372807|NCT01350232|Procedure|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
372808|NCT01350219|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
372809|NCT01350206|Procedure|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
372810|NCT01350206|Procedure|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
372811|NCT01350193|Device|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
372812|NCT01350193|Other|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
372813|NCT01350167|Procedure|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
372814|NCT01350154|Drug|Sildenafil|20 mg in gelatine capsules, oral, three times daily
372815|NCT01350154|Drug|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
372816|NCT01350141|Other|Placebo|An infusion lasting approximately 60 minutes
372817|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
372818|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
372819|NCT01350128|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
372820|NCT01350128|Drug|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
372821|NCT01350128|Other|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
372822|NCT01350115|Drug|LDE225|supplied as 100 mg capsules
372823|NCT01350115|Drug|Placebo|supplied in capsules
372824|NCT01350102|Drug|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
372825|NCT01350102|Drug|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
372826|NCT01350102|Dietary Supplement|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
372827|NCT01350089|Drug|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
372828|NCT01350089|Drug|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
372829|NCT01350089|Drug|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
372830|NCT01350089|Drug|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
372831|NCT01350076|Drug|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
372832|NCT01350076|Drug|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
372870|NCT01349842|Other|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
372833|NCT01350063|Drug|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
372834|NCT01350063|Device|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
372835|NCT01350063|Other|No intervention|
372836|NCT01350050|Drug|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.~In dentistry, articaine is used both for infiltration and block injections."
372837|NCT01350050|Other|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
372838|NCT01350037|Drug|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
372839|NCT01350037|Drug|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
372840|NCT01350024|Procedure|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
372841|NCT01350024|Procedure|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
372842|NCT01350011|Behavioral|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
372843|NCT01350011|Behavioral|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
372844|NCT01349998|Drug|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
372845|NCT01349985|Other|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
372846|NCT01349985|Other|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
372847|NCT01349972|Drug|alvocidib|Given IV
372848|NCT01349972|Drug|daunorubicin hydrochloride|Given IV
372849|NCT01349972|Drug|mitoxantrone hydrochloride|Given IV
372850|NCT01349972|Drug|cytarabine|Given IV
372851|NCT01349959|Drug|Azacitidine|Given SC
372852|NCT01349959|Drug|Entinostat|Given PO
372853|NCT01349959|Other|Laboratory Biomarker Analysis|Correlative studies
372854|NCT01349959|Other|Pharmacological Study|Correlative studies
372855|NCT01349933|Drug|Akt inhibitor MK2206|Given PO
372856|NCT01349920|Drug|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
372857|NCT01349907|Drug|Asenapine|One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
372858|NCT01349907|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam [up to 4 mg/day] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
372859|NCT01349894|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
372860|NCT01349881|Drug|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
372861|NCT01349881|Drug|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
372862|NCT01349881|Drug|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
372863|NCT01349881|Drug|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
372864|NCT01349868|Drug|PT005 MDI|PT005 MDI taken as two inhalations
372865|NCT01349868|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
372866|NCT01349868|Drug|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
372867|NCT01349868|Other|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
372868|NCT01349855|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
372871|NCT01349829|Biological|HAVpur Junior|"≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
372872|NCT01349829|Biological|Havrix 720 Junior|"≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)~Vaccination schedule: single doses at 0 and 6 months"
372873|NCT01349816|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
372874|NCT01349816|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
372875|NCT01349816|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
372876|NCT01349803|Drug|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
372877|NCT01349803|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
372878|NCT01349803|Drug|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
372879|NCT01349803|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
372880|NCT01349790|Drug|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
372881|NCT01349777|Drug|Pregrel®|Pregrel® 75mg daily for 12 months
372882|NCT01349777|Drug|Plavix®|Plavix® 75mg daily for 12 months
372883|NCT01349764|Drug|Vitamin D3|
372884|NCT01349751|Drug|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
372885|NCT01349751|Drug|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
372886|NCT01349738|Drug|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
372887|NCT01349725|Drug|ARRY-502|Oral; multiple dose, escalating
372888|NCT01349725|Drug|Placebo|Oral; matching placebo
372889|NCT01349699|Drug|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
372890|NCT01349699|Drug|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
372891|NCT01349699|Drug|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
372892|NCT01349699|Drug|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.~At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
372893|NCT01349686|Procedure|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
372894|NCT01349686|Procedure|Fasting|No intake of fluids during labour.
372895|NCT01349673|Drug|Budesonide Foam|Topical
372896|NCT01349660|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
372897|NCT01349660|Drug|BKM120|BKM120 orally (PO) once daily
372898|NCT01349647|Biological|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
372899|NCT01349647|Biological|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.~Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
372900|NCT01349634|Other|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
372901|NCT01349608|Behavioral|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
372902|NCT01349595|Drug|Bortezomib|"Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area)."
372903|NCT01349582|Procedure|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
372904|NCT01349582|Other|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
372905|NCT01349582|Procedure|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
372906|NCT01349582|Procedure|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
372907|NCT01349582|Procedure|surgical clipping|clipping of the aneurysm following invasive brain surgery
372908|NCT01349569|Drug|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
372951|NCT01349270|Drug|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
372991|NCT01349023|Other|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
372909|NCT01349569|Biological|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
372910|NCT01349569|Biological|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
372911|NCT01349556|Drug|Tretinoin|tretinoin 0.025% cream
372912|NCT01349543|Biological|RSV A Memphis 37|Intranasal administration
372913|NCT01349530|Other|Evaluating of usual care|RESEARCH IN CURRENT CARE
372914|NCT01349530|Other|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
372915|NCT01349517|Procedure|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
372916|NCT01349517|Procedure|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
372917|NCT01349517|Procedure|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
372918|NCT01349517|Procedure|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
372919|NCT01349491|Drug|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
372920|NCT01349491|Drug|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
372921|NCT01349478|Device|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
372922|NCT01349465|Drug|No treatment|No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
372923|NCT01349452|Drug|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
372924|NCT01349452|Drug|Artificial tear|Artificial tear 5 times per day
372925|NCT01349439|Drug|Propranolol|1mg per Kg (participant weight)
372926|NCT01349439|Drug|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
372927|NCT01349426|Device|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
372928|NCT01349413|Drug|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
372929|NCT01349413|Other|Placebo|Identical looking placebo
372930|NCT01349400|Other|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
372931|NCT01349400|Procedure|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.~These are all standard techniques in incisional hernia repair."
372932|NCT01349387|Drug|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
372933|NCT01349374|Other|skin biopsy|Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
372934|NCT01349361|Procedure|Daylight mediated photodynamic therapy|
372935|NCT01349348|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
372936|NCT01349348|Drug|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
372937|NCT01349348|Drug|placebo|tablet, 7.5/15mg , Qd, 7days.
372938|NCT01349335|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
372939|NCT01349335|Drug|Tolvaptan|tablet, 30 mg, Qd, 7 days
372940|NCT01349335|Drug|placebo|tablet, 30 mg, Qd, 7days.
372941|NCT01349322|Radiation|Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy|Patients undergo whole breast radiotherapy by 3D-CRT or IMRT
372942|NCT01349322|Radiation|Higher per daily radiation therapy|Patients undergo higher per daily radiation therapy
372943|NCT01349322|Radiation|Concurrent boost radiotherapy|Patients undergo concurrent boost radiotherapy
372944|NCT01349322|Radiation|Standard per daily radiation therapy|Patients undergo standard per daily radiation therapy
372945|NCT01349322|Radiation|Sequential boost radiotherapy|Patients undergo sequential boost radiotherapy
372946|NCT01349309|Behavioral|Swallowing Exercise Group|"Swallowing Exercises~Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.~Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)~Super Supraglottic Swallow:~Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)~Tongue Hold Maneuver:~Gently hold your tongue in between your front teeth and swallow your saliva.~Tongue Retraction:~Pull the back of your tongue to the back of your mouth and hold.~Mendelsohn Maneuver:~Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
372947|NCT01349296|Drug|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
372948|NCT01349283|Biological|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
372949|NCT01349283|Biological|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
372950|NCT01349270|Drug|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
372952|NCT01349257|Drug|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
372953|NCT01349231|Drug|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
372954|NCT01349218|Other|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
372955|NCT01349218|Other|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
372956|NCT01349205|Drug|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
372957|NCT01349205|Drug|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
372958|NCT01349205|Drug|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
372959|NCT01349192|Drug|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: <40kg : 15mg/kg daily for 14 days divided every 12 hours.
372960|NCT01349192|Drug|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: <40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
372961|NCT01349192|Drug|Minocycline|"only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.~Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: < 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day."
372962|NCT01349192|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
372963|NCT01349192|Drug|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
372964|NCT01349192|Drug|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
372965|NCT01349192|Behavioral|Environmental Decontamination|"wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.~wash all linens and towels in hot water once weekly for three weeks."
372966|NCT01349179|Device|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
372967|NCT01349166|Behavioral|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
372968|NCT01349153|Behavioral|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
372969|NCT01349153|Behavioral|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
372970|NCT01349140|Drug|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
372971|NCT01349127|Dietary Supplement|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
372972|NCT01349127|Dietary Supplement|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
372973|NCT01349127|Dietary Supplement|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
372974|NCT01349114|Drug|aliskiren 300 mg once daily|aliskiren 300 mg daily
372975|NCT01349114|Drug|Placebo/sugar pill|Sugar pill/placebo
372976|NCT01349101|Radiation|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)~Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
372977|NCT01349101|Drug|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days on days +3 and +4.
372978|NCT01349101|Drug|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
372979|NCT01349101|Drug|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
372980|NCT01349101|Drug|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
372981|NCT01349101|Drug|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
372982|NCT01349101|Genetic|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
372983|NCT01349088|Drug|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
372984|NCT01349088|Drug|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
372985|NCT01349088|Drug|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
372986|NCT01349075|Radiation|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
372987|NCT01349062|Drug|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
372988|NCT01349049|Drug|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
372989|NCT01349049|Drug|PLX3397|The drug product is available in capsule form, to be taken orally.
372994|NCT01348997|Behavioral|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
372995|NCT01348997|Behavioral|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
372996|NCT01348984|Drug|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
372997|NCT01348984|Drug|placebo patch|group 2 = placebo patch
372998|NCT01348971|Dietary Supplement|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
372999|NCT01348971|Other|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
373000|NCT01348958|Device|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.~During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
373001|NCT01348945|Other|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
373002|NCT01348919|Drug|CEP-18770|administered on days 1, 8, and 15 of each 28-day cycle
373003|NCT01348919|Drug|Lenalidomide|administered 25 mg on days 1 through 21 of each 28-day cycle
373004|NCT01348919|Drug|Dexamethasone|administered 40 mg on days 1, 8, 15, and 22 of each 28-day cycle
373005|NCT01348906|Procedure|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
373006|NCT01348893|Behavioral|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
373007|NCT01348880|Drug|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
373008|NCT01348880|Drug|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
373009|NCT01348867|Other|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
373010|NCT01348854|Device|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
373011|NCT01348841|Other|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
373012|NCT01348828|Device|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
373013|NCT01348802|Behavioral|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
373014|NCT01348802|Behavioral|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
373015|NCT01348789|Device|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
373016|NCT01348776|Device|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
373017|NCT01348763|Drug|Maraviroc|Maraviroc 150 mg daily
373018|NCT01348763|Drug|Truvada|daily until 10. day then stop
373019|NCT01348763|Drug|Darunavir|daily until 10. day then stop
373020|NCT01348750|Other|Healing Touch & Guided Imagery|"Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.~HT complements traditional health care and is used together with other approaches to health and healing.~Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing."
373021|NCT01348737|Drug|AZD3839|Single Oral Dose
373022|NCT01348737|Drug|AZD3839 Placebo|Single Oral Dose
373023|NCT01348724|Drug|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
373024|NCT01348698|Procedure|Tumor tissue biopsy|Participants whose tumor does not secrete hormones will have a tumor biopsy to collect tissue for the study.
373025|NCT01348698|Procedure|Surgery|Participants who have a large tumor or one that secretes hormones will have standard surgery to remove the tumor. Tissue will be collected for study.
373026|NCT01348685|Other|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
373027|NCT01348685|Other|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
373028|NCT01348685|Other|The effect of solid vs. liquid forms of whey protein on food intake|
373029|NCT01348659|Drug|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
373030|NCT01348659|Drug|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
373031|NCT01348646|Behavioral|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
373032|NCT01348620|Device|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)
373033|NCT01348620|Procedure|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
373034|NCT01348607|Drug|methylphenidate hydrochloride|Given orally
373035|NCT01348607|Drug|modafinil|Given orally
373036|NCT01348607|Drug|placebo|Given orally
373037|NCT01348581|Device|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
373038|NCT01348568|Dietary Supplement|low glycemic index diet with canola oil bread|
373039|NCT01348568|Dietary Supplement|High fiber diet|
373040|NCT01348555|Drug|Bronchodilatator|
373041|NCT01348555|Drug|Bronchodilatator|
373042|NCT01348542|Drug|Trazodone|50 mg once a day, for 3 months
373043|NCT01348542|Behavioral|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with 4 consultations held on a weekly basis and 4 held on a biweekly basis.
373044|NCT01348529|Behavioral|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
373045|NCT01348516|Drug|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
373046|NCT01348516|Drug|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
373047|NCT01348503|Drug|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
373048|NCT01348503|Drug|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
373049|NCT01348490|Drug|Ruxolitinib (INCB018424)|Ruxolitinib (INCB018424), 5 mg bid
373050|NCT01348477|Procedure|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
373051|NCT01348464|Procedure|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
373052|NCT01348451|Device|surgical implantation|human spinal cord stem cell implantation in ALS patients
373053|NCT01348438|Device|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
373054|NCT01348425|Device|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
373055|NCT01348425|Device|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
373056|NCT01348412|Drug|oxaliplatin|130 mg/m²Every 21 days
373057|NCT01348412|Drug|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
373058|NCT01348412|Drug|other intravenous chemotherapy drugs|
373059|NCT01348386|Drug|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
373060|NCT01348386|Drug|Placebo|
373061|NCT01348347|Drug|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
373062|NCT01348347|Drug|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
373063|NCT01348347|Drug|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
373064|NCT01348334|Procedure|Synthetic sling surgery|An incision of inverted A shape was inflicted on the anterior vaginal wall(AVW)of the vagina.The upper part of A shaped incision was formed into an island belonging to the vaginal wall.This patch was 3×4cm in most of the patients.Proximal AVWwas dissected as a flap.Synthetics mesh materials were first sutured onto the upper part of the A on the vaginal island with absorbable vicrly sutures.Then,with 2polypropilen sutures,these meshes were fixed on both the right and left sides of this island in a helical manner to form a suspension and using curved Kishner needles,the prolene sutures were transferred to suprapubic area.These sutures were ligated on the rectus fascia in a crosswise manner.The mobile lower wing was advanced onto the island and was sutured onto the vaginal skin with intermittent sutures using 3-0 monocryl sutures.After cystoscopy,the prolene sutures were ligated crosswise in the suprapubic region.Special attention was paid notto create much tension on the mesh material.
373065|NCT01348321|Drug|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
373066|NCT01348308|Drug|Maraviroc (Celsentri)|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
373067|NCT01348308|Drug|Placebo|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.~Duration: 72 weeks."
373068|NCT01348295|Other|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
373069|NCT01348282|Drug|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
373288|NCT01346553|Device|ESVV device|wearing the ESVV device for 6 hours
373070|NCT01348282|Drug|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
373071|NCT01348269|Drug|Aclasta|1 x intravenous non-current drip (infusion)
373072|NCT01348269|Drug|Placebo|NaCl Solution
373073|NCT01348256|Drug|Dendritic cells vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
373074|NCT01348243|Drug|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
373075|NCT01348243|Drug|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
373076|NCT01348230|Other|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
373077|NCT01348217|Radiation|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
373078|NCT01348217|Radiation|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
373079|NCT01348217|Radiation|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
373080|NCT01348217|Drug|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
373081|NCT01348204|Other|quercetin|health food supplement
373082|NCT01348191|Procedure|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
373083|NCT01348178|Procedure|Follow-up|Follow-up
373084|NCT01348165|Drug|BI 137882|Powder for oral solution
373085|NCT01348165|Drug|Placebo|Powder for oral solution
373086|NCT01348152|Drug|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
373087|NCT01348152|Drug|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
373088|NCT01348139|Drug|AZD3199|Inhaled via single inhaler device (SID)
373089|NCT01348139|Drug|AZD3199|Inhaled via Turbuhaler inhaler
373090|NCT01348139|Other|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
373091|NCT01348126|Drug|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
373092|NCT01348126|Drug|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
373093|NCT01348113|Other|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
373094|NCT01348100|Drug|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
373095|NCT01348100|Drug|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
373096|NCT01348100|Drug|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
373097|NCT01348087|Drug|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
373098|NCT01348074|Drug|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
373099|NCT01348048|Other|Specialised palliative care (SPC)|The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
373100|NCT01348009|Drug|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.~Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
373101|NCT01347996|Drug|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg [16,400 IU/kg] body weight twice daily for 10, 21 day cycles
373102|NCT01347983|Drug|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
373103|NCT01347970|Drug|carvedilol|Given PO
373104|NCT01347970|Other|placebo|Given PO
373105|NCT01347970|Other|pharmacogenomic studies|Correlative studies
373106|NCT01347970|Other|laboratory biomarker analysis|Correlative studies
373107|NCT01347970|Procedure|quality-of-life assessment|Ancillary studies
373108|NCT01347970|Genetic|polymorphism analysis|Correlative studies
373109|NCT01347970|Genetic|microarray analysis|Correlative studies
373110|NCT01347970|Genetic|polymerase chain reaction|Correlative studies
373111|NCT01347970|Other|enzyme-linked immunosorbent assay|Correlative studies
373112|NCT01347970|Other|questionnaire administration|Ancillary studies
373113|NCT01347957|Other|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
373114|NCT01347957|Other|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
373115|NCT01347944|Drug|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
373116|NCT01347931|Device|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
373117|NCT01347931|Device|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
373118|NCT01347918|Device|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
373119|NCT01347918|Dietary Supplement|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
373120|NCT01347905|Other|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
373121|NCT01347892|Other|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
373122|NCT01347879|Drug|Visonac PDT|cream application prior to illumination with red light
373123|NCT01347879|Drug|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
373124|NCT01347866|Drug|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
373125|NCT01347866|Drug|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
373126|NCT01347866|Drug|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
373127|NCT01347866|Drug|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
373128|NCT01347853|Drug|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
373129|NCT01347853|Drug|Placebo|Intranasal post-surgery for up to 5 days total
373130|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
373131|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
373132|NCT01347814|Drug|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
373133|NCT01347814|Drug|Placebo|Homeopathic (Sugar) pill-Placebo
373134|NCT01347801|Drug|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
373135|NCT01347801|Drug|Placebo (Saline)|Normal saline (NaCl 0,9%)
373136|NCT01347801|Drug|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
373137|NCT01347801|Other|OGTT|Oral glucose tolerance test with 75 g glucose
373138|NCT01347801|Other|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
373139|NCT01347788|Drug|cabozantinib|Cabozantinib PO QD
373140|NCT01347775|Device|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
373141|NCT01347775|Device|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
373142|NCT01347762|Drug|Nabilone|nabilone titrated to 1 mg by mouth twice daily
373143|NCT01347762|Drug|Placebo|one placebo capsule by mouth twice daily
373144|NCT01347749|Behavioral|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
373145|NCT01347749|Behavioral|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
373146|NCT01347736|Other|scrambler therapy|Undergo scrambler therapy
373147|NCT01347736|Other|questionnaire administration|Ancillary studies
373148|NCT01347736|Procedure|dermatologic complications management/prevention|Undergo scrambler therapy
373149|NCT01347723|Other|scrambler therapy|Undergo scrambler therapy
373150|NCT01347723|Other|questionnaire administration|Ancillary studies
373151|NCT01347723|Procedure|management of therapy complications|Undergo scrambler therapy
373152|NCT01347710|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis
373153|NCT01347710|Drug|99mTechnicium (sestamibi or tetrofosmin)|Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis
373154|NCT01347697|Procedure|Reconstruction with an acellular porcine collagen implant|Reconstruction of floor of lesser pelvis with an acellular porcine collagen implant after extended excision of rectum including levator muscles in advanced low rectal cancer.
373155|NCT01347697|Procedure|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
373156|NCT01347684|Behavioral|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
373157|NCT01347684|Drug|Standard care using current drugs|Standard Drug therapy
373158|NCT01347671|Drug|GRT6005|25µg/day once daily
373159|NCT01347671|Drug|GRT6005|75 µg/day once daily
373160|NCT01347671|Drug|GRT6005|200 µg/day once daily
373161|NCT01347671|Drug|Matching Placebo|Once daily
373162|NCT01347658|Dietary Supplement|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
373163|NCT01347645|Drug|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
373164|NCT01347645|Drug|E7820|"Test product: dose and mode of administration:~E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.~The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle)."
373165|NCT01347632|Drug|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
373166|NCT01347619|Other|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
373167|NCT01347619|Other|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
373168|NCT01347619|Other|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
373169|NCT01347593|Drug|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
373170|NCT01347580|Drug|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
373171|NCT01347580|Drug|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
373172|NCT01347567|Other|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
373173|NCT01347554|Device|Everolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
373174|NCT01347554|Device|Zotarolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
373175|NCT01347541|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
373176|NCT01347541|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
373177|NCT01347541|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
373178|NCT01347541|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
373179|NCT01347528|Behavioral|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
373247|NCT01346982|Drug|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
373248|NCT01346969|Drug|EXC 001|Single-dose administered by injection four different times
373180|NCT01347515|Other|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.~Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
373181|NCT01347463|Procedure|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
373182|NCT01347450|Dietary Supplement|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
373183|NCT01347450|Dietary Supplement|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
373184|NCT01347437|Behavioral|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team—is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
373185|NCT01347424|Drug|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3－4h， d1～15，q3w
373186|NCT01347424|Drug|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
373187|NCT01347411|Procedure|CPAP|Treatment with CPAP
373188|NCT01347398|Procedure|PSG|Sleep study made by PSG (polysomnography)
373189|NCT01347398|Procedure|MicroMESAM system|Sleep study made by MicroMESAM system
373190|NCT01347385|Procedure|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
373191|NCT01347385|Procedure|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
373192|NCT01347372|Behavioral|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
373193|NCT01347359|Behavioral|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
373194|NCT01347359|Behavioral|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
373195|NCT01347346|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
373196|NCT01347333|Radiation|Stereotactic body radiosurgery|36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)
373197|NCT01347333|Radiation|Stereotactic Body Radiotherapy|26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
373198|NCT01347320|Other|Preoperative MRI|Preoperative staging
373199|NCT01347307|Radiation|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
373200|NCT01347307|Radiation|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
373201|NCT01347294|Drug|Bleomycin|Intralesional
373202|NCT01347294|Drug|Fibrovein|Intralesional
373203|NCT01347294|Drug|Bleomycin + Fibrovein|Intralesional
373249|NCT01346969|Drug|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
373204|NCT01347281|Procedure|Injection of [18F]HX4|"Injection of [18F]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:~[18F]HX4 PET scans; 444 MBq (12 mCi) [18F]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.~Venous blood sampling: before injection of [18F]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): [18F]FDG PET in treatment position"
373205|NCT01347268|Procedure|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
373206|NCT01347268|Procedure|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
373207|NCT01347255|Drug|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
373208|NCT01347255|Drug|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
373209|NCT01347255|Drug|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
373210|NCT01347255|Drug|Daivobet® ointment|once daily application, 4 weeks
373211|NCT01347242|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
373212|NCT01347229|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
373213|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
373214|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
373215|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
373216|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
373217|NCT01347190|Biological|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
373218|NCT01347190|Biological|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
373219|NCT01347177|Procedure|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
373220|NCT01347177|Procedure|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
373221|NCT01347164|Behavioral|RISE life coaching intervention|6 2-hour sessions
373222|NCT01347164|Behavioral|HIV Counseling|Standard one-hour HIV counseling session
373223|NCT01347151|Device|The glidescope video laryngoscopy|
373224|NCT01347151|Device|The Pentax airwayscope|
373225|NCT01347138|Other|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
373226|NCT01347125|Device|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
373227|NCT01347112|Drug|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
373228|NCT01347112|Drug|placebo|sugar pill twice daily for 12 weeks
373229|NCT01347099|Behavioral|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
373230|NCT01347099|Behavioral|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
373231|NCT01347086|Drug|Matching placebo (low dose)|single dose of matching placebo
373232|NCT01347086|Drug|BI 207127 NA (medium dose)|Single does of BI 207127 NA
373233|NCT01347086|Drug|BI 207127 NA (low dose)|single dose of BI 207127 NA
373234|NCT01347086|Drug|Matching placebo (medium dose)|Single dose of matching placebo
373235|NCT01347086|Drug|BI 207127 NA (high dose)|Single dose of BI 207127 NA
373236|NCT01347086|Drug|Matching placebo (high dose)|Single dose of matching placebo
373237|NCT01347073|Drug|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
373238|NCT01347060|Drug|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
373239|NCT01347060|Drug|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
373240|NCT01347034|Procedure|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28~Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.~Day 78-91: First post-operative visit~Days 91-365: Clinical follow-up~Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
373241|NCT01347034|Biological|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.~Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
373242|NCT01347021|Procedure|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
373243|NCT01347008|Drug|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
373244|NCT01347008|Drug|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
373245|NCT01346995|Other|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
373246|NCT01346995|Other|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
373250|NCT01346969|Drug|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
373251|NCT01346969|Drug|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
373252|NCT01346943|Device|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
373253|NCT01346930|Drug|Macitentan|10 mg, tablet, once daily
373254|NCT01346917|Drug|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
373255|NCT01346917|Drug|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
373256|NCT01346865|Drug|Cilostazol|Cilostazol 100mg bid
373257|NCT01346865|Drug|Placebo|Placebo 1tablet bid
373258|NCT01346852|Drug|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
373259|NCT01346839|Behavioral|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
373260|NCT01346826|Drug|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
373261|NCT01346826|Drug|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
373262|NCT01346826|Drug|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
373263|NCT01346800|Drug|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
373264|NCT01346800|Drug|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
373265|NCT01346787|Drug|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
373266|NCT01346774|Drug|Cranberry powder capsules|2 cranberry powder capsules twice a day
373267|NCT01346774|Drug|Placebo powder capsules|2 placebo capsules twice a day
373268|NCT01346761|Behavioral|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
373269|NCT01346761|Behavioral|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
373270|NCT01346748|Drug|statin|Sinvastatin 80 mg per day - 21 days versus placebo
373271|NCT01346735|Other|No intervention|
373272|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
373273|NCT01346722|Other|Diet- CR|conventional rice-based diet
373274|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
373275|NCT01346722|Other|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
373276|NCT01346696|Device|OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)|
373277|NCT01346683|Device|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
373278|NCT01346670|Drug|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
373279|NCT01346657|Drug|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
373280|NCT01346644|Other|Infant formula|Powder infant formula
373281|NCT01346644|Other|Infant formula|Powder infant formula
373282|NCT01346631|Other|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
373283|NCT01346592|Biological|Trivalent split influenza vaccine (TIV)|
373284|NCT01346592|Biological|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
373285|NCT01346592|Biological|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
373286|NCT01346579|Other|laboratory biomarker analysis|Correlative sciences
373287|NCT01346566|Device|Cionni Modified Capsule Tension Ring|Cionni ring was used to fixate the capsular bag to the sclera and IOL was implanted in-the-bag
373289|NCT01346540|Drug|BIBF 1120|VEGF inhibitor
373290|NCT01346540|Drug|Placebo|BIBF 1120 placebo
373291|NCT01346514|Behavioral|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
373292|NCT01346514|Behavioral|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
373293|NCT01346475|Drug|valacyclovir|1000 mg orally three times daily for 5 weeks
373294|NCT01346475|Drug|Valacyclovir|500 mg orally once daily for 5 weeks
373295|NCT01346462|Behavioral|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
373296|NCT01346449|Behavioral|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
373297|NCT01346449|Behavioral|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
373298|NCT01346449|Behavioral|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
373299|NCT01346449|Behavioral|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
373300|NCT01346436|Procedure|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
373301|NCT01346423|Behavioral|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
373302|NCT01346423|Behavioral|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
373303|NCT01346410|Radiation|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
373304|NCT01346397|Drug|cyclosporine or tacrolimus|after alemtuzumab, cyclosporine or tacrolimus was administered
373305|NCT01346384|Device|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
373306|NCT01346371|Drug|Bepreve (bepotastine ophthalmic solution) 1.5%|Must add drops twice a day every day while enrolled in trial.
373307|NCT01346358|Biological|IMC-CS4|
373308|NCT01346332|Device|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
373309|NCT01346319|Drug|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
373310|NCT01346319|Drug|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
373311|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 1.
373312|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 2.
373313|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
373314|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
373315|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
373316|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
373317|NCT01346267|Procedure|Real Acupressure Band|Acupressure wristband
373318|NCT01346267|Procedure|Placebo Acupressure Band|Sham wristband
373319|NCT01346254|Drug|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
373320|NCT01346254|Drug|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
373321|NCT01346254|Behavioral|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
373322|NCT01346241|Behavioral|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
373323|NCT01346228|Behavioral|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
373324|NCT01346215|Biological|heparin sodium|5000 UI/mL
373325|NCT01346215|Biological|heparin sodium|5000 UI/mL
373326|NCT01346189|Behavioral|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
373327|NCT01346176|Other|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
373328|NCT01346163|Drug|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
373329|NCT01346163|Other|Placebo|Placebo will be used as a comparator to the active arm.
373330|NCT01346137|Drug|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
373331|NCT01346124|Radiation|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
373332|NCT01346098|Procedure|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
373333|NCT01346098|Procedure|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
373334|NCT01346085|Drug|CNI free immunosuppression|Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
373335|NCT01346072|Drug|tolvaptan|oral, 30 mg, single dose, one time administration
373336|NCT01346059|Drug|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
373337|NCT01346059|Drug|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
373338|NCT01346007|Biological|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
373339|NCT01345994|Procedure|electro-acupuncture|acupuncture stimulation with electricity
373340|NCT01345981|Drug|Lidocaine|dosage 20 mg and 40 mg
373341|NCT01345968|Drug|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
373342|NCT01345968|Drug|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
373343|NCT01345942|Drug|RO5428029|Single oral dose
373344|NCT01345929|Drug|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
373345|NCT01345929|Drug|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
373346|NCT01345916|Drug|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
373347|NCT01345916|Drug|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
373348|NCT01345916|Drug|BDP DPI 2 months|BDP DPI 2 months
373349|NCT01345903|Procedure|therapeutic conventional surgery|Undergo robotic-assisted surgery
373350|NCT01345890|Procedure|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
373351|NCT01345877|Procedure|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
373352|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
373353|NCT01345864|Drug|Scopolamine + Donepezil 5 mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
373354|NCT01345864|Drug|Scopolamine + Donepezil 10mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
373355|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
373356|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 15 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
373357|NCT01345851|Radiation|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
373358|NCT01345851|Other|laboratory biomarker analysis|Correlative studies
373359|NCT01345851|Radiation|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
373360|NCT01345851|Drug|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
373361|NCT01345851|Drug|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
373362|NCT01345851|Radiation|stereotactic body radiation therapy|Undergo hypofractionated RT
373363|NCT01345838|Procedure|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
373364|NCT01345825|Other|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
373365|NCT01345812|Drug|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
373366|NCT01345812|Drug|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
373367|NCT01345799|Drug|TRK-170|
373368|NCT01345799|Drug|Placebo|
373369|NCT01345786|Drug|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
373370|NCT01345786|Drug|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
373371|NCT01345786|Drug|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
373372|NCT01345773|Procedure|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
373373|NCT01345747|Device|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
373374|NCT01345734|Drug|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
373375|NCT01345721|Biological|MenACWY-CRM|
373376|NCT01345708|Drug|prednisone, low dose rituximab|"Patients with warm AIHA will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)~Patients with CHD will receive:~Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
373377|NCT01345682|Drug|Afatinib|Once daily
373378|NCT01345682|Drug|Methotrexate|Weekly
373379|NCT01345669|Drug|Placebo|Once daily
373380|NCT01345669|Drug|Afatinib|Once daily
373381|NCT01345656|Drug|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
373382|NCT01345656|Drug|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
373383|NCT01345656|Drug|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
373384|NCT01345656|Drug|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
373385|NCT01345656|Drug|Placebo|Placebo tablets for duration of 4 weeks
373386|NCT01345656|Drug|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
373387|NCT01345643|Other|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
373388|NCT01345643|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
373389|NCT01345630|Drug|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
373390|NCT01345630|Drug|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
373391|NCT01345630|Drug|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
373392|NCT01345630|Drug|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
373393|NCT01345630|Drug|placebo for maraviroc|placebo for maraviroc
373394|NCT01345604|Procedure|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
373395|NCT01345604|Procedure|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
373396|NCT01345591|Procedure|Fat Grafting|
373397|NCT01345578|Drug|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.~The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.~If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
373398|NCT01345578|Radiation|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
373496|NCT01344837|Other|Medical Chart Review|Correlative studies
373497|NCT01344837|Genetic|Microarray Analysis|Correlative studies
373498|NCT01344837|Other|Study of Socioeconomic and Demographic Variables|Correlative studies
373399|NCT01345565|Drug|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
373400|NCT01345552|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
373401|NCT01345539|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, adrenal, and liver sites were being treated, both lung sites could be treated Monday, Wednesday, and Friday, the liver on Tuesday, Thursday and the following Tuesday, and the adrenal on Monday, Wednesday, Friday of the second week.
373402|NCT01345526|Device|Reconval K1 Cream|
373403|NCT01345526|Device|Reconval Cream|
373404|NCT01345513|Other|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
373405|NCT01345500|Other|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
373406|NCT01345500|Other|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
373407|NCT01345500|Other|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
373408|NCT01345487|Other|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
373409|NCT01345487|Other|Animal protein|Protein in the form of minced pork/beef
373410|NCT01345461|Device|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
373411|NCT01345448|Drug|Brimonidine|0.1% Brimonidine Lotion, dosed once.
373412|NCT01345448|Drug|Placebo Lotion|Placebo Lotion dosed once.
373413|NCT01345435|Procedure|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
373414|NCT01345435|Procedure|Telemonitoring & Telemedicine|The Telemonitoring & Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
373415|NCT01345435|Other|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
373416|NCT01345422|Other|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
373417|NCT01345396|Behavioral|Health education about asthma|Three face-to-face appointments (<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
373418|NCT01345383|Procedure|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
373419|NCT01345370|Drug|Temozolomide|According to sites procedures
373420|NCT01345370|Radiation|Radiation Therapy|According to sites procedures
373499|NCT01344837|Genetic|Western Blotting|Correlative studies
373500|NCT01344824|Biological|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
373421|NCT01345357|Drug|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
373422|NCT01345357|Drug|Gemcitabine|Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
373423|NCT01345357|Drug|Cisplatin|Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
373424|NCT01345344|Behavioral|Cognitive Behavioral Therapy|Practicing certain strategies such as relaxation and changing negative thoughts about pain.
373425|NCT01345344|Behavioral|Education|Giving participants information about pain and how to change perceptions of pain.
373426|NCT01345331|Behavioral|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
373427|NCT01345318|Biological|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
373428|NCT01345318|Biological|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
373429|NCT01345292|Device|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
373430|NCT01345292|Drug|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
373431|NCT01345292|Drug|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
373432|NCT01345279|Drug|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
373433|NCT01345279|Drug|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
373434|NCT01345279|Drug|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
373435|NCT01345266|Procedure|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
373436|NCT01345253|Drug|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
373437|NCT01345253|Drug|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
373438|NCT01345240|Biological|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
373439|NCT01345240|Biological|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
373440|NCT01345240|Biological|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
373441|NCT01345240|Biological|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
373442|NCT01345240|Biological|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
373443|NCT01345240|Biological|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
373444|NCT01345240|Biological|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
373445|NCT01345240|Biological|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
373446|NCT01345227|Procedure|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
373447|NCT01345214|Drug|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
373448|NCT01345201|Biological|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
373449|NCT01345188|Drug|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
373450|NCT01345188|Drug|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
373451|NCT01345175|Drug|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
373501|NCT01344824|Drug|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
373452|NCT01345175|Drug|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
373453|NCT01345162|Drug|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
373454|NCT01345162|Drug|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
373455|NCT01345162|Drug|intraoperative analgesia|ketorolac 30 mg iv
373456|NCT01345162|Drug|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
373457|NCT01345149|Behavioral|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling"
373458|NCT01345136|Drug|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
373459|NCT01345123|Behavioral|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
373460|NCT01345123|Behavioral|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
373461|NCT01345097|Device|Total Hip Arthroplasty|Total Hip Arthroplasty
373462|NCT01345084|Radiation|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
373463|NCT01345084|Drug|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
373464|NCT01345084|Drug|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
373465|NCT01345058|Drug|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:~Week 1: 50 mg twice a day~Beginning Week 2: 100 mg twice a day."
373466|NCT01345058|Drug|levetiracetam|Low dose ≤1500 mg/day, High dose >1500 mg/day
373467|NCT01345045|Drug|ABT-639|ABT-639 Twice Daily for six weeks.
373468|NCT01345045|Drug|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
373469|NCT01345045|Drug|Placebo|Placebo twice daily for 6 weeks.
373470|NCT01345032|Other|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
373471|NCT01345032|Other|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
373472|NCT01345019|Drug|Denosumab|Administered by subcutaneous injection once every 4 weeks.
373473|NCT01345019|Drug|Zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
373474|NCT01345019|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks.
373475|NCT01345019|Drug|Placebo to zoledronic acid|Administered by intravenous infusion over 15 minutes once every 4 weeks
373476|NCT01345006|Biological|MA09-hRPE|"Cohort 1 50,000 cells~Cohort 2 100,000 cells~Cohort 2a Better Vision 100,000 cells~Cohort 3 150,000 cells~Cohort 4 200,000 cells"
373477|NCT01344993|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
373478|NCT01344980|Procedure|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
373479|NCT01344980|Procedure|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
373480|NCT01344980|Behavioral|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
373481|NCT01344980|Behavioral|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
373482|NCT01344967|Drug|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
373483|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
373484|NCT01344954|Drug|Rivaroxaban|Administered orally as a capsule once a day for 35 days
373485|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
373486|NCT01344928|Behavioral|HIT exercise intervention|
373487|NCT01344928|Behavioral|Aerobic exercise intervention|
373488|NCT01344915|Procedure|Locked knee brace|
373489|NCT01344915|Procedure|Locked knee brace|
373490|NCT01344902|Drug|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
373491|NCT01344876|Drug|OPB-51602|once daily during the treatment period
373492|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
373493|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
373494|NCT01344837|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
373495|NCT01344837|Other|Immunohistochemistry Staining Method|Correlative studies
373502|NCT01344824|Drug|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
373503|NCT01344824|Drug|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
373504|NCT01344811|Procedure|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
373505|NCT01344811|Other|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
373506|NCT01344798|Biological|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
373507|NCT01344785|Procedure|Intramedullary nailing|All patients will be treated with Intramedullary nailing
373508|NCT01344772|Procedure|Internal fixation|Two cannulated screws are placed under x-ray guidance
373509|NCT01344772|Procedure|Total hip arthroplasty|A total hip arthroplasty is performed through a standard posterior approach
373510|NCT01344759|Drug|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
373511|NCT01344759|Drug|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
373512|NCT01344720|Drug|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
373513|NCT01344720|Drug|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.~Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
373514|NCT01344707|Drug|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
373515|NCT01344694|Other|patient with liver fat|30 patient with liver fat
373516|NCT01344694|Other|pts. with excess of visceral fat|pts. with excess of visceral fat
373517|NCT01344694|Other|control|30 control subjects
373518|NCT01344681|Drug|Micafungin sodium|"Treatment period (active treatment): an average 14 days~Dosage:~- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)~Administration Method:~Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
373519|NCT01344681|Drug|Itraconazole|"Treatment period (active treatment): an average 14 days~Dosage:~- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)~Administration Method:~Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
373520|NCT01344668|Other|Enhanced Diabetes Education|Provide enhanced diabetes education
373521|NCT01344668|Other|Standard Diabetes Education|Provide Standard Diabetes Education
373522|NCT01344655|Drug|Atimos®|Formoterol 12 μg pMDI
373523|NCT01344655|Drug|Serevent™|Salmeterol 25 µg pMDI
373524|NCT01344655|Drug|Placebo|placebo
373525|NCT01344629|Drug|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
373526|NCT01344629|Drug|Telmisartan|Telmisartan 80 mg tablet
373527|NCT01344629|Drug|Amlodipin|Amlodipin 5mg tablet
373528|NCT01344616|Behavioral|lifestyle support|computer-based lifestyle improvement support and clinician support
373529|NCT01344590|Other|Normal Saline|Standard saline procedure will be utilized.
373530|NCT01344590|Other|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
373531|NCT01344564|Drug|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
373532|NCT01344551|Dietary Supplement|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
373533|NCT01344538|Drug|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
373534|NCT01344538|Dietary Supplement|Placebo Capsule|2.0 g per day
373535|NCT01344525|Procedure|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
373536|NCT01344525|Procedure|Gastric Banding|Gastric Banding
373537|NCT01344525|Procedure|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
373538|NCT01344525|Procedure|Roux-en-Y Bypass|Roux-en-Y Bypass
373539|NCT01344512|Drug|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
373540|NCT01344512|Drug|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
373658|NCT01343680|Drug|Normal saline|10ml normal saline IV weekly
373541|NCT01344512|Drug|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
373542|NCT01344499|Procedure|Carbon dioxide|standard pneumoperitoneum with 100% CO2
373543|NCT01344499|Procedure|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
373544|NCT01344499|Drug|Adept|instillation of 1 liter of fluid at the end of laparoscopy
373545|NCT01344499|Drug|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
373546|NCT01344486|Procedure|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
373547|NCT01344486|Procedure|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
373548|NCT01344473|Device|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
373549|NCT01344460|Drug|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
373550|NCT01344447|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
373551|NCT01344421|Procedure|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
373552|NCT01344408|Procedure|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
373553|NCT01344395|Drug|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
373554|NCT01344395|Drug|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
373555|NCT01344382|Behavioral|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
373556|NCT01344382|Behavioral|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
373557|NCT01344369|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
373558|NCT01344369|Drug|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
373559|NCT01344356|Radiation|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
373560|NCT01344356|Radiation|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
373561|NCT01344343|Other|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
373562|NCT01344304|Drug|Aprepitant / Fosaprepitant|"Aprepitant:~125 mg PO on day 1 80 mg PO on days 2 to 3~Fosaprepitant:~150 mg IV on day 1"
373563|NCT01344291|Drug|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
373564|NCT01344278|Behavioral|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
373565|NCT01344252|Drug|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
373566|NCT01344239|Procedure|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
373567|NCT01344226|Drug|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
373568|NCT01344213|Drug|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
373569|NCT01344213|Drug|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
373570|NCT01344213|Drug|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
373571|NCT01344213|Drug|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
373572|NCT01344200|Drug|Celecoxib|"All patients, on day of first scheduled LP, will receive celecoxib suspension 10 mg/kg by mouth 180 mins before their scheduled LP. Prior to beginning the second cycle of chemotherapy the patients will be randomly allocated to either of 2 cohorts (CSF dose timing cohort versus dose escalation cohort). The CSF dose timing cohort patients will be assigned to receive celecoxib 10 mg/kg at a predetermined time (60 mins, 120 mins, 300 mins and 900 mins before LP+/- BM) and they will rotate in chronological order for four chemotherapy cycles to complete the remaining time points of interest. The dose escalation cohort patients, at the beginning of each cycle of chemotherapy, will be administered either 6 or 14 mg/kg celecoxib 180 mins before LP for a total of 4 chemotherapy cycles.~Approximately 8-12 hours after the first dose, each patient will be required to ingest a second dose of celecoxib suspension (one half of the premedication dose) with food."
373573|NCT01344187|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
373574|NCT01344187|Drug|placebo solution|0.0% riboflavin ophthalmic solution
373575|NCT01344187|Device|KXL System|30 mW/cm2
373576|NCT01344174|Drug|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
373577|NCT01344161|Dietary Supplement|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
373578|NCT01344161|Dietary Supplement|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
373579|NCT01344148|Drug|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
373580|NCT01344135|Dietary Supplement|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily~Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)~Phase C, Follow-up (3 months): no supplementation"
373581|NCT01344135|Dietary Supplement|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily~Phase B, Maintenance (8 months): No supplementation~Phase C, Follow-up (3 months): No supplementation"
373582|NCT01344135|Behavioral|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling~Phase B, Maintenance (8 months): Nutritional counselling (4x)~Phase C, Follow-up (3 months): No counselling~Aim:~Optimising dietary intake to physical activity pattern and energy expenditure.~Minimize deterioration of dietary intake during acute exacerbations.~Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.~Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
373583|NCT01344135|Behavioral|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling~Phase B, Maintenance (8 months): Exercise counselling (2x)~Phase C, Follow-up (3 months): No exercise counselling~Aim:~Integration of exercise behaviour into daily routine~Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)~Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
373584|NCT01344122|Other|KPI training only|See comparison arm description.
373585|NCT01344122|Other|KPI plus OLI|See experimental arm description.
373586|NCT01344083|Drug|T1210|2 drops T1210 once a day
373587|NCT01344083|Drug|Olopatadine hydrochloride|2 drops once a day Olopatadine
373588|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
373589|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
373590|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
373591|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
373592|NCT01344057|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
373593|NCT01344044|Device|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
373594|NCT01344031|Drug|Akt Inhibitor MK2206|Given PO
373595|NCT01344031|Drug|Anastrozole|Given PO
373596|NCT01344031|Drug|Fulvestrant|Given IM
373597|NCT01344031|Other|Laboratory Biomarker Analysis|Correlative studies
373598|NCT01344018|Procedure|therapeutic conventional surgery|
373599|NCT01344018|Radiation|3-dimensional conformal radiation therapy|
373600|NCT01344005|Other|caregiver-related intervention or procedure|
373601|NCT01344005|Other|questionnaire administration|
373602|NCT01344005|Procedure|quality-of-life assessment|
373603|NCT01344005|Procedure|radiography|
373604|NCT01343992|Behavioral|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
373605|NCT01343992|Behavioral|No bedrest|Patients will not rest in bed after the embryo transfer.
373606|NCT01343966|Drug|MABT5102A|Repeating subcutaneous injection
373607|NCT01343966|Drug|MABT5102A|Repeating intravenous infusion
373608|NCT01343966|Drug|placebo|Repeating subcutaneous injection
373609|NCT01343966|Drug|placebo|Repeating intravenous infusion
373610|NCT01343953|Procedure|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
373611|NCT01343940|Behavioral|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
373612|NCT01343940|Behavioral|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
373613|NCT01343927|Behavioral|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
373614|NCT01343927|Behavioral|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
373657|NCT01343680|Drug|Heparin|5ml 10 units/ml IV heparin 3 times per week
373615|NCT01343927|Behavioral|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
373616|NCT01343901|Drug|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
373617|NCT01343888|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
373618|NCT01343888|Drug|BI 201335|BI 201335 once daily high dose
373619|NCT01343888|Drug|BI 201335|BI 201335 once daily low dose
373620|NCT01343888|Drug|Placebo|
373621|NCT01343875|Procedure|tear of the distal tendon in the biceps muscle|
373622|NCT01343862|Drug|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
373623|NCT01343862|Drug|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
373624|NCT01343836|Other|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
373625|NCT01343836|Other|Saline|Intratendinous saline injection with eccentric exercises
373626|NCT01343823|Drug|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
373627|NCT01343823|Drug|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
373628|NCT01343823|Drug|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
373629|NCT01343823|Drug|placebo|Administered as two SC 3 mL injections
373630|NCT01343823|Drug|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
373631|NCT01343823|Drug|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
373632|NCT01343810|Behavioral|Mindfulness Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
373633|NCT01343810|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
373634|NCT01343797|Other|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
373635|NCT01343784|Other|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
373636|NCT01343771|Drug|DHEA (Prasterone) + ERT (Aviane)|Micronized oral DHEA in a dose of 50 mg daily + ERT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse, 20 mcg ethinyl estradiol + 0.1 mg levonorgestrel for 9 months)
373637|NCT01343771|Other|Placebo|A placebo tablet will be developed by the Children's Hospital Pharmacy. Both treatments (DHEA+ERT and placebo) will be administered in a gelatin capsule.
373638|NCT01343758|Other|5% dextrose in normal saline|Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
373639|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
373640|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
373641|NCT01343745|Drug|Placebo|pressurised metered dose inhaler
373642|NCT01343732|Device|Deep TMS|deep transcranial magnetic stimulation
373643|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
373644|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
373645|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
373646|NCT01343719|Drug|BI 661051|low dose solution for oral administration
373647|NCT01343719|Drug|BI 661051|low dose solution for oral administration
373648|NCT01343719|Drug|BI 661051|low dose solution for oral administration
373649|NCT01343719|Drug|BI 661051|high dose solution for oral administration
373650|NCT01343719|Drug|BI 661051|high dose solution for oral administration
373651|NCT01343719|Drug|BI 661051|low dose tablet
373652|NCT01343719|Drug|Placebo|solution for administration
373653|NCT01343719|Drug|BI 661051|medium dose tablet
373654|NCT01343706|Drug|Placebo|Solution for oral administration
373655|NCT01343706|Drug|Placebo .|Immediate release solid oral dosage
373656|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage medium
373659|NCT01343667|Device|Gore Flow Reversal System|Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
373660|NCT01343667|Device|Gore Embolic Filter|Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
373661|NCT01343654|Behavioral|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
373662|NCT01343654|Behavioral|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
373663|NCT01343641|Drug|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
373664|NCT01343641|Drug|Placebo|Inactive Pill used as a comparator
373665|NCT01343628|Drug|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
373666|NCT01343628|Drug|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
373667|NCT01343615|Procedure|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
373668|NCT01343615|Procedure|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
373669|NCT01343602|Behavioral|mod. Constraint-Induced Movement Therapy|"Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training."
373670|NCT01343602|Other|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
373671|NCT01343589|Dietary Supplement|milk fat|39 g milk fat per day in 12 weeks
373672|NCT01343576|Dietary Supplement|milk fat|45 g milk fat per day in 4 weeks
373673|NCT01343563|Procedure|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
373674|NCT01343550|Other|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
373675|NCT01343537|Other|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
373676|NCT01343511|Biological|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
373677|NCT01343511|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
373678|NCT01343498|Drug|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
373679|NCT01343485|Behavioral|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
373680|NCT01343472|Behavioral|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
373681|NCT01343472|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
373682|NCT01343459|Radiation|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)~IOERT is performed on mobile or fixed linacs~Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).~WBRT~must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)~In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.~Single reference dose per fraction: 2,7 Gy (ICRU)~Number of fractions: 15, Number of fractions per week: 5~Total WBRT dose: 40,5 Gy"
373683|NCT01343420|Biological|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
373684|NCT01343407|Drug|MK-1029 10 mg|Six capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
373685|NCT01343407|Drug|MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
373686|NCT01343407|Drug|Placebo for MK-1029 10 mg|"Six capsules once daily for 5 days in Period 1, and the same in Period 2, 3, or 4 in a crossover design."
373687|NCT01343407|Drug|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days in Period 2, 3, or 4 in a crossover design
373688|NCT01343394|Biological|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
373689|NCT01343381|Drug|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
373690|NCT01343381|Drug|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
373691|NCT01343368|Drug|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
373692|NCT01343368|Biological|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
373693|NCT01343368|Biological|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
373694|NCT01343355|Drug|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
373695|NCT01343342|Dietary Supplement|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
373696|NCT01343329|Drug|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
373697|NCT01343329|Drug|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
373698|NCT01343316|Device|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
373699|NCT01343303|Drug|Placebo|Placebo tablet/capsule every 12 hours for 21 days
373700|NCT01343303|Drug|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
373701|NCT01343303|Drug|Naproxen|500 mg capsule every 12 hours for 21 days
373702|NCT01343303|Drug|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
373703|NCT01343290|Drug|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
373704|NCT01343277|Drug|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
373705|NCT01343277|Drug|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
373706|NCT01343238|Behavioral|Diet|12 week diet behavior modification
373707|NCT01343238|Behavioral|Exercise|12 week exercise behavioral intervention
373708|NCT01343238|Behavioral|Diet and Exercise|12 week diet and exercise behavioral modification intervention
373709|NCT01343225|Drug|atripla|once a day
373710|NCT01343225|Drug|darunavir ritonavir raltegravir|as directed
373711|NCT01343212|Other|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
373712|NCT01343186|Drug|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
373713|NCT01343186|Drug|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
373714|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
373715|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
373716|NCT01343173|Drug|Imatinib stop|To stop imatinib after inclusion.
373717|NCT01343160|Device|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
373718|NCT01343147|Other|Microwave diathermy|Deep tissue heating via microwave diathermy
373719|NCT01343147|Other|Superficial hyperthermia|Superficial heating via hot pack application
373720|NCT01343134|Device|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
373721|NCT01343121|Other|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
373722|NCT01343121|Other|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
373723|NCT01343121|Other|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
373724|NCT01343095|Device|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
373725|NCT01343095|Device|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
373726|NCT01343082|Drug|DE-111 ophthalmic solution|
373727|NCT01343069|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
373728|NCT01343056|Behavioral|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
373729|NCT01343056|Behavioral|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
373730|NCT01343056|Behavioral|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
373731|NCT01343056|Behavioral|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
373732|NCT01343043|Biological|NY-ESO-1(c259)T Cells|Cytoreductive chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
373865|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
374891|NCT01334242|Drug|Schedule D|Dosing immediately before lunch
373733|NCT01343017|Other|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
373734|NCT01343004|Drug|Placebo|Placebo 0 mcg subcutaneous daily
373735|NCT01343004|Drug|BA058 80 mcg|BA058 80 mcg subcutaneous daily
373736|NCT01343004|Drug|teriparatide|teriparatide 20 mcg subcutaneous daily
373737|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
373738|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy~This procedure will be performed under local anaesthetic with sedation as a day case~The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.~Pre-operative local anaesthesia will be given"
373739|NCT01342965|Drug|Erlotinib|Erlotinib was supplied as tablets.
373740|NCT01342965|Drug|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
373741|NCT01342952|Drug|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
373742|NCT01342939|Other|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
373743|NCT01342939|Other|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
373744|NCT01342939|Dietary Supplement|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
373745|NCT01342939|Other|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
373746|NCT01342939|Other|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
373747|NCT01342926|Drug|GSK933776|GSK933776
373748|NCT01342926|Drug|Placebo|Placebo
373749|NCT01342913|Drug|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
373750|NCT01342913|Drug|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
373751|NCT01342900|Device|connected to the InSpectra Monitor|
373752|NCT01342887|Drug|cyclosporine|Given IV
373753|NCT01342887|Drug|pravastatin sodium|Given PO
373754|NCT01342887|Drug|mitoxantrone hydrochloride|Given IV
373755|NCT01342887|Drug|etoposide|Given IV
373756|NCT01342887|Procedure|bone marrow aspiration|Correlative studies
373757|NCT01342874|Dietary Supplement|Inositol|inositol exposure in early GDM
373758|NCT01342861|Dietary Supplement|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
373759|NCT01342835|Drug|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
373760|NCT01342822|Device|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
373761|NCT01342809|Behavioral|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
373762|NCT01342796|Biological|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
373763|NCT01342796|Biological|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
373764|NCT01342783|Genetic|DNA analysis|
373765|NCT01342783|Genetic|RNA analysis|
373766|NCT01342783|Genetic|mutation analysis|
373767|NCT01342783|Genetic|nucleic acid sequencing|
373768|NCT01342783|Other|laboratory biomarker analysis|
373769|NCT01342770|Other|Laboratory Biomarker Analysis|Correlative studies
373770|NCT01342770|Drug|Pioglitazone Hydrochloride|Given PO
373771|NCT01342770|Other|Quality-of-Life Assessment|Ancillary studies
373772|NCT01342757|Drug|vorinostat|Given orally
373773|NCT01342757|Drug|temozolomide|Given orally
373774|NCT01342757|Procedure|magnetic resonance spectroscopic imaging|Undergo MRI
373775|NCT01342757|Other|survey administration|Ancillary studies
373776|NCT01342744|Drug|Metformin|Metformin(850 mg) 1tab oral twice aday
373777|NCT01342744|Drug|Placebo|Placebo 1 tab oral twice a day
373778|NCT01342731|Drug|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
373779|NCT01342718|Dietary Supplement|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)"
374892|NCT01334242|Drug|Schedule E|Split dose, dosing 1 hour before breakfast and dinner
373780|NCT01342718|Dietary Supplement|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
373781|NCT01342718|Dietary Supplement|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)"
373782|NCT01342718|Dietary Supplement|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).~Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
373783|NCT01342705|Procedure|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
373784|NCT01342692|Drug|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
373785|NCT01342692|Drug|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.~- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)~- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
373786|NCT01342692|Drug|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.~Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
373787|NCT01342692|Drug|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
373788|NCT01342679|Drug|dasatinib|100mg QD
373789|NCT01342666|Dietary Supplement|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
373790|NCT01342666|Dietary Supplement|Cucumber consumption|Daily consumption of 300g of cucumber.
373791|NCT01342653|Other|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
373792|NCT01342640|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
373793|NCT01342627|Drug|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.~In case of toxicities, dose reduction/interruption is permitted according to the protocol.~In case of disease progression Sorafenib administration will be discontinued."
373794|NCT01342614|Drug|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
373795|NCT01342614|Drug|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
373796|NCT01342601|Device|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
373797|NCT01342601|Device|Placebo products|Nasal Spray and Eye drops without Ectoin
373798|NCT01342588|Procedure|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
373799|NCT01342575|Procedure|Intra-operative exposure maneuvers|"Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed~Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.~Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed~Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed~Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
373800|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
373801|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
373802|NCT01342549|Drug|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
373803|NCT01342549|Drug|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
373866|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
373867|NCT01342198|Drug|erythromycin|A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
373804|NCT01342536|Behavioral|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.~The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.~Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
373805|NCT01342523|Other|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
373806|NCT01342523|Other|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
373807|NCT01342523|Other|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
373808|NCT01342523|Other|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
373809|NCT01342523|Other|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
373810|NCT01342523|Other|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
373811|NCT01342523|Other|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
373812|NCT01342510|Drug|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
373813|NCT01342510|Drug|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
373814|NCT01342510|Drug|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
373815|NCT01342510|Drug|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
373816|NCT01342497|Drug|isoniazide|Tablets, dosing 3 times daily, 12 weeks
373817|NCT01342497|Drug|placebo|tablets, dosing 3 times daily, 12 weeks
373818|NCT01342484|Drug|placebo|comparison of different dosages of drug (low vs high) vs placebo
373819|NCT01342484|Drug|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
373820|NCT01342484|Drug|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
373821|NCT01342471|Behavioral|TV commercial stepping|"Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
373822|NCT01342471|Behavioral|30-min walk|"Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
373823|NCT01342458|Other|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
373824|NCT01342445|Drug|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
373825|NCT01342445|Drug|Placebo|
373826|NCT01342432|Other|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
373827|NCT01342432|Other|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
373828|NCT01342367|Drug|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
373829|NCT01342367|Drug|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
373830|NCT01342367|Drug|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
373831|NCT01342367|Radiation|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
373832|NCT01342354|Radiation|Stereotactic Radiation|Escalating Doses of SBRT in periods of three doses over 10 days
373833|NCT01342341|Drug|Parafon Forte|"Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit"
373834|NCT01342328|Other|Normal saline infusion|Normal saline infusion
373949|NCT01341639|Biological|RotaTeq|RotaTeq (pentavalent combination live vaccine of 5 human-bovine reassortant rotavirus strains) 2 mL oral dose at 2, 3, and 4 months of age
374893|NCT01334229|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
373835|NCT01342328|Drug|Dexmedetomidine|"Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.~We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours."
373836|NCT01342328|Drug|Propofol|"For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.~Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.~Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol."
373837|NCT01342315|Drug|33525|Daily dosing
373838|NCT01342315|Drug|Placebo|Daily dosing
373839|NCT01342302|Behavioral|Psychosocial Intervention for Couples|Intervention delivered on line
373840|NCT01342289|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg/day IV. Days 3 and 4: 50 mg/kg/day IV.
373841|NCT01342289|Drug|Fludarabine|Days -6, -5, -4, -3, and -2: 30 mg/m^2/day IV.
373842|NCT01342289|Radiation|Total body irradiation|Day -1: 200 centigray in one fraction.
373843|NCT01342289|Drug|Mycophenolate Mofetil|Days 5 to 35: 15 mg/kg PO three times per day; max daily dose 1 g.
373844|NCT01342289|Drug|Tacrolimus 60|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 60.
373845|NCT01342289|Drug|Tacrolimus 90|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 90.
373846|NCT01342289|Drug|Tacrolimus 120|Begin dosing at 1 mg IV daily on Day 5. Dose is titrated according to serum levels. Stop at Day 120.
373847|NCT01342289|Biological|Bone marrow transplant|Donor stem cells infused IV on Day 0.
373848|NCT01342276|Behavioral|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
373849|NCT01342263|Behavioral|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
373850|NCT01342250|Biological|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
373851|NCT01342250|Biological|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
373852|NCT01342250|Biological|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
373853|NCT01342237|Drug|HDCT 1(TTC), HDCT2(MEC)|"TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
373854|NCT01342224|Biological|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
373855|NCT01342211|Biological|Placebo|Intravenous placebo monthly during treatment phase.
373856|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
373857|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
373858|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
373859|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
373860|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
373861|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
373862|NCT01342211|Drug|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
373863|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
373864|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
374894|NCT01334229|Drug|Placebo|Placebo for 6 weeks
373868|NCT01342185|Device|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
373869|NCT01342185|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
373870|NCT01342185|Drug|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
373871|NCT01342172|Drug|Lenalidomide|"Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression."
373872|NCT01342159|Procedure|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
373873|NCT01342146|Drug|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
373874|NCT01342146|Drug|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
373875|NCT01342146|Drug|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
373876|NCT01342107|Device|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
373877|NCT01342107|Device|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
373878|NCT01342107|Device|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
373879|NCT01342094|Drug|DE-111 ophthalmic solution|
373880|NCT01342094|Drug|Timolol ophthalmic solution 0.5%|
373881|NCT01342094|Drug|Placebo ophthalmic solution|
373882|NCT01342081|Drug|DE-111 ophthalmic solution|
373883|NCT01342081|Drug|Tafluprost ophthalmic solution 0.0015%|
373884|NCT01342081|Drug|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%|
373885|NCT01342055|Drug|Apetrol ES|sequences of administered drugs
373886|NCT01342042|Biological|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 [glucagon-like peptide-1] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
373887|NCT01342029|Drug|Ranolazine|"This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.~500-1,000 mg po bid for 2 weeks"
373888|NCT01342029|Drug|Placebo|500-1,000 mg po bid for 2 weeks
373889|NCT01342016|Drug|tacrolimus capsule|oral
373890|NCT01342016|Drug|tacrolimus placebo|oral
373891|NCT01342016|Drug|leflunomide tablet|oral
373892|NCT01342016|Drug|leflunomide placebo|oral
373893|NCT01342016|Drug|prednisone|oral
373894|NCT01341990|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
373895|NCT01341990|Device|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
373896|NCT01341990|Device|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
373897|NCT01341977|Device|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
373898|NCT01341977|Device|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
373899|NCT01341964|Drug|Clopidogrel|600mg (2 pills)
373900|NCT01341964|Drug|Aspirin|325mg (1 pill)
373901|NCT01341964|Drug|Aspirin|81mg (1 pill)
373902|NCT01341951|Drug|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
373903|NCT01341938|Drug|Commit® nicotine lozenges (4 mg).|Participants will be provided with instructions on the proper use of the lozenge and instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day.
373904|NCT01341938|Behavioral|Phone Counseling|Three phone counseling sessions to assist in cessation from use of all tobacco.
373905|NCT01341938|Behavioral|Self-help materials|"Participants receive the Enough Snuff video and printed guide providing strategies for tobacco cessation."
373950|NCT01341639|Biological|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
373951|NCT01341639|Biological|ProQuad™|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
373906|NCT01341925|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
373907|NCT01341925|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
373908|NCT01341925|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
373909|NCT01341912|Biological|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
373910|NCT01341899|Procedure|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
373911|NCT01341886|Drug|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
373912|NCT01341873|Other|educational intervention|Undergo APN FCI
373913|NCT01341873|Other|psychosocial support for caregiver|Undergo APN FCI
373914|NCT01341873|Procedure|quality-of-life assessment|Ancillary studies
373915|NCT01341873|Other|questionnaire administration|Ancillary studies
373916|NCT01341847|Procedure|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
373917|NCT01341847|Procedure|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
373918|NCT01341834|Drug|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
373919|NCT01341808|Biological|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
373920|NCT01341782|Drug|paricalcitol|
373921|NCT01341782|Drug|maxacalcitol|
373922|NCT01341782|Drug|paricalcitol placebo|
373923|NCT01341782|Drug|maxacalcitol placebo|
373924|NCT01341769|Other|Dietary Intervention|
373925|NCT01341769|Other|Dietary Intervention|
373926|NCT01341769|Other|Dietary Intervention|
373927|NCT01341769|Other|Dietary Intervention|
373928|NCT01341756|Radiation|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
373929|NCT01341743|Drug|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
373930|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
373931|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
373932|NCT01341730|Drug|Atorvastatin 20mg|20 mg QD for 3 months
373933|NCT01341730|Drug|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
373934|NCT01341717|Drug|Sitagliptin|100 mg once daily for 6 months
373935|NCT01341717|Drug|Glimepiride|1 mg/2 mg/3 mg once daily
373936|NCT01341717|Drug|Metformin|>=1000 mg twice daily
373937|NCT01341717|Drug|Insulin|TDD > 10 IU once/twice daily
373938|NCT01341704|Biological|MSP3-LSP/AlOH|"30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)~Secondary administration (Boost):~Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1"
373939|NCT01341704|Biological|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
373940|NCT01341704|Other|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
373941|NCT01341691|Other|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
373942|NCT01341678|Drug|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
373943|NCT01341678|Dietary Supplement|NeutraPhos|Diet will be supplemented with NeutraPhos
373944|NCT01341678|Other|Diet Only|Diet containing 1500mg of phosphorus
373945|NCT01341652|Biological|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
373946|NCT01341652|Biological|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
373947|NCT01341639|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
373948|NCT01341639|Biological|INFANRIX™ hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
374033|NCT01341002|Procedure|Transfusion|transfusion based on guidelines
373952|NCT01341626|Behavioral|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
373953|NCT01341626|Behavioral|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
373954|NCT01341613|Dietary Supplement|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
373955|NCT01341613|Dietary Supplement|Placebo capsule|Twice per day (BID), 9 weeks
373956|NCT01341600|Drug|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
373957|NCT01341600|Drug|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
373958|NCT01341587|Device|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
373959|NCT01341574|Procedure|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
373960|NCT01341574|Procedure|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
373961|NCT01341548|Drug|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
373962|NCT01341535|Radiation|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
373963|NCT01341535|Radiation|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
373964|NCT01341522|Procedure|MRI exam|MRI exam
373965|NCT01341522|Procedure|control|waiting room
373966|NCT01341509|Procedure|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
373967|NCT01341509|Procedure|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
373968|NCT01341509|Procedure|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
373969|NCT01341496|Biological|Epigenetically Modified Autologous Tumor|5x 10^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
373970|NCT01341496|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
373971|NCT01341496|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
373972|NCT01341470|Drug|LY2495655|administered intravenously or subcutaneously
373973|NCT01341470|Drug|Placebo|administered intravenously or subcutaneously
373974|NCT01341457|Drug|LY2603618|Administered intravenously
373975|NCT01341457|Drug|Gemcitabine|Administered intravenously
373976|NCT01341444|Device|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
373977|NCT01341444|Other|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
373978|NCT01341431|Drug|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
373979|NCT01341418|Procedure|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
373980|NCT01341418|Procedure|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
373981|NCT01341405|Drug|CG100649|capsule, 2 mg, once daily for 28 days
373982|NCT01341405|Drug|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
373983|NCT01341405|Drug|CG100649|capsule, 4 mg, once daily for 28 days
373984|NCT01341392|Drug|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
373985|NCT01341392|Drug|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
373986|NCT01341392|Drug|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
373987|NCT01341379|Drug|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
373988|NCT01341366|Other|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
374034|NCT01340989|Procedure|alteration of the insufflation gas|addition of 4% oxygen
374996|NCT01333397|Biological|Botulinum toxin type A|I.M. on day 1 (single treatment cycle)
373989|NCT01341366|Other|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
373990|NCT01341353|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
373991|NCT01341353|Drug|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
373992|NCT01341340|Device|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
373993|NCT01341301|Radiation|Total Body Irradiation|Undergo TBI
373994|NCT01341301|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
373995|NCT01341301|Drug|Cyclophosphamide|Given IV
373996|NCT01341301|Drug|Tacrolimus|Given IV or PO
373997|NCT01341301|Drug|Mycophenolate mofetil|Given IV or PO
373998|NCT01341301|Procedure|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
373999|NCT01341301|Other|Laboratory biomarker analysis|Correlative studies
374000|NCT01341288|Device|EUCLIDIAN Robot|EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
374001|NCT01341275|Biological|hepatitis B vaccine|10 ug dose, one-time administration
374002|NCT01341275|Biological|hepatitis B vaccine|20 ug dose, one-time administration
374003|NCT01341262|Drug|Thalidomide|"INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200~AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
374004|NCT01341262|Drug|Dexamethasone|"INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)~AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)~AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
374005|NCT01341262|Drug|Zoledronic acid|"INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)~AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)~AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
374006|NCT01341262|Drug|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
374007|NCT01341262|Drug|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
374008|NCT01341249|Drug|Experimental DW224aa|DW224aa tablet, single dose
374009|NCT01341249|Drug|Experimental DW224a|DW224a capsule, single dose
374010|NCT01341236|Other|different nutrional regimen|compare bolus versus intermittent nutrition
374011|NCT01341236|Other|comparison of different feeding regimens|compare intermittent versus bolus nutrition
374012|NCT01341197|Other|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
374013|NCT01341184|Drug|Rifabutin|Rifabutin 300 mg orally on days 20-41
374014|NCT01341184|Drug|Rifampin|Rifampin 600 mg orally on days 20-41
374015|NCT01341184|Drug|TMC207|TMC207 400 mg orally on days 1 and 29
374016|NCT01341158|Drug|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
374017|NCT01341145|Behavioral|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
374018|NCT01341145|Behavioral|Relaxation|12-week progressive muscle relaxation program (active control)
374019|NCT01341132|Procedure|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
374020|NCT01341106|Drug|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
374021|NCT01341093|Behavioral|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
374022|NCT01341093|Behavioral|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
374023|NCT01341080|Drug|Varenicline|Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
374024|NCT01341080|Drug|Sugar pill|1mg twice daily for eight weeks after a one week dose escalation phase.
374025|NCT01341054|Other|mouthwash with Chamomilla|The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
374026|NCT01341054|Other|Standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
374027|NCT01341041|Biological|chlorine dioxide|one time wash with 50ppm CD solution
374028|NCT01341041|Biological|saline|one time wash with 50-100 cc normal saline
374029|NCT01341028|Procedure|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
374030|NCT01341028|Procedure|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
374031|NCT01341015|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
374032|NCT01341002|Procedure|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 < 70% and guidelines
374035|NCT01340989|Procedure|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum~humidification~set temperature of 32°C"
374036|NCT01340989|Procedure|standard pneumoperitoneum|no intervention besides the use of CO2
374037|NCT01340976|Drug|LY2787106|Administered IV.
374038|NCT01340976|Dietary Supplement|Iron Supplementation|Administered orally.
374039|NCT01340950|Drug|zidovudine-lamivudine-nevirapine|96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
374040|NCT01340950|Drug|tenofovir-lamivudine-efavirenz|96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
374041|NCT01340937|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
374042|NCT01340937|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
374043|NCT01340937|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
374044|NCT01340937|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
374045|NCT01340937|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
374046|NCT01340911|Drug|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
374047|NCT01340911|Drug|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
374048|NCT01340898|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
374049|NCT01340898|Biological|SynflorixTM|Intramuscular injection
374050|NCT01340898|Biological|Infanrix-IPV/HiberixTM|Intramuscular injection
374051|NCT01340885|Drug|Strattera|10-30 mg b.i.d. for 6 weeks
374052|NCT01340885|Drug|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
374053|NCT01340885|Other|Placebo|2-6 pills for 6 weeks
374054|NCT01340872|Drug|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
374055|NCT01340872|Drug|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
374056|NCT01340859|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
374057|NCT01340846|Drug|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
374058|NCT01340846|Drug|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
374059|NCT01340846|Drug|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
374060|NCT01340846|Drug|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
374061|NCT01340846|Drug|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
374062|NCT01340833|Drug|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK2118436, starting 1.75 hours after the oral dose
374063|NCT01340820|Drug|AERAS-422|rBCG
374064|NCT01340820|Drug|BCG Tice|1-8 x 10^5 CFU
374065|NCT01340807|Other|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
374066|NCT01340794|Other|Laboratory Biomarker Analysis|Correlative studies
374067|NCT01340794|Drug|Pazopanib Hydrochloride|Given PO
374068|NCT01340781|Procedure|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
374069|NCT01340768|Drug|Sitagliptin|One 100 mg tablet taken orally once daily
374070|NCT01340768|Drug|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
374071|NCT01340768|Drug|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
374072|NCT01340755|Procedure|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
374073|NCT01340742|Procedure|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
374074|NCT01340742|Procedure|Control|Cuff placed on arm uninflated for 30 minutes.
374075|NCT01340729|Drug|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
374076|NCT01340716|Other|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
374077|NCT01340716|Other|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
374078|NCT01340703|Procedure|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
374079|NCT01340690|Dietary Supplement|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
374080|NCT01340690|Dietary Supplement|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
374081|NCT01340677|Drug|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
374082|NCT01340677|Drug|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
374083|NCT01340677|Drug|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
374997|NCT01333397|Drug|Placebo|I.M. on day 1 (single treatment cycle)
374084|NCT01340664|Drug|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
374085|NCT01340664|Drug|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
374086|NCT01340664|Drug|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
374087|NCT01340664|Drug|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
374088|NCT01340651|Drug|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
374089|NCT01340638|Device|cookgas mask|This group will be assigned to use cookgas mask
374090|NCT01340638|Device|LMA mask|LMA mask
374091|NCT01340625|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
374092|NCT01340625|Drug|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
374093|NCT01340612|Device|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
374094|NCT01340612|Device|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
374095|NCT01340599|Dietary Supplement|defined green tea catechin extract|Given PO
374096|NCT01340599|Other|placebo|Given PO
374097|NCT01340599|Other|immunohistochemistry staining method|Correlative studies
374098|NCT01340599|Other|immunoenzyme technique|Correlative studies
374099|NCT01340599|Other|questionnaire administration|Ancillary studies
374100|NCT01340599|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
374101|NCT01340599|Other|high performance liquid chromatography|Correlative studies
374102|NCT01340599|Other|mass spectrometry|Correlative studies
374103|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
374104|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
374105|NCT01340573|Drug|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
374106|NCT01340573|Drug|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.
374107|NCT01340560|Procedure|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
374108|NCT01340547|Drug|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
374109|NCT01340547|Drug|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
374110|NCT01340534|Device|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
374111|NCT01340534|Procedure|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
374112|NCT01340521|Drug|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
374113|NCT01340508|Radiation|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
374114|NCT01340495|Radiation|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
374115|NCT01340482|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
374116|NCT01340469|Biological|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
374117|NCT01340456|Drug|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
374118|NCT01340430|Drug|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
374119|NCT01340417|Other|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
374120|NCT01340404|Procedure|Stem cell transplantation|Stem cell transplantation
374121|NCT01340404|Procedure|Transfusion program|Transfusion program
374122|NCT01340391|Device|Omnicast|dorsal splint 2-5 weeks
374123|NCT01340365|Behavioral|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
374124|NCT01340365|Behavioral|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
374125|NCT01340339|Device|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
374126|NCT01340339|Device|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
374127|NCT01340326|Drug|high dose of valsartan|comparison of different dosages of drug
374128|NCT01340326|Drug|usual dose of valsartan|comparison of different dosages of drug
374129|NCT01340300|Behavioral|Exercise training|Two supervised exercise sessions per week
374130|NCT01340300|Drug|Metformin|Oral metformin QD for two weeks, then BID
374131|NCT01340300|Other|Educational information|educational information
374132|NCT01340287|Dietary Supplement|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
375000|NCT01333332|Drug|Capecitabine|Capecitabine
374133|NCT01340287|Dietary Supplement|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
374134|NCT01340274|Behavioral|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
374135|NCT01340274|Behavioral|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
374136|NCT01340261|Behavioral|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
374137|NCT01340248|Drug|Dilatrend 64mg capsule|"Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet~Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
374138|NCT01340235|Drug|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
374139|NCT01340222|Biological|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
374140|NCT01340209|Drug|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
374141|NCT01340209|Drug|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
374142|NCT01340209|Drug|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
374143|NCT01340196|Drug|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
374144|NCT01340183|Drug|AZD5099|IV Dose
374145|NCT01340183|Drug|Placebo|IV Dose
374146|NCT01340170|Device|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
374147|NCT01340157|Drug|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
374148|NCT01340131|Drug|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
374149|NCT01340131|Drug|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily~Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
374150|NCT01340118|Drug|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
374151|NCT01340105|Procedure|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
374152|NCT01340105|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
374153|NCT01340092|Other|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:~Help family identify key issues they need to address to get their child autism-specific services~Help family address barriers to obtaining these services and strategize approaches to overcome them."
374154|NCT01340079|Behavioral|virtual world|health education using virtual world Second Life
374155|NCT01340079|Behavioral|face to face|health education delivered in face to face groups
374156|NCT01340066|Drug|UISH001|sublingual dosing, 1 drop 3 times a day
374157|NCT01340066|Drug|matching placebo|sublingual dosing,1 drop 3 times a day
374158|NCT01340053|Drug|RDX5791|Capsule, QD
374159|NCT01340040|Drug|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
374160|NCT01340027|Drug|Mirabegron|oral
374161|NCT01340027|Drug|Solifenacin succinate|oral
374162|NCT01340027|Drug|Placebo|oral
374163|NCT01340014|Drug|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
374164|NCT01340014|Drug|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
374165|NCT01340001|Procedure|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
374166|NCT01339988|Drug|Busulfan/Cyclophosphamide|"Conditioning regimen:~Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days."
374167|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~on pre-operative d-1/d, post-operative d1 and d5(+/-2),~one month post-operative,~at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
374168|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample~before starting the therapy~at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)~at the end of the study or at the date of disease progression."
374169|NCT01339962|Other|Non-interventional|Non-interventional (retrospective chart reviews)
374170|NCT01339949|Device|IRay|low voltage external beam radiosurgery
374171|NCT01339949|Device|IRay|low voltage external beam radiosurgery
374172|NCT01339936|Device|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
374173|NCT01339923|Biological|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
374174|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
374175|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
374176|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses 2 months apart
374177|NCT01339923|Biological|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
374178|NCT01339923|Biological|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
374179|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
374180|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
374181|NCT01339910|Drug|Fludarabine and Busulfan|"(Flu/Bu)~Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)~Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
374182|NCT01339910|Drug|Fludarabine and Melphalan|"(Flu/Mel)~Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)~Melphalan: 140 mg/m^2 on Day -2"
374224|NCT01339624|Drug|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
374183|NCT01339910|Drug|Busulfan and Fludarabine|"(Bu/Flu)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2~Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)"
374184|NCT01339910|Drug|Busulfan and Cyclophosphamide|"(Bu/Cy)~Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
374185|NCT01339910|Drug|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)~TBI: 1200-1420 cGy on Days -7 to -4~Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
374186|NCT01339897|Drug|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
374187|NCT01339897|Drug|Placebo|Same administration procedures as active
374188|NCT01339897|Drug|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
374189|NCT01339897|Drug|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
374190|NCT01339884|Drug|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
374191|NCT01339871|Drug|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
374192|NCT01339871|Drug|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
374193|NCT01339858|Drug|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
374194|NCT01339858|Other|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
374195|NCT01339845|Biological|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
374196|NCT01339845|Behavioral|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
374197|NCT01339819|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
374198|NCT01339819|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
374199|NCT01339806|Behavioral|Cognitive Rehab|APT-III, Other standard individual and group interventions.
374200|NCT01339806|Behavioral|Brainworks|POSIT
374201|NCT01339806|Behavioral|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
374202|NCT01339780|Radiation|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
374203|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
374204|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
374205|NCT01339741|Dietary Supplement|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
374206|NCT01339741|Drug|Placebo|Placebo, oral route, 12 weeks
374207|NCT01339728|Procedure|far-infrared ray|The duration of far-infrared ray is 20 minutes.
374208|NCT01339715|Procedure|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
374209|NCT01339702|Other|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
374210|NCT01339689|Drug|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
374211|NCT01339689|Drug|Placebo|capsules, bid, up to 12 weeks
374212|NCT01339676|Drug|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
374213|NCT01339676|Drug|Placebo capsules|Identically appearing once weekly peroral placebo capsules
374214|NCT01339663|Drug|cyclophosphamide|Given IV
374215|NCT01339663|Biological|aldesleukin|Given SC
374216|NCT01339663|Biological|autologous tumor cell vaccine|Receive T-APC via IV
374217|NCT01339663|Other|laboratory biomarker analysis|Correlative studies
374218|NCT01339663|Other|immunologic technique|Correlative studies
374219|NCT01339663|Other|immunohistochemistry staining method|Correlative studies
374220|NCT01339663|Genetic|polymerase chain reaction|Correlative studies
374221|NCT01339663|Biological|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
374222|NCT01339650|Drug|ABT-767|ABT-767 once or twice daily for a 28 day cycle
374223|NCT01339624|Drug|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
374225|NCT01339611|Behavioral|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
374226|NCT01339598|Device|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
374227|NCT01339585|Device|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
374228|NCT01339572|Drug|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:~Pre-apheresis peripheral blood CD34+ count <20 cells/μL on day 5.~Estimated CD34+ cell collection is < 25% of target cell dose after 1 day of apheresis.~Estimated CD34+ cell collection is < 50% of target cell dose after 2 days of apheresis."
374229|NCT01339572|Drug|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:~Standard risk: 5 μg/kg SQ BID.~High risk: 10 μg/kg SQ BID."
374230|NCT01339559|Drug|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.~The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
374231|NCT01339546|Other|no intervention|
374232|NCT01339533|Device|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
374233|NCT01339520|Behavioral|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
374234|NCT01339520|Behavioral|Control|Standard of care for diabetes subjects
374235|NCT01339494|Dietary Supplement|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
374236|NCT01339481|Drug|abatacept|Intravenous Infusion
374237|NCT01339468|Drug|Advagraf|oral
374238|NCT01339468|Drug|Prograf|oral
374239|NCT01339468|Drug|Prograf|intravenous
374240|NCT01339455|Procedure|AHSCT|"AHSCT Procedure:~Mobilization and Harvesting:~Cyclophosphamide~Rituximab~GSCF~Dexamethasone~Apheresis~Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):~Cyclophosphamide~MESNA~Rabbit ATG~Rituximab~Methylprednisolone~Stem Cell infusion~GSCF"
374241|NCT01339442|Drug|BKM120|
374242|NCT01339442|Drug|Fulvestrant|
374243|NCT01339442|Procedure|biopsy|Correlative studies
374244|NCT01339429|Device|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
374245|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
374246|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
374247|NCT01339390|Behavioral|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
374248|NCT01339390|Behavioral|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
374249|NCT01339377|Device|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
374250|NCT01339364|Other|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
374251|NCT01339364|Other|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
374252|NCT01339364|Other|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
374253|NCT01339351|Behavioral|Therapeutic Group by Teleconference|10 sessions
374254|NCT01339338|Procedure|warming the contrast media|warm the contrast media with 37℃ water-bathing
374255|NCT01339325|Procedure|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.~Laparo-endoscopic single site cholecystectomy~The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
374256|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
374257|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
374258|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
374259|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
374260|NCT01339299|Drug|recombinant luteinizing hormone (r-LH)|administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
374261|NCT01339299|Drug|recombinant human chorionic gonadotropin (r-hCG)|administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
374359|NCT01338714|Other|dilute RHD-1|100 ml/per day
374427|NCT01337947|Drug|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
374262|NCT01339286|Drug|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
374263|NCT01339273|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
374264|NCT01339273|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
374265|NCT01339260|Drug|Netupitant and Palonosetron|
374266|NCT01339260|Drug|Palonosetron|
374267|NCT01339260|Drug|Dexamethasone|
374268|NCT01339247|Drug|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
374269|NCT01339247|Drug|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
374270|NCT01339234|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
374271|NCT01339221|Procedure|Stool samples|Stool samples collected and checked for the presence of rotavirus
374272|NCT01339208|Other|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
374273|NCT01339195|Behavioral|French adaptation of NINDS-Canadian Stroke Network battery|"clinical: post-stroke neurological follow-up assessment~neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery~MRI"
374274|NCT01339182|Drug|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
374275|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
374276|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
374277|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
374278|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
374279|NCT01339169|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
374280|NCT01339156|Drug|P3914|"Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
374281|NCT01339156|Drug|Placebo|"Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
374282|NCT01339143|Drug|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
374283|NCT01339143|Drug|pioglitazone|15mg, QD, PO, 16 weeks
374284|NCT01339130|Behavioral|Computerized tests and Electrophysiological measurements|"Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.~Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).~Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
374285|NCT01339117|Other|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
374286|NCT01339117|Other|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
374360|NCT01338701|Procedure|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
374287|NCT01339104|Drug|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
374288|NCT01339091|Drug|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
374289|NCT01339091|Drug|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
374290|NCT01339078|Procedure|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
374291|NCT01339078|Procedure|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
374292|NCT01339065|Drug|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
374293|NCT01339052|Drug|BKM120|
374294|NCT01339052|Procedure|Surgery|Surgery
374295|NCT01339039|Drug|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
374296|NCT01339039|Drug|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
374297|NCT01339039|Drug|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
374298|NCT01339039|Drug|Plerixafor|Daily administration for 5-9 days prior to surgery
374299|NCT01339039|Procedure|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 & 15).
374300|NCT01339026|Drug|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
374301|NCT01339026|Drug|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
374302|NCT01339013|Device|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
374303|NCT01339000|Drug|Glycosylated Recombinant Human Interleukin-7|Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
374304|NCT01339000|Biological|Diphtheria/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
374305|NCT01339000|Biological|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
374306|NCT01339000|Biological|Pneumococcal Vaccine|Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
374307|NCT01339000|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
374308|NCT01339000|Biological|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
374309|NCT01338987|Procedure|First Allogeneic Bone Marrow Transplant (BMT)|First Allogeneic Bone Marrow Transplant
374310|NCT01338987|Drug|Leuprolide|Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients <18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients > 18 years and as a 3 month injection (adult preparation) for patients < 18 years
374311|NCT01338987|Drug|18F FLT|For the first 23 patients undergoing 1st bone marrow transplant (BMT):[18F]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
374312|NCT01338987|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults > 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric </= 22 years)
374313|NCT01338987|Drug|Methotrexate|Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
374314|NCT01338987|Drug|Tacrolimus|Tacrolimus:0.02 mg/kg/day continuous intravenous infusion (CIV) on day -1.
374315|NCT01338987|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
374316|NCT01338987|Drug|Busulfan|Second choice is Busulfan (with goal steady state of 800-1000) with fludarabine or cyclophosphamide at myeloablative dosing or non-myeloablative dosing.
374317|NCT01338987|Drug|Fludarabine|Given with Busulfan as alternative to cyclophosphamide in second transplant setting only
374318|NCT01338987|Procedure|Second Allogeneic Bone Marrow Transplantation|Second Allogeneic Bone Marrow Transplantation
374319|NCT01338974|Genetic|gene expression analysis|
374320|NCT01338974|Genetic|proteomic profiling|
374321|NCT01338974|Other|flow cytometry|
374322|NCT01338974|Other|laboratory biomarker analysis|
374323|NCT01338961|Procedure|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
374324|NCT01338948|Procedure|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
374361|NCT01338701|Procedure|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
374428|NCT01337934|Drug|Lactated Ringer|Lactated Ringer
374429|NCT01337934|Drug|Albumin|Albumin 4%
374325|NCT01338935|Drug|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.~For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage *.~For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.~*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
374326|NCT01338935|Drug|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002~Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002~Bolus doses of ED95 are determined in Part I of the study."
374327|NCT01338935|Drug|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.~Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.~Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
374328|NCT01338922|Device|Continuous subcutaneous insulin infusion therapy|Insulin is given continuously using an insulin pump. Devices are allowed having marketing approval. Insulins are permitted with marketing approval.
374329|NCT01338922|Device|Multiple daily injection therapy|Multiple daily injection therapy with different devices and insulin types. Devices and insulin types have to have marketing approval.
374330|NCT01338909|Drug|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
374331|NCT01338909|Drug|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
374332|NCT01338896|Drug|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
374333|NCT01338883|Drug|Cenicriviroc 100 mg|100 mg CVC plus Truvada
374334|NCT01338883|Drug|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
374335|NCT01338883|Drug|Sustiva + Truvada|Sustiva plus Truvada
374336|NCT01338870|Drug|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
374337|NCT01338870|Drug|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
374338|NCT01338870|Drug|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
374339|NCT01338870|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
374340|NCT01338870|Drug|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
374341|NCT01338870|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
374342|NCT01338857|Drug|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.~Children/adolescents (< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily~Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily~NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
374343|NCT01338844|Dietary Supplement|Myo-inositol|
374344|NCT01338844|Dietary Supplement|D-chito-Inositol|
374345|NCT01338831|Drug|LFA102|
374346|NCT01338818|Drug|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
374347|NCT01338805|Drug|BGG492|
374348|NCT01338792|Drug|oxaliplatin|Given IV
374349|NCT01338792|Drug|pemetrexed disodium|Given IV
374350|NCT01338792|Other|questionnaire administration|Ancillary studies
374351|NCT01338792|Other|laboratory biomarker analysis|Correlative studies
374352|NCT01338792|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
374353|NCT01338792|Genetic|polymorphism analysis|Correlative studies
374354|NCT01338766|Procedure|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
374355|NCT01338753|Other|Bevacizumab, docetaxel and doxorubicin followed by surgery|"The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.~The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.~The surgical procedure will be done 4-6 weeks after completion of chemotherapy."
374356|NCT01338740|Drug|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
374357|NCT01338727|Behavioral|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
374358|NCT01338714|Other|Compound Herbal Formula (RHD-1)|100 ml/per day
374362|NCT01338701|Other|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
374363|NCT01338675|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
374364|NCT01338649|Device|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
374365|NCT01338649|Device|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
374366|NCT01338636|Drug|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
374367|NCT01338623|Drug|Tansulosine|capsule 0,4 mg
374368|NCT01338610|Biological|ESBA105 ophthalmic solution|
374369|NCT01338610|Other|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
374370|NCT01338597|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
374371|NCT01338584|Behavioral|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
374372|NCT01338584|Behavioral|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
374373|NCT01338558|Drug|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
374374|NCT01338558|Drug|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
374375|NCT01338558|Drug|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
374376|NCT01338532|Other|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
374377|NCT01338532|Other|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
374378|NCT01338506|Behavioral|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
374379|NCT01338493|Procedure|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
374380|NCT01338480|Other|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
374381|NCT01338467|Device|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
374382|NCT01338454|Drug|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
374383|NCT01338441|Drug|Erythromycin|4mg/Kg, IV during 20 min once
374384|NCT01338441|Drug|Placebo|4mg/Kg, IV during 20 min once
374385|NCT01338428|Behavioral|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge[ment]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
374386|NCT01338428|Behavioral|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
374387|NCT01338415|Drug|Bosentan|Oral dispersible tablet administered as 2mg/kg two (b.i.d.) or three (t.i.d.) times per day
374388|NCT01338402|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
374389|NCT01338402|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
374390|NCT01338402|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
374391|NCT01338389|Dietary Supplement|CITICOLINE|"Oral administration of CITICOLINE:~Form: Powder for solution Dosage: 800mg per day duration: 5 years"
374392|NCT01338389|Dietary Supplement|PLACEBO|"Oral administration of placebo:~Form: Powder for solution duration: 5 years"
374426|NCT01337960|Behavioral|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
374393|NCT01338376|Behavioral|Structured Education|"All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.~Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS~Physician Activity: frequent insulin titration"
374394|NCT01338376|Behavioral|Conventional Diabetes Education|"The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.~Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia~Physician Activity: less frequent insulin titration"
374395|NCT01338376|Drug|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
374396|NCT01338350|Drug|AZD5423|Inhalation, suspension
374397|NCT01338350|Drug|Placebo|Inhalation, solution
374398|NCT01338337|Drug|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
374399|NCT01338324|Drug|Simvastatin|Simvastatin 20 mg single dose on day 1
374400|NCT01338311|Drug|salbutamol|200mcg twice daily for a total of 7 doses
374401|NCT01338311|Drug|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
374402|NCT01338298|Drug|Aripiprazole|Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.
374403|NCT01338298|Drug|Placebo|The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
374404|NCT01338142|Other|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.~1.5 mg of 42Ca labeled CaCl2 through IV injection"
374405|NCT01338142|Other|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
374406|NCT01338129|Dietary Supplement|vitamin c|1000 mg of vitamin c for 45 days
374407|NCT01338129|Drug|placebo|placebo pills
374408|NCT01338116|Other|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
374409|NCT01338103|Drug|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
374410|NCT01338090|Drug|89Zr-bevacizumab|Intravenous injection 120 MBq
374411|NCT01338090|Drug|Everolimus|Oral use, 10 mg per day
374412|NCT01338077|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
374413|NCT01338077|Drug|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
374414|NCT01338051|Biological|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.~DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
374415|NCT01338025|Drug|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
374416|NCT01338025|Drug|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
374417|NCT01338012|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
374418|NCT01337999|Other|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
374419|NCT01337986|Drug|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
374420|NCT01337986|Drug|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
374421|NCT01337973|Behavioral|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
374422|NCT01337973|Behavioral|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
374423|NCT01337973|Behavioral|E-TAU|Enhanced Treatment as Usual
374424|NCT01337960|Behavioral|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
374425|NCT01337960|Behavioral|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
374430|NCT01337921|Dietary Supplement|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
374431|NCT01337895|Other|Low dairy|No more than 1 serving per day
374432|NCT01337895|Other|High dairy|4 or more servings per day
374433|NCT01337882|Other|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin [100, 300 & 1000 pmol/min]; acetylcholine [5, 10 & 20 µg/min]) and -independent [sodium nitroprusside [2, 4 & 8 µg/min]; verapamil [10, 30 & 100 µg/min]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
374434|NCT01337869|Procedure|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
374435|NCT01337869|Procedure|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
374436|NCT01337856|Other|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
374437|NCT01337843|Other|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
374438|NCT01337843|Other|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
374439|NCT01337830|Other|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
374440|NCT01337830|Other|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
374441|NCT01337817|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
374442|NCT01337817|Other|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
374443|NCT01337804|Drug|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
374444|NCT01337804|Drug|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
374445|NCT01337791|Drug|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
374446|NCT01337778|Behavioral|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
374447|NCT01337778|Behavioral|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
374448|NCT01337765|Drug|BEZ235 + MEK162|
374449|NCT01337752|Drug|BHQ880|
374450|NCT01337752|Drug|BHQ990|
374451|NCT01337739|Drug|Placebo Comparator|Placebo administration (.9 normal saline sterile)
374452|NCT01337739|Drug|Active Comparator|Administration of Dexmedetomidine
374453|NCT01337726|Behavioral|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
374454|NCT01337726|Behavioral|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
374455|NCT01337713|Other|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
374456|NCT01337713|Other|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
375108|NCT01332695|Drug|Placebo|placebo to match
374457|NCT01337700|Drug|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
374458|NCT01337700|Drug|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
374459|NCT01337687|Drug|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
374460|NCT01337687|Drug|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
374461|NCT01337674|Drug|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
374462|NCT01337674|Drug|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
374463|NCT01337674|Drug|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
374464|NCT01337674|Drug|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
374465|NCT01337635|Drug|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
374466|NCT01337622|Procedure|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
374467|NCT01337622|Procedure|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
374468|NCT01337609|Drug|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
374469|NCT01337609|Other|Placebo (sugar pill)|1 pill daily for 60 days
374470|NCT01337609|Other|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
374471|NCT01337596|Drug|LY2951742|Administered subcutaneously
374472|NCT01337596|Drug|Placebo|Administered subcutaneously
374473|NCT01337583|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
374474|NCT01337583|Other|Placebo|Vaginal Ring containing no drug substance
374475|NCT01337583|Drug|Dapivirine|
374476|NCT01337570|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
374477|NCT01337570|Other|Placebo|Vaginal Ring containing no drug substance
374478|NCT01337570|Drug|Dapivirine|
374479|NCT01337557|Drug|Bepotastine|1.5% bid
374480|NCT01337544|Other|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
374481|NCT01337531|Drug|Gonal-F, Fostimon|dosage form
374482|NCT01337531|Drug|Gonal-F, Fostimon|injection, daily, 10-15 days
374483|NCT01337518|Drug|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
374484|NCT01337505|Drug|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
374485|NCT01337492|Drug|Nexavar|400 mg of Sorafenib
374486|NCT01337466|Radiation|[124I]FIAU|This is a single dose study of 2 mCi [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
374487|NCT01337440|Drug|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
374488|NCT01337440|Drug|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.~UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
374489|NCT01337427|Drug|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
374490|NCT01337414|Behavioral|VMS diary booklet|
374491|NCT01337414|Behavioral|Standard of Care|
374492|NCT01337401|Drug|Cediranib|30mg once daily, oral until disease progression
374493|NCT01337401|Drug|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
374494|NCT01337375|Drug|peginterferon alfa 2a [Pegasys]|sc weekly
374495|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv weekly
374496|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|sc twice weekly
374497|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv twice weekly
374498|NCT01337362|Procedure|Insulin clamp|Patients will be exposed to low bloodsugar
374499|NCT01337349|Drug|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
374500|NCT01337349|Drug|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
374501|NCT01337336|Drug|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
374502|NCT01337336|Drug|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
374503|NCT01337323|Drug|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
374504|NCT01337310|Drug|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
374505|NCT01337297|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
375242|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
374506|NCT01337271|Procedure|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
374507|NCT01337271|Procedure|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
374508|NCT01337258|Drug|Dutasteride|dutasteride 0.5mg daily.
374509|NCT01337258|Drug|Placebo|Men taking placebo daily
374510|NCT01337245|Drug|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
374511|NCT01337232|Behavioral|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
374512|NCT01337219|Drug|Tobramycin|
374513|NCT01337206|Device|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
374514|NCT01337206|Procedure|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
374515|NCT01337193|Other|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
374516|NCT01337193|Other|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
374517|NCT01337167|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
374518|NCT01337167|Biological|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
374519|NCT01337167|Biological|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
374520|NCT01337167|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
374521|NCT01337167|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
374522|NCT01337167|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
374523|NCT01337167|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
374524|NCT01337167|Biological|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
374525|NCT01337154|Drug|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
374526|NCT01337154|Drug|Placebo|Tablets, orally, daily
374527|NCT01337141|Other|Control|7 face-to-face visits.
374528|NCT01337141|Device|Telecare system|5 telematic visits and 2 face-to-face visits.
374529|NCT01337128|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
374530|NCT01337128|Procedure|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
374531|NCT01337128|Procedure|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
374532|NCT01337128|Procedure|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
374533|NCT01337128|Procedure|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
374534|NCT01337128|Procedure|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
374535|NCT01337115|Procedure|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
374536|NCT01337115|Procedure|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
374537|NCT01337102|Procedure|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
374538|NCT01337102|Procedure|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
374539|NCT01337089|Drug|Nabiximols|
374540|NCT01337076|Device|cochlear implant|Cochlear implant surgery
374541|NCT01337063|Other|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
374542|NCT01337050|Drug|PF-03446962|PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
374585|NCT01336829|Drug|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
374586|NCT01336816|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
374587|NCT01336816|Other|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
374588|NCT01336803|Drug|Feraheme|5 mg/kg by intravenous (IV) administration
375243|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
374543|NCT01337037|Device|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.~Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
374544|NCT01337037|Procedure|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
374545|NCT01337037|Procedure|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
374546|NCT01337037|Procedure|Open lobectomy|standard lobectomy procedure by thoracotomy approach
374547|NCT01337011|Other|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
374548|NCT01336998|Dietary Supplement|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
374549|NCT01336985|Drug|Irinotecan|
374550|NCT01336985|Procedure|Chemoembolization|
374551|NCT01336985|Device|Drug-Eluting Beads|
374552|NCT01336985|Procedure|Biopsy|
374553|NCT01336972|Drug|Tolvaptan|Tolvaptan was supplied as 15 and 30 mg tablets.
374554|NCT01336959|Drug|BCT197 Part A|open label single dose administration of 10mg BCT197, 2 hours prior to surgery
374555|NCT01336959|Drug|Placebo|Single dose matching placebo administered 2 prior to surgery
374556|NCT01336959|Drug|BCT197 Part B|BCT197 50mg single dose administered 2 hours prior to surgery
374557|NCT01336946|Behavioral|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
374558|NCT01336946|Behavioral|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
374559|NCT01336933|Drug|prednisone|Given PO
374560|NCT01336933|Drug|cyclophosphamide|Given IV
374561|NCT01336933|Drug|etoposide|Given PO or IV
374562|NCT01336933|Drug|Vincristine|Given IV
374563|NCT01336933|Drug|pralatrexate|Given IV
374564|NCT01336933|Other|laboratory biomarker analysis|Correlative studies
374565|NCT01336933|Genetic|comparative genomic hybridization|Correlative studies
374566|NCT01336933|Genetic|gene expression analysis|Correlative studies
374567|NCT01336933|Genetic|nucleic acid sequencing|Correlative studies
374568|NCT01336933|Genetic|mutation analysis|Correlative studies
374569|NCT01336933|Other|immunohistochemistry staining method|Correlative studies
374570|NCT01336933|Genetic|microarray analysis|Correlative studies
374571|NCT01336933|Genetic|RNA analysis|Correlative studies
374572|NCT01336920|Drug|carfilzomib|Given IV
374573|NCT01336894|Procedure|therapeutic conventional surgery|Undergo surgery
374574|NCT01336894|Radiation|iodine I 125|Undergo seed implant radiotherapy
374575|NCT01336894|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
374576|NCT01336881|Genetic|RNA analysis|
374577|NCT01336881|Genetic|gene expression analysis|
374578|NCT01336881|Genetic|microarray analysis|
374579|NCT01336881|Genetic|nucleic acid sequencing|
374580|NCT01336881|Other|diagnostic laboratory biomarker analysis|
374581|NCT01336842|Drug|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.~Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
374582|NCT01336829|Drug|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
374583|NCT01336829|Drug|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
374584|NCT01336829|Drug|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
374589|NCT01336803|Procedure|Magnetic Resonance Imaging (MRI) scan|Standard of Care magnetic resonance imaging (MRI) scans using GE 1.5T and 3T MRI scanners/
374590|NCT01336764|Behavioral|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
374591|NCT01336764|Behavioral|Control|Unguided listening to radio/music.
374592|NCT01336751|Drug|Insulin glargine|solution for subcutaneous injection
374593|NCT01336751|Drug|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
374594|NCT01336738|Drug|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
374595|NCT01336738|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
374596|NCT01336738|Drug|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
374597|NCT01336738|Drug|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
374598|NCT01336738|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
374599|NCT01336725|Behavioral|Teaching life style changes|Single group: Teaching, group sessions, physical activity
374600|NCT01336725|Other|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
374601|NCT01336725|Other|Teaching|Morbid obesity group attend 40 hours of group sessions
374602|NCT01336712|Procedure|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
374603|NCT01336699|Other|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
374604|NCT01336699|Biological|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
374605|NCT01336699|Biological|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
374606|NCT01336686|Drug|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
374607|NCT01336686|Drug|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
374608|NCT01336686|Drug|Placebo comparator|Matching placebo once daily for 4 weeks
374609|NCT01336686|Drug|Colchicine|0.6 mg colchicine daily for flare prophylaxis
374610|NCT01336660|Biological|Equine F(ab')2 antivenom|A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
374611|NCT01336660|Other|Intensive care support plus placebo|Intensive care support as needed plus placebo
374612|NCT01336647|Drug|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
374613|NCT01336647|Drug|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
374614|NCT01336647|Drug|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
374615|NCT01336634|Drug|Dabrafenib|Dabrafenib study treatment will be provided by GSK as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt).
374616|NCT01336634|Device|Trametinib|Trametinib study treatment will be provided as 0.5 mg and 2 mg tablets. Each tablet will contain 0.5 mg or 2 mg of trametinib parent (present as the DMSO solvate)
374617|NCT01336621|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
374618|NCT01336608|Drug|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
374619|NCT01336608|Drug|Vilanterol|Inhaled long acting beta-agonist
374620|NCT01336608|Drug|Placebo|Placebo
374621|NCT01336595|Device|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
374622|NCT01336595|Device|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
374623|NCT01336582|Drug|taxotere|70 mg/m2 for age of ≥ 65
374624|NCT01336569|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
374625|NCT01336556|Procedure|Oral appliance|Anterior mandibular repositioner: used for two months
374626|NCT01336543|Drug|Chemotherapy following concurrent Chemoradiotherapy|"NSCLC (Non-Small Cell Lung Cancer)~PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)~Radiation 59.4 Gy with 2 cycles of PE~(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles~(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
374627|NCT01336530|Drug|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
374628|NCT01336530|Drug|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
374629|NCT01336530|Drug|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
374630|NCT01336530|Other|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
374631|NCT01336478|Procedure|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
374632|NCT01336478|Procedure|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
374633|NCT01336465|Drug|placebo|Repeating subcutaneous injection
374634|NCT01336465|Drug|rhuMAb Beta7|Repeating subcutaneous injection
374635|NCT01336452|Radiation|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
374680|NCT01336088|Drug|Placebo|oral administration
374636|NCT01336439|Drug|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.~After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.~After 4 weeks, the subjects had a post-injection polysomnography."
374637|NCT01336413|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
374638|NCT01336413|Drug|Placebo|Same as active comparator, except placebo dispensed.
374639|NCT01336400|Other|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
374640|NCT01336387|Drug|retinoid 9cUAB30|Given PO
374641|NCT01336387|Other|placebo|Given PO
374642|NCT01336387|Other|pharmacological study|Correlative studies
374643|NCT01336387|Other|laboratory biomarker analysis|Correlative studies
374644|NCT01336387|Other|cancer prevention|Disease prevention
374645|NCT01336361|Other|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
374646|NCT01336348|Drug|Prasugrel|60 mg loading dose given orally at presentation
374647|NCT01336348|Drug|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
374648|NCT01336335|Device|CPAP|CPAP
374649|NCT01336322|Drug|Metformin|Metformin 850 mg bid
374650|NCT01336322|Drug|Sitagliptin|Sitagliptin 100 mg qd
374651|NCT01336322|Drug|Sitagliptin + Metformin|sitagliptin 100mg + metformin 850mg
374652|NCT01336309|Behavioral|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
374653|NCT01336296|Drug|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
374654|NCT01336283|Other|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
374655|NCT01336283|Other|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
374656|NCT01336283|Other|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
374657|NCT01336270|Other|biological collection|to collect some human cell samples in melanoma
374658|NCT01336257|Other|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
374659|NCT01336244|Drug|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
374660|NCT01336244|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
374661|NCT01336218|Drug|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
374662|NCT01336218|Drug|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
374663|NCT01336205|Drug|NKTR-118|25 mg oral tablet once daily
374664|NCT01336205|Drug|Usual care|As prescribed by the investigator
374665|NCT01336192|Drug|Gemcitabine|Gemcitabine 1250mg/m^2 Day 1 and 8, 28 days per cycle until PD
374666|NCT01336192|Drug|Best supportive care|Best supportive care
374667|NCT01336179|Procedure|Salvadora persica|twice daily use, two minutes interval
374668|NCT01336179|Procedure|Toothbrush|Twice daily use two minutes interval
374669|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
374670|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
374671|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
374672|NCT01336166|Biological|Placebo control|120 adults were assigned to receive 1 dose of placebo.
374673|NCT01336153|Drug|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
374674|NCT01336153|Drug|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
374675|NCT01336140|Drug|Aminophylline|75 mg of intravenous aminophylline
374676|NCT01336140|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
374677|NCT01336127|Behavioral|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
374678|NCT01336101|Device|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
374679|NCT01336088|Drug|ADX48621|oral administration
374681|NCT01336075|Procedure|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
374682|NCT01336075|Procedure|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
374683|NCT01336062|Drug|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
374684|NCT01336049|Drug|Nimotuzumab|Nimotuzumab 200mg/week
374685|NCT01336023|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
374686|NCT01336023|Drug|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
374687|NCT01336023|Drug|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
374688|NCT01336010|Drug|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
374689|NCT01336010|Drug|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
374690|NCT01335997|Drug|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
374691|NCT01335997|Drug|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
374692|NCT01335997|Drug|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
374693|NCT01335997|Drug|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
374694|NCT01335997|Drug|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
374695|NCT01335984|Procedure|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.~The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
374696|NCT01335984|Procedure|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring & Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.~Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
374697|NCT01335984|Other|control group|"- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).~The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
374698|NCT01335971|Drug|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
374699|NCT01335971|Dietary Supplement|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
374700|NCT01335971|Other|Placebo|Microcrystalline cellulose once daily by mouth
374701|NCT01335958|Drug|DMUC5754A|Escalating intravenous dose
374702|NCT01335945|Procedure|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
374703|NCT01335932|Drug|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
374704|NCT01335932|Drug|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications."
374705|NCT01335906|Other|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
374706|NCT01335893|Drug|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
374707|NCT01335880|Behavioral|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
374708|NCT01335880|Behavioral|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
374709|NCT01335867|Drug|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
374710|NCT01335867|Drug|Placebo|Placebo pills
374711|NCT01335854|Behavioral|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
374751|NCT01335503|Dietary Supplement|AN-PEP|Endoprotease enzyme (AN-PEP)
374887|NCT01334255|Drug|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
374712|NCT01335854|Behavioral|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
374713|NCT01335841|Device|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
374714|NCT01335828|Device|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
374715|NCT01335789|Drug|Oxytocin|40 IUs
374716|NCT01335789|Drug|Saline|40 IUs
374717|NCT01335776|Behavioral|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
374718|NCT01335776|Behavioral|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
374719|NCT01335763|Drug|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
374720|NCT01335750|Other|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
374721|NCT01335750|Other|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
374722|NCT01335750|Other|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
374723|NCT01335750|Other|Multipurpose Solution #4|Saline Solution
374724|NCT01335737|Behavioral|aerobic training|12 weeks of aerobic training, 4 times/week
374725|NCT01335737|Behavioral|Wait list|wait list control condition
374726|NCT01335724|Drug|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
374727|NCT01335724|Drug|Placebo gel|Placebo gel
374728|NCT01335711|Drug|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)"
374729|NCT01335711|Drug|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
374730|NCT01335698|Drug|Atazanavir Sulphate|
374731|NCT01335698|Drug|Ritonavir|
374732|NCT01335685|Drug|Ixazomib|Ixazomib capsules
374733|NCT01335685|Drug|Melphalan|Melphalan tablets
374734|NCT01335685|Drug|Prednisone|Prednisone tablets
374735|NCT01335659|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
374736|NCT01335659|Device|IVUS|"intravascular ultrasound~:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
374737|NCT01335646|Procedure|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
374738|NCT01335646|Other|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
374739|NCT01335620|Drug|Raltegravir|400 mg twice daily
374740|NCT01335620|Drug|Tenofovir|245 mg once daily
374741|NCT01335620|Drug|Emtricitabine|200mg once daily
374742|NCT01335607|Drug|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
374743|NCT01335607|Drug|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
374744|NCT01335594|Procedure|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
374745|NCT01335581|Device|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
374746|NCT01335568|Procedure|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
374747|NCT01335542|Procedure|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
374748|NCT01335542|Procedure|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
374749|NCT01335529|Drug|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"Screen period from Week-8~Standard treatment from day 0 to week 4 (W4)~Three-drug-regimen (Boceprevir introduction) from W4 to W8~HCV RNA determination at W8 determines treatment group and participation duration:~If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,~If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
374750|NCT01335516|Other|Glypressin (terlipressin)|Study drug (without placebo)
374752|NCT01335490|Other|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
374753|NCT01335477|Drug|placebo|placebo matching BIBF 1120 BID
374754|NCT01335477|Drug|BIBF 1120|BIBF 1120 BID (twice daily)
374755|NCT01335464|Drug|placebo|placebo matching BIBF1120, BID
374756|NCT01335464|Drug|BIBF 1120|BIBF1120 BID (twice daily)
374757|NCT01335451|Drug|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
374758|NCT01335451|Drug|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
374759|NCT01335438|Device|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
374760|NCT01335438|Device|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
374761|NCT01335412|Biological|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
374762|NCT01335399|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
374763|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
374764|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
374765|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
374766|NCT01335399|Drug|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
374767|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
374768|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
374769|NCT01335386|Drug|KLYX|
374770|NCT01335386|Drug|Glycerine|
374771|NCT01335373|Drug|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
374772|NCT01335360|Drug|Nevirapine|200mg twice daily of nevirapine
374773|NCT01335347|Biological|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
374774|NCT01335347|Biological|Placebo control|Capsules of the same size and shape as experimental groups
374775|NCT01335334|Drug|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
374776|NCT01335321|Drug|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
374777|NCT01335321|Drug|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
374778|NCT01335308|Behavioral|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
374779|NCT01335308|Behavioral|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
374780|NCT01335308|Behavioral|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
374781|NCT01335295|Drug|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
374782|NCT01335269|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
374783|NCT01335256|Drug|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
374784|NCT01335243|Procedure|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
374785|NCT01335217|Procedure|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
374786|NCT01335204|Drug|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
374787|NCT01335191|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
374788|NCT01335191|Other|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
374831|NCT01334762|Drug|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
374888|NCT01334242|Drug|Schedule A|Dosing 1 hour before breakfast
374889|NCT01334242|Drug|Schedule B|Dosing 0.5 hour before breakfast
374890|NCT01334242|Drug|Schedule C|Dosing immediately before breakfast
374789|NCT01335178|Behavioral|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project [parents.org.il];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
374790|NCT01335165|Drug|ALXN1102|Single Ascending Dose IV
374791|NCT01335165|Drug|ALXN1103|Single Ascending Dose IV or SC
374792|NCT01335152|Behavioral|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
374793|NCT01335139|Biological|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
374794|NCT01335139|Biological|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
374795|NCT01335139|Other|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
374796|NCT01335126|Other|Emulsion type artificial tear|2 types of artificial tears
374797|NCT01335087|Other|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
374798|NCT01335087|Device|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
374799|NCT01335074|Drug|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
374800|NCT01335061|Biological|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
374801|NCT01335061|Biological|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
374802|NCT01335048|Drug|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
374803|NCT01335048|Drug|Clopidogrel|Clopidogrel 150 mg daily
374804|NCT01335035|Drug|deferasirox|
374805|NCT01335022|Behavioral|lecture|6 lectures on cardiovascular disease covering obesity, diet & exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
374806|NCT01335009|Biological|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
374807|NCT01334983|Behavioral|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
374808|NCT01334957|Drug|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
374809|NCT01334944|Drug|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
374810|NCT01334931|Radiation|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
374811|NCT01334931|Radiation|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
374812|NCT01334918|Drug|regadenoson|Administered by intravenous bolus.
374813|NCT01334918|Radiation|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
374814|NCT01334918|Radiation|Contrast|Administered by intravenous infusion.
374815|NCT01334918|Procedure|Single Photon Emission Computed Tomography|Procedure/Surgery
374816|NCT01334918|Procedure|Multidetector Computed Tomography|Procedure/Surgery
374817|NCT01334905|Drug|YM178|oral
374818|NCT01334892|Drug|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
374819|NCT01334879|Drug|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
374820|NCT01334866|Procedure|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
374821|NCT01334853|Other|No drug will be used|Biomarker
374822|NCT01334853|Other|No drug will be used|Biomarker
374823|NCT01334840|Dietary Supplement|Bicarbonated mineral water|"Volunteers fasted overnight consumed:~0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
374824|NCT01334840|Dietary Supplement|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:~0.5 L of the control water without meal or, 0.5 L of the control water with meal"
374825|NCT01334814|Device|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
374826|NCT01334801|Procedure|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:~BNP (Brain Natriuretic Peptide)~(PFA) Platelet Function Analyzer 100~von Willebrand Factor (vWF) antigen~(vWF) multimers~(vWF) *activity by latex aggregation~Plasma stored for development of new testing approaches"
374827|NCT01334788|Other|sleep deprivation|Sleep restriction
374828|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
374829|NCT01334775|Procedure|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
374830|NCT01334762|Drug|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
374832|NCT01334736|Behavioral|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
374833|NCT01334736|Behavioral|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
374834|NCT01334736|Behavioral|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
374835|NCT01334736|Behavioral|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
374836|NCT01334723|Drug|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
374837|NCT01334723|Drug|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
374838|NCT01334710|Drug|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
374839|NCT01334697|Drug|recombinant human cardiotrophin-1|Single dose intravenous administration
374840|NCT01334697|Other|Placebo|Single dose intravenous administration
374841|NCT01334684|Drug|Metformin|Metformin, pills, 850 mg three times a day for three months
374842|NCT01334671|Drug|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
374843|NCT01334658|Procedure|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
374844|NCT01334658|Drug|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
374845|NCT01334658|Drug|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
374884|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
374885|NCT01334268|Device|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
374846|NCT01334645|Other|Copeptin|"Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.~Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.~Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.~The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
374847|NCT01334632|Procedure|Continuous interscalene block|The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
374848|NCT01334632|Procedure|PCA morphine|Postoperative with iv self-administration of morphine
374849|NCT01334619|Procedure|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
374850|NCT01334606|Device|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
374851|NCT01334606|Device|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
374852|NCT01334580|Behavioral|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
374853|NCT01334580|Behavioral|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
374854|NCT01334567|Drug|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
374855|NCT01334554|Drug|Sildenafil|20 mg three times a day.
374856|NCT01334554|Drug|Placebo|No active drug
374857|NCT01334541|Behavioral|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:~Risk Assessment~Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.~Clinical Follow-Up Protocol"
374858|NCT01334515|Biological|hu14.18-IL2 fusion protein|Given IV
374859|NCT01334515|Drug|isotretinoin|Given PO
374860|NCT01334515|Biological|sargramostim|Given SC
374861|NCT01334515|Other|laboratory biomarker analysis|Correlative studies
374862|NCT01334502|Biological|rituximab|PO
374863|NCT01334502|Drug|cyclophosphamide|IV
374864|NCT01334502|Drug|doxorubicin hydrochloride|IV
374865|NCT01334502|Drug|everolimus|PO
374866|NCT01334502|Drug|prednisone|PO
374867|NCT01334502|Drug|vincristine sulfate|IV
374868|NCT01334489|Device|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).~It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
374869|NCT01334450|Device|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
374870|NCT01334424|Drug|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
374871|NCT01334398|Behavioral|Health & Wellness|"The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment."
374872|NCT01334372|Behavioral|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
374873|NCT01334359|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
374874|NCT01334346|Other|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
374875|NCT01334346|Other|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
374876|NCT01334346|Other|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
374877|NCT01334333|Drug|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
374878|NCT01334333|Drug|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
374879|NCT01334320|Procedure|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
374880|NCT01334307|Device|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
374881|NCT01334307|Device|Control|Standard of Care
374882|NCT01334294|Device|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
374883|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
374886|NCT01334268|Device|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
374895|NCT01334216|Other|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
374896|NCT01334216|Other|CHICA Placebo|This was CHICA without the study module.
374897|NCT01334203|Drug|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.~Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
374898|NCT01334177|Drug|TLR8 agonist VTX-2337|Given SC
374899|NCT01334177|Biological|cetuximab|Given IV
374900|NCT01334177|Other|laboratory biomarker analysis|Correlative studies
374901|NCT01334177|Other|pharmacogenomic studies|Correlative studies
374902|NCT01334164|Behavioral|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
374903|NCT01334164|Other|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
374904|NCT01334151|Drug|Insulin LISPRO|Single doses of: 0.15 U/kg
374905|NCT01334151|Drug|recombinant human insulin|Single doses of: 0.15 U/kg
374906|NCT01334138|Other|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.~Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
374907|NCT01334125|Drug|Metformin|Metformin 1000 mg once daily by mouth for 9 months
374908|NCT01334125|Drug|Placebo|2 capsules once daily by mouth for 9 months
374909|NCT01334112|Drug|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
374910|NCT01334099|Biological|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
374911|NCT01334099|Radiation|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
374912|NCT01334086|Drug|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
374913|NCT01334073|Drug|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
374914|NCT01334060|Biological|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
374915|NCT01334047|Biological|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
374916|NCT01334034|Drug|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
374917|NCT01334034|Drug|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
374918|NCT01334034|Drug|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
374919|NCT01334021|Procedure|Biopsy|Undergo tumor biopsy
374920|NCT01334021|Procedure|Conventional Surgery|Undergo surgery
374921|NCT01334021|Other|Genetic Testing|Undergo genetic testing
374922|NCT01334008|Biological|Blood sampling|30ml of patient peripherical blood will be collected
374923|NCT01333995|Behavioral|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
374924|NCT01333982|Other|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
374925|NCT01333982|Other|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
374926|NCT01333969|Procedure|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
374927|NCT01333956|Drug|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
374928|NCT01333956|Drug|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
374998|NCT01333371|Procedure|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
374929|NCT01333956|Drug|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
374930|NCT01333956|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
374931|NCT01333943|Procedure|Study Group: Experimental|The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
374932|NCT01333943|Procedure|Control Group|The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
374933|NCT01333930|Other|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
374934|NCT01333930|Other|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
374935|NCT01333917|Drug|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
374936|NCT01333904|Drug|PUR118|inhaled
374937|NCT01333891|Drug|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
374938|NCT01333891|Drug|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
374939|NCT01333891|Device|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
374940|NCT01333891|Device|Goldmann applanation tonometer|intraocular pressure measurements
374941|NCT01333891|Device|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
374942|NCT01333878|Biological|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
374943|NCT01333865|Drug|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.~During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
374944|NCT01333852|Drug|metformin up to 2500mg/d|metformin up to 2500mg/d
374945|NCT01333852|Drug|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
374946|NCT01333852|Drug|placebo|placebo
374947|NCT01333839|Other|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
374948|NCT01333826|Behavioral|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
374949|NCT01333813|Biological|Engerix-B™ Kinder|Intramuscular, single dose
374950|NCT01333800|Drug|Beclomethasone|200 to 400 mcg per day for 6 months
374951|NCT01333800|Drug|Ciclesonide|80 to 160 mcg per day for 6 months
374952|NCT01333787|Dietary Supplement|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.~The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
374953|NCT01333774|Drug|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
374954|NCT01333761|Device|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
374955|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
374956|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
374957|NCT01333722|Drug|Hydrocodone/Acetaminophen Extended Release|
374958|NCT01333722|Drug|Placebo|Placebo tablet
374959|NCT01333709|Drug|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
374999|NCT01333358|Drug|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
374960|NCT01333709|Other|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
374961|NCT01333709|Radiation|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
374962|NCT01333709|Radiation|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
374963|NCT01333709|Procedure|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
374964|NCT01333696|Drug|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
374965|NCT01333670|Device|Prontosan wound irrigation solution|"cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)~positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes~dressing with Prontosan Wound Irrigation solution"
374966|NCT01333670|Drug|Isotonic solution (saline or lactated ringer)|"cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)~positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes~dressing with isotonic solution"
374967|NCT01333631|Drug|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
374968|NCT01333618|Device|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
374969|NCT01333618|Device|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
374970|NCT01333605|Drug|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
374971|NCT01333592|Drug|KAD-1229|
374972|NCT01333579|Other|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
374973|NCT01333566|Behavioral|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
374974|NCT01333566|Behavioral|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
374975|NCT01333553|Device|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
374976|NCT01333540|Drug|TD-1211|Escalating doses
374977|NCT01333540|Drug|Placebo|Placebo once daily
374978|NCT01333527|Procedure|No Sling|Early range of motion
374979|NCT01333527|Procedure|Sling|Patients will use the sling for 6 weeks, as per usual care
374980|NCT01333514|Drug|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
374981|NCT01333514|Drug|aspart|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
374982|NCT01333501|Drug|Fingolimod|0.5 mg in capsules for oral administration once daily
374983|NCT01333501|Drug|Interferon beta 1b|250 μg injected s.c. every other day
374984|NCT01333488|Device|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
374985|NCT01333488|Drug|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
374986|NCT01333475|Drug|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
374987|NCT01333462|Biological|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
374988|NCT01333462|Other|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
374989|NCT01333449|Drug|Decitabine|20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
374990|NCT01333436|Other|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
374991|NCT01333423|Drug|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
374992|NCT01333423|Drug|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
374993|NCT01333410|Drug|tacrolimus ointment|2 applications per days for 6 months
374994|NCT01333410|Drug|Mometasone furoate|2 applications per day for 6 months
374995|NCT01333397|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 (single treatment cycle)
375001|NCT01333332|Radiation|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
375002|NCT01333306|Procedure|Transcranial direct current stimulation (tDCS)|
375003|NCT01333293|Drug|injections|subcutaneous injections
375004|NCT01333280|Behavioral|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
375005|NCT01333280|Behavioral|Treatment as usual|Receive usual treatment at the programs
375006|NCT01333267|Drug|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
375007|NCT01333267|Drug|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
375008|NCT01333267|Drug|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
375009|NCT01333254|Procedure|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
375010|NCT01333241|Behavioral|Lifestyle behavior interventon grop|
375011|NCT01333241|Other|Placebo Comparator: Control group|
375012|NCT01333228|Other|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
375013|NCT01333202|Other|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
375014|NCT01333189|Other|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
375015|NCT01333189|Other|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
375016|NCT01333176|Procedure|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If < 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result >6.5: Counseled that they may have diabetes. Given requisition as above.~Estimates about how many have undiagnosed diabetes will be calculated.~Did the clients who were counseled to do so get follow-up blood tests?~Were all the formal diagnostic tests performed?~Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?~Did the family physicians find this useful?"
375017|NCT01333176|Procedure|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
375018|NCT01333176|Procedure|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
375019|NCT01333176|Procedure|Blood test|HbA1c blood test
375020|NCT01333176|Procedure|Blood test|HbA1c finger poke blood test
375021|NCT01333163|Biological|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
375022|NCT01333163|Biological|Isotone NaCl|2 hours IV infusion.
375023|NCT01333150|Drug|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
375024|NCT01333150|Drug|Placebo|One single dose of placebo
375025|NCT01333137|Drug|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
375026|NCT01333137|Drug|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
375027|NCT01333124|Radiation|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
375028|NCT01333124|Radiation|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
375029|NCT01333111|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
375244|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
375030|NCT01333111|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
375031|NCT01333111|Drug|nonacog beta pegol|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
375032|NCT01333098|Drug|Mifepristone|300mg per day, by mouth, for 21-28 days
375033|NCT01333085|Drug|carboplatin|
375034|NCT01333085|Drug|RAD001|
375035|NCT01333085|Drug|paclitaxel|
375036|NCT01333072|Drug|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
375037|NCT01333072|Drug|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
375038|NCT01333059|Drug|Midazolam|
375039|NCT01333059|Drug|Normal saline|
375040|NCT01333059|Drug|Fentanyl|
375041|NCT01333046|Biological|Antigen-Escalation Stage|"Antigen-Escalation Stage~Each patient will receive 2 injections at the same dose (5 x 10^6 cells/m2), 28 days apart, according to the following schedules:~Schedule One:~Day 0: PRAME-specific T cells~Day 28: PRAME- and SSX-specific T cells~Schedule Two:~Day 0: PRAME- and SSX-specific T cells~Day 28: PRAME/SSX/MAGE-specific T cells~Schedule Three:~Day 0: PRAME/SSX/MAGE-specific T cells~Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells~Schedule Four:~Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells~Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells"
375042|NCT01333046|Biological|Dose-Escalation Stage|"Dose-Escalation Stage~Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:~DL1: Day 0 and Day 14: 5 x 10^6 cells/m^2~DL2: Day 0 and Day 14: 1 x 10^7 cells/m^2~DL3: Day 0 and Day 14: 2 x 10^7 cells/m^2"
375043|NCT01333046|Biological|azacytidine and multiTAA T cells Stage|"Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:~ANC >1,000 or Platelets >50,000 (or any other grade I AE attributable to aza)~Adjustment: None~ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)~Adjustment: 50% dose reduction~ANC <500 or any episode of febrile neutropenia or platelets <25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)~Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion"
375044|NCT01333046|Biological|Pediatric multiTAA T cells Stage|Patients < 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
375045|NCT01333033|Drug|Oxaliplatin|Given IV
375046|NCT01333033|Drug|Leucovorin Calcium|Given IV
375047|NCT01333033|Drug|Fluorouracil|Given IV
375048|NCT01333033|Drug|Carboplatin|Given IV
375049|NCT01333033|Drug|Paclitaxel|Given IV
375050|NCT01333033|Procedure|Positron Emission Tomography|Undergo PET/CT scan
375051|NCT01333033|Procedure|Computed Tomography|Undergo PET/CT scan
375052|NCT01333033|Radiation|Radiation Therapy|Undergo RT
375053|NCT01333020|Other|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
375054|NCT01332994|Drug|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
375055|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
375056|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
375057|NCT01332968|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
375058|NCT01332968|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
375059|NCT01332968|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
375060|NCT01332968|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
375061|NCT01332968|Drug|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
375062|NCT01332968|Drug|Bendamustine|Bendamustine 90 mg/m^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
375063|NCT01332968|Drug|Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m^2 every 2 months during maintenance period.
375064|NCT01332955|Drug|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir~Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
375065|NCT01332955|Biological|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
375066|NCT01332955|Drug|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
375067|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
375068|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
375069|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
375070|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
375071|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
375072|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
375073|NCT01332929|Drug|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.~For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.~For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
375074|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
375075|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
375076|NCT01332903|Drug|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
375077|NCT01332890|Other|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
375078|NCT01332890|Other|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
375079|NCT01332890|Other|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
375080|NCT01332890|Other|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
375081|NCT01332890|Other|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
375082|NCT01332890|Other|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
375083|NCT01332877|Behavioral|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
375084|NCT01332877|Behavioral|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
375085|NCT01332864|Procedure|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
375086|NCT01332864|Procedure|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
375087|NCT01332851|Behavioral|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
375088|NCT01332851|Behavioral|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
375089|NCT01332838|Procedure|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
375090|NCT01332838|Device|compression stockings (Sigvaris )|Specialized monoleg compression
375091|NCT01332825|Other|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
375092|NCT01332812|Drug|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
375093|NCT01332812|Other|control group|General anesthesia, without additional interventions
375094|NCT01332799|Drug|allopurinol or placebo|Daily active drug (allopurinol administered orally) administered orally for 3 years.
375095|NCT01332799|Other|Placebo|Sugar pill administered orally for 3 years.
375096|NCT01332786|Drug|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)~Level 1: 50 mg daily x 10 doses; 1 week rest~Level 2: 100 mg daily x 10 doses; 1 week rest~Level 3: 150 mg daily x 10 doses; 1 week rest~Level 4: 200 mg daily x 10 doses 1 week rest~Level 5: 250 mg daily x 10 doses; 1 week rest~Level 6: 300 mg daily x 10 doses; 1 week rest~Level 7: 350 mg daily x 10 doses; 1 week rest"
375097|NCT01332773|Procedure|Artery first procedure|early identification of SMA to evaluate infiltration
375098|NCT01332773|Procedure|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
375099|NCT01332760|Other|narrow diameter heavy dental tool|8mm diameter, heavy periodontal tool made from steel
375100|NCT01332760|Other|large diameter light weight tool|Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
375101|NCT01332747|Drug|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~to be given in a dosage of 5 gms twice daily"
375102|NCT01332747|Drug|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.~compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
375103|NCT01332747|Drug|Atorvastatin|atorvastatin 10 mgs once daily
375104|NCT01332734|Drug|Magnesium Sulfate|2 gram in 1 hour
375105|NCT01332721|Drug|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
375106|NCT01332708|Behavioral|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
375107|NCT01332695|Drug|ST101|tablets for oral administration
375109|NCT01332682|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
375110|NCT01332682|Behavioral|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
375111|NCT01332669|Procedure|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
375112|NCT01332656|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
375113|NCT01332656|Drug|Placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
375114|NCT01332656|Drug|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
375115|NCT01332656|Drug|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
375116|NCT01332643|Genetic|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
375117|NCT01332630|Drug|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."
375118|NCT01332630|Drug|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
375119|NCT01332630|Drug|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
375120|NCT01332630|Drug|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
375121|NCT01332617|Drug|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"Simvastatin 80 mg PO daily starting day -2 through day 10.~Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly~Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.~Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.~Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
375122|NCT01332604|Drug|GDC-0980|Oral escalating dose
375123|NCT01332604|Drug|bevacizumab|Intravenous repeating dose
375124|NCT01332604|Drug|capecitabine|Oral repeating dose
375125|NCT01332604|Drug|mFOLFOX6|Intravenous repeating dose
375126|NCT01332591|Procedure|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
375127|NCT01332578|Drug|Paracetamol|Present in both test and active comparator
375128|NCT01332578|Drug|Phenylephrine|Test product
375129|NCT01332578|Drug|Ascorbic Acid|Test product
375130|NCT01332565|Drug|GSK1349572|50mg tablet
375131|NCT01332552|Drug|GSK2485852 70 mg|single dose
375132|NCT01332552|Drug|GSK2485852 420 mg|single dose
375133|NCT01332552|Drug|placebo|single dose
375134|NCT01332552|Drug|placebo|Repeat dose, once daily for 3 days
375135|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
375136|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
375137|NCT01332552|Drug|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
375138|NCT01332552|Drug|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
375139|NCT01332552|Drug|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
375140|NCT01332552|Drug|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
375141|NCT01332539|Other|no intervention|non-interventional study
375142|NCT01332513|Drug|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
375143|NCT01332513|Drug|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
375144|NCT01332513|Drug|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
375145|NCT01332513|Drug|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
375146|NCT01332513|Drug|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
375147|NCT01332513|Drug|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
375148|NCT01332500|Drug|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
375149|NCT01332500|Drug|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
375150|NCT01332487|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
375151|NCT01332474|Drug|BOTOX|BOTOX
375152|NCT01332461|Drug|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
375245|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
375153|NCT01332461|Drug|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
375154|NCT01332448|Drug|Orlistat 120|Orlistat 120mg tid
375155|NCT01332448|Drug|Orlistat 60|Orlistat 60mg tid
375156|NCT01332435|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
375157|NCT01332422|Drug|Salmeterol and Fluticasone|Collection of safety data
375158|NCT01332409|Drug|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
375159|NCT01332396|Drug|Lapatinib|
375160|NCT01332383|Drug|Naratriptan|
375161|NCT01332370|Drug|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
375162|NCT01332370|Drug|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
375163|NCT01332357|Drug|Fluticasone propionate/salmeterol combination ED MD|Receipt of fluticasone propionate/salmeterol combination from the ED physician
375164|NCT01332357|Drug|Fluticasone propionate/salmeterol combination OP MD|Receipt of fluticasone propionate/salmeterol combination from the OP physician
375165|NCT01332344|Drug|Fluticasone propionate/salmeterol combination|Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
375166|NCT01332344|Drug|Inhaled corticosteroids|asthma subjects newly prescribed inhaled corticosteroids in clinical practice
375167|NCT01332331|Drug|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
375168|NCT01332331|Drug|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
375169|NCT01332318|Drug|XP13512|XP13512 once daily for 16 days
375170|NCT01332318|Drug|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
375171|NCT01332318|Drug|Placebo|XP13512 placebo once daily for 16 days
375172|NCT01332305|Drug|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
375173|NCT01332305|Drug|Placebo|Placebo orally once daily
375174|NCT01332292|Drug|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
375175|NCT01332292|Drug|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
375176|NCT01332279|Drug|everolimus|Given PO
375177|NCT01332279|Drug|erlotinib hydrochloride|Given PO
375178|NCT01332279|Procedure|biopsy|Correlative studies
375179|NCT01332279|Other|laboratory biomarker analysis|Correlative studies
375180|NCT01332279|Other|immunohistochemistry staining method|Correlative studies
375181|NCT01332279|Genetic|polyacrylamide gel electrophoresis|Correlative studies
375182|NCT01332279|Other|pharmacological study|Correlative studies
375183|NCT01332279|Radiation|external beam radiation therapy|Undergo EBRT
375184|NCT01332279|Genetic|microarray analysis|Correlative studies
375185|NCT01332266|Drug|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
375186|NCT01332266|Drug|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
375187|NCT01332253|Drug|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
375188|NCT01332253|Other|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
375189|NCT01332240|Procedure|Endoscopic ultrasonography|in order to stage the mediastinum
375190|NCT01332227|Drug|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
375191|NCT01332227|Drug|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
375192|NCT01332227|Drug|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
375193|NCT01332227|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
375194|NCT01332214|Drug|AZD2820|Subcutaneous Injection in abdomen or Thigh
375195|NCT01332214|Drug|Placebo|Subcutaneous Injection in abdomen or Thigh
375196|NCT01332201|Drug|Advagraf|oral
375197|NCT01332201|Drug|Prograf|oral
375198|NCT01332188|Drug|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
375199|NCT01332188|Drug|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
375200|NCT01332188|Drug|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
375201|NCT01332188|Drug|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
375202|NCT01332175|Device|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
375203|NCT01332175|Device|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
375204|NCT01332175|Procedure|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
375205|NCT01332162|Device|Biventricular pacing|All patients will be pacing during two years
375206|NCT01332162|Device|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
375207|NCT01332149|Drug|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.~At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
375208|NCT01332149|Drug|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
375209|NCT01332123|Device|Alignment perturbations|Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
375210|NCT01332110|Device|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
375211|NCT01332097|Drug|BCT197|
375212|NCT01332097|Drug|Prednisone placebo|capsules
375213|NCT01332097|Drug|BCT197 placebo|capsules
375214|NCT01332084|Other|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
375215|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
375216|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
375217|NCT01332058|Behavioral|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
375218|NCT01332045|Procedure|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
375219|NCT01332045|Procedure|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
375220|NCT01332032|Behavioral|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
375221|NCT01332032|Behavioral|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
375222|NCT01332032|Behavioral|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
375223|NCT01332019|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
375224|NCT01332006|Procedure|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
375225|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|
375226|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
375227|NCT01331993|Drug|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
375228|NCT01331993|Drug|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
375229|NCT01331993|Drug|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
375230|NCT01331980|Device|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
375231|NCT01331980|Device|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
375232|NCT01331967|Drug|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
375233|NCT01331954|Device|Ultrasonic ablation device|One or two HIFU procedures
375234|NCT01331941|Drug|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
375235|NCT01331941|Drug|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
375236|NCT01331928|Drug|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
375237|NCT01331915|Biological|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.~Injection: intradermally and subcutaneously."
375238|NCT01331902|Other|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
375239|NCT01331902|Other|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
375240|NCT01331876|Behavioral|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
375241|NCT01331863|Procedure|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
375246|NCT01331850|Drug|RO5024048|1000 mg oral doses twice a day for 24 weeks
375247|NCT01331850|Drug|danoprevir|100 mg oral doses twice a day for 24 weeks
375248|NCT01331850|Drug|ritonavir|100 mg oral doses twice a day for 24 weeks
375249|NCT01331837|Drug|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
375250|NCT01331837|Drug|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
375251|NCT01331824|Drug|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
375252|NCT01331811|Other|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:~interview on anamnesis~clinical examination~evaluation of HIV infection stage~hematology and biochemistry tests~CD4 count~HIV viral load~IGRA~chest radiograph~Abdominal ultrasonograph to detect abdominal lymphadenopathy~Tuberculin skin test~gastric aspirates, sputum and string tests according to the age of children~nasopharyngeal aspirate~stool sample~lymph node fine needle aspirate or other specimen collection if applicable~Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
375253|NCT01331798|Device|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
375254|NCT01331798|Procedure|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
375255|NCT01331785|Drug|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
375256|NCT01331772|Other|Control arm|Dietetic follow-up only
375257|NCT01331772|Other|Intervention arm|Dietetic follow up + adapted physical activity
375258|NCT01331759|Device|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
375259|NCT01331746|Drug|APD515|20 mg oromucosal-oral administration qds for 7 days
375260|NCT01331746|Drug|Placebo|qds for 7 days
375261|NCT01331733|Drug|hMG-HP|
375262|NCT01331733|Drug|hMG + GnRH antagonist|
375263|NCT01331720|Drug|hMG-HP|
375264|NCT01331707|Device|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
375265|NCT01331707|Device|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
375266|NCT01331694|Drug|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
375267|NCT01331694|Drug|tiotropium|patients initiating treatment with tiotropium
375268|NCT01331694|Drug|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
375269|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
375270|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
375271|NCT01331681|Procedure|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
375272|NCT01331655|Drug|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
375273|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
375274|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
375275|NCT01331629|Other|ART-THERAPIE|8 sessions of art therapy during radiotherapy
375276|NCT01331616|Drug|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
375277|NCT01331590|Drug|G-CSF|
375278|NCT01331590|Drug|Ifosfamide|
375279|NCT01331590|Drug|Etoposide|
375280|NCT01331590|Drug|Dexamethasone|
375281|NCT01331590|Drug|Mesna|
375282|NCT01331577|Behavioral|Cognitive Behavioural Training|Two day seminar
375283|NCT01331577|Behavioral|Integrative Kinesiology Intervention|Two day seminar
375284|NCT01331564|Behavioral|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
375285|NCT01331564|Behavioral|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
375286|NCT01331564|Behavioral|Control|Control women will receive non-weight related content during both time periods at the project website.
375287|NCT01331525|Biological|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
375288|NCT01331499|Device|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
375289|NCT01331499|Procedure|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
375290|NCT01331486|Dietary Supplement|Hawthorn|Hawthorn standardized extract liquid capsule
375291|NCT01331486|Dietary Supplement|Placebo capsule|Matched placebo liquid capsule
375292|NCT01331473|Procedure|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
375293|NCT01331473|Procedure|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
375294|NCT01331460|Behavioral|RBT|"Intervention for Injection Drug Using Women:~Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
375295|NCT01331460|Other|Case-Management|"Standard Intervention:~Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
375296|NCT01331447|Drug|exemestane|25 mg tablet
375297|NCT01331434|Drug|exemestane|25 mg tablet
375298|NCT01331421|Drug|exemestane|25 mg tablet
375299|NCT01331408|Device|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
375300|NCT01331395|Other|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
375301|NCT01331382|Dietary Supplement|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
375302|NCT01331382|Other|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
375303|NCT01331369|Behavioral|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
375304|NCT01331369|Other|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
375305|NCT01331356|Drug|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
375306|NCT01331343|Device|Guardian RT Telemetered Glucose Monitoring System|
375307|NCT01331330|Device|Deep Brain Stimulation|Normal DBS Programming
375308|NCT01331330|Device|Deep Brain Stimulation|Low Programming
375309|NCT01331317|Drug|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
375310|NCT01331304|Drug|Lithium|600-900mg per day over 6 months
375311|NCT01331304|Drug|Quetiapine|100-800mg a day over 6 months
375312|NCT01331291|Drug|bosutinib|Taken orally
375313|NCT01331278|Procedure|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
375314|NCT01331278|Procedure|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
375315|NCT01331252|Other|semi-recumbent|Patient rests in a semi-recumbent body position
375316|NCT01331252|Other|supine|Patient rests in a supine position
375317|NCT01331239|Drug|LCI699|
375318|NCT01331226|Behavioral|telephone counseling 3 sessions|3 sessions of telephone counseling
375319|NCT01331226|Behavioral|telephone counseling 1 session|1 session of telephone counseling
375320|NCT01331226|Behavioral|written materials only|written materials only
375321|NCT01331213|Drug|Pregabalin|FDA approved medication (capsules) at 200mg dose.
375322|NCT01331213|Drug|Placebo|Placebo capsules
375323|NCT01331187|Procedure|Pocket-size ultrasonography|Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
375324|NCT01331187|Other|Usual care|No intervention, except for usual care (goal-directed diagnostics)
375325|NCT01331174|Device|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
375326|NCT01331161|Biological|ZOSTAVAX|shingles vaccine, one dose
375327|NCT01331148|Drug|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
375328|NCT01331148|Other|Placebo|placebo with daily calcium/Vitamin D soft chews
375329|NCT01331135|Drug|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
375330|NCT01331122|Drug|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
375331|NCT01331109|Drug|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
375332|NCT01331083|Drug|PX-866|PX-866: 8mg orally taken daily
375333|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
375334|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
375335|NCT01331057|Other|NEEL test|An assessment for children in French with items extracted from the NEEL test
375336|NCT01331057|Other|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
375693|NCT01327781|Other|Laboratory Biomarker Analysis|Correlative studies
375337|NCT01331057|Other|Interview|For parents of children include in the study: A semi -structured interview
375338|NCT01331044|Dietary Supplement|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered ~ 125 kcal/kg in 1st 24 hours, ~ 150 kcal/kg in 2nd 24 hours, then~200k cal/kg by the third day).
375339|NCT01331044|Dietary Supplement|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day 125kcal/kg.day~Day 2: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 150kcal/kg.day~Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 175kcal/kg.day~Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 3 feed per day & khichuri 10gm/kg; 3 feed per day 200kcal/kg.day~Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) & halwa 20gm/kg; 3 feed per day & khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
375340|NCT01331018|Procedure|Bone Marrow Aspiration|Undergo bone marrow harvest
375341|NCT01331018|Biological|Filgrastim|Given SC
375342|NCT01331018|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
375343|NCT01331018|Other|Laboratory Biomarker Analysis|Correlative studies
375344|NCT01331018|Procedure|Leukapheresis|Undergo leukapheresis
375345|NCT01331018|Drug|Methylprednisolone|Given IV
375346|NCT01331018|Drug|Plerixafor|Given SC
375347|NCT01331018|Drug|Prednisone|Given PO
375348|NCT01331005|Drug|nepafenac 0.1% drops|One drop three times per day for one year
375349|NCT01331005|Other|Nepafenac Vehicle|Placebo
375350|NCT01330992|Other|Ocular light or darkness exposure|Ocular light or darkness exposure
375351|NCT01330979|Drug|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
375352|NCT01330966|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
375353|NCT01330953|Drug|Placebo|Single intravenous placebo dose.
375354|NCT01330953|Drug|LY2928057|Single intravenous dose.
375355|NCT01330940|Dietary Supplement|Orange soda|32 ounces per day
375356|NCT01330927|Drug|VA106483|"Once daily oral dose of placebo for 2 nights~Once daily oral dose of 0.5 mg VA106483 for 2 nights~Once daily oral dose of 1 mg VA106483 for 2 nights~Once daily oral dose of 2 mg VA106483 for 2 nights~Once daily oral dose of 4 mg VA106483 for 2 nights~Placebo: as above"
375357|NCT01330901|Drug|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
375358|NCT01330875|Other|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
375359|NCT01330849|Behavioral|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
375360|NCT01330849|Other|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
375361|NCT01330823|Dietary Supplement|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
375362|NCT01330823|Dietary Supplement|Placebo|tartaric acid same dose like L-Carnitine as placebo
375363|NCT01330810|Drug|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
375364|NCT01330784|Drug|hMG-HP|
375365|NCT01330771|Drug|hMG-HP/r-FSH|
375366|NCT01330758|Drug|AZD8931|40 mg AZD8931 wet granulation tablet formulation
375367|NCT01330758|Drug|AZD8931|40 mg AZD8931 roller compacted tablet formulation
375368|NCT01330745|Other|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
375369|NCT01330719|Procedure|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
375370|NCT01330719|Procedure|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
375371|NCT01330706|Drug|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
375372|NCT01330693|Drug|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
375373|NCT01330693|Drug|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
375374|NCT01330680|Dietary Supplement|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
375375|NCT01330680|Dietary Supplement|Decaffeinated coffee|40 mL dose of decaffeinated coffee
375376|NCT01330667|Dietary Supplement|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
375377|NCT01330654|Drug|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
375378|NCT01330641|Procedure|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
375379|NCT01330628|Device|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
375380|NCT01330628|Procedure|Balloon angioplasty|standard balloon catheters for PTA
375381|NCT01330615|Drug|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
375382|NCT01330615|Drug|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
375383|NCT01330602|Behavioral|IMPRESS intervention|"The key elements of the IMPRESS intervention include:~Promoting a healthy lifestyle~Supporting lifestyle and risk modification~Encouraging active self-management of risk and chronic disease~Improving coordination of care~Pharmacological therapy"
375384|NCT01330589|Drug|Placebo|Non-active placebo for 7 days: PO/TID
375385|NCT01330589|Drug|St. Johns Wort|For 7 days: 300mg PO/TID
375386|NCT01330576|Procedure|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
375387|NCT01330576|Procedure|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
375388|NCT01330563|Drug|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
375389|NCT01330550|Dietary Supplement|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
375390|NCT01330524|Drug|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
375391|NCT01330524|Other|placebo|2mg placebo
375392|NCT01330485|Behavioral|Affect Regulation Training|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
375393|NCT01330485|Behavioral|Common Factor Control Condition|The CFC is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
375394|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
375395|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
375396|NCT01330459|Drug|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
375397|NCT01330459|Drug|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
375398|NCT01330459|Drug|Ibuprofen|800 mg oral ibuprofen
375399|NCT01330459|Drug|Lorazepam|2 mg oral lorazepam
375400|NCT01330459|Drug|Lidocaine|20 ml 1% buffered lidocaine, injected
375401|NCT01330446|Drug|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
375402|NCT01330446|Other|Placebo|1 by mouth every morning for a 28 day cycle.
375403|NCT01330446|Behavioral|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
375404|NCT01330433|Device|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.~The dose regimen is as follows:~Patients weighing < 3kg will receive 1ml of CoSeal~Patients weighing 3-10kg will receive 1-2ml of CoSeal~Patients weighing >10kg will receive 2-4ml of CoSeal"
375405|NCT01330420|Behavioral|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:~Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.~Examination and reversal of negative thought patterns.~Physical movement, including stretching and yoga.~Healthy eating and other positive lifestyle behaviors.~Goal setting."
375406|NCT01330407|Procedure|cryopreserved skin allografts.|
375407|NCT01330407|Procedure|Cultured Epidermal Autografts|
375408|NCT01330394|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
375409|NCT01330381|Drug|prucalopride|"prucalopride~subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml~subjects with weight >50 kg: prucalopride 2 mg tablet once daily"
375410|NCT01330381|Drug|Placebo|Matching oral solution or oral tablets given once daily
375411|NCT01330381|Drug|PEG 4000|
375412|NCT01330355|Drug|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
375413|NCT01330355|Drug|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
375414|NCT01330329|Behavioral|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
375415|NCT01330329|Behavioral|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
375416|NCT01330316|Drug|BI 201335|BI 201335 for 24 weeks
375417|NCT01330316|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
375418|NCT01330303|Drug|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
375419|NCT01330303|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
375420|NCT01330290|Drug|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
375421|NCT01330238|Drug|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
375422|NCT01330199|Other|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
375423|NCT01330186|Other|FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
375424|NCT01330173|Drug|Vismodegib|Given PO
375425|NCT01330173|Other|Pharmacological Study|Correlative studies
375426|NCT01330173|Other|Laboratory Biomarker Analysis|Correlative studies
375427|NCT01330134|Drug|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
375428|NCT01330134|Drug|lidocaine|1% lidocaine subcutaneous injection alone
375429|NCT01330121|Other|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:~Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
375430|NCT01330108|Drug|ambrisentan|ambrisentan 2.5mg, 5mg, & 10mg. Daily dosage.
375431|NCT01330095|Dietary Supplement|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
375432|NCT01330082|Other|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
375433|NCT01330082|Other|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
375434|NCT01330082|Other|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
375435|NCT01330056|Procedure|FOPS|"Functional organ preservation (FOPS) as a first-line treatment modality~Postoperative RT or CRT may be included for the patients of this group."
375436|NCT01330056|Radiation|CRT|"Concurrent chemoradiotherapy as a first-line treatment modality~Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
375437|NCT01330043|Drug|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
375438|NCT01330043|Drug|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
375439|NCT01330043|Drug|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
375440|NCT01330030|Drug|Selegiline|6mg/24 hrs for 8 weeks
375441|NCT01330030|Other|matching placebo|placebo/24hrs for 8 weeks
375442|NCT01330017|Drug|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
375443|NCT01330017|Drug|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
375444|NCT01330017|Drug|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
375445|NCT01329991|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
375446|NCT01329991|Drug|Placebo|Matching placebo for PLX5622
375447|NCT01329978|Drug|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
375448|NCT01329978|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
375449|NCT01329978|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
375450|NCT01329965|Drug|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline—salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
375451|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
375452|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
375453|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
375454|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
375455|NCT01329926|Procedure|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
375456|NCT01329913|Drug|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
375457|NCT01329913|Drug|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
375458|NCT01329913|Drug|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
375459|NCT01329913|Drug|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
375460|NCT01329913|Drug|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
375461|NCT01329913|Drug|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
375462|NCT01329900|Drug|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
375463|NCT01329900|Drug|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
375464|NCT01329900|Drug|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
375465|NCT01329900|Drug|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)~2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)~After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
375466|NCT01329900|Drug|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
375467|NCT01329900|Procedure|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
375468|NCT01329887|Drug|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
375469|NCT01329874|Procedure|Type of block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
375470|NCT01329861|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
375471|NCT01329835|Behavioral|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
375472|NCT01329835|Other|brochure|brochure given after randomization
375473|NCT01329822|Behavioral|Caloric restriction|Caloric restriction
375474|NCT01329809|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
375475|NCT01329796|Drug|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
375476|NCT01329796|Drug|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
375477|NCT01329783|Other|maraviroc|No intervention is distributed during this trial.
375478|NCT01329770|Dietary Supplement|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|"Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)~Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks"
375479|NCT01329770|Dietary Supplement|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
375480|NCT01329757|Drug|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
375481|NCT01329757|Drug|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
375482|NCT01329744|Drug|mecasermin|a subcutaneous injection twice a day
375483|NCT01329744|Drug|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
375484|NCT01329731|Drug|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
375485|NCT01329731|Drug|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
375486|NCT01329718|Other|Blood Sample|Blood sample collection
375487|NCT01329705|Device|Ankle Dorsiflexion Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
375488|NCT01329705|Other|Standard of care|"Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:~range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature~strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature~gait training to improve heel strike and toe off, stride length, and gait progression~sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion~no electric stimulation (e-stim) will be utilized"
375489|NCT01329692|Behavioral|Lifestyle counseling|Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
375490|NCT01329679|Dietary Supplement|5 Hour Energy|5 Hour Energy, 2oz twice daily for 7 days
375491|NCT01329679|Drug|Placebo|Water, lime juice and cherry flavoring
375492|NCT01329666|Dietary Supplement|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
375493|NCT01329666|Dietary Supplement|Vitamin D3|"Baseline:~50,000 IU/week for 8 weeks~Week 8:~Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.~Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks."
375494|NCT01329653|Behavioral|aerobic training|12 weeks of aerobic training, 4X/week
375495|NCT01329653|Behavioral|Wait list|wait list control condition
375496|NCT01329640|Device|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;~Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
375497|NCT01329627|Drug|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;~Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
375498|NCT01329627|Drug|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:~Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
375499|NCT01329614|Behavioral|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
375500|NCT01329614|Drug|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
375501|NCT01329614|Behavioral|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
375502|NCT01329614|Behavioral|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
375503|NCT01329601|Behavioral|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
375504|NCT01329601|Behavioral|booklet based training|Home based training of episodic memory using paper-pencil exercizes
375505|NCT01329588|Drug|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
375506|NCT01329588|Drug|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
375507|NCT01329562|Drug|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
375508|NCT01329562|Drug|Placebo|A placebo tablet matching Treximet for oral administration.
375509|NCT01329549|Drug|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
375510|NCT01329549|Drug|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
375511|NCT01329549|Drug|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
375512|NCT01329510|Device|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
375513|NCT01329497|Other|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
375514|NCT01329484|Behavioral|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
375515|NCT01329484|Behavioral|Cognitive training|Cognitive training using a computerized system
375516|NCT01329484|Other|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
375517|NCT01329445|Other|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
375518|NCT01329432|Procedure|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
375519|NCT01329432|Procedure|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
375520|NCT01329419|Drug|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
375521|NCT01329406|Drug|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
375522|NCT01329406|Drug|Placebo|1 tablet by mouth twice daily for 28 days
375523|NCT01329393|Behavioral|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
375524|NCT01329393|Behavioral|Illness Management and Recovery|Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
375525|NCT01329367|Behavioral|Control group|"Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.~-10 weekly personal interviews with a registered nutritionist for body weight control."
375526|NCT01329367|Behavioral|Protein group|"Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
375527|NCT01329367|Behavioral|Antioxidant group|"Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).~-10 weekly personal interviews with a registered nutritionist for body weight control."
375528|NCT01329354|Biological|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
375529|NCT01329341|Other|Service Dogs|Service dogs will be trained to help Veterans with PTSD
375530|NCT01329328|Device|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
375531|NCT01329315|Behavioral|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
375532|NCT01329315|Behavioral|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
375533|NCT01329302|Procedure|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
375534|NCT01329289|Drug|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
375535|NCT01329289|Drug|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
375536|NCT01329289|Drug|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
375537|NCT01329276|Drug|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
375538|NCT01329263|Other|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
375539|NCT01329250|Drug|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
375540|NCT01329237|Other|dynamic physical exercise and OCT imaging|supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
375541|NCT01329224|Other|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
375542|NCT01329198|Device|NeuroPace RNS® System Deep Brain Stimulator|Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
375543|NCT01329185|Drug|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
375544|NCT01329185|Drug|Placebo|1 capsule twice a day for 14 days prior to transplant date
375545|NCT01329172|Other|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
375546|NCT01329172|Other|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
375547|NCT01329133|Procedure|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
375548|NCT01329120|Procedure|Minimally invasive repair of pectus excavatum|Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
375549|NCT01329120|Procedure|Open surgical repair of pectus carinatum|Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
375550|NCT01329107|Behavioral|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.~After operation the intervention group will be mobilised in a fast speed compared to standard care."
375551|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
375552|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
375553|NCT01329068|Behavioral|individual consult|regular individual consultations
375554|NCT01329068|Behavioral|group medical consult|group medical consult
375555|NCT01329042|Drug|Potassium-sodium citrate|The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
375556|NCT01329029|Drug|Roflumilast|500 µg, once daily
375557|NCT01329029|Drug|Placebo|once daily
375558|NCT01329016|Drug|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
375559|NCT01329016|Drug|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
375560|NCT01329016|Drug|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
375561|NCT01328990|Drug|sulfadoxine-pyrimethamine plus amodiaquine|one dose of sulfadoxine-pyrimethamine 25/1.25 mg/kg plus three daily doses of amodiaquine, 10 mg/kg/day
375562|NCT01328977|Behavioral|education|teaching
375563|NCT01328964|Drug|Fluticasone propionate|fluticasone propionate 44 mcg
375564|NCT01328964|Drug|Budesonide|budesonide
375565|NCT01328964|Drug|Montelukast|montelukast
375566|NCT01328951|Drug|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
375567|NCT01328951|Drug|Erlotinib|Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
375568|NCT01328951|Drug|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
375569|NCT01328938|Biological|GCPGC 3.6mg|Stage I:Single blinded
375570|NCT01328938|Biological|GCPGC 6mg|Stage I: Single blinded;
375571|NCT01328938|Biological|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
375572|NCT01328938|Biological|GCPGC 6mg|Experimental: Stage II
375573|NCT01328925|Drug|Nitazoxanide|"Nitazoxanide Oral Suspension dose based on age:~Age <12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days"
375640|NCT01328210|Procedure|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
375574|NCT01328912|Other|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
375575|NCT01328912|Other|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
375576|NCT01328899|Device|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
375577|NCT01328886|Drug|Omalizumab|omalizumab lyophilized 150 mg injection
375578|NCT01328873|Other|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
375579|NCT01328860|Biological|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
375580|NCT01328834|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
375581|NCT01328821|Drug|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
375582|NCT01328821|Drug|CTP-499|400 mg immediate release capsule
375583|NCT01328808|Drug|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.~In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
375584|NCT01328795|Other|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
375585|NCT01328782|Drug|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
375586|NCT01328782|Drug|Bupivacaine 0.25%|"Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)~Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)~All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
375587|NCT01328782|Drug|Ropivacaine 0.20%|"Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)~Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)~All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
375588|NCT01328769|Drug|Febuxostat|
375589|NCT01328769|Drug|Placebo|
375590|NCT01328756|Drug|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
375591|NCT01328743|Behavioral|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
375592|NCT01328730|Device|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
375593|NCT01328730|Device|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
375594|NCT01328717|Device|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
375595|NCT01328665|Other|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
375596|NCT01328652|Drug|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
375597|NCT01328639|Other|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
375598|NCT01328639|Other|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
375599|NCT01328626|Drug|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
375600|NCT01328587|Drug|Eltrombopag|Eltrombopag will be administered for 16 to 20 weeks at a starting dose of 150mg/day (East Asian ancestry 75mg /day). The dose will decreased and increased (maximum dose 300mg/day) based on safety and response.
375601|NCT01328574|Drug|TRC105|15 mg/kg intravenously
375602|NCT01328548|Drug|Zostavax|
375603|NCT01328535|Drug|temozolomide|Given PO
375604|NCT01328535|Other|flow cytometry|Correlative studies
375605|NCT01328535|Other|staining method|Correlative studies
375606|NCT01328535|Procedure|biopsy|Optional correlative studies
375607|NCT01328535|Other|laboratory biomarker analysis|Correlative studies
375608|NCT01328522|Drug|SAR153191 (REGN88)|"Pharmaceutical form:solution~Route of administration: subcutaneous"
375641|NCT01328197|Device|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
375642|NCT01328184|Drug|levonorgestrel|multiple doses
375643|NCT01328184|Drug|levonorgestrel|multiple doses
375644|NCT01328184|Drug|Ethinylestradiol|multiple doses
375645|NCT01328184|Drug|Microgynon + BI 10773|multiple doses BI 10773
375609|NCT01328496|Drug|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.~Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
375610|NCT01328483|Procedure|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
375611|NCT01328470|Drug|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
375612|NCT01328457|Drug|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
375613|NCT01328444|Drug|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
375614|NCT01328444|Drug|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
375615|NCT01328444|Drug|GSK 573719 125|125mcg
375616|NCT01328444|Drug|GSK 573719 62.5|62.5mcg
375617|NCT01328444|Drug|GW642444 25|25mcg
375618|NCT01328444|Drug|Plb|Comparator
375619|NCT01328431|Other|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
375620|NCT01328418|Procedure|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
375621|NCT01328405|Device|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
375622|NCT01328392|Drug|Dexlansoprazole|30mg a day, 3 months
375623|NCT01328379|Drug|Dalfampridine-ER 5mg|5mg, twice daily
375624|NCT01328379|Drug|Dalfampridine-ER 10mg|10mg, twice daily
375625|NCT01328379|Other|Placebo|placebo, twice daily
375626|NCT01328353|Other|telehealth plus aprn triage|aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
375627|NCT01328340|Other|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
375628|NCT01328340|Other|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
375629|NCT01328301|Other|Experimental|For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
375630|NCT01328301|Other|Speed-stable treadmill training|Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
375631|NCT01328288|Drug|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
375632|NCT01328275|Drug|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
375633|NCT01328262|Other|Calculated red blood cell transfusion|The subjects receive an amount of red blood cells that has been calculated from their body surface area.
375634|NCT01328262|Other|Standard red blood cell transfusion|The subjects in this group receive the prescribed number of red blood cell units.
375635|NCT01328249|Drug|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks.
375636|NCT01328236|Drug|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
375637|NCT01328236|Drug|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
375638|NCT01328236|Drug|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.~MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
375639|NCT01328223|Radiation|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
375646|NCT01328184|Drug|Ethinylestradiol|multiple doses
375647|NCT01328171|Drug|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
375648|NCT01328171|Drug|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
375649|NCT01328145|Drug|Acetylsalicylic acid|500 mg /day
375650|NCT01328132|Drug|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
375651|NCT01328132|Drug|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
375652|NCT01328119|Other|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
375653|NCT01328106|Drug|GSK1120212|Repeating oral dose
375654|NCT01328093|Drug|LY2140023|Administered orally
375655|NCT01328093|Drug|Aripiprazole|Administered orally
375656|NCT01328080|Radiation|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
375657|NCT01328067|Device|Exablate 2100|MRgFUS
375658|NCT01328067|Procedure|Myomectomy|Non-Hysteroscopic Myomectomy
375659|NCT01328054|Drug|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
375660|NCT01328054|Drug|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
375661|NCT01328041|Drug|dolutegravir|50 mg twice daily
375662|NCT01328028|Other|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
375663|NCT01328028|Other|Data collection|Log sheet
375664|NCT01328015|Drug|Oxybutynin 5 mg pills|"½ pill oral 12/12h for 3 days~01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks."
375665|NCT01328002|Drug|Milnacipran|"Maximum tolerated dose (50, 75, or 100 mg/day tablets) was determined during the open label phase of the study.~Oral administration, twice daily dosing"
375666|NCT01328002|Drug|Placebo|matching placebo tablets daily
375667|NCT01327989|Device|Solitaire™ FR device|Mechanical Thrombectomy
375668|NCT01327976|Device|vBloc (Active Device)|Active device will deliver vBloc Therapy
375669|NCT01327976|Device|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
375670|NCT01327963|Device|Transoral Incisionless Fundoplication|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following the standardized TIF2.0 protocol.
375671|NCT01327937|Device|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
375672|NCT01327937|Other|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
375673|NCT01327924|Drug|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
375674|NCT01327911|Biological|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
375675|NCT01327898|Behavioral|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
375676|NCT01327898|Behavioral|individual resilience counseling|one individual resilience counseling session
375677|NCT01327885|Drug|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
375678|NCT01327885|Drug|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 selected by the Principal Investigator [PI] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
375679|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
375680|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
375681|NCT01327872|Drug|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
375682|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
375683|NCT01327859|Drug|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
375684|NCT01327859|Drug|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
375685|NCT01327859|Drug|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
375686|NCT01327846|Drug|Canakinumab|
375687|NCT01327846|Drug|Placebo|
375688|NCT01327846|Drug|Standard of care|Standard of care post-MI background therapy includes, but is not limited to, lipid lowering, anti-hypertensive, beta blockers, and anti-platelet therapy as appropriate
375689|NCT01327794|Genetic|polymorphism analysis|
375690|NCT01327794|Other|immunologic technique|
375691|NCT01327794|Other|laboratory biomarker analysis|
375692|NCT01327794|Other|medical chart review|
375694|NCT01327781|Other|Pharmacological Study|Correlative studies
375695|NCT01327781|Other|Questionnaire Administration|Ancillary studies
375696|NCT01327781|Drug|Z-Endoxifen Hydrochloride|Given PO
375697|NCT01327768|Procedure|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
375698|NCT01327755|Dietary Supplement|Selenium|Selenium yeast containing selenomethionine 200 mcg per day for 2 years
375699|NCT01327755|Other|Placebo|Same number of pills, frequency, and duration as selenium intervention.
375700|NCT01327742|Device|Relay Thoracic Stent-Graft|Device implant
375701|NCT01327729|Drug|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
375702|NCT01327703|Drug|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
375703|NCT01327703|Drug|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
375704|NCT01327690|Behavioral|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
375705|NCT01327690|Behavioral|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
375706|NCT01327677|Drug|Fentanyl|25-50 mcg every 20 minutes
375707|NCT01327677|Drug|Fentanyl|20mcg/demand dose with an 8 minute lock out
375708|NCT01327664|Biological|AIN457|
375709|NCT01327651|Drug|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
375710|NCT01327651|Drug|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
375711|NCT01327651|Drug|Event-driven dosing|TDF/FTC as needed with a post exposure dose
375712|NCT01327638|Drug|etoricoxib|Patients with SpA/AS who took etoricoxib
375713|NCT01327638|Drug|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
375714|NCT01327638|Drug|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
375715|NCT01327625|Drug|azithromycin + N-acetylcystein + inhaled corticosteroid|"Azithromycin 500mg qd x 1 week --> 250mg qod x 6 months~N-acetylcystein 200mg tid x 6 months~Fluticasone 250mcg puff x2/day x 6 months"
375716|NCT01327612|Drug|FOLFOX6|Oxaliplatin: 100mg/m2, IV in 500mL of D5W over 120 minutes on Day 1 Leucovorin: 400mg/m2, IV diluted in D5W over 120 minutes (concurrently with oxaliplatin) on Day 1 Fluorouracil: 400 mg/m2, IV bolus, after leucovorin, on Day 1 Fluorouracil: 2400mg/m2, CIV over 46 hours (single dose) start on Day 1 Cycle frequency: repeat every 14 days until disease progression or unacceptable toxicity
375717|NCT01327612|Biological|Conatumumab|Conatumumab is an investigational, fully human monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR-5.
375718|NCT01327612|Biological|Conatumumab|Conatumumab is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR5.
375719|NCT01327612|Biological|Ganitumab|Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
375720|NCT01327612|Biological|Bevacizumab|Recombinant humanized monoclonal antibody targeted against vascular endothelial growth factor (VEGF); angiogenesis inhibitor.
375721|NCT01327612|Biological|Ganitumab|Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
375722|NCT01327599|Drug|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
375723|NCT01327586|Behavioral|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
375724|NCT01327586|Behavioral|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
375725|NCT01327573|Drug|eculizumab|"Eculizumab Induction 600mg IV every 7 days for 4 doses~Eculizumab 900mg IV 7 days later~Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
375726|NCT01327547|Drug|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
375727|NCT01327547|Drug|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
375728|NCT01327534|Drug|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
375729|NCT01327534|Drug|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
375730|NCT01327521|Device|CyberKnife|Standard of Care
375731|NCT01327521|Procedure|TACE|Standard of Care
375732|NCT01327521|Drug|CT Contrast|Standard of Care
375733|NCT01327521|Drug|doxorubicin|Standard of Care
375734|NCT01327521|Drug|Epirubicin|Standard of Care
375735|NCT01327521|Drug|5-fluorouracil|Standard of Care
375736|NCT01327521|Drug|Mitomycin C|Standard of Care
375737|NCT01327521|Drug|Gemcitabine|Standard of Care
375738|NCT01327521|Drug|Cisplatin|Standard of Care
375739|NCT01327521|Device|SMANCS|Standard of Care
375740|NCT01327508|Device|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
375741|NCT01327508|Other|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
375742|NCT01327495|Other|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
375743|NCT01327495|Other|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
375744|NCT01327495|Drug|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
375745|NCT01327495|Drug|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
375746|NCT01327495|Drug|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
375747|NCT01327495|Drug|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
375748|NCT01327495|Drug|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
375749|NCT01327495|Drug|Acyline|300 ug/kg subcutaneous injection every 2 weeks
375750|NCT01327482|Drug|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
375751|NCT01327469|Drug|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
375752|NCT01327469|Drug|Albendazole 400mg|Albendazole 400mg
375753|NCT01327469|Drug|Mebendazole 500mg|Mebendazole 500mg
375754|NCT01327469|Drug|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
375755|NCT01327469|Drug|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
375756|NCT01327456|Behavioral|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
375757|NCT01327443|Behavioral|Weight loss|Nutritional counseling
375758|NCT01327443|Behavioral|Exercise|Under direct supervision
375759|NCT01327430|Dietary Supplement|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
375760|NCT01327391|Procedure|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
375761|NCT01327391|Procedure|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
375762|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
375763|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
375764|NCT01327352|Drug|Oshadi D|oral administration
375765|NCT01327339|Drug|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
375766|NCT01327326|Drug|Naltrexone|Oral, 50 mg, 1 Time Dose
375767|NCT01327326|Drug|Placebo|Oral, 1 Time Dose
375768|NCT01327313|Biological|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
375769|NCT01327313|Biological|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
375770|NCT01327313|Biological|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
375771|NCT01327313|Biological|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
375772|NCT01327300|Drug|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
375773|NCT01327300|Other|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
375774|NCT01327274|Device|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery. The Magnimplant or Magnetic Mini-Mover device implant will surgically implanted on the sternum. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo brace treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25). Patients will be seen in clinic at least monthly until treatment is complete and the magnimplant device will be explanted from their sternum.
375775|NCT01327261|Drug|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
375776|NCT01327235|Drug|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
375777|NCT01327235|Drug|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
375778|NCT01327222|Drug|Bevacizumab|1.25 mg intravitreal bevacizumab
375779|NCT01327183|Procedure|Percutaneous Coronary Intervention (PCI)|at least 1 hour and up to 24 hours after completion of drug infusion
375780|NCT01327183|Drug|RO4905417|5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
375781|NCT01327183|Drug|RO4905417|20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
375782|NCT01327183|Drug|placebo|iv infusion, completed at least 1 hour and up to 24 hours before PCI
375783|NCT01327170|Procedure|Subthreshold diode micropulse laser|
375784|NCT01327157|Procedure|occlusal adjustment.|It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this to start. Will be held palpation of the muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After starts the adjustment following the rules of Guichet with a cylindrical drill with a thin cut . basic principles 1 Occlusive stress maximum distribution in centric relation 2 The occlusive strengths should by the teeth's major axis.3 When the contact is surface to surface, it must be exchanged to another surface point. 4 Once the stability to the centric relation is achieved, it should be kept. The rules to guide the occlusal adjustment selective grinding .
375890|NCT01326325|Drug|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
375785|NCT01327157|Behavioral|Visual analog scale.|"Visual analog scale-Graduation was held on the visual analogue scale in the first and last query to measure discomfort chewing.Graduation was held on the visual analogue scale .in the first and last query to measure discomfort chewing. After graduating dental cleaning was performed, with the purpose of blinding the study, Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient.~Dental Cleaning.With engine using low speed, brushes, and prophylactic paste is carried out dental cleaning in the teeth of all patient."
375786|NCT01327144|Drug|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
375787|NCT01327144|Drug|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
375788|NCT01327118|Drug|Prostaglandin F2alpha|intravenous injection
375789|NCT01327118|Drug|Isoton sodium chloride|intravenous injection
375790|NCT01327105|Device|TVU|Use of transvaginal ultrasound to determine location of micro-insert
375791|NCT01327092|Other|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
375792|NCT01327079|Drug|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
375793|NCT01327079|Drug|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.~Administration of inulin:~Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
375794|NCT01327066|Drug|Droxidopa|600 mg, single oral dose
375795|NCT01327066|Drug|Droxidopa|2000 mg, single oral dose
375796|NCT01327066|Drug|Moxifloxacin|400 mg, single oral dose
375797|NCT01327066|Drug|Placebo|Placebo matching Droxidopa or Moxifloxacin
375798|NCT01327053|Drug|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
375799|NCT01327040|Other|light exposure|12-hour light exposure of approximately 200 lux
375800|NCT01327027|Drug|Vasopressin, Arginine, ADH|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
375801|NCT01327027|Drug|Placebo; Sterile Saline|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
375802|NCT01327014|Drug|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
375803|NCT01327014|Drug|Placebo|4 capsules twice a day for 12 weeks.
375804|NCT01326988|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
375805|NCT01326962|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
375806|NCT01326949|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
375807|NCT01326949|Procedure|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.~NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.~AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
375808|NCT01326936|Behavioral|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
375809|NCT01326923|Drug|Cetuximab|Single arm phase II study of chemotherapy
375810|NCT01326910|Drug|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
375811|NCT01326910|Device|Topical Cream|Topical cream applied twice daily (or as needed)
375812|NCT01326897|Behavioral|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
375813|NCT01326897|Behavioral|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
375814|NCT01326884|Device|ZLP|ZLP Graft
375815|NCT01326871|Drug|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
375816|NCT01326871|Drug|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
375817|NCT01326871|Biological|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
375818|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
375819|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
375820|NCT01326858|Drug|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
375821|NCT01326845|Drug|Deferasirox|
375822|NCT01326832|Device|Primoris|Total hip arthroplasty with the new Primoris femoral component
375823|NCT01326806|Behavioral|Families Talking Together|The intervention will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth fora non-acute care visit. A mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. The healthcare provider will endorse the intervention separately for mothers and adolescents. There will be one follow-up booster session administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
375824|NCT01326806|Behavioral|Active Control on Hygiene & Nutrition|The active control group will take place in a pediatric health care clinic and will be coordinated through provider extenders when healthcare providers see youth for a non-acute care visit. The mother of the adolescent will meet with a provider extender for approximately 30 minutes while her child is being examined by a healthcare provider. During this time, the active control on hygiene and nutrition will be delivered to the mother.
375825|NCT01326793|Other|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
375826|NCT01326780|Drug|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
375827|NCT01326780|Drug|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
375828|NCT01326780|Drug|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
375829|NCT01326780|Other|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
375830|NCT01326767|Drug|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
375831|NCT01326767|Drug|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
375832|NCT01326754|Drug|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
375833|NCT01326754|Drug|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
375834|NCT01326754|Drug|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
375835|NCT01326728|Biological|Allogeneic stem cell transplant|Donors will undergo cell collection and recipients will receive cells (allotransplant).
375836|NCT01326715|Drug|Mangafodipir (Teslascan)|Contrast Agent
375837|NCT01326702|Drug|Bendamustine Hydrochloride|Given IV
375838|NCT01326702|Other|Pharmacological Study|Correlative studies
375839|NCT01326702|Biological|Rituximab|Given IV
375840|NCT01326702|Drug|Veliparib|Given PO
375841|NCT01326689|Drug|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
375842|NCT01326689|Drug|Placebo|
375843|NCT01326676|Drug|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.~Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
375844|NCT01326676|Drug|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
375845|NCT01326663|Drug|Medication Trial|
375846|NCT01326650|Drug|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
375847|NCT01326650|Drug|placebo|daily oral placebo supplement for three years
375848|NCT01326637|Other|Patient Overview Document|"The Intervention has two components:~Pre-visit care coordination:~5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.~The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.~Team Meeting:~On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
375849|NCT01326624|Device|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
375850|NCT01326611|Drug|Clarithromycin|
375851|NCT01326611|Drug|Dextrose|
375852|NCT01326598|Device|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
375853|NCT01326585|Drug|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
375854|NCT01326585|Drug|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
375889|NCT01326325|Drug|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
375855|NCT01326559|Drug|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):~Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles~Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles~Concurrent phase (weeks 10-16):~Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)~Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)~IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
375856|NCT01326546|Biological|Therapeutic HBV vaccine|Inject εPA-44 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
375857|NCT01326546|Drug|entecavir|0.5mg,per day,oral intake.
375858|NCT01326546|Other|placebo|Inject placebo 900μg at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48.
375859|NCT01326533|Drug|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
375860|NCT01326533|Other|Placebo|Thirteen weeks of oral placebo provided as capsules
375861|NCT01326520|Dietary Supplement|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
375862|NCT01326520|Dietary Supplement|diary product|The patients will consume daily 250 mL of a common dairy product.
375863|NCT01326507|Biological|Dosage de l'h-FABP|Dosage de l'h-FABP
375864|NCT01326494|Drug|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.~Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
375865|NCT01326481|Drug|TRC105|IV
375866|NCT01326481|Drug|Capecitabine|oral
375867|NCT01326468|Drug|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
375868|NCT01326468|Drug|Cetuximab|"All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.~Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy."
375869|NCT01326468|Drug|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
375870|NCT01326468|Device|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
375871|NCT01326455|Device|Terumo TR wristband|
375872|NCT01326455|Device|Terumo TR wristband|
375873|NCT01326455|Device|Clo-Sur-P.A.D.|
375874|NCT01326442|Other|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
375875|NCT01326442|Dietary Supplement|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
375876|NCT01326416|Dietary Supplement|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
375877|NCT01326416|Other|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
375878|NCT01326403|Drug|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.~GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.~Group C - A control group will only receive placebo in the emergency room and in the OR."
375879|NCT01326390|Device|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
375880|NCT01326390|Procedure|DSA arteriogram- hepatic arteries|Standard of care
375881|NCT01326390|Procedure|CO2 aortogram|Standard of care
375882|NCT01326364|Procedure|Stereotactic body radiotherapy|Standard of Care
375883|NCT01326364|Drug|Iodixanol|IV, calculated per patient
375884|NCT01326364|Drug|Iohexol|IV, Calculated per patient
375885|NCT01326351|Procedure|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
375886|NCT01326351|Procedure|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
375887|NCT01326351|Behavioral|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
375888|NCT01326338|Drug|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
376018|NCT01325311|Other|Pharmacological Study|Correlative studies
375891|NCT01326312|Drug|GTx-758|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
375892|NCT01326312|Drug|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
375893|NCT01326312|Drug|GTx-758|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
375894|NCT01326299|Other|Carbohydrate placebo|dissolve in water and consume with meal
375895|NCT01326299|Other|Nutritional ingredient|Dissolve in water and consume with meals
375896|NCT01326299|Other|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
375897|NCT01326299|Other|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
375898|NCT01326299|Other|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
375899|NCT01326273|Procedure|Lymphopheresis|Lymphopheresis
375900|NCT01326273|Procedure|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
375901|NCT01326273|Procedure|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
375902|NCT01326273|Procedure|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
375903|NCT01326247|Other|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
375904|NCT01326234|Behavioral|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
375905|NCT01326234|Behavioral|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
375906|NCT01326221|Drug|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
375907|NCT01326208|Procedure|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
375908|NCT01326195|Behavioral|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
375909|NCT01326195|Behavioral|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
375910|NCT01326182|Behavioral|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
375911|NCT01326182|Behavioral|MAAS|Group-based intervention including asthma education and education regarding general child health
375912|NCT01326169|Behavioral|Brief intervention|Telephone-delivered counseling
375913|NCT01326169|Behavioral|Standard care|No intervention
375914|NCT01326156|Device|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
375915|NCT01326143|Device|ORM Narval MRD|
375916|NCT01326130|Behavioral|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
375917|NCT01326117|Drug|tadalafil|7 days of Cialis for Daily Use (5mg)
375918|NCT01326104|Biological|TTRNA-xALT|TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
375919|NCT01326104|Biological|TTRNA-DCs|TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
375920|NCT01326091|Other|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
375921|NCT01326078|Drug|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
375922|NCT01326052|Procedure|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
375923|NCT01326052|Procedure|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
375924|NCT01326039|Drug|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
375925|NCT01326039|Drug|saline|perineural isotonic saline 20 ml
375926|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
375927|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
375928|NCT01326000|Drug|FOLFIRI|standard iv chemotherapy
375929|NCT01326000|Drug|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
375930|NCT01326000|Drug|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
375931|NCT01325987|Dietary Supplement|Vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
375932|NCT01325987|Other|Sugar pill|"group: vitamin D2 50000 IU weekly once for 8 weeks~nd group: placebo weekly once for 8 weeks"
375933|NCT01325961|Radiation|Intensity-Modulated Radiation Therapy|
375934|NCT01325935|Drug|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
375935|NCT01325922|Procedure|DFT Testing with a 50/50% tilt|
375936|NCT01325909|Behavioral|Exercise programme|
376014|NCT01325324|Device|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
376015|NCT01325311|Drug|Cholecalciferol|Given PO
375937|NCT01325896|Drug|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
375938|NCT01325870|Device|ACD-CPR|
375939|NCT01325870|Device|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
375940|NCT01325870|Procedure|S-CPR|standard manual CPR
375941|NCT01325870|Device|Impedance Threshold Device (ITD)|
375942|NCT01325857|Procedure|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
375943|NCT01325857|Procedure|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
375944|NCT01325857|Procedure|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
375945|NCT01325844|Procedure|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
375946|NCT01325831|Device|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
375947|NCT01325831|Device|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
375948|NCT01325818|Drug|pravastatin, rosuvastatin|"Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day~Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
375949|NCT01325805|Behavioral|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
375950|NCT01325805|Behavioral|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
375951|NCT01325792|Device|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
375952|NCT01325779|Drug|heparin|subcutaneous heparin 5000 units every 8 hours
375953|NCT01325779|Drug|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
375954|NCT01325766|Other|Yoga|Yoga 2 sessions per week for 8 weeks
375955|NCT01325753|Procedure|cryotherapy|Undergo CT-guided CA
375956|NCT01325753|Procedure|quality-of-life assessment|Ancillary studies
375957|NCT01325740|Drug|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
375958|NCT01325727|Other|Brief computerized feedback|Brief computerized feedback
375959|NCT01325727|Other|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
375960|NCT01325714|Behavioral|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
375961|NCT01325714|Behavioral|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.~Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
375962|NCT01325701|Drug|ibrutinib|ibrutinib is an inhibitor of BTK
375963|NCT01325688|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
375964|NCT01325688|Device|Aluminium disk|
375965|NCT01325688|Device|OpSite(TM) disk|
375966|NCT01325675|Behavioral|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
375967|NCT01325649|Procedure|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
375968|NCT01325649|Radiation|long course 5-FU bases radiochemotherapy|
375969|NCT01325636|Other|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21"
375970|NCT01325623|Device|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
375971|NCT01325610|Dietary Supplement|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
376016|NCT01325311|Drug|Genistein|Given PO
376017|NCT01325311|Other|Laboratory Biomarker Analysis|Correlative studies
375972|NCT01325597|Other|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
375973|NCT01325597|Other|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
375974|NCT01325597|Other|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
375975|NCT01325597|Other|Control group|No intervention
375976|NCT01325584|Drug|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
375977|NCT01325571|Drug|Tacrolimus capsule|oral
375978|NCT01325571|Drug|Placebo|oral
375979|NCT01325558|Biological|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
375980|NCT01325545|Other|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
375981|NCT01325532|Device|Active CES|CES current
375982|NCT01325532|Device|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
375983|NCT01325519|Other|video decision aid|video
375984|NCT01325506|Other|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
375985|NCT01325493|Drug|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
375986|NCT01325493|Drug|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
375987|NCT01325480|Device|Cardiac Pacing|
375988|NCT01325454|Device|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
375989|NCT01325441|Drug|BBI608|
375990|NCT01325441|Drug|Paclitaxel|
375991|NCT01325428|Drug|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
375992|NCT01325428|Drug|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
375993|NCT01325415|Drug|NKTR-118|25 mg tablet
375994|NCT01325415|Drug|moxifloxacin|400 mg tablet
375995|NCT01325415|Drug|Placebo|tablet
375996|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
375997|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
375998|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
375999|NCT01325389|Dietary Supplement|Myo-Mel|
376000|NCT01325389|Dietary Supplement|Placebo|
376001|NCT01325376|Behavioral|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
376002|NCT01325376|Behavioral|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
376003|NCT01325363|Device|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
376004|NCT01325350|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376005|NCT01325350|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376006|NCT01325350|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376007|NCT01325350|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376008|NCT01325350|Drug|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
376009|NCT01325337|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376010|NCT01325337|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376011|NCT01325337|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376012|NCT01325337|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
376013|NCT01325337|Drug|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
376020|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
376021|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
376022|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
376023|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
376024|NCT01325285|Device|RespirAct|"Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:~Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)~10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)~20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)~Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)~250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)~500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)~Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)"
376025|NCT01325259|Other|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
376026|NCT01325259|Radiation|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of [18F]AV-45
376027|NCT01325259|Radiation|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
376028|NCT01325259|Other|MRI|Magnetic Resonance Imaging
376029|NCT01325233|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
376030|NCT01325233|Drug|Placebo|500 ml normal saline, tiw, 2 weeks
376031|NCT01325220|Drug|arbaclofen|5 mg bid
376032|NCT01325220|Drug|arbaclofen|10 mg bid
376033|NCT01325220|Drug|arbaclofen|10 mg tid
376034|NCT01325220|Drug|Placebo|tid
376035|NCT01325207|Radiation|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
376036|NCT01325194|Drug|liposomal cytarabine|50 mg intrathecally three times
376037|NCT01325181|Drug|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
376038|NCT01325181|Drug|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
376039|NCT01325168|Drug|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
376040|NCT01325168|Drug|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
376041|NCT01325116|Behavioral|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
376042|NCT01325103|Procedure|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
376043|NCT01325090|Drug|BOTOX|A syringe of 1 ml contain 25 Allergan units.
376044|NCT01325090|Other|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
376045|NCT01325077|Other|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
376046|NCT01325051|Drug|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
376047|NCT01325038|Procedure|Isometric exercise|Isometric exercise several times/week for three months
376048|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location~conventional anatomical sequence T1, T2, FLAIR~diffusion tensor sequence (21 directions)~high angular resolution diffusion (HARDI) sequence~field map~reflexology T1, T2~spectroscopic imaging sequence"
376049|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location~conventional anatomical sequence T1, T2, FLAIR~diffusion tensor sequence (21 directions)~high angular resolution diffusion (HARDI) sequence~field map~reflexology T1, T2~spectroscopic imaging sequence"
376050|NCT01325012|Procedure|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
376051|NCT01325012|Procedure|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
376052|NCT01324999|Drug|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
376053|NCT01324986|Procedure|Laparoscopic anti-reflux surgery|
376054|NCT01324973|Behavioral|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
376055|NCT01324960|Drug|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
376056|NCT01324960|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
376057|NCT01324947|Drug|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
376144|NCT01324362|Drug|FSC500/50mcg|Twice daily dosing
376058|NCT01324934|Drug|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.~(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
376059|NCT01324921|Other|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
376060|NCT01324921|Other|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
376061|NCT01324921|Other|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
376062|NCT01324908|Procedure|extracorporeal photopheresis|Undergo ECP
376063|NCT01324908|Other|laboratory biomarker analysis|Correlative studies
376064|NCT01324882|Device|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
376065|NCT01324882|Device|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
376066|NCT01324869|Biological|KH902|Intravitreal injection of 0.5mg/eye/time KH902
376067|NCT01324856|Procedure|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
376068|NCT01324856|Procedure|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
376069|NCT01324843|Drug|EMLA Cream|
376070|NCT01324843|Drug|Aveeno Daily Moist|
376071|NCT01324843|Device|Derma Vax|
376072|NCT01324843|Procedure|Intradermal Electroporation|
376073|NCT01324843|Procedure|Visual Analogue Scale|
376074|NCT01324843|Procedure|Present Pain Intensity|
376075|NCT01324843|Procedure|McGill Pain Questionnaire|
376076|NCT01324843|Procedure|Skin Assessment|
376077|NCT01324830|Drug|day 1 to day 5|low to high dose
376078|NCT01324830|Drug|day 1 to day 14|low to high dose
376079|NCT01324817|Device|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
376080|NCT01324817|Device|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
376081|NCT01324791|Procedure|anti-reflux surgery|
376082|NCT01324778|Device|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
376083|NCT01324778|Device|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
376084|NCT01324765|Behavioral|TARGET|12-session group therapy twice weekly 6 weeks
376085|NCT01324765|Behavioral|SGT|12 sessions supportive group therapy twice weekly 6 weeks
376086|NCT01324752|Drug|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
376087|NCT01324752|Drug|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
376088|NCT01324752|Drug|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
376089|NCT01324739|Drug|human BNP-32|3pmol/kg/min infusion
376090|NCT01324700|Drug|High severity group: Escitalopram|Participants within high severity group were stratified to receive escitalopram.
376091|NCT01324700|Drug|High severity group: Placebo|Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
376092|NCT01324700|Drug|Low severity group: Escitalopram|Participants within low severity group were stratified to receive escitalopram.
376093|NCT01324700|Drug|Low severity group: Placebo|Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
376094|NCT01324687|Other|Telemedicine care|Availability of telemedicine
376095|NCT01324674|Other|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
376096|NCT01324674|Other|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
376097|NCT01324661|Behavioral|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
376098|NCT01324648|Behavioral|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
376099|NCT01324648|Behavioral|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
376145|NCT01324349|Device|Veriset Hemostatic Patch|Topical hemostat
376146|NCT01324349|Device|Fibrin Sealant (TachoSil®)|Topical hemostat
376100|NCT01324648|Other|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
376101|NCT01324635|Drug|Panobinostat|Given PO
376102|NCT01324635|Radiation|Stereotactic body radiation therapy|Undergo SBRT
376103|NCT01324635|Procedure|Quality-of-life assessment|Ancillary studies
376104|NCT01324635|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
376105|NCT01324622|Device|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
376106|NCT01324622|Procedure|laminectomy|standard procedure
376107|NCT01324596|Drug|Intravenous|Chemoimmunotheraphy
376108|NCT01324596|Drug|Bortezomib|Chemoimmunotheraphy
376109|NCT01324583|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution~Route of administration: intravenous"
376110|NCT01324583|Drug|prednisolone|"Pharmaceutical form:tablet~Route of administration: oral"
376111|NCT01324570|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
376112|NCT01324557|Procedure|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
376113|NCT01324544|Drug|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
376114|NCT01324531|Procedure|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
376115|NCT01324531|Procedure|Bankart repair|Bankart repair based on surgeon's preference
376116|NCT01324518|Drug|ORM-12741|60mg twice a day
376117|NCT01324518|Drug|ORM-12741|200mg twice a day
376118|NCT01324518|Drug|Placebo for ORM-12741|Placebo twice a day
376119|NCT01324505|Drug|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
376120|NCT01324505|Drug|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
376121|NCT01324505|Drug|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
376122|NCT01324492|Drug|RAD001|
376123|NCT01324479|Drug|INC280|
376124|NCT01324466|Drug|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
376125|NCT01324466|Drug|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
376126|NCT01324453|Procedure|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
376127|NCT01324453|Procedure|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
376128|NCT01324440|Biological|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
376129|NCT01324440|Biological|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
376130|NCT01324427|Behavioral|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
376131|NCT01324401|Drug|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
376132|NCT01324388|Biological|LY2189265|Administered subcutaneously
376133|NCT01324388|Drug|Metoprolol|Administered orally
376134|NCT01324388|Drug|Lisinopril|Administered orally
376135|NCT01324388|Drug|Placebo|Administered subcutaneously
376136|NCT01324375|Device|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
376137|NCT01324362|Drug|Placebo|Twice daily dosing
376138|NCT01324362|Drug|Placebo|Twice daily dosing
376139|NCT01324362|Drug|FP 100mcg|Twice daily dosing
376140|NCT01324362|Drug|FP 250mcg|Twice daily dosing
376141|NCT01324362|Drug|FP 500mcg|Twice daily dosing
376142|NCT01324362|Drug|FSC 100/50mcg|Twice daily dosing
376143|NCT01324362|Drug|FSC 250/50mcg|Twice daily dosing
376147|NCT01324336|Drug|6-Mercaptopurine|75 mg/m2/dose/day
376148|NCT01324323|Drug|Romidepsin|14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
376149|NCT01324323|Drug|Rifampin|600 mg oral once daily on Days 4-8
376150|NCT01324310|Drug|Romidepsin|Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
376151|NCT01324310|Drug|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
376152|NCT01324297|Other|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
376153|NCT01324284|Drug|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
376154|NCT01324271|Device|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
376155|NCT01324258|Drug|GSK1120212|Part1 and Part2
376156|NCT01324258|Drug|Gemcitabine|Part2
376157|NCT01324245|Drug|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
376158|NCT01324232|Drug|AVP-923|AVP-923 capsules administered twice-a-day, over a 12 week period
376159|NCT01324232|Drug|Placebo|Matching placebo
376160|NCT01324219|Behavioral|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
376161|NCT01324219|Behavioral|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
376162|NCT01324193|Dietary Supplement|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
376163|NCT01324180|Drug|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
376164|NCT01324180|Drug|Vincristine|1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
376165|NCT01324180|Drug|Dexamethasone|"10 mg/m^2/day divided BID~Take dexamethasone by mouth days 2-15"
376166|NCT01324180|Drug|PEG-asparaginase|"2500 IU's/m^2/day~Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23~If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.~Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
376167|NCT01324180|Drug|Doxorubicin|60 mg/m^2/day IV over 15 minutes on day 2
376168|NCT01324180|Drug|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
376169|NCT01324141|Drug|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of RT.
376170|NCT01324141|Drug|5-Fluorouracil|5-FU will be delivered as 1000mg/m2/day as 96 hour continuous infusion beginning on day 1 and 29.
376171|NCT01324141|Drug|Mitomycin-C|MMC will be delivered at a dose of 10mg/m2 on days 1 and 29
376172|NCT01324141|Procedure|Radiation Therapy|RT will be delivered to a total dose of 50-54 Gy based on tumor characteristics.
376173|NCT01324128|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
376174|NCT01324128|Drug|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
376175|NCT01324128|Drug|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
376176|NCT01324115|Drug|NG-nitro-L-arginine|
376177|NCT01324115|Other|laboratory biomarker analysis|
376178|NCT01324115|Other|pharmacological study|
376179|NCT01324115|Procedure|computed tomography|
376180|NCT01324115|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
376181|NCT01324102|Behavioral|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
376182|NCT01324089|Dietary Supplement|Resveratrol|Resveratrol 2.5 grams
376183|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
376184|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
376185|NCT01324076|Drug|doxorubicin-eluting beads|
376186|NCT01324076|Drug|sorafenib tosylate|
376187|NCT01324076|Other|laboratory biomarker analysis|
376188|NCT01324076|Other|pharmacogenomic studies|
376189|NCT01324076|Other|pharmacological study|
376190|NCT01324076|Procedure|quality-of-life assessment|
376191|NCT01324063|Biological|sargramostim|
376194|NCT01324063|Drug|daunorubicin hydrochloride|
376195|NCT01324063|Procedure|quality-of-life assessment|
376196|NCT01324050|Behavioral|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
376197|NCT01324050|Behavioral|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
376198|NCT01324037|Other|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
376199|NCT01324024|Drug|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
376200|NCT01324024|Drug|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
376201|NCT01324011|Behavioral|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
376202|NCT01323998|Drug|5ARI|Dutasteride or Finasteride
376203|NCT01323998|Drug|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
376204|NCT01323985|Drug|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
376205|NCT01323985|Drug|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
376206|NCT01323972|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
376207|NCT01323959|Biological|BoostrixTM Polio|Single dose, intramuscular administration.
376208|NCT01323946|Biological|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
376209|NCT01323933|Drug|AB0024|Comparison of different dosages of drug
376210|NCT01323920|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 IV
376211|NCT01323920|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
376212|NCT01323920|Drug|Methotrexate|Methotrexate 15 mg/m^2 IV
376213|NCT01323907|Drug|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
376214|NCT01323881|Device|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
376215|NCT01323855|Drug|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
376216|NCT01323842|Procedure|EDTU|bedside ultrasound imaging by the treating emergency physician
376217|NCT01323829|Other|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
376218|NCT01323816|Other|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
376219|NCT01323790|Drug|NKTR-118|12.5 mg oral tablet once daily
376220|NCT01323790|Drug|NKTR-118|25 mg oral tablet once daily
376221|NCT01323790|Drug|Placebo|Placebo to NKTR-118
376222|NCT01323777|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
376223|NCT01323764|Device|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
376224|NCT01323751|Drug|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
376225|NCT01323738|Behavioral|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
376226|NCT01323725|Behavioral|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
376227|NCT01323712|Dietary Supplement|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
376228|NCT01323699|Behavioral|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
376229|NCT01323686|Other|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.~Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate <30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
376230|NCT01323673|Drug|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
376231|NCT01323673|Drug|Vehicle / Placebo|2 times a day, 14 total days of study treatment
376232|NCT01323660|Drug|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
376233|NCT01323660|Drug|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
376234|NCT01323660|Drug|GSK573719 125|125mcg QID
376235|NCT01323660|Drug|GSK573719 62.5|62.5mcg QID
376236|NCT01323660|Drug|GW642444 25|25mcg QID
376237|NCT01323660|Device|placebo|Comparator QID
376238|NCT01323647|Biological|PoliorixTM|Single dose, intramuscular administration
376239|NCT01323647|Biological|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
376240|NCT01323634|Drug|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
376241|NCT01323634|Drug|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
376242|NCT01323621|Drug|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
376243|NCT01323621|Drug|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
376244|NCT01323621|Drug|Double-dummy placebo|inhalation powder
376245|NCT01323621|Drug|Salbutamol as needed|inhalation powder
376246|NCT01323608|Drug|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
376247|NCT01323608|Drug|Placebo|Placebo
376248|NCT01323595|Drug|Celecoxib|Celecoxib 200mg PO BID x 6 days
376249|NCT01323595|Drug|Sugar Pill|Sugar pill PO BID x 6 days
376250|NCT01323582|Drug|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
376251|NCT01323582|Drug|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
376252|NCT01323569|Drug|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
376253|NCT01323569|Drug|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
376254|NCT01323569|Drug|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
376255|NCT01323569|Drug|Placebo|16 placebo sprays and 4 placebo capsules
376256|NCT01323569|Drug|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
376257|NCT01323569|Drug|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
376258|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
376259|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
376260|NCT01323543|Device|Elaspine™|Implantation of device
376261|NCT01323530|Drug|Eribulin mesylate administration as a 2 to 5 min IV infusion at on Day 1|Oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles). If MTD is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m2 bid on Days 1-14(21-day cycles) depending on the toxicities observed and/or PK data when available. Eribulin as a 2 to 5 minute IV bolus or infusion in two different schedules and at three different dose levels.
376262|NCT01323530|Drug|Eribulin mesylate administration as a 2 to 5 min IV infusion on Day 1 and Day 8|Oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles). If MTD is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m2 bid on Days 1-14(21-day cycles) depending on the toxicities observed and/or PK data when available. Eribulin as a 2 to 5 minute IV bolus or infusion in two different schedules and at three different dose levels.
376263|NCT01323517|Drug|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
376264|NCT01323504|Other|Music|Patient are listen music during their local care
376265|NCT01323504|Other|no music|There are no music during the local care
376266|NCT01323491|Drug|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
376267|NCT01323478|Drug|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
376268|NCT01323465|Drug|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
376269|NCT01323465|Drug|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
376270|NCT01323465|Drug|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
376271|NCT01323465|Drug|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
376272|NCT01323465|Drug|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
376273|NCT01323465|Drug|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
376274|NCT01323452|Drug|Entecavir|once daily
376275|NCT01323439|Device|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
376276|NCT01323426|Procedure|Periurethral injection|Periurethral injection of autologous muscle fibers
376277|NCT01323400|Drug|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
376278|NCT01323400|Other|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).~Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
376279|NCT01323387|Device|Interbody Fusion|allograft spacer + anterior plate
376280|NCT01323374|Drug|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
376281|NCT01323374|Drug|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
376282|NCT01323374|Drug|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
376283|NCT01323374|Drug|Placebo|Oral, placebo TID
376284|NCT01323361|Procedure|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
376285|NCT01323348|Behavioral|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):~Measurement of HbA1c in office with immediate feedback~Measurement of blood pressure with immediate feedback~Assessment of retinopathy risk with immediate feedback~Personalized risk assessment reports based on current HbA1c~Brief assessment of patient understanding of key issues with immediate feedback~Supplemental diabetes management educational materials (provided at baseline only)~Feedback to primary care provider~Email reminder to study participants with email access of individualized risk assessment findings"
376286|NCT01323335|Drug|IV Uric Acid|
376287|NCT01323335|Drug|IV Rasburicase|
376288|NCT01323309|Behavioral|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
376289|NCT01323309|Behavioral|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
376290|NCT01323309|Behavioral|enhanced usual care (EUC)|"We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals."
376291|NCT01323296|Other|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
376292|NCT01323283|Dietary Supplement|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
376293|NCT01323283|Dietary Supplement|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
376294|NCT01323270|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
376295|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
376296|NCT01323270|Biological|Saline|0.5 mL dose, given at 0, 2 and 6 months.
376297|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
376298|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
376299|NCT01323257|Drug|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
376300|NCT01323257|Drug|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
376301|NCT01323257|Drug|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
376302|NCT01323257|Drug|TMC435|50 mg capsule once daily for 7 days (Trt F)
376303|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
376304|NCT01323244|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
376305|NCT01323231|Behavioral|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
376344|NCT01322906|Other|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
376561|NCT01320943|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
376306|NCT01323218|Drug|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
376307|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
376308|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
376309|NCT01323205|Drug|Placebo|Placebo capsule (s) orally twice daily with a meal for 4 weeks.
376310|NCT01323205|Drug|Antipsychotic medication|Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
376311|NCT01323192|Drug|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
376312|NCT01323192|Drug|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
376313|NCT01323166|Procedure|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
376314|NCT01323153|Drug|dalcetrapib|Oral doses of 600 mg once daily for 20 weeks
376315|NCT01323153|Drug|placebo|Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
376316|NCT01323140|Drug|testosterone matrix transdermal system|
376317|NCT01323127|Procedure|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
376318|NCT01323114|Procedure|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
376319|NCT01323114|Other|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
376320|NCT01323101|Drug|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
376321|NCT01323101|Other|No doxycycline|
376322|NCT01323088|Other|Control|Standard care control (no exercise)
376323|NCT01323088|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
376324|NCT01323088|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
376325|NCT01323075|Procedure|Truncal block|Patients will have a truncal block during hand or wrist surgery.
376326|NCT01323062|Drug|Bavituximab|Administered 3 mg/kg weekly
376327|NCT01323049|Procedure|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
376328|NCT01323049|Procedure|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
376329|NCT01323036|Dietary Supplement|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
376330|NCT01323036|Dietary Supplement|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
376331|NCT01323023|Behavioral|varies by project|
376332|NCT01323010|Drug|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
376333|NCT01323010|Drug|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg)
376334|NCT01322997|Device|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
376335|NCT01322997|Behavioral|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
376336|NCT01322997|Device|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
376337|NCT01322984|Behavioral|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
376338|NCT01322984|Behavioral|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
376339|NCT01322971|Drug|Metronidazole|Metronidazole 500mg orally twice daily for seven days
376340|NCT01322971|Drug|Placebo|Placebo will be administered orally twice daily for seven days
376341|NCT01322958|Device|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
376342|NCT01322919|Procedure|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.~The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.~In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
376343|NCT01322906|Other|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
376556|NCT01320982|Drug|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
376345|NCT01322906|Other|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
376346|NCT01322880|Behavioral|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
376347|NCT01322880|Behavioral|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
376348|NCT01322867|Drug|alprazolam tablet|0,25 mg oral tablets given once
376349|NCT01322867|Drug|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
376350|NCT01322854|Radiation|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
376351|NCT01322841|Other|CHICA Diagnosis Module|The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia
376352|NCT01322841|Other|CHICA Placebo|This was CHICA without the screening module
376353|NCT01322828|Procedure|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
376354|NCT01322815|Drug|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.~maintenance of GI-4000 injection and bevacizumab every 2 weeks"
376355|NCT01322815|Drug|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
376356|NCT01322802|Biological|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
376357|NCT01322802|Other|laboratory biomarker analysis|Correlative studies
376358|NCT01322789|Biological|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
376359|NCT01322776|Drug|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m^2 i.v. on days 1~3 of each 28-day cycle cyclophosphamide i.v. on days 1~2 of each 28-day cycle
376360|NCT01322737|Procedure|Tissue Access and Resection System|This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
376361|NCT01322724|Procedure|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
376362|NCT01322711|Drug|Atorvastatin|Atorvastatin 40 mg day
376363|NCT01322711|Drug|Placebo|Diet
376364|NCT01322698|Biological|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
376365|NCT01322659|Device|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
376366|NCT01322659|Device|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
376367|NCT01322646|Device|CarChipPro|On board driving monitor
376368|NCT01322646|Behavioral|Driver's Education|10 Session License to Learn Program.
376369|NCT01322646|Behavioral|STEER Program|8-session behavioral parent training and teen social skills/communication training program
376370|NCT01322646|Other|Driving Simulator Practice|Practice Driving on a driving simulator
376371|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
376372|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
376373|NCT01322620|Other|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
376374|NCT01322607|Behavioral|High-intensity Treadmill Exercise|High-intensity treadmill walking program
376375|NCT01322607|Behavioral|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
376376|NCT01322594|Biological|MEDI2338|MEDI2338 single intravenous (IV) dose (lowest dose)
376377|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
376378|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
376379|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
376380|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (highest dose)
376381|NCT01322594|Other|Placebo|Placebo single IV dose
376382|NCT01322503|Biological|Norovirus|Norovirus challenge pool administered to each subject
376383|NCT01322490|Biological|PROSTVAC-V|
376384|NCT01322490|Biological|PROSTVAC-F|
376385|NCT01322490|Drug|GM-CSF|
376386|NCT01322490|Other|GM-CSF Placebo|
376387|NCT01322490|Biological|Placebo|PROSTVAC V/F Placebo
376388|NCT01322477|Other|F18-FDG PET/CT|
376389|NCT01322464|Drug|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
376390|NCT01322464|Drug|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
376391|NCT01322464|Drug|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
376392|NCT01322464|Drug|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
376393|NCT01322451|Drug|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
376394|NCT01322451|Drug|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
376557|NCT01320982|Drug|placebo|placebo bid
376395|NCT01322438|Drug|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
376396|NCT01322399|Procedure|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
376397|NCT01322399|Procedure|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
376398|NCT01322386|Drug|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
376399|NCT01322360|Drug|Morphine Sulfate|
376400|NCT01322347|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
376401|NCT01322347|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
376402|NCT01322334|Behavioral|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
376403|NCT01322321|Drug|ACZ885|
376404|NCT01322321|Drug|Placebo|
376405|NCT01322308|Drug|pioglitazone|30 mg tablet QD (taken once daily)
376406|NCT01322308|Drug|placebo|tablet taken once a day
376407|NCT01322282|Drug|Cetirizine|A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
376408|NCT01322282|Drug|Cetirizine|A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
376409|NCT01322269|Drug|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
376410|NCT01322256|Procedure|Bone scintigraphy|Bone scintigraphy of the affected area
376411|NCT01322256|Procedure|Leukoscan|Scintigraphy with labeled neutrophils
376412|NCT01322256|Procedure|PET / CT|PET / CT of the affected area
376413|NCT01322256|Procedure|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
376414|NCT01322256|Biological|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
376415|NCT01322243|Other|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
376416|NCT01322230|Other|Control|Multimedia Control
376417|NCT01322230|Other|WISEMD Original|Current WISEMD
376418|NCT01322230|Other|Social Networking|Social networking feature
376419|NCT01322230|Other|Social Networking plus Emotional Design|social networking features plus user interface enhancements
376420|NCT01322204|Drug|Codeine|One single oral dose of 1 mg/kg of codeine
376421|NCT01322191|Drug|Morphine|A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
376422|NCT01322178|Drug|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1~Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h~repeated every two weeks for 4.5 months(9 cycles)"
376423|NCT01322152|Drug|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
376424|NCT01322139|Drug|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
376425|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
376426|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
376427|NCT01322139|Drug|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
376428|NCT01322126|Device|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
376429|NCT01322100|Device|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
376430|NCT01322100|Drug|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
376431|NCT01322087|Dietary Supplement|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.~All included patients received nutritional counseling and information about the new food concept by a clinical dietician.~Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
376432|NCT01322061|Drug|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
376433|NCT01322048|Drug|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
376434|NCT01322048|Drug|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
376435|NCT01322022|Behavioral|ParentTraining|5 sessions of individual parent training
376436|NCT01322022|Other|Parent Education|Parent Education to control for time and attention
376437|NCT01322009|Drug|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
376438|NCT01322009|Drug|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
376439|NCT01321996|Procedure|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
376440|NCT01321983|Other|Inspiratory muscular training - IMT|
376441|NCT01321970|Procedure|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
376442|NCT01321970|Procedure|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
376443|NCT01321970|Procedure|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:~Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)~Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)~Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
376444|NCT01321957|Drug|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
376445|NCT01321957|Drug|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
376446|NCT01321944|Other|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
376447|NCT01321931|Drug|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
376448|NCT01321931|Drug|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
376449|NCT01321931|Drug|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
376450|NCT01321918|Other|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
376451|NCT01321918|Other|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
376452|NCT01321905|Dietary Supplement|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.~Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
376453|NCT01321879|Drug|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
376454|NCT01321866|Procedure|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
376455|NCT01321866|Procedure|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
376456|NCT01321853|Other|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
376457|NCT01321853|Other|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
376458|NCT01321840|Procedure|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
376459|NCT01321827|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
376460|NCT01321827|Drug|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
376461|NCT01321814|Behavioral|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
376462|NCT01321801|Drug|Pregabalin|Preoperative administration of pregabalin 600mg
376463|NCT01321801|Drug|placebo|Preoperative administration of a matching placebo
376464|NCT01321788|Drug|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
376465|NCT01321788|Drug|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
376466|NCT01321775|Drug|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):~Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.~Adjuvant doses:~Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
376467|NCT01321749|Procedure|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
376468|NCT01321736|Dietary Supplement|dietary fiber|mixture of fiber sources added to liquid nutrition product
376469|NCT01321723|Drug|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
376470|NCT01321723|Drug|Placebo|
376471|NCT01321723|Drug|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
376472|NCT01321710|Behavioral|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.~It is administered to women during their last month of pregnancy."
376473|NCT01321710|Behavioral|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
376474|NCT01321710|Drug|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
376475|NCT01321697|Procedure|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
376476|NCT01321684|Other|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
376477|NCT01321684|Other|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
376478|NCT01321671|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
376479|NCT01321671|Drug|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
376480|NCT01321671|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
376481|NCT01321658|Other|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
376482|NCT01321645|Drug|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
376483|NCT01321632|Drug|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
376484|NCT01321619|Drug|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
376485|NCT01321619|Drug|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
376486|NCT01321606|Dietary Supplement|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10^10 organisms
376487|NCT01321606|Dietary Supplement|sugar pill (placebo)|Placebo identical to the active product will be given
376488|NCT01321580|Device|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
376489|NCT01321567|Drug|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
376490|NCT01321554|Drug|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
376491|NCT01321554|Drug|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
376558|NCT01320969|Behavioral|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
376559|NCT01320956|Behavioral|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
376492|NCT01321554|Drug|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.~The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
376493|NCT01321541|Drug|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
376494|NCT01321541|Drug|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
376495|NCT01321515|Drug|famciclovir|500 mg tablet
376496|NCT01321502|Drug|famciclovir|500 mg tablet
376497|NCT01321489|Drug|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
376498|NCT01321489|Drug|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
376499|NCT01321463|Drug|PH-797804|6 mg oral tablet once daily for 12 weeks
376500|NCT01321463|Drug|Placebo|Placebo oral tablet once daily for 12 weeks
376501|NCT01321437|Procedure|therapeutic conventional surgery|Undergo surgery
376502|NCT01321437|Other|laboratory biomarker analysis|Correlative studies
376503|NCT01321437|Drug|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
376504|NCT01321437|Other|pharmacological study|Correlative studies
376505|NCT01321411|Other|Near Infrared Spectroscopy|"Healthy Volunteers:~Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.~Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
376506|NCT01321411|Other|Near Infrared Spectroscopy|"Clinical Volunteers:~Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.~Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
376507|NCT01321398|Other|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
376508|NCT01321385|Other|laboratory biomarker analysis|
376509|NCT01321385|Other|study of socioeconomic and demographic variables|
376510|NCT01321359|Drug|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
376511|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
376512|NCT01321346|Drug|Cytarabine|"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
376513|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
376514|NCT01321333|Biological|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
376515|NCT01321320|Other|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
376516|NCT01321294|Procedure|laparoscopic anti-reflux surgery|
376517|NCT01321281|Dietary Supplement|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
376518|NCT01321281|Dietary Supplement|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.~The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
376519|NCT01321268|Dietary Supplement|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
376520|NCT01321268|Dietary Supplement|Viatmin E|oral, twice daily in morning and evening for 6 months
376521|NCT01321255|Drug|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
376522|NCT01321255|Drug|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
376560|NCT01320956|Other|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
376562|NCT01320943|Other|Stop TDF|Participants will stop TDF therapy
376523|NCT01321177|Behavioral|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:~education about schizophrenia and its treatment for the participants and their family members~medication for symptoms and preventing relapse that uses a computerized decision support system~strategies for managing the illness and building personal resilience~help getting back to school or work using a supported employment/education model"
376524|NCT01321177|Behavioral|Community Care|"Standard mental health treatments and services offered at the local agency that may include :~medication for symptoms and preventing relapse~psychosocial therapy which may include a range of behavioral treatments and supportive services~Case management"
376525|NCT01321164|Device|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.~Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
376526|NCT01321164|Drug|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
376527|NCT01321151|Drug|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
376528|NCT01321151|Drug|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
376529|NCT01321138|Procedure|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
376530|NCT01321138|Procedure|PCA morphine|Postoperative analgesia with self-administration iv morphine
376531|NCT01321125|Biological|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
376532|NCT01321125|Other|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
376533|NCT01321125|Biological|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
376534|NCT01321112|Drug|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
376535|NCT01321099|Other|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
376536|NCT01321099|Other|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
376537|NCT01321099|Other|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
376538|NCT01321086|Behavioral|Motivational Interviewing|9 sessions of MI from baseline to six months
376539|NCT01321086|Behavioral|PACE|9 sessions of PACE delivered from baseline to six months
376540|NCT01321073|Device|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
376541|NCT01321060|Procedure|Aspiration|
376542|NCT01321060|Procedure|Catheter drainage|
376543|NCT01321060|Drug|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
376544|NCT01321047|Drug|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV)
376545|NCT01321047|Drug|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
376546|NCT01321034|Drug|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
376547|NCT01321021|Drug|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
376548|NCT01321008|Radiation|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
376549|NCT01321008|Drug|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
376550|NCT01321008|Drug|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
376551|NCT01321008|Drug|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
376552|NCT01321008|Drug|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
376553|NCT01320995|Procedure|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
376554|NCT01320982|Drug|minocycline|minocycline 100 mg/bid
376555|NCT01320982|Drug|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
376563|NCT01320930|Behavioral|Pulmonary rehabilitation|
376564|NCT01320930|Behavioral|conventional care|
376565|NCT01320917|Device|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
376566|NCT01320917|Device|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
376567|NCT01320904|Procedure|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
376568|NCT01320904|Procedure|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
376569|NCT01320891|Behavioral|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
376570|NCT01320891|Behavioral|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
376571|NCT01320878|Drug|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
376572|NCT01320878|Drug|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
376573|NCT01320878|Drug|distilled water|distilled water 2 ml per session
376574|NCT01320852|Other|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
376575|NCT01320826|Procedure|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
376576|NCT01320813|Procedure|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
376577|NCT01320813|Procedure|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
376578|NCT01320800|Behavioral|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
376579|NCT01320800|Behavioral|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
376580|NCT01320787|Drug|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
376581|NCT01320774|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
376582|NCT01320761|Drug|ATX-101-BA-free|ATX-101-BA-free
376583|NCT01320761|Drug|ATX-101-BA|ATX-101-BA
376584|NCT01320748|Behavioral|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
376585|NCT01320748|Behavioral|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
376586|NCT01320722|Drug|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
376587|NCT01320722|Drug|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
376588|NCT01320722|Drug|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
376589|NCT01320722|Drug|Placebo|Placebo soft gel once per week for 8 weeks
376590|NCT01320722|Drug|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
376591|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
376592|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
376593|NCT01320709|Drug|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
376594|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
376595|NCT01320696|Biological|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
376596|NCT01320683|Drug|oxaliplatin|Given IV
376597|NCT01320683|Drug|leucovorin calcium|Given IV
376598|NCT01320683|Drug|fluorouracil|Given IV
376599|NCT01320683|Biological|bevacizumab|Given IV
376600|NCT01320683|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
376601|NCT01320683|Other|laboratory biomarker analysis|Correlative studies
376602|NCT01320683|Other|pharmacological study|Correlative studies
376603|NCT01320683|Drug|irinotecan hydrochloride|Given IV
376645|NCT01320319|Dietary Supplement|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
376646|NCT01320293|Drug|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
376604|NCT01320657|Device|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.~Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
376605|NCT01320605|Biological|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
376606|NCT01320592|Drug|PD0332991|
376607|NCT01320592|Drug|Paclitaxel|
376608|NCT01320579|Drug|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
376609|NCT01320579|Drug|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
376610|NCT01320579|Drug|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
376611|NCT01320579|Drug|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
376612|NCT01320566|Device|AeriSeal System|Not applicable. Follow-Up study only.
376613|NCT01320553|Drug|SPARC1102 I|SPARC1102 I will be administered in both eyes
376614|NCT01320553|Drug|SPARC1102 II|SPARC1102 II will be administered in both eyes
376615|NCT01320553|Drug|SPARC1102 III|SPARC1102 III will be administered in both eyes
376616|NCT01320553|Drug|Vehicle|Vehicle will be administered in both eyes
376617|NCT01320527|Dietary Supplement|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
376618|NCT01320527|Other|Placebo|A mixture of 6 vitamins and nutriceuticals
376619|NCT01320514|Drug|Fibrin Sealant (Artiss)|
376620|NCT01320501|Drug|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
376621|NCT01320475|Drug|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
376622|NCT01320475|Drug|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
376623|NCT01320462|Drug|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
376624|NCT01320462|Other|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
376625|NCT01320449|Drug|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
376626|NCT01320449|Behavioral|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
376627|NCT01320449|Other|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
376628|NCT01320436|Dietary Supplement|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
376629|NCT01320436|Drug|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
376630|NCT01320423|Procedure|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
376631|NCT01320410|Drug|ISM®|
376632|NCT01320397|Drug|Rostafuroxin|6 microgram capsules
376633|NCT01320397|Drug|Rostafuroxin|50 micrograms capsules
376634|NCT01320397|Drug|Rostafuroxin|500 micrograms capsules
376635|NCT01320397|Drug|Losartan|Losartan 50 mg once a day
376636|NCT01320384|Other|O2 conventional|standard low flow therapy
376637|NCT01320384|Device|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
376638|NCT01320384|Device|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
376639|NCT01320358|Drug|ECMPS-IEM|ECMPS-IEM
376640|NCT01320345|Drug|Fenofibrate|145 mg tablet of fenofibrate administered once daily for 36 months.
376641|NCT01320345|Drug|Inert lactose placebo|Insert lactose tablet matching active tablet administered once daily for 36 months.
376642|NCT01320332|Drug|ASP3291|Oral tablets
376643|NCT01320332|Drug|Placebo|Oral tablets
376644|NCT01320319|Other|Placebo|Capsule form, 960 mg to be taken three times a day.
376647|NCT01320280|Drug|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
376648|NCT01320267|Procedure|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
376649|NCT01320254|Drug|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
376650|NCT01320254|Drug|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
376651|NCT01320241|Device|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
376652|NCT01320241|Device|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
376653|NCT01320228|Dietary Supplement|Control|Alli treatment plus placebo (rice flour)
376654|NCT01320228|Dietary Supplement|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
376655|NCT01320228|Dietary Supplement|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
376656|NCT01320228|Dietary Supplement|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
376657|NCT01320215|Procedure|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
376658|NCT01320215|Procedure|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
376659|NCT01320202|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
376660|NCT01320202|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
376661|NCT01320189|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
376662|NCT01320176|Biological|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
376663|NCT01320176|Biological|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
376664|NCT01320163|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
376665|NCT01320163|Device|Laryngeal Mask Airway|supra-glottic airway device
376666|NCT01320137|Procedure|Blood withdrawal|Blood sampling
376667|NCT01320111|Drug|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15~AND~pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
376668|NCT01320111|Drug|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
376669|NCT01320098|Behavioral|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.~Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.~Increasing the quality and quantity of positive interactions between you and your child~Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.~Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
376670|NCT01320098|Behavioral|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.~The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.~Parents learn techniques and skills to promote positive interactions with their child, including:~Increasing the positive attention you give to your child.~Reducing the inappropriate use of commands, questions and criticisms.~Appropriate use of praise and physical attention (e.g., hugs) as rewards.~Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
376671|NCT01320098|Behavioral|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
376672|NCT01320085|Drug|MEK162|
376673|NCT01320059|Drug|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
376674|NCT01320059|Procedure|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
376675|NCT01320046|Other|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:~Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.~Medical history.~Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).~Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.~Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
376676|NCT01320033|Drug|CD2475/101 40 mg Tablets|CD2475/101 40 mg Tablets once a day for 16 weeks
376677|NCT01320033|Drug|Doxycycline 100 mg Capsules|Doxycycline 100 mg Capsules once a day for 16 weeks
376678|NCT01320033|Drug|Placebo Tablet, and Placebo Capsule|Matching Placebo Tablet, Matching Placebo Capsule once a day for 16 weeks
376679|NCT01320020|Drug|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
377751|NCT01311284|Device|McGrath|Intubate with McGrath device
376680|NCT01320007|Drug|Preset increase in frusemide dose|"All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.~If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week."
376681|NCT01320007|Other|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
376682|NCT01319994|Drug|Metformin|Metformin 850mg TDS (12 weeks)
376683|NCT01319994|Drug|Placebo|Placebo 850mg TDS (12 weeks)
376684|NCT01319981|Drug|Rituximab|In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
376685|NCT01319981|Drug|Imatinib|600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
376686|NCT01319981|Drug|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
376687|NCT01319981|Drug|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
376688|NCT01319981|Drug|Mesna|600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
376689|NCT01319981|Drug|VSLI|2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
376690|NCT01319981|Drug|Solu-Medrol|40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
376691|NCT01319981|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
376692|NCT01319981|Drug|Ara-C|3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
376693|NCT01319981|Drug|G-CSF|10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10^9/L by day 21.
376694|NCT01319981|Drug|Pegfilgrastim|6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
376695|NCT01319981|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
376696|NCT01319968|Drug|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
376697|NCT01319955|Biological|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
376698|NCT01319942|Other|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
376699|NCT01319929|Drug|LY2828360|Administered orally
376700|NCT01319929|Drug|Placebo|Administered orally
376701|NCT01319916|Drug|ATX-101|ATX-101 2mg/cm2
376702|NCT01319903|Biological|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
376703|NCT01319890|Procedure|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
376704|NCT01319864|Drug|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose~Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
376705|NCT01319851|Drug|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
376706|NCT01319838|Drug|Isotretinoin|>12 kg: 160 mg/m2/day, given PO, divided BID <=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
376707|NCT01319825|Drug|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
376708|NCT01319812|Device|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
376709|NCT01319812|Device|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
376710|NCT01319799|Other|Open heart surgery|TCD count of microembolic signals during surgical aortic valve replacement
376711|NCT01319786|Other|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
376712|NCT01319786|Other|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
376713|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
376714|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
376747|NCT01319565|Drug|Fludarabine|Arm 1 and Arm 2 - Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 15-30 minutes for 5 days.
377781|NCT01310998|Behavioral|High intensity exercise|4x4 intervals
376715|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
376716|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
376717|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
376718|NCT01319760|Device|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
376719|NCT01319760|Other|Standard of care (Control)|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
376720|NCT01319747|Procedure|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
376721|NCT01319747|Procedure|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
376722|NCT01319734|Dietary Supplement|Vitamin C|Vitamin C supplementation 500mg
376723|NCT01319734|Drug|glyburide|this group receiving glyburide 5 mg alone
376724|NCT01319721|Procedure|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
376725|NCT01319721|Procedure|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
376726|NCT01319721|Procedure|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
376727|NCT01319708|Procedure|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
376728|NCT01319708|Procedure|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
376729|NCT01319695|Drug|corifollitropin alfa|100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg
376730|NCT01319695|Drug|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are >18mm
376731|NCT01319682|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
376732|NCT01319682|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
376733|NCT01319669|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
376734|NCT01319656|Behavioral|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
376735|NCT01319643|Drug|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
376736|NCT01319630|Device|Sidestream Dark Field (SDF)|"SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.~After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus."
376737|NCT01319630|Device|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
376738|NCT01319617|Device|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
376739|NCT01319604|Device|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
376740|NCT01319604|Device|Tonometer|Tonometric assessment of IOP
376741|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
376742|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
376743|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
376744|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
376745|NCT01319565|Drug|Aldesleukin|Arm 1 and Arm 2 - Days 1 to 4: Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) for up to 5 days (maximum 15 doses).
376746|NCT01319565|Drug|Cyclophosphamide|Arm 1 and Arm 2 - Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mL D5W with Mesna 15 mg/kg /day X 2 days over 1 hr.
376748|NCT01319565|Biological|Young Tumor Infiltrating Lymphocytes|Arm 1 and Arm 2 - Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20-30 minutes.
376749|NCT01319565|Radiation|Total Body Irradiation (TBI)|Arm 2 - Days -3 to -1: Ondansetron 0.15 mg/kg IV x 1 dose pre-TBI. Patients will then receive 2 Gy TBI twice a day for 3 days (total dose 12 Gy) using a linear accelerator in Radiation Oncology.
376750|NCT01319552|Procedure|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
376751|NCT01319552|Procedure|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
376752|NCT01319539|Drug|Akt Inhibitor MK2206|Given PO
376753|NCT01319539|Procedure|Therapeutic Conventional Surgery|Undergo surgery
376754|NCT01319539|Other|Pharmacological Study|Correlative studies
376755|NCT01319539|Other|Laboratory Biomarker Analysis|Correlative studies
376756|NCT01319526|Genetic|DNA analysis|
376757|NCT01319526|Genetic|RNA analysis|
376758|NCT01319526|Other|laboratory biomarker analysis|
376759|NCT01319513|Other|whey protein bolus|single dose of 25 g whey protein
376760|NCT01319513|Other|whey protein pulses|10 2.5 g pulses of whey protein
376761|NCT01319487|Drug|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
376762|NCT01319487|Drug|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
376763|NCT01319487|Drug|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
376764|NCT01319474|Other|Whole-leg compression ultrasound|Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
376765|NCT01319461|Device|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
376766|NCT01319461|Device|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
376767|NCT01319448|Drug|Proguanil|Proguanil tablets, 1.5mg/kg/day
376768|NCT01319448|Drug|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
376769|NCT01319448|Drug|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
376770|NCT01319435|Procedure|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).~Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
376771|NCT01319422|Drug|Pomalidomide|Comparison of different dosages and schedules of drug
376772|NCT01319409|Procedure|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
376773|NCT01319409|Procedure|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
376774|NCT01319383|Drug|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
376775|NCT01319370|Drug|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
376776|NCT01319370|Drug|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
376777|NCT01319357|Drug|Saxagliptin|orally 5 mg/d for 6 weeks
376778|NCT01319357|Drug|Placebo|orally for 6 weeks
376779|NCT01319344|Drug|Eplerenone|25 mg o.d. per os
376780|NCT01319331|Drug|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
376781|NCT01319318|Procedure|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
376782|NCT01319305|Device|FinESS Sinus Treatment|balloon sinuplasty
376783|NCT01319279|Drug|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
376784|NCT01319266|Drug|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
376785|NCT01319240|Drug|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
376786|NCT01319240|Drug|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
376787|NCT01319240|Drug|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
376788|NCT01319227|Procedure|Hip replacement|Hip arthroplasty with uncemented components
376789|NCT01319214|Drug|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
376790|NCT01319188|Drug|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
376791|NCT01319188|Procedure|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
376792|NCT01319188|Other|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
376793|NCT01319175|Other|Hip flexion strength training|
376794|NCT01319162|Other|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
376795|NCT01319123|Device|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
376796|NCT01319110|Drug|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
376797|NCT01319110|Dietary Supplement|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
376798|NCT01319097|Other|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
376799|NCT01319071|Other|Blood sample|Extraction of blood sample from top-level athletes
376800|NCT01319058|Procedure|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
376801|NCT01319045|Drug|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
376802|NCT01319032|Other|Extraction of whole blood|Extraction of DNA from whole blood
376803|NCT01319019|Drug|GSK961081|Comparison of different doses and dosing regimens of the drug
376804|NCT01319019|Drug|Salmeterol|Positive control
376805|NCT01319019|Drug|Placebo|Placebo arm
376806|NCT01319006|Drug|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
376807|NCT01319006|Drug|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
376808|NCT01319006|Drug|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
376809|NCT01318993|Drug|GSK1605786A|500 milligrams twice daily
376810|NCT01318980|Drug|GSK2190915 100mg milled tablet|Taken orally
376811|NCT01318980|Drug|[14C] radiolabelled GSK2190915 solution|Microtracer solution
376812|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
376813|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
376814|NCT01318980|Drug|GSK2190915 100mg enteric-coated tablet.|Taken orally
376815|NCT01318967|Drug|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
376816|NCT01318967|Other|Placebo|
376817|NCT01318954|Biological|Allergen immunotherapy|
376818|NCT01318941|Drug|Ranibizumab|
376819|NCT01318941|Other|Ranibizumab|
376820|NCT01318928|Drug|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
376821|NCT01318915|Drug|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
376822|NCT01318915|Drug|Rituximab|375 mg/m^2 IV infusion on day -6 before transplant and on day 1 after transplant.
376823|NCT01318915|Drug|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
376824|NCT01318915|Drug|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
376825|NCT01318915|Drug|MMF|1 g twice daily on days 0 through 12
376826|NCT01318902|Drug|MLN9708|Patients will receive escalating doses of MLN9708 orally on Days 1, 8 and 15 of a 28-day cycle. If there is no hematologic response after completion of 3 cycles, dexamethasone will be added on Days 1 to 4 of every cycle beginning with Cycle 4. If there is no hematologic response after the completion of 6 cycles, patients will discontinue therapy.
376827|NCT01318889|Drug|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
376828|NCT01318850|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
376829|NCT01318850|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
376830|NCT01318850|Other|Healthy controls|No intervention
376831|NCT01318837|Drug|solifenacin|oral
376832|NCT01318824|Procedure|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
376833|NCT01318824|Procedure|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
376834|NCT01318811|Drug|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
376872|NCT01318460|Drug|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
376835|NCT01318811|Drug|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
376836|NCT01318785|Other|Compression Armsleeves|"Type: Compression Class II (according to RAL)~The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
376837|NCT01318772|Device|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.~The system includes a new digital camera and a new image processor."
376838|NCT01318746|Procedure|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
376839|NCT01318733|Drug|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
376840|NCT01318720|Other|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
376841|NCT01318694|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
376842|NCT01318694|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
376843|NCT01318694|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
376844|NCT01318694|Drug|ALV Placebo|ALV placebo soft gel capsules administered orally
376845|NCT01318681|Drug|cetirizine 10 mg|cetirizine 10 mg over encapsulated
376846|NCT01318681|Drug|fluticasone furoate|nasal spray 25ug per dose
376847|NCT01318681|Drug|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
376848|NCT01318668|Biological|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
376849|NCT01318655|Drug|NKTR-118|Tablet, Oral, Once daily
376850|NCT01318655|Drug|Placebo|Tablet, Oral, Once daily
376851|NCT01318642|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
376852|NCT01318642|Drug|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
376853|NCT01318642|Drug|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
376854|NCT01318616|Other|Strength training of the hip adductors|Adductor strength training
376855|NCT01318590|Drug|Bupivacaine & Triamcinolone Acetonide|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
376856|NCT01318590|Other|No intervention except EUS procedure|EUS procedure without any drug injection
376857|NCT01318564|Drug|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
376858|NCT01318564|Behavioral|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
376859|NCT01318551|Drug|BAY85-3934|single dose, 20 mg
376860|NCT01318551|Drug|BAY85-3934|single dose, 40 mg (optional)
376861|NCT01318551|Drug|BAY85-3934|single dose, 80 mg (optional)
376862|NCT01318538|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
376863|NCT01318538|Behavioral|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
376864|NCT01318525|Drug|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
376865|NCT01318525|Drug|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
376866|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
376867|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
376868|NCT01318499|Other|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
376869|NCT01318486|Other|Heparin free dialysis technique|Saline flushes or predilution
376870|NCT01318486|Device|Evodial|Evodial dialyer
376871|NCT01318473|Device|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
376873|NCT01318460|Drug|Placebo infusion|Twenty-four hour administration of placebo
376874|NCT01318447|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
376875|NCT01318434|Drug|EB-1010 25mg BID|capsule once daily
376876|NCT01318434|Drug|SSRI Active|Active Comparator
376877|NCT01318434|Drug|EB-1010 50mg BID|Experimental Active
376878|NCT01318434|Drug|Placebo|Placebo comparator
376879|NCT01318421|Drug|ELND002|
376880|NCT01318408|Drug|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
376881|NCT01318395|Drug|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
376882|NCT01318395|Drug|Placebo|orally once per day
376883|NCT01318382|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
376884|NCT01318369|Drug|Namisol|Single dose delta-9-tetrahydrocannabinol
376885|NCT01318369|Drug|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
376886|NCT01318356|Behavioral|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
376887|NCT01318356|Drug|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
376888|NCT01318356|Drug|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
376889|NCT01318330|Drug|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
376890|NCT01318317|Procedure|peripheral blood stem cell transplantation (PBSCT)|Undergo autologous PBSCT
376891|NCT01318317|Biological|filgrastim|Given IV
376892|NCT01318317|Genetic|polymerase chain reaction|Correlative studies
376893|NCT01318317|Biological|rituximab|Given IV
376894|NCT01318317|Biological|genetically engineered lymphocyte therapy|Receive ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR)
376895|NCT01318317|Other|laboratory biomarker analysis|Correlative studies
376896|NCT01318317|Drug|plerixafor|Given IV
376897|NCT01318317|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
376898|NCT01318304|Other|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
376899|NCT01318291|Behavioral|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
376900|NCT01318291|Behavioral|Control|Medical treatment alone
376901|NCT01318278|Drug|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
376902|NCT01318278|Drug|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
376903|NCT01318265|Drug|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
376904|NCT01318252|Drug|AL-54478 0.005%|
376905|NCT01318252|Drug|Latanoprost 0.005%|
376906|NCT01318252|Drug|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
376907|NCT01318239|Procedure|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
376908|NCT01318226|Drug|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
376909|NCT01318226|Drug|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
376910|NCT01318200|Procedure|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
376911|NCT01318200|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
376912|NCT01318187|Drug|paracetamol|1 gr
376913|NCT01318187|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
376914|NCT01318187|Drug|Paracetamol|1 gr intravenous
376915|NCT01318187|Drug|Paracetamol|intravenous 1 gr
376916|NCT01318187|Drug|Morphine|0.1 mg/kg intravenous
376917|NCT01318161|Drug|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
376918|NCT01318161|Drug|Morphine|Morphine via PCA pump
376919|NCT01318148|Drug|caspofungin|Intermittent intravenous application of caspofungin
376920|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
376921|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
377001|NCT01317524|Dietary Supplement|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
376922|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
376923|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
376924|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
376925|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
376926|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
376927|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
376928|NCT01318109|Drug|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
376929|NCT01318096|Drug|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
376930|NCT01318096|Drug|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
376931|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
376932|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
376933|NCT01318083|Drug|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
376934|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
376935|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
376936|NCT01318070|Drug|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
376937|NCT01318044|Drug|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.~An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
376938|NCT01318031|Drug|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
376939|NCT01318031|Drug|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
376940|NCT01318005|Drug|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
376941|NCT01318005|Drug|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
376942|NCT01318005|Drug|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
376943|NCT01317992|Drug|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
376944|NCT01317992|Drug|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
376945|NCT01317966|Drug|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
376946|NCT01317953|Dietary Supplement|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
376947|NCT01317940|Dietary Supplement|Vitamin D and Calcium Citrate|"Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months"
376948|NCT01317927|Drug|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
376949|NCT01317914|Other|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
376950|NCT01317901|Drug|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
376951|NCT01317901|Drug|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
376952|NCT01317901|Drug|Rituximab|Rituximab by IV administration at 375 mg/m^2 on Day 2 of each 28 day cycle.
376953|NCT01317888|Drug|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
376954|NCT01317875|Drug|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)~Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
376955|NCT01317862|Device|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
376956|NCT01317849|Drug|Folic Acid|0.8mg
376957|NCT01317849|Drug|Vitamin B6|10mg
376958|NCT01317849|Drug|Vitamin B12|500ug
376959|NCT01317849|Drug|placebo|0.8 mg
376960|NCT01317849|Drug|placebo|10mg
376961|NCT01317849|Drug|placebo|500ug
376962|NCT01317823|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
376963|NCT01317797|Drug|namilumab (MT203)|administered three times, subcutaneous in the abdomen
376964|NCT01317797|Drug|Placebo|administered three times, subcutaneous in the abdomen
377002|NCT01317511|Dietary Supplement|Protein|Protein drink
376965|NCT01317784|Device|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
376966|NCT01317784|Device|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
376967|NCT01317784|Device|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
376968|NCT01317784|Device|HIV only|Choice of 4 different tests for HIV only.
376969|NCT01317771|Procedure|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
376970|NCT01317758|Drug|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
376971|NCT01317758|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
376972|NCT01317758|Biological|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
376973|NCT01317745|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
376974|NCT01317745|Drug|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
376975|NCT01317745|Biological|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
376976|NCT01317732|Device|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
376977|NCT01317719|Procedure|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
376978|NCT01317706|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
376979|NCT01317693|Device|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
376980|NCT01317680|Device|Omnispec model ED1000|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
376981|NCT01317680|Device|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
376982|NCT01317667|Biological|RVEc|
376983|NCT01317654|Other|Observation|Collection of mortality data at 5 years post trial
376984|NCT01317641|Drug|ODM-201|ODM-201 administered orally daily
376985|NCT01317628|Behavioral|Tobacco smoke reduction trial intervention program|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
376986|NCT01317615|Drug|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
376987|NCT01317615|Drug|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
376988|NCT01317615|Drug|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
376989|NCT01317589|Drug|fentanyl|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
376990|NCT01317589|Drug|methadone|"T = 0~start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur~breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day~T=1~1 week~if necessary increase dose strong opioid with 50%~T=2 3 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T=3 5 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%~T = 4 9 weeks~if necessary increase dose strong opioid with 50%~if necessary decrease dose strong opioid with 30%"
376991|NCT01317576|Behavioral|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
376992|NCT01317563|Dietary Supplement|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
376993|NCT01317563|Dietary Supplement|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
376994|NCT01317550|Drug|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
376995|NCT01317550|Other|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
376996|NCT01317550|Drug|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
376997|NCT01317550|Behavioral|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
376998|NCT01317537|Other|Electronic personal health record|
376999|NCT01317524|Dietary Supplement|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
377000|NCT01317524|Dietary Supplement|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
377166|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900mg , BID
377003|NCT01317498|Other|Standard Care|CD4, liver function and CBC every 6 months
377004|NCT01317498|Other|Virological Monitoring|Viral Load test every 6 months
377005|NCT01317485|Procedure|Laparoscopic lavage and drainage|"[CLOSED] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.~***This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
377006|NCT01317485|Procedure|Sigmoidectomy with primary anastomosis|[OPEN] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
377007|NCT01317485|Procedure|Sigmoidectomy with end-colostomy|[OPEN] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
377008|NCT01317472|Drug|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
377009|NCT01317472|Drug|Placebo|1 tablet of placebo QAM (1 hour AC) for 2 months
377010|NCT01317459|Behavioral|Guided self-determination|Group counselling
377011|NCT01317446|Drug|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
377012|NCT01317433|Drug|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
377013|NCT01317433|Drug|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
377014|NCT01317420|Drug|BI 836845|Intravenous infusion once every three weeks
377015|NCT01317381|Procedure|Observational|Blood draw
377016|NCT01317368|Drug|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
377017|NCT01317368|Drug|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
377018|NCT01317368|Other|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
377019|NCT01317342|Device|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure < 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
377020|NCT01317329|Other|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
377021|NCT01317303|Procedure|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
377022|NCT01317303|Procedure|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
377023|NCT01317303|Procedure|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
377024|NCT01317303|Procedure|iTBS|190 seconds of intermittent theta-burst stimulation
377025|NCT01317290|Dietary Supplement|n-3 PUFA free olive oil|negative control
377026|NCT01317290|Dietary Supplement|linseed oil|
377027|NCT01317277|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group.
377028|NCT01317277|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
377029|NCT01317264|Other|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
377030|NCT01317264|Other|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
377031|NCT01317264|Other|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
377032|NCT01317264|Other|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
377033|NCT01317251|Other|Dietary intervention (without dairy products)|Control diet without dairy products
377034|NCT01317251|Other|Dietary intervention (high milk content)|Diet with a high content of milk (~1200 mg Ca/d from milk)
377035|NCT01317251|Other|Dietary intervention (high cheese content)|Diet with a high content of cheese (~1200 mg Ca/d from cheese)
377036|NCT01317238|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
377037|NCT01317225|Drug|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
377038|NCT01317225|Drug|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
377039|NCT01317212|Drug|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
377040|NCT01317199|Drug|Muscadine Plus Grape Skin Extract|Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
377041|NCT01317199|Drug|Low-dose MPX|Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).
377167|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900 mg
377042|NCT01317199|Drug|High-dose MPX|Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).
377043|NCT01317199|Drug|Placebo oral capsule|Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
377044|NCT01317160|Device|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
377045|NCT01317147|Procedure|Roux-en-Y gastric bypass (RYGBP)|
377046|NCT01317134|Device|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
377047|NCT01317134|Biological|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
377048|NCT01317108|Drug|CMF Chemotherapy|
377049|NCT01317095|Device|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
377050|NCT01317082|Device|Acupressure|P 6 Pressure Point
377051|NCT01317069|Drug|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
377052|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
377053|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
377054|NCT01317030|Other|Non-Contact Lens Wear|No intervention
377055|NCT01317017|Drug|Actimmune|"All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.~Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.~Patients will return at one to two weeks for suture removal.~Clinical assessments done at every visit.~Patients will also be evaluated at each visit for any adverse events."
377056|NCT01317004|Drug|Fingolimod|0.5 mg/day oral capsule
377057|NCT01317004|Drug|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
377058|NCT01316991|Dietary Supplement|Chewing Gum|chewing gum will be provided
377059|NCT01316991|Dietary Supplement|No Gum|no chewing gum will be provided
377060|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
377061|NCT01316978|Drug|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
377062|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
377063|NCT01316965|Behavioral|Multifaceted prevention program HELP(Hospital Elder Life Program)|"A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment~B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards~C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
377064|NCT01316952|Drug|Carvedilol immediate release only|All dosages of carvedilol immediate release
377065|NCT01316952|Drug|Carvedilol extended release only|All dosages of carvedilol extended release
377066|NCT01316952|Drug|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
377067|NCT01316952|Drug|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
377068|NCT01316952|Drug|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
377069|NCT01316952|Other|No β-blocker|No β-blocker within the month prior to the index date
377070|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams once daily
377071|NCT01316939|Drug|Placebo|Placebo
377072|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams twice daily
377073|NCT01316926|Drug|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
377074|NCT01316926|Drug|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
377075|NCT01316913|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
377076|NCT01316913|Drug|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
377077|NCT01316913|Drug|GSK573719|125 mcg once-daily
377078|NCT01316913|Drug|tiotropium bromide|18 mcg once-daily
377079|NCT01316900|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
377080|NCT01316900|Drug|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
377081|NCT01316900|Drug|GW642444|25 mcg once-daily
377082|NCT01316900|Drug|tiotropium bromide|18 mcg once-daily
377083|NCT01316887|Drug|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
377084|NCT01316887|Drug|125mcg once-daily GSK573719|GSK573719
377085|NCT01316887|Drug|Placebo once-daily|inactive
377086|NCT01316874|Drug|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
377087|NCT01316861|Drug|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
377088|NCT01316861|Drug|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
377089|NCT01316848|Drug|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
377090|NCT01316822|Drug|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
377091|NCT01316809|Drug|AZD8055|Patients will start at 120 mg once daily
377092|NCT01316796|Drug|Sodium Nitrite Cream|
377093|NCT01316770|Drug|Dexamethasone Parotid Irrigation|Irrigation of the parotid gland from one side of the mouth with dexamethasone.
377094|NCT01316770|Drug|Placebo Parotid Irrigation|Irrigation of the parotid gland on the opposite side of the mouth with placebo saline.
377095|NCT01316757|Biological|cetuximab|Given IV
377096|NCT01316757|Drug|paclitaxel|Given IV
377097|NCT01316757|Drug|carboplatin|Given IV
377098|NCT01316757|Drug|erlotinib hydrochloride|Given PO
377099|NCT01316757|Other|laboratory biomarker analysis|Correlative studies
377100|NCT01316744|Drug|ketamine hydrochloride|
377101|NCT01316744|Other|pharmacogenomic studies|
377102|NCT01316744|Other|questionnaire administration|
377103|NCT01316744|Procedure|assessment of therapy complications|
377104|NCT01316744|Procedure|quality-of-life assessment|
377105|NCT01316731|Other|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
377106|NCT01316718|Drug|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
377107|NCT01316718|Drug|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
377108|NCT01316692|Other|laboratory biomarker identification and analysis|Correlative studies
377109|NCT01316692|Procedure|biopsy|Correlative studies
377110|NCT01316692|Other|immunohistochemistry/tissue microarrays|Correlative studies
377111|NCT01316692|Genetic|TdT-mediated dUTP nick end labeling assay|Correlative studies
377112|NCT01316692|Other|mass spectrometry|Correlative studies
377113|NCT01316653|Behavioral|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
377114|NCT01316653|Behavioral|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
377115|NCT01316627|Behavioral|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
377116|NCT01316627|Behavioral|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
377117|NCT01316614|Device|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
377118|NCT01316601|Drug|QAX567|
377119|NCT01316588|Other|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
377120|NCT01316588|Other|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
377121|NCT01316575|Device|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
377122|NCT01316575|Device|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
377123|NCT01316536|Other|provide headphones with music playing|Participants will be provided with music through headphones
377124|NCT01316536|Other|Sounds|recorded ICU sounds will be provided to participants through headphones
377125|NCT01316523|Drug|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
377126|NCT01316523|Drug|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
377232|NCT01315496|Drug|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
377127|NCT01316510|Dietary Supplement|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
377128|NCT01316510|Other|Placebo|Dilute Nutramigen formula
377129|NCT01316497|Procedure|Remote ischemic preconditioning (RIPC)|RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
377130|NCT01316497|Procedure|Control|The cuff was applied on the leg without inflation in the control group.
377131|NCT01316471|Behavioral|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
377132|NCT01316471|Other|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
377133|NCT01316458|Drug|STI571 (Glivec®)|
377134|NCT01316445|Drug|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
377135|NCT01316432|Drug|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
377136|NCT01316432|Other|Placebo|Placebo will be administered as a 24-hour SQ infusion
377137|NCT01316419|Drug|Telmisartan|Telmisartan 40mg or 80mg
377138|NCT01316419|Drug|amlodipine|amlodipine 5mg or 10mg
377139|NCT01316406|Drug|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
377140|NCT01316393|Other|XER2020|mucoprotective product
377141|NCT01316380|Drug|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
377142|NCT01316380|Drug|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
377143|NCT01316380|Drug|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
377144|NCT01316367|Behavioral|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:~Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.~Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.~Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
377145|NCT01316367|Behavioral|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
377146|NCT01316354|Other|Bread types|Bread with 50 g available carbohydrate
377147|NCT01316341|Drug|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
377148|NCT01316341|Drug|Placebo|patient to receive two placebos
377149|NCT01316341|Drug|Placebo|patient to receive two placebos
377150|NCT01316341|Drug|Placebo|patient to receive two placebos
377151|NCT01316341|Drug|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
377152|NCT01316315|Drug|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
377153|NCT01316315|Drug|Placebo|Same as active
377154|NCT01316302|Drug|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
377155|NCT01316302|Drug|Placebo|Matching placebo, taken QD for 12 weeks.
377156|NCT01316276|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
377157|NCT01316263|Biological|Olaratumab|Administered IV
377158|NCT01316250|Drug|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
377159|NCT01316237|Drug|GS-6620|GS-6620 tablet, 50 mg QD
377160|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD
377161|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD
377162|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
377163|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
377164|NCT01316237|Drug|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
377165|NCT01316237|Drug|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
377168|NCT01316211|Device|Implantation of coflex™ after surgical decompression|The device will be implanted after surgical decompression in patients with spinal stenosis.
377169|NCT01316211|Procedure|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant
377170|NCT01316198|Dietary Supplement|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
377171|NCT01316198|Dietary Supplement|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
377172|NCT01316185|Drug|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
377173|NCT01316172|Behavioral|5 Cs|education on consultation
377174|NCT01316146|Drug|CAR.CD30 T cells|"Three dose levels will be evaluated:~Group One, 2x10^7 cells/m^2~Group Two, 1x10^8 cells/m^2~Group Three, 2x10^8 cells/m^2;~Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
377175|NCT01316133|Drug|tacrolimus|oral
377176|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
377177|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
377178|NCT01316107|Drug|ipragliflozin|oral
377179|NCT01316107|Drug|nateglinide|oral
377180|NCT01316094|Drug|ASP1941|oral
377181|NCT01316094|Drug|placebo|oral
377182|NCT01316081|Dietary Supplement|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg~Placebo Supplements: identical appearing tablets"
377183|NCT01316068|Drug|intravenous use of sulodexide followed by oral use|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
377184|NCT01316068|Drug|use of sulodexide orally only|Patients receive 1000 LSU per day orally for 52 weeks
377185|NCT01316055|Drug|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
377186|NCT01316042|Drug|sugar pill|2 pills per day for 12 months
377187|NCT01316042|Drug|Metformin, glucophage|2 212.5mg pills/day for 12 months
377188|NCT01316029|Procedure|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
377189|NCT01316016|Dietary Supplement|Rose hip|40 g of rose hip powder daily for 6 weeks.
377190|NCT01316003|Other|Optical coherence tomography|Optical coherence tomography
377191|NCT01315990|Drug|FOLFIRI + Cetuximab|"Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).~FOLFIRI regimen~Administration Schedule:~Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)~Irinotecan 180 mg/m² iv , 90 min on day 1~Folic acid (racemic) 400 mg/m², 120 min on day 1~5-FU 400 mg/m² bolus on day 1~5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
377192|NCT01315977|Dietary Supplement|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
377193|NCT01315964|Dietary Supplement|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
377194|NCT01315951|Biological|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
377195|NCT01315938|Drug|Abatacept|abatacept will be given as intravenous infusions at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.
377196|NCT01315938|Drug|Abatacept|Subjects will be treated with abatacept for 6 months and receive a total of up to 7 doses (intravenous infusions) the infusions will be given with the following intervals: at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.
377197|NCT01315912|Drug|Letrozole|2.5 mg /day for 5 days
377198|NCT01315899|Drug|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
377199|NCT01315899|Drug|ORM-12471|Given as a single dose once during the study as per Williams crossover design
377200|NCT01315899|Drug|placebo|Given once as a single dose during the study as per Williams crossover design
377201|NCT01315886|Drug|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
377202|NCT01315873|Drug|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m^2 after bortezomib . Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
377265|NCT01315210|Drug|D-Ribose Powder|5 g TID for 12 Weeks
377266|NCT01315210|Dietary Supplement|Placebo Powder|5 g TID for 12 Weeks
377267|NCT01315197|Other|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
377203|NCT01315873|Drug|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m^2 followed by bendamustine given at 90 mg/m^2. Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.~Patients will be treated until disease progression after at least one cycle of treatment."
377204|NCT01315860|Other|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
377205|NCT01315847|Drug|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
377206|NCT01315847|Drug|[11C]MK-4232|Single intravenous doses of ~300 MBq [11C]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
377207|NCT01315821|Drug|Saccharomyces boulardii|5 million units/day for 3 months
377208|NCT01315821|Drug|Placebo|Placebo for 3 months
377209|NCT01315795|Drug|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
377210|NCT01315756|Device|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
377211|NCT01315756|Device|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
377212|NCT01315743|Behavioral|Team COOL|1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
377213|NCT01315730|Device|Tactile Stimulation|See Arms
377214|NCT01315704|Drug|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
377215|NCT01315691|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
377216|NCT01315691|Drug|Placebo for liposomal amikacin for inhalation|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are the same as for Arikace™.~Placebo will be administered for 28 days."
377217|NCT01315678|Drug|Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
377218|NCT01315678|Drug|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.~Nebulization time is approximately 20 minutes for each administration.~Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
377219|NCT01315665|Dietary Supplement|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
377220|NCT01315652|Behavioral|Comorbidities treatment|" Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up"
377221|NCT01315652|Behavioral|Auto-DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
377222|NCT01315639|Biological|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
377223|NCT01315626|Other|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
377224|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"3 pulses at 50Hz repeated each 200 ms for 2 seconds~80% MT~20 days treatment"
377225|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
377226|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
377227|NCT01315574|Drug|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
377228|NCT01315574|Drug|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
377229|NCT01315561|Other|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
377230|NCT01315522|Device|ComVi stent|Endoscopic insertion of ComVi stent
377231|NCT01315522|Device|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
377233|NCT01315483|Other|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
377234|NCT01315470|Drug|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
377235|NCT01315444|Drug|Stop PPI gradually|
377236|NCT01315444|Drug|Stop PPI gradually|
377237|NCT01315431|Drug|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.~At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
377238|NCT01315418|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
377239|NCT01315418|Other|2-Non fermented dairy product (control)|
377240|NCT01315405|Behavioral|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease~+ 20 paired healthy volunteers (on sex, age, and education)~After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)~Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
377241|NCT01315392|Procedure|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
377242|NCT01315392|Procedure|immediate wound closure|traumatic and surgical wounds closed at the initial surgical intervention
377243|NCT01315379|Behavioral|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
377244|NCT01315366|Dietary Supplement|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
377245|NCT01315366|Dietary Supplement|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
377246|NCT01315353|Procedure|Cervical Cryotherapy|Participants had cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
377247|NCT01315353|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Loop Electrosurgical Excision Procedure (LEEP): Participants found to have CIN2+ by biopsy had LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
377248|NCT01315340|Procedure|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
377249|NCT01315327|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
377250|NCT01315327|Drug|Olive oil|Placebo
377251|NCT01315314|Drug|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
377252|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
377253|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
377254|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
377255|NCT01315288|Other|One of 6 video presentation by one of 4 presenters|
377256|NCT01315275|Drug|Ranibizumab|
377257|NCT01315262|Drug|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
377258|NCT01315249|Drug|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
377259|NCT01315249|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
377260|NCT01315249|Drug|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
377261|NCT01315249|Drug|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
377262|NCT01315236|Drug|Liposomal amikacin for inhalation (LAI)|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.~590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.~Administration time is approximately 13 minutes.~Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.~Subjects can continue with 84 additional days of dosing in the open label extension."
377263|NCT01315236|Drug|placebo|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.~Administration procedures, volume and administration time are similar to LAI.~Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
377264|NCT01315223|Other|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
377268|NCT01315184|Behavioral|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.~The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
377269|NCT01315171|Dietary Supplement|Medium chain triglycerides|4 tablespoons/day for 2 weeks
377270|NCT01315158|Drug|Propofol Alone|"Recommended Propofol doses before considering crossover:~Induction: 2-2.5 mg/kg~Maintenance: 0.1-0.2 mg/kg/min"
377271|NCT01315158|Drug|Propofol+Benzo/Opioids|"Recommended Versed:~a. Prior to intubation~patient is < 50 kg = 1 mg Versed~patient is 50-75 kg = 1.5 mg Versed~patient is > 75 kg = 2 mg Versed~Recommended Fentanyl~Prior to intubation = 0.5 ug/kg~Total procedural dose = 1 ug/kg"
377272|NCT01315145|Procedure|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
377273|NCT01315145|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
377274|NCT01315132|Device|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
377275|NCT01315119|Procedure|SPY Intra-Operative Angiography|Calculated per patient
377276|NCT01315106|Device|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
377277|NCT01315093|Drug|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
377278|NCT01315093|Drug|no heparin|
377279|NCT01315054|Behavioral|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
377280|NCT01315054|Behavioral|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
377281|NCT01315054|Other|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
377282|NCT01315041|Drug|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
377283|NCT01315041|Drug|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
377284|NCT01315028|Other|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
377285|NCT01315028|Other|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
377286|NCT01315015|Other|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
377287|NCT01315002|Drug|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
377288|NCT01315002|Drug|Placebo patch|Placebo patch
377289|NCT01314989|Drug|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
377290|NCT01314989|Drug|Sugar pill|liquid placebo
377291|NCT01314976|Drug|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.~1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
377292|NCT01314976|Drug|Placebo|"Placebo.~1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.~Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
377293|NCT01314963|Device|Prototype intraoperative handheld gamma camera (pIHGC)|The prototype intraoperative handheld gamma camera (pIHGC) consists of a parallel-hole lead collimator coupled to a pixilated sodium iodide-thallium [NaI(Tl)] scintillation crystal array, itself coupled to a flat panel, multi-anode Hamamatsu H8500 position-sensitive photomultiplier tube. The collimator is 5x5 cm2 large in area and 1.5 cm thick, with 1.3 mm hexagonal holes and 0.2 mm septa. The 1.7 mm pitch crystal array is composed of 29x29 individual crystals, each 1.5x1.5x6 mm3 in size.
377294|NCT01314963|Device|Lymphoscintigraphy with intraoperative gamma probes (GP)|Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)
377295|NCT01314963|Radiation|radioactive Tc99M|Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
377296|NCT01314950|Behavioral|Home based occupational therapy|"An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with homework each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs."
377297|NCT01314950|Behavioral|Best practices primary care|Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
377298|NCT01314937|Drug|Mebendazole|Single-dose 500 mg mebendazole tablet
377299|NCT01314937|Other|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
377300|NCT01314924|Dietary Supplement|Dark chocolate|70% cocoa
377301|NCT01314911|Drug|Oseltamivir|Subjects were prescribed Oseltamivir twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
377959|NCT01309646|Biological|Synflorix™|Intramuscular, 3 doses
377302|NCT01314911|Drug|Placebo|Subjects were prescribed the matching placebo twice daily for 5 days, and each dose consisted of one capsule of placebo.
377303|NCT01314898|Drug|3 mg PF-03882845|3 mg PF-03882845, single oral dose
377304|NCT01314898|Drug|10 mg PF-03882845|10 mg PF-03882845, single oral dose
377305|NCT01314898|Drug|30 mg PF-03882845|30 mg PF-03882845, single oral dose
377306|NCT01314898|Drug|100 mg PF-03882845|100 mg PF-03882845, single oral dose
377307|NCT01314898|Drug|Spironolactone|100 mg spironolactone, single oral dose
377308|NCT01314885|Drug|PF-03715455|20mg, Inhaled, single dose
377309|NCT01314885|Drug|PH-797804|30mg, Oral, single dose
377310|NCT01314885|Drug|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
377311|NCT01314885|Drug|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
377312|NCT01314872|Drug|Vibegron|Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
377313|NCT01314872|Drug|Tolterodine ER|Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
377314|NCT01314872|Drug|Placebo matching vibegron|Participants received placebo matching vibegron tablets, taken orally each morning.
377315|NCT01314872|Drug|Placebo matching tolterodine ER|Participants received placebo matching tolterodine ER capsule, taken orally each morning.
377316|NCT01314859|Drug|Nifedipine|"Oral Treatment with Nifedipine capsules (10mg)~Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~Maximum Duration of the treatment: 48 hours."
377317|NCT01314859|Drug|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)~Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~Maximum Duration of the treatment: 48 hours."
377318|NCT01314833|Drug|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide600 mg/m² D1~1 cycle = 21 days~TC*6"
377319|NCT01314833|Drug|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days 4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF*3-T*3"
377320|NCT01314833|Drug|Epirubicin Cyclophosphamide Paclitaxel|"1st -4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days 5th-8th Cycle: Paclitaxel 80mg/m² D1，8，15~1 cycle = 21 days EC*4-P*4"
377321|NCT01314820|Other|normal saline injection|20 cc normal saline injection into knee joint
377322|NCT01314820|Other|sham injection|no saline injection
377323|NCT01314781|Drug|solifenacin|solifenacin 5mg tablet once daily
377324|NCT01314781|Procedure|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
377325|NCT01314768|Behavioral|Brief intervention|Structured behavioural Brief intervention given by trained GPs
377326|NCT01314768|Other|Business as usual|GPs to treat patient as they have until now based on best established practice
377327|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
377328|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
377329|NCT01314755|Dietary Supplement|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an `immune-enhancing` feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
377330|NCT01314755|Dietary Supplement|An iso-caloric, iso-nitrogenous control feed|
377331|NCT01314742|Drug|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
377332|NCT01314742|Other|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
377333|NCT01314729|Device|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
377334|NCT01314729|Device|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
377335|NCT01314716|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
377336|NCT01314716|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
377337|NCT01314703|Drug|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
377338|NCT01314703|Drug|70% isopropyl alcohol|10.5 ml applicator
377339|NCT01314690|Other|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
377340|NCT01314677|Procedure|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
377341|NCT01314677|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
377342|NCT01314651|Behavioral|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
377343|NCT01314651|Behavioral|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
377344|NCT01314638|Other|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
377345|NCT01314612|Behavioral|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
377346|NCT01314599|Drug|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.~Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
377347|NCT01314586|Dietary Supplement|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
377348|NCT01314573|Behavioral|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
377349|NCT01314573|Behavioral|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
377350|NCT01314560|Other|Blood sample|Blood sample
377351|NCT01314508|Drug|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
377352|NCT01314495|Drug|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
377353|NCT01314495|Drug|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
377354|NCT01314482|Drug|Minocycline|200mg bd for 3 days before surgery
377355|NCT01314456|Device|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
377356|NCT01314443|Other|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
377357|NCT01314443|Dietary Supplement|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
377358|NCT01314443|Other|Placebo|Participants will take placebo for 7 days
377359|NCT01314443|Behavioral|Smoking cessation|Participants will quit smoking without any pharmacological aids
377360|NCT01314417|Drug|Methotrexate|400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
377361|NCT01314391|Genetic|mutation analysis|
377362|NCT01314391|Genetic|polymerase chain reaction|
377363|NCT01314391|Other|laboratory biomarker analysis|
377364|NCT01314378|Behavioral|Mindfulness Training|Eight session intensive behavioral training program for smokers
377365|NCT01314378|Behavioral|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
377366|NCT01314352|Drug|Desloratadine|Desloratadine Tablets, 5 mg
377367|NCT01314339|Drug|Desloratadine|Desloratadine Tablets, 5 mg
377368|NCT01314313|Device|TAVR Implantation with SAPIEN XT|Operable Group with SAPIEN XT
377369|NCT01314313|Device|SAVR Implantation|Control Group
377370|NCT01314300|Drug|Lidocaine|Lidocaine 5% plaster
377371|NCT01314274|Drug|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
377372|NCT01314274|Drug|NaCl|10ml of 0.9% NaCl intranasal submucosal
377373|NCT01314261|Drug|ABT-267|5 mg or 25 mg tablets
377374|NCT01314261|Drug|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
377375|NCT01314261|Drug|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
377376|NCT01314261|Other|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
377377|NCT01314248|Device|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
377378|NCT01314222|Drug|BMS-954561|
377379|NCT01314222|Drug|Pregabalin|
377380|NCT01314222|Drug|Placebo matching BMS-954561|
377381|NCT01314222|Drug|Placebo matching Pregabalin|
377382|NCT01314209|Drug|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
377383|NCT01314196|Other|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
377384|NCT01314196|Other|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
377385|NCT01314183|Other|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
377386|NCT01314183|Other|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
377387|NCT01314170|Device|Susanna Implant|device
377388|NCT01314157|Other|Isostretching|12 interventions (two times per week) for 45 minutes
377389|NCT01314144|Drug|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
377425|NCT01313884|Drug|Doxorubicin|Starting dose 75 mg/m2 to a maximum of 450mg/m2
377426|NCT01313884|Drug|Cytoxan|1200 mg/m2
377427|NCT01313884|Drug|Pegfilgrastim|6 mg subcutaneous within 24 to 48 hours after each Regimen A cycle
377428|NCT01313858|Drug|Simponi®|
377429|NCT01313858|Drug|Methotrexate|Given concomitantly with Simponi®
377390|NCT01314131|Behavioral|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :~a cognitive and behaviour assessment : MMSE, BREF, NPI, IA~an interest questionnaire for patients. It contains 40 questions about activities.~the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
377391|NCT01314118|Drug|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
377392|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
377393|NCT01314105|Drug|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
377394|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
377395|NCT01314092|Biological|Autologous cultured adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
377396|NCT01314092|Biological|Autologous cultured adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
377397|NCT01314066|Drug|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
377398|NCT01314066|Drug|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
377399|NCT01314040|Other|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
377400|NCT01314040|Other|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
377401|NCT01314040|Other|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
377402|NCT01314040|Other|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
377403|NCT01314027|Drug|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|"Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months."
377404|NCT01314027|Drug|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
377405|NCT01314014|Drug|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
377406|NCT01314001|Drug|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
377407|NCT01314001|Drug|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally~Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
377408|NCT01314001|Drug|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
377409|NCT01313988|Dietary Supplement|Plant sterols and fish oil|4 weeks intervention, 3 times daily
377410|NCT01313988|Dietary Supplement|Plant sterols|4 weeks intervention, 3 times daily
377411|NCT01313988|Dietary Supplement|Placebo|4 weeks, 3 times daily
377412|NCT01313962|Drug|Flufirvitide-3 0.05 mg single dose|Nasal Spray
377413|NCT01313962|Drug|Flufirvitide-3, 0.1 mg single dose|Nasal spray
377414|NCT01313962|Drug|Flufirvitide-3, 0.2 mg single dose|nasal spray
377415|NCT01313962|Drug|Flufirvitide-3, 0.4 mg single dose|Nasal spray
377416|NCT01313962|Other|Placebo|Nasal spray
377417|NCT01313949|Other|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors.
377418|NCT01313936|Drug|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
377419|NCT01313923|Drug|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
377420|NCT01313910|Dietary Supplement|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
377421|NCT01313897|Drug|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
377422|NCT01313884|Drug|Irinotecan|50 mg/m2/day x 5 days
377423|NCT01313884|Drug|Vincristine|2 mg/m2 to a maximum of 2 mg
377424|NCT01313884|Drug|Temozolomide|100 mg/m2/day x 5 days followed by 2 weeks treatment-free
377430|NCT01313845|Drug|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
377431|NCT01313845|Drug|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
377432|NCT01313832|Other|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
377433|NCT01313819|Drug|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
377434|NCT01313806|Device|Resonator|Treatment group vs. Placebo group
377435|NCT01313806|Device|Placebo|Inactive Resonator Device
377436|NCT01313793|Drug|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
377437|NCT01313793|Drug|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
377438|NCT01313780|Drug|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
377439|NCT01313780|Drug|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
377440|NCT01313767|Drug|Botulinum toxin type A|Botulinum toxin type A
377441|NCT01313767|Drug|Botulinum Toxin type A|Botulinum Toxin type A
377442|NCT01313754|Procedure|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
377443|NCT01313754|Procedure|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
377444|NCT01313741|Device|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
377445|NCT01313728|Drug|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
377446|NCT01313728|Drug|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
377447|NCT01313715|Biological|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
377448|NCT01313715|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
377449|NCT01313715|Biological|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
377450|NCT01313715|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
377451|NCT01313702|Drug|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
377452|NCT01313702|Drug|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
377453|NCT01313702|Drug|usual care|the drugs used in clinical practice, defined by physician
377454|NCT01313689|Drug|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
377455|NCT01313689|Drug|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
377456|NCT01313676|Drug|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
377457|NCT01313676|Drug|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
377458|NCT01313676|Drug|vilanterol|25mcg given once daily via novel dry powder inhaler
377459|NCT01313676|Other|Placebo|placebo comparator once daily via novel dry powder inhaler
377460|NCT01313663|Drug|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
377461|NCT01313663|Drug|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
377462|NCT01313650|Drug|62.5/25mcg|GSK573719/GW64244
377463|NCT01313650|Drug|62.5mcg|GSK573719
377464|NCT01313650|Drug|25mcg|GW642444
377465|NCT01313650|Drug|Placebo|Placebo
377466|NCT01313637|Drug|GSK573719/GW642444 125/25mcg|125/25mcg
377467|NCT01313637|Drug|GSK573719 125mcg|125mcg
377468|NCT01313637|Drug|GW642444 25mcg|25mcg
377469|NCT01313637|Drug|Placebo only|Placebo
377470|NCT01313624|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
377471|NCT01313624|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
377472|NCT01313611|Drug|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
377473|NCT01313598|Drug|GLPG0187|continuous IV infusion
377474|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
377475|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
377476|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
377477|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
377478|NCT01313572|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
377479|NCT01313572|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
377480|NCT01313559|Drug|Pasireotide|Given IM
377481|NCT01313559|Drug|Everolimus|Given PO
377482|NCT01313559|Other|Laboratory biomarker analysis|Correlative studies
377483|NCT01313546|Other|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
377484|NCT01313533|Drug|Polyarginine|Vein soak treated with polyarginine
377485|NCT01313533|Drug|Vein soak treated with Lactated Ringers Solution|Vein soak
377486|NCT01313520|Drug|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
377487|NCT01313520|Drug|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
377488|NCT01313507|Biological|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
377489|NCT01313494|Drug|Roflumilast|Roflumilast tablets
377490|NCT01313494|Drug|Placebo|Placebo tablets
377491|NCT01313494|Drug|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
377492|NCT01313481|Behavioral|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
377493|NCT01313481|Behavioral|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
377494|NCT01313468|Behavioral|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
377495|NCT01313468|Behavioral|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
377496|NCT01313468|Behavioral|Moderate continuous Training|47 minutes of Moderate continuous Training
377497|NCT01313429|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
377498|NCT01313429|Biological|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
377499|NCT01313429|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
377500|NCT01313416|Biological|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
377501|NCT01313416|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
377502|NCT01313403|Other|Antidepressant (SSRI)|
377503|NCT01313390|Drug|docetaxel|
377504|NCT01313390|Drug|everolimus|
377505|NCT01313390|Other|laboratory biomarker analysis|
377506|NCT01313390|Other|pharmacological study|
377507|NCT01313377|Drug|gemcitabine hydrochloride|
377508|NCT01313377|Drug|oxaliplatin|
377509|NCT01313377|Other|clinical observation|
377510|NCT01313377|Procedure|adjuvant therapy|
377511|NCT01313377|Procedure|quality-of-life assessment|
377512|NCT01313364|Device|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
377513|NCT01313325|Other|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
377514|NCT01313312|Biological|Botulinum toxin type A|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.~Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
377515|NCT01313299|Biological|Botulinum toxin type A|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
377516|NCT01313299|Biological|Botulinum toxin type A|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
377517|NCT01313299|Drug|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
377518|NCT01313286|Drug|LY2608204 Reference|Administered orally
377519|NCT01313286|Drug|LY2608204 Test|Administered orally.
377520|NCT01313273|Drug|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.~Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
377521|NCT01313273|Drug|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
377522|NCT01313247|Drug|paracetamol|1000 mg 4 times daily
377523|NCT01313247|Drug|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
377524|NCT01313234|Behavioral|Education|Theory based education and systematic daily assessment
377525|NCT01313221|Biological|etanercept|Administered by subcutaneous injection
377526|NCT01313221|Drug|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:~hydrocortisone 2.5%~betamethasone valerate 0.1%~betamethasone dipropionate 0.05%~clobetasol 0.05%~calcitriol~calcipotriol plus betamethsone dipropionate 0.05%"
377527|NCT01313208|Drug|etanercept|Administered by subcutaneous injection once weekly.
377528|NCT01313208|Drug|Placebo|Placebo subcutaneous injection
377529|NCT01313208|Drug|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
377530|NCT01313182|Drug|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
377960|NCT01309646|Biological|Rotarix™|Oral, 2 doses
377531|NCT01313182|Drug|Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
377532|NCT01313169|Other|EMR Reminder|EMR reminders displayed
377533|NCT01313169|Other|EMR Reminder + Panel management|EMR Reminder + Panel management
377534|NCT01313143|Drug|AOP200704|Comparison of AOP200704 with Esmolol
377535|NCT01313143|Drug|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
377536|NCT01313117|Drug|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
377537|NCT01313104|Procedure|colposcopy|Undergo colposcopy
377538|NCT01313104|Other|cervical Papanicolaou test|Undergo cervical Pap smear
377539|NCT01313104|Procedure|screening method|Undergo anal Pap smear
377540|NCT01313104|Procedure|screening method|Undergo high resolution anoscopy
377541|NCT01313078|Drug|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
377542|NCT01313065|Drug|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
377543|NCT01313052|Behavioral|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
377544|NCT01313052|Behavioral|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
377545|NCT01313039|Drug|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
377546|NCT01313026|Procedure|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
377547|NCT01313013|Behavioral|question prompt sheet|
377548|NCT01313000|Procedure|Autologous fat transfer|Autologous fat transfer from abdomen to upper arms
377549|NCT01312987|Dietary Supplement|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
377550|NCT01312961|Drug|Dupilumab|Solution for injection, one subcutaneous injection.
377551|NCT01312961|Drug|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
377552|NCT01312961|Drug|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
377553|NCT01312961|Drug|Fluticasone monotherapy|Oral inhalation twice daily.
377554|NCT01312961|Drug|Albuterol|Oral inhalation as needed.
377555|NCT01312961|Drug|Levalbuterol|Oral inhalation as needed.
377556|NCT01312948|Device|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
377557|NCT01312935|Drug|PMX-60056|investigational drug
377558|NCT01312922|Drug|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
377559|NCT01312922|Drug|Citalopram|oral once daily administration
377560|NCT01312922|Drug|Pipamperone|oral once daily administration
377561|NCT01312909|Drug|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
377562|NCT01312909|Drug|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
377563|NCT01312909|Drug|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
377564|NCT01312883|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
377565|NCT01312870|Dietary Supplement|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
377566|NCT01312870|Other|standard hospital diet|standard hospital diet
377567|NCT01312857|Drug|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
377568|NCT01312857|Drug|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.~All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
377569|NCT01312844|Drug|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
377570|NCT01312831|Other|Vitamin B12 (cyanocobalamin)|
377571|NCT01312818|Drug|Bortezomib|1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
377572|NCT01312818|Drug|Vorinostat|180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
377573|NCT01312818|Drug|Dexamethasone|6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.
377574|NCT01312818|Drug|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
377575|NCT01312818|Drug|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:~Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16."
377576|NCT01312805|Other|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
377577|NCT01312805|Other|CHICA Control|This is CHICA without the asthma module, and was used as a control
377578|NCT01312792|Other|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
377579|NCT01312792|Other|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
377580|NCT01312779|Device|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
377581|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
377582|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
377583|NCT01312740|Other|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
377584|NCT01312740|Other|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
377585|NCT01312727|Other|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
377586|NCT01312714|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
377587|NCT01312714|Drug|Placebo|3 tablets of 1000 IU daily for 26 weeks
377588|NCT01312688|Other|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
377589|NCT01312675|Device|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
377590|NCT01312649|Behavioral|Experimental psychology methods (computer tests)|
377591|NCT01312636|Drug|activated recombinant human factor VII|Data will be collected at the baseline visit and approximately once a year until end of study.
377592|NCT01312623|Other|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
377593|NCT01312610|Dietary Supplement|High flavanone orange juice|High flavonone orange juice drink.
377594|NCT01312610|Dietary Supplement|Control orange juice|Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
377595|NCT01312597|Other|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
377596|NCT01312584|Dietary Supplement|Processed High-flavanol|
377597|NCT01312571|Behavioral|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
377598|NCT01312571|Behavioral|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
377599|NCT01312558|Behavioral|Prudent diet group|
377600|NCT01312558|Behavioral|Mediterranean diet group|
377601|NCT01312545|Device|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
377602|NCT01312545|Device|Medpor|commercial porous polyethylene
377603|NCT01312532|Device|fixed-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson & Johnson, Leeds, UK
377604|NCT01312532|Device|mobile-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson & Johnson, Leeds, UK
377605|NCT01312519|Device|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
377606|NCT01312519|Device|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
377607|NCT01312493|Drug|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
377608|NCT01312493|Radiation|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
377609|NCT01312480|Other|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:~Ask if the patient smokes.~Advise every patient to quit.~Assess readiness to quit.~Assist in quitting and finding services.~Arrange for cessation services and follow-up."
377610|NCT01312480|Other|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
377611|NCT01312467|Drug|metformin hydrochloride|
377612|NCT01312454|Drug|AL-59412C injectable solution|Concentration 1 and Concentration 2
377613|NCT01312454|Drug|Travoprost injectable solution|
377614|NCT01312454|Drug|AL-59412C Vehicle|Inactive ingredients used as placebo
377615|NCT01312441|Drug|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
377616|NCT01312441|Drug|Placebo|Placebo by mouth once weekly for 6 months
377617|NCT01312428|Device|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
377618|NCT01312428|Device|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
377710|NCT01311661|Drug|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
377711|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
377619|NCT01312415|Drug|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
377620|NCT01312415|Drug|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
377621|NCT01312402|Drug|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
377622|NCT01312402|Drug|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
377623|NCT01312389|Biological|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
377624|NCT01312389|Biological|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
377625|NCT01312389|Biological|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
377626|NCT01312376|Biological|OC-DC vaccine|All subjects will receive a dose of 5-10 million cells of OC-DC intradermally
377627|NCT01312376|Drug|Bevacizumab|Patients will start receiving Bevacizumab at 15 mg/kg starting Day 30 and every 4 weeks thereafter until end of study.
377628|NCT01312376|Drug|cyclophosphamide 300 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous cyclophosphamide for 300 mg/m2/d for 3 days.
377629|NCT01312376|Drug|fludarabine 30 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous fludarabine 30 mg/m2/d for 3 days
377630|NCT01312376|Drug|ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells|All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109 (10-15 billion) T-cells with escalating doses in cohort 2 and 3.
377631|NCT01312363|Drug|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
377632|NCT01312350|Drug|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
377633|NCT01312350|Drug|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
377634|NCT01312337|Drug|salvage iressa|Iressa 250mg per day until progression
377635|NCT01312324|Drug|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
377636|NCT01312311|Drug|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1
377637|NCT01312298|Procedure|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
377638|NCT01312298|Procedure|Regional anesthesia|Patients will receive intrathecal anesthesia
377639|NCT01312285|Device|Resonator device|low level magnetic fields
377640|NCT01312272|Drug|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
377641|NCT01312272|Drug|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
377642|NCT01312259|Other|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
377643|NCT01312246|Device|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
377644|NCT01312233|Other|Medical Care|Participants allocated to all three treatment groups receive medical care over a 12‐week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self‐management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti‐inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.
377645|NCT01312233|Other|Dual Care|Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12‐week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity‐low amplitude or low velocity‐variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
377646|NCT01312233|Other|Shared Care|Participants allocated to Shared Care receive co‐managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
377712|NCT01311661|Drug|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
377647|NCT01312194|Procedure|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
377648|NCT01312194|Procedure|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
377649|NCT01312181|Behavioral|HealthCall and Motivational Interviewing|Patients access HealthCall by calling a toll-free number and putting a four-digit Personal Identification Number (PIN). The HealthCall system will then ask a short script of pre-recorded questions in English or Spanish, on substance use and other variables (e.g., medication adherence, unprotected sex, feeling of physical well-being, stress, etc). The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
377650|NCT01312181|Behavioral|Motivational Interviewing (MI)|The MI session focuses on reduce ambivalence and increase motivation to reduce non-injection drug use (NIDU), gain a commitment to change, if possible, and ultimately to reduce or eliminate NIDU. The intervention includes: a) identifying pros and cons of using and stopping; b) exploring ambivalence about stopping NIDU; c) eliciting change talk
377651|NCT01312181|Behavioral|HIV/AIDS health education|The purpose of this condition is to control for clinical attention associated with Motivational Interviewing (MI)participation, and to provide an analogue of standard care, i.e. brief advice but no other intervention.
377652|NCT01312168|Device|Therapeutic CPAP|CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
377653|NCT01312168|Device|Subtherapeutic CPAP|Subtherapeutic CPAP ventilator, pressure <3 cmH2O, daily use at sleep, six months
377654|NCT01312155|Other|Intubation|Intubation, endotracheal
377655|NCT01312129|Drug|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
377656|NCT01312129|Drug|Placebo|Placebo capsule x 3 doses 12 hours apart
377657|NCT01312116|Behavioral|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
377658|NCT01312116|Behavioral|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
377659|NCT01312103|Behavioral|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:~Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.~Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.~Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
377660|NCT01312103|Behavioral|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:~Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.~A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
377661|NCT01312090|Biological|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (−30°Cand−60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
377662|NCT01312090|Behavioral|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
377663|NCT01312077|Drug|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
377664|NCT01312077|Drug|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
377665|NCT01312064|Drug|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
377666|NCT01312064|Drug|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
377667|NCT01312038|Drug|Simethicone|single 125 mg chewable tablet
377668|NCT01312038|Drug|Placebo|chewable calcium tablet
377669|NCT01312025|Procedure|conventional laparoscopic cholecystectomy|
377670|NCT01312025|Procedure|modified laparoscopic cholecystectomy|
377713|NCT01311661|Drug|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
377750|NCT01311284|Device|Macintosh laryngoscope|intubate with the macintosh laryngoscope
377671|NCT01312012|Drug|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level > 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
377672|NCT01311960|Drug|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
377673|NCT01311960|Drug|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
377674|NCT01311947|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
377675|NCT01311908|Procedure|Methods of gastrojejunostomy reconstruction|Roux-en-Y reconstruction in pancreaticoduodenectomy
377676|NCT01311895|Drug|H2O|2 mg IV hydromorphone
377677|NCT01311895|Drug|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
377678|NCT01311882|Drug|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
377679|NCT01311882|Drug|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
377680|NCT01311882|Drug|Zopiclone|1 x 7.5 mg Zopiclone tablet
377681|NCT01311882|Drug|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
377682|NCT01311882|Drug|Matching Placebo for MK-4305|Matching Placebo for MK-4305
377683|NCT01311869|Dietary Supplement|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
377684|NCT01311869|Dietary Supplement|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
377685|NCT01311856|Behavioral|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
377686|NCT01311856|Behavioral|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
377687|NCT01311856|Behavioral|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
377688|NCT01311856|Behavioral|Exercise and Diet|15 minutes of strength exercise every other day, >30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
377689|NCT01311830|Behavioral|Telephone Counseling|
377690|NCT01311830|Behavioral|Written Materials|
377691|NCT01311817|Biological|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
377692|NCT01311804|Procedure|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
377693|NCT01311804|Procedure|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
377694|NCT01311791|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
377695|NCT01311791|Drug|Standard medical therapy|as defined per protocol
377696|NCT01311778|Drug|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.~Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
377697|NCT01311778|Drug|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
377698|NCT01311765|Other|Duration of antibiotic therapy limited to 8 days|Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
377699|NCT01311752|Procedure|surgical management of high grade lesions|"Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.~Surgical sample will be collected to study human papillomavirus related genital pathology."
377700|NCT01311739|Drug|Cyanocobalamin|
377701|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Dose escalation will proceed until the MTD is identified.
377702|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Patients will be administered CEP-9722 at the MTD identified in Part 1.
377703|NCT01311700|Drug|Injectable (i.v.) metoprolol tartrate (up to 15 mg).|"Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).~Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.~Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.~Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion."
377704|NCT01311687|Drug|pomalidomide|4 mg pomalidomide capsules administered orally
377705|NCT01311687|Drug|Dexamethasone|40 mg dexamethasone (or 20 mg for participants > 75 years of age) tablets administered orally
377706|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 20 ug/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 ug/1.0 mL
377707|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 40 ug/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 ug/1.0 mL
377708|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
377709|NCT01311661|Drug|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
377714|NCT01311648|Biological|Recombinant Factor VIII (Kovaltry, BAY81-8973)|PTPs prophylaxis treatment: 25-50 IU/kg at least 2x/week. PUPs/MTPs: 15 -50 IU/kg at least 1x/week.
377715|NCT01311635|Drug|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
377716|NCT01311635|Drug|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
377717|NCT01311635|Drug|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
377718|NCT01311622|Drug|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
377719|NCT01311622|Drug|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
377720|NCT01311609|Other|Systane|Systane Lubricant Eye Drops [1-2 Drops in each eye four times daily (QID)]
377721|NCT01311596|Other|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
377722|NCT01311583|Behavioral|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
377723|NCT01311570|Drug|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.~From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
377724|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
377725|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
377726|NCT01311531|Procedure|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
377727|NCT01311531|Procedure|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
377728|NCT01311518|Drug|Drug: Placebo|Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
377729|NCT01311518|Drug|Drug: Injectable Thymosin beta 4|Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
377730|NCT01311505|Drug|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
377731|NCT01311505|Drug|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
377732|NCT01311492|Behavioral|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
377733|NCT01311492|Behavioral|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
377734|NCT01311479|Procedure|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.~Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
377735|NCT01311466|Procedure|Liver transplantation|
377736|NCT01311440|Other|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
377737|NCT01311427|Behavioral|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
377738|NCT01311427|Behavioral|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
377739|NCT01311414|Drug|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
377740|NCT01311401|Other|NONE intervention|NONE intervention
377741|NCT01311375|Dietary Supplement|w3 supplement in SCI|"supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group"
377742|NCT01311375|Other|placebo|placebo+ capsule CA-D
377743|NCT01311362|Drug|St. Johns wort|"Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20~Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
377744|NCT01311336|Drug|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
377745|NCT01311336|Drug|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
377746|NCT01311323|Procedure|PCI|Percutaneous Coronary Intervention
377747|NCT01311323|Procedure|CABG|Coronary Artery Bypass Graft
377748|NCT01311310|Other|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
377749|NCT01311284|Device|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
377752|NCT01311284|Device|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
377753|NCT01311271|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,~Real: unaffected M1 hotspot~Sham: coil perpendicular to scalp"
377754|NCT01311245|Behavioral|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
377755|NCT01311245|Behavioral|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
377756|NCT01311219|Other|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
377757|NCT01311219|Procedure|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
377758|NCT01311219|Procedure|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
377759|NCT01311206|Other|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
377760|NCT01311206|Other|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
377761|NCT01311193|Other|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
377762|NCT01311180|Drug|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
377763|NCT01311180|Drug|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
377764|NCT01311167|Drug|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
377765|NCT01311167|Drug|Placebo|Daily administration of 2 mg of placebo for 4 days
377766|NCT01311141|Drug|doripenem|doripenem once i.v.500mg
377767|NCT01311128|Device|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This procedure will be repeated, for a second two-hour period, in the ICU postoperatively.
377768|NCT01311115|Behavioral|Group commitment contract|"Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.~The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.~Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
377769|NCT01311115|Behavioral|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
377770|NCT01311102|Drug|Lidocaine|1.33 cc 2% liquid lidocaine
377771|NCT01311102|Drug|Normal Saline|1.33cc normal saline
377772|NCT01311076|Drug|TAK-329|TAK-329 50 mg, tablets, orally, single dose, one day.
377773|NCT01311076|Drug|TAK-329|TAK-329 200 mg, tablets, orally, single dose, one day.
377774|NCT01311076|Drug|Insulin|Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
377775|NCT01311076|Drug|Placebo|TAK-329 placebo-matching tablets, orally, single dose, one day.
377776|NCT01311050|Drug|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
377777|NCT01311037|Other|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
377778|NCT01311024|Biological|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
377779|NCT01311024|Biological|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
377780|NCT01311011|Procedure|SCT|SCT
377782|NCT01310985|Drug|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
377783|NCT01310972|Other|Registry|Registry
377784|NCT01310959|Other|Database|Database
377785|NCT01310946|Other|Database|Database
377786|NCT01310920|Other|observation|genotyping
377787|NCT01310894|Drug|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
377788|NCT01310881|Drug|NSI-189 Phosphate|Once daily oral administration
377789|NCT01310868|Drug|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
377790|NCT01310868|Drug|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
377791|NCT01310868|Radiation|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
377792|NCT01310868|Drug|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
377793|NCT01310868|Drug|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
377794|NCT01310855|Drug|cediranib maleate|
377795|NCT01310855|Drug|gefitinib|
377796|NCT01310855|Drug|Placebo|
377797|NCT01310842|Behavioral|Questionnaires|Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
377798|NCT01310842|Drug|Nicotine Patch Therapy|4 weeks of nicotine patch therapy
377799|NCT01310842|Behavioral|Counseling Sessions|5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
377800|NCT01310829|Behavioral|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
377801|NCT01310829|Behavioral|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
377802|NCT01310829|Behavioral|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
377803|NCT01310816|Drug|IPI-926|Oral
377804|NCT01310816|Drug|Placebo Arm|oral placebo
377805|NCT01310803|Drug|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
377806|NCT01310803|Other|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
377807|NCT01310790|Procedure|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|"Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was >30%.~Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.~Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain."
377808|NCT01310777|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
377809|NCT01310777|Drug|Brinzolamide 1% ophthalmic suspension|
377810|NCT01310777|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
377811|NCT01310764|Procedure|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
377812|NCT01310751|Drug|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
377813|NCT01310751|Drug|distilled water|2 ml per session
377814|NCT01310738|Drug|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
377815|NCT01310738|Drug|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
377816|NCT01310738|Drug|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
377817|NCT01310738|Drug|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
377818|NCT01310738|Drug|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
377819|NCT01310725|Procedure|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
377820|NCT01310712|Drug|Oxybutynin|5 mg every 12 hours for 6 weeks
377821|NCT01310712|Drug|placebo|placebo twice a day for 42 days.
377822|NCT01310699|Device|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
377823|NCT01310673|Drug|Allopurinol|"Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
377824|NCT01310673|Drug|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
377825|NCT01310647|Drug|Testosterone|Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
377826|NCT01310647|Drug|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
377827|NCT01310647|Drug|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.~Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle."
377828|NCT01310634|Behavioral|Comprehensive intervention|Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
377829|NCT01310621|Drug|Bovine surfactant|"Dose of diluted surfactant : 20ml/kg~Type :Bovine surfactant~Phospholipid concentration: 5 mg/ml~Number of lavages to be given: 2 (10ml/kg each)"
377830|NCT01310608|Other|A-View|Pre-operative imaging of the thoracic aorta with A-View technique
377831|NCT01310595|Procedure|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
377832|NCT01310595|Procedure|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
377833|NCT01310582|Drug|Desflurane|
377834|NCT01310582|Drug|Sevoflurane|
377835|NCT01310556|Other|ogtt for patients with coronary artery disease|75 g OGTT
377836|NCT01310543|Behavioral|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
377837|NCT01310530|Radiation|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
377838|NCT01310504|Procedure|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
377839|NCT01310504|Procedure|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
377840|NCT01310491|Behavioral|Health coaching|Telephone based health coaching supported by tele-monitoring.
377841|NCT01310478|Drug|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
377842|NCT01310465|Drug|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
377843|NCT01310465|Drug|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
377844|NCT01310452|Drug|insulin detemir|insulin detemir once daily with metformin
377845|NCT01310452|Drug|neutral protamine insulin|neutral protamine insulin once daily with metformin
377846|NCT01310426|Other|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
377847|NCT01310413|Biological|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
377848|NCT01310413|Biological|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
377849|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
377850|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
377851|NCT01310400|Biological|Agrippal|"Agrippal influenza vaccine~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
377852|NCT01310387|Behavioral|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
377853|NCT01310361|Drug|Amoxicillin|
377854|NCT01310361|Drug|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
377855|NCT01310348|Device|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
377856|NCT01310348|Device|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
378214|NCT01307631|Other|Laboratory Biomarker Analysis|Correlative studies
377857|NCT01310335|Device|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
377858|NCT01310322|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
377859|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
377860|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
377861|NCT01310322|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
377862|NCT01310309|Device|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
377863|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
377864|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
377865|NCT01310283|Other|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
377866|NCT01310270|Dietary Supplement|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
377867|NCT01310270|Dietary Supplement|Omega 3 Fatty Acid|4.4 gm/day for 1 month
377868|NCT01310257|Other|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
377869|NCT01310244|Drug|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
377870|NCT01310231|Drug|Metformin|"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: Until progression or unacceptable toxicity develops."
377871|NCT01310231|Drug|Placebo|"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).~Number of cycles: until progression or unacceptable toxicity develops."
377872|NCT01310218|Other|extended postoperative dressing|2 weeks of bulky dressing
377873|NCT01310218|Other|short postoperative dressing|2 days bulky dressing followed by bandaid
377874|NCT01310205|Drug|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
377875|NCT01310192|Device|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
377876|NCT01310179|Genetic|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
377877|NCT01310166|Drug|Fingolimod|
377878|NCT01310153|Procedure|prone positioning|newborn babies in prone positioning
377879|NCT01310153|Procedure|Supine|newborn babies in supine positioning
377880|NCT01310127|Drug|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
377881|NCT01310127|Drug|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
377882|NCT01310114|Biological|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
377883|NCT01310114|Drug|Placebo|Thawed placebo
377884|NCT01310101|Drug|ofatumumab plus dexamethasone|"Dose and schedule~Cycle 1:~Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18~Cycles 2 to 6 (cycles every 28 days):~Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
377885|NCT01310088|Behavioral|Lifestyle intervention|Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
377886|NCT01310075|Device|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
377887|NCT01310075|Device|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
377888|NCT01310049|Drug|LEO 32731|"Part 1 and 2: Oral single dose of oral solution or capsule~Part 3: Twice daily dose of oral solution or capsule for 7 days"
377889|NCT01310036|Drug|Erlotinib|Erlotinib 150 mg was administered orally daily until disease progression or unacceptable toxicity.
377890|NCT01310010|Drug|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
377891|NCT01309997|Drug|imatinib mesylate|Given PO
377892|NCT01309997|Biological|rituximab|Given IV
377893|NCT01309984|Drug|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
377894|NCT01309984|Drug|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
377895|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
377896|NCT01309945|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
377897|NCT01309945|Drug|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
377898|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
377899|NCT01309945|Drug|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
377900|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
377901|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
378215|NCT01307618|Biological|NA17.A2 Peptide Vaccine|Given SC or ID
377902|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
377903|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
377904|NCT01309932|Biological|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
377905|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
377906|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
377907|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
377908|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
377909|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
377910|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
377911|NCT01309932|Drug|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
377912|NCT01309932|Drug|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
377913|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
377914|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
377915|NCT01309919|Device|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
377916|NCT01309919|Other|Diary|Subjects will keep a bleeding diary for three months
377917|NCT01309893|Device|Investigational Lens|Lenses worn on a daily wear basis for one week
377918|NCT01309893|Device|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
377919|NCT01309880|Device|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
377920|NCT01309880|Device|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
377921|NCT01309854|Drug|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
377922|NCT01309854|Drug|pioglitazone|oral tablets, 30mg single dose per period
377923|NCT01309841|Drug|NKTR-118|12.5 mg oral tablet once daily
377924|NCT01309841|Drug|NKTR-118|25 mg oral tablet once daily
377925|NCT01309841|Drug|Placebo|Oral tablet once daily
377926|NCT01309828|Drug|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
377927|NCT01309828|Drug|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
377928|NCT01309802|Drug|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
377929|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
377930|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
377931|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
377932|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
377933|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
377934|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
377935|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
377936|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
377937|NCT01309789|Drug|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
377938|NCT01309776|Drug|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
377939|NCT01309776|Drug|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
377940|NCT01309763|Biological|AFFITOPE AD03|s.c. injection
377941|NCT01309763|Biological|AFFITOPE AD03 + Alum|s.c. injection
377942|NCT01309750|Radiation|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
377943|NCT01309737|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
377944|NCT01309737|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
377945|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
377946|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
377947|NCT01309724|Other|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
377948|NCT01309698|Drug|Vildagliptin (LAF237)|
377949|NCT01309698|Drug|Voglibose|
377950|NCT01309698|Drug|Vildagliptin and Voglibose|
377951|NCT01309685|Drug|Varenicline|
377952|NCT01309672|Drug|abiraterone acetate|1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
377953|NCT01309672|Drug|Prednisone|5 mg, oral, 5 mg twice daily
377954|NCT01309659|Drug|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
377955|NCT01309659|Drug|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
377956|NCT01309646|Biological|Infanrix™-IPV+Hib|Intramuscular, 3 doses
377957|NCT01309646|Biological|Infanrix™ IPV|Intramuscular, 3 doses
377958|NCT01309646|Biological|Hiberix™|Intramuscular, 3 doses
377961|NCT01309633|Drug|12.5mg sunitinib with Cisplatin and Gemcitabine|"1) Arm A~Day -6 to Day 0 (total 7 days):~Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
377962|NCT01309633|Drug|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B~Day -6 to Day 0 (total 7 days):~Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
377963|NCT01309633|Drug|7.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 7.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered.
377964|NCT01309633|Drug|2.5mg/kg Bevacizumab alternating with Cisplatin and Gemcitabine|Day -7: IV bevacizumab 2.5mg/kg diluted in normal saline over 30 minutes Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 For locally advanced patients, 3 cycles of treatment will be administered. For metastatic patients, up to 6 cycles would be administered
377965|NCT01309620|Dietary Supplement|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
377966|NCT01309620|Dietary Supplement|Placebo|Placebo, Twice Daily
377967|NCT01309607|Drug|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:~Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle~Carboplatin AUC of 2, day 1, 8 of a 21-day cycle~Lapatinib 750mg daily continuously"
377968|NCT01309594|Procedure|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
377969|NCT01309581|Drug|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
377970|NCT01309581|Drug|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
377971|NCT01309555|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
377972|NCT01309542|Drug|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
377973|NCT01309516|Behavioral|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
377974|NCT01309490|Drug|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
377975|NCT01309477|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
377976|NCT01309451|Drug|Bevacizumab|intravitreal, 1.25mg., monthly
377977|NCT01309451|Drug|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
377978|NCT01309438|Drug|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
377979|NCT01309438|Drug|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
377980|NCT01309438|Drug|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
377981|NCT01309438|Drug|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
377982|NCT01309425|Drug|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
377983|NCT01309425|Drug|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
377984|NCT01309425|Drug|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
377985|NCT01309425|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
377986|NCT01309412|Drug|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
377987|NCT01309399|Drug|Teriparatide|six weeks of teriparatide
377988|NCT01309399|Other|placebo|placebo
377989|NCT01309386|Drug|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
377990|NCT01309386|Drug|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
377991|NCT01309373|Other|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
377992|NCT01309360|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
377993|NCT01309360|Drug|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
377994|NCT01309360|Drug|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
377995|NCT01309360|Drug|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
377996|NCT01309334|Procedure|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
377997|NCT01309334|Procedure|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
377998|NCT01309321|Behavioral|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
377999|NCT01309321|Behavioral|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
378000|NCT01309308|Procedure|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
378001|NCT01309308|Other|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
378002|NCT01309243|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
378003|NCT01309243|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
378004|NCT01309230|Biological|Vigil™|intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)
378005|NCT01309217|Behavioral|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
378006|NCT01309217|Other|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
378007|NCT01309204|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
378008|NCT01309204|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
378009|NCT01309204|Drug|Brinzolamide 1% ophthalmic suspension|
378010|NCT01309204|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
378011|NCT01309191|Drug|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
378012|NCT01309191|Other|Placebo|
378013|NCT01309178|Drug|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
378014|NCT01309178|Drug|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
378015|NCT01309165|Behavioral|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
378016|NCT01309165|Behavioral|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
378017|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
378018|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
378019|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
378020|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
378021|NCT01309126|Biological|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
378022|NCT01309126|Drug|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
378023|NCT01309113|Drug|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
378024|NCT01309100|Device|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
378025|NCT01309100|Device|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
378026|NCT01309100|Device|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
378027|NCT01309074|Drug|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
378028|NCT01309074|Drug|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
378029|NCT01309061|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
378030|NCT01309048|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
378031|NCT01309035|Procedure|Total Knee Arthroplasty|Surgery for OA knee pains
378032|NCT01309022|Drug|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
378033|NCT01309022|Drug|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
378034|NCT01309022|Drug|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
378216|NCT01307618|Biological|Recombinant MAGE-3.1 Antigen|Given SC or ID
378035|NCT01309022|Drug|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
378036|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
378037|NCT01309009|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
378038|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
378039|NCT01308996|Device|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft [recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
378040|NCT01308996|Procedure|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
378041|NCT01308983|Drug|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
378042|NCT01308970|Behavioral|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
378043|NCT01308970|Behavioral|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
378044|NCT01308970|Behavioral|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
378045|NCT01308957|Dietary Supplement|Omega-3 fatty acids|4 grams per day for 24 weeks
378046|NCT01308957|Dietary Supplement|corn oil|4 grams per day for 24 weeks
378047|NCT01308944|Drug|Propranolol|
378048|NCT01308905|Device|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
378049|NCT01308892|Dietary Supplement|High flavanol chocolate|chocolate high in flavanols
378050|NCT01308892|Dietary Supplement|Low flavanol chocolate|chocolate low in flavanols
378051|NCT01308892|Dietary Supplement|High fat challenge|Milkshake with 95g fat
378052|NCT01308879|Behavioral|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
378053|NCT01308866|Behavioral|Share decision tool|
378054|NCT01308853|Device|Macrolane|Device: Macrolane Treatment: Initial injection (incl touch-up) of a maximum of 120 ml/breast.
378055|NCT01308840|Drug|Panitumumab|Day 1 and 15 = 6 mg/kg IV
378056|NCT01308840|Drug|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
378057|NCT01308840|Drug|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
378058|NCT01308827|Procedure|Blood culture|A baseline blood culture will be obtained in all participants
378059|NCT01308827|Procedure|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
378060|NCT01308814|Drug|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
378061|NCT01308814|Drug|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
378062|NCT01308801|Device|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
378063|NCT01308801|Device|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
378064|NCT01308775|Behavioral|SIS.NET, Routine Follow-up|"SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.~Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
378065|NCT01308762|Biological|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.~Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
378066|NCT01308762|Biological|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
378067|NCT01308762|Biological|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
378068|NCT01308749|Drug|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
378069|NCT01308749|Drug|Placebo|Placebo Nasal Spray
378070|NCT01308736|Drug|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
378217|NCT01307618|Biological|Recombinant Interleukin-12|Given SC or ID
378071|NCT01308736|Drug|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
378072|NCT01308723|Drug|RO5323441|escalating doses iv
378073|NCT01308723|Drug|RO5323441|iv every 2 weeks
378074|NCT01308723|Drug|sorafenib|400 mg orally twice daily to once every other day
378075|NCT01308710|Dietary Supplement|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
378076|NCT01308697|Procedure|Operative fixation of flail chest|Plate fixation
378077|NCT01308697|Other|Non Operative management|Non Operative treatment of Flail Chest
378078|NCT01308684|Drug|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
378079|NCT01308684|Drug|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
378080|NCT01308671|Drug|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
378081|NCT01308671|Behavioral|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
378082|NCT01308658|Drug|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
378083|NCT01308658|Drug|ritonavir|on Day 3
378084|NCT01308645|Drug|SB injection|Infusion SB injection of 21.87 ml/m^2, IV route, 24 times for 4 months
378085|NCT01308632|Drug|Temozolamide, irinotecan|"Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
378086|NCT01308619|Drug|Doxycycline|doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
378087|NCT01308619|Other|Placebo|Placebo, oral, one capsule daily in the morning
378088|NCT01308606|Drug|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
378089|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
378090|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
378091|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
378092|NCT01308606|Drug|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
378093|NCT01308593|Device|Juvederm XC|Filler
378094|NCT01308593|Drug|Botox|26 units dosed one time
378095|NCT01308580|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion~Route of administration: Intravenous"
378096|NCT01308580|Drug|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet~Route of administration: Oral"
378097|NCT01308567|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
378098|NCT01308567|Drug|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
378099|NCT01308567|Drug|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
378100|NCT01308554|Drug|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
378101|NCT01308554|Drug|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
378102|NCT01308541|Drug|arm 1|"Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.~Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour."
378103|NCT01308541|Drug|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
378104|NCT01308541|Drug|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
378105|NCT01308528|Drug|Sodium enoxaparin|40 mg/mL
378106|NCT01308528|Drug|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
378107|NCT01308515|Device|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
378108|NCT01308515|Device|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
378109|NCT01308502|Device|Dx-pH probe|Dx-pH probe with 24 hour recording
378110|NCT01308489|Procedure|therapeutic conventional surgery|Undergo posterior spinal tumor resection
378111|NCT01308489|Procedure|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
378112|NCT01308489|Procedure|quality-of-life assessment|Ancillary studies
378113|NCT01308476|Procedure|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
378114|NCT01308476|Procedure|control group|no daily SMS to remind of treatment with tiotropium
378115|NCT01308463|Device|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
378116|NCT01308437|Biological|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
378117|NCT01308437|Biological|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
378118|NCT01308424|Drug|BTL TML HSV|Sublingual micro-dosing for 7 days
378119|NCT01308424|Drug|Matching placebo|sublingual dosing for 7 days
378120|NCT01308411|Other|50% step down reduction in inhaled corticosteroid dose|All participants will have their inhaled corticosteroid dose reduced by 50%
378121|NCT01308385|Other|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
378122|NCT01308359|Drug|IV glucose 5%|500 ml glucose 5% within 30 minutes
378123|NCT01308359|Drug|saline|saline
378124|NCT01308346|Device|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
378125|NCT01308346|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
378126|NCT01308320|Drug|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
378127|NCT01308320|Drug|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
378128|NCT01308307|Device|photorefraction|photorefraction is a name of device.
378129|NCT01308294|Biological|2 vaccine injections in 1 limb|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
378130|NCT01308294|Biological|2 vaccine injections in different limbs|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
378131|NCT01308294|Biological|2 vaccine injections in different limbs, the vaccine does not contain the MHC class II peptide MAGE-A3-DP4|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A peptide with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in different limbs.
378132|NCT01308281|Procedure|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
378133|NCT01308281|Procedure|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
378134|NCT01308268|Drug|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (>= 2 years old) single dose, PO
378135|NCT01308255|Drug|Infliximab|"Prior to week 26~Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)~Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.~Folic acid 5 mg daily except the day methotrexate is taken~Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
378136|NCT01308255|Drug|Methylprednisolone|Steroid
378137|NCT01308255|Drug|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
378138|NCT01308255|Dietary Supplement|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
378139|NCT01308242|Drug|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
378140|NCT01308229|Device|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
378141|NCT01308216|Procedure|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
378142|NCT01308203|Drug|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
378143|NCT01308203|Drug|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
378144|NCT01308190|Drug|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
378145|NCT01308190|Radiation|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
378146|NCT01308190|Procedure|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
378147|NCT01308190|Procedure|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
378148|NCT01308177|Drug|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
378149|NCT01308164|Device|MD Logic Pump Advisor|Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
378150|NCT01308151|Other|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
378151|NCT01308138|Behavioral|Exercise training|exercise training
378152|NCT01308138|Procedure|remote ischemic preconditioning|remote ischemic preconditioning
378218|NCT01307618|Biological|MART-1 Antigen|Given SC or ID
378219|NCT01307618|Other|Laboratory Biomarker Analysis|Correlative studies
379006|NCT01301586|Drug|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
378153|NCT01308125|Procedure|PICSO|"Baseline (hemodynamic) measurement~Intra coronary~Blood sampling~LAD occlusion: for 3 min or until pain with and without PICSO~Break recovery: the patient can recover from pain for 3 min~CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.~PICSO: start automatically and continued for 10 min.~PCI/PICSO: concomitantly for the whole duration of the PCI intervention.~24h Follow up: additional blood samples every 6 hours (4 times)~30 days follow up."
378154|NCT01308112|Dietary Supplement|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
378155|NCT01308099|Device|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.~The study lasts about 2 hours."
378156|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 12 cycles
378157|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 12 cycles
378158|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
378159|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
378160|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
378161|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 6 cycles
378162|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 6 cycles
378163|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
378164|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
378165|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
378166|NCT01308073|Device|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
378167|NCT01308060|Drug|Botulinum Toxin Type A|During part A, Azzalure will be adminitered at Baseline 60 Spey unit at canthal lines and compared with placebo.
378168|NCT01308047|Drug|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
378169|NCT01308034|Drug|sunitinib|"All patients will be treated with sunitinib (3 dose level) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.~Dose level 1 : 12.5 mg once daily Dose level 2 : 25 mg once daily Dose level 3 : 50 mg once daily. Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring."
378170|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
378171|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
378172|NCT01308021|Biological|Placebo|Placebo entero-coated capsules
378173|NCT01308008|Behavioral|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
378174|NCT01308008|Behavioral|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
378175|NCT01307982|Procedure|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
378176|NCT01307982|Procedure|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
378177|NCT01307969|Drug|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
378178|NCT01307956|Drug|Fluorouracil|Given IV
378179|NCT01307956|Other|Laboratory Biomarker Analysis|Correlative studies
378180|NCT01307956|Drug|Leucovorin Calcium|Given IV
378181|NCT01307956|Drug|Oxaliplatin|Given IV
378182|NCT01307956|Biological|Panitumumab|Given IV
378183|NCT01307956|Other|Pharmacological Study|Correlative studies
378184|NCT01307956|Radiation|Radiation Therapy|Undergo radiation therapy
378185|NCT01307956|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
378186|NCT01307943|Other|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
378187|NCT01307943|Other|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
378188|NCT01307930|Drug|Anidulafungin|Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
378189|NCT01307917|Dietary Supplement|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
378190|NCT01307904|Other|Glucose|Each healthy and Diabetic volunteers received 50 grams of glucose
378191|NCT01307904|Other|Dates|Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
378265|NCT01307293|Behavioral|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
378344|NCT01306773|Drug|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
378192|NCT01307891|Drug|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
378193|NCT01307891|Drug|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
378194|NCT01307878|Drug|chemotherapy ± targeted therapy|FOLFOX 6 ± targeted therapy
378195|NCT01307865|Drug|injectable poly-L-lactic acid|Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
378196|NCT01307852|Device|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
378197|NCT01307839|Drug|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
378198|NCT01307839|Drug|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
378199|NCT01307826|Other|massage|"session - 20 minutes.~Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:~latissimus muscle of the back~major pectoral muscle~supraspinous and infraspinous muscles~teres minor muscle~serratus anterior muscle~deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.~A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation."
378200|NCT01307826|Other|massage|classical massage (Swedish massage)
378201|NCT01307813|Device|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.~Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
378202|NCT01307800|Drug|LY2140023|Administered orally
378203|NCT01307800|Drug|Placebo|Administered orally
378204|NCT01307787|Other|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
378205|NCT01307787|Other|no intervention|waiting list control group with no intervention
378206|NCT01307748|Other|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
378207|NCT01307722|Other|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
378208|NCT01307683|Behavioral|Mindful Moms|"8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session"
378209|NCT01307657|Other|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
378210|NCT01307644|Behavioral|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
378211|NCT01307644|Behavioral|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
378212|NCT01307644|Behavioral|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
378213|NCT01307631|Drug|Akt Inhibitor MK2206|Given PO
379007|NCT01301573|Biological|rAAV-GAD|
378220|NCT01307605|Biological|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
378221|NCT01307605|Drug|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
378222|NCT01307592|Biological|rituximab|
378223|NCT01307592|Drug|gemcitabine hydrochloride|
378224|NCT01307592|Drug|lenalidomide|
378225|NCT01307592|Drug|oxaliplatin|
378226|NCT01307579|Drug|Caspofungin Acetate|Given IV
378227|NCT01307579|Drug|Fluconazole|Given IV or PO
378228|NCT01307579|Other|Laboratory Biomarker Analysis|Correlative studies
378229|NCT01307566|Device|Continuous Positive Airway Pressure CPAP|CPAP treatment
378230|NCT01307553|Device|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
378231|NCT01307540|Device|phototherapy|low level light therapy, broad band light wavelengths.
378232|NCT01307527|Drug|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
378233|NCT01307527|Device|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
378234|NCT01307501|Device|Cryoablation|Application of extremely cold temperatures to the identified tumor(s).
378235|NCT01307488|Drug|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
378236|NCT01307488|Drug|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
378237|NCT01307475|Other|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
378238|NCT01307475|Other|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
378239|NCT01307475|Other|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
378240|NCT01307475|Other|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
378241|NCT01307475|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
378242|NCT01307475|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
378243|NCT01307475|Other|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
378244|NCT01307475|Other|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
378245|NCT01307475|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
378246|NCT01307462|Drug|fluticasone propionate|Given inhaled PO
378247|NCT01307462|Drug|montelukast sodium|Given PO
378248|NCT01307462|Drug|azithromycin|Given PO
378249|NCT01307449|Biological|PNEUMOVAX|1 dose of PNEUMOVAX
378250|NCT01307449|Biological|Prevnar|1 dose of Prevnar
378251|NCT01307436|Biological|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
378252|NCT01307436|Biological|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
378253|NCT01307423|Drug|Apremilast 20mg|Apremilast 20mg twice daily, orally
378254|NCT01307423|Drug|Apremilast 30mg|Apremilast 30mg twice daily, orally
378255|NCT01307423|Drug|Placebo|Placebo
378256|NCT01307397|Drug|Vemurafenib|Participants will receive continuous oral doses of vemurafenib 960 mg (four 240 mg tablets) twice daily in each 28-day treatment cycle until the development of progressive disease, unacceptable toxicity, consent withdrawal, protocol violations endangering participant's safety, death, or study termination by the Sponsor, whichever occurs first.
378257|NCT01307384|Device|Continuum Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
378258|NCT01307358|Other|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
378259|NCT01307345|Behavioral|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
378260|NCT01307332|Drug|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
378261|NCT01307319|Drug|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
378262|NCT01307319|Drug|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
378263|NCT01307306|Drug|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
378264|NCT01307306|Drug|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
380027|NCT01293032|Other|Laboratory Biomarker Analysis|Correlative studies
378266|NCT01307280|Behavioral|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
378267|NCT01307280|Behavioral|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
378268|NCT01307280|Behavioral|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
378269|NCT01307267|Drug|PF-05082566|Intravenous, Dose escalation, once per month
378270|NCT01307267|Drug|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
378271|NCT01307267|Drug|PF-05082566|IV, Dose escalation, once per month
378272|NCT01307254|Procedure|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
378273|NCT01307228|Other|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
378274|NCT01307215|Drug|Ropivacaine|20mLs of 0.5%
378275|NCT01307215|Drug|Ropivacaine|30mLs of 0.33%
378276|NCT01307215|Drug|Ropivacaine|40mLs of 0.25%
378277|NCT01307202|Drug|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
378278|NCT01307202|Drug|Placebo|Placebo will match the the gabapentin pill and will be given orally.
378279|NCT01307189|Drug|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
378280|NCT01307189|Drug|Placebo|Placebo diskus inhalation powder, once daily
378281|NCT01307176|Behavioral|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
378282|NCT01307137|Behavioral|Peer-led intervention|"An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.~Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.~Weight management success is defined as a loss of at least 5% of the weight since enrollment~Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.~The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills."
378283|NCT01307137|Behavioral|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
378284|NCT01307124|Drug|kaletra|"The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW >35-50 kg 400/100 mg 300/75 mg"
378285|NCT01307111|Drug|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
378286|NCT01307111|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
378287|NCT01307098|Drug|Sebelipase alfa 0.35 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
378288|NCT01307098|Drug|Sebelipase alfa 1 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
378289|NCT01307098|Drug|Sebelipase alfa 3 mg/kg|Sebelipase alfa is a recombinant human lysosomal acid lipase.
378290|NCT01307085|Procedure|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
378291|NCT01307072|Procedure|Vitrectomy|Vitrectomy. Diabetic retinopathy
378292|NCT01307059|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
378293|NCT01307046|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
378294|NCT01307046|Drug|Losartan|Tablet containing losartan potassium (100 mg), once daily
378295|NCT01307046|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
378296|NCT01307046|Drug|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
378297|NCT01307046|Drug|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
378298|NCT01307033|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
378299|NCT01307033|Drug|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
378300|NCT01307033|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
378301|NCT01307033|Drug|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
378302|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
378303|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
378304|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
378305|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
378306|NCT01307020|Drug|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
378307|NCT01307020|Drug|Placebo|Placebo, oral film-coated table, once
378308|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
378309|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
378310|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
378311|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
378312|NCT01307007|Drug|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
378313|NCT01307007|Drug|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
378314|NCT01306994|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
378315|NCT01306994|Procedure|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
378316|NCT01306994|Other|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
378317|NCT01306994|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
378318|NCT01306994|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
378319|NCT01306994|Other|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
378320|NCT01306994|Other|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
378321|NCT01306981|Drug|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
378322|NCT01306981|Drug|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
378323|NCT01306968|Drug|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.~The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
378324|NCT01306968|Other|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
378325|NCT01306955|Drug|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
378326|NCT01306955|Other|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
378327|NCT01306942|Drug|Dasatinib|
378328|NCT01306942|Drug|Trastuzumab|
378329|NCT01306942|Drug|Paclitaxel|
378330|NCT01306929|Drug|pridopidine|45mg bid
378331|NCT01306903|Device|MECC|Minimized extracorporeal circulation
378332|NCT01306903|Device|MOPS|Modified and optimized perfusion system Frankfurt
378333|NCT01306903|Device|Super MOPS|Super modified and optimized perfusion system Frankfurt
378334|NCT01306890|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
378335|NCT01306877|Device|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
378336|NCT01306877|Device|Endosurgery Proximate PPH03 Stapling Set|Surgical device
378337|NCT01306864|Device|Hemospray Kit|Hemostasis of Arterial GI Bleeding
378338|NCT01306851|Drug|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
378339|NCT01306838|Dietary Supplement|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
378340|NCT01306838|Other|Routine care|Routine care
378341|NCT01306786|Drug|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.~Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
378342|NCT01306786|Drug|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
378343|NCT01306773|Drug|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing >= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
380491|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
378345|NCT01306760|Drug|Ketamine|Ketamine used as the anaesthetic during ECT.
378346|NCT01306760|Drug|Propofol|The standard anaesthetic used for ECT.
378347|NCT01306747|Behavioral|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
378348|NCT01306721|Drug|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
378349|NCT01306721|Drug|pseudoephedrine|"Pharmaceutical form:tablet~Route of administration: oral"
378350|NCT01306721|Drug|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
378351|NCT01306721|Drug|pseudoephedrine matching placebo|"Pharmaceutical form:tablet~Route of administration: oral"
378352|NCT01306708|Drug|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
378353|NCT01306695|Behavioral|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
378354|NCT01306695|Other|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
378355|NCT01306682|Biological|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
378356|NCT01306682|Biological|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
378357|NCT01306669|Biological|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
378358|NCT01306669|Biological|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
378359|NCT01306656|Drug|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week"
378360|NCT01306656|Other|Placebo|"Month 1: Placebo once a week~Months 2-6: Placebo once a week"
378361|NCT01306656|Dietary Supplement|Vitamin D|Daily multivitamin with 400 IU vitamin D.
378362|NCT01306643|Drug|Idelalisib|Tablet(s) administered orally twice daily
378363|NCT01306630|Drug|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
378364|NCT01306617|Drug|ABT-450|tablets
378365|NCT01306617|Drug|ABT-333|tablets
378366|NCT01306617|Drug|ribavirin|tablets
378367|NCT01306617|Drug|ritonavir|capsules
378368|NCT01306591|Drug|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
378369|NCT01306591|Drug|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
378370|NCT01306578|Drug|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
378371|NCT01306578|Procedure|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
378372|NCT01306565|Drug|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
378373|NCT01306565|Drug|High dose atorvastatin|80mg daily atorvastatin for 72 hours
378374|NCT01306552|Behavioral|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.~The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
378375|NCT01306552|Behavioral|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
378376|NCT01306552|Behavioral|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).~(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
378377|NCT01306539|Procedure|Stimulation of the subthalamic nucleus|Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
378378|NCT01306513|Biological|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
378379|NCT01306500|Procedure|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
378380|NCT01306487|Procedure|Vitrectomy|Macular hole surgery
378381|NCT01306461|Drug|Timolol and Tafluprost|"Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily~Treatment period 6 months"
378382|NCT01306461|Drug|Fixed Dose Combination of tafluprost and timolol|"Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.~For masking purposes also: vehicle for timolol administered twice daily~Treatment period 6 months"
378383|NCT01306448|Device|Vibrant capsule|vibrating capsule
378384|NCT01306435|Other|Laser|3-week treatment with three Laser sessions per week
378385|NCT01306435|Other|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
378386|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
378387|NCT01306422|Other|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
378388|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
378389|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
378390|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
378391|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
378392|NCT01306409|Drug|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
378393|NCT01306409|Drug|ESA|Sequential application of three different ESA
378394|NCT01306396|Behavioral|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
378395|NCT01306383|Other|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
378396|NCT01306370|Drug|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.~Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
378397|NCT01306370|Drug|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
378398|NCT01306370|Biological|Fibrin glue|Topical administration, before to close the surgical wound.
378399|NCT01306370|Other|Habitual haemostasis|The surgical habitual haemostasis.
378400|NCT01306357|Drug|Somatropin|4 mg or 10 mg delivered by needle-free device
378401|NCT01306331|Drug|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
378402|NCT01306331|Drug|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
378403|NCT01306318|Drug|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
378404|NCT01306318|Drug|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
378405|NCT01306305|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus~15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
378406|NCT01306292|Drug|SonoVue|dose of 4.8 mL administered intravenously one time
378407|NCT01306292|Drug|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
378408|NCT01306266|Drug|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
378409|NCT01306266|Drug|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
378410|NCT01306253|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Brisbane/60/2008-like virus~Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
378411|NCT01306240|Procedure|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
378412|NCT01306240|Procedure|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
378413|NCT01306227|Drug|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
378414|NCT01306227|Drug|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
378415|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
378416|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
378417|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
378418|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
378419|NCT01306214|Drug|BI 10773|BI 10773 low dose once daily
378420|NCT01306214|Drug|BI 10773|BI 10773 high dose once daily
378421|NCT01306188|Biological|Breast cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~The analysis of TCR and BCR repertoire diversity,~The phenotypic analysis of immune subpopulations,~The analysis of the global lymphopenia or subpopulations T,~The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
378422|NCT01306188|Biological|Lung cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.~For each patient, the following analyses is performed:~The analysis of TCR and BCR repertoire diversity,~The phenotypic analysis of immune subpopulations,~The analysis of the global lymphopenia or subpopulations T,~The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
378423|NCT01306175|Drug|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
378424|NCT01306175|Drug|Digoxin|Digoxin 0.5 mg as single dose
378425|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
378426|NCT01306162|Drug|Dabigatran etexilate|150 mg as single dose
378427|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
378428|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
378429|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
378430|NCT01306136|Behavioral|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
378431|NCT01306136|Behavioral|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
378432|NCT01306123|Drug|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
378433|NCT01306123|Drug|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
378434|NCT01306097|Drug|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
378435|NCT01306058|Drug|TRC 105|15 mg/kg intravenous (IV) every 2 weeks
378436|NCT01306058|Drug|Sorafenib|400 mg twice a day (bid) continuously in a 28 days cycle
378437|NCT01306045|Drug|AZD6244|75 mg bid po
378438|NCT01306045|Drug|MK-2206|200 mg qd po
378439|NCT01306045|Drug|Lapatinib|1500 mg qd po
378440|NCT01306045|Drug|Erlotinib|150 mg qd po
378441|NCT01306045|Drug|Sunitinib|50 mg qd po
378442|NCT01306045|Procedure|Molecular Profiling|Molecular profiling of tumor tissue
378443|NCT01306032|Drug|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
378444|NCT01306032|Drug|Cyclophosphamide|
378445|NCT01306019|Drug|Palifermin|Mucositis prophylaxis commenced - Infusion of keratinocyte growth factor (palifermin) at 60 mg/kg/day before (Days -6 to Day 4) administration of busulfan
378446|NCT01306019|Drug|Busulfan|Pre gene therapy conditioning regimen
378447|NCT01306019|Biological|Ex Vivo culture and transduction|Transduced cell product administered intravenously over <30 minutes by a PI or designated Associate Investigator at the NIH Clinical Center.
378448|NCT01306006|Biological|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
378449|NCT01305993|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
378450|NCT01305980|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
378451|NCT01305967|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, Intravenous route, 16times for 2.5 months
378452|NCT01305941|Drug|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
378453|NCT01305941|Drug|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
378454|NCT01305941|Drug|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
378455|NCT01305928|Other|Warm Hand-off|"Warm Hand-Off~Staff brief intervention and warm hand-off (5 min):~Assess withdrawal, need for medication change~Describe warm hand-off process~Provide 2-page flyer~Perform call, leave room~Notify patients' nurse patient is talking to quitline~Quitline session (20 min):~Collect minimum data set~Explore thoughts/feelings toward quitting~Provide medication education~Build plan to stay quit~Schedule next call~Staff check-back (5 min):~Ask patient how session went~Ask if patient requests cessation medication script on discharge"
378456|NCT01305928|Other|Fax|"Fax~Staff standard in-patient session: (30 minutes):~Assess withdrawal, need for medication change~Conduct assessment of smoking history, interest in quitting~Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting~Provide 2-page flyer~Provide medication education~Build plan to stay quit~Describe fax-referral process~Ask if patient requests cessation medication script on discharge"
378457|NCT01305915|Behavioral|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
378458|NCT01305902|Behavioral|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
378459|NCT01305889|Behavioral|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
378460|NCT01305889|Drug|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
378461|NCT01305876|Behavioral|yoga intervention|yoga session 2 x week over 3-1/2 months
378523|NCT01305356|Device|Augment® Injectable Bone Graft|Implantation of up to 9cc of Augment® Injectable Bone Graft
378462|NCT01305863|Device|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
378463|NCT01305863|Device|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
378464|NCT01305850|Drug|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
378465|NCT01305850|Drug|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
378466|NCT01305850|Drug|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
378467|NCT01305850|Drug|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
378468|NCT01305837|Drug|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
378469|NCT01305824|Drug|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
378470|NCT01305824|Drug|Placebo|Placebo administered at the time of AVF creation.
378471|NCT01305824|Drug|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
378472|NCT01305811|Device|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
378473|NCT01305798|Other|Scheduling and Active Choice for Biometric Participation|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
378474|NCT01305772|Drug|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 & 4 of RT alone or weeks 1 & 4 of cisplatin/RT if they tolerated first dose of panitumumab.
378475|NCT01305772|Procedure|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
378476|NCT01305772|Procedure|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
378477|NCT01305746|Drug|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
378478|NCT01305746|Drug|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
378479|NCT01305746|Drug|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
378480|NCT01305733|Drug|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
378481|NCT01305733|Other|saline injection|saline
378482|NCT01305720|Device|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
378483|NCT01305707|Device|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.~Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
378484|NCT01305707|Drug|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
378485|NCT01305694|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
378486|NCT01305681|Device|LoFric® catheters during clean intermittent catheterization|LoFric® catheters during clean intermittent catheterization
378487|NCT01305655|Drug|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM, 36 hour levels >30 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
378488|NCT01305642|Dietary Supplement|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.~Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
378522|NCT01305369|Drug|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
378489|NCT01305629|Behavioral|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
378490|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
378491|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
378492|NCT01305603|Drug|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
378493|NCT01305603|Procedure|Injection|Injection under ultrasound-guidance
378494|NCT01305590|Other|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
378495|NCT01305577|Drug|Deoxycholic acid injection|
378496|NCT01305577|Drug|Placebo|Phosphate buffered saline placebo for injection
378497|NCT01305564|Device|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
378498|NCT01305551|Drug|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
378499|NCT01305551|Drug|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
378500|NCT01305551|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
378501|NCT01305538|Drug|BMS-954561|
378502|NCT01305538|Drug|BMS-954561|
378503|NCT01305538|Drug|Placebo|
378504|NCT01305525|Device|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
378505|NCT01305512|Drug|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
378506|NCT01305499|Drug|Entinostat days 3, 10|Given orally on days 3, 10
378507|NCT01305499|Drug|5AC|
378508|NCT01305499|Drug|Entinostat days 10,17|Given orally on days 10, 17
378509|NCT01305460|Drug|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.~Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.~Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.~Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
378510|NCT01305447|Behavioral|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
378511|NCT01305447|Behavioral|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
378512|NCT01305447|Behavioral|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
378513|NCT01305434|Dietary Supplement|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
378514|NCT01305421|Procedure|grip test|Muscle strength measurement by hand-held dynamometer
378515|NCT01305408|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
378516|NCT01305408|Drug|Placebo|Matching placebo tablets, taken orally, once daily in the morning
378517|NCT01305395|Drug|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
378518|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
378519|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
378520|NCT01305395|Drug|Sirolimus|Will start sirolimus after they develop CAV by angiogram
378521|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
380492|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
378524|NCT01305356|Procedure|Autologous bone graft|Implantation of up to 9cc of autologous bone graft
378525|NCT01305343|Procedure|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
378526|NCT01305317|Drug|Lipitor|Atorvastatin 20mg daily for 6 months
378527|NCT01305304|Other|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
378528|NCT01305304|Other|Other|No history of endurance sports activity
378529|NCT01305291|Other|placebo|
378530|NCT01305291|Dietary Supplement|digestion-resistant maltodextrin|
378531|NCT01305278|Other|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
378532|NCT01305265|Device|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
378533|NCT01305252|Drug|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
378534|NCT01305252|Drug|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
378535|NCT01305239|Drug|Aromasin|Aromasin 25 mg daily.
378536|NCT01305226|Drug|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
378537|NCT01305226|Drug|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
378538|NCT01305213|Biological|Bevacizumab|Given IV
378539|NCT01305213|Drug|Fosbretabulin Tromethamine|Given IV
378540|NCT01305213|Other|Laboratory Biomarker Analysis|Correlative studies
378541|NCT01305200|Drug|supersaturated calcium phosphate rinse|Mouth rinse
378542|NCT01305200|Other|placebo|Mouth rinse
378543|NCT01305200|Other|questionnaire administration|Ancillary studies
378544|NCT01305200|Procedure|quality-of-life assessment|Ancillary studies
378545|NCT01305187|Device|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
378546|NCT01305174|Device|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
378547|NCT01305161|Other|Blood simple|Single Blood simple at Day 1
378548|NCT01305148|Device|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
378549|NCT01305135|Drug|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
378550|NCT01305122|Behavioral|neurocognitive tests|"inclusion~1 year~3 years~5 years"
378551|NCT01305109|Biological|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
378552|NCT01305109|Biological|Placebo|3 doses of 0.5 mL at 4 week intervals
378553|NCT01305096|Other|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
378554|NCT01305083|Drug|Udenafil|Placebo-control
378555|NCT01305083|Drug|Placebo|Placebo
378556|NCT01305070|Device|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
378557|NCT01305070|Device|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
378558|NCT01305057|Other|Pyridoxine tri-isopalmitate|2% dosage, oil-in-water emulsion, twice a day, 28 days
378559|NCT01305044|Behavioral|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
378560|NCT01305044|Behavioral|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
378561|NCT01305031|Other|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
378562|NCT01305031|Other|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
378563|NCT01305018|Dietary Supplement|BCAA|7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
378564|NCT01305018|Dietary Supplement|Leucine|7 g of leucine + 7 g of alanine per day during 9 days
378565|NCT01305018|Dietary Supplement|Placebo|14 g of alanine per day during 9 days
378566|NCT01304992|Dietary Supplement|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
378567|NCT01304992|Dietary Supplement|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
378568|NCT01304979|Procedure|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
378569|NCT01304979|Procedure|Control|Indirect therapies that mimic direct therapy intervention
378570|NCT01304966|Procedure|biopsy|excisional biopsy
378571|NCT01304953|Drug|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
378572|NCT01304953|Drug|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
378573|NCT01304953|Drug|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
378574|NCT01304953|Drug|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.~Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
378575|NCT01304927|Drug|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
378576|NCT01304927|Other|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
378577|NCT01304901|Drug|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
378578|NCT01304901|Drug|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
378579|NCT01304888|Other|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
378580|NCT01304888|Other|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
378581|NCT01304888|Other|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
378582|NCT01304888|Other|Control|No benefits were provided
378583|NCT01304862|Behavioral|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
378584|NCT01304862|Behavioral|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
378585|NCT01304849|Drug|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:~Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
378586|NCT01304836|Drug|Advagraf|oral
378587|NCT01304836|Drug|Mycophenolate Mofetil|oral
378588|NCT01304836|Drug|Simulect|IV
378589|NCT01304836|Drug|Corticosteroids|IV & oral
378590|NCT01304823|Dietary Supplement|lactisole|flavoring agent/sweet taste antagonist
378591|NCT01304823|Other|mixed liquid meal|Ensure Plus
378592|NCT01304810|Biological|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
378593|NCT01304810|Biological|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
378594|NCT01304797|Drug|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
378595|NCT01304797|Drug|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
378596|NCT01304797|Drug|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
378597|NCT01304797|Drug|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
378598|NCT01304784|Drug|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
378599|NCT01304784|Drug|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
378600|NCT01304784|Drug|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
378601|NCT01304784|Drug|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
378602|NCT01304784|Drug|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
378603|NCT01304771|Biological|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide [FOS], NutraFlora®).
378604|NCT01304758|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
378605|NCT01304745|Behavioral|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
378606|NCT01304745|Behavioral|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
378607|NCT01304719|Behavioral|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
378608|NCT01304719|Behavioral|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
378609|NCT01304706|Drug|Fluocinolone Acetonide|0.2 μg/day
378610|NCT01304693|Biological|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
378611|NCT01304693|Biological|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
378612|NCT01304641|Other|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
378613|NCT01304641|Other|Simvastatin Initiators|Retrospective database analysis no intervention performed.
378614|NCT01304628|Drug|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
378615|NCT01304615|Behavioral|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
378616|NCT01304615|Behavioral|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
378617|NCT01304615|Behavioral|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
378618|NCT01304602|Drug|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
378619|NCT01304602|Drug|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
378620|NCT01304589|Drug|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose) for 12 weeks - total treatment period is 18 weeks
378621|NCT01304576|Behavioral|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
378622|NCT01304576|Other|MRI|Cerebral MRI
378623|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
378624|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
378625|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
378626|NCT01304563|Biological|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
378627|NCT01304537|Drug|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
378628|NCT01304537|Drug|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
378629|NCT01304537|Drug|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
378630|NCT01304524|Biological|VGX 3100|1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
378631|NCT01304524|Biological|Placebo|1ml of placebo delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
378632|NCT01304524|Device|CELLECTRA™-5P|CELLECTRA™-5P is used for electroporation following IM delivery of VGX 3100 or placebo on Day 0, Week 4 and Week 12.
378633|NCT01304511|Drug|Orgalutran|
378634|NCT01304498|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
378635|NCT01304498|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
378636|NCT01304485|Drug|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
378637|NCT01304472|Drug|Prasugrel|Prasugrel 10mg per day
378638|NCT01304472|Drug|Clopidogrel|Clopidogrel 150mg per day
378639|NCT01304446|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
378640|NCT01304433|Drug|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
378641|NCT01304420|Device|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
378682|NCT01304095|Drug|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
378642|NCT01304394|Drug|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
378643|NCT01304381|Other|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
378644|NCT01304381|Other|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
378645|NCT01304368|Procedure|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
378646|NCT01304342|Drug|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
378647|NCT01304342|Drug|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
378648|NCT01304342|Drug|Normal saline|Normal saline intravenously and intranasally
378649|NCT01304329|Drug|BI 10773|Medium dose oral administration
378650|NCT01304329|Drug|simvastatin|Medium dose oral administration
378651|NCT01304329|Drug|simvastatin|Medium dose oral administration
378652|NCT01304329|Drug|BI 10773|Medium dose oral administration
378653|NCT01304316|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
378654|NCT01304303|Drug|SPARC1023 I|IV administration
378655|NCT01304303|Drug|SPARC1023 II|IV administration
378656|NCT01304290|Other|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
378657|NCT01304277|Biological|agalsidase alfa|
378658|NCT01304264|Device|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
378659|NCT01304251|Other|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
378660|NCT01304251|Other|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
378661|NCT01304238|Drug|lepirudin|lepirudin
378662|NCT01304238|Drug|danaparoid|danaparoid
378663|NCT01304238|Drug|argatroban|argatroban
378664|NCT01304238|Drug|fondaparinux|fondaparinux
378665|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
378666|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
378667|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
378668|NCT01304212|Drug|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
378669|NCT01304212|Drug|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
378670|NCT01304212|Drug|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
378671|NCT01304212|Drug|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
378672|NCT01304186|Behavioral|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
378673|NCT01304160|Radiation|stereotactic body radiotherapy|30Gray in 5 fractions
378674|NCT01304147|Drug|Ketamine|A single dose of intranasal ketamine up to 50 mg
378675|NCT01304147|Drug|placebo|Single dose of saline intranasal
378676|NCT01304134|Drug|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
378677|NCT01304134|Drug|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
378678|NCT01304121|Device|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
378679|NCT01304108|Other|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
378680|NCT01304108|Other|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
378681|NCT01304108|Other|Usual Care|No addition to the baseline system for care
378683|NCT01304082|Drug|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
378684|NCT01304082|Drug|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
378685|NCT01304082|Drug|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
378686|NCT01304069|Drug|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
378687|NCT01304069|Drug|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
378688|NCT01304069|Drug|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
378689|NCT01304056|Device|Ventilatory therapy|
378690|NCT01304043|Drug|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
378691|NCT01304030|Behavioral|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
378692|NCT01304030|Behavioral|Residency Training as usual|Residents will receive their typical didactic and clinical education
378693|NCT01304017|Other|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
378694|NCT01304017|Other|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
378695|NCT01304004|Other|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:~Experimental drinkable yogurt enriched in proteins and fibres~Placebo drinkable yogurt (isocaloric and isovolumetric)"
378696|NCT01303991|Other|Hexvix PDT with Karl Storz T-Light|
378697|NCT01303978|Drug|APD421|Single dose
378698|NCT01303965|Drug|Sirolimus|Start on Day -3 and continue for 1 year
378699|NCT01303965|Drug|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
378700|NCT01303965|Drug|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
378701|NCT01303952|Drug|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
378702|NCT01303939|Diagnostic Test|magnetic resonance imaging (MRI) of the brain|High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
378703|NCT01303926|Drug|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
378704|NCT01303926|Drug|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
378705|NCT01303887|Drug|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
378706|NCT01303887|Drug|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
378707|NCT01303887|Drug|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
378708|NCT01303887|Drug|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
378709|NCT01303887|Drug|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
378710|NCT01303874|Drug|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
378711|NCT01303874|Drug|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
378712|NCT01303861|Drug|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
378713|NCT01303861|Drug|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
378714|NCT01303861|Drug|Nicotine patches|"Nicotine Replacement Therapy Groups:~For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or~For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.~Varenicline and varenicline in combination with bupropion groups:~For smokers with high baseline CO: 42 mg/24 h for 1 week~For smokers with low baseline CO: 21 mg/24 h for 1 week"
378715|NCT01303861|Drug|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
378716|NCT01303848|Other|Blood Sampling|Blood Sampling over 24 hours
378717|NCT01303835|Drug|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
378718|NCT01303835|Drug|Placebo|Randomized patients received placebo to be taken every night before bed.
378719|NCT01303822|Behavioral|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
378756|NCT01303601|Drug|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.~daily 6 weeks"
378757|NCT01303601|Drug|Starch|
378758|NCT01303588|Behavioral|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
378759|NCT01303588|Behavioral|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
378760|NCT01303575|Behavioral|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
378720|NCT01303809|Other|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:~Pre-op carbohydrate loading~No pre-op GIK while NBM~Pre-medication~Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg~Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics~Fluid restriction~Standardised method of anaesthesia~Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites~10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure~Postoperative:~Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively~Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1~Post operative oxygenation~Incentive spirometry~Drains (e.g. IDC) removed in recovery~Full mobilisation 4-8 hours post op)~Early Follow up"
378721|NCT01303796|Drug|Sapacitabine|oral sapacitabine capsules
378722|NCT01303796|Drug|Decitabine|decitabine intravenous
378723|NCT01303783|Drug|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
378724|NCT01303783|Drug|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
378725|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
378726|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
378727|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
378728|NCT01303783|Drug|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
378729|NCT01303783|Drug|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
378730|NCT01303783|Drug|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
378731|NCT01303770|Behavioral|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
378732|NCT01303770|Behavioral|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
378733|NCT01303757|Behavioral|Dietary counselling|
378734|NCT01303744|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
378735|NCT01303744|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
378736|NCT01303744|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
378737|NCT01303744|Drug|Placebo|oral tablet, once a day in the morning for 12 weeks
378738|NCT01303731|Drug|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
378739|NCT01303731|Drug|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
378740|NCT01303718|Device|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
378741|NCT01303718|Other|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
378742|NCT01303705|Drug|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
378743|NCT01303705|Radiation|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
378744|NCT01303705|Drug|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
378745|NCT01303679|Drug|Paclitaxel|IV, 80mg/m² at d1, d8, d15
378746|NCT01303679|Drug|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
378747|NCT01303679|Drug|Exemestane|daily 25 mg (1 pill) oral intake
378748|NCT01303666|Procedure|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
378749|NCT01303666|Procedure|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.~After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
378750|NCT01303653|Procedure|endoscopic closure of gastrointestinal fistulas and perforations|novel endoscopic tissue closure devices will be used for endoscopic closure of gastrointestinal fistulas or perforations
378751|NCT01303640|Device|Biolimus-eluting stent|Biolimus-eluting stent
378752|NCT01303640|Device|Everolimus-eluting stent|Everolimus-eluting stent
378753|NCT01303627|Drug|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
378754|NCT01303614|Drug|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
378755|NCT01303614|Drug|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
378761|NCT01303575|Behavioral|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
378762|NCT01303562|Other|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
378763|NCT01303549|Drug|Anidulafungin|Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
378764|NCT01303549|Drug|Liposomal amphotericin B|Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
378765|NCT01303536|Drug|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
378766|NCT01303510|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
378767|NCT01303497|Drug|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
378768|NCT01303497|Drug|Bevacizumab|"Bevacizumab until progression or inacceptable toxicity :~During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV~After 6 cycles of chemotherapy : 15 mg/kg, IV"
378769|NCT01303484|Dietary Supplement|Bi2muno® GOS|5.5g/day for 10 weeks
378770|NCT01303484|Dietary Supplement|Maltodextrin|5.5g daily for 10 weeks
378771|NCT01303471|Drug|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
378772|NCT01303458|Behavioral|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
378773|NCT01303445|Drug|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
378774|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
378775|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
378776|NCT01303445|Drug|Omeprazole alone|omeprazole 80 once daily for 7 days
378777|NCT01303432|Dietary Supplement|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
378778|NCT01303432|Dietary Supplement|Yogurt|One yogurt (125mL) per day
378779|NCT01303419|Device|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
378780|NCT01303419|Device|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
378781|NCT01303406|Drug|Idebenone|All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
378782|NCT01303406|Drug|Placebo|
378783|NCT01303380|Drug|Canakinumab|
378784|NCT01303354|Procedure|Lumbar Transforaminal Epidural Steroid Injection|
378785|NCT01303341|Other|Laboratory Biomarker Analysis|Correlative studies
378786|NCT01303341|Other|Pharmacological Study|Correlative studies
378787|NCT01303341|Drug|Riluzole|Given PO
378788|NCT01303341|Drug|Sorafenib Tosylate|Given PO
378789|NCT01303328|Drug|C1|Local application of the experimental gel or placebo gel.
378790|NCT01303315|Device|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
378791|NCT01303302|Device|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
378792|NCT01303302|Device|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
378793|NCT01303289|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
378794|NCT01303289|Dietary Supplement|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
378795|NCT01303263|Behavioral|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
378796|NCT01303250|Drug|balanced 6% hydroxyethylstarch 130/0.4|Fluid administration and optimization based on cardiac output findings during surgery.
378797|NCT01303250|Drug|balanced crystalloid|Fluid administration and optimization based on cardiac output findings during surgery.
378798|NCT01303237|Drug|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
378799|NCT01303224|Drug|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
378800|NCT01303224|Drug|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
378801|NCT01303224|Drug|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
378802|NCT01303224|Drug|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
378803|NCT01303198|Device|APAP - Therapy|automatic positive pressure therapy
378832|NCT01302951|Drug|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
378804|NCT01303172|Biological|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.~A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL)will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.~Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
378805|NCT01303172|Drug|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.~Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).~Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
378806|NCT01303159|Device|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
378807|NCT01303146|Drug|rhARSA|intravenous infusion 100U/kg every other week for 18 months
378808|NCT01303120|Drug|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
378809|NCT01303120|Drug|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
378810|NCT01303120|Drug|Patient-controlled analgesia|Patient controlled analgesia with morphine
378811|NCT01303107|Drug|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
378812|NCT01303094|Drug|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
378813|NCT01303094|Other|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
378814|NCT01303081|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
378815|NCT01303081|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
378816|NCT01303081|Behavioral|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
378817|NCT01303081|Behavioral|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
378818|NCT01303081|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
378819|NCT01303068|Device|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
378820|NCT01303055|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
378821|NCT01303055|Drug|Metformin 750 mg|"Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %."
378822|NCT01303042|Drug|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
378823|NCT01303029|Drug|Gemcitabine+erlotinib|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
378824|NCT01303029|Drug|Gemcitabine+erlotinib+capecitabine|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
378825|NCT01303016|Dietary Supplement|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
378826|NCT01303003|Drug|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
378827|NCT01303003|Procedure|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
378828|NCT01302990|Biological|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
378829|NCT01302977|Procedure|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
378830|NCT01302964|Drug|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
378831|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg per week for subjects weighing less than 50 kg and up to 15 mg per week for subjects weighing more than 50 kg depending on efficacy and tolerability.
378833|NCT01302938|Drug|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
378834|NCT01302938|Drug|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
378835|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
378836|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
378837|NCT01302912|Procedure|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
378838|NCT01302899|Drug|Aliskiren|Aliskiren 150 mg (Tablet)
378839|NCT01302899|Drug|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
378840|NCT01302899|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
378841|NCT01302899|Drug|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
378842|NCT01302899|Drug|Ramipril|Ramipril 10mg (Tablet)
378843|NCT01302886|Drug|BHQ880|
378844|NCT01302873|Drug|BGG492A|
378845|NCT01302873|Drug|BGG492A|
378846|NCT01302860|Drug|ACZ885|
378847|NCT01302847|Drug|Dolutegravir (DTG) film-coated tablets|"Stage I: Initial starting dose of DTG tablet(s) at approximately 1 mg/kg, to be taken orally once or twice daily.~Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily."
378848|NCT01302847|Drug|DTG granules for suspension|"Stage I: DTG granules for suspension, to be taken orally once or twice daily. Dose will vary for each participant.~Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily. (Note: Cohort IIB will not be included in Stage II of the study)."
378849|NCT01302847|Drug|DTG dispersible tablets|"Stage I: DTG dispersible tablets, to be taken orally once or twice daily. Dose will vary for each participant.~Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily."
378850|NCT01302834|Biological|cetuximab|Given IV
378851|NCT01302834|Drug|cisplatin|Given IV
378852|NCT01302821|Biological|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
378853|NCT01302821|Drug|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
378854|NCT01302821|Radiation|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
378855|NCT01302808|Drug|erlotinib hydrochloride|
378856|NCT01302808|Drug|romidepsin|
378857|NCT01302808|Other|laboratory biomarker analysis|
378858|NCT01302808|Other|pharmacological study|
378859|NCT01302795|Drug|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
378860|NCT01302769|Device|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
378861|NCT01302756|Other|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
378862|NCT01302756|Dietary Supplement|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
378863|NCT01302743|Drug|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
378864|NCT01302743|Dietary Supplement|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
378865|NCT01302743|Dietary Supplement|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
378866|NCT01302717|Device|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
378867|NCT01302717|Device|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
378868|NCT01302691|Drug|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
378869|NCT01302691|Drug|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
378870|NCT01302691|Drug|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
378871|NCT01302691|Drug|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
378872|NCT01302691|Drug|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
378873|NCT01302691|Drug|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
378874|NCT01302639|Dietary Supplement|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
378875|NCT01302613|Drug|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
378876|NCT01302613|Drug|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
378877|NCT01302613|Drug|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
378878|NCT01302613|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
378999|NCT01301612|Radiation|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
378879|NCT01302613|Radiation|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
378880|NCT01302613|Procedure|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
378881|NCT01302600|Drug|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
378882|NCT01302600|Drug|Placebo|0.1ml/kg once a day with food at dinner.
378883|NCT01302587|Drug|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
378884|NCT01302574|Dietary Supplement|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
378885|NCT01302561|Dietary Supplement|Sucrose|5 g of sucrose twice daily for 24 weeks
378886|NCT01302561|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
378887|NCT01302548|Device|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
378888|NCT01302548|Procedure|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
378889|NCT01302535|Other|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
378890|NCT01302535|Other|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
378891|NCT01302522|Behavioral|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
378892|NCT01302509|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
378893|NCT01302496|Biological|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
378894|NCT01302483|Drug|3% tetracaine HCL with 0.05% oxymetazoline HCL|1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
378895|NCT01302483|Drug|Lidocaine Injection|Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
378896|NCT01302470|Procedure|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
378897|NCT01302470|Procedure|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
378898|NCT01302444|Drug|Tadalafil|Tadalafil 40mg for 12 weeks
378899|NCT01302444|Drug|Placebo|Placebo for 12 weeks
378900|NCT01302431|Other|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
378901|NCT01302418|Device|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
378902|NCT01302405|Drug|PRI-724|Dose escalation
378903|NCT01302392|Drug|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days [Days 1, 2, 8, 9, 15, 16] for individual subjects).
378904|NCT01302392|Drug|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).~Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
378905|NCT01302379|Drug|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
378906|NCT01302379|Drug|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
378907|NCT01302379|Behavioral|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
378908|NCT01302379|Behavioral|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
378909|NCT01302366|Drug|TBL12|
378910|NCT01302353|Drug|Emulsified Isoflurane|
379000|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
379008|NCT01301560|Radiation|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
379009|NCT01301560|Radiation|Observation|No local treatment
378911|NCT01302340|Drug|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
378912|NCT01302340|Drug|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
378913|NCT01302340|Drug|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
378914|NCT01302327|Drug|Exenatide|Exenatide
378915|NCT01302314|Behavioral|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
378916|NCT01302301|Procedure|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
378917|NCT01302288|Procedure|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
378918|NCT01302275|Drug|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
378919|NCT01302249|Drug|Latanoprost 0.005%|q.d.
378920|NCT01302249|Drug|AR-12286 Ophthalmic Solution 0.5%|
378921|NCT01302249|Drug|Timolol maleate ophthalmic solution 0.5%|
378922|NCT01302236|Drug|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
378923|NCT01302210|Drug|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
378924|NCT01302197|Other|No intervention|longitudinal follow-up after stroke
378925|NCT01302184|Device|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.~A physical therapist supervised the treatment, adjusting treadmill speed and BWS.~Treatment was performed for 3 days/week, for 4 weeks"
378926|NCT01302184|Device|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.~A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.~Treatment was performed for 3 days/week, for 4 weeks."
378927|NCT01302171|Drug|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
378928|NCT01302171|Procedure|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
378929|NCT01302158|Drug|ASP1941|oral
378930|NCT01302158|Drug|Glimepiride|oral
378931|NCT01302145|Drug|ASP1941|Tablet
378932|NCT01302145|Drug|Metformin|Tablet
378933|NCT01302145|Drug|Placebo|Tablet
378934|NCT01302132|Drug|ASP1941|Oral solution
378935|NCT01302119|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
378936|NCT01302119|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
378937|NCT01302106|Drug|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
378938|NCT01302093|Drug|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
378939|NCT01302093|Drug|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
378940|NCT01302080|Drug|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
378941|NCT01302080|Behavioral|psychotherapy|Non-interventional study- as above
378942|NCT01302067|Drug|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
378943|NCT01302067|Drug|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
378944|NCT01302067|Drug|Placebo|Oral, 1 tablet per day, 12 weeks duration
378945|NCT01302054|Drug|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
378946|NCT01302054|Drug|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
378947|NCT01302041|Drug|Enzalutamide|Oral
378948|NCT01302028|Drug|ASP1941|Oral
378949|NCT01302015|Biological|RNL-Vascostem®|
378950|NCT01302002|Drug|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
379001|NCT01301612|Radiation|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
379002|NCT01301599|Drug|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
379003|NCT01301599|Drug|alpha blocker monotherapy|alpha blocker monotherapy group
378951|NCT01301989|Behavioral|Sleep Counselor Intervention|Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
378952|NCT01301989|Other|Sleep Education Control|"The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers"
378953|NCT01301963|Drug|plerixafor|Given SC
378954|NCT01301963|Biological|filgrastim|Given SC
378955|NCT01301950|Other|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
378956|NCT01301950|Other|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
378957|NCT01301937|Drug|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~High continuous dose: 20 mg/kg/day for 30 continuous days.~Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose"
378958|NCT01301924|Drug|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:~High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
378959|NCT01301911|Drug|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
378960|NCT01301898|Drug|GC1111_0.5mg/kg|
378961|NCT01301898|Drug|GC1111_1.0mg/kg|
378962|NCT01301898|Drug|Elaprase_0.5mg/kg|
378963|NCT01301872|Other|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
378964|NCT01301859|Behavioral|TIP|Treatment visits as usual with MD
378965|NCT01301833|Drug|teneligliptin|
378966|NCT01301833|Drug|glinide|
378967|NCT01301833|Drug|biguanide|
378968|NCT01301833|Drug|alpha-glucosidase inhibitor|
378969|NCT01301820|Drug|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
378970|NCT01301820|Drug|Lenalidomide|lenalidomide 10mg/d (d1- d21)
378971|NCT01301807|Drug|Carfilzomib|Given IV
378972|NCT01301807|Drug|Panobinostat|Given PO
378973|NCT01301794|Dietary Supplement|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
378974|NCT01301781|Drug|BLI801|BLI801 laxative - oral solution
378975|NCT01301781|Drug|Placebo|BLI801 placebo - oral solution
378976|NCT01301768|Other|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
378977|NCT01301755|Procedure|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
378978|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
378979|NCT01301742|Drug|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
378980|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
378981|NCT01301729|Drug|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
378982|NCT01301729|Drug|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
378983|NCT01301729|Drug|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
378984|NCT01301716|Drug|GDC-0980|Oral escalating dose
378985|NCT01301716|Drug|bevacizumab|Intravenous repeating dose
378986|NCT01301716|Drug|carboplatin|Intravenous repeating dose
378987|NCT01301716|Drug|cisplatin|intravenous repeating dose
378988|NCT01301716|Drug|paclitaxel|Intravenous repeating dose
378989|NCT01301716|Drug|pemetrexed|intravenous repeating dose
378990|NCT01301703|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
378991|NCT01301677|Drug|Hydrocortisone|Hydrocortisone liquid formulation
378992|NCT01301677|Drug|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
378993|NCT01301677|Drug|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
378994|NCT01301664|Other|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
378995|NCT01301651|Behavioral|balance training|30 minute each time, 2 times per week for 6 weeks.
378996|NCT01301625|Device|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
378997|NCT01301612|Drug|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
378998|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
379004|NCT01301599|Drug|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
379005|NCT01301586|Drug|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
379010|NCT01301521|Drug|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
379011|NCT01301508|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
379012|NCT01301508|Drug|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
379013|NCT01301508|Drug|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
379014|NCT01301508|Drug|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
379015|NCT01301495|Device|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
379016|NCT01301482|Device|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
379017|NCT01301469|Drug|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
379018|NCT01301469|Drug|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
379019|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
379020|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
379021|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
379022|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
379023|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
379024|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
379025|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
379026|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
379027|NCT01301456|Biological|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
379028|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
379029|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
379030|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
379031|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
379032|NCT01301443|Drug|Subretinally injected RetinoStat|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
379033|NCT01301430|Drug|H-1PV|H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
379034|NCT01301417|Device|ColonRing™|Creation of a circular Compression Anastomosis
379035|NCT01301404|Dietary Supplement|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
379036|NCT01301391|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
379037|NCT01301378|Procedure|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
379038|NCT01301352|Other|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
379039|NCT01301326|Device|subthreshold and threshold laser treatment|subthreshold laser treatment
379040|NCT01301326|Device|Threshold laser treatment|threshold laser treatment
379041|NCT01301313|Drug|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
379042|NCT01301313|Drug|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
379043|NCT01301300|Device|Disinfecting Cap|Replace standard practice with using the disinfecting cap
379044|NCT01301287|Drug|Chlorella|
379045|NCT01301274|Drug|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
379046|NCT01301274|Drug|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
379047|NCT01301261|Drug|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
379048|NCT01301261|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
379049|NCT01301261|Drug|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
379050|NCT01301248|Other|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
379051|NCT01301248|Other|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
379052|NCT01301222|Drug|Inj. Octreotide|100 mcg subcutaneously for 5 days
379053|NCT01301196|Behavioral|Educational workshop|3h attendance at educational workshop plus self-monitoring
379054|NCT01301183|Drug|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.~Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
379122|NCT01300598|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
379055|NCT01301183|Drug|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
379056|NCT01301170|Procedure|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
379057|NCT01301157|Drug|M518101|Proper quantity twice a day
379058|NCT01301157|Drug|placebo|Proper quantity twice a day
379059|NCT01301157|Drug|Dovonex|Proper quantity twice a day
379060|NCT01301131|Other|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
379061|NCT01301131|Other|control|usual oral care
379062|NCT01301105|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
379063|NCT01301105|Behavioral|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
379064|NCT01301092|Biological|LY2189265|administered intravenous, subcutaneous or intramuscular
379065|NCT01301079|Drug|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
379066|NCT01301079|Drug|Saline|Patients in group N (placebo) was administrated saline during surgery.
379067|NCT01301066|Drug|Pitavastatin|Pitavastatin 4 mg QD
379068|NCT01301066|Drug|Pravastatin|Pravastatin 40 mg QD
379069|NCT01301053|Other|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
379070|NCT01301053|Other|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose <70 mg/dl)and severe hypoglycemia (blood glucose<50 mg/dl)."
379071|NCT01301040|Drug|epirubicin, cyclophosphamide, docetaxel|"Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.~Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles."
379072|NCT01301027|Drug|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
379073|NCT01301027|Drug|Placebo|1 pill a day for 26 weeks
379074|NCT01301001|Drug|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
379075|NCT01301001|Drug|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
379076|NCT01300988|Drug|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
379077|NCT01300988|Drug|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
379078|NCT01300975|Drug|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
379079|NCT01300975|Procedure|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
379080|NCT01300975|Drug|placebo cream|topical emollient crean 3 times a day during 21 days
379081|NCT01300962|Drug|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
379082|NCT01300962|Drug|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
379083|NCT01300962|Drug|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
379084|NCT01300962|Drug|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
379085|NCT01300962|Drug|Lapatinib|lapatinib daily for 21 days in each cycle.
379086|NCT01300949|Diagnostic Test|Spaeth/Richman Contrast Sensitivity Test|internet based computerized contrast sensitivity test measuring central and peripheral vision using black and white stripes that decrease in contrast by fading to a white background.
379087|NCT01300949|Diagnostic Test|Pelli-Robson Contrast Sensitivity Chart|wall chart contrast sensitivity test measuring central vision using black letters that decrease in contrast by fading to a white background.
379088|NCT01300923|Drug|Acamprosate|
379089|NCT01300910|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
379090|NCT01300910|Procedure|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
379091|NCT01300897|Procedure|Cortical Evoked Potentials|A probe with 2 ring electrodes is placed in the anorectum. A small amount of electric current is passed separately through the anal and rectal electrodes.. The cortical evoked potentials from the anal and rectal sites are measured.
379092|NCT01300897|Procedure|Transcranial motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the scalp at the anorectal site on each side, and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
379093|NCT01300897|Procedure|Translumbosacral motor evoked potentials|A probe with 2 ring electrodes is placed in the anorectum. A magnetic coil is placed on the back at the lumbar plexus and sacral plexus levels and discharged using magnetic energy. The motor evoked potentials at the anal and rectal sites are measured.
379202|NCT01299948|Drug|Prednisolone|5 mg prednisolone orally per day
379094|NCT01300858|Drug|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
379095|NCT01300845|Procedure|Humidification|From randomization, oxygen therapy is humidified
379096|NCT01300845|Procedure|No Humidification|oxygen therapy is never humidified
379097|NCT01300832|Procedure|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
379098|NCT01300819|Other|Placebo|"Placebo patches of 2, 4, 6 & 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
379099|NCT01300819|Drug|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours~Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.~Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
379100|NCT01300793|Drug|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 & 11 q. 28 days.
379101|NCT01300780|Drug|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
379102|NCT01300780|Other|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
379103|NCT01300767|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
379104|NCT01300767|Device|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
379105|NCT01300767|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
379106|NCT01300754|Procedure|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
379107|NCT01300754|Procedure|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
379108|NCT01300754|Other|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
379109|NCT01300741|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
379110|NCT01300741|Device|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
379111|NCT01300741|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
379112|NCT01300728|Drug|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
379113|NCT01300728|Other|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
379114|NCT01300715|Procedure|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
379115|NCT01300676|Drug|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.~Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.~Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
379116|NCT01300650|Drug|Anakinra|Anakinra 100 mg subcutaneous injection daily
379117|NCT01300637|Drug|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
379118|NCT01300637|Drug|placebo|identical-appearing pill of placebo
379119|NCT01300624|Behavioral|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
379120|NCT01300611|Drug|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
379121|NCT01300611|Drug|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
379240|NCT01299610|Drug|GW870086 0.2%|White to slightly colored opaque cream
379123|NCT01300585|Other|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
379124|NCT01300572|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
379125|NCT01300572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
379126|NCT01300572|Drug|Cyclosporine|Given PO or IV
379127|NCT01300572|Drug|Fludarabine Phosphate|Given IV
379128|NCT01300572|Biological|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
379129|NCT01300572|Other|Laboratory Biomarker Analysis|Correlative studies
379130|NCT01300572|Drug|Mycophenolate Mofetil|Given PO or IV
379131|NCT01300572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
379132|NCT01300572|Other|Pharmacological Study|Correlative studies
379133|NCT01300572|Radiation|Total-Body Irradiation|Undergo TBI
379134|NCT01300572|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
379135|NCT01300559|Device|Tissuelink device|Tissuelink device plus Unipolar electrocautery
379136|NCT01300546|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
379137|NCT01300546|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
379138|NCT01300533|Drug|BIND-014|
379139|NCT01300520|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
379140|NCT01300468|Drug|PHA-848125AC|
379141|NCT01300455|Drug|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
379142|NCT01300455|Drug|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
379143|NCT01300442|Other|TEDS in COPD patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
379144|NCT01300442|Other|TEDS in healthy patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
379145|NCT01300429|Genetic|obtain tissue specimens|One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
379146|NCT01300403|Other|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
379147|NCT01300403|Other|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
379148|NCT01300403|Other|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
379149|NCT01300377|Drug|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
379150|NCT01300377|Drug|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
379151|NCT01300364|Drug|Reboxetine|8mg/day.
379152|NCT01300364|Drug|citalopram (SSRI)|30mg/day
379153|NCT01300351|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
379154|NCT01300351|Drug|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
379155|NCT01300338|Device|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
379156|NCT01300338|Device|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
379157|NCT01300325|Other|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
379241|NCT01299610|Drug|FP 0.05%|White cream
379242|NCT01299610|Drug|Placebo|White to slightly colored opaque cream
379158|NCT01300312|Drug|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
379159|NCT01300312|Drug|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
379160|NCT01300299|Radiation|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within <2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
379161|NCT01300286|Drug|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
379162|NCT01300273|Dietary Supplement|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
379163|NCT01300260|Biological|LY2189265|Administered subcutaneously
379164|NCT01300260|Drug|Placebo|Administered subcutaneously
379165|NCT01300260|Drug|Insulin|Administered intravenously
379166|NCT01300260|Drug|Glucose|Administered intravenously
379167|NCT01300260|Drug|Glucagon|Administered intravenously
379168|NCT01300247|Drug|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
379169|NCT01300247|Drug|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
379170|NCT01300247|Drug|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
379171|NCT01300247|Drug|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
379172|NCT01300234|Drug|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
379173|NCT01300234|Drug|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
379174|NCT01300208|Drug|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
379175|NCT01300208|Other|Placebo|
379176|NCT01300182|Other|Whole body vibration therapy|The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
379177|NCT01300182|Other|Control|Conventional post-operative physical therapy exercises and rehabilitation.
379178|NCT01300169|Behavioral|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
379179|NCT01300169|Behavioral|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
379180|NCT01300156|Drug|Oxaliplatin-based chemotherapy (ESHAOx)|"Etoposide 40 mg/m2, D1-4~Methylprednisolone 500mg, D1-5~Cytarabine 2 g/m2, D5~Oxaliplatin 130 mg/m2, D1"
379181|NCT01300143|Other|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
379182|NCT01300143|Other|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
379183|NCT01300130|Dietary Supplement|low docosahexaenoic acid formula|
379184|NCT01300130|Dietary Supplement|medium docosahexaenoic acid formula|
379185|NCT01300130|Dietary Supplement|high docosahexaenoic acid formula|
379186|NCT01300130|Dietary Supplement|breast milk|a non randomized group of breast milk fed infants was included
379187|NCT01300104|Behavioral|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.~Restrictions: None."
379188|NCT01300104|Behavioral|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
379189|NCT01300104|Behavioral|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
379190|NCT01300078|Drug|MF101|MF101 10 g/day MF101 15 g/day
379191|NCT01300052|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
379192|NCT01300052|Drug|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
379193|NCT01300026|Drug|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
379194|NCT01300013|Drug|Placebo|48-hour infusion of placebo
379195|NCT01300013|Drug|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
379196|NCT01300000|Other|Human Milk|ad lib
379197|NCT01300000|Other|Investigational infant formula|ad lib
379198|NCT01300000|Other|Milk based standard infant formula|ad lib
379199|NCT01299987|Radiation|intraoperative radiotherapy|intraoperative single dose radiotherapy (20 Gy)
379200|NCT01299974|Other|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
379201|NCT01299961|Drug|abatacept|125 mg once a week up to 12 months.
379203|NCT01299935|Behavioral|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
379204|NCT01299935|Behavioral|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
379205|NCT01299922|Drug|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
379206|NCT01299922|Drug|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
379207|NCT01299909|Behavioral|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
379208|NCT01299909|Behavioral|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
379209|NCT01299909|Behavioral|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
379210|NCT01299896|Other|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
379211|NCT01299896|Other|Usual Care|Standard therapy to help participants with smoking cessation.
379212|NCT01299883|Other|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
379213|NCT01299870|Drug|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
379214|NCT01299870|Drug|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
379215|NCT01299857|Drug|Rituximab|375mg/m2
379216|NCT01299844|Behavioral|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
379217|NCT01299831|Behavioral|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
379218|NCT01299831|Behavioral|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
379219|NCT01299831|Drug|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
379220|NCT01299831|Drug|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.~During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
379221|NCT01299805|Drug|Vortioxetine|Encapsulated tablet
379222|NCT01299805|Drug|Placebo|Vortioxetine placebo-matching capsules.
379223|NCT01299792|Other|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
379224|NCT01299779|Drug|PEG-SD|"PEG-SD~Bisacodyl: two 5-mg tablets at 3 pm day prior~1L sports drink* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior~1L SD* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy~Same flavor, non-red Gatorade® for all patients."
379225|NCT01299779|Drug|PEG-ELS|"1L + 500 cc clear liquids at 6 pm night prior~1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
379226|NCT01299766|Behavioral|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
379227|NCT01299766|Behavioral|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
379228|NCT01299753|Drug|placebo|identically packed placebo
379229|NCT01299753|Drug|propranolol|20-40 mg q6-8h
379230|NCT01299740|Behavioral|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
379231|NCT01299740|Other|Control Group|Treatment as usual
379232|NCT01299727|Biological|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
379233|NCT01299727|Biological|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
379234|NCT01299727|Biological|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
379235|NCT01299701|Drug|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
379236|NCT01299662|Drug|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
379237|NCT01299636|Drug|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
379238|NCT01299623|Behavioral|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
379239|NCT01299610|Drug|GW870086 2.0%|White to slightly colored opaque cream
379388|NCT01298388|Other|study of socioeconomic and demographic variables|
379243|NCT01299597|Drug|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
379244|NCT01299597|Drug|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
379245|NCT01299597|Drug|SB649868|20mg daily given for 14 days.
379246|NCT01299584|Drug|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
379247|NCT01299571|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
379248|NCT01299558|Drug|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
379249|NCT01299558|Drug|fluticasone furoate|Single IV dose of FF (250mcg)
379250|NCT01299558|Drug|GW642444|Single IV dose of GW642444 (55mcg)
379251|NCT01299532|Device|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
379252|NCT01299519|Behavioral|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
379253|NCT01299519|Behavioral|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
379254|NCT01299493|Other|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
379255|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
379256|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
379257|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
379258|NCT01299480|Biological|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
379259|NCT01299480|Biological|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
379260|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
379261|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
379262|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
379263|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
379264|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
379265|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
379266|NCT01299454|Drug|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
379267|NCT01299441|Device|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
379268|NCT01299428|Device|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
379269|NCT01299415|Drug|Vadimezan™|
379270|NCT01299402|Dietary Supplement|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
379271|NCT01299402|Dietary Supplement|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
379272|NCT01299389|Drug|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
379273|NCT01299389|Drug|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
379274|NCT01299376|Drug|L50/H12.5/A5|
379275|NCT01299376|Drug|L50/H12.5|
379276|NCT01299376|Drug|Placebo to L50/H12.5/A5|
379277|NCT01299376|Drug|Placebo to L50/H12.5|
379278|NCT01299363|Behavioral|Dilator use|Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
379279|NCT01299350|Other|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
379280|NCT01299337|Drug|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
379281|NCT01299324|Device|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
379282|NCT01299311|Behavioral|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
379389|NCT01298362|Drug|Aromatase Inhibitors|
379283|NCT01299311|Behavioral|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
379284|NCT01299298|Drug|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
379285|NCT01299298|Drug|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
379286|NCT01299285|Drug|LY3009104|Administered orally
379287|NCT01299272|Drug|LY2216684|
379288|NCT01299272|Drug|Placebo|
379289|NCT01299272|Drug|SSRI|Participants should have been on their SSRI for at least 8 weeks prior and were to continue on their stable dose throughout the study.
379290|NCT01299259|Behavioral|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
379291|NCT01299246|Procedure|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
379292|NCT01299233|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
379293|NCT01299220|Drug|Acitretin|Acitretin 10 mg by mouth daily
379294|NCT01299194|Drug|ATORVASTATIN|80mg once daily for 3 months
379295|NCT01299181|Drug|Atorvastatin|80mg once daily orally
379296|NCT01299155|Device|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
379297|NCT01299155|Device|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
379298|NCT01299142|Drug|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
379299|NCT01299116|Drug|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
379300|NCT01299116|Drug|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
379301|NCT01299116|Drug|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
379302|NCT01299116|Drug|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
379303|NCT01299116|Drug|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
379304|NCT01299103|Device|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
379305|NCT01299090|Device|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
379306|NCT01299051|Behavioral|Steps to Health|"Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:~Face-to-face visit with counselor during Month 1 to set specific health goals.~Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.~Monthly generic health education materials sent via e-mail.~Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments."
379307|NCT01299051|Behavioral|Steps to Health Plus!|"The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:~Face-to-face visit with counselor at Month 1~Meeting with exercise physiologist in Month 2~Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)~Meeting with exercise physiologist during Month 5~Quarterly biometric feedback (Months 3, 6, 9, and 12)~Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments."
379308|NCT01299038|Drug|rosuvastatin|Taken orally once a day for 4 weeks
379309|NCT01299025|Other|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
379310|NCT01299012|Drug|Liraglutide|Liraglutide s/c 0.6mg once daily.
379311|NCT01298999|Drug|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
379312|NCT01298999|Drug|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
379313|NCT01298986|Procedure|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
379314|NCT01298986|Procedure|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
379390|NCT01298362|Drug|Chemotherapy|
379315|NCT01298986|Procedure|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
379316|NCT01298986|Procedure|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
379317|NCT01298973|Drug|Viscoat|One group will receive Viscoat for incision closure
379318|NCT01298973|Drug|Saline|One group will receive Saline to irrigate the wound
379319|NCT01298960|Drug|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
379320|NCT01298947|Device|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
379321|NCT01298934|Drug|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
379322|NCT01298921|Drug|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
379323|NCT01298921|Drug|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
379324|NCT01298908|Procedure|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
379325|NCT01298908|Procedure|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
379326|NCT01298908|Procedure|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
379327|NCT01298882|Drug|Diacerein|
379328|NCT01298882|Other|Placebo|
379329|NCT01298869|Biological|HPV-6/11/16/18 vaccine|HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
379330|NCT01298856|Procedure|hydrotherapy|hydrotherapy and ankle taping and land-based
379331|NCT01298843|Drug|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
379332|NCT01298830|Drug|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
379333|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
379334|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
379335|NCT01298804|Behavioral|Problem Solving Education and Activated Referral to Care|"The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time."
379336|NCT01298791|Behavioral|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
379337|NCT01298791|Behavioral|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
379338|NCT01298778|Drug|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
379339|NCT01298778|Drug|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
379340|NCT01298778|Drug|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
379341|NCT01298765|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
379342|NCT01298752|Drug|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
379343|NCT01298752|Drug|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
379344|NCT01298726|Other|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
379345|NCT01298726|Other|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
379346|NCT01298713|Drug|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
379347|NCT01298713|Drug|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
379348|NCT01298700|Drug|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
379349|NCT01298700|Drug|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
379350|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00013%|Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
379351|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00033%|Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
379352|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.001%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
379353|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00267%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
379354|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.004%|
379355|NCT01298687|Drug|Travoprost Vehicle|Inactive ingredients used as an active comparator
379356|NCT01298661|Other|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
379357|NCT01298635|Procedure|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
379358|NCT01298635|Procedure|trabeculectomy|
379359|NCT01298609|Device|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
379360|NCT01298596|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
379361|NCT01298596|Procedure|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
379362|NCT01298583|Behavioral|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
379363|NCT01298570|Drug|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
379364|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
379365|NCT01298570|Drug|Placebo|Placebo, 160 mg, PO, Days 4-10 and Days 18-24 of 28 day cycle
379366|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
379367|NCT01298544|Procedure|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
379368|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
379369|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
379370|NCT01298531|Drug|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
379371|NCT01298518|Drug|PF-04620110|5 mg of PF-04620110 given once daily
379372|NCT01298518|Drug|PF-04620110|2.5 mg of PF-04620110 given twice daily
379373|NCT01298518|Drug|Placebo|Matching placebo giving for 4 weeks
379374|NCT01298505|Drug|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
379375|NCT01298505|Drug|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
379376|NCT01298505|Drug|placebo|placebo given twice daily for 7 days
379377|NCT01298492|Drug|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
379378|NCT01298479|Other|Uniject|single use container
379379|NCT01298466|Drug|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
379380|NCT01298414|Genetic|RNA analysis|
379381|NCT01298414|Other|laboratory biomarker analysis|
379382|NCT01298401|Biological|ganitumab|
379383|NCT01298401|Drug|capecitabine|
379384|NCT01298401|Drug|gemcitabine hydrochloride|
379385|NCT01298401|Radiation|3-dimensional conformal radiation therapy|
379386|NCT01298388|Other|medical chart review|
379387|NCT01298388|Other|questionnaire administration|
379391|NCT01298336|Drug|Clarithromycin|500 mg twice a day seven days a week
379392|NCT01298336|Drug|Moxifloxacin|400 mg per day seven days a week
379393|NCT01298323|Behavioral|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
379394|NCT01298323|Drug|Vandetanib|Treatment 300mg vandetanib opel label.
379395|NCT01298310|Drug|Xylocaine|1 mg/mL solution for injection
379396|NCT01298310|Drug|Xylocaine|10 mg/mL solution for injection
379397|NCT01298310|Drug|Placebo|solution for injection
379398|NCT01298297|Drug|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
379399|NCT01298297|Drug|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
379400|NCT01298284|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
379401|NCT01298271|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
379402|NCT01298258|Drug|Aliskiren|Aliskiren 150mg
379403|NCT01298232|Other|Cardiophonogram|Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
379404|NCT01298219|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
379405|NCT01298219|Drug|Placebo|0 mcg capsules twice daily (BID)
379406|NCT01298193|Drug|Aprepitant|Efficacy phase (second cycle)
379407|NCT01298180|Drug|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
379408|NCT01298180|Procedure|DEXA, blood tests, H.G.P.O, osseous age.|"SPW, GHD, SPW-B :~blood tests : centralized dosage H.G.P.O : adjusted to children's age."
379409|NCT01298180|Procedure|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
379410|NCT01298167|Device|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
379411|NCT01298154|Other|Dietary intervention|Dietary treatments with beverages
379412|NCT01298141|Biological|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)~Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
379413|NCT01298128|Drug|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
379414|NCT01298128|Drug|marvelon|marvelon 21 daily
379415|NCT01298102|Biological|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
379416|NCT01298089|Device|Carriazo Pendular microkeratome|
379417|NCT01298076|Drug|bevacizumab|Anti-VEGF drug for intravitreal injection
379418|NCT01298076|Drug|dexamethasone|Slow-release steroid formulation for intravitreal injection
379419|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
379420|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
379421|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
379422|NCT01298050|Procedure|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
379423|NCT01298024|Other|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
379424|NCT01298011|Drug|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
379425|NCT01297998|Drug|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
379426|NCT01297985|Behavioral|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses.
379427|NCT01297972|Biological|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
379428|NCT01297959|Drug|E-101 Solution 300 GU/ml|8 mL of E-101 Solution at a pMPO concentration of 300 GU/ml applied topically twice to surgical wound site (just after incision without penetration of the rectus fascia or linea alba and just prior to skin closure after closure of rectus fascia or linea alba).
379429|NCT01297959|Drug|Saline solution|8 mL of Placebo topically twice to surgical wound site (just after incision without penetration of the peritoneal fascia and just prior to skin closure).
379430|NCT01297946|Device|Conventional continuous subcutaneous insulin infusion therapy|
379431|NCT01297946|Device|Dual-hormone closed-loop|
379432|NCT01297933|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
379433|NCT01297920|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
379434|NCT01297920|Drug|Brinzolamide ophthalmic suspension, 1%|
379435|NCT01297920|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
379436|NCT01297907|Other|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
379437|NCT01297907|Other|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
379438|NCT01297907|Other|Blood Test|Blood Tests (Eosinophil Count)
379439|NCT01297907|Other|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
379440|NCT01297894|Drug|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
379441|NCT01297894|Drug|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
379442|NCT01297868|Other|exercise|
379443|NCT01297855|Drug|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
379444|NCT01297855|Drug|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
379445|NCT01297842|Drug|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
379446|NCT01297842|Drug|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
379447|NCT01297829|Drug|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
379448|NCT01297829|Other|IV Placebo|IV normal saline
379449|NCT01297816|Drug|placebo|100mg,BD, fo three month
379450|NCT01297816|Drug|Minocycline|100mg
379451|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
379452|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
379453|NCT01297790|Other|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
379454|NCT01297790|Other|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
379455|NCT01297790|Other|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
379456|NCT01297777|Drug|Imatinib Mesylate|"In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.~In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
379457|NCT01297764|Drug|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)~15 15 300 40~20 15 300 40~20 25 300 40~20/27* 25 300 40~20/27* 25 400 40"
379458|NCT01297738|Other|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
379459|NCT01297738|Other|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
379460|NCT01297738|Other|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
379461|NCT01297738|Other|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
379462|NCT01297725|Procedure|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
379463|NCT01297725|Procedure|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
379464|NCT01297712|Device|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
379465|NCT01297699|Drug|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
379466|NCT01297699|Drug|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
379467|NCT01297686|Other|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
379468|NCT01297686|Other|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
379469|NCT01297686|Other|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
379470|NCT01297686|Other|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
379471|NCT01297686|Other|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
379472|NCT01297686|Other|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
379473|NCT01297686|Other|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
379621|NCT01296451|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
379474|NCT01297686|Drug|Dexamethasone|"A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area."
379475|NCT01297673|Procedure|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
379476|NCT01297660|Other|Video-urodynamic examination|
379477|NCT01297647|Procedure|urodynamic examination|"Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.~Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux."
379478|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
379479|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
379480|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.~Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
379481|NCT01297621|Procedure|reduction mammaplasty|conventional reduction mammaplasty
379482|NCT01297621|Other|control|follow up, questionnaire responses
379483|NCT01297608|Drug|caoted suppository|coated suppository with active drug
379484|NCT01297608|Drug|coated suppository|coated suppository with placebo
379485|NCT01297595|Drug|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
379486|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
379487|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
379488|NCT01297569|Drug|Ranibizumab|
379489|NCT01297556|Behavioral|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
379490|NCT01297543|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
379491|NCT01297543|Drug|G-CSF|Background therapy
379492|NCT01297530|Drug|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
379493|NCT01297517|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
379494|NCT01297517|Drug|Brinzolamide ophthalmic suspension, 1%|
379495|NCT01297517|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
379496|NCT01297491|Drug|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
379497|NCT01297465|Drug|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
379498|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
379499|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
379500|NCT01297465|Drug|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
379501|NCT01297452|Drug|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
379502|NCT01297452|Drug|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
379503|NCT01297452|Drug|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
379504|NCT01297452|Drug|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
379505|NCT01297439|Procedure|suctioning of fetal nose and mouth during delivery|"Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes)."
379622|NCT01296451|Biological|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
379506|NCT01297439|Procedure|Pushing maneuver|"The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia."
379507|NCT01297413|Biological|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
379508|NCT01297400|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
379509|NCT01297400|Procedure|Standard practice for partial thickness burns|Daily application of collagenase ointment with polysporin powder and covered with gauze dressings
379510|NCT01297387|Other|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
379511|NCT01297374|Behavioral|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
379512|NCT01297361|Other|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
379513|NCT01297348|Drug|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
379514|NCT01297348|Drug|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
379515|NCT01297335|Drug|clonidine|Intrathecal Clonidine
379516|NCT01297322|Other|Manual compression|Standard of Care
379517|NCT01297322|Device|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
379518|NCT01297309|Drug|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
379519|NCT01297283|Other|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
379520|NCT01297283|Other|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
379521|NCT01297270|Drug|BI201335|QD BI 201335
379522|NCT01297270|Drug|PegIFN/RBV|
379523|NCT01297270|Drug|BI201335|QD (once daily) BI 201335
379524|NCT01297270|Drug|Placebo|
379525|NCT01297257|Device|Stent implantation|Single arm, open label stent implantation
379526|NCT01297244|Drug|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
379527|NCT01297231|Other|MRI|"Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).~During Tamoxifen Treatment:~Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.~Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.~Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated."
379528|NCT01297218|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
379529|NCT01297205|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
379530|NCT01297192|Drug|solifenacin succinate|Oral
379531|NCT01297192|Drug|mirabegron|Oral
379532|NCT01297179|Drug|Mirabegron|Oral
379533|NCT01297179|Drug|Minidril|Oral
379534|NCT01297179|Drug|Placebo|Oral
379535|NCT01297166|Drug|LEO 27989 ointment|once daily application, 3weeks
379536|NCT01297166|Drug|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
379537|NCT01297166|Drug|Calcipotriol ointment|once daily application, 3weeks
379538|NCT01297166|Drug|Vehicle ointment|once daily application, 3weeks
379539|NCT01297153|Device|Intraocular Lens (Acrysof IOL)|IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
379540|NCT01297153|Device|No IOL|No IOL will be implanted in these eyes
379541|NCT01297140|Behavioral|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
379542|NCT01297114|Drug|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
379543|NCT01297101|Drug|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
379544|NCT01297088|Drug|BAY86-9596|One single dose administration of a diagnostic agent
379545|NCT01297075|Behavioral|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
379546|NCT01297062|Drug|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
379547|NCT01297062|Drug|Moxifloxacin|Oral Moxifloxacin (400 mg)
379548|NCT01297062|Drug|Placebo comparator|IV Placebo (matching volume of placebo)
379587|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
379623|NCT01296451|Biological|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
379549|NCT01297049|Behavioral|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
379550|NCT01297036|Drug|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
379551|NCT01297036|Drug|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
379552|NCT01297023|Dietary Supplement|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d]
379553|NCT01297023|Dietary Supplement|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 [10µg/d]
379554|NCT01297023|Dietary Supplement|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d] and vitamin d3 (10µg/d]
379555|NCT01297023|Other|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
379556|NCT01297010|Drug|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
379557|NCT01297010|Drug|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
379558|NCT01296997|Dietary Supplement|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
379559|NCT01296997|Other|placebo|the subjects consumed a bread without pentacalcium phosphate
379560|NCT01296971|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
379561|NCT01296971|Drug|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
379562|NCT01296971|Drug|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
379563|NCT01296958|Drug|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
379564|NCT01296958|Behavioral|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
379565|NCT01296945|Other|Kiosk|Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods
379566|NCT01296945|Other|paper|Participants will receive a paper handout with nutrition educational information.
379567|NCT01296945|Other|Kiosk PLUS paper|Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
379568|NCT01296945|Other|Kiosk PLUS web|Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
379569|NCT01296932|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
379570|NCT01296906|Behavioral|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
379571|NCT01296906|Behavioral|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
379572|NCT01296893|Behavioral|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
379573|NCT01296854|Other|Spa therapy|3 weeks of spa therapy
379574|NCT01296841|Device|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
379575|NCT01296815|Drug|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
379576|NCT01296802|Drug|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
379577|NCT01296789|Other|Tissue perfusion guided protocol|A tissue perfusion guided protocol is used to guide hemodynamic therapy
379578|NCT01296789|Other|Usual Care|Usual Care
379579|NCT01296776|Other|wellness control group.|Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
379580|NCT01296776|Device|whole-body electromyostimulation|3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
379581|NCT01296763|Drug|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
379582|NCT01296763|Drug|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
379583|NCT01296763|Drug|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
379584|NCT01296763|Drug|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
379585|NCT01296763|Drug|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
379586|NCT01296750|Other|Early Physiotherapy start|Physiotherapy starting at one day post op
379619|NCT01296490|Other|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
379588|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
379589|NCT01296711|Biological|CDP6038|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
379590|NCT01296698|Drug|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
379591|NCT01296698|Drug|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
379592|NCT01296672|Drug|Finasteride|Finasteride 5mg every day by mouth for 3 months
379593|NCT01296672|Drug|Placebo|Placebo every day by mouth for 3 months
379594|NCT01296659|Drug|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
379595|NCT01296646|Drug|Naltrexone|50 mg oral naltrexone once/day
379596|NCT01296646|Behavioral|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
379597|NCT01296646|Drug|Placebo|An inactive pill to control for non-pharmacological responses.
379598|NCT01296633|Behavioral|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
379599|NCT01296620|Drug|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
379600|NCT01296620|Drug|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
379601|NCT01296620|Drug|5% dextrose in water|Placebo
379602|NCT01296607|Drug|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
379603|NCT01296607|Drug|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
379604|NCT01296594|Other|Usual Care|Usual Care
379605|NCT01296594|Behavioral|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
379606|NCT01296581|Drug|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
379607|NCT01296568|Drug|LY2603618|Administered intravenously
379608|NCT01296568|Drug|Pemetrexed|Administered intravenously
379609|NCT01296568|Drug|Gemcitabine|Administered intravenously
379610|NCT01296555|Drug|Fulvestrant|Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics [SmPC]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
379611|NCT01296555|Drug|GDC-0032|Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
379612|NCT01296555|Drug|Letrozole|Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
379613|NCT01296555|Drug|Midazolam|Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.
379614|NCT01296516|Behavioral|Non-intervention group|A pedometer and written material on a healthy lifestyle.
379615|NCT01296516|Behavioral|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
379616|NCT01296516|Behavioral|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
379617|NCT01296503|Drug|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.~The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
379618|NCT01296503|Drug|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
379620|NCT01296464|Drug|Carbidopa|Capsules
379624|NCT01296438|Drug|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
379625|NCT01296438|Drug|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
379626|NCT01296425|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
379627|NCT01296412|Drug|sitagliptin|100 mg tablet, orally, once daily.
379628|NCT01296412|Drug|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
379629|NCT01296412|Drug|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
379630|NCT01296412|Drug|metformin|metformin tablets at a dose of ≥1500 mg per day
379631|NCT01296386|Biological|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
379632|NCT01296360|Biological|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
379633|NCT01296360|Biological|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
379634|NCT01296347|Drug|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
379635|NCT01296334|Drug|morphine LO|intravenous infusion, 10 mg, once, 4 hours
379636|NCT01296334|Drug|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
379637|NCT01296334|Drug|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
379638|NCT01296334|Drug|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
379639|NCT01296334|Other|saline|intravenous infusion, 0.9% saline, once, 4 hours
379640|NCT01296321|Behavioral|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
379641|NCT01296321|Behavioral|Waitlist|Passive waitlist during 8-10 weeks.
379642|NCT01296308|Other|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
379643|NCT01296295|Behavioral|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
379644|NCT01296295|Behavioral|Smoking cessation advice|Brief smoking cessation advice
379645|NCT01296282|Device|Medronics CRT Optivol Impedance Measurement|Pacemaker
379646|NCT01296282|Device|External Thoracic Impedance Measurement|
379647|NCT01296269|Drug|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
379648|NCT01296269|Drug|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
379649|NCT01296269|Drug|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
379650|NCT01296256|Drug|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
379651|NCT01296243|Drug|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
379652|NCT01296230|Procedure|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
379653|NCT01296217|Procedure|lymph nod detection|
379654|NCT01296204|Drug|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
379655|NCT01296191|Drug|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
379656|NCT01296191|Drug|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
379657|NCT01296178|Drug|IDARUBICINE|"Administration of chemotherapy induction~Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
379658|NCT01296178|Drug|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
379659|NCT01296165|Behavioral|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value <0.05 will be deemed to represent statistical significance.
379660|NCT01296152|Drug|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
379661|NCT01296139|Drug|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
379690|NCT01295840|Device|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
379691|NCT01295827|Biological|Pembrolizumab|IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
379662|NCT01296113|Drug|Chemotherapy|"Pemetrexed + Carboplatin~On D1 of a 21-day cycle:~Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:~Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:~Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance~• 4 cycles total"
379663|NCT01296100|Behavioral|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
379664|NCT01296100|Behavioral|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
379665|NCT01296087|Drug|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
379666|NCT01296087|Drug|Placebo|Matching placebo capsule given once daily on Days 1 to 28
379667|NCT01296074|Drug|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
379668|NCT01296048|Device|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
379669|NCT01296035|Biological|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
379670|NCT01296022|Device|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
379671|NCT01296022|Device|Implantation of transvenous ICD|Implantation of transvenous ICD
379672|NCT01296009|Drug|Traditional Chinese medicine(Zhuyun Recipe)|The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
379673|NCT01295970|Procedure|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
379674|NCT01295970|Procedure|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
379675|NCT01295957|Behavioral|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
379676|NCT01295957|Behavioral|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
379677|NCT01295957|Other|control|advise and informal counseling
379678|NCT01295944|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC x (CrCl + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician
379679|NCT01295944|Drug|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician.
379680|NCT01295931|Drug|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
379681|NCT01295931|Procedure|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
379682|NCT01295918|Dietary Supplement|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
379683|NCT01295905|Device|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
379684|NCT01295905|Device|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
379685|NCT01295892|Drug|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
379686|NCT01295879|Drug|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
379687|NCT01295866|Device|nasal nitric oxide|
379688|NCT01295853|Procedure|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
379689|NCT01295853|Procedure|t4 symapthicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
379692|NCT01295814|Drug|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
379693|NCT01295814|Other|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
379694|NCT01295788|Device|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
379695|NCT01295788|Device|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
379696|NCT01295775|Drug|sulodexide|"A (SULODEXIDE GROUP):~50 mg a day by oral route (1+1 capsules/day) for 360 days~B (PLACEBO GROUP):~Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A."
379697|NCT01295762|Other|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
379698|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
379699|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
379700|NCT01295736|Drug|Sildenafil|Sildenafil 20 mg TID per os during 90 days
379701|NCT01295736|Drug|placebo|Placebo pills TID per os during 90 days
379702|NCT01295723|Radiation|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)~Single reference dose per fraction: 2.7 Gy (ICRU)~Number of fractions: 15~Number of fractions per week: 5~Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)~Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
379703|NCT01295723|Radiation|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
379704|NCT01295710|Biological|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
379705|NCT01295710|Biological|Placebo|250 mL normal saline, IV infusion over 6-16 hours 3 days prior to transplantation
379706|NCT01295697|Drug|EZN-2208|Experimental
379707|NCT01295684|Other|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
379708|NCT01295684|Other|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
379709|NCT01295671|Behavioral|Provision of beverages|Home delivery of specified beverage type
379710|NCT01295645|Drug|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
379711|NCT01295645|Other|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
379712|NCT01295632|Drug|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
379713|NCT01295632|Drug|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
379714|NCT01295632|Drug|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
379715|NCT01295619|Device|I-020805|A thin layer of I-020805 applied up to two times on the sutured dura mater
379716|NCT01295606|Drug|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
379717|NCT01295593|Drug|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
379718|NCT01295580|Device|Hyaluronic acid, stabilized|Hyaluronic acid
379719|NCT01295580|Device|Hyaluronic acid|Hyaluronic acid
379720|NCT01295567|Drug|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
379721|NCT01295567|Drug|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
379722|NCT01295554|Other|NCE MRA and CE MRA|"Each patient will receive on the same day:~NCE MRA~CE MRA usually performed in the clinical routine~After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
379723|NCT01295528|Device|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
379724|NCT01295515|Drug|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
379725|NCT01295502|Drug|Carboplatin|Given IV
379726|NCT01295502|Drug|Cisplatin|Given IV
379727|NCT01295502|Radiation|External Beam Radiation Therapy|Undergo EBRT
379728|NCT01295502|Radiation|Internal Radiation Therapy|Undergo brachytherapy
379729|NCT01295502|Drug|Paclitaxel|Given IV
379730|NCT01295489|Other|Laboratory Biomarker Analysis|Correlative studies
379731|NCT01295476|Genetic|gene expression analysis|
379732|NCT01295476|Genetic|microarray analysis|
379733|NCT01295476|Other|laboratory biomarker analysis|
379734|NCT01295463|Other|questionnaire administration|
379735|NCT01295463|Other|study of socioeconomic and demographic variables|
379736|NCT01295463|Procedure|assessment of therapy complications|
379737|NCT01295463|Procedure|fertility assessment and management|
379738|NCT01295463|Procedure|psychosocial assessment and care|
379739|NCT01295463|Procedure|quality-of-life assessment|
379740|NCT01295450|Drug|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).~Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
380493|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
379741|NCT01295450|Drug|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
379742|NCT01295437|Device|Vypro II mesh|partly absorbable mesh
379743|NCT01295437|Device|Premilene LP|lightweight mesh
379744|NCT01295437|Device|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
379745|NCT01295424|Other|No intervention|Observational study, no interventions
379746|NCT01295411|Device|Magnetic Resonance Imaging|
379747|NCT01295411|Other|EVALUATION NEUROPSYCHOLOGICAL|
379748|NCT01295398|Device|nebulisations|
379749|NCT01295385|Other|NUCLEAR MAGNETIC RESONANCE IMAGING|"Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers."
379750|NCT01295385|Other|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
379751|NCT01295372|Drug|Zicronapine|7.5 mg/day; orally
379752|NCT01295372|Drug|Risperidone|5 mg/day; orally
379753|NCT01295359|Other|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
379754|NCT01295346|Other|Head CT scan and blood draw|
379755|NCT01295333|Drug|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
379756|NCT01295333|Drug|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
379757|NCT01295320|Procedure|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
379758|NCT01295307|Drug|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
379759|NCT01295294|Drug|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
379760|NCT01295294|Drug|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
379761|NCT01295294|Drug|Placebo|3 times daily per oral during bleeding/spotting episodes
379762|NCT01295294|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
379763|NCT01295281|Device|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
379764|NCT01295281|Device|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
379765|NCT01295268|Other|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
379766|NCT01295268|Other|Inert oil|A specified amount of inert oil will be applied daily to area.
379767|NCT01295229|Procedure|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
379768|NCT01295229|Behavioral|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
379769|NCT01295216|Behavioral|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
379770|NCT01295203|Behavioral|website assess|The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
379771|NCT01295177|Drug|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
379772|NCT01295164|Device|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
379773|NCT01295164|Device|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
379774|NCT01295151|Drug|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
379850|NCT01294605|Biological|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
379851|NCT01294592|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
379852|NCT01294592|Drug|tamsulosin|Take 1 capsule daily when escalation criteria met
379775|NCT01295151|Drug|Abatacept|"Abatacept will be administered at a dose determined by body weight:~Body Weight (kg) Dose (mg) < 60kg = 500 mg~> or equal to 60kg and < or equal to 100kg = 750 mg > 100 kg = 1000mg~The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
379776|NCT01295151|Biological|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).~In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.~Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
379777|NCT01295151|Drug|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
379778|NCT01295151|Drug|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.~The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
379779|NCT01295151|Drug|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.~The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.~Further treatment will be prescribed at the discretion of the treating clinician."
379780|NCT01295151|Drug|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.~Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.~The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
379781|NCT01295138|Drug|Lactulose|Lactulose liquid. 15mls twice daily
379782|NCT01295125|Device|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
379783|NCT01295125|Procedure|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
379784|NCT01295112|Drug|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
379785|NCT01295112|Drug|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
379786|NCT01295099|Drug|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
379787|NCT01295099|Radiation|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
379788|NCT01295099|Drug|Triamcinolone|TAC 10mg in 1ml injected intralesional
379789|NCT01295086|Drug|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
379790|NCT01295086|Drug|Oxaliplatin|100 mg/m² day 1 every 3. week
379791|NCT01295086|Drug|Capecitabine|1250 mg/² continuously
379792|NCT01295086|Drug|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
379793|NCT01295073|Drug|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.~All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
379794|NCT01295073|Other|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
379795|NCT01295060|Drug|Octreotide|84 mg Octreotide Implant
379796|NCT01295047|Drug|Atenolol|
379797|NCT01295047|Drug|VERAPAMIL|240 MG SR
379798|NCT01295047|Drug|Perindopril|4 MG
379799|NCT01295034|Dietary Supplement|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
379800|NCT01295034|Drug|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
379801|NCT01294995|Dietary Supplement|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
379802|NCT01294995|Dietary Supplement|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
379803|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
379804|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
379805|NCT01294982|Drug|Placebo|Placebo Oral Capsules twice daily
379806|NCT01294969|Drug|AL-4943A|Once daily topical ocular allergy medication used for 7 days
379807|NCT01294956|Other|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
379808|NCT01294956|Other|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
379809|NCT01294943|Device|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
379810|NCT01294930|Other|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
379811|NCT01294917|Device|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
379812|NCT01294917|Device|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
379813|NCT01294917|Device|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
379814|NCT01294891|Other|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
379853|NCT01294579|Biological|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase~1000 mg IV every 2 months for 2 years"
380155|NCT01292187|Drug|Oral calcitonin at bedtime|Oral calcitonin at bedtime
379815|NCT01294878|Drug|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
379816|NCT01294852|Other|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]).
379817|NCT01294839|Device|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
379818|NCT01294826|Drug|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
379819|NCT01294826|Drug|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
379820|NCT01294813|Device|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
379821|NCT01294800|Drug|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
379822|NCT01294800|Drug|Placebo tablet to match Preladenant|tablets taken orally BID
379823|NCT01294787|Drug|indacaterol and glycopyrronium bromide (QVA149)|
379824|NCT01294787|Drug|placebo|
379825|NCT01294787|Drug|tiotropium|
379826|NCT01294774|Drug|KRP203 - 1.2mg|
379827|NCT01294774|Drug|Placebo to KRP203 - 1.2 mg|
379828|NCT01294761|Drug|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir~Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID~from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
379829|NCT01294748|Device|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
379830|NCT01294748|Device|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
379831|NCT01294735|Drug|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
379832|NCT01294735|Drug|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
379833|NCT01294709|Drug|telcagepant|
379834|NCT01294709|Drug|Placebo to telcagepant|
379835|NCT01294696|Drug|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
379836|NCT01294683|Drug|Simvastatin|
379837|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
379838|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant (N/LRPT)|
379839|NCT01294683|Drug|Placebo|
379840|NCT01294670|Drug|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
379841|NCT01294657|Behavioral|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
379842|NCT01294657|Behavioral|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
379843|NCT01294644|Drug|Deoxycholic acid injection|
379844|NCT01294644|Drug|Placebo|Phosphate buffered saline placebo for injection
379845|NCT01294631|Drug|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.~Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
379846|NCT01294618|Drug|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
379847|NCT01294605|Biological|Boostrix™ (dTpa)|Intramuscular, 3 doses
379848|NCT01294605|Biological|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
379849|NCT01294605|Biological|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
379854|NCT01294579|Drug|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
379855|NCT01294566|Drug|GSK1322888|1 mg, 5 mg or 25 mg capsule
379856|NCT01294566|Drug|Placebo|matching placebo capsules
379857|NCT01294553|Drug|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
379858|NCT01294540|Drug|Drug: E2609|E2609 orally at varying ascending doses
379859|NCT01294540|Drug|Placebo|Matching Placebo
379860|NCT01294527|Device|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
379861|NCT01294501|Other|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
379862|NCT01294488|Behavioral|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
379863|NCT01294475|Behavioral|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
379864|NCT01294462|Drug|Ticagrelor|90 mg, oral dose twice daily
379865|NCT01294462|Drug|Clopidogrel|75 mg, oral dose once daily
379866|NCT01294462|Drug|Acetylsalicylic acid ASA|Low Dose ASA
379867|NCT01294449|Device|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
379868|NCT01294449|Device|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
379869|NCT01294436|Drug|Dapagliflozin|Oral Dose 5 or 10 mg
379870|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
379871|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
379872|NCT01294423|Drug|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
379873|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
379874|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
379875|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
379876|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
379877|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
379878|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
379879|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
379880|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
379881|NCT01294397|Drug|Etanercept|Administered by subcutaneous injection once a week
379882|NCT01294397|Drug|Denosumab|Administered by subcutaneous injection
379883|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
379884|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
379885|NCT01294384|Drug|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
379886|NCT01294358|Drug|Gemcitabine|Gemcitabine starting dose was 18mg/m(2)/24h via infusion pump on days 1-14. One cycle = 4 weeks for up to six cycles. Three to six patients enrolled per dose cohort. Patients were dosed at successive higher doses until maximum tolerated dose or up to 165 mg/m(2)/24h.
379887|NCT01294332|Other|Aerobic Exercise Training|supervised exercise on the treadmill at target heart rate range for 12 weeks, 3 times a week for 30 minutes.
379888|NCT01294319|Drug|Mifepristone|
379889|NCT01294319|Drug|Placebo|
379890|NCT01294319|Drug|Spironolactone|
379891|NCT01294319|Drug|Combined|
379892|NCT01294319|Drug|Dexamethasone|
379893|NCT01294306|Drug|Akt Inhibitor MK2206|Given PO
379894|NCT01294306|Drug|Erlotinib Hydrochloride|Given PO
379895|NCT01294306|Other|Laboratory Biomarker Analysis|Correlative studies
379896|NCT01294306|Other|Pharmacological Study|Correlative studies
379897|NCT01294293|Drug|TLR8 Agonist VTX-2337|Given SC
379898|NCT01294293|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
379899|NCT01294293|Other|Pharmacological Study|Correlative studies
379900|NCT01294293|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
379901|NCT01294293|Drug|Paclitaxel|Given IV
379902|NCT01294280|Other|Laboratory Biomarker Analysis|Correlative studies
379903|NCT01294267|Device|Circulatory Support System|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
379904|NCT01294254|Drug|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
379905|NCT01294254|Procedure|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
379906|NCT01294241|Drug|Oleogel-S10|1 cm or 125 µL or 115 mg Oleogel-S10 per cm2 wound area (corresponds to thickness of approximately 1 mm or 0.04 inch) every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
379907|NCT01294241|Device|Mepilex® soft silicone faced polyurethane foam dressing|Mepilex® soft silicone faced polyurethane foam dressing was changed about every 24 to 48 hours until discharge from hospital or until the end of treatment at Day 14 in 'recent wounds' or Day 28 in 'chronic wounds'.
379908|NCT01294215|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
379909|NCT01294202|Drug|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.~In part 2 an additional 6-9pts will be treated.~In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
379910|NCT01294176|Drug|Lipoic Acid|Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
379911|NCT01294163|Drug|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
379912|NCT01294163|Drug|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
379913|NCT01294163|Drug|Propofol|Hourly dose of 2-4 mg/kg
379914|NCT01294150|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
379915|NCT01294150|Other|Cystoscopy|The Control Group will undergo cystoscopy.
379916|NCT01294150|Device|Crossover|Subjects crossed over and received the UroLift System from the Control Group.
379917|NCT01294137|Device|ventilatory polygraphy|
379918|NCT01294111|Behavioral|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
379919|NCT01294098|Drug|Marcaine|0.75 cc/kg of 1/4% Marcaine
379920|NCT01294072|Dietary Supplement|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
379921|NCT01294072|Dietary Supplement|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
379922|NCT01294072|Other|No intervention|no treatment
379923|NCT01294059|Drug|Milnacipran|50 mg BID Oral x 6 Weeks
379924|NCT01294046|Device|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
379925|NCT01294033|Other|Fractional inspired oxygen (FiO2) 0.21|
379926|NCT01294033|Other|Fractional inspired oxygen 0.28|Supplemental oxygen
379927|NCT01294020|Drug|Tacrolimus|Oral capsule
379928|NCT01294020|Drug|Tacrolimus prolonged release|Oral capsule
379929|NCT01294007|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
379930|NCT01294007|Procedure|Autograft bone|Iliac Crest and Local Autograft Bone
379931|NCT01293981|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
379932|NCT01293968|Drug|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
379933|NCT01293968|Drug|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
379934|NCT01293955|Drug|JOINS 200mg|1 tablet at each time, 3 times a day
379935|NCT01293955|Drug|Placebo|placebo of Joins 200mg
379936|NCT01293942|Drug|irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab|IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
379937|NCT01293916|Other|Spica casting|single versus double leg spica casting
379938|NCT01293903|Drug|Qiliqiangxin capsule|Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
379939|NCT01293903|Drug|Placebo|Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
379940|NCT01293877|Procedure|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
379941|NCT01293838|Drug|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~10 mg tablets: 28~20 mg tablets: 84~Total for 30 participants:~10 mg tablets: 840~20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~*20 mg tablets: 1512"
379979|NCT01293526|Device|Experimental|Patients who respond will have their leads placed based on study measurements.
379942|NCT01293825|Drug|ziprasidone|"Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone."
379943|NCT01293812|Drug|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
379944|NCT01293812|Drug|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
379945|NCT01293799|Behavioral|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
379946|NCT01293773|Device|Taxus Element stent|paclitaxel-eluting stent
379947|NCT01293773|Device|Integrity Resolute stent|ABT 578-eluting stent
379948|NCT01293773|Device|Xience Prime stent|Everolimus-eluting stent
379949|NCT01293760|Other|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
379950|NCT01293760|Other|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
379951|NCT01293747|Drug|Estradiol + Progesterone|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
379952|NCT01293747|Drug|Estradiol + Progesterone|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
379953|NCT01293734|Other|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
379954|NCT01293734|Other|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
379955|NCT01293734|Other|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
379956|NCT01293734|Drug|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
379957|NCT01293721|Device|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
379958|NCT01293695|Behavioral|Hypnosis|Hypnosis relaxation in five weekly sessions
379959|NCT01293695|Other|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
379960|NCT01293682|Drug|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
379961|NCT01293669|Drug|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
379962|NCT01293669|Drug|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
379963|NCT01293656|Other|No intervention.|There is no study intervention. Participants will be treated locally per site standards.
379964|NCT01293643|Drug|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
379965|NCT01293643|Drug|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
379966|NCT01293630|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
379967|NCT01293630|Drug|Paclitaxel|"Pharmaceutical form:solution~Route of administration: intravenous"
379968|NCT01293630|Drug|Carboplatin|"Pharmaceutical form:solution~Route of administration: intravenous"
379969|NCT01293617|Other|Blackberries|300 g blackberries daily for 5 days
379970|NCT01293617|Other|Gelatin|300 g gelatin per day for 5 days
379971|NCT01293604|Other|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
379972|NCT01293591|Other|Control|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
379973|NCT01293591|Other|Garlic treatment|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.
379974|NCT01293578|Other|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
379975|NCT01293552|Biological|ANT-1207|single dose application
379976|NCT01293552|Biological|Vehicle|
379977|NCT01293539|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).~Standard dose:~2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (>3 years old)~Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.~Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.~Dose not to exceed 0.5mg/kg, per treatment cycle."
379978|NCT01293526|Device|Control|Patients who respond will have leads will be placed using standard procedures.
379980|NCT01293526|Device|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
379981|NCT01293513|Other|Gradual anti-HIV treatment interruption|Gradual interruption of anti-HIV treatment: the interruption initially for a week, up to six weeks' interruption, and continuing anti-HIV treatment for two weeks between successive interruptions
379982|NCT01293500|Procedure|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
379983|NCT01293487|Biological|RN564|Intravenous, single dose with experimental dose
379984|NCT01293474|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
379985|NCT01293461|Drug|CBX129801|Subcutaneous injection
379986|NCT01293461|Drug|Placebo|Subcutaneous injection
379987|NCT01293448|Device|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
379988|NCT01293422|Drug|Rifampicin|Rifampicin 600 mg daily for a week
379989|NCT01293409|Other|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
379990|NCT01293396|Drug|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
379991|NCT01293396|Drug|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
379992|NCT01293396|Drug|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
379993|NCT01293383|Drug|LEO 90105|Ointment
379994|NCT01293357|Drug|LEO 90105|Ointment
379995|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
379996|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
379997|NCT01293318|Other|No intervention|No intervention
379998|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
379999|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
380000|NCT01293292|Drug|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
380001|NCT01293266|Drug|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
380002|NCT01293253|Behavioral|Stair walking|Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
380003|NCT01293240|Device|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
380004|NCT01293227|Procedure|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
380005|NCT01293214|Procedure|Limb transplantation|
380006|NCT01293201|Drug|STAHIST|STAHIST dosed one tablet, BID
380007|NCT01293201|Drug|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
380008|NCT01293175|Dietary Supplement|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
380009|NCT01293162|Drug|Armolipid Prev|Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
380010|NCT01293149|Drug|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
380011|NCT01293149|Drug|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
380012|NCT01293136|Procedure|Femoral nerve block|Ropivacaine
380013|NCT01293136|Drug|Intravenous opioids|Whatever opioids prescribed
380014|NCT01293123|Drug|Raltegravir|raltegravir 400 mg PO twice daily
380015|NCT01293123|Drug|Efavirenz|efavirenz 600 mg PO once daily
380016|NCT01293097|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
380017|NCT01293097|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
380018|NCT01293084|Drug|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
380019|NCT01293084|Drug|7% saline|5mL 7% saline inhaled once over 20 minutes
380020|NCT01293071|Other|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
380021|NCT01293058|Drug|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
380022|NCT01293058|Drug|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
380023|NCT01293045|Dietary Supplement|hydrolyzed collagen|10g/day at breakfast during 90 days
380024|NCT01293045|Dietary Supplement|wheat protein|10g/day at breakfast during 90 days
380025|NCT01293032|Procedure|Neoadjuvant Therapy|Undergo neoadjuvant therapy
380026|NCT01293032|Procedure|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
380028|NCT01293032|Genetic|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
380029|NCT01293032|Drug|Systemic Chemotherapy|Undergo chemotherapy
380030|NCT01293032|Drug|Tamoxifen Citrate|Undergo hormonal therapy
380031|NCT01293032|Drug|Aromatase Inhibition Therapy|Undergo hormonal therapy
380032|NCT01293019|Procedure|Osteopathic treatment|Real treatment of osteopathy
380033|NCT01293019|Procedure|Sham Placebo|Sham treatment of osteopathy
380034|NCT01293019|Procedure|Usual care|Classical treatment of pain in cystic fibrosis patients
380035|NCT01293006|Drug|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants <65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
380036|NCT01293006|Drug|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
380037|NCT01292993|Drug|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
380038|NCT01292993|Drug|1000 mg metformin|1000 mg metformin given as a solid oral dose form
380039|NCT01292980|Device|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
380040|NCT01292967|Dietary Supplement|Low flavanol chocolate|48 mg of total flavanols from cocoa
380041|NCT01292967|Dietary Supplement|High-flavanol with sugar|high-flavanol containing 251 mg cocoa flavanols
380042|NCT01292967|Dietary Supplement|High flavanol Maltitol|high-flavanol containing 266 mg cocoa flavanols
380043|NCT01292954|Dietary Supplement|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
380044|NCT01292941|Device|Intermittent catheterisation|Speedicath, Intermittent catheterisation
380045|NCT01292941|Device|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
380046|NCT01292941|Device|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
380047|NCT01292941|Device|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
380048|NCT01292928|Device|Stent implantation|Stent implantation during the index procedure.
380049|NCT01292902|Other|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 < 88%.
380050|NCT01292902|Other|inspiratory muscle exercise|Equal to the group with chronic heart failure.
380051|NCT01292876|Device|Extracellular Matrix|Extracellular Matrix
380052|NCT01292863|Other|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
380053|NCT01292863|Other|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
380054|NCT01292837|Drug|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
380055|NCT01292824|Drug|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
380056|NCT01292811|Device|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
380057|NCT01292811|Other|Conventional Occupational therapy|"The Control group will receive conventional occupational therapy pertaining to hand function [15].~The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
380058|NCT01292798|Drug|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
380059|NCT01292785|Drug|Hormones|"FtM will receive~1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and~if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).~MtF will receive~50mg cyproterone acetate daily (Androcur®)~estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is > 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is < 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and~2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
380060|NCT01292772|Procedure|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
380061|NCT01292772|Radiation|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
380062|NCT01292746|Device|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
380063|NCT01292733|Other|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
380064|NCT01292733|Other|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
380065|NCT01292733|Other|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
380066|NCT01292720|Drug|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
380067|NCT01292720|Drug|Placebo|Placebo in matching volumes
380068|NCT01292707|Behavioral|Control|Standard national training
380069|NCT01292707|Behavioral|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
380070|NCT01292707|Behavioral|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
380071|NCT01292694|Drug|Losartan|Oral, single-dose, 50 mg tablet
380072|NCT01292694|Drug|Captopril|Oral, single-dose, 50 mg tablet
380073|NCT01292694|Drug|Placebo|Oral, single administration, gelatin capsule filled with microcrystalline cellulose
380074|NCT01292681|Other|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
380075|NCT01292668|Drug|methyl-5-aminolevulinate hydrochloride cream|Applied topically
380076|NCT01292668|Drug|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
380077|NCT01292668|Procedure|laser therapy|Undergo laser light photodynamic therapy
380078|NCT01292655|Drug|BMS-906024|
380079|NCT01292642|Behavioral|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
380080|NCT01292642|Drug|Nicotine Replacement Therapy|"21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks~14 m g patch for 8 weeks, then 7 mg patch for 2 weeks"
380081|NCT01292629|Device|iSert 251 intraocular lens|aphakic intraocular lens
380082|NCT01292616|Drug|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
380083|NCT01292603|Drug|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
380084|NCT01292603|Drug|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
380085|NCT01292603|Drug|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
380086|NCT01292603|Drug|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
380087|NCT01292603|Drug|rituximab [MabThera]|6 cycles of intravenous MabThera
380088|NCT01292590|Other|High fat meal|40 grams saturated fat
380089|NCT01292577|Behavioral|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
380090|NCT01292577|Behavioral|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
380091|NCT01292564|Device|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
380092|NCT01292564|Device|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
380093|NCT01292551|Drug|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
380094|NCT01292551|Drug|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
380095|NCT01292538|Device|Erchonia GLS|532 nm green diode low level laser light device
380096|NCT01292538|Device|Placebo laser|Sham light output with no therapeutic benefit
380097|NCT01292525|Drug|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
380098|NCT01292525|Drug|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
380099|NCT01292512|Other|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
380100|NCT01292499|Behavioral|Psychotherapy|10 sessions (50 min)
380101|NCT01292499|Behavioral|Psychoeducation|7 sessions + 7 phone calls
380102|NCT01292499|Behavioral|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
380103|NCT01292486|Device|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
380104|NCT01292473|Drug|Placebo|Placebo was supplied lyophilized in vials.
380105|NCT01292473|Drug|Omalizumab|Omalizumab was supplied lyophilized in vials.
380156|NCT01292187|Drug|Oral placebo at bedtime|Oral placebo at bedtime
380106|NCT01292460|Drug|Timolol/ FDC/ Placebo/ Tafluprost|"Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).~Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00)."
380107|NCT01292447|Drug|2% lidocaine gel|120mg lidocaine x 1
380108|NCT01292447|Drug|Placebo gel|Inert gel x 1
380109|NCT01292434|Behavioral|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
380110|NCT01292421|Biological|hepatitis B antigen peptide|Given PO
380111|NCT01292421|Other|placebo|Given orally (PO)
380112|NCT01292421|Other|immunoenzyme technique|Correlative studies
380113|NCT01292408|Drug|Hydrochloroquine|800 mg per os once, and then 400 mg per day
380114|NCT01292395|Other|Dietary Protein Intake|Protein intakes within the current recommendation
380115|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
380116|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
380117|NCT01292356|Drug|cetuximab|
380118|NCT01292343|Other|Colgate Total Toothpaste|Toothbrushing with Colgate Total Toothpaste
380119|NCT01292343|Other|Colgate Regular Toothpaste|Toothbrushing with Colgate regular toothpaste
380120|NCT01292330|Procedure|nutritional support before operation|nutritional support before operation for more than 4 days
380121|NCT01292317|Other|application of intravenous volume|weight based intravenous application of volume
380122|NCT01292317|Other|oral fluid application|oral fluid application
380123|NCT01292304|Drug|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
380124|NCT01292291|Other|biologic sample preservation procedure|
380125|NCT01292291|Other|laboratory biomarker analysis|
380126|NCT01292291|Other|study of socioeconomic and demographic variables|
380127|NCT01292291|Procedure|diffusion-weighted magnetic resonance imaging|
380128|NCT01292291|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
380129|NCT01292291|Procedure|multiparametric magnetic resonance imaging|
380130|NCT01292291|Procedure|quality-of-life assessment|
380131|NCT01292291|Procedure|transperineal prostate biopsy|
380132|NCT01292291|Procedure|transrectal prostate biopsy|
380133|NCT01292291|Procedure|ultrasound-guided prostate biopsy|
380134|NCT01292265|Biological|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
380135|NCT01292252|Biological|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
380136|NCT01292252|Biological|Placebo|Saline solution
380137|NCT01292239|Drug|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
380138|NCT01292239|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
380139|NCT01292239|Drug|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
380140|NCT01292239|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
380141|NCT01292226|Drug|mycophenolate mofetil|1 g PO BID for 24 weeks
380142|NCT01292226|Drug|antibody induction|According to manufacturer recommendation
380143|NCT01292226|Drug|Cyclosporine|According to manufacturer recommendation
380144|NCT01292226|Drug|corticosteroid|According to manufacturer recommendation
380145|NCT01292213|Procedure|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
380146|NCT01292213|Procedure|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
380147|NCT01292213|Procedure|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
380148|NCT01292213|Procedure|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
380149|NCT01292213|Procedure|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
380150|NCT01292213|Other|Data collection|Questionnaire completion.
380151|NCT01292200|Behavioral|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
380152|NCT01292200|Behavioral|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
380153|NCT01292187|Drug|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
380154|NCT01292187|Drug|Oral placebo at dinnertime|Oral placebo at dinnertime.
380481|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380157|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
380158|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
380159|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
380160|NCT01292161|Drug|Silymarin|Tab 210 mg, 630 mg, daily, six months.
380161|NCT01292135|Drug|PCI-32765|420 mg daily
380162|NCT01292122|Device|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
380163|NCT01292109|Drug|sodium picosulphate|Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
380164|NCT01292096|Other|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
380165|NCT01292083|Drug|azacitidine|Given IV
380166|NCT01292083|Other|laboratory biomarker analysis|Correlative studies
380167|NCT01292083|Other|immunohistochemistry staining method|Correlative studies
380168|NCT01292083|Genetic|polymerase chain reaction|Correlative studies
380169|NCT01292083|Genetic|western blotting|Correlative studies
380170|NCT01292083|Genetic|nucleic acid sequencing|Correlative studies
380171|NCT01292083|Procedure|therapeutic conventional surgery|Undergo definitive breast surgery
380172|NCT01292070|Biological|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.~Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm."
380173|NCT01292070|Biological|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
380174|NCT01292070|Biological|Positive Control - Histamine Prick|1.0 mg/mL
380175|NCT01292070|Biological|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
380176|NCT01292057|Drug|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
380177|NCT01292057|Drug|Placebo|Placebo to match active drug Aripiprazole for 8 days
380178|NCT01292044|Other|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
380179|NCT01292031|Drug|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
380180|NCT01292031|Drug|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
380181|NCT01292005|Drug|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
380182|NCT01292005|Drug|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
380183|NCT01291979|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
380184|NCT01291979|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
380185|NCT01291966|Behavioral|Motivational interview|
380186|NCT01291953|Procedure|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
380187|NCT01291953|Procedure|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
380188|NCT01291940|Other|Pediatric Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
380189|NCT01291940|Other|Adult Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
380190|NCT01291927|Procedure|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
380191|NCT01291927|Procedure|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
380192|NCT01291914|Drug|FX005|Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
380193|NCT01291914|Drug|Placebo 1 (Carrier)|Single intra-articular injection
380194|NCT01291914|Drug|Placebo 2 (Diluent)|Single intra-articular injection
380195|NCT01291901|Biological|NP2|NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
380196|NCT01291901|Biological|Placebo|The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
380197|NCT01291875|Procedure|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
380198|NCT01291875|Procedure|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
380199|NCT01291862|Device|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
380200|NCT01291849|Drug|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml−1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
380201|NCT01291823|Drug|gefitinib|gefitinib 250mg/day
380202|NCT01291823|Radiation|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
380203|NCT01291810|Biological|TNF Kinoid|TNF Kinoid
380204|NCT01291810|Biological|WFI|WFI
380205|NCT01291784|Biological|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
380206|NCT01291771|Procedure|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
380207|NCT01291758|Diagnostic Test|Submaximal bicycle exercise stress tests performed 24 hr apart|Submaximal bicycle exercise stress tests were performed for 25 min at 70% predicted heart rate, then ramped up to 85% predicted heart rate. Subjects could stop when they felt they had reached their maximum effort if before reaching 85% predicted heart rate.
380208|NCT01291732|Drug|Matching placebo|single dose of matching placebo
380209|NCT01291732|Drug|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
380210|NCT01291719|Device|glucose and insulin infusions|combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
380211|NCT01291706|Device|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
380212|NCT01291693|Behavioral|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
380213|NCT01291693|Behavioral|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
380214|NCT01291654|Drug|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
380215|NCT01291654|Drug|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
380216|NCT01291654|Drug|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
380217|NCT01291641|Drug|HMG-CoA Reductase Inhibitor|"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.~Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
380218|NCT01291641|Drug|Probucol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
380219|NCT01291641|Drug|Cilostazol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.~Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
380220|NCT01291628|Device|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
380221|NCT01291615|Drug|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
380222|NCT01291615|Drug|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
380223|NCT01291602|Drug|NXL104|IV Solution
380224|NCT01291602|Drug|CAZ104|IV Solution
380225|NCT01291602|Drug|Placebo|IV saline
380482|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380226|NCT01291589|Behavioral|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
380227|NCT01291576|Procedure|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
380228|NCT01291576|Procedure|Rectal nodule excision|Either full thickness excision or rectal shaving
380229|NCT01291563|Drug|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
380230|NCT01291563|Drug|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
380231|NCT01291563|Drug|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
380232|NCT01291563|Drug|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
380233|NCT01291537|Drug|Duodopa|
380234|NCT01291537|Drug|best médical treatment|
380235|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
380236|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
380237|NCT01291524|Drug|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
380238|NCT01291524|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
380239|NCT01291511|Drug|Iloperidone|Iloperidone capsules/tablets will be administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
380240|NCT01291511|Drug|Placebo|Matching placebo capsules will be administered orally duins a bid schedule during the double-blind period.
380241|NCT01291498|Device|High Intensity Focused Ultrasound|One or two HIFU sessions
380242|NCT01291485|Behavioral|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
380243|NCT01291472|Drug|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
380244|NCT01291459|Drug|MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir|MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
380245|NCT01291446|Dietary Supplement|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
380246|NCT01291433|Drug|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
380247|NCT01291433|Drug|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
380248|NCT01291433|Drug|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
380249|NCT01291433|Drug|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
380250|NCT01291433|Drug|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
380251|NCT01291433|Drug|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
380252|NCT01291420|Biological|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
380253|NCT01291407|Drug|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
380254|NCT01291407|Drug|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
380255|NCT01291407|Drug|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
380256|NCT01291407|Drug|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
380257|NCT01291407|Drug|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
380258|NCT01291407|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
380259|NCT01291394|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
380260|NCT01291381|Drug|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
380261|NCT01291381|Drug|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
380262|NCT01291355|Other|Specific maternal position during the labor|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts."
380263|NCT01291329|Genetic|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
380264|NCT01291316|Drug|Clonazepam|clonazepam, 1 mg, single oral dose
380265|NCT01291316|Drug|Tolterodine|Tolterodine 1,37mg, single oral dose
380266|NCT01291316|Drug|clobazam|clobazam 20 mg, single oral dose
380267|NCT01291303|Procedure|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
380268|NCT01291303|Procedure|Standard ventilation|"Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:~-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available)."
380269|NCT01291290|Procedure|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
380270|NCT01291277|Device|Endoscopic Variceal Ligation|Ligation of esophageal varices
380271|NCT01291238|Behavioral|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
380272|NCT01291225|Other|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
380273|NCT01291225|Behavioral|Educational campaign|Educational materials will be developed and distributed in Ross County.
380274|NCT01291212|Drug|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
380275|NCT01291212|Drug|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
380276|NCT01291199|Drug|vardenafil|10 mg p.o. bid for 6 weeks
380277|NCT01291199|Drug|Placebo|Placebo p.o. 6 weeks bid
380278|NCT01291186|Drug|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
380279|NCT01291186|Drug|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
380280|NCT01291186|Drug|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
380281|NCT01291186|Drug|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
380282|NCT01291186|Drug|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
380283|NCT01291186|Drug|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
380284|NCT01291186|Drug|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
380285|NCT01291186|Drug|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
380286|NCT01291186|Drug|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
380287|NCT01291186|Drug|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
380288|NCT01291186|Drug|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
380289|NCT01291186|Drug|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
380290|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
380291|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
380292|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
380293|NCT01291173|Drug|Placebo|Placebo capsule taken once daily for up to 11 weeks
380294|NCT01291160|Device|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
380295|NCT01291160|Other|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
380296|NCT01291147|Drug|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
380297|NCT01291147|Drug|0.9% Saline|0.9% saline continous infusion for 48 hours
380298|NCT01291134|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
380299|NCT01291121|Procedure|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
380300|NCT01291108|Drug|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
380301|NCT01291108|Drug|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
380302|NCT01291108|Drug|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
380303|NCT01291095|Drug|CISPLATIN|"IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.~IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN"
380304|NCT01291095|Radiation|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
380305|NCT01291069|Drug|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
380306|NCT01291069|Drug|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
380307|NCT01291056|Other|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
380308|NCT01291056|Drug|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
380309|NCT01291043|Other|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
380310|NCT01291030|Dietary Supplement|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of > 1,9 mg/dl.
380311|NCT01291017|Drug|PD0332991|PD0332991 125 mg PO days 1 - 21
380312|NCT01291004|Drug|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
380483|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
380313|NCT01291004|Drug|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
380314|NCT01291004|Drug|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
380315|NCT01290991|Device|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
380316|NCT01290978|Drug|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
380317|NCT01290978|Drug|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
380318|NCT01290965|Drug|Placebo|Oral tablet given once or three times daily for 15 consecutive days
380319|NCT01290965|Drug|SCY-635|oral capsule
380320|NCT01290952|Procedure|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
380321|NCT01290952|Procedure|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
380322|NCT01290939|Biological|bevacizumab|
380323|NCT01290939|Drug|lomustine|
380324|NCT01290939|Genetic|DNA methylation analysis|
380325|NCT01290939|Other|laboratory biomarker analysis|
380326|NCT01290939|Procedure|cognitive assessment|
380327|NCT01290939|Procedure|quality-of-life assessment|
380328|NCT01290926|Drug|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
380329|NCT01290913|Drug|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
380330|NCT01290900|Drug|NXL104|IV Solution
380331|NCT01290900|Drug|Ceftaroline|IV Solution
380332|NCT01290900|Drug|Placebo Infusion|IV Saline
380333|NCT01290900|Drug|Ceftazidime|IV Solution
380334|NCT01290900|Drug|Moxifloxacin|Tablet (1)
380335|NCT01290887|Drug|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
380336|NCT01290874|Drug|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
380337|NCT01290874|Drug|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
380338|NCT01290874|Drug|Formoterol|Formoterol 12 mcg twice daily for one year
380339|NCT01290848|Behavioral|Take TIME Health Campaign|"Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.~Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.~Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
380340|NCT01290835|Radiation|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
380341|NCT01290835|Radiation|stereotactic radiotherapy|
380342|NCT01290822|Device|BiVP|Biventricular pacing
380343|NCT01290822|Device|AAI Pacing|Atrial pacing
380344|NCT01290796|Device|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
380345|NCT01290783|Drug|Irintoecan|"Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~Repeat every two weeks.~8 months of treatment."
380346|NCT01290783|Drug|HA-Irinotecan solution for Infusion|"HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).~Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.~5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.~Repeat every two weeks~8 months of treatment."
380347|NCT01290770|Other|blood sample|blood sample at inclusion and 1 month after inclusion
380348|NCT01290757|Drug|Dabigatran etexilate|150 mg Capsugel (T)
380349|NCT01290757|Drug|Dabigatran etexilate|150 mg Qualicaps (R)
380350|NCT01290744|Drug|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
380351|NCT01290744|Drug|Placebo|Daily for 12 months
380352|NCT01290731|Drug|TMC435|100-mg capsule once daily for 12 weeks
380353|NCT01290731|Drug|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
380354|NCT01290731|Drug|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
380355|NCT01290718|Drug|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
380356|NCT01290718|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
380357|NCT01290705|Behavioral|High exercise therapy|
380358|NCT01290705|Behavioral|Low exercise therapy|
380359|NCT01290692|Biological|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
380360|NCT01290679|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
380361|NCT01290679|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
380362|NCT01290679|Drug|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
380363|NCT01290679|Drug|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
380364|NCT01290666|Device|Fistula Plug|Bioabsorbable fistula plug
380365|NCT01290653|Other|Dry needling|Deep dry needling until achieving twitch response of the muscle
380366|NCT01290653|Other|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
380367|NCT01290653|Other|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
380368|NCT01290640|Device|DePuy fixed-bearing Total Condylar III (TC3) TKA|
380369|NCT01290640|Device|DePuy PFC Rotating Platform TC3 TKA|
380370|NCT01290627|Device|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
380371|NCT01290627|Device|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
380372|NCT01290614|Other|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR <30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
380373|NCT01290614|Other|Usual Care|"Patients in the control arm will continue to receive usual care from their VA providers."
380374|NCT01290601|Drug|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
380375|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
380376|NCT01290601|Drug|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
380377|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
380378|NCT01290575|Drug|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
380379|NCT01290575|Drug|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
380380|NCT01290575|Drug|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
380381|NCT01290575|Drug|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
380382|NCT01290575|Drug|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
380383|NCT01290575|Drug|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
380384|NCT01290575|Drug|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
380385|NCT01290575|Drug|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
380386|NCT01290575|Drug|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
380387|NCT01290562|Radiation|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
380388|NCT01290549|Drug|Polatuzumab Vedotin|Participants will receive escalating intravenous dose of polatuzumab vedotin.
380389|NCT01290549|Drug|Rituximab|Rituximab will be administered by an IV infusion at 375 mg/m^2 body surface area dose q3w.
380390|NCT01290536|Device|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
380391|NCT01290523|Device|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
380392|NCT01290510|Device|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
380393|NCT01290497|Drug|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
380394|NCT01290497|Drug|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
380395|NCT01290497|Drug|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
380396|NCT01290484|Drug|Sildenafil|Sildenafil oral tablet three times daily
380397|NCT01290471|Drug|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
380398|NCT01290458|Dietary Supplement|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
380399|NCT01290445|Drug|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
380400|NCT01290445|Behavioral|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
380484|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380485|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380401|NCT01290445|Other|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
380402|NCT01290432|Dietary Supplement|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
380403|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
380404|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
380405|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
380406|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
380407|NCT01290419|Biological|Placebo|Placebo; Day 0 and Day 30
380408|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
380409|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
380410|NCT01290406|Drug|BEZ235|
380411|NCT01290393|Other|Data collection|Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
380412|NCT01290380|Drug|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
380413|NCT01290367|Biological|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
380414|NCT01290367|Procedure|Single injection of saline solution|Intradiscal control injection with saline solution
380415|NCT01290367|Procedure|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
380416|NCT01290367|Biological|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
380417|NCT01290354|Drug|Lapatinib|Unlabelled, administered orally
380418|NCT01290354|Drug|[11C] lapatinib|Radiolabelled, administered intravenously
380419|NCT01290341|Drug|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
380420|NCT01290341|Drug|Placebo|Topical; applied once daily for two weeks.
380421|NCT01290328|Drug|Epoetin Alfa|150 units/kg/weekly
380422|NCT01290315|Drug|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
380423|NCT01290315|Drug|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
380424|NCT01290302|Drug|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
380425|NCT01290302|Drug|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
380426|NCT01290289|Other|Epidura, CSE & IV|"Gp 1: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.~Gp 2: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.~Gp 3: received 50µg of E fentanyl analgesia & a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.~Gp 4: received analgesia: 50µg of E fentanyl & a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.~Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg."
380427|NCT01290276|Drug|Ond-PR1|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
380428|NCT01290276|Drug|Ond-PR1 + MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
380429|NCT01290276|Drug|Ond-PR2|Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
380430|NCT01290276|Drug|Ond-PR2 +_ MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
380431|NCT01290263|Drug|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.~For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.~For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
380432|NCT01290263|Drug|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
380433|NCT01290250|Other|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
380434|NCT01290237|Drug|vancomycin hydrocloride|see description of study arms
380435|NCT01290224|Other|scrambler therapy|Undergo MC5-A therapy
380436|NCT01290224|Procedure|sham intervention|Undergo sham procedure
380437|NCT01290224|Other|questionnaire administration|Ancillary studies
380438|NCT01290211|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
380439|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
380440|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
380441|NCT01290211|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
380442|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
380443|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
380444|NCT01290198|Drug|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
380445|NCT01290185|Device|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
380486|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
380487|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
380488|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
380489|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
380490|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380446|NCT01290172|Drug|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
380447|NCT01290172|Drug|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.~5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
380448|NCT01290159|Other|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
380449|NCT01290146|Drug|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
380450|NCT01290146|Drug|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~SBP ≥100 mmHg: 0.1 mcg/kg/min"
380451|NCT01290133|Drug|GW597599|Single dose IV infusion
380452|NCT01290133|Drug|Placebo|Single dose IV infusion
380453|NCT01290120|Drug|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
380454|NCT01290107|Genetic|DNA analysis|
380455|NCT01290107|Genetic|gene rearrangement analysis|
380456|NCT01290107|Genetic|microarray analysis|
380457|NCT01290107|Genetic|polymerase chain reaction|
380458|NCT01290107|Other|immunological diagnostic method|
380459|NCT01290107|Other|laboratory biomarker analysis|
380460|NCT01290094|Drug|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
380461|NCT01290081|Other|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
380462|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
380463|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
380464|NCT01290068|Device|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
380465|NCT01290055|Biological|Yellow fever vaccine or YFV-17D|The YFV-17D (YF-VAX®) manufactured by Sanofi Pasteur as a one-dose vial will be purchased from the manufacturer. Vaccine will be stored at the Emory Investigational Drug service between 2o to 8o C as per the manufacturer's instructions. It will be transported to the Hope clinic per the Standard Operating Procedures.
380466|NCT01290055|Biological|Deuterium (70% enriched 2H2O) labeled water|70% enriched 2H2O will be obtained from Cambridge Isotope Laboratories (Andover, MA) in sterile 1L containers. An Emory IDS pharmacist will prepare sterile 50ml aliquots with a tamper seal which will be transported to the Hope clinic at room temperature.
380467|NCT01290042|Drug|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
380468|NCT01290042|Other|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
380469|NCT01290029|Drug|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
380470|NCT01290016|Behavioral|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
380471|NCT01290016|Behavioral|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
380472|NCT01290016|Behavioral|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
380473|NCT01290003|Drug|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
380474|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
380475|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380476|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380477|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
380478|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380479|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380480|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
380494|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
380495|NCT01289990|Drug|Sitagliptin 100mg|Sitagliptin once daily
380496|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
380497|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380498|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380499|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380500|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380501|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
380502|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380503|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
380504|NCT01289964|Procedure|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
380505|NCT01289951|Drug|Raltegravir 400 mg/12hours|
380506|NCT01289951|Drug|Raltegravir 400 mg/12hours|
380507|NCT01289938|Drug|Diphenhydramine|Diphenhydramine 50 mg oral once
380508|NCT01289938|Drug|Metoclopramide|10 mg i.v. metoclopramide once
380509|NCT01289925|Dietary Supplement|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
380510|NCT01289925|Other|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
380511|NCT01289912|Drug|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
380512|NCT01289912|Drug|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.~Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time in the morning after a light, nonfat breakfast."
380513|NCT01289899|Drug|BR-A-657|120, 360mg or placebo 7days
380514|NCT01289886|Drug|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
380515|NCT01289860|Dietary Supplement|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
380516|NCT01289860|Dietary Supplement|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
380517|NCT01289847|Biological|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
380518|NCT01289834|Device|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH & Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
380519|NCT01289834|Device|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
380520|NCT01289821|Drug|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
380521|NCT01289821|Drug|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m^2 oxaliplatin as a 2 hour i.v. infusion.
380522|NCT01289821|Drug|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2 hour i.v. infusion.
380523|NCT01289821|Drug|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m^2 5 FU 46 hour i.v. infusion.
380524|NCT01289808|Drug|Glucose 25%|1ml of glucose 25% once
380525|NCT01289808|Drug|Glucose 25%|1ml glucose once per os
380526|NCT01289782|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
380527|NCT01289782|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
380528|NCT01289782|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
380529|NCT01289782|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
380530|NCT01289769|Drug|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
380531|NCT01289769|Drug|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
380532|NCT01289756|Drug|Clomiphene|clomiphene once 100 mg oral
380533|NCT01289756|Drug|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
380534|NCT01289756|Drug|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
380535|NCT01289743|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
380536|NCT01289730|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
380566|NCT01289457|Drug|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
380567|NCT01289457|Drug|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
380568|NCT01289457|Drug|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
380816|NCT01287598|Drug|Warfarin|CYP 2C9 (warfarin) at Cycle 1
380817|NCT01287598|Drug|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
380537|NCT01289704|Other|TreSPE|"treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.~Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.~Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.~Proprioceptive and postural kinesitherapy according to the Perfetti method.~Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls."
380538|NCT01289704|Other|SPE|"Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.~Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.~Proprioceptive and postural kinesitherapy according to the neurocognitive method.~Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls."
380539|NCT01289691|Other|One Lung Ventilation|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
380540|NCT01289691|Other|One Lung Ventilation|Patients in this group will be ventilated with only oxygen during one lung ventilation.
380541|NCT01289678|Drug|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
380542|NCT01289665|Procedure|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
380543|NCT01289665|Procedure|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
380544|NCT01289639|Drug|fenofibrate|micronized fenofibrate 200 mg 1 po qd
380545|NCT01289639|Drug|pioglitazone|pioglitazone 30 mg po qd
380546|NCT01289639|Drug|placebo|placebo 1 capsule po qd
380547|NCT01289626|Drug|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
380548|NCT01289626|Drug|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
380549|NCT01289600|Device|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
380550|NCT01289587|Behavioral|Physical activity intervention|36 sessions of physical activity offered at different frequencies
380551|NCT01289574|Drug|ASC-J9|Cream for twice daily topical application to the face
380552|NCT01289561|Drug|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
380553|NCT01289561|Drug|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
380554|NCT01289548|Device|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
380555|NCT01289535|Procedure|Blood sample|Blood sample of 7 ml
380556|NCT01289522|Biological|cetuximab IV|"Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.~Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.~Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.~Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles~G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy."
380557|NCT01289522|Other|Biopsies|No intervention, only biopsy for translational project.
380558|NCT01289509|Drug|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
380559|NCT01289509|Drug|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
380560|NCT01289496|Drug|Peg-interferon alpha-2a, Ribavirin|"4 weeks RBV priming;~24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);~24 weeks Follow-Up~Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.~Ribavirin 200 mg tablets"
380561|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
380562|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
380563|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
380564|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
380565|NCT01289457|Drug|Clofarabine|"Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.~Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle."
380818|NCT01287598|Drug|Midazolam|CYP 3A4 (midazolam) at Cycle 1
380569|NCT01289444|Behavioral|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
380570|NCT01289444|Behavioral|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
380571|NCT01289431|Drug|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
380572|NCT01289431|Drug|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
380573|NCT01289405|Device|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
380574|NCT01289392|Device|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
380575|NCT01289392|Device|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
380576|NCT01289392|Behavioral|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
380577|NCT01289379|Procedure|High Frequency Jet Ventilation|
380578|NCT01289379|Procedure|HFJV|
380579|NCT01289366|Device|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
380580|NCT01289353|Drug|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
380581|NCT01289353|Radiation|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
380582|NCT01289327|Drug|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (~2 minutes) or according to clinical judgment.
380583|NCT01289314|Procedure|TLH|Total laparoscopic hysterectomy (TLH)
380584|NCT01289314|Procedure|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
380585|NCT01289301|Drug|mTOR inhibitor (everolimus)|calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)
380586|NCT01289301|Drug|cyclosporine or tacrolimus|calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
380587|NCT01289288|Behavioral|Mailed printed materials and in-office training|"Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster~Two sessions of in-office training with two standardized patients"
380588|NCT01289275|Drug|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
380589|NCT01289275|Behavioral|Telephone Counseling|Up to 5 proactive counseling sessions from California Smokers' Helpline.
380590|NCT01289275|Behavioral|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
380591|NCT01289262|Procedure|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
380592|NCT01289262|Procedure|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
380593|NCT01289236|Drug|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
380594|NCT01289236|Drug|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
380595|NCT01289236|Drug|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
380596|NCT01289223|Drug|Bendamustine IV|
380597|NCT01289223|Other|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
380598|NCT01289210|Drug|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
380649|NCT01288833|Device|Close focus HD NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
380650|NCT01288820|Drug|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
380651|NCT01288820|Drug|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
380652|NCT01288807|Drug|Milnacipram|Titration to 200mg PO daily
380599|NCT01289197|Behavioral|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
380600|NCT01289171|Drug|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
380601|NCT01289145|Behavioral|Motivational intervention|The motivational intervention promotes positive outcome expectancies on physical activity.
380602|NCT01289145|Behavioral|Volitional intervention|The volitional intervention promotes the formulation of action plans for physical activity.
380603|NCT01289145|Behavioral|Active Control|Participants receive a quiz on physical activity and sports.
380604|NCT01289132|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
380605|NCT01289132|Drug|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
380606|NCT01289132|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
380607|NCT01289132|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
380608|NCT01289132|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
380609|NCT01289132|Drug|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
380610|NCT01289132|Drug|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
380611|NCT01289119|Drug|Alogliptin|Alogliptin tablets
380612|NCT01289119|Drug|Placebo to alogliptin|Alogliptin placebo-matching tablets.
380613|NCT01289119|Drug|Metformin|Stable metformin dose
380614|NCT01289119|Drug|Pioglitazone|Stable pioglitazone dose
380615|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
380616|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
380617|NCT01289106|Biological|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
380618|NCT01289080|Drug|OPC-34712|administered orally
380619|NCT01289067|Drug|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
380620|NCT01289054|Drug|Tasigna|
380621|NCT01289054|Drug|Gleevec|
380622|NCT01289041|Drug|BKM120|
380623|NCT01289028|Drug|Nilotinib|
380624|NCT01289015|Drug|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
380625|NCT01289015|Drug|Placebo|Topical; applied once daily for two weeks
380626|NCT01288989|Biological|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
380627|NCT01288976|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
380628|NCT01288976|Drug|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
380629|NCT01288976|Procedure|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
380630|NCT01288963|Drug|IL-2|Observation only
380631|NCT01288950|Dietary Supplement|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
380632|NCT01288937|Drug|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
380633|NCT01288937|Drug|Placebo|"Patients will be randomly assigned to placebo for 9wks (including a 1 week dose titration period):~Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day"
380634|NCT01288924|Drug|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
380635|NCT01288924|Other|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
380636|NCT01288911|Drug|enzalutamide|capsules
380637|NCT01288911|Drug|bicalutamide|tablets
380638|NCT01288898|Drug|ASP1941|Oral
380639|NCT01288898|Drug|Placebo|Oral
380640|NCT01288885|Drug|ASP1941|Oral
380641|NCT01288885|Drug|Placebo|Oral
380642|NCT01288872|Drug|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
380643|NCT01288859|Other|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
380644|NCT01288859|Other|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
380645|NCT01288859|Other|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
380646|NCT01288859|Other|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
380647|NCT01288859|Other|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
380648|NCT01288859|Other|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
380653|NCT01288794|Drug|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
380654|NCT01288794|Drug|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
380655|NCT01288781|Drug|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
380656|NCT01288781|Drug|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
380657|NCT01288768|Procedure|Knee arthroscopy|Knee arthroscopy within 4 weeks.
380658|NCT01288755|Drug|TMC278|One 25 mg tablet, once daily, for 11 days (TrtA and C)
380659|NCT01288755|Drug|Raltegravir|One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
380660|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
380661|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
380662|NCT01288742|Drug|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
380663|NCT01288742|Drug|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
380664|NCT01288742|Drug|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
380665|NCT01288729|Device|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
380666|NCT01288729|Device|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
380667|NCT01288716|Drug|Arbaclofen|
380668|NCT01288690|Behavioral|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
380669|NCT01288677|Drug|TMC649128|Escalated doses
380670|NCT01288664|Drug|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
380671|NCT01288651|Drug|Ferricarboxymaltose|"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.~Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."
380672|NCT01288638|Other|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
380673|NCT01288638|Other|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
380674|NCT01288625|Drug|Amifostine|500 mg sc, qod, 3 times per week
380675|NCT01288625|Radiation|Amifostine|500mg rinsing wash, qod, 3 times per week
380676|NCT01288612|Device|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
380677|NCT01288612|Device|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
380678|NCT01288599|Procedure|Laparoscopic surgery|Laparoscopic surgery where adnexectomy or cystectomy is performed.
380679|NCT01288586|Device|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
380680|NCT01288573|Drug|plerixafor|160 μg/kg subcutaneous (SC) injection
380681|NCT01288573|Drug|plerixafor|240 μg/kg subcutaneous (SC) injection
380682|NCT01288573|Drug|plerixafor|320 μg/kg subcutaneous (SC) injection
380683|NCT01288560|Other|Advanced cardiac imaging|
380684|NCT01288560|Other|Standard Cardiac Imaging|
380685|NCT01288547|Dietary Supplement|theobromine|700 mg theobromine in gelatin capsules given one time only
380686|NCT01288547|Dietary Supplement|Caffeine|120 mg caffeine in capsules given one time only
380687|NCT01288547|Dietary Supplement|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
380688|NCT01288547|Dietary Supplement|placebo|cellulose in capsules given one time only
380689|NCT01288534|Radiation|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
380690|NCT01288521|Drug|Tacrolimus + Ketoconazole, Then Tacrolimus alone|Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + ketoconazole 200 mg every 12 hours x 3 doses.
380691|NCT01288521|Drug|Tacrolimus alone, Then Tacrolimus + Ketoconazole|Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
380692|NCT01288508|Dietary Supplement|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
380693|NCT01288508|Dietary Supplement|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
380694|NCT01288495|Dietary Supplement|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
380695|NCT01288495|Dietary Supplement|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
380728|NCT01288261|Biological|bavituximab|Given IV
380729|NCT01288261|Other|laboratory biomarker analysis|Correlative studies
380730|NCT01288261|Other|pharmacological study|Correlative study
380696|NCT01288482|Device|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
380697|NCT01288482|Device|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
380698|NCT01288469|Drug|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
380699|NCT01288469|Drug|Placebo (for alirocumab)|One SC injection in the abdomen only.
380700|NCT01288469|Drug|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
380701|NCT01288469|Drug|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
380702|NCT01288443|Drug|Alirocumab|Two SC injections in the abdomen only.
380703|NCT01288443|Drug|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
380704|NCT01288443|Drug|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
380705|NCT01288430|Drug|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
380706|NCT01288417|Drug|boceprevir|10 days of boceprevir 800mg TID
380707|NCT01288417|Drug|raltegravir|raltegravir 400mg single dose
380708|NCT01288404|Drug|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
380709|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
380710|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
380711|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
380712|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
380713|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
380714|NCT01288378|Drug|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
380715|NCT01288365|Behavioral|Exercise training|Exercise training program for 3 months (two times a week).
380716|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.~Early-onset rhythm control therapy can consist of:~Optimal antiarrhythmic drug therapy~Catheter ablation with the aim of pulmonary vein isolation (PVI),~Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.~All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
380717|NCT01288339|Drug|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
380718|NCT01288339|Drug|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
380719|NCT01288326|Drug|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
380720|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
380721|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
380722|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
380723|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
380724|NCT01288300|Behavioral|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
380725|NCT01288300|Behavioral|Diabetes lecture|Diabetes self-management lecture
380726|NCT01288274|Other|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
380727|NCT01288261|Drug|paclitaxel|Given IV
380731|NCT01288248|Device|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.~The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
380732|NCT01288248|Device|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.~The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
380733|NCT01288235|Radiation|Proton radiotherapy|5 days a week
380734|NCT01288222|Biological|KIR genotype|KIR genotype from unrelated donor.
380735|NCT01288222|Biological|Unrelated donor transplant|hematopoietic cell transplant performed per each center's guidelines
380736|NCT01288209|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
380737|NCT01288209|Drug|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
380738|NCT01288209|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
380739|NCT01288196|Drug|Placebo IV|A single 30-minute IV infusion of placebo
380740|NCT01288196|Drug|CNTO 6785 1 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 1 mg/kg
380741|NCT01288196|Drug|CNTO 6785 3 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 3 mg/kg
380742|NCT01288196|Drug|CNTO 6785 10 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 10 mg/kg
380743|NCT01288196|Drug|CNTO 6785 SC|A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
380744|NCT01288196|Drug|Placebo SC|A single SC dose of placebo administered in up to 3 SC injections
380745|NCT01288183|Procedure|sham tDCS|"sham condition as delivered by the stimulator study mode (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day"
380746|NCT01288183|Procedure|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
380747|NCT01288170|Drug|Nebcinal Tobi|
380748|NCT01288170|Drug|Tobi Nebcinal|
380749|NCT01288157|Drug|Golimumab|Single dose of 100 mg subcutaneously
380750|NCT01288157|Drug|Golimumab|Single dose of 50 mg subcutaneously
380751|NCT01288144|Other|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
380752|NCT01288131|Drug|Cyclosporine combine with mycophenolate mofetil|Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
380753|NCT01288131|Drug|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
380754|NCT01288105|Device|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom >95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with <95% stent strut coverage will receive perioperative bridging.
380755|NCT01288092|Drug|BEZ235|
380756|NCT01288079|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
380757|NCT01288079|Drug|Duloxetine|Capsule, oral, once daily
380758|NCT01288079|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
380759|NCT01288066|Procedure|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
380760|NCT01288066|Procedure|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
380761|NCT01288053|Biological|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
380762|NCT01288040|Behavioral|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
380763|NCT01288027|Biological|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
380764|NCT01288001|Drug|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
380765|NCT01287988|Drug|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
380766|NCT01287988|Drug|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
380814|NCT01287611|Procedure|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
380815|NCT01287598|Drug|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
380767|NCT01287975|Other|Occupational Therapy|"Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.~Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.~Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively."
380768|NCT01287975|Device|BCI Haptic Knob|BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
380769|NCT01287975|Device|Haptic Knob|Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
380770|NCT01287962|Drug|apatinib|750 mg，po，QD； 28 days every cycle
380771|NCT01287962|Drug|placebo|po，QD； 28 days every cycle
380772|NCT01287949|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
380773|NCT01287936|Biological|SB623|SB623, a modified stem-cell product, will be administered at 3 dose levels. Each patient in one of three groups will be given a dose of 2.5, 5.0, or 10 million cells once. Each group will be completed before going to the next higher-dose group.
380774|NCT01287910|Other|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
380775|NCT01287897|Drug|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
380776|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
380777|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
380778|NCT01287884|Other|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
380779|NCT01287858|Drug|AC430|Healthy volunteers will either receive AC430 or placebo.
380780|NCT01287845|Drug|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
380781|NCT01287845|Drug|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
380782|NCT01287832|Drug|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
380783|NCT01287832|Drug|Daptomycin|
380784|NCT01287806|Drug|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
380785|NCT01287806|Drug|blank group|standard treatment
380786|NCT01287793|Drug|tigecycline|intravenous, 200 mg, single dose
380787|NCT01287793|Drug|tigecycline|intravenous, 50 mg, single dose
380788|NCT01287793|Drug|moxifloxacin|oral tablet, 400 mg, single dose
380789|NCT01287793|Drug|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
380790|NCT01287793|Drug|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
380791|NCT01287780|Device|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
380792|NCT01287767|Behavioral|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
380793|NCT01287754|Drug|erlotinib [Tarceva]|150 mg daily orally
380794|NCT01287741|Drug|Rituximab|Rituximab at a dose of 375 mg/m^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
380795|NCT01287741|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
380796|NCT01287741|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
380797|NCT01287741|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle.
380798|NCT01287741|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
380799|NCT01287741|Drug|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
380800|NCT01287728|Drug|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
380801|NCT01287715|Drug|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
380802|NCT01287715|Drug|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
380803|NCT01287702|Dietary Supplement|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
380804|NCT01287702|Dietary Supplement|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
380805|NCT01287702|Dietary Supplement|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
380806|NCT01287689|Other|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
380807|NCT01287663|Drug|Permethrin impregnated|
380808|NCT01287663|Drug|no Permethrin impregnated|
380809|NCT01287637|Procedure|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
380810|NCT01287637|Procedure|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
380811|NCT01287624|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
380812|NCT01287624|Drug|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
380813|NCT01287611|Procedure|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
380819|NCT01287598|Drug|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
380820|NCT01287585|Drug|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
380821|NCT01287585|Drug|Placebo|weekly, intramuscular, until disease progression or toxicity.
380822|NCT01287585|Other|Best Supportive Care|treatment of disease-related symptoms throughout the study.
380823|NCT01287546|Drug|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
380824|NCT01287546|Drug|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
380825|NCT01287546|Drug|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
380826|NCT01287546|Drug|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
380827|NCT01287533|Drug|Ibandronate|monthly dosage of ibandronate 150mg
380828|NCT01287533|Drug|Placebo|monthly dosage of placebo
380829|NCT01287520|Drug|LY2090314|Administered intravenously
380830|NCT01287520|Drug|pemetrexed|Administered intravenously
380831|NCT01287520|Drug|Carboplatin|Administered intravenously
380832|NCT01287520|Other|ranitidine|Per I2H-MC-JWYA Protocol Amendment (d) approved 11 March 2010, 50 mg ranitidine given as pretreatment to LY2090314 for stomach pain.
380833|NCT01287507|Dietary Supplement|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
380834|NCT01287494|Drug|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
380835|NCT01287481|Behavioral|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
380836|NCT01287481|Behavioral|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
380837|NCT01287481|Behavioral|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
380838|NCT01287455|Drug|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
380839|NCT01287455|Other|placebo|drops, 70 placebo drops, once weekly for 6 weeks
380840|NCT01287442|Procedure|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
380841|NCT01287429|Other|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
380842|NCT01287416|Behavioral|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
380843|NCT01287416|Behavioral|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
380844|NCT01287403|Other|Refined wheat flour|A treated cereal flour mixed with milk.
380845|NCT01287403|Other|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
380846|NCT01287403|Other|Wholegrain wheat flour|A treated cereal flour mixed with milk.
380847|NCT01287403|Other|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
380848|NCT01287403|Other|Wholegrain barley flour|A treated cereal flour mixed with milk.
380849|NCT01287403|Other|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
380850|NCT01287390|Procedure|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
380851|NCT01287390|Procedure|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
380852|NCT01287390|Other|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
380853|NCT01287390|Other|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
380854|NCT01287390|Other|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H&N 35).
380855|NCT01287377|Behavioral|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
380856|NCT01287377|Drug|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).~For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
380857|NCT01287364|Drug|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
380858|NCT01287364|Drug|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
380859|NCT01287351|Drug|extra-fine hydrofluoroalkane beclometasone dipropionate|
380860|NCT01287351|Drug|Fluticasone propionate|
380861|NCT01287338|Drug|Olopatadine|low dose
380862|NCT01287338|Drug|Olopatadine|high dose
380863|NCT01287325|Drug|DNK333 100 mg twice daily|
380864|NCT01287325|Drug|Placebo|
380865|NCT01287312|Procedure|Endoscopic repair of recurrent TEF by trichloroacetic acid aplications|
380866|NCT01287299|Other|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
380867|NCT01287299|Other|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
380868|NCT01287286|Dietary Supplement|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
380869|NCT01287286|Dietary Supplement|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
380870|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg twice daily (BID)
380871|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg once daily (OD)
380872|NCT01287247|Biological|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
380873|NCT01287234|Other|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
380874|NCT01287221|Drug|Rifampicin|300 mg, 2 times daily
380875|NCT01287221|Drug|placebo|placebo
380876|NCT01287208|Device|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
380877|NCT01287208|Device|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
380878|NCT01287195|Drug|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
380879|NCT01287195|Drug|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
380880|NCT01287182|Drug|Ateronon|Ateronon daily for 3 months
380881|NCT01287130|Drug|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
380882|NCT01287130|Drug|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
380883|NCT01287117|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
380884|NCT01287117|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
380885|NCT01287104|Biological|Natural Killer (NK) Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
380886|NCT01287104|Biological|Stem Cell Infusion|Transplant Day 0: >4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) >5000/microliters x2
380887|NCT01287091|Drug|GDC-0980|Oral tablet dose
380888|NCT01287091|Drug|GDC-0980|Oral capsule dose
380889|NCT01287091|Drug|GDC-0980|Oral tablet dose in fed state
380890|NCT01287091|Drug|GDC-0980|Oral repeating dose in fasting state
380891|NCT01287091|Drug|GDC-0980|Oral repeating dose in fed state
380892|NCT01287091|Drug|GDC-0980|Oral tablet in a fasting state
380893|NCT01287091|Drug|rabeprazole|Oral repeating dose
380894|NCT01287078|Drug|Cyclosporine Inhalation Solution|sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
380895|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
380896|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
380897|NCT01287065|Drug|Placebo AM|Inhalation powder
380898|NCT01287065|Drug|Placebo PM|Inhalation powder
380899|NCT01287052|Drug|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
380900|NCT01287039|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
380901|NCT01287039|Drug|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
380902|NCT01287026|Procedure|Cardiac Real-time MRI RHC (Right Heart Catheterization)|
380903|NCT01287013|Device|Cone-beam computed tomography (CT)|Imaging
380904|NCT01287013|Device|Conventional Computed Tomography (CT)|Imaging
380905|NCT01286987|Drug|Talazoparib|Oral capsule with multiple dosage forms given once daily
380906|NCT01286974|Drug|[14C]linifanib|[14C]linifanib, single administration, oral liquid
380907|NCT01286974|Drug|ABT-869, linifanib|linifanib once a day (QD), oral tablet
380908|NCT01286961|Drug|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
380909|NCT01286948|Drug|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).~All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
380910|NCT01286935|Drug|Safinamide|
380913|NCT01286922|Other|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:~• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.~Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:~• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
380914|NCT01286909|Dietary Supplement|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
380915|NCT01286896|Drug|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.~After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
380916|NCT01286870|Device|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
380917|NCT01286870|Device|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
380918|NCT01286857|Device|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
380919|NCT01286844|Drug|GSK2190915A 5mg|Oral powder for dispersion in water
380920|NCT01286844|Drug|GSK2190915A 10mg|Oral powder for dispersion in water
380921|NCT01286844|Drug|GSK2190915A 25mg|Oral powder for dispersion in water
380922|NCT01286844|Drug|GSK2190915A 50mg|Oral powder for dispersion in water
380923|NCT01286844|Drug|GSK2190915A 100mg|Oral powder for dispersion in water
380924|NCT01286831|Drug|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
380925|NCT01286818|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
380926|NCT01286818|Drug|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
380927|NCT01286818|Drug|levofolinate|IV infusion, 200 mg/m² every 2 weeks
380928|NCT01286818|Drug|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
380929|NCT01286805|Procedure|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
380930|NCT01286805|Procedure|Control|The control group will receive only a combined spinal-epidural.
380931|NCT01286779|Biological|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
380932|NCT01286766|Drug|DCS (docetaxel with cisplatin with TS-1)|"S-1: 70 mg/m2 #2 bid PO, D1-14~Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8~Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
380933|NCT01286766|Drug|DCF (docetaxel with cisplatin with 5-FU)|"5-FU: 1,000 mg/m2 CI, D1-3~Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by~Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.~Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)~treatment is repeated until 4 cycles"
380934|NCT01286753|Drug|Vemurafenib|Vemurafenib 960 mg orally twice daily.
380935|NCT01286740|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
380936|NCT01286727|Drug|BB3|intravenous drug
380937|NCT01286714|Device|CLIP OST|
380938|NCT01286701|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
380939|NCT01286688|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
380940|NCT01286675|Drug|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
380941|NCT01286649|Other|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
380942|NCT01286649|Other|Cell medium|Cell medium
380943|NCT01286636|Other|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
380944|NCT01286636|Other|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
380945|NCT01286610|Device|ProMedVi Vibrosphere|vibration therapy
380946|NCT01286610|Device|schwa-medico MUSKELaktiv|Electrical muscle stimulation
380947|NCT01286610|Device|Galileo Home Plus (ICU)|vibration therapy
380948|NCT01286597|Dietary Supplement|dietary restriction|restrict intake of lactose
381076|NCT01285544|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
380949|NCT01286584|Drug|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
380950|NCT01286584|Drug|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
380951|NCT01286571|Drug|BI 135585|one oral single dose per subject
380952|NCT01286571|Drug|BI 135585|one oral single dose per subject
380953|NCT01286558|Drug|40 mg telmisartan|once daily
380954|NCT01286558|Drug|5 mg amlodipine|once daily
380955|NCT01286558|Drug|5 mg amlodipine|once daily
380956|NCT01286558|Drug|80 mg telmisartan|once daily
380957|NCT01286493|Biological|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
380958|NCT01286480|Behavioral|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
380959|NCT01286467|Drug|PF-04449913|Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
380960|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
380961|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
380962|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
380963|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
380964|NCT01286454|Drug|fesoterodine|single dose of tablet
380965|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
380966|NCT01286441|Drug|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
380967|NCT01286441|Drug|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
380968|NCT01286441|Drug|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
380969|NCT01286441|Drug|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
380970|NCT01286415|Behavioral|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
380971|NCT01286415|Behavioral|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
380972|NCT01286402|Drug|Bupropion SR|"150mg, taken orally, taken daily for the 1st 3 days~300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
380973|NCT01286402|Other|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
380974|NCT01286389|Other|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
380975|NCT01286389|Behavioral|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
380976|NCT01286376|Dietary Supplement|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
380977|NCT01286376|Dietary Supplement|Maltodextrin|Maltodextrin
381077|NCT01285531|Device|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
381078|NCT01285518|Drug|PF-05231023|0.5 mg QD IV x 1 day
381079|NCT01285518|Drug|PF-05231023|1.5 mg QD IV x 1 day
381080|NCT01285518|Drug|PF-05231023|5 mg QD IV x 1 day
380978|NCT01286350|Behavioral|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
380979|NCT01286337|Procedure|bipolar vessel sealing|
380980|NCT01286337|Procedure|control|
380981|NCT01286324|Dietary Supplement|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
380982|NCT01286324|Drug|Placebo Tablet|
380983|NCT01286311|Behavioral|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
380984|NCT01286298|Procedure|Laser gingivectomy|Gingivectomy by diode laser
380985|NCT01286298|Procedure|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
380986|NCT01286272|Drug|Bendamustine Hydrochloride|Given IV
380987|NCT01286272|Drug|Bortezomib|Given IV or SC
380988|NCT01286272|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET
380989|NCT01286272|Other|Laboratory Biomarker Analysis|Correlative studies
380990|NCT01286272|Biological|Ofatumumab|Given IV
380991|NCT01286272|Procedure|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
380992|NCT01286259|Drug|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
380993|NCT01286246|Drug|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
380994|NCT01286246|Drug|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
380995|NCT01286233|Drug|Metformin|
380996|NCT01286233|Drug|Placebo|
380997|NCT01286220|Other|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
380998|NCT01286220|Other|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
380999|NCT01286207|Drug|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
381000|NCT01286207|Drug|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
381001|NCT01286207|Drug|Standard Care|Active standard care
381002|NCT01286194|Drug|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
381003|NCT01286181|Behavioral|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
381004|NCT01286168|Device|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
381005|NCT01286168|Device|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
381006|NCT01286168|Procedure|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
381007|NCT01286168|Device|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
381008|NCT01286129|Procedure|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
381009|NCT01286116|Device|Parachute Implant|Mechanical ventricular partitioning
381010|NCT01286103|Drug|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
381011|NCT01286103|Drug|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
381012|NCT01286090|Drug|Cisapride|One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
381013|NCT01286090|Drug|Placebo|One tablet taken orally 4 times a day for up to 8 weeks.
381014|NCT01286077|Drug|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
381015|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
381081|NCT01285518|Drug|PF-05231023|15 mg QD IV x 1 day
381016|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
381017|NCT01286051|Drug|Follistim administration|adminstation of FSH for ovulation induction
381018|NCT01286051|Drug|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
381019|NCT01286038|Drug|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
381020|NCT01286025|Behavioral|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
381021|NCT01286025|Behavioral|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
381022|NCT01286012|Drug|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
381023|NCT01286012|Drug|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
381024|NCT01286012|Drug|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
381025|NCT01286012|Drug|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
381026|NCT01285999|Device|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent
381027|NCT01285999|Device|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent
381028|NCT01285986|Procedure|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
381029|NCT01285960|Device|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
381030|NCT01285947|Device|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
381031|NCT01285947|Other|Needle Application|30-gauge needle insertion into skin
381032|NCT01285947|Device|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
381033|NCT01285947|Device|Ulthera|"Ultrasound Device at the following settings:~Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
381034|NCT01285934|Biological|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
381035|NCT01285934|Drug|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
381036|NCT01285921|Other|vestibular test before and after hippocampal surgery|"Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)~HIT (testing semicircular canal function at high frequency).Results: Gain in %~VEMp (testing saccular function). Results: Amplitude in μV and latency in ms~ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s~Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
381037|NCT01285908|Drug|Intravenous Norepinephrine Infusion|
381038|NCT01285882|Other|Representations|"A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.~To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :~1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.~2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.~Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
381039|NCT01285869|Other|Multidimensional intervention|The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
381082|NCT01285518|Drug|PF-05231023|50 mg QD IV x 1 day
381083|NCT01285518|Drug|PF-05231023|100 mg QD IV x 1 day
381084|NCT01285518|Drug|PF-05231023|200 mg QD IV x 1 day
381085|NCT01285518|Other|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
381086|NCT01285505|Drug|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
381478|NCT01282268|Drug|placebo|orally disintegrating tablet
381040|NCT01285856|Other|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.~Saliva sample, a method which gives similar results without the need for venous blood sampling."
381041|NCT01285843|Procedure|Anterior Minimally Invasive Approach (AMIS)|
381042|NCT01285830|Dietary Supplement|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
381043|NCT01285830|Dietary Supplement|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
381044|NCT01285817|Drug|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
381045|NCT01285804|Other|Cuffed ETT|Kimberly Clark
381046|NCT01285804|Other|Uncuffed ETT|Kimberly Clark
381047|NCT01285778|Drug|panitumumab, mytomicin C, 5-FU, radiation|"Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~Then Mitomycin C, 10mg/m2 on days 1 and 29~Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy."
381048|NCT01285765|Drug|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
381049|NCT01285752|Drug|AK106-001616|
381050|NCT01285752|Drug|AK106-001616|
381051|NCT01285752|Drug|Active comparator|
381052|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
381053|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
381054|NCT01285726|Other|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
381055|NCT01285713|Drug|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
381056|NCT01285713|Drug|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
381057|NCT01285700|Drug|Lamazym|ERT, infusion weekly
381058|NCT01285687|Device|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
381059|NCT01285674|Drug|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
381060|NCT01285661|Drug|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
381061|NCT01285648|Procedure|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
381062|NCT01285635|Drug|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
381063|NCT01285635|Drug|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
381064|NCT01285609|Drug|Ipilimumab|
381065|NCT01285609|Drug|Placebo|
381066|NCT01285609|Drug|Paclitaxel|
381067|NCT01285609|Drug|Carboplatin|
381068|NCT01285596|Drug|Mirabegron|oral
381069|NCT01285583|Drug|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
381070|NCT01285570|Drug|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
381071|NCT01285570|Drug|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
381072|NCT01285570|Drug|5% dextrose in water|Placebo
381073|NCT01285557|Drug|S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
381074|NCT01285557|Drug|Fluorouracil/cisplatin (control arm)|"5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles."
381075|NCT01285544|Drug|Atorvastatin (Lipinon)|treatment of dyslipidemia administration : PO, qod
381087|NCT01285505|Drug|alprazolam test sublingual tablet|0.5 mg tablet, single dose
381088|NCT01285492|Drug|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
381089|NCT01285492|Drug|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
381090|NCT01285479|Drug|Fingolimod|
381091|NCT01285466|Drug|BEZ235 + paclitaxel|
381092|NCT01285466|Drug|BKM120 + paclitaxel|
381093|NCT01285466|Drug|BEZ235 + paclitaxel + trastuzumab|
381094|NCT01285466|Drug|BKM120 + paclitaxel + trastuzumab|
381095|NCT01285453|Drug|vadimezan|
381096|NCT01285414|Drug|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide & Radiation Therapy
381097|NCT01285414|Drug|Temozolomide & Radiation Therapy|Temozolomide & Radiation Therapy
381098|NCT01285401|Drug|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day [mcg/day]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
381099|NCT01285401|Drug|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
381100|NCT01285401|Biological|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
381101|NCT01285388|Drug|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
381102|NCT01285375|Device|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
381103|NCT01285375|Device|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
381104|NCT01285362|Drug|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
381105|NCT01285362|Drug|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
381106|NCT01285349|Behavioral|Couple HIV/STI prevention intervention|
381107|NCT01285349|Behavioral|Couple-based HIV/STI prevention|
381108|NCT01285349|Behavioral|Individual HIV/STI prevention|
381109|NCT01285349|Behavioral|Couple Wellness Promotion|
381110|NCT01285323|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
381111|NCT01285323|Drug|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
381112|NCT01285310|Drug|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
381113|NCT01285310|Drug|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
381114|NCT01285310|Drug|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
381115|NCT01285297|Biological|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
381116|NCT01285284|Other|Music|A previously defined list of songs will be administered by headphones to these patients.
381117|NCT01285284|Other|No music|No music will be administered by the headphones connected to the MP3 device.
381118|NCT01285271|Drug|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
381119|NCT01285271|Drug|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
381120|NCT01285258|Procedure|hysterectomy|excluding the uterus with saving ovaries
381121|NCT01285245|Drug|kineret|once daily 100 mg of kineret subcutaneously for 8 days
381122|NCT01285232|Drug|Anakinra|150 mg sc once daily during four weeks
381123|NCT01285219|Drug|pegylated filgrastim and ﬁlgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
381124|NCT01285219|Drug|ﬁlgrastim and pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
381125|NCT01285206|Device|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
381126|NCT01285193|Behavioral|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
381127|NCT01285180|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
381128|NCT01285167|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
381129|NCT01285141|Biological|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
381130|NCT01285115|Drug|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
381131|NCT01285115|Drug|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
381132|NCT01285115|Drug|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
381165|NCT01284803|Behavioral|an educational intervention|To elaborate an educational program for the management of depression in primary care
381166|NCT01284790|Device|Cochlear implants|
381167|NCT01284777|Genetic|blood sample, thoracocentesis|20ml of blood only one thoracocentesis (the same that one for diagnostic)
381168|NCT01284764|Drug|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
381133|NCT01285102|Device|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
381134|NCT01285102|Procedure|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
381135|NCT01285089|Drug|activated recombinant human factor VII|Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
381136|NCT01285076|Other|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
381137|NCT01285063|Other|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.~Physical activity: physical trainings of 60 minutes each will be held twice a week.~behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
381138|NCT01285050|Drug|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
381139|NCT01285050|Drug|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
381140|NCT01285050|Drug|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
381141|NCT01285037|Drug|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
381142|NCT01285037|Drug|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
381143|NCT01285037|Drug|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
381144|NCT01285037|Drug|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
381145|NCT01285037|Drug|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
381146|NCT01285024|Device|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
381147|NCT01284959|Drug|risperidone|risperidone 3mg, PO, 3 times
381148|NCT01284959|Drug|paliperidone ER|paliperidone ER 6mg, PO,3 times
381149|NCT01284959|Drug|placebo|lactose PO, 3times
381150|NCT01284946|Drug|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
381151|NCT01284920|Drug|MDV3100|oral
381152|NCT01284907|Dietary Supplement|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
381153|NCT01284907|Dietary Supplement|Placebo Drops|
381154|NCT01284894|Device|Conventional manometry|Conventional esophageal manometry
381155|NCT01284894|Device|High resolution manometry|High resolution esophageal manometry
381156|NCT01284881|Device|MRA|daily wear overnight
381157|NCT01284868|Drug|mirabegron|oral
381158|NCT01284868|Drug|Bisoprolol|oral
381159|NCT01284868|Drug|propranolol|oral
381160|NCT01284868|Drug|placebo|oral
381161|NCT01284855|Drug|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
381162|NCT01284842|Other|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
381163|NCT01284829|Other|FDG-PET scan|
381164|NCT01284816|Procedure|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
381219|NCT01284361|Device|40 cm Intermittent Catheter|randomized cross-over
381169|NCT01284751|Other|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
381170|NCT01284738|Other|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~the dosages of MP carried out by the UMR 608 in Marseille,~the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.~In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
381171|NCT01284738|Other|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :~the dosages of MP carried out by the UMR 608 in Marseille,~the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
381172|NCT01284725|Drug|mycophenolate mofetil or azathioprine|
381173|NCT01284725|Other|immunosuppressive treatment discontinuation|
381174|NCT01284712|Biological|blood sample|blood sample coming from therapeutic bleeding in hospital
381175|NCT01284699|Procedure|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
381176|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
381177|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
381178|NCT01284673|Other|in vitro characterization of the cord blood stem cell|The quantitative and qualitative, functional characterization will insist on cell populations which could potentially participate to neuronal regeneration. and assessment such characteristics in conditions of cryo-preservation, compared to fresh cell preparation
381179|NCT01284660|Dietary Supplement|DHA|DHA ingested orally by heavy smokers
381180|NCT01284660|Dietary Supplement|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
381181|NCT01284647|Drug|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
381182|NCT01284647|Drug|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
381183|NCT01284634|Drug|GWP42003 200 mg/day Dose|GWP42003 was presented as Licaps® size double zero (Size 00) hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
381184|NCT01284634|Drug|GWP42003 400 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
381185|NCT01284634|Drug|GWP42003 800 mg/day Dose|GWP42003 was presented as Licaps® Size 00 hard gelatin capsules containing 100 mg of CBD dissolved in vehicle (Gelucire 44/14).
381186|NCT01284634|Drug|Placebo|Placebo was presented as Licaps® Size 00 hard gelatin capsules containing excipients (Gelucire 44/14).
381187|NCT01284621|Drug|BI 10773|medium dose, oral administration
381188|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
381189|NCT01284621|Drug|BI 10773|medium dose oral administration
381190|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
381191|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
381192|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
381193|NCT01284595|Drug|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
381194|NCT01284582|Biological|ATH03|4 vaccinations
381195|NCT01284569|Biological|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
381196|NCT01284569|Biological|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
381197|NCT01284556|Drug|Phenobarbital|tablet
381198|NCT01284556|Drug|Placebo tablet|tablet
381199|NCT01284543|Device|Use of the Tan EndoGlide to insert donor graft|Using the Tan EndoGlide to insert donor graft into the eye
381200|NCT01284543|Device|Busin Glide for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye
381201|NCT01284530|Drug|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
381202|NCT01284517|Drug|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
381203|NCT01284517|Drug|Placebo|Equivalent to Lurasidone dosing
381204|NCT01284504|Drug|Celecoxib|200 mg tablet oral
381205|NCT01284504|Other|placebo|Placebo, tab
381206|NCT01284491|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
381207|NCT01284491|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
381208|NCT01284478|Drug|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
381209|NCT01284465|Behavioral|Education and patient liaison combination|Group education sessions with Patient liaison using ecological momentary assessment principles
381210|NCT01284465|Behavioral|Control group|Group education sessions at baseline, 3 and 6 months
381211|NCT01284452|Drug|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
381212|NCT01284452|Drug|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
381213|NCT01284439|Drug|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
381214|NCT01284439|Drug|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
381215|NCT01284413|Drug|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
381216|NCT01284400|Other|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
381217|NCT01284387|Biological|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
381218|NCT01284361|Device|30 cm Intermittent Catheter|Randomized cross-over
381220|NCT01284348|Drug|Sotatercept 15 mg|Sotatercept 15 mg SC injection every 42 days, up to 4 doses/cycles
381221|NCT01284348|Drug|Sotatercept 30 mg|Sotatercept 30 mg subcutaneous injection Day 1 every 42 days, up to 4 doses/cycles
381222|NCT01284335|Drug|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
381223|NCT01284335|Drug|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
381224|NCT01284335|Drug|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
381225|NCT01284335|Drug|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
381226|NCT01284335|Drug|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criteria are met.
381227|NCT01284335|Drug|LY573636|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.
381228|NCT01284322|Drug|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
381229|NCT01284309|Drug|Mirabegron|oral
381230|NCT01284309|Drug|Placebo|oral
381231|NCT01284296|Drug|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
381232|NCT01284296|Device|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
381233|NCT01284283|Device|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
381234|NCT01284270|Other|Cardiac MRI|Cardiac MRI
381235|NCT01284244|Device|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
381236|NCT01284244|Device|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
381237|NCT01284231|Drug|MEDI-565|MEDI-565 will be administered by IV infusion
381238|NCT01284231|Drug|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
381239|NCT01284231|Drug|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
381240|NCT01284231|Drug|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
381241|NCT01284205|Biological|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
381242|NCT01284205|Biological|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
381243|NCT01284192|Drug|ASP3026|Tablet
381244|NCT01284179|Behavioral|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
381245|NCT01284179|Behavioral|Educational|Educational recordings regarding FCP and FGIDs.
381246|NCT01284166|Drug|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
381247|NCT01284140|Behavioral|Sleep and circadian rhythm promotion|This multifaceted intervention attempts to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. The intervention began the morning after enrollment and enforced a specific period of enhanced light exposure from 9:00 a.m. to noon. The initial target of 5,000 lux administered by light box (Sunsation, SunBox Co.) was reduced to 400-700 lux after the first 10 subjects were enrolled in the study.
381248|NCT01284140|Behavioral|Usual care|Usual care.
381249|NCT01284114|Drug|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
381250|NCT01284101|Device|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
381251|NCT01284101|Device|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
381252|NCT01284088|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
381253|NCT01284088|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
381254|NCT01284075|Behavioral|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
381255|NCT01284075|Behavioral|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
381256|NCT01284075|Other|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
381257|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
381258|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
381259|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
381260|NCT01284062|Other|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
381261|NCT01284049|Drug|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
381262|NCT01284049|Drug|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
381263|NCT01284036|Drug|PF-05230905|Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
381264|NCT01284023|Other|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
381265|NCT01284010|Genetic|DNA analysis|
381266|NCT01284010|Genetic|fluorescence in situ hybridization|
381267|NCT01284010|Genetic|gene expression analysis|
381268|NCT01284010|Genetic|microarray analysis|
381269|NCT01284010|Genetic|mutation analysis|
381270|NCT01284010|Genetic|polymerase chain reaction|
381271|NCT01284010|Other|laboratory biomarker analysis|
381272|NCT01283997|Other|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
381273|NCT01283997|Drug|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
381274|NCT01283984|Drug|AZD2115|Single dose, oral inhalation (nebuliser solution)
381275|NCT01283984|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
381276|NCT01283971|Drug|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
381277|NCT01283971|Drug|adalimumab|Adalimumab 40 mg SC every 2 weeks.
381278|NCT01283971|Drug|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
381279|NCT01283971|Drug|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
381280|NCT01283971|Drug|methotrexate|Methotrexate 10-25 mg weekly.
381281|NCT01283971|Drug|folate|Folate at least 5 mg weekly.
381282|NCT01283945|Drug|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.~Dose escalation - continuous schedule~Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)~Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
381283|NCT01283932|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
381284|NCT01283919|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
381285|NCT01283906|Device|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
381286|NCT01283906|Device|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
381287|NCT01283893|Procedure|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
381288|NCT01283867|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
381289|NCT01283854|Behavioral|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.~Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
381290|NCT01283841|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
381368|NCT01283217|Drug|SP|S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
381291|NCT01283815|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
381292|NCT01283815|Procedure|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
381293|NCT01283802|Procedure|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:~Direct ultrasound exploration without any contrast agents.~IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);~IOCUS injection of an air bolus into the bile duct."
381294|NCT01283789|Drug|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.~Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
381295|NCT01283776|Drug|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
381296|NCT01283763|Drug|Topical Imiquimod|16 weeks
381297|NCT01283763|Procedure|Conization|Large loop excision of the transformation zone
381298|NCT01283750|Behavioral|care coordination|dementia-related care coordination
381299|NCT01283737|Device|DBX Putty|OCD of the knee will be treated with DBX Putty
381300|NCT01283737|Procedure|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
381301|NCT01283724|Drug|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
381302|NCT01283711|Device|apollo device|RF treatments for wrinkles and rhytides reduction
381303|NCT01283698|Drug|Experimental: LAS 41004 dosage 1|dosage 1, once daily
381304|NCT01283698|Drug|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
381305|NCT01283698|Drug|Experimental: LAS 41004 dosage 3|dosage 3, once daily
381306|NCT01283698|Drug|Placebo Comparator: placebo|once daily
381307|NCT01283698|Drug|Reference|Active Comparator,once daily
381308|NCT01283685|Other|breathing helium-hyperoxia|40% O2, 60% He
381309|NCT01283685|Other|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
381310|NCT01283672|Other|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
381311|NCT01283659|Other|Standard Imaging|
381312|NCT01283659|Other|Advanced Imaging|
381313|NCT01283646|Drug|Apevitin BC|3.5 to 5 ml 3 times a daily
381314|NCT01283646|Drug|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
381315|NCT01283633|Device|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
381316|NCT01283620|Behavioral|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
381317|NCT01283620|Other|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
381318|NCT01283607|Behavioral|Digicoach|Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
381319|NCT01283594|Drug|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID."
381320|NCT01283594|Drug|Placebo|White-coated, modified-oval placebo tablets.
381321|NCT01283594|Drug|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
381322|NCT01283594|Drug|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID."
381323|NCT01283594|Drug|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID."
381324|NCT01283594|Drug|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID."
381325|NCT01283581|Drug|Delafloxacin|300mg IV every 12 hours for 5-14 days
381326|NCT01283581|Drug|Linezolid|600mg IV every 12 hours for 5-14 days
381327|NCT01283581|Drug|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
381328|NCT01283555|Drug|Tenofovir|Delivered using prefilled and user-filled applicator
381329|NCT01283542|Drug|Pasireotide LAR|20 and 40 mg of powder in vials and 2 mL of vehicle in ampoules (for reconstitution) administered as a depot intragluteal IM (intramuscular) injection
381330|NCT01283516|Drug|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
381331|NCT01283503|Drug|BKM120|
381473|NCT01282333|Drug|cisplatin|Given IV
381332|NCT01283490|Device|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
381333|NCT01283490|Device|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
381334|NCT01283477|Device|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
381335|NCT01283477|Device|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
381336|NCT01283464|Drug|Retinol|1.0% cream
381337|NCT01283464|Drug|Tretinoin|0.02% cream
381338|NCT01283451|Behavioral|Muscle contraction|Participants will perform a 30-60 second exercise designed to cause a temporary decrease in muscle oxygenation of a specific muscle group.
381339|NCT01283438|Device|Barricaid|CE Marked Device
381340|NCT01283438|Device|Standard of Care|Standard Limited discectomy
381341|NCT01283425|Device|InsuPatch|Heaters for single use and a permanent control unit.
381342|NCT01283412|Drug|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
381343|NCT01283412|Drug|Dexmedetomidine|Dexmedetomidine 0.1~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
381344|NCT01283386|Drug|Chlorambucil|10 mg/m^2 orally on Days 1-7 of each 28-day cycle for 6 cycles
381345|NCT01283386|Drug|Cyclophosphamide|150 mg/m^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles
381346|NCT01283386|Drug|Fludarabine|20 mg/m^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles
381347|NCT01283386|Drug|Rituximab|375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)
381348|NCT01283373|Drug|DSTP3086S|DSTP3086S administered intravenously
381349|NCT01283373|Drug|DSTP3086S|Escalating intravenous dose
381350|NCT01283360|Other|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
381351|NCT01283360|Drug|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
381352|NCT01283347|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG"
381353|NCT01283334|Drug|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
381354|NCT01283334|Drug|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
381355|NCT01283334|Drug|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
381356|NCT01283321|Drug|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT < 155 seconds, post CPB, with evidence of significant microvascular bleeding
381357|NCT01283321|Other|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT <155 seconds post CPB with evidence of significant microvascular bleeding.
381358|NCT01283308|Behavioral|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
381359|NCT01283308|Behavioral|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
381360|NCT01283282|Drug|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
381361|NCT01283282|Drug|Placebo|Placebo PO qday for 6 weeks
381362|NCT01283269|Behavioral|Memory Support System|Training in use of a memory notebook system
381363|NCT01283269|Behavioral|Computer Training|Computer brain fitness training
381364|NCT01283256|Drug|zonisamide|zonisamide 100mg tablets
381365|NCT01283243|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
381366|NCT01283230|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
381367|NCT01283217|Drug|DS|Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
381369|NCT01283204|Drug|SP|"<Every 3 weeks>~Day 1~14 : TS-1 80mg/m2/day (PO),~Day 1 : CDDP 60mg/m2/day IVF 2hours,~Day 15~21 : Rest."
381370|NCT01283204|Drug|FL/Tax|"<Every q 3 weeks>~Day1 : Paclitaxel 175mg/m2 IVF for 2hours~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
381371|NCT01283204|Drug|FL/Doc|"<Every q 3 weeks>~Day1 : Docetaxel 75mg/m2 IVF for 1hour~Day1 : Leucovorin 20mg/m2 IVF for 1hour~Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
381372|NCT01283204|Drug|FOLFOX|<Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
381373|NCT01283191|Behavioral|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
381374|NCT01283191|Behavioral|Education Control|Education class
381375|NCT01283178|Radiation|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
381376|NCT01283178|Drug|cisplatin|Given IV
381377|NCT01283178|Radiation|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
381378|NCT01283178|Other|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
381379|NCT01283178|Procedure|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
381380|NCT01283178|Radiation|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
381381|NCT01283165|Behavioral|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
381382|NCT01283152|Drug|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
381383|NCT01283152|Drug|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
381384|NCT01283139|Biological|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
381385|NCT01283139|Biological|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
381386|NCT01283139|Biological|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
381387|NCT01283139|Other|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
381388|NCT01283126|Procedure|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
381389|NCT01283100|Drug|GSK1349572|50mg once every 24 hours for 7 days
381390|NCT01283100|Drug|GSK2248761|200 mg once every 24 hours for 7 days
381391|NCT01283061|Drug|Zafirlukast|Zafirlukast tablets 20 mg
381392|NCT01283048|Drug|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
381393|NCT01283035|Drug|Akt Inhibitor MK2206|Given PO
381394|NCT01283035|Other|Laboratory Biomarker Analysis|Correlative studies
381395|NCT01283022|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
381396|NCT01283009|Drug|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
381397|NCT01282996|Other|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
381398|NCT01282983|Dietary Supplement|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
381399|NCT01282983|Dietary Supplement|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
381400|NCT01282970|Drug|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
381401|NCT01282970|Drug|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
381402|NCT01282957|Behavioral|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
381403|NCT01282957|Behavioral|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
381404|NCT01282944|Behavioral|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
381405|NCT01282944|Behavioral|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
381406|NCT01282918|Device|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
381407|NCT01282918|Device|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
381408|NCT01282892|Procedure|excess of visceral fat|excess of visceral fat
381409|NCT01282892|Procedure|patients with NAFLD|patients with NAFLD
381479|NCT01282255|Drug|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
381410|NCT01282879|Drug|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
381411|NCT01282866|Device|LightSheer Duet|LightSheer Duet HS handpiece
381412|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
381413|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
381414|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
381415|NCT01282840|Drug|Tolterodine SR|Tolterodine SR 4 mg qd
381416|NCT01282827|Device|rtACS (verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
381417|NCT01282827|Device|placebo stimulation|a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
381418|NCT01282814|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
381419|NCT01282814|Drug|Effexor® XR|150 mg Extended-Release Capsule
381420|NCT01282801|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
381421|NCT01282801|Drug|Effexor® XR|150 mg Extended-Release Capsule
381422|NCT01282788|Dietary Supplement|Caterpillar Cereal|Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
381423|NCT01282775|Behavioral|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
381424|NCT01282775|Behavioral|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
381425|NCT01282762|Biological|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.~HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
381426|NCT01282762|Biological|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.~Engerix-B booster injection = one dose of 2.0 mL volume when needed"
381427|NCT01282749|Behavioral|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
381428|NCT01282749|Behavioral|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
381429|NCT01282736|Behavioral|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
381430|NCT01282736|Behavioral|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
381431|NCT01282697|Drug|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
381432|NCT01282684|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
381433|NCT01282684|Drug|Placebo|Matching placebo for PLX5622.
381434|NCT01282671|Other|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
381435|NCT01282645|Device|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
381436|NCT01282632|Drug|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
381437|NCT01282632|Drug|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
381438|NCT01282619|Drug|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
381439|NCT01282619|Drug|huperzine A|Tablet, 200µg twice a day, 24 weeks
381440|NCT01282619|Drug|Placebo|placebo orally twice a day
381441|NCT01282606|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
381474|NCT01282320|Behavioral|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
381475|NCT01282307|Behavioral|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
381476|NCT01282294|Device|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
381477|NCT01282268|Drug|arbaclofen|orally disintegrating tablet
381442|NCT01282593|Other|Impact of CD9 expression level on motility assays|"1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL."
381443|NCT01282593|Other|Post-transcriptional regulation of CD9|"2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
381444|NCT01282580|Dietary Supplement|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
381445|NCT01282580|Other|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
381446|NCT01282567|Other|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
381447|NCT01282554|Device|electrostimulation program (Rehab 400)|"electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months."
381448|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
381449|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
381450|NCT01282528|Biological|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
381451|NCT01282515|Drug|clobetasolpropionate|continuously treatment
381452|NCT01282515|Drug|hexaminolevulinate|one PDT treatment
381453|NCT01282502|Drug|Midostaurin|50 mg BID for 8 cycles
381454|NCT01282476|Drug|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
381455|NCT01282463|Drug|Docetaxel|Docetaxel: 75 milligram/square meter (mg/m2) on Day 1 of each 21-day cycle
381456|NCT01282463|Biological|Ramucirumab DP|Ramucirumab (DP): 10 milligram/kilogram (mg/kg) intravenous (IV) on day 1 of each 21-day cycle
381457|NCT01282463|Biological|Icrucumab|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
381458|NCT01282450|Radiation|Radiotherapy|Radiotherapy
381459|NCT01282437|Radiation|Prophylactic Cranial Irradiation|"18 fractions of 2Gy~12 fractions of 2.5Gy~10 fractions of 3 Gy"
381460|NCT01282424|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
381461|NCT01282398|Drug|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
381462|NCT01282398|Drug|placebo|the control group wiil take placebo pills for at least two years.
381463|NCT01282385|Drug|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
381464|NCT01282385|Drug|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
381465|NCT01282359|Other|Clinical practice group|Clinical practice group will not receive any specific education
381466|NCT01282359|Other|"Gold Standard educational group"|"Gold Standard educational group will receive a formal program of structured and individualized education"
381467|NCT01282359|Other|Intervention group|Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
381468|NCT01282346|Device|SOLX Gold Shunt|Single use implant
381469|NCT01282333|Drug|gemcitabine hydrochloride|Given IV
381470|NCT01282333|Drug|veliparib|Given orally
381471|NCT01282333|Other|diagnostic laboratory biomarker analysis|Correlative studies
381472|NCT01282333|Other|pharmacological study|Correlative studies
381480|NCT01282255|Drug|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
381481|NCT01282242|Drug|IV rt-PA|open-label
381482|NCT01282229|Device|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
381483|NCT01282216|Biological|Havrix|1440 ELISA units, or 1 mL, IM
381484|NCT01282216|Biological|PCV13|0.5 mL IM
381485|NCT01282190|Behavioral|Motivational interview|Motivational interview
381486|NCT01282164|Procedure|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
381487|NCT01282164|Procedure|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
381488|NCT01282151|Drug|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
381489|NCT01282151|Drug|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
381490|NCT01282138|Drug|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
381491|NCT01282138|Other|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
381492|NCT01282073|Drug|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 ~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks"
381493|NCT01282073|Drug|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks"
381494|NCT01282047|Drug|Lenalidomide|oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
381495|NCT01282034|Procedure|Marrow stimulation - Drilling or Microfractures|"Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.~Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective."
381496|NCT01282034|Device|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
381497|NCT01281969|Drug|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
381498|NCT01281969|Drug|Placebo|Normal saline, IV (in the vein), over 2 days
381499|NCT01281956|Drug|PRX-00023|PRX-00023 (Selective 5HT1A agonist)
381500|NCT01281956|Drug|Placebo|Placebo
381501|NCT01281943|Drug|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|"Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle~Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle"
381502|NCT01281930|Procedure|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
381503|NCT01281930|Procedure|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
381504|NCT01281917|Drug|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
381505|NCT01281917|Drug|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
381506|NCT01281904|Behavioral|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
381507|NCT01281904|Behavioral|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
381508|NCT01281891|Drug|LIA|Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
381509|NCT01281891|Drug|I/T morphine|Morphine special 0.1 mg injected intrathecally
381510|NCT01281878|Drug|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
381511|NCT01281865|Other|diagnostic laboratory biomarker analysis|Correlative studies
381512|NCT01281865|Drug|everolimus|Given PO
381513|NCT01281865|Drug|imatinib mesylate|Given PO
381514|NCT01281852|Drug|Cisplatin|Given IV
381515|NCT01281852|Other|Laboratory Biomarker Analysis|Correlative studies
381516|NCT01281852|Drug|Paclitaxel|Given IV
381517|NCT01281852|Drug|Veliparib|Given PO
381518|NCT01281839|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
381519|NCT01281839|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
381520|NCT01281839|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
381521|NCT01281839|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
381522|NCT01281813|Drug|Darunavir|600 mg tablet, intake of 1 tablet twice a day in combination with ritonavir
381688|NCT01280643|Biological|cetuximab|Given IV
381689|NCT01280643|Drug|capecitabine|Given PO
381523|NCT01281813|Drug|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
381524|NCT01281813|Drug|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
381525|NCT01281813|Drug|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
381526|NCT01281813|Drug|Darunavir|375 mg tablet (made up of 2 x 150mg +1 x 75mg tablets), intake of 3 tablets twice a day in combination with Ritonavir
381527|NCT01281813|Drug|Darunavir|Darunavir oral suspension (dose dependent on weight) in combination with Ritonavir
381528|NCT01281813|Drug|Ritonavir|Ritonavir oral solution as 80 mg/mL (dose dependent on weight) in combination with Darunavir twice daily
381529|NCT01281813|Drug|Ritonavir|Ritonavir powder for oral suspension prepared as 100 mg/10 mL (dose dependent on weight) in combination with Darunavir
381530|NCT01281800|Procedure|Gemcitabine in long infusion|"TREATMENT A:~Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid [Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT], vitamin B-12 [OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.~TREATMENT B:~Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.~In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy."
381531|NCT01281787|Drug|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
381532|NCT01281787|Drug|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
381533|NCT01281774|Biological|CSL112|reconstituted high density lipoprotein
381534|NCT01281774|Biological|Placebo|Normal saline (0.9%)
381535|NCT01281761|Drug|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
381536|NCT01281748|Drug|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
381537|NCT01281748|Other|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
381538|NCT01281696|Drug|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
381539|NCT01281696|Drug|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
381540|NCT01281670|Other|vibration|8 week vibration
381541|NCT01281657|Drug|fingolimod|
381542|NCT01281644|Device|Diode Laser|810 nm diode laser
381543|NCT01281631|Drug|NP001|Low dose of NP001
381544|NCT01281631|Drug|NP001|High dose of NP001
381545|NCT01281631|Drug|Placebo|normal saline
381546|NCT01281618|Procedure|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
381547|NCT01281605|Behavioral|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(<110mg/dl).
381548|NCT01281605|Behavioral|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG>=110mg/dL, and by 4 IU/day if the FPG>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG < 70 mg/dL.
381549|NCT01281592|Drug|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
381550|NCT01281579|Drug|Canagliflozin 100 mg|Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
381551|NCT01281579|Drug|Canagliflozin 50 mg|Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
381552|NCT01281579|Drug|Canagliflozin 300 mg|Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
381553|NCT01281566|Drug|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
381554|NCT01281566|Drug|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
381555|NCT01281553|Drug|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
381556|NCT01281553|Drug|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
381557|NCT01281540|Drug|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
381558|NCT01281540|Drug|Placebo|one placebo tablet 4 times a day for 8 weeks
381559|NCT01281527|Drug|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
381560|NCT01281514|Drug|everolimus|Given PO
381561|NCT01281514|Drug|carboplatin|Given IV
381562|NCT01281514|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
381563|NCT01281514|Other|laboratory biomarker analysis|Correlative studies
381564|NCT01281501|Drug|Normal saline|10 ml of 0.9% sodium chloride solution
381565|NCT01281501|Drug|Pantoprazole|80 mg of intravenous pantoprazole
381566|NCT01281501|Drug|Oral antacid|30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
381567|NCT01281501|Drug|Hyoscine butylbromide|20 mg of intravenous hyoscine butylbromide
381568|NCT01281488|Procedure|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
381569|NCT01281488|Procedure|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
381570|NCT01281488|Drug|indocyanine green|Given IV
381571|NCT01281475|Drug|Levodopa|"Levodopa/Carbidopa (4:1)~Dosages are based on levodopa.~Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
381572|NCT01281475|Drug|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
381573|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
381574|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
381575|NCT01281462|Drug|Doripenem|500 mg doripenem IV q8h;
381576|NCT01281462|Drug|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
381577|NCT01281436|Other|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
381578|NCT01281436|Other|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
381579|NCT01281410|Procedure|Inspiratory Muscle Training|Inspiratory Muscle Training with Respifit (5 times per week)
381580|NCT01281410|Other|inspiratory muscle training|Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
381581|NCT01281384|Other|Advanced Imaging|
381582|NCT01281384|Other|Standard Imaging|
381583|NCT01281358|Other|HOP-ON|A programme of activities which promote motor development
381584|NCT01281358|Other|SMILES|Details are provided on ways for parents to interact with their premature infants
381585|NCT01281332|Device|Menopod|The mechanism of action of the device will not be revealed in advance.
381586|NCT01281332|Device|Inactive device|
381587|NCT01281306|Drug|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
381588|NCT01281306|Drug|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
381589|NCT01281306|Drug|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
381590|NCT01281306|Drug|Placebo|Placebo was supplied as tablets in blister cards.
381591|NCT01281267|Procedure|Facial Allograft Transplantation|Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
381592|NCT01281254|Drug|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
381593|NCT01281254|Drug|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.~PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
381594|NCT01281228|Drug|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
381595|NCT01281228|Drug|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
381596|NCT01281228|Drug|placebo|saline infusion
381597|NCT01281215|Behavioral|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
381598|NCT01281202|Drug|Vigabatrin|Tablets
381599|NCT01281202|Drug|Matching Placebo|Tablets
381600|NCT01281189|Drug|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
381601|NCT01281189|Drug|Placebo|Oral tablet twice daily for up to 18 months.
381602|NCT01281176|Drug|Carboplatin|Given IV
381603|NCT01281176|Other|Laboratory Biomarker Analysis|Correlative studies
381604|NCT01281176|Drug|Paclitaxel|Given IV
381605|NCT01281176|Other|Pharmacological Study|Correlative studies
381606|NCT01281176|Drug|Vorinostat|Given PO
381607|NCT01281163|Drug|Akt Inhibitor MK2206|Given PO
381608|NCT01281163|Other|Laboratory Biomarker Analysis|Correlative studies
381609|NCT01281163|Drug|Lapatinib Ditosylate|Given PO
381610|NCT01281163|Other|Pharmacogenomic Study|Correlative studies
381611|NCT01281163|Other|Pharmacological Study|Correlative studies
381612|NCT01281150|Drug|Carboplatin|Given IV
381613|NCT01281150|Other|Laboratory Biomarker Analysis|Correlative studies
381614|NCT01281150|Drug|Paclitaxel|Given IV
381615|NCT01281150|Other|Pharmacological Study|Correlative studies
381616|NCT01281150|Drug|Veliparib|Given PO
381617|NCT01281137|Genetic|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
381618|NCT01281137|Other|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
381619|NCT01281137|Procedure|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
381620|NCT01281124|Drug|Azacitidine|Given subcutaneously
381621|NCT01281124|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
381622|NCT01281124|Other|Pharmacological Study|Correlative studies
381623|NCT01281111|Drug|Dimethyl Fumarate (BG00012)|
381624|NCT01281111|Drug|Aspirin|
381625|NCT01281111|Drug|BG00012 matching placebo|
381626|NCT01281111|Drug|ASA matching placebo|
381627|NCT01281098|Procedure|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
381628|NCT01281098|Drug|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
381629|NCT01281072|Other|vaccine|
381630|NCT01281059|Device|BreathID - Breath Test - 13C Octanoate|
381631|NCT01281033|Procedure|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
381632|NCT01281033|Procedure|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
381633|NCT01281007|Drug|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
381634|NCT01281007|Drug|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
381635|NCT01280994|Drug|Xenon|"Each subject will receive up to but not exceeding 5 doses of hyperpolarized 129Xenon gas during any given imaging session. One of these doses is used for calibrating the MRI scanner and will contain 200 ml Xe, and 800ml N2. Xenon Doses used for image acquisition will contain up to 100% xenon at a volume up to 1 liter. Subjects will receive no more than 4 doses consisting of 100% xenon at 1 liter.~Xenon will be administered with at least a 10 minute interval between doses to ensure that there is no imaging or health effect from residual xenon"
381636|NCT01280981|Drug|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
381637|NCT01280968|Biological|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
381638|NCT01280968|Biological|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
381639|NCT01280955|Drug|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
381640|NCT01280942|Behavioral|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
381641|NCT01280942|Device|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
381642|NCT01280929|Procedure|Panretinal Photocoagulation (PRP)|
381643|NCT01280929|Drug|Intravitreous injection of ranibizumab|
381644|NCT01280916|Behavioral|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
381645|NCT01280903|Behavioral|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
381646|NCT01280903|Behavioral|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
381647|NCT01280890|Behavioral|Staff training using VIPS|Staff training using the VIPS framework
381648|NCT01280890|Behavioral|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
381649|NCT01280890|Behavioral|Control group|Filmed traditional Lectures will be given to care staff
381650|NCT01280877|Device|tACS|Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
381690|NCT01280643|Genetic|mutation analysis|Correlative studies
381691|NCT01280643|Genetic|gene expression analysis|Correlative studies
381692|NCT01280643|Other|laboratory biomarker analysis|Correlative studies
381693|NCT01280643|Other|immunohistochemistry staining method|Correlative studies
381694|NCT01280643|Genetic|nucleic acid sequencing|Correlative studies
381651|NCT01280877|Device|Sham stimulation|tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
381652|NCT01280851|Procedure|Magnetic Resonance Imaging|1 hour of MRI exam will be performed in addition to the standard of care procedures, using low dose of gadolinium-based contrast (not investigational drug).
381653|NCT01280838|Behavioral|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
381654|NCT01280838|Behavioral|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
381655|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
381656|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
381657|NCT01280812|Behavioral|Pedometer only|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
381658|NCT01280799|Behavioral|Acceptance-based separated family treatment|Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
381659|NCT01280786|Drug|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
381660|NCT01280773|Device|NAVA|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
381661|NCT01280760|Other|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance~In ICU following extubation NIV was performed as follows:~facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
381662|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
381663|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
381664|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
381665|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
381666|NCT01280734|Drug|Circadin (R) 2 mg|One 2 mg tablet at 23:00
381667|NCT01280734|Drug|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
381668|NCT01280734|Drug|Placebo|One tablet or encapsulated tablet at 23:00
381669|NCT01280721|Drug|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
381670|NCT01280708|Other|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
381671|NCT01280695|Drug|Placebo|Placebo Capsules
381672|NCT01280695|Drug|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
381673|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
381674|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
381675|NCT01280695|Drug|Pioglitazone|Pioglitazone 45 mg Capsules
381676|NCT01280682|Drug|rituximab|anti-CD20 monoclonal antibody 125mg/m^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
381677|NCT01280669|Drug|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
381678|NCT01280669|Drug|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
381679|NCT01280656|Drug|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
381680|NCT01280656|Drug|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
381681|NCT01280656|Drug|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
381682|NCT01280656|Drug|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
381683|NCT01280643|Drug|fluorouracil|Given IV
381684|NCT01280643|Drug|leucovorin calcium|Given IV
381685|NCT01280643|Drug|oxaliplatin|Given IV
381686|NCT01280643|Drug|irinotecan hydrochloride|Given IV
381687|NCT01280643|Biological|bevacizumab|Given IV
381695|NCT01280643|Genetic|protein expression analysis|Correlative studies
381696|NCT01280643|Genetic|polymerase chain reaction|Correlative studies
381697|NCT01280643|Genetic|DNA analysis|Correlative studies
381698|NCT01280617|Drug|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
381699|NCT01280617|Drug|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
381700|NCT01280604|Drug|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
381701|NCT01280591|Drug|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
381702|NCT01280591|Drug|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
381703|NCT01280591|Drug|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
381704|NCT01280591|Drug|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
381705|NCT01280578|Device|Transcatheter PFO Closure|Transcatheter PFO Closure
381706|NCT01280565|Drug|Masitinib|Masitinib 7.5 mg/kg/day
381707|NCT01280565|Drug|Dacarbazine|IV bolus at 1,000 mg/m2 once every 3 weeks
381708|NCT01280552|Biological|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
381709|NCT01280552|Biological|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
381710|NCT01280539|Device|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
381711|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
381712|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
381713|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
381714|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
381715|NCT01280513|Dietary Supplement|High protein intake|30% of energy intake coming from proteins
381716|NCT01280513|Dietary Supplement|Low Protein intake|9% of energy intake coming from proteins
381717|NCT01280500|Behavioral|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
381718|NCT01280500|Other|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
381719|NCT01280500|Other|usual care|No EMR
381720|NCT01280500|Other|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
381721|NCT01280500|Other|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
381722|NCT01280487|Drug|ZSTK474|Daily oral dosing for 21 days each cycle
381723|NCT01280409|Drug|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
381724|NCT01280409|Drug|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
381725|NCT01280383|Device|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
381726|NCT01280370|Procedure|Abdominal surgery|intraoperative mesh implantation
381727|NCT01280357|Device|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
381728|NCT01280357|Device|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
381729|NCT01280344|Drug|Saline Solution for Injection|Intravenous (IV)
381730|NCT01280344|Drug|Ipamorelin|Intravenous (IV)
381731|NCT01280331|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
381732|NCT01280331|Drug|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
381733|NCT01280331|Drug|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
381734|NCT01280318|Procedure|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
381735|NCT01280305|Drug|raloxifene|raloxifene 60 mg bid
381736|NCT01280305|Drug|placebo|Placebo bid
381737|NCT01280292|Drug|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
381738|NCT01280279|Other|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
381739|NCT01280266|Drug|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
381740|NCT01280240|Drug|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
381741|NCT01280227|Behavioral|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
381742|NCT01280214|Drug|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
381743|NCT01280201|Drug|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
381744|NCT01280188|Drug|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
381745|NCT01280188|Drug|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
381746|NCT01280175|Procedure|charcoal block|
381747|NCT01280175|Device|Aerochamber Plus spacer|
381748|NCT01280175|Drug|pMDI standard actuator|
381749|NCT01280162|Drug|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
381750|NCT01280149|Biological|substance P|injections of substance P and low dose allergen or placebo
381751|NCT01280149|Biological|substance P injections|injections of substance P for 8 weeks
381752|NCT01280136|Behavioral|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
381753|NCT01280123|Drug|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd~Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
381754|NCT01280123|Drug|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
381755|NCT01280110|Drug|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
381756|NCT01280110|Drug|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
381757|NCT01280071|Drug|aminophylline|
381758|NCT01280058|Drug|Carboplatin|Given IV
381759|NCT01280058|Other|Laboratory Biomarker Analysis|Correlative studies
381760|NCT01280058|Drug|Paclitaxel|Given IV
381761|NCT01280058|Biological|Wild-type Reovirus|Given IV
381762|NCT01280045|Procedure|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
381763|NCT01280032|Radiation|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
381764|NCT01280019|Procedure|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
381765|NCT01280006|Other|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
381766|NCT01280006|Drug|Indomethacin|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Indomethacin: 50 mg, Oral, three times per day for five days."
381767|NCT01280006|Drug|Celecoxib|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses."
381768|NCT01280006|Drug|Placebo|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.~Placebo: Oral, three times per day for five days."
381769|NCT01279993|Procedure|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
381770|NCT01279980|Other|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
381771|NCT01279980|Other|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
381772|NCT01279967|Drug|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
381773|NCT01279954|Drug|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.~Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
381774|NCT01279941|Behavioral|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
381775|NCT01279928|Procedure|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
381776|NCT01279928|Device|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
381777|NCT01279928|Procedure|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
381778|NCT01279928|Procedure|Laser Doppler Flowmetry|Examination of vascular flow
381779|NCT01279915|Drug|ASP0456|oral
381780|NCT01279915|Drug|Placebo|oral
381781|NCT01279902|Drug|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
381782|NCT01279876|Drug|Melatonin|3mg oral, daily, one hour before sleep
381783|NCT01279850|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
381784|NCT01279837|Behavioral|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
381785|NCT01279824|Behavioral|swallowing therapy|Standardized behavioral swallowing intervention
381786|NCT01279811|Other|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
381787|NCT01279798|Biological|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
381788|NCT01279785|Drug|123I-MIP-1072|Single IV dose
381789|NCT01279746|Device|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
381790|NCT01279733|Genetic|Microarray analysis|"Microarray performed on prenatal specimen:~Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.~Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
381791|NCT01279720|Biological|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
381792|NCT01279707|Biological|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
381793|NCT01279707|Biological|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
381794|NCT01279707|Biological|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
381795|NCT01279694|Drug|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
381796|NCT01279694|Drug|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
381797|NCT01279694|Drug|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
381798|NCT01279681|Biological|bevacizumab|Given IV
381799|NCT01279681|Drug|capecitabine|Given PO
381800|NCT01279681|Drug|fluorouracil|Given IV
381801|NCT01279681|Drug|leucovorin calcium|Given IV
381802|NCT01279681|Drug|oxaliplatin|Given IV
381803|NCT01279668|Drug|Montelukast|10mg tablets, once per day for 28 days.
381804|NCT01279668|Drug|Placebo|tablets, once per day for 28 days.
381805|NCT01279655|Device|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
381806|NCT01279655|Behavioral|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
381807|NCT01279642|Device|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
381808|NCT01279642|Other|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
381809|NCT01279629|Drug|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
381810|NCT01279616|Drug|Fludarabine monophosphate|180 mg/m2 over 6 days.
381811|NCT01279616|Drug|Rituximab|375 mg/m2 on day -13 and day -3
381812|NCT01279616|Drug|Busulfan|AUC 1000-1200 microM.mt
381813|NCT01279616|Drug|ATG|2.5 mg/kg for 3 days
381814|NCT01279616|Drug|Cyclophosphamide|50 mg/kg on day +3
381815|NCT01279616|Drug|Mycophenolate mofetil|15 mg/kg q 8 hours
381816|NCT01279616|Drug|Tacrolimus|0.03 mg/kg /d
381817|NCT01279603|Drug|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
381818|NCT01279590|Drug|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then~PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
381819|NCT01279590|Drug|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then~Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
381820|NCT01279590|Drug|Placebo|2 placebo capsules twice daily for 12 weeks
381821|NCT01279577|Drug|Low dose TSO|Low dose TSO suspension
381822|NCT01279577|Drug|Medium dose TSO|Medium dose TSO suspension
381823|NCT01279577|Drug|High dose TSO|High dose TSO suspension
381824|NCT01279577|Drug|Placebo|Placebo solution
381825|NCT01279564|Device|ETview TVT endotracheal tube|intubation
381826|NCT01279564|Device|Endotracheal tube|Intubation
381827|NCT01279551|Drug|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
381828|NCT01279551|Drug|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
381829|NCT01279538|Drug|ASKP1240|Intravenous (IV) infusion
381830|NCT01279538|Drug|Placebo|Intravenous (IV) infusion
381831|NCT01279525|Device|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
381832|NCT01279512|Drug|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
381833|NCT01279512|Drug|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
381834|NCT01279499|Drug|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
381835|NCT01279499|Drug|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
381836|NCT01279499|Drug|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR > 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
381837|NCT01279499|Drug|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR > 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
381838|NCT01279473|Drug|Nilotinib|
381839|NCT01279447|Drug|0.25% Bupivacaine|10cc, single dose, US guided injection
381840|NCT01279447|Drug|Normal Saline|10cc, single dose, US guided injection
381841|NCT01279434|Drug|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
381842|NCT01279434|Drug|Vitamin E|Vitamin E 400 mg BD daily for 12 months
381843|NCT01279421|Behavioral|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
381844|NCT01279421|Behavioral|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
381845|NCT01279408|Other|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
381846|NCT01279382|Behavioral|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
381847|NCT01279382|Behavioral|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
381848|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
381849|NCT01279343|Device|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
381850|NCT01279330|Other|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
381851|NCT01279330|Other|Control|No intervention (Patients receive by mail the materials needed for stool samples).
381852|NCT01279317|Dietary Supplement|placebo co-ingestion|25 ml water co-ingested with a glucose-containing beverage
381853|NCT01279317|Dietary Supplement|vinegar co-ingestion|25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
381854|NCT01279304|Radiation|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
381855|NCT01279304|Radiation|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
381856|NCT01279304|Radiation|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
381857|NCT01279291|Biological|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
381858|NCT01279291|Drug|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
381859|NCT01279291|Drug|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
381860|NCT01279291|Drug|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
381861|NCT01279278|Other|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
381862|NCT01279278|Other|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
381863|NCT01279265|Dietary Supplement|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
381864|NCT01279265|Dietary Supplement|Nutramigen A+|Hypoallergenic formula without lactobacillus
381865|NCT01279252|Drug|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
381866|NCT01279226|Device|Auralevée device|Single treatment with Auralevée device.
381867|NCT01279213|Drug|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
381868|NCT01279200|Other|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
381869|NCT01279200|Other|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
381870|NCT01279187|Drug|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
381871|NCT01279187|Drug|Placebo|20ug per day, self administered injection, for 7 weeks
381872|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
381873|NCT01279135|Radiation|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
381874|NCT01279135|Radiation|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
381875|NCT01279122|Device|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
381876|NCT01279109|Behavioral|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
381877|NCT01279109|Behavioral|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
381878|NCT01279096|Drug|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
381879|NCT01279083|Drug|DE-112|Topical ocular solution
381880|NCT01279083|Drug|DE-112|Topical ocular solution
381881|NCT01279083|Drug|DE-112|Topical ocular solution
381882|NCT01279083|Drug|DE-112|Topical ocular solution
381883|NCT01279083|Drug|DE-112 Vehicle Solution|Topical ocular solution
381884|NCT01279083|Drug|Timolol Maleate Solution|Topical ocular solution
381885|NCT01279070|Behavioral|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
381886|NCT01279057|Drug|Fluticasone Furoate (Lek Pharmaceuticals ) Nasal Spray|110 mcg per day
381887|NCT01279057|Drug|Fluticasone furoate (Veramyst®) nasal spray|110 mcg per day
381888|NCT01279057|Drug|Placebo nasal spray|
381889|NCT01279044|Behavioral|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications—beliefs, thoughts, and attitudes—that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
381890|NCT01279044|Behavioral|Standard HIV testing with information only|Standard HIV testing with information only
381891|NCT01279031|Device|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
381892|NCT01279031|Device|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
381893|NCT01278992|Dietary Supplement|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
381894|NCT01278979|Device|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.~Depth of tear, from the fourchette into the greatest depth of the perineal body.~Length of tear, from the fourchette to the apex of the vaginal tear.~Length of tear, from the fourchette along perineal skin towards the anus.~Length of the perineal body, from the fourchette to outer margin of anus."
381895|NCT01278979|Other|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
381896|NCT01278966|Other|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
381897|NCT01278953|Device|Catheter ablation to treat paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
381898|NCT01278940|Biological|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
381899|NCT01278940|Procedure|IL-2|IL-2 were administrated by intranodal injection
381900|NCT01278927|Behavioral|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
381901|NCT01278927|Behavioral|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
381902|NCT01278927|Behavioral|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
381903|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
381904|NCT01278914|Biological|Dendritic Cells (DC) prostate|
381905|NCT01278888|Procedure|Anterolateral thoracotomy|Standard anterolateral thoracotomy
381906|NCT01278888|Procedure|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
381907|NCT01278888|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
381908|NCT01278888|Procedure|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
381909|NCT01278862|Device|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
381910|NCT01278862|Device|Conventional Veneer|CAD/CAM milled Lava crown with lab fabricated veneer
381911|NCT01278849|Drug|ASA404|
381912|NCT01278836|Procedure|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
381913|NCT01278823|Procedure|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
381914|NCT01278823|Other|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
381915|NCT01278810|Drug|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
381916|NCT01278797|Drug|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
381917|NCT01278797|Drug|Amlodipine Monocomponent|Active Comparator
381918|NCT01278784|Device|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
381919|NCT01278784|Device|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
381920|NCT01278758|Drug|ASA404, DMXAA or DXAA|
381921|NCT01278745|Biological|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
381922|NCT01278745|Drug|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
381923|NCT01278732|Other|no intervention performed|no intervention is performed
381924|NCT01278706|Procedure|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
381925|NCT01278693|Drug|L-carnitine|500 mg,twice daily, 16 weeks
381926|NCT01278693|Drug|placebo|500 mg,twice daily, 16 weeks.
381927|NCT01278680|Behavioral|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
381928|NCT01278654|Behavioral|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
381929|NCT01278641|Behavioral|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
381930|NCT01278641|Behavioral|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
381931|NCT01278628|Other|exercise training|exercise class once a year
381932|NCT01278615|Other|Laboratory Biomarker Analysis|Correlative studies
381933|NCT01278615|Drug|Selumetinib|Given PO
381934|NCT01278602|Drug|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
381935|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
381936|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
381937|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
381938|NCT01278589|Dietary Supplement|Placebo|Liquid (80g) without Plantago asiatica L. extract
381939|NCT01278576|Drug|BOTOX-A®|200 units, single treatment only
381940|NCT01278563|Behavioral|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
381941|NCT01278537|Behavioral|Information|Booklet, motivational interviewing, brief advice
381942|NCT01278511|Other|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
381943|NCT01278498|Drug|Escitalopram|first week:5mg 2nd week~12 week:10mg
381944|NCT01278498|Drug|sugar pill|first week:5mg 2nd week~12 weeks:10mg
381945|NCT01278485|Drug|Sulphonylurea|SU administered according to usual practice.
381946|NCT01278485|Drug|Metformn|Metformin administered according to usual practice.
381947|NCT01278472|Device|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
381948|NCT01278472|Device|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
381949|NCT01278459|Drug|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
381950|NCT01278446|Other|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
381951|NCT01278446|Other|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
381952|NCT01278433|Biological|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
381953|NCT01278420|Device|Tecnis MF|30 subjects will be implanted with the Tecnis MF
381954|NCT01278420|Device|ReSTOR|30 subjects will be implanted with ReSTOR
381955|NCT01278407|Drug|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
381956|NCT01278407|Drug|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
381957|NCT01278407|Drug|Donepezil matched placebo|
381958|NCT01278394|Drug|AN2690 Solution, 5.0%|Once daily application for 360 days
381959|NCT01278381|Procedure|Pancreaticoduodenectomy|Resection of pancreatic lesion
381960|NCT01278368|Procedure|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
381961|NCT01278368|Procedure|Pancreatic resection|Pancreatic resection
381962|NCT01278355|Device|Ear acupuncture|Ear acupuncture
381963|NCT01278342|Drug|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
381964|NCT01278342|Drug|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
381965|NCT01278342|Drug|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~st week: 0.25 mg twice a week (0.50 mg/week)~nd week: 0.50 mg/week twice a week (1 mg/week)~rd week: 0.50 mg four times a week (2 mg/week)~th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
381966|NCT01278329|Other|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
381967|NCT01278316|Behavioral|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
381968|NCT01278316|Behavioral|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
381969|NCT01278303|Device|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
381970|NCT01278290|Drug|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate aqueous 0.1 mg/m2 subcutaneous. Gonadorelin acetate 100 ug intravenous.
381971|NCT01278290|Drug|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
381972|NCT01278277|Dietary Supplement|Saffron supplementation|Saffron supplementation 20 mg
381973|NCT01278277|Other|placebo|placebo supplementation
381974|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
381975|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
381976|NCT01278251|Procedure|Distal Biceps Re-Insertion|
381977|NCT01278238|Drug|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
381978|NCT01278238|Device|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
381979|NCT01278238|Other|Placebo|Neither phenylephrine nor lower limb bandaging
381980|NCT01278225|Behavioral|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
381981|NCT01278225|Behavioral|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
381982|NCT01278225|Behavioral|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
381983|NCT01278212|Radiation|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
381984|NCT01278199|Other|Medicals measures|"Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 > 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation."
381985|NCT01278199|Other|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
381986|NCT01278186|Procedure|Balloon angioplasty|Coronary angioplasty using the paclitaxel-coated balloon catheter
381987|NCT01278186|Procedure|Stent implantation|Coronary angioplasty using the paclitaxel-eluting stent
381988|NCT01278173|Drug|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
381989|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
381990|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
381991|NCT01278160|Drug|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
381992|NCT01278147|Behavioral|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
381993|NCT01278134|Drug|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
381994|NCT01278134|Drug|RO5024048|1000 mg bid orally, up to 24 weeks
381995|NCT01278134|Drug|danoprevir|100 mg bid orally, up to 24 weeks
381996|NCT01278134|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
382088|NCT01277510|Drug|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
381997|NCT01278134|Drug|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
381998|NCT01278134|Drug|ritonavir|100 mg bid orally, up to 24 weeks
381999|NCT01278121|Dietary Supplement|Diet A|3 days, 6 meals a day
382000|NCT01278121|Dietary Supplement|Diet B|10 days, 6 meals a day
382001|NCT01278108|Drug|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
382002|NCT01278108|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
382003|NCT01278108|Drug|GLPG0778|multiple dose, capsule, 7 days
382004|NCT01278108|Drug|placebo|multiple dose, capsule, 7 days
382005|NCT01278095|Drug|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
382006|NCT01278095|Drug|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
382007|NCT01278082|Drug|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
382008|NCT01278082|Drug|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
382009|NCT01278056|Drug|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
382010|NCT01278030|Procedure|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
382011|NCT01278017|Drug|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
382012|NCT01278004|Drug|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
382013|NCT01278004|Drug|Placebo|Capsule
382014|NCT01277991|Drug|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
382015|NCT01277991|Drug|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
382016|NCT01277991|Drug|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
382017|NCT01277991|Drug|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
382018|NCT01277965|Other|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
382019|NCT01277965|Other|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
382020|NCT01277965|Other|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
382021|NCT01277965|Other|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
382022|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change
382023|NCT01277952|Device|Deep Brain Stimulation|Brain pace maker, implanted in the brain
382024|NCT01277939|Behavioral|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
382025|NCT01277939|Behavioral|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
382026|NCT01277913|Drug|Vitamin D3|1000 IU once daily for 12 months
382027|NCT01277913|Drug|Vitamin D3|500 IU once daily for 12 months
382028|NCT01277900|Procedure|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
382029|NCT01277887|Behavioral|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
382030|NCT01277887|Behavioral|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
382031|NCT01277874|Device|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
382032|NCT01277874|Device|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
382033|NCT01277861|Drug|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
382034|NCT01277835|Drug|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
382035|NCT01277835|Drug|Placebo|Saline Infusion at same rate as experimental arm
382036|NCT01277822|Drug|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
382037|NCT01277822|Drug|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
382038|NCT01277822|Drug|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
382039|NCT01277822|Drug|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
382040|NCT01277809|Behavioral|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
382089|NCT01277510|Drug|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
382041|NCT01277809|Behavioral|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
382042|NCT01277796|Device|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
382043|NCT01277783|Device|Endocardial Left Ventricular pacing|Subjects receive an endocardial LV lead placement via superior approach using Medtronic Model 3830 lead and Medtronic Model 6227ATS deflectable delivery catheter and Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter, using trans esophageal echo (TEE) or intra-cardiac echo (ICE) to guide the procedure.
382044|NCT01277770|Drug|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
382045|NCT01277770|Other|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
382046|NCT01277770|Drug|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
382047|NCT01277757|Drug|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
382048|NCT01277757|Other|Laboratory Biomarker Analysis|Correlative studies
382049|NCT01277757|Other|Pharmacological Study|Correlative studies
382050|NCT01277744|Procedure|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
382051|NCT01277744|Drug|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
382052|NCT01277731|Drug|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
382053|NCT01277718|Drug|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
382054|NCT01277718|Drug|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
382055|NCT01277705|Biological|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
382056|NCT01277705|Biological|Boostrix™|Intramuscular, single dose
382057|NCT01277705|Biological|GSK Biologicals' IPV vaccine|Intramuscular, single dose
382058|NCT01277705|Biological|Revaxis®|Intramuscular, single dose
382059|NCT01277692|Drug|GSK2336805 10mg|single dose once daily
382060|NCT01277692|Drug|GSK2336805 30mg|single dose once daily
382061|NCT01277692|Drug|GSK2236805 100mg|single dose once daily
382062|NCT01277692|Drug|GSK2236805 200mg|single dose once daily
382063|NCT01277692|Drug|GSK2236805 10mg|repeat dose once daily for 7 days
382064|NCT01277692|Drug|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
382065|NCT01277692|Drug|GSK2236805 5mg|single dose in HCV infected patients
382066|NCT01277692|Drug|GSK2236805 30mg|single dose in HCV infected patients
382067|NCT01277692|Drug|GSK2236805 100mg|single dose in HCV infected patients
382068|NCT01277679|Procedure|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
382069|NCT01277666|Drug|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
382070|NCT01277666|Drug|GSK1605786A|500 mg once daily, administered orally for 12 weeks
382071|NCT01277666|Drug|Placebo|Placebo capsules, administered orally for 12 weeks
382072|NCT01277653|Device|tumor maker interval shortly|tumor maker interval every 3 month
382073|NCT01277640|Drug|dapivirine|"dosage form: gel 0.05%~dosage: 2.5g~frequency: once daily~duration: 7 days"
382074|NCT01277640|Drug|matched placebo|"dosage form: gel, no api~dosage: 2.5g~frequency: once daily~duration: 7 days"
382075|NCT01277640|Drug|universal placebo|"dosage form: gel, HEC-based~dosage: 2.5g~frequency: once daily~duration: 7 days"
382076|NCT01277627|Drug|Nevirapine|nevirapine: 400 mg a day.
382077|NCT01277627|Drug|efavirenz, protease inhibitors|efavirenz: 600 mg a day
382078|NCT01277614|Behavioral|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
382079|NCT01277601|Drug|TDF|TDF 300 mg tablets administered orally once daily
382080|NCT01277601|Drug|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
382081|NCT01277575|Device|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
382082|NCT01277575|Device|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
382083|NCT01277549|Device|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
382084|NCT01277523|Drug|tiotropium high dose|2 actuations once daily
382085|NCT01277523|Drug|placebo|2 actuations once daily
382086|NCT01277523|Drug|tiotropium low dose|2 actuations once daily
382087|NCT01277510|Drug|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
382090|NCT01277497|Drug|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
382091|NCT01277497|Drug|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
382092|NCT01277484|Drug|Decitabine|"1. Dose finding study (cycle 1-cycle4)~Indicated dose for 5 consecutive days every 28 days~Cohort 1: 5mg/m2 of decitabine~Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
382093|NCT01277471|Behavioral|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
382094|NCT01277471|Behavioral|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
382095|NCT01277445|Dietary Supplement|Prebiotic|Inulin-fructan 15mg/day for 28days
382096|NCT01277445|Dietary Supplement|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
382097|NCT01277432|Other|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~MINI~SSI-28 (somatization)"
382098|NCT01277432|Other|Depression screening - control|"All study participants will undergo;~a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~a detailed psychological and behavioral assessments using validated questionnaires~several specialist questionnaires on depression, self care and quality of life"
382099|NCT01277406|Drug|4SC-201(Resminostat)|oral administration
382100|NCT01277406|Drug|FOLFIRI|i.v. administration
382101|NCT01277367|Behavioral|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
382102|NCT01277367|Behavioral|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
382103|NCT01277367|Behavioral|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
382104|NCT01277367|Behavioral|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
382105|NCT01277367|Behavioral|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
382106|NCT01277367|Behavioral|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
382107|NCT01277354|Behavioral|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
382108|NCT01277354|Behavioral|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
382109|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
382110|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
382111|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
382112|NCT01277341|Drug|Placebo comparator|nasal spray
382113|NCT01277315|Drug|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
382114|NCT01277302|Drug|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
382115|NCT01277289|Drug|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
382116|NCT01277276|Device|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
382117|NCT01277263|Device|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
382118|NCT01277250|Behavioral|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
382119|NCT01277237|Drug|Omacor|Active comparator: omacor 4g/day
382120|NCT01277237|Drug|lactose tablet|placebo: lactose tablet 4g/day
382121|NCT01277224|Behavioral|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
382122|NCT01277211|Drug|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
382300|NCT01276054|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
382123|NCT01277211|Drug|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
382124|NCT01277185|Dietary Supplement|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
382125|NCT01277185|Dietary Supplement|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
382126|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
382127|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
382128|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
382129|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
382130|NCT01277159|Drug|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
382131|NCT01277159|Drug|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
382132|NCT01277159|Drug|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
382133|NCT01277159|Drug|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
382134|NCT01277159|Drug|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
382135|NCT01277146|Drug|OMP-59R5|IV infusion
382136|NCT01277107|Drug|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
382137|NCT01277107|Drug|Placebo capsule|Identical placebo capsule
382138|NCT01277094|Drug|Placebo|Oral daily doses for 12 weeks
382139|NCT01277094|Drug|RO5093151|Oral daily doses for 12 weeks
382140|NCT01277081|Drug|Paracetamol hot drink|Hot drink containing paracetamol
382141|NCT01277081|Drug|Paracetamol tablets|Paracetamol tablets
382142|NCT01277068|Procedure|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
382143|NCT01277042|Biological|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
382144|NCT01277042|Biological|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
382145|NCT01277029|Other|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
382146|NCT01277016|Drug|BMDex|"BMDex:~cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
382147|NCT01277003|Device|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
382148|NCT01277003|Device|TENS|tow therapeutic points, each for 15 minutes
382149|NCT01276990|Drug|BI 224436|Oral drinking solution
382150|NCT01276990|Drug|BI 224436|Oral drinking solution
382151|NCT01276990|Drug|BI 224436|Oral drinking solution
382152|NCT01276990|Drug|BI 224436|Oral drinking solution
382153|NCT01276990|Drug|BI 224436|Oral drinking solution
382154|NCT01276990|Drug|BI 224436|Oral drinking solution
382155|NCT01276990|Drug|BI 224436|Oral drinking solution
382156|NCT01276990|Drug|BI 224436|Oral drinking solution
382157|NCT01276990|Drug|BI 224436|Oral drinking solution
382158|NCT01276990|Drug|Placebo|Oral drinking solution
382159|NCT01276977|Drug|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
382160|NCT01276977|Drug|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
382161|NCT01276951|Dietary Supplement|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
382162|NCT01276951|Procedure|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
382163|NCT01276951|Procedure|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
382164|NCT01276951|Procedure|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
382165|NCT01276951|Procedure|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
382302|NCT01276054|Procedure|bioimpedance spectroscopy|Correlative studies
382166|NCT01276951|Procedure|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
382167|NCT01276938|Radiation|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
382168|NCT01276938|Radiation|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
382169|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
382170|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
382171|NCT01276925|Device|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
382172|NCT01276925|Procedure|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
382173|NCT01276925|Drug|Saline|Isotonic. 10 ml for the femoral nerve.
382174|NCT01276925|Procedure|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
382175|NCT01276925|Drug|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
382176|NCT01276912|Drug|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
382177|NCT01276912|Behavioral|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
382178|NCT01276899|Procedure|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study.~A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
382179|NCT01276899|Procedure|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study.~Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
382180|NCT01276886|Drug|antibiotic|
382181|NCT01276886|Procedure|Colonic resection with or without stoma|
382182|NCT01276873|Device|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
382183|NCT01276860|Device|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
382184|NCT01276847|Drug|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing > 100 kg on Day 1, and Weeks 4 and 16
382185|NCT01276847|Drug|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
382186|NCT01276834|Drug|everolimus|comparison of everolimus-based and CNI-based immunosuppression
382187|NCT01276821|Drug|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
382188|NCT01276821|Drug|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
382189|NCT01276808|Procedure|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
382190|NCT01276808|Procedure|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
382191|NCT01276795|Dietary Supplement|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
382192|NCT01276782|Drug|Levothyroxine|It is FDA approved drug for thyroid disease
382193|NCT01276769|Drug|Paclitaxel plus carboplatin|"Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.~1 cycle = 21days 2-6cycles"
382194|NCT01276769|Drug|Paclitaxel and epirubicin|"Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.~1 cycle = 21days~2-6cycles"
382195|NCT01276756|Drug|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
382196|NCT01276756|Drug|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
382197|NCT01276756|Drug|Ribavirin|Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
382198|NCT01276730|Drug|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
382199|NCT01276730|Drug|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
382200|NCT01276717|Drug|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
382201|NCT01276717|Drug|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
382202|NCT01276704|Drug|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
382203|NCT01276704|Drug|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
382204|NCT01276691|Drug|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
382205|NCT01276665|Procedure|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
382206|NCT01276665|Procedure|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
382207|NCT01276652|Behavioral|Environmental modification|Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
382208|NCT01276639|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
382209|NCT01276639|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
382210|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
382211|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
382212|NCT01276626|Dietary Supplement|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
382213|NCT01276626|Other|Maltodextrin|Powder containing only maltodextrin
382214|NCT01276613|Drug|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
382215|NCT01276613|Drug|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
382216|NCT01276600|Drug|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
382217|NCT01276587|Drug|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
382218|NCT01276561|Procedure|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
382219|NCT01276561|Procedure|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
382220|NCT01276548|Drug|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
382221|NCT01276548|Drug|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
382222|NCT01276535|Device|Erchonia MLS + Erchonia THL|"The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.~The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.~Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.~The intent is to evaluate the effectiveness of Erchonia MLS & Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL"
382223|NCT01276522|Drug|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
382224|NCT01276509|Drug|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
382225|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
382226|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
382227|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
382228|NCT01276496|Drug|Cilengitide|Given IV
382229|NCT01276496|Other|Laboratory Biomarker Analysis|Correlative studies
382230|NCT01276496|Drug|Paclitaxel|Given IV
382231|NCT01276496|Other|Pharmacological Study|Correlative studies
382232|NCT01276457|Drug|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
382233|NCT01276457|Drug|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
382234|NCT01276457|Drug|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
382235|NCT01276444|Device|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
382236|NCT01276444|Device|transpulmonary thermodilution + central venous saturation|Described in details above
382237|NCT01276431|Drug|Buprenorphine transdermal patch|
382238|NCT01276418|Device|CO2 laser|Ablation and coagulation of soft tissue
382239|NCT01276379|Drug|FOLFIRI (m)|"FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.~One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
382240|NCT01276379|Drug|FOLFOX-6 (m)|"FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:~Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.~l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.~One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.~5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
382241|NCT01276379|Drug|Cetuximab|- 500 mg/m2 i.v. Every 2 weeks.
382242|NCT01276366|Other|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
382301|NCT01276054|Procedure|axillary lymph node biopsy|Undergo axillary lymph node biopsy
382243|NCT01276366|Other|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
382244|NCT01276366|Other|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
382245|NCT01276353|Drug|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
382246|NCT01276353|Drug|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
382247|NCT01276340|Device|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
382248|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
382249|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
382250|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
382251|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
382252|NCT01276314|Drug|anti- TNF-a|25mg BIW, SC
382253|NCT01276314|Drug|Prednisolone|1-1.5 mg / kg / day
382254|NCT01276301|Drug|Verapamil|single dose verapamil
382255|NCT01276301|Drug|BI 10773|single dose BI 10773
382256|NCT01276301|Drug|BI 10773|single dose BI 10773
382257|NCT01276288|Drug|BI 10773|multiple oral doses
382258|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
382259|NCT01276288|Drug|torasemide|multiple oral doses
382260|NCT01276288|Drug|BI 10773|multiple oral doses
382261|NCT01276288|Drug|torasemide|multiple oral doses
382262|NCT01276288|Drug|BI 10773|multiple oral doses
382263|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
382264|NCT01276275|Drug|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
382265|NCT01276262|Drug|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
382266|NCT01276262|Drug|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
382267|NCT01276262|Drug|Placebo|Oral tablets BID, repeated doses for 21 days
382268|NCT01276249|Device|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
382269|NCT01276236|Drug|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.~Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.~Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
382270|NCT01276223|Drug|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
382271|NCT01276223|Other|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
382272|NCT01276210|Drug|sorafenib tosylate|Given PO
382273|NCT01276210|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
382274|NCT01276210|Other|laboratory biomarker analysis|Correlative studies
382275|NCT01276197|Other|Story-Telling DVD|DVD will contain both informational and story-telling components.
382276|NCT01276197|Other|Non-Storytelling DVD|DVD will contain only informational component.
382277|NCT01276184|Behavioral|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s) (phone call, letter, etc, as appropriate).
382278|NCT01276171|Procedure|Ultrasound|Participants will place arterial line using ultrasound technique
382279|NCT01276171|Procedure|Doppler|Participants will place arterial line using doppler technique
382280|NCT01276171|Procedure|Palpation|Participants will place arterial line using Palpation technique
382281|NCT01276158|Procedure|Ultrasound|Ultrasound used to place arterial line
382282|NCT01276158|Procedure|Doppler|Doppler used to place arterial line
382283|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
382284|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
382285|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single sc injection
382286|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
382287|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
382288|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single sc injection
382289|NCT01276106|Drug|AC-201, 25mg|Capsule, 25mg BID
382290|NCT01276106|Drug|AC-201, 50mg|Capsule, 50mg BID
382291|NCT01276106|Drug|AC-201, 75mg|Capsule, 75mg BID
382292|NCT01276106|Drug|Placebo|Placebo BID
382293|NCT01276093|Procedure|PVI ablation|Pulmonary Vein Ablation using RF.
382294|NCT01276093|Drug|Amiodarone|Amiodarone tablets
382295|NCT01276080|Drug|Donepezil|10 mg tablets
382296|NCT01276067|Drug|Donepezil|10 mg Tablet
382297|NCT01276054|Radiation|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
382298|NCT01276054|Drug|methylene blue|Given subcutaneously
382299|NCT01276054|Drug|indocyanine green solution|Given subcutaneously
382303|NCT01276054|Procedure|quality-of-life assessment|Ancillary studies
382304|NCT01276054|Other|lymphedema management|Undergo axillary reverse mapping
382305|NCT01276041|Drug|pertuzumab in combination with trastuzumab and paclitaxel|The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
382306|NCT01276028|Procedure|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.~Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
382307|NCT01276015|Drug|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
382308|NCT01276002|Procedure|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
382309|NCT01275989|Other|Ear acupuncture|
382310|NCT01275976|Drug|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
382311|NCT01275976|Other|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
382312|NCT01275950|Behavioral|Health Education|"Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.~Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.~Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute."
382313|NCT01275937|Drug|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
382314|NCT01275937|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
382315|NCT01275924|Device|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
382316|NCT01275924|Device|Syndesmotic screw|Quadricortical syndesmotic screw
382317|NCT01275911|Drug|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
382318|NCT01275911|Drug|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
382319|NCT01275885|Dietary Supplement|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
382320|NCT01275885|Dietary Supplement|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
382321|NCT01275885|Dietary Supplement|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
382322|NCT01275872|Other|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
382323|NCT01275859|Drug|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
382324|NCT01275846|Device|Health Guide using AHA heart failure protocols and content|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
382325|NCT01275833|Device|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
382326|NCT01275820|Dietary Supplement|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
382327|NCT01275807|Device|acupuncture|10 sessions of acupuncture
382328|NCT01275807|Other|self care|physical exercice, diet, self help groups, psychological support
382329|NCT01275781|Drug|[14C]-AZD9742|1000 mg intravenous over 2 hours
382330|NCT01275768|Procedure|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
382331|NCT01275755|Drug|Placebo|
382332|NCT01275755|Drug|ADL5945 0.25 mg|
382333|NCT01275742|Behavioral|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
382334|NCT01275729|Drug|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
382335|NCT01275716|Behavioral|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
382336|NCT01275677|Drug|Cyclophosphamide|Given IV
382337|NCT01275677|Drug|Docetaxel|Given IV
382338|NCT01275677|Drug|Doxorubicin|Given IV
382339|NCT01275677|Drug|Doxorubicin Hydrochloride|Given IV
382340|NCT01275677|Other|Laboratory Biomarker Analysis|Correlative studies
382341|NCT01275677|Drug|Paclitaxel|Given IV
382342|NCT01275677|Other|Quality-of-Life Assessment|Ancillary studies
382343|NCT01275677|Biological|Trastuzumab|Given IV
382344|NCT01275664|Procedure|Adjuvant Therapy|Ancillary studies
382345|NCT01275664|Drug|Aprepitant|Given IV and PO
382346|NCT01275664|Drug|Carboplatin|Given IP
382347|NCT01275664|Drug|Cisplatin|Given IP
382348|NCT01275664|Drug|Dexamethasone|Given PO
382349|NCT01275664|Drug|Granisetron Transdermal Patch|Apply one patch to upper arm
382350|NCT01275664|Procedure|Management of Therapy Complications|Ancillary studies
382351|NCT01275664|Other|Questionnaire Administration|Ancillary studies
382352|NCT01275651|Other|laboratory biomarker analysis|Correlative studies
382353|NCT01275638|Drug|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
382354|NCT01275625|Drug|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
382355|NCT01275612|Biological|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
382356|NCT01275599|Drug|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
382357|NCT01275599|Drug|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
382358|NCT01275586|Drug|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
382359|NCT01275573|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
382360|NCT01275560|Drug|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
382361|NCT01275560|Drug|CArbosylane|
382362|NCT01275547|Drug|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
382363|NCT01275547|Drug|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
382364|NCT01275521|Drug|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.~Interruption of the medical therapy 1 month after the injection;"
382365|NCT01275521|Drug|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
382366|NCT01275508|Drug|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
382367|NCT01275495|Behavioral|Telephone Assessment and Skill-Building Kit (TASK II)|
382368|NCT01275495|Behavioral|Information, Support, and Referral (ISR)|
382369|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
382370|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
382371|NCT01275469|Drug|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
382372|NCT01275469|Drug|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
382373|NCT01275456|Procedure|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
382374|NCT01275443|Drug|300mg TMC278LA|300mg TMC278LA intramuscular injection
382375|NCT01275443|Drug|150mg TMC278LA|150mg TMC278LA intramuscular injection
382376|NCT01275443|Drug|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
382377|NCT01275443|Drug|600mg TMC278LA|600mg TMC278LA intramuscular injection
382378|NCT01275430|Device|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
382379|NCT01275430|Other|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
382380|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patient‟s success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
382381|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
382382|NCT01275391|Behavioral|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
382383|NCT01275378|Behavioral|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
382384|NCT01275378|Behavioral|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
382385|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
382386|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
382387|NCT01275352|Drug|Eplerenone|Eplerenone 50 mg/day
382388|NCT01275352|Drug|placebo|placebo
382389|NCT01275339|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
382390|NCT01275339|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
382391|NCT01275313|Device|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
382392|NCT01275313|Device|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
382393|NCT01275300|Dietary Supplement|5 days of placebo followed by 600mg niacin|600 mg niacin
382394|NCT01275300|Dietary Supplement|aspirin first|5 days taking 81 mg Aspirin followed by a single dose of 600 mg Niacin
382395|NCT01275300|Drug|81 mg Aspirin|5 days taking 81 mg Aspirin
382396|NCT01275300|Dietary Supplement|Niaspan|dosage
382397|NCT01275300|Drug|Celebrex and niacin|Data will be handled exactly like phase 1.
382398|NCT01275287|Drug|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m^2 for patients > than 70 or with estimated Glomerular Filtration Rate (eGFR) < 20 ml/min) to be titrated up to 1 gm/m^2 depending on the 2 week white blood count (WBC) nadir > 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .~For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
382399|NCT01275287|Drug|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
382448|NCT01274910|Dietary Supplement|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.~Treatment: 5 capsules per day"
382449|NCT01274897|Biological|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
382450|NCT01274897|Biological|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
382451|NCT01274884|Procedure|Tightrope fixation|Arthroscopic repair
382452|NCT01274845|Other|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
382400|NCT01275274|Drug|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of < 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to < 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
382401|NCT01275274|Drug|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
382402|NCT01275261|Behavioral|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
382403|NCT01275248|Drug|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
382404|NCT01275248|Drug|Placebo|Oral tablet to match the experimental interventions
382405|NCT01275222|Drug|Everolimus|
382406|NCT01275222|Drug|Imatinib|Glevec is the brand name for imatinib.
382407|NCT01275209|Drug|HCD122|
382408|NCT01275196|Drug|Nilotinib|
382409|NCT01275196|Drug|Imatinib|
382410|NCT01275183|Drug|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours~Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19~Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles~Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
382411|NCT01275170|Drug|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
382412|NCT01275170|Drug|Imipenem + Cilastatin|250 mg IV over 30 minutes as a single dose
382413|NCT01275170|Drug|Caffeine|Caffeine caplet, single 200 mg dose, orally
382414|NCT01275170|Drug|Midazolam|Midazolam hcl syrup single 2.0 mg dose by mouth.
382415|NCT01275170|Drug|Omeprazole|Omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
382416|NCT01275157|Drug|LY2452473|Administered orally as a liquid suspension
382417|NCT01275144|Drug|LY2216684|Administered orally
382418|NCT01275144|Drug|Placebo|Administered orally
382419|NCT01275144|Drug|Lorazepam|Administered orally
382420|NCT01275131|Drug|Insulin aspart|
382421|NCT01275131|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
382422|NCT01275118|Device|Tecnis Multifocal IOL|Presbyopia correcting IOL
382423|NCT01275118|Device|crystalens Accommodating IOL|Presbyopia correcting IOL
382424|NCT01275105|Drug|Vehicle|one drop in each eye at designated visits
382425|NCT01275105|Drug|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
382426|NCT01275105|Drug|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
382427|NCT01275105|Drug|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
382428|NCT01275092|Device|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
382429|NCT01275066|Drug|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
382430|NCT01275066|Drug|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
382431|NCT01275066|Drug|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
382432|NCT01275053|Drug|leptin|0.01mg/kg
382433|NCT01275040|Other|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
382434|NCT01275040|Other|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
382435|NCT01275027|Dietary Supplement|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
382436|NCT01275014|Drug|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
382437|NCT01275014|Drug|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
382438|NCT01274988|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
382439|NCT01274988|Other|methadone maintenance treatment|methadone maintenance treatment
382440|NCT01274975|Other|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
382441|NCT01274962|Drug|FOLFOX|"Oxaliplatin* 85 mg/m2 IV in 500 mL of D5W over 120 minutes~Folinic Acid (Leucovorin)* 400 mg/m2 IV in 250 ml D5W over 120 minutes~5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid~5-Fluorouracil** 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.~Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.~If necessary the schedule may be modified +/- 3 days."
382442|NCT01274962|Radiation|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
382443|NCT01274949|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
382444|NCT01274936|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
382445|NCT01274936|Drug|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
382446|NCT01274923|Device|"MEDISPEC treatment probe"|shock wave treatment
382447|NCT01274910|Dietary Supplement|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .~Treatment: 5 capsules per day"
382453|NCT01274832|Device|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
382454|NCT01274819|Other|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
382455|NCT01274806|Other|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
382456|NCT01274793|Drug|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
382457|NCT01274793|Device|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
382458|NCT01274793|Device|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
382459|NCT01274780|Drug|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
382460|NCT01274780|Drug|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
382461|NCT01274741|Behavioral|Creating Change (CC)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format. The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
382462|NCT01274741|Behavioral|Seeking Safety (SS)|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD. It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders. In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
382463|NCT01274728|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
382464|NCT01274715|Behavioral|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
382465|NCT01274702|Other|Visual Reconstitutions Therapy|
382466|NCT01274702|Other|Saccadic Eye Movement Training|
382467|NCT01274689|Other|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
382468|NCT01274676|Device|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
382469|NCT01274676|Device|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
382470|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
382471|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
382472|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
382473|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
382474|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
382475|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
382476|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
382477|NCT01274650|Procedure|Indirect Calorimetry|Indirect Calorimetry
382478|NCT01274637|Drug|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
382479|NCT01274624|Biological|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
382480|NCT01274624|Drug|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
382481|NCT01274624|Drug|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
382482|NCT01274624|Drug|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
382483|NCT01274624|Drug|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
382484|NCT01274611|Drug|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
382485|NCT01274611|Device|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
382486|NCT01274598|Biological|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10^10 CFU by mouth twice daily for 28 days
382487|NCT01274585|Device|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
382488|NCT01274585|Device|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
382526|NCT01274182|Biological|MabThera|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
382489|NCT01274559|Drug|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
382490|NCT01274559|Drug|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
382491|NCT01274546|Device|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
382492|NCT01274533|Drug|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
382493|NCT01274520|Device|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
382494|NCT01274507|Other|Medical tests|All participants will undergo medical tests and will be observed.
382495|NCT01274481|Drug|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
382496|NCT01274455|Genetic|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
382497|NCT01274442|Other|anamnesis|To update the anamnesis.
382498|NCT01274442|Procedure|oral examination|A brief clinical oral examination will be performed.
382499|NCT01274442|Procedure|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
382500|NCT01274429|Drug|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
382501|NCT01274416|Behavioral|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
382502|NCT01274416|Behavioral|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
382503|NCT01274403|Drug|Melphalan, Prednisone and Thalidomide|
382504|NCT01274377|Biological|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
382505|NCT01274364|Other|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
382506|NCT01274364|Other|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
382507|NCT01274351|Drug|Tasigna|
382508|NCT01274338|Biological|Ipilimumab|Given IV
382509|NCT01274338|Other|Quality-of-Life Assessment|Ancillary studies
382510|NCT01274338|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
382511|NCT01274325|Drug|Sereflo|Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
382512|NCT01274325|Drug|Seretide|Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
382513|NCT01274312|Procedure|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
382514|NCT01274299|Procedure|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
382515|NCT01274273|Drug|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
382516|NCT01274273|Drug|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
382517|NCT01274273|Drug|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
382518|NCT01274260|Drug|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
382519|NCT01274260|Drug|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
382520|NCT01274247|Drug|Topical Benzocaine|Topical administration of a drop of benzocaine to the lingual frenulum
382521|NCT01274234|Device|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
382522|NCT01274221|Drug|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
382523|NCT01274221|Other|Placebo|1 capsule per day for one week of the double-blind crossover phase
382524|NCT01274195|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
382525|NCT01274182|Biological|GP2013|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
382527|NCT01274182|Biological|Rituxan|1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
382528|NCT01274156|Device|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
382529|NCT01274156|Device|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
382530|NCT01274156|Device|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
382531|NCT01274156|Device|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
382532|NCT01274143|Behavioral|TeleCARE|Personalized telephone-delivered cancer risk assessment.
382533|NCT01274143|Behavioral|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
382534|NCT01274130|Drug|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
382535|NCT01274117|Procedure|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
382536|NCT01274104|Dietary Supplement|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
382537|NCT01274104|Other|Placebo|Placebo
382538|NCT01274091|Other|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
382539|NCT01274091|Other|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
382540|NCT01274078|Biological|Blueberries|150 grams of frozen blueberries on the same day as exercise
382541|NCT01274065|Genetic|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
382542|NCT01274052|Other|Meal test|Liquid meal test
382543|NCT01274039|Drug|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
382544|NCT01274026|Drug|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.~Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
382545|NCT01274000|Drug|YM060|oral
382546|NCT01274000|Drug|placebo|oral
382547|NCT01273987|Procedure|Neobladder posterior wall suspended with round ligament of uterus|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
382548|NCT01273974|Biological|intradermal influenza vaccine|0.25ml ,intradermal
382549|NCT01273974|Biological|intramuscular influenza vaccine|0.5ml,intramuscular
382550|NCT01273961|Device|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
382551|NCT01273948|Drug|Bavituximab|"Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
382552|NCT01273948|Drug|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
382553|NCT01273922|Biological|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
382554|NCT01273909|Procedure|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
382555|NCT01273909|Procedure|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
382556|NCT01273896|Drug|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
382557|NCT01273883|Dietary Supplement|Magnesium|Magnesium 532 mg a day
382558|NCT01273883|Other|Placebo|matching form/dosage
382559|NCT01273857|Procedure|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
382560|NCT01273857|Procedure|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
382561|NCT01273844|Drug|Bortezomib|Bortezomib
382562|NCT01273831|Drug|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
382563|NCT01273831|Drug|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
382564|NCT01273818|Drug|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
382565|NCT01273818|Drug|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
382566|NCT01273818|Drug|Gentamicin|80 mg gentamicin application intraoperatively
382567|NCT01273805|Drug|Hydroxychloroquine|
382568|NCT01273779|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
382569|NCT01273779|Drug|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
382570|NCT01273766|Drug|deferasirox|Given orally
382571|NCT01273766|Other|laboratory biomarker analysis|Correlative studies
382572|NCT01273766|Other|enzyme-linked immunosorbent assay|Correlative studies
382691|NCT01272752|Dietary Supplement|IHBG-10|500 mg IHBG-10
382573|NCT01273753|Other|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
382574|NCT01273740|Procedure|External support|Bypass surgery with externally supported graft
382575|NCT01273727|Drug|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
382576|NCT01273727|Drug|dexamethasone|intravitreal implant 0.7 mg duration 6 months
382577|NCT01273714|Procedure|thyroid resection|bilateral subtotal versus total thyroidectomy
382578|NCT01273701|Behavioral|Psychosocial intervention|"The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.~-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)~-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.~-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1."
382579|NCT01273701|Behavioral|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
382580|NCT01273688|Behavioral|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
382581|NCT01273688|Device|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
382582|NCT01273662|Drug|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
382583|NCT01273649|Device|cryotherapy|cryotherapy is given with other physical training
382584|NCT01273623|Device|Jetstream Atherectomy System|to perform atherectomy on calcified lesions
382585|NCT01273610|Drug|Lapatinib|250 mg tablets
382586|NCT01273610|Drug|Trastuzumab|Intravenous injection
382587|NCT01273610|Other|laboratory biomarker analysis|
382588|NCT01273610|Other|pharmacological study|
382589|NCT01273584|Drug|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
382590|NCT01273584|Drug|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
382591|NCT01273571|Drug|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
382592|NCT01273558|Drug|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
382593|NCT01273545|Drug|PRILIGY (dapoxetine hydrochloride)|The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
382594|NCT01273532|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
382595|NCT01273532|Drug|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
382596|NCT01273506|Drug|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
382597|NCT01273506|Drug|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
382598|NCT01273493|Drug|Trabectedin|Trabectedin 0.58 or 1.3 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1.
382599|NCT01273493|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/m^2, 30 minutes prior to trabectedin.
382600|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
382601|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
382602|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
382603|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
382604|NCT01273467|Drug|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
382605|NCT01273467|Drug|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
382606|NCT01273454|Drug|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
382607|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
382608|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
382609|NCT01273428|Drug|HP011-101|
382610|NCT01273428|Device|HP-828-101|
382611|NCT01273428|Other|Standard Care|
382612|NCT01273402|Drug|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
382692|NCT01272752|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
382613|NCT01273389|Drug|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
382614|NCT01273389|Drug|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
382615|NCT01273376|Drug|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
382616|NCT01273350|Device|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
382617|NCT01273337|Biological|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
382618|NCT01273337|Procedure|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
382619|NCT01273324|Device|ADM Cup|ADM Cup
382620|NCT01273298|Drug|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
382621|NCT01273298|Drug|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
382622|NCT01273285|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
382623|NCT01273272|Behavioral|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
382624|NCT01273272|Behavioral|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
382625|NCT01273259|Drug|DHEA Treatment|DHEA : 200 mg/day hard gelatine capsule
382626|NCT01273259|Drug|DHEA Treatment|DHEA : 25 mg/day hard gelatine capsule
382627|NCT01273246|Biological|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
382628|NCT01273246|Biological|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
382629|NCT01273246|Biological|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
382630|NCT01273246|Biological|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
382631|NCT01273233|Biological|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
382632|NCT01273233|Other|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
382633|NCT01273207|Drug|Cyclosporine Inhalation Solution (CIS)|CIS is a sterile, clear, colorless, preservative-free solution of cyclosporine (USP) in propylene glycol developed specifically for administration by oral inhalation.
382634|NCT01273181|Biological|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
382635|NCT01273181|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
382636|NCT01273181|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
382637|NCT01273181|Drug|Fludarabine|25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
382638|NCT01273168|Drug|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit
382639|NCT01273155|Drug|Belinostat|Belinostat was administered intravenously (IV) over 30 minutes on days 1 through 5 of a 21-day cycle. All patients were administered a single dose of 400 mg/m(2) of belinostat on Cycle 1 Day -7 for pharmacokinetic analysis (the total length of Cycle 1 was 28 days).
382640|NCT01273116|Other|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:~will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;~a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;~will be discussed at least once in a multidisciplinary meeting;~a structured medication review will be carried out by a geriatrician;~is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;~may receive a consult of a geriatrician, if judged necessary;~will receive extra attention on discharge arrangements.~Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
382641|NCT01273103|Drug|200mg [14C]- GSK2248761|single oral suspension dose of [14C]- GSK2248761 200 mg
382642|NCT01273090|Drug|imetelstat sodium|
382643|NCT01273090|Other|laboratory biomarker analysis|
382644|NCT01273090|Other|pharmacological study|
382645|NCT01273064|Drug|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
382646|NCT01273064|Drug|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
382647|NCT01273064|Drug|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
382648|NCT01273064|Drug|Placebo|"Tablets identical in appearance to CTS-1027 containing inactive ingredients.~Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.~30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo)."
382649|NCT01273051|Drug|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
382650|NCT01273051|Radiation|radiotherapy|radiation 25x2 Gy
382651|NCT01273051|Procedure|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
382652|NCT01273051|Procedure|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.~After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
382653|NCT01273038|Device|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
382654|NCT01273038|Device|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
382655|NCT01273025|Dietary Supplement|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
382656|NCT01273012|Drug|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
382657|NCT01272986|Device|ALOA IgG-Elisa|measurement of IgG Level in blood
382658|NCT01272986|Device|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
382659|NCT01272973|Drug|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
382660|NCT01272973|Drug|placebo|Placebo (oral) administered once daily for 10 weeks.
382661|NCT01272973|Drug|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
382662|NCT01272960|Device|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
382663|NCT01272960|Device|Interval Insertion|Insertion of Mirena 4-8 weeks post partum after vaginal delivery
382664|NCT01272947|Drug|Diclofenac sodium|Topical gel 1%- 4 times daily
382665|NCT01272947|Other|Placebo|Topical gel - 4 times daily
382666|NCT01272934|Drug|Diclofenac Sodium|Topical gel 1%-4 times daily
382667|NCT01272934|Other|Placebo|Topical gel-4 times daily
382668|NCT01272921|Drug|Bupivacaine|Varying doses to determine the duration of analgesia
382669|NCT01272921|Drug|Ropivacaine|Varying doses to determine the duration of analgesia
382670|NCT01272908|Drug|rituximab|1000 mg intravenously on Days 1 and 15
382671|NCT01272895|Device|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
382672|NCT01272882|Device|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
382673|NCT01272869|Device|SenSura|The ostomy bag filter will be tested for a period of 14 days
382674|NCT01272869|Device|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
382675|NCT01272856|Drug|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
382676|NCT01272830|Drug|Placebo|Two capsules taken twice daily with meals
382677|NCT01272830|Drug|Apatone®B|Two capsules taken twice daily with meals
382678|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
382679|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
382680|NCT01272804|Drug|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
382681|NCT01272804|Drug|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
382682|NCT01272791|Biological|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
382683|NCT01272791|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
382684|NCT01272778|Drug|Lorazepam|Oral capsule, 0.2 mg, single acute dose
382685|NCT01272778|Drug|Lorazepam|oral capsule, 0.5 mg, single acute dose
382686|NCT01272778|Drug|Lorazepam|oral capsule, 1.0 mg, single acute dose
382687|NCT01272778|Drug|Lorazepam|oral capsule, 2.0 mg, single acute dose
382688|NCT01272778|Drug|Placebo|oral capsule, single acute dose
382689|NCT01272765|Other|Placebo|Placebo
382690|NCT01272765|Dietary Supplement|IHBG-10|500 mg IHBG-10
382693|NCT01272739|Dietary Supplement|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
382694|NCT01272739|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
382695|NCT01272726|Behavioral|Education|Education on the genetics of ADHD and treatment options for ADHD
382696|NCT01272713|Other|Oxygen therapy|"Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min~In-hospital oxygen as per hospital protocol"
382697|NCT01272713|Other|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
382698|NCT01272700|Procedure|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
382699|NCT01272700|Procedure|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
382700|NCT01272674|Other|exercise training|4 weeks supervised physical exercise training
382701|NCT01272661|Behavioral|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
382702|NCT01272661|Behavioral|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
382703|NCT01272661|Behavioral|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
382704|NCT01272648|Behavioral|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.~Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
382705|NCT01272635|Drug|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
382706|NCT01272635|Drug|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
382707|NCT01272635|Other|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
382708|NCT01272635|Drug|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
382709|NCT01272622|Radiation|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
382710|NCT01272622|Other|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
382711|NCT01272609|Drug|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
382712|NCT01272609|Device|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
382713|NCT01272583|Drug|Sitagliptin|100 mg once daily for six weeks
382714|NCT01272583|Drug|Placebo|placebo, once daily for six weeks
382715|NCT01272557|Drug|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
382716|NCT01272557|Drug|Sorafenib|Sorafenib 400 mg bid (oral) continuously
382717|NCT01272531|Drug|Mood stabilizer treatment|lithium or valproate
382718|NCT01272505|Procedure|converntional SILC|
382719|NCT01272505|Procedure|Harmonic scalpel Single incision laparoscopic cholecystectomy|
382720|NCT01272492|Other|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
382721|NCT01272466|Biological|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
382722|NCT01272427|Dietary Supplement|water with glucose|0.75 g/kg body weight of glucose added to water
382723|NCT01272427|Dietary Supplement|water and whey protein|0.75 g/kg body weight of whey protein added to water
382724|NCT01272427|Dietary Supplement|water with noncaloric sweetener|0.15 g of sucralose added to water
382725|NCT01272414|Drug|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
382726|NCT01272414|Drug|Saline injection|Injection of 0.4cc 0.9% normal saline
382727|NCT01272388|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
382728|NCT01272388|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
382729|NCT01272375|Drug|Treatment A|PF-04764793 250/50 using inhaler A
382730|NCT01272375|Drug|Treatment B|PF-04764793 250/50 using inhaler A
382731|NCT01272375|Drug|Treatment C|PF-04764793 250/50 using inhaler A
382732|NCT01272375|Drug|Treatment D|PF-04764793 250/50 using inhaler A
382733|NCT01272375|Drug|Treatment E|PF-04764793 250/50 using inhaler B
382734|NCT01272375|Drug|Treatment F|PF-04764793 250/50 using inhaler B
382735|NCT01272375|Drug|Treatment G|PF-04764793 250/50 using inhaler B
382736|NCT01272362|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
382818|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
382737|NCT01272349|Other|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
382738|NCT01272349|Other|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
382739|NCT01272336|Drug|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
382740|NCT01272336|Other|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
382741|NCT01272323|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
382742|NCT01272323|Biological|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
382743|NCT01272323|Biological|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
382744|NCT01272310|Biological|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.~Ribavirin - will be taken daily based on the patient body weight. If body weight is < 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
382745|NCT01272297|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
382746|NCT01272284|Device|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
382747|NCT01272258|Drug|PRO 140|SC injection
382748|NCT01272258|Drug|Placebo|SC injection
382749|NCT01272245|Drug|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
382750|NCT01272245|Drug|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
382751|NCT01272232|Drug|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
382752|NCT01272232|Drug|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
382753|NCT01272232|Drug|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
382754|NCT01272219|Drug|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
382755|NCT01272219|Drug|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
382756|NCT01272219|Drug|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
382757|NCT01272219|Drug|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
382758|NCT01272206|Drug|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
382759|NCT01272206|Drug|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
382760|NCT01272193|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
382761|NCT01272193|Drug|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
382762|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
382763|NCT01272180|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
382764|NCT01272180|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
382765|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
382766|NCT01272167|Behavioral|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
382767|NCT01272154|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
382768|NCT01272141|Drug|Lapatinib and Everolimus|"Lapatinib: 1250 mg by mouth daily~Everolimus: 5mg by mouth daily"
382769|NCT01272128|Drug|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
382819|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
382820|NCT01271777|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
382770|NCT01272115|Behavioral|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
382771|NCT01272089|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
382772|NCT01272050|Radiation|radiation therapy|"RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.~Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration."
382773|NCT01272037|Drug|Anastrozole|Given PO
382774|NCT01272037|Drug|Exemestane|Given PO
382775|NCT01272037|Other|Laboratory Biomarker Analysis|Correlative studies
382776|NCT01272037|Drug|Letrozole|Given PO
382777|NCT01272037|Other|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
382778|NCT01272037|Drug|Systemic Chemotherapy|Given IV
382779|NCT01272037|Drug|Tamoxifen Citrate|Given PO
382780|NCT01272024|Behavioral|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
382781|NCT01272024|Behavioral|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
382782|NCT01272011|Other|Intermittent Hypoxia|Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
382783|NCT01272011|Other|Locomotor Training|Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
382784|NCT01271998|Drug|TR-701 FA|200 mg, oral, once daily for 3 days.
382785|NCT01271985|Drug|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
382786|NCT01271985|Other|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
382787|NCT01271972|Drug|nesvacumab (REGN910/ SAR307746)|
382788|NCT01271946|Device|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
382789|NCT01271933|Drug|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
382790|NCT01271933|Drug|placebo|matching placebo tablet; given once daily
382791|NCT01271920|Drug|AUY922|
382792|NCT01271920|Drug|Trastuzumab|
382793|NCT01271907|Drug|fludarabine|Fludarabine 25 mg/m^2 x 5 days
382794|NCT01271907|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
382795|NCT01271907|Drug|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
382796|NCT01271907|Drug|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
382797|NCT01271894|Drug|Efavirenz|600 mg once daily; given as 3 x 200 mg once
382798|NCT01271894|Drug|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
382799|NCT01271881|Other|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
382800|NCT01271881|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
382801|NCT01271868|Biological|IB1001|
382802|NCT01271855|Drug|Belladonna and opioid suppository|Belladonna and opioid suppository 16.2mg/30mg per rectum every 8 hours for 24 hours following delivery
382803|NCT01271855|Drug|Glycerin Suppository|A vegetable oil suppository (placebo) per rectum every 8 hours for the first 24 hours following delivery.
382804|NCT01271829|Dietary Supplement|Avocado supplement|Calories from avocados replace calories of the control lunch
382805|NCT01271829|Dietary Supplement|Avocado included|Calories from avocados will be added to calories from the control lunch
382806|NCT01271803|Drug|Cobimetinib|Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
382807|NCT01271803|Drug|vemurafenib|Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
382808|NCT01271790|Drug|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
382809|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
382810|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
382811|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
382812|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg QD
382813|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
382814|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
382815|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
382816|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
382817|NCT01271790|Drug|GS-9451 placebo|placebo matching GS-9451 tablet QD
382821|NCT01271777|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
382822|NCT01271764|Other|no drug|The role of G9a protein in patients with endometrial cancer
382823|NCT01271751|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
382824|NCT01271751|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
382825|NCT01271738|Procedure|Remove tumor only|No additional margins (tissue) removed at the initial surgery
382826|NCT01271738|Procedure|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
382827|NCT01271725|Drug|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
382828|NCT01271725|Drug|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
382829|NCT01271725|Drug|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
382830|NCT01271712|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
382831|NCT01271712|Drug|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
382832|NCT01271712|Drug|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
382833|NCT01271686|Drug|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
382834|NCT01271660|Drug|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
382835|NCT01271660|Drug|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
382836|NCT01271647|Drug|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
382837|NCT01271647|Drug|placebo|granules,18g per time,two times per day,six months
382838|NCT01271621|Device|Intubation|Endotracheal intubation
382839|NCT01271608|Device|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
382840|NCT01271595|Other|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
382841|NCT01271582|Drug|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks [irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)]
382842|NCT01271569|Drug|Fospropofol disodium|Fospropofol disodium： 0.5g
382843|NCT01271556|Drug|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
382844|NCT01271556|Procedure|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
382845|NCT01271556|Other|Placebo|placebo, inhalatory (MDI) once
382846|NCT01271543|Device|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
382847|NCT01271530|Other|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
382848|NCT01271517|Drug|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
382849|NCT01271517|Drug|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
382850|NCT01271517|Drug|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
382851|NCT01271504|Drug|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
382852|NCT01271504|Drug|Sorafenib|"E7050 given orally at 200, 300 or 400 mg once daily.~Sorafenib given orally, 400 mg twice daily."
382853|NCT01271478|Drug|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
382854|NCT01271478|Drug|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
382855|NCT01271478|Drug|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
382856|NCT01271478|Drug|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
382857|NCT01271465|Procedure|Kidney Biopsy|biopsy of transplant kidney
382858|NCT01271452|Biological|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
382859|NCT01271452|Biological|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
383106|NCT01269450|Drug|placebo|placebo 200mg vaginal tablets
382860|NCT01271439|Drug|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
382861|NCT01271413|Behavioral|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
382862|NCT01271387|Drug|tasimelteon|20 mg tasimelteon capsules, PO single dose
382863|NCT01271374|Drug|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
382864|NCT01271374|Drug|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
382865|NCT01271361|Procedure|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
382866|NCT01271361|Procedure|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
382867|NCT01271348|Drug|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
382868|NCT01271348|Drug|placebo|Placebo tablet, q.d.
382869|NCT01271335|Biological|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
382870|NCT01271322|Radiation|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
382871|NCT01271296|Dietary Supplement|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
382872|NCT01271296|Dietary Supplement|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
382873|NCT01271283|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
382874|NCT01271283|Drug|Lenalidomide|Given orally
382875|NCT01271270|Drug|Palomid 529|
382876|NCT01271257|Drug|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
382877|NCT01271244|Drug|Escitalopram|10-20mg daily for 12 weeks
382878|NCT01271231|Drug|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
382879|NCT01271231|Drug|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
382880|NCT01271231|Drug|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
382881|NCT01271218|Other|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
382882|NCT01271218|Other|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
382883|NCT01271192|Procedure|surgical resection and adjuvant therapy|"Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
382884|NCT01271192|Procedure|Neoadjuvant followed by operation|"Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
382885|NCT01271179|Procedure|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
382886|NCT01271179|Procedure|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
382887|NCT01271166|Drug|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
382888|NCT01271153|Drug|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
382889|NCT01271153|Drug|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
382890|NCT01271140|Drug|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
382891|NCT01271127|Radiation|CT coronary angiography|patient will undergo one CT coronary angiography
382892|NCT01271114|Drug|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
382893|NCT01271114|Drug|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
382894|NCT01271088|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
382895|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
382896|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
382897|NCT01271062|Procedure|gastric bypass surgery|
382898|NCT01271062|Procedure|abdominal surgery|
382899|NCT01271062|Behavioral|very low caloric diet|
382900|NCT01271049|Other|Novel Food Product|Novel food product containing essential oil blend
382901|NCT01271049|Other|Control Food Product|Control food product
382902|NCT01271036|Device|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
382903|NCT01271023|Device|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
382904|NCT01271010|Drug|Cyclophosphamide|Participants received cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle.
382905|NCT01271010|Drug|Fludarabine|Participants received fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle.
382906|NCT01271010|Drug|Rituximab|Participants received 375 mg/m^2 IV on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle.
382907|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
382908|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
382909|NCT01270984|Drug|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
382910|NCT01270984|Drug|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
382911|NCT01270971|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
382912|NCT01270971|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
382913|NCT01270958|Drug|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.~Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
382914|NCT01270945|Drug|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
382915|NCT01270945|Procedure|Standard of Care|
382916|NCT01270932|Drug|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
382917|NCT01270919|Device|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.~The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
382918|NCT01270906|Drug|CHIR-258 (TKI258)|
382919|NCT01270893|Drug|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
382920|NCT01270880|Drug|Hsp90 inhibitor STA-9090|Given IV
382921|NCT01270880|Other|laboratory biomarker analysis|Correlative studies
382922|NCT01270880|Genetic|polymerase chain reaction|Correlative studies
382923|NCT01270880|Other|enzyme-linked immunosorbent assay|Correlative studies
382924|NCT01270880|Genetic|RNA analysis|Correlative studies
382925|NCT01270880|Other|spectrophotometry|Correlative studies
382926|NCT01270880|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
382927|NCT01270880|Genetic|gene expression analysis|Correlative studies
382928|NCT01270867|Device|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
382929|NCT01270854|Other|Plasmalyte A|Intravenous fluid
382930|NCT01270854|Other|Normal Saline|Intravenous fluid
382931|NCT01270841|Drug|Placebo|Placebo capsule 1x daily for 3 months
382932|NCT01270841|Drug|topical testosterone|testosterone gel applied 1x daily for 3 months
382933|NCT01270841|Drug|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
382934|NCT01270828|Drug|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
382935|NCT01270828|Drug|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
382936|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
382937|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
382938|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
382939|NCT01270815|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
382940|NCT01270802|Drug|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
382941|NCT01270802|Drug|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
382942|NCT01270802|Drug|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
382943|NCT01270789|Drug|Liraglutide|Liraglutide administered as once daily sc injection
382944|NCT01270789|Drug|placebo|placebo administered as once daily sc injection
382945|NCT01270776|Drug|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
382946|NCT01270776|Drug|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
382947|NCT01270763|Behavioral|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
382948|NCT01270763|Behavioral|Diabetes support and education|Behavioral intervention focused on diabetes support and education
382949|NCT01270750|Drug|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
382950|NCT01270737|Dietary Supplement|Whole soy (soy flour)|40g soy flour per day for six months
382951|NCT01270737|Dietary Supplement|daidzein|66mg daidzein per day for six months
382952|NCT01270737|Dietary Supplement|milk powder|40g low-fat dry milk per day for six months
382953|NCT01270724|Drug|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
382954|NCT01270711|Drug|Study Drug|non interventional study - usage as per usual care
382955|NCT01270698|Drug|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
382956|NCT01270672|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
382957|NCT01270672|Drug|carvedilol|50 mg per os, single dose
382958|NCT01270672|Drug|placebo|capsules identical to MDMA or carvedilol
382959|NCT01270659|Drug|Fentanyl|Fentanyl buccal tablet 100 mcg once
382960|NCT01270659|Drug|Fentanyl|Fentanyl buccal tablet 200 mcg once
382961|NCT01270659|Drug|Oxycodone/acetaminophen|Oxycodone/acetaminophen 5/325 mg once
382962|NCT01270659|Drug|oxycodone/acetaminophen|Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
382963|NCT01270646|Device|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.~Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
382964|NCT01270633|Device|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
382965|NCT01270633|Other|Standard of Care|Following sharp debridement, moist wound therapy
382966|NCT01270620|Drug|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
382967|NCT01270620|Drug|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
382968|NCT01270607|Procedure|Acupuncture|Treatment given twice per week for 4 weeks
382969|NCT01270594|Behavioral|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
382970|NCT01270594|Behavioral|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
382971|NCT01270581|Other|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
382972|NCT01270581|Other|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
382973|NCT01270568|Other|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
382974|NCT01270568|Behavioral|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
382975|NCT01270568|Behavioral|Recollection|Subjects record daily events on a weekly basis for 8 weeks
382976|NCT01270555|Drug|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
382977|NCT01270542|Drug|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
382978|NCT01270542|Other|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
383107|NCT01269437|Drug|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
383108|NCT01269424|Biological|MGMTP140K-encoding retroviral vector|
383109|NCT01269424|Drug|O6-benzylguanine|
382979|NCT01270529|Other|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
382980|NCT01270516|Drug|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
382981|NCT01270516|Drug|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
382982|NCT01270516|Drug|Saline|Control
382983|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
382984|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
382985|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
382986|NCT01270490|Drug|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
382987|NCT01270477|Other|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
382988|NCT01270464|Drug|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
382989|NCT01270464|Drug|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
382990|NCT01270451|Other|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
382991|NCT01270438|Drug|FOLFOX regimen|Given IV
382992|NCT01270438|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
382993|NCT01270438|Biological|bevacizumab|Given IV
382994|NCT01270438|Drug|oxaliplatin|Given IV
382995|NCT01270438|Drug|leucovorin calcium|Given IV
382996|NCT01270438|Drug|fluorouracil|Given IV
382997|NCT01270412|Biological|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
382998|NCT01270412|Drug|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
382999|NCT01270386|Drug|apatinib|Apatinib 750 mg p.o. once daily
383000|NCT01270386|Drug|placebo|placebo p.o. once daily
383001|NCT01270373|Drug|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
383002|NCT01270373|Drug|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Doxorubicin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
383003|NCT01270360|Device|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
383004|NCT01270347|Drug|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
383005|NCT01270347|Drug|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
383006|NCT01270334|Other|PH meassurment|meassuring ph USING PROBE
383007|NCT01270321|Drug|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
383008|NCT01270321|Drug|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
383009|NCT01270321|Drug|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
383010|NCT01270308|Drug|Lansoprazole|Lansoprazole DR Capsules 30 mg
383011|NCT01270282|Drug|AM-101 0.81 mg/mL|
383012|NCT01270282|Drug|Placebo|
383013|NCT01270269|Behavioral|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
383014|NCT01270269|Behavioral|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
383015|NCT01270256|Drug|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
383016|NCT01270256|Drug|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
383017|NCT01270230|Behavioral|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
383018|NCT01270230|Behavioral|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
383019|NCT01270217|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
383020|NCT01270191|Drug|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
383021|NCT01270191|Drug|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
383022|NCT01270178|Drug|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
383023|NCT01270165|Drug|telbivudine|600mg, oral daily over 12 months
383024|NCT01270152|Drug|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
383025|NCT01270139|Procedure|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
383026|NCT01270139|Procedure|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
383027|NCT01270139|Device|Stenting|60 - in sirolimus-eluting stenting control
383028|NCT01270126|Device|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
383029|NCT01270113|Behavioral|contingency management|
383030|NCT01270100|Behavioral|Recovery management|
383031|NCT01270087|Drug|Adalimumab|40 mg IV every 14 days
383032|NCT01270074|Drug|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
383033|NCT01270074|Drug|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
383034|NCT01270061|Behavioral|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
383035|NCT01270061|Behavioral|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
383036|NCT01270048|Drug|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
383037|NCT01270048|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
383038|NCT01270035|Drug|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
383039|NCT01270022|Other|Implementation|
383040|NCT01270022|Other|dissemination|
383041|NCT01269996|Drug|Janumet, Lantus|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
383042|NCT01269996|Drug|metformin, gliclazide, protaphane|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection."
383043|NCT01269983|Other|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
383044|NCT01269970|Other|18-FDG-PET-CT|
383045|NCT01269931|Procedure|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
383046|NCT01269918|Drug|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
383047|NCT01269918|Drug|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
383048|NCT01269892|Dietary Supplement|lactose-free milk|a milk without lactose
383049|NCT01269892|Dietary Supplement|conventional milk|a milk with lactose
383050|NCT01269879|Device|Flexi-Bar vibration device only|daily vibration training 10min twice
383051|NCT01269879|Device|Flexi-Bar + XCO-Trainer|"XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.~In addition Flexi-Bar vibration training as in the referred active comparator group"
383052|NCT01269866|Drug|Cymbalta|Cymbalta 60 to 120 mg PO QD
383110|NCT01269424|Drug|temozolomide|
383111|NCT01269424|Other|laboratory biomarker analysis|
383112|NCT01269424|Procedure|autologous hematopoietic stem cell transplantation|
383113|NCT01269424|Procedure|in vitro-treated peripheral blood stem cell transplantation|
383114|NCT01269424|Radiation|radiation therapy|
383120|NCT01269385|Biological|alemtuzumab|Given subcutaneously
383053|NCT01269853|Drug|Bevacizumab|"Experimental portion of this proposal:~This trial will have two experimental arms that will be open labeled and non-randomized.~ARM 1 (If the patient has multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.~If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.~Repeat Cycle"
383054|NCT01269853|Drug|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)~Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment~If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
383055|NCT01269827|Drug|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
383056|NCT01269827|Drug|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
383057|NCT01269814|Procedure|Gastroscopy|Gastroscopy
383058|NCT01269801|Drug|onabotulinumtoxinA|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
383059|NCT01269801|Drug|JUVÉDERM|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;~• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.~At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
383060|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
383061|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
383062|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
383063|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
383064|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
383065|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
383066|NCT01269775|Other|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
383067|NCT01269762|Drug|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
383068|NCT01269749|Radiation|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
383069|NCT01269749|Drug|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
383070|NCT01269736|Behavioral|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
383071|NCT01269723|Dietary Supplement|Broccoli sprout homogenate|Subjects will drink the broccoli shake homogenate
383072|NCT01269723|Dietary Supplement|Alfalfa sprout homogenate|Subjects will drink the alfalfa sprout homogenate.
383073|NCT01269697|Dietary Supplement|Nutrof Total|2 capsules 2 times per day during 6 month
383074|NCT01269697|Dietary Supplement|Placebo Nutrof total|2 capsules 2 times per day during 6 month
383075|NCT01269684|Drug|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
383076|NCT01269671|Drug|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
383077|NCT01269671|Other|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
383078|NCT01269658|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
383079|NCT01269658|Drug|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
383115|NCT01269411|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
383116|NCT01269411|Procedure|therapeutic conventional surgery|Undergo surgery
383117|NCT01269411|Other|pharmacological study|Correlative studies
383118|NCT01269411|Other|laboratory biomarker analysis|Correlative
383119|NCT01269398|Device|GO-LIF and SpineAssist SYSTEMS|
383080|NCT01269645|Behavioral|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
383081|NCT01269632|Biological|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up~clinical and therapeutic evaluation by physician~biological: blood sampling, specific biological exams and biobank~self administered questionnaires~In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)~HIV UNINFECTED at inclusion and after 3 years follow up~clinical evaluation by physician~biological: blood sampling, specific biological exams and biobank~self administered questionnaires"
383082|NCT01269619|Device|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
383083|NCT01269619|Device|Static back support|A standard wrap-around sacro lumbar support
383084|NCT01269606|Drug|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
383085|NCT01269606|Drug|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
383086|NCT01269606|Drug|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
383087|NCT01269606|Drug|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
383088|NCT01269593|Drug|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
383089|NCT01269567|Procedure|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit < 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
383090|NCT01269567|Procedure|No pelvic drainage|no aspiration drain at the end of intervention
383091|NCT01269541|Drug|Mupirocin|Topical in the nose 3 times daily for 5 days
383092|NCT01269541|Drug|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
383093|NCT01269528|Other|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
383094|NCT01269528|Other|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
383095|NCT01269528|Other|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
383096|NCT01269528|Other|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
383097|NCT01269528|Other|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
383098|NCT01269515|Drug|Etoricoxib|90 mg QD
383099|NCT01269502|Device|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
383100|NCT01269502|Other|Inspection|Inspection of feet daily for one year
383101|NCT01269476|Drug|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
383102|NCT01269476|Drug|Placebo|Same volumes and frequency as active.
383103|NCT01269463|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Methylphenidate Hydrochloride Extended Release Capsules to be dosed once daily
383104|NCT01269463|Drug|Placebo|Capsule without active drug
383105|NCT01269450|Drug|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
383121|NCT01269385|Biological|rituximab|Given IV
383122|NCT01269385|Drug|PGG beta-glucan|Given IV
383123|NCT01269385|Other|flow cytometry|Correlative studies
383124|NCT01269385|Other|laboratory biomarker analysis|Correlative studies
383125|NCT01269385|Genetic|DNA analysis|Correlative studies
383126|NCT01269385|Genetic|fluorescence in situ hybridization|Correlative studies
383127|NCT01269385|Genetic|polymerase chain reaction|Correlative studies
383128|NCT01269385|Genetic|polymorphism analysis|Correlative studies
383129|NCT01269385|Genetic|mutation analysis|Correlative studies
383130|NCT01269372|Device|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).~Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
383131|NCT01269372|Device|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
383132|NCT01269359|Procedure|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
383133|NCT01269346|Drug|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.~Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
383134|NCT01269333|Drug|omeprazole|omeprazole 20mg for 7 days
383135|NCT01269333|Drug|fluvoxamine|fluvoxamine 50mg for 7 days
383136|NCT01269333|Drug|placebo|placebo for 7 days
383137|NCT01269320|Drug|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
383138|NCT01269307|Procedure|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
383139|NCT01269307|Procedure|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.~May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
383140|NCT01269294|Drug|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
383141|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
383142|NCT01269294|Drug|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
383143|NCT01269294|Drug|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
383144|NCT01269294|Drug|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
383145|NCT01269294|Drug|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
383146|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
383147|NCT01269281|Drug|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
383148|NCT01269255|Drug|TS-1 with Cisplatin|"SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)~Step 1: Chemotherapy; TS-1/CDDP #2 cycles~Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP~Step 3: Surgery therapy"
383149|NCT01269242|Drug|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
383150|NCT01269242|Drug|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
383151|NCT01269242|Drug|placebo|bindarit-matching placebo tablets for 6 months.
383152|NCT01269229|Drug|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -> 2400mg/m2 46hrs continuous
383153|NCT01269229|Radiation|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
383154|NCT01269216|Drug|5-FU with leucovorin|5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
383155|NCT01269216|Drug|TS-1 with Irinotecan|Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
383156|NCT01269203|Drug|Curcumin|1000 mg per day
383157|NCT01269203|Other|Placebo|Administered daily same as Curcumin.
383158|NCT01269190|Procedure|High-Resolution Microendoscopy|Undergo evaluation of oral lesions using a high-resolution microendoscope
383159|NCT01269190|Procedure|Multispectral Imaging|Undergo evaluation of oral cavity using a widefield multispectral imaging
383160|NCT01269190|Drug|Proflavine|Proflavine) used to stain the mouth tissue after initial imaging.
383161|NCT01269177|Device|Non invasive ventilation|"Indications for the use of NIV are at least one of the following:~Respiratory Rate ≥ 30 bpm~PaO2/FiO2 < 200~pH < 7.35 and PaCO2 > 45 mmH~Contraindications for the use of NIV are at least one of the following:~Coma~Hemodynamic instability / shock~Lack of compliance~Indications for endotracheal intubation (ETI) are at least one of the following:~Respiratory or cardiac arrest~Coma~Hemodynamic instability"
383162|NCT01269164|Procedure|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
383163|NCT01269151|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
383164|NCT01269138|Drug|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
383165|NCT01269138|Drug|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
383166|NCT01269138|Drug|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
383167|NCT01269138|Drug|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
383168|NCT01269138|Drug|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
383169|NCT01269125|Drug|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
383170|NCT01269125|Procedure|IVF|Assisted Reproduction Technique.
383171|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
383172|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:~Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
383173|NCT01269099|Drug|IV-PCA|IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
383174|NCT01269099|Drug|Control|control group (No-PCA group)
383175|NCT01269086|Behavioral|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
383176|NCT01269060|Procedure|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
383177|NCT01269047|Drug|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
383178|NCT01269047|Drug|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
383179|NCT01269047|Drug|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
383180|NCT01269034|Drug|Exenatide|1.25 mcg before the boost sub-cutaneously.
383181|NCT01269034|Drug|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
383182|NCT01269034|Drug|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
383183|NCT01269021|Drug|mycophenolate mofetil plus lower dose of Prednisone|MMF 1.0-1.5g/d*6mons Prednisone 0.4-0.6 mg/kg/d
383184|NCT01269021|Drug|Prednisone in full dose|0.8-1mg/kg/d
383185|NCT01269008|Device|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
383186|NCT01268995|Drug|Cyclosporine A|"Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated."
383187|NCT01268995|Drug|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
383188|NCT01268982|Procedure|socket preservation|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
383189|NCT01268969|Procedure|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
383190|NCT01268969|Procedure|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
383191|NCT01268943|Drug|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
383192|NCT01268943|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
383193|NCT01268943|Drug|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
383194|NCT01268943|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
383195|NCT01268930|Procedure|Bipolar electrocautery for ovarian hemostasis|after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
383196|NCT01268930|Procedure|hemostatic matrix (FloSeal)|after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
383197|NCT01268917|Drug|aspirin|aspirin 100mg daily until the surgery day
383198|NCT01268917|Drug|aspirin|aspirin is stopped 5-7 days before operation
383199|NCT01268904|Drug|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
383200|NCT01268891|Drug|Placebo|Once daily; tablet; orally; 18 weeks
383201|NCT01268891|Drug|Azilect®|1 mg daily; tablet; orally; 18 weeks
383202|NCT01268852|Device|Damon self ligating orthodontic bracket|Orthodontic treatment with Damon self ligating bracket
383203|NCT01268852|Device|Insignia self ligating orthodontic bracket|Orthodontic treatment with Insignia self ligating bracket
383204|NCT01268839|Drug|TMC278|25mg tablet once daily for 28 days
383205|NCT01268839|Drug|TMC278|25mg tablet once daily for 14 days
383206|NCT01268839|Drug|Efavirenz|600mg tablet once daily for 14 days
383207|NCT01268813|Other|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
383208|NCT01268787|Biological|EV71 vaccine|Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
383209|NCT01268761|Drug|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
383210|NCT01268761|Drug|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
383282|NCT01268215|Drug|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
383211|NCT01268748|Procedure|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
383212|NCT01268748|Procedure|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
383213|NCT01268735|Drug|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
383214|NCT01268722|Device|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
383215|NCT01268722|Device|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
383216|NCT01268709|Drug|Doxepin|
383217|NCT01268709|Drug|Nortriptyline|
383218|NCT01268709|Drug|placebo|
383219|NCT01268683|Drug|RP-1127 (Glyburide for injection)|Bolus plus 72 hour IV infusion
383220|NCT01268670|Drug|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
383221|NCT01268670|Drug|Oxycodone|Subjects will receive topical LET and oral oxycodone.
383222|NCT01268670|Other|Placebo|Subjects will receive topical LET and oral placebo.
383223|NCT01268657|Behavioral|Education|Learning about anxiety
383224|NCT01268657|Behavioral|Relaxation Training|Learning skills to reduce tension
383225|NCT01268657|Behavioral|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
383226|NCT01268657|Behavioral|Behavioral Activation|Learning to initiate healthy activity
383227|NCT01268657|Behavioral|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
383228|NCT01268644|Drug|Leptin|weight based sub-cutaneous injection twice daily of Leptin
383229|NCT01268631|Drug|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
383230|NCT01268631|Drug|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
383231|NCT01268618|Dietary Supplement|Probiotic|"2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:~Lactobacillus acidophilus NAS, 30 billion CFU~Bifidobacterium bifidum Malyoth, 120 billion CFU~Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU"
383232|NCT01268618|Dietary Supplement|Placebo|2 capsules, 3x/day placebo capsules
383233|NCT01268605|Procedure|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
383234|NCT01268605|Procedure|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
383235|NCT01268592|Procedure|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
383236|NCT01268579|Drug|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
383237|NCT01268566|Drug|MEDI-575|MEDI-575 as an IV infusion.
383238|NCT01268553|Drug|Treprostinil|Transition to inhaled treprostinil
383239|NCT01268540|Device|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
383240|NCT01268540|Device|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
383241|NCT01268527|Drug|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
383242|NCT01268527|Drug|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
383243|NCT01268527|Drug|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
383244|NCT01268527|Drug|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
383245|NCT01268527|Drug|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
383246|NCT01268527|Drug|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
383247|NCT01268527|Other|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
383248|NCT01268527|Other|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
383249|NCT01268527|Other|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
383250|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
383251|NCT01268527|Other|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
383252|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
383253|NCT01268527|Drug|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
383254|NCT01268501|Device|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
383255|NCT01268488|Device|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
383256|NCT01268462|Other|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
383257|NCT01268462|Other|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
383258|NCT01268462|Other|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
383259|NCT01268462|Other|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
383260|NCT01268449|Radiation|Low dose laser|5mv laser with a wavelength of 650nm
383261|NCT01268449|Radiation|Placebo|The act of radiating laser to the ear is done while the set is off.
383262|NCT01268423|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
383263|NCT01268423|Procedure|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
383264|NCT01268397|Procedure|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
383265|NCT01268397|Procedure|closed reduction and plaster treatment|closed reduction, below elbow plaster cast, semicircular for 5 week
383266|NCT01268384|Drug|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
383267|NCT01268371|Device|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
383268|NCT01268371|Device|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
383269|NCT01268358|Drug|Lamazym|Lamazym, ERT, infusion weekly
383270|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
383271|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
383272|NCT01268332|Drug|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
383273|NCT01268319|Device|Embolic Protection Device (EPD)|"The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014 steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient."
383274|NCT01268319|Device|Intracoronary Spectroscopy and Ultrasonic Evaluation|This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
383275|NCT01268319|Device|Angioplasty and Stent Implant|The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
383276|NCT01268306|Device|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch & Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
383277|NCT01268293|Drug|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
383278|NCT01268280|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
383279|NCT01268280|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
383280|NCT01268280|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
383281|NCT01268267|Device|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
383283|NCT01268215|Drug|Pulmicort|Endotracheal instillation, once per week for three weeks
383284|NCT01268215|Other|Sham|None instilled through the endotracheal tube
383285|NCT01268202|Drug|Pravastatin|Pravastatin 40mg/day during 12 months
383286|NCT01268189|Device|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
383287|NCT01268189|Device|Standard of care dressing|Xeroform control dressing applied to control wound
383288|NCT01268176|Dietary Supplement|cholecalciferol|50,000 IU once per month for 3 months
383289|NCT01268163|Drug|European Taxotere®|60-100 mg/m^2 IV
383290|NCT01268163|Drug|American Taxotere®|60-100 mg/m^2 IV
383291|NCT01268163|Drug|Hospira Docetaxel Injection|60-100 mg/m^2 IV
383292|NCT01268150|Drug|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
383293|NCT01268137|Procedure|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
383294|NCT01268124|Drug|HTC-867|
383295|NCT01268111|Drug|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
383296|NCT01268111|Drug|Placebo|matching placebo
383297|NCT01268098|Drug|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
383298|NCT01268085|Other|Radiation Alert|A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part
383299|NCT01268085|Other|Control|Control with no inverention
383300|NCT01268059|Drug|Carboplatin/Paclitaxel/MEDI-575|Subjects will receive carboplatin/paclitaxel and MEDI-575 every 21 days for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
383301|NCT01268059|Drug|Carboplatin/Paclitaxel|Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6 mg/mL*min) for up to 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
383302|NCT01268059|Drug|Carboplatin/Paclitaxel/MEDI-575|Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6mg/mL*min) plus MEDI-575 at dose determined in the Dose Determination Phase. Carboplatin/paclitaxel and MEDI-575 to be given once every 21 days as an IV infusion for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
383303|NCT01268046|Drug|Estradiol oral capsule|1 oral capsule (1 mg estradiol) administered daily for one month
383304|NCT01268046|Drug|transderman estrogen patch|transdermal estrogen patch (50 mcg/day) for one month
383305|NCT01268046|Drug|trasdermal placebo patch|transdermal placebo patch with patch change every 84 hr for one month
383306|NCT01268046|Drug|placebo oral capsule|placebo oral capsule administered daily for one month.
383307|NCT01268033|Drug|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
383308|NCT01268033|Drug|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
383309|NCT01268020|Drug|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
383310|NCT01267994|Drug|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
383311|NCT01267981|Drug|Standard diet|"After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy."
383312|NCT01267981|Drug|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
383313|NCT01267981|Drug|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
383314|NCT01267968|Drug|GSK2251052|1500 mg (dosing detailed in Arm description)
383315|NCT01267955|Other|Laboratory Biomarker Analysis|Correlative studies
383316|NCT01267955|Other|Pharmacogenomic Study|Correlative studies
383317|NCT01267955|Drug|Vismodegib|Given PO
383318|NCT01267942|Drug|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.~Oral dose of the same at the same dosage for the active comparator arm."
383319|NCT01267929|Procedure|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
383320|NCT01267929|Procedure|The conventional physical therapy|The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
383321|NCT01267916|Device|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
383322|NCT01267916|Device|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
383323|NCT01267916|Device|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
383324|NCT01267916|Device|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
383325|NCT01267916|Device|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
383326|NCT01267916|Device|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
383327|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
383328|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
383329|NCT01267903|Biological|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
383330|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
383331|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
383332|NCT01267877|Other|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
383333|NCT01267877|Other|read favorable article prior to answering questions|"read A Backlash of Mistrust"
383334|NCT01267864|Drug|Metoclopramide|10mg IVSS
383335|NCT01267864|Drug|Ketorolac|30g IVSS
383336|NCT01267864|Drug|Valproate|1gm IVSS
383337|NCT01267838|Procedure|PCI|PCI of bifurcation lesions with double stenting
383338|NCT01267825|Drug|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
383339|NCT01267825|Drug|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
383340|NCT01267812|Drug|bortezomib|Given SC or IV
383341|NCT01267812|Biological|rituximab|Given IV
383342|NCT01267812|Other|laboratory biomarker analysis|Correlative studies
383343|NCT01267812|Other|immunohistochemistry staining method|Correlative studies
383344|NCT01267812|Genetic|RNA analysis|Correlative studies
383345|NCT01267812|Genetic|gene expression analysis|Correlative studies
383346|NCT01267812|Genetic|DNA analysis|Correlative studies
383347|NCT01267812|Other|pharmacological study|Correlative studies
383348|NCT01267812|Other|pharmacogenomic studies|Correlative studies
383349|NCT01267812|Other|Questionnaire Administration|
383350|NCT01267786|Procedure|Liver surgery|hepatectomy
383351|NCT01267773|Behavioral|Integrated Treatment|
383352|NCT01267760|Device|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
383353|NCT01267734|Device|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
383354|NCT01267734|Device|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
383355|NCT01267734|Drug|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
383356|NCT01267734|Drug|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
383357|NCT01267721|Procedure|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
383358|NCT01267695|Drug|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
383359|NCT01267695|Procedure|conventional surgery|All the patients should receive elective surgery with R0 resection.
383360|NCT01267682|Behavioral|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
383361|NCT01267669|Drug|Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
383362|NCT01267669|Drug|Placebo|Emergency EVL plus placebo infusion for 5 days
383363|NCT01267643|Drug|Alefacept|"Dose Escalation Schedule~Level -1 5 mg IV once weekly~Level 1 7.5 mg IV once weekly~Level 2 10 mg IV once weekly~Level 3 12.5 mg IV once weekly"
383364|NCT01267604|Drug|Recombinant FSH (rFSH)|225IU
383365|NCT01267604|Dietary Supplement|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
383366|NCT01267578|Biological|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
383367|NCT01267565|Other|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
383368|NCT01267552|Procedure|Non drains will be placed during operation|Non drains will be placed during operation
383369|NCT01267552|Procedure|Closed suction drainage|Closed suction drainage will be placed during operation
383370|NCT01267526|Device|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
383371|NCT01267500|Procedure|Non surgical therapy|patching or fusion exercises
383372|NCT01267487|Drug|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT > 480 sec. Supplemental doses of 50mg of heparin if ACT <480 sec during CPB.~Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
383373|NCT01267487|Drug|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
383374|NCT01267487|Drug|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.~Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
383375|NCT01267474|Other|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.~All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.~Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.~All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
383376|NCT01267474|Other|Control|The control group received only three one-hour general sessions on health issues.
383377|NCT01267461|Other|Tissue sample from tumor|Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
383378|NCT01267448|Drug|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
383523|NCT01266265|Drug|oral ERA|As prescribed by physician
383379|NCT01267448|Drug|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
383380|NCT01267448|Drug|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
383381|NCT01267435|Procedure|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
383382|NCT01267422|Drug|rAAV2-ND4|injection
383383|NCT01267409|Other|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
383384|NCT01267396|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
383385|NCT01267383|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
383386|NCT01267370|Dietary Supplement|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and > 10 years, 20 g/day.~The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.~Arms: Soy polysaccharide fiber, purified soy extract, with no fiber~Other Names:~Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
383387|NCT01267357|Other|no intervention|
383388|NCT01267344|Drug|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
383389|NCT01267344|Drug|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
383390|NCT01267331|Procedure|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
383391|NCT01267331|Procedure|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
383392|NCT01267305|Drug|Fondaparinux|2.5mg IH qd(8AM) after operation
383393|NCT01267305|Drug|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
383394|NCT01267305|Drug|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
383395|NCT01267292|Drug|Buspirone|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday] [weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday]
383396|NCT01267292|Drug|Placebo for Buspirone|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday] [weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday]
383397|NCT01267292|Drug|Methylphenidate|Methylphenidate serves as an acute stimulant challenge. [week 1: no Methylphenidate or Methylphenidate placebo] [week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
383398|NCT01267292|Drug|Placebo for Methylphenidate|[week 1: no Methylphenidate or Methylphenidate placebo] [week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
383399|NCT01267279|Drug|Zoledronic acid|Zoledronic acid per protocol
383400|NCT01267279|Other|Placebo|Placebo
383401|NCT01267266|Drug|saracatinib|Given orally
383402|NCT01267266|Other|hydrocortisone/placebo|Given orally
383403|NCT01267253|Drug|Brivanib Alaninate|Given PO
383404|NCT01267253|Other|Laboratory Biomarker Analysis|Correlative studies
383405|NCT01267240|Drug|Capecitabine|Given PO
383406|NCT01267240|Drug|Vorinostat|Given PO
383407|NCT01267227|Drug|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
383408|NCT01267227|Drug|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
383409|NCT01267227|Drug|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
383410|NCT01267227|Drug|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
383411|NCT01267214|Drug|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
383412|NCT01267214|Procedure|Osteotomy alone|no injection
383413|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
383414|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
383415|NCT01267201|Drug|methylprednisolone|tablet 32 mg single dose
383416|NCT01267188|Drug|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
383417|NCT01267175|Device|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
383418|NCT01267136|Drug|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg [=0.3 mL/kg] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
383419|NCT01267136|Drug|Tramadol suspension|Liquid tramadol 1.05 mg/kg [=0.3 mL/kg] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
383420|NCT01267123|Procedure|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
383421|NCT01267123|Procedure|Standard care|The patient will be placed in the standard horizontal position
383524|NCT01266265|Drug|oral PDE5 inhibitors|As prescribed by physician
383422|NCT01267110|Other|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
383423|NCT01267110|Other|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
383424|NCT01267097|Behavioral|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
383425|NCT01267097|Behavioral|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
383426|NCT01267084|Drug|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
383427|NCT01267084|Drug|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
383428|NCT01267084|Drug|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
383429|NCT01267071|Drug|A|GSK962040 (50 mg, SD, oral)
383430|NCT01267071|Drug|B|14C GSK962040 (100 μg, SD, iv)
383431|NCT01267058|Biological|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
383432|NCT01267058|Biological|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
383433|NCT01267058|Biological|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
383434|NCT01267045|Behavioral|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
383435|NCT01267032|Behavioral|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
383436|NCT01267032|Behavioral|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
383437|NCT01267032|Behavioral|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
383438|NCT01267019|Behavioral|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
383439|NCT01267019|Behavioral|social cognitive training|30 sessions of social cognitive training without in vivo exercises
383440|NCT01267019|Behavioral|non-social skills training|30 sessions of skills training that has no specific social content
383441|NCT01267006|Drug|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
383442|NCT01267006|Drug|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
383443|NCT01266993|Biological|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
383444|NCT01266993|Biological|Menjugate|Intramuscular, 1 dose
383445|NCT01266980|Drug|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
383446|NCT01266967|Drug|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
383447|NCT01266954|Drug|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
383448|NCT01266941|Drug|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
383449|NCT01266928|Drug|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
383450|NCT01266902|Drug|Rilpivirine|25 mg once daily
383514|NCT01266317|Drug|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
383518|NCT01266278|Other|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
383519|NCT01266265|Drug|inhaled prostacyclin|Tyvaso
383520|NCT01266265|Drug|inhaled prostacyclin|As prescribed by the physician
383521|NCT01266265|Drug|prostacyclin|As prescribed by the physician
383451|NCT01266889|Device|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
383452|NCT01266876|Drug|Alirocumab|Alirocumab two SC injections in the abdomen only.
383453|NCT01266876|Drug|Placebo|Placebo two SC injections in the abdomen only.
383454|NCT01266863|Other|E test method|E test strips directly applied to BAL
383455|NCT01266850|Biological|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
383456|NCT01266850|Biological|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
383457|NCT01266837|Drug|Everolimus|10 mg p.o once daily
383458|NCT01266824|Drug|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
383459|NCT01266811|Drug|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
383460|NCT01266811|Biological|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
383461|NCT01266798|Behavioral|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.~A checklist for critical assessment of health information~Access to research databases for health information and an introduction to research methods and principles of science~A checklist to the consultation"
383462|NCT01266785|Drug|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
383463|NCT01266772|Drug|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
383464|NCT01266772|Drug|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
383465|NCT01266759|Drug|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
383466|NCT01266759|Drug|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
383467|NCT01266746|Procedure|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
383468|NCT01266733|Behavioral|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
383469|NCT01266733|Behavioral|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
383470|NCT01266720|Biological|VEGFR1, VEGFR2|One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
383471|NCT01266720|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
383472|NCT01266707|Biological|antiangiogenic paptide vaccine|for drugs include administration time frame
383473|NCT01266694|Drug|Colchicines|oral form, 1 mg, once a day during 14 days
383474|NCT01266694|Drug|Placebo|oral form, placebo
383515|NCT01266291|Drug|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
383516|NCT01266278|Other|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
383517|NCT01266278|Other|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
383646|NCT01265485|Drug|coated suppository|Dose escalating study
383475|NCT01266681|Drug|amiodarone|"Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
383476|NCT01266681|Drug|Dronedarone|"Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.~Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.~Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires~Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires~Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires~Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires~Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
383477|NCT01266655|Drug|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
383478|NCT01266655|Drug|Placebo|Placebo
383479|NCT01266642|Radiation|Hypofractionated Whole Breast Irradiation|"42.56 Gy in 16 fractions delivered to the whole breast on consecutive treatment days.~Boost of 10 Gy in 4 fractions or 12.5 Gy in 5 fractions delivered on consecutive days beginning on treatment day following completion of whole breast irradiation."
383480|NCT01266642|Radiation|Conventionally Fractionated Whole Breast Irradiation|"50 Gy in 25 fractions delivered to whole breast on consecutive treatment days.~Boost of 10 Gy in 5 fractions or 14 Gy in 7 fractions delivered on consecutive treatment days, beginning on treatment day following completion of whole breast irradiation."
383481|NCT01266616|Biological|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
383482|NCT01266616|Biological|IL-12|Administered at Weeks 0, 4, and 12
383483|NCT01266616|Other|Placebo|Saline injections at Weeks 0, 4, and 12
383484|NCT01266603|Drug|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
383485|NCT01266603|Biological|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
383486|NCT01266590|Drug|LY2216684|Administered orally
383487|NCT01266590|Drug|Digoxin|Administered orally
383488|NCT01266551|Device|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
383489|NCT01266525|Drug|SAR110894|"Pharmaceutical form: Capsule~Route of administration: Oral"
383490|NCT01266525|Drug|placebo (for SAR110894)|"Pharmaceutical form: Capsule~Route of administration: Oral"
383491|NCT01266525|Drug|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
383492|NCT01266512|Drug|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
383493|NCT01266512|Radiation|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
383494|NCT01266512|Drug|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
383495|NCT01266499|Drug|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
383496|NCT01266499|Drug|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
383497|NCT01266499|Drug|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
383498|NCT01266499|Drug|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
383499|NCT01266486|Drug|Metformin|Extended release Metformin 1500mg once daily for 14-21 days
383500|NCT01266473|Other|Physiotherapy|Physiotherapy for Airway Clearance
383501|NCT01266460|Biological|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
383502|NCT01266460|Other|Laboratory Biomarker Analysis|Correlative studies
383503|NCT01266447|Biological|Filgrastim|Given SC
383504|NCT01266447|Other|Laboratory Biomarker Analysis|Correlative studies
383505|NCT01266447|Biological|Pegfilgrastim|Given SC
383506|NCT01266447|Drug|Topotecan Hydrochloride|Given IV
383507|NCT01266447|Drug|Veliparib|Given PO
383508|NCT01266434|Drug|Simvastatin|10 mg once daily for 8 weeks
383509|NCT01266434|Drug|B1-6-12|1 tablet once daily for 8 weeks
383510|NCT01266382|Device|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
383511|NCT01266369|Drug|masitinib|
383512|NCT01266330|Dietary Supplement|Low Dairy|Less than 0.5 standard servings of dairy products per day
383513|NCT01266330|Dietary Supplement|Adequate Dairy|3.5 standard servings of dairy foods per day
383522|NCT01266265|Drug|subcutaneous and intravenous prostacyclin|As prescribed by physician
383525|NCT01266252|Drug|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
383526|NCT01266239|Procedure|kissing balloon inflation|Kissing balloon inflation following the MV stenting
383527|NCT01266239|Device|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
383528|NCT01266226|Device|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
383529|NCT01266226|Device|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
383530|NCT01266213|Drug|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
383531|NCT01266213|Drug|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
383532|NCT01266213|Drug|Goserelin|Goserelin s.c.
383533|NCT01266200|Procedure|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
383534|NCT01266200|Procedure|XIA|Treatment of the fracture with Xia and conventional operation technique
383535|NCT01266187|Procedure|adjuvant surgery + FOLFOX + cetuximab|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
383536|NCT01266187|Procedure|perioperative/Folfox + cetuximab|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery~-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
383537|NCT01266174|Drug|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
383538|NCT01266174|Drug|Placebo|Placebo to match eltoprazine
383539|NCT01266161|Drug|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
383540|NCT01266161|Drug|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
383541|NCT01266148|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
383542|NCT01266148|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
383543|NCT01266148|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
383544|NCT01266148|Drug|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
383545|NCT01266148|Drug|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
383546|NCT01266135|Drug|QAX576|QAX576 10 mg/kg intravenous infusion
383547|NCT01266135|Drug|Placebo|Placebo to QAX576 intravenous infusion
383548|NCT01266122|Behavioral|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
383549|NCT01266109|Behavioral|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
383550|NCT01266109|Other|Usual Services (US)|Typical community-based substance abuse treatment services
383551|NCT01266096|Drug|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
383552|NCT01266083|Biological|WT1 peptide vaccine|Six vaccinations of the WT1 peptide preparation (1.0 ml of emulsion) will be administered on weeks 0, 2, 4, 6, 8, and 10. All vaccinations will be administered subcutaneously with vaccination sites rotated among extremities. Patients who are clinically stable and have not had disease progression, may receive up to 6 more vaccinations administered appropriately every month.
383553|NCT01266070|Drug|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
383554|NCT01266057|Drug|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
383555|NCT01266057|Drug|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
383556|NCT01266057|Drug|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
383557|NCT01266044|Procedure|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
383558|NCT01266044|Procedure|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
383559|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
383560|NCT01266044|Other|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
383561|NCT01266031|Drug|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
383562|NCT01266031|Drug|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
383563|NCT01266018|Drug|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m^2 (36.8 mg/m^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
383564|NCT01266005|Drug|Clevudine|30mg,QD
383565|NCT01266005|Drug|Entecavir|0.5mg QD
383648|NCT01265446|Drug|Lidocaine 8mg + CPC 2mg|one single dose
383566|NCT01265979|Procedure|Whole body diffusion MRI|These studies will be performed on a 3 Tesla (T) MR system. A major advantage of 3T compared to 1.5T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
383567|NCT01265953|Drug|SFN-rich broccoli sprout extract capsules|Four weeks SFN-rich broccoli sprout extract (BSE) capsules: 200µmol of SFN, 2 capsules (1 capsule B.I.D.) daily
383568|NCT01265953|Dietary Supplement|Gelatin capsule containing microcrystalline cellulose.|Four weeks placebo capsules: 2 capsules (1 capsule B.I.D.) daily
383569|NCT01265940|Drug|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.~In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
383570|NCT01265927|Drug|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
383571|NCT01265914|Biological|FP-01.1|Ascending doses of FP-01.1 will be administered
383572|NCT01265914|Biological|placebo|
383573|NCT01265901|Drug|Sunitinib|As per label.
383574|NCT01265901|Biological|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
383575|NCT01265901|Drug|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
383576|NCT01265901|Drug|IMA901|Intradermal vaccinations with IMA901 vaccine.
383577|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
383578|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
383579|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
383580|NCT01265875|Drug|Human Secretin|Dose Escalation
383581|NCT01265862|Procedure|Tracheal intubation through LMA-Fastrach®|Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube
383582|NCT01265862|Procedure|Tracheal intubation through I-gel®|Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
383583|NCT01265849|Biological|LI|LI 400IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 weeks administered in combination with cyclophosphamide indomethacin and zinc (CIZ) as adjuvant therapy prior to SOC, (surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100mg/m^2 intravenously) to determine if LI plus CIZ affects the overall survival of subjects at median 3 years.
383584|NCT01265849|Drug|Cyclophosphamide|Cyclophoshamidie is administered IV bolus at a dose of 300mg/m^2 three days prior to beginning treatment with LI. Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) or for higher risk subjects (subjects determined at surgery to have positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m2 intravenously 1x weekly for 3 weeks on day 1 of weeks 1, 4 and 7 of radiotherapy
383585|NCT01265849|Drug|Indomethacin|One 25mg capsule of indomethacin is administered orally beginning on day one of LI treatment daily until the day before surgery. for LI is administered 400 IU (2.0mL) 1/2 peritumorally and 1/2 perilymphatically 5 times a week for three weeks prior to SOC to determine the contribution of CIZ on LI activity.
383586|NCT01265849|Dietary Supplement|Zinc|One capsule daily beginning on day one of treatment with LI until one day before surgery
383587|NCT01265849|Procedure|Surgery|Surgery to remove tumor
383588|NCT01265849|Drug|Cisplatin|Cisplatin is administered 100mg/m^2 IV is administered with concurrent chemotherapy (cisplatin 100mg/m2 intravenously 1x weekly for 3 weeks on day 1 of weeks 1, 4 and 7 of radiotherapy i
383589|NCT01265849|Radiation|Radiotherapy|60 to 70Gy in 30 to 35 fractions over 6 to 7 weeks. In subjects determined at surgery to have positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m2 intravenously 1x weekly for 3 weeks on day 1 of weeks 1, 4 and 7 of radiotherapy
383590|NCT01265823|Biological|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
383591|NCT01265810|Other|supersaturated calcium-phosphate|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
383592|NCT01265810|Other|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
383593|NCT01265797|Device|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
383594|NCT01265797|Device|Sham Device|participant wears sham device for 20 minutes daily for 28 days
383595|NCT01265784|Drug|TP-434|
383596|NCT01265784|Drug|Ertapenem|
383597|NCT01265784|Drug|Placebo|Administered IV to maintain the blind.
383598|NCT01265771|Device|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
383599|NCT01265771|Device|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
383600|NCT01265758|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
383601|NCT01265745|Drug|Normal Saline for Injection|Equivalent amounts to subjects weight, once over 120 minutes
383647|NCT01265459|Device|Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml|Durolane is an intraarticular hyaluronic acid preparation
383602|NCT01265745|Biological|MDX1303|a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
383603|NCT01265732|Drug|PF-04191834|single dose, 100mg, dispersion
383604|NCT01265732|Drug|PF-04191834|single dose, 100mg, suspension
383605|NCT01265732|Drug|PF-04191834|single dose, 300mg, suspension
383606|NCT01265719|Other|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
383607|NCT01265719|Other|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
383608|NCT01265680|Drug|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
383609|NCT01265667|Drug|CF101|orally q12h
383610|NCT01265667|Drug|Placebo|orally q12h
383611|NCT01265641|Drug|AZD1981, 2000mg|Single oral dose, tablets
383612|NCT01265641|Drug|AZD1981, 200mg|Single oral dose, tablets
383613|NCT01265641|Drug|Moxifloxacin, 400mg|Single oral dose, capsule
383614|NCT01265641|Drug|Placebo|Single oral dose, tablets
383615|NCT01265628|Procedure|perimetry|automated static perimetry with adapted GATE strategy
383616|NCT01265615|Drug|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
383617|NCT01265615|Drug|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
383618|NCT01265615|Drug|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
383619|NCT01265615|Dietary Supplement|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
383620|NCT01265602|Drug|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
383621|NCT01265602|Drug|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
383622|NCT01265602|Drug|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
383623|NCT01265589|Drug|surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
383624|NCT01265589|Drug|surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
383625|NCT01265576|Drug|Sorafenib|Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
383626|NCT01265576|Drug|VT-122 (propranolol plus etodolac)|Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
383627|NCT01265576|Drug|Placebo|Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
383628|NCT01265563|Drug|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
383629|NCT01265563|Drug|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
383630|NCT01265563|Drug|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
383631|NCT01265563|Drug|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
383632|NCT01265563|Drug|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
383633|NCT01265550|Device|Nissen fundoplication|laparoscopic antireflux surgery
383634|NCT01265550|Drug|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.~The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
383635|NCT01265550|Drug|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
383636|NCT01265537|Drug|Tacrolimus|"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"
383637|NCT01265537|Drug|Tacrolimus|"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."
383638|NCT01265524|Drug|CLP|Oral administration
383639|NCT01265524|Drug|Placebo|Oral administration
383640|NCT01265511|Drug|Placebo|Oral tablets given bid for 28 days
383641|NCT01265511|Drug|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
383642|NCT01265511|Drug|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
383643|NCT01265511|Drug|Copegus|tablets given bid for up to 48 weeks
383644|NCT01265498|Drug|obeticholic acid|25 mg daily for 72 weeks
383645|NCT01265498|Drug|placebo|placebo capsule, 25 mg daily for 72 weeks
383649|NCT01265446|Drug|Lidocaine 1mg + CPC 2mg|one single dose
383650|NCT01265433|Biological|WT-1-vaccine Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
383651|NCT01265433|Biological|Montanide adjuvant + GM-CSF (This arm is closed)|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
383652|NCT01265420|Biological|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
383653|NCT01265394|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
383654|NCT01265368|Biological|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
383655|NCT01265355|Dietary Supplement|Anti-rotavirus protein|11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
383656|NCT01265355|Dietary Supplement|Maltodextrin|Maltodextrin 1 gm daily
383657|NCT01265342|Drug|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
383658|NCT01265342|Drug|Placebo|Placebo nebulised suspension twice a day for 10 days
383659|NCT01265329|Other|Negative selection|Sperm selection to continue the treatment with healthy sperm
383660|NCT01265316|Device|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
383661|NCT01265303|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
383662|NCT01265290|Device|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
383663|NCT01265290|Device|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
383664|NCT01265264|Drug|ulodesine|Oral dose administered daily for 84 days.
383665|NCT01265264|Drug|Placebo|Oral dose administered daily for 84 days.
383666|NCT01265251|Device|Computerized neuropsychological test|Computerized neuropsychological test battery.
383667|NCT01265251|Other|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
383668|NCT01265199|Drug|AT-406 in combination with daunorubicin and cytarabine|Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.
383669|NCT01265186|Device|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
383670|NCT01265186|Device|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
383671|NCT01265173|Drug|Cefotaxime|3 g
383672|NCT01265173|Drug|Ceftriaxone|2 g
383673|NCT01265173|Drug|Ciprofloxacin|400 mg
383674|NCT01265147|Drug|Cisplatin|40mg/m2/w
383675|NCT01265147|Drug|Nedaplatin|40mg/m2/w
383676|NCT01265121|Device|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
383677|NCT01265121|Other|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
383678|NCT01265108|Drug|Iron sucrose.|Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
383679|NCT01265108|Drug|Normal saline|Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
383680|NCT01265069|Drug|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
383681|NCT01265069|Drug|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
383682|NCT01265056|Drug|Gabapentin|"On Study day 1: 1200mg (single dose).~Study day 2,3: 300mg TID, 900mg daily.~Study day 4-7: 600mg TID 1800mg* daily.~Study day 8-11: 800mg TID 2400mg* daily [Optional increase to 2400 if pain scores are still 4 on NRS]~Study day 11: 1200mg TID 3600mg* daily [Optional increase to 3600 if pain scores are still >4 on NRS]~* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
383683|NCT01265056|Drug|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
384457|NCT01259297|Drug|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
383684|NCT01265043|Other|Oral hygiene intervention|Oral health promotion intervention
383685|NCT01265030|Drug|Sirolimus|"Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)~Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
383686|NCT01265017|Drug|Estradiol, medroxyprogesterone, hydrocortisone, GH|"Estradiol 1mg every 8 hours administered orally~Medroxyprogesterone 2.5 mg every 24 hours administered orally~Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally~Growth hormone 2 mg once a day administered by subcutaneous injection,"
383687|NCT01265017|Drug|Matching placebo|matching placebo
383688|NCT01265004|Procedure|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
383689|NCT01265004|Procedure|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
383690|NCT01265004|Procedure|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
383691|NCT01264991|Procedure|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
383692|NCT01264991|Procedure|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
383693|NCT01264978|Device|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.~Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.~Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).~Coils are cooled down to 5ºC before sessions."
383694|NCT01264965|Drug|long acting oxycodone|10mg twice daily
383695|NCT01264965|Drug|extra strength acetaminophen|1,000 mg twice daily
383696|NCT01264952|Procedure|Electrochemotherapy|"Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.~The maximum duration of procedure is 90 minutes."
383697|NCT01264939|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
383698|NCT01264939|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
383699|NCT01264939|Drug|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
383700|NCT01264939|Drug|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
383701|NCT01264913|Behavioral|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
383702|NCT01264900|Behavioral|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
383703|NCT01264887|Drug|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
383704|NCT01264874|Drug|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
383705|NCT01264874|Other|placebo|For 3 years IU every 50 days
383706|NCT01264861|Drug|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.~Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
383707|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
383708|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
383709|NCT01264835|Device|Slotted Anoscope|SA411
383741|NCT01264575|Drug|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
384418|NCT01259570|Dietary Supplement|Group 1|Skimmilk enriched with VD encapsulated in CM
383710|NCT01264822|Drug|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.~The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.~If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
383711|NCT01264809|Behavioral|Specific consultation for physical activity counseling|Specific consultation
383712|NCT01264809|Behavioral|Consultation for physical activity counseling|Specific consultation
383713|NCT01264796|Behavioral|culturally tailored diabetes education|lifestyle modification group education
383714|NCT01264783|Drug|RNS60|RNS60 for intravenous administration
383715|NCT01264783|Drug|Placebo|0.9% normal saline for injection
383716|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
383717|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
383718|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
383719|NCT01264770|Drug|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
383720|NCT01264770|Drug|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
383721|NCT01264757|Behavioral|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
383722|NCT01264757|Behavioral|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
383723|NCT01264731|Biological|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
383724|NCT01264731|Drug|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
383725|NCT01264718|Behavioral|Parent Mentors|After random assignment to the Parent Mentor group, minority low-income parents of Medicaid/CHIP eligible children met with Parent Mentors to receive instruction and help on completing, submitting applications for, and maintaining Medicaid/CHIP coverage for their child.
383726|NCT01264705|Drug|bavituximab and sorafenib|Bavituximab:0.3,1.0,and 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
383727|NCT01264692|Drug|ACT-280778|10 mg once daily for 28 ± 2 days
383728|NCT01264692|Drug|Placebo|Placebo oral capsules matching ACT-280778
383729|NCT01264692|Drug|Amlodipine|10 mg once daily for 28 ± 2 days
383730|NCT01264679|Drug|Ferumoxytol|IV Ferumoxytol
383731|NCT01264666|Dietary Supplement|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
383732|NCT01264666|Dietary Supplement|Chinese Meijiao liquor|
383733|NCT01264666|Dietary Supplement|Water control|
383734|NCT01264653|Drug|adrenalin|adrenalin 0.01%
383735|NCT01264640|Drug|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
383736|NCT01264627|Behavioral|Mindful Breathing (MB) Intervention|"The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor."
383737|NCT01264627|Behavioral|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
383738|NCT01264614|Behavioral|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
383739|NCT01264601|Biological|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
383740|NCT01264588|Other|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
383742|NCT01264575|Drug|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
383743|NCT01264575|Drug|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
383744|NCT01264575|Drug|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
383745|NCT01264575|Drug|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
383746|NCT01264575|Drug|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
383747|NCT01264575|Drug|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
383748|NCT01264575|Drug|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
383749|NCT01264575|Drug|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
383750|NCT01264575|Drug|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
383751|NCT01264575|Drug|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
383752|NCT01264575|Drug|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
383753|NCT01264549|Device|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
383754|NCT01264536|Dietary Supplement|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
383755|NCT01264536|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
383756|NCT01264523|Other|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
383757|NCT01264510|Other|audiological test battery|routine audiological measurements.
383758|NCT01264497|Drug|TH9507|1 and 2 mg, sc daily for 12 weeks
383759|NCT01264484|Device|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
383760|NCT01264471|Procedure|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
383761|NCT01264471|Procedure|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
383762|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
383763|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
383764|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 0
383765|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
383766|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
383767|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 4
383768|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
383769|NCT01264445|Biological|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
383770|NCT01264432|Other|Laboratory Biomarker Analysis|Correlative studies
383771|NCT01264432|Other|Quality-of-Life Assessment|Ancillary studies
383772|NCT01264432|Radiation|Radiation Therapy|Undergo LDFWAR
383773|NCT01264432|Drug|Veliparib|Given PO
383774|NCT01264419|Device|Silk Road Embolic Protection System|System that delivers a carotid artery stent, via transcervical access using reverse flow cerebral protection, as treatment for high-grade extracranial carotid artery disease
383775|NCT01264393|Behavioral|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
383776|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
383777|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
383778|NCT01264380|Drug|RO5185426|Single oral dose, fasted
383779|NCT01264380|Drug|RO5185426|Single oral dose, with high fat meal
383780|NCT01264380|Drug|RO5185426|Continuous administration, orally twice daily
383781|NCT01264367|Drug|Clevudine|30mg,QD
383782|NCT01264367|Drug|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
383783|NCT01264354|Drug|Clevudine 30mg|Clevudine 30mg
383784|NCT01264354|Drug|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
383785|NCT01264354|Drug|Clevudine 20mg|Clevudine 20mg
383786|NCT01264341|Drug|Bevacizumab|Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
383787|NCT01264341|Drug|Temsirolimus|Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
383788|NCT01264328|Drug|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
383789|NCT01264315|Drug|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:~absolute neutrophil count >1x109/L without growth factors~platelet count >75x109/L without transfusion support~calculated/measured creatinine clearance: ≥20mL/minute~total bilirubin <2 x the upper limit of normal~AST (SGOT) and ALT (SGPT) <2.5 x upper limit of normal~<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD~Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
383790|NCT01264302|Drug|Finasteride|Finasteride Tablets 5 mg
383791|NCT01264289|Drug|Finasteride|Finasteride Tablets 5 mg
383792|NCT01264250|Drug|AZD2927|Single dose of AZD2927
383793|NCT01264250|Drug|Placebo|Single dose of placebo
383794|NCT01264237|Drug|Etoricoxib|90mg Tablet QD at 10:00a.m.
383795|NCT01264237|Drug|Placebo|One tablet QD at 10:00a.m.
383796|NCT01264224|Drug|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
383797|NCT01264211|Drug|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
383798|NCT01264211|Drug|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
383799|NCT01264198|Behavioral|Resistance Training|Supervised Resistance Training
383800|NCT01264172|Procedure|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
383801|NCT01264172|Procedure|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
383802|NCT01264172|Procedure|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
383803|NCT01264159|Device|Lung impedence-guided therapy|
383804|NCT01264159|Other|Usual treatment of patients with developing acute heart failure|
383805|NCT01264146|Procedure|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
383806|NCT01264146|Procedure|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
383807|NCT01264133|Drug|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
383808|NCT01264120|Behavioral|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
383809|NCT01264094|Drug|Clevudine|clevudine 30 mg qd
383810|NCT01264081|Drug|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
383811|NCT01264068|Drug|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
383812|NCT01264042|Dietary Supplement|Ferrous Sulfate|60 mg with 200 mL water, single administration
383813|NCT01264029|Behavioral|Mindful Tai Chi Intervention|
383814|NCT01264029|Behavioral|Mindfulness Meditation|
383815|NCT01264029|Behavioral|Mall Walking|
383816|NCT01264029|Behavioral|Weekly Discussion|
383817|NCT01264016|Device|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
383818|NCT01264003|Drug|sefazolin|In prophylaxis
383819|NCT01263990|Device|NexFin|noninvasive finger cuff system
383820|NCT01263977|Device|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
383821|NCT01263964|Procedure|coronary angiogram|coronary angiogram
383822|NCT01263951|Drug|Everolimus|One 5 mg. tablet daily.
383823|NCT01263951|Drug|Sorafenib|200 mg. twice daily.
383824|NCT01263938|Drug|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.~For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
383825|NCT01263925|Drug|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
383826|NCT01263925|Drug|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
383827|NCT01263925|Drug|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.~4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
383828|NCT01263925|Drug|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.~4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
383829|NCT01263912|Dietary Supplement|LCPUFA Supplement|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
383830|NCT01263912|Dietary Supplement|Placebo|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
383831|NCT01263899|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
383832|NCT01263886|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:solution~Route of administration: intravenous"
383833|NCT01263886|Drug|placebo|"Pharmaceutical form:solution~Route of administration: intravenous"
383834|NCT01263873|Device|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
383835|NCT01263873|Device|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
383836|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
383837|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
383838|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
383839|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
383840|NCT01263847|Dietary Supplement|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
383841|NCT01263834|Drug|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
383842|NCT01263834|Drug|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
383843|NCT01263821|Procedure|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
383844|NCT01263821|Procedure|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
383845|NCT01263821|Procedure|Functional magnetic resonance imaging|Undergo functional MRI
383846|NCT01263821|Procedure|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
383847|NCT01263821|Procedure|Therapeutic conventional surgery|Undergo maximal surgical resection
383848|NCT01263821|Procedure|Quality-of-life assessment|Ancillary studies
383849|NCT01263821|Procedure|Radiation therapy treatment planning/simulation|Undergo IMRT planning
383850|NCT01263821|Procedure|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
383851|NCT01263821|Other|Questionnaire administration|Ancillary studies
383852|NCT01263808|Drug|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
383853|NCT01263808|Drug|Indacaterol 300 µg|QD via SDDPI
383854|NCT01263808|Drug|Indacaterol 600 µg|QD via SDDPI
383855|NCT01263808|Drug|Placebo|QD via SDDPI
383856|NCT01263808|Drug|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
383857|NCT01263782|Drug|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
383858|NCT01263782|Drug|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
383859|NCT01263782|Drug|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
383860|NCT01263782|Drug|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
383861|NCT01263769|Drug|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
383862|NCT01263743|Behavioral|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
383863|NCT01263743|Behavioral|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
383864|NCT01263730|Behavioral|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
383865|NCT01263717|Drug|tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
383866|NCT01263717|Drug|placebo|Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
383867|NCT01263704|Drug|Cyclophosphamide|150 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1-3 of each 28-day cycle for 6 cycles
383868|NCT01263704|Drug|Fludarabine|12.5 mg/m^2 IV on Days 1-3 of every 28-day cycle for 6 cycles
383869|NCT01263704|Drug|Rituximab|375 mg/m^2 IV Day 0 of Cycle 1, 500 mg/m^2 IV Day 1 of Cycles 2-6. Each cycle was 28 days.
383870|NCT01263691|Biological|BioThrax|BioThrax
383871|NCT01263691|Biological|AV7909 Formulation 1|AV7909 Formulation 1
383872|NCT01263691|Biological|AV7909 Formulation 2|AV7909 Formulation 2
383873|NCT01263691|Biological|AV7909 Formulation 3|AV7909 Formulation 3
383874|NCT01263691|Biological|AV7909 Formulation 4|AV7909 Formulation 4
383875|NCT01263691|Drug|Control|Saline control
383876|NCT01263678|Behavioral|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
383877|NCT01263678|Other|Usual Care|Patient views DA and completes post DA survey.
383878|NCT01263665|Device|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
383879|NCT01263652|Drug|Diclofenac hydroxyethylpyrrolidine|IM/PO
383880|NCT01263652|Drug|orphenadrine|IM/PO orphenadrine
383881|NCT01263652|Drug|Tramadol|IM/PO tramadol
383882|NCT01263652|Drug|Dipyrone|PO/IM Dipyrone
383928|NCT01263249|Procedure|Catheter Anterior to the Femoral Nerve|Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
383883|NCT01263639|Other|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
383884|NCT01263639|Other|Standard of care - No biosketch card|Standard of care
383885|NCT01263613|Procedure|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
383886|NCT01263574|Drug|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
383887|NCT01263561|Procedure|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
383888|NCT01263561|Procedure|trabeculectomy|trabeculectomy filtering surgery
383889|NCT01263548|Drug|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
383890|NCT01263535|Device|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
383891|NCT01263522|Other|different training programs|two different endurance programs and one strength endurance program
383892|NCT01263522|Other|control condition|unchanged lifestyle
383893|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
383894|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
383895|NCT01263496|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
383896|NCT01263496|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
383897|NCT01263496|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
383898|NCT01263496|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
383899|NCT01263496|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
383900|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
383901|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
383902|NCT01263483|Drug|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
383903|NCT01263470|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
383904|NCT01263470|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
383905|NCT01263470|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
383906|NCT01263470|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
383907|NCT01263470|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
383908|NCT01263470|Drug|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
383909|NCT01263457|Device|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
383910|NCT01263444|Drug|Brinzolamide 1% / timolol 0.5% Fixed Combination|
383911|NCT01263444|Drug|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
383912|NCT01263431|Procedure|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
383913|NCT01263431|Procedure|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
383914|NCT01263418|Drug|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
383915|NCT01263392|Device|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria & leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
383916|NCT01263379|Biological|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
383917|NCT01263366|Drug|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
383918|NCT01263353|Drug|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
383919|NCT01263353|Drug|Everolimus followed by Pasireotide LAR + Everolimus|
383920|NCT01263327|Biological|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
383921|NCT01263314|Drug|MK-8266|Oral capsules, 0.1 mg potency
383922|NCT01263314|Drug|Placebo|Oral placebo capsules to match MK-8266 capsules
383923|NCT01263301|Device|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
383924|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
383925|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
383926|NCT01263288|Dietary Supplement|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
383927|NCT01263275|Device|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
384070|NCT01262378|Procedure|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
383929|NCT01263249|Procedure|Catheter Posterior to the Femoral Nerve|Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
383930|NCT01263236|Drug|LY2940094|Administered orally
383931|NCT01263236|Drug|Placebo|Administered orally
383932|NCT01263223|Drug|LY2216684|Administered orally
383933|NCT01263223|Drug|Placebo|Administered orally
383934|NCT01263210|Biological|Prevenar|
383935|NCT01263197|Drug|LY2216684|administered orally
383936|NCT01263197|Drug|albuterol|administered orally
383937|NCT01263197|Drug|propranolol|administered orally
383938|NCT01263197|Drug|placebo for LY2216684|administered orally
383939|NCT01263197|Drug|placebo for albuterol|administered orally
383940|NCT01263197|Drug|placebo for propranolol|administered orally
383941|NCT01263171|Drug|Leucovorin|
383942|NCT01263171|Drug|fluorouracil|
383943|NCT01263171|Drug|leucovorin calcium|
383944|NCT01263171|Drug|oxaliplatin|
383945|NCT01263171|Procedure|adjuvant therapy|
383946|NCT01263171|Procedure|neoadjuvant therapy|
383947|NCT01263171|Procedure|therapeutic conventional surgery|
383948|NCT01263171|Radiation|radiation therapy|
383949|NCT01263158|Other|Expectancy of standard oxytocin treatment|
383950|NCT01263145|Drug|Akt Inhibitor MK2206|Given PO
383951|NCT01263145|Other|Laboratory Biomarker Analysis|Correlative studies
383952|NCT01263145|Drug|Paclitaxel|Given IV
383953|NCT01263145|Other|Pharmacological Study|Correlative studies
383954|NCT01263132|Drug|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
383955|NCT01263132|Drug|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
383956|NCT01263119|Drug|Warfarin|10-mg warfarin oral dose
383957|NCT01263119|Drug|LY2216684|18-mg LY2216684 oral dose
383958|NCT01263106|Drug|LY2216684|18-mg LY2216684 oral dose
383959|NCT01263106|Drug|Theophylline|200-mg theophylline oral dose
383960|NCT01263093|Drug|Clopidogrel|
383961|NCT01263093|Drug|LY2216684|
383962|NCT01263080|Drug|mirtazapine|mirtazapine 30mg QD
383963|NCT01263080|Drug|folic acid placebo|folic acid placebo 1 tablet QD
383964|NCT01263080|Drug|mirtazapine placebo|mirtazapine placebo 1 tablet QD
383965|NCT01263080|Drug|folic acid|folic acid 0.4mg QD
383966|NCT01263067|Behavioral|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
383967|NCT01263067|Behavioral|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
383968|NCT01263054|Device|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
383969|NCT01263054|Other|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
383970|NCT01263041|Drug|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
383971|NCT01263041|Drug|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
383972|NCT01263028|Drug|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
383973|NCT01263015|Drug|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
383974|NCT01263015|Drug|Atripla|Atripla once daily on an empty stomach
383975|NCT01263015|Drug|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
383976|NCT01263015|Drug|Abacavir/Lamivudine Placebo|matching placebo taken once daily
383977|NCT01263015|Drug|Dolutegravir placebo|matching placebo taken once daily
383978|NCT01263015|Drug|Atripla placebo|matching placebo taken once daily on an empty stomach
383979|NCT01263002|Drug|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd~Assess the complete virological response(HBV DNA < 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd~Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd~During medication of Clevudine, virological breakthrough : add adefovir 10mg qd~During treatment period, composite virological response : stop the medication and F/U for 2 years~Recurrence after stopping treatment(HBV DNA > 2,000IU/ml) retreat medication at composite virological response.~complete virological response: HBV DNA < 60 IU/ml~virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
383980|NCT01262989|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
383981|NCT01262989|Drug|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
383982|NCT01262976|Biological|GSK's investigational vaccine 692342|Intramuscular, 2 doses
383983|NCT01262976|Biological|Physiological saline|Intramuscular, 2 doses
383984|NCT01262963|Drug|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
383985|NCT01262950|Other|portable motion detector|
384223|NCT01261078|Drug|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
383986|NCT01262937|Device|Confocal Imaging|Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
383987|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
383988|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
383989|NCT01262924|Biological|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
383990|NCT01262911|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
383991|NCT01262911|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
383992|NCT01262898|Drug|GSK962040 (5 mg tablet)|5 mg tablet
383993|NCT01262898|Drug|GSK962040 (25 mg tablet)|25 mg tablet
383994|NCT01262898|Drug|GSK962040 (125 mg tablet)|125 mg tablet
383995|NCT01262898|Drug|Placebo|matching placebo tablet
383996|NCT01262885|Drug|GSK2251052|500 mg tablet, dose levels detailed in Arm description
383997|NCT01262885|Drug|Placebo|matching placebo tablet
383998|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
383999|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
384000|NCT01262872|Biological|Synflorix™|Intramuscular injection
384001|NCT01262872|Biological|Prevnar13™|Intramuscular injection
384002|NCT01262872|Biological|Tritanrix™-HepB/Hib|Intramuscular injection
384003|NCT01262872|Biological|Polio Sabin™|Orally
384004|NCT01262872|Biological|M-Vac™|Intramuscular injection
384005|NCT01262872|Biological|Stamaril™|Intramuscular injection
384006|NCT01262859|Drug|bevacizumab|Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
384007|NCT01262846|Biological|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
384008|NCT01262846|Biological|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
384009|NCT01262820|Drug|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
384010|NCT01262807|Other|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
384011|NCT01262794|Biological|CDP6038|100 mg/mL solution for injection, single dose
384012|NCT01262794|Biological|Placebo|0.9% sodium chloride for injection Single-dose
384013|NCT01262768|Behavioral|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
384014|NCT01262755|Behavioral|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
384015|NCT01262742|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
384016|NCT01262742|Drug|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
384017|NCT01262742|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
384018|NCT01262742|Drug|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
384019|NCT01262742|Drug|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
384020|NCT01262729|Procedure|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
384021|NCT01262729|Drug|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
384022|NCT01262703|Device|ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
384023|NCT01262690|Drug|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
384024|NCT01262690|Drug|PF-05230901|Single dose SC
384025|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
384026|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
384027|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
384028|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
384029|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
384030|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
384031|NCT01262677|Drug|placebo|matched to the active drug
384032|NCT01262664|Drug|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
384033|NCT01262651|Drug|Nabiximols|
384034|NCT01262651|Drug|Placebo (GA-0034)|
384035|NCT01262638|Drug|ETC-1002|ETC-1002 daily for 12 weeks
384036|NCT01262638|Drug|Placebo|Placebo daily for 12 weeks
384037|NCT01262625|Device|CCTA|Complete diagnostic CCTA per protocol specifications.
384456|NCT01259297|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
384038|NCT01262625|Device|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
384039|NCT01262612|Drug|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
384040|NCT01262612|Drug|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
384041|NCT01262599|Device|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
384042|NCT01262599|Device|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
384043|NCT01262586|Drug|Vildagliptin|
384044|NCT01262586|Drug|Glimepiride|
384045|NCT01262573|Procedure|Closure of vaginal cuff|Closure of the vaginal cuff
384046|NCT01262560|Drug|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
384047|NCT01262560|Drug|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
384048|NCT01262560|Drug|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
384049|NCT01262547|Device|Dermabrasion-Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
384050|NCT01262547|Procedure|Dermabrasion|Only dermabrasion (removal of epidermis) alone will be done at baseline.
384051|NCT01262534|Other|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
384052|NCT01262534|Other|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
384053|NCT01262534|Other|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
384054|NCT01262521|Dietary Supplement|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
384055|NCT01262521|Dietary Supplement|Water|150 ml Chapelle mineral water
384056|NCT01262495|Other|cryopreservation|cryopreservation of testicular tissue
384057|NCT01262482|Drug|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
384058|NCT01262482|Drug|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
384059|NCT01262469|Drug|lapatinib + capecitabine|"For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.~For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles."
384060|NCT01262456|Drug|Desmopressin|
384061|NCT01262456|Drug|Placebo|
384062|NCT01262443|Procedure|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
384063|NCT01262430|Procedure|OtisMed|OtisMed Custom-fit Shapematching Guides
384064|NCT01262430|Procedure|Computer Assisted Surgery (CAS)|Stryker Navigation System
384065|NCT01262417|Procedure|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
384066|NCT01262417|Procedure|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
384067|NCT01262391|Drug|Solifenacin succinate suspension 2.5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 2.5 mg of solifenacin once daily in adults.
384068|NCT01262391|Drug|Solifenacin succinate suspension 5 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses of 5 mg dose of solifenacin once daily in adults.
384069|NCT01262391|Drug|Solifenacin succinate suspension 10 mg|Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent doses 10 mg dose of solifenacin once daily in adults.
384071|NCT01262365|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
384072|NCT01262365|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
384073|NCT01262365|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
384074|NCT01262352|Drug|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
384075|NCT01262352|Drug|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
384076|NCT01262339|Drug|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
384077|NCT01262326|Other|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = <20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
384078|NCT01262313|Behavioral|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
384079|NCT01262300|Biological|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
384080|NCT01262287|Drug|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
384081|NCT01262287|Drug|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
384082|NCT01262274|Drug|Anastrozole|ANA is given 1mg daily for 24 weeks.
384083|NCT01262274|Drug|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
384084|NCT01262261|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
384085|NCT01262235|Drug|TKM-080301|Repeat dose IV infusion.
384086|NCT01262222|Other|endothelial function testing|After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
384087|NCT01262209|Device|portable CCTV|This is a small handheld mini screen intended to improve reading.
384088|NCT01262209|Device|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
384089|NCT01262209|Device|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
384090|NCT01262196|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
384091|NCT01262196|Drug|Saline|Normal saline (0.9%) solution
384092|NCT01262183|Drug|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
384093|NCT01262183|Drug|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
384094|NCT01262170|Dietary Supplement|CigRx Lozenge|lozenge made of dietary supplements
384095|NCT01262170|Other|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
384096|NCT01262157|Device|Extracorporeal Shockwave Therapy Generator (Vascuspec)|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
384097|NCT01262157|Device|Low intensity shock wave therapy|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
384098|NCT01262144|Radiation|Radiotherapy|Radiotherapy for cervical cancer
384099|NCT01262131|Device|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
384100|NCT01262131|Device|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
384101|NCT01262131|Device|placebo therapy|Application of inactive magnetic fields using the Resonator device
384102|NCT01262118|Drug|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
384103|NCT01262105|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
384104|NCT01262092|Drug|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
384105|NCT01262066|Behavioral|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
384106|NCT01262053|Other|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
384224|NCT01261078|Drug|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
384107|NCT01262053|Other|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
384108|NCT01262053|Other|Control|Parallel control with no intervention
384109|NCT01262040|Other|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
384110|NCT01262027|Drug|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
384111|NCT01262014|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
384112|NCT01262001|Drug|FG-3019|Cohort 1 and Cohort 1-EX: 15 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
384113|NCT01262001|Drug|FG-3019|Cohort 2 and Cohort 2-EX: 30 mg/kg by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years).
384114|NCT01261988|Device|VIPER|Comparison of ostomy systems
384115|NCT01261988|Device|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
384116|NCT01261975|Procedure|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
384117|NCT01261975|Procedure|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
384118|NCT01261962|Dietary Supplement|zinc|zinc sulfate, 35 mg twice daily for 4 months
384119|NCT01261962|Other|Placebo|Placebo, One capsule, twice daily for 4 months
384120|NCT01261949|Device|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
384121|NCT01261949|Device|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
384122|NCT01261923|Drug|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
384123|NCT01261910|Behavioral|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
384124|NCT01261897|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
384125|NCT01261897|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
384126|NCT01261884|Behavioral|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
384127|NCT01261884|Behavioral|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
384128|NCT01261858|Device|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
384129|NCT01261832|Drug|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
384130|NCT01261819|Device|cystoscopy|
384131|NCT01261806|Behavioral|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
384132|NCT01261806|Behavioral|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
384133|NCT01261793|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
384134|NCT01261793|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
384135|NCT01261793|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
384136|NCT01261780|Device|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
384137|NCT01261780|Drug|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
384138|NCT01261767|Drug|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
384139|NCT01261767|Drug|placebo|Placebo for subcutaneous (under the skin) injection
384140|NCT01261754|Radiation|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
384141|NCT01261754|Radiation|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
384142|NCT01261741|Drug|Memantine|Each subject will receive memantine 10mg tablets once daily
384143|NCT01261741|Drug|Placebo|Each subject will receive matching placebo tablets once daily
384144|NCT01261728|Drug|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
384145|NCT01261715|Procedure|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
384146|NCT01261702|Drug|Placebo|Normal saline IV
384147|NCT01261702|Drug|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
384148|NCT01261689|Drug|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
384149|NCT01261689|Other|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
384150|NCT01261676|Other|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
384151|NCT01261663|Other|oral nutritional energy and protein enriched supplement (NOS)|
384152|NCT01261650|Device|transcranial direct current stimulation|
384153|NCT01261650|Device|sham treatment|
384154|NCT01261637|Drug|Saline placebo|20ml saline
384155|NCT01261637|Drug|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
384156|NCT01261624|Drug|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
384157|NCT01261611|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
384158|NCT01261611|Biological|Botulinum toxin type A|I.M. injection on day 1 of treatment cycle 1.
384159|NCT01261611|Drug|Placebo|I.M. injection on day 1 of treatment cycle 1.
384160|NCT01261598|Procedure|Positron Emission Tomography|Positron Emission Tomography
384161|NCT01261572|Drug|degarelix|periodic injection
384162|NCT01261559|Device|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
384163|NCT01261546|Drug|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present~Ranitidine 5 mg/kg IV, q.d. for 2 days~Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
384164|NCT01261546|Drug|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.~Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.~Ranitidine 5 mg/kg IV, q.d. for 2 days.~Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
384165|NCT01261533|Device|foldable capsular vitreous body(FCVB)|FCVB with silicone oil inside is tamponaded into the vitreous cavity
384166|NCT01261520|Behavioral|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
384167|NCT01261494|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
384168|NCT01261494|Drug|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
384169|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
384170|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
384171|NCT01261468|Device|Active SCS|SCS IPG activated
384172|NCT01261468|Device|Deactivated|SCS IPG deactivated
384173|NCT01261455|Procedure|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
384174|NCT01261442|Procedure|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
384175|NCT01261429|Drug|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.~The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
384176|NCT01261416|Drug|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
384177|NCT01261403|Biological|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
384178|NCT01261403|Drug|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7~Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
384179|NCT01261390|Behavioral|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
384180|NCT01261390|Device|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
384225|NCT01261078|Drug|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
384226|NCT01261078|Drug|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
384181|NCT01261390|Device|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
384182|NCT01261390|Device|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
384183|NCT01261377|Device|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
384184|NCT01261377|Drug|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
384185|NCT01261377|Device|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
384186|NCT01261364|Behavioral|GeneSightRx|Multi-genetic pharmacogenomic panel
384187|NCT01261364|Behavioral|Treatment as usual|Treatment as usual
384188|NCT01261338|Drug|olestra|non-absorbable dietary fat
384189|NCT01261325|Drug|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
384190|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
384191|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
384192|NCT01261325|Drug|Antiepileptic drugs with market authorization available per country|
384193|NCT01261312|Drug|SGI-110|"SGI-110 subcutaneous injection administered on Days 1-5~SGI-110 subcutaneous injection administered on Days 1-5 and 8-12"
384194|NCT01261312|Drug|SGI-110|"SGI-110 administered weekly on Days 1, 8 and 15~SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18"
384195|NCT01261299|Drug|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
384196|NCT01261286|Drug|verapamil|
384197|NCT01261260|Drug|Uridine|1 gram tablets BID for 7 days
384198|NCT01261247|Drug|panobinostat|Given orally
384199|NCT01261247|Other|laboratory biomarker analysis|Correlative studies
384200|NCT01261247|Genetic|western blotting|Correlative studies
384201|NCT01261247|Genetic|DNA analysis|Correlative studies
384202|NCT01261247|Other|flow cytometry|Correlative studies
384203|NCT01261247|Other|pharmacological study|Correlative studies
384204|NCT01261247|Other|immunohistochemistry staining method|Optional correlative studies
384205|NCT01261234|Drug|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
384206|NCT01261182|Other|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
384207|NCT01261182|Other|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
384208|NCT01261169|Drug|Myfortic|Myfortic in uveitis
384209|NCT01261156|Drug|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
384210|NCT01261156|Drug|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
384211|NCT01261143|Drug|BK-C-0701|tablet, 8 weeks
384212|NCT01261130|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
384213|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
384214|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
384215|NCT01261130|Biological|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
384216|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
384217|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
384218|NCT01261130|Biological|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
384219|NCT01261117|Drug|oral ibuprofen|oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
384220|NCT01261091|Procedure|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
384221|NCT01261091|Procedure|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
384222|NCT01261078|Drug|Placebo|intrathecal 8 mg of bupivacaine only
384227|NCT01261065|Drug|carvedilol|Patients with heart failure and LVEF < 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight > 80 kg.
384228|NCT01261052|Device|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
384229|NCT01261052|Device|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.~The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
384230|NCT01261039|Radiation|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
384231|NCT01261000|Drug|Pegvisomant|Pegvisomant used as indicated
384232|NCT01260987|Drug|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
384233|NCT01260987|Drug|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
384234|NCT01260974|Drug|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
384235|NCT01260961|Dietary Supplement|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
384236|NCT01260961|Dietary Supplement|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
384237|NCT01260948|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
384238|NCT01260948|Drug|Aricept®|10 mg Orally Disintegrating Tablet
384239|NCT01260935|Procedure|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
384240|NCT01260935|Procedure|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
384241|NCT01260922|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
384242|NCT01260922|Drug|Aricept®|10 mg Orally Disintegrating Tablet
384243|NCT01260909|Device|Real-time kV/MV Prostate Imaging|The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
384244|NCT01260896|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
384245|NCT01260896|Drug|Effexor® XR|150 mg Extended-Release Capsule
384246|NCT01260883|Drug|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
384247|NCT01260883|Drug|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
384248|NCT01260883|Drug|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
384249|NCT01260870|Device|Cotavance Paclitaxel Coated Balloon|DEB
384250|NCT01260870|Device|Standard balloon angioplasty|POBA
384251|NCT01260857|Drug|Aldazide|Aldazide 25 mg OD
384252|NCT01260844|Drug|briakinumab|single dose briakinumab and 2 doses of CYP substrates
384253|NCT01260831|Other|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
384254|NCT01260831|Other|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
384255|NCT01260818|Drug|Tranexamic Acid|1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
384256|NCT01260818|Drug|normal saline|100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
384257|NCT01260805|Drug|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
384258|NCT01260805|Drug|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
384259|NCT01260792|Other|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
384260|NCT01260792|Other|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
384416|NCT01259583|Procedure|CO2|CO2 insufflation
384261|NCT01260779|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
384262|NCT01260766|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
384263|NCT01260766|Device|Placebo Patch|same as active patch
384264|NCT01260753|Drug|UR-63325|UR-63325
384265|NCT01260753|Drug|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
384266|NCT01260753|Drug|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
384267|NCT01260727|Biological|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
384268|NCT01260727|Biological|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
384269|NCT01260727|Biological|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
384270|NCT01260727|Biological|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
384271|NCT01260714|Drug|Azacitidine|Given SC
384272|NCT01260714|Drug|Etoposide|Given IV
384273|NCT01260714|Other|Laboratory Biomarker Analysis|Correlative studies
384274|NCT01260714|Drug|Mitoxantrone Hydrochloride|Given IV
384275|NCT01260701|Drug|Akt Inhibitor MK2206|Given PO
384276|NCT01260688|Drug|cediranib maleate|Given orally
384277|NCT01260688|Drug|dasatinib|Given orally
384278|NCT01260675|Drug|Buprenorphine HCl/Naloxone HCl|
384279|NCT01260662|Drug|Propofol|1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
384280|NCT01260662|Drug|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
384281|NCT01260662|Drug|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
384282|NCT01260649|Drug|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
384283|NCT01260649|Other|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
384284|NCT01260649|Procedure|ECT|ECT will be administered as per standard of care
384285|NCT01260649|Drug|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
384286|NCT01260649|Drug|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
384287|NCT01260636|Drug|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
384288|NCT01260636|Drug|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
384289|NCT01260623|Drug|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
384290|NCT01260610|Drug|Tenofovir|300 mg of Tenofovir daily
384291|NCT01260610|Drug|Telbivudine|600 mg of Telbivudine daily
384292|NCT01260610|Drug|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
384293|NCT01260597|Behavioral|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
384294|NCT01260597|Behavioral|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
384295|NCT01260584|Drug|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
384296|NCT01260584|Drug|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
384297|NCT01260571|Drug|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
384298|NCT01260558|Device|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
384299|NCT01260558|Device|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
384300|NCT01260545|Drug|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
384301|NCT01260519|Drug|Heparin|unfractionated heparin 2000 unites
384302|NCT01260506|Drug|VB-111|
384303|NCT01260506|Drug|Bevacizumab|Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
384304|NCT01260493|Other|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
384305|NCT01260480|Other|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of [18F]-ML-10. The dose for each [18F]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
384306|NCT01260467|Drug|memantine|10 milligrams orally twice a day
384307|NCT01260454|Drug|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
384308|NCT01260441|Other|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
384309|NCT01260428|Device|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
384310|NCT01260415|Drug|Panitumumab, Oxaliplatin, 5-FU|"Panitumumab 6 mg / kg, given over 60 minutes~Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~5FU 400 mg / m2, by bolus infusion~5FU 2400 mg / m2, given over 46 hours"
384417|NCT01259583|Procedure|Warm water|warm water irrigation
384311|NCT01260402|Device|Resynchronization using a transeptal approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.~Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire"
384312|NCT01260402|Device|Resynchronization using a coronary sinus approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.~Devices used for procedure : RADI PressureWire, routine catheters chosen by operator"
384313|NCT01260389|Behavioral|control|usual pharmacist care
384314|NCT01260389|Behavioral|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
384315|NCT01260376|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
384316|NCT01260363|Procedure|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
384317|NCT01260363|Procedure|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
384318|NCT01260350|Drug|SOF|Sofosbuvir (SOF) tablets administered orally once daily
384319|NCT01260350|Drug|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
384320|NCT01260350|Drug|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
384321|NCT01260350|Drug|LDV|Ledipasvir (LDV) tablets administered orally once daily
384322|NCT01260350|Drug|GS-9669|GS-9669 tablets administered orally once daily
384323|NCT01260350|Drug|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
384324|NCT01260337|Behavioral|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
384325|NCT01260337|Other|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
384326|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
384327|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
384328|NCT01260311|Drug|Fesoterodine|Any dose of Fesoterodine
384329|NCT01260298|Device|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
384330|NCT01260285|Drug|Vardenafil|10 mg PO once
384331|NCT01260272|Other|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
384332|NCT01260272|Other|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
384333|NCT01260259|Procedure|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
384334|NCT01260259|Procedure|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
384335|NCT01260246|Drug|sitagliptin|pill, 100mg/daily for 6 months
384336|NCT01260246|Drug|placebo|placebo match for 6 months
384337|NCT01260233|Other|Smoking cessation program|"Smoking cessation program includes:~brief smoking cessation counselling by preadmission nurse (less than 5 minutes)~smoking cessation brochures~referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society~free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
384338|NCT01260220|Procedure|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
384339|NCT01260220|Procedure|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
384340|NCT01260207|Other|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
384341|NCT01260194|Drug|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
384342|NCT01260181|Drug|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
384343|NCT01260155|Drug|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
384344|NCT01260155|Drug|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
384345|NCT01260155|Drug|E5501|Treatment C: 40 mg new tablet formulation administered with food
384346|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
384347|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
384348|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
384349|NCT01260129|Drug|Silodosin|Silodosin 8 mg orally, once daily after morning meal
384350|NCT01260129|Drug|Silodosin|Silodosin 4 mg orally, twice daily after morning and evening meal
384351|NCT01260103|Drug|Temozolomide|Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
384352|NCT01260103|Drug|ANP Therapy|Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
384353|NCT01260090|Device|Vagus nerve stimulation;|"Name of the Device:~We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).~FDA Facility Registration Number: 1644487"
384354|NCT01260090|Device|No stimulation|Vagus nerve stimulation
384355|NCT01260064|Procedure|Open appendectomy|The subjects will have traditional open appendectomy procedure.
384356|NCT01260064|Procedure|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
384357|NCT01260064|Procedure|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
384358|NCT01260025|Drug|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
384359|NCT01260012|Dietary Supplement|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
384360|NCT01260012|Other|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
384361|NCT01260012|Dietary Supplement|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
384362|NCT01260012|Dietary Supplement|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
384363|NCT01259999|Dietary Supplement|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
384364|NCT01259986|Procedure|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
384365|NCT01259973|Drug|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
384366|NCT01259973|Drug|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
384367|NCT01259973|Drug|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
384368|NCT01259947|Drug|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
384369|NCT01259934|Drug|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
384370|NCT01259934|Drug|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
384371|NCT01259921|Behavioral|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
384372|NCT01259908|Procedure|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
384373|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
384374|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
384375|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
384376|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
384377|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
384378|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
384379|NCT01259869|Drug|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
384380|NCT01259856|Drug|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
384381|NCT01259856|Drug|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
384382|NCT01259856|Drug|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
384383|NCT01259830|Drug|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
384384|NCT01259830|Drug|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
384385|NCT01259817|Drug|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
384386|NCT01259817|Drug|Aspirin|81 or 100 mg daily.
384387|NCT01259804|Dietary Supplement|Peanut oral immunotherapy|Daily doses of peanut flour
384388|NCT01259791|Drug|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
384389|NCT01259791|Drug|Placebo|Placebo
384390|NCT01259765|Drug|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
384391|NCT01259765|Drug|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
384392|NCT01259752|Device|compression stockings|compression stockings
384393|NCT01259752|Other|standard non compressive stockings|standard non compressive stockings
384394|NCT01259739|Other|Cocoa|dissolved in water twice-daily intervention
384395|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
384396|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
384397|NCT01259726|Other|Placebo|10 mL placebo once daily for 14 days
384398|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 14 days
384399|NCT01259713|Drug|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
384400|NCT01259713|Drug|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
384401|NCT01259700|Behavioral|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
384402|NCT01259700|Behavioral|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
384403|NCT01259687|Device|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
384404|NCT01259674|Device|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
384405|NCT01259674|Other|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
384406|NCT01259661|Other|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
384407|NCT01259648|Drug|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
384408|NCT01259648|Drug|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
384409|NCT01259648|Drug|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
384410|NCT01259635|Device|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
384411|NCT01259622|Drug|saline|intravenous infusion
384412|NCT01259622|Drug|K201|intravenous infusion
384413|NCT01259609|Procedure|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
384414|NCT01259596|Behavioral|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
384415|NCT01259596|Behavioral|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
384419|NCT01259570|Dietary Supplement|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
384420|NCT01259570|Dietary Supplement|group 3|3% fat milk wherein the VD will be in CM
384421|NCT01259570|Dietary Supplement|Group 4|Placebo: un-enriched skimmilk.
384422|NCT01259557|Drug|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
384423|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
384424|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
384425|NCT01259531|Drug|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
384426|NCT01259518|Drug|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
384427|NCT01259518|Drug|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
384428|NCT01259505|Biological|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
384429|NCT01259492|Drug|Placebo|Placebo Comparator: Placebo
384430|NCT01259492|Drug|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
384431|NCT01259492|Drug|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
384432|NCT01259479|Drug|Satraplatin|Orally, once daily for 5 days repeated every 28 days, dose-escalation
384433|NCT01259466|Drug|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
384434|NCT01259453|Biological|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
384435|NCT01259440|Behavioral|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
384436|NCT01259440|Behavioral|Usual Care|Consists of one week telephone call and one month clinic visit
384437|NCT01259427|Behavioral|Ending Self Stigma (ESS)|Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
384438|NCT01259427|Behavioral|Health and Wellness Group|The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
384439|NCT01259414|Other|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
384440|NCT01259414|Other|Solvent with specific gravity equivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
384441|NCT01259401|Behavioral|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
384442|NCT01259401|Behavioral|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
384443|NCT01259388|Drug|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
384444|NCT01259375|Drug|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
384445|NCT01259362|Procedure|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
384446|NCT01259362|Procedure|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
384447|NCT01259349|Procedure|one percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
384448|NCT01259349|Procedure|40 percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
384449|NCT01259336|Drug|Itraconazole|Tablet 200 mg twice daily for 6 months
384450|NCT01259336|Drug|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
384451|NCT01259323|Biological|REGN668|Dose 1: REGN668 or placebo
384452|NCT01259323|Biological|REGN668|Dose 2: REGN668 or placebo
384453|NCT01259323|Biological|REGN668|Dose 3: REGN668 or placebo
384454|NCT01259297|Drug|Aliskiren|Aliskiren 150/300 mg once daily
384455|NCT01259297|Drug|Amlodipine|Amlodipine 5 mg
384458|NCT01259297|Drug|Placebo for Amlodipine|Placebo for Amlodipine
384459|NCT01259297|Drug|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
384460|NCT01259284|Drug|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
384461|NCT01259284|Dietary Supplement|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
384462|NCT01259284|Other|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
384463|NCT01259271|Device|Selective Nerve Stimulation (SNS) stimulator device|Two hours per study visit separated by a minimum of a 20 hour wash out period between stimulations.
384464|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
384465|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
384466|NCT01259245|Other|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
384467|NCT01259245|Other|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
384468|NCT01259219|Drug|Mycobutin|"Indication and Usage:~Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.~Dosage and Directions for use:~Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.~Identification:~Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
384469|NCT01259193|Drug|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
384470|NCT01259180|Procedure|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
384471|NCT01259180|Procedure|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1~2inches away from real acupuncture point
384472|NCT01259141|Drug|Moxifloxacin|0.4 Qd for 7days
384473|NCT01259141|Drug|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
384474|NCT01259128|Drug|SER120 Nasal Spray 500 ng/day|SER120 Level 1
384475|NCT01259128|Drug|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
384476|NCT01259115|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
384477|NCT01259115|Drug|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
384478|NCT01259115|Drug|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
384479|NCT01259102|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
384480|NCT01259089|Drug|erlotinib hydrochloride|Given orally
384481|NCT01259089|Drug|Hsp90 inhibitor AUY922|Given IV
384482|NCT01259089|Other|laboratory biomarker analysis|Correlative studies
384483|NCT01259089|Procedure|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
384484|NCT01259089|Genetic|mutation analysis|Correlative studies
384485|NCT01259089|Other|pharmacological study|Correlative studies
384486|NCT01259076|Procedure|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
384487|NCT01259076|Procedure|digital mammography|Undergo digital mammography at baseline and 1 year later.
384488|NCT01259076|Procedure|conventional surgery|Undergo gastric bypass surgery
384489|NCT01259063|Drug|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
384490|NCT01259050|Drug|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
384491|NCT01259024|Device|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
384492|NCT01259011|Behavioral|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
384493|NCT01258998|Drug|Akt inhibitor MK2206|Given PO
384494|NCT01258998|Other|laboratory biomarker analysis|Correlative studies
384495|NCT01258985|Behavioral|Tai Chi|12 weeks of Tai Chi
384496|NCT01258985|Behavioral|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
384497|NCT01258972|Device|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
384498|NCT01258972|Device|POBA|Balloon angioplasty
384537|NCT01258699|Drug|BK-C-0701 320mg|320mg for 1 day
384538|NCT01258699|Drug|BK-C-0701 480mg|480mg for 1 day
384499|NCT01258959|Procedure|Ultrasound detection of local anesthetics spread|During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
384500|NCT01258933|Drug|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
384501|NCT01258920|Drug|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
384502|NCT01258907|Drug|MLDL1278A|Single intravenous dose
384503|NCT01258907|Drug|MLDL1278A|Repeating intravenous dose
384504|NCT01258907|Drug|placebo|Repeating intravenous dose
384505|NCT01258907|Drug|statin, stable dose|Repeating oral dose
384506|NCT01258868|Drug|Celebrex|400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
384507|NCT01258868|Biological|Tumor cell vaccine|A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
384508|NCT01258855|Biological|Aldesleukin|Given IV
384509|NCT01258855|Other|Laboratory Biomarker Analysis|Correlative studies
384510|NCT01258855|Biological|Ziv-Aflibercept|Given IV
384511|NCT01258842|Dietary Supplement|Bifidobacterium lactis HN019|B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
384512|NCT01258842|Dietary Supplement|Placebo|Placebo sachet, consumed once per day for 12 weeks
384513|NCT01258829|Other|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
384514|NCT01258829|Other|ECHO optimisation|Standard ECHO optimisation method
384515|NCT01258816|Drug|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
384516|NCT01258803|Drug|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
384517|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
384518|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
384519|NCT01258803|Drug|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
384520|NCT01258803|Drug|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
384521|NCT01258803|Drug|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
384522|NCT01258790|Device|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
384523|NCT01258790|Device|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
384524|NCT01258777|Drug|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
384525|NCT01258777|Drug|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
384526|NCT01258764|Drug|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
384527|NCT01258764|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
384528|NCT01258751|Drug|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
384529|NCT01258738|Biological|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
384530|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
384531|NCT01258738|Other|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
384532|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
384533|NCT01258725|Procedure|amnioinfusion procedure|Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
384534|NCT01258712|Drug|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
384535|NCT01258712|Drug|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
384536|NCT01258699|Drug|Thiocacid HR Tab 600mg|600mg for 1 day
384539|NCT01258686|Drug|Silymarin|700mg thrice daily
384540|NCT01258686|Drug|Placebo|Placebo 700mg thrice daily
384541|NCT01258673|Drug|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
384542|NCT01258673|Drug|Fimasartan|Fimasartan 60mg, 120mg
384543|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
384544|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
384545|NCT01258647|Dietary Supplement|caterpillar cereal|A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
384546|NCT01258634|Drug|Dexrazoxane|"Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1"
384547|NCT01258634|Drug|Doxorubicin|"Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0~Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0"
384548|NCT01258634|Drug|Cisplatin|"Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol~Postoperative Chemotherapy for Poor Responders:~Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol"
384549|NCT01258634|Drug|G-CSF|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000~Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000"
384550|NCT01258634|Drug|PEG-filgrastim|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy~Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy"
384551|NCT01258634|Drug|Etoposide|"Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1~Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4"
384552|NCT01258634|Drug|Ifosfamide|"Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4~Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4"
384553|NCT01258634|Drug|Mesna|"Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)~Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)"
384554|NCT01258634|Drug|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is <0.1 uM
384555|NCT01258621|Procedure|Laparoscopy|Laparoscopic distal pancreatectomy
384556|NCT01258608|Drug|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
384557|NCT01258608|Drug|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
384558|NCT01258608|Drug|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
384559|NCT01258595|Biological|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
384560|NCT01258595|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
384561|NCT01258582|Procedure|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
384562|NCT01258582|Procedure|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
384563|NCT01258569|Drug|Entereg|Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
384564|NCT01258569|Drug|Entereg|oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
384565|NCT01258569|Drug|placebo|12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
384566|NCT01258556|Dietary Supplement|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10*9 cfu/ml daily for 30 days.
384567|NCT01258556|Dietary Supplement|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
384872|NCT01256151|Drug|Alprazolam tablet|1 mg single dose of alprazolam conventional tablet
384568|NCT01258543|Other|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
384569|NCT01258530|Drug|over-encapsulated oseltamivir|75 mg once
384570|NCT01258530|Drug|oseltamivir|75 mg once
384571|NCT01258517|Device|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
384572|NCT01258504|Drug|St. Johns Wort|"Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.~Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
384573|NCT01258491|Drug|Nicotinic Acids|
384574|NCT01258478|Other|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
384575|NCT01258478|Other|Usual care|Usual care
384576|NCT01258465|Behavioral|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
384577|NCT01258465|Behavioral|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
384578|NCT01258452|Drug|CHF 5074|Drug is administered to subject in a fasting state
384579|NCT01258452|Drug|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
384580|NCT01258439|Drug|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
384581|NCT01258439|Drug|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
384582|NCT01258413|Procedure|Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
384583|NCT01258413|Procedure|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
384584|NCT01258387|Drug|Glial growth factor 2/ Neuregulin 1β3|
384585|NCT01258387|Other|Placebo|
384586|NCT01258374|Drug|Raltegravir|Raltegravir, 400 mg bid
384587|NCT01258374|Drug|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
384588|NCT01258361|Procedure|echocardiography|Echocardiography is performed for all patients
384589|NCT01258348|Drug|Drug: LY573636-sodium|"Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression."
384590|NCT01258348|Drug|Sunitinib|"37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression."
384591|NCT01258335|Dietary Supplement|Omega 3|Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
384592|NCT01258335|Other|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
384593|NCT01258322|Drug|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
384594|NCT01258309|Drug|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
384595|NCT01258309|Drug|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
384596|NCT01258296|Drug|Fentanyl|25 mcg/hr transdermal patch
384597|NCT01258296|Drug|Inactive patch|placebo patch (no drug)
384598|NCT01258283|Other|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
384599|NCT01258270|Procedure|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
384600|NCT01258270|Procedure|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
384601|NCT01258257|Procedure|Insertion of a lumbar drain|In patients in the LD group, after insertion of the drain CSF is drained slowly and steadily at a rate of approximately 5 ml per hour. This leads to a planned daily CSF drainage of about 120 ml per day via lumbar route. To facilitate accuracy of drainage, regular drainage control every other hour and stopping in case of unwarranted excess drainage is strongly recommended by the principal investigators. In case of neurological decline suspiciously related to the lumbar drainage, the drain is closed immediately and may be gradually restarted after 12 to 24 hours, after performing a CCT scan. The drain is planned to remain in place until the control angiography on day 7 to 10 after the initial hemorrhage.
384602|NCT01258244|Other|Audiovisual Feedback|EMTs will get audiovisual feedback on CPR technique during CPR
384603|NCT01258218|Device|Implantation of an Accent MRI device|Implantation of an Accent MRI device
384604|NCT01258205|Drug|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
384605|NCT01258192|Drug|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
384606|NCT01258179|Other|Analysis of PSP and PAP from venous blood samples|to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
384607|NCT01258166|Procedure|Surgery or immobilization|
384608|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
384609|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
384610|NCT01258153|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
384611|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
384612|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
384613|NCT01258114|Other|SPA treatment (ST)|"Drug: spa treatment soon after randomization :~Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;~nutritional counseling (french nutritional recommendations booklet) ;~caloric restriction and physical training on demand (non mandatory)."
384614|NCT01258114|Other|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
384615|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
384616|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
384617|NCT01258101|Drug|ribavirin|800 mg orally daily
384618|NCT01258101|Drug|ribavirin|400 mg orally daily
384619|NCT01258088|Drug|AN2728 Ointment|5mg/cm2, BID
384620|NCT01258088|Drug|AN2728 Vehicle|5mg/cm2 BID
384621|NCT01258075|Drug|High-dose colesevelam|3.75 grams colesevelam hydrochloride in oral suspension
384622|NCT01258075|Drug|Low-dose colesevelam|0.625 grams colesevelam hydrochloride in oral suspension
384623|NCT01258062|Drug|GelVac™ nasal powder H5N1 influenza vaccine.|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
384624|NCT01258062|Drug|Placebo|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
384625|NCT01258049|Drug|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
384626|NCT01258049|Drug|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
384627|NCT01258036|Radiation|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
384628|NCT01258036|Biological|Sampling|Urine and blood samples
384629|NCT01258036|Radiation|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
384630|NCT01258023|Biological|Fluad 1x|"15 µg antigen/strain:~A/California/07/2009 (H1N1) - like strain~A/Perth/16/2009 (H3N2) - like strain~B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml"
384631|NCT01258010|Drug|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
384632|NCT01258010|Drug|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
384633|NCT01257997|Biological|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).~Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
384634|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
384635|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
384636|NCT01257958|Drug|19 nor vitamin d|
384637|NCT01257945|Behavioral|Aerobic Exercise|
384638|NCT01257945|Behavioral|Flexibility and Function exercise program|
384639|NCT01257945|Behavioral|Home exercise program|
384640|NCT01257932|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
384641|NCT01257919|Drug|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
384642|NCT01257919|Drug|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
384643|NCT01257906|Drug|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
384644|NCT01257906|Drug|ZIANA®|Topical Gel applied in the evening for 84 days
384645|NCT01257906|Drug|Vehicle Control|Topical Gel applied in the evening for 84 days.
384646|NCT01257893|Drug|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
384647|NCT01257893|Drug|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
384648|NCT01257867|Dietary Supplement|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
384649|NCT01257867|Dietary Supplement|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
384650|NCT01257841|Drug|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
384651|NCT01257841|Behavioral|Fasting|Complete fasting, save for water and multivitamin, for four days.
384652|NCT01257828|Drug|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
384653|NCT01257828|Drug|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
384654|NCT01257815|Drug|Ranibizumab|
384655|NCT01257802|Drug|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
384656|NCT01257802|Drug|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
384657|NCT01257789|Procedure|laparoscopic gastric bypass|laparoscopic gastric bypass
384658|NCT01257776|Drug|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
384659|NCT01257763|Device|Transdermal Microchannel Skin System|A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
384660|NCT01257763|Device|Sham device|The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
384661|NCT01257750|Drug|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
384662|NCT01257737|Drug|HPN-100|Participants received individualized doses of HPN-100 orally, three times daily (TID) with meals. The initial dose was the same dose administered at the end of the HPN-100-005SE, HPN-100-007, or HPN-100-012SE studies. Dose adjustments (including frequency adjustments) were permitted as judged clinically appropriate by the investigator based on assessment of ammonia-scavenging needs (e.g., severity of the UCD defect, dietary protein intake, and urinary phenylacetylglutamine [PAGN] excretion). The maximum recommended dose of HPN-100 in participants weighing less than 20 kg was 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and was 11.48 mL/m²/day in heavier subjects (equivalent to 13g/m²/day of NaPBA). The maximum HPN-100 dose recommended per protocol was 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
384663|NCT01257724|Other|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:~an online searchable database of HIV-relevant systematic reviews;~monthly email updates highlighting new reviews;~access to user-friendly summaries produced by us or by others (when available);~links to scientific abstracts;~peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;~an interface for participants to leave comments in the records of systematic reviews in the database;~links to full-text articles (when publicly available); and~access to worksheets that help CBOs find and use research evidence"
384664|NCT01257711|Procedure|Roux-en-Y or Billroth II|Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
384665|NCT01257698|Drug|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
384666|NCT01257672|Drug|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
384667|NCT01257672|Drug|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
384668|NCT01257672|Drug|placebo|placebo
384669|NCT01257659|Procedure|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
384670|NCT01257659|Procedure|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
384671|NCT01257646|Other|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
384672|NCT01257633|Procedure|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
384673|NCT01257620|Dietary Supplement|Probiotic|Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
384674|NCT01257607|Drug|MIM-D3 Ophthalmic Solution|28 Days, BID
384675|NCT01257607|Drug|Placebo Ophthalmic Solution|28 Days, BID
384676|NCT01257594|Drug|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
384677|NCT01257594|Procedure|Cytoreductive Surgery|Standard procedure
384678|NCT01257581|Drug|creatine|creatine monohydrate powder
384679|NCT01257581|Drug|tamoxifen|Tamoxifen citrate capsules
384680|NCT01257568|Device|Rejuvenate Modular Hip|Rejuvenate Modular Hip
384681|NCT01257555|Device|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
384682|NCT01257542|Drug|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
384683|NCT01257542|Drug|Placebo|A single 10 mL dose of matching placebo syrup
384684|NCT01257529|Drug|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
384685|NCT01257529|Drug|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
384686|NCT01257529|Drug|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
384687|NCT01257529|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
384688|NCT01257516|Drug|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
384689|NCT01257516|Drug|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
384690|NCT01257503|Drug|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
384691|NCT01257503|Drug|placebo|liquid made to look like the active homeopathic remedy
385024|NCT01254721|Drug|lithium|300mg tablet, oral
384692|NCT01257490|Behavioral|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
384693|NCT01257464|Drug|Sitagliptin|100mg po one dose
384694|NCT01257464|Drug|Placebo|Sugar pill po one dose
384695|NCT01257451|Drug|Vildagliptin|vildagliptin 50mg bid
384696|NCT01257451|Drug|Placebo|Placebo 50mg bid
384697|NCT01257438|Device|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
384698|NCT01257438|Device|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
384699|NCT01257425|Drug|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.~Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
384700|NCT01257412|Drug|Dapagliflozin|5mg Oral dose od
384701|NCT01257412|Drug|Dapagliflozin|10 mg Oral dose od
384702|NCT01257412|Drug|placebo|5/10 mg Oral dose od
384703|NCT01257399|Drug|Asacol®|400 mg tablets
384704|NCT01257399|Drug|Mesalazine|400mg tablets
384705|NCT01257386|Drug|Asacol®|400mg tablets
384706|NCT01257386|Drug|Mesalazine|400mg tablets
384707|NCT01257373|Device|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
384708|NCT01257360|Drug|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
384709|NCT01257360|Radiation|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
384710|NCT01257347|Behavioral|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (<10 minutes) in the interpretation and use of the report at the time of enrollment.
384711|NCT01257347|Device|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
384712|NCT01257334|Drug|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
384713|NCT01257295|Dietary Supplement|control: no fiber addition|liquid breakfast without addition of fiber
384714|NCT01257295|Dietary Supplement|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
384715|NCT01257295|Dietary Supplement|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
384716|NCT01257295|Dietary Supplement|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
384717|NCT01257295|Dietary Supplement|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
384718|NCT01257295|Dietary Supplement|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
384719|NCT01257269|Other|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
384720|NCT01257243|Drug|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
384721|NCT01257243|Drug|Syrup of guaifenesin|5ml each 4 hours
384722|NCT01257230|Drug|tiotropium Respimat low dose|IMP
384723|NCT01257230|Drug|placebo Respimat|placebo representing comparator
384724|NCT01257230|Drug|tiotropium Respimat high dose|IMP
384725|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
384726|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
384727|NCT01257217|Device|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
384728|NCT01257217|Device|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
384729|NCT01257204|Drug|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
384730|NCT01257204|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
384731|NCT01257204|Drug|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
384732|NCT01257204|Drug|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
384733|NCT01257191|Drug|Carbon Black|source: commercial
384734|NCT01257191|Drug|Diesel Exhaust Particles|source: diesel engine
384735|NCT01257191|Drug|Fine Concentrated Ambient Particles|source: concentrated ambient air
384736|NCT01257191|Drug|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
384737|NCT01257191|Drug|Saline|Saline solution
384738|NCT01257178|Drug|LY2624803|Administered orally
384739|NCT01257165|Drug|Zopiclone|Zopiclone pill 5 or 10 mg, given orally as a single dose.
384740|NCT01257165|Drug|Ethanol|50 mg per 70 kg body weight, given orally as a single dose
384741|NCT01257165|Drug|Placebo pill|Placebo pill identical to zopiclone pill, given orally as a single dose
384742|NCT01257165|Drug|Placebo drink|Placebo drink, given orally as a single dose
384743|NCT01257139|Procedure|Dual-agent therapy or docetaxel alone or best supportive care|"ARM B: (245 patients)~Treatment if the SGS screening test is negative:~non epidermoid tumor:~Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.~epidermoid tumor:~Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management."
384744|NCT01257126|Drug|diclofenac potassium|
384745|NCT01257126|Drug|nimesulide|
384746|NCT01257113|Other|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
384747|NCT01257113|Other|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
384748|NCT01257087|Drug|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
384749|NCT01257074|Drug|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
384750|NCT01257074|Drug|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
384751|NCT01257061|Drug|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
384752|NCT01257061|Drug|Group 2|Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
384753|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram on visit 5 single dose
384754|NCT01257048|Drug|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
384755|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
384756|NCT01257035|Other|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
384757|NCT01257022|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
384758|NCT01257009|Drug|Atorvastatin|6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
384759|NCT01256996|Procedure|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
384760|NCT01256983|Behavioral|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
384761|NCT01256983|Behavioral|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
384762|NCT01256957|Device|HEPA filter|
384763|NCT01256905|Drug|Armodafinil|Armodafinil 150 mg
384764|NCT01256892|Procedure|induction of labour|
384765|NCT01256879|Drug|Drug: cimetidine|cimetidine 200mg total dose (single dose) as either CimTest-A capsules, CimTest-B capsules, sorbitol-free solution, or commercial cimetidine solution
384766|NCT01256866|Drug|Dexmedetomidine|
384767|NCT01256866|Drug|Midazolam|
384768|NCT01256853|Drug|MVA Vaccine|The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
384769|NCT01256814|Behavioral|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
384770|NCT01256801|Biological|cytokine|interleukin 2 2 million unit every week
384771|NCT01256788|Device|Euflexxa|4 injections of 2ml of Euflexxa
384772|NCT01256788|Other|Saline|4 injections of 3 ml of sterile saline
384773|NCT01256775|Drug|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
384774|NCT01256775|Drug|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
384775|NCT01256762|Drug|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
384776|NCT01256762|Drug|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
384777|NCT01256762|Drug|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
384778|NCT01256736|Drug|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
384873|NCT01256151|Drug|Alprazolam sublingual|1 mg single dose of alprazolam sublingual tablet
384779|NCT01256736|Drug|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
384780|NCT01256710|Device|Implantation of the Trifecta Valve|Implantation of the bioprothesis valve, Trifecta Valve
384781|NCT01256697|Dietary Supplement|Alga Dunaliella Bardawil|9-cis Rich Powder
384782|NCT01256697|Dietary Supplement|Alga Dunaliella Bardawill|9-cis Rich Powder
384783|NCT01256697|Other|Sugar pill|Sugar pill
384784|NCT01256684|Drug|Placebo|Placebo vaginal suppository
384785|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
384786|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
384787|NCT01256671|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
384788|NCT01256658|Drug|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
384789|NCT01256645|Other|blood transfusion|application of single units of red blood cell transfusions
384790|NCT01256632|Drug|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
384791|NCT01256619|Drug|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
384792|NCT01256593|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
384793|NCT01256580|Drug|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
384794|NCT01256580|Drug|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
384795|NCT01256567|Biological|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
384796|NCT01256567|Drug|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.
384797|NCT01256554|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
384798|NCT01256554|Behavioral|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
384799|NCT01256541|Drug|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
384800|NCT01256528|Procedure|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
384801|NCT01256515|Behavioral|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
384802|NCT01256515|Behavioral|Health Education Training|8 weeks of group training regarding health education techniques.
384803|NCT01256502|Device|SERI® Surgical Scaffold|Breast reconstruction surgery
384804|NCT01256489|Drug|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
384805|NCT01256476|Drug|pitavastatin|pitavastatin 4 mg once daily (QD)
384806|NCT01256476|Drug|pravastatin|Pravastatin 40 mg once daily (QD)
384807|NCT01256463|Behavioral|HIV prevention intervention|
384808|NCT01256450|Drug|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
384809|NCT01256450|Drug|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
384810|NCT01256437|Drug|Threolone ointment|ointment once daily for 1 month
384811|NCT01256437|Drug|ointment Synthomycine|ointment once daily for 1 month
384812|NCT01256437|Drug|Aqua cream|ointment once daily for 1 month
384813|NCT01256424|Drug|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
384814|NCT01256424|Drug|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
384815|NCT01256424|Drug|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
384816|NCT01256424|Drug|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
384817|NCT01256411|Drug|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
384818|NCT01256411|Drug|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
384819|NCT01256411|Drug|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
384820|NCT01256398|Biological|Alemtuzumab|Given IV
384821|NCT01256398|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
384822|NCT01256398|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
384823|NCT01256398|Drug|Cyclophosphamide|Given IV
384824|NCT01256398|Drug|Cytarabine|Given IV
384825|NCT01256398|Drug|Dasatinib|Given PO
384826|NCT01256398|Drug|Daunorubicin Hydrochloride|Given IV
384827|NCT01256398|Drug|Dexamethasone|Given PO or IV
384828|NCT01256398|Drug|Etoposide Phosphate|Given IV
384829|NCT01256398|Biological|Filgrastim|Given SC
384830|NCT01256398|Drug|Fludarabine Phosphate|Given IV
384831|NCT01256398|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
384832|NCT01256398|Other|Laboratory Biomarker Analysis|Correlative studies
384833|NCT01256398|Drug|Leucovorin Calcium|Given IV or PO
384834|NCT01256398|Drug|Melphalan|Given IV
384835|NCT01256398|Drug|Mercaptopurine|Given PO
384836|NCT01256398|Drug|Methotrexate|Given IT, IV, or PO
384837|NCT01256398|Biological|Pegfilgrastim|Given SC
384838|NCT01256398|Other|Pharmacological Study|Correlative studies
384839|NCT01256398|Drug|Tacrolimus|Given IV or PO
384840|NCT01256398|Drug|Vincristine Sulfate|Given IV
384841|NCT01256385|Biological|Cetuximab|Given IV
384842|NCT01256385|Other|Laboratory Biomarker Analysis|Correlative studies
384843|NCT01256385|Drug|Temsirolimus|Given IV
384844|NCT01256372|Drug|AP214|AP214
384845|NCT01256372|Drug|Placebo|Placebo; intravenous infusion
384846|NCT01256359|Drug|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
384847|NCT01256359|Drug|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
384848|NCT01256346|Device|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
384849|NCT01256320|Other|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
384850|NCT01256320|Other|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
384851|NCT01256307|Other|training and educational program|8 weeks
384852|NCT01256307|Other|educational program|8 weeks
384853|NCT01256294|Drug|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
384854|NCT01256294|Drug|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
384855|NCT01256281|Procedure|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
384856|NCT01256268|Drug|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
384857|NCT01256268|Drug|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
384858|NCT01256268|Drug|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
384859|NCT01256242|Device|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
384860|NCT01256242|Procedure|Standard Suture Repair|standard suture repair
384861|NCT01256229|Device|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
384862|NCT01256229|Device|hearing aids|This is the conventional therapy for deaf children with developmental delays.
384863|NCT01256216|Device|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
384864|NCT01256203|Drug|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
384865|NCT01256203|Procedure|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
384866|NCT01256190|Biological|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
384867|NCT01256190|Device|Gelatin sponge|absorbable gelatin sponge for topical use
384868|NCT01256177|Drug|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
384869|NCT01256177|Drug|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
384870|NCT01256164|Device|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
384871|NCT01256164|Device|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
384874|NCT01256112|Behavioral|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
384875|NCT01256112|Behavioral|Nutrition/Activity Education (NAE)|
384876|NCT01256099|Behavioral|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
384877|NCT01256099|Behavioral|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
384878|NCT01256099|Behavioral|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
384879|NCT01256086|Drug|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
384880|NCT01256086|Drug|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
384881|NCT01256086|Drug|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
384882|NCT01256086|Drug|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
384883|NCT01256073|Drug|IPH2101|IPH2101 fully human anti-KIR monoclonal antibody
384884|NCT01256060|Drug|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
384885|NCT01256047|Dietary Supplement|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
384886|NCT01256034|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
384887|NCT01256021|Drug|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
384888|NCT01256008|Behavioral|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
384889|NCT01256008|Behavioral|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.~Following are major elements:~Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
384890|NCT01255995|Device|Capsular Tension Ring|Capsular Tension Ring
384891|NCT01255969|Other|Exercise|Personalized exercise program
384892|NCT01255956|Device|Rapamycin eluting stent implantation|Rapamycin eluting stent implantation for in-stent restenosis treatment
384893|NCT01255956|Device|Paclitaxel eluting balloon catheter|Paclitaxel eluting balloon catheter for in-stent restenosis treatment
384894|NCT01255943|Behavioral|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
384895|NCT01255904|Drug|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
384896|NCT01255904|Drug|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
384897|NCT01255904|Other|Oral placebo|Oral saline administered
384898|NCT01255904|Other|Intranasal placebo|Intranasal saline administered
384899|NCT01255891|Radiation|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
384900|NCT01255878|Device|occlusal stabilization splint|
384901|NCT01255878|Drug|Gabapentine|100 mg(1 capsule)three times per day for two months
384902|NCT01255852|Drug|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
384903|NCT01255839|Device|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
384904|NCT01255839|Drug|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
384905|NCT01255826|Procedure|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is < 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
384951|NCT01255423|Drug|Placebo|Placebo, 4 times daily
384952|NCT01255410|Biological|10^6 PFU rHMPV-Pa vaccine|Single dose of 10^6 PFU rHMPV-Pa vaccine delivered intranasally
384906|NCT01255826|Procedure|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
384907|NCT01255813|Device|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
384908|NCT01255813|Device|Stimulation (Full)|Stimulation applied above the perception threshold
384909|NCT01255813|Other|Control|No stimulation applied
384910|NCT01255800|Drug|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.~Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
384911|NCT01255787|Drug|Vortioxetine|Vortioxetine tablets
384912|NCT01255787|Drug|Placebo|Vortioxetine placebo-matching tablets
384913|NCT01255774|Drug|ranibizumab|An open-label, study of intravitreally administered ranibizumab
384914|NCT01255761|Biological|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4~200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
384915|NCT01255748|Radiation|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
384916|NCT01255722|Drug|iobitridol|single IV injection
384917|NCT01255722|Drug|iopromide|Single IV injection
384918|NCT01255722|Drug|iomeprol|Single IV injection
384919|NCT01255709|Drug|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
384920|NCT01255709|Drug|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
384921|NCT01255709|Drug|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
384922|NCT01255696|Biological|ALV003|
384923|NCT01255696|Biological|ALV003 placebo|
384924|NCT01255683|Drug|oral corticosteroid taper|This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
384925|NCT01255670|Drug|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
384926|NCT01255657|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
384927|NCT01255644|Drug|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
384928|NCT01255631|Device|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
384929|NCT01255631|Device|Sham PEMF Device|Inactive PEMF device, delivers no PMF
384930|NCT01255618|Device|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
384931|NCT01255592|Drug|AZD5069|Oral dose bid
384932|NCT01255592|Drug|Placebo|Oral dose bid
384933|NCT01255579|Drug|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
384934|NCT01255579|Drug|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
384935|NCT01255553|Radiation|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
384936|NCT01255527|Drug|Bortezomib|Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
384937|NCT01255514|Drug|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
384938|NCT01255501|Drug|NI-0701|
384939|NCT01255501|Drug|Placebo|
384940|NCT01255488|Behavioral|Access to EBN-Search (without full-text manuscripts)|Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
384941|NCT01255475|Drug|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
384942|NCT01255475|Drug|Placebo|Patients will receive placebo
384943|NCT01255462|Biological|LFG316|
384944|NCT01255462|Biological|LFG316|
384945|NCT01255462|Biological|LFG316|
384946|NCT01255462|Biological|LFG316|
384947|NCT01255449|Drug|albuterol|400 mcg by inhalation
384948|NCT01255436|Other|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
384949|NCT01255436|Other|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
384950|NCT01255423|Drug|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
384953|NCT01255410|Biological|10^5 PFU rHMPV-Pa vaccine|Single dose of 10^5 PFU rHMPV-Pa vaccine delivered intranasally
384954|NCT01255410|Biological|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
384955|NCT01255397|Procedure|Male Infertility Protocol|"Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.~Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.~When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.~35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.~If the follicle has collapsed than IUI will be performed~It the total motile sperm count is above 5 million sperm/ml then IUI will be done~If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI~6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
384956|NCT01255371|Drug|Lopinavir|Evaluation of second line antiretroviral regimen including boosted lopinavir
384957|NCT01255371|Drug|Atazanavir|Evaluation of second line antiretroviral regimen including boosted atazanavir
384958|NCT01255358|Drug|Dexamethasone|dexamethasone encapsulated in human erythrocytes. One infusion per month of about 10-15 mg of dexamethasone. The treatment covers 1 month of therapy-
384959|NCT01255345|Other|Chronic pelvic pain|A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
384960|NCT01255306|Other|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~On 7th postoperative day~On 30th postoperative day~On 90th postoperative day~On 180th postoperative day"
384961|NCT01255306|Drug|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
384962|NCT01255293|Procedure|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
384963|NCT01255293|Procedure|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
384964|NCT01255280|Behavioral|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
384965|NCT01255280|Behavioral|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
384966|NCT01255254|Procedure|Gingival scaling|Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
384967|NCT01255228|Other|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
384968|NCT01255215|Drug|Inhaled Nitric Oxide|Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
384969|NCT01255189|Device|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
384970|NCT01255189|Device|invos 5100|near infrared spectroscopy: invos 5100
384971|NCT01255176|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
384972|NCT01255163|Drug|Exendin-4 SC|Exenatide 5 mcg or 10 mcg SC twice daily
384973|NCT01255163|Drug|Placebo SC|Placebo SC twice daily
384974|NCT01255137|Drug|Axitinib|5 mg tab orally twice a day with food every 28 days
384975|NCT01255085|Dietary Supplement|yellow pea protein|Served in a tomato soup
384976|NCT01255085|Dietary Supplement|yellow pea fiber|Served in a tomato soup
384977|NCT01255085|Dietary Supplement|Control Tomato Soup|Served in a tomato soup
384978|NCT01255072|Procedure|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
384979|NCT01255072|Procedure|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
384980|NCT01255046|Drug|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
384981|NCT01255046|Drug|STA-1|300mg/tab, 2 tab/tid for 72 weeks
384982|NCT01255046|Drug|placebo|2 tab/tid for 72 weeks
384983|NCT01255033|Device|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices~Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
384984|NCT01255020|Drug|α-Keto Acid with restricted protein diet|"α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.~Restricted Protein Diet: Diet contain protein 1.0g/kg/d"
384985|NCT01255020|Drug|Placebo plus restricted protein diet|"placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.~Diet contain protein 1.0 g/kg/d."
384986|NCT01255007|Other|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
384987|NCT01254994|Drug|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
384988|NCT01254994|Drug|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
384989|NCT01254981|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
384990|NCT01254955|Biological|H1N1 vaccine Pandemrix|
384991|NCT01254942|Other|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
384992|NCT01254942|Other|Usual Care|
384993|NCT01254929|Device|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
384994|NCT01254929|Device|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
384995|NCT01254903|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
384996|NCT01254890|Drug|Azacitidine|75 mg/m^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
384997|NCT01254890|Drug|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
384998|NCT01254877|Drug|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
384999|NCT01254877|Drug|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
385000|NCT01254877|Drug|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
385001|NCT01254864|Drug|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
385002|NCT01254864|Drug|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
385003|NCT01254864|Drug|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
385004|NCT01254864|Drug|Dasatinib|100 mg by mouth each day of a 28 day cycle.
385005|NCT01254851|Behavioral|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
385006|NCT01254838|Biological|HLA-A02 restricted HIG2|
385007|NCT01254825|Procedure|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
385008|NCT01254825|Procedure|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
385009|NCT01254799|Drug|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
385010|NCT01254799|Drug|Placebo|Placebo capsules twice daily for 5 days
385011|NCT01254786|Procedure|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min."
385012|NCT01254786|Procedure|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.~Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min.~Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
385013|NCT01254773|Drug|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
385014|NCT01254760|Device|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
385015|NCT01254760|Device|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
385016|NCT01254747|Device|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
385017|NCT01254747|Device|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
385018|NCT01254747|Device|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
385019|NCT01254747|Device|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
385020|NCT01254734|Procedure|transoral robotic surgery|Undergo transoral robotic microsurgery
385021|NCT01254734|Other|laboratory biomarker analysis|Correlative studies
385022|NCT01254734|Procedure|quality-of-life assessment|Ancillary studies
385023|NCT01254721|Drug|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
385025|NCT01254708|Drug|Ambisome ®|liposomal amphotericin B
385026|NCT01254708|Drug|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
385027|NCT01254695|Device|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
385028|NCT01254682|Device|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
385029|NCT01254682|Procedure|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
385030|NCT01254669|Behavioral|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
385031|NCT01254656|Drug|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
385032|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
385033|NCT01254656|Drug|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
385034|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
385035|NCT01254656|Drug|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
385036|NCT01254656|Drug|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
385037|NCT01254643|Biological|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
385038|NCT01254630|Biological|V212|V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.
385039|NCT01254630|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
385040|NCT01254617|Biological|Cetuximab|Given IV
385041|NCT01254617|Other|Laboratory Biomarker Analysis|Correlative studies
385042|NCT01254617|Drug|Lenalidomide|Given PO
385043|NCT01254604|Drug|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
385044|NCT01254604|Drug|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
385045|NCT01254591|Other|18F-fluoromisonidazole|
385046|NCT01254591|Other|fluorescence angiography|
385047|NCT01254591|Other|laboratory biomarker analysis|
385048|NCT01254591|Procedure|infrared thermography|
385049|NCT01254591|Procedure|magnetic resonance imaging|
385050|NCT01254591|Procedure|therapeutic conventional surgery|
385051|NCT01254591|Radiation|[18F]-ML-10|
385052|NCT01254591|Radiation|fludeoxyglucose F 18|
385053|NCT01254591|Radiation|rubidium Rb-82|
385054|NCT01254578|Other|Laboratory Biomarker Analysis|Correlative studies
385055|NCT01254578|Drug|Lenalidomide|Given orally
385056|NCT01254578|Other|Pharmacological Study|Correlative studies
385057|NCT01254565|Drug|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
385058|NCT01254565|Drug|Placebo|Administered intravenously at the end of hemodialysis
385059|NCT01254552|Drug|iobitridol|Xenetix 350 was administered at a dose up to 180 ml, according to the patient's body weight measured on the day of administration.
385060|NCT01254552|Drug|gadoterate meglumine|Dotarem was administered at a dose of 0.1 mmol/kg body weight (0.2 ml/kg body weight)
385061|NCT01254539|Procedure|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
385062|NCT01254539|Procedure|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.~Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
385063|NCT01254539|Procedure|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
385064|NCT01254526|Drug|GDC-0980|Oral repeating dose
385065|NCT01254526|Drug|bevacizumab|Intravenous repeating dose
385066|NCT01254526|Drug|paclitaxel|Intravenous repeating dose
385067|NCT01254513|Drug|Docetaxel every 3 weeks + Prednisone|"Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~Prednisone 10 mg/day continuously"
385068|NCT01254513|Drug|Docetaxel weekly+ Prednisone|"Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~Prednisone 10 mg/day continuously"
385069|NCT01254474|Device|Cardiac chambers mapping with MAP 4|
385070|NCT01254461|Drug|AZD1981|100 mg per oral, twice daily for 8 days
385071|NCT01254461|Drug|AZD1981|4x100 mg per oral, twice daily for 8 days
385072|NCT01254461|Drug|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
385073|NCT01254448|Drug|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
385074|NCT01254448|Drug|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
385075|NCT01254435|Procedure|Colonoscopy|Recording of colonoscopic extubation
385076|NCT01254422|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
385077|NCT01254422|Biological|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension
385078|NCT01254409|Biological|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
385079|NCT01254409|Other|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
385080|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
385081|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
385082|NCT01254383|Drug|Sildenafil Tablet|Tablet, 50 mg, Single Dose
385083|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
385084|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
385085|NCT01254370|Drug|Latanoprost|0.005%
385086|NCT01254370|Drug|Travatan Z|0.004%
385087|NCT01254357|Other|Questionnaire self report|Burn specific outcome measurement and global health measurement
385088|NCT01254344|Drug|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
385089|NCT01254344|Drug|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
385090|NCT01254344|Drug|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
385091|NCT01254344|Drug|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
385092|NCT01254331|Drug|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
385093|NCT01254318|Other|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
385094|NCT01254305|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
385095|NCT01254305|Drug|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
385096|NCT01254305|Drug|Placebo|Matching placebo capsules, oral administration, once daily dosing
385097|NCT01254292|Drug|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
385098|NCT01254292|Drug|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
385099|NCT01254279|Drug|CABAZITAXEL|Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
385100|NCT01254266|Behavioral|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
385101|NCT01254266|Behavioral|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
385102|NCT01254266|Procedure|bariatric surgery|bariatric surgery.
385103|NCT01254266|Behavioral|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
385104|NCT01254253|Device|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
385105|NCT01254240|Device|UVA / UVB phototherapy|UVA / UVB phototherapy
385106|NCT01254240|Device|UVB phototherapy|UVB phototherapy
385107|NCT01254227|Drug|Deferasirox and Deferoxamine|
385108|NCT01254214|Behavioral|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
385109|NCT01254214|Behavioral|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
385110|NCT01254188|Drug|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
385111|NCT01254175|Biological|rHPIV3cp45 Vaccine|10^5 TCID^50 of rHPIV3cp45 vaccine, delivered as nose drops
385112|NCT01254175|Biological|Placebo Vaccine|Placebo vaccine, delivered as nose drops
385113|NCT01254162|Drug|MTC896 Gel|0.75% w/w gel applied daily for 28 days to the forehead
385114|NCT01254136|Drug|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
385115|NCT01254136|Drug|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
385185|NCT01253473|Drug|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
385116|NCT01254136|Drug|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
385117|NCT01254123|Drug|Exenatide infusion|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.~Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
385118|NCT01254123|Drug|Placebo infusion.|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.~Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
385119|NCT01254097|Dietary Supplement|Probiotic|Probiotic capsule, 2 capsules twice daily
385120|NCT01254084|Dietary Supplement|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
385121|NCT01254084|Dietary Supplement|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
385122|NCT01254071|Drug|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
385123|NCT01254045|Drug|placebo|intranasal placebo (48 international units)
385124|NCT01254045|Drug|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
385125|NCT01254045|Drug|oxytocin 48IU|intranasal oxytocin (48 international units)
385126|NCT01254019|Drug|GSK2402968 6mg/kg/week|subcutaneous
385127|NCT01254006|Drug|forskolin, rutin and vitamins B1 and B2|
385128|NCT01253980|Drug|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
385129|NCT01253980|Drug|Placebo|"Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days"
385130|NCT01253967|Procedure|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
385131|NCT01253967|Other|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
385132|NCT01253941|Other|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
385133|NCT01253928|Drug|Pioglitazone|45mg qd for 4 months
385134|NCT01253915|Drug|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
385135|NCT01253915|Drug|Placebo|10 sec/nostril up to 4 times to treat a migraine
385136|NCT01253902|Drug|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
385137|NCT01253902|Drug|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
385138|NCT01253902|Drug|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
385139|NCT01253889|Drug|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
385140|NCT01253889|Other|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
385141|NCT01253876|Dietary Supplement|soy milk, Caw's milk|
385142|NCT01253863|Other|exploration|exploration of wound for determining damaged tissue
385143|NCT01253837|Drug|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.~Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.~Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
385144|NCT01253824|Drug|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
385145|NCT01253824|Drug|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
385146|NCT01253811|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
385184|NCT01253486|Behavioral|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
385147|NCT01253798|Other|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
385148|NCT01253759|Procedure|TTT + ICG-based PDT|
385149|NCT01253733|Behavioral|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
385150|NCT01253720|Behavioral|PACE CALL/Fit4Life|"The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.~The Fit4Life intervention includes:~Web-based weight loss program Text and Picture messages Counseling Calls Health Coach"
385151|NCT01253707|Drug|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
385152|NCT01253694|Drug|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
385153|NCT01253681|Drug|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
385154|NCT01253668|Drug|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
385155|NCT01253668|Genetic|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
385156|NCT01253668|Other|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
385157|NCT01253668|Procedure|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
385158|NCT01253668|Genetic|Protein expression analysis|Correlative studies
385159|NCT01253668|Other|Immunohistochemistry|correlative studies
385160|NCT01253655|Drug|PF-05212365|Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
385161|NCT01253642|Procedure|Biopsy of Prostate|Undergo transrectal ultrasound (TRUS) guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
385162|NCT01253642|Drug|Docetaxel|Given IV
385163|NCT01253642|Other|Laboratory Biomarker Analysis|Correlative studies
385164|NCT01253642|Drug|Phenelzine Sulfate|Given PO
385165|NCT01253629|Drug|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
385166|NCT01253629|Drug|Placebo|Placebo medication identical in appearance to active medication was provided
385167|NCT01253616|Device|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
385168|NCT01253603|Drug|QAW039 capsules once daily for 28 days|
385169|NCT01253603|Drug|Placebo to QAW039 capsules once daily for 28 days|
385170|NCT01253603|Drug|Fluticasone propionate inhaler twice daily for 28 days|
385171|NCT01253590|Behavioral|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
385172|NCT01253577|Device|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
385173|NCT01253577|Device|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
385174|NCT01253564|Drug|RO5185426|960 mg b.i.d. orally
385175|NCT01253551|Drug|Treatment sequence AB|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
385176|NCT01253551|Drug|Treatment sequence BA|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
385177|NCT01253525|Biological|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
385178|NCT01253525|Drug|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
385179|NCT01253512|Drug|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
385180|NCT01253512|Drug|Placebo|Intravenous
385181|NCT01253499|Drug|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
385182|NCT01253486|Behavioral|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
385183|NCT01253486|Behavioral|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
385186|NCT01253473|Drug|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
385187|NCT01253473|Drug|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
385188|NCT01253460|Drug|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
385189|NCT01253460|Drug|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
385190|NCT01253460|Drug|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
385191|NCT01253447|Drug|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
385192|NCT01253447|Other|laboratory biomarker analysis|Correlative studies
385193|NCT01253434|Drug|E2022|E2022 Type A patch
385194|NCT01253434|Drug|E2022|E2022 Type B patch
385195|NCT01253434|Drug|E2022|E2022 Type C patch
385196|NCT01253434|Drug|E2022|E2022 Type D patch
385197|NCT01253434|Drug|E2022|E2022 Type E patch
385198|NCT01253421|Drug|amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
385199|NCT01253421|Drug|placebo|single-dose placebo capsule
385200|NCT01253408|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
385201|NCT01253408|Drug|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
385202|NCT01253395|Behavioral|Strength training|Daily supervised strength training.
385203|NCT01253395|Behavioral|Aerobic exercise|Daily supervised aerobic exercise.
385204|NCT01253382|Biological|ecallantide|10 - 30mg subcutaneous injection.
385205|NCT01253369|Drug|Pazopanib|
385206|NCT01253356|Device|IABP|Insertion of intra-aortic balloon < or = 3 hours before noncardiac surgery and maintained > or = 12-24 hours after surgery
385207|NCT01253330|Other|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
385208|NCT01253317|Drug|rhIGF-1|1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
385209|NCT01253304|Drug|LY2189265|Subcutaneous (SC) injection
385210|NCT01253291|Drug|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
385211|NCT01253278|Drug|LY2393910|as capsules, administered orally once daily for two weeks
385212|NCT01253278|Drug|Placebo|as capsules, administered orally once daily for two weeks
385213|NCT01253265|Drug|LY2439821|Administered subcutaneously
385214|NCT01253265|Drug|Placebo|Administered subcutaneously
385215|NCT01253252|Radiation|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.~The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.~The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
385216|NCT01253252|Radiation|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
385217|NCT01253252|Biological|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
385218|NCT01253226|Drug|LY2127399 (Tabalumab)|Administered subcutaneously
385219|NCT01253226|Drug|Placebo|Administered subcutaneously
385220|NCT01253213|Drug|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
385221|NCT01253200|Device|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
385222|NCT01253200|Device|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
385223|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
385224|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg / L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
385225|NCT01253187|Drug|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
385226|NCT01253174|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
385227|NCT01253174|Drug|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
385228|NCT01253174|Drug|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
385269|NCT01252849|Device|iStent|Implantation of One iStent through a small temporal clear corneal incision.
385229|NCT01253161|Drug|Pasireotide Long Acting Release (LAR)|Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
385230|NCT01253148|Device|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
385231|NCT01253135|Biological|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
385232|NCT01253135|Other|White Petrolatum|Topical application
385233|NCT01253122|Drug|TRx0037|
385234|NCT01253109|Device|SENSIMED Triggerfish|Contact lens-based device for continuous IOP monitoring
385235|NCT01253096|Drug|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
385236|NCT01253083|Behavioral|mobility training with dynamic body weight support|
385237|NCT01253070|Procedure|Biopsy|Undergo biopsy
385238|NCT01253070|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspirate
385239|NCT01253070|Drug|Cytarabine|Given IV
385240|NCT01253070|Drug|Daunorubicin Hydrochloride|Given IV
385241|NCT01253070|Other|Laboratory Biomarker Analysis|Correlative studies
385242|NCT01253070|Other|Quality-of-Life Assessment|Ancillary studies
385243|NCT01253070|Other|Questionnaire Administration|Ancillary studies
385244|NCT01253070|Drug|Sorafenib Tosylate|Given PO
385245|NCT01253044|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
385246|NCT01253044|Behavioral|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
385247|NCT01253018|Behavioral|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
385248|NCT01253018|Behavioral|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
385249|NCT01253005|Behavioral|Nutritional intervention|This study will investigate the effects of particle size of different triglyceride emulsions as well as the dynamics of intragastric structure formation and breakdown of the emulsions on GI function, the kinetics of the endocrine and the satiation response in healthy volunteers.
385250|NCT01252992|Genetic|Genetic analysis|"identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;~Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.~One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
385251|NCT01252992|Radiation|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
385252|NCT01252992|Other|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
385253|NCT01252992|Other|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
385254|NCT01252979|Dietary Supplement|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
385255|NCT01252966|Behavioral|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
385256|NCT01252966|Behavioral|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
385257|NCT01252953|Drug|Anacetrapib|tablet, 100mg daily
385258|NCT01252953|Drug|Placebo anacetrapib|tablet, 1 tablet daily
385259|NCT01252940|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
385260|NCT01252940|Drug|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
385261|NCT01252940|Drug|RTV|Ritonavir (RTV) was administered according to prescribing information.
385262|NCT01252940|Drug|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
385263|NCT01252927|Other|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
385264|NCT01252914|Device|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
385265|NCT01252888|Device|iStents|Implantation of two iStents through a small temporal clear corneal incision
385266|NCT01252875|Procedure|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
385267|NCT01252875|Procedure|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
385268|NCT01252862|Device|iStent|Implantation of two iStents through a small temporal clear corneal incision
385490|NCT01251250|Other|flow cytometry|Correlative studies
385270|NCT01252849|Device|iStent|Implantation of Two iStents through a small temporal clear corneal incision
385271|NCT01252849|Device|iStent|Implantation of Three iStents through a small temperal clear corneal incision
385272|NCT01252836|Device|AWBAT-D|Application of AWBAT-D bioengineered device
385273|NCT01252823|Device|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
385274|NCT01252810|Drug|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
385275|NCT01252797|Radiation|Stereotactic Radiosurgery (15 Gy)|"Group A will start at dose level II: 15 Gy~Group B will start at dose level I: 12 Gy"
385276|NCT01252797|Radiation|Stereotactic Radiosurgery (12 Gy)|Group B will start at Dose Level I: 12 Gy
385277|NCT01252771|Other|PKM Algorithm|"The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.~If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.~The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet."
385278|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 1|
385279|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 2|
385280|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 3|
385281|NCT01252758|Other|Placebo|
385282|NCT01252758|Drug|Albuterol|
385283|NCT01252758|Drug|Albuterol|
385284|NCT01252745|Drug|10.0 mg of Testosterone, 4.0% TID|
385285|NCT01252745|Drug|13.5 mg of Testosterone, 4.5% B.I.D|
385286|NCT01252745|Drug|11.25 mg of Testosterone, 4.5% T.I.D|
385287|NCT01252732|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
385288|NCT01252732|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
385289|NCT01252719|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
385290|NCT01252719|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
385291|NCT01252706|Behavioral|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
385292|NCT01252693|Drug|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
385293|NCT01252693|Drug|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
385294|NCT01252680|Biological|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
385295|NCT01252680|Biological|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
385296|NCT01252680|Biological|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
385297|NCT01252680|Biological|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
385298|NCT01252667|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
385299|NCT01252667|Drug|Clofarabine|Given IV
385300|NCT01252667|Drug|Cyclosporine|Given PO
385301|NCT01252667|Other|Laboratory Biomarker Analysis|Correlative studies
385302|NCT01252667|Drug|Mycophenolate Mofetil|Given PO
385303|NCT01252667|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
385304|NCT01252667|Other|Pharmacological Study|Optional correlative studies
385305|NCT01252667|Radiation|Total-Body Irradiation|Undergo TBI
385306|NCT01252641|Biological|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
385307|NCT01252628|Drug|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
385308|NCT01252628|Drug|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
385309|NCT01252628|Drug|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
385310|NCT01252628|Drug|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
385311|NCT01252615|Behavioral|patient only|education, behavioral strategies, psychological interventions
385312|NCT01252615|Behavioral|patient and partner intervention|education, psychological support, behavioral strategies
385313|NCT01252589|Other|HRQOL questionnaire|
385314|NCT01252563|Drug|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
385315|NCT01252550|Dietary Supplement|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
385316|NCT01252550|Dietary Supplement|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
385317|NCT01252524|Drug|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
385318|NCT01252524|Drug|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
385414|NCT01251770|Drug|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 surface.
385319|NCT01252511|Procedure|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
385320|NCT01252459|Radiation|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
385321|NCT01252459|Radiation|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
385322|NCT01252433|Other|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
385323|NCT01252420|Drug|Enoxaparin|1.5mg/kg daily for 2 weeks
385324|NCT01252407|Other|transcutaneous electrical nerve stimulation|Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
385325|NCT01252381|Other|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
385326|NCT01252368|Biological|hypertension|patients taking daily ACE inhibitors or sartanes
385327|NCT01252355|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
385328|NCT01252355|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
385329|NCT01252355|Drug|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.~Administration according to the package insert."
385330|NCT01252342|Drug|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
385331|NCT01252342|Drug|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
385332|NCT01252329|Procedure|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
385333|NCT01252316|Other|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
385334|NCT01252316|Other|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
385335|NCT01252303|Behavioral|Nutrisystem|Nutrisystem meal replacements for 12 weeks
385336|NCT01252290|Drug|Lovaza™|4 capsules daily for 6 months
385337|NCT01252277|Drug|Lovaza™|4 capsules daily for 6 months
385338|NCT01252251|Drug|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
385339|NCT01252238|Drug|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
385340|NCT01252238|Drug|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
385341|NCT01252238|Drug|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
385342|NCT01252225|Drug|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
385343|NCT01252225|Drug|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
385344|NCT01252225|Drug|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
385345|NCT01252212|Behavioral|SMS medication adherence|SMS messages to cell phones.
385346|NCT01252212|Behavioral|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
385347|NCT01252199|Drug|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
385348|NCT01252199|Drug|Placebo|Placebo administered over 1 hour + standard of care
385349|NCT01252186|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
385350|NCT01252186|Drug|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
385351|NCT01252186|Drug|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
385352|NCT01252160|Drug|QUTENZA|Cutaneous patch
385353|NCT01252147|Other|No treatment|No treatment (intervention) will be provided in this study
385354|NCT01252134|Device|Biotrue multipurpose solution|Contact lens care solution
385355|NCT01252134|Device|Sauflon Synergi multipurpose solution|Contact lens care solution
385356|NCT01252134|Device|OTE Elements multipurpose solution|Contact lens care solution
385357|NCT01252134|Device|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
385358|NCT01252121|Other|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
385359|NCT01252121|Other|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
385360|NCT01252121|Other|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
385361|NCT01252108|Drug|SQ109|300 mg SQ109 daily for 14 days
385451|NCT01251575|Radiation|Total-Body Irradiation|Undergo total-body irradiation
385491|NCT01251250|Genetic|fluorescence in situ hybridization|Correlative studies
385492|NCT01251250|Biological|azadirachta indica|Given orally
385362|NCT01252095|Drug|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
385363|NCT01252082|Procedure|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
385364|NCT01252069|Drug|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
385365|NCT01252069|Drug|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
385366|NCT01252056|Drug|Probucol|250mg,Bid
385367|NCT01252056|Drug|Probucol and Cilostazol|50-100mg,Bid
385368|NCT01252030|Device|physical activity monitors|physical activity monitors
385369|NCT01252030|Other|No physical activity monitors|No physical activity monitors
385370|NCT01252017|Drug|nilotinib|nilotinib (200mg/tab) 1 tab everyday
385371|NCT01251991|Drug|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
385372|NCT01251991|Dietary Supplement|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
385373|NCT01251991|Dietary Supplement|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
385374|NCT01251991|Other|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
385375|NCT01251978|Drug|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
385376|NCT01251978|Drug|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
385377|NCT01251965|Drug|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.~Phase II - MTD reached in Phase I."
385378|NCT01251952|Drug|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.~Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
385379|NCT01251939|Device|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
385380|NCT01251926|Drug|EZN-2208|
385381|NCT01251926|Drug|Bevacizumab|
385382|NCT01251887|Dietary Supplement|Linoleic Acid|
385383|NCT01251887|Dietary Supplement|Docosahexaenoic Acid|
385384|NCT01251887|Dietary Supplement|Eicosapentaenoic Acid|
385385|NCT01251874|Drug|Carboplatin|Given IV
385386|NCT01251874|Other|Fluorothymidine F-18|Correlative studies
385387|NCT01251874|Other|Laboratory Biomarker Analysis|Correlative studies
385388|NCT01251874|Other|Pharmacological Study|Correlative studies
385389|NCT01251874|Procedure|Positron Emission Tomography|Correlative studies
385390|NCT01251874|Drug|Veliparib|Given PO
385391|NCT01251861|Drug|Akt Inhibitor MK2206|Given PO
385392|NCT01251861|Drug|Bicalutamide|Given PO
385393|NCT01251861|Other|Clinical Observation|Undergo clinical observation
385394|NCT01251861|Other|Laboratory Biomarker Analysis|Correlative studies
385395|NCT01251848|Drug|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
385396|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
385397|NCT01251848|Drug|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
385398|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
385399|NCT01251835|Drug|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
385400|NCT01251835|Drug|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
385401|NCT01251835|Drug|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
385402|NCT01251822|Drug|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
385403|NCT01251822|Drug|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.~Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
385404|NCT01251809|Drug|Oncaspar|2000 U/m2 BSA, single infusion
385405|NCT01251809|Drug|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
385406|NCT01251796|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
385407|NCT01251783|Dietary Supplement|Infant Formula|Only Infant Formula without Lactobacillus, Metlin OR Metlos
385408|NCT01251783|Dietary Supplement|Exclusively breast milk|Children non randomized which mothers decided to feed them with exclusively breast milk
385409|NCT01251783|Dietary Supplement|Metlin+metlos+Lactobacillus GG|A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
385410|NCT01251783|Dietary Supplement|Metlin + Lactobacillus GG|A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
385411|NCT01251783|Dietary Supplement|Metlos + lactobacillus GG|A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
385412|NCT01251783|Dietary Supplement|Lactobacillus GG|An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
385413|NCT01251770|Drug|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 body surface.
385488|NCT01251250|Genetic|gene expression analysis|Correlative studies
385489|NCT01251250|Other|pharmacological study|Correlative studies
385415|NCT01251757|Other|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
385416|NCT01251757|Other|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
385417|NCT01251744|Procedure|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
385418|NCT01251744|Procedure|Cord blood sample|Cord blood sample taken at the time of delivery.
385419|NCT01251744|Procedure|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
385420|NCT01251744|Procedure|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
385421|NCT01251744|Procedure|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
385422|NCT01251731|Drug|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
385423|NCT01251731|Drug|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
385424|NCT01251731|Drug|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
385425|NCT01251731|Drug|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
385426|NCT01251718|Drug|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
385427|NCT01251692|Procedure|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
385428|NCT01251679|Behavioral|Hand washing|hand washing education and material
385429|NCT01251679|Device|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
385430|NCT01251666|Other|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
385431|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
385432|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
385433|NCT01251653|Drug|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
385434|NCT01251653|Drug|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
385435|NCT01251640|Drug|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
385436|NCT01251627|Drug|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
385437|NCT01251614|Biological|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
385438|NCT01251614|Drug|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
385439|NCT01251614|Biological|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
385440|NCT01251614|Drug|Placebo to Methotrexate|Orally once a week
385441|NCT01251601|Other|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
385442|NCT01251588|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
385443|NCT01251588|Procedure|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
385444|NCT01251575|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
385445|NCT01251575|Drug|Cyclosporine|Given PO or IV
385446|NCT01251575|Drug|Fludarabine Phosphate|Given IV
385447|NCT01251575|Other|Laboratory Biomarker Analysis|Correlative studies
385448|NCT01251575|Drug|Mycophenolate Mofetil|Given PO
385449|NCT01251575|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
385450|NCT01251575|Drug|Sirolimus|Given PO
385452|NCT01251562|Drug|Sterile Compound C31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
385453|NCT01251549|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
385454|NCT01251536|Drug|Dose escalation of cetuximab|"Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
385455|NCT01251536|Drug|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)~Arm allocation at day 22:~Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
385456|NCT01251523|Behavioral|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
385457|NCT01251523|Behavioral|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
385458|NCT01251497|Behavioral|diabetes self-management education|
385459|NCT01251484|Drug|BIBF1120|Tablet 200 mg twice daily until progression
385460|NCT01251471|Drug|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
385461|NCT01251458|Drug|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
385462|NCT01251419|Other|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
385463|NCT01251406|Drug|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
385464|NCT01251406|Drug|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
385465|NCT01251406|Drug|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
385466|NCT01251393|Drug|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
385467|NCT01251393|Drug|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
385468|NCT01251380|Biological|Botulinum toxin type A|Intramuscular (IM) injection on day 1 of each treatment cycle.
385469|NCT01251367|Biological|Botulinum toxin type A|I.M. (intramuscular) injection on day 1 of each treatment cycle.
385470|NCT01251354|Drug|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
385471|NCT01251341|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
385472|NCT01251341|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
385473|NCT01251341|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
385474|NCT01251328|Procedure|General anaesthesia|general anaesthesia is performed according to the hospitals standard
385475|NCT01251328|Procedure|Sedation|Sedation is performed according to the hospitals standard
385476|NCT01251315|Drug|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
385477|NCT01251315|Drug|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
385478|NCT01251315|Drug|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
385479|NCT01251315|Drug|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
385480|NCT01251315|Drug|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
385481|NCT01251315|Drug|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
385482|NCT01251302|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
385483|NCT01251276|Biological|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
385484|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
385485|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
385486|NCT01251250|Other|laboratory biomarker analysis|Correlative studies
385487|NCT01251250|Genetic|western blotting|Correlative studies
385493|NCT01251250|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
385494|NCT01251237|Drug|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
385495|NCT01251224|Other|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
385496|NCT01251224|Other|Education|This group will receive education about mouse IPM.
385497|NCT01251211|Drug|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
385498|NCT01251185|Device|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
385499|NCT01251172|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
385500|NCT01251172|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
385501|NCT01251172|Procedure|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
385502|NCT01251172|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
385503|NCT01251172|Other|Laboratory Biomarker Analysis|Correlative studies
385504|NCT01251172|Drug|Melphalan|Given IV
385505|NCT01251159|Genetic|mutation analysis|
385506|NCT01251159|Genetic|polymerase chain reaction|
385507|NCT01251159|Other|immunologic technique|
385508|NCT01251159|Other|laboratory biomarker analysis|
385509|NCT01251146|Drug|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
385510|NCT01251146|Drug|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
385511|NCT01251133|Biological|LBVH0101 (Hib vaccine)|0.5mL
385512|NCT01251133|Biological|Hiberix™ Vaccine|0.5mL
385513|NCT01251120|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
385514|NCT01251120|Drug|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
385515|NCT01251107|Drug|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
385516|NCT01251107|Drug|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
385517|NCT01251107|Drug|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
385518|NCT01251107|Drug|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
385519|NCT01251107|Drug|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
385520|NCT01251107|Drug|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
385521|NCT01251107|Drug|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
385522|NCT01251107|Drug|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
385523|NCT01251107|Drug|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
385524|NCT01251107|Drug|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
385525|NCT01251107|Drug|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
385526|NCT01251081|Other|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
385527|NCT01251081|Other|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
385528|NCT01251068|Device|near infrared spectroscopy: invos 5100|duration:six hours
385529|NCT01251068|Device|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
385530|NCT01251068|Device|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
385531|NCT01251055|Drug|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
385532|NCT01251055|Drug|Placebo|starch
385533|NCT01251042|Device|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
385534|NCT01251029|Drug|N-acetylcysteine|1200 mg orally; 600mg i.v.
385535|NCT01251029|Drug|Siran (N-acetylcysteine)|
385536|NCT01251003|Biological|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
385537|NCT01250990|Drug|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
385538|NCT01250990|Other|Placebo|Placebo
385539|NCT01250977|Drug|Donepezil|
385540|NCT01250977|Drug|Placebo|
385541|NCT01250964|Procedure|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
385542|NCT01250951|Drug|Deferasirox|
385543|NCT01250938|Behavioral|ESI - Community Outreach|This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
385544|NCT01250925|Drug|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
385545|NCT01250925|Drug|OPTI-FREE® RepleniSH®|Contact Lens care regimen
385546|NCT01250925|Drug|Clear Care®|Contact lens care regimen
385547|NCT01250912|Drug|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
385548|NCT01250899|Dietary Supplement|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
385549|NCT01250886|Drug|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
385550|NCT01250886|Drug|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
385551|NCT01250886|Drug|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
385552|NCT01250873|Drug|LY2216684|po administration
385553|NCT01250873|Drug|Sertraline|po administration
385554|NCT01250860|Other|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
385555|NCT01250860|Behavioral|Sham therapy|
385556|NCT01250847|Drug|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50~800mg Seroquel-XR once daily for total of 12 weeks.
385557|NCT01250834|Drug|Atorvastatin|Administered orally.
385558|NCT01250834|Biological|LY2189265|Administered subcutaneously.
385559|NCT01250821|Drug|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).~Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
385560|NCT01250808|Drug|Bortezomib/Dexamethasone/Melphalan|"Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.~Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.~Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.~ASCT therapy:~Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times."
385561|NCT01250795|Biological|HAI-05 Influenza Vaccine|injection, vaccine, twice every 3 weeks
385562|NCT01250795|Other|Saline|
385563|NCT01250782|Drug|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
385564|NCT01250782|Drug|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
385565|NCT01250769|Device|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
385566|NCT01250769|Device|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
385567|NCT01250756|Biological|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
385568|NCT01250756|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
385569|NCT01250756|Biological|DTaP|0.5 mL per dose, 4 doses
385570|NCT01250743|Dietary Supplement|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
385571|NCT01250730|Drug|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
385572|NCT01250730|Drug|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
385573|NCT01250730|Drug|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
385574|NCT01250717|Drug|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
385575|NCT01250717|Drug|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
385576|NCT01250717|Drug|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
385577|NCT01250717|Drug|Zoladex|Given subcutaneously for 4 doses every three months
385578|NCT01250717|Drug|Casodex|Taken orally once a day for 6 months
385579|NCT01250717|Procedure|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
385580|NCT01250691|Other|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
385581|NCT01250652|Drug|Levocetirizine|20 mg levocetirizine for 5 days
385582|NCT01250652|Drug|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
385583|NCT01250600|Behavioral|Home exercise|Daily home exercise for 3 months
385584|NCT01250587|Drug|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
385585|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
385586|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
385587|NCT01250561|Drug|Gabapentin|gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
385588|NCT01250561|Drug|Valacyclovir|valacyclovir 1000mg three-times daily x 7 days
385589|NCT01250548|Biological|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
385590|NCT01250548|Other|Placebo|
385591|NCT01250535|Drug|Warfarin|10 mg, po, single dose on day 7
385592|NCT01250535|Drug|Placebo|po, once a day, days 1 through 14
385593|NCT01250535|Drug|Lovastatin|40 mg, po, once a day, days 1 through 14
385594|NCT01250509|Behavioral|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
385595|NCT01250496|Drug|Aminophylline|75 mg of intravenous aminophylline
385596|NCT01250496|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
385597|NCT01250483|Other|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
385598|NCT01250470|Other|Laboratory Biomarker Analysis|Correlative studies
385599|NCT01250470|Drug|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
385600|NCT01250470|Biological|Sargramostim|Given SC
385601|NCT01250457|Drug|topical Timolol|topical Timolol 0.5% solution applied twice daily
385602|NCT01250444|Other|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
385603|NCT01250431|Behavioral|EFT (Emotional Freedom Techniques)|10 EFT sessions
385604|NCT01250418|Drug|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
385605|NCT01250405|Drug|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
385606|NCT01250405|Drug|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
385607|NCT01250392|Behavioral|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.~The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
385608|NCT01250379|Drug|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
385609|NCT01250379|Drug|Chemotherapy|Standard chemotherapy (doublets not allowed)
385610|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
385611|NCT01250366|Drug|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
385612|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
385613|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
385614|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
385615|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
385616|NCT01250366|Drug|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
385617|NCT01250366|Drug|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
385618|NCT01250366|Drug|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
385619|NCT01250353|Procedure|pterygium surgery|pterygium was removed surgically
385620|NCT01250340|Drug|Aspirin|100 mg/day for 30 days
385621|NCT01250340|Drug|Placebo|1 cp day for 30 days
385622|NCT01250327|Device|Melody|insertion of a pulmonic valved stent
385623|NCT01250327|Device|bare stent|insertion of a bare metal stent
385624|NCT01250327|Procedure|Surgery|conventional surgery methode
385625|NCT01250314|Other|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
385626|NCT01250314|Other|Biological, biochemical and genetic samples|"*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone~Urinary samples :~Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample~*Assessment of possible determinants of fractures in man~Blood samples plasma (5 ml):~Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH~Homocysteine~IGF1~Extraction of DNA for a genetic polymorphism study:~Sample of 10 ml of blood on EDTA for DNA extraction.~Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor~Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
385658|NCT01250080|Dietary Supplement|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
385840|NCT01248494|Drug|BEZ235|"Dose level 1: 400mg PO BID~Dose level -1: 400mg PO in AM and 200mg PO in PM~Dose level -2: 200mg PO BID"
385627|NCT01250301|Other|De-nicotinised cigarettes + standard treatment|"Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.~Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline)."
385628|NCT01250301|Other|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
385629|NCT01250288|Other|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients & their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
385630|NCT01250275|Other|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
385631|NCT01250275|Other|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
385632|NCT01250275|Other|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
385633|NCT01250275|Other|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
385634|NCT01250275|Other|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
385635|NCT01250275|Other|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
385636|NCT01250275|Other|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
385637|NCT01250262|Other|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
385638|NCT01250262|Other|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
385639|NCT01250262|Other|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
385640|NCT01250249|Biological|BCG Vaccine IP - Serum Institute of India|0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
385641|NCT01250236|Drug|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
385642|NCT01250236|Drug|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
385643|NCT01250210|Drug|levonorgestrel and ethinyl estradiol|pregnancy prevention
385644|NCT01250197|Drug|AR-12286|Ophthalmic Solution
385645|NCT01250184|Other|Physical therapy|Twelve sessions (3 per week)
385646|NCT01250184|Drug|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
385647|NCT01250184|Other|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
385648|NCT01250171|Biological|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
385649|NCT01250171|Biological|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
385650|NCT01250171|Biological|Placebo|The placebo solution for infusion contained 5% glucose.
385651|NCT01250158|Device|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.~The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.~The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.~The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
385652|NCT01250145|Drug|LY333334|Transdermal patch
385653|NCT01250145|Drug|Placebo|Transdermal patch
385654|NCT01250132|Other|Biological and behavioral explorations|"Blood dosages:~biochemistry~pituitary gland~somatotropic axis~corticotropic axis~gonadotropic axis~thyrotropic axis~antidiuretic axis~Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)"
385655|NCT01250119|Drug|erlotinib [Tarceva]|150 mg daily, orally
385656|NCT01250106|Dietary Supplement|Lactobacillus reuteri|twice daily
385657|NCT01250093|Device|acupuncture|
385730|NCT01249404|Biological|Botulinum toxin type A|I.M. injection on day 1 (single treatment cycle)
385659|NCT01250080|Other|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
385660|NCT01250067|Procedure|Motor-related cortical potential (Procedure)|
385661|NCT01250054|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
385662|NCT01250054|Device|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
385663|NCT01250041|Procedure|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
385664|NCT01250041|Procedure|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
385665|NCT01250002|Drug|Placebo|Placebo will receive the same volume of saline infusion.
385666|NCT01250002|Drug|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
385667|NCT01249989|Behavioral|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
385668|NCT01249989|Behavioral|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
385669|NCT01249989|Behavioral|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
385670|NCT01249976|Other|blood culture|blood culture
385671|NCT01249963|Dietary Supplement|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
385672|NCT01249963|Dietary Supplement|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
385673|NCT01249950|Other|feasibility|feasibility
385674|NCT01249937|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
385675|NCT01249937|Drug|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
385676|NCT01249924|Device|auto-titrated CPAP|Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
385677|NCT01249924|Device|Control|Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
385678|NCT01249911|Dietary Supplement|Lreuteri|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
385679|NCT01249911|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
385680|NCT01249872|Drug|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
385681|NCT01249872|Drug|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
385682|NCT01249872|Drug|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
385683|NCT01249872|Drug|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
385731|NCT01249404|Drug|Placebo|I.M. injection on day 1 (single treatment cycle)
385732|NCT01249391|Device|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
385684|NCT01249872|Drug|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
385685|NCT01249872|Drug|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
385686|NCT01249846|Drug|PerioChip ®|
385687|NCT01249833|Drug|Oseltamivir|Oseltamivir 75mg BID for 5 days
385688|NCT01249820|Drug|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
385689|NCT01249820|Drug|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
385690|NCT01249794|Procedure|non invasive ventilation|continuous positive airways pressure
385691|NCT01249742|Behavioral|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
385692|NCT01249716|Dietary Supplement|individual nutritional therapy|individual nutritional therapy provided by a registered dietician by means of three follow-up home visits
385693|NCT01249690|Drug|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
385694|NCT01249690|Drug|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
385695|NCT01249677|Drug|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
385696|NCT01249664|Biological|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
385697|NCT01249664|Procedure|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
385698|NCT01249651|Drug|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
385699|NCT01249638|Drug|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
385700|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
385701|NCT01249638|Drug|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
385702|NCT01249638|Drug|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
385703|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
385704|NCT01249625|Device|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
385705|NCT01249625|Device|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
385706|NCT01249612|Other|Thermotherapy|Knee joint icing
385707|NCT01249612|Other|Thermotherapy|Elbow joint icing
385708|NCT01249599|Procedure|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
385709|NCT01249586|Other|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
385710|NCT01249573|Other|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
385711|NCT01249547|Drug|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
385712|NCT01249534|Other|gastroesophageal cancer surgery|gastroesophageal cancer surgery
385713|NCT01249521|Drug|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
385714|NCT01249508|Other|nutrition label|
385715|NCT01249495|Procedure|Sharp debridement|After use of local anestetics a sharp currette is used to debride slough and nonviable tissue from the ulcer surface until a healthy tissue is seen.
385716|NCT01249469|Other|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
385717|NCT01249443|Drug|vorinostat|Given PO
385718|NCT01249443|Other|diagnostic laboratory biomarker analysis|Correlative studies
385719|NCT01249443|Other|pharmacological study|Correlative studies
385720|NCT01249443|Drug|carboplatin|Given IV
385721|NCT01249443|Drug|paclitaxel|Given IV
385722|NCT01249430|Drug|Azacitidine|Given IV
385723|NCT01249430|Drug|Cytarabine|Given IV
385724|NCT01249430|Drug|Etoposide Phosphate|Given IV
385725|NCT01249430|Other|Laboratory Biomarker Analysis|Correlative studies
385726|NCT01249430|Drug|Mitoxantrone Hydrochloride|Given IV
385727|NCT01249430|Other|Pharmacological Study|Correlative studies
385728|NCT01249417|Biological|Botulinum toxin type A|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
385729|NCT01249417|Drug|Placebo|I.M. injection on day 1 of a single treatment cycle.
385733|NCT01249378|Other|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :~10 g non emulsified~or 40 g non emulsified~or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
385734|NCT01249365|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
385735|NCT01249352|Drug|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
385736|NCT01249352|Drug|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
385737|NCT01249352|Drug|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
385738|NCT01249352|Radiation|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
385739|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
385740|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
385741|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
385742|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
385743|NCT01249326|Other|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
385744|NCT01249300|Other|No intervention|No intervention
385745|NCT01249274|Drug|Progesterone|100mgs progesterone twice daily
385746|NCT01249274|Other|Placebo|Matched placebo pills to be taken twice daily
385747|NCT01249261|Drug|Risedronate|5 mg/day
385748|NCT01249261|Drug|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 & 7 and no drug year 8
385749|NCT01249248|Device|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
385750|NCT01249235|Procedure|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
385751|NCT01249222|Procedure|plasmapheresis|Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
385752|NCT01249222|Other|plasmapheresis|plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
385753|NCT01249209|Device|lifestyle advice|
385754|NCT01249196|Drug|SK-PC-B70M|for dosage
385755|NCT01249183|Biological|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
385756|NCT01249183|Biological|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
385757|NCT01249170|Behavioral|First year program|Information on group that underwent new educational program
385758|NCT01249170|Other|Control comparison|Information from group that did not undergo new first year program
385759|NCT01249157|Device|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
385760|NCT01249144|Device|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
385761|NCT01249131|Drug|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
385762|NCT01249118|Drug|GDC-0973 IV Infusion|IV infusion.
385763|NCT01249118|Drug|GDC-0973 Oral Capsules|Oral dose.
385764|NCT01249105|Drug|MK-2206|Taken orally once a week
385765|NCT01249092|Drug|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
385766|NCT01249079|Other|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
385767|NCT01249040|Procedure|Physical therapy|
385768|NCT01249040|Procedure|steroid intraarticular injection|
385769|NCT01249027|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
385770|NCT01249014|Other|Warmed fluids|IV fluids warmed by a Belmont fluid warmer
385771|NCT01249014|Other|Fluid warmer and warming blanket|Warm are blown into a Bair hugger warming blanket covering the patient
385772|NCT01249014|Device|Belmont fluid warmer|Belmont fluid warmer used to warm fluids
385773|NCT01249014|Device|Bair hugger warming blanket|Bair hugger warming blanket laid on body
385774|NCT01249001|Drug|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
385775|NCT01249001|Drug|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
385933|NCT01247896|Drug|PF-05190457|Single Dose - to be determined
385776|NCT01248988|Other|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
385777|NCT01248975|Drug|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
385778|NCT01248975|Drug|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
385779|NCT01248975|Drug|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
385780|NCT01248975|Drug|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
385781|NCT01248975|Drug|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
385782|NCT01248975|Drug|Placebo capsule (PM)|Placebo capsule (PM)
385783|NCT01248962|Drug|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
385784|NCT01248962|Drug|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
385785|NCT01248949|Drug|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
385786|NCT01248949|Drug|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
385787|NCT01248949|Drug|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
385788|NCT01248949|Drug|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
385789|NCT01248936|Drug|RO5185426|
385790|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
385791|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
385792|NCT01248923|Drug|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
385793|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
385794|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
385795|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
385796|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
385797|NCT01248910|Behavioral|Alpine Skiing|
385798|NCT01248897|Other|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
385799|NCT01248884|Biological|Infanrix hexa™|3 doses, intramuscular into left thigh
385800|NCT01248884|Biological|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
385801|NCT01248884|Biological|GSK217744|3 doses, intramuscular into left thigh
385802|NCT01248871|Drug|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
385803|NCT01248871|Drug|volatile agent only during reperfusion|Active Comparator
385804|NCT01248871|Drug|propofol-remifentanil/sufentanil|Active Comparator
385805|NCT01248858|Drug|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
385806|NCT01248845|Other|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
385807|NCT01248832|Behavioral|Telephone Counseling|"Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse."
385808|NCT01248832|Behavioral|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
385809|NCT01248819|Drug|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
385838|NCT01248520|Other|influenza and general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
385810|NCT01248819|Drug|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
385811|NCT01248806|Radiation|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
385812|NCT01248793|Drug|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
385813|NCT01248793|Drug|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
385814|NCT01248793|Drug|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
385815|NCT01248780|Drug|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
385816|NCT01248780|Drug|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
385817|NCT01248780|Drug|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
385818|NCT01248754|Procedure|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
385819|NCT01248741|Radiation|HDR prostate brachytherapy|"HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy"
385820|NCT01248728|Dietary Supplement|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
385821|NCT01248728|Dietary Supplement|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
385822|NCT01248715|Drug|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
385823|NCT01248702|Other|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
385824|NCT01248689|Other|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:~7%, 5%, 2%, 0.5%"
385825|NCT01248689|Other|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:~7%, 2%, 5%, 0.5%"
385826|NCT01248689|Other|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:~7%, 0.5%, 5%, 2%"
385827|NCT01248676|Other|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
385828|NCT01248663|Procedure|antecolic reconstruction|see study arm description
385829|NCT01248663|Procedure|retrocolic reconstruction|see study arm description
385830|NCT01248650|Drug|nalfurafine hydrochloride|
385831|NCT01248637|Drug|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 <= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
385832|NCT01248624|Behavioral|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
385833|NCT01248611|Drug|fentanyl|nasally, dose titrated to effect
385834|NCT01248585|Drug|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
385835|NCT01248585|Drug|Placebo|2 placebo tablets taken once daily for 5 days
385836|NCT01248572|Device|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
385837|NCT01248546|Procedure|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
385839|NCT01248520|Other|general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
385841|NCT01248494|Drug|BKM 120|"Dose Level 1: BKM120, 100 mg PO daily~Dose level -1: BKM120, 80 mg PO daily~Dose Level -2: BKM120, 60 mg PO daily"
385842|NCT01248494|Drug|Letrozole|All levels: 2.5mg/day PO
385843|NCT01248494|Drug|BKM120|"Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly~Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly~Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
385844|NCT01248481|Drug|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
385845|NCT01248468|Drug|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
385846|NCT01248468|Drug|Sumatriptan|100 mg Sumatriptan
385847|NCT01248468|Drug|Placebo|placebo
385848|NCT01248455|Drug|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
385849|NCT01248442|Drug|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
385850|NCT01248442|Drug|Placebo|Matching Placebo
385851|NCT01248429|Biological|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
385852|NCT01248429|Other|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
385853|NCT01248416|Drug|Aromatase Inhibitor|
385854|NCT01248416|Drug|Growth Hormone|
385855|NCT01248416|Drug|Aromatase Inhibitor and Growth Hormone|
385856|NCT01248403|Drug|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
385857|NCT01248403|Drug|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
385858|NCT01248390|Behavioral|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
385859|NCT01248377|Procedure|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
385860|NCT01248364|Drug|BI 10773|BI 10773 tablets once daily high dose
385861|NCT01248351|Other|autologous stored platelets|Administration of autologous stored platelets
385862|NCT01248351|Other|administration of autologous stored platelets|administration of autologous stored platelets
385863|NCT01248351|Biological|autologous stored platelets|transfusion of autologous stored platelets
385864|NCT01248338|Drug|metoprolol succinate|once daily 50 or 100 mg for one year
385865|NCT01248338|Drug|Nebivolol|once daily 5 mg capsule for one year
385866|NCT01248325|Drug|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
385867|NCT01248325|Drug|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
385868|NCT01248312|Device|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
385869|NCT01248312|Device|sentec monitor|transcutaneous monitoring
385870|NCT01248299|Drug|FU-CDDP|"every 21 days:~Fluoro-uracil [800 mg/m2, day 1 to day 5]~CisPlatin [75 mg/m2, day 1 or day 2]"
385871|NCT01248299|Drug|LV5FU2-CDDP|"every 14 days:~Elvorin [200 mg/m2, 2h IV, day 1 and day 2]~Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]~Fluoro-uracil [600 mg/m2, 22h continous infusion, day 1 and day 2]~CisPlatin [50 mg/m2, day 2]"
385872|NCT01248299|Drug|FOLFOX|"every 14 days:~Oxaliplatin [85 mg/m2 by 2h infusion, day 1]~Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]~Fluoro-uracil [600 mg/m2, by 22h continous infusion, day 1 and day 2]~Elvorin [500 mg/m2, day 1 and day 2]"
385873|NCT01248299|Drug|TPF|"every 21 days:~Docetaxel [30 mg/m2, day 1 and day 8]~CisPlatin [60 mg/m2, day 1]~Fluoro-uracil [200 mg/m2/day by continous infusion]~Or every 21 days:~Docetaxel [50 mg/m2, day 1]~CisPlatine [70 mg/m2, day 1]~Fluoro-uracile [700 mg/m2 /day, day 1 to day 5]"
385874|NCT01248299|Other|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
385875|NCT01248286|Other|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
385876|NCT01248286|Other|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
385877|NCT01248273|Biological|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
385878|NCT01248260|Dietary Supplement|Folic Acid|4mg of higher strength folic acid once a day until delivery
385879|NCT01248247|Drug|Erlotinib|150 mg by mouth each day of a 28 day cycle.
385880|NCT01248247|Drug|AZD6244|100 mg by mouth daily of a 28 day cycle.
385881|NCT01248247|Drug|MK-2206|100 mg by mouth every week of a 28 day cycle.
385882|NCT01248247|Drug|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
385883|NCT01248247|Drug|Erlotinib|150 mg by mouth daily of a 28 day cycle.
385884|NCT01248247|Drug|MK-2206|135 mg by mouth every week of a 28 day cycle.
385885|NCT01248234|Drug|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
385886|NCT01248234|Drug|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
385887|NCT01248234|Drug|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
385888|NCT01248221|Drug|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
385889|NCT01248208|Biological|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
385890|NCT01248208|Biological|"Intramuscular influenza injection (flu shot)"|"Subjects < 2 years or > 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.~Age 6-36 months: 0.25 mL IM x 1; Age >36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
385891|NCT01248195|Drug|Amisulpride open label|4-week open label amisulpride treatment
385892|NCT01248195|Drug|6-week amisulpride double blind treatment|6-week amisulpride double blind treatment
385893|NCT01248195|Drug|6-week olanzapine double blind treatment|6-week olanzapine double blind treatment
385894|NCT01248195|Drug|12-week clozapine open-label treatment|12-week clozapine open-label treatment
385895|NCT01248195|Behavioral|Psychosocial intervention|Psychosocial intervention
385896|NCT01248143|Dietary Supplement|Green tea|9 gram per day
385897|NCT01248143|Dietary Supplement|FPP|2 sachets twice daily
385898|NCT01248130|Drug|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
385899|NCT01248117|Drug|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
385900|NCT01248104|Drug|Tranexamic Acid|Infusion during cardiac surgery
385901|NCT01248104|Drug|Aminocaproic Acid|Infusion during cardiac surgery
385902|NCT01248091|Procedure|Nitroprusside Gel|10 cc nitroprusside gel
385903|NCT01248091|Procedure|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
385904|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
385905|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
385906|NCT01248078|Drug|saline solution|100cc administered before skin incision
385907|NCT01248065|Drug|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
385908|NCT01248065|Drug|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
385909|NCT01248052|Drug|LY2979165|administered orally
385910|NCT01248052|Drug|Placebo|administered orally
385911|NCT01248026|Other|Buttermilk|"Consumption of the 2 experimental periods~buttermilk (45 g/d)~placebo (45 g/d,)"
385912|NCT01248013|Behavioral|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
385913|NCT01248000|Procedure|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
385914|NCT01247987|Procedure|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
385915|NCT01247987|Procedure|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
385916|NCT01247974|Device|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
385917|NCT01247961|Drug|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
385918|NCT01247961|Other|Placebo|Normal saline
385919|NCT01247948|Procedure|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
385920|NCT01247948|Procedure|traditional spine surgery|traditional spine surgery without navigation assist
385921|NCT01247935|Other|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
385922|NCT01247935|Other|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
385923|NCT01247935|Other|Control|Patients are monitored for pain and discomfort
385924|NCT01247922|Drug|Erlotinib|continuous oral Erlotinib 85 mg/m^2 per day
385925|NCT01247909|Drug|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
385926|NCT01247896|Drug|PF-05190457|Single Dose 2 mg
385927|NCT01247896|Drug|PF-05190457|Single Dose 10 mg
385928|NCT01247896|Drug|PF-05190457|Single Dose 30 mg
385929|NCT01247896|Drug|PF-05190457|Single Dose 100 mg
385930|NCT01247896|Drug|PF-05190457|Single Dose 300 mg
385931|NCT01247896|Drug|PF-05190457|Single Dose 600 mg
385932|NCT01247896|Drug|PF-05190457|Single Dose - to be determined with food
385934|NCT01247896|Drug|Placebo|Single Dose Placebo
385935|NCT01247883|Drug|PF-04634817|single dose, 20mg, tablet
385936|NCT01247883|Drug|PF-04634817|single dose, 20mg, solution
385937|NCT01247870|Drug|Metformin|Metformin 1 g twice daily for 28-35 days
385938|NCT01247870|Drug|Placebo|Placebo
385939|NCT01247857|Drug|Ropivacaine 30 mg|"Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
385940|NCT01247857|Drug|Ropivacaine 30 mg|"intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.~Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
385941|NCT01247857|Drug|Saline|Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
385942|NCT01247844|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
385943|NCT01247831|Procedure|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
385944|NCT01247818|Drug|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
385945|NCT01247818|Drug|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
385946|NCT01247818|Drug|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
385947|NCT01247818|Drug|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
385948|NCT01247805|Drug|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
385949|NCT01247805|Drug|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
385950|NCT01247805|Drug|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
385951|NCT01247792|Behavioral|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
385952|NCT01247779|Procedure|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
385953|NCT01247779|Procedure|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
385954|NCT01247753|Behavioral|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
385955|NCT01247740|Drug|NuTRIflex Lipid peri|parenteral nutrition
385956|NCT01247740|Drug|compounded monobag|parenteral nutrition
385957|NCT01247714|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
385958|NCT01247714|Dietary Supplement|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
385959|NCT01247714|Dietary Supplement|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
385960|NCT01247714|Dietary Supplement|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
385961|NCT01247701|Drug|Busulfan|Busulfan dosing will be as follows: Patients < 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients > 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
385962|NCT01247701|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours. The total dose to be given over 4 days is 200 mg/kg.
385963|NCT01247701|Drug|Fludarabine|Fludarabine 40 mg/m^2 will be given IV daily over 1 hour on Days -3, -2 and -1.
385964|NCT01247701|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
385965|NCT01247688|Drug|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
385966|NCT01247688|Drug|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
385967|NCT01247688|Radiation|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
385968|NCT01247688|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
385969|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
385970|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
385971|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
385972|NCT01247675|Drug|Omnitrope|s.c., daily injection
385973|NCT01247649|Device|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
386021|NCT01247220|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
385974|NCT01247636|Other|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
385975|NCT01247636|Other|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
385976|NCT01247623|Biological|GV1001|
385977|NCT01247584|Genetic|DNA analysis|
385978|NCT01247584|Genetic|mutation analysis|
385979|NCT01247584|Genetic|polymerase chain reaction|
385980|NCT01247584|Other|laboratory biomarker analysis|
385981|NCT01247571|Drug|Pazopanib Hydrochloride|Given PO
385982|NCT01247558|Other|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for >120 days
385983|NCT01247558|Other|Not treated with Metanx®|Non-treated comparative cohort
385984|NCT01247545|Procedure|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
385985|NCT01247545|Procedure|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
385986|NCT01247532|Behavioral|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
385987|NCT01247519|Other|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
385988|NCT01247493|Drug|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
385989|NCT01247467|Other|Breast Tumor Blocks|
385990|NCT01247454|Behavioral|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
385991|NCT01247454|Behavioral|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
385992|NCT01247454|Behavioral|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
385993|NCT01247441|Other|Clinical data|
385994|NCT01247428|Device|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
385995|NCT01247402|Device|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
385996|NCT01247402|Device|standard balloon angioplasty|standard balloon angioplasty
385997|NCT01247389|Procedure|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
385998|NCT01247376|Device|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
385999|NCT01247363|Drug|LY2608204|Administered orally.
386000|NCT01247350|Drug|LY3009104|Administered orally
386001|NCT01247350|Drug|Placebo|Administered orally
386002|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
386003|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
386004|NCT01247324|Drug|Interferon beta-1a|
386005|NCT01247324|Drug|Ocrelizumab-matching placebo|
386006|NCT01247324|Drug|Ocrelizumab|
386007|NCT01247324|Drug|Interferon beta-1a-matching placebo|
386008|NCT01247311|Dietary Supplement|Dietary supplement|Placebo given orally 3xweek for six months
386009|NCT01247311|Dietary Supplement|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
386010|NCT01247311|Dietary Supplement|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
386011|NCT01247298|Combination Product|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
386012|NCT01247285|Drug|Fluoxetine Hydrochloride|90 mg Capsules
386013|NCT01247285|Drug|PROZAC WEEKLY®|90 mg Capsules
386014|NCT01247272|Drug|Fluoxetine Hydrochloride|90 mg Capsules
386015|NCT01247272|Drug|PROZAC WEEKLY®|90 mg Capsules
386016|NCT01247259|Drug|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
386017|NCT01247246|Drug|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
386018|NCT01247246|Drug|Placebo|Placebo
386019|NCT01247233|Radiation|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50Gy + Boost 16 Gy or Whole breast, either 40Gy in 15 fractions in 3 weeks or 42,5Gy in 16 fractions in 3 weeks
386020|NCT01247233|Radiation|Accelerated partial breast irradiation|Tumor bed 40Gy in 10 fractions, 2 fractions of 4Gy per day in 5 to 7 days.
386022|NCT01247220|Procedure|Peripheral Laser|Angiography-directed peripheral laser
386023|NCT01247207|Drug|Ataluren|Ataluren will be administered as per the dose and schedule specified in the arm.
386024|NCT01247194|Drug|PPI-461|capsule, oral, once daily for 3 days
386025|NCT01247194|Drug|Placebo|capsules, oral, once daily for 3 days
386026|NCT01247181|Other|Mobile phone text message|Weekly message with motivational content
386027|NCT01247181|Other|Usual care|Usual care provided at clinic
386028|NCT01247168|Drug|AZD2461|oral capsules, continuous dosing and intermittent dosing
386029|NCT01247129|Procedure|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
386030|NCT01247103|Drug|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
386031|NCT01247103|Drug|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
386032|NCT01247103|Other|Placebo|Placebo to match AZD4316
386033|NCT01247090|Drug|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU * 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
386034|NCT01247090|Drug|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU * 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
386035|NCT01247090|Drug|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
386036|NCT01247077|Other|selenium|200 ug selenium once daily
386037|NCT01247077|Other|placebo|
386038|NCT01247064|Drug|Nebulized 3% saline|4 mL of nebulized 3% saline once
386039|NCT01247064|Drug|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
386040|NCT01247051|Procedure|Precoating|preoperative filling of heart lung machine with patients blood
386041|NCT01247051|Procedure|Standard priming|preoperative filling of heart lung machine with colloids
386042|NCT01247038|Device|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
386043|NCT01247038|Device|Metal-on-Metal|Metal on Metal articulation
386044|NCT01247025|Other|No intervention|This study will not contain a specific intervention
386045|NCT01247012|Dietary Supplement|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
386046|NCT01247012|Dietary Supplement|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
386047|NCT01246999|Biological|Live attenuated Influenza vaccine|0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
386048|NCT01246999|Biological|Trivalent Influenza Vaccine|.25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.
386049|NCT01246999|Biological|TIV followed by LAIV|TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
386050|NCT01246999|Biological|LAIV followed by TIV|LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
386051|NCT01246986|Drug|LY2157299|Administered orally
386052|NCT01246986|Drug|Sorafenib|Administered orally
386053|NCT01246986|Drug|Ramucirumab|Administered IV
386054|NCT01246973|Drug|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
386055|NCT01246973|Drug|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
386056|NCT01246960|Biological|Ramucirumab|Administered intravenously
386057|NCT01246960|Drug|Placebo|Administered intravenously
386058|NCT01246960|Drug|Oxaliplatin|Administered intravenously
386059|NCT01246960|Drug|Leucovorin|Administered intravenously
386060|NCT01246960|Drug|5-Fluorouracil|Administered intravenously
386061|NCT01246947|Procedure|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
386062|NCT01246947|Other|Mitral surgery alone|Randomized to Mitral surgery alone
386063|NCT01246934|Other|ASR METHOD|
386064|NCT01246921|Drug|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
386065|NCT01246908|Drug|Placebo|Placebo administered twice per day for six weeks.
386066|NCT01246908|Drug|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
386067|NCT01246895|Device|Microfracture with BST-CarGel|
386068|NCT01246895|Device|Microfracture without BST-CarGel|
386069|NCT01246882|Behavioral|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
386070|NCT01246882|Behavioral|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
386071|NCT01246830|Radiation|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
386072|NCT01246830|Radiation|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
386073|NCT01246817|Drug|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
386074|NCT01246804|Drug|raltegravir single dose|single dose 400mg raltegravir
386075|NCT01246804|Drug|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
386076|NCT01246791|Drug|NPC-01|NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
386077|NCT01246752|Biological|Human Stem Cell Transplantation|Human allogenic stem cells
386078|NCT01246752|Drug|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
386079|NCT01246739|Procedure|Adrenalectomy|Adrenalectomy (open or laparoscopic)
386080|NCT01246726|Procedure|CT SCAN|Prior to radiotherapy + after radiotherapy completion
386081|NCT01246726|Procedure|MRI scan|Prior to radiotherapy + after completion of radiotherapy
386082|NCT01246726|Procedure|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
386083|NCT01246713|Drug|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
386084|NCT01246713|Drug|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
386085|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
386086|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.~Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
386087|NCT01246687|Behavioral|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
386088|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
386089|NCT01246648|Procedure|biopsy|dental extraction and gingival epithelial biopsy
386090|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
386091|NCT01246635|Device|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
386092|NCT01246635|Procedure|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
386093|NCT01246622|Drug|cytarabine|Given IV
386094|NCT01246622|Drug|lenalidomide|Given PO
386095|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,[1] thus helping to establish a periodontium that is free of disease.[2]
386096|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
386097|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
386098|NCT01246583|Drug|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
386099|NCT01246583|Drug|Vehicle 1|Vehicle 1 twice daily for 4 weeks
386100|NCT01246583|Drug|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
386101|NCT01246583|Drug|Vehicle 2|Vehicle 2 twice daily for 4 weeks
386102|NCT01246570|Behavioral|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
386103|NCT01246570|Other|Control|The patients will receive the usual care provided by the hospitals and the community health services
386104|NCT01246557|Drug|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.~REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
386105|NCT01246557|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
386106|NCT01246518|Drug|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
386107|NCT01246505|Device|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
386108|NCT01246492|Dietary Supplement|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
386109|NCT01246479|Procedure|Blood draw|blood draw at Month 12, Month 24 and Month 36.
386110|NCT01246479|Biological|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
386111|NCT01246466|Device|Hybrid ablation procedure|AtriCure Bipolar System plus a catheter ablation
386112|NCT01246453|Drug|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
386185|NCT01245751|Biological|Zoster Vaccine, Live|Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
386113|NCT01246440|Drug|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
386114|NCT01246427|Drug|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
386115|NCT01246427|Drug|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
386116|NCT01246401|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
386117|NCT01246375|Device|Dual energy X-ray absorptiometry|Device which measures bone density
386118|NCT01246362|Drug|Control|Given placebo
386119|NCT01246362|Drug|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
386120|NCT01246349|Behavioral|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
386121|NCT01246349|Behavioral|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
386122|NCT01246336|Other|collection of exhaled breath|no intervention
386123|NCT01246323|Procedure|Spinal anesthesia with Fentanyl+ Morphine|Fentanyl 15 microgram Morphine 0.1-0.5 mg
386124|NCT01246310|Dietary Supplement|Inositol|
386125|NCT01246310|Dietary Supplement|Placebo|
386126|NCT01246297|Other|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
386127|NCT01246297|Other|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
386128|NCT01246284|Drug|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
386129|NCT01246284|Other|Normal saline|
386130|NCT01246258|Other|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
386131|NCT01246258|Other|Utricular centrifugation test|Standard test of balance function
386132|NCT01246232|Drug|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
386133|NCT01246232|Drug|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
386134|NCT01246219|Drug|GH treatment (Genotropin)|4 years treatment with GH
386135|NCT01246219|Drug|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
386136|NCT01246206|Drug|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
386137|NCT01246193|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
386138|NCT01246193|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily~Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
386139|NCT01246180|Drug|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
386140|NCT01246180|Drug|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
386141|NCT01246167|Device|Philos|"Conservative treatment versus Philos locking plate in 2 part fracture group.~Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group."
386142|NCT01246167|Device|Epoca|Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group
386143|NCT01246167|Other|Control group|Conservative control group
386144|NCT01246154|Other|EXERCISE TRAINING|EXERCISE TRAINING
386145|NCT01246102|Drug|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
386146|NCT01246089|Drug|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
386147|NCT01246076|Drug|Lenalidomide|
386148|NCT01246063|Drug|carfilzomib|
386149|NCT01246063|Drug|pegylated liposomal doxorubicin (PLD)|
386150|NCT01246063|Drug|Dexamethasone|
386186|NCT01245725|Drug|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
386222|NCT01245491|Other|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
386151|NCT01246050|Other|HF training|These are CBOC Providers who received HF Training as the active intervention. HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds. Providers were given access to clinical pharmacist services Including medication and disease teaching, adjustment and uptitration. There was quarterly analysis of patient compliance including individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
386152|NCT01246050|Other|No HF training|These are control providers drawn from the same CBOCs who have not received HF training, access to clinical pharmacist medication titration services or performance feedback
386153|NCT01246037|Drug|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
386154|NCT01246024|Device|ERG|scotopic and photopic ERG
386155|NCT01246011|Drug|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
386156|NCT01245998|Drug|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
386157|NCT01245998|Drug|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
386158|NCT01245985|Radiation|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
386159|NCT01245972|Procedure|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
386160|NCT01245959|Drug|Docetaxel, cisplatin and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
386161|NCT01245959|Radiation|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
386162|NCT01245946|Procedure|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
386163|NCT01245946|Drug|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
386164|NCT01245920|Biological|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
386165|NCT01245920|Other|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
386166|NCT01245907|Behavioral|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
386167|NCT01245894|Drug|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
386168|NCT01245894|Drug|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
386169|NCT01245881|Device|Non-ablative fractional photothermolysis laser|"Wavelength: 1,550 nm;~Energy: 15 mJ/MTZ;~Total coverage: 20%;~Total density: 1,048 MTZs/cm2;~Density per pass: 131 MTZ/cm2;~Number of passes: 8."
386170|NCT01245881|Other|broad-spectrum sunblock (SPF 50+)|
386171|NCT01245868|Drug|Lidocaine|
386172|NCT01245868|Drug|bupivacaine|
386173|NCT01245855|Drug|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
386174|NCT01245842|Other|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
386175|NCT01245829|Other|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
386176|NCT01245816|Drug|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
386177|NCT01245816|Drug|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
386178|NCT01245816|Drug|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
386179|NCT01245803|Drug|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
386180|NCT01245803|Drug|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
386181|NCT01245790|Drug|fostamatinib|Oral tablets, single dose
386182|NCT01245777|Drug|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
386183|NCT01245764|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
386184|NCT01245764|Biological|Placebo|
386187|NCT01245725|Drug|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.~Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
386188|NCT01245712|Radiation|Accelerated Partial Breast Irradiation|Undergo APBI delivered with proton radiation
386189|NCT01245712|Radiation|Proton Beam Radiation Therapy|Undergo APBI delivered with proton radiation
386190|NCT01245712|Other|Quality-of-Life Assessment|Ancillary studies
386191|NCT01245699|Behavioral|scenario-based training, real-time audiovisual CPR feedback, and post-event debriefing|scenario-based training for CPR, real-time audiovisual CPR feedback using R Series monitor-defibrillator during treatment, and post-event debriefing
386192|NCT01245686|Behavioral|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
386193|NCT01245673|Biological|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
386194|NCT01245673|Other|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion ~day 2 post-transplant. The target number of costimulated T-cells for infusion will be ~ 5 x 10e10 T-cells total in 100-500 mL total volume.
386195|NCT01245673|Drug|Revlamid® (Lenalidomide)|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose Revlamid® (Lenalidomide) 10 mg/day for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
386196|NCT01245673|Biological|MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF [+ coinjection of 2mg of Hiltonol®(Poly-ICLC)]. At Day #14, Day #42, Day #90, Day #120 and Day #150 patients will receive an additional immunization with MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC).
386197|NCT01245660|Drug|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
386198|NCT01245647|Drug|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
386199|NCT01245647|Other|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
386200|NCT01245634|Drug|Placebo|iv infusion every 4 weeks, 32 weeks
386201|NCT01245634|Drug|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
386202|NCT01245621|Behavioral|Later entry group|"Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~Comprehensive Palliative Care Team Assessment & Management Plan."
386203|NCT01245621|Behavioral|Early palliative care intervention|"Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and~Comprehensive Palliative Care Team Assessment & Management Plan."
386204|NCT01245608|Drug|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
386205|NCT01245595|Drug|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
386206|NCT01245595|Drug|Placebo|Normal Saline
386207|NCT01245582|Drug|oxaliplatin (SR96669)|"Pharmaceutical form:injection~Route of administration: intravenous"
386208|NCT01245582|Drug|capecitabine|"Pharmaceutical form:tablet~Route of administration: oral"
386209|NCT01245582|Drug|sorafenib|"Pharmaceutical form:tablet~Route of administration: oral"
386210|NCT01245569|Drug|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
386211|NCT01245569|Drug|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
386212|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
386213|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
386214|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
386215|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
386216|NCT01245543|Drug|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
386217|NCT01245543|Drug|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
386218|NCT01245530|Drug|Aricept|Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks
386219|NCT01245530|Drug|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks
386220|NCT01245517|Other|Education|Dietary Phosphorus Education Program
386221|NCT01245504|Other|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
386223|NCT01245465|Other|Profermin|Medical Food (food for special medical purposes)
386224|NCT01245452|Drug|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
386225|NCT01245452|Drug|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
386226|NCT01245439|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
386227|NCT01245426|Drug|GW870086 2mg|oral inhalation
386228|NCT01245426|Drug|GW870086 4mg|oral inhalation
386229|NCT01245426|Drug|GW870086 Placebo|oral inhalation
386230|NCT01245426|Drug|GW870086 1mg|oral inhalation
386231|NCT01245426|Drug|GW870086 3mg|oral inhalation
386232|NCT01245413|Device|SenSura|Adhesive to stoma bag
386233|NCT01245413|Device|Athena|Adhesive to stoma bag
386234|NCT01245400|Device|Z-Lig|ACL replacement
386235|NCT01245400|Device|allograft|ACL replacement
386236|NCT01245387|Drug|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
386237|NCT01245374|Device|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
386238|NCT01245361|Drug|Infliximab|Infliximab 3 mg/kg wk 0,2,6
386239|NCT01245361|Drug|sodium chloride|Group II : Placebo wk 0,2,6
386240|NCT01245348|Genetic|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
386241|NCT01245335|Device|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
386242|NCT01245335|Device|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
386243|NCT01245322|Drug|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
386244|NCT01245309|Procedure|scratching|endometrial scratching before COH in IVF
386245|NCT01245309|Procedure|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
386246|NCT01245296|Procedure|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
386247|NCT01245283|Other|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
386248|NCT01245283|Other|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
386249|NCT01245283|Other|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
386250|NCT01245270|Dietary Supplement|Bilberry capsule first, then control cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
386251|NCT01245270|Dietary Supplement|Control capsule first then bilberry cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).~Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
386252|NCT01245244|Drug|Morphine|Morphine oral mixture
386253|NCT01245244|Other|orange juice|orange juice
386254|NCT01245231|Genetic|protein expression analysis|
386255|NCT01245231|Genetic|western blotting|
386256|NCT01245231|Other|flow cytometry|
386257|NCT01245231|Other|laboratory biomarker analysis|
386258|NCT01245231|Other|medical chart review|
386259|NCT01245205|Drug|Akt inhibitor MK2206|Given PO
386260|NCT01245205|Drug|lapatinib ditosylate|Given PO
386261|NCT01245205|Other|pharmacological study|Correlative studies
386262|NCT01245205|Other|laboratory biomarker analysis|Correlative studies
386263|NCT01245179|Drug|panobinostat|"Panobinostat oral capsules taken THRICE WEEKLY (Monday, Wednesday, and Friday) for 12 weeks, exploring the following dosing regimens:~15 mg MWF 3 weeks on, 1 week off (if needed)~15 mg MWF every week (starting dose)~20 mg MWF 3 weeks on, 1 week off~20 mg MWF every week"
386264|NCT01245166|Drug|Acarbose|Acarbose 50 mg, per orem, thrice daily
386265|NCT01245166|Drug|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
386266|NCT01245153|Other|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
386267|NCT01245153|Other|Pelvic floor muscle training (PFMT)|Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
386268|NCT01245140|Drug|alitretinoin|to receive verum (20 patients)
386269|NCT01245140|Drug|Placebo|to receive placebo (10 patients)
386270|NCT01245127|Drug|Ilaris|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).~At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.~Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.~If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
386271|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
386272|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
386273|NCT01245088|Drug|chondroitin sulfate|400 mg orally three times daily for 8 weeks
386274|NCT01245075|Other|Deep brain stimulation|Deep brain stimulation on
386275|NCT01245075|Other|Placebo|deep brain stimulation off
386276|NCT01245062|Drug|GSK1120212|MEK inhibitor
386277|NCT01245062|Drug|Chemotherapy|Investigator Choice of DTIC or paclitaxel
386278|NCT01245049|Biological|Boostrix PolioTM|Single dose, intramuscular administration.
386279|NCT01245049|Biological|RepevaxTM|Single dose, intramuscular administration.
386280|NCT01245049|Biological|PriorixTM|Single dose, intramuscular or subcutaneous administration.
386281|NCT01245036|Drug|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.<50 kg and 600 mg/day if wt. >50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
386282|NCT01245023|Procedure|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
386283|NCT01245023|Procedure|Placebo-surgery|skin incisions without laparoscopy or related procedures
386284|NCT01245010|Other|Water|Water and education will be provided
386285|NCT01245010|Other|Education|Education
386286|NCT01244997|Procedure|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
386287|NCT01244984|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
386288|NCT01244984|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
386289|NCT01244971|Drug|Acarbose|100mg, 3 times daily
386290|NCT01244971|Behavioral|Exercise|Moderate combined exercise, 50 minutes 3 times per week
386291|NCT01244971|Other|Exercise + Acarbose|See respective monotherapy description
386292|NCT01244958|Biological|Rituximab|1000 mg Rituximab infusion
386293|NCT01244958|Drug|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
386294|NCT01244945|Dietary Supplement|L. reuteri DSM 17938|L. reuteri will be administered at 1x10^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10^8 CFU/die) for 90 days.
386295|NCT01244945|Other|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
386296|NCT01244932|Drug|bupivacaine 0.5%|Patients will be given bupivacaine 0.5% in different doses (up-down study).
386297|NCT01244906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
386298|NCT01244893|Device|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
386299|NCT01244893|Device|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
386300|NCT01244880|Other|Saline|Saline infusion for 56 minutes
386301|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg single dose
386302|NCT01244880|Other|Ketamine|"Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes~PF-02545920 10 mg tablet"
386303|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg tablet single dose
386304|NCT01244880|Other|Saline|Saline infusion for 56 minutes
386305|NCT01244880|Other|Placebo|Placebo tablet single dose
386306|NCT01244880|Other|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
386307|NCT01244880|Other|Placebo|Placebo tablet single dose
386308|NCT01244867|Biological|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
386309|NCT01244867|Biological|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
386310|NCT01244867|Biological|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
386311|NCT01244867|Biological|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
386312|NCT01244867|Biological|Placebo|2 doses given 21 days apart of the placebo
386313|NCT01244854|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
386314|NCT01244841|Procedure|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
386315|NCT01244828|Drug|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
386316|NCT01244815|Drug|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
386317|NCT01244815|Drug|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
386318|NCT01244815|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
386319|NCT01244789|Drug|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
386320|NCT01244789|Other|observation|active observation
386321|NCT01244776|Device|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
386322|NCT01244763|Drug|FG-4592|Different dose levels and schedules
386323|NCT01244750|Other|Non-Interventional|Non-Interventional
386324|NCT01244737|Drug|[18F] FLT|[18F] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
386325|NCT01244724|Drug|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
386326|NCT01244711|Drug|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
386327|NCT01244698|Drug|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
386328|NCT01244698|Drug|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
386329|NCT01244685|Device|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
386330|NCT01244672|Procedure|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
386331|NCT01244672|Procedure|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
386332|NCT01244659|Drug|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
386333|NCT01244659|Drug|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
386334|NCT01244633|Drug|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
386335|NCT01244620|Drug|sitaxentan|sitaxsentan 100 mg QD for 6 days
386336|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
386337|NCT01244620|Drug|sitaxsentan|sitaxsentan 100 mg QD for 6 days
386338|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
386339|NCT01244620|Drug|sitaxsentan|sitaxentan 100 mg QD for 6 days
386340|NCT01244620|Drug|sildenafil|sildenafil 20 mg TID for 6 days
386341|NCT01244607|Drug|Placebo|single i.v. administration
386342|NCT01244607|Drug|NI-0801|single i.v. administration
386343|NCT01244594|Other|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
386344|NCT01244581|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
386345|NCT01244581|Drug|Placebo|Placebo mixture in two daily doses for 7 days
386346|NCT01244568|Behavioral|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
386347|NCT01244555|Other|ultrasound|Twice weekly ultrasound sessions for 6 weeks
386348|NCT01244555|Other|massage|Twice weekly massage sessions for 6 weeks
386349|NCT01244542|Other|unpleasant stimuli|
386350|NCT01244529|Device|galy A Plus|galyfilcon A Plus, BC: 8.3 or 8.7
386351|NCT01244529|Device|seno A|senofilcon A, BC:8.4 or 8.8
386352|NCT01244529|Device|galy A|galyfilcon A , BC: 8.3 or 8.7
386353|NCT01244516|Device|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
386354|NCT01244516|Device|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
386355|NCT01244516|Device|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
386356|NCT01244503|Drug|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
386357|NCT01244490|Drug|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
386358|NCT01244490|Drug|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
386359|NCT01244490|Drug|Placebo Comparator|Placebo
386360|NCT01244477|Behavioral|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
386361|NCT01244464|Biological|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
386362|NCT01244451|Drug|Ofatumumab|Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.
386363|NCT01244451|Drug|Bendamustine|Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
386364|NCT01244438|Drug|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
386365|NCT01244425|Drug|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
386366|NCT01244425|Other|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
386367|NCT01244399|Dietary Supplement|Inositol|
386368|NCT01244360|Dietary Supplement|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
386369|NCT01244360|Other|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
386370|NCT01244347|Drug|folic acid|
386371|NCT01244347|Drug|folic acid|
386372|NCT01244334|Drug|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
386373|NCT01244334|Drug|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
386374|NCT01244295|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
386375|NCT01244295|Behavioral|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
386376|NCT01244282|Procedure|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
386377|NCT01244269|Drug|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
386378|NCT01244269|Drug|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
386379|NCT01244269|Drug|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
386380|NCT01244269|Drug|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
386381|NCT01244256|Drug|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
386382|NCT01244256|Drug|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
386383|NCT01244243|Device|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
386384|NCT01244230|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
386385|NCT01244217|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water~Route of administration: oral"
386386|NCT01244204|Dietary Supplement|Vitamin D|Daily dose of 800IU of vitamin D
386387|NCT01244204|Dietary Supplement|Placebo|Identically appearing capsules
386388|NCT01244191|Drug|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
386389|NCT01244191|Drug|Placebo|Tivantinib Placebo tablets given twice a day
386390|NCT01244191|Drug|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
386391|NCT01244178|Drug|Insulin|Intravenous Hyperinsulinemic therapy
386392|NCT01244178|Drug|Insulin|Standard Intravenous Insulin Therapy
386393|NCT01244165|Device|Cytrix|
386394|NCT01244165|Other|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
386395|NCT01244152|Behavioral|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
386396|NCT01244152|Behavioral|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
386397|NCT01244139|Drug|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
386398|NCT01244139|Drug|Placebo|IV infusion dummy drug
386399|NCT01244126|Drug|Intranasal fentanyl|2mcg/kg fentanyl IN
386400|NCT01244126|Drug|morphine IM|0.1 mg/kg morphine IM for postop pain
386401|NCT01244126|Drug|IV morphine|0.1 mg/kg morphine IV
386402|NCT01244113|Drug|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
386403|NCT01244100|Drug|PL2200 fasted|Fasted state
386404|NCT01244100|Drug|PL2200 fed|Fed state
386405|NCT01244074|Behavioral|biofeedback training|
386406|NCT01244061|Drug|Varenicline|Varenicline 1mg twice daily
386407|NCT01244061|Drug|Placebo|Matched placebo twice daily
386408|NCT01244048|Dietary Supplement|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
386409|NCT01244035|Drug|Treatment A|MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
386410|NCT01244035|Drug|Treatment B|MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
386411|NCT01244035|Drug|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
386412|NCT01244035|Drug|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
386413|NCT01244035|Drug|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
386414|NCT01244035|Drug|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
386415|NCT01244022|Procedure|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
386416|NCT01244009|Drug|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
386417|NCT01243996|Drug|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
386418|NCT01243983|Drug|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:~Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.~Treatment Arm B: placebo p.o. b.i.d.~Dosage Form:~• Soft gelatin capsule~Duration of treatment:~• 24 weeks"
386419|NCT01243970|Drug|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg *~* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
386420|NCT01243970|Drug|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. *~* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
386421|NCT01243957|Drug|LY2216684|LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27
386422|NCT01243957|Drug|Fluoxetine|Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
386423|NCT01243944|Drug|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
386424|NCT01243944|Other|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each participant. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
386425|NCT01243931|Drug|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
386426|NCT01243918|Other|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
386427|NCT01243905|Other|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
386428|NCT01243905|Other|Treatment as usual|Treatment as usual administered by physicians
386429|NCT01243892|Device|NuSpin|Device for administration of doses of somatropin.
386430|NCT01243892|Drug|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
386431|NCT01243879|Other|Starvation|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
386432|NCT01243866|Other|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
386433|NCT01243866|Other|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
386601|NCT01242488|Biological|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
386434|NCT01243853|Dietary Supplement|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
386435|NCT01243827|Drug|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
386436|NCT01243827|Drug|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
386437|NCT01243814|Device|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
386438|NCT01243814|Device|placebo injection|joint injection with saline solution for placebo
386439|NCT01243801|Drug|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
386440|NCT01243788|Drug|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
386441|NCT01243775|Drug|Belotaxel|60 mg/m2 3 weekly (day 1)
386442|NCT01243775|Drug|Belloxa|70 mg/m2 3 weekly (day 2)
386443|NCT01243762|Drug|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
386444|NCT01243762|Drug|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
386445|NCT01243762|Drug|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
386446|NCT01243762|Drug|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
386447|NCT01243736|Drug|Combination Prep|"combination bowel preparation, which consists of:~drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;~drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;~drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;~lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
386448|NCT01243723|Drug|Eductyl suppository|One suppository every morning during 21 days
386449|NCT01243723|Drug|Placebo suppository|One suppository every morning during 21 days
386450|NCT01243710|Device|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
386451|NCT01243697|Drug|desogestrel|Tablets of 75 µg, once daily during 112 days
386452|NCT01243684|Device|DTI - Diffusor Tensor Imaging|Radiology intervention
386453|NCT01243671|Biological|Adalimumab|
386454|NCT01243658|Drug|Oxytocin|Oxytocin
386455|NCT01243658|Other|placebo|placebo
386456|NCT01243645|Behavioral|biofeedback training|
386457|NCT01243632|Drug|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
386458|NCT01243619|Drug|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
386459|NCT01243606|Behavioral|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
386460|NCT01243606|Behavioral|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
386461|NCT01243593|Procedure|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
386462|NCT01243593|Procedure|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
386463|NCT01243580|Drug|Ortho-Cyclen|Ortho-Cyclen is an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
386464|NCT01243580|Drug|AG200-15|AG200-15 is a transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
386465|NCT01243567|Drug|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
386466|NCT01243567|Drug|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
386467|NCT01243554|Behavioral|Exercise|Exercise training at the hospital
386468|NCT01243541|Procedure|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
386469|NCT01243541|Other|questionnaire administration|Ancillary studies
386470|NCT01243541|Procedure|quality-of-life assessment|Ancillary studies
386471|NCT01243541|Procedure|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
386472|NCT01243541|Procedure|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
386473|NCT01243528|Other|Laboratory values|Laboratory values which represent nutritional status
386474|NCT01243515|Device|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
386475|NCT01243515|Procedure|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
386476|NCT01243502|Drug|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
386477|NCT01243502|Drug|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
386478|NCT01243489|Other|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
386479|NCT01243476|Drug|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
386480|NCT01243476|Other|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
386481|NCT01243450|Drug|Tretinoin|Treatment of acne
386482|NCT01243450|Drug|placebo|treatment of acne
386483|NCT01243437|Drug|ciprofloxacin|"For adults and children aged > 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
386484|NCT01243437|Drug|doxyxcycline|"For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;~For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
386485|NCT01243424|Drug|linagliptin|linagliptin tablets 5mg QD
386486|NCT01243424|Drug|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
386487|NCT01243424|Drug|linagliptin placebo|linagliptin placebo
386488|NCT01243424|Drug|glimepride placebo|glimepiride placebo
386489|NCT01243411|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
386490|NCT01243398|Procedure|quality-of-life assessment|
386491|NCT01243385|Drug|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
386492|NCT01243372|Genetic|mutation analysis|
386493|NCT01243372|Other|laboratory biomarker analysis|
386494|NCT01243359|Drug|sunitinib malate|Given PO
386495|NCT01243359|Biological|bevacizumab|Given IV
386496|NCT01243359|Other|pharmacological study|Correlative studies
386497|NCT01243359|Other|laboratory biomarker analysis|Correlative studies
386498|NCT01243359|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
386499|NCT01243359|Procedure|positron emission tomography|Undergo FLT PET/CT
386500|NCT01243359|Procedure|computed tomography|Undergo FLT PET/CT
386501|NCT01243346|Drug|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
386502|NCT01243333|Radiation|[F-18]fluorodeoxyglucose|Undergo PET scans with [F-18]fluorodeoxyglucose
386503|NCT01243333|Radiation|[F-18]fluorothymidine|Undergo PET scans with fluorine [F-18]fluorothymidine
386504|NCT01243333|Procedure|Positron Emission Tomography|Undergo PET scans with 3 radiotracers (fludeoxyglucose F 18, fluorine F 18 fluorothymidine, and water O-15)
386505|NCT01243333|Radiation|Water O-15|Undergo PET scans with water O-15 tracers
386506|NCT01243320|Drug|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
386507|NCT01243320|Drug|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
386508|NCT01243307|Drug|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
386509|NCT01243294|Device|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
386510|NCT01243294|Device|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
386511|NCT01243281|Drug|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
386512|NCT01243268|Drug|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
386513|NCT01243242|Drug|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
386514|NCT01243216|Device|Ultrasound|Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
386515|NCT01243203|Drug|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
386516|NCT01243190|Drug|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
386517|NCT01243177|Drug|Lacosamide|"Lacosamide:~Strengths: 50 mg / 100 mg~Form: tablets~Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose~Duration: up to 118 weeks"
386600|NCT01242501|Behavioral|20-Min education session|Patients receive a single 20 min education session for STI/HIV information.
386518|NCT01243177|Drug|Carbamazepine-Controlled Release|"Carbamazepine-CR:~Strengths: 200 mg~Form: tablets~Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose~Duration: up to 118 weeks"
386519|NCT01243164|Other|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
386520|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
386521|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
386522|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
386523|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
386524|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
386525|NCT01243125|Drug|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
386526|NCT01243125|Drug|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
386527|NCT01243112|Drug|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
386528|NCT01243112|Drug|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
386529|NCT01243112|Drug|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
386530|NCT01243112|Drug|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
386531|NCT01243086|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
386532|NCT01243086|Drug|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
386533|NCT01243073|Drug|Imetelstat|
386534|NCT01243060|Drug|Almorexant|100mg
386535|NCT01243060|Drug|Almorexant|200mg
386536|NCT01243060|Drug|Zolpidem 10mg|10mg
386537|NCT01243060|Drug|Placebo|One-time dose of Placebo
386538|NCT01243047|Drug|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
386539|NCT01243008|Drug|Application of SHB001|"Cohort 1: Application of SHB001 on the skin of right thigh~Cohort 2:~Application of SHB001 on the skin of right thigh~punch biopsies of treated skin areas"
386540|NCT01242995|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
386541|NCT01242982|Procedure|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
386542|NCT01242982|Procedure|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
386543|NCT01242956|Behavioral|verum group|video-based training after stroke
386544|NCT01242956|Behavioral|Placebo group|non-video group
386545|NCT01242943|Drug|131I-L19SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.~Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167."
386546|NCT01242930|Drug|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
386547|NCT01242930|Drug|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
386548|NCT01242930|Drug|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
386549|NCT01242917|Drug|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
386550|NCT01242917|Drug|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
386551|NCT01242917|Drug|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
386552|NCT01242904|Drug|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
386553|NCT01242904|Drug|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
386554|NCT01242891|Device|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
386555|NCT01242865|Behavioral|Attention and Interpretation Therapy|"Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book."
386556|NCT01242852|Procedure|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS & hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions & endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
386557|NCT01242839|Device|CACICOL20|CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
386558|NCT01242839|Device|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
386559|NCT01242826|Drug|biphasic insulin aspart 50|A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
386560|NCT01242813|Drug|ACZ885|
386561|NCT01242800|Procedure|palliative surgery|Undergo standard palliative surgery
386562|NCT01242800|Procedure|therapeutic conventional surgery|Undergo early surgery
386563|NCT01242800|Radiation|palliative radiation therapy|Undergo standard palliative radiotherapy
386564|NCT01242800|Radiation|radiation therapy|Undergo radiotherapy
386565|NCT01242787|Drug|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
386566|NCT01242787|Drug|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
386567|NCT01242774|Drug|Panobinostat|Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
386568|NCT01242748|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
386569|NCT01242748|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
386570|NCT01242735|Behavioral|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
386571|NCT01242735|Behavioral|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
386572|NCT01242722|Device|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
386573|NCT01242696|Procedure|Coronary artery stenting|Coronary artery stenting with drug eluting stents
386574|NCT01242683|Behavioral|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.~Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.~Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.~Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
386575|NCT01242670|Biological|Ross River Virus Vaccine|Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
386576|NCT01242657|Behavioral|Physical Activity Module|"Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log."
386577|NCT01242657|Behavioral|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
386578|NCT01242644|Device|pain pump containing ropivacaine|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
386579|NCT01242644|Device|saline pain pump with injectable medication|30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
386580|NCT01242644|Drug|ropivacaine, ketorolac , morphine sulfate|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
386581|NCT01242631|Drug|Everolimus|Everolimus 10 mg orally per day.
386582|NCT01242618|Biological|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
386583|NCT01242605|Drug|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
386584|NCT01242605|Drug|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
386585|NCT01242605|Drug|cisplatin|cisplatin: 25 mg/m*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
386586|NCT01242592|Drug|Anti-Tuberculosis Treatment|
386587|NCT01242579|Drug|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
386588|NCT01242579|Drug|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
386589|NCT01242579|Drug|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
386590|NCT01242579|Drug|Matching Placebo Gel|Matching placebo gel containing 2.5g
386591|NCT01242566|Drug|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
386592|NCT01242527|Drug|placebo|4 capsules (1g) daily for 12 weeks
386593|NCT01242527|Drug|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
386594|NCT01242527|Drug|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
386595|NCT01242527|Drug|omefas|4 capsules (1g)daily for 12 weeks
386596|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg twice daily
386597|NCT01242514|Drug|Fostamatinib|Fostamatinib 150mg once daily
386598|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg once daily
386599|NCT01242501|Behavioral|60 Minute HIV/STI risk reduction counseling|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
386602|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
386603|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
386604|NCT01242488|Biological|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
386605|NCT01242488|Biological|CDP6038|60 mg sc at Weeks 0, 4 and 8
386606|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 4 and 8
386607|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 4 and 8
386608|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
386609|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
386610|NCT01242488|Other|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
386611|NCT01242475|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
386612|NCT01242475|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
386613|NCT01242462|Procedure|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 & Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
386614|NCT01242462|Other|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is >/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH >/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
386615|NCT01242449|Drug|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
386616|NCT01242449|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
386617|NCT01242436|Procedure|intravenous contrast administration|"The additional burden is restricted to a WB-DWI scan before and during therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
386618|NCT01242423|Device|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
386619|NCT01242410|Device|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
386620|NCT01242397|Device|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
386621|NCT01242384|Device|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
386622|NCT01242371|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
386623|NCT01242371|Dietary Supplement|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
386624|NCT01242358|Device|Capnography|Capnographic monitoring
386625|NCT01242358|Device|Standard monitoring|Standard monitoring
386626|NCT01242345|Device|Capnography|Monitoring of the capnography curve for early detection of apnea
386627|NCT01242332|Drug|Pregabalin|75 mg po 2 hrs before surgery
386628|NCT01242319|Behavioral|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
386629|NCT01242306|Drug|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
386630|NCT01242293|Other|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
386631|NCT01242293|Other|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
386632|NCT01242293|Other|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
386633|NCT01242280|Device|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
386634|NCT01242280|Device|Tamponade|Sengstaken-Blakemore tube
386674|NCT01241916|Device|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
386635|NCT01242267|Drug|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 400mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
386636|NCT01242254|Biological|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
386637|NCT01242241|Drug|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
386638|NCT01242241|Drug|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
386639|NCT01242228|Drug|ipragliflozin|oral
386640|NCT01242228|Drug|DPP-4 inhibitor|oral
386641|NCT01242215|Device|ipragliflozin|oral
386642|NCT01242215|Drug|Placebo|oral
386643|NCT01242215|Drug|Sulfonylurea|oral
386644|NCT01242202|Drug|ipragliflozin|oral
386645|NCT01242202|Drug|alpha glucosidase inhibitor|oral
386646|NCT01242176|Drug|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
386647|NCT01242176|Drug|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
386648|NCT01242150|Device|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow >40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
386649|NCT01242150|Device|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
386650|NCT01242124|Procedure|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
386651|NCT01242124|Procedure|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
386652|NCT01242111|Drug|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
386653|NCT01242098|Drug|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
386654|NCT01242098|Drug|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
386655|NCT01242085|Procedure|trumatch group|these patient will have CT based customized knee instruments used for surgery
386656|NCT01242085|Procedure|control group|these patients will have standard instrumentation used for for knee replacement
386657|NCT01242072|Drug|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
386658|NCT01242059|Dietary Supplement|yellow pea protein|Served in a tomato soup
386659|NCT01242059|Other|yellow pea fiber|Served in a tomato soup
386660|NCT01242059|Dietary Supplement|Control|Served in a tomato soup
386661|NCT01242046|Dietary Supplement|Caffeine|400 mg of caffeine in tablet form
386662|NCT01242046|Dietary Supplement|Placebo|Inert tablet
386663|NCT01242033|Dietary Supplement|red raspberries|single serving of one, two or four cups red raspberries
386664|NCT01242033|Dietary Supplement|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
386665|NCT01242020|Drug|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
386666|NCT01242007|Other|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
386667|NCT01241994|Other|AASD dialysis technique|
386668|NCT01241968|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
386669|NCT01241968|Device|Placebo|Placebo
386670|NCT01241955|Behavioral|video decision aid|video of CPR
386671|NCT01241942|Device|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNC Hospitals (UNCH) where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNCH based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
386672|NCT01241942|Other|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
386673|NCT01241929|Behavioral|video decision aid|video of CPR
387205|NCT01238003|Other|Interpretation of blood test results|Interpretation of blood test results
386675|NCT01241916|Device|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
386676|NCT01241903|Drug|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
386677|NCT01241903|Drug|placebo|frequency and duration
386678|NCT01241877|Dietary Supplement|astaxanthin|astaxanthin
386679|NCT01241877|Dietary Supplement|placebo|placebo
386680|NCT01241864|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
386681|NCT01241864|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
386682|NCT01241851|Behavioral|Aerobic exercise|
386683|NCT01241851|Behavioral|Resistance exercise|
386684|NCT01241838|Device|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
386685|NCT01241825|Other|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
386686|NCT01241825|Other|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
386687|NCT01241812|Behavioral|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
386688|NCT01241799|Procedure|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
386689|NCT01241799|Procedure|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
386690|NCT01241786|Drug|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and < 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
386691|NCT01241786|Drug|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
386692|NCT01241773|Drug|raltegravir|One 400 mg tablet twice daily for 7 days
386693|NCT01241773|Drug|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
386694|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 7 days
386695|NCT01241773|Drug|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
386696|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 14 days
386697|NCT01241773|Drug|efavirenz|One 600 mg tablet once daily for 14 days
386698|NCT01241760|Drug|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
386699|NCT01241760|Drug|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
386700|NCT01241760|Drug|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
386701|NCT01241760|Drug|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
386702|NCT01241747|Behavioral|Walking Exercise|3 times per week for 3 months
386703|NCT01241747|Behavioral|Control|Resistance training 3 times per week for 3 months
386704|NCT01241734|Drug|Revlimid|"Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days"
386705|NCT01241721|Device|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
386706|NCT01241708|Drug|Bortezomib|Bortezomib 1.6mg/m2 on day -4 and day -1
386707|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
387495|NCT01235572|Procedure|quality-of-life assessment|Ancillary studies
386708|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
386709|NCT01241682|Biological|DC + CTX|3x 50x10e6 DC + cyclophosphamide
386710|NCT01241669|Drug|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
386711|NCT01241669|Drug|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
386712|NCT01241656|Behavioral|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
386713|NCT01241656|Behavioral|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
386714|NCT01241656|Behavioral|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
386715|NCT01241643|Drug|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
386716|NCT01241630|Procedure|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
386717|NCT01241617|Device|Duet TRS|Endo GIA stapler with integrated Duet TRS
386718|NCT01241617|Device|Endo GIA|Endo GIA stapler with Single Use Loading Units
386719|NCT01241604|Device|BiPAP S/T|Mechanical Non-invasive Ventilation
386720|NCT01241604|Device|BiPAP Auto SV3|Auto Servo Ventilation Device
386721|NCT01241591|Drug|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
386722|NCT01241591|Drug|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
386723|NCT01241591|Biological|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
386724|NCT01241591|Other|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
386725|NCT01241578|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
386726|NCT01241565|Device|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
386727|NCT01241552|Biological|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
386728|NCT01241552|Biological|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
386729|NCT01241552|Biological|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
386730|NCT01241552|Biological|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
386731|NCT01241552|Drug|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
386732|NCT01241539|Drug|Dabigatran etexilate|150 mg capsule
386733|NCT01241539|Drug|Dabigatran etexilate|75 mg capsule
386734|NCT01241539|Drug|Dabigatran etexilate|110 mg capsule
386735|NCT01241526|Other|Disease Management|"Individual, group and phone education sessions~Telephone supporter follow-up~LTOT monitoring"
386736|NCT01241526|Other|Usual site management|"Usual education as per site protocol~Usual follow-up as per site protocol~LTOT monitoring"
386737|NCT01241513|Drug|NAC|NAC provided to determine if beneficial at altitude
386738|NCT01241513|Drug|Placebo|Placebo
386739|NCT01241500|Drug|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
386740|NCT01241487|Drug|valsartan/amlodipine|160/10 mg
386741|NCT01241474|Dietary Supplement|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
386742|NCT01241474|Dietary Supplement|Maize (corn) oil|6 x 1g capsules per day for 9 months
386743|NCT01241461|Drug|LY2584702|"Dose escalation starting at 50 milligram (mg). On Day 1, subjects will receive a single oral dose. After a two-day observation period, subjects will receive oral doses twice daily for a 28-day cycle.~Patients may continue 28-day cycles of twice daily dosing until discontinuation criteria are met."
386744|NCT01241448|Drug|LY2409021|Administered Orally
386745|NCT01241448|Drug|Placebo|Administered Orally
386746|NCT01241435|Drug|LY2216684|Administered orally
387206|NCT01237977|Drug|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
386747|NCT01241422|Drug|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
386748|NCT01241422|Drug|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
386749|NCT01241422|Drug|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
386750|NCT01241409|Drug|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
386751|NCT01241409|Drug|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
386752|NCT01241409|Drug|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
386753|NCT01241396|Other|Any MMY treatment|Any line of treatment for MMY
386754|NCT01241383|Drug|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
386755|NCT01241357|Device|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
386756|NCT01241344|Drug|CMX001|"Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.~Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW"
386757|NCT01241331|Drug|BLI1100|BLI110 topical cream
386758|NCT01241331|Drug|Vehicle cream|Vehicle topical cream
386759|NCT01241318|Drug|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
386760|NCT01241318|Procedure|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
386761|NCT01241292|Biological|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
386762|NCT01241292|Biological|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
386763|NCT01241279|Device|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
386764|NCT01241279|Device|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
386765|NCT01241253|Other|Whole cooked beans with rice meals|Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
386766|NCT01241240|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
386767|NCT01241240|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
386768|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
386769|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 4) & matching placebo administered orally once daily
386770|NCT01241214|Drug|Cetirizine|Ceterizine administered once daily
386771|NCT01241214|Drug|Placebo|Matching placebo administered twice daily.
386772|NCT01241201|Dietary Supplement|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
386773|NCT01241188|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
386774|NCT01241188|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
386775|NCT01241175|Drug|Magnesium Sulfate|
386776|NCT01241175|Drug|normal saline|
386777|NCT01241162|Biological|Autologous dendritic cell vaccine with adjuvant|"Week 1:~Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)~Weeks 2 and 3:~Vaccine: 3-5 E6 peptide pulsed DC (Mon)~Hiltonol applied topically to vaccine site before and after vaccination"
386778|NCT01241149|Procedure|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
386779|NCT01241136|Procedure|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
386780|NCT01241136|Procedure|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
386781|NCT01241123|Procedure|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
386782|NCT01241123|Drug|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
387207|NCT01237977|Drug|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
386783|NCT01241123|Radiation|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
386784|NCT01241123|Device|pedometers|to record the amount of ambulation
386785|NCT01241110|Drug|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
386786|NCT01241110|Drug|azitromycin|azitromicin vs ofluxacin
386787|NCT01241097|Drug|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
386788|NCT01241084|Dietary Supplement|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
386789|NCT01241084|Dietary Supplement|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
386790|NCT01241071|Other|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
386791|NCT01241071|Other|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
386792|NCT01241032|Drug|Udenafil|200mg Single Oral Dose of
386793|NCT01241032|Dietary Supplement|Alcohol|Alcohol 39g / 240ml
386794|NCT01241019|Drug|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
386795|NCT01241006|Drug|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
386796|NCT01241006|Drug|Prednisone|Prednisone 60mg PO q day for 5 days
386797|NCT01240993|Behavioral|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
386798|NCT01240993|Behavioral|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
386799|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
386800|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
386801|NCT01240980|Drug|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
386802|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
386803|NCT01240980|Drug|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
386804|NCT01240980|Drug|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
386805|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
386806|NCT01240980|Drug|Placebo|Solution, Oral, 0 mg, once daily, 1 day
386807|NCT01240980|Drug|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
386808|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
386809|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
386810|NCT01240980|Drug|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
386811|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
386812|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
386813|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
386814|NCT01240967|Drug|TC-5214|Oral tablets, single dose
386815|NCT01240954|Drug|OSIRIS|OSIRIS current practice
386816|NCT01240954|Drug|OSIRIS other concentration 1|OSIRIS new concentration 1
386817|NCT01240954|Drug|OSIRIS other concentration 2|OSIRIS new concentration 2
386818|NCT01240941|Drug|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
386819|NCT01240941|Drug|Exemestane|25 mg orally daily
386820|NCT01240941|Drug|Goserelin|3.6 mg orally monthly
386821|NCT01240928|Drug|MSK-2206|Level 1: MK-2206 135mg weekly
386822|NCT01240928|Drug|Exemestane|Level 1: Exemestane - 25mg daily
386823|NCT01240928|Drug|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
386824|NCT01240915|Drug|placebo|once every 7 days for 1- 3 doses
386825|NCT01240915|Drug|MultiStem low dose|1-3 doses
386826|NCT01240915|Drug|placebo|Single dose at week 8
386827|NCT01240915|Drug|MultiStem low dose|Single dose at week 8
386828|NCT01240915|Drug|placebo|Single dose Day 1
386829|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
386830|NCT01240915|Drug|placebo|Single dose at week 8
386831|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
386832|NCT01240915|Drug|placebo|Single dose Day 1
386833|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
386834|NCT01240915|Drug|placebo|Single dose at week 8
386835|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
386836|NCT01240902|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
386837|NCT01240902|Device|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
386838|NCT01240889|Drug|Fluticasone|nasal spray
386839|NCT01240889|Drug|Fluticason|2 sprays per day in each nostril
386840|NCT01240876|Drug|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
386841|NCT01240876|Drug|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
386920|NCT01240161|Drug|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
386921|NCT01240148|Drug|AZD3161|Single dose, intradermal injection
386922|NCT01240148|Drug|Lidocaine|Single dose, intradermal injection
386923|NCT01240148|Drug|AZD3161 Placebo|
386842|NCT01240863|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
386843|NCT01240863|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
386844|NCT01240850|Drug|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
386845|NCT01240850|Drug|Prednisone|
386846|NCT01240837|Other|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
386847|NCT01240837|Other|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
386848|NCT01240837|Other|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
386849|NCT01240824|Drug|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
386850|NCT01240811|Drug|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
386851|NCT01240811|Drug|Levonorgestrel IUD|
386852|NCT01240811|Drug|Copper T380A IUD|
386853|NCT01240785|Drug|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
386854|NCT01240785|Drug|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
386855|NCT01240772|Device|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
386856|NCT01240772|Device|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
386857|NCT01240759|Drug|S-707106 Dose A|One S-707106 A tablet
386858|NCT01240759|Drug|S-707106 Dose B|One S-707106 B tablet
386859|NCT01240759|Drug|S-707106 Dose C|Four S-707106 4 X B tablets
386860|NCT01240759|Drug|Placebo A tablet|Up to 4 Placebo A tablets
386861|NCT01240759|Drug|Metformin|The standard of care dose of metformin for each patient
386862|NCT01240746|Biological|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
386863|NCT01240746|Biological|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
386864|NCT01240746|Biological|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to <9 years), Intramuscular
386865|NCT01240720|Drug|131I-F16SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.~Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
386866|NCT01240707|Other|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
386867|NCT01240694|Drug|Lupuzor|200 mcg
386868|NCT01240681|Procedure|FLT PET and BOLD MRI scan|Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
386869|NCT01240655|Drug|LCL161|
386870|NCT01240655|Drug|Paclitaxel|
386871|NCT01240642|Drug|ASA404|
386872|NCT01240629|Other|laboratory biomarker analysis|Correlative study
386873|NCT01240629|Other|questionnaire administration|Correlative study
386874|NCT01240629|Drug|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
386875|NCT01240590|Drug|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
386876|NCT01240590|Drug|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
386877|NCT01240577|Drug|IPdR|
386878|NCT01240551|Drug|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
386879|NCT01240538|Biological|wild-type reovirus|Given IV
386880|NCT01240538|Drug|cyclophosphamide|Given PO
386881|NCT01240538|Other|laboratory biomarker analysis|Correlative studies
386882|NCT01240538|Other|pharmacological study|Correlative studies
386883|NCT01240525|Other|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
386884|NCT01240525|Other|No DLI|Patients will not receive DLI as trial treatment
386885|NCT01240512|Drug|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
386961|NCT01239862|Other|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
386886|NCT01240499|Other|Health-At-Every-Size (HAES)|"HAES group: 14 weekly sessions.~Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.~SS group: 14 weekly sessions.~The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian & psychologist) are not counselors (as in HAES group) but only facilitators.~Outcome measures: For all women under study."
386887|NCT01240473|Drug|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
386888|NCT01240460|Drug|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
386889|NCT01240460|Drug|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
386890|NCT01240447|Biological|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
386891|NCT01240447|Other|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
386892|NCT01240434|Procedure|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
386893|NCT01240421|Drug|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
386894|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
386895|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
386896|NCT01240395|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
386897|NCT01240382|Drug|3% DE-089 ophthalmic solution|
386898|NCT01240382|Drug|0.1% sodium hyaluronate ophthalmic solution|
386899|NCT01240356|Device|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
386900|NCT01240356|Device|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
386901|NCT01240330|Device|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
386902|NCT01240304|Drug|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
386903|NCT01240304|Radiation|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
386904|NCT01240304|Procedure|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
386905|NCT01240291|Dietary Supplement|Dipeptiven|Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
386906|NCT01240291|Dietary Supplement|normal saline|0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
386907|NCT01240265|Dietary Supplement|Vitamin D3|150,000 IU orally given once
386908|NCT01240265|Dietary Supplement|Vitamin D3|5000 IU given orally daily for 28 days
386909|NCT01240252|Drug|Human insulin|U100 Humulin at a rate of 80 mU/m^2 surface area per minute one time over 4 hours
386910|NCT01240226|Drug|GDC-0941|Oral repeating dose
386911|NCT01240226|Drug|GDC-0941|Oral repeating dose
386912|NCT01240226|Drug|ketoconazole|Oral repeating dose
386913|NCT01240213|Dietary Supplement|Vitamin D|2000 IU per day of Vitamin D
386914|NCT01240213|Dietary Supplement|Placebo|1 Placebo per day
386915|NCT01240200|Drug|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
386916|NCT01240200|Device|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
386917|NCT01240187|Drug|perampanel|Single dose of 6 tablets 2 mg orally
386918|NCT01240187|Drug|perampanel|Single dose of 1 tablet 12 mg orally
386919|NCT01240174|Behavioral|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
386924|NCT01240135|Device|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
386925|NCT01240135|Device|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
386926|NCT01240135|Device|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
386927|NCT01240122|Device|Biotrue MPS|Multi-purpose contact lens care solution
386928|NCT01240122|Device|Investigational MPS|Multi-purpose contact lens care solution
386929|NCT01240109|Drug|Remifentanil|"propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml~sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
386930|NCT01240096|Drug|Mirtazapine|Mirtazapine 15 mg daily
386931|NCT01240083|Device|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
386932|NCT01240083|Device|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
386933|NCT01240083|Device|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
386934|NCT01240070|Other|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
386935|NCT01240057|Procedure|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
386936|NCT01240057|Other|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
386937|NCT01240044|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
386938|NCT01240044|Procedure|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
386939|NCT01240031|Other|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:~Thorough sensory and nutrition assessment (questionnaire).~Nutrition plan adjusted daily according to the assessment.~Serving appetising, energy- and protein-dense meals, snacks and drinks."
386940|NCT01240031|Other|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
386941|NCT01240018|Dietary Supplement|Probiotic|Parallel, randomized, controlled 2 arms study.
386942|NCT01240005|Biological|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
386943|NCT01239992|Drug|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
386944|NCT01239966|Device|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
386945|NCT01239953|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
386946|NCT01239953|Device|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
386947|NCT01239940|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
386948|NCT01239940|Device|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
386949|NCT01239927|Procedure|Primary sigmoid resection with end colostomy (Hartmann)|
386950|NCT01239927|Procedure|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
386951|NCT01239888|Drug|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
386952|NCT01239888|Drug|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
386953|NCT01239888|Drug|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
386954|NCT01239875|Biological|dendritic cell vaccine therapy|Given intratumorally
386955|NCT01239875|Procedure|cryotherapy|Undergo cryoablation
386956|NCT01239875|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
386957|NCT01239875|Other|laboratory biomarker analysis|Correlative studies
386958|NCT01239875|Other|immunoenzyme technique|Correlative studies
386959|NCT01239875|Other|immunohistochemistry staining method|Correlative studies
386960|NCT01239875|Biological|autologous dendritic cell-tumor fusion vaccine|Given intradermally
386962|NCT01239849|Drug|Atorvastatin, 10mg, 20mg, 40mg|"If initial LDL cholesterol between 100~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130~159 mg/dl is 20 mg, 160~220mg/dl is 40mg.~After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.~After 4 weeks treatment, recheck the LDL cholesterol"
386963|NCT01239836|Behavioral|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
386964|NCT01239836|Behavioral|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
386965|NCT01239836|Behavioral|General health lecture|Participants will attend a lecture on general women`s health issues that does not address urinary incontinence.
386966|NCT01239823|Other|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
386967|NCT01239823|Other|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
386968|NCT01239810|Drug|Hyaluronic Acid|Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
386969|NCT01239797|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
386970|NCT01239797|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
386971|NCT01239797|Drug|Dexamethasone (Oral)|"On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.~On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
386972|NCT01239797|Drug|Dexamethasone (IV)|"On weeks without Elotuzumab dosing: Not Applicable (N/A)~On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
386973|NCT01239797|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
386974|NCT01239784|Behavioral|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
386975|NCT01239771|Drug|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
386976|NCT01239771|Drug|Placebo|Two subjects in each cohort will be given placebo.
386977|NCT01239758|Biological|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
386978|NCT01239758|Biological|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
386979|NCT01239758|Biological|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
386980|NCT01239745|Drug|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
386981|NCT01239732|Drug|Paclitaxel|175 mg/m^2 on Day 1 every 3 weeks or at a dose of 80 mg/m^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
386982|NCT01239732|Drug|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
386983|NCT01239732|Drug|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
386984|NCT01239719|Drug|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
386985|NCT01239719|Drug|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
386986|NCT01239706|Drug|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
386987|NCT01239693|Dietary Supplement|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
386988|NCT01239693|Dietary Supplement|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
386989|NCT01239693|Dietary Supplement|LNS|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
386990|NCT01239680|Drug|Glutamine|Intravenous 25 grams once over 6 hours
386991|NCT01239680|Drug|Ringer's Lactate|Intravenous 1 liter once over 6 hours
386992|NCT01239680|Drug|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
386993|NCT01239667|Other|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
386994|NCT01239654|Device|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
386995|NCT01239641|Procedure|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
386996|NCT01239563|Drug|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
386997|NCT01239563|Drug|Basiliximab|Intravenous 20mg, day 0&4
386998|NCT01239550|Drug|Detemir|"Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.~Insulin injections will be given subcutaneously preferably in the thigh or abdomen."
386999|NCT01239537|Drug|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
387000|NCT01239524|Procedure|denervation of thoracodorsal nerve or saving the nerve|
387001|NCT01239511|Drug|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
387002|NCT01239498|Procedure|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.~Injection of Saline + Lidocaine 1%"
387003|NCT01239498|Procedure|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
387004|NCT01239485|Drug|Irinotecan|"Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, & 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr~*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4."
387005|NCT01239472|Drug|Everolimus|Replacement of tacrolimus by everolimus, 30 days after transplat. It was done after kidney biopsy (excluding acute rejection), blood and urine analysis.
387006|NCT01239459|Drug|Teriflunomide HMR1726|"Pharmaceutical form:film coated tablet~Route of administration: oral administration on Day 1 under fasted condition"
387007|NCT01239459|Drug|Cholestyramine|"Pharmaceutical form:powder~Route of administration: oral administration 3 times per day on Day 54 and 55"
387008|NCT01239446|Other|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
387009|NCT01239407|Behavioral|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:~1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).~1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.~2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).~3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
387010|NCT01239394|Drug|ofatumumab|Weekly infusion for 8 weeks
387011|NCT01239381|Radiation|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
387012|NCT01239368|Procedure|Adoptive Immunotherapy|Th1 (type 1 T helper cells)/Tc1 (T cytotoxic cells, type 1) Rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immune depleting chemotherapy (pentostatin plus cyclophosphamide regimen).
387013|NCT01239368|Biological|Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells)|Six Th1/Tc1 Rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e(5) to 15 x 10e(6) cells/kg of body weight.
387014|NCT01239368|Biological|Th1/Tc1 Rapa Cell Therapy|Th1/Tc1Rapa: 5 x 10e(6) cells/kg
387015|NCT01239355|Drug|Akt Inhibitor MK2206|Given PO
387016|NCT01239355|Other|Laboratory Biomarker Analysis|Correlative studies
387017|NCT01239342|Drug|Akt Inhibitor MK2206|Given PO
387018|NCT01239342|Drug|Everolimus|Given PO
387019|NCT01239342|Other|Laboratory Biomarker Analysis|Optional correlative studies
387020|NCT01239316|Other|Laboratory Biomarker Analysis|Correlative studies
387021|NCT01239316|Other|Pharmacological Study|Correlative studies
387022|NCT01239316|Drug|Vismodegib|Given PO
387023|NCT01239303|Dietary Supplement|Citrulline|single dose
387024|NCT01239303|Dietary Supplement|alanine|single dose
387025|NCT01239277|Other|protein|20g protein
387026|NCT01239277|Other|protein and carbohydrate|20g protein and 20g carbohydrate
387027|NCT01239277|Other|protein and leucine|20g protein, 2.5g leucine
387028|NCT01239251|Other|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
387029|NCT01239225|Device|Abdominal ultra-sound|
387030|NCT01239225|Procedure|Abdominal ultrasound|
387031|NCT01239212|Drug|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
387032|NCT01239199|Other|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
387033|NCT01239186|Other|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
387034|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
387035|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
387036|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
387202|NCT01238042|Drug|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
387037|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
387038|NCT01239160|Device|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
387039|NCT01239160|Device|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
387040|NCT01239147|Other|Diet rich in whole grain|Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
387041|NCT01239147|Other|Refined grain|Ready-to-eat breakfast cereals and other cereal products, low in whole grain
387042|NCT01239134|Biological|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
387043|NCT01239121|Other|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
387044|NCT01239121|Other|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
387045|NCT01239108|Drug|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
387046|NCT01239095|Drug|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
387047|NCT01239082|Procedure|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
387048|NCT01239082|Procedure|FIT|Annual FIT testing
387049|NCT01239069|Drug|DE-110 ophthalmic suspension high dose|ophthalmic suspension; high dose; QID
387050|NCT01239069|Drug|DE-110 ophthalmic suspension low dose|ophthalmic suspension; low dose; QID
387051|NCT01239069|Other|Placebo|DE-110 ophthalmic suspension vehicle;QID
387052|NCT01239056|Procedure|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
387053|NCT01239043|Biological|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
387054|NCT01239043|Biological|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
387055|NCT01239030|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
387056|NCT01239017|Biological|REGN475|
387057|NCT01239017|Other|Placebo|
387058|NCT01239004|Drug|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
387059|NCT01239004|Drug|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
387060|NCT01238991|Biological|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
387061|NCT01238991|Biological|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
387062|NCT01238991|Biological|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
387063|NCT01238978|Drug|Vildagliptin|
387064|NCT01238978|Drug|"Usual Care"|
387065|NCT01238965|Drug|panobinostat|Given orally
387066|NCT01238965|Drug|fluorouracil|Given IV
387067|NCT01238965|Drug|leucovorin calcium|Given IV
387068|NCT01238965|Procedure|biopsy|Correlative studies
387069|NCT01238965|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
387070|NCT01238965|Genetic|western blotting|Correlative studies
387071|NCT01238965|Other|laboratory biomarker analysis|Correlative studies
387072|NCT01238965|Genetic|gene expression analysis|Correlative studies
387073|NCT01238965|Genetic|RNA analysis|Correlative studies
387074|NCT01238965|Genetic|polymorphism analysis|Correlative studies
387075|NCT01238952|Drug|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
387076|NCT01238939|Drug|NK012 and 5-FU|NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
387077|NCT01238926|Dietary Supplement|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
387078|NCT01238926|Other|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
387079|NCT01238926|Other|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
387080|NCT01238913|Procedure|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
387081|NCT01238900|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
387082|NCT01238887|Dietary Supplement|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
387083|NCT01238887|Dietary Supplement|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
387496|NCT01235559|Drug|Placebo|Oral doses, once a day for 52 weeks
387084|NCT01238887|Dietary Supplement|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
387085|NCT01238874|Device|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
387086|NCT01238861|Biological|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
387087|NCT01238861|Biological|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
387088|NCT01238861|Biological|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
387089|NCT01238861|Other|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
387090|NCT01238848|Drug|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
387091|NCT01238848|Drug|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
387092|NCT01238835|Device|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
387093|NCT01238822|Drug|Methylphenidate|18 mg methylphenidate
387094|NCT01238822|Drug|placebo|Placebo
387095|NCT01238822|Drug|Methylphenidate|36 mg methylphenidate
387096|NCT01238822|Drug|Methylphenidate|54 mg methylphenidate
387097|NCT01238796|Drug|telavancin|Intravenous
387098|NCT01238783|Drug|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
387099|NCT01238783|Drug|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
387100|NCT01238783|Drug|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
387101|NCT01238783|Drug|Vehicle|Topical ocular dosed 3 times per day for 3 days
387102|NCT01238770|Drug|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally~Phase II:~Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
387103|NCT01238757|Other|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
387104|NCT01238757|Other|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
387105|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
387106|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
387107|NCT01238744|Dietary Supplement|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
387108|NCT01238744|Dietary Supplement|Control drink|Control drink
387109|NCT01238718|Drug|Lidocaine|lidocaine 1.5 mg/kg intravenously
387110|NCT01238718|Drug|Placebo|normal saline
387111|NCT01238705|Drug|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
387112|NCT01238705|Drug|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.~Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
387113|NCT01238692|Drug|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
387114|NCT01238692|Drug|Rituximab|"Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL)."
387115|NCT01238679|Drug|PF-04958242 0.03 mg|0.03 mg dose tablet every 12 hours for 14 days
387116|NCT01238679|Drug|PF-04958242 0.05 mg|PF-04958242 0.05 mg dose tablet every 24 hours for 14 days
387117|NCT01238679|Drug|Placebo|Placebo tablet every 12 hours or every 24 hours for 14 days
387118|NCT01238640|Drug|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
387119|NCT01238640|Drug|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
387120|NCT01238640|Drug|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
387121|NCT01238627|Drug|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
387122|NCT01238627|Drug|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
387123|NCT01238614|Other|CHICA PSF plus JIT|
387124|NCT01238614|Other|CHICA maternal depression PSF|
387125|NCT01238614|Other|Control|
387126|NCT01238588|Drug|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
387127|NCT01238575|Other|placebo|Administered for up to 8 weeks.
387128|NCT01238575|Drug|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
387208|NCT01237964|Drug|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
387129|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
387130|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
387131|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
387132|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
387133|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
387134|NCT01238536|Procedure|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
387135|NCT01238536|Procedure|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
387136|NCT01238536|Drug|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
387137|NCT01238536|Drug|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
387138|NCT01238523|Procedure|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
387139|NCT01238523|Procedure|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
387140|NCT01238510|Procedure|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.~Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
387141|NCT01238510|Procedure|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.~Stent type: Everolimus-eluting stent only"
387142|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
387143|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
387144|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
387145|NCT01238484|Other|Standard of care|shoe modification home stretching exercises
387146|NCT01238484|Device|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
387147|NCT01238471|Drug|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
387148|NCT01238471|Drug|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
387149|NCT01238458|Drug|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.~Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
387150|NCT01238419|Device|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
387151|NCT01238419|Device|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
387152|NCT01238406|Device|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
387153|NCT01238406|Device|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
387154|NCT01238393|Drug|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
387155|NCT01238380|Other|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.~Stage 2: Pancreatic auto-antibodies measurement (GAD65 & IA2); if negative progress to genetic testing.~Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.~Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
387156|NCT01238367|Drug|turoctocog alfa|Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
387157|NCT01238354|Behavioral|With friend|
387158|NCT01238354|Behavioral|Without friend|
387159|NCT01238341|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
387203|NCT01238029|Drug|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
387204|NCT01238016|Device|experimental|
387160|NCT01238328|Drug|Conditioning regimen|"For sibling full match:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~Fludarabine 160 mg/m^2"
387161|NCT01238328|Drug|Graft-versus-host disease (GVHD) prophylaxis|"Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po~10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)"
387162|NCT01238328|Procedure|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~Sibling full match~Other related full match~Sibling or other related with 1 mismatch antigen~Cord Blood~Haploidentical"
387163|NCT01238315|Biological|HuCNS-SC|Surgery to implant human CNS stem cells
387164|NCT01238302|Procedure|Conventional arthroscopic rotator cuff repair|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
387165|NCT01238302|Procedure|Arthroscopic rotator cuff repair with PRP|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4-5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repair of full thickness rotator cuff tear was done with suture anchors.~After tying sutures of the medial row, PRP gels were applied on the repair site.~The lateral row was secured using suture anchors.~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound."
387166|NCT01238289|Behavioral|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
387167|NCT01238289|Behavioral|Control|This group continues with standard care at the community health center
387168|NCT01238276|Drug|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
387169|NCT01238276|Device|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
387170|NCT01238237|Drug|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
387171|NCT01238224|Drug|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
387172|NCT01238211|Drug|Cytarabine|Given IV
387173|NCT01238211|Drug|Dasatinib|Given PO
387174|NCT01238211|Drug|Daunorubicin Hydrochloride|Given IV
387175|NCT01238211|Other|Laboratory Biomarker Analysis|Correlative studies
387176|NCT01238185|Drug|acetylsalicylic acid|
387177|NCT01238185|Genetic|gene expression analysis|
387178|NCT01238185|Genetic|protein expression analysis|
387179|NCT01238185|Other|laboratory biomarker analysis|
387180|NCT01238185|Other|questionnaire administration|
387181|NCT01238185|Procedure|biopsy|
387182|NCT01238172|Other|dietary education and counseling|
387183|NCT01238172|Other|prostate cancer foundation booklet|
387184|NCT01238159|Radiation|CCRT+MIDLE chemotherapy|Patients are planned to be treated with CCRT plus MIDLE chemotherapy
387185|NCT01238146|Drug|bendamustine hydrochloride|Given IV
387186|NCT01238146|Drug|obatoclax mesylate|Given IV
387187|NCT01238146|Biological|rituximab|Given IV
387188|NCT01238133|Drug|Carboplatin|Given IV
387189|NCT01238133|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
387190|NCT01238133|Other|Laboratory Biomarker Analysis|Correlative studies
387191|NCT01238133|Drug|Paclitaxel|Given IV
387192|NCT01238133|Other|Pharmacological Study|Ancillary studies
387193|NCT01238133|Procedure|Therapeutic Conventional Surgery|Undergo surgery
387194|NCT01238120|Drug|Ibuprofen|200 mg BID and 8 hours apart
387195|NCT01238120|Behavioral|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
387196|NCT01238120|Drug|Placebo|200mg BID and 8 hours apart
387197|NCT01238107|Drug|MT-102|BETA BLOCKER
387198|NCT01238094|Drug|Simvastatin|simvastatin 40 mg qd daily until disease progression
387199|NCT01238068|Device|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
387200|NCT01238055|Drug|Docetaxel + Sunitinib|"Docetaxel 60 mg/m2 iv, every 3 weeks~Sunitinib 37.5 mg qd daily, every 3 weeks"
387201|NCT01238055|Drug|Docetaxel only|Docetaxel 60 mg/m2 iv
387209|NCT01237951|Drug|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.~60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
387210|NCT01237951|Drug|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
387211|NCT01237951|Drug|Gemcitabine|1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
387212|NCT01237951|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.~Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
387213|NCT01237951|Drug|Melphalan|60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
387214|NCT01237951|Procedure|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
387215|NCT01237951|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
387216|NCT01237938|Behavioral|Low Glycemic Diet|Changing to low glycemic diet
387217|NCT01237925|Drug|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
387218|NCT01237925|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
387219|NCT01237899|Drug|LY2623091|Administered orally.
387220|NCT01237899|Drug|Placebo|Administered orally.
387221|NCT01237899|Drug|Eplerenone|Administered orally.
387222|NCT01237873|Drug|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
387223|NCT01237860|Device|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
387224|NCT01237847|Behavioral|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
387225|NCT01237847|Behavioral|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
387226|NCT01237847|Behavioral|Wait list comparison group|Wait list comparison group to receive intervention at later point.
387227|NCT01237821|Drug|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
387228|NCT01237821|Drug|Effaclar|Topical, Bid, 12 weeks
387229|NCT01237808|Drug|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
387230|NCT01237808|Drug|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
387231|NCT01237808|Drug|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
387232|NCT01237795|Other|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
387233|NCT01237782|Drug|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
387234|NCT01237782|Drug|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
387235|NCT01237769|Drug|Vitamin D3|2200 IU/day
387236|NCT01237769|Behavioral|Lifestyle advice|Diet and exercise
387237|NCT01237756|Device|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
387238|NCT01237743|Device|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
387239|NCT01237730|Drug|cefuroxime|Use the cefuroxime as prophylaxis.
387240|NCT01237730|Drug|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
387241|NCT01237704|Behavioral|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
387242|NCT01237704|Behavioral|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
387243|NCT01237691|Behavioral|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
387244|NCT01237691|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
387245|NCT01237678|Drug|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
387246|NCT01237678|Drug|Carboplatin and Etoposide|Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
387247|NCT01237665|Drug|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
387248|NCT01237639|Other|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
387249|NCT01237613|Device|Artelon|Artelon Tissue Reinforcement
387250|NCT01237600|Procedure|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
387251|NCT01237587|Drug|Duloxetine|Administered orally
387252|NCT01237587|Drug|Placebo|Administered orally
387253|NCT01237574|Other|Intervention according to the standard of care.|Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.
387254|NCT01237561|Other|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
387255|NCT01237548|Other|Smoking Narghile for 30 min|No Other intervention will be used
387302|NCT01237080|Device|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
387303|NCT01237080|Device|Fastrach|The Fastrach is an intubation laryngeal mask.
387256|NCT01237535|Drug|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
387257|NCT01237535|Drug|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
387258|NCT01237535|Procedure|Insemination without luteal support|Routine insemination procedure without luteal support
387259|NCT01237522|Drug|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
387260|NCT01237509|Device|Hypo device|
387261|NCT01237496|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
387262|NCT01237483|Drug|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
387263|NCT01237470|Procedure|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
387264|NCT01237470|Procedure|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
387265|NCT01237457|Drug|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
387266|NCT01237444|Drug|lopinavir/ritonavir plus one nucleoside|"ARM 1:~Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
387267|NCT01237444|Drug|lopinavir /ritonavir plus two nucleosides|"ARM 2:~3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
387268|NCT01237431|Dietary Supplement|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
387269|NCT01237405|Drug|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at ~1 minute) SPECT/CT of both knees; a late phase (at ~60 minutes) SPECT/CT image of both knees; and a late phase (at ~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
387270|NCT01237392|Device|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
387271|NCT01237366|Behavioral|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
387272|NCT01237353|Dietary Supplement|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
387273|NCT01237353|Drug|Rabeprazole|rabeprazole po daily x 5 days
387274|NCT01237340|Drug|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
387275|NCT01237327|Drug|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
387276|NCT01237327|Drug|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
387277|NCT01237301|Device|CGM Group|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
387278|NCT01237301|Device|SMBG Group|Fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes. Used CGM blinded once every four weeks.
387279|NCT01237288|Drug|Z-521|
387280|NCT01237275|Drug|SSRI treated group|characterize in arm of a study (SSRI treated group)
387281|NCT01237262|Drug|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.~Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
387282|NCT01237249|Drug|Melphalan|
387283|NCT01237249|Drug|Prednisone|
387284|NCT01237249|Drug|Velcade|
387285|NCT01237249|Drug|Revlimid|
387286|NCT01237249|Drug|Dexamethasone|
387287|NCT01237236|Drug|LEE011|
387288|NCT01237223|Drug|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
387289|NCT01237223|Drug|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
387290|NCT01237223|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
387291|NCT01237223|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
387292|NCT01237223|Drug|Placebo of Aliskiren|Aliskiren placebo tablet
387293|NCT01237223|Drug|Placebo of Amlodipine|Amlodipine placebo capsule
387294|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
387295|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
387296|NCT01237197|Drug|Exenatide|Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
387297|NCT01237197|Drug|Placebo|Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
387298|NCT01237171|Radiation|Cesium-131 Brachytherapy Seed|85 Gray Dose
387299|NCT01237119|Drug|Liraglutide|1.8 mg once daily, subcutaneous injection
387300|NCT01237119|Other|Liraglutide-placebo|1.8 mg once-daily, subcutaneous injection
387301|NCT01237106|Other|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
387304|NCT01237067|Drug|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
387305|NCT01237067|Drug|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
387306|NCT01237054|Drug|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
387307|NCT01237054|Other|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
387308|NCT01237054|Drug|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
387309|NCT01237041|Drug|Niacin First|Niacin 500 mg po four times on one of the inpatient days, then placebo on another inpatient day
387310|NCT01237041|Drug|Placebo First|Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day
387311|NCT01237041|Drug|Dose-Establishing Study 1 Niacin 250mg|Niacin 250 mg po three times at 2 hour intervals on an inpatient day
387312|NCT01237041|Drug|Dose-Establishing Study 1 Niacin 500mg|Niacin 500 mg po three times at 2 hour intervals on an inpatient day
387313|NCT01237041|Drug|Dose-Establishing Study 2 Niacin 500mg|Open-Label Niacin 500mg four times at 1 hour intervals on an inpatient day
387314|NCT01237028|Drug|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
387315|NCT01237015|Device|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
387316|NCT01236989|Procedure|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
387317|NCT01236989|Procedure|Non-anatomical liver resection|non-anatomical liver resection
387318|NCT01236976|Device|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It has adjustable ergonomic seating for the therapists, a dedicated computer, surge protector, battery backup, custom software and controls, and a closed-loop feedback system. A therapist/assistant is positioned behind the participant to stabilise the pelvis and trunk, and to assist with appropriate weight shifting and hip rotation during the step cycle. Two additional therapists are seated in front of the participant to provide manual assistance for the lower limbs to facilitate knee extension during stance and knee flexion and toe clearance during swing, maintaining appropriate alignment of the limbs. A fourth person controls the treadmill. This system is being used in US universities and rehabilitation facilities throughout North America and is registered with the FDA (Regulation Number 890.5380).
387319|NCT01236976|Device|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD). Surface electrodes will be applied to the quadriceps, gluteal, hamstrings and calf muscles according to a standardized protocol. The pedal cadence will be set to 15-50 rev•min-1. Stimulation intensity will be gradually increased to a maximum of 140 mA with a pulse width of 0.3ms and frequency of 35Hz (Eser et al. 2003; Fornusek & Davis, 2008). Participants will exercise at the maximal power output possible at their level of recovery. Participants will commence with 10 minutes of training and gradually build up to a period of 30 minutes. The frequency, power output at each minute, and training duration will be recorded at each training session.
387320|NCT01236976|Other|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality. These may be provided in lying (e.g. supine, prone) and in weight-bearing positions (e.g. kneeling, standing). Task-specific practice of functional tasks, involving moving the upper body over and outside the base of support, will also be undertaken. Participants may also be given exercises in motor imagery, imagining movements of their body
387321|NCT01236976|Other|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
387322|NCT01236963|Drug|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
387323|NCT01236963|Device|Dental Floss|
387324|NCT01236950|Drug|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
387325|NCT01236950|Drug|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
387326|NCT01236937|Device|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:~The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
387327|NCT01236924|Other|Global postural reeducation|
387328|NCT01236911|Other|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
387329|NCT01236898|Drug|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
387330|NCT01236885|Other|computer-assisted intervention|Undergo blood glucose management using Glucommander
387331|NCT01236872|Dietary Supplement|Beetroot juice|250ml once of beetroot juice
387332|NCT01236872|Dietary Supplement|Water|250ml once of low-nitrate mineral water
387333|NCT01236859|Drug|Gabapentin|Neurontin®, Pfizer
387334|NCT01236846|Dietary Supplement|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
387335|NCT01236846|Dietary Supplement|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
387336|NCT01236833|Drug|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
387337|NCT01236807|Procedure|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
387338|NCT01236807|Procedure|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
387339|NCT01236794|Behavioral|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a ~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
387340|NCT01236781|Device|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
387341|NCT01236781|Device|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
387342|NCT01236768|Drug|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
387343|NCT01236768|Drug|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
387344|NCT01236755|Device|single-vision glasses|Daily wear of glasses to correct vision in the first seven months of the study
387345|NCT01236755|Device|ortho-k lenses|Nightly wear of lenses to correct vision in day time in the second seven months of the study
387346|NCT01236742|Device|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
387347|NCT01236742|Device|single-vision glasses|daily wear of spectacle glasses to correct vision
387348|NCT01236716|Drug|Albumin paclitaxel plus carboplatin|Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
387349|NCT01236716|Drug|Gemcitabine plus carboplatin|Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
387350|NCT01236690|Drug|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
387351|NCT01236664|Behavioral|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
387352|NCT01236664|Behavioral|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
387353|NCT01236651|Drug|Meperidine|administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
387354|NCT01236651|Drug|Drotaverine|administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
387355|NCT01236638|Drug|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
387356|NCT01236625|Procedure|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
387357|NCT01236612|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
387358|NCT01236612|Biological|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
387359|NCT01236612|Biological|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
387360|NCT01236612|Biological|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
387361|NCT01236612|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
387362|NCT01236599|Other|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
387363|NCT01236586|Drug|RO4929097|
387364|NCT01236586|Drug|Dexamethasone|
387365|NCT01236573|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
387366|NCT01236573|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
387491|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
388555|NCT01227837|Dietary Supplement|omga3|use of omega 3
387367|NCT01236573|Biological|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
387368|NCT01236560|Biological|Bevacizumab|Given IV
387369|NCT01236560|Drug|Temozolomide|Given PO
387370|NCT01236560|Drug|Vorinostat|Given PO
387371|NCT01236547|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
387372|NCT01236547|Drug|Paclitaxel|Given IV
387373|NCT01236547|Drug|Pazopanib Hydrochloride|Given PO
387374|NCT01236547|Other|Placebo|Given PO
387375|NCT01236534|Drug|Lubiprostone|24 mcg twice daily for 21 days.
387376|NCT01236534|Drug|Placebo|matching placebo twice daily for 21 days.
387377|NCT01236521|Drug|Pharmacological (PHARM)|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.~The Patients in the PHARM arm will be asked to sign an opioid treatment agreement at enrollment."
387378|NCT01236521|Behavioral|Behavioral treatment (BEH)|There will be 8 sessions of pain self-management and coping skills.
387379|NCT01236508|Radiation|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
387380|NCT01236495|Drug|spinal morphine 0.3 mg|spinal morphine 0.3 mg
387381|NCT01236495|Drug|spinal morphine 0.2 mg|spinal morphine 0.2 mg
387382|NCT01236482|Drug|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
387383|NCT01236469|Procedure|Echocardiogram|A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
387384|NCT01236456|Drug|Cyclophosphamide|
387385|NCT01236443|Drug|HPPH|3 mg/m2 IV
387386|NCT01236430|Drug|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
387387|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
387388|NCT01236430|Drug|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
387389|NCT01236430|Drug|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
387390|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
387391|NCT01236417|Behavioral|Exercising block|Exercising for 8 weeks using an elastic band
387392|NCT01236404|Drug|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
387393|NCT01236404|Drug|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
387394|NCT01236391|Drug|PCI-32765|560 mg daily
387395|NCT01236378|Drug|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
387396|NCT01236365|Drug|Atorvastatin|10 or 20 mg daily
387397|NCT01236365|Drug|Atorvastatin Placebo|10 or 20 mg daily
387398|NCT01236352|Drug|BMS-911543|
387399|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
387400|NCT01236339|Procedure|LVP|Large Volume Paracentesis
387401|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
387402|NCT01236326|Procedure|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
387403|NCT01236326|Procedure|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
387404|NCT01236313|Procedure|TEE report|Information will be collected during cardiac surgery.
387405|NCT01236300|Device|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
387406|NCT01236287|Drug|Voclosporin|Subjects will receive voclosporin capsules, twice daily to maintain a trough level > 20 ng/mL.
387407|NCT01236261|Other|Non intervention|Non interventional study
387408|NCT01236248|Behavioral|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
387409|NCT01236222|Behavioral|Cycling to school|Regular cycling to school
387410|NCT01236209|Other|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
387411|NCT01236209|Other|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
387412|NCT01236196|Behavioral|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
387413|NCT01236196|Behavioral|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
387414|NCT01236144|Drug|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
387492|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
387415|NCT01236144|Drug|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
387416|NCT01236144|Drug|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
387417|NCT01236131|Other|no intervention|Not Applicable- no intervention
387418|NCT01236118|Drug|LY2439821|Administered subcutaneously
387419|NCT01236105|Drug|LY2624803|Administered orally (po), once.
387420|NCT01236105|Other|Activated Charcoal|Administered po
387421|NCT01236092|Other|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
387422|NCT01236079|Behavioral|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
387423|NCT01236066|Other|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children <5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
387424|NCT01236053|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
387425|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
387426|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
387427|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
387428|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
387429|NCT01236040|Other|Placebo|Intramuscular injection, two doses
387430|NCT01236027|Other|no intervention|not applicable-no intervention
387431|NCT01236014|Drug|Eltrombopag|Eltrombopag & standard of care
387432|NCT01236014|Drug|Romiplostim|Romiplostim & standard of care
387433|NCT01236014|Drug|Placebo|Placebo & standard of care
387434|NCT01236001|Drug|Lacosamide|
387435|NCT01235988|Drug|Eltrombopag|Eltrombopag 50mg & standard of care
387436|NCT01235988|Drug|Placebo|Placebo + standard of care
387437|NCT01235975|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
387438|NCT01235975|Biological|MencevaxACWY TM|Subcutaneous injection
387439|NCT01235962|Drug|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
387440|NCT01235962|Drug|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
387441|NCT01235949|Biological|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
387442|NCT01235949|Biological|Infanrix hexa|Intramuscular injection, 3 doses
387443|NCT01235949|Biological|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
387444|NCT01235949|Drug|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
387445|NCT01235949|Drug|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
387446|NCT01235936|Drug|AKB-6548|Different dose levels
387447|NCT01235923|Drug|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
387448|NCT01235923|Drug|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
387449|NCT01235910|Drug|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
387450|NCT01235897|Drug|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
387451|NCT01235897|Drug|Paclitaxel|80 mg/m2 weekly - paclitaxel
387452|NCT01235897|Drug|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
387453|NCT01235884|Dietary Supplement|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
387454|NCT01235884|Dietary Supplement|Placebo|5 drops daily for 28 days
387455|NCT01235871|Drug|SB1578|JAK2 Inhibitor
387456|NCT01235871|Drug|Placebo|Control arm
387457|NCT01235858|Procedure|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
387458|NCT01235858|Procedure|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
387459|NCT01235845|Biological|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.~DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
387493|NCT01235572|Procedure|standard follow-up care|Undergo early discharge and standard outpatient care
387494|NCT01235572|Other|medical chart review|Undergo early discharge and standard outpatient care
387460|NCT01235832|Other|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
387461|NCT01235832|Other|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
387462|NCT01235832|Other|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
387463|NCT01235819|Drug|Insulin|Exenatide Sitagliptin
387464|NCT01235819|Drug|Sitagliptin|Sitagliptin 100 mg per day oral
387465|NCT01235819|Drug|Exenatide|Exenatide 10 micrograms daily twice
387466|NCT01235806|Radiation|MRI|MRI of the scaphoid bone fracture suspicion
387467|NCT01235793|Drug|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
387468|NCT01235767|Other|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
387469|NCT01235754|Drug|transdermal testosterone gel 1%|300 mcg once daily transdermal testosterone gel 1%
387470|NCT01235754|Drug|placebo gel|once daily transdermal placebo gel
387471|NCT01235741|Drug|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
387472|NCT01235741|Drug|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
387473|NCT01235728|Drug|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
387474|NCT01235728|Drug|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
387475|NCT01235728|Drug|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
387476|NCT01235715|Drug|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
387477|NCT01235702|Behavioral|12-week lifestyle modification|
387478|NCT01235689|Biological|Adalimumab|If adalimumab was initiated, it was administered subcutaneously as a 160 mg induction dose the first week, followed by 80 mg 2 weeks later, followed by 40 mg every other week as a maintenance dose. The dose of adalimumab was increased from 40 mg eow to 40 mg every week in participants with an inadequate response and de-escalated to 40 mg eow in participants who met success criteria.
387479|NCT01235689|Drug|Prednisone|The suggested regimen for participants initiating prednisone consisted of a maximum dose of prednisone 40 mg/day for 2 weeks, followed by a fixed taper for 6 weeks.
387480|NCT01235689|Drug|Azathioprine|Participants with normal thiopurine methyltransferase (TPMT) enzyme activity could receive oral azathioprine 2.5 mg/kg/day. In participants with intermediate TPMT enzyme activity azathioprine was initiated at a dose of 1.25 mg/kg/day. The dose of azathioprine was adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
387481|NCT01235676|Behavioral|diet|calorie restriction to reduce weight gain
387482|NCT01235676|Behavioral|Exercise|Exercise to reduce weight gain
387483|NCT01235663|Behavioral|advisory support|regular advisory support to the prolong breast-feeding period
387484|NCT01235637|Drug|Alfentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
387485|NCT01235637|Drug|Sufentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.~Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK~Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
387486|NCT01235624|Genetic|genetic analysis|
387487|NCT01235598|Other|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
387488|NCT01235598|Biological|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
387489|NCT01235598|Biological|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
387490|NCT01235585|Drug|Placebo|Oral doses, once a day for 52 weeks
387497|NCT01235559|Drug|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
387498|NCT01235559|Drug|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
387499|NCT01235546|Drug|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
387500|NCT01235546|Drug|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
387501|NCT01235533|Dietary Supplement|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
387502|NCT01235520|Drug|Placebo|Oral doses, once a day for 52 weeks
387503|NCT01235520|Drug|RO4917838|Oral dose level 1, once a day for 52 weeks
387504|NCT01235520|Drug|RO4917838|Oral dose level 2, once a day for 52 weeks
387505|NCT01235507|Drug|methotrexate|stable dose as prescribed
387506|NCT01235507|Drug|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
387507|NCT01235494|Other|polarised 3 helium|1 inhalation (= 1 litre)
387508|NCT01235481|Device|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
387509|NCT01235481|Behavioral|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
387510|NCT01235468|Biological|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
387511|NCT01235455|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
387512|NCT01235442|Drug|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
387513|NCT01235442|Drug|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
387514|NCT01235429|Behavioral|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
387515|NCT01235429|Behavioral|Partners in Care|Diabetes self-management education
387516|NCT01235416|Drug|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
387517|NCT01235403|Drug|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.~Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.~Taper phase if needed: 3 to 4 weeks"
387518|NCT01235390|Dietary Supplement|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
387519|NCT01235377|Other|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
387520|NCT01235364|Device|Foley catheter|The Foley catheter was placed with the digital method
387521|NCT01235364|Device|Foley catheter|The Foley catheter was placed with a speculum
387522|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
387523|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily
387524|NCT01235338|Drug|LDX + Venlafaxine XR|"Day 1-5 LDX 30mg~Day 6-10 LDX 50mg~Day 11-15 LDX 70mg~Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily~Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily~Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily~Day 31-34 Venlafaxine XR 150mg daily~Day 35-38 Venlafaxine XR 75mg daily."
387525|NCT01235338|Drug|Venlafaxine XR + LDX|"Day 1-5 Venlafaxine XR 75mg~Day 6-10 Venlafaxine XR 150mg~Day 11-15 Venlafaxine XR 225mg~Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily~Day 21-25 Venlafaxine XR and LDX 50mg daily~Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily~Day 31-34 Venlafaxine XR 150mg~Day 35-38 Venlafaxine XR 75mg."
387526|NCT01235325|Dietary Supplement|phylloquinone (vitamin K1)|1000 mcg phylloquinone (vitamin K1) once daily for 12 months
387527|NCT01235325|Dietary Supplement|placebo|placebo oil capsule
387528|NCT01235286|Procedure|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.~The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
387529|NCT01235273|Drug|Growth Hormone|growth hormone administration
387530|NCT01235273|Other|Placebo|standard placebo
387531|NCT01235260|Other|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
387532|NCT01235260|Drug|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
387533|NCT01235247|Behavioral|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
387534|NCT01235234|Drug|CF101|orally q12h
387535|NCT01235221|Drug|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
387536|NCT01235208|Other|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
387537|NCT01235195|Drug|sertraline hydrochloride|50 mg capsule, single-dose
387538|NCT01235195|Drug|sertraline hydrochloride|50 mg tablet, single-dose
387539|NCT01235169|Device|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
387540|NCT01235143|Drug|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
387541|NCT01235143|Drug|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
387542|NCT01235130|Drug|OMEGA-3|600mg, 2 caps, twice a day
387543|NCT01235130|Drug|Placebo soybean oil|600mg, 2caps twice a day
387544|NCT01235117|Drug|azacitidine|
387545|NCT01235117|Other|laboratory biomarker analysis|
387546|NCT01235104|Procedure|Total nephrectomy|Total nephrectomy
387547|NCT01235091|Behavioral|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
387548|NCT01235091|Behavioral|Standard Intervention plus Well-Woman Exam|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
387549|NCT01235091|Behavioral|Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
387550|NCT01235078|Device|EZ-IO|powered intraosseous vascular access system
387551|NCT01235065|Device|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
387552|NCT01235052|Radiation|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy [18F]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. [18F]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe [18F]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
387553|NCT01235039|Drug|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
387554|NCT01235039|Drug|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
387555|NCT01235039|Drug|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
387556|NCT01235026|Dietary Supplement|Synbiotic|"5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10^10 CFU/g), twice a day, for 6 weeks."
387557|NCT01235026|Dietary Supplement|Placebo|6g of maltodextrin, twice a day for 6 weeks.
387558|NCT01235013|Drug|Maraviroc|150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
387559|NCT01235000|Biological|2010-11 trivalent inactivated influenza vaccine|A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
387560|NCT01234974|Drug|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
387561|NCT01234974|Drug|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
387562|NCT01234961|Behavioral|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
387563|NCT01234961|Other|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
387564|NCT01234935|Drug|dasatinib|Given orally
387565|NCT01234935|Drug|gemcitabine hydrochloride|Given IV
387566|NCT01234935|Other|laboratory biomarker analysis|Correlative studies
387567|NCT01234935|Genetic|mutation analysis|Correlative studies
387568|NCT01234935|Genetic|nucleic acid sequencing|Correlative studies
387569|NCT01234935|Other|immunohistochemistry staining method|Correlative studies
387570|NCT01234922|Drug|lisinopril|Given orally
387571|NCT01234922|Drug|losartan potassium|Given orally
387572|NCT01234922|Other|laboratory biomarker analysis|Correlative studies
387573|NCT01234922|Drug|benazepril hydrochloride|Given orally
387574|NCT01234922|Drug|ramipril|Given orally
387575|NCT01234896|Drug|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
387576|NCT01234896|Drug|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
387577|NCT01234896|Drug|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
387578|NCT01234896|Drug|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
387579|NCT01234883|Drug|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
387580|NCT01234883|Drug|saline|IV solutions dosed as clinically indicated for rehydration
387581|NCT01234870|Drug|Gadolinium|
387582|NCT01234870|Drug|Adenosine|
387583|NCT01234857|Drug|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
387584|NCT01234857|Drug|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
387585|NCT01234857|Drug|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
387586|NCT01234857|Drug|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
387587|NCT01234844|Behavioral|care of guinea pigs|twice weekly sessions of care with guinea pigs
387588|NCT01234844|Behavioral|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
387589|NCT01234831|Device|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
387590|NCT01234831|Other|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
387591|NCT01234818|Device|Mirena (LNG-IUS)|General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
387592|NCT01234805|Procedure|yoga therapy|Participates in yoga classes and yoga at home
387593|NCT01234805|Other|questionnaire administration|Ancillary studies
387594|NCT01234805|Procedure|quality-of-life assessment|Ancillary studies
387595|NCT01234792|Drug|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
387596|NCT01234792|Drug|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
387597|NCT01234792|Drug|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
387598|NCT01234779|Drug|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
387599|NCT01234779|Drug|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
387600|NCT01234779|Drug|olanzapine|15 mg orally daily, 4 weeks
387601|NCT01234779|Drug|placebo|orally daily, 4 weeks
387602|NCT01234766|Drug|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
387603|NCT01234766|Drug|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
387604|NCT01234766|Radiation|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
387605|NCT01234753|Other|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
387606|NCT01234740|Drug|bafetinib|Given orally
387607|NCT01234740|Procedure|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
387608|NCT01234740|Other|pharmacological study|Correlative studies
387609|NCT01234740|Other|liquid chromatography|Correlative studies
387610|NCT01234740|Other|mass spectrometry|Correlative studies
387611|NCT01234740|Other|laboratory biomarker analysis|Correlative studies
387612|NCT01234740|Genetic|protein expression analysis|Correlative studies
387613|NCT01234740|Genetic|western blotting|Correlative studies
387614|NCT01234740|Other|immunohistochemistry staining method|Correlative studies
387615|NCT01234740|Procedure|therapeutic conventional surgery|debulking craniotomy
387616|NCT01234714|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
387617|NCT01234714|Procedure|Major liver resection|Hepatectomy of >= 3 liver segments
387618|NCT01234701|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
387619|NCT01234701|Procedure|Liver resection|Hepatectomy with an intention to cure
387620|NCT01234701|Other|Histopathology diagnosis of resected liver specimen|Histopathology diagnosis by expert pathologist.
387621|NCT01234688|Other|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
387622|NCT01234675|Drug|Milnacipran|50 mg twice daily
387623|NCT01234675|Drug|Placebo|50 mg twice daily
387624|NCT01234662|Procedure|SPA|Spinal anesthesia and opioids
387625|NCT01234662|Procedure|CSE|CSE and epidural opioids
387626|NCT01234662|Procedure|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
387627|NCT01234649|Drug|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
387699|NCT01234116|Drug|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
387961|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
387628|NCT01234649|Drug|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
387629|NCT01234636|Dietary Supplement|Placebo oil|Placebo oil of 4g/day
387630|NCT01234623|Other|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
387631|NCT01234610|Behavioral|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
387632|NCT01234597|Drug|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
387633|NCT01234597|Drug|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
387634|NCT01234584|Procedure|spk|implants using SPK Abutments
387635|NCT01234584|Procedure|CPK Abutments|implants using CPK Abutments
387636|NCT01234558|Drug|GLYX-13|single IV dose
387637|NCT01234545|Drug|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
387638|NCT01234532|Drug|entinostat|orally
387639|NCT01234532|Drug|anastrozole|Given PO
387640|NCT01234532|Other|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.~Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
387641|NCT01234532|Procedure|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
387642|NCT01234519|Drug|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
387643|NCT01234519|Drug|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
387644|NCT01234506|Dietary Supplement|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
387645|NCT01234493|Procedure|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
387646|NCT01234493|Procedure|no fixation|No syndesmosis fixation.
387647|NCT01234467|Drug|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
387648|NCT01234467|Drug|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
387649|NCT01234454|Drug|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
387650|NCT01234454|Drug|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
387651|NCT01234441|Dietary Supplement|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
387652|NCT01234441|Dietary Supplement|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
387653|NCT01234441|Behavioral|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
387654|NCT01234428|Procedure|Laparoscopic surgery|Gastric banding
387655|NCT01234428|Procedure|gastric banding|laparoscopic gastric banding
387656|NCT01234415|Device|Rhinoplasty|Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
387657|NCT01234402|Biological|Ramucirumab DP|"10 mg/kg I.V.~Day 1 of every-21-day cycle"
387658|NCT01234402|Biological|IMC-18F1|"12 mg/kg I.V.~Days 1 and 8 of every-21-day cycle"
387659|NCT01234402|Drug|Capecitabine|"1000 mg/m^2 orally~Twice a day for 14 days"
387660|NCT01234389|Device|Electrochemical H. pylori detection method|Determination of H. pylori infection.
387661|NCT01234389|Device|IHC|Determination of H. pylori infection.
387662|NCT01234389|Device|C13-urea breath test|Determination of H. pylori infection.
387663|NCT01234389|Device|HUT|Determination of H. pylori infection.
387664|NCT01234376|Device|Confocal laser endomicroscopy|Confocal laser endomicroscopy
387665|NCT01234363|Device|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
387666|NCT01234337|Drug|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
387748|NCT01233778|Dietary Supplement|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
387749|NCT01233778|Dietary Supplement|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
388246|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 250mg TID
387667|NCT01234337|Drug|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
387668|NCT01234337|Drug|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,
387669|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
387670|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
387671|NCT01234311|Drug|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
387672|NCT01234311|Drug|Placebo|
387673|NCT01234298|Drug|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
387674|NCT01234298|Drug|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
387675|NCT01234298|Drug|Placebo|Placebo capsule taken once-daily for up to 26 weeks
387676|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
387677|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
387678|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
387679|NCT01234285|Drug|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
387680|NCT01234272|Drug|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
387681|NCT01234272|Drug|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
387682|NCT01234259|Device|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
387683|NCT01234233|Procedure|duration of preoperative active warming|"duration of prewarming by forced air warming"
387684|NCT01234207|Device|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
387685|NCT01234207|Device|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
387686|NCT01234194|Drug|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
387687|NCT01234194|Drug|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
387688|NCT01234181|Procedure|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10^7 BMSCs Sham Comparator: inject the same volume saline
387689|NCT01234155|Behavioral|Exercise Training - Interval Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
387690|NCT01234155|Behavioral|Exercise - Continuous Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
387691|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
387692|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
387693|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
387694|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
387695|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
387696|NCT01234142|Drug|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
387697|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
387698|NCT01234129|Drug|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
388247|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 375mg BID
387700|NCT01234103|Behavioral|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
387701|NCT01234077|Device|CPC M1|CPC M1
387702|NCT01234064|Device|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
387703|NCT01234064|Device|No Graduated Compression Stockings|No stockings will be applied.
387704|NCT01234051|Drug|Docetaxel, Oxaliplatin|"1. Treatment Schedule~1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.~1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days."
387705|NCT01234038|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
387706|NCT01234038|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
387707|NCT01234038|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
387708|NCT01234038|Drug|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
387709|NCT01234038|Drug|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
387710|NCT01234025|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
387711|NCT01234025|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
387712|NCT01234025|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
387713|NCT01234025|Drug|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
387714|NCT01234025|Drug|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
387715|NCT01234012|Biological|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
387716|NCT01233999|Drug|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
387717|NCT01233973|Other|video decision aid|video
387718|NCT01233960|Drug|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
387719|NCT01233947|Drug|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
387720|NCT01233947|Drug|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
387721|NCT01233934|Drug|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
387722|NCT01233934|Drug|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
387723|NCT01233921|Biological|palifermin|Given IV
387724|NCT01233921|Other|flow cytometry|Correlative studies
387725|NCT01233921|Other|laboratory biomarker analysis|Correlative studies
387726|NCT01233921|Other|pharmacological study|Correlative studies
387727|NCT01233895|Drug|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
387728|NCT01233895|Drug|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
387729|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
387730|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
387731|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
387732|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
387733|NCT01233869|Drug|Bosutinib|Once daily oral dose of 200 mg of bosutinib
387734|NCT01233869|Drug|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
387735|NCT01233869|Drug|Placebo|Once daily oral dose of placebo
387736|NCT01233843|Drug|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
387737|NCT01233843|Drug|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
387738|NCT01233843|Radiation|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
387739|NCT01233830|Drug|AZD2423|oral solution
387740|NCT01233830|Drug|Placebo|oral solution
387741|NCT01233817|Other|Progressive strength training|the systematic increase in resistance weights
387742|NCT01233804|Other|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
387743|NCT01233791|Drug|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
387744|NCT01233791|Drug|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
387745|NCT01233778|Dietary Supplement|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
387746|NCT01233778|Dietary Supplement|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
387747|NCT01233778|Dietary Supplement|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
390040|NCT01216644|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
387750|NCT01233752|Drug|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.~Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h)."
387751|NCT01233739|Drug|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
387752|NCT01233739|Drug|Placebo|Administration of 2 capsules of placebo orally.
387753|NCT01233726|Dietary Supplement|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
387754|NCT01233726|Dietary Supplement|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
387755|NCT01233726|Dietary Supplement|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
387756|NCT01233713|Procedure|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
387757|NCT01233713|Procedure|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
387758|NCT01233700|Behavioral|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
387759|NCT01233700|Behavioral|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
387760|NCT01233687|Drug|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg~The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
387761|NCT01233661|Other|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
387762|NCT01233648|Other|rate control via CRT-D and AVN ablation|rate control
387763|NCT01233648|Other|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
387764|NCT01233635|Other|no drug|none, no drug
387765|NCT01233635|Drug|start cozaar|start cozaar
387766|NCT01233635|Drug|continue cozaar|continue cozaar
387767|NCT01233622|Drug|Vildagliptin|
387768|NCT01233622|Drug|Placebo|
387769|NCT01233609|Drug|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
387770|NCT01233609|Drug|Placebo|Dosage per subject weight- same schedule as the active comparator
387771|NCT01233596|Device|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
387772|NCT01233583|Drug|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
387773|NCT01233570|Drug|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
387774|NCT01233544|Procedure|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
387775|NCT01233531|Behavioral|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
387776|NCT01233531|Behavioral|B--No cash transfers|No monthly cash transfers
387777|NCT01233518|Device|FFR|Fractional flow reserve measured during cardiac catheterization
387778|NCT01233505|Drug|veliparib|Given PO
387779|NCT01233505|Drug|capecitabine|Given PO
387780|NCT01233505|Drug|oxaliplatin|Given IV
387781|NCT01233505|Other|pharmacological study|Correlative studies
387782|NCT01233505|Other|laboratory biomarker analysis|Correlative studies
387783|NCT01233492|Drug|boron phenylalanine|
387784|NCT01233492|Drug|mannitol|
387785|NCT01233492|Other|biologic sample preservation procedure|
387786|NCT01233492|Radiation|radiation therapy treatment planning/simulation|
387787|NCT01233479|Drug|systemic chemotherapy|
387788|NCT01233479|Other|laboratory biomarker analysis|
387789|NCT01233479|Procedure|therapeutic surgical procedure|
387790|NCT01233479|Radiation|radiation therapy|
387791|NCT01233453|Device|the everolimus eluting ® stent|stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
387792|NCT01233453|Device|the Biolimus A9 eluting NOBORI® stent|stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
387793|NCT01233440|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
387794|NCT01233440|Biological|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
387795|NCT01233414|Behavioral|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
387833|NCT01233089|Device|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
387796|NCT01233414|Other|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
387797|NCT01233401|Other|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
387798|NCT01233388|Other|Text message surveillance|Text message surveillance for vaccine adverse events
387799|NCT01233375|Drug|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
387800|NCT01233362|Biological|Modified killed oral cholera vaccine at 14 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
387801|NCT01233362|Biological|Modified killed oral cholera vaccine at 28 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
387802|NCT01233349|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
387803|NCT01233349|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
387804|NCT01233297|Drug|Azithromycin|10 mg/kg peroral for 3 consecutive days
387805|NCT01233297|Other|Placebo mixture|Placebo mixture containing no active substance.
387806|NCT01233284|Drug|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
387807|NCT01233284|Drug|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
387808|NCT01233284|Drug|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
387809|NCT01233284|Drug|tiotropium bromide 1.25µg once daily|IMP
387810|NCT01233271|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
387811|NCT01233258|Biological|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
387812|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
387813|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
387814|NCT01233245|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
387815|NCT01233232|Drug|Placebo|Oral dose bid
387816|NCT01233232|Drug|AZD5069 50mg|Oral dose bid
387817|NCT01233232|Drug|AZD5069 80mg|Oral dose bid
387818|NCT01233219|Drug|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.~At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.~Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS<4 maximum x 3 daily.~Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h)."
387819|NCT01233206|Drug|Metformin|Metformin pre-treatment and co-administration
387820|NCT01233206|Drug|Placebo administration|Placebo pre-treatment and co-administration
387821|NCT01233193|Behavioral|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
387822|NCT01233180|Other|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
387823|NCT01233180|Device|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
387824|NCT01233167|Drug|clopidogrel|clopidogrel 75 mg po per day for 12 months
387825|NCT01233167|Drug|placebo|placebo 75mg po per day for 12 months
387826|NCT01233167|Drug|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
387827|NCT01233154|Dietary Supplement|probiotic|
387828|NCT01233154|Dietary Supplement|probiotic|
387829|NCT01233102|Drug|Conserved Therapy|Conserved Therapy
387830|NCT01233102|Procedure|Hepatic artery infusion or Intravenous infusion|Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
387831|NCT01233089|Device|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
387832|NCT01233089|Device|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
387834|NCT01233089|Device|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
387835|NCT01233076|Device|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
387836|NCT01233076|Device|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
387837|NCT01233063|Behavioral|Physical Activity and Diet Intervention via Alive2|Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
387838|NCT01233050|Drug|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
387839|NCT01233050|Drug|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
387840|NCT01233024|Dietary Supplement|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
387841|NCT01233024|Dietary Supplement|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
387842|NCT01233024|Dietary Supplement|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
387843|NCT01233024|Dietary Supplement|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
387844|NCT01233024|Dietary Supplement|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
387845|NCT01232985|Device|RD047-26|RD047-26 emollient gel
387846|NCT01232972|Procedure|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
387847|NCT01232959|Device|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
387848|NCT01232946|Drug|liraglutide|1.8mg subcutaneous qd for 3 months
387849|NCT01232946|Drug|insulin detemir|5units subcutaneous bid titrated to fasting glucose of <130mg/dL for 3 months
387850|NCT01232946|Drug|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose <130mg/dL for 3 months.
387851|NCT01232933|Device|VPS System|Use of the navigational VPS system during catheter placement
387852|NCT01232920|Drug|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
387853|NCT01232920|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
387854|NCT01232907|Drug|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
387855|NCT01232894|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
387856|NCT01232894|Drug|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
387857|NCT01232881|Procedure|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
387858|NCT01232881|Procedure|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
387859|NCT01232868|Biological|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
387860|NCT01232855|Genetic|protein expression analysis|
387861|NCT01232855|Genetic|western blotting|
387862|NCT01232855|Other|flow cytometry|
387863|NCT01232855|Other|laboratory biomarker analysis|
387864|NCT01232842|Genetic|cytogenetic analysis|
387865|NCT01232842|Other|HUMARA assay|
387866|NCT01232842|Other|fluorescence activated cell sorting|
387867|NCT01232842|Other|laboratory biomarker analysis|
387868|NCT01232829|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
387869|NCT01232803|Drug|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
387870|NCT01232803|Drug|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
387871|NCT01232803|Drug|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
387872|NCT01232790|Dietary Supplement|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
387873|NCT01232790|Drug|Placebo|Placebo
387874|NCT01232777|Drug|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
387875|NCT01232764|Other|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)~Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.~Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.~All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
387876|NCT01232751|Dietary Supplement|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
387877|NCT01232738|Drug|rasagiline|rasagiline 2 mg daily for 12 months
387878|NCT01232725|Dietary Supplement|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
387879|NCT01232712|Biological|ImMucin, hGM-CSF|"Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin~After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.~In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
387880|NCT01232699|Behavioral|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
387881|NCT01232699|Behavioral|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
387882|NCT01232699|Behavioral|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
387883|NCT01232686|Other|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
387884|NCT01232673|Procedure|BMAC application in Critical Limb Ischemia|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
387885|NCT01232660|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
387886|NCT01232647|Drug|Phylloquinone|1.0 mg daily of vitamin K1
387887|NCT01232647|Drug|Menatetrenone (MK4)|Menatetrenone (MK4) 45 mg daily
387888|NCT01232647|Drug|placebo|placebo vitamin K1 and placebo MK4 given daily for 18 months
387889|NCT01232621|Other|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
387890|NCT01232608|Behavioral|Exercise|12 months of exercise training
387891|NCT01232595|Drug|LFF571|
387892|NCT01232595|Drug|Vancomycin (POC)|
387893|NCT01232582|Device|Exablate treatment|MR guided Focused Ultrasound treatment
387894|NCT01232569|Drug|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
387895|NCT01232569|Drug|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
387896|NCT01232556|Drug|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
387897|NCT01232556|Drug|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
387898|NCT01232556|Drug|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
387899|NCT01232556|Drug|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
387900|NCT01232543|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
387901|NCT01232504|Drug|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
387902|NCT01232504|Drug|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
387903|NCT01232504|Drug|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
387904|NCT01232491|Drug|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
387905|NCT01232491|Dietary Supplement|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
387906|NCT01232478|Behavioral|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
387907|NCT01232452|Drug|Pemetrexed|Administered intravenously (IV)
387908|NCT01232452|Drug|Cisplatin|Administered IV
387909|NCT01232452|Drug|Cixutumumab|Administered IV
387910|NCT01232439|Drug|opioid receptor kappa antagonist|"Starting dose of 2 mg, administered orally, once.~The potential dose range for this study is 0.2 mg to 30 mg"
387911|NCT01232426|Procedure|Biodegradable Meniscus Arrow®|Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
387912|NCT01232426|Device|Mallet splint|Conservative treatment of the Mallet fracture with the traditional Mallet splint.
387913|NCT01232413|Drug|Placebo|Oral
387914|NCT01232413|Drug|ASP1941|Oral
387915|NCT01232413|Drug|Moxifloxacin|Oral
387916|NCT01232400|Drug|Esmolol|"The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:~Heart rate less than 70 bpm.~Systolic blood pressure less than 120 mmHg~Maximum dose of esmolol of 200 mcg/kg/minute is reached."
387917|NCT01232374|Drug|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
387918|NCT01232374|Drug|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
387919|NCT01232374|Drug|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
387920|NCT01232374|Radiation|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.~Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
387921|NCT01232309|Dietary Supplement|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
387922|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
387923|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
387924|NCT01232309|Dietary Supplement|Placebo|3 x 500 mg capsules (tid)
387925|NCT01232296|Drug|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
387926|NCT01232296|Drug|sorafenib|400 mg p.o. b.i.d.
387927|NCT01232283|Drug|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
387928|NCT01232283|Drug|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
387929|NCT01232283|Other|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
387930|NCT01232270|Drug|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
387931|NCT01232257|Drug|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
387932|NCT01232244|Other|GLP-1 infusion|1 pmol/kg/min
387933|NCT01232244|Other|Glucagon infusion|3ng/kg/min
387934|NCT01232244|Other|Oxyntomodulin infusion|3 pmol/kg/min
387935|NCT01232244|Other|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
387936|NCT01232244|Other|Placebo|NaCl 9 g/L infusion
387937|NCT01232231|Drug|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
387938|NCT01232231|Behavioral|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
387939|NCT01232218|Other|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
387940|NCT01232218|Other|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
387941|NCT01232205|Dietary Supplement|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
387942|NCT01232205|Dietary Supplement|Control|supplementation with milk
387943|NCT01232192|Behavioral|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:~Midwife training~Pregnant women campaigning~Early detection with self pH detection~Treatment of bacterial vaginosis"
387944|NCT01232179|Procedure|conventional prp|pan retinal photocoagulation
387945|NCT01232179|Procedure|targeted prp|1200-1600 spot in far periphery retin, anterior equator
387946|NCT01232166|Other|Auscultation|
387947|NCT01232166|Other|Observation of symmetric chest movements|
387948|NCT01232166|Other|Tube depth|
387949|NCT01232166|Other|All three|
387950|NCT01232153|Device|Non invasive ventilation|Non invasive ventilation
387951|NCT01232140|Other|CRP-guided antibiotic treatment|If CRP> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
387952|NCT01232127|Drug|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
387953|NCT01232127|Drug|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
387954|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
387955|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
387956|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
387957|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
387958|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
387959|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
387960|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
387962|NCT01232101|Device|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
387963|NCT01232075|Drug|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
387964|NCT01232075|Drug|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.~Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .~Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.~Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
387965|NCT01232049|Drug|Multiple Oral Dose of|Pitavastatin 4mg
387966|NCT01232049|Drug|Multiple Oral Dose of|Valsartan 320mg
387967|NCT01232036|Drug|Glucophage 500mg|Single Oral Dose of
387968|NCT01232036|Drug|HL-018 500mg|Single Oral Dose of
387969|NCT01232036|Other|No administration of Drug|
387970|NCT01232023|Drug|Indobufen|Single Oral Dose of
387971|NCT01232010|Drug|Mirodenafil|50mg Single Oral Dose of
387972|NCT01231997|Drug|Udenafil|100mg Single Oral Dose of
387973|NCT01231984|Device|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
387974|NCT01231984|Device|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
387975|NCT01231984|Device|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
387976|NCT01231971|Drug|Florbetapir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) (+/- 10%) florbetapir F18. At approximately 50-minutes post dose, scanning will begin. An approximately 20-minute image acquisition scan will be performed.
387977|NCT01231971|Drug|Flortaucipir|Participants will receive a single bolus intravenous injection of 10 mCi (370 MBq) flortaucipir injection followed by a saline flush. At approximately 75-minutes post dose, scanning will begin. An approximately 30-minute image acquisition scan will be performed.
387978|NCT01231958|Behavioral|The Heart Healthy Initiative for Hispanic Adults (HIP)|This randomized controlled pilot intervention study will include 150 Hispanic adults (45-75y) in the Greater Boston area. Participants will be randomized to either the intervention or control group after completing their baseline interview. The intervention group will receive 6 months of weekly group educational sessions, Zumba fitness classes and interactions with an embodied computer agent (ECA). The fitness classes and interactions with the ECA will continue for the second 6 months of the 1 year intervention. Intervention activities will occur at community centers in the greater Boston area. Control participants will receive standard of care for the first 6 months and will be offered the full intervention (weekly group educational sessions, Zumba fitness classes and interactions with the ECA) for the second 6 months of the study. Participants will complete an interview and blood draw at baseline, 6 months, and 12 months.
387979|NCT01231919|Drug|Akt inhibitor MK2206|Given PO
387980|NCT01231919|Other|diagnostic laboratory biomarker analysis|Correlative studies
387981|NCT01231919|Other|pharmacological study|Correlative studies
387982|NCT01231906|Drug|Cyclophosphamide|Given IV
387983|NCT01231906|Drug|Doxorubicin Hydrochloride|Given IV
387984|NCT01231906|Drug|Etoposide|Given IV
387985|NCT01231906|Drug|Ifosfamide|Given IV
387986|NCT01231906|Other|Laboratory Biomarker Analysis|Correlative studies
387987|NCT01231906|Drug|Topotecan Hydrochloride|Given IV
387988|NCT01231906|Drug|Vincristine Sulfate|Given IV
387989|NCT01231893|Procedure|olfactory mucosa ensheathing cell grafting, rehabilitation|In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.
387990|NCT01231893|Other|rehabilitation|In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
387991|NCT01231880|Drug|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
387992|NCT01231880|Drug|Monthly IPT using DP|Given every month
387993|NCT01231880|Drug|Placebo given every month|No active ingredient
388042|NCT01231568|Drug|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
388043|NCT01231568|Drug|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
387994|NCT01231854|Drug|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
387995|NCT01231854|Drug|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
387996|NCT01231841|Drug|cyclosporine|Given orally
387997|NCT01231841|Biological|anti-thymocyte globulin|Given IV
387998|NCT01231828|Drug|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
387999|NCT01231828|Drug|Lactulose|Lactulose (30-60 ml per day)
388000|NCT01231815|Radiation|15O-H2O PET -|Assessment of coronary reserve using PET
388001|NCT01231815|Radiation|MRI|Assessment of coronary reserve using MRI
388002|NCT01231802|Drug|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, & 15
388003|NCT01231802|Drug|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, & 16
388004|NCT01231802|Drug|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, & 17
388005|NCT01231802|Drug|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
388006|NCT01231789|Procedure|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
388007|NCT01231789|Procedure|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
388008|NCT01231776|Other|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
388009|NCT01231763|Other|No intervention (not applicable)|No intervention (not applicable)
388010|NCT01231750|Drug|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
388011|NCT01231750|Other|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
388012|NCT01231737|Drug|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
388013|NCT01231724|Device|Allstate Nasal Spray|Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
388014|NCT01231724|Device|Placebo Nasal Spray|2 sprays in each nostril
388015|NCT01231711|Behavioral|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:~The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).~The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
388016|NCT01231698|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
388017|NCT01231698|Other|control|standard treatment without strict heart rate control
388018|NCT01231685|Drug|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
388019|NCT01231685|Drug|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
388020|NCT01231672|Biological|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
388021|NCT01231659|Drug|Everolimus + Letrozole|
388022|NCT01231646|Other|No intervention|No intervention. This is a cross-sectional study.
388023|NCT01231633|Drug|Ozurdex|Ozurdex, 0.7mg dexamethasone
388024|NCT01231633|Drug|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
388025|NCT01231620|Drug|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
388026|NCT01231620|Drug|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
388027|NCT01231620|Drug|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
388028|NCT01231620|Drug|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
388029|NCT01231607|Drug|1mg Finasteride active|1mg finasteride active, by mouth once daily
388030|NCT01231607|Drug|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
388031|NCT01231607|Drug|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
388032|NCT01231607|Drug|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
388033|NCT01231607|Drug|Finasteride placebo|finasteride placebo, by mouth once daily
388034|NCT01231607|Drug|Dutasteride placebo|dutasteride placebo, by mouth once daily
388035|NCT01231594|Drug|GSK2118436|Study Drug
388036|NCT01231594|Drug|GSK1120212|Study Drug
388037|NCT01231594|Drug|Other approved anti-cancer agent|Study Drug
388038|NCT01231581|Drug|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
388039|NCT01231581|Drug|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
388040|NCT01231581|Drug|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
388041|NCT01231568|Drug|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
390041|NCT01216644|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
388044|NCT01231568|Drug|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
388045|NCT01231555|Drug|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
388046|NCT01231555|Drug|GSK2248761 200 mg once daily|2x100 mg capsules
388047|NCT01231555|Drug|Efavirenz 600 mg once daily|1x600mg tablet
388048|NCT01231542|Drug|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
388049|NCT01231542|Drug|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
388050|NCT01231542|Drug|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
388051|NCT01231529|Drug|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
388052|NCT01231516|Drug|GSK1349572|50mg once daily
388053|NCT01231516|Drug|Raltegravir|400mg twice daily
388054|NCT01231516|Drug|GSK1349572 Placebo|Inactive placebo tablet once daily
388055|NCT01231516|Drug|Raltegravir Placebo|Inactive placebo tablet twice daily
388056|NCT01231503|Biological|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
388057|NCT01231503|Biological|Engerix-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=< 7 days of age)
388058|NCT01231503|Biological|Tritanrix HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
388059|NCT01231503|Biological|BCG|1 dose, intradermal route, in shoulder at birth (=< 7 days of age)
388060|NCT01231503|Biological|OPV|4 doses, orally, at birth (=< 7 days of age) and at 6, 10 and 14 weeks of age
388061|NCT01231503|Biological|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
388062|NCT01231490|Drug|Placebo|Placebo
388063|NCT01231490|Drug|Naproxen|Capsule
388064|NCT01231464|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
388065|NCT01231464|Drug|placebo|placebo
388066|NCT01231451|Drug|DMPA|All subjects will take DMPA
388067|NCT01231438|Drug|Renvela|800mg t.i.d. over 2 weeks
388068|NCT01231438|Drug|Etalpha|0.25ug o.d. for 2 weeks
388069|NCT01231412|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
388070|NCT01231412|Drug|Cyclosporine|Given PO or IV
388071|NCT01231412|Drug|Fludarabine Phosphate|Given IV
388072|NCT01231412|Drug|Mycophenolate Mofetil|Given PO
388073|NCT01231412|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
388074|NCT01231412|Drug|Sirolimus|Given PO
388075|NCT01231412|Radiation|Total-Body Irradiation|Undergo TBI
388076|NCT01231399|Drug|fluorouracil|Given IV
388077|NCT01231399|Drug|leucovorin calcium|Given IV
388078|NCT01231399|Drug|oxaliplatin|Given IV
388079|NCT01231399|Drug|everolimus|Given orally
388080|NCT01231399|Other|laboratory biomarker analysis|Correlative studies
388081|NCT01231399|Other|immunohistochemistry staining method|Correlative studies
388082|NCT01231399|Genetic|microarray analysis|Correlative studies
388083|NCT01231373|Drug|polidocanol injectable foam, 0.125%|active placebo for blinding
388084|NCT01231373|Drug|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
388085|NCT01231373|Drug|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
388086|NCT01231373|Drug|Vehicle|injection of vehicle comparator
388087|NCT01231360|Other|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
388088|NCT01231360|Other|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
388089|NCT01231347|Drug|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
388090|NCT01231347|Drug|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
388091|NCT01231347|Drug|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
388092|NCT01231347|Drug|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
388093|NCT01231334|Drug|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
388094|NCT01231334|Drug|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
388095|NCT01231321|Drug|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
388248|NCT01230138|Drug|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
388249|NCT01230138|Drug|FP187|Oral tablets, up to 3 times daily for 20 weeks.
390042|NCT01216644|Drug|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
388096|NCT01231308|Procedure|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
388097|NCT01231308|Behavioral|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
388098|NCT01231282|Other|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
388099|NCT01231269|Other|MRI|MRI scan without administration of contrast/without radiation
388100|NCT01231256|Behavioral|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
388101|NCT01231243|Procedure|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
388102|NCT01231230|Drug|fluticasone|220- mcg once
388103|NCT01231230|Drug|placebo inhalation|placebo inhalation once
388104|NCT01231230|Drug|Salmeterol|50 mcg salmeterol once
388105|NCT01231230|Drug|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
388106|NCT01231217|Other|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
388107|NCT01231217|Other|Coffee|Patients are recommended to drink as much coffee as they tolerate.
388108|NCT01231204|Procedure|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
388109|NCT01231204|Procedure|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
388110|NCT01231191|Drug|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
388111|NCT01231191|Drug|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
388112|NCT01231178|Dietary Supplement|Alginate beverage|The dosage is 3x500ml daily
388113|NCT01231178|Dietary Supplement|Control beverage|The dosage is 3x500ml daily
388114|NCT01231165|Drug|Amiloride|5mg/daily for 12th months
388115|NCT01231165|Drug|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
388116|NCT01231139|Drug|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
388117|NCT01231139|Drug|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
388118|NCT01231126|Drug|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
388119|NCT01231113|Drug|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
388120|NCT01231113|Drug|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
388121|NCT01231100|Other|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
388122|NCT01231074|Drug|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
388123|NCT01231061|Radiation|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
388124|NCT01231061|Radiation|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
388125|NCT01231009|Drug|Corticosteroids|Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
388126|NCT01231009|Other|Vestibular exercises|Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
388127|NCT01230996|Drug|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
388128|NCT01230996|Radiation|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
388250|NCT01230125|Drug|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
388129|NCT01230996|Procedure|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
388130|NCT01230983|Drug|asparaginase|Given IV
388131|NCT01230983|Drug|cytarabine|Given IV
388132|NCT01230983|Drug|dexrazoxane hydrochloride|Given IV
388133|NCT01230983|Drug|doxorubicin hydrochloride|Given IV
388134|NCT01230983|Drug|leucovorin calcium|Given IV
388135|NCT01230983|Drug|mercaptopurine|Given orally
388136|NCT01230983|Drug|methotrexate|Given IV
388137|NCT01230983|Drug|prednisone|Given orally
388138|NCT01230983|Drug|therapeutic hydrocortisone|Given IT
388139|NCT01230983|Drug|vincristine sulfate|Given IV
388140|NCT01230983|Radiation|radiation therapy|Radiation to cranium
388141|NCT01230970|Drug|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
388142|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
388143|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
388144|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
388145|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
388146|NCT01230957|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
388147|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
388148|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
388149|NCT01230944|Procedure|Laparoscopic Nissen fundoplication|
388150|NCT01230944|Procedure|Open Nissen fundoplication|
388151|NCT01230931|Device|Vitagel|Vitagel (by Stryker) is a topical surgical hemostat spray that results in coagulation. The components are as follows: autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors; this is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
388152|NCT01230931|Procedure|Standard of care|Standard of care for hemostasis in acetabular surgery includes electrocautery/ligation of bleeding vessels, fracture reduction and stabilization, cell-saver, lap packing.
388153|NCT01230918|Radiation|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.~Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
388154|NCT01230905|Radiation|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
388155|NCT01230892|Drug|Nebivolol|10 mg PO qday
388156|NCT01230892|Drug|Atenolol|100 mg PO qday
388157|NCT01230879|Other|EFR and TDM|EFR : Pulmonary function test TDM : tomodensitometry
388158|NCT01230866|Radiation|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
388159|NCT01230866|Radiation|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
388160|NCT01230853|Drug|Active Comparator: A|BAN2401 Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
388161|NCT01230853|Drug|Placebo Comparator B|Placebo Matching Placebo Infusion
388162|NCT01230853|Drug|Active Comparator B|BAN2401 Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
388163|NCT01230853|Drug|Placebo Comparator A|Placebo Matching Placebo Infusion
388164|NCT01230840|Dietary Supplement|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
388165|NCT01230840|Dietary Supplement|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
388166|NCT01230827|Drug|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
388167|NCT01230827|Drug|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
388168|NCT01230827|Drug|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
388169|NCT01230814|Drug|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
388170|NCT01230814|Drug|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
388171|NCT01230801|Biological|BMN 701|GILT-tagged recombinant human GAA
388172|NCT01230788|Drug|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
388243|NCT01230151|Device|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
388244|NCT01230151|Device|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
388173|NCT01230775|Drug|Anagrelide retard|"Week 1:~1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.~Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.~Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.~Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
388174|NCT01230775|Drug|Placebo|"Week 1:~x1 tablet/d of placebo will be administered in week 1.~Week 2~Placebo:~x1 tablet/d of placebo will be administered in week 2.~Week 3 - Week 4~Placebo:~In week 3 and week 4 the maximum dose is 4 tablets per day.~Placebo:~In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:~Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
388175|NCT01230762|Drug|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
388176|NCT01230749|Drug|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
388177|NCT01230749|Drug|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
388178|NCT01230749|Drug|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
388179|NCT01230736|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
388180|NCT01230723|Device|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
388181|NCT01230723|Device|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
388182|NCT01230710|Drug|Erlotinib|Erlotinib was supplied as tablets.
388183|NCT01230697|Drug|Sorafenib|Sorafenib 800mg/die oral
388184|NCT01230684|Procedure|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
388185|NCT01230671|Other|Yoga|A 12 week yoga session will be offered to women with breast cancer.
388186|NCT01230645|Drug|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
388187|NCT01230645|Drug|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
388188|NCT01230632|Dietary Supplement|high fat overfeeding|Dietary Supplement:3 days overfeeding
388189|NCT01230619|Drug|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
388190|NCT01230619|Drug|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
388191|NCT01230606|Other|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
388192|NCT01230593|Drug|Hot Compress plus Tobramycin Drops and Ointment|In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
388193|NCT01230593|Drug|Hot compress plus Tobramycin/Dexamethasone Drops and Ointment|In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
388194|NCT01230593|Other|Hot Compresses|Hot compresses 3x/day to eyelids
388195|NCT01230580|Drug|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
388196|NCT01230580|Drug|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
388197|NCT01230554|Device|Daily disposable cosmetic tint lens|Bausch & Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
388198|NCT01230541|Drug|Placebo|Daily, oral tablet
388199|NCT01230541|Drug|Udenafil|Daily tablet
388200|NCT01230515|Other|Individual patient interview, focus group and structured survey|
388201|NCT01230515|Other|interview, focus group and structured survey|
388202|NCT01230515|Other|interview, focus group and structured survey|
388203|NCT01230515|Other|interview, focus group and structured survey|
388204|NCT01230502|Drug|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
388205|NCT01230502|Other|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
388206|NCT01230502|Other|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
388207|NCT01230489|Biological|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
388208|NCT01230476|Drug|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
388209|NCT01230463|Drug|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
388210|NCT01230463|Drug|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
388211|NCT01230450|Procedure|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
388212|NCT01230450|Other|stand standard mid-urethral sling (TVT-O)|
388213|NCT01230424|Drug|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
388214|NCT01230424|Drug|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
388215|NCT01230411|Other|saline placebo|250 cc of placebo administered IV
388216|NCT01230411|Drug|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
388217|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
388218|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
388219|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
388220|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
388221|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
388222|NCT01230359|Dietary Supplement|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
388223|NCT01230359|Other|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
388224|NCT01230346|Other|questionnaire administration|Ancillary studies
388225|NCT01230346|Other|survey administration|Ancillary studies
388226|NCT01230346|Other|counseling intervention|Telephone intervention
388227|NCT01230346|Other|educational intervention|Telephone intervention
388228|NCT01230320|Procedure|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:~the reproduction of denture-bearing tissues by means of impression techniques and casts;~the registration of maxillo-mandibular relations;~try-in of artificial teeth and carved denture bases."
388229|NCT01230307|Drug|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
388230|NCT01230307|Drug|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
388231|NCT01230281|Other|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
388232|NCT01230268|Other|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
388233|NCT01230255|Procedure|Percutaneous catheter drainage|Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
388234|NCT01230242|Device|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
388235|NCT01230229|Procedure|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
388236|NCT01230229|Other|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
388237|NCT01230216|Drug|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
388238|NCT01230216|Drug|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
388239|NCT01230203|Procedure|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
388240|NCT01230190|Dietary Supplement|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1*10^9 Colony Forming Units/g.~Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
388241|NCT01230190|Dietary Supplement|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
388242|NCT01230177|Drug|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
388245|NCT01230138|Drug|Placebo|Placebo tablets
388251|NCT01230125|Drug|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
388252|NCT01230099|Behavioral|Supportive Information Team Group|A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
388253|NCT01230086|Device|ICD Implantation without DFT testing|Implantation
388254|NCT01230086|Device|Upper limit of vulnerability testing|Upper limit of vulnerability testing
388255|NCT01230086|Device|T-wave shock with induction of ventricular fibrillation|Traditional safety margin testing for defibrillation threshold
388256|NCT01230073|Device|Home-Monitoring|Home-Monitoring
388257|NCT01230073|Device|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
388258|NCT01230060|Device|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
388259|NCT01230047|Behavioral|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
388260|NCT01230034|Drug|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
388261|NCT01230034|Drug|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
388262|NCT01230021|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
388263|NCT01230008|Radiation|no drugs|Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
388264|NCT01229995|Device|dental implants - zirconia abutmetns - prefabricated abutments|
388265|NCT01229982|Drug|Latanoprost-PPDS|Punctal Plug
388266|NCT01229969|Other|Wii Fit Balance Games|Ski Slaloms and Table Tilt
388267|NCT01229969|Other|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
388268|NCT01229956|Genetic|DNA methylation analysis|
388269|NCT01229956|Genetic|gene expression analysis|
388270|NCT01229956|Genetic|microarray analysis|
388271|NCT01229956|Genetic|reverse transcriptase-polymerase chain reaction|
388272|NCT01229956|Other|laboratory biomarker analysis|
388273|NCT01229943|Biological|Bevacizumab|Given IV
388274|NCT01229943|Drug|Everolimus|Given PO
388275|NCT01229943|Drug|Octreotide Acetate|Given IM
388276|NCT01229930|Drug|carboplatin|
388277|NCT01229930|Drug|cediranib maleate|
388278|NCT01229930|Drug|paclitaxel|
388279|NCT01229930|Other|laboratory biomarker analysis|
388280|NCT01229930|Other|pharmacological study|
388281|NCT01229930|Procedure|quality-of-life assessment|
388282|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 1|
388283|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 2|
388284|NCT01229917|Other|Standard fruit juice|
388285|NCT01229904|Behavioral|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
388286|NCT01229891|Dietary Supplement|plain yogurt drink|daily intake of two bottle of plain yogurt drink
388287|NCT01229891|Dietary Supplement|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
388288|NCT01229891|Dietary Supplement|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
388289|NCT01229878|Dietary Supplement|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
388290|NCT01229865|Drug|VB-111|
388291|NCT01229852|Device|DSF-rTMS|Effective Transcranial Magnetic Stimulation
388292|NCT01229839|Other|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
388293|NCT01229839|Other|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
388294|NCT01229839|Other|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
388295|NCT01229826|Radiation|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
388296|NCT01229813|Drug|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
388297|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
388298|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
388299|NCT01229813|Drug|low dose capecitabine|capecitabine 500 mg twice daily
388300|NCT01229800|Drug|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
388334|NCT01229527|Drug|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
388335|NCT01229514|Other|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
388336|NCT01229488|Device|Intervention|Project was withdrawn before starting. There were no interventions
390043|NCT01216644|Drug|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
388301|NCT01229800|Drug|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
388302|NCT01229774|Drug|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
388303|NCT01229774|Drug|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
388304|NCT01229761|Drug|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
388305|NCT01229761|Drug|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
388306|NCT01229761|Behavioral|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
388307|NCT01229761|Behavioral|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
388308|NCT01229748|Behavioral|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
388309|NCT01229748|Behavioral|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
388310|NCT01229748|Behavioral|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
388311|NCT01229735|Drug|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
388312|NCT01229735|Drug|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
388313|NCT01229722|Device|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
388314|NCT01229722|Device|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
388315|NCT01229709|Behavioral|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
388316|NCT01229696|Procedure|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
388317|NCT01229696|Procedure|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
388318|NCT01229683|Procedure|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
388319|NCT01229670|Other|exercise|"1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
388320|NCT01229644|Drug|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
388321|NCT01229631|Dietary Supplement|Juice plus+|Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)
388322|NCT01229631|Dietary Supplement|Placebo non active capsules|Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
388323|NCT01229618|Drug|Hyperpolarized Pyruvate (13C) injection|single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
388324|NCT01229605|Drug|Cyclophosphamide and docetaxel|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
388325|NCT01229592|Drug|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
388326|NCT01229592|Drug|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
388327|NCT01229579|Drug|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
388328|NCT01229579|Drug|Placebo|2.5 ml syrup daily with no elemental zinc from day 14 to 18 weeks of age.
388329|NCT01229566|Drug|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
388330|NCT01229553|Drug|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
388331|NCT01229540|Genetic|genetic analyzer|
388332|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
388333|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
390044|NCT01216644|Drug|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
388337|NCT01229475|Procedure|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
388338|NCT01229475|Procedure|Linear ablation|Linear ablation for AF ablation
388339|NCT01229462|Drug|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
388340|NCT01229462|Drug|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
388341|NCT01229462|Drug|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
388342|NCT01229462|Other|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
388343|NCT01229449|Drug|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet, single dose taken orally with 300 ml water
388344|NCT01229449|Drug|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg, single dose taken orally with 300 ml water
388345|NCT01229449|Drug|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®), single dose taken orally with 300 ml water
388346|NCT01229449|Drug|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra), single dose taken orally with 300 ml water
388347|NCT01229449|Drug|Placebo|Two placebo tablets, single dose taken orally with 300 ml water
388348|NCT01229436|Drug|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
388349|NCT01229423|Drug|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
388350|NCT01229410|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
388351|NCT01229410|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
388352|NCT01229397|Biological|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
388353|NCT01229397|Biological|Inflexal V|Inflexal V 0.5 mL administrated once only
388354|NCT01229384|Device|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
388355|NCT01229384|Device|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
388356|NCT01229371|Biological|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
388357|NCT01229371|Biological|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
388358|NCT01229358|Other|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
388359|NCT01229345|Drug|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
388360|NCT01229332|Drug|Saline|Continuous 24 h administration
388361|NCT01229332|Drug|Carbidopa|Continuous 24 h administration
388362|NCT01229319|Drug|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
388363|NCT01229319|Drug|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
388364|NCT01229306|Procedure|Ablation|Ablation of atrial fibrillation
388365|NCT01229293|Procedure|Articular Surface Replacement (ASR)|Articular surface replacement, DePuy, posterolateral approach used
388366|NCT01229293|Procedure|Standard Total Hip Arthroplasty (THA)|Device: Biomet 28mm
388367|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of darifenacin
388368|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
388369|NCT01229267|Biological|V212|V212 viral antigen for HZ. Participants will receive consistency Lot 1, 2, or 3 or the High Antigen Lot.
388370|NCT01229267|Biological|Matching placebo|Vaccine stabilizer for V212 with no virus antigen
388371|NCT01229254|Drug|Amiodarone|Patients on Amiodarone
388372|NCT01229254|Drug|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
388373|NCT01229254|Drug|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
388374|NCT01229254|Drug|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
388375|NCT01229241|Drug|local anesthetic|"postoperative 48h epidural continuous infusion,~ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml"
388376|NCT01229228|Drug|Naproxen Test|200-mg single dose
388377|NCT01229228|Drug|Naproxen Test|400-mg (2 x 200-mg)
388378|NCT01229228|Drug|Naprosyn|single dose
388379|NCT01229228|Drug|Naprosyn|single dose
388380|NCT01229228|Drug|Placebo|single dose
388381|NCT01229215|Drug|FCFD4514S|Repeating intravitreal injection
388382|NCT01229215|Drug|sham|Repeating sham injection
388383|NCT01229202|Drug|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
388384|NCT01229189|Dietary Supplement|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
388385|NCT01229189|Dietary Supplement|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
388386|NCT01229176|Biological|Vi-CRM197 vaccine|
388387|NCT01229176|Biological|Vi Polysaccharide (PS) vaccine|
388388|NCT01229176|Biological|Pneumococcal conjugate vaccine|
388389|NCT01229163|Device|Automated Contingency Management (ACM) software|
388390|NCT01229150|Drug|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
388391|NCT01229150|Drug|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
388392|NCT01229150|Drug|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
388393|NCT01229137|Device|SRD-1 conversion|
388394|NCT01229124|Genetic|RNA analysis|
388395|NCT01229124|Genetic|nucleic acid sequencing|
388396|NCT01229124|Genetic|reverse transcriptase-polymerase chain reaction|
388397|NCT01229124|Other|laboratory biomarker analysis|
388398|NCT01229111|Drug|cediranib maleate|Given PO
388399|NCT01229111|Drug|oxaliplatin|Given IV
388400|NCT01229111|Drug|leucovorin calcium|Given IV
388401|NCT01229111|Drug|fluorouracil|Given IV
388402|NCT01229098|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
388403|NCT01229085|Drug|memotasone + salicylic acid|mometasone 0,1% + salicylic acid 5%.
388404|NCT01229072|Biological|Heparin sodic|Heparin sodic 150UI/kg
388405|NCT01229072|Biological|heparin liquemine|Heparin sodic 150UI/kg
388406|NCT01229059|Dietary Supplement|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
388407|NCT01229046|Drug|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
388408|NCT01229033|Procedure|Ablation|Ablation of atrial tachycardia
388409|NCT01229033|Procedure|Cardioversion|Cardioversion of atrial tachycardia
388410|NCT01229020|Other|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
388411|NCT01229007|Biological|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
388412|NCT01228994|Drug|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
388413|NCT01228994|Drug|placebo pill|placebo pill
388414|NCT01228994|Drug|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
388415|NCT01228942|Device|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
388416|NCT01228929|Other|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
388417|NCT01228916|Behavioral|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
388418|NCT01228903|Drug|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
388419|NCT01228903|Other|Placebo|Placebo tablets with no active ingredient
388420|NCT01228890|Behavioral|CATCH-IT|"The CATCH-IT 2-R intervention has a motivational (3 PCP motivational interviews at time 0, 1.5 months and 12 months and 3 coaching phone calls at 2 and 4 weeks and 18 months) and an Internet component (with separate adolescent [14 modules] and parent [5 modules] programs). This revised and expanded intervention will include a comprehensive approach to reducing modifiable risk factors and enhancing resiliency factors associated with increased or decreased risk of depression, respectively, proposed by Spence and Reinecke.148 The revised CATCH-IT Tracker will monitor time in study and deploy elements of the intervention based on time since enrollment, including computer and human elements (e.g. calls, doctor visits)."
388421|NCT01228890|Behavioral|AMPE|The AMPE components are similar to those employed in previous primary care based quality improvement/Chronic Care Model Interventions (patient education [psycho-education described below], provider training [described in Case Finding and Recruitment], active monitoring and referral [case management, discussed under assessments], physician and nurse education and routine contact with PCP [study design rationale]). This Internet site will focus on assisting parents and adolescents in early identification of need for treatment and will also target stigma and negative attitudes toward treatment of mental disorders we have previously identified as barriers to seeking and adhering to treatment.
388422|NCT01228877|Other|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
388423|NCT01228864|Procedure|quality of life|survey
388424|NCT01228864|Procedure|Quality of life|
388425|NCT01228851|Other|Balance Training|Group balance training sessions three times a week for 8 weeks
388426|NCT01228838|Drug|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
388427|NCT01228838|Drug|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
388428|NCT01228799|Procedure|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
388429|NCT01228799|Procedure|Canaloplasty|Canaloplasty with implant of suture
388461|NCT01228539|Behavioral|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
388462|NCT01228539|Behavioral|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
388430|NCT01228773|Behavioral|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
388431|NCT01228760|Drug|ASG-5ME|IV
388432|NCT01228747|Drug|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
388433|NCT01228747|Drug|Placebo|Matching oral placebo tablets twice daily for 28 weeks
388434|NCT01228734|Drug|Cetuximab|Cetuximab was administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
388435|NCT01228734|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
388436|NCT01228734|Drug|Folinic Acid|FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
388437|NCT01228734|Drug|5Fluorouracil|5-FU as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
388438|NCT01228721|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
388439|NCT01228708|Other|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
388440|NCT01228695|Other|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
388441|NCT01228682|Drug|Tolvaptan|Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
388442|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
388443|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
388444|NCT01228669|Drug|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
388445|NCT01228656|Drug|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
388446|NCT01228656|Drug|Mometasone furoate|Dermatologic ointment applied once a day
388447|NCT01228643|Biological|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
388448|NCT01228643|Device|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
388449|NCT01228630|Drug|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
388450|NCT01228630|Drug|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
388451|NCT01228617|Drug|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
388452|NCT01228617|Drug|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
388453|NCT01228604|Drug|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
388454|NCT01228591|Device|Acuvue Advance Plus|Silicone hydrogel contact lens.
388455|NCT01228591|Device|Acuvue Advance|Silicone hydrogel contact lens
388456|NCT01228578|Dietary Supplement|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
388457|NCT01228565|Other|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
388458|NCT01228565|Other|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
388459|NCT01228552|Drug|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
388460|NCT01228552|Other|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
388463|NCT01228526|Device|PriMatrix|
388464|NCT01228513|Drug|ZK245186|Daily topical application
388465|NCT01228513|Drug|Placebo (vehicle without active ingredient)|Daily topical application
388466|NCT01228500|Device|PriMatrix|Dermal Repair Scaffold
388467|NCT01228474|Other|Select the Number of embryos to transfer|Select the Number of embryos to transfer
388468|NCT01228448|Procedure|PET scan|In-Room PET scan
388469|NCT01228435|Drug|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
388470|NCT01228422|Biological|Interferon alpha 2a|3MUI
388471|NCT01228409|Drug|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
388472|NCT01228396|Drug|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
388473|NCT01228383|Biological|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
388474|NCT01228383|Biological|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
388475|NCT01228383|Biological|Placebo|Placebo intramuscularly on Day 0.
388476|NCT01228383|Biological|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
388477|NCT01228383|Biological|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
388478|NCT01228370|Drug|silodosin|silodosin 8mg once a day for 12 weeks
388479|NCT01228357|Drug|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
388480|NCT01228357|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
388481|NCT01228344|Other|Artemether-lumefantrine|
388482|NCT01228331|Drug|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
388483|NCT01228331|Drug|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
388484|NCT01228331|Drug|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
388485|NCT01228331|Drug|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
388486|NCT01228331|Drug|Daunorubicin hydrochloride|part of induction and reinduction therapy
388487|NCT01228331|Drug|Dexamethasone|part of reinduction therapy
388488|NCT01228331|Drug|Doxorubicin hydrochloride|part of reinduction therapy
388489|NCT01228331|Drug|Etoposide phosphate|part of different chemotherapy blocks
388490|NCT01228331|Drug|Mercaptopurine|part of different chemotherapy blocks
388491|NCT01228331|Drug|Methotrexate|part of different chemotherapy blocks
388492|NCT01228331|Drug|Methylprednisolone|part of different chemotherapy blocks
388493|NCT01228331|Drug|Pegaspargase|part of different chemotherapy blocks
388494|NCT01228331|Drug|Thioguanine|part of different chemotherapy blocks
388495|NCT01228331|Drug|Vincristine sulfate|part of intravenous chemotherapy
388496|NCT01228331|Radiation|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
388497|NCT01228318|Drug|Zoledronic acid|"A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.~A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
388498|NCT01228305|Other|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
388499|NCT01228292|Drug|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
388500|NCT01228292|Drug|Citrasate|Citrasate is infused as a dialysate
388501|NCT01228279|Other|DIANEAL|"Weeks 1 to 6 (6 weeks):~CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~*same regimen as weeks 1 to 6, for both CAPD and CCPD patients"
388502|NCT01228279|Other|EXTRANEAL|"Weeks 1 to 6 (6 weeks):~CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night~CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night~Weeks 7 to 18 (12 weeks):~CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night~CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night"
388503|NCT01228266|Biological|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
388504|NCT01228253|Device|rTMS: repetitive transcranial magnetic stimulation|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
388505|NCT01228253|Device|SHAM rTMS: repetitive transcranial magnetic stimulation is off|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
388506|NCT01228240|Drug|Metformin|
388507|NCT01228227|Drug|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
388508|NCT01228227|Drug|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
388509|NCT01228214|Drug|Placebo|Placebo 5mg/daily for 12 months
388510|NCT01228214|Drug|amiloride|5mg/daily for 12 months
388511|NCT01228201|Behavioral|Moderate continuous training|Three training sessions per week in a total of 12 weeks
388512|NCT01228201|Behavioral|Aerobic interval training|Three training sessions per week in a total of 12 weeks
388553|NCT01227863|Drug|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
388554|NCT01227837|Dietary Supplement|placebo|placebo given to patients
388513|NCT01228188|Procedure|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
388514|NCT01228175|Drug|Placebo|25mg look alike riboflavin tablets to match active study medication.
388515|NCT01228175|Drug|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
388516|NCT01228162|Procedure|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
388517|NCT01228149|Drug|Trabeculectomy with preoperative Diamox/DexaEDO treatment|Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
388518|NCT01228149|Drug|Trabeculectomy with preoperative Cosopt S treatment|Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
388519|NCT01228136|Drug|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
388520|NCT01228136|Other|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
388521|NCT01228123|Other|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
388522|NCT01228123|Other|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
388523|NCT01228110|Drug|Hydrocortison|
388524|NCT01228110|Drug|Saline Solution|
388525|NCT01228084|Drug|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
388526|NCT01228084|Other|Laboratory biomarker analysis|Correlative studies
388527|NCT01228084|Other|Pharmacological study|Correlative studies
388528|NCT01228071|Drug|testosterone gel 2%|40 mg testosterone gel 2%
388529|NCT01228058|Procedure|RapidTEG test|The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
388530|NCT01228045|Drug|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
388531|NCT01228032|Other|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
388532|NCT01228019|Drug|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
388533|NCT01228006|Dietary Supplement|NatusGerin|1 capsule, 2 times a day.
388534|NCT01228006|Other|Placebo capsules|1 capsule, 2 times a day
388535|NCT01227993|Drug|Finasteride|
388536|NCT01227980|Drug|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
388537|NCT01227980|Drug|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
388538|NCT01227967|Drug|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
388539|NCT01227967|Drug|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
388540|NCT01227954|Radiation|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
388541|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
388542|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of the cycle.
388543|NCT01227928|Drug|Pazopanib|Pazopanib 800 mg daily for 24 months
388544|NCT01227928|Drug|Placebo comparator|Placebo 800 mg daily for 24 months
388545|NCT01227915|Drug|Tobracort|tobramycin 0.3% + dexamethasone 1%
388546|NCT01227915|Drug|Tobradex|tobramycin 0.3% + dexamethasone 1%
388547|NCT01227902|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
388548|NCT01227889|Drug|GSK2118436|150 mg twice daily
388549|NCT01227889|Drug|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
388550|NCT01227876|Drug|Ster|prednisolone 1% ophthalmic suspension
388551|NCT01227876|Drug|Pred Fort|prednisolone 1% ophthalmic suspension
388552|NCT01227863|Drug|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
388556|NCT01227824|Drug|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
388557|NCT01227824|Drug|raltegravir|raltegravir 400mg taken twice daily
388558|NCT01227824|Other|GSK1349572 Placebo|GSK1349572 placebo taken once daily
388559|NCT01227824|Other|ABC/3TC|Abacavir/Lamivudine background therapy once daily
388560|NCT01227824|Other|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
388561|NCT01227824|Other|raltegravir Placebo|raltegravir placebo taken twice daily
388562|NCT01227811|Drug|Darifenacin|Single oral dose Darisec(R) 15.0 mg
388563|NCT01227811|Drug|Darifenacin|Single oral dose Enablex(R) 15 mg
388564|NCT01227798|Drug|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
388565|NCT01227798|Drug|Placebo|Normal Saline
388566|NCT01227785|Device|INCEPTA ICD or CRT-D|
388567|NCT01227772|Biological|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
388568|NCT01227759|Drug|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
388569|NCT01227759|Drug|Placebo|Placebo containing no active ingredient
388570|NCT01227746|Procedure|Tumor biopsies|
388571|NCT01227733|Other|Breast Tumor Blocks|
388572|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
388573|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
388574|NCT01227720|Drug|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
388575|NCT01227720|Drug|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
388576|NCT01227707|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
388577|NCT01227707|Drug|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
388578|NCT01227707|Radiation|Radiation therapy|Total dose of 45 Gy over 38 days
388579|NCT01227707|Procedure|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
388580|NCT01227707|Drug|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
388581|NCT01227707|Drug|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
388582|NCT01227707|Drug|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
388583|NCT01227694|Other|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
388584|NCT01227681|Drug|G-CSF|G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
388585|NCT01227681|Drug|Placebo|Sodium Chloride (NaCl) 0.9 %
388586|NCT01227668|Drug|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
388587|NCT01227668|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
388588|NCT01227655|Drug|BIA 9-1067|Capsules will be used.
388589|NCT01227655|Drug|Placebo|comparator
388590|NCT01227655|Drug|Levodopa|
388591|NCT01227655|Drug|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
388592|NCT01227655|Drug|Benserazide|DOPA decarboxylase inhibitor
388593|NCT01227642|Other|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
388594|NCT01227642|Other|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
388595|NCT01227642|Other|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
388596|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
388597|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
388598|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
388599|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
388600|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
388601|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
388602|NCT01227629|Drug|warfarin|comparator
388603|NCT01227629|Drug|dabigatran without ASA|dose comparison
388604|NCT01227629|Drug|dabigatran without ASA|dose comparison
388605|NCT01227629|Drug|dabigatran without ASA|dose comparison
388606|NCT01227616|Drug|Ferumoxytol|IV Ferumoxytol
388607|NCT01227616|Drug|Iron Sucrose|IV Iron Sucrose
388608|NCT01227603|Drug|Nifedipine-candesartan FDC (BAY 98-7106)|Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
388609|NCT01227603|Drug|Nifedipine GITS (Adalat LA, BAYA1040)|Single oral dose of 1 tablet of nifedipine GITS 60 mg
388610|NCT01227603|Drug|Candesartan (Atacand)|Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
388611|NCT01227590|Drug|Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
388612|NCT01227577|Drug|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
388613|NCT01227564|Biological|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
388614|NCT01227564|Biological|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
390965|NCT01209195|Drug|MM-121|increasing doses of MM-121 IV QW
388615|NCT01227564|Other|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
388616|NCT01227551|Biological|Coxsackievirus A21 (CVA21)|CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
388617|NCT01227538|Other|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
388618|NCT01227525|Device|Vibraject|The VibraJect clips onto the barrel of a conventional and intraligamentary dental syringe (and some disposable syringes) and vibrates the needle at a high frequency while injections are administered.
388619|NCT01227512|Drug|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
388620|NCT01227512|Other|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.~Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
388621|NCT01227486|Device|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
388622|NCT01227473|Behavioral|Mindfulness-based diabetes prevention education group|The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.
388623|NCT01227473|Behavioral|Conventional diabetes prevention education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
388624|NCT01227460|Drug|Sitagliptin|pill/tablet form of 100mg each. will take one tablet a day throughout study
388625|NCT01227460|Drug|Sugar Pill|100mg tablet once a day
388626|NCT01227434|Drug|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
388627|NCT01227434|Drug|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
388628|NCT01227434|Procedure|Resection as clinical care|Indicated, intended, surgical resection as clinical care
388629|NCT01227421|Drug|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
388630|NCT01227421|Drug|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
388631|NCT01227421|Drug|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
388632|NCT01227408|Drug|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
388633|NCT01227395|Drug|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.~Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
388634|NCT01227382|Procedure|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
388635|NCT01227369|Other|OPSAT-Q|A linguistically validated Korean version of OPSAT-Q
388636|NCT01227356|Drug|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
388637|NCT01227330|Behavioral|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
388638|NCT01227330|Behavioral|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
388639|NCT01227317|Other|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
388640|NCT01227304|Device|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
388641|NCT01227291|Drug|SYL040012|SYL040012 ophthalmic drops, daily single dose administration
388642|NCT01227278|Other|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
388643|NCT01227278|Biological|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
388644|NCT01227265|Drug|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
388645|NCT01227265|Drug|Placebo|Preladenant-matching placebo oral tablet taken twice daily
388646|NCT01227252|Drug|LY2886721|5 milligrams (mg) up to 35 mg, administered orally as capsules, daily for 14 days
388647|NCT01227252|Drug|Placebo|Administered orally as capsules, daily for 14 days
388648|NCT01227239|Drug|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
388649|NCT01227239|Drug|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
388650|NCT01227239|Radiation|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
388651|NCT01227226|Drug|Artificial tears|Instill one drop of artificial tears
388652|NCT01227200|Drug|dypiron, tramadol|dypiron 4 ML, tramadol 50 mg flashtab
388889|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
388653|NCT01227187|Drug|Drotrecogin alfa activated|We plan to determine the optimal dose of Xigris needed to achieve PTT between 65 and 100 secs. The study will test different dose regimens of Xigris. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via the pre-filter arterial drip chamber via a standard intravenous pump. The PTT will be assessed from blood samples drawn at baseline,15,30,60,120 and 180 mins. The dose of Xigris will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains <65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
388654|NCT01227174|Drug|Propofol|Procedural sedation will be achieved using propofol
388655|NCT01227148|Other|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
388656|NCT01227148|Other|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
388657|NCT01227135|Drug|hydroxychloroquine|
388658|NCT01227135|Drug|imatinib mesylate|
388659|NCT01227135|Genetic|cytogenetic analysis|
388660|NCT01227135|Genetic|polymerase chain reaction|
388661|NCT01227135|Other|laboratory biomarker analysis|
388662|NCT01227135|Other|pharmacological study|
388663|NCT01227096|Device|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
388664|NCT01227057|Behavioral|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
388665|NCT01227057|Behavioral|Case Management|Case management
388666|NCT01227044|Drug|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
388667|NCT01227044|Other|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
388668|NCT01227018|Drug|STA-9090|Given IV
388669|NCT01227018|Radiation|Radiologic imaging|radiologic modalities used to evaluate response to treatment
388670|NCT01227018|Procedure|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
388671|NCT01227005|Biological|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
388672|NCT01226992|Drug|Vancomycin|"Oral Vancomycin:~Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
388673|NCT01226992|Biological|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
388674|NCT01226979|Radiation|High-dose endorectal brachytherapy|The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
388675|NCT01226966|Drug|liraglutide|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
388676|NCT01226953|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
388677|NCT01226927|Other|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
388678|NCT01226914|Drug|EVICEL|EVICEL
388679|NCT01226901|Drug|MK-4827|MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
388680|NCT01226875|Procedure|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
388681|NCT01226849|Drug|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
388682|NCT01226836|Other|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
388683|NCT01226823|Drug|Ursodeoxycholic Acid|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
388684|NCT01226823|Drug|Placebo|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
388685|NCT01226797|Drug|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
388686|NCT01226797|Drug|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
388687|NCT01226784|Behavioral|Physcial activity|Strenght training Relaxation exercise
388688|NCT01226771|Drug|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
388689|NCT01226771|Drug|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
388690|NCT01226771|Drug|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
388691|NCT01226758|Biological|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
388692|NCT01226758|Biological|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
388693|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
388694|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
388695|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
388696|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
388697|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
388698|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
388699|NCT01226732|Drug|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
388700|NCT01226732|Drug|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
388701|NCT01226719|Drug|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
388702|NCT01226719|Drug|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
388703|NCT01226719|Drug|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
388704|NCT01226719|Drug|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
388705|NCT01226719|Drug|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
388706|NCT01226706|Drug|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
388707|NCT01226706|Drug|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
388708|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
388709|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
388710|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
388711|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
388712|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
388713|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
388714|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
388715|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
388716|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
388717|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
388718|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
388719|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
388720|NCT01226680|Drug|Tasocitinib|0.005% QD for 12 weeks
388721|NCT01226680|Drug|Tasocitinib|0.003% QD for 12 weeks
388722|NCT01226680|Drug|vehicle for Tasocitinib|vehicle QD for 12 weeks
388723|NCT01226667|Drug|Pregabalin|"Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.~Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly."
388724|NCT01226654|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
388725|NCT01226641|Device|Telemedicine|CPAP treatment with telemedicine system
388726|NCT01226641|Device|Standard care|Standard care, including CPAP
388727|NCT01226628|Biological|CNTO 2476|
388728|NCT01226628|Procedure|iTrack Model 275 micro catheter|CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
388729|NCT01226615|Drug|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
388730|NCT01226615|Drug|Placebo|Two placebo capsules taken once a day for four months.
388731|NCT01226602|Drug|AZD6140|P2Y12 receptor antagonist
388732|NCT01226602|Drug|Placebo|
388733|NCT01226589|Procedure|MRS|
388734|NCT01226576|Device|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
388803|NCT01225926|Device|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
388735|NCT01226563|Device|IK-5001|4 mL (+/- 0.2 mL) administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
388736|NCT01226563|Device|Saline Solution|4 mL (+/- 0.2 mL) slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
388737|NCT01226550|Procedure|cytoreductive surgery and HIPEC|"The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).~The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.~Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU)."
388738|NCT01226537|Drug|Taurine|500 mg taurine capsules twice per day for 6 months
388739|NCT01226524|Drug|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
388740|NCT01226511|Drug|Duloxetine|Administered orally
388741|NCT01226511|Drug|Placebo|Administered orally
388742|NCT01226498|Procedure|Red blood Cells auto-transfusion|Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
388743|NCT01226485|Drug|Taladegib|Administered IV
388744|NCT01226472|Biological|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
388745|NCT01226459|Drug|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
388746|NCT01226459|Drug|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
388747|NCT01226446|Drug|vitamin D|Vitamin D on top of the standard treatment
388748|NCT01226420|Drug|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
388749|NCT01226407|Drug|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
388750|NCT01226394|Procedure|laparotomy plus HIPEC|Laparotomy + HIPEC
388751|NCT01226381|Drug|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
388752|NCT01226368|Other|Biological Sample collection|Cervix cells
388753|NCT01226355|Device|stent|"NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.~Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd."
388754|NCT01226342|Device|Transcutaneous electrical muscle stimulation|On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
388755|NCT01226329|Behavioral|Right Question Project - Mental Health (RQP-MH)|"The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager."
388756|NCT01226329|Behavioral|Pamphlet|"Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress."
388757|NCT01226316|Drug|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
388758|NCT01226316|Drug|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
388759|NCT01226316|Drug|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
388760|NCT01226316|Drug|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
388761|NCT01226303|Drug|ATRA|see the protocol
388762|NCT01226303|Drug|ATRA + IDA|see the protocol
388763|NCT01226290|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
388764|NCT01226277|Drug|GDC-0917|Oral repeating dose
388884|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
388765|NCT01226264|Procedure|Diffusion weighted MRI (DW- MRI)|"An MRI examination (including diffusion-weighted sequences) belongs to the standard protocol for patients with cervical uterine cancer. The additional burden is therefore restricted to an extra MRI scan during and/or early after therapy.~MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.~During the examination, an intravenous and vaginal contrast medium will be administered. In most cases, patients do not experience any discomfort and the use of these contrast agents is part of the clinical routine."
388766|NCT01226251|Device|In vitro chair side test|Colour evaluation of a strip
388767|NCT01226238|Other|Online self-help|Provision of online self-help
388768|NCT01226225|Behavioral|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
388769|NCT01226225|Behavioral|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
388770|NCT01226212|Dietary Supplement|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
388771|NCT01226212|Dietary Supplement|Placebo|maltodextrose
388772|NCT01226186|Behavioral|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
388773|NCT01226186|Behavioral|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
388774|NCT01226173|Device|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
388775|NCT01226160|Procedure|Postoperative face-down posturing|Postoperative face-down posturing for 10 days after surgery.
388776|NCT01226160|Procedure|Postoperative non-posturing group|avoid a face-up position only for 10 days after surgery
388777|NCT01226147|Drug|Tamibarotene|4mg/day for 24 weeks.
388778|NCT01226134|Drug|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
388779|NCT01226134|Drug|Placebo|placebo capsules,thrice a day for four weeks
388780|NCT01226121|Biological|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
388781|NCT01226108|Device|Patch|"One patch per day, Duration: three weeks, Administration: behind the ear~--------------------------------------------------------------------------------"
388782|NCT01226082|Device|Transcranial Direct Current Stimulation|Patients will recieve tDCS in a 5-day period of treatment
388783|NCT01226069|Drug|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
388784|NCT01226069|Drug|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
388785|NCT01226069|Other|No application|No application
388786|NCT01226056|Drug|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
388787|NCT01226043|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
388788|NCT01226030|Drug|M2ES 7.5mg|M2ES 7.5mg
388789|NCT01226030|Drug|M2ES 15mg|M2ES 15mg
388790|NCT01226030|Drug|M2ES 30mg|M2ES 30mg
388791|NCT01226030|Drug|M2ES 60mg|M2ES 60mg
388792|NCT01226017|Other|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
388793|NCT01225991|Drug|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
388794|NCT01225978|Device|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.~The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
388795|NCT01225965|Device|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
388796|NCT01225965|Device|Placebo|Once daily inhalation of Placebo Inhalation Solution
388797|NCT01225952|Device|Crystalens AO|Bausch & Lomb model silicone multi-piece accommodating IOL.
388798|NCT01225952|Device|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
388799|NCT01225952|Device|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
388800|NCT01225939|Drug|AZD8329|tablet
388801|NCT01225939|Drug|AZD8329|Solution
388802|NCT01225926|Device|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
388885|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
388804|NCT01225913|Drug|fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
388805|NCT01225913|Drug|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
388806|NCT01225887|Drug|Nintedanib|Given PO
388807|NCT01225874|Drug|SC-PEG E. coli L-asparaginase|Given IM
388808|NCT01225874|Drug|cytarabine|Given IT
388809|NCT01225874|Drug|daunorubicin hydrochloride|Given IV
388810|NCT01225874|Drug|dexamethasone|Given orally
388811|NCT01225874|Drug|methotrexate|Given IT
388812|NCT01225874|Drug|pegaspargase|Given IM
388813|NCT01225874|Drug|prednisone|Given orally
388814|NCT01225874|Drug|vincristine sulfate|Given IV
388815|NCT01225835|Drug|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
388816|NCT01225835|Drug|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
388817|NCT01225835|Drug|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
388818|NCT01225835|Drug|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
388819|NCT01225835|Drug|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
388820|NCT01225822|Drug|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
388821|NCT01225822|Drug|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
388822|NCT01225822|Drug|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
388823|NCT01225822|Drug|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
388824|NCT01225822|Drug|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
388825|NCT01225796|Drug|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
388826|NCT01225783|Other|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
388827|NCT01225770|Dietary Supplement|green tea|Gargling three times daily for 90 days
388828|NCT01225757|Device|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
388829|NCT01225744|Drug|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.~Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA > 2 m2 ."
388830|NCT01225744|Drug|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
388831|NCT01225744|Drug|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
388832|NCT01225744|Drug|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
388833|NCT01225731|Biological|tildrakizumab|SC administration of tildrakizumab at assigned dose
388834|NCT01225731|Drug|Placebo|SC administration of Placebo
388835|NCT01225705|Drug|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
388836|NCT01225705|Drug|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
388837|NCT01225692|Behavioral|Head Injury Guideline|
388838|NCT01225679|Device|positive airway pressure, Non-invasive mechanic ventilation|"Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.~Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O."
388839|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
388840|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
388841|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
388842|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
388843|NCT01225653|Drug|Latanoprost|Topical application
388844|NCT01225640|Drug|PNU-100480|600 mg twice daily (BID) for 14 days
388845|NCT01225640|Drug|PNU-100480|1200 mg once daily (QD) for 14 days
388846|NCT01225640|Drug|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
388886|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 24 weeks
388887|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
388888|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
388847|NCT01225627|Other|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
388848|NCT01225627|Other|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
388849|NCT01225614|Device|Bilevel pressure ventilator|Nocturnal home ventilation
388850|NCT01225601|Behavioral|Tabacco discontinuation|Tabacco discontinuation
388851|NCT01225575|Drug|co.don chondrosphere®|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.~The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect"
388852|NCT01225562|Drug|Ticagrelor 90 mg|Oral dose twice a day
388853|NCT01225562|Drug|Ticagrelor 60 mg|Oral dose twice a day
388854|NCT01225562|Drug|Ticagrelor Placebo|Oral dose twice a day
388855|NCT01225549|Drug|AZD5423|Suspension for nebulisation once daily 7 days
388856|NCT01225549|Drug|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
388857|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
388858|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
388859|NCT01225536|Drug|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
388860|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
388861|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
388862|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
388863|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
388864|NCT01225497|Procedure|Standard eccentric exercise|"Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.~The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.~All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain."
388865|NCT01225497|Procedure|Eccentric exercise-Experimental group|Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
388866|NCT01225484|Procedure|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
388867|NCT01225484|Procedure|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
388868|NCT01225471|Biological|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
388869|NCT01225458|Other|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
388870|NCT01225458|Other|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
388871|NCT01225458|Other|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
388872|NCT01225445|Drug|Ramipril|2.5 mg daily
388873|NCT01225432|Other|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
388874|NCT01225419|Drug|Plerixafor, mozobil|Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
388875|NCT01225406|Drug|Tenofovir|
388876|NCT01225393|Drug|MLTA3698A|Subcutaneous repeating dose
388877|NCT01225393|Drug|adalimumab|Subcutaneous repeating dose
388878|NCT01225393|Drug|leflunomide|Stable dose if not on methotrexate
388879|NCT01225393|Drug|methotrexate|Stable dose if not on leflunomide
388880|NCT01225393|Drug|placebo|Subcutaneous repeating dose
388881|NCT01225380|Drug|GS-9190|GS-9190 capsule, 20 mg BID, 16 or 24 weeks
388882|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 16 or 24 weeks
388883|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
388890|NCT01225380|Drug|GS-9256 placebo|placebo matching GS-9256 capsule BID, 24 weeks
388891|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
388892|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), 48 weeks
388893|NCT01225367|Device|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
388894|NCT01225354|Drug|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
388895|NCT01225341|Drug|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
388896|NCT01225341|Other|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
388897|NCT01225328|Behavioral|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
388898|NCT01225315|Drug|Placebo|Matching placebo administered orally twice daily
388899|NCT01225315|Drug|Setipiprant|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
388900|NCT01225302|Drug|Linifanib|Low dose linifanib (once a day)
388901|NCT01225302|Drug|Linifanib|High dose linifanib (once a day)
388902|NCT01225302|Drug|Carboplatin|Given on Day 1 of every 21-day cycle
388903|NCT01225302|Drug|Paclitaxel|Given on Day 1 of every 21-day cycle
388904|NCT01225289|Dietary Supplement|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
388905|NCT01225289|Drug|Placebo|1 capsule per day for six months
388906|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
388907|NCT01225276|Drug|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
388908|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
388909|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
388910|NCT01225263|Drug|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
388911|NCT01225263|Dietary Supplement|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
388912|NCT01225263|Other|Placebo|Two placebo pills, taken twice daily for 6 months
388913|NCT01225250|Device|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
388914|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
388915|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
388916|NCT01225237|Drug|Ramosetron|oral
388917|NCT01225237|Drug|Placebo|oral
388918|NCT01225224|Drug|peficitinib|oral
388919|NCT01225224|Drug|Placebo|oral
388920|NCT01225211|Drug|Lumacaftor|Tablet
388921|NCT01225211|Drug|Ivacaftor|Tablet.
388922|NCT01225211|Drug|Lumacaftor Placebo|Matching placebo tablet.
388923|NCT01225211|Drug|Ivacaftor Placebo|Matching placebo tablet.
388924|NCT01225198|Dietary Supplement|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
388925|NCT01225198|Other|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
388926|NCT01225172|Drug|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
388927|NCT01225172|Drug|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
388928|NCT01225159|Drug|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
388929|NCT01225159|Drug|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
388930|NCT01225146|Drug|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
389054|NCT01224093|Drug|rituximab [MabThera/Rituxan]|as prescribed
388931|NCT01225133|Other|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
388932|NCT01225133|Other|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
388933|NCT01225120|Other|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
388934|NCT01225107|Dietary Supplement|Cranberry Extract|500mg TID
388935|NCT01225107|Drug|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
388936|NCT01225094|Drug|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.
388937|NCT01225094|Other|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
388938|NCT01225081|Drug|ipragliflozin|oral
388939|NCT01225081|Drug|Placebo|oral
388940|NCT01225081|Drug|Pioglitazone|oral
388941|NCT01225068|Drug|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
388942|NCT01225068|Drug|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
388943|NCT01225055|Drug|Teriparatide|20 ug daily over 12 months
388944|NCT01225055|Device|vibration|10 min/day for 12 months
388945|NCT01225042|Dietary Supplement|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
388946|NCT01225042|Dietary Supplement|placebo|placebo consisting of carrier material powder of identical appearance
388947|NCT01225029|Other|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
388948|NCT01225016|Drug|Definity contrast agent|Thyroid ultrasound using contrast agent
388949|NCT01224990|Procedure|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
388950|NCT01224977|Drug|azithromycin|azithromycin 500 mg 3/week for 3 months
388951|NCT01224964|Drug|Montelukast|Montelukast, 10 mg
388952|NCT01224964|Drug|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
388953|NCT01224951|Drug|Beclomethasone|400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
388954|NCT01224925|Procedure|Direct pulp capping with Dycal|Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling
388955|NCT01224925|Procedure|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.
388956|NCT01224912|Behavioral|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
388957|NCT01224899|Procedure|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
388958|NCT01224886|Behavioral|Physical activity|Supervised exercise intervention
388959|NCT01224860|Drug|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
388960|NCT01224860|Drug|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
388961|NCT01224847|Drug|Tetracaine|1 gtt
388962|NCT01224847|Drug|Cocaine|1 gtt
388963|NCT01224847|Drug|Lidocaine|Lidocaine soaked pledget
388964|NCT01224834|Drug|Sublingual tablet of ragweed pollen allergen extract|administered once a day over 10 days
388965|NCT01224821|Biological|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
388966|NCT01224808|Biological|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
388967|NCT01224795|Drug|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
388968|NCT01224795|Drug|Placebo Comparator|Placebo Peramivir, administered intravenously.
388969|NCT01224769|Drug|bendamustine +/- rituximab|
388970|NCT01224756|Drug|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
388971|NCT01224756|Drug|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
388972|NCT01224743|Dietary Supplement|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
388973|NCT01224743|Dietary Supplement|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
388974|NCT01224743|Dietary Supplement|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
388975|NCT01224730|Drug|perifosine|100 mg daily
388976|NCT01224717|Drug|PTH134|
388977|NCT01224717|Drug|Placebo|
388978|NCT01224717|Drug|Forsteo|
388979|NCT01224678|Dietary Supplement|vitamin D|Given orally
388980|NCT01224678|Other|placebo|Given orally
388981|NCT01224665|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
388982|NCT01224665|Procedure|therapeutic standard lymphadenectomy|Patients undergo standard pelvic lymphadenectomy.
388983|NCT01224665|Procedure|therapeutic extended lymphadenectomy|Patients undergo extended pelvic lymphadenectomy
388984|NCT01224652|Drug|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
388985|NCT01224652|Drug|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
388986|NCT01224639|Biological|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, and TDV-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU
388987|NCT01224639|Biological|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, and TDV-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. TDV administered intradermally.
388988|NCT01224639|Biological|Placebo|Phosphate Buffered Saline (PBS)
388989|NCT01224626|Drug|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
388990|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit # 1
388991|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit #1
388992|NCT01224600|Other|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
388993|NCT01224587|Drug|D1000078|Oral, one single dose
388994|NCT01224587|Drug|D1000082|Oral, one single dose
388995|NCT01224587|Drug|D1000083|Oral, one single dose
388996|NCT01224587|Drug|D1000085|Oral, one single dose
388997|NCT01224561|Behavioral|Lipid overnutrition|During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
388998|NCT01224548|Other|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
388999|NCT01224548|Other|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
389000|NCT01224535|Dietary Supplement|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
389001|NCT01224522|Procedure|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
389002|NCT01224522|Procedure|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
389003|NCT01224509|Drug|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
389004|NCT01224509|Other|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
389005|NCT01224496|Drug|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
389006|NCT01224470|Drug|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
389007|NCT01224457|Drug|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
389008|NCT01224444|Other|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
389009|NCT01224431|Drug|Buffered Lidocaine J-tip|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
389010|NCT01224418|Drug|Tacrolimus|oral
389011|NCT01224405|Drug|Docetaxel + LH-RH analogues|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration."
389012|NCT01224405|Drug|Docetaxel|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.~In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues."
389645|NCT01219309|Dietary Supplement|Omega 3/6 fatty acids|3 capsules bid orally
389013|NCT01224405|Drug|Docetaxel|Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced >50%. Docetaxel treatment will be resumed when the serum PSA will rise by >50% from the lowest PSA level recorded and will be >10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
389014|NCT01224405|Drug|Continuous Docetaxel|Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced >50% or will reach a level <4 ng/mL.
389015|NCT01224405|Drug|Continuous Docetaxel|Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced >50% or will reach a level <4 ng/mL.
389016|NCT01224392|Other|Chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
389017|NCT01224392|Radiation|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
389018|NCT01224379|Device|Topping off system|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
389019|NCT01224379|Device|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
389020|NCT01224366|Drug|Vildagliptin|
389021|NCT01224366|Drug|Placebo|
389022|NCT01224353|Drug|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
389023|NCT01224353|Other|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
389024|NCT01224340|Behavioral|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
389025|NCT01224340|Behavioral|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
389026|NCT01224340|Other|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
389027|NCT01224327|Biological|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
389028|NCT01224327|Drug|Conserved therapy|Oral or intravenous administration
389029|NCT01224314|Other|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
389030|NCT01224301|Behavioral|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
389031|NCT01224301|Behavioral|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
389032|NCT01224288|Procedure|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
389033|NCT01224275|Other|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
389034|NCT01224262|Biological|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
389035|NCT01224262|Biological|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
389036|NCT01224262|Biological|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
389037|NCT01224249|Dietary Supplement|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
389038|NCT01224236|Drug|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
389039|NCT01224236|Drug|control|multivitamin solution without iron
389040|NCT01224210|Drug|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
389041|NCT01224197|Drug|TMC435|100 or 200 mg capsule, one single dose
389042|NCT01224197|Drug|TMC435|100 or 200 mg capsule, once daily for 5 days
389043|NCT01224184|Behavioral|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
389044|NCT01224184|Behavioral|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
389045|NCT01224171|Drug|vedolizumab|Vedolizumab for intravenous infusion
389046|NCT01224171|Other|Placebo|Placebo intravenous infusion
389047|NCT01224145|Drug|4, 5x5cm bupivacaine collagen sponges|
389048|NCT01224132|Drug|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
389049|NCT01224119|Device|Amplex|225 micrograms of B2A per cc of ceramic granules
389050|NCT01224119|Procedure|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
389051|NCT01224106|Drug|Gantenerumab|Participants will receive gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection q4w.
389052|NCT01224106|Drug|Placebo|Participants will receive placebo SC injection q4w.
389053|NCT01224093|Drug|Chemotherapy|as prescribed
389055|NCT01224080|Device|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
389056|NCT01224067|Drug|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
389057|NCT01224041|Drug|Tacrolimus|oral
389058|NCT01224028|Drug|Tacrolimus|oral
389059|NCT01224028|Drug|Placebo|oral
389060|NCT01224015|Drug|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
389061|NCT01224015|Biological|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
389062|NCT01224015|Biological|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
389063|NCT01223989|Other|hypocaloric diet balanced + nutrition education + ruled physical activity|
389064|NCT01223976|Other|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.~QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
389065|NCT01223937|Drug|Desmopressin|
389066|NCT01223937|Drug|Placebo|
389067|NCT01223924|Other|placebo|placebo
389068|NCT01223924|Drug|M2ES|M2ES IV 7.5mg-90mg
389069|NCT01223911|Drug|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
389070|NCT01223911|Drug|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
389071|NCT01223898|Drug|Tasigna|
389072|NCT01223885|Dietary Supplement|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
389073|NCT01223872|Other|interview|"Standard Interview (2-15 years from last treatment)~Demographic data interview (pre-initial study interview)"
389074|NCT01223872|Other|clinic visit and interview|"REACH Clinic Visit(initial or regular)~Post-REACH Clinic Interview (3mos from initial or regular clinic visit)~Demographic data interview(pre-initial study interview)"
389075|NCT01223872|Other|interviews and clinic visit|"Pre-REACH Clinic Interview(2-15 yrs from last treatment)~REACH Clinic Visit(initial or regular)~Post-REACH Clinic Interview(1mo from initial clinic visit)~Post-REACH Clinic Interview(3mos from initial or regular clinic visit)~Demographic data interview(pre-initial study interview)"
389076|NCT01223859|Procedure|Interstitial soft palate surgery|Soft palate RF surgery in local anaesthesia
389077|NCT01223820|Drug|Capsaicin|5x nasal application in one day, 1 hour between each application
389078|NCT01223807|Other|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
389079|NCT01223781|Behavioral|Biofeedback-based motor learning for PD|Prior to freezing episodes, auditory stimulation is triggered
389080|NCT01223768|Drug|Acetyl-l-Carnitine|2g per day
389081|NCT01223768|Drug|placebo|twice per day
389082|NCT01223755|Drug|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
389083|NCT01223755|Drug|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure <130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
389084|NCT01223742|Dietary Supplement|ACETYL-L-CARNITINE|2 g acetylcarnitine taken orally twice a day.
389085|NCT01223742|Drug|placebo|placebo twice per day
389086|NCT01223729|Drug|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
389087|NCT01223729|Other|placebo|placebo twice per day
389088|NCT01223716|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
389089|NCT01223716|Behavioral|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
389090|NCT01223716|Behavioral|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).~Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
389091|NCT01223703|Drug|n-3 PUFAs|1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
389092|NCT01223703|Drug|Placebo|1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
389646|NCT01219309|Dietary Supplement|Placebo (olive oil)|3 capsules bid orally
389093|NCT01223690|Drug|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
389094|NCT01223690|Drug|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
389095|NCT01223677|Behavioral|Rumination Focused CBT|see arms
389096|NCT01223664|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
389097|NCT01223664|Drug|Conserved therapy|Oral or intravenous administration
389098|NCT01223651|Procedure|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
389099|NCT01223638|Other|Audiometry|Audiometry
389100|NCT01223625|Drug|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
389101|NCT01223625|Drug|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
389102|NCT01223612|Drug|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
389103|NCT01223612|Procedure|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
389104|NCT01223560|Drug|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
389105|NCT01223560|Other|Exercise|Exercise on tread mill
389106|NCT01223560|Dietary Supplement|Carbohydrate|Carbohydrate intake
389107|NCT01223547|Other|Education|Participants are taught the principles of carb counting
389108|NCT01223547|Other|Education|Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
389109|NCT01223534|Drug|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
389110|NCT01223534|Drug|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
389111|NCT01223521|Device|Immediate intrauterine contraception|A Cu-IUD or LNG-IUS is inserted after abortion.
389112|NCT01223469|Device|Contact force assisted irrigated RF ablation|radiofrequency ablation of atrial fibrillation or SVT
389113|NCT01223443|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
389114|NCT01223430|Drug|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal < 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
389115|NCT01223404|Drug|Placebo|Participants are administered a placebo patch and a placebo capsule
389116|NCT01223404|Drug|Nicotine|Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule
389117|NCT01223404|Drug|Mecamylamine|Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine
389118|NCT01223391|Other|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
389119|NCT01223391|Other|No abdominal binder|Standing without abdominal binder for 3 minutes
389120|NCT01223378|Drug|BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
389121|NCT01223378|Drug|Latanoprost|0.005% ophthalmic solution, QD 28 days
389122|NCT01223365|Drug|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
389123|NCT01223352|Drug|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
389124|NCT01223339|Drug|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
389125|NCT01223339|Drug|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
389126|NCT01223339|Drug|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
389127|NCT01223339|Drug|Placebo|Placebo tablets administered once daily in the fed state for 7 days
389128|NCT01223326|Drug|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
389129|NCT01223326|Drug|Saline|Na Cl 0.9% infusion
389130|NCT01223313|Device|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
389647|NCT01219257|Biological|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
389131|NCT01223274|Device|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
389132|NCT01223274|Device|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
389133|NCT01223248|Radiation|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
389134|NCT01223248|Radiation|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & within 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
389135|NCT01223235|Biological|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
389136|NCT01223222|Drug|LTX-109|Topical administration. 3 times daily. 5 days.
389137|NCT01223209|Drug|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
389138|NCT01223196|Drug|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
389139|NCT01223196|Drug|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
389140|NCT01223183|Drug|hypertonic saline (7%)|single treatment by inhalation
389141|NCT01223183|Drug|isotonic saline|single treatment by inhalation
389142|NCT01223170|Behavioral|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
389143|NCT01223170|Behavioral|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
389144|NCT01223170|Behavioral|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
389145|NCT01223170|Behavioral|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
389146|NCT01223157|Biological|Biological data|Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
389147|NCT01223144|Behavioral|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
389148|NCT01223131|Drug|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
389149|NCT01223131|Drug|NPH insulin|"Pharmaceutical form:aqueous solution for injection~Route of administration: Subcutaneous"
389150|NCT01223118|Procedure|Vitrification and PGD|Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
389151|NCT01223105|Procedure|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
389152|NCT01223105|Procedure|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
389153|NCT01223079|Drug|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
389154|NCT01223079|Drug|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
389155|NCT01223053|Drug|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
389156|NCT01223053|Drug|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
389157|NCT01223040|Other|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
389158|NCT01223027|Drug|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
389159|NCT01223027|Drug|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
389160|NCT01223014|Drug|AZD2423|AZD2423
389161|NCT01223001|Drug|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
389162|NCT01223001|Drug|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
389163|NCT01222988|Dietary Supplement|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
389164|NCT01222975|Drug|Risperidone|orally disintegrating tablets
389165|NCT01222962|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
389166|NCT01222949|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
389167|NCT01222936|Drug|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
389168|NCT01222923|Drug|Risperidone|1 mg orally disintegrating tablets
389169|NCT01222910|Drug|Valacyclovir hydrochloride|
389170|NCT01222897|Drug|Valacyclovir hydrochloride|
389171|NCT01222884|Drug|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
389172|NCT01222884|Drug|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
389173|NCT01222871|Drug|Triamcinolone|Triamcinolone soaked nasopore dressing
389174|NCT01222871|Drug|Saline soaked sponge|saline soaked sponge
389175|NCT01222858|Behavioral|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
389176|NCT01222858|Behavioral|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
389177|NCT01222845|Drug|Test meal|Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
389178|NCT01222832|Drug|Bacitracin|Bacitracin soaked nasopore sponge
389179|NCT01222819|Drug|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
389180|NCT01222806|Device|Repetitive Transcranial Magnetic Stimulation|
389181|NCT01222780|Drug|Marqibo|"Marqibo® will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.~The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.~Detailed pharmacokinetic studies will be performed during the first treatment cycle"
389182|NCT01222767|Drug|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
389183|NCT01222754|Drug|Lenalidomide|"With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.~Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course."
389184|NCT01222754|Radiation|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
389185|NCT01222715|Biological|Bevacizumab|Given IV
389186|NCT01222715|Drug|Cyclophosphamide|Given IV
389187|NCT01222715|Other|Laboratory Biomarker Analysis|Correlative studies
389188|NCT01222715|Drug|Temsirolimus|Given IV
389189|NCT01222715|Drug|Vinorelbine Tartrate|Given IV
389190|NCT01222702|Drug|Cadazolid|Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
389191|NCT01222702|Drug|Vancomycin|Vancomycin, provided as capsules (125 mg) for oral administration
389192|NCT01222702|Drug|Placebo-matching cadazolid|Placebo of cadazolid powder for oral suspension
389193|NCT01222702|Drug|Placebo-matching vancomycin|Placebo of vancomycin capsules
389194|NCT01222689|Drug|erlotinib hydrochloride|Given PO
389195|NCT01222689|Drug|selumetinib|Given PO
389196|NCT01222689|Other|laboratory biomarker analysis|Correlative studies
389197|NCT01222676|Drug|cisplatin|
389198|NCT01222676|Drug|gemcitabine hydrochloride|
389199|NCT01222676|Drug|sorafenib tosylate|
389200|NCT01222676|Other|imaging biomarker analysis|
389201|NCT01222676|Other|laboratory biomarker analysis|
389202|NCT01222676|Procedure|computed tomography|
389203|NCT01222676|Procedure|neoadjuvant therapy|
389204|NCT01222676|Radiation|fludeoxyglucose F 18|
389205|NCT01222663|Device|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
389206|NCT01222663|Device|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
389207|NCT01222650|Drug|KSO-0400|
389208|NCT01222650|Drug|KSO-0400|
389209|NCT01222650|Drug|Silodosin|
389210|NCT01222650|Drug|Placebo|
389211|NCT01222637|Drug|CetuGEX™|
389212|NCT01222624|Drug|PankoMab-GEX™|
389213|NCT01222611|Drug|Fosamprenavir|HAART including fosamprenavir boosted with ritonavir
389488|NCT01220505|Procedure|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
389214|NCT01222585|Drug|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with >=14 postnatal days and every 24 hours for infants <14 postnatal days.
389215|NCT01222572|Radiation|Stereotactic boost|
389216|NCT01222572|Radiation|Conventional RT|
389217|NCT01222572|Drug|Etoposide|
389218|NCT01222572|Drug|Cisplatin|
389219|NCT01222559|Drug|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
389220|NCT01222559|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
389221|NCT01222546|Drug|CH5132799|
389222|NCT01222533|Drug|Tiotropium medium|Tiotropium inhalation solution medium dose
389223|NCT01222533|Drug|Tiotropium low|Tiotropium inhalation solution low dose
389224|NCT01222533|Drug|Tiotropium high|Tiotropium inhalation solution high dose
389225|NCT01222533|Drug|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
389226|NCT01222533|Drug|Tiotropium placebo|Placebo inhalation solution
389227|NCT01222520|Drug|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
389228|NCT01222520|Drug|Telmisartan|80 mg once a daily
389229|NCT01222494|Behavioral|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
389230|NCT01222494|Behavioral|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
389231|NCT01222468|Drug|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
389232|NCT01222468|Drug|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
389233|NCT01222455|Drug|Fostamatinib|Oral tablets, single dose
389234|NCT01222442|Drug|AZD3199|Single dose, oral inhalation
389235|NCT01222442|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
389236|NCT01222442|Other|Placebo comparator|Single dose, oral inhalation
389237|NCT01222429|Other|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
389238|NCT01222429|Other|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
389239|NCT01222416|Radiation|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
389240|NCT01222416|Radiation|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
389241|NCT01222403|Biological|Fluad_MF59-adjuvanted trivalent influenza subunit vaccine|
389242|NCT01222403|Biological|Vantaflu_MF59-adjuvanted trivalent influenza subunit vaccine|
389243|NCT01222390|Device|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
389244|NCT01222377|Procedure|endoscopic surgery|Undergo endoscopic breast surgery
389245|NCT01222377|Procedure|quality-of-life assessment|Ancillary studies
389246|NCT01222364|Procedure|Standard Cord Clamping|Immediate clamping (<5 seconds) of the umbilical cord after delivery.
389247|NCT01222364|Procedure|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
389248|NCT01222351|Drug|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
389249|NCT01222338|Biological|V-5 immunitor|once per day dosing for 2 months
389250|NCT01222325|Procedure|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
389251|NCT01222312|Drug|Cisplatin|75 mg/m2, d1 every 3 weeks
389252|NCT01222312|Drug|Oxaliplatin|85 mg/m², d1 every 2 weeks
389253|NCT01222312|Drug|Docetaxel|75 mg/m2, d1 every 3 weeks
389254|NCT01222312|Drug|Docetaxel|50mg/m2, d1 every 2 weeks
389255|NCT01222299|Drug|bepotastine besilate nasal product - low dose|sterile nasal product
389256|NCT01222299|Drug|bepotastine besilate nasal product - medium dose|sterile nasal product
389257|NCT01222299|Drug|bepotastine besilate nasal product - high dose|sterile nasal product
389258|NCT01222299|Drug|placebo comparator nasal product|sterile nasal product
389259|NCT01222286|Drug|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
389260|NCT01222273|Dietary Supplement|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
389261|NCT01222260|Drug|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
389262|NCT01222260|Drug|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
389489|NCT01220492|Drug|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 8 weeks.
390966|NCT01209195|Drug|Paclitaxel|Paclitaxel - 80 mg/m2 IV QW
389263|NCT01222247|Drug|Betamethasone|The active study drug, betamethasone. 3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later.
389264|NCT01222247|Drug|Placebo|Similar course of identical appearing placebo: 2 mL IM injections, 24 hours apart.
389265|NCT01222234|Drug|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
389266|NCT01222234|Device|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
389267|NCT01222234|Drug|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
389268|NCT01222221|Biological|glioblastoma multiforme multipeptide vaccine IMA950|
389269|NCT01222221|Biological|sargramostim|
389270|NCT01222221|Drug|temozolomide|
389271|NCT01222221|Other|laboratory biomarker analysis|
389272|NCT01222221|Other|pharmacological study|
389273|NCT01222221|Procedure|adjuvant therapy|
389274|NCT01222221|Radiation|radiation therapy|
389275|NCT01222208|Dietary Supplement|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
389276|NCT01222208|Dietary Supplement|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
389277|NCT01222195|Drug|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
389278|NCT01222195|Drug|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
389279|NCT01222182|Drug|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
389280|NCT01222169|Drug|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
389281|NCT01222156|Procedure|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
389282|NCT01222156|Device|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
389283|NCT01222143|Drug|NOVE-HiDAC|"NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.~During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10."
389284|NCT01222143|Drug|Nilotinib|"The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.~During induction, nilotinib will be given orally on Days 1-12.~During consolidation, nilotinib will be given orally on Days 1-10."
389285|NCT01222117|Biological|Plasmin|Plasmin prepared in 0.9% saline for injection
389286|NCT01222117|Biological|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
389287|NCT01222117|Other|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
389288|NCT01222091|Drug|Propranolol|Propranolol administered intravenously, initially set to target plasma concentration of 5 ng/mL, titrated upward in 5 ng/mL intervals until a final concentration of 15 ng/mL is achieved.
389289|NCT01222091|Drug|Placebo to Match Propranolol|
389290|NCT01222091|Drug|Remifentanil|Remifentanil administered intravenously at a plasma concentration of 3 ng/mL.
389291|NCT01222078|Biological|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
389292|NCT01222052|Drug|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|"Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks~Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks"
389293|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
389294|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.~Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
389295|NCT01222026|Drug|Strontium Ranelate + Ca/Vitamin-D|2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
389296|NCT01222026|Drug|Placebo|Placebo 1000mg Calcium 800 IE Vitamin-D
389297|NCT01222013|Drug|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
389341|NCT01221701|Behavioral|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
389648|NCT01219244|Behavioral|caloric restriction|6 months of caloric restriction (15 %)
389298|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
389299|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
389300|NCT01221987|Procedure|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
389301|NCT01221987|Other|Data collection|Questionnaire completion
389302|NCT01221974|Device|Essure Micro Insert|
389303|NCT01221961|Device|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
389304|NCT01221948|Device|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
389305|NCT01221935|Other|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
389306|NCT01221935|Other|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
389307|NCT01221935|Other|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
389308|NCT01221935|Other|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
389309|NCT01221922|Device|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
389310|NCT01221909|Drug|Tranexamic acid|Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
389311|NCT01221909|Drug|saline solution|5cc saline solution
389312|NCT01221896|Procedure|C11-Choline PET/CT|
389313|NCT01221883|Drug|Diazepam|Single dose 10mg Diazepam tablet
389314|NCT01221870|Drug|Tesetaxel once every 3 weeks|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
389315|NCT01221870|Drug|Tesetaxel once weekly|Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
389316|NCT01221857|Drug|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
389317|NCT01221844|Dietary Supplement|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
389318|NCT01221844|Drug|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
389319|NCT01221831|Drug|estetrol, P 1 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~Days 1-24: one estetrol tablet and one P1 tablet per day~Days 25-28: two placebo tablets per day"
389320|NCT01221831|Drug|estetrol, P2 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~Days 1-24: one estetrol tablet and one P2 tablet per day~Days 25-28: two placebo tablets per day"
389321|NCT01221831|Drug|Estradiol valerate, dienogest and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:~Days 1-26: one tablet of Estradiol valerate/dienogest per day~Days 26-28: one placebo tablet per day"
389322|NCT01221818|Drug|E6007|E6007 25mg single dose or matching placebo
389323|NCT01221818|Drug|E6007|E6007 50mg single dose or matching placebo
389324|NCT01221818|Drug|E6007|E6007 100mg single dose or matching placebo
389325|NCT01221818|Drug|E6007|E6007 200mg single dose or matching placebo
389326|NCT01221818|Drug|E6007|E6007 400mg single dose or matching placebo
389327|NCT01221818|Drug|E6007|E6007 600 mg single dose or matching placebo
389328|NCT01221792|Drug|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.~1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
389329|NCT01221792|Drug|Placebo|Non active comparator
389330|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
389331|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
389332|NCT01221753|Drug|docetaxel|
389333|NCT01221753|Drug|cisplatin|Given intravenously on day 1 of each cycle
389334|NCT01221753|Drug|5-FU|
389335|NCT01221753|Radiation|IMRT|
389336|NCT01221753|Drug|cetuximab|
389337|NCT01221753|Drug|carboplatin|
389338|NCT01221740|Drug|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
389339|NCT01221727|Drug|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
389340|NCT01221727|Drug|Midazolam|All subjects will receive two oral dose administrations of midazolam.
389455|NCT01220700|Other|Triclosane|Triclosane coated suture material
389456|NCT01220700|Other|Control|Ordinary suture material
391013|NCT01208935|Drug|Nicotine Patch|
389342|NCT01221688|Procedure|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
389343|NCT01221688|Procedure|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
389344|NCT01221675|Drug|Antibody TF2|preciblage with an antibody
389345|NCT01221675|Radiation|IMP-288-Lutetium|Internal Radiation
389346|NCT01221675|Radiation|IMP-288-Indium|Imaging
389347|NCT01221662|Drug|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
389348|NCT01221649|Device|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
389349|NCT01221636|Drug|Abatacept|Solution for injection, Intravenous, 750 mg, 1 day
389350|NCT01221623|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
389351|NCT01221623|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
389352|NCT01221610|Device|Passeo-18 Lux DRB|
389353|NCT01221610|Device|Standard PTA (POBA)|
389354|NCT01221597|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
389355|NCT01221597|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
389356|NCT01221571|Drug|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
389357|NCT01221558|Dietary Supplement|lycopene|
389358|NCT01221545|Drug|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
389359|NCT01221545|Drug|Placebo|Placebo
389360|NCT01221532|Behavioral|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus~a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;~two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;~the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
389361|NCT01221519|Drug|AZD1656|3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
389362|NCT01221506|Drug|Pazopanib|800 mg PO QD x 28 days
389363|NCT01221506|Device|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
389364|NCT01221493|Procedure|Cryo biopsy|Cryoprobe, Erbe Company
389365|NCT01221467|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
389366|NCT01221454|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
389367|NCT01221454|Drug|Conserved therapy|Oral or intravenous administration
389368|NCT01221441|Biological|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
389369|NCT01221441|Drug|Normal Saline|Single intraarticular injection of normal saline as a placebo control
389370|NCT01221428|Biological|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1*10/7).
389371|NCT01221402|Drug|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
389372|NCT01221389|Drug|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
389373|NCT01221376|Drug|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
389374|NCT01221363|Behavioral|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
389375|NCT01221350|Dietary Supplement|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
389457|NCT01220687|Drug|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
389376|NCT01221350|Dietary Supplement|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
389377|NCT01221337|Other|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
389378|NCT01221311|Device|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
389379|NCT01221311|Device|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
389380|NCT01221298|Drug|ABT-450|tablets
389381|NCT01221298|Drug|ABT-072|tablets
389382|NCT01221298|Drug|Ribavirin|tablets
389383|NCT01221298|Drug|Ritonavir|capsules
389384|NCT01221285|Biological|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
389385|NCT01221272|Drug|Ranolazine|"One 500 mg tablet in the evening on Day 1 of the period~One 500 mg tablet, twice daily on Days 2-3 of the period~Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
389386|NCT01221272|Drug|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
389387|NCT01221272|Procedure|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
389388|NCT01221272|Behavioral|Exercise|Treadmill stress test
389389|NCT01221259|Drug|E2212|single ascending doses ranging from 10mg to 250mg
389390|NCT01221259|Drug|placebo|a single dose of matching placebo
389391|NCT01221246|Drug|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
389392|NCT01221246|Drug|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
389393|NCT01221233|Other|Neuromuscular Electrical Stimulation|"Neuromuscular Electrical Stimulation (NMES) to the low back muscles (i.e. spinal extensors) will be applied at the parameters previously used in the knee muscles at the maximal tolerable intensity, which results in a full, sustained isometric contraction of the back muscles. Pad placement will be just below the waist line, with 2, 2X2 inch pads, on either side of the spine. Participants will be positioned on their belly with 2 pillows under their stomach to level the spine and secured to a table using a belt that crosses the buttock.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
389394|NCT01221233|Other|Moist Heat|"For participants who do not receive NMES, moist heat will be applied for 15 minutes in a position of comfort for the participant.~The lumbar stabilization program will include exercises targeting the back muscles in three positions: standing, prone (belly), and quadruped (hands and knees)."
389395|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
389396|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
389397|NCT01221207|Device|Total Contact Cast|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
389398|NCT01221207|Device|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
389399|NCT01221207|Device|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
389400|NCT01221194|Behavioral|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
389401|NCT01221194|Device|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
389402|NCT01221181|Drug|Eculizumab|Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
389403|NCT01221142|Device|"Cincinnati Sub-Zero, Blanketrol III"|
389404|NCT01221129|Other|Acclimation|11 mg Zn/day as a controlled intake level
389405|NCT01221129|Other|Dietary zinc depletion|< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
389406|NCT01221129|Other|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
389407|NCT01221116|Drug|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
391014|NCT01208935|Drug|Nicotine Gum|
389408|NCT01221103|Drug|Combination of dexamethasone, ofatumumab and bendamustine|"Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle~Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity~Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
389409|NCT01221090|Behavioral|PDA|Technological assistance
389410|NCT01221090|Behavioral|CDSMP|6-week classes
389411|NCT01221090|Behavioral|PDA/CDSMP|Combined technology and education
389412|NCT01221077|Drug|OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
389413|NCT01221077|Drug|Erlotinib|Erlotinib administered orally
389414|NCT01221077|Drug|Placebo|As of 01 March 2013, the matching placebo is no longer being administered
389415|NCT01221064|Procedure|Early drainage removal|Drainage will be removed in postoperative day 1
389416|NCT01221064|Procedure|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
389417|NCT01221051|Procedure|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
389418|NCT01221051|Procedure|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
389419|NCT01221025|Drug|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
389420|NCT01220999|Drug|CS-1008|CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111^In (5-7 mCi).
389421|NCT01220986|Procedure|Liver biopsy|0, 30, 60, 90 min post inflow-division
389422|NCT01220973|Drug|atorvastatin calcium|
389423|NCT01220973|Drug|celecoxib|
389424|NCT01220973|Other|laboratory biomarker analysis|
389425|NCT01220960|Other|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
389426|NCT01220947|Drug|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
389427|NCT01220947|Drug|Danoprevir|Danoprevir 50 mg BID
389428|NCT01220947|Drug|Danoprevir|Danoprevir 100 mg BID
389429|NCT01220947|Drug|Danoprevir|Danoprevir 200 mg BID
389430|NCT01220947|Drug|Pegasys|Pegasys 180 microgram sc qw
389431|NCT01220947|Drug|Ritonavir|Ritonavir 100 mg
389432|NCT01220921|Procedure|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
389433|NCT01220921|Procedure|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
389434|NCT01220908|Device|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
389435|NCT01220908|Device|Coils|Lung Volume Reduction Coil(s)
389436|NCT01220895|Biological|CMV-specific T-cells, single infusion following single positive CMV PCR result|"Intravenous ganciclovir 5mg/kg twice daily~Oral valganciclovir 900mg twice daily~Intravenous foscarnet 90 mg/kg twice daily"
389437|NCT01220882|Radiation|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
389438|NCT01220869|Drug|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
389439|NCT01220856|Drug|Reparixin|Reparixin + immunosuppression
389440|NCT01220843|Drug|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
389441|NCT01220843|Drug|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
389442|NCT01220830|Device|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
389443|NCT01220817|Drug|3 POMx capsules|3 POMx capsules daily
389444|NCT01220817|Drug|1 POMx capsule|1 POMx capsule daily
389445|NCT01220791|Other|In vitro fertilization treatment for infertility|IVF treatment
389446|NCT01220778|Behavioral|Exercise|
389447|NCT01220765|Device|Capnography|In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 > 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
389448|NCT01220752|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
389449|NCT01220739|Device|Transcranial Laser Therapy|Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
389450|NCT01220726|Drug|Botox|Botox injection
389451|NCT01220726|Drug|Placebo|Placebo injection
389452|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
389453|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
389454|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
389458|NCT01220687|Other|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
389459|NCT01220674|Other|cognitive testing|computer-based cognitive assessment
389460|NCT01220661|Drug|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
389461|NCT01220648|Drug|Nilotinib, interferon-alfa|
389462|NCT01220635|Behavioral|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
389463|NCT01220635|Behavioral|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
389464|NCT01220622|Drug|Nimodipine|Administration of nimodipine 30mg tid for 6 months
389465|NCT01220622|Drug|Placebo|Administration of placebo 30mg tid for 6 months
389466|NCT01220609|Drug|Ixabepilone|Given IV
389467|NCT01220609|Other|Laboratory Biomarker Analysis|Correlative studies
389468|NCT01220596|Drug|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
389469|NCT01220596|Drug|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
389470|NCT01220583|Drug|cisplatin|Given IV
389471|NCT01220583|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
389472|NCT01220583|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
389473|NCT01220570|Drug|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
389474|NCT01220570|Drug|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
389475|NCT01220570|Drug|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
389476|NCT01220557|Behavioral|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
389477|NCT01220557|Behavioral|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
389478|NCT01220544|Biological|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain > 8 x 10e6 CD34+ cells/kg and < 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
389479|NCT01220531|Biological|Thymus Tissue for Transplantation|Potential thymus recipient subjects are screened for eligibility. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue is transplanted into the subject's quadriceps. Two to three months post-transplantation, if medically stable, the subject may undergo allograft biopsy. At the time of transplantation and biopsy, skin biopsy may be conducted. Subjects undergo laboratory testing for approximately one-year post-transplantation. At approximately year 2 post-transplantation, subjects are contacted for data collection.
389480|NCT01220531|Procedure|Blood Draw|Biological Mothers of Thymus Recipients may be asked to participate in the study and undergo phlebotomy to allow for testing of T cell identity in the complete DiGeorge subjects. If blood is not obtainable, then a buccal swab may be done.
389481|NCT01220531|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV prior to thymus transplantation for immune suppression groups 2, 3, and 4. Each dose is given over 12 hours. RATGAM is usually given on days -5, -4, and -3 prior to thymus transplantation.
389482|NCT01220531|Drug|Cyclosporine|Csa may be given every 8 to 12 hours orally or IV before and after thymus transplantation for immune suppression groups 3 and 4. The Csa dose is dependent on T cell numbers and the target CSA trough levels. Csa is weaned as per protocol.
389483|NCT01220531|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 to 12 hours orally or IV before and after thymus transplantation. FK506 dose is dependent on T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
389484|NCT01220531|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and/or after thymus transplantation. Administration and dosage depends on T cell numbers. Steroids are weaned as per protocol.
389485|NCT01220531|Drug|Basiliximab|A single dose of Basiliximab 5 mg/kg IV may be given. Administration of Basiliximab depends on T cell numbers and T cell activation. A single dose of Basiliximab may be given after the administration of rabbit anti-thymocyte globulin and before thymus transplantation. If Basiliximab is not given before thymus transplantation, and, depending on the T cell numbers and T cell activation, a single dose of Basiliximab may be given 3 to 5 days after thymus transplantation.
389486|NCT01220531|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) may be given if the T cell count remains elevated 5 days after thymus transplantation. If MMF is given, the dose is 15 mg/kg/dose every 8 hours IV or orally. MMF may be stopped at 35 days or continued for up to six months after thymus transplantation.
389487|NCT01220518|Drug|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
389490|NCT01220492|Drug|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
389491|NCT01220479|Behavioral|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.~Control groups are relatively inactive."
389492|NCT01220466|Device|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
389493|NCT01220440|Drug|Methylphenidate|Methylphenidate:10mg x 3 for one week
389494|NCT01220440|Drug|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
389495|NCT01220440|Drug|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
389496|NCT01220414|Drug|Naltrexone, then placebo|50 mg of naltrexone
389497|NCT01220414|Drug|Placebo, then Naltrexone|sugar pill
389498|NCT01220401|Behavioral|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
389499|NCT01220388|Dietary Supplement|L-lysine|L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
389500|NCT01220388|Dietary Supplement|placebo|placebo, 3 times a day, orally, during meals
389501|NCT01220375|Drug|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
389502|NCT01220375|Drug|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
389503|NCT01220375|Drug|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
389504|NCT01220375|Drug|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
389505|NCT01220362|Drug|Bupivacain 0.125%|Bupivacain 0.125%
389506|NCT01220362|Drug|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
389507|NCT01220349|Device|Echocardiographic 2D strain analysis|Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
389508|NCT01220336|Behavioral|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model [Bodenheimer 2007] for 12 months.
389509|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
389510|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
389511|NCT01220310|Behavioral|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
389512|NCT01220297|Drug|Sirolimus|"Immunosuppressant administered orally to:~Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.~Children < 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.~Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
389513|NCT01220297|Drug|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
389514|NCT01220297|Drug|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
389515|NCT01220297|Drug|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
389516|NCT01220297|Drug|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.~For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.~For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
389517|NCT01220297|Drug|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
389518|NCT01220284|Drug|Satraplatin in combo with vinorelbine|"Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)~Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
389519|NCT01220271|Drug|LY2157299|Administered orally
389520|NCT01220271|Drug|Radiation|Administered as approved
389521|NCT01220271|Drug|Temozolomide|Administered orally
389522|NCT01220258|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
389523|NCT01220245|Procedure|Heparin-bonded ePTFE endoluminal fem-pop bypass|Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
389524|NCT01220245|Procedure|Surgical femoro-popliteal bypass.|Surgical femoro-popliteal bypass.
389525|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
389526|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
389527|NCT01220232|Drug|Lersivirine|Lersivirine 750 mg QD for 10 days
389528|NCT01220219|Drug|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
389529|NCT01220219|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
389530|NCT01220219|Drug|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
389531|NCT01220206|Drug|Placebo|2 placebo capsules daily
389532|NCT01220206|Drug|One POMx capsule daily|One POMx capsule, one placebo capsule daily
389533|NCT01220206|Drug|2 POMx Capsules|2 POMx Capsules daily
389534|NCT01220180|Drug|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
389535|NCT01220180|Drug|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.~Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
389536|NCT01220180|Drug|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
389537|NCT01220167|Drug|Ondansetron|"Participants were served dinner to ensure a minimum of 10 hours of fasting. Participants were dosed with a 3 day washout period between each administration.~Blood samples were obtained."
389538|NCT01220167|Drug|Ondansetron|"Participants were served dinner to ensure a minimum of 10 hours of fasting. Participants were dosed with a 3 day washout period between each administration.~Blood samples were obtained."
389539|NCT01220154|Drug|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
389540|NCT01220154|Drug|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
389541|NCT01220154|Drug|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
389542|NCT01220141|Drug|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
389543|NCT01220128|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
389544|NCT01220128|Drug|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
389545|NCT01220128|Drug|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
389546|NCT01220128|Drug|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
389547|NCT01220128|Drug|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
389548|NCT01220128|Drug|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
389549|NCT01220128|Drug|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
389550|NCT01220128|Drug|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
389594|NCT01219803|Drug|Placebo|The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
389649|NCT01219244|Behavioral|omega-3 supplementation|6 months of omega-3 supplementation
389551|NCT01220128|Drug|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
389552|NCT01220128|Drug|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
389553|NCT01220128|Drug|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
389554|NCT01220102|Drug|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
389555|NCT01220089|Behavioral|Standard maintenance|Participants will receive written materials in months 7-18
389556|NCT01220089|Behavioral|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
389557|NCT01220076|Drug|tamoxifen|
389558|NCT01220063|Radiation|Radiation|10 Gy for 4 times (total 40 Gy)
389559|NCT01220063|Drug|Irinotecan|40 mg/m² : Day 1 and day 8
389560|NCT01220050|Drug|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
389561|NCT01220050|Drug|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
389562|NCT01220037|Behavioral|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
389563|NCT01220024|Drug|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
389564|NCT01220024|Drug|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
389565|NCT01220011|Procedure|Fetoscopic laser surgery|Fetoscopic laser surgery
389566|NCT01219985|Other|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.~Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.~Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
389567|NCT01219959|Drug|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
389568|NCT01219959|Drug|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
389569|NCT01219933|Drug|methylprednisolone|starting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule
389570|NCT01219933|Drug|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
389571|NCT01219920|Drug|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
389572|NCT01219920|Drug|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
389573|NCT01219907|Biological|HER-2/neu peptide vaccine|Given intradermally
389574|NCT01219907|Drug|cyclophosphamide|Given IV
389575|NCT01219907|Biological|ex vivo-expanded HER2-specific T cells|Given IV
389576|NCT01219907|Other|laboratory biomarker analysis|Correlative studies
389577|NCT01219907|Other|flow cytometry|Correlative studies
389578|NCT01219907|Other|immunoenzyme technique|Correlative studies
389579|NCT01219881|Drug|Desflurane|5.4 to 7.4% desflurane
389580|NCT01219881|Drug|Sevoflurane|1.4 to 2.5% Sevoflurane
389581|NCT01219868|Behavioral|Physician-nurse team supervision|Physician-nurse team will supervise patient's flow in the ED
389582|NCT01219855|Drug|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
389583|NCT01219855|Drug|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
389584|NCT01219855|Drug|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
389585|NCT01219855|Drug|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
389586|NCT01219855|Drug|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
389587|NCT01219842|Procedure|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
389588|NCT01219842|Other|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
389589|NCT01219816|Drug|Epratuzumab|Combination of chemotherapy + Epratuzumab
389590|NCT01219816|Drug|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
389591|NCT01219803|Drug|High Dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,5 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
389592|NCT01219803|Drug|Mild dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
389593|NCT01219803|Drug|Low dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc, 150ml/bag, twice in a day
389643|NCT01219322|Drug|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
389595|NCT01219790|Radiation|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
389596|NCT01219790|Drug|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
389597|NCT01219777|Drug|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
389598|NCT01219777|Drug|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
389599|NCT01219777|Drug|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 & 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
389600|NCT01219764|Drug|Rabeprazole, metronidazole, Clarithromycin, Amoxicillin|"Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days."
389601|NCT01219751|Drug|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
389602|NCT01219738|Drug|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
389603|NCT01219738|Drug|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
389604|NCT01219738|Drug|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
389605|NCT01219738|Drug|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
389606|NCT01219738|Drug|Placebo|A single inhaled dose of placebo from a DPI.
389607|NCT01219725|Behavioral|Exercise training|6 months of moderate intensity exercise training 3 times per week
389608|NCT01219712|Procedure|Colloids, dobutamin, levosimendan|": The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.~Hb would be optimized to > 90 g/l~SaO2 > 96%~Stroke volume index (SVI) > 30~Heart rate should ideally be < 80~Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal"
389609|NCT01219699|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
389610|NCT01219699|Drug|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
389611|NCT01219686|Drug|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
389612|NCT01219686|Drug|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
389613|NCT01219686|Drug|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
389614|NCT01219673|Other|Placebo|1 by mouth twice a day.
389615|NCT01219673|Drug|Armodafinil|150 mg by mouth once a day.
389616|NCT01219673|Drug|Minocycline|100 mg by mouth twice a day.
389617|NCT01219673|Drug|Bupropion|100 mg by mouth twice a day.
389618|NCT01219647|Behavioral|exercise|subjects will participate in one of two forms of exercise
389619|NCT01219647|Behavioral|stretching|subjects will particiopate in supervised stretching as described in arm description.
389620|NCT01219621|Procedure|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
389621|NCT01219608|Dietary Supplement|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
389622|NCT01219608|Dietary Supplement|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
389623|NCT01219608|Dietary Supplement|Enteral Nutrition|Ordinary Enteral Nutrition
389624|NCT01219595|Other|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
389625|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
389626|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
389627|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
389628|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
389629|NCT01219595|Other|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
389630|NCT01219582|Drug|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
389631|NCT01219569|Drug|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
389632|NCT01219569|Drug|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
389633|NCT01219556|Drug|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
389634|NCT01219543|Drug|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
389635|NCT01219543|Drug|AZD1480 BID|Oral Dose, Capsule, BID Dosing
389636|NCT01219517|Other|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
389637|NCT01219465|Biological|umbilical cord mesenchymal stem cells|Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
389638|NCT01219452|Biological|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
389639|NCT01219426|Other|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
389640|NCT01219413|Drug|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
389641|NCT01219400|Drug|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
389642|NCT01219348|Biological|IDO peptide vaccination|Vaccination every second week
389644|NCT01219322|Drug|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
389650|NCT01219244|Behavioral|resveratrol supplementation|6 months of resveratrol supplementation
389651|NCT01219244|Behavioral|Placebo|6 months of placebo intake
389652|NCT01219244|Behavioral|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
389653|NCT01219244|Behavioral|2nd step: intervention + control|most effective dietary intervention plus control
389654|NCT01219231|Behavioral|Exercise|6 months of aerobic exercise
389655|NCT01219218|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
389656|NCT01219205|Procedure|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
389657|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
389658|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
389659|NCT01219192|Drug|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
389660|NCT01219192|Drug|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
389661|NCT01219179|Other|Sterile water feedings|"Control group- no intervention~Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.~The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.~The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
389662|NCT01219166|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
389663|NCT01219153|Drug|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
389664|NCT01219153|Drug|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.~Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.~GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
389665|NCT01219140|Dietary Supplement|2 POMx Capsules|2 POMx Capsules daily
389666|NCT01219140|Dietary Supplement|2 placebo Capsules|2 placebo Capsules daily
389667|NCT01219127|Other|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
389668|NCT01219101|Drug|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
389669|NCT01219101|Drug|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
389670|NCT01219088|Drug|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
389671|NCT01219075|Dietary Supplement|soy isoflavones|Given orally
389672|NCT01219075|Other|placebo|Given orally
389673|NCT01219075|Other|questionnaire administration|Ancillary studies
389674|NCT01219075|Procedure|magnetic resonance imaging|Correlative studies
389675|NCT01219075|Procedure|biopsy|Correlative studies
389676|NCT01219075|Other|immunohistochemistry staining method|Correlative studies
389677|NCT01219075|Other|laboratory biomarker analysis|Correlative studies
389678|NCT01219075|Procedure|mammography|Correlative studies
389679|NCT01219062|Drug|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
389680|NCT01219062|Other|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
389681|NCT01219062|Drug|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
389682|NCT01219049|Drug|Tyrosine|1000 mg / day
389683|NCT01219049|Drug|Tyrosine|2000 mg / day
389684|NCT01219049|Drug|Placebo|Placebo daily
389685|NCT01219036|Drug|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
389686|NCT01219023|Drug|sildenafil citrate|Subjects will be given 2 types of topical creams, one containing 1% sildenafil and one containing placebo control. Subjects will be randomized to apply sildenafil cream to either the right or left hand/foot; placebo cream will be applied to the opposite hand/foot. The cream will be supplied to subjects with proper labeling to indicate right and left application assignment. Cream will be applied to each affected hand/foot two times per day.
389687|NCT01219010|Biological|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
389851|NCT01217918|Drug|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
389688|NCT01218997|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
389689|NCT01218997|Drug|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
389690|NCT01218984|Drug|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
389691|NCT01218984|Drug|Medisorb naltrexone 150 mg|Single administration via IM injection.
389692|NCT01218984|Drug|Medisorb naltrexone 300 mg|Single administration via IM injection.
389693|NCT01218984|Drug|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
389694|NCT01218984|Drug|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
389695|NCT01218971|Drug|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
389696|NCT01218971|Drug|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
389697|NCT01218958|Drug|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
389698|NCT01218958|Drug|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
389699|NCT01218958|Drug|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
389700|NCT01218958|Drug|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
389701|NCT01218945|Procedure|Cell Culture|Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
389702|NCT01218932|Drug|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
389703|NCT01218932|Drug|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
389704|NCT01218893|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
389705|NCT01218893|Biological|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
389706|NCT01218893|Biological|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
389707|NCT01218893|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
389708|NCT01218880|Drug|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
389709|NCT01218880|Drug|M2ES 15mg|M2ES Dosage：15mg/m2
389710|NCT01218880|Drug|M2ES 30mg|M2ES Dosage：30mg/m2
389711|NCT01218880|Drug|M2ES 45mg|M2ES Dosage：45mg/m2
389712|NCT01218867|Biological|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
389713|NCT01218867|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
389714|NCT01218867|Biological|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
389715|NCT01218867|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
389716|NCT01218854|Device|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
389717|NCT01218841|Dietary Supplement|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
389718|NCT01218841|Dietary Supplement|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
389719|NCT01218828|Other|LVEDP -Based hydration strategy|
389720|NCT01218828|Other|Standard hydration|
389721|NCT01218815|Procedure|IRA stenting in culprit lesion only|stenting
389722|NCT01218815|Procedure|IRA stenting|Complete IRA revascularization
389723|NCT01218802|Drug|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
389724|NCT01218802|Drug|Placebo|participants will take a sugar pill daily for 96 weeks
389725|NCT01218789|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
389726|NCT01218750|Procedure|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
389727|NCT01218737|Drug|0.3% gatifloxacin and 1.0% prednisolone acetate association|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
389728|NCT01218737|Drug|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.~This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
389729|NCT01218724|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
389730|NCT01218711|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
389731|NCT01218698|Drug|Losartan Potassium Tablets|
389732|NCT01218685|Biological|Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS|1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.
389733|NCT01218672|Device|GreenLight XPS vs. TURP|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study."
389734|NCT01218659|Drug|migalastat hydrochloride|150-mg capsule administered orally QOD
389735|NCT01218659|Biological|agalsidase|Agalsidase via intravenous infusion as prescribed by the participant's treating physician and in accordance with the approved prescribing information
389736|NCT01218646|Biological|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
389737|NCT01218646|Biological|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
389738|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
389739|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
389740|NCT01218633|Drug|saline infusion|saline infused at 30ml/hour
389741|NCT01218633|Drug|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
389742|NCT01218633|Drug|Exendin-9,39 at low dose|infused at 30pmol/kg/min
389743|NCT01218633|Drug|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
389744|NCT01218620|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
389745|NCT01218620|Drug|Ketoconazole|Given PO
389746|NCT01218620|Drug|Rifampin|Given PO
389747|NCT01218620|Drug|Midazolam Hydrochloride|Given IV
389748|NCT01218620|Drug|Omeprazole|Given PO
389749|NCT01218620|Drug|Tolbutamide|Given PO
389750|NCT01218620|Drug|Dextromethorphan Hydrobromide|Given PO
389751|NCT01218620|Other|Pharmacological Study|Correlative studies
389752|NCT01218620|Other|Laboratory Biomarker Analysis|Correlative studies
389753|NCT01218607|Drug|Bosentan|Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.
389754|NCT01218607|Drug|Placebo|Placebo will be taken twice daily for 16 weeks
389755|NCT01218594|Drug|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
389756|NCT01218581|Drug|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
389757|NCT01218568|Drug|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
389758|NCT01218568|Drug|Lactulose|Lactulose 30-60 ml in two or three divided doses.
389759|NCT01218555|Drug|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
389760|NCT01218555|Drug|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
389761|NCT01218542|Radiation|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
389762|NCT01218529|Drug|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
389763|NCT01218516|Biological|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.~Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
389764|NCT01218516|Other|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.~Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
389765|NCT01218516|Drug|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL^min [AUC5-6]
389766|NCT01218516|Drug|Paclitaxel|Paclitaxel 200 mg/m2 will be administered intravenously
389767|NCT01218516|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered intravenously
389768|NCT01218516|Drug|Cisplatin|Cisplatin 75 mg/m2 will be administered intravenously
389769|NCT01218503|Behavioral|CHOICES - obese|Standard group behavioral weight loss treatment
389770|NCT01218490|Procedure|ovarian cancer surgery|
389771|NCT01218477|Drug|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
389772|NCT01218477|Drug|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
389773|NCT01218464|Drug|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 12 weeks.
389774|NCT01218464|Drug|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
389775|NCT01218451|Biological|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
389776|NCT01218451|Biological|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
389777|NCT01218451|Biological|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
389778|NCT01218438|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
389779|NCT01218438|Drug|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
389780|NCT01218425|Drug|Methylphenidate 40 mg|Oral dose 40 mg
389781|NCT01218425|Drug|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
389782|NCT01218425|Drug|Domperidon 10 mg|Domperidon 10 mg
389783|NCT01218412|Behavioral|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
389784|NCT01218399|Drug|Symbicort|
389785|NCT01218386|Drug|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.~Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
389786|NCT01218373|Device|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
389787|NCT01218373|Device|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
389788|NCT01218360|Drug|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
389789|NCT01218347|Drug|Rosuvastatin|20 mg once daily for 21 days
389790|NCT01218334|Device|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
389791|NCT01218321|Biological|antiepileptic treatment|White blood cells from peripheral blood samples
389792|NCT01218308|Biological|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
389793|NCT01218308|Biological|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
389794|NCT01218295|Device|Spirotiger®|training session :10 minutes twice a day X 4 weeks
389795|NCT01218282|Behavioral|Home exercise training|20-30 min/day for at least 4 days/week
389796|NCT01218282|Behavioral|NO Exercise Training|No intervention
389797|NCT01218269|Device|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
389798|NCT01218256|Other|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
389799|NCT01218243|Device|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
389800|NCT01218230|Drug|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
389801|NCT01218217|Drug|SQ109|SQ109 150 mg tablet
389802|NCT01218217|Drug|Rifampicin|Rifampicin 150 mg capsules
389803|NCT01218204|Drug|10mg atorvastatin|10mg
389804|NCT01218204|Drug|80mg atorvastatin|80mg
389805|NCT01218204|Drug|GSK1292263 Placebo|Placebo
389806|NCT01218204|Drug|100mg GSK1292263|100mg
389807|NCT01218204|Drug|300mg GSK1292263|300mg
389808|NCT01218204|Drug|800mg GSK1292263|800mg
389809|NCT01218204|Drug|10mg ezetimibe|10mg
389810|NCT01218204|Other|Washout|No interventions - washout period
389811|NCT01218178|Drug|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
389812|NCT01218178|Drug|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
389813|NCT01218165|Dietary Supplement|Probiotic drink|This group receives a probiotic drink daily for 6 week.
389814|NCT01218165|Other|Control Group|without intervention
389815|NCT01218126|Drug|losmapimod|comparison of different dosages of drug 2.5 mg, 7.5 mg or 15 mg
389816|NCT01218126|Drug|placebo|placebo comparison with active
389817|NCT01218113|Biological|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
389818|NCT01218113|Drug|Placebo|1 or 3 doses according to protocol schedule
389852|NCT01217918|Drug|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
389853|NCT01217918|Drug|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
389854|NCT01217905|Drug|AZD7687|Oral suspension
389855|NCT01217892|Drug|dapagliflozin|2.5 mg tablet, taken orally, twice daily
389819|NCT01218100|Drug|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks~nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks~nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
389820|NCT01218100|Drug|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks~nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)~nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
389821|NCT01218100|Drug|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
389822|NCT01218100|Drug|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
389823|NCT01218087|Device|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
389824|NCT01218087|Device|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
389825|NCT01218074|Device|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
389826|NCT01218074|Device|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
389827|NCT01218061|Other|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
389828|NCT01218048|Drug|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
389829|NCT01218048|Procedure|Surgery|Surgery for tumor
389830|NCT01218048|Radiation|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
389831|NCT01218048|Drug|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
389832|NCT01218035|Drug|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
389833|NCT01218022|Drug|Losartan Potassium Tablets|
389834|NCT01218009|Drug|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
389835|NCT01218009|Drug|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.~The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
389836|NCT01217996|Behavioral|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
389837|NCT01217996|Behavioral|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
389838|NCT01217970|Drug|Ibudilast|Ibudilast oral 20mg BID for 7 days
389839|NCT01217970|Drug|Ibudilast|Ibudilast oral 50mg BID for 7 days
389840|NCT01217970|Drug|Ibudilast|Placebo oral BID 7 days
389841|NCT01217957|Drug|Ixazomib|Ixazomib capsules
389842|NCT01217957|Drug|Lenalidomide|Lenalidomide capsules
389843|NCT01217957|Drug|Dexamethasone|Dexamethasone tablets
389844|NCT01217944|Drug|Ranibizumab|0.5 mg ranibizumab intravitreal injection
389845|NCT01217944|Drug|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
389846|NCT01217944|Drug|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
389847|NCT01217944|Drug|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
389848|NCT01217931|Drug|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
389849|NCT01217931|Drug|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
389850|NCT01217931|Drug|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
389856|NCT01217892|Drug|dapagliflozin|5 mg tablet taken orally, twice daily
389857|NCT01217892|Drug|dapagliflozin|10 mg tablet taken orally, once daily
389858|NCT01217892|Drug|metformin|>/= 1500 mg total daily dose, tablets taken orally, twice daily
389859|NCT01217892|Drug|placebo|placebo
389860|NCT01217879|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
389861|NCT01217866|Procedure|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
389862|NCT01217853|Device|SENSIMED Triggerfish|Contact lens-based device for continuous intraocular pressure monitoring
389863|NCT01217840|Drug|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
389864|NCT01217840|Drug|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
389865|NCT01217827|Behavioral|Clinical Reminder|
389866|NCT01217814|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
389867|NCT01217814|Drug|Placebo|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
389868|NCT01217814|Drug|Golimumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
389869|NCT01217814|Drug|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
389870|NCT01217814|Drug|Folic/folinic acid|"Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard."
389871|NCT01217801|Drug|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
389872|NCT01217801|Drug|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
389873|NCT01217788|Drug|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
389874|NCT01217775|Drug|PH80|PH80 intranasal spray 800 nanograms
389875|NCT01217775|Drug|Placebo intranasal spray|Placebo intranasal spray
389876|NCT01217762|Device|IRay|Low voltage stereotactic radiotherapy system
389877|NCT01217749|Drug|PCI-32765|420 mg PO daily
389878|NCT01217749|Drug|ofatumumab|per package insert as an IV infusion
389879|NCT01217736|Drug|aliskiren|single dose, tablet
389880|NCT01217736|Drug|placebo|single dose, tablet
389881|NCT01217736|Drug|VTP-27999|single dose, tablet
389882|NCT01217723|Biological|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
389883|NCT01217723|Other|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
389884|NCT01217710|Behavioral|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
389885|NCT01217697|Drug|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
389886|NCT01217697|Drug|Prednisone\Prednisolone|Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).
389887|NCT01217671|Biological|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
389888|NCT01217671|Other|Placebo|Placebo
389889|NCT01217658|Behavioral|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
389890|NCT01217658|Behavioral|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
389891|NCT01217645|Radiation|150 mg [14C] AZD6765|
389892|NCT01217632|Drug|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
389893|NCT01217632|Drug|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
389894|NCT01217632|Drug|Entecavir|
389895|NCT01217619|Drug|erlotinib|erlotinib 150mg/d continuously for 56 days
389896|NCT01217606|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
389897|NCT01217606|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
389898|NCT01217593|Procedure|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
389899|NCT01217593|Procedure|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
389900|NCT01217580|Drug|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
389901|NCT01217580|Drug|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
389902|NCT01217567|Procedure|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
389990|NCT01216995|Biological|Dose A|ADRC Dose A
389991|NCT01216995|Biological|Placebo|Placebo Comparator
389903|NCT01217567|Procedure|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
389904|NCT01217541|Other|Education and Supervision|Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.
389905|NCT01217541|Other|Control|A control group of nursing home units that do not get any form of active intervention
389906|NCT01217528|Device|device settings for group A|VT zone: 350ms VF zone: 280ms
389907|NCT01217528|Device|Device settings for group B|VT zone: 320ms VF zone: 250ms
389908|NCT01217515|Drug|Diltiazem hydrochloride 4% cream|3 times daily
389909|NCT01217515|Drug|Diltiazem hydrochloride 2% cream|3 times daily
389910|NCT01217515|Other|Placebo|3 times daily
389911|NCT01217502|Behavioral|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
389912|NCT01217502|Behavioral|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
389913|NCT01217489|Procedure|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
389914|NCT01217476|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
389915|NCT01217463|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
389916|NCT01217450|Drug|selumetinib|Given orally
389917|NCT01217450|Biological|cetuximab|Given IV
389918|NCT01217450|Other|laboratory biomarker analysis|Correlative studies
389919|NCT01217450|Other|pharmacological study|Correlative studies
389920|NCT01217437|Biological|Bevacizumab|Given IV
389921|NCT01217437|Drug|Irinotecan Hydrochloride|Given IV
389922|NCT01217437|Drug|Temozolomide|Given PO
389923|NCT01217424|Other|questionnaire administration|
389924|NCT01217424|Procedure|aromatherapy and essential oils|
389925|NCT01217424|Procedure|management of therapy complications|
389926|NCT01217424|Procedure|massage therapy|
389927|NCT01217424|Procedure|psychosocial assessment and care|
389928|NCT01217424|Procedure|reflexology procedure|
389929|NCT01217411|Drug|Gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
389930|NCT01217411|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
389931|NCT01217411|Radiation|Stereotactic radiosurgery (SRS)|Undergo SRS
389932|NCT01217411|Procedure|Cognitive assessment|Ancillary studies
389933|NCT01217411|Other|Laboratory biomarker analysis|Correlative studies
389934|NCT01217398|Biological|bevacizumab|
389935|NCT01217398|Drug|temozolomide|
389936|NCT01217398|Genetic|polymorphism analysis|
389937|NCT01217398|Other|pharmacogenomic studies|
389938|NCT01217385|Procedure|DOSI|Bedside DOSI images of the tissue concentrations of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctHbO2), water (ctH2O), lipid, tissue oxygen saturation (StO2), and TOI (ctHHb x tH2O/lipid) were acquired on both breasts up to four times during neoadjuvant chemotherapy (NAC) treatment.
389939|NCT01217372|Dietary Supplement|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
389940|NCT01217359|Drug|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
389941|NCT01217346|Other|no intervention is involved in this study|no intervention is involved in this study
389942|NCT01217333|Behavioral|In-person CP|CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.
389943|NCT01217333|Behavioral|Tele-CP|Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
389944|NCT01217320|Dietary Supplement|creatine|5g/d throughout 12 weeks
389945|NCT01217320|Dietary Supplement|placebo (dextrose)|5g/d throughout 12 weeks
389946|NCT01217307|Drug|Metformin|Metformin 500mg twice daily during 4 months
389947|NCT01217307|Drug|Placebo|Placebo twice daily during 4 months
389948|NCT01217294|Procedure|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
389949|NCT01217294|Procedure|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
389950|NCT01217281|Procedure|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
389951|NCT01217268|Behavioral|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
389952|NCT01217229|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
389953|NCT01217216|Behavioral|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
389954|NCT01217216|Behavioral|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
389955|NCT01217203|Drug|IPH2101 combined to lenalidomide|"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)~Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"
389956|NCT01217190|Drug|Ondansetron Orally Dissolving Film|Two-wy cross-over study to compare ondansetron ODSF with Zofran ODT
389957|NCT01217190|Drug|Ondansetron Orally Disintegrating Tablet|Two way cross-over study to compare ondansetron ODSF with Zonfran ODT
389958|NCT01217190|Drug|Ondansetron OSF|Two way cross-over study to compare ondansetron ODSF with Zonfran ODT
389959|NCT01217177|Drug|everolimus|
389960|NCT01217164|Dietary Supplement|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
389961|NCT01217151|Device|Hemodynamic monitoring|Hemodynamic monitoring based on the NICOM device
389962|NCT01217151|Other|Usual treatment|Hemodynamic monitoring based on common practice
389963|NCT01217138|Device|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
389964|NCT01217125|Drug|Sirolimus|plasma levels between 4 and 8
389965|NCT01217112|Drug|GWP42003|100 mg capsules, PO, BD, 91 days
389966|NCT01217112|Drug|GWP42003|5 mg capsules, PO, BD, 91 days
389967|NCT01217112|Drug|GWP42004|5 mg capsules, PO, BD, 91 days
389968|NCT01217112|Drug|Placebo|0 mg capsules, QDS, PO, 91 days
389969|NCT01217099|Drug|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
389970|NCT01217099|Drug|azithromycin|control patients were iv azithromycin for 5 days.
389971|NCT01217086|Drug|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
389972|NCT01217073|Drug|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
389973|NCT01217073|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
389974|NCT01217073|Drug|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
389975|NCT01217073|Drug|Metformin|Metformin 500 mg oral tablet administered once or twice daily
389976|NCT01217073|Drug|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
389977|NCT01217060|Drug|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
389978|NCT01217060|Drug|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
389979|NCT01217060|Radiation|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
389980|NCT01217060|Procedure|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
389981|NCT01217060|Drug|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
389982|NCT01217047|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
389983|NCT01217047|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
389984|NCT01217047|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
389985|NCT01217047|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
389986|NCT01217034|Drug|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
389987|NCT01217034|Procedure|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
389988|NCT01217021|Drug|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]MNI-558, followed by PET imaging.
389989|NCT01217008|Biological|GRNOPC1|One injection of 2 million GRNOPC1 cells.
389992|NCT01216982|Drug|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
389993|NCT01216982|Drug|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
389994|NCT01216956|Drug|Extended-release nicotinic acid versus placebo|Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
389995|NCT01216943|Drug|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
389996|NCT01216930|Other|Observation|Observation
389997|NCT01216904|Drug|nicotine patch|7 mg patches to be worn for 16 hours per day
389998|NCT01216904|Drug|placebo|placebo patch to be worn 16 hours per day
389999|NCT01216891|Behavioral|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
390000|NCT01216878|Drug|losartan potassium|100 mg tablet
390001|NCT01216865|Biological|umbilical cord mesenchymal stem cells|5*10/7 per ischemic limb
390002|NCT01216865|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
390003|NCT01216852|Drug|Losartan Potassium|100 mg tablet
390004|NCT01216839|Drug|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
390005|NCT01216826|Drug|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
390006|NCT01216813|Other|informational intervention|
390007|NCT01216813|Procedure|assessment of therapy complications|
390008|NCT01216813|Procedure|psychosocial assessment and care|
390009|NCT01216800|Procedure|adjuvant therapy|
390010|NCT01216800|Procedure|assessment of therapy complications|
390011|NCT01216800|Procedure|quality-of-life assessment|
390012|NCT01216800|Radiation|3-dimensional conformal radiation therapy|
390013|NCT01216800|Radiation|intensity-modulated radiation therapy|
390014|NCT01216787|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
390015|NCT01216787|Other|pharmacological study|
390016|NCT01216787|Procedure|therapeutic conventional surgery|
390017|NCT01216787|Other|laboratory biomarker analysis|Correlative studies
390018|NCT01216774|Other|Strength training|"Leg extension exercise:~Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
390019|NCT01216761|Drug|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
390020|NCT01216761|Drug|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
390021|NCT01216761|Drug|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
390022|NCT01216748|Other|quiet breathing|Subjects were instructed to breath normally at room air.
390023|NCT01216748|Other|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
390024|NCT01216748|Other|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
390025|NCT01216748|Other|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
390026|NCT01216735|Drug|Fluticasone|220 ug twice a day for 3 weeks
390027|NCT01216735|Drug|Placebo|Placebo for 3 weeks
390028|NCT01216722|Other|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
390029|NCT01216709|Dietary Supplement|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
390030|NCT01216709|Other|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
390031|NCT01216709|Other|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
390032|NCT01216696|Drug|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
390033|NCT01216683|Biological|rituximab|Given IV
390034|NCT01216683|Drug|bendamustine hydrochloride|Given IV
390035|NCT01216683|Drug|bortezomib|Given IV
390036|NCT01216683|Drug|lenalidomide|Given orally
390037|NCT01216670|Behavioral|remote patient's management|scheduled remote CareLink data transmission
390038|NCT01216657|Drug|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
390039|NCT01216644|Drug|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
390045|NCT01216644|Drug|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
390046|NCT01216631|Drug|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
390047|NCT01216631|Drug|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
390048|NCT01216631|Drug|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
390049|NCT01216618|Device|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
390050|NCT01216605|Drug|Syntocinon 24 IU|
390051|NCT01216605|Drug|Placebo|
390052|NCT01216592|Other|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
390053|NCT01216579|Other|mannitol (an airway challenge agent)|
390054|NCT01216566|Device|Occiflex Device|This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
390055|NCT01216553|Other|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
390056|NCT01216527|Procedure|Neo-adjuvant Chemoradiotherapy followed by Surgery|"Radiotherapy combined with concomitant chemotherapy:~Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~Number of cycles:two~surgery:Mckeown Modification Surgery and total two-field lymphadenectomy"
390057|NCT01216527|Procedure|surgery|two field lymphadenectomy
390058|NCT01216488|Drug|Xylocaine|40 ml or 25 ml of Xylocaine injection
390059|NCT01216475|Procedure|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
390060|NCT01216475|Procedure|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
390061|NCT01216449|Drug|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
390062|NCT01216449|Drug|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
390063|NCT01216436|Biological|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
390064|NCT01216410|Drug|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
390065|NCT01216410|Drug|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
390066|NCT01216410|Drug|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
390067|NCT01216397|Drug|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
390068|NCT01216397|Drug|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
390069|NCT01216384|Drug|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
390070|NCT01216384|Drug|placebo|Subjects will receive according to the dose group matching number of placebo tablets
390071|NCT01216371|Drug|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
390072|NCT01216371|Drug|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
390073|NCT01216345|Drug|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
390074|NCT01216332|Drug|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
390075|NCT01216332|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
390076|NCT01216319|Device|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
390077|NCT01216306|Behavioral|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
390078|NCT01216293|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, capsules, orally, once daily for up to 26 weeks.
390079|NCT01216293|Drug|Esomeprazole|Esomeprazole 40 mg, capsules, orally, once daily for up to 26 weeks.
390080|NCT01216293|Drug|Placebo|Placebo-matching capsules, orally, once daily for up to 26 weeks.
390081|NCT01216280|Drug|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
390246|NCT01214993|Drug|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
390082|NCT01216280|Drug|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
390083|NCT01216280|Drug|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
390084|NCT01216267|Drug|Lansoprazole|lansoprazole 30 mg HS x 7 days
390085|NCT01216267|Drug|lansoprazole|lanzoprazole 30 mg HS for 7 days
390086|NCT01216254|Device|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
390087|NCT01216241|Drug|Daptomycin|8 MG/KG IV
390088|NCT01216241|Other|Saline Placebo|50 ml normal saline once daily
390089|NCT01216241|Drug|Daptomycin|8 mg/kg once daily
390090|NCT01216176|Drug|Anastrozole|
390091|NCT01216176|Drug|AZD0530 (saracatinib)|
390092|NCT01216176|Drug|Placebo|
390093|NCT01216163|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
390094|NCT01216163|Drug|Acetaminophen|Single-dose of acetaminophen (1000mg)
390095|NCT01216163|Drug|Placebo|Single-dose of placebo
390096|NCT01216137|Other|Exercise: Vestibular Rehabilitation|Balance and eye movement training
390097|NCT01216137|Other|Exercise|Bicycle ergometry and stretching
390098|NCT01216124|Drug|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2~1 cycle=21 days DO*6"
390099|NCT01216111|Drug|Paclitaxel Cisplatin|"Paclitaxel 100 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15~1 cycle = 28days~PC*6"
390100|NCT01216098|Behavioral|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
390101|NCT01216085|Drug|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
390102|NCT01216072|Drug|Fingolimod|0.5 mg/day oral capsule
390103|NCT01216072|Drug|Standard MS DMTs|
390104|NCT01216059|Procedure|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
390105|NCT01216046|Drug|VX-809|capsule, taken once daily
390106|NCT01216046|Drug|VX-770|tablet, taken once every 12 hours
390107|NCT01216046|Drug|VX-809 placebo|capsule, taken once daily
390108|NCT01216046|Drug|VX-770 placebo|tablet, taken once every 12 hours
390109|NCT01216033|Drug|111-In-ABY-025|Intravenous injection of the agent
390110|NCT01216020|Drug|cetuximab|"Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.~Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
390111|NCT01216020|Drug|cisplatin (associated to radiotherapy)|"CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.~Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
390112|NCT01216007|Drug|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
390113|NCT01216007|Drug|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
390114|NCT01215981|Biological|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
390115|NCT01215981|Biological|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
390116|NCT01215968|Biological|LY2189265|1.5 mg administered subcutaneously
390117|NCT01215968|Drug|Placebo|Administered subcutaneously
390118|NCT01215955|Drug|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
390119|NCT01215955|Drug|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
390120|NCT01215942|Drug|LY2127399|Administered Subcutaneously
390121|NCT01215929|Drug|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
390122|NCT01215929|Drug|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
390165|NCT01215617|Behavioral|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
390166|NCT01215617|Behavioral|Control|Standard medical treatment
392183|NCT01199770|Other|control, medium|control pasta, medium portion
390123|NCT01215916|Drug|LY573636|"Individualized dose is dependent on a patient's height, weight, and gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid [350 micrograms (µg) to 1000 µg orally, daily], Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone [4 milligrams (mg) orally, twice daily or equivalent]."
390124|NCT01215916|Drug|Pemetrexed|"375 to 500 milligrams per square meter (mg/m^2), intravenous dosing is completed once per cycle (cycle equals either 21 or 28 days).~Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria are met.~Patients are pretreated with folic acid (350 µg to 1000 µg orally, daily), Vitamin B12 (1000 µg intramuscular injection every 9 weeks), and dexamethasone (4 mg orally, twice daily or equivalent)."
390125|NCT01215903|Dietary Supplement|Fish gelatin and omega-3 polyunsaturated fatty acid|
390126|NCT01215903|Dietary Supplement|Omega-3 polyunsaturated fatty acid|
390127|NCT01215890|Drug|risedronate|
390128|NCT01215890|Drug|placebo|
390129|NCT01215877|Drug|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months~In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,~the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC < 1,500/mm3, a platelet count < 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.~for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
390130|NCT01215864|Drug|TCD-717|"Patients will receive TCD-717 at the following dose levels:~2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m^2"
390131|NCT01215851|Drug|PA-824|200 mg tablet, once daily for 14 days
390132|NCT01215851|Drug|Pyrazinamide|Dosed by Weight
390133|NCT01215851|Drug|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
390134|NCT01215851|Drug|Rifafour|Rifafour e-275
390135|NCT01215851|Drug|Moxifloxacin|moxifloxacin 400 mg
390136|NCT01215799|Drug|Bafetinib|Bafetinib 240 mg bid
390137|NCT01215786|Drug|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
390138|NCT01215786|Drug|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
390139|NCT01215786|Drug|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
390140|NCT01215773|Drug|Placebo|Matching to HEA 200 mg tablet, oral administration
390141|NCT01215773|Drug|BI 671800|High dose oral administration
390142|NCT01215773|Drug|BI 671800|Medium dose oral administration
390143|NCT01215760|Other|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
390144|NCT01215760|Other|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
390145|NCT01215747|Drug|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
390146|NCT01215747|Drug|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
390147|NCT01215734|Biological|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
390148|NCT01215734|Biological|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
390149|NCT01215721|Drug|Vesicare|5 mg daily
390150|NCT01215708|Drug|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
390151|NCT01215695|Device|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
390152|NCT01215695|Device|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
390153|NCT01215682|Dietary Supplement|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
390154|NCT01215682|Dietary Supplement|placebo|sweetened water
390155|NCT01215669|Biological|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
390156|NCT01215669|Biological|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
390157|NCT01215669|Biological|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
390158|NCT01215669|Biological|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
390159|NCT01215656|Dietary Supplement|Lactobacillus fermentum|
390160|NCT01215656|Dietary Supplement|Follow on formula without probiotics|
390161|NCT01215643|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
390162|NCT01215643|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
390163|NCT01215643|Drug|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
390164|NCT01215630|Behavioral|Aerobic Interval Training|One interval training session
390208|NCT01215266|Drug|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
390209|NCT01215266|Drug|Placebo|Day 3-21 2x2 800 mg(milligram) daily
390247|NCT01214993|Drug|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
390167|NCT01215591|Procedure|Gradual weaning from Nasal CPAP in preterm neonates|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
390168|NCT01215578|Drug|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
390169|NCT01215565|Drug|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
390170|NCT01215552|Drug|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
390171|NCT01215539|Drug|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
390172|NCT01215513|Drug|Degarelix|
390173|NCT01215500|Radiation|Hypofractionated RT|"RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:~For all sites the dose levels are as follows:~8 Gy/ fraction x 3 fractions = 24 Gy~10 Gy/fraction x 3 fractions = 30 Gy~12 Gy/fraction x 3 fractions = 36 Gy~14 Gy/fraction x 3 fractions = 42 Gy~16 Gy/fraction x 3 fractions = 48 Gy~18 Gy/fraction x 3 fractions = 52 Gy~20 Gy/fraction x 3 fractions = 60 Gy"
390174|NCT01215487|Procedure|Stem Cell and Mutational Assay|Laboratory blood testing
390175|NCT01215448|Dietary Supplement|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
390176|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
390177|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
390178|NCT01215422|Procedure|timed intubation|timed intubation
390179|NCT01215409|Drug|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
390180|NCT01215396|Dietary Supplement|AminoVital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener.
390181|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
390182|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
390183|NCT01215370|Other|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
390184|NCT01215370|Other|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
390185|NCT01215370|Other|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
390186|NCT01215370|Other|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
390187|NCT01215370|Other|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
390188|NCT01215357|Drug|Ecopipam|50mg tablets
390189|NCT01215344|Drug|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
390190|NCT01215344|Drug|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
390191|NCT01215344|Drug|Dexamethasone|20 mg the day before and the day after receiving VELCADE
390192|NCT01215344|Drug|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
390193|NCT01215344|Drug|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
390194|NCT01215344|Drug|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
390195|NCT01215344|Drug|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
390196|NCT01215331|Drug|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
390197|NCT01215331|Drug|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.~Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.~Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
390198|NCT01215318|Device|modified vaginal tampon|modified vaginal tampons versus unmodified vaginal tampons, comparing the urinary contamination
390199|NCT01215292|Drug|Acyline|300 mcg/kg on Day 1
390200|NCT01215292|Drug|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
390201|NCT01215292|Drug|ketoconazole 400|400 mg PO daily, Days 3-10
390202|NCT01215292|Drug|Ketoconazole 800|800 mg PO daily, Day 3-10
390203|NCT01215292|Drug|Dutasteride|2.5 mg PO daily, Day 3-10
390204|NCT01215292|Drug|Anastrozole|1 mg PO daily, Day 3-10
390205|NCT01215292|Drug|Placebo ketoconazole|placebo to mimic ketoconazole
390206|NCT01215279|Drug|AZD2423|100 mg oral treatment once daily for 28 days
390207|NCT01215279|Drug|Placebo to AZD2423|Oral treatment once daily for 28 days
390210|NCT01215253|Drug|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
390211|NCT01215240|Device|Peritoneal dialysis|Prophylactic peritoneal dialysis
390212|NCT01215227|Drug|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
390213|NCT01215227|Drug|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
390214|NCT01215227|Drug|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
390215|NCT01215227|Drug|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
390216|NCT01215214|Drug|midazolam|midazolam: 3mg iv
390217|NCT01215201|Procedure|Scaling and Root Planing|Use periodontal hand instruments (curettes) to remove plaque, bacteria, and deposits on the root's surfaces.
390218|NCT01215201|Procedure|Diode Laser + Scaling and Root Planing|First: Periodontal hand instruments (curettes) were used to remove plaque, bacteria, and deposits on the root's surfaces (within a periodontal pocket) Then: Biolase 940 nm Ezlase diode laser was used to sterilize a periodontal pocket. Power: 0.80 Watts Wavelength: 940 nm Energy level: 0.80 Joules/second Mode of beam delivery: continuous
390219|NCT01215188|Biological|V114 Aluminum-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
390220|NCT01215188|Biological|V114 Non-adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
390221|NCT01215188|Biological|Prevnar 13®|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
390222|NCT01215175|Biological|Prevnar™|13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
390223|NCT01215175|Biological|V114, Aluminum Adjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
390224|NCT01215175|Biological|V114, Aluminum Nonadjuvanted|15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.0 mcg each), serotype 6B (4.0 mcg) in each 0.5 mL dose.
390225|NCT01215162|Radiation|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
390226|NCT01215149|Biological|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10^10 vp, delivered IM
390227|NCT01215149|Biological|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10^10 vp delivered IM
390228|NCT01215149|Biological|Placebo Control|Colorless 10mm Tris/HCl buffer
390229|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
390230|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
390231|NCT01215136|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
390232|NCT01215123|Drug|Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
390233|NCT01215110|Drug|TMC207|
390234|NCT01215110|Drug|Rifafour e-275 mg|
390235|NCT01215097|Drug|Linagliptin|once a day
390236|NCT01215097|Drug|placebo|once a day
390237|NCT01215084|Drug|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
390238|NCT01215071|Procedure|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
390239|NCT01215071|Procedure|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
390240|NCT01215045|Device|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
390241|NCT01215032|Drug|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
390242|NCT01215019|Drug|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
390243|NCT01215019|Drug|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
390244|NCT01214993|Drug|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
390245|NCT01214993|Drug|Placebo|Placebo is a tablet with no drug in it.
390248|NCT01214980|Device|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
390249|NCT01214980|Other|Standard of care|Standard of care provided per site-specific protocol
390250|NCT01214967|Behavioral|Problem Solving Education|psycho-educational intervention
390251|NCT01214954|Other|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
390252|NCT01214954|Other|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
390253|NCT01214941|Drug|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
390254|NCT01214941|Drug|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
390255|NCT01214941|Drug|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
390256|NCT01214928|Drug|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
390257|NCT01214915|Drug|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
390258|NCT01214902|Device|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
390259|NCT01214902|Behavioral|play|play which encourages the use of the hemiplegic hand
390260|NCT01214889|Biological|PENTAXIM™: DTacP IPV//PRP~T combined vaccine|0.5 mL, intramuscular
390261|NCT01214889|Biological|TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine|0.5 mL of each vaccine; intramuscular
390262|NCT01214863|Device|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
390263|NCT01214863|Device|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
390264|NCT01214863|Device|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
390265|NCT01214850|Biological|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
390266|NCT01214850|Biological|MenACWY-CRM conjugate vaccine|
390267|NCT01214850|Biological|Japanese Encephalitis vaccine|
390268|NCT01214837|Biological|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
390269|NCT01214837|Biological|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
390270|NCT01214837|Biological|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
390271|NCT01214824|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
390272|NCT01214811|Device|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
390273|NCT01214785|Behavioral|Provision of household latrines|WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
390274|NCT01214772|Drug|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
390275|NCT01214759|Drug|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
390276|NCT01214759|Drug|Raltegravir|Raltegravir 400mg twice a day
390277|NCT01214746|Drug|Placebo|1 tablet Unikalk 1 time pr day for 5 days
390278|NCT01214746|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
390279|NCT01214733|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
390280|NCT01214720|Drug|bevacizumab [Avastin]|Intervenous repeating dose
390281|NCT01214707|Other|Exercise|Exercise during EMU stay
390282|NCT01214694|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
390283|NCT01214694|Behavioral|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
390284|NCT01214694|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
390285|NCT01214681|Dietary Supplement|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
390286|NCT01214681|Dietary Supplement|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
390287|NCT01214681|Dietary Supplement|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
390288|NCT01214681|Dietary Supplement|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
390289|NCT01214668|Drug|LY573636-sodium|"Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Intravenous dosing is done on Day 1 of a 28-day cycle.~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 milligrams per square meter (mg/m²) of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion is met."
392852|NCT01194648|Procedure|quality-of-life assessment|
390290|NCT01214668|Drug|Liposomal Doxorubicin|"40 mg/m² on Day 1, given intravenously of each 28-day cycle~Participants may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m² of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
390291|NCT01214655|Drug|LY2523355|Administered as a 1-hour IV infusion for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
390292|NCT01214642|Drug|pegfilgrastim|Administered subcutaneously
390293|NCT01214642|Drug|LY2523355|Administered intravenously
390294|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
390295|NCT01214629|Drug|LY2523355|Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
390296|NCT01214629|Drug|pegfilgrastim|6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
390297|NCT01214616|Drug|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
390298|NCT01214616|Drug|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
390299|NCT01214616|Drug|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
390300|NCT01214603|Drug|LY2090314|Administered intravenously
390301|NCT01214590|Device|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
390302|NCT01214577|Drug|PEP005 (ingenol mebutate) Gel|0.015%
390303|NCT01214564|Drug|PEP005 (ingenol mebutate) Gel|0.05%
390304|NCT01214512|Other|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
390305|NCT01214499|Procedure|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
390306|NCT01214499|Procedure|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
390307|NCT01214486|Drug|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA < 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
390308|NCT01214473|Other|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
390309|NCT01214473|Other|Maltodextrin|Only maltodextrin as placebo
390310|NCT01214447|Other|No intervention|Observational study - no intervention
390311|NCT01214434|Device|Promiseb Topical Cream|topical non steroidal cream, twice daily
390312|NCT01214434|Other|Bland emollient|Eucerin cream twice daily
390313|NCT01214421|Drug|Tolvaptan|Daily split-dose of tolvaptan titrated to the maximally tolerated dose. Starting daily tolvaptan dose of 45mg/15mg titrated to 60mg/30mg, then 90mg/30mg based on tolerability.
390314|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
390315|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
390316|NCT01214395|Drug|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
390317|NCT01214382|Drug|Sertraline|Single dose sertraline 100 mg, tablet and solution
390318|NCT01214369|Procedure|Type of Supplementary Injection|Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
390319|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
390320|NCT01214356|Dietary Supplement|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
390321|NCT01214343|Drug|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
390322|NCT01214343|Drug|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
390323|NCT01214330|Device|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
390324|NCT01214317|Procedure|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
390325|NCT01214304|Other|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
390326|NCT01214304|Other|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
390327|NCT01214291|Drug|Toremifene|Toremifene 80mg daily
390328|NCT01214278|Drug|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
390329|NCT01214278|Drug|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
390330|NCT01214278|Drug|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
390331|NCT01214278|Drug|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
390332|NCT01214265|Device|EMKinetics non-invasive Magnetic neurostimulator|Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
390333|NCT01214252|Device|Permacol Surgical Implant|Permacol Surgical Implant
390334|NCT01214239|Drug|Placebo|once a day
390335|NCT01214239|Drug|Linagliptin|once a day
390336|NCT01214226|Drug|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
390337|NCT01214226|Drug|placebo|prolonged-release tablets 3 time per day for 1 month
390338|NCT01214200|Device|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. Hypercapnic COPD participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) via a Synchrony ventilator if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
390339|NCT01214187|Drug|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
390340|NCT01214187|Other|Oxygen|Room air oxygen concentrations will be administered as placebo
390341|NCT01214174|Drug|IBI-10090|
390342|NCT01214161|Drug|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
390343|NCT01214161|Other|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.~Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
390344|NCT01214148|Device|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
390345|NCT01214122|Drug|AZD9668|60 mg orally twice daily for 11 days
390346|NCT01214122|Drug|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
390347|NCT01214109|Drug|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
390348|NCT01214109|Drug|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
390349|NCT01214109|Drug|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
390350|NCT01214109|Drug|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
390351|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration:0.6ug/kg/day for 10days
390352|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration 1.2ug/kg/day for 10 days
390353|NCT01214096|Drug|rhNRG-1|Vein infusion:0.6ug/kg/day for 10 days
390354|NCT01214096|Drug|placebo|Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
390355|NCT01214083|Drug|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
390356|NCT01214083|Drug|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
390357|NCT01214083|Drug|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
390358|NCT01214070|Other|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
390359|NCT01214070|Behavioral|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
390360|NCT01214070|Behavioral|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
390361|NCT01214070|Behavioral|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
390386|NCT01213836|Drug|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
390615|NCT01211964|Drug|LEO 22811|Oral administration of solution and tablet.
390616|NCT01211951|Drug|KCT-0809|
390617|NCT01211951|Drug|KCT-0809|
390362|NCT01214057|Drug|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
390363|NCT01214057|Drug|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
390364|NCT01214044|Drug|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
390365|NCT01214031|Device|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
390366|NCT01214018|Other|Questionnaires and interview|Questionnaires and interview
390367|NCT01214005|Behavioral|smoking abstinence|3 days of biologically-confirmed smoking abstinence
390368|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
390369|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
390370|NCT01213979|Drug|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
390371|NCT01213979|Drug|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
390372|NCT01213966|Drug|OZ439|po, single dose
390373|NCT01213940|Behavioral|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
390374|NCT01213940|Procedure|bariatric surgery|bariatric surgery for weight loss
390375|NCT01213914|Device|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:~double lumen dialysis catheter should be placed in the internal jugular or femoral vein~Anticoagulation will be determined by prescribing physician~Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours~Blood flow rate will be set to ensure a filtration fraction of no more than 25%~Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours~Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized~All antibiotics will be dose adjusted for renal replacement therapy"
390376|NCT01213914|Other|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
390377|NCT01213901|Procedure|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
390378|NCT01213888|Drug|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
390379|NCT01213888|Drug|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
390380|NCT01213875|Behavioral|Home based education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
390381|NCT01213862|Behavioral|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
390382|NCT01213849|Drug|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
390383|NCT01213849|Drug|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
390384|NCT01213849|Drug|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
390385|NCT01213849|Drug|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
390618|NCT01211951|Drug|KCT-0809|
390619|NCT01211951|Drug|Placebo|
392853|NCT01194648|Procedure|transperineal prostate biopsy|
390387|NCT01213836|Drug|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
390388|NCT01213836|Drug|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
390389|NCT01213836|Drug|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
390390|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
390391|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
390392|NCT01213810|Biological|Zostavax|Biological/Vaccine
390393|NCT01213784|Other|all antidiabetic drugs will be appliable|We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
390394|NCT01213771|Procedure|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
390395|NCT01213758|Other|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
390396|NCT01213745|Other|Intervention|
390397|NCT01213745|Other|Attention|
390398|NCT01213745|Other|Control|
390399|NCT01213732|Other|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
390400|NCT01213719|Dietary Supplement|creatine|20g/d throughout 10 days
390401|NCT01213719|Dietary Supplement|betaine|2g/d throughout 10 days
390402|NCT01213719|Dietary Supplement|dextrose|dextrose (placebo), 20 g/d throughout 10 days
390403|NCT01213719|Dietary Supplement|creatine plus betaine|creatine (20g/d) plus betaine (2g/d) throughout 10 days
390404|NCT01213706|Device|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
390405|NCT01213706|Device|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
390406|NCT01213693|Drug|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
390407|NCT01213693|Drug|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
390408|NCT01213680|Drug|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
390409|NCT01213680|Drug|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
390410|NCT01213667|Drug|Ranibizumab|upload (three monthly injections), re-treatment as needed
390411|NCT01213628|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
390412|NCT01213615|Device|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
390413|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
390414|NCT01213576|Drug|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
390415|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
390416|NCT01213576|Drug|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
390417|NCT01213563|Drug|Actrapid insulin+Gloucose|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
390418|NCT01213563|Drug|Actrapid insulin|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
390419|NCT01213550|Drug|Chlorhexidine gluconate|
390420|NCT01213550|Drug|Placebo mouthrinse|
390421|NCT01213524|Behavioral|sensorimotor replacement|denicotinized cigarettes
390422|NCT01213524|Drug|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
390423|NCT01213524|Drug|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
390424|NCT01213524|Other|usual brand smoking|participant smokes usual brand of cigarette
390425|NCT01213511|Procedure|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
390462|NCT01213290|Device|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
390426|NCT01213511|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
390427|NCT01213498|Drug|Atorvastatin|Zarator, 80 mg pr. day for 5 days
390428|NCT01213498|Drug|Unikalk|1 tablet Unikalk pr day for 5. days
390429|NCT01213472|Biological|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
390430|NCT01213459|Procedure|Cervical samples|Human papillomavirus detection and typing in cervical samples.
390431|NCT01213459|Other|Data collection|Questionnaire completion
390432|NCT01213446|Biological|Biostate|"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.~Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
390433|NCT01213433|Drug|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
390434|NCT01213420|Other|Nivea Cream for scar hydration|3 applications per day during 6 months
390435|NCT01213420|Other|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
390436|NCT01213420|Other|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
390437|NCT01213420|Other|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
390438|NCT01213407|Drug|Trivax, Temozolomide, Surgery, Radiotherapy|"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32~Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.~Break: weeks 7, 8, 9, 10.~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
390439|NCT01213407|Drug|Temozolomide, Surgery, Radiotherapy|"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy~Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6~Break: weeks 7, 8, 9, 10~Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
390440|NCT01213394|Drug|mycophenolate mofetil|"Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.~Target CNI trough levels in the Symphony study:~Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.~Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses* with a target trough level of 3-7 ng/mL (*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)"
390441|NCT01213394|Other|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
390442|NCT01213381|Drug|Iniparib (SAR240550 - BSI-201)|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
390443|NCT01213381|Drug|Gemcitabine|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
390444|NCT01213381|Drug|Carboplatin|"Pharmaceutical form:sterile aqueous solution~Route of administration: intravenous"
390445|NCT01213368|Drug|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets~Route of administration: oral"
390446|NCT01213368|Drug|placebo|"Pharmaceutical form: tablets~Route of administration: oral"
390447|NCT01213355|Drug|Placebo|Capsule, single dose, oral, 1 day
390448|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
390449|NCT01213355|Drug|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
390450|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
390451|NCT01213355|Drug|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
390452|NCT01213355|Drug|scopolamine|injectable subcutaneous formulation, single dose, 1 day
390453|NCT01213355|Drug|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
390454|NCT01213355|Drug|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
390455|NCT01213355|Drug|Donepezil|Tablet, 10mg, single dose, 1 day
390456|NCT01213355|Drug|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
390457|NCT01213342|Dietary Supplement|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:~EPA (Eicosapentaenoic Acid) 1300mg~DHA (Docosahexaenoic Acid) 900 mg~Other Omega-3's 360mg~Total Omega 3's 2560 mg"
390458|NCT01213342|Dietary Supplement|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
390459|NCT01213329|Drug|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
390460|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
390461|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
390550|NCT01212718|Drug|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
390551|NCT01212705|Device|Adaptive servoventilation|Background expiratory positive airway pressure with some inspiratory pressure support when needed
390463|NCT01213290|Device|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
390464|NCT01213277|Other|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
390465|NCT01213277|Other|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
390466|NCT01213264|Other|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
390467|NCT01213264|Drug|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
390468|NCT01213264|Drug|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.~As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
390469|NCT01213251|Device|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
390470|NCT01213251|Device|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
390471|NCT01213238|Drug|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
390472|NCT01213238|Drug|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
390473|NCT01213238|Drug|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
390474|NCT01213212|Other|Caloric restriction|Caloric restriction.
390475|NCT01213212|Other|No intervention|"Diet ad libitum"
390476|NCT01213199|Drug|Adapalene|Adapalene Gel 0.3%
390477|NCT01213186|Drug|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5*10E6/kg for 48 weeks.
390478|NCT01213186|Drug|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5*10E6/kg for 48 weeks.
390479|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
390480|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
390481|NCT01213160|Drug|AZD4547|film coated tablet, PO, twice daily
390482|NCT01213147|Drug|clomiphene citrate|100 mg per day oral for 7 days
390483|NCT01213147|Drug|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
390484|NCT01213121|Drug|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
390485|NCT01213108|Behavioral|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
390486|NCT01213108|Behavioral|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
390487|NCT01213095|Drug|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
390488|NCT01213082|Drug|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
390489|NCT01213082|Drug|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
390490|NCT01213082|Drug|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
390491|NCT01213069|Other|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
390492|NCT01213056|Behavioral|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
390493|NCT01213043|Biological|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
390494|NCT01213043|Biological|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
390495|NCT01213030|Drug|[F-18] FMISO|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
390496|NCT01213030|Drug|[F-18] HX4|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
390497|NCT01213017|Drug|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
390498|NCT01213004|Procedure|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
390620|NCT01211938|Radiation|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
390499|NCT01213004|Procedure|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
390500|NCT01212991|Drug|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
390501|NCT01212991|Drug|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
390502|NCT01212978|Behavioral|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
390503|NCT01212965|Drug|Selenium|400 μg once a day for 6 months by mouth
390504|NCT01212952|Drug|pomalidomide|Given orally
390505|NCT01212952|Drug|bortezomib|Given IV
390506|NCT01212952|Drug|dexamethasone|Given orally
390507|NCT01212952|Other|laboratory biomarker analysis|Optional correlative studies
390508|NCT01212952|Other|gene expression analysis|Optional correlative studies
390509|NCT01212926|Device|Echographic analysis of myocardial deformation in 2D strain|
390510|NCT01212913|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
390511|NCT01212913|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
390512|NCT01212913|Drug|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
390513|NCT01212900|Drug|Statins, HMG CoA|Statin therapy
390514|NCT01212887|Biological|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
390515|NCT01212887|Biological|aldesleukin|
390516|NCT01212887|Drug|cyclophosphamide|
390517|NCT01212887|Drug|fludarabine phosphate|
390518|NCT01212887|Other|laboratory biomarker analysis|
390519|NCT01212887|Other|pharmacological study|
390520|NCT01212874|Drug|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
390521|NCT01212874|Drug|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
390522|NCT01212861|Device|Suprachoroidal Dissection Instrument (SDI)|The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
390523|NCT01212848|Device|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
390524|NCT01212848|Device|Transcranial Magnetic Stimulation - Sham Comparator|"The control group will receive an identical dosing schedule of sham repetitive TMS over three days."
390525|NCT01212835|Procedure|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
390526|NCT01212835|Procedure|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
390527|NCT01212822|Biological|bevacizumab|Given IV
390528|NCT01212822|Drug|oxaliplatin|Given IV
390529|NCT01212822|Drug|leucovorin calcium|Given IV
390530|NCT01212822|Drug|fluorouracil|Given IV
390531|NCT01212822|Procedure|therapeutic conventional surgery|Undergo surgical resection
390532|NCT01212822|Other|laboratory biomarker analysis|Correlative studies
390533|NCT01212809|Device|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
390534|NCT01212809|Device|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
390535|NCT01212783|Behavioral|In-Home Cognitive Behavioral Therapy|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
390536|NCT01212783|Behavioral|Present-Centered Therapy|Present-Centered Therapy is a supportive psychotherapy.
390537|NCT01212770|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
390538|NCT01212770|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
390539|NCT01212770|Drug|Placebo|
390540|NCT01212757|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
390541|NCT01212757|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
390542|NCT01212757|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
390543|NCT01212757|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
390544|NCT01212744|Drug|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
390545|NCT01212731|Radiation|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
390546|NCT01212731|Radiation|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
390547|NCT01212731|Behavioral|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
390548|NCT01212731|Device|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
390549|NCT01212718|Drug|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
390552|NCT01212692|Behavioral|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
390553|NCT01212679|Drug|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
390554|NCT01212679|Drug|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
390555|NCT01212666|Procedure|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
390556|NCT01212666|Procedure|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
390557|NCT01212653|Drug|Simponi|Golimumab 50mg monthly
390558|NCT01212653|Other|0.9ml sodium chloride|0.9ml sodium chloride
390559|NCT01212627|Drug|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
390560|NCT01212627|Drug|Ridaforolimus|
390561|NCT01212614|Procedure|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
390562|NCT01212588|Drug|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
390563|NCT01212588|Drug|Placebo|3 tablets once daily for seven days
390564|NCT01212562|Procedure|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
390565|NCT01212549|Procedure|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
390566|NCT01212549|Procedure|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
390567|NCT01212536|Device|Airtraq laryngoscopy|laryngoscopy and intubation
390568|NCT01212523|Drug|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
390569|NCT01212510|Other|Blood sampling|blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
390570|NCT01212497|Behavioral|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
390571|NCT01212484|Drug|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
390572|NCT01212484|Drug|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
390573|NCT01212471|Drug|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
390574|NCT01212471|Drug|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
390575|NCT01212471|Drug|Placebo Comparator|sterile ophthalmic solution
390576|NCT01212458|Drug|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
390577|NCT01212445|Drug|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
390578|NCT01212432|Drug|Daptomycin|Daptomycin kinetics in CRRT
390579|NCT01212406|Drug|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
390580|NCT01212393|Behavioral|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
390581|NCT01212380|Drug|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
390582|NCT01212380|Other|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
390583|NCT01212380|Other|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
390584|NCT01212380|Other|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
390608|NCT01212133|Drug|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
390609|NCT01212120|Biological|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
390610|NCT01212107|Drug|FGF Receptor|LY2874455 administered orally.
390611|NCT01212107|Drug|Phosphate Binders|
390612|NCT01212094|Drug|Rituximab|
390585|NCT01212380|Other|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
390586|NCT01212367|Biological|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
390587|NCT01212367|Biological|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
390588|NCT01212354|Radiation|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
390589|NCT01212341|Biological|Allogeneic NK cells|
390590|NCT01212328|Other|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
390591|NCT01212328|Other|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
390592|NCT01212315|Device|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
390593|NCT01212302|Drug|Optimizing ASA and clopidogrel treatment|"ASA 100 mg, ASA 300 mg, ASA 500 mg~Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:~In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient."
390594|NCT01212276|Drug|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
390595|NCT01212263|Drug|Step-up HP u FSH|HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
390596|NCT01212263|Drug|Clomiphine citrate plus low dose uFSH|Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
390597|NCT01212250|Drug|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
390598|NCT01212250|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
390599|NCT01212237|Procedure|fMRI Evaluation|Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
390600|NCT01212211|Other|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
390601|NCT01212185|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
390602|NCT01212185|Other|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
390603|NCT01212172|Device|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
390604|NCT01212172|Device|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
390605|NCT01212159|Device|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
390606|NCT01212146|Dietary Supplement|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10^10 CFU.
390607|NCT01212146|Dietary Supplement|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
390613|NCT01212094|Other|normal saline|normal saline
390614|NCT01211977|Drug|XOMA 052|
390621|NCT01211938|Radiation|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
390622|NCT01211925|Procedure|distal venous arterialisation|The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
390623|NCT01211925|Drug|Aspirin|100 mg per day continuous
390624|NCT01211912|Drug|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
390625|NCT01211912|Drug|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
390626|NCT01211873|Drug|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
390627|NCT01211873|Drug|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
390628|NCT01211860|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
390629|NCT01211847|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 126 days
390630|NCT01211847|Drug|Placebo|Placebo matching DCCR
390631|NCT01211834|Drug|tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
390632|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
390633|NCT01211834|Drug|Placebo|intravenously over 1 hour infusion every 4weeks
390634|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs
390635|NCT01211821|Drug|metoprolol|Tablets, Oral, 200 mg, once, 1 day
390636|NCT01211821|Drug|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
390637|NCT01211808|Drug|BMS-914832|Tablets, Oral, 30 mg, once, 1 day
390638|NCT01211808|Drug|Diltiazem|Tablets, Oral, 360 mg, once daily, 10 days
390639|NCT01211795|Drug|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
390640|NCT01211795|Other|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
390641|NCT01211782|Drug|caprylic triglyceride|oral, 20 gm, daily x 6 months
390642|NCT01211782|Drug|long-chain triglyceride|oral, 14 gm, daily x 6 months
390643|NCT01211769|Drug|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
390644|NCT01211769|Drug|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
390645|NCT01211769|Drug|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
390646|NCT01211769|Drug|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
390647|NCT01211756|Drug|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
390648|NCT01211756|Drug|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
390649|NCT01211743|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
390650|NCT01211743|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
390651|NCT01211730|Drug|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
390652|NCT01211717|Dietary Supplement|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
390653|NCT01211717|Other|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
390654|NCT01211704|Drug|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
390655|NCT01211704|Drug|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
390656|NCT01211691|Drug|KB004, Monoclonal Antibody|
390657|NCT01211665|Drug|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
390658|NCT01211665|Drug|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
390659|NCT01211626|Drug|ANA773|ANA773 Tosylate Capsule
390660|NCT01211626|Drug|Placebo|Matching Placebo Capsule
390661|NCT01211613|Procedure|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
390662|NCT01211613|Device|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
390663|NCT01211613|Other|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
390664|NCT01211600|Other|Staples|Interrupted Ethicon Staples
390665|NCT01211600|Other|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
390666|NCT01211587|Drug|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
390667|NCT01211587|Drug|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
390668|NCT01211574|Behavioral|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
390669|NCT01211574|Behavioral|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
390670|NCT01211574|Behavioral|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
390671|NCT01211561|Drug|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
390672|NCT01211561|Drug|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
390673|NCT01211548|Other|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
390674|NCT01211535|Device|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
390675|NCT01211535|Device|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
390676|NCT01211535|Device|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
390677|NCT01211522|Drug|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
390678|NCT01211522|Drug|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
390679|NCT01211522|Drug|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
390680|NCT01211509|Drug|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
390681|NCT01211496|Behavioral|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
390682|NCT01211496|Behavioral|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
390683|NCT01211483|Drug|U3-1287|Liquid 70 mg/mL for IV infusion at high dose or low dose
390684|NCT01211483|Drug|Erlotinib|Tablet 150 mg for oral administration
390685|NCT01211483|Drug|Placebo|Placebo liquid matching U3-1287 for IV infusion
390686|NCT01211470|Drug|Daptomycin|Active Comparator: Daptomycin.
390687|NCT01211470|Drug|PMX-30063-investigational drug|Experimental: PMX-30063
390688|NCT01211457|Drug|sapacitabine and decitabine (Part 1 - completed)|decitabine will be administered in alternating cycles with sapacitabine
390689|NCT01211457|Drug|sapacitabine and venetoclax (Part 2 - recruiting)|sapacitabine will be administered concomitantly with venetoclax
390690|NCT01211444|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
390691|NCT01211431|Drug|Reference|Intrathécale morphine is used for post-cesarean pain control
390692|NCT01211431|Drug|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
390693|NCT01211418|Behavioral|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.~Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB & IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.~Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
390694|NCT01211418|Behavioral|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.~The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
390695|NCT01211405|Drug|Low dose MDMA|30 mg MDMA administered p.o. once during each experimental session. Upon mutual agreement this maybe followed by a supplemental dose of 15 mg MDMA 1.5 to 2 hours later
390696|NCT01211405|Drug|Medium dose MDMA|75 mg MDMA adminis5tered p.o. once at start of an experimental session. Upon mutual agreement, may be followed 1.5 to 2 hours later by a supplemental dose of 37.5 mg
390697|NCT01211405|Drug|Full dose MDMA|125 mg MDMA administered p.o. at start of an experimental session. By mutual agreement, may be followed 1.5 to 2 hours later by a supplemental dose of 62.5 mg MDMA.
390698|NCT01211405|Behavioral|Psychotherapy|Psychotherapy throughout main study
390699|NCT01211392|Other|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
390700|NCT01211379|Behavioral|FLU-FOBT Program|Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
390701|NCT01211366|Other|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
390702|NCT01211366|Other|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
390703|NCT01211353|Behavioral|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
390704|NCT01211353|Behavioral|Education-Only|Educational information about alcohol use
390705|NCT01211340|Behavioral|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
390706|NCT01211327|Drug|Cyclosporine A|Cyclosporine 2% eye drops
390707|NCT01211327|Drug|Dexamethasone|Dexamethasone 0,1% eye drops
390708|NCT01211314|Drug|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
390709|NCT01211301|Behavioral|Food-based, Reduced Energy Diet Plan|Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
390710|NCT01211301|Other|Medifast 5 & 1 Plan|Participants randomized to the Medifast group will enroll online in the Medifast 5 & 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean & Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are >70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 & 1 Plan. The Medifast 5 & 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean & Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 & 1 Plan.
390711|NCT01211275|Biological|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
390712|NCT01211275|Drug|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
390713|NCT01211262|Drug|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of patients will be treated at the RP2D or MTD.
390714|NCT01211249|Drug|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
390715|NCT01211249|Drug|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
390716|NCT01211249|Drug|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
390717|NCT01211249|Drug|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
390718|NCT01211236|Other|application of wound dressing made of bio-bags (vitapads) containing maggots|
390719|NCT01211236|Other|application of classical hydrogel/alginate wound dressing|
390720|NCT01211223|Drug|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
390721|NCT01211210|Drug|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
390722|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
390723|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
390724|NCT01211197|Drug|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
390725|NCT01211197|Drug|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
390726|NCT01211197|Drug|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
390727|NCT01211184|Dietary Supplement|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
390728|NCT01211184|Dietary Supplement|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
390729|NCT01211184|Behavioral|Fasting.|The patient is fasting from midnight before the surgery.
390730|NCT01211171|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
390731|NCT01211158|Drug|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
390732|NCT01211158|Drug|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
390733|NCT01211145|Drug|Placebo|Placebo nasal spray
390734|NCT01211145|Drug|Zolmitriptan|0.5 mg nasal spray
390735|NCT01211145|Drug|Zolmitriptan|2.5 mg nasal spray
390736|NCT01211145|Drug|Zolmitriptan|5.0 mg nasal spray
390737|NCT01211132|Device|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
390738|NCT01211132|Device|Standard|Without attaching a transparent cap to the tip of colonoscope.
390739|NCT01211119|Other|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
390740|NCT01211106|Behavioral|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
390741|NCT01211106|Behavioral|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
390742|NCT01211093|Procedure|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
390743|NCT01211093|Procedure|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
390744|NCT01211093|Procedure|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
390745|NCT01211080|Drug|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
390746|NCT01211067|Procedure|Lichtenstein hernioplasty|"Mesh hernioplasty~Ultrapro mesh (Ethicon, Johnson & Johnson)"
390747|NCT01211028|Biological|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
390748|NCT01211002|Radiation|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
390749|NCT01211002|Drug|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 ~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
390750|NCT01210989|Drug|Phyllanthus urinaria|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
390751|NCT01210989|Drug|Placebo|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
390752|NCT01210976|Drug|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
390753|NCT01210976|Drug|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
390754|NCT01210963|Device|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
390755|NCT01210950|Biological|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
390756|NCT01210937|Procedure|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
390757|NCT01210911|Drug|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
390758|NCT01210911|Drug|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
390759|NCT01210911|Drug|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
390760|NCT01210911|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
390761|NCT01210898|Biological|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
390762|NCT01210885|Biological|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
390763|NCT01210872|Other|questionnaire administration|
390764|NCT01210872|Procedure|quality-of-life assessment|
390765|NCT01210872|Procedure|standard follow-up care|
390766|NCT01210846|Drug|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
390767|NCT01210833|Device|HandTutor System|Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
390768|NCT01210820|Device|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
390769|NCT01210807|Device|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
390770|NCT01210807|Device|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
390771|NCT01210781|Procedure|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
390772|NCT01210768|Drug|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
390773|NCT01210768|Drug|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
392854|NCT01194648|Procedure|transrectal prostate biopsy|
390774|NCT01210755|Drug|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
390775|NCT01210755|Drug|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
390776|NCT01210742|Device|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
390777|NCT01210742|Other|Routine management|Routine non-operative management for knee OA (NICE guidelines)
390778|NCT01210729|Device|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
390779|NCT01210716|Device|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
390780|NCT01210677|Drug|Prednisone|Prednisone 0.5 mg/Kg orally per day for 3 months
390781|NCT01210664|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10^8 cells. The second cohort will receive 0.4 x10^8 cells. The third cohort will receive 3.2 x10^8 cells. The fourth cohort will receive 26 x10^8 cells.
390782|NCT01210651|Behavioral|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
390783|NCT01210651|Behavioral|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
390784|NCT01210638|Drug|Oxymorphone|10 mg tablet
390785|NCT01210625|Dietary Supplement|Nutrabiotix|Fiber supplement: 9mg or 12mg
390786|NCT01210625|Dietary Supplement|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
390787|NCT01210612|Device|five-toed socks|five-toed socks usage
390788|NCT01210599|Drug|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
390789|NCT01210586|Behavioral|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
390790|NCT01210573|Device|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.~For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
390791|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
390792|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
390793|NCT01210560|Drug|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
390794|NCT01210560|Drug|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
390795|NCT01210560|Drug|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
390796|NCT01210534|Other|No intervention|No intervention
390797|NCT01210521|Drug|Vitamin D|Vitamin D, (2000IU) will be administered orally, once a day, for one month.
390798|NCT01210495|Drug|Axitinib (AG-013736)|Axitinib [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
390799|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
390800|NCT01210495|Drug|Placebo|Placebo [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
390801|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
390802|NCT01210482|Drug|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30~60 minutes. The dosage is to be appropriately reduced according to patients' status.
390803|NCT01210469|Other|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
390804|NCT01210469|Other|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
390877|NCT01209780|Biological|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children <4 years.
392855|NCT01194635|Genetic|fluorescence in situ hybridization|
390805|NCT01210456|Drug|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.~154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.~In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
390806|NCT01210443|Drug|Sitaxentan|sitaxentan sodium 100 mg
390807|NCT01210430|Drug|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
390808|NCT01210430|Drug|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
390809|NCT01210430|Drug|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
390810|NCT01210417|Other|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
390811|NCT01210404|Drug|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
390812|NCT01210391|Other|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
390813|NCT01210391|Other|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
390814|NCT01210378|Drug|Nitroglycerin patch|Nitroglycerin patch
390815|NCT01210365|Drug|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
390816|NCT01210365|Drug|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
390817|NCT01210352|Drug|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
390818|NCT01210339|Drug|Clopidogrel|Clopidogrel
390819|NCT01210339|Drug|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
390820|NCT01210326|Procedure|extaction|TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
390821|NCT01210326|Procedure|testicular sperm extraction|testicular sperm extraction
390822|NCT01210326|Procedure|testicular sperm aspiration|testicular sperm aspiration
390823|NCT01210287|Drug|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
390824|NCT01210261|Device|Compumedics Somnilink SPAP - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
390825|NCT01210261|Device|Resmed Autoset S8 - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.~Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.~All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
390826|NCT01210248|Other|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
390827|NCT01210235|Behavioral|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
390828|NCT01210222|Biological|Trebananib|Given IV
390829|NCT01210209|Other|genome-wide association study|
390830|NCT01210196|Procedure|MRI|Cardiac MRI after 12 and 24 months.
390831|NCT01210183|Drug|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
390832|NCT01210170|Drug|placebo|placebo inhalation before albuterol.
390833|NCT01210170|Drug|mometasone 400 mcg|mometasone inhalation before albuterol.
390834|NCT01210170|Drug|mometasone 200 mcg|200ug mometasone before albuterol.
390835|NCT01210144|Drug|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
390836|NCT01210144|Drug|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (>) 16 millimeter (mm), and with estradiol (E2) > 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
390837|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
390838|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
390839|NCT01210131|Drug|[18F]HX4|Intravenous injection
390840|NCT01210118|Behavioral|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
390841|NCT01210118|Behavioral|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
390842|NCT01210079|Drug|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
390843|NCT01210079|Drug|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
390844|NCT01210066|Drug|Fentanyl|IV fentanyl 1mcg/kg
390845|NCT01210066|Other|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
390846|NCT01210066|Other|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
390847|NCT01210053|Drug|malate Given orally|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
390848|NCT01210040|Dietary Supplement|Folic Acid|2.8mg
390849|NCT01210040|Dietary Supplement|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
390850|NCT01210014|Drug|zinc sulphate 220mg/day in one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
390851|NCT01210014|Drug|placebo: one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
390852|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 low dose
390853|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
390854|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
390855|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
390856|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
390857|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
390858|NCT01209988|Drug|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
390859|NCT01209988|Other|No medication|No medication
390860|NCT01209975|Procedure|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
390861|NCT01209949|Drug|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
390862|NCT01209936|Device|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
390863|NCT01209923|Device|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
390864|NCT01209910|Other|Water|Subjects in this arm will be able to drink water with some conditions.
390865|NCT01209897|Behavioral|Smoking cessation booklet|
390866|NCT01209871|Biological|Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine|Given ID
390867|NCT01209871|Other|Laboratory Biomarker Analysis|Correlative studies
390868|NCT01209858|Drug|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
390869|NCT01209858|Drug|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
390870|NCT01209845|Drug|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
390871|NCT01209832|Drug|Tasisulam|Patient specific dose, administered intravenously, on Day 1 of a 28-day cycle. Minimum of one (1) 28-day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
390872|NCT01209832|Drug|Midazolam|1.2 milligrams (mg), administered orally once prior to the initiation of tasisulam therapy and once on Day 8 after initiation of tasisulam therapy
390873|NCT01209806|Drug|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
390874|NCT01209793|Biological|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
390875|NCT01209780|Biological|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
390876|NCT01209780|Biological|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
390963|NCT01209208|Drug|Mesalamine|3 g per day
390964|NCT01209208|Other|Placebo|0 g per day
390878|NCT01209767|Device|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
390879|NCT01209767|Procedure|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
390880|NCT01209767|Other|Control|
390881|NCT01209741|Drug|telcagepant potassium|[INTERVENTION NAME: MK-0974 12MoRT] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
390882|NCT01209741|Drug|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
390883|NCT01209741|Drug|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
390884|NCT01209728|Other|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
390885|NCT01209715|Drug|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
390886|NCT01209715|Drug|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
390887|NCT01209702|Biological|tocilizumab|Administered intravenously (iv) every 4 weeks
390888|NCT01209702|Drug|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
390889|NCT01209689|Drug|Tocilizumab|
390890|NCT01209689|Drug|Placebo|
390891|NCT01209676|Drug|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
390892|NCT01209663|Other|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
390893|NCT01209650|Drug|BIBW 2992|tablets
390894|NCT01209637|Behavioral|exercise training|exercise training min. 4 times a day for at least 30 min
390895|NCT01209637|Behavioral|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
390896|NCT01209611|Procedure|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
390897|NCT01209611|Procedure|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
390898|NCT01209598|Drug|Palbociclib 200mg|Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
390899|NCT01209598|Drug|Palbociclib 125mg|"Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.~Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
390900|NCT01209585|Other|Blood samples|Subjects will have visits on Days 1, 30 and 120.
390901|NCT01209585|Other|Synovial fluid aspiration|Subjects will have visits on Days 1, 30, and 120.
390902|NCT01209585|Other|Synovial tissue sample|Subjects will have visits on Days 1, 30, and 120.
390903|NCT01209572|Device|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
390904|NCT01209572|Device|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
390905|NCT01209546|Other|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
390906|NCT01209546|Other|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
390907|NCT01209546|Other|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
390908|NCT01209546|Other|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
390909|NCT01209533|Drug|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
390910|NCT01209520|Drug|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
390911|NCT01209520|Drug|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
390912|NCT01209520|Drug|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
390913|NCT01209520|Drug|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
390914|NCT01209520|Procedure|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
390915|NCT01209520|Procedure|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
390916|NCT01209520|Drug|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
390917|NCT01209520|Drug|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
390918|NCT01209520|Drug|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
390919|NCT01209507|Other|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
390920|NCT01209481|Behavioral|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
390921|NCT01209468|Device|monobloc oral appliance|one piece oral appliance
390922|NCT01209468|Device|twinblock oral appliance|two-piece oral appliance
390923|NCT01209455|Drug|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
390924|NCT01209455|Drug|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of ~12 mg/l. To achieve a desired concentration of ~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
390925|NCT01209455|Drug|Paracetamol|To achieve a local paracetamol concentration of ~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
390926|NCT01209442|Drug|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
390927|NCT01209442|Drug|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
390928|NCT01209442|Radiation|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
390929|NCT01209429|Drug|GH hormone infusion|Norditropin 30 ng/kg/min
390930|NCT01209429|Behavioral|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
390931|NCT01209429|Behavioral|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
390932|NCT01209416|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
390933|NCT01209416|Drug|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
390934|NCT01209416|Other|Placebo|placebo tablets or saline infusion
390935|NCT01209403|Drug|Glucose-infusion|Continuous iv infusion of glucose
390936|NCT01209403|Drug|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
390937|NCT01209390|Device|Chondromimetic|"The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.~The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate."
390938|NCT01209377|Behavioral|standard|EMDR treatment with bilateral stimulation via eye movement
390939|NCT01209377|Behavioral|fixed|EMDR treatment with fixed eyes
390940|NCT01209377|Behavioral|no focus|trauma exposure without external focus
390941|NCT01209377|Procedure|EMDR|Eye Movement Desensitization and Reprocessing (EMDR)
390942|NCT01209364|Device|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
390943|NCT01209351|Drug|Placebo|placebo
390944|NCT01209351|Drug|teduglutide|teduglutide 4 mg
390945|NCT01209338|Behavioral|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
390946|NCT01209325|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
390947|NCT01209325|Other|laboratory biomarker analysis|
390948|NCT01209312|Other|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
390949|NCT01209299|Genetic|DNA methylation analysis|
390950|NCT01209299|Genetic|gene expression analysis|
390951|NCT01209299|Other|laboratory biomarker analysis|
390952|NCT01209286|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
390953|NCT01209260|Device|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
390954|NCT01209260|Device|Mechanical Needle|Mechanical needle for transseptal access
390955|NCT01209247|Other|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
390956|NCT01209234|Behavioral|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
390957|NCT01209234|Drug|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
390958|NCT01209221|Drug|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
390959|NCT01209221|Drug|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
390960|NCT01209221|Drug|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
390961|NCT01209221|Drug|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
390962|NCT01209208|Drug|Budesonide|9 mg per day
390967|NCT01209156|Drug|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of [18F]PBR111, followed by PET imaging.
390968|NCT01209143|Drug|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
390969|NCT01209143|Drug|Rosiglitazone|Rosiglitazone was supplied in tablets.
390970|NCT01209143|Drug|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
390971|NCT01209130|Drug|DCDT2980S|Intravenous repeating dose
390972|NCT01209130|Drug|rituximab|Intravenous repeating dose
390973|NCT01209117|Drug|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
390974|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
390975|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
390976|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
390977|NCT01209117|Drug|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
390978|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
390979|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
390980|NCT01209078|Drug|GSK1322322|GSK1322322 1500mg BID
390981|NCT01209078|Drug|Linezolid|Linezolid 600mg
390982|NCT01209078|Drug|GSK1322322 placebo|Placebo
390983|NCT01209078|Drug|Linezolid placebo|placebo
390984|NCT01209065|Drug|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
390985|NCT01209065|Drug|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
390986|NCT01209065|Drug|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
390987|NCT01209052|Drug|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
390988|NCT01209052|Other|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
390989|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
390990|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
390991|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
390992|NCT01209026|Drug|Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination|Novel dry powder inhaler
390993|NCT01209026|Drug|Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination|Novel dry powder inhaler
390994|NCT01209026|Drug|Placebo Inhaler|Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
390995|NCT01209026|Drug|Moxifloxacin 400mg|Film coated oral tablet
390996|NCT01209026|Drug|Moxifloxacin placebo|Film coated oral tablet
390997|NCT01209013|Device|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
390998|NCT01209013|Procedure|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
390999|NCT01209013|Procedure|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
391000|NCT01209013|Procedure|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
391001|NCT01209013|Procedure|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
391002|NCT01209013|Procedure|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
391003|NCT01209013|Procedure|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
391004|NCT01209000|Procedure|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.
391005|NCT01208987|Other|Medication History was printed|
391006|NCT01208974|Procedure|Nipple-Sparing Mastectomy|Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.
391007|NCT01208974|Procedure|Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.
391008|NCT01208974|Procedure|Axillary Surgery|Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
391009|NCT01208974|Radiation|Prophylactic Nipple-Areolar Complex RT|Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
391010|NCT01208961|Drug|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
391011|NCT01208961|Drug|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
391012|NCT01208948|Drug|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
391015|NCT01208922|Drug|Rifamycin SV-MMX®|2 Rifamycin SV-MMX® 200 mg tablets and 1 placebo to ciprofloxacin capsule, b.i.d.
391016|NCT01208922|Drug|Ciprofloxacin|1 ciprofloxacin 500 mg capsule and 2 placebos to Rifamycin SV-MMX® 200 mg tablets, b.i.d.
391017|NCT01208909|Procedure|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
391018|NCT01208896|Drug|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
391019|NCT01208883|Other|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment [18F]FDG-PET for treatment adaptation
391020|NCT01208870|Behavioral|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
391021|NCT01208870|Behavioral|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
391022|NCT01208831|Drug|LDE225|
391023|NCT01208818|Drug|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):~Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.~Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
391024|NCT01208818|Drug|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):~Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.~Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
391025|NCT01208818|Device|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
391026|NCT01208818|Device|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient > 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
391027|NCT01208805|Behavioral|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
391028|NCT01208792|Procedure|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
391029|NCT01208792|Other|Blood Sample|a blood sample will be collected
391030|NCT01208766|Drug|Bortezomib, Melphalan, Prednisone (VMP)|"Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32~Melphalan _ 9 mg/m² _ p.o. _ days 1-4~Prednisone _ 60 mg/m² _ p.o. _ days 1-4"
391031|NCT01208766|Drug|1 or 2 cycle(s) HDM (High Dose Melphalan)|"- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2*~*Patients with renal insufficiency 100 mg/m2 only at day -3~If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR."
391032|NCT01208766|Drug|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|"Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11~Lenalidomide _ 25 mg _ p.o. _ days 1-21~Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12"
391033|NCT01208753|Drug|GLPG0555|two different aqueous formulations
391034|NCT01208753|Drug|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
391035|NCT01208753|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
391036|NCT01208740|Drug|Metformin|500 mg three times daily
391037|NCT01208740|Drug|Placebo|1 pill three times daily
391038|NCT01208727|Procedure|postconditioning|Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.
391039|NCT01208714|Drug|Optimal medical therapy|"Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.~All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c < 6.5%)."
391040|NCT01208714|Procedure|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
391041|NCT01208701|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
391042|NCT01208701|Drug|Unikalk|1 tablet Unikalk pr day for 5 days
391043|NCT01208688|Device|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
391044|NCT01208688|Device|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
391079|NCT01208402|Drug|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
391080|NCT01208389|Biological|voretigene neparvovec-rzyl|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector in 300 microliters to the contralateral, previously uninjected eye.
391081|NCT01208376|Other|Fibroscan|Fibroscan and Serum Fibrose-marker
391045|NCT01208688|Other|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
391046|NCT01208662|Drug|Lenalidomide|"Oral, 25 mg/day, days 1-14 for 8 total cycles for Arm A. Oral, 25 mg/day, days 1-14 for 5 total cycles for Arm B.~Oral, 10-15 mg/day, daily for 12 months in maintenance for Arm A and Arm B."
391047|NCT01208662|Drug|Bortezomib|IV, days 1, 4, 8 and 11 for 8 total cycles for Arm A. IV, days 1, 4, 8 and 11 for 5 total cycles for Arm B.
391048|NCT01208662|Drug|Dexamethasone|"Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 8 total cycles for Arm A. Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 5 total cycles for Arm B.~Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
391049|NCT01208662|Procedure|Autologous Stem Cell Transplant|Stem cell transplant
391050|NCT01208649|Drug|Exenatide|Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
391051|NCT01208584|Other|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
391052|NCT01208571|Other|"Booster session"|Motivational interview
391053|NCT01208558|Behavioral|Diet A|"Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.~Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day."
391054|NCT01208558|Behavioral|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
391055|NCT01208558|Behavioral|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
391056|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
391057|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
391058|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
391059|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
391060|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
391061|NCT01208506|Drug|placebo|A single dose of NNC0114-0000-0005 placebo.
391062|NCT01208493|Other|preterm infant formula with high protein levels|minimum 3 weeks feeding until hospital discharge
391063|NCT01208493|Other|preterm standard infant formula|minimum 3 weeks feeding until hospital discharge
391064|NCT01208480|Drug|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
391065|NCT01208467|Other|Laboratory Biomarker Analysis|Correlative studies
391066|NCT01208454|Drug|Isotretinoin|Given PO
391067|NCT01208454|Other|Laboratory Biomarker Analysis|Correlative studies
391068|NCT01208454|Other|Pharmacological Study|Correlative studies
391069|NCT01208454|Drug|Vorinostat|Given PO
391070|NCT01208441|Drug|letrozole|
391071|NCT01208441|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
391072|NCT01208441|Procedure|therapeutic conventional surgery|
391073|NCT01208441|Procedure|breast biopsy|
391074|NCT01208441|Other|diagnostic laboratory biomarker analysis|
391075|NCT01208441|Other|pharmacological study|
391076|NCT01208428|Behavioral|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
391077|NCT01208428|Behavioral|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
391078|NCT01208415|Device|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
391215|NCT01207440|Drug|Ponatinib|45 mg dose taken orally once daily
391216|NCT01207427|Drug|Placebo|
391082|NCT01208363|Dietary Supplement|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
391083|NCT01208350|Behavioral|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
391084|NCT01208350|Behavioral|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
391085|NCT01208350|Behavioral|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
391086|NCT01208337|Drug|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
391087|NCT01208324|Drug|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
391088|NCT01208324|Drug|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
391089|NCT01208324|Drug|Placebo Patch|placebo
391090|NCT01208324|Drug|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
391091|NCT01208298|Device|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
391092|NCT01208285|Drug|VX-770|150 mg oral tablet
391093|NCT01208272|Behavioral|Cognitive Behavioral Therapy (CBT)|
391094|NCT01208272|Behavioral|Interpersonal Therapy (IPT)|
391095|NCT01208259|Behavioral|Cognitive Behavioral Therapy (CBT)|
391096|NCT01208259|Behavioral|Interpersonal Therapy (IPT)|
391097|NCT01208233|Drug|PF-03049423|1 mg of PF-03049423 daily for 90 days
391098|NCT01208233|Drug|PF-03049423|3 mg of PF-03049423 daily for 90 days
391099|NCT01208233|Drug|PF-03049423|6 mg of PF-03049423 daily for 90 days
391100|NCT01208233|Other|Placebo|Placebo of PF-03049423 daily for 90 days
391101|NCT01208220|Device|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
391102|NCT01208220|Biological|Collagenase Ointment|Apply TIW
391103|NCT01208207|Drug|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
391104|NCT01208207|Drug|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
391105|NCT01208207|Drug|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
391106|NCT01208207|Drug|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
391107|NCT01208207|Drug|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
391108|NCT01208207|Drug|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
391109|NCT01208207|Drug|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
391110|NCT01208207|Drug|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
391111|NCT01208207|Drug|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
391112|NCT01208207|Drug|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
391113|NCT01208207|Drug|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
391114|NCT01208207|Drug|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
391115|NCT01208194|Drug|MGN1703|solution, 60 mg, twice a week, until progression
391116|NCT01208194|Drug|Placebo|solution, 60 mg, twice a week, until progression
391117|NCT01208181|Drug|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
391118|NCT01208181|Drug|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
391119|NCT01208181|Drug|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
391120|NCT01208181|Drug|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
391121|NCT01208168|Drug|NAB001|nail lacquer, once daily, 52 weeks
391122|NCT01208168|Drug|Vehicle alone|nail lacquer, once daily, 52 weeks
391123|NCT01208155|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
391124|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
391125|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
391126|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
391127|NCT01208142|Other|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
391128|NCT01208142|Device|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
391129|NCT01208129|Drug|NAB001|nail lacquer, once daily, 52 weeks
391130|NCT01208129|Drug|Placebo control|nail lacquer, once daily, 52 weeks
391131|NCT01208116|Other|Cardiovascular events|"Coronary intervention~Infarction~Congestive heart failure~Stroke~Cardiac death"
391132|NCT01208103|Biological|Bevacizumab|Given IV
391133|NCT01208103|Drug|Capecitabine|Given PO
391134|NCT01208103|Drug|Oxaliplatin|Given CVC
391135|NCT01208090|Drug|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
391136|NCT01208090|Drug|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
391137|NCT01208064|Drug|pazopanib hydrochloride|
391138|NCT01208064|Other|laboratory biomarker analysis|
391139|NCT01208064|Other|pharmacogenomic studies|
391140|NCT01208064|Other|pharmacological study|
391141|NCT01208064|Procedure|quality-of-life assessment|
391142|NCT01208051|Drug|Cediranib|Given PO
391143|NCT01208051|Drug|Cediranib Maleate|Given PO
391144|NCT01208051|Other|Laboratory Biomarker Analysis|Correlative studies
391145|NCT01208051|Drug|Lenalidomide|Given PO
391146|NCT01208038|Drug|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
391147|NCT01208025|Other|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
391148|NCT01208012|Drug|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
391149|NCT01207999|Procedure|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
391150|NCT01207999|Other|Data collection|Questionnaire completion
391151|NCT01207986|Radiation|Low dose computed tomography (CT)|
391152|NCT01207973|Drug|BI 113823|5 dose-groups of multiple oral doses of BI 113823
391153|NCT01207960|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
391154|NCT01207947|Drug|Vardenafil (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
391155|NCT01207934|Dietary Supplement|placebo|saline placebo
391156|NCT01207934|Drug|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
391157|NCT01207934|Drug|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
391158|NCT01207921|Drug|Lenalidomide|
391159|NCT01207908|Drug|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
391160|NCT01207908|Other|Standard steroid treatment|Will complete all study related procedures and evaluations
391161|NCT01207895|Device|PET imaging with [18F]-FLT|Up to three [18F]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
391162|NCT01207895|Drug|[18F]-fluorodeoxythymidine|[18F]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
391163|NCT01207869|Biological|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
391164|NCT01207869|Other|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
391165|NCT01207856|Behavioral|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
391166|NCT01207856|Behavioral|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
391167|NCT01207856|Other|no intervention|no intervention
391168|NCT01207843|Behavioral|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
391169|NCT01207830|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
391170|NCT01207817|Other|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
391171|NCT01207804|Device|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
391172|NCT01207791|Behavioral|screening|Brief screening to assess eligibility and collect minimal baseline data
391173|NCT01207791|Behavioral|assessment|comprehensive substance use assessment
391174|NCT01207791|Behavioral|referral|referral to treatment if indicated or requested
391175|NCT01207791|Behavioral|Brief intervention|30-minute brief intervention session in ED
391176|NCT01207791|Behavioral|booster sessions|two 15-minute booster counseling sessions conducted by telephone
391177|NCT01207765|Drug|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
391217|NCT01207427|Drug|ADL5945 0.1 mg|
391218|NCT01207427|Drug|ADL5945 0.25 mg|
391178|NCT01207765|Drug|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
391179|NCT01207752|Drug|Systane Balance|Artificial tear emulsion drop
391180|NCT01207752|Drug|Optive Lubricant Eye Drops|Artificial tear eye drop
391181|NCT01207739|Drug|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
391182|NCT01207739|Drug|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
391183|NCT01207739|Drug|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
391184|NCT01207726|Drug|Azacitidine|Given SC
391185|NCT01207726|Drug|Entinostat|Given PO
391186|NCT01207726|Other|Laboratory Biomarker Analysis|Correlative studies
391187|NCT01207700|Behavioral|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
391188|NCT01207687|Biological|bevacizumab|Given IV
391189|NCT01207687|Other|laboratory biomarker analysis|Correlative studies
391190|NCT01207687|Procedure|quality-of-life assessment|Ancillary studies
391191|NCT01207674|Other|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
391192|NCT01207661|Biological|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
391193|NCT01207648|Drug|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
391194|NCT01207635|Procedure|Ductal Lavage Fluid Collection|Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
391195|NCT01207622|Drug|Atomoxetine|
391196|NCT01207622|Drug|Placebo|
391197|NCT01207609|Procedure|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
391198|NCT01207596|Drug|Hydromorphone|Oral hydromorphone extended release, once daily
391199|NCT01207583|Other|Non-interventional observational study|Non-interventional observational study
391200|NCT01207570|Procedure|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
391201|NCT01207570|Procedure|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
391202|NCT01207557|Behavioral|Standard Education Only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
391203|NCT01207557|Behavioral|Standard Education Plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
391204|NCT01207544|Behavioral|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
391205|NCT01207544|Behavioral|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
391206|NCT01207518|Behavioral|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
391207|NCT01207518|Behavioral|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
391208|NCT01207505|Behavioral|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
391209|NCT01207492|Drug|nilotinib|Taken orally twice daily
391210|NCT01207479|Device|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
391211|NCT01207466|Device|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
391212|NCT01207466|Device|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
391213|NCT01207453|Drug|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
391214|NCT01207453|Drug|Placebo|
391219|NCT01207414|Drug|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
391220|NCT01207401|Drug|Lidocaine|1% Lidocaine
391221|NCT01207388|Drug|Blinatumomab|Continuous intravenous infusion
391222|NCT01207375|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
391223|NCT01207375|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
391224|NCT01207349|Behavioral|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
391225|NCT01207349|Behavioral|standard follow up|
391226|NCT01207336|Device|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
391227|NCT01207323|Drug|MEHD7945A|MEHD7945A will be administered as specified in the individual arms.
391228|NCT01207310|Behavioral|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
391229|NCT01207310|Drug|Nicotine patch|8 weeks' worth of nicotine patches
391230|NCT01207310|Device|alphanumeric pager|therapeutic messages to be delivered for three months
391231|NCT01207297|Drug|Tacrolimus|"The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).~20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration."
391232|NCT01207297|Drug|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
391233|NCT01207284|Other|Physical Therapy|strengthening passive and active stretching balance training gait training
391234|NCT01207271|Behavioral|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
391235|NCT01207271|Behavioral|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
391236|NCT01207258|Behavioral|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
391237|NCT01207245|Other|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
391238|NCT01207232|Behavioral|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
391239|NCT01207232|Behavioral|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
391240|NCT01207219|Behavioral|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
391241|NCT01207219|Behavioral|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
391242|NCT01207206|Drug|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).~The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
391243|NCT01207193|Biological|cell injection|injection of mesenchymal cells to bone cyst defect
391244|NCT01207180|Other|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
391245|NCT01207180|Other|Satisfaction survey|Patients will be given a satisfaction survey.
391246|NCT01207180|Other|Control group --- no intervention|Control group
391247|NCT01207128|Drug|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
391248|NCT01207115|Drug|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
391249|NCT01207115|Drug|Placebo|Placebo capsules - twice daily for 8 weeks
391250|NCT01207115|Drug|Naproxen|Naproxen capsules - twice daily for 8 weeks
391251|NCT01207102|Drug|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
391252|NCT01207102|Drug|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
391253|NCT01207089|Drug|AZD8329|AZD8329 Oral Solution 20mg/ml
391254|NCT01207089|Drug|Placebo|Placebo AZD8329 Oral Solution
391255|NCT01207076|Biological|90Y-AHN-12|"The intervention consists of two parts.~The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.~Dose escalation of nonradiolabeled AHN-12:~Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg~Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.~the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
391256|NCT01207063|Other|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
391257|NCT01207050|Drug|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
391258|NCT01207050|Dietary Supplement|Placebo|Control treatment
391259|NCT01207037|Procedure|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
391260|NCT01207024|Other|knee MRI|knee MRI before surgery (inclusion) and one year after
392856|NCT01194635|Genetic|gene expression analysis|
391261|NCT01207011|Drug|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
391262|NCT01207011|Drug|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
391263|NCT01206998|Drug|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
391264|NCT01206998|Drug|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
391265|NCT01206985|Other|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
391266|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
391267|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
391268|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
391269|NCT01206972|Drug|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
391270|NCT01206946|Drug|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
391271|NCT01206946|Other|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
391272|NCT01206907|Drug|oxymorphone IR|oxymorphone IR liquid
391273|NCT01206894|Procedure|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
391274|NCT01206881|Drug|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
391275|NCT01206868|Procedure|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
391276|NCT01206868|Procedure|Control|Standard kidney transplantation
391277|NCT01206855|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
391278|NCT01206855|Other|Standard Postoperative Incision Care|Incision cleansing, topical creams, and dressing as needed
391279|NCT01206842|Other|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
391280|NCT01206829|Behavioral|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
391281|NCT01206829|Behavioral|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
391282|NCT01206816|Drug|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
391283|NCT01206803|Drug|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg & daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
391284|NCT01206790|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
391285|NCT01206777|Drug|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
391286|NCT01206764|Drug|RAD001|
391287|NCT01206751|Other|Chest imaging technique and case presentation|
391288|NCT01206738|Behavioral|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
391289|NCT01206738|Behavioral|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
391290|NCT01206738|Behavioral|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
391291|NCT01206725|Other|Exercise|"Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
391292|NCT01206699|Drug|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
391293|NCT01206699|Drug|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
391294|NCT01206686|Behavioral|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
391295|NCT01206686|Behavioral|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
391296|NCT01206686|Behavioral|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
391297|NCT01206673|Other|Blood sampling|One blood sampling is required for the research
391298|NCT01206660|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
391299|NCT01206660|Drug|placebo|Placebo administered to affected area twice a day for 28 days
391300|NCT01206647|Drug|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
391301|NCT01206634|Procedure|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
391302|NCT01206634|Behavioral|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
392857|NCT01194635|Genetic|polymerase chain reaction|
391303|NCT01206608|Drug|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
391304|NCT01206608|Drug|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
391305|NCT01206595|Drug|SKY0402|Single dose of SKY0402 administered as a nerve block
391306|NCT01206595|Drug|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
391307|NCT01206582|Biological|Hemin|10 iv infusions for 8 weeks
391308|NCT01206582|Biological|Albumin|10 iv infusions for 8 weeks
391309|NCT01206569|Drug|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
391310|NCT01206543|Other|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
391311|NCT01206530|Drug|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
391312|NCT01206530|Drug|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
391313|NCT01206530|Drug|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
391314|NCT01206530|Drug|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
391315|NCT01206530|Drug|5-fluorouracil|"Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.~Treatment Administration: Days 1-2"
391316|NCT01206530|Drug|Bevacizumab|
391317|NCT01206517|Drug|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
391318|NCT01206517|Drug|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
391319|NCT01206517|Drug|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
391320|NCT01206504|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
391321|NCT01206478|Drug|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
391322|NCT01206478|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
391323|NCT01206478|Drug|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
391324|NCT01206465|Drug|pralatrexate|Given IV
391325|NCT01206465|Drug|fluorouracil|Given IV
391326|NCT01206465|Other|laboratory biomarker analysis|Correlative studies
391327|NCT01206465|Genetic|DNA analysis|Correlative studies
391328|NCT01206465|Other|high performance liquid chromatography|Correlative studies
391329|NCT01206465|Genetic|polymerase chain reaction|Correlative studies
391330|NCT01206465|Genetic|nucleic acid sequencing|Correlative studies
391331|NCT01206465|Other|pharmacological study|Correlative studies
391332|NCT01206465|Other|pharmacogenomic studies|Correlative studies
391333|NCT01206465|Genetic|polymorphism analysis|Correlative studies
391334|NCT01206452|Drug|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
391335|NCT01206452|Other|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
391336|NCT01206452|Procedure|Ablation Procedure|Atrial Fibrillation (AF) ablation
391337|NCT01206439|Drug|nebivolol|nebivolol 5 or 10 mg oral, daily
391338|NCT01206413|Dietary Supplement|Low glycemic index diet|
391339|NCT01206413|Dietary Supplement|High glycemic index diet|
391340|NCT01206413|Other|Home-based exercise intervention|
391341|NCT01206413|Other|Non-exercisers|
391342|NCT01206387|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
391343|NCT01206387|Drug|placebo comparator|Placebo administered to affected area twice a day for 28 days
391344|NCT01206361|Drug|XALACOM|Xalacom eye drops
391345|NCT01206361|Drug|Duotrav|Duotrav eye drops
391346|NCT01206361|Drug|Ganfort|Ganfort eye drops
391347|NCT01206348|Drug|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
391348|NCT01206335|Drug|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
391349|NCT01206322|Drug|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
391350|NCT01206322|Drug|Placebo|The acute effects of intranasal sterile saline.
391351|NCT01206296|Drug|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2~Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
391352|NCT01206283|Procedure|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:~Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);~Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;~Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;~Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.~Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
391353|NCT01206283|Procedure|Cerebral perfusion pressure-targeted therapy|"ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);~Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);~No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;~Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes [Na, Cl and K]);"
391354|NCT01206270|Drug|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
391355|NCT01206270|Drug|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
391356|NCT01206257|Drug|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
391357|NCT01206218|Drug|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
391358|NCT01206218|Drug|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
391359|NCT01206205|Drug|Lenalidomide, Bortezomib|"Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
391360|NCT01206179|Biological|cell injection|Injection of mesenchymal cells in fractured zone
391361|NCT01206166|Drug|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
391362|NCT01206153|Drug|metformin|
391363|NCT01206140|Other|Laboratory Biomarker Analysis|Correlative studies
391364|NCT01206140|Drug|Selumetinib|Given PO
391365|NCT01206140|Drug|Temsirolimus|Given IV
391366|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
391367|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
391368|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
391369|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
391370|NCT01206101|Drug|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
391371|NCT01206101|Drug|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
391372|NCT01206088|Drug|nilotinib|administration of nilotinib as 2nd line
391373|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
391374|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
391375|NCT01206075|Drug|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
391376|NCT01206062|Drug|Intensive control of SBP|"Participants in the Intensive arm have a goal of SBP <120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:~Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics~Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies."
391377|NCT01206062|Drug|Standard control of SBP|Participants in the Standard BP arm have a goal of SBP <140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
391378|NCT01206049|Drug|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
391379|NCT01206049|Drug|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
391380|NCT01206049|Drug|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
391381|NCT01206049|Drug|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
391382|NCT01206049|Drug|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
391383|NCT01206036|Drug|Docetaxel|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
391384|NCT01206036|Drug|Temsirolimus|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
391385|NCT01206023|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
391421|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
391422|NCT01205828|Drug|Temozolomide|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
391386|NCT01206010|Drug|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
391387|NCT01206010|Drug|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
391388|NCT01206010|Drug|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
391389|NCT01205997|Drug|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
391390|NCT01205997|Drug|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
391391|NCT01205997|Drug|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
391392|NCT01205984|Drug|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
391393|NCT01205971|Behavioral|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
391394|NCT01205971|Behavioral|Dental Preventive Services|Written oral health educational materials
391395|NCT01205958|Procedure|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
391396|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
391397|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
391398|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
391399|NCT01205932|Drug|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
391400|NCT01205919|Behavioral|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
391401|NCT01205919|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
391402|NCT01205906|Behavioral|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
391403|NCT01205906|Behavioral|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
391404|NCT01205906|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
391405|NCT01205893|Device|Neovasc Reducer|Implantation of the Reducer
391406|NCT01205893|Device|Control|Control - No device implanted
391407|NCT01205880|Drug|Calcitriol ointment|twice daily
391408|NCT01205880|Drug|Clobetasol spray|twice daily
391409|NCT01205867|Drug|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
391410|NCT01205854|Device|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
391411|NCT01205841|Procedure|Ottawa Ankle and Foot Rules|As previously published
391412|NCT01205841|Procedure|Buffalo Rule|As previously published
391413|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
391414|NCT01205841|Procedure|Thompson Test|As previously published
391415|NCT01205841|Procedure|Palpation of the fibula|Palpation of the fibula over its entire length.
391416|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
391417|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
391418|NCT01205841|Procedure|Malleolar Zone Algorithm|As previously published
391419|NCT01205841|Procedure|Low Risk Exam|As previously published
391420|NCT01205841|Procedure|Bernese Ankle Rules|As previously published
391423|NCT01205828|Drug|ABT-888|ABT-888 40 mg BID PO Days 1-7 every 28 days
391424|NCT01205815|Other|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
391425|NCT01205802|Procedure|MHV reconstruction|MHV reconstruction with PTFE or homograft
391426|NCT01205776|Device|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
391427|NCT01205776|Procedure|CABG|Those patients receiving CABG
391428|NCT01205750|Other|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
391429|NCT01205737|Biological|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
391430|NCT01205737|Biological|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
391431|NCT01205724|Drug|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
391432|NCT01205724|Drug|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
391433|NCT01205724|Drug|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
391434|NCT01205711|Drug|FOLFIRI regimen|
391435|NCT01205711|Drug|fluorouracil|
391436|NCT01205711|Drug|irinotecan hydrochloride|
391437|NCT01205711|Drug|leucovorin calcium|
391438|NCT01205711|Drug|zibotentan|
391439|NCT01205711|Other|laboratory biomarker analysis|
391440|NCT01205711|Other|pharmacogenomic studies|
391441|NCT01205698|Other|Nutritional drink|
391442|NCT01205685|Drug|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)~During the safety run portion of the study~Dose level 2 = 150 mg twice a day~Dose level 1 = 100 mg twice a day~Dose level -1 = 100 mg twice a day~Dose level -2 = 100 mg twice a day"
391443|NCT01205685|Drug|Erlotinib|"During the safety run phase of the study:~Dose Level 2 = 100 mg/d~Dose Level 1 = 100 mg/d~Dose Level -1= 75 mg/d~Dose Level -2 = 50 mg/d"
391444|NCT01205685|Drug|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
391445|NCT01205685|Drug|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
391446|NCT01205672|Drug|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
391447|NCT01205646|Drug|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
391448|NCT01205646|Device|PET Scan|2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
391449|NCT01205633|Procedure|venous angioplasty|catheter venous angioplasty via femoral vein approach
391450|NCT01205620|Device|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
391451|NCT01205620|Other|No intervention|No intervention will be performed in the control group
391452|NCT01205607|Device|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
391453|NCT01205607|Device|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
391454|NCT01205594|Device|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
391455|NCT01205581|Biological|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
391456|NCT01205581|Biological|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
391457|NCT01205568|Device|Transcatheter Cutting Balloon therapy|
391458|NCT01205568|Procedure|High Pressure Balloon Angioplasty|
391459|NCT01205555|Device|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :~13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.~If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (<8 IU\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\L) the insemination will be the next day."
391460|NCT01205542|Behavioral|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
391461|NCT01205542|Behavioral|Reference|Health check and advice to continue ordinary physical activity
391462|NCT01205529|Drug|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
391463|NCT01205516|Drug|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
391464|NCT01205516|Drug|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
391465|NCT01205503|Drug|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
391466|NCT01205503|Drug|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
391467|NCT01205503|Drug|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
391468|NCT01205503|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
391595|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
391469|NCT01205490|Other|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
391470|NCT01205477|Drug|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
391471|NCT01205477|Drug|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
391472|NCT01205464|Drug|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
391473|NCT01205464|Drug|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
391474|NCT01205451|Drug|Botulinum toxin type A|Botulinum toxin type A
391475|NCT01205438|Drug|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
391476|NCT01205438|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
391477|NCT01205438|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
391478|NCT01205425|Other|PCI on the basis of coronary angiography|Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
391479|NCT01205425|Procedure|CT guided PCI|The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
391480|NCT01205412|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
391481|NCT01205386|Device|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
391482|NCT01205373|Drug|BI 671800|High dose oral drinking solution
391483|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
391484|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
391485|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
391486|NCT01205347|Drug|Simvastatin 80mg|Simvastatin 80mg once a day
391487|NCT01205347|Drug|Simvastatin 10mg|Simvastatin 10mg once a day
391488|NCT01205334|Biological|Autologous CMV-specific CTL|"CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.~At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion."
391489|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
391490|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
391491|NCT01205308|Dietary Supplement|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
391492|NCT01205295|Other|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
391493|NCT01205282|Drug|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
391494|NCT01205282|Drug|Placebo|There will be a 2 week period of placebo run-in.
391495|NCT01205269|Drug|AZD8683, 50 mcg|Dry powder for inhalation, single dose
391496|NCT01205269|Drug|Placebo|Dry powder for inhalation, single dose
391497|NCT01205269|Drug|AZD8683, 200 mcg|Dry powder for inhalation, single dose
391498|NCT01205256|Drug|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
391499|NCT01205243|Drug|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
391500|NCT01205230|Drug|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
391501|NCT01205217|Drug|Lapatinib|Lapatinib 1000 mg orally once daily continuously
391502|NCT01205217|Drug|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
391503|NCT01205217|Drug|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
391504|NCT01205217|Drug|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
391505|NCT01205217|Drug|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
391596|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
391506|NCT01205204|Drug|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
391507|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
391508|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
391509|NCT01205204|Drug|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
391510|NCT01205191|Behavioral|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
391511|NCT01205191|Behavioral|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
391512|NCT01205191|Behavioral|CBT|CBT for anxiety disorders
391513|NCT01205178|Drug|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
391514|NCT01205178|Drug|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
391515|NCT01205178|Drug|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
391516|NCT01205165|Drug|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
391517|NCT01205152|Biological|asfotase alfa|
391518|NCT01205139|Drug|TMC435|150 mg capsule once daily for 7 days
391519|NCT01205139|Drug|TDF|300 mg tablet once daily for 7 days
391520|NCT01205139|Drug|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
391521|NCT01205139|Drug|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
391522|NCT01205139|Drug|TMC278|25 mg tablet once daily for 11 days
391523|NCT01205139|Drug|TMC435|150 mg capsule once daily for 11 days
391524|NCT01205126|Drug|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
391525|NCT01205126|Drug|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
391526|NCT01205126|Drug|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
391527|NCT01205100|Behavioral|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
391528|NCT01205100|Drug|Placebo|
391529|NCT01205087|Drug|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
391530|NCT01205074|Device|13C Methacetin Breath Test|
391531|NCT01205074|Dietary Supplement|Grape fruit juice|
391532|NCT01205074|Drug|Non selective beta blocker - Propranolol|
391533|NCT01205074|Dietary Supplement|Ethanol|
391534|NCT01205061|Device|Emervel Deep Lidocaine|20 mg/ml + 0.3% lidocaine
391535|NCT01205061|Device|Juvederm® Ultra Plus|24 mg/ml
391536|NCT01205048|Device|Emervel Classic Lidocaine|20 mg/ml + 0.3% lidocaine
391537|NCT01205048|Device|Juvederm® Ultra|24mg/ml
391538|NCT01205035|Drug|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
391539|NCT01205022|Drug|irinotecan hydrochloride|Given IV
391540|NCT01205022|Drug|leucovorin calcium|Given IV
391541|NCT01205022|Drug|fluorouracil|Given IV
391542|NCT01205022|Biological|bevacizumab|Given IV
391543|NCT01205022|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
391544|NCT01205022|Other|laboratory biomarker analysis|Correlative studies
391545|NCT01205009|Drug|Ovitrelle|One dose of Ovitrelle 250 mcg
391546|NCT01204996|Drug|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
391547|NCT01204996|Drug|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
391548|NCT01204996|Drug|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
391549|NCT01204996|Drug|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
391550|NCT01204957|Dietary Supplement|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
391551|NCT01204957|Dietary Supplement|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
391552|NCT01204918|Drug|Riluzole|Riluzole 100mg PO
391553|NCT01204918|Drug|placebo|placebo
391554|NCT01204905|Drug|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, ~12 hours (10 to 14 hours) apart~Maraviroc 300 mg tablet twice a day, ~12 hours (10 to 14 hours) apart"
391555|NCT01204892|Procedure|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
391556|NCT01204892|Procedure|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
391557|NCT01204879|Behavioral|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
391597|NCT01204658|Biological|Synflorix|Intramuscular injection
391598|NCT01204658|Biological|Prevenar 13|Intramuscular injection
392858|NCT01194635|Genetic|protein analysis|
391558|NCT01204866|Biological|Valortim and selected Components|"Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.~Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.~Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1~Histamine (1 mg/mL), positive control~Saline (0.9%), negative control"
391559|NCT01204866|Drug|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.~Only one subject will be skin tested in a single day.~The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
391560|NCT01204853|Drug|Sitaxentan|sitaxentan sodium 100 mg
391561|NCT01204840|Drug|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
391562|NCT01204840|Drug|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
391563|NCT01204827|Device|13C Methacetin Breath Test (BreathID)|
391564|NCT01204801|Device|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
391565|NCT01204801|Drug|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
391566|NCT01204788|Procedure|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
391567|NCT01204788|Procedure|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
391568|NCT01204775|Drug|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
391569|NCT01204775|Drug|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
391570|NCT01204775|Drug|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
391571|NCT01204775|Drug|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
391572|NCT01204775|Drug|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
391573|NCT01204762|Drug|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
391574|NCT01204762|Drug|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
391575|NCT01204762|Drug|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
391576|NCT01204762|Drug|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
391577|NCT01204749|Drug|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
391578|NCT01204749|Drug|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
391579|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
391580|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
391581|NCT01204723|Drug|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
391582|NCT01204723|Drug|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
391583|NCT01204710|Biological|Olaratumab|15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
391584|NCT01204710|Drug|Mitoxantrone|"Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)"
391585|NCT01204710|Drug|Prednisone|5 mg orally (PO) twice daily (BID) on each day
391586|NCT01204697|Drug|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
391587|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
391588|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally as monotherapy
391589|NCT01204684|Biological|autologous tumor lysate-pulsed DC vaccination|
391590|NCT01204684|Biological|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
391591|NCT01204684|Biological|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
391592|NCT01204671|Biological|Influenza vaccine GSK2321138A|One intramuscular injection
391593|NCT01204671|Biological|FluarixTM|One intramuscular injection
391594|NCT01204671|Biological|Influenza vaccine GSK2604409A|One intramuscular injection
392859|NCT01194635|Genetic|protein expression analysis|
391599|NCT01204658|Biological|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
391600|NCT01204619|Behavioral|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
391601|NCT01204606|Procedure|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4 or 5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repaired of rotator cuff tear was done with suture anchors.~Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound.~Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
391602|NCT01204606|Procedure|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~The surgical area was prepared and draped with Betadine.~Small stab incisions were made in the creation of 4 or 5 portals as needed.~A scope was explored via the arthroscopic portal into the GH joint & subacromial space.~Repaired of rotator cuff tear was done with suture anchors.~43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~The skin was closed with Nylon or medical staples.~Sterile dressing was applied on surgical wound.~Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
391603|NCT01204593|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
391604|NCT01204593|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
391605|NCT01204580|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
391606|NCT01204567|Other|Aerobic training|Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
391607|NCT01204554|Drug|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
391608|NCT01204528|Drug|Zemplar|Vitamin D receptor activator (VDRA)
391609|NCT01204502|Biological|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD~dose 1 5x104 cells/kg~dose 2 5x105 cells/kg"
391610|NCT01204489|Behavioral|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
391611|NCT01204476|Biological|Cixutumumab|Given IV
391612|NCT01204476|Drug|Everolimus|Given PO
391613|NCT01204476|Other|Laboratory Biomarker Analysis|Correlative studies
391614|NCT01204476|Drug|Octreotide Acetate|Given IM
391615|NCT01204476|Other|Pharmacological Study|Correlative studies
391616|NCT01204450|Drug|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
391617|NCT01204450|Drug|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
391618|NCT01204437|Drug|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
391619|NCT01204437|Drug|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
391620|NCT01204437|Drug|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
391621|NCT01204424|Device|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
391622|NCT01204424|Device|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.~The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
391623|NCT01204411|Drug|Artesunate-amodiaquine fixed-dose combination|"artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;~artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;~artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;"
391624|NCT01204398|Drug|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
391625|NCT01204385|Procedure|Sample collection|Middle ear fluid and urine
391841|NCT01202656|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
391842|NCT01202656|Drug|Saline|intrauterine saline infusion 1 cc
391626|NCT01204372|Drug|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.~Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.~Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.~Erlotinib: oral route 100 mg/day from C1D1."
391627|NCT01204359|Radiation|Iodine 131|iodine 131，185、370、555mBq，6 months
391628|NCT01204346|Other|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
391629|NCT01204346|Other|treatment as usual|less intensive and structured psychotherapeutic program
391630|NCT01204333|Drug|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
391631|NCT01204333|Drug|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
391632|NCT01204320|Procedure|Paclitaxel-coated Balloon|POBA
391633|NCT01204320|Device|Paclitaxel-eluting Stent|Stenting
391634|NCT01204307|Drug|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
391635|NCT01204307|Drug|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
391636|NCT01204294|Drug|Linagliptin|Linagliptin once daily
391637|NCT01204294|Drug|Linagliptin|Linagliptin once daily
391638|NCT01204294|Drug|Metformin|Metformin twice or three time per day
391639|NCT01204294|Drug|Metformin|Metformin twice or three time per day
391640|NCT01204294|Drug|Linagliptin|Linagliptin once daily
391641|NCT01204294|Drug|Linagliptin|Linagliptin once daily
391642|NCT01204294|Drug|Linagliptin|Linagliptin once daily
391643|NCT01204281|Other|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
391644|NCT01204268|Procedure|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
391645|NCT01204268|Procedure|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
391646|NCT01204255|Drug|lorazepam|Given topically
391647|NCT01204255|Drug|diphenhydramine hydrochloride|Given topically
391648|NCT01204255|Drug|haloperidol|Given topically
391649|NCT01204255|Other|questionnaire administration|Ancillary studies
391650|NCT01204255|Other|laboratory biomarker analysis|Correlative studies
391651|NCT01204242|Drug|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
391652|NCT01204242|Drug|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.~Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
391653|NCT01204229|Behavioral|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
391654|NCT01204229|Behavioral|Brief Motivational Intervention (BMI)|Integrate drinking intervention
391655|NCT01204216|Biological|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
391656|NCT01204216|Biological|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.~These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.~small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
391657|NCT01204216|Behavioral|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
391658|NCT01204203|Drug|Zometa|Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
391659|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
391660|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
391661|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
391662|NCT01204177|Drug|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
391663|NCT01204164|Drug|TG02 citrate|TG02 citrate capsules given orally.
391664|NCT01204164|Drug|Carfilzomib|Carfilzomib per PI
391665|NCT01204164|Drug|Dexamethasone|Dexamethasone (Oral or IV)
391666|NCT01204151|Behavioral|discrete-trial training|
391667|NCT01204138|Drug|Apremilast|Apremilast 30mg BID
391668|NCT01204138|Drug|Placebo|Placebo BID
391669|NCT01204125|Drug|paclitaxel|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
391670|NCT01204125|Drug|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion~Route of administration :Intravenous"
391671|NCT01204112|Drug|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
391672|NCT01204099|Drug|Docetaxel|
391673|NCT01204099|Drug|PX-866|
391674|NCT01204086|Drug|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
391675|NCT01204086|Drug|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
391676|NCT01204073|Drug|TAK-441|"TAK-441 will be administered as an oral tablet as follows:~Patients enrolled in the dose escalation cohorts will receive:~A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed~Continuous daily dosing on Days 8 through 28 in Cycle 1~In subsequent cycles, continuous daily dosing over 21 days, repeated continuously~Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
391677|NCT01204060|Other|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
391678|NCT01204060|Other|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
391679|NCT01204034|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
391680|NCT01204021|Behavioral|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
391681|NCT01204021|Behavioral|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
391682|NCT01204008|Procedure|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
391683|NCT01204008|Procedure|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
391684|NCT01203995|Behavioral|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
391685|NCT01203995|Behavioral|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
391686|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 5mg/day for one year
391687|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 40mg/day for one year
391688|NCT01203969|Procedure|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
391689|NCT01203969|Procedure|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
391690|NCT01203956|Device|SmartFlex|Device used with smartflex engaged.
391691|NCT01203956|Device|Standard|
391692|NCT01203943|Drug|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
391693|NCT01203943|Other|Placebo|Placebo
391694|NCT01203943|Drug|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
391695|NCT01203943|Drug|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
391696|NCT01203930|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
391697|NCT01203930|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks
391698|NCT01203917|Drug|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
391699|NCT01203878|Drug|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
391700|NCT01203878|Drug|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
391701|NCT01203852|Drug|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily~Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
391702|NCT01203852|Drug|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
391703|NCT01203839|Radiation|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
391704|NCT01203826|Biological|Asfotase Alfa|
391705|NCT01203813|Other|Electronic Decision Support|"Physicians randomized to the intervention will receive:~Electronic alerts during office visits for patients with chronic kidney disease~Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
391706|NCT01203787|Drug|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
391707|NCT01203787|Drug|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
391708|NCT01203774|Drug|Glargine insulin|20-180 units per day
391709|NCT01203748|Procedure|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
391710|NCT01203748|Procedure|PVI|Pulmonary vein antrum isolation
391711|NCT01203748|Procedure|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
391712|NCT01203735|Drug|Valproic acid|800mg per day for entire period of RT
391713|NCT01203722|Drug|Fludarabine|Fludarabine 30 mg/m2/day
391714|NCT01203722|Drug|Cytoxan|Pre-BMT: Cytoxan 14.5 mg/kg/day administered IV; Post-Transplantation: High-dose Cytoxan 50mg/kg/day
391715|NCT01203722|Radiation|Total Body Irradiation|400 cGy TBI administered in a single fraction
391716|NCT01203722|Procedure|Allogeneic Blood or Marrow Transplant|
391717|NCT01203722|Procedure|Peripheral Blood Stem Cell Transplant|
391718|NCT01203722|Drug|Mycophenolate Mofetil|15mg/kg by mouth three times daily
391719|NCT01203722|Drug|Sirolimus|Loading Dose: Sirolimus 6mg by mouth once; Maintenance dose: Sirolimus 2mg by mouth daily
391720|NCT01203722|Drug|Tacrolimus|Tacrolimus 1mg intravenously, daily
391721|NCT01203709|Drug|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
391722|NCT01203696|Drug|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
391723|NCT01203696|Drug|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
391724|NCT01203683|Behavioral|Active computer-based training|8 sessions across 4 weeks.
391725|NCT01203683|Behavioral|Inert computer training|8 sessions across 4 weeks.
391726|NCT01203670|Dietary Supplement|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
391727|NCT01203657|Behavioral|Tai Chi|Tai Chi classes, 60 minutes, 2x week
391728|NCT01203644|Drug|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
391729|NCT01203644|Drug|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
391730|NCT01203631|Drug|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
391731|NCT01203631|Drug|Placebo|A single dose administered subcutaneously (s.c., under the skin)
391732|NCT01203618|Drug|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
391733|NCT01203592|Drug|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
391734|NCT01203566|Procedure|LESS appendectomy|See under arms description
391735|NCT01203566|Procedure|Conventional 3-port laparoscopic appendectomy|See under arms description
391736|NCT01203553|Procedure|Abdominal surgery|Intraoperative mesh implantation
391737|NCT01203540|Drug|NAABAK eyedrops|
391738|NCT01203540|Drug|Saline eyedrops|
391739|NCT01203514|Drug|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
391740|NCT01203514|Other|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
391741|NCT01203488|Drug|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
391742|NCT01203488|Other|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
391743|NCT01203462|Other|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
391744|NCT01203462|Other|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
391745|NCT01203436|Procedure|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
391746|NCT01203436|Procedure|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
391747|NCT01203397|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
391748|NCT01203384|Drug|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
391749|NCT01203384|Drug|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
391750|NCT01203384|Drug|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
391751|NCT01203384|Drug|Placebo|oral tablet, placebo, once a day in the morning for 14 days
391752|NCT01203371|Drug|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
391753|NCT01203371|Drug|Tamsulosin|0,4 mg/day
391754|NCT01203358|Drug|Exosurf|Infants received up to four intratracheal doses of the surfactant.
391755|NCT01203358|Drug|Survanta|Infants received up to four intratracheal doses of the surfactant.
391756|NCT01203345|Drug|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
391757|NCT01203345|Drug|Placebo|An equal volume of 5 percent albumin solution
391758|NCT01203332|Behavioral|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
391759|NCT01203319|Biological|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
391760|NCT01203319|Biological|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
391761|NCT01203319|Biological|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
392860|NCT01194635|Other|enzyme-linked immunosorbent assay|
391762|NCT01203306|Drug|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
391763|NCT01203293|Behavioral|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
391764|NCT01203293|Behavioral|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
391765|NCT01203280|Other|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
391766|NCT01203267|Drug|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
391767|NCT01203254|Drug|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
391768|NCT01203254|Drug|Placebo|Placebo tablet: 3 times daily 2 tablets
391769|NCT01203241|Procedure|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
391770|NCT01203241|Procedure|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
391771|NCT01203228|Other|Reduced Intensity Conditioning|"Busilvex®:~6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available)~Busulfan:~8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Fludarabine:~5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
391772|NCT01203228|Other|Myeloablative conditioning|"Busilvex®:~12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)~or (if i.v.-application is not available):~Busulfan:~16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW~plus:~Cyclophosphamide:~120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
391773|NCT01203215|Behavioral|2 print based physical activity interventions|physical activity promotion
391774|NCT01203202|Drug|Clomipramine|15mg and 30mg on demand
391775|NCT01203189|Drug|ketoconazole 2% foam|Subjects in the Foam (F) group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
391776|NCT01203189|Drug|ketoconazole 2% shampoo|Subjects in the Shampoo (S) group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
391777|NCT01203176|Procedure|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
391778|NCT01203150|Other|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
391779|NCT01203124|Drug|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
391780|NCT01203124|Drug|Placebo|Placebo
391781|NCT01203111|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
391782|NCT01203111|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
391783|NCT01203098|Drug|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
391784|NCT01203098|Drug|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
391785|NCT01203098|Drug|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
391786|NCT01203072|Drug|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
391787|NCT01203072|Drug|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
391788|NCT01203072|Drug|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
391789|NCT01203072|Drug|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
391790|NCT01203072|Drug|Placebo|Matching placebo oral tablets, once daily for 2 weeks
391791|NCT01203046|Drug|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
391792|NCT01203020|Drug|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
391793|NCT01203020|Drug|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
391794|NCT01203007|Dietary Supplement|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
391795|NCT01203007|Dietary Supplement|Low antigen content diet|Low-antigen content diet for one month
391796|NCT01202994|Drug|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).~For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.~The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
391843|NCT01202643|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
391844|NCT01202643|Drug|Saline|One intrauterine saline infusions of 1 cc
391845|NCT01202630|Dietary Supplement|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
391797|NCT01202968|Procedure|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
391798|NCT01202955|Drug|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
391799|NCT01202955|Drug|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
391800|NCT01202942|Other|Quest|Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
391801|NCT01202929|Procedure|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
391802|NCT01202903|Drug|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
391803|NCT01202903|Drug|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
391804|NCT01202890|Drug|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.~Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
391805|NCT01202890|Drug|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
391806|NCT01202877|Drug|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
391807|NCT01202877|Drug|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
391808|NCT01202851|Other|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
391809|NCT01202851|Behavioral|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
391810|NCT01202851|Other|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
391811|NCT01202838|Device|Composite Implant|Subjects receiving composite implants
391812|NCT01202825|Drug|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
391813|NCT01202825|Drug|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
391814|NCT01202825|Drug|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
391815|NCT01202825|Drug|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
391816|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
391817|NCT01202825|Drug|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
391818|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
391819|NCT01202825|Drug|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
391820|NCT01202825|Drug|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
391821|NCT01202825|Drug|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
391822|NCT01202812|Dietary Supplement|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
391823|NCT01202812|Other|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
391824|NCT01202799|Drug|2% w/w diclofenac sodium topical gel|2% w/w diclofenac sodium topical gel
391825|NCT01202799|Drug|1.5% w/w diclofenac sodium topical solution|1.5% w/w diclofenac sodium topical solution
391826|NCT01202799|Drug|75 mg diclofenac sodium delayed release tablet|75 mg diclofenac sodium delayed release tablet
391827|NCT01202773|Drug|LY2127399|Administered Subcutaneously (SC)
391828|NCT01202773|Drug|Placebo Q4W|Administered SC
391829|NCT01202773|Drug|Placebo Q2W|Administered SC
391830|NCT01202760|Drug|LY2127399|
391831|NCT01202760|Drug|Placebo|
391832|NCT01202747|Device|LipiFlow System|In-office treatment for meibomian gland dysfunction
391833|NCT01202734|Drug|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
391834|NCT01202721|Drug|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
391835|NCT01202721|Drug|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
391836|NCT01202708|Device|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
391837|NCT01202708|Device|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
391838|NCT01202695|Drug|AVP-21D9|intravenously, single dose
391839|NCT01202695|Drug|Placebo|Placebo comparator
391840|NCT01202669|Other|No intervention planned, observational study only.|No intervention planned, observational study only.
391846|NCT01202630|Dietary Supplement|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
391847|NCT01202591|Drug|AZD4547|Tablet oral twice daily
391848|NCT01202591|Drug|Exemestane|Tablet oral once daily
391849|NCT01202591|Drug|Placebo|Tablet oral twice daily
391850|NCT01202591|Drug|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
391851|NCT01202578|Device|tympanostomy tube|tympanostomy tube delivery system
391852|NCT01202552|Biological|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
391853|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
391854|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
391855|NCT01202513|Drug|Bimatoprost 0.03% topical ophthalmic solution|
391856|NCT01202500|Procedure|reducing treatment to 3 months|The treatment will be stopped after 3 months
391857|NCT01202500|Procedure|registered length of treatment|The treatment procedure will follow the actual recommandation
391858|NCT01202487|Drug|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
391859|NCT01202474|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
391860|NCT01202474|Drug|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
391861|NCT01202461|Procedure|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.~IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
391862|NCT01202448|Procedure|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
391863|NCT01202435|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
391864|NCT01202435|Drug|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
391865|NCT01202422|Drug|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
391866|NCT01202422|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
391867|NCT01202422|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
391868|NCT01202409|Drug|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
391869|NCT01202383|Behavioral|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
391870|NCT01202383|Behavioral|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
391871|NCT01202370|Drug|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 & 15 of a 21 day cycle (7.5 mg/m^2).
391872|NCT01202357|Behavioral|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
391873|NCT01202344|Other|Additional x-ray images|Approximately 3 additional x-ray images following angioplasty (within 1 hour)
391874|NCT01202331|Drug|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
391875|NCT01202305|Procedure|Lymph node biopsy|Inguinal lymph node biopsy
391876|NCT01202292|Behavioral|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
391877|NCT01202279|Drug|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
391878|NCT01202279|Device|Placebo|Placebo bid for 7 days
391879|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
391880|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
391881|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
391882|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
391883|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
391884|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
391885|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
392000|NCT01201213|Drug|local anaesthetic injection|Single bolus of drug for pain relief in early labour
391886|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
391887|NCT01202253|Drug|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
391888|NCT01202240|Drug|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
391889|NCT01202227|Drug|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
391890|NCT01202214|Drug|1440115|
391891|NCT01202214|Drug|Placebo|matching placebo
391892|NCT01202201|Other|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
391893|NCT01202188|Drug|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
391894|NCT01202188|Drug|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
391895|NCT01202188|Drug|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
391896|NCT01202188|Drug|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
391897|NCT01202188|Drug|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
391898|NCT01202175|Drug|Nebivolol|Oral nebivolol 2.5-5mg once daily
391899|NCT01202162|Drug|Desflurane|Administratino of Desflurane
391900|NCT01202162|Drug|Administration of Sevoflurane|Administration of Sevoflurane
391901|NCT01202149|Device|Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)|
391902|NCT01202110|Drug|Propranolol|
391903|NCT01202097|Drug|Salmeterol/Fluticasone|
391904|NCT01202097|Drug|Seretide|
391905|NCT01202084|Drug|Formoterol/Fluticasone|
391906|NCT01202084|Drug|Foraseq®|
391907|NCT01202084|Drug|Fluticasone|
391908|NCT01202071|Drug|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
391909|NCT01202071|Drug|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
391910|NCT01202071|Drug|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
391911|NCT01202071|Drug|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.~Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.~Day 2 to Day 4: participants received a single dose with 200 mL of water, >=2 hours after the completion of breakfast."
391912|NCT01202058|Device|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol~Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
391913|NCT01202058|Device|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
391914|NCT01202032|Drug|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.~The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).~The therapy regimens for each dose level are respectively:~BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.~Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
391915|NCT01202019|Other|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
391916|NCT01202006|Other|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
391917|NCT01201967|Other|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
391918|NCT01201967|Other|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
391919|NCT01201954|Drug|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
392001|NCT01201187|Drug|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
392002|NCT01201187|Drug|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
391920|NCT01201941|Other|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
391921|NCT01201928|Drug|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
391922|NCT01201928|Drug|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
391923|NCT01201915|Drug|Vismodegib|Vismodegib was supplied in gelatin capsules.
391924|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
391925|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
391926|NCT01201902|Biological|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
391927|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
391928|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
391929|NCT01201863|Drug|Androgel (Testosterone Gel)|2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
391930|NCT01201863|Drug|Androgel Placebo|2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
391931|NCT01201850|Drug|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
391932|NCT01201837|Drug|Placebo|Weekly injection
391933|NCT01201837|Drug|CER-001|Weekly injection
391934|NCT01201824|Procedure|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
391935|NCT01201811|Drug|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
391936|NCT01201798|Drug|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
391937|NCT01201798|Drug|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
391938|NCT01201785|Drug|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
391939|NCT01201772|Drug|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
391940|NCT01201759|Drug|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
391941|NCT01201759|Drug|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
391942|NCT01201746|Procedure|Delayed treatment|Scaling, Root Planing and oral hygiene instruction
391943|NCT01201746|Procedure|Periodontal therapy|Scaling, root planning and oral hygiene instructions
391944|NCT01201733|Other|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
391945|NCT01201733|Other|Ultrasound therapy and hot pack|
391946|NCT01201720|Procedure|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
391947|NCT01201707|Procedure|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
391948|NCT01201707|Other|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
391949|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
391950|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
391951|NCT01201642|Drug|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
391952|NCT01201642|Device|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
391953|NCT01201642|Other|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
392129|NCT01200147|Procedure|Dilation|
391954|NCT01201629|Device|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
391955|NCT01201629|Device|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
391956|NCT01201616|Other|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
391957|NCT01201616|Other|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
391958|NCT01201603|Dietary Supplement|orange juice|250ml of orange juice or a sugars matched orange drink
391959|NCT01201590|Dietary Supplement|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
391960|NCT01201590|Dietary Supplement|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
391961|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536|2 capsules od
391962|NCT01201577|Dietary Supplement|Active hexose correlated compound (AHCC)|One capsule tds
391963|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
391964|NCT01201577|Dietary Supplement|Corn starch placebo capsule|One capsule tds and two capsules od
391965|NCT01201577|Drug|Azithromycin|250mg od
391966|NCT01201564|Procedure|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
391967|NCT01201564|Procedure|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
391968|NCT01201551|Drug|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
391969|NCT01201551|Drug|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
391970|NCT01201551|Drug|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
391971|NCT01201538|Drug|Nilotinib|
391972|NCT01201525|Procedure|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
391973|NCT01201525|Procedure|Control|Part 2 of the surgical scar will serve as a within patient control.
391974|NCT01201499|Drug|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or ~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
391975|NCT01201499|Drug|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
391976|NCT01201434|Dietary Supplement|Bio-25 probiotic|2 tablets per day for 6 months
391977|NCT01201382|Behavioral|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
391978|NCT01201382|Behavioral|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
391979|NCT01201369|Device|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
391980|NCT01201369|Device|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
391981|NCT01201356|Drug|Fingolimod|0.5 mg/day
391982|NCT01201343|Drug|Interferon beta-1a|
391983|NCT01201317|Drug|AZD2423|20 mg tablet
391984|NCT01201317|Drug|AZD2423|150 mg tablet
391985|NCT01201317|Drug|Placebo|Placebo
391986|NCT01201304|Behavioral|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
391987|NCT01201304|Behavioral|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
391988|NCT01201304|Behavioral|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
391989|NCT01201304|Behavioral|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
391990|NCT01201291|Other|Normobaric oxygen|Fraction of inspired oxygen
391991|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
391992|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
391993|NCT01201278|Drug|Insulin LISPRO|Subcutaneous insulin lispro 8 U
391994|NCT01201265|Drug|Bevacizumab|15 mg/kg iv every 3 weeks
391995|NCT01201265|Drug|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
391996|NCT01201265|Drug|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
391997|NCT01201252|Procedure|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
391998|NCT01201239|Drug|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
391999|NCT01201226|Other|Removal of half an ovary|Removal of half an ovary
392003|NCT01201174|Other|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
392004|NCT01201161|Drug|Ranibizumab|Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
392005|NCT01201161|Other|Sham injection|Simulation of intravitreal injection one week before pars plana vitrectomy
392006|NCT01201148|Device|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
392007|NCT01201122|Drug|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).~Patients will be randomized in blocks of six stratified by weight groups: 15- <30 kg, 30-40kg, >40kg.~For body wt. 15- <20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).~For body wt: 20- <30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).~For Body wt. 30- <40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).~For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
392008|NCT01201096|Radiation|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
392009|NCT01201096|Procedure|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
392010|NCT01201070|Drug|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
392011|NCT01201057|Drug|0.5% SPL7013 Gel|Vaginal gel
392012|NCT01201057|Drug|1.0% SPL7013 Gel|Vaginal gel
392013|NCT01201057|Drug|3.0% SPL7013 Gel|Vaginal gel
392014|NCT01201057|Other|Placebo Gel|Vaginal gel
392015|NCT01201044|Drug|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 & D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
392016|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
392017|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
392018|NCT01201044|Drug|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV~Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
392019|NCT01201018|Drug|Oshadi D, Oshadi R|Oral administration
392020|NCT01201005|Dietary Supplement|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
392021|NCT01201005|Dietary Supplement|Sham injection|needle injection without any substance given
392022|NCT01200992|Biological|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
392023|NCT01200992|Biological|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
392024|NCT01200940|Other|Sucralose|sucralose will be given at doses of 68 mg (equivalent to one 12 oz soda) 170 mg (equivalent to two and one-half 12 oz sodas, and 250 mg (equal to 100% of the FDA s acceptable daily intake for a 50kg individual).
392025|NCT01200940|Other|Aspartame|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
392026|NCT01200940|Other|Acesulfame-Potassium|To determine the impact of sucralose and acesulfame- potassium ( aspartame) together on GLP-1 secretion, satiety, and the rate of intestinal glucose absorption. The doses of sucralose and acesulfame- potassium reflect the sweetener concentrations in the previously used Diet Rite Cola .
392027|NCT01200940|Other|Control|360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
392028|NCT01200927|Other|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
392029|NCT01200914|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
392030|NCT01200914|Procedure|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
392031|NCT01200901|Drug|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
392032|NCT01200875|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
392033|NCT01200875|Procedure|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
392034|NCT01200862|Drug|Investigational new drug company code: BGS649|
392035|NCT01200862|Drug|Placebo|
392036|NCT01200849|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
392037|NCT01200810|Other|placebo|Given orally
392038|NCT01200810|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
392039|NCT01200810|Drug|bicalutamide|Given orally
392040|NCT01200797|Drug|SJG-136|Given IV
392041|NCT01200797|Other|laboratory biomarker analysis|Correlative studies
392042|NCT01200784|Drug|Nicotinamide|dosage
392043|NCT01200771|Procedure|TEP|Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
392044|NCT01200758|Drug|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
392182|NCT01199770|Other|Experimental pasta C, small|experimental pasta C, small portion
392045|NCT01200758|Drug|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
392046|NCT01200758|Drug|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m^2 IV) administered every 3 weeks.
392047|NCT01200758|Drug|Doxorubicin|Eight cycles of doxorubicin (50 mg/m^2 IV) administered every 3 weeks.
392048|NCT01200758|Drug|Vincristine|Eight cycles of doxorubicin (1.4 mg/m^2 IV) administered every 3 weeks.
392049|NCT01200758|Drug|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
392050|NCT01200745|Drug|Capsaicin patch|Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
392051|NCT01200732|Drug|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
392052|NCT01200719|Device|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: < 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity ~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
392053|NCT01200706|Drug|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
392054|NCT01200693|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
392055|NCT01200693|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
392056|NCT01200693|Device|Zotarolimus eluting stent|Implantation of Zotarolimus eluting stent
392057|NCT01200654|Drug|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
392058|NCT01200641|Drug|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
392059|NCT01200641|Drug|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
392060|NCT01200641|Drug|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6~mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
392061|NCT01200628|Behavioral|DEPITAC|heteroevaluation scale by a nurse during hospitalization
392062|NCT01200615|Behavioral|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
392063|NCT01200602|Drug|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
392064|NCT01200602|Other|clinical observation|No treatment is given.
392065|NCT01200589|Biological|Ofatumumab|liquid concentrate for solution for infusion in glass vials containing 50 mL of solution at a concentration of 20mg/ml to provide 1000 mg per vial.
392066|NCT01200589|Biological|Rituximab|sourced locally from commercial stock
392067|NCT01200589|Biological|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
392068|NCT01200589|Biological|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
392069|NCT01200563|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
392070|NCT01200563|Device|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
392071|NCT01200563|Device|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
392072|NCT01200537|Drug|Estradiol|This group of patients will receive estradiol patches prior to the IVF cycle.
392073|NCT01200537|Drug|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
392074|NCT01200524|Drug|AZD2423|20 mg tablet
392075|NCT01200524|Drug|AZD2423|50 mg tablet
392076|NCT01200524|Drug|Placebo|Placebo
392077|NCT01200511|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
392078|NCT01200498|Drug|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
392079|NCT01200485|Drug|Rasburicase|"Cycle 1: All receive 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.~Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
392080|NCT01200485|Drug|Allopurinol|Arm B: 300 mg/day by vein over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
392081|NCT01200472|Drug|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
392082|NCT01200472|Drug|Placebo|Placebo capsules identical to apremilast
392083|NCT01200459|Behavioral|Social/mobile weight loss promotion intervention.|Social/mobile intervention for weight loss promotion, compared to control group.
392084|NCT01200446|Dietary Supplement|Docosahexaenoic Acid|8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.
392085|NCT01200446|Dietary Supplement|Placebo Docosahexaenoic Acid|8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
392086|NCT01200433|Drug|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
392087|NCT01200433|Drug|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
392088|NCT01200420|Drug|miravirsen|SC injection
392089|NCT01200420|Drug|saline|SC injection
392090|NCT01200407|Drug|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
392091|NCT01200394|Drug|PF-00489791|Tablet, 20 mg once daily for 12 weeks
392092|NCT01200394|Drug|Placebo|Tablet, placebo once daily for 12 weeks
392093|NCT01200381|Other|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
392094|NCT01200381|Other|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
392095|NCT01200381|Other|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
392096|NCT01200368|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
392097|NCT01200368|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
392098|NCT01200368|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
392099|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
392100|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
392101|NCT01200355|Drug|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
392102|NCT01200355|Drug|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
392103|NCT01200342|Drug|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
392104|NCT01200342|Drug|Paclitaxel|175 mg/m^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
392105|NCT01200342|Drug|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
392106|NCT01200329|Drug|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
392107|NCT01200329|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient~AUC 4,000 by vein over about 3 hours on days -8 to -5."
392108|NCT01200329|Drug|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
392109|NCT01200329|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
392110|NCT01200329|Drug|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
392111|NCT01200316|Procedure|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
392112|NCT01200316|Procedure|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
392113|NCT01200316|Behavioral|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
392114|NCT01200303|Procedure|non-cathartic CTC|non-cathartic, CAD-assisted CT Colonography
392115|NCT01200290|Drug|LY2127399|120 milligrams (mg) administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
392116|NCT01200277|Procedure|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
392117|NCT01200277|Procedure|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
392118|NCT01200264|Drug|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
392119|NCT01200251|Drug|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
392120|NCT01200238|Drug|STA-9090|
392121|NCT01200212|Drug|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
392122|NCT01200212|Drug|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
392123|NCT01200186|Drug|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
392124|NCT01200186|Drug|Progestin Only Pills|At the discretion of the attending physician
392125|NCT01200173|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
392126|NCT01200173|Other|2-Non fermented dairy product (control)|
392127|NCT01200160|Drug|Niacin|
392128|NCT01200147|Procedure|Biopsy|
392130|NCT01200134|Other|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
392131|NCT01200121|Drug|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
392132|NCT01200121|Other|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
392133|NCT01200108|Drug|Budesonide|
392134|NCT01200108|Drug|Budesonide|
392135|NCT01200108|Drug|Budesonide|
392136|NCT01200069|Drug|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
392137|NCT01200069|Drug|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
392138|NCT01200056|Drug|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
392139|NCT01200043|Other|fructose restriction diet|fruits and vegetables only
392140|NCT01200030|Behavioral|electrical stimulation with exercises|electrical stimulation with exercises
392141|NCT01200030|Behavioral|placebo stimulation with exercises|placebo stimulation with exercises
392142|NCT01200017|Biological|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
392143|NCT01200004|Drug|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
392144|NCT01200004|Drug|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
392145|NCT01200004|Drug|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
392146|NCT01199978|Radiation|Fractionated proton radiation|Given daily for approximately 5.5 weeks
392147|NCT01199965|Drug|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
392148|NCT01199965|Drug|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
392149|NCT01199952|Behavioral|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
392150|NCT01199939|Drug|Etravirine|400mg once daily orally for 48 weeks
392151|NCT01199939|Drug|Ritonavir|100mg once daily orally for 48 weeks
392152|NCT01199939|Drug|Darunavir|800mg once daily orally for 48 weeks
392153|NCT01199926|Dietary Supplement|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
392154|NCT01199926|Drug|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
392155|NCT01199913|Other|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
392156|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
392157|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
392158|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
392159|NCT01199900|Drug|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
392160|NCT01199900|Drug|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
392161|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
392162|NCT01199900|Drug|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
392163|NCT01199887|Drug|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
392164|NCT01199874|Biological|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
392165|NCT01199861|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
392166|NCT01199861|Drug|Placebo|Matching placebo capsules for oral administration.
392167|NCT01199861|Biological|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
392168|NCT01199861|Biological|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
392169|NCT01199848|Dietary Supplement|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
392170|NCT01199848|Dietary Supplement|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
392171|NCT01199848|Dietary Supplement|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
392172|NCT01199848|Dietary Supplement|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
392173|NCT01199848|Dietary Supplement|Placebonofiber|Placebo without Fiber
392174|NCT01199835|Other|High Calcium intake from dairy products|High dietary intake of calcium from dairy products (~1200 mg/d)
392175|NCT01199822|Biological|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
392176|NCT01199809|Drug|Placebo|multiple doses
392177|NCT01199809|Drug|RO5310074|multiple ascending doses
392178|NCT01199783|Drug|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
392179|NCT01199783|Drug|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
392180|NCT01199770|Other|Control, small|control pasta, small portion
392181|NCT01199770|Other|Experimental B, small|experimental pasta, small portion
392184|NCT01199770|Other|experimental pasta B, medium|experimental pasta B, medium portion
392185|NCT01199770|Other|experimental pasta C, medium|experimental pasta C, medium portion
392186|NCT01199770|Other|NL|no pasta, water only
392187|NCT01199757|Drug|Fluticasone furoate|cohort of patients receiving fluticasone furate
392188|NCT01199757|Drug|mometasone furoate|cohort receiving mometasone furoate
392189|NCT01199757|Drug|fluticasone propionate|cohort of patients on fluticasone propionate
392190|NCT01199744|Drug|zanamivir|zanamivir
392191|NCT01199731|Drug|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
392192|NCT01199731|Drug|GSK2248761 200 mg once daily|2 100mg capsules OAD
392193|NCT01199731|Drug|Etravirine|2 100mg tablets twice daily
392194|NCT01199718|Drug|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
392195|NCT01199705|Biological|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
392196|NCT01199679|Procedure|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
392197|NCT01199679|Procedure|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
392198|NCT01199666|Other|Text message|text message appointment and immunization reminders
392199|NCT01199653|Procedure|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
392200|NCT01199653|Procedure|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
392201|NCT01199640|Drug|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
392202|NCT01199627|Drug|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
392203|NCT01199627|Drug|B|"Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
392204|NCT01199627|Drug|C|"Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.~2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
392205|NCT01199614|Drug|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
392206|NCT01199601|Behavioral|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
392207|NCT01199588|Drug|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
392208|NCT01199588|Drug|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
392209|NCT01199588|Drug|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
392210|NCT01199575|Drug|Revlimid|
392211|NCT01199575|Drug|Rituximab|
392212|NCT01199562|Procedure|infection prophylaxis and management|Undergo infection prophylaxis and management
392213|NCT01199562|Other|laboratory biomarker analysis|Correlative studies
392214|NCT01199562|Other|flow cytometry|Correlative studies
392215|NCT01199562|Genetic|DNA analysis|Correlative studies
392216|NCT01199562|Genetic|RNA analysis|Correlative studies
392217|NCT01199562|Procedure|management of therapy complications|undergo infection prophylaxis and management
392218|NCT01199562|Drug|ganciclovir|Given IV
392219|NCT01199562|Drug|valganciclovir|Given orally
392220|NCT01199562|Drug|foscarnet sodium|Given orally
392221|NCT01199562|Procedure|antiviral therapy|undergo infection prophylaxis and management
392222|NCT01199562|Genetic|polymerase chain reaction|Correlative studies
392223|NCT01199562|Genetic|protein expression analysis|Correlative studies
392224|NCT01199523|Drug|Placebo|oral
392225|NCT01199523|Drug|mirabegron|oral
392226|NCT01199523|Drug|moxifloxacin|oral
392227|NCT01199510|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
392228|NCT01199510|Other|Standard of Care|Post Cataract Surgery Standard of Care
392229|NCT01199497|Drug|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
392230|NCT01199497|Drug|Group 2|placebo
392231|NCT01199484|Other|Cow's milk|
392232|NCT01199458|Drug|alfentanil|20 mikrogr/kg
392233|NCT01199458|Drug|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
392234|NCT01199445|Dietary Supplement|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
392235|NCT01199432|Drug|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
392236|NCT01199432|Drug|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
392237|NCT01199432|Drug|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
392238|NCT01199419|Procedure|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
392239|NCT01199406|Drug|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
392240|NCT01199380|Behavioral|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
392241|NCT01199380|Behavioral|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
392242|NCT01199380|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
392243|NCT01199367|Drug|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
392244|NCT01199354|Procedure|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
392245|NCT01199341|Drug|AZD1981|100 mg per oral, twice daily for 14 days
392246|NCT01199341|Drug|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
392247|NCT01199341|Drug|AZD1981|4 x 100 mg per oral, twice daily for 14 days
392248|NCT01199328|Drug|Aspirin|81mg Tablet oral, once daily
392249|NCT01199328|Drug|Esomeprazole|20 mg Tablet oral, once daily
392250|NCT01199315|Drug|AZD1446|oral capsule, Moderate Release
392251|NCT01199315|Drug|Placebo|oral capsule
392252|NCT01199302|Drug|AMG 827|350 mg AMG 827 administered intraveneously at baseline, week 4, and every 4 weeks thereafter.
392253|NCT01199289|Drug|AMG 827|210 mg AMG 827 SC
392254|NCT01199289|Drug|Placebo|Placebo SC
392255|NCT01199289|Drug|AMG 827|140 mg AMG 827 SC
392256|NCT01199289|Drug|AMG 827|280 mg AMG 827 SC
392257|NCT01199276|Drug|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
392258|NCT01199276|Drug|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
392259|NCT01199263|Other|Laboratory Biomarker Analysis|Correlative studies
392260|NCT01199263|Drug|Paclitaxel|Given IV
392261|NCT01199263|Biological|Pelareorep|Given IV
392262|NCT01199250|Other|Laboratory Biomarker Analysis|Correlative studies
392263|NCT01199237|Drug|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
392264|NCT01199237|Drug|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
392265|NCT01199237|Drug|Rocuronium|
392266|NCT01199237|Drug|Neostigmine|
392267|NCT01199237|Drug|Glycopyrrolate|
392268|NCT01199224|Drug|veliparib|veliparib formulation A
392269|NCT01199224|Drug|veliparib|veliparib formulation B
392270|NCT01199224|Drug|veliparib|veliparib formulation C
392271|NCT01199224|Drug|veliparib|veliparib formulation C
392272|NCT01199211|Other|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
392273|NCT01199198|Drug|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
392274|NCT01199198|Drug|Placebo|Placebo by mouth once a day for 14 days.
392275|NCT01199185|Behavioral|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
392276|NCT01199185|Behavioral|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
392277|NCT01199172|Behavioral|voice hygiene|subjects will receive voice hygiene training
392278|NCT01199172|Behavioral|VH + VP|subjects will be trained in voice hygiene and voice production training
392279|NCT01199159|Drug|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
392280|NCT01199159|Drug|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
392281|NCT01199146|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
392282|NCT01199133|Drug|Dpte and Dfar Allergen Extracts|300 IR, once a day, for one year.
392283|NCT01199133|Drug|placebo|once a day, for one year.
392284|NCT01199120|Dietary Supplement|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
392285|NCT01199107|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
392286|NCT01199107|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
392287|NCT01199107|Behavioral|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
392288|NCT01199081|Drug|Dronedarone|"Pharmaceutical form: tablet~Route of administration: oral (together with meal)~Dose regimen: 400 mg twice daily"
392289|NCT01199068|Drug|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice a daily
392290|NCT01199068|Drug|Erlotinib|Erlotinib 150 mg once daily
392291|NCT01199055|Drug|CS-7017|Drug: CS-7017 from 0.25 mg bid to 0.50 mg bid for up to 4~6 cycles (1 cycle: 3 weeks)
392292|NCT01199055|Drug|Carboplatin|Drug: Carboplatin IV, AUC of 6, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
392293|NCT01199055|Drug|Paclitaxel|Drug: Paclitaxel IV, 200mg/m2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
392294|NCT01199042|Device|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
392295|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
392296|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
392297|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
392298|NCT01199029|Drug|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
392299|NCT01199029|Drug|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
392300|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
392301|NCT01199029|Drug|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
392302|NCT01199016|Procedure|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
392303|NCT01199016|Procedure|Nose/throat swab|To be performed at every study visit
392304|NCT01199016|Biological|Observational|Observational Study Only
392305|NCT01198990|Behavioral|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
392306|NCT01198990|Behavioral|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
392307|NCT01198977|Behavioral|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
392308|NCT01198977|Other|Education counseling|Mailed informational video of exercise programs
392309|NCT01198964|Procedure|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
392310|NCT01198938|Other|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
392311|NCT01198925|Drug|piperacillin continuous infusion|piperacillin continuous infusion
392312|NCT01198925|Drug|piperacillin extended infusion|piperacillin extended infusion
392313|NCT01198912|Drug|placebo|during 56 days
392314|NCT01198912|Drug|doxycycline 100 mg|during 56 days
392315|NCT01198899|Other|blood sampling|Blood sampling will be used.
392316|NCT01198886|Other|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
392317|NCT01198886|Other|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
392318|NCT01198873|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
392319|NCT01198873|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
392320|NCT01198860|Drug|CTH Chronic Hepatitis B|"Drug:~Tenofovir/ 300mg daily~Phyllanthus Urinaria/300mg daily~Adenosma Glutinosum/150mg daily~Eclipta Prostrata/150mg daily~Ascorbic Acid / 500mg daily"
392321|NCT01198847|Behavioral|Dietary, physical activity and sleeping|"The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.~The Low intensity arm will only receive written information and no direct face to face support"
392322|NCT01198834|Drug|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
392323|NCT01198834|Drug|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
392324|NCT01198834|Drug|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
392325|NCT01198834|Drug|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
392326|NCT01198821|Drug|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
392327|NCT01198821|Drug|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
392328|NCT01198795|Drug|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
392329|NCT01198782|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
392330|NCT01198769|Biological|Rotarix TM|Oral, 2 doses
392331|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
392332|NCT01198756|Biological|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
392333|NCT01198756|Biological|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
392334|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
392335|NCT01198730|Drug|Acarbose|Acarbose 25 mg tid, titrate to 100 mg tid.
392336|NCT01198704|Other|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
392337|NCT01198691|Device|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
392338|NCT01198691|Device|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
392339|NCT01198678|Dietary Supplement|Boost Nutritional Supplement|Boost- Nutritional Supplement
392340|NCT01198665|Drug|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
392341|NCT01198639|Device|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
392342|NCT01198639|Device|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
392343|NCT01198626|Drug|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
392344|NCT01198626|Drug|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
392345|NCT01198626|Drug|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
392346|NCT01198613|Biological|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
392347|NCT01198613|Biological|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
392348|NCT01198600|Device|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
392349|NCT01198600|Device|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
392350|NCT01198600|Device|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
392351|NCT01198587|Drug|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.~For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
392352|NCT01198587|Drug|Placebo oral capsule|Effervescent oral capsules with similar taste to treatment drug Zinc Sulfate is provided to each patient randomized to the placebo arms of the study
392353|NCT01198574|Dietary Supplement|Iron group|Ferrous fumarate, 60 mg, weekly dose
392354|NCT01198574|Dietary Supplement|Vitamin A group|Retinol, weekly dose, 15,000 IU
392355|NCT01198574|Dietary Supplement|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
392356|NCT01198574|Dietary Supplement|Placebo group|folic acid only as placebo group
392357|NCT01198561|Device|repetitive Transcranial Magnetic Stimulation|10 times repetitive TMS, high frequency
392358|NCT01198548|Drug|leucovorin calcium|Given IV
392359|NCT01198548|Biological|bevacizumab|Given IV
392360|NCT01198548|Dietary Supplement|cholecalciferol|Given PO
392361|NCT01198548|Drug|fluorouracil|Given IV
392362|NCT01198548|Drug|oxaliplatin|Given IV
392363|NCT01198548|Other|pharmacological study|Correlative studies
392364|NCT01198535|Biological|Cetuximab|Given IV
392365|NCT01198535|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
392366|NCT01198535|Other|Laboratory Biomarker Analysis|Correlative studies
392367|NCT01198535|Other|Pharmacological Study|Correlative studies
392403|NCT01198236|Drug|Itraconazole|"Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.~In transplant patients, the end of at-risk period is defined as a stable engraftment of 1*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells> 0.5*109/L).~If needed, the patients will take itraconazole solution orally after intravenous administration."
392404|NCT01198223|Drug|garlic , nystatin|mouthwash
392405|NCT01198210|Drug|saline|local peritonsillar infiltration of 2 ml saline,
392368|NCT01198522|Drug|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.~Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
392369|NCT01198509|Drug|doxycycline|doxycycline - 100 mg twice per day, for 2 months
392370|NCT01198509|Drug|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
392371|NCT01198496|Drug|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|<Study drugs and treatment steps> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
392372|NCT01198483|Procedure|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
392373|NCT01198483|Procedure|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
392374|NCT01198470|Device|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
392375|NCT01198457|Drug|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
392376|NCT01198444|Drug|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
392377|NCT01198431|Behavioral|Sleep duration|Duration of sleep per night
392378|NCT01198418|Behavioral|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
392379|NCT01198405|Device|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
392380|NCT01198405|Drug|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
392381|NCT01198392|Drug|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
392382|NCT01198392|Drug|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.~Number of Cycles: until progression or unacceptable toxicity develops."
392383|NCT01198379|Drug|aspirin|aspirin 100 mg qd for 3 years
392384|NCT01198379|Drug|Placebo|
392385|NCT01198366|Biological|AERAS-402 1.5 x 10^10 vp|
392386|NCT01198366|Biological|AERAS-402 3.0 x 10^10 vp|
392387|NCT01198366|Biological|AERAS-402 1.0 x 10^11 vp|
392388|NCT01198366|Biological|Placebo|
392389|NCT01198353|Drug|Ziprasidone|100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
392390|NCT01198340|Procedure|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
392391|NCT01198340|Procedure|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
392392|NCT01198327|Drug|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
392393|NCT01198327|Other|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
392394|NCT01198314|Procedure|immunosuppression withdrawal|tapering off immunosuppressant
392395|NCT01198314|Procedure|continue of taking immunosuppressant|maintain immunosuppression
392396|NCT01198288|Other|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
392397|NCT01198288|Other|Standard Care|As describe in the standard care arm
392398|NCT01198275|Drug|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
392399|NCT01198275|Drug|Placebo|1.0 g of olive oil,one capsule twice a day
392400|NCT01198275|Drug|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
392401|NCT01198275|Drug|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
392402|NCT01198249|Drug|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
392406|NCT01198210|Drug|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
392407|NCT01198210|Drug|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
392584|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
392408|NCT01198210|Drug|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
392409|NCT01198197|Drug|NOP-1A|
392410|NCT01198184|Drug|temsirolimus|Given IV or PO
392411|NCT01198184|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
392412|NCT01198184|Other|laboratory biomarker analysis|Correlative studies
392413|NCT01198184|Other|pharmacological study|Correlative studies
392414|NCT01198171|Other|Laboratory Biomarker Analysis|Correlative studies
392415|NCT01198171|Other|Study of Socioeconomic and Demographic Variables|
392416|NCT01198158|Biological|Bevacizumab|Given IV
392417|NCT01198158|Drug|Everolimus|Given PO
392418|NCT01198158|Other|Laboratory Biomarker Analysis|Correlative studies
392419|NCT01198158|Other|Pharmacological Study|Correlative studies
392420|NCT01198145|Drug|sulfasalazine|Given orally
392421|NCT01198145|Other|placebo|Given orally
392422|NCT01198132|Dietary Supplement|Cholecalciferol (Vitamin D3)|Subjects receive Cholecalciferol 100,000 IU one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) for 96 weeks treatment period along with subcutaneous Rebif 44 mcg 3 times a week.
392423|NCT01198132|Dietary Supplement|Placebo|Subjects receive matching placebo to Cholecalciferol once every two weeks orally along with subcutaneous injection of Rebif 44 mcg 3 times weekly.
392424|NCT01198132|Drug|Rebif|Subjects receive subcutaneous injection of Rebif 44 mcg 3 times weekly.
392425|NCT01198119|Device|Location of the suspected lesions|"The suspected lesions will be located before the excision, during the surgery.~With traditional light~NBI technique The images will be recorded and compared"
392426|NCT01198119|Procedure|Biopsy|In case of suspected lesions detected by the NBI technique, this area is biopsied
392427|NCT01198119|Procedure|Lesion excision/Surgery|In case of positive biopsy, the suspected lesions is excised
392428|NCT01198106|Drug|scopolamine|0.6 mg
392429|NCT01198106|Drug|cinnarizine|50 mg
392430|NCT01198080|Biological|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
392431|NCT01198067|Drug|Pomalidomide|Given PO
392432|NCT01198054|Drug|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.~In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
392433|NCT01198028|Drug|Erlotinib|Given PO
392434|NCT01198002|Drug|LY2127399|Administered Subcutaneously (SC)
392435|NCT01198002|Drug|Placebo Q2W|Administered SC
392436|NCT01198002|Drug|Placebo Q4W|Administered SC
392437|NCT01198002|Drug|Methotrexate|Methotrexate is a background therapy.
392438|NCT01197989|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
392439|NCT01197989|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
392440|NCT01197976|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
392441|NCT01197976|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
392442|NCT01197963|Procedure|Sleeve Gastrectomy and Ileal transposition|Laparoscopic sleeve gastrectomy with ileal transposition
392443|NCT01197963|Dietary Supplement|dietary and medical management|dietary and medical routine management patients are currently following with an endocrinologist.
392444|NCT01197950|Device|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
392445|NCT01197950|Device|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
392446|NCT01197924|Other|IRMf Bold|IRMf BOLD of the working memory
392447|NCT01197911|Drug|aleglitazar|single oral dose
392448|NCT01197898|Biological|Collagenase Santyl Ointment|Topical daily application
392449|NCT01197898|Other|Placebo Comparator|Topical daily application
392450|NCT01197885|Drug|IMAB362|Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
392451|NCT01197872|Other|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
392452|NCT01197846|Drug|Quetiapine|quetiapine 300 mg or 600 mg
392453|NCT01197846|Drug|Placebo|Placebo
392454|NCT01197833|Drug|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
392455|NCT01197833|Drug|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
392456|NCT01197833|Drug|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
392500|NCT01197404|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
392501|NCT01197391|Biological|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
392502|NCT01197378|Drug|Cysteamine Bitartrate Delayed-release Capsules|"Participants who entered the trial from the RP103-03 study continued treatment with cysteamine bitartrate every 12 hours at the last dose level prescribed during their participation in that study.~Participants not entering the trial from Study RP103-03 were started on twice a day administration of cysteamine bitartrate at a total daily RP103 dose of 70% of their pre-study total daily stable Cystagon® dose."
392457|NCT01197820|Device|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.~In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.~Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
392458|NCT01197807|Procedure|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
392459|NCT01197807|Procedure|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
392460|NCT01197794|Drug|AZD1981|AZD1981 twice daily
392461|NCT01197794|Drug|AZD1981|AZD1981 once daily
392462|NCT01197794|Drug|Placebo|Placebo to match AZD1981
392463|NCT01197781|Drug|FOSTAMATIN|Oral tablets - single dose
392464|NCT01197781|Drug|Verapamil|Oral tablets - administered 3 times daily over 4 days
392465|NCT01197768|Behavioral|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
392466|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily
392467|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
392468|NCT01197755|Drug|placebo|Placebo twice daily
392469|NCT01197664|Drug|paricalcitol|Given PO
392470|NCT01197664|Radiation|radiation therapy|Undergo radiotherapy
392471|NCT01197664|Other|laboratory biomarker analysis|Correlative studies
392472|NCT01197664|Drug|fluorouracil|Given PO
392473|NCT01197625|Biological|Dendritic cell vaccine|Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
392474|NCT01197612|Drug|pulmicort|applied to nasal packing after surgery
392475|NCT01197573|Drug|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
392476|NCT01197573|Other|No TPA Treatment|Standard of Care
392477|NCT01197560|Drug|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
392478|NCT01197560|Drug|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m^2 IV days 1 and 15 every 28 days for 6 Cycles
392479|NCT01197560|Drug|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m^2 IV day 1 for 21 days for 6 Cycles
392480|NCT01197560|Drug|Rituximab|Suggested starting dose for Rituximab is 375 mg/m^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
392481|NCT01197560|Drug|Etoposide|"Suggested starting doses for Etoposide are:~100 mg/m^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m^2 oral days 1-10 every 28 days for 6 Cycles"
392482|NCT01197547|Device|Genesys HTA|Genesys HTA Endometrial Ablation
392483|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily
392484|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
392485|NCT01197534|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
392486|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily
392487|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
392488|NCT01197521|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
392489|NCT01197508|Drug|TC-5214|Twice daily for 8 weeks.
392490|NCT01197508|Drug|Placebo|Twice daily for 8 weeks.
392491|NCT01197495|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
392492|NCT01197469|Drug|Tadalafil|Tadalafil 10mg once daily for 3 months
392493|NCT01197469|Drug|Placebo|
392494|NCT01197443|Behavioral|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
392495|NCT01197443|Behavioral|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
392496|NCT01197430|Other|exercise training|
392497|NCT01197417|Drug|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
392498|NCT01197417|Drug|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
392499|NCT01197404|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
392861|NCT01194635|Other|immunohistochemistry staining method|
392503|NCT01197365|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.~Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
392504|NCT01197365|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
392505|NCT01197352|Behavioral|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
392506|NCT01197352|Behavioral|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
392507|NCT01197339|Behavioral|resonant voice|A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
392508|NCT01197339|Behavioral|voice rest|A 4-hr voice rest will be prescribed to subjects following vocal loading.
392509|NCT01197339|Behavioral|Breathy voice|A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.
392510|NCT01197339|Behavioral|Relaxation exercise|A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.
392511|NCT01197339|Behavioral|Resonant voice and relaxation exercise|A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.
392512|NCT01197326|Device|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
392513|NCT01197313|Other|Home-based exercise|
392514|NCT01197300|Drug|Zoledronic acid|intravenous infusion
392515|NCT01197287|Drug|QAK423A|
392516|NCT01197287|Drug|QAK423A|
392517|NCT01197287|Drug|QAK423A|
392518|NCT01197274|Device|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
392519|NCT01197261|Drug|Oxycodone naloxone prolonged release tablets|2 tablets/ day
392520|NCT01197261|Drug|Placebo tablets|2 tablets/ day
392521|NCT01197248|Procedure|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
392522|NCT01197248|Procedure|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
392523|NCT01197235|Drug|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
392524|NCT01197235|Drug|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
392525|NCT01197222|Device|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
392526|NCT01197209|Biological|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
392527|NCT01197196|Behavioral|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
392528|NCT01197196|Other|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief [HLMR]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
392529|NCT01197170|Drug|Anastrozole|1 mg by mouth daily of a 28 day cycle.
392530|NCT01197170|Drug|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
392531|NCT01197170|Drug|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
392532|NCT01197170|Drug|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
392533|NCT01197170|Drug|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
392534|NCT01197157|Drug|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
392535|NCT01197157|Drug|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
392536|NCT01197144|Drug|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
392537|NCT01197144|Drug|Placebo|Subcutaneous, every other week for 4 weeks
392538|NCT01197118|Radiation|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.~Postoperative chemotherapy regimen: see arm 2"
392539|NCT01197118|Drug|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1~5, i.v.; leucovorin, 200 mg/m2/day on day 1~5, i.v.; every 21 days repeated, for 6 cycles.
392540|NCT01197105|Biological|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
392541|NCT01197092|Dietary Supplement|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:~ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
392542|NCT01197092|Dietary Supplement|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
392543|NCT01197092|Device|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
392544|NCT01197092|Behavioral|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
392545|NCT01197079|Other|Survey|Self administered anonymous survey
392546|NCT01197066|Drug|Certolizumab Pegol|Certolizumab Pegol 200mg
392547|NCT01197053|Biological|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
392548|NCT01197053|Biological|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
392549|NCT01197040|Drug|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
392550|NCT01197040|Drug|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
392551|NCT01197027|Behavioral|Standard counseling|Standard HIV counseling
392552|NCT01197014|Drug|Amlodipine plus Losartan|Amlodipine/Losartan high dose
392553|NCT01197014|Drug|Amlodipine, Losartan|Amlodipine, Losartan
392554|NCT01197001|Drug|Amlodipine plus Losartan|Amlodipine/Losartan low dose
392555|NCT01197001|Drug|Amlodipine, Losartan|Amlodipine, Losartan
392556|NCT01196988|Biological|Influenza vaccine GSK2321138A|intramuscular injections
392557|NCT01196988|Biological|FluarixTM|intramuscular injections
392558|NCT01196988|Biological|Influenza vaccine GSK2604409A|intramuscular injections
392559|NCT01196975|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
392560|NCT01196975|Biological|FluLavalTM-VB|Single intramuscular dose
392561|NCT01196975|Biological|FluLavalTM-YB|Single intramuscular dose
392562|NCT01196962|Device|Central venous catheter|Central venous catheter insertion to subclavian vein
392563|NCT01196949|Other|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
392564|NCT01196949|Other|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
392565|NCT01196936|Drug|Tamoxifen Citrate|5 mg PO Daily
392566|NCT01196936|Drug|Placebo|1 tablet daily
392567|NCT01196936|Procedure|Digital mammography|Correlative studies
392568|NCT01196936|Other|immunohistochemistry staining method|Correlative Studies
392569|NCT01196936|Other|pharmacological study|Correlative Studies
392570|NCT01196936|Other|laboratory biomarker analysis|Correlative Studies
392571|NCT01196936|Genetic|protein expression analysis|correlative studies
392572|NCT01196936|Other|pharmacogenomic studies|correlative studies
392573|NCT01196936|Other|questionnaire administration|Ancillary studies
392574|NCT01196936|Procedure|Fine needle aspiration|
392575|NCT01196936|Other|Quality of Life Assessment|Ancillary Studies
392576|NCT01196923|Device|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
392577|NCT01196910|Device|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).~Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
392578|NCT01196897|Device|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
392579|NCT01196871|Drug|Migalastat HCl|Oral capsules, single dose
392580|NCT01196871|Biological|Agalsidase Beta|IV infusion, single dose
392581|NCT01196871|Biological|Agalsidase Alfa|IV infusion, single dose
392582|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
392583|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
392585|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
392586|NCT01196832|Procedure|blood sample|blood sample for fibrocytes analysis
392587|NCT01196832|Procedure|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
392588|NCT01196819|Device|Firehawk|Implantation of Firehawk drug eluting stent
392589|NCT01196819|Device|Xience V|Implantation of Xience V drug eluting stent
392590|NCT01196767|Drug|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:~ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.~same protocol, with normal saline instead of ropivacaine."
392591|NCT01196754|Other|sevoflurane|
392592|NCT01196741|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
392593|NCT01196741|Drug|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
392594|NCT01196741|Drug|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
392595|NCT01196728|Drug|CM3.1-AC100|SAD study with single ascending subcutaneous doses
392596|NCT01196715|Drug|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
392597|NCT01196715|Drug|Filgrastim|300 mcg vials twice a week, 3-4 days apart
392598|NCT01196715|Procedure|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
392599|NCT01196689|Drug|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
392600|NCT01196676|Drug|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
392601|NCT01196676|Drug|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
392602|NCT01196663|Device|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
392603|NCT01196663|Device|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
392604|NCT01196650|Drug|IN 10 003 formulation A|
392605|NCT01196650|Drug|IN 10 003 formulation B|
392606|NCT01196650|Drug|Placebo capsules|
392607|NCT01196624|Device|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
392608|NCT01196624|Device|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
392609|NCT01196611|Behavioral|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
392610|NCT01196611|Behavioral|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
392611|NCT01196598|Other|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist."
392612|NCT01196585|Procedure|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
392613|NCT01196585|Procedure|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
392614|NCT01196572|Procedure|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
392615|NCT01196559|Drug|Vinorelbine and Gemcitabine|Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
392616|NCT01196546|Drug|vildagliptin/metformin|
392617|NCT01196533|Device|Non invasive peripheral blood monitoring|non invasive monitoring
392618|NCT01196507|Drug|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
392619|NCT01196507|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
392620|NCT01196494|Procedure|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
392621|NCT01196481|Drug|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD & capsule VSL#3 1 TDS for 2 year
392622|NCT01196481|Procedure|Endoscopic variceal ligation|In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
392623|NCT01196468|Other|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
392624|NCT01196468|Other|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
392625|NCT01196455|Drug|Capecitabine and Mitomycin C|"Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks~Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks"
392626|NCT01196442|Other|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
392627|NCT01196442|Other|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
392628|NCT01196429|Drug|Carboplatin|Given IV
392629|NCT01196429|Drug|Docetaxel|Given IV
392630|NCT01196429|Other|Laboratory Biomarker Analysis|Correlative studies
392631|NCT01196429|Drug|Paclitaxel|Given IV
392632|NCT01196429|Drug|Temsirolimus|Given IV
392633|NCT01196416|Drug|Cisplatin|Given IV
392634|NCT01196416|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
392635|NCT01196416|Other|Laboratory Biomarker Analysis|Correlative studies
392636|NCT01196416|Other|Pharmacological Study|Correlative studies
392637|NCT01196416|Drug|Temozolomide|Given PO
392638|NCT01196416|Drug|Vinblastine Sulfate|Given IV
392639|NCT01196403|Other|questionnaire administration|
392640|NCT01196403|Procedure|quality-of-life assessment|
392641|NCT01196403|Procedure|robot-assisted laparoscopic surgery|
392642|NCT01196403|Procedure|therapeutic conventional surgery|
392643|NCT01196403|Procedure|therapeutic laparoscopic surgery|
392644|NCT01196390|Drug|Carboplatin|Given IV
392645|NCT01196390|Other|Laboratory Biomarker Analysis|Correlative studies
392646|NCT01196390|Drug|Paclitaxel|Given IV
392647|NCT01196390|Other|Quality-of-Life Assessment|Ancillary studies
392648|NCT01196390|Radiation|Radiation Therapy|Undergo radiation therapy
392649|NCT01196390|Procedure|Therapeutic Conventional Surgery|Undergo surgery
392650|NCT01196390|Biological|Trastuzumab|Given IV
392651|NCT01196377|Drug|Albuterol|Nebulized albuterol
392652|NCT01196364|Other|Dietary Supplement: water with noncalorie sweetener|
392653|NCT01196364|Other|Activity: With noncalorie sweetener or glucose|
392654|NCT01196351|Other|Dietary Supplement: water with noncalorie sweetener|
392655|NCT01196351|Other|Activity: With noncalorie sweetener or glucose|
392656|NCT01196338|Behavioral|Early weight-bearing and range of motion exercises|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;~At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;~After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
392657|NCT01196338|Behavioral|non-weight bearing, no range of motion|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;~At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;~At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;~After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
392658|NCT01196312|Behavioral|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
392659|NCT01196286|Behavioral|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
392660|NCT01196286|Behavioral|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
392661|NCT01196273|Other|Comprehensive non invasive cardiovascular examination|"The examination includes:~Anamnesis incl. admission form~Physical examination~Documentation of the medical therapy (incl. HAART)~Electrocardiogram~Transthoracic echocardiography~Exercise electrocardiogram~6 minute walk test~Blood collection~Questionnaire to quality of life and health economics"
392662|NCT01196260|Drug|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
392663|NCT01196247|Drug|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
392664|NCT01196234|Drug|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
392665|NCT01196234|Drug|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
392666|NCT01196208|Drug|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
392667|NCT01196195|Drug|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
392668|NCT01196195|Drug|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
392669|NCT01196169|Drug|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
392670|NCT01196169|Drug|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if > one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of < 50 ml/min. Patients with creatinine clearance of < 50 ml/min will only receive one dose.
392862|NCT01194635|Other|laboratory biomarker analysis|
392671|NCT01196130|Behavioral|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
392672|NCT01196130|Other|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
392673|NCT01196117|Device|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
392674|NCT01196117|Device|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
392675|NCT01196104|Drug|Technosphere® Insulin Inhalation Powder|
392676|NCT01196104|Drug|Insulin Aspart|Usual Care
392677|NCT01196104|Drug|Insulin Glargine|
392678|NCT01196091|Drug|LY2127399|120 mg administered via subcutaneous (SC) injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
392679|NCT01196091|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose of corticosteroids, NSAIDs, antimalarials, or immunosuppressants will also be administered at the first dose
392680|NCT01196091|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
392681|NCT01196091|Drug|Standard of Care|
392682|NCT01196078|Drug|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
392683|NCT01196078|Drug|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
392684|NCT01196065|Drug|RO5313534|single oral dose
392685|NCT01196065|Drug|memantine|multiple doses to steady state
392686|NCT01196052|Drug|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
392687|NCT01196039|Drug|MEMP1972A|Intravenous repeating dose
392688|NCT01196039|Drug|placebo|Intravenous repeating dose
392689|NCT01196026|Biological|Fluarix™|One or two intramuscular injections
392690|NCT01196026|Biological|Havrix™ Junior|Two intramuscular injections
392691|NCT01196013|Drug|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
392692|NCT01196000|Procedure|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
392693|NCT01196000|Procedure|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
392694|NCT01196000|Procedure|quality-of-life assessment|Ancillary studies
392695|NCT01196000|Other|questionnaire administration|Ancillary studies
392696|NCT01195974|Drug|YASMIN|YASMIN for 21 days
392697|NCT01195974|Drug|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
392698|NCT01195974|Other|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
392699|NCT01195948|Drug|B27PD|
392700|NCT01195948|Drug|Placebo|Capsule with no active ingredients to mimic B27PD
392701|NCT01195922|Drug|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT & amp; PET scans will be done for tumor measurement.
392702|NCT01195896|Device|New NPWT system|According clinical routine (Instruction for Use)
392703|NCT01195883|Drug|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
392704|NCT01195883|Drug|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
392705|NCT01195844|Biological|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children < 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
392706|NCT01195831|Drug|Xamiol® gel|Once daily application
392707|NCT01195831|Drug|Calcipotriol scalp solution|Twice daily application
392708|NCT01195818|Drug|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
392709|NCT01195805|Drug|Spironolactone|1 tablet twice a day for 28 days
392710|NCT01195805|Other|Placebo|1 tablet twice a day for 28 days
392711|NCT01195805|Drug|Amiloride|1 tablet twice a day for 28 days
392712|NCT01195792|Drug|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
392713|NCT01195792|Drug|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
392714|NCT01195779|Biological|GSK Bio's influenza vaccine GSK2584786A, different formulations|Intramuscular injections
392715|NCT01195779|Biological|GSK Bio's influenza vaccine GSK2321138A|Intramuscular injections
392716|NCT01195779|Biological|Fluarix™|Intramuscular injections
392717|NCT01195766|Drug|Ofatumumab|Ofatumumab in addition with ESHAP therapy
392718|NCT01195753|Biological|HHLivC|multiple infusion of liver cells
392757|NCT01195363|Drug|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
392758|NCT01195337|Behavioral|PA Prescription Plan|Exercise program and instructions.
392759|NCT01195337|Device|Pedometer|Step monitor for individual PA progress.
392760|NCT01195337|Behavioral|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
392761|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
392719|NCT01195740|Behavioral|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
392720|NCT01195740|Behavioral|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
392721|NCT01195727|Drug|Apixaban|
392722|NCT01195714|Drug|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
392723|NCT01195688|Drug|BI 638683 or placebo|oral doses given to 6 subjects per dose group
392724|NCT01195688|Drug|Placebo solution|oral doses given to 2 subjects per dose group
392725|NCT01195675|Drug|BI 10773 (low)|single oral dose
392726|NCT01195675|Drug|Moxifloxacin|single oral dose
392727|NCT01195675|Drug|BI 10773 Placebo|2 times single dose
392728|NCT01195675|Drug|BI 10773 (high)|single oral dose
392729|NCT01195662|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
392730|NCT01195662|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
392731|NCT01195649|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
392732|NCT01195636|Drug|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
392733|NCT01195636|Drug|Placebo|Twice daily application of Placebo ointment
392734|NCT01195623|Procedure|preoperative duplex examination|
392735|NCT01195623|Procedure|Preoperative duplex|
392736|NCT01195610|Behavioral|Dietary intervention|Instruction to diet for 6 month
392737|NCT01195597|Device|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
392738|NCT01195571|Biological|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
392739|NCT01195558|Other|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
392740|NCT01195545|Device|Veritas® Collagen Matrix|biological mesh in hernia repair
392741|NCT01195493|Other|Essential Oils solution|(Essential oils solution, Listerine®, Johnson & Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
392742|NCT01195493|Other|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
392743|NCT01195480|Genetic|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10^8/m2
392744|NCT01195480|Biological|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in > 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.~Vaccination will consist of 3 doses of 5 x 10^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
392745|NCT01195467|Drug|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
392746|NCT01195454|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection~Route of administration: subcutaneous"
392747|NCT01195454|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection~Route of administration: subcutaneous"
392748|NCT01195428|Drug|Simvastatin|Simvastatin 40 mg daily
392749|NCT01195428|Drug|Placebo|Placebo
392750|NCT01195415|Drug|Gemcitabine Hydrochloride|Given IV
392751|NCT01195415|Other|Laboratory Biomarker Analysis|Correlative studies
392752|NCT01195415|Drug|Vismodegib|Given PO
392753|NCT01195402|Procedure|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
392754|NCT01195389|Device|Resonator|Treatment group vs. Placebo group
392755|NCT01195376|Drug|BEZ235|
392756|NCT01195363|Drug|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
392762|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
392763|NCT01195311|Drug|INCB024360|INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
392764|NCT01195298|Drug|Capecitabine and Bevacizumab|"Drugs will be administered in 3-week cycles as follows:~Bevacizumab 15mg/kg via i.v. infusion on day 1~Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14."
392765|NCT01195285|Procedure|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
392766|NCT01195285|Procedure|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
392767|NCT01195272|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
392768|NCT01195259|Drug|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
392769|NCT01195246|Biological|HEPLISAV|Intramuscular (IM) injection on Day1
392770|NCT01195246|Biological|Engerix-B|Intramuscular (IM) injection on Day 1
392771|NCT01195246|Biological|Fendrix|Intramuscular (IM) injection on Day 1
392772|NCT01195233|Drug|bioxtra|spray /mouth rinse
392773|NCT01195220|Behavioral|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
392774|NCT01195220|Behavioral|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
392775|NCT01195220|Behavioral|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
392776|NCT01195207|Biological|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
392777|NCT01195207|Biological|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
392778|NCT01195207|Biological|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
392779|NCT01195207|Biological|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
392780|NCT01195207|Biological|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
392781|NCT01195207|Biological|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
392782|NCT01195207|Biological|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
392783|NCT01195207|Biological|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
392784|NCT01195194|Drug|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).~Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.~Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
392785|NCT01195181|Drug|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
392786|NCT01195155|Dietary Supplement|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
392787|NCT01195129|Device|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
392788|NCT01195129|Device|Non-hydrogel coils|Cerecyte or bare platinum coils
392789|NCT01195116|Drug|Dexmedetomidine|1 mcg/kg/hour
392790|NCT01195116|Drug|Normal Saline|1mcg/kg/hr
392791|NCT01195103|Drug|Fospropofol disodium|10 mg/kg bolus
392792|NCT01195103|Drug|Fospropofol disodium|6.5 mg/kg bolus
392793|NCT01195103|Drug|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients <60 kg; 1.5 mg for patients ≥60 kg to <90 kg; or 2 mg for patients ≥90 kg
392794|NCT01195103|Drug|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients <60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
392795|NCT01195090|Drug|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
392796|NCT01195090|Drug|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
392797|NCT01195077|Other|seaweed, spirulina, seaweed + spirulina|"Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.~Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day."
392798|NCT01195051|Other|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
392799|NCT01195038|Biological|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
392800|NCT01195025|Drug|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
392801|NCT01195025|Drug|colloid|Infusion of starch 10 ml/kg over 30 min
392802|NCT01195025|Drug|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
392803|NCT01195025|Device|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
392804|NCT01195012|Behavioral|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
392805|NCT01194999|Device|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
392806|NCT01194986|Other|[11C]AZ12807110|Radioligand
392807|NCT01194986|Drug|AZD5213|
392808|NCT01194973|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
392809|NCT01194960|Drug|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
392810|NCT01194960|Drug|TroVax + Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
392811|NCT01194947|Device|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
392812|NCT01194934|Drug|NOX-A12|4 mg/kg daily IV for 5 days
392813|NCT01194934|Drug|NOX-A12|2 mg/kg daily IV for 5 days
392814|NCT01194934|Drug|Filgrastim|5 µg/kg SC daily for 5 days
392815|NCT01194934|Drug|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
392816|NCT01194908|Drug|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
392817|NCT01194895|Other|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
392818|NCT01194895|Other|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
392819|NCT01194882|Drug|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
392820|NCT01194882|Drug|Insuplant|"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use~Dose regimen:"
392821|NCT01194869|Drug|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
392822|NCT01194869|Drug|Cisplatin|75 mg/m² given IV
392823|NCT01194869|Drug|Paclitaxel|175 mg/m² given IV
392824|NCT01194856|Drug|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
392825|NCT01194856|Drug|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
392826|NCT01194843|Drug|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
392827|NCT01194843|Drug|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
392828|NCT01194830|Drug|Linagliptin|Active drug 1 tablet PO QD
392829|NCT01194830|Drug|Placebo|1 Tablet PO QD
392830|NCT01194817|Device|High-Flexion Knee Replacement System using Cemented Fixation|
392831|NCT01194817|Device|High-Flexion Knee Replacement System using Cementless Fixation|
392832|NCT01194804|Drug|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
392833|NCT01194791|Drug|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
392834|NCT01194791|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
392835|NCT01194791|Drug|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
392836|NCT01194778|Dietary Supplement|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
392837|NCT01194778|Dietary Supplement|vitamin K1|15 µg vitamin K1 per day during 12 weeks
392838|NCT01194778|Dietary Supplement|vitamin K2|15 µg vitamin K2 per day during 12 weeks
392839|NCT01194778|Dietary Supplement|vitamin K2|30 µg vitamin K2 per day during 12 weeks
392840|NCT01194778|Dietary Supplement|vitamin K2|45 µg vitamin K2 per day during 12 weeks
392841|NCT01194765|Other|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
392842|NCT01194713|Behavioral|Sleep deprivation|subjects will undergo one night of full sleep deprivation
392843|NCT01194700|Drug|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
392844|NCT01194700|Drug|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
392845|NCT01194700|Drug|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
392846|NCT01194700|Drug|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
392847|NCT01194674|Drug|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
392848|NCT01194648|Other|questionnaire administration|
392849|NCT01194648|Procedure|assessment of therapy complications|
392850|NCT01194648|Procedure|high-intensity focused ultrasound ablation|
392851|NCT01194648|Procedure|multiparametric magnetic resonance imaging|
392863|NCT01194622|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
392864|NCT01194622|Drug|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
392865|NCT01194622|Drug|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
392866|NCT01194609|Biological|Immune cell|InnoLak two consecutive weeks every 3 weeks for 3 times
392867|NCT01194609|Radiation|Low dose radiation|20cGy whole body radiation every three weeks for three times
392868|NCT01194596|Behavioral|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
392869|NCT01194596|Behavioral|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
392870|NCT01194570|Drug|Ocrelizumab|Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
392871|NCT01194570|Other|Placebo|Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
392872|NCT01194557|Device|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
392873|NCT01194557|Drug|Lumartem|Presumptive treatment of malaria/fever
392874|NCT01194531|Device|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
392875|NCT01194518|Behavioral|Lifestyle Intervention Program|
392876|NCT01194505|Other|Sciatic, femoral, obturator nerve blocks|Ultrasound guided blocks with ropivacaine
392877|NCT01194505|Other|Sciatic nerve block, posterior lumbar plexus block|Ultrasound and neurostimulator nerve blocks with ropivacaine
392878|NCT01194492|Radiation|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
392879|NCT01194479|Drug|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
392880|NCT01194479|Other|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
392881|NCT01194466|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
392882|NCT01194453|Drug|cisplatin, dexamethasone,vitamin B12, folic acid|Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
392883|NCT01194453|Drug|cisplatin, gemcitabine|cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
392884|NCT01194440|Drug|letrozole|Given orally
392885|NCT01194440|Drug|zoledronic acid|Given IV
392886|NCT01194427|Drug|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
392887|NCT01194414|Drug|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
392888|NCT01194414|Drug|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
392889|NCT01194414|Drug|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
392890|NCT01194414|Drug|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
392891|NCT01194414|Drug|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
392892|NCT01194388|Device|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
392893|NCT01194375|Drug|Low Strength IDP-107|Once a day for 16 weeks
392894|NCT01194375|Drug|High Strength IDP-107|Once a day for 16 weeks
392895|NCT01194375|Drug|Placebo|Once a day for 16 weeks
392896|NCT01194336|Drug|Huperzine A|dosage form: tablet dose frequency: once only
392897|NCT01194336|Drug|Donepezil|dosage form: tablet dosage frequency: once only
392898|NCT01194336|Drug|Galantamine|dosage form: tablet dosage frequency: once only
392899|NCT01194336|Other|Placebo|dosage form: tablet dosage frequency: once only
392900|NCT01194310|Procedure|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
392901|NCT01194310|Procedure|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
392902|NCT01194310|Procedure|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
392903|NCT01194297|Biological|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
392904|NCT01194297|Biological|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
392905|NCT01194284|Drug|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
392906|NCT01194271|Drug|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
392907|NCT01194271|Drug|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
392908|NCT01194271|Procedure|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
392909|NCT01194258|Drug|Insulin lispro|
392910|NCT01194258|Drug|Insulin aspart|
392911|NCT01194258|Drug|Recombinant human hyaluronidase PH20|
392912|NCT01194258|Drug|Insulin glulisine|
392913|NCT01194258|Drug|Insulin glargine|
392914|NCT01194245|Drug|Insulin lispro|
392915|NCT01194245|Drug|recombinant human hyaluronidase PH20|
392916|NCT01194245|Drug|Insulin aspart|
392917|NCT01194245|Drug|Insulin glulisine|
392918|NCT01194245|Drug|Insulin glargine|
392919|NCT01194232|Drug|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
392920|NCT01194219|Drug|Apremilast|
392921|NCT01194219|Drug|Placebo|Identical matching placebo
392922|NCT01194219|Drug|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
392923|NCT01194206|Radiation|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
392924|NCT01194193|Drug|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
392925|NCT01194180|Biological|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
392926|NCT01194180|Biological|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
392927|NCT01194167|Drug|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
392928|NCT01194154|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
392929|NCT01194154|Drug|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
392930|NCT01194141|Behavioral|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
392931|NCT01194128|Behavioral|Psychoeducational Support|The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
392932|NCT01194128|Behavioral|Information only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information."
392933|NCT01194115|Drug|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
392934|NCT01194115|Drug|placebo|placebo representing standard of care
392935|NCT01194102|Behavioral|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
392936|NCT01194102|Other|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
392937|NCT01194102|Other|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
392938|NCT01194089|Drug|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
392939|NCT01194089|Drug|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
392940|NCT01194076|Behavioral|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
392941|NCT01194063|Drug|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
392942|NCT01194037|Drug|recombinant variant of interferon-alpha 2b|SC, Weekly
392943|NCT01194037|Drug|Peginterferon alfa-2a|SC Weekly
392944|NCT01194024|Other|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
392945|NCT01194011|Behavioral|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
392946|NCT01193998|Other|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
392947|NCT01193998|Other|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
392948|NCT01193985|Device|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
392949|NCT01193972|Other|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
392950|NCT01193946|Dietary Supplement|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
392951|NCT01193933|Procedure|autologous HSCT|T-cell ALL patients recieve late consolidation with BEAM conditioning and stem cell support
392952|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
392953|NCT01193920|Other|Saline solution|Subjects received two injection of saline solution.
392954|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
392955|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
392956|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
392957|NCT01193920|Other|saline solution|Subjects received one injection of saline solution.
392958|NCT01193907|Biological|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
392959|NCT01193907|Biological|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
392960|NCT01193907|Biological|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
392961|NCT01193907|Biological|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
392962|NCT01193894|Other|Profermin|Medical Food (food for special medical purposes)
392963|NCT01193894|Other|Fresubin|Medical food (food for special medical purposes)
392964|NCT01193881|Drug|Erlotinib Hydrochloride|Given PO
392965|NCT01193881|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
392966|NCT01193881|Other|Laboratory Biomarker Analysis|Correlative studies
392967|NCT01193881|Other|Pharmacological Study|Correlative studies
392968|NCT01193868|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
392969|NCT01193868|Other|laboratory biomarker analysis|Correlative studies
392970|NCT01193868|Other|pharmacological study|Correlative studies
392971|NCT01193855|Drug|dutasteride|
392972|NCT01193855|Drug|gadolinium-chelate|
392973|NCT01193855|Other|active surveillance|
392974|NCT01193855|Procedure|diffusion-weighted magnetic resonance imaging|
392975|NCT01193855|Procedure|functional magnetic resonance imaging|
392976|NCT01193855|Procedure|prostate biopsy|
392977|NCT01193855|Procedure|ultrasound imaging|
392978|NCT01193842|Drug|Cyclophosphamide|Given IV
392979|NCT01193842|Drug|Doxorubicin Hydrochloride|Given IV
392980|NCT01193842|Drug|Etoposide|Given IV
392981|NCT01193842|Other|Laboratory Biomarker Analysis|Correlative studies
392982|NCT01193842|Other|Pharmacological Study|Correlative studies
392983|NCT01193842|Drug|Prednisone|Given PO
392984|NCT01193842|Biological|Rituximab|Given IV
392985|NCT01193842|Drug|Vincristine Sulfate|Given IV
392986|NCT01193842|Drug|Vorinostat|Given PO
392987|NCT01193816|Drug|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
392988|NCT01193816|Drug|Placebo|Placebo
392989|NCT01193803|Procedure|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.~Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
392990|NCT01193790|Procedure|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
392991|NCT01193777|Drug|L-Carnitine|4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
392992|NCT01193777|Drug|Normal Saline|Bolus followed by 1 L NS infusion over 12 hours.
392993|NCT01193764|Dietary Supplement|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
393034|NCT01193517|Drug|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
393035|NCT01193504|Drug|Pred Forte|Pred Forte BID for 4 weeks postop
393036|NCT01193504|Drug|Lotemax|Lotemax BID for 4 weeks postop.
393090|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
392994|NCT01193764|Dietary Supplement|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
392995|NCT01193738|Procedure|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
392996|NCT01193725|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
392997|NCT01193725|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
392998|NCT01193725|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
392999|NCT01193712|Procedure|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
393000|NCT01193699|Drug|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
393001|NCT01193686|Other|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
393002|NCT01193660|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
393003|NCT01193660|Drug|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
393004|NCT01193660|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
393005|NCT01193660|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
393006|NCT01193660|Other|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
393007|NCT01193634|Device|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
393008|NCT01193621|Drug|haloperidol, PET|"Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan~D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4~above doses will be administrated orally every 24 hours for 7 days."
393009|NCT01193608|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
393010|NCT01193608|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
393011|NCT01193608|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
393012|NCT01193608|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
393013|NCT01193608|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
393014|NCT01193608|Other|Placebo|Placebo, IV
393015|NCT01193595|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
393016|NCT01193595|Drug|bevacizumab|"Pharmaceutical form:Solution for infusion~Route of administration: Intravenous"
393017|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~4 doses starting from 121 to < 212 days of age"
393018|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~3 doses starting from 212 days to < 12 months of age"
393019|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~2 doses starting from 12 months to < 24 months of age"
393020|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml~Frequency:~1 dose starting from 24 months to < 72 months of age"
393021|NCT01193556|Device|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
393022|NCT01193556|Device|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
393023|NCT01193543|Dietary Supplement|calanus oil|1 gram twice daily
393024|NCT01193543|Dietary Supplement|olive oil|1 gram twice daily
393025|NCT01193530|Other|Bright Light Therapy|30 minutes every day for 14 days. After enrollment on day 0, blinded phase of study intervention (i.e. daily bright light or red light) from day 1 to day 14+/-3, then proceed to the open label phase and receive daily bright light between day 15+/-3 and day 28+/-3.
393026|NCT01193530|Other|Dim Red Light Therapy|From day 1 to day 14+/-3, daily dim red light therapy for 30 minutes for 14 days where red light device accounts for placebo of the blinded phase of study intervention, then between day 15+/-3 and day 28+/-3 open label phase with daily bright light.
393027|NCT01193530|Behavioral|Questionnaires|Weekly
393028|NCT01193530|Behavioral|Study Diaries|Daily logs
393029|NCT01193530|Device|Red Light Litebook|Control red light device produced by Litebook identical in appearance and dimensions to the bright light device, with the exception it emits at wavelength 680nm (i.e. red light) and at an intensity of 50 lux.
393030|NCT01193530|Device|Bright Light Litebook|Bright light device consists of 60 LEDs with spectral emission peak at approximately 464nm and fluorescent phosphors which provide a broader, secondary spectral peak near 564nm. Collectively the emitted light appears white.
393031|NCT01193517|Drug|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
393032|NCT01193517|Drug|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
393033|NCT01193517|Drug|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
393037|NCT01193491|Drug|IPI-493|Capsules, ascending dose, multiple schedules
393038|NCT01193478|Drug|GS-5885|tablet, oral, 3 mg once daily for 3 days
393039|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
393040|NCT01193478|Drug|GS-5885|tablet, oral, 10 mg once daily for 3 days
393041|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
393042|NCT01193478|Drug|GS-5885|tablet, oral, 30 mg once daily for 3 days
393043|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
393044|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
393045|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
393046|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
393047|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
393048|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
393049|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
393050|NCT01193465|Device|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
393051|NCT01193465|Device|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
393052|NCT01193465|Device|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
393053|NCT01193465|Device|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
393054|NCT01193452|Drug|S-1, Leucovorin|"S-1 :~The initial dosage of S-1 is determined by the body surface area:~Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day~Leucovorin:~25mg twice per day po.~The treatment is given for one week,and no chemotherapy is given for the following one week."
393055|NCT01193452|Drug|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;~5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours~repeat every 2 weeks"
393056|NCT01193426|Other|Ascite liquid puncture|Ascitic fluid obtained by paracentesis
393057|NCT01193400|Drug|Clofarabine|
393058|NCT01193400|Drug|Cytarabine|
393059|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
393060|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
393061|NCT01193374|Behavioral|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
393062|NCT01193374|Behavioral|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
393063|NCT01193374|Behavioral|basic educational brochure|Booklet by ADA sent x 1.
393064|NCT01193361|Drug|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
393065|NCT01193361|Drug|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
393066|NCT01193361|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
393067|NCT01193361|Drug|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
393068|NCT01193361|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
393069|NCT01193348|Drug|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
393070|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
393071|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
393072|NCT01193296|Drug|Vildagliptin|
393073|NCT01193296|Drug|Sitagliptin|
393074|NCT01193283|Drug|Cyclophosphamide|30 my/kg for 4 days
393075|NCT01193283|Drug|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
393076|NCT01193270|Drug|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
393077|NCT01193270|Drug|Placebo|Sterile water in volume equal to that of the comparator drug
393078|NCT01193257|Drug|Orteronel|Orteronel tablets
393079|NCT01193257|Drug|Prednisone|Prednisone tablets
393080|NCT01193257|Drug|Orteronel Placebo|Orteronel placebo-matching tablets
393081|NCT01193244|Drug|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
393082|NCT01193244|Drug|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.
393083|NCT01193244|Drug|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
393084|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
393085|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
393086|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
393087|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
393088|NCT01193218|Drug|BI 10773|BI 10773 tablets low dose once a day
393089|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
393091|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
393092|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-high dose once a day
393093|NCT01193218|Drug|BI 10773|BI 10773 tablets high dose once a day
393094|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
393095|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
393096|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
393097|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
393098|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-low dose once a day
393099|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
393100|NCT01193205|Behavioral|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
393101|NCT01193192|Other|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
393102|NCT01193192|Other|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
393103|NCT01193179|Drug|OPC-262|Oral administration of tablets for 52 weeks
393104|NCT01193166|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
393105|NCT01193166|Drug|risperidone|flexible dosing as prescribed by the study doctor for 12 months
393106|NCT01193166|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
393107|NCT01193166|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
393108|NCT01193166|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
393109|NCT01193166|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
393110|NCT01193166|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
393111|NCT01193166|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
393112|NCT01193153|Drug|Placebo|monthly by i.m. injection for 15 months
393113|NCT01193153|Drug|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
393114|NCT01193140|Drug|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
393115|NCT01193140|Drug|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
393116|NCT01193127|Drug|OMS302 Solution|
393117|NCT01193127|Drug|OMS302 Mydriatic Solution|
393118|NCT01193127|Drug|OMS302 Anti-inflammatory Solution|
393119|NCT01193127|Drug|Balanced Salt Solution (BSS) Solution|
393120|NCT01193114|Behavioral|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
393121|NCT01193114|Behavioral|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
393122|NCT01193101|Drug|LCZ696|LCZ696
393123|NCT01193101|Drug|Placebo|matching placebo to LCZ696
393124|NCT01193062|Drug|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
393125|NCT01193062|Drug|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
393126|NCT01193049|Drug|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
393127|NCT01193049|Drug|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
393128|NCT01193036|Behavioral|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
393129|NCT01193036|Behavioral|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
393130|NCT01193023|Other|Pressure Support|Ventilation under pressure support
393131|NCT01193023|Device|NAVA|Ventilation under NAVA
393132|NCT01193010|Procedure|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
393133|NCT01193010|Procedure|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
393134|NCT01192997|Biological|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
393135|NCT01192997|Biological|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
393136|NCT01192984|Biological|KW-0761|Intravenously 8 times at 1-week intervals
393137|NCT01192971|Drug|Apatinib|apatinib p.o. once daily for 4 weeks
393138|NCT01192932|Radiation|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~90 quality ref mAs with care-dose ON~120 kV~Pitch 1.4~Rotation time 0.33 s~Acquired images 64 x 0.6 mm"
393139|NCT01192906|Drug|Placebo|Oral doses, once a day for 52 weeks
393140|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
393141|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
393142|NCT01192880|Drug|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
393143|NCT01192880|Drug|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
393144|NCT01192880|Drug|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
393145|NCT01192867|Drug|Placebo|Placebo will be administered orally QD for 56 weeks
393146|NCT01192867|Drug|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
393147|NCT01192867|Drug|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
393148|NCT01192854|Drug|Clevudine|Clevudine flexible dosages of 30 mg/day
393149|NCT01192854|Drug|Adefovir|Adefovir flexible dosages of 10 mg/day
393150|NCT01192841|Other|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
393151|NCT01192828|Drug|taurine|Take Taurine for 4 1/2 days, two doses per day
393152|NCT01192815|Drug|erlotinib hydrochloride|Given orally or via gastronomy tube
393153|NCT01192815|Radiation|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
393154|NCT01192815|Other|pharmacogenomic studies|Optional correlative studies
393155|NCT01192815|Other|gene expression analysis|Correlative studies
393156|NCT01192815|Radiation|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.~The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
393157|NCT01192815|Other|biopsy|Optional correlative studies
393158|NCT01192815|Other|pharmacological study|Optional correlative studies
393159|NCT01192815|Other|laboratory biomarker analysis|Optional correlative studies
393160|NCT01192815|Other|questionnaire administration|Optional ancillary studies
393161|NCT01192815|Other|enzyme-linked immunosorbent assay|Optional correlative studies
393162|NCT01192815|Other|polymorphism analysis|Optional correlative studies
393163|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
393164|NCT01192802|Drug|albendazole|single 1 tablet of 400 mg of albendazole
393165|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
393166|NCT01192789|Drug|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
393167|NCT01192789|Other|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
393168|NCT01192776|Procedure|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
393169|NCT01192763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
393170|NCT01192763|Other|laboratory biomarker analysis|Correlative studies
393171|NCT01192763|Other|pharmacological study|Correlative studies
393172|NCT01192763|Procedure|neoadjuvant therapy|
393173|NCT01192763|Procedure|therapeutic conventional surgery|
393174|NCT01192750|Other|immunohistochemistry staining method|
393175|NCT01192750|Other|laboratory biomarker analysis|
393176|NCT01192750|Other|medical chart review|
393177|NCT01192724|Drug|Cilostazol|100 mg BID, for 3 months
393178|NCT01192724|Drug|Aspirin|Aspirin 100 mg QD, for 1 year
393179|NCT01192724|Drug|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
393180|NCT01192711|Device|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
393181|NCT01192698|Drug|IV interferon|IV interferon 5MU during anhepatic phase
393182|NCT01192685|Procedure|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
393183|NCT01192685|Device|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
393184|NCT01192672|Behavioral|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
393185|NCT01192672|Behavioral|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
393186|NCT01192646|Behavioral|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
393187|NCT01192633|Drug|GVP|"Drug: gemcitabine, vincristine,cisplatin~cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
393188|NCT01192607|Device|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
393189|NCT01192594|Behavioral|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
393190|NCT01192594|Behavioral|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
393191|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
393192|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
393193|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
393194|NCT01192568|Drug|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
393229|NCT01192217|Procedure|Axillary mini-thoracotomy|Axillary mini-thoracotomy
393230|NCT01192204|Drug|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
393195|NCT01192555|Biological|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells|"1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.~Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.~Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
393196|NCT01192555|Drug|Cytoxan|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
393197|NCT01192542|Device|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
393198|NCT01192542|Device|enfilcon A lens|Marketed silicone hydrogel contact lens
393199|NCT01192529|Dietary Supplement|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.~Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
393200|NCT01192529|Dietary Supplement|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
393201|NCT01192516|Behavioral|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
393202|NCT01192516|Behavioral|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
393203|NCT01192503|Drug|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
393204|NCT01192503|Drug|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
393205|NCT01192490|Drug|Lidocaine|5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
393206|NCT01192490|Drug|Lubricant|KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
393207|NCT01192477|Other|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
393208|NCT01192464|Drug|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
393209|NCT01192438|Procedure|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
393210|NCT01192412|Procedure|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is >105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP <100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
393211|NCT01192412|Procedure|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is <80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is >85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
393212|NCT01192399|Biological|Eculizumab|
393213|NCT01192373|Other|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
393214|NCT01192373|Other|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
393215|NCT01192360|Procedure|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
393216|NCT01192360|Procedure|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
393217|NCT01192321|Device|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
393218|NCT01192321|Device|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
393219|NCT01192308|Drug|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
393220|NCT01192295|Drug|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
393221|NCT01192282|Procedure|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
393222|NCT01192269|Dietary Supplement|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
393223|NCT01192243|Drug|Gefitinib|250mg qd po d3-16
393224|NCT01192243|Drug|Pemetrexed|500mg/m2 venous infusion,D1,q3w
393225|NCT01192243|Drug|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
393226|NCT01192230|Drug|Endostatins|7.5mg/m2 qd *14d,q3w
393227|NCT01192230|Drug|Docetaxel|75mg/m2 D1, q3w,4-6cycles
393228|NCT01192217|Procedure|Modified thoracoscopic technique|Two-port thoracoscopic technique
393231|NCT01192204|Drug|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
393232|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
393233|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
393234|NCT01192178|Drug|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
393235|NCT01192178|Drug|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
393236|NCT01192165|Drug|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
393237|NCT01192165|Drug|Docetaxel|Chemotherapy
393238|NCT01192165|Drug|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
393239|NCT01192165|Drug|Pemetrexed|Chemotherapy
393240|NCT01192165|Drug|Carboplatin|Chemotherapy
393241|NCT01192165|Drug|nab-Paclitaxel|Chemotherapy
393242|NCT01192165|Drug|Cisplatin|Chemotherapy
393243|NCT01192152|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
393244|NCT01192152|Drug|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
393245|NCT01192152|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
393246|NCT01192139|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
393247|NCT01192139|Drug|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
393248|NCT01192139|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
393249|NCT01192126|Device|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
393250|NCT01192126|Device|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
393251|NCT01192113|Drug|Mecobalamin IV Injection|Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
393252|NCT01192113|Drug|Mecobalamin IM injection|Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
393253|NCT01192113|Drug|Mecobalamin IV or IM injection|Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
393254|NCT01192100|Behavioral|Breakfast Skipping|Participants will continue to skip breakfast each morning.
393255|NCT01192100|Behavioral|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
393256|NCT01192100|Behavioral|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
393257|NCT01192087|Drug|Cetuximab|cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
393258|NCT01192074|Device|Ultrasound|Preprocedure ultrasound examination of the spine
393259|NCT01192048|Other|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome sequencing.
393260|NCT01192035|Drug|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
393261|NCT01192035|Drug|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
393262|NCT01192022|Biological|TachoSil®|Intraoperative application as secondary hemostatic treatment
393263|NCT01192022|Device|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
393264|NCT01192009|Dietary Supplement|Leucine|7.2 g of leucine during 2 weeks
393265|NCT01192009|Dietary Supplement|Placebo|7.2 g of alanine during 2 weeks
393266|NCT01191996|Biological|MIS416|MIS416 intravenously every week
393267|NCT01191983|Drug|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
393268|NCT01191957|Drug|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest~Followed by:~Cyclophosphamide, 120 mg/kg iv:~Day -4: 60 mg/kg Day -3: 60 mg/kg"
393269|NCT01191957|Drug|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:~Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:~Fludarabine, 4 x 40 mg/m² iv:~Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
393270|NCT01191944|Drug|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
393271|NCT01191944|Drug|pramipexole extended release tablet|0.375mg-4.5mg, once a day
393272|NCT01191918|Drug|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
393273|NCT01191918|Drug|Placebo plus Lithium|
393274|NCT01191905|Drug|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
393275|NCT01191905|Drug|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
393276|NCT01191892|Drug|carboplatin|
393277|NCT01191892|Drug|gemcitabine hydrochloride|
393278|NCT01191892|Drug|vandetanib|
393279|NCT01191892|Drug|Placebo|Placebo of vandetanib tablet
393280|NCT01191879|Other|Blood test|Blood test
393281|NCT01191866|Behavioral|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
393282|NCT01191840|Drug|Vancomycin|Duration
393283|NCT01191840|Drug|Vancomycin|Duration
393284|NCT01191814|Procedure|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
393285|NCT01191814|Procedure|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
393286|NCT01191801|Drug|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
393287|NCT01191801|Drug|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin~Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
393288|NCT01191788|Behavioral|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
393289|NCT01191788|Behavioral|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
393290|NCT01191775|Drug|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
393291|NCT01191762|Drug|sevelamer carbonate|2400 mg with each meal for 4 weeks
393292|NCT01191762|Drug|placebo|3 tablets with each meal
393293|NCT01191749|Drug|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
393294|NCT01191736|Behavioral|No training, assessed within 60 mins|Subjects receive no training in resuscitation
393295|NCT01191736|Behavioral|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
393296|NCT01191736|Behavioral|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
393297|NCT01191736|Behavioral|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
393298|NCT01191736|Behavioral|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
393299|NCT01191736|Behavioral|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
393300|NCT01191736|Behavioral|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
393301|NCT01191723|Drug|MAP0004|3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
393302|NCT01191723|Drug|Inhaler Placebo|Placebo for Inhaler administered in Treatments A and C
393303|NCT01191723|Drug|Moxifloxacin|400mg encapsulated tablet administered in Treatment A as per protocol
393304|NCT01191723|Drug|Placebo Capsule|Placebo for Moxifloxacin administered in Treatment B and Treatment C
393305|NCT01191710|Other|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
393306|NCT01191697|Drug|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
393307|NCT01191697|Drug|trastuzumab|Given intravenously on day 1 of each treatment cycle
393308|NCT01191697|Drug|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
393309|NCT01191697|Drug|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
393310|NCT01191684|Other|laboratory biomarker analysis|Correlative studies
393311|NCT01191684|Other|enzyme-linked immunosorbent assay|Correlative studies
393312|NCT01191684|Other|flow cytometry|Correlative studies
393313|NCT01191684|Other|immunoenzyme technique|Correlative studies
393314|NCT01191684|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
393315|NCT01191645|Drug|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
393316|NCT01191645|Drug|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
393317|NCT01191645|Drug|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
393318|NCT01191645|Drug|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
393319|NCT01191632|Radiation|one time radiation|"Radiation: one time Radiation with an intensity of~0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
393320|NCT01191632|Radiation|No Radiation|Control group with 0Gy
393321|NCT01191619|Procedure|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
393322|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
393353|NCT01191385|Drug|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
393354|NCT01191372|Drug|placebo control|sterile saline for injection
393355|NCT01191372|Drug|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
393323|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
393324|NCT01191593|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
393325|NCT01191593|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
393326|NCT01191580|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
393327|NCT01191580|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
393328|NCT01191580|Behavioral|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
393329|NCT01191567|Procedure|VAC treatment|wound treatment with VAC-therapy
393330|NCT01191567|Procedure|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
393331|NCT01191554|Drug|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
393332|NCT01191541|Drug|Ara-c|"Drug: ATRA 25mg/m2 day until complete remission (CR)~Drug: As2O3 Induction:0.15-0.2mg/kg d1-28 iv Consolidation: 0.15-0.2mg/kg d1-28 iv in cycle 2 Drug: Idarubicin 10 mg/m2 days1-3 in Consolidation1 Drug: Ara-C some patients consolidation with Ara-C in cycles 3 and 4. Ara-c 1g/m2 d1-3 iv Drug: DNR 45 mg/m2 days1-3 in Consolidation 3 and 4"
393333|NCT01191528|Device|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.~End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
393334|NCT01191515|Device|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
393335|NCT01191489|Device|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
393336|NCT01191489|Device|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
393337|NCT01191489|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
393338|NCT01191476|Drug|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
393339|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
393340|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
393341|NCT01191463|Other|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
393342|NCT01191463|Other|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
393343|NCT01191450|Drug|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
393344|NCT01191450|Drug|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
393345|NCT01191424|Drug|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
393346|NCT01191424|Drug|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
393347|NCT01191411|Other|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
393348|NCT01191411|Other|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
393349|NCT01191411|Other|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
393350|NCT01191398|Drug|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
393351|NCT01191398|Drug|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
393352|NCT01191398|Drug|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
393356|NCT01191359|Biological|oral immunotherapy|orally applied specific immunotherapy
393357|NCT01191346|Other|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
393358|NCT01191333|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
393359|NCT01191333|Device|Sham Device|Placebo Device that simulates active rTMS treatment
393360|NCT01191320|Drug|Placebo|Placebo capsule 1x daily for 3 months
393361|NCT01191320|Drug|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
393362|NCT01191294|Other|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
393363|NCT01191281|Behavioral|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
393364|NCT01191281|Other|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
393365|NCT01191268|Drug|Insulin Glargine|
393366|NCT01191268|Drug|LY2189265|
393367|NCT01191268|Drug|Insulin Lispro|
393368|NCT01191255|Drug|ferric citrate, ca acetate, sevelamer carbonate, placebo|All intervention doses will be based on serum phosphorus levels and/or drug label requirements
393369|NCT01191229|Device|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
393370|NCT01191229|Device|Crystalens AO|25 patients that are previously implanted
393371|NCT01191216|Drug|1-methyl-d-tryptophan|
393372|NCT01191216|Drug|docetaxel|
393373|NCT01191216|Other|diagnostic laboratory biomarker analysis|
393374|NCT01191216|Other|pharmacological study|
393375|NCT01191203|Drug|Copper IUD|Copper IUD (CuT360)
393376|NCT01191203|Drug|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
393377|NCT01191190|Drug|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.~Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.~Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
393378|NCT01191177|Drug|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
393379|NCT01191177|Dietary Supplement|Corn oil|1 gram per kilogram body weight per day, not exceeding 4 grams
393380|NCT01191164|Procedure|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|"Target Volumes: The surgical cavity will be assessed with US & CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.~Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.~Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre."
393381|NCT01191138|Procedure|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
393382|NCT01191138|Procedure|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
393383|NCT01191125|Other|medical food with AN777|Two(220 mL)servings every day for six months
393384|NCT01191125|Other|oral nutritional formula|Two (220 mL) servings daily for six months
393385|NCT01191112|Other|Peptide based enteral formula|Sole source nutrition as per HCP
393386|NCT01191099|Device|Pimonidazol|0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
393387|NCT01191086|Drug|USL255|
393388|NCT01191073|Device|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
393389|NCT01191073|Device|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
393390|NCT01191060|Drug|Lenalidomide, Bortezomib|"Lenalidomide/Bortézomib/Dexamethasone cycles:~Number of cycles: 8 cycles for arm A~Cycle length~Dosage:~Lenalidomide: 25 mg/day on days 1-14 of each cycle~Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
393391|NCT01191060|Drug|Lenalidomide, Bortezomib|"Lenalidomide Bortezomib Dexamethasone cycles:~Number of cycles: 5 cycles for arm B~Cycle length~Dosage:~Lenalidomide: 25 mg/day on days 1-14 of each cycle~Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle~Maintenance phase (12 months):~Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
393392|NCT01191034|Drug|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.~This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
393393|NCT01191021|Drug|Propofol Anesthesia|Volunteers will undergo propofol anesthesia for 90 min.
393394|NCT01191008|Drug|Latanoprost-timolol maleate fixed combination ophthalmic solution|"Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily."
393508|NCT01190228|Biological|JE-CV Vaccine|0.5 mL (single dose), Subcutaneous
393509|NCT01190228|Biological|Varicella Vaccine|0.5 mL (single dose), Subcutaneous
393395|NCT01190995|Drug|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
393396|NCT01190995|Drug|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
393397|NCT01190982|Drug|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
393398|NCT01190969|Dietary Supplement|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
393399|NCT01190943|Other|Laboratory Biomarker Analysis|Correlative studies
393400|NCT01190930|Drug|Cyclophosphamide|Given IV
393401|NCT01190930|Drug|Cytarabine|Given IT, IV, or SC
393402|NCT01190930|Drug|Dexamethasone|Given orally (PO) or IV
393403|NCT01190930|Drug|Doxorubicin Hydrochloride|Given IV
393404|NCT01190930|Other|Laboratory Biomarker Analysis|Correlative studies
393405|NCT01190930|Drug|Leucovorin Calcium|Given PO
393406|NCT01190930|Drug|Mercaptopurine|Given PO
393407|NCT01190930|Drug|Methotrexate|Given IT, PO, or IV
393408|NCT01190930|Drug|Pegaspargase|Given IV
393409|NCT01190930|Other|Quality-of-Life Assessment|Ancillary studies
393410|NCT01190930|Other|Questionnaire Administration|Ancillary studies
393411|NCT01190930|Drug|Thioguanine|Given PO
393412|NCT01190930|Drug|Vincristine Sulfate|Given IV
393413|NCT01190917|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
393414|NCT01190917|Behavioral|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
393415|NCT01190891|Procedure|Manual Physical Therapy|Same as arm description
393416|NCT01190891|Procedure|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
393417|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed QD
393418|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed BID
393419|NCT01190878|Drug|DuraSite Vehicle|Vehicle dosed BID
393420|NCT01190878|Drug|Xibrom™|0.09% bromfenac dosed BID
393421|NCT01190865|Biological|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
393422|NCT01190852|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
393423|NCT01190852|Drug|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
393424|NCT01190852|Drug|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
393425|NCT01190839|Biological|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
393426|NCT01190839|Drug|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
393427|NCT01190826|Drug|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
393428|NCT01190826|Drug|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
393429|NCT01190826|Drug|Placebo|Placebo administered once by inhalation
393430|NCT01190813|Drug|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
393431|NCT01190813|Drug|Placebo|Oral placebo tid
393432|NCT01190813|Other|Patching|Two hours of daily patching
393433|NCT01190787|Drug|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
393434|NCT01190787|Drug|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
393510|NCT01190215|Biological|FluarixTM|One Intramuscular injection
393435|NCT01190787|Drug|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
393436|NCT01190774|Behavioral|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
393437|NCT01190774|Behavioral|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
393438|NCT01190761|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
393439|NCT01190761|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
393440|NCT01190748|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
393441|NCT01190748|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
393442|NCT01190735|Drug|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
393443|NCT01190722|Drug|etoricoxib|120 mg once daily for the 1st 6 postoperative days
393444|NCT01190722|Drug|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
393445|NCT01190709|Procedure|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
393446|NCT01190709|Procedure|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
393447|NCT01190696|Procedure|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
393448|NCT01190696|Device|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
393449|NCT01190683|Drug|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
393450|NCT01190683|Drug|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
393451|NCT01190683|Drug|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
393452|NCT01190683|Other|lactose placebo|similar number of granules and tablets as active group
393453|NCT01190683|Other|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
393454|NCT01190670|Drug|Tacrolimus|Oral and Intravenous
393455|NCT01190670|Drug|ASP015K|Oral
393456|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 14 days
393457|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 56 days
393458|NCT01190644|Drug|ACE 011|35 mg subcutaneous (SC) dose on study Day 1, Day 43, Day 85
393459|NCT01190631|Device|Acrysof IQ (SN60WF) IOL|Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
393460|NCT01190592|Other|Resistance Training with Milk Supplementation in Adolescents|"On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.~On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day."
393461|NCT01190553|Drug|Amantadine|Initiation: IV amantadine 200mg/500ml * 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
393462|NCT01190540|Behavioral|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
393463|NCT01190540|Behavioral|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
393464|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
393570|NCT01189734|Procedure|laparoscopic common bile duct exploration|
393465|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
393466|NCT01190527|Radiation|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
393467|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
393468|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
393469|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
393470|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
393471|NCT01190501|Device|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.~Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
393472|NCT01190488|Behavioral|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
393473|NCT01190488|Behavioral|Active Comparator|TAU
393474|NCT01190475|Drug|BGS649|
393475|NCT01190475|Drug|BGS649|
393476|NCT01190475|Drug|Placebo|
393477|NCT01190462|Biological|cetuximab|
393478|NCT01190462|Drug|simvastatin|
393479|NCT01190462|Other|laboratory biomarker analysis|
393480|NCT01190449|Biological|ofatumumab|Given IV
393481|NCT01190436|Drug|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
393482|NCT01190423|Behavioral|Family Based Therapy for young adults|Individual and Group Therapy Sessions
393483|NCT01190410|Drug|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
393484|NCT01190410|Drug|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
393485|NCT01190397|Device|Warming goggles|
393486|NCT01190397|Device|warm and moist compresses|
393487|NCT01190384|Other|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
393488|NCT01190384|Dietary Supplement|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
393489|NCT01190384|Other|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
393490|NCT01190371|Drug|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
393491|NCT01190358|Dietary Supplement|Placebo|Sugar pill containing maltodextrin.
393492|NCT01190358|Dietary Supplement|Grape seed extract|Meganatural Gold® contains 300mg of grape seed extract.
393493|NCT01190345|Drug|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
393494|NCT01190345|Drug|no bevacizumab|no bevacizumab
393495|NCT01190332|Procedure|endoscopic sphincterotomy by conventional method|
393496|NCT01190332|Procedure|endoscopic sphincterotomy by rendezvous method|
393497|NCT01190319|Other|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
393498|NCT01190319|Other|Placebo|Placebo beverage, 8 weeks
393499|NCT01190306|Device|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
393500|NCT01190306|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
393501|NCT01190293|Drug|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
393502|NCT01190280|Procedure|Cholecystectomy operation|Cholecystectomy after randomization
393503|NCT01190267|Drug|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
393504|NCT01190254|Drug|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
393505|NCT01190254|Drug|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
393506|NCT01190254|Drug|placebo|asenapine-matched placebo tablets for sublingual administration
393507|NCT01190241|Drug|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
393511|NCT01190215|Biological|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
393512|NCT01190202|Procedure|Blood sampling|Capillary blood samples collected by finger/heel prick
393513|NCT01190202|Procedure|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
393514|NCT01190189|Biological|GSK580299 (Cervarix)|3-dose schedule intramuscularly vaccination
393515|NCT01190176|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
393516|NCT01190176|Biological|Cervarix|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
393517|NCT01190176|Biological|Placebo control|Subjects received 3 doses of the control [Al(OH)3] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
393518|NCT01190163|Drug|Dinoprostone|
393519|NCT01190163|Drug|Oxytocin|
393520|NCT01190150|Drug|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
393521|NCT01190137|Dietary Supplement|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
393522|NCT01190111|Biological|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
393523|NCT01190098|Drug|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:~Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
393524|NCT01190098|Drug|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
393525|NCT01190085|Drug|Ghrelin|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
393526|NCT01190085|Drug|Ghrelin|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
393527|NCT01190085|Drug|Saline solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
393528|NCT01190059|Drug|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
393529|NCT01190046|Behavioral|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
393530|NCT01190033|Device|Neurotome OFF|In this intervention the neurotome will be unconnected.
393531|NCT01190033|Procedure|neurolysis|In this procedure the neurotome will be connected
393532|NCT01190020|Drug|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
393533|NCT01190020|Drug|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
393534|NCT01190007|Drug|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
393535|NCT01189994|Procedure|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
393536|NCT01189994|Behavioral|Orientation|Orientation sessions focusing in fibromyalgia
393537|NCT01189981|Behavioral|Lifestyle counseling|One health conversation at baseline
393538|NCT01189981|Behavioral|eHealth intervention|SMS based encouragements to intensive exercise
393539|NCT01189968|Drug|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
393540|NCT01189955|Procedure|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
393541|NCT01189955|Procedure|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
393571|NCT01189734|Procedure|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
393605|NCT01189409|Drug|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
393542|NCT01189942|Drug|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
393543|NCT01189929|Drug|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
393544|NCT01189929|Drug|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
393545|NCT01189929|Drug|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
393546|NCT01189916|Procedure|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
393547|NCT01189903|Drug|Regorafenib|
393548|NCT01189890|Drug|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
393549|NCT01189890|Drug|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
393550|NCT01189890|Drug|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
393551|NCT01189890|Drug|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
393552|NCT01189877|Procedure|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
393553|NCT01189864|Drug|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
393554|NCT01189864|Drug|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
393555|NCT01189864|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
393556|NCT01189851|Device|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
393557|NCT01189825|Behavioral|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
393558|NCT01189812|Drug|Lithium Carbonate|300 mg one time per day for 4 weeks
393559|NCT01189812|Drug|Placebo|Take one time daily for 4 weeks
393560|NCT01189812|Drug|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
393561|NCT01189799|Behavioral|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
393562|NCT01189799|Other|Dual Recovery Anonymous/Treatment as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
393563|NCT01189786|Device|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
393564|NCT01189773|Drug|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
393565|NCT01189760|Biological|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
393566|NCT01189760|Biological|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
393567|NCT01189760|Drug|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
393568|NCT01189747|Biological|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
393569|NCT01189747|Drug|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
393572|NCT01189721|Drug|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.~group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
393573|NCT01189708|Device|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
393574|NCT01189708|Other|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
393575|NCT01189695|Drug|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
393576|NCT01189695|Drug|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
393577|NCT01189682|Procedure|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
393578|NCT01189669|Dietary Supplement|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
393579|NCT01189669|Dietary Supplement|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
393580|NCT01189656|Biological|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
393581|NCT01189643|Drug|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
393582|NCT01189617|Device|Formula PD-F-7619|Off-White to Beige Lotion
393583|NCT01189604|Drug|Placebo|Infusion of placebo, same infusion rates as for arm 2
393584|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
393585|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
393586|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
393587|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
393588|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
393589|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
393590|NCT01189591|Device|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
393591|NCT01189552|Behavioral|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
393592|NCT01189552|Behavioral|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
393593|NCT01189526|Drug|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
393594|NCT01189526|Procedure|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
393595|NCT01189513|Drug|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
393596|NCT01189500|Drug|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
393597|NCT01189500|Drug|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
393598|NCT01189487|Drug|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
393599|NCT01189474|Device|Blephasteam|Eye lid warming goggles
393600|NCT01189461|Drug|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
393601|NCT01189448|Drug|Pyrimethamine/Sulfadiazine|"Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.~Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy."
393602|NCT01189448|Drug|Spiramycine|"Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.~Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures"
393603|NCT01189435|Drug|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
393604|NCT01189422|Drug|teplizumab or placebo|infusion or injection
394355|NCT01183650|Drug|Tadalafil|5 mg, administered orally, daily for 10 days
393606|NCT01189409|Drug|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
393607|NCT01189396|Drug|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
393608|NCT01189396|Drug|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
393609|NCT01189396|Drug|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
393610|NCT01189383|Biological|IL15-DC Vaccine|Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
393611|NCT01189370|Drug|sorafenib|"Dose Level:~400mg twice daily, continuous.~600mg twice daily, days 1-5 of each week.~800mg twice daily, days 1-5 of each week."
393612|NCT01189344|Drug|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
393613|NCT01189331|Device|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
393614|NCT01189318|Drug|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4~28 50~150mg (increments and deduction of 50mg are allowed)
393615|NCT01189305|Behavioral|Behavioral Couples Therapy|Behavioral Couples Therapy
393616|NCT01189305|Behavioral|Individual Drug Counseling|Individual Drug Counseling
393617|NCT01189292|Drug|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
393618|NCT01189292|Other|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
393619|NCT01189279|Drug|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
393620|NCT01189279|Drug|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
393621|NCT01189279|Drug|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
393622|NCT01189266|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
393623|NCT01189266|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
393624|NCT01189266|Other|Laboratory Biomarker Analysis|Correlative studies
393625|NCT01189266|Drug|Vorinostat|Given PO
393626|NCT01189253|Drug|doxorubicin hydrochloride|
393627|NCT01189253|Drug|trabectedin|
393628|NCT01189253|Other|laboratory biomarker analysis|
393629|NCT01189253|Procedure|quality-of-life assessment|
393630|NCT01189240|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
393631|NCT01189240|Biological|bevacizumab|Given IV
393632|NCT01189240|Other|laboratory biomarker analysis|Correlative studies
393633|NCT01189240|Other|pharmacological study|Correlative studies
393634|NCT01189227|Procedure|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
393635|NCT01189227|Procedure|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
393636|NCT01189214|Drug|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
393637|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
393638|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
393639|NCT01189201|Drug|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
393640|NCT01189201|Drug|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
393641|NCT01189188|Procedure|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
393642|NCT01189188|Procedure|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
393643|NCT01189175|Drug|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
393644|NCT01189175|Drug|BI 113823|single oral dose
393645|NCT01189162|Device|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
393646|NCT01189149|Procedure|IV fluids|Infants will be allocated to IV fluids
393647|NCT01189149|Procedure|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
393648|NCT01189136|Device|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
393649|NCT01189136|Other|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
393650|NCT01189123|Biological|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
393651|NCT01189123|Biological|fluzone by sanofi pasteur|standard dose fluzone
393710|NCT01188720|Behavioral|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
393652|NCT01189110|Device|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
393653|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
393654|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
393655|NCT01189084|Biological|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
393656|NCT01189071|Drug|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
393657|NCT01189058|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
393658|NCT01189058|Procedure|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for >90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
393659|NCT01189045|Behavioral|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
393660|NCT01189045|Behavioral|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
393661|NCT01189032|Drug|DE-089 ophthalmic solution|
393662|NCT01189032|Drug|DE-089 ophthalmic solution|
393663|NCT01189032|Drug|Placebo ophthalmic solution|
393664|NCT01189019|Drug|ranibizumab|2mg intravitreal injection monthly
393665|NCT01189019|Drug|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
393666|NCT01189006|Drug|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
393667|NCT01188993|Combination Product|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
393668|NCT01188967|Drug|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
393669|NCT01188967|Drug|Placebo|Placebo
393670|NCT01188954|Drug|doxycycline|50 ml/mg
393671|NCT01188954|Other|No intervention|Normal Saline/Water
393672|NCT01188941|Behavioral|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
393673|NCT01188928|Drug|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
393674|NCT01188928|Drug|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
393675|NCT01188928|Drug|Calcipotriene|Topical suspension once daily for up to 8 weeks.
393676|NCT01188928|Drug|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
393677|NCT01188915|Procedure|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
393678|NCT01188902|Dietary Supplement|walnut|walnut consumption 48 g/d
393799|NCT01188070|Behavioral|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
393679|NCT01188889|Drug|RAD001|"Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."
393680|NCT01188889|Drug|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
393681|NCT01188876|Drug|carboplatin|Given intravenously on Day 1 of each 28-day cycle
393682|NCT01188876|Drug|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
393683|NCT01188876|Drug|Folic Acid|Given orally on a daily basis starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate.
393684|NCT01188876|Drug|Vitamin B12 Injection|Given vitamin B12 injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks after the first dose of pralatrexate.
393685|NCT01188863|Drug|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
393686|NCT01188863|Drug|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
393687|NCT01188863|Drug|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
393688|NCT01188850|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
393689|NCT01188837|Other|Full Kinetic Chain Manipulative Therapy|"Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.~Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email."
393690|NCT01188837|Other|Full Kinetic Chain Rehabilitation|"Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.~This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.~The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home"
393691|NCT01188837|Other|Full Kinetic Chain Manipulative Therapy with Rehabilitation|"This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.~This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
393692|NCT01188824|Drug|Cilostazol|100 mg, bid p.o.
393693|NCT01188824|Other|placebo|1 tablet, bid
393694|NCT01188811|Drug|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
393695|NCT01188811|Drug|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
393696|NCT01188798|Drug|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
393697|NCT01188798|Drug|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
393698|NCT01188785|Drug|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.~Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
393699|NCT01188772|Drug|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
393700|NCT01188772|Drug|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
393701|NCT01188772|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
393702|NCT01188772|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
393703|NCT01188759|Drug|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
393704|NCT01188759|Drug|Anidulafungin|"Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole."
393705|NCT01188759|Drug|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks."
393706|NCT01188746|Behavioral|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
393707|NCT01188733|Drug|Long acting octreotide 10mg|Comparison of different doses
393708|NCT01188733|Drug|Long acting Octreotide 30mg|Comparison of drug doses
393709|NCT01188733|Drug|Saline|Comparison of drug doses
393711|NCT01188707|Drug|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.~When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.~3 patients will be treated at each dose level."
393712|NCT01188694|Drug|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
393713|NCT01188694|Behavioral|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
393714|NCT01188694|Behavioral|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
393715|NCT01188681|Drug|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
393716|NCT01188681|Drug|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
393717|NCT01188681|Drug|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
393718|NCT01188681|Drug|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
393719|NCT01188668|Drug|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
393720|NCT01188668|Drug|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
393721|NCT01188655|Drug|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.~To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
393722|NCT01188642|Behavioral|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
393723|NCT01188629|Behavioral|Safety Training|IT intervention focuses on safety in the home.
393724|NCT01188629|Behavioral|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
393725|NCT01188616|Behavioral|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
393726|NCT01188603|Drug|flibanserin 100 mg dose every evening|all subjects receive flibanserin
393727|NCT01188590|Device|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
393728|NCT01188577|Drug|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
393729|NCT01188577|Drug|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
393730|NCT01188564|Drug|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
393731|NCT01188564|Drug|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
393732|NCT01188551|Drug|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
393733|NCT01188551|Drug|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
393734|NCT01188551|Drug|Midazolam|Sedative given pre-op.
393735|NCT01188538|Drug|Epiduo gel|Once daily application on the face in the evening for 12 weeks
393736|NCT01188538|Drug|BPO|Once daily application on the face in the evening for 12 weeks
393737|NCT01188525|Drug|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
393738|NCT01188512|Biological|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
393739|NCT01188512|Biological|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
393740|NCT01188499|Drug|Birinapant|
393741|NCT01188486|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Standard of care diagnostic radiotherapy procedure
393742|NCT01188486|Radiation|Computed Tomography (CT)|For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast
393743|NCT01188486|Device|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
393744|NCT01188486|Device|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
393745|NCT01188486|Device|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
393746|NCT01188486|Drug|Iohexol|Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
393747|NCT01188486|Drug|Iodixanol|Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
393800|NCT01188057|Drug|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
394278|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
393748|NCT01188473|Other|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
393749|NCT01188460|Behavioral|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
393750|NCT01188460|Behavioral|Sleep diary|
393751|NCT01188447|Procedure|Canadian C-Spine Rule|Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
393752|NCT01188434|Behavioral|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
393753|NCT01188434|Behavioral|Services as Usual|Services as usual referred by child welfare
393754|NCT01188421|Drug|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
393755|NCT01188421|Drug|Clonidine|up to 0.8 mg per day (oral)
393756|NCT01188421|Drug|Tramadol ER|up to 600 mg per day
393757|NCT01188408|Drug|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
393758|NCT01188382|Procedure|CSF dynamic investigation|
393759|NCT01188369|Drug|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
393760|NCT01188369|Drug|placebo drug|Intravenous infusion, colour identical to levosimendan
393761|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
393762|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
393763|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
393764|NCT01188330|Behavioral|WITH Comprehensive Geriatric assessment|"Each month after randomization, a nurse practitioner will systematically review the intervention plan.~In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose"
393765|NCT01188330|Behavioral|Conventional|no Comprehensive Geriatric assessment
393766|NCT01188317|Drug|aleglitazar|repeated daily doses
393767|NCT01188317|Drug|placebo|repeated daily doses
393768|NCT01188317|Drug|ibuprofen|repeated daily doses
393769|NCT01188304|Drug|aleglitazar|repeated daily doses
393770|NCT01188304|Drug|aspirin|repeated daily doses
393771|NCT01188304|Drug|placebo|repeated daily doses
393772|NCT01188278|Drug|Imatinib|Drug being observed but not provided
393773|NCT01188265|Drug|Valproate|
393774|NCT01188265|Drug|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
393775|NCT01188265|Drug|Placebo|VPA plus placebo
393776|NCT01188265|Drug|Dextromethorphan 30 mg|VPA & Dextromethorphan 30 mg per day
393777|NCT01188252|Drug|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
393778|NCT01188226|Device|Denture teeth|Denture teeth made of nano hybrid composite material
393779|NCT01188213|Dietary Supplement|Methylsulfonylmethane (MSM)|
393780|NCT01188200|Other|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
393781|NCT01188200|Other|Standard food|Standard meal prior to test time
393782|NCT01188187|Drug|Custirsen|
393783|NCT01188187|Drug|Docetaxel|
393784|NCT01188187|Drug|Prednisone|
393785|NCT01188187|Drug|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
393786|NCT01188174|Drug|Clofarabine|The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
393787|NCT01188161|Device|Rotating Chair|Subjects will be spun in rotating chair
393788|NCT01188148|Drug|Memantine|5 mg per day of memantine
393789|NCT01188148|Drug|Placebo|
393790|NCT01188135|Behavioral|Interactive voice messaging or Interactive voice messaging + psycho ed materials|Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
393791|NCT01188122|Device|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
393792|NCT01188109|Drug|Gemcitabine|"Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days"
393793|NCT01188109|Drug|Cisplatin|"Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days"
393794|NCT01188096|Drug|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
393795|NCT01188083|Dietary Supplement|Fructose Drink|Fructose Based beverage 8 oz
393796|NCT01188083|Dietary Supplement|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
393797|NCT01188070|Behavioral|Usual Care|Educational materials
393798|NCT01188070|Behavioral|Psycho-education|Educational group sessions
393801|NCT01188057|Drug|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
393802|NCT01188031|Drug|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
393803|NCT01188031|Drug|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
393804|NCT01188018|Behavioral|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
393805|NCT01188018|Behavioral|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
393806|NCT01188018|Behavioral|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
393807|NCT01188005|Device|n-CPAP|administration of continuous positive airway pressure through a nasal device
393808|NCT01188005|Device|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
393809|NCT01188005|Drug|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
393810|NCT01187992|Drug|Atorvastatin|80 mg/day
393811|NCT01187979|Behavioral|Cash incentives|Cash incentives paid to learners for reaching pre-determined milestones
393812|NCT01187979|Behavioral|Life skills curriculum|Standard department of education lifeskills curriculum
393813|NCT01187966|Drug|Safinamide|
393814|NCT01187966|Drug|Safinamide|
393815|NCT01187966|Drug|Placebo|
393816|NCT01187953|Drug|Prograf (tacrolimus)|Administered per current product labeling
393817|NCT01187953|Drug|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
393818|NCT01187940|Behavioral|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
393819|NCT01187927|Biological|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
393820|NCT01187901|Drug|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
393821|NCT01187901|Drug|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
393822|NCT01187901|Drug|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
393823|NCT01187901|Drug|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
393824|NCT01187888|Drug|Rasagiline|tablet once daily 1 mg 1 year
393825|NCT01187888|Drug|Sugar pill|tablet once daily one year
393826|NCT01187875|Dietary Supplement|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
393827|NCT01187875|Dietary Supplement|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
393828|NCT01187875|Dietary Supplement|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
393829|NCT01187875|Dietary Supplement|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
393830|NCT01187862|Drug|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
393831|NCT01187849|Drug|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
393832|NCT01187849|Drug|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
393833|NCT01187836|Drug|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
393834|NCT01187836|Drug|Placebo|Placebo administered for 14 hours.
393835|NCT01187823|Device|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
393836|NCT01187823|Device|Nocturnal oxygen|Nocturnal use of oxygen
393837|NCT01187810|Drug|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
393838|NCT01187810|Drug|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
393839|NCT01187810|Drug|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
393840|NCT01187797|Other|Emotional stimulation|Increase of the physical correlates of an emotion
393841|NCT01187784|Behavioral|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
393877|NCT01187433|Biological|Meningococcal A+C vaccine|0.5 mL, Intramuscular
393878|NCT01187407|Drug|LY2216684|
393879|NCT01187407|Drug|Placebo|
393880|NCT01187407|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
394348|NCT01183663|Drug|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
393842|NCT01187771|Procedure|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
393843|NCT01187771|Procedure|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
393844|NCT01187758|Behavioral|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
393845|NCT01187745|Other|CT Scan followed by ultrasound|A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
393846|NCT01187732|Device|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
393847|NCT01187719|Drug|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
393848|NCT01187693|Other|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
393849|NCT01187680|Device|Spraygel|
393850|NCT01187680|Device|Control|Good surgical technique, no adhesion barrier
393851|NCT01187654|Biological|AC133|intra coronary injection of bone marrow derived AC133+ cells
393852|NCT01187654|Biological|MNC|intra coronary injection of bone marrow derived MNC
393853|NCT01187654|Biological|CONTROL|autologous serum injection
393854|NCT01187628|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
393855|NCT01187615|Drug|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
393856|NCT01187615|Drug|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
393857|NCT01187589|Device|Pulsehaler|
393858|NCT01187589|Drug|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
393859|NCT01187576|Behavioral|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
393860|NCT01187576|Behavioral|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
393861|NCT01187550|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit [IU]/kg body weight) per day by subcutaneous injection.
393862|NCT01187537|Procedure|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to < 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
393863|NCT01187511|Drug|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
393864|NCT01187511|Drug|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
393865|NCT01187498|Behavioral|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
393866|NCT01187498|Drug|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
393867|NCT01187485|Drug|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
393868|NCT01187485|Drug|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
393869|NCT01187485|Drug|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
393870|NCT01187459|Dietary Supplement|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
393871|NCT01187459|Dietary Supplement|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
393872|NCT01187446|Radiation|Total skin electron beam therapy (TSEBT)|TSEBT is administered as 12 Gy fractionated at 2 grey (Gy)/cycle (each cycle requiring 2 days of treatment); 4 days each week; for 3 weeks.
393873|NCT01187446|Drug|Vorinostat|Starting doses of is vorinostat 400 mg/day, continuing for 8 weeks.
393874|NCT01187433|Biological|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
393875|NCT01187433|Biological|NaCl 0.9%|0.5 mL, Subcutaneous
393876|NCT01187433|Biological|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
393881|NCT01187381|Drug|Trastuzumab|Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
393882|NCT01187368|Device|EVAHEART Left Ventricular Assist System (LVAS)|continuous flow implantable left ventricular assist system (LVAS) for patients who are at risk of imminent death from severe left ventricular failure for use as a bridge-to-transplantation in candidates listed for cardiac transplant
393883|NCT01187355|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
393884|NCT01187355|Device|renu fresh Multi-Purpose Solution (MPS)|Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
393885|NCT01187355|Device|Contact lenses|Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
393886|NCT01187329|Other|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is <110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose > 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
393887|NCT01187329|Other|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose >150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose < 180 mg/dL.
393888|NCT01187316|Device|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
393889|NCT01187316|Other|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
393890|NCT01187303|Drug|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
393891|NCT01187290|Radiation|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
393892|NCT01187277|Behavioral|conventional therapy|conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
393893|NCT01187277|Device|conventional plus robotic gait assisted therapy|individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
393894|NCT01187264|Drug|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
393895|NCT01187238|Drug|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
393896|NCT01187225|Drug|Fibrinogen concentrate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
393897|NCT01187225|Drug|Cryoprecipitate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
393898|NCT01187212|Drug|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
393899|NCT01187212|Drug|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
393900|NCT01187199|Drug|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
393901|NCT01187199|Drug|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
393902|NCT01187199|Drug|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
393903|NCT01187199|Drug|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
393904|NCT01187199|Drug|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
393905|NCT01187186|Drug|ASP1941|oral
393906|NCT01187160|Procedure|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
393907|NCT01187147|Dietary Supplement|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
393908|NCT01187134|Behavioral|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
393909|NCT01187108|Drug|N-acetylcysteine|NAC 600 mg oral once daily
393910|NCT01187108|Drug|Acetazolamide|Acetazolamide 250 mg oral once daily
393911|NCT01187108|Drug|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
393912|NCT01187095|Behavioral|Expressive writing|3 consecutive days of writing
393913|NCT01187095|Behavioral|Active ctrl|Control
394009|NCT01186393|Behavioral|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
393914|NCT01187082|Behavioral|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
393915|NCT01187082|Behavioral|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
393916|NCT01187069|Behavioral|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
393917|NCT01187056|Behavioral|Training programme|2 x 2 hours of training (workshops)
393918|NCT01187043|Drug|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
393919|NCT01187017|Drug|Cyclophosphamide|60 mg/kg
393920|NCT01187017|Drug|Fludarabine|125 mg/m squared
393921|NCT01186991|Drug|Onartuzumab|Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
393922|NCT01186991|Drug|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
393923|NCT01186991|Drug|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
393924|NCT01186991|Drug|Bevacizumab Placebo|Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
393925|NCT01186991|Drug|Onartuzumab Placebo|Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
393926|NCT01186978|Radiation|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
393927|NCT01186965|Behavioral|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
393928|NCT01186952|Behavioral|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
393929|NCT01186952|Behavioral|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
393930|NCT01186939|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m^2/day.
393931|NCT01186926|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
393932|NCT01186900|Procedure|ultrasound-guided needle aspiration|one time drainage at time of randomization
393933|NCT01186887|Drug|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
393934|NCT01186887|Drug|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
393935|NCT01186861|Drug|OSI-906|Tablet administered with food and with up to 200 mL of water
393936|NCT01186861|Drug|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
393937|NCT01186861|Drug|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
393938|NCT01186848|Device|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
393939|NCT01186848|Device|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
393940|NCT01186835|Procedure|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
393941|NCT01186835|Procedure|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
393942|NCT01186822|Device|Lung Flute|Used twice daily
394010|NCT01186380|Device|PET-512MC|Transesophageal Transducer
393943|NCT01186809|Biological|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
393944|NCT01186796|Drug|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~**Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
393945|NCT01186783|Drug|ivabradine|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate<90bpm (acute renal failure: 70bpm≥heart rate <90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm"
393946|NCT01186770|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
393947|NCT01186770|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arms.
393948|NCT01186757|Drug|PF-03715455|PF-03715455 1.6 mg BID
393949|NCT01186757|Drug|PF-03715455|PF-03715455 4mg BID
393950|NCT01186757|Drug|PF-03715455|PF-03715455 10 mg BID
393951|NCT01186757|Drug|Placebo|Placebo
393952|NCT01186744|Drug|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
393953|NCT01186744|Drug|CP-690,550|10 mg oral BID
393954|NCT01186744|Drug|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
393955|NCT01186744|Drug|CP-690,550|5 mg oral BID
393956|NCT01186731|Drug|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
393957|NCT01186705|Drug|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
393958|NCT01186692|Device|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
393959|NCT01186679|Procedure|laminectomy|surgical laminectomy with glial scar resection
393960|NCT01186679|Procedure|Intrathecal|direct into the CSF through lumbar puncture
393961|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
393962|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
393963|NCT01186653|Drug|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
393964|NCT01186653|Drug|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
393965|NCT01186640|Drug|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
393966|NCT01186640|Drug|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
393967|NCT01186614|Device|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
393968|NCT01186614|Device|ECMO|Insertion of peripheral VA ECMO
393969|NCT01186614|Procedure|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
393970|NCT01186614|Procedure|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
393971|NCT01186601|Drug|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of </= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
393972|NCT01186588|Drug|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
393973|NCT01186575|Other|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
393974|NCT01186562|Drug|Sitagliptin|100 mg PO daily
393975|NCT01186562|Drug|Placebo|Placebo
394011|NCT01186367|Behavioral|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
394349|NCT01183663|Drug|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
393976|NCT01186549|Drug|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
393977|NCT01186549|Drug|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
393978|NCT01186549|Drug|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
393979|NCT01186549|Drug|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
393980|NCT01186549|Drug|normal saline 2ml|"Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
393981|NCT01186536|Dietary Supplement|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
393982|NCT01186536|Dietary Supplement|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
393983|NCT01186536|Dietary Supplement|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
393984|NCT01186523|Other|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
393985|NCT01186510|Procedure|lung perfusion|see literature of proceeding
393986|NCT01186510|Procedure|no lung perfusion|see literature of proceeding
393987|NCT01186497|Drug|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
393988|NCT01186497|Drug|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
393989|NCT01186497|Drug|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
393990|NCT01186497|Drug|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
393991|NCT01186497|Drug|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
393992|NCT01186484|Drug|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
393993|NCT01186471|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
393994|NCT01186471|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
393995|NCT01186471|Drug|placebo|placebo - three times daily during each treatment period
393996|NCT01186458|Drug|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
393997|NCT01186458|Drug|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
393998|NCT01186458|Drug|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
393999|NCT01186445|Drug|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
394000|NCT01186445|Drug|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
394001|NCT01186432|Drug|PDS 1.0|
394002|NCT01186419|Drug|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
394003|NCT01186406|Drug|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
394004|NCT01186406|Radiation|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
394005|NCT01186406|Drug|Avastin|"Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.~Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days."
394006|NCT01186406|Drug|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
394007|NCT01186393|Behavioral|Control|Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
394008|NCT01186393|Behavioral|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
394091|NCT01185834|Device|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
394012|NCT01186367|Behavioral|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
394013|NCT01186367|Behavioral|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
394014|NCT01186367|Other|Cardiopulmonary exercise test (CPET)|
394015|NCT01186367|Other|Blood draws|Complete blood count
394016|NCT01186354|Behavioral|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
394017|NCT01186328|Drug|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29. Dose levels: L0 (level zero): 1.5 mg/kg, L1: 2.5 mg/kg, L2: 5 mg/kg, L3: 6.5 mg/kg
394018|NCT01186328|Drug|Cytarabine|"Given intrathecally on day -6. Patients who may have received intrathecal chemotherapy within 7 days of day 0 as part of their prior maintenance chemotherapy (e.g. before the diagnosis of relapse) or as part of the diagnostic workup will not receive this dose of IT cytarabine. If given, dose is defined by age:~1-1.99 years: 30 mg 2-2.99 years: 50 mg~Greater than or equal to 3 years: 70 mg.~Cytarabine is also part of the triple intrathecal therapy given to CNS 3 patients on Days 8, 15, 22 and 29. Dose is defined by age:~- 1.99 years: 16 mg~- 2.99 years: 20 mg~- 8.99 years: 24 mg~Greater than or equal to 9 years: 30 mg"
394019|NCT01186328|Drug|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
394020|NCT01186328|Drug|Prednisone|40 mg/m2/day divided BID or TID given orally on days 1 through 29. For patients who are unable to tolerate prednisone orally, substitute IV methylprednisolone at 80% of the oral prednisone dose.
394021|NCT01186328|Drug|Vincristine|1.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
394022|NCT01186328|Drug|PEG-asparaginase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23. If available, Erwinia L-asparaginase may be substituted for pegaspargase in patients with clinically significant prior allergies to pegaspargase.
394023|NCT01186328|Drug|Methotrexate|"Given intrathecally to patients with CNS1 or CNS2 disease at the dose defined by age below on days 15 and 36:~1-1.99 years: 8 mg 2-2.99 years: 10 mg 3-8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg~Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
394024|NCT01186328|Drug|Hydrocortisone|"Given as part of the Triple intrathecal therapy to patients with CNS 3 disease at the doses defined by age below on days 8, 15, 22 and 29:~- 1.99 years: 8 mg~- 2.99 years: 10 mg~- 8.99 years: 12 mg~Greater than or equal to 9 years: 15 mg"
394025|NCT01186315|Behavioral|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
394026|NCT01186315|Behavioral|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use & CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
394027|NCT01186302|Other|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
394028|NCT01186289|Drug|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
394029|NCT01186276|Dietary Supplement|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
394030|NCT01186276|Dietary Supplement|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
394031|NCT01186263|Drug|MAA for diagnostic SPECT imaging|Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
394032|NCT01186263|Drug|Diagnostic B20- SPECT imaging.|Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
394033|NCT01186250|Drug|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
394034|NCT01186250|Drug|Placebo|placebo taken daily for one year
394035|NCT01186237|Procedure|Early urinary catheter removal|All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
394036|NCT01186224|Drug|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.~The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
394037|NCT01186198|Device|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
394038|NCT01186185|Drug|Fludrocortisone|Fludrocortisone 0.2 mg by mouth daily for 30 days
394039|NCT01186172|Drug|Ethanol-lock therapy|Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
394040|NCT01186172|Drug|Antibiotic-lock|Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
394041|NCT01186159|Drug|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
394042|NCT01186146|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
394043|NCT01186146|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
394044|NCT01186120|Device|Biolimus A9-eluting stent|drug-eluting stent
394045|NCT01186120|Device|Everolimus-eluting stent|drug-eluting stent
394046|NCT01186107|Device|Endeavor Resolute stent|zotarolimus-eluting stent
394047|NCT01186107|Device|Cypher stent|sirolimus-eluting stent
394048|NCT01186094|Device|Cypher|Sirolimus-eluting stent
394049|NCT01186094|Device|Endeavor Resolute|Zotarolimus-eluting Stent
394050|NCT01186081|Radiation|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
394051|NCT01186081|Radiation|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
394052|NCT01186068|Drug|V-101|Cream QD
394053|NCT01186068|Other|vehicle|Cream QD
394054|NCT01186055|Behavioral|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
394055|NCT01186042|Other|Observational|No intervention
394056|NCT01186029|Drug|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
394057|NCT01186016|Behavioral|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
394058|NCT01186016|Behavioral|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
394059|NCT01186003|Drug|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
394060|NCT01185977|Drug|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
394061|NCT01185977|Drug|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
394062|NCT01185964|Biological|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
394063|NCT01185964|Drug|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
394064|NCT01185951|Drug|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
394065|NCT01185951|Device|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
394066|NCT01185951|Drug|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
394067|NCT01185951|Behavioral|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
394068|NCT01185951|Behavioral|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
394069|NCT01185951|Behavioral|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
394070|NCT01185938|Drug|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
394071|NCT01185925|Drug|Sildenafil|Sildenafil, 50 mg 3 times/day
394072|NCT01185925|Drug|Placebo|Placebo
394073|NCT01185912|Procedure|Ventricle muscle tissue samples|
394074|NCT01185886|Genetic|gene expression analysis|
394075|NCT01185886|Genetic|mutation analysis|
394076|NCT01185886|Genetic|polymorphism analysis|
394077|NCT01185886|Other|biologic sample preservation procedure|
394078|NCT01185886|Other|laboratory biomarker analysis|
394079|NCT01185886|Other|pharmacogenomic studies|
394080|NCT01185873|Drug|danoprevir|Repeated oral doses
394081|NCT01185873|Drug|ritonavir|Repeated oral doses
394082|NCT01185860|Drug|danoprevir|oral doses
394083|NCT01185860|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
394084|NCT01185860|Drug|placebo|oral doses
394085|NCT01185860|Drug|ribavirin|1000-1200mg/day po
394086|NCT01185860|Drug|ritonavir|oral doses
394087|NCT01185847|Drug|RO5083945|intravenously, until disease progression
394088|NCT01185847|Drug|cisplatin|standard treatment, up to 6 cycles
394089|NCT01185847|Drug|gemcitabine|standard treatment, up to 6 cycles
394090|NCT01185847|Drug|pemetrexed|standard treatment, up to 6 cycles
394133|NCT01185418|Drug|amisulpride|
394092|NCT01185821|Drug|BAF312|BAF312 was supplied in film-coated tablets in strengths of 5, 4 ,2, 1, .5 and .25 mg. The actual doses taken were 10, 2, 1.25, .5 and .25 mg taken orally once a day.
394093|NCT01185808|Biological|Vitamin D|Vitamin D 5000IU/day for 6 weeks
394094|NCT01185795|Dietary Supplement|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
394095|NCT01185795|Dietary Supplement|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
394096|NCT01185782|Drug|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
394097|NCT01185782|Drug|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
394098|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
394099|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
394100|NCT01185756|Radiation|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
394101|NCT01185743|Drug|olanzapine|olanzapine 10mg od + placebo od
394102|NCT01185743|Drug|ziprasidone|ziprasidone 40mg td
394103|NCT01185743|Drug|placebo|placebo td
394104|NCT01185730|Procedure|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
394105|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
394106|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
394107|NCT01185704|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
394108|NCT01185704|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
394109|NCT01185691|Device|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
394110|NCT01185678|Drug|Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)|One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
394111|NCT01185665|Device|TENS|Transcutaneous Electrical Nerve Stimulator
394112|NCT01185665|Device|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
394113|NCT01185639|Radiation|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
394114|NCT01185626|Other|SCP care|
394115|NCT01185613|Device|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.~The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter~IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.~Cool Point™ Irrigation Pump~Cool Point™ Tubing set~Data Logger"
394116|NCT01185600|Biological|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
394117|NCT01185600|Biological|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
394118|NCT01185574|Dietary Supplement|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
394119|NCT01185561|Behavioral|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
394120|NCT01185548|Drug|Tolbutamide|Administered orally
394121|NCT01185548|Drug|Tasisulam|Administered intravenously
394122|NCT01185535|Procedure|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
394123|NCT01185509|Drug|trastuzumab|
394124|NCT01185509|Drug|vinorelbine|
394125|NCT01185470|Device|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
394126|NCT01185444|Procedure|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
394127|NCT01185444|Procedure|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
394128|NCT01185431|Dietary Supplement|Ficus carica (Fig paste)|Ficus carica paste 300g/day
394129|NCT01185431|Dietary Supplement|Placebo (Placebo paste)|Placebo composition 300g/day
394130|NCT01185418|Drug|risperidone|
394131|NCT01185418|Drug|aripiprazole|
394132|NCT01185418|Drug|haloperidol|
394135|NCT01185405|Other|Use of different strategy for voriconazole dosage adjustment|Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (< 1 µg/ml: 50% increase, 1~5.5 µg/ml: no change, > 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
394136|NCT01185379|Dietary Supplement|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
394137|NCT01185379|Dietary Supplement|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
394138|NCT01185379|Dietary Supplement|Placebo|4 x 500 mg capsules to be taken daily for 6 months
394139|NCT01185366|Drug|Everolimus|10 mg by mouth once a day.
394140|NCT01185366|Drug|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
394141|NCT01185353|Drug|LY3009104|Administered orally
394142|NCT01185353|Drug|Placebo|Administered orally
394143|NCT01185353|Drug|Methotrexate|Administered orally as background therapy
394144|NCT01185340|Drug|LY2216684|
394145|NCT01185340|Drug|Placebo|
394146|NCT01185340|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
394147|NCT01185327|Behavioral|Breastfeeding|Breastfeeding
394148|NCT01185314|Procedure|Testing for mutation status|EGFR mutation test
394149|NCT01185301|Biological|adalimumab|Pre-filled syringe every other week
394150|NCT01185301|Drug|methotrexate|weekly oral capsule dosing
394151|NCT01185288|Biological|Adalimumab|Adalimumab in pre-filled syringes
394152|NCT01185288|Drug|Methotrexate|Methotrexate capsule
394153|NCT01185275|Device|Alair system|Bronchial thermoplasty
394154|NCT01185262|Drug|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.~Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).~In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.~If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).~In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
394155|NCT01185249|Procedure|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
394156|NCT01185236|Drug|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
394157|NCT01185236|Drug|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
394158|NCT01185223|Drug|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
394159|NCT01185223|Drug|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
394160|NCT01185210|Dietary Supplement|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
394161|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
394162|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
394163|NCT01185197|Drug|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
394164|NCT01185197|Drug|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
394165|NCT01185184|Drug|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
394166|NCT01185171|Drug|ZD 1839 500mg|"Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance [CC] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
394167|NCT01185158|Drug|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
394168|NCT01185145|Radiation|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
394169|NCT01185145|Radiation|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
394170|NCT01185132|Radiation|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
394171|NCT01185132|Radiation|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
394172|NCT01185119|Drug|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
394173|NCT01185080|Drug|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
394174|NCT01185080|Drug|Placebo|Nasal spray solution, intranasal, three times weekly for one month
394175|NCT01185080|Drug|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
394205|NCT01184820|Biological|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
394350|NCT01183663|Drug|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
394176|NCT01185067|Drug|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
394177|NCT01185054|Other|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
394178|NCT01185054|Other|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
394179|NCT01185041|Dietary Supplement|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
394180|NCT01185028|Drug|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
394181|NCT01185015|Drug|Sigmart (nicorandil)|Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.
394182|NCT01185002|Other|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
394183|NCT01185002|Other|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
394184|NCT01185002|Other|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
394185|NCT01184989|Drug|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
394186|NCT01184976|Biological|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
394187|NCT01184963|Dietary Supplement|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
394188|NCT01184963|Dietary Supplement|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
394189|NCT01184950|Other|Trainer Curriculum|
394190|NCT01184937|Behavioral|Patient education program|"All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the Pro-Self education program. The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs."
394191|NCT01184924|Behavioral|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
394192|NCT01184911|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
394193|NCT01184898|Drug|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
394194|NCT01184898|Drug|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
394195|NCT01184898|Drug|Etoposide|100 mg/m2/day IV
394196|NCT01184898|Drug|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
394197|NCT01184885|Drug|Hyper-CVAD|"Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are < 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.~Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
394198|NCT01184885|Drug|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
394199|NCT01184872|Drug|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
394200|NCT01184872|Drug|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
394201|NCT01184859|Drug|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
394202|NCT01184859|Drug|Placebo|Placebo melt tablet for sublingual administration
394203|NCT01184846|Biological|10% liquid formulation of human immunoglobulin|
394204|NCT01184833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
394276|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
394206|NCT01184820|Biological|BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))|Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
394207|NCT01184807|Drug|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
394208|NCT01184794|Drug|levobupivacaine|40 ml over 48 hours
394209|NCT01184781|Device|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
394210|NCT01184755|Behavioral|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
394211|NCT01184755|Device|RESPeRate|
394212|NCT01184716|Other|Vitamin D fortification|Bread and milk fortified with vitamin D3
394213|NCT01184703|Other|Low GI food|Comparison of carbohydrates in diabetic patients
394214|NCT01184690|Procedure|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
394215|NCT01184690|Procedure|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
394216|NCT01184677|Device|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
394217|NCT01184677|Device|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
394218|NCT01184664|Drug|Nicotine Patch|Varenicline + nicotine patch
394219|NCT01184664|Drug|Placebo|Varenicline + placebo patch
394220|NCT01184664|Drug|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
394221|NCT01184651|Behavioral|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
394222|NCT01184651|Behavioral|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
394223|NCT01184638|Drug|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
394224|NCT01184638|Drug|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
394225|NCT01184625|Other|Physical Exercise|12 weeks of physical exercise.
394226|NCT01184612|Behavioral|Motivational Interviewing; MI|"MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client."
394227|NCT01184599|Drug|aliskiren|150 mg/day p.o.
394228|NCT01184586|Device|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
394229|NCT01184586|Device|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
394230|NCT01184560|Drug|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
394231|NCT01184560|Drug|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.~Treatment period: The total dosing period is 12 weeks.~Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily~Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
394232|NCT01184547|Behavioral|Combex|12 weeks of exercise with a trainer post discharge.
394233|NCT01184547|Behavioral|Standard of Care|No exercise training received.
394234|NCT01184534|Behavioral|Video|5 minute multimedia presentation (video)
394235|NCT01184534|Behavioral|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
394236|NCT01184508|Drug|Placebo|Administered orally, once daily, for 12 weeks
394237|NCT01184508|Drug|LY2300559|300 milligrams (mg) administered orally, once daily, for 12 weeks
394238|NCT01184495|Drug|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
394239|NCT01184495|Drug|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
394240|NCT01184482|Drug|cetuximab and lapatinib|"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly~Lapatinib: Start once daily on Day 1. Dose escalating cohorts:~750 mg (3 tabs)~1000 mg (4 tabs)~1250 mg (5 tabs)"
394241|NCT01184456|Dietary Supplement|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
394242|NCT01184456|Drug|Placebo|1 capsule per day for 90 days.
394277|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
394465|NCT01182714|Procedure|immediate removal of in-dwelling catheter|
394243|NCT01184443|Drug|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
394244|NCT01184430|Device|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
394245|NCT01184417|Drug|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
394246|NCT01184417|Drug|placebo|100 m l saline
394247|NCT01184404|Drug|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
394248|NCT01184391|Drug|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
394249|NCT01184391|Drug|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
394250|NCT01184378|Dietary Supplement|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
394251|NCT01184365|Behavioral|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
394252|NCT01184365|Behavioral|Energy Management Program|The goal of the EnMP-2 is to control for group effects
394253|NCT01184352|Device|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
394254|NCT01184339|Device|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.~Approximately 5 hour rapid test."
394255|NCT01184326|Drug|pazopanib|
394256|NCT01184326|Drug|everolimus|
394257|NCT01184313|Procedure|aortic valve surgery with CPB|elective aortic valve surgery with CPB
394258|NCT01184300|Genetic|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
394259|NCT01184287|Drug|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
394260|NCT01184274|Drug|SB939|"Dose Levels for Part A~-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~(starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing~4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
394261|NCT01184261|Behavioral|behavioral intervention|8 session behavioral intervention.
394262|NCT01184248|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
394263|NCT01184235|Drug|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
394264|NCT01184222|Device|great occipital nerve stimulation|"Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.~Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted."
394265|NCT01184196|Drug|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
394266|NCT01184196|Drug|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
394267|NCT01184183|Procedure|Comparing Accuseal Vs. Bovine Pericardial in CEA|"Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.~Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis."
394268|NCT01184170|Behavioral|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
394269|NCT01184157|Behavioral|Home screening|
394270|NCT01184157|Behavioral|Clinic screening|
394271|NCT01184144|Drug|Pioglitazone|Pioglitazone, 30 mg, by mouth daily for 2 weeks
394272|NCT01184131|Other|Mentor Training|Four 2 hour sessions of Mentor Training
394273|NCT01184118|Drug|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
394274|NCT01184105|Drug|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
394275|NCT01184105|Drug|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
394466|NCT01182714|Procedure|24 hours delayed removal of catheter|
394279|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
394280|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
394281|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
394282|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
394283|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
394284|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
394285|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
394286|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
394287|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
394288|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
394289|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
394290|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
394291|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
394292|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
394293|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
394294|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
394295|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
394296|NCT01184066|Behavioral|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
394297|NCT01184066|Behavioral|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
394298|NCT01184053|Drug|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
394299|NCT01184040|Behavioral|VIP CM|Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
394300|NCT01184027|Behavioral|nutrition /swallowing counseling|general nutrition and swalling information
394301|NCT01184027|Behavioral|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
394302|NCT01184027|Behavioral|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
394303|NCT01184014|Drug|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
394304|NCT01184014|Drug|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
394305|NCT01184001|Drug|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
394306|NCT01184001|Drug|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
394307|NCT01184001|Drug|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
394308|NCT01184001|Drug|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
394309|NCT01183962|Dietary Supplement|Vitamin D|Vitamin D 3000 IU daily
394310|NCT01183962|Other|No medication|No intervention
394311|NCT01183949|Drug|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m^2/dose and will be increased to 27mg/m^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
394312|NCT01183949|Drug|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
394313|NCT01183936|Procedure|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
394314|NCT01183936|Procedure|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
394315|NCT01183923|Other|Broccoli Sprouts|Broccoli Sprouts will be eaten daily in a sandwich form during the intervention period for broccoli sprouts.
394316|NCT01183923|Other|Alfalfa Sprouts|Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.
394317|NCT01183910|Dietary Supplement|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
394318|NCT01183910|Dietary Supplement|Calcium Carbonate|Oral Tablet Taken Twice a Day
394351|NCT01183663|Drug|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
394352|NCT01183663|Drug|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
394353|NCT01183663|Drug|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
394354|NCT01183663|Drug|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
394319|NCT01183897|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.~Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
394320|NCT01183884|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.~Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in > or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
394321|NCT01183871|Procedure|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
394322|NCT01183858|Drug|Erlotinib [Tarceva]|Single daily oral dose
394323|NCT01183845|Procedure|Colon Capsule Endoscopy|Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
394324|NCT01183819|Behavioral|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
394325|NCT01183819|Behavioral|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
394326|NCT01183819|Behavioral|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
394327|NCT01183819|Behavioral|Control Games|Control games session 3 times a week for 12 weeks
394328|NCT01183806|Drug|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
394329|NCT01183806|Other|Exercise training program|Exercise training program
394330|NCT01183793|Radiation|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
394331|NCT01183780|Biological|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
394332|NCT01183780|Biological|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
394333|NCT01183780|Drug|Irinotecan|180 milligrams/square meter (mg/m^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
394334|NCT01183780|Drug|Folinic Acid|400 mg/m^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
394335|NCT01183780|Drug|5-Fluorouracil|400 mg/m^2 bolus immediately followed by 2400 mg/m^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
394336|NCT01183767|Drug|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
394337|NCT01183767|Drug|Placebo|
394338|NCT01183728|Other|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
394339|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
394340|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
394341|NCT01183702|Procedure|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
394342|NCT01183702|Other|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
394343|NCT01183689|Behavioral|Small Behavior Changes|"The Self-Regulation Plus Small Behavior Changes Intervention will focus on making small changes in diet and physical activity on a daily basis to prevent weight gain.~Diet: The dietary approach used in this group is to identify small changes in what and how much participants eat each day. The general concept is that these are small, manageable changes that will produce small reductions in overall intake and can easily be made on a daily basis and maintained over time.~Exercise: At the start of the program, participants will be given a pedometer and asked to record their current or baseline number of steps. They will then be given the goal of increasing their daily steps by 2000 steps per day over this baseline level."
394344|NCT01183689|Behavioral|Large Behavior Changes|"The focus of this intervention group will be on periodically making large changes in diet and physical activity, with the goal of losing 5-10 pounds to buffer against the weight gain that often occurs during young adulthood.~Diet: Individuals with a BMI of 21-24.9 kg/m2 will be encouraged to lose 5 pounds; those with a BMI of 25-30 kg/m2 will be encouraged to lose 10 pounds.~Exercise: The Large Changes group will be instructed to gradually increase their minutes of physical activity until achieving 250 minutes per week (5 days/week with 50 minutes per day) using activities similar in intensity to brisk walking."
394345|NCT01183676|Drug|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
394346|NCT01183676|Drug|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
394347|NCT01183663|Drug|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
394356|NCT01183637|Device|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
394357|NCT01183637|Procedure|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
394358|NCT01183624|Other|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
394359|NCT01183624|Other|Placebo Patch|Control patch with no herbal ingredients
394360|NCT01183611|Biological|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
394361|NCT01183611|Biological|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
394362|NCT01183611|Biological|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
394363|NCT01183611|Biological|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
394364|NCT01183611|Biological|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
394365|NCT01183598|Drug|tocilizumab [RoActemra/Actemra]|maintenance dose
394366|NCT01183585|Drug|RO4917838 and Rosuvastatin|multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
394367|NCT01183572|Dietary Supplement|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
394368|NCT01183572|Dietary Supplement|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
394369|NCT01183572|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid
394370|NCT01183559|Drug|ZD6474 (Zactima)|
394371|NCT01183533|Drug|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
394372|NCT01183520|Dietary Supplement|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
394373|NCT01183507|Behavioral|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
394374|NCT01183507|Behavioral|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
394375|NCT01183494|Drug|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1*1/*1 and UGT1A1*1/*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
394376|NCT01183481|Drug|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
394377|NCT01183481|Radiation|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
394378|NCT01183481|Drug|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
394379|NCT01183468|Biological|Aralast NP 45 mg dose|- 45 mg/kg/week
394380|NCT01183468|Biological|Aralast NP 90 mg dose|- 90 mg/kg/week
394381|NCT01183468|Biological|Aralast NP 180 mg dose|- 180 mg/kg/week
394382|NCT01183455|Drug|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
394383|NCT01183455|Drug|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
394384|NCT01183442|Drug|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
394385|NCT01183429|Drug|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. *High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
394386|NCT01183416|Drug|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are ~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
394387|NCT01183390|Drug|Anastrozole|1 mg Tablets
394388|NCT01183390|Drug|Anastrozole|1 mg Tablets
394389|NCT01183364|Drug|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
394390|NCT01183351|Behavioral|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
394531|NCT01182142|Drug|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
394391|NCT01183325|Device|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
394392|NCT01183312|Drug|Flumazenil|Sublingual flumazenil
394393|NCT01183299|Other|Dietary salt intake|
394394|NCT01183286|Behavioral|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
394395|NCT01183286|Behavioral|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
394396|NCT01183273|Procedure|Microlaparoscopic gastric bypass|microlaparoscopic gastric bypass will be performed using standard of care procedure.
394397|NCT01183273|Procedure|Laparoscopic Surgery|laparoscopic gastric bypass will be performed using standard of care procedure.
394398|NCT01183260|Device|Trabecular Metal Revision Cup|Revision of the acetabular cup
394399|NCT01183260|Device|Trabecular Metal Modular Cup|Revision of the acetabular cup
394400|NCT01183247|Drug|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
394401|NCT01183247|Drug|Everolimus|Add everolimus de novo to tacrolimus and MMF
394402|NCT01183247|Drug|Prednisone|Add prednisone de novo to tacrolimus and MMF
394403|NCT01183234|Drug|SPD544|two 30mg capsules, single oral dose
394404|NCT01183234|Drug|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
394405|NCT01183221|Drug|Syntocinon|One dose of 24 IU (3 sprays/nostril)
394406|NCT01183208|Drug|Intervention A|A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
394407|NCT01183208|Drug|Intervention B|A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
394408|NCT01183208|Drug|Intervention C|A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
394409|NCT01183208|Drug|Intervention D|A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
394410|NCT01183208|Drug|Intervention E|A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
394411|NCT01183182|Device|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
394412|NCT01183169|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
394413|NCT01183169|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
394414|NCT01183169|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
394415|NCT01183169|Drug|Placebo|ALV placebo soft gel capsules administered orally
394416|NCT01183156|Behavioral|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
394417|NCT01183156|Behavioral|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
394418|NCT01183143|Drug|GONAL-f®|GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
394419|NCT01183130|Device|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
394420|NCT01183117|Device|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
394421|NCT01183117|Device|PTA|balloon angioplasty
394422|NCT01183104|Drug|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=< <50).
394423|NCT01183104|Drug|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
394424|NCT01183091|Procedure|Ablation of atrial fibrillation|Ablation of atrial fibrillation
394425|NCT01183078|Procedure|free-hand|Free-hand technique utilizes x-rays to find screw holes.
394426|NCT01183078|Procedure|Wand technique|Wand technique is utilized to find screw holes.
394427|NCT01183065|Drug|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
394428|NCT01183052|Other|Training|20 sessions of training
394429|NCT01183039|Other|Training|20 sessions of training
394430|NCT01183013|Drug|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
394431|NCT01183013|Drug|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
394432|NCT01183013|Drug|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
394433|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
394434|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
394435|NCT01183013|Drug|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
394436|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
394437|NCT01183000|Procedure|Closure of the peritoneum at cs|Injection of 5 mg Marcaine (anesthetic solution) to the leg
394438|NCT01182987|Behavioral|Dementia Care Management|"The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.~Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution."
394439|NCT01182974|Drug|paracetamol|1 gr of paracetamol PO/PZ/PR
394440|NCT01182974|Drug|dypirone|1 gr PO/PZ/PR/IM
394441|NCT01182961|Other|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
394442|NCT01182961|Other|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
394443|NCT01182961|Other|exercise group|standard of care exercise group to improve strength and balance
394444|NCT01182948|Behavioral|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
394445|NCT01182948|Behavioral|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
394446|NCT01182922|Behavioral|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
394447|NCT01182883|Drug|IMC-A12|
394448|NCT01182883|Drug|Temsirolimus|
394449|NCT01182870|Drug|choleclaciferol|800-6000 IU cholecalciferol per day
394450|NCT01182844|Dietary Supplement|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
394451|NCT01182831|Procedure|percutaneous fluoro guided celiac plexus neurolysis|It is percutaneous injection of neurolytic agent in and around the celiac ganglion
394452|NCT01182831|Procedure|EUS guided neurolysis|It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
394453|NCT01182805|Device|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
394454|NCT01182805|Device|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
394455|NCT01182805|Device|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
394456|NCT01182792|Dietary Supplement|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
394457|NCT01182792|Dietary Supplement|Placebo|1 month Placebo
394458|NCT01182779|Radiation|Carbon ion|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
394459|NCT01182779|Radiation|Protons|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
394460|NCT01182766|Drug|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
394461|NCT01182766|Drug|Placebo with brief behavioral enhancement therapy|placebo
394462|NCT01182753|Radiation|carbon ion therapy|"Arm A (carbon ion therapy):~Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
394463|NCT01182753|Radiation|proton therapy|"Arm B (proton therapy):~Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
394464|NCT01182727|Drug|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
394467|NCT01182701|Behavioral|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
394468|NCT01182675|Drug|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
394469|NCT01182675|Drug|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
394470|NCT01182662|Other|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
394471|NCT01182662|Other|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
394472|NCT01182649|Device|coronary stent|coronary angioplasty with stent implantation
394473|NCT01182649|Device|stent|coronary angioplasty with stent implantation
394474|NCT01182636|Drug|Adapalene|0.1% Topical Gel
394475|NCT01182636|Drug|Differin®|0.1% Topical Gel
394476|NCT01182636|Drug|Placebo|Gel Base
394477|NCT01182623|Other|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
394478|NCT01182610|Drug|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
394479|NCT01182610|Drug|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
394480|NCT01182610|Drug|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
394481|NCT01182610|Drug|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
394482|NCT01182597|Drug|Pantoprazole (Pantoloc)|Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs
394483|NCT01182597|Drug|Lansoprazole (Takepron OD)|Lansoprazole (Takepron OD) 30mg q12h PO
394484|NCT01182558|Other|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
394485|NCT01182558|Other|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
394486|NCT01182558|Other|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
394487|NCT01182558|Other|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
394488|NCT01182545|Procedure|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
394489|NCT01182532|Other|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
394490|NCT01182532|Drug|TCM Syndrome Differentiation and Treatment|"Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction.~Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.~Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.~Dosage: Adjusting by age and weight of patients. Decoction."
394491|NCT01182532|Other|Western therapy plus TCM treatment|"Symptomatic treatment using the same treatment methods in western therapy group;~Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
394492|NCT01182519|Behavioral|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
394493|NCT01182506|Behavioral|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.~The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
394494|NCT01182493|Device|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
395441|NCT01175356|Other|pharmacological study|Correlative studies
394495|NCT01182480|Behavioral|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:~7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.~3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
394496|NCT01182467|Radiation|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
394497|NCT01182441|Device|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
394498|NCT01182441|Drug|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
394499|NCT01182428|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
394500|NCT01182428|Device|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
394501|NCT01182415|Procedure|Autologous stem cell transplant|Autologous stem cell transplant following high-dose chemotherapy
394502|NCT01182415|Drug|High-dose chemotherapy|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide
394503|NCT01182402|Device|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
394504|NCT01182389|Procedure|Robotic VT Ablation|Robotic VT Ablation
394505|NCT01182389|Other|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
394506|NCT01182376|Drug|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
394507|NCT01182376|Drug|Placebo|Placebo will be administered by the patient's team according to established guidelines.
394508|NCT01182363|Behavioral|Project Solve Education|Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
394509|NCT01182350|Drug|Bevacizumab|
394510|NCT01182350|Drug|Erlotinib|
394511|NCT01182350|Drug|Temozolomide|•
394512|NCT01182350|Radiation|Radiation|
394513|NCT01182337|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
394514|NCT01182337|Drug|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
394515|NCT01182285|Drug|Valproic Acid|"Week 1:~(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
394516|NCT01182285|Drug|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
394517|NCT01182272|Drug|sorafenib tosylate|
394518|NCT01182272|Other|laboratory biomarker analysis|
394519|NCT01182272|Procedure|neoadjuvant therapy|
394520|NCT01182272|Procedure|therapeutic conventional surgery|
394521|NCT01182246|Drug|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.~A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).~AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
394522|NCT01182233|Radiation|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
394523|NCT01182207|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
394524|NCT01182207|Drug|YAZ®|3 mg/0.02 mg Tablets
394525|NCT01182194|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
394526|NCT01182194|Drug|YAZ®|3 mg/0.02 mg Tablets
394527|NCT01182181|Drug|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
394528|NCT01182181|Drug|Anastrozole (Arimidex®)|1 mg Tablets
394529|NCT01182168|Drug|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
394530|NCT01182155|Procedure|Exhaled Breath Sampling|Standard of care
394532|NCT01182129|Drug|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
394533|NCT01182129|Drug|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
394534|NCT01182116|Procedure|J Pouch|Comparing J pouch, side to end coloanal surgery
394535|NCT01182090|Procedure|Colposacropexy|In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
394536|NCT01182090|Procedure|Colposacropexy|In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
394537|NCT01182077|Drug|ASP015K|Oral
394538|NCT01182077|Drug|Midazolam|Oral
394539|NCT01182051|Behavioral|CBT or relaxation training|8 weeks of CBT or relaxation training.
394540|NCT01182038|Device|BirthRite birthing seat|Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
394541|NCT01182025|Other|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.~Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
394542|NCT01182025|Drug|Xiyanping Injection|"Dosage for child medication:~5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor."
394543|NCT01182025|Drug|Xiyanping Injection with western medicine|"Symptomatic treatment using the same treatment methods in western therapy group;~Symptomatic treatment using the same treatment methods in Xiyanpin injection group."
394544|NCT01182012|Behavioral|Lifestyle counseling|Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
394545|NCT01181999|Drug|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
394546|NCT01181986|Drug|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
394547|NCT01181986|Drug|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
394548|NCT01181986|Drug|Placebo SC|Placebo sc BID/10days
394549|NCT01181986|Drug|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
394550|NCT01181986|Drug|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
394551|NCT01181973|Drug|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
394552|NCT01181973|Drug|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
394553|NCT01181973|Drug|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
394554|NCT01181973|Drug|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
394555|NCT01181960|Drug|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
394556|NCT01181960|Drug|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
394557|NCT01181960|Drug|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
394558|NCT01181960|Drug|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
394559|NCT01181947|Device|TEVAR|Thoracic endovascular aneurysm repair
394560|NCT01181934|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
394561|NCT01181934|Drug|placebo|placebo - three times daily during each treatment period
394562|NCT01181934|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
394563|NCT01181921|Drug|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
394564|NCT01181908|Drug|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
394565|NCT01181895|Drug|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
394566|NCT01181895|Drug|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
395442|NCT01175356|Other|questionnaire administration|Ancillary studies
394567|NCT01181895|Drug|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
394568|NCT01181895|Drug|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
394569|NCT01181882|Dietary Supplement|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
394570|NCT01181869|Device|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
394571|NCT01181856|Biological|MVA 85A|Single injection of 1 x 108 pfu MVA85A
394572|NCT01181830|Drug|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
394573|NCT01181830|Drug|placebo|administration of 8.1 mmol bid of placebo
394574|NCT01181817|Other|fMRI and MRS|fMRI and MRS
394575|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
394576|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
394577|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
394578|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
394579|NCT01181791|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
394580|NCT01181791|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
394581|NCT01181765|Biological|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
394582|NCT01181726|Drug|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
394583|NCT01181726|Drug|Activella®|1 mg/0.5 mg Tablets
394584|NCT01181700|Drug|Treatment A|PF-00241939 300 ug using inhaler A
394585|NCT01181700|Drug|Treatment B|PF-00241939 300 ug using inhaler A
394586|NCT01181700|Drug|Treatment C|PF-00241939 300 ug using inhaler A
394587|NCT01181700|Drug|Treatment D|PF-00241939 300 ug using inhaler B
394588|NCT01181700|Drug|Treatment E|PF-00241939 300 ug using inhaler B
394589|NCT01181700|Drug|Treatment F|PF-00241939 300 ug using inhaler B
394590|NCT01181700|Drug|Treatment G|PF-00241939 300 ug using inhaler B
394591|NCT01181674|Drug|insulin glargine|sc injection
394592|NCT01181674|Drug|metformin|oral administration
394593|NCT01181674|Drug|acarbose|oral administration
394594|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
394595|NCT01181674|Drug|insulin glargine|sc injection
394596|NCT01181674|Drug|metformin|oral administration
394597|NCT01181674|Drug|acarbose|oral administration
394598|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
394599|NCT01181674|Other|Standard glycemic care|as informed by the current clinical practice guidelines
394600|NCT01181661|Behavioral|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
394601|NCT01181661|Behavioral|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
394602|NCT01181648|Behavioral|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
394603|NCT01181635|Behavioral|Psychotherapy|Standard psychotherapy for psychiatric disorders.
394604|NCT01181622|Drug|denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
394605|NCT01181622|Drug|0.9% w/v sodium chloride solution|0.9% w/v sodium chloride solution by oral inhalation three times daily
394606|NCT01181609|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
394607|NCT01181583|Behavioral|Tailored Internet-delivered CBT|"This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
394608|NCT01181583|Behavioral|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
394609|NCT01181583|Behavioral|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
394610|NCT01181570|Drug|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
394611|NCT01181570|Drug|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
394612|NCT01181544|Procedure|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
394613|NCT01181531|Drug|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
394614|NCT01181531|Drug|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
394615|NCT01181505|Drug|Tolterodine|
394616|NCT01181479|Drug|AG200-15 (cycles 1-13)|AG200-15 containing ethinyl estradiol and levonorgestrel
394617|NCT01181479|Drug|Lessina crossover to AG200-15|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen for 6 cycles followed by AG200-15 for 6 cycles.
394618|NCT01181466|Device|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
394619|NCT01181453|Device|Dermagraft|Weekly application of Dermagraft(R) with standard care
394620|NCT01181453|Other|Comparator|Weekly application of standard care
394621|NCT01181440|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
394622|NCT01181440|Other|Conventional care|Weekly application of conventional care
394623|NCT01181427|Drug|ABT-267|See arm description
394624|NCT01181427|Drug|Placebo|See arms description
394625|NCT01181427|Procedure|Blood Sample Collection|See arm description
394626|NCT01181427|Drug|Cytochrome P450 inhibitor|See arm description
394627|NCT01181414|Procedure|Atrio ventricular junction ablation with radio-frequency|Atrioventricular junction ablation by using radiofrequency energy.
394628|NCT01181414|Drug|Beta blocker/digoxine/amiodarone|Ventricular rate control by using drug treatment.
394629|NCT01181401|Drug|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
394630|NCT01181401|Drug|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
394631|NCT01181401|Radiation|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
394632|NCT01181388|Procedure|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
394633|NCT01181388|Procedure|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
394634|NCT01181375|Other|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
394635|NCT01181362|Procedure|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
394636|NCT01181349|Other|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug[s]) are not specified in the protocol.
394637|NCT01181349|Other|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug[s]) are not specified in the protocol.
394638|NCT01181336|Biological|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
394639|NCT01181336|Biological|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
394640|NCT01181323|Other|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
394641|NCT01181323|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
394642|NCT01181323|Other|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
394643|NCT01181323|Biological|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
394644|NCT01181310|Drug|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
394645|NCT01181310|Drug|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
394646|NCT01181310|Drug|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
394647|NCT01181310|Drug|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
394821|NCT01180101|Procedure|Bariatric Surgery|Patients will undergo bariatric surgery
394648|NCT01181310|Drug|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
394649|NCT01181297|Other|Extensively Hydrolyzed Formula with a Probiotic|
394650|NCT01181297|Other|Extensively Hydrolyzed Formula without a Probiotic|
394651|NCT01181271|Drug|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
394652|NCT01181271|Drug|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
394653|NCT01181271|Drug|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
394654|NCT01181271|Drug|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
394655|NCT01181271|Other|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
394656|NCT01181271|Drug|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
394657|NCT01181271|Drug|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
394658|NCT01181271|Drug|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
394659|NCT01181271|Other|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10^6/kg of recipient's actual body weight
394660|NCT01181271|Drug|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
394661|NCT01181271|Drug|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
394662|NCT01181271|Drug|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
394663|NCT01181258|Drug|Rituximab|375 mg/m^2 administered intravenously (IV) weekly * 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
394664|NCT01181258|Biological|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day * 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight < 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
394665|NCT01181258|Biological|Natural killer cells|administered intravenously 1.5 to 8 * 10^7 cells/kg on Day 0 (day of NK cell infusion)
394666|NCT01181258|Drug|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
394667|NCT01181258|Drug|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
394668|NCT01181258|Drug|Fludarabine|25 mg/m^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
394669|NCT01181245|Drug|FG-3019|3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
394670|NCT01181232|Drug|Zolpidem MR|oral
394671|NCT01181232|Drug|Zolpidem IR|oral
394672|NCT01181219|Procedure|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
394673|NCT01181219|Procedure|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
394674|NCT01181206|Procedure|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
394675|NCT01181193|Other|Surgery|Craniotomy with total or partial removal of the brain tumor
394676|NCT01181193|Radiation|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
394677|NCT01181193|Drug|Temozolomide|"75 mg/m2/day for entire period of radiotherapy~150-200 mg/m2/day for 5 days every 28 days, 6 cycles total"
394678|NCT01181193|Drug|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
394679|NCT01181180|Dietary Supplement|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
394680|NCT01181167|Drug|edoxaban|
394681|NCT01181167|Drug|enoxaparin sodium|
394682|NCT01181154|Drug|rituximab (Mabthera®)|1000 mg at day 1 and day 15
394683|NCT01181154|Drug|Placebo|equivalent volume total
394684|NCT01181141|Drug|DU-176b (edoxaban)|
394685|NCT01181141|Drug|Enoxaparin sodium 20mg|
394686|NCT01181128|Drug|Factor VIII (rFVIIIFc)|
394687|NCT01181128|Drug|Advate®|
394688|NCT01181115|Drug|Avonex|Interferon treatment for MS
394689|NCT01181102|Drug|edoxaban|
394690|NCT01181102|Drug|enoxaparin sodium|
394691|NCT01181089|Biological|Placebo|
394692|NCT01181089|Biological|Baminercept|
394693|NCT01181076|Dietary Supplement|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
394892|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
394694|NCT01181063|Drug|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
394695|NCT01181050|Drug|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
394696|NCT01181050|Drug|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
394697|NCT01181024|Drug|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
394698|NCT01181024|Drug|RO5303253|Cohorts receiving single ascending doses
394699|NCT01181024|Drug|RO5303253|Single dose
394700|NCT01181024|Drug|RO5303253|Multiple doses
394701|NCT01181011|Drug|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
394702|NCT01180998|Device|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
394703|NCT01180998|Device|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
394704|NCT01180985|Device|galyfilcon A prototype lens|silicone hydrogel contact lens
394705|NCT01180985|Device|comfilcon A|silicone hydrogel contact lens
394706|NCT01180959|Drug|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
394707|NCT01180959|Drug|Erlotinib|150 mg by mouth once a day.
394708|NCT01180946|Dietary Supplement|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
394709|NCT01180946|Other|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
394710|NCT01180933|Dietary Supplement|fish oil|400 mg of DHA and 150 mg of eicosapentaenoic acid per day
394711|NCT01180933|Dietary Supplement|folate|400 µg per day
394712|NCT01180933|Dietary Supplement|fish oil + folate|500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
394713|NCT01180933|Dietary Supplement|placebo|only vitamins and minerals as recommended, but no fish oil or folate
394714|NCT01180894|Drug|Iron sucrose|100 mg IV TIW
394715|NCT01180894|Drug|Placebo|
394716|NCT01180855|Drug|Placebo|Placebo pill nightly for 42 nights.
394717|NCT01180855|Drug|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
394718|NCT01180855|Other|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
394719|NCT01180842|Other|Yoga treatment program|yoga program designed specifically for the patient with CF
394720|NCT01180829|Behavioral|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
394721|NCT01180829|Behavioral|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
394722|NCT01180816|Drug|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
394723|NCT01180803|Device|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
394724|NCT01180803|Device|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
394725|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
394726|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
394727|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
394728|NCT01180790|Drug|Placebo|Powder in capsule once daily
394729|NCT01180790|Drug|Pegylated Interferon alpha-2a|180 ug once a week by subcutaneous injection
394730|NCT01180790|Drug|Ribavirin|400 mg or 600 mg (am) and 600 mg (pm) capsules taken orally twice daily
394731|NCT01180777|Device|etafilcon A (A)|Daily wear contact lens
394732|NCT01180777|Device|etafilcon A (B)|Daily wear contact lens
394733|NCT01180777|Device|etafilcon A (C)|Daily wear contact lens
394734|NCT01180764|Drug|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
394735|NCT01180764|Drug|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
394736|NCT01180751|Radiation|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
394737|NCT01180738|Behavioral|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
394738|NCT01180738|Behavioral|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
394739|NCT01180725|Dietary Supplement|Dried Plum|
394740|NCT01180725|Dietary Supplement|Metamucil|
394741|NCT01180712|Dietary Supplement|Mirtoselect|"Male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.~Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
394742|NCT01180699|Biological|Influenza vaccine: Vaxigrip or Fluviral and Intanza|Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
394743|NCT01180686|Device|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
394744|NCT01180686|Device|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
394787|NCT01180348|Drug|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
394745|NCT01180673|Behavioral|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
394746|NCT01180673|Behavioral|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
394747|NCT01180660|Drug|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
394748|NCT01180660|Drug|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
394749|NCT01180647|Drug|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
394750|NCT01180647|Behavioral|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
394751|NCT01180634|Drug|MP-376 (Levofloxacin solution for Inhalation)|240 mg of MP-376 administered BID for 28 days
394752|NCT01180634|Drug|Placebo|same volume and frequency as study drug
394753|NCT01180621|Biological|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
394754|NCT01180608|Other|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:~gamma-aminobutyric acid (GABA)~glutamate (Glu)~glutamine (Gln)~N-acetylaspartate (NAA)~Choline-containing compounds (Cho)~Creatine plus phophocreatine (total creatine: Cr)~Myo-inositiol (Ins)~Choline (Cho)~Glucose (Glc)~Lactate (Lac)"
394755|NCT01180595|Device|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
394756|NCT01180595|Device|Trabecular Metal Monoblock Tibial Total Knee Component|
394757|NCT01180582|Device|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
394758|NCT01180569|Drug|lenalidomide|"Patient enrollment FNA of palpable lymph node prior to escalation phase~Escalation phase of Lenalidomide:~Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase~Treatment phase of Lenalidomide:~15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles"
394759|NCT01180556|Dietary Supplement|Probiotics|Daily oral supplementation for four weeks
394760|NCT01180556|Dietary Supplement|Placebo|Placebo administration
394761|NCT01180543|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
394762|NCT01180543|Device|Placebo Patch|same as active patch
394763|NCT01180530|Device|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
394764|NCT01180517|Procedure|Percutaneous coronary intervention (PCI)|balloon angioplasty
394765|NCT01180517|Procedure|PCI|balloon angioplasty
394766|NCT01180504|Radiation|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
394767|NCT01180491|Device|K101 nail solution|
394768|NCT01180478|Device|White Light|White Light Cystoscopy
394769|NCT01180478|Device|Narrow Band Imaging|Narrow Band Imaging
394770|NCT01180465|Drug|LIPO-102|LIPO-102 High dose
394771|NCT01180465|Drug|LIPO-102 Low|LIPO-102 Low dose
394772|NCT01180465|Drug|LIPO-102, Placebo|Placebo
394773|NCT01180452|Procedure|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
394774|NCT01180439|Device|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
394775|NCT01180426|Drug|CHR-2797|120mg once daily oral for 48 weeks
394776|NCT01180413|Drug|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
394777|NCT01180413|Drug|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
394778|NCT01180413|Drug|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
394779|NCT01180413|Drug|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
394780|NCT01180400|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
394781|NCT01180400|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
394782|NCT01180374|Drug|Cannabidiol|Active Cannabidiol 5mg.
394783|NCT01180374|Drug|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
394784|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
394785|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
394786|NCT01180348|Drug|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
394788|NCT01180335|Drug|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
394789|NCT01180335|Drug|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
394790|NCT01180322|Drug|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)~Consolidation therapy:~Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).~Elderly patients (>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
394791|NCT01180322|Drug|Idarubicin|"First induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.~Arm B:~12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.~Second induction therapy:~Arm A, C, D:~12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)~Arm B:~12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
394792|NCT01180322|Drug|Etoposide|"Induction therapy:~Arm A, C, D:~100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.~Arm B:~100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
394793|NCT01180322|Drug|Azacitidine|"Induction therapy:~Arm B and C:~100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Arm D:~100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.~Maintenance therapy:~Arm B, C, D:~50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
394794|NCT01180322|Drug|Lenograstim|"Consolidation therapy:~subcutaneously daily beginning on day 10 until neutrophil count > 0.5 x 109/l."
394795|NCT01180296|Drug|oral micronized progesterone|oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks
394796|NCT01180296|Drug|Identical Placebo tablet|Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
394797|NCT01180283|Drug|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
394798|NCT01180244|Device|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
394799|NCT01180244|Device|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
394800|NCT01180231|Drug|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
394801|NCT01180231|Other|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
394802|NCT01180218|Procedure|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
394803|NCT01180218|Procedure|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
394804|NCT01180205|Drug|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
394805|NCT01180205|Drug|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
394806|NCT01180205|Drug|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
394807|NCT01180205|Drug|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
394808|NCT01180192|Drug|oxygen|either 8 L/minute O2 via face mask for 2 hours
394809|NCT01180179|Drug|Lansoprazole|30mg once daily
394810|NCT01180179|Drug|Famotidine|40mg once daily
394811|NCT01180166|Drug|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
394812|NCT01180153|Drug|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
394813|NCT01180140|Device|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
394814|NCT01180127|Dietary Supplement|Flavanol containing food product|12 weeks, 2X/day, 20g serving
394815|NCT01180127|Behavioral|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
394816|NCT01180127|Dietary Supplement|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
394817|NCT01180127|Behavioral|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
394818|NCT01180114|Behavioral|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
394819|NCT01180114|Other|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
394820|NCT01180101|Behavioral|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
394822|NCT01180088|Procedure|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
394823|NCT01180075|Drug|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
394824|NCT01180075|Drug|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
394825|NCT01180075|Drug|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
394826|NCT01180075|Drug|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
394827|NCT01180075|Procedure|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
394828|NCT01180062|Drug|Latanoprost|"Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.~Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.~Duration of drug release is expected to be 3-6 months.~Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost."
394829|NCT01180062|Drug|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
394830|NCT01180062|Drug|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
394831|NCT01180049|Drug|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
394832|NCT01180049|Drug|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
394833|NCT01180036|Drug|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of cluster of differentiation (CD) 19+ B cell count
394834|NCT01180036|Drug|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by High Performance Liquid Chromatography (HPLC), are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine >30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
394835|NCT01180023|Procedure|Sweeping|Sweeping of membranes during digital exam
394836|NCT01180010|Procedure|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
394837|NCT01179997|Device|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
394838|NCT01179997|Device|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
394839|NCT01179984|Device|Bard® LifeStent® Vascular Stent System|Stent Implantation
394840|NCT01179971|Dietary Supplement|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
394841|NCT01179958|Behavioral|aerobic training|24 weeks of aerobic training, 4X/week
394842|NCT01179958|Behavioral|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
394843|NCT01179945|Other|benzoate containing test drinks|"Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.~Each solution will be consumed over 5 minutes."
394844|NCT01179945|Other|non sodium benzoate containing test drinks|"Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.~Each solution will be consumed over 5 minutes."
394845|NCT01179932|Other|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
394846|NCT01179919|Drug|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
394847|NCT01179906|Behavioral|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
394848|NCT01179906|Behavioral|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
394849|NCT01179893|Biological|IVIG|Intravenous immunoglobulin
394850|NCT01179893|Procedure|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
394851|NCT01179880|Drug|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
394852|NCT01179880|Drug|Placebo|Matching placebo for each step
394893|NCT01179594|Drug|placebo|orally daily, 24 weeks (weeks 12-36)
394894|NCT01179581|Drug|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
394895|NCT01179581|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
394896|NCT01179581|Drug|GLPG0634|multiple dose, capsule, 10 days
394897|NCT01179581|Drug|placebo|multiple dose, capsule, 10 days
394853|NCT01179867|Other|Electronic Medication Reconciliation|"At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications~At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient~The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes"
394854|NCT01179854|Drug|Remegal|Drug/ placebo
394855|NCT01179841|Behavioral|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
394856|NCT01179841|Behavioral|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
394857|NCT01179841|Behavioral|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
394858|NCT01179828|Drug|Oxycodone 15mg|15mg single administration p.o.
394859|NCT01179828|Drug|Clobazam|20mg single administration p.o.
394860|NCT01179828|Drug|Imipramine|75mg single administration p.o.
394861|NCT01179828|Drug|Tolterodine|1 mg single administration p.o.
394862|NCT01179802|Other|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
394863|NCT01179789|Behavioral|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform
394864|NCT01179789|Dietary Supplement|VSL#3®|probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
394865|NCT01179789|Dietary Supplement|AISA-5203-L|fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
394866|NCT01179789|Dietary Supplement|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
394867|NCT01179776|Drug|Ilomedin|Ilomedin
394868|NCT01179776|Drug|Placebo|i.v saline
394869|NCT01179776|Drug|Ilomedin|
394870|NCT01179776|Drug|Ilomedin and standard low dose treatment|
394871|NCT01179763|Other|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
394872|NCT01179750|Device|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
394873|NCT01179737|Drug|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
394874|NCT01179737|Drug|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
394875|NCT01179724|Drug|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
394876|NCT01179724|Drug|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
394877|NCT01179711|Device|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
394878|NCT01179698|Procedure|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
394879|NCT01179698|Procedure|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
394880|NCT01179685|Procedure|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
394881|NCT01179672|Drug|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
394882|NCT01179672|Drug|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
394883|NCT01179659|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
394884|NCT01179646|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
394885|NCT01179633|Device|OPLON active patch|
394886|NCT01179633|Device|Sham patch|
394887|NCT01179620|Drug|Certoparin|Certoparin
394888|NCT01179607|Drug|M0002|
394889|NCT01179607|Drug|Placebo|
394890|NCT01179594|Drug|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
394891|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
394898|NCT01179568|Drug|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
394899|NCT01179568|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
394900|NCT01179568|Other|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
394901|NCT01179555|Behavioral|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
394902|NCT01179555|Behavioral|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
394903|NCT01179529|Drug|Omalizumab (Xolair®)|
394904|NCT01179516|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
394905|NCT01179516|Drug|Placebo|Vortioxetine placebo-matching capsules
394906|NCT01179503|Dietary Supplement|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
394907|NCT01179503|Dietary Supplement|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
394908|NCT01179490|Drug|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
394909|NCT01179490|Drug|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
394910|NCT01179477|Device|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
394911|NCT01179464|Drug|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
394912|NCT01179464|Drug|Simvastatin|40 mg once daily
394913|NCT01179451|Device|echocardiogram|echocardiogram
394914|NCT01179438|Drug|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
394915|NCT01179425|Other|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
394916|NCT01179412|Drug|2% povidone-iodine|apply 4 times a day for one week
394917|NCT01179412|Drug|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
394918|NCT01179399|Drug|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
394919|NCT01179373|Device|TMS, H coil|TMS, H Coil, High/ Low Frequency
394920|NCT01179360|Other|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
394921|NCT01179347|Drug|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
394922|NCT01179347|Drug|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
394923|NCT01179334|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
394924|NCT01179334|Drug|Placebo|Placebo for 12 weeks
394925|NCT01179334|Drug|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
394926|NCT01179321|Other|Early referral to Dietitian for assessment and nutrition support|
394927|NCT01179308|Other|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
394928|NCT01179308|Other|Balanced general anesthesia and postoperative opioids|General anesthesia alone
394929|NCT01179295|Drug|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
394930|NCT01179295|Drug|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
394931|NCT01179295|Drug|BAY86-9766|BAY86-9766 100 mg once a day (od)
394932|NCT01179295|Drug|BAY86-9766|BAY86-9766 60 mg once a day (od)
394933|NCT01179282|Biological|dust mite extract or placebo|intervention will be to stop study drug or placebo
394934|NCT01179269|Drug|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
394935|NCT01179256|Dietary Supplement|CURCUMIN|oral supplementation of curcumin 2000mg
394936|NCT01179256|Other|no intervention other than stopping study|no intervention other than stopping study
394937|NCT01179230|Other|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
394938|NCT01179230|Other|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
394939|NCT01179217|Drug|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
394940|NCT01179217|Drug|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
394941|NCT01179204|Procedure|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
395132|NCT01177683|Drug|Filgrastim|"Phase II component:~Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC >1000"
395170|NCT01177332|Other|exercise|2 hours cycling exercise at 50 % of maximal power output
394942|NCT01179191|Drug|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
394943|NCT01179165|Other|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
394944|NCT01179152|Drug|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
394945|NCT01179139|Other|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith & Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
394946|NCT01179126|Procedure|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
394947|NCT01179126|Procedure|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
394948|NCT01179113|Drug|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
394949|NCT01179113|Drug|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
394950|NCT01179100|Drug|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
394951|NCT01179074|Procedure|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
394952|NCT01179074|Procedure|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
394953|NCT01179061|Drug|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
394954|NCT01179061|Drug|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
394955|NCT01179048|Drug|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
394956|NCT01179048|Drug|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
394957|NCT01179035|Other|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
394958|NCT01179035|Other|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
394959|NCT01179009|Drug|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. [18% (0.0125 mg/kg-min.)
394960|NCT01179009|Drug|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
394961|NCT01179009|Drug|placebo|IV saline (i.e. placebo ketamine)
394962|NCT01178996|Biological|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
394963|NCT01178996|Drug|Ribavirin|Ribavirin 1000 mg (<75 kg) or 1200 mg (>75 kg) daily with food divided in two doses orally for 48 weeks
394964|NCT01178996|Biological|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
394965|NCT01178996|Drug|Placebo|Placebo
394966|NCT01178983|Device|surface electromyography|Surface electromyography (SEMG) telebiofeedback
394967|NCT01178983|Device|surface electromyography|conventional biofeedback
394968|NCT01178970|Behavioral|Resistance training|
394969|NCT01178957|Other|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
394970|NCT01178944|Other|Laboratory Biomarker Analysis|Correlative studies
394971|NCT01178944|Drug|Oxaliplatin|Given IV
394972|NCT01178944|Drug|Pralatrexate|Given IV
394973|NCT01178931|Drug|Oral dydrogesterone|oral-2x10mg
394974|NCT01178931|Drug|Crinone 8% gel|vaginal-1x90mg
394975|NCT01178905|Procedure|ultrashort heat inactivation|
394976|NCT01178892|Dietary Supplement|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
394977|NCT01178892|Dietary Supplement|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
395133|NCT01177657|Procedure|Stool sampling|Stool samples collected and checked for the presence of rotavirus
395134|NCT01177644|Drug|PDS 1.0|
395171|NCT01177319|Drug|Glutathione|
394978|NCT01178892|Behavioral|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
394979|NCT01178892|Behavioral|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
394980|NCT01178892|Behavioral|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
394981|NCT01178879|Behavioral|Telehealth consultation|"The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.~The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line."
394982|NCT01178853|Drug|Warfarin|Warfarin 5 mg once daily
394983|NCT01178853|Drug|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
394984|NCT01178853|Drug|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
394985|NCT01178840|Device|WC then FC2|4 uses of WC followed by 4 uses of FC2
394986|NCT01178840|Device|FC2 then WC|4 uses of WC followed by 4 uses of FC2
394987|NCT01178827|Drug|trospium chloride|trospium chloride (60mg) once daily for 10 days
394988|NCT01178827|Drug|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
394989|NCT01178827|Drug|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
394990|NCT01178814|Drug|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
394991|NCT01178788|Drug|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
394992|NCT01178788|Drug|micronized Progesterone|daily administration of vaginal progesterone
394993|NCT01178788|Procedure|Control|
394994|NCT01178775|Behavioral|walking|use a pedometer for records steps.
394995|NCT01178762|Drug|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
394996|NCT01178736|Procedure|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
394997|NCT01178736|Procedure|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
394998|NCT01178736|Procedure|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
394999|NCT01178736|Procedure|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
395000|NCT01178723|Dietary Supplement|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.~(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.~Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).~The instructions will be adapted to each patient individually"
395001|NCT01178710|Drug|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
395002|NCT01178697|Drug|Bevasizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
395003|NCT01178697|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
395004|NCT01178671|Drug|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
395005|NCT01178671|Drug|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
395006|NCT01178671|Other|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
395007|NCT01178658|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
395008|NCT01178645|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
395009|NCT01178632|Drug|Passiflora|01 tablet Passiflora p.o., b.i.d.
395010|NCT01178632|Drug|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
395011|NCT01178593|Other|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
395012|NCT01178554|Behavioral|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
395013|NCT01178554|Behavioral|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
395014|NCT01178554|Behavioral|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita & Weisz, 2004)
395015|NCT01178528|Drug|ivabradine|7.5 mg bd
395016|NCT01178528|Drug|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
395017|NCT01178528|Drug|Carvedilol|25 mg bd
395018|NCT01178515|Other|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
395019|NCT01178515|Other|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
395020|NCT01178515|Other|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
395021|NCT01178476|Device|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
395022|NCT01178463|Other|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
395023|NCT01178463|Other|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
395024|NCT01178450|Procedure|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
395025|NCT01178450|Drug|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
395026|NCT01178437|Device|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
395027|NCT01178424|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
395028|NCT01178424|Behavioral|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
395029|NCT01178411|Drug|ARQ 197 as monotherapy or in combination with other drug(s)|ARQ 197 as monotherapy or in combination with other drug(s) at the same dose(s), and same schedule(s) in which they were originally enrolled.
395030|NCT01178385|Behavioral|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
395031|NCT01178385|Behavioral|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
395032|NCT01178372|Drug|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
395033|NCT01178372|Drug|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
395034|NCT01178359|Drug|nitrite|
395035|NCT01178346|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
395036|NCT01178346|Biological|Placebo|Placebo vaccine given 6 times over 6 months
395037|NCT01178320|Drug|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
395038|NCT01178307|Behavioral|Questionnaires|10 minutes to complete 3 questionnaires for development of MDASI-GIST
395039|NCT01178307|Behavioral|Interview|Each interview will take approximately 30 minutes.
395040|NCT01178307|Behavioral|MDASI-GIST Questionnaire|Every 4 weeks for one year
395041|NCT01178294|Biological|OBI-1|Intravenous infusion
395042|NCT01178281|Drug|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
395043|NCT01178281|Drug|Placebo|Placebo Comparator to active drug; Placebo capsule taken by mouth once daily
395044|NCT01178281|Drug|Pomalidomide|Pomalidomide 0.5 mg capsule taken by mouth once daily.
395045|NCT01178268|Device|XIENCE V EECSS|Patients who will receive this stent.
395046|NCT01178268|Device|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
395047|NCT01178255|Drug|homeopathic q-potencies|individualised homeopathic medicines
395048|NCT01178255|Drug|Placebo|placebo
395049|NCT01178255|Other|homeopathic case history taking type I|one special homeopathic technique for case history taking
395050|NCT01178255|Other|homeopathic case history type II|another type of homeopathic case history taking
395172|NCT01177306|Drug|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
395051|NCT01178242|Procedure|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
395052|NCT01178229|Other|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.~The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.~Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.~All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
395053|NCT01178216|Biological|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
395054|NCT01178203|Drug|Placebo|Placebo
395055|NCT01178203|Drug|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
395056|NCT01178203|Drug|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
395057|NCT01178203|Drug|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
395058|NCT01178164|Genetic|Blood sampling for biological and genetic analysis|"Clinical examination~Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
395059|NCT01178151|Drug|Everolimus|10mg daily orally
395060|NCT01178138|Drug|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
395061|NCT01178125|Drug|DR-102|
395062|NCT01178112|Drug|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
395063|NCT01178112|Drug|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
395064|NCT01178112|Drug|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
395065|NCT01178112|Drug|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
395066|NCT01178112|Other|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
395067|NCT01178099|Drug|Prasugrel|Oral, daily for 12 days
395068|NCT01178086|Drug|Rituximab|Rituximab IV
395069|NCT01178073|Drug|ambrisentan|ambrisentan (target dose: 10mg)
395070|NCT01178073|Drug|tadalafil|tadalafil (target dose: 40mg)
395071|NCT01178060|Other|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
395072|NCT01178060|Other|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
395073|NCT01178047|Drug|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
395074|NCT01178034|Genetic|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
395075|NCT01178021|Drug|Chloroquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2
395076|NCT01178021|Drug|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
395077|NCT01178008|Procedure|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
395078|NCT01178008|Procedure|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
395079|NCT01177995|Behavioral|Social Network Intervention|Social network leaders will communicate HIV prevention messages to members of their social networks.
395080|NCT01177982|Behavioral|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
395081|NCT01177982|Behavioral|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
395082|NCT01177982|Behavioral|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
395083|NCT01177982|Behavioral|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
395084|NCT01177982|Behavioral|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
395085|NCT01177982|Behavioral|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
395135|NCT01177631|Procedure|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
395086|NCT01177982|Behavioral|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
395087|NCT01177982|Behavioral|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
395088|NCT01177969|Behavioral|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
395089|NCT01177969|Behavioral|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
395090|NCT01177956|Biological|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.~Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
395091|NCT01177956|Drug|Cisplatin|Subjects will receive 75 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
395092|NCT01177956|Drug|5-Fluorouracil|Subjects will receive 750 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
395093|NCT01177943|Drug|Atomoxetine|Administered orally, once.
395094|NCT01177917|Other|Infant Formula|
395095|NCT01177904|Other|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
395096|NCT01177904|Other|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
395097|NCT01177865|Other|informational intervention|
395098|NCT01177865|Other|questionnaire administration|
395099|NCT01177852|Drug|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).~Posology: The medicine treat will be as follows:~- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
395100|NCT01177852|Drug|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:~Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml~Pseudoephedrine hydrochloride + brompheniramine maleate:~Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
395101|NCT01177839|Other|Screening sheets|Reviewing screening sheets
395102|NCT01177826|Procedure|Sample collection|Stool sample
395103|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
395104|NCT01177813|Drug|BI 10773|BI 10773 low dose tablet once daily
395105|NCT01177813|Drug|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
395106|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
395107|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
395108|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
395109|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
395110|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
395111|NCT01177813|Drug|BI10773|BI 10773 high dose tablets once daily
395112|NCT01177813|Drug|Sitagliptin|Sitagliptin tablets 100 mg once daily
395113|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
395114|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
395115|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
395116|NCT01177800|Drug|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
395117|NCT01177800|Drug|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
395118|NCT01177787|Device|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
395119|NCT01177787|Device|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
395120|NCT01177761|Procedure|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
395121|NCT01177735|Drug|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
395122|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
395123|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
395124|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
395125|NCT01177722|Biological|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
395126|NCT01177709|Drug|Metformin|metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
395127|NCT01177696|Behavioral|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
395128|NCT01177683|Drug|Bendamustine|"Phase I component:~Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
395129|NCT01177683|Drug|Doxorubicin|"Phase I and II components:~Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
395130|NCT01177683|Drug|Bortezomib|"Phase I and II components:~Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
395131|NCT01177683|Drug|Bendamustine|"Phase II component:~Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
395136|NCT01177605|Other|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
395137|NCT01177592|Device|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
395138|NCT01177579|Dietary Supplement|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
395139|NCT01177566|Drug|pimecrolimus|pimecrolimus 1% cream twice daily
395140|NCT01177566|Device|topical medical device|Eletone cream three times daily
395141|NCT01177553|Procedure|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
395142|NCT01177553|Device|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
395143|NCT01177540|Drug|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
395144|NCT01177540|Drug|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
395145|NCT01177514|Drug|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
395146|NCT01177514|Drug|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
395147|NCT01177501|Drug|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
395148|NCT01177488|Behavioral|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
395149|NCT01177475|Other|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
395150|NCT01177475|Other|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
395151|NCT01177449|Procedure|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
395152|NCT01177436|Biological|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
395153|NCT01177423|Procedure|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
395154|NCT01177410|Drug|Placebo|placebo capsules once daily for 12 weeks
395155|NCT01177410|Drug|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
395156|NCT01177410|Drug|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
395157|NCT01177397|Drug|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
395158|NCT01177384|Drug|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
395159|NCT01177384|Drug|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
395160|NCT01177384|Drug|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
395161|NCT01177384|Drug|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
395162|NCT01177371|Drug|busulfan|Given orally
395163|NCT01177371|Drug|cyclophosphamide|Given IV
395164|NCT01177371|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
395165|NCT01177371|Drug|methylprednisolone|Given IV or orally
395166|NCT01177371|Drug|methotrexate|Given IV
395167|NCT01177371|Drug|cyclosporine|Given IV or orally
395168|NCT01177358|Drug|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.~5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
395169|NCT01177358|Drug|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
395173|NCT01177293|Drug|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
395174|NCT01177293|Drug|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
395175|NCT01177228|Drug|Vedolizumab|Vedolizumab for intravenous infusion
395176|NCT01177228|Drug|Placebo|Placebo intravenous infusion
395177|NCT01177215|Procedure|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
395178|NCT01177202|Biological|HAC1 Vaccine|Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
395179|NCT01177189|Dietary Supplement|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
395180|NCT01177176|Other|Extended Care Management|Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
395181|NCT01177176|Other|Standard Care|Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
395182|NCT01177163|Drug|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
395183|NCT01177163|Drug|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
395184|NCT01177163|Drug|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
395185|NCT01177150|Drug|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
395186|NCT01177150|Drug|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
395187|NCT01177137|Device|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
395188|NCT01177137|Device|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
395189|NCT01177137|Behavioral|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
395190|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
395191|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
395192|NCT01177124|Behavioral|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
395193|NCT01177111|Other|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
395194|NCT01177111|Other|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
395195|NCT01177098|Drug|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
395356|NCT01175837|Other|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
395196|NCT01177098|Drug|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
395197|NCT01177085|Behavioral|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
395198|NCT01177072|Other|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
395199|NCT01177072|Other|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
395200|NCT01177059|Genetic|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
395201|NCT01177033|Other|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
395202|NCT01177020|Other|Biological specimen|Biological specimen taken from placenta
395203|NCT01177007|Device|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
395204|NCT01176994|Device|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
395205|NCT01176981|Drug|High Dose Methotrexate|"Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days)."
395206|NCT01176968|Drug|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
395207|NCT01176968|Drug|Placebo|Matching placebo tablets
395208|NCT01176955|Behavioral|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
395209|NCT01176955|Drug|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
395210|NCT01176942|Dietary Supplement|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
395211|NCT01176929|Other|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:~A series of three telephone calls ( the second week , one month and three months after discharge from hospital )~A systematic telephone contact with the referring physician~A telephone helpline for people who made a suicide attempt and referring physicians."
395212|NCT01176929|Other|Usual Treatment|Usual Treatment
395213|NCT01176916|Drug|Aromasin (exemestane)|the dosage, frequency and duration base on the LPD approved by SFDA.
395214|NCT01176903|Drug|Glycopyrrolate|pressurized metered dose inhaler
395215|NCT01176903|Drug|Tiotropium|inhalation powder, hard capsule
395216|NCT01176903|Drug|placebo|pressurized metered dose inhaler
395217|NCT01176890|Drug|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
395218|NCT01176890|Other|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied"
395219|NCT01176877|Behavioral|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
395220|NCT01176864|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy
395221|NCT01176864|Procedure|Single-balloon enteroscopy|Single-balloon enteroscopy
395222|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
395223|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
395224|NCT01176851|Drug|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
395225|NCT01176825|Behavioral|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
395226|NCT01176799|Drug|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
395227|NCT01176799|Drug|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
395357|NCT01175837|Other|laboratory biomarker analysis|Correlative studies
395228|NCT01176786|Other|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
395229|NCT01176773|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
395230|NCT01176760|Drug|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
395231|NCT01176760|Other|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
395232|NCT01176747|Drug|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
395233|NCT01176734|Device|tVNS-Device|Active treatment with the t-VNS device.
395234|NCT01176721|Device|t-VNS verum|Active stimulation of the left auricle by t-VNS
395235|NCT01176721|Device|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
395236|NCT01176708|Drug|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
395237|NCT01176708|Other|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
395238|NCT01176708|Other|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
395239|NCT01176695|Drug|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
395240|NCT01176695|Drug|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
395241|NCT01176669|Drug|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
395242|NCT01176643|Other|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
395243|NCT01176617|Device|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
395244|NCT01176604|Radiation|Yttrium Y 90 Glass Microspheres|Given via catheter
395245|NCT01176591|Drug|Aprepitant|80 mg per session, oral administration.
395246|NCT01176591|Drug|Placebo|Placebo, one per session, oral administration
395247|NCT01176578|Other|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
395248|NCT01176565|Drug|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.~Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
395249|NCT01176552|Drug|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
395250|NCT01176539|Device|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
395251|NCT01176513|Drug|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
395252|NCT01176500|Drug|(18)Fluciclatide|
395253|NCT01176487|Other|questionnaire administration|
395254|NCT01176487|Procedure|quality-of-life assessment|
395255|NCT01176487|Radiation|3-dimensional conformal radiation therapy|
395256|NCT01176487|Radiation|palliative radiation therapy|
395257|NCT01176487|Radiation|whole-brain radiation therapy|
395258|NCT01176474|Biological|NY-ESO-1 157-165 (165V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment."
395259|NCT01176474|Drug|Nivolumab|"Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).~Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.~Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
395260|NCT01176474|Biological|gp100:280-288 (288V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.~Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.~Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity."
395358|NCT01175824|Drug|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
395261|NCT01176474|Drug|Montanide ISA 51 vegetable grade (VG)|"Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.~Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion."
395262|NCT01176474|Drug|Ipilimumab|"Ipilimumab will be given at the following dosage: 3 mg/kg.~Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
395263|NCT01176474|Procedure|Apheresis Procedure|"Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug."
395264|NCT01176461|Biological|MART-1|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
395265|NCT01176461|Biological|NY-ESO-1|NY-ESO-1 peptide vaccine
395266|NCT01176461|Biological|gp100:209-217(210M)|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
395267|NCT01176461|Biological|gp100:280-288(288V)|gp100:280-288(288V) peptide vaccine
395268|NCT01176461|Drug|Montanide ISA 51 VG|Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
395269|NCT01176461|Biological|BMS-936558|BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen [HLA] unrestricted)
395270|NCT01176448|Device|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
395271|NCT01176448|Device|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
395272|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
395273|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
395274|NCT01176435|Drug|Placebo|Solution taken orally three times a day.
395275|NCT01176422|Genetic|Blood sample|Blood samples will be collected before and after treatment completion.
395276|NCT01176409|Drug|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
395277|NCT01176409|Drug|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
395278|NCT01176396|Other|Caries prevention active intervention|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.~High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
395279|NCT01176396|Other|control treatment|"Subjects will be treated related to their caries risk:~Low Caries Risk~The intervention and control treatments for low caries risk are the same:~4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months~Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).~High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
395280|NCT01176383|Genetic|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
395281|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation of a heart assist device that provide counterpulsation without blood contact for an extended period.
395282|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
395283|NCT01176344|Drug|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
395284|NCT01176344|Drug|Placebo|Inert placebo capsules once monthly for 2 years.
395285|NCT01176331|Procedure|20 and 23 gauge pars plana vitrectomy|
395286|NCT01176318|Drug|Erdosteine|capsule 300mg twice daily for 10 days
395287|NCT01176318|Drug|Placebo|placebo capsule, twice daily for 10 days
395288|NCT01176292|Device|Rotating Platform High-Flex Cruciate Substituting TKA|
395289|NCT01176292|Device|Rotating Platform Cruciate Substituting TKA|
395290|NCT01176279|Procedure|Manual and automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.~In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.~Additional line washing is made through the fast flow valve of the system BD DTXPlus ™."
395359|NCT01175824|Drug|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
395291|NCT01176279|Procedure|Automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.~With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.~With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.~Line washing will be made through the fast flow valve of the system BD DTXPlus ™."
395292|NCT01176266|Drug|asfotase alfa|
395293|NCT01176253|Procedure|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
395294|NCT01176240|Drug|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
395295|NCT01176240|Other|Placebo|Placebo
395296|NCT01176227|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:~Lactobacillus gasseri KS-13 1.2~Bifidobacterium bifidum G9-1 0.15~Bifidobacterium longum MM-2 0.15~Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
395297|NCT01176227|Dietary Supplement|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
395298|NCT01176214|Procedure|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
395299|NCT01176214|Procedure|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
395300|NCT01176201|Drug|SLV337 suspension|400 mg experimental
395301|NCT01176201|Drug|SLV337 capsule|5 x 200 mg immediate release capsule
395302|NCT01176188|Other|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
395303|NCT01176188|Other|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
395304|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
395305|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
395306|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
395307|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
395308|NCT01176149|Behavioral|SMBG plus intensive education|
395309|NCT01176136|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
395310|NCT01176123|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia
395311|NCT01176110|Device|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
395312|NCT01176097|Drug|AZD5658|oral suspension, escalating single doses
395313|NCT01176097|Drug|Placebo|oral suspension,single doses
395314|NCT01176084|Behavioral|low carbohydrate diet|
395315|NCT01176084|Behavioral|low carbohydrate diet and exercise|
395316|NCT01176058|Drug|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
395317|NCT01176032|Drug|Aliskiren|Aliskiren 300 mg film coated tablets
395318|NCT01176032|Drug|Losartan|Losartan 100 mg tablets
395319|NCT01176032|Drug|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
395320|NCT01176032|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (<140/90 mmHg) had not been reached.
395360|NCT01175824|Drug|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
395321|NCT01176019|Device|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
395322|NCT01176006|Procedure|Reduced-intensity hematopoietic stem cell|Stem cell transplant
395323|NCT01176006|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
395324|NCT01176006|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
395325|NCT01176006|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
395326|NCT01176006|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
395327|NCT01176006|Procedure|Donor peripheral blood stem cell mobiliation and collection|Donors undergo peripheral blood stem cell (PBSC) collection by apheresis will have their CD34 cells mobilized into the blood with filgrastim (Neupogen, Amgen)
395328|NCT01176006|Procedure|Bone Marrow Harvest Procedure|Bone marrow from haploidentical related donors, and, in some cases, matched related donors will be harvested under routine conditions in the operating room. General or spinal anesthesia will be employed.
395329|NCT01175993|Other|Exercise|Elliptical training focused on speed
395330|NCT01175993|Other|Mood Therapy|Bright light therapy
395331|NCT01175980|Other|Laboratory Biomarker Analysis|Correlative studies
395332|NCT01175980|Drug|Vorinostat|Given PO
395333|NCT01175967|Other|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
395334|NCT01175967|Other|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
395335|NCT01175967|Other|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
395336|NCT01175967|Other|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
395337|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
395338|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
395339|NCT01175941|Drug|NRL001|10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
395340|NCT01175941|Drug|Placebo control|Matched placebo - administered as a 2 g suppository, once daily for 7 days
395341|NCT01175928|Device|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
395342|NCT01175928|Device|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
395343|NCT01175915|Other|Western therapy|"Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;~Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;~No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.~Intervention time: 3-7 days; Follow-up time: 3 days."
395344|NCT01175915|Other|Reduning Injection|"Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;~Reduning Injection, 0.5~15ml, depending on patient's condition, IV per day, or according to the instruction;~Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.~Intervention time: 3-7 days; Follow-up time: 3 days."
395345|NCT01175915|Other|Reduning Injection plus western therapy|"General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;~Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;~Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.~Intervention time: 3-7 days; Follow-up time: 3 days."
395346|NCT01175902|Drug|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
395347|NCT01175902|Drug|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
395348|NCT01175889|Device|E-Z Clean ACE Blade|The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
395349|NCT01175876|Device|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
395350|NCT01175876|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
395351|NCT01175863|Device|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
395352|NCT01175863|Device|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
395353|NCT01175850|Device|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
395354|NCT01175850|Device|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
395355|NCT01175837|Other|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
395440|NCT01175356|Drug|isotretinoin|Given PO
395361|NCT01175811|Drug|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
395362|NCT01175811|Drug|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
395363|NCT01175811|Drug|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
395364|NCT01175798|Drug|Cholecalciferol|50,000 IU PO weekly x 6 weeks
395365|NCT01175785|Procedure|umbilical cord blood transplantation|Undergo unmanipulated umbilical cord blood transplant
395366|NCT01175785|Drug|fludarabine phosphate|Given IV
395367|NCT01175785|Drug|cyclophosphamide|Given IV
395368|NCT01175785|Biological|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
395369|NCT01175785|Radiation|total-body irradiation|Undergo TBI
395370|NCT01175785|Drug|cyclosporine|Given IV
395371|NCT01175785|Drug|mycophenolate mofetil|Given IV and PO
395372|NCT01175785|Other|laboratory biomarker analysis|Correlative studies
395373|NCT01175772|Drug|Cytophosphan, Celecoxib, Methotrexate|"Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~Cytophosphan tab 50 mg -1x1 per day, continuous~Celecoxib tab 200 mg - 1x2 per day, continuous~Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly"
395374|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
395375|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
395376|NCT01175746|Drug|Nicardipine|
395377|NCT01175746|Drug|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
395378|NCT01175733|Drug|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
395379|NCT01175720|Procedure|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
395380|NCT01175707|Drug|Daptomycin|
395381|NCT01175707|Drug|Vancomycin|
395382|NCT01175694|Radiation|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
395383|NCT01175681|Procedure|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
395384|NCT01175668|Drug|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores <8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
395385|NCT01175668|Drug|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.~NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
395386|NCT01175655|Other|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
395387|NCT01175642|Behavioral|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
395388|NCT01175642|Behavioral|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
395389|NCT01175616|Drug|Creatine|Oral Creatine 5 grams daily.
395390|NCT01175603|Behavioral|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
395391|NCT01175590|Drug|Besivance|Ocular administration to affected eye for 7 days
395392|NCT01175590|Drug|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
395393|NCT01175577|Dietary Supplement|Chlorophyll complex, Standard Process|One capsule, twice daily with meals for 28 days
395394|NCT01175577|Dietary Supplement|"Betatene, sold as Full Spectrum Carotenoid Complex"|One capsule per day with meals for 28 days
395395|NCT01175577|Other|Small carotenoid-rich meals|Single carotenoid-enriched soup or salad serving eaten daily
395396|NCT01175577|Other|Placebo|Safflower oil-filled capsules, one twice daily with meals
395397|NCT01175564|Drug|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
395398|NCT01175564|Drug|Placebo|Placebo tablet, single dose and 6 days repeated dose
395399|NCT01175538|Drug|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
395400|NCT01175538|Drug|Lactulose|lactulose will be used in 30-60ml/day
395401|NCT01175525|Drug|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
395402|NCT01175525|Drug|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
395403|NCT01175512|Drug|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
395404|NCT01175499|Device|Direct Rigid Endoscopy|Laryngoscopy is performed under general anesthesia with a rigid laryngoscope. Mucosal surfaces of the oropharynx, hypopharynx, and glottis (base of tongue, vallecula, epiglottis, aryepiglottic folds, arytenoids, piriform sinuses, true and false vocal cords, and esophageal inlet) are systematically visualized. Areas of irregularity are biopsied with 2mm and/or 4mm cupped forceps. Esophagoscopy and bronchoscopy will be performed per the standard of care.
395405|NCT01175499|Device|Transnasal Flexible Endoscopy with Narrowband Imaging|Transnasal flexible endoscopy with and without narrowband imaging- additional diagnostic test. This examination is performed after topical intranasal anesthesia with 2% Pontocaine spray. A fiberoptic laryngoscope is passed into the nasal cavity to the pharynx where mucosal surfaces of the UADT can be visualized. The optics of a standard fiberoptic scope are generally considered to be inferior to direct visualization. The addition of narrowband imaging does not change the procedure, but enhances visualization of the mucosal vasculature. Biopsies are performed through a second channel in the endoscope with 1.8mm cupped forceps and will require an additional dose of topical anesthesia.
395406|NCT01175486|Drug|Actos (Pioglitazone)|Actos 30 mg for 6 months
395407|NCT01175486|Drug|Acarbose|Acarbose 50 mg tid for 6 months
395408|NCT01175473|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
395409|NCT01175473|Device|Pen auto-injector|
395410|NCT01175473|Drug|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
395411|NCT01175473|Device|Pre-filled pen injector|
395412|NCT01175473|Drug|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
395413|NCT01175460|Drug|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
395414|NCT01175447|Drug|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
395415|NCT01175434|Other|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
395416|NCT01175408|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
395417|NCT01175408|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
395418|NCT01175408|Other|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
395419|NCT01175408|Other|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
395420|NCT01175395|Drug|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
395421|NCT01175382|Behavioral|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
395422|NCT01175382|Drug|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
395423|NCT01175382|Other|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
395424|NCT01175369|Behavioral|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
395425|NCT01175356|Drug|cyclophosphamide|Given IV
395426|NCT01175356|Drug|topotecan hydrochloride|Given IV
395427|NCT01175356|Drug|cisplatin|Given IV
395428|NCT01175356|Drug|etoposide phosphate|Given IV
395429|NCT01175356|Drug|vincristine sulfate|Given IV
395430|NCT01175356|Drug|doxorubicin hydrochloride|Given IV
395431|NCT01175356|Radiation|iobenguane I 131|Given IV
395432|NCT01175356|Procedure|therapeutic conventional surgery|Undergo surgery
395433|NCT01175356|Drug|busulfan|Given IV
395434|NCT01175356|Drug|melphalan|Given IV
395435|NCT01175356|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
395436|NCT01175356|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
395437|NCT01175356|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
395438|NCT01175356|Radiation|external beam radiation therapy|Undergo radiotherapy
395439|NCT01175356|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
395443|NCT01175356|Other|laboratory biomarker analysis|Correlative studies
395444|NCT01175343|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
395445|NCT01175343|Other|Laboratory Biomarker Analysis|Correlative studies
395446|NCT01175330|Drug|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
395447|NCT01175330|Drug|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
395448|NCT01175317|Procedure|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
395449|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
395450|NCT01175291|Drug|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + MK-0646 (Investigational).
395451|NCT01175291|Drug|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
395452|NCT01175278|Procedure|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
395453|NCT01175278|Other|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
395454|NCT01175265|Other|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
395455|NCT01175252|Other|Database analysis|Review and collect data from database
395456|NCT01175239|Genetic|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
395457|NCT01175226|Drug|BTA798|BTA798 twice daily
395458|NCT01175226|Drug|Placebo|Placebo twice daily
395459|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the SC route. Treatment occurred once every week. The dose was the weekly equivalent of the most recent IV dose (adjusted per body weight) and multiplied by 1.37."
395460|NCT01175213|Biological|SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)|"Participants are to continue on the same doses and treatment intervals of IGSC, 10% adjusted for body weight, and rHuPH20 that were used for the last infusions in Study epoch 2 of Study 160603 (NCT00814320).~After 3 infusions, participants are to change treatment to a 2-week interval, if agreed with participant and investigator.~During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route. Treatment occurred once every 3-4 weeks. The weekly dose equivalent was 100% of the most recent IV dose."
395461|NCT01175213|Biological|IV treatment with IGSC, 10%|During this safety follow-up period, participants are treated with IGSC, 10% via the intravenous (IV) route.
395462|NCT01175200|Drug|Clopidogrel|antiplatelet agent
395463|NCT01175200|Drug|Prasugrel|antiplatelet agent
395464|NCT01175200|Drug|Lansoprazole|proton pum inhibitor
395465|NCT01175200|Drug|Placebo|placebo comparator similar to lansoprazole
395466|NCT01175161|Device|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
395467|NCT01175148|Drug|Atorvastatin calcium (Lipitor)|40 mg PO daily
395468|NCT01175135|Drug|PF-02545920|5 mg tablet every 12 hours for 28 days
395469|NCT01175135|Drug|PF-02545920|15 mg tablet every 12 hours for 28 days
395470|NCT01175135|Drug|Placebo|One tablet/capsule every 12 hours for 28 days
395471|NCT01175135|Drug|Risperidone|3 mg capsule every 12 hours for 28 days
395472|NCT01175122|Biological|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
395473|NCT01175109|Drug|Imatinib + LBH589|Escalating doses of imatinib and LBH589 will be administered.
395474|NCT01175096|Drug|RAD001 (everolimus, Afinitor®)|"RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.~2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days."
395475|NCT01175083|Biological|GSK1024850A (Synflorix)|2, 3 or 4 intramuscular injection
395476|NCT01175083|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
395477|NCT01175083|Biological|Polio Sabin|4 oral doses
395478|NCT01175070|Drug|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen [TM]) 0.3mg every 6 weeks over a 30 week period.
395519|NCT01174693|Drug|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
395479|NCT01175044|Procedure|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
395480|NCT01175044|Procedure|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
395481|NCT01175031|Other|Manipulation of Positive Airway Pressure (PAP)|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
395482|NCT01175018|Drug|Anakinra|Anakinra 100 mg s.c. daily for 14 days
395483|NCT01175018|Drug|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
395484|NCT01174992|Biological|Evicel|EVICEL is a human plasma derived fibrin sealant
395485|NCT01174992|Other|Sutures only|Standard of care
395486|NCT01174979|Drug|Caroverin|treatment with eardrops 2 times for 48 hours
395487|NCT01174953|Drug|finasteride|"Finasteride 5 mg once daily~Soy 4 capsules twice daily (160 mg total)"
395488|NCT01174940|Drug|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
395489|NCT01174927|Drug|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
395490|NCT01174927|Other|Placebo|Saline
395491|NCT01174914|Other|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
395492|NCT01174914|Drug|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
395493|NCT01174914|Drug|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
395494|NCT01174888|Drug|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
395495|NCT01174888|Drug|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
395496|NCT01174888|Drug|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
395497|NCT01174888|Drug|etoposide|Patients receive etoposide IV over 1 hour
395498|NCT01174888|Drug|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
395499|NCT01174849|Drug|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
395500|NCT01174849|Drug|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
395501|NCT01174849|Drug|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
395502|NCT01174836|Other|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
395503|NCT01174823|Drug|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
395504|NCT01174823|Drug|placebo comparator ophthalmic solution|sterile ophthalmic solution
395505|NCT01174810|Drug|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
395506|NCT01174784|Device|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
395507|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
395508|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
395509|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
395510|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
395511|NCT01174732|Drug|Placebo|placebo, lactose inhalation carrier
395512|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
395513|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
395514|NCT01174719|Drug|volume replacement|Hydroxyethylstarch up to 50mL/kg/24 hrs
395515|NCT01174719|Drug|Humanalbumin 5%|Humanalbumin 5% up to 50 mL/kg/24 hours
395516|NCT01174719|Drug|volume replacement|up 10 50mL/kg/24 hours
395517|NCT01174706|Behavioral|Information prescriptions|One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
395518|NCT01174693|Drug|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
395520|NCT01174680|Procedure|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
395521|NCT01174667|Procedure|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
395522|NCT01174667|Other|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
395523|NCT01174654|Behavioral|Contingency management|A 12-week contingency management intervention
395524|NCT01174641|Other|trans-cranial magnetic stimulation|1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
395525|NCT01174641|Other|trans-cranial magnetic stimulation|trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
395526|NCT01174602|Behavioral|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
395527|NCT01174602|Behavioral|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
395528|NCT01174589|Other|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
395529|NCT01174576|Other|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
395530|NCT01174563|Drug|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
395531|NCT01174550|Procedure|Coronary Angiography|Use of standard equipment for usual-care testing
395532|NCT01174550|Procedure|Stress Echocardiogram|Use of standard equipment for usual-care testing
395533|NCT01174550|Procedure|Nuclear Stress Test|Use of standard equipment for usual-care testing
395534|NCT01174550|Procedure|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
395535|NCT01174537|Biological|New Castle Disease Virus|Patients will receive IV 1*10^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
395536|NCT01174524|Drug|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
395537|NCT01174524|Drug|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
395538|NCT01174511|Drug|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
395539|NCT01174498|Device|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
395540|NCT01174498|Device|t-VNS Sham stimulation|t-VNS Sham stimulation
395541|NCT01174485|Procedure|exercise|combined resistance and aerobic training
395542|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
395543|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
395544|NCT01174446|Biological|BAX 326|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX~Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only~Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
395545|NCT01174446|Biological|BeneFIX|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.~BeneFIX only used in Part 1 of this study.~Study Part 2 and 3 only utilized BAX326"
395546|NCT01174433|Device|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
395547|NCT01174420|Device|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
395548|NCT01174420|Drug|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
395549|NCT01174407|Other|cd 35, cd21, cd55|Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
395550|NCT01174394|Procedure|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
395551|NCT01174394|Procedure|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
395552|NCT01174394|Procedure|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
395553|NCT01174394|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
395554|NCT01174381|Behavioral|lifestyle modification|Lifestyle modification for six months
395555|NCT01174368|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
395556|NCT01174355|Drug|ND0801|Confidential
395557|NCT01174329|Device|"Automatic neuro-electrostimulation by Saliwell Crown"|"Continuous stimulation of the lingual nerve by Saliwell Crown"
395558|NCT01174329|Device|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"On-demand stimulation of the lingual nerveby Saliwell Crown"
395594|NCT01174082|Procedure|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
395559|NCT01174316|Device|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
395560|NCT01174316|Device|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
395561|NCT01174303|Drug|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
395562|NCT01174303|Drug|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
395563|NCT01174290|Drug|Haloperidol decanoate|"IV q6h.~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~The patient is discharged from the ICU at Tufts MC.~10 days of study drug administration occurs.~The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
395564|NCT01174290|Drug|Placebo|"D5W 0.2mL IV q6h~Study drug will be continued until one of the following study withdrawal/termination criteria is met:~Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.~The patient is discharged from the ICU at Tufts MC.~10 days of study drug administration occurs.~The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
395565|NCT01174277|Other|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
395566|NCT01174264|Other|Pharmacological Study|Correlative studies
395567|NCT01174264|Drug|Vismodegib|Given PO
395568|NCT01174238|Drug|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
395569|NCT01174238|Drug|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
395570|NCT01174238|Drug|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
395571|NCT01174225|Device|Flexi T 380(+) IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
395572|NCT01174225|Device|Nova T IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
395573|NCT01174212|Procedure|Prophylactic Antibiotics|Preoperative Antibiotics
395574|NCT01174212|Procedure|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
395575|NCT01174199|Drug|vorinostat|Given orally
395576|NCT01174199|Drug|temsirolimus|Given IV
395577|NCT01174199|Other|laboratory biomarker analysis|Correlative study
395578|NCT01174199|Procedure|positron emission tomography/computed tomography|PET scan
395579|NCT01174186|Drug|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
395580|NCT01174173|Drug|Ranolazine|ranolazine 1000 mg PO BID for 3 months
395581|NCT01174160|Drug|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
395582|NCT01174160|Drug|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
395583|NCT01174134|Other|Nutritional beverage|
395584|NCT01174121|Biological|Young TIL|Day 0, cells will be infused intravenously 9IV) on the Patient Care Unit over 20 - 30 minutes (one to four days after the last dose of fludarabine).
395585|NCT01174121|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum of 12 doses.)
395586|NCT01174121|Drug|Cyclophosphamide|Days -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W Mesna 15mg/kg/day x2 days over 1 hr.
395587|NCT01174121|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days.
395588|NCT01174121|Drug|Pembrolizumab (Keytruda)|"Arm 3: Pembrolizumab 2mg /kg IV over approximately 30 minutes on Days -2, 21, 42, and 63~Arm 4:~Pembrolizumab 2mg /kg IV over approximately 30 minutes (for patients who meet progressive disease per RECIST criteria and have resolved major toxicities after cell infusion or anytime during the post-treatment evaluation period; starting within 4 weeks of progression; may receive up to 8 doses every 3 weeks)."
395589|NCT01174108|Device|Miltenyi CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.
395590|NCT01174108|Other|Donor derived G-CSF mobilized PBC|Cell Therapy
395591|NCT01174082|Biological|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
395592|NCT01174082|Biological|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
395593|NCT01174082|Drug|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
396074|NCT01170494|Drug|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
395595|NCT01174082|Procedure|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
395596|NCT01174069|Procedure|NOTES assisted laparoscopic cholecystectomy|Surgical removal of the gallbladder using endoscopic instruments.
395597|NCT01174056|Drug|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
395598|NCT01174056|Drug|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
395599|NCT01174056|Drug|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
395600|NCT01174056|Drug|Pioglitazone|PPAR-gamma agonist
395601|NCT01174043|Drug|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
395602|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
395603|NCT01174030|Drug|Vehicle Gel|Vehicle Gel QD
395604|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
395605|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
395606|NCT01174030|Drug|Vehicle Gel|Vehicle Gel BID
395607|NCT01174017|Radiation|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
395608|NCT01174017|Radiation|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
395609|NCT01174004|Drug|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
395610|NCT01174004|Drug|placebo|placebo, tablet, once daily by mouth for 6 weeks
395611|NCT01173991|Behavioral|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
395612|NCT01173978|Behavioral|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
395613|NCT01173978|Other|No intervention|
395614|NCT01173965|Device|MEA|Microwave endometrial ablation device
395615|NCT01173965|Device|Novasure|Bipolar impedence control system
395616|NCT01173939|Drug|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of <120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
395617|NCT01173939|Drug|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of <70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
395618|NCT01173926|Drug|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
395619|NCT01173926|Drug|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
395620|NCT01173926|Drug|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
395621|NCT01173913|Drug|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
395622|NCT01173913|Drug|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
395623|NCT01173913|Drug|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
395624|NCT01173900|Biological|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
395625|NCT01173887|Drug|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
395626|NCT01173887|Biological|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
395627|NCT01173874|Drug|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
395628|NCT01173861|Behavioral|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
395629|NCT01173848|Drug|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
395630|NCT01173848|Drug|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
395631|NCT01173835|Behavioral|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
395681|NCT01173393|Procedure|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:~LMA/ Intubation and ventilation with 100% oxygen~Measure temperature using tympanic probe and record~Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR~If temperature >34.5ºC, infuse further 10mL/kg stat~After ROSC, infuse further (max 2 litres) ice-cold saline~If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
395682|NCT01173380|Other|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
395632|NCT01173822|Other|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
395633|NCT01173809|Drug|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
395634|NCT01173809|Drug|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
395635|NCT01173796|Procedure|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
395636|NCT01173796|Procedure|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
395637|NCT01173770|Drug|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
395638|NCT01173770|Drug|ADC3680B|ADC3680B or Placebo for 7 days
395639|NCT01173770|Drug|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
395640|NCT01173757|Drug|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
395641|NCT01173744|Device|Gamma-3 Nail|Gamma-3 Nail (stryker)
395642|NCT01173744|Device|DHS|DHS (Zimmer)
395643|NCT01173731|Drug|AFQ056|
395644|NCT01173718|Device|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
395645|NCT01173692|Drug|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
395646|NCT01173692|Drug|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
395647|NCT01173679|Drug|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
395648|NCT01173679|Drug|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
395649|NCT01173679|Drug|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
395650|NCT01173666|Procedure|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
395651|NCT01173666|Drug|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
395652|NCT01173653|Other|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
395653|NCT01173653|Other|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
395654|NCT01173640|Drug|Midazolam|2 mg oral dose
395655|NCT01173640|Dietary Supplement|resveratrol (single dose)|1 g oral dose
395656|NCT01173640|Dietary Supplement|resveratrol (multiple dose)|1 g oral dose for 8 days
395657|NCT01173627|Drug|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
395658|NCT01173627|Drug|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
395659|NCT01173601|Drug|LY2216684|
395660|NCT01173601|Drug|Placebo|
395661|NCT01173601|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
395662|NCT01173588|Other|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
395663|NCT01173562|Drug|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
395664|NCT01173549|Drug|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
395665|NCT01173549|Other|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
395666|NCT01173536|Drug|GDC-0449|Oral repeating dose
395667|NCT01173536|Drug|moxifloxacin|Oral single dose
395668|NCT01173536|Drug|placebo|Oral repeating dose
395669|NCT01173523|Drug|STA-9090|
395670|NCT01173510|Drug|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
395671|NCT01173510|Drug|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
395672|NCT01173497|Drug|INIPARIB + irinotecan|21 day cycle
395673|NCT01173471|Drug|AZD4017|tablet, oral, one tablet once daily, 28 days
395674|NCT01173471|Drug|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
395675|NCT01173471|Drug|AZD4017|tablet, oral 2 tablets twice daily, 28 days
395676|NCT01173471|Drug|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
395677|NCT01173432|Device|continuous positive airway pressure|an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
395678|NCT01173419|Device|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
395679|NCT01173419|Device|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
395680|NCT01173406|Behavioral|CPAP education|Standard CPAP education plus an session and one telephone follow up
395683|NCT01173380|Other|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
395684|NCT01173367|Other|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
395685|NCT01173367|Other|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
395686|NCT01173354|Dietary Supplement|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
395687|NCT01173354|Dietary Supplement|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
395688|NCT01173341|Diagnostic Test|Echocardiography|Prior to chemotherapy, prior to and after anthracyclines, every 6 weeks during trastuzumab, and yearly for up to 10 years.
395689|NCT01173341|Other|Blood Collection|Drawn at first chemo treatment and periodically during treatment (exact schedule varies with clinically ordered treatment plan), then annually for up to 10 years. Blood is banked for future biomarker testing.
395690|NCT01173341|Other|Symptoms Questionnaire|Survey collected at first chemotherapy, periodically during therapy (exact schedule determined by clinically ordered treatment regimen), and annually for up to 10 years.
395691|NCT01173328|Behavioral|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
395692|NCT01173328|Behavioral|Normal Breathing|
395693|NCT01173315|Dietary Supplement|vitamin and mineral supplementation|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
395694|NCT01173302|Biological|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
395695|NCT01173289|Radiation|External Beam Radiotherapy|"Definition of target volume:~Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan~Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)~Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.~Radiation dose and planning~Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks~Dose prescription: 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
395696|NCT01173276|Other|Sperm Washing with Intrauterine Insemination (IUI)|For semen samples, seminal fluid will be separated from sperm using a density gradient/swim-up separation technique. The purified sperm sample will be washed, and screened for HIV RNA using sensitive real-time RT-PCR. Samples with detectable traces of HIV RNA will not be used for insemination. Samples with no detectable traces of HIV RNA will be used for a standard intrauterine insemination of the female partner.
395697|NCT01173263|Other|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
395698|NCT01173263|Other|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
395699|NCT01173263|Other|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
395700|NCT01173250|Procedure|adding diverting ileostomy|
395701|NCT01173250|Procedure|omitting diverting ileostomy|
395702|NCT01173237|Procedure|Use tracheal intubation for surfactant therapy|Surfactant endotracheal administration after tracheal intubation
395703|NCT01173237|Procedure|Use of Proseal laryngeal mask airway for surfactant therapy|Surfactant use by proseal laryngeal mask airway
395704|NCT01173224|Drug|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
395705|NCT01173224|Drug|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
395706|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
395707|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
395708|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
395709|NCT01173198|Device|WAVEFRONT Optimized LASIK|30 patients
395710|NCT01173198|Device|WAVEFRONT GUIDED LASIK|30 patients
395895|NCT01171950|Device|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
395711|NCT01173172|Radiation|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
395712|NCT01173159|Drug|Omegaven|For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
395713|NCT01173120|Device|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
395714|NCT01173107|Drug|colchicine|colchicine 1T tid
395715|NCT01173094|Device|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
395716|NCT01173094|Device|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
395717|NCT01173081|Drug|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
395718|NCT01173081|Drug|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
395719|NCT01173068|Drug|Ertapenem|Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
395720|NCT01173055|Drug|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
395721|NCT01173055|Drug|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
395722|NCT01173042|Dietary Supplement|Peanuts|Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
395723|NCT01173042|Dietary Supplement|Glucose and whipping cream|An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
395724|NCT01173042|Dietary Supplement|Oil Blend|Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
395725|NCT01173029|Drug|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
395726|NCT01173016|Drug|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
395727|NCT01173003|Drug|Mifepristone, misoprostol|
395728|NCT01172990|Procedure|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
395729|NCT01172990|Procedure|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
395730|NCT01172964|Drug|flucytosine|Given orally
395731|NCT01172964|Other|polymerase chain reaction|Correlative studies
395732|NCT01172964|Other|immunohistochemistry staining method|Correlative studies
395733|NCT01172964|Biological|gene therapy|Injected at the time of the surgery to resect the tumor
395734|NCT01172964|Other|pharmacological study|Correlative studies
395735|NCT01172964|Other|3-Tesla magnetic resonance imaging|Correlative studies
395736|NCT01172964|Other|laboratory biomarker analysis|Correlative studies
395737|NCT01172964|Procedure|therapeutic conventional surgery|Surgery to resect the tumor
395738|NCT01172964|Biological|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
395739|NCT01172951|Other|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
395740|NCT01172951|Other|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
395741|NCT01172938|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
395742|NCT01172938|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
395743|NCT01172938|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
395744|NCT01172938|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
395745|NCT01172925|Drug|Tiotropium|Inhaler
395746|NCT01172925|Drug|Placebo|Inhaler
395747|NCT01172912|Biological|filgrastim|
395748|NCT01172912|Biological|pegfilgrastim|
395749|NCT01172912|Drug|carboplatin|
395750|NCT01172912|Drug|cisplatin|
395751|NCT01172912|Drug|dexamethasone|
395752|NCT01172912|Drug|etoposide|
395753|NCT01172912|Drug|ifosfamide|
395754|NCT01172912|Other|high-dose chemotherapy with autologous stem cell rescue|
395755|NCT01172912|Other|laboratory biomarker analysis|
395756|NCT01172912|Procedure|autologous hematopoietic stem cell transplantation|
395757|NCT01172912|Procedure|peripheral blood stem cell transplantation|
395758|NCT01172899|Procedure|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
395759|NCT01172899|Behavioral|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
395760|NCT01172873|Drug|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
395896|NCT01171937|Drug|Risperidone|children get randomized to either placebo or active risperidone
395761|NCT01172873|Behavioral|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
395762|NCT01172860|Device|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
395763|NCT01172847|Drug|oseltamivir [Tamiflu]|multiple oral doses
395764|NCT01172847|Drug|rimantadine|multiple oral doses
395765|NCT01172834|Behavioral|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
395766|NCT01172821|Drug|placebo|Placebo that represents BI drug
395767|NCT01172821|Drug|placebo|Placebo that represents comparator
395768|NCT01172821|Drug|placebo|Placebo that represents comparator
395769|NCT01172821|Drug|tiotropium Respimat® low dose|IMP
395770|NCT01172821|Drug|placebo|Placebo that represents BI drug
395771|NCT01172821|Drug|tiotropium Respimat® high dose|IMP
395772|NCT01172821|Drug|50 mcg salmeterol HFA MDI|Active comparator
395773|NCT01172821|Drug|placebo|Placebo that represents comparator
395774|NCT01172808|Drug|Placebo|Placebo that represents comparator
395775|NCT01172808|Drug|tiotropium Respimat® low dose|IMP
395776|NCT01172808|Drug|Placebo|Placebo that represents comparator
395777|NCT01172808|Drug|Placebo|Placebo that represents comparator
395778|NCT01172808|Drug|tiotropium Respimat® high dose|IMP
395779|NCT01172808|Drug|50 mcg salmeterol HFA MDI|Active comparator
395780|NCT01172808|Drug|Placebo|Placebo that represents BI drug
395781|NCT01172808|Drug|Placebo|Placebo that represents BI drug
395782|NCT01172795|Behavioral|Relaxation session|30 minutes relaxation session (audiotape)
395783|NCT01172795|Behavioral|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
395784|NCT01172782|Drug|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
395785|NCT01172769|Biological|Temsirolimus|"After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.~Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered."
395786|NCT01172756|Drug|Riociguat (BAY63-2521)|0.5 mg single oral dose
395787|NCT01172756|Drug|Riociguat (BAY63-2521)|1 mg single oral dose
395788|NCT01172756|Drug|Riociguat (BAY63-2521)|2 mg single oral dose
395789|NCT01172756|Drug|Placebo|single oral dose
395790|NCT01172730|Device|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
395791|NCT01172717|Drug|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
395792|NCT01172704|Behavioral|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
395793|NCT01172691|Procedure|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
395794|NCT01172652|Drug|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
395795|NCT01172652|Drug|Placebo|Inactive control
395796|NCT01172639|Drug|Methotrexate|Methotrexate tablet
395797|NCT01172639|Drug|Sulfasalazine|Sulfasalazine tablet
395798|NCT01172639|Drug|Leflunomide|Leflunomide tablet
395799|NCT01172639|Drug|Prednisone|Prednisone tablet
395800|NCT01172626|Drug|valproate sodium|oral administration,15－30mg/kg,daily
395801|NCT01172626|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
395802|NCT01172626|Other|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
395803|NCT01172600|Other|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
395804|NCT01172600|Other|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
395805|NCT01172587|Other|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
395806|NCT01172574|Other|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
395807|NCT01172561|Behavioral|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
395808|NCT01172561|Behavioral|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
395809|NCT01172548|Drug|imatinib mesylate|
395810|NCT01172535|Drug|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
395811|NCT01172522|Drug|Fexofenadine|Fexofenadine 1%
395812|NCT01172522|Drug|Placebo|Placebo
395813|NCT01172509|Drug|R-baclofen|oral R-baclofen at 0x2, 3, 10, and 25 mg
395814|NCT01172496|Drug|treprostinil diethanolamine|Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
395815|NCT01172483|Procedure|general practice in primary care and education|education of chronic disorders in PC
395816|NCT01172483|Other|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
395817|NCT01172470|Drug|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
395818|NCT01172470|Drug|Pemetrexed|"Induction Chemotherapy:~4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.~Chemoradiotherapy:~Day 1,22, and 43through IV infusion over a period of 10 minutes"
395819|NCT01172470|Drug|Carboplatin|"Chemoradiotherapy:~Day 1, 22 and 4 through IV infusion over a period of 1 hour."
395820|NCT01172457|Procedure|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
395821|NCT01172457|Procedure|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
395822|NCT01172444|Drug|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
395823|NCT01172444|Drug|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
395824|NCT01172444|Drug|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
395825|NCT01172431|Drug|Indapamide|Indapamide SR 1.5mg qd
395826|NCT01172431|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
395827|NCT01172418|Drug|Alemtuzumab|Alemtuzumab used as part of combined Induction.
395828|NCT01172418|Drug|Daclizumab|Daclizumab used as part of combined induction.
395829|NCT01172418|Drug|Thymoglobulin|Thymoglobulin used as part of combined induction.
395830|NCT01172405|Drug|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
395831|NCT01172405|Drug|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
395832|NCT01172392|Drug|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
395833|NCT01172392|Drug|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
395834|NCT01172379|Drug|E2007|"Experimental 1 Drug: E2007~0.5 mg 1 tablet per day"
395835|NCT01172379|Drug|E2007|"Experimental 2 Drug: E2007~1.0 mg 1 tablet per day"
395836|NCT01172379|Drug|E2007|"Drug: E2007~2.0 mg 1 tablet per day"
395837|NCT01172379|Other|Placebo Comparator|Placebo 1 tablet per day
395838|NCT01172353|Drug|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
395839|NCT01172353|Drug|saline|hydration with saline 1ml/Kg/h for 6 hours
395840|NCT01172340|Behavioral|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
395841|NCT01172340|Behavioral|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
395842|NCT01172327|Behavioral|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
395843|NCT01172327|Behavioral|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
395844|NCT01172314|Dietary Supplement|EAA+LEU vs total AA|15 g as a bolus
395845|NCT01172314|Dietary Supplement|Total AA vs EAA+LEU|15 g as a bolus
395846|NCT01172301|Dietary Supplement|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
395847|NCT01172288|Drug|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
395848|NCT01172288|Drug|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
395849|NCT01172275|Drug|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
395897|NCT01171937|Drug|Placebo|Children get randomized to either placebo or risperidone
396162|NCT01169844|Biological|AIN457A|
395850|NCT01172275|Other|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
395851|NCT01172262|Procedure|MRI|This is an observational study, no intervention will occur.
395852|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
395853|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
395854|NCT01172236|Drug|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.~Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
395855|NCT01172236|Drug|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
395856|NCT01172223|Drug|Myocet (Non-pegylated liposomal doxorubicin (NPLD))|60 mg/m^2 i.v. day 1 q3 weeks
395857|NCT01172223|Drug|Paclitaxel|175 mg/m^2 i.v. day 1 q3 weeks
395858|NCT01172223|Drug|Lapatinib (GW572016, Tykerb)|750-1500 mg/d orally daily until the day of the definitive surgery
395859|NCT01172197|Drug|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
395860|NCT01172197|Drug|Ropivacaine|Bolus and infusion
395861|NCT01172184|Procedure|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
395862|NCT01172171|Drug|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
395863|NCT01172171|Drug|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
395864|NCT01172145|Drug|Modafinil|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
395865|NCT01172145|Drug|Placebo|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
395866|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
395867|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
395868|NCT01172119|Device|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
395869|NCT01172106|Behavioral|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
395870|NCT01172106|Behavioral|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
395871|NCT01172106|Behavioral|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
395872|NCT01172080|Other|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
395873|NCT01172067|Device|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
395874|NCT01172067|Device|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
395875|NCT01172054|Biological|VAX128|one IM injection
395876|NCT01172054|Biological|Placebo|One IM injection
395877|NCT01172041|Device|Real time position management system|Device to monitor respiration by using optical monitoring of a marker block placed on the abdomen of the patient.
395878|NCT01172041|Device|LS PET/CT|PET/CT scanner for acquiring CT and PET images (3D and 4D)
395879|NCT01172041|Drug|18-FDG|15mCi
395880|NCT01172028|Drug|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
395881|NCT01172028|Drug|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
395882|NCT01172015|Other|blood samples|
395883|NCT01172002|Drug|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
395884|NCT01172002|Drug|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.~Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
395885|NCT01171989|Biological|GSK2202083A vaccine|Intramuscular, one dose.
395886|NCT01171989|Biological|Infanrix hexa™|Intramuscular, one dose.
395887|NCT01171989|Biological|Menjugate™|Intramuscular, one dose.
395888|NCT01171989|Biological|NeisVac-C™|Intramuscular, one dose.
395889|NCT01171989|Biological|Synflorix™|Intramuscular, one dose.
395890|NCT01171976|Drug|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
395891|NCT01171963|Biological|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
395892|NCT01171963|Biological|Placebo|Oral administration
395893|NCT01171963|Biological|Infanrix™|Intramuscular administration
395894|NCT01171963|Biological|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
395898|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
395899|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
395900|NCT01171911|Drug|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
395901|NCT01171898|Drug|ARN-509 (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
395902|NCT01171898|Drug|ARN-509 (Phase 2)|ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
395903|NCT01171885|Drug|0.9% saline|20 ml of 0.9% saline
395904|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.25%.
395905|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.5%.
395906|NCT01171859|Drug|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
395907|NCT01171846|Other|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).~Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
395908|NCT01171833|Drug|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
395909|NCT01171833|Drug|Desflurane|6.0 vol% prefilled in a corrugated circuit.
395910|NCT01171833|Drug|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
395911|NCT01171820|Device|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
395912|NCT01171820|Device|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
395913|NCT01171807|Drug|Dexamethasone 21-phosphate|6 monthly infusions of dexamethasone 21-phosphate loaded into autologous erythrocytes
395914|NCT01171794|Drug|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
395915|NCT01171794|Drug|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
395916|NCT01171781|Drug|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
395917|NCT01171781|Drug|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
395918|NCT01171755|Drug|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
395919|NCT01171742|Procedure|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
395920|NCT01171729|Biological|Autologous dendritic cell|Autologous dendritic cells pulsed with prostate cancer antigen and KLH
395921|NCT01171716|Other|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
395922|NCT01171703|Device|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
395923|NCT01171703|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
395924|NCT01171690|Drug|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
395925|NCT01171677|Behavioral|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
395926|NCT01171664|Drug|Placebo|Tablet, one BID
395927|NCT01171664|Drug|STAHIST|STAHIST in tablet form dosed one BID
395928|NCT01171651|Drug|JX-594 followed by sorafenib|Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
395929|NCT01171638|Device|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
395930|NCT01171625|Device|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
395963|NCT01171326|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
396843|NCT01164566|Other|questionnaire administration|Ancillary studies
395931|NCT01171599|Behavioral|Fit4Life|As previously described, the purpose of this study is to develop a web and text message based weight loss intervention for childhood acute lymphoblastic leukemia survivors (ALL) survivor. The web and text message based intervention that is being developed will be evaluated in a separate ACS (American Cancer Society) funded trial randomized control trial. The web and text message based intervention (there are other intervention features that do not relate to the web & text based platforms that were developed as part of this NIH funded study) is a 16-week program that includes:
395932|NCT01171586|Behavioral|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
395933|NCT01171573|Procedure|Venepuncture|Venepuncture - Taking blood
395934|NCT01171560|Procedure|endotracheal intubation|The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
395935|NCT01171547|Drug|Daptomycin|once daily over 5 days
395936|NCT01171534|Device|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
395937|NCT01171534|Device|Vessel loop|Vessel loops and staples for fasciotomy closure
395938|NCT01171521|Device|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
395939|NCT01171508|Device|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
395940|NCT01171508|Device|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
395941|NCT01171508|Device|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
395942|NCT01171508|Procedure|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
395943|NCT01171508|Other|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
395944|NCT01171508|Other|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
395945|NCT01171508|Other|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
395946|NCT01171495|Dietary Supplement|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
395947|NCT01171495|Dietary Supplement|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
395948|NCT01171482|Drug|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
395949|NCT01171482|Drug|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
395950|NCT01171482|Drug|sorafenib|400 mg BID every 28 days
395951|NCT01171469|Biological|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
395952|NCT01171469|Drug|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
395953|NCT01171456|Drug|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
395954|NCT01171456|Drug|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
395955|NCT01171430|Device|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:~1 WB-DCE-MRI before induction of chemotherapy(initial MRI).~1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).~1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
395956|NCT01171391|Drug|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
395957|NCT01171391|Other|Placebo|Placebo on Day 1
395958|NCT01171378|Drug|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.~Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
395959|NCT01171365|Drug|Ciclesonide|Inhaled ciclesonide 320mcg twice daily
395960|NCT01171365|Drug|Placebo|Matched placebo inhaler two inhalations twice daily
395961|NCT01171352|Procedure|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
395962|NCT01171339|Other|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#~#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
395964|NCT01171313|Drug|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
395965|NCT01171313|Drug|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
395966|NCT01171313|Drug|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
395967|NCT01171313|Drug|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
395968|NCT01171300|Other|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
395969|NCT01171300|Other|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
395970|NCT01171287|Procedure|Driving with an Aircast Walker|
395971|NCT01171287|Procedure|Driving with a walking cast|
395972|NCT01171287|Procedure|Driving with a running shoe|
395973|NCT01171274|Behavioral|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.~One class of 90 minutes per week, 10 minutes training at home each day."
395974|NCT01171274|Behavioral|Information regarding exercises and behaviour|"9 weeks of exercises practiced at home.~Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
395975|NCT01171261|Behavioral|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
395976|NCT01171209|Drug|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
395977|NCT01171183|Drug|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
395978|NCT01171183|Drug|Placebo|Placebo
395979|NCT01171170|Drug|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
395980|NCT01171170|Drug|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
395981|NCT01171157|Other|Routine sample collection|Collection of routine nasal/throat swab samples
395982|NCT01171144|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
395983|NCT01171144|Other|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
395984|NCT01171144|Other|Hospital discharge records|Reviewing the hospital discharge records
395985|NCT01171131|Other|Blood/saliva sampling|one-time blood sample (~ 1 TBS) and saliva sample (~ 1 tsp)
395986|NCT01171118|Drug|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
395987|NCT01171118|Drug|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
395988|NCT01171118|Drug|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
395989|NCT01171105|Drug|AZD5213|oral solution, multiple ascending doses
395990|NCT01171105|Drug|Placebo to AZD5213|
395991|NCT01171092|Drug|bortezomib and G-CSF|"Bortezomib injection:~1.3mg/m2 11 days before and 8 days before the stem cell collection~G-CSF injection:~10mcg/kg on days -4 to day -1 once daily"
395992|NCT01171079|Device|application of oxidized regenerated cellulose|
395993|NCT01171053|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
395994|NCT01171053|Behavioral|Therapist support|Weekly therapist support without CBT-interventions
395995|NCT01171040|Other|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
395996|NCT01171027|Procedure|NOTES Cholecystectomy|The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
396036|NCT01170715|Drug|Etanercept|self-administered for 52 weeks
395997|NCT01171027|Procedure|Laparoscopic Cholecystectomy|This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
395998|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
395999|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
396000|NCT01171014|Dietary Supplement|Placebo|Placebo, once a day for 14 days
396001|NCT01170988|Procedure|T-Graft|T-Graft
396002|NCT01170975|Drug|Tesetaxel 10 mg with and then without food|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
396003|NCT01170975|Drug|Tesetaxel 10 mg without and then with food|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
396004|NCT01170962|Drug|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
396005|NCT01170962|Drug|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
396006|NCT01170962|Drug|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
396007|NCT01170962|Drug|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
396008|NCT01170962|Drug|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
396009|NCT01170949|Drug|Miltefosine|50 or 100 or 150mg per day
396010|NCT01170949|Drug|Placebo|Placebo
396011|NCT01170936|Drug|canakinumab|Single dose of canakinumab 300mg s.c. injection
396012|NCT01170923|Device|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
396013|NCT01170923|Device|CT|CT performed after 3 cycles of chemotherapy
396014|NCT01170910|Procedure|Static incubation|"Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.~."
396015|NCT01170910|Procedure|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
396016|NCT01170897|Drug|PEGPH20|PEGylated Recombinant Human Hyaluronidase
396017|NCT01170884|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
396018|NCT01170884|Drug|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
396019|NCT01170871|Drug|Ixabepilone|
396020|NCT01170871|Drug|Pemetrexed|
396021|NCT01170858|Drug|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
396022|NCT01170858|Drug|glucose solutions|
396023|NCT01170845|Drug|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
396024|NCT01170819|Device|Double balloon catheter|The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
396025|NCT01170819|Drug|Dinoprostone 10 mg controlled-release vaginal insert|Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
396026|NCT01170806|Drug|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
396027|NCT01170793|Behavioral|educative telephone coaching (ETC)|a 30 to 45 minutes phone call, by appointment, by the nurse
396028|NCT01170780|Drug|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
396029|NCT01170780|Drug|Saline|2 ml IV
396030|NCT01170767|Drug|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
396031|NCT01170767|Drug|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
396032|NCT01170754|Drug|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
396033|NCT01170754|Drug|Golytely 4 liters|Golytely 4 liters
396034|NCT01170741|Behavioral|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
396035|NCT01170728|Device|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
396037|NCT01170702|Drug|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
396038|NCT01170702|Drug|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
396039|NCT01170702|Drug|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
396040|NCT01170702|Drug|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
396041|NCT01170676|Behavioral|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
396042|NCT01170676|Behavioral|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
396043|NCT01170663|Biological|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
396044|NCT01170663|Drug|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
396045|NCT01170663|Drug|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
396046|NCT01170650|Drug|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
396047|NCT01170650|Drug|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
396048|NCT01170650|Drug|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
396049|NCT01170650|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
396050|NCT01170637|Drug|Ibuprofen|200 mg oral administration (RhinAdvil(R))
396051|NCT01170637|Drug|Ibuprofen|200 mg oral administration (BI product)
396052|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (BI product)
396053|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
396054|NCT01170624|Device|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
396055|NCT01170611|Device|PACEMAKER SYMPHONY 2550|
396056|NCT01170598|Other|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
396057|NCT01170585|Drug|Rosuvastatin|All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
396058|NCT01170585|Drug|Placebo|Placebo
396059|NCT01170572|Other|No intervention|No intervention
396060|NCT01170559|Device|Implantable Loop Recorder|
396061|NCT01170546|Other|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
396062|NCT01170546|Other|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
396063|NCT01170546|Other|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
396064|NCT01170533|Drug|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
396065|NCT01170520|Device|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
396066|NCT01170507|Drug|vitamin D3 1000 IU orally daily for 5 months|
396067|NCT01170507|Drug|vitamin D3 3000 IU orally daily for 5 months|
396068|NCT01170507|Drug|vitamin D3 5000 IU orally daily for 5 months|
396069|NCT01170507|Drug|Placebo orally daily for 5 months|
396070|NCT01170494|Drug|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
396071|NCT01170494|Drug|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
396072|NCT01170494|Drug|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
396073|NCT01170494|Drug|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
396075|NCT01170494|Drug|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
396076|NCT01170494|Drug|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
396077|NCT01170494|Drug|placebo orally everyday|placebo orally everyday
396078|NCT01170468|Drug|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
396079|NCT01170468|Drug|Placebo|Placebo orally, daily for 2 years
396080|NCT01170455|Device|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
396081|NCT01170455|Device|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
396082|NCT01170442|Drug|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
396083|NCT01170442|Drug|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
396084|NCT01170442|Drug|Placebo|placebo orally, daily for six months
396085|NCT01170429|Drug|Procaterol hydrochloride|25µg BID for 8 weeks
396086|NCT01170429|Drug|Meptin placebo|25µg BID for 8 weeks
396087|NCT01170416|Other|12-lead body surface mapping|An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
396088|NCT01170390|Drug|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
396089|NCT01170390|Drug|Portia|30 mcg EE/0.15 mg LNG cyclically
396090|NCT01170390|Drug|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
396091|NCT01170364|Drug|Sibutramine|1 week of active sibutramine (15mg)
396092|NCT01170364|Drug|Placebo|2 weeks of placebo
396093|NCT01170351|Drug|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
396094|NCT01170338|Drug|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
396095|NCT01170338|Drug|control|this is the placebo that will help us maintain a blinded study
396096|NCT01170325|Drug|Divalproex Sodium|
396097|NCT01170325|Drug|Placebo Comparator|
396098|NCT01170312|Biological|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
396099|NCT01170312|Other|Normal saline|Normal saline injection
396100|NCT01170299|Dietary Supplement|dietary intervention|
396101|NCT01170299|Other|laboratory biomarker analysis|
396102|NCT01170299|Procedure|gastrointestinal complications management/prevention|
396103|NCT01170299|Procedure|management of therapy complications|
396104|NCT01170299|Radiation|selective external radiation therapy|
396105|NCT01170286|Biological|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
396106|NCT01170286|Biological|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
396107|NCT01170273|Dietary Supplement|vitamin D|cholecalciferol
396108|NCT01170273|Dietary Supplement|placebo|placebo tablet
396109|NCT01170260|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
396110|NCT01170260|Behavioral|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
396111|NCT01170260|Behavioral|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
396112|NCT01170247|Drug|Ketamine|Intranasal Ketamine (100 mg/mL)
396113|NCT01170247|Drug|Ketamine|Intramuscular Ketamine
396114|NCT01170234|Device|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
396115|NCT01170221|Drug|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
396116|NCT01170221|Drug|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
396117|NCT01170208|Device|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
396118|NCT01170195|Dietary Supplement|Calmera-Licorice Root Extract (Licogen)|100 mg per day
396119|NCT01170182|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
396120|NCT01170182|Device|Prilosec® 40 mg|Prilosec® 40 mg
396121|NCT01170169|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
396122|NCT01170169|Drug|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
396123|NCT01170156|Device|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
396124|NCT01170143|Drug|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
396125|NCT01170130|Drug|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
396163|NCT01169831|Other|Exercise Training|2 weeks of daily aerobic exercise training
396164|NCT01169831|Other|Exercise Cessation|Stopping all exercise for 2 weeks
396126|NCT01170117|Drug|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
396127|NCT01170117|Drug|Placebo|Control Group will receive placebo pill
396128|NCT01170104|Drug|Sorafenib|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
396129|NCT01170104|Procedure|TACE (Transcatheter arterial chemoembolization)|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
396130|NCT01170078|Drug|Epoetin Hospira|IV dose 3 times a week.
396131|NCT01170078|Drug|Epogen|IV dose 3 times a week
396132|NCT01170065|Drug|BIBF 1120|Intermediate dose BIBF 1120 twice daily
396133|NCT01170065|Drug|BIBF 1120|High dose BIBF 1120 twice daily
396134|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 twice daily
396135|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 once daily
396136|NCT01170052|Drug|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
396137|NCT01170052|Drug|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
396138|NCT01170052|Drug|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
396139|NCT01170039|Drug|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
396140|NCT01170039|Drug|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
396141|NCT01170026|Behavioral|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion & Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
396142|NCT01170026|Behavioral|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
396143|NCT01170013|Behavioral|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
396144|NCT01170013|Behavioral|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
396145|NCT01169974|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 & 3 minutes
396146|NCT01169948|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
396147|NCT01169935|Drug|Administration of intra-dermal Endorem|single dose, intradermal
396148|NCT01169935|Biological|Mantoux test|single dose, intradermal
396149|NCT01169935|Biological|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
396150|NCT01169935|Drug|Administration of Endorem|single dose, intravenous
396151|NCT01169922|Behavioral|SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
396152|NCT01169922|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION|1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
396153|NCT01169909|Drug|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
396154|NCT01169883|Behavioral|Coping Peer Support|The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.
396155|NCT01169883|Behavioral|Doctor Asthma Messages|The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.
396156|NCT01169883|Behavioral|Coping Peer Asthma Messages|The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.
396157|NCT01169883|Behavioral|Asthma Supervision|A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
396158|NCT01169883|Behavioral|Music Tracks|Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
396159|NCT01169870|Drug|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
396160|NCT01169870|Drug|Paclitaxel|
396161|NCT01169857|Drug|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
396165|NCT01169818|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous~Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
396166|NCT01169805|Drug|Ondansetron|Ondansetron/single injection/4 mg/IV
396167|NCT01169805|Drug|Ramosetron|Ramosetron HCl/single injection/0.3mg/IV
396168|NCT01169805|Drug|Palonosetron|Palonosetron HCl/single injection/0.075mg/IV
396169|NCT01169805|Drug|Normal saline inj|normal saline injection 2ml
396170|NCT01169792|Drug|tamoxifen|
396171|NCT01169779|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
396172|NCT01169779|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
396173|NCT01169779|Device|Pen auto-injector|
396174|NCT01169779|Drug|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
396175|NCT01169779|Drug|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c <8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
396176|NCT01169753|Drug|Placebo|Oral tablet every morning for 2 weeks
396177|NCT01169753|Drug|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
396178|NCT01169740|Procedure|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
396179|NCT01169714|Drug|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
396180|NCT01169714|Drug|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
396181|NCT01169714|Drug|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
396182|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
396183|NCT01169714|Drug|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
396184|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
396185|NCT01169701|Drug|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
396186|NCT01169701|Drug|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
396187|NCT01169701|Drug|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
396188|NCT01169688|Other|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
396189|NCT01169675|Drug|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
396190|NCT01169675|Drug|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
396191|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
396192|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
396193|NCT01169675|Drug|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
396194|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
396195|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
396196|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
396197|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
396198|NCT01169675|Drug|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
396199|NCT01169675|Drug|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
396200|NCT01169675|Drug|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
396201|NCT01169662|Dietary Supplement|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
396202|NCT01169662|Dietary Supplement|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
396203|NCT01169649|Drug|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
396204|NCT01169636|Drug|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
396205|NCT01169636|Drug|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
396206|NCT01169636|Drug|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
396207|NCT01169636|Drug|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
396208|NCT01169636|Drug|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
396209|NCT01169636|Drug|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
396210|NCT01169623|Other|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
396211|NCT01169610|Drug|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
396212|NCT01169597|Drug|prednisone|prednisone 12.5 mg daily po
396213|NCT01169584|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10^6 pfu/kg to 3 x 10^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
396214|NCT01169571|Drug|Dexmedetomidine|
396267|NCT01169220|Drug|Go Lytely|Bowel cleansing agent
397100|NCT01162590|Biological|Rotarix ™|Oral, single dose
396215|NCT01169558|Drug|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
396216|NCT01169558|Drug|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
396217|NCT01169532|Drug|ridaforolimus|Given PO
396218|NCT01169532|Drug|vorinostat|Given PO
396219|NCT01169532|Procedure|biopsy|Optional correlative studies
396220|NCT01169532|Other|pharmacological study|Correlative studies
396221|NCT01169532|Other|laboratory biomarker analysis|Correlative studies
396222|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
396223|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
396224|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
396225|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
396226|NCT01169506|Device|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
396227|NCT01169493|Device|VVI-40|Pacing mode set to VVI-40, RV only pacing
396228|NCT01169493|Device|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
396229|NCT01169493|Device|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
396230|NCT01169480|Behavioral|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
396231|NCT01169467|Drug|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
396232|NCT01169467|Other|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
396233|NCT01169428|Behavioral|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
396234|NCT01169428|Behavioral|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors [e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information & education]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
396235|NCT01169415|Drug|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
396236|NCT01169415|Drug|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
396237|NCT01169402|Drug|Fluconazole|25mg/kg intravenously once weekly while on ECMO
396238|NCT01169389|Procedure|Intraarticular injection|Durolane, one vial
396239|NCT01169389|Procedure|Intra-articular injection of 0.5% Bupivacaine|
396240|NCT01169376|Genetic|DNA analysis|
396241|NCT01169376|Genetic|DNA methylation analysis|
396242|NCT01169376|Genetic|RNA analysis|
396243|NCT01169376|Genetic|comparative genomic hybridization|
396244|NCT01169376|Genetic|mutation analysis|
396245|NCT01169376|Genetic|polymorphism analysis|
396246|NCT01169363|Genetic|proteomic profiling|
396247|NCT01169363|Other|flow cytometry|
396248|NCT01169363|Other|laboratory biomarker analysis|
396249|NCT01169350|Radiation|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
396250|NCT01169350|Other|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
396251|NCT01169350|Procedure|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
396252|NCT01169350|Procedure|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
396253|NCT01169350|Other|laboratory biomarker analysis|Correlative studies
396254|NCT01169337|Other|Clinical Observation|Undergo observation
396255|NCT01169337|Drug|Lenalidomide|Given PO
396256|NCT01169337|Other|Quality-of-Life Assessment|Ancillary studies
396257|NCT01169324|Other|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
396258|NCT01169311|Device|Hemorrhoidopexy|
396259|NCT01169298|Drug|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
396260|NCT01169272|Device|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
396261|NCT01169259|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
396262|NCT01169259|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
396263|NCT01169259|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
396264|NCT01169259|Dietary Supplement|Fish oil placebo|Fish oil placebo
396265|NCT01169233|Device|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
396266|NCT01169220|Drug|Go-Lytely|Bowel cleansing agent
396268|NCT01169181|Device|AMES + brain stimulation|Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
396269|NCT01169155|Other|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
396270|NCT01169142|Dietary Supplement|Vitamin D3|50,000 units of Vitamin D3 weekly
396271|NCT01169142|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 units weekly
396272|NCT01169129|Other|surgery|resection of brain metastases
396273|NCT01169129|Radiation|radiosurgery|radiosurgery to brain metastases
396274|NCT01169116|Radiation|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
396275|NCT01169103|Drug|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
396276|NCT01169103|Drug|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
396277|NCT01169090|Drug|SK-0403|SK-0403
396278|NCT01169090|Drug|Placebo|Placebo
396279|NCT01169090|Drug|Sitagliptin|Sitagliptin
396280|NCT01169077|Drug|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
396281|NCT01169077|Biological|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
396282|NCT01169064|Device|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
396283|NCT01169064|Device|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
396284|NCT01169038|Drug|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD~**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
396285|NCT01169025|Drug|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
396286|NCT01169025|Drug|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
396287|NCT01169012|Drug|Clofarabine|Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
396288|NCT01168999|Other|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
396289|NCT01168999|Other|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
396290|NCT01168999|Other|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
396291|NCT01168986|Other|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
396292|NCT01168986|Other|Exercise|Participants perform an exercise to strengthen the deep neck flexors
396293|NCT01168973|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
396294|NCT01168973|Drug|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
396295|NCT01168973|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) (60 mg/m^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
396296|NCT01168960|Behavioral|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
396297|NCT01168947|Other|5% dextrose solution|The extracorporeal circuit of the dialysis machine will be primed and rinsed with a 5% dextrose solution instead of 0.9% saline.
396298|NCT01168934|Drug|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
396299|NCT01168934|Drug|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
396300|NCT01168921|Drug|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
396301|NCT01168908|Drug|Sildenafil|20mg tablet three times daily
396302|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
396303|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
396372|NCT01168245|Device|Sham-NICE-System|sham TMS and sham cognitive training
396304|NCT01168882|Drug|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
396305|NCT01168843|Other|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
396306|NCT01168830|Device|AMS-3.0|
396307|NCT01168817|Drug|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
396308|NCT01168817|Drug|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
396309|NCT01168817|Drug|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
396310|NCT01168804|Drug|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
396311|NCT01168791|Drug|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.~doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
396312|NCT01168791|Drug|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.~placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
396313|NCT01168778|Behavioral|Physician Workshop|Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
396314|NCT01168765|Behavioral|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
396315|NCT01168752|Drug|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
396316|NCT01168739|Dietary Supplement|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
396317|NCT01168739|Dietary Supplement|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
396318|NCT01168726|Behavioral|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
396319|NCT01168726|Behavioral|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
396320|NCT01168726|Behavioral|Alcohol Education|Educational information about harms associated with heavy drinking.
396321|NCT01168713|Drug|Levofloxacin|"Levofloxacin once daily for 5 days:~Levofloxacin 750 mg PO Days 1-5"
396322|NCT01168713|Drug|CEM-101|"CEM-101 once daily for 5 days:~CEM-101 800 mg PO Day 1~CEM-101 400 mg PO Days 2-5"
396323|NCT01168700|Drug|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
396324|NCT01168700|Drug|Placebo|Placebo 1.2 g per day for 12 weeks.
396325|NCT01168687|Drug|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.~Group B: Twenty moderate to heavy social alcohol users as described above will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
396326|NCT01168687|Drug|Placebo|
396327|NCT01168674|Drug|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
396328|NCT01168674|Drug|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
396329|NCT01168661|Behavioral|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) >= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
396330|NCT01168661|Behavioral|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
396331|NCT01168661|Behavioral|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
396332|NCT01168648|Behavioral|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
396333|NCT01168648|Other|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
396373|NCT01168245|Device|NICE-System|TMS combined with cognitive training
396374|NCT01168232|Drug|Ixabepilone|Given IV
396375|NCT01168232|Other|Laboratory Biomarker Analysis|Correlative studies
396334|NCT01168635|Behavioral|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|"The Spirometry 360 program includes:~Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;~Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;~Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic."
396335|NCT01168609|Procedure|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
396336|NCT01168596|Drug|Rasagiline|"Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
396337|NCT01168596|Drug|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
396338|NCT01168557|Device|EIT (Electrical Impedance Tomography)|EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
396339|NCT01168544|Dietary Supplement|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
396340|NCT01168544|Dietary Supplement|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
396341|NCT01168544|Dietary Supplement|Vitamin D 800 IU /day|800 IU vit D3/day
396342|NCT01168531|Drug|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
396343|NCT01168531|Drug|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
396344|NCT01168531|Drug|placebo|vitamin B complex formula
396345|NCT01168505|Drug|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
396346|NCT01168492|Drug|ketamine|0.5mg/kg ketamine iv
396347|NCT01168479|Radiation|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
396348|NCT01168479|Radiation|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
396349|NCT01168466|Behavioral|QEEG-based Neurofeedback Training|EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
396350|NCT01168453|Behavioral|head position change|AL-US distance measure using the ultrasound in two different head position
396351|NCT01168440|Drug|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
396352|NCT01168427|Device|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
396353|NCT01168414|Drug|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
396354|NCT01168414|Drug|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
396355|NCT01168401|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years~Cohort A1: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (5/5 mcg)~Cohort A2: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (15/15 mcg)~Cohort A3: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort A4: IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (150/150 mcg)~Cohort B: 50-64 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort C: 65-85 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)~Cohort D: 18-49 Years IM Norovirus Bivalent GI.1/GII.4 VLP Vaccine (50/50 mcg)"
396356|NCT01168401|Biological|Saline|Two doses 28 days apart
396357|NCT01168375|Drug|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
396358|NCT01168375|Drug|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
396359|NCT01168349|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
396360|NCT01168336|Drug|Betahistine standard formulation|betahistine 24 mg tablets
396361|NCT01168336|Drug|Betahistine Extended Release formulation|betahistine 32 mg tablets
396362|NCT01168336|Drug|Placebo|matching placebo
396363|NCT01168323|Behavioral|Online spaced education|Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
396364|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
396365|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
396366|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
396367|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
396368|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
396369|NCT01168310|Drug|Formoterol Fumarate|Inhalation Solution
396370|NCT01168310|Drug|Placebo|Inhalation Solution
396371|NCT01168284|Behavioral|Coping Effectiveness Training|
396376|NCT01168219|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
396377|NCT01168219|Biological|Anti-Thymocyte Globulin|Given IV
396378|NCT01168219|Drug|Azacitidine|Given SC or IV
396379|NCT01168219|Drug|Busulfan|Given IV
396380|NCT01168219|Drug|Fludarabine Phosphate|Given IV
396381|NCT01168219|Other|Laboratory Biomarker Analysis|Correlative studies
396382|NCT01168219|Drug|Methotrexate|Given IV
396383|NCT01168219|Other|Pharmacological Study|Correlative studies
396384|NCT01168219|Drug|Tacrolimus|Given PO or IV
396385|NCT01168206|Dietary Supplement|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
396386|NCT01168206|Dietary Supplement|1 capsule, 3 times per day|Placebo
396387|NCT01168193|Other|No intervention|
396388|NCT01168180|Other|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
396389|NCT01168180|Other|Ultrasound therapy and hot pack|
396390|NCT01168154|Dietary Supplement|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
396391|NCT01168154|Dietary Supplement|placebo|placebo
396392|NCT01168141|Drug|ZD4054|10mg ZD4054 daily in tablet form
396393|NCT01168128|Other|Tailored Change Strategy|e.g. Education, decision support tools
396394|NCT01168063|Drug|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
396395|NCT01168063|Drug|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|"2 lines of treatments :~1) PPI + Amoxicillin + Clarithromycin for 7 days~1) PPI + Amoxicillin + Metronidazole for 14 days"
396396|NCT01168050|Drug|Nilotinib|Nilotinib 400 mg twice per day
396397|NCT01168037|Device|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
396398|NCT01168037|Procedure|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
396399|NCT01168024|Device|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
396400|NCT01168024|Other|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
396401|NCT01168011|Drug|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
396402|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
396403|NCT01167985|Device|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
396404|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
396405|NCT01167959|Procedure|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
396406|NCT01167959|Behavioral|Prodimed dietary intervention|3 months of using the prodimed diet
396407|NCT01167946|Drug|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
396408|NCT01167946|Drug|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
396409|NCT01167946|Drug|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
396410|NCT01167933|Drug|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
396411|NCT01167920|Other|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
396412|NCT01167907|Device|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
396413|NCT01167907|Drug|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
396414|NCT01167894|Drug|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
396415|NCT01167881|Drug|BI 10773|Medium dose once daily
396416|NCT01167881|Drug|Glimepiride|1-4 mg once daily
396417|NCT01167881|Drug|Placebo|Placebo matching BI 10773
396418|NCT01167881|Drug|Placebo|Placebo matching Glimepiride
396419|NCT01167868|Drug|FosD|oral tablet
396420|NCT01167868|Drug|Placebo|oral tablet
396631|NCT01166191|Radiation|Radiotherapy|Radiotherapy
396421|NCT01167855|Other|Asthma Education Sessions|Comprehensive asthma education sessions delivered via telemedicine.
396422|NCT01167855|Other|Asthma Health Assessment via Telemonitoring|Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
396423|NCT01167855|Other|Provider Treatment Prompt|A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
396424|NCT01167855|Other|School Absenteeism|Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
396425|NCT01167855|Other|Prescription Filling Profile|Study personnel will monitor participants' prescription profiles.
396426|NCT01167829|Drug|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
396427|NCT01167829|Drug|Acyline|300 ug/kg injection on Day 0
396428|NCT01167816|Drug|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
396429|NCT01167803|Drug|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
396430|NCT01167803|Drug|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
396431|NCT01167790|Procedure|buccal cavity examination|autofluorescence examination
396432|NCT01167764|Drug|tranexamic acid, placebo|tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
396433|NCT01167751|Biological|MNC|Implantation of BM derived MNC
396434|NCT01167751|Biological|AC 133|Implantation of BM derived AC133
396435|NCT01167751|Biological|Control|Injection of cell carrier
396436|NCT01167738|Drug|capecitabine|1250 mg/mq days 1-28 every 4 weeks
396437|NCT01167738|Drug|cisplatin|30 mg/mq on days 1 and 15 every 4 weeks
396438|NCT01167738|Drug|epirubicin|30 mg/mq on days 1 and 15 every 4 weeks
396439|NCT01167738|Drug|gemcitabine|800 mg/mq on days 1 and 15 every 4 weeks
396440|NCT01167738|Drug|metformin|2 g days 1-28 every 4 weeks
396441|NCT01167725|Biological|bevacizumab|Given IV
396442|NCT01167725|Biological|cetuximab|Given IV
396443|NCT01167725|Drug|FOLFIRI regimen|Given IV
396444|NCT01167725|Drug|FOLFOX regimen|Given IV
396445|NCT01167725|Drug|capecitabine|Given IV
396446|NCT01167725|Drug|fluorouracil|Given IV
396447|NCT01167725|Drug|irinotecan hydrochloride|Given IV
396448|NCT01167725|Drug|leucovorin calcium|Given IV
396449|NCT01167725|Drug|mitomycin C|Given intraperitoneally
396450|NCT01167725|Drug|oxaliplatin|Given IV
396451|NCT01167725|Procedure|therapeutic conventional surgery|Patients undergo cytoreductive surgery
396452|NCT01167712|Biological|Bevacizumab|Given IV
396453|NCT01167712|Drug|Carboplatin|Given IV
396454|NCT01167712|Procedure|Computed Tomography|Correlative studies
396455|NCT01167712|Drug|Paclitaxel|Given IV
396456|NCT01167712|Procedure|Therapeutic Conventional Surgery|Undergo surgery
396457|NCT01167699|Drug|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
396458|NCT01167686|Dietary Supplement|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
396459|NCT01167673|Dietary Supplement|coltect|green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
396460|NCT01167673|Dietary Supplement|Placebo|placebo
396461|NCT01167660|Device|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
396462|NCT01167634|Behavioral|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
396463|NCT01167634|Behavioral|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
396464|NCT01167634|Behavioral|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
396465|NCT01167608|Other|No Intervention. This is a cross-sectional survey study.|No intervention.
396466|NCT01167595|Other|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
396467|NCT01167582|Biological|Red blood cell transfusion|Liberal versus restrictive transfusion
396468|NCT01167569|Drug|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
396469|NCT01167569|Other|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
396470|NCT01167556|Behavioral|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
396471|NCT01167530|Drug|Everolimus|First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.
396472|NCT01167517|Other|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
396473|NCT01167504|Other|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
396474|NCT01167491|Biological|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
396475|NCT01167478|Dietary Supplement|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
396476|NCT01167478|Dietary Supplement|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
396477|NCT01167465|Other|Moussik Diaper Rash Mousse|To be used as instructed
396478|NCT01167465|Other|Desitin Creamy Ointment|To be used as instructed
396479|NCT01167452|Drug|Sulfamethoxazole/trimethoprim|2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
396480|NCT01167439|Procedure|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
396481|NCT01167426|Drug|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
396482|NCT01167426|Drug|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
396483|NCT01167413|Device|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
396484|NCT01167413|Other|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
396485|NCT01167400|Behavioral|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
396486|NCT01167400|Behavioral|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
396487|NCT01167387|Dietary Supplement|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
396488|NCT01167387|Other|water|The control group will receive plain water with the same volume and timing of treatment.
396489|NCT01167374|Radiation|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
396490|NCT01167348|Procedure|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
396491|NCT01167335|Drug|BGG492|
396492|NCT01167335|Drug|Placebo|
396493|NCT01167322|Drug|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
396494|NCT01167309|Drug|LEO 27847|First in patient
396495|NCT01167296|Device|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
396496|NCT01167283|Device|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
396497|NCT01167283|Device|Sham stimulation|Sham stimulation: 1 h; 5 times/week
396498|NCT01167270|Behavioral|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
396499|NCT01167270|Behavioral|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
396500|NCT01167257|Drug|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
396501|NCT01167257|Drug|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
396502|NCT01167244|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
396503|NCT01167231|Drug|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
396504|NCT01167205|Dietary Supplement|astaxanthin|astaxanthin 20mg for 12 weeks
396505|NCT01167192|Drug|Cisplatin|
396506|NCT01167192|Drug|Carboplatin|
396507|NCT01167192|Radiation|Radiation therapy|
396508|NCT01167192|Procedure|Mastectomy (recommended but not mandatory)|
396509|NCT01167179|Behavioral|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
396510|NCT01167166|Drug|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
396511|NCT01167153|Drug|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
396512|NCT01167153|Drug|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
396513|NCT01167140|Device|Cryo-Touch II|Percutaneous treatment with the device
396514|NCT01167127|Drug|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
396515|NCT01167114|Drug|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
396516|NCT01167101|Drug|Rebamipide|Rebamipide 100mg Tid for 28days
396517|NCT01167101|Drug|pantoprazole|pantoprazole 40mg qd for 28days
396518|NCT01167088|Drug|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
396519|NCT01167088|Drug|Placebo|Placebo
396520|NCT01167075|Dietary Supplement|Fresubin Original|
396521|NCT01167075|Dietary Supplement|Intestamin plus Fresubin Original|
396522|NCT01167062|Drug|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
396523|NCT01167062|Other|Placebo|One tablet OD for a maximum of 28 days
396524|NCT01167049|Drug|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
396525|NCT01167036|Device|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
396526|NCT01167036|Other|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
396527|NCT01167023|Drug|Prasugrel|Administered orally, once daily for 30 days.
396528|NCT01167023|Drug|Placebo|Administered orally, once daily for 30 days.
396529|NCT01167010|Drug|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
396530|NCT01167010|Drug|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
396531|NCT01167010|Drug|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
396532|NCT01166997|Device|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver < 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
396533|NCT01166997|Drug|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
396534|NCT01166984|Drug|AB103|AB103 intravenous one infusion
396535|NCT01166971|Device|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
396536|NCT01166971|Device|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
396537|NCT01166958|Drug|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
396538|NCT01166958|Drug|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
396539|NCT01166945|Drug|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
396540|NCT01166945|Drug|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
396541|NCT01166932|Drug|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
396542|NCT01166932|Drug|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
396543|NCT01166919|Device|Matrix Radiofrequency|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
396544|NCT01166906|Device|pain blocking|pain blocking
396545|NCT01166893|Device|Modulated Imaging and Laser Speckle Imaging|wound healing
396546|NCT01166880|Device|Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
396547|NCT01166867|Device|Photo-plethysmography monitoring|monitoring vital sign in infant
396548|NCT01166854|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
396549|NCT01166841|Procedure|PSVC line clamped|A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
396550|NCT01166828|Behavioral|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
396551|NCT01166815|Dietary Supplement|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
396552|NCT01166815|Other|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
396553|NCT01166789|Drug|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
396554|NCT01166789|Drug|Placebo|2 capsules daily, taken in morning and evening
396555|NCT01166763|Drug|vitamin D3|oral capsules, 10,000 IU per week for 6 months
396556|NCT01166750|Behavioral|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
396557|NCT01166750|Behavioral|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
396558|NCT01166737|Procedure|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
396559|NCT01166724|Drug|Sirolimus|Tacrolimus to Sirolimus
396560|NCT01166724|Drug|Tacrolimus|dosage per trough level
396632|NCT01166178|Drug|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
396561|NCT01166711|Device|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"standard techniques will be used~maximal vasodilatation after nitro application~baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~6 French guiding catheter at least~target lesion will be crossed with standard guidewire~direct stenting at the discretion of the investigator~if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~full lesion coverage will be ensured (with one or more stents)~only insert assigned stent type~BMS needs to be fully embedded in vessel wall~post-dilation with high pressure is required before treatment with DEB~DEB will be inflated with nominal pressure (balloon equates to vessel diameter)~length of DEB should exceed the BMS by 2-3 mm on each side~if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
396562|NCT01166711|Device|Coroflex Please (DES)|"standard techniques will be used~maximal vasodilatation after nitro application~baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)~6 French guiding catheter at least~target lesion will be crossed with standard guidewire~direct stenting at the discretion of the investigator~if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)~full lesion coverage will be ensured (with one or more stents)~only insert assigned stent type"
396563|NCT01166698|Drug|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
396564|NCT01166698|Drug|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
396565|NCT01166698|Drug|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
396566|NCT01166685|Device|Everolimus-eluting stent|Everolimus-eluting stent
396567|NCT01166685|Device|Bare-metal stent|Bare metal stent
396568|NCT01166685|Device|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
396569|NCT01166659|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
396570|NCT01166646|Drug|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
396571|NCT01166646|Drug|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
396572|NCT01166633|Drug|pitavastatin|pitavastatin 2mg per daily
396573|NCT01166633|Drug|atorvastatin|atorvastatin 10mg per daily
396574|NCT01166594|Drug|Bevacizumab|Intrableb injection
396575|NCT01166594|Drug|Control|intrableb BSS injection
396576|NCT01166568|Device|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants and followed for 24 months.
396577|NCT01166555|Drug|PF-04236921|single subcutaneous dose
396578|NCT01166542|Biological|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
396579|NCT01166542|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
396580|NCT01166542|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
396581|NCT01166542|Drug|Placebo|Placebo
396582|NCT01166529|Procedure|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
396583|NCT01166516|Device|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
396584|NCT01166503|Procedure|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
396585|NCT01166503|Procedure|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
396586|NCT01166503|Procedure|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
396587|NCT01166503|Procedure|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
396588|NCT01166503|Procedure|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
396589|NCT01166490|Drug|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
396590|NCT01166477|Drug|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
396591|NCT01166477|Drug|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
396592|NCT01166464|Behavioral|text messaging for smoking cessation|A 7-week program of daily text messages
396593|NCT01166464|Behavioral|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
396594|NCT01166451|Dietary Supplement|Low-iron formula|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
396633|NCT01166178|Drug|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
396595|NCT01166451|Dietary Supplement|High-iron formula|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
396596|NCT01166438|Drug|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
396597|NCT01166438|Drug|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
396598|NCT01166438|Drug|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
396599|NCT01166438|Drug|Trospium chloride|Oral Trospium chloride XR 60mg once a day for up to 2 months
396600|NCT01166425|Drug|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
396601|NCT01166425|Drug|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
396602|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
396603|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
396604|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
396605|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
396606|NCT01166386|Behavioral|FANCI|compresensive neubehavioral sessions with therapist administrating treatment components
396607|NCT01166386|Behavioral|FANCI|Watching DVDs chosen by participants on various topics.
396608|NCT01166373|Behavioral|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
396609|NCT01166373|Procedure|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
396610|NCT01166373|Procedure|ULS|uterosacral ligament suspension to suspend the vaginal apex
396611|NCT01166373|Behavioral|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
396612|NCT01166373|Other|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
396613|NCT01166347|Device|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
396614|NCT01166347|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
396615|NCT01166334|Behavioral|WebQuit study group|Description withheld to protect integrity of study
396616|NCT01166334|Behavioral|WebQuit control group|Identity and description withheld to protect integrity of study
396617|NCT01166321|Radiation|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
396618|NCT01166308|Radiation|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
396619|NCT01166308|Radiation|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
396620|NCT01166282|Biological|adalimumab|Adalimumab solution for subcutaneous injection.
396621|NCT01166282|Biological|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
396622|NCT01166269|Biological|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
396623|NCT01166269|Biological|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
396624|NCT01166269|Other|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
396625|NCT01166256|Device|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 >92% or PaO2 >65 mmHg.
396626|NCT01166256|Device|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 >92% or PaO2 >65 mmHg.
396627|NCT01166243|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
396628|NCT01166243|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
396629|NCT01166217|Drug|PF-04620110|"The five treatments are:~A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
396630|NCT01166204|Radiation|Radiotherapy|Radiotherapy
396634|NCT01166178|Dietary Supplement|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
396635|NCT01166165|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
396636|NCT01166165|Drug|Placebo|3 placebo tablets daily for 20 weeks
396637|NCT01166152|Behavioral|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
396638|NCT01166139|Drug|Nilotinib (Tasigna)|Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
396639|NCT01166126|Drug|temsirolimus|Given IV
396640|NCT01166126|Drug|selumetinib|Given orally
396641|NCT01166126|Other|laboratory biomarker analysis|Correlative studies
396642|NCT01166113|Drug|Pomalidomide, Cyclophosphamide, Prednisone|"Induction~This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.~In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.~The dose level associated with an updated DLT is recommended for the next patient cohort.~Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d~In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.~Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
396643|NCT01166100|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
396644|NCT01166087|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
396645|NCT01166074|Biological|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
396646|NCT01166061|Biological|Placebo|Solution resembling active solution but without peptides
396647|NCT01166061|Biological|ToleroMune Grass|1 x4 administrations 4 weeks apart
396648|NCT01166048|Drug|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)~day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg~day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
396649|NCT01166048|Drug|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
396650|NCT01166035|Drug|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~Disease progression~Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~Major violation of the study protocol.~Withdrawal of consent~Lost to follow up~Death~Suspected pregnancy"
396651|NCT01166035|Drug|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~Disease progression~Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~Major violation of the study protocol.~Withdrawal of consent~Lost to follow up~Death~Suspected pregnancy"
396652|NCT01166022|Other|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
396653|NCT01165996|Other|flow cytometry|Correlative studies
396654|NCT01165996|Other|DNA methylation analysis|Correlative studies
396655|NCT01165996|Other|cytogenetic analysis|Correlative studies
396656|NCT01165996|Drug|decitabine|Given subcutaneously
396657|NCT01165996|Genetic|microarray analysis|Correlative studies
396658|NCT01165996|Genetic|gene expression analysis|Correlative studies
396659|NCT01165996|Other|pharmacological study|Correlative studies
396660|NCT01165996|Genetic|polymorphism analysis|Correlative studies
396661|NCT01165983|Drug|Placebo|0mg tablet, taken orally for 12 weeks daily
396662|NCT01165983|Drug|Aliskiren|150mg tablet, taken orally for 12 weeks daily
396663|NCT01165970|Drug|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
396664|NCT01165970|Device|Saliva natura|Saliva substitute without restriction to be used
396665|NCT01165944|Drug|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
396666|NCT01165931|Drug|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
396667|NCT01165905|Drug|ON 01910.Na|The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
396668|NCT01165905|Drug|Gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
396669|NCT01165892|Drug|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
396724|NCT01165463|Behavioral|SOPT basic training|10 hours of basic training
396725|NCT01165463|Behavioral|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
396670|NCT01165866|Drug|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
396671|NCT01165866|Drug|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
396672|NCT01165853|Other|Glucose|25% dose at 8-week intervention assigned to subjects.
396673|NCT01165853|Other|Fructose|25% dose at 8-week intervention assigned to subjects.
396674|NCT01165840|Drug|Dapsone|100 mg PO x 1 dose
396675|NCT01165814|Drug|Naproxen Tramadol|
396676|NCT01165801|Procedure|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
396677|NCT01165788|Procedure|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
396678|NCT01165775|Device|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
396679|NCT01165762|Drug|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.~The IDE used in this study is the column used for hematopoietic cell sorting."
396680|NCT01165749|Behavioral|stop exercising|
396681|NCT01165736|Drug|PF-05186462|single intravenous infusion of 100 microgram
396682|NCT01165736|Drug|PF-05186462|single oral administration of 100 microgram
396683|NCT01165736|Drug|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
396684|NCT01165736|Drug|PF-05089771|single oral administration of 100 microgram PF-05089771
396685|NCT01165736|Drug|PF-05150122|single intravenous administration of 100 microgram PF-05150122
396686|NCT01165736|Drug|PF-05150122|single oral administration of 100 microgram PF-05150122
396687|NCT01165736|Drug|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
396688|NCT01165736|Drug|PF-05241328|single oral administration 100 microgram PF-05241328
396689|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
396690|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
396691|NCT01165710|Other|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
396692|NCT01165697|Other|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
396693|NCT01165684|Drug|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.~Doses individually adjusted."
396694|NCT01165684|Drug|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
396695|NCT01165684|Drug|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
396696|NCT01165671|Radiation|Carbon Ion Radiotherapy|Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
396697|NCT01165671|Radiation|Proton Radiotherapy|Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
396698|NCT01165658|Radiation|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
396699|NCT01165645|Drug|lopinavir|Given orally
396700|NCT01165645|Drug|ritonavir|Given orally
396701|NCT01165645|Genetic|polymerase chain reaction|Correlative studies
396702|NCT01165645|Other|flow cytometry|Correlative studies
396703|NCT01165645|Other|enzyme-linked immunosorbent assay|Correlative studies
396704|NCT01165645|Other|laboratory biomarker analysis|Correlative studies
396705|NCT01165632|Procedure|biopsy|Correlative studies
396706|NCT01165632|Procedure|computed tomography|Undergo computed tomography
396707|NCT01165632|Procedure|therapeutic conventional surgery|Undergo stereotactic craniotomy
396708|NCT01165632|Radiation|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
396709|NCT01165632|Radiation|radiation therapy|Undergo radiation therapy
396710|NCT01165632|Procedure|magnetic resonance imaging|Undergo magnetic resonance imaging
396711|NCT01165632|Procedure|positron emission tomography|Undergo positron emission tomography
396712|NCT01165632|Drug|fluorine F 18 fluorodopa|Given IV
396713|NCT01165606|Procedure|Chest physiotherapy|
396714|NCT01165593|Other|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
396715|NCT01165580|Drug|valganciclovir [Valcyte]|oral dose, Days 1 and 2
396716|NCT01165567|Drug|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
396717|NCT01165554|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
396718|NCT01165541|Drug|Mirtazapine|mirtazapine (7.5-45mg)
396719|NCT01165541|Drug|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
396720|NCT01165528|Procedure|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
396721|NCT01165502|Drug|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
396722|NCT01165502|Drug|Placebo|Placebo for compound CM3.1-AC100 s.c.
396723|NCT01165476|Drug|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
397101|NCT01162590|Biological|Placebo|Oral, single dose
396726|NCT01165463|Behavioral|SOPT booster training|4 hours of subsequent booster-training
396727|NCT01165450|Drug|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
396728|NCT01165450|Drug|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
396729|NCT01165437|Device|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
396730|NCT01165424|Drug|mometasone furoate|"MFNS 50 μg spray device~3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.~12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
396731|NCT01165385|Drug|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
396732|NCT01165385|Drug|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
396733|NCT01165372|Drug|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
396734|NCT01165359|Drug|ITX 5061|"For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days."
396735|NCT01165359|Drug|Placebo ITX 5061|"For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days."
396736|NCT01165346|Radiation|Fiducials|Implantation of fiducials
396737|NCT01165346|Radiation|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
396738|NCT01165333|Drug|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.~The Cilengitide dose (mg/m²/infusion)levels are as follows :~240~480~720~1200~1800"
396739|NCT01165333|Drug|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
396740|NCT01165333|Radiation|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
396741|NCT01165333|Biological|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
396742|NCT01165333|Biological|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
396743|NCT01165333|Biological|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
396744|NCT01165320|Drug|Caspofungin|
396745|NCT01165307|Drug|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
396746|NCT01165307|Drug|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
396747|NCT01165307|Device|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
396748|NCT01165294|Drug|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
396749|NCT01165294|Drug|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
396750|NCT01165281|Drug|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
396751|NCT01165281|Drug|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
396752|NCT01165268|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
396753|NCT01165255|Drug|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
396796|NCT01164969|Drug|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
396797|NCT01164956|Drug|methylphenidate|
396798|NCT01164956|Other|Placebo|
396799|NCT01164943|Procedure|Stimulation with human FSH|Human FSH
396800|NCT01164943|Procedure|Stimulation with recombinant FSH|Recombinant FSH
396801|NCT01164930|Behavioral|Acceptance and Commitment Therapy|8-week ACT group
396964|NCT01163630|Drug|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
396754|NCT01165255|Drug|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
396755|NCT01165255|Drug|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
396756|NCT01165242|Biological|Meningococcal vaccine GSK 134612|One intramuscular injection
396757|NCT01165242|Biological|Menactra®|One intramuscular injection
396758|NCT01165229|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
396759|NCT01165229|Biological|Placebo|Intramuscular injection.
396760|NCT01165216|Drug|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
396761|NCT01165216|Drug|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
396762|NCT01165216|Drug|Paclitaxel|IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
396763|NCT01165216|Drug|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
396764|NCT01165203|Biological|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
396765|NCT01165203|Biological|Placebo|intramuscular injection
396766|NCT01165177|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
396767|NCT01165177|Biological|Placebo|Intramuscular injection
396768|NCT01165164|Other|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
396769|NCT01165151|Behavioral|behavioral weight loss program|weekly, group-based lifestyle weight loss program
396770|NCT01165138|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
396771|NCT01165138|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
396772|NCT01165138|Drug|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
396773|NCT01165125|Drug|FF / GW642444|200mcg/25mcg Novel DPI
396774|NCT01165125|Drug|ketoconazole|400mcg overencapsulated tablets
396775|NCT01165125|Drug|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
396776|NCT01165112|Drug|Bendamustine Hydrochloride|Given IV
396777|NCT01165112|Drug|Carboplatin|Given IV
396778|NCT01165112|Biological|Rituximab|Given IV
396779|NCT01165112|Drug|Etoposide|Given IV
396780|NCT01165112|Other|Laboratory Biomarker Analysis|Correlative studies
396781|NCT01165099|Procedure|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
396782|NCT01165086|Other|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
396783|NCT01165073|Dietary Supplement|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
396784|NCT01165073|Dietary Supplement|Normal oral intake & supplementation if necessary|Enteral nutrition
396785|NCT01165060|Drug|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
396786|NCT01165047|Drug|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
396787|NCT01165034|Other|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
396788|NCT01165021|Drug|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
396789|NCT01165021|Drug|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
396790|NCT01165021|Drug|Folic Acid|Administered orally.
396791|NCT01165021|Drug|Vitamin B12|Administered Intramuscular injection.
396792|NCT01165021|Drug|Dexamethasone|Administered orally.
396793|NCT01165008|Drug|Anakinra|
396794|NCT01164995|Drug|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
396795|NCT01164982|Device|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
396802|NCT01164917|Drug|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
396803|NCT01164917|Drug|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
396804|NCT01164904|Drug|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
396805|NCT01164891|Drug|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
396806|NCT01164865|Device|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
396807|NCT01164865|Device|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
396808|NCT01164865|Device|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
396809|NCT01164852|Procedure|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
396810|NCT01164826|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
396811|NCT01164826|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
396812|NCT01164813|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
396813|NCT01164813|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
396814|NCT01164800|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
396815|NCT01164800|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
396816|NCT01164787|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
396817|NCT01164787|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
396818|NCT01164774|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
396819|NCT01164774|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
396820|NCT01164761|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
396821|NCT01164761|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
396822|NCT01164748|Radiation|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
396823|NCT01164735|Other|Laboratory Biomarker Analysis|Correlative studies
396824|NCT01164722|Other|clinical observation|Patients undergo observation
396825|NCT01164722|Device|infrared photocoagulation therapy|Anal infrared coagulator ablation
396826|NCT01164709|Drug|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
396827|NCT01164709|Drug|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
396828|NCT01164696|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
396829|NCT01164683|Behavioral|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
396830|NCT01164683|Other|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
396831|NCT01164657|Device|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
396832|NCT01164644|Drug|Arnica montana|Subjects will take twelve pills by mouth three times a day over four days.
396833|NCT01164644|Drug|Placebo|Subjects will take twelve pills by mouth three times a day over four days.
396834|NCT01164631|Device|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
396835|NCT01164618|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
396836|NCT01164618|Other|Exercise|Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
396837|NCT01164605|Drug|Raltegravir|60 tablets (30-day supply)
396838|NCT01164592|Device|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
396839|NCT01164579|Drug|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
396840|NCT01164579|Drug|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
396841|NCT01164579|Drug|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
396842|NCT01164566|Procedure|endoscopic procedure|
396844|NCT01164553|Biological|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
396845|NCT01164540|Drug|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
396846|NCT01164540|Drug|Placebo|Oral dose (od)
396847|NCT01164514|Biological|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
396848|NCT01164514|Biological|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
396849|NCT01164514|Drug|Placebo|Normal saline.
396850|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
396851|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
396852|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
396853|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
396854|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
396855|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
396856|NCT01164488|Drug|danoprevir|Repeated daily doses
396857|NCT01164488|Drug|ketoconazole|Repeated daily doses
396858|NCT01164488|Drug|ritonavir|Repeated daily doses
396859|NCT01164475|Drug|Granulocyte-colony stimulating factor (G-CSF)|
396860|NCT01164475|Drug|Fixed Dose Plerixafor|
396861|NCT01164475|Drug|Weight-Based Plerixafor|
396862|NCT01164462|Biological|blood test: rapid finger-stick blood specimen test|
396863|NCT01164462|Biological|blood test: conventional test|
396864|NCT01164449|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
396865|NCT01164423|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
396866|NCT01164384|Drug|Baminercept|
396867|NCT01164345|Drug|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
396868|NCT01164332|Other|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
396869|NCT01164319|Procedure|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.~The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
396870|NCT01164306|Behavioral|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.~Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
396871|NCT01164306|Behavioral|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.~Parents will also be given health related information by mail to parallel the information students receive in school health classes."
396872|NCT01164306|Behavioral|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
396873|NCT01164293|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
396874|NCT01164280|Other|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
396875|NCT01164267|Drug|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
396876|NCT01164228|Drug|gemcitabine hydrochloride|Given IV
396877|NCT01164228|Drug|sunitinib malate|Given
396878|NCT01164215|Drug|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
396879|NCT01164215|Drug|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
396880|NCT01164215|Drug|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
396881|NCT01164202|Drug|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
396882|NCT01164202|Drug|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
396883|NCT01164202|Procedure|transarterial chemoembolization|Chimioembolisation
396884|NCT01164189|Biological|Bevacizumab|Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
396885|NCT01164189|Drug|Temozolomide|Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
396886|NCT01164176|Drug|everolimus|
396887|NCT01164176|Other|laboratory biomarker analysis|
396888|NCT01164163|Drug|ruxolitinib phosphate|
396889|NCT01164163|Other|laboratory biomarker analysis|
396890|NCT01164163|Other|pharmacological study|
397208|NCT01161524|Drug|Placebo|Matching Placebo taken once daily.
396891|NCT01164150|Radiation|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
396892|NCT01164137|Behavioral|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
396893|NCT01164124|Dietary Supplement|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
396894|NCT01164124|Other|Placebo|routine feedings
396895|NCT01164111|Other|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
396896|NCT01164098|Drug|Rituximab|Induction therapy
396897|NCT01164085|Drug|Intravitreal Ketorolac|4mg of intravitreal ketorolac
396898|NCT01164059|Drug|Olanzapine|Olanzapine 10, 15, or 20 mg / day
396899|NCT01164059|Drug|Flupentixol|Flupentixol 6, 9, or 12 mg / day
396900|NCT01164059|Drug|Quetiapine|Quetiapine 400, 600, or 800 mg / day
396901|NCT01164059|Drug|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
396902|NCT01164059|Drug|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
396903|NCT01164046|Drug|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
396904|NCT01164046|Drug|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
396905|NCT01164033|Drug|RO5045337|single oral dose
396906|NCT01164020|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
396907|NCT01164020|Other|Placebo (Dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
396908|NCT01164020|Other|Resistance training|resistance training twice a week for 24 weeks
396909|NCT01164007|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
396910|NCT01164007|Drug|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 28-day cycle.
396911|NCT01163994|Drug|ceftriaxone|intravenously, 2 g, qd, 15 days
396912|NCT01163994|Drug|doxycycline|orally, 100 mg, bid, 15 days
396913|NCT01163994|Other|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
396914|NCT01163981|Other|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
396915|NCT01163968|Behavioral|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
396916|NCT01163955|Other|Time to fatigue|5 minutes while playing video games
396917|NCT01163942|Drug|G-CSF|Yes/no addition of G-CSF
396918|NCT01163942|Drug|Early retreatment with ATG|Yes/no early retreatment with ATG
396919|NCT01163929|Drug|paclitaxel|"Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks"
396920|NCT01163903|Drug|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
396921|NCT01163903|Drug|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
396922|NCT01163890|Behavioral|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
396923|NCT01163890|Behavioral|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
396924|NCT01163877|Dietary Supplement|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
396925|NCT01163864|Behavioral|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
396926|NCT01163864|Behavioral|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
396927|NCT01163851|Biological|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
396928|NCT01163851|Biological|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
396929|NCT01163838|Biological|Placebo|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
396930|NCT01163838|Biological|1 mg/kg every 2 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
397099|NCT01162603|Drug|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution
396931|NCT01163838|Biological|2 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
396932|NCT01163838|Biological|4 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
396933|NCT01163838|Biological|4 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
396934|NCT01163838|Biological|8 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
396935|NCT01163838|Biological|12 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
396936|NCT01163825|Drug|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
396937|NCT01163812|Procedure|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
396938|NCT01163799|Drug|Alefacept (ASP0485)|Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
396939|NCT01163786|Drug|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
396940|NCT01163773|Other|MILK|"Consumption of the 2 experimental diets~Milk diet~Control diet"
396941|NCT01163760|Device|etafilcon A|daily disposable contact lens
396942|NCT01163760|Device|ocufilcon D|daily disposable contact lens
396943|NCT01163747|Biological|tocilizumab|Intravenous repeating dose
396944|NCT01163747|Drug|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
396945|NCT01163747|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
396946|NCT01163747|Biological|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
396947|NCT01163734|Drug|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
396948|NCT01163734|Other|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
396949|NCT01163721|Drug|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
396950|NCT01163721|Drug|Placebo|Placebo to match ranolazine administered orally twice daily
396951|NCT01163708|Device|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
396952|NCT01163708|Device|Navigation System|
396953|NCT01163695|Behavioral|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families—and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
396954|NCT01163682|Other|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
396955|NCT01163682|Other|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The elecrto-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
396956|NCT01163656|Device|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
396957|NCT01163656|Device|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
396958|NCT01163643|Drug|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
396959|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
396960|NCT01163643|Drug|Placebo Comparator: Vehicle|Placebo Comparator: Vehicle BID for 12 weeks.
396961|NCT01163643|Drug|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
396962|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension AM|2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
396963|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension PM|Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
396965|NCT01163617|Device|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
396966|NCT01163617|Device|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
396967|NCT01163617|Device|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
396968|NCT01163617|Device|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
396969|NCT01163604|Drug|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
396970|NCT01163604|Drug|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
396971|NCT01163565|Device|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
396972|NCT01163552|Procedure|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
396973|NCT01163526|Procedure|CT perfusion|
396974|NCT01163500|Dietary Supplement|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
396975|NCT01163500|Other|Placebo|Placebo controlled (dextrin)
396976|NCT01163487|Drug|Dichloroacetate|25-50mg/kg per day; oral
396977|NCT01163487|Device|EF5|21 mg/kg; IV
396978|NCT01163474|Other|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
396979|NCT01163461|Behavioral|speech therapy|individuals will receive 60 hours of behavioral speech therapy
396980|NCT01163448|Radiation|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
396981|NCT01163435|Drug|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
396982|NCT01163435|Drug|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
396983|NCT01163435|Drug|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
396984|NCT01163435|Drug|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
396985|NCT01163422|Device|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
396986|NCT01163409|Procedure|exercise training|exercise training comprises aerobic and strength training
396987|NCT01163409|Procedure|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
396988|NCT01163409|Procedure|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
396989|NCT01163396|Drug|Bevacizumab|
396990|NCT01163396|Drug|Irinotecan|
396991|NCT01163396|Drug|Oxaliplatin|
396992|NCT01163396|Drug|5-fluorouracil/leucovorin|
396993|NCT01163383|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
396994|NCT01163383|Drug|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
396995|NCT01163370|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
396996|NCT01163370|Other|exercise training|resistance training twice a week for 24 weeks
396997|NCT01163370|Other|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
396998|NCT01163357|Drug|bortezomib|Given IV
396999|NCT01163357|Drug|fludarabine phosphate|Given IV
397000|NCT01163357|Other|melphalan|Given IV
397001|NCT01163357|Radiation|total marrow irradiation|Undergo TMI
397002|NCT01163357|Drug|tacrolimus|Given IV and orally
397003|NCT01163357|Drug|sirolimus|Given orally
397004|NCT01163357|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
397005|NCT01163357|Other|laboratory biomarker analysis|Correlative studies
397006|NCT01163331|Other|Singing Therapy|Singing therapy as a way to improve voice quality
397007|NCT01163305|Drug|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
397008|NCT01163279|Behavioral|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
397009|NCT01163279|Behavioral|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
397010|NCT01163266|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
397011|NCT01163266|Drug|Placebo|Vortioxetine placebo-matching capsules
397012|NCT01163253|Drug|CP-690,550|5 mg oral BID
397013|NCT01163253|Drug|CP-690,550|10 mg oral BID
397014|NCT01163227|Drug|Placebo (single and multiple doses)|
397015|NCT01163227|Drug|AQW051 2 mg (single and multiple doses)|
397016|NCT01163227|Drug|AQW051 15mg (single and multiple doses)|
397017|NCT01163227|Drug|AQW051 100mg (single dose), and 50mg (multiple doses)|
397018|NCT01163214|Drug|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
397019|NCT01163214|Drug|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
397020|NCT01163201|Biological|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10^6/kg, 10 x 10^6/kg, 30 x 10^6/kg, 100 x 10^6/kg and 300 x 10^6/kg)
397021|NCT01163201|Biological|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10^6 cells/kg, 6 x 10^6 cells/kg, 9 x 10^6 cells/kg, 12 x 10^6 cells/kg, and 15 x 10^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
397022|NCT01163201|Drug|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m^2 over 1 hour
397023|NCT01163201|Drug|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
397024|NCT01163201|Radiation|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
397025|NCT01163201|Biological|Umbilical cord blood transplantation|Infusion given on day 0
397026|NCT01163175|Other|Ruminant trans fats|"Consumption of the 4 experimental diets:~a diet rich in ruminant TFA (8 g/day);~a diet moderately rich in ruminant TFA (4 g/day);~a diet rich in industrial TFA (8 g/d);~a control diet (minimal dietary TFA of industrial and ruminant sources)."
397027|NCT01163162|Drug|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
397028|NCT01163149|Drug|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
397029|NCT01163149|Drug|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
397030|NCT01163110|Dietary Supplement|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
397031|NCT01163097|Drug|Palifermin|40 µg/kg IV bolus injections for three consecutive days
397032|NCT01163097|Drug|Heparin|Heparin continuous IV infusion
397033|NCT01163084|Drug|Goserelin Acetate|Given SC
397034|NCT01163084|Other|Laboratory Biomarker Analysis|Correlative studies
397035|NCT01163084|Drug|Leuprolide Acetate|Given IM
397036|NCT01163084|Drug|Vismodegib|Given PO
397037|NCT01163071|Drug|ABI-011|ABI-011
397038|NCT01163045|Procedure|thyroidectomy|total thyroidectomy and lobectomy
397039|NCT01163032|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
397040|NCT01163032|Drug|Placebo|Placebo capsules, PO daily for 6 months
397041|NCT01163006|Other|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
397042|NCT01162993|Procedure|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
397043|NCT01162967|Drug|Benznidazole|Standard dosage
397044|NCT01162967|Drug|Posaconazole|
397045|NCT01162954|Drug|DA-6034|
397046|NCT01162954|Drug|Placebo|
397047|NCT01162941|Other|Steroid refractory ITP|a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
397048|NCT01162928|Drug|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
397049|NCT01162928|Drug|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
397050|NCT01162915|Biological|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
397051|NCT01162902|Drug|Diltiazem treated group|Diltiazem 180mg for 9 months
397052|NCT01162902|Drug|Bisoprolol treated group|Bisoprolol 5mg for 9 months
397053|NCT01162902|Drug|Candesartan treated group|Candesartan 32mg for 9 months
397054|NCT01162889|Drug|Placebo SC Injection|Single injection
397055|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
397056|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
397057|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
397058|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
397059|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
397060|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
397061|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
397062|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
397063|NCT01162889|Drug|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
397064|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
397065|NCT01162876|Drug|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
397066|NCT01162863|Drug|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
397067|NCT01162863|Drug|Placebo|taken orally for 28 days
397068|NCT01162863|Other|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
397069|NCT01162850|Dietary Supplement|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
397070|NCT01162850|Dietary Supplement|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
397071|NCT01162837|Device|BEAM device|A red/blue LED device for the treatment of acne
397072|NCT01162824|Drug|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
397073|NCT01162824|Drug|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
397074|NCT01162811|Behavioral|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
397075|NCT01162798|Other|infant formula|test infant formula fed to infants until 6 months corrected gestational age
397076|NCT01162798|Other|control infant formula|commercially available infant formula
397077|NCT01162785|Drug|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
397078|NCT01162759|Behavioral|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
397079|NCT01162746|Drug|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.~Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
397080|NCT01162746|Drug|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
397081|NCT01162733|Drug|Vancomycin|15mg/kg
397082|NCT01162733|Drug|Vancomycin|30mg/kg
397083|NCT01162720|Procedure|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
397084|NCT01162720|Procedure|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
397085|NCT01162707|Device|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
397086|NCT01162694|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
397087|NCT01162694|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
397088|NCT01162681|Drug|A-623|High dose given subcutaneously once a week for up to 52 weeks
397089|NCT01162681|Drug|A-623|Low dose given subcutaneously once a week for up to 52 weeks
397090|NCT01162681|Drug|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
397091|NCT01162681|Other|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
397092|NCT01162655|Behavioral|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
397093|NCT01162642|Dietary Supplement|Green Tea|Green Tea 4 cups daily
397094|NCT01162642|Other|Placebo|4 cups placebo tea for 6 weeks
397095|NCT01162629|Device|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
397096|NCT01162616|Dietary Supplement|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
397097|NCT01162603|Device|Goldmann and Perkins applanation tonometry|IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
397098|NCT01162603|Drug|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution
397102|NCT01162577|Behavioral|Weight Concerns|Standard Quitline plus weight coaching
397103|NCT01162564|Device|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
397104|NCT01162551|Drug|Sirolimus and Methotrexate|"Single Arm Efficacy Trial:~Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.~Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.~One cycle is 28 days."
397105|NCT01162525|Procedure|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
397106|NCT01162512|Behavioral|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
397107|NCT01162499|Drug|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
397108|NCT01162499|Other|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
397109|NCT01162486|Drug|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
397110|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
397111|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
397112|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
397113|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
397114|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
397115|NCT01162473|Dietary Supplement|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
397116|NCT01162473|Drug|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
397117|NCT01162473|Other|Food Challenge|
397118|NCT01162460|Drug|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.~Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.~Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.~Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
397119|NCT01162421|Biological|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
397120|NCT01162421|Drug|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
397121|NCT01162395|Drug|AZD3514|Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
397122|NCT01162382|Device|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
397123|NCT01162330|Other|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
397124|NCT01162317|Other|Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
397125|NCT01162317|Other|Sham Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
397126|NCT01162304|Drug|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
397127|NCT01162304|Drug|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
397128|NCT01162278|Radiation|SBRT|Single fraction SBRT
397163|NCT01161927|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
397164|NCT01161927|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
397165|NCT01161914|Drug|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
397166|NCT01161914|Drug|ISU302|administered by IV infusion for a dose of 60 U/kg
397207|NCT01161524|Drug|Perampanel|2 mg titrated up to 8-12 mg maximum; taken once daily.
397129|NCT01162252|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
397130|NCT01162252|Behavioral|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
397131|NCT01162239|Drug|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.
397132|NCT01162239|Behavioral|Individual counseling|Five 90 minute individual counseling sessions.
397133|NCT01162239|Behavioral|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
397134|NCT01162239|Behavioral|individual counseling|Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.
397135|NCT01162226|Behavioral|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
397136|NCT01162213|Dietary Supplement|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
397137|NCT01162200|Radiation|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
397138|NCT01162174|Dietary Supplement|Oligonol|
397139|NCT01162148|Behavioral|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
397140|NCT01162148|Device|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
397141|NCT01162148|Device|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
397142|NCT01162148|Device|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
397143|NCT01162135|Drug|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
397144|NCT01162122|Biological|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
397145|NCT01162122|Biological|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
397146|NCT01162109|Dietary Supplement|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.~A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
397147|NCT01162096|Device|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
397148|NCT01162070|Other|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
397149|NCT01162070|Other|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
397150|NCT01162044|Other|Computer game|Playing with specially designed computer game while in emergency room
397151|NCT01162031|Drug|Velcade|IV
397152|NCT01162018|Procedure|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
397153|NCT01162018|Other|placebo|
397154|NCT01162005|Drug|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
397155|NCT01161992|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
397156|NCT01161979|Drug|Zonisamide|Zonisamide capsules 100 mg
397157|NCT01161979|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
397158|NCT01161966|Drug|Zonisamide|Zonisamide capsules 100 mg
397159|NCT01161966|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
397160|NCT01161953|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
397161|NCT01161940|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
397162|NCT01161940|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
397205|NCT01161537|Drug|VX-770|Tablet.
397167|NCT01161901|Procedure|blood sample|"This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.~The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS."
397168|NCT01161888|Drug|Imiquimod|250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.
397169|NCT01161875|Device|Neurally Adjusted Ventilatory Assistance|"In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:~facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation~helmet use with non-invasive pressure support ventilation mode to define adequate settings~helmet use with neurally adjusted ventilatory assist mode, based on previous settings"
397170|NCT01161862|Device|Bi-hormonal (insulin and glucagon) artificial pancreas|Subjects wore a bionic pancreas consisting of a continuous glucose monitor, an insulin pump and a glucagon pump
397171|NCT01161836|Drug|Iniparib|"Solution for infusion~60-minute intravenous infusion"
397172|NCT01161810|Other|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
397173|NCT01161784|Dietary Supplement|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
397174|NCT01161784|Dietary Supplement|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
397175|NCT01161771|Procedure|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
397176|NCT01161758|Other|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
397177|NCT01161758|Other|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
397178|NCT01161732|Procedure|Early surgery|Early surgery is performed within 2 months of randomization.
397179|NCT01161719|Behavioral|parent training|Behavioral management skill training
397180|NCT01161706|Other|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
397181|NCT01161693|Device|TROOP® elevation pillow|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
397182|NCT01161693|Device|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
397183|NCT01161693|Device|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
397184|NCT01161667|Drug|naratriptan hydrochloride|2.5 mg tablet
397185|NCT01161654|Drug|naratriptan hydrochoride|2.5 mg tablet
397186|NCT01161641|Drug|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
397187|NCT01161641|Drug|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
397188|NCT01161641|Drug|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
397189|NCT01161628|Drug|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
397190|NCT01161615|Drug|MRX-7EAT|Application of up to two patches for up to 7 days.
397191|NCT01161615|Drug|Placebo|Application of up to two patches for up to 7 days.
397192|NCT01161602|Drug|Pumosetrag|
397193|NCT01161602|Drug|Pumosetrag|
397194|NCT01161602|Other|Placebo|
397195|NCT01161602|Drug|Pumosetrag|
397196|NCT01161576|Biological|AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
397197|NCT01161576|Biological|AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
397198|NCT01161563|Drug|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
397199|NCT01161563|Drug|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
397200|NCT01161550|Drug|Granulocyte colony-stimulating factor (G-CSF)|
397201|NCT01161550|Drug|Cladribine|
397202|NCT01161550|Drug|Cytarabine|
397203|NCT01161550|Drug|All-Trans Retinoic Acid (ATRA)|
397204|NCT01161550|Drug|Midostaurin|
397209|NCT01161511|Biological|XmAb5574|Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
397210|NCT01161498|Biological|Talimogene Laherparepvec|Administered by intratumoral injection
397211|NCT01161498|Radiation|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
397212|NCT01161498|Drug|Cisplatin|Administered by intravenous infusion
397213|NCT01161485|Behavioral|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
397214|NCT01161485|Behavioral|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
397215|NCT01161485|Behavioral|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
397216|NCT01161472|Drug|4mg fesoterodine|4mg tablet once daily for 6 days
397217|NCT01161472|Drug|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
397218|NCT01161472|Drug|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
397219|NCT01161472|Drug|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
397220|NCT01161459|Drug|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
397221|NCT01161459|Drug|FK506|capsule
397222|NCT01161446|Behavioral|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
397223|NCT01161446|Device|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
397224|NCT01161433|Behavioral|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.~The program includes:~Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;~Case-based, interactive webinars; and~an Internet-based spirometry quality feedback reporting system."
397225|NCT01161420|Device|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
397226|NCT01161407|Dietary Supplement|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
397227|NCT01161407|Dietary Supplement|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
397228|NCT01161394|Drug|Pioglitazone 15mg|
397229|NCT01161394|Drug|pioglitazone 30mg|
397230|NCT01161394|Drug|placebo|
397231|NCT01161381|Device|Estimation of nonlinear indices from Polysomnography|All subjects underwent full night polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) were extracted from three biosignals (airflow from a nasal cannula, thoracic movement and Oxygen saturation) providing input to a data mining application for the creation of predictive models for AHI.
397232|NCT01161368|Drug|Lapatinib, Vinorelbine|"Lapatinib 1250mg orally once daily continuously~plus~Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
397233|NCT01161355|Drug|AZD9668|Tablets of AZD9668 and IV dose of [C14]AZD9668
397234|NCT01161329|Other|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
397235|NCT01161316|Drug|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
397236|NCT01161316|Drug|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
397237|NCT01161290|Behavioral|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
397238|NCT01161277|Drug|Aripiprazole|Dose: 5-10 mg depending on subject weight
397239|NCT01161277|Drug|Haloperidol|Dose: 1-2 mg depending on subject weight
397240|NCT01161277|Drug|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
397241|NCT01161264|Biological|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
397242|NCT01161238|Other|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
397243|NCT01161225|Behavioral|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
397244|NCT01161225|Behavioral|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
397245|NCT01161212|Other|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
397246|NCT01161212|Other|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
397247|NCT01161199|Procedure|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
397248|NCT01161186|Drug|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
397249|NCT01161173|Drug|Erlotinib|Erlotinib was provided in the retail versions of the product.
397250|NCT01161160|Biological|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
397251|NCT01161160|Biological|GSK Biologicals' - GSK2340272A|Intramuscular injection
397252|NCT01161147|Drug|Meloxicam|Meloxicam Tablets 15 mg
397253|NCT01161134|Drug|Meloxicam|Meloxicam Tablets 15 mg
397254|NCT01161121|Drug|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
397255|NCT01161121|Drug|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
397256|NCT01161108|Drug|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
397257|NCT01161108|Drug|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
397258|NCT01161108|Drug|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.~The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
397259|NCT01161108|Drug|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.~The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
397260|NCT01161095|Device|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
397261|NCT01161082|Drug|REGN727(SAR236553)|subcutaneous
397262|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
397263|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
397264|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
397265|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
397266|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
397267|NCT01161069|Drug|Placebo|Placebo in oral solution, given once daily for 14 days
397268|NCT01161030|Dietary Supplement|Almonds|
397269|NCT01161017|Drug|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
397270|NCT01161017|Drug|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
397271|NCT01161004|Drug|Sugammadex - Nacl 9/00|"Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.~Nacl 9/00: same volume as Sugammadex"
397272|NCT01161004|Drug|Nacl 9/00 - sugammadex|"Nacl 9/00: same volume as Sugammadex~Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
397273|NCT01160991|Procedure|Glucose clamp technique|euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
397274|NCT01160991|Drug|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
397275|NCT01160991|Drug|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
397276|NCT01160991|Drug|Placebo|Placebo capsules are given at 8:00 a.m.
397277|NCT01160978|Drug|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
397278|NCT01160978|Drug|Control Rx|The transplant recipients who have received an organ from non-treated donors.
397279|NCT01160965|Drug|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
397280|NCT01160965|Drug|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
397281|NCT01160952|Drug|itraconazole|the two groups are defined by different treatment duration
397282|NCT01160939|Other|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
397283|NCT01160926|Drug|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd~Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
397284|NCT01160926|Drug|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od~Oral tablets"
397285|NCT01160913|Procedure|Continuous wound infusion|
397286|NCT01160913|Procedure|Continuous wound|
397287|NCT01160900|Procedure|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
397288|NCT01160874|Other|Polysomnography|Sleep study monitoring
397289|NCT01160874|Other|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
397290|NCT01160874|Behavioral|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
397291|NCT01160874|Other|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
397292|NCT01160861|Drug|MEMP1972A|Repeating ascending dose
397293|NCT01160861|Drug|placebo|Repeating ascending dose
397294|NCT01160848|Drug|Area cleaned with saline water and occluded with Tegaderm|
397295|NCT01160848|Drug|Area cleaned with saline water|
397296|NCT01160848|Drug|Area cleaned with Ethyl alcohol solution|
397297|NCT01160848|Drug|Visonac left on the skin for 24 hours in facial area one|
397298|NCT01160848|Drug|Visonac wiped off after one hour|
397299|NCT01160848|Drug|Visonac left on the skin 24 hours in facial area two|
397300|NCT01160835|Procedure|total knee arthroplastyinstruments|Quadriceps-sparing arthrotomy with side-cutting instruments
397301|NCT01160822|Biological|Canakinumab|Intra-articular injection
397302|NCT01160822|Drug|Placebo to canakinumab|Intra-articular injection
397303|NCT01160822|Drug|Naproxen|Tablets for oral administration
397304|NCT01160822|Drug|Placebo to Naproxen|Tablets for oral administration
397305|NCT01160809|Other|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
397306|NCT01160796|Drug|placebo|1x14-day course of treatment during 4 cycles
397307|NCT01160796|Drug|Lcr35®|1x14-day course of treatment during 4 cycles
397308|NCT01160770|Drug|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
397309|NCT01160757|Device|ultrasound|ultrasound exposure on acute acne lesions
397310|NCT01160744|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
397311|NCT01160744|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
397312|NCT01160744|Drug|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
397313|NCT01160744|Drug|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
397314|NCT01160744|Drug|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
397315|NCT01160744|Drug|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
397316|NCT01160731|Drug|cisplatin|
397317|NCT01160731|Drug|etoposide phosphate|
397318|NCT01160731|Drug|panobinostat|
397319|NCT01160731|Other|laboratory biomarker analysis|
397320|NCT01160731|Other|pharmacological study|
397321|NCT01160718|Drug|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
397322|NCT01160718|Drug|selumetinib|AZD6244 75 mg p.o. bid
397323|NCT01160705|Drug|docetaxel|
397324|NCT01160705|Genetic|RNA analysis|
397325|NCT01160705|Genetic|reverse transcriptase-polymerase chain reaction|
397326|NCT01160705|Other|circulating tumor cell analysis|
397327|NCT01160705|Other|laboratory biomarker analysis|
397328|NCT01160692|Dietary Supplement|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
397329|NCT01160692|Other|Placebo|Daily oral intake of matching placebo tablets for 3 months
397330|NCT01160666|Drug|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
397331|NCT01160653|Device|FES-IM|implantable Functional Electrical Stimulation
397332|NCT01160653|Other|Cognitive training|training of impaired cognitive processes
397333|NCT01160640|Drug|Ceftriaxone|ceftrixone 250mg IM single dose
397334|NCT01160640|Drug|Doxycycline|Doxycycline 100 mg PO bid x 14 days
397335|NCT01160640|Drug|Metronidazole|metronidazole 500 mg PO bid x 14 days
397336|NCT01160640|Drug|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
397337|NCT01160627|Other|Hydration|Saline hydration
397338|NCT01160627|Drug|Acetylcysteine|Acetylcystein tablets for 2 days
397339|NCT01160627|Drug|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
397340|NCT01160627|Drug|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
397341|NCT01160614|Drug|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
397342|NCT01160601|Drug|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
397343|NCT01160601|Drug|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
397344|NCT01160588|Drug|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
397345|NCT01160484|Drug|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
397346|NCT01160458|Drug|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
397347|NCT01160445|Drug|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
397348|NCT01160445|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
397349|NCT01160432|Drug|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient`s individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week`s periods for four weeks.
397350|NCT01160419|Drug|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
397351|NCT01160419|Drug|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
397352|NCT01160419|Drug|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
397353|NCT01160419|Drug|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
397354|NCT01160393|Device|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
397355|NCT01160380|Drug|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
397356|NCT01160380|Drug|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
397357|NCT01160367|Other|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
397358|NCT01160367|Other|standard of care|Patient-family dyads will receive standard of care in health decision-making
397359|NCT01160354|Drug|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
397360|NCT01160354|Drug|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
397361|NCT01160341|Drug|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
397362|NCT01160328|Drug|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
397363|NCT01160328|Drug|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
397364|NCT01160315|Drug|Triptorelin|Triptorelin: intramusculAR injection every 3 months
397365|NCT01160315|Drug|Norethisterone acetate|5 mg/day per os until during chemotherapy
397366|NCT01160302|Drug|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
397367|NCT01160289|Drug|LY2452473|Administered orally, once daily for 12 weeks
397368|NCT01160289|Drug|tadalafil|Administered orally, once daily for 12 weeks
397369|NCT01160289|Drug|placebo (tadalafil)|Administered orally, once daily for 12 weeks
397370|NCT01160289|Drug|placebo (LY2452473)|Administered orally, once daily for 12 weeks
397371|NCT01160276|Drug|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
397372|NCT01160276|Drug|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
397373|NCT01160263|Drug|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.~123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
397374|NCT01160250|Drug|vismodegib (GDC-0449)|Oral repeating dose
397375|NCT01160237|Biological|PandemrixTM|One dose intramuscular injection
397376|NCT01160237|Biological|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
397377|NCT01160224|Drug|GW766944|Drug: GW766944 (Active Drug Treatment)
397378|NCT01160224|Other|Placebo|This is placebo to match.
397379|NCT01160211|Drug|lapatinib|1000 mg by mouth once a day
397380|NCT01160211|Drug|trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
397381|NCT01160211|Drug|Aromatase inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
397382|NCT01160211|Drug|lapatinib|1500 mg by mouth once daily
397383|NCT01160198|Drug|ferrous ascorbate|100 mg elemental iron
397384|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
397385|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
397386|NCT01160185|Drug|paclitaxel|paclitacel
397387|NCT01160185|Drug|cisplatin|cisplatin monotherapy
397388|NCT01160185|Drug|topotecan|topotecan
397389|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
397390|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
397391|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
397392|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
397393|NCT01160172|Drug|Saline placebo|intramuscular vaccination according to protocol schedule
397394|NCT01160159|Other|Tests|Arterial parameters
397395|NCT01160159|Other|Healthy volunteers|Arterial parameters and blood test
397396|NCT01160133|Other|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
397397|NCT01160133|Other|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
397398|NCT01160120|Drug|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
397399|NCT01160107|Drug|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR > 50%; 2. The study stop (if PR <40% and grade 3-4 adverse events >25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are < 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are > 50% and PR rate > 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
397400|NCT01160094|Drug|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
397401|NCT01160081|Other|Serum sample|Serum samples collected
397402|NCT01160068|Drug|Metformin|Metformin Tablets 1000 mg
397403|NCT01160068|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
397404|NCT01160055|Procedure|Middle ear fluid and urine.|Middle ear fluid and urine collection.
397405|NCT01160042|Drug|Metformin|Metformin Tablets 1000 mg
397406|NCT01160042|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
397407|NCT01160029|Drug|Nateglinide|Nateglinide Tablets 120 mg
397408|NCT01160003|Drug|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
397409|NCT01160003|Drug|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
397410|NCT01159990|Biological|rAd5 Gag-Pol Env A/B/C|1×10^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
397411|NCT01159990|Biological|rAd5 Gag-Pol|5×10^9 PU rAd5 Gag-Pol delivered via intramuscular injection
397412|NCT01159977|Behavioral|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
397413|NCT01159977|Behavioral|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
397414|NCT01159977|Behavioral|Usual practice|No protected time provided.
397415|NCT01159964|Biological|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
397416|NCT01159951|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
397417|NCT01159938|Drug|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
397418|NCT01159925|Procedure|Serum sample|Serum samples collected
397419|NCT01159912|Drug|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
397420|NCT01159912|Drug|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
397421|NCT01159912|Drug|Placebo|Placebo inhalation powder
397422|NCT01159899|Procedure|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
397423|NCT01159886|Procedure|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.~Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
397424|NCT01159873|Drug|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
397425|NCT01159873|Drug|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
397426|NCT01159860|Procedure|cryosurgery|freezing of lesion with liquid nitrogen
397427|NCT01159860|Procedure|Curettage|the lesion will be anesthetized and destroyed with a curette.
397428|NCT01159847|Drug|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
397429|NCT01159847|Drug|Insulin|
397430|NCT01159821|Drug|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
397431|NCT01159808|Drug|INX-08189|3, 25 and 100 mg capsules; oral administration, single dose
397432|NCT01159808|Drug|Placebo|matching placebo capsules, oral administration, single dose
397433|NCT01159782|Other|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
397434|NCT01159769|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
397435|NCT01159756|Drug|Travacom|Travacom ophthalmic solution (1 drop per day)
397436|NCT01159730|Drug|VB-201 or Placebo|
397437|NCT01159704|Behavioral|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
397438|NCT01159704|Behavioral|HIV Counseling and Education Model|"The C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
397439|NCT01159678|Behavioral|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:~Important of sexuality to quality of life. & Definitions of sexual desire and arousal.~Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.~Sexual beliefs.~Mindfulness.~Genital anatomy and physiology.~Body Image.~Relationship satisfaction and communication.~Body-oriented mindfulness exercises (focusing and self-observation).~Using Thought records.~Mindfulness and the thought stream.~Sexual aids to boost arousal.~Moving on.~In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
397440|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
397441|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
397442|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
397443|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
397444|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
397445|NCT01159652|Drug|zaleplon|10 mg
397446|NCT01159652|Drug|zolpidem extended release|12.5 mg
397447|NCT01159652|Drug|bedtime placebo|placebo
397448|NCT01159652|Drug|middle of the night placebo|placebo
397449|NCT01159639|Drug|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
397450|NCT01159626|Drug|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
397451|NCT01159626|Drug|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
397452|NCT01159626|Drug|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
397453|NCT01159626|Drug|Placebo|Oral single dose as matching placebo
397454|NCT01159626|Drug|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
397455|NCT01159626|Drug|Placebo|Oral multiple doses as matching placebo for 7 days
397456|NCT01159613|Other|Responders|Responders
397457|NCT01159613|Other|Non Responders|Non Responders
397458|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
397459|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
397460|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose open label
397461|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose
397462|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
397463|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily low dose
397464|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
397465|NCT01159587|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
397466|NCT01159587|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|On-demand treatment with product given only for bleeding episodes
397467|NCT01159574|Drug|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
397468|NCT01159574|Drug|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
397469|NCT01159574|Drug|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
397470|NCT01159561|Biological|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
397471|NCT01159548|Drug|Promethazine|
397472|NCT01159548|Drug|Promethazine|
397473|NCT01159535|Behavioral|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
397474|NCT01159535|Behavioral|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
397475|NCT01159535|Behavioral|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
397476|NCT01159522|Drug|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
397477|NCT01159509|Behavioral|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
397478|NCT01159496|Drug|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
397479|NCT01159496|Drug|Placebo|Oral capsule, once daily for 14 days
397480|NCT01159483|Drug|PF-04958242|oral PIB, single dose, 0.01 mg, 0.03 mg, 0.1 mg
397481|NCT01159483|Drug|PF-04958242|"oral PIB, single dose, 0.3 mg, 0.6 mg*, 1.0 mg*~*Unlikely to be administered as expected to exceed exposure limits."
397482|NCT01159457|Biological|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
397483|NCT01159457|Biological|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
397484|NCT01159431|Device|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
397485|NCT01159418|Drug|Panobinostat (LBH589), Carboplatin and Paclitaxel|"Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression."
397486|NCT01159405|Radiation|Radiolabeled (99mTc) GP (Glycopeptide)|one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg & 20 mg of GP will be injected
397487|NCT01159379|Drug|ertapenem|intravenous, 1 gram, once
397488|NCT01159366|Procedure|percutaneous coronary intervention|early timing
397489|NCT01159353|Drug|Insulin glulisine|Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
397490|NCT01159353|Drug|Insulin aspart|Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
397491|NCT01159327|Drug|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
397492|NCT01159314|Procedure|Baerveldt Device surgical Procedure|Implant surgery
397493|NCT01159301|Drug|entinostat|Given orally (PO)
397494|NCT01159301|Drug|sorafenib tosylate|Given PO
397495|NCT01159301|Other|pharmacological study|Correlative studies
397496|NCT01159301|Other|laboratory biomarker analysis|Correlative studies
397497|NCT01159288|Biological|Dex2|"Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.~Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)~Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
397498|NCT01159275|Drug|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
397499|NCT01159275|Drug|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
397500|NCT01159262|Drug|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
397501|NCT01159262|Drug|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
397502|NCT01159262|Drug|Dexmedetomidine|
397503|NCT01159249|Drug|Vildagliptin|
397504|NCT01159236|Drug|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
397505|NCT01159236|Drug|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
397506|NCT01159236|Drug|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
397507|NCT01159236|Drug|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
397508|NCT01159236|Drug|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
397509|NCT01159236|Drug|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
397510|NCT01159223|Drug|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
397511|NCT01159210|Biological|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
397512|NCT01159197|Behavioral|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
397513|NCT01159171|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
397514|NCT01159171|Drug|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
397515|NCT01159171|Drug|oxaliplatin|40 mg/m2 iv weekly
397516|NCT01159158|Drug|Nateglinide|Nateglinide Tablets 120 mg
397517|NCT01159145|Drug|D961H|Oral, capsule
397518|NCT01159145|Drug|Omeprazole|Oral, tablet
397519|NCT01159132|Drug|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
397520|NCT01159119|Drug|EUR-1066-A|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
397521|NCT01159119|Drug|Zenpep|Capsules taken for daily for 28 days during treatment period 2
397522|NCT01159119|Drug|EUR-1066-B|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
397523|NCT01159106|Other|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
397524|NCT01159106|Other|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).~The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
397525|NCT01159093|Behavioral|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
397526|NCT01159093|Behavioral|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
397527|NCT01159093|Other|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
397528|NCT01159093|Other|Control|Usual care
397529|NCT01159080|Drug|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
397530|NCT01159080|Drug|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
397531|NCT01159067|Drug|deferasirox|Given orally
397532|NCT01159054|Drug|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
397533|NCT01159041|Behavioral|Family Focused Treatment (FFT)|FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
397534|NCT01159041|Behavioral|Individual Treatment (IP)|The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
397535|NCT01159028|Drug|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
397536|NCT01159028|Drug|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
397537|NCT01159015|Drug|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
397538|NCT01159015|Drug|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
397539|NCT01159002|Device|SmartPill|Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
397540|NCT01158989|Device|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
397541|NCT01158976|Dietary Supplement|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
397542|NCT01158976|Other|Placebo|soybean oils with strawberry flavoring
397543|NCT01158950|Drug|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
397544|NCT01158950|Other|Placebo|Placebo (200mg) administered at study visit
397545|NCT01158950|Drug|Entacapone|Entacapone 200mg (single dose) administered at study visit
397546|NCT01158937|Drug|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
397547|NCT01158924|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
397548|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
397549|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
397550|NCT01158898|Drug|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
397551|NCT01158885|Drug|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
397552|NCT01158885|Drug|Cytarabine intravenous|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
397553|NCT01158885|Drug|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:~8 mg for patients age 1-1.99~10 mg for patients age 2-2.99~12 mg for patients 3-8.99 years of age~15 mg for patients >9 years of age"
397554|NCT01158885|Drug|Intrathecal (IT) Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.~If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.~Dose should be given according to age as defined below:~30 mg for patients age 1-1.99~50 mg for patients age 2-2.99~70 mg for patients >3 years of age"
397555|NCT01158859|Drug|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
397556|NCT01158846|Drug|prasugrel/bivalirudin|60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
397557|NCT01158846|Drug|clopidogrel/abciximab|600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
397558|NCT01158833|Other|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
397559|NCT01158820|Drug|Dexmedetomidine load|Dexmedetomidine 1 µg/kg prior to bronchoscopy
397560|NCT01158820|Drug|Ketamine load|Ketamine 30 mg bolus prior to bronchoscopy
397561|NCT01158820|Drug|Midazolam load|2 mg bolus prior to bronchoscopy
397562|NCT01158820|Drug|Fentanyl load|50 µg bolus prior to bronchoscopy
397563|NCT01158820|Drug|Dexmedetomidine maintenance|0.5 µg/kg/hour for the duration of bronchoscopy (58.5 minutes average)
397564|NCT01158820|Drug|Ketamine maintenance|8 µg/kg/min for the duration of bronchoscopy (58.5 minutes average)
397565|NCT01158820|Drug|Midazolam demand|0.5 mg demand bolus at discretion of pulmonologist
397566|NCT01158820|Drug|Fentanyl demand|12.5 µg demand bolus at discretion of pulmonologist
397567|NCT01158820|Drug|Benadryl demand|25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
397568|NCT01158781|Behavioral|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
397569|NCT01158755|Drug|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
397570|NCT01158742|Other|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
397571|NCT01158742|Other|Glomerular Filtration Rate with Iohexol|used to determine kidney function
397572|NCT01158729|Drug|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = [(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg] X (1 mL/175 Units)
397573|NCT01158729|Other|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = [(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg] X (1 mL/175 Units)
397574|NCT01158716|Other|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
397575|NCT01158703|Drug|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
397576|NCT01158703|Drug|sugar pill|sugar pill by mouth daily for 12 months
397577|NCT01158703|Drug|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
397578|NCT01158690|Other|resource card|the intervention group receives an envelop with resource card
397579|NCT01158690|Other|no resource card|the control group receives an envelop without resource card
397580|NCT01158677|Procedure|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
397581|NCT01158664|Device|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
397582|NCT01158664|Device|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
397583|NCT01158651|Drug|RAD001 (Everolimus)|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).~You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
397584|NCT01158638|Behavioral|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
397585|NCT01158625|Other|Change of time of administration|Change of time of administration
397586|NCT01158612|Drug|Growth Hormone|infusion of Growth hormone in the patella tendon.
397587|NCT01158599|Biological|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
397588|NCT01158586|Drug|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
397589|NCT01158560|Dietary Supplement|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
397590|NCT01158560|Behavioral|Gargling|gargling with tap water, twice daily
397591|NCT01158560|Dietary Supplement|Placebo|matched placebo for active vitamin D
397592|NCT01158534|Drug|celecoxib|Given orally
397593|NCT01158534|Biological|recombinant interferon alfa-2b|Given subcutaneously
397594|NCT01158534|Other|polymerase chain reaction|Correlative studies
397595|NCT01158534|Other|laboratory biomarker analysis|Correlative studies
397596|NCT01158534|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
397597|NCT01158534|Other|immunologic technique|Correlative studies
397598|NCT01158534|Other|immunohistochemistry staining method|Correlative studies
397599|NCT01158534|Other|flow cytometry|Correlative studies
397600|NCT01158521|Drug|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
397601|NCT01158521|Procedure|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
397602|NCT01158508|Procedure|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
397603|NCT01158495|Procedure|Intubation with a cuffed ET Tube|
397604|NCT01158495|Procedure|CT scan Radiation|
397605|NCT01158482|Procedure|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
397606|NCT01158443|Behavioral|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
397607|NCT01158443|Behavioral|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
397608|NCT01158430|Behavioral|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours
397609|NCT01158417|Drug|Placebo|oral
397610|NCT01158417|Drug|Resveratrol 40 mg oral three times a day|Drug
397611|NCT01158417|Drug|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
397612|NCT01158404|Drug|LY900009 - Dose Escalation Phase (Part A)|"2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
397613|NCT01158404|Drug|LY900009 - Dose Confirmation Phase (Part B)|"30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle.~Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
397614|NCT01158391|Device|NTrainer® Intervention|
397615|NCT01158391|Device|Control Intervention|
397616|NCT01158378|Device|Adherus Dural Sealant|In situ polymerizing sealant
397617|NCT01158365|Drug|LACTIC ACID (Dermacid)|Route of administration: local
397618|NCT01158365|Drug|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
397619|NCT01158352|Dietary Supplement|Nutritional supplementation formula|Nutritional supplementation formula
397620|NCT01158352|Dietary Supplement|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
397621|NCT01158339|Behavioral|Arm 2: CBGT-ISE|Intervention with active performance of the feared movements during group sessions.
397622|NCT01158339|Behavioral|Arm 1: CBGT|Intervention according to previously mentioned methods.
397623|NCT01158326|Drug|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
397624|NCT01158326|Other|Placebo|10 ml of oral placebo every 6 hours for 48 hours
397625|NCT01158313|Dietary Supplement|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
397626|NCT01158300|Drug|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
397627|NCT01158287|Drug|sorafenib tosylate|
397628|NCT01158287|Other|laboratory biomarker analysis|
397629|NCT01158274|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
397630|NCT01158274|Drug|capecitabine|Given orally
397631|NCT01158274|Other|laboratory biomarker analysis|Correlative studies
397632|NCT01158261|Biological|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
397633|NCT01158248|Biological|panitumumab|
397634|NCT01158248|Drug|cisplatin|
397635|NCT01158248|Radiation|brachytherapy|
397636|NCT01158248|Radiation|external beam radiation therapy|
397637|NCT01158235|Drug|LTX-109|1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
397638|NCT01158222|Drug|sunitinib malate|Given orally
397639|NCT01158209|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
397640|NCT01158196|Device|infra-red diode laser|"laser treatment of scar after keloid excision~laser treatment of surgery scar"
397641|NCT01158183|Drug|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
397642|NCT01158170|Radiation|Prophylactic cranial irradiation|25GY/10fraction
397643|NCT01158170|Drug|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
397644|NCT01158157|Biological|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
397645|NCT01158144|Drug|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
397684|NCT01157741|Behavioral|C-C|Mx as H-C plus positioning follow up in the community clinic
397685|NCT01157741|Other|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
397646|NCT01158144|Drug|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
397647|NCT01158131|Behavioral|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
397648|NCT01158118|Drug|Sargramostim|
397649|NCT01158118|Drug|Plerixafor|
397650|NCT01158105|Drug|Bortezomib|1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
397651|NCT01158092|Device|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
397652|NCT01158092|Other|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
397653|NCT01158079|Drug|ALN-VSP02|The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
397654|NCT01158066|Procedure|CT Cardiac|the patient will undergo cardiac CT
397655|NCT01158053|Device|FFR and VH-IVUS|"Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) >48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent~No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.~All lesion level inclusion criteria and no exclusion criteria are met.~FFR followed by VH-IVUS of study lesion(s)~Any additional PCI based on routine clinical practice and FFR/IVUS data?~If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years~If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
397656|NCT01158053|Device|IVUS and FFR|
397657|NCT01158027|Other|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
397658|NCT01158014|Procedure|Fibrin Glue, Quixil|quixil 0.1 ml
397659|NCT01158014|Procedure|Suture|vicryl 10/0
397660|NCT01158001|Behavioral|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
397661|NCT01157988|Drug|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count > 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
397662|NCT01157975|Drug|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
397663|NCT01157975|Drug|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
397664|NCT01157962|Procedure|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
397665|NCT01157949|Drug|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
397666|NCT01157936|Drug|Allopurinol|daily dosage
397667|NCT01157936|Other|placebo|daily dosage
397668|NCT01157923|Device|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
397669|NCT01157897|Biological|VMP001|Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B
397670|NCT01157897|Other|P. vivax sporozoite challenge|P. vivax sporozoite challenge
397671|NCT01157871|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
397672|NCT01157871|Drug|placebo|"Pharmaceutical form:solution~Route of administration: intramuscular"
397673|NCT01157858|Drug|Everolimus|2.5 mg every day orally
397674|NCT01157858|Drug|Octreotide LAR|40 mg every 28 days IM
397675|NCT01157845|Device|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
397676|NCT01157819|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
397677|NCT01157819|Drug|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
397678|NCT01157806|Radiation|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
397679|NCT01157793|Drug|r-hGH|r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
397680|NCT01157793|Drug|r-hGH|Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
397681|NCT01157780|Drug|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
397682|NCT01157767|Other|standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.|Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
397683|NCT01157754|Drug|levonorgestrel and ethynilestradiol|
397686|NCT01157741|Other|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
397687|NCT01157741|Other|As C-C but with both SF & PS (C-SF+PS)|Giving both SF & PS
397688|NCT01157741|Other|H-C|Follow-up at Hospital
397689|NCT01157715|Biological|intravitreal injection of KH902|
397690|NCT01157702|Biological|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
397691|NCT01157676|Other|Quality of Life Questionnaires|Quality of Life Questionnaires
397692|NCT01157676|Other|Get up and Go test|Timed Get up and Go test
397693|NCT01157676|Other|Hand Grip test|Hand grip strength test
397694|NCT01157663|Other|Adapted balance training|during 8 weeks
397695|NCT01157663|Other|Balance Training|Balance training with unipedal standing during 8 weeks
397696|NCT01157650|Other|Autologous mesenchymal stem cells|"The trial is divided in three phases:~I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.~II.- Treatment phase includes:~Liposuction procedure to obtain adipose tissue.~Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)~ASCs implant~III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
397697|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
397698|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
397699|NCT01157611|Behavioral|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
397700|NCT01157598|Device|bispectral index monitoring|parameter monitoring of bispectral index
397701|NCT01157585|Drug|paliperidone ER|8 week prospective study
397702|NCT01157572|Drug|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
397703|NCT01157572|Drug|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
397704|NCT01157559|Drug|Ziprasidone|8 week prospective study
397705|NCT01157546|Procedure|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
397706|NCT01157546|Procedure|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
397707|NCT01157533|Drug|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
397708|NCT01157507|Drug|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
397709|NCT01157507|Procedure|Bladder overdistension|Bladder overdistension
397710|NCT01157507|Drug|Placebo|One single injection of placebo
397711|NCT01157494|Other|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
397712|NCT01157481|Drug|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
397713|NCT01157481|Drug|Conventional therapy|Conventional therapy
397714|NCT01157455|Procedure|Everolimus Drug Eluting Stent|Implantation
397715|NCT01157455|Drug|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
397716|NCT01157455|Drug|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.~75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
397717|NCT01157455|Drug|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
397718|NCT01157442|Behavioral|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
397719|NCT01157429|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
397720|NCT01157429|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
397721|NCT01157429|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
397722|NCT01157416|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
397723|NCT01157416|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
397724|NCT01157416|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
397725|NCT01157403|Biological|Autologous transplantation|Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
397726|NCT01157390|Other|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage & frequency: Fed as need Duration: at least 3 months
397727|NCT01157390|Other|Breast feeding|Breast feeding
397728|NCT01157377|Drug|AGN-214868|AGN-214868 injected into the bladder.
397729|NCT01157377|Drug|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
397730|NCT01157364|Drug|bimatoprost 20 µg generation 2|Single dose of bimatoprost ophthalmic formulation A administered in the study eye on Day 1.
397731|NCT01157364|Drug|bimatoprost 15 µg generation 2|Single dose of bimatoprost ophthalmic formulation B administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
397732|NCT01157364|Drug|bimatoprost 10 µg generation 2|Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
397733|NCT01157364|Drug|bimatoprost 6 µg generation 2|Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
397734|NCT01157364|Drug|bimatoprost 15 µg generation 1|Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
397735|NCT01157364|Drug|bimatoprost 10 µg generation 1|Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
397736|NCT01157364|Drug|bimatoprost 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
397737|NCT01157351|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
397738|NCT01157351|Drug|risperidone|flexible dosing as prescribed by the study doctor for 15 months
397739|NCT01157351|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
397740|NCT01157351|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
397741|NCT01157351|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
397742|NCT01157351|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
397743|NCT01157351|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
397744|NCT01157351|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
397745|NCT01157338|Procedure|diagnostic cardiac catheterization|coronary intervention: angiography
397746|NCT01157338|Procedure|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
397747|NCT01157325|Procedure|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
397748|NCT01157325|Procedure|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
397749|NCT01157312|Drug|clomiphene citrate +highly purified uFSH|
397750|NCT01157312|Drug|clomiphene citrate|
397751|NCT01157260|Drug|Kremezin|AST-120 2g three times a day
397752|NCT01157247|Procedure|Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture|
397753|NCT01157234|Drug|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of < 140/ 90.
397754|NCT01157234|Drug|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure < 140/90.
397755|NCT01157221|Other|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
397756|NCT01157221|Other|EMSMTA|end-range mobilization/scapular mobilization treatment approach
397757|NCT01157208|Other|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
397758|NCT01157208|Other|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
397759|NCT01157195|Behavioral|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
397760|NCT01157195|Behavioral|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
397761|NCT01157182|Drug|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
397762|NCT01157182|Drug|Activella®|1/0.5 mg Tablets
397763|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
397764|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
397765|NCT01157156|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form:solution~Route of administration: intramuscular"
397766|NCT01157143|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form : solution~Route of administration : intramuscular"
397767|NCT01157130|Other|Exercise Regimen|Exercise instruction
397768|NCT01157117|Biological|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
397769|NCT01157117|Biological|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
397770|NCT01157117|Drug|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
397771|NCT01157104|Drug|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
397772|NCT01157104|Drug|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
397773|NCT01157104|Drug|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
397774|NCT01157104|Drug|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
397775|NCT01157091|Drug|pazopanib hydrochloride|Given orally
397776|NCT01157091|Other|laboratory biomarker analysis|Correlative studies
397777|NCT01157091|Other|immunologic technique|Correlative studies
397778|NCT01157078|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
397779|NCT01157078|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
397780|NCT01157065|Drug|AL-78898A|Investigational treatment
397781|NCT01157065|Drug|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
397782|NCT01157052|Other|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.~XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.~Ca2+/Mg2: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1 (Arm A) or cycle 2 (Arm B)"
397783|NCT01157039|Dietary Supplement|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
397784|NCT01157026|Dietary Supplement|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
397785|NCT01157026|Other|placebo plus tamoxifen|20mg tamoxifen daily
397786|NCT01157013|Other|Positron emission tomography with fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
397787|NCT01157000|Drug|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
397788|NCT01156987|Device|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:~an IV line is placed by nurse,~patient is placed in the 4 T MRI scanner at CMRR,~initial scout images and manual linear shims are adjusted,~Pre-contrast SWIFT T1 weighted images and T1 map are obtained,~continuous SWIFT acquisition begins immediately before contrast injection,~contrast injection,~continuous SWIFT acquisition continues for 12 min after contrast,~late enhancement images may also be obtained.~10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
397789|NCT01156974|Behavioral|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
397790|NCT01156974|Behavioral|education only|patients receive education about care goals
397791|NCT01156961|Drug|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
397792|NCT01156961|Drug|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
397793|NCT01156948|Drug|misoprostol|400ug vaginally the day before surgery
397794|NCT01156948|Drug|oral misoprostol|400ug misoprostol orally the day before the surgery
397795|NCT01156935|Other|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
397796|NCT01156922|Drug|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.~Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
397797|NCT01156909|Drug|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.~Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
397798|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose in the fasting state.
397799|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
397800|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
397801|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
397802|NCT01156883|Drug|asparaginase|
397803|NCT01156883|Drug|cyclophosphamide|
397804|NCT01156883|Drug|cytarabine|
397805|NCT01156883|Drug|daunorubicin hydrochloride|
397806|NCT01156883|Drug|dexamethasone|
397807|NCT01156883|Drug|doxorubicin hydrochloride|
397808|NCT01156883|Drug|ifosfamide|
397809|NCT01156883|Drug|mercaptopurine|
397810|NCT01156883|Drug|methotrexate|
397811|NCT01156883|Drug|methylprednisolone|
397812|NCT01156883|Drug|prednisone|
397813|NCT01156883|Drug|thioguanine|
397814|NCT01156883|Drug|vincristine sulfate|
397815|NCT01156883|Drug|vindesine|
397816|NCT01156870|Drug|SAR566658|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
397817|NCT01156857|Drug|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
397818|NCT01156857|Drug|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
397819|NCT01156844|Drug|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
397820|NCT01156844|Drug|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
397821|NCT01156805|Other|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
397822|NCT01156792|Drug|FP 100|FP 100mcg BID
397823|NCT01156792|Drug|GSK2190915 100|GSK2190915 100mg QD (AM)
397824|NCT01156792|Drug|GSK2190915 300|GSK2190915 300mg QD (AM)
397825|NCT01156792|Drug|montelukast|montelukast 10mg QD (PM)
397826|NCT01156792|Drug|placebo|placebo BID
397827|NCT01156792|Drug|FP/SAL 100/50|FP/SAL 100/50mcg BID
397828|NCT01156779|Drug|SR-exenatide|Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
397829|NCT01156766|Device|- locking anterior plate|"The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.~The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis."
397830|NCT01156753|Drug|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
397831|NCT01156753|Drug|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
397832|NCT01156740|Drug|Penicillin G, Benzathine|IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg)
397833|NCT01156740|Drug|Amoxicillin|750 mg/QD
397834|NCT01156714|Behavioral|Treadmill training with aerobic exercise|walk on treadmill for aerobic exercise
397835|NCT01156714|Behavioral|Memory training with computerized memory program|memory testing and training on computer program
397836|NCT01156714|Behavioral|Combination of treadmill training and computerized memory|both exercise and cognitive computer training
397837|NCT01156701|Drug|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
397838|NCT01156701|Other|No prophylaxis with Relenza|No prophylaxis with Relenza
397839|NCT01156688|Drug|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
397840|NCT01156688|Drug|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
397841|NCT01156675|Device|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
397842|NCT01156675|Device|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
397843|NCT01156662|Device|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
397844|NCT01156662|Device|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
397845|NCT01156649|Device|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
397846|NCT01156649|Device|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
397847|NCT01156636|Drug|Sildenafil|50 mg 3 times/day for 1 year
397848|NCT01156636|Drug|Placebo|
397849|NCT01156623|Procedure|EBUS-TBNA|All included patients received TBNA for lymph node study via a flexible ultrasonic bronchoscope with a linear scanning probe on the tip (BF-UC206F-OL8, Olympus). The curved-probe scanned parallel to the insertion direction of bronchoscope, and the obtained images were linked to the ultrasound scanner (EU-2000C, Olympus) incorporated with Doppler-flow imaging. Each lymph node greater than 5mm in short axis measured by cursors was selected for subsequent TBNA with a 22-gauge (NA-201SX-4022, Olympus) needle in a condition of real-time EBUS guidance. A cytology examination was sent for pathologist blinded for the clinical history and image result of patients. When a tissue core was obtained by TBNA, the specimen was also sent for pathology study.
397850|NCT01156610|Behavioral|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.~Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.~Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
397851|NCT01156597|Drug|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
397852|NCT01156584|Biological|Toca 511 vector|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
397853|NCT01156584|Drug|Toca FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
397854|NCT01156571|Drug|cangrelor P2Y12 (platelet) inhibitor|
397855|NCT01156571|Drug|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
397856|NCT01156571|Drug|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
397857|NCT01156545|Drug|BIBW 2992|BIBW 2992 40mg, once a day, oral intake, every day
397858|NCT01156545|Drug|simvastatin|simvastatin 40mg, once a day, oral intake, every day.
397859|NCT01156519|Other|Salivary Cortisol|"Day 1: 1st salivary cortisol at 23 hours~Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)~Day 3: serum cortisol at 8 am~Between Day 4 and Month 3: if serum cortisol at 8 am > 18ng/mL:~Cortisol for 24 hours~dexamethasone suppression test (2mg/j during 2 days)~Cortisol and ACTH cycle~Noriodocholesterol scintigraphy"
397860|NCT01156493|Other|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
397899|NCT01156168|Genetic|protein expression analysis|
397900|NCT01156168|Other|immunohistochemistry staining method|
397901|NCT01156168|Other|laboratory biomarker analysis|
397902|NCT01156155|Radiation|Digital xray of jaw and teeth|one time xray of jaw and teeth
397861|NCT01156480|Drug|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
397862|NCT01156480|Drug|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
397863|NCT01156467|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
397864|NCT01156467|Device|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
397865|NCT01156454|Procedure|X-ray|surgical specimen taken to radiology and contents x-rayed
397866|NCT01156441|Procedure|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.~Intraoperative transesophageal echocardiography will be performed on all study volunteers."
397867|NCT01156415|Drug|AGO178|
397868|NCT01156415|Drug|AGO178|
397869|NCT01156402|Behavioral|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
397870|NCT01156389|Drug|Ritonavir and pyronaridine/artesunate|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and pyronaridine/artesunate 180 mg/60 mg (3 to 4 tablets once per day according to weight for 3 days).
397871|NCT01156389|Drug|pyronaridine/artesunate|Pyronaridine/artesunate 180 mg/60 mg (3 to 4 tablets once per day according to weight for 3 days).
397872|NCT01156376|Device|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
397873|NCT01156376|Device|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
397874|NCT01156376|Device|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
397875|NCT01156363|Procedure|Dialysis|regular haemodialysis or peritoneal dialysis
397876|NCT01156363|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
397877|NCT01156350|Drug|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained < 2.5 x 104 CD3+ cells/kg
397878|NCT01156324|Behavioral|Online Stress Management Group (Upliv)|Personalized online stress management program
397879|NCT01156324|Behavioral|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
397880|NCT01156311|Drug|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
397881|NCT01156285|Other|Filling in a patient questionnaire|Filling in a patient questionnaire
397882|NCT01156272|Device|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
397883|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
397884|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
397885|NCT01156246|Drug|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
397886|NCT01156233|Procedure|Anesthesia induction|Cuff palpation technique: identification of the cuff position in the trachea by palpation.
397887|NCT01156233|Procedure|Anesthesia induction|Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
397888|NCT01156220|Drug|Furosemide|Injection, 40 mg, single dose over 5 min
397889|NCT01156220|Drug|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
397890|NCT01156207|Drug|Aliskiren|300mg Aliskiren qd for 6 month
397891|NCT01156194|Drug|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
397892|NCT01156194|Drug|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
397893|NCT01156194|Drug|Placebo|globule identical to true homeopathy comparators
397894|NCT01156181|Procedure|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
397895|NCT01156181|Procedure|control|Embryo transfer without any intervention
397896|NCT01156168|Genetic|DNA analysis|
397897|NCT01156168|Genetic|gene expression analysis|
397898|NCT01156168|Genetic|polymorphism analysis|
397903|NCT01156155|Procedure|Blood draw|Three to four tablespoons of blood drawn.
397904|NCT01156155|Other|questionnaires|completed questionnaires regarding patient's health and functional ability.
397905|NCT01156155|Procedure|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
397906|NCT01156155|Other|Bilateral digital xray of hands|One time digital xray of hands
397907|NCT01156142|Drug|doxepin hydrochloride|Oral rinse
397908|NCT01156142|Other|placebo|Oral rinse
397909|NCT01156129|Drug|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
397910|NCT01156129|Device|Arm B: Acupressure bracelet|Bioband
397911|NCT01156129|Dietary Supplement|sugar free gum|Orbit
397912|NCT01156116|Device|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.~________________________________________"
397913|NCT01156116|Drug|Placebo|oral placebo tablet
397914|NCT01156103|Behavioral|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
397915|NCT01156077|Drug|TR-701 FA|Oral TR-701 FA 200 mg will be given as a single oral dose
397916|NCT01156077|Drug|TR-701 FA|TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
397917|NCT01156064|Device|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
397918|NCT01156064|Device|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
397919|NCT01156051|Drug|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
397920|NCT01156051|Drug|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
397921|NCT01156038|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
397922|NCT01156025|Drug|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
397923|NCT01156025|Drug|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
397924|NCT01156012|Drug|T2345|One drop of T2345
397925|NCT01156012|Drug|Prostaglandin|One drop
397926|NCT01155999|Drug|T1225|one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
397927|NCT01155999|Drug|Tobramycin|1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
397928|NCT01155986|Drug|Lidocaine 5% medicated plaster|Topical hydrogel plaster (700mg lidocaine)
397929|NCT01155986|Drug|Placebo topical plaster|Topical hydrogel plaster
397930|NCT01155973|Behavioral|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
397931|NCT01155973|Other|Control group|SCORE oral information and counseling as standard practice care
397932|NCT01155960|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
397933|NCT01155947|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
397934|NCT01155934|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
397935|NCT01155921|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
397936|NCT01155908|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
397937|NCT01155895|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
397938|NCT01155882|Procedure|Whipple at the Splenic Artery (WATSA)|
397939|NCT01155869|Drug|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
397940|NCT01155869|Drug|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
397941|NCT01155856|Other|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
397942|NCT01155817|Drug|Nilotinib|200, 400, 800, oral
397985|NCT01155531|Drug|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
397986|NCT01155518|Drug|testosterone|intramuscular every 2 weeks
397987|NCT01155518|Drug|clomiphene|thrice a week
397988|NCT01155518|Drug|placebo|intramuscular saline injections every 2 weeks
397989|NCT01155518|Drug|placebo|oral
397990|NCT01155505|Drug|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
397943|NCT01155804|Behavioral|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
397944|NCT01155791|Drug|Docetaxel|IV 75 mg/m2
397945|NCT01155791|Drug|Biosyn|IV dosage varies
397946|NCT01155791|Drug|Prednisone|5mg, orally
397947|NCT01155778|Biological|Recombinant human heparan N-sulfatase (rhHNS)|
397948|NCT01155765|Drug|Prasugrel|Prasugrel 10 mg/day for 15 days
397949|NCT01155765|Drug|Clopidogrel|Clopidogrel 150 mg/day for 15 days
397950|NCT01155752|Drug|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
397951|NCT01155752|Drug|placebo|identical placebo
397952|NCT01155726|Device|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
397953|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
397954|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
397955|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
397956|NCT01155726|Device|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
397957|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
397958|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
397959|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
397960|NCT01155713|Drug|TKI258|
397961|NCT01155700|Drug|omalizumab|
397962|NCT01155661|Drug|LY2216684 (edivoxetine)|12 to 18 milligrams (mg), administered orally, once daily for 54 weeks, adjunctive to a selective serotonin reuptake inhibitor (SSRI)
397963|NCT01155661|Drug|SSRI|Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study.
397964|NCT01155648|Device|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
397965|NCT01155648|Device|Chest wall compression for ten minutes in chest|
397966|NCT01155635|Drug|Carvedilol|Use of Carvedilol with any dose
397967|NCT01155635|Drug|No Carvedilol|No use of Carvedilol
397968|NCT01155622|Procedure|Endovascular Cooling|Infusion of <8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
397969|NCT01155609|Procedure|quality-of-life assessment|Ancillary studies
397970|NCT01155609|Procedure|management of therapy complications|Discontinue supplement; treat symptomatically
397971|NCT01155609|Dietary Supplement|L-lysine|Given PO
397972|NCT01155596|Behavioral|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
397973|NCT01155583|Drug|azacitidine|Given SC
397974|NCT01155583|Drug|lenalidomide|Given orally
397975|NCT01155583|Drug|dexamethasone|Given orally
397976|NCT01155583|Other|DNA methylation analysis|Correlative studies
397977|NCT01155583|Other|gene expression analysis|Correlative studies
397978|NCT01155583|Other|bone marrow aspiration|Correlative studies
397979|NCT01155583|Other|immunohistochemistry staining method|Correlative studies
397980|NCT01155583|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
397981|NCT01155583|Other|flow cytometry|Correlative studies
397982|NCT01155557|Device|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
397983|NCT01155557|Behavioral|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
397984|NCT01155544|Behavioral|Behavioral Intervention|Preventing recurrence of substance use.
398151|NCT01154452|Other|Pharmacological Study|Correlative studies
397991|NCT01155479|Drug|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
397992|NCT01155479|Drug|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
397993|NCT01155479|Drug|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
397994|NCT01155479|Drug|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
397995|NCT01155479|Drug|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
397996|NCT01155479|Drug|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
397997|NCT01155466|Drug|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
397998|NCT01155466|Drug|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
397999|NCT01155466|Drug|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
398000|NCT01155466|Drug|Placebo to Preladenant Tablet|one tablet orally twice daily
398001|NCT01155466|Drug|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
398002|NCT01155466|Drug|Placebo to Rasagiline capsule|one capsule orally in AM
398003|NCT01155453|Drug|BKM120|
398004|NCT01155453|Drug|GSK1120212|
398005|NCT01155440|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
398006|NCT01155440|Procedure|Thoracic epidural block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
398007|NCT01155414|Other|Hydrolysate based infant formula|Infant formula ad lib
398008|NCT01155414|Other|Investigational Infant Formula A|Investigational infant formula ad lib
398009|NCT01155414|Other|Investigational Infant Formula B|Investigational infant formula ad lib
398010|NCT01155388|Drug|Ferumoxytol|Experimental: Ferumoxytol
398011|NCT01155388|Drug|Oral Iron|Active Comparator: Oral iron
398012|NCT01155375|Drug|Ferumoxytol|Experimental: Ferumoxytol
398013|NCT01155375|Drug|Oral Iron|Active Comparator: Oral iron
398014|NCT01155362|Biological|Human Placenta-Derived Cells PDA001 Intravenous Infusion|
398015|NCT01155362|Drug|Vehice Control|
398016|NCT01155349|Behavioral|InSight|A cognitive intervention designed to enhance speed of visual processing.
398017|NCT01155349|Other|No contact-control group|No contact-control group.
398018|NCT01155336|Drug|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
398019|NCT01155336|Drug|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
398020|NCT01155323|Device|etafilcon A|1-day soft contact lens
398021|NCT01155323|Device|omafilcon A|1-day soft contact lens
398022|NCT01155310|Drug|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
398023|NCT01155310|Drug|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.~Patients will then receive the Air/Oxygen mixture with usual devices."
398024|NCT01155297|Behavioral|Physical training|"The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.~After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration."
398025|NCT01155297|Behavioral|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
398026|NCT01155284|Drug|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo~Subjects age 11-17 years at Visit 2 will take 1 capsule once daily~Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
398027|NCT01155284|Drug|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
398028|NCT01155271|Other|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)~1 technical visit and 1 nursing visit every two months at home for the CPAP"
398029|NCT01155258|Drug|temsirolimus|Given IV
398030|NCT01155258|Drug|vinorelbine ditartrate|Given IV
398031|NCT01155245|Drug|Forteo|Forteo pen
398032|NCT01155232|Drug|Teriparatide|Forteo (teriparatide)pen daily for 24 months
398033|NCT01155219|Drug|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
398034|NCT01155219|Drug|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
398035|NCT01155206|Drug|glucagon|glucagon 3ng/kg/min
398036|NCT01155180|Drug|Leptin|Hormone - daily self injections for 6 months
398037|NCT01155180|Drug|Placebo|Placebo
398038|NCT01155167|Drug|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
398039|NCT01155167|Other|Placebo|Placebo
398040|NCT01155154|Drug|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
398041|NCT01155154|Drug|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
398042|NCT01155154|Drug|placebo|Two placebo capsules every 6 hours for 7 days
398043|NCT01155141|Drug|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
398044|NCT01155128|Behavioral|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
398045|NCT01155115|Procedure|Sputum Collection|Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.
398046|NCT01155115|Procedure|Pulmonary Function Testing|Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.
398047|NCT01155115|Procedure|Exhaled Nitric Oxide|The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
398048|NCT01155102|Drug|Anastrozole|1 mg tablet
398049|NCT01155089|Drug|Anastrozole|1 mg tablet
398050|NCT01155076|Dietary Supplement|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
398051|NCT01155076|Dietary Supplement|Placebo|Placebo taken twice a day for 8 weeks
398052|NCT01155063|Other|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
398053|NCT01155050|Device|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
398054|NCT01155050|Behavioral|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
398055|NCT01155050|Device|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
398056|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
398057|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
398058|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
398059|NCT01155024|Device|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
398060|NCT01155024|Device|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
398061|NCT01155011|Behavioral|Physical Activity|"MIPARC will focus on 3 physical activity goals:~increasing walking behavior through gradually increasing step goals~increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,~reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
398062|NCT01155011|Behavioral|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
398063|NCT01155011|Behavioral|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:~health check~step goal check~barrier identification~problem solving~specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
398064|NCT01155011|Behavioral|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.~The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
398065|NCT01155011|Behavioral|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
398066|NCT01155011|Behavioral|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
398067|NCT01155011|Behavioral|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
398110|NCT01154712|Device|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
398111|NCT01154712|Device|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
398068|NCT01155011|Behavioral|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
398069|NCT01155011|Behavioral|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
398070|NCT01155011|Behavioral|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
398071|NCT01154985|Drug|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
398072|NCT01154985|Drug|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
398073|NCT01154985|Drug|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
398074|NCT01154972|Procedure|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
398075|NCT01154959|Drug|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
398076|NCT01154933|Drug|exenatide 5 mcg|exenatide 5 mcg
398077|NCT01154933|Drug|exenatide 10 mcg|exenatide 10 mcg
398078|NCT01154933|Drug|placebo|saline sq
398079|NCT01154920|Drug|Paclitaxel|135 mg/m^2 weekly, Weeks 1 - 6
398080|NCT01154920|Drug|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
398081|NCT01154920|Drug|Cetuximab|"PCC Arm: 400 mg/m^2 by vein over about 1-2 hours on Day 1; 250 mg/m^2 weeks 2 - 6.~C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
398082|NCT01154920|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
398083|NCT01154920|Drug|Cisplatin|100 mg/m^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
398084|NCT01154920|Drug|Fluorouracil|700 mg/m^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
398085|NCT01154920|Radiation|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
398086|NCT01154920|Other|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
398087|NCT01154907|Drug|Praziquantel|One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
398088|NCT01154894|Other|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
398089|NCT01154881|Drug|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
398090|NCT01154868|Procedure|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
398091|NCT01154855|Procedure|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
398092|NCT01154829|Drug|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
398093|NCT01154829|Drug|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
398094|NCT01154816|Drug|Alisertib|Given orally
398095|NCT01154816|Other|Laboratory Biomarker Analysis|Correlative studies
398096|NCT01154816|Other|Pharmacological Study|Correlative studies
398097|NCT01154803|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
398098|NCT01154803|Dietary Supplement|Micronutrient Powder (MNP)|2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
398099|NCT01154790|Drug|CG100649|6 subjects: study drug 2 subjects: placebo
398100|NCT01154790|Drug|Placebo|6 subjects: study drug 2 subjects: placebo
398101|NCT01154790|Drug|Naproxen|6 subjects: study drug 2 subjects: placebo
398102|NCT01154777|Behavioral|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
398103|NCT01154764|Drug|CG100649|I period: CG 100649 single dose 6 mg II period: Ketoconalzole + CG100649 at the same time washout period: 42 days
398104|NCT01154764|Drug|CG100649 and ketoconazole|I period: ketoconazole 400 mg + CG100649 6 mg II period: CG 100649 single dose 6 mg washout period: 42 days
398105|NCT01154751|Device|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
398106|NCT01154738|Drug|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
398107|NCT01154738|Drug|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
398108|NCT01154725|Behavioral|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
398109|NCT01154725|Behavioral|habitual patient education|habitual patient education
398112|NCT01154699|Device|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
398113|NCT01154699|Other|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
398114|NCT01154699|Other|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
398115|NCT01154686|Behavioral|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
398116|NCT01154673|Drug|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
398117|NCT01154673|Drug|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
398118|NCT01154673|Drug|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
398119|NCT01154673|Drug|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
398120|NCT01154660|Other|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
398121|NCT01154647|Drug|citalopram|intravenous
398122|NCT01154647|Drug|1 ml 0.9 % NaCl|intravenous
398123|NCT01154634|Drug|AZD2516, 5 mg|Capsule, oral
398124|NCT01154634|Drug|AZD2516, 16 mg|Capsule, oral
398125|NCT01154634|Drug|AZD2516, 40 mg|Capsule, oral
398126|NCT01154634|Drug|Placebo|Capsule, oral
398127|NCT01154621|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
398128|NCT01154621|Drug|Placebo|Sterile 5% dextrose solution
398129|NCT01154608|Drug|Creon|
398130|NCT01154608|Other|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
398131|NCT01154595|Dietary Supplement|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
398132|NCT01154595|Behavioral|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
398133|NCT01154582|Dietary Supplement|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
398134|NCT01154582|Dietary Supplement|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
398135|NCT01154569|Drug|Azithromycin|500 mg single dose
398136|NCT01154530|Other|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
398137|NCT01154504|Other|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
398138|NCT01154504|Procedure|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
398139|NCT01154504|Procedure|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
398140|NCT01154491|Drug|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
398141|NCT01154491|Drug|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
398142|NCT01154491|Drug|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.~Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
398143|NCT01154478|Other|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
398144|NCT01154478|Other|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
398145|NCT01154478|Other|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
398146|NCT01154478|Other|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
398147|NCT01154465|Procedure|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.~The patients' skin disinfection before catheter insertion and care will follow the protocol:~Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).~Rinse with sterile water and then drying.~First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.~Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.~After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
398148|NCT01154465|Device|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.~A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:~- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
398149|NCT01154452|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
398150|NCT01154452|Other|Laboratory Biomarker Analysis|Correlative studies
398152|NCT01154452|Drug|Vismodegib|Given PO
398153|NCT01154439|Drug|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
398154|NCT01154439|Drug|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
398155|NCT01154439|Drug|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).~Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
398156|NCT01154439|Drug|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
398157|NCT01154439|Drug|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
398158|NCT01154426|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
398159|NCT01154426|Drug|Gemcitabine Hydrochloride|Given IV
398160|NCT01154426|Other|Pharmacological Study|Correlative studies
398161|NCT01154426|Drug|Veliparib|Given orally
398162|NCT01154413|Behavioral|Intensive education of the doctor/nursing team on the protocol|
398163|NCT01154400|Dietary Supplement|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
398164|NCT01154400|Dietary Supplement|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
398165|NCT01154400|Dietary Supplement|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
398166|NCT01154400|Dietary Supplement|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
398167|NCT01154387|Drug|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
398168|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
398169|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
398170|NCT01154387|Drug|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
398171|NCT01154387|Drug|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
398172|NCT01154387|Drug|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
398173|NCT01154374|Drug|MEBO Wound Ointment|Topical application twice daily
398174|NCT01154374|Procedure|Standard of Care (sterile saline moistened gauze)|
398175|NCT01154361|Drug|Icatibant (subcutaneous) and plazebo (intravenous)|
398176|NCT01154361|Drug|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
398177|NCT01154348|Drug|S-707106|Tablet, taken once daily with morning meal
398178|NCT01154348|Drug|Placebo|Placebo tablet, taken once daily with morning meal
398179|NCT01154348|Drug|Metformin, S-707106 plus metformin|Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
398180|NCT01154348|Drug|Metformin, placebo plus metformin|Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
398181|NCT01154335|Drug|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
398182|NCT01154335|Drug|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
398183|NCT01154322|Device|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
398184|NCT01154309|Behavioral|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
398185|NCT01154296|Behavioral|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
398186|NCT01154283|Device|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
398187|NCT01154270|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
398188|NCT01154257|Procedure|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
398189|NCT01154257|Procedure|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
398190|NCT01154244|Other|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
398191|NCT01154231|Drug|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.~Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).~The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
398229|NCT01153919|Biological|romiplostim|Given subcutaneously
398230|NCT01153919|Drug|ribavirin|Given orally
398231|NCT01153919|Other|placebo|Given subcutaneously
398232|NCT01153919|Biological|PEG-interferon alfa-2a|Given subcutaneously
398192|NCT01154218|Drug|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.~Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.~Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.~Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
398193|NCT01154192|Drug|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
398194|NCT01154192|Drug|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
398195|NCT01154179|Other|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
398196|NCT01154166|Drug|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
398197|NCT01154166|Drug|Placebo|Placebo
398198|NCT01154153|Drug|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
398199|NCT01154153|Drug|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >=6 yrs to <12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
398200|NCT01154153|Drug|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).~For children who were >=2 to <6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.~For children who were >= 6 yrs to <12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
398201|NCT01154153|Drug|Claritin® Syrup|Children's Claritin® Syrup [5 mg of loratadine per 5 mL] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
398202|NCT01154140|Drug|treatment|crizotinib 250mg orally continuous twice daily dosing
398203|NCT01154140|Drug|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
398204|NCT01154127|Drug|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
398205|NCT01154127|Drug|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
398206|NCT01154114|Drug|darapladib|darapladib 40 mg oral dose
398207|NCT01154101|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
398208|NCT01154101|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
398209|NCT01154088|Biological|Mencevax ACWY|One dose, Subcutaneous injection
398210|NCT01154088|Biological|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
398211|NCT01154062|Drug|Pazopanib|Pazopanib tablet
398212|NCT01154049|Biological|sm14 antigen plus adjuvant GLA|Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
398213|NCT01154036|Drug|ezetimibe 10 mg|
398214|NCT01154036|Drug|atorvastatin|
398215|NCT01154036|Drug|Comparator: rosuvastatin|
398216|NCT01154023|Behavioral|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 & 6 were delivered individually by phone.
398217|NCT01154010|Device|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
398218|NCT01154010|Device|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
398219|NCT01153997|Drug|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
398220|NCT01153997|Drug|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
398221|NCT01153997|Drug|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
398222|NCT01153997|Drug|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
398223|NCT01153984|Drug|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
398224|NCT01153971|Drug|rituximab|1
398225|NCT01153958|Drug|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
398226|NCT01153958|Drug|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
398227|NCT01153932|Drug|GSK2402968|Subcutaneous injection
398228|NCT01153932|Drug|matched placebo|Subcutaneous injection
398233|NCT01153919|Other|laboratory biomarker analysis|Correlative studies
398234|NCT01153906|Other|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
398235|NCT01153893|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
398236|NCT01153893|Biological|InfanrixTM|Intramuscular injection, 1dose
398237|NCT01153880|Drug|Retapamulin|Prescription sales claim of retapamulin
398238|NCT01153880|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
398239|NCT01153867|Behavioral|Schema Focused Therapy|SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
398240|NCT01153854|Drug|Racecadotril|oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
398241|NCT01153854|Drug|Placebo groups|Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
398242|NCT01153841|Biological|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
398243|NCT01153841|Biological|Infanrix hexa™|Intramuscular, 3 doses
398244|NCT01153828|Drug|Retapamulin|Prescription for retapamulin
398245|NCT01153828|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
398246|NCT01153828|Drug|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
398247|NCT01153815|Drug|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
398248|NCT01153815|Drug|placebo|placebo
398249|NCT01153802|Drug|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|"This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.~Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study."
398250|NCT01153789|Procedure|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
398251|NCT01153789|Other|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
398252|NCT01153776|Procedure|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
398253|NCT01153763|Drug|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
398254|NCT01153750|Drug|Glivec|
398255|NCT01153737|Other|Manual therapy (MT)|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
398256|NCT01153737|Other|TENS|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
398257|NCT01153724|Drug|BI 1744|10 mcg solution for oral inhalation
398258|NCT01153724|Drug|Fluconazole|400 mg capsule
398259|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
398260|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
398261|NCT01153711|Drug|Ketoconazole|400 mg tablet
398262|NCT01153711|Drug|Ketoconazole|400 mg tablet
398263|NCT01153698|Drug|dabigatran|anticoagulation
398264|NCT01153685|Biological|Fluviral®|Intramuscular injection, one dose
398265|NCT01153672|Drug|vorinostat|Given PO
398266|NCT01153672|Other|laboratory biomarker analysis|Correlative studies
398267|NCT01153672|Procedure|biopsy|Optional correlative studies
398268|NCT01153672|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
398269|NCT01153672|Procedure|positron emission tomography|Correlative studies
398270|NCT01153672|Drug|anastrozole|Given PO
398271|NCT01153672|Drug|letrozole|Given PO
398272|NCT01153672|Drug|exemestane|Given PO
398273|NCT01153672|Genetic|gene expression analysis|Correlative studies
398274|NCT01153659|Drug|E3810|RAB ER 50 mg capsule once per day on Days 1-5
398275|NCT01153659|Drug|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
398276|NCT01153659|Drug|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
398277|NCT01153646|Genetic|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
398303|NCT01153373|Behavioral|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
398722|NCT01149850|Genetic|DNA methylation analysis|Correlative studies
398768|NCT01149525|Drug|Placebo|oral solution, twice per day (morning/evening), during 3 months
398278|NCT01153633|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
398279|NCT01153633|Device|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:~Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation~Secondary dressing to be a semi occlusive dressing~Secure the dressing to the wound with tubifast and short stretch compression system~Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
398280|NCT01153620|Drug|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes"
398281|NCT01153620|Other|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
398282|NCT01153607|Drug|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
398283|NCT01153607|Drug|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
398284|NCT01153607|Drug|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
398285|NCT01153594|Behavioral|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
398286|NCT01153581|Drug|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
398287|NCT01153581|Drug|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
398288|NCT01153581|Drug|Progesterone|progesterone, 200 mg day−1 oral
398289|NCT01153568|Dietary Supplement|Vitamin D 3|Patients will bew given a single capsule to take once daily
398290|NCT01153568|Other|placebo|placebo tablets
398291|NCT01153542|Drug|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
398292|NCT01153542|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
398293|NCT01153503|Procedure|TAP block|"Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block~First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine~24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
398294|NCT01153490|Behavioral|Behavioral Intervention|Substance-related
398295|NCT01153477|Behavioral|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
398296|NCT01153464|Behavioral|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
398297|NCT01153451|Other|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
398298|NCT01153425|Other|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
398299|NCT01153425|Drug|Teriparatide|Participants are clinically indicated for treatment.
398300|NCT01153425|Drug|Zoledronic Acid|Participants are clinically indicated for treatment.
398301|NCT01153412|Other|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
398302|NCT01153386|Drug|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
398766|NCT01149538|Dietary Supplement|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
398304|NCT01153373|Behavioral|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
398305|NCT01153360|Drug|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
398306|NCT01153360|Drug|placebo|vitamin B12
398307|NCT01153347|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
398308|NCT01153347|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
398309|NCT01153334|Drug|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
398310|NCT01153321|Drug|AZD2423|100mg Oral dose od
398311|NCT01153321|Drug|AZD2423 Placebo|Oral dose od
398312|NCT01153308|Other|Observational Study|This is an Observational study
398313|NCT01153295|Procedure|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
398314|NCT01153295|Procedure|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
398315|NCT01153269|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
398316|NCT01153256|Drug|magnesium sulphate|The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
398317|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
398318|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
398319|NCT01153243|Drug|Ergocalciferol|"Active Comparator: Ergocalciferol~The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
398320|NCT01153243|Drug|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
398321|NCT01153217|Drug|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
398322|NCT01153204|Behavioral|Group Psychotherapy|
398323|NCT01153204|Other|Group Psychotherapy plus Sildenafil citrate|
398324|NCT01153204|Drug|Sildenafil citrate|
398325|NCT01153191|Procedure|Normal saline pressurized irrigation|same
398326|NCT01153191|Drug|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
398327|NCT01153165|Drug|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
398328|NCT01153165|Drug|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
398329|NCT01153139|Device|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
398330|NCT01153126|Behavioral|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
398331|NCT01153113|Biological|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
398332|NCT01153113|Biological|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
398333|NCT01153100|Drug|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
398334|NCT01153074|Device|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
398335|NCT01153061|Device|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
398336|NCT01153061|Device|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
398363|NCT01152918|Behavioral|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
398364|NCT01152918|Behavioral|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
398365|NCT01152918|Behavioral|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
398767|NCT01149525|Drug|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
398337|NCT01153048|Other|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
398338|NCT01153035|Device|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
398339|NCT01153022|Other|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
398340|NCT01153009|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
398341|NCT01153009|Drug|Duloxetine|Overencapsulated duloxetine delayed-release capsules
398342|NCT01153009|Drug|Placebo|Placebo-matching capsules
398343|NCT01152996|Drug|Vortioxetine|Vortioxetine tablets
398344|NCT01152983|Device|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
398345|NCT01152957|Behavioral|CARIÑO Project|Care Attention Resources Information Nutrition & Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
398346|NCT01152957|Behavioral|Enhanced Usual Care|Usual care plus 4 health education brochures
398347|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
398348|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
398349|NCT01152931|Drug|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
398350|NCT01152931|Dietary Supplement|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
398351|NCT01152931|Dietary Supplement|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
398352|NCT01152931|Dietary Supplement|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
398353|NCT01152931|Dietary Supplement|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
398354|NCT01152931|Dietary Supplement|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
398355|NCT01152931|Dietary Supplement|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
398356|NCT01152931|Dietary Supplement|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
398357|NCT01152931|Dietary Supplement|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if > 1year. 50ug daily for 4 days if < 1 year.
398358|NCT01152931|Dietary Supplement|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if < 1 year. 10,000 IU orally daily for 4 days if > 1 year.
398359|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
398360|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
398361|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
398362|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if < 1 year. 25 mg orally daily for 4 days if > 1 year.
398445|NCT01152177|Device|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
398366|NCT01152918|Behavioral|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
398367|NCT01152918|Behavioral|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
398368|NCT01152918|Behavioral|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
398369|NCT01152879|Dietary Supplement|Home Parenteral Nutrition|Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
398370|NCT01152866|Drug|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
398371|NCT01152853|Drug|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
398372|NCT01152840|Drug|RAD001|"RAD001 10 mg po daily medication~Treatments will be continued until any of the following events occur:~progression of disease,~the subject develops unacceptable toxicity,~consent to participate in the study is withdrawn."
398373|NCT01152827|Drug|RAD001|"RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~progression of disease~the subject develops unacceptable toxicity~consent to participate in the study is withdrawn"
398374|NCT01152814|Biological|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
398375|NCT01152801|Drug|Everolimus (RAD001)|
398376|NCT01152788|Drug|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
398377|NCT01152788|Drug|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
398378|NCT01152775|Other|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
398379|NCT01152775|Other|No Media|This group will not be exposed to multimedia
398380|NCT01152762|Procedure|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
398381|NCT01152749|Drug|Nicotine|Single-dose of new NRT product
398382|NCT01152749|Drug|Nicotine Gum|Single-dose of marketed nicotine gum
398383|NCT01152736|Drug|Nicotine|2 mg Single-dose
398384|NCT01152723|Drug|Nicotine|2 mg, Single Dose
398385|NCT01152710|Drug|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
398386|NCT01152697|Drug|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
398387|NCT01152697|Drug|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
398388|NCT01152697|Behavioral|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
398389|NCT01152671|Drug|Placebo|single oral dose
398390|NCT01152671|Drug|RO5024048|single oral dose
398391|NCT01152658|Biological|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
398392|NCT01152658|Other|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
398393|NCT01152645|Drug|ARQ 197|Orally twice daily administration of ARQ 197
398394|NCT01152632|Other|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
398395|NCT01152619|Drug|Placebo|Subcutaneous repeated dose
398396|NCT01152619|Drug|RO4989991|Subcutaneous repeated dose
398397|NCT01152606|Drug|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
398398|NCT01152593|Drug|Mupirocin|Intranasal cream given to patient after confirmation of colonization
398399|NCT01152580|Dietary Supplement|melatonin|3mg p.o. at bedtime daily
398400|NCT01152580|Dietary Supplement|sugar pill|lactose p.o. at bedtime daily
398401|NCT01152554|Drug|TC-5214|Tablet, oral, twice daily for 52 weeks
398402|NCT01152554|Drug|Placebo|Tablet, oral, twice daily for 52 weeks
398403|NCT01152541|Drug|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
398404|NCT01152541|Drug|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
398405|NCT01152528|Device|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
398406|NCT01152515|Drug|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
398550|NCT01151241|Other|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
398407|NCT01152489|Device|Device: Buzzy|"Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back."
398408|NCT01152489|Device|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
398409|NCT01152476|Drug|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
398410|NCT01152476|Drug|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
398411|NCT01152463|Procedure|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
398412|NCT01152450|Drug|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
398413|NCT01152450|Drug|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
398414|NCT01152450|Drug|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
398415|NCT01152437|Drug|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
398416|NCT01152437|Drug|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
398417|NCT01152411|Other|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
398418|NCT01152398|Biological|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
398419|NCT01152385|Drug|AZD1656|Oral tablet administered twice daily during 4 months
398420|NCT01152385|Drug|Placebo|administered twice daily during 4 months
398421|NCT01152372|Procedure|Insulin, glucose and staple isotopes|
398422|NCT01152359|Behavioral|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
398423|NCT01152359|Behavioral|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
398424|NCT01152346|Drug|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
398425|NCT01152346|Drug|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
398426|NCT01152333|Drug|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
398427|NCT01152333|Drug|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
398428|NCT01152320|Behavioral|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
398429|NCT01152307|Behavioral|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
398430|NCT01152294|Behavioral|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
398431|NCT01152281|Behavioral|Maximal Control|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
398432|NCT01152281|Behavioral|Instrumental and Empowering|Mix of Instrumental and empowering messages with stories of people living with HIV
398433|NCT01152281|Behavioral|Minimal Control|Control messages to increase awareness of HIV risk
398434|NCT01152281|Behavioral|Instrumental|Instrumental messages with stories of people living with HIV
398435|NCT01152281|Behavioral|Empowering|Empowering messages with stories of people living with HIV
398436|NCT01152255|Drug|MK6186|Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose <= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose <= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
398437|NCT01152255|Drug|Comparator: Placebo|Placebo tablets taken orally for seven day
398438|NCT01152242|Drug|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
398439|NCT01152242|Drug|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
398440|NCT01152216|Drug|Dimebon|20 mg orally three times daily
398441|NCT01152203|Drug|Bendamustine|Starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle
398442|NCT01152203|Drug|Bevacizumab|10 mg/kg by vein on Days 1 & 15 of every 28 day cycle
398443|NCT01152190|Drug|Tadalafil|Administered orally, once daily for 8 weeks
398444|NCT01152190|Drug|Placebo|Administered orally, once daily for 8 weeks
398446|NCT01152164|Behavioral|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
398447|NCT01152151|Device|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
398448|NCT01152151|Device|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
398449|NCT01152151|Device|Reminder letters|up to four reminder letters in september - december 2010
398450|NCT01152138|Device|Open cells stent|Cobalt Chromium Stent with open cell design
398451|NCT01152138|Device|Closed Cells Stent|Cobalt Chromium stent with closed cell design
398452|NCT01152125|Other|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
398453|NCT01152112|Device|Myomectomy|Removal of fibroids and / or polyps
398454|NCT01152099|Other|Compression Bandaging|"Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
398455|NCT01152099|Other|Manual Lymph Drainage (MLD) and Compression Bandaging|"Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
398456|NCT01152086|Other|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.~Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;~Program:~Endurance training (performed within 70-85% of the maximum heart rate)~Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)~Stretching after hiking (ca. 5 min)~Short break at half-time (ca. 15 min)"
398457|NCT01152073|Dietary Supplement|Placebo|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
398458|NCT01152073|Dietary Supplement|Second Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
398459|NCT01152073|Dietary Supplement|Third Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
398460|NCT01152047|Drug|oxytocin|40mU/min as infusion of oxytocin
398461|NCT01152034|Behavioral|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
398462|NCT01152021|Drug|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
398463|NCT01152021|Drug|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
398464|NCT01152008|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
398465|NCT01151995|Other|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
398466|NCT01151995|Other|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
398467|NCT01151982|Behavioral|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.~We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.~The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.~The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
398468|NCT01151969|Behavioral|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
398469|NCT01151943|Other|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
398470|NCT01151943|Other|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
398471|NCT01151930|Drug|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
398472|NCT01151904|Drug|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
398473|NCT01151904|Drug|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
398474|NCT01151878|Dietary Supplement|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
398475|NCT01151878|Dietary Supplement|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
398476|NCT01151865|Drug|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.~Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
398477|NCT01151865|Drug|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
398478|NCT01151852|Drug|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
398479|NCT01151852|Drug|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
398480|NCT01151839|Procedure|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
398481|NCT01151839|Procedure|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
398482|NCT01151813|Drug|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
398483|NCT01151813|Drug|Placebo|Placebo
398484|NCT01151800|Other|Using IVR to maintain ACS patients on best practice guidelines|
398485|NCT01151787|Drug|cyclobenzaprine hydrochloride|15mg daily for 3 months
398486|NCT01151787|Drug|placebo|placebo
398487|NCT01151761|Procedure|Stereotactic Body Radiotherapy|Standard of care
398488|NCT01151761|Drug|Gemcitabine|100 mg/m2, IV
398489|NCT01151761|Drug|Cisplatin|25 mg/m2, IV
398490|NCT01151761|Drug|Carboplatin|AUC 2, based on Calvert formula, IV
398491|NCT01151761|Drug|Capecitabine|1000 mg/m2, PO
398492|NCT01151761|Drug|5FU|200 mg/m2
398493|NCT01151761|Procedure|Liver transplantation|
398494|NCT01151748|Procedure|Intra-arterial infusion of chemotherapy|
398495|NCT01151735|Drug|C-1-esterase|1000 units of C-1-esterase inhibitor
398496|NCT01151735|Drug|C-1-esterase|1500 units of C-1-esterase inhibitor
398497|NCT01151735|Drug|placebo|placebo
398498|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection before vitrectomy
398499|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection after vitrectomy
398500|NCT01151696|Drug|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
398501|NCT01151696|Drug|Placebo|Placebo
398502|NCT01151683|Dietary Supplement|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
398503|NCT01151683|Dietary Supplement|placebo|Two capsules of placebo per oral twice a day
398504|NCT01151670|Drug|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
398505|NCT01151670|Drug|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
398506|NCT01151657|Dietary Supplement|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
398507|NCT01151657|Dietary Supplement|Placebo|Placebo capsules containing maltodextrin
398508|NCT01151644|Biological|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
398509|NCT01151631|Device|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
398510|NCT01151618|Device|Respironics Synchrony ventilator (Non Invasive Ventilation)|Non Invasive Ventilation using forced oscillation technique (FOT)
398511|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
398512|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
398513|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
398514|NCT01151592|Drug|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
398515|NCT01151579|Drug|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
398516|NCT01151579|Drug|Albuterol|Nebulized albuterol 2.5mg
398517|NCT01151553|Device|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
398518|NCT01151540|Drug|Rufinamide|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
398519|NCT01151514|Other|Nephrologist referral|Nephrologist specialty, renal replacement therapy
398592|NCT01150890|Drug|AMG 827 210 MG|210 mg AMG 827 IV (in the vein)
398593|NCT01150890|Drug|AMG 827 700 MG|700 mg AMG 827 IV (in the vein)
398520|NCT01151501|Device|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) >92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2＞92%.
398521|NCT01151488|Other|Resistance Training|RT 3x/wk for 4 months
398522|NCT01151449|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
398523|NCT01151449|Other|laboratory biomarker analysis|Correlative studies
398524|NCT01151436|Device|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
398525|NCT01151423|Biological|Caplacizumab|"Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure.~All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~Subjects received caplacizumab up to 30 days after the last PE session."
398526|NCT01151423|Biological|Placebo|"Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session).~The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure.~All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose.~Subjects received placebo up to 30 days after the last PE session."
398527|NCT01151410|Drug|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg~Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg~High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
398528|NCT01151410|Drug|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg~Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg~High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
398529|NCT01151397|Drug|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
398530|NCT01151397|Drug|Peg + Ribavirin|Peg+ Ribavirin for 6 months
398531|NCT01151384|Drug|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
398532|NCT01151371|Device|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
398533|NCT01151371|Device|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
398534|NCT01151371|Device|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
398535|NCT01151345|Drug|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
398536|NCT01151345|Drug|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
398537|NCT01151319|Biological|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10^9 virus particles.
398538|NCT01151319|Biological|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10^10 virus particles.
398539|NCT01151319|Biological|pSG2.HIVconsv|DNA at 4mg per dose.
398540|NCT01151319|Biological|MVA.HIVconsv|Attenuated poxvirus at 4x10^8 plaque forming units per dose.
398541|NCT01151319|Other|Placebo|Phosphate buffered saline
398542|NCT01151306|Drug|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
398543|NCT01151306|Drug|Lactose tablet|One tablet taken each evening for 6 weeks
398544|NCT01151280|Device|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
398545|NCT01151267|Other|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
398546|NCT01151267|Device|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
398547|NCT01151254|Drug|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
398548|NCT01151254|Other|Propofol|Propofol for sedation in the CVICU
398549|NCT01151241|Procedure|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
398594|NCT01150890|Drug|Placebo|Placebo IV (in the vein)
398551|NCT01151241|Other|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
398552|NCT01151228|Other|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
398553|NCT01151215|Drug|AZD8931|Tablet, oral, bd
398554|NCT01151215|Drug|anastrozole|Tablet, oral, od
398555|NCT01151215|Drug|Placebo|Tablet, oral
398556|NCT01151202|Drug|AG NPP709syrup|
398557|NCT01151189|Biological|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
398558|NCT01151189|Biological|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
398559|NCT01151176|Drug|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
398560|NCT01151176|Drug|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:~Blood Glucose >141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; > 400=16U"
398561|NCT01150916|Procedure|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
398562|NCT01150851|Other|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
398563|NCT01150851|Other|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
398564|NCT01150838|Drug|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
398565|NCT01150747|Drug|ceftriaxone|250mg IM once
398566|NCT01150747|Drug|Azithromycin|1 gm once
398567|NCT01149226|Drug|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
398568|NCT01151137|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
398569|NCT01151137|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
398570|NCT01151124|Biological|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
398571|NCT01151111|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
398572|NCT01151098|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
398573|NCT01151085|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:~Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.~Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:~administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.~Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.~However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.~In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.~Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
398574|NCT01151072|Drug|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
398575|NCT01151059|Biological|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
398576|NCT01151046|Drug|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
398577|NCT01151046|Drug|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
398578|NCT01151046|Drug|Exemestane|Exemestane (25 mg) administered orally once per day
398579|NCT01151033|Device|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
398580|NCT01151020|Device|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
398581|NCT01150994|Behavioral|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
398582|NCT01150981|Drug|Rosiglitazone|One 8mg capsule daily for 6 weeks.
398583|NCT01150981|Drug|Placebo|One capsule daily for 6 weeks.
398584|NCT01150968|Behavioral|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
398585|NCT01150955|Dietary Supplement|Resveratrol|500 mg three times a day for five weeks.
398586|NCT01150955|Other|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
398587|NCT01150942|Biological|JE vaccine|3 times, IM
398588|NCT01150929|Device|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
398589|NCT01150903|Other|no intervention|non-interventional study
398590|NCT01150903|Other|no intervention|non-interventional study
398591|NCT01150890|Drug|AMG 827 350 MG|350 mg AMG 827 IV (in the vein)
398595|NCT01150877|Drug|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
398596|NCT01150864|Device|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
398597|NCT01150812|Drug|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
398598|NCT01150786|Dietary Supplement|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
398599|NCT01150786|Other|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
398600|NCT01150760|Drug|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
398601|NCT01150695|Other|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
398602|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine [approximately 1x10^9 colony forming units (cfu)/mL] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
398603|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
398604|NCT01150682|Genetic|RNA analysis|
398605|NCT01150682|Genetic|reverse transcriptase-polymerase chain reaction|
398606|NCT01150682|Other|enzyme-linked immunosorbent assay|
398607|NCT01150682|Other|immunohistochemistry staining method|
398608|NCT01150682|Other|laboratory biomarker analysis|
398609|NCT01150669|Other|laboratory biomarker analysis|Samples are analyzed in laboratory studies
398610|NCT01150656|Genetic|gene expression analysis|
398611|NCT01150656|Genetic|microarray analysis|
398612|NCT01150656|Genetic|protein expression analysis|
398613|NCT01150656|Genetic|reverse transcriptase-polymerase chain reaction|
398614|NCT01150656|Genetic|western blotting|
398615|NCT01150656|Other|laboratory biomarker analysis|
398616|NCT01150656|Other|pharmacological study|
398617|NCT01150643|Genetic|gene expression analysis|
398618|NCT01150643|Genetic|microarray analysis|
398619|NCT01150643|Genetic|polymerase chain reaction|
398620|NCT01150643|Genetic|polymorphism analysis|
398621|NCT01150643|Other|immunohistochemistry staining method|
398622|NCT01150643|Other|laboratory biomarker analysis|
398623|NCT01150630|Drug|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
398624|NCT01150630|Drug|cisplatin|30 mg/mq every 14 days for 6 months
398625|NCT01150630|Drug|epirubicin|30 mg/mq every 14 days for 6 months
398626|NCT01150630|Drug|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
398627|NCT01150617|Drug|Insulin glargine plus insulin analogues|"Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c<6.5% at the end of the follow-up.~Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of < 7.0% at the end of the follow-up."
398628|NCT01150604|Behavioral|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
398629|NCT01150578|Drug|No intervention|No intervention
398630|NCT01150565|Drug|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
398631|NCT01150539|Other|16-week exercise training program|The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
398632|NCT01150539|Other|Control Group without PCOS|A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
398633|NCT01150526|Dietary Supplement|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
398634|NCT01150526|Dietary Supplement|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
398635|NCT01150526|Dietary Supplement|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
398636|NCT01150526|Dietary Supplement|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
398637|NCT01150513|Drug|EC-T|four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
398638|NCT01150513|Drug|TP|six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
398639|NCT01150500|Device|MDT-4107 Zotarolimus-Eluting Coronary Stent|
398640|NCT01150487|Procedure|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
398641|NCT01150474|Drug|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
398642|NCT01150474|Drug|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
398643|NCT01150461|Drug|losartan|Losartan 50 mg b.i.d
398644|NCT01150461|Drug|placebo|Placebo b.i.d.
398720|NCT01149850|Other|immunohistochemistry staining method|Correlative studies
398645|NCT01150448|Drug|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
398646|NCT01150448|Drug|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
398647|NCT01150422|Other|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
398648|NCT01150409|Drug|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
398649|NCT01150409|Drug|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
398650|NCT01150383|Other|Physical exercise training with supplemental oxygen|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.~After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above)."
398651|NCT01150383|Other|"Physical exercise training with room air supplementation"|"Prior to the exercise training, an intervention-free control period with usual care is planned.~Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.~After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above)."
398652|NCT01150370|Device|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
398653|NCT01150357|Drug|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
398654|NCT01150357|Drug|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
398655|NCT01150357|Drug|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
398656|NCT01150344|Drug|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
398657|NCT01150344|Drug|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
398658|NCT01150331|Drug|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
398659|NCT01150331|Drug|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
398660|NCT01150318|Drug|Administration of 131 iodine|100 mCi 131 iodine irradiation
398661|NCT01150305|Biological|blood sample|Peripheral whole blood sample, 5 ml
398662|NCT01150292|Dietary Supplement|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
398663|NCT01150292|Dietary Supplement|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
398664|NCT01150266|Drug|Alteplase (tPA)|0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
398665|NCT01150253|Dietary Supplement|L. paracasei fermented milk|
398666|NCT01150214|Procedure|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
398667|NCT01150201|Drug|Aliskiren|For CKD treatment
398668|NCT01150201|Drug|Losartan|Control
398669|NCT01150188|Dietary Supplement|Amino acids|11 g amino acids two times per day for eight weeks
398670|NCT01150188|Dietary Supplement|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
398671|NCT01150175|Procedure|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
398672|NCT01150175|Procedure|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
398673|NCT01150162|Drug|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
398674|NCT01150162|Drug|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
398675|NCT01150149|Behavioral|No face touch|
398676|NCT01150149|Device|Surgical face mask|
398677|NCT01150149|Device|Surgical face mask + no face touch|
398678|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- low dose|
398679|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- High dose|
398680|NCT01150123|Biological|Placebo- Saline|
398721|NCT01149850|Genetic|microarray analysis|Correlative studies
398681|NCT01150110|Device|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.~Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
398682|NCT01150097|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
398683|NCT01150097|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
398684|NCT01150097|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
398685|NCT01150097|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
398686|NCT01150097|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
398687|NCT01150097|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
398688|NCT01150084|Other|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
398689|NCT01150084|Other|delayed treatment|to start at week 10
398690|NCT01150058|Genetic|western blotting|
398691|NCT01150058|Other|flow cytometry|
398692|NCT01150058|Other|laboratory biomarker analysis|
398693|NCT01150045|Drug|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
398694|NCT01150045|Drug|5-fluorouracil|Patients receive 400 mg/m^2 intravenous bolus then 2400 mg/m^2 continuous intravenous infusion over 46-48 hours.
398695|NCT01150045|Other|placebo|Patients receive placebo administered by mouth, once daily.
398696|NCT01150045|Drug|oxaliplatin|Patients receive 85 mg/m^2 intravenous over two hours.
398697|NCT01150045|Drug|leucovorin|Patients receive 400 mg/m^2 intravenous over two hours.
398698|NCT01150032|Other|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:~hip and wrist Dual energy X-ray Absorptiometry (DXA)~wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)~hip Quantitative Computed Tomography (QCT)~High Resolution Digital X-Ray of calcaneum using BMA(tm) system~low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
398699|NCT01150019|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
398700|NCT01150006|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
398701|NCT01149993|Drug|Myfortic (mycophenolic acid)|720mg twice a day for 7 days prior to transplantation
398702|NCT01149993|Drug|Myfortic (mycophenolic acid)|720mg twice a day after transplant
398703|NCT01149993|Drug|Thymoglobulin (anti-thymocyte globulin)|up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
398704|NCT01149993|Drug|Thymoglobulin (anti-thymocyte globulin)|standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
398705|NCT01149980|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
398706|NCT01149967|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
398707|NCT01149954|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
398708|NCT01149941|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
398709|NCT01149915|Drug|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
398710|NCT01149902|Biological|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
398711|NCT01149889|Procedure|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
398712|NCT01149876|Other|Nu Skin Product|Thin layer of Nu Skin product applied to face.
398713|NCT01149876|Other|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
398714|NCT01149876|Drug|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
398715|NCT01149876|Other|CeraVe moisturizer|Thin layer of CeraVe applied to face.
398716|NCT01149863|Drug|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
398717|NCT01149850|Biological|bevacizumab|Given IV
398718|NCT01149850|Drug|temozolomide|Given orally
398719|NCT01149850|Other|laboratory biomarker analysis|Correlative studies
398723|NCT01149837|Device|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
398724|NCT01149824|Drug|Salvinorin A|
398725|NCT01149824|Drug|Placebo|
398726|NCT01149811|Drug|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
398727|NCT01149811|Drug|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
398728|NCT01149798|Drug|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.~Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
398729|NCT01149785|Drug|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
398730|NCT01149785|Drug|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
398731|NCT01149785|Drug|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
398732|NCT01149772|Behavioral|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
398733|NCT01149759|Drug|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
398734|NCT01149746|Drug|Tamsulosin|Test 0.4 mg Capsule
398735|NCT01149746|Drug|Tamsulosin|Reference Listed 0.4 mg Capsule
398736|NCT01149733|Drug|Tamsulosin|Test 0.4 mg Capsule
398737|NCT01149733|Drug|Tamsulosin|Reference Listed 0.4 Capsule
398738|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
398739|NCT01149720|Drug|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
398740|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
398741|NCT01149707|Drug|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
398742|NCT01149707|Drug|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
398743|NCT01149707|Drug|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
398744|NCT01149707|Drug|Placebo Enema|Placebo Enema, once-daily, intrarectally
398745|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
398746|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
398747|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
398748|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
398749|NCT01149681|Drug|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).~Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
398750|NCT01149668|Drug|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
398751|NCT01149655|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
398752|NCT01149655|Drug|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
398753|NCT01149642|Dietary Supplement|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
398754|NCT01149642|Dietary Supplement|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
398755|NCT01149629|Drug|Droxidopa|One capsule containing 300 mg droxidopa, given once
398756|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
398757|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
398758|NCT01149616|Drug|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
398759|NCT01149616|Drug|placebo|2 ml normal saline IV x1
398760|NCT01149603|Device|HeartMate II Ventricular Assist Device|The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
398761|NCT01149590|Procedure|Computer Tomography Angiography|Computed Tomography Angiography
398762|NCT01149577|Drug|Olanzapine|06 weeks treatment with Olanzapine in a flexible dosage schedule.
398763|NCT01149564|Drug|iv ibuprofen|
398764|NCT01149564|Drug|oral ibuprofen|
398765|NCT01149538|Drug|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
398769|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
398770|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
398771|NCT01149486|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
398772|NCT01149486|Drug|Hyzaar®|100/25 mg Tablets
398773|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
398774|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
398775|NCT01149460|Drug|Valacyclovir|Test 1000 mg Tablet
398776|NCT01149460|Drug|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
398777|NCT01149434|Drug|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
398778|NCT01149434|Drug|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
398779|NCT01149421|Drug|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
398780|NCT01149421|Drug|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
398781|NCT01149408|Drug|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
398782|NCT01149395|Drug|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
398783|NCT01149369|Drug|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
398784|NCT01149369|Drug|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
398785|NCT01149356|Drug|Exemestane|Given orally
398786|NCT01149356|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
398787|NCT01149356|Drug|Goserelin Acetate|Given subcutaneously to premenopausal patients
398788|NCT01149343|Biological|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
398789|NCT01149330|Drug|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
398790|NCT01149317|Procedure|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
398791|NCT01149304|Drug|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
398792|NCT01149304|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
398793|NCT01149304|Drug|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
398794|NCT01149278|Drug|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
398795|NCT01149278|Other|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
398796|NCT01149265|Behavioral|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
398797|NCT01149265|Behavioral|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
398798|NCT01149252|Other|Psoralait|Cream to be used as instructed.
398799|NCT01149252|Other|Placebo cream.|Cream to be used as instructed
398800|NCT01149213|Device|transcranial direct current stimulation|tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
398801|NCT01149200|Drug|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
398802|NCT01149200|Drug|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
398803|NCT01149174|Drug|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
398804|NCT01149161|Procedure|Routine central neck dissection|Level VI neck node dissection during thyroid operation
398805|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation~Check head and cannula position~Increase mean arterial pressure~Increase pump flow~Increase systemic oxygenation~Increase PaCO2 > 45~Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses~Consider PRBC transfusion for Hct < 21%"
398806|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
398807|NCT01149135|Device|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
398808|NCT01149135|Device|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
398809|NCT01149122|Drug|Gemcitabine/Oxaliplatin|GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
398810|NCT01149122|Drug|Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)|GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
398811|NCT01149109|Drug|Temozolomide and lomustine|
398812|NCT01149109|Drug|Temozolomide|
398813|NCT01149096|Biological|filgrastim|Given subcutaneously
398814|NCT01149096|Procedure|bone marrow donation|Undergo bone marrow harvest
398815|NCT01149096|Other|laboratory biomarker analysis|Optional correlative studies
398816|NCT01149083|Drug|Carboplatin|Given IV
398817|NCT01149083|Other|Laboratory Biomarker Analysis|Correlative studies
398818|NCT01149083|Drug|Veliparib|Given PO
398819|NCT01149057|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
398820|NCT01149044|Procedure|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
398821|NCT01149031|Device|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
398822|NCT01149018|Drug|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
398823|NCT01149018|Drug|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
398824|NCT01149005|Drug|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
398825|NCT01149005|Drug|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
398826|NCT01148992|Drug|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
398827|NCT01148992|Drug|Placebo|0mg
398828|NCT01148979|Drug|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
398829|NCT01148979|Drug|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
398830|NCT01148966|Drug|aminolevulinic acid|Given PO
398831|NCT01148966|Other|laboratory biomarker analysis|Correlative studies
398832|NCT01148966|Procedure|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
398833|NCT01148953|Drug|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
398834|NCT01148953|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
398835|NCT01148914|Other|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
398836|NCT01148901|Drug|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
398837|NCT01148888|Drug|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
398838|NCT01148875|Behavioral|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
398839|NCT01148862|Device|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
398840|NCT01148849|Biological|MGAH22|"MGAH22 will be administered by IV infusion once per week for 4 weeks in the following dose escalation cohorts: 0.1, 0.3, 1.0, 3.0, and 6.0 mg/kg; and once every 3 weeks in the following dose escalation cohorts: 10.0, 15.0, and 18.0 mg/kg.~An additional cohort of up to 24 patients with breast or gastric cancer will be enrolled and treated at a dose of 15 mg/kg every three weeks."
398841|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
398842|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
398843|NCT01148823|Other|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
398844|NCT01148823|Other|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
398845|NCT01148810|Drug|BAF312|
398846|NCT01148810|Drug|Placebo|
398847|NCT01148797|Drug|Canakinumab|
398848|NCT01148784|Procedure|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
398849|NCT01148771|Drug|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
398850|NCT01148771|Drug|ertapenem|1 gram 30 minute infusion q24h for 3 days
398851|NCT01148758|Drug|RO5323441|cohorts receiving multiple doses iv
398852|NCT01148745|Drug|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
398853|NCT01148732|Procedure|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
398854|NCT01148719|Other|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
398855|NCT01148706|Device|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
398856|NCT01148693|Drug|gentamicin|10mg per 10ml of contrast media
398857|NCT01148693|Drug|Placebo|Distilled water
398858|NCT01148680|Biological|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
398859|NCT01148667|Dietary Supplement|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
398860|NCT01148667|Dietary Supplement|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
398861|NCT01148641|Dietary Supplement|LNS|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
398960|NCT01147848|Drug|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
398862|NCT01148628|Drug|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
398863|NCT01148615|Drug|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
398864|NCT01148615|Drug|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
398865|NCT01148602|Other|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
398866|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
398867|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
398868|NCT01148576|Drug|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
398869|NCT01148576|Drug|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
398870|NCT01148563|Device|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
398871|NCT01148537|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 * 20 mcg/h.
398872|NCT01148537|Drug|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 * 20.
398873|NCT01148537|Drug|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
398874|NCT01148524|Biological|No Vaccine|
398875|NCT01148524|Biological|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
398876|NCT01148511|Drug|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
398877|NCT01148498|Drug|solanezumab|400mg administered once intravenously
398878|NCT01148485|Other|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
398879|NCT01148472|Drug|Escitalopram|20mg once daily; orally
398880|NCT01148472|Drug|Duloxetine|60mg once daily; orally
398881|NCT01148459|Biological|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
398882|NCT01148459|Biological|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly"
398883|NCT01148459|Biological|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.~The vaccine will be administered intramuscularly."
398884|NCT01148446|Drug|Cyclophosphamide|750 mg/mq IV, day 1
398885|NCT01148446|Drug|Cyclophosphamide|50 mg/mq IV, day 1
398886|NCT01148446|Drug|Doxorubicin|50 mg/mq IV, day1
398887|NCT01148446|Drug|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
398888|NCT01148446|Drug|Prednisone|75 mg/mq IV, days 1-5
398889|NCT01148446|Drug|Prednisone|60 mg/mq IV/PO, days 1-5
398890|NCT01148446|Drug|Epirubicin|50 mg/mq IV, day 1
398891|NCT01148446|Drug|Vinblastine|5 mg/mq IV, day 1
398892|NCT01148446|Drug|Rituximab|375 mg/mq IV, day 1
398893|NCT01148446|Drug|G-CSF|300 µg tot., SC; days 7-11
398894|NCT01148420|Drug|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
398895|NCT01148420|Drug|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
398896|NCT01148394|Other|Multimodal rehabilitation|
398897|NCT01148368|Drug|fimasartan|single administration of fimasartan 120mg
398898|NCT01148342|Drug|MDMA|
398899|NCT01148342|Drug|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 &amp; 1.6 mg/kg
398900|NCT01148329|Device|Coronary stenting|The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
398901|NCT01148316|Drug|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
398902|NCT01148316|Behavioral|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
398903|NCT01148303|Drug|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
398904|NCT01148303|Drug|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
398905|NCT01148303|Drug|Placebo|Placebo
398906|NCT01148290|Procedure|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
398907|NCT01148290|Procedure|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
398908|NCT01148277|Drug|Propofol and Remifentnyl|Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
398909|NCT01148277|Drug|midazolam and fentanyl|Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
399056|NCT01147263|Other|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
398910|NCT01148277|Drug|midazolam anf fentanyl|group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
398911|NCT01148264|Drug|olanzapine|1x10mg per day for three days
398912|NCT01148264|Drug|metoclopramide|3x10mg per day for three days
398913|NCT01148225|Drug|adalimumab|Adalimumab, pre-filled syringe, administered by SC injection
398914|NCT01148199|Device|Self-expandable metalic stent|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
398915|NCT01148199|Device|Multiple plastic stents|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
398916|NCT01148186|Behavioral|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
398917|NCT01148173|Drug|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
398918|NCT01148160|Drug|voriconazole|intravenous, oral administration
398919|NCT01148147|Drug|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
398920|NCT01148147|Drug|Placebo|Intracoronary Placebo administration
398921|NCT01148121|Other|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
398922|NCT01148108|Drug|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
398923|NCT01148095|Drug|AZD2516|Oral, single, daily, 11 days
398924|NCT01148095|Drug|Placebo|
398925|NCT01148082|Procedure|Self administered Surveys|
398926|NCT01148082|Procedure|Interviews|
398927|NCT01148069|Procedure|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
398928|NCT01148056|Radiation|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
398929|NCT01148043|Drug|Hydroxychloroquine|200 mg capsule, 2 capsules QD for 24 weeks.
398930|NCT01148043|Drug|cellulose|capsule, 2 capsules QD for 24 weeks
398931|NCT01148030|Drug|3M Skin and Nasal Antiseptic|Intra-nasal dosing
398932|NCT01148017|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
398933|NCT01148004|Drug|Fenofibrate|
398934|NCT01148004|Drug|Ritonavir|
398935|NCT01148004|Drug|Lopinavir/Ritonavir|
398936|NCT01147991|Biological|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
398937|NCT01147991|Other|laboratory biomarker analysis|
398938|NCT01147991|Other|pharmacological study|
398939|NCT01147978|Behavioral|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
398940|NCT01147965|Biological|AD5 CEA Vaccine|AD5[E1-, E2b-]-CEA Vector Vaccine
398941|NCT01147952|Behavioral|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
398942|NCT01147939|Drug|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
398943|NCT01147939|Drug|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
398944|NCT01147926|Drug|Placebo|Placebo matched to Prucalopride tablet orally once daily.
398945|NCT01147926|Drug|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
398946|NCT01147913|Behavioral|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
398947|NCT01147913|Behavioral|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
398948|NCT01147900|Biological|Boostrix™|Intramuscular, single dose
398949|NCT01147900|Biological|Boostrix™-US formulation|Intramuscular, single dose
398950|NCT01147887|Drug|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
398951|NCT01147874|Procedure|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
398952|NCT01147861|Drug|GSK256073|5mg in the AM and 5mg in the PM
398953|NCT01147861|Drug|GSK256073|10mg in the AM
398954|NCT01147861|Drug|GSK256073|50mg in the AM
398955|NCT01147861|Drug|GSK256073|25mg in the AM and 25mg in the PM
398956|NCT01147861|Other|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
398957|NCT01147848|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
398958|NCT01147848|Drug|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
398959|NCT01147848|Drug|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
398961|NCT01147835|Dietary Supplement|Chinese Licorice Root|Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
398962|NCT01147822|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
398963|NCT01147822|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
398964|NCT01147809|Drug|Eltrombopag olamine|thrombopoietin receptor agonist
398965|NCT01147809|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
398966|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
398967|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
398968|NCT01147783|Other|CT, MRI|
398969|NCT01147770|Drug|progesterone|duration
398970|NCT01147757|Drug|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
398971|NCT01147744|Drug|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
398972|NCT01147744|Drug|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
398973|NCT01147744|Drug|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
398974|NCT01147744|Drug|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
398975|NCT01147744|Drug|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
398976|NCT01147744|Drug|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
398977|NCT01147744|Drug|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
398978|NCT01147744|Drug|Placebo montelukast|Placebo capsule once daily in the evening
398979|NCT01147744|Drug|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
398980|NCT01147744|Drug|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
398981|NCT01147731|Biological|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
398982|NCT01147718|Biological|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
398983|NCT01147705|Drug|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
398984|NCT01147705|Drug|Placebo|Same appearance/dosing as active drug.
398985|NCT01147692|Biological|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
398986|NCT01147666|Drug|FG-4592|Different dose levels
398987|NCT01147666|Drug|Epoetin Alfa|Per current label instruction
398988|NCT01147666|Drug|FG-4592|Different dose levels
398989|NCT01147666|Other|Placebo|Inactive capsules matching appearance of FG-4592 capsules
398990|NCT01147666|Drug|Epoetin Alfa|Per current label instruction
398991|NCT01147653|Biological|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
398992|NCT01147653|Other|Placebo|Placebo
398993|NCT01147640|Drug|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
398994|NCT01147640|Drug|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
398995|NCT01147627|Drug|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
398996|NCT01147627|Drug|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
398997|NCT01147627|Drug|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
398998|NCT01147614|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
398999|NCT01147614|Behavioral|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
399000|NCT01147601|Drug|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
399001|NCT01147601|Drug|Control (placebo) group|Control (placebo) group
399002|NCT01147588|Drug|lansoprazole|60 mg (2x30-mg capsule), once daily
399003|NCT01147588|Drug|omeprazole|80 mg (2x40-mg capsule), once daily
399004|NCT01147588|Drug|esomeprazole|40 mg (1x40-mg capsule), once daily
399005|NCT01147588|Drug|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
399006|NCT01147575|Dietary Supplement|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
399007|NCT01147575|Dietary Supplement|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
399008|NCT01147562|Procedure|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
399009|NCT01147549|Drug|[C14]AZD9668|Oral Solution 60 mg Single Dose
399010|NCT01147536|Biological|HSPPC-96|HSPPC-96 intradermal injection every week for 4 weeks, followed by an injection every other week for 8 weeks
399011|NCT01147523|Drug|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
399012|NCT01147510|Drug|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
399013|NCT01147510|Drug|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
399014|NCT01147497|Drug|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
399015|NCT01147497|Drug|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
399016|NCT01147484|Drug|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
399017|NCT01147471|Device|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
399018|NCT01147471|Procedure|operative rib fixation surgery|
399019|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
399020|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
399021|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
399022|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
399023|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
399024|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
399025|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
399026|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
399027|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
399028|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
399029|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
399030|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
399031|NCT01147445|Biological|Double Mutant Heat- Labile Toxin (dmLT)|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
399032|NCT01147432|Drug|PF-04427429|Single dose IV infusion up to 300mg
399033|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
399034|NCT01147432|Drug|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
399035|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
399036|NCT01147432|Other|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
399037|NCT01147419|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
399038|NCT01147419|Device|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
399039|NCT01147406|Drug|N6022|This is an injectible formulation which will be given at 5, 15 & 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
399040|NCT01147406|Drug|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
399041|NCT01147393|Drug|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over ~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
399042|NCT01147393|Biological|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
399043|NCT01147380|Biological|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
399044|NCT01147367|Behavioral|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
399045|NCT01147354|Dietary Supplement|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
399046|NCT01147354|Other|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
399047|NCT01147341|Drug|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
399048|NCT01147341|Drug|Placebo|prefilled saline syringe
399049|NCT01147328|Other|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
399050|NCT01147315|Procedure|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
399051|NCT01147302|Biological|Placebo|
399052|NCT01147302|Biological|C1 Esterase Inhibitor (Human)|
399053|NCT01147289|Drug|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
399054|NCT01147289|Drug|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
399055|NCT01147276|Drug|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
399249|NCT01145755|Drug|Duloxetine|60 mg once daily
399057|NCT01147250|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
399058|NCT01147250|Drug|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
399059|NCT01147237|Device|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
399060|NCT01147224|Drug|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
399061|NCT01147211|Drug|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
399062|NCT01147198|Dietary Supplement|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
399063|NCT01147198|Dietary Supplement|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
399064|NCT01147185|Device|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
399065|NCT01147185|Device|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
399066|NCT01147172|Device|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
399067|NCT01147159|Other|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
399068|NCT01147146|Drug|propofol, fentanyl, atracurium|general anesthesia
399069|NCT01147146|Drug|bupivacaine|spinal anesthesia
399070|NCT01147146|Drug|bupivacaine, Midazolam|spinal anesthesia & sedation
399071|NCT01147133|Drug|Plavix|1x75 mg
399072|NCT01147133|Drug|Kardogrel|1x75 mg
399073|NCT01147120|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
399074|NCT01147120|Procedure|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
399075|NCT01147107|Drug|Raltegravir|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
399076|NCT01147107|Drug|Efavirenz|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
399077|NCT01147081|Biological|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
399078|NCT01147068|Biological|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
399079|NCT01147055|Drug|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
399080|NCT01147055|Drug|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
399081|NCT01147055|Drug|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
399082|NCT01147042|Drug|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
399083|NCT01147029|Drug|angiogenesis inhibitor GSAO|
399084|NCT01147029|Other|laboratory biomarker analysis|
399085|NCT01147029|Other|pharmacological study|
399086|NCT01147029|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
399087|NCT01147016|Biological|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
399088|NCT01147016|Drug|cyclophosphamide|As prescribed by physician, standard of care.
399089|NCT01147016|Drug|doxorubicin hydrochloride|As prescribed by physician, standard of care.
399090|NCT01147016|Drug|paclitaxel|As prescribed by physician, standard of care.
399091|NCT01147016|Other|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
399092|NCT01147016|Procedure|neoadjuvant therapy|As prescribed by physician, standard of care.
399093|NCT01147016|Procedure|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
399094|NCT01147003|Drug|Investigational new drug, company code: BGG492|
399095|NCT01147003|Drug|Placebo|
399096|NCT01147003|Drug|Investigational new drug, company code: BGG492|
399097|NCT01146990|Drug|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
399098|NCT01146977|Other|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
399099|NCT01146977|Other|Autologous HCT|"After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.~If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
399100|NCT01146964|Procedure|MSSICS|Manual super small incision cataract surgery
399101|NCT01146964|Procedure|Phacoemulsification|cataract surgery with Phacoemulsification
399102|NCT01146951|Drug|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.~Target maintenance dose:~15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
399103|NCT01146951|Drug|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
399104|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
399105|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
399106|NCT01146925|Drug|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
399107|NCT01146925|Drug|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
399108|NCT01146912|Other|Text Message|Text message vaccine reminders
399109|NCT01146912|Other|automated call|Automated call
399110|NCT01146899|Other|Provider Alert|Provider influenza vaccine alert
399111|NCT01146886|Drug|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
399112|NCT01146886|Drug|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
399113|NCT01146873|Drug|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
399114|NCT01146873|Drug|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
399115|NCT01146873|Drug|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
399116|NCT01146873|Drug|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
399117|NCT01146860|Drug|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
399118|NCT01146860|Drug|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
399119|NCT01146847|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
399120|NCT01146834|Drug|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
399121|NCT01146834|Drug|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
399122|NCT01146834|Drug|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C)
399123|NCT01146821|Dietary Supplement|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight [IBW] fish oil in addition to standard care
399124|NCT01146821|Dietary Supplement|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight [IBW] fish oil in addition to standard care.
399125|NCT01146808|Drug|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
399126|NCT01146795|Drug|Carboplatin, paclitaxel, and bevacizumab|"Carboplatin will be administered at an AUC of 5-6 (at the discretion of the physician) day 1 every 3 weeks, paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks and bevacizumab 15 mg/kg day 1 every 3 weeks.~After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill ALL of the following criteria to be considered eligible for surgical exploration. 1) ≥50% reduction in pretreatment CA-125 and 2) No medical contraindications to surgery.~After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4."
399127|NCT01146782|Device|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
399128|NCT01146769|Other|Pelvic floor exercise|Pelvic floor strengthening exercise
399129|NCT01146756|Drug|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
399130|NCT01146743|Procedure|EUS-guided gallbladder drainage|EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
399131|NCT01146743|Procedure|percutaneous transhepatic gallbladder drainage|Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
399132|NCT01146730|Behavioral|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
399133|NCT01146730|Behavioral|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
399134|NCT01146717|Behavioral|Exercise|Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
399135|NCT01146717|Behavioral|Balance training|A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
399208|NCT01146093|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
399136|NCT01146704|Dietary Supplement|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 15% protein and 55% carbohydrate.
399137|NCT01146704|Dietary Supplement|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 30% protein and 40% carbohydrate.
399138|NCT01146691|Other|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
399139|NCT01146678|Drug|Insulin glargine HOE901|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
399140|NCT01146678|Drug|Lixisenatide AVE0010|"Pharmaceutical form:solution for injection~Route of administration: subcutaneous"
399141|NCT01146665|Behavioral|Computer-based PAF|This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
399142|NCT01146665|Behavioral|Computer-based Sham|This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
399143|NCT01146652|Drug|SAR153191 (REGN88)|"Pharmaceutical form: solution~Route of administration: subcutaneous"
399144|NCT01146639|Radiation|DynaCT|One extra set of images with DynaCT including one extra injection of contrast medium.
399145|NCT01146639|Drug|Iodixanol|One extra set of images with DynaCT including one extra injection of 50 ml contrast medium.
399146|NCT01146626|Drug|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
399147|NCT01146626|Drug|Peg+ Ribavirine|Peg+ Ribavirine
399148|NCT01146613|Drug|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
399149|NCT01146613|Drug|Placebo|identical matched placebo x 2, 2xday, 13 weeks
399150|NCT01146600|Drug|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
399151|NCT01146600|Drug|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
399152|NCT01146587|Device|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
399153|NCT01146587|Device|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
399154|NCT01146587|Other|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
399155|NCT01146574|Biological|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
399156|NCT01146574|Biological|Placebo|Placebo
399157|NCT01146561|Biological|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
399158|NCT01146561|Other|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
399159|NCT01146548|Drug|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
399160|NCT01146535|Drug|Interferon-alpha|150 IU lozenges bid for 5 days
399161|NCT01146535|Drug|Oseltamivir|75 mg capsules bid for 5 days
399162|NCT01146535|Other|maltose|200 mg maltose lozenges bid for 5 days
399163|NCT01146522|Drug|LCQ908|
399164|NCT01146522|Drug|Placebo|
399165|NCT01146509|Drug|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
399166|NCT01146496|Device|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
399167|NCT01146483|Drug|Rosuvastatin, Pantoprazole|"Rosuvastatin, 10 mg tablets, single dose on the morning~Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study."
399168|NCT01146470|Dietary Supplement|RGC|dosage of Red Grape Cells once a day, during 3 months
399169|NCT01146470|Dietary Supplement|Placebo|dosage of Placebo once a day, during 3 months
399170|NCT01146457|Drug|Morphine|Active dosage
399171|NCT01146457|Drug|Saline|Saline Control
399172|NCT01146444|Other|UV A and B irradiation|UV irradiation
399173|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
399174|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
399175|NCT01146418|Biological|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
399176|NCT01146418|Biological|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
399209|NCT01146080|Device|Promus Element|Promus Element implanted to treat coronary artery lesions.
399177|NCT01146379|Other|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
399178|NCT01146340|Radiation|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
399179|NCT01146327|Drug|PF-04620110|Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
399180|NCT01146327|Drug|PF-04620110|Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
399181|NCT01146327|Drug|PF-04620110|Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
399182|NCT01146327|Drug|PF-04620110|Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
399183|NCT01146327|Drug|Placebo|Multiple oral doses of placebo will be given once daily for 2 weeks.
399184|NCT01146314|Behavioral|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
399185|NCT01146301|Drug|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
399186|NCT01146288|Drug|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
399187|NCT01146288|Drug|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
399188|NCT01146275|Radiation|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
399189|NCT01146262|Other|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
399190|NCT01146262|Procedure|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
399191|NCT01146249|Other|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
399192|NCT01146236|Device|Sutures|Orthopedic surgical wounds closed with sutures
399193|NCT01146236|Device|Staples|Orthopedic surgical wounds closed with metallic staples
399194|NCT01146223|Other|laboratory biomarker analysis|Correlative studies
399195|NCT01146210|Other|laboratory biomarker analysis|Correlative studies
399196|NCT01146197|Drug|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
399197|NCT01146184|Device|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
399198|NCT01146171|Drug|BMS-844203 (CT-322)|Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
399199|NCT01146158|Procedure|Axillary dissection for breast carcinomas|surgery Axillary dissection
399200|NCT01146145|Drug|Ketamine|intravenous morphine titration combined to ketamine
399201|NCT01146132|Dietary Supplement|Conventional diet +/- wine|usual eating habits
399202|NCT01146132|Dietary Supplement|Luxembourg variant of Mediterranean diet + physical activity +/- wine|"Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet"
399203|NCT01146119|Biological|Multimeric-001, 500 mcg|Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
399204|NCT01146119|Biological|Adjuvanted PBS|Adjuvanted PBS was administered twice with an interval of 19-23 days.
399205|NCT01146119|Biological|PBS and TIV 15%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
399206|NCT01146119|Biological|PBS and TIV 50%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
399207|NCT01146106|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
399248|NCT01145755|Drug|Placebo|
399210|NCT01146080|Device|Promus|Promus stent implanted to treat coronary artery lesions
399211|NCT01146067|Drug|Rivastigmine|Rivastigmine capsules 1.5 mg
399212|NCT01146054|Device|CyberKnife based stereotactic radiotherapy|"Initial orthogonal images will be obtained to confirm location of fiducial seeds.~Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.~Quality assurance will be performed as per standard practice at each participating institution."
399213|NCT01146054|Drug|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
399214|NCT01146054|Drug|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
399215|NCT01146041|Drug|Rivastigmine|Rivastigmine 1.5 mg Capsules
399216|NCT01146028|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
399217|NCT01146015|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
399218|NCT01146002|Drug|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
399219|NCT01145989|Drug|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
399220|NCT01145976|Drug|Cy-ATG|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
399221|NCT01145976|Drug|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
399222|NCT01145963|Other|Control pasta|control pasta
399223|NCT01145963|Other|Experimental pasta B|experimental pasta
399224|NCT01145963|Other|Experimental pasta C|experimental pasta
399225|NCT01145950|Drug|LBEC0101|Etanercept 25mg, single dose
399226|NCT01145950|Drug|Enbrel|Etanercept 25mg, single dose
399227|NCT01145937|Procedure|PET|Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty
399228|NCT01145937|Procedure|DALK|Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
399229|NCT01145924|Procedure|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
399230|NCT01145898|Drug|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
399231|NCT01145885|Drug|BI 6727|PLK-1 inhibitor
399232|NCT01145872|Behavioral|Mindfulness Based Cognitive Therapy|
399233|NCT01145872|Behavioral|Health Enhancement Program|
399234|NCT01145859|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
399235|NCT01145846|Drug|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
399236|NCT01145833|Other|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
399237|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
399238|NCT01145820|Dietary Supplement|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
399239|NCT01145807|Drug|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
399240|NCT01145807|Drug|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
399241|NCT01145807|Drug|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
399242|NCT01145794|Behavioral|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
399243|NCT01145781|Procedure|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
399244|NCT01145768|Drug|TC-5214|4 mg tablet, oral, BID, group 1
399245|NCT01145768|Drug|TC-5214|TBD tablet, oral, BID, groups 2-6
399246|NCT01145768|Drug|Placebo|
399247|NCT01145755|Drug|AZD2066|18 mg once daily
399250|NCT01145742|Behavioral|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
399251|NCT01145729|Behavioral|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
399252|NCT01145716|Procedure|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
399253|NCT01145703|Dietary Supplement|RDA Vitamin D3 only|800 IU of Vitamin D3 daily for 6 months
399254|NCT01145703|Dietary Supplement|Vitamin D2/3 Repletion only|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
399255|NCT01145703|Other|Vitamin D2/3 Repletion + AEX|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
399256|NCT01145703|Other|Vitamin D2/3 Repletion + RT|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
399257|NCT01145677|Drug|Topiramate|Topiramate 100-300 mg/day orally twice per day
399258|NCT01145664|Drug|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
399259|NCT01145664|Drug|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
399260|NCT01145664|Drug|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
399261|NCT01145638|Drug|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
399262|NCT01145638|Drug|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
399263|NCT01145625|Drug|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
399264|NCT01145625|Drug|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
399265|NCT01145612|Drug|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
399266|NCT01145612|Drug|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
399267|NCT01145586|Drug|Lactase Oral Tablets|3 tablets/day for 42 days Take with breakfast, lunch and dinner
399268|NCT01145573|Dietary Supplement|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
399269|NCT01145560|Drug|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
399270|NCT01145560|Drug|Placebo|Placebo
399271|NCT01145547|Device|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
399272|NCT01145534|Drug|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
399273|NCT01145534|Other|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
399274|NCT01145508|Drug|Docetaxel|Given IV
399275|NCT01145508|Other|Laboratory Biomarker Analysis|Correlative studies
399276|NCT01145508|Drug|Prednisone|Given PO
399277|NCT01145508|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
399278|NCT01145508|Biological|Rilimogene Galvacirepvec|Given SC
399279|NCT01145495|Other|Laboratory Biomarker Analysis|Correlative studies
399280|NCT01145495|Drug|Lenalidomide|Given PO
399281|NCT01145495|Biological|Rituximab|Given IV
399282|NCT01145482|Drug|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
399283|NCT01145482|Other|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
399284|NCT01145469|Genetic|DNA analysis|
399285|NCT01145469|Genetic|gene expression analysis|
399286|NCT01145469|Genetic|polymorphism analysis|
399287|NCT01145469|Other|laboratory biomarker analysis|
399288|NCT01145469|Other|medical chart review|
399289|NCT01145456|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
399290|NCT01145456|Drug|gemcitabine hydrochloride|Given IV
399291|NCT01145456|Other|pharmacological study|Correlative studies
399292|NCT01145456|Other|laboratory biomarker analysis|Correlative studies
399293|NCT01145443|Other|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
399294|NCT01145430|Other|Laboratory Biomarker Analysis|Correlative studies
399295|NCT01145430|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
399296|NCT01145430|Other|Pharmacological Study|Correlative studies
399297|NCT01145430|Drug|Veliparib|Given PO
399298|NCT01145417|Drug|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
399299|NCT01145404|Drug|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
399300|NCT01145404|Drug|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
399347|NCT01145014|Drug|Placebo|matching placebo (oral drinking solution and IR tablets)
399348|NCT01145001|Behavioral|Cognitive Behavioural Therapy|Weekly CBT for all subjects
399301|NCT01145391|Other|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
399302|NCT01145365|Procedure|Exam under anesthesia (EUA)|EUA established drainage of perianal fistulas &/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
399303|NCT01145352|Drug|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
399304|NCT01145339|Drug|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
399305|NCT01145326|Drug|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
399306|NCT01145326|Drug|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
399307|NCT01145248|Device|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
399308|NCT01145248|Device|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
399309|NCT01145222|Drug|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
399310|NCT01145222|Drug|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
399311|NCT01145222|Drug|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
399312|NCT01145222|Drug|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
399313|NCT01145209|Drug|Fludarabine Phosphate|Given IV
399314|NCT01145209|Biological|Ofatumumab|Given IV
399315|NCT01145209|Drug|Cyclophosphamide|Given IV
399316|NCT01145183|Drug|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
399317|NCT01145183|Drug|Placebo|Matched placebo daily dosing
399318|NCT01145170|Radiation|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
399319|NCT01145170|Biological|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
399320|NCT01145157|Device|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
399321|NCT01145157|Device|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
399322|NCT01145157|Device|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
399323|NCT01145144|Drug|dehydroepiandrosterone crystalline fine powder|
399324|NCT01145131|Other|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
399325|NCT01145105|Procedure|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
399326|NCT01145105|Procedure|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
399327|NCT01145092|Behavioral|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
399328|NCT01145079|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent
399329|NCT01145079|Device|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
399330|NCT01145079|Device|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
399331|NCT01145079|Device|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
399332|NCT01145066|Drug|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
399333|NCT01145066|Dietary Supplement|fish oil|1.6g/day EPA and 1.08g/day DHA
399334|NCT01145066|Dietary Supplement|corn oil|contains 4.5 g/day linoleic acid
399335|NCT01145027|Other|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
399336|NCT01145014|Drug|BI 660848|2 mg oral drinking solution
399337|NCT01145014|Drug|BI 660848|10 mg oral drinking solution
399338|NCT01145014|Drug|BI 660848|20 mg oral drinking solution
399339|NCT01145014|Drug|BI 660848|50 mg oral drinking solution
399340|NCT01145014|Drug|BI 660848|100 mg oral drinking solution
399341|NCT01145014|Drug|BI 660848|150 mg oral drinking solution
399342|NCT01145014|Drug|BI 660848|200 mg oral drinking solution
399343|NCT01145014|Drug|BI 660848|400 mg oral drinking solution
399344|NCT01145014|Drug|BI 660848|600 mg oral drinking solution
399345|NCT01145014|Drug|BI 660848|10,0 mg immediate release tablet
399346|NCT01145014|Drug|BI 660848|50,0 mg immediate release tablet
399349|NCT01145001|Behavioral|Contingency Management|incentives given for abstinence based on urine analysis
399350|NCT01145001|Drug|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
399351|NCT01144988|Drug|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
399352|NCT01144975|Drug|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
399353|NCT01144975|Drug|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
399354|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
399355|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
399356|NCT01144949|Drug|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
399357|NCT01144949|Drug|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
399358|NCT01144936|Drug|VX-985 or matching placebo|low dose
399359|NCT01144936|Drug|VX-985 or matching placebo|high dose
399360|NCT01144936|Drug|VX-985 or matching placebo|dose TBD
399361|NCT01144923|Other|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
399362|NCT01144923|Procedure|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
399363|NCT01144923|Other|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
399364|NCT01144910|Other|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
399365|NCT01144910|Other|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.~the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
399366|NCT01144897|Radiation|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
399367|NCT01144897|Drug|Carbon-11 labeled Acetate|C-11 Acetate is a radiotracer used in PET scanning
399368|NCT01144884|Other|Procedure (education and exercise)|education/exercise
399369|NCT01144858|Other|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
399370|NCT01144845|Procedure|Thoracic surgery|Thoracoscopy or anterior thoracotomy
399371|NCT01144832|Drug|ebastine|20 milligram capsule once daily
399372|NCT01144832|Drug|placebo capsule|one capsule once daily
399373|NCT01144806|Behavioral|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
399374|NCT01144806|Dietary Supplement|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
399375|NCT01144767|Behavioral|Computer-generated advisor|Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
399376|NCT01144767|Behavioral|Comparison control condition|Weekly/biweekly sessions with a group facilitator to receive health education and information.
399377|NCT01144754|Drug|Rituximab|Calculated per patient
399378|NCT01144741|Other|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
399379|NCT01144741|Other|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
399380|NCT01144741|Other|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
399381|NCT01144741|Other|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
399382|NCT01144741|Other|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
399383|NCT01144741|Other|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
399384|NCT01144741|Other|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
399385|NCT01144728|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
399419|NCT01144494|Drug|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
399420|NCT01144494|Drug|Artificial tears|Lubricating drops added three times a day for six weeks
399421|NCT01144455|Drug|Gemzar (Gemcitabine)|1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
399537|NCT01143402|Other|Quality-of-Life Assessment|Ancillary studies
399386|NCT01144715|Device|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
399387|NCT01144715|Device|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
399388|NCT01144702|Drug|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
399389|NCT01144689|Behavioral|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
399390|NCT01144689|Behavioral|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
399391|NCT01144676|Drug|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
399392|NCT01144676|Drug|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
399393|NCT01144676|Drug|dapivirine|"25mg dapivirine per ring.~The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
399394|NCT01144676|Drug|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
399395|NCT01144663|Biological|Nimenrix™|4- or 3-dose intramuscular injection
399396|NCT01144663|Biological|Menjugate®|3-dose intramuscular injection
399397|NCT01144663|Biological|NeisVac-CTM|3-dose intramuscular injection
399398|NCT01144663|Biological|Infanrix™ hexa|4-dose intramuscular injection
399399|NCT01144663|Biological|Synflorix™|4-dose intramuscular injection
399400|NCT01144650|Drug|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
399401|NCT01144650|Drug|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
399402|NCT01144637|Biological|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
399403|NCT01144637|Other|Placebo|0.5 ml TBS
399404|NCT01144624|Drug|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
399405|NCT01144624|Drug|Placebo|Intravenous infusion of a saline solution
399406|NCT01144611|Drug|bIAP bolus and 8h infusion|intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
399407|NCT01144611|Drug|placebo bolus and 8h infusion|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
399408|NCT01144585|Procedure|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
399409|NCT01144585|Procedure|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
399410|NCT01144559|Procedure|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
399411|NCT01144559|Procedure|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
399412|NCT01144546|Procedure|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
399413|NCT01144533|Procedure|isotonic saline injection into the glenohumeral joint|"Total volume of injection drugs: 8ml~isotonic saline 4ml + telebrix(contrast media) 4ml~The number of injections : only once during the study period~Injection site : glenohumeral joint~Material : 22-gauze spinal needle~Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
399414|NCT01144533|Procedure|steroid injection into the glenohumeral joint|"Total volume of injection drugs: 8ml~triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml~The number of injections : only once during the study period~Injection Site : glenohumeral joint~Material : 22-gauze spinal needle~Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
399415|NCT01144533|Procedure|sodium hyaluronate injection into the glenohumeral joint|"Total volume of injection drugs: 8ml~sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml~The number of injections : only once during the study period~Injection Site : glenohumeral joint~Material : 22-gauze spinal needle~Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
399416|NCT01144533|Procedure|steroid and hyaluronate injection into the glenohumeral joint|"Total volume of injection drugs: 8ml~triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml~The number of injections : only once during the study period~Injection Site : glenohumeral joint~Material : 22-gauze spinal needle~Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
399417|NCT01144507|Procedure|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
399418|NCT01144507|Other|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
399422|NCT01144455|Drug|TH-302|240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
399423|NCT01144455|Drug|TH-302|340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
399424|NCT01144442|Drug|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
399425|NCT01144442|Other|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
399426|NCT01144442|Procedure|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.~If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
399427|NCT01144442|Drug|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
399428|NCT01144442|Drug|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
399429|NCT01144429|Biological|Allergoid, allergenic extract of 100% Birch|Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
399430|NCT01144416|Biological|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
399431|NCT01144416|Biological|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
399432|NCT01144416|Drug|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
399433|NCT01144416|Drug|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
399434|NCT01144403|Drug|Cyclophosphamide|as prescribed, 6 cycles
399435|NCT01144403|Drug|Fludarabine|as prescribed, 6 cycles
399436|NCT01144403|Drug|Mitoxantrone|as prescribed, 6 cycles
399437|NCT01144403|Drug|Rituximab|375 mg/m^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
399438|NCT01144390|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
399439|NCT01144390|Drug|methadone maintenance treatment|methadone maintenance treatment
399440|NCT01144377|Drug|LY2541546|Administered subcutaneously
399441|NCT01144377|Drug|Placebo|Administered subcutaneously
399442|NCT01144364|Drug|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
399443|NCT01144351|Drug|ELND002|
399444|NCT01144351|Drug|Placebo|
399445|NCT01144338|Drug|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
399446|NCT01144338|Drug|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
399447|NCT01144325|Procedure|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.~In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
399448|NCT01144312|Drug|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
399449|NCT01144299|Biological|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
399450|NCT01144286|Drug|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
399451|NCT01144286|Drug|placebo|placebo, single dose
399452|NCT01144273|Procedure|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.~To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.~Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.~After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
399453|NCT01144260|Drug|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
399454|NCT01144247|Drug|alloreactive CTL|cellular immunotherapy with alloCTL
399455|NCT01144234|Behavioral|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
399456|NCT01144234|Behavioral|Information letter|In this arm the pregnant women got an information letter
399457|NCT01144221|Procedure|Intramyocardial Cell therapy|Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
399538|NCT01143402|Drug|Selumetinib|Given PO
399539|NCT01143402|Drug|Temozolomide|Given PO
399458|NCT01144195|Drug|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
399459|NCT01144182|Behavioral|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
399460|NCT01144169|Drug|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
399461|NCT01144156|Drug|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
399462|NCT01144143|Drug|Infliximab|the study drug will be injected into the joint through a needle
399463|NCT01144143|Drug|Placebo|the placebo will be injected into the joint through a needle
399464|NCT01144143|Drug|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
399465|NCT01144117|Drug|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
399466|NCT01144104|Behavioral|Public Service Announcement|
399467|NCT01144104|Behavioral|Interactive Multi-Media Computer Program|
399468|NCT01144104|Behavioral|Sleep Hygiene Video|
399469|NCT01144091|Drug|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
399470|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
399471|NCT01144091|Drug|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
399472|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
399473|NCT01144078|Behavioral|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
399474|NCT01144078|Behavioral|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
399475|NCT01144065|Procedure|Hair sampling for the measurement of cortisol and testosterone|Hair sampling for the measurement of cortisol and testosterone
399476|NCT01144052|Drug|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])
399477|NCT01144052|Drug|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
399478|NCT01144039|Drug|LG-group|
399479|NCT01144039|Drug|HG-group|
399480|NCT01144039|Drug|Placebo-group|
399481|NCT01144026|Biological|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
399482|NCT01144026|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
399483|NCT01144000|Drug|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
399484|NCT01143987|Drug|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
399485|NCT01143974|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
399486|NCT01143961|Device|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
399487|NCT01143948|Drug|Glargine & Glulisine|Basal Glargine & bolus Glulisine
399488|NCT01143948|Drug|Regular insulin|Sliding scale regular insulin
399489|NCT01143948|Drug|NPH & regular insulin|Basal NPH & bolus regular insulin
399490|NCT01143909|Other|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
399529|NCT01143584|Drug|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:~Begin with 0.5 mg twice a week~mg twice a week - second week 1.5 mg twice a week - third week~mg twice a week - fourth week~4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also >50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
399530|NCT01143558|Device|Lyme Disease Xenodiagnosis|Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
399531|NCT01143545|Biological|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
399491|NCT01143896|Other|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
399492|NCT01143883|Other|Silverlon|Silverlon dressings are gauze impregnated with silver ions
399493|NCT01143883|Other|Standard of Care Dressing|Standard dry gauze dressing
399494|NCT01143870|Other|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
399495|NCT01143857|Drug|Varenicline|Varenicline 2.0 mg/day or Placebo
399496|NCT01143831|Dietary Supplement|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
399497|NCT01143818|Drug|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
399498|NCT01143805|Drug|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
399499|NCT01143805|Drug|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
399500|NCT01143792|Behavioral|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
399501|NCT01143792|Behavioral|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
399502|NCT01143792|Behavioral|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
399503|NCT01143779|Drug|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
399504|NCT01143766|Drug|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
399505|NCT01143766|Other|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
399506|NCT01143753|Drug|RO5212054|Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
399507|NCT01143740|Drug|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
399508|NCT01143727|Drug|Santyl|Apply one 24-hr period sufficient to cover the wound.
399509|NCT01143727|Drug|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
399510|NCT01143714|Drug|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
399511|NCT01143714|Other|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
399512|NCT01143701|Other|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
399513|NCT01143688|Drug|albuterol|
399514|NCT01143688|Drug|placebo inhaler|
399515|NCT01143688|Procedure|placebo acupuncture|
399516|NCT01143662|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
399517|NCT01143662|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
399518|NCT01143649|Device|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
399519|NCT01143649|Procedure|constraint induced movement therapy (CIMT)|
399520|NCT01143649|Device|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
399521|NCT01143636|Device|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
399522|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
399523|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
399524|NCT01143623|Other|Placebo|Placebo
399525|NCT01143610|Procedure|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
399526|NCT01143610|Other|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
399527|NCT01143597|Other|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
399528|NCT01143584|Drug|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.~Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
399532|NCT01143545|Drug|Celecoxib|400 g po bid
399533|NCT01143545|Drug|cyclophosphamide|50 mg po bid
399534|NCT01143441|Biological|DAC-HYP|
399535|NCT01143402|Drug|Dacarbazine|Given IV
399536|NCT01143402|Other|Laboratory Biomarker Analysis|Correlative studies
399540|NCT01143389|Drug|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
399541|NCT01143389|Device|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
399542|NCT01143376|Behavioral|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
399543|NCT01143376|Behavioral|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
399544|NCT01143376|Behavioral|Moderate intensity exercise|
399545|NCT01143363|Behavioral|resting - control|
399546|NCT01143363|Behavioral|Moderate intensity exercise|
399547|NCT01143363|Behavioral|High intensity intermittent training|
399548|NCT01143363|Behavioral|Short sprint|
399549|NCT01143350|Other|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:~after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.~of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
399550|NCT01143350|Other|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
399551|NCT01143337|Drug|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
399552|NCT01143337|Drug|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
399553|NCT01143324|Device|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
399554|NCT01143311|Genetic|Arm A|"4 distinct biopsies will be taken~in a non UV-exposed area (inner arm)~in a UV-exposed area (external surface of the forearm)~in a pretumoral region (actinic keratosis)~inside the tumor"
399555|NCT01143298|Drug|LEO 27847 oral solution|
399556|NCT01143285|Other|Early and active nutritional support.|The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
399557|NCT01143272|Drug|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
399558|NCT01143272|Drug|Placebo|Placebo
399559|NCT01143259|Drug|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
399560|NCT01143259|Drug|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
399561|NCT01143246|Drug|Terlipressin|Blinded terlipressin reconstituted with 5 mL of sterile 0.9% sodium chloride solution for injection will be administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
399562|NCT01143246|Drug|Placebo|Lyophilized mannitol reconstituted with 5 mL of sterile 0.9% sodium chloride solution administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
399563|NCT01143233|Other|control formula|infants are fed a commercial hydrolyzed formula
399564|NCT01143233|Other|intervention formula 1|formula has hydrolysed protein and a different protein content
399565|NCT01143233|Other|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
399566|NCT01143233|Other|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
399567|NCT01143220|Other|No specific interventions|Observational investigation, only procedures according to local hospital standard.
399568|NCT01143207|Drug|Medroxyprogesterone acetate|Injectable hormonal contraceptive
399569|NCT01143194|Dietary Supplement|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
399570|NCT01143194|Dietary Supplement|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
399571|NCT01143194|Dietary Supplement|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
399572|NCT01143194|Dietary Supplement|Placebo|1 capsule of placebo twice a day
399573|NCT01143181|Drug|CMX001|CMX001 administered orally twice weekly for up to 3 months. Treatment may be extended for up to 6 months depending on the patient's clinical response.
399574|NCT01143168|Biological|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
399575|NCT01143142|Behavioral|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
399576|NCT01143129|Drug|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
399577|NCT01143129|Drug|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
399578|NCT01143103|Device|Cough assist (Philips,respironics)|
399579|NCT01143103|Other|Usual respiratory therapy|
399580|NCT01143090|Drug|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
399581|NCT01143077|Drug|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
399582|NCT01143064|Drug|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
399583|NCT01143064|Drug|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
399584|NCT01143051|Drug|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
399585|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
399586|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
399587|NCT01143038|Biological|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
399588|NCT01143025|Drug|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
399589|NCT01143025|Drug|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
399590|NCT01143025|Drug|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
399591|NCT01143012|Other|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
399592|NCT01143012|Other|Control group|The control group will not attend the group eczema education session.
399593|NCT01142999|Drug|Sunflower oil|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
399594|NCT01142999|Drug|Control group|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
399595|NCT01142999|Drug|Aquaphor ointment|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
399596|NCT01142999|Drug|Cetaphil cream|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
399597|NCT01142986|Behavioral|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
399598|NCT01142986|Behavioral|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
399599|NCT01142960|Dietary Supplement|Starch|1350mg/day
399600|NCT01142960|Dietary Supplement|Lycium Barbarum|1350mg/day
399601|NCT01142947|Drug|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
399602|NCT01142934|Device|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
399603|NCT01142921|Device|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
399604|NCT01142921|Device|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
399605|NCT01142908|Behavioral|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
399606|NCT01142882|Behavioral|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
399607|NCT01142882|Behavioral|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
399608|NCT01142869|Drug|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
399609|NCT01142856|Biological|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
399610|NCT01142843|Drug|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
399611|NCT01142804|Behavioral|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
399612|NCT01142791|Device|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
399613|NCT01142778|Drug|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
399614|NCT01142778|Drug|Docetaxel|Docetaxel at a dose of 100 mg/m^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
399615|NCT01142778|Drug|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
399616|NCT01142778|Procedure|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
399617|NCT01142778|Radiation|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
399618|NCT01142778|Drug|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
399619|NCT01142765|Biological|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
399620|NCT01142765|Biological|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
399621|NCT01142765|Biological|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
399622|NCT01142765|Biological|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
399623|NCT01142765|Biological|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
399624|NCT01142739|Other|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
399625|NCT01142739|Other|Clinical variables|Demography, Biological variables.
399626|NCT01142739|Other|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
399627|NCT01142726|Drug|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
399628|NCT01142726|Drug|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
399629|NCT01142726|Drug|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
399630|NCT01142726|Drug|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
399631|NCT01142713|Radiation|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
399632|NCT01142700|Drug|BMS-824393|Capsule, Oral, 10 mg, once daily
399633|NCT01142700|Drug|BMS-824393|Capsule, Oral, 30 mg, once daily
399634|NCT01142700|Drug|BMS-824393|Capsule, Oral, 100 mg, once daily
399635|NCT01142700|Drug|Placebo|Capsule, Oral, 0 mg, once daily
399636|NCT01142700|Drug|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
399637|NCT01142700|Drug|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
399638|NCT01142687|Dietary Supplement|dihydrocapsiate capsule|"Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.~Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner~Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
399639|NCT01142661|Drug|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
399640|NCT01142648|Drug|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
399641|NCT01142648|Drug|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
399642|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
399643|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
399644|NCT01142622|Drug|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
399645|NCT01142622|Drug|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
399646|NCT01142609|Behavioral|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
399647|NCT01142596|Drug|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
399648|NCT01142596|Drug|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
399649|NCT01142570|Other|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
399650|NCT01142570|Other|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
399651|NCT01142570|Dietary Supplement|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
399652|NCT01142570|Dietary Supplement|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
399800|NCT01141465|Drug|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
399653|NCT01142570|Dietary Supplement|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
399654|NCT01142557|Drug|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
399655|NCT01142544|Other|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
399656|NCT01142531|Radiation|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)~90 quality ref mAs with care-dose ON~120 kV~Pitch 1.4~Rotation time 0.33 s~Acquired images 64 x 0.6 mm"
399657|NCT01142518|Drug|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
399658|NCT01142505|Drug|Mannitol|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
399659|NCT01142505|Drug|Montelukast|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
399660|NCT01142492|Drug|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
399661|NCT01142479|Drug|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
399662|NCT01142466|Drug|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
399663|NCT01142453|Drug|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
399664|NCT01142440|Behavioral|behavioral intervention|"Dietary instructions~Oral hygiene instructions: GC plaque indicator kit~Antibacterial therapy: medident sol. one week a month, for 6 months~Fluorides: VOCO Profluorid varnish, once every 3 month~Restoration~Follow ups"
399665|NCT01142427|Other|Cytology Specimen Collection Procedure|Correlative studies
399666|NCT01142427|Other|Laboratory Biomarker Analysis|Correlative studies
399667|NCT01142414|Biological|panitumumab|
399668|NCT01142414|Drug|cisplatin|
399669|NCT01142414|Drug|fluorouracil|
399670|NCT01142414|Other|laboratory biomarker analysis|
399671|NCT01142414|Procedure|adjuvant therapy|
399672|NCT01142414|Procedure|quality-of-life assessment|
399673|NCT01142414|Radiation|3-dimensional conformal radiation therapy|
399674|NCT01142414|Radiation|intensity-modulated radiation therapy|
399675|NCT01142401|Drug|Bortezomib|Given IV
399676|NCT01142401|Drug|Fulvestrant|Given IM
399677|NCT01142401|Other|Laboratory Biomarker Analysis|Correlative studies
399678|NCT01142388|Biological|Cixutumumab|Given IV
399679|NCT01142388|Other|Laboratory Biomarker Analysis|Correlative studies
399680|NCT01142388|Drug|Paclitaxel|Given IV
399681|NCT01142388|Other|Pharmacological Study|Correlative studies
399682|NCT01142362|Biological|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
399683|NCT01142349|Behavioral|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
399684|NCT01142349|Behavioral|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
399685|NCT01142349|Behavioral|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
399686|NCT01142336|Drug|Simvastatin|Simvastatin 40mg qHS for 1 year
399687|NCT01142336|Drug|Placebo|Placebo 1 tablet qHS for 1 year
399688|NCT01142323|Drug|fenofibrate|160 mg po daily
399689|NCT01142310|Drug|Lamotrigine|Lamotrigine will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
399690|NCT01142310|Drug|Placebo|
399691|NCT01142297|Device|dental implant and modified dental implant|standard SLA surface and chemically modified surface
399692|NCT01142284|Drug|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol~Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID~Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID~Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
399693|NCT01142271|Procedure|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
399694|NCT01142271|Procedure|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
399695|NCT01142258|Drug|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
399696|NCT01142258|Drug|Placebo|Inactive or inert pill which will be used as a comparator
399697|NCT01142245|Drug|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
399698|NCT01142245|Drug|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus~Esomeprazole intravenous infusion 8mg/hr for 72 hours"
399699|NCT01142232|Drug|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
399801|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
399700|NCT01142232|Drug|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
399701|NCT01142219|Drug|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
399702|NCT01142219|Drug|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
399703|NCT01142206|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
399704|NCT01142206|Behavioral|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
399705|NCT01142206|Behavioral|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
399706|NCT01142193|Drug|USL255|
399707|NCT01142193|Drug|Placebo|
399708|NCT01142180|Procedure|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
399709|NCT01142180|Procedure|No TAE|No TAE procedure will be performed after endoscopic treatment
399710|NCT01142167|Procedure|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
399711|NCT01142167|Procedure|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
399712|NCT01142154|Drug|Prodarsan|Prodarsan TID, oral solution, 6-8 days
399713|NCT01142141|Other|manual therapy, kinesiotherapy|
399714|NCT01142128|Drug|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
399715|NCT01142128|Drug|Placebo to Nexium|one capsule per day for one month
399716|NCT01142128|Drug|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
399717|NCT01142128|Drug|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
399718|NCT01142115|Device|Intermittent catheter CP063CC|intermittent catheterisation
399719|NCT01142115|Device|SpeediCath|intermittent catheterisation
399720|NCT01142102|Radiation|Radiation Therapy|"A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.~Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.~Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV."
399721|NCT01142089|Drug|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
399722|NCT01142089|Drug|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
399723|NCT01142076|Drug|Xinju Xiaogao Prescription|treatment group
399724|NCT01142076|Drug|placebo|Therapeutic dose of 10%
399725|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
399726|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
399727|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
399728|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
399729|NCT01142050|Biological|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
399730|NCT01142037|Dietary Supplement|Cooked parsnips with parsley|Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
399731|NCT01142024|Drug|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
399732|NCT01142024|Drug|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
399733|NCT01142011|Drug|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour."
399734|NCT01141998|Drug|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
399735|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. Week 0-10.
399736|NCT01141998|Radiation|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
399737|NCT01141998|Radiation|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
399738|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. From week 14 to 52.
399739|NCT01141985|Device|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
399802|NCT01141465|Drug|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
400264|NCT01137877|Other|Human Milk|Human milk ad lib
399740|NCT01141972|Dietary Supplement|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
399741|NCT01141972|Other|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
399742|NCT01141946|Procedure|thoracic ultrasound|All patients will receive pre-operative pleural-based ultrasound during their initial consultation.
399743|NCT01141946|Procedure|pleural aspiration|Before proceeding to pleural aspiration, a radiography of the chest will be performed in order to ascertain the presence of a pleural effusion.
399744|NCT01141933|Other|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
399745|NCT01141933|Other|Usual care|This group receive the usual treatment only.
399746|NCT01141920|Behavioral|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
399747|NCT01141920|Behavioral|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
399748|NCT01141907|Behavioral|Heart Failure Self Care Support|The intervention is aimed at preventing HF exacerbations and hospitalizations by improving self management with the support of the Home Automated Telemonitoring (HAT) system. The intervention was delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention was initiated during the index hospitalization. The RN-CHN team collaborated with participants, caregivers, and their usual source of HF care. Intervention strategies included tracking of weight and HF symptoms to provide feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and promoting communication with providers.
399749|NCT01141907|Other|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
399750|NCT01141894|Other|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
399751|NCT01141894|Other|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
399752|NCT01141881|Drug|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
399753|NCT01141868|Behavioral|Internet Intervention|online treatment for insomnia
399754|NCT01141855|Drug|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days~1mb b.d. for 70 days (full course 3 months)"
399755|NCT01141855|Behavioral|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
399756|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
399757|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
399758|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
399759|NCT01141816|Other|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
399760|NCT01141803|Dietary Supplement|Apples|550g of apples/day
399761|NCT01141803|Dietary Supplement|Apple pomace|22g apple pomace/day
399762|NCT01141790|Other|Music and voice message|
399763|NCT01141777|Dietary Supplement|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
399764|NCT01141777|Dietary Supplement|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
399765|NCT01141764|Procedure|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.~This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
399766|NCT01141764|Procedure|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
399803|NCT01141465|Drug|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
399804|NCT01141452|Drug|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
399767|NCT01141764|Other|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
399768|NCT01141738|Behavioral|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
399769|NCT01141738|Behavioral|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
399770|NCT01141725|Drug|bendamustine hydrochloride|Given IV
399771|NCT01141725|Drug|idarubicin|Given IV
399772|NCT01141712|Procedure|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
399773|NCT01141712|Drug|BCNU|Participants will receive BCNU 300 mg/m^2 Day -6
399774|NCT01141712|Drug|Etoposide|Participants will receive Etoposide 100 mg/m^2 BID Days -5 to -2
399775|NCT01141712|Drug|Cytarabine|Participants will receive Cytarabine 100 mg/m^2 BID Days -5 to -2
399776|NCT01141712|Drug|Melphalan|Participants will receive Melphalan 140 mg/m^2 Day -1
399777|NCT01141660|Device|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
399778|NCT01141660|Device|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
399779|NCT01141647|Behavioral|Vocational Rehabilitation|SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
399780|NCT01141634|Other|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
399781|NCT01141608|Other|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
399782|NCT01141608|Other|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
399783|NCT01141595|Drug|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
399784|NCT01141569|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
399785|NCT01141569|Other|Laboratory Biomarker Analysis|Correlative studies
399786|NCT01141556|Drug|Selenase|After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
399787|NCT01141543|Drug|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.~Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
399788|NCT01141530|Other|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
399789|NCT01141517|Behavioral|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
399790|NCT01141504|Dietary Supplement|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
399791|NCT01141504|Dietary Supplement|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
399792|NCT01141504|Dietary Supplement|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
399793|NCT01141504|Dietary Supplement|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
399794|NCT01141491|Biological|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
399795|NCT01141491|Biological|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
399796|NCT01141478|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
399797|NCT01141478|Drug|Sorafenib|400 mg po bid
399798|NCT01141465|Drug|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
399799|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
399918|NCT01140503|Drug|Apremilast|Apremilast 20mg PO BID
399805|NCT01141452|Drug|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
399806|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
399807|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
399808|NCT01141452|Drug|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
399809|NCT01141452|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
399810|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
399811|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
399812|NCT01141439|Drug|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
399813|NCT01141439|Drug|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
399814|NCT01141439|Drug|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
399815|NCT01141439|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
399816|NCT01141426|Behavioral|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
399817|NCT01141426|Behavioral|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
399818|NCT01141374|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
399819|NCT01141374|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
399820|NCT01141361|Procedure|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
399821|NCT01141348|Behavioral|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
399822|NCT01141348|Behavioral|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
399823|NCT01141335|Device|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
399824|NCT01141335|Device|Infinit® PTFE mesh (WL Gore)|A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
399825|NCT01141322|Drug|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
399826|NCT01141322|Drug|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
399827|NCT01141309|Drug|sorafenib with everolimus|"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles *Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
399828|NCT01141296|Drug|fenofibrate|fenofibrate 200 mg PO daily for 1 year
399829|NCT01141296|Drug|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
399830|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
399831|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
399832|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
399833|NCT01141270|Drug|AFOLIA|single sc injection, 225 IU
399834|NCT01141270|Drug|Gonal-f|single sc injection, 225IU
399835|NCT01141257|Drug|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
399836|NCT01141244|Drug|temsirolimus|Given IV
399837|NCT01141244|Drug|temozolomide|Given orally
399838|NCT01141244|Drug|irinotecan hydrochloride|Given IV
399839|NCT01141244|Other|laboratory biomarker analysis|Correlative studies
399840|NCT01141218|Other|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
399841|NCT01141205|Biological|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
399842|NCT01141205|Drug|Saline|1.2 ml saline intramuscularly
399843|NCT01141192|Dietary Supplement|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
399844|NCT01141192|Dietary Supplement|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
399845|NCT01141179|Drug|LEO 27847|2 mL (0.1 mg) dose of oral solution
399846|NCT01141166|Behavioral|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
399847|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel + acenocoumarol|"Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent"
399848|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel|"Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily~Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent."
399849|NCT01141140|Behavioral|Healthy|Favourable nutritional characteristics.
399850|NCT01141140|Behavioral|Diet|Benefits of an ingredient/nutrient for weight management
399851|NCT01141140|Behavioral|Unhealthy|Hedonic characteristics and less healthy ingredients.
399852|NCT01141127|Drug|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
399853|NCT01141114|Other|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
399854|NCT01141114|Other|Usual care|Usual care
399855|NCT01141088|Procedure|Bilateral stent-in-stent insertion|Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
399856|NCT01141088|Procedure|Bilateral side-by-side insertion|Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
399857|NCT01141075|Drug|Ataluren (PTC124)|Ataluren (PTC124) will be provided as a vanilla-flavored powder to be mixed with water. Ataluren (PTC124) will be taken 3 times per day, with dosing based on the patient's body weight. Ataluren (PTC124) will be taken at two different dose levels. In Cycle 1, the dose level is 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening for 28 days. In Cycle 2, the dose level is 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 28 days.
399858|NCT01141062|Device|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
399859|NCT01141049|Drug|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
399860|NCT01141049|Other|Placebo|Placebo, TID
399861|NCT01141036|Drug|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
399862|NCT01141036|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
399863|NCT01141023|Drug|DaTscan|
399864|NCT01141010|Other|Language|Plain language without psychological intervention
399865|NCT01141010|Other|Language|Psychological linguistic intervention will be given
399866|NCT01140997|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
399867|NCT01140997|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
399868|NCT01140984|Drug|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
399869|NCT01140971|Drug|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
399870|NCT01140971|Device|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
399871|NCT01140932|Drug|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
399872|NCT01140932|Behavioral|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
399873|NCT01140906|Drug|Placebo|capsules, daily, orally
399874|NCT01140906|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
399875|NCT01140906|Drug|Duloxetine|encapsulated capsules, daily, orally
399919|NCT01140490|Procedure|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
399920|NCT01140477|Device|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
399876|NCT01140893|Drug|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.~From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
399877|NCT01140893|Drug|Placebo|Placebo
399878|NCT01140880|Drug|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
399879|NCT01140867|Drug|zonisamide|zonisamide 100 mg tablet
399880|NCT01140854|Procedure|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
399881|NCT01140854|Other|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
399882|NCT01140841|Drug|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
399883|NCT01140841|Drug|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
399884|NCT01140828|Drug|Rabeprazole|Rabeprazole 20mg once daily
399885|NCT01140828|Drug|Rabeprazole Placebo|one tab once daily
399886|NCT01140815|Device|Total Knee Replacement|Smith and Nephew Total Knee Replacement
399887|NCT01140815|Device|Deuce|Smith and Nephew Bicompartmental Knee Replacement
399888|NCT01140763|Device|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin & eosin (H&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
399889|NCT01140737|Drug|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
399890|NCT01140711|Procedure|fMRI imaging following visual stimulation of food and non-food images|"fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.~fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.~Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 * w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape."
399891|NCT01140698|Other|Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge|Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
399892|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
399893|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
399894|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
399895|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
399896|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
399897|NCT01140672|Drug|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
399898|NCT01140659|Procedure|Video-assisted sympathectomy|All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
399899|NCT01140646|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
399900|NCT01140646|Other|questionnaire administration|Ancillary studies
399901|NCT01140646|Procedure|quality-of-life assessment|Ancillary studies
399902|NCT01140620|Drug|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
399903|NCT01140620|Drug|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
399904|NCT01140620|Drug|saline|saline infusion. Duration approximately 3 hours
399905|NCT01140620|Drug|placebo risperidone|placebo capsule to match risperidone 2 mg capsule
399906|NCT01140607|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
399907|NCT01140594|Procedure|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
399908|NCT01140594|Procedure|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
399909|NCT01140581|Drug|DRONEDARONE|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
399910|NCT01140568|Drug|nilotinib|400mg po (orally) BID (twice daily)
399911|NCT01140555|Device|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
399912|NCT01140542|Drug|Roflumilast|500µg, once daily
399913|NCT01140529|Drug|Dexmedetomidine|Bolus and continuous infusion
399914|NCT01140529|Drug|Haloperidol|Bolus doses
399915|NCT01140529|Drug|Saline|Bolus and continuous infusion
399916|NCT01140516|Drug|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
399917|NCT01140516|Other|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
399921|NCT01140477|Device|Accommodating Lens|Accommodating lens implanted after cataract extraction
399922|NCT01140464|Other|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
399923|NCT01140464|Other|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
399924|NCT01140451|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (10 mg/kg with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner) for up to 48 weeks.
399925|NCT01140438|Drug|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
399926|NCT01140438|Drug|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
399927|NCT01140425|Drug|PF-00232798|600 mg oral solution once daily x 7 days
399928|NCT01140425|Drug|PF-00232798|300 mg oral solution once daily x 7 days
399929|NCT01140425|Drug|Placebo|Oral solution once daily x 7 days
399930|NCT01140425|Drug|Moxifloxacin|400 mg tablet single dose
399931|NCT01140412|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
399932|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
399933|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
399934|NCT01140412|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
399935|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
399936|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
399937|NCT01140399|Drug|Furosemide or Furosemide and Dopamine|"Patients randomized to pharmacological treatment receive~either intravenous diuretics at escalating doses up to 20 mg/h~or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m."
399938|NCT01140399|Device|Ultrafiltration|"All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight~less than 3 kg 200 ml/h~more than 3 kg and less than 5 kg 300 mlh~more than 5 kg 500 mlh~Criteria for achievement of target UF goals are removal of > 50% and <70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited"
399939|NCT01140373|Biological|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
399940|NCT01140373|Drug|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 10^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
399941|NCT01140360|Drug|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
399942|NCT01140347|Biological|Placebo|8 mg/kg IV every 2 weeks
399943|NCT01140347|Biological|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
399944|NCT01140347|Other|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
399945|NCT01140334|Behavioral|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
399946|NCT01140334|Behavioral|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
399947|NCT01140321|Drug|Neridronate|"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
399948|NCT01140308|Drug|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
399949|NCT01140308|Drug|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
399950|NCT01140295|Drug|polyethylene glycol, senna|"Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age >12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days."
399951|NCT01140282|Other|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
399952|NCT01140282|Procedure|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
399953|NCT01140282|Procedure|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
399954|NCT01140282|Behavioral|exercise intervention|12 week exercise intervention
399955|NCT01140269|Other|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
399956|NCT01140243|Dietary Supplement|LCPUFA|premature infant formula supplemented with LCPUFA
399957|NCT01140217|Drug|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
399958|NCT01140204|Device|Implantation of a bare metal stent|Bare Metal Stent
399959|NCT01140191|Drug|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
399960|NCT01140178|Drug|HPPH|Given IV
399961|NCT01140165|Other|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
399962|NCT01140139|Biological|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
399963|NCT01140126|Drug|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
399964|NCT01140113|Procedure|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
399965|NCT01140100|Drug|propofol|
399966|NCT01140100|Drug|thiopental,propofol|
399967|NCT01140087|Procedure|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
399968|NCT01140074|Drug|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
399969|NCT01140061|Drug|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
399970|NCT01140061|Drug|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
399971|NCT01140061|Drug|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
399972|NCT01140061|Drug|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
399973|NCT01140061|Drug|Plain patch|Plain patch containing no MK-0873 or placebo
399974|NCT01140035|Other|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
399975|NCT01140022|Other|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
399976|NCT01140009|Biological|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
399977|NCT01140009|Biological|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
399978|NCT01139996|Drug|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
399979|NCT01139996|Drug|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
399980|NCT01139983|Genetic|DNA analysis|
399981|NCT01139983|Genetic|RNA analysis|
399982|NCT01139983|Genetic|fluorescence in situ hybridization|
399983|NCT01139983|Genetic|microarray analysis|
399984|NCT01139983|Genetic|polymerase chain reaction|
399985|NCT01139983|Genetic|reverse transcriptase-polymerase chain reaction|
399986|NCT01139983|Other|laboratory biomarker analysis|
399987|NCT01139970|Other|Laboratory Biomarker Analysis|Correlative studies
399988|NCT01139970|Other|Pharmacological Study|Correlative studies
399989|NCT01139970|Drug|Temozolomide|Given PO
399990|NCT01139970|Drug|Veliparib|Given PO
399991|NCT01139957|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
399992|NCT01139957|Other|Quality-of-Life Assessment|Ancillary studies
399993|NCT01139957|Other|Questionnaire Administration|Ancillary studies
399994|NCT01139957|Procedure|Study of High Risk Factors|Ancillary studies
399995|NCT01139944|Genetic|DNA methylation analysis|
399996|NCT01139944|Genetic|polymerase chain reaction|
399997|NCT01139944|Other|laboratory biomarker analysis|
399998|NCT01139931|Genetic|DNA methylation analysis|
399999|NCT01139931|Genetic|gene expression analysis|
400000|NCT01139931|Genetic|microarray analysis|
400001|NCT01139931|Genetic|polymorphism analysis|
400002|NCT01139931|Other|laboratory biomarker analysis|
400003|NCT01139905|Other|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
400004|NCT01139892|Procedure|Surgical management|
400005|NCT01139892|Procedure|Endovascular management|
400006|NCT01139879|Device|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
400007|NCT01139853|Device|Nasogastric Tube|Insertion of a 10 French Nasogastric tube prior to surgery
400008|NCT01139840|Dietary Supplement|vitamin D2|Study Supplement
400009|NCT01139840|Dietary Supplement|vitamin D3|Study Supplement
400010|NCT01139814|Device|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
400011|NCT01139801|Drug|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration starting 2 milliunits per minute.
400012|NCT01139801|Drug|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
400013|NCT01139788|Drug|LY2624587|"6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.~If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
400014|NCT01139775|Drug|Pemetrexed|Administered intravenously as a continuous 10-minute infusion
400015|NCT01139775|Drug|Cisplatin|Administered intravenously as a continuous 1-hour infusion
400016|NCT01139775|Drug|LY2603618|Administered intravenously as a continuous 1-hour infusion
400017|NCT01139762|Drug|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
400018|NCT01139762|Drug|Placebo|Administered orally, once daily for 26 weeks
400019|NCT01139762|Drug|Finasteride|5mg administered orally, once daily for 26 weeks
400020|NCT01139749|Drug|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
400021|NCT01139749|Drug|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
400022|NCT01139736|Dietary Supplement|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
400023|NCT01139723|Drug|MINT1526A|Intravenous escalating dose
400024|NCT01139723|Drug|bevacizumab|Intravenous repeating dose
400025|NCT01139697|Other|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
400026|NCT01139684|Behavioral|Repeated sprint test|
400027|NCT01139671|Drug|Remifentanil|"Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses."
400028|NCT01139645|Drug|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
400029|NCT01139606|Other|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
400030|NCT01139580|Drug|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
400031|NCT01139580|Drug|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
400032|NCT01139541|Behavioral|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
400033|NCT01139528|Procedure|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
400034|NCT01139515|Drug|Eletriptan commercial tablet|20 mg tablet, single dose
400035|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
400036|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
400037|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
400038|NCT01139502|Behavioral|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
400039|NCT01139502|Behavioral|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
400040|NCT01139489|Other|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
400041|NCT01139463|Drug|Haloperidol or olanzapine|Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
400042|NCT01139450|Drug|0417|Topical 0417 test product applied twice daily for 4 weeks
400043|NCT01139450|Drug|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
400044|NCT01139450|Drug|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
400045|NCT01139437|Biological|Standard Dose HPIV2 Vaccine|10^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
400046|NCT01139437|Biological|Low dose HPIV2 vaccine|10^5 TCID50 administered in a single dose
400047|NCT01139437|Other|Placebo|Matched placebo
400048|NCT01139424|Device|endoscopic suturing|endoscopic suturing of the anastomotic leak
400049|NCT01139411|Behavioral|Behavioral Weight Control with Enhanced Parent Involvement|
400050|NCT01139411|Behavioral|Behavioral Weight Control with Minimal Parent Involvement|
400051|NCT01139398|Dietary Supplement|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
400052|NCT01139385|Procedure|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
400342|NCT01137253|Drug|Placebo|Response to intrabrachial vasodilators during IV saline infusion
400053|NCT01139385|Procedure|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
400054|NCT01139372|Other|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
400055|NCT01139359|Drug|darinaparsin|I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
400056|NCT01139359|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
400057|NCT01139346|Drug|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
400058|NCT01139333|Genetic|gene expression analysis|
400059|NCT01139333|Genetic|western blotting|
400060|NCT01139333|Other|flow cytometry|
400061|NCT01139333|Other|laboratory biomarker analysis|
400062|NCT01139320|Genetic|DNA analysis|
400063|NCT01139320|Genetic|polymerase chain reaction|
400064|NCT01139320|Other|laboratory biomarker analysis|
400065|NCT01139320|Other|pharmacological study|
400066|NCT01139307|Other|cell culture procedure|
400067|NCT01139307|Other|laboratory biomarker analysis|
400068|NCT01139294|Drug|Hylenex|1ml subcutaneous with initiation of intravenous fluids then every 24 hrs with a maximum dose of 3 injections in 72 hours
400069|NCT01139281|Drug|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
400070|NCT01139281|Drug|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
400071|NCT01139255|Behavioral|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
400072|NCT01139242|Behavioral|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
400073|NCT01139242|Behavioral|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
400074|NCT01139229|Other|hybrid everted esophagogastric anastomosis|
400075|NCT01139229|Other|the conventional hand-sewn anastomosis|
400076|NCT01139229|Other|a stapled anastomosis|
400077|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
400078|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
400079|NCT01139216|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
400080|NCT01139203|Drug|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
400081|NCT01139190|Drug|PL3100|Oral administration
400082|NCT01139190|Drug|Naproxen|Oral administration
400083|NCT01139177|Device|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
400084|NCT01139164|Drug|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
400085|NCT01139164|Drug|Regimen B|Other malignancies not addressed in A or C
400086|NCT01139164|Drug|Regimen C|B-Cell Lymphomas
400087|NCT01139151|Drug|3 Day Thiarabine|Starting dose 70 mg/m^2 IV over 1 hour (±15 minutes) daily x 3
400088|NCT01139151|Drug|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
400089|NCT01139138|Drug|Panitumumab|Panitumumab 6mg/kg IV every 14 days
400090|NCT01139138|Drug|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
400091|NCT01139138|Drug|Everolimus|Everolimus daily po (dosage varies with cohort)
400092|NCT01139125|Drug|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
400093|NCT01139099|Behavioral|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
400094|NCT01139060|Behavioral|organized care program for chronic or recurrent depression|
400095|NCT01139047|Drug|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
400096|NCT01139047|Drug|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
400097|NCT01139034|Device|Self-designed surface functional electrical stimulator|Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
400098|NCT01139021|Biological|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
400099|NCT01139008|Drug|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
400100|NCT01139008|Drug|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
400443|NCT01136278|Drug|Clonidine|150 μg per os
400101|NCT01138995|Device|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
400102|NCT01138995|Device|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
400103|NCT01138982|Behavioral|Youth Mentoring program|
400104|NCT01138969|Drug|esomeprazole|esomeprazole 20 mg qd for 6 months
400105|NCT01138956|Drug|N-acetylcysteine|N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
400106|NCT01138956|Drug|Pentavalent antimonial|Pentavalent antimonial, 20mg/kg/day, 28 days, IV
400107|NCT01138943|Drug|Synthodont|"15 ml, tree times/day for 07 days~Arm: Chlorhexidine alcohol-base mouthrinse"
400108|NCT01138943|Drug|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days~Arm: Experimental: non alcohol chlorhexidine mouthrinse"
400109|NCT01138930|Drug|Berberine|1.5g daily for 3 month
400110|NCT01138930|Drug|Placebo|placebo daily
400111|NCT01138917|Device|ReCell and Split-thickness skin graft|The surgeon will be required to select two similar non-contiguous injury areas with both areas being at least 100cm2 and second degree depth/severity. One area will be treated using ReCell and the second using Split-thickness Skin Graft.
400112|NCT01138904|Drug|irinotecan, oxaliplatin|"OXIR: FOLFOX -> FOLFIRI~IROX: FOLFIRI -> FOLFOX~FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
400113|NCT01138904|Drug|oxaliplatin, irinotecan|"FOLFOX REGIMEN~D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks~FOLFILI REGIMEN~D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr~Every 2 weeks"
400114|NCT01138878|Other|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
400115|NCT01138878|Other|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
400116|NCT01138878|Other|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
400117|NCT01138878|Other|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
400118|NCT01138865|Device|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
400119|NCT01138865|Device|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
400120|NCT01138852|Drug|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
400121|NCT01138852|Drug|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
400122|NCT01138839|Drug|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
400123|NCT01138839|Drug|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
400124|NCT01138826|Drug|Amlodipine - reference|10 mg tablet, single dose, with water
400125|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
400126|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
400127|NCT01138787|Dietary Supplement|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
400128|NCT01138787|Dietary Supplement|Placebo spread|Single dose (30 gr) of regular light margarine
400129|NCT01138787|Dietary Supplement|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
400130|NCT01138774|Dietary Supplement|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
400131|NCT01138761|Behavioral|Nurse instruction|"The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group."
400132|NCT01138748|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
400133|NCT01138735|Drug|adapalene/benzoyl peroxide|daily topical application for 12 weeks
400134|NCT01138735|Drug|Topical Gel Vehicle|daily topical application for 12 weeks
400135|NCT01138722|Radiation|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
400136|NCT01138709|Device|Vitala|Vitala™ Continence Control Device
400137|NCT01138696|Other|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
400138|NCT01138696|Other|RX|X-rays and clinical investigation of the knee 20 years after surgery
400139|NCT01138683|Procedure|ultrafiltration|Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
400140|NCT01138683|Drug|diuretics|Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
400141|NCT01138657|Biological|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
400142|NCT01138657|Drug|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
400143|NCT01138657|Drug|Placebo|Administered by subcutaneous injection
400144|NCT01138631|Device|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
400145|NCT01138618|Device|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
400146|NCT01138618|Device|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
400147|NCT01138605|Drug|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
400148|NCT01138605|Drug|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
400149|NCT01138605|Drug|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
400150|NCT01138605|Drug|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
400151|NCT01138605|Drug|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
400152|NCT01138605|Drug|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
400153|NCT01138605|Drug|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
400154|NCT01138605|Drug|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
400155|NCT01138605|Drug|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
400156|NCT01138605|Drug|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
400157|NCT01138605|Drug|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
400158|NCT01138605|Drug|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
400159|NCT01138605|Drug|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
400160|NCT01138605|Drug|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
400161|NCT01138605|Drug|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
400162|NCT01138579|Drug|FBTA05|
400163|NCT01138553|Drug|Mifepristone|200mg capsules daily for 5-28 days
400164|NCT01138540|Other|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
400165|NCT01138527|Other|MRI examination|45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
400166|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
400167|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
400168|NCT01138514|Drug|Placebo|Placebo
400169|NCT01138501|Drug|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
400170|NCT01138501|Drug|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
400171|NCT01138488|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
400172|NCT01138475|Drug|Paricalcitol|1 microgram by mouth daily for 6 weeks
400173|NCT01138475|Drug|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
400174|NCT01138475|Drug|Placebo|Inactive substance, one capsule daily for 6 weeks
400175|NCT01138462|Other|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.~Daily direct resident's environmental disinfection during decolonisation."
400176|NCT01138449|Drug|Vitamin A|Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
400177|NCT01138436|Drug|MEBO Wound Ointment (MEBO)|Topical application once a day
400178|NCT01138436|Procedure|Standard of Care|Application of Profore multilayer compression bandage system
400179|NCT01138423|Drug|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
400180|NCT01138423|Drug|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
400258|NCT01137890|Drug|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
400181|NCT01138423|Drug|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
400182|NCT01138423|Drug|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
400183|NCT01138423|Drug|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
400184|NCT01138410|Biological|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
400185|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
400186|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
400187|NCT01138384|Drug|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
400188|NCT01138384|Drug|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
400189|NCT01138371|Procedure|LDL Apheresis|LDL Apheresis
400190|NCT01138358|Other|medical chart review|
400191|NCT01138358|Other|study of socioeconomic and demographic variables|
400192|NCT01138358|Other|survey administration|
400193|NCT01138358|Procedure|quality-of-life assessment|
400194|NCT01138345|Genetic|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
400195|NCT01138345|Genetic|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
400196|NCT01138345|Other|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
400197|NCT01138345|Other|medical chart review|perform medical chart review for all subjects
400198|NCT01138345|Other|questionnaire administration|each cohort will be given the same questionnaire
400199|NCT01138332|Genetic|western blotting|
400200|NCT01138332|Other|laboratory biomarker analysis|
400201|NCT01138319|Genetic|DNA analysis|
400202|NCT01138319|Genetic|mutation analysis|
400203|NCT01138319|Genetic|polymerase chain reaction|
400204|NCT01138319|Other|laboratory biomarker analysis|
400205|NCT01138306|Genetic|gene expression analysis|
400206|NCT01138306|Genetic|mutation analysis|
400207|NCT01138306|Other|flow cytometry|
400208|NCT01138306|Other|laboratory biomarker analysis|
400209|NCT01138293|Device|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
400210|NCT01138280|Device|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
400211|NCT01138254|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
400212|NCT01138254|Other|no intervention|no intervention
400213|NCT01138241|Other|Tc99mDTPA renal clearance|"Tc99mDTPA renal clearance only for 200 patients~Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria~serum creatinine prior and during TDF~TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels~stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)~serum for cystanin C ( stored sample prior taking ARV and present time)~intensive 24 hours pharmacokinetic study of TDF in 20 patients"
400214|NCT01138215|Biological|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
400215|NCT01138202|Drug|LPV/r|LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
400216|NCT01138189|Procedure|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
400217|NCT01138189|Procedure|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
400218|NCT01138176|Procedure|Cooling|Reduction of rectal temperature to 33.5 C
400259|NCT01137890|Behavioral|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
400260|NCT01137890|Behavioral|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
400261|NCT01137877|Other|Milk based infant formula powder|milk based infant formula ad lib
400262|NCT01137877|Other|Investigational Infant Formula #1|Milk based infant formula ad lib
400263|NCT01137877|Other|Investigational Infant Formula #2|Milk based infant formula powder ad lib
400219|NCT01138163|Drug|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
400220|NCT01138150|Drug|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
400221|NCT01138150|Drug|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
400222|NCT01138137|Drug|Paclitaxel|"Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle~Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle~6 treatment cycles"
400223|NCT01138137|Drug|N-acetylcysteine|"A group of 5 subjects will be evaluated at each dose level.~On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.~6 treatment cycles~Dose escalation schema:~Level 1: 150mg/kg~Level 2: 300mg/kg~Level 3: 600mg/kg~Level 4: 800mg/kg~Level 5: 1000mg/kg~Level 6: 1200mg/kg"
400224|NCT01138137|Drug|Cisplatin|"Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion~6 treatment cycles"
400225|NCT01138124|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
400226|NCT01138111|Drug|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
400227|NCT01138098|Biological|Engerix™-B|Intramuscular, single dose
400228|NCT01138085|Drug|GSK1120212|MEK inhibitor
400229|NCT01138085|Drug|GSK2141795|AKT Inhibitor
400230|NCT01138072|Drug|GSK2248761|200mg once daily
400231|NCT01138072|Drug|Simvastatin|20 mg Simvastatin single dose
400232|NCT01138072|Drug|Atorvastatin|20 mg atorvastatin single dose
400233|NCT01138072|Drug|Rosuvastatin|10 mg rosuvastatin single dose
400234|NCT01138046|Drug|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
400235|NCT01138033|Drug|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
400236|NCT01138020|Behavioral|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
400237|NCT01138020|Behavioral|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
400238|NCT01138007|Drug|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
400239|NCT01138007|Drug|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
400240|NCT01137994|Drug|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
400241|NCT01137994|Biological|Trastuzumab|monoclonal antibody directed to HER2 receptor
400242|NCT01137994|Drug|Docetaxel|Taxane chemotherapy
400243|NCT01137994|Drug|Paclitaxel|Taxane chemotherapy
400244|NCT01137994|Drug|Vinorelbine|Vinka alkaloid
400245|NCT01137981|Drug|Any Antiretroviral Therapy|Any exposure to an antiretroviral therapy: Abacavir, Amprenavir, Delavirdine, Fosamprenavir, Lamivudine, Maraviroc, Zidovudine, Combivir (Zidovudine+Lamivudine), Epzicom (Abacavir+Lamivudine), and/or Trizivir (Abacavir+Lamivudine+Zidovudine)
400246|NCT01137968|Drug|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
400247|NCT01137968|Drug|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
400248|NCT01137955|Drug|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
400249|NCT01137955|Drug|Placebo|Placebo orally three times a day for 10 days total
400250|NCT01137942|Drug|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
400251|NCT01137916|Drug|Imatinib|800 mg
400252|NCT01137903|Procedure|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
400253|NCT01137903|Drug|Ciprofloxacin|500 mg/ 12 hours during 90 days
400254|NCT01137903|Drug|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
400255|NCT01137903|Drug|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
400256|NCT01137890|Drug|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
400257|NCT01137890|Drug|Placebo|capsules administered in split doses at 22:00 and 09:00.
400265|NCT01137864|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
400266|NCT01137812|Drug|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
400267|NCT01137812|Drug|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
400268|NCT01137812|Drug|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
400269|NCT01137812|Drug|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
400270|NCT01137799|Drug|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
400271|NCT01137799|Drug|placebo|Once daily (single dose)
400272|NCT01137799|Drug|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
400273|NCT01137799|Drug|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
400274|NCT01137799|Drug|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
400275|NCT01137799|Drug|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
400276|NCT01137786|Drug|Non ionic contrast media comparator|One time administration for PCI
400277|NCT01137786|Drug|Non ionic contrast media comparator|one time administration for PCI
400278|NCT01137773|Drug|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
400279|NCT01137773|Drug|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
400280|NCT01137760|Dietary Supplement|Sucrose|5 g of sucrose daily for 8 weeks
400281|NCT01137760|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
400282|NCT01137760|Dietary Supplement|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
400283|NCT01137747|Drug|Carfilzomib|
400284|NCT01137734|Device|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty rean, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
400285|NCT01137734|Device|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
400286|NCT01137708|Drug|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
400287|NCT01137708|Drug|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
400288|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months.
400289|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
400290|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months
400291|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
400292|NCT01137682|Drug|Pasireotide|"Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
400293|NCT01137682|Drug|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
400294|NCT01137682|Drug|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
400295|NCT01137669|Biological|Live attenuated herpes zoster vaccine|ZOSTAVAX® (Zoster Vaccine Live) is a live attenuated vaccine provided as a single-dose, sterile, lyophilized, preservative-free frozen formulation. The vaccine will be supplied in 3-mL glass vials. Sterile diluent will be used to reconstitute study vaccine. The reconstituted vial will be gently agitated to mix thoroughly. The entire contents of the reconstituted vaccine vial (approximately 0.65 mL) will be withdrawn into a syringe. The vaccine will be administered immediately subcutaneously in the deltoid region.
400296|NCT01137669|Other|Placebo|Placebo for Zoster Vaccine Live (ZOSTAVAX®) is sterile normal saline which will be obtained from the Fisher Repository in single-dose containers. 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. The placebo will be administered subcutaneously in the deltoid region.
400297|NCT01137656|Drug|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
400298|NCT01137643|Other|biologic sample preservation procedure|All samples collected during routine clinical care.
400299|NCT01137643|Other|cytology specimen collection procedure|All Samples collected during routine clinical care.
400300|NCT01137630|Drug|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
400401|NCT01136746|Drug|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
400301|NCT01137630|Drug|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
400302|NCT01137630|Drug|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
400303|NCT01137604|Drug|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
400304|NCT01137604|Drug|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
400305|NCT01137591|Drug|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
400306|NCT01137591|Drug|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
400307|NCT01137578|Procedure|Ultrasound|Ultrasounds to be performed on children with central venous catheters
400308|NCT01137578|Drug|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
400309|NCT01137578|Procedure|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
400310|NCT01137565|Drug|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
400311|NCT01137565|Drug|Placebo|Placebo to AMG 853
400312|NCT01137552|Drug|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
400313|NCT01137539|Device|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
400314|NCT01137526|Drug|ABT-384|Subjects will take study drug once daily for 12 weeks
400315|NCT01137526|Drug|donepezil|Subjects will take study drug once daily for 12 weeks.
400316|NCT01137526|Drug|placebo|Subjects will take study drug once daily for 12 weeks
400317|NCT01137513|Device|Observational Measurement of T-wave Alternans|Measurement is similar to typical EKG
400318|NCT01137513|Device|T-wave Alternans|T-Wave Alternans will be measured in an observational fashion
400319|NCT01137487|Procedure|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
400320|NCT01137487|Procedure|not monitoring of residual gastric volume|no measurements of residual gastric volume
400321|NCT01137474|Drug|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
400322|NCT01137474|Drug|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
400323|NCT01137461|Procedure|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
400324|NCT01137448|Behavioral|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
400325|NCT01137435|Biological|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
400326|NCT01137396|Drug|Modafinil|Modafinil 400mg PO QDaily following up-titration for ~8weeks
400327|NCT01137396|Behavioral|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
400328|NCT01137383|Drug|Pegaferon (pegylated interferon alpha 2a) + ribavirin|pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
400329|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
400330|NCT01137357|Dietary Supplement|Yoghurt with L.casei|Intake of yoghurt during 4 weeks
400331|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
400332|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Yoghurt with L. plantarum strain
400333|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
400334|NCT01137357|Dietary Supplement|Yoghurt|Intake of yoghurt during 4 weeks
400335|NCT01137331|Drug|K301|Liquid- applied once daily prior to bed
400336|NCT01137331|Drug|Placebo|Liquid- applied once daily prior to bed
400337|NCT01137318|Behavioral|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
400338|NCT01137305|Other|VR- training|"Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: camera and instrument navigation, coordination, grasping, lifting and grasping, clip applying and diathermy cutting in different levels of difficulty- medium and hard referring to time to complete task, economy of instrument motion and tissue damage; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training"
400339|NCT01137292|Drug|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
400340|NCT01137266|Device|TENS|TENS
400341|NCT01137253|Drug|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
400343|NCT01137240|Procedure|gastric emptying scan|"subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.~In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal."
400344|NCT01137214|Device|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
400345|NCT01137201|Procedure|Suturing of mesenteric defects|
400346|NCT01137188|Dietary Supplement|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
400347|NCT01137149|Behavioral|Behavioral Activation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
400348|NCT01137149|Behavioral|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
400349|NCT01137123|Drug|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
400350|NCT01137123|Procedure|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
400351|NCT01137123|Procedure|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
400352|NCT01137123|Procedure|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
400353|NCT01137110|Other|Brief LEV|Levetiracetam 1000mg BID x 3 days for prophylaxis
400354|NCT01137110|Other|Extended LEV|Levetiracetam 1000mg BID for length of hospital stay for prophylaxis
400355|NCT01137097|Procedure|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
400356|NCT01137084|Drug|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
400357|NCT01137084|Drug|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
400358|NCT01137071|Biological|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
400359|NCT01137058|Device|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
400360|NCT01137058|Device|SMBG group|Glucose control with self monitoring of blood glucose.
400361|NCT01137045|Biological|SPEEDA and TRCS SPEEDA|"For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.~For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.~For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI"
400362|NCT01137032|Drug|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
400363|NCT01137019|Device|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
400364|NCT01137019|Device|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
400365|NCT01137006|Biological|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into Cohort 2A."
400402|NCT01136733|Drug|Lenvatinib|taken orally, once a day
400403|NCT01136733|Drug|Everolimus|taken orally, once a day
400366|NCT01137006|Biological|IMC-20D7S (Cohort 2A)|"10 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A, then enrollment into Cohort 3A."
400367|NCT01137006|Biological|IMC-20D7S (Cohort 3A)|"20 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A, then enrollment into Cohort 4A."
400368|NCT01137006|Biological|IMC-20D7S (Cohort 4A)|"30 mg/kg i.v. every 2 weeks.~Administered every other week on Days 1 and 15 of each treatment cycle."
400369|NCT01137006|Biological|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into Cohort 2B."
400370|NCT01137006|Biological|IMC-20D7S (Cohort 2B)|"20 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle.~If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B, then enrollment into Cohort 3B."
400371|NCT01137006|Biological|IMC-20D7S (Cohort 3B)|"30 mg/kg i.v. every 3 weeks.~Administered every 3 weeks on Days 1 and 22 of each treatment cycle."
400372|NCT01136980|Device|TIF Transoral Fundoplication|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
400373|NCT01136980|Other|Sham placebo procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
400374|NCT01136967|Drug|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
400375|NCT01136954|Drug|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
400376|NCT01136941|Drug|Zileuton|Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
400377|NCT01136928|Drug|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
400378|NCT01136915|Drug|Iopamidol 370|one time administration for PCI
400379|NCT01136915|Drug|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
400380|NCT01136902|Dietary Supplement|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
400381|NCT01136889|Other|PFMT|Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
400382|NCT01136876|Drug|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
400383|NCT01136876|Drug|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
400384|NCT01136863|Drug|Felodipine|
400385|NCT01136863|Drug|Placebo|
400386|NCT01136850|Drug|chloroquine, sulphadoxine pyrimethamine, LLIN|"> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.~Given at enrolment, 14-26 weeks gestation, by mouth."
400387|NCT01136850|Drug|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
400388|NCT01136837|Other|primary pcı|
400389|NCT01136824|Other|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:~Demographic & health Trait anxiety Quality of life Nausea Expectations Anxiety & total mood disturbance Nausea & vomiting Multiple symptoms"
400390|NCT01136811|Device|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
400391|NCT01136798|Drug|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
400392|NCT01136798|Drug|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
400393|NCT01136785|Device|active CPAP Therapy|7 days of active CPAP therapy
400394|NCT01136785|Device|sham CPAP therapy|7 days of sham CPAP therapy
400395|NCT01136772|Drug|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
400396|NCT01136772|Drug|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
400397|NCT01136759|Drug|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
400398|NCT01136759|Other|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
400399|NCT01136746|Drug|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
400400|NCT01136746|Drug|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
400442|NCT01136278|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
400404|NCT01136668|Procedure|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
400405|NCT01136668|Procedure|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
400406|NCT01136655|Drug|80/2.25 μg Symbicort pMDI|inhalation
400407|NCT01136655|Drug|80/4.5 μg Symbicort pMDI|inhalation
400408|NCT01136655|Drug|Foradil Aerolizer 12 μg|inhalation
400409|NCT01136655|Drug|40 μg budesonide HFA pMDI|inhalation
400410|NCT01136655|Drug|placebo HFA pMDI|inhalation
400411|NCT01136642|Drug|Nicotrol|
400412|NCT01136603|Device|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
400413|NCT01136590|Drug|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
400414|NCT01136590|Drug|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
400415|NCT01136577|Device|Phototherapy|Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
400416|NCT01136564|Drug|Zemplar|2 capsules of 1 microgram daily
400417|NCT01136564|Drug|Placebo|2 capsules daily
400418|NCT01136551|Drug|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
400419|NCT01136538|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
400420|NCT01136525|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
400421|NCT01136499|Drug|LBH589 (Panobinostat®)|"40 mg MWF.~40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity."
400422|NCT01136447|Procedure|Ultrasound|Block catheter will be introduced using ultraosound
400423|NCT01136421|Drug|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
400424|NCT01136421|Drug|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
400425|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
400426|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
400427|NCT01136408|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
400428|NCT01136395|Drug|Rituximab|375mg/m2 4 weeks before ABOi LD transplantation
400429|NCT01136395|Procedure|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
400430|NCT01136395|Procedure|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK virus (BKV), JC virus (JCV)), respectively
400431|NCT01136382|Drug|budesonide|pMDI, inhalation, bid, 6 weeks
400432|NCT01136382|Drug|placebo|pMDI, inhalation, bid, 6 weeks
400433|NCT01136369|Device|OSNA Breast Cancer System|"For in vitro diagnostic use only.~The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
400434|NCT01136356|Drug|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
400435|NCT01136356|Drug|morphine|parenteral morphine may be administered multiple times each day
400436|NCT01136343|Other|lifestyle modified project|education, counseling
400437|NCT01136317|Drug|Omeprazole|
400438|NCT01136317|Drug|Rabeprazole|
400439|NCT01136317|Drug|Lactose|
400440|NCT01136304|Drug|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
400441|NCT01136291|Other|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.~The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.~These women also received nutrition counseling and prenatal care."
400444|NCT01136278|Drug|placebo|capsules identical to MDMA or clonidine
400445|NCT01136252|Drug|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
400446|NCT01136239|Drug|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
400447|NCT01136239|Drug|Placebo|Placebo (600mg twice daily)
400448|NCT01136226|Drug|Eligard (TM)|Eligard (TM) 22.5 mg administered at baseline and Month 3
400449|NCT01136213|Radiation|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
400450|NCT01136213|Other|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
400451|NCT01136213|Drug|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
400452|NCT01136200|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
400453|NCT01136187|Procedure|Access site in primary PCI|
400454|NCT01136174|Drug|Placebo|Placebo BID for cohort 1,2,3
400455|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
400456|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
400457|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
400458|NCT01136161|Biological|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
400459|NCT01136161|Biological|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
400460|NCT01136161|Biological|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
400461|NCT01136161|Biological|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
400462|NCT01136148|Behavioral|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
400463|NCT01136135|Other|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
400464|NCT01136122|Device|CPAP Treatment|Effective CPAP treatment for one month
400465|NCT01136096|Behavioral|Physical activity promoting intervention|"An interview with a physiotherapist~An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home~An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model~The daily record to check their body weight, exercise mode and duration~Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details~Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
400466|NCT01136096|Behavioral|General instruction and education|"Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic~Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule~Without individualized exercise program and interview with a physiotherapist"
400467|NCT01136083|Behavioral|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
400468|NCT01136083|Other|Usual care|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
400469|NCT01136057|Biological|Collection of Anti-Influenza A Immune Plasma|
400470|NCT01136044|Other|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
400471|NCT01136031|Drug|Paclitaxel and irinotecan|"In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)~100 100~100 120~135 120~135 160~every 3 week"
400472|NCT01136018|Procedure|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
400473|NCT01136005|Other|dexpanthenol 5% cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
400474|NCT01136005|Other|Cetomacrogol cream|Apply at least two times a day on face, chest and upper arms during the 6 week treatment period
400475|NCT01135992|Drug|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
400476|NCT01135992|Drug|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
400477|NCT01135966|Behavioral|Conventional resistance training program|Conventional resistance training program is followed.
400478|NCT01135966|Behavioral|Whole body vibration resistance training program|WBV training on FITVIBE
400479|NCT01135953|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
400480|NCT01135953|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
400481|NCT01135953|Other|Transcranial direct Stimulation (tDCS) and D-cycloserine|"Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).~D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session."
400482|NCT01135940|Device|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
400483|NCT01135940|Device|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
400484|NCT01135927|Drug|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
400485|NCT01135927|Drug|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
400486|NCT01135914|Drug|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
400487|NCT01135914|Procedure|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
400488|NCT01135901|Behavioral|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
400489|NCT01135888|Device|Skin cooling devices|Cooling vest and cooling bandana
400490|NCT01135875|Other|GBM Patients|2 teaspoons of blood will be collected during select clinic visits.
400491|NCT01135875|Other|Normal Controls|2 teaspoons of blood will be collected once.
400492|NCT01135862|Drug|platelets|6 packs of platelets will be administered
400493|NCT01135836|Procedure|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
400494|NCT01135836|Procedure|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
400495|NCT01135836|Procedure|Control group|CO2 was removed by passive exsufflation through the port site.
400496|NCT01135823|Procedure|Patient survey|
400497|NCT01135810|Behavioral|Hypnosis|
400498|NCT01135810|Behavioral|Meditation|
400499|NCT01135784|Dietary Supplement|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
400500|NCT01135784|Dietary Supplement|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
400501|NCT01135771|Other|glucose and insulin IV to alter blood glucose|
400502|NCT01135758|Drug|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
400503|NCT01135745|Device|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
400504|NCT01135732|Procedure|brush cytology|brush cytology during ERCP
400505|NCT01135719|Procedure|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
400506|NCT01135706|Other|No Intervention|This study does not include an intervention but is observational in nature.
400507|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
400508|NCT01135680|Drug|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
400509|NCT01135680|Drug|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
400510|NCT01135680|Drug|Moxifloxacin|single oral 400-mg dose on study Day 3
400511|NCT01135680|Drug|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
400512|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
400513|NCT01135667|Drug|clopidogrel|clopidogrel 150 mg once daily for 30 days
400514|NCT01135667|Drug|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
400515|NCT01135654|Other|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|"We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much."
400516|NCT01135641|Drug|Rituximab|Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
400517|NCT01135641|Drug|Ciclosporine|
400518|NCT01135641|Drug|Corticosteroids|
400519|NCT01135628|Other|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
400520|NCT01135628|Dietary Supplement|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
400521|NCT01135628|Drug|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
400522|NCT01135615|Drug|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
400523|NCT01135615|Drug|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
400524|NCT01135602|Drug|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
400525|NCT01135589|Drug|Micafungin|i.v.
400526|NCT01135576|Dietary Supplement|non-fortified fruit juices consumed as part of the usual diet|
400527|NCT01135576|Dietary Supplement|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
400528|NCT01135563|Drug|Vinblastine and Sirolimus|"Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.~Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough"
400529|NCT01135550|Drug|High dose dexamethasone|"Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
400530|NCT01135550|Drug|Low dose dexamethasone|"Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
400531|NCT01135537|Biological|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.~Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
400532|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
400533|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
400534|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
400535|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
400536|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
400537|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
400538|NCT01135511|Drug|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
400539|NCT01135511|Drug|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
400540|NCT01135498|Drug|bevacizumab [Avastin]|Intravenous repeating dose
400541|NCT01135498|Drug|eloxatin|Intravenous repeating dose
400542|NCT01135498|Drug|capecitabine [Xeloda]|Oral repeating dose
400543|NCT01135498|Drug|erlotinib [Tarceva]|Oral repeating dose
400544|NCT01135472|Drug|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
400545|NCT01135459|Drug|Lupuzor|200 mcg.
400546|NCT01135459|Drug|Placebo|Matching placebo was administered subcutaneously every 4 weeks for 20 weeks for a maximum of 6 doses.
400547|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
400548|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
400549|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
400550|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
400551|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 1 mg, once on Day 1 only, 2 days
400552|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
400553|NCT01135433|Drug|ipragliflozin|oral
400554|NCT01135433|Drug|Placebo|oral
400555|NCT01135433|Drug|metformin|oral
400556|NCT01135420|Behavioral|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
400557|NCT01135420|Other|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
400558|NCT01135407|Other|Recording during computerized tests|"Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.~The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions."
400559|NCT01135407|Other|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
400595|NCT01135082|Biological|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
400560|NCT01135407|Other|Recording during computerized tests|Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
400561|NCT01135394|Drug|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
400562|NCT01135381|Behavioral|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
400563|NCT01135368|Drug|Lansoprazole|Lansoprazole capsules
400564|NCT01135342|Behavioral|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
400565|NCT01135342|Behavioral|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
400566|NCT01135342|Behavioral|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
400567|NCT01135329|Drug|Fludarabine|30 mg/m^2 IV daily on Day -6 through Day -2.
400568|NCT01135329|Drug|Busulfan|1 mg/kg PO OR 0.8 mg/kg IV four times daily on Day -6 through Day -3.
400569|NCT01135329|Drug|Cyclophosphamide|50 mg/kg IV daily on Day +3 and Day +4.
400570|NCT01135329|Drug|Mycophenolate Mofetil|15 mg/kg PO three times daily (max daily dose of 3g) starting on Day +5.
400571|NCT01135329|Drug|Tacrolimus|Dosed based on drug levels; begin on Day +5 at 1 mg IV daily.
400572|NCT01135316|Drug|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
400573|NCT01135303|Device|VistaO2 device|Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
400574|NCT01135290|Drug|Aquaphor|
400575|NCT01135290|Drug|HP828-101|
400576|NCT01135264|Behavioral|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
400577|NCT01135264|Behavioral|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
400578|NCT01135251|Drug|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
400579|NCT01135251|Drug|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
400580|NCT01135225|Device|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
400581|NCT01135225|Device|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
400582|NCT01135212|Drug|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
400583|NCT01135212|Drug|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
400584|NCT01135212|Drug|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
400585|NCT01135199|Drug|pomalidomide (CC-4047|
400586|NCT01135186|Drug|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
400587|NCT01135173|Behavioral|Waterpipe smoking cessation|The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
400588|NCT01135147|Behavioral|Diet|Dietary therapy and physical education
400589|NCT01135147|Procedure|Surgery|Adenotonsillectomy along with diet and physical therapy
400590|NCT01135134|Drug|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:~5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
400591|NCT01135134|Drug|Placebo|"MF Placebo nasal spray and administration will be as follows:~5 to 11 years: one spray per nostril once daily in the morning for 2 weeks~12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
400592|NCT01135108|Drug|Placebo|Placebo IV Infusion
400593|NCT01135108|Drug|KAI-1678|KAI-1678 IV Infusion
400594|NCT01135095|Radiation|low-dose imaging|"The study is designed to assess the validity of a low dose (~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.~D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient"
400596|NCT01135069|Drug|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
400597|NCT01135069|Drug|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
400598|NCT01135069|Drug|placebo microsphere gel|treatment of acne vulgaris
400599|NCT01135056|Device|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
400600|NCT01135056|Drug|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
400601|NCT01135043|Behavioral|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
400602|NCT01135043|Behavioral|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
400603|NCT01135030|Procedure|Total knee|Primary Total knee
400604|NCT01135017|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
400605|NCT01135017|Drug|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
400606|NCT01135004|Procedure|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
400607|NCT01134991|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
400608|NCT01134978|Behavioral|Practice Order|"Blocked order - predictable~Random order - unpredictable"
400609|NCT01134965|Drug|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
400610|NCT01134965|Drug|Digoxin|Digoxin 0.5 mg as single dose
400611|NCT01134952|Drug|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
400612|NCT01134926|Drug|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
400613|NCT01134900|Other|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
400614|NCT01134887|Other|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
400615|NCT01134887|Behavioral|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
400616|NCT01134887|Other|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
400617|NCT01134887|Behavioral|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
400618|NCT01134887|Other|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
400619|NCT01134874|Behavioral|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
400620|NCT01134874|Behavioral|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
400621|NCT01134874|Behavioral|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
400622|NCT01134861|Drug|cisplatin|100 mg/m2 i.v. over 30-60 minutes, days 1 & 29
400623|NCT01134861|Drug|Etoposide|Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area < 1.7 m2
400624|NCT01134861|Drug|Vinblastine|5 mg/m2 i.v. bolus weekly first 5 weeks of RT
400625|NCT01134861|Radiation|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
400626|NCT01134861|Drug|Cisplatin|50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
400627|NCT01134861|Radiation|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
400628|NCT01134861|Radiation|Radiation therapy|69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
400629|NCT01134848|Drug|Morphine|10mg IM
400630|NCT01134848|Drug|Neostigmine|1mg IM
400631|NCT01134848|Drug|0.9% saline|0.1 ml/kg
400632|NCT01134848|Drug|Secretin|1 unit/kg IV
400633|NCT01134848|Drug|0.9% saline|1ml IM
400634|NCT01134835|Other|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
400635|NCT01134835|Drug|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
400636|NCT01134809|Procedure|Major abdominal surgery|All adult patients having major abdominal surgery
400637|NCT01134783|Behavioral|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
400676|NCT01134484|Procedure|Peripheral Blood Stem Cell (PBSC) collection|"Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)~G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
400638|NCT01134757|Biological|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
400639|NCT01134731|Drug|paliperidone|1-5 mg daily (QD)
400640|NCT01134731|Drug|lithium|300-1500mg QD
400641|NCT01134731|Drug|Placebo|1-5 placebo capsules
400642|NCT01134718|Drug|TMC435 (G006)|one morning dose of 150 mg
400643|NCT01134718|Drug|TMC435 (F021)|one morning dose of 150 mg
400644|NCT01134718|Drug|TMC435 (G007)|one morning dose of 150 mg
400645|NCT01134705|Drug|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
400646|NCT01134705|Drug|Placebo Nasal Aerosol|HFA Vehicle Aerosol
400647|NCT01134692|Drug|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
400648|NCT01134679|Behavioral|Multi-disciplinary disease management approach|Follow up with phone calls
400649|NCT01134666|Drug|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
400650|NCT01134653|Other|Jump Stretch|distraction with early mobilization
400651|NCT01134627|Drug|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
400652|NCT01134627|Drug|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
400653|NCT01134614|Biological|Ipilimumab|Given IV
400654|NCT01134614|Biological|Sargramostim|Given SC
400655|NCT01134601|Procedure|Radiation Therapy|
400656|NCT01134601|Drug|Capecitabine|
400657|NCT01134601|Drug|AZD6244|
400658|NCT01134588|Other|Paper questionnaire|
400659|NCT01134588|Other|Touch screen questionnaire|
400660|NCT01134575|Drug|CMC-544 (Inotuzumab Ozogamycin)|"First patients > 16 years and < 16 years receive CMC-544 at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2."
400661|NCT01134575|Drug|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
400662|NCT01134562|Drug|Placebo|Single IV injection.
400663|NCT01134562|Drug|Etelcalcetide|Single IV injection. The initial dose was 5 mg and dose escalation proceeded with subsequent doses of 10 mg, 20 mg, 40 mg and 60 mg.
400664|NCT01134549|Drug|Etelcalcetide|Administered as a single intravenous (IV) injection
400665|NCT01134549|Drug|Placebo|Administered as a single intravenous (IV) injection
400666|NCT01134536|Drug|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight <20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight >=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
400667|NCT01134523|Drug|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
400668|NCT01134523|Drug|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
400669|NCT01134510|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
400670|NCT01134510|Drug|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
400671|NCT01134497|Drug|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
400672|NCT01134497|Drug|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
400673|NCT01134484|Drug|Velcade|"INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)~REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
400674|NCT01134484|Drug|Thalidomide|"INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)~AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200~AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200~REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
400675|NCT01134484|Drug|Dexamethasone|"INDUCTION THERAPY~VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)~TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)~AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)~AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months~REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)~VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)~TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
401204|NCT01130506|Other|Laboratory Biomarker Analysis|Correlative studies
400677|NCT01134484|Procedure|First Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
400678|NCT01134484|Procedure|Second Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)~G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
400679|NCT01134471|Device|Ostene|applied to sternal surface
400680|NCT01134471|Device|Bonewax|applied to sternal surface
400681|NCT01134458|Behavioral|Web-Based Intervention|"Health Dialog Cardiac Risk Calculator~Health Dialog's Living with Coronary Heart Disease~Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
400682|NCT01134445|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
400683|NCT01134432|Drug|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.~Mabthera: 375 mg/m2 once a week for four weeks"
400684|NCT01134432|Drug|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
400685|NCT01134419|Other|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
400686|NCT01134419|Other|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
400687|NCT01134406|Device|Hydros Joint Therapy|Single intra-articular injection.
400688|NCT01134406|Device|Hydros-TA Joint Therapy|Single intra-articular injection
400689|NCT01134406|Device|Synvisc-One|Single intra-articular injection.
400690|NCT01134393|Drug|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
400691|NCT01134341|Drug|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
400692|NCT01134341|Drug|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met."
400693|NCT01134341|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
400694|NCT01134341|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
400695|NCT01134328|Drug|AC-150 Combo|1 drop in each eye for up to 14 days
400696|NCT01134328|Drug|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
400697|NCT01134328|Drug|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
400698|NCT01134328|Drug|Vehicle|1 drop in each eye once per day for up to 14 days
400699|NCT01134315|Drug|Paricalcitol|
400700|NCT01134315|Drug|Calcitriol|
400701|NCT01134302|Procedure|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
400702|NCT01134302|Procedure|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.~The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
400703|NCT01134289|Procedure|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
400704|NCT01134276|Procedure|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
400705|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
400706|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
400707|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, SC
400708|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 ml, Subcutaneous (SC)
400709|NCT01134263|Biological|Placebo: NaCl 0.9%|0.5 ml, SC
400710|NCT01134250|Drug|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
400711|NCT01134237|Drug|urokinase|intrapleural urokinase injection
400712|NCT01134237|Drug|placebo|Normal saline as a placebo for control arm
400713|NCT01134224|Drug|insulin degludec/insulin aspart|0.4 U/kg body weight injected subcutaneously (under the skin) once
400714|NCT01134224|Drug|insulin degludec/insulin aspart|0.6 U/kg body weight injected subcutaneously (under the skin) once
400715|NCT01134224|Drug|insulin degludec/insulin aspart|0.8 U/kg body weight injected subcutaneously (under the skin) once
400716|NCT01134224|Drug|biphasic insulin aspart 30|0.4 U/kg body weight injected subcutaneously (under the skin) once
400717|NCT01134224|Drug|biphasic insulin aspart 30|0.6 U/kg body weight injected subcutaneously (under the skin) once
400718|NCT01134224|Drug|biphasic insulin aspart 30|0.8 U/kg body weight injected subcutaneously (under the skin) once
400719|NCT01134211|Device|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
400720|NCT01134211|Device|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
400721|NCT01134198|Drug|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
400722|NCT01134198|Drug|placebo|placebo
400723|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
400724|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
400725|NCT01134185|Drug|prucalopride|single dose of 2 mg prucalopride
400726|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status. A member of the study team will call a subset of patients who have completed both baseline and follow-up surveys to clarify responses to previous questions. Patients will be considered lost to follow- up if surveys A or C have not been completed two years from the participant's consent date (participants who enroll but do not complete survey A are not prompted for survey C). Deviations will not be filed until the end of the study, as there are opportunities over the course of study follow- up to collect previously missing information.
400727|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion.
400728|NCT01134146|Radiation|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
400729|NCT01134133|Other|Anti-gurgling intervention|1. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
400730|NCT01134120|Drug|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
400731|NCT01134107|Drug|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
400732|NCT01134107|Drug|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
400733|NCT01134094|Procedure|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
400734|NCT01134094|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
400735|NCT01134081|Biological|CelTx™|CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
400736|NCT01134081|Procedure|Free Gingival Graft|Harvested tissue from palate
400737|NCT01134068|Other|Evaluation of a modified DD cut-off to rule out PE|Evaluation of a modified DD cut-off to rule out PE
400738|NCT01134055|Drug|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
400739|NCT01134055|Drug|placebo|placebo eye drops
400740|NCT01134055|Biological|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
400741|NCT01134042|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
400742|NCT01134042|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
400743|NCT01134042|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
400744|NCT01134042|Other|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
400745|NCT01134042|Other|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
400746|NCT01134029|Behavioral|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
400747|NCT01134016|Drug|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.~Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.~The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
400748|NCT01133990|Drug|FOLIRI|The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional). The 5-FU IV bolus (400 mg/m2) and CIV infusion (2400 mg/m2) over 46 hours is repeated on Days 15 and 16 of each cycle.
400785|NCT01133730|Drug|Placebo Arm|US-guided TFP block with 20ml of 5% dextrose solution
400786|NCT01133704|Biological|sipuleucel-T|
400787|NCT01133704|Biological|APC-Placebo|
401205|NCT01130506|Other|Pharmacological Study|Correlative studies
400749|NCT01133990|Drug|FOLIRI plus E7820|E7820 is administered orally in tablet form once daily, every day of each 28-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Phase II portion, the dose will be the MTD recommended Phase IB dose in combination with FOLFIRI, as determined during the Phase Ib portion of the study.
400750|NCT01133990|Drug|FOLFIRI plus Bevacizumab|Bevacizumab at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle
400751|NCT01133977|Drug|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
400752|NCT01133977|Drug|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
400753|NCT01133977|Drug|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
400754|NCT01133964|Dietary Supplement|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
400755|NCT01133951|Drug|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
400756|NCT01133951|Drug|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
400757|NCT01133925|Device|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
400758|NCT01133925|Device|Sirolimus Eluting Stent|Cypher stents implanted in overlap
400759|NCT01133925|Device|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
400760|NCT01133925|Device|Zotarolimus eluting stent|Endeavor stents implanted in overlap
400761|NCT01133912|Drug|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
400762|NCT01133899|Dietary Supplement|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
400763|NCT01133899|Dietary Supplement|GAA-4|4.8 grams of guanidinoacetic acid
400764|NCT01133899|Dietary Supplement|GAA-1|1.2 grams of guanidinoacetic acid
400765|NCT01133899|Dietary Supplement|PLACEBO|celulose
400766|NCT01133886|Drug|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
400767|NCT01133873|Drug|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
400768|NCT01133873|Drug|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
400769|NCT01133860|Drug|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
400770|NCT01133847|Drug|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
400771|NCT01133847|Behavioral|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
400772|NCT01133847|Behavioral|Parent Training|Nine sessions on parenting a child with ADHD
400773|NCT01133847|Drug|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
400774|NCT01133847|Drug|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
400775|NCT01133847|Drug|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
400776|NCT01133821|Drug|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
400777|NCT01133821|Drug|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.~The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).~Medication Dosing~The research pharmacy will dispense medication in the following unit-dose packs:~Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
400778|NCT01133795|Drug|Midodrine plus Albumin|MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
400779|NCT01133782|Procedure|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
400780|NCT01133756|Drug|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
400781|NCT01133756|Drug|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
400782|NCT01133756|Drug|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
400783|NCT01133743|Drug|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
400784|NCT01133730|Drug|Active treatment|US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
400788|NCT01133691|Dietary Supplement|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
400789|NCT01133678|Drug|Everolimus escalating dose|Phase I Portion (2 21-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus escalating dose
400790|NCT01133678|Drug|Everolimus or Placebo|Phase II Portion (2 28-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus dose determined in phase I
400791|NCT01133665|Drug|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
400792|NCT01133652|Device|Veinviewer|Veinviewer machine
400793|NCT01133652|Device|Ultrasound|Ultrasound
400794|NCT01133652|Other|Conventional technique|Conventional IV placement by nurses
400795|NCT01133639|Drug|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
400796|NCT01133639|Drug|Placebo|Placebo plus standard of care
400797|NCT01133626|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
400798|NCT01133626|Drug|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
400799|NCT01133626|Drug|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
400800|NCT01133626|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
400801|NCT01133613|Drug|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
400802|NCT01133600|Drug|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is <30ml/min.
400803|NCT01133600|Drug|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
400804|NCT01133587|Other|wait list control|"Patient-guided admissions contract regarding patient-guided admissions starting a year after."
400805|NCT01133587|Behavioral|admissions contract|"contract regarding patient-guided admissions starting immediately"
400806|NCT01133574|Drug|SLV354 capsules|20 mg
400807|NCT01133574|Drug|SLV354 capsules|60 mg
400808|NCT01133574|Drug|SLV354 capsules|120 mg
400809|NCT01133574|Drug|SLV354 capsules|250 mg
400810|NCT01133574|Drug|SLV354 capsules|500 mg
400811|NCT01133574|Drug|SLV354 capsules|750 mg
400812|NCT01133574|Drug|SLV354 capsules|1000 mg
400813|NCT01133574|Drug|SLV354 capsules|1250 mg
400814|NCT01133574|Drug|Placebo capsules|placebo
400815|NCT01133574|Drug|SLV354 capsules|low dose group 1
400816|NCT01133574|Drug|SLV354 capsules|high dose group 1
400817|NCT01133574|Drug|SLV354 capsules|low dose group 2
400818|NCT01133574|Drug|SLV354 capsules|high dose group 2
400819|NCT01133574|Drug|Placebo capsules|placebo
400820|NCT01133561|Drug|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
400821|NCT01133561|Drug|actozone B|one tablet of vehicle without active ingredient pioglitazone
400822|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
400823|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
400824|NCT01133522|Biological|Evolocumab|Administered by subcutaneous injection
400825|NCT01133522|Biological|Placebo|Administered by subcutaneous injection
400826|NCT01133509|Drug|Gardasil|0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
400827|NCT01133496|Drug|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
400828|NCT01133483|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
400829|NCT01133470|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
400830|NCT01133457|Drug|Finasteride|Finasteride tablets 1 mg
400831|NCT01133444|Drug|Finasteride|Finasteride tablets 1 mg
400832|NCT01133431|Drug|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
400833|NCT01133431|Drug|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
400834|NCT01133418|Other|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
400835|NCT01133418|Other|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
400836|NCT01133405|Drug|LY2886721|Oral capsules
400837|NCT01133405|Drug|Placebo|Oral capsules
400838|NCT01133392|Drug|Insulin lispro A|20 units (U) subcutaneously (SC).
400839|NCT01133392|Drug|Insulin lispro B|20 U subcutaneously (SC).
400840|NCT01133379|Device|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
401206|NCT01130506|Drug|Vorinostat|Given PO
400841|NCT01133379|Device|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
400842|NCT01133379|Device|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
400843|NCT01133366|Drug|warfarin sodium|25 mg of warfarin oral (single dose)
400844|NCT01133366|Drug|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
400845|NCT01133353|Drug|Tetrabenazine MR|Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
400846|NCT01133353|Drug|Placebo|1 to 5 tablets once per day depending on weight for 12 weeks
400847|NCT01133340|Radiation|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
400848|NCT01133327|Device|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.~The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
400849|NCT01133301|Drug|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
400850|NCT01133301|Drug|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
400851|NCT01133288|Device|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (~30 minutes per day) over a 3 month period.
400852|NCT01133275|Drug|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
400853|NCT01133275|Drug|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
400854|NCT01133236|Dietary Supplement|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction."
400855|NCT01133223|Device|Penumbra™ System|Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)
400856|NCT01133223|Drug|Recombinant tissue plasminogen activator|Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
400857|NCT01133210|Drug|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
400858|NCT01133210|Other|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
400859|NCT01133184|Biological|Sci B vac|Sci B vac
400860|NCT01133171|Behavioral|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
400861|NCT01133171|Behavioral|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
400862|NCT01133158|Drug|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv Dexamethasone 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
400863|NCT01133145|Procedure|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
400864|NCT01133132|Behavioral|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
400865|NCT01133132|Other|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
400866|NCT01133119|Drug|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
400867|NCT01133119|Drug|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.~Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
400914|NCT01132755|Procedure|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
400915|NCT01132729|Drug|Valacyclovir Hydrochloride|1000 mg caplet
400916|NCT01132716|Drug|Valacyclovir Hydrochloride|1000 mg caplet
400868|NCT01133106|Behavioral|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.~Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
400869|NCT01133106|Other|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
400870|NCT01133080|Drug|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
400871|NCT01133080|Drug|placebo|"placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.~From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses."
400872|NCT01133054|Procedure|revascularization|surgery or stenting
400873|NCT01133041|Other|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
400874|NCT01133041|Other|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
400875|NCT01133028|Behavioral|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
400876|NCT01133028|Behavioral|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
400877|NCT01133015|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
400878|NCT01133015|Device|IVUS|intravascular ultrasound
400879|NCT01132989|Drug|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and < 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
400880|NCT01132976|Behavioral|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
400881|NCT01132976|Behavioral|Treatment as usual|No specific motivational interview
400882|NCT01132963|Other|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
400883|NCT01132963|Other|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
400884|NCT01132950|Behavioral|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
400885|NCT01132950|Other|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
400886|NCT01132911|Drug|Vorinostat (SAHA)|
400887|NCT01132911|Drug|Velcade (PS-341, Bortezomib)|
400888|NCT01132846|Other|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
400889|NCT01132846|Drug|Nesiritide|"Active Comparator: Low Dose Nesiritide~Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
400890|NCT01132846|Drug|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
400891|NCT01132833|Other|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
400892|NCT01132833|Other|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
400893|NCT01132833|Other|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
400894|NCT01132820|Drug|Cediranib Maleate|Given PO
400895|NCT01132820|Other|Laboratory Biomarker Analysis|Correlative studies
400896|NCT01132807|Biological|Bleomycin Sulfate|Given IV
400897|NCT01132807|Drug|Doxorubicin Hydrochloride|Given IV
400898|NCT01132807|Drug|Procarbazine Hydrochloride|Given PO
400899|NCT01132807|Drug|Vinblastine Sulfate|Given IV
400900|NCT01132807|Drug|Dacarbazine|Given IV
400901|NCT01132807|Drug|Cyclophosphamide|Given IV
400902|NCT01132807|Drug|Etoposide phosphate|Given IV
400903|NCT01132807|Drug|prednisone|Given PO
400904|NCT01132807|Drug|Radiation Therapy|Undergo radiation therapy
400905|NCT01132807|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
400906|NCT01132807|Procedure|computed tomography|Undergo FDG PET/CT
400907|NCT01132807|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
400908|NCT01132794|Drug|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
400909|NCT01132794|Drug|Placebo|Intranasal nasal saline
400910|NCT01132781|Drug|Theophylline (Intervention Group)|200 mg twice daily of slow release theophylline
400911|NCT01132781|Drug|Placebo (Placebo Group)|200 mg twice daily of placebo drug
400912|NCT01132768|Drug|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
400913|NCT01132768|Drug|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
400917|NCT01132703|Drug|RP-1127 (Glyburide for injection)|RP-1127 is administered as a bolus followed by continuous infusion for 72 hours
400918|NCT01132703|Drug|Placebo (RP-1127 excipients, excluding active)|RP-1127 excipients, excluding active
400919|NCT01132690|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
400920|NCT01132677|Device|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
400921|NCT01132677|Drug|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
400922|NCT01132664|Drug|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
400923|NCT01132664|Drug|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
400924|NCT01132664|Drug|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
400925|NCT01132651|Other|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
400926|NCT01132651|Other|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
400927|NCT01132638|Drug|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
400928|NCT01132638|Drug|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
400929|NCT01132625|Drug|AUY922|
400930|NCT01132612|Drug|AIN457|AIN457A 150 mg powder for solution
400931|NCT01132612|Drug|Placebo|Placebo to AIN457A 150 mg powder for solution
400932|NCT01132599|Dietary Supplement|C-11 choline|
400933|NCT01132599|Radiation|18F-fluoromethylcholine|
400934|NCT01132586|Drug|Lenalidomide|Given PO
400935|NCT01132586|Drug|Cytarabine|Given IV
400936|NCT01132586|Drug|Idarubicin|Given IV
400937|NCT01132586|Other|Pharmacological Study|Correlative studies
400938|NCT01132586|Other|Laboratory Biomarker Analysis|Correlative studies
400939|NCT01132573|Drug|entinostat|Given PO
400940|NCT01132573|Drug|clofarabine|Given IV
400941|NCT01132573|Other|pharmacological study|Correlative studies
400942|NCT01132573|Other|laboratory biomarker analysis|Correlative studies
400943|NCT01132560|Genetic|RNA analysis|
400944|NCT01132560|Genetic|gene expression analysis|
400945|NCT01132560|Genetic|reverse transcriptase-polymerase chain reaction|
400946|NCT01132560|Other|laboratory biomarker analysis|
400947|NCT01132547|Drug|cyproheptadine hydrochloride|Given orally
400948|NCT01132547|Other|placebo|Given orally
400949|NCT01132521|Drug|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
400950|NCT01132521|Drug|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
400951|NCT01132508|Device|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
400952|NCT01132495|Other|Stenting plus OMT|FFR guided PCI, plus OMT
400953|NCT01132495|Other|OMT|OMT alone
400954|NCT01132495|Other|Standard of care|FFR > 0.80; treatment according to local practice
400955|NCT01132482|Drug|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
400956|NCT01132482|Drug|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
400957|NCT01132469|Procedure|Endoscopic Submucosal Dissection|5-years follow-up after Endoscopic Submucosal Dissection
400958|NCT01132456|Device|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
400959|NCT01132443|Drug|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily
400960|NCT01132430|Behavioral|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
400961|NCT01132430|Behavioral|Usual care|Standard medical care within 4-6 week period
400962|NCT01132417|Drug|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
400963|NCT01132404|Drug|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
400964|NCT01132404|Drug|TAK-448|"Phase 1 portion of study:~Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site~Phase 2 portion of the study:~Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
400965|NCT01132391|Drug|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
400966|NCT01132378|Procedure|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
400967|NCT01132365|Device|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
400968|NCT01132352|Drug|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
400969|NCT01132326|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
400970|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
400971|NCT01132313|Drug|BI 201335|40 weeks, QD
400972|NCT01132313|Drug|BI 207127|4 weeks, low dose TID
400973|NCT01132313|Drug|BI 201335|24 weeks, QD
400974|NCT01132313|Drug|Ribavirin|16 weeks, according to label
400975|NCT01132313|Drug|Ribavirin|28 weeks, according to label
400976|NCT01132313|Drug|Ribavirin|28 weeks, according to label
400977|NCT01132313|Drug|BI 207127|40 weeks, high dose, TID
400978|NCT01132313|Drug|BI 207127|24 weeks, very high dose, BID
400979|NCT01132313|Drug|BI 207127|16 weeks, standard dose, BID
400980|NCT01132313|Drug|BI 201335|24 weeks, QD
400981|NCT01132313|Drug|Ribavirin|48 weeks, according to label
400982|NCT01132313|Drug|Ribavirin|40 weeks, according to label
400983|NCT01132313|Drug|BI 207127|16 weeks, high dose, TID
400984|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
400985|NCT01132313|Drug|BI 201335|28 weeks, QD
400986|NCT01132313|Drug|BI 201335|16 weeks, QD
400987|NCT01132313|Drug|Ribavirin|24 weeks, according to label
400988|NCT01132313|Drug|BI 201335|24 weeks, QD
400989|NCT01132313|Drug|BI 201335|28 weeks, QD
400990|NCT01132313|Drug|BI 207127|24 weeks, standard dose, BID
400991|NCT01132313|Drug|BI 201335|24 weeks, QD
400992|NCT01132313|Drug|BI 201335|16 weeks, QD
400993|NCT01132313|Drug|BI 207127|16 weeks, high dose, BID
400994|NCT01132313|Drug|BI 201335|24 weeks, QD
400995|NCT01132313|Drug|Ribavirin|16 weeks, according to label
400996|NCT01132313|Drug|Ribavirin|16 weeks, according to label
400997|NCT01132313|Drug|BI 207217|28 weeks, high dose BID
400998|NCT01132313|Drug|BI 201335|16 weeks, QD
400999|NCT01132313|Drug|BI 207127|24 weeks, high dose, TID
401000|NCT01132313|Drug|Ribavirin|48 weeks, according to label
401001|NCT01132313|Drug|BI 207127|4 weeks, high dose, TID
401002|NCT01132313|Drug|BI 201335|28 weeks, QD
401003|NCT01132313|Drug|Ribavirin|24 weeks, according to label
401004|NCT01132313|Drug|Ribavirin|24 weeks, according to label
401005|NCT01132300|Device|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
401006|NCT01132287|Other|FID 112903|lubricant eye drop FID 112903
401007|NCT01132274|Procedure|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
401008|NCT01132274|Procedure|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
401009|NCT01132261|Other|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
401010|NCT01132248|Drug|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
401011|NCT01132248|Drug|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
401012|NCT01132235|Biological|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
401013|NCT01132222|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
401014|NCT01132209|Procedure|Closure of the abdominal wall after midline incisions|Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
401015|NCT01132196|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
401016|NCT01132183|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
401017|NCT01132170|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
401018|NCT01132157|Drug|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
401019|NCT01132157|Drug|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
401020|NCT01132144|Procedure|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
401021|NCT01132144|Procedure|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
401022|NCT01132131|Other|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
401070|NCT01131624|Drug|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
401207|NCT01130493|Drug|IPX066|experimental product
401208|NCT01130493|Drug|CLE|active comparator
401023|NCT01132118|Drug|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
401024|NCT01132105|Device|Vestibular myogenic evoked potential analyzer|
401025|NCT01132079|Drug|cream treatment|
401026|NCT01132066|Other|tDCS|tDCS will lead to an increase in cortical excitability
401027|NCT01132066|Other|Sham|Sham will provide identical subjective sensation as tDCS
401028|NCT01132040|Drug|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
401029|NCT01132027|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
401030|NCT01132014|Biological|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
401031|NCT01131988|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
401032|NCT01131975|Drug|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
401033|NCT01131962|Procedure|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
401034|NCT01131949|Drug|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
401035|NCT01131936|Drug|Amlodipine|Amlodipine Tablets, 10 mg
401036|NCT01131923|Drug|Amlodipine|Amlodipine Tablets, 10 mg
401037|NCT01131910|Biological|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
401038|NCT01131910|Biological|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
401039|NCT01131910|Biological|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
401040|NCT01131897|Drug|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
401041|NCT01131884|Drug|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
401042|NCT01131884|Drug|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
401043|NCT01131871|Behavioral|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
401044|NCT01131871|Behavioral|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
401045|NCT01131858|Drug|Vigantol|Vigantol 4000IU/day
401046|NCT01131858|Drug|Placebo|Placebo
401047|NCT01131845|Drug|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
401048|NCT01131832|Dietary Supplement|Plant sterol|
401049|NCT01131832|Dietary Supplement|Placebo|
401050|NCT01131819|Device|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
401051|NCT01131806|Drug|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
401052|NCT01131806|Drug|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
401053|NCT01131793|Device|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
401054|NCT01131780|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
401055|NCT01131767|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
401056|NCT01131754|Other|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
401057|NCT01131741|Drug|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
401058|NCT01131741|Drug|Control|This group receives 3 mL of saline IV during operation.
401059|NCT01131728|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
401060|NCT01131702|Drug|Ranitidine|Ranitidine Tablets, 300 mg
401061|NCT01131689|Drug|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
401062|NCT01131676|Drug|BI 10773 low dose|BI 10773 tablets once daily
401063|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
401064|NCT01131676|Drug|BI 10773 high dose|BI 10773 tablets once daily
401065|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
401066|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
401067|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
401068|NCT01131637|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
401069|NCT01131637|Drug|placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
401071|NCT01131624|Drug|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
401072|NCT01131611|Behavioral|CBPT|Cognitive-Behavioral Based Physical Therapy
401073|NCT01131611|Other|Control-Attention|Standard of Care + weekly phone calls
401074|NCT01131585|Procedure|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
401075|NCT01131585|Drug|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
401076|NCT01131585|Drug|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
401077|NCT01131572|Drug|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
401078|NCT01131559|Drug|Lisdexamfetamine|Oral; 20-70mg/day
401079|NCT01131559|Drug|Placebo control|Oral; 20-70mg/day
401080|NCT01131546|Drug|Levamlodipine besylate|Once daily, 7AM - 10AM
401081|NCT01131546|Drug|Amlodipine maleate|Once daily, 7AM - 10AM
401082|NCT01131533|Procedure|Vitrectomy|vitrectomy following intravitreal erythropoietin
401083|NCT01131520|Behavioral|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
401084|NCT01131520|Behavioral|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
401085|NCT01131507|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
401086|NCT01131494|Other|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
401087|NCT01131481|Device|Intraocular lens|
401088|NCT01131468|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
401089|NCT01131455|Biological|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
401090|NCT01131429|Drug|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
401091|NCT01131429|Drug|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
401092|NCT01131429|Drug|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
401093|NCT01131429|Drug|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
401094|NCT01131429|Drug|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
401095|NCT01131429|Drug|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
401096|NCT01131416|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
401097|NCT01131390|Device|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
401098|NCT01131377|Drug|acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.~If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
401099|NCT01131377|Drug|Saline|They will receive saline 50ml via IV q 24h.
401100|NCT01131364|Drug|F16IL2 in combination with doxorubicin|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
401101|NCT01131351|Drug|OPC-67683|Dosage-500-800 mg Strength 250-400 mg Frequency b.i.d.
401102|NCT01131325|Drug|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
401103|NCT01131312|Device|Thinprep|Pap test
401104|NCT01131312|Device|Hybrid capture 2|Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) Test
401105|NCT01131312|Procedure|Colposcopy|Procedure performed by a healthcare practitioner to examine the cervix, vagina, and vulva.
401106|NCT01131299|Other|Placebo|2 tablets PO 3 times a day for 12-14 weeks
401107|NCT01131299|Drug|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
401108|NCT01131273|Drug|methadone|12 weeks of methadone maintenance with counseling
401109|NCT01131273|Drug|buprenorphine-naloxone (Suboxone) for 12 weeks|12 weeks of maintenance with counseling
401110|NCT01131260|Device|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
401151|NCT01131000|Other|Normal Saline|Normal Saline, 100 ml, Single-dose
401111|NCT01131247|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
401112|NCT01131234|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
401113|NCT01131234|Drug|Cediranib Maleate|Given PO
401114|NCT01131234|Other|Pharmacological Study|Correlative studies
401115|NCT01131234|Other|Laboratory Biomarker Analysis|Correlative studies
401116|NCT01131221|Other|laboratory biomarker analysis|
401117|NCT01131208|Genetic|gene expression analysis|
401118|NCT01131208|Other|laboratory biomarker analysis|
401119|NCT01131195|Biological|bevacizumab, Paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.
401120|NCT01131195|Biological|Bevacizumab, Cyclophosphamide, Capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
401121|NCT01131182|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
401122|NCT01131182|Drug|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
401123|NCT01131182|Drug|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
401124|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
401125|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
401126|NCT01131156|Behavioral|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
401127|NCT01131143|Behavioral|Provider Voice|A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
401128|NCT01131143|Behavioral|Generic Voice|A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
401129|NCT01131130|Device|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
401130|NCT01131130|Device|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
401131|NCT01131130|Device|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
401132|NCT01131104|Drug|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
401133|NCT01131091|Drug|SK-0403|SK-0403 400 mg
401134|NCT01131078|Drug|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
401135|NCT01131078|Drug|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m^2 twice daily (Day 2 to 15) or as 650 mg/m^2 twice daily on Days 1 to 21.
401136|NCT01131078|Drug|Irinotecan|Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
401137|NCT01131065|Drug|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
401138|NCT01131052|Drug|Insulin Glargine|glargine once a day
401139|NCT01131052|Drug|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
401140|NCT01131052|Drug|Insulin glulisine|glulisine given as needed before meals
401141|NCT01131039|Drug|Gemcitabine/Bevacizumab|"Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression"
401142|NCT01131026|Drug|Levofloxacin|tablet, 500 mg, once a day for ten days
401143|NCT01131026|Drug|Amoxicillin|tablet, 1000 mg, once a day for ten days
401144|NCT01131026|Drug|Lansoprazole|capsule, 30 mg, twice a day for ten days
401145|NCT01131013|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
401146|NCT01131013|Drug|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
401147|NCT01131013|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
401148|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
401149|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
401150|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
401152|NCT01130987|Other|Computerized handoff tool|Computer program that facilitates accurate transmission of patient information between residents
401153|NCT01130987|Behavioral|Team training|Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
401154|NCT01130974|Device|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
401155|NCT01130974|Device|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
401156|NCT01130948|Other|altitude exposure|exposure to 490m, 1700m and 2590m
401157|NCT01130922|Drug|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
401158|NCT01130922|Drug|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
401159|NCT01130909|Drug|AZD6765|75 mg
401160|NCT01130909|Drug|AZD6765|150 mg
401161|NCT01130909|Drug|Ketamine|0.5 mg/kg
401162|NCT01130909|Drug|Placebo|125 mL sterile NaCl 0.9%
401163|NCT01130870|Device|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
401164|NCT01130870|Device|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
401165|NCT01130870|Device|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
401166|NCT01130844|Drug|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
401167|NCT01130844|Drug|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
401168|NCT01130844|Drug|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
401169|NCT01130831|Drug|Lanthanum carbonate|
401170|NCT01130818|Drug|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
401171|NCT01130818|Drug|placebo|single dose, oral solution
401172|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), fasting
401173|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), after high fat breakfast
401174|NCT01130805|Drug|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
401175|NCT01130792|Dietary Supplement|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
401176|NCT01130792|Dietary Supplement|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
401177|NCT01130779|Drug|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
401178|NCT01130766|Procedure|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
401179|NCT01130753|Drug|Erlotinib|Erlotinib 150mg per day for 8 weeks
401180|NCT01130740|Behavioral|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
401181|NCT01130727|Other|green tea extract|1.21g of green tea extract (965 mg of flavonols)
401182|NCT01130727|Other|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
401183|NCT01130727|Other|placebo|placebo
401184|NCT01130727|Other|low polyphenol cocoa extract|placebo
401185|NCT01130714|Behavioral|Exercise|Resistance training with resistance bands.
401186|NCT01130701|Other|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.~Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.~After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
401187|NCT01130688|Drug|Zileuton|Imatinib combined with Zileuton
401188|NCT01130675|Other|caffeinated coffee|8 oz. of caffeinated cofee/breakfast&noon meal. No intervention for 2nd arm.
401189|NCT01130662|Drug|combination therapy using decitabine and midostaurin|"Cohort 1:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.~Cohort 2:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.~Cohort 3:~Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle."
401190|NCT01130649|Device|HealthBuddy|Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
401191|NCT01130636|Drug|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
401192|NCT01130623|Drug|Pazopanib (GW786034)|
401193|NCT01130597|Drug|patiromer|Active investigational drug
401194|NCT01130597|Drug|spironolactone|
401195|NCT01130584|Other|Pyruvate kinase isoform M2|
401196|NCT01130571|Procedure|Xenografts and cell cultures|
401197|NCT01130558|Other|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
401198|NCT01130532|Drug|Tadalafil|Administer orally
401199|NCT01130532|Drug|Placebo|Administer orally
401200|NCT01130519|Drug|Bevacizumab|Commercially available. Administered by intravenous infusion.
401201|NCT01130519|Drug|Erlotinib|Commercially available. Administered orally
401202|NCT01130506|Drug|Cytarabine|Given IV
401203|NCT01130506|Drug|Decitabine|Given IV
401209|NCT01130480|Device|Accu-Chek Integra Glucometer|
401210|NCT01130467|Drug|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
401211|NCT01130467|Drug|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
401212|NCT01130467|Behavioral|behavioral modification|Parenting and teaching skill education
401213|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
401214|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
401215|NCT01130441|Behavioral|psychotherapy|short problem-solving skills therapy intervention
401216|NCT01130428|Device|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.~The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading [38]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
401217|NCT01130376|Biological|GTU-MultiHIV B clade vaccine1mg|Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
401218|NCT01130376|Drug|Interleukin-2|5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
401219|NCT01130376|Drug|GM-CSF|150 ug administered subcutaneously once daily 4 hours from IL-2 injections
401220|NCT01130376|Drug|Growth Hormone|4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
401221|NCT01130337|Drug|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
401222|NCT01130337|Drug|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
401223|NCT01130337|Drug|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
401224|NCT01130324|Drug|VIBATIV|Observational
401225|NCT01130311|Drug|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
401226|NCT01130311|Drug|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
401227|NCT01130298|Drug|Testosterone Gel 1.62%|5 grams
401228|NCT01130285|Genetic|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
401229|NCT01130272|Drug|Eluxadoline|Tablets, orally, twice daily.
401230|NCT01130272|Drug|Placebo|Matching placebo oral tablets twice daily.
401231|NCT01130259|Drug|iniparib|5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
401232|NCT01130246|Drug|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
401233|NCT01130246|Drug|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
401234|NCT01130233|Procedure|robotic assisted rectal resection|robotic assisted rectal resection
401235|NCT01130233|Procedure|laparoscopic rectal resection|laparoscopic rectal resection
401236|NCT01130220|Other|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
401237|NCT01130194|Other|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
401238|NCT01130181|Drug|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
401239|NCT01130181|Drug|Placebo|Matching placebo
401240|NCT01130168|Drug|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
401241|NCT01130168|Drug|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
401242|NCT01130168|Drug|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
401243|NCT01130142|Drug|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
401244|NCT01130142|Drug|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
401245|NCT01130129|Other|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
401246|NCT01130103|Drug|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
401247|NCT01130103|Behavioral|Prolonged Exposure Therapy|Weekly for 10 weeks
401248|NCT01130090|Device|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
401249|NCT01130077|Biological|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
401250|NCT01130077|Biological|Poly-ICLC|Vaccine given every 3 weeks
401251|NCT01130064|Biological|QAX576|every 3 weeks via intravenous infusion
401252|NCT01130064|Drug|Placebo|every 3 weeks via intravenous infusion
401253|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
401254|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
401255|NCT01130025|Drug|Warfarin|Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.
401256|NCT01130025|Drug|Innohep®|Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
401257|NCT01130012|Behavioral|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
401258|NCT01130012|Behavioral|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
401259|NCT01129999|Behavioral|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
401260|NCT01129999|Behavioral|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
401261|NCT01129986|Device|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
401262|NCT01129960|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
401263|NCT01129960|Drug|Placebo|Tablets will be used.
401264|NCT01129947|Drug|DHEA|DHEA 25 mg tid
401265|NCT01129934|Drug|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
401266|NCT01129934|Drug|morphine|Administration of intravenous morphine 0.1 mg/kg
401267|NCT01129921|Device|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
401268|NCT01129921|Device|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
401269|NCT01129895|Behavioral|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
401270|NCT01129882|Drug|Aripiprazole|Aripiprazole IM Depot - 300mg or 400mg
401271|NCT01129856|Drug|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
401272|NCT01129856|Drug|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
401273|NCT01129843|Drug|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
401274|NCT01129830|Dietary Supplement|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
401275|NCT01129817|Other|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
401276|NCT01129817|Other|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
401277|NCT01129804|Behavioral|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
401278|NCT01129791|Behavioral|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
401279|NCT01129791|Behavioral|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
401280|NCT01129791|Behavioral|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
401281|NCT01129778|Drug|Zegerid (proton pump inhibitor)|
401282|NCT01129778|Procedure|Bravo pH monitoring|
401283|NCT01129765|Device|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
401284|NCT01129752|Other|No intervention|there is no intervention for this study
401285|NCT01129739|Other|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
401286|NCT01129739|Other|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
401287|NCT01129726|Device|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
401288|NCT01129713|Drug|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
401289|NCT01129713|Drug|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
401290|NCT01129700|Radiation|Radiation: short-course preoperative chemoradiotherapy|"Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).~Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day)."
401291|NCT01129687|Procedure|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
401292|NCT01129687|Procedure|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
401293|NCT01129674|Drug|LY2140023|Administered orally, twice daily for 104 weeks
401294|NCT01129674|Drug|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
401295|NCT01129674|Drug|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
401296|NCT01129674|Drug|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
401297|NCT01129674|Drug|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
401298|NCT01129661|Biological|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
401299|NCT01129661|Biological|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
401300|NCT01129648|Drug|Placebo|Administered daily for 21 days
401301|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401302|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401303|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401304|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
401305|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401306|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401307|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401308|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
401309|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401310|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401311|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401312|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
401313|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401314|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401315|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
401316|NCT01129648|Drug|BCX4208|Adminstered daily for 21 days
401317|NCT01129635|Procedure|Cardiac Resynchronization Therapy (CRT) implantation|"The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.~Arm: CRT Candidate"
401318|NCT01129622|Drug|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
401319|NCT01129609|Device|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
401320|NCT01129596|Drug|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
401321|NCT01129583|Drug|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
401322|NCT01129583|Drug|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
401323|NCT01129570|Drug|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
401324|NCT01129557|Drug|Aliskiren|
401325|NCT01129557|Drug|Valsartan|
401326|NCT01129544|Biological|Gene transfer|Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
401327|NCT01129531|Drug|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
401328|NCT01129531|Drug|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
401329|NCT01129518|Biological|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.~Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
401330|NCT01129518|Biological|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
401331|NCT01129505|Behavioral|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.~Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.~Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
401332|NCT01129492|Device|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
401333|NCT01129479|Drug|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
401334|NCT01129479|Drug|Placebo pill|Placebo pill each morning with food for 12 weeks.
401470|NCT01128582|Drug|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
401335|NCT01129466|Dietary Supplement|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
401336|NCT01129466|Dietary Supplement|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
401337|NCT01129453|Biological|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10^6, 10^7, 10^8, or 10^9 CFU per mL. Route: oral.
401338|NCT01129453|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
401339|NCT01129440|Device|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
401340|NCT01129440|Device|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.~After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
401341|NCT01129427|Drug|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
401342|NCT01129427|Drug|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
401343|NCT01129427|Drug|Pantoprazole|"Pharmaceutical form: delayed-release tablet~Route of administration: oral"
401344|NCT01129414|Drug|Clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
401345|NCT01129414|Drug|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
401346|NCT01129414|Drug|Omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration: oral"
401347|NCT01129401|Behavioral|Stonewall Project|The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
401348|NCT01129388|Drug|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
401349|NCT01129388|Drug|Placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
401350|NCT01129388|Drug|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
401351|NCT01129375|Drug|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
401352|NCT01129375|Drug|placebo|"Pharmaceutical form: matching tablet~Route of administration: oral"
401353|NCT01129375|Drug|omeprazole|"Pharmaceutical form: delayed-release capsule~Route of administration:oral"
401354|NCT01129362|Biological|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
401355|NCT01129362|Biological|Other Pertussis Vaccines|0.5 mL, Intramuscular
401356|NCT01129349|Drug|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
401357|NCT01129336|Drug|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
401358|NCT01129336|Drug|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
401359|NCT01129323|Drug|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
401360|NCT01129310|Drug|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
401361|NCT01129284|Drug|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
401362|NCT01129271|Drug|clopidogrel|"Pharmaceutical form: tablet~Route of administration: oral"
401363|NCT01129271|Drug|Matching placebo|"Pharmaceutical form: tablet~Route of administration: oral"
401364|NCT01129258|Drug|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
401365|NCT01129258|Drug|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
401366|NCT01129245|Drug|Celebrex|400 mg PO daily intermittently based on hormone and ultrasound findings
401367|NCT01129245|Drug|Placebo|Placebo identical to celecoxib
401368|NCT01129232|Drug|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
401369|NCT01129232|Other|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
401370|NCT01129219|Other|Strength training|Strength training for 24 weeks
401371|NCT01129206|Drug|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
401372|NCT01129206|Drug|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
401373|NCT01129206|Radiation|fludeoxyglucose F 18|Correlative studies
401374|NCT01129206|Procedure|positron emission tomography|Correlative studies
401375|NCT01129193|Other|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).~Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
401376|NCT01129193|Other|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
401471|NCT01128569|Drug|Fluticasone Furoate|FF
401377|NCT01129193|Other|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
401378|NCT01129193|Drug|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
401379|NCT01129180|Drug|azacitidine|Given SC
401380|NCT01129180|Drug|bortezomib|Given IV
401381|NCT01129180|Procedure|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
401382|NCT01129154|Drug|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
401383|NCT01129141|Procedure|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
401384|NCT01129141|Procedure|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
401385|NCT01129128|Biological|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
401386|NCT01129128|Biological|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
401387|NCT01129128|Biological|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
401388|NCT01129115|Behavioral|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
401389|NCT01129115|Behavioral|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
401390|NCT01129115|Behavioral|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
401391|NCT01129115|Behavioral|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
401392|NCT01129102|Drug|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
401393|NCT01129102|Drug|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
401394|NCT01129102|Drug|Placebo|Placebo for NPC-01
401395|NCT01129089|Dietary Supplement|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
401396|NCT01129089|Dietary Supplement|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
401397|NCT01129089|Dietary Supplement|Micronutrient powder|Micronutrient powder for infant and young children
401398|NCT01129063|Drug|Clopidogrel|"Pharmaceutical form : tablet~Route of administration: oral"
401399|NCT01129050|Dietary Supplement|Fish Oil|Fish oil capsule
401400|NCT01129050|Dietary Supplement|Flaxseed Oil|Flaxseed oil capsule
401401|NCT01129050|Dietary Supplement|Placebo|Soybean oil capsule
401402|NCT01129037|Other|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased < 10% in response to receding VL: SV is optimized, no further VL required.
401403|NCT01129024|Drug|S-888711 0.5 mg tablet|The starting dose was 0.5 mg q.d., if the platelet response was not sufficient, the dose could be increased at 0.5 mg q.d. increments up to 2.0 mg q.d.
401404|NCT01129011|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
401405|NCT01129011|Drug|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
401406|NCT01128998|Drug|Sorafenib|"Name: Sorafenib~Dosage form: 200 mg / Tablet~Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1"
401407|NCT01128998|Drug|S-1|"Name:S-1~Dosage form: 20 mg or 25 mg / Capsule~Dosing schedule: 20-40 mg/m2 bid,po, 14 days on & 7 days off"
401408|NCT01128985|Drug|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
401409|NCT01128985|Drug|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
401410|NCT01128985|Drug|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
401411|NCT01128985|Drug|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
401412|NCT01128972|Drug|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
401413|NCT01128972|Drug|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
401414|NCT01128972|Drug|Sterile water|Sterile water rinse
401415|NCT01128959|Drug|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
401416|NCT01128946|Drug|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
401417|NCT01128946|Drug|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
401418|NCT01128946|Drug|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
401419|NCT01128933|Procedure|Renal artery stenting|
401420|NCT01128920|Behavioral|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
401421|NCT01128920|Other|No intervention - assessment-only condition|No intervention is assigned in this condition
401422|NCT01128894|Biological|albiglutide|albiglutide weekly subcutaneous injection
401423|NCT01128894|Drug|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
401424|NCT01128881|Biological|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
401425|NCT01128868|Device|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
401426|NCT01128868|Device|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
401427|NCT01128855|Drug|3 mg/kg GSK2402968|Weekly subcutaneous injection
401428|NCT01128855|Drug|6 mg/kg GSK2402968|Weekly subcutaneous injection
401429|NCT01128855|Drug|9 mg/kg GSK2402968|Weekly subcutaneous injection
401430|NCT01128855|Drug|12 mg/kg GSK2402968|Weekly subcutaneous injection
401431|NCT01128855|Other|Placebo|Weekly Placebo
401432|NCT01128842|Drug|Neratinib|240 mg once daily by mouth.
401433|NCT01128842|Drug|Capecitabine|1500 mg/m^2 twice daily by mouth.
401434|NCT01128829|Other|Water|60 ml of water were drank 10 min before doing a OGTT
401435|NCT01128829|Other|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
401436|NCT01128816|Device|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
401437|NCT01128803|Procedure|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration > 2mm
401438|NCT01128790|Other|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
401439|NCT01128790|Other|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
401440|NCT01128777|Behavioral|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
401441|NCT01128777|Behavioral|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
401442|NCT01128764|Behavioral|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
401443|NCT01128764|Behavioral|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
401444|NCT01128751|Procedure|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
401445|NCT01128751|Procedure|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
401446|NCT01128751|Procedure|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
401447|NCT01128738|Drug|GSK1358820|Onabotulinum toxin type A
401448|NCT01128738|Drug|Placebo|Placebo
401449|NCT01128725|Other|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments~psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy~Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.~In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
401450|NCT01128712|Drug|Pregabalin|150 mg /day
401451|NCT01128712|Drug|Pregabalin|450 mg/day
401452|NCT01128699|Drug|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
401453|NCT01128699|Device|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
401454|NCT01128686|Other|No intervention|This study is retrospective chart review
401455|NCT01128673|Device|mRI|
401456|NCT01128647|Dietary Supplement|Fructose:glucose drink|
401457|NCT01128647|Dietary Supplement|glucose drink|
401458|NCT01128634|Drug|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
401459|NCT01128634|Drug|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
401460|NCT01128621|Drug|GSK1292263|Tablet
401461|NCT01128621|Drug|GSK1292263 matching placebo|Tablet
401462|NCT01128621|Drug|Sitagliptin|Tablet
401463|NCT01128608|Procedure|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
401464|NCT01128608|Procedure|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
401465|NCT01128595|Drug|FF/GW642444M|
401466|NCT01128595|Drug|GW642444M|
401467|NCT01128595|Drug|Fluticasone Furoate|
401468|NCT01128595|Drug|Placebo|
401469|NCT01128582|Drug|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
401472|NCT01128569|Drug|FF/Vilanterol (VI; GW642444M)|FF/VI
401473|NCT01128569|Drug|Placebo|Placebo Inhaler
401474|NCT01128556|Drug|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
401475|NCT01128556|Drug|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
401476|NCT01128543|Drug|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
401477|NCT01128530|Drug|JNJ-32729463|250 mg tablet twice daily
401478|NCT01128530|Drug|linezolid|600 mg tablet twice daily
401479|NCT01128530|Drug|JNJ-32729463 placebo|1 placebo tablet twice daily
401480|NCT01128530|Drug|linezolid placebo|1 placebo tablet, twice daily
401481|NCT01128517|Behavioral|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.~Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 & 2006).~First session --> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~Second session -->breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~Third session --> previous sessions recall. protein based and iron rich food encouragement.~The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
401482|NCT01128517|Behavioral|Education|Maternal education on complementary food
401483|NCT01128478|Procedure|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
401484|NCT01128452|Drug|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
401485|NCT01128452|Drug|Placebo|HPMC Placebo capsules, once daily for 28 days
401486|NCT01128439|Other|No intervention|No intervention
401487|NCT01128426|Other|No Intervention|No Intervention
401488|NCT01128413|Device|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
401489|NCT01128413|Device|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
401490|NCT01128413|Device|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
401491|NCT01128413|Behavioral|CURVES Questionnaire|The CURVES (CardiovascUlar Response & Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
401492|NCT01128413|Biological|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, & 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
401493|NCT01128413|Biological|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
401494|NCT01128413|Biological|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
401495|NCT01128387|Drug|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
401496|NCT01128374|Procedure|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
401528|NCT01128140|Behavioral|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
401676|NCT01126879|Procedure|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
401497|NCT01128361|Behavioral|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
401498|NCT01128361|Behavioral|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
401499|NCT01128348|Behavioral|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
401500|NCT01128335|Drug|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
401501|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
401502|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
401503|NCT01128335|Drug|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
401504|NCT01128322|Drug|S-Amlodipine, Telmisartan|
401505|NCT01128322|Drug|S-Amlodipine|
401506|NCT01128322|Drug|Telmisartan|
401507|NCT01128322|Drug|Placebo|
401508|NCT01128309|Behavioral|Stress Reduction Intervention|eight week group program, plus daily homework practice
401509|NCT01128309|Behavioral|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
401510|NCT01128296|Drug|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
401511|NCT01128296|Drug|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
401512|NCT01128270|Drug|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
401513|NCT01128270|Drug|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
401514|NCT01128270|Drug|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
401515|NCT01128270|Drug|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
401516|NCT01128257|Drug|alendronate|As prescribed by physician
401517|NCT01128257|Drug|ibandronate [Bonviva/Boniva]|As prescribed by physician
401518|NCT01128244|Dietary Supplement|Vitamin B6|Subjects will receive vitamin B6 supplementation.
401519|NCT01128244|Procedure|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
401520|NCT01128218|Drug|Tumor fluorescence|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
401521|NCT01128192|Drug|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
401522|NCT01128179|Drug|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
401523|NCT01128179|Drug|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
401524|NCT01128166|Device|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
401525|NCT01128153|Drug|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
401526|NCT01128153|Drug|Placebo|tablet once daily for 24 weeks to be taken orally
401527|NCT01128140|Behavioral|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
401529|NCT01128127|Behavioral|Group education, audit-feedback and computer support|"Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.~Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
401530|NCT01128127|Behavioral|Audit-feedback and computer support|"Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs~CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
401531|NCT01128127|Behavioral|Control|"Usual intervention includes:~Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.~Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.~Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID."
401532|NCT01128114|Drug|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
401533|NCT01128101|Drug|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
401534|NCT01128075|Device|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
401535|NCT01128075|Device|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
401536|NCT01128049|Behavioral|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
401537|NCT01128049|Procedure|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
401538|NCT01128049|Drug|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
401539|NCT01128023|Other|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
401540|NCT01127984|Drug|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
401541|NCT01127984|Procedure|drainage system|application of vacuum drainage system
401542|NCT01127958|Device|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
401543|NCT01127958|Device|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
401544|NCT01127945|Drug|statin|"adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy~acute heart failure therapy"
401545|NCT01127932|Behavioral|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
401546|NCT01127932|Behavioral|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
401547|NCT01127919|Behavioral|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
401548|NCT01127919|Other|Cognitive Component|Provide general information about health and fitness
401549|NCT01127906|Drug|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
401550|NCT01127906|Drug|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
401551|NCT01127906|Drug|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
401552|NCT01127906|Drug|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
401553|NCT01127906|Drug|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
401554|NCT01127893|Biological|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
401555|NCT01127893|Biological|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
401556|NCT01127893|Biological|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
401557|NCT01127880|Drug|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
401558|NCT01127880|Drug|Placebo|.9% Normal Saline as a placebo
401559|NCT01127867|Dietary Supplement|dietary intervention|dietary intervention
401560|NCT01127841|Drug|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
401561|NCT01127828|Other|Arla Yoghurt with no probiotic|two servings of 200 ml of investigational products per day
401562|NCT01127828|Other|Probiotic yoghurt (Cultura)|200 ml per day
401563|NCT01127789|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
401564|NCT01127776|Device|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
401565|NCT01127776|Other|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
401566|NCT01127763|Drug|RAD001|
401567|NCT01127763|Drug|Carboplatin|
401568|NCT01127750|Drug|FTY720|
401569|NCT01127737|Behavioral|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
401570|NCT01127737|Behavioral|Placebo|Completed surveys
401571|NCT01127724|Drug|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
401572|NCT01127685|Device|Smart_Step weight bearing insole|The use of a weight-bearing measuring device in determining weight-bearing deficits following Anterior Cruciate Ligament Reconstruction
401573|NCT01127672|Biological|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).~Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
401574|NCT01127672|Drug|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.~This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.~The patient will be monitored for 10 minutes in clinic for adverse reactions."
401575|NCT01127659|Drug|testosterone|intramuscular every 2 weeks
401576|NCT01127659|Drug|placebo|saline intramuscular every 2 weeks
401577|NCT01127646|Drug|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
401578|NCT01127646|Drug|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
401579|NCT01127646|Drug|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
401580|NCT01127633|Drug|Solanezumab|400 mg of solanezumab administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
401581|NCT01127633|Drug|Placebo|Participants were from feeder studies (LZAM or LZAN). Placebo administered intravenously every 4 weeks through Week 80.
401582|NCT01127620|Drug|Bilastine|20 mg encapsulated tablets
401583|NCT01127620|Drug|Cetirizine|10 mg encapsulated tablets
401584|NCT01127620|Drug|Placebo|encapsulated tablets
401585|NCT01127607|Drug|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
401586|NCT01127594|Drug|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
401587|NCT01127581|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
401588|NCT01127581|Drug|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
401589|NCT01127568|Drug|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
401590|NCT01127555|Drug|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
401591|NCT01127542|Drug|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
401592|NCT01127529|Biological|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
401593|NCT01127503|Drug|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day [2000 mg/day if metyrosine]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
401594|NCT01127503|Drug|Placebo|Placebo capsules were identically matched to Metyrosine.
402214|NCT01122641|Drug|Placebo|Matched tablets
401595|NCT01127490|Drug|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
401596|NCT01127490|Procedure|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
401597|NCT01127477|Drug|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
401598|NCT01127464|Drug|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
401599|NCT01127464|Drug|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
401600|NCT01127464|Drug|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
401601|NCT01127451|Drug|Denileukin diftitox|"Test product: dose and mode of administration:~denileukin diftitox was originally administered by intravenous infusion over 30-60 minutes according to 1 of 2 treatment arms:~12 mcg/kg/day on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks);~12 mcg/kg/day on Days 1, 8, and 15 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks)~ARM 2 is now closed. Patients experiencing clinical benefit (irSD, irPR, or irCR per irRC) after 4 cycles of treatment, may continue their denileukin diftitox treatment for up to 8 cycles."
401602|NCT01127438|Drug|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight < 60 kg and Age < 65 years and ASAI and II)
401603|NCT01127438|Drug|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight <60 kg and Age <65 years and ASAI and II)
401604|NCT01127438|Drug|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight < 60 kg and Age >/=65 years and ASA 3 or 4
401605|NCT01127438|Drug|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight <60 kg and Age >/=65 years and ASA 3 or 4
401606|NCT01127438|Drug|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
401607|NCT01127438|Drug|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
401608|NCT01127425|Procedure|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
401609|NCT01127425|Procedure|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
401610|NCT01127412|Behavioral|Physical activity stimulating program|
401611|NCT01127386|Drug|Lenalidomide|25mg od, dose reduction according to toxicity
401612|NCT01127386|Drug|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
401613|NCT01127386|Other|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
401614|NCT01127373|Radiation|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
401615|NCT01127373|Behavioral|BreastQ questionnaire-|MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
401616|NCT01127360|Drug|Bevacizumab|Intravitreal injections
401617|NCT01127360|Drug|Ranibizumab|Intravitreal injections
401618|NCT01127321|Other|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
401619|NCT01127321|Biological|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
401620|NCT01127321|Biological|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
401621|NCT01127321|Biological|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
401622|NCT01127321|Biological|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
401623|NCT01127308|Drug|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of [14C]ertugliflozin
401624|NCT01127295|Drug|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
401625|NCT01127282|Drug|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
401626|NCT01127282|Drug|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
401627|NCT01127269|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
401628|NCT01127256|Drug|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
401629|NCT01127256|Drug|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
401630|NCT01127243|Procedure|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
401631|NCT01127243|Procedure|inpatient LSH|patients discharged home the day after the operation
401632|NCT01127217|Drug|amlodipine/losartan|amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
401633|NCT01127217|Drug|amlodipine|amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
401634|NCT01127204|Drug|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
401635|NCT01127204|Drug|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
401636|NCT01127191|Other|military equipment|Military exercise of 24 hours
401637|NCT01127178|Drug|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
401638|NCT01127165|Drug|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1~2 weeks to 3~4mg/kg/day.
401639|NCT01127165|Drug|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2~4 weeks to 6~8mg/kg/day.
401640|NCT01127152|Procedure|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
401641|NCT01127126|Drug|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.~Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
401642|NCT01127113|Other|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
401643|NCT01127113|Other|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
401644|NCT01127100|Drug|transdermal fentanyl matrix, gabapentin|"transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.~Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained."
401645|NCT01127087|Drug|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.~Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
401646|NCT01127074|Biological|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).~Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
401647|NCT01127061|Behavioral|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 70% of heart rate reserve and exercising 60 minutes 4-7 days per week.
401648|NCT01127048|Drug|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
401649|NCT01127048|Drug|Placebo|Suppositories containing no Ivy leaves dry extract
401650|NCT01127035|Biological|sublingual immunotherapy|
401651|NCT01127035|Biological|placebo|
401652|NCT01127022|Dietary Supplement|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline [from choline chloride] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
401653|NCT01127022|Dietary Supplement|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline [from choline chloride] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
401654|NCT01127009|Drug|bortezomib|Given IV
401655|NCT01127009|Drug|mitoxantrone hydrochloride|Given IV
401656|NCT01127009|Drug|etoposide|Given IV
401657|NCT01127009|Drug|cytarabine|Given IV
401658|NCT01127009|Other|flow cytometry|Correlative studies
401659|NCT01126996|Procedure|Venepuncture|"Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.~A booster dose of a MenC conjugate vaccine (optional)."
401660|NCT01126983|Device|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
401661|NCT01126983|Device|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
401662|NCT01126970|Drug|Velneperit 400 mg|Velneperit 400 mg q.d.
401663|NCT01126970|Drug|Orlistat 120 mg|Orlistat 120 mg t.i.d
401664|NCT01126970|Drug|Orlistat Placebo|Orlistat Placebo t.i.d.
401665|NCT01126970|Drug|Velneperit Placebo|Velneperit Placebo q.d
401666|NCT01126970|Other|Reduced Calorie Diet|Reduced calorie diet
401667|NCT01126957|Drug|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
401668|NCT01126957|Drug|Placebo|Placebo given as an bolus to control group.
401669|NCT01126957|Drug|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
401670|NCT01126957|Drug|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
401671|NCT01126944|Device|heart mate II|left ventricular assist device
401672|NCT01126918|Behavioral|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
401673|NCT01126892|Drug|Nilotinib|
401674|NCT01126879|Dietary Supplement|genistein|Given orally
401675|NCT01126879|Other|placebo|Given orally
402641|NCT01119586|Genetic|polymerase chain reaction|
401677|NCT01126866|Drug|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
401678|NCT01126853|Biological|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
401679|NCT01126840|Behavioral|Telephone Interview|The phone interview should take 30-45 minutes to complete.
401680|NCT01126840|Behavioral|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
401681|NCT01126827|Behavioral|Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy|12 weekly group therapy sessions
401682|NCT01126814|Drug|Imatinib (Gleevec)|
401683|NCT01126801|Drug|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
401684|NCT01126801|Other|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
401685|NCT01126762|Behavioral|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
401686|NCT01126762|Behavioral|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
401687|NCT01126749|Drug|gemcitabine plus cisplatin|Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin
401688|NCT01126749|Drug|E7389 in combination with gemcitabine plus cisplatin|Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin
401689|NCT01126736|Drug|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
401690|NCT01126736|Drug|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
401691|NCT01126736|Drug|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
401692|NCT01126723|Other|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
401693|NCT01126723|Other|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
401694|NCT01126697|Drug|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
401695|NCT01126684|Drug|Atorvastatin|10 mg of atorvastatin once daily for six months
401696|NCT01126684|Drug|Placebo|placebo once daily for six months
401697|NCT01126671|Drug|Supplemental Vitamin D|Subjects were randomized to either take 200 IU of vitamin D or 1000 IU of vitamin D daily for 11 weeks and labs were compared before and after.
401698|NCT01126658|Other|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
401699|NCT01126645|Procedure|RFA|"A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).~The study procedure guide will contain further instructions for RFA."
401700|NCT01126645|Procedure|Radioembolization (SIRT)|"One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.~Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm."
401701|NCT01126606|Drug|Dermacid Silver (Lactic acid)|Liquid soap, daily use
401702|NCT01126606|Drug|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
401703|NCT01126593|Drug|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
401704|NCT01126593|Drug|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
401705|NCT01126580|Drug|Metformin|
401706|NCT01126580|Drug|LY2189265|
401707|NCT01126580|Drug|Placebo (oral)|
401708|NCT01126580|Drug|Placebo (subcutaneous)|
401709|NCT01126567|Other|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
401710|NCT01126541|Drug|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
401711|NCT01126528|Dietary Supplement|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
401712|NCT01126528|Dietary Supplement|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
401713|NCT01126515|Procedure|Magnetic Resonance Imaging|Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
401714|NCT01126515|Procedure|Computed Tomography Angiography|Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
401715|NCT01126502|Drug|alvespimycin hydrochloride|Given IV
401716|NCT01126502|Other|diagnostic laboratory biomarker analysis|
401717|NCT01126502|Other|pharmacogenomic studies|
401718|NCT01126502|Other|pharmacological study|
401719|NCT01126476|Other|Proton Radiotherapy|
401720|NCT01126463|Drug|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
401721|NCT01126450|Drug|lenalidomide|Given orally
401722|NCT01126450|Biological|cetuximab|Given IV
401723|NCT01126450|Other|mutation analysis|Correlative studies
401724|NCT01126450|Other|polymerase chain reaction|Correlative studies
401725|NCT01126450|Genetic|polymorphism analysis|Correlative studies
401726|NCT01126437|Drug|tiotropium 18 mcg|HandiHaler
401727|NCT01126437|Drug|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
401728|NCT01126437|Drug|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
401729|NCT01126424|Drug|Solifenacin|tablet
401730|NCT01126424|Drug|Oxybutynin|capsule
401731|NCT01126424|Drug|Placebo|tablet
401732|NCT01126411|Procedure|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
401733|NCT01126398|Procedure|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
401734|NCT01126385|Device|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
401735|NCT01126359|Drug|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
401736|NCT01126359|Drug|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
401737|NCT01126346|Behavioral|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
401738|NCT01126346|Behavioral|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
401739|NCT01126346|Other|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
401740|NCT01126320|Device|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
401741|NCT01126320|Device|routine mechanical ventilator|routine mechanical ventilation
401742|NCT01126307|Drug|Verapamil|80 mg tid
401743|NCT01126307|Drug|placebo|placebo tid
401744|NCT01126294|Dietary Supplement|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
401745|NCT01126294|Dietary Supplement|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
401746|NCT01126294|Dietary Supplement|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
401747|NCT01126281|Procedure|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
401748|NCT01126268|Drug|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
401749|NCT01126255|Drug|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
401750|NCT01126255|Drug|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
401751|NCT01126242|Device|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
401752|NCT01126242|Device|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
401783|NCT01126021|Behavioral|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
401784|NCT01126021|Behavioral|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
401991|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
401753|NCT01126242|Device|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
401754|NCT01126229|Dietary Supplement|Placebo|2 capsules of placebo daily for 12 weeks
401755|NCT01126229|Drug|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
401756|NCT01126229|Drug|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
401757|NCT01126216|Drug|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32,
401758|NCT01126216|Radiation|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
401759|NCT01126216|Drug|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33
401760|NCT01126216|Radiation|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
401761|NCT01126203|Procedure|SLT|All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
401762|NCT01126203|Procedure|ALT|All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with ~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
401763|NCT01126190|Biological|Neugranin|Neugranin 40 mg administered approximately 24 hours following chemotherapy for 4 treatment cycles
401764|NCT01126190|Biological|Pegfilgrastim|Pegfilgrastim 6 mg administered approximately 24 hours following chemotherapy for 4 treatment cycles
401765|NCT01126190|Drug|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 in combination
401766|NCT01126177|Drug|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
401767|NCT01126177|Drug|Placebo|Placebo (excipients of the SNG001 solution only)
401768|NCT01126164|Behavioral|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
401769|NCT01126151|Behavioral|parent handbook|parent handbook
401770|NCT01126138|Drug|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
401771|NCT01126138|Drug|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.~Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
401772|NCT01126125|Dietary Supplement|Iodized oil|400 mg of iodine vs 100 mg of iodine as iodized oil
401773|NCT01126112|Biological|Panitumumab|Panitumumab: 6 mg/Kg Q2W
401774|NCT01126099|Drug|Prazosin|4 mg capsules twice daily for 12 weeks
401775|NCT01126099|Drug|Placebo|Placebo capsules twice daily for 12 weeks
401776|NCT01126086|Drug|otamixaban XRP0673|"Pharmaceutical form: solution for injection~Route of administration: intravenous"
401777|NCT01126073|Drug|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
401778|NCT01126073|Drug|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
401779|NCT01126060|Drug|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
401780|NCT01126060|Procedure|Thyroidectomy|surgical removal of bilateral thyroid glands
401781|NCT01126047|Other|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
401782|NCT01126034|Other|intervention letter|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:~The name and medical record # of the patients involved~Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy~A reminder of the adverse effect of long-term metoclopramide therapy~A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients~A request that the physician document the discontinuation trial in the electronic medical record"
401785|NCT01126008|Drug|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
401786|NCT01125995|Radiation|early CCRT|"patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.~radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
401787|NCT01125995|Radiation|late CCRT|"patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.~radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
401788|NCT01125982|Drug|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
401789|NCT01125982|Drug|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
401790|NCT01125969|Behavioral|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
401791|NCT01125969|Behavioral|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
401792|NCT01125969|Behavioral|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
401793|NCT01125956|Behavioral|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
401794|NCT01125956|Behavioral|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
401795|NCT01125943|Drug|Acetylcholine|Intra-arterial infusion
401796|NCT01125943|Drug|Nitroprusside|Intra arterial infusion
401797|NCT01125943|Drug|Bevacizumab|Intra arterial infusion
401798|NCT01125930|Drug|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
401799|NCT01125930|Drug|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
401800|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
401801|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
401802|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
401803|NCT01125904|Drug|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
401804|NCT01125891|Drug|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
401805|NCT01125891|Drug|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
401806|NCT01125878|Dietary Supplement|Placebo|placebo
401807|NCT01125878|Dietary Supplement|Starch composite B|fiber mixture
401808|NCT01125878|Dietary Supplement|Starch composite C|fiber mixture
401809|NCT01125878|Dietary Supplement|Starch composite D|fiber mixture
401810|NCT01125865|Device|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
401811|NCT01125865|Device|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
401812|NCT01125852|Procedure|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
401813|NCT01125852|Procedure|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
401814|NCT01125813|Biological|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
401815|NCT01125800|Drug|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
401816|NCT01125787|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
401817|NCT01125774|Drug|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
401818|NCT01125774|Drug|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
401819|NCT01125761|Drug|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
401820|NCT01125761|Drug|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
401821|NCT01125748|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
401822|NCT01125748|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
401823|NCT01125748|Drug|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
401866|NCT01125397|Behavioral|LEARN group|Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
401824|NCT01125735|Device|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
401825|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
401826|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
401827|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
401828|NCT01125696|Drug|Tenofovir/lamivudine/lopinavir-ritonavir|Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
401829|NCT01125696|Drug|Zidovudine/lamivudine/lopinavir-ritonavir|Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
401830|NCT01125683|Drug|AZD1446|Capsule, oral single and multiple dose
401831|NCT01125683|Drug|Donepezil|Capsule, oral and single dose
401832|NCT01125683|Drug|Placebo|Capsule, oral and single dose
401833|NCT01125670|Drug|YM150|oral
401834|NCT01125657|Drug|YM150|oral
401835|NCT01125644|Drug|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
401836|NCT01125631|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 8 weeks (4 doses total)
401837|NCT01125631|Drug|Placebo|Placebo every 8 weeks (4 doses total)
401838|NCT01125618|Other|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
401839|NCT01125618|Other|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
401840|NCT01125592|Device|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
401841|NCT01125566|Drug|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
401842|NCT01125566|Drug|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
401843|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
401844|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
401845|NCT01125553|Drug|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
401846|NCT01125540|Device|Acuvue (Standard Daily Disposable Contact Lens)|
401847|NCT01125540|Device|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
401848|NCT01125527|Biological|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
401849|NCT01125527|Biological|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
401850|NCT01125514|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
401851|NCT01125514|Drug|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
401852|NCT01125514|Drug|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
401853|NCT01125514|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet
401854|NCT01125501|Dietary Supplement|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources [Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)].
401855|NCT01125488|Device|LNG-IUS|levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
401856|NCT01125488|Drug|GnRH agonist (triptorelin)|GnRH agonist (triptorelin 3.75 mg, sc q28day)
401857|NCT01125475|Device|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
401858|NCT01125462|Other|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
401859|NCT01125449|Drug|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
401860|NCT01125436|Dietary Supplement|Cholecalciferol|50,000 IU weekly for 6 months
401861|NCT01125436|Dietary Supplement|Cholecalciferol|Placebo weekly for 6 months
401862|NCT01125423|Drug|Milnacipran|Subject will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
401863|NCT01125423|Procedure|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
401864|NCT01125410|Drug|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
401865|NCT01125410|Drug|Clindamycin|vaginal cream, 2%, once daily for 7 days
401867|NCT01125384|Other|additional swabbing|physician swabs patient`s throat according to standard rules before referral of the patient to throat swabbing by nurse.
401868|NCT01125371|Behavioral|Computerized brief alcohol intervention + IVR booster calls|1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
401869|NCT01125371|Behavioral|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
401870|NCT01125371|Behavioral|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
401871|NCT01125358|Drug|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
401872|NCT01125358|Drug|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
401873|NCT01125345|Procedure|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
401874|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
401875|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
401876|NCT01125319|Other|blood sample|
401877|NCT01125306|Device|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
401878|NCT01125293|Drug|Everolimus|Taken orally on a daily basis
401879|NCT01125293|Drug|Rituximab|Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only
401880|NCT01125293|Drug|Bortezomib|Given intravenously on days 1, 8 and 15 of every cycle
401881|NCT01125280|Procedure|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
401882|NCT01125267|Behavioral|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
401883|NCT01125267|Behavioral|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
401884|NCT01125254|Drug|Amlodipine|5mg po for 12 months
401885|NCT01125241|Drug|wuling capsule|orally, three tablets each time,three times a day
401886|NCT01125241|Drug|placebo of wuling capsule|orally, three tablets each time and three times a day
401887|NCT01125215|Drug|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
401888|NCT01125215|Drug|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
401889|NCT01125202|Behavioral|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
401890|NCT01125202|Behavioral|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
401891|NCT01125189|Drug|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
401892|NCT01125189|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
401893|NCT01125189|Drug|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
401894|NCT01125189|Drug|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
401895|NCT01125189|Drug|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
401896|NCT01125176|Drug|thalidomide|50 mg oral dosing every other day
401897|NCT01125176|Drug|lenalidomide|varying oral doses every other day (max 25 mg/day)
401898|NCT01125176|Biological|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
401899|NCT01125163|Dietary Supplement|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120 ml/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted postmenstrual age.
401900|NCT01125163|Dietary Supplement|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted postmenstrual age
401901|NCT01125150|Drug|Metformin|Dosage to be determined by Endocrinologist
401902|NCT01125150|Behavioral|Dietary Modification|To be determined by Endocrinologist
401903|NCT01125137|Procedure|Removal of Keloid|Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
401904|NCT01125124|Drug|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
401905|NCT01125111|Procedure|surgery(robot versus laparoscopy)|
401906|NCT01125098|Other|PRO-CT values|"continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection~continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability~stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability~stop antibiotics if all the PRO-CT values are < 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value < 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection."
401907|NCT01125085|Radiation|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|"Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy~Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.~Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.~Total treatment duration is up to 4 weeks"
401908|NCT01125072|Other|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
401909|NCT01125059|Drug|Methadone|0.2 mg/kg methadone IV bolus
401910|NCT01125059|Drug|Saline|3 mL saline IV bolus
401911|NCT01125046|Biological|bevacizumab|Given IV
401912|NCT01125033|Drug|Vitamin C & Vitamin E|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
401913|NCT01125033|Drug|Vitamin C|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
401914|NCT01125033|Drug|Vitamin E|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
401915|NCT01125033|Drug|Vitamin C Placebo & Vitamin E Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
401916|NCT01125020|Drug|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
401917|NCT01125020|Drug|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
401918|NCT01125007|Device|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
401919|NCT01124994|Procedure|Endoscopic mucosal resection|Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
401920|NCT01124981|Drug|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
401921|NCT01124981|Drug|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
401922|NCT01124968|Other|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
401923|NCT01124955|Other|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
401924|NCT01124955|Other|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
401925|NCT01124942|Device|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
401926|NCT01124942|Device|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
401927|NCT01124929|Drug|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
401928|NCT01124929|Drug|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
401929|NCT01124916|Procedure|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
401930|NCT01124916|Procedure|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
401931|NCT01124903|Procedure|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
401932|NCT01124890|Device|percutaneous coronary intervention|
401933|NCT01124877|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
401934|NCT01124864|Drug|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
401935|NCT01124851|Drug|ABT-652|See arm description for details
401936|NCT01124851|Drug|Placebo|See arm description for details
401937|NCT01124838|Drug|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
401938|NCT01124838|Drug|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
401939|NCT01124838|Drug|Placebo|Administered by subcutaneous injection
401940|NCT01124825|Device|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
401941|NCT01124825|Device|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
401942|NCT01124812|Other|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:~Cohorts 1, 2 & 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 & 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 & 3. Treatment cycles will be repeated every 28 days.~Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.~Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).~Total treatment duration is 8-16 weeks"
401943|NCT01124799|Drug|TMC435|one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
401944|NCT01124799|Drug|Placebo|placebo dose in the morning, at noon and in the evening, for 9 days
401945|NCT01124799|Drug|Ciprofloxacin|one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
401946|NCT01124786|Drug|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
401947|NCT01124786|Drug|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
401948|NCT01124760|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
401949|NCT01124760|Drug|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
401950|NCT01124760|Drug|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
401951|NCT01124747|Drug|ASP1585|Oral
401952|NCT01124747|Drug|14C-Labeled ASP1585|Oral
401953|NCT01124734|Drug|Interleukin-2|Participants will receive IL-2 up to a maximum of 14 doses at 600,000 IU/kg
401954|NCT01124734|Drug|Temozolomide|Participants receive temozolomide at 75 mg/m2 after completion of the second cycle of high dose IL-2. Participants take the medication at bedtime daily. Four weeks after Cycle 2 of a course, they would take it for 21 days.
401955|NCT01124721|Behavioral|Cognitive training|Cognitive computerized training for several days per week.
401956|NCT01124721|Behavioral|Cognitive training-placebo|Cognitive training that only minimally increases in difficulty
401957|NCT01124708|Drug|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
401958|NCT01124708|Drug|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
401959|NCT01124695|Drug|tamoxifen citrate|
401960|NCT01124695|Other|laboratory biomarker analysis|
401961|NCT01124682|Procedure|diagnostic cystoscopy|
401962|NCT01124682|Procedure|diffusion-weighted magnetic resonance imaging|
401963|NCT01124682|Procedure|implanted fiducial-based imaging|
401964|NCT01124682|Procedure|quality-of-life assessment|
401965|NCT01124682|Radiation|3-dimensional conformal radiation therapy|
401966|NCT01124682|Radiation|image-guided radiation therapy|
401967|NCT01124682|Radiation|selective external radiation therapy|
401968|NCT01124669|Genetic|DNA analysis|
401969|NCT01124669|Genetic|mutation analysis|
401970|NCT01124669|Other|laboratory biomarker analysis|
401971|NCT01124656|Drug|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
401972|NCT01124643|Biological|Replagal|0.2 mg/kg administered intravenously [IV] every other week
401973|NCT01124630|Drug|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
401974|NCT01124630|Drug|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
401975|NCT01124617|Drug|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
401976|NCT01124617|Drug|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
401977|NCT01124604|Drug|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
401978|NCT01124604|Drug|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
401979|NCT01124591|Behavioral|Brief motivational intervention|two session delivered two weeks apart
401980|NCT01124565|Drug|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
401981|NCT01124552|Drug|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
401982|NCT01124552|Drug|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
401983|NCT01124552|Other|Vehicle|Vehicle Control
401984|NCT01124552|Drug|Placebo|Placebo Comparator
401985|NCT01124539|Drug|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
401986|NCT01124526|Drug|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
401987|NCT01124513|Procedure|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
401988|NCT01124500|Drug|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
401989|NCT01124487|Dietary Supplement|The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers|
401990|NCT01124474|Other|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
401992|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
401993|NCT01124435|Drug|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
401994|NCT01124422|Drug|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
401995|NCT01124422|Drug|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
401996|NCT01124409|Radiation|EPID Verification|Set up error verification and correction by EPID
401997|NCT01124409|Radiation|CBCT verification|Setup error verification and correction by CBCT
401998|NCT01124396|Drug|DSP-3025|
401999|NCT01124396|Drug|Placebo|
402000|NCT01124383|Procedure|General anesthesia|For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
402001|NCT01124383|Procedure|Local anesthesia with sedation|For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score < 4.
402002|NCT01124370|Device|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
402003|NCT01124357|Device|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
402004|NCT01124357|Device|thermachoice|ThermachoiceTM III thermal balloon ablation
402005|NCT01124344|Drug|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
402006|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
402007|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
402008|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
402009|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
402010|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
402011|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
402012|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
402013|NCT01124331|Procedure|Higher oxygen saturation target range (91%-95%)|higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
402014|NCT01124331|Procedure|Lower oxygen saturation (85%-89%)|Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
402015|NCT01124318|Drug|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
402016|NCT01124318|Drug|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
402017|NCT01124305|Device|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
402018|NCT01124305|Device|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
402019|NCT01124292|Procedure|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
402020|NCT01124292|Device|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.~Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
402021|NCT01124279|Drug|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
402022|NCT01124266|Procedure|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
402023|NCT01124266|Procedure|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
402024|NCT01124253|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
402025|NCT01124240|Drug|Cilengitide|"Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.~Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).~After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles."
402026|NCT01124227|Drug|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
402027|NCT01124214|Procedure|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
402028|NCT01124201|Other|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
402029|NCT01124188|Drug|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
402030|NCT01124188|Behavioral|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
402031|NCT01124188|Behavioral|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
402032|NCT01124175|Drug|Losartan|100 mg Tablets
402033|NCT01124175|Drug|Cozaar®|100 mg Tablets
402034|NCT01124162|Drug|Losartan|100 mg Tablet
402035|NCT01124162|Drug|Cozaar®|100 mg Tablet
402036|NCT01124149|Drug|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
402037|NCT01124136|Device|Neurostimulation + Medication Management (Standard of Care)|In addition to medication management, adding investigational implanted neurostimulator to heart
402038|NCT01124136|Drug|Standard of Care (Control)|Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
402039|NCT01124123|Drug|Bilastine|20 mg oral tablet
402040|NCT01124123|Drug|Bilastine|10 mg endovenous bilastine
402041|NCT01124110|Behavioral|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
402042|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
402043|NCT01124097|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
402044|NCT01124097|Drug|Placebo|Tablets will be used.
402045|NCT01124071|Behavioral|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
402046|NCT01124071|Behavioral|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
402047|NCT01124058|Drug|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
402048|NCT01124058|Drug|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
402049|NCT01124045|Drug|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
402050|NCT01124045|Drug|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
402051|NCT01124032|Drug|methylphenidate|a capsule containing 20 mg
402052|NCT01124006|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
402053|NCT01124006|Other|Water for injection|Sterile water for injection
402054|NCT01123993|Device|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
402055|NCT01123980|Drug|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
402056|NCT01123980|Drug|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.~Japan: Tablets, 250 mg. Min 500 mg/day."
402057|NCT01123980|Drug|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.~Japan: Tablets, 1 mg. Min. 4 mg/day."
402058|NCT01123980|Drug|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
402059|NCT01123967|Other|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
402060|NCT01123967|Other|telephone counseling (TC)|free telephone counseling
402061|NCT01123967|Other|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
402062|NCT01123967|Other|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
402063|NCT01123954|Biological|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
402064|NCT01123941|Biological|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
402065|NCT01123941|Biological|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
402066|NCT01123928|Behavioral|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
402067|NCT01123915|Biological|Opal-HIV-Gag(c) Low Dose|
402068|NCT01123915|Biological|Opal-HIV-Gag(c) Medium dose|
402069|NCT01123915|Biological|Opal-HIV-Gag(c) High dose|
402070|NCT01123915|Other|Dimethyl Sulfoxide|
402071|NCT01123902|Device|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
402072|NCT01123902|Device|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
402073|NCT01123889|Biological|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
402074|NCT01123889|Drug|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
402075|NCT01123876|Drug|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
402076|NCT01123863|Other|Brigance Preschool Screen -II|Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
402077|NCT01123863|Other|Brigance Preschool Screen -II|"Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.~The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian."
402078|NCT01123850|Device|Copios|Bone Void Filler
402079|NCT01123837|Other|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.~The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
402080|NCT01123837|Other|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.~The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
402081|NCT01123824|Drug|CLOPIDOGREL|"Pharmaceutical form: tablets~Route of administration: oral"
402082|NCT01123824|Drug|placebo|"Pharmaceutical form: matching tablets~Route of administration: oral"
402083|NCT01123811|Drug|Cetuximab IF|Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
402084|NCT01123798|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
402085|NCT01123785|Drug|INO-8875|eye drops for 14 days in one eye
402086|NCT01123785|Drug|Placebo|Matched vehicle-control
402087|NCT01123772|Drug|INO-8875|eye drops for 14 days in one eye
402088|NCT01123772|Other|Placebo control|Matched placebo
402089|NCT01123759|Other|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
402090|NCT01123707|Drug|Aripiprazole/Escitalopram combination therapy|Aripiprazole/Escitalopram combination therapy: 3 mg/10 mg, 3 mg/20 mg, 6 mg/10 mg, 6 mg/20 mg, 12 mg/10 mg or 12 mg/20 mg
402091|NCT01123694|Other|Survey Study|Survey regarding quality of life
402092|NCT01123681|Device|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
402093|NCT01123655|Drug|APLA12|Intervention: Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
402094|NCT01123655|Drug|Placebo|Drug treatment will be stopped or interrupted if indicated. Medical care will be provided at no cost to the patient.
402095|NCT01123616|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
402096|NCT01123577|Other|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
402097|NCT01123564|Drug|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
402098|NCT01123564|Radiation|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
402099|NCT01123551|Drug|nebulized morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
402100|NCT01123551|Drug|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
402101|NCT01123538|Drug|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
402102|NCT01123538|Drug|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
402103|NCT01123525|Drug|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
402104|NCT01123512|Device|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
402105|NCT01123486|Drug|hydromorphone|hydromorphone 0.02 mg/kg
402106|NCT01123473|Drug|capecitabine|
402107|NCT01123473|Drug|cisplatin|
402108|NCT01123473|Drug|epirubicin hydrochloride|
402109|NCT01123473|Drug|fluorouracil|
402110|NCT01123473|Drug|lapatinib ditosylate|
402111|NCT01123460|Other|enzyme-linked immunosorbent assay|
402112|NCT01123460|Other|laboratory biomarker analysis|
402113|NCT01123447|Procedure|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
402114|NCT01123447|Procedure|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
402115|NCT01123408|Drug|Clozapine|500 mg/day
402116|NCT01123408|Drug|Olanzapine|20 mg/day
402117|NCT01123408|Drug|Haloperidol|20 mg/day
402118|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
402119|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
402120|NCT01123382|Device|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
402121|NCT01123382|Other|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
402122|NCT01123356|Drug|Ofatumumab|"Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)~Treatment to be administered for up to 6 cycles"
402123|NCT01123356|Drug|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
402124|NCT01123343|Device|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
402125|NCT01123330|Behavioral|Motivational Interviewing|
402126|NCT01123317|Drug|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
402127|NCT01123304|Drug|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
402128|NCT01123291|Procedure|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
402129|NCT01123291|Procedure|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
402130|NCT01123278|Drug|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
402131|NCT01123278|Drug|Placebo|Placebo transdermal gel (5 gr)
402132|NCT01123265|Drug|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
402133|NCT01123265|Drug|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
402134|NCT01123252|Dietary Supplement|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
402135|NCT01123252|Dietary Supplement|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
402136|NCT01123239|Behavioral|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care."
402137|NCT01123239|Behavioral|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
402138|NCT01123226|Procedure|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
402139|NCT01123226|Procedure|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
402140|NCT01123200|Device|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
402141|NCT01123187|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
402142|NCT01123174|Behavioral|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.~If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
402143|NCT01123161|Device|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
402144|NCT01123161|Drug|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
402145|NCT01123148|Device|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
402146|NCT01123135|Drug|Estrogen cream|1gm of estrogen vaginal cream [EVC] at bed time 3 times a week
402147|NCT01123135|Drug|Placebo|Placebo
402148|NCT01123122|Other|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
402149|NCT01123109|Procedure|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
402150|NCT01123096|Procedure|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
402151|NCT01123096|Other|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
402152|NCT01123083|Biological|Otelixizumab|infusion
402153|NCT01123083|Biological|Placebo|Infusion
402154|NCT01123070|Biological|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
402155|NCT01123070|Biological|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
402156|NCT01123057|Procedure|riboflavin-induced collagen cross-linking treatment|"The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment.~The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application."
402157|NCT01123057|Device|Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia|Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)
402158|NCT01123044|Biological|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
402159|NCT01123044|Procedure|Medical Therapy|Under usual care treatment
402160|NCT01123031|Drug|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
402161|NCT01123031|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
402162|NCT01123018|Behavioral|Memtrax Memory screening test|Memory Screening test
402163|NCT01123005|Procedure|PET Scan|radiation calculated per patient
402164|NCT01123005|Drug|EF5|10 mCi, IV
402165|NCT01123005|Drug|Carbogen|Calculated per patient
402166|NCT01123005|Drug|Dichloroacetate|
402167|NCT01122992|Procedure|Limbal relaxing incision|
402168|NCT01122979|Drug|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
402169|NCT01122979|Drug|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
402170|NCT01122979|Drug|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
402171|NCT01122979|Drug|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
402172|NCT01122966|Drug|intraocular injections of bevacizumab|intracameral and subconjunctival injections
402173|NCT01122953|Drug|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
402174|NCT01122953|Drug|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
402175|NCT01122940|Drug|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
402176|NCT01122940|Drug|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
402177|NCT01122927|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
402178|NCT01122914|Drug|Anakinra|
402179|NCT01122901|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
402180|NCT01122901|Procedure|therapeutic conventional surgery|Undergo surgery
402181|NCT01122901|Other|pharmacological study|Correlative studies
402182|NCT01122901|Other|laboratory biomarker analysis|Correlative studies
402183|NCT01122888|Drug|Cilengitide|Given IV
402184|NCT01122888|Other|Clinical Observation|Patients undergo a 2-week rest period
402185|NCT01122888|Other|Laboratory Biomarker Analysis|Correlative studies
402186|NCT01122875|Drug|MFGR1877S|Intravenous repeating dose
402187|NCT01122862|Drug|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
402188|NCT01122862|Other|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
402189|NCT01122862|Other|Sterile water|Sterile water
402190|NCT01122849|Device|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
402191|NCT01122849|Device|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
402192|NCT01122849|Device|Placebo Nasal Strip|Placebo strip
402193|NCT01122836|Other|Massage|Therapeutic Massage
402194|NCT01122823|Behavioral|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
402195|NCT01122810|Procedure|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
402196|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
402197|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
402198|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
402199|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
402200|NCT01122771|Drug|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
402201|NCT01122771|Drug|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
402202|NCT01122771|Drug|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
402203|NCT01122771|Drug|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
402204|NCT01122719|Device|Drug Eluting Stent|
402205|NCT01122706|Other|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
402206|NCT01122693|Device|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
402207|NCT01122693|Device|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
402208|NCT01122680|Drug|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
402209|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
402210|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
402211|NCT01122680|Drug|Placebo|placebo inhalation solution
402212|NCT01122667|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
402213|NCT01122641|Drug|Vildagliptin|Vildagliptin 50mg bid
402215|NCT01122628|Device|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
402216|NCT01122615|Drug|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
402217|NCT01122615|Drug|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
402218|NCT01122602|Drug|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
402219|NCT01122602|Drug|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
402220|NCT01122602|Drug|Placebo|Two placebo tablets
402221|NCT01122589|Behavioral|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
402222|NCT01122589|Other|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
402223|NCT01122576|Device|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
402224|NCT01122576|Device|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
402225|NCT01122576|Device|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
402226|NCT01122563|Drug|Solifenacin|oral
402227|NCT01122511|Drug|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
402228|NCT01122511|Biological|ranibizumab|Intravitreal injection of ranibizumab into study eye
402229|NCT01122511|Other|sham|Sham needle-less injection administered in the study eye
402230|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
402231|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
402232|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
402233|NCT01122485|Other|PG201|two tablets
402234|NCT01122485|Other|Placebo|two tablets
402235|NCT01122472|Drug|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
402236|NCT01122472|Drug|Placebo|Daily for 3 weeks every 4 weeks for 24 months
402237|NCT01122459|Other|fluid administration|1.5mls/kg/hr fasting
402238|NCT01122446|Other|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
402239|NCT01122446|Drug|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.~Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
402240|NCT01122433|Device|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
402241|NCT01122420|Other|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
402242|NCT01122420|Other|Health Web Sites|Access to publicly available health-related web sites
402243|NCT01122407|Drug|L-NMMA|L-NMMA 250 ug/Kg/min
402244|NCT01122407|Drug|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
402245|NCT01122394|Behavioral|TI|Tailored intervention based on the transtheoretical model
402246|NCT01122394|Behavioral|AP|Attention placebo
402247|NCT01122381|Drug|ethosuximide|ethosuximide (ESX)
402248|NCT01122381|Other|placebo comparator|placebo
402249|NCT01122368|Drug|micafungin|IV
402250|NCT01122368|Drug|placebo|IV
402251|NCT01122355|Drug|lipid modification|1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
402252|NCT01122342|Drug|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
402253|NCT01122329|Dietary Supplement|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
402254|NCT01122329|Dietary Supplement|Placebo|
402255|NCT01122316|Drug|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
402256|NCT01122264|Drug|Tadalafil|Administered orally for 24 weeks.
402257|NCT01122264|Drug|Sildenafil Citrate|Administered orally for 24 weeks.
402258|NCT01122251|Drug|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
402259|NCT01122251|Drug|Lercanidipine or Valsartan|L10, L20, V80, V160
402260|NCT01122251|Drug|Placebo|Placebo of Lercanidipine and Valsartan
402261|NCT01122238|Drug|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
402262|NCT01122238|Drug|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
402263|NCT01122238|Behavioral|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
402324|NCT01121783|Other|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
402642|NCT01119586|Genetic|polymorphism analysis|
402264|NCT01122238|Behavioral|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
402265|NCT01122238|Other|No Intervention|No Intervention
402266|NCT01122238|Drug|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
402267|NCT01122199|Drug|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
402268|NCT01122186|Behavioral|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
402269|NCT01122186|Behavioral|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
402270|NCT01122173|Device|Ablation|Atrial fibrillation ablation procedure
402271|NCT01122160|Drug|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
402272|NCT01122160|Drug|placebo|Placebo with berries (blackberries + strawberries)
402273|NCT01122147|Drug|chamomilla tincture mouthwash|The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
402274|NCT01122147|Drug|placebo mouthwash|The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
402275|NCT01122134|Drug|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
402276|NCT01122121|Drug|Leuprorelin SR|Leuprorelin SR injection
402277|NCT01122121|Radiation|Radiotherapy|Radiotherapy 70 +/- 4 Gy
402278|NCT01122121|Drug|Flutamide|Flutamide tablets
402279|NCT01122108|Drug|Cholestyramine|Cholestyramine 12 grams, one time dose
402280|NCT01122108|Drug|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
402281|NCT01122082|Behavioral|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
402282|NCT01122069|Other|Perflutren Lipid Microsphere ultrasound contrast|Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
402283|NCT01122056|Other|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
402284|NCT01122043|Device|Endoglide|Device
402285|NCT01122030|Drug|Naldemedine|Tablets or solution for oral administration
402286|NCT01122030|Drug|Placebo|Tablets or solution for oral administration
402287|NCT01122017|Procedure|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
402288|NCT01122004|Drug|Pregabalin|
402289|NCT01122004|Drug|Pregabalin|
402290|NCT01121991|Drug|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
402291|NCT01121978|Procedure|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
402292|NCT01121965|Procedure|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
402293|NCT01121952|Other|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
402294|NCT01121939|Drug|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over~90 minutes. If no adverse reactions occur after the initial dose, the second dose should~be administered over a minimum of 60 minutes. If no adverse reactions occur after the~second dose, all subsequent doses should be administered over a minimum of 30~minutes. Bevacizumab will be infused prior to pertuzumab."
402398|NCT01121237|Drug|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
402295|NCT01121939|Drug|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.~If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
402296|NCT01121939|Drug|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
402297|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
402298|NCT01121926|Drug|Trazodone HCl|"Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
402299|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
402300|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
402301|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
402302|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
402303|NCT01121900|Drug|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl~Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
402304|NCT01121900|Drug|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl~Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
402305|NCT01121887|Behavioral|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
402306|NCT01121887|Behavioral|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.~Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
402307|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
402308|NCT01121874|Procedure|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
402309|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
402310|NCT01121861|Procedure|Phacoemulsification with implantation of toric IOL|
402311|NCT01121848|Drug|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:"
402312|NCT01121848|Drug|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV~Dose regimen:"
402313|NCT01121848|Drug|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV~Dose regimen:"
402314|NCT01121835|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
402315|NCT01121835|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
402316|NCT01121835|Drug|PREMIXED INSULIN|"Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico~25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only"
402317|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
402318|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
402319|NCT01121809|Drug|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
402320|NCT01121809|Drug|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
402321|NCT01121796|Dietary Supplement|Vitamin D|
402322|NCT01121796|Other|Water or milk|
402323|NCT01121796|Dietary Supplement|Vitamin D enriched milk|
402325|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
402326|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
402327|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
402328|NCT01121770|Drug|fondaparinux sodium injection|1.5mg subcutaneously every day
402329|NCT01121757|Drug|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
402330|NCT01121757|Drug|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
402331|NCT01121744|Device|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
402332|NCT01121731|Drug|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
402333|NCT01121731|Drug|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
402334|NCT01121731|Drug|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
402335|NCT01121718|Drug|ICG Intervention|NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
402336|NCT01121705|Drug|Peg Interferon alpha2b + Ribavirin|"B 1 I or II: Experimental~variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR"
402337|NCT01121692|Behavioral|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
402338|NCT01121692|Behavioral|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
402339|NCT01121692|Behavioral|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
402340|NCT01121666|Drug|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
402341|NCT01121653|Drug|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
402342|NCT01121640|Procedure|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
402343|NCT01121640|Procedure|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
402344|NCT01121640|Procedure|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
402345|NCT01121627|Other|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
402346|NCT01121614|Device|LOTUS|Device used to seal blood vessel
402347|NCT01121614|Device|Ethicon Harmonic Scalpel|
402348|NCT01121614|Device|LigaSure bipolar vessel sealing device|
402349|NCT01121601|Procedure|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
402350|NCT01121601|Procedure|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
402351|NCT01121588|Drug|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
402352|NCT01121575|Drug|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
402353|NCT01121575|Drug|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
402354|NCT01121575|Drug|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
402355|NCT01121575|Drug|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
402356|NCT01121562|Drug|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
402357|NCT01121549|Drug|Aromasin|25 mg daily continuously
402358|NCT01121536|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
402359|NCT01121523|Behavioral|Cue directed tactile stimulation|Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
402591|NCT01119885|Drug|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
402360|NCT01121510|Device|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
402361|NCT01121497|Drug|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
402362|NCT01121484|Drug|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
402363|NCT01121484|Drug|placebo|Placebo tablets taken orally once daily.
402364|NCT01121471|Dietary Supplement|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
402365|NCT01121471|Dietary Supplement|Safflower OIl|8.0g/day safflower oil
402366|NCT01121458|Drug|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP< 80 mmHg), hypertension (SBP>150 mmHg), tachycardia (120 beats per minute), bradycardia (<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
402367|NCT01121445|Device|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
402368|NCT01121432|Procedure|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
402369|NCT01121406|Drug|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
402370|NCT01121406|Drug|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
402371|NCT01121406|Drug|Topotecan|Patients receive topotecan in 3 or 4 week schedule
402372|NCT01121406|Drug|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
402373|NCT01121406|Drug|BI 6727|Patients receive BI 6727 infusion every 3 weeks
402374|NCT01121393|Drug|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
402375|NCT01121393|Drug|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related Adverse Event (AE), dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
402376|NCT01121380|Drug|BL-1021|"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 & 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
402377|NCT01121380|Drug|1021|1021
402378|NCT01121354|Drug|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
402379|NCT01121354|Drug|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
402380|NCT01121341|Procedure|Vein harvesting|Endoscopic versus conventional vein harvesting
402381|NCT01121328|Biological|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
402382|NCT01121328|Biological|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.~Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.~Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.~RBCs will be separated and kept till need (Hb less than 10 gm%)."
402383|NCT01121302|Drug|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
402384|NCT01121302|Drug|Placebo|
402385|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
402386|NCT01121289|Drug|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
402387|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
402388|NCT01121289|Drug|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
402389|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
402390|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
402391|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
402392|NCT01121276|Drug|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
402393|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
402394|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
402395|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
402396|NCT01121250|Behavioral|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
402397|NCT01121250|Behavioral|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
402399|NCT01121224|Device|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
402400|NCT01121224|Device|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
402401|NCT01121224|Drug|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
402402|NCT01121224|Drug|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
402403|NCT01121224|Drug|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
402404|NCT01121211|Drug|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
402405|NCT01121211|Drug|Placebo|Placebo transdermal patch x 24 weeks
402406|NCT01121198|Drug|ASP1941|oral
402407|NCT01121198|Drug|placebo|oral
402408|NCT01121185|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
402409|NCT01121185|Other|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
402410|NCT01121159|Procedure|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
402411|NCT01121146|Device|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
402412|NCT01121133|Drug|navitoclax|Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
402413|NCT01121133|Drug|Rifampin|Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
402414|NCT01121120|Drug|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
402415|NCT01121120|Drug|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
402416|NCT01121107|Device|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
402417|NCT01121107|Device|Patient Advisory Module|Handheld device that provides medication reminders
402418|NCT01121081|Drug|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
402419|NCT01121081|Drug|Placebo|"Drug: Alga Dunaliella Bardawil~4 capsules per day, 2 in the morning 2 in the evening for 3 month"
402420|NCT01121068|Other|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
402421|NCT01121055|Drug|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
402422|NCT01121055|Drug|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
402423|NCT01121042|Drug|Ondansetron|8mg per day oral capsule
402424|NCT01121042|Drug|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
402425|NCT01121029|Procedure|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
402426|NCT01121016|Drug|Montelukast|10mg, qn, 4 weeks
402427|NCT01121016|Other|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
402428|NCT01121003|Behavioral|weight maintenance, low sugar diet|
402429|NCT01121003|Behavioral|weight maintenance, high fructose diet|
402430|NCT01121003|Behavioral|weight maintenance, high fructose diet+ exercise|
402431|NCT01120990|Other|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
402432|NCT01120964|Drug|Intravenous L-Citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass, the addition of L-citrulline at a concentration of 200 umol/L or placebo to the filtration and hemoconcentration fluid utilized during cardiopulmonary bypass in addition to a 20mg/kg bolus 30 minutes after separation from cardiopulmonary bypass immediately followed by a continuous infusion of 9mg/kg/hr IV, and ending at 48 hours continuous infusion or discharge from the PCCU.
402433|NCT01120964|Drug|Placebo of Intravenous L-Citrulline|Placebo of Intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
402434|NCT01120925|Biological|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
402435|NCT01120925|Biological|CD133|5-15 X 106 cells in 20ML suspension IPV
402436|NCT01120925|Biological|Control|Injection of 20 ml Normal saline via IPV
402437|NCT01120912|Drug|Oshadi Oral Insulin|Oral insulin single administration
402438|NCT01120899|Drug|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
402439|NCT01120873|Drug|Metamin 3D|Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
402440|NCT01120860|Device|MRI|MRI - routine imaging sequences, designed for anatomical quantification
402441|NCT01120834|Drug|azacytidine|"Dose level 1: azacitidine 55 mg/m2 on days 1-5~Dose level 2: azacitidine 75 mg/m2 on days 1-5~Dose level 3: azacitidine 55 mg/m2 on days 1-5~Dose level 4: azacitidine 75 mg/m2 on days 1-5~Each cycle = 28 days. Subjects may receive up to 6 cycles."
402442|NCT01120834|Drug|vorinostat|"Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.~Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.~Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.~Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.~Each cycle = 28 days. Subjects receive up to 6 cycles."
402443|NCT01120821|Drug|Gleevec|400 mg once daily for 12 months
402444|NCT01120808|Procedure|Paper tape|Paper tape assigned to each participant's randomly selected foot.
402592|NCT01119885|Drug|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
402445|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
402446|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
402447|NCT01120782|Device|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
402448|NCT01120782|Device|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
402449|NCT01120769|Drug|Acetaminophen|single dose
402450|NCT01120769|Drug|Placebo|single dose
402451|NCT01120756|Behavioral|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
402452|NCT01120756|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
402453|NCT01120730|Drug|fluid resuscitation|fluid resuscitation with HES
402454|NCT01120730|Drug|Fluid resuscitation|Fluid resuscitation in standardized fashion
402455|NCT01120717|Drug|QVA149|capsules for inhalation, delivered by an SDDPI
402456|NCT01120717|Drug|Placebo|capsules for inhalation, delivered by an SDDPI
402457|NCT01120704|Drug|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes >10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.~IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
402458|NCT01120704|Drug|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes >10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.~IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
402459|NCT01120704|Behavioral|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 & 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
402460|NCT01120704|Behavioral|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
402461|NCT01120704|Behavioral|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
402462|NCT01120704|Behavioral|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.~Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 & 23."
402463|NCT01120691|Drug|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
402464|NCT01120691|Drug|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
402465|NCT01120691|Drug|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
402466|NCT01120691|Drug|Salbutamol/albuterol|As needed throughout the study
402467|NCT01120665|Drug|Estradiol valerate|estradiol valerate, 1 mg/day, orally.
402468|NCT01120665|Other|Aerobic training|Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)
402469|NCT01120665|Drug|Placebo|lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
402470|NCT01120665|Other|Control|The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
402471|NCT01120652|Behavioral|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
402472|NCT01120652|Behavioral|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
402473|NCT01120639|Drug|Temozolomide|75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
402474|NCT01120639|Procedure|Stereotactic Radiosurgery (SRS)|Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)
402475|NCT01120626|Drug|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
402476|NCT01120626|Drug|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
402477|NCT01120613|Drug|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:~ACE or ARB~Calcium Channel Blockers~Alpha Blocker~Beta Blocker~If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
402478|NCT01120600|Drug|Odanacatib|One 50 mg tablet once weekly
402479|NCT01120600|Drug|Placebo for Odanacatib|One 50 mg tablet once weekly
402480|NCT01120600|Dietary Supplement|Vitamin D3|5600 IU of open-label Vitamin D3 once weekly
402481|NCT01120600|Dietary Supplement|Calcium carbonate|Sufficient amount of open-label calcium carbonate so that daily calcium intake from both dietary and supplementary sources in approximately 1200 mg
402482|NCT01120574|Other|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
402483|NCT01120561|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
402484|NCT01120548|Other|ventilation therapy|"The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.~There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.~Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient."
402485|NCT01120535|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
402486|NCT01120522|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
402487|NCT01120509|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
402488|NCT01120496|Drug|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
402489|NCT01120496|Drug|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
402490|NCT01120470|Drug|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
402491|NCT01120470|Drug|Prednisone|"Control Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization~Experimental Arm:~Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
402492|NCT01120457|Drug|BMS-936564 (Anti-CXCR4)|
402493|NCT01120444|Device|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
402494|NCT01120444|Device|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
402495|NCT01120431|Other|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
402496|NCT01120431|Drug|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
402497|NCT01120418|Drug|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
402498|NCT01120405|Drug|Xenon|
402499|NCT01120405|Drug|Sevoflurane|
402500|NCT01120392|Other|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
402501|NCT01120392|Other|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
402632|NCT01119599|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
402633|NCT01119599|Other|Laboratory Biomarker Analysis|Correlative studies
402502|NCT01120379|Device|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
402503|NCT01120366|Drug|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
402504|NCT01120366|Drug|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
402505|NCT01120340|Drug|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
402506|NCT01120340|Other|placebo|2 pills/day for ten days/month until 24 months
402507|NCT01120327|Drug|Placebo|Placebo
402508|NCT01120327|Drug|Amlodipine|Amlodipine
402509|NCT01120314|Drug|OTAMIXABAN (XRP0673)|"Form: solution for injection~Route: intravenous"
402510|NCT01120301|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
402511|NCT01120288|Drug|EZN-2968|
402512|NCT01120275|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
402513|NCT01120275|Other|laboratory biomarker analysis|Correlative studies
402514|NCT01120262|Genetic|gene expression analysis|
402515|NCT01120262|Genetic|polymorphism analysis|
402516|NCT01120262|Other|laboratory biomarker analysis|
402517|NCT01120249|Drug|everolimus|Given orally
402518|NCT01120249|Other|placebo|Given orally
402519|NCT01120236|Drug|Bicalutamide|Given PO
402520|NCT01120236|Biological|Cixutumumab|Given IV
402521|NCT01120236|Drug|Goserelin Acetate|Given SC
402522|NCT01120236|Other|Laboratory Biomarker Analysis|Correlative studies
402523|NCT01120236|Drug|Leuprolide Acetate|Given IM
402524|NCT01120236|Other|Pharmacological Study|Correlative studies
402525|NCT01120223|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
402526|NCT01120210|Drug|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
402527|NCT01120210|Drug|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
402528|NCT01120210|Drug|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
402529|NCT01120210|Drug|Placebo|1-hour infusion of matching placebo on Day 1
402530|NCT01120210|Drug|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
402531|NCT01120197|Other|Exercise group|Weekly exercises
402532|NCT01120197|Other|Control Group|No Intervention, control group only
402533|NCT01120184|Drug|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
402534|NCT01120184|Drug|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
402535|NCT01120184|Drug|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
402536|NCT01120184|Drug|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
402537|NCT01120184|Drug|trastuzumab [Herceptin]|trastuzumab [Herceptin] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
402538|NCT01120184|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
402539|NCT01120171|Drug|Cyclophosphamide|"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity."
402540|NCT01120171|Drug|Liposomal-encapsulated doxorubicin|"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity."
402541|NCT01120158|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
402542|NCT01120158|Drug|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
402543|NCT01120132|Drug|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
402544|NCT01120132|Drug|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
402545|NCT01120132|Drug|PA|Suspension of Prednisolone Acetate administered during 28 days
402546|NCT01120132|Drug|Placebo|Placebo solution administered during 28 days
402547|NCT01120119|Drug|Calcitriol|
402548|NCT01120106|Drug|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
402549|NCT01120106|Drug|placebo|saline continuous infusion
402550|NCT01120093|Drug|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
402551|NCT01120093|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
402552|NCT01120093|Drug|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
402553|NCT01120093|Drug|Placebo|Placebo via inhalation in the morning and evening for 7 days
402554|NCT01120093|Drug|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
402634|NCT01119599|Other|Pharmacological Study|Correlative studies
402635|NCT01119599|Drug|Temozolomide|Given PO
402636|NCT01119599|Procedure|Therapeutic Conventional Surgery|Undergo surgery
402637|NCT01119586|Genetic|DNA analysis|
402638|NCT01119586|Genetic|genetic linkage analysis|
402639|NCT01119586|Genetic|microarray analysis|
402640|NCT01119586|Genetic|nucleic acid sequencing|
402555|NCT01120080|Behavioral|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
402556|NCT01120080|Behavioral|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
402557|NCT01120067|Behavioral|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
402558|NCT01120067|Behavioral|Treatment as Usual|Treatment as Usual.
402559|NCT01120041|Behavioral|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
402560|NCT01120041|Behavioral|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
402561|NCT01120041|Behavioral|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
402562|NCT01120041|Behavioral|health education|Traditional health education given during the prenatal phase and the postpartum phase
402563|NCT01120028|Drug|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
402564|NCT01120028|Drug|Basiliximab|20 mg intravenously, two doses 96 hours apart
402565|NCT01120028|Drug|Sirolimus|Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
402566|NCT01120028|Drug|Tacrolimus|Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
402567|NCT01120015|Drug|diacerein|Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
402568|NCT01120002|Drug|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
402569|NCT01120002|Drug|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
402570|NCT01119989|Dietary Supplement|Fructose+maltodextrin placebo|
402571|NCT01119989|Dietary Supplement|amino-acid + fructose|
402572|NCT01119976|Behavioral|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
402573|NCT01119976|Behavioral|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
402574|NCT01119963|Drug|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
402575|NCT01119963|Drug|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
402576|NCT01119950|Drug|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
402577|NCT01119950|Drug|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
402578|NCT01119950|Drug|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
402579|NCT01119950|Drug|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
402580|NCT01119950|Drug|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
402581|NCT01119950|Drug|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
402582|NCT01119950|Drug|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
402583|NCT01119950|Drug|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
402584|NCT01119937|Drug|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
402585|NCT01119937|Drug|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
402586|NCT01119924|Drug|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
402587|NCT01119924|Drug|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
402588|NCT01119911|Other|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
402589|NCT01119898|Drug|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
402590|NCT01119898|Drug|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
402593|NCT01119872|Other|Positive End-expiratory Pressure (PEEP)|"All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.~Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment."
402594|NCT01119859|Drug|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
402595|NCT01119859|Drug|Adalimumab|
402596|NCT01119859|Drug|Placebo to tocilizumab|
402597|NCT01119859|Drug|Placebo to adalimumab|
402598|NCT01119846|Drug|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
402599|NCT01119846|Drug|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
402600|NCT01119846|Drug|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
402601|NCT01119833|Drug|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
402602|NCT01119833|Drug|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
402603|NCT01119820|Other|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
402604|NCT01119807|Device|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
402605|NCT01119807|Device|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
402606|NCT01119807|Device|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
402607|NCT01119794|Drug|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
402608|NCT01119781|Drug|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
402609|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
402610|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
402611|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
402612|NCT01119742|Drug|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
402613|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
402614|NCT01119742|Drug|Vehicle A|Twice daily application for 7 days
402615|NCT01119742|Drug|Vehicle B|Twice daily application for 7 days
402616|NCT01119703|Biological|Tetanus & Diphtheria booster vaccine (Td)|Tetanus & Diphtheria booster vaccine (Td), single intramuscular dose
402617|NCT01119703|Biological|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], intramuscular, two doses of standard three dose regimen (opposite arms)
402618|NCT01119703|Biological|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
402619|NCT01119690|Dietary Supplement|Cold-pressed turnip rapeseed oil (CTPRO)|"In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.~In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO."
402620|NCT01119690|Dietary Supplement|milk fat|"In dietary period of 6 to 8 weeks: 37.5 grams of butter.~In the 5-hour oral glucose and fat tolerance test: glucose and cream"
402621|NCT01119677|Drug|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
402622|NCT01119664|Drug|SCH 721015|
402623|NCT01119651|Drug|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated & will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
402624|NCT01119638|Drug|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
402625|NCT01119638|Drug|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
402626|NCT01119625|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
402627|NCT01119625|Biological|Infanrix-IPV/Hib|Intramuscular injection, one dose
402628|NCT01119612|Dietary Supplement|Iron|Daily oral dose of 60 mg from enrollment until delivery
402629|NCT01119612|Other|Placebo|Daily oral dose from enrollment until delivery
402630|NCT01119599|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
402631|NCT01119599|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
402643|NCT01119586|Other|laboratory biomarker analysis|
402644|NCT01119573|Genetic|RNA analysis|
402645|NCT01119573|Genetic|microarray analysis|
402646|NCT01119573|Genetic|reverse transcriptase-polymerase chain reaction|
402647|NCT01119573|Other|laboratory biomarker analysis|
402648|NCT01119560|Other|Cytology Specimen Collection Procedure|Correlative studies
402649|NCT01119560|Other|Laboratory Biomarker Analysis|Correlative studies
402650|NCT01119560|Other|Questionnaire Administration|Ancillary studies
402651|NCT01119547|Other|Exercise in a group|The patient do their individual exercise program in a group.
402652|NCT01119547|Other|Home exercise|The patient exercise their individual program at home during 6 v.
402653|NCT01119534|Drug|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
402654|NCT01119534|Drug|guaiacol suppository|2 times per day
402655|NCT01119534|Drug|Guaifenesin syrup|4.19 mL - 4 in 4 hours
402656|NCT01119521|Biological|BCG strain Danish|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10^5 colony forming units (CFU) BCG.
402657|NCT01119521|Drug|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets [5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)].
402658|NCT01119508|Drug|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
402659|NCT01119508|Drug|Temozolomide|Induction Phase, 200 mg/m^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
402660|NCT01119482|Biological|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
402661|NCT01119469|Behavioral|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
402662|NCT01119456|Biological|IMC-RON8|"5 milligrams per kilogram (mg/kg) intravenously (IV)~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 1"
402663|NCT01119456|Biological|IMC-RON8|"10 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 2"
402664|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once a week for each 4-week treatment cycle, for a total of four doses per cycle. The initial 4-week treatment cycle will be followed by a 2-week observation period.~Cohort 3"
402665|NCT01119456|Biological|IMC-RON8|"15 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 4"
402666|NCT01119456|Biological|IMC-RON8|"20 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 5"
402667|NCT01119456|Biological|IMC-RON8|"25 or 30 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 6"
402668|NCT01119456|Biological|IMC-RON8|"30, 35, or 40 mg/kg IV~Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.~Cohort 7"
402669|NCT01119456|Biological|IMC-RON8|"20 or 25 mg/kg IV~Once every week for each 4-week treatment cycle, for a total of four doses per cycle.~Cohort 8"
402670|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
402671|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
402672|NCT01119430|Drug|DU125530|20mg/twice a day
402673|NCT01119430|Drug|Placebo|Similar pill as active comparator twice a day
402674|NCT01119417|Drug|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
402675|NCT01119417|Drug|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
402676|NCT01119417|Drug|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
402677|NCT01119417|Drug|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
402678|NCT01119417|Drug|Saline|2-3 IV saline infusions for 15 min each.
402679|NCT01119391|Behavioral|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
402680|NCT01119378|Other|Dual isotope technique|Dual isotope technique using stable isotopes
402681|NCT01119365|Other|Bright light|Bright (1000 lux) light
402682|NCT01119352|Drug|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
402683|NCT01119352|Drug|Placebo|Oral suspension, once daily. Totally 8 doses
402684|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 1, once daily
402685|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 2, once daily
402686|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 3, once daily
402687|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 4, once daily
402688|NCT01119339|Drug|LAS 41004|LAS 41004 , dosage 5, once daily
402689|NCT01119339|Drug|LAS 41004 dosage 6|LAS 41004, dosage 6, once daily
402690|NCT01119339|Drug|Placebo|Placebo, once daily
402691|NCT01119339|Drug|Reference|Reference, once daily
402692|NCT01119326|Procedure|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
402693|NCT01119313|Drug|LAS 41002|LAS 41002, once daily
402694|NCT01119313|Drug|Active|Active, once daily
402695|NCT01119300|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
402696|NCT01119300|Other|Standard care|Standard care
402697|NCT01119287|Drug|Dexamethasone 0.1% ophthalmic suspension|Maxidex
402698|NCT01119287|Drug|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
402699|NCT01119287|Other|Inactive ingredients, used as placebo|Tears Naturale II
402700|NCT01119274|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
402701|NCT01119274|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
402702|NCT01119261|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
402703|NCT01119261|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
402704|NCT01119248|Other|axillary temperature before MRI and after the MRI|observation of body temperature changes with axillary temperature measurement with MRI compatible device
402705|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
402706|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
402707|NCT01119222|Drug|Gabapentin|Capsule, single 1200mg dose
402708|NCT01119222|Drug|Diphenhydramine|Tablet, single 50mg dose
402709|NCT01119222|Drug|Morphine|IV, single 10mg dose
402710|NCT01119222|Drug|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
402711|NCT01119209|Drug|Ropivacaine|Approved by the Danish Medicines Agency
402712|NCT01119209|Drug|Saline|Approved by the Danish Medicines Agency
402713|NCT01119196|Other|Icodextrin dialysate|use of alternate SOC dialysate
402714|NCT01119183|Behavioral|No intervention for this arm|No educational literature will be offered to this group
402715|NCT01119183|Behavioral|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
402716|NCT01119183|Behavioral|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
402717|NCT01119170|Other|Starter formula|standard starter formula given from birth to 6 months of age
402718|NCT01119170|Other|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
402719|NCT01119157|Biological|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
402720|NCT01119144|Device|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
402721|NCT01119144|Device|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
402722|NCT01119131|Drug|Vitamin D3|Vitamin D3 at 10,000 IU a day
402723|NCT01119131|Dietary Supplement|calcium|1000mg calcium daily
402724|NCT01119131|Other|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
402725|NCT01119118|Drug|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
402726|NCT01119105|Drug|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
402727|NCT01119105|Drug|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
402728|NCT01119105|Drug|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
402729|NCT01119092|Other|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
402730|NCT01119092|Other|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
402731|NCT01119079|Other|Normal Saline|10ml Normal Saline instilled in the epidural space
402732|NCT01119079|Procedure|Administration of epidural anesthesia for labor|Standard procedure
402733|NCT01119066|Radiation|total body irradiation|dose of 1375-1500 cGy
402734|NCT01119066|Drug|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
402735|NCT01119066|Drug|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
402736|NCT01119066|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
402737|NCT01119066|Drug|Melphalan|70mg/m2/day x 2
402738|NCT01119066|Drug|Fludarabine|25mg/m2/ day x 5
402739|NCT01119066|Drug|Clofarabine|20mg/m2/ day x 5 (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
402740|NCT01119066|Procedure|(CliniMACS) T-cell depleted PBSC Transplant|
402741|NCT01119053|Device|VNS Pulse Model 102|Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.
402742|NCT01119053|Device|VNS Pulse Model 102|Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
402743|NCT01119040|Procedure|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
402744|NCT01119014|Drug|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
402745|NCT01119014|Drug|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
402907|NCT01117675|Other|Standard of Care|Standard of Care
402746|NCT01119001|Device|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
402747|NCT01118988|Behavioral|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
402748|NCT01118975|Drug|Vorinostat|"300 mg 4 days on then 3 days off~As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
402749|NCT01118975|Drug|Lapatinib|1,250 mg once daily
402750|NCT01118962|Drug|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
402751|NCT01118949|Drug|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
402752|NCT01118936|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
402753|NCT01118936|Dietary Supplement|Placebo|3 tablets of placebo daily for 12 weeks
402754|NCT01118923|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
402755|NCT01118923|Dietary Supplement|Placebo|3 placebo-tablets daily for 12 weeks
402756|NCT01118910|Drug|Vusion|Vusion will be applied to areas of intertrigo
402757|NCT01118897|Radiation|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)~Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.~Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
402758|NCT01118884|Drug|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
402759|NCT01118871|Drug|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
402760|NCT01118871|Drug|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
402761|NCT01118845|Drug|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.~SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
402762|NCT01118845|Drug|Rituximab|The administration of rituximab at 375 mg/m^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
402763|NCT01118819|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
402764|NCT01118793|Drug|Clopidogrel|150 mg dosage of Clopidogrel for 7 to 10 days.
402765|NCT01118780|Drug|Duloxetine|Administered by mouth, daily for 10 weeks
402766|NCT01118780|Drug|Placebo|Administered by mouth, daily for 10 weeks
402767|NCT01118767|Other|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
402768|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
402769|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
402770|NCT01118754|Drug|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
402771|NCT01118741|Drug|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
402772|NCT01118728|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
402773|NCT01118715|Device|Compression glove|A compression glove worn during recovery from distal radius fracture
402774|NCT01118702|Drug|Ritalin-SR|3-20mg tablets, once
402775|NCT01118702|Drug|Concerta|one 54mg tablet, once
402776|NCT01118702|Drug|Novo-Methylphenidate ER-C|one 54mg tablet, once
402777|NCT01118689|Drug|MLN0128|MLN0128 administered orally once daily for 28 days
402778|NCT01118676|Drug|cilengitide, radiochemotherapy|"Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.~The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).~After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy."
402779|NCT01118663|Drug|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
402780|NCT01118663|Drug|Acetadote|Acetadote [old formulation] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
402781|NCT01118637|Behavioral|StopPulling.com|subsidized access to an interactive self-help website for TTM
402782|NCT01118624|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes.~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
402783|NCT01118624|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
402784|NCT01118624|Dietary Supplement|Folic Acid|"1.0-1.25 mg orally~Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."
402785|NCT01118611|Drug|Aurora B/C kinase inhibitor GSK1070916A|
402786|NCT01118611|Other|laboratory biomarker analysis|
402787|NCT01118611|Other|pharmacological study|
402788|NCT01118611|Procedure|diffusion-weighted magnetic resonance imaging + PET CT|
402789|NCT01118611|Radiation|fludeoxyglucose F 18 dynomic contrast|
402790|NCT01118598|Drug|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
402791|NCT01118598|Drug|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
402792|NCT01118585|Procedure|TIF Procedure|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
402793|NCT01118572|Drug|YM177|oral
402794|NCT01118572|Drug|etodolac|oral
402795|NCT01118572|Drug|Placebo|oral
402796|NCT01118559|Drug|YM150|oral
402797|NCT01118533|Device|metal reusable blades MacIntosh|laryngoscope blades
402798|NCT01118533|Device|Single use plastic blades HEINE XP®|laryngoscope blades
402799|NCT01118520|Drug|perindopril arginine|10mgs orally daily for the duration of the trial
402800|NCT01118520|Drug|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
402801|NCT01118520|Drug|placebo|one daily
402802|NCT01118455|Device|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
402803|NCT01118455|Drug|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
402804|NCT01118429|Drug|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
402805|NCT01118429|Drug|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
402806|NCT01118416|Behavioral|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
402807|NCT01118403|Drug|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
402808|NCT01118390|Device|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
402809|NCT01118390|Other|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
402810|NCT01118377|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
402811|NCT01118377|Radiation|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
402812|NCT01118364|Other|Cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving"
402813|NCT01118364|Other|tobacco|"a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving"
402814|NCT01118351|Drug|sunitinib malate|Given orally
402815|NCT01118351|Other|immunohistochemistry staining method|Correlative studies
402816|NCT01118351|Other|TdT-mediated dUTP nick end labeling assay|Correlative studies
402817|NCT01118351|Other|light microscopy|Correlative studies
402818|NCT01118351|Other|laboratory biomarker analysis|Correlative studies
402819|NCT01118325|Drug|ticagrelor|Drug oral treatment
402820|NCT01118325|Drug|clopidogrel|Drug oral treatment
402821|NCT01118312|Drug|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day for 6 months
402822|NCT01118312|Other|Placebo|Intranasal placebo spray
402823|NCT01118299|Device|AMPLATZER Cardiac Plug|AMPLATZER Cardiac Plug is a percutaneous transcatheter device
402908|NCT01117662|Drug|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
402909|NCT01117662|Drug|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
402824|NCT01118286|Drug|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
402825|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
402826|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
402827|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
402828|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
402829|NCT01118273|Drug|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
402830|NCT01118273|Drug|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
402831|NCT01118260|Procedure|total intravenous anaesthesia|propofol and remifentanil
402832|NCT01118260|Procedure|spinal anaesthesia|bupivacaine and fentanyl
402833|NCT01118247|Procedure|Uncemented primary total hip arthroplasty|Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
402834|NCT01118234|Drug|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
402835|NCT01118221|Behavioral|pulmonary rehabilitation|structured exercise program
402836|NCT01118208|Other|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
402837|NCT01118208|Other|Dispense as usual|Dispensing prescription medications in standard pill bottles.
402838|NCT01118156|Other|Education|75-minute training teaching utilization of new standardized suicide nomenclature
402839|NCT01118143|Behavioral|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
402840|NCT01118117|Device|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
402841|NCT01118104|Other|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
402842|NCT01118091|Biological|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
402843|NCT01118091|Biological|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10^8) and the administration of high-dose aldesleukin.
402844|NCT01118078|Genetic|DNA methylation analysis|Undergo DNA methylation analysis
402845|NCT01118078|Genetic|gene expression analysis|Undergo gene expression analysis
402846|NCT01118078|Genetic|microarray analysis|Undergo microarray analysis
402847|NCT01118078|Genetic|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
402848|NCT01118078|Other|diagnostic laboratory biomarker analysis|Correlative studies
402849|NCT01118065|Drug|everolimus|
402850|NCT01118052|Other|Laboratory Biomarker Analysis|Correlative studies
402851|NCT01118052|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
402852|NCT01118039|Drug|sunitinib malate|
402853|NCT01118039|Other|immunohistochemistry staining method|
402854|NCT01118039|Other|laboratory biomarker analysis|
402855|NCT01118039|Other|pharmacological study|
402856|NCT01118039|Procedure|quality-of-life assessment|
402857|NCT01118026|Drug|ABVD|doxorubicin 25 mg/m^2 IV bleomycin 10 units/m^2 IV vinblastine 6 mg/m^2 IV dacarbazine 375 mg/m^2 IV
402858|NCT01118026|Drug|BEACOPP|bleomycin 10 units/m^2 IV on Day 8 etoposide 200 mg/m^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m^2 IV on Day 1 cyclophosphamide 1250 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 8 procarbazine 100 mg/m^2 orally on Days 1-7 prednisone 40 mg/m^2 orally on Days 1-14
402859|NCT01118026|Radiation|radiation therapy|
402860|NCT01118013|Biological|anti-thymocyte globulin|
402861|NCT01118013|Biological|donor lymphocytes|
402862|NCT01118013|Biological|filgrastim|
402863|NCT01118013|Biological|therapeutic allogeneic lymphocytes|
402864|NCT01118013|Drug|busulfan|
402865|NCT01118013|Drug|fludarabine phosphate|
402866|NCT01118013|Drug|methotrexate|
402867|NCT01118013|Drug|mycophenolate mofetil|
402868|NCT01118013|Drug|tacrolimus|
402869|NCT01118013|Other|reduced-intensity transplant conditioning procedure|
402870|NCT01118013|Procedure|allogeneic hematopoietic stem cell transplantation|
402871|NCT01118013|Procedure|peripheral blood stem cell transplantation|
402872|NCT01118000|Procedure|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
402910|NCT01117649|Drug|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
402911|NCT01117649|Drug|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
402912|NCT01117649|Drug|balanced electrolyte solution|plasma adapted Ringer's solution
402981|NCT01117233|Drug|PF-04427429|single intravenous infusion of 1000 mg PF-04427429 or placebo
402873|NCT01117987|Drug|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
402874|NCT01117987|Drug|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
402875|NCT01117974|Procedure|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
402876|NCT01117961|Behavioral|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
402877|NCT01117948|Drug|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
402878|NCT01117948|Drug|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
402879|NCT01117935|Radiation|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate~Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes~High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
402880|NCT01117922|Other|Psychological intervention|Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
402881|NCT01117922|Other|Usual Care Group|
402882|NCT01117909|Other|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
402883|NCT01117909|Other|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
402884|NCT01117896|Other|Chest compression on adult and pedi manikins|Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
402885|NCT01117896|Other|Use of stepstool during chest compressions|In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
402886|NCT01117883|Other|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
402887|NCT01117870|Other|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
402888|NCT01117870|Other|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
402889|NCT01117857|Drug|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
402890|NCT01117844|Radiation|Proton Radiation|Prons has been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
402891|NCT01117831|Other|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
402892|NCT01117818|Biological|active: AFFITOPE AD02|vaccination
402893|NCT01117818|Biological|control: Placebo|vaccination
402894|NCT01117805|Behavioral|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
402895|NCT01117792|Device|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
402896|NCT01117779|Device|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
402897|NCT01117766|Drug|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
402898|NCT01117766|Drug|Placebo|BID dosing for 28 days
402899|NCT01117753|Behavioral|OutPatient Treatment for Adolescents (OPT-A)|
402900|NCT01117753|Behavioral|Treatment As Usual|
402901|NCT01117740|Behavioral|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
402902|NCT01117727|Device|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
402903|NCT01117714|Procedure|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
402904|NCT01117701|Procedure|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
402905|NCT01117688|Procedure|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
402906|NCT01117675|Other|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
402913|NCT01117636|Drug|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter [mL]) between 14 hours post dental surgery.
402914|NCT01117636|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
402915|NCT01117636|Drug|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
402916|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402917|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402918|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402919|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402920|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402921|NCT01117623|Drug|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402922|NCT01117623|Drug|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402923|NCT01117623|Drug|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
402924|NCT01117610|Drug|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
402925|NCT01117610|Drug|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
402926|NCT01117597|Radiation|low RF exposure level|Exposure with 1.5 W/kg
402927|NCT01117597|Radiation|sham exposure|intervention with sham RF exposure
402928|NCT01117597|Radiation|high RF exposure|intervention with high RF exposure
402929|NCT01117584|Drug|ipragliflozin|oral tablet
402930|NCT01117584|Drug|Placebo|oral tablet
402931|NCT01117584|Drug|Metformin|oral tablet
402932|NCT01117571|Device|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
402933|NCT01117545|Behavioral|EFT (Emotional Freedom Techniques)|Six sessions of EFT
402934|NCT01117532|Behavioral|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
402935|NCT01117519|Drug|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
402936|NCT01117506|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
402937|NCT01117493|Behavioral|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
402938|NCT01117493|Behavioral|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
402939|NCT01117467|Other|Simulation scenario|Students performing their scenario will be paired, not solo
402940|NCT01117467|Other|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
402941|NCT01117454|Drug|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
402942|NCT01117454|Drug|Placebo|placebo, similar in appearance to flecainide
402943|NCT01117454|Drug|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
402944|NCT01117441|Drug|PEG-L-asparaginase|see detailed protocol description
402945|NCT01117441|Drug|cyclophosphamide|see detailed protocol description
402946|NCT01117441|Drug|cytarabine|see detailed protocol description
402947|NCT01117441|Drug|daunorubicin hydrochloride|see detailed protocol description
402948|NCT01117441|Drug|dexamethasone|see detailed protocol description
402949|NCT01117441|Drug|doxorubicin hydrochloride|see detailed protocol description
402950|NCT01117441|Drug|etoposide|see detailed protocol description
402951|NCT01117441|Drug|ifosfamide|see detailed protocol description
402952|NCT01117441|Drug|mercaptopurine|see detailed protocol description
402953|NCT01117441|Drug|methotrexate|see detailed protocol description
402954|NCT01117441|Drug|prednisone|see detailed protocol description
402955|NCT01117441|Drug|thioguanine|see detailed protocol description
402956|NCT01117441|Drug|vincristine sulfate|see detailed protocol description
402957|NCT01117441|Drug|vindesine|see detailed protocol description
402958|NCT01117441|Drug|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
402959|NCT01117441|Drug|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
402960|NCT01117441|Radiation|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
402961|NCT01117428|Drug|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.~In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.~In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.~In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.~In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
402962|NCT01117402|Radiation|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.~Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
402963|NCT01117376|Drug|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
402964|NCT01117376|Drug|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
402965|NCT01117363|Other|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
402966|NCT01117350|Drug|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
402967|NCT01117350|Drug|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
402968|NCT01117350|Drug|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
402969|NCT01117337|Procedure|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
402970|NCT01117311|Device|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
402971|NCT01117311|Device|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
402972|NCT01117298|Drug|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
402973|NCT01117298|Drug|Placebo|Tab Placebo every alternate day for 8 weeks
402974|NCT01117285|Other|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).~The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
402975|NCT01117285|Other|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.~OTs receive:~3-day post-graduate course~2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.~Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.~Discussion platform~Web-based registration system: Provides guidance in using the COTiD program for every individual client.~Regional meetings: successes and difficulties in using the COTiD are discussed.~Managers and physicians receive:~Information on the COTiD program through a website and newsletters.~Motivational reminders."
402976|NCT01117246|Device|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
402977|NCT01117233|Drug|PF-04427429|single intravenous infusion of 10 mg PF-04427429 or placebo
402978|NCT01117233|Drug|PF-04427429|single intravenous infusion of 30 mg PF-04427429 or placebo
402979|NCT01117233|Drug|PF-04427429|single intravenous infusion of 100 mg PF-04427429 or placebo
402980|NCT01117233|Drug|PF-04427429|single intravenous infusion of 300 mg PF-04427429 or placebo
402982|NCT01117220|Drug|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
402983|NCT01117220|Drug|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
402984|NCT01117194|Device|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
402985|NCT01117181|Drug|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
402986|NCT01117181|Drug|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
402987|NCT01117181|Other|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.~The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:~Review and adjustment of the patient and caregiver supportive care plans~Emotional support and opportunity to ventilate feelings~Counseling regarding specific caregiving skills~Assistance with problem solving of specific issues that the caregiver brings to the sessions~Answers for questions regarding the educational materials~The educational materials will consist of a copy of the book The 36-Hour Day"
402988|NCT01117129|Drug|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
402989|NCT01117129|Drug|placebo|i.v. infusion on day 1 and 15
402990|NCT01117129|Drug|methotrexate|10-25 mg weekly
402991|NCT01117129|Drug|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
402992|NCT01117116|Drug|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
402993|NCT01117116|Drug|budesonide and formoterol|80/4.5 two puffs twice daily
402994|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
402995|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
402996|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
402997|NCT01117051|Drug|placebo|placebo
402998|NCT01117051|Drug|prucalopride|1 or 2 mg prucalopride once daily before breakfast
402999|NCT01117038|Drug|avanafil and enalapril|enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
403000|NCT01117038|Drug|avanafil and amlodipine|amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
403001|NCT01117025|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
403002|NCT01117025|Procedure|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.~After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
403003|NCT01117012|Drug|Ivacaftor|
403004|NCT01116999|Procedure|light guided tracheal intubation|Tracheal intubation light guided technique.
403005|NCT01116986|Behavioral|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
403006|NCT01116986|Behavioral|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
403007|NCT01116986|Behavioral|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
403008|NCT01116986|Behavioral|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
403009|NCT01116986|Behavioral|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
403010|NCT01116986|Drug|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF > 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.~Gum:~IF > 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks."
403011|NCT01116986|Drug|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|"If randomized to this condition:~After the target quit day:~Patch:~IF > 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.~IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.~Gum:~IF > 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks."
403012|NCT01116986|Drug|Pre-Quit Nicotine Gum|"If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day."
403013|NCT01116986|Drug|Pre-Quit Nicotine Patch|"If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):~Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day."
403014|NCT01116986|Drug|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|"If randomized to both the Prequit Patch and Prequit Gum Conditions:~Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day."
403015|NCT01116973|Other|PICC|Peripheral inserted catheter placement to take the reading
403016|NCT01116947|Other|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
403017|NCT01116921|Device|Nasal continuous positive airway pressure (nCPAP)|nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
403018|NCT01116921|Device|Laryngeal Mask Airway (LMA) to deliver surfactant|Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)
403019|NCT01116921|Drug|Surfactants, Pulmonary|Curosurf®, Chiesi USA, Inc., Cary, NC
403020|NCT01116908|Device|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
403021|NCT01116895|Drug|LEO 22811|Oral solution
403022|NCT01116895|Drug|Placebo|Placebo
403023|NCT01116882|Procedure|PCI|
403024|NCT01116856|Other|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
403025|NCT01116843|Drug|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
403026|NCT01116830|Drug|Placebo|Orally daily for 6 weeks
403027|NCT01116830|Drug|RO4917838|10 mg daily orally for 6 weeks
403028|NCT01116830|Drug|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
403029|NCT01116817|Procedure|Lumbar puncture|Lumbar puncture at week 0
403030|NCT01116817|Procedure|Lumbar puncture|Lumbar puncture at week 0
403031|NCT01116804|Procedure|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
403032|NCT01116804|Procedure|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
403033|NCT01116804|Procedure|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
403034|NCT01116804|Procedure|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
403035|NCT01116791|Procedure|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)~HIPC is administered immediately after CRS"
403036|NCT01116778|Biological|eN-Lac®|One capsule with 2x10^9 colony forming unit (cfu) LP GMNL-32, once daily, po
403037|NCT01116778|Other|Placebo|One placebo capsule, once daily, po
403038|NCT01116765|Other|no stimulation of the oral structure|
403039|NCT01116765|Other|stimulation of the oral structure|
403040|NCT01116752|Other|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children <1 year old and 25% of those >1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
403041|NCT01116739|Device|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
403042|NCT01116739|Behavioral|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
403043|NCT01116739|Other|Dental services delivered by the Indian Health Service.|
403044|NCT01116726|Behavioral|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
403045|NCT01116726|Behavioral|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
403046|NCT01116713|Drug|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
403047|NCT01116713|Drug|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
403048|NCT01116700|Drug|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
403049|NCT01116687|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
403050|NCT01116687|Other|laboratory biomarker analysis|Correlative studies
403051|NCT01116661|Drug|5-Aminolevuline Acid (ALA)|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
403052|NCT01116648|Drug|Cediranib Maleate|Given PO
403053|NCT01116648|Other|Laboratory Biomarker Analysis|Correlative studies
403054|NCT01116648|Drug|Olaparib|Given PO
403055|NCT01116648|Other|Pharmacological Study|Correlative studies
403056|NCT01116635|Drug|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
403057|NCT01116622|Drug|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
403058|NCT01116622|Drug|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
403059|NCT01116609|Drug|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
403060|NCT01116596|Drug|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
403061|NCT01116583|Drug|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)~Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)~Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)~Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)~Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
403062|NCT01116583|Drug|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules~Postoperative day 1: 1 placebo capsule x 2~Postoperative day 2: 1 placebo capsule x 3~Postoperative day 3: 1 placebo capsule x 4~Postoperative day 4: 1 placebo capsule x 4~Postoperative day 5: 1 placebo capsule x 4"
403063|NCT01116570|Other|Physical training|Physical training during 24 weeks
403064|NCT01116570|Other|Control|No intervention
403065|NCT01116557|Device|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
403066|NCT01116557|Device|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
403067|NCT01116544|Device|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
403068|NCT01116531|Drug|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
403100|NCT01116258|Drug|AZD5847|oral suspension, 15 days
403101|NCT01116258|Drug|Placebo|oral suspension, 15 days
403069|NCT01116531|Drug|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is < 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
403070|NCT01116531|Drug|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is < 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
403071|NCT01116518|Procedure|physiotherapy|
403072|NCT01116518|Procedure|acromioplasty|
403073|NCT01116518|Procedure|acromioplasty and rotator cuff reconstruction|
403074|NCT01116505|Dietary Supplement|Gluten-free diet|gluten-containing cereals removed from diet
403075|NCT01116492|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
403076|NCT01116492|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
403077|NCT01116479|Other|Blood transfusion|Blood transfusion with packed erythrocytes
403078|NCT01116466|Device|ActiGait|ActiGait - implantable drop foot stimulator
403079|NCT01116453|Procedure|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
403080|NCT01116453|Procedure|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
403081|NCT01116440|Drug|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
403082|NCT01116440|Drug|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
403083|NCT01116427|Biological|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
403084|NCT01116427|Drug|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
403085|NCT01116401|Drug|leuprolide|Leuprolide acetate is a widely used GnRH agonist. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women (one 3.75-mg intramuscular injection).
403086|NCT01116388|Other|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
403087|NCT01116388|Other|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
403088|NCT01116362|Procedure|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
403089|NCT01116362|Procedure|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
403090|NCT01116349|Procedure|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
403091|NCT01116349|Device|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
403092|NCT01116336|Drug|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
403093|NCT01116336|Dietary Supplement|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
403094|NCT01116310|Drug|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
403095|NCT01116310|Drug|Placebo|Bottles containing 60 capsules.
403096|NCT01116297|Device|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
403097|NCT01116284|Procedure|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
403098|NCT01116271|Drug|AZD6244|50 or 75mg, capsules, PO, BID, 28 days
403099|NCT01116271|Drug|Irinotecan|180mg/m2, IV, Day 1& 15 of each cycle
403102|NCT01116245|Biological|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
403103|NCT01116245|Drug|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
403104|NCT01116232|Biological|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
403105|NCT01116232|Biological|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.~In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
403106|NCT01116232|Drug|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
403107|NCT01116232|Drug|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
403108|NCT01116232|Other|laboratory biomarker analysis|laboratory biomarker analysis
403109|NCT01116232|Procedure|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
403110|NCT01116232|Procedure|management of therapy complications|management of therapy complications
403111|NCT01116232|Procedure|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
403112|NCT01116219|Biological|bevacizumab, erlotinib|"Bevacizumab 7.5 mg/kg i.v. every 3 weeks and~Erlotinib 150 mg p.o. daily until progression."
403113|NCT01116219|Drug|bevacizumab, pemetrexed, cisplatin|"Induction chemotherapy with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. and~Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with~Bevacizumab 7.5 mg/kg i.v. and~Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
403114|NCT01116206|Drug|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
403115|NCT01116206|Drug|Placebo|1 tablet, orally once dailyfor 12 weeks
403116|NCT01116193|Drug|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
403117|NCT01116180|Drug|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
403118|NCT01116180|Drug|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
403119|NCT01116167|Drug|Letrozole -Berberine|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine~1.5g daily for 6 month."
403120|NCT01116167|Drug|Letrozole|"Letrozole~2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.~Berberine Placebo~5 tablet tds for 6 months"
403121|NCT01116167|Drug|Berberine|"Berberine~1.5g daily for 6 month.~Letrozole placebo~1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6."
403122|NCT01116154|Drug|lenalidomide|Given orally
403123|NCT01116154|Drug|vorinostat|Given orally
403124|NCT01116154|Other|laboratory biomarker analysis|Correlative studies
403125|NCT01116141|Drug|CH-4051|Different doses CH-4051 to be compared
403126|NCT01116141|Drug|Methotrexate (MTX)|20 mg MTX weekly
403127|NCT01116141|Drug|Folic Acid|1 mg folic acid daily
403128|NCT01116128|Drug|dasatinib|100 mg QD continuously (from day 1 to day 28)
403129|NCT01116128|Drug|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
403130|NCT01116128|Drug|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
403131|NCT01116115|Other|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
403132|NCT01116115|Other|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
403133|NCT01116102|Drug|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
403134|NCT01116089|Drug|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
403135|NCT01116089|Drug|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
403136|NCT01116076|Behavioral|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
403137|NCT01116063|Drug|Inhaled iloprost|Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
403138|NCT01116050|Drug|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
403139|NCT01116050|Drug|Placebo|5 tablets in opque introducer
403140|NCT01116037|Device|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
403141|NCT01116024|Device|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
403142|NCT01116011|Drug|AZD7268|Capsule, Oral, BID
403143|NCT01116011|Drug|Placebo|Capsule, Oral, BID
403144|NCT01115998|Other|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
403145|NCT01115998|Other|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
403146|NCT01115985|Drug|ASP1585|oral
403147|NCT01115985|Drug|atorvastatin|oral
403148|NCT01115972|Drug|ASP1585|oral
403149|NCT01115972|Drug|valsartan|oral
403150|NCT01115959|Drug|valproic acid|treatment of 1 month dosage of 400 mg BID
403151|NCT01115959|Drug|placebo bid|
403152|NCT01115946|Drug|ASP1585|oral
403153|NCT01115946|Drug|enalapril|oral
403154|NCT01115933|Device|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
403155|NCT01115920|Drug|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
403156|NCT01115907|Device|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
403157|NCT01115894|Drug|Naltrexone|100 mg oral dosage daily for 12 weeks
403158|NCT01115894|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
403159|NCT01115894|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
403160|NCT01115894|Drug|Placebo|Placebo
403161|NCT01115868|Drug|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
403162|NCT01115868|Drug|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
403163|NCT01115868|Drug|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
403164|NCT01115868|Drug|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
403165|NCT01115855|Drug|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
403166|NCT01115855|Drug|Placebo|Placebo once daily or every once daily
403167|NCT01115842|Drug|Vitamin D|Vitamin D 4000IU per day for 5 days
403168|NCT01115803|Drug|LY2584702|Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
403169|NCT01115803|Drug|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.~Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
403170|NCT01115803|Drug|Everolimus|Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
403171|NCT01115790|Drug|Prexasertib|Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
403172|NCT01115777|Other|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
403173|NCT01115751|Drug|LY2780301|"Administered orally, daily for two 28-day cycles.~Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression."
403174|NCT01115738|Drug|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
403175|NCT01115738|Drug|Clopidogrel|Loading dose administered once orally.
403176|NCT01115738|Drug|Placebo|Loading dose administered once orally
403177|NCT01115725|Drug|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
403178|NCT01115712|Drug|Placebo|Placebo (to match pioglitazone 30 mg) once daily
403179|NCT01115712|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
403180|NCT01115712|Drug|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
403181|NCT01115699|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
403182|NCT01115686|Drug|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.~The treatment will last 3 weeks."
403183|NCT01115686|Drug|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.~The treatment will last 3 weeks."
403184|NCT01115673|Drug|Acetaminophen|Acetaminophen Caplet - single dose
403185|NCT01115673|Drug|Placebo Control|0 mg Caplet - single dose
403186|NCT01115660|Behavioral|stroke education|call by medication coach 2 weeks after hospital discharge
403187|NCT01115647|Dietary Supplement|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
403588|NCT01112397|Drug|AZD1480|continuous daily oral capsule
403188|NCT01115647|Dietary Supplement|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
403189|NCT01115647|Behavioral|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
403190|NCT01115634|Biological|Fibroblast|20 million cell in three injection
403191|NCT01115634|Biological|fibroblast and gel|20 million cell in three injection plus filler
403192|NCT01115621|Other|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
403193|NCT01115608|Other|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
403194|NCT01115595|Biological|Intervention|Dermatophagoides pteronyssinus from ALK company
403195|NCT01115595|Other|Control|Injection by buffer solution WITH standard allergic medication (oral antihistamine and/or topical nasal steroid)
403196|NCT01115582|Drug|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.~Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
403197|NCT01115569|Drug|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
403198|NCT01115556|Drug|Ranibizumab|2.0 mg
403199|NCT01115556|Drug|Ranibizumab|0.5 mg
403200|NCT01115543|Drug|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
403201|NCT01115530|Other|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
403202|NCT01115530|Dietary Supplement|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
403203|NCT01115517|Drug|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
403204|NCT01115517|Drug|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
403205|NCT01115504|Drug|Thiamine|300 mg daily for 30 days
403206|NCT01115491|Drug|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
403207|NCT01115491|Drug|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
403208|NCT01115478|Dietary Supplement|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
403209|NCT01115478|Dietary Supplement|Zinc|Daily oral dose of 25 mg from enrollment until delivery
403210|NCT01115478|Other|Placebo|Daily oral dose from enrollment until delivery
403211|NCT01115465|Device|Macroplastique|Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
403212|NCT01115452|Drug|5% Potassium nitrate|5% potassium nitrate solution
403213|NCT01115452|Drug|2.5% Potassium nitrate|2.5% potassium nitrate solution
403214|NCT01115452|Other|Sterile water|Sterile water
403215|NCT01115439|Drug|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
403216|NCT01115426|Drug|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
403217|NCT01115387|Other|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
403218|NCT01115387|Other|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing."
403219|NCT01115374|Procedure|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
403220|NCT01115374|Device|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
403221|NCT01115361|Behavioral|Family planning for postpartum women|"A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.~B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.~C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.~D.Convenient offer of FP services to women attending vaccination services for their infants."
403222|NCT01115335|Procedure|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
403223|NCT01115322|Drug|Tazarotene Foam without irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.~This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
403224|NCT01115322|Drug|Tazarotene Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
403225|NCT01115322|Drug|Tazarotene Foam with UVA, UVB, and visible light|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
403226|NCT01115322|Drug|Vehicle Foam without irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
403227|NCT01115322|Drug|Vehicle Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
403228|NCT01115322|Drug|Vehicle Foam with UVA and UVB and visible light irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
403229|NCT01115322|Drug|No Treatment without irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
403230|NCT01115322|Drug|No Treatment with UVA and UVB irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
403231|NCT01115322|Drug|No Treatment with UVA and UVB and visible light irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).~Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
403232|NCT01115309|Device|XprESS Balloon Device|Procedure completed with the XprESS Balloon Device
403233|NCT01115296|Dietary Supplement|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
403234|NCT01115296|Other|Placebo|Placebo
403235|NCT01115283|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
403236|NCT01115283|Behavioral|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
403237|NCT01115283|Behavioral|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
403238|NCT01115270|Other|Non-invasive measures|assessment of cerebrovascular fluid movement
403239|NCT01115257|Procedure|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
403240|NCT01115257|Procedure|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
403241|NCT01115244|Drug|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
403242|NCT01115218|Procedure|Trabeculectomy|Trabeculectomy with mitomycin C
403243|NCT01115205|Behavioral|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
403244|NCT01115205|Behavioral|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
403245|NCT01115192|Procedure|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
403246|NCT01115192|Procedure|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
403247|NCT01115179|Drug|propofol|Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
403248|NCT01115179|Drug|Intralipid 10%|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
403249|NCT01115179|Drug|Saline|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
403250|NCT01115153|Other|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
403251|NCT01115153|Other|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
403252|NCT01115140|Drug|metformin plus placebo|metformin 850 mg cp, 2 cps daily
403253|NCT01115140|Drug|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
403254|NCT01115140|Drug|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
403255|NCT01115140|Drug|placebo alone|placebo cp, 2 cps daily
403256|NCT01115127|Dietary Supplement|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
403257|NCT01115127|Dietary Supplement|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
403258|NCT01115127|Dietary Supplement|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
403259|NCT01115114|Behavioral|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
403260|NCT01115114|Behavioral|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
403261|NCT01115114|Behavioral|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
403262|NCT01115101|Drug|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
403263|NCT01115101|Drug|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
403264|NCT01115088|Dietary Supplement|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
403265|NCT01115088|Dietary Supplement|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
403266|NCT01115088|Dietary Supplement|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
403267|NCT01115075|Other|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
403268|NCT01115075|Behavioral|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
403269|NCT01115062|Drug|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
403270|NCT01115062|Drug|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
403271|NCT01115062|Drug|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
403272|NCT01115049|Drug|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
403273|NCT01115049|Drug|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
403274|NCT01115036|Drug|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
403275|NCT01115023|Other|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
403276|NCT01115010|Device|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
403277|NCT01115010|Device|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
403278|NCT01115010|Device|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
403279|NCT01114997|Drug|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
403280|NCT01114997|Drug|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
403281|NCT01114997|Drug|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)~Maintenance Infusion rate after Induction:~Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
403282|NCT01114971|Drug|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
403283|NCT01114971|Drug|Labetalol|"Labetalol 5 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
403284|NCT01114971|Drug|Esmolol|"Esmolol 10 mg/ml boluses will be given:~at the induction time~at the time before surgical incision, and~as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
403285|NCT01114958|Drug|Cisplatin, Thiosulfate|Cisplatin (150 mg/m^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m^2).
403286|NCT01114945|Device|McGrath|Intubation with the McGrath device
403287|NCT01114945|Device|GlideScope|Intubation with the GlideScope device
403288|NCT01114945|Device|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
403289|NCT01114945|Device|Video-Mac|Intubation with the Video-Mac device
403290|NCT01114919|Behavioral|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
403291|NCT01114919|Behavioral|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
403292|NCT01114893|Drug|Travoprost 0.004%|1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
403293|NCT01114893|Drug|Travoprost Vehicle|1 drop in each eye 8 times daily for 5 days
403294|NCT01114893|Drug|Travoprost (Groups A, B and C)|1 drop in each eye 8 times daily for 5 days
403295|NCT01114880|Biological|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
403296|NCT01114880|Other|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
403297|NCT01114854|Drug|Topiramate IR|
403298|NCT01114854|Drug|Topiramate ER|
403299|NCT01114841|Drug|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
403300|NCT01114841|Drug|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.~There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).~These patches will then be evaluated at 24, 48, and 72 hours.~There may be a second rest period and a second 48-hour patch application and evaluation, if required."
403301|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
403302|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
403432|NCT01113710|Drug|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
403303|NCT01114802|Behavioral|Project Onward website + social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
403304|NCT01114802|Behavioral|Project Onward website|Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
403305|NCT01114789|Other|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
403306|NCT01114750|Drug|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
403307|NCT01114737|Drug|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
403308|NCT01114737|Drug|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
403309|NCT01114724|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
403310|NCT01114698|Drug|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
403311|NCT01114698|Drug|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
403312|NCT01114698|Drug|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
403313|NCT01114685|Dietary Supplement|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
403314|NCT01114685|Dietary Supplement|AlgaeCal-2|Taking 7 capsules a day for six months
403315|NCT01114672|Drug|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
403316|NCT01114672|Drug|Placebo|oral placebo once weekly
403317|NCT01114646|Device|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
403318|NCT01114646|Device|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
403319|NCT01114620|Biological|Arepanrix™|Intramuscular administration, one dose
403320|NCT01114607|Drug|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
403321|NCT01114607|Drug|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
403322|NCT01114607|Drug|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
403323|NCT01114607|Drug|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
403324|NCT01114607|Drug|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
403325|NCT01114581|Drug|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
403326|NCT01114581|Drug|Placebo|Placebo given as 2 tablets
403327|NCT01114568|Drug|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
403328|NCT01114568|Drug|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
403329|NCT01114568|Drug|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
403330|NCT01114555|Drug|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
403331|NCT01114542|Drug|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
403332|NCT01114542|Drug|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
403333|NCT01114529|Drug|Everolimus|Early CNI to everolimus conversion
403334|NCT01114529|Drug|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
403335|NCT01114516|Drug|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
403336|NCT01114503|Drug|Otelixizumab - low dose|8 day dose rising intravenous infusions of a low dose of otelixizumab
403337|NCT01114503|Drug|Otelixizumab - medium low dose|8 day dose rising intravenous infusions of a medium low dose of otelixizumab
403338|NCT01114503|Drug|Otelixizumab - medium high dose|8 day dose rising intravenous infusions of a medium high dose of otelixizumab
403339|NCT01114503|Drug|Otelixizumab - high dose|8 day dose rising intravenous infusions of a high dose of otelixizumab
403340|NCT01114503|Drug|Otelixizumab|8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
403341|NCT01114503|Drug|Methylprednisolone|Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
403342|NCT01114490|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
403343|NCT01114451|Procedure|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
403344|NCT01114438|Device|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
403345|NCT01114425|Drug|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
403346|NCT01114425|Drug|Truvada®|
403584|NCT01112423|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
403585|NCT01112423|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
403347|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
403348|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
403349|NCT01114399|Dietary Supplement|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
403350|NCT01114386|Procedure|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:~physical examination~6' Minute Walk test~pulmonary function testing (spirometry + volumes and reversibility testing)~carbon monoxide diffusing capacity (DLCO) with single-breathe technique~ECG~echocardiography"
403351|NCT01114373|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
403352|NCT01114373|Drug|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
403353|NCT01114360|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
403354|NCT01114360|Drug|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
403355|NCT01114347|Dietary Supplement|cranberry type A pro anthocyandines|One gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water
403356|NCT01114347|Dietary Supplement|Placebo|One placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
403357|NCT01114334|Behavioral|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
403358|NCT01114334|Behavioral|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
403359|NCT01114321|Behavioral|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
403360|NCT01114308|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
403361|NCT01114308|Drug|placebo implant|Implant contains ethylene vinyl acetate
403362|NCT01114308|Drug|Buprenorphine|sublingual buprenorphine/naloxone tablets
403363|NCT01114295|Device|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
403364|NCT01114295|Radiation|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
403365|NCT01114282|Drug|velcade|
403366|NCT01114282|Drug|Pralatrexate|
403367|NCT01114256|Procedure|FNA Biopsy|
403368|NCT01114243|Device|Ultrasound imaging|
403369|NCT01114230|Drug|AGS-16M8F|IV
403370|NCT01114217|Drug|Ferumoxytol|IV Ferumoxytol
403371|NCT01114204|Drug|Ferumoxytol|IV Ferumoxytol
403372|NCT01114204|Drug|Iron Sucrose|IV Iron Sucrose
403373|NCT01114191|Drug|ABT-869|2.5mg [5 mg days 1, 8 and 12. 17.5 mg on days 13 and after]
403374|NCT01114191|Drug|ketoconazole|400 mg days 6-11
403375|NCT01114178|Other|questionnaire|self completed questionnaire supervised by a technician
403376|NCT01114165|Other|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
403377|NCT01114165|Other|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
403378|NCT01114152|Drug|AZD9742|IV Formulation
403379|NCT01114152|Drug|Placebo|IV Formulation
403380|NCT01114139|Drug|Ferumoxytol|IV Ferumoxytol
403381|NCT01114139|Other|Placebo|IV Placebo
403382|NCT01114126|Drug|Neu-P11|comparison of different dosages of drug
403383|NCT01114126|Drug|Neu-P11 placebo|comparison of different dosages
403384|NCT01114113|Drug|pancelipase/placebo|"ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule."
403385|NCT01114113|Device|SmartPill capsule|Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
403386|NCT01114113|Device|SmartPill capsule|"Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule"
403387|NCT01114113|Device|SmartPill capsule|SmartPill capsule
403388|NCT01114100|Drug|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
403389|NCT01114100|Drug|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
403390|NCT01114087|Drug|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
403391|NCT01114061|Device|Insupatch|Applying heat to the infusion site using the insupatch device
403392|NCT01114048|Drug|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1~28 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D 1~4, 15-18 Repeated every 28 days~Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days~Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
403393|NCT01114035|Genetic|blood samples and skin biopsies|to detect mutations
403394|NCT01114035|Genetic|Skin biopsies|to detect mutations
403395|NCT01114022|Device|Experimental 1|oeso pharyngeal device
403396|NCT01114022|Device|Experimental|oeso pharyngeal device
403397|NCT01114022|Device|experimental 3|oeso pharyngeal device
403398|NCT01114022|Device|Active comparator|oeso pharyngeal device
403399|NCT01114009|Procedure|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
403400|NCT01114009|Procedure|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
403401|NCT01113996|Behavioral|Protein supplementation and strength training|Protein supplementation and strength training
403402|NCT01113996|Dietary Supplement|Protein supplementation|Protein supplementation
403403|NCT01113983|Drug|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transfemoral or transapical approach
403404|NCT01113970|Drug|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
403405|NCT01113957|Drug|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
403406|NCT01113957|Drug|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
403407|NCT01113957|Drug|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
403408|NCT01113944|Behavioral|Program 1|
403409|NCT01113944|Behavioral|Program 2|
403410|NCT01113931|Drug|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
403411|NCT01113931|Drug|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
403412|NCT01113892|Device|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
403413|NCT01113879|Behavioral|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
403414|NCT01113879|Behavioral|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
403415|NCT01113840|Behavioral|Exercise|Exercise classes three times per week in a controlled, supervised environment.
403416|NCT01113840|Behavioral|Control|Control group continues daily life as prior to randomization.
403417|NCT01113827|Dietary Supplement|Olive Extract|Capsule form ingested 1x/day for 6 weeks
403418|NCT01113827|Dietary Supplement|Placebo|Placebo
403419|NCT01113814|Device|FibroScan|
403420|NCT01113814|Device|Acoustic Radiation Force Impulse (ARFI)- Imaging|
403421|NCT01113801|Drug|LY2382770|Subcutaneous injection given monthly for 12 months
403422|NCT01113801|Drug|Placebo|Subcutaneous injection given monthly for 12 months
403423|NCT01113788|Device|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
403424|NCT01113762|Device|articular surface replacement ASR, DePuy|posterolateral incision
403425|NCT01113762|Device|ReCap/Magnum modular head, Biomet|posterolateral incision
403426|NCT01113762|Device|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
403427|NCT01113762|Device|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
403428|NCT01113749|Other|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
403429|NCT01113736|Biological|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
403430|NCT01113723|Device|Fiberoptic bronchoscope|Fiberoptic bronchoscope device
403431|NCT01113723|Device|CMAC|CMAC Device
403433|NCT01113684|Device|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
403434|NCT01113671|Drug|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
403435|NCT01113671|Drug|Placebo|includes inactive Ingredients
403436|NCT01113658|Device|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.~The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
403437|NCT01113645|Procedure|Cerebral perfusion evaluation|The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
403438|NCT01113632|Drug|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
403439|NCT01113619|Drug|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
403440|NCT01113619|Drug|RP-G28 or placebo|Daily dosing
403441|NCT01113606|Other|Obagi New-Derm System|
403442|NCT01113606|Other|Standard of Care|
403443|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
403444|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
403445|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
403446|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
403447|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
403448|NCT01113580|Biological|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
403449|NCT01113567|Dietary Supplement|Lactose-free milk|3.5 g of lactose
403450|NCT01113567|Dietary Supplement|Whole milk|Whole milk with 24 g lactose
403451|NCT01113554|Other|questionnaire administration|
403452|NCT01113554|Behavioral|exercise intervention|
403453|NCT01113554|Procedure|quality-of-life assessment|
403454|NCT01113554|Other|survey administration|
403455|NCT01113554|Procedure|management of therapy complications|
403456|NCT01113554|Procedure|psychosocial assessment and care|
403457|NCT01113541|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
403458|NCT01113528|Other|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
403459|NCT01113528|Drug|Sugar pill|3 times daily
403460|NCT01113515|Drug|Esmolol hydrochloride|
403461|NCT01113515|Drug|Esmolol hydrochloride|
403462|NCT01113515|Drug|Esmolol hydrochloride|
403463|NCT01113515|Drug|Placebo gel|
403464|NCT01113502|Drug|Eltrombopag|
403465|NCT01113489|Drug|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
403466|NCT01113489|Drug|placebo|1 ml b.i.d.
403467|NCT01113476|Drug|Nab-paclitaxel|Starting dose of 50 mg/m^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
403468|NCT01113476|Drug|Bevacizumab|Starting dose of 5 mg/m^2 on Day 1 + 15 every 28 days (+/- 2 days)
403469|NCT01113476|Drug|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
403470|NCT01113463|Drug|TPI 287|Starting dose of 160 mg/m^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
403471|NCT01113437|Drug|Omalizumab|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
403472|NCT01113437|Drug|Placebo|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
403473|NCT01113424|Drug|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
403474|NCT01113424|Drug|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
403475|NCT01113411|Device|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
403476|NCT01113411|Other|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.~The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.~The patient will complete a daily diary to validate the frequency and intensity of the exercises."
403477|NCT01113411|Other|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
403478|NCT01113398|Drug|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
403479|NCT01113398|Drug|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
403480|NCT01113385|Drug|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
403481|NCT01113372|Drug|Clopidogrel|Clopidogrel 75mg daily.
403482|NCT01113346|Drug|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
403483|NCT01113346|Drug|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
403484|NCT01113333|Drug|placebo|"Pharmaceutical form:injection~Route of administration: intra-articular"
403485|NCT01113333|Drug|SAR113945|"Pharmaceutical form:injection~Route of administration: intra-articular"
403486|NCT01113320|Drug|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
403487|NCT01113320|Drug|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
403488|NCT01113307|Biological|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
403489|NCT01113294|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
403490|NCT01113281|Biological|VPM1002 live vaccine|
403491|NCT01113281|Biological|commercially available live vaccine BCG|
403492|NCT01113268|Other|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
403493|NCT01113255|Procedure|bench-evaluation, of three ventilators|to select in-VITRO the most appropriate ventilator for a given pathology.
403494|NCT01113242|Other|Neuropsychological Assessment|Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,…) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) <16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
403495|NCT01113229|Drug|Misoprostol|two misoprostol tablets taken orally (400µg)
403496|NCT01113203|Behavioral|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
403497|NCT01113190|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
403498|NCT01113190|Behavioral|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller & Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
403586|NCT01112410|Other|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.~(Randomised crossover trial)"
403499|NCT01113190|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
403500|NCT01113190|Behavioral|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
403501|NCT01113177|Device|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
403502|NCT01113164|Drug|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
403503|NCT01113151|Dietary Supplement|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
403504|NCT01113151|Other|Placebo|3 placebo tablets daily for 12 weeks
403505|NCT01113138|Dietary Supplement|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
403506|NCT01113138|Drug|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
403507|NCT01113125|Drug|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
403508|NCT01113125|Drug|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
403509|NCT01113099|Other|Academic detailing|Education of physicians by pharmacists regarding indications for statins in diabetic patients
403510|NCT01113086|Device|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
403511|NCT01113073|Other|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
403512|NCT01113073|Other|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
403513|NCT01113073|Other|passive leg raising test|performing the passive leg raising test
403514|NCT01113047|Drug|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
403515|NCT01113034|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
403516|NCT01113034|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
403517|NCT01113021|Device|Photon stimulation by low level laser therapy|
403518|NCT01113008|Procedure|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
403519|NCT01113008|Procedure|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
403520|NCT01112995|Dietary Supplement|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
403521|NCT01112995|Dietary Supplement|Sugar pill (placebo)|placebo identical to the active product will be given
403522|NCT01112982|Other|Magnetic Resonance Imaging|An Magnetic Resonance Imaging (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
403523|NCT01112982|Drug|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is > 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
403524|NCT01112982|Drug|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
403525|NCT01112969|Behavioral|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
403526|NCT01112969|Other|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
403527|NCT01112943|Other|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
403528|NCT01112943|Other|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
403529|NCT01112943|Other|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
403530|NCT01112917|Device|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
403531|NCT01112917|Procedure|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
403532|NCT01112891|Drug|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
403533|NCT01112891|Drug|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
403534|NCT01112891|Drug|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
403535|NCT01112878|Drug|Sugar pill|"Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
403587|NCT01112410|Other|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
403536|NCT01112878|Drug|Gabapentin|"Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
403537|NCT01112878|Drug|Clonidine|"Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~once in the preoperative holding area and once before discharge from PACU~continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
403538|NCT01112865|Device|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
403539|NCT01112865|Device|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
403540|NCT01112865|Device|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
403541|NCT01112865|Device|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
403542|NCT01112852|Drug|pantoloc 40 mg|pantoloc iv. infusion per day
403543|NCT01112852|Drug|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
403544|NCT01112839|Behavioral|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
403545|NCT01112839|Behavioral|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
403546|NCT01112826|Drug|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
403547|NCT01112813|Drug|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
403548|NCT01112787|Drug|Tazarotene Foam|Tazarotene Foam
403549|NCT01112787|Drug|Vehicle Foam|Vehicle Foam
403550|NCT01112787|Drug|Sodium Laural Sulfate|Sodium Laural Sulfate
403551|NCT01112787|Drug|Distilled Water|Distilled Water
403552|NCT01112774|Device|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
403553|NCT01112761|Device|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
403554|NCT01112748|Drug|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
403555|NCT01112735|Biological|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
403556|NCT01112735|Procedure|Standard of care|Standard of care
403557|NCT01112722|Biological|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
403558|NCT01112722|Biological|histamine|imitates pain and erythema of honeybee venom
403559|NCT01112709|Behavioral|SCT-based Resistance Training exercise program|Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.
403560|NCT01112709|Other|Standard Intervention with minimal contact|This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
403561|NCT01112696|Device|Sensor wear|All subjects to wear sensors
403562|NCT01112683|Drug|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
403563|NCT01112683|Drug|Placebo|These are identically-looking pills to those in the Memantine Arm.
403564|NCT01112670|Drug|Sitagliptin|sitagliptin 100 mg x 1 dose
403565|NCT01112670|Drug|atorvastatin|atorvastatin 40 mg x 5 doses
403566|NCT01112644|Drug|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
403567|NCT01112644|Other|Placebo (PLA)|Different daily doses; intake every 12 hours
403568|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
403569|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Medical management
403570|NCT01112540|Drug|Morphine|0.1 mg/kg Intravenous bolus
403571|NCT01112527|Drug|PF-00299804|Taken orally once a day
403572|NCT01112514|Drug|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
403573|NCT01112488|Other|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
403574|NCT01112462|Drug|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
403575|NCT01112462|Drug|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
403576|NCT01112449|Other|Placebo|no active medication
403577|NCT01112449|Dietary Supplement|selenomethionine|200 µg/day of selenomethionine (SM)
403578|NCT01112449|Dietary Supplement|low dose selenized-yeast|200 µg/day of SY
403579|NCT01112449|Dietary Supplement|high dose selenized-yeast|285 µg/day of SY
403580|NCT01112436|Drug|periarticular injection of multidrug regimen|periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
403581|NCT01112436|Drug|none of medication preoperatively and intraoperatively|Patients in Group C wil receive none of medication preoperatively and intraoperatively
403582|NCT01112423|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
403583|NCT01112423|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
403589|NCT01112384|Drug|SB939|Given orally 3 times per week
403590|NCT01112371|Drug|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
403591|NCT01112358|Drug|r-FSH|r-FSH will be administered as specified in the arm description.
403592|NCT01112358|Drug|r-hLH|r-hLH will be administered as specified in the arm description.
403593|NCT01112358|Drug|Analogous GnRH antagonist|Analogous GnRH antagonist will be administered as specified in the arm description.
403594|NCT01112358|Drug|r-hCG|r-hCG will be administered as specified in the arm description.
403595|NCT01112358|Drug|Progesterone|Progesterone will be administered as specified in the arm description.
403596|NCT01112332|Device|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
403597|NCT01112319|Device|Elf care|elfcare device
403598|NCT01112319|Other|control group|regular physiotherapy treatment
403599|NCT01112306|Drug|ACT-293987|Tablets, twice daily
403600|NCT01112293|Drug|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
403601|NCT01112280|Device|cap-assisted chromoendoscopy|A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy. For chromoendoscopy, 0.09% indigocarmine was administered via irrigation cap .
403602|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
403603|NCT01112267|Drug|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
403604|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
403605|NCT01112267|Drug|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
403606|NCT01112254|Procedure|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
403607|NCT01112241|Drug|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
403608|NCT01112228|Procedure|Bariatric surgery|Gastric bypass, Sleeve gastrectomy, or Gastric banding
403609|NCT01112215|Drug|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
403610|NCT01112215|Drug|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
403611|NCT01112189|Procedure|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
403612|NCT01112189|Other|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.~Week 3 -4: Without treatment.~Week 5 - 6: With compressed sleeve treatment"
403613|NCT01112176|Procedure|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
403614|NCT01112163|Device|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
403615|NCT01112150|Device|NormaTec Pump|Normatec Pump
403616|NCT01112137|Drug|Clopidogrel|
403617|NCT01112137|Drug|Clopidogrel|
403618|NCT01112137|Drug|Clopidogrel|
403619|NCT01112137|Drug|Clopidogrel|
403620|NCT01112111|Drug|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
403621|NCT01112098|Behavioral|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
403622|NCT01112085|Drug|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
403623|NCT01112085|Drug|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
403624|NCT01112072|Drug|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
403625|NCT01112059|Drug|Doxycycline|100 mg twice a day for 8 days
403626|NCT01112059|Other|placebo|placebo
403627|NCT01112046|Procedure|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
403628|NCT01112046|Procedure|Laparoscopic resection|Surgical treatment performed under general anesthesia
403629|NCT01112020|Device|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
403630|NCT01112020|Device|Biopatch|Biopatch applied to 7 sites
403631|NCT01112020|Device|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
403632|NCT01111994|Drug|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
403633|NCT01111981|Drug|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
403634|NCT01111968|Biological|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
403635|NCT01111968|Biological|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
403636|NCT01111968|Biological|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
403637|NCT01111968|Biological|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
403638|NCT01111968|Biological|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
403639|NCT01111968|Biological|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
403640|NCT01111968|Biological|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
403641|NCT01111968|Biological|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
403642|NCT01111968|Biological|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
403643|NCT01111968|Biological|placebo group 14|All elements of the vaccine but antigen and adjuvant
403644|NCT01111955|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
403645|NCT01111955|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
403646|NCT01111955|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
403647|NCT01111955|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
403648|NCT01111955|Drug|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
403649|NCT01111942|Other|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;~Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.~Induction Triple Therapy Treatment with TPF:~Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta* 6 mg SC Day 5 (*Neupogen may be substituted at the investigator's discretion)"
403650|NCT01111942|Procedure|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
403651|NCT01111929|Drug|Counseling for LAM+ LNG-EC|"They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer."
403652|NCT01111903|Drug|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
403653|NCT01111890|Drug|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
403654|NCT01111890|Drug|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
403655|NCT01111864|Dietary Supplement|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
403656|NCT01111864|Dietary Supplement|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
403657|NCT01111851|Drug|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
403658|NCT01111851|Drug|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
403659|NCT01111851|Drug|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
403660|NCT01111851|Drug|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
403661|NCT01111851|Drug|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
403662|NCT01111851|Drug|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
403663|NCT01111851|Drug|MK0999|I.V. infusion of MK0999 containing ~100 MBq (~3 mCi) containing ≤ 5 ug of MK0999)
403664|NCT01111838|Drug|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
404556|NCT01105117|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
403665|NCT01111825|Drug|Temsirolimus|"28 day treatment cycle Phase 1~Weekly intravenously (IV) on days 1, 8, 15, and 22~Starting dose 8 mg IV weekly (dose level 1). Three patients initially enrolled in each cohort~Phase 2~Dose escalation cohort - 8 mg IV weekly on Days 1, 8, 15, and 22, and then 15 mg IV weekly starting on Day 29~HER2-amplified and Triple negative - 8 mg IV weekly on Days 1, 8, 15, and 22"
403666|NCT01111825|Drug|Neratinib|"28 day treatment cycle~• 240 mg orally daily"
403667|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
403668|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
403669|NCT01111799|Procedure|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
403670|NCT01111773|Drug|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
403671|NCT01111747|Procedure|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
403672|NCT01111747|Procedure|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
403673|NCT01111734|Dietary Supplement|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
403674|NCT01111734|Drug|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
403675|NCT01111721|Behavioral|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
403676|NCT01111721|Behavioral|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
403677|NCT01111708|Procedure|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
403678|NCT01111695|Device|ApisSept|honey and ionic silver based dressing
403679|NCT01111682|Drug|Mannitol|0.9% normal saline infusion and boluses of mannitol
403680|NCT01111682|Drug|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
403681|NCT01111669|Drug|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
403682|NCT01111669|Drug|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
403683|NCT01111656|Drug|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
403684|NCT01111656|Drug|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
403685|NCT01111643|Device|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
403686|NCT01111630|Drug|recomon (Epoetin Beta)|administer once weekly
403687|NCT01111630|Drug|recomon (Epoetin Beta)|administer three times weekly
403688|NCT01111617|Procedure|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
403689|NCT01111604|Biological|Ramucirumab|8 mg/kg IV Q2W
403690|NCT01111604|Biological|Icrucumab|15 mg/kg IV Q2W
403691|NCT01111604|Drug|mFOLFOX-6|"Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W"
403692|NCT01111591|Drug|Cox2 inhibitor (Celecoxib)|From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
403693|NCT01111578|Device|Enteral feeding tube|The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
403694|NCT01111565|Drug|Escitalopram|Escitalopram monotherapy
403695|NCT01111565|Drug|Aripiprazole|Aripiprazole monotherapy
403696|NCT01111565|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
403697|NCT01111552|Drug|Escitalopram|Escitalopram monotherapy
403698|NCT01111552|Drug|Aripiprazole|Aripiprazole monotherapy
403699|NCT01111552|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
403700|NCT01111539|Drug|Escitalopram|Escitalopram monotherapy
403701|NCT01111539|Drug|Aripiprazole|Aripiprazole monotherapy
403702|NCT01111539|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
403703|NCT01111526|Drug|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.~DL -1: 1.25 mg/m^2 IV; DL 1: 2.5 mg/m^2 IV; DL 2: 5 mg/m^2 IV; DL 3: 7.5 mg/m^2 IV; DL 4: 10 mg/m^2 IV.~Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.~DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.~Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
403820|NCT01110499|Drug|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
403704|NCT01111513|Drug|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
403705|NCT01111513|Drug|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
403706|NCT01111513|Drug|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
403707|NCT01111500|Device|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
403708|NCT01111500|Device|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
403709|NCT01111487|Device|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
403710|NCT01111474|Other|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
403711|NCT01111474|Radiation|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1J/cm2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (660nm).
403712|NCT01111461|Drug|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
403713|NCT01111448|Drug|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
403714|NCT01111422|Drug|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
403715|NCT01111409|Device|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
403716|NCT01111383|Drug|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
403717|NCT01111370|Device|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
403718|NCT01111357|Biological|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
403719|NCT01111344|Dietary Supplement|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~1 to 3.9 cm2 ______________3 daily applications~4 to 6.9 cm2 ______________4 daily applications~7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
403720|NCT01111344|Dietary Supplement|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).~1 to 3.9 cm2 ______________3 daily applications~4 to 6.9 cm2 ______________4 daily applications~7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.~Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
403721|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
403722|NCT01111331|Drug|Warfarin 25 mg|25 mg Warfarin single dose
403723|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
403724|NCT01111331|Drug|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
403725|NCT01111318|Drug|BI 10773|2 tablets BI 10773 25 mg single dose
403726|NCT01111305|Drug|Reslizumab|
403727|NCT01111305|Drug|Diethylcarbamazine|
403728|NCT01111305|Other|Placebo|
403729|NCT01111292|Drug|Inositol|Given PO
403730|NCT01111292|Other|Placebo|Given PO
403731|NCT01111279|Biological|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
403732|NCT01111279|Biological|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
403733|NCT01111279|Biological|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
403734|NCT01111266|Device|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
403735|NCT01111253|Drug|Amoxicillin-clavulanate|"Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.~In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days."
403736|NCT01111227|Drug|Propofol and isoflurane|Comparison of two anesthetic drugs
403737|NCT01111214|Other|no intervention|There is no intervention. This is a non interventional study.
403738|NCT01111201|Behavioral|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
403821|NCT01110499|Drug|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
403739|NCT01111188|Drug|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.~(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
403740|NCT01111188|Drug|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.~(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
403741|NCT01111162|Biological|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
403742|NCT01111149|Other|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
403743|NCT01111149|Drug|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
403744|NCT01111149|Drug|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
403745|NCT01111136|Behavioral|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
403746|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
403747|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
403748|NCT01111110|Device|anti-static then static|Albuterol using static chambers
403749|NCT01111110|Device|Static then anti-static chamber|albuterol with Static then anti-static chambers
403750|NCT01111097|Drug|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
403751|NCT01111084|Drug|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
403752|NCT01111058|Drug|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
403753|NCT01111058|Other|Placebo|
403754|NCT01111045|Drug|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
403755|NCT01111045|Drug|Placebo|Placebo
403756|NCT01111019|Drug|Recombinant human growth hormone (r-hGH)|Subjects will receive a single subcutaneous injection of recombinant human growth hormone (r-hGH) equivalent to a dose of 0.057 milligram per kilogram per day (mg/kg/day). The dose will be subsequently adjusted during the trial and subjects will be treated for at least 3 years or until near final height is reached.
403757|NCT01111006|Device|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
403758|NCT01110980|Other|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
403759|NCT01110980|Other|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
403760|NCT01110954|Drug|PD L 506|Two different doses will be compared
403761|NCT01110941|Drug|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40~60mg, Bid,p.o., day1~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
403762|NCT01110928|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
403763|NCT01110915|Device|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
403764|NCT01110915|Device|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
403765|NCT01110902|Drug|Agomelatine (AGO178C)|
403766|NCT01110902|Drug|Placebo|
403767|NCT01110889|Drug|Agomelatine (AGO178C)|
403768|NCT01110889|Drug|Agomelatine (AGO178C)|
403769|NCT01110889|Drug|Placebo|
403770|NCT01110876|Drug|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.~Phase II Dose: MTD from Phase I."
404557|NCT01105117|Drug|Flolan®|per Prescribing Information
403771|NCT01110876|Drug|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.~Phase II Dose: MTD from Phase I."
403772|NCT01110876|Drug|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
403773|NCT01110837|Other|Allergen|Allergen nasal challenge
403774|NCT01110837|Other|Placebo challenge|Placebo nasal challenge
403775|NCT01110824|Drug|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
403776|NCT01110811|Procedure|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
403777|NCT01110798|Other|intraoperative complication management/prevention|
403778|NCT01110798|Procedure|assessment of therapy complications|
403779|NCT01110798|Procedure|gastrointestinal complications management/prevention|
403780|NCT01110798|Procedure|quality-of-life assessment|
403781|NCT01110798|Procedure|therapeutic conventional surgery|
403782|NCT01110785|Biological|panitumumab|
403783|NCT01110785|Drug|simvastatin|
403784|NCT01110785|Other|laboratory biomarker analysis|
403785|NCT01110772|Device|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
403786|NCT01110772|Device|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
403787|NCT01110746|Drug|Viaject 7|100IU/mL administered subcutaneously
403788|NCT01110746|Drug|LISPRO|100IU/mL administered subcutaneously
403789|NCT01110720|Drug|Davunetide|Davunetide Nasal Spray 30 mg BID IN 52 weeks
403790|NCT01110720|Drug|Placebo|Placebo Nasal Spray BID IN 52 weeks
403791|NCT01110707|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day [mg/day]).
403792|NCT01110707|Drug|Recombinant human luteinizing hormone (r-hLH)|Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
403793|NCT01110681|Device|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|
403794|NCT01110668|Drug|Nilotinib|
403795|NCT01110655|Other|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
403796|NCT01110655|Other|Oral hypertonic saline|Oral 100mL bolus of 3% saline
403797|NCT01110642|Drug|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
403798|NCT01110629|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
403799|NCT01110629|Drug|Placebo|daily dose: 3 tablets TID for 8 weeks.
403800|NCT01110616|Drug|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
403801|NCT01110616|Drug|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
403802|NCT01110616|Drug|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
403803|NCT01110603|Drug|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
403804|NCT01110603|Drug|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
403805|NCT01110603|Drug|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
403806|NCT01110603|Drug|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
403807|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
403808|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
403809|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
403810|NCT01110590|Drug|Placebo|Placebo
403811|NCT01110551|Drug|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
403812|NCT01110551|Drug|Placebo (ID)|Phosphate buffered saline administered intradermally.
403813|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered subcutaneously.
403814|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered intradermally.
403815|NCT01110525|Drug|AZD1981|4X100 mg per oral, twice daily for 28 days
403816|NCT01110525|Drug|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
403817|NCT01110525|Drug|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
403818|NCT01110512|Drug|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day."
403819|NCT01110512|Drug|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)~1 tablet, 2 times per day"
403822|NCT01110499|Drug|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
403823|NCT01110499|Drug|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
403824|NCT01110499|Drug|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
403825|NCT01110499|Drug|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
403826|NCT01110499|Drug|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
403827|NCT01110499|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
403828|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
403829|NCT01110486|Drug|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
403830|NCT01110486|Drug|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
403831|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
403832|NCT01110486|Drug|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
403833|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
403834|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
403835|NCT01110473|Drug|ABT-348 and azacitidine|An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
403836|NCT01110473|Drug|ABT-348|An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
403837|NCT01110447|Drug|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
403838|NCT01110447|Other|Placebo|Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
403839|NCT01110434|Drug|Topiramate|Topiramate (200 mg daily)
403840|NCT01110434|Drug|Placebo|Placebo (daily)
403841|NCT01110421|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
403842|NCT01110421|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
403843|NCT01110421|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
403844|NCT01110421|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
403845|NCT01110421|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
403846|NCT01110408|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
403847|NCT01110408|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
403848|NCT01110408|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
403849|NCT01110408|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
403850|NCT01110408|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
403851|NCT01110382|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
403852|NCT01110382|Drug|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
403853|NCT01110382|Drug|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
403854|NCT01110382|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
403855|NCT01110382|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
403856|NCT01110369|Dietary Supplement|Protein drink|Protein drink twice a day during 6 months.
403857|NCT01110369|Other|Resistance exercise training|Resistance exercise training twice per week during 6 months.
403858|NCT01110369|Dietary Supplement|Placebo drink|Placebo drink twice a day during 6 months.
403886|NCT01110148|Other|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
403859|NCT01110356|Drug|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
403860|NCT01110356|Other|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
403861|NCT01110343|Behavioral|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
403862|NCT01110343|Behavioral|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
403863|NCT01110330|Drug|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
403864|NCT01110330|Drug|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
403865|NCT01110330|Drug|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
403866|NCT01110317|Drug|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
403867|NCT01110304|Other|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
403868|NCT01110304|Device|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
403869|NCT01110291|Drug|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.~Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
403870|NCT01110265|Behavioral|attention training|
403871|NCT01110265|Behavioral|placebo training|
403872|NCT01110252|Drug|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
403873|NCT01110252|Procedure|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
403874|NCT01110252|Genetic|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
403875|NCT01110239|Procedure|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
403876|NCT01110226|Drug|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 7.5 mg. The Dose will be increased until Maximum Tolerated Dose is established.~KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
403877|NCT01110226|Drug|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
403878|NCT01110213|Behavioral|Physical activity|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
403879|NCT01110213|Behavioral|Fruit and vegetable|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
403880|NCT01110200|Drug|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
403881|NCT01110200|Drug|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
403882|NCT01110187|Drug|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
403883|NCT01110187|Drug|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
403884|NCT01110174|Diagnostic Test|HD PET/CT|imaging
403885|NCT01110161|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
403887|NCT01110148|Other|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
403888|NCT01110135|Drug|bendamustine hydrochloride|Given IV
403889|NCT01110135|Drug|dexamethasone|Given PO
403890|NCT01110135|Biological|filgrastim|Given SC
403891|NCT01110135|Procedure|leukapheresis|Given IV
403892|NCT01110135|Other|laboratory biomarker analysis|Correlative studies
403893|NCT01110135|Other|flow cytometry|Correlative studies
403894|NCT01110135|Drug|etoposide|Given IV
403895|NCT01110122|Dietary Supplement|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
403896|NCT01110096|Behavioral|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
403897|NCT01110096|Behavioral|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
403898|NCT01110096|Behavioral|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
403899|NCT01110083|Drug|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
403900|NCT01110070|Device|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
403901|NCT01110070|Device|ChonDux|single use device
403902|NCT01110057|Drug|Placebo|Placebo to match GW856553
403903|NCT01110057|Drug|GS856553|GW586553 7.5mg bid
403904|NCT01110044|Biological|251154 vaccine|Intramuscular, single dose
403905|NCT01110044|Biological|Infanrix hexa™|Intramuscular, four doses
403906|NCT01110044|Biological|Synflorix™|Intramuscular, four doses
403907|NCT01110044|Biological|Rotarix™|Oral, two doses
403908|NCT01110031|Biological|Ofatumumab|Anti-CD20 monoclonal antibody
403909|NCT01110018|Drug|GSK573719 (SOLUTION)|20μg /mL solution for IV and Oral dosing
403910|NCT01110018|Drug|GSK573719 (INHALATION POWDER)|500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
403911|NCT01110005|Other|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
403912|NCT01110005|Other|Lactated Ringer's Solution (LR)|LR IV fluid
403913|NCT01109992|Drug|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
403914|NCT01109992|Drug|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
403915|NCT01109979|Drug|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
403916|NCT01109979|Drug|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
403917|NCT01109966|Other|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age."
403918|NCT01109966|Other|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age."
403919|NCT01109953|Other|Breath-Hold PET/CT image set|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
403920|NCT01109940|Biological|AIN457A|
403921|NCT01109927|Drug|Insulin|Insulin treatment in accordance to glucose values
403922|NCT01109914|Biological|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:~Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*~Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria* −Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
403923|NCT01109901|Procedure|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
403924|NCT01109901|Procedure|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
403925|NCT01109888|Drug|Cetrotide|
403926|NCT01109875|Other|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
403927|NCT01109862|Procedure|Total hip arthroplasty|All cemented THA
403928|NCT01109862|Procedure|Hemiarthroplasty|Cemented bipolar HAP
403929|NCT01109849|Behavioral|behavior therapy|combination of individual and group parent training plus school consultation
403930|NCT01109849|Drug|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
403931|NCT01109849|Other|monitoring|monthly weight, height and BMI checks
403932|NCT01109849|Other|drug holiday|switch from seven day a week dosing to medication only on school days
403933|NCT01109849|Dietary Supplement|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
403934|NCT01109836|Behavioral|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
403935|NCT01109823|Drug|intravenous administration of levofloxacin|Intravenous administration of levofloxacin is used.
403936|NCT01109797|Behavioral|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
403937|NCT01109797|Behavioral|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
403938|NCT01109784|Drug|prasugrel|prasugrel 10 mg/day
403939|NCT01109784|Drug|clopidogrel|clopidogrel per os 150mg/day
403940|NCT01109771|Device|permanent mesh fixation|Permanent mesh fixation will be used.
403941|NCT01109771|Device|absorbable mesh fixation|Absorbable mesh fixation will be used.
403942|NCT01109758|Drug|Fenofibrate|145 mg
403943|NCT01109745|Other|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
403944|NCT01109745|Other|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
403945|NCT01109732|Other|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
403946|NCT01109706|Other|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
403947|NCT01109693|Drug|Sertraline|Sertraline 50 mg/d or 100 mg/d for 6 more weeks
403948|NCT01109693|Drug|Mirtazapine|Augment with or switch to mirtazapine 15-45 mg/d
403949|NCT01109680|Drug|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
403950|NCT01109654|Drug|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
403951|NCT01109641|Device|diagnostic electrophysiology catheter|electrical measurements through a diagnostic electrophysiology catheter
403952|NCT01109628|Dietary Supplement|Protein drink|Twice a day during 6 months
403953|NCT01109628|Dietary Supplement|Placebo drink|Twice a day during 6 months
403954|NCT01109615|Drug|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
403955|NCT01109615|Drug|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
403956|NCT01109602|Other|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
403957|NCT01109576|Behavioral|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
403958|NCT01109563|Behavioral|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
403959|NCT01109550|Procedure|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
404075|NCT01108510|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
403960|NCT01109524|Drug|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
403961|NCT01109524|Drug|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
403962|NCT01109524|Drug|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
403963|NCT01109511|Drug|naloxone|
403964|NCT01109511|Drug|oxycodone|
403965|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
403966|NCT01109498|Drug|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
403967|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
403968|NCT01109498|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
403969|NCT01109485|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|1-2 drops 4 times per day
403970|NCT01109472|Other|patient magazine|patient magazine individually tailored to patient's prior feedback
403971|NCT01109459|Other|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
403972|NCT01109459|Other|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
403973|NCT01109446|Biological|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
403974|NCT01109446|Procedure|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
403975|NCT01109446|Drug|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
403976|NCT01109381|Drug|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
403977|NCT01109355|Other|lung mechanics ventilatory|To perform the evaluation of lung mechanics ventilatory mode was changed to control volume with the following parameters: tidal volume (Vt) = 8ml/kg weight, peak flow (PF) = 6 x minute volume, fraction of inspired O2 (FiO2) = 40%, respiratory rate (RR) = 16 bpm, sensitivity = 1 cmH2O. The following variables were monitored: PIC, Blood Pressure (BP), heart rate (HR), peak pressure in the airways (pp.) and plateau pressure of the respiratory system (Ppl.), these values were monitored with PEEP = 5 cmH2O. PEEP employed ranged from 0 to 14 cmH2O. To eliminate a possible physiological accommodation by the progressive increase of PEEP, the range of values was determined by drawing a sealed envelope for each patient, ranging from 2 to 2 cmH2O.
403978|NCT01109355|Other|Hemodynamic and intracranial pressure|At each value of PEEP the patient was ventilated for a period of five minutes to carry out monitoring of ICP, BP, HR, PPC and peripheral oxygen saturation (SpO2). The ICP monitoring catheter was kept closed for drainage and open for monitoring, since the arrival of the surgical block, was only open for drainage if there was an increase in ICP above 20 mmHg.
403979|NCT01109329|Biological|HMPV challenge virus|Single dose of 10^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
403980|NCT01109316|Drug|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
403981|NCT01109316|Drug|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
403982|NCT01109316|Drug|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
403983|NCT01109303|Procedure|TightRope System- Arthrex® / Dynamic Implant|Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
403984|NCT01109303|Procedure|Screw fixation - Synthes® / Static Implant|Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
403985|NCT01109264|Drug|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
403986|NCT01109264|Drug|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
403987|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
403988|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.~The auto-measures will be performed according the methodology recommended by HAS."
403989|NCT01109225|Biological|blood sample|
403990|NCT01109225|Procedure|MRI|
403991|NCT01109225|Procedure|echocardiography|
403992|NCT01109225|Biological|urine sample|
403993|NCT01109225|Procedure|pulmonary echography|
403994|NCT01109225|Procedure|vascular check|
403995|NCT01109225|Procedure|renal echography|
403996|NCT01109212|Drug|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
403997|NCT01109212|Drug|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
403998|NCT01109199|Dietary Supplement|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
403999|NCT01109199|Dietary Supplement|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
404000|NCT01109186|Other|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
404076|NCT01108510|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
404001|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
404002|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
404003|NCT01109173|Other|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
404004|NCT01109173|Other|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
404005|NCT01109160|Drug|Azithromycin Dihydrate|"Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.~Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment)."
404006|NCT01109147|Other|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
404007|NCT01109147|Genetic|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
404008|NCT01109134|Drug|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
404009|NCT01109134|Drug|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
404010|NCT01109121|Drug|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
404011|NCT01109121|Drug|Allopurinol|Allopurinol 400 mg, QD
404012|NCT01109121|Drug|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
404013|NCT01109095|Biological|HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:~1 x 10^6/m^2~3 x 10^6/m^2~1 x 10^7/m^2~3 x 10^7/m^2~1 x 10^8/m^2"
404014|NCT01109082|Procedure|posterior spine fusion|vertebrae are fused to straighten a spinal curve
404015|NCT01109069|Drug|PCI-32765|Dose based on parent protocol
404016|NCT01109056|Drug|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
404017|NCT01109056|Drug|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
404018|NCT01109043|Drug|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
404019|NCT01109030|Drug|Pioglitazone+Citalopram+Chlordiazepoxide|"Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
404020|NCT01109030|Drug|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks"
404021|NCT01109017|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
404022|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
404023|NCT01109004|Drug|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
404024|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
404025|NCT01108991|Behavioral|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
404026|NCT01108991|Other|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
404027|NCT01108978|Drug|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
404028|NCT01108978|Drug|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
404029|NCT01108939|Drug|Antimalarial treatment|
404030|NCT01108939|Other|Observation|
404031|NCT01108926|Drug|Atripla®|All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
404032|NCT01108913|Drug|Bimosiamose|
404033|NCT01108913|Drug|Placebo|
404034|NCT01108900|Drug|sildenafil|tables, 25,50,100 mg, on demand, 1 month
404035|NCT01108874|Drug|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
404036|NCT01108861|Device|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
404037|NCT01108861|Device|Plain old balloon angioplasty|Plain old balloon angioplasty
404038|NCT01108848|Biological|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
404039|NCT01108835|Other|Comprehensive care programme|"Intervention group:~Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions~Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)~Respiratory physician assessment and optimization of treatment~Patients will also be taught about a personalized action plan by the physician and respiratory nurse.~Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
404040|NCT01108809|Drug|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
404041|NCT01108783|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
404042|NCT01108783|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
404043|NCT01108783|Drug|Placebo|(encapsulated) Tablets QD/14 days
404044|NCT01108757|Drug|Bactrim|Bactrim DS BID for 3 days
404045|NCT01108757|Other|Placebo|Corn starch capsules
404046|NCT01108744|Drug|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
404047|NCT01108744|Drug|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
404048|NCT01108731|Drug|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
404049|NCT01108731|Drug|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
404050|NCT01108718|Other|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
404051|NCT01108718|Other|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
404052|NCT01108705|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
404053|NCT01108705|Drug|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
404054|NCT01108692|Other|Telecardiology|"Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.~A retrospective analysis will be performed at the end of the study to compare the results in the two groups."
404055|NCT01108666|Drug|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
404056|NCT01108653|Other|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
404057|NCT01108653|Other|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient`s sick-leave and follow-up.
404058|NCT01108627|Drug|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
404059|NCT01108627|Drug|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
404060|NCT01108627|Drug|foradil|open-labeled inhaled corticosteroids (ICS); foradil
404061|NCT01108614|Behavioral|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
404062|NCT01108601|Drug|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
404063|NCT01108588|Drug|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
404064|NCT01108588|Drug|Aspirin|Aspirin 300 mg daily
404065|NCT01108588|Drug|Clopidogrel|Clopidogrel 75 mg daily
404066|NCT01108588|Drug|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
404067|NCT01108575|Other|IMST|inspiratory muscle strength training
404068|NCT01108575|Other|Sham IMST|sham inspiratory muscle strength training
404069|NCT01108562|Drug|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
404070|NCT01108562|Other|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
404071|NCT01108549|Dietary Supplement|Ribose|Ribose 5 grams PO TID was taken daily
404072|NCT01108536|Device|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
404073|NCT01108523|Device|HP828-101|
404074|NCT01108510|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
404077|NCT01108510|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
404078|NCT01108510|Drug|COBI placebo|Placebo to match COBI administered orally once daily
404079|NCT01108510|Drug|RTV placebo|Placebo to match RTV administered orally once daily
404080|NCT01108497|Procedure|Bone Marrow Aspiration|
404081|NCT01108484|Behavioral|Exercise|Supervised exercise: Three 90-minutes sessions per week.
404082|NCT01108484|Behavioral|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
404083|NCT01108484|Behavioral|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
404084|NCT01108458|Drug|Pertuzumab|iv, 840 mg, 420 mg
404085|NCT01108458|Drug|Erlotinib|PO, 150 mg
404086|NCT01108445|Drug|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
404087|NCT01108445|Drug|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
404088|NCT01108432|Other|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
404089|NCT01108419|Other|Fermented dairy product|
404090|NCT01108419|Other|milk-based non-fermented dairy product|
404091|NCT01108406|Device|Sonitus SoundBite System|Non Surgical Bone Conduction Device
404092|NCT01108406|Device|SoundBite Hearing System|
404093|NCT01108393|Drug|Agomelatine A|"Agomelatine 25 mg film-coated tablet~Agomelatine 2x25mg film-coated tablet"
404094|NCT01108393|Drug|Placebo|Placebo
404095|NCT01108380|Procedure|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
404096|NCT01108341|Drug|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
404097|NCT01108341|Drug|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
404098|NCT01108328|Dietary Supplement|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
404099|NCT01108315|Other|Report symptoms via web or phone-based system|The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
404100|NCT01108302|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
404101|NCT01108289|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
404102|NCT01108276|Device|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
404103|NCT01108263|Drug|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
404104|NCT01108250|Genetic|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
404105|NCT01108237|Other|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
404106|NCT01108237|Device|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
404107|NCT01108224|Behavioral|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
404108|NCT01108211|Device|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
404109|NCT01108198|Drug|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
404110|NCT01108198|Drug|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
404111|NCT01108172|Other|Virtual Ward|A multidisciplinary team to optimize medical and social care for patients residing in their own homes
404112|NCT01108172|Other|Usual care|The usual care provided to patients after discharge from hospital
404113|NCT01108159|Procedure|Blood Draw|
404114|NCT01108159|Procedure|Skin Biopsy|
404115|NCT01108146|Drug|Arm 1 Hydrocortisone 10 mg|"Group 1: Administration of Hydrocortisone and/or Placebo in the following order:~1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone"
404116|NCT01108146|Drug|Arm 2 Hydrocortisone 30 mg|"Drug: Hydrocortisone 30 mg~Group 2: Administration of Hydrocortisone and/or Placebo in the following order:~1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
404117|NCT01108133|Drug|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
404118|NCT01108133|Drug|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
404119|NCT01108133|Drug|Placebo|Placebo
404555|NCT01105130|Dietary Supplement|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
404120|NCT01108120|Drug|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
404121|NCT01108120|Drug|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
404122|NCT01108107|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
404123|NCT01108107|Drug|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
404124|NCT01108107|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
404125|NCT01108107|Drug|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
404126|NCT01108107|Biological|Panitumumab|9 mg/kg intravenously on day 1 of a 3-weekly cycle
404127|NCT01108094|Drug|Itraconazole|"Cohort A: oral itraconazole 400 mg as 200 mg twice daily; for 1 month~Cohort B: oral itraconazole 200 mg as 100 mg twice daily; for up to 3 months"
404128|NCT01108081|Behavioral|Physical activity|Moderate-intensity physical activity
404129|NCT01108081|Behavioral|Diet|Dietary weight loss
404130|NCT01108081|Behavioral|Health education|Attention control intervention
404131|NCT01108068|Drug|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
404132|NCT01108055|Drug|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
404133|NCT01108055|Drug|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
404134|NCT01108042|Drug|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
404135|NCT01108029|Drug|memantine|2 tablets of 10 mg of memantine 1 time a day in the morning
404136|NCT01108029|Drug|placebo|2 tablets of placebo 1 time a day in the morning
404137|NCT01108016|Behavioral|Videoconferencing support group|
404138|NCT01108003|Drug|broccoli sprout extract|Given orally
404139|NCT01108003|Other|laboratory biomarker analysis|Correlative studies
404140|NCT01108003|Other|Mango Juice|given orally
404141|NCT01107977|Behavioral|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
404142|NCT01107964|Drug|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
404143|NCT01107964|Drug|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
404144|NCT01107951|Drug|Rituximab and dexamethasone|"Rituximab 100mg IV days 1,8,15,22.~Dexamethasone 40mg PO days 1-4 (four days)"
404145|NCT01107938|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
404146|NCT01107938|Drug|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
404147|NCT01107938|Drug|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
404148|NCT01107925|Drug|prasugrel|Administered orally, daily for 12 days
404149|NCT01107925|Drug|clopidogrel|Administered orally, daily for 12 days
404150|NCT01107912|Drug|prasugrel|administered orally, daily for 12 days
404151|NCT01107912|Drug|clopidogrel|Administered orally, daily for 12 days
404152|NCT01107899|Drug|clopidogrel|taken orally, day one, single dose
404153|NCT01107899|Drug|prasugrel|taken orally, day one, single dose
404154|NCT01107886|Drug|Saxagliptin|5 mg or 2.5 mg once daily
404155|NCT01107886|Drug|Placebo|
404156|NCT01107860|Device|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
404157|NCT01107860|Device|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
404158|NCT01107847|Procedure|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
404159|NCT01107821|Device|Engenex™ pump and Bio-Dome™ Wound Dressing|Engenex™ pump and Bio-Dome™ Wound Dressing is used.
404160|NCT01107808|Drug|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
404161|NCT01107808|Drug|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
404162|NCT01107795|Procedure|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
404163|NCT01107782|Drug|sildenafil|50 mg TDS orally until birth
404164|NCT01107782|Drug|placebo|50mg tid
404165|NCT01107756|Drug|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
404197|NCT01107509|Drug|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
404198|NCT01107496|Drug|SPN-812|Viloxazine, oral, 300mg, tid, 6 weeks
404199|NCT01107496|Drug|Placebo|Placebo, oral, tid, 6 weeks
404166|NCT01107743|Drug|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.~Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.~For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.~Amlodipine~Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.~Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin~Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.~Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
404167|NCT01107730|Drug|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
404168|NCT01107730|Drug|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
404169|NCT01107730|Drug|Placebo|Placebo
404170|NCT01107717|Drug|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c < 6.5%
404171|NCT01107717|Drug|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c < 6.5%
404172|NCT01107704|Behavioral|Family Support Intervention|Multifaceted family support intervention
404173|NCT01107691|Other|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
404174|NCT01107678|Other|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
404175|NCT01107665|Drug|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
404176|NCT01107639|Biological|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
404177|NCT01107639|Drug|cisplatin|"Cisplatin 75 mg/m2 1h infusion d1, 22~Cisplatin 25 mg/m2 1h infusion weekly x5"
404178|NCT01107639|Drug|docetaxel|"Docetaxel 75 mg/m2 1h infusion d1, 22~Docetaxel 20 mg/m2 1/2h infusion weekly x5"
404179|NCT01107639|Procedure|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
404180|NCT01107639|Procedure|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
404181|NCT01107626|Biological|bevacizumab|Given IV
404182|NCT01107626|Drug|pemetrexed disodium|Given IV
404183|NCT01107613|Other|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader letter sent to the primary care provider outlining the needs of this patient.
404184|NCT01107600|Procedure|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
404185|NCT01107587|Biological|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
404186|NCT01107587|Biological|Placebo|Oral, two doses.
404187|NCT01107574|Drug|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
404188|NCT01107574|Procedure|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
404189|NCT01107574|Other|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
404190|NCT01107561|Other|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
404191|NCT01107561|Device|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
404192|NCT01107548|Other|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
404193|NCT01107535|Biological|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
404194|NCT01107522|Drug|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
404195|NCT01107522|Drug|CTO and Temodar®|"Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle"
404196|NCT01107522|Drug|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
404200|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
404201|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
404202|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
404203|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
404204|NCT01107457|Biological|Ixekizumab|Administered subcutaneously
404205|NCT01107457|Drug|Placebo|Administered subcutaneously
404206|NCT01107444|Drug|Docetaxel|Administered intravenously
404207|NCT01107444|Drug|LY2181308|Administered intravenously
404208|NCT01107431|Dietary Supplement|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
404209|NCT01107431|Dietary Supplement|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
404210|NCT01107418|Drug|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
404211|NCT01107418|Drug|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
404212|NCT01107418|Drug|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
404213|NCT01107418|Drug|RO5185426|960 mg orally twice daily, from day 22 onward
404214|NCT01107418|Drug|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
404215|NCT01107405|Drug|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
404216|NCT01107405|Drug|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
404217|NCT01107405|Drug|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
404218|NCT01107405|Drug|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
404219|NCT01107405|Drug|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
404220|NCT01107392|Drug|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
404221|NCT01107392|Drug|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
404222|NCT01107379|Device|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
404223|NCT01107366|Procedure|lupiae technique|it's a new hybrid technique for the treatment of aortic aneurism and dissection.
404224|NCT01107366|Procedure|lupiae technique|"LUPIAE technique~Hybrid repair of thoracic or thoraco-abdominal aneurysms of different etiology and type A dissections with a two-stage procedure:~surgical arch reconstruction with a Dacron multibranched surgical prothesis~endovascular implantation of a thoracic stent graft"
404225|NCT01107353|Drug|Imipramine Pamoate|75 mg capsule
404226|NCT01107340|Device|AMIStem Hip System|
404227|NCT01107327|Procedure|FDG-PET/CT|"The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer light up on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also lights up in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project."
404228|NCT01107314|Other|Phlebotomy|Blood draws (total 48 cc blood)
404229|NCT01107288|Other|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
404230|NCT01107288|Other|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
404231|NCT01107275|Biological|rabies vaccine|intradermal vaccination
404232|NCT01107249|Device|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
404233|NCT01107236|Drug|IW-6118|Single dose
404234|NCT01107236|Drug|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
404235|NCT01107236|Drug|Naproxen Sodium|Single dose
404236|NCT01107223|Other|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
404237|NCT01107223|Other|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
404238|NCT01107197|Dietary Supplement|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
404239|NCT01107197|Dietary Supplement|Control formula|Isonitrogenous isocaloric oral formula
404240|NCT01107184|Procedure|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
404241|NCT01107184|Procedure|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
404242|NCT01107171|Drug|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
404243|NCT01107171|Drug|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
404244|NCT01107171|Drug|Placebo|Tang-min-Ling pills analogue 6g,tid,po
404245|NCT01107158|Biological|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
404246|NCT01107145|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
404247|NCT01107145|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
404248|NCT01107145|Drug|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
404249|NCT01107119|Other|integrated care pathway|communication and follow-up program for integrated care
404250|NCT01107119|Other|usual care|
404251|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
404252|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
404253|NCT01107093|Drug|CDB-2914 (ulipristal acetate)|single oral dose of 30 mg
404254|NCT01107093|Drug|Placebo|single oral dose
404255|NCT01107067|Drug|Sustanon|250 mg/21 days
404256|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
404257|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
404258|NCT01107054|Drug|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
404259|NCT01107054|Drug|placebo|A single oral dose of non-matched placebo on Day 4.
404260|NCT01107041|Behavioral|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
404261|NCT01107028|Other|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
404262|NCT01107015|Device|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
404263|NCT01107015|Device|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
404264|NCT01107015|Device|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
404265|NCT01107002|Procedure|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
404266|NCT01106989|Drug|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
404267|NCT01106963|Procedure|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
404268|NCT01106950|Biological|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is < or = 8 x 10^7 nucleated cells/kilogram.
404269|NCT01106950|Drug|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
404270|NCT01106950|Drug|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
404271|NCT01106950|Drug|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
404272|NCT01106950|Procedure|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
404273|NCT01106950|Drug|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m^2 every other day for 6 doses).
404274|NCT01106924|Other|Probiotic|daily probiotic consumption
404275|NCT01106924|Other|Placebo|daily placebo consumption
404276|NCT01106911|Device|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
404277|NCT01106898|Drug|cyclophosphamide|Given IV
404278|NCT01106898|Drug|paclitaxel|Given IV
404279|NCT01106898|Biological|trastuzumab|Given IV
404280|NCT01106898|Other|laboratory biomarker analysis|Correlative studies
404281|NCT01106885|Behavioral|Medication Care Management (MCM)|"Basic physical activity counseling~Notify PCP and facilitate initiation of antidepressants~Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks*~1/mo monitoring in continuation phase (mos. 4-12)*~Report & recommendations to PCP after each patient call~Note: *average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
404282|NCT01106885|Behavioral|Cognitive-Behavioral Therapy (CBT)|"Notify PCP~CBT Manual~Weekly CBT focused counseling for 12 weeks**~Monthly CBT in months 4-12**~Behavioral physical activity counseling~Report & recommendations to PCP after each patient call~Note: **average of 50 minutes of telephone time each"
404283|NCT01106872|Drug|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
404284|NCT01106859|Drug|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
404285|NCT01106859|Drug|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
404286|NCT01106859|Drug|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
404287|NCT01106859|Drug|Placebo|Placebo matching zopiclone
404288|NCT01106846|Drug|Group A: Saline Group|Saline continuous infusion
404289|NCT01106846|Drug|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
404290|NCT01106833|Drug|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
404291|NCT01106833|Drug|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.~Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
404292|NCT01106820|Other|Supervised progressive resistance training|Supervised progressive resistance training
404293|NCT01106820|Other|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
404294|NCT01106807|Drug|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
404295|NCT01106807|Drug|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
404296|NCT01106807|Drug|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
404297|NCT01106807|Drug|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
404298|NCT01106755|Device|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
404299|NCT01106755|Device|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
404300|NCT01106742|Dietary Supplement|AndoSan|AndoSan, 20mlx3, 12 days
404301|NCT01106729|Dietary Supplement|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
404302|NCT01106716|Drug|Placebo|Placebo IV Infusion
404303|NCT01106716|Drug|KAI-1678|KAI-1678 IV Infusion
404304|NCT01106716|Drug|Lidocaine|Lidocaine
404305|NCT01106703|Dietary Supplement|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
404306|NCT01106703|Other|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
404307|NCT01106690|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
404308|NCT01106690|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
404309|NCT01106690|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
404310|NCT01106690|Drug|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
404311|NCT01106690|Drug|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
404312|NCT01106677|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
404313|NCT01106677|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
404314|NCT01106677|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
404315|NCT01106677|Drug|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
404316|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
404317|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
404318|NCT01106651|Drug|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
404319|NCT01106651|Drug|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
404320|NCT01106651|Drug|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, metformin, insulin [all types]) and their combinations (sulfonylurea agent and insulin [all types], metformin and insulin [all types], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]) are used as per protocol specifications.
404321|NCT01106651|Drug|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
404322|NCT01106638|Behavioral|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
404323|NCT01106638|Behavioral|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
404324|NCT01106625|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
404325|NCT01106625|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
404326|NCT01106625|Drug|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
404327|NCT01106625|Drug|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
404328|NCT01106612|Procedure|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
404329|NCT01106612|Procedure|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
404330|NCT01106599|Drug|GDC-0623|Repeating oral dose
404331|NCT01106586|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
404332|NCT01106586|Drug|ATV|Atazanavir 300 mg capsule administered orally once daily
404333|NCT01106586|Drug|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
404334|NCT01106586|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
404335|NCT01106586|Drug|Stribild Placebo|Placebo to match Stribild administered orally once daily
404336|NCT01106586|Drug|ATV Placebo|Placebo to match ATV administered orally once daily
404337|NCT01106586|Drug|RTV Placebo|Placebo to match RTV administered orally once daily
404338|NCT01106586|Drug|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
404339|NCT01106560|Procedure|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
404340|NCT01106560|Procedure|Standard postero-lateral approach|
404341|NCT01106547|Drug|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
404342|NCT01106547|Drug|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
404343|NCT01106534|Drug|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
404344|NCT01106534|Drug|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
404345|NCT01106534|Device|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
404346|NCT01106521|Radiation|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
404347|NCT01106508|Drug|LEQ506|
404348|NCT01106495|Device|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
404349|NCT01106495|Drug|Simvastatin|Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
404350|NCT01106482|Other|Serology blood draw|Blood draw only, no vaccine
404351|NCT01106469|Drug|JNJ-41443532|25mg tablet once daily
404352|NCT01106469|Drug|JNJ-41443532|250mg tablet once daily
404353|NCT01106469|Drug|JNJ-41443532|1500mg once daily (with 250mg tablets)
404354|NCT01106469|Drug|JNJ-41443532|100mg tablet once daily
404355|NCT01106469|Drug|JNJ-41443532|1000mg once daily (with 250mg tablets)
404356|NCT01106469|Drug|Placebo|Matching placebo
404357|NCT01106469|Drug|JNJ-41443532|500mg once daily (with 250mg tablets)
404358|NCT01106456|Behavioral|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
404359|NCT01106456|Behavioral|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
404360|NCT01106456|Drug|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
404405|NCT01106014|Drug|Placebo|Placebo tablets matching selexipag
404361|NCT01106443|Procedure|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
404362|NCT01106443|Procedure|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
404363|NCT01106443|Procedure|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
404364|NCT01106443|Procedure|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
404365|NCT01106430|Drug|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
404366|NCT01106430|Drug|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
404367|NCT01106417|Procedure|NeoFuse|Single Dose NeoFuse Surgical Implantation
404368|NCT01106417|Procedure|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
404369|NCT01106404|Device|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
404370|NCT01106391|Device|"Cordis AAA stent graft system INCRAFT TM"|
404371|NCT01106365|Device|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
404372|NCT01106352|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
404373|NCT01106352|Drug|Docetaxel|Docetaxel (75 mg/m^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
404374|NCT01106326|Behavioral|Intervention|"Teens participating in this study will have:~directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study~three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
404375|NCT01106287|Drug|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
404376|NCT01106287|Drug|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
404377|NCT01106274|Radiation|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
404378|NCT01106261|Procedure|Metastasectomy|Pulmonary Metastasectomy
404379|NCT01106261|Procedure|Active monitoring|Active monitoring
404380|NCT01106248|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
404381|NCT01106235|Biological|therapeutic autologous lymphocytes|Given IV
404382|NCT01106235|Biological|aldesleukin|Given SC
404383|NCT01106235|Drug|cyclophosphamide|Given IV
404384|NCT01106235|Procedure|biopsy|Optional correlative studies
404385|NCT01106183|Dietary Supplement|transfer factor|capsules, 2 per day by mouth for 7 weeks.
404386|NCT01106183|Dietary Supplement|Placebo|cornstarch, 2 capsules per day by mouth.
404387|NCT01106170|Drug|Provex CV|dietary supplement, 2 capsules per day by mouth
404388|NCT01106170|Other|placebo|corn starch, 2 capsules per day by mouth
404389|NCT01106157|Drug|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
404390|NCT01106157|Drug|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
404391|NCT01106157|Drug|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
404392|NCT01106131|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
404393|NCT01106131|Drug|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
404394|NCT01106118|Drug|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
404395|NCT01106092|Biological|GSK2036874A vaccine|Intramuscular, single dose
404396|NCT01106092|Biological|Zilbrix™/Hib vaccine|Intramuscular, single dose
404397|NCT01106092|Biological|Poliorix™|Intramuscular, single dose
404398|NCT01106079|Drug|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
404399|NCT01106079|Drug|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
404400|NCT01106066|Drug|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
404401|NCT01106053|Drug|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
404402|NCT01106040|Drug|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
404403|NCT01106027|Drug|Eculizumab|Eculizumab 900 mg and 1200 mg, administered intravenously (IV)
404404|NCT01106014|Drug|Selexipag|Selexipag 200 µg tablets
404406|NCT01106001|Drug|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
404407|NCT01106001|Drug|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
404408|NCT01105988|Other|Radiologic exams|FLT PET scan x 2 MRI scan x 2
404409|NCT01105975|Drug|LY2484595|Administered daily by mouth for 12 weeks
404410|NCT01105975|Drug|Atorvastatin|Administered daily by mouth for 12 weeks
404411|NCT01105975|Drug|Simvastatin|Administered daily by mouth for 12 weeks
404412|NCT01105975|Drug|Rosuvastatin|Administered daily by mouth for 12 weeks
404413|NCT01105975|Drug|Placebo for LY2484595|Administered daily by mouth for 12 weeks
404414|NCT01105975|Drug|Placebo for Statins|Administered daily by mouth for 12 weeks
404415|NCT01105949|Device|Marketed nasal strip|Marketed nasal strip
404416|NCT01105949|Device|NexGen AB 2R11|Nasal strip prototype
404417|NCT01105949|Device|NexGen JB Organic PET/PE|Nasal strip
404418|NCT01105936|Drug|Paracetamol|665 mg sustained release paracetamol caplets
404419|NCT01105936|Drug|Placebo|Placebo caplets
404420|NCT01105923|Other|MAPLE|MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
404421|NCT01105910|Other|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
404422|NCT01105910|Other|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
404423|NCT01105897|Procedure|Endometriosis surgery|Complete surgical excision of all visible endometriosis by multidisciplinary approach
404424|NCT01105884|Procedure|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
404425|NCT01105884|Procedure|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
404426|NCT01105884|Procedure|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
404427|NCT01105884|Procedure|Hydrogel|All the subjects in this group will be treated with Hydrogel
404428|NCT01105884|Procedure|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
404429|NCT01105871|Drug|naloxone|4 mg naloxone in 10 ml saline given iv bolus
404430|NCT01105871|Drug|Placebo|10 ml of normal saline iv bolus
404431|NCT01105832|Drug|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
404432|NCT01105819|Procedure|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
404433|NCT01105819|Procedure|Chlorhexidine for standard oral care|"A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).~This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day"
404434|NCT01105806|Behavioral|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
404435|NCT01105806|Behavioral|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
404436|NCT01105793|Drug|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
404437|NCT01105780|Drug|Placebo|Matching placebo
404438|NCT01105780|Drug|JNJ-41443532|250mg tablet once daily for 1 day
404439|NCT01105767|Drug|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
404440|NCT01105767|Other|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
404441|NCT01105754|Behavioral|Multifaceted Prompting Intervention MPI|"Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.~Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form."
404442|NCT01105728|Procedure|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
404443|NCT01105702|Drug|Temozolomide|
404444|NCT01105702|Drug|Bevacizumab|
404445|NCT01105702|Drug|Lithium Carbonate|
404446|NCT01105702|Radiation|Radiation|
404447|NCT01105676|Procedure|skin biopsy|Two skin biopsies will be taken one time
404554|NCT01105130|Dietary Supplement|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
404448|NCT01105663|Other|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
404449|NCT01105650|Drug|Fludarabine|Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).
404450|NCT01105650|Drug|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
404451|NCT01105650|Drug|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
404452|NCT01105650|Biological|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10^7 cells/kg will be given.
404453|NCT01105650|Drug|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m^2 3 times per week for 6 doses).
404454|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
404455|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
404456|NCT01105650|Drug|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m^2 3 times per week for 6 doses).
404457|NCT01105637|Behavioral|Augmented Exercise Program|12 week (3 x per week) exercise prescription
404458|NCT01105624|Drug|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
404459|NCT01105624|Drug|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
404460|NCT01105611|Drug|Raltegravir|400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
404461|NCT01105611|Drug|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
404462|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
404463|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
404464|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
404465|NCT01105585|Device|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
404466|NCT01105585|Device|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
404467|NCT01105572|Device|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
404468|NCT01105572|Other|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
404469|NCT01105546|Drug|recombinant activated factor VII|90 µg/kg/day i.v.
404470|NCT01105546|Drug|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
404471|NCT01105533|Drug|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
404472|NCT01105533|Drug|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
404473|NCT01105533|Drug|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
404474|NCT01105533|Drug|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
404475|NCT01105533|Drug|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
404476|NCT01105533|Drug|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
404477|NCT01105533|Drug|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
404478|NCT01105533|Drug|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
404479|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
404480|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
404481|NCT01105520|Procedure|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
404482|NCT01105507|Drug|canakinumab (company code: ACZ885D)|
404483|NCT01105494|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
404484|NCT01105481|Drug|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
404485|NCT01105481|Drug|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
404486|NCT01105468|Device|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
404487|NCT01105468|Device|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
404488|NCT01105455|Other|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
404489|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
404490|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
404491|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
404492|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
404493|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
404494|NCT01105429|Drug|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
404495|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
404496|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
404497|NCT01105429|Drug|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
404498|NCT01105429|Drug|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
404499|NCT01105429|Drug|Placebo|Capsule, Oral, (TBD), once daily, 2 days
404500|NCT01105416|Behavioral|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
404501|NCT01105416|Behavioral|ESC|Enhanced standard care
404502|NCT01105403|Drug|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
404503|NCT01105390|Biological|rilotumumab|Given IV
404504|NCT01105390|Drug|cisplatin|Given IV
404505|NCT01105390|Drug|pemetrexed disodium|Given IV
404506|NCT01105390|Other|laboratory biomarker analysis|Correlative studies
404507|NCT01105377|Drug|entinostat|Given orally
404508|NCT01105377|Drug|azacitidine|Given SC
404509|NCT01105377|Other|laboratory biomarker analysis|Correlative studies
404510|NCT01105364|Drug|antiangiogenesis therapy|
404511|NCT01105364|Drug|stabilized sulphur hexafluoride microbubble-based contrast agent|
404512|NCT01105364|Other|imaging biomarker analysis|
404513|NCT01105364|Other|pharmacological study|
404514|NCT01105364|Procedure|computed tomography|
404515|NCT01105364|Procedure|magnetic resonance imaging|
404516|NCT01105351|Dietary Supplement|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
404517|NCT01105351|Dietary Supplement|folic acid|folic acid 400 µg
404518|NCT01105338|Behavioral|Green tea drink|Green tea drink
404519|NCT01105338|Dietary Supplement|green tea capsules|green tea capsules
404520|NCT01105338|Other|Green tea placebo capsules|Green tea placebo capsules
404521|NCT01105338|Dietary Supplement|Lycopene capsules|Lycopene capsules
404522|NCT01105338|Other|Lycopene placebo capsules|Lycopene placebo capsules
404523|NCT01105338|Other|Tomato rich diet|Tomato rich diet
404524|NCT01105312|Drug|letrozole|
404525|NCT01105312|Drug|panobinostat|
404526|NCT01105312|Genetic|RNA analysis|
404527|NCT01105312|Genetic|microarray analysis|
404528|NCT01105312|Genetic|reverse transcriptase-polymerase chain reaction|
404529|NCT01105312|Other|enzyme-linked immunosorbent assay|
404530|NCT01105312|Other|immunohistochemistry staining method|
404531|NCT01105312|Other|laboratory biomarker analysis|
404532|NCT01105299|Drug|CJ anastrozole 1 mg tablet|
404533|NCT01105286|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
404534|NCT01105273|Biological|anti-thymocyte globulin|On days -3 to -1
404535|NCT01105273|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
404536|NCT01105273|Drug|Fludarabine|30mg/M2 once daily IV on days -6 to -2
404537|NCT01105273|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
404538|NCT01105273|Procedure|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
404539|NCT01105247|Drug|PCI-32765|420 mg daily or 840 mg daily
404540|NCT01105234|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
404541|NCT01105221|Device|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
404542|NCT01105221|Drug|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
404543|NCT01105208|Drug|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
404544|NCT01105208|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
404545|NCT01105195|Other|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
404546|NCT01105195|Other|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
404547|NCT01105182|Procedure|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
404548|NCT01105169|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
404549|NCT01105169|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
404550|NCT01105156|Behavioral|VEW Questionnaire|Patient Self reported questionnaire filled in.
404551|NCT01105143|Behavioral|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
404552|NCT01105143|Behavioral|placebo|no intervention, only follow up
404553|NCT01105130|Other|Placebo|Given orally
404596|NCT01104792|Drug|Cariprazine|Cariprazine was supplied in capsules.
404558|NCT01105104|Device|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
404559|NCT01105104|Device|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
404560|NCT01105091|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
404561|NCT01105091|Drug|Flolan®|Per Prescribing Information
404562|NCT01105078|Procedure|Flow rate|Different flow rate during cardiopulmonary bypass
404563|NCT01105065|Drug|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
404564|NCT01105052|Behavioral|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
404565|NCT01105026|Device|Alveolar Bone Defect Regeneration Following Tooth Extraction|"Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.~Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed."
404566|NCT01105013|Drug|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
404567|NCT01104987|Drug|alendronate|One tablet of alendronate à 70 mg once a week during two years.
404568|NCT01104961|Device|Contact lens packaging solution|These test solutions are the intervention being tested.
404569|NCT01104961|Device|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
404570|NCT01104948|Drug|DA-8031|
404571|NCT01104948|Drug|Placebo|
404572|NCT01104935|Drug|trastuzumab monotherapy|
404573|NCT01104935|Drug|trastuzumab and chemotherapy|
404574|NCT01104922|Other|Cetuximab and stereotactic radiosurgery|Treatments Administered: - Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy); - Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: * Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) * Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery. Administration of cetuximab may or not be the same day that a fraction of SRS is given. Infusion reactions may occurring during the administration of cetuximab and rarely post-infusion.
404575|NCT01104909|Procedure|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
404576|NCT01104909|Device|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
404577|NCT01104896|Drug|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
404578|NCT01104896|Drug|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
404579|NCT01104883|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
404580|NCT01104883|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
404581|NCT01104870|Drug|UT-15C|oral
404582|NCT01104857|Procedure|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
404583|NCT01104857|Procedure|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
404584|NCT01104844|Drug|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
404585|NCT01104844|Drug|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
404586|NCT01104844|Drug|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
404587|NCT01104844|Drug|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
404588|NCT01104844|Drug|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
404589|NCT01104844|Drug|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
404590|NCT01104844|Drug|Placebo|2 placebo tablets
404591|NCT01104831|Device|Cryotherapy|cooled sleeve placed over fracture site.
404592|NCT01104831|Device|Room temperature cuff|sleeve with room temperature water placed over fracture site.
404593|NCT01104818|Behavioral|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
404594|NCT01104805|Behavioral|Therapeutic Education System (TES)|Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
404595|NCT01104805|Behavioral|Treatment-as-Usual (TAU)|Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
404597|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
404598|NCT01104779|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
404599|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
404600|NCT01104766|Drug|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
404601|NCT01104766|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
404602|NCT01104740|Other|Biological sample collection|Blood (serum) sample collection
404603|NCT01104727|Procedure|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
404604|NCT01104727|Procedure|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.~In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
404605|NCT01104701|Drug|exenatide once weekly|subcutaneous injection, 2 mg, once a week
404606|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
404607|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
404608|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
404609|NCT01104675|Drug|ENMD-2076|275 mg (or 250 mg for BSA < 1.65) per day in oral capsules in 28 day continuous cycles
404610|NCT01104662|Drug|Vancomycin|
404611|NCT01104662|Drug|Daptomycin|
404612|NCT01104662|Drug|Semi-Synthetic Penicillin|
404613|NCT01104649|Drug|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
404614|NCT01104649|Drug|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
404615|NCT01104636|Drug|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
404616|NCT01104610|Device|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
404617|NCT01104597|Procedure|Flow Mediated Doppler (FMD)|Non-invasive assessment of flow-mediated dilation (FMD) will be performed using brachial artery ultrasound.
404618|NCT01104597|Drug|Nitroglycerin 0.4 mg sublingual|Nitroglycerin 0.4 mg (a small tablet that dissolves under the tongue) will be given to dilate the arteries. Images of the arm will be recorded via non-invasive flow-mediated doppler for 5 minutes to assess for endothelium dysfunction. as outlined above.
404619|NCT01104584|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
404620|NCT01104571|Biological|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery
404621|NCT01104571|Drug|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.~Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
404622|NCT01104571|Other|laboratory biomarker analysis|
404623|NCT01104571|Procedure|adjuvant therapy|
404624|NCT01104571|Procedure|neoadjuvant therapy|
404625|NCT01104571|Procedure|therapeutic conventional surgery|therapeutic conventional surgery
404626|NCT01104558|Drug|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
404627|NCT01104545|Drug|MK-3614|
404628|NCT01104545|Drug|Comparator: Placebo|
404629|NCT01104532|Drug|ASP1941|oral tablet
404630|NCT01104532|Drug|sitagliptin|oral tablet
404631|NCT01104519|Drug|Niaspan|Oral doses of 2000 mg of Niaspan once daily for 7 days.
404632|NCT01104519|Drug|Comparator: Placebo|Oral doses of placebo once daily for 7 days.
404633|NCT01104506|Procedure|fMRI|
404634|NCT01104506|Procedure|mTMS|
404635|NCT01104493|Biological|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
404636|NCT01104493|Other|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
404637|NCT01104480|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
404638|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
404639|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
404640|NCT01104467|Other|Placebo|1 bolus injection of placebo IV
404641|NCT01104428|Drug|Placebo|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
404642|NCT01104428|Drug|"ziying granules"|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
404643|NCT01104415|Drug|Telotristat etiprate|Telotristat etiprate capsules orally three times daily.
404644|NCT01104402|Device|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
404645|NCT01104389|Device|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
404646|NCT01104376|Drug|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
404647|NCT01104376|Drug|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
404648|NCT01104363|Procedure|Snow white plaster 2|Test. Plaster impression not splinted.
404649|NCT01104363|Procedure|Primopattern LC gel + PVS|Control PVS impression
404650|NCT01104350|Other|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.~Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)~Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)~Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
404651|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
404652|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
404653|NCT01104337|Drug|Placebo|Treatment consisted of two matching placebo tablets three times a day.
404654|NCT01104311|Procedure|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
404655|NCT01104311|Procedure|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
404656|NCT01104298|Drug|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
404657|NCT01104298|Drug|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
404658|NCT01104272|Device|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
404659|NCT01104259|Drug|veliparib|Given PO
404660|NCT01104259|Drug|cisplatin|Given IV
404661|NCT01104259|Drug|vinorelbine tartrate|Given IV
404662|NCT01104259|Other|laboratory biomarker analysis|Correlative studies
404663|NCT01104259|Other|pharmacological study|Correlative studies
404664|NCT01104246|Drug|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
404665|NCT01104233|Device|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
404666|NCT01104220|Other|Weight loss|Bariatric surgery-induced weight loss to achieve ~20%-30% reduction in initial body weight
404667|NCT01104207|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
404668|NCT01104207|Device|placebo rTMS|placebo rTMS
404669|NCT01104194|Dietary Supplement|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
404670|NCT01104194|Dietary Supplement|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
404671|NCT01104181|Device|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
404672|NCT01104155|Drug|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
404673|NCT01104155|Drug|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
404674|NCT01104142|Device|CGM|Continuous Glucose Monitoring System
404675|NCT01104116|Radiation|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
404676|NCT01104103|Device|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
404677|NCT01104103|Device|Standard elastic constricting band|Standard therapy
404678|NCT01104090|Device|C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and later indirect laryngoscopy
404679|NCT01104090|Device|C-MAC Indirect laryngoscopy|Patients for this arm will be intubated with C-MAC using indirect technique
404680|NCT01104064|Device|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
404681|NCT01104064|Device|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
404682|NCT01104038|Behavioral|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
404683|NCT01104038|Behavioral|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
404684|NCT01104038|Behavioral|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
404685|NCT01104025|Drug|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
404686|NCT01104025|Drug|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
404687|NCT01104025|Drug|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
404688|NCT01104025|Drug|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
404689|NCT01104025|Drug|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
404690|NCT01104012|Biological|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
404691|NCT01104012|Biological|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
404692|NCT01103986|Behavioral|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
404693|NCT01103986|Behavioral|Control Group|No intervention
404694|NCT01103973|Behavioral|Mind/Body Program|Ten week group mind/body program
404695|NCT01103973|Behavioral|Control|Spa gift certificates
404696|NCT01103960|Drug|Telmisartan80mg+Amlodipine5mg|combination therapy
404697|NCT01103960|Drug|amlodipine 5mg|monotherapy
404698|NCT01103960|Drug|Telmisartan80mg+Amlodipine 5mg|combination therapy
404699|NCT01103947|Device|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
404700|NCT01103947|Device|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
404701|NCT01103947|Device|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
404702|NCT01103947|Device|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
404703|NCT01103934|Drug|Vitamin D3|4000 IU once daily
404704|NCT01103934|Drug|Placebo|Placebo taken once daily
404705|NCT01103934|Drug|Fluticasone Propionate|200 mcg daily, intranasal
404706|NCT01103921|Other|Glucose|25% dose at 2-week intervention assigned to subjects.
404707|NCT01103921|Other|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
404708|NCT01103921|Other|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
404709|NCT01103921|Other|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
404710|NCT01103908|Device|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
404711|NCT01103856|Behavioral|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
404712|NCT01103856|Behavioral|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
404713|NCT01103843|Drug|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
404714|NCT01103843|Drug|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
404834|NCT01103037|Drug|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
404835|NCT01103024|Biological|AIN457|
404836|NCT01103024|Biological|AIN457|
404715|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
404716|NCT01103830|Drug|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
404717|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
404718|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
404719|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
404720|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.~1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
404721|NCT01103817|Dietary Supplement|Vitamin D|"Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.~If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily."
404722|NCT01103791|Drug|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
404723|NCT01103778|Drug|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle).
404724|NCT01103765|Procedure|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
404725|NCT01103765|Procedure|stent deployment without post-dilatation|stent deployment without systematic post dilatation
404726|NCT01103752|Other|no intervention, descriptive study|no intervention, descriptive study
404727|NCT01103739|Drug|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
404728|NCT01103739|Drug|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
404729|NCT01103739|Drug|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
404730|NCT01103739|Drug|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
404731|NCT01103726|Drug|PF-02545920|1 and 5 mg tablets, 6 mg single dose
404732|NCT01103726|Drug|placebo|matching placebo tablets, single dose
404733|NCT01103726|Drug|PF-02545920|1 mg tablets, 3 mg single dose
404734|NCT01103726|Drug|PF-02545920|5 mg tablets, 15 mg single dose
404735|NCT01103726|Drug|Placebo|matching placebo tablets, single dose
404736|NCT01103713|Drug|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
404737|NCT01103687|Biological|Ad26.ENVA.01 (rAd26)|5 x 10^10 virus particles (VP) vaccine delivered intramuscularly (IM)
404738|NCT01103687|Biological|Placebo Vaccine|Placebo vaccine delivered IM
404739|NCT01103674|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
404740|NCT01103661|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
404741|NCT01103648|Drug|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
404742|NCT01103648|Drug|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
404743|NCT01103648|Drug|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study."
404744|NCT01103635|Biological|CD40 agonist monoclonal antibody CP-870,893|Given IV
404745|NCT01103635|Biological|tremelimumab|Given IV
404746|NCT01103635|Other|laboratory biomarker analysis|Correlative studies
404747|NCT01103622|Drug|AZD1656|Oral tablet bd, step-wise increased dosage
404748|NCT01103622|Drug|Digoxin|Oral tablet od on Day 4
404749|NCT01103622|Drug|Placebo|Oral tablet bd, step-wise increased dosage
404750|NCT01103609|Drug|Warfarin|Oral tablet od on Day 4
404751|NCT01103609|Drug|Placebo|Oral tablet bd, stepwise increased
404752|NCT01103609|Drug|AZD1656|Oral tablet bd, stepwise increased
404753|NCT01103583|Drug|Hydroxyurea|500 mg/die per os for two years
404754|NCT01103583|Other|placebo|500 mg/die per os for two years
404755|NCT01103570|Procedure|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
404837|NCT01103024|Biological|AIN457|
404838|NCT01103024|Biological|Placebo|
404839|NCT01103011|Drug|ND0611|Continuous delivery of ND0611
404840|NCT01103011|Drug|ND0611|Solution of ND0611 delivered continuously
404756|NCT01103570|Procedure|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
404757|NCT01103557|Procedure|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
404758|NCT01103531|Behavioral|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
404759|NCT01103531|Behavioral|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
404760|NCT01103518|Drug|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
404761|NCT01103505|Diagnostic Test|ForeseeHome AMD Monitoring Device|Earlier detection of progression from intermediate dry age-related macular degeneration to CNV between routine eye exams through home diagnostic testing with the ForeseeHome AMD Monitoring device
404762|NCT01103492|Device|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
404763|NCT01103479|Behavioral|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
404764|NCT01103479|Behavioral|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
404765|NCT01103466|Device|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
404766|NCT01103466|Device|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
404767|NCT01103466|Device|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
404768|NCT01103453|Behavioral|Virtual Action Planning Supermarket (VAP-S) Software|"The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.~We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention."
404769|NCT01103440|Drug|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
404770|NCT01103440|Drug|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
404771|NCT01103427|Device|Internet-based behavioral coaching|"Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile."
404772|NCT01103427|Device|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
404773|NCT01103427|Device|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
404774|NCT01103427|Device|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
404775|NCT01103414|Drug|Mitoglitazone|50 mg capsules, once daily for 84 days
404776|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
404777|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
404778|NCT01103414|Drug|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
404779|NCT01103414|Drug|Placebo|Placebo, once daily for 84 days
404780|NCT01103401|Drug|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
404781|NCT01103401|Drug|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
404782|NCT01103388|Drug|Rituximab|375 mg/m^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
404783|NCT01103375|Drug|erlotinib hydrochloride|Given PO
404784|NCT01103375|Drug|isotretinoin|Given PO
404785|NCT01103375|Other|laboratory biomarker analysis|Correlative study
404786|NCT01103375|Genetic|protein expression analysis|Correlative study
404787|NCT01103362|Drug|flibanserin|all patients will receive open-label flibanserin 100mg
404788|NCT01103349|Drug|BI671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI617800 in patients with symptomatic asthma
404789|NCT01103349|Drug|Placebo|Patients receive placebo capsules and/or encapsulated tablets
404790|NCT01103349|Drug|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI671800 in patients with symptomatic asthma
404841|NCT01102985|Behavioral|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
404791|NCT01103336|Drug|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography~Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
404792|NCT01103323|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
404793|NCT01103323|Drug|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
404794|NCT01103323|Other|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
404795|NCT01103310|Drug|BAY94-9392|
404796|NCT01103297|Device|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
404797|NCT01103284|Drug|DiaPep277|1.0 mg dose in 0.5 mL of solution
404798|NCT01103284|Drug|Placebo|"40 mg mannitol in 0.5 mL of solution.~Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
404799|NCT01103271|Other|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
404800|NCT01103258|Procedure|high ligation and stripping (surgery)|surgery consisting of high ligation in combination with long saphenous stripping
404801|NCT01103258|Procedure|FOAM|duplex guided foam sclerotherapy
404802|NCT01103245|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg daily
404803|NCT01103245|Drug|Aliskiren 150 mg (ALI 150)|Aliskiren 150mg daily
404804|NCT01103245|Drug|Spironolactone (SPL 25)|spironolactone 25mg daily
404805|NCT01103245|Drug|Aliskiren 300 mg (ALI 300)|Aliskiren 300mg daily
404806|NCT01103245|Drug|Spironolactone 50 mg (SPL 50)|Spironolactone 50 mg daily
404807|NCT01103232|Procedure|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
404808|NCT01103232|Procedure|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
404809|NCT01103219|Dietary Supplement|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
404810|NCT01103206|Drug|cinacalcet|Intake of a single tablet of cinacalcet
404811|NCT01103206|Drug|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
404812|NCT01103206|Drug|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
404813|NCT01103193|Drug|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
404814|NCT01103193|Drug|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
404815|NCT01103180|Drug|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
404816|NCT01103167|Behavioral|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
404817|NCT01103154|Drug|carvedilol|6.25mg per day, increase to 6.25mg bid
404818|NCT01103154|Drug|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
404819|NCT01103141|Device|Micropuncture needle set|Groin access for vascular intervention
404820|NCT01103141|Device|Standard gauge-18 needle set|Groin access for vascular intervention
404821|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
404822|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
404823|NCT01103115|Dietary Supplement|Placebo|placebo tablets
404824|NCT01103102|Drug|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
404825|NCT01103102|Drug|Placebo|Placebo
404826|NCT01103076|Device|Polyamide HD membrane|Single use polyamide membrane
404827|NCT01103063|Drug|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
404828|NCT01103063|Drug|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
404829|NCT01103050|Drug|QAV680 + Cetirizine Placebo|
404830|NCT01103050|Drug|QAV680 + Cetirizine|
404831|NCT01103050|Drug|Cetirizine + QAV680 Placebo|
404832|NCT01103050|Drug|QAV680 Placebo + Cetirizine Placebo|
404833|NCT01103037|Drug|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
404842|NCT01102985|Behavioral|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
404843|NCT01102972|Drug|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
404844|NCT01102972|Drug|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
404845|NCT01102959|Device|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
404846|NCT01102946|Drug|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
404847|NCT01102946|Procedure|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
404848|NCT01102920|Behavioral|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.~Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.~Treatments are provided by a physical therapist and a dietician."
404849|NCT01102920|Device|CPAP|CPAP-treatment as usual (during nights)
404850|NCT01102907|Other|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
404851|NCT01102907|Other|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
404852|NCT01102894|Device|SmartPill|SmartPill
404853|NCT01102881|Dietary Supplement|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
404854|NCT01102881|Dietary Supplement|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
404855|NCT01102881|Dietary Supplement|placebo|low fiber breakfast cereal and muffin
404856|NCT01102868|Device|Needle in acupuncture point Li11|Acupuncture needle in acupuncture point Li11
404857|NCT01102868|Device|IMS of the musculus pronator teres|Acupuncture needle in musculus pronator teres
404858|NCT01102816|Other|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.~Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.~Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
404859|NCT01102816|Other|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
404860|NCT01102803|Behavioral|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
404861|NCT01102803|Drug|D-Cycloserine|D-Cycloserine
404862|NCT01102803|Drug|Placebo|Sugar Pill
404863|NCT01102777|Behavioral|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
404864|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
404865|NCT01102764|Behavioral|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
404866|NCT01102764|Behavioral|In Person|PE therapy delivered in person at the VAMC
404867|NCT01102712|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
404868|NCT01102699|Drug|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
404869|NCT01102686|Drug|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
404870|NCT01102686|Drug|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
404871|NCT01102673|Drug|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
404872|NCT01102673|Drug|Placebo|Placebo to match PF-04991532 will be provided
404873|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
404874|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
404875|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
404876|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
404877|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
404878|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
404879|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
404880|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
404881|NCT01102647|Dietary Supplement|phytosterol ester|1.6 g phytosterols/day for 29 days
404882|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
404883|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
404884|NCT01102608|Drug|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
404885|NCT01102595|Drug|Temozolomide|"Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~Temozolomide 75 mg/m2/d x 42-49 days~Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
404886|NCT01102595|Drug|Bevacizumab|"2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~Bevacizumab 10 mg/kg every 15 days, three dosis."
404887|NCT01102595|Radiation|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
404888|NCT01102517|Procedure|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
404889|NCT01102517|Procedure|axillary thoracotomy|axillary thoracotomy lobectomy
404890|NCT01102504|Drug|Placebo|Placebo
404891|NCT01102504|Dietary Supplement|Ateronon|Tomato extract containing 28 mg lycopene/ day
404892|NCT01102491|Drug|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
404893|NCT01102478|Drug|losartan potassium / hydrochlorothiazide|100 mg / 25 mg tablet
404894|NCT01102465|Drug|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
404895|NCT01102452|Dietary Supplement|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
404896|NCT01102452|Dietary Supplement|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
404897|NCT01102439|Drug|Clopidogrel|300 mg loading dose, then 75 mg daily
404898|NCT01102439|Drug|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
404899|NCT01102439|Drug|Aspirin|81 mg daily
404900|NCT01102439|Drug|Aspirin|325 mg daily
404901|NCT01102426|Drug|plitidepsin + dexamethasone|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
404902|NCT01102426|Drug|dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
404903|NCT01102413|Drug|Monofer|Infusion or injections
404904|NCT01102413|Drug|Iron Sulphate|Oral intake
404905|NCT01102400|Drug|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
404906|NCT01102387|Drug|LAS41003|Once daily, topically
404907|NCT01102387|Drug|LAS189962|Once daily, topically
404908|NCT01102387|Drug|LAS189961|Once daily, topically
404909|NCT01102374|Drug|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
404910|NCT01102374|Drug|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
404911|NCT01102374|Drug|Placebo|Placebo monthly
404912|NCT01102374|Dietary Supplement|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
404913|NCT01102361|Procedure|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
404914|NCT01102348|Other|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
404915|NCT01102335|Procedure|Transcatheter arterial chemoembolization (TACE)|The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
404916|NCT01102335|Drug|Telbivudine|anti-HBV drug
404917|NCT01102322|Behavioral|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
404918|NCT01102309|Device|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
404919|NCT01102309|Other|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
404920|NCT01102296|Biological|Hepatitis A vaccine|2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
404921|NCT01102283|Device|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
404922|NCT01102270|Drug|Eszopiclone|3mg tablet once prior to sleep
404923|NCT01102270|Drug|Placebo|1 placebo capsule prior to sleep
404924|NCT01102257|Drug|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA"
404925|NCT01102257|Drug|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
404926|NCT01102244|Drug|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
404927|NCT01102244|Drug|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
404928|NCT01102231|Drug|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
404929|NCT01102231|Drug|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
404930|NCT01102231|Radiation|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
404931|NCT01102218|Drug|Erythropoietin|Standard of Care
404932|NCT01102218|Drug|Erythropoietin|Standard of Care
404933|NCT01102218|Drug|Pentoxifylline|400 mg qd po for 6 months
404934|NCT01102166|Other|Acapella with nebulization|"st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.~The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.~nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.~Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
404935|NCT01102153|Device|Coolgard|invasive cooling via femoral ICY-catheter
404936|NCT01102153|Device|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
404937|NCT01102140|Drug|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
404938|NCT01102140|Drug|Sugar Pill|Matching sugar pill
404939|NCT01102127|Device|Elastography|Performance of US, elastography and FNA.
404940|NCT01102114|Biological|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
404941|NCT01102114|Biological|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
404942|NCT01102101|Drug|Remifentanil|Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
404943|NCT01102088|Radiation|Radiation Therapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.~For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions."
404944|NCT01102075|Device|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
404945|NCT01102075|Device|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
404946|NCT01102062|Dietary Supplement|orange juice|
404947|NCT01102049|Dietary Supplement|fish, beef, fruit|
404948|NCT01102036|Other|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
404949|NCT01102036|Other|Yoghurt without probiotics|Yoghurt without probiotics
404950|NCT01102023|Other|ordinary salt based- diet|
404951|NCT01102010|Biological|Blood transfusion|An expanded indication for blood transfusion in the frail elderly
404952|NCT01101997|Device|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
404953|NCT01101984|Drug|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
404954|NCT01101984|Drug|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
404955|NCT01101971|Other|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
404956|NCT01101958|Device|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
404957|NCT01101958|Device|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
404958|NCT01101945|Drug|dutogliptin|400 mg QD
404959|NCT01101932|Drug|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
404960|NCT01101932|Drug|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
404961|NCT01101932|Drug|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
404962|NCT01101919|Drug|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
404963|NCT01101906|Drug|OSI-906|OSI-906 administered orally
404964|NCT01101906|Drug|Placebo|Matching placebo administered orally
404965|NCT01101893|Drug|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
404966|NCT01101893|Drug|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
404967|NCT01101893|Drug|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
404968|NCT01101880|Biological|filgrastim|Given SC
404969|NCT01101880|Drug|clofarabine|Given IV
404970|NCT01101880|Drug|cytarabine|Given IV
404971|NCT01101867|Drug|Aspart fixed dose|fixed dose
404972|NCT01101867|Drug|Aspart flexible dose|dose based upon carbohydrate intake and total daily requirements
404973|NCT01101841|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
404974|NCT01101841|Drug|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
404975|NCT01101815|Drug|Oral Naltrexone|50 mg/day-oral
404976|NCT01101815|Drug|Naltrexone Implant|monthly-implant
404977|NCT01101815|Behavioral|Group Drug Counseling Manual Driven|Given to both groups biweekly, weeks 2 - 48. Counseling will consist of three components: 1) giving advice, support and clinical management aimed to maintain abstinence; 2) adherence enhancement to encourage keeping appointments, taking ART medications as prescribed and getting treatment for associated problems; and 3) reviewing behaviors that are likely to spread HIV and other infectious diseases, and counseling on how to stop them.
404978|NCT01101802|Drug|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
404979|NCT01101802|Drug|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
404980|NCT01101789|Procedure|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
404981|NCT01101789|Procedure|regular sutures for surgical wound closure|
404982|NCT01101776|Drug|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
404983|NCT01101750|Biological|Quadrivalent HPV for types 6, 11, 16 and 18|Gardasil 0.5ml IM injection on day one, month 2, and month 6. Serum samples on day one, month 3 and month 7
404984|NCT01101737|Other|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
404985|NCT01101724|Behavioral|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
404986|NCT01101698|Drug|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
404987|NCT01101698|Drug|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
404988|NCT01101685|Drug|Escitalopram|7 days dosing of 10mg per day
404989|NCT01101685|Drug|Placebo|7 days dosing at 10mg daily
404990|NCT01101672|Procedure|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
404991|NCT01101672|Procedure|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
404992|NCT01101659|Drug|JNJ-40411813|500 mg as 20 mL of oral suspension
404993|NCT01101659|Drug|normal saline|single dose
404994|NCT01101659|Drug|ketamine|20 mL of oral suspension
404995|NCT01101659|Drug|Placebo|single dose
404996|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
404997|NCT01101646|Drug|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
404998|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
404999|NCT01101633|Dietary Supplement|Alginate|a 500 ml alginate beverage per meal test
405000|NCT01101633|Dietary Supplement|Alginate|a 330 ml alginate beverage per meal test
405001|NCT01101633|Dietary Supplement|Placebo|a 500 ml placebo beverage per meal test
405002|NCT01101633|Dietary Supplement|Placebo|a 330 ml placebo beverage per meal test
405003|NCT01101620|Drug|Levosimendan|
405004|NCT01101607|Procedure|Distal Forearm Fracture Reduction|Fracture reduction
405005|NCT01101594|Drug|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 & 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
405006|NCT01101581|Drug|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 & 3 (days 8 & 15).
405007|NCT01101581|Drug|90Y-epratuzumab tetraxetan|
405008|NCT01101581|Drug|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
405009|NCT01101568|Drug|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
405010|NCT01101568|Drug|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
405011|NCT01101568|Drug|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
405012|NCT01101555|Drug|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
405013|NCT01101555|Other|Placebo|Placebo will be given to one member of each cohort.
405014|NCT01101542|Biological|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
405015|NCT01101542|Other|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
405095|NCT01100905|Other|Iron-containing food product|
405584|NCT01097083|Drug|Coriolus Versicolor|
405016|NCT01101529|Drug|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
405017|NCT01101529|Drug|Placebo|Placebo will be administered instead of Emend
405018|NCT01101503|Drug|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The intensive multifactorial therapy group:~For blood glucose control, target HbA1c >=5.5%and <=6.0%,fasting blood glucose >=5.0 mmol/L and <=6.0 mmol/L, postprandial 2 hour glucose >= 6.0 mmol/L and <= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.~For blood lipids control, target LDL-C < =1.9 mmol/L, triglyceride < =1.5 mmol/L. The drugs include statin and fibrate.~For blood pressure control, target >=120/70 mmHg and <= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~Others, such as aspirin."
405019|NCT01101503|Drug|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.~The conventional multifactorial therapy group:~For blood glucose control, target HbA1c >6.5%and <=7.0%,fasting blood glucose >6.0 mmol/L and <=7.0 mmol/L, postprandial 2 hour glucose > 7.8 mmol/L and <= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.~For blood lipids control, target LDL-C > 1.9 mmol/L and < =2.5 mmol/L, triglyceride > 1.5 mmol/L and < = 2.5 mmol/L. The drugs include statin and fibrate.~For blood pressure control, target >130/80 mmHg and <= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.~Others, such as aspirin."
405020|NCT01101477|Procedure|TCI titration by different Cet.|"Induction:~After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.~If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.~Maintenance:~The Cet will be increased according to the assigned regimens if:~Patients become irritant and interfere procedures.~Patients open eyes or talk to express uncomfortable.~The Cet will be decreased if:~Systolic blood pressure is less than 90mmHg;~Mean arterial blood pressure is less than 65mmHg;~Oxyhemoglobin saturation is less than 90 %~with any duration."
405021|NCT01101464|Drug|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
405022|NCT01101464|Drug|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
405023|NCT01101451|Drug|Cisplatin|Given IV
405024|NCT01101451|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
405025|NCT01101451|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
405026|NCT01101451|Other|Laboratory Biomarker Analysis|Correlative studies
405027|NCT01101451|Other|Quality-of-Life Assessment|Ancillary studies
405028|NCT01101451|Other|Questionnaire Administration|Ancillary studies
405029|NCT01101438|Drug|metformin hydrochloride|Given orally
405030|NCT01101438|Other|placebo|Given orally
405031|NCT01101412|Drug|Edetate Calcium Disodium|Given through CVC or PVC.
405032|NCT01101412|Drug|Ethanol|Given through CVC or PVC
405033|NCT01101412|Drug|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
405034|NCT01101412|Other|Hypertonic Saline|Given through CVC or PVC
405035|NCT01101399|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
405036|NCT01101386|Drug|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
405037|NCT01101360|Device|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
405038|NCT01101360|Device|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
405039|NCT01101360|Device|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
405040|NCT01101347|Device|Aneurysm-Embolization System|
405041|NCT01101334|Drug|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
405042|NCT01101334|Drug|erlotinib|Erlotinib; One 150mg tablet administered once daily
405043|NCT01101321|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
405044|NCT01101321|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
405045|NCT01101308|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
405046|NCT01101308|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
405047|NCT01101282|Device|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
405048|NCT01101269|Drug|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
405266|NCT01099579|Drug|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
405049|NCT01101269|Drug|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
405050|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every week
405051|NCT01101243|Radiation|Broadband UVB|UVB dose: 4 SED every second week
405052|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every second week
405053|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every month
405054|NCT01101243|Other|Control group|No intervention
405055|NCT01101230|Other|Almonds|1.5 oz almonds/day
405056|NCT01101217|Drug|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
405057|NCT01101217|Drug|placebo|placebo daily for 6 weeks
405058|NCT01101204|Drug|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
405059|NCT01101191|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
405060|NCT01101191|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
405061|NCT01101178|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
405062|NCT01101178|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
405063|NCT01101165|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
405064|NCT01101165|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
405065|NCT01101152|Drug|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;~1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
405066|NCT01101139|Drug|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
405067|NCT01101139|Drug|Placebo|Placebo: single intravenous injection Saline 0.9%
405068|NCT01101126|Other|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
405069|NCT01101126|Other|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
405070|NCT01101113|Drug|cinacalcet|cinacalcet 25mg qd or 50 mg qd
405071|NCT01101113|Drug|control|vit D + P binder
405072|NCT01101100|Drug|AMG 827|210 mg SC or 140 mg SC
405073|NCT01101087|Device|Taurolock|
405074|NCT01101087|Other|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
405075|NCT01101074|Other|This is non-intervention observational study|This is non-intervention observational study
405076|NCT01101061|Drug|Romosozumab|Administered by subcutaneous injection
405077|NCT01101061|Drug|Placebo|Administered by subcutaneous injection
405078|NCT01101048|Drug|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
405079|NCT01101048|Drug|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
405080|NCT01101035|Drug|Febuxostat|Febuxostat tablets
405081|NCT01101035|Drug|Allopurinol|Allopurinol tablets
405082|NCT01101022|Drug|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
405083|NCT01101022|Other|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
405084|NCT01101009|Drug|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
405085|NCT01101009|Drug|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
405086|NCT01100996|Other|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
405087|NCT01100996|Other|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
405088|NCT01100957|Procedure|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
405089|NCT01100944|Drug|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
405090|NCT01100931|Drug|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).~Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
405091|NCT01100931|Drug|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
405092|NCT01100931|Drug|Paclitaxel|200 mg/m^2 intravenous on day 1
405093|NCT01100918|Device|BiV ICD|Biventricular ICD
405094|NCT01100918|Device|ICD|Implantable Defibrillator
405096|NCT01100892|Drug|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
405097|NCT01100879|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.~Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).~Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
405098|NCT01100866|Dietary Supplement|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
405099|NCT01100866|Other|Placebo|placebo capsules
405100|NCT01100853|Drug|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
405101|NCT01100827|Other|EGFR mutation status in patients|
405102|NCT01100801|Drug|TS-1 with cisplatin|
405103|NCT01100801|Drug|TS-1 with oxaliplatin|
405104|NCT01100788|Dietary Supplement|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g~Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
405105|NCT01100788|Other|Placebo|Treatment without scFOS fiber
405106|NCT01100788|Dietary Supplement|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
405107|NCT01100775|Drug|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
405108|NCT01100775|Drug|Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
405109|NCT01100762|Device|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
405110|NCT01100762|Device|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
405111|NCT01100762|Device|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
405112|NCT01100736|Drug|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
405113|NCT01100736|Drug|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
405114|NCT01100736|Drug|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
405115|NCT01100736|Biological|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
405116|NCT01100723|Other|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
405117|NCT01100684|Drug|Asimadoline|0.5 mg Asimadoline BID
405118|NCT01100684|Drug|Placebo|Placebo
405119|NCT01100671|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
405120|NCT01100658|Drug|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
405121|NCT01100658|Drug|Placebo|1 capsule per day for 1 week.
405122|NCT01100645|Drug|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
405123|NCT01100645|Drug|Placebo|Excipient
405124|NCT01100632|Dietary Supplement|Ginseng, vitamins, minerals|2 capsules per day
405125|NCT01100632|Other|Placebo - Gelatin capsule|2 capsules per day
405126|NCT01100619|Drug|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
405127|NCT01100619|Drug|XL184|dosed with capsules daily
405128|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
405129|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
405130|NCT01100593|Procedure|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
405131|NCT01100580|Dietary Supplement|low salt diet|Daily salt intake less than 4 g/day
405132|NCT01100580|Dietary Supplement|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
405133|NCT01100567|Device|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
405134|NCT01100554|Device|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
405362|NCT01098812|Device|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
405135|NCT01100541|Device|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
405136|NCT01100528|Biological|recombinant interferon alfa-2b|Given subcutaneously (SC) 3 times a week for 24 weeks
405137|NCT01100528|Drug|dacarbazine|Given IV on days 1 and 29
405138|NCT01100528|Other|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
405139|NCT01100515|Other|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
405140|NCT01100515|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
405141|NCT01100502|Drug|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
405142|NCT01100502|Drug|placebo|Every 21 days by IV infusion
405143|NCT01100489|Radiation|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
405144|NCT01100489|Other|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
405145|NCT01100489|Procedure|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins < 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
405146|NCT01100476|Device|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
405147|NCT01100463|Drug|Cream|Twice daily lotion to prevent HFS
405148|NCT01100463|Drug|0.1% Uracil Cream|Twice daily lotion to prevent HFS
405149|NCT01100450|Behavioral|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
405150|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
405151|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
405152|NCT01100424|Device|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
405153|NCT01100424|Device|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
405154|NCT01100424|Device|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
405155|NCT01100424|Other|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
405156|NCT01100411|Device|Air Optix Aqua|Contact lens material: Lotrafilcon A
405157|NCT01100411|Device|Biofinity|Contact lens material: Comfilcon A
405158|NCT01100411|Device|Proclear|Contact lens material: Omafilcon A
405159|NCT01100411|Device|Acuvue Oasys|Contact lens material: Senofilcon A
405160|NCT01100411|Device|Acuvue 2|Contact lens material: Etafilcon A
405161|NCT01100411|Device|Purevision|Contact lens material: Balafilcon A
405162|NCT01100398|Procedure|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
405163|NCT01100385|Dietary Supplement|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
405164|NCT01100385|Dietary Supplement|Placebo|Matched placebo capsule, taken once daily for 56 days
405165|NCT01100372|Drug|gemcitabine hydrochloride|
405166|NCT01100372|Drug|liposome-encapsulated doxorubicin citrate|
405167|NCT01100372|Procedure|quality-of-life assessment|
405168|NCT01100359|Drug|carboplatin|
405169|NCT01100359|Drug|liposome-encapsulated doxorubicin citrate|
405170|NCT01100359|Other|laboratory biomarker analysis|
405171|NCT01100359|Procedure|quality-of-life assessment|
405172|NCT01100346|Drug|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
405173|NCT01100333|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
405174|NCT01100320|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
405175|NCT01100320|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
405176|NCT01100307|Drug|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
405177|NCT01100307|Other|sham injection|sham injection every 6 weeks
405178|NCT01100294|Biological|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.~Dose: 0.25 ml (total 3 μg HA), single dose."
405179|NCT01100281|Behavioral|Neuropsychological examination|Examination including especially concept formation
405180|NCT01100281|Other|MRI|MRI performed in T1-weighted three dimensional sequence
405363|NCT01098812|Device|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
405181|NCT01100268|Drug|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
405182|NCT01100255|Drug|Ketamine infusion|0.5mg/kg IV over 40 minutes
405183|NCT01100255|Other|Saline|saline infusion
405184|NCT01100242|Drug|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
405185|NCT01100216|Other|Nicotine Lozenge|4 mg for 12 days
405186|NCT01100216|Other|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
405187|NCT01100216|Other|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
405188|NCT01100216|Other|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
405189|NCT01100203|Drug|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
405190|NCT01100190|Device|NUVANCE Facial Rejuvenation System|The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
405191|NCT01100177|Drug|Sunitinib|Sunitinib 37.5mg/m2/d
405192|NCT01100177|Radiation|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
405193|NCT01100164|Drug|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
405194|NCT01100164|Drug|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
405195|NCT01100151|Drug|RDC-1036 (ALKS 37)|Capsules for oral administration
405196|NCT01100151|Drug|Placebo|Capsules for oral administration
405197|NCT01100125|Drug|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
405198|NCT01100125|Drug|insulin dose increase|insulin dose increase
405199|NCT01100112|Drug|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
405200|NCT01100099|Dietary Supplement|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
405201|NCT01100086|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
405202|NCT01100086|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
405203|NCT01100060|Drug|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
405204|NCT01100060|Drug|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
405205|NCT01100060|Drug|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
405206|NCT01100060|Drug|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
405207|NCT01100047|Drug|AZD5069|Oral suspension
405208|NCT01100047|Drug|Placebo|Oral suspension
405209|NCT01100034|Drug|Etanercept|Expected duration of 24 weeks as one course
405210|NCT01100021|Drug|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
405211|NCT01100021|Drug|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
405212|NCT01100008|Procedure|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
405213|NCT01099995|Other|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
405214|NCT01099995|Other|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
405215|NCT01099969|Device|Glidescope videolaryngoscope|
405216|NCT01099969|Device|McGrath videolaryngoscope|
405217|NCT01099969|Device|Non-styletted Endotrol endotracheal tube (ETT)|
405218|NCT01099969|Device|Regular endotracheal tube (ETT) with Gliderite stylet|
405219|NCT01099943|Other|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
405220|NCT01099930|Other|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.~Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
405221|NCT01099930|Other|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
405222|NCT01099917|Drug|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.~Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
405223|NCT01099904|Drug|RO5024048|multiple oral doses for 5 days
405224|NCT01099891|Drug|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
405225|NCT01099891|Drug|Placebo|Placebo, Spray type, Twice a day
405585|NCT01097070|Drug|Bevirimat|
405226|NCT01099878|Device|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
405227|NCT01099878|Device|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
405228|NCT01099852|Other|biological sample collection|blood sample collection
405229|NCT01099852|Other|quality of life questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
405230|NCT01099852|Other|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
405231|NCT01099839|Drug|ASP1941|oral
405232|NCT01099839|Drug|Miglitol|oral
405233|NCT01099826|Behavioral|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
405234|NCT01099826|Behavioral|Motivational Interview|motivational interview by trained MI counselors by phone
405235|NCT01099826|Behavioral|control|Usual care
405236|NCT01099774|Drug|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
405237|NCT01099774|Drug|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
405238|NCT01099761|Biological|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
405239|NCT01099761|Biological|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
405240|NCT01099761|Other|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
405241|NCT01099748|Drug|Methadone|Methadone 50 - 150 mg QD (Day 1)
405242|NCT01099748|Drug|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
405243|NCT01099722|Drug|Flutiform|inhaler 2 puffs bd daily
405244|NCT01099722|Drug|Symbicort Turbohaler|2 puffs bd daily
405245|NCT01099709|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
405246|NCT01099709|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
405247|NCT01099696|Dietary Supplement|B. infantis 35624|B. infantis 35624 in white capsules
405248|NCT01099696|Dietary Supplement|placebo|white placebo capsules
405249|NCT01099683|Drug|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
405250|NCT01099683|Drug|Placebo|All subjects will receive rectal suppository containing placebo
405251|NCT01099670|Drug|NRL001|Rectal suppository Placebo
405252|NCT01099670|Drug|Placebo|Placebo
405253|NCT01099657|Behavioral|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
405254|NCT01099657|Behavioral|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
405255|NCT01099644|Biological|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
405256|NCT01099631|Biological|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10^5, Level 2 = 10^6, Level 3 = 10^7, Level 4 = 10^8, Level 5 = 10^9, Level 6 = 10^10.
405257|NCT01099618|Drug|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
405258|NCT01099618|Drug|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
405259|NCT01099618|Drug|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
405260|NCT01099605|Device|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
405261|NCT01099605|Device|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
405262|NCT01099592|Drug|Citalopram|All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not < 8, the dose will increase to 40 mg.
405263|NCT01099579|Drug|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to <10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to <15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to <25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
405264|NCT01099579|Drug|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
405265|NCT01099579|Drug|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
405586|NCT01097057|Drug|Carboplatin|Given IV
405267|NCT01099566|Drug|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
405268|NCT01099566|Drug|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
405269|NCT01099553|Other|Educational video|Instructions to view an educational video about preparing for a colonoscopy
405270|NCT01099553|Other|Written instructions|Written instructions on preparing for a colonoscopy
405271|NCT01099540|Drug|Pazopanib|Pazopanib 800 mg qd daily
405272|NCT01099527|Drug|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
405273|NCT01099527|Drug|Capecitabine|dose escalation of capecitabine, everolimus
405274|NCT01099514|Drug|Nilotinib|D1~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
405275|NCT01099501|Dietary Supplement|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
405276|NCT01099501|Dietary Supplement|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
405277|NCT01099501|Dietary Supplement|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
405278|NCT01099488|Procedure|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
405279|NCT01099475|Procedure|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
405280|NCT01099475|Procedure|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
405281|NCT01099462|Drug|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
405282|NCT01099449|Drug|calcium gluconate|Given IV
405283|NCT01099449|Drug|magnesium sulfate|Given IV
405284|NCT01099449|Other|placebo|Given IV
405285|NCT01099449|Drug|oxaliplatin|
405286|NCT01099436|Drug|cyclophosphamide|
405287|NCT01099436|Drug|docetaxel|
405288|NCT01099436|Drug|doxorubicin hydrochloride|
405289|NCT01099436|Drug|zoledronic acid|
405290|NCT01099436|Procedure|neoadjuvant therapy|
405291|NCT01099423|Procedure|timing of surgery|
405292|NCT01099423|Genetic|gene expression analysis|
405293|NCT01099423|Other|biologic sample preservation procedure|
405294|NCT01099423|Other|laboratory biomarker analysis|
405295|NCT01099423|Procedure|therapeutic conventional surgery|
405296|NCT01099410|Procedure|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
405297|NCT01099410|Procedure|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
405298|NCT01099410|Procedure|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
405299|NCT01099397|Other|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
405300|NCT01099384|Behavioral|Written self-help materials|Written materials to help adolescents stop tobacco use
405301|NCT01099384|Behavioral|Group behavioral counseling|group behavioral counseling (2 day weekend program)
405302|NCT01099371|Other|exercise|progressive resistance training
405303|NCT01099358|Drug|Cetuximab|Administered Intravenously
405304|NCT01099358|Drug|Cisplatin|Administered Intravenously
405305|NCT01099358|Drug|5 - Fluorouracil|Administered Intravenously
405306|NCT01099345|Procedure|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
405307|NCT01099345|Procedure|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
405308|NCT01099332|Other|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
405309|NCT01099332|Other|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
405310|NCT01099319|Dietary Supplement|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
405311|NCT01099319|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
405312|NCT01099306|Other|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
405313|NCT01099280|Drug|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
405314|NCT01099280|Drug|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
405315|NCT01099228|Other|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
405316|NCT01099228|Other|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
405317|NCT01099215|Biological|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
405318|NCT01099202|Drug|Procrit (epoetin alfa)|Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
405319|NCT01099176|Drug|To compare monotherapies and combined therapy with each other|"Each patient received two tablets per day. Time interval between pills - 12 hours.~In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets"
405320|NCT01099163|Dietary Supplement|Tonalin SG1000T FFA|
405321|NCT01099150|Dietary Supplement|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~900 mg of total flavan-3-ols and procyanidins.
405322|NCT01099150|Dietary Supplement|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~400 mg total flavan-3-ols and procyanidins.
405323|NCT01099150|Dietary Supplement|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
405324|NCT01099137|Drug|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
405325|NCT01099137|Drug|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
405326|NCT01099124|Drug|M2ES|polyethylene glycol rh recombinant endostatin
405327|NCT01099085|Drug|Simvastatin|simvastatin 40 mg qd daily
405328|NCT01099085|Drug|Placebo|Placebo
405329|NCT01099072|Drug|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
405330|NCT01099072|Drug|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
405331|NCT01099059|Drug|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
405332|NCT01099059|Drug|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)
405333|NCT01099046|Behavioral|Lifestyle|water intake, tympanic tubing, regular sleep
405334|NCT01099007|Behavioral|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
405335|NCT01099007|Behavioral|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
405336|NCT01098994|Dietary Supplement|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
405337|NCT01098994|Other|Dummy pills|Daily placebo administration for 8 weeks
405338|NCT01098981|Device|Transcranial ultrasound as an adjunctive therapy to tPA|"tPA per approved labeling administered over 60 minutes~Ultrasonic headframe with active insonation for 120 minutes"
405339|NCT01098981|Drug|Standard of care tPA therapy for acute ischemic stroke|"tPA per approved labeling administered over 60 minutes~Ultrasonic headframe with sham (inactive) insonation for 120 minutes"
405340|NCT01098968|Behavioral|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
405341|NCT01098955|Behavioral|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
405342|NCT01098955|Behavioral|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
405343|NCT01098955|Drug|Varenicline|2 mg daily for 12 weeks
405344|NCT01098916|Radiation|Home X-rays|X-rays examinations performed at home
405345|NCT01098916|Radiation|X-rays in hospital|
405346|NCT01098890|Drug|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
405347|NCT01098890|Drug|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
405348|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose
405349|NCT01098877|Drug|PF-04634817|Oral solution, 1mg, single dose
405350|NCT01098877|Drug|PF-04634817|Oral solution, 3mg, single dose
405351|NCT01098877|Drug|PF-04634817|Oral solution, 10mg, single dose
405352|NCT01098877|Drug|PF-04634817|Oral solution, 30mg, single dose
405353|NCT01098877|Drug|PF-04634817|Oral solution, 100mg, single dose
405354|NCT01098877|Drug|PF-04634817|Oral solution, 300mg, single dose
405355|NCT01098877|Drug|PF-04634817|Oral solution, 600mg, single dose
405356|NCT01098877|Drug|PF-04634817|Oral solution, 900mg, single dose
405357|NCT01098877|Drug|PF-04634817|Oral solution, up to 900mg, single dose after food
405358|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose after food
405359|NCT01098864|Device|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
405360|NCT01098838|Drug|LCL161|
405361|NCT01098825|Other|web-based survey|Anonymous web-based survey
405364|NCT01098786|Biological|Cell-derived A/H1N1 influenza HA vaccine|Single group vaccinated
405365|NCT01098760|Drug|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
405366|NCT01098747|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
405367|NCT01098747|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
405368|NCT01098747|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
405369|NCT01098747|Drug|Placebo|Single-dose of placebo
405370|NCT01098734|Drug|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
405371|NCT01098721|Drug|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
405372|NCT01098695|Other|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
405373|NCT01098656|Drug|lenalidomide|"The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.~Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)"
405374|NCT01098643|Other|computer-assisted intervention|
405375|NCT01098643|Other|medical chart review|
405376|NCT01098643|Other|questionnaire administration|
405377|NCT01098643|Other|survey administration|
405378|NCT01098630|Other|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
405379|NCT01098630|Other|Questionnaire Administration|Ancillary studies
405380|NCT01098604|Device|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
405381|NCT01098604|Device|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
405382|NCT01098591|Other|cell therapy|
405383|NCT01098578|Drug|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
405384|NCT01098565|Device|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
405385|NCT01098539|Biological|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
405386|NCT01098539|Drug|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
405387|NCT01098526|Drug|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
405388|NCT01098526|Drug|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
405389|NCT01098513|Drug|GSK1349572 formulation AP|GSK1349572 50 mg single dose fasted.
405390|NCT01098513|Drug|GSK1349572 formulation AW|GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
405391|NCT01098513|Drug|GSK1349572 formulation AX|GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
405392|NCT01098500|Drug|Tyrosine kinase inhibitors|Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
405393|NCT01098487|Drug|Eltrombopag olamine|Thrombopoietin receptor agonist
405394|NCT01098474|Biological|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
405395|NCT01098474|Biological|Tritanrix™ HB+Hib|Intramuscular, 3 doses
405396|NCT01098474|Biological|Prevnar™|Intramuscular, 3 doses
405397|NCT01098474|Biological|Polio Sabin™|Oral, 3 doses
405398|NCT01098474|Biological|Menjugate™|Intramuscular, 3 doses
405399|NCT01098461|Biological|albiglutide|subcutaneous injection of albiglutide
405400|NCT01098461|Biological|placebo|subcutaneous injection of placebo to match albiglutide
405401|NCT01098448|Other|scaling and root planing|scaling and root planing as a single therapy
405402|NCT01098448|Drug|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm
405403|NCT01098448|Drug|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
405404|NCT01098448|Other|surgery|periodontal surgery in residual pockets of >4mm
405405|NCT01098448|Drug|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
405406|NCT01098448|Other|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm and periodontal surgery in residual pockets of >4mm
405407|NCT01098448|Other|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets >4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
405408|NCT01098448|Other|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets >4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets >5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
405409|NCT01098435|Drug|RDC-0313 (ALKS 33)|Capsules for daily oral administration
405410|NCT01098435|Drug|Placebo|Capsules containing lactose and no active drug for daily oral administration
405574|NCT01097122|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
405411|NCT01098422|Device|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
405412|NCT01098409|Drug|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
405413|NCT01098409|Drug|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
405414|NCT01098383|Drug|Acetyl-Choline Esterase Inhibitors and Choline supplements|"Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers & Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose."
405415|NCT01098383|Drug|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
405416|NCT01098357|Drug|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
405417|NCT01098357|Drug|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
405418|NCT01098357|Drug|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
405419|NCT01098357|Drug|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
405420|NCT01098344|Drug|Notch signaling pathway inhibitor MK0752|
405421|NCT01098344|Drug|gemcitabine hydrochloride|
405422|NCT01098344|Other|imaging biomarker analysis|
405423|NCT01098344|Other|laboratory biomarker analysis|
405424|NCT01098344|Other|pharmacological study|
405425|NCT01098331|Other|counseling intervention|
405426|NCT01098331|Other|educational intervention|
405427|NCT01098331|Procedure|quality-of-life assessment|
405428|NCT01098331|Procedure|therapeutic conventional surgery|
405429|NCT01098331|Radiation|iodine I 125|
405430|NCT01098331|Radiation|palladium Pd 103|
405431|NCT01098318|Dietary Supplement|Herbal extract|340-1,360 mg daily
405432|NCT01098318|Drug|Sertraline|50-200 mg daily
405433|NCT01098318|Other|Lactose monohydrate|1-4 capsules daily
405434|NCT01098305|Drug|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
405435|NCT01098305|Behavioral|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
405436|NCT01098266|Drug|NGR-hTNF plus Best Investigator's Choice (BIC)|"NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
405437|NCT01098266|Drug|Placebo plus Best Investigator's Choice (BIC)|"Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.~Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis~Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:~Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles~Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles~Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
405438|NCT01098253|Behavioral|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
405439|NCT01098240|Drug|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
405440|NCT01098240|Other|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
405441|NCT01098201|Drug|Certolizumab|Subcutaneous administration on a monthly basis for six months
405442|NCT01098188|Drug|LFB-R603|intravenous administration, dose-escalation study
405443|NCT01098149|Other|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
405444|NCT01098136|Other|Chiropractic|Manual treatment of musculoskeletal complaints
405445|NCT01098136|Other|Conventional medical intervention|Medical, physiotherapy
405446|NCT01098136|Other|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
405447|NCT01098110|Drug|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
405448|NCT01098110|Drug|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
405449|NCT01098110|Drug|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
405575|NCT01097096|Biological|CAD106|
405450|NCT01098097|Biological|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
405451|NCT01098097|Drug|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
405452|NCT01098084|Drug|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
405453|NCT01098071|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
405454|NCT01098058|Other|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
405455|NCT01098058|Other|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
405456|NCT01098032|Device|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate >300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
405457|NCT01098032|Drug|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
405458|NCT01098019|Drug|Xeomin|Patients will receive Xeomin only at Day 0.
405459|NCT01098019|Drug|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
405460|NCT01098006|Other|Blood withdrawal|Blood sampling
405461|NCT01097993|Other|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
405462|NCT01097993|Other|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
405463|NCT01097980|Drug|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
405464|NCT01097980|Drug|Placebo|Placebo
405465|NCT01097967|Other|CPAP|
405466|NCT01097941|Biological|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
405467|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
405468|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
405469|NCT01097928|Procedure|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
405470|NCT01097902|Drug|Ibuprofen|800 mg oral one time only
405471|NCT01097902|Drug|Placebo tablet|Placebo tablet oral one time only
405472|NCT01097889|Dietary Supplement|Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.|A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein
405473|NCT01097889|Dietary Supplement|RUSF (ready-to-use supplementary foods) Supplementary Plumpy®|"Peanut-based fortified supplement~One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein"
405474|NCT01097876|Drug|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
405475|NCT01097876|Drug|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
405476|NCT01097863|Device|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
405477|NCT01097863|Device|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
405478|NCT01097863|Device|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
405479|NCT01097850|Drug|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
405480|NCT01097837|Other|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
405481|NCT01097811|Drug|Erythromycin|250 mg orally q.i.d.
405482|NCT01097811|Drug|Neomycin|1 g orally q.i.d.
405483|NCT01097798|Drug|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
405484|NCT01097798|Drug|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
405485|NCT01097785|Drug|Simvastatin|40 mg, P.O.,daily for 30 days
405486|NCT01097785|Drug|Placebo|1 capsule daily for 30 days
405487|NCT01097772|Device|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
405488|NCT01097759|Procedure|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
405489|NCT01097746|Biological|Bevacizumab|Given IV
405490|NCT01097746|Drug|Carboplatin|Given IV
405491|NCT01097746|Drug|Paclitaxel|Given IV
405492|NCT01097733|Other|Randomization of Pre-knowledge of CT coronary venography|
405493|NCT01097707|Drug|LY500307|Administered orally, daily for 24 weeks
405494|NCT01097707|Drug|Placebo|Administered orally, daily for 24 weeks
405576|NCT01097096|Biological|CAD106|
405577|NCT01097096|Biological|CAD106|
405495|NCT01097694|Drug|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
405496|NCT01097694|Drug|Placebo|Placebo
405497|NCT01097681|Drug|ASP1941|oral
405498|NCT01097668|Biological|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
405499|NCT01097642|Drug|Cetuximab|Cetuximab will be given at 400mg/m^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m^2 IV over 60 minutes.
405500|NCT01097642|Drug|Ixabepilone|Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
405501|NCT01097629|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
405502|NCT01097629|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
405503|NCT01097629|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
405504|NCT01097616|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
405505|NCT01097616|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
405506|NCT01097616|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
405507|NCT01097590|Device|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
405508|NCT01097590|Device|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
405509|NCT01097577|Drug|pregabalin|1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
405510|NCT01097577|Drug|Placebo|1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
405511|NCT01097564|Genetic|COL4A1 genetic testing|genetic testing
405512|NCT01097551|Drug|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
405513|NCT01097551|Drug|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
405514|NCT01097551|Drug|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
405515|NCT01097551|Device|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
405516|NCT01097538|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
405517|NCT01097538|Other|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
405518|NCT01097525|Procedure|WFG PRK|
405519|NCT01097525|Procedure|WFG LASIK|
405520|NCT01097525|Procedure|WFO PRK|
405521|NCT01097525|Procedure|WFO LASIK|
405522|NCT01097512|Drug|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
405523|NCT01097512|Drug|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
405524|NCT01097499|Device|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
405525|NCT01097486|Biological|NeoFuse|Single Dose NeoFuse Surgical Implantation
405526|NCT01097486|Procedure|Allograft|Single Dose Allograft Surgical Implantation
405527|NCT01097473|Procedure|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
405528|NCT01097460|Drug|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
405529|NCT01097434|Device|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
405530|NCT01097434|Device|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
405531|NCT01097421|Drug|Pramipexole Extended Release|
405532|NCT01097408|Drug|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
405533|NCT01097408|Drug|Placebo comparator|Placebo capsules
405534|NCT01097395|Drug|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
405535|NCT01097382|Drug|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
405536|NCT01097356|Dietary Supplement|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
405537|NCT01097343|Drug|clopidogrel 75 mg|75 mg once daily
405538|NCT01097343|Drug|Clopidogrel 150 mg|clopidogrel 150 mg
405539|NCT01097330|Procedure|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
405540|NCT01097330|Drug|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
405541|NCT01097317|Drug|carboplatin|
405542|NCT01097317|Drug|vinorelbine tartrate|
405543|NCT01097317|Other|neuromuscular electrical stimulation|
405544|NCT01097317|Other|physiologic testing|
405545|NCT01097317|Procedure|fatigue assessment and management|
405546|NCT01097317|Procedure|quality-of-life assessment|
405547|NCT01097304|Drug|Ursodiol|Given PO
405548|NCT01097304|Other|Laboratory Biomarker Analysis|Correlative studies
405549|NCT01097278|Dietary Supplement|cholecalciferol|Given orally
405550|NCT01097278|Other|placebo|Given orally
405551|NCT01097265|Drug|capecitabine|
405552|NCT01097265|Drug|oxaliplatin|
405553|NCT01097265|Other|active surveillance|
405554|NCT01097265|Other|laboratory biomarker analysis|
405555|NCT01097265|Procedure|adjuvant therapy|
405556|NCT01097265|Procedure|lymph node mapping|
405557|NCT01097265|Procedure|sentinel lymph node biopsy|
405558|NCT01097252|Radiation|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
405559|NCT01097252|Drug|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
405560|NCT01097252|Drug|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
405561|NCT01097239|Device|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
405562|NCT01097226|Other|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
405563|NCT01097226|Other|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
405564|NCT01097226|Other|Apple granules delivering 70 mg epicatechin|Delivered as a puree
405565|NCT01097226|Other|Water delivering no epicatechin|Delivered as flavoured water
405566|NCT01097213|Drug|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
405567|NCT01097213|Drug|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
405568|NCT01097200|Device|Elevate mesh|The correction of the prolapse can be made by this new technique.
405569|NCT01097200|Device|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
405570|NCT01097174|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
405571|NCT01097161|Behavioral|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
405572|NCT01097148|Drug|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
405573|NCT01097135|Drug|Duraprep Surgical Solution|
405588|NCT01097057|Biological|Filgrastim|Given SC
405589|NCT01097057|Drug|Ifosfamide|Given IV
405590|NCT01097057|Procedure|Leukapheresis|Given through catheter
405591|NCT01097057|Drug|Plerixafor|Given SC
405592|NCT01097057|Biological|Rituximab|Given IV
405593|NCT01097044|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months. (3 implants in total)
405594|NCT01097044|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months. (3 implants in total)
405595|NCT01097031|Other|Infusion Intermittent|
405596|NCT01097018|Drug|Capecitabine|1000 mg/m2 BID/ Days 1-14
405597|NCT01097018|Drug|Perifosine|50 mg daily x 21 days
405598|NCT01097018|Drug|Placebo|1 pill daily x 21 days
405599|NCT01096992|Drug|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)~Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
405600|NCT01096992|Drug|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
405601|NCT01096992|Drug|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
405602|NCT01096979|Drug|LIPO-102|subcutaneous injection
405603|NCT01096979|Drug|Placebo|Placebo
405604|NCT01096966|Drug|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
405605|NCT01096966|Drug|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
405606|NCT01096953|Behavioral|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
405607|NCT01096953|Behavioral|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
405608|NCT01096940|Drug|AZD1656|Oral tablet, BID dose
405609|NCT01096940|Drug|simvastatin|Oral tablet, single dose
405610|NCT01096927|Drug|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
405611|NCT01096914|Procedure|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
405612|NCT01096914|Procedure|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
405613|NCT01096901|Behavioral|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
405614|NCT01096888|Behavioral|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
405615|NCT01096875|Drug|Atorvastatin|40mg/day once daily for two weeks prior to surgery
405616|NCT01096875|Drug|Placebo|1tb/day once daily for two weeks prior to surgery
405617|NCT01096862|Drug|peficitinib|oral
405618|NCT01096862|Drug|Placebo|oral
405619|NCT01096849|Drug|levofloxacin|
405620|NCT01096849|Drug|plazomicin|
405621|NCT01096849|Drug|placebo|
405622|NCT01096836|Other|macronutrient and energy manipulation|
405623|NCT01096823|Behavioral|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
405624|NCT01096810|Drug|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
405625|NCT01096797|Drug|Sevoflurane|"Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~Anaesthesia maintenance: sevoflurane 2-3 %~Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
405626|NCT01096784|Drug|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
405627|NCT01096771|Drug|ClinOleic 20%|96 hour continuous infusion.
405628|NCT01096771|Drug|Intralipid 20%|96 hour continuous infusion.
405629|NCT01096745|Drug|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
405630|NCT01096745|Drug|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
405631|NCT01096732|Drug|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
405632|NCT01096719|Behavioral|Standard Behavioral Weight Loss Intervention|12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies
405633|NCT01096719|Behavioral|Dietary Goal: Reduction in Energy Density of Dietary Intake|Consume low ED foods (ED < 1.0) for at least 10 items consumed per day and limit high ED foods (ED > 3.0) to two items consumed per day.
405634|NCT01096719|Behavioral|Dietary Goal: Reduction of Energy Intake|Limit energy intake to 1200 to 1500 kcals/day and < 30% kcals from fat.
405698|NCT01096368|Other|Laboratory Biomarker Analysis|Optional correlative studies
405699|NCT01096368|Drug|Vincristine Sulfate Liposome|Given IV
405700|NCT01096355|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
405701|NCT01096355|Other|diagnostic laboratory biomarker analysis|
405702|NCT01096355|Other|pharmacogenomic studies|
405703|NCT01096355|Other|pharmacological study|
405704|NCT01096342|Drug|dinaciclib|Given IV
405635|NCT01096706|Drug|NO clamp|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
405636|NCT01096706|Drug|Saline|"After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
405637|NCT01096706|Drug|Fluconazole|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
405638|NCT01096706|Drug|Aspirin|"Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.~Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
405639|NCT01096706|Drug|Combined|"Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.~This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.~Blood samples are taken as per previous arms."
405640|NCT01096693|Drug|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
405641|NCT01096693|Drug|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
405642|NCT01096680|Drug|SPD489 20 mg|Single oral dose of 20 mg
405643|NCT01096680|Drug|SPD489 50 mg|Single oral dose of 50 mg
405644|NCT01096680|Drug|SPD489 70 mg|Single oral dose of 70 mg
405645|NCT01096680|Drug|Armodafinil|Single oral dose of 250 mg
405646|NCT01096680|Drug|Placebo|Single oral dose
405647|NCT01096667|Drug|Placebo to Ertuglilflozin 1 or 5 mg|Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
405648|NCT01096667|Drug|Ertugliflozin 1 mg|Ertugliflozin tablet 1 mg once daily for 28 days
405649|NCT01096667|Drug|Ertugliflozin 5 mg|Ertugliflozin tablet 5 mg once daily for 28 days
405650|NCT01096667|Drug|Ertugliflozin 25 mg|Ertugliflozin tablet 25 mg once daily for 28 days
405651|NCT01096667|Drug|HCTZ 12.5mg|Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
405652|NCT01096667|Drug|Placebo to HCTZ|Placebo to HCTZ 12.5 mg capsule once daily for 28 days
405653|NCT01096667|Drug|Placebo to ertuglilflozin 25 mg|Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
405654|NCT01096654|Other|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
405655|NCT01096641|Behavioral|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
405656|NCT01096641|Behavioral|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
405705|NCT01096342|Other|laboratory biomarker analysis|Correlative studies
405706|NCT01096329|Drug|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
405707|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
405657|NCT01096628|Other|Chiropractic + Exercise|"Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.~Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise."
405658|NCT01096628|Other|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
405659|NCT01096615|Dietary Supplement|Placebo|"Description:~- capsule size 3~Composition of the product:~45 mg of microcristalline cellulose,~132 mg of maltodextrin,~3 mg of magnesium stearate.~Composition of the capsule:~46 mg of hypromellose,~1 mg of titanium dioxide.~Packaging:~Products are packaged in aluminium tubes of 30 capsules.~Storage:~The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.~The study products will be consumed daily for 7 weeks."
405660|NCT01096615|Dietary Supplement|Lactobacillus paracasei LP-33|"Description:~minimum 2.0x109 CFU of Lactobacillus paracasei LP-33~capsule size 3 1 capsule daily together with a meal, with a glass of water."
405661|NCT01096602|Biological|DC AML Vaccine|Group 1: 2-3 doses of the vaccine at 4 week intervals
405662|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
405663|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
405664|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
405665|NCT01096589|Device|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
405666|NCT01096576|Drug|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
405667|NCT01096576|Drug|placebo|orally twice daily for 5 days
405668|NCT01096563|Drug|AZD9164|"Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).~The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose."
405669|NCT01096563|Drug|Placebo|Dry powder for inhalation via Turbuhaler, JSMAD.
405670|NCT01096550|Behavioral|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
405671|NCT01096550|Behavioral|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
405672|NCT01096524|Other|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
405673|NCT01096524|Device|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.~Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
405674|NCT01096511|Drug|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
405675|NCT01096498|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
405676|NCT01096498|Drug|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
405677|NCT01096485|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of 1.5 mg coated tablet
405678|NCT01096485|Drug|Levonorgestrel (Postday)|Single dose of two 0.75 mg tablets
405679|NCT01096472|Drug|LAS41003|Once daily
405680|NCT01096472|Drug|LAS189961|Once daily
405681|NCT01096472|Drug|LAS189962|Once daily
405682|NCT01096459|Procedure|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
405683|NCT01096446|Drug|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
405684|NCT01096433|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
405685|NCT01096420|Procedure|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.~Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).~Sterile disposable and steel needle (3210) were used .~The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
405686|NCT01096420|Drug|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.~The study phase consists of a 4-week titration and a 8-week maintenance period.~All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).~Study drug was administered daily in equally divided twice daily doses."
405687|NCT01096407|Other|laboratory biomarker analysis|Collection of urine samples
405688|NCT01096407|Other|questionnaire administration|Completion of questionnaires
405689|NCT01096407|Procedure|assessment of therapy complications|An assessment will be completed.
405690|NCT01096381|Other|laboratory biomarker analysis|Blood collection
405691|NCT01096381|Other|questionnaire administration|Survey regarding baseline health and activity level.
405692|NCT01096368|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo conformal radiotherapy
405693|NCT01096368|Drug|Carboplatin|Given IV
405694|NCT01096368|Drug|Cisplatin|Given IV
405695|NCT01096368|Other|Clinical Observation|Patients undergo observation
405696|NCT01096368|Drug|Cyclophosphamide|Given IV
405708|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
405709|NCT01096316|Behavioral|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
405710|NCT01096290|Drug|lubiprostone|24mcg BID, capsule, oral 30days
405711|NCT01096290|Drug|Matched placebo|Twice daily for 30days, oral
405712|NCT01096277|Drug|Sitagliptin|oral tablets 100 mg per day for two weeks
405713|NCT01096277|Drug|Placebo|oral tablet, one per day for two weeks
405714|NCT01096277|Other|Control|no intervention
405715|NCT01096264|Other|SSI and SphygmoCor® evaluations|"SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.~SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
405716|NCT01096251|Behavioral|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
405717|NCT01096225|Biological|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
405718|NCT01096212|Drug|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
405719|NCT01096212|Drug|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
405720|NCT01096199|Drug|TS-ONE, Cisplatin, RAD001|
405721|NCT01096186|Drug|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
405722|NCT01096186|Drug|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
405723|NCT01096186|Drug|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
405724|NCT01096186|Drug|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
405725|NCT01096160|Drug|MK-8226 BID, 1 mg|MK-8266 1 mg administered as oral capsules (0.7 mg + 0.3 mg), BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
405726|NCT01096160|Drug|MK-8266 BID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (1 mg + 0.8 mg), BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
405727|NCT01096160|Drug|MK-8266 TID, 1.8 mg|MK-8266 1.8 mg administered as oral capsules (0.6 mg), TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
405728|NCT01096160|Drug|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel D), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
405729|NCT01096160|Drug|MK-8266 TID, 2.4 mg|MK-8266 TID (Panel E), 2.4 mg administered as oral capsules (0.8 mg), TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
405730|NCT01096160|Drug|Placebo BID (Panel A)|Placebo administered as oral capsules BID for 10 consecutive days. Panel A was completed prior to initiation of Panel B.
405731|NCT01096160|Drug|Placebo BID (Panel B)|Placebo administered as oral capsules BID for 10 consecutive days. Panel B was completed prior to initiation of Panel C.
405732|NCT01096160|Drug|Placebo TID (Panel C)|Placebo administered as oral capsules TID for 10 consecutive days. Panel C was completed prior to initiation of Panel D.
405733|NCT01096160|Drug|Placebo TID (Panel D)|Placebo administered as oral capsules TID for 10 consecutive days. Panel D was completed prior to initiation of Panel E.
405734|NCT01096160|Drug|Placebo TID (Panel E)|Placebo administered as oral capsules TID for 10 consecutive days. Panel E was initiated after completion of Panel D.
405735|NCT01096147|Device|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
405736|NCT01096134|Biological|HPV Vaccine (Gardasil)|"HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.~FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:~20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection"
405737|NCT01096121|Drug|Enalapril|"during 1 month : 0,2 mg/kg/day~then during 2 months (if no adverse event): 0,35 mg/kg/day~and then during 6 months (if no adverse event): 0,5 mg/kg/day"
405738|NCT01096121|Drug|Placebo|Glucose
405739|NCT01096108|Behavioral|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
405740|NCT01096108|Behavioral|Motivational and Problem-Solving|Counseling phone calls
405741|NCT01096108|Behavioral|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
405742|NCT01096095|Drug|Placebo|Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
405743|NCT01096095|Drug|Sodium Phenylbutyrate|Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
405744|NCT01096082|Drug|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
405745|NCT01096082|Drug|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
405746|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
405747|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
405748|NCT01096056|Biological|Fluarix|Intramuscular administration, 1 dose
405749|NCT01096043|Drug|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
405750|NCT01096043|Drug|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
405751|NCT01096043|Drug|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
405752|NCT01096043|Drug|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
405753|NCT01096030|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
405754|NCT01096017|Drug|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
405755|NCT01096017|Drug|Salbutamol pMDI|200 μg, inhalation, single dose
405756|NCT01096017|Other|pMDI placebo pMDI|Placebo pMDI 2 inhalations
405757|NCT01096017|Other|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
405758|NCT01096004|Drug|AZD4017|oral suspension, 1200mg, once daily, for 10 days
405759|NCT01096004|Drug|Placebo|
405760|NCT01095991|Drug|AZD1656|Oral tablet bd,
405761|NCT01095991|Drug|Sitagliptin|Oral tablet od
405762|NCT01095978|Drug|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
405763|NCT01095965|Behavioral|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
405764|NCT01095952|Device|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
405765|NCT01095939|Drug|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
405766|NCT01095939|Drug|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
405767|NCT01095926|Drug|doxorubicin|blood sampling before, during and after doxorubicin administration
405768|NCT01095913|Drug|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
405769|NCT01095900|Procedure|conservative lateral internal sphincterotomy|
405770|NCT01095900|Procedure|Intra-sphincteric Botulinum-toxin injection|
405771|NCT01095887|Drug|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
405772|NCT01095861|Device|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
405773|NCT01095861|Device|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT~Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
405774|NCT01095848|Biological|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
405775|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
405776|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
405777|NCT01095835|Drug|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
405778|NCT01095822|Drug|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
405779|NCT01095809|Drug|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
405780|NCT01095809|Drug|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
405781|NCT01095796|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
405782|NCT01095796|Drug|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
405783|NCT01095796|Drug|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
405784|NCT01095796|Drug|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
405785|NCT01095783|Procedure|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
405786|NCT01095783|Procedure|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
405787|NCT01095770|Procedure|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
405788|NCT01095770|Procedure|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
405789|NCT01095770|Device|Reveal XT|Reveal XT implantable loop recorder monitored group
405790|NCT01095770|Device|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
405913|NCT01094808|Drug|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
405791|NCT01095757|Drug|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is > 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
405792|NCT01095731|Drug|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
405793|NCT01095731|Drug|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
405794|NCT01095718|Behavioral|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
405795|NCT01095718|Behavioral|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
405796|NCT01095718|Behavioral|Trial and Error|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps."
405797|NCT01095705|Procedure|Conventional procedure|Local anaesthesia (Lidocaïne)
405798|NCT01095705|Procedure|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
405799|NCT01095692|Procedure|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
405800|NCT01095692|Procedure|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
405801|NCT01095679|Drug|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
405802|NCT01095679|Drug|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
405803|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
405804|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
405805|NCT01095666|Drug|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
405806|NCT01095666|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
405807|NCT01095666|Drug|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
405808|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
405809|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
405810|NCT01095653|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
405811|NCT01095653|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
405812|NCT01095640|Drug|adapalene 0.3% topical gel|once a day, 84 days
405813|NCT01095627|Other|Metacholine challenge|Exhaled breath analysis following metacholine challenge
405814|NCT01095601|Drug|Avanafil|"Treatment A: 2x100 mg Formulation II avanafil tablet, fasted~Treatment B: 2x100 mg Formulation II avanafil tablet, fed~Treatment C: 2x100 mg Formulation I avanafil tablet, fasted~Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
405815|NCT01095588|Drug|200 mg Avanafil|2 X 100mg tablets avanafil
405816|NCT01095588|Drug|Placebo|2 tablets
405817|NCT01095575|Drug|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
405818|NCT01095562|Drug|ABT-126|ABT-126 Dose 1, ABT-126 Dose 2
405819|NCT01095562|Drug|Placebo|Placebo
405820|NCT01095549|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
405821|NCT01095549|Device|Placebo device|A device without far infrared therapy
405822|NCT01095523|Procedure|Laparotomy+ HIPEC +/- CRS|
405823|NCT01095510|Biological|CINRYZE|
405824|NCT01095497|Biological|CINRYZE|C1 esterase inhibitor (human)
405825|NCT01095484|Drug|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
405914|NCT01094808|Drug|Placebo|Placebo capsules
405826|NCT01095471|Biological|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
405827|NCT01095458|Behavioral|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
405828|NCT01095445|Drug|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
405829|NCT01095432|Procedure|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
405830|NCT01095419|Other|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
405831|NCT01095419|Other|Control|no intervention
405832|NCT01095406|Device|S1 ventilation|Ventilation with a O2 and CO2 controller
405833|NCT01095380|Other|Locomotor training|Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
405834|NCT01095367|Procedure|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.~Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
405835|NCT01095354|Drug|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: >6 years Multiple Breath Washout: Tidal breathing using a facemask <9 years or mouthpiece >9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches <0.1%.~Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.~Induced sputum in asthma subjects >10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
405836|NCT01095341|Other|No intervention performed|
405837|NCT01095328|Other|screening|screening for Q-fever with a single blood sampling
405838|NCT01095315|Other|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
405839|NCT01095302|Drug|OMBRABULIN (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
405840|NCT01095302|Drug|cisplatin|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
405841|NCT01095302|Drug|docetaxel|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
405842|NCT01095276|Drug|Pulmozyme (nebulized dornase alpha)|nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
405843|NCT01095276|Drug|Saline|Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
405844|NCT01095263|Device|DBS|130Hz, 90us pulsewidth, 4V Amplitude
405845|NCT01095263|Device|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
405846|NCT01095250|Drug|AIN457|
405847|NCT01095250|Drug|AIN457|
405848|NCT01095250|Drug|AIN457|
405849|NCT01095250|Drug|Placebo|
405850|NCT01095237|Device|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
405851|NCT01095224|Biological|rAd35 Env A|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
405852|NCT01095224|Biological|rAd5 Env A|1 x 10^10 PU administered as 1 mL IM in deltoid
405853|NCT01095224|Biological|rAd5 Env B|1 x 10^10 PU administered as 1 mL IM in deltoid
405854|NCT01095211|Drug|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
405855|NCT01095198|Device|offer of vaginal self collection|Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
405856|NCT01095198|Other|2nd reminder letter for Pap testing|Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
405857|NCT01095185|Drug|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
405858|NCT01095185|Drug|Placebo|Simvastatin placebo
405859|NCT01095172|Drug|Rituximab|375mg/m^2, single dose given 2-4 weeks prior to transplantation
405860|NCT01095172|Drug|Tacrolimus|dose calculated to give levels of 3-7ng/ml
405861|NCT01095172|Drug|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
405862|NCT01095172|Drug|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
405863|NCT01095172|Drug|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
405864|NCT01095172|Drug|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
405865|NCT01095159|Device|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
405866|NCT01095159|Device|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
405867|NCT01095133|Drug|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
405868|NCT01095133|Drug|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
405869|NCT01095120|Drug|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.~For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.~For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
405870|NCT01095107|Dietary Supplement|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
405871|NCT01095107|Dietary Supplement|Increased fat intake|increased fat intake : Intake > 50 grams of fat per day between meals and snacks
405872|NCT01095094|Drug|ritonavir|Given orally
405873|NCT01095094|Drug|lopinavir|Given orally
405874|NCT01095081|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
405875|NCT01095068|Behavioral|Physical exercise|
405876|NCT01095055|Biological|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly
405877|NCT01095055|Biological|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly
405878|NCT01095042|Behavioral|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
405879|NCT01095029|Device|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
405880|NCT01095016|Drug|Meptin swinghaler|"Dose: 10ug/puff, 2 puffs daily~Frequency: QD (total 20ug/day)~Treatment duration: 2 days"
405881|NCT01095016|Drug|Berotec|"Dose: 100ug/puff, 2 puffs daily~Frequency: QD (total 200ug/day)~Treatment duration: 2 days"
405882|NCT01095003|Drug|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks~Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
405883|NCT01095003|Drug|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
405884|NCT01094990|Drug|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
405885|NCT01094977|Drug|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
405886|NCT01094977|Drug|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
405887|NCT01094977|Drug|Saline Placebo|
405888|NCT01094964|Biological|BCG solution|
405889|NCT01094964|Biological|recombinant interferon alfa|
405890|NCT01094964|Drug|epirubicin hydrochloride|
405891|NCT01094964|Drug|mitomycin C|
405892|NCT01094964|Other|laboratory biomarker analysis|
405893|NCT01094964|Procedure|hyperthermia treatment|
405894|NCT01094964|Procedure|quality-of-life assessment|
405895|NCT01094951|Behavioral|ENGAGE|During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
405896|NCT01094925|Drug|lactose|Single oral dose
405897|NCT01094925|Drug|Gabapentin 300mg|Single oral dose of 300mg gabapentin
405898|NCT01094925|Drug|Gabapentin 600mg|Single oral dose of 600mg gabapentin
405899|NCT01094912|Drug|opioids|
405900|NCT01094899|Radiation|Radiography|Radiography, microscanner, osteodensitometry
405901|NCT01094899|Other|Urine and Blood sampling|mainly dosage of bones metabolism
405902|NCT01094899|Other|Echography|body bones echography
405903|NCT01094886|Drug|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
405904|NCT01094873|Biological|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
405905|NCT01094873|Biological|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
405906|NCT01094860|Drug|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
405907|NCT01094847|Drug|DWJ1252|tablet(oral) administration following the schedule of each arm
405908|NCT01094834|Drug|DWP05195|tablets, oral administration, multiple administration
405909|NCT01094821|Drug|ATI-7505|3 mg three times daily for 9 days
405910|NCT01094821|Drug|Placebo|Placebo capsule three times daily for 9 days
405911|NCT01094821|Drug|ATI-7505|10 mg ATI-7505 three times daily for 9 days
405912|NCT01094821|Drug|ATI-7505|20 mg ATI-7505 three times daily for 9 days
405915|NCT01094808|Other|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
405916|NCT01094782|Other|Acupuncture|Subjects receive 6 acupuncture treatments for neck or back pain.
405917|NCT01094782|Other|Sham Acupuncture|Subjects receive 6 sham acupuncture treatments for neck or back pain.
405918|NCT01094769|Drug|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
405919|NCT01094769|Drug|Placebo|lactose capsule taken once daily
405920|NCT01094756|Dietary Supplement|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
405921|NCT01094743|Device|galyfilcon A prototype lens|Silicone hydrogel contact lens
405922|NCT01094743|Device|lotrafilcon B lens|Silicon Hydrogel contact lens
405923|NCT01094730|Device|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
405924|NCT01094730|Device|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
405925|NCT01094717|Drug|Acitretin 25Mg Oral Capsule|Acitretin 25 mg oral daily for 12 weeks
405926|NCT01094717|Device|Excimer laser|Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser.
405927|NCT01094717|Drug|Tazarotene 0.1% Gel,Top|Topical tazarotene 0.1% gel was applied daily to active lesions.
405928|NCT01094717|Device|Sham excimer laser|Lesions on randomly assigned left or right side of body were treated with sham excimer laser (opaque cover on the laser device).
405929|NCT01094704|Drug|sodium chloride (7%)|4mL nebulized 7% sodium chloride
405930|NCT01094691|Procedure|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
405931|NCT01094678|Device|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
405932|NCT01094665|Procedure|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
405933|NCT01094652|Dietary Supplement|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
405934|NCT01094652|Dietary Supplement|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
405935|NCT01094639|Procedure|Scaling root planing|Deep gum cleaning with local anesthesia
405936|NCT01094639|Procedure|Supragingival Prophylaxis|Plaque removal
405937|NCT01094626|Drug|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
405938|NCT01094613|Drug|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.~Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
405939|NCT01094613|Drug|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
405940|NCT01094600|Drug|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
405941|NCT01094587|Procedure|Gastroschisis closure with suture|
405942|NCT01094587|Procedure|Gastroschisis closure without suture|
405943|NCT01094574|Drug|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
405944|NCT01094574|Drug|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
405945|NCT01094574|Drug|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
405946|NCT01094561|Drug|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
405947|NCT01094561|Procedure|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
405948|NCT01094561|Procedure|Secretin-Enhanced Endoscopic Ultrasound|
405949|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
405982|NCT01094288|Drug|Alisertib|Alisertib ECT
405950|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
405951|NCT01094548|Drug|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
405952|NCT01094548|Drug|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
405953|NCT01094535|Drug|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
405954|NCT01094522|Drug|Methadone|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
405955|NCT01094522|Drug|Morphine|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
405956|NCT01094509|Behavioral|Tai Chi|Tai Chi classes and exercises
405957|NCT01094509|Behavioral|Guided autobiography|Autobiographical writing in class and at home
405958|NCT01094509|Behavioral|Qigong|Qigong classes and exercises (exploratory)
405959|NCT01094509|Behavioral|Successful aging|Seminar series on the theme of successful aging
405960|NCT01094509|Behavioral|Combination|Combination of Tai Chi exercises and autobiographical writing
405961|NCT01094509|Behavioral|Comparison|No assigned behavioral activity (exploratory)
405962|NCT01094496|Biological|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
405963|NCT01094496|Drug|Chemotherapy|
405964|NCT01094483|Drug|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
405965|NCT01094483|Drug|ASA|Asprin 81 mg enteric coated tablet
405966|NCT01094483|Drug|Placebo|
405967|NCT01094470|Device|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
405968|NCT01094457|Drug|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
405969|NCT01094457|Drug|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
405970|NCT01094444|Other|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
405971|NCT01094418|Other|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.~NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
405972|NCT01094405|Biological|Recombinant Epstein-Barr Virus (EBV) Vaccine|
405973|NCT01094379|Procedure|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
405974|NCT01094379|Procedure|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
405975|NCT01094366|Procedure|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
405976|NCT01094366|Procedure|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
405977|NCT01094353|Procedure|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
405978|NCT01094353|Procedure|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
405979|NCT01094340|Drug|Thalidomide|fixed dose over 8 clinic visits
405980|NCT01094314|Other|embryo culture medium|comparison between two types of embryo culture medium
405981|NCT01094301|Device|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
405983|NCT01094288|Drug|Docetaxel|Docetaxel IV infusion
405984|NCT01094275|Drug|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
405985|NCT01094262|Drug|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
405986|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
405987|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
405988|NCT01094262|Drug|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
405989|NCT01094249|Drug|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
405990|NCT01094236|Behavioral|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
405991|NCT01094223|Behavioral|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
405992|NCT01094223|Behavioral|Health Education|Psychoeducation group focused on various topics pertaining to physical health
405993|NCT01094210|Drug|Fluorides, Topical|500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
405994|NCT01094184|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 mg/kg Q2W or 15 mg/kg Q3W as intravenous infusion.
405995|NCT01094184|Drug|Paclitaxel|Paclitaxel will be administered as intravenous infusion Q1W as per discretion of the treating physician.
405996|NCT01094184|Drug|Docetaxel|Docetaxel will be administered as intravenous infusion Q3W as per discretion of the treating physician. Protocol amendment 2 (dated 17-Feb-2011) removed the option to choose docetaxel.
405997|NCT01094171|Biological|Poliorix TM|Intramuscular administration, 3 doses
405998|NCT01094171|Biological|Infanrix TM|Intramuscular administration, 3 doses
405999|NCT01094158|Drug|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
406000|NCT01094158|Drug|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
406001|NCT01094158|Drug|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
406002|NCT01094145|Other|Deep brain stimulation|DBS in the Nucleus basalis Meynert
406003|NCT01094132|Device|Multispectral Digital Colposcope (MDC)|"The MDC has 2 components: an optical probe & a multispectral colposcope. The optical wand makes use of fluorescence & reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer & healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence & polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.~This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.~All study subjects will receive this same intervention."
406004|NCT01094119|Device|heated blanket|heated blanket
406005|NCT01094119|Device|heated pad|patients will be warmed with a heated pad during surgery.
406006|NCT01094106|Drug|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
406007|NCT01094106|Drug|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
406008|NCT01094093|Drug|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
406009|NCT01094080|Other|standard infant formula|infants are fed a commercial formula
406010|NCT01094080|Other|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
406011|NCT01094080|Other|breast milk|infants are breast fed
406012|NCT01094067|Drug|ACT-050089|5 mg/h intravenously, Tezosentan
406013|NCT01094067|Other|Placebo|Matching placebo
406014|NCT01094054|Procedure|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
406015|NCT01094054|Behavioral|Dietary and lifestyle modification|"Dietary and lifestyle modification~Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
406016|NCT01094041|Other|Gluten free diet|A 4-week gluten free diet provided
406017|NCT01094041|Other|Gluten rich diet|A 4-week gluten rich diet is provided
406018|NCT01094028|Drug|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
406019|NCT01094015|Drug|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
406020|NCT01094015|Other|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
406021|NCT01094002|Other|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.~Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.~Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
406022|NCT01093989|Dietary Supplement|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
406023|NCT01093976|Drug|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
406024|NCT01093963|Drug|Lisdexamfetamine|oral; 20-70mg/day
406025|NCT01093963|Drug|Placebo|oral; 20-70mg/day
406026|NCT01093937|Drug|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
406027|NCT01093924|Behavioral|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
406028|NCT01093911|Biological|CDP7657|Ascending single doses of CDP7657
406029|NCT01093911|Other|Placebo|Placebo: 0.9% sodium chloride aqueous solution
406030|NCT01093885|Drug|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
406031|NCT01093872|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions~Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
406032|NCT01093859|Drug|PRX-105|Sterile solution for intravenous injection
406033|NCT01093846|Drug|AIN457|300mg every 4 weeks
406034|NCT01093846|Drug|AIN457|300mg every 2 weeks
406035|NCT01093846|Drug|Placebo AIN457|Placebo to AIN457
406036|NCT01093833|Device|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
406037|NCT01093833|Device|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
406038|NCT01093833|Device|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
406039|NCT01093820|Drug|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
406040|NCT01093807|Drug|Placebo|once daily for 10 weeks
406041|NCT01093807|Drug|Lercanidipine|10 mg once daily for 10 weeks
406042|NCT01093807|Drug|Lercanidipine|20 mg once daily for 10 weeks
406043|NCT01093807|Drug|Enalapril|10 mg once daily for 10 weeks
406044|NCT01093807|Drug|Enalapril|20 mg once daily for 10 weeks
406045|NCT01093807|Drug|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
406046|NCT01093807|Drug|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
406047|NCT01093807|Drug|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
406048|NCT01093807|Drug|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
406049|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
406050|NCT01093794|Drug|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
406051|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
406052|NCT01093794|Drug|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
406053|NCT01093781|Drug|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
406054|NCT01093768|Drug|Oxytocin|
406055|NCT01093768|Drug|Vasopressin|
406056|NCT01093755|Drug|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
406057|NCT01093755|Drug|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
406058|NCT01093742|Drug|HM10560A|Subcutaneously administrate at 0 hour on Day 1
406059|NCT01093742|Drug|Placebo|Placebo
406060|NCT01093729|Drug|HM11260C|HM11260C 0.5mcg/kg or Placebo
406061|NCT01093729|Drug|HM11260C|HM11260C 2mcg/kg or Placebo
406062|NCT01093729|Drug|HM11260C|HM11260C 4mcg/kg or Placebo
406063|NCT01093729|Drug|HM11260C|HM11260C 8mcg/kg or Placebo
406064|NCT01093729|Drug|HM11260C|HM11260C 14mcg/kg or Placebo
406065|NCT01093716|Device|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
406291|NCT01092156|Behavioral|Education|Education on Infant-led latching
406066|NCT01093703|Other|Medication Adjustment|"Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.~Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.~Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.~Awake SBP>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time."
406067|NCT01093690|Drug|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
406068|NCT01093690|Drug|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
406069|NCT01093677|Drug|LIM-0705|Oral solution 750 mg LIM 0705 BID for 14 days.
406070|NCT01093677|Drug|Placebo|Oral solution placebo BID for 14 days.
406071|NCT01093664|Biological|AFFITOPE AD02|s.c. injection
406072|NCT01093651|Drug|Sitagliptin|100 mg sitagliptin daily for 4-6 months
406073|NCT01093651|Drug|Placebo|Daily placebo for 4-6 months
406074|NCT01093638|Biological|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
406075|NCT01093638|Biological|Placebo|Oral formulation of placebo fed concomitantly with infant formula
406076|NCT01093625|Device|Narafilcon B Contact Lens|
406077|NCT01093625|Device|Spectacles|spectacle wearers
406078|NCT01093612|Procedure|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
406079|NCT01093612|Radiation|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
406080|NCT01093612|Procedure|Biopsy|Correlative Studies
406081|NCT01093612|Other|Immunohistochemistry staining method|Correlative studies
406082|NCT01093612|Other|laboratory biomarker analysis|Correlative studies
406083|NCT01093612|Genetic|mutation analysis|Correlative studies
406084|NCT01093599|Behavioral|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
406085|NCT01093599|Behavioral|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
406086|NCT01093586|Procedure|double-unit umbilical cord blood transplantation|Undergo transplantation
406087|NCT01093586|Other|cytogenetic analysis|Correlative studies
406088|NCT01093586|Procedure|bone marrow aspiration|Correlative studies
406089|NCT01093586|Other|fluorescence in situ hybridization|Correlative studies
406090|NCT01093586|Drug|busulfan|Given orally
406091|NCT01093586|Drug|cyclophosphamide|Given IV
406092|NCT01093586|Drug|anti-thymocyte globulin|Given IV
406093|NCT01093586|Drug|methylprednisolone|Given IV
406094|NCT01093586|Drug|cyclosporine|Given IV
406095|NCT01093586|Drug|mycophenolate mofetil|Given orally or IV
406096|NCT01093586|Other|flow cytometry|Correlative studies
406097|NCT01093586|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
406098|NCT01093573|Drug|midostaurin|Given orally
406099|NCT01093573|Drug|azacitidine|Given IV
406100|NCT01093573|Other|laboratory biomarker analysis|Correlative study
406101|NCT01093573|Other|bone marrow aspiration|Correlative study
406102|NCT01093573|Other|liquid chromatography|Correlative study
406103|NCT01093573|Other|flow cytometry|Correlative study
406104|NCT01093573|Other|mutation analysis|Correlative study
406105|NCT01093573|Other|pharmacological study|Correlative study
406106|NCT01093573|Other|mass spectrometry|Correlative study
406107|NCT01093573|Other|protein expression analysis|Correlative study
406108|NCT01093560|Dietary Supplement|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
406109|NCT01093547|Procedure|Blood samples|Samples taken monthly
406110|NCT01093547|Procedure|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
406111|NCT01093534|Drug|Placebo|Matching solifenacin placebo tablet
406112|NCT01093534|Drug|solifenacin|Tablet for oral administration
406113|NCT01093521|Drug|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
406114|NCT01093521|Drug|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
406115|NCT01093508|Drug|APD916|
406116|NCT01093495|Device|CPAP|CPAP
406117|NCT01093495|Device|Nasal Cannula|Nasal Cannula
406118|NCT01093469|Drug|Atopiclair Nonsteroidal Cream|
406119|NCT01093469|Other|Aquaphor Healing Ointment|
406120|NCT01093469|Drug|EpiCeram|
406121|NCT01093443|Drug|ovarian stimulation|rFSH with GnRH antagonists
406122|NCT01093443|Drug|ovarian stimulation|GnRH antagonist, rFSH, GnRH antagonist
406123|NCT01093430|Procedure|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
406124|NCT01093430|Procedure|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
406125|NCT01093417|Drug|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
406126|NCT01093417|Other|Placebo|Placebo pills will be administered to enrollees in this arm
406127|NCT01093404|Procedure|Thrombus aspiration|Aspiration of thrombus material before angioplasty
406207|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
406292|NCT01092143|Drug|BI671800|double blind randomized parallel group study
406293|NCT01092143|Drug|BI671800|double blind randomized parallel group study
406294|NCT01092143|Drug|BI 671800|double blind randomized parallel
406128|NCT01093391|Device|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
406129|NCT01093391|Device|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
406130|NCT01093365|Drug|Varenicline|"0.0 mg orally twice per day for three days (placebo)~0.5 mg orally twice per day for three days~1.0 mg orally twice per day for three days"
406131|NCT01093352|Procedure|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
406132|NCT01093326|Drug|Ponesimod 10 mg|Ponesimod 10 mg oral use
406133|NCT01093326|Drug|Ponesimod 20 mg|Ponesimod 20 mg oral use
406134|NCT01093326|Drug|Ponesimod 40 mg|Ponesimod 40 mg oral use
406135|NCT01093313|Behavioral|Cognitive therapy|
406136|NCT01093313|Behavioral|attention training|
406137|NCT01093300|Device|Paclitaxel-eluting balloon catheter|
406138|NCT01093300|Device|Everolimus-eluting stent|
406139|NCT01093274|Drug|Sodium Picosulphate|2 Sachets
406140|NCT01093274|Drug|Polyethylene Glycol|3 Liters solution
406141|NCT01093261|Drug|Placebo|"Placebo:~continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
406142|NCT01093261|Drug|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
406143|NCT01093235|Biological|bevacizumab|
406144|NCT01093235|Drug|cyclophosphamide|
406145|NCT01093235|Drug|docetaxel|
406146|NCT01093235|Drug|epirubicin hydrochloride|
406147|NCT01093235|Drug|fluorouracil|
406148|NCT01093235|Procedure|assessment of therapy complications|
406149|NCT01093235|Procedure|neoadjuvant therapy|
406150|NCT01093235|Procedure|quality-of-life assessment|
406151|NCT01093235|Procedure|therapeutic conventional surgery|
406152|NCT01093222|Drug|Erlotinib Hydrochloride|Given PO
406153|NCT01093222|Drug|Sorafenib Tosylate|Given PO
406154|NCT01093209|Device|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
406155|NCT01093196|Drug|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period [different doses according to the age of patients (65-75 or >75 years old);oral Prednisone for 4 days followed by a 24 day rest period.~Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.~ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
406156|NCT01093196|Drug|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period [day 21 to 28]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
406157|NCT01093196|Drug|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
406158|NCT01093183|Drug|lenalidomide|Given PO
406159|NCT01093183|Drug|cyclophosphamide|Given PO
406160|NCT01093183|Other|laboratory biomarker analysis|Correlative studies
406161|NCT01093183|Other|questionnaire administration|Ancillary studies
406162|NCT01093183|Other|quality-of-life assessment|Ancillary studies
406163|NCT01093170|Drug|RNA-144101|Intravitreous administration of RNA-144101
406282|NCT01092247|Other|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
406283|NCT01092234|Other|Traditional ward|provision of care in a traditional unit/ward.
406164|NCT01093157|Drug|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
406165|NCT01093144|Device|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
406166|NCT01093131|Other|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
406167|NCT01093131|Drug|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
406168|NCT01093131|Other|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
406169|NCT01093131|Drug|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
406170|NCT01093118|Drug|TMI-358|Micro implant monthly x 3
406171|NCT01093118|Drug|MMI-467|Micro implant monthly x 3
406172|NCT01093092|Dietary Supplement|Calcitriol|Given PO
406173|NCT01093092|Drug|Cisplatin|Given IV
406174|NCT01093092|Drug|Gemcitabine Hydrochloride|Given IV
406175|NCT01093092|Other|Pharmacological Study|Correlative studies
406176|NCT01093079|Procedure|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
406177|NCT01093079|Procedure|Open partial nephrectomy|Open partial nephrectomy
406178|NCT01093066|Drug|optimal TURB|The TURB will always try to be optically complete.
406179|NCT01093053|Behavioral|Mind-Body Skills Groups|The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
406180|NCT01093053|Other|Standard Treatment|May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
406181|NCT01093040|Drug|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
406182|NCT01093040|Drug|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
406183|NCT01093040|Drug|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
406184|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
406185|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
406186|NCT01093014|Behavioral|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
406187|NCT01093014|Behavioral|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
406188|NCT01093014|Behavioral|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
406189|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
406190|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
406191|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
406192|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
406193|NCT01092988|Device|Exablate 2100|MR guided focused ultrasound
406194|NCT01092975|Drug|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
406195|NCT01092962|Drug|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
406196|NCT01092962|Drug|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
406197|NCT01092949|Device|MRI|MRI, 45 minutes
406198|NCT01092936|Other|Rating Scale administration|Movement Disorder Society_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
406199|NCT01092923|Drug|sevoflurane on air/O2|sevoflurane on air/O2
406200|NCT01092923|Drug|sevoflurane in N2O/O2|sevoflurane in N2O/O2
406201|NCT01092910|Device|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
406202|NCT01092884|Dietary Supplement|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
406203|NCT01092884|Other|Placebo|This placebo capsule will be taken orally three times daily
406204|NCT01092858|Drug|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
406205|NCT01092858|Drug|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
406206|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
406817|NCT01088048|Drug|Lenalidomide|Lenalidomide administered orally
406208|NCT01092832|Drug|voriconazole|"Subjects 12 - <18 yrs (excluding subjects 12 - 14 yrs weighing <50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - <12 yrs, and subjects 12 - 14 weighing <50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
406209|NCT01092819|Other|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
406210|NCT01092806|Drug|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
406211|NCT01092793|Dietary Supplement|Krill|
406212|NCT01092793|Dietary Supplement|Fish oil|
406213|NCT01092780|Drug|MK-7288|one or two 10 mg capsules, orally, single dose
406214|NCT01092780|Drug|Placebo to MK-7288|one or two capsules, orally, single dose
406215|NCT01092780|Drug|Modafinil|two 100 mg tablets, orally, single dose
406216|NCT01092780|Drug|Placebo to modafinil|two 100 mg tablets, orally, single dose
406217|NCT01092767|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
406218|NCT01092754|Procedure|MRI|contrast enhanced MRI
406219|NCT01092754|Procedure|MRI|contrast enhanced MRI
406220|NCT01092754|Drug|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
406221|NCT01092741|Drug|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
406222|NCT01092728|Drug|Dasatinib|100 mg daily.
406223|NCT01092728|Procedure|Surgical Resection|Complete surgical resection of tumor(s).
406224|NCT01092715|Procedure|Spinal mobilization|Non thrust mobilization to the cervical spine
406225|NCT01092715|Procedure|Massage|Sedative massage to cervical paraspinal muscles
406226|NCT01092715|Procedure|Neck exercises|Range of motion exercises to include foraminal opening
406227|NCT01092702|Drug|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
406228|NCT01092689|Drug|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies [14C]PhIP
406229|NCT01092676|Drug|Ibuprofen Regular Dosing|Regular dosing
406230|NCT01092676|Drug|PRN dosing Ibuprofen|PRN dosing Ibupofen
406231|NCT01092663|Drug|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
406232|NCT01092663|Drug|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
406233|NCT01092650|Drug|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
406234|NCT01092624|Drug|Solifenacin|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
406235|NCT01092624|Drug|Placebo|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
406236|NCT01092624|Device|Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
406237|NCT01092611|Procedure|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
406238|NCT01092611|Biological|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
406284|NCT01092234|Other|Organizational change|Observational unit (new organizational unit) for organizing in-hospital care
406285|NCT01092221|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, BID
406286|NCT01092221|Drug|Placebo|Placebo 1 capsule, 300 mg, BID
406287|NCT01092195|Biological|Gardasil|3 separate 0.5 ml intramuscular
406288|NCT01092182|Drug|EPOCH-R|EPOCH-R every 21 days for 6 cycles
406239|NCT01092585|Drug|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.~In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
406240|NCT01092572|Drug|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
406241|NCT01092572|Drug|placebo|placebo 1 tablet once daily for 12 weeks
406242|NCT01092559|Drug|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
406243|NCT01092546|Drug|[18F]Flutemetamol|All subjects will receive an IV dose of [18F]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 MBq.
406244|NCT01092533|Drug|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
406245|NCT01092533|Drug|Decortin|Maintenance dose 5 mg/d
406246|NCT01092520|Drug|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
406247|NCT01092507|Biological|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
406248|NCT01092507|Biological|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
406249|NCT01092481|Drug|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
406250|NCT01092468|Procedure|Diathermy|flap dissection with conventional diathermy
406251|NCT01092468|Procedure|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
406252|NCT01092455|Drug|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
406253|NCT01092442|Procedure|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
406254|NCT01092416|Device|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
406255|NCT01092403|Drug|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
406256|NCT01092403|Drug|Placebo|Placebo once daily by inhalation
406257|NCT01092390|Dietary Supplement|Lovaza (fish oil)|4 grams per day
406258|NCT01092377|Dietary Supplement|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
406259|NCT01092377|Dietary Supplement|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
406260|NCT01092377|Other|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
406261|NCT01092377|Other|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
406262|NCT01092364|Behavioral|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
406263|NCT01092351|Drug|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
406264|NCT01092338|Drug|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
406265|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
406266|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
406267|NCT01092325|Drug|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
406268|NCT01092325|Drug|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
406269|NCT01092325|Drug|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
406270|NCT01092325|Drug|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
406271|NCT01092312|Procedure|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
406272|NCT01092312|Procedure|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
406273|NCT01092299|Drug|AZD1446|ER Fast, 90mg, p.o. capsule
406274|NCT01092299|Drug|AZD1446|ER Moderate, 90mg, p.o. capsule
406275|NCT01092299|Drug|AZD1446|ER Slow, 90mg, p.o. capsule
406276|NCT01092299|Drug|AZD1446|MR
406277|NCT01092299|Drug|AZD1446|IR, 90 mg p.o. capsule
406278|NCT01092299|Drug|Placebo|IR
406279|NCT01092299|Drug|Placebo|ER/MR
406280|NCT01092286|Other|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
406281|NCT01092247|Other|Nutritional support with Standard diet|Nutritional support with Standard diet
406289|NCT01092182|Drug|EPOCH-RR|EPOCH-R every 21 days for 3 cycles
406295|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
406296|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
406297|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
406298|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
406299|NCT01092143|Drug|Fluticasone|double blind randomized parallel
406300|NCT01092143|Drug|BI 671800 Placebo|double blind randomized parallel
406301|NCT01092143|Drug|BI 671800 Placebo|double blind randomized parallel
406302|NCT01092130|Drug|Vitamin D|2000 IU vitamin D daily, for 6 weeks
406303|NCT01092117|Device|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
406304|NCT01092104|Drug|TBR-652|TBR-652 25 mg
406305|NCT01092104|Drug|TBR-652 Matching Placebo|Matching Placebo
406306|NCT01092104|Drug|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
406307|NCT01092104|Drug|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
406308|NCT01092104|Drug|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
406309|NCT01092104|Drug|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
406310|NCT01092091|Biological|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
406311|NCT01092078|Behavioral|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
406312|NCT01092078|Behavioral|Patient Navigation|Patient navigation for colonoscopy.
406313|NCT01092065|Drug|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
406314|NCT01092065|Drug|Placebo|hard gelatin capsule to be taken bid for six weeks
406315|NCT01092052|Drug|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
406316|NCT01092039|Dietary Supplement|lactoferrin, L-Glutamine and beta-glucans|Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
406317|NCT01092039|Dietary Supplement|Placebo Comparator|Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
406318|NCT01092026|Other|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
406319|NCT01092013|Behavioral|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
406320|NCT01092013|Behavioral|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
406321|NCT01092013|Behavioral|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
406322|NCT01092000|Behavioral|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
406323|NCT01092000|Other|Education|Monthly exercise tips handout.
406324|NCT01091987|Behavioral|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
406325|NCT01091974|Drug|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
406326|NCT01091974|Drug|Placebo Comparator|Placebo for 47 days
406327|NCT01091974|Behavioral|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
406328|NCT01091961|Procedure|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
406329|NCT01091948|Device|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
406330|NCT01091948|Device|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
406331|NCT01091922|Dietary Supplement|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
406332|NCT01091922|Dietary Supplement|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
406333|NCT01091909|Procedure|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
406334|NCT01091896|Drug|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
406335|NCT01091896|Drug|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
406336|NCT01091883|Device|Exablate treatment|MR Guided Focused Ultrasound
406337|NCT01091883|Radiation|Radiation|External Beam Radiation
406338|NCT01091870|Drug|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
406339|NCT01091870|Drug|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
406340|NCT01091870|Drug|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
406341|NCT01091857|Behavioral|STRIDE|
406342|NCT01091844|Procedure|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
406343|NCT01091831|Drug|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
406344|NCT01091831|Drug|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
406345|NCT01091831|Drug|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
406346|NCT01091831|Drug|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
406347|NCT01091818|Drug|dexmedetomidine|Dexemedethomidine is given as major sedative drug
406348|NCT01091818|Drug|Midazolam|Midazolam is given as major sedative drug
406349|NCT01091792|Drug|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
406350|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
406351|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
406352|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
406353|NCT01091753|Drug|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
406354|NCT01091740|Device|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
406355|NCT01091740|Device|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
406356|NCT01091727|Drug|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
406357|NCT01091714|Dietary Supplement|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
406358|NCT01091714|Dietary Supplement|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
406359|NCT01091714|Dietary Supplement|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
406360|NCT01091701|Biological|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
406361|NCT01091701|Other|Plasmalyte-A|Single IV dose of Plasmalyte-A
406362|NCT01091688|Behavioral|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
406363|NCT01091675|Drug|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
406364|NCT01091662|Drug|Eslicarbazepine acetate 1600 mg|1600 mg once per day
406365|NCT01091662|Drug|Eslicarbazepine acetate 1200 mg|1200 once per day
406366|NCT01091649|Drug|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
406367|NCT01091649|Drug|ritonavir|ritonavir see Arm Description for more information
406368|NCT01091649|Drug|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
406369|NCT01091636|Procedure|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
406370|NCT01091623|Other|training|
406371|NCT01091623|Other|training|
406372|NCT01091623|Other|training|
406373|NCT01091610|Other|no intervention|purely observational retrospective study. no interventions are planned.
406374|NCT01091597|Procedure|usual PV ablation|usual PV ablation, per above
406375|NCT01091597|Procedure|Box isolation of pulmonary veins|as above
406376|NCT01091584|Device|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
406377|NCT01091571|Drug|Dipyridamole|Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
406378|NCT01091571|Drug|Placebo|Placebo twice daily during seven consecutive days
406379|NCT01091571|Other|LPS|The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
406380|NCT01091545|Radiation|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
406381|NCT01091532|Drug|UK-396,082|"100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
406382|NCT01091532|Drug|placebo|given orally twice daily for 14 days
406383|NCT01091532|Drug|UK-396,082|"300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
406384|NCT01091532|Drug|placebo|given orally twice daily for 14 days
406385|NCT01091532|Drug|UK-396,082|"1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
406386|NCT01091532|Drug|placebo|given orally twice daily for 14 days
406387|NCT01091532|Drug|UK-396,082|"UK-396,082 given orally, once on Days 1 & 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
406388|NCT01091532|Drug|placebo|given orally, once on Days 1 & 14, and twice daily on Days 3-13.
406389|NCT01091519|Other|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
406390|NCT01091519|Other|Toviaz(fesoterodine) without educational materials|No educational materials
406391|NCT01091506|Other|Placebo|Placebo once a day for 12 weeks
406392|NCT01091506|Other|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
406393|NCT01091493|Drug|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
406394|NCT01091454|Drug|brostallicin|Given IV
406395|NCT01091454|Drug|cisplatin|Given IV
406396|NCT01091428|Drug|Alisertib|Alisertib tablets
406397|NCT01091428|Drug|Paclitaxel|Paclitaxel intravenous infusion
406398|NCT01091415|Procedure|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
406399|NCT01091402|Procedure|autologous serum skin test, serum IL-18|
406400|NCT01091389|Procedure|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
406401|NCT01091376|Drug|Erlotinib|Erlotinib 150mg/day
406402|NCT01091376|Radiation|Thoracic radiotherapy|60-70Gy/30-35f
406403|NCT01091363|Behavioral|Standard|10 minute brief cessation counseling
406404|NCT01091363|Behavioral|Deep Cultural|Deep culturally tailored cognitive behavioral therapy
406405|NCT01091350|Device|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
406406|NCT01091350|Device|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
406407|NCT01091337|Drug|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
406408|NCT01091337|Drug|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
406409|NCT01091324|Drug|Dextromethorphan|60 mg, bid
406410|NCT01091324|Drug|Silymarin|150 mg , tid
406411|NCT01091324|Drug|sugar pill|placebo
406412|NCT01091311|Device|Blephasteam|Eye lid warming goggles
406413|NCT01091298|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
406414|NCT01091298|Other|Placebo|Single dose (0.5 mL) of the placebo administered orally
406415|NCT01091285|Device|Foley Catheter|Foley Catheter 16-19 H
406416|NCT01091285|Device|Double Balloon Catheter|Double Balloon Catheter for 16-19H
406417|NCT01091272|Drug|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
406418|NCT01091272|Drug|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
406419|NCT01091272|Drug|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
406420|NCT01091272|Drug|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
406421|NCT01091259|Drug|Irinotecan|
406422|NCT01091259|Drug|Bevacizumab|
406423|NCT01091246|Biological|Q/LAIV (MEDI3250)|10 ^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
406424|NCT01091246|Biological|FluMist/B/Yamagata|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
406425|NCT01091246|Biological|FluMist/B/Victoria|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
406426|NCT01091233|Procedure|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
406427|NCT01091220|Biological|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
406428|NCT01091220|Biological|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
406429|NCT01091207|Drug|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
406430|NCT01091194|Other|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
406431|NCT01091181|Procedure|hysterotomy at cesarean|incision to open the uterus at cesarean.
406432|NCT01091168|Drug|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
406433|NCT01091168|Drug|Alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
406434|NCT01091155|Device|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
406435|NCT01091142|Drug|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
406436|NCT01091142|Drug|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
406437|NCT01091129|Device|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
406438|NCT01091116|Drug|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
406439|NCT01091116|Drug|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
406440|NCT01091116|Drug|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
406441|NCT01091116|Drug|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
406442|NCT01091116|Drug|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
406443|NCT01091103|Drug|Enzalutamide|
406444|NCT01091090|Behavioral|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
406445|NCT01091090|Behavioral|Control|Treatment as usual
408382|NCT01075256|Device|Placebo toothpaste|Placebo toothpaste
406446|NCT01091077|Dietary Supplement|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
406447|NCT01091064|Other|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
406448|NCT01091051|Drug|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
406449|NCT01091051|Drug|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
406450|NCT01091038|Other|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
406451|NCT01091038|Other|Routine Care|Routine Care
406452|NCT01091025|Other|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
406453|NCT01091012|Drug|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
406454|NCT01090999|Other|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
406455|NCT01090973|Drug|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.~After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
406456|NCT01090960|Drug|GDC-0068|Oral repeating dose
406457|NCT01090947|Device|ProtoCAD|Aquiring acoustic signals from heart patients.
406458|NCT01090934|Device|High Resolution EEG|High Resolution EEG
406459|NCT01090934|Device|Stereo-electroencephalography|SEEG
406460|NCT01090921|Drug|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
406461|NCT01090908|Drug|Antibiotic|
406462|NCT01090895|Drug|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
406463|NCT01090895|Drug|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
406464|NCT01090882|Drug|Bupivocaine|20ml 0.25% at beginning of operation
406465|NCT01090882|Drug|0.9% normal saline solution|20ml 0.9% NaCl
406466|NCT01090869|Behavioral|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
406467|NCT01090856|Procedure|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
406468|NCT01090843|Procedure|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
406469|NCT01090843|Device|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
406470|NCT01090843|Device|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
406517|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
408383|NCT01075243|Drug|Paracetamol 1000 mg|Paracetamol 1000mg
406471|NCT01090830|Drug|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
406472|NCT01090817|Drug|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
406473|NCT01090804|Device|BreatheMAX breathing device|secretion clearance, breathing exercise
406474|NCT01090791|Device|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
406475|NCT01090791|Device|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
406476|NCT01090778|Drug|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
406477|NCT01090765|Drug|TRC105|
406478|NCT01090752|Drug|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
406479|NCT01090752|Drug|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
406480|NCT01090739|Device|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
406481|NCT01090726|Device|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
406482|NCT01090726|Device|Airtraq|Airtraq being used for the actual intubation
406483|NCT01090713|Drug|lisdexamfetamine|oral; 20-70mg/day
406484|NCT01090713|Drug|Placebo control|20-70mg; oral
406485|NCT01090700|Drug|TMC435|TMC435 150 mg daily for 7 days
406486|NCT01090700|Drug|Escitalopram|Escitalopram 10 mg daily for 7 days
406487|NCT01090700|Drug|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
406488|NCT01090687|Radiation|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
406489|NCT01090687|Device|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
406490|NCT01090674|Other|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
406491|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen intravenous (IV) (single dose)
406492|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen subcutaneous (SC) (single dose)
406493|NCT01090661|Drug|moxifloxacin hydrochloride (Avelox®)|400 mg of moxifloxacin intravenous (IV) single dose
406494|NCT01090661|Drug|placebo|placebo intravenous (IV) single dose
406495|NCT01090661|Drug|placebo|placebo subcutaneous (SC) single dose
406496|NCT01090648|Drug|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
406497|NCT01090622|Drug|XPF-001|Oral capsule
406498|NCT01090622|Drug|Placebo|Oral capsule
406499|NCT01090609|Device|Stent implantation|Stent implantation
406500|NCT01090596|Drug|Naproxen|500mg naproxen, twice daily for 7 days
406501|NCT01090596|Drug|Placebo|1 tab,twice a day for a seven days
406502|NCT01090583|Other|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
406503|NCT01090570|Drug|PLX3397|Once-daily oral capsules
406504|NCT01090557|Other|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
406505|NCT01090544|Device|Nasal Insufflation|Breathing therapy
406506|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
406507|NCT01090518|Drug|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
406508|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
406509|NCT01090505|Drug|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
406510|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
406511|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
406512|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
406513|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
406514|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
406515|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
406516|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
406605|NCT01089751|Drug|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
406518|NCT01090479|Drug|2% Chlorhexidine cloth|The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
406519|NCT01090466|Drug|cisplatin|
406520|NCT01090466|Drug|gemcitabine hydrochloride|
406521|NCT01090466|Drug|temsirolimus|
406522|NCT01090466|Other|pharmacological study|
406523|NCT01090453|Biological|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
406524|NCT01090453|Biological|Prevenar 13®|3 co-administered doses
406525|NCT01090453|Biological|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
406526|NCT01090453|Biological|Menjugate®|3 co-administered doses
406527|NCT01090453|Biological|Rotarix™|Oral, two doses
406528|NCT01090440|Drug|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
406529|NCT01090427|Drug|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
406530|NCT01090427|Drug|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
406531|NCT01090427|Other|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
406532|NCT01090414|Drug|Idelalisib|Idelalisib tablets or capsules administered orally
406533|NCT01090401|Device|Linox smart S DX|ICD lead
406534|NCT01090375|Other|Exercise|
406535|NCT01090375|Other|Non Exercise|
406536|NCT01090349|Device|Implantation of an ICD/CRT-D device|The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.
406537|NCT01090349|Device|Merlin.NET PCN|The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
406538|NCT01090323|Drug|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
406539|NCT01090310|Drug|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
406540|NCT01090310|Drug|Placebo|Matching placebo to AIN457
406541|NCT01090297|Device|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
406542|NCT01090297|Device|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
406543|NCT01090297|Device|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.~These 3 types of CPAP can be set in both mode of pressure."
406544|NCT01090284|Device|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
406545|NCT01090271|Device|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
406546|NCT01090258|Device|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate [RR], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
406547|NCT01090258|Other|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
406548|NCT01090245|Behavioral|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
406549|NCT01090245|Behavioral|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
406550|NCT01090232|Other|blood samples|
406551|NCT01090232|Other|blood samples|
406552|NCT01090219|Procedure|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
406553|NCT01090206|Dietary Supplement|Vitamin D and calcium|Doses will be based on Vitamin D levels
406554|NCT01090193|Procedure|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
406555|NCT01090180|Drug|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
406556|NCT01090180|Drug|Placebo (sugar pill)|inactive
406557|NCT01090167|Drug|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
406558|NCT01090154|Drug|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
406559|NCT01090141|Drug|Micafungin|100 mg IV infusion over 1 hour
406560|NCT01090141|Drug|Micafungin|300 mg IV infusion over 1 hour
406561|NCT01090128|Drug|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
406562|NCT01090128|Drug|doxorubicin|50 mg/m2 every 3 weeks
406563|NCT01090128|Drug|cyclophosphamide|500 mg/m2 given every 3 weeks
406564|NCT01090102|Drug|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).~Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
406565|NCT01090102|Drug|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).~Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
406566|NCT01090089|Drug|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
406567|NCT01090089|Drug|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
406568|NCT01090076|Dietary Supplement|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
406569|NCT01090063|Drug|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
406570|NCT01090050|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
406571|NCT01090050|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
406572|NCT01090037|Drug|TRK-100STP high dose|
406573|NCT01090037|Drug|TRK-100STP low dose|
406574|NCT01090037|Drug|Placebo|
406575|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
406576|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
406577|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
406578|NCT01090024|Drug|Placebo|Patients receive placebo capsules
406579|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
406580|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
406581|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
406582|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
406583|NCT01089998|Drug|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
406584|NCT01089998|Drug|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
406585|NCT01089998|Drug|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
406586|NCT01089998|Drug|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
406587|NCT01089985|Drug|Autologous serum eyedrops|3 times a day for the duration of the study
406588|NCT01089972|Device|22 gauge catheter|radial artery cannulation using 22 gauge catheter
406589|NCT01089972|Device|20 gauge catheter|radial artery cannulation using 20 gauge catheter
406590|NCT01089959|Drug|Esomeprazole|40 mg daily for 7 days
406591|NCT01089959|Drug|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
406592|NCT01089933|Procedure|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
406593|NCT01089933|Procedure|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
406594|NCT01089920|Other|Green tea|Infusion (tea bags) from commercially available green tea
406595|NCT01089920|Other|Coffee|Soluble coffee commercially available
406596|NCT01089855|Drug|Carbamazepine|
406597|NCT01089842|Behavioral|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
406598|NCT01089842|Other|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
406599|NCT01089829|Other|Foot examination|"Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system"
406600|NCT01089816|Biological|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
406601|NCT01089790|Drug|Dutogliptin|400 mg tablet, once daily
406602|NCT01089790|Drug|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
406603|NCT01089777|Device|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
406604|NCT01089764|Behavioral|Couplelinks.ca website|Participation in the Couplelinks.ca program, an online intervention.
406606|NCT01089751|Drug|placebo|Placebo once daily on an empty stomach for 14 weeks.
406607|NCT01089738|Drug|PF-03382792 0.5mg|0.5 mg PF-03382792, qd, for 14 days or placebo
406608|NCT01089738|Drug|PF-03382792 1.5 mg|1.5 mg PF-03382792, qd, for 14 days or placebo
406609|NCT01089738|Drug|PF-03382792 5 mg|5 mg PF-03382792, qd, for 14 days or placebo
406610|NCT01089738|Drug|PF-03382792 15 mg|15 mg PF-03382792, qd, for 14 days or placebo
406611|NCT01089725|Biological|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
406612|NCT01089725|Biological|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
406613|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
406614|NCT01089725|Biological|Placebo IV|1 ml placebo administered IV every 8 weeks
406615|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
406616|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
406617|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
406618|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
406619|NCT01089725|Biological|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
406620|NCT01089725|Biological|Placebo SC|1ml placebo administered SC every 8 weeks
406621|NCT01089699|Behavioral|online support group|online support group
406622|NCT01089699|Behavioral|online support group|online support group
406623|NCT01089699|Behavioral|home study support materials|self-study materials
406624|NCT01089686|Procedure|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
406625|NCT01089686|Procedure|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
406626|NCT01089673|Other|data collection|retrospective data collection
406627|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.3 mL, Intramuscular (IM)
406628|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular (IM)
406629|NCT01089647|Drug|budesonide and montelukast|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
406630|NCT01089647|Drug|Placebo|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
406631|NCT01089621|Drug|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
406632|NCT01089608|Drug|Azithromycin|"Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
406633|NCT01089608|Drug|Povidone|"Eye drops Single dose unit~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
406634|NCT01089595|Drug|Nilotinib|Nilotinib 400 mg po bid
406635|NCT01089595|Drug|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
406636|NCT01089582|Other|No intervention|
406637|NCT01089569|Drug|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
406638|NCT01089569|Drug|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
406639|NCT01089556|Drug|Duloxetine|Administered orally
406640|NCT01089556|Drug|Pregabalin|Administered orally
406641|NCT01089556|Drug|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
406642|NCT01089543|Drug|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
406643|NCT01089543|Drug|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
406644|NCT01089543|Drug|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
406645|NCT01089543|Drug|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
406646|NCT01089530|Behavioral|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
406647|NCT01089517|Drug|E10030 plus Lucentis|once a month intravitreal injection
406648|NCT01089517|Drug|Lucentis|10 mg/mL intravitreal injection monthly
406649|NCT01089504|Drug|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
406650|NCT01089504|Drug|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
406651|NCT01089465|Other|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
406652|NCT01089452|Drug|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
406653|NCT01089452|Drug|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
406654|NCT01089452|Drug|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
406655|NCT01089439|Drug|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm~40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
406656|NCT01089439|Drug|Placebo|placebo
406657|NCT01089426|Drug|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
406658|NCT01089426|Other|Historical Controls|Standard of Care
406659|NCT01089413|Drug|bevacizumab [Avastin]|As prescribed by physician
408384|NCT01075243|Drug|Paracetamol 650 mg|Paracetamol 650 mg
406660|NCT01089387|Biological|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
406661|NCT01089374|Radiation|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
406662|NCT01089361|Drug|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
406663|NCT01089361|Drug|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
406664|NCT01089348|Drug|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
406665|NCT01089348|Drug|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
406666|NCT01089335|Procedure|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
406667|NCT01089322|Drug|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
406668|NCT01089309|Drug|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
406669|NCT01089296|Other|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant`s condition allows it. The length of each treatment session will be adjusted dependent on the infant`s response and condition. Maximum treatment time is 10 minutes.
406670|NCT01089231|Dietary Supplement|Fish oil|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
406671|NCT01089231|Dietary Supplement|Placebo (corn oil)|corn oil (6 capsules per day)
406672|NCT01089218|Drug|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
406673|NCT01089218|Drug|control|no intervention with the same procedure of FB
406674|NCT01089205|Drug|Metformin|
406675|NCT01089192|Drug|Metformin|
406676|NCT01089179|Drug|Metformin|
406677|NCT01089166|Drug|Metformin|
406678|NCT01089140|Drug|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
406679|NCT01089140|Drug|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
406680|NCT01089140|Drug|Saline solution|Saline placebo
406681|NCT01089127|Drug|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
406682|NCT01089127|Drug|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
406683|NCT01089127|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
406684|NCT01089127|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
406685|NCT01089101|Other|Laboratory Biomarker Analysis|Correlative studies
406686|NCT01089101|Other|Pharmacological Study|Correlative studies
406687|NCT01089101|Drug|Selumetinib|Given PO
406688|NCT01089088|Drug|cisplatin|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
406689|NCT01089088|Drug|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
406690|NCT01089088|Drug|sunitinib malate|"Up to six 21 day chemotherapy cycles:~Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
406691|NCT01089075|Drug|Hydrocortisone|20 mg po for 7 days (2 tablets)
406692|NCT01089075|Drug|Placebo|2 tablets po
406693|NCT01089062|Drug|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
406694|NCT01089062|Drug|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
406695|NCT01089062|Drug|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
406696|NCT01089062|Drug|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
406697|NCT01089049|Dietary Supplement|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
406698|NCT01089023|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
406699|NCT01089010|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
406700|NCT01089010|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
406701|NCT01089010|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
406702|NCT01088997|Drug|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
406703|NCT01088984|Drug|Bendamustine|
406704|NCT01088971|Dietary Supplement|Duolac7S|1 capsule two times everyday for 6 weeks
406705|NCT01088971|Dietary Supplement|starch|1capsule two times everyday for 6 weeks
406818|NCT01088035|Drug|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
406706|NCT01088958|Dietary Supplement|Micronutrient powders (Sprinkles)|"Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:~Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg"
406707|NCT01088945|Behavioral|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
406708|NCT01088932|Drug|SRX246|capsules
406709|NCT01088919|Drug|ASP1941|oral tablet
406710|NCT01088919|Drug|pioglitazone hydrochloride|oral tablet
406711|NCT01088906|Drug|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
406712|NCT01088893|Drug|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
406713|NCT01088880|Drug|Canakinumab|
406714|NCT01088867|Other|Acupuncture|Electroacupuncture
406715|NCT01088854|Device|CPAP|unique session of 30-minute of continuous airway positive pressure
406716|NCT01088841|Dietary Supplement|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
406717|NCT01088828|Other|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
406718|NCT01088815|Drug|Gemcitabine, nab-Paclitaxel, GDC-0449|"One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
406719|NCT01088802|Radiation|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
406720|NCT01088802|Drug|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
406721|NCT01088802|Drug|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
406722|NCT01088789|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.|"A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.~The vaccine is administered every 6 months."
406723|NCT01088776|Dietary Supplement|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.~Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
406724|NCT01088776|Dietary Supplement|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
406725|NCT01088763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
406726|NCT01088763|Other|diagnostic laboratory biomarker analysis|Correlative studies
406727|NCT01088763|Other|pharmacological study|Correlative studies
406728|NCT01088763|Drug|dexamethasone|Given IV
406729|NCT01088750|Drug|cyclophosphamide|
406730|NCT01088750|Drug|prednisolone|
406731|NCT01088750|Drug|vinblastine sulfate|
406732|NCT01088750|Other|watchful waiting|
406733|NCT01088750|Procedure|therapeutic conventional surgery|
406734|NCT01088737|Drug|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
406735|NCT01088724|Drug|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
406736|NCT01088711|Drug|Omarigliptin|Once-weekly 50 mg capsule
406737|NCT01088711|Drug|Placebo|Once-weekly placebo capsule
406738|NCT01088698|Radiation|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
406739|NCT01088685|Device|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
406740|NCT01088685|Device|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
406741|NCT01088672|Procedure|Mechanical Thrombectomy|The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
406742|NCT01088659|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
406743|NCT01088659|Drug|placebo|orally daily, 96 weeks
406744|NCT01088659|Drug|tenofovir|245mg po daily, 96 weeks
406771|NCT01088451|Drug|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
406745|NCT01088646|Device|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.~Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.~The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
406746|NCT01088633|Other|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
406747|NCT01088620|Drug|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.~In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
406748|NCT01088620|Drug|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
406749|NCT01088620|Drug|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
406750|NCT01088607|Drug|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
406751|NCT01088594|Drug|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
406752|NCT01088594|Drug|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
406753|NCT01088594|Drug|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
406754|NCT01088594|Drug|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
406755|NCT01088594|Drug|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
406756|NCT01088594|Drug|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
406757|NCT01088581|Drug|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
406758|NCT01088568|Procedure|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
406759|NCT01088568|Procedure|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
406760|NCT01088555|Drug|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
406761|NCT01088542|Behavioral|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
406762|NCT01088529|Drug|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
406763|NCT01088529|Drug|Prednisone|5 mg orally daily.
406764|NCT01088529|Drug|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
406765|NCT01088516|Drug|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
406766|NCT01088503|Drug|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
406767|NCT01088477|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
406768|NCT01088464|Biological|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
406769|NCT01088464|Biological|IMC-11F8|800 mg intravenously, every 2 weeks
406770|NCT01088464|Biological|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
406772|NCT01088438|Behavioral|Contextualization workshop|A four-hour course on contextualization.
406773|NCT01088425|Other|Observation|"Alberta infant motor scale~Griffiths test~Kauffmann ABC"
406774|NCT01088412|Drug|Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)|Dose, frequency and duration at discretion of attending physician.
406775|NCT01088399|Drug|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
406776|NCT01088373|Drug|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
406777|NCT01088347|Drug|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
406778|NCT01088347|Drug|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
406779|NCT01088347|Radiation|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
406780|NCT01088334|Other|screening|CT-Chest/abdomen and mammography in women
406781|NCT01088308|Procedure|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
406782|NCT01088308|Procedure|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
406783|NCT01088295|Drug|Telmisartan|
406784|NCT01088282|Procedure|Cataract surgery|Implantation of multifocal or monofocal IOL
406785|NCT01088256|Drug|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
406786|NCT01088256|Drug|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
406787|NCT01088243|Drug|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
406788|NCT01088243|Drug|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
406789|NCT01088230|Other|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
406790|NCT01088230|Other|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
406791|NCT01088204|Procedure|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
406792|NCT01088204|Procedure|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
406793|NCT01088191|Biological|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
406794|NCT01088191|Drug|Hyaluronan|Hyaluronan alone
406795|NCT01088178|Device|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
406796|NCT01088165|Drug|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
406797|NCT01088165|Drug|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).~Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
406798|NCT01088165|Other|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.~Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
406799|NCT01088152|Behavioral|Celiac school|Structured education of adult celiac patients at 10 sessions.
406800|NCT01088152|Behavioral|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
406801|NCT01088139|Dietary Supplement|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
406802|NCT01088126|Procedure|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
406803|NCT01088100|Genetic|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
406804|NCT01088087|Dietary Supplement|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
406805|NCT01088074|Device|Histoacryl Tissue Adhesive|
406806|NCT01088074|Device|Dermabond|
406807|NCT01088074|Device|Staples|
406808|NCT01088074|Device|Monocryl 4-0|
406809|NCT01088048|Drug|Idelalisib|Idelalisib tablet administered orally
406810|NCT01088048|Drug|Rituximab|Rituximab administered intravenously
406811|NCT01088048|Drug|Bendamustine|Bendamustine administered intravenously
406812|NCT01088048|Drug|Ofatumumab|Ofatumumab administered intravenously
406813|NCT01088048|Drug|Fludarabine|Fludarabine administered orally
406814|NCT01088048|Drug|Everolimus|Everolimus administered orally twice daily until disease progression
406815|NCT01088048|Drug|Bortezomib|Bortezomib administered as a subcutaneous injection
406816|NCT01088048|Drug|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
406819|NCT01088022|Drug|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
406820|NCT01088022|Drug|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
406821|NCT01088009|Drug|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
406822|NCT01088009|Drug|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
406823|NCT01088009|Drug|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
406824|NCT01087996|Biological|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
406825|NCT01087996|Biological|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
406826|NCT01087983|Drug|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
406827|NCT01087983|Drug|Sirolimus|Starting oral dose 1 mg daily.
406828|NCT01087983|Drug|Metformin|Starting oral dose 1000 mg daily.
406829|NCT01087970|Drug|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
406830|NCT01087970|Drug|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.~After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
406831|NCT01087970|Drug|Carboplatin|Administered intravenously, for a maximum of 6 cycles
406832|NCT01087970|Drug|Cisplatin|Administered intravenously, for a maximum of 6 cycles
406833|NCT01087957|Device|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
406834|NCT01087957|Other|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
406835|NCT01087944|Device|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
406836|NCT01087944|Device|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
406837|NCT01087931|Drug|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
406838|NCT01087931|Other|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
406839|NCT01087918|Device|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
406840|NCT01087918|Other|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
406841|NCT01087905|Drug|Nicotine patch|"If > 10 cigs/day: one 21 mg nicotine patch per day~If < or = 10 cigs/day: one 14 mg nicotine patch per day"
406842|NCT01087905|Drug|Nicotine gum|"If < 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.~If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
406843|NCT01087905|Behavioral|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
406844|NCT01087892|Dietary Supplement|Probiotic drink containing the live strain|Probiotic drink contains no strain
406845|NCT01087892|Dietary Supplement|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
406846|NCT01087879|Drug|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
406847|NCT01087879|Drug|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
406848|NCT01087879|Drug|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
406849|NCT01087866|Drug|Metformin|
406850|NCT01087866|Drug|Insulin|
406851|NCT01087853|Drug|Crystalloid|2 litres intravenous infusion in 60 minutes
406852|NCT01087853|Drug|Colloid|1 litre intravenous infusion over 30 minutes
406853|NCT01087840|Drug|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.~Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
406854|NCT01087814|Drug|Efavirenz|Subject will take efavirenz for 5 days.
406855|NCT01087814|Drug|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
406856|NCT01087801|Drug|ChiRhoStim|Human Secretin for Injection
406857|NCT01087801|Drug|Placebo|Saline for Injection
406858|NCT01087788|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
406859|NCT01087788|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
406860|NCT01087788|Other|Placebo|Matching Placebo to CZP injection.
406861|NCT01087775|Behavioral|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
406862|NCT01087762|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
406863|NCT01087762|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
406864|NCT01087762|Other|Placebo|Matching Placebo to CZP injection.
406865|NCT01087749|Drug|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
406866|NCT01087749|Drug|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
406867|NCT01087749|Drug|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
406868|NCT01087736|Drug|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
406869|NCT01087736|Other|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
406870|NCT01087723|Drug|Bivalirudin|
406871|NCT01087723|Drug|Heparin|
406872|NCT01087710|Other|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
406873|NCT01087710|Other|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
406874|NCT01087697|Device|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
406875|NCT01087684|Procedure|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
406876|NCT01087684|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
406877|NCT01087671|Drug|tafluprost|prostaglandin analogue
406878|NCT01087658|Drug|Glutamine|Per os
406879|NCT01087658|Drug|Calcium and Magnesium|Intravenous
406880|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
406881|NCT01087645|Drug|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
406882|NCT01087645|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
406883|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
406884|NCT01087645|Drug|placebo|Subjects will be randomised to receive a single dose of placebo
406885|NCT01087632|Dietary Supplement|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
406886|NCT01087619|Procedure|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
406887|NCT01087593|Drug|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
406888|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
406889|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
406890|NCT01087580|Drug|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.~GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.~GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
406891|NCT01087567|Drug|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
406892|NCT01087567|Drug|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
406893|NCT01087554|Drug|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.~Expansion Phase starting dose: MTD from Escalation Phase."
406894|NCT01087554|Drug|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.~Expansion Phase starting dose: MTD from Escalation Phase.~Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
407135|NCT01085617|Procedure|allogeneic hematopoietic stem cell transplantation|
406895|NCT01087554|Drug|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.~Expansion Phase: MTD from Escalation Phase."
406896|NCT01087554|Drug|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.~Expansion Phase: MTD from Escalation Phase."
406897|NCT01087541|Behavioral|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
406898|NCT01087528|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
406899|NCT01087515|Other|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).~In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.~In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
406900|NCT01087502|Drug|Glimepiride|1-4 mg daily after 12 weeks
406901|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
406902|NCT01087502|Drug|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
406903|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
406904|NCT01087502|Drug|Linagliptin|5 mg once daily
406905|NCT01087489|Drug|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
406906|NCT01087489|Drug|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
406907|NCT01087476|Drug|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
406908|NCT01087463|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
406909|NCT01087437|Dietary Supplement|gastrolith calcium|
406910|NCT01087424|Drug|R mini CHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
406911|NCT01087411|Behavioral|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
406912|NCT01087411|Behavioral|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
406913|NCT01087411|Dietary Supplement|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
406914|NCT01087411|Dietary Supplement|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
406915|NCT01087398|Drug|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg~For haploidentical:~Busulfan 16 mg/kg >5year - 20 mg/kg <5year po~Cyclophosphamide 200 mg/kg iv~Fludarabine 160 mg/m^2"
406916|NCT01087398|Procedure|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:~Sibling full match~Other related full match~Sibling or other related with 1 mismatch antigen~Cord Blood~Haploidentical"
406917|NCT01087398|Drug|Cyclosporin, Methotrexate (GVHD prophylaxis)|"Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po~10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)"
406918|NCT01087359|Drug|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
406919|NCT01087346|Behavioral|Reading Information|Reading information about risk factors for obesity among children
406920|NCT01087294|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant
406921|NCT01087294|Biological|Anti-CDl9-chimeric- antigen-receptor- transduced T cells|"Patients receive T cells genetically engineered to express an anti-CD19 CAR.The cells are cultured in media containing IL-21, IL- 7, and TWS119.~TWS119 is a glycogen synthase 3 inhibitor"
406922|NCT01087294|Procedure|Leukapheresis|Donors will undergo leukapheresis
406923|NCT01087268|Other|questionnaire administration|
406924|NCT01087268|Procedure|gastrointestinal complications management/prevention|
406925|NCT01087268|Procedure|quality-of-life assessment|
406926|NCT01087255|Device|Electronic Pillbox Monitoring System|Daily exposure for six months
406927|NCT01087242|Drug|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
406928|NCT01087229|Drug|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
406929|NCT01087229|Drug|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
407136|NCT01085617|Radiation|total-body irradiation|
406930|NCT01087216|Device|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
406931|NCT01087216|Drug|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
406932|NCT01087203|Biological|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
406933|NCT01087203|Biological|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
406934|NCT01087190|Drug|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
406935|NCT01087177|Other|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
406936|NCT01087164|Behavioral|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
406937|NCT01087164|Behavioral|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
406938|NCT01087151|Drug|ABT-263|Oral repeating dose
406939|NCT01087151|Drug|rituximab|Intravenous repeating dose
406940|NCT01087138|Behavioral|exercise|exercise class 3x's/week
406941|NCT01087138|Behavioral|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
406942|NCT01087125|Drug|No Interventions|No Interventions
406943|NCT01087112|Behavioral|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
406944|NCT01087112|Behavioral|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
406945|NCT01087099|Drug|Albendazole|Treatment with albendazole
406946|NCT01087086|Behavioral|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
406947|NCT01087086|Behavioral|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
406948|NCT01087073|Behavioral|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
406949|NCT01087073|Behavioral|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
406950|NCT01087073|Behavioral|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
406951|NCT01087073|Behavioral|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
406952|NCT01087060|Procedure|partial or radical nephrectomy|
406953|NCT01087047|Device|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
406954|NCT01087034|Device|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
406955|NCT01087034|Radiation|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
406956|NCT01087034|Other|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
406957|NCT01087021|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion~Route of administration: intravenous"
406958|NCT01087008|Drug|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
406959|NCT01087008|Other|No treatment control|Patients doesn't receive treatment
406960|NCT01086982|Drug|Octreotide acetate LAR|30 mg, single dose
406961|NCT01086982|Drug|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
406962|NCT01086969|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
406963|NCT01086956|Drug|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
406964|NCT01086943|Device|LT2420|
407039|NCT01086371|Other|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
408385|NCT01075243|Drug|Placebo|Placebo
406965|NCT01086930|Device|ReJoyce Workstation|The device has two parts. The first part is a muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff, word on the forearm and triggered when the user clicks his/her teeth. The tooth clicks (vibrations) are detected by an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. This is turn stimulates the hand to open or close, allowing patients to grasp and release objects. The second part of the device is a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association. The device is currently being used in a study conducted through the University of Alberta.
406966|NCT01086930|Other|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units. This will be provided as part of regular physiotherapy, vocational, recreational and occupational therapy and provided by participants' usual treating therapists. These therapists will not be involved in administering the study-specific interventions.
406967|NCT01086917|Biological|PfSPZ Challenge|each volunteer to receive a single dose
406968|NCT01086904|Biological|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
406969|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
406970|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
406971|NCT01086878|Drug|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
406972|NCT01086865|Drug|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
406973|NCT01086852|Biological|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.~Post surgery- FX trough levels of 50% should be achieved.~Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
406974|NCT01086839|Drug|sodium chloride 6%|"one ampoule sodium chloride 6% per day~inhalation use~for 28 days"
406975|NCT01086839|Drug|sodium chloride 0,9%|"one ampoule sodium chloride 0,9% per day~inhalation use~for 28 days"
406976|NCT01086826|Drug|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
406977|NCT01086826|Drug|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
406978|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
406979|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.~RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
406980|NCT01086813|Drug|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
406981|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
406982|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
406983|NCT01086800|Other|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
406984|NCT01086787|Other|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
406985|NCT01086774|Other|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
406986|NCT01086761|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye.
406987|NCT01086748|Drug|Risperidone|Administered orally.
406988|NCT01086748|Drug|Placebo|Administered orally.
406989|NCT01086748|Drug|LY2140023|Administered orally.
406990|NCT01086735|Biological|donor lymphocyte infusion|Donor T-cell transduction
406991|NCT01086722|Drug|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
406992|NCT01086696|Drug|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
406993|NCT01086683|Behavioral|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
406994|NCT01086670|Other|Physical Exercise|"Children will be assigned either an elliptical machine or cycle to take home. Each exercise will be performed for 20 minutes per day, 5 days per week for a period of 12 consecutive weeks, or 60 sessions in all. To avoid excessive fatigue or overtraining effects, children are asked to adhere to this exact schedule and not to exercise more than this. Children are asked to complete as many of the sessions as they can. To allow for sick days or vacation during the program, the duration of the training can be extended up to 2 more weeks if needed to try to complete all 60 sessions.~Compliance (percent sessions completed) will be correlated with outcomes in the statistical analyses."
406995|NCT01086657|Biological|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
406996|NCT01086657|Biological|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
406997|NCT01086631|Drug|Rituximab|
406998|NCT01086618|Drug|systemic chemotherapy|
406999|NCT01086618|Procedure|adjuvant therapy|
407000|NCT01086618|Procedure|quality-of-life assessment|
407001|NCT01086618|Procedure|therapeutic conventional surgery|
407002|NCT01086605|Drug|pixantrone dimaleate|Given IV
407003|NCT01086592|Other|No intervention|Daily life activities
407004|NCT01086592|Other|Strong progressive strengthening exercises of lower limbs|Lower limb weight
407005|NCT01086592|Other|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
407006|NCT01086592|Other|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
407007|NCT01086579|Device|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
407008|NCT01086579|Device|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
407009|NCT01086566|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
407010|NCT01086553|Drug|budesonide|9mg budesonide OD
407011|NCT01086553|Drug|budesonide|3mg budesonide TID
407012|NCT01086540|Biological|Rituximab|"Participants receive rituximab intravenous (IV) infusions, 1000 mg each, 14 days apart (Day 0 and Week 2).~Rituximab is supplied as a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials, which must be diluted before administration~Standard rituximab pre-medications will be provided in preparation for the rituximab infusions."
407013|NCT01086540|Other|Placebo|"Participants receive placebo intravenous (IV) infusions 14 days apart (Day 0 and Week 2).~Standard pre-medications will be provided in preparation for the infusions."
407014|NCT01086540|Diagnostic Test|CMRI|Up to 20 participants from each treatment arm will be assessed by CMRI at Baseline and at Week 24.
407015|NCT01086540|Drug|prednisone|Prednisone dose of 40 mg (or equivalent) by mouth administered the night before and the morning of each study drug infusion.
407016|NCT01086540|Drug|methylprednisolone|Methylprednisolone (or equivalent corticosteroid) administered intravenously 30 minutes prior to each study drug infusion.
407017|NCT01086540|Drug|diphenhydramine|"Diphenhydramine 50 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
407018|NCT01086540|Drug|acetaminophen|"Acetaminophen 650 mg (or equivalent) administered by mouth approximately thirty to sixty minutes prior to each study drug infusion.~Dose may be repeated every four hours, as needed."
407019|NCT01086527|Drug|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
407020|NCT01086514|Procedure|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
407021|NCT01086488|Drug|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
407022|NCT01086475|Drug|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
407023|NCT01086475|Drug|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
407024|NCT01086462|Drug|GSK2239633|100 ug GSK2239633 containing approximately 10kBq [14C]-GSK2239633
407025|NCT01086449|Biological|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
407026|NCT01086436|Biological|Rotarix ™|Oral, single dose
407027|NCT01086436|Biological|Placebo|Oral, single dose
407028|NCT01086423|Biological|Infanrix-IPV/Hib™|Intramuscular, three doses
407029|NCT01086423|Biological|Infanrix Hib™|Intramuscular, three doses
407030|NCT01086423|Biological|Poliorix™|Intramuscular, three doses
407031|NCT01086410|Drug|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
407032|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
407033|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
407034|NCT01086410|Drug|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
407035|NCT01086410|Drug|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
407036|NCT01086397|Procedure|Urine sample collection|All subjects have non-invasive urine sample collection performed
407037|NCT01086384|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
407038|NCT01086384|Drug|Fluticasone furoate|Inhaled corticosteroid
407040|NCT01086371|Other|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
407041|NCT01086358|Drug|Triptan|Usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
407042|NCT01086358|Drug|Treximet 85Mg-500Mg Tablet|Treximet is 85 mg sumatriptan plus 500 mg naproxen sodium
407043|NCT01086345|Radiation|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
407044|NCT01086345|Biological|bevacizumab|Given IV
407045|NCT01086345|Drug|irinotecan hydrochloride|Given IV
407046|NCT01086332|Drug|Nelfinavir|1250 mg twice daily
407047|NCT01086332|Drug|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
407048|NCT01086267|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
407049|NCT01086267|Drug|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
407050|NCT01086267|Drug|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
407051|NCT01086254|Drug|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: 60-minute IV infusion"
407052|NCT01086254|Drug|gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: 30-minute IV infusion"
407053|NCT01086254|Drug|cisplatin|"Pharmaceutical form: solution for infusion~Route of administration: 1- to 4-hour IV infusion, according to the local standard"
407054|NCT01086241|Procedure|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
407055|NCT01086241|Procedure|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
407056|NCT01086228|Device|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
407057|NCT01086176|Device|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
407058|NCT01086163|Drug|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
407059|NCT01086150|Other|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
407060|NCT01086150|Other|Skin biopsy|Skin biopsy specimens will be processed and analyzed for nerve fiber count, nerve and skin morphology and sodium channel specific epitope expression in keratinocytes.
407061|NCT01086085|Drug|Adefovir|Adefovir 10 mg po once daily for 36 weeks
407062|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
407063|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
407064|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
407065|NCT01086046|Drug|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour~Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
407066|NCT01086020|Drug|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
407067|NCT01086020|Drug|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
407068|NCT01085994|Other|Literature search|Literature search followed by systematic review and meta-analysis
407069|NCT01085981|Drug|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
407070|NCT01085981|Drug|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
407071|NCT01085981|Drug|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
407072|NCT01085968|Behavioral|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
407073|NCT01085929|Procedure|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
407074|NCT01085929|Procedure|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
407075|NCT01085903|Drug|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
407076|NCT01085903|Drug|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
407077|NCT01085903|Behavioral|Baseline|Observations made at baseline before any intervention
407078|NCT01085903|Behavioral|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
407079|NCT01085903|Behavioral|Post CPS|20 minutes following the CPS condition.
407080|NCT01085903|Behavioral|Follow up|Follow up testing occurred at 3 months
407081|NCT01085890|Behavioral|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
407082|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
407083|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
407084|NCT01085851|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
407085|NCT01085851|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
407086|NCT01085838|Drug|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
407087|NCT01085825|Procedure|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
407088|NCT01085812|Drug|F2695 SR|Drug: F2695 SR (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
407089|NCT01085812|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily.
407090|NCT01085799|Behavioral|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
407091|NCT01085786|Drug|14-day sequential treatment|"14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days"
407092|NCT01085786|Drug|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
407093|NCT01085773|Behavioral|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
407094|NCT01085773|Behavioral|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
407095|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
407096|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
407097|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
407098|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
407099|NCT01085760|Drug|Vancomycin|Comparison of different drug doses
407100|NCT01085734|Drug|Avastin|1.25mg intravitreally
407101|NCT01085734|Drug|Osurdex|0.7mg intravitreally
407102|NCT01085734|Drug|Avastin|1.25mg intravitreally
407103|NCT01085721|Drug|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
407104|NCT01085721|Drug|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
407105|NCT01085708|Drug|rabeprazole|10 mg normal tablet
407106|NCT01085708|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
407107|NCT01085708|Drug|rabeprazole|Type 2 granules containing rabeprazole 10 mg
407108|NCT01085708|Drug|rabeprazole|Type 3 granules containing rabeprazole 10 mg
407109|NCT01085695|Drug|rabeprazole|10 mg normal tablet
407110|NCT01085695|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
407111|NCT01085695|Drug|rabeprazole|Type 2 granule containing rabeprazole 10 mg
407112|NCT01085695|Drug|rabeprazole|Type 3 granule containing rabeprazole 10 mg
407113|NCT01085682|Behavioral|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
407114|NCT01085682|Behavioral|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
407115|NCT01085669|Device|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
407116|NCT01085656|Drug|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.~Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.~Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.~Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
407117|NCT01085643|Drug|Lubiprostone|24mcg PO taken once
407118|NCT01085643|Drug|Placebo|24mcg placebo capsule taken once
407119|NCT01085630|Drug|pemetrexed disodium|Given IV
407120|NCT01085630|Other|clinical observation|
407121|NCT01085617|Biological|palifermin|
407122|NCT01085617|Biological|rituximab|
407123|NCT01085617|Drug|cyclophosphamide|
407124|NCT01085617|Drug|cytarabine|
407125|NCT01085617|Drug|daunorubicin hydrochloride|
407126|NCT01085617|Drug|etoposide|
407127|NCT01085617|Drug|fludarabine phosphate|
407128|NCT01085617|Drug|imatinib mesylate|
407129|NCT01085617|Drug|melphalan|
407130|NCT01085617|Drug|mercaptopurine|
407131|NCT01085617|Drug|methotrexate|
407132|NCT01085617|Drug|nelarabine|
407133|NCT01085617|Drug|pegaspargase|
407134|NCT01085617|Drug|vincristine sulfate|
407137|NCT01085604|Other|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.~Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
407138|NCT01085591|Drug|CB-183,315|
407139|NCT01085591|Drug|Placebo|
407140|NCT01085591|Drug|Vancomycin|
407141|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
407142|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
407143|NCT01085578|Drug|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
407144|NCT01085565|Device|ExAblate 2100|Conformal Bone System
407145|NCT01085552|Drug|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
407146|NCT01085526|Biological|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
407147|NCT01085526|Drug|Alutard phl prat|
407148|NCT01085513|Device|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
407149|NCT01085500|Behavioral|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
407150|NCT01085500|Procedure|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
407151|NCT01085487|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
407152|NCT01085487|Drug|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
407153|NCT01085487|Drug|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
407154|NCT01085474|Other|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
407155|NCT01085474|Other|2|The best intervention used in the pilot study will be chosen and included in the main study.
407156|NCT01085448|Other|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.~Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.~Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.~Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
407157|NCT01085435|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
407158|NCT01085422|Drug|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
407159|NCT01085422|Drug|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
407160|NCT01085383|Drug|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
407161|NCT01085370|Other|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
407162|NCT01085357|Procedure|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
407163|NCT01085357|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
407164|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
407165|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
407166|NCT01085331|Drug|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
407167|NCT01085331|Drug|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
407168|NCT01085331|Drug|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter [mg/m^2] intravenous [i.v] infusion over 90 minutes or leucovorin [dl-leucovorin] 400 mg/m^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m^2 given as a 90-minute infusion in 500 milliliter [mL] dextrose 5%; followed by a bolus 5-fluorouracil [FU] 400 mg/m^2 and a 46-hour infusion 5-FU 2400 mg/m^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
407169|NCT01085318|Drug|Rebif|44 mcg tiw
408485|NCT01074398|Genetic|gene expression analysis|
407170|NCT01085305|Behavioral|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
407171|NCT01085305|Behavioral|TAU|Usual treatment for behavioral disorders
407172|NCT01085292|Drug|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
407173|NCT01085292|Drug|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
407174|NCT01085279|Device|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
407175|NCT01085279|Drug|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
407176|NCT01085266|Drug|Dimebon (latrepirdine)|
407177|NCT01085253|Other|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
407178|NCT01085240|Other|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
407179|NCT01085214|Other|Laboratory Biomarker Analysis|Correlative studies
407180|NCT01085214|Drug|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
407181|NCT01085201|Drug|Lexiscan|Given as an infusion
407182|NCT01085188|Behavioral|ACC|Weekly community based behavioral counseling and case management
407183|NCT01085188|Behavioral|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
407184|NCT01085188|Behavioral|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
407185|NCT01085175|Drug|LMI 1195|Single bolus intravenous injection of LMI 1195
407186|NCT01085162|Drug|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
407187|NCT01085149|Drug|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
407188|NCT01085136|Drug|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
407189|NCT01085136|Drug|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
407190|NCT01085123|Drug|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
407191|NCT01085123|Drug|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
407192|NCT01085097|Drug|laquinimod|Laquinimod 0.5 mg or 1 mg
407193|NCT01085097|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF)
407194|NCT01085097|Drug|prednisolone/prednisone|corticosteroids
407195|NCT01085097|Drug|Placebo|Placebo
407196|NCT01085084|Drug|Laquinimod|Laquinimod 0.5 mg once daily for 12 weeks
407197|NCT01085084|Drug|Laquinimod|Laquinimod 1 mg oral once daily for 12 weeks
407198|NCT01085084|Other|Placebo|Placebo oral once daily for 12 weeks
407199|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
407200|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
407201|NCT01085058|Drug|lenograstim|
407202|NCT01085045|Drug|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
407203|NCT01085045|Drug|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
407204|NCT01085045|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
407205|NCT01085045|Drug|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
407206|NCT01085045|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
407207|NCT01085045|Drug|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
407208|NCT01085032|Drug|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
407209|NCT01085032|Drug|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.~The same step-down dosing algorithm as in the experimental condition is used."
407210|NCT01085019|Dietary Supplement|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
407211|NCT01085019|Dietary Supplement|Oregano|2.8g/day of oregano in capsules during 4 weeks.
407212|NCT01085019|Dietary Supplement|Ginger|2.8g/day of ginger in capsules during 4 weeks.
407213|NCT01085019|Dietary Supplement|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
407214|NCT01085019|Dietary Supplement|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
407215|NCT01085019|Dietary Supplement|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
407216|NCT01085006|Drug|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
407217|NCT01085006|Drug|Normal saline|Tranexamic acid in cases, normal saline in controls
407218|NCT01084993|Drug|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
407219|NCT01084993|Drug|Heparin|70 U/kg
407220|NCT01084980|Drug|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
407257|NCT01084577|Device|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
407258|NCT01084577|Device|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
407221|NCT01084941|Behavioral|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
407222|NCT01084941|Behavioral|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
407223|NCT01084928|Behavioral|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
407224|NCT01084902|Drug|Latanoprost|once daily
407225|NCT01084902|Drug|Brinzolamide|Two times daily
407226|NCT01084889|Device|surgical mesh implantation (TiLOOP® Total 6)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The surgical mesh TiLOOP® Total 6 is placed transvaginal by the aid of TiLOOP® surgical instruments to place the mesh arms.
407227|NCT01084876|Drug|CT-P6|Administered every 3 weeks
407228|NCT01084876|Drug|Herceptin|Administered every 3 weeks
407229|NCT01084876|Drug|Paclitaxel|Administered every 3weeks
407230|NCT01084863|Drug|CT-P6|CT-P6: administered every 3 weeks
407231|NCT01084863|Drug|Herceptin|Herceptin: administered every 3 weeks
407232|NCT01084863|Drug|Paclitaxel|Paclitaxel: administered every 3 weeks
407233|NCT01084837|Drug|velcade|"INDUCTIoN (Cycles 1-4)~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)~For patients wich is not planned autotransplantation, add:~Cycles 5-8~Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment~Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)~EXTENSION TREATMENT(Cycles 9-12)~Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22~Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
407234|NCT01084824|Drug|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
407235|NCT01084824|Drug|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
407236|NCT01084811|Procedure|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
407237|NCT01084772|Other|Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation or standard instrumentation, depending on randomization assignment.
407238|NCT01084772|Other|Total Knee Arthroplasty|TKA will be performed with VISIONAIRE patient matched instrumentation or standard instrumentation, depending on randomization assignment.
407239|NCT01084759|Drug|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
407240|NCT01084759|Drug|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
407241|NCT01084746|Behavioral|PC-based tailored intervention|Patients will receive a tailored interactive PC-based intervention at a freestanding kiosk.
407242|NCT01084746|Behavioral|Printed educational materials|Patients will receive generic printed educational materials about CRCS in the PEC when they arrive at the Main Campus for their appointment.
407243|NCT01084720|Drug|V0034 CR|
407244|NCT01084707|Drug|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
407245|NCT01084707|Drug|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
407246|NCT01084707|Drug|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
407247|NCT01084681|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
407248|NCT01084681|Device|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
407249|NCT01084655|Drug|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
407250|NCT01084655|Drug|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
407251|NCT01084655|Drug|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
407252|NCT01084603|Drug|Oral Nicotine|A new l mg oral nicotine product
407253|NCT01084603|Drug|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
407254|NCT01084603|Drug|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
407255|NCT01084590|Behavioral|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
407256|NCT01084590|Behavioral|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
407259|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
407260|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
407261|NCT01084551|Drug|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
407262|NCT01084538|Drug|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
407263|NCT01084525|Drug|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
407264|NCT01084525|Drug|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
407265|NCT01084525|Drug|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
407266|NCT01084499|Drug|Femara (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
407267|NCT01084499|Drug|Peratra (Sequence 1)|Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.
407268|NCT01084499|Drug|Femara (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
407269|NCT01084499|Drug|Peratra (Sequence 2)|Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.
407270|NCT01084486|Drug|Metformin|
407271|NCT01084473|Drug|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
407272|NCT01084473|Drug|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
407273|NCT01084473|Drug|Placebo|0.9 % NaCl will be infused.
407274|NCT01084447|Device|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
407275|NCT01084447|Device|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
407276|NCT01084434|Dietary Supplement|probiotic|Bifidobacterium lactis HN019 10^9 CFU/day 1 sachet once a day for 7 weeks
407277|NCT01084434|Dietary Supplement|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
407278|NCT01084434|Dietary Supplement|Synbiotic|(Bifidobacterium lactis 10^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
407279|NCT01084434|Dietary Supplement|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
407280|NCT01084421|Behavioral|Computer-based parent-adolescent HIV communication|The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
407281|NCT01084408|Device|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
407282|NCT01084408|Device|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
407283|NCT01084395|Behavioral|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
407284|NCT01084395|Behavioral|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
407285|NCT01084395|Other|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
407286|NCT01084395|Other|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
407287|NCT01084382|Dietary Supplement|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.~One group will so haved received Arthrospira platensis for 24 weeks."
407333|NCT01084083|Drug|Cisplatin|Given IV, 75 mg/m^2 on day 1
407334|NCT01084070|Other|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
407460|NCT01082939|Drug|Fludarabine|25 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
407288|NCT01084369|Drug|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
407289|NCT01084343|Biological|MYM-V101|"Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
407290|NCT01084330|Drug|AUY922|70mg/m2
407291|NCT01084330|Drug|Docetaxel|Docetaxel 75mg/m2
407292|NCT01084330|Drug|Irinotecan|Docetaxel or Iriniotecan
407293|NCT01084317|Other|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
407294|NCT01084291|Biological|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
407295|NCT01084291|Other|Placebo injection|Subcutaneous injection of placebo
407296|NCT01084278|Drug|Colchicine|Colchicine tablets
407297|NCT01084265|Drug|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units [IU]) injection s.c. once daily.
407298|NCT01084265|Drug|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
407299|NCT01084265|Drug|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
407300|NCT01084252|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
407301|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
407302|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: tablet~Route of administration: oral"
407303|NCT01084239|Radiation|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
407304|NCT01084226|Dietary Supplement|Rye-2008|
407305|NCT01084213|Drug|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
407306|NCT01084213|Drug|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
407307|NCT01084200|Drug|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
407308|NCT01084200|Drug|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
407309|NCT01084200|Drug|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
407310|NCT01084187|Drug|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
407311|NCT01084174|Drug|Peanut powder|Delivered orally
407312|NCT01084174|Drug|Peanut extract|Delivered sublingually
407313|NCT01084174|Drug|Placebo extract|Delivered sublingually
407314|NCT01084174|Drug|Placebo powder|Delivered orally
407315|NCT01084161|Drug|N1539|5 mg IV once per day
407316|NCT01084161|Drug|N1539|7.5 mg IV once per day
407317|NCT01084161|Drug|N1539|15 mg IV once per day
407318|NCT01084161|Drug|N1539|30 mg IV once per day
407319|NCT01084161|Drug|placebo|IV placebo once per day
407320|NCT01084161|Drug|Morphine|morphine 10-15 mg IV once per day
407321|NCT01084161|Drug|N1539|60 mg IV once per day
407322|NCT01084148|Drug|V0034CR01B|
407323|NCT01084148|Drug|V0034CR01B vehicle|
407324|NCT01084135|Drug|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
407325|NCT01084135|Other|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
407326|NCT01084122|Drug|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
407327|NCT01084109|Other|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
407328|NCT01084109|Other|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
407329|NCT01084096|Behavioral|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:~Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.~Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.~Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
407330|NCT01084083|Biological|cetuximab|Given IV
407331|NCT01084083|Radiation|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
407332|NCT01084083|Drug|Paclitaxel|Given IV, 90 mg/m^2 on days 1, 8 and 15
407335|NCT01084070|Other|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
407336|NCT01084057|Drug|vorinostat|Given orally
407337|NCT01084057|Drug|ixabepilone|Given IV
407338|NCT01084057|Other|laboratory biomarker analysis|Correlative studies
407339|NCT01084057|Other|pharmacological study|Correlative studies
407340|NCT01084044|Drug|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
407341|NCT01084031|Drug|propofol|intravenous propofol with sevoflurane inhalation induction
407342|NCT01084018|Behavioral|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
407343|NCT01084005|Drug|linagliptin|patients receive linagliptin 5 mg tablets once daily
407344|NCT01084005|Drug|placebo|patients receive placebo matching linagliptin 5 mg once daily
407345|NCT01083992|Drug|Galvus (vitagliptin)|Galvus (vitagliptin)
407346|NCT01083992|Drug|Galvus + vitamin D|Galvus + vitamin D
407347|NCT01083979|Drug|Liposomes|Intravesical instillation
407348|NCT01083966|Drug|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
407349|NCT01083953|Drug|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
407350|NCT01083953|Drug|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
407351|NCT01083940|Other|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
407352|NCT01083927|Procedure|Rotational Narrow Strip Conjunctival Graft|Surgical technique
407353|NCT01083927|Procedure|Full Conjunctival Graft|Surgical technique
407354|NCT01083901|Behavioral|Resistance training|high intensity progressive resistance exercise training
407355|NCT01083888|Drug|ASP1517|oral
407356|NCT01083875|Drug|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
407357|NCT01083875|Drug|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
407358|NCT01083862|Behavioral|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
407359|NCT01083862|Behavioral|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
407360|NCT01083823|Other|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
407361|NCT01083810|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
407362|NCT01083797|Drug|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
407363|NCT01083797|Drug|Chloral Hydrate|Initial dose=50 mg/kg
407364|NCT01083784|Drug|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
407365|NCT01083784|Drug|Control group|Control group
407366|NCT01083771|Dietary Supplement|Olive Oil|Minimum of 3 tablespoon of olive oil per day
407367|NCT01083758|Drug|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
407368|NCT01083732|Drug|dabigatran etexilate|Experimental dose chosen based on age and weight
407369|NCT01083719|Procedure|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
407370|NCT01083706|Drug|azacitidine|Given SC or IV
407371|NCT01083706|Other|laboratory biomarker analysis|Correlative studies
407372|NCT01083667|Drug|Pyrimethamine|Open Label, dose escalating,
407373|NCT01083654|Behavioral|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
407415|NCT01083368|Biological|bevacizumab|Given IV
407416|NCT01083368|Genetic|polymorphism analysis|Correlative studies
407417|NCT01083368|Other|laboratory biomarker analysis|Correlative studies
407374|NCT01083654|Behavioral|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
407375|NCT01083641|Drug|Estradiol|10mg oral three times daily
407376|NCT01083628|Behavioral|Group CBT for Depression with MoodText|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
407377|NCT01083628|Behavioral|Group CBT for Depression|Standard group CBT for depression using BRIGHT manual
407378|NCT01083615|Drug|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
407379|NCT01083615|Drug|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
407380|NCT01083615|Drug|docetaxel|
407381|NCT01083615|Drug|cabazitaxel|
407382|NCT01083615|Drug|prednisone|
407383|NCT01083602|Drug|panobinostat|PAN 20 mg PO given TIW, weeks 1&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
407384|NCT01083602|Drug|bortezomib|
407385|NCT01083602|Drug|dexamethasone|
407386|NCT01083589|Drug|Imatinib Mesylate|Oral 400 mg daily
407387|NCT01083589|Drug|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
407388|NCT01083576|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
407389|NCT01083576|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
407390|NCT01083550|Other|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
407391|NCT01083537|Drug|Cisplatin|"1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.~Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn~Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
407392|NCT01083537|Drug|Paclitaxel|"2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.~Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo~Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn~Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
407393|NCT01083524|Drug|Dichloroacetate Sodium|3 mg po bid for 28 weeks
407394|NCT01083524|Drug|Dichloroacetate Sodium|6.25 mg po bid
407395|NCT01083524|Drug|Dichloroacetate Sodium|12.5 mg po bid
407396|NCT01083498|Device|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
407397|NCT01083485|Drug|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
407398|NCT01083485|Drug|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
407399|NCT01083472|Device|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
407400|NCT01083472|Procedure|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
407401|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
407402|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions during fast
407403|NCT01083433|Behavioral|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
407404|NCT01083433|Device|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
407405|NCT01083420|Drug|Minocycline|Minocycline 0.2% mouthwash
407406|NCT01083420|Drug|Dexamethasone|Dexamethasone 0.01% mouthwash
407407|NCT01083407|Drug|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
407408|NCT01083407|Other|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
407409|NCT01083394|Device|PTA|PTA using a conventional balloon
407410|NCT01083394|Device|PTA with PEB|PTA using a paclitaxel eluting balloon
407411|NCT01083394|Procedure|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
407412|NCT01083381|Drug|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
407413|NCT01083381|Drug|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
407414|NCT01083368|Drug|temsirolimus|Given IV
407418|NCT01083342|Drug|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
407419|NCT01083329|Behavioral|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
407420|NCT01083329|Drug|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
407421|NCT01083329|Drug|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
407422|NCT01083316|Drug|Bortezomib|"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
407423|NCT01083316|Drug|Dexamethasone|"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
407424|NCT01083316|Drug|Melphalan|"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"
407425|NCT01083303|Behavioral|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
407426|NCT01083290|Drug|Spironolactone|single dose of one tablet; 25 mg tablet
407427|NCT01083290|Drug|Spironolactone|single dose of one tablet; 50 mg tablet
407428|NCT01083290|Drug|Spironolactone|single dose of one tablet; 100 mg tablet
407429|NCT01083277|Device|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
407430|NCT01083277|Other|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
407431|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
407432|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
407433|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
407434|NCT01083251|Drug|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
407435|NCT01083251|Drug|Peginterferon|180 mcg/week
407436|NCT01083251|Drug|Sebivo|Telbivudine 600 mg daily
407437|NCT01083251|Drug|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
407438|NCT01083238|Drug|AZD5069|120mg single oral dose
407439|NCT01083225|Behavioral|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
407440|NCT01083225|Behavioral|Treatment as usual|Treatment as usual, consultations
407441|NCT01083212|Drug|AZD1656|Single dose,oral tablet
407442|NCT01083212|Drug|Gemfibrozil|Oral tablet bid on day 1 - 5.
407443|NCT01083212|Drug|Placebo|Oral tablet bid on day 1-5
407444|NCT01083199|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
407445|NCT01083147|Device|FORESEE HOME|Home Monitoring
407446|NCT01083108|Other|Roux-en-Y Gastric Bypass|The surgical group will be studied before and 6 days after bariatric surgery.
407447|NCT01083108|Other|Caloric Restriction|The non-surgical group will be studied before and after receiving a hypocaloric diet for 6 days mimicking the typical postoperative diet.
407448|NCT01083095|Biological|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
407449|NCT01083030|Procedure|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
407450|NCT01083017|Drug|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
407451|NCT01083017|Behavioral|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
407452|NCT01083017|Drug|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
407453|NCT01083004|Procedure|Indocyanine green|Using indocyanine green as intraoperative dye
407454|NCT01083004|Procedure|Brilliant blue arm|Using brilliant blue as intraoperative dye
407455|NCT01082991|Other|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
407456|NCT01082978|Device|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
407457|NCT01082978|Device|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
407458|NCT01082965|Drug|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
407459|NCT01082965|Drug|Placebo|matching placebo
407461|NCT01082939|Drug|Cyclophosphamide|250 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
407462|NCT01082939|Drug|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
407463|NCT01082939|Drug|Rituximab|"Cycle 1 (Week 1): 375 mg/m^2/day IV on Day 2 over 4- 6 hours~Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV on Day 2 over 4- 6 hours"
407464|NCT01082926|Biological|therapeutic allogeneic lymphocytes|Given intratumorally
407465|NCT01082926|Biological|aldesleukin|Given intratumorally
407466|NCT01082926|Other|laboratory biomarker analysis|Optional correlative studies
407467|NCT01082926|Procedure|positron emission tomography|Optional correlative studies
407468|NCT01082913|Device|SSE|Use of SSE or not use of SSE
407469|NCT01082900|Other|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)~CONTROL GROUP: Provision of standard care in the Delivery Room"
407470|NCT01082887|Other|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
407471|NCT01082874|Drug|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
407472|NCT01082874|Drug|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
407473|NCT01082874|Drug|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
407474|NCT01082874|Drug|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
407475|NCT01082861|Biological|Cervarix|Cervarix, HPV vaccin
407476|NCT01082861|Biological|Engerix-B|Engerix-B, HBV vaccin
407477|NCT01082848|Drug|aripiprazole|10 mg QD during 26 weeks
407478|NCT01082848|Drug|placebo|QD during 26 weeks
407479|NCT01082822|Biological|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
407480|NCT01082809|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
407481|NCT01082796|Drug|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
407482|NCT01082770|Device|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
407483|NCT01082770|Device|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
407484|NCT01082744|Drug|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
407485|NCT01082744|Drug|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
407486|NCT01082731|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
407487|NCT01082731|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
407488|NCT01082718|Drug|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
407489|NCT01082705|Drug|artemether-lumefantrine|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
407490|NCT01082705|Drug|Dihydroartemisinin-piperaquine|once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
407491|NCT01082692|Biological|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
407492|NCT01082679|Drug|Methadone|daily for 12 months
407493|NCT01082679|Drug|buprenorphine (Suboxone)|daily for 12 months
407494|NCT01082666|Device|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
407495|NCT01082666|Device|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
407496|NCT01082653|Biological|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
407497|NCT01082640|Drug|Febuxostat|Febuxostat capsules
407498|NCT01082640|Drug|Placebo|Febuxostat placebo-matching capsules
407499|NCT01082627|Drug|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
407500|NCT01082627|Other|common daily practice|common daily practice
407501|NCT01082614|Device|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV > 12%.
407685|NCT01081210|Other|Ultrasound examination|Screening with bedside ultrasound examination
407502|NCT01082601|Procedure|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
407503|NCT01082588|Drug|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
407504|NCT01082588|Drug|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
407505|NCT01082575|Device|Oxygen Monitoring|No intervention
407506|NCT01082562|Drug|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
407507|NCT01082562|Drug|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg~SAD: Once, 1 Day~MAD: IV loading followed by 4 weekly doses, 29 Days"
407508|NCT01082549|Drug|gemcitabine/carboplatin|i.v.
407509|NCT01082549|Drug|gemcitabine/carboplatin plus Iniparib|i.v.
407510|NCT01082523|Other|Text message reminders|Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
407511|NCT01082510|Drug|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
407512|NCT01082510|Drug|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
407513|NCT01082497|Behavioral|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
407514|NCT01082484|Drug|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
407515|NCT01082484|Drug|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
407516|NCT01082484|Drug|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
407517|NCT01082471|Drug|Morphine 6-glucuronide|
407518|NCT01082471|Drug|Morphine|
407519|NCT01082458|Drug|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.~Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
407520|NCT01082445|Drug|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
407521|NCT01082445|Drug|Placebo|Placebo
407522|NCT01082432|Other|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
407523|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For group A the measurement is made by a second and a third investigator during the same examination."
407524|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For all other groups (B, C, D, E) ARFI is measured only once."
407525|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.~For groups F and G : ARFI is measured again after clinical healing."
407526|NCT01082406|Drug|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
407527|NCT01082406|Drug|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
407528|NCT01082393|Drug|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
407529|NCT01082393|Drug|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
407530|NCT01082393|Drug|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
407531|NCT01082393|Drug|cold cream|4 applications (day 1, day 3, day 6 and day 10)
407532|NCT01082380|Drug|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of [14C]PF 02341066
407533|NCT01082367|Drug|TOBI|TOBI (tobramycin inhaled solution)
407534|NCT01082367|Drug|Placebo|Placebo
407535|NCT01082354|Drug|recombinant somatropin|as per standard practice
407536|NCT01082341|Biological|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.~14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
407537|NCT01082328|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
407538|NCT01082315|Drug|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
407539|NCT01082302|Drug|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
407540|NCT01082302|Other|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
407541|NCT01082289|Drug|Lurasidone|
407542|NCT01082276|Drug|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
408486|NCT01074398|Genetic|polymorphism analysis|
407543|NCT01082263|Drug|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
407544|NCT01082250|Drug|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
407545|NCT01082237|Drug|Escitalopram|Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
407546|NCT01082224|Drug|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
407547|NCT01082224|Drug|motexafin gadolinium|motexafin gadolinium
407548|NCT01082224|Other|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
407549|NCT01082211|Radiation|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
407550|NCT01082198|Biological|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
407551|NCT01082198|Biological|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
407552|NCT01082198|Biological|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
407553|NCT01082198|Biological|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
407554|NCT01082198|Biological|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
407555|NCT01082198|Other|flow cytometry|
407556|NCT01082198|Procedure|adjuvant therapy|
407557|NCT01082185|Device|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
407558|NCT01082172|Device|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
407559|NCT01082159|Procedure|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
407560|NCT01082146|Drug|Lurasidone|40 mg suspension, PO, for 7 days
407561|NCT01082133|Drug|Chemotherapy|Busulfan 0.4-1.0 mg/Kg/dose IV Q 12 hours X4 Doses Fludarabine 35 mg/m2/dose IV once daily X4 Doses Cyclophosphamide 10 mg/Kg/dose IV once daily X4 Doses Anti-thymocyte globulin - Thymoglobulin 2.5 mg/Kg/dose IV daily X4 Doses
407562|NCT01082133|Biological|Miltenyi CliniMACS|The CliniMACs device (Miltenyi Biotec, Auburn, CA) will be employed for the CD34 selection procedure. It consists of tubing, bags, and a pair of columns, placed at appropriate locations in the Tubing Set to facilitate the cell selection process.
407563|NCT01082120|Drug|AZD1656|Tablets orally, twice daily for 10 days
407564|NCT01082120|Drug|Pioglitazone|Tablet oral single dose for 10 days
407565|NCT01082107|Other|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
407566|NCT01082094|Biological|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
407567|NCT01082081|Drug|Paracetamol 1000 mg|Paracetamol 1000 mg
407568|NCT01082081|Drug|Paracetamol 500 mg|Paracetamol 500 mg
407569|NCT01082081|Drug|Placebo|Placebo
407570|NCT01082068|Drug|XL147 (SAR245408)|given orally once daily as tablets
407571|NCT01082068|Drug|XL765 (SAR245409)|given orally twice daily as capsules
407572|NCT01082068|Drug|letrozole (Femara)|given orally once daily as tablets
407573|NCT01082029|Drug|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
407574|NCT01082029|Drug|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
407575|NCT01082016|Other|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
407576|NCT01082003|Drug|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
407577|NCT01081990|Drug|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
407578|NCT01081977|Procedure|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
407579|NCT01081977|Procedure|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
407580|NCT01081964|Drug|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
407581|NCT01081964|Drug|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
407582|NCT01081964|Drug|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
407583|NCT01081951|Drug|olaparib|Oral dose capsule 200mg BID day 1-10 of every 21 day cycle, Oral dose capsule 400mg BID continuously after completion of combination therapy
407584|NCT01081951|Drug|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
407585|NCT01081951|Drug|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
407586|NCT01081951|Drug|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
407587|NCT01081951|Drug|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
407588|NCT01081938|Drug|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.~Dose regimen: Single daily dose of Insulin Glargine"
407589|NCT01081938|Drug|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)~Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device~Dose regimen:~Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
407590|NCT01081912|Drug|Placebo|Capsules, no active substance, shells identical to active comparator capsules
407591|NCT01081912|Drug|Hydrocodone bitartrate|"dosage form: capsule~Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
407592|NCT01081899|Other|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
407593|NCT01081886|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
407594|NCT01081886|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
407595|NCT01081873|Drug|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
407596|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|50 ug
407597|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|50 ug
407598|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|100 ug
407599|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|100 ug
407600|NCT01081847|Other|Placebo|PLacebo: Isotonic saline solution
407601|NCT01081834|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
407602|NCT01081834|Drug|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
407603|NCT01081834|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
407604|NCT01081821|Drug|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
407605|NCT01081821|Drug|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
407606|NCT01081808|Biological|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
407607|NCT01081795|Drug|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
407608|NCT01081795|Drug|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
407609|NCT01081782|Drug|ONO-4641|0.15 mg once per day for 26 weeks
407610|NCT01081782|Drug|ONO-4641|0.1 mg once per day for 26 weeks
407611|NCT01081782|Drug|ONO-4641|0.05 mg once per day for 26 weeks
407612|NCT01081782|Drug|ONO-4641 placebo|Placebo once per day for 26 weeks
407613|NCT01081769|Drug|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
407614|NCT01081769|Drug|oral antipsychotics|daily treatment according to local label for maximally 24 months
407615|NCT01081756|Drug|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
407616|NCT01081756|Drug|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
407617|NCT01081743|Other|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
407618|NCT01081730|Biological|anti-TNF biologics|as prescribed
407619|NCT01081730|Other|general population|non-treated cohort
407620|NCT01081730|Biological|non-anti-TNF biologics|as prescribed
407621|NCT01081730|Biological|ustekinumab|as prescribed
407622|NCT01081730|Drug|systemic non-biological treatments|as prescribed
407623|NCT01081717|Drug|systemic non-biological treatments|as prescribed
407624|NCT01081717|Biological|anti-TNF biologics|as prescribed
407625|NCT01081717|Biological|golimumab|as prescribed
407626|NCT01081717|Biological|non-anti-TNF biologics|as prescribed
407627|NCT01081717|Other|general population|non-treated cohort
407628|NCT01081704|Drug|ustekinumab|Single dose of 45 mg subcutaneous injection
407629|NCT01081704|Drug|ustekinumab|Single dose of 90 mg subcutaneous injection
407630|NCT01081691|Biological|CNTO 5825|10 mg/kg single dose IV or matching placebo
407631|NCT01081691|Biological|CNTO 5825|3 mg/kg single dose IV or matching placebo
407632|NCT01081691|Biological|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
407633|NCT01081691|Biological|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
407634|NCT01081691|Biological|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
407635|NCT01081691|Biological|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
407636|NCT01081691|Biological|CNTO 5825|1 mg/kg single dose IV or matching placebo
407637|NCT01081678|Drug|Placebo|Administered by subcutaneous (under the skin) injection
407638|NCT01081678|Drug|Romosozumab|Administered by subcutaneous injection
407639|NCT01081652|Drug|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
407640|NCT01081652|Drug|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
407715|NCT01080872|Device|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
407716|NCT01080859|Device|OCT|Optical coherence tomography
407641|NCT01081639|Drug|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
407642|NCT01081639|Drug|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
407643|NCT01081626|Drug|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
407644|NCT01081613|Other|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
407645|NCT01081600|Other|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
407646|NCT01081587|Procedure|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
407647|NCT01081587|Behavioral|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
407648|NCT01081587|Other|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
407649|NCT01081574|Drug|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
407650|NCT01081561|Drug|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
407651|NCT01081548|Drug|atorvastatin|20 mg
407652|NCT01081548|Drug|atorvastatin|20 mg
407653|NCT01081535|Drug|ketorolac, fentanyl|intravenous PCA
407654|NCT01081483|Drug|ABT-072|See arm description for more information
407655|NCT01081483|Drug|Placebo|See arm description for more information
407656|NCT01081457|Device|Deep brain stimulation|Comparison ON vs OFF
407657|NCT01081444|Device|rTMS|effective and active cortical magnetic stimulations
407658|NCT01081444|Device|Placebo rTMS|non active cortical magnetic stimulation
407659|NCT01081431|Drug|Lenalidomide|10 mg d1-d21 of a 28-day cycle
407660|NCT01081418|Behavioral|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
407661|NCT01081405|Other|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
407662|NCT01081392|Biological|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
407663|NCT01081353|Drug|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
407664|NCT01081353|Drug|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
407665|NCT01081353|Drug|Aspirin Migraine|One effervescent tablet under fasting conditions
407666|NCT01081353|Drug|Aspirin Aspro|One effervescent tablet under fasting conditions
407667|NCT01081340|Behavioral|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
407668|NCT01081340|Behavioral|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
407669|NCT01081314|Behavioral|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
407670|NCT01081314|Behavioral|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
407671|NCT01081301|Behavioral|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
407672|NCT01081288|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
407673|NCT01081275|Behavioral|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
407674|NCT01081275|Behavioral|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
407675|NCT01081262|Biological|Bevacizumab|Given IV
407676|NCT01081262|Drug|Capecitabine|Given PO
407677|NCT01081262|Drug|Carboplatin|Given IV
407678|NCT01081262|Other|Laboratory Biomarker Analysis|Correlative studies
407679|NCT01081262|Drug|Oxaliplatin|Given IV
407680|NCT01081262|Drug|Paclitaxel|Given IV
407681|NCT01081262|Other|Quality-of-Life Assessment|Ancillary studies
407682|NCT01081249|Drug|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
407683|NCT01081249|Drug|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
407684|NCT01081223|Biological|Cancer vaccine plus immune adjuvant, plus activated white blood cells|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
407717|NCT01080859|Device|OCT|Optical coherence tomography
407686|NCT01081197|Other|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
407687|NCT01081184|Biological|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
407688|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b(PegIntron)~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
407689|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518~Biologic: Peginterferon alfa-2b~Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days~Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
407690|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
407691|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
407692|NCT01081145|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
407693|NCT01081145|Other|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
407694|NCT01081132|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
407695|NCT01081132|Other|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
407696|NCT01081119|Behavioral|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
407697|NCT01081106|Procedure|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.~administration."
407698|NCT01081093|Procedure|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
407699|NCT01081054|Other|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
407700|NCT01081041|Drug|Cetuximab|Administered intravenously
407701|NCT01081041|Drug|Cisplatin|Administered intravenously
407702|NCT01081041|Drug|Carboplatin|Administered intravenously
407703|NCT01081041|Drug|5-Fluorouracil|Administered intravenously
407704|NCT01081002|Drug|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
407705|NCT01081002|Drug|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
407706|NCT01080989|Other|diagnosis, treatment and education|"Drug:~anti-intestinal parasitic drugs:~mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)~albendazole(400 mg bid * 7days) or Ivermectin(200 mcg/kg/day * 2 days) (For Strongyloidiasis).~Behavior:~Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.~Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
407707|NCT01080963|Drug|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
407708|NCT01080963|Drug|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
407709|NCT01080924|Device|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
407710|NCT01080911|Drug|Morphine|spinal morphine 0.05 mg
407711|NCT01080911|Drug|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
407712|NCT01080898|Other|tests|color photographs, FLUORESCEIN angiography and OCT
407713|NCT01080885|Behavioral|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
407714|NCT01080885|Behavioral|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
407718|NCT01080846|Drug|Misoprostol|600 mcg of sublingual misoprostol
407719|NCT01080833|Device|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
407720|NCT01080820|Drug|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
407721|NCT01080820|Drug|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
407722|NCT01080820|Drug|Viread|One single oral dose of 300mg Viread.
407723|NCT01080807|Drug|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
407724|NCT01080807|Drug|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
407725|NCT01080794|Device|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.~M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).~Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
407726|NCT01080768|Drug|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
407727|NCT01080768|Drug|Amlodipine|Amlodipine 5 mg/day.
407728|NCT01080768|Drug|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
407729|NCT01080768|Drug|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
407730|NCT01080742|Drug|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
407731|NCT01080729|Drug|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml [22 micrograms/0.5 ml]; 450 IU/0.75 ml [33 micrograms/0.75 ml]; or 900 IU/1.5 ml [66 micrograms/1.5 ml].~The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
407732|NCT01080716|Biological|Part 1/Arm 1 of Study: WRSS1 vaccine|Single, oral dose of WRSS1
407733|NCT01080716|Biological|Part 1/Arm 2 of Study: Placebo vaccine|Placebo vaccine
407734|NCT01080716|Biological|Part 2/Arm 1 of Study: S. sonnei 53G|Subject from Part 1/Arm 1 of Study are given 53G S. sonnei
407735|NCT01080716|Biological|Part 2/Arm 2 of Study: S. sonnei 53G|10 naïve controls are given S. sonnei 53G
407736|NCT01080703|Other|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
407737|NCT01080690|Procedure|EGD|In this arm EGD will be performed before EUS.
407738|NCT01080690|Procedure|EUS|In this arm EUS will be performed before EGD.
407739|NCT01080677|Drug|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
407740|NCT01080677|Drug|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
407741|NCT01080664|Drug|AS703569|"Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops"
407742|NCT01080664|Drug|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
407743|NCT01080651|Drug|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
407744|NCT01080638|Drug|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
407745|NCT01080625|Drug|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
407746|NCT01080625|Drug|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
407747|NCT01080625|Drug|placebo control|10ml of normal saline is administered at the time of reperfusion
407748|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
407749|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
407830|NCT01079936|Procedure|Stem Cell Infusion|Stem cell infusion on Day 0.
407750|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
407751|NCT01080612|Drug|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
407752|NCT01080599|Procedure|obturator nerve block|
407753|NCT01080586|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
407754|NCT01080560|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
407755|NCT01080547|Procedure|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
407756|NCT01080547|Drug|XELOX Chemotherapy|XELOX chemotherapy
407757|NCT01080547|Drug|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
407758|NCT01080547|Other|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
407759|NCT01080547|Other|Conventional Perioperative Treatment|Conventional treatment during perioperation period
407760|NCT01080547|Procedure|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
407761|NCT01080534|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
407762|NCT01080521|Procedure|Cognitive Assessment|Ancillary studies
407763|NCT01080521|Other|Quality-of-Life Assessment|Ancillary studies
407764|NCT01080508|Other|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
407765|NCT01080508|Other|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
407766|NCT01080495|Procedure|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
407767|NCT01080482|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
407768|NCT01080469|Drug|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
407769|NCT01080456|Drug|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
407770|NCT01080443|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
407771|NCT01080430|Other|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
407772|NCT01080417|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
407773|NCT01080404|Procedure|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
407774|NCT01080404|Device|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
407775|NCT01080391|Drug|Dexamethasone|40 mg orally or IV on days 1, 8, 15, 22
407776|NCT01080391|Drug|Lenalidomide|25 mg orally on days 1-21
407777|NCT01080391|Drug|Carfilzomib|20 mg/m², 27 mg/m² intravenously
407778|NCT01080378|Procedure|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
407779|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
407780|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
407781|NCT01080352|Drug|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
407782|NCT01080326|Device|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
407783|NCT01080313|Other|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
407784|NCT01080300|Drug|Gabapentin Extended Release|Gabapentin ER 1800mg daily
407785|NCT01080300|Drug|Placebo|Sugar pill
407786|NCT01080261|Device|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System
407787|NCT01080248|Drug|Gemcitabine|
407788|NCT01080248|Drug|Pazopanib|
407789|NCT01080235|Other|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
407790|NCT01080235|Other|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
407791|NCT01080222|Drug|telaprevir|tablet, 1125-mg, twice daily
407792|NCT01080222|Drug|VX-222|capsule, 100-mg, twice daily
407793|NCT01080222|Drug|ribavirin|tablet, 1000-mg for subjects weighing <75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
407794|NCT01080222|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
407795|NCT01080222|Drug|VX-222|capsule, 400-mg, twice daily
407796|NCT01080209|Drug|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
407797|NCT01080209|Other|Sham|Patients who recieved sham in a previous study.
408487|NCT01074398|Genetic|protein expression analysis|
407798|NCT01080196|Behavioral|RENEW|"RENEW will occur on a recumbent ergometer that appears like a normal stepper ergometer. While resisting the foot pedal movement the participant experiences eccentric muscle contractions about the knee and hip while performing negative work. The progression of the 3 x/week (every other day), 12 week RENEW program will be determined as a function of the rating of perceived exertion (RPE) using a target workload on the monitor. RENEW will be increased very slowly over the first 3 weeks and, subsequently, to maintain an 11-13 perceived exertion. During the formal RENEW training regimen the participants become fully acclimated to the device (week 3-4) the total RENEW load will increase weekly with no increase in their RPE."
407799|NCT01080183|Other|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
407800|NCT01080157|Device|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
407801|NCT01080144|Other|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
407802|NCT01080131|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
407803|NCT01080131|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
407804|NCT01080131|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
407805|NCT01080131|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
407806|NCT01080118|Device|Airtraq|Subjects were taught with the Airtraq video laryngoscope
407807|NCT01080118|Other|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
407808|NCT01080105|Behavioral|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
407809|NCT01080105|Behavioral|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
407810|NCT01080105|Behavioral|Educational website|Participants will receive access to a static educational website for 12 weeks.
407811|NCT01080092|Behavioral|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
407812|NCT01080092|Behavioral|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
407813|NCT01080079|Drug|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
407814|NCT01080079|Other|Purified Water|Purified Water
407815|NCT01080066|Other|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
407816|NCT01080027|Drug|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
407817|NCT01079988|Drug|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
407818|NCT01079988|Drug|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
407819|NCT01079988|Drug|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
407820|NCT01079988|Drug|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
407821|NCT01079988|Drug|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
407822|NCT01079962|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
407823|NCT01079962|Drug|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
407824|NCT01079949|Drug|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
407825|NCT01079949|Drug|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
407826|NCT01079949|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
407827|NCT01079949|Drug|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
407828|NCT01079936|Drug|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
407829|NCT01079936|Drug|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
407831|NCT01079923|Dietary Supplement|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
407832|NCT01079923|Dietary Supplement|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
407833|NCT01079910|Drug|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
407834|NCT01079910|Drug|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
407835|NCT01079897|Device|Atopiclair|topical applied cream, twice daily
407836|NCT01079897|Device|EHK02-01|topical applied cream containing 7% ectoine
407837|NCT01079884|Drug|esomeprazole 40 mg|40 mg daily for 4 weeks
407838|NCT01079871|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
407839|NCT01079858|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
407840|NCT01079845|Behavioral|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
407841|NCT01079832|Radiation|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
407842|NCT01079832|Procedure|quality-of-life assessment|Ancillary studies
407843|NCT01079819|Drug|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
407844|NCT01079819|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
407845|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
407846|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
407847|NCT01079806|Drug|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
407848|NCT01079806|Drug|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
407849|NCT01079793|Drug|ixabepilone|
407850|NCT01079793|Procedure|adjuvant therapy|
407851|NCT01079793|Radiation|intensity-modulated radiation therapy|
407852|NCT01079780|Biological|cetuximab|Given IV
407853|NCT01079780|Biological|ramucirumab|Given IV
407854|NCT01079780|Drug|irinotecan hydrochloride|Given IV
407855|NCT01079767|Drug|temsirolimus|
407856|NCT01079754|Drug|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
407857|NCT01079754|Drug|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
407858|NCT01079741|Biological|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.~Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
407859|NCT01079715|Drug|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).~In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.~In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.~In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:~Atropine.~Isoproterenol hydrochloride (isoprenaline.~Terlipressin.~Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
407860|NCT01079702|Drug|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
407861|NCT01079702|Drug|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
407862|NCT01079689|Other|needle stimulation|stimulation with acupuncture needles
407863|NCT01079676|Drug|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
407864|NCT01079676|Drug|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
407865|NCT01079663|Drug|Chlorhexidine 2.5 mg|
407866|NCT01079663|Drug|Placebo chip|
407867|NCT01079637|Procedure|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
407868|NCT01079637|Procedure|Cast treatment|Cast treatment
407869|NCT01079624|Other|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
407870|NCT01079598|Device|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
407871|NCT01079585|Dietary Supplement|Nutrigal Okara - 100|
407872|NCT01079572|Other|in-person|Follow-up appointments will be completed in-person as per usual
407873|NCT01079572|Other|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
407905|NCT01079260|Dietary Supplement|High Energy, low volume ONS|High energy, low volume ONS
407906|NCT01079247|Other|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
407907|NCT01079247|Other|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
407908|NCT01079234|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily
407874|NCT01079559|Device|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
407875|NCT01079559|Device|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
407876|NCT01079533|Behavioral|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
407877|NCT01079533|Behavioral|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
407878|NCT01079520|Procedure|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
407879|NCT01079520|Procedure|Mediastinoscopy|Traditional surgical method to stage lung cancers
407880|NCT01079494|Other|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
407881|NCT01079481|Drug|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
407882|NCT01079455|Drug|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
407883|NCT01079442|Other|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):~08:00 100mL beverage~12:00 100mL beverage~16:00 100mL beverage"
407884|NCT01079442|Other|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:~08:00 100mL beverage~12:00 100mL beverage~16:00 100mL beverage"
407885|NCT01079429|Genetic|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
407886|NCT01079416|Device|Capsule endoscopy, Esophagogastroduodenoscopy|
407887|NCT01079390|Device|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
407888|NCT01079364|Drug|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
407889|NCT01079364|Drug|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
407890|NCT01079364|Drug|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
407891|NCT01079351|Drug|Intravenous Carbamazepine|10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
407892|NCT01079338|Other|caffeine|
407893|NCT01079325|Drug|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
407894|NCT01079325|Other|Saline|
407895|NCT01079312|Device|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
407896|NCT01079312|Device|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
407897|NCT01079312|Drug|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
407898|NCT01079312|Drug|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
407899|NCT01079312|Drug|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
407900|NCT01079312|Drug|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
407901|NCT01079299|Device|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
407902|NCT01079286|Drug|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
407903|NCT01079273|Biological|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
407904|NCT01079260|Dietary Supplement|Standard ONS|Standard ONS
407909|NCT01079234|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
407910|NCT01079234|Drug|insulin aspart|At least three daily doses at meal-time
407911|NCT01079221|Behavioral|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at < 90 % of peak power, 3 days/week for 6 weeks
407912|NCT01079208|Other|test starter infant formula|infants are fed for 6 months with this starter formula
407913|NCT01079208|Other|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
407914|NCT01079208|Other|control standard formula|infant are fed 6 months with this formula
407915|NCT01079169|Dietary Supplement|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
407916|NCT01079143|Drug|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
407917|NCT01079143|Drug|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
407918|NCT01079143|Drug|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.~In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.~An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
407919|NCT01079143|Drug|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
407920|NCT01079143|Drug|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
407921|NCT01079130|Drug|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
407922|NCT01079130|Drug|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
407923|NCT01079130|Drug|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
407924|NCT01079130|Drug|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
407925|NCT01079117|Drug|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
407926|NCT01079117|Drug|Slow release oral morphine|
407927|NCT01079117|Drug|Methadone|
407928|NCT01079104|Device|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
407929|NCT01079104|Procedure|Standard Medical Therapy|Standard of care treatment
407930|NCT01079091|Device|ADVOS (Hepa Wash)|"Intervention frequency: 1-10 treatments (decision of the investigator)~Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
407931|NCT01079091|Procedure|Standard Medical Therapy|Standard of care treatment
407932|NCT01079078|Drug|Acetaminophen|
407933|NCT01079065|Drug|Famotidine|Tablets
407934|NCT01079052|Drug|Famotidine|Tablets
407935|NCT01079013|Drug|treosulfan|12 g/m2 x 3 days
407936|NCT01079000|Behavioral|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
407937|NCT01079000|Behavioral|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
407938|NCT01079000|Behavioral|Usual care|Usual care provided to asthma patients when discharged from the ED
407939|NCT01078987|Procedure|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
407940|NCT01078974|Drug|pomalidomide|Taken orally once a day
407941|NCT01078974|Drug|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
407942|NCT01078974|Drug|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
407943|NCT01078961|Drug|bortezomib|Given intravenously on days 1, 8 and 15 of each 28 day cycle
407944|NCT01078961|Drug|sorafenib|400mg taken orally twice a day
407945|NCT01078948|Device|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
407946|NCT01078935|Dietary Supplement|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
407947|NCT01078935|Dietary Supplement|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
407948|NCT01078922|Drug|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
407949|NCT01078909|Biological|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
407950|NCT01078870|Drug|Lexapro|10mg/cap 1~2# QD
407951|NCT01078870|Drug|Cymbalta|30mg/cap 30~60mg/QD
407952|NCT01078870|Drug|Placebo|1~2#/cap QD
407953|NCT01078857|Other|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
407954|NCT01078844|Drug|memantine|memantine 5-20 mg daily
407955|NCT01078844|Drug|Placebo|Look-alike placebo
407956|NCT01078831|Other|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
407957|NCT01078818|Drug|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up~1 month 1 oral placebo /24h"
407958|NCT01078818|Drug|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)~Postoperative Period:~200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
407959|NCT01078818|Drug|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
407960|NCT01078805|Drug|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
407961|NCT01078792|Other|CT pulmonary angio, blood tests|
407962|NCT01078779|Drug|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
407963|NCT01078779|Drug|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
407964|NCT01078766|Other|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
407965|NCT01078753|Drug|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
407966|NCT01078753|Drug|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
407967|NCT01078727|Device|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
407968|NCT01078714|Drug|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
407969|NCT01078701|Biological|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
407970|NCT01078701|Biological|Placebo|SPGN buffer
407971|NCT01078675|Drug|rosuvastatin calcium|5 mg, oral, once daily, 24 months
407972|NCT01078675|Drug|rosuvastatin calcium|10 mg, oral, once daily, 24 months
407973|NCT01078675|Drug|rosuvastatin calcium|20 mg, oral, once daily, 24 months
407974|NCT01078662|Drug|olaparib|400mg (8 x 50mg capsules), oral BID until progression of the disease
407975|NCT01078649|Drug|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
407976|NCT01078623|Drug|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
407977|NCT01078623|Drug|Placebo|Placebo control twice daily
407978|NCT01078623|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
407979|NCT01078623|Drug|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
407980|NCT01078623|Drug|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
407981|NCT01078610|Biological|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
407982|NCT01078571|Biological|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
408040|NCT01077973|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
408041|NCT01077973|Drug|Placebo|Single-dose of placebo
408488|NCT01074398|Other|immunohistochemistry staining method|
407983|NCT01078545|Drug|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
407984|NCT01078532|Other|SMART PHR|Patient receives an active PHR
407985|NCT01078532|Other|usual care|Usual passive PHR
407986|NCT01078519|Drug|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
407987|NCT01078493|Device|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
407988|NCT01078480|Procedure|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
407989|NCT01078480|Procedure|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
407990|NCT01078454|Drug|melphalan|Given PO
407991|NCT01078454|Drug|dexamethasone|Given PO
407992|NCT01078454|Drug|bortezomib|Given IV
407993|NCT01078441|Drug|liposomal doxorubicin|Given IV
407994|NCT01078441|Drug|bortezomib|Given subcutaneously.
407995|NCT01078441|Drug|dexamethasone|Given orally
407996|NCT01078441|Drug|cyclophosphamide|Given IV
407997|NCT01078428|Other|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
407998|NCT01078428|Other|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
407999|NCT01078415|Device|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
408000|NCT01078389|Drug|Febuxostat|Febuxostat capsules
408001|NCT01078389|Drug|Placebo for Febuxostat|Febuxostat placebo-matching capsules
408002|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
408003|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
408004|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
408005|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
408006|NCT01078363|Drug|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
408007|NCT01078363|Drug|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
408008|NCT01078350|Procedure|tumor tissue aspiration|
408009|NCT01078350|Procedure|phlebotomy|
408010|NCT01078337|Procedure|bone marrow aspiration|
408011|NCT01078337|Procedure|peripheral blood sampling|
408012|NCT01078298|Drug|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
408013|NCT01078298|Drug|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
408014|NCT01078285|Behavioral|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
408015|NCT01078285|Behavioral|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
408016|NCT01078272|Other|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
408017|NCT01078272|Other|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
408018|NCT01078194|Device|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
408019|NCT01078181|Procedure|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
408020|NCT01078168|Drug|Acitretin|30mg per day from Day 1 to Day 28
408021|NCT01078168|Drug|Placebo|Placebo
408022|NCT01078142|Drug|Temsirolimus, Rituximab, Bendamustin|"Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
408023|NCT01078129|Behavioral|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
408024|NCT01078129|Behavioral|non-CRT|waiting list
408025|NCT01078051|Procedure|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
408026|NCT01078051|Drug|optimal medical therapy|optimal medical therapy
408027|NCT01078038|Device|Cypher|Sirolimus-eluting stent implantation
408028|NCT01078038|Device|Xience V|Everolimus-eluting Stent implantation
408029|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
408030|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
408031|NCT01078012|Behavioral|Trained counselling|
408032|NCT01077999|Drug|Carboplatin|Carboplatin AUC = 2 , weekly.
408033|NCT01077999|Drug|Paclitaxel|Paclitaxel 50 mg/m2, weekly
408034|NCT01077999|Drug|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
408035|NCT01077999|Radiation|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
408036|NCT01077986|Drug|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
408037|NCT01077986|Drug|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
408038|NCT01077986|Drug|Everolimus|Everolimus will be administered daily, starting on day 1.
408039|NCT01077973|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
408042|NCT01077960|Biological|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
408043|NCT01077947|Procedure|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
408044|NCT01077947|Procedure|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
408045|NCT01077934|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
408046|NCT01077921|Drug|Propranolol|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
408047|NCT01077921|Drug|Placebo|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
408048|NCT01077908|Biological|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
408049|NCT01077908|Drug|Best available antiviral drug therapy|"Intravenous ganciclovir 5mg/kg twice daily~Oral valganciclovir 900mg twice daily~Intravenous foscarnet 90 mg/kg twice daily"
408050|NCT01077895|Procedure|CVVH|"CVVH is started using following parameters:~Blood flow is started at 150 mL/min~Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.~In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution~Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
408051|NCT01077895|Procedure|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol~Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:~Vasopressor or inotrope medication dose is increased by > 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)~When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV > 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h~If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
408052|NCT01077895|Procedure|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
408053|NCT01077882|Behavioral|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
408054|NCT01077882|Behavioral|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
408055|NCT01077882|Behavioral|Lifestyle factors and psycho-education|by dietician and psychiatrist
408056|NCT01077882|Other|no educational program|standard care without educational program
408057|NCT01077869|Procedure|endoscopic examination|on a weekly basis during 7 weeks
408058|NCT01077869|Procedure|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
408059|NCT01077843|Drug|Etoricoxib|Cox-2 inhibitor
408060|NCT01077843|Drug|Other Cox-2 inhibitors|Cox-2 inhibitor
408061|NCT01077843|Drug|Other Non-selective NSAIDs|Non-selective NSAID
408062|NCT01077843|Other|No anti-inflammatory treatment|No anti-inflammatory prescription
408063|NCT01077817|Drug|Alendronate|
408064|NCT01077817|Drug|Etidronate|
408065|NCT01077817|Drug|Ibandronate|
408066|NCT01077817|Drug|Risedronate|
408067|NCT01077817|Drug|Raloxifene|
408068|NCT01077791|Behavioral|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
408069|NCT01077778|Procedure|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
408070|NCT01077765|Device|Eutrophill|Polyacrylamide Hydrogel
408071|NCT01077752|Drug|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
408072|NCT01077752|Drug|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
408073|NCT01077752|Drug|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
408074|NCT01077752|Drug|NaCl|NaCl
408075|NCT01077739|Drug|fluorouracil (5FU)|standard FOLFOX regimen
408076|NCT01077739|Drug|leucovorin|standard FOLFOX regimen
408077|NCT01077739|Drug|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
408078|NCT01077739|Drug|capecitabine [Xeloda]|standard XELOX regimen
408079|NCT01077739|Drug|oxaliplatin|standard XELOX or FOLFOX regimen
408080|NCT01077726|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
408081|NCT01077713|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
408082|NCT01077713|Drug|cisplatin|60mg/m2 on day 1 of each 3 week cycle
408083|NCT01077713|Drug|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
408084|NCT01077713|Drug|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
408085|NCT01077700|Drug|ABT-288 Low Dose|
408086|NCT01077700|Drug|Placebo|inactive substance
408087|NCT01077700|Drug|ABT-288 High Dose|
408088|NCT01077661|Drug|Nebivolol|patients administrated Nebivolol according to the prescribing information
408489|NCT01074398|Other|laboratory biomarker analysis|
408089|NCT01077648|Drug|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
408090|NCT01077635|Drug|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
408091|NCT01077622|Drug|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
408092|NCT01077609|Drug|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
408093|NCT01077609|Drug|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
408094|NCT01077596|Drug|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
408095|NCT01077596|Drug|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
408096|NCT01077596|Drug|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
408097|NCT01077596|Drug|Regular use of any other antidepressant|"Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA."
408098|NCT01077570|Drug|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
408099|NCT01077557|Other|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
408100|NCT01077557|Drug|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
408101|NCT01077544|Drug|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.~Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
408102|NCT01077531|Drug|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
408103|NCT01077531|Drug|Matching placebo|Matching placebo for intravenous infusion
408104|NCT01077518|Drug|Ofatumumab (Arm A)|Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
408105|NCT01077518|Drug|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
408106|NCT01077518|Drug|Bendamustine infusion (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg).
408107|NCT01077505|Biological|albiglutide|albiglutide 50mg weekly subcutaneous injection
408108|NCT01077505|Drug|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
408109|NCT01077492|Other|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
408110|NCT01077479|Drug|Metformin|Metformin 1500mg nocte for 6 months
408111|NCT01077466|Drug|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
408112|NCT01077453|Drug|letrozole|Given orally
408113|NCT01077453|Other|quality-of-life assessment|Ancillary studies
408114|NCT01077453|Other|laboratory biomarker analysis|Correlative studies
408115|NCT01077440|Genetic|DNA analysis|DNA analysis will be performed on samples collected.
408116|NCT01077440|Genetic|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
408117|NCT01077440|Other|flow cytometry|Flow cytometry will be done on the samples collected.
408118|NCT01077440|Other|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
408119|NCT01077427|Device|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²)~Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²)~Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course~* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
408120|NCT01077427|Drug|Gemcitabine + Capecitabine|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)~Capecitabine: daily dose of 1660 mg/m²; administered orally for 21 days followed by 7 days' rest (one cycle) for six cycles"
408121|NCT01077401|Drug|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
408122|NCT01077401|Drug|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
408123|NCT01077388|Behavioral|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
408124|NCT01077375|Drug|Placebo|"Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
408125|NCT01077375|Drug|Milnacipran|"Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
408126|NCT01077362|Drug|placebo|SC injections
408127|NCT01077362|Drug|ustekinumab 45 mg|SC injections
408128|NCT01077362|Drug|ustekinumab 90 mg|SC injections
408129|NCT01077349|Procedure|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
408130|NCT01077349|Procedure|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:~Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR~Diuresis < 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR~Or serum urea > 36 mmol/l OR~Or life threatening hyperkalemia"
408131|NCT01077323|Drug|exenatide|subcutaneous injection, dosing according to normal clinical practice
408132|NCT01077323|Drug|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
408133|NCT01077323|Other|No diabetes therapy|Subjects not diagnosed with diabetes
408134|NCT01077310|Drug|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
408135|NCT01077310|Drug|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
408136|NCT01077297|Drug|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
408137|NCT01077284|Drug|Febuxostat|Febuxostat capsules
408138|NCT01077284|Drug|Allopurinol|Allopurinol capsules
408139|NCT01077284|Drug|Placebo|Placebo-matching capsules
408140|NCT01077245|Drug|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
408141|NCT01077245|Drug|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
408142|NCT01077206|Drug|Simvastatin|80mg daily versus 40mg daily, for 21 days.
408143|NCT01077193|Procedure|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.~The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.~At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
408144|NCT01077180|Device|Implantation of the Rheos System|Open label
408145|NCT01077180|Other|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
408146|NCT01077167|Drug|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
408147|NCT01077154|Drug|Placebo|Administered subcutaneously for up to 5 years
408148|NCT01077154|Drug|Denosumab|Administered subcutaneously for up to 5 years
408149|NCT01077115|Procedure|Laparoscopic cholecystectomy|
408150|NCT01077115|Procedure|Open Surgery|
408151|NCT01077102|Other|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
408152|NCT01077076|Drug|Zegerid|Zegerid taken once daily for 11 days.
408153|NCT01077076|Drug|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
408154|NCT01077076|Other|Placebo|Placebo taken once daily for 11 days.
408155|NCT01077063|Procedure|paracentesis|surgical drainage of malignant ascites
408156|NCT01077063|Device|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
408157|NCT01077050|Device|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
408158|NCT01077037|Other|Decision Aid|Chest pain choice decision aid
408195|NCT01076725|Device|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
408159|NCT01077024|Other|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
408160|NCT01077011|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
408161|NCT01077011|Other|GenTeal Gel|1 drop in each eye, one time
408162|NCT01076998|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
408163|NCT01076998|Other|Refresh PM Ointment|1 drop in each eye, one time
408164|NCT01076985|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
408165|NCT01076972|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
408166|NCT01076933|Procedure|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
408167|NCT01076933|Procedure|sham rTMS|sham rTMS
408168|NCT01076920|Genetic|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
408169|NCT01076907|Other|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
408170|NCT01076907|Other|Control|Air will be used instead of warm water for unsedated colonoscopy.
408171|NCT01076894|Procedure|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
408172|NCT01076894|Procedure|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
408173|NCT01076881|Behavioral|exercise training|
408174|NCT01076868|Drug|Primaquine|Primaquine x 14 days
408175|NCT01076842|Drug|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
408176|NCT01076842|Drug|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
408177|NCT01076842|Drug|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
408178|NCT01076842|Device|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
408179|NCT01076842|Device|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
408180|NCT01076829|Other|Spice polyphenols|spice
408181|NCT01076816|Drug|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
408182|NCT01076816|Procedure|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
408183|NCT01076816|Procedure|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
408184|NCT01076803|Drug|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
408185|NCT01076790|Drug|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
408186|NCT01076790|Drug|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
408187|NCT01076777|Behavioral|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
408188|NCT01076777|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
408189|NCT01076764|Drug|Otamixaban|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
408190|NCT01076764|Drug|Placebo (for Otamixaban)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
408191|NCT01076764|Drug|UFH|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
408192|NCT01076764|Drug|Placebo (for UFH)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
408193|NCT01076764|Drug|Eptifibatide|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
408194|NCT01076764|Drug|Placebo (for Eptifibatide)|"Pharmaceutical form: Intravenous (IV) solution~Route of administration: IV bolus followed by continuous IV infusion"
408196|NCT01076725|Device|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
408197|NCT01076712|Other|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
408198|NCT01076712|Other|Education Classes|Education Classes
408199|NCT01076699|Drug|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
408200|NCT01076699|Drug|0.125 mg RVX-100|This group is taking an average dose of RVX-100
408201|NCT01076699|Drug|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
408202|NCT01076699|Drug|placebo|This group is taking a placebo
408203|NCT01076686|Drug|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
408204|NCT01076673|Biological|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
408205|NCT01076673|Drug|Hyaluronic Acid|Hyaluronic acid injections
408206|NCT01076647|Drug|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
408207|NCT01076647|Drug|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
408208|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
408209|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
408210|NCT01076621|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
408211|NCT01076595|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
408212|NCT01076582|Drug|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
408213|NCT01076582|Drug|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
408214|NCT01076569|Other|laboratory biomarker analysis|Correlative studies
408215|NCT01076556|Drug|Alvocidib Hydrochloride|Given IV
408216|NCT01076556|Drug|Cyclophosphamide|Given IV
408217|NCT01076556|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
408218|NCT01076556|Other|Pharmacological Study|Correlative studies
408219|NCT01076556|Biological|Rituximab|Given IV
408220|NCT01076543|Other|Laboratory Biomarker Analysis|Correlative studies
408221|NCT01076543|Drug|Lenalidomide|Given PO
408222|NCT01076543|Drug|Temsirolimus|Given IV
408223|NCT01076530|Drug|vorinostat|
408224|NCT01076530|Drug|temozolomide|
408225|NCT01076530|Other|diagnostic laboratory biomarker analysis|
408226|NCT01076530|Other|pharmacological study|
408227|NCT01076517|Device|Therasphere|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
408228|NCT01076504|Drug|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
408229|NCT01076504|Drug|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
408230|NCT01076504|Drug|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
408231|NCT01076491|Drug|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
408232|NCT01076478|Drug|Cilostazol|100 mg, 200mg tablet Cilostazol
408233|NCT01076465|Other|Disease management program|1. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
408234|NCT01076465|Behavioral|Usual care|Usual care
408235|NCT01076452|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
408236|NCT01076439|Drug|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
408237|NCT01076439|Drug|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
408238|NCT01076439|Drug|Saline Nasal Spray|Placebo
408239|NCT01076426|Drug|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
408240|NCT01076426|Dietary Supplement|Oligosaccharide|oligosaccharide one pack per day
408241|NCT01076413|Behavioral|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
408242|NCT01076413|Behavioral|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
408243|NCT01076400|Drug|MK-1775|MK-1775 capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
408244|NCT01076400|Drug|Topotecan|Topotecan is administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3.
408245|NCT01076400|Drug|Cisplatin|Cisplatin is administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
408246|NCT01076400|Drug|Placebo to MK-1775|Placebo to MK-1775 capsules are administered in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle.
408247|NCT01076387|Procedure|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
408248|NCT01076387|Procedure|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
408249|NCT01076335|Drug|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
408250|NCT01076335|Drug|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
408251|NCT01076322|Drug|Meptin® Swinghaler|"Meptin® Swinghaler®~Ingredient: Procaterol HCL~Dosage form: 10g/puff~Dose(s): 10g~Dosing schedule: 20g (total 20g)"
408379|NCT01075282|Drug|Glimepiride|
408252|NCT01076322|Drug|Ventolin® MDI|"Ventolin® MDI~Ingredient: Salbutamol sulfate~Dosage form: 100g/puff~Dose(s): 100g~Dosing schedule: 200g (total 200g)"
408253|NCT01076283|Drug|Baclofen|Baclofen 10mg t.i.d.
408254|NCT01076283|Drug|Cyproheptadine|'active' placebo
408255|NCT01076270|Drug|plerixafor|Given SC
408256|NCT01076270|Biological|filgrastim|Given SC
408257|NCT01076270|Procedure|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
408258|NCT01076270|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
408259|NCT01076257|Behavioral|Modified Constraint-induced Movement Therapy|"Home based CIT~Restriction of the less affected limb~Intensive practice using affected limb~Positive experience~Functional task (task)"
408260|NCT01076244|Procedure|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
408261|NCT01076231|Radiation|proton beam radiation therapy|
408262|NCT01076231|Drug|cisplatin|Given IV
408263|NCT01076231|Drug|etoposide|Given IV
408264|NCT01076231|Procedure|therapeutic conventional surgery|
408265|NCT01076218|Device|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
408266|NCT01076166|Drug|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
408267|NCT01076153|Drug|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
408268|NCT01076140|Drug|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
408269|NCT01076140|Drug|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
408270|NCT01076127|Behavioral|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
408271|NCT01076127|Behavioral|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
408272|NCT01076088|Drug|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
408273|NCT01076088|Drug|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
408274|NCT01076088|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
408275|NCT01076088|Drug|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
408276|NCT01076088|Drug|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
408277|NCT01076075|Drug|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
408278|NCT01076075|Drug|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
408279|NCT01076075|Drug|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
408280|NCT01076075|Drug|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
408281|NCT01076075|Drug|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
408282|NCT01076075|Drug|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed~by investigator, of metformin; Phase B (Weeks 24-~54): stable dose, as prescribed by investigator, of~metformin"
408283|NCT01076075|Drug|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
408284|NCT01076062|Procedure|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
408285|NCT01076049|Other|observation of SOP|standard treatment of infection
408286|NCT01076049|Device|IrriSept Irrigation|irrigation of the wound using IrriSept
408287|NCT01076036|Device|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
408288|NCT01076036|Device|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
408289|NCT01076010|Drug|Tivozanib|Tivozanib will be orally administered once daily, at least 1 hour before or 2 hours after ingesting any food or other medication, for as long as the subject tolerates treatment in the absence of disease progression or unacceptable toxicity. Study drug will be administered beginning on Day 1 of Cycle 1.
408290|NCT01076010|Drug|Sorafenib|Sorafenib will be orally administered twice daily (unless reduced in parent protocol). Sorafenib should be taken without food at least 1 hour before or 2 hours after ingesting any food or other medications. Study drug will be administered beginning on Day 1 of Cycle 1.
408380|NCT01075256|Device|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
408381|NCT01075256|Device|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
408291|NCT01075997|Device|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
408292|NCT01075997|Device|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
408293|NCT01075984|Drug|Posaconazole|
408294|NCT01075984|Drug|Dextrose 5% in water|
408295|NCT01075971|Drug|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
408296|NCT01075971|Drug|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
408297|NCT01075945|Drug|Dihydroartemisinin- piperaquine|three tablets per day
408298|NCT01075945|Drug|artemether- lumefantrine|twenty tablet in eight doses
408299|NCT01075932|Dietary Supplement|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
408300|NCT01075932|Dietary Supplement|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
408301|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
408302|NCT01075919|Dietary Supplement|Placebo|1 g olive oil taken daily for 12 weeks
408303|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
408304|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
408305|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
408306|NCT01075880|Drug|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
408307|NCT01075854|Drug|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
408308|NCT01075841|Drug|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
408309|NCT01075828|Drug|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
408310|NCT01075815|Drug|Recombinant human luteinizing hormone (rhLH)|
408311|NCT01075815|Drug|Recombinant follicle-stimulating hormone (rFSH)|
408312|NCT01075802|Drug|Tamoxifen|Dose escalation
408313|NCT01075789|Drug|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
408314|NCT01075789|Drug|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
408315|NCT01075776|Drug|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
408316|NCT01075776|Drug|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
408317|NCT01075776|Drug|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
408318|NCT01075763|Drug|Interferon beta-1a|Interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per week (tiw)] administered subcutaneously (sc)
408319|NCT01075763|Drug|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
408320|NCT01075724|Device|Patient Warming with Forced Air|Forced Air warming via BairHugger
408321|NCT01075724|Device|Resistive Warming|Resistive Warming via HotDog device
408322|NCT01075711|Drug|Prednisone|According to SPC
408323|NCT01075698|Drug|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
408324|NCT01075698|Drug|ARB (Telmisartan)|Telmisartan 20-80 mg/day
408325|NCT01075685|Behavioral|interactive online programme to reduce alcohol consumption|"The programme includes several steps:~personalized feedback on alcohol consumption and related risks~reviewing motivations and fears regarding drinking reduction~analyse of drinking habits~reduction goal setting~follow-up tools (alcohol diary, craving scales, well-being scales)~a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
408326|NCT01075685|Behavioral|Minimum information|"This intervention includes:~information about hazardous drinking~an alcohol diary"
408327|NCT01075672|Behavioral|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
408328|NCT01075659|Drug|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
408329|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
408330|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
408331|NCT01075646|Drug|ropivacaine|"Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.~Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.~Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h."
408332|NCT01075646|Drug|saline solution|"Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.~Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.~Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h"
408333|NCT01075633|Procedure|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
408334|NCT01075633|Procedure|Colonoscopy with sedation|Colonoscopy with sedation
408335|NCT01075620|Device|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
408336|NCT01075620|Device|LPS RP|non-posterior stabilized rotating platform design
408337|NCT01075581|Drug|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
408338|NCT01075581|Drug|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
408339|NCT01075568|Dietary Supplement|Nutrigal Okara - 100|
408340|NCT01075555|Drug|pravastatin sodium|
408341|NCT01075555|Drug|sorafenib tosylate|
408342|NCT01075542|Device|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
408343|NCT01075542|Device|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
408344|NCT01075529|Drug|fluoxetine|fluoxetine 20 mg/d
408345|NCT01075503|Procedure|brachial plexus block|0.5% Ropivacaine 40ml
408346|NCT01075490|Drug|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
408347|NCT01075490|Drug|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
408348|NCT01075477|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
408349|NCT01075464|Drug|MEGF0444A|Intravenous escalating dose
408350|NCT01075464|Drug|bevacizumab|Intravenous repeating dose
408351|NCT01075464|Drug|paclitaxel|Intravenous repeating dose
408352|NCT01075438|Biological|Prevenar® (7-valent pneumococcal conjugate vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
408353|NCT01075438|Biological|Pneumovax® (pneumococcal polysaccharide vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)~Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
408354|NCT01075425|Drug|bortezomib|Given IV
408355|NCT01075425|Drug|belinostat|Given IV
408356|NCT01075425|Other|laboratory biomarker analysis|Correlative studies
408357|NCT01075425|Genetic|western blotting|Correlative studies
408358|NCT01075425|Other|pharmacological study|Correlative studies
408359|NCT01075425|Other|flow cytometry|Correlative studies
408360|NCT01075412|Drug|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
408361|NCT01075399|Drug|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with [F 18]HX4
408362|NCT01075347|Other|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
408363|NCT01075347|Other|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
408364|NCT01075334|Dietary Supplement|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
408365|NCT01075334|Dietary Supplement|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
408366|NCT01075321|Drug|everolimus|Given orally
408367|NCT01075321|Drug|lenalidomide|Given orally
408368|NCT01075321|Other|laboratory biomarker analysis|Correlative studies
408369|NCT01075321|Genetic|polymorphism analysis|Correlative studies
408370|NCT01075321|Other|immunohistochemistry staining method|Optional correlative studies
408371|NCT01075321|Genetic|microarray analysis|Optional correlative studies
408372|NCT01075321|Genetic|fluorescence in situ hybridization|Optional correlative studies
408373|NCT01075308|Drug|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
408374|NCT01075295|Behavioral|Behavioural Intervention for the Prevention of Weight Gain|"The intervention consists of four steps:~STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2~STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake & physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3~STEP 3 (Nutrition & Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4~STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)"
408375|NCT01075295|Other|TAU|Treatment as provided by individuals' existing healthcare providers
408376|NCT01075282|Drug|Insulin Glargine|
408377|NCT01075282|Drug|LY2189265|
408378|NCT01075282|Drug|Metformin|
408386|NCT01075230|Procedure|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
408387|NCT01075217|Drug|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
408388|NCT01075217|Drug|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
408389|NCT01075204|Drug|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
408390|NCT01075165|Other|silicone spray|application of silicone spray to predefined area qd 12 weeks
408391|NCT01075165|Other|saline spray|application of saline spray to predefined area qd 12 weeks
408392|NCT01075152|Drug|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
408393|NCT01075152|Biological|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
408394|NCT01075139|Behavioral|Brief Motivational Intervention|30 minute one-on-one meeting
408395|NCT01075139|Behavioral|Educational information|Educational handouts/brochures
408396|NCT01075126|Drug|Depakote|
408397|NCT01075126|Drug|Lithium|
408398|NCT01075113|Drug|sorafenib tosylate|Given orally
408399|NCT01075113|Drug|vorinostat|Given orally
408400|NCT01075100|Drug|Ixabepilone|20 mg/m2 on Days 1 and 8
408401|NCT01075100|Drug|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
408402|NCT01075087|Drug|Placebo|Bilateral TAP block using sterile normal saline.
408403|NCT01075087|Drug|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
408404|NCT01075074|Procedure|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
408405|NCT01075061|Other|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
408406|NCT01075061|Other|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
408407|NCT01075061|Other|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
408408|NCT01075048|Drug|Tivantinib|ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
408409|NCT01075048|Drug|Placebo|Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
408410|NCT01075048|Drug|Cetuximab|Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
408411|NCT01075048|Drug|Irinotecan|60 minutes after cetuximab, Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
408412|NCT01075022|Drug|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
408413|NCT01075022|Drug|Placebo|Placebo Capsule, Single Dose
408414|NCT01074996|Drug|S-1|40-60mg bid , days 1-14, every 3 weeks
408415|NCT01074996|Drug|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
408416|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
408417|NCT01074970|Drug|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
408418|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
408419|NCT01074957|Device|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
408420|NCT01074957|Device|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
408421|NCT01074957|Other|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
408422|NCT01074944|Drug|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
408423|NCT01074931|Drug|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.~The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
408424|NCT01074918|Drug|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
408425|NCT01074918|Drug|Potassium Chloride|Potassium Chloride
408426|NCT01074905|Drug|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
408427|NCT01074905|Drug|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
408428|NCT01074905|Drug|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
408429|NCT01074892|Drug|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
408687|NCT01072864|Other|Walnuts|Consumption of 20 g of walnuts.
408430|NCT01074892|Drug|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
408431|NCT01074892|Device|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
408432|NCT01074879|Dietary Supplement|Whey protein|Dietary supplement after training
408433|NCT01074879|Dietary Supplement|Milk protein|Dietary supplement after training
408434|NCT01074879|Dietary Supplement|Carbohydrates|Dietary supplement after training
408435|NCT01074866|Device|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
408436|NCT01074853|Drug|propranolol|10mg twice daily escalated to 80mg once daily
408437|NCT01074853|Drug|placebo|Matched placebo
408438|NCT01074840|Other|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
408439|NCT01074827|Other|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
408440|NCT01074814|Drug|(will be assigned based on molecular profile and RPMA)|treatment will be assigned based on IHC< FISH, DNA microarray and RPMA results
408441|NCT01074801|Other|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
408442|NCT01074801|Other|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
408443|NCT01074788|Behavioral|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
408444|NCT01074775|Biological|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
408445|NCT01074762|Behavioral|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
408446|NCT01074749|Device|Accent Pacemaker|Implantation of pacemaker
408447|NCT01074723|Dietary Supplement|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
408448|NCT01074710|Drug|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
408449|NCT01074710|Drug|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
408450|NCT01074697|Drug|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
408451|NCT01074697|Drug|Placebo|Saline water
408452|NCT01074671|Device|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
408453|NCT01074658|Device|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
408454|NCT01074645|Drug|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
408455|NCT01074632|Drug|Lurasidone HCl|
408456|NCT01074619|Drug|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
408457|NCT01074619|Drug|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
408458|NCT01074606|Device|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
408459|NCT01074593|Biological|Interferon beta-1a|12.000UI - single dose
408460|NCT01074593|Biological|Interferon beta-1a|12.000UI - Single dose
408461|NCT01074567|Drug|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
408462|NCT01074554|Drug|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
408463|NCT01074554|Drug|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
408464|NCT01074541|Radiation|UVB|0.375 SED x 4 in a week
408465|NCT01074541|Radiation|UVB|0.75 SED x 4 in a week
408466|NCT01074541|Radiation|UVB|1.5 SED x 4 in a week
408467|NCT01074541|Radiation|UVB|3.0 SED x 4 in a week
408468|NCT01074528|Behavioral|mindfulness based stress reduction program|8-week mindfulness training program
408469|NCT01074502|Drug|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
408470|NCT01074476|Dietary Supplement|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
408471|NCT01074476|Other|Placebo|Placebo tablets, twice per day for 3 months
408472|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
408473|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
408474|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
408475|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
408476|NCT01074437|Drug|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
408477|NCT01074437|Drug|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
408478|NCT01074437|Drug|Placebo|Liquid placebo will be given during the two month treatment trial.
408479|NCT01074424|Genetic|proteomic profiling|
408480|NCT01074424|Other|laboratory biomarker analysis|
408481|NCT01074411|Drug|Bortezomib|Given IP
408482|NCT01074411|Drug|Carboplatin|Given IP
408483|NCT01074411|Other|Laboratory Biomarker Analysis|Correlative studies
408484|NCT01074411|Other|Pharmacological Study|Correlative studies
408490|NCT01074385|Behavioral|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
408491|NCT01074372|Drug|REGN727|4 cohorts (dose 1, 2, 3, 4)
408492|NCT01074372|Drug|Placebo|4 cohorts (dose 1, 2, 3, 4)
408493|NCT01074359|Drug|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
408494|NCT01074359|Drug|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
408495|NCT01074346|Drug|Interferon-β-1a|Interferon-β-1a according to the standard practice
408496|NCT01074333|Drug|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
408497|NCT01074320|Other|Other|Observational study
408498|NCT01074307|Drug|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
408499|NCT01074307|Drug|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
408500|NCT01074294|Drug|OPDC-34712 + Stimulant Therapy|Tablets, Oral, 0.25 or 1.0 mg OPDC-34712 and FDA approved stimulant therapy
408501|NCT01074294|Drug|Placebo + Stimulant Therapy|Placebo plus a FDA approved stimulant therapy
408502|NCT01074281|Drug|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
408503|NCT01074268|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
408504|NCT01074268|Drug|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
408505|NCT01074268|Drug|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
408506|NCT01074255|Drug|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
408507|NCT01074229|Drug|Placebo|placebo injection
408508|NCT01074229|Drug|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
408509|NCT01074229|Drug|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
408510|NCT01074216|Drug|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
408511|NCT01074203|Drug|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery >12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
408512|NCT01074190|Drug|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
408513|NCT01074190|Drug|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
408514|NCT01074190|Drug|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
408515|NCT01074177|Drug|BIBW 2992|Taken orally once a day
408516|NCT01074164|Other|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
408517|NCT01074164|Device|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
408518|NCT01074151|Drug|duloxetine|any exposure to duloxetine that occurred during pregnancy
408519|NCT01074138|Drug|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
408520|NCT01074125|Drug|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
408521|NCT01074112|Device|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
408522|NCT01074112|Device|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
408688|NCT01072864|Other|Walnuts|Consumption of 30 g of walnuts.
408689|NCT01072864|Other|Walnuts|Consumption of 40 g of walnuts.
408523|NCT01074112|Procedure|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
408524|NCT01074112|Device|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
408525|NCT01074112|Device|Cardiac Ultrasound|Ultrasound views of the heart
408526|NCT01074099|Biological|BMAC|Injection of BMAC into ischemic myocardium during CABG
408527|NCT01074099|Procedure|CABG only|Control subjects will undergo CABG surgery without BMAC injection
408528|NCT01074086|Drug|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
408529|NCT01074073|Drug|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
408530|NCT01074060|Drug|plerixafor|Given IV
408531|NCT01074060|Biological|filgrastim|Given SC
408532|NCT01074060|Drug|cyclophosphamide|Given IV
408533|NCT01074060|Procedure|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
408534|NCT01074060|Other|laboratory biomarker analysis|Correlative studies
408535|NCT01074047|Drug|Azacitidine|75 mg/m^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
408536|NCT01074047|Drug|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:~Intensive chemotherapy (cytarabine 100-200 mg/m^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~Best Supportive Care only; until study end"
408537|NCT01074034|Device|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
408538|NCT01074021|Drug|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy:~Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
408539|NCT01074021|Drug|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy~Radiotherapy:~IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.~CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin~Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
408540|NCT01074008|Drug|ABT-450|50 mg capsules co-administered with ritonavir
408541|NCT01074008|Drug|ABT-072|50 mg tablet
408542|NCT01074008|Drug|ABT-333|400 mg tablet
408543|NCT01074008|Drug|Ritonavir|100 mg capsules co-administered with ABT-450
408544|NCT01074008|Drug|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
408545|NCT01074008|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
408546|NCT01074008|Other|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
408547|NCT01073995|Drug|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
408548|NCT01073982|Dietary Supplement|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
408549|NCT01073969|Other|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
408550|NCT01073969|Other|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
408551|NCT01073956|Procedure|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
408552|NCT01073956|Procedure|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
408553|NCT01073956|Procedure|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
408554|NCT01073943|Drug|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
408555|NCT01073943|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
408556|NCT01073943|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
408557|NCT01073930|Drug|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
408558|NCT01073930|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
408559|NCT01073930|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
408560|NCT01073917|Other|Spontaneous Breathing|
408561|NCT01073917|Other|Pressure Controlled Ventilation|
408562|NCT01073917|Other|Pressure Support Ventilation|
408563|NCT01073904|Drug|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
408564|NCT01073904|Drug|Postinor 2|Single dose of 1.5 mg tablet
408565|NCT01073891|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
408566|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
408567|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
408568|NCT01073878|Device|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
408569|NCT01073865|Drug|ZD9393 (Zoladex) 10.8 mg|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
408570|NCT01073865|Drug|ZD9393 (Zoladex) 3.6 mg|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
408571|NCT01073852|Drug|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
408572|NCT01073852|Drug|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
408573|NCT01073839|Drug|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
408574|NCT01073826|Behavioral|Sport|
408575|NCT01073826|Drug|Tocilizumab|
408576|NCT01073826|Drug|Sitagliptin|
408577|NCT01073813|Drug|Minocycline|100mg twice daily
408578|NCT01073800|Drug|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
408579|NCT01073800|Drug|placebo|placebo
408580|NCT01073787|Drug|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
408581|NCT01073774|Behavioral|Side by side|
408582|NCT01073774|Behavioral|couples control condition|
408583|NCT01073761|Drug|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days~Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
408584|NCT01073748|Drug|paracetamol|single dose of paracetamol 15mg/kg.
408585|NCT01073722|Device|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
408586|NCT01073722|Device|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
408587|NCT01073709|Drug|Acetaminophen|
408588|NCT01073696|Drug|granisetron IV|IV
408589|NCT01073696|Drug|granisetron patch|patch
408590|NCT01073683|Procedure|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
408591|NCT01073683|Drug|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
408592|NCT01073670|Drug|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
408593|NCT01073670|Drug|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
408594|NCT01073670|Drug|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
408595|NCT01073657|Other|Supported Education|Rehabilitation counseling using peers to achieve educational goals
408596|NCT01073657|Other|General Peer Support|Matched peer support for any personal goal other than education
408597|NCT01073644|Drug|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
408598|NCT01073631|Drug|voriconazole tablet|200 mg PO bid (orally, twice a day)
408599|NCT01073618|Drug|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
408600|NCT01073605|Drug|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
408601|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
408602|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
408726|NCT01072630|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
408603|NCT01073579|Drug|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.~Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
408604|NCT01073566|Device|Finesse|Finesse Insulin Delivery Patch
408605|NCT01073566|Device|Pen/Syringe (Usual injection device)|Pen/Syringe
408606|NCT01073553|Drug|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
408607|NCT01073553|Drug|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
408608|NCT01073540|Drug|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
408609|NCT01073540|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
408610|NCT01073527|Drug|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
408611|NCT01073527|Drug|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
408612|NCT01073501|Drug|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
408613|NCT01073501|Drug|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
408614|NCT01073488|Behavioral|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
408615|NCT01073475|Other|There is no intervention associated with this study.|There is no intervention associated with this study
408616|NCT01073449|Procedure|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
408617|NCT01073436|Other|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
408618|NCT01073423|Behavioral|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
408619|NCT01073423|Behavioral|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
408620|NCT01073397|Behavioral|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
408621|NCT01073384|Drug|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
408622|NCT01073371|Drug|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
408623|NCT01073358|Procedure|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
408624|NCT01073345|Procedure|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
408625|NCT01073345|Procedure|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
408626|NCT01073345|Procedure|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
408627|NCT01073332|Dietary Supplement|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
408628|NCT01073332|Dietary Supplement|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
408629|NCT01073319|Other|Placebo|Administration of placebo pill
408630|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
408631|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
408632|NCT01073306|Biological|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
408633|NCT01073306|Other|Placebo|Subcutaneous injection of placebo
408634|NCT01073293|Biological|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
408635|NCT01073293|Biological|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
408636|NCT01073293|Biological|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
408637|NCT01073280|Procedure|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
408638|NCT01073267|Radiation|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
408639|NCT01073241|Procedure|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
408640|NCT01073241|Procedure|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
408641|NCT01073228|Drug|EVP-6124|
408642|NCT01073228|Drug|Placebo|
408690|NCT01072851|Behavioral|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
408643|NCT01073215|Behavioral|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
408644|NCT01073215|Behavioral|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).~Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
408645|NCT01073202|Drug|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
408646|NCT01073202|Drug|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
408647|NCT01073189|Drug|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
408648|NCT01073189|Drug|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
408649|NCT01073176|Other|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
408650|NCT01073163|Drug|Bendamustine|Bendamustine at 90 mg/m^2 IV on Days 1 and 2 of a 28-day cycle.
408651|NCT01073163|Drug|Rituximab|Rituximab at 375 mg/m^2 IV on Day 1 of a 28-day cycle.
408652|NCT01073150|Drug|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
408653|NCT01073124|Procedure|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
408654|NCT01073111|Device|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
408655|NCT01073111|Device|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
408656|NCT01073111|Device|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
408657|NCT01073098|Other|Vascular occlusion test|Reperfusion slope after vascular occlusion test
408658|NCT01073085|Behavioral|"Web-based automated coaching by e-mails"|
408659|NCT01073085|Behavioral|Self-help guide|
408660|NCT01073072|Procedure|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
408661|NCT01073072|Procedure|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
408662|NCT01073059|Drug|Valproic acid and Ertapenem|
408663|NCT01073046|Device|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
408664|NCT01073033|Dietary Supplement|milk supplement 1|milk supplement with probiotics
408665|NCT01073033|Dietary Supplement|milk supplement 2|milk supplement without probiotics
408666|NCT01073020|Procedure|Laparoscopic Adjustable Gastric Band|Allergan Adjustable Gastric Band (Device) compared to Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
408667|NCT01073020|Procedure|Roux-en-Y Gastric Bypass (Surgery)|Roux-en-Y Gastric Bypass (Surgery) versus Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
408668|NCT01073020|Other|Intensive Medical Diabetes & Weight Management|Intensive Medical Diabetes & Weight Management
408669|NCT01073020|Device|Allergan Adjustable Gastric Band|Allergan Adjustable Gastric Band (Device) compared to Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
408670|NCT01073007|Drug|Simvastatin|Simvastatin 40 mgrs daily for three months.
408671|NCT01072994|Dietary Supplement|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
408672|NCT01072981|Biological|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
408673|NCT01072981|Drug|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
408674|NCT01072981|Radiation|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
408675|NCT01072968|Drug|BF2.649|1 capsule per day in the morning before the breakfast
408676|NCT01072968|Drug|Placebo|1 capsule per day in the morning before the breakfast
408677|NCT01072955|Biological|Bovine Heparin|5.000UI/mL bottle with 5mL
408678|NCT01072955|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
408679|NCT01072942|Drug|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
408680|NCT01072942|Drug|Placebo|Placebo TID for 10 days
408681|NCT01072929|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
408682|NCT01072929|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
408683|NCT01072890|Drug|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
408684|NCT01072877|Drug|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
408685|NCT01072877|Drug|Placebo Vehicle|Placebo vehicle
408686|NCT01072864|Other|Walnuts|Consumption of 5 g of walnuts.
408691|NCT01072851|Behavioral|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
408692|NCT01072851|Behavioral|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
408693|NCT01072838|Radiation|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each."
408694|NCT01072838|Device|Contura MLB Breast Brachytherapy Catheter|
408695|NCT01072825|Other|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
408696|NCT01072825|Biological|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
408697|NCT01072825|Other|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
408698|NCT01072825|Other|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
408699|NCT01072825|Other|Bone evaluation|PQCT scanner, BMD assessment
408700|NCT01072812|Drug|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
408701|NCT01072799|Biological|Placebo|Two doses (Day 1 and Day 22); 0.5mL
408702|NCT01072799|Biological|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 & Day 22); 0.5mL
408703|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30)
408704|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30-200,201)
408705|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30)
408706|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30-200,201)
408707|NCT01072786|Biological|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
408708|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
408709|NCT01072773|Drug|bortezomib|1.3 mg/m^2, by IV on days 1, 8 and 15 every 28 days
408710|NCT01072773|Drug|cyclophosphamide|300 mg/m^2, orally, on days 1, 8, 15 & 22 every 28 days.
408711|NCT01072773|Drug|dexamethasone|40 mg, orally, on days 1, 8, 15 & 22 every 28 days
408712|NCT01072760|Procedure|K wire|Mallet finger treatment
408713|NCT01072747|Biological|bovine heparin|5.000UI/mL bottle with 5mL
408714|NCT01072747|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
408715|NCT01072734|Drug|Vaccine|Influenza vaccine
408716|NCT01072721|Other|Elastometry|Fibrosis detection with FIBROSCANN
408717|NCT01072708|Other|Prospective cohort with an annual follow-up|"Annualfollow-up including :~oral glucose tolerance test~dietary survey~biological evaluation~bacteriological and respiratory measures~dual-energy x-ray absorptiometry~physical activity survey"
408718|NCT01072695|Drug|GS-9256|75 mg BID x 28 days
408719|NCT01072695|Drug|GS-9190|40 mg BID x 28 days
408720|NCT01072695|Drug|Ribavirin|1000-1200 mg/day given BID
408721|NCT01072695|Drug|Peginterferon alfa-2a|180 ug q week
408722|NCT01072682|Device|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
408723|NCT01072669|Drug|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily[if the lower dose is tolerated] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
408724|NCT01072656|Device|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
408725|NCT01072643|Drug|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
408727|NCT01072630|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
408728|NCT01072617|Device|Transcranial magnetic stimulation via MagPro x100 device|"Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.~Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system."
408729|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
408730|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
408731|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
408732|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
408733|NCT01072591|Drug|MEDI-578|intravenous infusion, once
408734|NCT01072591|Drug|Placebo for MEDI-578|Intravenous infusion, once
408735|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
408736|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
408737|NCT01072565|Other|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
408738|NCT01072565|Other|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
408739|NCT01072539|Drug|tigecycline|As prescribed by physician in usual clinical practice
408740|NCT01072526|Drug|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
408741|NCT01072526|Drug|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
408742|NCT01072513|Other|Semen analysis|Semen analysis before and after proton radiation therapy.
408743|NCT01072500|Behavioral|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
408744|NCT01072500|Behavioral|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
408745|NCT01072487|Procedure|Capnography|Monitoring of the capnography curve for early detection of apnea
408746|NCT01072474|Procedure|Capnography|Capnographic monitoring
408747|NCT01072474|Procedure|Standard monitoring|Standard monitoring
408748|NCT01072461|Behavioral|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
408749|NCT01072461|Behavioral|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
408750|NCT01072461|Behavioral|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
408751|NCT01072448|Drug|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
408752|NCT01072448|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
408753|NCT01072435|Device|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
408754|NCT01072435|Device|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
408755|NCT01072422|Behavioral|Counseling based on answers to the assessment protocol|Each patient in the Protocol arm will fill in a TTQ at baseline. On the basis of the patients' answers, the nurse will provide individual counseling aimed at helping this patient overcome obstacles to smoking cessation.
408756|NCT01072409|Device|Nucleus 5 Cochlear implant|Cochlear implant surgery
408757|NCT01072409|Device|Cochlear implantation|Implantation
408758|NCT01072396|Drug|Tiotropium|double blind randomized crossover
408759|NCT01072396|Drug|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
408760|NCT01072383|Drug|BT061|administration of BT061 either intravenous or subcutaneous
408761|NCT01072383|Drug|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
408762|NCT01072370|Biological|Cord Blood Infusion|red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion
408763|NCT01072370|Biological|Intravenous Sham|intravenous infusion of 5% dextrose, ¼ normal saline solution
408764|NCT01072357|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
408765|NCT01072357|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
408766|NCT01072344|Drug|Chamomile (Matricaria recutita)|500 mg 3 times daily
408767|NCT01072331|Drug|MP-513|MP-513 10 mg, once a day, for 4 weeks
408768|NCT01072331|Drug|MP-513|MP-513 20 mg, once a day, for 4 weeks
408769|NCT01072331|Drug|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
408770|NCT01072318|Drug|Letrozole|Letrozole 2.5mg
408771|NCT01072305|Device|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
408858|NCT01071499|Drug|Morphine|One dose of morphine (0.3 mg/kg)
409386|NCT01067365|Drug|Androxal|12.5 mg once daily
408772|NCT01072305|Device|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
408773|NCT01072292|Behavioral|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
408774|NCT01072279|Other|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
408775|NCT01072279|Other|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
408776|NCT01072266|Drug|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
408777|NCT01072253|Procedure|eye amputation|
408778|NCT01072240|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
408779|NCT01072227|Procedure|Sample Collection|Tissue
408780|NCT01072214|Drug|pazopanib|gw786034
408781|NCT01072214|Drug|pazopanib|gw786034
408782|NCT01072214|Drug|pazopanib|gw786034
408783|NCT01072214|Drug|Placebo|placebo
408784|NCT01072201|Drug|Triclosan and Fluoride|Brush twice daily
408785|NCT01072201|Drug|Fluoride|Brush twice daily
408786|NCT01072188|Device|Arginine/Calcium Carbonate|One time treatment
408787|NCT01072188|Device|Nupro - Fluoride Free|Brush twice daily
408788|NCT01072175|Drug|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
408789|NCT01072175|Drug|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
408790|NCT01072162|Drug|Eltrombopag|25 mg tablet
408791|NCT01072162|Drug|Eltrombopag|25 mg powder for oral suspension
408792|NCT01072149|Drug|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
408793|NCT01072149|Device|placebo|placebo
408794|NCT01072136|Other|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
408795|NCT01072136|Drug|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
408796|NCT01072136|Drug|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
408797|NCT01072123|Other|Quest for the Code|interactive asthma-based computer program
408798|NCT01072110|Procedure|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
408799|NCT01072110|Procedure|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
408800|NCT01072097|Drug|Atorvastatin|Atorvastatin 20mg/day for 6 months
408801|NCT01072097|Drug|Placebo|Placebo for 6 months
408802|NCT01072071|Drug|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.~Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
408803|NCT01072058|Drug|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
408804|NCT01072045|Drug|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
408805|NCT01072045|Drug|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
408806|NCT01072032|Device|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
408807|NCT01072019|Other|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
408808|NCT01071993|Drug|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
408809|NCT01071993|Drug|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
408810|NCT01071980|Other|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
408811|NCT01071967|Other|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
408812|NCT01071954|Biological|Romiplostim|Administered by subcutaneous injection once a week.
408813|NCT01071941|Biological|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
408814|NCT01071928|Drug|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
408815|NCT01071928|Drug|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
408859|NCT01071486|Drug|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
409387|NCT01067365|Drug|Androxal|25 mg once daily
408816|NCT01071915|Drug|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
408817|NCT01071902|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
408818|NCT01071902|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
408819|NCT01071902|Other|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
408820|NCT01071902|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
408821|NCT01071889|Drug|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
408822|NCT01071889|Drug|Placebo|Placebo - only excipients with no API
408823|NCT01071876|Drug|BF2.649|1 capsule in the morning before breakfast
408824|NCT01071876|Drug|Placebo|1 capsule in the morning before breakfast
408825|NCT01071850|Drug|ipragliflozin|oral tablet
408826|NCT01071850|Drug|Metformin|oral tablet
408827|NCT01071850|Drug|Placebo|oral tablet
408828|NCT01071837|Drug|APG101|400mg weekly as intravenous infusion
408829|NCT01071837|Procedure|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
408830|NCT01071824|Procedure|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
408831|NCT01071824|Procedure|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
408832|NCT01071811|Behavioral|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
408833|NCT01071798|Drug|Rituximab|As prescribed by physician
408834|NCT01071785|Dietary Supplement|guar gum|guar gum 10g/day for six weeks
408835|NCT01071772|Drug|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
408836|NCT01071720|Drug|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
408837|NCT01071694|Drug|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
408838|NCT01071681|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
408839|NCT01071655|Drug|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1~BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1~BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly~BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
408840|NCT01071655|Drug|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
408841|NCT01071642|Drug|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
408842|NCT01071642|Drug|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
408843|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
408844|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
408845|NCT01071616|Drug|Cannabis Cigarette|
408846|NCT01071564|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
408847|NCT01071564|Other|Laboratory Biomarker Analysis|Correlative studies
408848|NCT01071564|Other|Pharmacogenomic Study|Correlative studies
408849|NCT01071564|Other|Pharmacological Study|Correlative studies
408850|NCT01071564|Drug|Vismodegib|Given PO
408851|NCT01071551|Behavioral|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
408852|NCT01071551|Behavioral|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
408853|NCT01071538|Drug|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
408854|NCT01071525|Drug|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\Laropiprant
408855|NCT01071512|Drug|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
408856|NCT01071499|Drug|Morphine|One dose of morphine (0.1 mg/kg)
408857|NCT01071499|Drug|Morphine|One dose of morphine (0.2 mg/kg)
408860|NCT01071473|Other|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
408861|NCT01071460|Device|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy~Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:~Contralateral retrograde common femoral cross-over access or antegrade access~Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion~Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis~Deployment of an appropriately sized FlexStent® to cover target lesion~Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter~Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
408862|NCT01071447|Other|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
408863|NCT01071434|Procedure|MR Imaging|
408864|NCT01071421|Device|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
408865|NCT01071408|Other|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
408866|NCT01071395|Drug|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
408867|NCT01071395|Drug|Placebo|Sugar pill given 3 times daily
408868|NCT01071369|Drug|Xylocaine|0.5% Xylocaine
408869|NCT01071369|Drug|Xylocaine and Celestone|non-particulate Celestone
408870|NCT01071356|Behavioral|Intensive MI|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
408871|NCT01071356|Behavioral|Single session MI|Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
408872|NCT01071343|Device|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
408873|NCT01071317|Drug|Naproxen|Naproxen 500mg PO bid prn headache
408874|NCT01071317|Drug|Sumatriptan|100mg po q day prn headache
408875|NCT01071317|Behavioral|Migraine education|Educational program available through NIH/ national library of medicine/ X-plain
408876|NCT01071317|Behavioral|Reenforcement of diagnosis|Patient advised has migraine headache and how the headache meets migraine criteria
408877|NCT01071317|Other|Typical care|Care to be determined by attending physician
408878|NCT01071304|Drug|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
408879|NCT01071304|Drug|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
408880|NCT01071291|Drug|Niaspan|Niaspan™
408881|NCT01071291|Drug|Comparator: Placebo|Placebo
408882|NCT01071265|Procedure|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
408883|NCT01071265|Procedure|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
408884|NCT01071252|Drug|AIN457|
408885|NCT01071252|Drug|Placebo|
408886|NCT01071239|Device|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
408887|NCT01071239|Drug|Busulfan|Chemotherapy administered as a part of the HSCT conditioning regimen.
408888|NCT01071239|Drug|Fludarabine|Chemotherapy administered as a part of the HSCT conditioning regimen.
408889|NCT01071239|Drug|Cyclophosphamide|Chemotherapy administered as a part of the HSCT conditioning regimen.
408890|NCT01071239|Drug|ATG|Chemotherapy administered as a part of the HSCT conditioning regimen.
408891|NCT01071226|Device|CliniMACS (CD+3, CD+19 depletion)|Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
408892|NCT01071226|Device|CliniMACS (CD 34+ positive selection)|Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
408893|NCT01071226|Other|HSCT|Peripheral Blood Stem Cell Transplant
408894|NCT01071200|Drug|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
408895|NCT01071200|Drug|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
408896|NCT01071187|Drug|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
408897|NCT01071187|Drug|Placebo|Placebo
408898|NCT01071174|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
408899|NCT01071174|Other|Placebo|Vaginal Ring containing no drug substance
408900|NCT01071161|Drug|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
408901|NCT01071161|Drug|placebo|placebo
408938|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
408939|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
408902|NCT01071135|Drug|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
408903|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
408904|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
408905|NCT01071122|Drug|Valsartan|Valsartan 160mg, Once daily
408906|NCT01071109|Procedure|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
408907|NCT01071096|Drug|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
408908|NCT01071096|Drug|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
408909|NCT01071083|Drug|natalizumab|300 mg intravenous every 4 weeks
408910|NCT01071083|Drug|interferon beta 1-a|30 ug intramuscular once per week
408911|NCT01071083|Drug|methylprednisolone|1000 mg intravenous every 4 weeks
408912|NCT01071083|Other|IV placebo|placebo intravenous every 4 weeks
408913|NCT01071083|Drug|glatiramer acetate|20 mg subcutaneous once daily
408914|NCT01071070|Drug|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
408915|NCT01071057|Drug|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
408916|NCT01071057|Drug|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
408917|NCT01071044|Drug|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
408918|NCT01071044|Drug|"Placebo 30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
408919|NCT01071031|Biological|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant~Administration: A single subcutaneous injection"
408920|NCT01071031|Biological|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant~Administration: A single subcutaneous injection"
408921|NCT01071031|Biological|HIV-v (Control)|"Adjuvant only or Water for injection only~Administration: A single subcutaneous injection"
408922|NCT01071018|Drug|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
408923|NCT01071018|Drug|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
408924|NCT01071005|Drug|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
408925|NCT01071005|Drug|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
408926|NCT01070979|Drug|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
408927|NCT01070979|Drug|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
408928|NCT01070979|Drug|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
408929|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
408930|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
408931|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
408932|NCT01070940|Drug|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
408933|NCT01070927|Drug|RO4929097|80mg po daily, 3 days on 4 days off schedule
408934|NCT01070927|Drug|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
408935|NCT01070888|Drug|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
408936|NCT01070888|Drug|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
408937|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
409006|NCT01070394|Drug|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
408940|NCT01070862|Drug|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
408941|NCT01070862|Drug|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
408942|NCT01070862|Drug|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
408943|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
408944|NCT01070849|Other|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
408945|NCT01070849|Other|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
408946|NCT01070849|Other|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
408947|NCT01070836|Drug|natalizumab|Administered as specified in the treatment arm
408948|NCT01070823|Drug|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
408949|NCT01070810|Drug|D5W|Dextrose 5%
408950|NCT01070810|Drug|Thiamine|Thiamine 200mg in 50ml D5W
408951|NCT01070797|Biological|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:~Level One: 5 x 10^6 rCTLs/m2~Level Two: 1 x 10^7 rCTLs/m2~Level Three: 2 x 10^7 rCTLs/m2~Level Four: 5 x 10^7 rCTLs/m2~If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
408952|NCT01070784|Drug|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
408953|NCT01070784|Drug|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
408954|NCT01070771|Device|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
408955|NCT01070758|Drug|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
408956|NCT01070745|Drug|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
408957|NCT01070745|Drug|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
408958|NCT01070732|Drug|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
408959|NCT01070706|Drug|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
408960|NCT01070693|Procedure|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
408961|NCT01070693|Device|Prolene Hernia System|Prolene Hernia System
408962|NCT01070693|Procedure|Lichtenstein technique|Lichtenstein technique
408963|NCT01070680|Drug|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
408964|NCT01070680|Drug|sodium chlorid 0,9%|continuous intravenous infusion
408965|NCT01070667|Drug|Dronedarone|400mg orally once per day for 3 months
408966|NCT01070667|Drug|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
408967|NCT01070654|Procedure|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
408968|NCT01070654|Device|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
408969|NCT01070641|Drug|Carvedilol|Carvedilol 12.5mg QD
408970|NCT01070641|Procedure|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
408971|NCT01070628|Drug|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
408972|NCT01070628|Drug|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
408973|NCT01070615|Drug|Prucalopride|
408974|NCT01070602|Procedure|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
408975|NCT01070576|Other|no intervention|no intervention
408976|NCT01070563|Other|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
408977|NCT01070550|Drug|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
408978|NCT01070537|Device|Bonfils fiberscope intubation|
408979|NCT01070524|Drug|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
408980|NCT01070524|Drug|Budesonide extrafine pMDI|Budesonide extrafine pMDI
408981|NCT01070524|Drug|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
408982|NCT01070511|Drug|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose—10 mg— will be administered the afternoon before the study. The second dose -20 mg—will be administered the morning of the study.
408983|NCT01070511|Drug|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
408984|NCT01070498|Drug|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
408985|NCT01070485|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
408986|NCT01070472|Drug|Misoprostol|titrated oral misoprostol solution
408987|NCT01070459|Behavioral|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
408988|NCT01070459|Behavioral|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
408989|NCT01070459|Behavioral|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
408990|NCT01070459|Behavioral|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
408991|NCT01070459|Behavioral|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
408992|NCT01070446|Dietary Supplement|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
408993|NCT01070433|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
408994|NCT01070433|Other|Standard of Care|Topical application twice a day
408995|NCT01070420|Other|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min−1•kg−1) via Rt central femoral vein.
408996|NCT01070420|Other|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min−1•kg−1) via continuous peripheral vein.
408997|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
408998|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
408999|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
409000|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
409001|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
409002|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
409003|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 8.
409004|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 8.
409005|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10^10vp at week 8.
409007|NCT01070381|Device|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
409008|NCT01070381|Device|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
409009|NCT01070368|Other|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
409010|NCT01070355|Drug|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
409011|NCT01070355|Drug|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
409012|NCT01070342|Device|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
409013|NCT01070329|Drug|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
409014|NCT01070329|Drug|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
409015|NCT01070316|Drug|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
409016|NCT01070303|Biological|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
409017|NCT01070290|Drug|ARQ 197|120 mg capsule administered twice daily
409018|NCT01070290|Drug|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
409019|NCT01070277|Drug|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
409020|NCT01070277|Drug|Placebo control|"2 placebo pills X2 /day for 2 days followed by~1 placebo Pill X2 / day for 7 days"
409021|NCT01070264|Dietary Supplement|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
409022|NCT01070251|Behavioral|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
409023|NCT01070251|Behavioral|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
409024|NCT01070238|Dietary Supplement|Isomaltulose|
409025|NCT01070225|Drug|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
409026|NCT01070212|Other|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
409027|NCT01070212|Other|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
409028|NCT01070212|Other|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
409029|NCT01070199|Behavioral|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
409030|NCT01070199|Behavioral|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
409080|NCT01069822|Drug|AZD6765|IV solution
409081|NCT01069822|Drug|midazolam|
409082|NCT01069809|Biological|AGS-004|HIV-1 Immune Therapy
409083|NCT01069809|Biological|Placebo|Inactive Placebo Injection
409084|NCT01069796|Drug|Paclitaxel|80 mg/m² weekly
409085|NCT01069796|Drug|Bevacizumab|10 mg/kg d1 d15
409031|NCT01070199|Behavioral|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
409032|NCT01070199|Behavioral|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
409033|NCT01070186|Drug|Sunitinib|50mg/day for 4 weeks
409034|NCT01070186|Other|Tumor biopsy|Conducted prior to administration of sunitinib therapy
409035|NCT01070186|Procedure|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
409036|NCT01070186|Other|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.~Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
409037|NCT01070160|Drug|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
409038|NCT01070160|Drug|Metformin|per clinical care guidelines
409039|NCT01070147|Other|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
409040|NCT01070134|Behavioral|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
409041|NCT01070134|Behavioral|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
409042|NCT01070108|Drug|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
409043|NCT01070108|Drug|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
409044|NCT01070108|Drug|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
409045|NCT01070095|Other|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
409046|NCT01070069|Device|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
409047|NCT01070069|Device|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
409048|NCT01070069|Device|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
409049|NCT01070056|Behavioral|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
409050|NCT01070056|Behavioral|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
409051|NCT01070043|Drug|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
409052|NCT01070043|Drug|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.~Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
409086|NCT01069796|Drug|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 & 3
409087|NCT01069783|Drug|A3309|A3309 in two different dosage levels
409088|NCT01069783|Drug|A3309|A3309 in two different dosage levels for the duration of the study
409089|NCT01069783|Drug|Placebo|Placebo comparator once daily for the duration of the trial
409090|NCT01069770|Drug|Sunitinib|50mg daily(4 weeks on & 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
409091|NCT01069757|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
409053|NCT01070030|Drug|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
409054|NCT01070017|Other|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
409055|NCT01070004|Other|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
409056|NCT01070004|Other|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
409057|NCT01069991|Behavioral|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
409058|NCT01069991|Behavioral|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
409059|NCT01069965|Drug|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
409060|NCT01069965|Drug|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
409061|NCT01069965|Drug|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
409062|NCT01069965|Drug|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
409063|NCT01069965|Drug|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
409064|NCT01069965|Drug|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
409065|NCT01069952|Device|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
409066|NCT01069939|Drug|Esomeprazole|20mg, capsule, 72 weeks
409067|NCT01069939|Drug|Placebo|Placebo, capsule, 72 weeks
409068|NCT01069926|Drug|AZD1656|Single dose oral tablet
409069|NCT01069913|Drug|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation & Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API & Following 7 day washout period, 240 mg BG00012 Standard Formulation."
409070|NCT01069900|Drug|Moxifloxacin (Avelox, BAY12-8039)|For subjects 12 to less than (<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to < 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to < 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
409071|NCT01069900|Drug|Ertapenem|For subjects 13 to <18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to < 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
409072|NCT01069900|Drug|Amoxicillin/Clavulanate|Subjects 2 years to < 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
409073|NCT01069900|Drug|Moxifloxacin placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
409074|NCT01069900|Drug|Ertapenem placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
409075|NCT01069900|Drug|Amoxicillin/Clavulanate placebo|Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
409076|NCT01069874|Dietary Supplement|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
409077|NCT01069874|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
409078|NCT01069861|Drug|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
409079|NCT01069848|Device|Vedera KXS|One treatment session with Vedera KXS
409092|NCT01069705|Drug|Tobramycin inhalation powder|Tobramycin inhaled powder
409093|NCT01069692|Drug|SBR759A|SBR759A 6g daily
409094|NCT01069692|Drug|SBR759A|Placebo Comparator 0g daily
409095|NCT01069692|Drug|SBR759A|SBR759A 3g daily
409096|NCT01069692|Drug|SBR759A|9g daily
409097|NCT01069692|Drug|SBR759A|12g daily
409098|NCT01069653|Biological|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
409099|NCT01069640|Biological|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
409100|NCT01069627|Drug|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
409101|NCT01069627|Drug|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
409102|NCT01069614|Device|TopClosure 3S System|
409103|NCT01069601|Biological|Focetria (2x H1N1 vaccine with MF59 adjuvants)|7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
409104|NCT01069575|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
409105|NCT01069562|Other|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
409106|NCT01069562|Other|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
409107|NCT01069536|Drug|metoclopramide 10 mg|
409108|NCT01069523|Drug|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
409109|NCT01069523|Drug|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
409110|NCT01069510|Drug|Spironolactone 25mg|Spironolactone 25 mg daily for 12 months
409111|NCT01069510|Other|Placebo|Placebo daily for 12 months
409112|NCT01069497|Other|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:~a slide-show of recommendations (commented by an expert),~recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
409113|NCT01069484|Other|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
409114|NCT01069471|Biological|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
409115|NCT01069458|Other|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
409116|NCT01069445|Dietary Supplement|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
409117|NCT01069445|Dietary Supplement|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
409118|NCT01069445|Dietary Supplement|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
409119|NCT01069445|Behavioral|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
409120|NCT01069432|Other|No Intervention|No Intervention
409121|NCT01069393|Other|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
409122|NCT01069367|Biological|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
409123|NCT01069354|Device|Radiesse® Injectable Dermal Filler with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier with 3% lidocaine hydrochloride (HCl)
409124|NCT01069354|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier without 3% lidocaine hydrochloride (HCl)
409125|NCT01069341|Drug|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
409126|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
409127|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
409128|NCT01069328|Drug|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
409129|NCT01069328|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenously
409130|NCT01069328|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
409131|NCT01069328|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenously
409132|NCT01069328|Drug|Paclitaxel|Paclitaxel 200 mg/m² intravenously
409133|NCT01069328|Drug|Carboplatin|Carboplatin AUC 6 intravenously
409134|NCT01069315|Procedure|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
409135|NCT01069315|Procedure|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
409136|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
409137|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
409138|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
409139|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
409140|NCT01069289|Drug|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
409141|NCT01069289|Drug|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
409142|NCT01069276|Other|No intervention in this study|No intervention in this study
409143|NCT01069263|Other|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
409144|NCT01069263|Drug|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
409145|NCT01069250|Other|There are no interventions in this study|
409146|NCT01069237|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
409147|NCT01069237|Device|Clear Care|Lens Care Solution for contact lenses
409148|NCT01069198|Drug|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged <5 and >=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
409149|NCT01069198|Other|Placebo|Placebo
409150|NCT01069185|Procedure|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
409151|NCT01069185|Procedure|Routine endotracheal suctioning|Endotracheal suctioning every two hours
409152|NCT01069172|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
409153|NCT01069172|Procedure|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
409154|NCT01069159|Drug|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
409155|NCT01069159|Drug|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
409156|NCT01069146|Procedure|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
409157|NCT01069133|Drug|Rifaximin|550mg BID open-label
409158|NCT01069133|Drug|rifaximin|550mg PO BID
409159|NCT01069120|Drug|Proellex|2, 25 mg capsules once per day
409160|NCT01069120|Drug|Proellex|1, 25 mg capsule once per day
409161|NCT01069107|Other|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
409162|NCT01069094|Drug|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
409163|NCT01069094|Drug|Progenta|25 mg, administered as a once daily oral dose for 90 days.
409164|NCT01069094|Drug|Progenta|50 mg, administered as a once daily oral dose for 90 days.
409165|NCT01069094|Drug|Lucron Depot|3.75 mg IM monthly
409166|NCT01069094|Drug|Placebo|Administered as a once daily oral dose for 90 days.
409167|NCT01069081|Drug|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
409168|NCT01069081|Drug|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
409169|NCT01069081|Drug|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
409170|NCT01069055|Other|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
409171|NCT01069055|Drug|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
409172|NCT01069055|Drug|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
409173|NCT01069042|Drug|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
409174|NCT01069016|Procedure|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
409175|NCT01069016|Procedure|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
409176|NCT01069003|Drug|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
409177|NCT01069003|Drug|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
409178|NCT01069003|Device|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
409179|NCT01068977|Drug|bevacizumab|Repeating intravenous dose
409180|NCT01068977|Drug|MetMAb|Repeating escalating intravenous dose
409181|NCT01068977|Drug|MetMAb|Repeating intravenous dose
409182|NCT01068964|Drug|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
409183|NCT01068964|Drug|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
409184|NCT01068951|Biological|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
409185|NCT01068938|Device|three different perimeters: HFA, Octopus, MATRIX|visual fields
409186|NCT01068925|Drug|GSK1349572|"GSK1349572 QD x 5 days~TPV/RTV 500/200mg BID x 7 days~GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
409187|NCT01068912|Drug|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
409188|NCT01068912|Drug|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
409189|NCT01068912|Drug|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
409190|NCT01068886|Procedure|External pancreatic stent|stent through pancreatic anastomosis
409191|NCT01068873|Drug|lopinavir/ritonavir plus maraviroc|Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
409192|NCT01068860|Drug|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
409193|NCT01068860|Drug|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
409194|NCT01068847|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
409195|NCT01068834|Genetic|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
409196|NCT01068821|Other|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
409197|NCT01068821|Other|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
409198|NCT01068808|Procedure|skin prick test|skin prick test to aeroallergen
409199|NCT01068795|Drug|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
409200|NCT01068782|Drug|XL184|given orally as capsules
409201|NCT01068769|Drug|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
409202|NCT01068756|Drug|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
409203|NCT01068756|Drug|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
409204|NCT01068743|Drug|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
409205|NCT01068743|Drug|metformin|Tablets, Oral, 850 mg, once daily, single dose
409206|NCT01068743|Drug|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
409207|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 500 mg, Once daily, single dose
409208|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 500 mg, Once Daily, single dose
409209|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 1000 mg, Once daily, single dose
409210|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 1000 mg, Once daily, single dose
409211|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
409212|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
409213|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
409214|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
409215|NCT01068704|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, ~ 12 months depending on response
409216|NCT01068704|Drug|Lapatinib|Tablets, Oral, 1500 mg, once daily, ~ 12 months depending on response
409217|NCT01068704|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response
409218|NCT01068691|Procedure|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)~Blood pressure~Obstructive sleep apnea syndrome (OSAS)~Carotid-to-femoral pulse wave velocity (PWV)~Biological parameters"
409219|NCT01068678|Drug|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
409220|NCT01068678|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
409221|NCT01068665|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
409222|NCT01068665|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
409223|NCT01068652|Drug|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
409224|NCT01068652|Drug|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
409225|NCT01068652|Drug|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
409226|NCT01068652|Drug|metformin|1000-2000 mg/day in combination with insulin treatment
409227|NCT01068639|Behavioral|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
409228|NCT01068626|Drug|Rosuvastatin|10 mg once daily
409229|NCT01068626|Drug|Placebo for rosuvastatin|once daily
409230|NCT01068613|Drug|QAX028|QAX028 60 mcg via inhalation device
409231|NCT01068613|Drug|QAX028|QAX028 20 mcg via inhalation device
409232|NCT01068613|Drug|Tiotropium|Tiotropium via inhalation device
409233|NCT01068613|Drug|Placebo|Placebo to QAX028 via inhalation device
409234|NCT01068600|Drug|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
409235|NCT01068600|Drug|Placebo to indacaterol|Once daily via SDDPI
409236|NCT01068587|Drug|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
409237|NCT01068587|Drug|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
409238|NCT01068587|Other|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
409239|NCT01068574|Other|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
409240|NCT01068561|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
409241|NCT01068548|Other|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
409242|NCT01068522|Device|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
409243|NCT01068522|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
409244|NCT01068509|Biological|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
409245|NCT01068483|Drug|BKM120|
409246|NCT01068444|Drug|Pioglitazone|"Name: GLITOS（Pioglitazone）~Dosage form: Tablets~Dose(s): 30mg~Dosing schedule: QD~Duration: 6 months"
409247|NCT01068444|Drug|placebo|placebo 30 mg/d for 6 months
409248|NCT01068431|Other|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
409249|NCT01068418|Dietary Supplement|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
409250|NCT01068405|Drug|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
409251|NCT01068405|Drug|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
409252|NCT01068392|Drug|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)~D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr~D1-5 Prednisolone 40-30-30 mg/day P.O~every 3 weeks"
409253|NCT01068379|Procedure|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
409254|NCT01068379|Procedure|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
409255|NCT01068353|Biological|Etanercept|50 mg given as a once weekly subcutaneous injection
409256|NCT01068353|Other|Placebo|Placebo injection given once weekly
409257|NCT01068327|Drug|gemcitabine hydrochloride|Given IV
409258|NCT01068327|Drug|leucovorin calcium|Given IV
409259|NCT01068327|Drug|fluorouracil|Given IV
409260|NCT01068327|Drug|nelfinavir mesylate|Given PO
409261|NCT01068327|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
409262|NCT01068327|Radiation|hypofractionated radiation therapy|Undergo radiotherapy
409263|NCT01068327|Procedure|therapeutic conventional surgery|Undergo surgery
409264|NCT01068314|Other|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
409300|NCT01068106|Device|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
409301|NCT01068106|Device|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
409302|NCT01068093|Drug|Ezetimibe|10mg daily
409388|NCT01067352|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
409265|NCT01068301|Drug|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
409266|NCT01068288|Procedure|Laparoscopic or open appendectomy|
409267|NCT01068288|Procedure|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.~For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
409268|NCT01068275|Procedure|lumbar plexus catheter|lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
409269|NCT01068275|Procedure|femoral nerve catheter|femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
409270|NCT01068275|Procedure|single-shot femoral block|single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
409271|NCT01068262|Drug|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
409272|NCT01068262|Drug|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
409273|NCT01068249|Drug|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
409274|NCT01068249|Drug|RAD001 (Everolimus)|10 mg by mouth daily
409275|NCT01068236|Behavioral|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
409276|NCT01068223|Drug|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
409277|NCT01068223|Drug|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
409278|NCT01068223|Drug|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
409279|NCT01068210|Behavioral|Exercise Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (~70%-100% VO2peak / ~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
409280|NCT01068210|Behavioral|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
409281|NCT01068197|Behavioral|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.~Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
409282|NCT01068184|Drug|AZD6553|Single or multiple oral dose
409283|NCT01068184|Drug|Placebo|single or multiple oral dose
409284|NCT01068171|Other|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
409285|NCT01068171|Other|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
409286|NCT01068158|Drug|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
409287|NCT01068158|Drug|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
409288|NCT01068145|Drug|SCH 527123|Very low dose SCH 527123, once daily for 7 days
409289|NCT01068145|Drug|SCH 527123|Low dose SCH 527123, once daily for 7 days
409290|NCT01068145|Drug|SCH 527123|Medium dose SCH 527123, once daily for 7 days
409291|NCT01068145|Drug|SCH 527123|High dose SCH 527123, once daily for 7 days
409292|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
409293|NCT01068145|Drug|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
409294|NCT01068145|Drug|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
409295|NCT01068145|Drug|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
409296|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
409297|NCT01068132|Drug|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
409298|NCT01068132|Drug|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
409299|NCT01068119|Procedure|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
409343|NCT01067781|Biological|Placebo|Travelers' Diarrhea Vaccine System
409303|NCT01068067|Other|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
409304|NCT01068067|Drug|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
409305|NCT01068054|Drug|tacrolimus|0.1% ointment,apply bid, 8 weeks
409306|NCT01068054|Drug|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
409307|NCT01068041|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
409308|NCT01068028|Drug|ORM-12741|Ascending multiple doses to sequential panels
409309|NCT01068028|Drug|Placebo for ORM-12741|
409310|NCT01068015|Other|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
409311|NCT01067989|Drug|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"Cyclophosphamide Tab. 50mg, 1x1/day, continuously.~Capecitabine Tab. 500mg, 1+2/day, continuously.~Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.~Celecoxib Tab. 200mg, 1x2/day, continuously.~Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
409312|NCT01067976|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
409313|NCT01067963|Behavioral|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
409314|NCT01067963|Behavioral|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
409315|NCT01067950|Procedure|Isolated Pancreas Transplant|
409316|NCT01067950|Drug|Intensive Insulin Therapy|
409317|NCT01067937|Procedure|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
409318|NCT01067924|Behavioral|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
409319|NCT01067911|Dietary Supplement|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
409320|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
409321|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
409322|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
409323|NCT01067898|Dietary Supplement|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
409324|NCT01067898|Other|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
409325|NCT01067898|Dietary Supplement|calcium carbonate|1000 mg calcium per os every day for one year
409326|NCT01067885|Device|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
409327|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
409328|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
409329|NCT01067859|Drug|Placebo|Infusion of placebo during 48 hours
409330|NCT01067846|Drug|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
409331|NCT01067846|Drug|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
409332|NCT01067846|Behavioral|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
409333|NCT01067833|Drug|K201 Tablet|oral tablet, x28 days
409334|NCT01067833|Drug|Placebo Tablet|oral tablet, x28 days
409335|NCT01067820|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
409336|NCT01067820|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
409337|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) [Original], single dose
409338|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
409339|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) [Blended], single dose
409340|NCT01067807|Drug|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) [Blended], single dose
409341|NCT01067794|Drug|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
409342|NCT01067781|Biological|Heat-Labile Enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
409344|NCT01067768|Other|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.~The attending physician decides withdraw or no withdraw the urinary catheter"
409345|NCT01067755|Device|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
409346|NCT01067729|Device|AWBAT Wound Dressing|
409347|NCT01067729|Device|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
409348|NCT01067716|Device|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
409349|NCT01067703|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
409350|NCT01067703|Procedure|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
409351|NCT01067690|Drug|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
409352|NCT01067677|Drug|Metaclopramide|0.5 mg/kg for rescue after PONV
409353|NCT01067677|Drug|Ondansetron|0.1 mg/kg (max 4 mg0
409354|NCT01067677|Drug|diphenhydramine|0.25 mg/kg (max 25 mg)
409355|NCT01067677|Drug|Saline|equal volume (5 ml)as experimental rescue medications
409356|NCT01067651|Device|Plaster of Paris (POP) casting using the Ponseti Method|
409357|NCT01067651|Device|Semi-Rigid Fiberglass softcast using the Ponseti Method|
409358|NCT01067638|Drug|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
409359|NCT01067625|Device|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
409360|NCT01067599|Other|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
409361|NCT01067599|Other|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
409362|NCT01067599|Other|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
409363|NCT01067547|Drug|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
409364|NCT01067547|Drug|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
409365|NCT01067534|Drug|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
409366|NCT01067521|Drug|Glatiramer acetate (GA)|GA 40 mg/mL administered 3 times a week by subcutaneous injection for a period of 12 months for participants assigned to GA treatment in the Double-Blind Period, and GA 40 mg/mL administered 3 times a week by subcutaneous injection for all participants in the Open-Label Extension Period.
409367|NCT01067521|Drug|Placebo|Placebo comparator administered by subcutaneous injection three times each week for 12 months during the Double-Blind Period.
409368|NCT01067508|Other|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
409369|NCT01067495|Behavioral|Cardiac rehabilitation|Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
409370|NCT01067469|Drug|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
409371|NCT01067469|Drug|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
409372|NCT01067469|Drug|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
409373|NCT01067456|Radiation|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
409374|NCT01067443|Drug|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
409375|NCT01067443|Drug|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
409376|NCT01067443|Drug|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
409377|NCT01067430|Drug|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
409378|NCT01067430|Drug|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
409379|NCT01067417|Drug|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
409380|NCT01067417|Drug|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
409381|NCT01067404|Biological|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
409382|NCT01067391|Drug|tadalafil|20 mg tablet, administered once per study protocol
409383|NCT01067391|Drug|placebo|placebo tablet administered once per study protocol
409384|NCT01067378|Other|Peer-led debriefing|
409385|NCT01067378|Other|Expert instructor debriefing|
409389|NCT01067339|Drug|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
409390|NCT01067339|Drug|placebo|placebo, by mouth, once daily for six months
409391|NCT01067326|Drug|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
409392|NCT01067326|Drug|Placebo|1 pill per day by mouth for 4 months
409393|NCT01067313|Device|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
409394|NCT01067313|Device|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
409395|NCT01067300|Procedure|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
409396|NCT01067287|Drug|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
409397|NCT01067287|Biological|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
409398|NCT01067274|Drug|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
409399|NCT01067274|Drug|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
409400|NCT01067274|Drug|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
409401|NCT01067261|Device|Transcutaneous mechanical nerve stimulation (TMNS)|"Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)~A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes."
409402|NCT01067261|Other|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
409403|NCT01067235|Drug|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
409404|NCT01067235|Drug|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
409405|NCT01067222|Drug|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
409406|NCT01067222|Drug|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
409407|NCT01067222|Drug|Placebo|Placebo oral capsules, 4 capsules per day
409408|NCT01067183|Behavioral|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
409409|NCT01067170|Device|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
409410|NCT01067157|Behavioral|LOGIC|"Experimental group:~Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)"
409411|NCT01067144|Drug|Gabapentin|1200 mg Gabapentin preoperative dose, 300 mg of Gabapentin 3-times a day postoperative doses for 72-hour post-surgical period.
409412|NCT01067144|Drug|Lorazepam (active control)|0.5 mg Lorazepam (active control) given pre-operatively in a single dose.
409413|NCT01067144|Drug|Placebo (inactive)|2 capsules of inactive placebo given 3-times a day post-operatively for the 72-hour post-surgical period.
409414|NCT01067131|Biological|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
409415|NCT01067131|Biological|PEV7C9|capsule intravaginal application contains excipient only
409416|NCT01067131|Biological|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
409417|NCT01067131|Biological|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
409418|NCT01067118|Drug|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
409419|NCT01067118|Drug|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
409420|NCT01067105|Drug|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
409421|NCT01067092|Behavioral|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
409422|NCT01067092|Behavioral|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
409423|NCT01067079|Other|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
409424|NCT01067066|Drug|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
409573|NCT01065688|Procedure|Roux-en Y reconstruction|surgical procedure
409425|NCT01067066|Drug|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m^2 by mouth (PO) daily, Day 1 to 5.
409426|NCT01067053|Drug|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:~bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.~capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.~oxaliplatin: 130/mg/m2(iv),1st day of each cycle.~After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
409427|NCT01067027|Dietary Supplement|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
409428|NCT01067014|Device|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
409429|NCT01066988|Other|ORB Ocular Emulsion|lubricant eye drop
409430|NCT01066988|Other|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
409431|NCT01066962|Drug|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~raltegravir 400 mg, 1 tablet twice daily (BID)"
409432|NCT01066962|Drug|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)~ritonavir 100 mg, 1 tablet once daily (QD)~tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
409433|NCT01066949|Behavioral|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
409434|NCT01066949|Behavioral|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
409435|NCT01066923|Drug|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
409436|NCT01066923|Other|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
409437|NCT01066923|Drug|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
409438|NCT01066923|Other|Passive cooling|Removing protective garments for passive cooling following exercise
409439|NCT01066923|Drug|Daily placebo|Placebo comparator for daily aspirin therapy
409440|NCT01066923|Drug|Acute placebo|Placebo comparator for acute aspirin therapy
409441|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
409442|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
409443|NCT01066897|Drug|Pramipexole|Patients will received increasing dose of pramipexole
409444|NCT01066884|Drug|erlotinib [Tarceva]|150mg po daily
409445|NCT01066871|Drug|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
409446|NCT01066871|Drug|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
409447|NCT01066871|Drug|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
409448|NCT01066871|Other|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
409449|NCT01066858|Drug|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
409450|NCT01066845|Drug|tadalafil|prescribed in accordance with usual clinical practice
409451|NCT01066832|Drug|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
409452|NCT01066819|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
409453|NCT01066819|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
409454|NCT01066806|Behavioral|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
409455|NCT01066806|Other|observation|observe normal dairy intake
409456|NCT01066793|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
409457|NCT01066793|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
409458|NCT01066780|Device|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
409459|NCT01066767|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
409460|NCT01066754|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
409461|NCT01066741|Drug|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
409462|NCT01066741|Drug|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
409463|NCT01066728|Other|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
409464|NCT01066728|Drug|Theophylline|
409465|NCT01066715|Drug|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
409466|NCT01066715|Drug|Placebo|Sterile solution subcutaneously administered monthly for 6 months
409467|NCT01066702|Biological|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
409468|NCT01066702|Procedure|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
409469|NCT01066689|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
409470|NCT01066689|Drug|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
409471|NCT01066676|Drug|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
409472|NCT01066676|Drug|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
409473|NCT01066663|Drug|pyrimethamine|Taken orally once a day
409474|NCT01066650|Device|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
409475|NCT01066650|Device|Xience V (Everolimus-eluting stent)|Drug eluting stent
409476|NCT01066637|Drug|[18F](+/-)NOS|Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis
409477|NCT01066624|Drug|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
409478|NCT01066624|Other|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
409479|NCT01066624|Device|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
409480|NCT01066611|Drug|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
409481|NCT01066611|Drug|Placebo|CAL-263 10 mg or placebo once daily for 7 days
409482|NCT01066598|Drug|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
409483|NCT01066585|Drug|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
409484|NCT01066585|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
409485|NCT01066572|Drug|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
409486|NCT01066572|Drug|Placebo|Matched placebo; identical tablets to Lisinopril.
409487|NCT01066559|Procedure|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
409488|NCT01066559|Procedure|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
409489|NCT01066559|Biological|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
409490|NCT01066559|Biological|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
409491|NCT01066546|Drug|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
409492|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
409493|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
409494|NCT01066520|Drug|Traumeel S ointment|2 g, 3 times daily topical during 14 days
409495|NCT01066520|Drug|Traumeel S gel|2 g, 3 times daily topical during 14 days
409496|NCT01066520|Drug|Diclofenac gel|2 g, 3 times daily topical during 14 days
409497|NCT01066494|Drug|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
409498|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
409499|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
409500|NCT01066481|Drug|Placebo|Placebo three times daily for 6 months
409501|NCT01066468|Drug|Gleevec/Glivec|
409502|NCT01066442|Drug|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
409503|NCT01066429|Drug|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
409504|NCT01066416|Procedure|Endoscopic Sinus Surgery|
409505|NCT01066416|Other|medical therapy|Subjects will undergo surgery 6 months after randomization
409506|NCT01066403|Drug|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
409507|NCT01066390|Biological|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
409508|NCT01066377|Dietary Supplement|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10^8 - 10^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested).
409509|NCT01066364|Drug|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
409510|NCT01066351|Drug|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
409511|NCT01066351|Drug|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
409512|NCT01066325|Behavioral|Neuro Emotional Technique|"NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.~During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief."
409513|NCT01066325|Other|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
409514|NCT01066299|Drug|Syntocinon®|single dose of OXT (24 IU)
409515|NCT01066299|Drug|inactive nasal spray|single dose (24 IU)
409516|NCT01066273|Device|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
409517|NCT01066260|Dietary Supplement|Probiotic formulation|Twice a day for 24 days
409518|NCT01066260|Other|Placebo|Twice a day for 24 days
409519|NCT01066247|Drug|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
409520|NCT01066247|Drug|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
409521|NCT01066234|Radiation|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
409522|NCT01066234|Drug|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
409523|NCT01066195|Drug|iressa|iressa 250mg per day every day
409524|NCT01066195|Drug|alimta|alimta 500mg/m2 every 3 weeks
409525|NCT01066182|Dietary Supplement|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
409526|NCT01066182|Dietary Supplement|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
409527|NCT01066169|Biological|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
409528|NCT01066156|Drug|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
409529|NCT01066143|Drug|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
409530|NCT01066130|Behavioral|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
409531|NCT01066130|Behavioral|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
409532|NCT01066117|Other|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
409533|NCT01066104|Drug|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
409534|NCT01066104|Drug|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
409535|NCT01066091|Other|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
409536|NCT01066091|Other|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
409537|NCT01066091|Other|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
409538|NCT01066078|Other|Echocardiography and SonR recording|
409539|NCT01066052|Drug|r-hGH|Subcutaneous administration.
409540|NCT01066039|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
409574|NCT01065688|Procedure|Billroth-I reconstruction|surgical procedure
409541|NCT01066026|Device|Injection of hyaluronic acid in nasolabial folds|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:~In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;~In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.~Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
409542|NCT01066013|Other|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
409543|NCT01066000|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
409544|NCT01065987|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
409545|NCT01065974|Behavioral|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
409546|NCT01065974|Dietary Supplement|Meal Replacements|Weight loss using CBT and meal replacements.
409547|NCT01065974|Behavioral|Nutritrol|To make widespread nutritional changes to participants personal food environments.
409548|NCT01065961|Drug|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
409549|NCT01065961|Drug|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
409550|NCT01065948|Device|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
409551|NCT01065935|Drug|ALN-RSV01|Administered by nebulization once daily for 5 days
409552|NCT01065935|Drug|Normal Saline|Administered by nebulization once daily for 5 days
409553|NCT01065883|Behavioral|community health worker|community health workers will provide education in the home
409554|NCT01065883|Behavioral|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
409555|NCT01065870|Drug|Neoadjuvant gemcitabine, capecitabine, and docetaxel|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment."
409556|NCT01065870|Drug|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.~Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.~Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.~Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.~Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm."
409557|NCT01065857|Drug|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
409558|NCT01065857|Drug|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
409559|NCT01065844|Drug|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
409560|NCT01065831|Behavioral|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
409561|NCT01065818|Drug|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
409562|NCT01065805|Biological|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.~Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
409563|NCT01065779|Drug|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
409564|NCT01065779|Drug|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
409565|NCT01065766|Drug|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
409566|NCT01065753|Behavioral|Lifestyle Counseling|Diet control with exercise
409567|NCT01065740|Other|Patient education|
409568|NCT01065727|Other|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
409569|NCT01065727|Other|natalizumab|monthly natalizumab during 3 years
409570|NCT01065714|Drug|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
409571|NCT01065714|Drug|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
409572|NCT01065701|Drug|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
409646|NCT01065129|Drug|G-CSF|
409575|NCT01065675|Other|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
409576|NCT01065662|Drug|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
409577|NCT01065662|Drug|cediranib|Taken orally daily
409578|NCT01065649|Drug|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
409579|NCT01065649|Drug|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
409580|NCT01065636|Behavioral|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
409581|NCT01065636|Behavioral|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
409582|NCT01065636|Behavioral|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
409583|NCT01065623|Drug|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
409584|NCT01065610|Drug|Oxytocin|
409585|NCT01065610|Drug|Placebo|
409586|NCT01065597|Device|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
409587|NCT01065571|Dietary Supplement|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
409588|NCT01065571|Other|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
409589|NCT01065558|Drug|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
409590|NCT01065545|Drug|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
409591|NCT01065532|Device|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
409592|NCT01065532|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
409593|NCT01065519|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
409594|NCT01065519|Device|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
409595|NCT01065506|Behavioral|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
409596|NCT01065506|Drug|Nicotine Patch|Nicotine Patch
409597|NCT01065506|Behavioral|Wellness Program|Wellness Program
409598|NCT01065506|Behavioral|Aerobic Exercise|Aerobic Exercise
409599|NCT01065493|Other|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
409600|NCT01065493|Behavioral|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
409601|NCT01065480|Behavioral|Live teleconference supervision|Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
409602|NCT01065480|Behavioral|Taped Review Supervision|Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
409603|NCT01065467|Drug|LBH589|Taken orally three times per week.
409604|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
409605|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
409606|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
409607|NCT01065454|Drug|Placebo|Placebo three times a day
409608|NCT01065441|Biological|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10^7 cells
409609|NCT01065441|Procedure|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
409610|NCT01065441|Biological|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10^7 cells
409611|NCT01065441|Biological|AlloStim|intravenous AlloStim-TM at doses between 1 x 10^7 to 1 x 10^9 cells
409612|NCT01065441|Biological|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
409613|NCT01065441|Biological|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10^7 cells.
409614|NCT01065441|Biological|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
409615|NCT01065402|Dietary Supplement|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
409616|NCT01065402|Dietary Supplement|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
409647|NCT01065129|Drug|Plerixafor|
409648|NCT01065129|Drug|Azacitidine|
409649|NCT01065116|Drug|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
409617|NCT01065389|Behavioral|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
409618|NCT01065389|Behavioral|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
409619|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
409620|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
409621|NCT01065363|Behavioral|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
409622|NCT01065350|Drug|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
409623|NCT01065350|Drug|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
409624|NCT01065337|Biological|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
409625|NCT01065337|Biological|bone marrow stem cells (BMC)|bone marrow stem cells
409626|NCT01065311|Behavioral|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
409627|NCT01065311|Behavioral|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
409628|NCT01065311|Biological|Standard psychiatric care|"Antidepressant medication and medical care.~Standard psychiatric outpatient care:~All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
409629|NCT01065298|Biological|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of >40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
409630|NCT01065285|Biological|Evaluation of vaccines against flu|evaluate efficacy and tolerance
409631|NCT01065272|Drug|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
409632|NCT01065272|Drug|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
409633|NCT01065259|Drug|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
409634|NCT01065259|Drug|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
409635|NCT01065246|Drug|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
409636|NCT01065233|Genetic|DNA extraction|DNA extraction of blood sample for DNAship analysis
409637|NCT01065220|Drug|Testolactone undecanoate|4ml i.m.
409638|NCT01065220|Drug|Lynestrenol|2/day
409639|NCT01065220|Drug|Cyproterone Acetate|50mg per day
409640|NCT01065220|Drug|Estradiol|100 microgram TTS twice a week
409641|NCT01065220|Drug|5-alpha reductase inhibitor|1mg daily
409642|NCT01065207|Biological|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.~Clinical events as neoplasia will be collected"
409643|NCT01065194|Drug|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
409644|NCT01065194|Drug|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
409645|NCT01065142|Procedure|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
409650|NCT01065116|Drug|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
409651|NCT01065103|Procedure|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
409652|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
409653|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
409654|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
409655|NCT01065077|Drug|Placebo|Infusion of placebo during 48h
409656|NCT01065064|Procedure|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
409657|NCT01065051|Drug|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
409658|NCT01065051|Drug|Placebo|Single oral dose
409659|NCT01065038|Drug|Anagrelide|
409660|NCT01065038|Drug|Hydroxyurea|
409661|NCT01065025|Drug|4SC-205|Repeated ascending oral doses of 4SC-205.
409662|NCT01065012|Drug|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
409663|NCT01065012|Drug|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
409664|NCT01065012|Drug|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
409665|NCT01065012|Drug|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
409666|NCT01065012|Drug|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
409667|NCT01065012|Drug|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
409668|NCT01064999|Drug|Oxaliplatin|CRT:50mg/m2,IV,weekly*5 cycle CT: 130mg/m2,IV,d1,q 21 day
409669|NCT01064999|Drug|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
409670|NCT01064999|Radiation|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
409671|NCT01064999|Procedure|Surgery|Lower anterior resection or abdominoperineal resection
409672|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (~5 minutes)
409673|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
409674|NCT01064986|Biological|Placebo|Saline vehicle (placebo)
409675|NCT01064986|Biological|Hydrocortisone|Hydrocortisone
409676|NCT01064973|Drug|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
409677|NCT01064960|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
409678|NCT01064947|Drug|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
409679|NCT01064934|Procedure|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
409680|NCT01064934|Other|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
409681|NCT01064921|Drug|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
409682|NCT01064921|Drug|cisplatin|Given IV
409683|NCT01064921|Radiation|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
409684|NCT01064921|Procedure|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
409685|NCT01064908|Device|OxyMask|Novel vortex oxygen delivery mask
409686|NCT01064895|Device|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
409687|NCT01064882|Drug|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
409688|NCT01064882|Drug|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
409689|NCT01064882|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
409736|NCT01064570|Drug|all-trans retinoic acid (ATRA)|
409737|NCT01064557|Drug|all-trans retinoic acid (ATRA)|
409738|NCT01064544|Procedure|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
409789|NCT01064180|Drug|Carvedilol|Carvedilol Tablets 25 mg
409690|NCT01064869|Behavioral|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:~1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour~This will be followed by an individualised package incorporating:~A structured asthma education programme, to address any gaps in asthma knowledge or requests for information~Motivational interviewing based on stages of change model to encourage change and adherence~Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
409691|NCT01064856|Biological|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
409692|NCT01064856|Biological|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
409693|NCT01064843|Device|Imtec MDI|4 Imtec MDI
409694|NCT01064830|Drug|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
409695|NCT01064830|Drug|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
409696|NCT01064817|Drug|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
409697|NCT01064817|Drug|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
409698|NCT01064804|Drug|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
409699|NCT01064791|Drug|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
409700|NCT01064791|Drug|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
409701|NCT01064791|Drug|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
409702|NCT01064791|Drug|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
409703|NCT01064778|Other|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
409704|NCT01064778|Other|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
409705|NCT01064752|Drug|Minocycline|100 mg po bid for 8 weeks
409706|NCT01064739|Dietary Supplement|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
409707|NCT01064739|Other|Fixed Sodium Diet|Fixed sodium low monoamine diet
409708|NCT01064726|Drug|Ibuprofen|800 mg oral
409709|NCT01064726|Drug|Fluticasone propionate|200 mcg intra-nasal
409710|NCT01064726|Drug|Placebo|Placebo
409711|NCT01064713|Drug|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days."
409712|NCT01064700|Device|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
409713|NCT01064700|Device|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
409714|NCT01064687|Drug|LY2189265|
409715|NCT01064687|Drug|Exenatide|
409716|NCT01064687|Drug|Placebo|
409717|NCT01064687|Drug|Metformin|
409718|NCT01064687|Drug|Pioglitazone|
409719|NCT01064674|Other|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
409720|NCT01064661|Dietary Supplement|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10^10 cfu total bacteria per day)
409721|NCT01064661|Dietary Supplement|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10^10 cfu total bacteria per day)
409722|NCT01064648|Drug|Cediranib Maleate|Given orally
409723|NCT01064648|Drug|Cisplatin|Given IV
409724|NCT01064648|Other|Laboratory Biomarker Analysis|Correlative studies
409725|NCT01064648|Drug|Pemetrexed Disodium|Given IV
409726|NCT01064648|Other|Placebo|Given orally
409727|NCT01064635|Drug|Letrozole|letrozole for 2-3 years after Tam
409728|NCT01064635|Drug|Letrozole|Letrozole for 5 years after Tam
409729|NCT01064622|Drug|vismodegib|Given PO
409730|NCT01064622|Drug|gemcitabine hydrochloride|Given IV
409731|NCT01064622|Other|hydrocortisone/placebo|Given PO
409732|NCT01064609|Procedure|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
409733|NCT01064609|Procedure|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
409734|NCT01064596|Other|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
409735|NCT01064583|Other|cocoa|dissolved in water twice-daily intervention
409739|NCT01064518|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) or Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
409740|NCT01064505|Drug|QPI-1007 at various doses|Single Intravitreal Injection
409741|NCT01064492|Drug|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
409742|NCT01064479|Drug|Carboplatin|Given IV
409743|NCT01064479|Drug|Cisplatin|Given IV
409744|NCT01064479|Drug|Docetaxel|Given IV
409745|NCT01064479|Drug|Erlotinib Hydrochloride|Given PO
409746|NCT01064479|Other|Laboratory Biomarker Analysis|Optional correlative studies
409747|NCT01064479|Other|Pharmacological Study|Optional correlative studies
409748|NCT01064479|Other|Placebo|Given PO
409749|NCT01064479|Other|Quality-of-Life Assessment|Ancillary studies
409750|NCT01064466|Drug|ETOPOSIDE - Usual|Etoposide Injection plus Methotrexate Injection plus Topotecan Injection
409751|NCT01064466|Drug|ETOPOSIDE - Study|Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule
409752|NCT01064453|Drug|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
409753|NCT01064440|Biological|Low Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
409754|NCT01064440|Biological|High Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
409755|NCT01064440|Other|Placebo|Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
409756|NCT01064414|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
409757|NCT01064414|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
409758|NCT01064401|Biological|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
409759|NCT01064401|Drug|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
409760|NCT01064401|Biological|Interferon beta-1a|Interferon beta-1a for intramuscular injection
409761|NCT01064401|Drug|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
409762|NCT01064388|Drug|AZD9742|IV infusion, 15 days
409763|NCT01064388|Drug|Placebo|IV infusion, 15 days
409764|NCT01064375|Biological|tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
409765|NCT01064375|Device|Derma Vax (electroporation device)|Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
409766|NCT01064375|Biological|GM-CSF|GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
409767|NCT01064375|Drug|Cyclophosphamide|One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
409768|NCT01064362|Drug|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
409769|NCT01064362|Drug|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
409770|NCT01064349|Drug|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
409771|NCT01064336|Drug|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
409772|NCT01064323|Device|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
409773|NCT01064310|Drug|pazopanib|oral anti-angiogenic treatment
409774|NCT01064310|Drug|sunitinib|oral anti-angiogenic treatment
409775|NCT01064297|Drug|Lamotrigine monotherapy|Lamotrigine monotherapy
409776|NCT01064297|Drug|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
409777|NCT01064297|Drug|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
409778|NCT01064284|Drug|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
409779|NCT01064284|Drug|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
409780|NCT01064271|Drug|Risperidone|Risperidone Tablets 1 mg
409781|NCT01064258|Device|CPAP|CPAP at 4 cm H2O
409782|NCT01064258|Device|autoCPAP|autoCPAP working between 4 and 15 cm H2O
409783|NCT01064245|Drug|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
409784|NCT01064245|Other|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
409785|NCT01064232|Drug|Risperidone|Risperidone Tablets 1 mg
409786|NCT01064219|Drug|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
409787|NCT01064193|Procedure|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:~Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.~Insert carefully the pipelle de Cornier® in the uterus through the cervix.~Withdraw the piston to create a negative pression~Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.~Withdraw the pipelle de Cornier® when filled with tissue~Reinsert internal piston to deposit sample in cup filled with a fixative."
409788|NCT01064193|Procedure|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
409790|NCT01064167|Drug|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
409791|NCT01064154|Drug|Carvedilol|Carvedilol Tablets 25 mg
409792|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
409793|NCT01064141|Biological|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
409794|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
409795|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
409796|NCT01064128|Procedure|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
409797|NCT01064128|Procedure|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
409798|NCT01064115|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
409799|NCT01064102|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
409800|NCT01064089|Drug|HSP990|
409801|NCT01064076|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
409802|NCT01064063|Device|Vanguard CR|The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
409803|NCT01064063|Device|AGC knee|The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
409804|NCT01064050|Device|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
409805|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
409806|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
409807|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
409808|NCT01064037|Drug|Placebo|Infusion during 48h
409809|NCT01064024|Drug|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
409810|NCT01064024|Drug|Placebo|Tablets, every 8 hours for 48 hours
409811|NCT01064011|Procedure|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
409812|NCT01064011|Procedure|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
409813|NCT01063998|Other|Urine Marker|Urinary KIM-1 measurements
409814|NCT01063972|Behavioral|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
409815|NCT01063972|Behavioral|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
409816|NCT01063959|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
409817|NCT01063959|Procedure|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
409818|NCT01063946|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution~Route of administration: intravenous infusion"
409819|NCT01063933|Drug|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
409820|NCT01063920|Drug|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
409821|NCT01063920|Drug|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
409822|NCT01063907|Drug|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
409823|NCT01063907|Drug|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
409824|NCT01063894|Other|breakfast cereal|breakfast cereal and milk
409825|NCT01063894|Other|water|water
409826|NCT01063881|Drug|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
409827|NCT01063868|Drug|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
409828|NCT01063868|Drug|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
409829|NCT01063855|Drug|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
409830|NCT01063855|Drug|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
409865|NCT01063582|Other|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
409831|NCT01063855|Drug|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
409832|NCT01063842|Drug|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
409833|NCT01063842|Drug|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
409834|NCT01063829|Drug|60 mg AIC246|Oral administration
409835|NCT01063829|Drug|120 mg AIC246|Oral administration
409836|NCT01063829|Drug|240 mg AIC246|Oral administration
409837|NCT01063829|Other|Placebo|Oral administration
409838|NCT01063816|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
409839|NCT01063816|Drug|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
409840|NCT01063816|Drug|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
409841|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
409842|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
409843|NCT01063790|Behavioral|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
409844|NCT01063777|Other|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.~All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
409845|NCT01063777|Other|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
409846|NCT01063764|Drug|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.~Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
409847|NCT01063751|Device|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
409848|NCT01063738|Dietary Supplement|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
409849|NCT01063738|Other|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
409850|NCT01063738|Other|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
409851|NCT01063738|Dietary Supplement|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
409852|NCT01063725|Dietary Supplement|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
409853|NCT01063725|Other|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
409854|NCT01063712|Device|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.~The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
409855|NCT01063699|Procedure|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
409856|NCT01063686|Device|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
409857|NCT01063660|Drug|Treosulfan|14 g/m²/d day -6 to -4
409858|NCT01063647|Drug|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
409859|NCT01063647|Drug|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
409860|NCT01063647|Drug|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
409861|NCT01063621|Drug|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
409862|NCT01063608|Biological|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
409863|NCT01063595|Biological|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
409864|NCT01063595|Biological|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
409866|NCT01063582|Procedure|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
409867|NCT01063569|Drug|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
409868|NCT01063569|Drug|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
409869|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
409870|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
409871|NCT01063530|Device|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
409872|NCT01063530|Device|DIstilled water|Application of distilled water in cervical lesions
409873|NCT01063517|Drug|olaparib|100mg BID oral tablet continuous
409874|NCT01063517|Drug|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
409875|NCT01063517|Drug|Placebo|100mg BID oral tablet to match olaparib tablet
409876|NCT01063504|Drug|teriparatide|
409877|NCT01063491|Procedure|bypass graft angiography|
409878|NCT01063478|Drug|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
409879|NCT01063465|Device|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
409880|NCT01063452|Device|Truvalve|Atkinson Product Design urinary slide valve
409881|NCT01063452|Other|Control (catheter drainage bag)|urinary catheter drainage bag
409882|NCT01063439|Drug|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
409883|NCT01063426|Drug|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
409884|NCT01063426|Drug|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
409885|NCT01063400|Other|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
409886|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
409887|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
409888|NCT01063374|Dietary Supplement|low glycemic diet instruction|
409889|NCT01063374|Dietary Supplement|high cereal fibre diet instruction|
409890|NCT01063361|Dietary Supplement|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
409891|NCT01063361|Dietary Supplement|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
409892|NCT01063348|Drug|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
409893|NCT01063348|Drug|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
409894|NCT01063283|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 intravenously over 10 minutes
409895|NCT01063283|Drug|Carboplatin|Carboplatin at a dose calculated to produce an area under the concentration-time curve of 6 mg/ml•min intravenously over 30 minutes
409896|NCT01063283|Drug|Bevacizumab 7.5 mg/kg|Bevacizumab at 7.5 mg/kg intravenously over 90 minutes
409897|NCT01063283|Drug|Bevacizumab 15 mg/kg|Bevacizumab at 15 mg/kg intravenously over 90 minutes
409898|NCT01063270|Drug|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
409899|NCT01063270|Procedure|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
409900|NCT01063257|Drug|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:~DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).~The DLa will be the following:~DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
409901|NCT01063244|Device|foley balloon only|place foley balloon only in cervix
409902|NCT01063244|Device|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
409903|NCT01063231|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
409904|NCT01063218|Other|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
409905|NCT01063205|Drug|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
409906|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
409907|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
409908|NCT01063192|Drug|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
409909|NCT01063192|Drug|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
409979|NCT01062594|Other|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
409910|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:~9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.~Maintenance therapy:~Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
409911|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
409912|NCT01063153|Drug|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
409913|NCT01063140|Biological|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
409914|NCT01063140|Biological|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
409915|NCT01063127|Other|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
409916|NCT01063127|Other|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
409917|NCT01063114|Radiation|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
409918|NCT01063101|Other|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
409919|NCT01063101|Other|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
409920|NCT01063088|Biological|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
409921|NCT01063075|Drug|Cetuximab|Administered Intravenously
409922|NCT01063075|Drug|Carboplatin|Administered Intravenously
409923|NCT01063075|Drug|5 - FU|Administered Intravenously
409924|NCT01063062|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
409925|NCT01063062|Drug|Methotrexate|methotrexate as per standard of care in clinical practice.
409926|NCT01063049|Drug|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
409927|NCT01063049|Drug|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
409928|NCT01063049|Drug|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
409929|NCT01063049|Drug|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
409930|NCT01063036|Drug|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
409931|NCT01063036|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
409932|NCT01063023|Drug|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
409933|NCT01063023|Drug|BMS-650032|Tablets, Oral, 600 mg, BID
409934|NCT01063010|Drug|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
409935|NCT01063010|Drug|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
409936|NCT01062984|Procedure|Continuous Venovenous Hemofiltration (CVVH)|The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVHthe target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
409937|NCT01062984|Procedure|Continuous Venovenous Hemodialysis (CVVHD)|The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
409938|NCT01062971|Drug|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
409939|NCT01062958|Other|Neevo® (a medical food)|
409940|NCT01062958|Other|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
409941|NCT01062945|Drug|Placebo|Matching administration of a placebo pill.
409942|NCT01062945|Drug|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
409943|NCT01062932|Drug|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
409944|NCT01062932|Drug|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
410108|NCT01061593|Dietary Supplement|Immunoxel|1 lozenge once per day
409945|NCT01062919|Procedure|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
409946|NCT01062919|Procedure|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
409947|NCT01062906|Drug|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
409948|NCT01062906|Drug|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
409949|NCT01062893|Other|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
409950|NCT01062893|Other|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
409951|NCT01062880|Behavioral|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
409952|NCT01062867|Drug|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
409953|NCT01062854|Other|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
409954|NCT01062841|Behavioral|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.~Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.~Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
409955|NCT01062828|Diagnostic Test|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
409956|NCT01062815|Dietary Supplement|Parenteral Nutrition|Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
409957|NCT01062802|Drug|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
409958|NCT01062802|Other|Placebo|Placebo given once daily for 4 weeks.
409959|NCT01062789|Device|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
409960|NCT01062776|Biological|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
409961|NCT01062776|Biological|Placebo|No dehydration is induced
409962|NCT01062763|Drug|spironolactone|25 to 50 mg once daily
409963|NCT01062763|Drug|placebo|addition of placebo 1 to 2 tablets daily
409964|NCT01062750|Biological|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
409965|NCT01062737|Drug|ASU|
409966|NCT01062724|Other|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
409967|NCT01062711|Dietary Supplement|Whey or soy protein|Whey and casein are isolated milk proteins
409968|NCT01062698|Drug|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
409969|NCT01062698|Procedure|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
409970|NCT01062685|Diagnostic Test|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
409971|NCT01062646|Behavioral|Multimodal music therapy|
409972|NCT01062646|Behavioral|Community treatment as usual|
409973|NCT01062633|Dietary Supplement|A, erythritol|2,5 g 3 times a day
409974|NCT01062633|Dietary Supplement|xylitol|2,5 g 3 times a day
409975|NCT01062633|Dietary Supplement|C, sorbitol|2,5 g 3 times aday
409976|NCT01062620|Drug|AXL1717|Phase I study with increasing dosage and treatment duration
409977|NCT01062594|Other|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
409978|NCT01062594|Other|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
409980|NCT01062568|Drug|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
409981|NCT01062568|Drug|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
409982|NCT01062555|Drug|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409983|NCT01062555|Drug|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409984|NCT01062555|Drug|Cyclosporine, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409985|NCT01062555|Drug|Prograf, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409986|NCT01062555|Drug|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409987|NCT01062555|Drug|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409988|NCT01062555|Drug|Low dose CNI (CSA or FK), Rapamune, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409989|NCT01062555|Drug|Rapamune, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
409990|NCT01062542|Procedure|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
409991|NCT01062529|Drug|Somatostatin|4 h of 150 microgram infusion
409992|NCT01062516|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
409993|NCT01062516|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
409994|NCT01062503|Drug|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
409995|NCT01062490|Drug|Treosulfan|14 g/m2/d, day -6 to -4
409996|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
409997|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
409998|NCT01062477|Biological|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
409999|NCT01062451|Drug|Perindopril|8 mg taken orally from days 0 through 7.
410000|NCT01062451|Drug|Placebo|Placebo treatment daily.
410001|NCT01062451|Drug|Candesartan|16 mg taken orally from days 0 through 7.
410002|NCT01062438|Genetic|DNA analysis|
410003|NCT01062438|Genetic|RNA analysis|
410004|NCT01062438|Genetic|gene expression analysis|
410005|NCT01062438|Genetic|gene rearrangement analysis|
410006|NCT01062438|Genetic|mutation analysis|
410007|NCT01062438|Other|laboratory biomarker analysis|
410008|NCT01062425|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiotherapy
410009|NCT01062425|Drug|Cediranib Maleate|Given PO
410010|NCT01062425|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
410011|NCT01062425|Other|Laboratory Biomarker Analysis|Correlative studies
410012|NCT01062425|Other|Placebo|Given PO
410013|NCT01062425|Drug|Temozolomide|Given PO
410014|NCT01062399|Drug|concurrent RAD001 10 mg/day|During radiation: RAD001 10 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
410015|NCT01062399|Drug|concurrent temozolomide|During radiation: temozolomide 75 mg/m2/day orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42. Dose rounded to the nearest 5 mg.
410016|NCT01062399|Radiation|Radiation therapy|Intensity Modulated RT (IMRT) allowed. For both IMRT and 3D conformal radiotherapy (3D-CRT) plans, one treatment of 2 Gy given daily 5 days per week for a total of 60 Gy over 6 weeks.
410017|NCT01062399|Drug|concurrent RAD001 2.5 mg/day|During radiation: RAD001 2.5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
410018|NCT01062399|Drug|concurrent RAD001 5 mg/day|During radiation: RAD001 5 mg orally daily during radiation therapy; one hour prior to radiation and in the morning on weekends on days 1-42.
410019|NCT01062399|Drug|post-radiation RAD001 10 mg/day|Post-radiation: RAD001 10 mg orally daily on days 1-28 of each cycle, for up to 12 cycles, starting 28 days after the completion of radiation therapy (Cycle = 28 days).
410020|NCT01062399|Drug|post-radiation temozolomide|Post-radiation: temozolomide 150 mg/m2/day - 200 mg/m2/day orally daily on days 1-5 of each cycle, starting 28 days after the completion of radiation therapy for up to 12 cycles (Cycle = 28 days)
410021|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
410109|NCT01061593|Other|Placebo|1 lozenge once per day
410022|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
410023|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
410024|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
410025|NCT01062360|Drug|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
410026|NCT01062360|Drug|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
410027|NCT01062347|Biological|Zinc|
410028|NCT01062334|Procedure|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
410029|NCT01062308|Procedure|Taping and Sham Taping|"Taping shoulder with Hospiplast tape.~Taping the shoulder after acute stroke to prevent shoulder injury and pain.~Taping the shoulder after acute stroke and compare with sham taping group.~Treatments:~Positioning technique~Handling technique~Range of motion exercises~Taping technique"
410030|NCT01062308|Procedure|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
410031|NCT01062295|Device|Siesta-System|
410032|NCT01062295|Device|Standard headrest|
410033|NCT01062282|Drug|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
410034|NCT01062269|Drug|Cholestyramine|Cholestyramine 4 grams one time dose
410035|NCT01062269|Drug|Cholestyramine|Cholestyramine 12 grams one dose, one day
410036|NCT01062269|Drug|Tang|Tang one dose one day
410037|NCT01062256|Drug|Placebo|One placebo tablet administered orally as a single dose
410038|NCT01062256|Drug|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
410039|NCT01062256|Other|Buckwheat Honey|10 mL administered orally as a single dose
410040|NCT01062243|Behavioral|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
410041|NCT01062230|Drug|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles."
410042|NCT01062204|Device|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
410043|NCT01062204|Device|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
410044|NCT01062191|Device|Aquacel AG, typical carboxymethylcellulose dressing|"4 X 4, Aquacel silver sheet"
410045|NCT01062191|Device|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
410046|NCT01062178|Drug|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
410047|NCT01062165|Drug|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
410048|NCT01062152|Drug|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM & 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
410049|NCT01062152|Drug|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
410050|NCT01062139|Drug|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
410051|NCT01062139|Drug|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
410052|NCT01062113|Drug|Celecoxib|"Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS"
410053|NCT01062113|Drug|Celecoxib|Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
410054|NCT01062113|Drug|Placebo|Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
410055|NCT01062100|Device|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
410056|NCT01062087|Drug|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
410057|NCT01062061|Biological|VARIVAX™|Attenuated live varicella vaccine
410058|NCT01062048|Drug|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
410059|NCT01062048|Drug|Sulfonylurea|Sulfonylurea administered in general use according to the local label
410060|NCT01062048|Biological|Insulin|Insulin administered in general use according to the local label
410061|NCT01062022|Behavioral|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
410106|NCT01061632|Procedure|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
410062|NCT01062022|Behavioral|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
410063|NCT01062009|Drug|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
410064|NCT01061996|Drug|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
410065|NCT01061983|Device|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
410066|NCT01061970|Drug|Fispemifene|once daily for 4 weeks
410067|NCT01061931|Procedure|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
410068|NCT01061918|Device|Tecnis MF|20 patients in the Tecnis MF group.
410069|NCT01061918|Device|ReSTOR|20 patients in the ReSTOR group.
410070|NCT01061905|Behavioral|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
410071|NCT01061905|Behavioral|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
410072|NCT01061905|Behavioral|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
410073|NCT01061866|Drug|3-phthalimidoglutarimide (Thalidomide)|Thalidomide at 200 mg dosage bid was administered during a twelve month period.
410074|NCT01061853|Drug|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE*)1mg/ml bid during 3 months
410075|NCT01061853|Drug|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE*)0.05% bid during 3 months
410076|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
410077|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
410078|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
410079|NCT01061814|Drug|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
410080|NCT01061814|Drug|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
410081|NCT01061801|Behavioral|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
410082|NCT01061788|Drug|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level~Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab~3-6 subjects, Study drug administered per dose level~3-6 subjects, Study drug administered per dose level~Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level~NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
410083|NCT01061775|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
410084|NCT01061762|Behavioral|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
410085|NCT01061762|Behavioral|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
410086|NCT01061762|Behavioral|Health Counseling|3-session of health improvement counseling to serve as an attention control.
410087|NCT01061749|Biological|Cixutumumab|Given IV
410088|NCT01061749|Other|Laboratory Biomarker Analysis|Correlative studies
410089|NCT01061749|Other|Pharmacological Study|Correlative studies
410090|NCT01061749|Drug|Selumetinib|Given PO
410091|NCT01061736|Drug|Sarilumab|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
410092|NCT01061736|Drug|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous"
410093|NCT01061736|Drug|Methotrexate|Same weekly dose as received prior to enrollment
410094|NCT01061736|Drug|Folic Acid|According to local standard
410095|NCT01061723|Drug|Sarilumab|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
410096|NCT01061723|Drug|Placebo|"Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous"
410097|NCT01061710|Drug|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
410098|NCT01061697|Drug|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
410099|NCT01061671|Drug|simvastatin|40 mgms of simvastatin daily
410100|NCT01061671|Drug|Placebo|Matched placebo pill daily
410101|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
410102|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
410103|NCT01061658|Other|Placebo|Placebo
410104|NCT01061645|Drug|MOC31-PE|Immunotoxines
410105|NCT01061632|Procedure|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
410107|NCT01061606|Drug|temsirolimus|Given IV
410196|NCT01061047|Drug|Ertapeneme|
410110|NCT01061580|Device|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
410111|NCT01061554|Dietary Supplement|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
410112|NCT01061554|Dietary Supplement|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
410113|NCT01061541|Biological|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
410114|NCT01061541|Biological|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
410115|NCT01061541|Biological|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
410116|NCT01061541|Biological|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
410117|NCT01061541|Biological|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
410118|NCT01061528|Drug|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
410119|NCT01061515|Drug|Intraperitoneal Oxaliplatin|
410120|NCT01061515|Drug|Bevacizumab|
410121|NCT01061515|Drug|Capecitabine|
410122|NCT01061502|Device|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
410123|NCT01061502|Device|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
410124|NCT01061489|Other|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
410125|NCT01061489|Other|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
410126|NCT01061476|Device|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
410127|NCT01061476|Other|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
410128|NCT01061476|Other|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
410129|NCT01061450|Drug|Simvastatin|80 mg once a day
410130|NCT01061450|Drug|Placebo|1 pill once a day
410131|NCT01061437|Drug|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
410132|NCT01061437|Drug|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
410133|NCT01061437|Drug|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
410134|NCT01061424|Behavioral|community health worker|community health worker provides home visits for education
410135|NCT01061424|Behavioral|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
410136|NCT01061411|Drug|Dalteparin|Given SC
410137|NCT01061411|Other|Pharmacological Study|Correlative studies
410138|NCT01061411|Drug|Sunitinib Malate|Given PO
410139|NCT01061398|Procedure|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
410140|NCT01061398|Procedure|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
410141|NCT01061385|Device|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
410142|NCT01061385|Other|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
410143|NCT01061372|Drug|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
410144|NCT01061372|Drug|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
410145|NCT01061372|Drug|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
410146|NCT01061359|Drug|Epirubicin: Observational Study|Observational: Chemotherapy
410147|NCT01061346|Other|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
410148|NCT01061346|Other|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
410149|NCT01061346|Other|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
410150|NCT01061333|Drug|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
410151|NCT01061333|Drug|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
410152|NCT01061333|Drug|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
410153|NCT01061333|Drug|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
410154|NCT01061320|Drug|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
410155|NCT01061320|Drug|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
410156|NCT01061307|Dietary Supplement|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
410157|NCT01061294|Procedure|Advanced CustomVue™ iLASIK procedure|
410158|NCT01061294|Device|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
410159|NCT01061281|Device|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
410160|NCT01061281|Device|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
410161|NCT01061268|Drug|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
410162|NCT01061268|Drug|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
410163|NCT01061255|Other|Evaluation of the stress|"Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).~Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.~Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender."
410164|NCT01061242|Behavioral|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
410165|NCT01061229|Drug|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
410166|NCT01061229|Other|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
410167|NCT01061216|Device|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
410168|NCT01061216|Device|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
410169|NCT01061203|Drug|Grazax|Treatment with 75.000 SQ-T once daily
410170|NCT01061203|Drug|Placebo|Tablet with no active grass component.
410171|NCT01061190|Drug|Propranolol|oral application of 160 mg Propranolol for 30 days
410172|NCT01061177|Drug|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
410173|NCT01061151|Drug|Zidovudine (ZDV)|300 mg twice daily
410174|NCT01061151|Drug|Nevirapine (NVP): Antepartum Mothers|200 mg at onset of labor
410175|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail|200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
410176|NCT01061151|Drug|Lamivudine-Zidovudine (3TC-ZDV)|150 mg/300 mg twice daily
410177|NCT01061151|Drug|Lopinavir-ritonavir (LPV-RTV)|400 mg/100 mg twice daily beginning at >= 14 weeks gestation; 600 mg/150 mg twice daily beginning at >= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.
410178|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|200 mg/300 mg
410179|NCT01061151|Drug|Nevirapine (NVP): Infant short-course|Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
410180|NCT01061151|Drug|Nevirapine (NVP): Infant extended|Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.
410181|NCT01061151|Other|No Intervention|"Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail."
410182|NCT01061151|Other|Discontinue triple ARVs|ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
410183|NCT01061151|Other|Continue triple ARVs|Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
410184|NCT01061125|Other|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
410185|NCT01061112|Drug|Flurbiprofen Control - Flurbiprofen Only|A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
410186|NCT01061112|Drug|Flurbiprofen Inhibition - Flurbiprofen & Fluconazole|A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
410187|NCT01061112|Drug|Ketoprofen Control - Ketoprofen Only|A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
410188|NCT01061112|Drug|Ketoprofen Inhibition - Ketoprofen & Fluconazole|A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
410189|NCT01061112|Drug|Tolbutamide Control - Tolbutamide Only|A single 500 mg tolbutamide dose taken at the start of the study period. No other drugs administered during this study period.
410190|NCT01061112|Drug|Tolbutamide Inhibition - Tolbutamide & Fluconazole|A single 500 mg tolbutamide dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
410191|NCT01061099|Biological|Mesenchymal Stromal Cells|Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
410192|NCT01061073|Drug|Omexel|
410193|NCT01061073|Drug|spasfon|
410194|NCT01061060|Drug|Prostaglandin I2|oral
410195|NCT01061060|Drug|Placebo|oral
410197|NCT01061034|Drug|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
410198|NCT01061021|Behavioral|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
410199|NCT01061021|Behavioral|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
410200|NCT01061008|Other|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
410201|NCT01061008|Other|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
410202|NCT01060982|Device|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
410203|NCT01060969|Drug|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
410204|NCT01060969|Drug|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
410205|NCT01060956|Other|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
410206|NCT01060956|Other|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
410207|NCT01060943|Device|KOKEN|"atelocollagen filler~1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
410208|NCT01060943|Device|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
410209|NCT01060930|Drug|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
410210|NCT01060917|Device|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
410211|NCT01060917|Procedure|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
410212|NCT01060917|Device|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
410213|NCT01060904|Drug|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
410214|NCT01060904|Drug|doxorubicin|25 mg/m2 IV every 2 weeks
410215|NCT01060904|Drug|vinblastine|6 mg/m2 IV every 2 weeks
410216|NCT01060904|Drug|dacarbazine|375 mg/m2 IV every 2 weeks
410217|NCT01060904|Drug|bleomycin|10 units/m2 IV every 2 weeks
410218|NCT01060904|Drug|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
410219|NCT01060891|Drug|colimycin|
410220|NCT01060878|Drug|PYM50028|IMP
410221|NCT01060878|Drug|Placebo|Matching placebo comprising identical vehicle to active doses
410222|NCT01060865|Drug|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
410223|NCT01060852|Behavioral|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
410224|NCT01060839|Behavioral|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
410225|NCT01060826|Other|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
410226|NCT01060826|Drug|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
410227|NCT01060826|Drug|somatostatin|Intravenous bolus 250 micrograms
410228|NCT01060813|Dietary Supplement|Leucine supplements|leucine supplements
410229|NCT01060787|Procedure|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
410230|NCT01060787|Procedure|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
410231|NCT01060774|Drug|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
410232|NCT01060774|Drug|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
410233|NCT01060761|Behavioral|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.~Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
410313|NCT01060072|Drug|Loteprednol etabonate|Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
410234|NCT01060748|Biological|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
410235|NCT01060748|Biological|Placebo|Placebo
410236|NCT01060735|Dietary Supplement|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
410237|NCT01060722|Drug|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
410238|NCT01060722|Drug|Placebo|Single subcutaneous dose of placebo material
410239|NCT01060696|Drug|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
410240|NCT01060683|Biological|Hemoglobin determination + NaCl 0.9% bolus|
410241|NCT01060683|Biological|hemoglobin determination + Venofundin bolus|
410242|NCT01060670|Device|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
410243|NCT01060670|Other|Conventional Wound Therapy|Conventional Wound Therapy
410244|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
410245|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
410246|NCT01060618|Other|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
410247|NCT01060605|Drug|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
410248|NCT01060592|Device|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
410249|NCT01060579|Drug|AR-12286 0.5% ophthalmic solution|q.d. PM
410250|NCT01060579|Drug|AR-12286 0.25% Ophthalmic solution|q.d. PM
410251|NCT01060579|Drug|Latanoprost ophthalmic solution|q.d. PM
410252|NCT01060566|Drug|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
410253|NCT01060566|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
410254|NCT01060553|Other|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
410255|NCT01060540|Genetic|genetic testing for type 2 diabetes|TCF7L2, PPARG, or KCNJ11
410256|NCT01060540|Behavioral|Conventional risk counseling|Risk based on lifetime risk, fasting plasma glucose results, and family history.
410257|NCT01060540|Behavioral|eye disease counseling|addresses risk for age-related macular degeneration, glaucoma, cataracts
410258|NCT01060514|Drug|Pazopanib|dose escalation, administered orally, daily
410259|NCT01060514|Drug|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
410260|NCT01060501|Drug|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
410261|NCT01060488|Other|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
410262|NCT01060488|Other|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
410263|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
410264|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
410265|NCT01060475|Drug|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
410266|NCT01060475|Drug|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
410267|NCT01060462|Drug|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
410268|NCT01060449|Other|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing~Arm 1: LV lead low output Arm 2: LV lead high output"
410269|NCT01060436|Device|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
410270|NCT01060423|Drug|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
410271|NCT01060423|Drug|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
410314|NCT01060072|Drug|Vehicle of Loteprednol Etabonate|Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
410272|NCT01060423|Device|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
410273|NCT01060410|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
410274|NCT01060410|Drug|Cyclophosphamide|intravenous injection, 0.2g, once every two days
410275|NCT01060410|Other|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
410276|NCT01060397|Behavioral|Extended Brief Intervention|Frames motivational interviewing approach
410277|NCT01060397|Behavioral|Control|Usual care
410278|NCT01060384|Drug|Lenalidomide|"Dose Cohort -1^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1^^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~^Used only if Dose Cohort +1 requires further reduction~^^Starting Dose Cohort in Phase I"
410279|NCT01060384|Drug|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
410280|NCT01060371|Genetic|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
410281|NCT01060358|Procedure|method (non-surgical) to measure neuromuscular neutral zones|
410282|NCT01060345|Drug|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
410283|NCT01060332|Other|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
410284|NCT01060293|Drug|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
410285|NCT01060293|Drug|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
410286|NCT01060293|Drug|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
410287|NCT01060280|Behavioral|Education on active management|Routine clinical practice plus education on active management.
410288|NCT01060280|Other|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
410289|NCT01060280|Other|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
410290|NCT01060267|Drug|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
410291|NCT01060267|Drug|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
410292|NCT01060254|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
410293|NCT01060254|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
410294|NCT01060241|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
410295|NCT01060228|Drug|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
410296|NCT01060228|Drug|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
410297|NCT01060215|Procedure|Normal saline|20 cc normal saline injection into the knee joint
410298|NCT01060202|Drug|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
410299|NCT01060189|Drug|Ulinastatin|
410300|NCT01060189|Drug|Tranexamic Acid|
410301|NCT01060189|Drug|Saline Solution|
410302|NCT01060176|Drug|Tranexamic Acid|
410303|NCT01060176|Drug|Saline Solution|
410304|NCT01060163|Drug|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
410305|NCT01060163|Drug|Saline|Saline served as placebo
410306|NCT01060150|Drug|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
410307|NCT01060137|Drug|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
410308|NCT01060124|Drug|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
410309|NCT01060111|Drug|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
410310|NCT01060111|Drug|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
410311|NCT01060111|Drug|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
410312|NCT01060098|Drug|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
410315|NCT01060059|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
410316|NCT01060059|Drug|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
410317|NCT01060033|Device|MR Spectroscopy|
410318|NCT01060033|Device|Fat-Saturation and Diffusion-Weighted Imaging|
410319|NCT01060033|Device|Dynamic Contrast Enhancement MRI (MR-DCE)|
410320|NCT01060033|Device|Diffusion Tensor Imaging (DTI)|
410321|NCT01060020|Drug|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
410322|NCT01060007|Radiation|External beam radiation|
410323|NCT01060007|Drug|Oxaliplatin|
410324|NCT01060007|Drug|Leucovorin|
410325|NCT01060007|Drug|5-FU|
410326|NCT01060007|Drug|Capecitabine|
410327|NCT01059994|Drug|Placebo sildenafil|Oral, daily, 1 week.
410328|NCT01059994|Drug|Sildenafil|oral, 25mg, daily for 1 week
410329|NCT01059955|Drug|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
410330|NCT01059955|Drug|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
410331|NCT01059942|Other|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
410332|NCT01059942|Other|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
410333|NCT01059929|Drug|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
410334|NCT01059929|Drug|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
410335|NCT01059929|Drug|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
410336|NCT01059929|Drug|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS>+2)
410337|NCT01059929|Behavioral|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
410338|NCT01059903|Drug|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
410339|NCT01059890|Drug|cefotaxime|
410340|NCT01059890|Drug|Metronidazole|
410341|NCT01059890|Drug|Ciprofloxacin|
410342|NCT01059890|Drug|Fosfocine|
410343|NCT01059877|Device|1072nm infrared Photobiomodulation|1072nm infrared light delivering 2.6 Joules (2.6J)/sq cm over a 6 minute treatment period.
410344|NCT01059877|Device|Photobiomodulation SIMULATED|Device mounted and procedure followed but with no stimulation.
410345|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
410346|NCT01059864|Drug|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
410347|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
410348|NCT01059864|Drug|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
410349|NCT01059851|Drug|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with ~240 mL of water after an 8 hour fast
410350|NCT01059838|Behavioral|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
410351|NCT01059825|Drug|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
410352|NCT01059825|Drug|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
410353|NCT01059825|Drug|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
410354|NCT01059825|Drug|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
410355|NCT01059825|Drug|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
410356|NCT01059825|Drug|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
410357|NCT01059825|Drug|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
410358|NCT01059812|Drug|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
410359|NCT01059812|Drug|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
410360|NCT01059799|Drug|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
410361|NCT01059799|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
410362|NCT01059786|Drug|Pentostatin|28 patients to pentostatin 4 mg/m2 days 1 and 15 of each cycle.
410363|NCT01059786|Drug|Rituximab|Rituximab 375 mg/m2 on day 1, 15 for 6 x 28-day cycles (all 68 patients)
410364|NCT01059786|Drug|Bendamustine|28 patients to bendamustine 90 mg/m2/day, days 1 and 2 each cycle
410365|NCT01059773|Drug|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
410366|NCT01059773|Drug|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
410367|NCT01059760|Behavioral|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
410368|NCT01059760|Behavioral|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
410369|NCT01059747|Other|no intervention applied|no intervention applied
410370|NCT01059734|Genetic|DNA analysis|
410371|NCT01059734|Genetic|RNA analysis|
410372|NCT01059734|Genetic|mutation analysis|
410373|NCT01059734|Genetic|polymerase chain reaction|
410374|NCT01059734|Genetic|polymorphism analysis|
410375|NCT01059734|Other|laboratory biomarker analysis|
410376|NCT01059721|Procedure|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
410377|NCT01059682|Drug|Dalcetrapib|Dalcetrapib 600 mg orally once daily
410378|NCT01059682|Drug|Placebo|Placebo orally once daily
410379|NCT01059669|Other|diagnostic test|
410380|NCT01059656|Drug|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
410381|NCT01059643|Drug|LY2523355|Dose determined by participant body surface area: 5 milligrams/square meter(mg/m²) or 6 mg/m², administered intravenously as a 1-hour infusion on Days 1, 2 and 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
410382|NCT01059643|Drug|pegfilgrastim|6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
410383|NCT01059630|Drug|Obinutuzumab|IV infusion.
410384|NCT01059630|Drug|Bendamustine|IV infusion.
410385|NCT01059617|Biological|GSK Biologicals' FluLaval®|Intramuscular injection
410386|NCT01059617|Biological|Placebo (saline)|Intramuscular injection
410387|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
410388|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
410389|NCT01059604|Drug|Sumatriptan|Sumatriptan
410390|NCT01059604|Drug|Naratriptan|Naratriptan
410391|NCT01059604|Drug|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
410392|NCT01059591|Drug|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
410393|NCT01059591|Drug|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
410394|NCT01059591|Radiation|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
410395|NCT01059578|Drug|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
410396|NCT01059578|Drug|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
410397|NCT01059578|Radiation|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
410398|NCT01059565|Drug|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
410399|NCT01059565|Drug|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
410400|NCT01059552|Drug|vorinostat|vorinostat once daily for 12 weeks of therapy
410401|NCT01059539|Drug|Cariprazine|Cariprazine was supplied in capsules.
410402|NCT01059526|Drug|ecallantide|30 mg SC
410403|NCT01059500|Device|Pilot Phase|Non-intervention phase to test webtool technical reliability, accurate low PTP, and calibration.
410404|NCT01059500|Device|Intervention group, receive the numeric PTP estimate|Receive the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP <2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP >5.5%: proceed to provocative testing. For PE, PTP<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP>20% consider empiric anticoagulation with heparin if no contraindications.
410405|NCT01059500|Device|No Intervention|Standard (no webtool output)
410406|NCT01059487|Other|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
410407|NCT01059474|Drug|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.~Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
410408|NCT01059461|Drug|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
410409|NCT01059448|Drug|AMG 827|AMG 827 210 mg
410410|NCT01059435|Drug|Romosozumab|Administered subcutaneously or intravenously
410411|NCT01059435|Drug|Placebo|Administered subcutaneously or intravenously
410412|NCT01059422|Drug|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
410413|NCT01059409|Procedure|Meniscal Allograft|Meniscal Allograft
410414|NCT01059396|Drug|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
410415|NCT01059396|Drug|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
410416|NCT01059396|Drug|placebo|placebo propranolol / carvedilol
410417|NCT01059383|Drug|VECAM 40/300|1 capsule, orally, once daily at bedtime.
410703|NCT01057199|Genetic|gene expression analysis|
410418|NCT01059383|Drug|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
410419|NCT01059370|Procedure|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
410420|NCT01059357|Device|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
410421|NCT01059344|Drug|Mesalamin|4.8g/day, 800 mg tablets
410422|NCT01059331|Drug|Pregabalin|150 mg x 2 daily for 2 days
410423|NCT01059331|Drug|Sugar pill|1 tablet x 2 daily, for 2 days
410424|NCT01059318|Drug|Everolimus|
410425|NCT01059318|Drug|Everolimus|
410426|NCT01059318|Drug|Everolimus|
410427|NCT01059305|Drug|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
410428|NCT01059266|Drug|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
410429|NCT01059253|Other|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
410430|NCT01059188|Drug|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
410431|NCT01059188|Drug|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
410432|NCT01059188|Drug|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
410433|NCT01059188|Radiation|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
410434|NCT01059188|Procedure|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
410435|NCT01059175|Device|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
410436|NCT01059175|Device|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
410437|NCT01059162|Device|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
410438|NCT01059149|Device|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
410439|NCT01059136|Drug|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
410440|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
410441|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
410442|NCT01059110|Drug|Salicylate ointment|cream, one application every night, for 90 days
410443|NCT01059110|Drug|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
410444|NCT01059110|Drug|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
410445|NCT01059110|Drug|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
410446|NCT01059097|Procedure|Pancreaticoduodenectomy|
410447|NCT01059084|Drug|Valacyclovir|1000 mg tid
410448|NCT01059071|Drug|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.~DFMO at current cohort Dose Level orally each day for 21 day cycles~Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
410449|NCT01059071|Drug|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
410450|NCT01059058|Procedure|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
410451|NCT01059058|Procedure|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
410452|NCT01059058|Procedure|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
410453|NCT01059045|Procedure|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
410454|NCT01059045|Other|Control|No intervention
410455|NCT01059032|Other|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
410456|NCT01059019|Dietary Supplement|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
410457|NCT01059006|Procedure|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
410486|NCT01058707|Drug|MLN0128|MLN0128 will be administered orally with one of 4 different dosing schedules - once daily (QD), once weekly (QW), once daily for 3 days on;4 days off repeated each week (QDX3d QW), and once daily for 5 days on;2 days off repeated each week (QDX5d QW)
410487|NCT01058694|Behavioral|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
410458|NCT01058993|Drug|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
410459|NCT01058980|Procedure|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
410460|NCT01058980|Procedure|No additional ablation|Presence of dormant PV conduction, no additional ablation.
410461|NCT01058980|Procedure|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
410462|NCT01058980|Procedure|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
410463|NCT01058941|Drug|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
410464|NCT01058941|Drug|Placebo|Placebo LA and placebo oil capsules for 18 months
410465|NCT01058928|Other|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
410466|NCT01058915|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
410467|NCT01058915|Drug|Rosuvastatin 40mg|Rosuvastatin 40mg/day
410468|NCT01058902|Drug|Aspirin 75 mg|Aspirin 75 mg
410469|NCT01058902|Other|no aspirin|nothing
410470|NCT01058889|Device|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
410471|NCT01058876|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
410472|NCT01058863|Drug|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
410473|NCT01058863|Drug|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
410474|NCT01058863|Other|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
410475|NCT01058850|Biological|Rindopepimut|250 or 500 mcg; intradermal injection
410476|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
410477|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
410478|NCT01058785|Biological|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
410479|NCT01058772|Other|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score < 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
410480|NCT01058759|Drug|Enoxaparin|
410481|NCT01058759|Other|No Enoxaparin|
410482|NCT01058746|Other|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
410483|NCT01058746|Other|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
410484|NCT01058733|Other|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
410485|NCT01058720|Dietary Supplement|Vitamin D3|2000 IU orally once daily for 12 weeks
410522|NCT01058343|Biological|IFN-K|3 to 4 IM injections over 3 months
410704|NCT01057199|Genetic|mutation analysis|
410705|NCT01057199|Genetic|protein expression analysis|
410488|NCT01058681|Dietary Supplement|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.~Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.~PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
410489|NCT01058668|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
410490|NCT01058668|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
410491|NCT01058655|Drug|Everolimus|
410492|NCT01058655|Drug|Tivozanib|
410493|NCT01058642|Drug|ADL5747|
410494|NCT01058642|Drug|Placebo|
410495|NCT01058642|Drug|Pregabalin|
410496|NCT01058629|Device|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
410497|NCT01058616|Drug|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
410498|NCT01058603|Other|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
410499|NCT01058603|Other|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
410500|NCT01058577|Device|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
410501|NCT01058577|Procedure|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
410502|NCT01058564|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, magnetic esophageal sphincter
410503|NCT01058551|Device|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
410504|NCT01058538|Drug|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
410505|NCT01058525|Procedure|median nerve block|median nerve block performed using ultrasound guidance
410506|NCT01058525|Procedure|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
410507|NCT01058512|Drug|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:~Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days~Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days~Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days~Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
410508|NCT01058499|Behavioral|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
410509|NCT01058486|Behavioral|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.~A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.~Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
410510|NCT01058460|Procedure|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
410511|NCT01058447|Drug|AZD1981|Oral tablet, 250 mg, single dose
410512|NCT01058434|Drug|TKI258|
410513|NCT01058421|Procedure|intensive physical therapy|four week course of daily intensive physical therapy
410514|NCT01058421|Procedure|control group|four weeks of routine physical therapy
410515|NCT01058408|Radiation|Intensity modulated radiotherapy|Administered daily 5 days per week
410516|NCT01058408|Drug|RAD001|Taken orally once a day
410517|NCT01058408|Drug|cisplatin|Administered intravenously once a week
410518|NCT01058395|Drug|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
410519|NCT01058382|Drug|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
410520|NCT01058382|Drug|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
410521|NCT01058369|Drug|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
410523|NCT01058330|Other|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of 5 lower extremity exercises and 5 upper extremity exercises
410524|NCT01058317|Drug|Propranolol|Propranolol 2mg/kg divided twice daily
410525|NCT01058304|Other|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
410526|NCT01058304|Other|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
410527|NCT01058291|Drug|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
410528|NCT01058291|Drug|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
410529|NCT01058278|Procedure|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
410530|NCT01058265|Other|Integrative|Integrative Medicine medical evaluation.
410531|NCT01058265|Other|Standard|Standard general medical evaluation.
410532|NCT01058252|Drug|Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:~In previous cycles, cycle length and ovulatory status must be assessed and documented.~STEP 1: ANOVULATION by ORAL CONTRACEPTION~Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.~Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst > 10 mm).~Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.~STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).~On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.~Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
410533|NCT01058252|Procedure|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.~• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.~The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)~No need of LH testing, or E2 testsing during the stimulated cycle."
410534|NCT01058252|Procedure|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:~E2 level is over 150 pg/ml/per mature follicle (> 15 mm)~Domminent follicle is greater than 18 mm in mean diameter~LH Remains as Baseline, OR~The day when Urinary LH Surge is positive"
410535|NCT01058252|Procedure|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.~Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.~Maximum of 2 embryos are transferred, using ultrasound guided transfer.~Cancellation Criteria:~Poor patient compliance~Premature Ovulation~Premature LH Surge~Endometrium < 7 mm~Poor Follicular Development~E2 Level > 2,500 pg/ml"
410536|NCT01058252|Procedure|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 30000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
410537|NCT01058239|Drug|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
410538|NCT01058239|Drug|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
410539|NCT01058226|Biological|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
410540|NCT01058213|Behavioral|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (~1-2 seconds for concentric and eccentric contraction) will be used.
410640|NCT01057550|Procedure|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
410641|NCT01057550|Procedure|TVT|Standard TVT as described by Ulmsten 1996
410541|NCT01058213|Behavioral|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
410542|NCT01058200|Device|iCup|new vacuum extractor: sterile disposable plastic cup
410543|NCT01058200|Device|reference cup|reference cup of the obstetrical ward: metallic cup
410544|NCT01058174|Drug|micafungin|intravenous infusion
410545|NCT01058174|Drug|fluconazole|intravenous infusion
410546|NCT01058174|Drug|liposomal amphotericin B|intravenous infusion
410547|NCT01058174|Drug|caspofungin|intravenous infusion
410548|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
410549|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
410550|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
410551|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
410552|NCT01058135|Other|Hi-maize starch (Low dose)|resistant starch
410553|NCT01058135|Other|Hi-maize starch (High-dose)|resistant starch
410554|NCT01058135|Other|Control (starch)|rapidly digestible starch
410555|NCT01058122|Procedure|Collection of adverse drug events|
410556|NCT01058109|Other|calcium-rich diet|dietary calcium intake of 1500 mg/d
410557|NCT01058109|Other|Calcium rich diet|dietary intake of 1500 mg/d from food
410558|NCT01058096|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
410559|NCT01058096|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
410560|NCT01058083|Drug|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
410561|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
410562|NCT01058083|Drug|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
410563|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
410564|NCT01058083|Drug|Placebo|Placebo, Oral, 0 mg, daily, 28 days
410565|NCT01058070|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
410566|NCT01058057|Drug|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
410567|NCT01058044|Other|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
410568|NCT01058031|Behavioral|MBSR|Mindfulness Based Stress Reduction
410569|NCT01058018|Drug|RVX000222|RVX000222 twice a day for 12 weeks
410570|NCT01058018|Drug|Placebo|Placebo twice a day for 12 weeks
410571|NCT01058005|Drug|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
410572|NCT01058005|Drug|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
410573|NCT01058005|Drug|glatiramer acetate|20 mg subcutaneous injection once daily
410574|NCT01057992|Device|Magnetic Esophageal Sphincter|Implantable device
410575|NCT01057979|Behavioral|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
410576|NCT01057979|Behavioral|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
410577|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
410578|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
410579|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
410580|NCT01057953|Genetic|Blood drawn|Blood drawn for patient
410581|NCT01057940|Procedure|DBE PEJ placement|One time procedure with follow-up telephone call.
410582|NCT01057927|Drug|OC000459|OC000459 capsules 2x100mg BID for 28 days
410583|NCT01057927|Drug|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
410584|NCT01057914|Dietary Supplement|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
410585|NCT01057914|Other|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
410586|NCT01057914|Other|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
410587|NCT01057901|Drug|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
410588|NCT01057901|Drug|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
410589|NCT01057888|Other|Autodialer|Autodialer telephone calls
410590|NCT01057888|Other|Letters|Mailed reminder letters
410591|NCT01057875|Other|caffeine|Starbuck's Grande Pike Roast coffee
410592|NCT01057875|Other|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
410593|NCT01057862|Drug|Naltrexone|Targeted dosage of 50mg PO daily
410594|NCT01057862|Other|Placebo|Sugar pills daily PO
410595|NCT01057849|Drug|risperidone|3-6 mg per day
410596|NCT01057849|Drug|olanzapine|5-20 mg per day
410597|NCT01057849|Drug|Aripiprazole|10-30 mg per day
410598|NCT01057836|Behavioral|Neck endurance training|
410599|NCT01057836|Behavioral|Stretching|
410642|NCT01057550|Procedure|Pelvicol|retropubic mid urethral sling made from Pelvicol
410706|NCT01057199|Other|fluorescence activated cell sorting|
410707|NCT01057199|Other|laboratory biomarker analysis|
410600|NCT01057810|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
410601|NCT01057810|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
410602|NCT01057797|Behavioral|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
410603|NCT01057797|Behavioral|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
410604|NCT01057797|Behavioral|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
410605|NCT01057784|Procedure|Bariatric surgery.|Bariatric Surgery
410606|NCT01057771|Behavioral|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
410607|NCT01057771|Behavioral|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
410608|NCT01057758|Drug|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
410609|NCT01057758|Drug|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
410610|NCT01057719|Other|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
410611|NCT01057706|Other|chiropractic|spinal manipulation and mobilization
410612|NCT01057706|Behavioral|exercise|strengthening, stretching, balance
410613|NCT01057693|Drug|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
410614|NCT01057693|Drug|Placebo|Placebo is supplied as capsules and given 3 times daily.
410615|NCT01057680|Dietary Supplement|creatine monohydrate|Powder, 0.1 g per day, 12 months
410616|NCT01057680|Dietary Supplement|sugar placebo|powder, 0.1 g/day, 12 months
410617|NCT01057667|Drug|RO5024048|1000mg bid po, 24 weeks
410618|NCT01057667|Drug|Ribavirin [Copegus]|1000mg or 1200mg po daily
410619|NCT01057667|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
410620|NCT01057654|Drug|Pravastatin|Pravastatin 40 mg
410621|NCT01057654|Drug|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
410622|NCT01057641|Procedure|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
410623|NCT01057641|Other|physiotherapy|physiotherapy
410624|NCT01057628|Drug|ipragliflozin|oral
410625|NCT01057628|Drug|placebo|oral
410626|NCT01057615|Dietary Supplement|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
410627|NCT01057615|Dietary Supplement|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
410628|NCT01057615|Dietary Supplement|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
410629|NCT01057615|Dietary Supplement|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
410630|NCT01057589|Drug|Pemetrexed|"Triplet Combination Therapy: 500 mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles~Maintenance Therapy: 500mg/m^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity"
410631|NCT01057589|Drug|Cetuximab|"Triplet Combination Therapy: 400 mg/m^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.~Maintenance Therapy: 250 mg/m^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity"
410632|NCT01057589|Drug|Cisplatin|Triplet Combination Therapy: 75mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
410633|NCT01057589|Dietary Supplement|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
410634|NCT01057589|Dietary Supplement|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
410635|NCT01057576|Dietary Supplement|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
410636|NCT01057576|Other|Placebo|capsule, daily dosage
410637|NCT01057563|Device|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
410638|NCT01057563|Device|bare-metal stent (BMS)|BMS implantation
410639|NCT01057563|Device|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
410643|NCT01057537|Drug|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):~Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
410644|NCT01057537|Drug|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
410645|NCT01057524|Device|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
410646|NCT01057524|Other|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
410647|NCT01057511|Drug|Crinone 8%|Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
410648|NCT01057511|Drug|Progesterone|Progesterone 20mg/ i.m./ Qd, 7 days totally.
410649|NCT01057498|Drug|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
410650|NCT01057498|Drug|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
410651|NCT01057485|Procedure|AF ablation and AV node ablation|AF ablation and AV node ablation
410652|NCT01057485|Procedure|AV node ablation|AV node ablation
410653|NCT01057459|Other|laboratory biomarker analysis|Correlative studies
410654|NCT01057433|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
410655|NCT01057433|Drug|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
410656|NCT01057420|Drug|oxygen inhalation|Inhalation of 80% oxygen via face mask
410657|NCT01057407|Drug|ASP1585|oral
410658|NCT01057407|Drug|Sevelamer hydrochloride|oral
410659|NCT01057394|Device|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
410660|NCT01057394|Device|RF PVI Ablation|Radiofrequency ablation
410661|NCT01057381|Drug|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
410662|NCT01057381|Drug|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
410663|NCT01057381|Drug|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
410664|NCT01057381|Drug|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
410665|NCT01057368|Behavioral|Day of intensive meditation practice|Long-term meditators practice for ~6 hours of meditation at each time point
410666|NCT01057368|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
410667|NCT01057368|Behavioral|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
410668|NCT01057355|Procedure|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
410669|NCT01057342|Drug|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
410670|NCT01057342|Drug|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
410671|NCT01057342|Drug|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
410672|NCT01057329|Drug|Atomoxetine|mg according to body weight
410673|NCT01057329|Drug|Duloxetine|30 mg / die
410674|NCT01057329|Drug|Olanzapine|5mg 1 wwek and 10 mg from second week
410675|NCT01057329|Drug|Aripiprazole|5 mg from week 1, 10 mg from week 2
410676|NCT01057316|Device|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
410677|NCT01057316|Device|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
410678|NCT01057316|Device|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
410679|NCT01057303|Genetic|RNA analysis|
410680|NCT01057303|Genetic|gene expression analysis|
410681|NCT01057303|Genetic|reverse transcriptase-polymerase chain reaction|
410682|NCT01057303|Other|laboratory biomarker analysis|
410683|NCT01057290|Genetic|gene expression analysis|
410684|NCT01057290|Genetic|protein expression analysis|
410685|NCT01057290|Other|fluorescence activated cell sorting|
410686|NCT01057290|Other|immunologic technique|
410687|NCT01057290|Other|laboratory biomarker analysis|
410688|NCT01057277|Drug|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
410689|NCT01057264|Drug|HAI Abraxane|Starting dose: 120 mg/m^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
410690|NCT01057264|Drug|Gemcitabine|Starting dose: 600 mg/m^2 by IV on Days 1 and 8 of 21 day cycle
410691|NCT01057264|Drug|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
410692|NCT01057264|Drug|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
410693|NCT01057251|Drug|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
410694|NCT01057251|Drug|Placebo|5 mg or 20 mg once daily, oral administration
410695|NCT01057238|Other|Intensive Communication System|Regular family meetings once a week, using a standard protocol
410696|NCT01057225|Drug|carfilzomib|Given IV
410697|NCT01057225|Drug|cyclophosphamide|Given orally
410698|NCT01057225|Drug|thalidomide|Given orally
410699|NCT01057225|Drug|dexamethasone|Given orally
410700|NCT01057212|Drug|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
410701|NCT01057212|Drug|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
410702|NCT01057199|Genetic|RNA analysis|
410708|NCT01057186|Dietary Supplement|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
410709|NCT01057186|Drug|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
410710|NCT01057173|Procedure|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
410711|NCT01057173|Procedure|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
410712|NCT01057160|Drug|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
410713|NCT01057147|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
410714|NCT01057147|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
410715|NCT01057121|Drug|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
410716|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg BID
410717|NCT01057108|Other|FOSTRAP Chewing Gum|40 mg BID
410718|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
410719|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
410720|NCT01057108|Other|Placebo chewing gum|
410721|NCT01057095|Genetic|RNA analysis|
410722|NCT01057095|Genetic|gene expression analysis|
410723|NCT01057095|Genetic|reverse transcriptase-polymerase chain reaction|
410724|NCT01057095|Other|laboratory biomarker analysis|
410725|NCT01057082|Dietary Supplement|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
410726|NCT01057082|Dietary Supplement|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
410727|NCT01057069|Drug|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
410728|NCT01057069|Drug|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
410729|NCT01057069|Drug|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.~This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
410730|NCT01057056|Other|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
410731|NCT01057043|Device|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
410732|NCT01057030|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
410733|NCT01057030|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
410734|NCT01057017|Biological|intervention|
410735|NCT01056991|Other|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
410736|NCT01056991|Other|warming blanket|
410737|NCT01056965|Drug|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
410738|NCT01056965|Drug|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
410739|NCT01056952|Procedure|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 > 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
410740|NCT01056952|Procedure|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher & Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 > 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
410741|NCT01056952|Procedure|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 > 90%
410742|NCT01056939|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
410743|NCT01056939|Device|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
410744|NCT01056926|Behavioral|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
410745|NCT01056926|Drug|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
410746|NCT01056926|Drug|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
410747|NCT01056913|Device|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
410748|NCT01056913|Other|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
410749|NCT01056900|Procedure|Autologous Chondrocyte Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected."
410750|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose
410751|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
410752|NCT01056874|Drug|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
410753|NCT01056861|Drug|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
410754|NCT01056835|Drug|prostaglandin I2 analogue|
410755|NCT01056822|Drug|1|Continue with same dose of MMF as patient was taking before randomisation
410756|NCT01056822|Drug|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
410757|NCT01056809|Procedure|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
410758|NCT01056796|Device|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
410759|NCT01056783|Drug|OC000459|OC000459 100mg, twice daily, tablet
410760|NCT01056783|Drug|Placebo|Placebo tablets to match OC000459 tablets, twice daily
410761|NCT01056770|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
410762|NCT01056757|Drug|Ribavirin|1000 mg bid, po, q28days
410763|NCT01056744|Device|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
410764|NCT01056731|Drug|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
410765|NCT01056718|Drug|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
410766|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
410767|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
410768|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
410769|NCT01056705|Biological|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
410770|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
410771|NCT01056692|Drug|OC000459|Capsules twice daily for 15 days
410772|NCT01056692|Drug|Placebo|Capsules twice daily for 15 days
410773|NCT01056679|Drug|Doxorubicine|50mg/m2 day 1 + 15
410774|NCT01056679|Drug|DTIC|375mg/m2 day 1 + 15
410775|NCT01056679|Drug|Lenalidomide|day 1 - 21
410776|NCT01056679|Drug|Vinblastine|6mg/m2 day 1 + 15
410777|NCT01056666|Device|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
410778|NCT01056666|Device|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
410779|NCT01056653|Behavioral|Standard Dose|Two intevention home visits
410780|NCT01056653|Behavioral|High Dose|Four intervention home visits
410781|NCT01056653|Behavioral|Comparison Group|One home visit, information only
410782|NCT01056640|Device|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
410783|NCT01056640|Other|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
410784|NCT01056627|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
410785|NCT01056614|Drug|fludarabine phosphate|Given IV
410786|NCT01056614|Drug|busulfan|Given IV
410787|NCT01056614|Biological|anti-thymocyte globulin|Given IV
410788|NCT01056614|Drug|tacrolimus|Given IV and orally
410789|NCT01056614|Drug|methotrexate|Given IV
410790|NCT01056614|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
410791|NCT01056614|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
410792|NCT01056614|Other|laboratory biomarker analysis|Correlative studies
410793|NCT01056601|Drug|Bortezomib|1.3 mg/m^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
410794|NCT01056601|Drug|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
410795|NCT01056588|Behavioral|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
410796|NCT01056588|Behavioral|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
410797|NCT01056575|Drug|OC000459|OC000459 100mg tablet, twice daily
410798|NCT01056549|Drug|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
410799|NCT01056536|Behavioral|Structured intervention for the prevention of sexually transmitted infections (STI)|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
410800|NCT01056523|Drug|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
410801|NCT01056523|Drug|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
410913|NCT01055535|Drug|Microplasmin|125 µg intravitreal injection
410802|NCT01056510|Drug|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
410803|NCT01056510|Drug|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
410804|NCT01056510|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
410805|NCT01056497|Drug|alpha lipoic acid|A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
410806|NCT01056484|Behavioral|Mindfulness Based Relapse Prevention for Alcohol Dependence|"All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study."
410807|NCT01056484|Other|"Wait-list control"|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
410808|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.
410809|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
410810|NCT01056458|Other|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
410811|NCT01056458|Other|sham acupressure|use only tape without ear adhesive beads under the same ways
410812|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
410813|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
410814|NCT01056419|Procedure|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
410815|NCT01056419|Drug|Propylthiouracil|150-600 mg in two-three divided doses
410816|NCT01056406|Behavioral|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
410817|NCT01056393|Drug|ibalizumab 800mg Q2Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg every 2 weeks.
410818|NCT01056393|Drug|ibalizumab 2000mg Q4Weeks|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 2000mg every 4 weeks.
410819|NCT01056380|Drug|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
410820|NCT01056380|Drug|Placebo|Tablet, twice daily with food for 5 days
410821|NCT01056341|Drug|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
410822|NCT01056341|Drug|Placebo|Treatment with placebo for 6 months
410823|NCT01056328|Device|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
410824|NCT01056328|Device|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
410825|NCT01056315|Drug|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
410826|NCT01056315|Drug|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
410827|NCT01056302|Procedure|Surgical repair of maxillofacial trauma|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated outcome using the proposed software tool.
410828|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
410829|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
410830|NCT01056289|Drug|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
410831|NCT01056276|Drug|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
410832|NCT01056276|Drug|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.~Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
410833|NCT01056276|Drug|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
410834|NCT01056263|Drug|axitinib: observational study|Non-interventional observational study
410835|NCT01056250|Procedure|SILS cholangiography|intraoperative
410836|NCT01056237|Drug|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
410837|NCT01056237|Drug|Azathioprine|1.0-2.0mg/kg/d
410838|NCT01056224|Drug|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
410839|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
410840|NCT01056211|Procedure|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
410841|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
410842|NCT01056198|Drug|Santyl|2 mm Santyl applied once daily.
410843|NCT01056198|Procedure|Control|Daily gauze and optional sharp debridement
410844|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 16 weeks"
410845|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week~Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)~Treatment duration: 24 weeks"
410846|NCT01056159|Drug|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
410847|NCT01056159|Drug|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
410848|NCT01056146|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
410849|NCT01056146|Behavioral|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
410850|NCT01056133|Other|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
410851|NCT01056120|Device|Pro Kinetic Energy bare metal stent|PCI
410852|NCT01056107|Drug|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
410853|NCT01056107|Drug|Placebo|Placebo subcutaneous injection daily
410854|NCT01056094|Drug|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
410855|NCT01056081|Other|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).~The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
410856|NCT01056042|Drug|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
410857|NCT01056042|Drug|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
410858|NCT01056029|Drug|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
410859|NCT01056016|Other|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
410860|NCT01056003|Other|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
410861|NCT01055990|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
410862|NCT01055990|Other|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
410863|NCT01055964|Drug|Tacrolimus|
410864|NCT01055951|Device|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
410865|NCT01055938|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
410866|NCT01055925|Device|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
410867|NCT01055925|Device|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
410963|NCT01055301|Other|laboratory biomarker analysis|
410964|NCT01055301|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
410868|NCT01055912|Drug|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
410869|NCT01055912|Drug|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
410870|NCT01055899|Biological|REGN88|Single SC Dose
410871|NCT01055899|Biological|REGN88|Single SC Dose
410872|NCT01055899|Biological|REGN88|Single SC Dose
410873|NCT01055886|Drug|nicotine patch|Nicotine patch, 7-21 mg.
410874|NCT01055886|Drug|placebo patch|placebo patch used from weeks 4-6
410875|NCT01055873|Biological|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
410876|NCT01055847|Drug|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
410877|NCT01055847|Drug|Placebo|Saline Placebo
410878|NCT01055834|Drug|Eszopiclone 3 mg|"Group A Period I, Group B Period II:~Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours.~Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.~Group B Period III:~Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.~Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast & the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
410879|NCT01055834|Drug|Eszopiclone 1 mg|"Group A Period II, Group B Period I:~Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.~Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
410880|NCT01055821|Drug|pegylated interferon and ribavirin|48 weeks
410881|NCT01055821|Biological|TG4040 + SOC|6 injections
410882|NCT01055821|Biological|TG4040 + SOC|13 injections
410883|NCT01055808|Drug|Insulins|Individual dose and frequency and duration as determined by the treating physician
410884|NCT01055795|Drug|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~3-6, All study drugs administered per dose level~Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
410885|NCT01055782|Device|Endoguide|Use of endoguide to facilitate completion of endoscopy
410886|NCT01055769|Drug|Linezolid|"Linezolid OS 600 MG~Linezolid Tablet 600 MG"
410887|NCT01055769|Drug|Linezolid|"Linezolid Tablet 600 MG~Linezolid OS 600 MG"
410888|NCT01055756|Drug|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
410889|NCT01055743|Procedure|Radical resection|Radical resection of hepatocellular carcinoma
410890|NCT01055743|Drug|Fluorouracil Implants|Implanted during the surgical treatment
410891|NCT01055730|Other|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
410892|NCT01055717|Other|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
410893|NCT01055704|Drug|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
410894|NCT01055704|Drug|Codeine only|30 mg taken orally four times daily for 5 days
410895|NCT01055704|Drug|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
410896|NCT01055704|Drug|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
410897|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
410898|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
410899|NCT01055691|Drug|Metformin|metformin IR tablet 850 mg Oral Single dose
410900|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
410901|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
410902|NCT01055691|Drug|Metformin|metformin IR tablet 1000 mg Oral Single dose
410903|NCT01055678|Drug|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
410904|NCT01055678|Procedure|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
410905|NCT01055665|Other|cognitive behavior therapy|6 cognitive behavior therapy groups
410906|NCT01055652|Drug|Dapagliflozin|10mg, oral, once daily
410907|NCT01055639|Behavioral|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
410908|NCT01055639|Behavioral|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
410909|NCT01055613|Device|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
410910|NCT01055613|Device|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
410911|NCT01055600|Drug|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
410912|NCT01055561|Other|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
410914|NCT01055522|Drug|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
410915|NCT01055522|Drug|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
410916|NCT01055522|Drug|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
410917|NCT01055509|Behavioral|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
410918|NCT01055496|Drug|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
410919|NCT01055496|Drug|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
410920|NCT01055483|Drug|panobinostat/LBH589B|
410921|NCT01055470|Drug|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
410922|NCT01055470|Drug|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
410923|NCT01055457|Device|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
410924|NCT01055457|Device|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
410925|NCT01055444|Drug|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
410926|NCT01055431|Other|Control bread|Control bread
410927|NCT01055431|Other|Teff Bread|Teff bread
410928|NCT01055418|Dietary Supplement|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
410929|NCT01055405|Drug|Sildenafil|Sildenafil 20mg TID orally
410930|NCT01055405|Other|Placebo|Placebo TID orally
410931|NCT01055392|Drug|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
410932|NCT01055392|Drug|Placebo|Identical placebo tablets were administered twice-a-day for two years.
410933|NCT01055379|Drug|Rasagiline|1 mg/day for 12 weeks; orally
410934|NCT01055379|Drug|Placebo|Once daily for 12 weeks; orally
410935|NCT01055366|Drug|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
410936|NCT01055340|Drug|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
410937|NCT01055340|Drug|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
410938|NCT01055340|Drug|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
410939|NCT01055327|Drug|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
410940|NCT01055327|Drug|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
410941|NCT01055327|Drug|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
410942|NCT01055314|Biological|Cixutumumab|Given IV
410943|NCT01055314|Drug|Cyclophosphamide|Given IV
410944|NCT01055314|Biological|Dactinomycin|Given IV
410945|NCT01055314|Drug|Doxorubicin Hydrochloride|Given IV
410946|NCT01055314|Drug|Etoposide|Given IV
410947|NCT01055314|Drug|Ifosfamide|Given IV
410948|NCT01055314|Drug|Irinotecan Hydrochloride|Given IV
410949|NCT01055314|Other|Laboratory Biomarker Analysis|Correlative studies
410950|NCT01055314|Drug|Temozolomide|Given PO
410951|NCT01055314|Drug|Vincristine Sulfate Liposome|Given IV
410952|NCT01055301|Drug|bortezomib|
410953|NCT01055301|Drug|cisplatin|
410954|NCT01055301|Drug|cyclophosphamide|
410955|NCT01055301|Drug|dexamethasone|
410956|NCT01055301|Drug|doxorubicin hydrochloride|
410957|NCT01055301|Drug|etoposide|
410958|NCT01055301|Drug|lenalidomide|
410959|NCT01055301|Drug|melphalan|
410960|NCT01055301|Drug|thalidomide|
410961|NCT01055301|Genetic|gene expression analysis|
410962|NCT01055301|Genetic|microarray analysis|
410965|NCT01055275|Device|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
410966|NCT01055262|Device|Heatwrap 1|8 hours continuous topically-applied heat
410967|NCT01055249|Drug|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
410968|NCT01055249|Drug|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
410969|NCT01055236|Drug|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
410970|NCT01055223|Drug|TZD only (RSG or PIO or troglitazone)|Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
410971|NCT01055223|Drug|TZD + spironolactone|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days."
410972|NCT01055223|Drug|TZD + amiloride|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.~In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days."
410973|NCT01055210|Device|Optimisation of VV delay|Programmed VV delay altered on device
410974|NCT01055197|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
410975|NCT01055197|Radiation|Radiation Therapy|Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
410976|NCT01055184|Biological|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
410977|NCT01055171|Drug|Propranolol|40 mg; Single Administration.
410978|NCT01055171|Drug|Placebo|40 mg; Single Dose.
410979|NCT01055158|Behavioral|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
410980|NCT01055158|Behavioral|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
410981|NCT01055145|Drug|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
410982|NCT01055132|Device|Etafilcon A toric contact lens|contact lens to correct astigmatism
410983|NCT01055132|Device|Nelfilcon A toric contact lens|contact lens to correct astigmatism
410984|NCT01055119|Dietary Supplement|Omega-3 fatty acids|duration: 4 month
410985|NCT01055106|Drug|GW05|vaginal gel once daily regimen A
410986|NCT01055106|Drug|GW05|vaginal gel once daily regimen B
410987|NCT01055106|Drug|GW05|vaginal gel once daily regimen C
410988|NCT01055106|Drug|Metronidazole|vaginal gel 0.75% once daily for 5 days
410989|NCT01055080|Dietary Supplement|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
410990|NCT01055067|Drug|Tivantinib (ARQ 197)|Capsule, 120 mg, BID (360 mg), approximately 112 days
410991|NCT01055041|Drug|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
410992|NCT01055041|Drug|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
410993|NCT01055041|Drug|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
410994|NCT01055028|Drug|Bevacizumab|15 mg/kg, IV every 21 days x 6 cycles.
410995|NCT01055028|Drug|Paclitaxel|"Regimen A / Treatment 1: 200 mg/m² IV over 3 hours every 21 days.~Regimen B / Treatment 2: 90 mg/m² weekly x 3 of a 28-day cycle"
410996|NCT01055015|Drug|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
410997|NCT01055015|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
410998|NCT01055002|Biological|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
410999|NCT01054989|Biological|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
411000|NCT01054976|Drug|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
411064|NCT01054495|Drug|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
411213|NCT01053442|Dietary Supplement|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
411001|NCT01054963|Behavioral|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
411002|NCT01054950|Behavioral|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
411003|NCT01054950|Behavioral|Placebo phone call|Phone call w/ no behavioral counseling
411004|NCT01054937|Drug|4SC-203|i.v. administration
411005|NCT01054937|Drug|Placebo|i.v. administration
411006|NCT01054911|Drug|Sunitinib|All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.
411007|NCT01054911|Procedure|Surgery|Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
411008|NCT01054898|Behavioral|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
411009|NCT01054898|Behavioral|usual community services|standard care for abused women in the community
411010|NCT01054885|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
411011|NCT01054885|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
411012|NCT01054885|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
411013|NCT01054885|Drug|Placebo|Placebo
411014|NCT01054872|Biological|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
411015|NCT01054872|Biological|HIV-1 recombinant Ad5 vaccine|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
411016|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
411017|NCT01054859|Other|alcohol|0.5 g/kg alcohol
411018|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD
411019|NCT01054846|Other|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
411020|NCT01054846|Other|Bicycle helmet education only|As described under the respective arm
411021|NCT01054833|Procedure|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
411022|NCT01054820|Drug|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
411023|NCT01054807|Device|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
411024|NCT01054807|Device|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
411025|NCT01054807|Device|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
411026|NCT01054794|Device|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
411027|NCT01054781|Drug|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
411028|NCT01054768|Dietary Supplement|alpha-lipoic acid and acetyl-L-carnitine|none to report
411029|NCT01054768|Drug|Placebo|none to report
411030|NCT01054742|Drug|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
411031|NCT01054742|Drug|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
411032|NCT01054729|Drug|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
411033|NCT01054729|Drug|Placebo|Placebo to match sofosbuvir administered orally once daily
411034|NCT01054729|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
411035|NCT01054729|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
411036|NCT01054703|Device|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
411037|NCT01054690|Device|Bactiguard Infection Protection (BIP) Cathter.|
411038|NCT01054690|Device|Silicone Urinary Catheter|
411039|NCT01054677|Behavioral|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
411040|NCT01054651|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
411041|NCT01054651|Drug|Praziquantel|
411065|NCT01054495|Device|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
411042|NCT01054638|Drug|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline & follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.~Subdivide person-time according to recent, past & non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), & Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).~Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline & follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
411043|NCT01054625|Biological|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
411044|NCT01054612|Other|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
411045|NCT01054599|Drug|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
411046|NCT01054599|Other|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
411047|NCT01054599|Drug|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
411048|NCT01054586|Drug|Intervention A Standard dose|HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of <2.0.
411049|NCT01054586|Drug|Intervention B Reduced Dose|HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
411050|NCT01054586|Drug|Intervention C|HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
411051|NCT01054586|Drug|Intervention D|HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
411052|NCT01054586|Drug|Intervention E|HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
411053|NCT01054573|Drug|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
411054|NCT01054573|Drug|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
411055|NCT01054573|Drug|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
411056|NCT01054560|Device|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
411057|NCT01054560|Device|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
411058|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
411059|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
411060|NCT01054534|Procedure|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
411061|NCT01054521|Procedure|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.~For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
411062|NCT01054521|Device|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
411063|NCT01054508|Drug|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
411066|NCT01054495|Device|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
411067|NCT01054482|Drug|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
411211|NCT01053468|Behavioral|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
411378|NCT01052038|Drug|Placebo administration|Placebo administration
411068|NCT01054482|Other|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op & Post-Op: 2 cycles (total 4 cycles).~Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
411069|NCT01054469|Procedure|TAP block placement with placebo|20 ml of normal saline (placebo)
411070|NCT01054469|Procedure|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
411071|NCT01054456|Drug|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
411072|NCT01054443|Drug|placebo to S-888711|Tablet
411073|NCT01054443|Drug|S-888711|Tablet
411074|NCT01054443|Drug|S-888711|Tablet
411075|NCT01054443|Drug|S-888711|Tablet
411076|NCT01054430|Drug|avanafil|200 mg avanafil tablets QD
411077|NCT01054404|Drug|Furosemide|Furosemide 0.3 mg/kg
411078|NCT01054404|Drug|Placebo|Placebo (up to 5mL)
411079|NCT01054391|Device|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
411080|NCT01054378|Procedure|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
411081|NCT01054352|Drug|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
411082|NCT01054352|Drug|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
411083|NCT01054352|Drug|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
411084|NCT01054352|Drug|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
411085|NCT01054339|Drug|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
411086|NCT01054326|Other|Exercises|
411087|NCT01054313|Drug|Docetaxel (Taxotere)|Starting dose 30 mg/m^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
411088|NCT01054313|Drug|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
411089|NCT01054313|Drug|Prednisone|5 mg by mouth twice a day with prostate cancer.
411090|NCT01054300|Drug|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (two 1 mg strength tablets), administered as a single dose
411091|NCT01054300|Drug|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (1 mg strength tablet) administered twice daily x 1 day
411092|NCT01054300|Drug|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (four 1 mg strength tablets), administered as a single dose
411093|NCT01054300|Drug|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (two 1 mg strength tablets) administered twice daily x 1 day
411094|NCT01054300|Drug|Placebo|Placebo to ertugliflozin administered as a single dose
411095|NCT01054287|Other|Multifactorial falls prevention program|
411096|NCT01054287|Other|No falls prevention intervention|
411097|NCT01054274|Device|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
411098|NCT01054274|Device|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
411099|NCT01054261|Drug|avanafil|200 mg avanafil tablet QD
411100|NCT01054248|Drug|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
411101|NCT01054248|Drug|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
411102|NCT01054248|Drug|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
411103|NCT01054235|Behavioral|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
411104|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
411105|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
411106|NCT01054209|Device|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.~Inditherm Alpha systems, OTM1: 1900mm x 585mm"
411107|NCT01054196|Drug|lenalidomide|daily dose dependent on dose-escalation schedule
411108|NCT01054196|Drug|melphalan|100 mg/m2 given Days -2 and -1
411109|NCT01054183|Device|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
411110|NCT01054183|Device|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
411111|NCT01054170|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
411112|NCT01054170|Drug|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
411113|NCT01054144|Drug|Lenalidomide|"Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;~Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;~Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;~Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;~Dose Level -4: Discontinue"
411114|NCT01054144|Drug|Prednisone|"Starting Dose: 100 mg PO days 1-5 every 28 days;~Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;~Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;~Dose level -3: Discontinue"
411115|NCT01054144|Drug|Dexamethasone|"Starting Dose: 40 mg daily on days 1 - 4 every 28 days;~Dose level -1: 20 mg daily on days 1 - 4 every 28 days;~Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;~Dose level -2: 10 mg daily on days 1 - 4 every 28 days;~Dose level -3: Discontinue"
411212|NCT01053455|Device|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
411116|NCT01054131|Behavioral|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
411117|NCT01054118|Drug|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
411118|NCT01054118|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
411119|NCT01054118|Drug|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
411120|NCT01054118|Drug|Placebo|Placebo suspension and placebo capsule administered as single doses
411121|NCT01054105|Drug|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
411122|NCT01054092|Drug|ipragliflozin|oral
411123|NCT01054079|Other|laboratory biomarker analysis|Correlative study
411124|NCT01054079|Procedure|quality-of-life assessment|Ancillary study
411125|NCT01054079|Other|questionnaire administration|Ancillary study
411126|NCT01054079|Drug|cinacalcet hydrochloride|Given PO
411127|NCT01054066|Behavioral|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
411128|NCT01054040|Other|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
411129|NCT01054027|Drug|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
411130|NCT01054014|Drug|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
411131|NCT01054014|Drug|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
411132|NCT01054014|Drug|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
411133|NCT01054001|Drug|sildenafil 100mg|sildenafil 100mg per oral twice a week
411134|NCT01053988|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
411135|NCT01053988|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
411136|NCT01053988|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
411137|NCT01053988|Drug|Placebo|Placebo
411138|NCT01053962|Drug|SP-304|Subjects receiving SP-304 1.0 mg for 14 consecutive days
411139|NCT01053962|Drug|SP-304|Subjects receiving SP-304 3.0 mg for 14 consecutive days
411140|NCT01053962|Drug|SP-304|Subjects receiving SP-304 9.0 mg for 14 consecutive days
411141|NCT01053962|Drug|Placebo|Subjects receiving Placebo for 14 consecutive days
411142|NCT01053962|Drug|SP-304 0.3 mg|Subjects receiving SP-304 0.3 mg for 14 consecutive
411143|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
411144|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
411145|NCT01053936|Drug|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
411146|NCT01053923|Other|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
411147|NCT01053910|Drug|Ramipril|tablet of Ramipril once daily
411148|NCT01053897|Biological|GBT009|Intradermal Injection following surgery
411149|NCT01053897|Biological|Placebo|Intradermal Injection following surgery
411150|NCT01053884|Drug|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC > 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
411151|NCT01053871|Drug|propofol|conscious sedation using propofol
411152|NCT01053871|Drug|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
411153|NCT01053858|Procedure|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
411154|NCT01053845|Other|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
411155|NCT01053832|Device|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
411156|NCT01053819|Drug|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
411157|NCT01053806|Drug|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
411158|NCT01053793|Other|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
411159|NCT01053780|Other|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
411160|NCT01053780|Behavioral|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
411161|NCT01053767|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study."
411162|NCT01053754|Biological|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
411163|NCT01053741|Biological|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
411164|NCT01053741|Biological|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
411165|NCT01053728|Drug|SAR161271|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
411166|NCT01053728|Drug|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection~Route of administration: subcutaneous"
411167|NCT01053702|Drug|R475|IV
411168|NCT01053702|Drug|Placebo|Placebo
411169|NCT01053689|Drug|Glimepiride tablets 1 mg|
411170|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
411171|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
411172|NCT01053663|Drug|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
411173|NCT01053650|Drug|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
411174|NCT01053637|Drug|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
411175|NCT01053637|Drug|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
411176|NCT01053624|Procedure|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
411177|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
411178|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
411179|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
411180|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
411181|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
411182|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
411183|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
411184|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
411185|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
411186|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
411187|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
411188|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
411189|NCT01053585|Drug|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
411190|NCT01053585|Drug|Placebo|Placebo single 'dose' 90 minutes prior to study
411191|NCT01053572|Procedure|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
411192|NCT01053559|Drug|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
411193|NCT01053546|Behavioral|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
411194|NCT01053546|Other|questionnaire administration|Ancillary study
411195|NCT01053546|Procedure|quality-of-life assessment|Ancillary study
411196|NCT01053533|Drug|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction& supportive therapy and antivirus therapy when necessary
411197|NCT01053533|Drug|western therapy|supportive therapy and antivirus therapy when necessary
411198|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
411199|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
411200|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
411201|NCT01053507|Drug|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
411202|NCT01053507|Drug|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
411203|NCT01053494|Procedure|massage therapy|Undergo massage therapy
411204|NCT01053494|Other|questionnaire administration|Ancillary studies
411205|NCT01053494|Procedure|quality-of-life assessment|Ancillary studies
411206|NCT01053494|Other|intervention by caregiver|Undergo massage by caregiver
411207|NCT01053494|Procedure|standard follow-up care|Undergo standard follow-up care
411208|NCT01053481|Dietary Supplement|vitamin D|Vitamin D supplement
411209|NCT01053481|Behavioral|exercise program (rebounding on a trampoline)|40 days at 30 min/d
411210|NCT01053468|Behavioral|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.~Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
412381|NCT01044693|Drug|Nebivolol 5 mg|Nebivolol 5mg single oral dose
411214|NCT01053442|Dietary Supplement|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
411215|NCT01053429|Drug|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
411216|NCT01053416|Procedure|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
411217|NCT01053403|Drug|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
411218|NCT01053390|Drug|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
411219|NCT01053390|Drug|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
411220|NCT01053377|Drug|Tamiflu (verum)|
411221|NCT01053377|Drug|Tamiflu placebo|
411222|NCT01053364|Device|NL-Prow interspinous spacer implant|Interspinous spacer implant
411223|NCT01053338|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
411224|NCT01053325|Drug|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
411225|NCT01053325|Drug|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
411226|NCT01053312|Drug|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of [18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels (MBq).
411227|NCT01053299|Other|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
411228|NCT01053273|Procedure|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
411229|NCT01053273|Procedure|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
411230|NCT01053260|Behavioral|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
411231|NCT01053260|Behavioral|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
411232|NCT01053247|Drug|0416|Topical 0416 test product applied twice daily for 2 weeks
411233|NCT01053247|Drug|Vehicle of 0416 test product|Vehicle of 0416 test product applied twice daily for 2 weeks
411234|NCT01053247|Drug|tacrolimus ointment 0.1%|Reference Product for 0416 test product. Apply twice daily for 2 weeks.
411235|NCT01053234|Dietary Supplement|Standardised meals|
411236|NCT01053221|Drug|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
411237|NCT01053221|Drug|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
411238|NCT01053208|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
411239|NCT01053195|Behavioral|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
411240|NCT01053182|Procedure|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
411241|NCT01053182|Procedure|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
411242|NCT01053169|Biological|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
411243|NCT01053169|Biological|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
411244|NCT01053169|Other|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
411245|NCT01053156|Drug|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
411246|NCT01053156|Drug|Placebo|Placebo will be given daily for 3 months.
411247|NCT01053143|Biological|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
411248|NCT01053130|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
411249|NCT01053130|Behavioral|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
411250|NCT01053117|Other|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
411251|NCT01053091|Behavioral|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
411252|NCT01053078|Drug|Naltrexone|1 month treatment
411253|NCT01053078|Drug|Naltrexone|Naltrexone 25 mg once daily with dose escalation to 50 mg BID to day 28
411254|NCT01053065|Drug|Atorvastatin - Cholestyramine - Sitosterol|
411255|NCT01053052|Device|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
411256|NCT01053039|Drug|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
411257|NCT01053039|Drug|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
411258|NCT01053026|Drug|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
411259|NCT01053013|Biological|Cancer macrobead placement in abdominal cavity|8 macrobeads per kilogram
411299|NCT01052662|Drug|Memantine|30mg/day Memantine orally everyday for 12 weeks
411300|NCT01052662|Drug|Memantine|15 mg/day Memantine orally everyday for 12 weeks
411301|NCT01052662|Drug|Placebo|Placebo orally everyday for 12 weeks
411260|NCT01053000|Drug|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
411261|NCT01052987|Drug|Tranilast|Tranilast tablets, 300 mg, QD
411262|NCT01052987|Drug|Allopurinol|Allopurinol tablets 300 mg, QD
411263|NCT01052987|Drug|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
411264|NCT01052987|Drug|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
411265|NCT01052987|Drug|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
411266|NCT01052974|Drug|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.~Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
411267|NCT01052961|Drug|Oseltamivir|oseltamivir 150 mg bd for 5 days
411268|NCT01052948|Other|Retrospective study-|
411269|NCT01052948|Other|Retrospective study-|
411270|NCT01052948|Other|Retrospective study-|
411271|NCT01052948|Other|Retrospective study-|
411272|NCT01052935|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.~Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
411273|NCT01052922|Other|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
411274|NCT01052922|Other|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
411275|NCT01052922|Other|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
411276|NCT01052909|Drug|Glimepiride|Glimepiride tablets 1 mg
411277|NCT01052896|Drug|Gabapentin|300mg po TID
411278|NCT01052896|Drug|Placebo|Look-alike of gabapentin 300mg given po tid
411279|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
411280|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
411281|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
411282|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
411283|NCT01052870|Drug|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
411284|NCT01052857|Procedure|acupuncture|acupuncture application
411285|NCT01052844|Drug|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
411286|NCT01052844|Drug|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
411287|NCT01052831|Drug|Naltrexone|50-100 mg qd for 8 weeks
411288|NCT01052831|Drug|Placebo|50-100 mg qd for 8 weeks
411289|NCT01052805|Procedure|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
411290|NCT01052792|Drug|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
411291|NCT01052779|Drug|Ferumoxytol|IV Ferumoxytol
411292|NCT01052779|Drug|Iron Sucrose|IV Iron Sucrose
411293|NCT01052766|Procedure|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
411294|NCT01052727|Procedure|Laparoscopic Cholecystectomy|
411295|NCT01052714|Behavioral|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
411296|NCT01052701|Drug|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV alone 600 mg orally every 12 hours (Body Weight >75 kg)"
411297|NCT01052701|Drug|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)~OR~Daily RBV 600 mg orally every 12 hours (Body Weight >75 kg)~Plus~Daily Abacavir 300 mg orally every 12 hours"
411298|NCT01052688|Other|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
411303|NCT01052636|Other|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
411304|NCT01052623|Drug|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
411305|NCT01052610|Drug|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
411306|NCT01052610|Drug|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
411307|NCT01052597|Drug|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
411308|NCT01052584|Drug|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
411309|NCT01052584|Drug|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
411310|NCT01052584|Drug|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
411311|NCT01052571|Procedure|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
411312|NCT01052558|Device|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
411313|NCT01052558|Procedure|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
411314|NCT01052545|Behavioral|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
411315|NCT01052519|Other|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
411316|NCT01052506|Drug|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
411317|NCT01052506|Drug|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
411318|NCT01052493|Drug|PP 1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 2, 4, 8 mg.
411319|NCT01052493|Drug|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
411320|NCT01052480|Biological|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
411321|NCT01052480|Drug|Standard Care|All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
411322|NCT01052467|Drug|Xamiol® Gel|Once daily application for about 4 weeks
411323|NCT01052454|Behavioral|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
411324|NCT01052428|Drug|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
411325|NCT01052428|Drug|Placebo|Placebo 100 mg once a day for 2 years
411326|NCT01052415|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
411327|NCT01052402|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
411328|NCT01052389|Drug|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
411329|NCT01052389|Drug|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
411330|NCT01052389|Drug|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.~Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
411331|NCT01052376|Device|Confocal endomicroscopy|
411332|NCT01052363|Drug|Bevacizumab, CA4P|
411333|NCT01052337|Drug|anaesthetics: sevofluorane|0.5%of sevofluorane with air
411334|NCT01052324|Drug|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
411335|NCT01052311|Drug|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
411336|NCT01052311|Drug|Placebo|Placebo tablets once daily
411337|NCT01052311|Drug|Tredaptive|Tredaptive 1 g [Laropiprant 20 mg(LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
411338|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
411379|NCT01052038|Drug|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
411339|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
411340|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
411341|NCT01052298|Drug|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
411342|NCT01052285|Procedure|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
411343|NCT01052285|Procedure|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
411344|NCT01052285|Procedure|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
411345|NCT01052272|Drug|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
411346|NCT01052272|Drug|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
411347|NCT01052272|Drug|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
411348|NCT01052259|Drug|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
411349|NCT01052246|Drug|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
411350|NCT01052246|Device|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:~Wavelength 585 nm~Energy fluence 3 J/cm2~Pulse duration 0.35 msec~Spot size 7 mm"
411351|NCT01052233|Procedure|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
411352|NCT01052233|Procedure|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
411353|NCT01052220|Behavioral|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.~The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
411354|NCT01052220|Behavioral|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
411355|NCT01052194|Drug|Placebo|tablet, placebo b.i.d. for 12 weeks
411356|NCT01052194|Drug|VX-509|tablets, 25mg b.i.d. for 12 weeks
411357|NCT01052194|Drug|VX-509|tablet, 50 mg b.i.d. for 12 weeks
411358|NCT01052194|Drug|VX-509|tablet, 100 mg b.i.d. for 12 weeks
411359|NCT01052194|Drug|VX-509|tablet, 150 mg b.i.d. for 12 weeks
411360|NCT01052181|Drug|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
411361|NCT01052181|Drug|placebo|2 sachets monthly for an year
411362|NCT01052168|Other|skills training|participants will train using different performance goals (based on different metrics)
411363|NCT01052155|Other|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
411364|NCT01052142|Biological|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
411365|NCT01052129|Drug|Naproxen sodium|Naproxen Sodium Tablets 550 mg
411366|NCT01052116|Drug|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
411367|NCT01052116|Drug|Placebo|Placebo
411368|NCT01052103|Drug|LY2140023|40mg, oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20mg or a maximum of 80mg.
411369|NCT01052103|Drug|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
411370|NCT01052103|Drug|Standard of Care|U.S. label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
411371|NCT01052090|Drug|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
411372|NCT01052077|Drug|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
411373|NCT01052077|Drug|Placebo|Placebo
411374|NCT01052077|Drug|ADT|
411375|NCT01052064|Device|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
411376|NCT01052051|Dietary Supplement|Vitamin D3|Vitamin D3 2000 IU/daily
411377|NCT01052051|Dietary Supplement|Calcium carbonate|Calcium carbonate 1500mg / daily
411380|NCT01052038|Drug|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
411381|NCT01052025|Drug|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
411382|NCT01052012|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; SABER™-Bupivacaine /Once
411383|NCT01052012|Drug|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
411384|NCT01052012|Drug|SABER™-Placebo|Injectable Solution; SABER™-Placebo/Once
411385|NCT01051999|Dietary Supplement|Glutamine|Oral glutamine powder
411386|NCT01051999|Dietary Supplement|L-alanine|L-alanine oral powder
411387|NCT01051986|Procedure|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
411388|NCT01051986|Procedure|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
411389|NCT01051973|Behavioral|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
411390|NCT01051973|Behavioral|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
411391|NCT01051960|Drug|Ambrisentan|Ambrisentan 5mg or 10mg once daily
411392|NCT01051947|Drug|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
411393|NCT01051947|Drug|Metoprolol|dosage prescribed prior to starting on study
411394|NCT01051934|Drug|SS1 (dsFv) PE38|
411395|NCT01051934|Drug|Paclitaxel|
411396|NCT01051934|Drug|Carboplatin|
411397|NCT01051934|Drug|Bevacizumab|
411398|NCT01051921|Drug|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
411399|NCT01051921|Drug|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
411400|NCT01051921|Drug|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
411401|NCT01051895|Other|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
411402|NCT01051895|Other|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
411403|NCT01051882|Biological|MSC-NTF cells transplantation (IM)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
411404|NCT01051882|Biological|MSC-NTF cells transplantation (IT)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
411405|NCT01051869|Procedure|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.~In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
411406|NCT01051869|Procedure|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
411407|NCT01051856|Device|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
411408|NCT01051856|Procedure|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
411409|NCT01051830|Other|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
411410|NCT01051817|Drug|AIN457|infusion 10 mg/Kg
411411|NCT01051817|Drug|Placebo|infusion
411412|NCT01051804|Other|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
411413|NCT01051804|Other|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
411414|NCT01051791|Drug|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
411415|NCT01051778|Drug|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
411442|NCT01051570|Drug|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
411443|NCT01051570|Drug|RAD 001|5 mg orally starting on Day 2 then continuous
411416|NCT01051778|Drug|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
411417|NCT01051765|Drug|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
411418|NCT01051739|Procedure|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
411419|NCT01051726|Other|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
411420|NCT01051726|Other|None essential oil|Baby oil
411421|NCT01051713|Behavioral|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
411422|NCT01051713|Behavioral|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
411423|NCT01051700|Drug|GW786034|Investigational product
411424|NCT01051700|Other|Placebo|Placebo
411425|NCT01051687|Drug|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.~For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
411426|NCT01051674|Other|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
411427|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
411428|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
411429|NCT01051661|Biological|Placebo|Intramuscular injection, one dose
411430|NCT01051648|Drug|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy
411431|NCT01051635|Drug|LMP 400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
411432|NCT01051635|Drug|LMP 776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
411433|NCT01051622|Other|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
411434|NCT01051609|Other|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
411435|NCT01051609|Other|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
411436|NCT01051609|Behavioral|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
411437|NCT01051609|Other|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
411438|NCT01051609|Procedure|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
411439|NCT01051596|Drug|Temozolomide|150mg/m2 Days 1-5 of each 28 day cycle
411440|NCT01051596|Drug|ABT-888|40mg orally BID Days 1-7 of each 28 day cycle
411441|NCT01051583|Procedure|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
411444|NCT01051570|Drug|prednisone|5 mg orally twice a day starting on Day 1 then continuous
411445|NCT01051570|Other|laboratory biomarker analysis|Samples will be collected from archival tissue.
411446|NCT01051570|Other|pharmacological study|Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2
411447|NCT01051557|Other|Laboratory Biomarker Analysis|Correlative studies
411448|NCT01051557|Drug|Perifosine|Given PO
411449|NCT01051557|Drug|Temsirolimus|Given IV
411450|NCT01051557|Procedure|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
411451|NCT01051544|Drug|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
411452|NCT01051544|Drug|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
411453|NCT01051531|Drug|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
411454|NCT01051518|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
411455|NCT01051505|Drug|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
411456|NCT01051505|Drug|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
411457|NCT01051479|Drug|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
411458|NCT01051466|Drug|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
411459|NCT01051440|Drug|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
411460|NCT01051440|Drug|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
411461|NCT01051427|Device|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
411462|NCT01051427|Device|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
411463|NCT01051414|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
411464|NCT01051414|Drug|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
411465|NCT01051401|Drug|rosuvastatin|Given PO
411466|NCT01051401|Other|placebo|Given PO
411467|NCT01051401|Other|survey administration|Correlative study
411468|NCT01051401|Procedure|management of therapy complications|
411469|NCT01051388|Drug|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
411470|NCT01051388|Drug|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
411471|NCT01051388|Drug|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
411472|NCT01051375|Behavioral|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
411473|NCT01051362|Drug|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
411474|NCT01051349|Biological|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
411475|NCT01051349|Biological|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
411476|NCT01051336|Device|TARIS Placebo|
411477|NCT01051336|Procedure|Sham Procedure|
411478|NCT01051323|Drug|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
411479|NCT01051310|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
411480|NCT01051284|Radiation|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
411481|NCT01051271|Drug|midazolam|midazolam 1.5 mg
411482|NCT01051258|Device|AeriSeal System|AeriSeal System for Lung Volume Reduction
411483|NCT01051245|Behavioral|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
411484|NCT01051245|Other|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
411485|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
411486|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
411487|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
411488|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
411489|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
411490|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
411491|NCT01051219|Drug|Losartan|50 milligrams to be taken orally, daily
411638|NCT01050140|Dietary Supplement|high sugar diet|25% of dietary energy from fructose or glucose
411492|NCT01051206|Drug|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
411493|NCT01051193|Drug|Oxcarbazepine|
411494|NCT01051180|Procedure|HALO|Ligation of haemorrhoidal arteries
411495|NCT01051167|Drug|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
411496|NCT01051154|Dietary Supplement|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
411497|NCT01051154|Dietary Supplement|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
411498|NCT01051141|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
411499|NCT01051141|Behavioral|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
411500|NCT01051141|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
411501|NCT01051128|Device|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
411502|NCT01051115|Drug|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
411503|NCT01051102|Drug|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
411504|NCT01051102|Drug|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
411505|NCT01051089|Behavioral|Lifestyle modification|Exercise and diet education
411506|NCT01051076|Drug|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
411507|NCT01051063|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
411508|NCT01051050|Behavioral|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
411509|NCT01051050|Behavioral|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
411510|NCT01051037|Radiation|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
411511|NCT01051037|Radiation|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
411512|NCT01051024|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
411513|NCT01051024|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
411514|NCT01051011|Drug|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
411515|NCT01051011|Drug|metformin|as prescribed
411516|NCT01051011|Drug|taspoglutide|10mg sc weekly, 24 (-52) weeks
411517|NCT01051011|Drug|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
411518|NCT01050998|Biological|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
411519|NCT01050998|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
411520|NCT01050998|Biological|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
411521|NCT01050998|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
411522|NCT01050998|Other|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
411523|NCT01050985|Drug|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
411639|NCT01050127|Drug|ABT-436|See Arm Description for details.
411640|NCT01050127|Drug|Placebo|See Arm Description for details.
411524|NCT01050972|Behavioral|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
411525|NCT01050959|Device|bion|
411526|NCT01050946|Biological|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.~Conditioning Regimens Choice of regimen at the discretion of the treating physician~Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)~Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)~Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
411527|NCT01050933|Drug|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
411528|NCT01050920|Biological|Blood collection|
411529|NCT01050907|Drug|miltefosine|2.5 mg/kg/day for 28 days
411530|NCT01050868|Device|Accu-Chek Combo Kit mg DE/de|
411531|NCT01050855|Drug|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
411532|NCT01050855|Drug|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
411533|NCT01050855|Drug|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
411534|NCT01050842|Drug|bicalutamide|Given orally
411535|NCT01050842|Drug|raloxifene|Given orally
411536|NCT01050842|Procedure|quality-of-life assessment|Ancillary study
411537|NCT01050829|Drug|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
411538|NCT01050829|Drug|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
411539|NCT01050816|Procedure|Chondron(autologous chondrocyte) Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)~Directions and dosage:~Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.~*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
411540|NCT01050803|Behavioral|FDSME group|"In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
411541|NCT01050803|Behavioral|FDSME|"In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
411542|NCT01050790|Drug|Azacitidine|Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
411543|NCT01050777|Drug|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
411544|NCT01050777|Drug|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
411545|NCT01050777|Drug|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
411546|NCT01050777|Drug|Placebo|Placebo
411547|NCT01050764|Drug|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:~Cohort 1~T-reg: 1 x 10e5/kg~T-con: 3 x10e5/kg~Cohort 2~T-reg: 3 x 10e5/kg~T-con: 1 x 10e6/kg~Cohort 3~T-reg: 1 x 10e6/kg~T-con: 3 x 10e6/kg~Cohort 4~T-reg: 3 x 10e6/kg~T-con: 1 x 10e7/kg"
411548|NCT01050764|Drug|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
411549|NCT01050764|Drug|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
411550|NCT01050764|Drug|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
411551|NCT01050764|Device|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
411552|NCT01050764|Drug|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
411553|NCT01050764|Drug|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
411554|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
411555|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
411556|NCT01050738|Procedure|Position of catheter|Position of catheter for administration of local anestesia.
411557|NCT01050712|Drug|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
411558|NCT01050712|Drug|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
411559|NCT01050699|Drug|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
411560|NCT01050699|Drug|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
411561|NCT01050686|Procedure|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
411562|NCT01050686|Procedure|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
411563|NCT01050673|Device|VERSAJET|Hydro-surgery debridement
411564|NCT01050673|Procedure|Scalpel or blade|Conventional Surgical Debridement
411565|NCT01050660|Other|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
411566|NCT01050660|Other|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
411567|NCT01050647|Drug|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
411568|NCT01050647|Other|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
411569|NCT01050634|Drug|Aromasin (exemestane)|25mg oral tablet, daily, for >1yr
411570|NCT01050621|Dietary Supplement|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
411571|NCT01050608|Device|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
411572|NCT01050608|Drug|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
411573|NCT01050608|Behavioral|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
411574|NCT01050608|Behavioral|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
411575|NCT01050595|Drug|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance <30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
411576|NCT01050595|Drug|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
411577|NCT01050582|Drug|Risperidone|As per local prescribing practices
411578|NCT01050582|Drug|Other atypical antipsychotic drugs|As per local prescribing practices
411579|NCT01050569|Drug|Nicotine Patch|21 mg
411580|NCT01050569|Other|VLNC Cigarette|Cigarette where the tobacco contains <0.1 mg of nicotine yield.
411581|NCT01050569|Other|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
411582|NCT01050556|Other|Placebo|daily, 24 weeks
411583|NCT01050556|Dietary Supplement|folic acid|400 ug/d for 12 or 24 weeks
411584|NCT01050556|Dietary Supplement|folic acid|800 µg/d for 12 or 24 weeks
411585|NCT01050556|Dietary Supplement|creatine|3 mg/d for 12 weeks
411586|NCT01050556|Dietary Supplement|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
411587|NCT01050543|Drug|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
411588|NCT01050543|Drug|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
411589|NCT01050530|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
411590|NCT01050530|Drug|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
411591|NCT01050517|Drug|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
411592|NCT01050517|Drug|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
411593|NCT01050504|Other|Cytology Specimen Collection Procedure|Correlative studies
411594|NCT01050504|Other|Laboratory Biomarker Analysis|Correlative studies
411595|NCT01050491|Drug|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
411596|NCT01050491|Drug|placebo|placebo, one per day, during one year. Bronchial fibroscopy
411597|NCT01050478|Drug|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
411598|NCT01050478|Drug|Benzodiazepine|Participants may receive the benzodiazepine lorazepam [0-7.5 milligram (mg) per day] as needed for sedation or rescue medication at the investigator's discretion.
411599|NCT01050465|Other|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
411600|NCT01050452|Drug|albendazole|albendazole (400 mg on dose)
411601|NCT01050452|Drug|mebendazole|mebendazole (500 mg one dose)
411602|NCT01050452|Drug|ivermectin|ivermectin (200 microgram/kg body weight)
411603|NCT01050452|Drug|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
411604|NCT01050452|Drug|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
411605|NCT01050439|Procedure|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
411606|NCT01050439|Other|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
411607|NCT01050426|Other|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
411608|NCT01050426|Other|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
411609|NCT01050400|Genetic|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
411610|NCT01050387|Dietary Supplement|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
411611|NCT01050374|Drug|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
411612|NCT01050374|Drug|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
411613|NCT01050361|Procedure|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
411614|NCT01050348|Drug|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
411615|NCT01050348|Drug|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
411616|NCT01050335|Behavioral|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
411617|NCT01050322|Drug|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
411618|NCT01050322|Drug|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
411619|NCT01050322|Drug|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
411620|NCT01050309|Drug|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
411621|NCT01050283|Procedure|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
411622|NCT01050270|Drug|Ondansetron|4mgs iv bolus
411623|NCT01050270|Drug|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
411624|NCT01050270|Drug|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
411625|NCT01050257|Drug|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
411626|NCT01050257|Drug|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
411627|NCT01050244|Dietary Supplement|Whole soybean soymilk powder|
411628|NCT01050244|Dietary Supplement|Whole milk powder|
411629|NCT01050231|Device|Type I Robotic Group (Functional activities and individual joints)|Subjects participate in 11 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder) , 3 days per week, 1 hour per day with the robotic exercise program.
411630|NCT01050231|Device|Type II Robotic therapy (Individual joints only)|Subjects participate in 11 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements as the patient plays interactive computer games.
411631|NCT01050218|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
411632|NCT01050205|Behavioral|Current Intervention|"Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
411633|NCT01050205|Behavioral|Delayed Intervention|"Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.~GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
411634|NCT01050179|Other|carbon dioxide|sinusoidal carbon dioxide delivery
411635|NCT01050166|Other|Transplantation of labeled islets|
411636|NCT01050153|Drug|Dalteparin sodium|Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
411637|NCT01050153|Drug|Dalteparin sodium/aspirin|Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
411641|NCT01050114|Drug|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.~Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
411642|NCT01050114|Drug|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
411643|NCT01050101|Dietary Supplement|No fiber|"The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.~Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
411644|NCT01050101|Dietary Supplement|Low GI high fiber viscous meal|"Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
411645|NCT01050101|Dietary Supplement|Low GI high fiber non-viscous|"Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
411646|NCT01050088|Dietary Supplement|sucrose solution|5cc 5% sucrose solution P/O
411647|NCT01050088|Dietary Supplement|Saline|5cc saline p/o
411648|NCT01050075|Other|acupuncture therapy|acupuncture therapy
411649|NCT01050075|Other|questionnaire administration|Ancillary study
411650|NCT01050075|Other|management of therapy complications|To be determined by the treating physician
411651|NCT01050062|Drug|Telmisartan 80mg|Combination tablet
411652|NCT01050062|Drug|Telmisartan 40mg|Combination tablet
411653|NCT01050062|Drug|Hydrochlorothiazide 12.5mg|Combination tablet
411654|NCT01050036|Procedure|autologous hematopoietic cell transplantation|"Autologous peripheral blood stem cell (PBSCs) harvesting~After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy~Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy~Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.~Conditioning regimen for autologous HCT~Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)~Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)~Autologous cell infusion and waiting for engraftment"
411655|NCT01050023|Device|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
411656|NCT01050023|Device|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
411657|NCT01050010|Other|MRI|dedicated extremity MRI
411658|NCT01049984|Drug|Rasagiline|1mg tablet daily for 18 weeks
411659|NCT01049984|Drug|Placebo|one tablet daily for 18 weeks
411660|NCT01049971|Device|wound protector|after minilaparotomy, the wound protector is applied
411661|NCT01049971|Device|no wound protector|use of woven drape instead of wound protector
411662|NCT01049945|Drug|bendamustine hydrochloride|Given IV
411663|NCT01049945|Drug|lenalidomide|Given orally
411664|NCT01049945|Drug|dexamethasone|Given orally or IV
411665|NCT01049932|Drug|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
411666|NCT01049919|Device|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
411667|NCT01049919|Procedure|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
411668|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
411669|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
411670|NCT01049893|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
411671|NCT01049880|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
411672|NCT01049867|Procedure|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
411673|NCT01049854|Drug|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
411674|NCT01049854|Drug|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
411675|NCT01049854|Drug|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
411932|NCT01048138|Drug|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
411676|NCT01049854|Drug|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
411677|NCT01049841|Drug|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
411678|NCT01049828|Other|No intervention|No treatment for tinnitus will occur in this study.
411679|NCT01049815|Drug|sevelamer hydrochloride|800-3200 mg with each meal
411680|NCT01049815|Drug|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
411681|NCT01049802|Device|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
411682|NCT01049789|Behavioral|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.~Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
411683|NCT01049789|Behavioral|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.~Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
411684|NCT01049776|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
411685|NCT01049763|Drug|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
411686|NCT01049750|Other|type 2 diabetic patients|males; type 2 diabetic patients
411687|NCT01049724|Other|Tear collection|Tear collection
411688|NCT01049711|Drug|erythropoietin|
411689|NCT01049698|Behavioral|Resistance Training|3 d/wk resistance training
411690|NCT01049698|Behavioral|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
411691|NCT01049685|Drug|First-line Antiretroviral Therapy|"Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background~Efavirenz: 01 capsules day, plus NRTI background"
411692|NCT01049672|Drug|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
411693|NCT01049672|Drug|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
411694|NCT01049659|Behavioral|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
411695|NCT01049646|Drug|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
411696|NCT01049646|Drug|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
411697|NCT01049633|Biological|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
411698|NCT01049633|Drug|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
411699|NCT01049633|Biological|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
411700|NCT01049633|Drug|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
411701|NCT01049633|Drug|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
411702|NCT01049633|Drug|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
411703|NCT01049633|Drug|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
411704|NCT01049633|Drug|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
411705|NCT01049633|Drug|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
411706|NCT01049633|Drug|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
411707|NCT01049633|Drug|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
411708|NCT01049633|Drug|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
411741|NCT01049399|Drug|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
411709|NCT01049620|Drug|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21~Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21~Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21~Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
411710|NCT01049607|Procedure|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
411711|NCT01049607|Procedure|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
411712|NCT01049581|Procedure|aquatic therapy|two hours per week, one hour per time, total 12 weeks
411713|NCT01049568|Behavioral|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.~Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
411714|NCT01049555|Other|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
411715|NCT01049542|Drug|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
411716|NCT01049529|Dietary Supplement|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
411717|NCT01049529|Dietary Supplement|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
411718|NCT01049516|Behavioral|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
411719|NCT01049516|Behavioral|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
411720|NCT01049516|Behavioral|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
411721|NCT01049516|Behavioral|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
411722|NCT01049503|Other|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
411723|NCT01049490|Biological|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
411724|NCT01049477|Other|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
411725|NCT01049477|Other|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
411726|NCT01049464|Drug|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
411727|NCT01049464|Drug|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
411728|NCT01049451|Drug|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
411729|NCT01049451|Drug|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
411730|NCT01049438|Drug|nasal mupirocin|twice daily for 10 days
411731|NCT01049438|Drug|topical 3% hexachlorophene body wash|daily for 10 days
411732|NCT01049438|Drug|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
411733|NCT01049425|Drug|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
411734|NCT01049425|Drug|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
411735|NCT01049425|Drug|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
411736|NCT01049425|Drug|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
411737|NCT01049425|Drug|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
411738|NCT01049412|Drug|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
411739|NCT01049412|Drug|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
411740|NCT01049399|Drug|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
411933|NCT01048138|Drug|Placebo|5mg IV(in the vein)every 6 hours for 10 days
411742|NCT01049399|Drug|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
411743|NCT01049386|Other|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
411744|NCT01049386|Procedure|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
411745|NCT01049373|Drug|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
411746|NCT01049373|Drug|Placebo solution|10 drops, t.i.d, 15 weeks
411747|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
411748|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
411749|NCT01049360|Drug|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
411750|NCT01049360|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
411751|NCT01049360|Drug|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
411752|NCT01049347|Drug|amitriptyline|150 mg oral, daily, single evening dose, 35 days
411753|NCT01049347|Drug|paroxetine|40 mg oral, single dose, morning, 35 days
411754|NCT01049334|Drug|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
411755|NCT01049334|Drug|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
411756|NCT01049321|Dietary Supplement|DASH diet|
411757|NCT01049321|Dietary Supplement|a usual diabetic diet|
411758|NCT01049295|Dietary Supplement|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
411759|NCT01049295|Other|corn oil pearls|corn oil pearls 3 times a day
411760|NCT01049282|Biological|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
411761|NCT01049282|Biological|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
411762|NCT01049256|Other|carbon dioxide|sinusoidal carbon dioxide administration
411763|NCT01049243|Drug|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
411764|NCT01049230|Radiation|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
411765|NCT01049217|Drug|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
411766|NCT01049217|Drug|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
411767|NCT01049204|Drug|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
411768|NCT01049204|Drug|placebo|Placebo twice daily for 24 weeks
411769|NCT01049178|Drug|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
411770|NCT01049178|Drug|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
411771|NCT01049178|Drug|Placebo|
411772|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
411773|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
411774|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
411775|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
411776|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
411777|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
411778|NCT01049165|Drug|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
411779|NCT01049165|Drug|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
411780|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
411781|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
411782|NCT01049152|Device|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
411783|NCT01049139|Behavioral|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
411784|NCT01049139|Behavioral|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
411785|NCT01049126|Other|ChemoFx|Chemoresponse Marker Assay
411786|NCT01049113|Drug|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
411787|NCT01049100|Procedure|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
411934|NCT01048125|Device|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
411788|NCT01049100|Other|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--> CT controlled biopsy
411789|NCT01049087|Radiation|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
411790|NCT01049087|Radiation|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
411791|NCT01049074|Other|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
411792|NCT01049074|Other|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
411793|NCT01049061|Drug|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
411794|NCT01049048|Dietary Supplement|Vitamin D3|2500 IU Vitamin D3
411795|NCT01049048|Dietary Supplement|Placebo|No (0 IU) vitamin D3 added to cookie.
411796|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
411797|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
411798|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
411799|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
411800|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
411801|NCT01049035|Biological|Pentacel®|As in the prescribing information (All are licensed vaccines)
411802|NCT01049035|Biological|M-M-R®II|As in the prescribing information
411803|NCT01049035|Biological|Varivax®|As in the prescribing information
411804|NCT01049035|Biological|Prevnar®|As in the prescribing information
411805|NCT01049035|Biological|RotaTeq®|As in the prescribing information
411806|NCT01049035|Biological|Engerix-B®|As in the prescribing information
411807|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (<=) 14 years.
411808|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
411809|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to < 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
411810|NCT01049009|Drug|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
411811|NCT01049009|Drug|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
411812|NCT01048983|Drug|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
411813|NCT01048983|Drug|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
411814|NCT01048983|Drug|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
411815|NCT01048983|Drug|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
411816|NCT01048983|Behavioral|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
411817|NCT01048970|Other|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
411818|NCT01048970|Dietary Supplement|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
411819|NCT01048957|Behavioral|Real Time Feedback Training|
411820|NCT01048944|Drug|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
411821|NCT01048944|Drug|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
411822|NCT01048944|Drug|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
411823|NCT01048931|Procedure|single-port LAVH|single-port LAVH
411824|NCT01048905|Drug|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children < 15 years of age.
411825|NCT01048905|Drug|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children < 15 years of age.
411826|NCT01048892|Biological|Seneca Valley virus-001|
411827|NCT01048892|Drug|cyclophosphamide|
411828|NCT01048892|Other|laboratory biomarker analysis|
411829|NCT01048892|Other|pharmacological study|
411830|NCT01048879|Procedure|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
411831|NCT01048879|Procedure|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
411862|NCT01048606|Dietary Supplement|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
411832|NCT01048866|Drug|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
411833|NCT01048866|Drug|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
411834|NCT01048866|Drug|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
411835|NCT01048853|Procedure|Conservative Surgery|Removal of the pelvic lymph nodes (pelvic lymphadenectomy)
411836|NCT01048827|Drug|Busulfan|"1250 uMol*min (AUC to time 6 hrs)^~1400 uMol*min (AUC to time 6 hrs~1550 uMol*min (AUC to time 6 hrs)^"
411837|NCT01048814|Other|ChemoFx|Chemoresponse Marker Assay
411838|NCT01048801|Device|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
411839|NCT01048801|Other|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
411840|NCT01048788|Drug|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
411841|NCT01048762|Other|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
411842|NCT01048762|Other|home training|one instruction in home based exercise training
411843|NCT01048749|Other|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
411844|NCT01048749|Other|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
411845|NCT01048736|Behavioral|Exercise Only|4 d/wk of aerobic exercise
411846|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss).
411847|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
411848|NCT01048723|Drug|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
411849|NCT01048710|Other|No intervention|
411850|NCT01048697|Drug|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
411851|NCT01048684|Drug|Mannitol|Variation of mannitol dose
411852|NCT01048684|Drug|Mannitol|Variation of mannitol dose
411853|NCT01048671|Drug|Raltegravir|Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
411854|NCT01048671|Drug|ARV (non-raltegravir)|ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
411855|NCT01048658|Drug|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
411856|NCT01048658|Other|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
411857|NCT01048645|Drug|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
411858|NCT01048645|Other|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
411859|NCT01048632|Drug|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
411860|NCT01048619|Drug|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
411861|NCT01048606|Behavioral|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
411863|NCT01048606|Other|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.~Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
411864|NCT01048593|Drug|IBI-10090|Single intraocular injection
411865|NCT01048580|Drug|Perifosine|Perifosine 50 mg orally once a day (Days 1-21)
411866|NCT01048580|Drug|Capecitabine|Capecitabine 1000 mg/m2 orally twice per day (Days 1-14)
411867|NCT01048567|Other|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
411868|NCT01048567|Other|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
411869|NCT01048554|Drug|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
411870|NCT01048554|Drug|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
411871|NCT01048541|Device|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
411872|NCT01048541|Device|SpeediCath|Catheter for intermittent catheterisation
411873|NCT01048528|Behavioral|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
411874|NCT01048515|Drug|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
411875|NCT01048502|Drug|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
411876|NCT01048502|Drug|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
411877|NCT01048502|Drug|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
411878|NCT01048489|Behavioral|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.~(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.~(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
411879|NCT01048476|Dietary Supplement|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
411880|NCT01048476|Dietary Supplement|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
411881|NCT01048476|Dietary Supplement|placebo|Dietary Supplement: placebo; daily supplementation one year
411882|NCT01048476|Drug|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
411883|NCT01048463|Drug|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
411884|NCT01048463|Drug|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
411885|NCT01048463|Drug|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
411886|NCT01048463|Drug|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
411887|NCT01048463|Drug|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
411888|NCT01048450|Radiation|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
411889|NCT01048450|Procedure|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
411890|NCT01048450|Procedure|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
411891|NCT01048437|Behavioral|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
411892|NCT01048437|Behavioral|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
411928|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
411929|NCT01048177|Drug|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
411930|NCT01048164|Procedure|Massage|Chair Massage
411931|NCT01048151|Biological|TNFerade™ Biologic|AdGVEGR.TNF.11D
412383|NCT01044693|Drug|Sildenafil25 mg|Sildenafil 25 mg single oral dose
411893|NCT01048424|Device|RESPeRATE|"RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate."
411894|NCT01048424|Other|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
411895|NCT01048411|Drug|Naja-comp.|homeopathic remedy
411896|NCT01048411|Drug|Placebo|s.c. injection of NaCl-solution three times a week
411897|NCT01048398|Drug|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
411898|NCT01048398|Drug|paracetamol|Control group: intravenous paracetamol 1g
411899|NCT01048385|Dietary Supplement|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
411900|NCT01048385|Dietary Supplement|Placebo|Treated with capsules containing the vehicle (Sesame oil).
411901|NCT01048359|Behavioral|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
411902|NCT01048359|Behavioral|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
411903|NCT01048359|Behavioral|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
411904|NCT01048346|Behavioral|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
411905|NCT01048333|Drug|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
411906|NCT01048333|Drug|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
411907|NCT01048333|Drug|Placebo|Placebo Diskus and Placebo Turbuhaler
411908|NCT01048320|Drug|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.~Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:~Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
411909|NCT01048320|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
411910|NCT01048320|Drug|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.~Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
411911|NCT01048307|Device|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):~• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound~Saline (control group):~cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;~placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;~fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
411912|NCT01048294|Device|Original Energy Light,|9000 lux, 30 minutes in the morning
411913|NCT01048294|Device|Original Energy Light prototype|9000 lux 20 minutes in the morning
411914|NCT01048294|Device|Original Energy Light prototype|9000 lux 30 minutes in the morning
411915|NCT01048281|Procedure|Blood draw|
411916|NCT01048281|Procedure|Tissue tumor biopsy|
411917|NCT01048268|Drug|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.~For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
411918|NCT01048268|Drug|Placebo|copy GIP infusion rates
411919|NCT01048255|Drug|VX-765|300mg Oral Tablet, 900mg TID
411920|NCT01048242|Drug|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
411921|NCT01048242|Drug|Placebo|placebo
411922|NCT01048229|Drug|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
411923|NCT01048229|Drug|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
411924|NCT01048216|Radiation|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
411925|NCT01048203|Drug|ABR-215050|1 mg ABR-215050
411926|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
411927|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
411935|NCT01048125|Behavioral|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
411936|NCT01048125|Drug|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
411937|NCT01048125|Other|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
411938|NCT01048125|Device|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
411939|NCT01048112|Biological|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
411940|NCT01048099|Procedure|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
411941|NCT01048099|Drug|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
411942|NCT01048099|Drug|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
411943|NCT01048086|Drug|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children <12 kg.
411944|NCT01048086|Drug|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
411945|NCT01048060|Procedure|Bone marrow specimen banking|
411946|NCT01048047|Drug|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
411947|NCT01048034|Drug|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
411948|NCT01048034|Drug|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
411949|NCT01048021|Procedure|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.~At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
411950|NCT01048008|Drug|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.~At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.~The MTD will be where 2 DLTs are noted and the study is discontinued."
411951|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
411952|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days~Phase 2~Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days~Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
411953|NCT01047982|Dietary Supplement|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
411954|NCT01047982|Other|folic acid 400 mcg|2 pills a day
411955|NCT01047969|Drug|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
411956|NCT01047969|Procedure|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
411957|NCT01047956|Drug|Methadone; NAC|Methadone NAC
411958|NCT01047956|Drug|Methadone|Methadone
411959|NCT01047943|Drug|Topical application of STA-21 ointment for treatment of psoriasis|
411960|NCT01047930|Behavioral|Exercise|"Each 3-day experimental period will include one of the following conditions:~Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;~Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;~No exercise - subject will watch television or read and they will be required to remain sedentary."
411961|NCT01047917|Behavioral|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
411962|NCT01047904|Device|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
411963|NCT01047891|Drug|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
412116|NCT01046773|Drug|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
411964|NCT01047852|Procedure|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
411965|NCT01047839|Biological|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
411966|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
411967|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
411968|NCT01047826|Procedure|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
411969|NCT01047826|Procedure|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
411970|NCT01047800|Behavioral|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:~First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions~Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
411971|NCT01047787|Other|Polysomnography|examination for sleep disorders
411972|NCT01047774|Dietary Supplement|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
411973|NCT01047774|Dietary Supplement|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
411974|NCT01047761|Other|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity~Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
411975|NCT01047748|Drug|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
411976|NCT01047748|Drug|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
411977|NCT01047735|Procedure|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
411978|NCT01047735|Procedure|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
411979|NCT01047735|Behavioral|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
411980|NCT01047722|Drug|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
411981|NCT01047722|Procedure|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
411982|NCT01047709|Device|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
411983|NCT01047696|Device|Plancha|locally developed chimney stove
411984|NCT01047683|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) 4 capsules/day for 40 weeks (Weeks 13-52)
411985|NCT01047683|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 2 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) 4 capsules/day for 40 weeks (Weeks 13-52)
411986|NCT01047683|Drug|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) for 40 weeks (Weeks 13-52)
411987|NCT01047683|Drug|Placebo|Placebo 2 capsules/day for 12 weeks (Weeks 1-12)
411988|NCT01047670|Drug|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
411989|NCT01047657|Behavioral|Low caloric diet plus orlistat and sibutramine|All subjetcs
411990|NCT01047644|Other|Reduced port-flush schedule|3-month port-flushing
411991|NCT01047631|Behavioral|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Exercise classes & activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.~Follow-up:~-Monthly phone calls during the 12 week follow up period."
412117|NCT01046773|Drug|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
412118|NCT01046760|Behavioral|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
412382|NCT01044693|Drug|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
411992|NCT01047631|Behavioral|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.~Measure general fitness levels such as walking, strength and balance.~Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.~Blood and urine tests and a heart ultrasound.~Questionnaires & activity measures.~Group assignment for 12 weeks:~-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.~Follow-up:~-No follow up support"
411993|NCT01047605|Drug|Neurapas balance|6 tablets single dose
411994|NCT01047605|Drug|Pascoflair 425 mg|3 tablets , single dose
411995|NCT01047605|Drug|P-Tabletten weiß|3 tablets, single dose
411996|NCT01047592|Drug|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
411997|NCT01047592|Drug|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
411998|NCT01047592|Drug|placebo|placebo,oral, for 12 weeks
411999|NCT01047579|Drug|Rivastigmine transdermal|
412000|NCT01047566|Drug|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
412001|NCT01047566|Drug|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
412002|NCT01047553|Drug|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
412003|NCT01047540|Drug|AIC316|Oral administration
412004|NCT01047540|Drug|AIC316|Oral administration
412005|NCT01047540|Drug|AIC316|Oral administration
412006|NCT01047540|Drug|AIC316|Oral administration
412007|NCT01047540|Drug|Placebo|Oral administration
412008|NCT01047527|Drug|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
412009|NCT01047514|Behavioral|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
412010|NCT01047501|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
412011|NCT01047501|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 2 capsules/day for 12 weeks
412012|NCT01047501|Drug|Placebo|Placebo 4 capsules/day for 12 weeks
412013|NCT01047501|Drug|Placebo|Placebo 2 capsules/day for 12 weeks
412014|NCT01047488|Drug|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
412015|NCT01047488|Drug|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
412016|NCT01047488|Drug|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
412017|NCT01047488|Drug|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
412018|NCT01047475|Drug|MB-6|6# TID with meal
412019|NCT01047475|Drug|Placebo|6# TID with meal
412020|NCT01047462|Procedure|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
412021|NCT01047449|Procedure|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
412022|NCT01047449|Dietary Supplement|Fish oil supplementation vs placebo|Fish oil supplementation [1g tablets (55% fish oils - EPA:DHA 33%:22%)] taken twice daily for 1 year post-op
412023|NCT01047436|Drug|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
412024|NCT01047436|Drug|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
412025|NCT01047423|Drug|Simvastatin|40mg encapsulated once daily for 12 weeks
412026|NCT01047423|Drug|Placebo|Encapsulated oral once daily for 12 weeks
412027|NCT01047410|Other|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
412028|NCT01047410|Other|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
412029|NCT01047397|Drug|1278863A|25mg, 50mg, 100mg
412030|NCT01047397|Drug|Placebo|matching placebo
412031|NCT01047384|Procedure|acupuncture-moxibustion therapy|
412032|NCT01047384|Procedure|Regular therapy|
412033|NCT01047358|Drug|Aromasin|25 mg table QD
412034|NCT01047358|Drug|Aromasin|25 mg table QD
412035|NCT01047345|Biological|V503|V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
412036|NCT01047345|Biological|Placebo to V503|Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
412037|NCT01047332|Device|Partially Covered Wallstent|Partially covered wallstent
412038|NCT01047332|Device|Uncovered Wallstent|Uncovered wallstent
412039|NCT01047319|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
412040|NCT01047306|Other|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
412154|NCT01046487|Procedure|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :~11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
412041|NCT01047293|Drug|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~Directly on the tumor cells by inhibiting tumor cell growth and proliferation~Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
412042|NCT01047293|Drug|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
412043|NCT01047293|Drug|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
412044|NCT01047280|Dietary Supplement|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
412045|NCT01047280|Dietary Supplement|Safflower oil|3.5 g/d of safflower oil
412046|NCT01047280|Dietary Supplement|G-c9, t11|3.5 g/day of c9, t11 CLA
412047|NCT01047254|Drug|Elontril|flexible dose of Bupropion 150-300 mg
412048|NCT01047254|Drug|placebo|
412049|NCT01047241|Drug|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
412050|NCT01047215|Drug|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
412051|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
412052|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
412053|NCT01047202|Biological|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
412054|NCT01047189|Drug|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
412055|NCT01047189|Drug|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
412056|NCT01047189|Drug|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
412057|NCT01047137|Behavioral|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
412058|NCT01047137|Behavioral|General Supportive Therapy|There is no focus on stress intervention.
412059|NCT01047124|Other|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
412060|NCT01047111|Procedure|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
412061|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
412062|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
412063|NCT01047098|Dietary Supplement|Placebo|Placebo capsule
412064|NCT01047085|Procedure|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
412065|NCT01047072|Drug|fludarabine phosphate|Given IV
412066|NCT01047072|Radiation|total-body irradiation|Undergo total-body irradiation
412067|NCT01047072|Drug|tacrolimus|Given orally
412068|NCT01047072|Drug|mycophenolate mofetil|Given orally
412069|NCT01047072|Biological|rituximab|Given IV
412070|NCT01047072|Drug|cyclophosphamide|Given orally
412071|NCT01047072|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
412072|NCT01047072|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
412073|NCT01047059|Drug|Erlotinib, Bevacizumab|Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
412074|NCT01047059|Drug|Fluoro-D-glucose|Tracer for PET imaging
412075|NCT01047059|Drug|Fluoro-L-thymidine|FLT-PET tracer for imaging
412076|NCT01047059|Drug|Gadolinium-DPTA|Contrast agent for DCE-MRI imaging
412203|NCT01046097|Biological|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
412204|NCT01046084|Drug|Lansoprazole|30 mg Delayed-Release Capsule
412205|NCT01046084|Drug|Prevacid®|30 mg Delayed-Release Capsule
412206|NCT01046071|Procedure|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
412077|NCT01047046|Other|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.~The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
412078|NCT01047033|Behavioral|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
412079|NCT01047033|Other|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
412080|NCT01047007|Drug|MK-1775 20 mg|MK-1775 20 mg capsule administered orally on days 1-5 of a 21 day cycle.
412081|NCT01047007|Drug|5-FU 1000 mg/m^2/day|5-FU 1000 mg/m^2/day administered as an intravenous (IV) infusion on Days 1-4 of a 21-day cycle
412082|NCT01047007|Drug|CDDP|CDDP 60 mg/m^2 to 100 mg/m^2 administered as an IV infusion on Day 1.
412083|NCT01047007|Drug|MK-1775 65 mg|MK-1775 65 mg capsule administered orally on days 1-5 of a 21 day cycle.
412084|NCT01046994|Procedure|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
412085|NCT01046994|Drug|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
412086|NCT01046981|Procedure|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
412087|NCT01046981|Procedure|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
412088|NCT01046968|Dietary Supplement|Lepticore|300 mg twice daily
412089|NCT01046955|Drug|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
412090|NCT01046942|Drug|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
412091|NCT01046942|Drug|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
412092|NCT01046929|Dietary Supplement|limonene|oral dosing at 2 gram QD
412093|NCT01046916|Drug|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
412094|NCT01046903|Drug|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
412095|NCT01046890|Drug|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
412096|NCT01046877|Device|Tympanostomy Tube Delivery System|Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
412097|NCT01046864|Drug|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
412098|NCT01046864|Drug|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
412099|NCT01046864|Drug|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
412100|NCT01046864|Drug|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
412101|NCT01046864|Drug|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
412102|NCT01046864|Drug|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
412103|NCT01046864|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
412104|NCT01046851|Drug|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
412105|NCT01046851|Drug|Placebo|Placebo in a manner similar to the active comparator
412106|NCT01046838|Drug|Sildenafil|40 mg three times daily for 9 weeks
412107|NCT01046838|Drug|Placebo|tablet 3 times daily for 9 weeks
412108|NCT01046825|Drug|COPAD|Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF
412109|NCT01046825|Drug|COP, COPD M3, CYM|GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab
412110|NCT01046825|Drug|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.~COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.~COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, Rituximab, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, Rituximab, G-CSF.~Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.~Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.~Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications."
412111|NCT01046812|Drug|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
412112|NCT01046799|Drug|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
412113|NCT01046786|Biological|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
412114|NCT01046786|Drug|Methylprednisolone|30 mg/kg methylprednisolone
412115|NCT01046786|Drug|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
412119|NCT01046747|Procedure|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
412120|NCT01046721|Drug|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
412121|NCT01046721|Drug|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
412122|NCT01046708|Drug|micronized progesterone|600mg in 3 separate doses per day
412123|NCT01046695|Device|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
412124|NCT01046682|Drug|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
412125|NCT01046669|Device|TORAYMYXIN PMX-20R (PMX cartridge)|TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
412126|NCT01046669|Other|Standard medical care for septic shock|Standard medical care for septic shock
412127|NCT01046656|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
412128|NCT01046643|Drug|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
412129|NCT01046643|Drug|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
412130|NCT01046643|Drug|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
412131|NCT01046630|Drug|AZD6765|single infusion
412132|NCT01046630|Drug|Ketamine|single infusion
412133|NCT01046630|Drug|Placebo|single infusion
412134|NCT01046617|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
412135|NCT01046604|Drug|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
412136|NCT01046591|Procedure|Polysomnography|Overnight sleep studies will be performed on all children.
412137|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
412138|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
412139|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
412140|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
412141|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
412142|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
412143|NCT01046565|Drug|adapalene cream 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
412144|NCT01046565|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
412145|NCT01046552|Procedure|preoperative ERCP and LC|preoperative ERCP followed by LC
412146|NCT01046552|Procedure|Intraoperative ERCP and LC|LC and intraoperative ERCP
412147|NCT01046539|Drug|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
412148|NCT01046539|Drug|Placebo|0 mg
412149|NCT01046500|Dietary Supplement|myo-inositol|2 grams twice a day
412150|NCT01046500|Drug|Metformin|pill, 250 mg, twice a day
412151|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
412152|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
412153|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):~Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
412207|NCT01046071|Procedure|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
412208|NCT01046058|Drug|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
412155|NCT01046474|Behavioral|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.~Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.~Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
412156|NCT01046461|Drug|Ramosetron, Aprepitant, Dexamethasone|"Day 1:~Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy~Day 2 - 3:~Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning~Day 4 Dexamethasone 8 mg PO. in the morning"
412157|NCT01046435|Procedure|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
412158|NCT01046435|Procedure|Two placebos|Two placebos 3 times a day for 7 days
412159|NCT01046422|Drug|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
412160|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
412161|NCT01046422|Drug|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
412162|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
412163|NCT01046422|Drug|Placebo|Capsule, Oral, 0mg, Daily, 28 days
412164|NCT01046422|Drug|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
412165|NCT01046409|Other|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
412166|NCT01046396|Drug|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
412167|NCT01046396|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
412168|NCT01046383|Dietary Supplement|IMN1207|20 grams of IMN1207 per day for 40 weeks.
412169|NCT01046383|Dietary Supplement|Casein|20 grams of Casein per day for 40 weeks
412170|NCT01046370|Behavioral|Amygdala Retraining Program|Mind-body intervention.
412171|NCT01046357|Drug|AZD7687|Single oral dose
412172|NCT01046357|Drug|Placebo|Single oral dose
412173|NCT01046318|Drug|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
412174|NCT01046305|Behavioral|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
412175|NCT01046305|Behavioral|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
412176|NCT01046305|Behavioral|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
412177|NCT01046292|Drug|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
412178|NCT01046279|Drug|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
412179|NCT01046266|Drug|RO5083945|700mg iv weekly
412180|NCT01046266|Drug|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
412181|NCT01046253|Drug|Lansoprazole|30 mg Delayed-Release Capsules
412182|NCT01046253|Drug|Prevacid®|30 mg Delayed-Release Capsule
412183|NCT01046240|Drug|Palonosetron|Palonosetron 3 mg administered SC or IV
412184|NCT01046227|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
412185|NCT01046214|Drug|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
412186|NCT01046214|Drug|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
412187|NCT01046188|Other|Knowledge Questionnaire|Administered before and after teaching intervention
412188|NCT01046188|Other|Perceived Stress Scale|Administered before and after teaching intervention
412189|NCT01046188|Other|Satisfaction questionnaire|Administered after the intervention and at study completion
412190|NCT01046188|Other|Web-based IVF teaching|Web-based IVF teaching
412191|NCT01046188|Other|Didactic lecture|Didactic lecture
412192|NCT01046175|Procedure|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
412193|NCT01046175|Procedure|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
412194|NCT01046162|Drug|Alprazolam|Single tablet
412195|NCT01046162|Drug|Alprazolam|Single tablet
412196|NCT01046149|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
412197|NCT01046149|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
412198|NCT01046136|Drug|guaifenesin (Mucinex)|bid 7 days
412199|NCT01046136|Drug|placebo|bid 7 days
412200|NCT01046123|Radiation|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
412201|NCT01046110|Drug|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
412202|NCT01046110|Drug|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
412209|NCT01046045|Drug|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
412210|NCT01046032|Drug|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
412211|NCT01046032|Drug|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
412212|NCT01046006|Drug|Bortezomib, Rituximab, Dexamethasone|"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.~On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.~Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"
412213|NCT01045993|Device|Heat Device|8-Hour Heatwrap
412214|NCT01045993|Device|Sham Device|Inactive wrap worn for 8 hours
412215|NCT01045993|Drug|marketed analgesic|2 x 200 mg ibuprofen tablets
412216|NCT01045993|Drug|Placebo|2 x placebo tablets
412217|NCT01045980|Drug|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
412218|NCT01045980|Drug|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
412219|NCT01045980|Drug|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
412220|NCT01045980|Device|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
412221|NCT01045967|Drug|Lansoprazole|30 mg delayed-release Capsule
412222|NCT01045967|Drug|Prevacid®|30 mg delayed-release Capsule
412223|NCT01045954|Drug|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
412224|NCT01045941|Drug|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
412225|NCT01045941|Procedure|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
412226|NCT01045928|Drug|lenalidomide|Given orally
412227|NCT01045928|Biological|rituximab|Given IV
412228|NCT01045928|Genetic|polymerase chain reaction|Correlative study
412229|NCT01045928|Genetic|nucleic acid sequencing|Correlative study
412230|NCT01045928|Genetic|polymorphism analysis|Correlative study
412231|NCT01045928|Other|flow cytometry|Correlative study
412232|NCT01045928|Other|laboratory biomarker analysis|Correlative study
412233|NCT01045915|Biological|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
412234|NCT01045902|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
412235|NCT01045902|Drug|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
412236|NCT01045889|Other|Rituximab and CHOP regimen + PBSCT|
412237|NCT01045876|Drug|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
412238|NCT01045876|Other|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
412239|NCT01045863|Drug|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
412240|NCT01045863|Drug|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
412241|NCT01045863|Drug|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
412242|NCT01045863|Drug|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
412243|NCT01045863|Drug|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
412244|NCT01045837|Drug|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
412245|NCT01045837|Behavioral|Gluten free diet|Only gluten free diet will be given in this group
412246|NCT01045811|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
412247|NCT01045811|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
412248|NCT01045798|Drug|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
412249|NCT01045798|Drug|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
412250|NCT01045772|Drug|rilonacept|160mg of rilonacept 1x/week
412251|NCT01045746|Device|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
412252|NCT01045746|Device|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
412253|NCT01045733|Device|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
412254|NCT01045733|Device|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
412255|NCT01045733|Procedure|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
412256|NCT01045720|Drug|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
412257|NCT01045720|Drug|Placebo|Placebo (starch)
412258|NCT01045707|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
412259|NCT01045707|Drug|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
412260|NCT01045694|Drug|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
412261|NCT01045694|Drug|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
412262|NCT01045694|Drug|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
412263|NCT01045681|Drug|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
412264|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
412265|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
412266|NCT01045655|Behavioral|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
412267|NCT01045642|Drug|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
412268|NCT01045629|Other|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
412269|NCT01045590|Drug|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
412270|NCT01045590|Drug|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
412271|NCT01045577|Drug|Masitinib|6 mg/kg/day
412272|NCT01045577|Drug|Masitinib|3 mg/kg/day
412273|NCT01045577|Drug|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
412274|NCT01045564|Biological|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
412275|NCT01045551|Drug|Apremilast|20mg taken orally twice per day for 12 weeks
412276|NCT01045538|Drug|Vorinostat, capecitabine, and cisplatin|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
412277|NCT01045525|Procedure|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
412278|NCT01045525|Behavioral|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
412279|NCT01045512|Drug|fluvastatin|40-80mg once daily
412280|NCT01045499|Device|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
412281|NCT01045486|Drug|ATP mixed probiotics|- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
412282|NCT01045486|Drug|Placebo|- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
412283|NCT01045460|Biological|Activated marrow infiltrating lymphocytes|Administered on Days 3 and 4.
412284|NCT01045460|Biological|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine. Administered on Days 21, 60, 180, and 300.
412285|NCT01045460|Drug|Cyclophosphamide|Administered at 2.5 g/m^2.
412286|NCT01045460|Biological|Filgrastim|Administered post cyclophosphamide daily until leukapheresis.
412287|NCT01045460|Procedure|Leukapheresis|Performed approximately 12 days post cyclophosphamide. Exact date depends on peripheral blood CD34+ cell counts.
412288|NCT01045460|Drug|Melphalan|100 mg/m^2/day given on Days -2 and -1.
412289|NCT01045460|Biological|Autologous stem cell transplant|Infused on Day 0.
412290|NCT01045447|Drug|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
412291|NCT01045447|Drug|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
412292|NCT01045434|Drug|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
412335|NCT01045083|Drug|placebo|Oral single dose
412293|NCT01045421|Drug|MLN8237 (Alisertib)|"Phase 1:~MLN8237 will be administered orally twice a day on a 7-day dosing schedule~Phase 2:~MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
412294|NCT01045408|Dietary Supplement|Berry extract|Berry extract for weeks
412295|NCT01045395|Dietary Supplement|Corn starch|90mg/d
412296|NCT01045395|Dietary Supplement|Unique Marine Algae Concentrate (UMAC)|90mg/d
412297|NCT01045395|Dietary Supplement|Golden brown algae|90mg/d
412298|NCT01045382|Biological|Mesenchymal stem cells|Mesenchymal stem cell injection
412299|NCT01045382|Other|Isotonic solution|Isotonic solution injection
412300|NCT01045369|Drug|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
412301|NCT01045343|Other|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
412302|NCT01045343|Other|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
412303|NCT01045330|Behavioral|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
412304|NCT01045317|Drug|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
412305|NCT01045304|Drug|Iniparib|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
412306|NCT01045304|Drug|Gemcitabine|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
412307|NCT01045304|Drug|Carboplatin|"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
412308|NCT01045291|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
412309|NCT01045278|Drug|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
412310|NCT01045265|Other|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
412311|NCT01045239|Device|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
412312|NCT01045239|Device|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
412313|NCT01045226|Procedure|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
412314|NCT01045226|Other|Quality-of-Life assessment|Quality of Life Assessment
412315|NCT01045226|Other|Questionnaire Administration|Questionnaire Administration
412316|NCT01045213|Other|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
412317|NCT01045200|Other|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
412318|NCT01045187|Radiation|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
412319|NCT01045187|Radiation|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
412320|NCT01045174|Device|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
412321|NCT01045161|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.
412322|NCT01045161|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
412323|NCT01045148|Radiation|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
412324|NCT01045148|Radiation|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
412325|NCT01045122|Drug|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
412326|NCT01045122|Drug|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
412327|NCT01045109|Dietary Supplement|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
412328|NCT01045109|Dietary Supplement|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
412329|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
412330|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
412331|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
412332|NCT01045083|Drug|RO4917523|Oral single dose
412333|NCT01045083|Drug|escitalopram|Oral single dose
412334|NCT01045083|Drug|methylphenidate|Oral single dose
412336|NCT01045057|Device|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
412337|NCT01045018|Drug|Placebo|placebo 400 mg
412338|NCT01045018|Drug|Mesalamine|
412339|NCT01045018|Drug|Mesalamine|
412340|NCT01045005|Other|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non−harmful/non−toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
412341|NCT01045005|Other|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non−harmful/non−toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
412342|NCT01044992|Radiation|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
412343|NCT01044992|Drug|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
412344|NCT01044966|Drug|ITV DepoCyt + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
412345|NCT01044953|Other|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
412346|NCT01044927|Other|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
412347|NCT01044927|Other|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
412348|NCT01044901|Procedure|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
412349|NCT01044888|Drug|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
412350|NCT01044875|Procedure|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
412351|NCT01044862|Drug|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
412352|NCT01044862|Drug|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
412353|NCT01044862|Drug|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
412354|NCT01044836|Biological|HD203|Injectable form
412355|NCT01044823|Other|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
412356|NCT01044810|Drug|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
412357|NCT01044771|Drug|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
412358|NCT01044758|Drug|Levetiracetam 62.5mg|62.5mg twice daily (2 weeks)
412359|NCT01044758|Drug|Levetiracetam 125mg|125mg twice daily (2 weeks)
412360|NCT01044758|Drug|Levetiracetam 250mg|250mg twice daily (2 weeks)
412361|NCT01044758|Drug|Placebo|placebo capsule twice daily (2 weeks)
412362|NCT01044745|Drug|rituximab|Given IV
412363|NCT01044745|Drug|mycophenolate mofetil|Given IV or PO
412364|NCT01044745|Drug|tacrolimus|Given IV
412365|NCT01044745|Drug|anti-thymocyte globulin|Given IV
412366|NCT01044745|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
412367|NCT01044745|Other|laboratory biomarker analysis|Correlative studies
412368|NCT01044745|Biological|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
412369|NCT01044745|Drug|cyclophosphamide|Given PO or IV
412370|NCT01044745|Drug|fludarabine phosphate|Given IV
412371|NCT01044745|Drug|busulfan|Given IV
412372|NCT01044745|Radiation|total-body irradiation|Undergo TBI
412373|NCT01044745|Biological|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
412374|NCT01044745|Biological|immunosuppressive therapy|Undergo immunosuppressive therapy
412375|NCT01044732|Device|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
412376|NCT01044719|Drug|Ceftazidime|Ceftazidime 2g TDS IV
412377|NCT01044719|Drug|Tobramycin|Tobramycin 7mg/kg/day OD IV
412378|NCT01044719|Drug|Meropenem|Meropenem 2g TDS IV
412379|NCT01044706|Drug|Bicalutamide|50 mg Oral Tablet
412380|NCT01044693|Drug|Placebo|Placebo capsule
412384|NCT01044680|Dietary Supplement|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
412385|NCT01044680|Dietary Supplement|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
412386|NCT01044667|Behavioral|GI and Quality of Life Assessment|
412387|NCT01044654|Genetic|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
412388|NCT01044628|Device|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
412389|NCT01044628|Device|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
412390|NCT01044602|Other|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
412391|NCT01044602|Other|Best Medical Management|Standard of care.
412392|NCT01044602|Procedure|Roux-en-Y gastric bypass surgery|Surgical treatment.
412393|NCT01044589|Device|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
412394|NCT01044589|Other|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
412395|NCT01044563|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
412396|NCT01044563|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
412397|NCT01044550|Procedure|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
412398|NCT01044550|Other|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
412399|NCT01044537|Drug|Placebo|Placebo to match PF-04937319 will be provided.
412400|NCT01044537|Drug|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
412401|NCT01044524|Radiation|SLV 334|2000 mg via i.v. solution
412402|NCT01044511|Behavioral|Home visits|home visits by specialist nurse 2 times and 1 phonecall
412403|NCT01044511|Behavioral|standard|hotline
412404|NCT01044498|Drug|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
412405|NCT01044498|Drug|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
412406|NCT01044485|Drug|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
412407|NCT01044485|Drug|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
412408|NCT01044459|Drug|Aclidinium Bromide 200 µg|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
412409|NCT01044459|Drug|Aclidinium Bromide 400 µg|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
412410|NCT01044446|Drug|Icodextrin|one exchange daily
412411|NCT01044446|Drug|glucose-based peritoneal dialysate|original exchange frequency
412412|NCT01044433|Drug|lapatinib ditosylate|Given orally
412413|NCT01044433|Drug|capecitabine|Given orally
412414|NCT01044420|Drug|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
412415|NCT01044407|Device|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
412416|NCT01044394|Drug|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
412417|NCT01044381|Drug|Luliconazole Solution, 10%|28 days of daily application
412418|NCT01044368|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
412419|NCT01044355|Device|CPAP|6 weeks treatment with fixed CPAP
412420|NCT01044355|Device|APAP|6 weeks of treatment with auto-titrating positive airway pressure
412421|NCT01044342|Drug|AZD1446|capsule; single oral dose
412422|NCT01044342|Drug|AZD1446|capsule, single oral dose
412423|NCT01044342|Drug|donepezil|capsule, single oral dose
412424|NCT01044342|Drug|Placebo|capsule, single oral dose
412425|NCT01044329|Drug|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
412426|NCT01044329|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
412427|NCT01044316|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
412428|NCT01044303|Drug|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
412429|NCT01044290|Other|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
412430|NCT01044290|Other|Attention Control|Subjects listened to a non-guided relaxation CD
412431|NCT01044277|Drug|Glutathione supplementation|500 mg, two times daily
412432|NCT01044277|Drug|Gluthathione peroxidases|125 mg, two times daily
412433|NCT01044277|Other|Placebo|2 times daily
412434|NCT01044264|Drug|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
412435|NCT01044264|Drug|Placebo|Placebo
412436|NCT01044251|Drug|Frovatriptan|2.5 mg po bid for 10 days
412437|NCT01044251|Drug|Placebo|1 tab po bid for 10 days
412438|NCT01044238|Drug|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
412439|NCT01044238|Drug|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
412440|NCT01044225|Drug|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
412441|NCT01044225|Drug|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
412442|NCT01044212|Drug|Docusate|Docusate 100mg BID
412443|NCT01044212|Drug|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
412444|NCT01044199|Biological|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
412445|NCT01044199|Biological|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
412446|NCT01044186|Drug|ICL670|
412447|NCT01044173|Device|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
412448|NCT01044147|Behavioral|VLM-S|Online program for weight loss - standard
412449|NCT01044147|Behavioral|VLM-M|Online program for weight loss - modulated
412450|NCT01044147|Behavioral|OGR|Online program for weight loss - resources
412451|NCT01044134|Behavioral|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
412452|NCT01044121|Other|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
412453|NCT01044108|Drug|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
412454|NCT01044108|Drug|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
412455|NCT01044108|Drug|placebo|Placebo will be administered as a comparator at each dose level.
412456|NCT01044095|Biological|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
412457|NCT01044095|Biological|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
412458|NCT01044082|Procedure|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
412459|NCT01044082|Procedure|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
412460|NCT01044069|Biological|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed & frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, & transduced with the 19-28z chimeric receptor & expanded. All relapsed (either MRD+ or morphologic) & refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo & highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
412461|NCT01044056|Drug|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
412462|NCT01044056|Drug|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
412463|NCT01044056|Drug|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
412464|NCT01044043|Procedure|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
412465|NCT01044030|Drug|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
412466|NCT01044030|Drug|Placebo|7.5 mL by mouth three times daily
412467|NCT01044017|Drug|Placebo|single oral dose
412468|NCT01044017|Drug|RO4998452|single oral doses
412469|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
412470|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
412471|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
412472|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
412473|NCT01043991|Drug|Darbepoetin alfa|
412474|NCT01043991|Drug|Placebo|
412475|NCT01043978|Behavioral|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
412476|NCT01043965|Drug|Metformin|Metformin 850mg
412477|NCT01043952|Drug|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
412478|NCT01043952|Drug|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
412479|NCT01043952|Device|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
412480|NCT01043939|Other|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
412481|NCT01043939|Other|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
412482|NCT01043926|Drug|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
412483|NCT01043913|Drug|Guarana extract|Guarana extract 50mg q12 hours for 21 days
412484|NCT01043900|Procedure|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
412485|NCT01043887|Drug|ridaforolimus|single oral dose administration 10 mg ridaforolimus
412486|NCT01043874|Drug|Nilotinib|400 mg BID
412487|NCT01043848|Procedure|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.~intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).~intervention device: contic+~stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
412488|NCT01043835|Procedure|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
412489|NCT01043835|Procedure|Open gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
412490|NCT01043809|Behavioral|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
412491|NCT01043809|Behavioral|expanded school-based handwashing promotion|Procter & Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
412492|NCT01043796|Other|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
412493|NCT01043796|Other|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
412494|NCT01043783|Other|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
412495|NCT01043770|Behavioral|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
412496|NCT01043757|Behavioral|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
412497|NCT01043744|Drug|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~1 tablet (for patients weighing 5-14 kg)~2 tablets (for patients weighing 15-24 kg)"
412498|NCT01043731|Procedure|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
412531|NCT01043484|Drug|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
412532|NCT01043471|Other|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
412533|NCT01043471|Other|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
412499|NCT01043718|Behavioral|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
412500|NCT01043718|Behavioral|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
412501|NCT01043692|Other|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
412502|NCT01043679|Drug|Utapine|Efficacy and Safety of Utapine
412503|NCT01043679|Drug|Seroquel|Efficacy and Safety of Seroquel
412504|NCT01043666|Drug|YM178|oral
412505|NCT01043666|Drug|Placebo|oral
412506|NCT01043666|Drug|tolterodine ER|oral
412507|NCT01043640|Drug|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
412508|NCT01043640|Drug|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
412509|NCT01043640|Drug|Busulfan|Administered every 6 hours: If < or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
412510|NCT01043640|Procedure|Allogeneic stem cell transplantation|Administered > 24 hours after last dose of busulfan.
412511|NCT01043640|Drug|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:~If body weight is ≤ 40 kg dosing will be 3 times daily~If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
412512|NCT01043640|Drug|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.
412513|NCT01043614|Behavioral|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
412514|NCT01043601|Drug|Inhaled PT005|inhaled, twice daily for 1 week duration
412515|NCT01043601|Drug|Inhaled Placebo|inhaled, twice daily for 1 week duration
412516|NCT01043601|Drug|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
412517|NCT01043588|Procedure|TURP|TransUrethral Resection of the Prostate
412518|NCT01043588|Procedure|PVP|Photo selective Vaporization of the Prostate
412519|NCT01043575|Drug|Rifapentine|During the first 8 weeks of therapy for TB participants > 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants < 45 kg participants will receive 450 mg orally given 5 days per week
412520|NCT01043575|Drug|Rifampin|During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
412521|NCT01043562|Diagnostic Test|Defibrillator threshold testing|Measurement of the defibrillation threshold was performed using a modified binary search protocol. This protocol specified three distinct inductions of ventricular fibrillation (VF) for all subjects, with a 3-5 minute observation/waiting period between inductions. The initial shock energy was programmed at 9 joules (J) for all patients, with internal rescue shocks at 31J followed by device-specific maximum deliverable energy. The outcome of the initial induction determined the programmed energies for both the initial and internal rescue shocks for the second induction, and likewise for the third induction. All shocks were biphasic and delivered at manufacturers' default tilt, polarity and duration, and all final programmed shock vectors included an active can. External defibrillation pads were in place for delivery of external rescue shock should the internal shocks fail.
412522|NCT01043562|Other|Observation of post-shock intrinsic cardiac rhythm|Prior to each of the three ventricular fibrillation inductions performed as part of the binary search protocol, post-shock pacing was re-programmed using a pre-determined, stepwise protocol that progressively decreased the lower rate limit. For the purpose of this protocol, post-shock pacing was considered necessary if 1) ≥7 ventricular-paced beats or 2) asystole >4 seconds was observed in the first 20 seconds after defibrillation, or if the systolic blood pressure demonstrated a >10% decrease from pre-induction baseline at follow-up measurement 1 minute post-defibrillation. Rescue ventricular pacing via the programmer was available for all subjects.
412523|NCT01043549|Device|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
412524|NCT01043549|Device|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
412525|NCT01043536|Radiation|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
412526|NCT01043536|Drug|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
412527|NCT01043523|Drug|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
412528|NCT01043510|Drug|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
412529|NCT01043510|Drug|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
412530|NCT01043484|Drug|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
412534|NCT01043458|Drug|ABT-126|ABT-126 Low Dose & ABT-126 High Dose
412535|NCT01043458|Drug|Placebo for ABT-126|Matching Placebo for Arms 1 & 2
412536|NCT01043445|Dietary Supplement|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
412537|NCT01043445|Dietary Supplement|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
412538|NCT01043445|Dietary Supplement|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
412539|NCT01043419|Drug|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
412540|NCT01043406|Device|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
412541|NCT01043393|Drug|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
412542|NCT01043380|Drug|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
412543|NCT01043380|Drug|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
412544|NCT01043367|Dietary Supplement|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
412545|NCT01043367|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
412546|NCT01043354|Behavioral|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
412547|NCT01043354|Behavioral|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
412548|NCT01043354|Behavioral|attention placebo intervention|6 monthly counseling sessions about general health topics
412549|NCT01043341|Behavioral|educative folder|folder about HPV infection and vaccines
412550|NCT01043289|Other|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
412551|NCT01043276|Drug|Treatment A|PF-00258210 220 µg using inhaler A
412552|NCT01043276|Drug|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
412553|NCT01043276|Drug|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
412554|NCT01043276|Drug|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
412555|NCT01043276|Drug|Treatment E|PF-00258210 220 µg using inhaler B
412556|NCT01043263|Drug|EN3324 (axomadol)|twice daily dosing
412557|NCT01043263|Drug|Placebo|twice daily dosing
412558|NCT01043224|Drug|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
412559|NCT01043211|Drug|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
412560|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
412561|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
412562|NCT01043198|Genetic|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)~Standardized screening with :~radiological (hands, feet, spine ; and renal ultrasonography)~biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
412563|NCT01043185|Drug|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
412564|NCT01043185|Drug|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
412565|NCT01043185|Drug|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
412566|NCT01043185|Drug|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
412567|NCT01043185|Drug|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
412568|NCT01043172|Drug|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
412569|NCT01043146|Drug|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
412570|NCT01043146|Drug|placebo|intravenous 0.9 % NaCl
412571|NCT01043133|Behavioral|social marketing-based medical education intervention|social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
412572|NCT01043120|Drug|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
412573|NCT01043120|Drug|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
412574|NCT01043094|Drug|Pitavastatin 4mg|Pitavastatin 4mg single dose
412575|NCT01043068|Drug|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
412576|NCT01043042|Other|No interventions will be used in this study|No interventions will be used in this study
412577|NCT01043029|Drug|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
412578|NCT01043029|Drug|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
412579|NCT01043016|Procedure|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
412580|NCT01043003|Other|educational intervention|Undergo Bilingual Breast Cancer Educational Intervention
412581|NCT01043003|Procedure|quality-of-life assessment|Ancillary studies
412582|NCT01043003|Other|Questionnaire Administration|Ancillary studies
412583|NCT01043003|Other|psychosocial support for caregiver|Support for caregiver
412584|NCT01043003|Procedure|assessment of therapy complications|Ancillary study
412585|NCT01043003|Other|informational intervention|Undergo evaluation sessions
412586|NCT01042990|Other|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
412587|NCT01042977|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
412588|NCT01042977|Drug|Placebo|matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
412589|NCT01042964|Drug|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
412590|NCT01042951|Biological|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
412591|NCT01042951|Other|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
412592|NCT01042938|Drug|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
412593|NCT01042938|Drug|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
412594|NCT01042925|Drug|XL147 (SAR245408)|administered orally once daily as tablet(s)
412595|NCT01042925|Biological|trastuzumab|administered by IV once every 3 weeks
412596|NCT01042925|Drug|paclitaxel|administered by IV once every week
412597|NCT01042899|Behavioral|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
412598|NCT01042899|Behavioral|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
412599|NCT01042899|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
412600|NCT01042886|Behavioral|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
412601|NCT01042886|Behavioral|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
412602|NCT01042873|Drug|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
412603|NCT01042860|Dietary Supplement|Lutein|Lutein supplement, 10 mg daily
412604|NCT01042860|Dietary Supplement|Placebo|Placebo
412605|NCT01042834|Other|Air pollution study on healthy volunteers.|"The subjects are examined three times:~First the volunteers get used to equipments.~Second and third the volunteers sleep in a pollution or purified air."
412606|NCT01042821|Procedure|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
412607|NCT01042821|Procedure|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
412608|NCT01042795|Drug|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
412609|NCT01042782|Drug|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)~Mitomycin C 5 mg/m2 i.v. every 3 weeks"
412610|NCT01042769|Drug|Aleglitazar|aleglitazar 150 micrograms po daily
412611|NCT01042769|Drug|Placebo|placebo control po daily
412612|NCT01042743|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
412613|NCT01042743|Procedure|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
412614|NCT01042730|Drug|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
412615|NCT01042717|Drug|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
412616|NCT01042704|Drug|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
412617|NCT01042704|Drug|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
412618|NCT01042704|Drug|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
412619|NCT01042704|Drug|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
412620|NCT01042704|Drug|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
412621|NCT01042704|Drug|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
412622|NCT01042704|Other|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
412623|NCT01042704|Other|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
412624|NCT01042704|Other|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
412625|NCT01042704|Other|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:~Physical exam~Performance status (check of ability to perform daily functions)~Recording of any new symptoms and any new medications being taken~Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)~Urine test (24hr urine)~Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).~A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
412626|NCT01042691|Drug|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
412627|NCT01042678|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye
412628|NCT01042665|Drug|latanoprost 0.005%|Active comparator
412629|NCT01042665|Drug|Placebo|Placebo comparator
412630|NCT01042652|Drug|Raltegravir|Raltegarvir 400mg bid
412631|NCT01042639|Behavioral|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
412632|NCT01042626|Other|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
412633|NCT01042613|Procedure|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
412634|NCT01042613|Procedure|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
412635|NCT01042600|Device|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
412636|NCT01042600|Device|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
412637|NCT01042587|Other|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
412638|NCT01042587|Other|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
412639|NCT01042574|Drug|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
412640|NCT01042561|Dietary Supplement|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
412641|NCT01042561|Dietary Supplement|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
412642|NCT01042535|Biological|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
412643|NCT01042535|Drug|1-methyl-d-tryptophan|Given orally (PO)
412644|NCT01042535|Other|Laboratory biomarker analysis|Correlative studies
412645|NCT01042522|Biological|Bleomycin Sulfate|Given IV
412646|NCT01042522|Drug|Carboplatin|Given IV
412647|NCT01042522|Drug|Cisplatin|Given IV
412648|NCT01042522|Drug|Etoposide Phosphate|Given IV
412649|NCT01042522|Other|Laboratory Biomarker Analysis|Correlative studies
412650|NCT01042522|Drug|Paclitaxel|Given IV
412651|NCT01042509|Drug|Alemtuzumab and rituximab|Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
412652|NCT01042496|Drug|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
412653|NCT01042496|Procedure|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
412654|NCT01042483|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
412655|NCT01042457|Drug|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
412656|NCT01042444|Device|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.~The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
412657|NCT01042431|Other|No Intervention|No intervention
412658|NCT01042418|Other|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
412659|NCT01042392|Drug|Aliskiren|150 mg Aliskiren as film-coated tablet
412660|NCT01042392|Drug|Ramipril|Ramipril 5 mg was given in capsule form.
412661|NCT01042392|Drug|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
412662|NCT01042392|Drug|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
412663|NCT01042379|Drug|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
412664|NCT01042379|Drug|AMG 386 with or without Trastuzumab|Arm is closed.
412665|NCT01042379|Drug|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
412666|NCT01042379|Drug|MK-2206 with or without Trastuzumab|Arm is closed.
412667|NCT01042379|Drug|AMG 386 and Trastuzumab|Arm is closed.
412668|NCT01042379|Drug|T-DM1 and Pertuzumab|Arm is closed.
412669|NCT01042379|Drug|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
412670|NCT01042379|Drug|Ganetespib|Arm is closed.
412671|NCT01042379|Drug|ABT-888|Arm is closed.
412672|NCT01042379|Drug|Neratinib|Arm is closed.
412673|NCT01042379|Drug|PLX3397|Arm is closed.
412674|NCT01042379|Drug|Pembrolizumab - 4 cycle|Arm is closed.
412675|NCT01042379|Drug|Talazoparib plus Irinotecan|Arm is closed.
412676|NCT01042379|Drug|Patritumab and Trastuzumab|Arm is closed.
412677|NCT01042379|Drug|Pembrolizumab - 8 cycle|Pembrolizumab: 200mg IV cycles 1,4,7,10,13,14,15,16 Paclitaxel: 80 mg/m2 IV cycles 1-12
412678|NCT01042379|Drug|SGN-LIV1A|SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
412679|NCT01042379|Drug|Durvalumab plus Olaparib|Durvalumab: 1500 mg IV cycles 1, 5 and 9 Olaparib: 200mg cycles 1-11, daily Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16
412680|NCT01042379|Drug|SD-101 + Pembrolizumab|SD-101: 2 mg/ml cycles 1,2,3,4,7,10 Pembrolizumab: 200mg cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16
412681|NCT01042379|Drug|Tucatinib|Tucatinib: 300mg BID cycles 1-12 Trastuzumab: 4 mg/kg (loading dose) cycle 1, 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg (loading dose) cycle 1, 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16
412682|NCT01042366|Biological|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
412683|NCT01042353|Procedure|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
412684|NCT01042353|Procedure|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
412685|NCT01042340|Other|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
412686|NCT01042327|Device|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
412687|NCT01042327|Device|Fresenius FX100 dialyzer|
412688|NCT01042314|Drug|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
412689|NCT01042314|Drug|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
412690|NCT01042301|Other|Blood samplings|
412691|NCT01042288|Drug|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
412692|NCT01042288|Drug|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
412693|NCT01042288|Drug|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
412694|NCT01042262|Other|Oxygen|100% Oxygen at a flow of 2 L/min
412695|NCT01042262|Other|Placebo|No oxygen flow
412696|NCT01042249|Other|Pelvic Floor Muscle training|12 week training program including home exercises
412697|NCT01042236|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
412698|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
412699|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
412700|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
412701|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
412702|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
412703|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
412704|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
412705|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
412706|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
412707|NCT01042184|Drug|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
412708|NCT01042184|Drug|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
412709|NCT01042184|Drug|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
412710|NCT01042158|Drug|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
412711|NCT01042145|Drug|Prednisone|2 mgs/kg for 3 days
412712|NCT01042145|Drug|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
412713|NCT01042132|Procedure|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
412714|NCT01042132|Procedure|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
412715|NCT01042106|Drug|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
412716|NCT01042106|Drug|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
412717|NCT01042093|Drug|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
412718|NCT01042093|Drug|Toradol|Toradol 30mg/ml (1 ml)
412719|NCT01042093|Drug|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
412720|NCT01042093|Drug|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
412721|NCT01042080|Device|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
412722|NCT01042080|Other|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
412723|NCT01042067|Other|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
412724|NCT01042054|Other|Standard optimised recovery protocol.|"Epidural analgesia for the first 48 hours postoperatively.~Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
412725|NCT01042054|Other|Wound catheter plus patient-controlled analgesia.|"Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.~Additional patient-controlled intravenous opiate analgesia available to patient during this time period.~Sham epidural catheter applied to the patient's back for purposes of blinding.~Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.~Optimised recovery protocol followed throughout."
412726|NCT01042041|Drug|sorafenib tosylate|Given orally
412727|NCT01042041|Drug|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
412728|NCT01042041|Drug|cisplatin|Given via transarterial/hepatic chemoembolization
412729|NCT01042041|Drug|mitomycin C|Given via transarterial/hepatic chemoembolization
412730|NCT01042041|Procedure|transarterial chemoembolization|
412731|NCT01042041|Procedure|hepatic artery embolization|
412732|NCT01042028|Drug|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
412733|NCT01042028|Drug|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
412734|NCT01042015|Combination Product|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
412735|NCT01042015|Other|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
412736|NCT01042002|Behavioral|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
412737|NCT01041989|Behavioral|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
412738|NCT01041989|Behavioral|Exercise|Guided muscle strength training and aerobic exercise.
412739|NCT01041989|Behavioral|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
412740|NCT01041989|Other|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
412741|NCT01041976|Behavioral|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
412742|NCT01041976|Behavioral|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
412743|NCT01041963|Drug|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
412744|NCT01041963|Drug|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
412745|NCT01041963|Drug|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
412746|NCT01041950|Procedure|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
412747|NCT01041937|Procedure|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
412748|NCT01041937|Procedure|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
412749|NCT01041924|Other|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
412750|NCT01041924|Other|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
412751|NCT01041911|Drug|Euphorbia tablets|50 mg, tablet, once daily, 14 days
412752|NCT01041911|Drug|Euphorbia tablets|100 mg, tablet, once daily, 14 days
412753|NCT01041911|Drug|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
412754|NCT01041911|Drug|Placebo tablets|placebo, tablet, once daily, 14 days
412755|NCT01041885|Device|INSTRUCT|INSTRUCT PolyActive scaffold implantation
412756|NCT01041872|Drug|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
412757|NCT01041872|Drug|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
412758|NCT01041872|Drug|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
412759|NCT01041872|Drug|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
412760|NCT01041872|Drug|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
412761|NCT01041872|Drug|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
412762|NCT01041859|Drug|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
412763|NCT01041859|Drug|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
412764|NCT01041846|Drug|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
412765|NCT01041833|Drug|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
412766|NCT01041833|Drug|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
412767|NCT01041820|Behavioral|Exercise|Children will be exposed to a 10-week exercise intervention
412768|NCT01041807|Drug|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
412769|NCT01041781|Drug|carboplatin|Given IV
412770|NCT01041781|Drug|celecoxib|Given orally
412771|NCT01041781|Drug|gemcitabine hydrochloride|Given IV
412772|NCT01041781|Drug|pemetrexed disodium|Given IV
412773|NCT01041781|Other|placebo|Given orally
412774|NCT01041768|Procedure|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
412775|NCT01041755|Drug|L-ornithine-L-aspartate|a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
412776|NCT01041755|Drug|Lactose|a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
413040|NCT01039675|Drug|Placebo once daily|Inactive, excipients only
412777|NCT01041742|Procedure|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
412778|NCT01041729|Drug|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
412779|NCT01041729|Drug|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment."
412780|NCT01041716|Other|None - Observational study|None - Observational study
412781|NCT01041690|Drug|Bevacizumab|
412782|NCT01041677|Drug|R256918|10 mg capsule twice daily
412783|NCT01041677|Drug|placebo|placebo capsule twice daily
412784|NCT01041677|Drug|R256918|15 mg capsule twice daily
412785|NCT01041638|Biological|Aldesleukin|Given IV
412786|NCT01041638|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
412787|NCT01041638|Biological|Dinutuximab|Given IV
412788|NCT01041638|Drug|Isotretinoin|Given PO
412789|NCT01041638|Biological|Sargramostim|Given IV or SC
412790|NCT01041625|Drug|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
412791|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
412792|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
412793|NCT01041586|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
412794|NCT01041573|Biological|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
412795|NCT01041573|Biological|Havrix®720|0.5 ml im. at day 0 and month 7
412796|NCT01041573|Biological|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
412797|NCT01041534|Other|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
412798|NCT01041521|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
412799|NCT01041508|Drug|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry.
412800|NCT01041508|Radiation|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
412801|NCT01041508|Other|Stem Cell Infusion|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
412802|NCT01041508|Drug|Cyclosporins|"Cyclosporin (CSP) should be started on day -1 after completion of Clofarabine. CSP levels should be maintained between 300-400 ng/ml.~Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs). Age > 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)"
412803|NCT01041508|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) will be at 15 mg/kg, based on adjusted body weight, every 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant.
412804|NCT01041495|Drug|cyclobenzaprine ER (AMRIX)|active drug
412805|NCT01041495|Drug|placebo|matching placebo for AMRIX
412806|NCT01041482|Drug|sorafenib|sorafenib 400mg twice daily
412807|NCT01041443|Drug|5-fluoro-2-deoxycytidine|Given IV
412808|NCT01041443|Drug|tetrahydrouridine|Given IV
412809|NCT01041443|Other|laboratory biomarker analysis|Correlative studies
412810|NCT01041443|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
412811|NCT01041443|Genetic|DNA methylation analysis|Correlative studies
412812|NCT01041430|Other|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
412813|NCT01041430|Other|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
412814|NCT01041417|Drug|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
412815|NCT01041417|Drug|Placebo|Saline injection
412816|NCT01041404|Drug|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
412817|NCT01041404|Drug|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
412818|NCT01041404|Drug|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
412819|NCT01041404|Drug|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
412820|NCT01041391|Procedure|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
412821|NCT01041378|Drug|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
412822|NCT01041352|Device|laryngeal mask|LMA Proseal
412823|NCT01041352|Device|endotracheal tube|Unomedical endotracheal tube
412824|NCT01041326|Radiation|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
412825|NCT01041326|Procedure|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
412826|NCT01041313|Drug|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
412867|NCT01040936|Drug|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
412912|NCT01040689|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
412913|NCT01040689|Drug|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
412827|NCT01041313|Drug|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
412828|NCT01041300|Device|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).~Total Duration of device: 15 minutes"
412829|NCT01041300|Device|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).~Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).~Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).~Total Duration with Device: 2 hours and 30 minutes"
412830|NCT01041287|Drug|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is >125/80 for the remaining 8 weeks
412831|NCT01041287|Drug|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is >125/80 for the remaining 8 weeks
412832|NCT01041274|Drug|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
412833|NCT01041274|Drug|Placebo|Placebo by mouth daily for 12 months.
412834|NCT01041274|Behavioral|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
412835|NCT01041274|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
412836|NCT01041274|Radiation|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
412837|NCT01041261|Dietary Supplement|BariatrX Essentials 360 Treatment|Medical food
412838|NCT01041248|Drug|Tocilizumab|8mg/kg every 2 weeks i.v.
412839|NCT01041235|Drug|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
412840|NCT01041222|Drug|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
412841|NCT01041209|Behavioral|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
412842|NCT01041209|Behavioral|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
412843|NCT01041183|Drug|intravenous ramosetron|0.3 mg IV ramosetron (group I)
412844|NCT01041183|Drug|oral ramosetron|0.1 mg oral ramosetron (group II)
412845|NCT01041183|Drug|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
412846|NCT01041170|Drug|THC|
412847|NCT01041170|Drug|Rimonobant|
412848|NCT01041170|Drug|Rimonabant|
412849|NCT01041157|Other|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
412850|NCT01041144|Behavioral|lifestyle counseling|supporting diabetes patients using Internet communication
412851|NCT01041092|Drug|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
412852|NCT01041066|Drug|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
412853|NCT01041066|Drug|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
412854|NCT01041040|Drug|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
412855|NCT01041027|Drug|Paclitaxel|Given IV
412856|NCT01041027|Drug|Carboplatin|Given IV
412857|NCT01041027|Radiation|Internal Radiation Therapy|Undergo HDR brachytherapy
412858|NCT01041027|Radiation|External Beam Radiation Therapy|Undergo EBRT
412859|NCT01041027|Other|Laboratory Biomarker Analysis|Correlative studies
412860|NCT01041014|Behavioral|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
412861|NCT01041001|Biological|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
412862|NCT01041001|Procedure|Microfracture treatment|
412863|NCT01040975|Behavioral|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
412864|NCT01040949|Behavioral|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
412865|NCT01040949|Behavioral|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
412866|NCT01040936|Drug|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
412868|NCT01040923|Device|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
412869|NCT01040910|Drug|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
412870|NCT01040910|Drug|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
412871|NCT01040897|Behavioral|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
412872|NCT01040897|Behavioral|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
412873|NCT01040884|Other|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
412874|NCT01040871|Drug|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
412875|NCT01040871|Drug|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
412876|NCT01040871|Drug|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
412877|NCT01040871|Drug|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
412878|NCT01040871|Drug|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
412879|NCT01040871|Drug|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
412880|NCT01040858|Behavioral|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
412881|NCT01040858|Other|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
412882|NCT01040845|Drug|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
412883|NCT01040845|Drug|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
412884|NCT01040845|Drug|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
412885|NCT01040832|Drug|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
412886|NCT01040832|Drug|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram [mg/kg] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
412887|NCT01040819|Drug|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin >162 mg/d, steroids and prostaglandin analogs will be prohibited.
412888|NCT01040806|Behavioral|Usual care|Patients will receive their usual medical care
412889|NCT01040806|Behavioral|Health coaching|Peer health coaches will counsel patients with diabetes
412890|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
412891|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
412892|NCT01040793|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
412893|NCT01040793|Drug|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
412894|NCT01040793|Drug|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
412895|NCT01040780|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
412896|NCT01040780|Drug|Gefitinib|250 mg every 24 hours by mouth
412897|NCT01040767|Other|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
412898|NCT01040754|Other|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
412899|NCT01040741|Other|Non-intervention observational study|Non-intervention observational study
412900|NCT01040728|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
412901|NCT01040728|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
412902|NCT01040728|Drug|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
412903|NCT01040728|Drug|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
412904|NCT01040728|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
412905|NCT01040715|Biological|TNFa Kinoid|TNFa kinoid
412906|NCT01040715|Biological|TNF kinoid|IM administration 2 or 3 injections within 28 days
412907|NCT01040702|Drug|methylphenidate|a single doses of 10-20 mg in each one of two visits
412908|NCT01040702|Dietary Supplement|sweetener pill|a capsule containing a sweetener pill
412909|NCT01040689|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
412910|NCT01040689|Drug|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
412911|NCT01040689|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
412914|NCT01040676|Behavioral|Automated Telephone Nutrition Support|See Intervention Group description.
412915|NCT01040663|Other|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
412916|NCT01040637|Drug|TD-1211|Dose level 1
412917|NCT01040637|Drug|TD-1211|Dose level 2
412918|NCT01040637|Drug|TD-1211|Dose level 3
412919|NCT01040637|Drug|TD-1211|Dose Level 4
412920|NCT01040637|Drug|TD-1211|Ascending doses
412921|NCT01040637|Drug|TD-1211|Ascending doses
412922|NCT01040637|Drug|TD-1211|Ascending doses
412923|NCT01040637|Drug|TD-1211|Ascending doses
412924|NCT01040637|Drug|TD-1211|Ascending doses
412925|NCT01040637|Drug|Placebo|Ascending doses
412926|NCT01040624|Radiation|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
412927|NCT01040624|Radiation|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
412928|NCT01040611|Behavioral|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
412929|NCT01040598|Biological|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
412930|NCT01040585|Drug|Linezolid|Treatment for VAP as indication approved and as physician criterium.
412931|NCT01040559|Drug|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
412932|NCT01040546|Behavioral|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
412933|NCT01040546|Behavioral|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
412934|NCT01040494|Drug|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
412935|NCT01040494|Drug|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
412936|NCT01040468|Procedure|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
412937|NCT01040468|Procedure|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
412938|NCT01040468|Behavioral|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
412939|NCT01040455|Drug|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
412940|NCT01040455|Drug|placebo|placebo once daily for eight weeks
412941|NCT01040442|Other|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
412942|NCT01040429|Drug|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients < 35 kg; 50 microgram (2 capsula) x 2/day for patients > 35 kg.~Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients < 35 kg; 25 microgram (2 capsula) x 2/day for patients > 35 kg."
412943|NCT01040429|Drug|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients < 35 kg; 2 capsula x 2/day for patients > 35 kg.~Day 57-63 (week 9): 1 capsula x 1/day for patients < 35 kg; 1 capsula x 2/day for patients > 35 kg"
412944|NCT01040403|Drug|olodaterol (BI 1744) low|olodaterol (BI 1744) low
412945|NCT01040403|Drug|low tiotropium bromide|low tiotropium bromide
412946|NCT01040403|Drug|olodaterol (BI 1744) high|olodaterol (BI 1744) high
412947|NCT01040403|Drug|medium tiotropium bromide|medium tiotropium bromide
412948|NCT01040403|Drug|high tiotropium bromide|high tiotropium bromide
412949|NCT01040403|Drug|Placebo|Placebo
412950|NCT01040403|Device|Respimat|Respimat inhaler
412951|NCT01040390|Drug|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
412952|NCT01040351|Procedure|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
412953|NCT01040338|Drug|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
412954|NCT01040325|Biological|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
412955|NCT01040325|Biological|TD Vaccine System|TD Vaccine System Containing Placebo Product
412956|NCT01040312|Drug|CPT-11|CPT-11 blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog.
412957|NCT01040312|Drug|Platinum analogues|Platinum compounds produce changes in DNA structure, which causes cancer cell death (apoptosis). They are typically used alone or in combination with other chemotherapy drugs.
412958|NCT01040299|Device|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
412959|NCT01040299|Device|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
412960|NCT01040299|Other|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
412961|NCT01040286|Drug|Flurbiprofen|2.0 mg
412962|NCT01040286|Drug|Chlorhexidine|2.5mg
412963|NCT01040273|Drug|Bupivacaine|
412964|NCT01040273|Drug|Placebo|
412965|NCT01040260|Other|Counseling|Smoking cessation counseling
412966|NCT01040260|Behavioral|Contingency management|Use of tangible rewards for abstinence from smoking
412967|NCT01040260|Drug|Nicotine patches|Nicotine patches
412968|NCT01040247|Other|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
412969|NCT01040234|Procedure|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
412970|NCT01040221|Drug|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
412971|NCT01040208|Drug|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
412972|NCT01040208|Drug|flibanserin 100 mg qhs|100mg qhs
412973|NCT01040208|Drug|placebo 2 tablets qhs|50 mg placebo
412974|NCT01040195|Drug|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
412975|NCT01040195|Drug|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
412976|NCT01040169|Device|Arginine/Calcium Carbonate|One application
412977|NCT01040169|Device|Mint Prophy paste - Fluoride free|one application
412978|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
412979|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
412980|NCT01040130|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
412981|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high dose
412982|NCT01040130|Drug|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
412983|NCT01040117|Procedure|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
412984|NCT01040117|Procedure|Conventional neurorehabilitation treatment|"The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.~Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position."
412985|NCT01040104|Other|Skin sample|Taken from regularly discarded tissue during routine operation
412986|NCT01040104|Other|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
412987|NCT01040104|Other|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
412988|NCT01040104|Other|Blood taking|Blood taking on day 0
412989|NCT01040104|Other|Blood taking|Blood taking on day 90
412990|NCT01040091|Drug|Emtricitabine (FTC)|200 mg once a day
412991|NCT01040091|Drug|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
412992|NCT01040091|Drug|Efavirenz (EFV)|600 mg once a day
412993|NCT01040091|Drug|Truvada|200 mg emtricitabine + 300 mg TDF once a day
412994|NCT01040078|Biological|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
412995|NCT01040078|Biological|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
412996|NCT01040078|Biological|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
412997|NCT01040065|Procedure|distal clavicle resection|Presence of tenderness at 2 years after surgery
412998|NCT01040052|Biological|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
412999|NCT01040026|Other|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at <1x10e5/kg
413000|NCT01040013|Procedure|Laparoscopy|Laparoscopic Left-Colectomy
413001|NCT01040013|Procedure|left colectomy by laparotomy|PatientS will be operated by laparotomy
413002|NCT01040000|Drug|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
413003|NCT01039974|Drug|GSK962040|"GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
413004|NCT01039974|Drug|Ketoconazole|400 mg
413005|NCT01039961|Drug|losmapimod 1 mg|IV infusion
413006|NCT01039961|Drug|losmapimod|IV infusion (dose to be determined based on PK from first dose)
413007|NCT01039961|Drug|losmapimod 15 mg|oral, two 7.5 mg tablets
413008|NCT01039948|Biological|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
413009|NCT01039948|Drug|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
413010|NCT01039909|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
413011|NCT01039909|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
413012|NCT01039896|Drug|Period I : SLM0807, Period II : HKB0701 and SLM0807|
413013|NCT01039896|Drug|Period I : HKB0710 and SLM0807, Period II : SLM0807|
413014|NCT01039883|Drug|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
413015|NCT01039883|Drug|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
413016|NCT01039870|Procedure|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
413017|NCT01039870|Procedure|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
413018|NCT01039857|Behavioral|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
413019|NCT01039857|Behavioral|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
413020|NCT01039844|Drug|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.~Phase II Starting Dose: Maximum tolerated dose from Phase I."
413021|NCT01039818|Radiation|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
413022|NCT01039818|Radiation|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
413023|NCT01039805|Drug|GSK962040 (50 mg)|Cohort 1 = 50 mg
413024|NCT01039805|Drug|Placebo|matching placebo
413025|NCT01039805|Drug|GSK962040 (75 mg)|Cohort 2 = 75 mg
413026|NCT01039792|Drug|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
413027|NCT01039792|Dietary Supplement|Placebo|placebo
413028|NCT01039779|Behavioral|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
413029|NCT01039766|Drug|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
413030|NCT01039766|Drug|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
413031|NCT01039740|Drug|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
413032|NCT01039727|Other|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
413033|NCT01039727|Other|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
413034|NCT01039701|Drug|AZD1446|capsules, oral, 3 times daily
413035|NCT01039701|Drug|Placebo|capsules, oral, 3 times daily, 4 weeks
413036|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
413037|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
413038|NCT01039688|Drug|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
413039|NCT01039675|Drug|500mcg/25mcg once daily|GSK573719/GW642444
413041|NCT01039662|Dietary Supplement|L-arabinose and indigestible dextrin|
413042|NCT01039662|Dietary Supplement|Placebo|
413043|NCT01039636|Drug|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
413044|NCT01039623|Biological|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
413045|NCT01039610|Drug|GSK945237|Dose detailed in Arm description
413046|NCT01039610|Drug|Placebo|matching placebo tablet
413047|NCT01039610|Drug|Linezolid|600 mg BID, 14 Days
413048|NCT01039610|Drug|Moxifloxacin|40 mg single dose
413049|NCT01039597|Drug|ORE1001|Oral capsules containing 300 mg of the active, study drug
413050|NCT01039597|Drug|Placebo|placebo capsules
413051|NCT01039584|Drug|Butoconazole Nitrate Vaginal Cream|vaginal cream
413052|NCT01039584|Drug|Placebo|vaginal cream
413053|NCT01039584|Drug|Gynazole 1 vaginal cream|vaginal cream
413054|NCT01039571|Procedure|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
413055|NCT01039558|Drug|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
413056|NCT01039558|Drug|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
413057|NCT01039558|Drug|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
413058|NCT01039545|Drug|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
413059|NCT01039545|Drug|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
413060|NCT01039519|Drug|Ganetespib|Ganetespib 200 mg/m^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
413061|NCT01039506|Drug|CPT-11 based regimens|
413062|NCT01039467|Device|Medtronic Adapta Dual Chamber Pacemaker|Medtronic Adapta Dual Chamber Pacemaker
413063|NCT01039454|Drug|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
413064|NCT01039454|Drug|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
413065|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
413066|NCT01039441|Procedure|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
413067|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
413068|NCT01039441|Other|normal saline|
413069|NCT01039428|Dietary Supplement|HS219|Chewing for 30 min three time a day far after meal
413070|NCT01039428|Dietary Supplement|Placebo|Chewing for 30 min three times a day far after meal
413071|NCT01039389|Drug|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
413072|NCT01039389|Drug|Placebo|bid placebo
413073|NCT01039376|Biological|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
413074|NCT01039376|Other|Observation|Observation/Safety Evaluation
413075|NCT01039363|Drug|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:~Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)~Maintenance:~Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles~Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.~Gemtuzumab will be omitted in a consolidation schedule.~Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
413076|NCT01039350|Drug|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
413077|NCT01039337|Other|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
413078|NCT01039337|Other|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
413079|NCT01039337|Other|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
413080|NCT01039324|Other|Reports|Primary care event reports and patient letters
413081|NCT01039324|Other|Reports and Notices|Primary care event reports, patient letters and care manager notices
413082|NCT01039324|Other|Usual care|This is the study's control group
413083|NCT01039311|Device|Optical Coherence Tomography|Obtain OCT images.
413084|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
413413|NCT01036061|Drug|GSK618334 High Dose|GSK618334 High Dose
413085|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
413086|NCT01039285|Drug|Curosurf|2.5 ml/kg instilled in the trachea
413087|NCT01039285|Other|Air|2.5ml/kg of Air will be instilled in the trachea
413088|NCT01039259|Device|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
413089|NCT01039233|Drug|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
413090|NCT01039220|Biological|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
413091|NCT01039207|Other|Laboratory Biomarker Analysis|Correlative studies
413092|NCT01039207|Biological|Rilotumumab|Given IV
413093|NCT01039194|Drug|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
413094|NCT01039194|Drug|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
413095|NCT01039194|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
413096|NCT01039181|Drug|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
413097|NCT01039168|Behavioral|Workplace dialogue|
413098|NCT01039168|Other|Care as usual|
413099|NCT01039155|Drug|Azacitidine|Given IV
413100|NCT01039155|Other|Laboratory Biomarker Analysis|Correlative studies
413101|NCT01039155|Drug|Oxaliplatin|Given IV
413102|NCT01039155|Other|Pharmacological Study|Correlative studies
413103|NCT01039142|Drug|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
413104|NCT01039129|Procedure|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
413105|NCT01039129|Procedure|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
413106|NCT01039129|Procedure|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
413107|NCT01039116|Behavioral|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
413108|NCT01039116|Behavioral|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
413109|NCT01039103|Drug|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
413110|NCT01039103|Drug|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
413111|NCT01039090|Drug|Continuous Apomorphine infusion|Continuous Apomorphine infusion during 6 months
413112|NCT01039090|Drug|Usual dopaminergic per os treatment|No specific change in the dopaminergic per os treatment
413113|NCT01039077|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
413114|NCT01039051|Behavioral|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
413115|NCT01039038|Radiation|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
413116|NCT01039025|Drug|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m^2 intravenously given over 30 minutes on Days 1 - 5.
413117|NCT01039025|Drug|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m^2/day intravenously given over 2 hours on Days 1 - 3.
413118|NCT01039025|Drug|Melphalan|After stem cells are collected, Melphalan 70 mg/m^2/day intravenously given on Days 4 and 5.
413119|NCT01039025|Other|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
413120|NCT01039012|Other|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
413121|NCT01039012|Other|Standard Care|Participant follow the standard care recommended by their physician.
413122|NCT01038999|Biological|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
413123|NCT01038986|Biological|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
413124|NCT01038960|Behavioral|Exercise training|3 months supervised interval training
413125|NCT01038947|Biological|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
413126|NCT01038934|Procedure|samples collected by buccal cytobrush|
413127|NCT01038921|Drug|Melatonin|8 mg dose of Melatonin
413128|NCT01038921|Drug|Placebo|Placebo
413129|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~Pre-incision: SLN is identified~Inject blue dye into patient's arm~Complete procedure (SLNB and/or ALND)"
413130|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe~Pre-incision: SLN is not identified (No localization)~Inject blue dye into breast (nothing in arm)~i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
413131|NCT01038895|Drug|Ramipril|tablet; 10 mg; od; 3 months
413132|NCT01038895|Drug|Experimental|tablet; 300 mg; od; 3 months
413133|NCT01038882|Drug|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of >2 min to maintain conscious sedation
413134|NCT01038882|Other|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
413135|NCT01038869|Drug|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
413136|NCT01038856|Drug|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
413137|NCT01038843|Drug|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.~Placebo: as above"
413138|NCT01038817|Drug|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
413139|NCT01038804|Drug|YM155|intravenous infusion
413140|NCT01038804|Drug|Docetaxel|intravenous infusion
413141|NCT01038791|Device|heated humidification|temperature 35°
413142|NCT01038791|Device|heat and moisture exchanger|single patient device
413143|NCT01038791|Device|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
413144|NCT01038778|Biological|Aldesleukin|Given IV
413145|NCT01038778|Procedure|Computed Tomography|Undergo FDG-PET/CT
413146|NCT01038778|Drug|Entinostat|Given PO
413147|NCT01038778|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
413148|NCT01038778|Other|Laboratory Biomarker Analysis|Correlative studies
413149|NCT01038778|Other|Pharmacological Study|Correlative studies
413150|NCT01038778|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
413151|NCT01038765|Behavioral|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
413152|NCT01038752|Drug|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
413153|NCT01038752|Drug|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
413154|NCT01038739|Drug|Mesalazine|3 g per day
413155|NCT01038739|Drug|Mesalazine|1.5 g per day
413156|NCT01038739|Drug|Placebo|0 g per day
413157|NCT01038726|Other|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
413158|NCT01038726|Other|Cognitive Training|Based on cognitive training program Brain Fitness®
413159|NCT01038726|Other|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
413160|NCT01038726|Other|Educational Sessions|DVD-based educational programs on history, art, and literature
413161|NCT01038713|Device|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
413162|NCT01038687|Drug|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
413163|NCT01038687|Drug|placebo|placebo
413164|NCT01038674|Drug|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
413165|NCT01038674|Drug|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
413166|NCT01038661|Drug|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-hour IV"
413167|NCT01038661|Drug|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)~Route(s) of administration: 1-3-hour IV"
413168|NCT01038661|Other|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief—but not chemotherapy — that is considered appropriate by the investigator
413169|NCT01038648|Drug|Sitagliptin|100mg/day
413170|NCT01038648|Other|life style modification at base line|Advice on physical activity, diet and drug adherence.
413171|NCT01038635|Drug|5-Azacytidine|75 mg/m^2 IV daily x 5 days on days 1 to 5.
413172|NCT01038635|Drug|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
413173|NCT01038622|Drug|L-arginine|5-day L-arginine treatment
413174|NCT01038622|Drug|placebo|5-day placebo treatment
413175|NCT01038609|Drug|Hydrocodone/Acetaminophen Extended Release|
413176|NCT01038609|Drug|Acetaminophen|
413177|NCT01038609|Drug|Morphine Extended Release|
413178|NCT01038609|Drug|Placebo|
413179|NCT01038583|Drug|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
413180|NCT01038583|Drug|Placebo|100 mg enteric-coated placebo
413181|NCT01038570|Drug|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
413182|NCT01038570|Drug|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
413183|NCT01038557|Biological|RBC units|When a transfusion is ordered, enrolled subjects will receive RBC units 1) up to 14 days old, 2) 14-42 days old, or 3) that are frozen when stored.
413184|NCT01038544|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
413185|NCT01038544|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
413186|NCT01038531|Other|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
413187|NCT01038531|Other|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
413188|NCT01038505|Drug|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
413189|NCT01038492|Behavioral|p16 Methylation and Lung Cancer Education|"patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details~patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing~a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits~patients are called again at three months and asked about any changes in their attitudes or smoking habits."
413190|NCT01038479|Dietary Supplement|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
413191|NCT01038479|Behavioral|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
413192|NCT01038453|Dietary Supplement|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
413193|NCT01038453|Other|placebo tablet|placebo 2 tablet, once a day,
413194|NCT01038453|Dietary Supplement|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.~In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
413195|NCT01038440|Dietary Supplement|Safflower Oil|One softgel consumed daily with food
413196|NCT01038440|Dietary Supplement|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
413197|NCT01038440|Dietary Supplement|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
413198|NCT01038427|Drug|Mometasone Furoate|Test product - 200 mcg per day
413199|NCT01038427|Drug|Mometasone Furoate|Reference listed drug - 200 mcg per day
413200|NCT01038427|Drug|Placebo|Placebo
413201|NCT01038414|Behavioral|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
413202|NCT01038401|Procedure|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
413203|NCT01038401|Biological|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
413204|NCT01038388|Drug|Bortezomib|1.3mg/m² given IV or subcutaneously
413205|NCT01038388|Drug|Lenalidomide|25 mg given PO
413206|NCT01038388|Drug|Dexamethasone|20 mg given PO
413207|NCT01038388|Drug|Vorinostat|100, 200, or 300 mg given PO
413208|NCT01038375|Behavioral|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
413209|NCT01038362|Other|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
413210|NCT01038362|Other|No Almonds|NCEP Step 1 diet without almonds
413211|NCT01038349|Other|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
413212|NCT01038336|Behavioral|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
413213|NCT01038336|Behavioral|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
413214|NCT01038323|Other|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
413215|NCT01038323|Behavioral|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
413216|NCT01038323|Drug|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
413217|NCT01038297|Drug|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
413218|NCT01038297|Drug|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
413219|NCT01038284|Behavioral|Patient education|Pharmaceutical care of patients with PAH
413220|NCT01038284|Other|Data collection|Clinical and biological data, treatment, medication errors and ADEs
413221|NCT01038271|Other|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
413222|NCT01038271|Other|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
413223|NCT01038258|Procedure|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
413224|NCT01038206|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
413225|NCT01038193|Other|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
413226|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
413227|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
413228|NCT01038167|Drug|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
413229|NCT01038167|Drug|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
413230|NCT01038167|Drug|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
413231|NCT01038167|Drug|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
413232|NCT01038154|Drug|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
413233|NCT01038141|Procedure|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
413234|NCT01038128|Drug|Memantine|Drug: Memantine, 10-40 mg daily
413235|NCT01038115|Procedure|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
413236|NCT01038102|Other|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
413237|NCT01038102|Other|SFA diet|Diet high in saturated fat (15E%)
413238|NCT01038089|Dietary Supplement|Resveratrol|Resveratrol
413239|NCT01038076|Behavioral|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
413240|NCT01038063|Drug|Artemether-lumefantrine combination|
413241|NCT01038050|Drug|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
413242|NCT01038037|Drug|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
413243|NCT01038037|Drug|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
413244|NCT01038037|Drug|panitumumab|i.v. day 1: 9 mg/kg q3w
413245|NCT01038024|Dietary Supplement|1 tablet composed of antioxidants and minerals|1 tablet daily
413246|NCT01038011|Drug|drug treatment|
413247|NCT01037998|Drug|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
413248|NCT01037985|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
413249|NCT01037985|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
413250|NCT01037972|Behavioral|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
413251|NCT01037972|Behavioral|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
413252|NCT01037959|Drug|Norfloxacin|400 mg/day (per os) for 6 months
413253|NCT01037959|Drug|Placebo|1 pill/day (per os) for 6 months
413254|NCT01037946|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
413255|NCT01037933|Other|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
413256|NCT01037933|Other|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
413257|NCT01037920|Behavioral|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
413258|NCT01037920|Behavioral|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
413259|NCT01037907|Drug|Pleneva TM BGC20-0134|Placebo or 5 g dose
413260|NCT01037907|Drug|Placebo|Placebo or 5 g dose
413261|NCT01037894|Procedure|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
413262|NCT01037894|Procedure|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
413263|NCT01037881|Drug|LEO 29102|comparison of different dosages of drug
413264|NCT01037881|Drug|Elidel®|comparison
413265|NCT01037868|Other|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
413266|NCT01037855|Other|Non-intervention observational study|Non-intervention observational study
413267|NCT01037842|Drug|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day~for 16 weeks"
413268|NCT01037842|Drug|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
413269|NCT01037829|Other|Non-intervention observational study|Non-intervention observational study
413270|NCT01037816|Drug|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
413271|NCT01037816|Other|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
413272|NCT01037790|Drug|PD-0332991|Given orally, 125 mg QD on a 21-day
413273|NCT01037790|Other|pharmacological study|Correlative study
413274|NCT01037764|Procedure|alloHCT|"[ alloHCT arm ] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.~BuFluATG conditioning; Bu 3.2 mg/kg*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.~Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
413275|NCT01037751|Behavioral|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
413276|NCT01037751|Behavioral|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
413277|NCT01037738|Procedure|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
413278|NCT01037725|Drug|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.~Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
413279|NCT01037725|Drug|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
413280|NCT01037712|Drug|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
413281|NCT01037712|Drug|Placebo|placebo
413282|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
413283|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
413284|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
413285|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
413286|NCT01037686|Radiation|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
413287|NCT01037686|Behavioral|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
413288|NCT01037686|Device|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
413289|NCT01037673|Procedure|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
413290|NCT01037673|Procedure|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
413291|NCT01037660|Drug|Metformin|Metformin 1 gram per day
413292|NCT01037647|Other|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
413293|NCT01037634|Drug|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
413294|NCT01037621|Drug|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
413295|NCT01037608|Drug|Sativex(Registered Trademark)|
413296|NCT01037608|Drug|THC|
413297|NCT01037595|Drug|turmeric|turmeric 500 md tid orally for 8 weeks
413298|NCT01037595|Drug|placebo|placebo 3 time orally for 8 weeks
413299|NCT01037595|Drug|turmeric|500 mg tid orally for 8 weeks
413300|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
413301|NCT01037582|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
413302|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
413303|NCT01037582|Drug|placebo|Subjects will be randomized to receive a single dose of placebo.
413304|NCT01037582|Drug|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
413305|NCT01037582|Drug|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
413306|NCT01037556|Drug|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
413307|NCT01037543|Drug|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
413308|NCT01037530|Drug|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
413309|NCT01037517|Drug|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
413310|NCT01037517|Other|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
413311|NCT01037504|Drug|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
413503|NCT01035255|Drug|Enalapril 10 mg BID|Enalapril 10 mg BID
413312|NCT01037504|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
413313|NCT01037491|Drug|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
413314|NCT01037478|Drug|Resminostat (4SC-201)|oral administration
413315|NCT01037465|Drug|N-acetylcysteine|N-acetylcysteine
413316|NCT01037465|Drug|Placebo|Placebo
413317|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
413318|NCT01037452|Drug|Lansoprazole|Tablet
413319|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide|Tablet
413320|NCT01037452|Drug|Placebo|Tablet
413321|NCT01037426|Other|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect~History of falls and fractures during the 12 months before pacemaker implantation~Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)~History of falls and fractures during the 12 months after pacemaker implantation~Medical and Arrhythmia History~Cardiovascular Events~Cardiovascular Medication~Device programming information"
413322|NCT01037413|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
413323|NCT01037413|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
413324|NCT01037387|Drug|Control|Current treatment according to the ATS/ERS guidelines
413325|NCT01037387|Device|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
413326|NCT01037374|Other|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
413327|NCT01037348|Drug|ranibizumab 0.5mg|
413328|NCT01037335|Drug|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
413329|NCT01037322|Drug|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
413330|NCT01037322|Drug|placebo in drops|olive oil containing no drug given in drops twice daily
413331|NCT01037309|Drug|PRO044 SC|Subcutaneous injection, once a week, for five weeks
413332|NCT01037309|Drug|PRO044 IV|Intravenous injection, once a week, for five weeks
413333|NCT01037296|Procedure|catheter ablation|ablation procedure performed with Hansen robotic navigation system
413334|NCT01037296|Procedure|catheter ablation|Ablation will be performed as normal treatment
413335|NCT01037283|Behavioral|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
413336|NCT01037244|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
413337|NCT01037244|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
413338|NCT01037231|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU oxalobacter formigenes twice daily for 24 weeks
413339|NCT01037231|Drug|Placebo|placebo
413340|NCT01037218|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
413341|NCT01037218|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
413342|NCT01037205|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
413343|NCT01037205|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
413344|NCT01037192|Drug|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
413345|NCT01037192|Drug|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
413346|NCT01037179|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
413347|NCT01037166|Drug|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
413348|NCT01037140|Drug|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
413349|NCT01037140|Drug|placebo|oral placebo tablets similar to active comparator
413350|NCT01037127|Drug|GSK1120212|Daily oral dosing
413351|NCT01037114|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
413352|NCT01037114|Biological|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
413353|NCT01037114|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
413354|NCT01037101|Behavioral|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
413355|NCT01037101|Behavioral|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
413356|NCT01037101|Drug|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
413357|NCT01037101|Drug|Placebo|50 mg placebo administered 30 minutes before the session
413358|NCT01037088|Drug|Mild dose cannabis|3.53% THC by weight
413359|NCT01037088|Drug|Low dose cannabis|1.29% THC by weight
413360|NCT01037088|Drug|Cannabis|0.00% THC by weight
413361|NCT01037062|Drug|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
413362|NCT01037049|Other|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
413363|NCT01037036|Drug|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
413364|NCT01037036|Drug|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
413365|NCT01037023|Drug|Topotecan|patients administrated Topotecan according to the prescribing information
413366|NCT01036932|Drug|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
413367|NCT01036932|Drug|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
413368|NCT01036893|Drug|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
413369|NCT01036854|Drug|EUR-1025|orally, 24 mg, daily for 6 days
413370|NCT01036854|Drug|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
413371|NCT01036854|Drug|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
413372|NCT01036854|Drug|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
413373|NCT01036841|Drug|desmopressin tablet|Administration of desmopressine tablet
413374|NCT01036841|Drug|desmopressin MELT formulation|Administration of desmopressine MELT formulation
413375|NCT01036802|Drug|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
413376|NCT01036802|Drug|Placebo|
413377|NCT01036724|Device|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX[TM]) and measuring the amount of radiation exposure duration for each.
413378|NCT01036659|Drug|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
413379|NCT01036633|Device|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
413380|NCT01036594|Drug|Ketoconazole, hydrocortisone|Ketoconazole 400mg po tid Hydrocortisone 20mg po qam and 10mg po qpm
413381|NCT01036594|Drug|Ketoconazole, dexamethasone|Ketoconazole 400md po tid Dexamethasone 1mg po bid
413382|NCT01036529|Device|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
413383|NCT01036529|Procedure|Back Surgery|Different types of back surgery may be performed
413384|NCT01036490|Other|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
413385|NCT01036438|Device|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
413386|NCT01036438|Device|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
413387|NCT01036412|Drug|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
413388|NCT01036412|Behavioral|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
413389|NCT01036399|Drug|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
413390|NCT01036360|Other|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
413391|NCT01036321|Drug|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
413392|NCT01036321|Drug|Methyl cellulose blend|Placebo - Take 2 capsules daily
413393|NCT01036308|Dietary Supplement|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
413394|NCT01036308|Dietary Supplement|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
413395|NCT01036282|Behavioral|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
413396|NCT01036282|Behavioral|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
413397|NCT01036243|Dietary Supplement|test formula 1|hydrolyzed formula with probiotics
413398|NCT01036243|Dietary Supplement|test formula 2|acidified hydrolyzed formula
413399|NCT01036243|Dietary Supplement|test formula 3|hydrolyzed formula without probiotics
413400|NCT01036243|Dietary Supplement|reference formula|standard infant formula
413401|NCT01036165|Device|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
413402|NCT01036139|Drug|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
413403|NCT01036113|Drug|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
413404|NCT01036087|Drug|Panitumumab|2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
413405|NCT01036087|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
413406|NCT01036087|Drug|Carboplatin|AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
413407|NCT01036087|Drug|5-Fluorouracil|500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
413408|NCT01036087|Drug|Epirubicin|100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
413409|NCT01036087|Drug|Cyclophosphamide|500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
413410|NCT01036061|Drug|GSK618334 Low Dose|GSK618334 low dose
413411|NCT01036061|Drug|GSK618334 PET subjects|PET subjects
413412|NCT01036061|Drug|GSK618334 Medium Dose|Medium Dose
413414|NCT01036048|Device|drug eluting stent|pts with cabg disease treated with drug eluting stent
413415|NCT01036048|Device|bare metal stent|pts with cabg disease treated with bare metal stent
413416|NCT01036035|Drug|Tolterodine|Comparison of different dosages of drug
413417|NCT01036035|Drug|Pilocarpine|Comparison of different dosages of drug
413418|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
413419|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
413420|NCT01036035|Drug|placebo capsule|Comparison of different dosages of drug
413421|NCT01036022|Drug|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
413422|NCT01036009|Other|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
413423|NCT01035983|Drug|Frovatriptan 2.5 mg|
413424|NCT01035944|Device|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
413425|NCT01035944|Device|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
413426|NCT01035905|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
413427|NCT01035905|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
413428|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
413429|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
413430|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
413431|NCT01035879|Drug|Sitagliptin|tablets and capsule once daily
413432|NCT01035879|Drug|placebo|tablets and capsule once daily
413433|NCT01035853|Drug|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
413434|NCT01035801|Drug|IN-105|Prandial Oral Insulin
413435|NCT01035801|Drug|Insulin Lispro Injection|Insulin Lispro Injection
413436|NCT01035788|Behavioral|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
413437|NCT01035788|Behavioral|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
413438|NCT01035775|Procedure|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
413439|NCT01035775|Procedure|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
413440|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
413441|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
413442|NCT01035749|Biological|Placebo (saline)|One dose intramuscularly
413443|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
413444|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
413445|NCT01035671|Drug|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
413446|NCT01035658|Drug|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
413447|NCT01035658|Drug|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
413448|NCT01035645|Drug|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
413449|NCT01035619|Drug|moxidectin|Single Dose Moxidectin 4 mg
413450|NCT01035606|Behavioral|training in goal-directed attention regulation|training in goal-directed attention regulation
413451|NCT01035606|Behavioral|brain health education|brain health education workshops
413452|NCT01035606|Behavioral|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
413453|NCT01035593|Procedure|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
413454|NCT01035593|Drug|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
413455|NCT01035580|Drug|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
413456|NCT01035580|Drug|curcumin|all patients received the drug
413457|NCT01035567|Procedure|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
413458|NCT01035567|Procedure|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
413459|NCT01035554|Other|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
413460|NCT01035554|Other|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
413461|NCT01035554|Other|Usual Care|Standard care
413462|NCT01035554|Other|Printed Materials|National Institutes of Health Printed Materials on hypertension
413463|NCT01035541|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
413464|NCT01035528|Drug|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
413465|NCT01035528|Drug|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
413466|NCT01035515|Drug|Placebo|Single dose oral capsule placebo comparator
413467|NCT01035515|Drug|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
413468|NCT01035515|Drug|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
413469|NCT01035502|Drug|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.~Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.~It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
413470|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
413471|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
413472|NCT01035476|Behavioral|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
413473|NCT01035463|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic stem cell transplant
413474|NCT01035463|Drug|Carmustine|Given IV
413475|NCT01035463|Drug|Cytarabine|Given IV
413476|NCT01035463|Drug|Etoposide|Given IV
413477|NCT01035463|Drug|Lenalidomide|Given PO
413478|NCT01035463|Drug|Melphalan|Given IV
413479|NCT01035463|Biological|Rituximab|Given IV
413480|NCT01035450|Device|Everolimus-eluting stent|Everolimus-eluting stent
413481|NCT01035450|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
413482|NCT01035437|Drug|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
413483|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLE494
413484|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLF497
413485|NCT01035411|Drug|AZD9668|2 x 30 mg tablet variant 1
413486|NCT01035385|Drug|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
413487|NCT01035372|Dietary Supplement|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
413488|NCT01035359|Procedure|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
413489|NCT01035359|Procedure|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
413490|NCT01035346|Drug|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
413491|NCT01035346|Drug|Placebo|Single dose of a placebo
413492|NCT01035333|Drug|Orlistat|60mg capsule three times a day for up to 6 months
413493|NCT01035320|Drug|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
413494|NCT01035307|Genetic|gene expression analysis|
413495|NCT01035307|Genetic|microarray analysis|
413496|NCT01035307|Genetic|proteomic profiling|
413497|NCT01035307|Other|laboratory biomarker analysis|
413498|NCT01035294|Behavioral|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
413499|NCT01035294|Behavioral|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
413500|NCT01035281|Drug|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
413501|NCT01035268|Procedure|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
413502|NCT01035255|Drug|LCZ696 200 mg BID|LCZ696 200 mg BID
413504|NCT01035242|Behavioral|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
413505|NCT01035242|Behavioral|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
413506|NCT01035229|Drug|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
413507|NCT01035229|Drug|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
413508|NCT01035229|Other|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
413509|NCT01035216|Drug|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
413510|NCT01035203|Behavioral|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
413511|NCT01035203|Behavioral|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
413512|NCT01035190|Drug|Budesonide|Inhalation, 200 µg/puff
413513|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
413514|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
413515|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
413516|NCT01035151|Behavioral|Experimental|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
413517|NCT01035151|Behavioral|Control|Written Cessation Materials
413518|NCT01035138|Drug|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
413519|NCT01035125|Behavioral|Self-management program|Participants will receive a one week inpatient self-management program
413520|NCT01035112|Procedure|MRI|
413521|NCT01035099|Drug|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:~Serum Estradiol level <150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;"
413522|NCT01035099|Drug|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
413523|NCT01035086|Dietary Supplement|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
413524|NCT01035073|Drug|Duloxetine|30-60 mg daily for 8 weeks
413525|NCT01035047|Other|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
413526|NCT01035034|Procedure|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
413527|NCT01035034|Procedure|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
413528|NCT01035021|Drug|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
413529|NCT01035008|Procedure|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
413530|NCT01034995|Drug|SSR125543|"Pharmaceutical form: capsule~Route of administration: oral"
413531|NCT01034995|Drug|escitalopram|"Pharmaceutical form: encapsulated tablets~Route of administration: oral"
413532|NCT01034995|Drug|placebo|"Pharmaceutical form: capsule~Route of administration: oral"
413533|NCT01034982|Drug|AZD9668|20 mg
413534|NCT01034982|Drug|AZD9668|60 mg
413627|NCT01034189|Drug|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
413535|NCT01034956|Device|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
413536|NCT01034943|Procedure|External fixation|Operation with external fixation and optional addition of k-wire
413537|NCT01034943|Procedure|Volar plate|Operation with a Synthes volar two column plate (TCP)
413538|NCT01034930|Procedure|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
413539|NCT01034917|Drug|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
413540|NCT01034917|Drug|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
413541|NCT01034878|Drug|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
413542|NCT01034852|Procedure|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
413543|NCT01034787|Drug|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
413544|NCT01034774|Drug|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
413545|NCT01034774|Drug|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
413546|NCT01034761|Behavioral|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
413547|NCT01034748|Drug|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
413548|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
413549|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
413550|NCT01034735|Biological|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
413551|NCT01034683|Drug|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
413552|NCT01034670|Device|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
413553|NCT01034670|Device|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
413554|NCT01034670|Device|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
413555|NCT01034670|Drug|fluorescent Peptide|microdosing; Topical through the endoscope
413556|NCT01034670|Drug|fluorescein|100 mcg topical
413557|NCT01034670|Drug|indocyanine green|100 mcg topical
413558|NCT01034657|Drug|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
413559|NCT01034657|Drug|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
413560|NCT01034631|Drug|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
413561|NCT01034631|Drug|BNC105P|BNC105P, up to 16 mg/m^2
413562|NCT01034618|Dietary Supplement|Protein hydrolyzation|
413563|NCT01034605|Dietary Supplement|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
413564|NCT01034592|Drug|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
413565|NCT01034579|Other|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
413566|NCT01034579|Other|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
413567|NCT01034566|Radiation|Proton Beam Radiation Therapy|
413568|NCT01034553|Drug|Aurora A kinase inhibitor MLN8237|Given orally
413569|NCT01034553|Drug|bortezomib|Given IV
413570|NCT01034540|Drug|POM3|4 g/day
413571|NCT01034540|Drug|Placebo|matching placebo capsule, 4 g/day
413572|NCT01034527|Other|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
413573|NCT01034514|Device|Real-time Position Management system|Standard of Care
413574|NCT01034514|Device|Discovery ST multislice PET/CT scanner|Standard of Care
413575|NCT01034514|Device|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
413576|NCT01034514|Device|Pinnacle3 treatment planning system|Standard of Care
413577|NCT01034514|Device|SKYLight nuclear camera|Standard of Care
413578|NCT01034514|Drug|DTPA|1 mCi; inhalation
413579|NCT01034514|Drug|TECHNETIUM TC 99M MAA|3 mCi; iv
413580|NCT01034501|Device|sham procedure|non activated laser tip
413581|NCT01034501|Device|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
413582|NCT01034488|Biological|Suine|5000UI /mL
413583|NCT01034488|Biological|Suine|5000UI/mL
413679|NCT01033747|Drug|Deferasirox|5 mg/kg or 30 mg/kg orally daily
413584|NCT01034475|Drug|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient & traditional stages):~Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered.~Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
413585|NCT01034462|Drug|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
413586|NCT01034462|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
413587|NCT01034449|Other|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
413588|NCT01034436|Dietary Supplement|fatty acid quality and overweight|Duration 12 weeks
413589|NCT01034423|Dietary Supplement|Omega-3|Capsules with omega-3 fatty acids.
413590|NCT01034423|Dietary Supplement|sun flower oil|Capsules with sun flower oil.
413591|NCT01034410|Drug|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
413592|NCT01034410|Drug|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
413593|NCT01034397|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
413594|NCT01034397|Drug|placebo|iv every 4 weeks for 24 weeks
413595|NCT01034397|Drug|non-biological DMARDs|stable dose at investigator's prescription
413596|NCT01034371|Procedure|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
413597|NCT01034371|Procedure|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.~Device: Polymer-based Sirolimus-Eluting Stents (SES)."
413598|NCT01034371|Procedure|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
413599|NCT01034358|Biological|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
413600|NCT01034345|Drug|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
413601|NCT01034345|Drug|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
413602|NCT01034332|Procedure|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
413603|NCT01034319|Behavioral|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
413604|NCT01034319|Behavioral|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
413605|NCT01034306|Drug|CF101|orally q12h
413606|NCT01034306|Drug|Placebo control|orally q12 hours
413607|NCT01034293|Dietary Supplement|low feeding frequency (3x)|3 meals a day
413608|NCT01034293|Dietary Supplement|High feeding frequency (14x)|14 meals a day
413609|NCT01034267|Drug|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
413610|NCT01034254|Biological|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
413611|NCT01034254|Biological|saline placebo|Vaccination of pregnant women with saline placebo.
413612|NCT01034241|Dietary Supplement|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
413613|NCT01034241|Dietary Supplement|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
413614|NCT01034241|Dietary Supplement|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
413615|NCT01034241|Dietary Supplement|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
413616|NCT01034228|Other|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
413617|NCT01034228|Other|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
413618|NCT01034215|Behavioral|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
413619|NCT01034215|Behavioral|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
413620|NCT01034202|Drug|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
413621|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
413622|NCT01034202|Drug|placebo|Placebo comparator
413623|NCT01034202|Drug|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
413624|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
413625|NCT01034189|Drug|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
413626|NCT01034189|Drug|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
413628|NCT01034189|Radiation|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
413629|NCT01034176|Drug|levofloxacin|500 mg tablet, daily, 30 days
413630|NCT01034176|Drug|placebo|no dose, tablet, daily, 30 days
413631|NCT01034163|Drug|Panobinostat|
413632|NCT01034163|Drug|Placebo|Placebo
413633|NCT01034150|Device|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
413634|NCT01034150|Device|Placebo stimulation|Placebo stimulation
413635|NCT01034137|Drug|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
413636|NCT01034137|Drug|placebo MTX|orally weekly
413637|NCT01034137|Drug|placebo TCZ|iv every 4 weeks
413638|NCT01034137|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
413639|NCT01034124|Drug|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
413640|NCT01034111|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
413641|NCT01034111|Drug|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
413642|NCT01034046|Other|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
413643|NCT01034046|Other|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
413644|NCT01034020|Drug|Nicotine|
413645|NCT01034007|Combination Product|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
413646|NCT01033994|Biological|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
413647|NCT01033981|Drug|Sunitinib|Treatment for mRCC as indication approved and physician criterium
413648|NCT01033968|Procedure|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
413649|NCT01033955|Drug|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
413650|NCT01033955|Drug|Placebo|identical appearing encapsulated placebo.
413651|NCT01033942|Drug|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
413652|NCT01033942|Drug|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
413653|NCT01033942|Behavioral|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
413654|NCT01033929|Biological|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
413655|NCT01033916|Other|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
413656|NCT01033903|Drug|misoprostol|800 micrograms intravaginally ONCE
413657|NCT01033877|Biological|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
413658|NCT01033877|Biological|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d)
413659|NCT01033864|Drug|MMF|1 g per day b.i.d. p.o. for at least 1 month
413660|NCT01033864|Drug|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
413661|NCT01033864|Drug|Prednisone|5 mg per day p.o.
413662|NCT01033851|Behavioral|Mindfulness Based Stress Reduction|8 week course
413663|NCT01033851|Behavioral|Stress Management Education|8 week course
413664|NCT01033838|Procedure|rectosigmoid resection|
413665|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
413666|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
413667|NCT01033825|Drug|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
413668|NCT01033825|Drug|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
413669|NCT01033825|Drug|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
413670|NCT01033825|Drug|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
413671|NCT01033825|Drug|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
413672|NCT01033799|Other|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
413673|NCT01033799|Other|Non fermented dairy product (control)|
413674|NCT01033773|Drug|Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin|Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
413675|NCT01033773|Behavioral|Diabetes survival skills self-management education|Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
413676|NCT01033760|Drug|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
413677|NCT01033760|Drug|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
413678|NCT01033747|Drug|Deferasirox|10 mg/kg or 30 mg/kg orally daily
413680|NCT01033734|Drug|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
413681|NCT01033721|Drug|Palomid 529|comparison of different dosages of drug
413682|NCT01033708|Behavioral|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
413683|NCT01033669|Device|CRC-749|There is no drug being used. This is a device.
413684|NCT01033669|Device|Diskus|There is no drug being used. This is a device.
413685|NCT01033669|Device|Twisthaler|There is no drug being used. This is a device.
413686|NCT01033669|Device|Miat Monohaler|There is no drug being used. This is a device.
413687|NCT01033656|Drug|anakinra|100 mg subcutaneous injection daily
413688|NCT01033656|Drug|comparators|po drugs, comparators
413689|NCT01033643|Drug|MK3614|0.25 mg BID every 12 hours for 10 days
413690|NCT01033643|Drug|Comparator: MK3614 .75 mg 1st|0.50 mg in the AM, 0.25 mg in the PM 12 hours apart for 10 days
413691|NCT01033643|Drug|Comparator: MK3614 titrating down dose|Day 1 subjects will receive 0.50 mg three times a day every 8 hours. Days 4-13 subjects will receive 0.50 mg twice a day every 12 hours.
413692|NCT01033643|Drug|Comparator: MK3614 multiple rising dose|Day 1 subjects will receive 0.50 mg twice a day every 12 hours. Day 2 subjects will receive 3 doses (0.50/0.50/0.25 mg) each 8 hours apart. Days 3-4 subjects will receive 3 doses of 0.50 mgs 8 hours apart. Days 5-14 subjects will receive 0.75 mgs twice a day every 12 hours.
413693|NCT01033643|Drug|Comparator: Placebo Panel A|Oral Placebo BID every 12 hours for 10 days
413694|NCT01033643|Drug|Comparator: Placebo Panel B-C|Oral Placebo in the AM, 0.25 mg in the PM 12 hours apart for 10 days
413695|NCT01033643|Drug|Comparator: Placebo Panel D|Day 1 subjects will receive oral placebo three times a day every 8 hours. Days 4-13 subjects will receive oral placebo twice a day every 12 hours.
413696|NCT01033643|Drug|Comparator: Placebo Panel E|Day 1 subjects will receive oral placebo twice a day every 12 hours. Day 2 subjects will receive 3 doses of oral placebo each 8 hours apart. Days 3-4 subjects will receive 3 doses of oral placebo 8 hours apart. Days 5-14 subjects will receive oral placebo twice a day every 12 hours.
413697|NCT01033630|Drug|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
413698|NCT01033630|Drug|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
413699|NCT01033630|Drug|Placebo|Image-matched placebo, made with starch.
413700|NCT01033617|Procedure|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
413701|NCT01033604|Procedure|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
413702|NCT01033604|Procedure|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
413703|NCT01033591|Behavioral|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
413704|NCT01033591|Behavioral|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
413705|NCT01033578|Other|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.~TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
413706|NCT01033565|Drug|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
413707|NCT01033552|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
413708|NCT01033552|Drug|Fludarabine|40 mg/m^2/day intravenously on Days -6, -5, -4, -3 and -2.
413709|NCT01033552|Drug|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
413710|NCT01033552|Drug|Cyclosporine A|Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.
413711|NCT01033552|Drug|Mycophenolate mofetil|15 mg/kg intravenous twice per day on days -3 through 30.
413712|NCT01033552|Procedure|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
413713|NCT01033552|Radiation|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
413714|NCT01033552|Procedure|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
413715|NCT01033539|Other|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
413716|NCT01033526|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
413717|NCT01033526|Drug|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
413718|NCT01033500|Drug|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
413719|NCT01033487|Drug|placebo|oral inhaled formulation, single dose
413720|NCT01033487|Drug|active comparator|oral inhaled formulation, single dose
413721|NCT01033487|Drug|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
413722|NCT01033487|Drug|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
413723|NCT01033487|Drug|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
413724|NCT01033461|Dietary Supplement|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
413725|NCT01033461|Dietary Supplement|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
413726|NCT01033461|Other|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
413727|NCT01033448|Drug|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
413728|NCT01033448|Drug|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
413729|NCT01033435|Other|No intervention|
413730|NCT01033422|Drug|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
413731|NCT01033422|Drug|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
413732|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^7 CFU in 10 mL phosphate-buffered saline
413733|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^8 CFU in 10 mL phosphate-buffered saline
413734|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^9 CFU in 10 mL phosphate-buffered saline
413735|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^10 CFU in 10 mL phosphate-buffered saline
413736|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
413737|NCT01033396|Drug|Allegra|Fexofenadine single dose 60 mg
413738|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
413739|NCT01033396|Drug|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
413740|NCT01033396|Drug|Placebo|Placebo single dose
413741|NCT01033383|Dietary Supplement|Placebo|36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
413742|NCT01033383|Dietary Supplement|Cranberry Capsule|36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
413743|NCT01033370|Drug|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes & titrated to the desired BP lowering effect to SBP goal of < 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
413744|NCT01033357|Device|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
413745|NCT01033357|Device|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
413746|NCT01033344|Biological|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
413747|NCT01033344|Biological|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
413748|NCT01033344|Biological|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
413749|NCT01033318|Drug|MK1809|single oral doses of MK1809
413750|NCT01033318|Drug|Comparator: Losartan|single oral doses of 100 mg Losartan
413751|NCT01033318|Drug|Comparator: Placebo|Placebo to MK1809
413752|NCT01033305|Drug|CyCol™|Orally, once per day for 4 weeks
413753|NCT01033305|Drug|Placebo|Orally, once per day for 4 weeks
413754|NCT01033292|Drug|BSI-201|IV infusion, 5.6 mg/kg
413755|NCT01033279|Other|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
413756|NCT01033266|Device|CPAP|CPET will be done on patients with overlap syndrome before and after CPAP treatment
413757|NCT01033253|Behavioral|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
413758|NCT01033240|Drug|CS-1008|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg, followed by 4 mg/kg if tolerated, followed by 6 mg/kg if tolerated.
413759|NCT01033240|Drug|sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
413760|NCT01033227|Drug|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
413761|NCT01033214|Device|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
413762|NCT01033201|Other|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
413763|NCT01033188|Procedure|Single bundle|"Procedure:~Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
413795|NCT01033006|Procedure|Active Comparator: Arm 3: catheter and transarterial injection|
413796|NCT01032993|Dietary Supplement|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
413764|NCT01033188|Procedure|Double bundle|"Procedure:~Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith & Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
413765|NCT01033175|Procedure|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
413766|NCT01033175|Procedure|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
413767|NCT01033162|Behavioral|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:~Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)~Reduce patients' negative affect and increase their emotional well being~Improve patients' sense of social support~Improve patients' health self-efficacy~Improve patients' ratings of experience with cancer specialty care services~Improve patients' health related quality of life (HRQL)~Improve clinicians' ratings of quality of patient contacts~Reduce healthcare utilization and costs (obtained via the EMR)"
413768|NCT01033149|Drug|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
413769|NCT01033136|Behavioral|Multiple Channel Exposure Therapy - Veterans|MCET-V offers individual therapy that provides psychoeducation about panic attacks and trauma and involves behavioral and cognitive exposure exercises.
413770|NCT01033136|Behavioral|Cognitive Processing Therapy|CPT offers individual therapy that targets trauma and PTSD symptoms via cognitive restructuring.
413771|NCT01033123|Drug|BSI-201|IV infusion, 5.6 mg/kg
413772|NCT01033110|Behavioral|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
413773|NCT01033097|Drug|DNK333 5 mg|5 mg oral
413774|NCT01033097|Drug|Placebo to 5 mg|5 mg placebo oral
413775|NCT01033097|Drug|DNK333 25 mg|25 mg oral
413776|NCT01033097|Drug|Placebo to 25 mg|25 mg placebo oral
413777|NCT01033097|Drug|DNK333 100 mg|100 mg oral
413778|NCT01033097|Drug|Placebo to 100 mg|100 mg placebo oral
413779|NCT01033097|Drug|Betamethasone 4 mg|4 mg oral
413780|NCT01033097|Drug|DNK333 1mg|1 mg oral
413781|NCT01033097|Drug|Placebo to 1mg|1 mg placebo oral
413782|NCT01033084|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
413783|NCT01033084|Drug|Sertraline|Patient will receive sertraline 50mg/day.
413784|NCT01033084|Other|double placebo|double placebo arm (sham stimulation/placebo pill)
413785|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
413786|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
413787|NCT01033071|Drug|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.~Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.~Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
413788|NCT01033058|Drug|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
413789|NCT01033058|Drug|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
413790|NCT01033032|Drug|Amrubicin|"Phase I: dose escalating portion with the starting dose of amrubicin at 90mg/m2 IV q21 days. Dose escalations are as follows:~DL2 - 100mg/m2; DL3 - 110mg/m2; and DL4 - 120mg/m2. All cycles are q21 days~Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
413791|NCT01033019|Drug|LDE225 0.75%|0.75% cream
413792|NCT01033019|Drug|Vehicle|matching placebo cream to 0.75% LDE225 cream
413793|NCT01033006|Procedure|Active Comparator: Arm 1: catheter injection|
413794|NCT01033006|Procedure|Active Comparator: Arm 2: transarterial injection|
413921|NCT01031979|Drug|Yohimbine|alpha-2 adrenergic receptor antagonist
413797|NCT01032993|Other|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
413798|NCT01032967|Procedure|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
413799|NCT01032967|Radiation|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
413800|NCT01032954|Drug|Botulinum toxin|"The following list shows the indications for eligibility and total doses that will be applied in each part of the face, according to the consensus meeting recommendations, at the 1 visit:~Upper face:~Crow's feet wrinkles - 70 U~Glabella - 50 U~Forehead - 40 U~Mid face:~Lower eyelid - 5 U~Nasal wrinkles - 20 U~Malar wrinkles - 10 U~Lower face:~Peri-oral wrinkles - 15U~Asymmetric smile or gummy smile - 5U~Cellulitic chin - 20U~Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.~Patients will be allocated in each group according to the total dose received at visit 1(described above). At visit 2, all the patients will receive a touch-up of a standard dose of 25 Units of Dysport®, distributed on the treated areas according patient's needs."
413801|NCT01032941|Drug|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
413802|NCT01032928|Behavioral|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
413803|NCT01032915|Biological|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
413804|NCT01032915|Biological|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
413805|NCT01032915|Biological|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
413806|NCT01032915|Drug|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
413807|NCT01032902|Device|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
413808|NCT01032889|Drug|Deoxycholic acid injection|
413809|NCT01032889|Drug|Placebo|Phosphate buffered saline placebo for injection
413810|NCT01032876|Procedure|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
413811|NCT01032876|Procedure|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
413812|NCT01032850|Drug|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
413813|NCT01032837|Drug|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
413814|NCT01032837|Drug|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
413815|NCT01032837|Drug|Placebo|Matching placebo provided as capsules and as a suspension.
413816|NCT01032824|Behavioral|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
413817|NCT01032824|Other|Group Arm|10-session didactic telephone group
413818|NCT01032824|Other|Book Arm|Book only.
413819|NCT01032798|Drug|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
413820|NCT01032785|Device|no interventions|no interventions
413821|NCT01032772|Behavioral|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
413822|NCT01032772|Behavioral|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
413823|NCT01032759|Drug|Memantine|20 mg, BID
413824|NCT01032759|Drug|Placebo|BID
413825|NCT01032746|Other|educational intervention|
413826|NCT01032746|Other|internet-based intervention|
413827|NCT01032746|Procedure|evaluation of cancer risk factors|
413828|NCT01032746|Procedure|fecal occult blood test|
413829|NCT01032746|Procedure|screening colonoscopy|
413830|NCT01032733|Behavioral|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
413831|NCT01032733|Other|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
413832|NCT01032720|Procedure|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
413833|NCT01032720|Procedure|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
413834|NCT01032694|Drug|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
413835|NCT01032694|Drug|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
413836|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
413837|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 2: CPA plus 0,6mg/kg - 0,9mg/kg~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
413838|NCT01032681|Biological|EMD 521873|"Dose escalation steps:~Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)~Disease control and decision of continuation in patient who benefit from the treatment:~Every second cycle"
413839|NCT01032668|Drug|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
413840|NCT01032655|Drug|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid~plus either one of the following~Klaricid, 500 mg, bid~Cravit, 250 mg, bid~Tetracycline, 500 mg, bid"
413841|NCT01032642|Device|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
413842|NCT01032629|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily
413843|NCT01032629|Drug|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
413844|NCT01032629|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
413845|NCT01032616|Other|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
413846|NCT01032616|Other|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
413847|NCT01032603|Procedure|Bilateral lateral rectus recession (BLRc)|Bilateral lateral rectus recession surgery
413848|NCT01032603|Procedure|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
413849|NCT01032590|Behavioral|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
413850|NCT01032564|Other|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
413851|NCT01032551|Behavioral|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
413852|NCT01032512|Dietary Supplement|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
413853|NCT01032512|Dietary Supplement|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
413854|NCT01032499|Drug|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
413855|NCT01032499|Drug|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
413856|NCT01032486|Drug|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
413857|NCT01032460|Device|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
413858|NCT01032460|Device|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
413859|NCT01032460|Device|intubate with the Airtraq device|intubate with the Airtraq device
413860|NCT01032447|Behavioral|Navigator Support|Standard of Care
413861|NCT01032434|Drug|sertraline|sertraline: 50-200mg/day
413862|NCT01032421|Procedure|IVF procedure|
413863|NCT01032408|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
413864|NCT01032408|Biological|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
413865|NCT01032395|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
413866|NCT01032395|Biological|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
413867|NCT01032395|Biological|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
413868|NCT01032382|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
413869|NCT01032382|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
413870|NCT01032369|Other|Nutritional intervention and physical activity|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
413871|NCT01032369|Other|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:~Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.~Physical activity:~All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).~Behavioral treatment:~This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
413872|NCT01032356|Device|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
413873|NCT01032343|Dietary Supplement|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
413874|NCT01032343|Dietary Supplement|Gelatine|One capsule daily for 3 months
413875|NCT01032330|Device|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
413919|NCT01031992|Drug|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
413920|NCT01031992|Drug|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
413876|NCT01032317|Device|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
413877|NCT01032304|Drug|Erdosteine|One 300 mg capsule twice a day
413878|NCT01032304|Drug|Placebo|One capsule twice a day
413879|NCT01032291|Drug|cetuximab|Intravenous infusions of cetuximab (400 mg/m^2 Cycle 1 Day 1, thereafter 250 mg/m^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
413880|NCT01032291|Drug|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
413881|NCT01032278|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
413882|NCT01032278|Behavioral|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
413883|NCT01032265|Behavioral|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
413884|NCT01032265|Behavioral|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
413885|NCT01032252|Other|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.~Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
413886|NCT01032239|Drug|intrathecal baclofen|ITB test, implant, 6 months follow-up
413887|NCT01032213|Drug|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
413888|NCT01032213|Drug|normal saline|Group S received the same volume of isotonic saline as same method.
413889|NCT01032200|Drug|Armodafinil|Given orally
413890|NCT01032200|Other|placebo|Given orally
413891|NCT01032187|Drug|Meglumine antimoniate|20mg/kg/day IV for 20 days
413892|NCT01032187|Drug|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
413893|NCT01032174|Drug|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
413894|NCT01032174|Drug|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
413895|NCT01032148|Drug|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
413896|NCT01032135|Behavioral|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
413897|NCT01032135|Behavioral|Telephone counseling|one telephone counseling session per week for 10 weeks.
413898|NCT01032135|Behavioral|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
413899|NCT01032135|Drug|medication management|Prescription for naltrexone
413900|NCT01032135|Behavioral|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
413901|NCT01032122|Drug|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
413902|NCT01032109|Drug|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
413903|NCT01032083|Drug|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
413904|NCT01032083|Drug|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
413905|NCT01032070|Drug|erlotinib|oral
413906|NCT01032070|Drug|etoposide|oral
413907|NCT01032057|Drug|capecitabine|
413908|NCT01032057|Drug|gemcitabine hydrochloride|
413909|NCT01032057|Procedure|quality-of-life assessment|
413910|NCT01032057|Radiation|3-dimensional conformal radiation therapy|
413911|NCT01032044|Device|Standard endoscopic evaluation|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
413912|NCT01032044|Device|pCLE guided evaluation|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
413913|NCT01032031|Dietary Supplement|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
413914|NCT01032031|Dietary Supplement|Placebo capsule|One capsule daily for 3 months
413915|NCT01032018|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
413916|NCT01032018|Drug|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
413917|NCT01032018|Other|Standard care|Participants will receive standard of care from the current physicians
413918|NCT01032005|Other|double fortified salt|Refined salt of particle size < 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
413923|NCT01031966|Biological|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
413924|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
413925|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
413926|NCT01031953|Drug|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
413927|NCT01031953|Drug|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
413928|NCT01031953|Other|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
413929|NCT01031953|Procedure|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
413930|NCT01031940|Device|macintosh laryngoscope|intubate with the macintosh laryngoscope
413931|NCT01031940|Device|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
413932|NCT01031940|Device|Airtraq device|intubate with the Airtraq device
413933|NCT01031927|Drug|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
413934|NCT01031914|Device|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
413935|NCT01031901|Drug|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
413936|NCT01031901|Drug|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
413937|NCT01031901|Drug|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
413938|NCT01031888|Drug|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
413939|NCT01031888|Drug|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
413940|NCT01031875|Drug|pazopanib hydrochloride|
413941|NCT01031875|Radiation|fludeoxyglucose F 18|
413942|NCT01031862|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
413943|NCT01031849|Drug|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
413944|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
413945|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
413946|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
413947|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
413948|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
413949|NCT01031836|Drug|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
413950|NCT01031823|Behavioral|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
413951|NCT01031810|Drug|tranylcypromine|MAO-Inhibitor 60mg-120mg
413952|NCT01031784|Device|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
413953|NCT01031784|Device|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
413954|NCT01031758|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
413955|NCT01031745|Behavioral|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
413956|NCT01031745|Other|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
413957|NCT01031732|Procedure|MIS-2 THA|MIS two-incision THA
413958|NCT01031732|Procedure|MIS-WJ|MIS-Watson Jones THA
413959|NCT01031732|Procedure|MIS-AL THA|Transgluteal approach
413960|NCT01031732|Procedure|MIS-PL THA|Posterolateral approach
413961|NCT01031719|Biological|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
413962|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
413963|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
413964|NCT01031706|Drug|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
413965|NCT01031706|Drug|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
413966|NCT01031693|Device|Transcranial Magnetic Stimulation|daily sessions for 5 days
413967|NCT01031680|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
413968|NCT01031680|Drug|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
413969|NCT01031667|Drug|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
413970|NCT01031628|Drug|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
413971|NCT01031628|Drug|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
413972|NCT01031628|Drug|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
413973|NCT01031615|Behavioral|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
413974|NCT01031615|Behavioral|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
413975|NCT01031602|Behavioral|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
413976|NCT01031589|Drug|TMC278 (Rilpivirine) LA; Placebo|
413977|NCT01031550|Drug|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
413978|NCT01031550|Drug|propofol|standard of care
413979|NCT01031537|Biological|FSME-IMMUN 0.5ml Baxter|Vaccine
413980|NCT01031524|Biological|PfCS102|Antigen of the sporozoite protein
413981|NCT01031524|Biological|Montanide ISA 720|adjuvant alone
413982|NCT01031511|Behavioral|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
413983|NCT01031511|Other|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
413984|NCT01031498|Drug|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
413985|NCT01031498|Drug|Palonosetron|"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.~Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."
413986|NCT01031485|Dietary Supplement|Milk peptides and plant sterols|
413987|NCT01031485|Other|Placebo|
413988|NCT01031472|Drug|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
413989|NCT01031472|Drug|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
413990|NCT01031472|Drug|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
413991|NCT01031472|Drug|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
413992|NCT01031459|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
413993|NCT01031446|Drug|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
413994|NCT01031446|Drug|everolimus|Taken daily by mouth.
413995|NCT01031446|Drug|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
413996|NCT01031446|Other|laboratory biomarker analysis|Blood collection
413997|NCT01031420|Drug|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
413998|NCT01031394|Other|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
413999|NCT01031381|Drug|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
414000|NCT01031381|Drug|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
414001|NCT01031368|Drug|cytarabine|Given IV
414002|NCT01031368|Drug|clofarabine|Given IV
414003|NCT01031368|Drug|filgrastim|Given SC
414004|NCT01031368|Biological|Ex-vivo expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
414005|NCT01031368|Other|laboratory biomarker analysis|Correlative studies
414006|NCT01031355|Drug|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
414007|NCT01031355|Drug|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
414008|NCT01031355|Drug|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
414009|NCT01031342|Procedure|Early colonoscopy|Colonoscopy within 12 hours of presentation
414010|NCT01031342|Procedure|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
414011|NCT01031329|Procedure|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
414012|NCT01031316|Other|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
414013|NCT01031316|Other|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
414014|NCT01031303|Biological|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
414015|NCT01031290|Device|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
414016|NCT01031225|Drug|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
414017|NCT01031212|Drug|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
414018|NCT01031212|Drug|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
414019|NCT01031212|Drug|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
414020|NCT01031212|Drug|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
414021|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
414022|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
414023|NCT01031186|Drug|GSK356278|GSK356278
414024|NCT01031186|Drug|PLACEBO|PLACEBO
414025|NCT01031173|Biological|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
414026|NCT01031147|Other|Examination|3D−TOF−MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
414027|NCT01031134|Behavioral|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
414028|NCT01031134|Other|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
414029|NCT01031108|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.~Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
414030|NCT01031108|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
414031|NCT01031095|Other|coronary intervention|elective coronary intervention
414032|NCT01031082|Procedure|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
414033|NCT01031069|Biological|GSK Biologicals' HPV vaccine 580299|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
414034|NCT01031069|Biological|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
414035|NCT01031056|Procedure|Blood Draw|
414036|NCT01031056|Procedure|Frozen Tumor Specimens|
414037|NCT01031043|Drug|Bethanechol|Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
414038|NCT01031030|Drug|cyclophosphamide|
414039|NCT01031030|Drug|epirubicin hydrochloride|
414040|NCT01031030|Drug|fluorouracil|
414041|NCT01031030|Drug|methotrexate|
414042|NCT01031030|Other|laboratory biomarker analysis|
414043|NCT01031030|Procedure|adjuvant therapy|
414044|NCT01031017|Drug|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
414045|NCT01031017|Drug|placebo|placebo
414046|NCT01031004|Device|narafilcon B|contact lens
414047|NCT01031004|Device|etafilcon A|contact lens
414048|NCT01030978|Behavioral|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
414049|NCT01030978|Behavioral|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
414050|NCT01030965|Drug|GSK573719 125mcg|125mcg once-daily
414051|NCT01030965|Drug|GSK573719 250mcg|250mcg once-daily
414052|NCT01030965|Drug|GSK573719 500mcg|500mcg once-daily
414053|NCT01030965|Drug|Placebo|once-daily
414054|NCT01030952|Drug|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
414055|NCT01030952|Drug|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
414056|NCT01030939|Drug|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
414057|NCT01030926|Drug|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
414058|NCT01030926|Drug|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
414059|NCT01030900|Biological|campath|campath plus EPOCH and rituximab every 3 weeks for up to 6 cycles
414060|NCT01030900|Biological|Rituximab|rituximab plus EPOCH and campath every 3 weeks for up to 6 cycles
414061|NCT01030900|Drug|EPOCH|EPOCH plus rituximab and campath every 3 weeks for up to 6 cycles
414062|NCT01030887|Behavioral|Exercise programme|Moderate intensity exercise
414205|NCT01029821|Drug|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
414063|NCT01030874|Other|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
414064|NCT01030874|Dietary Supplement|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
414065|NCT01030874|Other|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
414066|NCT01030874|Other|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
414067|NCT01030874|Drug|Drug|Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily [Mukai 2002; Grubb 2003]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily [Low, 1997]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
414068|NCT01030861|Drug|Teplizumab|intravenous infusions
414069|NCT01030861|Drug|Placebo infusion|Placebo for Teplizumab
414070|NCT01030848|Device|Total Knee Replacement (LCS rotating platform)|
414071|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
414072|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
414073|NCT01030809|Other|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
414074|NCT01030796|Behavioral|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
414075|NCT01030783|Drug|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
414076|NCT01030783|Drug|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
414077|NCT01030770|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
414078|NCT01030770|Drug|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
414079|NCT01030757|Radiation|Tomotherapy treatment|"A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~Dose will be prescribed to the isodose line which covers at least 90% of the PTV~Dose homogeneity +/- 5%"
414080|NCT01030731|Drug|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
414081|NCT01030718|Drug|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
414082|NCT01030692|Drug|Placebo|The placebo groups will receive the same dosage throughout the study.
414083|NCT01030692|Drug|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
414084|NCT01030692|Drug|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
414085|NCT01030692|Drug|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
414086|NCT01030692|Drug|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
414087|NCT01030679|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
414088|NCT01030679|Drug|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
414089|NCT01030679|Drug|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
414090|NCT01030679|Drug|Placebo|orally, 1 tablet once daily for 8 weeks
414091|NCT01030666|Drug|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
414092|NCT01030666|Drug|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
414093|NCT01030666|Procedure|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
414094|NCT01030666|Biological|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
414095|NCT01030666|Drug|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
414096|NCT01030666|Drug|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
414097|NCT01030666|Drug|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
414098|NCT01030653|Drug|Voriconazole low dose|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
414099|NCT01030653|Drug|Voriconazole high dose|Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
414100|NCT01030640|Other|placebo|single dose of the drug formulation
414101|NCT01030640|Biological|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
414102|NCT01030627|Device|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
414103|NCT01030614|Drug|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
414104|NCT01030614|Drug|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
414105|NCT01030601|Drug|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
414106|NCT01030575|Drug|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
414107|NCT01030575|Drug|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
414108|NCT01030575|Drug|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
414109|NCT01030575|Drug|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
414110|NCT01030536|Drug|CAT-8015 20 mcg/kg|Participants will receive 20 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
414111|NCT01030536|Drug|CAT-8015 30 mcg/kg|Participants will receive 30 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
414112|NCT01030536|Drug|CAT-8015 40 mcg/kg|Participants will receive 40 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
414113|NCT01030536|Drug|CAT-8015 50 mcg/kg|Participants will receive 50 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
414114|NCT01030536|Drug|CAT-8015 60 mcg/kg|Participants will receive 60 mcg/kg Moxetumomab pasudotox (CAT-8015) as an intravenous (IV) infusion over 30 minutes on Days 1, 3, and 5 of every 28-day cycle.
414115|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
414116|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)
414117|NCT01030510|Drug|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
414118|NCT01030471|Behavioral|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
414119|NCT01030458|Drug|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
414120|NCT01030458|Drug|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
414121|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
414122|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
414123|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
414124|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
414125|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
414126|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
414127|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
414128|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
414129|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
414201|NCT01029847|Drug|Adalimumab|Sc. inj. adalimumab 40 mg every other week for 42 to 48 weeks. At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
414206|NCT01029795|Drug|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
414130|NCT01030419|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
414131|NCT01030419|Behavioral|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
414132|NCT01030406|Drug|40/0mg taken first|8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
414133|NCT01030406|Drug|80/0mg taken first|8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
414134|NCT01030406|Drug|40/240mg taken first|8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
414135|NCT01030406|Drug|80/480mg taken first|8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
414136|NCT01030406|Drug|0/0mg taken first|Placebo All arms taken with a 48 hour washout between doses
414137|NCT01030393|Drug|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
414138|NCT01030380|Device|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
414139|NCT01030367|Drug|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
414140|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
414141|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
414142|NCT01030341|Device|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
414143|NCT01030328|Drug|Placebo|2 sugar pills by mouth once a day.
414144|NCT01030328|Drug|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
414145|NCT01030315|Drug|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
414146|NCT01030302|Drug|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
414147|NCT01030289|Device|real tDCS|transcranial direct current stimulation
414148|NCT01030289|Device|sham tDCS|transcranial direct current stimulation
414149|NCT01030276|Other|Bright light therapy|Bright light therapy
414150|NCT01030276|Other|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
414151|NCT01030263|Other|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
414152|NCT01030263|Other|Random four-quadrant biopsies.|Random four-quadrant biopsies.
414153|NCT01030237|Other|FID 114657|1 drop both eyes four times a day for 6 weeks
414154|NCT01030237|Other|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
414155|NCT01030224|Drug|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
414156|NCT01030224|Drug|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
414157|NCT01030211|Procedure|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
414158|NCT01030211|Other|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
414159|NCT01030198|Device|RevLite (Laser Treatment)|
414160|NCT01030185|Device|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
414161|NCT01030159|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
414162|NCT01030146|Drug|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
414163|NCT01030133|Device|Operator Role Real TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
414164|NCT01030133|Device|Receiver Role Real TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Real TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
414165|NCT01030133|Device|Operator Role Sham TMS|"In two of the four visits, the participant will be assigned to the operator condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The operator's performance will control the painfulness delivered to both participants. Each participant will play each role twice."
414202|NCT01029847|Drug|Placebo|"sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines."
414166|NCT01030133|Device|Receiver Role Sham TMS|"In two of the four visits, the participant will be assigned to the receiver condition receiving Sham TMS. The participant will be assigned a partner and both participants will participate in a numeric-combination-guessing task. Performance on this task will be directly related to the painfulness of a series of thermal stimuli that participants receive. The receiver's performance on the task will be unrelated to his/her stimulus painfulness. Each participant will play each role twice."
414167|NCT01030133|Device|All Participants Operator Role|All participants in Operator Role (Receiving real or sham TMS)
414168|NCT01030120|Drug|etanercept|etanercept 50mg BIW S.Q.
414169|NCT01030120|Drug|placebo|placebo
414170|NCT01030107|Behavioral|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
414171|NCT01030107|Behavioral|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
414172|NCT01030094|Drug|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
414173|NCT01030094|Drug|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
414174|NCT01030094|Drug|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
414175|NCT01030094|Drug|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
414176|NCT01030081|Drug|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
414177|NCT01030081|Drug|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
414178|NCT01030068|Behavioral|Yoga|Yoga twice weekly
414179|NCT01030068|Behavioral|Wellness|Health and wellness classes twice weekly
414180|NCT01030068|Other|Smoking cessation therapy|Smoking cessation therapy
414181|NCT01030055|Drug|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
414182|NCT01030042|Drug|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
414183|NCT01030042|Drug|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.~IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
414184|NCT01030029|Device|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point [2]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
414185|NCT01030029|Device|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
414186|NCT01030016|Drug|atenolol|25 mg/day, twice a day for 6 weeks
414187|NCT01029990|Other|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
414188|NCT01029990|Other|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
414189|NCT01029964|Behavioral|Individually and in groups|During three year in a clinical setting.
414190|NCT01029951|Procedure|manipulation|
414191|NCT01029951|Procedure|Mobilisation|
414192|NCT01029951|Device|Activator instrument|
414193|NCT01029938|Procedure|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
414194|NCT01029938|Procedure|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
414195|NCT01029925|Drug|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
414196|NCT01029912|Device|Electrical stimulator|"6-week intervention~15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.~Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
414197|NCT01029886|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly
414198|NCT01029886|Drug|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
414199|NCT01029873|Drug|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
414200|NCT01029873|Biological|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses~Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)~Stage 2: dose expansion (dose at MTD)"
414203|NCT01029834|Behavioral|family based lifestyle and behavioral counseling|16 group meetings
414204|NCT01029834|Behavioral|counseling focused on the child|16 meetings
414207|NCT01029795|Drug|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
414208|NCT01029795|Drug|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
414209|NCT01029782|Drug|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
414210|NCT01029782|Drug|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
414211|NCT01029769|Drug|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
414212|NCT01029756|Device|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
414213|NCT01029756|Device|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
414214|NCT01029743|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
414215|NCT01029743|Drug|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
414216|NCT01029730|Drug|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
414217|NCT01029730|Drug|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
414218|NCT01029730|Drug|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
414219|NCT01029717|Device|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
414220|NCT01029717|Device|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
414221|NCT01029717|Device|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
414222|NCT01029704|Drug|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.~Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
414223|NCT01029704|Drug|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.~Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
414224|NCT01029691|Device|Positive Airway Pressure|Women will use positive airway pressure until delivery
414225|NCT01029678|Drug|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
414226|NCT01029678|Drug|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
414227|NCT01029678|Radiation|Radiotherapy|66Gy, 33 fractions, 6 week
414228|NCT01029652|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
414229|NCT01029652|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
414230|NCT01029652|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
414231|NCT01029652|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
414232|NCT01029639|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
414233|NCT01029626|Procedure|Endoscopy|Realization of an upper GI endoscopy
414234|NCT01029613|Drug|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
414235|NCT01029600|Procedure|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
414236|NCT01029600|Procedure|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
414237|NCT01029587|Drug|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
414238|NCT01029574|Other|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
414239|NCT01029561|Device|CPAP|Treatment with Continuous Positive Airway Pressure
414240|NCT01029561|Behavioral|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
414241|NCT01029535|Device|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
414242|NCT01029522|Drug|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
414243|NCT01029522|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
414244|NCT01029509|Drug|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
414276|NCT01029197|Other|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
414245|NCT01029496|Procedure|different time of umbilical cord clamping|"for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.~control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.~for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):~experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.~control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
414246|NCT01029483|Other|Low carbohydrate diet|Ad libitum low carbohydrate diet (<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
414247|NCT01029483|Other|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
414248|NCT01029483|Other|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at ~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
414249|NCT01029470|Drug|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
414250|NCT01029444|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
414251|NCT01029431|Device|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted & the evaluation described below will be conducted. The first LMA will then be removed & the other device inserted & assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment & before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, & inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
414252|NCT01029418|Drug|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
414253|NCT01029405|Drug|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
414254|NCT01029405|Drug|Placebo|Ointment B Vehicle applied once or twice daily
414255|NCT01029392|Drug|Vitamin D|2000iu once a day
414256|NCT01029366|Biological|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
414257|NCT01029353|Procedure|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
414258|NCT01029353|Procedure|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
414259|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
414260|NCT01029340|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
414261|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
414262|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
414263|NCT01029301|Device|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
414264|NCT01029288|Other|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
414265|NCT01029288|Other|Statin Choice Decision Aid|Statin Choice Cards
414266|NCT01029288|Other|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
414267|NCT01029288|Other|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
414268|NCT01029275|Drug|Pre-treatment with octreotide|Pre-treatment with octreotide
414269|NCT01029262|Drug|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
414270|NCT01029262|Other|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
414271|NCT01029236|Other|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
414272|NCT01029223|Drug|ivabradine|
414273|NCT01029223|Drug|metoprolol|
414274|NCT01029223|Drug|placebo|
414275|NCT01029197|Behavioral|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
414617|NCT01026545|Drug|PF-04287881|500 mg once daily for 10 days
414277|NCT01029184|Other|commercialized complete cereals|complete cereals suitable for the weaning period
414278|NCT01029184|Other|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
414279|NCT01029171|Behavioral|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
414280|NCT01029171|Behavioral|control; usual care|Usual care as prescribed by geriatrician.
414281|NCT01029158|Drug|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
414282|NCT01029158|Drug|RN1006 (Avotermin)|250 ng, intradermal injection, twice
414283|NCT01029158|Drug|RN1006 (Avotermin)|205 ng, Intradermal injection, once
414284|NCT01029158|Drug|RN1006 (Avotermin)|500ng, intradermal injection, once
414285|NCT01029158|Drug|Juvista (Avotermin)|250 ng, intradermal injection, twice
414286|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
414287|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
414288|NCT01029158|Drug|RN1006 (Avotermin)|500 ng, intradermal injection, twice
414289|NCT01029158|Drug|Placebo|Placebo
414290|NCT01029132|Drug|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
414291|NCT01029106|Procedure|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
414292|NCT01029093|Other|no intervention, MRI and motor skill test|Two MR Investigations at two different times
414293|NCT01029080|Other|no interventions|No interventions
414294|NCT01029067|Behavioral|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
414295|NCT01029067|Behavioral|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
414296|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
414297|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
414298|NCT01029041|Other|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
414299|NCT01029041|Other|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
414300|NCT01029015|Procedure|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
414301|NCT01029015|Procedure|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
414302|NCT01029002|Drug|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
414303|NCT01029002|Other|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
414304|NCT01028989|Dietary Supplement|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein~Glycemic Load <=46 per 1000 calories"
414305|NCT01028989|Dietary Supplement|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein~Glycemic Load >=77 per 1000 calories"
414306|NCT01028976|Dietary Supplement|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
414307|NCT01028976|Dietary Supplement|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
414308|NCT01028963|Drug|Placebo|Placebo capsules once daily
414309|NCT01028963|Drug|pioglitazone|pioglitazone 30 mg tablet once daily
414310|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
414311|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group D)
414312|NCT01028950|Drug|YM150|oral
414313|NCT01028937|Device|Optimal Keratoplasty|Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
414314|NCT01028924|Drug|Teduglutide|subcutaneous (SC), single dose
414315|NCT01028911|Drug|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
414316|NCT01028911|Drug|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.~Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
414317|NCT01028885|Procedure|radiation therapy treatment planning/simulation|
414318|NCT01028885|Procedure|intensity-modulated radiation therapy|
414319|NCT01028885|Procedure|image-guided radiation therapy|
414320|NCT01028885|Procedure|magnetic resonance imaging|
414321|NCT01028885|Procedure|computed tomography|
414322|NCT01028872|Device|Intraocular lens|
414323|NCT01028872|Device|Intraocular lens|
414324|NCT01028872|Device|Intraocular lens|
414325|NCT01028859|Drug|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 ~ mg/m2; Day 1, Day 8 every 3 weeks
414326|NCT01028846|Drug|Diazoxide|4mg-6mg/kg orally once before study
414327|NCT01028846|Drug|Glyburide|Administered orally at beginning of study
414328|NCT01028846|Device|Vagal Nerve Stimulator|Device approved for the purpose of decreasing seizure frequency in patients with poorly-controlled epilepsy
414329|NCT01028833|Other|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
414330|NCT01028820|Drug|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
414331|NCT01028807|Other|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
414332|NCT01028807|Other|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
414333|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
414334|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
414335|NCT01028781|Drug|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
414336|NCT01028768|Drug|Teduglutide|10 mg, one-time subcutaneous
414337|NCT01028755|Drug|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
414338|NCT01028729|Drug|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
414339|NCT01028729|Drug|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
414340|NCT01028716|Drug|Cyclophosphamide|Given IV
414341|NCT01028716|Biological|Filgrastim|Given IV
414342|NCT01028716|Drug|Fludarabine Phosphate|Given IV
414343|NCT01028716|Procedure|Laboratory Biomarker Analysis|Correlative studies
414344|NCT01028716|Drug|Mycophenolate Mofetil|Given PO
414345|NCT01028716|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
414346|NCT01028716|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
414347|NCT01028716|Drug|Tacrolimus|Given IV or PO
414348|NCT01028716|Radiation|Total-Body Irradiation|Undergo total-body irradiation (TBI)
414349|NCT01028716|Drug|Fludarabine|Given IV
414350|NCT01028690|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
414351|NCT01028690|Dietary Supplement|Placebo|placebo
414352|NCT01028677|Drug|intranasal spray with oxytocin|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
414353|NCT01028677|Other|nasal spray without oxytocin|6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
414354|NCT01028664|Device|SENSIMED Triggerfish|2-hour continuous IOP monitoring
414355|NCT01028651|Drug|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
414356|NCT01028638|Other|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.~PET scans are made on day 1, day 15 and day 43."
414357|NCT01028625|Behavioral|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
414358|NCT01028625|Other|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
414359|NCT01028612|Radiation|thermal ablation with external beam radiation|thermal ablation with external beam radiation
414360|NCT01028599|Other|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
414361|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
414362|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
414363|NCT01028586|Drug|Placebo|matching placebo tablets
414364|NCT01028573|Drug|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
414365|NCT01028573|Drug|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
414670|NCT01026311|Drug|placebo|1 placebo q d during treatment period
414366|NCT01028573|Drug|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
414367|NCT01028573|Drug|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
414368|NCT01028560|Biological|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety, the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
414369|NCT01028560|Other|Standard of care|standard of care asthma and allergy treatment
414370|NCT01028547|Drug|dexamethasone|single Bolus dose of dexamethasone 8mg
414371|NCT01028547|Other|normal saline|2 ml 0.9% saline
414372|NCT01028534|Drug|Olmesartan and Azelnidipine|"Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months~Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months~Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
414373|NCT01028521|Drug|CM3.1-AC100|Solution for sc injection, single ascending doses
414374|NCT01028521|Drug|Placebo|Solution for sc injection
414375|NCT01028508|Drug|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
414376|NCT01028508|Procedure|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
414377|NCT01028495|Drug|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
414378|NCT01028482|Drug|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months~group B- weekly psychotherapy- for 3 months~group C- sertraline 50-100 mg/day-for 3 months"
414379|NCT01028482|Drug|placebo|placebo
414380|NCT01028482|Other|psychotherapy|psychotherapy
414381|NCT01028469|Device|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
414382|NCT01028456|Other|Light Therapy|10,000 lux / 30 minutes a day
414383|NCT01028456|Other|100 lux|Placebo light
414384|NCT01028443|Drug|Sandimmune|
414385|NCT01028443|Drug|Artelose|
414386|NCT01028417|Device|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
414387|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
414388|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
414389|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
414390|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
414391|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
414392|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
414393|NCT01028391|Drug|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
414394|NCT01028391|Drug|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
414395|NCT01028391|Drug|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
414396|NCT01028378|Device|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
414397|NCT01028365|Other|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
414398|NCT01028352|Drug|Duloxetine|"Patients will be treated with open-label duloxetine:~30 mg daily x 7 days, then~60 mg daily x 3 weeks, then~If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8~If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.~After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
414399|NCT01028339|Drug|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
414400|NCT01028339|Drug|Mannitol|Mannitol
414401|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
414402|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
414403|NCT01028326|Biological|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
414404|NCT01028313|Drug|LBH589|20 mg PO three times weekly
414405|NCT01028313|Drug|Methylprednisolone|1 mg/kg/day PO continuously
414406|NCT01028300|Device|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
414407|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
414408|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
414409|NCT01028274|Dietary Supplement|Placebo|Two capsules, twice daily with meals for 12 weeks.
414410|NCT01028274|Dietary Supplement|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
414411|NCT01028274|Dietary Supplement|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
414412|NCT01028261|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
414413|NCT01028248|Drug|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
414414|NCT01028222|Drug|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
414415|NCT01028222|Drug|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
414416|NCT01028209|Drug|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]PBR06, followed by PET imaging.
414417|NCT01028170|Drug|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
414418|NCT01028170|Drug|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
414419|NCT01028157|Behavioral|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
414420|NCT01028157|Behavioral|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
414421|NCT01028144|Behavioral|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
414422|NCT01028144|Behavioral|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
414423|NCT01028131|Behavioral|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
414424|NCT01028131|Behavioral|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
414425|NCT01028118|Other|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
414426|NCT01028105|Other|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
414427|NCT01028092|Drug|Anti R-IL2 + Cyclosporine|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
414428|NCT01028092|Drug|Thymoglobulin + Everolimus|"Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days~Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0~everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
414429|NCT01028092|Drug|Anti R-IL2 + Cyclosporine then Everolimus|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)~Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0~cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml~corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
414430|NCT01028079|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
414431|NCT01028079|Drug|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
414432|NCT01028079|Drug|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
414522|NCT01027286|Device|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
414616|NCT01026558|Drug|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
414433|NCT01028066|Other|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
414434|NCT01028066|Behavioral|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
414435|NCT01028053|Drug|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
414436|NCT01028040|Drug|AZD3043|Intravenous, single dose
414437|NCT01028040|Drug|AZD3043|Infusion, single dose
414438|NCT01028027|Drug|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
414439|NCT01028027|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
414440|NCT01028014|Drug|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
414441|NCT01028014|Drug|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
414442|NCT01028014|Drug|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
414443|NCT01028014|Drug|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
414444|NCT01028014|Drug|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
414445|NCT01028014|Drug|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
414446|NCT01027975|Procedure|laparoscopic Nissen/laparoscopic Thal|
414447|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training.
414448|NCT01027949|Drug|Treprostinil diethanolamine|Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
414449|NCT01027923|Drug|Plerixafor|
414450|NCT01027923|Drug|Mitoxantrone|
414451|NCT01027923|Drug|Etoposide|
414452|NCT01027923|Drug|Cytarabine|
414453|NCT01027910|Drug|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
414454|NCT01027910|Drug|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
414455|NCT01027910|Drug|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
414456|NCT01027897|Drug|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
414457|NCT01027884|Drug|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
414458|NCT01027884|Drug|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
414459|NCT01027871|Drug|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
414460|NCT01027871|Drug|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
414461|NCT01027858|Behavioral|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
414462|NCT01027858|Behavioral|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
414463|NCT01027845|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
414464|NCT01027845|Biological|DTPa|Subcutaneous injection, 4 doses
414465|NCT01027832|Drug|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
414466|NCT01027819|Device|Mobile bearing|Mobile bearing in total knee arthroplasty
414467|NCT01027819|Device|Fixed bearing|Fixed bearing in total knee arthroplasty
414468|NCT01027806|Drug|Montelukast|1 pill per day for 4 months
414469|NCT01027793|Drug|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
414470|NCT01027793|Device|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
414471|NCT01027780|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
414472|NCT01027767|Device|Molecular Breast Imaging|Molecular Breast Imaging
414473|NCT01027754|Drug|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
414474|NCT01027754|Drug|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
414475|NCT01027741|Behavioral|Phone Referral|Participants receive phone referral to cancer control and prevention services.
414476|NCT01027741|Behavioral|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
414477|NCT01027741|Behavioral|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
414612|NCT01026610|Drug|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
414613|NCT01026597|Drug|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
414614|NCT01026597|Drug|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
414478|NCT01027728|Drug|CCX 354-C|"Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
414479|NCT01027715|Other|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
414480|NCT01027702|Biological|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10^4, 4 x 10^4, 5 x 10^4, 6 X 10^4, 8 x 10^4, and 10 X10^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
414481|NCT01027689|Drug|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
414482|NCT01027689|Drug|alprazolam test sublingual tablet|1 mg tablet, single dose
414483|NCT01027676|Drug|Study treatment|Gefitinib 250mg/QD plus vorinostat D1~7 & D15-21 / QD q 4weeks
414484|NCT01027663|Dietary Supplement|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
414485|NCT01027650|Drug|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
414486|NCT01027650|Drug|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
414487|NCT01027637|Other|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
414488|NCT01027611|Drug|proparacaine HCL 0.5%|
414489|NCT01027611|Drug|proparacaine HCL 0.5% + 4% lidocaine solution|
414490|NCT01027611|Drug|3.5% viscous lidocaine gel|
414491|NCT01027598|Drug|Pazopanib|Pazopanib: 600 mg orally daily
414492|NCT01027598|Drug|Erlotinib|Erlotinib: 150 mg orally daily
414493|NCT01027572|Device|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
414494|NCT01027559|Drug|Sertraline|Depressed participants will be randomized to SRT or CBT treatment. For those in the SRT treatment condition, visits will involve dispensing medications, checking for side effects and administering the Hamilton Depression rating scale occurring at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed patients treated with SRT will titrate up to a maximum dose of 200 mg daily depending on tolerability and inadequate antidepressant response. Depressed subjects will start their SRT treatment once their first MRI and computer testing sessions are completed.
414495|NCT01027559|Behavioral|Cognitive Behavioral Therapy|Depressed participants will be randomized to SRT or CBT treatment. For those in the CBT treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed.
414496|NCT01027546|Drug|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
414497|NCT01027533|Other|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
414498|NCT01027520|Other|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
414499|NCT01027494|Drug|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
414500|NCT01027481|Drug|Lucentis|intravitreally administration of 0.05 ml Lucentis
414501|NCT01027468|Drug|Bevacizumab|intraocular bevacizumab injection
414502|NCT01027455|Device|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
414503|NCT01027455|Procedure|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
414504|NCT01027455|Procedure|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
414505|NCT01027442|Device|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
414506|NCT01027442|Device|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
414507|NCT01027442|Device|Dental Implants|Dental implants placed via conventional free-hand method
414508|NCT01027429|Drug|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
414509|NCT01027429|Drug|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
414510|NCT01027429|Drug|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
414511|NCT01027416|Drug|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
414512|NCT01027390|Behavioral|physical training exercise|physical exercise training at the work site during work time
414513|NCT01027377|Drug|rFVIIIFc|Single dose
414514|NCT01027377|Drug|rFVIIIFc|Single dose
414515|NCT01027364|Drug|Factor IX (rFIXFc)|
414516|NCT01027364|Drug|rFIX|
414517|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
414518|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
414519|NCT01027338|Other|Tai chi exercise|
414520|NCT01027325|Other|Dietary Intervention|Starch digestibility and carbohydrate quantity
414521|NCT01027299|Device|Biventricular pacing|Optimised temporary biventricular pacing.
415019|NCT01023490|Drug|Placebo|Placebo
414523|NCT01027273|Behavioral|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
414524|NCT01027273|Behavioral|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
414525|NCT01027260|Drug|Itopride HCI 50 mg|Variable dosing
414526|NCT01027260|Drug|Itopride HCI 100 mg|Variable dosing
414527|NCT01027260|Drug|Placebo|Variable dosing
414528|NCT01027247|Device|Ologen TM|
414529|NCT01027234|Drug|AZD8418|Single oral dose
414530|NCT01027234|Drug|Placebo|single oral dose
414531|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, four dimensions (4D) planned, image guided, Radiation at a dose of 0,5 Gy in Intensity modulated radiotherapy (IMRT)-technique 2 days before resection
414532|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
414533|NCT01027221|Radiation|neoadjuvant photon radiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
414534|NCT01027208|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
414535|NCT01027195|Device|Bipolar Radiofrequency (Aquamantys 6.0)|
414536|NCT01027195|Device|Standard Bovie Electrocautery|
414537|NCT01027182|Drug|Raltegravir|One 400mg tablet on day 1.
414538|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
414539|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
414540|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
414541|NCT01027156|Behavioral|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
414542|NCT01027143|Dietary Supplement|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
414543|NCT01027143|Drug|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
414544|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
414545|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
414546|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
414547|NCT01027104|Other|Education|Firearm injury prevention anticipatory guidance curriculum
414548|NCT01027065|Drug|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
414549|NCT01027065|Drug|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
414550|NCT01027052|Other|Hamburger meat patty with salt|hamburger meat cooked with salt
414551|NCT01027052|Other|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
414552|NCT01027026|Other|Early discharge|The patients are discharged the same day as coronary angiography.
414553|NCT01027026|Other|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
414554|NCT01027013|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
414555|NCT01027013|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
414556|NCT01027000|Biological|rituximab|
414557|NCT01027000|Drug|busulfan|
414558|NCT01027000|Drug|cyclophosphamide|
414559|NCT01027000|Drug|fludarabine phosphate|
414560|NCT01027000|Drug|methotrexate|
414561|NCT01027000|Drug|sirolimus|
414562|NCT01027000|Drug|tacrolimus|
414563|NCT01027000|Procedure|allogeneic stem cell transplant|
414564|NCT01026987|Drug|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
414565|NCT01026987|Drug|AMD3100|
414566|NCT01026987|Procedure|Leukapheresis|
414567|NCT01026987|Procedure|Stem Cell Infusion|
414568|NCT01026974|Biological|rMenB|
414569|NCT01026974|Biological|rMenB+OMV NZ|
414570|NCT01026961|Drug|Phenylephrine HCL|Phenylephrine HCL 10mg
414571|NCT01026961|Drug|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
414572|NCT01026948|Drug|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
414573|NCT01026948|Device|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
414574|NCT01026935|Device|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
414575|NCT01026909|Drug|Aristospan 20mg|Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
414576|NCT01026883|Other|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
414577|NCT01026870|Drug|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
414578|NCT01026870|Drug|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
414579|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
414580|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
414581|NCT01026857|Drug|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
414582|NCT01026844|Drug|erlotinib|Taken orally once a day
414583|NCT01026844|Drug|hydroxychloroquine|Taken orally once a day
414584|NCT01026831|Drug|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
414585|NCT01026831|Drug|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
414586|NCT01026818|Drug|Tadalafil|Administered by mouth for 9 months
414587|NCT01026818|Drug|Placebo|Administered by mouth, daily or on demand for 9 months
414588|NCT01026805|Device|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
414589|NCT01026792|Drug|Temsirolimus|Given IV
414590|NCT01026792|Other|Laboratory Biomarker Analysis|Correlative studies
414591|NCT01026753|Behavioral|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
414592|NCT01026740|Drug|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
414593|NCT01026727|Drug|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
414594|NCT01026727|Drug|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
414595|NCT01026714|Drug|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
414596|NCT01026714|Drug|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
414597|NCT01026714|Drug|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
414598|NCT01026701|Drug|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
414599|NCT01026688|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
414600|NCT01026688|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
414601|NCT01026675|Procedure|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
414602|NCT01026662|Procedure|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
414603|NCT01026662|Device|eMatrixCO2|
414604|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
414605|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
414606|NCT01026636|Drug|Ceftobiprole|
414607|NCT01026623|Biological|Cixutumumab|Given IV
414608|NCT01026623|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
414609|NCT01026623|Drug|Temsirolimus|Given IV
414610|NCT01026610|Drug|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
414611|NCT01026610|Drug|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
414615|NCT01026584|Drug|Aripiprazole|6 week prospective study
414618|NCT01026545|Drug|Placebo|To match 500 mg dose once daily for 10 days
414619|NCT01026545|Drug|PF-04287881|750 mg once daily for 10 days
414620|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
414621|NCT01026545|Drug|PF-04287881|1100 mg once daily for 10 days
414622|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
414623|NCT01026545|Drug|PF-04287881|Optional cohort with dose not greater than 1100 mg
414624|NCT01026545|Drug|Placebo|Optional cohort to match dose not greater than 1100 mg
414625|NCT01026545|Drug|PF-04287881|750 mg dose once daily for 10 days
414626|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
414627|NCT01026545|Drug|PF-04287881|1100 mg dose once daily for 10 days
414628|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
414629|NCT01026532|Biological|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
414630|NCT01026519|Drug|REGN88|Single dose of REGN88 and 43 day follow up.
414631|NCT01026519|Other|Placebo|Placebo to match REGN88 administration
414632|NCT01026506|Dietary Supplement|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
414633|NCT01026493|Drug|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
414634|NCT01026493|Drug|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
414635|NCT01026493|Drug|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
414636|NCT01026493|Drug|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
414637|NCT01026493|Drug|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
414638|NCT01026493|Drug|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
414639|NCT01026467|Drug|cisplatin|Given IV
414640|NCT01026467|Drug|carboplatin|Given IV
414641|NCT01026467|Other|questionnaire administration|
414642|NCT01026454|Drug|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
414643|NCT01026454|Drug|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
414644|NCT01026441|Device|Vela100 (Aesthetic)|6 treatments once a week
414645|NCT01026428|Drug|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
414646|NCT01026428|Other|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
414647|NCT01026415|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
414648|NCT01026415|Drug|rifampin|600 mg/day PO
414649|NCT01026415|Drug|midazolam|1 mg IV
414650|NCT01026415|Drug|ketoconazole|400 mg/day PO
414651|NCT01026415|Drug|brentuximab vedotin|1.2 mg/kg IV every 21 days
414652|NCT01026402|Drug|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
414653|NCT01026389|Drug|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
414654|NCT01026389|Drug|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
414655|NCT01026376|Drug|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
414656|NCT01026376|Drug|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
414657|NCT01026363|Drug|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
414658|NCT01026363|Drug|Calcitriol|0.25 mcg tablet once daily for 14 days
414659|NCT01026350|Dietary Supplement|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
414660|NCT01026337|Genetic|mutation analysis|Correlative study
414661|NCT01026337|Other|pharmacological study|Correlative study
414662|NCT01026337|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
414663|NCT01026337|Drug|sunitinib malate|Given orally
414664|NCT01026337|Other|immunohistochemistry staining method|Correlative study
414665|NCT01026337|Other|laboratory biomarker analysis|Correlative study
414666|NCT01026324|Drug|dinaciclib|Given IV
414667|NCT01026324|Other|pharmacological study|Correlative studies
414668|NCT01026324|Other|laboratory biomarker analysis|Correlative studies
414669|NCT01026311|Drug|Coenzyme q 10|200 mg of Coenzyme q 10
414671|NCT01026298|Other|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
414672|NCT01026285|Drug|Risperidone Long-Acting injectable or oral antipsychotics|According to label
414673|NCT01026259|Other|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
414674|NCT01026259|Other|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
414675|NCT01026246|Drug|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
414676|NCT01026246|Biological|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
414677|NCT01026233|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
414678|NCT01026220|Biological|bleomycin sulfate|Given IV or SC
414679|NCT01026220|Drug|doxorubicin hydrochloride|Given IV
414680|NCT01026220|Drug|liposomal vincristine sulfate|Given IV
414681|NCT01026220|Drug|vinorelbine tartrate|Given IV
414682|NCT01026220|Drug|cyclophosphamide|Given IV
414683|NCT01026220|Drug|etoposide phosphate|Given IV
414684|NCT01026220|Drug|prednisone|Given IV
414685|NCT01026220|Biological|filgrastim|Given IV or SC
414686|NCT01026220|Drug|ifosfamide|Given IV
414687|NCT01026207|Device|Polysomnography|Sleep study polysomnography compared with portable monitoring
414688|NCT01026194|Drug|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
414689|NCT01026194|Drug|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
414690|NCT01026155|Other|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
414691|NCT01026142|Drug|Capecitabine|1000 mg/m2 po twice daily for 14 days every 3 weeks
414692|NCT01026142|Drug|Capecitabine|1250 mg/m2 po twice daily for 14 days every 3 weeks
414693|NCT01026142|Drug|Pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
414694|NCT01026142|Drug|Trastuzumab|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
414695|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
414696|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
414697|NCT01026129|Drug|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
414698|NCT01026116|Drug|Epirubicin|
414699|NCT01026116|Drug|Cyclophosphamide|
414700|NCT01026116|Drug|Paclitaxel|
414701|NCT01026103|Device|Tri Staple Technology stapler|This is a single arm study.
414702|NCT01026090|Drug|Dronedarone|"Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)"
414703|NCT01026090|Drug|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)"
414704|NCT01026064|Other|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
414705|NCT01026064|Drug|Azithromycin|Zithromax (250 mg oral capsule).
414706|NCT01026064|Drug|Placebo|Matching placebo
414707|NCT01026051|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
414708|NCT01026038|Biological|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
414709|NCT01026025|Device|Duet TRS|This is a single arm study.
414710|NCT01026012|Drug|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
414711|NCT01025999|Other|No intervention|
414712|NCT01025960|Procedure|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
414713|NCT01025960|Procedure|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
414714|NCT01025934|Drug|Bevacizumab|
414715|NCT01025934|Other|sham|
414716|NCT01025921|Drug|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
414717|NCT01025921|Other|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
414718|NCT01025908|Behavioral|Psychotherapy|Cognitive Behavioral Therapy
414719|NCT01025908|Behavioral|Supportative psychotherapy|Supportative psychotherapy
414720|NCT01025895|Procedure|acl reconstruction - double bundle technique|
414721|NCT01025895|Procedure|acle reconstruction - single bundle technique|
414722|NCT01025882|Drug|gemcitabine hydrochloride|Given IV
414723|NCT01025882|Radiation|stereotactic body radiation therapy|Given as a single fraction
414724|NCT01025869|Device|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
414725|NCT01025856|Other|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
414726|NCT01025856|Other|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
414727|NCT01025856|Other|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
414728|NCT01025856|Other|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
414729|NCT01025843|Drug|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
414730|NCT01025843|Drug|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
414731|NCT01025843|Drug|Comparator: Pbo|Placebo
414732|NCT01025830|Drug|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
414733|NCT01025830|Drug|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
414734|NCT01025817|Drug|Everolimus and tacrolimus|"Everolimus:~Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets~Dose: 1.5 mg per day~Frequency: 0.75 mg twice daily~Tacrolimus:~Dose adjusted to maintain specific blood levels"
414735|NCT01025817|Drug|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
414736|NCT01025791|Drug|MK-8266 0.1 mg|Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
414737|NCT01025791|Drug|MK-8266 1.0 mg|MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
414738|NCT01025791|Drug|Placebo|Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
414739|NCT01025778|Drug|Clofarabine for remission induction|
414740|NCT01025778|Drug|Etoposide for remission induction|
414741|NCT01025778|Drug|Cyclophosphamide for remission induction|
414742|NCT01025778|Drug|Clofarabine in conditioning before transplantation|
414743|NCT01025778|Drug|Thiotepa in conditioning before transplantation|
414744|NCT01025778|Drug|Melfalan in conditioning before transplantation|
414745|NCT01025778|Procedure|Haploidentical transplantation of T-cell depleted graft|
414746|NCT01025778|Procedure|Donor lymphocyte infusion|
414747|NCT01025765|Drug|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
414748|NCT01025765|Drug|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
414749|NCT01025765|Drug|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
414750|NCT01025752|Behavioral|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
414751|NCT01025752|Behavioral|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
414752|NCT01025739|Device|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
414753|NCT01025726|Behavioral|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
414754|NCT01025726|Behavioral|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
414755|NCT01025726|Behavioral|General Health Education|Host community events for chronic disease education
414756|NCT01025713|Drug|GS-9411|Inhaled GS-9411
414757|NCT01025713|Drug|Placebo|Inhaled Placebo
414758|NCT01025700|Drug|Cesemat|1 mg capsule per day for 21 days
414759|NCT01025687|Dietary Supplement|water with noncalorie sweetener|
414760|NCT01025687|Dietary Supplement|water with glucose|
414761|NCT01025687|Behavioral|TV program showed while feeding|
414762|NCT01025687|Behavioral|TV program showed while feeding|
414763|NCT01025674|Behavioral|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
414764|NCT01025661|Other|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
414765|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
414766|NCT01025648|Drug|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
414767|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
414768|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
414769|NCT01025648|Drug|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
414770|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
414771|NCT01025635|Drug|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
414772|NCT01025635|Drug|Vehicle foam|Applied topically twice daily for 12 weeks
414773|NCT01025622|Biological|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
414774|NCT01025596|Drug|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
414775|NCT01025583|Dietary Supplement|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
414776|NCT01025583|Dietary Supplement|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
414777|NCT01025570|Drug|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
414778|NCT01025557|Other|Dietary intervention|Dietary treatments with beverages
414779|NCT01025544|Biological|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
414780|NCT01025544|Biological|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
414781|NCT01025518|Other|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
414782|NCT01025518|Dietary Supplement|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
414783|NCT01025518|Dietary Supplement|Placebo|Maltodextrine
414784|NCT01025505|Drug|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
414785|NCT01025505|Drug|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
414786|NCT01025492|Drug|Trilipix|135 mg po daily
414787|NCT01025492|Drug|placebo|one tablet po daily
414788|NCT01025466|Drug|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
414789|NCT01025466|Drug|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
414790|NCT01025453|Drug|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
414791|NCT01025440|Device|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.~Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)~Duration:"
414792|NCT01025427|Drug|Raltegravir, tenofovir/emtricitabine|Ten elite controllers and 10 untreated non-controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
414793|NCT01025414|Drug|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
414794|NCT01025414|Drug|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
414795|NCT01025401|Device|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
414796|NCT01025375|Dietary Supplement|inulin|10gram/day inulin for 13-day treatment
414797|NCT01025375|Dietary Supplement|inulin|16gram/day inulin for 13-day treatment
414798|NCT01025375|Dietary Supplement|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
414799|NCT01025362|Behavioral|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
414800|NCT01025362|Behavioral|Standard care|Child Health Services offered standard care
414801|NCT01025349|Drug|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
414802|NCT01025336|Other|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
414803|NCT01025336|Other|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
414804|NCT01025323|Behavioral|Lifestyle modification|DASH diet and exercise advice
414805|NCT01025323|Behavioral|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
414806|NCT01025297|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
414807|NCT01025284|Drug|LY2523355|Administered intravenously as a 1-hour infusion
414808|NCT01025284|Drug|Granulocyte colony-stimulating factor (G-CSF)|Administered subcutaneously
414809|NCT01025271|Drug|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
414810|NCT01025258|Behavioral|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
414811|NCT01025258|Behavioral|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
414812|NCT01025245|Drug|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ & Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
414813|NCT01025232|Drug|Ranibizumab|Intravitreal Injection of 2.0mg formulation
414814|NCT01025219|Genetic|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
414815|NCT01025206|Biological|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
414816|NCT01025193|Drug|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
414817|NCT01025180|Other|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:~< 0.25 ng/ml: antibiotic should be stopped~0.25 < PCT <0.5: antibiotic prescription is not recommended~> 0.5 ng/ml: antibiotic should be used"
414818|NCT01025167|Dietary Supplement|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
414819|NCT01025167|Dietary Supplement|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
414820|NCT01025154|Drug|Clofarabine|Induction Cycle: 20 mg/m^2 IV over approximately 1 hour daily for 5 days (days 1-5)
414821|NCT01025154|Drug|Idarubicin|Induction Cycle: 10 mg/m^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
414822|NCT01025154|Drug|Cytarabine|Induction Cycle: 1 g/m^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
414823|NCT01025141|Device|Skeletal anchorage (MINISCREW)|Skeletal anchorage
414824|NCT01025141|Device|dental anchorage|dental anchorage (reference)
414825|NCT01025128|Drug|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
414826|NCT01025115|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
414827|NCT01025115|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
414828|NCT01025102|Drug|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
414829|NCT01025089|Drug|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
414830|NCT01025076|Device|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
414831|NCT01025050|Procedure|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
414832|NCT01025037|Device|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
414833|NCT01025024|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
414834|NCT01025011|Device|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
414835|NCT01024998|Biological|AAV2-sFLT01|2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
414836|NCT01024998|Biological|AAV2-sFLT01|2 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
414837|NCT01024998|Biological|AAV2-sFLT01|6 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
414838|NCT01024998|Biological|AAV2-sFLT01|2 x 10^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
414839|NCT01024972|Drug|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
414840|NCT01024972|Drug|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
414841|NCT01024959|Other|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
414842|NCT01024946|Drug|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
414843|NCT01024933|Behavioral|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
414844|NCT01024933|Behavioral|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
414845|NCT01024920|Drug|BIBF 1120|VEGF inhibitor
414846|NCT01024920|Drug|sunitinib|VEGF inhibitor
414847|NCT01024907|Radiation|proton beam radiation therapy|Undergo radiation
414848|NCT01024907|Procedure|quality-of-life assessment|Ancillary study
414849|NCT01024907|Other|questionnaire administration|Ancillary study
414850|NCT01024894|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
414851|NCT01024881|Procedure|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
414852|NCT01024881|Procedure|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
414853|NCT01024868|Drug|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
414854|NCT01024855|Device|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
414855|NCT01024842|Biological|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu at week 0, 4 and 12.
414856|NCT01024842|Other|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
414857|NCT01024842|Biological|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu at week 0, 4 and 12.
414858|NCT01024842|Other|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
414859|NCT01024829|Radiation|Radiotherapy|Radiotherapy
414860|NCT01024816|Behavioral|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.~Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
414861|NCT01024816|Behavioral|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.~Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
414862|NCT01024803|Device|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.~Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
414863|NCT01024790|Behavioral|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
414864|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
414865|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
414866|NCT01024751|Device|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
414867|NCT01024751|Device|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
414868|NCT01024738|Drug|Fluoride|Brush half mouth twice daily for four days.
414869|NCT01024738|Drug|Triclosan, fluoride|Brush twice daily
414870|NCT01024738|Drug|Chlorhexidine Gluconate|Rinse mouth twice a day
414871|NCT01024725|Other|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
414872|NCT01024712|Drug|carboplatin|
414873|NCT01024712|Drug|gefitinib|
414874|NCT01024712|Drug|paclitaxel|
414875|NCT01024712|Procedure|quality-of-life assessment|
414876|NCT01024686|Biological|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
414877|NCT01024686|Biological|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
414878|NCT01024686|Biological|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
414879|NCT01024660|Drug|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
414880|NCT01024660|Drug|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
414881|NCT01024660|Drug|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
414882|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
414883|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
414884|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
414885|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
414886|NCT01024634|Behavioral|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
414887|NCT01024621|Device|Endomicroscope|Pentax EC3870K, Tokyo, Japan
414888|NCT01024621|Device|Standard endoscopy|Pentax EG-2931 gastroscope
414889|NCT01024608|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
414890|NCT01024608|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
414891|NCT01024582|Procedure|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
414892|NCT01024582|Procedure|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
414893|NCT01024582|Radiation|accelerated partial breast irradiation|
414894|NCT01024582|Radiation|image-guided radiation therapy|
414895|NCT01024569|Behavioral|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
414896|NCT01024543|Drug|Angiotensin II|Angiotensin II
414897|NCT01024543|Drug|Phenylephrine|Phenylephrine
414898|NCT01024543|Drug|Placebo|
414899|NCT01024517|Drug|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
414900|NCT01024517|Drug|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
414901|NCT01024504|Drug|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
414902|NCT01024504|Drug|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
414903|NCT01024504|Drug|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
414904|NCT01024491|Drug|paroxetine|daily dose of paroxetine 15mg for 12 weeks
414905|NCT01024491|Drug|paroxetine|active daily treatment with paroxetine 20 mg
414906|NCT01024491|Drug|placebo|active daily treatment with placebo
414907|NCT01024465|Device|ReShape Duo Balloon|ReShape Duo Balloon
414908|NCT01024452|Device|DAWN AC|computerized dosing management system for anticoagulation clinics
414909|NCT01024452|Device|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
414910|NCT01024439|Procedure|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.~Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
414911|NCT01024439|Procedure|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.~Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
414912|NCT01024426|Procedure|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
414913|NCT01024426|Other|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
414914|NCT01024413|Drug|erlotinib|study arm.erlotinib 150 mg oral till disease progression
414915|NCT01024413|Drug|gefitinib|study arm.gefitinib 250 mg oral till disease progression
414916|NCT01024400|Biological|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
414917|NCT01024387|Drug|AMG 479|
414918|NCT01024361|Device|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
414919|NCT01024348|Drug|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
414920|NCT01024348|Drug|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
414921|NCT01024335|Drug|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
414922|NCT01024335|Drug|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
414923|NCT01024322|Drug|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
414924|NCT01024322|Drug|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
414925|NCT01024322|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
414926|NCT01024309|Procedure|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
414927|NCT01024309|Procedure|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
414928|NCT01024296|Device|Port Close|Device for applying loop suture to close surgical site
414929|NCT01024270|Drug|Misoprostol|
414930|NCT01024257|Radiation|beta-irradiation|
414931|NCT01024257|Procedure|conjunctival autograft|
414932|NCT01024244|Drug|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
414933|NCT01024244|Drug|LY2599506|Administered po for 12 weeks
414934|NCT01024231|Drug|BMS-936558 (MDX1106-04)|
414935|NCT01024231|Drug|Ipilimumab|
414936|NCT01024218|Device|NovoFine® needle 8 mm|
414937|NCT01024218|Device|autocover needle|
414938|NCT01024205|Drug|sunitinib malate|
414939|NCT01024205|Other|laboratory biomarker analysis|
414940|NCT01024205|Procedure|adjuvant therapy|
414941|NCT01024205|Procedure|neoadjuvant therapy|
414942|NCT01024205|Procedure|therapeutic conventional surgery|
414943|NCT01024192|Drug|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
414944|NCT01024179|Device|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
414945|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
414946|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
414947|NCT01024153|Behavioral|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
414948|NCT01024140|Drug|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
414949|NCT01024127|Other|Laboratory Biomarker Analysis|Correlative studies
414950|NCT01024101|Drug|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
414951|NCT01024075|Drug|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
414952|NCT01024075|Drug|Saline|8cc of Saline mixed with Sinufoam
414953|NCT01024062|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
414954|NCT01024036|Drug|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
414955|NCT01024036|Drug|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
414956|NCT01024036|Drug|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
414957|NCT01024023|Device|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
414958|NCT01024010|Drug|Cyclophosphamide|Given IV
414959|NCT01024010|Other|Laboratory Biomarker Analysis|Correlative studies
414960|NCT01024010|Biological|Ofatumumab|Given IV
414961|NCT01024010|Drug|Pentostatin|Given IV
414962|NCT01023984|Procedure|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
414963|NCT01023984|Procedure|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
414964|NCT01023958|Drug|BI 6727, IV infusion|phase II
414965|NCT01023945|Drug|ASP1941|oral
414966|NCT01023945|Drug|Placebo|oral
414967|NCT01023932|Device|Cochlear Implants|
414968|NCT01023919|Device|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
414969|NCT01023880|Drug|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
414970|NCT01023867|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
414971|NCT01023854|Procedure|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
415238|NCT01021657|Procedure|trabeculectomies, non penetrating deep sclerectomies|
414972|NCT01023841|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
414973|NCT01023841|Drug|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
414974|NCT01023815|Drug|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
414975|NCT01023815|Drug|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
414976|NCT01023815|Drug|Prednison (continuous steroids)|continuous steroids
414977|NCT01023789|Device|ABSORB BVS|Absorb Bioresorbable Vascular Scaffold (BVS) System implantation
414978|NCT01023776|Biological|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
414979|NCT01023763|Other|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
414980|NCT01023750|Drug|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
414981|NCT01023737|Drug|Hydroxychloroquine|The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
414982|NCT01023737|Drug|Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
414983|NCT01023724|Drug|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
414984|NCT01023724|Drug|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
414985|NCT01023711|Biological|Inactivated H1N1 vaccine|0.5 ml IM into Deltoid region of arm
414986|NCT01023711|Biological|Inactivated H1N1 vaccine|0.5 mL IM X 1 dose
414987|NCT01023698|Procedure|laser photocoagulation|Laser photocoagulation
414988|NCT01023685|Biological|CAD106|
414989|NCT01023672|Drug|Armodafinil|150-250 mg armodafinil by mouth daily
414990|NCT01023659|Drug|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
414991|NCT01023659|Drug|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
414992|NCT01023659|Behavioral|motivational emails|brief motivational emails, sent weekly for 12 weeks
414993|NCT01023646|Other|Carbohydrate + Protein|Light Tuna Packed in water.
414994|NCT01023646|Other|Carbohydrate + Fat|Butter
414995|NCT01023646|Other|Fiber|Unrefined Carbohydrate
414996|NCT01023646|Other|Carbohydrate load|Carbohydrate
414997|NCT01023633|Drug|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.~FOLFOX4 regimen:~OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
414998|NCT01023620|Drug|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
414999|NCT01023620|Other|Observation|Participants will be observed for 16 weeks but will not receive drug
415000|NCT01023607|Drug|Atorvastatin|Atorvastatin 20mg/day
415001|NCT01023607|Drug|Atorvastatin|Atorvastatin, 60mg/day
415002|NCT01023607|Drug|Rosuvastatin|Rosuvastatin,10mg/day
415003|NCT01023594|Procedure|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
415004|NCT01023581|Drug|Alogliptin|Alogliptin tablets.
415005|NCT01023581|Drug|Metformin|Metformin capsules
415006|NCT01023581|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets.
415007|NCT01023581|Drug|Metformin Placebo|Metformin placebo-matching capsules.
415008|NCT01023568|Device|Macintosh blade|Intubation with Macintosh blade laryngoscope
415009|NCT01023568|Device|Glidescope|Intubation with Glidescope laryngoscope.
415010|NCT01023568|Device|Truview PCD|Intubation with Truview PCD laryngoscope.
415011|NCT01023555|Other|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
415012|NCT01023542|Drug|delayed, low-dose CNI|immunosuppression
415013|NCT01023542|Drug|BU-CNI|Immunosuppression
415014|NCT01023542|Drug|BU-Everolimus|Immunosuppression
415015|NCT01023529|Radiation|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
415016|NCT01023516|Drug|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
415017|NCT01023516|Drug|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
415018|NCT01023490|Drug|Vitamin D|34,5000 IU vitamin D per week
415020|NCT01023477|Drug|Chloroquine Standard Dose (500mg/week)|Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
415021|NCT01023477|Drug|Chloroquine Low Dose (250mg/week)|Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
415022|NCT01023477|Procedure|Breast Biopsy|Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
415023|NCT01023464|Other|FID114657|artificial tears
415024|NCT01023464|Other|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
415025|NCT01023438|Other|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
415026|NCT01023438|Other|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
415027|NCT01023425|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
415028|NCT01023412|Dietary Supplement|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
415029|NCT01023399|Drug|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
415030|NCT01023386|Drug|YM155|I.V.
415031|NCT01023373|Drug|Medical treatment|hypotensive drugs, statins and anti-platelets
415032|NCT01023373|Procedure|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
415033|NCT01023373|Device|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
415034|NCT01023373|Device|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
415035|NCT01023360|Drug|Clopidogrel and proton pump inhibitors|"baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->~1 week washout --> aspirin 100mg PO QD for 1 week"
415036|NCT01023347|Drug|Paclitaxel (Genexol®)|
415037|NCT01023347|Drug|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
415038|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
415039|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
415040|NCT01023321|Drug|GLPG0555|single ascending doses, oral solution
415041|NCT01023321|Drug|placebo|single dose, oral solution
415042|NCT01023321|Drug|GLPG0555|multiple dose, oral solution, 7 or 14 days
415043|NCT01023321|Drug|placebo|multiple dose, oral solution, 7 or 14 days
415044|NCT01023308|Drug|Panobinostat|Panobinostat was administered 3x week ( 2 weeks on 1 week off)
415045|NCT01023308|Drug|Bortezomib|Bortezomib was administered 2 x week ( 2weeks on 1 week off)
415046|NCT01023308|Drug|Placebo|Placebo was administered 3x week ( 2 weeks on 1 week off)
415047|NCT01023295|Drug|fosbretabulin|single dose, intravenous infusion
415048|NCT01023295|Drug|Saline|single dose, intravenous infusion
415049|NCT01023282|Drug|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
415050|NCT01023282|Drug|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
415051|NCT01023269|Device|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
415052|NCT01023256|Drug|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
415053|NCT01023256|Drug|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
415054|NCT01023256|Drug|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
415055|NCT01023243|Other|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
415056|NCT01023243|Other|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
415057|NCT01023230|Drug|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
415058|NCT01023230|Drug|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
415059|NCT01023217|Drug|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
415060|NCT01023217|Drug|Entecavir|Entecavir 1 mg/day orally
415061|NCT01023217|Drug|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
415062|NCT01023204|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
415063|NCT01023191|Procedure|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
415064|NCT01023191|Procedure|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
415065|NCT01023178|Drug|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
415066|NCT01023178|Drug|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
415067|NCT01023178|Drug|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
415068|NCT01023178|Drug|Progesterone, micronized|Given starting at 18 months
415069|NCT01023165|Procedure|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
415239|NCT01021644|Behavioral|aerobic exercise-training|3 times per week for 6 months
415070|NCT01023152|Procedure|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
415071|NCT01023139|Behavioral|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
415072|NCT01023126|Behavioral|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
415073|NCT01023113|Procedure|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
415074|NCT01023113|Procedure|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
415075|NCT01023100|Drug|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
415076|NCT01023087|Drug|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
415077|NCT01023087|Drug|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
415078|NCT01023074|Behavioral|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
415079|NCT01023074|Other|MS: Control Activity|MS group not receiving auditory training, doing control activity
415080|NCT01023061|Drug|abiraterone acetate|Given PO
415081|NCT01023061|Drug|prednisone|Given PO
415082|NCT01023061|Drug|leuprolide acetate|Given via injection
415083|NCT01023061|Other|laboratory biomarker analysis|Correlative study
415084|NCT01023061|Radiation|external beam radiation therapy|Undergo radiotherapy
415085|NCT01023061|Drug|goserelin acetate|Given via injection
415086|NCT01023048|Other|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
415087|NCT01023035|Drug|Boceprevir|800 mg given three times a day (TID), orally (PO)
415088|NCT01023035|Drug|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
415089|NCT01023035|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
415090|NCT01023035|Drug|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
415091|NCT01023022|Other|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
415092|NCT01023009|Procedure|vitrectomy|
415093|NCT01022996|Drug|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
415094|NCT01022983|Drug|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
415095|NCT01022983|Drug|Placebo|ml/kg/hours - same infusion rate as active comparator
415096|NCT01022970|Drug|QAX576 placebo|
415097|NCT01022970|Drug|QAX576|
415098|NCT01022957|Genetic|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
415099|NCT01022944|Procedure|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
415100|NCT01022944|Procedure|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
415101|NCT01022918|Drug|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
415102|NCT01022918|Drug|Temodal/radiotherapy|
415103|NCT01022905|Biological|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
415104|NCT01022879|Procedure|vitrectomy|
415105|NCT01022853|Drug|BI 6727|intravenous each 21 days
415106|NCT01022853|Drug|BIBF 1120|oral continuously
415107|NCT01022840|Drug|S-Ketamine|drug
415108|NCT01022840|Other|Placebo Comparison|saline control
415109|NCT01022827|Other|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes [about 6 minutes for each muscle and order was random] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
415110|NCT01022814|Device|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
415111|NCT01022801|Drug|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
415112|NCT01022788|Behavioral|Home-based counselling|
415113|NCT01022775|Procedure|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
415114|NCT01022775|Procedure|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
415115|NCT01022762|Drug|repaglinide|Individually adjusted dose for 16 weeks
415116|NCT01022762|Drug|gliclazide|Individually adjusted dose for 16 weeks
415117|NCT01022749|Drug|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
415118|NCT01022749|Biological|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
415119|NCT01022736|Drug|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
415120|NCT01022697|Other|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
415240|NCT01021644|Behavioral|stretch exercise|3 times per week for 6 months
415408|NCT01020019|Drug|Dronabinol|Dronabinol: 20 mg/TID
415121|NCT01022684|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
415122|NCT01022671|Drug|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
415123|NCT01022658|Drug|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
415124|NCT01022645|Device|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
415125|NCT01022645|Device|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
415126|NCT01022632|Dietary Supplement|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
415127|NCT01022632|Drug|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
415128|NCT01022632|Dietary Supplement|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
415129|NCT01022606|Other|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
415130|NCT01022580|Drug|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8.
415131|NCT01022567|Procedure|Appendicectomy|Standard appendicectomy
415132|NCT01022567|Drug|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
415133|NCT01022541|Drug|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.~(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)~Courses as per detailed description above."
415134|NCT01022541|Drug|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.~(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)~Courses as per detailed description above."
415135|NCT01022541|Drug|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.~The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes~Courses as per detailed description above."
415136|NCT01022541|Procedure|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
415137|NCT01022528|Drug|Dexamethasone (0.1 mg/kg)|
415138|NCT01022528|Drug|Dexamethasone (0.2 mg/kg)|
415139|NCT01022528|Other|Saline|
415140|NCT01022515|Other|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
415141|NCT01022515|Other|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.~Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
415142|NCT01022502|Drug|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
415143|NCT01022502|Drug|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
415144|NCT01022489|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
415145|NCT01022489|Device|Placebo (sham coil) treatment|Sham coil treatment
415146|NCT01022476|Drug|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
415147|NCT01022463|Drug|Ivabradine|Ivabradine 5 mg BId for 4 weeks
415148|NCT01022463|Drug|Atenolol|50 mg od for 4 weeks
415149|NCT01022437|Other|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
415150|NCT01022424|Drug|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
415151|NCT01022411|Dietary Supplement|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
415152|NCT01022398|Drug|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
415153|NCT01022385|Dietary Supplement|24-hour low-residual diet|
415154|NCT01022372|Procedure|Endometrial biopsy|For all the groups
415155|NCT01022359|Device|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
415156|NCT01022359|Device|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
415157|NCT01022346|Drug|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
415158|NCT01022346|Drug|RO5217790|RO5217790 will be administered at a dose of 5*10^7 pfu subcutaneously on Days 1, 8, and 15.
415159|NCT01022333|Dietary Supplement|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
415160|NCT01022320|Procedure|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
415161|NCT01022294|Drug|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
415162|NCT01022294|Drug|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
415163|NCT01022255|Biological|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
415164|NCT01022242|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
415165|NCT01022242|Drug|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
415166|NCT01022229|Dietary Supplement|Compound Natural Health Product|"15-35 mg zinc citrate~150-350 mg magnesium lactate~30-70 mg pyridoxine hydrochloride~150-350 mg calcium ascorbate~Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
415167|NCT01022229|Dietary Supplement|Placebo|Placebo
415168|NCT01022216|Device|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
415169|NCT01022216|Device|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
415170|NCT01022203|Behavioral|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
415171|NCT01022203|Other|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
415172|NCT01022190|Drug|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
415173|NCT01022177|Procedure|acupuncture|acupuncture of the eye in traditional chinese schematics
415174|NCT01022164|Procedure|fibrin glue|
415175|NCT01022151|Drug|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L [group P]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
415176|NCT01022151|Drug|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL [group A2]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
415177|NCT01022151|Drug|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL [group A3]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
415178|NCT01022151|Drug|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL [group A4]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
415179|NCT01022151|Drug|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL [group A5]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
415180|NCT01022151|Drug|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL [group D]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
415181|NCT01022138|Biological|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
415182|NCT01022138|Drug|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
415183|NCT01022138|Other|Laboratory biomarker analysis|The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
415184|NCT01022125|Drug|TMC435|
415185|NCT01022112|Drug|TA-7284-Low|TA-7284-Low
415186|NCT01022112|Drug|TA-7284-Low-middle|TA-7284-Low-middle
415187|NCT01022112|Drug|TA-7284-High-middle|TA-7284-High-middle
415188|NCT01022112|Drug|TA-7284-High|TA-7284-High
415189|NCT01022112|Drug|Placebo|Placebo
415190|NCT01022099|Procedure|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.~The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.~The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
415191|NCT01022086|Procedure|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
415235|NCT01021683|Drug|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
415192|NCT01022086|Biological|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.~Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
415193|NCT01022060|Dietary Supplement|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
415194|NCT01022060|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
415195|NCT01022047|Drug|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
415196|NCT01022047|Drug|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
415197|NCT01022034|Procedure|sacral rectopexy with sutures or meshes|
415198|NCT01022034|Procedure|full rectal mobilization from the sacrum without sacral rectopexy|
415199|NCT01022021|Drug|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
415200|NCT01022021|Drug|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
415201|NCT01022008|Device|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
415202|NCT01021995|Drug|echinacea|drops, 0.9 ml, tid for 4 months
415203|NCT01021995|Drug|placebo|drops, 0.9 ml tid for 4 months
415204|NCT01021969|Other|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
415205|NCT01021956|Drug|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
415206|NCT01021943|Drug|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
415207|NCT01021943|Drug|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
415208|NCT01021930|Device|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
415209|NCT01021904|Biological|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
415210|NCT01021891|Drug|Technosphere®/Insulin|
415211|NCT01021878|Other|icodextrin|glucose sparing dialysis solution
415212|NCT01021878|Other|Dianeal|glucose based dialysis solution
415213|NCT01021865|Drug|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
415214|NCT01021852|Drug|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
415215|NCT01021852|Drug|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
415216|NCT01021839|Procedure|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
415217|NCT01021813|Drug|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
415218|NCT01021813|Drug|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
415219|NCT01021800|Biological|MIS|Cell infusion
415220|NCT01021787|Drug|Titanium dioxide|Topical cream
415221|NCT01021774|Procedure|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
415222|NCT01021761|Drug|Ketorolac Tromethamine|ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
415223|NCT01021761|Drug|Bromfenac|Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
415224|NCT01021761|Drug|nepafenac|drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
415225|NCT01021748|Drug|MK-2206|Oral tablets
415226|NCT01021748|Drug|AZD6244|Oral capsules
415227|NCT01021735|Drug|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
415228|NCT01021735|Drug|Rituximab|1g x2 by IV infusion repeated every 5 months or more
415229|NCT01021722|Procedure|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
415230|NCT01021709|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 & 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
415231|NCT01021696|Drug|Paracetamol|Paracetamol Max. dose: 3g/d
415232|NCT01021696|Drug|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
415233|NCT01021696|Drug|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
415234|NCT01021696|Drug|Pregabalin|25mgx1/d; max 300mg/d
415236|NCT01021670|Drug|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
415237|NCT01021670|Other|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
415241|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
415242|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
415243|NCT01021618|Drug|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
415244|NCT01021618|Other|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
415245|NCT01021605|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive or invasive ventilation and then the Hemolung RAS. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
415246|NCT01021592|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
415247|NCT01021579|Drug|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
415248|NCT01021579|Drug|Metfomin plus Simvastatin|
415249|NCT01021566|Device|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
415250|NCT01021566|Drug|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
415251|NCT01021553|Drug|GSK557296|50 mg GSK557296
415252|NCT01021553|Drug|GSK557296|150 mg GSK557296
415253|NCT01021553|Drug|placebo|placebo
415254|NCT01021540|Drug|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
415255|NCT01021527|Other|Comparator: Treatment A|No Treatment
415256|NCT01021527|Drug|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
415257|NCT01021527|Drug|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
415258|NCT01021527|Procedure|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
415259|NCT01021501|Drug|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
415260|NCT01021488|Drug|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
415261|NCT01021488|Drug|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
415262|NCT01021475|Procedure|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
415263|NCT01021475|Drug|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
415264|NCT01021462|Procedure|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
415265|NCT01021436|Drug|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
415266|NCT01021423|Drug|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
415267|NCT01021423|Other|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
415268|NCT01021397|Drug|rHPIV3cp45|10^5 TCID50 nasal drops
415269|NCT01021397|Drug|rHPIV3cp45 placebo|1X-L15 nasal drops
415270|NCT01021384|Behavioral|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
415271|NCT01021371|Behavioral|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
415272|NCT01021358|Drug|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
415273|NCT01021358|Drug|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
415274|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
415275|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
415365|NCT01020539|Drug|Isotretinoin|JMML patients only
415366|NCT01020526|Drug|pregabalin|Oral capsule 75-450 mg/day
415367|NCT01020474|Drug|placebo|matching placebo capsules twice daily.
415368|NCT01020474|Drug|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
415409|NCT01020019|Drug|Placebo|Placebo control
415276|NCT01021306|Device|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
415277|NCT01021306|Device|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
415278|NCT01021306|Other|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
415279|NCT01021306|Other|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
415280|NCT01021293|Biological|Poliorix™|3 doses, intramuscular administration
415281|NCT01021293|Biological|Oral Poliovirus vaccine|3 doses, oral administration
415282|NCT01021267|Drug|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
415283|NCT01021241|Biological|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
415284|NCT01021215|Drug|Zileuton|1200 mg twice daily given orally (PO) for 6 days
415285|NCT01021215|Drug|Celecoxib|200 mg twice daily given orally for 6 days
415286|NCT01021215|Other|laboratory biomarker analysis|Correlative studies
415287|NCT01021202|Procedure|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
415288|NCT01021189|Drug|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
415289|NCT01021189|Drug|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
415290|NCT01021176|Other|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
415291|NCT01021176|Drug|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
415292|NCT01021163|Drug|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
415293|NCT01021150|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution~Route of administration: intravenous infusion"
415294|NCT01021150|Drug|cisplatin|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
415295|NCT01021111|Device|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
415296|NCT01021072|Drug|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
415297|NCT01021059|Biological|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
415298|NCT01021046|Procedure|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
415299|NCT01021046|Procedure|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
415300|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
415301|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
415302|NCT01021020|Drug|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
415303|NCT01021007|Drug|Iodine|Rinse 2 times per day for 6 weeks
415304|NCT01021007|Other|water|Use 2 times per day for 6 weeks
415305|NCT01020994|Drug|LAS41003|Once daily, topically
415306|NCT01020994|Drug|LAS189962|Once daily, topically
415307|NCT01020994|Drug|LAS189961|Once daily, topically
415308|NCT01020968|Biological|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
415309|NCT01020968|Other|Vehicle Control|will receive approximately 12-20 intramyocardial injections of 0.4 mL each of vehicle control into the left ventricle.
415310|NCT01020955|Drug|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
415311|NCT01020955|Drug|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
415369|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate venous blood sampling
415370|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
415312|NCT01020942|Procedure|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
415313|NCT01020942|Procedure|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
415314|NCT01020929|Device|Blunt Coude|Type of needle tip
415315|NCT01020929|Device|Quincke|Type of needle tip
415316|NCT01020929|Device|Trucath|Type of needle tip
415317|NCT01020916|Procedure|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
415318|NCT01020916|Procedure|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
415319|NCT01020903|Procedure|Aprepitant|40 mg po pre-op
415320|NCT01020903|Drug|Placebo|Orally, pre-op
415321|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
415322|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
415323|NCT01020864|Drug|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
415324|NCT01020864|Drug|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
415325|NCT01020864|Drug|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
415326|NCT01020851|Behavioral|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
415327|NCT01020851|Behavioral|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
415328|NCT01020838|Drug|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
415329|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
415330|NCT01020825|Drug|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
415331|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
415332|NCT01020812|Procedure|TACE|Standard of Care
415333|NCT01020812|Procedure|SBRT|Standard of Care
415334|NCT01020799|Drug|AZD7268|15 mg, oral, twice daily (BID)
415335|NCT01020799|Drug|Escitalopram|20 mg, oral, once daily (QD)
415336|NCT01020799|Drug|Placebo capsules|Placebo capsules to match AZD7268
415337|NCT01020799|Drug|Placebo tablets|Placebo tablets to match encapsulated escitalopram
415338|NCT01020786|Drug|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.~Maintenance Therapy: 500 mg/m^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
415339|NCT01020786|Drug|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
415340|NCT01020773|Behavioral|spontaneous breathing trial|
415341|NCT01020760|Behavioral|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
415342|NCT01020747|Drug|Avastin® (bevacizumab)|Bevacizumab injections (~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
415343|NCT01020747|Drug|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
415344|NCT01020734|Biological|anti-thymocyte globulin|
415345|NCT01020734|Drug|busulfan|
415346|NCT01020734|Drug|cyclophosphamide|
415347|NCT01020734|Drug|cyclosporine|
415348|NCT01020734|Drug|fludarabine phosphate|
415349|NCT01020734|Drug|methotrexate|
415350|NCT01020734|Procedure|allogeneic hematopoietic stem cell transplantation|
415351|NCT01020643|Drug|controlled administration of propofol|comparison of propofol sedation
415352|NCT01020630|Drug|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
415353|NCT01020630|Drug|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
415354|NCT01020617|Dietary Supplement|Ls-33|10~10 CFU/day
415355|NCT01020591|Other|Osteopathic evaluation|evaluation of movement and tissue mobility
415356|NCT01020591|Other|Osteopathic evaluation with treatment|osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
415357|NCT01020578|Other|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
415358|NCT01020565|Drug|Entecavir|Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
415359|NCT01020552|Other|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
415360|NCT01020539|Drug|Fludarabine|Conditioning Regimen
415361|NCT01020539|Drug|Busulfan|Conditioning Regimen
415362|NCT01020539|Drug|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
415363|NCT01020539|Drug|Gemtuzumab Ozogamicin|Dose Escalation
415364|NCT01020539|Drug|Anti-Thymocyte Globulin|Unrelated Donors only
415371|NCT01020448|Drug|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
415372|NCT01020435|Other|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
415373|NCT01020435|Other|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
415374|NCT01020422|Procedure|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
415375|NCT01020409|Procedure|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
415376|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
415377|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
415378|NCT01020357|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
415379|NCT01020357|Drug|placebo|normal saline
415380|NCT01020344|Procedure|Lung volume reduction surgery|Lung volume reduction surgery
415381|NCT01020331|Drug|Memantine|
415382|NCT01020305|Drug|Temsirolimus|"Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"
415383|NCT01020305|Drug|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
415384|NCT01020279|Drug|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d."
415385|NCT01020279|Drug|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
415386|NCT01020266|Procedure|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
415387|NCT01020266|Procedure|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
415388|NCT01020253|Drug|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
415389|NCT01020240|Behavioral|Avolition|- avolition for cesarean discomforts
415390|NCT01020240|Behavioral|Orientation|"avolition of cesarean discomfort~physiotherapy orientation"
415391|NCT01020240|Behavioral|Guide|"avolition of cesarean discomfort~physiotherapy orientation~guide orientation"
415392|NCT01020227|Behavioral|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
415393|NCT01020214|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
415394|NCT01020214|Drug|Benicar HCT® Tablets 40 mg/25 mg|
415395|NCT01020175|Procedure|Bone marrow transplantation|Patients received bone marrow transplantation
415396|NCT01020175|Procedure|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
415397|NCT01020162|Drug|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
415398|NCT01020162|Procedure|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
415399|NCT01020149|Other|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
415400|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
415401|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
415402|NCT01020123|Drug|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
415403|NCT01020123|Drug|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
415404|NCT01020123|Drug|Glipizide|Glipizide administered to 1 group of patients
415405|NCT01020071|Procedure|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
415406|NCT01020058|Procedure|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
415407|NCT01020032|Other|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
415410|NCT01020019|Drug|Lofexidine|Lofex: .6 mg/ TID
415411|NCT01020006|Drug|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.~All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are >3.50,a reduced dosage will be calculated."
415412|NCT01020006|Drug|Gemcitabine|
415413|NCT01019993|Procedure|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory [I: E] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio <0.3 and R.R 60 breaths/min.
415414|NCT01019980|Drug|Diclofenac potassium|Diclofenac potassium
415415|NCT01019980|Drug|Acetaminophen|Acetaminophen
415416|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
415417|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
415418|NCT01019928|Drug|AZD1386|95 mg, oral solution, single dose
415419|NCT01019928|Drug|Placebo to AZD1386|Placebo, oral solution, single dose
415420|NCT01019915|Device|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
415421|NCT01019889|Drug|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
415422|NCT01019889|Drug|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
415423|NCT01019889|Drug|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
415424|NCT01019876|Drug|Fludarabine|Fludarabine/Busulfan/Alemtuzumab
415425|NCT01019876|Drug|Cyclophosphamide|Cyclophosphamide/Fludarabine/TMG
415426|NCT01019876|Drug|Cyclophosphamide 40|Cyclophosphamide/Fludarabine/ATG/TBI
415427|NCT01019876|Drug|Cyclophosphamide 30|Cyclophosphamide /Fludarabine/TMG
415428|NCT01019863|Drug|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
415429|NCT01019850|Drug|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
415430|NCT01019850|Radiation|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
415431|NCT01019850|Procedure|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
415432|NCT01019850|Drug|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
415433|NCT01019837|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
415434|NCT01019824|Drug|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
415435|NCT01019811|Procedure|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
415436|NCT01019798|Drug|sunitinib, docetaxel, cisplatin|"Sunitinib given 10 days within 14 days of each cycle。~Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.~Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.~Overall 12 cycles (24 weeks)"
415437|NCT01019785|Dietary Supplement|Ergocalciferol|100 000 U drops is given once
415438|NCT01019785|Dietary Supplement|Ergocalciferol|500 U drops given once
415439|NCT01019772|Biological|LBVH0101 (Hib vaccine)|
415440|NCT01019772|Biological|Hiberix™ Vaccine|
415441|NCT01019759|Procedure|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
415442|NCT01019746|Drug|propofol|propofol administration
415443|NCT01019733|Procedure|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
415592|NCT01019187|Other|Placebo|Given orally
415593|NCT01019187|Procedure|Fatigue Assessment and Management|
415444|NCT01019707|Drug|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
415445|NCT01019707|Drug|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
415446|NCT01019694|Drug|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
415447|NCT01019694|Drug|Combivent Respimat 20/100 mcg|Open label randomized parallel
415448|NCT01019694|Drug|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
415449|NCT01019681|Biological|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.~Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
415450|NCT01019668|Drug|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
415451|NCT01019668|Drug|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
415452|NCT01019655|Drug|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
415453|NCT01019642|Drug|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
415454|NCT01019642|Drug|placebo|no active principles given.
415455|NCT01019616|Drug|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
415456|NCT01019603|Drug|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
415457|NCT01019603|Drug|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
415458|NCT01019590|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
415459|NCT01019590|Drug|Benicar HCT ® Tablets 40 mg/25 mg|
415460|NCT01019577|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
415461|NCT01019564|Device|Complete Easy Rub Formula MPS|Multi-purpose solution
415462|NCT01019564|Device|Aquify MPS|Multi-purpose solution
415463|NCT01019551|Drug|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
415464|NCT01019551|Biological|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
415465|NCT01019538|Other|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
415466|NCT01019499|Other|berry products|"effects of berry consumption on cardiovascular indicators~two portions daily"
415467|NCT01019499|Other|control products|two portions daily
415468|NCT01019486|Drug|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
415469|NCT01019486|Drug|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
415470|NCT01019473|Drug|AFQ056|
415471|NCT01019473|Drug|Placebo|
415472|NCT01019460|Procedure|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
415473|NCT01019447|Other|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
415474|NCT01019447|Other|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
415475|NCT01019434|Drug|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
415476|NCT01019434|Drug|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
415477|NCT01019421|Drug|Lu AE58054|Add-on treatment to donepezil
415478|NCT01019421|Drug|Placebo|Add-on treatment to donepezil
415479|NCT01019408|Drug|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
415480|NCT01019395|Drug|Daptomycin|"Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion."
415481|NCT01019382|Drug|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
415482|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
415483|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
415484|NCT01019356|Drug|Rosiglitazone|4 mg twice daily for 8 weeks orally
415485|NCT01019356|Drug|Acarbose|100 mg three times daily for 8 weeks orally
415486|NCT01019343|Procedure|Transcranial Direct Current Stimulation(tDCS)|Transcranial direct current stimulation involves the application of weak direct currents, delivered between two surface electrodes, placed over the scalp.
415487|NCT01019343|Device|Eye-tracking Device|The purpose of this device is to assess eye movement. Participants may sit down in front of a computer screen or a real-world environment, stand on a treadmill, or lie down in an MRI scanner. Small infrared cameras attached to the cap or glasses will be positioned in front of their eyes. Eye tracking might be performed alone, or in conjunction with EEG, EMG, fMRI or treadmill. The eye- tracking device is FDA approved and commercially available.
415488|NCT01019343|Device|Pulsed vibrator|This device would be used in experiments to see if gait can be improved and, if so, what parameters of stimulation are optimal.
415489|NCT01019343|Other|Gait Trainer Treadmill (GTT)|The Gait Trainer is a specialized rehabilitation treadmill, which operates in both the forward and backwards mode allowing subjects to both train and undergo performance tasks in a relatively safe and expedient manner. The GTT is equipped with a mounted deck with built in sensors which monitors and records subjects gait speed, step length, right to left time distribution, and symmetry in real time in both forward and reverse modes.
415490|NCT01019343|Other|Standard psychiatric scales SCID-I, YBOCS and SCI-OBS-lifetime and cognitive scalesMMSE and MOCA|Scales of motor function, cognitive function and psychiatric function are valuable supplements to clinical assessments of patients, giving quantitative information concerning these different aspects of brain function. Selected scales would be used only when potentially useful in a sub-study where such quantitative information would be correlated with a physiological or imaging result.
415491|NCT01019343|Device|iMobility|This test uses the iMobility system. iMobility Device is a small device designed to measure movement through sensors (test monitors) worn by a patient via Velcro straps around an ankle or wrist or worn as a pendant around the neck to lie over the sternum. The device is a nonsignificant risk device.The iMobility Device has been used before, in the same format with a similar paradigm, in previous NIH studies.
415492|NCT01019343|Device|QMAT|The purpose of this study is to assess the ability of the QMAT (quantitative motor assessment tool) to assess slowness of movement associated with Parkinson Disease. The QMAT device is FDA approved and has been used before, in the same format with a similar paradigm, in previous NIH studies.
415493|NCT01019343|Diagnostic Test|Treadmill Test|Subjects will be fitted in a weight support harness for safety. Sensors will be placed on the subject s shoes and harness. The sensors (VICON system) will be used to record their stride length, position and velocity as they walk on a treadmill. This system is a motion- tracking system that is designed to measure various aspects of a person s gait.
415494|NCT01019343|Device|Arm Intellistretch Device|The purpose of the Arm Intellistretch device is to objectively quantify wrist tone. It is used for rehabilitation applications in hospitals and office settings. Currently, rigidity is evaluated clinically using a subjective scale, zero to four and is part of the UPDRS. The Arm Intellistretch device is manufactured by Rehabtek, Inc., is FDA approved, and has been determined to be a non- significant risk device by the CNS IRB.
415495|NCT01019343|Procedure|Transcranial Sonography (TCS)|Transcranial sonography will be conducted by a physician in the Clinical Center using the Acuson Antares ultrasound machine. This techniques uses ultrasound signals to image the brain. It entails having the subject sit in a chair or lay in a bed while the sonographer places a lubricated 2- inch ultrasound probe over the skin of the temporal area just above the patient s ear. Ultrasound images are then recorded. The procedure is not invasive and will last about 45 minutes.
415496|NCT01019343|Other|Behavioral tasks|To assess the changes in cerebral physiology in the brain, subjects will be presented sensory stimuli (e.g., primary visual stimulation with flashing lights or checkerboard, auditory with tone or speech, or olfactory stimuli), or will be asked to perform non- exercise motor tasks (e.g., tapping of fingers, squeezing ball, moving joystick), to perform cognitive tasks such as a working memory task (e.g., n-back with or without catch rules, word finding), or to just rest or sleep.
415497|NCT01019343|Procedure|TMS single/paired pulse|For MEP acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles (see subsection EMG 7.1.3.1 for the details of the procedure).
415498|NCT01019343|Procedure|MEG|MEG recordings will be performed together with experienced personnel in the NIMH MEG lab in the NMR center in Building 10. For these recording sessions, subjects will sit in a chair or lay down with a helmet placed over the head. The helmet used for MEG does not require the application of conductive gel. Scan times vary from 20 minutes to 2 hours.
415499|NCT01019343|Procedure|EEG|EEGs will be recorded by, or together with, experienced personnel in the HMCS EEG lab in Building 10, or in the NMR center.
415500|NCT01019343|Procedure|MRI techniques|MRI sub-studies will be conducted on 3.0 T or 7T units in the NMR Research Center. All volunteers will comply with the yearly requirement of a standard clinical diagnostic MRI scan of the head performed at 3.0T, to be submitted to the Diagnostic Radiology Department of the Clinical Center for interpretation. If the subject does not have a clinical scan performed within 12 month of the exam, a standard clinical MRI will be performed and reviewed before the research MR. The standard examination takes approximately 15 minutes to complete; after that, the research MR scans will be performed. Standard clinical MRI of the head will be repeated on an annual basis and read by the Diagnostic Radiology Department of the Clinical Center.
415501|NCT01019343|Procedure|Peripheral Nerve Stimulation|Constant-current, 0.1 to 0.5 ms square- wave single pulses of electrical stimulation will be delivered through standard bar electrodes to nerves of the upper limb or of the lower limb. To study somatosensory evoked potentials, for example, the stimulus intensity will be set at just above the motor threshold for evoking a slight limb movement. Location of the electrical stimulation will depend on the specific objective of the sub-study. Peripheral nerve stimulation might be delivered during other types of experiments as well.
415502|NCT01019343|Procedure|EMG|EMG measures the electrical activity of muscles. For our research purposes, only surface EMG will be used to measure the effects of central and peripheral nervous system stimulation. For surface EMG, electrodes will be coated with a conductive gel and taped to the skin. For motor evoked potential (MEP) acquisition during TMS, electrodes will be placed over the belly and the tendon of the distal muscles of the hand or foot and/or proximal muscles.
415594|NCT01019187|Procedure|Sleep Disorder Therapy|
415595|NCT01019187|Drug|Armodafinil|Given orally
415596|NCT01019187|Procedure|Quality-of-life assessment|Ancillary studies
415503|NCT01019330|Other|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
415504|NCT01019330|Other|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
415505|NCT01019317|Drug|Cytarabine|0.5 grams/m^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients > 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3).
415506|NCT01019317|Drug|Fludarabine|15 mg/m^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients > 65 years and 3 days in patients with PS > 3).
415507|NCT01019291|Other|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
415508|NCT01019291|Other|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
415509|NCT01019265|Drug|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
415510|NCT01019252|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
415511|NCT01019239|Procedure|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
415512|NCT01019239|Procedure|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
415513|NCT01019213|Other|Septal pacing|Septal lead activated
415514|NCT01019213|Other|His lead activated|His lead will be activated 80 ms before septal lead
415515|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
415516|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
415517|NCT01019161|Drug|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
415518|NCT01019161|Drug|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
415519|NCT01019135|Behavioral|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
415520|NCT01019109|Device|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
415521|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
415522|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
415523|NCT01019083|Other|Control|Control will be selected from the Arsenic non contaminated Area
415524|NCT01019083|Drug|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
415525|NCT01019083|Drug|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
415526|NCT01019083|Other|Arsenic|Participant will be selected from the Arsenic Contaminated Area
415527|NCT01019070|Drug|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
415528|NCT01019057|Procedure|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
415529|NCT01019044|Procedure|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
415530|NCT01019018|Device|subtenon block|subtenon block with stevens cannula
415531|NCT01019018|Device|subtenon block|subtenon block with Olive tip cannula cannula
415532|NCT01019005|Device|Catheter|Catheter inserted into either perineural tibial nerve or wound
415533|NCT01018992|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
415534|NCT01018992|Drug|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
415535|NCT01018979|Drug|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
415536|NCT01018979|Drug|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
415537|NCT01018966|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
415597|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
415598|NCT01019187|Procedure|Fatigue Assessment and Management|
415599|NCT01019187|Procedure|Management of Therapy|
415600|NCT01019187|Procedure|Sleep disorder therapy|
415601|NCT01019187|Procedure|cognitive assessment|
415538|NCT01018953|Drug|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
415539|NCT01018927|Device|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
415540|NCT01018914|Drug|Prograf|oral
415541|NCT01018914|Drug|Advagraf|oral
415542|NCT01018914|Drug|Myfortic|oral
415543|NCT01018888|Device|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
415544|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
415545|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
415546|NCT01018862|Drug|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
415547|NCT01018849|Dietary Supplement|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
415548|NCT01018849|Dietary Supplement|Placebo|placebo by mouth every 2 months for 1 year
415549|NCT01018836|Drug|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
415550|NCT01018836|Radiation|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
415551|NCT01018823|Drug|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
415552|NCT01018823|Drug|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
415553|NCT01018810|Drug|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
415554|NCT01018810|Drug|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
415555|NCT01018810|Drug|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
415556|NCT01018810|Drug|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
415557|NCT01018797|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
415558|NCT01018784|Drug|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
415559|NCT01018771|Procedure|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
415560|NCT01018771|Procedure|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
415561|NCT01018758|Drug|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
415562|NCT01018745|Drug|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
415563|NCT01018732|Biological|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
415564|NCT01018719|Device|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
415565|NCT01018693|Drug|VAK694; Alutard Avanz SQ|
415566|NCT01018693|Drug|VAK694 placebo infusion; Alutard Avanz SQ|
415567|NCT01018693|Drug|VAK694 placebo infusion; Saline|
415568|NCT01018680|Drug|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
415569|NCT01018680|Drug|Placebo|Taken by mouth, once daily for 10 weeks
415570|NCT01018654|Behavioral|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
415571|NCT01018654|Behavioral|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
415572|NCT01020708|Drug|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
415573|NCT01020708|Drug|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
415574|NCT01020708|Drug|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
415575|NCT01020487|Drug|Paricalcitol|Paricalcitol capsules taken with water.
415576|NCT01020487|Drug|Placebo|Placebo capsules taken with water
415577|NCT01020383|Drug|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
415578|NCT01020383|Drug|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
415579|NCT01020292|Drug|Nelfinavir|
415580|NCT01020097|Drug|fluorine F18 EF5|Given IV
415581|NCT01020097|Procedure|immunohistochemistry staining method|Correlative study
415582|NCT01020097|Procedure|biopsy|Correlative study
415583|NCT01020097|Procedure|Positron Emission tomography|Undergo scan
415584|NCT01019954|Drug|Levulan|
415585|NCT01019512|Other|questionnaire administration|Ancillary studies
415586|NCT01019512|Other|lymphedema management|
415587|NCT01019278|Radiation|proton beam radiation therapy|Undergo external proton beam radiation
415588|NCT01019278|Radiation|radiation therapy treatment planning/simulation|
415589|NCT01019278|Drug|cisplatin|Given IV
415590|NCT01019187|Procedure|Quality-of-Life Assessment|Ancillary Studies
415591|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
415602|NCT01019187|Procedure|Quality of Life assessment|Ancillary Studies
415603|NCT01019187|Other|Questionnaire Administration|Ancillary studies
415604|NCT01019187|Other|Placebo|Given orally
415605|NCT01019187|Procedure|Fatigue assessment and management|
415606|NCT01019187|Procedure|Management of therapy and complications|
415607|NCT01019187|Procedure|Sleep disorder therapy|
415608|NCT01019187|Drug|Armodafinil|Given orally
415609|NCT01019187|Procedure|Cognitive Assessment|
415610|NCT01019187|Procedure|Quality of Life Assessment|Quality of Life Assessment
415611|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
415612|NCT01019187|Procedure|Fatifue assessment and management|
415613|NCT01019122|Radiation|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
415614|NCT01018901|Other|Survey Administration|Patients complete survey
415615|NCT01018875|Drug|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
415616|NCT01018875|Drug|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
415617|NCT01018875|Drug|placebo|Subjects will take 4 capsules once daily for 12 weeks.
415618|NCT01018641|Biological|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
415619|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
415620|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
415621|NCT01018641|Biological|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
415622|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
415623|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
415624|NCT01018641|Biological|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
415625|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
415626|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
415627|NCT01018641|Biological|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:~Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm~In stage 2 the subject will receive no vaccine."
415628|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
415629|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
415630|NCT01018641|Procedure|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.~In stage 2 the subject will receive no vaccine."
415631|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
415632|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
415633|NCT01018628|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
415634|NCT01018628|Drug|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
415635|NCT01018615|Drug|silymarin|capsules, 700 mg, twice daily, 12 days
415636|NCT01018615|Dietary Supplement|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
415637|NCT01018602|Drug|vildagliptin|100 mg per day over 24 months
415638|NCT01018602|Drug|inactive pill|1 pill per day over 24 months
415639|NCT01018589|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.~To the patient will be explained the technique of the application."
415640|NCT01018576|Other|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
415641|NCT01018563|Drug|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
415642|NCT01018550|Drug|AMG 853|AMG 853 5 mg (BID)
415643|NCT01018550|Drug|AMG 853|AMG 853 200 mg (QD)
415644|NCT01018550|Drug|AMG 853|AMG 853 25 mg (BID)
415645|NCT01018550|Drug|AMG 853|AMG 853 100 mg (BID)
415646|NCT01018550|Drug|Placebo|Placebo
415647|NCT01018524|Procedure|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
415648|NCT01018511|Drug|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
415649|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
415650|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
415691|NCT01018251|Radiation|FLT-PET/CT|
415651|NCT01018511|Drug|tamsulosin hydrochloride OCAS 0.4 mg|tablet
415652|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
415653|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
415654|NCT01018498|Behavioral|Restricted FODMAPs diet|Restricted fermentable substrate diet
415655|NCT01018485|Drug|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
415656|NCT01018472|Dietary Supplement|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
415657|NCT01018472|Other|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
415658|NCT01018459|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10^9 viral particles (vp)/mL, 10^10 vp/mL, 5 x 10^10 vp/mL, and 10^11 vp/mL.
415659|NCT01018459|Drug|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
415660|NCT01018446|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
415661|NCT01018433|Behavioral|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
415662|NCT01018433|Other|Treatment as usual|Can include other psychotherapy and pharmacotherapy
415663|NCT01018420|Drug|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
415664|NCT01018420|Drug|Moxifloxacin|400 mg capsule at the 6 hour point
415665|NCT01018407|Behavioral|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen & Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
415666|NCT01018407|Behavioral|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
415667|NCT01018394|Drug|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
415668|NCT01018394|Drug|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
415669|NCT01018381|Procedure|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).~Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
415670|NCT01018381|Procedure|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
415671|NCT01018381|Procedure|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
415672|NCT01018381|Procedure|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
415673|NCT01018381|Dietary Supplement|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
415674|NCT01018381|Drug|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
415675|NCT01018368|Drug|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
415676|NCT01018368|Drug|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
415677|NCT01018355|Device|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
415678|NCT01018342|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
415679|NCT01018342|Drug|Macrobid® Capsules 100 mg|
415680|NCT01018329|Procedure|Magnetic Resonance Imaging|
415681|NCT01018329|Procedure|Diffusion Tensor Imaging|
415682|NCT01018329|Procedure|Magnetic Resonance Spectroscopic Imaging|
415683|NCT01018329|Procedure|Dynamic Contract-Enhanced magnetic resonance imaging|
415684|NCT01018329|Procedure|Diffusion-weighted magnetic resonance imaging|
415685|NCT01018303|Dietary Supplement|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
415686|NCT01018277|Other|Mobilization (walking)|25 meters twice
415687|NCT01018264|Drug|solifenacin succinate (VESIcare)|up to 10mg every day orally
415688|NCT01018264|Drug|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
415689|NCT01018251|Other|3'-deoxy-3'-[18F]fluorothymidine|Given IV
415690|NCT01018251|Procedure|Positron Emission Tomography/computed tomography|
415692|NCT01018238|Drug|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
415693|NCT01018238|Drug|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
415694|NCT01018225|Drug|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
415695|NCT01018225|Drug|Placebo|Placebo pill, once a day, for six weeks
415696|NCT01018212|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
415697|NCT01018199|Other|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
415698|NCT01018199|Other|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
415699|NCT01018186|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
415700|NCT01018186|Drug|Fluticasone propionate|Inhaled corticosteroid
415701|NCT01018173|Drug|placebo|sc weekly
415702|NCT01018173|Drug|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
415703|NCT01018160|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
415704|NCT01018147|Procedure|4-dimensional computed tomography|Undergo 4-D CT imaging
415705|NCT01018134|Drug|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
415706|NCT01018134|Drug|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
415707|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
415708|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
415709|NCT01018134|Drug|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
415710|NCT01018134|Drug|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
415711|NCT01018121|Behavioral|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
415712|NCT01018121|Other|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
415713|NCT01018108|Procedure|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
415714|NCT01018108|Procedure|Acupuncture Therapy|Undergo acupuncture
415715|NCT01018108|Other|Questionnaire Administration|Ancillary study
415716|NCT01018108|Other|Laboratory Biomarker Analysis|Correlative Study
415717|NCT01018095|Drug|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
415718|NCT01018069|Drug|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
415719|NCT01018056|Drug|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
415720|NCT01018056|Drug|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
415721|NCT01018056|Drug|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
415722|NCT01018043|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
415723|NCT01018030|Drug|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
415724|NCT01018030|Drug|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
415725|NCT01018030|Drug|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
415726|NCT01018017|Drug|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
415727|NCT01018017|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
415728|NCT01018004|Other|follow-up care|
415729|NCT01018004|Other|questionnaire administration|
415730|NCT01018004|Procedure|quality-of-life assessment|
415731|NCT01017991|Other|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
415834|NCT01017172|Other|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
415732|NCT01017991|Other|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
415733|NCT01017978|Procedure|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
415734|NCT01017965|Device|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
415735|NCT01017952|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
415736|NCT01017952|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
415737|NCT01017939|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
415738|NCT01017939|Drug|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
415739|NCT01017939|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
415740|NCT01017939|Drug|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
415741|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
415742|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
415743|NCT01017913|Other|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
415744|NCT01017913|Other|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
415745|NCT01017900|Procedure|local excision|surgical excision by orthopaedic surgeon under local anesthesia
415746|NCT01017887|Device|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
415747|NCT01017887|Device|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
415748|NCT01017874|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
415749|NCT01017874|Drug|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
415750|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
415751|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
415752|NCT01017822|Biological|conatumumab|
415753|NCT01017822|Drug|capecitabine|
415754|NCT01017822|Drug|gemcitabine hydrochloride|
415755|NCT01017822|Radiation|3-dimensional conformal radiation therapy|
415756|NCT01017809|Drug|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
415757|NCT01017796|Drug|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
415758|NCT01017783|Behavioral|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
415759|NCT01017783|Behavioral|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
415760|NCT01017783|Behavioral|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
415761|NCT01017770|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
415762|NCT01017770|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
415763|NCT01017757|Procedure|High-resolution CT scanning|High-resolution CT scanning
415764|NCT01017744|Device|Anesthetic Conserving Device|"Ventilation in PSV with the Anesthetic Conserving Device with remifentanil~Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
415765|NCT01017731|Biological|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
415766|NCT01017731|Drug|Moxifloxacin|Administered orally
415767|NCT01017731|Drug|Diphenhydramine|Administered IV
415768|NCT01017692|Procedure|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
415769|NCT01017679|Drug|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
415770|NCT01017666|Drug|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
415771|NCT01017666|Drug|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
415772|NCT01017653|Drug|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
415773|NCT01017653|Drug|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
415774|NCT01017640|Other|Laboratory Biomarker Analysis|Correlative studies
415775|NCT01017640|Drug|Mitomycin|Given IV
415776|NCT01017640|Drug|Veliparib|Given PO
415777|NCT01017627|Other|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
415778|NCT01017627|Other|No change from normal routine|Normal unit policy for labs and anemia treatment
416077|NCT01015430|Drug|RO4917523|RO4917523 fixed dose daily po
415779|NCT01017614|Drug|Monofer|"administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained~administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
415780|NCT01017614|Drug|Iron Sulphate|200 mg daily
415781|NCT01017601|Biological|Seneca Valley virus-001|Given IV
415782|NCT01017601|Other|placebo|Given IV
415783|NCT01017588|Device|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
415784|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
415785|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
415786|NCT01017575|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
415787|NCT01017575|Drug|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
415788|NCT01017575|Drug|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
415789|NCT01017549|Radiation|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
415790|NCT01017536|Biological|AERAS-402|AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
415791|NCT01017536|Biological|Placebo|Placebo was the identical buffer solution in which AERAS-402 is formulated.
415792|NCT01017523|Behavioral|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
415793|NCT01017523|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
415794|NCT01017510|Device|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
415795|NCT01017510|Device|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.~Left scalp: syringe without a needle.~All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.~The distance between injection locations will be 1 cm."
415796|NCT01017497|Radiation|Stereotactic Radiosurgery|PTV Diameter < 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
415797|NCT01017484|Other|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
415798|NCT01017471|Procedure|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
415799|NCT01017458|Drug|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
415800|NCT01017458|Drug|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
415801|NCT01017458|Drug|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
415802|NCT01017458|Drug|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
415803|NCT01017445|Other|Boonme stick exercise|individual exercise daily
415804|NCT01017419|Behavioral|Counseling|Informational Counseling provided after hearing aid fitting
415805|NCT01017406|Device|PSU heel cushion and plantar fascia specific stretching exercise|"Wear heel cushion during daily activity~Plantar fascia stretching exercise 3 times per day"
415806|NCT01017393|Drug|Ketamine|
415807|NCT01017393|Drug|ketamine free|
415808|NCT01017380|Drug|Celecoxib|celecoxib 400 mg 1 cap before surgery
415809|NCT01017380|Drug|etoricoxib|120 mg 1 tab before surgery
415810|NCT01017367|Drug|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
415811|NCT01017367|Drug|Placebo|Placebo
415812|NCT01017354|Drug|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
415813|NCT01017354|Dietary Supplement|ViDe3 (CH)|60000 vitamin D3 orally and once per month
415814|NCT01017354|Dietary Supplement|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
415815|NCT01017341|Device|PSU hip protector|hip protetor
415816|NCT01017315|Drug|Baby talcum|50 grams apply locally prior cast application
415817|NCT01017302|Drug|Placebo|Subcutenaous once weekly for 4 weeks
415818|NCT01017302|Drug|Placebo|Single subcutaneous dose in week 5
415819|NCT01017302|Drug|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
415820|NCT01017302|Drug|RO5095932|Single subcutenaous dose in week 5
415821|NCT01017289|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
415822|NCT01017276|Drug|ASP1585|oral
415823|NCT01017263|Drug|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
415824|NCT01017250|Radiation|Stereotactic Radiosurgery (SRS)|Tumor Volume < 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
415825|NCT01017250|Drug|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
415826|NCT01017237|Drug|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
415827|NCT01017237|Drug|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
415828|NCT01017237|Drug|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
415829|NCT01017224|Other|18F-FAZA|PET scan
415830|NCT01017211|Other|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.~Sham group to receive ear needles at points thought to be ineffective but standardized."
415831|NCT01017198|Drug|BIIB021 and Food|Assessing the effect of food use on BIIB021
415832|NCT01017198|Drug|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
415833|NCT01017185|Drug|HF10|
415835|NCT01017159|Drug|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
415836|NCT01017146|Drug|Tazarotene foam|Tazarotene foam once a day application to the face
415837|NCT01017146|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
415838|NCT01017133|Radiation|fludeoxyglucose F 18|Given IV
415839|NCT01017133|Radiation|Fluorine F 18 EF5|Given IV
415840|NCT01017133|Procedure|Positron emission tomography|Undergo scan
415841|NCT01017120|Drug|Tazarotene Foam|Tazarotene foam once a day application to the face
415842|NCT01017120|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
415843|NCT01017107|Drug|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
415844|NCT01017094|Drug|silversulfadiazine|apply once a day
415845|NCT01017081|Other|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
415846|NCT01017081|Other|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
415847|NCT01017068|Drug|OME|4g/100ml) dose: п gutt tid x 1/52
415848|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
415849|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
415850|NCT01017068|Drug|OME|(4g/100ml) dose: п gutt tid x 1/52
415851|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
415852|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
415853|NCT01017055|Other|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
415854|NCT01017042|Drug|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
415855|NCT01017029|Drug|Everolimus|
415856|NCT01017029|Drug|Mycophenolate mofetil + Everolimus|
415857|NCT01017003|Drug|colchicine tablets|0.6mg colchicine tablet
415858|NCT01017003|Drug|colchicine tablets|0.6mg q12 hours for 10 days
415859|NCT01016990|Drug|valproic acid|
415860|NCT01016990|Genetic|western blotting|
415861|NCT01016990|Other|laboratory biomarker analysis|
415862|NCT01016990|Other|pharmacological study|
415863|NCT01016977|Drug|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
415864|NCT01016977|Drug|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
415865|NCT01016964|Device|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
415866|NCT01016964|Device|Sham Device|Sham Device
415867|NCT01016951|Drug|AZD9164 Turbuhaler®|"Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.~The COPD patients will receive a dose of 1000 µg."
415868|NCT01016951|Drug|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
415869|NCT01016925|Procedure|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
415870|NCT01016912|Drug|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
415871|NCT01016912|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
415872|NCT01016912|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
415873|NCT01016912|Drug|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
415874|NCT01016912|Drug|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
415875|NCT01016899|Radiation|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
415876|NCT01016886|Drug|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg~bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
415877|NCT01016873|Device|IRay|Low voltage stereotactic radiotherapy system
415878|NCT01016860|Drug|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
415879|NCT01016860|Drug|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
415880|NCT01016847|Drug|Montelukast|10 mg Q day
415881|NCT01016847|Other|Sugar pill|Sugar pill that looks like Montelukast that will be given Q day
415882|NCT01016834|Device|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
415883|NCT01016834|Drug|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
415884|NCT01016821|Drug|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
415885|NCT01016808|Drug|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
415886|NCT01016808|Drug|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
415887|NCT01016808|Drug|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
415888|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
415889|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
415932|NCT01016457|Device|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
416649|NCT01011387|Device|NPWT system|3 dressing changes/week for maximum 4 weeks.
415890|NCT01016795|Drug|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
415891|NCT01016782|Drug|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
415892|NCT01016769|Drug|Temsirolimus + Weekly Paclitaxel + Carboplatin|"Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.~Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week."
415893|NCT01016743|Device|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
415894|NCT01016730|Drug|Bortezomib|Given IV
415895|NCT01016730|Other|Laboratory Biomarker Analysis|Correlative studies
415896|NCT01016730|Other|Questionnaire Administration|Ancillary studies
415897|NCT01016717|Drug|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
415898|NCT01016717|Drug|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
415899|NCT01016704|Behavioral|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
415900|NCT01016691|Drug|High Dose Drug Device|device inserted for 4 days
415901|NCT01016691|Drug|Low Dose Drug Device|device inserted for 4 days
415902|NCT01016691|Drug|Placebo Device|device inserted for 4 days
415903|NCT01016691|Drug|bimatoprost 0.03%|one drop in each eye on one day only
415904|NCT01016678|Drug|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
415905|NCT01016678|Drug|Placebo|Dummy pill comparator
415906|NCT01016665|Drug|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
415907|NCT01016652|Device|etafilcon A multifocal contact lens|low-add multifocal contact lens
415908|NCT01016652|Device|etafilcon A Contact Lens|standard sphere contact lens
415909|NCT01016639|Other|oxaliplatin, capecitabine, radiotherapy|
415910|NCT01016626|Drug|CKD-4101 tablet|"CKD-4101 tablet 1000 mg~500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
415911|NCT01016626|Drug|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg~250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
415912|NCT01016600|Drug|Lenalidomide|
415913|NCT01016600|Drug|Azacitidine|
415914|NCT01016574|Device|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
415915|NCT01016561|Radiation|intracavitary balloon brachytherapy|
415916|NCT01016561|Radiation|external beam radiation therapy|
415917|NCT01016561|Radiation|intensity-modulated radiation therapy|
415918|NCT01016561|Radiation|radiation therapy treatment planning/simulation|
415919|NCT01016561|Radiation|3-dimensional conformal radiation therapy|
415920|NCT01016561|Drug|Cisplatin|
415921|NCT01016548|Biological|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
415922|NCT01016522|Dietary Supplement|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
415923|NCT01016509|Drug|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of <180 mg/dl.
415924|NCT01016509|Drug|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of <200 mg/dl.
415925|NCT01016496|Other|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
415926|NCT01016496|Other|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
415927|NCT01016483|Drug|Pimasertib|
415928|NCT01016483|Drug|Gemcitabine|
415929|NCT01016483|Drug|Placebo|
415930|NCT01016470|Dietary Supplement|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
415931|NCT01016470|Dietary Supplement|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
416132|NCT01015001|Procedure|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
415933|NCT01016431|Other|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
415934|NCT01016431|Other|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
415935|NCT01016418|Dietary Supplement|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
415936|NCT01016379|Genetic|DNA analysis|
415937|NCT01016379|Other|biologic sample preservation procedure|
415938|NCT01016379|Other|laboratory biomarker analysis|
415939|NCT01016366|Drug|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
415940|NCT01016366|Drug|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
415941|NCT01016353|Device|NPWT|ABThera Open Abdomen Negative Pressure Therapy System
415942|NCT01016353|Device|BVPT|Barker's Vacuum Packing Technique
415943|NCT01016340|Drug|MCS|MCS-5 Softgel 5 mg
415944|NCT01016327|Drug|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
415945|NCT01016314|Device|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
415946|NCT01016314|Device|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
415947|NCT01016301|Other|Pharmacist service|Medication Review, medication report
415948|NCT01016275|Device|Misago (stent placement)|Misago iliac stent
415949|NCT01016262|Drug|MAX-002|MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.
415950|NCT01016262|Drug|Placebo|Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
415951|NCT01016262|Drug|Canasa®|Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
415952|NCT01016249|Drug|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
415953|NCT01016249|Drug|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
415954|NCT01016249|Drug|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
415955|NCT01016223|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
415956|NCT01016223|Drug|placebo|Matched placebo swallowed two puffs twice daily
415957|NCT01016210|Drug|Leuveris|IV
415958|NCT01016210|Drug|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
415959|NCT01016197|Procedure|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
415960|NCT01016197|Procedure|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
415961|NCT01016184|Dietary Supplement|Vitamin D|Oral vitamin D 100,000 IU
415962|NCT01016184|Dietary Supplement|Placebo|Placebo
415963|NCT01016158|Drug|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
415964|NCT01016145|Drug|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
415965|NCT01016145|Drug|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
415966|NCT01016132|Device|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
415967|NCT01016119|Drug|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
415968|NCT01016119|Drug|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
415969|NCT01016106|Genetic|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
415970|NCT01016093|Drug|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
415971|NCT01016093|Drug|Placebo|Placebo
415972|NCT01016080|Drug|glutathione|250 mg capsules, twice daily, orally
415973|NCT01016080|Drug|placebo|250 mg capsules, twice daily, orally
415974|NCT01016067|Device|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
415975|NCT01016067|Procedure|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
415976|NCT01016054|Biological|AGS-8M4|IV infusion
415977|NCT01016054|Drug|Pegylated liposomal doxorubicin (PLD)|IV infusion
415978|NCT01016054|Drug|gemcitabine|IV infusion
415979|NCT01016054|Drug|carboplatin|IV infusion
415980|NCT01016041|Device|everolimus stent|stenting
415981|NCT01016041|Device|paclitaxel stent|stenting
416073|NCT01015443|Other|Best Supportive Care (BSC)|The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
415982|NCT01016028|Behavioral|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
415983|NCT01016028|Behavioral|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
415984|NCT01016028|Behavioral|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
415985|NCT01016015|Biological|Cixutumumab|Given IV
415986|NCT01016015|Other|Laboratory Biomarker Analysis|Correlative studies
415987|NCT01016015|Drug|Temsirolimus|Given IV
415988|NCT01016002|Drug|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.~Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
415989|NCT01015989|Other|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
415990|NCT01015989|Other|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
415991|NCT01015976|Procedure|bariatric surgery|Roux en Y bariatric surgery
415992|NCT01015976|Other|control|No surgery
415993|NCT01015963|Other|laboratory biomarker analysis|Perform DNA sample analysis
415994|NCT01015950|Dietary Supplement|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
415995|NCT01015950|Dietary Supplement|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
415996|NCT01015950|Dietary Supplement|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
415997|NCT01015950|Dietary Supplement|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
415998|NCT01015937|Drug|Turmeric extract|turmeric 500 mg TID for 45 days
415999|NCT01015937|Drug|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
416000|NCT01015924|Procedure|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
416001|NCT01015924|Procedure|ESIN|Elastiv stable intramedullary nailing
416002|NCT01015911|Drug|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
416003|NCT01015898|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
416004|NCT01015872|Device|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
416005|NCT01015859|Device|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
416006|NCT01015846|Other|Exercise|Redcord (sling exercise) and traditional exercise
416007|NCT01015846|Other|Core stability exercise|Traditional core stability exercise
416008|NCT01015833|Drug|Doxorubicin Hydrochloride|Given IV
416009|NCT01015833|Other|Laboratory Biomarker Analysis|Correlative studies
416010|NCT01015833|Other|Pharmacogenomic Study|Correlative studies
416011|NCT01015833|Drug|Sorafenib Tosylate|Given PO
416012|NCT01015820|Procedure|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
416013|NCT01015820|Device|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
416014|NCT01015807|Drug|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
416015|NCT01015807|Drug|Clonidine Placebo|2 x 1mL 0.9% NaCl
416016|NCT01015807|Drug|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
416017|NCT01015807|Drug|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
416018|NCT01015794|Drug|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
416019|NCT01015794|Drug|ephedrine hydrochloride|single dose of 1 mg/kg body weight
416020|NCT01015781|Procedure|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
416021|NCT01015781|Procedure|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
416022|NCT01015768|Device|ReNu Multiplus multipurpose disinfecting solution|New lenses (PureVision) soaked 6 hours to overnight in ReNu Multiplus
416023|NCT01015768|Device|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
416024|NCT01015755|Behavioral|combined therapy treatment|mouth care
416074|NCT01015430|Drug|Placebo (for RO4917523 ascending doses)|Placebo daily po
416075|NCT01015430|Drug|Placebo (for RO4917523 fixed dose)|Placebo daily po
416025|NCT01015742|Drug|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4~Cyclophosphamide : 60 mg/m² daily on days -3 to -2~Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2~Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90~Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
416026|NCT01015729|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
416027|NCT01015729|Drug|Esomeprazole|oral, single dose
416028|NCT01015729|Drug|ASA|Tablet, oral, single dose
416029|NCT01015716|Behavioral|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
416030|NCT01015716|Behavioral|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
416031|NCT01015703|Biological|CoVaccine HT|intramuscular injection, dose escalation
416032|NCT01015677|Drug|MK-6913|
416033|NCT01015677|Drug|17-β estradiol|
416034|NCT01015677|Drug|Placebo to MK-6913|
416035|NCT01015677|Drug|Placebo to 17-β estradiol|
416036|NCT01015677|Drug|MK-6913 25 mg|
416037|NCT01015664|Drug|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
416038|NCT01015664|Drug|cisplatin|75 mg/m2 IV over 60 minutes on day 1
416039|NCT01015664|Drug|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
416040|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
416041|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
416042|NCT01015638|Drug|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
416043|NCT01015638|Drug|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
416044|NCT01015625|Procedure|Surgery|lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
416045|NCT01015625|Procedure|Surgery on Demand|if necessary local therapy on demand
416046|NCT01015612|Device|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
416047|NCT01015599|Behavioral|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
416048|NCT01015586|Drug|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
416049|NCT01015586|Drug|Placebo|Placebo once daily for 12 weeks
416050|NCT01015573|Device|magnetic sensor system to measure the movements of finger tapping|
416051|NCT01015560|Drug|anti-CCR2 monoclonal antibody MLN1202|
416052|NCT01015560|Genetic|polymorphism analysis|
416053|NCT01015560|Other|laboratory biomarker analysis|
416054|NCT01015547|Drug|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
416055|NCT01015547|Drug|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
416056|NCT01015547|Drug|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
416057|NCT01015534|Drug|Temozolomide|
416058|NCT01015534|Radiation|Whole brain irradiation|
416059|NCT01015521|Drug|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
416060|NCT01015508|Other|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
416061|NCT01015508|Other|Weight maintenance|10 months
416062|NCT01015495|Drug|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
416063|NCT01015482|Drug|Remifentanil|Remifentanil Infusion
416064|NCT01015482|Drug|Midazolam|Midazolam Infusion
416065|NCT01015469|Procedure|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
416066|NCT01015469|Procedure|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
416067|NCT01015456|Drug|mycophenolate sodium|per oral, twice daily, for 12 months
416068|NCT01015456|Drug|cyclophosphamide|intravenous, monthly, for 6 months
416069|NCT01015443|Biological|Tecemotide|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
416070|NCT01015443|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
416071|NCT01015443|Drug|Placebo|Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
416072|NCT01015443|Other|Saline|A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
416076|NCT01015430|Drug|RO4917523|RO4917523 ascending doses daily po
416078|NCT01015417|Drug|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
416079|NCT01015417|Other|No medication|no postoperative antibiotics
416080|NCT01015404|Drug|Trafermin|Administered to the bone defect during flap operation
416081|NCT01015391|Drug|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
416082|NCT01015391|Drug|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
416083|NCT01015378|Procedure|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
416084|NCT01015365|Procedure|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
416085|NCT01015352|Drug|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
416086|NCT01015352|Drug|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections~NeoRecormon®"
416087|NCT01015339|Drug|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
416088|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
416089|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
416090|NCT01015339|Drug|cisplatin|80mg/m2, day 1 of every 3 weeks
416091|NCT01015326|Other|Questionnaire|Administered questionnaire
416092|NCT01015326|Other|Questionnaire|Administered questionnaire
416093|NCT01015313|Other|intensive sodium management|"dietary sodium restriction~avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
416094|NCT01015300|Drug|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
416095|NCT01015287|Drug|Placebo|Administered once orally
416096|NCT01015287|Drug|Prasugrel|Administered orally
416097|NCT01015261|Procedure|Bone Marrow Transplantation|Allogenic Bone Marrow Transplantation
416098|NCT01015261|Procedure|Chemotherapy|"Cyclophosphamide 1200 mg/m2 D15~Daunorubicin 45 mg/m2 D15—D18~Vincristine 1 mg/m2 D15, D22~Dexamethasone 24 mg/d D12—D28"
416099|NCT01015248|Drug|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
416100|NCT01015235|Drug|Placebo|Subcutaneous infusion-once over 4 hours
416101|NCT01015235|Drug|KAI-1678|Subcutaneous infusion-once over 4 hours
416102|NCT01015235|Drug|Ketorolac Tromethamine|Active comparator, IV infusion, once
416103|NCT01015222|Drug|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
416104|NCT01015222|Drug|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
416105|NCT01015222|Drug|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
416106|NCT01015209|Device|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
416107|NCT01015196|Drug|Zavedos|
416108|NCT01015196|Drug|Cerubidine|
416109|NCT01015183|Drug|Zinc Sulfate|Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
416110|NCT01015183|Drug|Placebo|Placebo: as the same of intervention group
416111|NCT01015170|Drug|bupropion HCl|150mg BID for up to 8 weeks + counseling
416112|NCT01015157|Procedure|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
416113|NCT01015144|Drug|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
416114|NCT01015131|Radiation|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
416115|NCT01015118|Drug|Placebo|comparator to BIBF 1120
416116|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
416117|NCT01015118|Drug|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
416118|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
416119|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
416120|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
416121|NCT01015105|Other|observation|observation
416122|NCT01015066|Drug|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
416123|NCT01015066|Drug|Naltrexone|Oral tables, 50 mg/d, once a day for six months
416124|NCT01015053|Procedure|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
416125|NCT01015053|Procedure|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
416126|NCT01015040|Drug|solifenacin succinate suspension|Oral
416127|NCT01015040|Drug|solifenacin succinate tablet|Oral
416128|NCT01015027|Biological|REGN668|4 IV Cohorts (Dose 1, 2, 3, & 4)
416129|NCT01015014|Drug|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
416130|NCT01015014|Drug|Placebo|0.9% sodium chloride for injection
416131|NCT01015001|Procedure|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
416133|NCT01015001|Procedure|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
416134|NCT01014988|Drug|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
416135|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
416136|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
416137|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
416138|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
416139|NCT01014962|Drug|Placebo|Placebo oral once daily for 5 days
416140|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
416141|NCT01014962|Drug|Placebo|Placebo oral every 12 hours for 5 days
416142|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
416143|NCT01014962|Drug|Placebo|Placebo oral every 8 hours for 5 days
416144|NCT01014949|Other|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine [140 ug/kg/min] to induce steady state maximal hyperemia."
416145|NCT01014936|Drug|MSC2156119J|
416146|NCT01014923|Behavioral|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
416147|NCT01014910|Other|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
416148|NCT01014910|Device|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
416149|NCT01014897|Device|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
416150|NCT01014884|Other|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
416151|NCT01014884|Other|Multidisciplinary team bimonthly visits either in person or via telephone.|
416152|NCT01014884|Other|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
416153|NCT01014871|Drug|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
416154|NCT01014871|Drug|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
416155|NCT01014858|Drug|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
416156|NCT01014845|Biological|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
416157|NCT01014845|Biological|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
416158|NCT01014832|Drug|Intensive insulin therapy|Intensive insulin therapy
416159|NCT01014806|Biological|Influenza VLP Vaccine|Single dose; 0.5mL
416160|NCT01014806|Biological|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
416161|NCT01014793|Drug|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
416162|NCT01014767|Drug|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3~All Arms, Cycles 4 & 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
416163|NCT01014767|Drug|Cisplatin|Cycles 1 & 2: 70 mg/m²/d IV over 6 hours on day 4
416164|NCT01014767|Drug|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m^2 IV over 1 hour on day 2 and 3~All Arms, Cycles 3 & 5: 1 g/m^2 IV over 1 hour on day 2 and 3"
416165|NCT01014767|Drug|Dactinomycin|Cycles 1 & 2: 45 µg/kg/day (max. 2 mg), IV on day 1
416166|NCT01014767|Drug|Doxorubicin|Cycles 1 & 2: 25 mg/m²/day IV over 12 hrs on days 1-3
416167|NCT01014767|Drug|Etoposide|"Standard Arm (1), Cycles 1 & 2:~100 mg/m2 IV over 1 hour on days 1-5~All Arms, Cycles 4-6:~100 mg/m2 IV over 1 hour on days 1-5"
416168|NCT01014767|Drug|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 & 2:~50 mg/m2/day x 5 days as 1 hour IV infusions"
416169|NCT01014767|Drug|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
416170|NCT01014767|Drug|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
416171|NCT01014767|Drug|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
416172|NCT01014767|Drug|Vincristine|"Standard Arm (1), Cycles 1 & 2 : 1.5 mg/m^2 IV over 15 minutes on day 5~Doxorubicin/cisplatin arm (2), Cycles 1 & 2: 1.5 mg/m^2/day (max. 2 mg), i.v. on days 8, 15~For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
416173|NCT01014741|Drug|Ibutilide|0.25mg IV ibutilide after PV isolation prior to CFE ablation
416174|NCT01014741|Drug|Placebo|Placebo after PV isolation prior to CFE ablation.
416175|NCT01014728|Drug|propofol|100-200mcg/kg/min by infusion
416176|NCT01014728|Drug|sevoflurane|1-3% of sevoflurane (expired)
416177|NCT01014715|Other|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
416178|NCT01014702|Device|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
416179|NCT01014702|Device|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
416180|NCT01014689|Drug|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
416181|NCT01014689|Drug|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
416182|NCT01014676|Dietary Supplement|Probiotic|
416183|NCT01014676|Other|Placebo|
416184|NCT01014663|Behavioral|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
416185|NCT01014663|Behavioral|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
416186|NCT01014650|Drug|GLYX-13|single IV or SC dose
416187|NCT01014650|Drug|IV normal saline|Single IV dose of normal saline
416188|NCT01014637|Drug|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
416189|NCT01014637|Drug|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
416190|NCT01014624|Drug|prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria."
416191|NCT01014624|Drug|clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.~After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria."
416192|NCT01014598|Drug|Cisplatin|Given intra-arterially via isolated lung suffusion
416193|NCT01014598|Other|Pharmacological Study|Correlative studies
416194|NCT01014585|Drug|Placebo|Placebo tablets administered orally twice daily
416195|NCT01014585|Drug|Milnacipran|Milnacipran tablets administered orally twice daily
416196|NCT01014572|Behavioral|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
416197|NCT01014572|Drug|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
416198|NCT01014572|Behavioral|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
416199|NCT01014559|Drug|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
416200|NCT01014559|Drug|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
416201|NCT01014546|Drug|Arsenic Trioxide|Given PO
416202|NCT01014546|Dietary Supplement|Ascorbic Acid|Given PO
416203|NCT01014546|Other|Laboratory Biomarker Analysis|Correlative studies
416204|NCT01014546|Other|Pharmacological Study|Correlative studies
416205|NCT01014533|Drug|Placebo dispensed to subject.|Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
416206|NCT01014533|Drug|Gabapentin dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
416207|NCT01014520|Drug|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
416208|NCT01014507|Drug|8 cycles BEACOPPesc plus oral contraceptive|
416209|NCT01014507|Drug|8 cycles BEACOPPesc plus Goserelin|
416210|NCT01014494|Device|Adaprev|Class III Medical Device
416211|NCT01014481|Drug|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
416212|NCT01014468|Drug|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
416956|NCT01009255|Drug|Placebo|Placebo to match GSK239512
416213|NCT01014468|Drug|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
416214|NCT01014455|Behavioral|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
416215|NCT01014455|Behavioral|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
416216|NCT01014442|Drug|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
416217|NCT01014429|Drug|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
416218|NCT01014416|Drug|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
416219|NCT01014403|Drug|enoxaparin|Enoxaparin 30 mg sq q 12 hours
416220|NCT01014403|Drug|placebo|vehicle
416221|NCT01014390|Device|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
416222|NCT01014377|Device|VascuActive|
416223|NCT01014364|Drug|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
416224|NCT01014364|Drug|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
416225|NCT01014351|Drug|Paclitaxel|Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
416226|NCT01014351|Drug|Carboplatin|Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle
416227|NCT01014351|Drug|Everolimus|Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
416228|NCT01014338|Drug|Fosinopril|10mg od
416229|NCT01014338|Other|lactose|placebo
416230|NCT01014325|Biological|Allergen extract|sublingual application
416231|NCT01014325|Biological|Placebo|sublingual application
416232|NCT01014312|Behavioral|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
416233|NCT01014312|Behavioral|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
416234|NCT01014299|Other|Recruitment maneuver|"Assigned interventions:~No intervention after tracheal intubation (control group)~Alveolar recruitment maneuver (RM group) immediately after intubation"
416235|NCT01014273|Procedure|Percutaneous Coronary Intervention|
416236|NCT01014260|Drug|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
416237|NCT01014260|Drug|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
416238|NCT01014247|Drug|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
416239|NCT01014247|Drug|Placebo|Single dose of matching tablet
416240|NCT01014234|Drug|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
416241|NCT01014234|Drug|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
416242|NCT01014221|Other|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
416243|NCT01014221|Drug|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
416244|NCT01014208|Drug|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
416245|NCT01014208|Drug|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
416246|NCT01014195|Other|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
416462|NCT01012778|Behavioral|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
416247|NCT01014169|Behavioral|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
416248|NCT01014156|Drug|epoprostenol|titration up to 4 ng/kg/min
416249|NCT01014143|Drug|Fluoride|Half mouth toothbrushing twice a day for four days.
416250|NCT01014143|Drug|Chlorhexidine digluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
416251|NCT01014143|Drug|Fluoride, triclosan|Half mouth Brushing twice daily
416252|NCT01014130|Radiation|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
416253|NCT01014130|Radiation|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
416254|NCT01014117|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
416255|NCT01014117|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
416256|NCT01014104|Drug|Methylprednisolone|Administration of Methylprednisolone
416257|NCT01014104|Drug|Control|Normal salin injection
416258|NCT01014091|Biological|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
416259|NCT01014078|Drug|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
416260|NCT01014078|Drug|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
416261|NCT01014052|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
416262|NCT01014039|Procedure|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
416263|NCT01014026|Other|Screening test|Two Vaginal self sampling devices and HPV test
416264|NCT01014013|Drug|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
416265|NCT01014013|Drug|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
416266|NCT01014000|Device|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
416267|NCT01014000|Device|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
416268|NCT01013987|Drug|maraviroc|maraviroc: one 150 mg pill twice daily
416269|NCT01013987|Drug|Raltegravir|raltegravir : one 400 mg pill twice daily
416270|NCT01013987|Drug|Darunavir/ritonavir|"darunavir : two 300 mg pills twice daily with meal~ritonavir: one 100 mg pill twice daily with meal"
416271|NCT01013974|Drug|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
416272|NCT01013974|Drug|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
416273|NCT01013974|Drug|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
416274|NCT01013974|Drug|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
416275|NCT01013961|Biological|alemtuzumab|Given IV
416276|NCT01013961|Biological|rituximab|Given IV
416277|NCT01013948|Other|Non-Interventional|Non-Investigational Product (Survey Study)
416278|NCT01013935|Other|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
416279|NCT01013935|Other|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
416280|NCT01013909|Drug|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
416281|NCT01013909|Drug|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
416282|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
416283|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
416284|NCT01013909|Drug|Lamisil Once|One application of Lamisil Once
416285|NCT01013896|Behavioral|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
416463|NCT01012765|Drug|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
416464|NCT01012765|Drug|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
416286|NCT01013896|Other|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).~The Cystic Fibrosis Education serves as the attention control group."
416287|NCT01013870|Drug|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
416288|NCT01013870|Drug|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
416289|NCT01013857|Behavioral|Health coaching|Calling patients every week to discuss medication adherence
416290|NCT01013857|Behavioral|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
416291|NCT01013844|Behavioral|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter > or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
416292|NCT01013831|Drug|Erlotinib Hydrochloride|Given PO
416293|NCT01013831|Other|Laboratory Biomarker Analysis|Correlative studies
416294|NCT01013831|Other|Pharmacological Study|Correlative studies
416295|NCT01013818|Drug|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
416296|NCT01013805|Radiation|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.~Weeks 8-10: as per Weeks 3-5"
416297|NCT01013805|Drug|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
416298|NCT01013805|Drug|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.~Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
416299|NCT01013805|Drug|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
416300|NCT01013805|Procedure|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
416301|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
416302|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
416303|NCT01013779|Drug|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).~After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
416304|NCT01013779|Drug|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
416305|NCT01013779|Radiation|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions~Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
416306|NCT01013766|Drug|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
416307|NCT01013766|Drug|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
416308|NCT01013753|Drug|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
416309|NCT01013753|Drug|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
416310|NCT01013753|Drug|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
416311|NCT01013753|Drug|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
416312|NCT01013753|Drug|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
416313|NCT01013753|Drug|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
416314|NCT01013740|Drug|Vinorelbine|Vinorelbine
416315|NCT01013740|Drug|Lapatinib|Lapatinib
416316|NCT01013740|Drug|Capecitabine|Capecitabine
416317|NCT01013727|Radiation|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
416318|NCT01013714|Procedure|Cardiac Sympathetic Denervation (CSD)|Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.
416319|NCT01013714|Drug|Routine Care|Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
416320|NCT01013701|Drug|fluticasone furoate|nasal steroid spray
416321|NCT01013701|Other|placebo|nasal steroid vehicle without drug
416322|NCT01013688|Procedure|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
416323|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
416324|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
416325|NCT01013662|Procedure|glycemic control|exogenous insulin
416326|NCT01013649|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
416327|NCT01013649|Drug|Capecitabine|Given PO
416328|NCT01013649|Drug|Chemotherapy|Given combination chemotherapy
416329|NCT01013649|Drug|Erlotinib Hydrochloride|Given PO
416330|NCT01013649|Drug|Fluorouracil|Given IV
416331|NCT01013649|Drug|Gemcitabine Hydrochloride|Given IV
416332|NCT01013649|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
416333|NCT01013649|Other|Laboratory Biomarker Analysis|Correlative studies
416334|NCT01013649|Other|Quality-of-Life Assessment|Ancillary studies
416335|NCT01013636|Procedure|Blood sampling|"Anaplasma diagnosis test : serology and PCR~If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
416336|NCT01013623|Procedure|Surgery|surgical resection to remove all known disease
416337|NCT01013623|Procedure|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
416338|NCT01013623|Other|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
416339|NCT01013610|Drug|LNK-754|Escalating dose
416340|NCT01013610|Drug|Placebo|Escalating dose
416341|NCT01013597|Drug|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
416342|NCT01013584|Dietary Supplement|cholecalciferol|daily dose
416343|NCT01013571|Drug|insulin glargine|pre-filled disposable pen, in package of 5.
416344|NCT01013571|Drug|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
416345|NCT01013558|Drug|Remifentanil|0.15 microgram/kg/min continuous infusion.
416346|NCT01013558|Drug|saline|continuous infusion
416347|NCT01013545|Behavioral|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
416348|NCT01013532|Drug|Cilostazol|Cilostazol 100mg bid
416349|NCT01013532|Drug|Probucol|Probucol 250mg bid
416350|NCT01013532|Drug|Aspirin|Aspirin 100mg qd
416351|NCT01013532|Drug|placebo of cilostazol|same shape and size of active cilostazol
416352|NCT01013532|Drug|placebo of aspirin|same size and shape of active aspirin 100mg
416353|NCT01013532|Device|ankle-brachial index (ABI)|measurement of ABI every years during follow up
416354|NCT01013532|Device|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
416355|NCT01013532|Device|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
416356|NCT01013532|Device|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
416357|NCT01013506|Drug|IGF-1R inhibitor OSI-906|Given orally
416358|NCT01013506|Drug|erlotinib hydrochloride|Given orally
416359|NCT01013506|Drug|goserelin|Given subcutaneously
416360|NCT01013506|Drug|letrozole|Given orally
416361|NCT01013480|Drug|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
416362|NCT01013467|Behavioral|"CoCo colour coded blood pressure control"|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
416363|NCT01013454|Drug|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload [drug amount loaded in each patch]) will be applied to the upper back over a single 24 hour period
416364|NCT01013441|Biological|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
416365|NCT01013428|Other|Ultrasound|Ultrasound will be used to evaluate tendons.
416366|NCT01013415|Drug|HAART|
416367|NCT01013415|Biological|T cells|
416465|NCT01012765|Drug|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
416466|NCT01012752|Biological|modified allergen extract|subcutaneous injections
416368|NCT01013402|Drug|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
416369|NCT01013402|Drug|Human Insulin|0.1U/kg IV pulse.
416370|NCT01013389|Procedure|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
416371|NCT01013389|Procedure|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
416372|NCT01013376|Drug|MC-1101|MC-1101 1.0%
416373|NCT01013376|Drug|Vehicle|Vehicle
416374|NCT01013363|Other|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
416375|NCT01013337|Procedure|acupuncture therapy|
416376|NCT01013337|Procedure|sham intervention|Placebo acupuncture
416377|NCT01013324|Drug|XL147 (SAR245408)|dosed as capsules taken orally daily
416378|NCT01013298|Device|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
416379|NCT01013285|Biological|bevacizumab|
416380|NCT01013285|Drug|temozolomide|
416381|NCT01013285|Radiation|external beam radiation therapy|
416382|NCT01013272|Drug|Entecavir|Entecavir 0.5mg orally daily
416383|NCT01013272|Drug|Lamivudine|Lamivudine 100mg orally, daily
416384|NCT01013259|Drug|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
416385|NCT01013259|Drug|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
416386|NCT01013246|Other|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
416387|NCT01013233|Behavioral|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
416388|NCT01013233|Other|control group|no intervention
416389|NCT01013220|Other|Depression Product Detailing|"two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits~technical assistance in purchasing high quality depression management products"
416390|NCT01013220|Other|Depression HEDIS detailing|"academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition~technical assistance"
416391|NCT01013207|Device|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
416392|NCT01013207|Device|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
416393|NCT01013207|Device|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
416394|NCT01013194|Other|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.~Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.~Cell infusion: between 5 and 10x10^8 cells. Number of sessions: up to 2."
416395|NCT01013168|Procedure|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
416396|NCT01013155|Drug|perindopril erbumine|8 mg tablet
416397|NCT01013142|Drug|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
416398|NCT01013142|Drug|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
416399|NCT01013142|Drug|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
416400|NCT01013129|Genetic|DNA analysis|saliva samples will be collected from men (probands) who join the study as well as from first degree relatives who join the study
416401|NCT01013129|Genetic|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
416402|NCT01013129|Other|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
416403|NCT01013129|Other|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
416404|NCT01013129|Other|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
416405|NCT01013129|Procedure|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
416406|NCT01013129|Procedure|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
416407|NCT01013116|Biological|modified allergen extract of house dust mites|subcutaneous injections
416408|NCT01013116|Biological|placebo|subcutaneous injections
416467|NCT01012752|Biological|Placebo|subcutaneous injections
416409|NCT01013103|Drug|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
416410|NCT01013103|Drug|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
416411|NCT01013090|Drug|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
416412|NCT01013090|Drug|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
416413|NCT01013077|Drug|Optive|Use a minimum of 2 drops per day for 1 month.
416414|NCT01013077|Drug|Soothe|Use a minimum of 2 drops per day for 1 month.
416415|NCT01013077|Drug|New Emulsion|Use a minimum of 2 drops per day for 1 month.
416416|NCT01013064|Drug|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
416417|NCT01013038|Procedure|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
416418|NCT01013038|Procedure|conventional PCI|balloon angioplasty and/or stent implantation
416419|NCT01013025|Procedure|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
416420|NCT01013012|Drug|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
416421|NCT01013012|Drug|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
416422|NCT01012999|Drug|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
416423|NCT01012986|Other|Assessment of reading skills|
416424|NCT01012973|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
416425|NCT01012973|Other|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
416426|NCT01012960|Drug|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
416427|NCT01012947|Behavioral|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
416428|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
416429|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
416430|NCT01012947|Behavioral|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
416431|NCT01012947|Behavioral|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
416432|NCT01012934|Drug|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
416433|NCT01012934|Drug|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
416434|NCT01012921|Device|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
416435|NCT01012921|Device|MembraGel|Device application at surgery
416436|NCT01012921|Other|Bio-Gide® membrane|Device application at surgery
416437|NCT01012908|Dietary Supplement|Norzyme - Bergamo|2 - 8 tablets per day.
416438|NCT01012908|Dietary Supplement|Creon|2 - 8 tablets pet day
416439|NCT01012895|Drug|BMS-790052|Tablets, Oral, 60 mg, once daily, 24 weeks
416440|NCT01012895|Drug|BMS-650032|Tablets, Oral, 600 mg, twice daily, 24 weeks
416441|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200mg, twice daily, 24 weeks
416442|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200 mg, once daily, 24 weeks
416443|NCT01012895|Drug|Pegylated-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly
416444|NCT01012895|Drug|Ribavirin|"Tablets, Oral~For subjects weighing < 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg~Twice daily (< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks"
416445|NCT01012882|Biological|sublingual immunotherapy with allergen extract|sublingual application
416446|NCT01012882|Biological|sublingual immunotherapy with placebo|sublingual application
416447|NCT01012869|Device|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
416448|NCT01012856|Behavioral|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
416449|NCT01012856|Behavioral|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
416450|NCT01012843|Drug|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
416451|NCT01012843|Drug|Placebo|oral Placebo tablets two times a day for 10 days
416452|NCT01012830|Drug|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
416453|NCT01012817|Other|Laboratory Biomarker Analysis|Correlative studies
416454|NCT01012817|Other|Pharmacogenomic Study|Correlative studies
416455|NCT01012817|Other|Pharmacological Study|Correlative studies
416456|NCT01012817|Drug|Topotecan Hydrochloride|Given IV
416457|NCT01012817|Drug|Veliparib|Given PO
416458|NCT01012804|Genetic|western blotting|
416459|NCT01012804|Other|immunohistochemistry staining method|
416460|NCT01012804|Other|laboratory biomarker analysis|
416461|NCT01012791|Other|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
416468|NCT01012739|Drug|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
416469|NCT01012739|Drug|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
416470|NCT01012739|Drug|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
416471|NCT01012739|Drug|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
416472|NCT01012726|Procedure|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
416473|NCT01012713|Drug|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
416474|NCT01012713|Drug|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
416475|NCT01012713|Procedure|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
416476|NCT01012700|Drug|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
416477|NCT01012687|Drug|perindopril erbumine|8 mg tablet
416478|NCT01012674|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
416479|NCT01012674|Other|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
416480|NCT01012661|Device|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
416481|NCT01012661|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
416482|NCT01012648|Drug|Fluid resuscitation|Volume resuscitation
416483|NCT01012648|Drug|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
416484|NCT01012635|Other|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
416485|NCT01012635|Other|Meditation|"Meditation: focus on a single word (one) for the entire session."
416486|NCT01012635|Other|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
416487|NCT01012635|Other|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
416488|NCT01012622|Drug|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
416489|NCT01012609|Other|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
416490|NCT01012596|Behavioral|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
416491|NCT01012570|Drug|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
416492|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
416493|NCT01012557|Biological|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
416494|NCT01012557|Biological|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
416495|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
416496|NCT01012544|Drug|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
416497|NCT01012531|Biological|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
416498|NCT01012531|Biological|Subcutaneous injection with placebo|cluster schedule
416499|NCT01012518|Device|Standard PCT|The standard technique, performed without video guidance
416500|NCT01012518|Device|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
416501|NCT01012505|Other|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.~stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
416502|NCT01012492|Drug|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
416503|NCT01012479|Drug|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
416541|NCT01012219|Drug|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
416542|NCT01012219|Drug|Comparator: placebo|placebo oral tablet once daily for 7 days
416543|NCT01012206|Behavioral|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
416544|NCT01012193|Drug|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
416650|NCT01011374|Drug|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
416504|NCT01012453|Behavioral|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
416505|NCT01012440|Device|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
416506|NCT01012440|Device|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
416507|NCT01012427|Procedure|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase > 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
416508|NCT01012414|Drug|paricalcitol|2 mcg oral paricalcitol daily
416509|NCT01012414|Drug|placebo|placebo
416510|NCT01012401|Other|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
416511|NCT01012388|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
416512|NCT01012375|Drug|AZD1446|10 mg capsule, oral dose
416513|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
416514|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
416515|NCT01012375|Drug|Placebo|Matching capsule, oral dose
416516|NCT01012362|Drug|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
416517|NCT01012362|Drug|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
416518|NCT01012349|Drug|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
416519|NCT01012349|Drug|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
416520|NCT01012336|Drug|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.~Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.~Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
416521|NCT01012323|Biological|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
416522|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
416523|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
416524|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
416525|NCT01012310|Drug|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
416526|NCT01012297|Biological|Bevacizumab|Given IV
416527|NCT01012297|Drug|Docetaxel|Given IV
416528|NCT01012297|Biological|Filgrastim|Given SC
416529|NCT01012297|Drug|Gemcitabine Hydrochloride|Given IV
416530|NCT01012297|Biological|Pegfilgrastim|Given SC
416531|NCT01012297|Other|Placebo|Given IV
416532|NCT01012284|Drug|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
416533|NCT01012271|Other|MRI|MR arthrography is used to evaluate wrist abnormalities
416534|NCT01012258|Biological|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially~Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by~Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
416535|NCT01012245|Other|no intervention|
416536|NCT01012232|Drug|20 mL ropivacaine 5 mg/mL|
416537|NCT01012232|Drug|10 mL ropivacaine 10 mg/mL|
416538|NCT01012219|Drug|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
416539|NCT01012219|Drug|Comparator: aspirin|81 mg oral tablet once daily for 7 days
416540|NCT01012219|Drug|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
416545|NCT01012167|Drug|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
416546|NCT01012167|Drug|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
416547|NCT01012167|Other|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
416548|NCT01012167|Other|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
416549|NCT01012154|Device|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
416550|NCT01012141|Dietary Supplement|phytochemical|
416551|NCT01012141|Drug|Docetaxel|
416552|NCT01012102|Biological|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
416553|NCT01012102|Biological|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
416554|NCT01012102|Biological|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
416555|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
416556|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
416557|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
416558|NCT01012089|Drug|Daptomycin|Daptomycin IV 5 mg/kg one time dose
416559|NCT01012076|Behavioral|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
416560|NCT01012063|Drug|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
416561|NCT01012063|Drug|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
416562|NCT01012050|Device|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
416563|NCT01012050|Other|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
416564|NCT01012037|Drug|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
416565|NCT01012037|Drug|placebo|patient to receive placebo tablet(s) matching linagliptin
416566|NCT01012037|Drug|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
416567|NCT01012011|Drug|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
416568|NCT01011998|Drug|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.~Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
416569|NCT01011972|Drug|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
416570|NCT01011959|Biological|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
416571|NCT01011946|Device|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
416572|NCT01011933|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
416573|NCT01011933|Drug|Selumetinib|Given PO
416574|NCT01011920|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
416575|NCT01011920|Drug|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
416576|NCT01011920|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
416577|NCT01011920|Drug|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4
416578|NCT01011920|Radiation|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
416579|NCT01011920|Drug|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
416580|NCT01011920|Other|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
416581|NCT01011907|Drug|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
416582|NCT01011907|Drug|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
416643|NCT01011439|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.~Number of cycles: until disease progression or unacceptable toxicity."
416644|NCT01011426|Drug|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
416583|NCT01011894|Drug|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
416584|NCT01011881|Other|pleural level of procalcitonin|no intervention
416585|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
416586|NCT01011868|Drug|BI 10773 low dose|BI 10773 low dose
416587|NCT01011868|Drug|BI 10773 high dose|BI 10773 high dose
416588|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
416589|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
416590|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
416591|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
416592|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
416593|NCT01011855|Device|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
416594|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
416595|NCT01011842|Procedure|Radiotherapy|Standard of care
416596|NCT01011842|Procedure|Align RT|Standard of care
416597|NCT01011829|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
416598|NCT01011829|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
416599|NCT01011816|Biological|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
416600|NCT01011816|Drug|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
416601|NCT01011803|Other|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
416602|NCT01011790|Behavioral|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
416603|NCT01011777|Drug|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
416604|NCT01011764|Behavioral|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
416605|NCT01011751|Drug|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
416606|NCT01011751|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
416607|NCT01011751|Drug|Venlafaxine|Venlafaxine capsule.
416608|NCT01011751|Drug|Leuprorelin|Leuprorelin injection.
416609|NCT01011751|Drug|Flutamide|Flutamide tablet
416610|NCT01011751|Drug|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
416611|NCT01011725|Drug|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
416612|NCT01011725|Drug|Placebo|Placebo oral tablet b.i.d for 12 weeks
416645|NCT01011426|Drug|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
416646|NCT01011413|Drug|Efavirenz|3 x EFV 200mg tablets once daily
416647|NCT01011413|Drug|Efavirenz|2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily
416613|NCT01011699|Drug|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;~Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:~0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
416614|NCT01011699|Drug|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.~Increase of sevelamer dose up to 12 tablets, as follows:~0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
416615|NCT01011699|Drug|cinacalcet|"After 6 months of treatment, patient screening on PTH level:~For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH < 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be < 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia < 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.~A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
416616|NCT01011686|Biological|ANT-SM|autologous adipose-derived stem cell
416617|NCT01011673|Drug|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
416618|NCT01011673|Drug|Ketorolac|ketorolac 30mg IVSS
416619|NCT01011660|Drug|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
416620|NCT01011634|Drug|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
416621|NCT01011621|Drug|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
416622|NCT01011621|Drug|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
416623|NCT01011608|Other|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
416624|NCT01011608|Other|standard hospital food|standard hospital diet ad. lib.
416625|NCT01011595|Procedure|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
416626|NCT01011595|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
416627|NCT01011595|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
416628|NCT01011556|Drug|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
416629|NCT01011556|Drug|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
416630|NCT01011543|Procedure|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
416631|NCT01011530|Drug|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
416632|NCT01011517|Dietary Supplement|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
416633|NCT01011491|Other|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 & 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
416634|NCT01011491|Other|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 & 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
416635|NCT01011478|Drug|rosuvastatin|
416636|NCT01011478|Other|placebo|
416637|NCT01011465|Drug|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
416638|NCT01011465|Drug|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
416639|NCT01011465|Behavioral|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
416640|NCT01011465|Behavioral|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
416641|NCT01011452|Drug|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
416642|NCT01011452|Drug|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
416648|NCT01011387|Procedure|NPWT System|Dressing change 3 times per week
416651|NCT01011348|Dietary Supplement|Coenzyme Q10|100mg/day for three months
416652|NCT01011348|Dietary Supplement|Coenzyme Q10|300mg/day for three months
416653|NCT01011348|Dietary Supplement|Placebo|Three month period
416654|NCT01011335|Biological|Monovalent rAT|10, 25, 50 or 100 μg
416655|NCT01011335|Biological|Monovalent rLukS-PV|10, 25, 50 or 100 μg
416656|NCT01011335|Biological|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
416657|NCT01011335|Biological|Placebo with adjuvant|Placebo with adjuvant
416658|NCT01011335|Biological|Placebo|Placebo saline
416659|NCT01011322|Drug|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
416660|NCT01011322|Drug|placebo|placebo
416661|NCT01011309|Biological|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
416662|NCT01011309|Drug|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
416663|NCT01011296|Drug|PF-04427429|Single 0.2mg dose of intravenous infusion
416664|NCT01011296|Drug|PF-04427429|Single 1mg dose of intravenous infusion
416665|NCT01011296|Drug|PF-04427429|Single 3 mg dose of intravenous infusion
416666|NCT01011283|Drug|decitabine|decitabine 20 mg/m^2 /day intravenous (IV) infusion for 5 days every 28 days
416667|NCT01011283|Drug|azacitidine|azacitidine 75 mg/m^2 /day subcutaneous (SC) injection for 7 days every 28 days
416668|NCT01011257|Drug|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
416669|NCT01011257|Drug|Clopidogrel|clopidogrel 75 mg bid
416670|NCT01011244|Biological|ADIPOPLUS|"autologous cultured adipose-derived stem cells~1x10e7 cells/1cm2 depending on surface area of fistula"
416671|NCT01011231|Procedure|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
416672|NCT01011218|Behavioral|BBT-I|Brief Behavioral Intervention for Insomnia (BBT-I): 2 sessions in person and additional brief sessions over the phone
416673|NCT01011218|Behavioral|Control|Control behavioral intervention is a sleep hygiene handout completed by participant.
416674|NCT01011218|Drug|Armodafinil|150 mg by mouth. Armodafinil is the enantiopure compound of the eugeroic modafinil (Provigil), containing only the (R)-(−)-enantiomer of the racemic modafinil.
416675|NCT01011205|Drug|Advagraf|Capsule
416676|NCT01011205|Drug|Mycophenolate Mofetil|Solution for infusion
416677|NCT01011205|Drug|Basiliximab|IV infusion
416678|NCT01011205|Drug|Corticosteroids|IV bolus
416679|NCT01011179|Behavioral|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
416680|NCT01011179|Behavioral|Self-Management|"Adolescents' own best efforts at managing their JIA"
416681|NCT01011166|Drug|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
416682|NCT01011166|Drug|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
416683|NCT01011166|Biological|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
416684|NCT01011166|Drug|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
416685|NCT01011140|Behavioral|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
416686|NCT01011127|Drug|pravastatin, rosuvastatin|
416687|NCT01011114|Drug|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
416688|NCT01011114|Drug|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
416689|NCT01011088|Other|Not available|Not any artificial interventions were given
416690|NCT01011075|Drug|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
416691|NCT01011075|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
416692|NCT01011062|Procedure|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
416693|NCT01011062|Drug|Losartan|Acute administration of losartan 200mg total prior to clamp
416694|NCT01011062|Drug|Saline|Infusion of Saline as a volume control intervention
416695|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
416696|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
416697|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
416698|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
416699|NCT01011036|Drug|clobazam|test substance
416700|NCT01011036|Drug|clonazepam|positive control
416701|NCT01011036|Drug|tolterodine|active placebo
416702|NCT01011023|Other|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
416703|NCT01011010|Drug|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
416744|NCT01010737|Biological|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
416704|NCT01011010|Drug|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
416705|NCT01011010|Drug|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
416706|NCT01011010|Other|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
416707|NCT01011010|Other|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
416708|NCT01010997|Device|Foresee Home|using the Foresee home device
416709|NCT01010984|Device|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicin will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
416710|NCT01010971|Drug|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
416711|NCT01010971|Drug|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
416712|NCT01010971|Drug|Placebo|Placebo HFA Nasal Aerosol once daily
416713|NCT01010958|Drug|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
416714|NCT01010945|Drug|erlotinib|administered orally
416715|NCT01010945|Drug|gemcitabine|administered intravenously
416716|NCT01010945|Drug|nab-paclitaxel|administered intravenously
416717|NCT01010932|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
416718|NCT01010932|Other|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
416719|NCT01010919|Dietary Supplement|Chicory root extract|
416720|NCT01010906|Drug|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
416721|NCT01010906|Drug|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
416722|NCT01010893|Biological|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
416723|NCT01010893|Biological|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
416724|NCT01010880|Drug|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
416725|NCT01010867|Drug|Lactobacillus plantarum strains 299 and 299v|"Patients will receive a daily dose of Lactobacillus plantarum: 1 x10^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.~Colony forming units (CFU)"
416726|NCT01010854|Drug|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
416727|NCT01010841|Dietary Supplement|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
416728|NCT01010841|Other|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
416729|NCT01010828|Procedure|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
416730|NCT01010828|Procedure|Incision technique|Mini Mid-Vastus Approach
416731|NCT01010815|Procedure|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
416732|NCT01010815|Other|stool collection|Stool will be collected from participants at study entry
416733|NCT01010815|Procedure|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
416734|NCT01010815|Other|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
416735|NCT01010802|Drug|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
416736|NCT01010789|Drug|Armodafinil|flexible dose 150-250mg/day
416737|NCT01010789|Drug|Armodafinil|150-250mg/day; flexible dose
416738|NCT01010789|Drug|Matching placebo|Placebo comparator
416739|NCT01010776|Drug|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
416740|NCT01010763|Device|Total Hip Arthroplasty|Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
416741|NCT01010750|Drug|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
416742|NCT01010750|Drug|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
416743|NCT01010750|Drug|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
416827|NCT01010217|Drug|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
416745|NCT01010737|Biological|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
416746|NCT01010737|Biological|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
416747|NCT01010737|Biological|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
416748|NCT01010737|Biological|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
416749|NCT01010737|Biological|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
416750|NCT01010737|Biological|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
416751|NCT01010724|Drug|bIAP|
416752|NCT01010724|Drug|Placebo|
416753|NCT01010711|Dietary Supplement|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
416754|NCT01010698|Drug|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
416755|NCT01010685|Procedure|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
416756|NCT01010672|Drug|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
416757|NCT01010659|Device|Lacrimal Tube|Lacrimal Tube
416758|NCT01010646|Drug|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
416759|NCT01010646|Drug|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
416760|NCT01010646|Drug|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
416761|NCT01010633|Drug|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
416762|NCT01010633|Drug|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
416763|NCT01010620|Behavioral|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
416764|NCT01010607|Device|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
416765|NCT01010607|Device|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
416766|NCT01010607|Device|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
416767|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
416768|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment.
416769|NCT01010581|Drug|SC12267 (4SC-101)|oral administration
416770|NCT01010581|Drug|Placebo|oral administration
416771|NCT01010581|Drug|Methotrexate|oral administration
416772|NCT01010581|Drug|Folic Acid|oral administration
416773|NCT01010568|Drug|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
416774|NCT01010555|Device|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
416775|NCT01010555|Device|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
416776|NCT01010555|Device|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
416777|NCT01010555|Device|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
416778|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
416779|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
416780|NCT01010529|Other|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
416781|NCT01010516|Drug|High-dose rosuvastatin|40 of rosuvastatin daily
416782|NCT01010516|Drug|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
416783|NCT01010516|Drug|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
416784|NCT01010503|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
416785|NCT01010490|Procedure|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
416786|NCT01010490|Procedure|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
416787|NCT01010490|Procedure|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
416788|NCT01010477|Drug|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
416957|NCT01009242|Biological|CDP6038|"Single dose:~1 mg/kg CDP6038 IV"
416789|NCT01010477|Behavioral|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
416790|NCT01010464|Procedure|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
416791|NCT01010451|Procedure|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
416792|NCT01010451|Procedure|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
416793|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
416794|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
416795|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
416796|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
416797|NCT01010425|Drug|Placebo|Placebo, s.c., single-dose
416798|NCT01010425|Drug|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
416799|NCT01010412|Device|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
416800|NCT01010412|Device|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
416801|NCT01010399|Dietary Supplement|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
416802|NCT01010399|Drug|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
416803|NCT01010386|Procedure|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
416804|NCT01010386|Procedure|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
416805|NCT01010373|Drug|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
416806|NCT01010347|Procedure|Volar Splint|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
416807|NCT01010347|Procedure|Cast|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
416808|NCT01010334|Other|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
416809|NCT01010321|Device|confocal microscopy|non-invasive imaging
416810|NCT01010308|Drug|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
416811|NCT01010295|Drug|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
416812|NCT01010282|Drug|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
416813|NCT01010282|Drug|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
416814|NCT01010282|Drug|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
416815|NCT01010269|Device|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
416816|NCT01010269|Device|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
416817|NCT01010243|Drug|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.~Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"
416818|NCT01010230|Device|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
416819|NCT01010230|Device|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
416820|NCT01010217|Drug|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
416821|NCT01010217|Drug|Fludarabine|40 mg/m^2 IV over 1 hour on Days -6, -5, -4, and -3.
416822|NCT01010217|Drug|Melphalan|140 mg/m^2 IV (or 100 mg/m^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
416823|NCT01010217|Drug|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
416824|NCT01010217|Drug|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
416825|NCT01010217|Procedure|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
416826|NCT01010217|Drug|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
416828|NCT01010217|Drug|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
416829|NCT01010217|Drug|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery > 1000/mcl.
416830|NCT01010204|Drug|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
416831|NCT01010204|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
416832|NCT01010191|Other|Sugar pill|
416833|NCT01010178|Drug|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
416834|NCT01010152|Drug|Codeine Sulfate|30 mg Tablet
416835|NCT01010139|Drug|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
416836|NCT01010126|Biological|Bevacizumab|Given IV
416837|NCT01010126|Drug|Temsirolimus|Given IV
416838|NCT01010113|Other|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
416839|NCT01010113|Other|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
416840|NCT01010100|Drug|Acarbose (Glucobay, BAYG5421)|50 mg TID
416841|NCT01010100|Drug|Placebo|50 mg TID
416842|NCT01010087|Drug|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
416843|NCT01010061|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
416844|NCT01010061|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
416845|NCT01010061|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
416846|NCT01010048|Drug|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
416847|NCT01010035|Other|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
416848|NCT01010022|Drug|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
416849|NCT01010022|Drug|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
416850|NCT01010009|Dietary Supplement|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
416851|NCT01010009|Other|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
416852|NCT01009996|Procedure|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
416853|NCT01009983|Biological|panitumumab|Given IV
416854|NCT01009983|Drug|paclitaxel|Given IV
416855|NCT01009983|Drug|carboplatin|Given IV
416856|NCT01009983|Procedure|laboratory biomarker analysis|Correlative study
416857|NCT01009983|Procedure|immunohistochemistry staining method|Correlative study
416858|NCT01009970|Drug|Rituximab|375 mg/m2 day 1
416859|NCT01009970|Drug|Cyclophosphamide|750 mg/m2 day 2
416860|NCT01009970|Drug|Vincristine|1,4 mg/m2 (max 2 mg) day 2
416861|NCT01009970|Drug|Prednisone|40 mg/m2 day 2-6
416862|NCT01009970|Drug|Doxorubicin|50 mg/m2 day 2
416863|NCT01009957|Drug|Everolimus|0.75 mg x 2 / day
416864|NCT01009944|Drug|Lisinopril, Atenolol|once a day for 14 weeks
416865|NCT01009931|Drug|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
416866|NCT01009931|Drug|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
416867|NCT01009931|Drug|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.~Up to 6 cycles."
416868|NCT01009918|Drug|Coreg CR®|Given orally
416869|NCT01009918|Drug|lisinopril|Given orally
416870|NCT01009918|Other|placebo|Given orally
416871|NCT01009905|Drug|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
416872|NCT01009892|Drug|Codeine Sulfate|Tablet
416873|NCT01009879|Drug|Etanercept|Etanercept 50 mg SQ qweek
416918|NCT01009554|Drug|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
416919|NCT01009541|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
416920|NCT01009541|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
416921|NCT01009541|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
416874|NCT01009866|Biological|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
416875|NCT01009853|Drug|Codeine Sulfate|15 mg tablet
416876|NCT01009840|Drug|IV busulfan|PK-directed dosing of IV busulfan for 4 days
416877|NCT01009840|Drug|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m^2.
416878|NCT01009840|Procedure|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
416879|NCT01009827|Other|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
416880|NCT01009814|Drug|BMS-663068 with or without ritonavir|"8-day treatment with BMS-663068 with or without ritonavir~Group 1: BMS-663068 600 mg Q12H + ritonavir 100 mg Q12H~Group 2: BMS-663068 1200 mg QHS + ritonavir 100 mg QHS~Group 3: BMS-663068 1200 mg Q12H + ritonavir100 mg Q12H~Group 4: BMS-663068 1200 mg Q12H + ritonavir 100 mg QAM~Group 5: BMS-663068 1200 mg Q12H"
416881|NCT01009801|Drug|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
416882|NCT01009801|Drug|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
416883|NCT01009801|Other|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
416884|NCT01009788|Drug|ABT-888|Capsules taken orally twice a day on days 1-7 of each 28 day cycle
416885|NCT01009788|Drug|temozolomide|capsules taken orally once a day on days 1 through 5 of a 28 day cycle
416886|NCT01009775|Drug|YM155|intravenous infusion
416887|NCT01009775|Drug|Docetaxel|intravenous infusion
416888|NCT01009762|Biological|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
416889|NCT01009749|Behavioral|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
416890|NCT01009749|Behavioral|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
416891|NCT01009736|Dietary Supplement|tomato-soy juice|
416892|NCT01009736|Other|laboratory biomarker analysis|
416893|NCT01009736|Other|pharmacological study|
416894|NCT01009736|Procedure|therapeutic conventional surgery|
416895|NCT01009697|Drug|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
416896|NCT01009671|Drug|ART 44|
416897|NCT01009671|Drug|ART 50|
416898|NCT01009658|Dietary Supplement|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
416899|NCT01009658|Dietary Supplement|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
416900|NCT01009645|Behavioral|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
416901|NCT01009645|Behavioral|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
416902|NCT01009645|Behavioral|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
416903|NCT01009645|Behavioral|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
416904|NCT01009632|Behavioral|Resonant voice|4-hr of resonant voice exercise
416905|NCT01009632|Behavioral|Voice rest|4-hr of complete refrain from any voice use
416906|NCT01009632|Behavioral|Spontaneous speech|
416907|NCT01009619|Drug|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
416908|NCT01009619|Drug|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
416909|NCT01009606|Other|Usual strategy|Usual strategy
416910|NCT01009606|Other|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
416911|NCT01009593|Drug|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
416912|NCT01009593|Drug|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
416913|NCT01009580|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
416914|NCT01009580|Drug|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
416915|NCT01009567|Drug|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
416916|NCT01009567|Drug|Control|Receive human albumin 20% infusion
416917|NCT01009554|Device|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
416922|NCT01009541|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
416923|NCT01009528|Device|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
416924|NCT01009515|Drug|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
416925|NCT01009502|Drug|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
416926|NCT01009476|Drug|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
416927|NCT01009476|Drug|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
416928|NCT01009463|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
416929|NCT01009463|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
416930|NCT01009450|Procedure|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
416931|NCT01009450|Procedure|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
416932|NCT01009437|Drug|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.~Phase II: Dose will be maximum tolerated dose from Phase I."
416933|NCT01009437|Procedure|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
416934|NCT01009424|Drug|R7103|escalating inhaled dose
416935|NCT01009398|Other|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
416936|NCT01009385|Procedure|cervical epidural steroid injection|"After aseptic preparation and skin infiltration with 1% lidocaine~20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level~identification of the epidural space confirmed by injection of contrast medium under fluoroscope~injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).~Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
416937|NCT01009385|Procedure|epidural pressure measurement|"The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.~Identification of the epidural space and measurement of EP was performed with a closed measurement system."
416938|NCT01009372|Behavioral|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
416939|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
416940|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
416941|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
416942|NCT01009346|Drug|RAD001|"Dose Level -1 2.5mg/day~Dose Level 1 5mg/day*~Dose Level 2 10mg/day~MTD RAD001"
416943|NCT01009346|Drug|Cetuximab|250mg/m2/week
416944|NCT01009346|Drug|Cisplatin|40mg/m2 Day 1, 8 every 28 days
416945|NCT01009346|Drug|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
416946|NCT01009333|Device|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
416947|NCT01009333|Device|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
416948|NCT01009333|Device|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
416949|NCT01009307|Genetic|polymorphism analysis|
416950|NCT01009307|Other|laboratory biomarker analysis|
416951|NCT01009307|Other|medical chart review|
416952|NCT01009294|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner) for up to 48 weeks.
416953|NCT01009281|Drug|AIN457|
416954|NCT01009268|Procedure|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
416955|NCT01009255|Drug|GSK239512|Histamine H3 Antagonist
416958|NCT01009242|Biological|CDP6038|"Single dose:~0.1mg/kg CDP6038 IV"
416959|NCT01009242|Biological|CDP6038|"Single dose:~1.0mg/kg CDP6038 SC"
416960|NCT01009242|Other|Placebo IV|"Single dose:~Placebo IV"
416961|NCT01009242|Other|Placebo SC|"Single dose:~Placebo SC"
416962|NCT01009242|Drug|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
416963|NCT01009229|Dietary Supplement|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
416964|NCT01009216|Drug|ABT-384|Doses will be administered daily for 5 days.
416965|NCT01009203|Drug|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
416966|NCT01009203|Drug|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
416967|NCT01009190|Drug|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
416968|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
416969|NCT01009190|Drug|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
416970|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
416971|NCT01009177|Drug|Bosentan|Bosentan 500 mg bid
416972|NCT01009177|Drug|Placebo|Placebo
416973|NCT01009151|Behavioral|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
416974|NCT01009151|Behavioral|Heart Care Self Tracker|Web-based Home Tele-monitoring System
416975|NCT01009138|Behavioral|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:~Problem Analysis and Definition~Problem Solving Intervention~Cognitive Restructuring~Activation of personal and social Resources~Goal Definition and Agreement"
416976|NCT01009138|Behavioral|Standard Diabetes Education|"Standard Diabetes Education Lesson including~Health Care and specific Topics (e. g. Blood Pressure)~Social Aspects of Living with Diabetes~Diabetes Complications~Sports, Activities and Exercise~Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes~Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
416977|NCT01009125|Other|$2 cash|$2 cash incentive will be included in the mailed survey
416978|NCT01009125|Other|$5 cash|$5 cash incentive will be included in the mailed survey
416979|NCT01009112|Behavioral|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
416980|NCT01009112|Behavioral|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
416981|NCT01009099|Other|breathing retraining|breathing retraining using a metronome
416982|NCT01009099|Other|exercise training|treadmill exercise training
416983|NCT01009086|Drug|Placebo|SC injections
416984|NCT01009086|Drug|Ustekinumab 45 mg|SC injections
416985|NCT01009086|Drug|Ustekinumab 90 mg|SC injections
416986|NCT01009073|Drug|ABT-263|"ABT-263 is taken orally.~Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
416987|NCT01009073|Drug|erlotinib|150 mg of erlotinib is taken orally once daily.
416988|NCT01009073|Drug|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
416989|NCT01009073|Drug|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
416990|NCT01009060|Drug|GSK239512|Histamine H3 Antagonist
416991|NCT01009060|Drug|Placebo|Placebo to match GSK239512
416992|NCT01009047|Drug|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
416993|NCT01009047|Drug|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
416994|NCT01009034|Other|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
416995|NCT01009021|Drug|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
416996|NCT01009008|Device|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
416997|NCT01008995|Drug|placebo|Subcutaneous injection at Week 0 and 4
416998|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
416999|NCT01008995|Drug|placebo|Subcutaneous injection at Week 12
417000|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
417001|NCT01008982|Drug|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
417002|NCT01008969|Other|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
417003|NCT01008956|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
417004|NCT01008943|Biological|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
417005|NCT01008930|Procedure|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
417006|NCT01008917|Drug|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
417007|NCT01008904|Drug|magnesium oxide|Given PO
417008|NCT01008904|Other|questionnaire administration|Ancillary studies
417009|NCT01008904|Procedure|quality-of-life assessment|Ancillary studies
417010|NCT01008878|Behavioral|interdisciplinary intervention|
417011|NCT01008865|Procedure|Studer Pouch orthotopic urinary diversion|
417012|NCT01008865|Procedure|T-Pouch orthotopic urinary diversion|
417013|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
417014|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
417015|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
417016|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
417017|NCT01008852|Drug|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
417018|NCT01008826|Dietary Supplement|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
417019|NCT01008813|Biological|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (3,8 microgram) adjuvanted with AS 03A
417020|NCT01008813|Biological|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (15 microgram)
417021|NCT01008800|Behavioral|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey & Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
417022|NCT01008800|Behavioral|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy & Grusec, 2001).
417023|NCT01008787|Behavioral|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
417024|NCT01008787|Behavioral|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
417025|NCT01008787|Behavioral|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
417026|NCT01008787|Behavioral|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
417027|NCT01008774|Device|Paxman Cooling Machine|Scalp cooling procedures
417028|NCT01008774|Device|Cold Caps|Scalp cooling procedures
417029|NCT01008761|Drug|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
417030|NCT01008761|Drug|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
417031|NCT01008748|Drug|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke >10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
417032|NCT01008748|Behavioral|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
417033|NCT01008748|Behavioral|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
417034|NCT01008748|Behavioral|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
417035|NCT01008709|Device|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
417036|NCT01008709|Device|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
417037|NCT01008696|Drug|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
417038|NCT01008696|Drug|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
417039|NCT01008657|Procedure|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
417040|NCT01008644|Other|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
417041|NCT01008644|Other|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
417042|NCT01008631|Drug|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
417043|NCT01008618|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
417044|NCT01008618|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
417045|NCT01008605|Other|delivery system|syringe
417046|NCT01008592|Drug|levocetirizine or placebo|oral administration, single tablet, 5 mg.
417047|NCT01008566|Biological|Cixutumumab|Given IV
417048|NCT01008566|Other|Laboratory Biomarker Analysis|Correlative studies
417049|NCT01008566|Drug|Sorafenib Tosylate|Given orally
417050|NCT01008553|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
417051|NCT01008553|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
417052|NCT01008540|Biological|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
417053|NCT01008527|Drug|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
417054|NCT01008527|Biological|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
417055|NCT01008527|Biological|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
417056|NCT01008514|Procedure|adjuvant therapy|
417057|NCT01008514|Radiation|accelerated partial breast irradiation|
417058|NCT01008514|Radiation|intracavitary balloon brachytherapy|
417059|NCT01008488|Drug|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
417060|NCT01008475|Drug|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
417061|NCT01008475|Drug|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
417062|NCT01008475|Drug|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
417063|NCT01008475|Drug|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
417064|NCT01008475|Drug|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until DLT.~Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
417065|NCT01008475|Drug|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .~Randomized part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
417066|NCT01008462|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
417067|NCT01008462|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
417068|NCT01008462|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
417069|NCT01008462|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
417070|NCT01008462|Drug|Carmustine|Given IV
417071|NCT01008462|Drug|Cyclophosphamide|Given IV
417072|NCT01008462|Drug|Cytarabine|Given IV
417073|NCT01008462|Drug|Etoposide|Given IV
417074|NCT01008462|Drug|Fludarabine Phosphate|Given IV
417075|NCT01008462|Other|Laboratory Biomarker Analysis|Correlative study
417076|NCT01008462|Drug|Melphalan|Given IV
417077|NCT01008462|Drug|Mycophenolate Mofetil|Given PO
417078|NCT01008462|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
417079|NCT01008462|Drug|Tacrolimus|Given IV or PO
417080|NCT01008462|Radiation|Total-Body Irradiation|Undergo TBI
417081|NCT01008449|Device|Surgical staples|Surgical staples will be used once for wound closure.
417082|NCT01008449|Device|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
417083|NCT01008436|Drug|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
417084|NCT01008436|Drug|Control|Traditional surgical Hemostasis
417085|NCT01008423|Drug|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
417086|NCT01008423|Drug|Placebo|Placebo matching to budesonide will be administered as per the dose and schedule specified in the respective arm.
417087|NCT01008410|Drug|Budesonide|Budesonide will be administered as per the dose and schedule specified in the respective arm.
417088|NCT01008410|Drug|Placebo|Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
417089|NCT01008397|Drug|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
417090|NCT01008384|Dietary Supplement|Vitamin D3|50,000 units taken orally once a week for 8 weeks
417091|NCT01008345|Drug|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
417092|NCT01008332|Biological|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
417093|NCT01008332|Biological|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
417094|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
417095|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
417096|NCT01008293|Drug|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
417097|NCT01008293|Drug|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
417098|NCT01008280|Drug|baclofen|baclofen 10 mg tid
417099|NCT01008280|Drug|placebo|placebo pill tid
417100|NCT01008254|Behavioral|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
417101|NCT01008254|Behavioral|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
417102|NCT01008254|Other|No musical prompt|No intervention.
417103|NCT01008228|Procedure|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
417104|NCT01008228|Procedure|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
417105|NCT01008215|Other|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
417106|NCT01008176|Behavioral|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
417107|NCT01008150|Drug|Paclitaxel|
417108|NCT01008150|Drug|Trastuzumab|
417109|NCT01008150|Drug|Neratinib|
417110|NCT01008150|Drug|Doxorubicin|
417111|NCT01008150|Drug|Cyclophosphamide|
417112|NCT01008137|Biological|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
417113|NCT01008137|Biological|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
417114|NCT01008124|Other|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
417115|NCT01008124|Other|Placebo maneuver|3 cycles placebo maneuver initial session.
417116|NCT01008111|Drug|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
417117|NCT01008111|Drug|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
417118|NCT01008098|Drug|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
417119|NCT01008085|Device|Stentys coronary stent|Self-expanding Nitinol stent
417120|NCT01008085|Device|Balloon-expandable stent|VISION/Driver
417121|NCT01008059|Drug|Alfentanil|No drug treatment before alfentanil
417122|NCT01008046|Drug|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
417123|NCT01008046|Drug|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
417124|NCT01008033|Drug|IDP-108|Topical application once a day for 48 weeks
417125|NCT01008033|Drug|Vehicle|Topical application once a day for 48 weeks
417126|NCT01008020|Dietary Supplement|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
417127|NCT01008007|Dietary Supplement|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
417128|NCT01008007|Drug|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
417129|NCT01007994|Drug|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril < 40 kg starting dose 2.5 mg titrate to 5 mg > 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine < 40 kg 2.5 mg > 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol <40 kg starting dose 10 mg titrate to 20 mg >40 kg starting dose 20 mg titrate to 40 mg"
417130|NCT01007968|Drug|LBH589|
417131|NCT01007929|Drug|14C-AZD1236|Oral solution 1mg/mL
417132|NCT01007916|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
417133|NCT01007916|Device|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
417134|NCT01007903|Behavioral|Tai Chi exercise|12-week tai chi exercise class
417135|NCT01007890|Other|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
417136|NCT01008358|Biological|CP 675,206|
417137|NCT01008189|Behavioral|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
417138|NCT01008189|Behavioral|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
417139|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
417140|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
417141|NCT01008163|Drug|YY-351|comparison of different dosages of drug
417142|NCT01008163|Drug|Placebo|comparison of different dosages of drug
417143|NCT01007942|Drug|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
417144|NCT01007942|Drug|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
417145|NCT01007942|Drug|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
417146|NCT01007942|Drug|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
417147|NCT01007877|Other|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
417148|NCT01007864|Drug|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
417149|NCT01007864|Drug|pramipexole or ropinirole|continuation of pre-study treatment regimen
417150|NCT01007851|Drug|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
417151|NCT01007851|Drug|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
417152|NCT01007838|Other|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
417153|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
417154|NCT01007838|Other|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
417155|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
417156|NCT01007812|Device|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
417157|NCT01007812|Device|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
417158|NCT01007799|Dietary Supplement|vitamin D placebo|12 weeks of placebo
417159|NCT01007799|Dietary Supplement|Vitamin D|12 weeks supplementation based on serum vitamin D levels
417248|NCT01007279|Drug|ROSUVASTATIN|40 mg before procedure
417249|NCT01007266|Behavioral|Assignment of a Lay Patient Partner|
417650|NCT01004783|Genetic|reverse transcriptase-polymerase chain reaction|
417160|NCT01007773|Drug|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
417161|NCT01007773|Drug|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP < 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
417162|NCT01007773|Drug|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
417163|NCT01007773|Drug|Propofol|Propofol will be titrated to an ICP < 20 mm Hg until achievement of sustained ICP control.
417164|NCT01007760|Other|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
417165|NCT01007747|Other|Geranium oil|Daily topical application over neuropathic pain
417166|NCT01007721|Drug|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
417167|NCT01007721|Drug|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
417168|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
417169|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
417170|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
417171|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
417172|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
417173|NCT01007721|Drug|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
417174|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
417175|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
417176|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
417177|NCT01007721|Drug|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
417178|NCT01007721|Drug|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
417179|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
417180|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
417181|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
417182|NCT01007721|Drug|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
417183|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
417184|NCT01007721|Drug|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
417185|NCT01007721|Drug|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
417186|NCT01007708|Drug|IDP-108|Topical application once a day for 48 weeks
417187|NCT01007708|Drug|Vehicle|Topical application once a day for 48 weeks
417188|NCT01007695|Drug|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
417189|NCT01007682|Other|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
417190|NCT01007669|Behavioral|Physical activity and Health check|Strength training, aerobic capacity training.
417191|NCT01007669|Behavioral|Health check only|Health check
417192|NCT01007656|Dietary Supplement|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
417193|NCT01007643|Other|Wii Fit (TM) Interactive Video Game|Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
417194|NCT01007643|Other|Traditional Home Exercise Program|Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
417195|NCT01007630|Drug|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
417196|NCT01007630|Drug|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
417197|NCT01007617|Device|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.~Main evaluation criteria: mucositis maximal intensity (WHO scale).~Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
417198|NCT01007604|Device|Peristaltic pulse PCD|Daily use for two hours
417199|NCT01007604|Other|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
417200|NCT01007591|Drug|LEO 80190|Applied once daily
417201|NCT01007591|Drug|Hydrocortisone|Applied once daily
417202|NCT01007578|Device|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
417203|NCT01007565|Procedure|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
417204|NCT01007552|Drug|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
417205|NCT01007539|Dietary Supplement|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
417206|NCT01007539|Dietary Supplement|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
417207|NCT01007526|Other|CCRT followed by VIDL chemotherapy|CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
417208|NCT01007513|Procedure|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
417209|NCT01007513|Procedure|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
417210|NCT01007500|Drug|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
417211|NCT01007500|Drug|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
417212|NCT01007474|Device|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
417213|NCT01007474|Device|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
417214|NCT01007474|Device|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
417215|NCT01007474|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
417216|NCT01007474|Device|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
417217|NCT01007461|Drug|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started > 5 minutes but < 20 minutes (approximately) prior to coronary artery reperfusion.
417218|NCT01007461|Drug|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
417219|NCT01007448|Drug|Bexarotene|Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food.
417220|NCT01007435|Drug|Tocilizumab|Tocilizumab was supplied in vials.
417221|NCT01007435|Drug|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
417222|NCT01007435|Drug|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
417223|NCT01007435|Drug|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
417224|NCT01007422|Behavioral|telephone-based intervention|
417225|NCT01007422|Other|communication intervention|
417226|NCT01007422|Other|intervention by caregiver|
417227|NCT01007422|Other|medical chart review|
417228|NCT01007422|Other|survey administration|
417229|NCT01007422|Procedure|end-of-life treatment/management|
417230|NCT01007422|Procedure|pain therapy|
417231|NCT01007422|Procedure|psychosocial assessment and care|
417232|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
417233|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
417234|NCT01007396|Other|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
417235|NCT01007383|Drug|LEO 27847|First in man
417236|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
417237|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
417238|NCT01007357|Device|Body MR imaging|Body MR imaging will be performed to optimize sequences
417239|NCT01007344|Dietary Supplement|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
417240|NCT01007344|Dietary Supplement|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
417241|NCT01007331|Behavioral|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10^10 colony forming units pr day of probiotics
417242|NCT01007318|Procedure|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
417243|NCT01007318|Procedure|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
417244|NCT01007305|Procedure|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy
417245|NCT01007305|Procedure|Ovarian conservation|Both ovaries and fallopian tubes not removed at the time of hysterectomy
417246|NCT01007292|Drug|YM155|intravenous infusion
417247|NCT01007292|Biological|Rituximab|intravenous infusion
417250|NCT01007253|Drug|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
417251|NCT01007253|Drug|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
417252|NCT01007253|Drug|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
417253|NCT01007253|Drug|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
417254|NCT01007240|Device|polyethylenimine (PEI) nanoparticles.|
417255|NCT01007227|Other|Lifestyle instruction|Instruction dietetic and exercise therapy
417256|NCT01007214|Procedure|Prostatectomy|Elective prostatectomy
417257|NCT01007201|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
417258|NCT01007188|Other|1.5PD almonds|average American diet plus 1.5 oz per day almonds
417259|NCT01007188|Other|3.0PD almonds|average American diet plus 3.0 oz per day almonds
417260|NCT01007188|Other|Base (without almonds)|average American diet without almonds
417261|NCT01007175|Biological|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
417262|NCT01007175|Biological|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
417263|NCT01007175|Biological|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
417264|NCT01007175|Biological|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
417265|NCT01007175|Biological|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
417266|NCT01007149|Drug|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
417267|NCT01007149|Drug|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
417268|NCT01007136|Device|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
417269|NCT01007136|Device|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
417270|NCT01007123|Drug|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
417271|NCT01007110|Dietary Supplement|DHA|Docosahexaenoic Acid (DHA) from algal oil
417272|NCT01007110|Other|Placebo|Placebo capsule
417273|NCT01007097|Drug|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
417274|NCT01007097|Drug|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
417275|NCT01007097|Drug|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
417276|NCT01007097|Drug|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
417277|NCT01007097|Drug|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
417278|NCT01007097|Drug|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
417279|NCT01007097|Drug|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
417280|NCT01007084|Drug|Propranolol|40 mg
417281|NCT01007084|Drug|Propranolol ER|120 mg twice per day
417282|NCT01007084|Drug|Sugar pills|sugar pill
417283|NCT01007071|Drug|Human Growth Hormone (1-134)|Subjects randomized to human growth hormone (1-134) for 16 weeks. In this arm, growth hormone is dosed sc on a daily basis and increased over first 6 weeks (Men: start at 0.2 mg sc/d, increase to 0.6 mg sc/d after 4 weeks. Women, postmenopausal: start at 0.3 mg sc/d, increase to 0.9 mg sc/d after 4 weeks. Women premenopausal or on estrogen: start at 0.6 mg sc/d, increase to 1.3 mg sc/d after 4 weeks.) Dose adjustments based on serum IGF-1 levels at 6 and 12 weeks, with final IGF-1 measurement for efficacy performed at 16 weeks, with goal in range of -0.5 SD to +2SD. An elevated serum IGF-1 value will result in a 20% dose reduction in GH in an active and random placebo patient. Similarly, a low serum IGF-1 will result in a 20% dose increase in an active and random placebo subject.
417284|NCT01007071|Drug|Placebo|Subjects randomized to placebo
417285|NCT01007032|Biological|Cixutumumab|Cixutumumab intravenously
417286|NCT01007019|Drug|YH4808 30mg|YH4808 30mg (single dose)
417287|NCT01007019|Drug|YH4808 50mg|YH4808 50mg (single dose)
417288|NCT01007019|Drug|YH4808 100mg|YH4808 100mg (single dose)
417289|NCT01007019|Drug|YH4808 200mg|YH4808 200mg (single dose)
417290|NCT01007019|Drug|YH4808|YH4808 400mg (single dose)
417291|NCT01007019|Drug|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
417292|NCT01007019|Drug|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
417293|NCT01007019|Drug|YH4808 600mg|YH4808 600mg
417294|NCT01007019|Drug|YH4808 800mg (single dose)|YH4808 800mg (single dose)
417295|NCT01007019|Drug|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
417296|NCT01007019|Drug|Placebo|10 volunteers will be administered matched placebo.
417297|NCT01007019|Drug|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
417298|NCT01007006|Device|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
417299|NCT01006993|Device|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
417300|NCT01006980|Drug|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
417301|NCT01006980|Drug|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
417302|NCT01006967|Device|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
417303|NCT01006967|Other|Physical Therapy|Standard program of physical therapy for gait and balance
417304|NCT01006954|Drug|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
417305|NCT01006954|Drug|Flare up|Flare up protocol in poor responders for IVF/ICSI
417306|NCT01006941|Biological|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
417307|NCT01006928|Other|Questionaire|Questionaire to mothers
417308|NCT01006915|Procedure|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
417309|NCT01006889|Drug|Exenatide|The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
417310|NCT01006876|Drug|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
417311|NCT01006876|Drug|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
417312|NCT01006876|Drug|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
417313|NCT01006863|Drug|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
417314|NCT01006863|Drug|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
417315|NCT01006863|Drug|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine [group 5 (n=30)] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
417316|NCT01006824|Other|Capsule endoscopy|Capsule endoscopy
417317|NCT01006824|Other|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
417318|NCT01006811|Dietary Supplement|modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
417319|NCT01006811|Other|modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
417320|NCT01006798|Other|Placebo|enteric coated capsule containing no vaccine virus
417321|NCT01006798|Biological|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
417322|NCT01006798|Biological|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
417323|NCT01006785|Drug|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
417324|NCT01006785|Drug|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
417325|NCT01006772|Other|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
417326|NCT01006759|Other|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
417327|NCT01006746|Other|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
417328|NCT01006733|Genetic|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
417329|NCT01006733|Drug|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
417330|NCT01006720|Drug|Sugammadex|"Single intravenous injection of either:~Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
417331|NCT01006720|Drug|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
417332|NCT01006720|Drug|Saline|Saline 0.9% (Saline)
417370|NCT01006421|Dietary Supplement|GINGKO BILOBA|MEMOREX 60 MG BID
417333|NCT01006707|Drug|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
417334|NCT01006694|Other|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
417335|NCT01006694|Drug|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
417336|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate~Intra muscular"
417337|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate~Intramuscular injection"
417338|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
417339|NCT01006668|Drug|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
417340|NCT01006668|Drug|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
417341|NCT01006655|Drug|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
417342|NCT01006655|Drug|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
417343|NCT01006629|Biological|palivizumab|palivizumab 15 mg/kg intramuscularly
417344|NCT01006616|Drug|Navarixin|Navarixin 10 mg and 30 mg capsules
417345|NCT01006616|Drug|Placebo|Placebo to navarixin capsules
417346|NCT01006616|Drug|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
417347|NCT01006603|Drug|Saxagliptin|5 mg, oral tablet, once daily
417348|NCT01006603|Drug|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
417349|NCT01006590|Drug|Saxagliptin|5 mg, oral tablet, once daily
417350|NCT01006590|Drug|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
417351|NCT01006577|Procedure|side-to-end anastomosis|Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
417352|NCT01006577|Procedure|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
417353|NCT01006564|Other|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
417354|NCT01006564|Other|Other|Insertion of gold seeds into prostate for image registration.
417355|NCT01006551|Drug|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
417356|NCT01006538|Device|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the choroidal neovascular membrane (CNV) lesion. Each device is calibrated for a set duration.
417357|NCT01006538|Drug|Ranibizumab|intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
417358|NCT01006525|Drug|zolpidem|placebo or zolpidem (10mg)daily for one year
417359|NCT01006499|Drug|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
417360|NCT01006486|Other|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
417361|NCT01006486|Other|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
417362|NCT01006473|Other|Exercise training|
417363|NCT01006460|Drug|Rhodiola rosea, L|3 Capsules twice a day
417364|NCT01006460|Drug|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
417365|NCT01006460|Drug|Panax ginseng|3 capsules twice a day
417366|NCT01006460|Drug|Placebo - dark brown sugar|3 capsules twice a day
417367|NCT01006447|Behavioral|Instructor contact|
417368|NCT01006447|Behavioral|Instructor contact|
417369|NCT01006434|Other|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
417454|NCT01005836|Other|Usual clinic care|
417371|NCT01006408|Procedure|Low Level Laser|Low Level Laser twice a week for 8 weeks
417372|NCT01006408|Procedure|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
417373|NCT01006395|Drug|Zoledronic acid|yearly infusion
417374|NCT01006395|Drug|Placebo|yearly infusion
417375|NCT01006369|Biological|bevacizumab|"Arm A: FOLFOX6 + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 5 mg/kg in 100 cc Normal Saline every 14 days on day one~Arm B: XELOX + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 7.5 mg/kg in 100 cc Normal Saline every 21 days"
417376|NCT01006369|Drug|XELOX regimen|Capecitabine will be started at a dose of 1,000 mg/m2/day bid po (total daily dose = 2,000 mg/m2) for 14 days (28 doses) of the 21 day cycle. This cycle will be repeated every 21 days. Oxaliplatin will be started at a dose of 130 mg/m2, in 250 ml of D5W over 2 hours given day 1 of each cycle. This cycle will be repeated every 21 days.
417377|NCT01006369|Drug|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
417378|NCT01006356|Drug|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
417379|NCT01006343|Other|Higher Protein (HP)|
417380|NCT01006343|Other|Lower Protein (LP)|
417381|NCT01006317|Behavioral|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
417382|NCT01006317|Behavioral|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
417383|NCT01006317|Other|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
417384|NCT01006304|Drug|JNJ-39439335, Placebo|
417385|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
417386|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
417387|NCT01006291|Drug|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
417388|NCT01006265|Drug|ACT-128800 Dose 1|ACT-128800 (Dose 1) administered orally once daily
417389|NCT01006265|Drug|Placebo|Matching placebo administered orally once daily
417390|NCT01006265|Drug|ACT-128800 Dose 2|ACT-128800 (Dose 2) administered orally once daily
417391|NCT01006265|Drug|ACT-128800 Dose 3|ACT-128800 (Dose 3) administered orally once daily
417392|NCT01006252|Drug|Tasisulam-sodium|Administered intravenously on Day 1 of a 28-day cycle, until disease progression.
417393|NCT01006252|Drug|Paclitaxel|80 mg/m^2 administered intravenously on Days 1, 8, and 15 of a 28-day cycle, until disease progression
417394|NCT01006239|Other|No study intervention|The is no study related intervention.
417395|NCT01006226|Drug|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
417396|NCT01006213|Behavioral|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
417397|NCT01006187|Drug|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
417398|NCT01006187|Drug|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
417399|NCT01006187|Other|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
417400|NCT01006187|Other|Distraction|By means of self-selected reading material or video
417401|NCT01006174|Other|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
417402|NCT01006174|Other|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
417403|NCT01006174|Other|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
417404|NCT01006161|Drug|SCH 527123|Low dose
417405|NCT01006161|Drug|SCH 527123|Medium dose
417406|NCT01006161|Drug|SCH 527123|High dose
417407|NCT01006161|Drug|SCH 527123|Placebo to match SCH 527123
417408|NCT01006148|Biological|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
417409|NCT01006122|Drug|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
417410|NCT01006122|Drug|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
417411|NCT01006096|Drug|erlotinib|100mg tablet, once daily for 16 weeks
417412|NCT01006096|Other|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
417413|NCT01006070|Procedure|kyphoplasty|surgical kyphoplasty
417414|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
417415|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
417416|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
417417|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
417418|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
417419|NCT01006044|Biological|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
417420|NCT01006031|Drug|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
417421|NCT01006018|Drug|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
417422|NCT01006018|Drug|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
417423|NCT01006018|Drug|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
417424|NCT01005992|Procedure|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
417425|NCT01005992|Procedure|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
417426|NCT01005979|Drug|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles~Patients will receive a total of 6-8 cycles."
417427|NCT01005966|Drug|Sodium Fluoride Toothpaste|Test product
417428|NCT01005966|Drug|Amine Fluoride Toothpaste|Test product
417429|NCT01005966|Drug|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
417430|NCT01005966|Drug|Placebo|placebo and washout treatment
417431|NCT01005966|Drug|675 ppmf toothpaste|dose response
417432|NCT01005940|Device|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
417433|NCT01005927|Dietary Supplement|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
417434|NCT01005914|Drug|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
417435|NCT01005914|Drug|cytarabine|Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
417436|NCT01005914|Drug|dexamethasone|Day 1-4; 11-14: 40 mg daily
417437|NCT01005914|Drug|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
417438|NCT01005914|Drug|imatinib mesylate|600 mg/day
417439|NCT01005914|Drug|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
417440|NCT01005914|Drug|methylprednisolone|Day 1-3: 50mg IV BID
417441|NCT01005914|Drug|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
417442|NCT01005914|Drug|vincristine sulfate|Day 4 & 11: 2 mg IV
417443|NCT01005901|Drug|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
417444|NCT01005901|Drug|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
417445|NCT01005888|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
417446|NCT01005888|Drug|Placebo (saline)|
417447|NCT01005875|Drug|Sorafenib|Nexavar in bottles of 120 tables
417448|NCT01005875|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT
417449|NCT01005862|Biological|PF-04360365|10 mg/kg, single dose administered intravenously
417450|NCT01005862|Drug|Placebo|Placebo
417451|NCT01005849|Dietary Supplement|Protecflor|1 Capsule to be taken once a day during the entire study period
417452|NCT01005849|Dietary Supplement|Placebo|1 Capsule to be taken once a day during the entire study period
417453|NCT01005836|Behavioral|Cognitive behavioral therapy for youth anxiety|
417455|NCT01005836|Behavioral|Cognitive behavioral treatment for youth depression|
417456|NCT01005823|Drug|LEO 29102 cream|Twice daily application for 7 days
417457|NCT01005823|Drug|LEO 29102 placebo cream|LEO 29102 placebo cream
417458|NCT01005810|Drug|N-Acetylcysteine|1200 mg twice daily for 8 weeks
417459|NCT01005810|Drug|placebo|2 capsules twice daily for 8 weeks
417460|NCT01005810|Behavioral|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
417461|NCT01005797|Drug|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
417462|NCT01005784|Drug|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
417463|NCT01005784|Drug|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
417464|NCT01005771|Drug|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
417465|NCT01005771|Drug|Placebo|Matching placebo
417466|NCT01005758|Drug|cyclophosphamide|
417467|NCT01005758|Drug|cytarabine|
417468|NCT01005758|Drug|dexamethasone|
417469|NCT01005758|Drug|doxorubicin hydrochloride|
417470|NCT01005758|Drug|etoposide phosphate|
417471|NCT01005758|Drug|hydrocortisone sodium succinate|
417472|NCT01005758|Drug|imatinib mesylate|
417473|NCT01005758|Drug|mercaptopurine|
417474|NCT01005758|Drug|methotrexate|
417475|NCT01005758|Drug|methylprednisolone|
417476|NCT01005758|Drug|pegaspargase|
417477|NCT01005758|Drug|prednisolone|
417478|NCT01005758|Drug|prednisone|
417479|NCT01005758|Drug|vincristine sulfate|
417480|NCT01005758|Other|laboratory biomarker analysis|
417481|NCT01005758|Radiation|radiation therapy|
417482|NCT01005745|Procedure|Surgery|Surgery to remove a tumor for growth of TIL
417483|NCT01005745|Drug|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
417484|NCT01005745|Other|Adoptive Cell Transfer|T-cell infusion
417485|NCT01005745|Drug|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
417486|NCT01005732|Device|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and <5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
417487|NCT01005719|Drug|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
417488|NCT01005719|Drug|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
417489|NCT01005706|Drug|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.~Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
417490|NCT01005706|Drug|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.~At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
417491|NCT01005693|Other|questionnaire administration|
417492|NCT01005693|Procedure|cognitive assessment|
417493|NCT01005693|Procedure|examination|
417494|NCT01005693|Procedure|management of therapy complications|
417495|NCT01005680|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
417496|NCT01005680|Drug|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
417497|NCT01005680|Drug|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
417498|NCT01005667|Device|BirthTrack|Measurement of cervical dilation and head station
417499|NCT01005641|Drug|exemestane|25 mg daily
417500|NCT01005641|Drug|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
417501|NCT01005628|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
417502|NCT01005615|Device|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
417503|NCT01005615|Device|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
417504|NCT01005602|Other|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
417505|NCT01005602|Drug|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
417506|NCT01005576|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
417507|NCT01005563|Other|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
417508|NCT01005563|Other|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
417509|NCT01005550|Drug|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
417510|NCT01005550|Drug|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
417511|NCT01005550|Drug|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
417512|NCT01005550|Drug|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
417513|NCT01005537|Biological|aldesleukin|Given IV and orally
417514|NCT01005537|Biological|therapeutic autologous lymphocytes|Given IV
417515|NCT01005537|Drug|cyclophosphamide|Given IV
417516|NCT01005511|Device|Grindcare|Active treatment
417517|NCT01005511|Device|Grindcare - inactive|Placebo treatment
417518|NCT01005498|Dietary Supplement|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
417519|NCT01005498|Dietary Supplement|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
417520|NCT01005472|Drug|sunitinib malate|
417521|NCT01005472|Drug|temozolomide|
417522|NCT01005459|Drug|Tetracaine|Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
417523|NCT01005459|Drug|Bupivacaine|Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
417524|NCT01005446|Device|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
417525|NCT01005433|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
417526|NCT01005433|Drug|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
417527|NCT01005420|Dietary Supplement|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
417528|NCT01005420|Dietary Supplement|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
417529|NCT01005407|Biological|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
417530|NCT01005407|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
417531|NCT01005394|Device|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
417532|NCT01005381|Dietary Supplement|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
417533|NCT01005381|Dietary Supplement|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
417534|NCT01005381|Dietary Supplement|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
417535|NCT01005381|Dietary Supplement|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.~Given twice daily."
417536|NCT01005368|Genetic|fluorescence in situ hybridization|
417537|NCT01005368|Genetic|mutation analysis|
417538|NCT01005368|Genetic|nucleic acid sequencing|
417539|NCT01005368|Genetic|polymerase chain reaction|
417540|NCT01005368|Genetic|western blotting|
417541|NCT01005368|Other|flow cytometry|
417542|NCT01005368|Other|laboratory biomarker analysis|
417543|NCT01005355|Biological|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
417544|NCT01005342|Other|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
417545|NCT01005342|Other|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
417546|NCT01005342|Other|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
417547|NCT01005342|Other|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
417548|NCT01005342|Other|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
417549|NCT01005342|Other|Control|No fiber was added to control meal (250 g black-currant beverage)
417550|NCT01005329|Biological|Bevacizumab|Given IV
417551|NCT01005329|Drug|Carboplatin|Given IV
417552|NCT01005329|Drug|Cisplatin|Given IV
417553|NCT01005329|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
417554|NCT01005329|Drug|Paclitaxel|Given IV
417555|NCT01005316|Drug|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
417556|NCT01005316|Drug|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
417557|NCT01005316|Drug|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
417558|NCT01005316|Procedure|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
417559|NCT01005316|Procedure|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
417560|NCT01005316|Drug|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
417561|NCT01005316|Drug|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
417562|NCT01005303|Drug|Placebo|1 Tablet Daily
417563|NCT01005303|Drug|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
417564|NCT01005290|Drug|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
417565|NCT01005290|Drug|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
417566|NCT01005277|Genetic|gene expression analysis|
417567|NCT01005277|Genetic|microarray analysis|
417568|NCT01005277|Genetic|polymorphism analysis|
417569|NCT01005264|Device|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
417570|NCT01005264|Device|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
417571|NCT01005251|Drug|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
417572|NCT01005251|Drug|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
417573|NCT01005251|Drug|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
417574|NCT01005251|Drug|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
417575|NCT01005251|Drug|Placebo|oral,capsules, bid for 4 w
417576|NCT01005238|Drug|Lamivudine|
417577|NCT01005238|Drug|Telbivudine|
417578|NCT01005212|Drug|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
417579|NCT01005199|Drug|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
417580|NCT01005199|Drug|sorafenib tosylate|Sorafenib 2 x 400 mg daily
417581|NCT01005186|Behavioral|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
417582|NCT01005160|Drug|Metformin|CKD-501 0.5mg, metformin 1000mg
417583|NCT01005160|Drug|CKD-501|CKD-501 0.5mg, metformin 1000mg
417584|NCT01005147|Drug|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
417585|NCT01005147|Other|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
417586|NCT01005121|Drug|colchicine|2mg, per-os, once daily for six months
417587|NCT01005108|Drug|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
417588|NCT01005095|Dietary Supplement|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
417589|NCT01005095|Dietary Supplement|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
417590|NCT01005082|Behavioral|Low salt diet|
417591|NCT01005082|Behavioral|Water therapy alone|
417592|NCT01005069|Drug|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
417593|NCT01005069|Drug|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
417594|NCT01005069|Drug|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
417595|NCT01005069|Drug|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
417596|NCT01005069|Drug|Placebo capsule|Placebo capsules once daily and lifestyle modification
417597|NCT01005056|Drug|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
417598|NCT01005043|Radiation|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:~Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
417599|NCT01005030|Other|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
417649|NCT01004783|Genetic|polymerase chain reaction|
417600|NCT01005017|Procedure|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
417601|NCT01005004|Biological|HuCNS-SC cells|intracerebral transplantation
417602|NCT01004991|Biological|rituximab|375 mg/m2 on Day 8 of each of 6 cycles
417603|NCT01004991|Drug|cyclophosphamide|750 mg/m2 on Day 8 of each of 6 cycles
417604|NCT01004991|Drug|vincristine|1.4 mg/m2 on Day 8 of each of 6 cycles
417605|NCT01004991|Drug|doxorubicin|50 mg/m2 on Day 8 of each of 6 cycles
417606|NCT01004991|Drug|prednisone|100 mg PO days 8-12 of each of 6 cycles
417607|NCT01004991|Drug|azacytidine|﻿Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
417608|NCT01004978|Drug|Cisplatin|Undergo TACE
417609|NCT01004978|Drug|Doxorubicin Hydrochloride|Undergo TACE
417610|NCT01004978|Drug|Doxorubicin-Eluting Beads|Undergo TACE
417611|NCT01004978|Other|Laboratory Biomarker Analysis|Correlative studies
417612|NCT01004978|Drug|Mitomycin|Undergo TACE
417613|NCT01004978|Other|Pharmacological Study|Correlative studies
417614|NCT01004978|Other|Placebo|Given PO
417615|NCT01004978|Drug|Sorafenib Tosylate|Given PO
417616|NCT01004965|Other|laboratory biomarker analysis|
417617|NCT01004952|Behavioral|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
417618|NCT01004939|Drug|fondaparinux|fondaparinux
417619|NCT01004926|Device|Echelon foot|One Echelon foot for each subject, for a period of a month.
417620|NCT01004900|Procedure|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
417621|NCT01004900|Drug|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
417622|NCT01004887|Other|diagnostic laboratory biomarker analysis|
417623|NCT01004874|Drug|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
417624|NCT01004874|Drug|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
417625|NCT01004874|Radiation|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
417626|NCT01004874|Drug|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
417627|NCT01004861|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
417628|NCT01004848|Behavioral|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
417629|NCT01004822|Drug|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417630|NCT01004822|Drug|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417631|NCT01004822|Drug|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417632|NCT01004822|Drug|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417633|NCT01004822|Drug|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417634|NCT01004822|Drug|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417635|NCT01004822|Drug|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417636|NCT01004822|Drug|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
417637|NCT01004809|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
417638|NCT01004796|Genetic|cytogenetic analysis|
417639|NCT01004796|Genetic|microarray analysis|
417640|NCT01004796|Genetic|mutation analysis|
417641|NCT01004796|Other|immunohistochemistry staining method|
417642|NCT01004796|Other|immunologic technique|
417643|NCT01004796|Other|mass spectrometry|
417644|NCT01004783|Genetic|DNA methylation analysis|
417645|NCT01004783|Genetic|gene expression analysis|
417646|NCT01004783|Genetic|loss of heterozygosity analysis|
417647|NCT01004783|Genetic|microarray analysis|
417648|NCT01004783|Genetic|mutation analysis|
417651|NCT01004783|Other|laboratory biomarker analysis|
417652|NCT01004770|Drug|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
417653|NCT01004770|Drug|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
417654|NCT01004757|Other|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
417655|NCT01004757|Other|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
417656|NCT01004744|Drug|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
417657|NCT01004731|Drug|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
417658|NCT01004718|Radiation|Fludeoxyglucose F18|Undergo FDG PET/CT scans
417659|NCT01004718|Procedure|Computed Tomography|Undergo FDG PET/CT scans
417660|NCT01004718|Procedure|Positron emission tomography|Undergo FDG PET/CT scans
417661|NCT01004705|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
417662|NCT01004705|Drug|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
417663|NCT01004692|Device|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
417664|NCT01004653|Biological|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
417665|NCT01004640|Genetic|DNA analysis|
417666|NCT01004640|Genetic|Southern blotting|
417667|NCT01004640|Genetic|cytogenetic analysis|Correlative studies
417668|NCT01004640|Genetic|polymerase chain reaction|
417669|NCT01004627|Procedure|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
417670|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
417671|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
417672|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
417673|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
417674|NCT01004601|Drug|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
417675|NCT01004601|Drug|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
417676|NCT01004588|Dietary Supplement|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
417677|NCT01004588|Dietary Supplement|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
417678|NCT01004575|Device|implantation of Kaname Cobalt-Chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
417679|NCT01004562|Other|informational intervention|
417680|NCT01004536|Device|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
417681|NCT01004536|Other|no treatment|left untreated during the study period
417682|NCT01004523|Genetic|fluorescence in situ hybridization|
417683|NCT01004523|Genetic|loss of heterozygosity analysis|
417684|NCT01004523|Genetic|polymerase chain reaction|
417685|NCT01004523|Other|flow cytometry|
417686|NCT01004523|Other|immunohistochemistry staining method|
417687|NCT01004510|Drug|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
417688|NCT01004497|Drug|Dasatinib|After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
417689|NCT01004497|Drug|Cyclophosphamide|300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
417690|NCT01004497|Drug|Vincristine|1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 & 11
417691|NCT01004497|Drug|Daunorubicin|45 mg/m2/day, IV for 1 hour, days 4 & 11
417692|NCT01004497|Drug|Dexamethasone|40 mg/day, IV push, days 1-4 & days 11-14
417693|NCT01004497|Drug|Cytarabine|2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
417694|NCT01004497|Drug|Mitoxantrone|12 mg/m2/day, IV for 30 minutes, days 1-2
417695|NCT01004484|Other|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving), once daily.
417696|NCT01004484|Other|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
417697|NCT01004458|Behavioral|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
417698|NCT01004458|Other|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
417699|NCT01004445|Drug|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
417700|NCT01004445|Drug|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
417701|NCT01004445|Drug|Placebo|Two aerosol treatments per day (one treatment every 12hr)
417702|NCT01004432|Drug|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
417703|NCT01004432|Drug|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
417704|NCT01004432|Drug|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
417705|NCT01004432|Drug|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
417706|NCT01004432|Drug|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
417707|NCT01004419|Drug|ZD6474 (vandetanib)|vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
417708|NCT01004419|Drug|Faslodex (Fulvestrant)|Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
417709|NCT01004406|Device|intensive LDL-lowering therapy|The intensive LDL-lowering therapy uses LDL-apheresis in addition to the standard statin therapy. The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks
417710|NCT01004406|Drug|standard statin monotherapy|The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.
417711|NCT01004393|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
417712|NCT01004380|Drug|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
417713|NCT01004367|Other|Experimental|Environmental- and individual based components carried out in the school.
417714|NCT01004367|Other|No intervention|No intervention carried out in the school
417715|NCT01004354|Drug|Ergocalciferols|2000 international units by mouth daily for 8 weeks.
417716|NCT01004341|Behavioral|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
417717|NCT01004328|Other|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
417718|NCT01004315|Drug|KUC-7483|
417719|NCT01004315|Drug|Placebo|
417720|NCT01004315|Drug|Tolterodine|
417721|NCT01004302|Procedure|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
417722|NCT01004289|Procedure|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
417723|NCT01004289|Procedure|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
417724|NCT01004276|Other|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
417725|NCT01004263|Drug|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
417726|NCT01004250|Drug|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
417727|NCT01004250|Drug|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
417728|NCT01004250|Drug|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
417729|NCT01004237|Drug|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
417730|NCT01004224|Drug|BGJ398|
417731|NCT01004211|Procedure|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
417732|NCT01004211|Procedure|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
417733|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
417734|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
417735|NCT01004198|Drug|Ringers Lactate solution|Ringers Lactate solution for Injection
417736|NCT01004185|Drug|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM & 2 Asacol 400mg PM; 33-<54kg = 5 Asacol 400 mg AM & 4 Asacol 400mg PM; 54-<90kg = 6 Asacol 400mg AM & PM
417737|NCT01004185|Drug|Asacol 400 mg|17-<33kg = 2 Asacol 400mg & 1 placebo AM, 1 Asacol 400mg & 1 placebo PM; 33-<54kg = 3 Asacol 400mg & 2 placebo AM, 2 Asacol 400mg & 2 placebo PM; 54-<90kg = 3 Asacol 400mg & 3 placebo AM & PM
417738|NCT01004172|Drug|carboplatin|
417739|NCT01004172|Drug|bevacizumab|
417740|NCT01004172|Drug|herceptin|
417741|NCT01004159|Drug|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
417742|NCT01004146|Procedure|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
417743|NCT01004120|Dietary Supplement|Bimuno|5.5g daily intake
417744|NCT01004120|Dietary Supplement|Maltodextrin|5.5g daily intake
417745|NCT01004107|Device|Radiesse Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
417746|NCT01004094|Behavioral|simple goal setting|This group will set goals only
417747|NCT01004094|Behavioral|goal setting plus action intentions|This group will set goals and form action intentions (plans)
417748|NCT01004094|Behavioral|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
417749|NCT01004094|Behavioral|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
417750|NCT01004081|Drug|BIIB021|BID orally for 28 days
417751|NCT01004081|Drug|BIIB021|TIW orally for 28 days
417752|NCT01004081|Drug|exemestane (Aromasin)|Daily in tablet form for 28 days
417753|NCT01004068|Other|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
417754|NCT01004068|Drug|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
417755|NCT01004068|Behavioral|Structured exercise program plus hypocaloric diet|SET plus diet
417756|NCT01004055|Device|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
417757|NCT01004055|Drug|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
417758|NCT01004055|Drug|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
417759|NCT01004042|Drug|Botulinum Toxin Type A - BOTOX|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
417760|NCT01004029|Drug|Hydroxyprogesterone Caproate Injection, 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
417761|NCT01004029|Drug|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
417762|NCT01004016|Drug|KPS-0373|
417763|NCT01004016|Drug|Placebo|
417764|NCT01004003|Drug|Sorafenib|
417765|NCT01004003|Drug|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
417766|NCT01003990|Drug|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
417767|NCT01003990|Drug|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
417768|NCT01003990|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
417769|NCT01003990|Drug|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
417770|NCT01003964|Drug|Irinotecan, Cisplatin, Gemcitabine, Pemetrexed, Docetaxel|"GP:~Gemcitabine (1250 mg/m2) IV on day1, 8. Cisplatin (75 mg/m2) IV on day1 every 3 weeks~IP:~Irinotecan (65 mg/m2) IV on day 1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks~2nd or 3rd: Pemetrexed (500 mg/m2) D1 with premedication every 3 weeks Docetaxel (75 mg/m2) D1 with premedication every 3 weeks"
417771|NCT01003951|Procedure|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.~Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
417772|NCT01003938|Drug|Topotecan|
417773|NCT01003938|Drug|Erlotinib|
417774|NCT01003925|Behavioral|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
417775|NCT01003925|Behavioral|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
417776|NCT01003912|Biological|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
417777|NCT01003899|Drug|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
417778|NCT01003886|Drug|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
417779|NCT01003873|Biological|Evaluation of the endocannabinoid system|The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
417780|NCT01003873|Procedure|Biopsy of visceral and peripheral adipose tissue|The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
417781|NCT01003873|Biological|Evaluation of metabolic parameters|The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
417782|NCT01003873|Behavioral|Evolution of behavioral parameters|The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
417783|NCT01003873|Behavioral|Dietician consultation|The evaluation of the metabolic status will also be seen by a dietician.
417784|NCT01003873|Behavioral|Psychologist consultation|The behavioural evaluation will de done with a psychologist consultation
417785|NCT01003847|Drug|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
417786|NCT01003834|Behavioral|Computerized brief intervention|Intervention based on Motivational Interviewing technique
417787|NCT01003834|Behavioral|Computerized health screening|Behavioral intervention
417788|NCT01003834|Behavioral|Computerized assessment|Behavioral intervention
417789|NCT01003834|Behavioral|Therapist-delivered motivational intervention|Behavioral intervention
417790|NCT01003808|Biological|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
417791|NCT01003769|Drug|Lenalidomide|Given PO
417792|NCT01003769|Drug|R-(-)-Gossypol Acetic Acid|Given PO
417793|NCT01003769|Other|Laboratory Biomarker Analysis|Correlative studies
417794|NCT01003756|Other|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
417795|NCT01003743|Device|endolumenal tissue approximation|
417796|NCT01003730|Other|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
417797|NCT01003704|Procedure|Lower extremity amputation|
417798|NCT01003691|Biological|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
417799|NCT01003691|Biological|Placebo|Intravenous, multiple dose with experimental dose
417800|NCT01003678|Drug|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.~Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
417801|NCT01003652|Procedure|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
417802|NCT01003639|Drug|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
417803|NCT01003639|Drug|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
417804|NCT01003639|Behavioral|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
417805|NCT01003626|Procedure|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
417806|NCT01003626|Device|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
417807|NCT01003613|Drug|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
417808|NCT01003613|Other|Beriplast P|0.1 ml to attach graft
417809|NCT01003600|Behavioral|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
417810|NCT01003587|Behavioral|District health information package|"The intervention package consists of:~A report on disease burden, disease control priorities and health system performance in India~Condensed fact sheet based on the report~District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district~Customized speech for district level officials detailing key actions to reduce deaths~Reminder materials including poster version of the DRCs and video on key points and actionable messages"
417811|NCT01003574|Behavioral|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
417812|NCT01003574|Behavioral|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
417813|NCT01003561|Procedure|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
417814|NCT01003548|Device|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
417815|NCT01003548|Device|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
417816|NCT01003522|Other|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
417817|NCT01003522|Other|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
417818|NCT01003522|Procedure|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
417819|NCT01003522|Procedure|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
417820|NCT01003522|Other|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
417942|NCT01002573|Drug|ibuprofen|Ibuprofen, 10 mg/kg
417943|NCT01002573|Drug|acetaminophen|Acetaminophen, 10mg/kg
417821|NCT01003522|Other|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
417822|NCT01003522|Other|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
417823|NCT01003509|Procedure|modified shouldice and double|one arm modified shouldice, other one is double repair
417824|NCT01003496|Behavioral|Treatment as Usual (TAU)|Outpatient substance abuse treatment
417825|NCT01003496|Behavioral|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
417826|NCT01003483|Drug|orlistat|Tablet,120mg,three times a day,three months
417827|NCT01003470|Other|acupuncture|Xing Nao Kai Qiao Acupuncture
417828|NCT01003470|Behavioral|rehabilitation|Kinesitherapy
417829|NCT01003470|Other|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
417830|NCT01003457|Other|ultrasonography|transvaginal ultrasonography of bladder wall thickness
417831|NCT01003444|Procedure|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
417832|NCT01003431|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
417833|NCT01003431|Biological|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
417834|NCT01003431|Biological|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
417835|NCT01003418|Biological|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
417836|NCT01003418|Biological|Infanrix™-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
417837|NCT01003418|Biological|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
417838|NCT01003405|Drug|KUC-7483|
417839|NCT01003379|Drug|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
417840|NCT01003379|Drug|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
417841|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
417842|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
417843|NCT01003353|Behavioral|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
417844|NCT01003340|Behavioral|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
417845|NCT01003327|Device|I-gel|intubation with I-gel airway
417846|NCT01003327|Device|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
417847|NCT01003314|Biological|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later
417848|NCT01003314|Biological|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
417849|NCT01003301|Drug|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
417850|NCT01003301|Drug|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
417851|NCT01003288|Biological|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)~* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
417852|NCT01003275|Drug|Paricalcitol|Two 1 mcg soft gels by mouth daily for 8 weeks
417853|NCT01003275|Drug|Placebo|Two soft gels by mouth daily for 8 weeks
417854|NCT01003262|Other|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
417855|NCT01003262|Other|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
418462|NCT00998621|Other|Adherence questionnaire|Adherence questionnaire
417856|NCT01003249|Drug|Baclofen|"Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
417857|NCT01003249|Drug|Placebo|"Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen). After the 3 week washout period, questionnaires, diary, EMG and uroflowmetry will be repeated. Then patients initially assigned to the baclofen group will be assigned to the placebo group, and those assigned to the placebo group will be assigned to the baclofen group.~Patients would then receive a dose of baclofen 10 mg PO twice daily (or placebo twice daily), and then the dose will be escalated to 80 mg."
417858|NCT01003236|Drug|placebo|140 mg placebo tablets, 3 times per day for 3 months
417859|NCT01003236|Drug|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
417860|NCT01003223|Other|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
417861|NCT01003210|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
417862|NCT01003184|Drug|exenatide once weekly|subcutaneous injection, 2mg, once a week
417863|NCT01003184|Drug|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
417864|NCT01003171|Drug|MCS-2 soft-gel capsule|MCS-2 30 mg/day
417865|NCT01003158|Drug|AZD8931|Tablet Oral bid
417866|NCT01003158|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off
417867|NCT01003145|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
417868|NCT01003132|Other|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
417869|NCT01003119|Behavioral|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
417870|NCT01003106|Drug|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
417871|NCT01003106|Drug|Ranibizumab 2.0mg (monthly)|
417872|NCT01003106|Drug|Pro re nata (prn) ranibizumab|
417873|NCT01003106|Procedure|Pro re nata (prn) Laser photocoagulation|
417874|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
417875|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
417876|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
417877|NCT01003080|Device|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
417878|NCT01003080|Other|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
417879|NCT01003067|Device|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
417880|NCT01003054|Drug|Busulfan|130 mg/m^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
417881|NCT01003054|Drug|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
417882|NCT01003054|Drug|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is >1500/mcl and platelets >50,000 /mcl, may be titrated to maintain ANC >1.0 and platelets >50,000 /mcl.
417883|NCT01003054|Procedure|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
417884|NCT01003028|Drug|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
417885|NCT01003028|Drug|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
417886|NCT01003015|Drug|BAY73-4506|160 mg BAY73-4506
417887|NCT01003002|Drug|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
417888|NCT01002989|Device|Doppler Ankle-Brachial Index measurement|Measurement of the Ankle-Brachial Index by Doppler.
417889|NCT01002989|Device|WatchBP Office Ankle-Brachial Index measurement.|Measurement of Ankle-Brachial Index by WatchBP Office device.
417890|NCT01002963|Drug|PF-04418948|solution, 30 mg, single
417891|NCT01002963|Drug|PF-04418948|solution, 100 mg, single
417892|NCT01002963|Drug|PF-04418948|solution, 300 mg, single
417893|NCT01002963|Drug|PF-04418948|solution, 1000 mg, single
417894|NCT01002963|Drug|PF-04418948|solution, 3000 mg, single
417895|NCT01002963|Drug|PF-04418948|solution, 4500 mg, single
417896|NCT01002963|Drug|PF-04418948|solution, 6000 mg, single
417897|NCT01002950|Drug|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
417898|NCT01002950|Drug|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
417899|NCT01002924|Drug|EC145|EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
418014|NCT01001975|Drug|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
417900|NCT01002911|Drug|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
417901|NCT01002911|Drug|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
417902|NCT01002898|Drug|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
417903|NCT01002872|Drug|Lanthanum Carbonate|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill TID Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus <3.5mg/dL Reduce to 1 pill BID. If Phosphorus >5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is <3.5mg/dL Reduce to 1 pill daily. If phosphorus >5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus <3.5mg/dL stop the drug If phosphorus is >5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
417904|NCT01002872|Drug|Fosrenol|Initial dose of drug will be 1500mg TID
417905|NCT01002872|Drug|placebo|Initial dose of placebo will be 1 pill three times a day
417906|NCT01002859|Drug|Sandimmum|Intravenous injection of cyclosporine
417907|NCT01002859|Drug|Placebo|Intravenous Injection of NaCl solution
417908|NCT01002846|Procedure|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
417909|NCT01002833|Biological|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
417910|NCT01002820|Drug|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
417911|NCT01002807|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
417912|NCT01002807|Drug|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
417913|NCT01002807|Drug|Glucophage|Tablets, Oral, 1000 mg, Single Dose
417914|NCT01002794|Procedure|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital.
417915|NCT01002794|Other|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training.
417916|NCT01002781|Drug|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
417917|NCT01002768|Drug|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
417918|NCT01002768|Drug|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
417919|NCT01002755|Drug|Lenalidomide|Given PO
417920|NCT01002755|Biological|Ofatumumab|Given IV
417921|NCT01002742|Drug|Mycophenolate Mofetil|"Oral dosing should be delivered in 250 mg units. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~Patients who weight > 60 kg should receive MMF 1 gm PO/IV every 8 hours.~Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~Patients who weight <40 kg should receive 20 mg/kg IV or PO every 8 hours."
417922|NCT01002742|Drug|Placebo|"Oral dosing should be delivered in 250 mg units blinded placebo. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~Patients who weight > 60 kg should receive placebo 1 gm PO/IV every 8 hours.~Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~Patients who weight <40 kg should receive 20 mg/kg IV or PO every 8 hours."
417923|NCT01002729|Other|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI < 30 given Oseltamivir
417924|NCT01002729|Other|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI > 40 given Oseltamivir
417925|NCT01002716|Biological|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
417926|NCT01002703|Drug|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
417927|NCT01002690|Drug|Etoricoxib|90 mg/day orally for 10-13 days
417928|NCT01002677|Behavioral|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
417929|NCT01002677|Behavioral|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
417930|NCT01002664|Drug|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
417931|NCT01002664|Drug|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
417932|NCT01002651|Dietary Supplement|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
417933|NCT01002651|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
417934|NCT01002638|Other|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
417935|NCT01002638|Procedure|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
417936|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
417937|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
417938|NCT01002599|Device|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
417939|NCT01002599|Device|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
417940|NCT01002586|Other|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
417941|NCT01002586|Other|Walking exercise program|walking exercise program
417944|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
417945|NCT01002547|Drug|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
417946|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
417947|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
417948|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
417949|NCT01002547|Drug|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
417950|NCT01002534|Drug|Vardenafil|Nasal instillation of Vardenafil
417951|NCT01002534|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
417952|NCT01002508|Biological|Influenza vaccine|One dose of influenza vaccine
417953|NCT01002495|Biological|VM202|Endocardial injections on Day 0.
417954|NCT01002482|Device|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.~CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.~The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
417955|NCT01002482|Device|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
417956|NCT01002469|Other|sodium [1-13C] acetate|
417957|NCT01002456|Other|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
417958|NCT01002456|Other|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
417959|NCT01002443|Drug|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
417960|NCT01002443|Drug|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
417961|NCT01002430|Biological|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
417962|NCT01002417|Drug|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
417963|NCT01002417|Drug|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
417964|NCT01002417|Drug|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
417965|NCT01002404|Procedure|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
417966|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
417967|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
417968|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
417969|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
417970|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
417971|NCT01002365|Other|Oxygen delivery|
417972|NCT01002365|Other|Oxygen administration|
417973|NCT01002339|Drug|Tacrolimus with rapid steroid withdrawal|"Basiliximab induction (4 mg i.v., days 0 and 4).~Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.~Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
417974|NCT01002339|Drug|Tacrolimus with steroids minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.~Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
417975|NCT01002339|Drug|CsA with steroid minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)~Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.~CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.~Mycophenolate mofetil 1 gr b.i.d"
417976|NCT01002326|Behavioral|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
418015|NCT01001962|Drug|empagliflozin|ACTIVE TREATMENT FOR DIABETES
418016|NCT01001962|Drug|Metformin|ACTIVE TREATMENT FOR DIABETES
418065|NCT01001572|Drug|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
417977|NCT01002300|Drug|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
417978|NCT01002287|Device|SprayShield Adhesion Barrier System|Adhesion Barrier Device
417979|NCT01002287|Procedure|Good Surgical Technique Alone|Good Surgical Technique Alone
417980|NCT01002274|Drug|MCS-2|2 soft-gel capsules Qd for 40 weeks
417981|NCT01002248|Drug|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
417982|NCT01002248|Drug|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
417983|NCT01002248|Drug|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
417984|NCT01002248|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
417985|NCT01002235|Biological|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
417986|NCT01002222|Drug|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
417987|NCT01002209|Procedure|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).~HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
417988|NCT01002209|Procedure|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
417989|NCT01002196|Behavioral|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).~2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.~3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.~4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).~5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
417990|NCT01002196|Behavioral|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
417991|NCT01002183|Drug|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
417992|NCT01002157|Dietary Supplement|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
417993|NCT01002157|Other|Placebo capsules|Capsules containing no Menaquinone-7
417994|NCT01002144|Other|blood sampling|
417995|NCT01002131|Device|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
417996|NCT01002118|Drug|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
417997|NCT01002118|Drug|Placebo|4 capsules each day for 16 weeks
417998|NCT01002105|Drug|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
417999|NCT01002105|Other|Control group|psychosocial intervention and placebo for 12 weeks
418000|NCT01002092|Drug|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
418001|NCT01002092|Drug|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
418002|NCT01002079|Drug|BMS-708163|Capsule, Oral, 125 mg, Once daily, 1 day
418003|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 7 days
418004|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 6 days
418005|NCT01002053|Procedure|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
418006|NCT01002040|Biological|Arepanrix|Group A receives one dose of Arepanrix
418007|NCT01002040|Biological|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
418008|NCT01002027|Behavioral|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
418009|NCT01002014|Procedure|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
418010|NCT01001988|Other|Blood sample|Blood sample for immunogenicity assessment
418011|NCT01001988|Biological|JE-CV administered in Study JEC02|Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
418012|NCT01001975|Drug|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
418013|NCT01001975|Drug|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
418017|NCT01001949|Dietary Supplement|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
418018|NCT01001949|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
418019|NCT01001936|Drug|SKI-606|
418020|NCT01001923|Drug|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
418021|NCT01001923|Drug|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
418022|NCT01001910|Drug|Carboplatin|Given IV
418023|NCT01001910|Other|Laboratory Biomarker Analysis|Correlative studies
418024|NCT01001910|Drug|Pemetrexed Disodium|Given IV
418025|NCT01001897|Drug|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
418026|NCT01001897|Drug|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
418027|NCT01001884|Other|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
418028|NCT01001871|Dietary Supplement|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
418029|NCT01001871|Dietary Supplement|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
418030|NCT01001858|Other|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
418031|NCT01001845|Drug|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
418032|NCT01001845|Drug|vit E|200 mg twice daily for 3 weeks
418033|NCT01001845|Drug|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
418034|NCT01001832|Drug|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
418035|NCT01001832|Drug|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
418036|NCT01001806|Drug|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
418037|NCT01001806|Drug|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
418038|NCT01001806|Drug|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
418039|NCT01001793|Device|Levacor Ventricular Assist Device|Surgical procedure
418040|NCT01001780|Drug|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
418041|NCT01001767|Drug|Lovaza|Lovaza one gram twice a day for 24 weeks
418042|NCT01001767|Drug|Placebo|Placebo
418043|NCT01001754|Drug|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
418044|NCT01001754|Drug|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
418045|NCT01001754|Drug|Ribavirin|Daily oral administration (400-600 mg BID)
418046|NCT01001741|Other|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
418047|NCT01001728|Radiation|Imaging investigations (with radiation)|
418048|NCT01001715|Drug|REGN475/SAR164877|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
418049|NCT01001715|Drug|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution~Route of administration: intravenous infusion over 30 minutes"
418050|NCT01001702|Drug|Aripiprazole|Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
418051|NCT01001689|Behavioral|Nutritional counseling + exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
418052|NCT01001676|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
418053|NCT01001676|Device|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
418054|NCT01001663|Device|FemoSeal®|Closure device for femoral artery access closure
418055|NCT01001663|Other|Manual compression|Conventional manual compression
418056|NCT01001650|Biological|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,~Group 2: 4 doses of 30,000 PfSPZ/immunization,~Group 3: 4 doses of 135,000 PfSPZ/immunization, and~Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.~If > 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
418057|NCT01001637|Dietary Supplement|Curcumin Formulation|2000mg or 3000mg daily BID
418058|NCT01001637|Dietary Supplement|Placebo|Placebo
418059|NCT01001624|Other|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
418060|NCT01001624|Other|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
418061|NCT01001611|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
418062|NCT01001611|Drug|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
418063|NCT01001598|Drug|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
418064|NCT01001585|Drug|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
418463|NCT00998608|Drug|risperidone|risperidone 4mg/d
418066|NCT01001572|Drug|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
418067|NCT01001572|Drug|Placebo|1 capsule or tablet taken orally once daily
418068|NCT01001559|Drug|L-methylfolate|Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
418069|NCT01001559|Drug|Selective serotonin reuptake inhibitor (SSRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
418070|NCT01001559|Drug|Serotonin and norepinephrine reuptake inhibitor (SNRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
418071|NCT01001546|Behavioral|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
418072|NCT01001546|Behavioral|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
418073|NCT01001520|Drug|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
418074|NCT01001520|Drug|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.~The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
418075|NCT01001507|Procedure|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
418076|NCT01001494|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
418077|NCT01001494|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
418078|NCT01001494|Drug|Placebo|Placebo twice-daily by inhalation for 24 weeks
418079|NCT01001481|Other|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
418080|NCT01001468|Drug|VB-201|Single daily dose of oral VB-201 20 mg
418081|NCT01001468|Drug|VB-201|Single daily dose or oral VB-201 80 mg
418082|NCT01001468|Other|Placebo|Single daily dose of oral placebo
418083|NCT01001442|Drug|BT062|intravenous administration
418084|NCT01001429|Drug|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
418085|NCT01001429|Drug|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
418086|NCT01001403|Drug|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
418087|NCT01001403|Drug|Normal saline|10 ml of normal saline
418088|NCT01001390|Device|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
418089|NCT01001377|Drug|Cetuximab|Administered by intravenous infusion
418090|NCT01001377|Drug|Panitumumab|Administered by intravenous infusion
418091|NCT01001364|Drug|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
418092|NCT01001364|Drug|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
418093|NCT01001351|Drug|PRT-201|Applied topically during surgery.
418094|NCT01001351|Drug|Placebo|Applied topically during surgery
418095|NCT01001338|Drug|RDEA594|Uricosuric agent for the treatment of gout.
418096|NCT01001338|Drug|Placebo|Matching Placebo
418097|NCT01001338|Drug|Allopurinol|Allopurinol
418098|NCT01001325|Biological|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
418099|NCT01001325|Biological|Normal saline|0.5 mL intramuscular
418100|NCT01001312|Other|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
418101|NCT01001312|Other|Clinical volume status assessment|Volume assessment based on history and physical examination
418102|NCT01001299|Drug|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
418103|NCT01001299|Drug|RO5185426|960 mg orally twice daily
418104|NCT01001286|Behavioral|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
418105|NCT01001273|Other|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
418106|NCT01001260|Drug|No ASA|Alternative antiplatelet therapy instead of aspirin
418107|NCT01001260|Drug|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
418108|NCT01001260|Drug|325 mg ASA|high dose of aspirin prior to PTCA
418109|NCT01001247|Drug|TMC278; Omeprazole|
418110|NCT01001234|Drug|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).~Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
418111|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
418112|NCT01001234|Drug|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder [moderate or severe pain 15 minutes after dose] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.~Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
418113|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
418114|NCT01001221|Drug|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion~Route of administration: Intravenous infusion over 60 minutes~Dosage:~Study part 1: 15, 20 or 25 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1"
418115|NCT01001221|Drug|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)~Route of administration: Intravenous infusion over 30 minutes~Dosage:~Study part 1: 700, 900 or 1000 mg/m^2 according to pre-defined dose escalation schedule~Study part 2: MTD as determined in Study part 1."
418116|NCT01001208|Drug|Methotrexate|Methotrexate tablets over-encapsulated for blinding
418117|NCT01001208|Drug|Etanercept|1 mL for subcutaneous injection
418118|NCT01001208|Drug|Placebo|Matching placebo to methotrexate capsules
418119|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
418120|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
418121|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
418122|NCT01001195|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
418123|NCT01001182|Other|non interventional|non interventional
418124|NCT01001169|Biological|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
418125|NCT01001156|Other|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
418126|NCT01001143|Drug|Decitabine|
418127|NCT01001143|Drug|Bexarotene|
418128|NCT01001130|Drug|fluticasone furoate group|patients who are administered fluticasone furoate at least once
418129|NCT01001117|Device|LensAR laser surgery|Use of laser for cataract surgery
418130|NCT01001117|Device|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
418131|NCT01001104|Drug|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
418132|NCT01001104|Drug|Placebo|Administered by SC injection, QW for 12 weeks.
418133|NCT01001091|Drug|AL-38583 ophthalmic solution|
418134|NCT01001091|Drug|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
418135|NCT01001091|Drug|Dexamethasone ophthalmic suspension, 0.1%|
418136|NCT01001078|Device|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
418137|NCT01001078|Device|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
418138|NCT01001078|Device|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
418139|NCT01001065|Procedure|Vascular ultrasound|RI ist predictive for arteriosclerosis
418140|NCT01001052|Drug|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
418141|NCT01001026|Biological|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
418142|NCT01001026|Biological|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
418143|NCT01001013|Drug|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
418144|NCT01001000|Procedure|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
418145|NCT01000987|Drug|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
418146|NCT01000987|Drug|placebo|placebo
418147|NCT01000974|Biological|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
418148|NCT01000974|Biological|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
418149|NCT01000974|Biological|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
418150|NCT01000974|Biological|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
418151|NCT01000974|Biological|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
418152|NCT01000974|Biological|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
418153|NCT01000974|Biological|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
418154|NCT01000974|Biological|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
418155|NCT01000961|Drug|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
418156|NCT01000961|Drug|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
418157|NCT01000948|Drug|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
418158|NCT01000935|Other|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
418159|NCT01000935|Other|Platelet Rich plasma|The study group will have a surgical repair and will receive PRP treatment where the control group will undergo surgery without the PRP application.
418160|NCT01000922|Drug|Regular Human Insulin|Individual dose of RHI administered subcutaneously
418161|NCT01000922|Drug|Lispro|Individual dose of lispro administered subcutaneously
418162|NCT01000922|Drug|VIAject|Individual dose of VIAject administered subcutaneously
418163|NCT01000922|Drug|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
418164|NCT01000922|Drug|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
418165|NCT01000922|Drug|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
418166|NCT01000909|Procedure|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
418167|NCT01000896|Drug|AZD0530|film coated tablet, PO, daily
418168|NCT01000896|Drug|Carboplatin|intravenous, 3 weeks
418169|NCT01000896|Drug|paclitaxel|intravenous, 3 weeks
418170|NCT01000883|Other|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
418171|NCT01000883|Other|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
418172|NCT01000883|Procedure|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
418173|NCT01000870|Drug|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
418174|NCT01000857|Drug|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
418175|NCT01000831|Biological|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
418176|NCT01000818|Drug|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
418177|NCT01000818|Drug|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
418178|NCT01000818|Drug|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
418179|NCT01000805|Drug|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
418180|NCT01000805|Drug|Placebo|Participants received placebo QD, po for 8 weeks.
418181|NCT01000792|Drug|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
418182|NCT01000792|Drug|Levocetirizine|Levocetirizine
418183|NCT01000779|Drug|Propranolol|upto 320mg/day maximum
418184|NCT01000779|Device|multi band ligator for esophageal varices|to obliterate esophageal varices
418185|NCT01000753|Other|Cytology Specimen Collection Procedure|Correlative studies
418186|NCT01000740|Genetic|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
418187|NCT01000740|Genetic|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
418188|NCT01000727|Drug|Darapladib 160 mg|Lp-PLA2 inhibitor
418189|NCT01000727|Drug|Placebo|Placebo administered
418190|NCT01000727|Other|Standard Therapy|Guideline mandated therapy for individual's condition
418191|NCT01000714|Drug|Psirelax|
418192|NCT01000688|Drug|vildagliptin + acarbose|4 week treatment
418193|NCT01000688|Drug|acarbose + vildagliptin|4 week treatment
418194|NCT01000662|Radiation|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
418195|NCT01000662|Radiation|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
418196|NCT01000649|Drug|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
418197|NCT01000649|Drug|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
418198|NCT01000649|Drug|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
418199|NCT01000649|Other|Placebo|Isotonic saline infused.
418200|NCT01000636|Procedure|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp."
418201|NCT01000623|Drug|venlafaxine|Given orally
418202|NCT01000623|Drug|placebo|Given orally
418203|NCT01000623|Procedure|hypnotherapy|Practice hypnosis
418204|NCT01000623|Procedure|mind-body intervention procedure|Practice focused attention
418205|NCT01000610|Drug|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
418206|NCT01000610|Drug|methotrexate|10-25 mg weekly (oral or parenteral)
418207|NCT01000610|Drug|methylprednisolone|100 mg iv prior to each rituximab infusion
418208|NCT01000597|Drug|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).~A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
418209|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
418210|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
418211|NCT01000558|Other|biologic sample preservation procedure|
418212|NCT01000545|Drug|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
418213|NCT01000545|Drug|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
418214|NCT01000532|Device|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
418215|NCT01000532|Device|Pacemaker therapy|Pacemaker therapy
418216|NCT01000532|Device|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
418217|NCT01000519|Other|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
418218|NCT01000519|Other|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
418219|NCT01000506|Biological|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
418220|NCT01000506|Biological|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
418221|NCT01000506|Biological|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
418222|NCT01000506|Drug|Placebo saline|Placebo saline every four weeks by i.v.
418223|NCT01000493|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
418224|NCT01000493|Other|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
418225|NCT01000480|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
418226|NCT01000480|Drug|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
418227|NCT01000480|Radiation|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
418228|NCT01000467|Drug|probucol|group 3: 250 mg 1 tablet in the morning and evening
418229|NCT01000467|Drug|probucol|group 1: 250 mg
418230|NCT01000467|Drug|probucol|group 2: 250 mg 2 tablets at once in the morning
418231|NCT01000441|Drug|infliximab, etanercept, adalimumab|
418232|NCT01000441|Drug|abatacept, rituximab or tocilizumab|
418233|NCT01000415|Other|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
418234|NCT01000402|Drug|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
418235|NCT01000389|Device|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
418236|NCT01000376|Drug|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m^2 alone on Day 1, then eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
418237|NCT01000376|Drug|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
418238|NCT01000350|Drug|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
418239|NCT01000350|Other|Placebo|Placebo x1 lactose tablet
418240|NCT01000337|Drug|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
418241|NCT01000337|Drug|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
418242|NCT01000324|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
418243|NCT01000324|Biological|Engerix-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
418244|NCT01000324|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
418245|NCT01000311|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
418246|NCT01000311|Biological|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
418247|NCT01000311|Biological|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
418248|NCT01000311|Biological|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
418249|NCT01000311|Biological|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
418250|NCT01000298|Drug|Placebo|liquid placebo medication given twice per day for 7 days
418251|NCT01000298|Drug|Amoxicillin|liquid amoxicillin given twice per day for 7 days
418252|NCT01000298|Drug|Cefdinir|liquid cefdinir given twice per day for 7 days
418253|NCT01000285|Drug|Bortezomib|
418254|NCT01000285|Drug|Etoposide|
418255|NCT01000285|Drug|Vincristine|
418256|NCT01000285|Drug|Doxorubicin|
418257|NCT01000285|Drug|Prednisone|
418258|NCT01000285|Drug|Cyclophosphamide|
418259|NCT01000285|Drug|Raltegravir|
418260|NCT01000259|Other|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
418261|NCT01000246|Biological|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
418262|NCT01000233|Dietary Supplement|Phytine (phytate)|300 mg tid * 24 months
418263|NCT01000233|Dietary Supplement|Placebo|Phytine (Phytate)
418264|NCT01000220|Drug|Omeprazole|
418265|NCT01000220|Drug|Placebo|
418266|NCT01000207|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
418267|NCT01000194|Dietary Supplement|High fat meal|A high fat milkshake containing 55g of fat
418268|NCT01000181|Other|PET-CT with CuATSM|PET-CT with CuATSM
418269|NCT01000168|Other|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.~The conventional group received traditional walking therapy for the same time period."
418270|NCT01000155|Drug|vorinostat|
418271|NCT01000142|Procedure|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
418272|NCT01000142|Procedure|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
418273|NCT01000129|Other|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
418274|NCT01000129|Other|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
418275|NCT01000116|Procedure|Fibrin glue|Tissucol 2 ml
418276|NCT01000116|Procedure|Tacks|Protacks
418277|NCT01000103|Device|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
418278|NCT01000103|Device|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
418279|NCT01000064|Drug|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
418280|NCT01000064|Procedure|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
418281|NCT01000064|Drug|Placebo|Placebo capsules taken every morning for 6 weeks.
418282|NCT01000051|Drug|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
418283|NCT01000051|Drug|Placebo|Once a day, orally for 8 weeks.
418284|NCT01000038|Other|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
418285|NCT01000038|Other|Walking|Half hour daily, five days a week for 8 weeks
418286|NCT01000025|Drug|PF-00299804|PF-804 45 mg PO, daily
418287|NCT01000025|Drug|Placebo|Placebo 45 mg PO, daily
418288|NCT01000012|Device|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
418289|NCT01000012|Device|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.~The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
418726|NCT00996502|Drug|Erlotinib|200 mg of Erlotinib PO daily days 2-16
418290|NCT00999999|Procedure|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
418291|NCT00999986|Drug|cyclophosphamide|50 mg oral per day for 7 days
418292|NCT00999973|Drug|Mitomycin C 0.02%|
418293|NCT00999973|Drug|Placebo|
418294|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
418295|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
418296|NCT00999921|Drug|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
418297|NCT00999921|Drug|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
418298|NCT00999908|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
418299|NCT00999908|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
418300|NCT00999908|Drug|Placebo|Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
418301|NCT00999882|Drug|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
418302|NCT00999869|Drug|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
418303|NCT00999869|Drug|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
418304|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
418305|NCT00999856|Device|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
418306|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
418307|NCT00999856|Device|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
418308|NCT00999856|Device|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
418309|NCT00999843|Drug|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
418310|NCT00999830|Drug|IPH2101|One infusion of IPH2101 every 4 weeks
418311|NCT00999817|Drug|reference [dextromethorphan]|single 30 mg oral dose
418312|NCT00999817|Drug|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
418313|NCT00999804|Drug|Lapatinib|1000 mg of Lapatinib by mouth daily
418314|NCT00999804|Drug|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
418315|NCT00999804|Drug|Trastuzumab|6 mg/kg intravenously, every 3 weeks
418316|NCT00999791|Drug|Bevacizumab|
418317|NCT00999791|Drug|Diclofenac|
418318|NCT00999778|Behavioral|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
418319|NCT00999778|Behavioral|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
418320|NCT00999765|Behavioral|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
418321|NCT00999752|Drug|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure <140/90
418322|NCT00999752|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
418323|NCT00999739|Biological|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
418324|NCT00999713|Drug|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
418325|NCT00999713|Other|Air placebo|Endotracheal air administration
418326|NCT00999700|Drug|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
418327|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
418328|NCT00999700|Drug|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
418329|NCT00999700|Drug|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
418330|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.~Standard radiotherapy:~Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
418331|NCT00999687|Drug|Indigo Naturalis Extract in Oil|Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks
418457|NCT00998673|Device|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
418727|NCT00996502|Drug|Prednisone|5 mg of Prednisone PO bid
418332|NCT00999687|Other|Olive Oil|Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
418333|NCT00999674|Other|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
418334|NCT00999648|Other|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
418335|NCT00999648|Other|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
418336|NCT00999635|Device|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
418337|NCT00999622|Other|laboratory biomarker analysis|
418338|NCT00999622|Other|questionnaire administration|
418339|NCT00999609|Biological|AAV2-hRPE65v2,voretigene neparvovec-rzyl|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
418340|NCT00999583|Drug|EPOETINE ALPHA|5 injections of 40000 UI of EPO
418341|NCT00999583|Other|Control arm|Usual take care of cardiac arrest
418342|NCT00999570|Other|Specialty training for knee surgeons|
418343|NCT00999557|Drug|bimatoprost ophthalmic solution|Applied topically
418344|NCT00999557|Drug|placebo|Applied topically
418345|NCT00999544|Drug|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
418346|NCT00999544|Drug|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
418347|NCT00999544|Drug|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
418348|NCT00999544|Drug|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
418349|NCT00999544|Drug|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
418350|NCT00999544|Drug|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
418351|NCT00999544|Drug|Oxycodone 0mg, IN|Oxycodone 0mg, IN
418352|NCT00999544|Drug|Oxycodone 15mg, IN|Oxycodone 15mg, IN
418353|NCT00999544|Drug|Oxycodone 30mg, IN|Oxycodone 30mg, IN
418354|NCT00999531|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
418355|NCT00999531|Drug|Placebo|Inhaled Placebo, sterile saline
418356|NCT00999518|Biological|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
418357|NCT00999518|Biological|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
418358|NCT00999518|Biological|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
418359|NCT00999518|Biological|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
418360|NCT00999518|Other|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
418361|NCT00999505|Drug|Amantadine|Amantadine 200mg twice a day over 12 weeks
418362|NCT00999505|Drug|Placebo|Placebo capsules twice a day over 12 weeks
418363|NCT00999492|Device|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
418364|NCT00999479|Drug|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
418365|NCT00999479|Drug|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
418366|NCT00999466|Drug|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
418367|NCT00999466|Drug|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
418368|NCT00999453|Other|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
418369|NCT00999440|Drug|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
418370|NCT00999427|Drug|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
418458|NCT00998673|Device|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
418459|NCT00998660|Device|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
418371|NCT00999414|Drug|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.~Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.~For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
418372|NCT00999401|Drug|sapacitabine and seliciclib|sequential or concomitant administration of sapacitabine and seliciclib
418373|NCT00999375|Behavioral|Education|
418374|NCT00999375|Behavioral|Problem Solving|
418375|NCT00999375|Behavioral|Social Learning|
418376|NCT00999375|Behavioral|Behavior Modification|
418377|NCT00999349|Drug|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
418378|NCT00999349|Drug|Placebo|
418379|NCT00999336|Drug|Betrixaban|80 mg betrixaban qd for 8 days
418380|NCT00999323|Device|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
418381|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
418382|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
418383|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
418384|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
418385|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
418386|NCT00999284|Drug|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
418387|NCT00999271|Other|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:~0.8 pmol/kg/min~1.5 pmol/kg/min for 300 minutes"
418388|NCT00999258|Drug|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.~The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
418389|NCT00999245|Other|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
418390|NCT00999245|Other|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
418391|NCT00999232|Drug|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
418392|NCT00999232|Drug|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
418393|NCT00999219|Drug|FK199B|oral
418394|NCT00999219|Drug|Zolpidem|oral
418395|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
418396|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
418397|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
418398|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
418399|NCT00999193|Procedure|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
418400|NCT00999193|Procedure|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
418401|NCT00999193|Other|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
418402|NCT00999180|Procedure|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
418403|NCT00999180|Procedure|Saline and Kinesiotherapy|Saline and Kinesiotherapy
418404|NCT00999167|Drug|HPN-100|Part B: 6 mL BID for 16 weeks.
418405|NCT00999167|Drug|Placebo|Part B: same as experimental arm
418406|NCT00999141|Biological|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
418407|NCT00999128|Drug|GDC-0941|Oral repeating dose
418408|NCT00999128|Drug|rabeprazole|Oral repeating dose
418409|NCT00999115|Drug|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
418410|NCT00999102|Drug|Metoprolol|Metoprolol 50 mg, Metoprolol 100 mg,
418411|NCT00999102|Drug|Nebivolol|Nebivolol 5 mg, Nebivolol 10 mg.
418412|NCT00999089|Procedure|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
418413|NCT00999089|Procedure|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
418414|NCT00999089|Procedure|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
418460|NCT00998647|Device|modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus|usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
418461|NCT00998634|Drug|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
418415|NCT00999050|Procedure|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
418416|NCT00999037|Drug|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
418417|NCT00999037|Other|Placebo|1 inert tablet tid x 12 weeks
418418|NCT00999011|Procedure|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
418419|NCT00999011|Procedure|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
418420|NCT00998998|Behavioral|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
418421|NCT00998998|Behavioral|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
418422|NCT00998998|Dietary Supplement|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
418423|NCT00998985|Drug|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
418424|NCT00998985|Drug|Placebo|Placebo tablet, orally, once a day for 7 days
418425|NCT00998972|Drug|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
418426|NCT00998959|Behavioral|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
418427|NCT00998959|Behavioral|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
418428|NCT00998946|Drug|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~Initial dose: 30 mg/m2~Dose reductions: to 20 mg/m2 weekly per protocol defined criteria.~Administered on days 1, 8 and 15 of a 4-week (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
418429|NCT00998946|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
418430|NCT00998946|Dietary Supplement|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
418431|NCT00998933|Drug|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
418432|NCT00998920|Drug|S-equol|oral, BID, 14 days
418433|NCT00998920|Drug|Placebo|oral, BID, 14 days
418434|NCT00998907|Device|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
418435|NCT00998907|Device|PDS II|polyglactin 910 suture material for abdominal wall closure
418436|NCT00998881|Drug|Teneligliptin 20 mg|
418437|NCT00998881|Drug|Placebo|
418438|NCT00998855|Behavioral|Exercise|12 wk aerobic or/ resistance exercise program
418439|NCT00998842|Device|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
418440|NCT00998842|Device|GE 5000 ECG Monitor System|Wired ECG system
418441|NCT00998829|Other|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
418442|NCT00998816|Drug|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
418443|NCT00998790|Device|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
418444|NCT00998777|Procedure|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
418445|NCT00998764|Drug|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
418446|NCT00998751|Drug|oral masitinib|7.5 mg/kg/day
418447|NCT00998738|Drug|Calcium Gluconate|Given IV
418448|NCT00998738|Drug|Magnesium Sulfate|Given IV
418449|NCT00998738|Other|Placebo|Given IV
418450|NCT00998738|Other|Quality-of-Life Assessment|Ancillary studies
418451|NCT00998738|Other|Questionnaire Administration|Ancillary studies
418452|NCT00998738|Drug|Ixabepilone|Given IV
418453|NCT00998699|Drug|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
418454|NCT00998699|Drug|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
418455|NCT00998686|Drug|dutogliptin|400 mg
418456|NCT00998686|Drug|sitagliptin|100 mg
418464|NCT00998595|Other|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
418465|NCT00998582|Drug|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
418466|NCT00998569|Behavioral|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
418467|NCT00998569|Behavioral|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
418468|NCT00998556|Drug|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
418469|NCT00998517|Dietary Supplement|Soy/peanut fortified spread|75kcal/kg/day
418470|NCT00998517|Dietary Supplement|Milk fortified corn/soy blend|75 kcal/kg/day
418471|NCT00998517|Dietary Supplement|Supplementary Plumpy®|75 kcal/kg/day
418472|NCT00998504|Dietary Supplement|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
418473|NCT00998504|Dietary Supplement|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
418474|NCT00998478|Other|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
418475|NCT00998465|Other|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
418476|NCT00998465|Other|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
418477|NCT00998465|Other|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
418478|NCT00998465|Radiation|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
418479|NCT00998465|Radiation|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
418480|NCT00998465|Radiation|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
418481|NCT00998465|Other|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
418482|NCT00998465|Other|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
418483|NCT00998465|Dietary Supplement|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
418484|NCT00998452|Behavioral|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
418485|NCT00998439|Device|SeQuent® Please|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
418486|NCT00998439|Device|SeQuent® II|"6 F, 7 F, or 8 F guiding catheters have to be used~after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))~additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour~Nitroglycerin (0.2 mg i.c.) prior to first contrast injection~ISR must be predilated with uncoated balloon~balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use~inflation time has to be ≥ 30 sec~select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %~each Paclitaxel-eluting balloon catheter is allowed for single use only~additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness~if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
418521|NCT00998153|Behavioral|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
418522|NCT00998114|Behavioral|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
418523|NCT00998101|Drug|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
418487|NCT00998426|Procedure|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
418488|NCT00998426|Biological|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
418489|NCT00998413|Behavioral|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
418490|NCT00998400|Behavioral|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
418491|NCT00998361|Procedure|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
418492|NCT00998348|Behavioral|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
418493|NCT00998335|Drug|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
418494|NCT00998335|Drug|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
418495|NCT00998322|Biological|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
418496|NCT00998322|Drug|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
418497|NCT00998309|Drug|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
418498|NCT00998296|Drug|BIBW 2992|EGFR inhibitor
418499|NCT00998296|Drug|BIBF 1120|VEGF inhibitor
418500|NCT00998283|Drug|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
418501|NCT00998283|Drug|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
418502|NCT00998283|Drug|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
418503|NCT00998283|Drug|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
418504|NCT00998283|Drug|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
418505|NCT00998283|Drug|Placebo|Subcutaneously administrate at 0 hour on Day 1
418506|NCT00998270|Procedure|Autologous bone marrow transplantation|"Autologous transplantation:~Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day~G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days~Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
418507|NCT00998270|Procedure|Allogeneic bone marrow transplantation|"Allogeneic~Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days~Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
418508|NCT00998257|Drug|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
418509|NCT00998244|Other|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
418510|NCT00998231|Biological|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
418511|NCT00998218|Drug|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
418512|NCT00998218|Drug|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
418513|NCT00998205|Drug|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.
418514|NCT00998205|Drug|Atropine bolus|If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
418515|NCT00998192|Biological|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
418516|NCT00998192|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
418517|NCT00998192|Drug|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
418518|NCT00998179|Device|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
418519|NCT00998179|Device|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
418520|NCT00998166|Drug|Pemetrexed, Cisplatin, Bevacizumab|"Pre-hydration for 1-1/2 hours at 250 ml/hour~Pemetrexed 500 mg/m2 IV over 10 minutes~Return to hydration for 30 minutes at 250 ml/hour~Cisplatin 75mg/m2 IV over 60-120 minutes~Bevacizumab 15mg/kg IV over 90 minutes"
418524|NCT00998101|Drug|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
418525|NCT00998101|Drug|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
418526|NCT00998088|Other|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
418527|NCT00998088|Drug|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
418528|NCT00998088|Device|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
418529|NCT00998088|Device|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
418530|NCT00998088|Other|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
418531|NCT00998088|Other|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
418532|NCT00998088|Device|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
418533|NCT00998075|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
418534|NCT00998075|Drug|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
418535|NCT00998075|Drug|ASA|Tablet, oral, single dose
418536|NCT00998049|Drug|plerixafor|Plerixafor 160mg/kg/dose by IV on days 5-8
418537|NCT00998049|Drug|filgrastim|Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
418538|NCT00998036|Drug|Temsirolimus|"Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg"
418539|NCT00998036|Drug|Cisplatin|Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
418540|NCT00998036|Drug|Erlotinib|"Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg"
418541|NCT00998023|Device|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
418542|NCT00998023|Device|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
418543|NCT00998010|Drug|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200cGy daily doses to a total dose of 6000 cGy.
418544|NCT00997997|Drug|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
418545|NCT00997984|Drug|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
418546|NCT00997984|Drug|placebo|dosed in the AM or PM
418547|NCT00997984|Drug|extended-release guanfacine hydrochloride|Dosed in the PM
418548|NCT00997971|Other|Modilac Rose 1|Infant formula used for non-breastfed children
418549|NCT00997958|Drug|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.~Each patient will be treated for eight weeks (56 days)."
418550|NCT00997945|Drug|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
418551|NCT00997932|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
418552|NCT00997919|Drug|MABT5102A|single SC dose
418553|NCT00997919|Drug|MABT5102A|single IV dose
418554|NCT00997906|Drug|carboplatin,|Given IV
418555|NCT00997906|Drug|cisplatin|Given IV
418556|NCT00997906|Drug|gemcitabine hydrochloride|Given IV
418557|NCT00997906|Drug|paclitaxel|Given IV
418558|NCT00997906|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
418559|NCT00997893|Dietary Supplement|Phytoestrogen|Women in the phytoestrogen intervention group will take one active Novasoy® (55 mg) pill at breakfast and active Novasoy® (55 mg) pill at dinner, for a total daily dose of 110 mg Novasoy® and 0 mg estradiol.
418560|NCT00997893|Drug|Estradiol|Women in estradiol intervention group will take one active estradiol pill (1 mg) at breakfast and one placebo pill at dinner, for a total daily dose of 1 mg estradiol and 0 mg Novasoy®.
418561|NCT00997893|Drug|medroxyprogesterone acetate|At week 12 , after the participant completes her final assessments, women will begin taking MPA (10 mg/d for 10 days).
418562|NCT00997893|Other|Placebo|Women in this intervention group will take one placebo pill at breakfast and one placebo pill at dinner, for a total daily dose of 0 mg Novasoy® and 0 mg estradiol.
418563|NCT00997893|Other|Placebo|At week 12, after the participant completes her final assessments, women will begin taking placebo(10 days).
418564|NCT00997880|Drug|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
418565|NCT00997880|Drug|Rosuvastatin calcium10mg|Rosuvastatin 10mg
418566|NCT00997867|Procedure|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
418567|NCT00997854|Other|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
418568|NCT00997841|Procedure|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
418569|NCT00997828|Device|everolimus-eluting stent|Xience V stent
418570|NCT00997828|Procedure|coronary artery bypass graft surgery|coronary artery bypass graft surgery
418571|NCT00997815|Drug|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
418572|NCT00997815|Drug|Normal saline injection|Using normal saline 2.5 ml injected in control side
418573|NCT00997802|Device|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
418574|NCT00997789|Drug|Rebamide|Rebamipide 100 mg Tablet, three times a day
418575|NCT00997776|Other|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
418576|NCT00997776|Other|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
418577|NCT00997763|Device|XIENCE V|everolimus-eluting stent
418578|NCT00997763|Device|CYPHER|sirolimus-eluting stent
418579|NCT00997750|Drug|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
418580|NCT00997737|Device|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
418581|NCT00997724|Procedure|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
418582|NCT00997711|Device|Cypher|Sirolimus-eluting stents
418583|NCT00997685|Drug|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,~4 pre-operative cycles, 4 post-operative cycles"
418584|NCT00997672|Drug|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
418585|NCT00997672|Drug|Placebo|
418586|NCT00997659|Dietary Supplement|chromium picolinate|1000 mg per day
418587|NCT00997620|Drug|Fluticasone furoate Nasal Spray 110 mcg|Fluticasone fuorate nasal spray 110 mcg 2 sprays each nostril am will be compared to similar appearing placebo given 2 sprays each nostril am. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of fluticasone furoate 110 mcg once daily and continue the evaluations.
418588|NCT00997620|Drug|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo. The subjects will receive one week placebo nasal spray to establish a baseline then they will then be switched to a nasal spray of Placebo once daily and continue the evaluations.
418589|NCT00997607|Biological|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
418590|NCT00997607|Biological|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
418591|NCT00997607|Other|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
418592|NCT00997594|Procedure|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
418593|NCT00997581|Drug|apremilast|apremilast 20 mg taken twice daily by mouth
418594|NCT00997581|Drug|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
418595|NCT00997568|Device|PET-511BTM|Transesophageal Transducer
418596|NCT00997555|Procedure|bronchoscopy|Scheduled bronchoscopy.
418597|NCT00997542|Drug|Allopurinol|
418598|NCT00997542|Drug|Placebo|
418599|NCT00997529|Drug|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 & 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 & 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction & immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression & do not have signs of GVHD, will receive a DLI
418600|NCT00997516|Procedure|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
418601|NCT00997516|Procedure|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
418602|NCT00997503|Device|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
418603|NCT00997503|Drug|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
418604|NCT00997503|Drug|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
418605|NCT00997503|Drug|aspirin|"Oral, as prescribed by physician through end of study.~."
418606|NCT00997490|Drug|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
418607|NCT00997490|Drug|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
418608|NCT00997477|Drug|Foradil Combi (Formoterol-budesonide)|
418609|NCT00997451|Behavioral|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
418610|NCT00997451|Behavioral|Symptom monitoring|Daily symptom via web diary
418611|NCT00997438|Dietary Supplement|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
418612|NCT00997425|Device|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
418613|NCT00997412|Drug|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
418614|NCT00997412|Drug|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
418615|NCT00997399|Drug|panobinostat (LBH589)|
418616|NCT00997386|Drug|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
418617|NCT00997373|Drug|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
418618|NCT00997360|Drug|PKI-179|
418619|NCT00997347|Drug|Mifepristone and misoprostol|"200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
418620|NCT00997334|Drug|Erlotinib|
418621|NCT00997321|Drug|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
418622|NCT00997321|Drug|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
418623|NCT00997308|Drug|AZD1446|Solution, oral, for 4 weeks
418624|NCT00997308|Drug|Placebo|
418625|NCT00997282|Drug|OPC-262 2.5 mg|orally administered once daily for 24 weeks
418626|NCT00997282|Drug|OPC-262 5 mg|orally administered once daily for 24 weeks
418627|NCT00997282|Drug|Placebo|orally administered once daily for 24 weeks
418628|NCT00997269|Dietary Supplement|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
418629|NCT00997269|Dietary Supplement|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
418630|NCT00997256|Drug|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
418631|NCT00997256|Drug|film-coated sugar-pill|3 x 2 tablets / day over 3 days
418632|NCT00997243|Biological|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
418633|NCT00997243|Drug|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
418634|NCT00997217|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
418635|NCT00997204|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
418636|NCT00997191|Procedure|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
418637|NCT00997191|Drug|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
418638|NCT00997191|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
418639|NCT00997178|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
418640|NCT00997178|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
418641|NCT00997152|Drug|JTT-654|Tablets
418642|NCT00997152|Drug|JTT-654 Placebo|Tablets
418643|NCT00997139|Drug|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
418644|NCT00997126|Drug|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
418645|NCT00997126|Drug|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
418646|NCT00997113|Drug|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
418647|NCT00997113|Drug|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
418648|NCT00997100|Drug|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
418649|NCT00997087|Drug|Flumazenil|Sublingual daily
418650|NCT00997074|Drug|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
418651|NCT00997061|Drug|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
418652|NCT00997048|Procedure|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
418653|NCT00997048|Procedure|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
418685|NCT00996801|Drug|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
418686|NCT00996801|Drug|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
418654|NCT00997035|Drug|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing <40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
418655|NCT00997035|Drug|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.~Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
418656|NCT00997022|Drug|Sorafenib|"Dose escalation:~Dose level 1: 200mg of sorafenib daily~Dose level 2: 200mg of sorafenib BID (twice daily)~Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)~Dose level 4: 400mg BID (twice daily)"
418657|NCT00997009|Drug|paclitaxel|175 mg/m2 IV day 1, every 21 days
418658|NCT00997009|Drug|carboplatin|AUC 5 IV day 1 every 21 days
418659|NCT00997009|Drug|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
418660|NCT00996996|Biological|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
418661|NCT00996983|Drug|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
418662|NCT00996957|Biological|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
418663|NCT00996944|Drug|Ropinirole immediate release (IR)|"Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem."
418664|NCT00996944|Drug|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
418665|NCT00996931|Drug|lenalidomide|2.5 mgs per day orally for 12 weeks
418666|NCT00996918|Drug|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
418667|NCT00996918|Drug|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
418668|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
418669|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
418670|NCT00996892|Drug|Cobimetinib|Repeated oral dosing.
418671|NCT00996892|Drug|Pictilisib|Repeated oral dosing.
418672|NCT00996879|Drug|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
418673|NCT00996879|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
418674|NCT00996866|Drug|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
418675|NCT00996866|Drug|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
418676|NCT00996853|Other|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
418677|NCT00996840|Drug|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
418678|NCT00996840|Drug|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
418679|NCT00996840|Drug|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
418680|NCT00996840|Drug|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
418681|NCT00996840|Other|Placebo|Placebo to match intervention
418682|NCT00996814|Behavioral|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
418683|NCT00996801|Drug|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
418684|NCT00996801|Drug|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
418687|NCT00996801|Drug|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
418688|NCT00996801|Drug|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
418689|NCT00996788|Drug|Rebamipide|Rebamipide 100 mg tid for 28 days
418690|NCT00996775|Behavioral|brief alcohol intervention|this intervention consists of brief assessment and feedback
418691|NCT00996775|Behavioral|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
418692|NCT00996762|Drug|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
418693|NCT00996749|Dietary Supplement|omega-3 fatty acid|Given PO
418694|NCT00996749|Other|bone scan|Correlative studies
418695|NCT00996749|Other|dual x-ray absorptometry|Correlative studies
418696|NCT00996749|Other|laboratory biomarker analysis|Correlative studies
418697|NCT00996749|Procedure|biopsy|Correlative studies
418698|NCT00996736|Drug|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
418699|NCT00996736|Drug|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
418700|NCT00996723|Drug|vandetanib and dasatinib|Two oral investigational agents (vandetanib [VEGFR2, RET, and EGFR inhibitor] and dasatinib [bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
418701|NCT00996697|Drug|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
418702|NCT00996697|Drug|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
418703|NCT00996684|Drug|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
418704|NCT00996684|Drug|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
418705|NCT00996671|Drug|GSK2256098|focal adhesion kinase inhibitor given as a single dose
418706|NCT00996671|Drug|Placebo|Placebo to be used as comparator for GSK2256098
418707|NCT00996658|Drug|Placebo|Placebo matching linagliptin tablets once daily
418708|NCT00996658|Drug|Linagliptin|Linagliptin tablets once daily
418709|NCT00996645|Other|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
418710|NCT00996632|Procedure|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
418711|NCT00996632|Procedure|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
418712|NCT00996619|Procedure|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
418713|NCT00996606|Drug|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
418714|NCT00996606|Drug|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
418715|NCT00996593|Biological|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
418716|NCT00996580|Drug|DR-103|"One tablet daily.~Four 91-day cycles of the DR-103 regimen:~42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
418717|NCT00996567|Drug|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
418718|NCT00996554|Procedure|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
418719|NCT00996554|Procedure|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
418720|NCT00996541|Behavioral|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
418721|NCT00996528|Behavioral|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
418722|NCT00996515|Drug|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
418723|NCT00996515|Drug|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
418724|NCT00996502|Drug|Docetaxel|"Phase I:~Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
418725|NCT00996502|Drug|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
418728|NCT00996489|Device|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
418729|NCT00996476|Drug|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
418730|NCT00996476|Drug|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
418731|NCT00996476|Drug|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
418732|NCT00996463|Procedure|Electro-thermo-coagulation|Electro-thermo-coagulation
418733|NCT00996463|Drug|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
418734|NCT00996463|Drug|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
418735|NCT00996437|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
418736|NCT00996437|Drug|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
418737|NCT00996424|Drug|Acetylcysteine|Inhalation with N-Acetylcysteine
418738|NCT00996424|Drug|normal saline|Inhalation with normal saline solution
418739|NCT00996411|Drug|Salvinorin A|This is an initial dose ranging study
418740|NCT00996398|Other|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
418741|NCT00996385|Drug|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
418742|NCT00996372|Drug|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
418743|NCT00996372|Drug|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
418744|NCT00996359|Biological|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
418745|NCT00996359|Radiation|total-body irradiation|100 cGy TBI
418746|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
418747|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
418748|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
418749|NCT00996333|Drug|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11~This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
418750|NCT00996320|Other|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
418751|NCT00996307|Biological|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
418752|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
418753|NCT00996307|Biological|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
418754|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
418755|NCT00996294|Procedure|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
418756|NCT00996281|Drug|Azilsartan medoxomil and chlorthalidone|Combination tablet.
418757|NCT00996281|Drug|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
418758|NCT00996268|Drug|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
418759|NCT00996268|Drug|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
418760|NCT00996255|Drug|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
418761|NCT00996242|Drug|L-lysine|6 g/day for four weeks
418762|NCT00996229|Behavioral|Caloric restriction|20-30% CR for 6 months
418763|NCT00996229|Dietary Supplement|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
418764|NCT00996229|Dietary Supplement|Placebo|Daily corn oil capsules for 6 months
418765|NCT00996229|Dietary Supplement|Resveratrol|daily resveratrol for 6 months
418766|NCT00996216|Drug|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
418767|NCT00996216|Drug|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
418768|NCT00996203|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
418769|NCT00996203|Drug|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
418770|NCT00996190|Drug|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
418771|NCT00996177|Drug|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
418772|NCT00996177|Drug|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
418773|NCT00996164|Drug|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
418774|NCT00996164|Drug|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
418775|NCT00996151|Drug|Testosterone MD-Lotion|Single dose Testosterone MD-Lotion 2%
418776|NCT00996138|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
418777|NCT00996125|Biological|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
418778|NCT00996125|Other|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
418779|NCT00996099|Device|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
418780|NCT00996099|Other|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
418781|NCT00996086|Device|CRT device implant|CRT device-recipients
418782|NCT00996073|Biological|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
418783|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
418784|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
418785|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~In this cohort, Hydralazine is administered at 10 mg/day."
418786|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 25 mg/day in this cohort."
418787|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 50 mg/day in this cohort."
418788|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
418789|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
418790|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
418791|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.~Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
418792|NCT00996047|Genetic|cytogenetic analysis|
418793|NCT00996047|Genetic|fluorescence in situ hybridization|
418794|NCT00996034|Biological|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
418795|NCT00996034|Radiation|[123I]5-IA-85380|up to 10 mCi of [123I]5-IA-85380, I.V. on each of two SPECT Scan days
418796|NCT00996034|Drug|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
418797|NCT00996021|Drug|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
418798|NCT00996021|Drug|Placebo Suspension|Placebo is a liquid with no drug in it.
418799|NCT00996021|Drug|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
418800|NCT00996008|Drug|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
418801|NCT00996008|Drug|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
418802|NCT00995995|Drug|Rosiglitazone|Rosiglitazone
418803|NCT00995982|Biological|VRC-FLUDNA056-00VP|
418804|NCT00995969|Drug|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
418805|NCT00995969|Drug|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
418806|NCT00995930|Drug|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
418807|NCT00995930|Drug|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
418808|NCT00995917|Other|Vitamin K acupoint injection|Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
418809|NCT00995917|Other|Saline Injection|Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
418810|NCT00995904|Drug|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
418811|NCT00995904|Drug|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
418812|NCT00995904|Drug|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
418972|NCT00994695|Biological|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
418813|NCT00995878|Procedure|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
418814|NCT00995878|Procedure|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
418815|NCT00995865|Biological|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10^8 VE/0.5mL and Mid dose = 2.2 x 10^7 VE/0.5mL
418816|NCT00995865|Biological|Placebo|NaCl Injectable 0.9%
418817|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
418818|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
418819|NCT00995839|Drug|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
418820|NCT00995839|Drug|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
418821|NCT00995839|Drug|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
418822|NCT00995826|Drug|CS-8958|Inhaled CS-8958
418823|NCT00995826|Other|Placebo|Inhaled placebo
418824|NCT00995813|Biological|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
418825|NCT00995800|Drug|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
418826|NCT00995787|Drug|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
418827|NCT00995787|Drug|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
418828|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
418829|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
418830|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
418831|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
418832|NCT00995761|Drug|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
418833|NCT00995735|Procedure|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
418834|NCT00995735|Procedure|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
418835|NCT00995722|Drug|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
418836|NCT00995722|Drug|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
418837|NCT00995709|Drug|AIN457|
418838|NCT00995709|Drug|AIN457|
418839|NCT00995709|Drug|Placebo|
418840|NCT00995696|Behavioral|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
418841|NCT00995683|Drug|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
418842|NCT00995683|Drug|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
418843|NCT00995670|Drug|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
418844|NCT00995670|Drug|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
418845|NCT00995670|Drug|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
418846|NCT00995670|Drug|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
418847|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
418848|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
418849|NCT00995631|Procedure|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
418850|NCT00995618|Drug|Tranilast|Tranilast tablets, 300 mg, QD
418851|NCT00995618|Drug|Febuxostat|Febuxostat Tablets, 40 mg, QD
418852|NCT00995618|Drug|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
418853|NCT00995605|Drug|AMAP102|AMAP102 or Placebo
418930|NCT00995033|Drug|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
419018|NCT00994318|Drug|FCM (Ferric carboxymaltose) high ferritin target|
418854|NCT00995592|Behavioral|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
418855|NCT00995566|Drug|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
418856|NCT00995553|Behavioral|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
418857|NCT00995553|Behavioral|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
418858|NCT00995540|Drug|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
418859|NCT00995540|Drug|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
418860|NCT00995540|Drug|Placebo|Placebo tid subcutaneous injection for 12 weeks
418861|NCT00995501|Drug|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
418862|NCT00995501|Drug|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
418863|NCT00995501|Drug|anesthesia management|Light anesthesia to maintain BIS about 55
418864|NCT00995501|Other|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
418865|NCT00995501|Other|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
418866|NCT00995501|Other|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
418867|NCT00995488|Drug|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
418868|NCT00995475|Drug|Fluticasone propionate|
418869|NCT00995475|Drug|Placebo|
418870|NCT00995462|Behavioral|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
418871|NCT00995449|Biological|KB003|KB003 IV x5 doses
418872|NCT00995449|Other|Placebo Comparator|Placebo IV x5 doses
418873|NCT00995436|Device|Extraoral anchorage|Extra oral anchorage
418874|NCT00995436|Device|Miniscrews|Intraoral skeletal anchorage using mini screws
418875|NCT00995436|Device|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
418876|NCT00995423|Device|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
418877|NCT00995423|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent
418878|NCT00995410|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
418879|NCT00995397|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
418880|NCT00995397|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
418881|NCT00995384|Procedure|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
418882|NCT00995371|Device|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
418883|NCT00995371|Drug|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
418884|NCT00995358|Biological|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
418885|NCT00995345|Drug|KRP-104|Tablet
418886|NCT00995345|Drug|Placebo|Tablet
418887|NCT00995332|Drug|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
418888|NCT00995306|Drug|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks~Civamide Cream 0.01%, TID for 12 weeks"
418889|NCT00995293|Drug|DOCETAXEL|Intravenous
418890|NCT00995293|Drug|CISPLATIN|Intravenous
418891|NCT00995293|Drug|5-FLUOROURACIL|Intravenous
418892|NCT00995280|Device|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
418893|NCT00995280|Device|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
418894|NCT00995267|Behavioral|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:~5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories & pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.~Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
418931|NCT00995020|Procedure|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
418895|NCT00995254|Behavioral|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
418896|NCT00995241|Drug|Raltegravir|Raltegravir 800 mg / 24 hours.
418897|NCT00995215|Procedure|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
418898|NCT00995215|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
418899|NCT00995202|Other|diagnostic laboratory biomarker analysis|
418900|NCT00995202|Procedure|computed tomography|
418901|NCT00995202|Procedure|diagnostic colonoscopy|
418902|NCT00995202|Procedure|standard follow-up care|
418903|NCT00995202|Procedure|ultrasound imaging|
418904|NCT00995189|Device|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
418905|NCT00995189|Device|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
418906|NCT00995189|Device|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
418907|NCT00995150|Drug|LNG20|levonorgestrel-releasing intrauterine system for contraception
418908|NCT00995150|Drug|Mirena|Mirena intrauterine system
418909|NCT00995137|Biological|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
418910|NCT00995124|Drug|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
418911|NCT00995124|Drug|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
418912|NCT00995124|Drug|Moov Head Lice Solution|Single application for head lice with 10 min application time.
418913|NCT00995098|Dietary Supplement|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
418914|NCT00995098|Dietary Supplement|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
418915|NCT00995085|Drug|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
418916|NCT00995072|Drug|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
418917|NCT00995072|Drug|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
418918|NCT00995059|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
418919|NCT00995059|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
418920|NCT00995059|Drug|bortezomib|Given IV
418921|NCT00995059|Drug|melphalan|Given IV
418922|NCT00995059|Drug|anti-thymocyte globulin|Given IV
418923|NCT00995059|Drug|sirolimus|Given orally
418924|NCT00995059|Drug|tacrolimus|Given oral or IV
418925|NCT00995059|Radiation|total-body irradiation|Undergo total-body irradiation
418926|NCT00995046|Drug|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
418927|NCT00995046|Drug|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
418928|NCT00995033|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
418929|NCT00995033|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
418971|NCT00994708|Drug|esomeprazole|
419019|NCT00994318|Drug|FCM (Ferric carboxymaltose) low ferritin target|
418932|NCT00995020|Procedure|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
418933|NCT00995007|Drug|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
418934|NCT00995007|Drug|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
418935|NCT00994994|Drug|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
418936|NCT00994981|Drug|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
418937|NCT00994981|Drug|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
418938|NCT00994968|Drug|cyclophosphamide|
418939|NCT00994968|Drug|docetaxel|
418940|NCT00994968|Drug|doxorubicin hydrochloride|
418941|NCT00994968|Drug|tegafur-gimeracil-oteracil potassium|
418942|NCT00994968|Procedure|neoadjuvant therapy|
418943|NCT00994968|Procedure|therapeutic conventional surgery|
418944|NCT00994955|Device|selective retina therapy (SRT)|laser treatment
418945|NCT00994942|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
418946|NCT00994929|Biological|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
418947|NCT00994916|Drug|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
418948|NCT00994903|Drug|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
418949|NCT00994903|Drug|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
418950|NCT00994890|Biological|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
418951|NCT00994890|Biological|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
418952|NCT00994890|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
418953|NCT00994864|Drug|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
418954|NCT00994851|Drug|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
418955|NCT00994851|Drug|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
418956|NCT00994838|Other|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
418957|NCT00994825|Drug|Levosimendan|
418958|NCT00994825|Drug|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
418959|NCT00994812|Drug|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
418960|NCT00994799|Drug|ranibizumab|10mg/ml intravitreal injection
418961|NCT00994799|Radiation|macular grid-pattern laser|macular grid-pattern laser therapy
418962|NCT00994786|Drug|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
418963|NCT00994786|Drug|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
418964|NCT00994773|Drug|Simvastatin|daily doses for 14 days
418965|NCT00994773|Drug|Tenofovir|
418966|NCT00994773|Drug|Entecavir|Entecavir
418967|NCT00994760|Drug|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
418968|NCT00994747|Other|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
418969|NCT00994747|Other|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
418970|NCT00994734|Drug|Mifepristone|home administration of mifepristone
418973|NCT00994682|Drug|Pioglitazone study drug|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
418974|NCT00994682|Drug|Placebo|An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
418975|NCT00994682|Drug|Pioglitazone Open Label|Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
418976|NCT00994656|Device|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
418977|NCT00994643|Biological|Rituximab|Given IV
418978|NCT00994643|Biological|Interleukin-2|Given SC
418979|NCT00994617|Drug|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
418980|NCT00994617|Drug|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
418981|NCT00994604|Drug|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
418982|NCT00994591|Drug|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
418983|NCT00994578|Behavioral|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
418984|NCT00994578|Behavioral|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
418985|NCT00994578|Behavioral|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
418986|NCT00994565|Behavioral|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
418987|NCT00994552|Other|Pressure support ventilation|Pressure support ventilation
418988|NCT00994552|Other|Pressure control ventilation|Pressure control ventilation
418989|NCT00994539|Drug|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
418990|NCT00994526|Other|Ham|Ham : 180 g per day during 4 days
418991|NCT00994526|Other|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
418992|NCT00994526|Other|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
418993|NCT00994513|Dietary Supplement|Alpha Lipoic Acid|1200 mg/day
418994|NCT00994513|Dietary Supplement|Placebo|1200 mg/day
418995|NCT00994500|Drug|vorinostat|Given orally
418996|NCT00994500|Drug|bortezomib|Given IV
418997|NCT00994500|Other|pharmacological study|Correlative studies
418998|NCT00994500|Other|laboratory biomarker analysis|Correlative studies
418999|NCT00994487|Other|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
419000|NCT00994487|Other|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
419001|NCT00994474|Procedure|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
419002|NCT00994474|Procedure|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
419003|NCT00994461|Drug|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
419004|NCT00994461|Drug|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
419005|NCT00994461|Drug|Placebo|Placebo tablet three times a day with meal for 2 weeks
419006|NCT00994448|Drug|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
419007|NCT00994448|Drug|Placebo tablets|One placebo tablet twice daily
419008|NCT00994422|Drug|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
419009|NCT00994422|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
419010|NCT00994396|Dietary Supplement|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
419011|NCT00994396|Dietary Supplement|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
419012|NCT00994383|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
419013|NCT00994357|Device|Real-time CGM|See previous description.
419014|NCT00994357|Other|Standard care|See text.
419015|NCT00994344|Drug|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
419016|NCT00994344|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
419017|NCT00994331|Procedure|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
419020|NCT00994318|Drug|Oral Iron (Ferrous sulphate)|
419021|NCT00994305|Drug|N-acetylcysteine|600 mg bid po 0-7 PO
419022|NCT00994305|Drug|control|No treatment: standard care provided. No N-acetylcysteine administration.
419023|NCT00994292|Drug|YM150|oral
419024|NCT00994292|Drug|Placebo|oral
419025|NCT00994279|Behavioral|Yoga|Yoga sessions
419026|NCT00994279|Behavioral|Education|Educational Wellness Group
419027|NCT00994266|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
419028|NCT00994266|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
419029|NCT00994253|Drug|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
419030|NCT00994253|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
419031|NCT00994240|Procedure|Electrodessication & Curettage|Electrodessication & Curettage 1 or 3 cycles
419032|NCT00994227|Procedure|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
419033|NCT00994214|Drug|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
419034|NCT00994201|Other|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.~Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
419035|NCT00994188|Procedure|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
419036|NCT00994175|Drug|Pioglitazone|
419037|NCT00994175|Drug|Placebo|
419038|NCT00994162|Device|EZCARE Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
419039|NCT00994149|Drug|Diazoxide|10mg/kg/d divide every 8 hours
419040|NCT00994149|Drug|Ora-plus|placebo, give every 8 hours.
419041|NCT00994136|Drug|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
419042|NCT00994123|Drug|MM-121|MM-121 (SAR256212) = intravenous solution
419043|NCT00994123|Drug|Erlotinib|erlotinib = daily oral tablet
419044|NCT00994110|Drug|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
419045|NCT00994110|Other|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.~Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
419046|NCT00994097|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
419047|NCT00994097|Drug|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
419048|NCT00994097|Drug|Gemcitabine|Gemcitabine: 1,250 mg/m² intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
419049|NCT00994097|Drug|Pemetrexed|Pemetrexed: 500 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
419050|NCT00994084|Behavioral|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
419051|NCT00994084|Behavioral|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
419052|NCT00994071|Drug|Temozolomide|
419053|NCT00994071|Drug|ABT-888|
419054|NCT00994058|Device|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.~Patients with preterm contractions (< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
419055|NCT00994045|Biological|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
419056|NCT00994045|Biological|Fresh Frozen Plasma|
419057|NCT00994032|Procedure|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
419058|NCT00994032|Other|Medical treatment|standard antalgic medical treatment
419059|NCT00994006|Dietary Supplement|Magnesium oxide|520 mg of elemental magnesium q.d.
419060|NCT00994006|Dietary Supplement|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
419061|NCT00993980|Procedure|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
419062|NCT00993980|Procedure|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
419063|NCT00993967|Drug|idebenone|Idebenone 1350 mg/d, patients < or equal 45 kg Idebenone 2250 mg/d, patients > 45 kg
419064|NCT00993954|Procedure|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
419065|NCT00993941|Procedure|Autologous BMSCs transplantation|10 ml autologous BMSCs(7~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
419066|NCT00993941|Drug|Conserved therapy|Oral or intravenous administration
419067|NCT00993928|Behavioral|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
419068|NCT00993915|Drug|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
419069|NCT00993902|Procedure|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
419070|NCT00993902|Procedure|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
419071|NCT00993889|Behavioral|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
419072|NCT00993889|Behavioral|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
419073|NCT00993889|Behavioral|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
419074|NCT00993876|Drug|citalopram|20 to 30 mg per day for 4 weeks
419075|NCT00993876|Drug|reboxetine|4 to 8 mg per day for 4 weeks
419076|NCT00993876|Behavioral|interpersonal psychotherapy|
419077|NCT00993863|Drug|Placebo|single dose
419078|NCT00993863|Drug|ADL5859 30 mg|single dose
419079|NCT00993863|Drug|ADL5859 100 mg|single dose
419080|NCT00993863|Drug|ADL5859 200 mg|single dose
419081|NCT00993863|Drug|ibuprofen 400 mg|single dose
419082|NCT00993850|Behavioral|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
419083|NCT00993850|Other|Bipolar education|Psychoeducation
419084|NCT00993837|Procedure|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
419085|NCT00993824|Drug|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
419086|NCT00993824|Drug|placebo|
419087|NCT00993811|Device|Shang Ring circumcision|novel device for adult male circumcision
419088|NCT00993798|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
419089|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
419090|NCT00993798|Drug|Bupivacaine HCl Treatment 1c|20.0 ml
419091|NCT00993798|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
419092|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
419093|NCT00993798|Drug|Bupivacaine HCl Treatment 2c|20.0 ml
419094|NCT00993785|Device|Costar Coronary Stent Delivery System|
419095|NCT00993759|Drug|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
419096|NCT00993746|Drug|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
419097|NCT00993746|Drug|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
419098|NCT00993733|Procedure|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
419099|NCT00993720|Drug|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
419100|NCT00993720|Drug|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
419101|NCT00993720|Other|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
419102|NCT00993707|Drug|CTX-100 (formerly ETX-100) (hyaluronic acid)|"3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.~Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort."
419103|NCT00993694|Drug|chemotherapy|
419104|NCT00993694|Drug|dapsone|
419105|NCT00993694|Other|medical chart review|
419106|NCT00993694|Procedure|assessment of therapy complications|
419107|NCT00993681|Biological|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
419108|NCT00993681|Biological|TD Vaccine System|placebo
419109|NCT00993668|Other|Placebo|Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
419309|NCT00992381|Drug|PN400|500mg Naproxen and 20mg esomeprazole
419110|NCT00993668|Biological|Certolizumab pegol|Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
419111|NCT00993655|Drug|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
419112|NCT00993655|Drug|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
419113|NCT00993655|Drug|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
419114|NCT00993642|Drug|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
419115|NCT00993629|Drug|pregnenolone|"Administered adjunctively to treatment as usual"
419116|NCT00993629|Drug|placebo|adjunctive placebo
419117|NCT00993616|Drug|belinostat|Given IV
419118|NCT00993616|Drug|carboplatin|Given IV
419119|NCT00993603|Behavioral|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
419120|NCT00993590|Behavioral|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
419121|NCT00993577|Other|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
419122|NCT00993577|Device|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
419123|NCT00993577|Device|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
419124|NCT00993551|Procedure|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
419125|NCT00993538|Procedure|Blood sampling|
419126|NCT00993538|Procedure|Bone marrow aspiration|
419127|NCT00993525|Drug|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
419128|NCT00993512|Drug|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
419129|NCT00993512|Drug|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
419130|NCT00993512|Other|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
419131|NCT00993499|Drug|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
419132|NCT00993499|Drug|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
419133|NCT00993486|Biological|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
419134|NCT00993473|Drug|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve the following glycemic targets without hypoglycemia:~Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,~Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,~Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and~HbA1c <7.5%."
419135|NCT00993473|Drug|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U~Dose: titrated to achieve glycemic targets as described above for insulin glargine"
419136|NCT00993473|Drug|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
419137|NCT00993447|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
419138|NCT00993447|Biological|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
419139|NCT00993434|Behavioral|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
419140|NCT00993434|Behavioral|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
419141|NCT00993421|Drug|LY377604|Given daily, orally for 24 weeks
419142|NCT00993421|Drug|Sibutramine|given daily, orally for 24 weeks
419143|NCT00993421|Drug|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
419144|NCT00993421|Drug|Placebo sibutramine|given daily, orally for 24 weeks
419145|NCT00993421|Drug|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
419146|NCT00993421|Drug|Placebo LY377604|given daily, orally for 24 weeks
419147|NCT00993408|Device|ACT-293987 (NS-304)|
419148|NCT00993395|Behavioral|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
419149|NCT00993382|Drug|Celivarone|"Pharmaceutical form: capsule~Route of administration: oral"
419150|NCT00993382|Drug|Amiodarone|"Pharmaceutical form: capsule~Route of administration: oral"
419151|NCT00993382|Drug|Matching placebo|"Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake"
419152|NCT00993369|Other|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
419153|NCT00993356|Drug|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
419154|NCT00993356|Procedure|Transsphenoidal surgery|
419155|NCT00993343|Drug|Sirolimus/tacrolimus|Standard GVHD prophylaxis
419156|NCT00993343|Drug|cyclosporine/methotrexate|Standard GVHD prophylaxis
419157|NCT00993317|Drug|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
419158|NCT00993317|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
419159|NCT00993317|Drug|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.~The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
419160|NCT00993304|Drug|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
419161|NCT00993304|Drug|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
419162|NCT00993291|Procedure|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
419163|NCT00993291|Procedure|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
419164|NCT00993278|Dietary Supplement|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
419165|NCT00993278|Dietary Supplement|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
419166|NCT00993265|Drug|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
419167|NCT00993265|Drug|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
419168|NCT00993252|Procedure|CT Scan|CT scan
419169|NCT00993239|Drug|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
419170|NCT00993226|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
419171|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
419172|NCT00993226|Drug|Bupivacaine HCl Treatment 1c|40 ml
419173|NCT00993226|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
419174|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
419175|NCT00993226|Drug|Bupivacaine HCl Treatment 2c|40 ml
419176|NCT00993213|Procedure|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
419177|NCT00993213|Other|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
419178|NCT00993200|Genetic|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
419179|NCT00993200|Drug|Warfarin|Usual care warfarin dosing
419180|NCT00993187|Drug|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
419181|NCT00993187|Drug|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
419182|NCT00993187|Drug|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
419183|NCT00993187|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
419184|NCT00993174|Procedure|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
419185|NCT00993174|Procedure|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
419186|NCT00993161|Device|Motriplate|Number of contact couples
419187|NCT00993161|Device|Motriplate|Number of contact couples
419188|NCT00993148|Drug|maraviroc|150 mg tab by mouth once daily for 96 weeks
419189|NCT00993148|Drug|darunavir|800 mg tab by mouth once daily for 96 weeks
419190|NCT00993148|Drug|ritonavir|100 mg capsule by mouth once daily for 96 weeks
419191|NCT00993135|Drug|methotrexate|
419192|NCT00993135|Other|medical chart review|
419193|NCT00993135|Procedure|assessment of therapy complications|
419194|NCT00993122|Drug|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
419195|NCT00993109|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
419196|NCT00993109|Drug|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
419197|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
419198|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
419310|NCT00992381|Drug|Naprosyn|500mg Naproxen
419199|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
419200|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
419201|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
419202|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
419203|NCT00993083|Biological|MVA-NP+M1|Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
419204|NCT00993070|Drug|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
419205|NCT00993070|Drug|placebo|vehicle gel, applied 4 times per day for 8 weeks
419206|NCT00993057|Drug|Insulin|Adjustable insulin infusion scale with loading doses
419207|NCT00993044|Drug|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
419208|NCT00993044|Drug|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
419209|NCT00993044|Drug|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
419210|NCT00993044|Drug|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1~* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
419211|NCT00993031|Drug|Lopinavir/ritonavir|LPV 200mg/r 50mg
419212|NCT00993031|Drug|Efavirenz|600mg
419213|NCT00993031|Drug|Zidovudine|Zidovudine 300 mg
419214|NCT00993031|Drug|Lamivudine|Lamivudine 150 mg
419215|NCT00993018|Drug|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
419216|NCT00993018|Drug|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
419217|NCT00993018|Drug|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
419218|NCT00993018|Drug|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
419219|NCT00993005|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
419220|NCT00993005|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
419221|NCT00992992|Biological|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
419451|NCT00991237|Other|Pulsed Radiofrequency|Pulsed Radiofrequency
419222|NCT00992979|Procedure|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
419223|NCT00992979|Procedure|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
419224|NCT00992953|Behavioral|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
419225|NCT00992953|Behavioral|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
419226|NCT00992940|Procedure|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
419227|NCT00992940|Procedure|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
419228|NCT00992927|Procedure|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
419229|NCT00992927|Procedure|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
419230|NCT00992914|Procedure|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
419231|NCT00992914|Procedure|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
419232|NCT00992901|Drug|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
419233|NCT00992901|Drug|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
419234|NCT00992901|Drug|GLP-1 and GIP|A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
419235|NCT00992888|Device|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
419236|NCT00992875|Behavioral|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
419237|NCT00992862|Drug|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
419238|NCT00992862|Drug|Univasc® 15mg Tablets|
419239|NCT00992849|Drug|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
419240|NCT00992836|Biological|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
419241|NCT00992823|Drug|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
419242|NCT00992823|Biological|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
419243|NCT00992810|Procedure|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
419244|NCT00992810|Procedure|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
419245|NCT00992797|Drug|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D < 100 nmol/L. If serum 25(OH)D > 100 placebo will be given. The cholecalciferol will be given in orange juice.
419246|NCT00992797|Other|Orange juice|Orange juice at randomization day and at week 5.
419247|NCT00992784|Biological|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
419248|NCT00992784|Biological|FluarixTM|Single dose, intramuscular injection
419249|NCT00992771|Drug|varenicline|up to 1mg BID for 8 weeks
419250|NCT00992771|Drug|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
419251|NCT00992758|Biological|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.~Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
419252|NCT00992745|Drug|123-I-MIP-1072|Single 10 mCi intravenous injection
419253|NCT00992745|Drug|111-In capromab pendetide|Single 5 mCi intravenous injection
419254|NCT00992745|Drug|123-I-MIP-1072|Single 5 mCi intravenous injection
419255|NCT00992732|Drug|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
419256|NCT00992732|Drug|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
419257|NCT00992719|Biological|Inactivated H1N1 Vaccine|H1N1 vaccine [Influenza A (H1N1) 2009 Monovalent Vaccine] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
420751|NCT00982592|Other|laboratory biomarker analysis|Correlative studies
419258|NCT00992706|Drug|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
419259|NCT00992706|Drug|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
419260|NCT00992693|Drug|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.~1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
419261|NCT00992680|Device|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
419262|NCT00992667|Drug|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
419263|NCT00992654|Drug|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
419264|NCT00992641|Other|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
419265|NCT00992641|Other|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
419266|NCT00992628|Device|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
419267|NCT00992628|Device|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
419268|NCT00992615|Procedure|prostate biopsy|prostate cores - 12 or 20
419269|NCT00992602|Drug|methotrexate|Given IV
419270|NCT00992602|Drug|liposomal cytarabine|Given IT or via LP
419271|NCT00992602|Other|quality-of-life assessment|Ancillary studies
419272|NCT00992602|Other|laboratory biomarker analysis|Correlative studies
419273|NCT00992589|Drug|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
419274|NCT00992589|Drug|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
419275|NCT00992589|Drug|Placebo|Matching placebo capsules once daily in the morning.
419276|NCT00992576|Drug|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
419277|NCT00992576|Drug|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
419278|NCT00992563|Drug|AL-39324 ophthalmic suspension|
419279|NCT00992563|Drug|Ranibizumab 10 mg/mL|
419280|NCT00992550|Drug|Cigarette|
419281|NCT00992550|Drug|Hookah|
419282|NCT00992537|Drug|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
419283|NCT00992537|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
419284|NCT00992537|Drug|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
419285|NCT00992524|Drug|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
419286|NCT00992524|Drug|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
419287|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
419288|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
419289|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
419290|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
419291|NCT00992485|Drug|ADIPOPLUS|autologous adipose-derived stem cell
419292|NCT00992472|Drug|Prochlorperazine suppositories, 25mg|
419293|NCT00992472|Drug|Compazine® suppositories, 25mg|
419294|NCT00992459|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
419295|NCT00992459|Drug|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
419296|NCT00992446|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
419297|NCT00992446|Drug|Bortezomib|Given IV
419298|NCT00992446|Drug|Carmustine|Given IV
419299|NCT00992446|Drug|Cytarabine|Given IV
419300|NCT00992446|Drug|Etoposide|Given IV
419301|NCT00992446|Drug|Melphalan|Given IV
419302|NCT00992446|Drug|Rituximab|Given IV
419303|NCT00992446|Drug|Vorinostat|Given PO
419304|NCT00992433|Biological|Inactivated Influenza H1N1 vaccine|Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
419305|NCT00992407|Drug|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
419306|NCT00992407|Drug|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
419307|NCT00992394|Drug|etanercept|etanercept 50 mg once weekly as requested.
419308|NCT00992394|Drug|etanercept|etanercept 25 mg or 50 mg as requested.
419311|NCT00992368|Procedure|reduction mammaplasty|patients submitted to reduction mammaplasty
419312|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1%|
419313|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
419314|NCT00992342|Drug|PF-03893787|oral solution, 5 mg, QD for 14 days
419315|NCT00992342|Drug|PF-03893787|oral solution, 15 mg, QD for 14 days
419316|NCT00992342|Drug|PF-03893787|oral solution, 50 mg, QD for 14 days
419317|NCT00992329|Drug|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
419318|NCT00992316|Drug|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
419319|NCT00992303|Other|biologic sample preservation procedure|
419320|NCT00992303|Other|medical chart review|
419321|NCT00992303|Other|questionnaire administration|
419322|NCT00992290|Biological|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
419323|NCT00992290|Biological|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
419324|NCT00992277|Procedure|Ablation and skin resurfacing|
419325|NCT00992264|Behavioral|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
419326|NCT00992264|Behavioral|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
419327|NCT00992264|Behavioral|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
419328|NCT00992264|Behavioral|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
419329|NCT00992238|Drug|Flavoxate Hydrochloride Tablets, 100mg|
419330|NCT00992238|Drug|Urispas® Tablets, 100mg|
419331|NCT00992225|Drug|LY573636-sodium|Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
419332|NCT00992212|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
419333|NCT00992199|Drug|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
419334|NCT00992186|Drug|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
419335|NCT00992173|Drug|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg [3.7 MBq/kg] (a minimum dose of 1.0 mCi [37 MBq] but not to exceed 5.0 mCi [185 MBq]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
419336|NCT00992160|Drug|GW597599|GW597599 15mg tablet
419337|NCT00992160|Drug|Placebo|Placebo to match GW597599 15mg tablet
419338|NCT00992147|Drug|Adipocell|autologous cultured adipocytes (ANTG-adip)
419339|NCT00992134|Drug|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.~Four to six cycles. Recycle every 28 days."
419340|NCT00992121|Drug|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
419341|NCT00992121|Drug|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
419342|NCT00992121|Drug|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).~Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
419343|NCT00992108|Drug|lidocaine|1cc 1%
419344|NCT00992108|Drug|chemodenervation|botulinum toxin
419345|NCT00992095|Drug|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
419346|NCT00992082|Drug|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
419347|NCT00992082|Drug|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
419348|NCT00992069|Drug|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
419349|NCT00992069|Drug|TMC207|Single oral dose of 400 mg in the morning
419350|NCT00992056|Drug|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
419351|NCT00992056|Drug|Metoprolol|Metoprolol 50 mg titrated to 100 mg
419352|NCT00992043|Dietary Supplement|creatine|
419353|NCT00992043|Other|Exercise training|
419354|NCT00992030|Drug|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
419454|NCT00991224|Other|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
419355|NCT00992030|Radiation|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
419356|NCT00992017|Biological|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
419357|NCT00992004|Dietary Supplement|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
419358|NCT00991991|Genetic|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
419359|NCT00991991|Genetic|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
419360|NCT00991991|Genetic|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
419361|NCT00991991|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
419362|NCT00991991|Other|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
419363|NCT00991978|Other|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
419364|NCT00991965|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
419365|NCT00991952|Drug|alvocidib|Given IV
419366|NCT00991952|Drug|irinotecan hydrochloride|Given IV
419367|NCT00991952|Other|laboratory biomarker analysis|Correlative studies
419368|NCT00991939|Drug|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients < 60 kg and 40 mg/day for patients > 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
419369|NCT00991939|Drug|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients > 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients < 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
419370|NCT00991926|Drug|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
419371|NCT00991926|Other|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
419372|NCT00991900|Device|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
419373|NCT00991887|Radiation|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
419374|NCT00991861|Drug|LAS41007 o.d.|Once daily, topical application
419375|NCT00991861|Drug|LAS41007 b.i.d.|Twice daily, topical application
419376|NCT00991861|Drug|LAS106521|Twice daily, topical application
419377|NCT00991848|Drug|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
419378|NCT00991822|Drug|Dorzolamide 2%|
419379|NCT00991822|Drug|Timolol 0.5%|
419380|NCT00991809|Drug|Alfentanil|15 mcg/kg IM
419381|NCT00991809|Drug|Diphenhydramine|25 mg IM
419382|NCT00991796|Drug|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
419383|NCT00991796|Drug|Placebo|Placebo
419384|NCT00991796|Drug|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
419385|NCT00991796|Drug|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
419386|NCT00991783|Drug|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
419387|NCT00991770|Other|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
419388|NCT00991770|Other|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
419389|NCT00991757|Drug|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
419390|NCT00991744|Drug|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
419391|NCT00991744|Drug|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
419392|NCT00991731|Behavioral|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
419393|NCT00991731|Behavioral|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
419394|NCT00991718|Drug|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
419395|NCT00991718|Drug|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
419396|NCT00991718|Drug|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
419397|NCT00991705|Drug|Atorvastatin|
419398|NCT00991705|Drug|Fimasartan|
419399|NCT00991692|Other|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
419400|NCT00991666|Procedure|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
419401|NCT00991653|Procedure|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
419402|NCT00991640|Behavioral|2-day preceptorship on obesity management|
419403|NCT00991627|Drug|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
419404|NCT00991627|Drug|Morphine|200 µg of a 100 µg/ml solution, intrathecally
419405|NCT00991627|Drug|Lactated Ringer's solution|25 ml/min intravenously
419406|NCT00991627|Drug|Ephedrine, continuous infusion|37.5 mg/h intravenously
419407|NCT00991627|Drug|Ephedrine, bolus|"6.25 mg IV bolus prn.~Hypotension defined according to study protocol for each arm."
419408|NCT00991627|Drug|Atropine|"0.1 mg/kg iv bolus prn~Bradycardia defined as 50% drop in heart rate from baseline values."
419409|NCT00991614|Device|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
419410|NCT00991601|Procedure|FNAC (fine needle aspiration cytology)|UL guided biopsy
419411|NCT00991588|Procedure|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
419412|NCT00991562|Drug|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
419413|NCT00991549|Behavioral|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
419414|NCT00991523|Dietary Supplement|protein|protein
419415|NCT00991523|Dietary Supplement|placebo|placebo control
419416|NCT00991510|Drug|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
419417|NCT00991510|Drug|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
419418|NCT00991497|Device|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
419419|NCT00991471|Behavioral|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
419420|NCT00991471|Behavioral|No MDRNSTAT|Standard management of nurse-only triage for assignment of CTAS
419421|NCT00991458|Drug|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
419422|NCT00991458|Drug|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
419423|NCT00991458|Drug|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
419424|NCT00991445|Procedure|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
419452|NCT00991224|Biological|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
419453|NCT00991224|Biological|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
419425|NCT00991445|Procedure|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
419426|NCT00991432|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
419427|NCT00991419|Drug|[18F]AZD4694|[18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
419428|NCT00991406|Device|FES|Surface stimulation to contract the muscles in the lower extremity
419429|NCT00991393|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
419430|NCT00991380|Behavioral|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
419431|NCT00991380|Behavioral|Usual Care|Control
419432|NCT00991367|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
419433|NCT00991367|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
419434|NCT00991354|Biological|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
419435|NCT00991354|Biological|IL-12 DNA plasmids|Adjuvant for HIV vaccines
419436|NCT00991341|Biological|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored <=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
419437|NCT00991341|Biological|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored >=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
419438|NCT00991328|Procedure|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
419439|NCT00991302|Behavioral|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
419440|NCT00991289|Drug|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
419441|NCT00991289|Drug|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
419442|NCT00991289|Drug|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
419443|NCT00991276|Drug|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
419444|NCT00991276|Drug|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
419445|NCT00991276|Drug|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
419446|NCT00991263|Genetic|gene expression analysis|
419447|NCT00991263|Genetic|polymerase chain reaction|
419448|NCT00991263|Other|laboratory biomarker analysis|
419449|NCT00991250|Biological|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
419450|NCT00991250|Drug|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
419455|NCT00991211|Drug|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
419456|NCT00991211|Drug|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
419457|NCT00991198|Drug|Topical oxygen|0.5% concentration of Topical oxygen
419458|NCT00991198|Drug|Topical oxygen|0.25% concentration topical oxygen
419459|NCT00991198|Drug|placebo|no O2
419460|NCT00991172|Drug|REGN475|Single Subcutaneous injection dose level 1
419461|NCT00991172|Drug|REGN475|Single subcutaneous injection dose level 2
419462|NCT00991172|Drug|Placebo Injection|Placebo Subcutaneous injection
419463|NCT00991159|Biological|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
419464|NCT00991146|Drug|canakinumab|canakinumab
419465|NCT00991133|Drug|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
419466|NCT00991120|Device|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
419467|NCT00991107|Drug|HE3286|HE3286 20 mg (10 mg BID) for 28 days
419468|NCT00991081|Behavioral|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling~One week prior to the target quit date (TQD)~Two weeks post-TQD~Four weeks post-TQD"
419469|NCT00991081|Behavioral|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
419470|NCT00991081|Drug|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy~Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)~Participants with the A2 allele (CC) were assigned to receive bupropion"
419471|NCT00991081|Behavioral|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
419472|NCT00991081|Behavioral|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
419473|NCT00991068|Drug|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
419474|NCT00991055|Drug|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.~(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
419475|NCT00991042|Other|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
419476|NCT00991029|Drug|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
419477|NCT00991029|Drug|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
419478|NCT00991016|Drug|PF-04805712|ascending single and multiple doses starting at 30 mg
419479|NCT00991003|Procedure|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
419480|NCT00991003|Procedure|Conventional Colonoscopy|
419481|NCT00990990|Drug|PNU-100480|100 mg BID for 14 days
419482|NCT00990990|Drug|Placebo|to match 100 mg BID for 14 days
419483|NCT00990990|Drug|PNU-100480|300 mg BID for 14 days
419484|NCT00990990|Drug|Placebo|to match 300 mg BID for 14 days
419485|NCT00990990|Drug|PNU-100480|600 mg BID for 14 days
419486|NCT00990990|Drug|Placebo|to match 600 mg BID for 14 days
419487|NCT00990990|Drug|PNU-100480|1200 mg QD for 14 days
419488|NCT00990990|Drug|Placebo|to match 1200 mg QD for 14 days
419489|NCT00990990|Drug|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
419490|NCT00990990|Drug|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
419491|NCT00990990|Drug|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
419492|NCT00990990|Drug|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
419493|NCT00990990|Drug|Linezolid|300 mg QD for 4 days (open label)
419494|NCT00990977|Behavioral|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
419495|NCT00990964|Device|Attain Success Lead|Attain Success Lead
419496|NCT00990951|Drug|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub~1 tablet PO twice a day"
419497|NCT00990938|Drug|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
419498|NCT00990938|Drug|Saline|Subcutaneous injection once per week for four weeks
419499|NCT00990925|Behavioral|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
419500|NCT00990925|Other|Usual Care|Care as usual
419501|NCT00990912|Drug|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
419502|NCT00990912|Drug|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
419503|NCT00990912|Drug|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
419504|NCT00990886|Drug|Placebo|Once daily for 12 weeks
419505|NCT00990886|Drug|Oxybutynin chloride|15 mg once daily for 12 weeks
419506|NCT00990873|Genetic|gene expression analysis|
419507|NCT00990873|Genetic|microarray analysis|
419508|NCT00990873|Genetic|reverse transcriptase-polymerase chain reaction|
419509|NCT00990873|Other|laboratory biomarker analysis|
419510|NCT00990860|Drug|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
419511|NCT00990860|Procedure|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
419512|NCT00990847|Drug|Procaterol, Salbultamol|
419513|NCT00990834|Drug|simvastatin|simvastatin 80 mg PO daily for one to eight months.
419514|NCT00990821|Drug|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
419515|NCT00990821|Drug|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
419516|NCT00990821|Drug|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
419517|NCT00990821|Drug|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
419518|NCT00990821|Drug|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
419519|NCT00990821|Drug|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
419520|NCT00990821|Drug|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
419521|NCT00990821|Drug|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
419522|NCT00990821|Drug|Placebo|Placebo matching MK-0517
419523|NCT00990821|Drug|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
419524|NCT00990821|Drug|125 mg Aprepitant|Aprepitant oral tablet, single dose
419525|NCT00990821|Drug|2 mg Midazolam|Midazolam oral tablet, single dose
419526|NCT00990808|Drug|anacetrapib|[Intervention Name: MK0859] MK0859 100 mg tablet once daily for 8 weeks.
419527|NCT00990808|Drug|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
419528|NCT00990808|Drug|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
419529|NCT00990808|Drug|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
419530|NCT00990795|Drug|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
419531|NCT00990795|Drug|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
419532|NCT00990782|Diagnostic Test|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
419533|NCT00990769|Other|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
419534|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
419535|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
419536|NCT00990743|Drug|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
419537|NCT00990717|Biological|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~Level I: 1x10^9 cells/m^2~Level II: 3x10^9 cells/m^2~Level III: 5x10^9 cells/m^2"
419538|NCT00990704|Drug|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
419539|NCT00990704|Drug|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
419540|NCT00990691|Drug|Administration of a high dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~From 15 to 25 kg : 50 mg ;~From 26 to 35 kg : 75 mg ;~From 36 to 45 kg : 100 mg ;~> 46 kg : 150 mg."
419541|NCT00990691|Drug|Administration of a low dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :~From 15 to 25 kg : 25 mg ;~From 26 to 35 kg : 50 mg ;~From 36 to 45 kg : 75 mg ;~> 46 kg : 100 mg."
419542|NCT00990691|Drug|Administration of a placebo|Administration of a daily dose of placebo
419543|NCT00990678|Drug|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
419544|NCT00990678|Drug|Vitamin D|tablets, vitamin D3, 30 microgram daily
419545|NCT00990678|Drug|Calcium|tablets, 400 mg calcium, 3 times daily
419546|NCT00990665|Device|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
419547|NCT00990652|Drug|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
419548|NCT00990652|Drug|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
419549|NCT00990639|Drug|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.~UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
419550|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
419551|NCT00990613|Drug|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
419552|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
419553|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
419554|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
419555|NCT00990600|Other|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
419556|NCT00990587|Drug|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
419557|NCT00990574|Device|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
419558|NCT00990574|Device|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
419559|NCT00990561|Drug|Ultravate ointment twice daily + LacHydrin lotion twice daily|Topical corticosteroid
419560|NCT00990561|Drug|Ultravate ointment once daily + LacHydrin lotion twice daily|Topical corticosteroid
419561|NCT00990535|Drug|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
419562|NCT00990522|Procedure|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
419563|NCT00990509|Drug|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
419564|NCT00990509|Drug|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
419565|NCT00990509|Procedure|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~Baseline~48 hours after enrollment(approximately Day 3)~96 hours after drug treatment begins (approximately Day 5)"
419566|NCT00990496|Drug|Fludarabine|30 mg/m2
419567|NCT00990496|Drug|Cyclophosphamide|600 mg/m2
419568|NCT00990496|Biological|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
419569|NCT00990457|Behavioral|Weight Loss Diets Plus Exercise|"The weight loss diet will be either a low-carbohydrate diet or a low-fat, low-calorie diet. All participants will also be enrolled in a supervised exercise program.~The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training."
419570|NCT00990444|Drug|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
419571|NCT00990431|Procedure|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
419572|NCT00990431|Procedure|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
419573|NCT00990418|Drug|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
419574|NCT00990405|Drug|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
419575|NCT00990392|Drug|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
419576|NCT00990392|Other|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
419577|NCT00990366|Device|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
419578|NCT00990340|Device|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
419579|NCT00990340|Procedure|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
419580|NCT00990327|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
419581|NCT00990327|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
419582|NCT00990314|Drug|Beraprost Sodium Modified Release|
419583|NCT00990301|Drug|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
419584|NCT00990301|Drug|Uniretic® 15mg/25mg Tablets|reference drug
419585|NCT00990288|Drug|Hemostatic Matrix|FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.
419586|NCT00990275|Other|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
419587|NCT00990262|Radiation|Cardiac Computed Tomography|"Localization of the heart position in a projectional topographic scan of the chest.~Determination of contrast agent transit time: 10 ml contrast agent.~CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
419588|NCT00990249|Drug|Busulfan|Test Dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
419589|NCT00990249|Drug|Clofarabine|40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3
419590|NCT00990249|Drug|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
419591|NCT00990249|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
419592|NCT00990236|Drug|Dose-adjusted Lovenox based on TEG|Lovenox doses will be adjusted (10 mg BID) based on delta-R results from TEG. Delta-R < 1.0 min - increase dose by 10 mg BID; delta-R >/= 1.0 min and </= 2.0 min - no change; delta-R > 2.0 min - decrease dose by 10 mg BID.
419593|NCT00990223|Drug|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
419594|NCT00990197|Drug|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
419595|NCT00990184|Drug|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
419596|NCT00990184|Other|placebo|tablet (s) orally given with evening meal
419597|NCT00990158|Drug|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
419598|NCT00990158|Drug|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
419599|NCT00990145|Drug|EDP-322|
419600|NCT00990132|Device|Home mechanical ventilation|Nocturnal non-invasive ventilation
419601|NCT00990132|Device|Long term oxygen therapy|LTOT established as per national guidelines
419602|NCT00990119|Device|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
419603|NCT00990106|Drug|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
419604|NCT00990106|Drug|placebo|placebo
419605|NCT00990093|Device|test intermittent catheter|CH 12 hydrophilic coated catheter
419606|NCT00990093|Device|Intermittent catheterization|CH 12 hydrophilic catheter
419607|NCT00990080|Biological|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
419608|NCT00990067|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
419609|NCT00990067|Drug|Duloxetine|120 mg two doses 12h and 2h before MDMA
419610|NCT00990067|Drug|Placebo|capsules identical to MDMA or duloxetine
419611|NCT00990054|Drug|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
419612|NCT00990028|Drug|Rosuvastatin|20 mg oral, for 10 days
419613|NCT00990028|Drug|Placebo|20 mg vehicle
419614|NCT00990015|Drug|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
419615|NCT00990015|Drug|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
419616|NCT00989989|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
419617|NCT00989989|Procedure|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
419618|NCT00989989|Drug|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
419619|NCT00989989|Procedure|Sham laser photocoagulation|Sham laser treatment administered at day 1.
419620|NCT00989976|Behavioral|normal sleep times|8.5 h bedtimes
419621|NCT00989976|Behavioral|bedtime restriction|4.5 h restricted bedtimes
419622|NCT00989963|Drug|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
419623|NCT00989950|Drug|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
419624|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
419625|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
419626|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
419627|NCT00989937|Drug|Oxytocin|20 IU BID or 40 IU BID
419628|NCT00989937|Drug|Placebo|20 IU BID or 40 IU BID
419629|NCT00989911|Drug|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
419630|NCT00989898|Other|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
419631|NCT00989885|Other|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
419632|NCT00989872|Drug|EDP-322|
419633|NCT00989859|Device|Plethysmographic monitoring|Plethysmographic monitoring
419634|NCT00989846|Other|biomarker|measuring serum-biomarkers
419635|NCT00989833|Drug|budesonide|400 yg x 1
419636|NCT00989833|Drug|terbutaline|0.4 mg as-needed
419637|NCT00989833|Drug|budesonide/formoterol|160/4.5 yg as-needed
419638|NCT00989820|Drug|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
419639|NCT00989807|Drug|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
419640|NCT00989794|Device|GelrinC|Applied once during surgery
419641|NCT00989781|Radiation|3-D Ultrasound|One time pelvic ultrasound
419642|NCT00989781|Drug|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
419643|NCT00989781|Drug|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
419644|NCT00989781|Drug|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
419645|NCT00989781|Drug|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
419646|NCT00989781|Drug|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
419647|NCT00989768|Drug|Botulinum Toxin Type A (Dysport®)|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 5 units will be injected in the left or right forehead side."
419648|NCT00989768|Drug|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
419649|NCT00989768|Drug|Botulinum Toxin Type A/Dysport®|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox."
419650|NCT00989755|Other|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
419651|NCT00989742|Drug|Doxycycline|50mg od
419652|NCT00989742|Drug|Placebo|50mg od
419653|NCT00989729|Drug|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
419654|NCT00989729|Drug|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
419655|NCT00989716|Drug|Transdermal glyceryl trinitrate patch|5mg per day
419656|NCT00989716|Drug|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
419657|NCT00989703|Drug|placebo|oral solution, daily for 14 days
419658|NCT00989703|Drug|GLPG0259|oral solution
419659|NCT00989703|Drug|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
419660|NCT00989690|Drug|docetaxel|
419661|NCT00989690|Drug|erlotinib hydrochloride|
419662|NCT00989690|Drug|pemetrexed disodium|
419663|NCT00989690|Genetic|fluorescence in situ hybridization|
419664|NCT00989690|Genetic|mutation analysis|
419665|NCT00989690|Genetic|proteomic profiling|
419666|NCT00989690|Other|immunohistochemistry staining method|
419667|NCT00989690|Other|laboratory biomarker analysis|
419668|NCT00989690|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
419669|NCT00989690|Procedure|breath test|
419670|NCT00989664|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
419671|NCT00989651|Biological|Bevacizumab|Given IV
419672|NCT00989651|Drug|Carboplatin|Given IV
419673|NCT00989651|Drug|Cisplatin|Given IP
419674|NCT00989651|Other|Laboratory Biomarker Analysis|Correlative studies
419675|NCT00989651|Drug|Paclitaxel|Given IV or IP
419676|NCT00989651|Drug|Veliparib|Given PO
419677|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
419678|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
419679|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
419680|NCT00989612|Biological|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
419735|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
419681|NCT00989599|Other|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
419682|NCT00989599|Other|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
419683|NCT00989586|Biological|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
419684|NCT00989586|Biological|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
419685|NCT00989586|Procedure|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
419686|NCT00989586|Procedure|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
419687|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
419688|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
419689|NCT00989586|Procedure|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
419690|NCT00989586|Biological|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
419691|NCT00989573|Drug|Placebo|oral administration of placebo once-daily for 8 weeks
419692|NCT00989573|Drug|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
419693|NCT00989573|Drug|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
419694|NCT00989560|Procedure|endoscopy|patients receive best treatment and care with an additional endoscopy
419695|NCT00989547|Other|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
419696|NCT00989534|Behavioral|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
419697|NCT00989534|Behavioral|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
419698|NCT00989521|Drug|PUR003|PUR003 for inhalation
419699|NCT00989521|Drug|Placebo|Normal saline for inhalation
419700|NCT00989508|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
419701|NCT00989508|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
419702|NCT00989495|Device|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
419703|NCT00989482|Behavioral|Computer kiosk Education|computerized patient education; guidelines for physicians
419704|NCT00989469|Drug|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
419705|NCT00989456|Behavioral|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
419706|NCT00989456|Behavioral|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
419707|NCT00989443|Drug|Cidofovir gel|topical gel applied once a week for 3 weeks
419708|NCT00989430|Behavioral|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
419709|NCT00989417|Other|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
419710|NCT00989404|Drug|Zanamivir|Rotahaler placebo 10mg BID 5 days
419711|NCT00989404|Drug|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
419712|NCT00989404|Drug|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
419713|NCT00989391|Drug|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
419714|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
419715|NCT00989391|Drug|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
419716|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
419717|NCT00989391|Drug|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
419718|NCT00989391|Drug|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
419719|NCT00989378|Behavioral|baseline study|normal bedtimes
419720|NCT00989365|Other|Aerobic training|Treadmill training
419721|NCT00989352|Drug|Methotrexate|3g/m² i.v. max. 9 times
419722|NCT00989352|Drug|Lomustine|110 mg/m² p.o., max. 3 times
419723|NCT00989352|Drug|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
419724|NCT00989352|Drug|Rituximab|375 mg/m² i.v., max. 10 times
419725|NCT00989339|Drug|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
419726|NCT00989326|Other|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
419727|NCT00989313|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
419728|NCT00989300|Drug|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
419729|NCT00989300|Drug|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
419730|NCT00989300|Other|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
419731|NCT00989287|Biological|GSK2340272A|Two intramuscular injections in the deltoid region of the non-dominant arm.
419732|NCT00989287|Biological|GSK2340269A|Two intramuscular injections in the deltoid region of the non-dominant arm.
419733|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
419734|NCT00989274|Biological|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
419786|NCT00988949|Drug|PF-04455242|Single 30 mg oral dose of PF-04455242.
419736|NCT00989261|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
419737|NCT00989248|Other|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
419738|NCT00989235|Drug|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
419739|NCT00989235|Drug|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
419740|NCT00989222|Procedure|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
419741|NCT00989222|Procedure|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
419742|NCT00989209|Drug|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
419743|NCT00989209|Procedure|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
419744|NCT00989196|Biological|Human-cl rhFVIII|50 IU/kg for PK dose
419745|NCT00989196|Biological|Kogenate FS|50 IU/kg for PK dose
419746|NCT00989183|Other|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
419747|NCT00989170|Behavioral|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
419748|NCT00989170|Behavioral|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
419749|NCT00989157|Drug|Duloxetine|Single dose of 60 mg of duloxetine
419750|NCT00989131|Drug|Paclical®|"250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
419751|NCT00989131|Drug|Taxol®|"175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.~Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
419752|NCT00989118|Procedure|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
419753|NCT00989105|Other|immunohistochemistry staining method|
419754|NCT00989105|Other|laboratory biomarker analysis|
419755|NCT00989105|Other|pharmacological study|
419756|NCT00989105|Procedure|computed tomography|
419757|NCT00989105|Procedure|magnetic resonance imaging|
419758|NCT00989105|Procedure|single photon emission computed tomography|
419759|NCT00989105|Radiation|technetium Tc 99m demobesin-4|
419760|NCT00989092|Biological|darbepoetin alfa|Administered subcutaneously.
419761|NCT00989079|Drug|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
419762|NCT00989079|Drug|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
419763|NCT00989053|Drug|escitalopram|10 mg/d for a duration of 8 weeks
419764|NCT00989053|Drug|placebo|1 pill per day for 8 weeks
419765|NCT00989040|Drug|usual treatment: Versatis|"To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.~To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
419766|NCT00989027|Drug|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
419767|NCT00989027|Drug|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
419768|NCT00989027|Drug|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
419769|NCT00989027|Drug|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
419770|NCT00989027|Drug|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
419771|NCT00989014|Drug|CD07805/47|0.5% Topical Gel
419772|NCT00989014|Drug|CD07805/47|0.18% Topical Gel
419773|NCT00989014|Drug|CD07805/47|0.07% Topical Gel
419774|NCT00989014|Drug|CD07805/47 placebo|Vehicle Topical Gel
419775|NCT00989001|Drug|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
419776|NCT00989001|Drug|Placebo|Injection
419777|NCT00988988|Drug|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
419778|NCT00988988|Drug|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
419779|NCT00988988|Drug|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
419780|NCT00988975|Procedure|Insertion of pelvicol graft|Pelvicol graft
419781|NCT00988962|Behavioral|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
419782|NCT00988949|Drug|PF-04455242|Single oral 18 mg dose of PF-04455242.
419783|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
419784|NCT00988949|Other|Placebo|Oral placebo.
419785|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
419787|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
419788|NCT00988936|Drug|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with [F-18]RGD-K5
419789|NCT00988923|Other|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
419790|NCT00988923|Other|No intervention|the intervention tool was switched in off, only bolus was activated
419791|NCT00988910|Drug|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
419792|NCT00988910|Drug|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
419793|NCT00988897|Drug|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
419794|NCT00988897|Drug|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
419795|NCT00988897|Drug|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
419796|NCT00988897|Drug|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
419797|NCT00988884|Biological|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
419798|NCT00988884|Biological|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
419799|NCT00988884|Biological|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
419800|NCT00988884|Biological|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
419801|NCT00988884|Biological|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
419802|NCT00988871|Device|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
419803|NCT00988858|Drug|LY2603618|150 milligram per square meter (mg/m^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
419804|NCT00988858|Drug|Pemetrexed|500 mg/m^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
419805|NCT00988845|Dietary Supplement|Indole-3-carbinol|200 mg bid po X 8 weeks
419806|NCT00988832|Biological|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
419807|NCT00988806|Drug|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
419808|NCT00988806|Drug|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.~Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
419809|NCT00988793|Procedure|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
419810|NCT00988793|Procedure|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
419811|NCT00988780|Drug|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
419812|NCT00988780|Drug|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.~Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
419813|NCT00988767|Biological|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
419814|NCT00988754|Behavioral|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
419815|NCT00988741|Drug|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
419816|NCT00988741|Drug|Placebo|The placebo is provided in a capsule form.
419817|NCT00988728|Drug|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
419818|NCT00988728|Drug|Placebo|"Oral capsules and tablets containing excipients only.~Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
419819|NCT00988728|Drug|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.~Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
419820|NCT00988715|Biological|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
419821|NCT00988715|Drug|Cyclosporine|Given IV
419822|NCT00988715|Drug|Mycophenolate Mofetil|Given PO
419823|NCT00988715|Radiation|Total-Body Irradiation|Undergo total-body irradiation
419824|NCT00988715|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
419825|NCT00988715|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
419826|NCT00988715|Drug|Fludarabine Phosphate|Given IV
419827|NCT00988715|Other|Pharmacological Study|Correlative studies
419828|NCT00988715|Other|Laboratory Biomarker Analysis|Correlative studies
419829|NCT00988702|Behavioral|Dan Tian Breathing|Dan Tian Breathing for one month
419830|NCT00988702|Behavioral|Progressive muscle training|Progressive muscle training for one month
419831|NCT00988689|Other|Dietary Intervention|soup with or without starch
419832|NCT00988663|Drug|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
419833|NCT00988663|Drug|Placebo|will give placebo that looks like memantine
419834|NCT00988650|Other|isocaloric diet|
419835|NCT00988650|Other|free living conditions|
419836|NCT00988637|Drug|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
419837|NCT00988637|Drug|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
419838|NCT00988624|Drug|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
419839|NCT00988624|Drug|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
419840|NCT00988624|Drug|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
419841|NCT00988624|Drug|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
419842|NCT00988624|Drug|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
419843|NCT00988611|Other|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
419844|NCT00988598|Drug|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
419845|NCT00988598|Drug|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
419846|NCT00988585|Dietary Supplement|EPA 600|EPA 600 mg/day for 6 weeks
419847|NCT00988585|Dietary Supplement|EPA 1800|1800 mg/day for 6 weeks
419848|NCT00988585|Dietary Supplement|Olive Oil|600 mg/day for 6 weeks
419849|NCT00988585|Dietary Supplement|DHA|600 mg/day for 6 weeks
419850|NCT00988572|Other|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
419851|NCT00988559|Biological|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
419852|NCT00988559|Device|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
419853|NCT00988559|Biological|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
419854|NCT00988559|Biological|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
419855|NCT00988559|Procedure|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
419856|NCT00988559|Drug|imiquimod|imiquimod applied to the cervix by the physician
419857|NCT00988546|Other|Computer based template for exam documentation|exam documentation performed using computer based template
419858|NCT00988546|Other|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
419859|NCT00988533|Drug|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
419860|NCT00988520|Drug|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
419861|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
419862|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
419863|NCT00988520|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
419864|NCT00988520|Drug|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
419865|NCT00988507|Drug|Ferroquine (SSR97193)|"Pharmaceutical form: capsule~Route of administration: oral"
419866|NCT00988507|Drug|Placebo|"Pharmaceutical form: capsule~Route of administration: oral"
419867|NCT00988507|Drug|artesunate|"Pharmaceutical form: tablets~Route of administration: oral"
419868|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
419869|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
419870|NCT00988494|Drug|Placebo ophthalmic solution|Topical ocular application
419871|NCT00988481|Drug|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
421575|NCT00976937|Device|Pen auto-injector|
419872|NCT00988468|Procedure|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
419873|NCT00988468|Behavioral|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
419874|NCT00988468|Behavioral|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
419875|NCT00988455|Radiation|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
419876|NCT00988442|Behavioral|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
419877|NCT00988442|Behavioral|Standard care|Usual ACTG site care.
419878|NCT00988429|Drug|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
419879|NCT00988429|Drug|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
419880|NCT00988429|Drug|Placebo|Placebo tablet given QD
419881|NCT00988416|Procedure|PET-CT|Pancreas Protocol PET-CT
419882|NCT00988403|Dietary Supplement|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
419883|NCT00988403|Dietary Supplement|Fructan - 10|Subjects will consume 10 grams of fructan
419884|NCT00988403|Dietary Supplement|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
419885|NCT00988403|Dietary Supplement|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
419886|NCT00988390|Behavioral|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
419887|NCT00988377|Other|dietary intervention|whey protein 10-40 g
419888|NCT00988377|Other|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
419889|NCT00988364|Drug|Simvastatin|Simvastatin 20mg daily for 3 months.
419890|NCT00988364|Drug|Vytorin|Vytorin 20/10mg daily for 3 months.
419891|NCT00988364|Drug|Placebo|Placebo one tablet daily times 3 months.
419892|NCT00988364|Drug|Ezetimibe|Ezetimibe 10mg daily for 3 months.
419893|NCT00988351|Device|Continuous positive airway pressure|continuous positive airway pressure determined by polysomnography titration
419894|NCT00988351|Device|Auto-adjusting positive airway pressure treatment|Pressure range 4-18 centimeters of water (cm H2O)
419895|NCT00988338|Biological|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
419896|NCT00988325|Drug|Tamiflu|oral repeating dose
419897|NCT00988312|Biological|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
419898|NCT00988299|Other|exercise|exercise sessions at 45% and 60% of maximum effort
419899|NCT00988286|Procedure|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
419900|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
419901|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
419902|NCT00988260|Drug|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
419903|NCT00988260|Drug|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
419904|NCT00988260|Drug|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
419905|NCT00988247|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
419906|NCT00988247|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
419907|NCT00988234|Procedure|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
419908|NCT00988234|Procedure|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
419909|NCT00988234|Procedure|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
419910|NCT00988234|Procedure|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
419911|NCT00988221|Drug|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
419912|NCT00988221|Drug|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
419913|NCT00988208|Drug|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
419914|NCT00988208|Drug|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
419915|NCT00988208|Drug|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
419916|NCT00988208|Drug|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
419917|NCT00988195|Biological|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
419918|NCT00988195|Drug|Doxorubicin|Weeks 13-24 (once every 3 weeks)
419919|NCT00988182|Other|dietary intervention|whey protein
419920|NCT00988182|Other|water control|
419966|NCT00987909|Biological|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
419967|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
419968|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
419921|NCT00988169|Drug|oral erlotinib and pulsed doses of oral AT-101|Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
419922|NCT00988156|Drug|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
419923|NCT00988156|Drug|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
419924|NCT00988143|Biological|2009-2010 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
419925|NCT00988143|Biological|2008-2009 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
419926|NCT00988143|Biological|Quadrivalent Influenza Virus Vaccine|0.5 mL, Intramuscular
419927|NCT00988130|Other|laboratory biomarker analysis|
419928|NCT00988130|Other|questionnaire administration|
419929|NCT00988130|Procedure|assessment of therapy complications|
419930|NCT00988130|Procedure|high-intensity focused ultrasound ablation|
419931|NCT00988130|Procedure|quality-of-life assessment|
419932|NCT00988117|Drug|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
419933|NCT00988104|Behavioral|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
419934|NCT00988104|Behavioral|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
419935|NCT00988091|Device|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
419936|NCT00988091|Device|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
419937|NCT00988078|Drug|Placebo|Capsule (without biologic action) administered three times a day for six months
419938|NCT00988078|Drug|Metformin|Metformin 500mg three times a day for six months
419939|NCT00988065|Drug|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
419940|NCT00988065|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
419941|NCT00988065|Drug|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
419942|NCT00988065|Drug|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
419943|NCT00988052|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
419944|NCT00988039|Drug|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily~The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
419945|NCT00988039|Drug|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily"
419946|NCT00988039|Drug|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily~raltegravir (400mg) twice daily for the first 12 weeks only"
419947|NCT00988026|Drug|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
419948|NCT00988013|Radiation|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
419949|NCT00988013|Radiation|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
419950|NCT00988013|Radiation|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
419951|NCT00988013|Radiation|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
419952|NCT00988000|Other|telephone consultation|alternative to face to face consultation for new referrals
419953|NCT00988000|Other|No intervention|no alternative to face to face consultation
419954|NCT00987987|Procedure|donor lymphocyte infusion|regulatory T cells depletion
419955|NCT00987974|Drug|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
419956|NCT00987974|Drug|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
419957|NCT00987974|Drug|placebo|placebo for 3 days.
419958|NCT00987974|Drug|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
419959|NCT00987974|Drug|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
419960|NCT00987974|Drug|placebo 7 days|placebo 7 days
419961|NCT00987961|Behavioral|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
419962|NCT00987948|Drug|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
419963|NCT00987935|Drug|Sorafenib|400 mg twice daily
419964|NCT00987935|Drug|BIBF 1120|Twice daily
419965|NCT00987922|Device|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
420009|NCT00987675|Procedure|quality-of-life assessment|
419969|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
419970|NCT00987896|Device|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
419971|NCT00987870|Drug|BFH772|
419972|NCT00987870|Drug|Placebo|
419973|NCT00987870|Drug|BFH772|
419974|NCT00987870|Drug|Placebo|
419975|NCT00987870|Drug|calcipotriol/betamethasone|
419976|NCT00987857|Procedure|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
419977|NCT00987857|Procedure|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
419978|NCT00987857|Procedure|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
419979|NCT00987857|Procedure|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
419980|NCT00987857|Procedure|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
419981|NCT00987857|Procedure|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
419982|NCT00987857|Procedure|screening method|All Barretts patients to be screened
419983|NCT00987844|Drug|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
419984|NCT00987831|Other|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
419985|NCT00987831|Other|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
419986|NCT00987831|Drug|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
419987|NCT00987818|Other|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
419988|NCT00987805|Dietary Supplement|Banhasasim-tang|Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
419989|NCT00987805|Dietary Supplement|Corn-starch granules|This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
419990|NCT00987792|Drug|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
419991|NCT00987779|Drug|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
419992|NCT00987779|Drug|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
419993|NCT00987766|Drug|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
419994|NCT00987766|Drug|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
419995|NCT00987766|Drug|oxaliplatin|Given through a vein in the arm 1 time every other week.
419996|NCT00987766|Other|laboratory biomarker analysis|Blood and tissue collection.
419997|NCT00987753|Drug|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
419998|NCT00987740|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
419999|NCT00987727|Drug|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
420000|NCT00987727|Drug|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
420001|NCT00987714|Procedure|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
420002|NCT00987701|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
420003|NCT00987701|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
420004|NCT00987688|Other|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
420005|NCT00987675|Other|pharmacological study|
420006|NCT00987675|Other|questionnaire administration|
420007|NCT00987675|Procedure|assessment of therapy complications|
420008|NCT00987675|Procedure|high-intensity focused ultrasound ablation|
420010|NCT00987662|Drug|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg.
420011|NCT00987662|Drug|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg
420012|NCT00987636|Drug|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.~Patients < 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.~Patients >= 18 years will receive a bodyweight-dependent dose:~Patients >40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
420013|NCT00987636|Drug|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: <9 kg= 1mg/kg BW 9 - <16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW >23 - 34 kg= 0.95 mg/kg BW >34 kg = 0.8 mg/kg BW
420014|NCT00987636|Drug|Treosulfan|12 g/m² d-5 to d-3
420015|NCT00987623|Device|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
420016|NCT00987623|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
420017|NCT00987610|Device|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
420018|NCT00987597|Behavioral|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
420019|NCT00987597|Behavioral|conventional follow-up|nicotinic substitutes
420020|NCT00987558|Drug|Eslicarbazepine acetate|
420021|NCT00987558|Drug|Simvastatin|
420022|NCT00987545|Drug|QAX576|QAX576 injection
420023|NCT00987545|Drug|QAX576 placebo|Placebo to QAX576 injection
420024|NCT00987532|Behavioral|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
420025|NCT00987532|Behavioral|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
420026|NCT00987506|Device|XIENCE V®|Participants with placement of a XIENCE V® EESS
420027|NCT00987493|Biological|rituximab|day 1 at a fixed dose of 375mg/m2
420028|NCT00987493|Drug|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
420029|NCT00987493|Drug|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
420030|NCT00987480|Drug|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
420031|NCT00987480|Device|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
420032|NCT00987467|Drug|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
420033|NCT00987454|Drug|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
420034|NCT00987454|Drug|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
420035|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
420036|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
420037|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
420038|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
420039|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
420040|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
420041|NCT00987428|Procedure|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
420042|NCT00987428|Procedure|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
420043|NCT00987415|Drug|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
420044|NCT00987415|Drug|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
420045|NCT00987402|Other|Plain soap and water (PSW)|Presence or absence of infection
420046|NCT00987402|Other|Alcohol-based hand rub (ABHR)|Presence or absence of infection
420047|NCT00987389|Procedure|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
420048|NCT00987389|Drug|Glucocorticoids|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following either a standard regimen or a reduced regimen.
420049|NCT00987376|Device|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
420329|NCT00985439|Drug|Placebo|Capsules 2 Single-dose
420050|NCT00987363|Other|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
420051|NCT00987350|Device|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
420052|NCT00987350|Device|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
420053|NCT00987350|Biological|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
420054|NCT00987337|Drug|Filibuvir|300 mg BID
420055|NCT00987337|Drug|Filibuvir|600 mg BID
420056|NCT00987337|Drug|Placebo|BID
420057|NCT00987324|Device|Taxus stent|Implantation of paclitaxel-eluting stent
420058|NCT00987324|Device|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
420059|NCT00987324|Device|Conventional Balloon Catheter|Ryuijin, Trek
420060|NCT00987311|Dietary Supplement|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
420061|NCT00987311|Dietary Supplement|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
420062|NCT00987311|Dietary Supplement|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
420063|NCT00987298|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
420064|NCT00987285|Behavioral|CASM +|Computer Assisted Self Management plus Social Support
420065|NCT00987285|Behavioral|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
420066|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
420067|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
420068|NCT00987272|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
420069|NCT00987272|Drug|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
420070|NCT00987246|Drug|Placebo Gel|Topical
420071|NCT00987246|Drug|LAS41005|Topical
420072|NCT00987246|Drug|LAS106521|Topical
420073|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
420074|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
420075|NCT00987233|Drug|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
420076|NCT00987220|Drug|Placebo|Oral
420077|NCT00987220|Drug|donepezil (Aricept)|5mg oral
420078|NCT00987207|Drug|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
420079|NCT00987207|Other|No injection|No cyclosporine A is administered before aortic cross-declamping.
420080|NCT00987168|Drug|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
420081|NCT00987155|Device|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
420082|NCT00987142|Drug|CX501|Cultured chimeric skin
420083|NCT00987142|Device|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
420084|NCT00987116|Drug|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.~Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
420085|NCT00987103|Drug|Tacrolimus|Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
420086|NCT00987090|Biological|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
420087|NCT00987090|Radiation|MRI|intervention at the inclusion and 18 months after
420088|NCT00987090|Procedure|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
420089|NCT00987090|Biological|Apolipoprotein E genotyping|genotyping at the inclusion
420090|NCT00987090|Biological|Study of cerebrospinal fluid|intervention at the inclusion
420091|NCT00987077|Device|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
420092|NCT00987064|Device|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
420093|NCT00987064|Device|Placebo TLA|TLA treatment with disabled filtration function
420094|NCT00987051|Procedure|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
420095|NCT00987038|Drug|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
420096|NCT00987038|Drug|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
420097|NCT00987025|Behavioral|Telehealth|Use of telehealth blood pressure station every week
420098|NCT00987025|Behavioral|Educational materials|Control
420099|NCT00987012|Dietary Supplement|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
420100|NCT00987012|Dietary Supplement|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
420101|NCT00986999|Drug|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
420102|NCT00986986|Drug|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
420103|NCT00986973|Drug|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
420104|NCT00986960|Drug|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
420105|NCT00986960|Drug|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
420106|NCT00986947|Drug|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.~If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
420107|NCT00986921|Drug|mifepristone 200 mg|mifepristone would be given the day before the procedure
420108|NCT00986921|Device|osmotic dilator insertion|osmotic dilators (3-6) would be inserted as usual the day before the procedure
420109|NCT00986895|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
420110|NCT00986882|Drug|SAF312A|
420111|NCT00986882|Drug|Placebo|
420112|NCT00986882|Drug|Ibuprofen|
420113|NCT00986869|Procedure|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
420114|NCT00986856|Drug|Fucidin® cream|
420115|NCT00986843|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
420116|NCT00986830|Device|FinESS Sinus Treatment|
420117|NCT00986817|Drug|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
420118|NCT00986817|Drug|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
420119|NCT00986804|Drug|Decitabine|
420120|NCT00986791|Other|GSP-A|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
420121|NCT00986778|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
420122|NCT00986778|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
420123|NCT00986778|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
420124|NCT00986765|Drug|Lovenox® (enoxaparin)|Injectable solution 4000 UI
420125|NCT00986765|Drug|Aspegic ® (Aspirin)|100 mg/day
420126|NCT00986752|Device|Stenting (Smart Stent)|Nitinol stent
420127|NCT00986752|Device|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
420128|NCT00986752|Procedure|Atherectomy (SilverHawk device)|Atherectomy
420129|NCT00986713|Drug|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
420130|NCT00986700|Dietary Supplement|late night meal|Three different kinds of late night meal each for 2 days.
420131|NCT00986674|Biological|cixutumumab|Given IV
420132|NCT00986674|Drug|carboplatin|Given IV
420133|NCT00986674|Drug|paclitaxel|Given IV
420134|NCT00986674|Biological|cetuximab|Given IV
420135|NCT00986661|Drug|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
420136|NCT00986609|Biological|MUC-1 peptide vaccine|Given subcutaneously
420137|NCT00986609|Biological|poly ICLC|Given intramuscularly
420138|NCT00986609|Biological|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
420139|NCT00986609|Other|laboratory biomarker analysis|Correlative studies
420140|NCT00986609|Other|enzyme-linked immunosorbent assay|Correlative studies
420141|NCT00986609|Other|flow cytometry|Correlative studies
420142|NCT00986596|Dietary Supplement|vitamin D3|4000 IU once daily by mouth for 4 months
420143|NCT00986596|Dietary Supplement|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
420144|NCT00986583|Drug|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
420145|NCT00986570|Biological|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
420146|NCT00986557|Biological|adoptive immunotherapy|
420147|NCT00986557|Biological|alemtuzumab|
420148|NCT00986557|Biological|in vitro-treated peripheral blood lymphocyte therapy|
420149|NCT00986557|Drug|foscarnet sodium|
420150|NCT00986557|Drug|ganciclovir|
420151|NCT00986557|Genetic|polymerase chain reaction|
420152|NCT00986557|Procedure|allogeneic hematopoietic stem cell transplantation|
420153|NCT00986557|Procedure|infection prophylaxis and management|
420154|NCT00986557|Procedure|peripheral blood stem cell transplantation|
420155|NCT00986557|Procedure|standard follow-up care|
420156|NCT00986557|Radiation|radiation therapy|
420157|NCT00986544|Procedure|no drain|drain positioned on the skin
420158|NCT00986544|Procedure|drain positioned|drain positioned in the subhepatic space
420159|NCT00986544|Procedure|drain not positioned|Drain positioned in the abdominal wall
420160|NCT00986531|Drug|AZD8529|2 capsules by mouth for 3 days
420161|NCT00986531|Drug|Placebo to match AZD8529|2 capsules by mouth for 3 days
420162|NCT00986518|Biological|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
420163|NCT00986505|Drug|Lidocaine|Intravenous lidocaine once a week
420164|NCT00986479|Drug|AZD6765|Single IV infusion of 150 mg AZD6765.
420165|NCT00986479|Drug|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
420166|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
420167|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
420168|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
420169|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
420170|NCT00986453|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
420171|NCT00986453|Procedure|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
420172|NCT00986440|Drug|CS-7017|CS-7017
420173|NCT00986440|Drug|Placebo|Placebo
420174|NCT00986427|Drug|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
420175|NCT00986427|Drug|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
420176|NCT00986414|Drug|AFQ056|
420177|NCT00986414|Drug|AFQ056|
420178|NCT00986414|Drug|AFQ056|
420179|NCT00986414|Drug|AFQ056|
420180|NCT00986414|Drug|AFQ056|
420181|NCT00986414|Drug|Placebo|
420182|NCT00986401|Drug|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
420183|NCT00986401|Drug|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
420184|NCT00986375|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
420185|NCT00986375|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
420186|NCT00986362|Drug|Ocriplasmin|175µg ocriplasmin intravitreal injection
420187|NCT00986362|Drug|Placebo|Placebo intravitreal injection
420188|NCT00986349|Device|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
420189|NCT00986336|Drug|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
420190|NCT00986336|Drug|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
420191|NCT00986336|Drug|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
420192|NCT00986336|Drug|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
420193|NCT00986323|Device|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
420194|NCT00986323|Device|Placebo TLA|Placebo TLA (without filtration and TLA function)
420195|NCT00986310|Drug|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
420196|NCT00986310|Drug|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
420197|NCT00986297|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
420198|NCT00986284|Drug|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
420199|NCT00986271|Procedure|EVLI was determinated by PiCCO plus system.|
420200|NCT00986258|Drug|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (PR) twice daily. Opioid rotation to tapentadol was scheduled as follows:~if less than 100 mg morphine equivalent start with 50 mg tapentadol PR;~if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol PR;~if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol PR.~Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks, the doses of tapentadol PR were kept stable (start of Maintenance phase). The tapentadol PR formulation was administered for up to 12 weeks. Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release any more when a daily dose of 500 mg tapentadol PR was reached."
420201|NCT00986245|Drug|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
420202|NCT00986232|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
420203|NCT00986232|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
420204|NCT00986232|Biological|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
420205|NCT00986206|Diagnostic Test|Biomarker LPA and HE4|Non Interventional Trial
420206|NCT00986193|Procedure|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
420207|NCT00986193|Procedure|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
420208|NCT00986180|Drug|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
420209|NCT00986180|Drug|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
420210|NCT00986167|Drug|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
420211|NCT00986154|Drug|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
420212|NCT00986154|Drug|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.~Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
420213|NCT00986154|Drug|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
420214|NCT00986141|Procedure|Surgery|Selective Laser Trabeculoplasty for glaucoma
420215|NCT00986141|Procedure|Selective Laser Trabeculoplasty|Glaucoma Treatment
420216|NCT00986128|Drug|topiramate|100 mg tablet twice daily for 3 weeks
420217|NCT00986128|Drug|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
420218|NCT00986115|Drug|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
420219|NCT00986115|Drug|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
420220|NCT00986102|Drug|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
420221|NCT00986076|Drug|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
420222|NCT00986076|Drug|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
420223|NCT00986063|Genetic|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
420224|NCT00986063|Other|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
420225|NCT00986050|Drug|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
420226|NCT00986050|Device|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
420227|NCT00986050|Device|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
420228|NCT00986037|Drug|ABT-308|Single IV doses
420229|NCT00986037|Drug|ABT-308|Multiple SC doses x 3
420230|NCT00986037|Drug|Placebo|Single IV dose
420231|NCT00986037|Drug|Placebo|Multiple SC doses x 3
420232|NCT00986024|Behavioral|aerobic exercise|carried out 3 times per week for 12 weeks
420233|NCT00986024|Behavioral|strength training|carried out 3 times per week for 12 weeks
420234|NCT00986011|Other|questionnaire administration|
420235|NCT00986011|Other|study of socioeconomic and demographic variables|
420236|NCT00986011|Other|survey administration|
420237|NCT00986011|Procedure|study of high risk factors|
420238|NCT00985998|Drug|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4~6cycles).~the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12~18 weeks)."
420239|NCT00985985|Drug|Nicotine|2 mg or 4 mg nicotine lozenge
420240|NCT00985985|Drug|Placebo|placebo lozenge
420241|NCT00985972|Behavioral|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
420242|NCT00985959|Drug|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
420243|NCT00985959|Drug|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
420244|NCT00985959|Drug|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
420245|NCT00985959|Drug|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
420246|NCT00985959|Drug|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
420330|NCT00985426|Biological|HEPLISAV|Intramuscular (IM) injections of HEPLISAV at Weeks 0, 4, and 24
420247|NCT00985946|Drug|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
420248|NCT00985933|Drug|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
420249|NCT00985933|Drug|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
420250|NCT00985920|Drug|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
420251|NCT00985920|Drug|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).~The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
420252|NCT00985907|Drug|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
420253|NCT00985894|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
420254|NCT00985894|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
420255|NCT00985881|Device|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
420256|NCT00985881|Device|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
420257|NCT00985868|Drug|multikinase inhibitor AT9283|
420258|NCT00985868|Other|enzyme-linked immunosorbent assay|
420259|NCT00985868|Other|immunohistochemistry staining method|
420260|NCT00985868|Other|laboratory biomarker analysis|
420261|NCT00985868|Other|pharmacological study|
420262|NCT00985855|Drug|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
420263|NCT00985855|Drug|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
420264|NCT00985842|Device|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
420265|NCT00985842|Device|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
420266|NCT00985842|Device|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
420267|NCT00985842|Device|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
420268|NCT00985842|Device|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
420269|NCT00985829|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
420270|NCT00985816|Dietary Supplement|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
420271|NCT00985816|Dietary Supplement|Placebo|Placebo
420272|NCT00985803|Other|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
420273|NCT00985803|Other|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.~The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
420274|NCT00985790|Biological|Influenza vaccine GSK2321138A|Intramuscular injection
420275|NCT00985790|Biological|Fluarix™|Intramuscular injection
420276|NCT00985777|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
420277|NCT00985764|Procedure|cesarean delivery|
420278|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
420279|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
420280|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
420281|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
420282|NCT00985751|Biological|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
420283|NCT00985738|Drug|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
420284|NCT00985738|Other|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
420285|NCT00985725|Drug|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
420286|NCT00985725|Drug|Matching placebo|oral, once daily
420287|NCT00985712|Drug|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
420288|NCT00985712|Drug|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
420289|NCT00985712|Device|HumaPen Memoir|subcutaneously, daily for 24 weeks
420290|NCT00985712|Device|HumaPen Luxura|subcutaneously, daily for 24 weeks
420291|NCT00985699|Genetic|polymorphism analysis|
420292|NCT00985699|Other|laboratory biomarker analysis|
420293|NCT00985699|Other|pharmacogenomic studies|
420294|NCT00985686|Other|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
420295|NCT00985673|Biological|GSK2340274A|Two intramuscular injections
420296|NCT00985673|Biological|GSK2340273A|Two intramuscular injections
420297|NCT00985673|Biological|Seasonal trivalent influenza vaccine (TIV)|Single intramuscular injection
420298|NCT00985673|Biological|Saline placebo|Single intramuscular injection
420299|NCT00985660|Drug|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
420300|NCT00985660|Drug|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
420301|NCT00985647|Drug|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
420302|NCT00985634|Device|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
420303|NCT00985634|Device|Control|Vessel loops
420304|NCT00985621|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
420305|NCT00985621|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
420306|NCT00985621|Drug|oxycodone|oxycodone CR, 10-40 mg q12h
420307|NCT00985621|Other|placebo|placebo
420308|NCT00985608|Drug|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
420309|NCT00985608|Drug|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
420310|NCT00985556|Drug|capecitabine|Given orally
420311|NCT00985556|Drug|oxaliplatin|Given IV
420312|NCT00985556|Drug|tegafur-gimeracil-oteracil potassium|Given orally
420313|NCT00985543|Drug|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
420314|NCT00985530|Drug|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle
420315|NCT00985530|Drug|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
420316|NCT00985517|Biological|CERE-120: Adeno-Associated Virus Delivery of Neurturin|CERE-120 2.4 X 10^12 vg
420317|NCT00985517|Procedure|Sham Surgery|Sham Surgery
420318|NCT00985504|Drug|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
420319|NCT00985504|Drug|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
420320|NCT00985491|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
420321|NCT00985478|Drug|SLV342|25 mg once daily - Maximal Tolerated Dose
420322|NCT00985478|Drug|placebo|matching placebo
420323|NCT00985465|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
420324|NCT00985452|Other|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
420325|NCT00985452|Other|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
420326|NCT00985439|Drug|Diclofenac Test (lower dose)|18-mg Single dose
420327|NCT00985439|Drug|Diclofenac Test (upper dose)|35-mg Single dose
420328|NCT00985439|Drug|Celecoxib 400 mg|Capsules 2 x 200 mg Single-dose
420331|NCT00985426|Biological|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
420332|NCT00985426|Other|Placebo|Placebo(saline) intramuscular (IM) injection at Week 8
420333|NCT00985400|Behavioral|Exercise Program|Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day
420334|NCT00985400|Behavioral|Telephone-based intervention|Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.
420335|NCT00985400|Other|Counseling intervention|Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.
420336|NCT00985400|Other|Questionnaire administration|
420337|NCT00985400|Behavioral|Relaxation Program|Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
420338|NCT00985387|Drug|Solifenacin|oral
420339|NCT00985374|Drug|RAD001|5mg or 10mg po daily
420340|NCT00985374|Drug|RG1507|16mg/kg iv every 3 weeks
420341|NCT00985361|Dietary Supplement|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
420342|NCT00985361|Dietary Supplement|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
420343|NCT00985348|Drug|Levetiracetam (Keppra)|"Test Drug :~Levetiracetam dry syrup~Reference Drug :~500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
420344|NCT00985335|Other|Neem Based External Application Cream|Apply externally 3-4 times per day
420345|NCT00985322|Drug|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
420346|NCT00985322|Drug|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
420347|NCT00985283|Behavioral|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
420348|NCT00985283|Behavioral|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
420349|NCT00985270|Drug|Rifampicin|
420350|NCT00985270|Drug|Placebo|
420351|NCT00985257|Device|DIDGET (Investigational Blood Glucose Monitoring System)|Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
420352|NCT00985244|Drug|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
420353|NCT00985244|Drug|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
420354|NCT00985231|Device|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
420355|NCT00985231|Device|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
420356|NCT00985218|Device|SMART System|microfluidic embryo culture system
420357|NCT00985218|Device|Culture dish|Standard IVF culture dish
420358|NCT00985205|Dietary Supplement|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.
420359|NCT00985205|Dietary Supplement|Placebo|Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
420360|NCT00985192|Drug|everolimus|
420361|NCT00985192|Other|laboratory biomarker analysis|
420362|NCT00985179|Behavioral|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
420363|NCT00985166|Biological|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
420364|NCT00985166|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
420365|NCT00985166|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
420366|NCT00985166|Biological|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
420367|NCT00985153|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A Single 0.5 mL subcutaneous injection at Day 0
420368|NCT00985153|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 0
420369|NCT00985153|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 0
420370|NCT00985140|Radiation|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
420371|NCT00985127|Drug|placebo|administered daily for 21 days
420372|NCT00985127|Drug|BCX4208|Administered daily for 21 days.
420373|NCT00985114|Device|EndoBarrier|EndoBarrier implant
420374|NCT00985114|Behavioral|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
420375|NCT00985088|Biological|GSK2340274A|one or two intramuscular injections
420376|NCT00985088|Biological|GSK2340273A|one or two intramuscular injections
420377|NCT00985088|Biological|Saline placebo|One injection
420378|NCT00985062|Procedure|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
420476|NCT00984503|Drug|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
420379|NCT00985062|Procedure|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
420380|NCT00985036|Procedure|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
420381|NCT00985023|Procedure|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
420382|NCT00985023|Procedure|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
420383|NCT00984997|Procedure|Surgery|Segmentectomy or lobectomy with en bloc resection of the involved chest.
420384|NCT00984997|Radiation|Chest Irradiation|Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
420385|NCT00984997|Drug|Cisplatin|50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
420386|NCT00984997|Drug|Etoposide|given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
420387|NCT00984997|Radiation|Prophylactic Cranial Irradiation|25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
420388|NCT00984984|Drug|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
420389|NCT00984984|Drug|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
420390|NCT00984971|Drug|Tenofovir|Topical gel applied rectally
420391|NCT00984971|Drug|HEC Placebo|Placebo gel applied rectally
420392|NCT00984971|Drug|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
420393|NCT00984958|Device|Bulkamid|injection of Bulkamid in the urethra
420394|NCT00984958|Device|Bulkamid expectation|expectance
420395|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
420396|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
420397|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
420398|NCT00984945|Biological|Placebo|0.5 mL, IM, two injections 21 days apart
420399|NCT00984932|Drug|Rosuvastatin|40 mg of rosuvastatin daily
420400|NCT00984919|Other|high performance liquid chromatography|
420401|NCT00984919|Other|laboratory biomarker analysis|
420402|NCT00984919|Other|mass spectrometry|
420403|NCT00984906|Other|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
420404|NCT00984893|Drug|zoledronic acid|
420405|NCT00984893|Drug|Any oral bisphosphonates marketed in Canada|
420406|NCT00984880|Drug|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
420407|NCT00984867|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
420408|NCT00984867|Drug|Placebo|Matching placebo tablet
420409|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
420410|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
420411|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
420412|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
420413|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
420414|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
420415|NCT00984854|Drug|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
420416|NCT00984841|Other|Tailored letter|
420417|NCT00984828|Drug|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
420418|NCT00984815|Drug|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
420419|NCT00984802|Drug|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
420420|NCT00984802|Drug|Placebo control|Vehicle solution for IV administration single dose.
420421|NCT00984789|Drug|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
420422|NCT00984789|Drug|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
420423|NCT00984776|Other|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
420424|NCT00984763|Biological|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
420425|NCT00984750|Drug|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day~simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
420426|NCT00984750|Drug|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
420427|NCT00984737|Drug|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.~Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
420428|NCT00984724|Behavioral|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
420429|NCT00984724|Behavioral|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period~MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
420430|NCT00984724|Behavioral|Quitline|Letter referring participants to a Quitline providing quit smoking services.
420431|NCT00984724|Behavioral|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
420432|NCT00984698|Behavioral|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
420433|NCT00984698|Behavioral|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
420434|NCT00984659|Drug|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
420435|NCT00984659|Drug|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
420436|NCT00984659|Drug|Placebo|Placebo DISKUS twice a day for 8 weeks
420437|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420438|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420439|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420440|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420441|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420442|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420443|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420444|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420445|NCT00984646|Drug|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
420446|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
420447|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
420448|NCT00984633|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
420449|NCT00984633|Drug|Propofol|4-10 mg/kg/hr maintenance anesthesia
420450|NCT00984620|Drug|BI 201335|BI 201335
420451|NCT00984620|Drug|BI 201335|BI 201335
420452|NCT00984620|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
420453|NCT00984620|Drug|Ribavirin (RBV)|Ribavirin (RBV)
420454|NCT00984607|Procedure|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
420455|NCT00984594|Other|Primary injury site|Autograft will be placed in the primary defect site.
420456|NCT00984594|Other|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
420457|NCT00984581|Drug|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
420458|NCT00984581|Drug|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
420459|NCT00984581|Drug|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
420460|NCT00984568|Biological|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
420461|NCT00984568|Drug|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
420462|NCT00984568|Drug|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
420463|NCT00984568|Drug|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
420464|NCT00984542|Drug|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
420465|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
420466|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
420467|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
420468|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
420469|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
420470|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
420471|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
420472|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
420473|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
420474|NCT00984503|Drug|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
420475|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
422157|NCT00972881|Procedure|therapeutic conventional surgery|
420477|NCT00984490|Drug|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
420478|NCT00984490|Other|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
420479|NCT00984477|Drug|AZD5122|A single dose of oral suspension
420480|NCT00984477|Drug|Placebo|A single dose of oral suspension
420481|NCT00984477|Drug|AZD5122|A single intravenous infusion
420482|NCT00984464|Biological|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
420483|NCT00984464|Drug|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
420484|NCT00984464|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
420485|NCT00984451|Biological|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
420486|NCT00984438|Drug|BCNU Wafer|Implantable during surgical resection into the tumor bed
420487|NCT00984438|Drug|Irinotecan|IV every 2 weeks for up to one year
420488|NCT00984438|Drug|Bevacizumab|IV every 2 weeks for up to one year
420489|NCT00984425|Drug|Lapatinib and Sorafenib|Comparison of different dosages of two drug
420490|NCT00984412|Procedure|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
420491|NCT00984399|Drug|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
420492|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
420493|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
420494|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
420495|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
420496|NCT00984386|Drug|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
420497|NCT00984360|Drug|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
420498|NCT00984347|Drug|Oxytocin|"For low risk group (women at deliveries 1-5):~IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.~For high risk group (grandmultiparas [6th delivery and up] or women with a previous cesarean section)~IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
420499|NCT00984347|Procedure|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
420500|NCT00984334|Drug|Naloxone SR 5 mg capsules|
420501|NCT00984334|Drug|Placebo|
420502|NCT00984334|Drug|Naloxone SR 10 mg capsules|
420503|NCT00984334|Drug|Naloxone SR 20mg capsules|
420504|NCT00984334|Drug|Naloxone SR 2.5 mg capsules|
420505|NCT00984321|Behavioral|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
420506|NCT00984321|Behavioral|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
420507|NCT00984321|Behavioral|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
420508|NCT00984308|Procedure|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
420509|NCT00984295|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
420510|NCT00984295|Biological|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
420511|NCT00984295|Biological|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
420512|NCT00984295|Biological|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
420513|NCT00984295|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
420514|NCT00984282|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
420515|NCT00984282|Drug|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
420516|NCT00984269|Procedure|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
420517|NCT00984256|Drug|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
420666|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
420704|NCT00983021|Drug|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
420518|NCT00984256|Other|Procedure - malaria challenge|2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
420519|NCT00984243|Procedure|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm^2 Excimer-dye laser: 100-200 Joules/cm^2"
420520|NCT00984230|Other|BSF|feeding amount according to individual baby need
420521|NCT00984230|Other|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
420522|NCT00984230|Other|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
420523|NCT00984217|Radiation|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
420524|NCT00984217|Drug|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
420525|NCT00984204|Device|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
420526|NCT00984191|Radiation|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
420527|NCT00984178|Other|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
420528|NCT00984178|Other|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
420529|NCT00984165|Procedure|Single fraction radiation|8-Gy fraction of radiation
420530|NCT00984165|Biological|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
420531|NCT00984165|Procedure|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
420532|NCT00984152|Drug|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
420533|NCT00984152|Drug|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
420534|NCT00984139|Biological|Engerix™-B Kinder|Intramuscular, one dose.
420535|NCT00984126|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
420536|NCT00984126|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
420537|NCT00984113|Drug|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
420538|NCT00984100|Procedure|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
420539|NCT00984087|Device|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
420540|NCT00984074|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
420541|NCT00984074|Procedure|diffusion tensor imaging|
420542|NCT00984074|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
420543|NCT00984074|Procedure|functional magnetic resonance imaging|
420544|NCT00984074|Radiation|intensity-modulated radiation therapy|
420545|NCT00984074|Radiation|radiation therapy treatment planning/simulation|
420546|NCT00984061|Drug|colchicine|0.6mg tablet administered at 9am on Day 1
420547|NCT00984061|Drug|clarithromycin|250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
420548|NCT00984061|Drug|colchicine|0.6 mg tablet administered at 9am on Day 29
420549|NCT00984048|Other|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
420550|NCT00984035|Other|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
420551|NCT00984035|Other|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
420552|NCT00984035|Other|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
420553|NCT00984022|Device|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
420554|NCT00984022|Device|Type of dressing - Aquacel|Aquacel dressing
420555|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
420556|NCT00984009|Other|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
420557|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
420558|NCT00983996|Drug|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
420559|NCT00983996|Drug|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
420560|NCT00983983|Dietary Supplement|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
420749|NCT00982592|Other|placebo|Given PO
420561|NCT00983983|Dietary Supplement|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
420562|NCT00983983|Dietary Supplement|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
420563|NCT00983970|Behavioral|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
420564|NCT00983970|Behavioral|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
420565|NCT00983957|Drug|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
420566|NCT00983957|Drug|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
420567|NCT00983944|Biological|bleomycin sulfate|Given IV
420568|NCT00983944|Biological|rituximab|Given IV
420569|NCT00983944|Drug|EPOCH regimen|Given IV or orally
420570|NCT00983944|Drug|cyclophosphamide|Given IV or orally
420571|NCT00983944|Drug|doxorubicin hydrochloride|Given IV or orally
420572|NCT00983944|Drug|etoposide|Given IV or orally
420573|NCT00983944|Drug|prednisone|Given IV or orally
420574|NCT00983944|Drug|vincristine sulfate|Given IV or orally
420575|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
420576|NCT00983931|Drug|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
420577|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
420578|NCT00983918|Drug|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
420579|NCT00983918|Drug|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
420580|NCT00983918|Drug|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
420581|NCT00983918|Drug|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
420582|NCT00983905|Drug|Theophylline|single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
420583|NCT00983905|Drug|Colchicine|one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
420584|NCT00983892|Behavioral|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
420585|NCT00983866|Behavioral|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
420586|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
420587|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
420588|NCT00983853|Biological|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
420589|NCT00983853|Drug|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
420590|NCT00983853|Drug|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
420591|NCT00983840|Other|Family Eats|8-session web-based program on healthy eating for African American families
420592|NCT00983827|Device|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
420593|NCT00983814|Drug|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID, provided as oral capsules taken TID from Baseline to end of Week 8
420594|NCT00983814|Drug|Placebo|Placebo matched oral capsules taken TID from Baseline to end of Week 8
420668|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
420595|NCT00983801|Drug|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
420596|NCT00983788|Drug|Bezafibrate|3 x 200 mg/ day
420597|NCT00983788|Other|Placebo|Placebo
420598|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
420599|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
420600|NCT00983749|Device|Full-pressure ECP|A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
420601|NCT00983749|Device|Sham-pressure ECP|A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
420602|NCT00983736|Drug|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
420603|NCT00983736|Drug|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).~Subject will take the study drug for about 27 weeks."
420604|NCT00983710|Behavioral|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
420605|NCT00983710|Behavioral|Usual care|Booklet on coping with localized prostate cancer
420606|NCT00983697|Procedure|therapeutic conventional surgery|
420607|NCT00983697|Radiation|fludeoxyglucose F 18|
420608|NCT00983684|Device|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
420609|NCT00983684|Radiation|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
420610|NCT00983658|Drug|huMAb OX40L|Intravenous repeating dose
420611|NCT00983658|Drug|placebo|Intravenous repeating dose
420612|NCT00983645|Drug|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
420613|NCT00983645|Drug|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
420614|NCT00983632|Procedure|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.~For details see detailed study description"
420615|NCT00983632|Device|selective vagus nerve stimulation|electrical vagus stimulation
420616|NCT00983619|Drug|MEDI-551|A humanized Immunoglobulin G (IgG)1 kappa monoclonal antibody (MAb) directed against human CD19.
420617|NCT00983619|Drug|Rituximab|Anti CD-20 and MEDI-551
420618|NCT00983593|Behavioral|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
420619|NCT00983580|Drug|Aspirin|Given PO
420620|NCT00983580|Drug|Eflornithine|Given PO
420621|NCT00983580|Other|Laboratory Biomarker Analysis|Correlative study
420622|NCT00983580|Other|Placebo|Given PO
420623|NCT00983580|Other|Telephone-Based Intervention|Ancillary studies
420624|NCT00983567|Other|teen web|Min web
420625|NCT00983554|Drug|Anastrazole|Arimidex 1mg daily
420626|NCT00983554|Drug|Testosterone|Testim 10g daily
420627|NCT00983554|Drug|Dutasteride|Avodart 2.5mg daily
420628|NCT00983554|Drug|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
420629|NCT00983541|Drug|Fluorouracil (5-FU)|5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
420630|NCT00983541|Radiation|Brachytherapy or SBRT (Stereotactic body radiation therapy)|Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).
420664|NCT00983307|Drug|Erlotinib|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
420667|NCT00983294|Drug|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
420631|NCT00983541|Drug|Gemcitabine|"Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.~Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.~Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.~Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC."
420632|NCT00983528|Biological|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
420633|NCT00983528|Drug|Clofarabine|"Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
420634|NCT00983515|Drug|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
420635|NCT00983515|Drug|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
420636|NCT00983515|Drug|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
420637|NCT00983489|Behavioral|video demonstration|video will be shown to mothers
420638|NCT00983489|Behavioral|counselling|breast feeding counselling
420639|NCT00983476|Behavioral|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
420640|NCT00983476|Behavioral|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
420641|NCT00983450|Other|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
420642|NCT00983450|Other|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity [Celnik et al., 2008]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
420643|NCT00983437|Drug|Armodafinil|
420644|NCT00983424|Drug|Cyclosporins|dose escalation, administered orally twice a day
420645|NCT00983424|Drug|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
420646|NCT00983411|Other|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
420647|NCT00983398|Drug|Carboplatin|Given IA
420648|NCT00983398|Drug|Mannitol|Given IA
420649|NCT00983398|Drug|Melphalan|Given IA
420650|NCT00983398|Other|Quality-of-Life Assessment|Ancillary studies
420651|NCT00983398|Other|Questionnaire Administration|Ancillary studies
420652|NCT00983398|Drug|Sodium Thiosulfate|Given IV
420653|NCT00983385|Drug|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusted with 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed a dose of 500 mg of Tapentadol per day.
420654|NCT00983385|Other|Observation period|Eligibility assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
420655|NCT00983385|Drug|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR participants were not permitted to exceed a total daily tapentadol dose of 500 mg.
420656|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
420657|NCT00983372|Drug|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
420658|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
420659|NCT00983359|Radiation|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
420660|NCT00983346|Drug|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
420661|NCT00983333|Device|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
420662|NCT00983320|Drug|quetiapine|flexible dosage (50 to 300 mg)
420663|NCT00983320|Drug|placebo|placebo
420665|NCT00983307|Radiation|Hypofractionated Radiotherapy|Patients undergo hypofractionated thoracic RT 5 days a week for approximately 2.5 weeks beginning on day 0. Patients also receive erlotinib hydrochloride PO daily beginning on day -5 and continuing for up to 24 months in the absence of disease progression or unacceptable toxicity.
420750|NCT00982592|Drug|vismodegib|Given PO
420669|NCT00983281|Drug|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
420670|NCT00983268|Drug|capecitabine|1000 mg taken by mouth on the days of radiation only.
420671|NCT00983268|Drug|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:~Vorinostat,at 100 mg~Vorinostat,at 200 mg~Vorinostat, at 300 mg~Vorinostat, at 400 mg"
420672|NCT00983268|Radiation|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
420673|NCT00983268|Procedure|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
420674|NCT00983255|Drug|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 & 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
420675|NCT00983255|Drug|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
420676|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
420677|NCT00983242|Drug|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
420678|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
420679|NCT00983229|Procedure|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
420680|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
420681|NCT00983216|Drug|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
420682|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
420683|NCT00983203|Other|FID 114657 ORB Preserved Ocular Emulsion|1 drop OU
420684|NCT00983203|Other|Soothe XP Lubricant Eye Drops|1 drop OU
420685|NCT00983190|Device|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
420686|NCT00983177|Drug|Colchicine|0.5 mg twice daily for 4 months
420687|NCT00983177|Drug|lactose|lactose capsules twice daily
420688|NCT00983164|Dietary Supplement|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
420689|NCT00983151|Drug|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
420690|NCT00983138|Drug|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
420691|NCT00983125|Drug|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.~To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
420692|NCT00983112|Drug|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
420693|NCT00983112|Drug|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
420694|NCT00983099|Drug|Neramexane|single and multiple dose, tablets, oral
420695|NCT00983086|Drug|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
420696|NCT00983073|Drug|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
420697|NCT00983060|Drug|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
420698|NCT00983060|Drug|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
420699|NCT00983047|Drug|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.~Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity."
420700|NCT00983034|Drug|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
420701|NCT00983021|Drug|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
420702|NCT00983021|Drug|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
420703|NCT00983021|Drug|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
420705|NCT00983008|Behavioral|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
420706|NCT00982995|Drug|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
420707|NCT00982982|Drug|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes~Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes."
420708|NCT00982982|Drug|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
420709|NCT00982930|Drug|Tobramycin inhalation powder|Tobramycin inhaled powder
420710|NCT00982917|Behavioral|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
420711|NCT00982917|Behavioral|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
420712|NCT00982904|Drug|Fexinidazole/Placebo|
420713|NCT00982891|Drug|Opioid (morphine sulphate) in low dose|individualized titration
420714|NCT00982878|Drug|Maraviroc|150mg twice daily
420715|NCT00982865|Drug|MSC1936369B|
420716|NCT00982865|Drug|MSC1936369B|
420717|NCT00982865|Drug|MSC1936369B|
420718|NCT00982865|Drug|MSC1936369B|
420719|NCT00982839|Procedure|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
420720|NCT00982839|Procedure|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
420721|NCT00982826|Drug|ABT-072|See Arms information for a detailed description.
420722|NCT00982826|Drug|Placebo|See Arms information for a detailed description.
420723|NCT00982813|Other|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.~Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
420724|NCT00982800|Drug|Gabapentin|200mg 3x/day for 3 days (9 doses total)
420725|NCT00982800|Drug|Placebo Sugar Pill|
420726|NCT00982787|Drug|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract~Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)~Frequency: Once/Twice a day~Duration: 11 week intervention period"
420727|NCT00982774|Biological|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
420728|NCT00982748|Behavioral|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
420729|NCT00982722|Drug|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
420730|NCT00982722|Drug|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
420731|NCT00982709|Behavioral|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
420732|NCT00982696|Biological|Opioid Growth Factor|250ug per kilogram weekly IV infusions
420733|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
420734|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
420735|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
420736|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
420737|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
420738|NCT00982657|Drug|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
420739|NCT00982644|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
420740|NCT00982644|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
420741|NCT00982631|Drug|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
420742|NCT00982618|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
420743|NCT00982618|Procedure|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
420744|NCT00982618|Drug|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
420745|NCT00982605|Procedure|EBUS_TBNA|EBUS during bronchoscopy
420746|NCT00982592|Drug|oxaliplatin|Given IV
420747|NCT00982592|Drug|leucovorin calcium|Given IV
420748|NCT00982592|Drug|fluorouracil|Given IV
420752|NCT00982579|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
420753|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
420754|NCT00982566|Drug|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
420755|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
420756|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
420757|NCT00982553|Drug|Ribavirin|800mg once daily
420758|NCT00982553|Drug|Raltegravir|400mg twice daily
420759|NCT00982540|Drug|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
420760|NCT00982527|Drug|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
420761|NCT00982527|Drug|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
420762|NCT00982501|Drug|WS® 1442 900 mg/d|
420763|NCT00982501|Drug|WS® 1442 1800 mg/d|
420764|NCT00982501|Behavioral|Nordic walking training 2 x 30 min/week|
420765|NCT00982501|Behavioral|Nordic walking training 4x45 min/week|
420766|NCT00982488|Drug|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
420767|NCT00982488|Drug|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
420768|NCT00982475|Procedure|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
420769|NCT00982462|Dietary Supplement|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
420770|NCT00982462|Dietary Supplement|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
420771|NCT00982449|Other|FIAU-PET-CT-2|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
420772|NCT00982449|Other|FIAU-PET-CT-4|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
420773|NCT00982436|Drug|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
420774|NCT00982436|Radiation|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
420775|NCT00982436|Drug|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
420776|NCT00982423|Drug|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
420777|NCT00982410|Behavioral|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
420778|NCT00982410|Behavioral|educational supportive group|A control condition providing social support and education about pain and/or drug use.
420779|NCT00982397|Device|Protecta VR-ICD|Protecta single-chamber implantable cardioverter defibrillators.
420780|NCT00982397|Device|Protecta DR-ICD or CRT-D|Protecta dual-chamber implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators.
420781|NCT00982384|Other|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
420782|NCT00982384|Other|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
420783|NCT00982358|Drug|Valsartan|
420784|NCT00982358|Other|Placebo|
420785|NCT00982345|Drug|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
420786|NCT00982332|Drug|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
420787|NCT00982332|Drug|isotonic sodium chloride solution (placebo)|4 ml intramuscular
420788|NCT00982319|Drug|Broccoli sprout extract|100 µmols of sulforaphane (dissolvable)
420789|NCT00982319|Drug|Mango juice|150 mL of mango juice
420790|NCT00982306|Behavioral|Brief intervention|20 minute one to one counseling session
420791|NCT00982293|Device|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
420792|NCT00982293|Device|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
420793|NCT00982280|Drug|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.~Maintenance Period: Participants continuing on the dose established in the previous period."
420794|NCT00982267|Drug|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
420795|NCT00982254|Drug|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
420796|NCT00982254|Drug|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
420797|NCT00982241|Dietary Supplement|water|drinking water / normal dietary fluids for oral intake
420798|NCT00982228|Drug|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
420799|NCT00982228|Drug|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
420800|NCT00982228|Drug|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
420886|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
420801|NCT00982215|Drug|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
420802|NCT00982215|Drug|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
420803|NCT00982202|Drug|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for ~18months
420804|NCT00982202|Drug|Placebo|1 to 3 tablets daily for ~18 months
420805|NCT00982189|Drug|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
420806|NCT00982189|Drug|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
420807|NCT00982176|Other|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).~MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
420808|NCT00982150|Drug|Talampanel|50mg capsules tid
420809|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
420810|NCT00982137|Biological|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
420811|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
420812|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
420813|NCT00982124|Drug|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
420814|NCT00982111|Drug|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
420815|NCT00982111|Drug|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
420816|NCT00982111|Biological|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
420817|NCT00982098|Procedure|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
420818|NCT00982072|Drug|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
420819|NCT00982072|Drug|prednisolone|Prednisolone 1mg/kg maximum 60mg od
420820|NCT00982059|Other|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
420821|NCT00982046|Device|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
420822|NCT00982046|Device|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
420823|NCT00982046|Device|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
420824|NCT00982046|Device|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
420825|NCT00982046|Device|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
420826|NCT00982046|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
420827|NCT00982033|Drug|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
420828|NCT00982033|Drug|placebo|placebo qd for 24 weeks
420829|NCT00982020|Drug|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
420830|NCT00982020|Behavioral|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
420831|NCT00982020|Behavioral|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
420832|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
420833|NCT00982007|Drug|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
420834|NCT00982007|Drug|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
420835|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
420836|NCT00981994|Behavioral|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
420837|NCT00981981|Dietary Supplement|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
420838|NCT00981981|Dietary Supplement|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
420839|NCT00981981|Dietary Supplement|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
420840|NCT00981981|Dietary Supplement|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
420841|NCT00981981|Dietary Supplement|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
420842|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
420843|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
420844|NCT00981955|Dietary Supplement|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
420845|NCT00981942|Drug|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
420846|NCT00981929|Drug|Tramadol|50 mg single oral dose
420847|NCT00981929|Drug|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
420848|NCT00981929|Drug|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
420849|NCT00981903|Drug|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
420850|NCT00981890|Drug|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
420851|NCT00981877|Drug|GB (Florestor)|S. Boulardii preparation of 1 gram twice daily for 5 days
420852|NCT00981877|Drug|GRALB|mixed probiotic preparation 1 gram twice daily for 5 days.
420853|NCT00981877|Drug|GC (placebo)|Placebo 1 gram twice daily for 5 days.
420854|NCT00981864|Radiation|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
420855|NCT00981851|Drug|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
420856|NCT00981851|Drug|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
420857|NCT00981838|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients > 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
420858|NCT00981825|Drug|Fluoride|Whole mouth brushing for 7 days
420859|NCT00981825|Drug|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
420860|NCT00981812|Procedure|PEM Breast Biopsy|Breast biopsy using PEM guidance and Stereo Navigator software
420861|NCT00981799|Drug|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
420862|NCT00981799|Drug|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
420863|NCT00981799|Drug|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
420864|NCT00981799|Drug|Methotrexate|"Give between day 29 and 36 or when ANC>750 and PLTS>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.~Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but <2 years of age 10 mg for patients age greater than or equal to 2, but <3 years of age 12 mg for patients greater than or equal to 3, but < 9 years of age 15 mg for patients greater than or equal to >9 years of age"
420865|NCT00981799|Drug|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000/mm3 for two consecutive days.
420866|NCT00981786|Drug|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
420867|NCT00981786|Drug|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
420868|NCT00981773|Drug|Maraviroc|Maraviroc 150 mg bid
420869|NCT00981773|Drug|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
420870|NCT00981747|Drug|Sildenafil|Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
420871|NCT00981747|Drug|Losartan|Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
420872|NCT00981747|Drug|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
420873|NCT00981747|Drug|Placebo Oral Tablet|Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
420874|NCT00981734|Other|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
420875|NCT00981721|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
420876|NCT00981708|Drug|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.~Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.~Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.~The cycle is to be repeated every 28 days (4 weeks)"
420877|NCT00981695|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
420878|NCT00981682|Drug|SER120|once a day treatment of nocturia
420879|NCT00981669|Biological|rotavirus vaccine|3 doses with 6 weeks interval
420880|NCT00981669|Biological|placebo|3 doses with 6 weeks interval
420881|NCT00981656|Drug|cisplatin|Given IV
420882|NCT00981656|Drug|fluorouracil|Given IV
420883|NCT00981656|Drug|mitomycin C|Given IV
420884|NCT00981643|Behavioral|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
420885|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
420887|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
420888|NCT00981630|Biological|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
420889|NCT00981617|Drug|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
420890|NCT00981617|Drug|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
420891|NCT00981617|Drug|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
420892|NCT00981617|Drug|Placebo|Matching placebo taken once daily for 12 weeks
420893|NCT00981604|Procedure|SILS|Single Incision Laparoscopic Cholecystectomy
420894|NCT00981604|Procedure|Standard Laparoscopic Cholecystectomy|4 port technique
420895|NCT00981591|Drug|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
420896|NCT00981591|Drug|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
420897|NCT00981578|Device|ExAblate 2100|Conformal Bone System
420898|NCT00981565|Procedure|open carpal tunnel release|surgery to release the carpal tunnel
420899|NCT00981565|Other|Night-cast|individual night time splinting
420900|NCT00981552|Radiation|IMRT planning|
420901|NCT00981552|Radiation|4-Field Radiation Planning|
420902|NCT00981539|Procedure|enema|"pre operative rectal enema~one adult bottle to be used rectally the night before surgery"
420903|NCT00981526|Drug|Telmisartan|"Telmisartan 40mg/day for the first 2 weeks.~Telmisartan 80mg/day for the next 10 weeks."
420904|NCT00981526|Drug|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
420905|NCT00981526|Drug|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
420906|NCT00981526|Drug|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
420907|NCT00981513|Biological|Trivalent live attenuated seasonal influenza vaccine|One dose
420908|NCT00981513|Biological|Monovalent live attenuated pandemic influenza vaccine|One dose
420909|NCT00981513|Biological|Saline|One dose
420910|NCT00981500|Procedure|gastric bypass|Roux-en-Y gastric bypass
420911|NCT00981500|Procedure|gastric banding|laparoscopic adjustable gastric banding
420912|NCT00981500|Procedure|sleeve gastrectomy|vertical sleeve gastrectomy
420913|NCT00981487|Drug|Ondansetron|24 mg one time
420914|NCT00981487|Drug|Ondansetron|24 mg, on time in the am
420915|NCT00981474|Drug|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
420916|NCT00981474|Device|Control group|Institutional standard of care.
420917|NCT00981461|Device|HairMax LaserComb|Device application 3 times week, for 26 weeks
420918|NCT00981461|Device|Control Device|Device application 3 times week, for 26 weeks
420919|NCT00981448|Dietary Supplement|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
420920|NCT00981435|Drug|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
420921|NCT00981435|Drug|Ketorolac|Ketorolac 0.5% to lasered eye 4 times/day for 4.5 days
420922|NCT00981435|Drug|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
420923|NCT00981409|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
420924|NCT00981409|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
420925|NCT00981396|Behavioral|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
420926|NCT00981396|Behavioral|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
420927|NCT00981383|Dietary Supplement|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
420928|NCT00981383|Other|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
420929|NCT00981370|Drug|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
420930|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
420931|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
420932|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
420933|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
420934|NCT00981344|Other|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
420935|NCT00981331|Procedure|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
420936|NCT00981331|Procedure|Sham subtalar joint manipulation|The sham manipulation is conducted by placing the ankle in a non-manipulative position, and the operator simply engages the toggle board to simulate the audible noise of the toggle board dropping. No force or thrust is applied to the ankle.
420937|NCT00981318|Drug|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
420938|NCT00981305|Drug|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
420939|NCT00981305|Drug|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
420940|NCT00981292|Dietary Supplement|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
422158|NCT00972881|Radiation|radiation therapy|
420941|NCT00981292|Dietary Supplement|Placebo|Pharmaceutical grade silica was utilized as placebo
420942|NCT00981266|Device|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
420943|NCT00981253|Behavioral|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
420944|NCT00981253|Behavioral|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
420945|NCT00981240|Drug|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion~Route of administration: Intravenous infusion"
420946|NCT00981227|Drug|Eslicarbazepine acetate|Scored tablets
420947|NCT00981227|Drug|Placebo|oral route
420948|NCT00981214|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
420949|NCT00981201|Drug|Celecoxib|"Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
420950|NCT00981201|Drug|Celecoxib|"Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
420951|NCT00981201|Drug|Placebo|"Months 1-3:~By mouth twice daily."
420952|NCT00981201|Drug|Placebo|"Months 4-6:~By mouth twice daily."
420953|NCT00981175|Biological|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
420954|NCT00981175|Biological|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
420955|NCT00981162|Drug|sorafenib tosylate|Given PO
420956|NCT00981162|Drug|everolimus|Given PO
420957|NCT00981162|Other|laboratory biomarker analysis|Correlative study
420958|NCT00981162|Other|pharmacogenomic studies|Correlative study
420959|NCT00981162|Other|pharmacological study|Correlative study
420960|NCT00981149|Drug|duloxetine|Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
420961|NCT00981149|Drug|Placebo|Placebo match duloxetine for 6 week period.
420962|NCT00981136|Procedure|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
420963|NCT00981136|Procedure|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
420964|NCT00981110|Device|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
420965|NCT00981110|Device|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
420966|NCT00981097|Genetic|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
420967|NCT00981097|Other|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
420968|NCT00981084|Drug|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
420969|NCT00981058|Biological|Necitumumab|"800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.~Continues until progressive disease, toxicity, noncompliance, or withdrawal."
420970|NCT00981058|Drug|Gemcitabine|"1250 mg/m2 on Days 1 and 8 of every 3 week cycle.~Continues for a maximum of six cycles."
420971|NCT00981058|Drug|Cisplatin|"75 mg/m2 IV on Day 1 of every 3 week cycle.~Continues for a maximum of six cycles."
420972|NCT00981045|Drug|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
420973|NCT00981045|Drug|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
420974|NCT00981032|Behavioral|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
420975|NCT00981032|Behavioral|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
420976|NCT00981006|Procedure|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
420977|NCT00980980|Drug|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
422335|NCT00971724|Drug|Prednisolone|Oral administration
420978|NCT00980967|Other|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
420979|NCT00980954|Drug|carboplatin|Given IV
420980|NCT00980954|Drug|cisplatin|Given IV
420981|NCT00980954|Drug|paclitaxel|Given IV
420982|NCT00980941|Dietary Supplement|soup with or without starch|
420983|NCT00980889|Device|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
420984|NCT00980889|Device|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
420985|NCT00980876|Drug|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
420986|NCT00980876|Drug|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
420987|NCT00980863|Behavioral|lifestyle intervention to increase physical activity|
420988|NCT00980850|Biological|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
420989|NCT00980850|Biological|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
420990|NCT00980824|Behavioral|Cognitive behavioural therapy|Six sessions brief CBT.
420991|NCT00980824|Other|Standard treatment|Referral to NHS services appropriate to patient's needs
420992|NCT00980798|Drug|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
420993|NCT00980798|Drug|Placebo|placebo tablet once daily for 16 weeks
420994|NCT00980785|Drug|Ramipril|Ramipril 5 mg/day
420995|NCT00980785|Drug|Placebo|Matching Placebo
420996|NCT00980759|Radiation|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
420997|NCT00980759|Radiation|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
420998|NCT00980746|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
420999|NCT00980746|Drug|Placebo|oral route
421000|NCT00980733|Dietary Supplement|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
421001|NCT00980733|Dietary Supplement|Yoghurt|Plain yoghurt same as in intervention group without fortification
421002|NCT00980707|Drug|Inhaled corticosteroid (fluticasone)|inhaled fluticasone 220 ug/bid
421003|NCT00980694|Dietary Supplement|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
421004|NCT00980681|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
421005|NCT00980681|Other|Time of Flight|Each subject will undergo a TOF MRA
421006|NCT00980655|Biological|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.~Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
421007|NCT00980655|Biological|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
421008|NCT00980642|Device|Draeger double-sensor|The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.
421009|NCT00980642|Device|Esophageal stethoscope temperature sensor|Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.
421010|NCT00980642|Device|Foley catheter temperature sensor|Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
421011|NCT00980629|Drug|M516102|Twice a day
421012|NCT00980629|Drug|placebo|Twice a day
421013|NCT00980616|Drug|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
421014|NCT00980603|Drug|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
421015|NCT00980603|Drug|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
421016|NCT00980603|Drug|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
421017|NCT00980590|Device|Airway Scope|Tracheal intubation by Airway Scope
421018|NCT00980590|Device|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
421019|NCT00980577|Device|NUUS|Sonosite Micro Maxx
421020|NCT00980551|Drug|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
421021|NCT00980551|Drug|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
421022|NCT00980551|Drug|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
421023|NCT00980551|Drug|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
421024|NCT00980538|Drug|Etravirine|Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
421025|NCT00980512|Behavioral|Parent Training|16 weeks of parent training led by trained group facilitator
421026|NCT00980473|Procedure|Argon Laser Iridoplasty|
421027|NCT00980473|Drug|Travatan/ Timolol/Azopt|
421028|NCT00980460|Drug|Cisplatin|Given IV
421029|NCT00980460|Drug|Dexrazoxane|Given IV
421030|NCT00980460|Drug|Doxorubicin Hydrochloride|Given IV
421031|NCT00980460|Drug|Fluorouracil|Given IV
421032|NCT00980460|Drug|Irinotecan Hydrochloride|Given IV
421033|NCT00980460|Other|Laboratory Biomarker Analysis|Correlative studies
421034|NCT00980460|Procedure|Liver Transplantation|Undergo liver transplant
421035|NCT00980460|Drug|Temsirolimus|Given IV
421036|NCT00980460|Procedure|Therapeutic Conventional Surgery|Undergo surgery
421037|NCT00980460|Drug|Vincristine Sulfate|Given IV
421038|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
421039|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
421040|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
421041|NCT00980421|Dietary Supplement|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
421042|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
421043|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
421044|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
421045|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
421046|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
421047|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
421048|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
421049|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
421050|NCT00980395|Drug|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
421051|NCT00980395|Drug|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
421052|NCT00980395|Drug|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
421053|NCT00980382|Drug|S-1, Docetaxel|"Phase I study~S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14~Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8~Phase II study~S-1 (80mg/m2/day) q 12 hours po Days 1-14~Docetaxel (35 mg/m2) iv : Days 1, 8"
421054|NCT00980356|Drug|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
421055|NCT00980343|Drug|vismodegib|Given orally
421056|NCT00980343|Procedure|therapeutic conventional surgery|undergo surgery
421057|NCT00980343|Other|laboratory biomarker analysis|correlative studies
421058|NCT00980343|Other|pharmacological study|correlative studies
421059|NCT00980330|Drug|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
421060|NCT00980330|Drug|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
421061|NCT00980330|Drug|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
421062|NCT00980330|Drug|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
421063|NCT00980317|Procedure|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
421064|NCT00980304|Drug|Rituximab|
421065|NCT00980278|Procedure|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
421066|NCT00980278|Biological|Aastrom BRCs|sinus augmentation, BRC application, dental implant
421067|NCT00980252|Behavioral|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
421068|NCT00980239|Drug|Irinotecan|Starting dose of 35 mg/m^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
421069|NCT00980239|Drug|Bevacizumab|10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
421070|NCT00980239|Drug|Oxaliplatin|Starting dose 60 mg/m^2 by vein over 2 hours on Days 1 and 15 of every cycle.
421071|NCT00980239|Drug|Cetuximab|500 mg/m^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
421072|NCT00980213|Drug|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
421073|NCT00980200|Drug|Dose 4 QD|QD once daily
421074|NCT00980200|Drug|Dose 3 QD|QD once daily
421075|NCT00980200|Drug|placebo|placebo
421076|NCT00980200|Drug|Dose 2 QD|QD once daily
421077|NCT00980200|Drug|Dose 1 BD|BD twice daily
421078|NCT00980187|Drug|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
421079|NCT00980187|Drug|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
421080|NCT00980174|Drug|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
421081|NCT00980174|Other|Placebo|Placebo for denosumab (SC injection every 6 months)
421082|NCT00980148|Drug|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
421083|NCT00980148|Drug|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
421084|NCT00980135|Device|Sinecort cream|Application over 29 days
421085|NCT00980135|Drug|Hydrocortison cream|Application over 29 days
421086|NCT00980135|Other|Untreated skin|n.a
421087|NCT00980109|Drug|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
421088|NCT00980109|Drug|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
421089|NCT00980109|Drug|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
421090|NCT00980109|Drug|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
421091|NCT00980083|Drug|Saline|
421092|NCT00980083|Drug|Exendin(9-39)amide|
421093|NCT00980070|Device|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
421094|NCT00980070|Device|Lumbar Puncture Device|Lumbar Puncture positioner
421095|NCT00980070|Other|Standard of Care|Lumbar Puncture positioner
421096|NCT00980057|Device|Adaptive CRT (aCRT)|Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function
421097|NCT00980057|Device|Echo|Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
421098|NCT00980044|Drug|Tramadol|Oral Medication
421099|NCT00980044|Drug|Placebo|Oral Medication
421100|NCT00980031|Drug|Eplerenone|25mg PO daily (QD)for 6 months
421101|NCT00980031|Drug|Lactose Tablet|Lactose tablet
421102|NCT00980018|Drug|Nilotinib|participants will take nilotinib 400mg twice daily by mouth every morning and every evening approximately 12 hours apart. Participants will take two 200mg capsules at each dosing. Nilotinib is taken on an empty stomach with 8 ounces of water. No food is to be eaten for 2 hours prior to the nilotinib dose or for one hour following the dose.
421103|NCT00980005|Biological|GSK investigational vaccine GSK1557482A|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
421104|NCT00980005|Biological|Fluzone®|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
421105|NCT00979992|Other|Laboratory Biomarker Analysis|Correlative studies
421106|NCT00979992|Drug|Sunitinib Malate|Given PO
421107|NCT00979966|Drug|Temsirolimus|25 mg intravenously, once weekly infusion
421108|NCT00979966|Drug|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
421109|NCT00979953|Drug|ADL5859|
421110|NCT00979953|Drug|ADL5747|
421111|NCT00979953|Drug|Oxycodone CR|
421112|NCT00979953|Drug|Placebo|
421113|NCT00979940|Drug|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
421114|NCT00979927|Drug|SPC3649|5 weekly doses
421115|NCT00979927|Drug|saline|5 weekly doses
421116|NCT00979914|Other|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
421117|NCT00979901|Drug|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
421118|NCT00979901|Drug|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
421119|NCT00979901|Drug|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
421120|NCT00979901|Drug|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
421121|NCT00979888|Other|educational intervention|
421122|NCT00979888|Other|informational intervention|
421123|NCT00979888|Other|psychosocial support for caregiver|
421124|NCT00979888|Other|questionnaire administration|
421125|NCT00979888|Procedure|dyspnea management|
421126|NCT00979888|Procedure|management of therapy complications|
421127|NCT00979875|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
421128|NCT00979875|Drug|Insulin lispro|
421129|NCT00979875|Drug|Insulin glulisine|
421130|NCT00979875|Drug|Insulin aspart|
421131|NCT00979862|Drug|Cediranib Maleate|Given PO
421132|NCT00979862|Drug|Cilengitide|Given IV
421133|NCT00979862|Other|Laboratory Biomarker Analysis|Correlative studies
421134|NCT00979849|Drug|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
421135|NCT00979849|Drug|Placebo|Solution for nebulisation, inhaled
421136|NCT00979836|Drug|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
421137|NCT00979823|Other|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
421138|NCT00979823|Other|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
421139|NCT00979810|Drug|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
421140|NCT00979797|Other|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
421141|NCT00979784|Behavioral|Better Weight|Standard cognitive behavioral treatment focused on dietary & exercise behavior
421142|NCT00979784|Behavioral|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
421143|NCT00979771|Drug|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
421144|NCT00979771|Drug|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
421145|NCT00979758|Drug|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
421146|NCT00979745|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
421147|NCT00979745|Drug|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
421148|NCT00979732|Dietary Supplement|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
421149|NCT00979732|Dietary Supplement|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
421280|NCT00978679|Device|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
421150|NCT00979719|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
421151|NCT00979719|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
421152|NCT00979706|Drug|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.~All patients will be followed-up during 1 year."
421153|NCT00979706|Drug|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.~All patients will be followed-up during 1 year."
421154|NCT00979693|Drug|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
421155|NCT00979693|Drug|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
421156|NCT00979680|Radiation|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
421157|NCT00979680|Radiation|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
421158|NCT00979667|Drug|Oseltamivir|75 mg twice daily for 5 days
421159|NCT00979667|Drug|Zanamivir|10 mg twice daily for 5 days
421160|NCT00979667|Drug|Placebo of Oseltamivir|twice daily for 5 days
421161|NCT00979654|Drug|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
421162|NCT00979641|Drug|Docetaxel|
421163|NCT00979628|Drug|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
421164|NCT00979628|Drug|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
421165|NCT00979628|Drug|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
421166|NCT00979615|Drug|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
421167|NCT00979615|Drug|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
421168|NCT00979602|Biological|GSK2340274A|One intramuscular injection
421169|NCT00979602|Biological|GSK2340273A|One intramuscular injection
421170|NCT00979589|Drug|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
421171|NCT00979589|Drug|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
421172|NCT00979576|Drug|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m^2
421173|NCT00979576|Drug|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m^2
421174|NCT00979576|Drug|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m^2
421175|NCT00979576|Drug|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m^2
421176|NCT00979576|Drug|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m^2
421177|NCT00979563|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
421178|NCT00979550|Drug|Imiquimod|commercially available topical antiviral drug
421179|NCT00979550|Drug|non-medicated petroleum cream|Over the counter topical cream used to aid the healing process in skin lesions
421180|NCT00979537|Drug|Nisoldipine Extended-release Tablets, 40 mg|
421181|NCT00979537|Drug|Sular Tablets, 40 mg|
421182|NCT00979524|Behavioral|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
421183|NCT00979511|Other|milk and exercise|"milk fortified with 1000mg calcium or low-calcium milk~weight-bearing exercise or passive exercise"
421184|NCT00979472|Drug|Solifenacin|oral
421185|NCT00979459|Drug|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
421186|NCT00979459|Drug|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
421187|NCT00979446|Behavioral|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
421188|NCT00979446|Behavioral|Self-directed|Received study materials but no phone coaching
421189|NCT00979433|Device|Bubble CPAP|Bubble CPAP will be delivered using Fischer & Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
421230|NCT00979121|Drug|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
421281|NCT00978679|Device|Spectacles|Daily use of single vision lenses to correct refractive errors
421190|NCT00979433|Device|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
421191|NCT00979407|Biological|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
421192|NCT00979407|Biological|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
421193|NCT00979381|Biological|influenza vaccine|influenza vaccination
421194|NCT00979368|Drug|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
421195|NCT00979368|Drug|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
421196|NCT00979368|Drug|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
421197|NCT00979368|Drug|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
421198|NCT00979368|Drug|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
421199|NCT00979368|Drug|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
421200|NCT00979355|Device|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
421201|NCT00979342|Device|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
421202|NCT00979329|Other|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
421203|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
421204|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
421205|NCT00979316|Drug|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
421206|NCT00979316|Drug|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
421207|NCT00979303|Device|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
421208|NCT00979264|Behavioral|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
421209|NCT00979251|Drug|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
421210|NCT00979251|Drug|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
421211|NCT00979238|Genetic|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
421212|NCT00979238|Drug|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
421213|NCT00979225|Other|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
421214|NCT00979225|Other|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
421215|NCT00979212|Drug|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
421216|NCT00979212|Drug|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
421217|NCT00979212|Drug|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
421218|NCT00979212|Procedure|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
421219|NCT00979199|Other|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
421220|NCT00979186|Device|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
421221|NCT00979173|Drug|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
421222|NCT00979160|Drug|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
421223|NCT00979147|Procedure|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
421224|NCT00979147|Procedure|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
421225|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
421226|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
421227|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
421228|NCT00979134|Drug|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
421229|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
421282|NCT00978653|Drug|allopurinol|150 mg once a day
421231|NCT00979121|Drug|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
421232|NCT00979108|Other|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
421233|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
421234|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
421235|NCT00979069|Behavioral|Aerobic group|12 weeks of aerobic exercise 3 times a week
421236|NCT00979056|Drug|Rifaximin|400 mg per day, oral use, maximum duration 28 days
421237|NCT00979056|Drug|Lactose|Coated Tablet, Oral Use
421238|NCT00979043|Behavioral|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
421239|NCT00979043|Behavioral|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
421240|NCT00979017|Drug|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
421241|NCT00979017|Drug|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
421242|NCT00979017|Drug|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
421243|NCT00979004|Drug|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
421244|NCT00978978|Drug|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'~Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
421245|NCT00978965|Genetic|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
421246|NCT00978952|Device|Large Diameter Advanta™ V12 Covered Stent|Stent placement
421247|NCT00978939|Other|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
421248|NCT00978939|Other|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
421249|NCT00978913|Biological|DC vaccine|DC vaccination, one vaccine biweekly
421250|NCT00978900|Dietary Supplement|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
421251|NCT00978900|Dietary Supplement|Water|
421252|NCT00978887|Other|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
421253|NCT00978887|Other|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
421254|NCT00978874|Radiation|fludeoxyglucose F 18|
421255|NCT00978874|Radiation|fluorine F 18 EF5|
421256|NCT00978861|Drug|Hydrogen Peroxide|Whitening product syringe type
421257|NCT00978835|Behavioral|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
421258|NCT00978835|Behavioral|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
421259|NCT00978822|Drug|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
421260|NCT00978809|Other|Epley maneuver|
421261|NCT00978809|Other|Semont maneuver|
421262|NCT00978796|Drug|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
421263|NCT00978796|Drug|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
421264|NCT00978783|Device|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
421265|NCT00978783|Device|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
421266|NCT00978770|Drug|systemic chemotherapy|
421267|NCT00978770|Procedure|diffusion-weighted magnetic resonance imaging|
421268|NCT00978770|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
421269|NCT00978770|Procedure|magnetic resonance spectroscopic imaging|
421270|NCT00978770|Procedure|neoadjuvant therapy|
421271|NCT00978757|Drug|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
421272|NCT00978757|Other|Placebo|saline solution
421273|NCT00978731|Drug|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:~5 days on, 2 days off~6 days on, 1 day off~Continuous daily dosing~Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
421274|NCT00978718|Dietary Supplement|high-selenium baker's yeast|Given orally
421275|NCT00978718|Dietary Supplement|selenium|Given orally
421276|NCT00978718|Other|placebo|Given orally
421277|NCT00978705|Drug|Autologous cultured keratinocyte cell|3x10^7 cell/ vial
421278|NCT00978692|Device|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
421279|NCT00978692|Device|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
421283|NCT00978640|Other|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
421284|NCT00978640|Other|exercise|exercise 1 h 50% VO2max
421285|NCT00978627|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
421286|NCT00978627|Drug|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
421287|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
421288|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
421289|NCT00978614|Drug|Neramexane|"Dosage form:~25 mg immediate release [IR] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"
421290|NCT00978601|Procedure|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
421291|NCT00978588|Drug|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
421292|NCT00978575|Drug|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
421293|NCT00978575|Drug|Ferrosulfate|200mg daily for 12 weeks
421294|NCT00978575|Drug|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
421295|NCT00978562|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
421296|NCT00978562|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
421297|NCT00978562|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
421298|NCT00978562|Drug|Gadolinium|Given IV
421299|NCT00978549|Drug|docetaxel|
421300|NCT00978549|Drug|steroid therapy|
421301|NCT00978549|Other|questionnaire administration|
421302|NCT00978549|Procedure|nausea and vomiting therapy|
421303|NCT00978549|Procedure|pain therapy|
421304|NCT00978549|Procedure|quality-of-life assessment|
421305|NCT00978549|Procedure|standard follow-up care|
421306|NCT00978549|Radiation|radiation therapy|
421307|NCT00978536|Other|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
421308|NCT00978523|Drug|AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)|Oral, dose-escalation
421309|NCT00978497|Drug|placebo|oral BID
421310|NCT00978497|Drug|ANA598|oral 200mg BID
421311|NCT00978497|Drug|ANA598|oral 400mg BID
421312|NCT00978497|Drug|Peginterferon|180 μg dose via subcutaneous injection weekly
421313|NCT00978497|Drug|Ribavirin|oral 1000 mg/day for patients who weighed < 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
421314|NCT00978484|Behavioral|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
421315|NCT00978484|Behavioral|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
421316|NCT00978471|Drug|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
421317|NCT00978458|Drug|temozolomide|Given orally
421318|NCT00978458|Radiation|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
421319|NCT00978458|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
421320|NCT00978445|Other|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
421321|NCT00978432|Drug|RAD001|10 mg/day for Part 1 of the trial
421322|NCT00978432|Drug|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
421323|NCT00978432|Drug|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
421324|NCT00978419|Drug|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
421325|NCT00978419|Drug|Placebo|Placebo administered every day for up to 28 days
421326|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
421327|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
421328|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
421329|NCT00978393|Drug|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
421330|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
421331|NCT00978393|Drug|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
421332|NCT00978380|Drug|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
421333|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
421334|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
421482|NCT00977457|Genetic|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
421335|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
421336|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
421337|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
421338|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
421339|NCT00978354|Drug|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
421340|NCT00978354|Drug|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
421341|NCT00978341|Drug|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
421342|NCT00978341|Drug|Placebo for pregabalin|Placebo capsules BID for 7.5 days
421343|NCT00978328|Drug|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
421344|NCT00978315|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
421345|NCT00978315|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
421346|NCT00978302|Drug|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
421347|NCT00978302|Drug|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
421348|NCT00978302|Drug|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
421349|NCT00978302|Drug|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
421350|NCT00978302|Drug|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
421351|NCT00978302|Drug|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
421352|NCT00978302|Drug|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
421353|NCT00978263|Drug|metformin-based Oral Antidiabetic Drugs|
421354|NCT00978263|Drug|Glargine|
421355|NCT00978250|Drug|5-Fluoro-2-Deoxycytidine (FdCyd) + THU|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the AUC of the pare compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into DNA and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNM and in turn DNA methylation,can result in the re-expression of tumor suppressor genes.
421356|NCT00978237|Drug|EFV|one pill QD VO.
421357|NCT00978237|Drug|LPV/r|2 pills QD VO
421358|NCT00978224|Dietary Supplement|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
421359|NCT00978224|Dietary Supplement|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
421360|NCT00978211|Drug|DOTA-TOC Treatment|"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~renal toxicity~loss of patient transferability or~denial of further treatment."
421361|NCT00978198|Drug|ASP1517|oral
421362|NCT00978198|Drug|Placebo|oral
421363|NCT00978185|Other|medical chart review|
421364|NCT00978185|Other|questionnaire administration|
421365|NCT00978185|Procedure|acupressure therapy|
421366|NCT00978185|Procedure|quality-of-life assessment|
421367|NCT00978185|Procedure|sham intervention|
421368|NCT00978185|Procedure|standard follow-up care|
421369|NCT00978172|Drug|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
421370|NCT00978159|Drug|esomeprazole|esomeprazole 20 mg po for 4 weeks
421371|NCT00978159|Drug|Famotidine|Famotidine 40 mg po for 4 weeks
421372|NCT00978146|Drug|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
421373|NCT00978133|Procedure|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
421374|NCT00978133|Procedure|Skin closure with skin staples|Skin closure with skin staples
421375|NCT00978120|Biological|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
421376|NCT00978120|Biological|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
421377|NCT00978107|Biological|MVA-FCU1, flucytosine|"TG4023: single IT injection; possibility to re-administer once,~Percutaneous IT injections, under radiological or ultrasound imaging guidance~Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),~MTD injected to up to 3 different lesions (Cohort #4)~5-FC (5-fluorocytosine)/flucytosine~Dose and dosing schedule:~Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L~Duration: 2 weeks.~Possible routes of administration:~PO: 500 mg tablets, qid~IV: 1% 250 mL vials, 45-minute infusions."
421378|NCT00978081|Drug|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
421379|NCT00978068|Drug|Lopinavir/Ritonavir (LPV/r)|
421380|NCT00978068|Drug|Nevirapine (NVP)|NVP will be used for children < 3 years of age
421381|NCT00978068|Drug|Efavirenz (EFV)|EFV for children ≥3 years of age
421382|NCT00978068|Drug|2 nucleoside reverse transcriptase inhibitor (NRTI)|The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons.
421383|NCT00978055|Drug|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
421384|NCT00978055|Drug|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg~2 x 50 mcg, single-dose, fasting"
421385|NCT00978042|Device|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
421386|NCT00978029|Drug|Placebo|Placebo sublingual tablet, once daily
421387|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
421388|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
421389|NCT00978016|Drug|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
421390|NCT00978016|Drug|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
421391|NCT00978016|Drug|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
421392|NCT00978016|Drug|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
421393|NCT00978016|Drug|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
421394|NCT00978016|Drug|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
421395|NCT00977977|Drug|Rituximab Infusion|2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
421396|NCT00977977|Drug|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
421397|NCT00977964|Other|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
421398|NCT00977964|Other|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
421399|NCT00977964|Other|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
421400|NCT00977964|Other|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
421401|NCT00977964|Other|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
421402|NCT00977964|Other|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
421403|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
421404|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
421405|NCT00977951|Drug|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
421406|NCT00977951|Drug|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
421407|NCT00977938|Drug|Placebo & Aspirin|
421408|NCT00977938|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|
421409|NCT00977925|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
421410|NCT00977925|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
421411|NCT00977912|Dietary Supplement|Probiotic supplementation|one capsule containing probiotics per day added to milk
421412|NCT00977912|Dietary Supplement|Milk containing placebo|one capsule containing placebo per day added to milk
421413|NCT00977899|Biological|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
421414|NCT00977886|Drug|Placebo|Oral, 10 days
421415|NCT00977886|Drug|ELB353|Oral, 10 days
421416|NCT00977873|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
421417|NCT00977873|Dietary Supplement|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
421418|NCT00977860|Radiation|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
421419|NCT00977847|Other|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
421420|NCT00977821|Other|IVF|
421421|NCT00977821|Other|Oocyte Vitrification|
421422|NCT00977808|Device|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
421483|NCT00977457|Genetic|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
421738|NCT00975754|Drug|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
421423|NCT00977808|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
421424|NCT00977795|Drug|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
421425|NCT00977769|Drug|carbetocin 100 µg|Hemodynamic effect of
421426|NCT00977769|Drug|oxytocin 5 u|Hemodynamic effect of
421427|NCT00977769|Drug|placebo (NaCl)|Hemodynamic effect of
421428|NCT00977756|Drug|Raltegravir (RAL)|400 mg twice daily (BID)
421429|NCT00977756|Drug|Atazanavir (ATV)|300 mg daily
421430|NCT00977756|Drug|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
421431|NCT00977756|Drug|Tenofovir (TDF)|300 mg daily
421432|NCT00977756|Drug|Etravirine (ETV)|200 mg BID
421433|NCT00977756|Drug|Darunavir (DRV)|Dosing by weight
421434|NCT00977756|Drug|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
421435|NCT00977756|Drug|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
421436|NCT00977730|Dietary Supplement|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
421437|NCT00977730|Dietary Supplement|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
421438|NCT00977704|Device|Restylane and Perlane|
421439|NCT00977691|Procedure|PBSC Transplant|PBSC transplant
421440|NCT00977691|Drug|Alemtuzumab|alemtuzumab
421441|NCT00977691|Drug|Sirolimus|sirolimus
421442|NCT00977691|Drug|Cyclophosphamide|cyclophosphamide
421443|NCT00977691|Procedure|Low Dose Irradiation|low dose irradiation
421444|NCT00977678|Other|open access gastroscopy|access to gastroscopy without preceding appointment
421445|NCT00977678|Other|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
421446|NCT00977665|Drug|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
421447|NCT00977665|Drug|placebo|placebo tablet for 48 weeks
421448|NCT00977652|Procedure|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
421449|NCT00977652|Procedure|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
421450|NCT00977639|Procedure|Pathwork TOO test|
421451|NCT00977626|Drug|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
421452|NCT00977626|Drug|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
421453|NCT00977626|Drug|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
421454|NCT00977613|Behavioral|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
421455|NCT00977600|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
421456|NCT00977600|Drug|Ammonul|
421457|NCT00977600|Drug|Buphenyl|
421458|NCT00977587|Drug|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
421459|NCT00977587|Drug|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:~Calcium phosphate, Dibasic 472.0 mg~Maltodextrin DE14 112.1 mg~Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
421460|NCT00977574|Biological|Bevacizumab|Given IV
421461|NCT00977574|Drug|Carboplatin|Given IV
421462|NCT00977574|Drug|Ixabepilone|Given IV
421463|NCT00977574|Other|Laboratory Biomarker Analysis|Correlative studies
421464|NCT00977574|Drug|Paclitaxel|Given IV
421465|NCT00977574|Drug|Temsirolimus|Given IV
421466|NCT00977561|Drug|figitumumab|Figitumumab (20 mg/kg)
421467|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
421468|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
421469|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
421470|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
421471|NCT00977548|Drug|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
421472|NCT00977522|Drug|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
421473|NCT00977522|Drug|Placebo|Placebo tablet BID
421474|NCT00977496|Procedure|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
421475|NCT00977483|Drug|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
421476|NCT00977483|Drug|Placebo|1 tablet once daily 4 years double-blind treatment period
421477|NCT00977470|Drug|Erlotinib|150 mg taken orally once daily
421478|NCT00977470|Drug|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
421479|NCT00977457|Genetic|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
421480|NCT00977457|Genetic|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
421481|NCT00977457|Genetic|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
421484|NCT00977457|Other|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
421485|NCT00977457|Procedure|therapeutic conventional surgery|
421486|NCT00977444|Drug|kondrium|intraarticular injections once month
421487|NCT00977444|Drug|kondrium f|intraarticular injections once month
421488|NCT00977444|Drug|methyl prednisolone (corticosteroid)|intraarticular injections once month
421489|NCT00977431|Drug|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
421490|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
421491|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
421492|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
421493|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
421494|NCT00977418|Behavioral|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
421495|NCT00977418|Other|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
421496|NCT00977405|Device|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
421497|NCT00977392|Behavioral|compliance monitoring|
421498|NCT00977392|Other|cervical Papanicolaou test|
421499|NCT00977392|Other|educational intervention|
421500|NCT00977392|Other|screening questionnaire administration|
421501|NCT00977392|Other|survey administration|
421502|NCT00977392|Procedure|colposcopy|
421503|NCT00977379|Radiation|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
421504|NCT00977379|Drug|Capecitabine|825 mg/m^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
421505|NCT00977379|Drug|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
421506|NCT00977366|Other|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
421507|NCT00977366|Other|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
421508|NCT00977353|Drug|citalopram|20-60 mg/day, oral, for 6 weeks
421509|NCT00977353|Drug|sarcosine|500-1500 mg/day, oral, for 6 weeks
421510|NCT00977340|Behavioral|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
421511|NCT00977340|Behavioral|confrontation|Confrontation
421512|NCT00977340|Behavioral|imagination|Imagination
421513|NCT00977327|Device|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
421514|NCT00977327|Device|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
421515|NCT00977314|Device|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
421516|NCT00977314|Device|SoundBite|
421517|NCT00977314|Device|SoundBite Hearing System|
421518|NCT00977301|Drug|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
421519|NCT00977301|Drug|olanzapine|15 mg olanzapine single dose
421520|NCT00977301|Drug|olanzapine|10 mg olanzapine single dose
421521|NCT00977288|Drug|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
421522|NCT00977288|Drug|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
421523|NCT00977288|Drug|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
421524|NCT00977275|Radiation|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
421525|NCT00977262|Other|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
421526|NCT00977262|Other|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
421527|NCT00977262|Other|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
421528|NCT00977249|Behavioral|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
421529|NCT00977249|Drug|varenicline|
421530|NCT00977249|Drug|placebo|
421531|NCT00977236|Device|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
421532|NCT00977236|Device|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
421533|NCT00977223|Drug|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
421534|NCT00977210|Drug|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
421535|NCT00977197|Drug|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
421536|NCT00977197|Drug|Placebo|A matching placebo will be administered twice a day
421537|NCT00977184|Procedure|50 HZ Repetitive TMS|
421538|NCT00977184|Procedure|Sham rTMS|
421539|NCT00977171|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
421540|NCT00977158|Procedure|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
421541|NCT00977145|Biological|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.~Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
421542|NCT00977132|Drug|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme~day morning dose midday dose evening dose contents of 1 tablet~1+2 0 0 1 500 mg~3+4 ½ 0 1 500 mg~5+6 1 0 1 500 mg~7+8 1 ½ 1 500 mg~9+10 1 1 1 500 mg~11+12 1 1 1 500 mg~In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
421543|NCT00977132|Drug|Lenalidomide|"5 mg/day, continuous therapy~Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.~Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
421544|NCT00977119|Other|Side-effect questionnaires|Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
421545|NCT00977119|Other|research blood samples|Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
421546|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
421547|NCT00977106|Drug|placebo|single iv infusion
421548|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
421549|NCT00977093|Other|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
421550|NCT00977093|Other|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
421551|NCT00977080|Drug|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
421552|NCT00977080|Drug|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
421553|NCT00977067|Drug|GDC-0152|Intravenous escalating dose
421554|NCT00977054|Drug|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
421555|NCT00977054|Drug|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
421556|NCT00977041|Behavioral|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
421557|NCT00977028|Drug|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
421558|NCT00977028|Procedure|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
421559|NCT00977015|Drug|Treatment A|Inhaled, 750/150, single dose
421560|NCT00977015|Drug|Treatment B|Inhaled, 750/150, single dose
421561|NCT00977002|Other|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
421562|NCT00977002|Other|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
421563|NCT00976989|Drug|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
421564|NCT00976989|Drug|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
421565|NCT00976989|Drug|FEC|5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2 and cyclophosphamide 600 mg/m^2.
421566|NCT00976989|Drug|Docetaxel|75 mg/m^2 for the first dose; 100 mg/m^2 if no dose limiting toxicity occurs.
421567|NCT00976989|Drug|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m^2. All treatments were given every three weeks by the IV route.
421568|NCT00976976|Drug|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
421569|NCT00976963|Drug|Fosfomycin|3g sachet single dose
421570|NCT00976963|Drug|TMP/SMX DS|160/800mg BID x 3 days
421571|NCT00976950|Drug|Tipranavir|
421572|NCT00976950|Drug|ritonavir|low-dose
421573|NCT00976937|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
421574|NCT00976937|Drug|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
421576|NCT00976937|Drug|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
421577|NCT00976937|Drug|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
421578|NCT00976937|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
421579|NCT00976924|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
421580|NCT00976911|Drug|bevacizumab [Avastin]|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
421581|NCT00976911|Drug|liposomal doxorubicin|40mg/m2 iv every 4 weeks
421582|NCT00976911|Drug|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
421583|NCT00976911|Drug|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
421584|NCT00976898|Radiation|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
421585|NCT00976872|Drug|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
421586|NCT00976872|Drug|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
421587|NCT00976859|Behavioral|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
421588|NCT00976859|Behavioral|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
421589|NCT00976846|Device|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
421590|NCT00976833|Other|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
421591|NCT00976833|Other|Usual Care|Usual Physical Therapy care
421592|NCT00976820|Biological|GSK2340274A|Two intramuscular injections
421593|NCT00976820|Biological|GSK2340273A|Two intramuscular injections
421594|NCT00976807|Other|Pulmonary Rehabilitation|"Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.~Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.~Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.~Each session will also include an education session where relevant."
421595|NCT00976794|Drug|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
421596|NCT00976794|Drug|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
421597|NCT00976768|Drug|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
421598|NCT00976755|Drug|everolimus|"Everolimus:~10mg daily"
421599|NCT00976742|Behavioral|Endurance exercise training|
421600|NCT00976729|Drug|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
421601|NCT00976729|Drug|NOX-E36|single SC doses, at safe and tolerable dose level
421602|NCT00976729|Drug|Placebo|
421603|NCT00976716|Drug|Celecoxib|"Day 1~The first dose: Celecoxib 400mg~The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed~Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)~- Celecoxib 200mg twice daily"
421604|NCT00976703|Other|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
421605|NCT00976703|Other|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
421606|NCT00976690|Drug|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
421607|NCT00976677|Drug|erlotinib hydrochloride|Given PO
421608|NCT00976677|Drug|paclitaxel|Given IV
421609|NCT00976677|Drug|carboplatin|Given IV
421610|NCT00976677|Biological|bevacizumab|Given IV
421611|NCT00976664|Device|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
421612|NCT00976664|Device|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
421613|NCT00976651|Drug|human menopausal gonadotropin|200 IU per day in the late follicular phase
421614|NCT00976638|Other|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
421615|NCT00976638|Other|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
421616|NCT00976625|Procedure|Aortic Valve Replacement|Surgical valve replacement of the aorta
421617|NCT00976612|Drug|Nilotinib|Nilotinib 400mg bid daily
421786|NCT00975481|Drug|alprazolam|Oral capsule; 3 mg alprazolam, single dose
421618|NCT00976599|Drug|CP-690,550 + methotrexate|CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
421619|NCT00976599|Drug|Placebo + Methotrexate|Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
421620|NCT00976573|Biological|bevacizumab|Given IV
421621|NCT00976573|Drug|carboplatin|Given IV
421622|NCT00976573|Drug|everolimus|Given orally
421623|NCT00976573|Drug|paclitaxel|Given IV
421624|NCT00976560|Drug|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
421625|NCT00976560|Other|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
421626|NCT00976534|Drug|AZD1386|90 mg, capsules, oral, during 3 weeks
421627|NCT00976534|Drug|Placebo|capsules, oral, during 3 weeks
421628|NCT00976521|Drug|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
421629|NCT00976521|Other|No local infusion|Intervention without local infusion
421630|NCT00976521|Procedure|Thrombus aspiration|Thrombus aspiration
421631|NCT00976508|Drug|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
421632|NCT00976508|Drug|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
421633|NCT00976495|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
421634|NCT00976495|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
421635|NCT00976495|Drug|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
421636|NCT00976469|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
421637|NCT00976469|Biological|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
421638|NCT00976456|Drug|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
421639|NCT00976456|Drug|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
421640|NCT00976443|Drug|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
421641|NCT00976443|Drug|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
421642|NCT00976430|Procedure|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
421643|NCT00976404|Biological|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
421644|NCT00976404|Drug|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
421645|NCT00976404|Drug|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
421646|NCT00976391|Biological|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
421647|NCT00976391|Drug|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
421648|NCT00976378|Drug|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
421649|NCT00976378|Drug|NOX-A12|single IV dose, at efficacious dose level
421650|NCT00976365|Dietary Supplement|THL-P|20ml/bottle, TID, 24weeks
421651|NCT00976352|Drug|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
421652|NCT00976352|Other|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
421653|NCT00976339|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
421654|NCT00976326|Drug|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
421655|NCT00976313|Procedure|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
421656|NCT00976313|Other|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
421657|NCT00976300|Drug|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
421658|NCT00976300|Drug|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
421737|NCT00975754|Drug|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
421869|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
421659|NCT00976287|Procedure|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
421660|NCT00976287|Procedure|Conserved Therapy|Conserved Therapy
421661|NCT00976274|Dietary Supplement|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
421662|NCT00976274|Dietary Supplement|starch|5 capsules three times everyday for 12 weeks
421663|NCT00976261|Drug|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
421664|NCT00976261|Drug|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
421665|NCT00976261|Other|Placebo|Comparator
421666|NCT00976248|Drug|RAD001|Taken orally once a day
421667|NCT00976235|Device|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
421668|NCT00976222|Drug|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
421669|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
421670|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
421671|NCT00976183|Drug|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
421672|NCT00976183|Drug|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
421673|NCT00976170|Drug|GC33(RO5137382)|IV administration at 6 escalating dose levels.
421674|NCT00976170|Drug|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
421675|NCT00976157|Procedure|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
421676|NCT00976144|Drug|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
421677|NCT00976131|Drug|Coenzyme Q10|"Dose Level 1:~300mg/d (2 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d placebo (2 capsules)taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.~Dose Level 2:~600mg/d (4 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d placebo (4 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.~Dose Level 3:~1200mg/d (8 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d placebo (8 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin."
421678|NCT00976131|Other|Coenzyme Q10 Placebo|"Dose Level 1:~300mg/d placebo (2 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d (2 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.~Dose Level 2:~600mg/d placebo (4 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d (4 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.~Dose Level 3:~1200mg/d placebo (8 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d (8 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin."
421679|NCT00976118|Drug|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
421680|NCT00976118|Drug|placebo|matching placebo to masitinib
421681|NCT00976105|Drug|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
421682|NCT00976105|Drug|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
421683|NCT00976092|Drug|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
421684|NCT00976092|Drug|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
421685|NCT00976092|Drug|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
421686|NCT00976092|Drug|Heparin|i.v. bolus of 70-100 IU/kg body weight
421687|NCT00976079|Device|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
421688|NCT00976079|Device|Placebo TENS|Placebo TENS use
421689|NCT00976066|Drug|Part A Assessing GSK1521498|"Each participant will receive up to three [11C]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.~Each subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
421690|NCT00976066|Drug|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three [11C]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).~Each Part B subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
421691|NCT00976066|Drug|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three [11C]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
421692|NCT00976053|Procedure|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
421693|NCT00976040|Other|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.~In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
421694|NCT00976027|Biological|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
421695|NCT00976027|Biological|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
421696|NCT00976001|Other|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
421697|NCT00976001|Other|As the general practitioner wants to do|
421698|NCT00975988|Drug|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
421699|NCT00975975|Drug|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
421700|NCT00975962|Drug|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
421701|NCT00975962|Procedure|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
421702|NCT00975949|Other|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
421703|NCT00975936|Drug|[14C]-GSK706769|50µg [14C]-GSK706769 containing 250 nCi
421704|NCT00975936|Drug|Ketoconazole|200 mg Ketoconazole (Q12)
421705|NCT00975923|Behavioral|Collaborative Group|"In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams."
421706|NCT00975923|Behavioral|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
421707|NCT00975910|Drug|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
421708|NCT00975910|Drug|saline|Saline arm: infused at the same rate as lidocaine
421709|NCT00975897|Biological|bevacizumab|
421710|NCT00975897|Biological|cetuximab|
421711|NCT00975897|Drug|fluorouracil|
421712|NCT00975897|Drug|irinotecan hydrochloride|
421713|NCT00975897|Drug|leucovorin calcium|
421714|NCT00975897|Drug|oxaliplatin|
421715|NCT00975897|Genetic|RNA analysis|
421716|NCT00975897|Genetic|cytogenetic analysis|
421717|NCT00975897|Genetic|fluorescence in situ hybridization|
421718|NCT00975897|Genetic|gene expression analysis|
421719|NCT00975897|Genetic|mutation analysis|
421720|NCT00975897|Genetic|protein expression analysis|
421721|NCT00975897|Other|diagnostic laboratory biomarker analysis|
421722|NCT00975897|Other|immunohistochemistry staining method|
421723|NCT00975897|Other|questionnaire administration|
421724|NCT00975897|Procedure|cognitive assessment|
421725|NCT00975884|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
421726|NCT00975858|Procedure|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
421727|NCT00975845|Other|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
421728|NCT00975819|Drug|sirolimus|liquid dosing based on trough levels
421729|NCT00975806|Drug|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
421730|NCT00975806|Drug|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
421731|NCT00975793|Other|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
421732|NCT00975780|Other|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
421733|NCT00975780|Other|Usual oral care|Usual oral care and feeding positioning
421734|NCT00975767|Drug|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
421735|NCT00975767|Drug|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
421736|NCT00975754|Drug|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
421739|NCT00975754|Drug|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
421740|NCT00975741|Device|OXIMAX|
421741|NCT00975741|Device|ASMANEX TWISTHALER|
421742|NCT00975728|Dietary Supplement|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
421743|NCT00975715|Drug|TRI476|TRI476 oral suspension doses, based on body weight twice daily
421744|NCT00975715|Drug|Placebo to TRI476|Placebo oral suspension, taken twice daily
421745|NCT00975715|Drug|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
421746|NCT00975702|Procedure|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
421747|NCT00975689|Drug|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
421748|NCT00975676|Other|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
421749|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
421750|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
421751|NCT00975650|Drug|Nasobol®|Intra-nasal Testosterone (2 syringes), b.i.d.
421752|NCT00975650|Drug|Androderm® (Positive Control)|QD administration
421753|NCT00975637|Drug|70 mg SC|70 mg SC
421754|NCT00975637|Drug|210 mg SC|210 mg SC
421755|NCT00975637|Drug|140 mg SC|140 mg SC
421756|NCT00975637|Drug|280 mg SC|280 mg SC
421757|NCT00975637|Drug|Placebo|Placebo SC
421758|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
421759|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
421760|NCT00975611|Drug|Placebo|tablets BID, for 4 weeks
421761|NCT00975585|Device|senofilcon A|soft contact lens, 2-week replacement indicated
421762|NCT00975585|Device|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
421763|NCT00975572|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
421764|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
421765|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
421766|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
421767|NCT00975572|Biological|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
421768|NCT00975572|Biological|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
421769|NCT00975546|Other|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
421770|NCT00975546|Procedure|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
421771|NCT00975533|Device|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
421772|NCT00975533|Drug|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
421773|NCT00975520|Other|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
421774|NCT00975520|Radiation|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
421775|NCT00975507|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
421776|NCT00975507|Biological|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
421777|NCT00975507|Biological|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
421778|NCT00975507|Biological|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
421779|NCT00975494|Drug|Sildenafil|
421780|NCT00975494|Drug|Placebo|
421781|NCT00975481|Drug|dimebon|Oral tablet; 20 mg dimebon, single dose
421782|NCT00975481|Drug|dimebon|Oral tablet; 40 mg dimebon, single dose
421783|NCT00975481|Drug|dimebon|Oral tablet; 60 mg dimebon, single dose
421784|NCT00975481|Drug|placebo|Oral tablet or capsule; placebo, single dose
421785|NCT00975481|Drug|alprazolam|Oral capsule; 1 mg alprazolam, single dose
421787|NCT00975468|Other|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
421788|NCT00975442|Other|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
421789|NCT00975442|Device|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
421790|NCT00975442|Device|Forearm band|All patients were instructed to use a forearm band during all daily activities.
421791|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
421792|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
421793|NCT00975416|Behavioral|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
421794|NCT00975416|Drug|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
421795|NCT00975416|Drug|Placebo|Placebo given in the context of cognitive behavioral therapy
421796|NCT00975403|Device|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
421797|NCT00975403|Device|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
421798|NCT00975390|Dietary Supplement|Carbohydrate|1.2 g/kg/h
421799|NCT00975390|Dietary Supplement|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
421800|NCT00975390|Dietary Supplement|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
421801|NCT00975377|Procedure|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
421802|NCT00975351|Dietary Supplement|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
421803|NCT00975338|Other|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
421804|NCT00975338|Other|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
421805|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
421806|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
421807|NCT00975312|Drug|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
421808|NCT00975312|Drug|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
421809|NCT00975299|Drug|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
421810|NCT00975299|Drug|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
421811|NCT00975286|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
421812|NCT00975286|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
421813|NCT00975286|Drug|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
421814|NCT00975286|Device|Pen auto-injector|Lantus® SoloStar® OptiClik®
421815|NCT00975286|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
421816|NCT00975286|Drug|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
421817|NCT00975273|Behavioral|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
421818|NCT00975273|Behavioral|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
421819|NCT00975247|Other|Receiving an educational booklet|Patients who receive an educational booklet will be considered to be receiving an intervention
421820|NCT00975234|Procedure|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
421821|NCT00975234|Procedure|Revascularisation|Revascularisation surgery
421822|NCT00975221|Drug|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
421823|NCT00975221|Drug|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
421824|NCT00975195|Drug|tiotropium inhalation|
421825|NCT00975195|Drug|salmeterol xinafoate|
421826|NCT00975195|Drug|fluticasone propionate|
421827|NCT00975195|Drug|placebo matched for fluticasone propionate|
421828|NCT00975182|Drug|GDC-0941|Oral repeating dose
421829|NCT00975182|Drug|erlotinib HCl|Oral repeating dose
421830|NCT00975156|Other|Physical Therapy|Conventional physical therapy
421831|NCT00975156|Device|Lokomat|Robotic-assisted walking device
421832|NCT00975143|Drug|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
421833|NCT00975143|Drug|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
421834|NCT00975130|Biological|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
421835|NCT00975130|Biological|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
421836|NCT00975117|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
421837|NCT00975117|Dietary Supplement|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
421838|NCT00975104|Drug|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
421839|NCT00975104|Drug|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
421840|NCT00975104|Drug|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
421841|NCT00975104|Drug|Placebo|Placebo IV QW
421842|NCT00975091|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
421843|NCT00975091|Drug|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
421844|NCT00975078|Procedure|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.~All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.~Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.~On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
421845|NCT00975078|Drug|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
421846|NCT00975065|Drug|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
421847|NCT00975065|Drug|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
421848|NCT00975052|Drug|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
421849|NCT00975052|Drug|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
421850|NCT00975052|Drug|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
421851|NCT00975052|Drug|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
421852|NCT00975039|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
421853|NCT00975026|Procedure|Massages ± Stretches|Chair Massage
421854|NCT00975000|Drug|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
421855|NCT00975000|Drug|Placebo|Administered orally following the same dosing regimen as the experimental arm.
421856|NCT00974987|Radiation|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
421857|NCT00974987|Radiation|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
421858|NCT00974987|Drug|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
421859|NCT00974974|Drug|IPX066|extended-release carbidopa-levodopa capsules
421860|NCT00974974|Drug|IR CD-LD|immediate-release carbidopa-levodopa tablets
421861|NCT00974961|Drug|bupivacaine, levobupivacaine|intrathecal injection 15~20mg(for Levobupivacaine) or 10~15mg(for Bupivacaine) once
421862|NCT00974948|Procedure|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
421863|NCT00974935|Drug|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
421864|NCT00974935|Biological|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
421865|NCT00974922|Drug|Aliskiren|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
421866|NCT00974922|Dietary Supplement|Cholecalciferol|3000 I.U. once daily for 6 weeks
421867|NCT00974922|Dietary Supplement|Placebo|Placebo for two weeks
421868|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system
421870|NCT00974896|Drug|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
421871|NCT00974883|Procedure|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
421872|NCT00974883|Procedure|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
421873|NCT00974870|Procedure|needling treatment|Needling treatment applied to half of the face at each study visit
421874|NCT00974857|Device|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
421875|NCT00974857|Other|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
421876|NCT00974831|Other|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
421877|NCT00974831|Other|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
421878|NCT00974818|Drug|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
421879|NCT00974818|Biological|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
421880|NCT00974805|Drug|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
421881|NCT00974792|Biological|pegfilgrastim|
421882|NCT00974792|Biological|rituximab|
421883|NCT00974792|Drug|cyclophosphamide|
421884|NCT00974792|Drug|cytarabine|
421885|NCT00974792|Drug|doxorubicin hydrochloride|
421886|NCT00974792|Drug|etoposide phosphate|
421887|NCT00974792|Drug|ifosfamide|
421888|NCT00974792|Drug|leucovorin calcium|
421889|NCT00974792|Drug|methotrexate|
421890|NCT00974792|Drug|vincristine sulfate|
421891|NCT00974779|Device|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
421892|NCT00974779|Device|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
421893|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
421894|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
421895|NCT00974753|Drug|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
421896|NCT00974753|Other|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
421897|NCT00974740|Drug|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
421898|NCT00974740|Drug|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
421899|NCT00974727|Other|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
421900|NCT00974714|Drug|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
421901|NCT00974714|Other|placebo|oral placebo 2 g twice a day for 14 weeks
421902|NCT00974701|Device|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
421903|NCT00974688|Behavioral|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
421904|NCT00974688|Behavioral|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
421905|NCT00974675|Biological|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
421906|NCT00974675|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
421907|NCT00974675|Biological|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
421908|NCT00974675|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
421909|NCT00974662|Drug|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 & 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
421910|NCT00974649|Behavioral|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
422780|NCT00968253|Drug|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
421911|NCT00974636|Dietary Supplement|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
421912|NCT00974636|Dietary Supplement|Usual Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
421913|NCT00974623|Device|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
421914|NCT00974597|Device|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
421915|NCT00974584|Drug|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\n\n\n\n\n\n
421916|NCT00974584|Drug|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
421917|NCT00974584|Drug|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter*minute (mg/mL*min).\n
421918|NCT00974584|Drug|cisplatin|Cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of every 3-week cycle.\n
421919|NCT00974584|Drug|paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of every 3-week cycle.\n\n
421920|NCT00974584|Drug|pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 of every 3-week cycle.
421921|NCT00974571|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
421922|NCT00974571|Drug|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
421923|NCT00974571|Drug|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
421924|NCT00974558|Device|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
421925|NCT00974532|Dietary Supplement|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
421926|NCT00974532|Dietary Supplement|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
421927|NCT00974519|Drug|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
421928|NCT00974519|Drug|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
421929|NCT00974519|Drug|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.~Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
421930|NCT00974506|Other|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
421931|NCT00974506|Other|Routine care therapy|Routine care therapy by general practitioner
421932|NCT00974493|Drug|Antibiotics|"The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines."
421933|NCT00974480|Other|Redermic|Cosmetic cream formulation 609637 43.
421934|NCT00974480|Drug|Tretinoin (Rejuva-A)|Tretinoin 0.025% cream.
421935|NCT00974467|Behavioral|After The Injury website|Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
421936|NCT00974467|Other|Control|Usual hospital care provided.
421937|NCT00974454|Drug|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
421938|NCT00974454|Drug|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
421939|NCT00974441|Drug|Divalproex Sodium|500 mg Extended Release Tablet
421940|NCT00974441|Drug|Depakote®|500 mg Extended Release Tablet
421941|NCT00974428|Dietary Supplement|Wobenzym® N|4 tablets TID, 6 weeks
421942|NCT00974428|Dietary Supplement|Placebo|4 tablets TID
421943|NCT00974415|Procedure|CO2|CO2 treatment delivered to randomized flank at each study visit
421944|NCT00974415|Procedure|Sham|Sham treatment to other flank at each study visit
421945|NCT00974402|Behavioral|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
421946|NCT00974389|Biological|bevacizumab|
421947|NCT00974389|Drug|tegafur-gimeracil-oteracil potassium|
421948|NCT00974376|Drug|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
421949|NCT00974376|Drug|Placebo|1200mg/day of placebo for 12 weeks
421950|NCT00974376|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
421951|NCT00974363|Procedure|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
421952|NCT00974350|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER™-Bupivacaine/Once
421953|NCT00974350|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER™-Bupivacaine/Once
421954|NCT00974350|Drug|SABER™-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER™-Placebo/Once
421955|NCT00974324|Drug|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks~CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
421956|NCT00974311|Drug|Enzalutamide|MDV3100, 160 mg orally per day
421957|NCT00974311|Drug|Placebo|Placebo comparator
421958|NCT00974298|Procedure|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
421959|NCT00974285|Drug|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
421960|NCT00974285|Drug|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
421961|NCT00974272|Drug|Exenatide|Single subcutaneous injection (10 μg)
421962|NCT00974272|Other|Normal Saline|Single subcutaneous injection
421963|NCT00974259|Device|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (> 20 mm Hg) or pBrO2 (< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
421964|NCT00974259|Device|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
421965|NCT00974246|Drug|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
421966|NCT00974233|Drug|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
421967|NCT00974233|Drug|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
421968|NCT00974233|Drug|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
421969|NCT00974220|Drug|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
421970|NCT00974220|Drug|normal saline (placebo)|single dose, 0.9% saline solution
421971|NCT00974194|Procedure|Single Trocar CCK|CCK using Triport
421972|NCT00974194|Procedure|Standard CCK|CCK using three or four ports
421973|NCT00974181|Device|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
421974|NCT00974181|Device|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
421975|NCT00974168|Radiation|Cumulative BED ≤ 100|Radiation
421976|NCT00974168|Radiation|Cumulative BED ≤ 130 Gy2|Radiation
421977|NCT00974155|Drug|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
421978|NCT00974155|Drug|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
421979|NCT00974142|Drug|Cyclosporine|Fifteen patients will receive cyclosporine at an initial dosing of 3.0 mg/kg/day.
421980|NCT00974142|Drug|Placebo|Fifteen patients will receive will receive placebo.
421981|NCT00974116|Behavioral|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
421982|NCT00974116|Behavioral|Control Group|No intervention
421983|NCT00974103|Other|exercise advise|Exercises
421984|NCT00974103|Other|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
421985|NCT00974090|Drug|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
421986|NCT00974090|Drug|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
421987|NCT00974077|Behavioral|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
421988|NCT00974077|Other|Waiting List Control|Patients receive MBCT with a delay of 6 months.
421989|NCT00974051|Drug|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
421990|NCT00974051|Other|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
421991|NCT00974051|Other|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
421992|NCT00974038|Behavioral|psychotherapy|1) cognitive-behavioral therapy or 2) supportive psychotherapy
421993|NCT00974025|Dietary Supplement|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
421994|NCT00974025|Dietary Supplement|Placebo|Placebo will be administered twice daily for four weeks
421995|NCT00974012|Drug|Divalproex Sodium|500 mg ER Tablet
421996|NCT00974012|Drug|Depakote®|500 mg ER Tablet
421997|NCT00973999|Drug|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
422152|NCT00972907|Drug|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
421998|NCT00973986|Drug|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
421999|NCT00973973|Drug|Placebo|Matching placebo tablets taken orally once a day
422000|NCT00973973|Drug|Elagolix|Immediate release (IR) tablets taken orally once a day
422001|NCT00973947|Other|questionnaire administration|
422002|NCT00973947|Radiation|3-dimensional conformal radiation therapy|
422003|NCT00973947|Radiation|radiation therapy treatment planning/simulation|
422004|NCT00973934|Device|Magstim Theta|
422005|NCT00973934|Device|Thymatron System IV|
422006|NCT00973908|Drug|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
422007|NCT00973908|Drug|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
422008|NCT00973895|Biological|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
422009|NCT00973882|Drug|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
422010|NCT00973882|Drug|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
422011|NCT00973869|Dietary Supplement|curcumin|
422012|NCT00973869|Other|high performance liquid chromatography|
422013|NCT00973869|Other|laboratory biomarker analysis|
422014|NCT00973869|Other|pharmacological study|
422015|NCT00973869|Procedure|diagnostic endoscopic procedure|
422016|NCT00973869|Procedure|therapeutic conventional surgery|
422017|NCT00973856|Other|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
422018|NCT00973856|Other|Placebo Solution|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
422019|NCT00973830|Other|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
422020|NCT00973817|Biological|ELAD plus standard of care treatment|Use of ELAD plus standard of care
422021|NCT00973817|Other|Standard of care|Standard of care in the treatment of AOCH will be administered
422022|NCT00973804|Drug|EPOCH-F/R|
422023|NCT00973804|Drug|FLAG|
422024|NCT00973804|Drug|Transplant Preparative Regimen (Flu/Cy/Mes)|
422025|NCT00973804|Drug|GVHD Prophylaxis (tacrolimus and sirolimus)|
422026|NCT00973804|Procedure|Double Cord Blood Transplantation|
422027|NCT00973791|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
422028|NCT00973791|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
422029|NCT00973778|Other|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
422030|NCT00973765|Drug|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
422031|NCT00973765|Drug|placebo|placebo 2 pills po BID x 7 days
422032|NCT00973752|Drug|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
422033|NCT00973752|Drug|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
422034|NCT00973752|Drug|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
422035|NCT00973752|Drug|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
422036|NCT00973752|Drug|Cytarabine|Intrathecally during Induction and CNS therapy
422037|NCT00973752|Drug|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
422038|NCT00973752|Drug|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
422039|NCT00973752|Drug|Clofarabine|Intravenously during Consolidation 1 Therapy
422040|NCT00973752|Drug|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
422041|NCT00973739|Drug|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response."
422042|NCT00973726|Other|Glucose test|Subjects ingest an oral glucose tolerance test.
422043|NCT00973713|Drug|RAD001|10mg/d
422044|NCT00973700|Biological|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
422045|NCT00973700|Biological|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
422046|NCT00973687|Drug|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
422047|NCT00973687|Drug|Dexamethasone|
422048|NCT00973674|Drug|Premarin IV|One time dose of Premarin IV
422049|NCT00973674|Drug|Placebo|One time dose of Placebo
422050|NCT00973661|Behavioral|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
422051|NCT00973635|Other|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
422052|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
422053|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
422054|NCT00973622|Device|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
422055|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
422056|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
422057|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.~Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
422058|NCT00973583|Dietary Supplement|vitamin D|vitamin D3 400 IU daily
422059|NCT00973583|Dietary Supplement|placebo|placebo
422060|NCT00973570|Behavioral|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
422061|NCT00973544|Other|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
422062|NCT00973531|Device|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
422063|NCT00973531|Device|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
422064|NCT00973505|Drug|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
422065|NCT00973492|Other|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.~On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.~Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.~A one-day follow-up takes place 3 months later."
422066|NCT00973479|Drug|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
422067|NCT00973479|Other|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
422068|NCT00973479|Drug|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
422069|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml Additional maintenance: 2 two-weekly injections 2.0* ml~*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
422070|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml.~Additional maintenance: 2 two-weekly injections 2.0* ml~*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
422071|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2*, 1.6* and 2.0*ml.~Additional maintenance: 2 two-weekly injections 2.0* ml~*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
422072|NCT00973414|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
422073|NCT00973414|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
422074|NCT00973401|Other|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
422075|NCT00973388|Drug|Telaprevir; Moxifloxacin; Placebo|
422153|NCT00972881|Biological|cetuximab|
422154|NCT00972881|Drug|capecitabine|
422076|NCT00973362|Device|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
422077|NCT00973362|Device|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
422078|NCT00973349|Biological|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
422079|NCT00973336|Drug|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
422080|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
422081|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
422082|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
422083|NCT00973323|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
422084|NCT00973310|Other|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
422085|NCT00973297|Other|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
422086|NCT00973284|Biological|Norwalk VLP vaccine|Norwalk VLP vaccine dry powder
422087|NCT00973284|Biological|mannitol and sucrose|Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
422088|NCT00973284|Biological|Norwalk virus|Norwalk virus solution
422089|NCT00973271|Drug|290 mg DCCR|290 mg diazoxide choline
422090|NCT00973271|Drug|435 mg DCCR|435 mg diazoxide choline
422091|NCT00973271|Drug|135 mg fenofibric acid|135 mg fenofibric acid
422092|NCT00973271|Drug|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
422093|NCT00973271|Drug|atorvastatin|20 mg atorvastatin
422094|NCT00973258|Dietary Supplement|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
422095|NCT00973258|Other|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
422096|NCT00973258|Other|Cognitive Training|"The proposed cognitive training intervention program comprises:~Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.~Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.~Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
422097|NCT00973258|Other|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
422098|NCT00973258|Other|Placebo|Participants will receive their usual diet and placeboes.
422099|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
422100|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
422101|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
422102|NCT00973245|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
422103|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
422104|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
422105|NCT00973232|Drug|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
422106|NCT00973232|Drug|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
422107|NCT00973232|Drug|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
422108|NCT00973232|Drug|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
422109|NCT00973232|Drug|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
422155|NCT00972881|Drug|irinotecan hydrochloride|
422156|NCT00972881|Procedure|neoadjuvant therapy|
422110|NCT00973219|Drug|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
422111|NCT00973193|Drug|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
422112|NCT00973180|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
422113|NCT00973167|Device|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
422114|NCT00973154|Drug|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
422115|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
422116|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
422117|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
422118|NCT00973141|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
422119|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
422120|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
422121|NCT00973128|Drug|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
422122|NCT00973128|Drug|Meglumine antimoniate|20mg/daily for 20 days
422123|NCT00973115|Drug|Simvastatin CR|
422124|NCT00973102|Drug|Premarin IV|One time dose of Premarin IV
422125|NCT00973102|Drug|Placebo|One time dose of placebo.
422126|NCT00973089|Other|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
422127|NCT00973076|Drug|AZD8055|Tablets, orally administered, twice daily
422128|NCT00973063|Behavioral|Routine sterile gloving|routinely new sterile gloving just before sampling
422129|NCT00973050|Drug|Bicalutamide|50 mg Tablet
422130|NCT00973050|Drug|Casodex®|50 mg Tabelt
422131|NCT00973037|Drug|Tamoxifen|Tamoxifen 20mg qd
422132|NCT00973024|Drug|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
422133|NCT00973024|Drug|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
422134|NCT00973024|Drug|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
422135|NCT00973024|Drug|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
422136|NCT00973024|Drug|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
422137|NCT00973011|Drug|FCFD4514S|Intravitreal escalating dose
422138|NCT00972998|Drug|Phenyephrine|Phenyephrine coated suppositories
422139|NCT00972985|Drug|modafinil|oral tablet, 100 mg, single acute dose
422140|NCT00972985|Drug|methylphenidate|oral tablet, 20 mg, single acute dose
422141|NCT00972985|Drug|lorazepam|oral tablet, 1 mg, single, acute dose
422142|NCT00972985|Drug|placebo|oral tablet, single acute dose
422143|NCT00972972|Dietary Supplement|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
422144|NCT00972972|Dietary Supplement|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
422145|NCT00972959|Drug|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
422146|NCT00972959|Drug|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
422147|NCT00972959|Drug|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
422148|NCT00972946|Biological|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
422149|NCT00972946|Drug|Administration of Endorem|single dose, intravenous
422150|NCT00972933|Drug|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
422151|NCT00972920|Procedure|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
422159|NCT00972868|Device|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
422160|NCT00972855|Drug|Bicalutamide|50 mg Tablet
422161|NCT00972855|Drug|Casodex®|50 mg Tablet
422162|NCT00972842|Drug|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles~Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
422163|NCT00972829|Drug|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
422164|NCT00972829|Drug|Ezetimibe|Ezetimibe 5 or 10 milligrams
422165|NCT00972816|Biological|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
422166|NCT00972803|Drug|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
422167|NCT00972803|Drug|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
422168|NCT00972803|Drug|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
422169|NCT00972790|Procedure|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
422170|NCT00972777|Drug|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
422171|NCT00972777|Drug|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
422172|NCT00972738|Drug|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
422173|NCT00972738|Drug|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
422174|NCT00972738|Drug|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
422175|NCT00972725|Biological|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
422176|NCT00972725|Drug|Chloroquine|One dose of 300 mg
422177|NCT00972712|Drug|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)~Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)~Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)~Schema B~Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)~Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
422178|NCT00972699|Behavioral|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
422179|NCT00972686|Drug|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
422180|NCT00972673|Drug|Placebo|comparator
422181|NCT00972673|Drug|GW685698X|Inhaled steroid
422182|NCT00972660|Biological|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).~Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
422183|NCT00972660|Drug|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus~Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
422184|NCT00972647|Procedure|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
422185|NCT00972634|Other|computer-assisted intervention|symptom assessment
422186|NCT00972634|Other|questionnaire administration|Symptom assessment
422187|NCT00972634|Procedure|assessment of therapy complications|Symptom assessment
422188|NCT00972634|Procedure|quality-of-life assessment|Symptom assessment
422189|NCT00972621|Device|Vitrax II|Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
422190|NCT00972621|Device|Viscoat|Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
422191|NCT00972608|Other|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
422192|NCT00972595|Drug|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
422193|NCT00972595|Drug|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
422194|NCT00972582|Dietary Supplement|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
422195|NCT00972569|Drug|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
422196|NCT00972569|Drug|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
422197|NCT00972556|Drug|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
422198|NCT00972556|Drug|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
422199|NCT00972543|Biological|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.~Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
422200|NCT00972543|Biological|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
422201|NCT00972530|Behavioral|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)~Control group: normal activity without restrictions"
422202|NCT00972517|Biological|GSK investigational vaccine GSK2340272A|Three intramuscular injections
422203|NCT00972504|Drug|GSK835726 10mg|GSK835726 10mg tablet
422204|NCT00972504|Drug|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
422205|NCT00972504|Drug|Cetirizine 10mg|Cetirizine 10mg active comparator
422206|NCT00972504|Drug|placebo|placebo to match actives
422207|NCT00972491|Procedure|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
422208|NCT00972478|Drug|Cyclophosphamide|Given IV
422209|NCT00972478|Drug|Doxorubicin Hydrochloride|Given IV
422210|NCT00972478|Other|Laboratory Biomarker Analysis|Correlative studies
422211|NCT00972478|Drug|Prednisone|Given IV
422212|NCT00972478|Biological|Rituximab|Given IV
422213|NCT00972478|Drug|Vincristine Sulfate|Given IV
422214|NCT00972478|Drug|Vorinostat|Given PO
422215|NCT00972465|Drug|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan~the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)~the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
422216|NCT00972452|Behavioral|Exercise|short period of exercise training (5-10 days)
422217|NCT00972439|Drug|Oral Contraceptive: Ortho-Novum® 1/35|
422218|NCT00972439|Drug|Oral Contraceptive: Ovcon Fe®|
422219|NCT00972426|Drug|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
422220|NCT00972413|Radiation|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
422221|NCT00972413|Radiation|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
422222|NCT00972413|Radiation|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
422223|NCT00972400|Genetic|protein analysis|
422224|NCT00972400|Other|laboratory biomarker analysis|
422225|NCT00972400|Other|mass spectrometry|
422226|NCT00972400|Other|questionnaire administration|
422227|NCT00972400|Procedure|assessment of therapy complications|
422228|NCT00972400|Procedure|cognitive assessment|
422229|NCT00972400|Procedure|quality-of-life assessment|
422230|NCT00972387|Dietary Supplement|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
422231|NCT00972387|Dietary Supplement|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
422232|NCT00972387|Dietary Supplement|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
422233|NCT00972387|Dietary Supplement|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
422234|NCT00972374|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
422235|NCT00972374|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
422236|NCT00972374|Other|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
422237|NCT00972348|Other|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
422238|NCT00972348|Other|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
422239|NCT00972335|Drug|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
422240|NCT00972335|Drug|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
422241|NCT00972322|Drug|MK-8245|MK-8245 50 mg twice daily for 28 days
422242|NCT00972322|Drug|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
422243|NCT00972309|Biological|TARP peptide vaccine|Will receive an admixture of the wildtype and epitopeenhanced TARP peptides emulsified with Montanide ISA 51 VG and GM-CSF. TARP peptide will be administered subcutaneously at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96
422244|NCT00972309|Biological|TARP dendritic cell vaccine|Will receive peptidepulsed dendritic cells administered intradermally in two vaccination sites. TARP pulsed dendritic cells will be administered at weeks 3, 6, 9, 12 and 15 for a total of five vaccinations with a booster dose of vaccine at Weeks 48 and 96.
422245|NCT00972296|Device|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
422246|NCT00972283|Drug|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
422247|NCT00972283|Drug|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
422248|NCT00972283|Drug|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
422249|NCT00972270|Device|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
422250|NCT00972270|Device|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
422251|NCT00972257|Drug|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
422252|NCT00972257|Drug|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
422253|NCT00972244|Drug|Dapagliflozin|once daily, 12 weeks
422254|NCT00972244|Drug|Placebo|once daily, 12 weeks
422255|NCT00972231|Other|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
422256|NCT00972218|Biological|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
422257|NCT00972205|Drug|paclitaxel|Paclitaxel 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
422258|NCT00972205|Drug|CBT-1(Registered Trademark)|CBT-1 500 mg/m^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
422259|NCT00972205|Radiation|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
422260|NCT00972192|Behavioral|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
422261|NCT00972192|Behavioral|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
422262|NCT00972179|Drug|AMG 157 Placebo|A total of 12 subjects will be receiving multiple doses of AMG 157 placebo. Each subject enrolled in cohorts 1-3 will receive three SC doses; each subject enrolled in cohort 4 will receive six SC doses; each subject enrolled in cohort 5 will receive 12 SC doses; and each subject enrolled in cohort 6 will receive three IV doses throughout the study period of 169 days.
422263|NCT00972179|Drug|AMG 157|A total of 36 subjects will be receiving multiple doses of AMG 157 (dose escalating by cohort). Each subject enrolled in cohorts 1-3 will receive three SC doses; each subject enrolled in cohort 4 will receive six SC doses; each subject enrolled in cohort 5 will receive 12 SC doses; and each subject enrolled in cohort 6 will receive three IV doses throughout the study period of 169 days.
422264|NCT00972153|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
422265|NCT00972153|Device|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
422266|NCT00972140|Drug|Formoterol|Formoterol-HFA pMDI 12µg twice daily
422267|NCT00972140|Drug|Formoterol|Formoterol-DPI 12 µg twice daily
422268|NCT00972127|Drug|Neramexane|25 mg or 2x25mg tablets
422269|NCT00972114|Procedure|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
422270|NCT00972114|Procedure|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
422271|NCT00972114|Procedure|CABG alone|Coronary artery bypass graft surgery alone
422272|NCT00972101|Radiation|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
422273|NCT00972101|Drug|Melphalan|140 mg/m^2 by vein over 30 minutes as a single dose on Day -8
422274|NCT00972101|Drug|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
422275|NCT00972101|Drug|Fludarabine|40 mg/m^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
422276|NCT00972101|Drug|Rituximab|"Regimen 1:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -9 if needed~Regimen 2:~375 mg/m^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
422277|NCT00972101|Drug|Etoposide|60 mg/m^2 by vein over 1-2 hours as a single dose on Day -3.
422278|NCT00972101|Drug|Anti-thymocyte globulin (ATG)|"Regimen 1:~1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.~Regimen 2:~0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
422279|NCT00972101|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
422280|NCT00972101|Drug|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
422281|NCT00972101|Procedure|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
422282|NCT00972101|Drug|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is > 2.5 x 10e^9/L.
422283|NCT00972101|Procedure|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e^5 T cells/kg on Day 14+.
423668|NCT00961649|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
422284|NCT00972088|Device|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
422285|NCT00972075|Drug|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
422286|NCT00972075|Drug|placebo|one tablet per day 2 hours before going to bed
422287|NCT00972062|Other|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
422288|NCT00972062|Other|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
422289|NCT00972049|Drug|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
422290|NCT00972049|Drug|Placebo|Capsule administered once orally
422291|NCT00972036|Device|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
422292|NCT00972023|Drug|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
422293|NCT00972023|Procedure|Surgical resection|Surgical procedure of the invasive breast cancer
422294|NCT00971997|Drug|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
422295|NCT00971984|Other|Medical records summary|Summary of Medical files and laboratory results.
422296|NCT00971971|Procedure|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
422297|NCT00971971|Procedure|Standard SLED|
422298|NCT00971958|Procedure|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
422299|NCT00971958|Device|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
422300|NCT00971958|Device|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
422301|NCT00971958|Device|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
422302|NCT00971945|Drug|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
422303|NCT00971932|Drug|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
422304|NCT00971932|Drug|Cisplatin/Carboplatin|Subjects will receive 100 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 [AUC5]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
422305|NCT00971932|Drug|5-Fluorouracil|Subjects will receive 1000 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
422306|NCT00971919|Other|questionnaire administration|
422307|NCT00971919|Procedure|assessment of therapy complications|
422308|NCT00971919|Procedure|psychosocial assessment and care|
422309|NCT00971919|Procedure|quality-of-life assessment|
422310|NCT00971906|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant,or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups
422311|NCT00971893|Drug|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
422312|NCT00971880|Other|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
422313|NCT00971867|Drug|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
422314|NCT00971854|Procedure|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
422315|NCT00971841|Drug|Paclitaxel|
422316|NCT00971815|Drug|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
422317|NCT00971815|Drug|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
422318|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
422319|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
422320|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
422321|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
422322|NCT00971789|Radiation|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
422323|NCT00971789|Drug|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
422324|NCT00971789|Other|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
422325|NCT00971776|Device|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
422326|NCT00971763|Biological|rituximab|
422327|NCT00971763|Drug|cyclophosphamide|
422328|NCT00971763|Drug|gemcitabine hydrochloride|
422329|NCT00971763|Drug|prednisolone|
422330|NCT00971763|Drug|vincristine sulfate|
422331|NCT00971737|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
422332|NCT00971737|Biological|trastuzumab|Given IV
422333|NCT00971737|Drug|cyclophosphamide|Given IV
422334|NCT00971724|Drug|Placebo|Oral administration, once daily, for 15 days
422336|NCT00971711|Biological|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
422337|NCT00971685|Drug|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
422338|NCT00971672|Other|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis."
422339|NCT00971659|Drug|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
422340|NCT00971659|Drug|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
422341|NCT00971659|Drug|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
422342|NCT00971646|Other|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
422343|NCT00971646|Other|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
422344|NCT00971646|Other|EuroQol-5D|This questionnaire grades the health condition of the subject.
422345|NCT00971646|Other|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
422346|NCT00971633|Drug|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
422347|NCT00971633|Drug|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
422348|NCT00971633|Drug|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
422349|NCT00971620|Biological|Botulinum toxin type A|Given as an intralesional injection.
422350|NCT00971620|Other|Placebo|Given as an intralesional injection
422351|NCT00971607|Drug|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
422352|NCT00971607|Drug|Oxygen (placebo)|Control will receive oxygen only.
422353|NCT00971594|Behavioral|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of ~0.2-0.4 kg/wk
422354|NCT00971594|Behavioral|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
422355|NCT00971581|Drug|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
422356|NCT00971542|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
422357|NCT00971516|Procedure|Implant placement|dental implant placement
422358|NCT00971516|Procedure|Implants surgery|dental implant surgery
422359|NCT00971503|Procedure|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
422360|NCT00971503|Other|Saline injection|Injection of saline solution for 5 days
422361|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
422362|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
422363|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
422364|NCT00971477|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
422365|NCT00971477|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
422366|NCT00971464|Behavioral|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
422367|NCT00971464|Device|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
422368|NCT00971451|Other|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
422369|NCT00971451|Other|TENS|continuous use of TENS during the exercise session
422370|NCT00971438|Procedure|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
422371|NCT00971425|Biological|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
422372|NCT00971425|Biological|Fluarix™|1 dose intramuscular injection
422373|NCT00971425|Biological|Placebo|1 dose intramuscular injection
422374|NCT00971399|Drug|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
422375|NCT00971399|Drug|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
422376|NCT00971386|Behavioral|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
422377|NCT00971373|Other|Vestagen scrubs|antimicrobial impregnated textile
422378|NCT00971360|Other|conversion disorder|Proinflammatory cytokine levels in conversion disorder
423669|NCT00961649|Other|Vehicle|Inactive ingredients used as placebo
422379|NCT00971347|Other|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
422380|NCT00971347|Behavioral|nutrition brochure|one-time at baseline visit
422381|NCT00971321|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
422382|NCT00971308|Drug|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
422383|NCT00971308|Drug|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
422384|NCT00971308|Drug|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
422385|NCT00971308|Drug|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
422386|NCT00971308|Drug|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
422387|NCT00971295|Drug|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
422388|NCT00971295|Drug|Eslicarbazepine acetate|
422389|NCT00971282|Drug|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
422390|NCT00971282|Other|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits."
422391|NCT00971269|Device|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
422392|NCT00971243|Drug|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
422393|NCT00971243|Drug|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
422394|NCT00971243|Drug|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
422395|NCT00971243|Drug|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
422396|NCT00971243|Drug|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
422397|NCT00971230|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
422398|NCT00971230|Drug|Placebo|Placebo
422399|NCT00971217|Other|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
422400|NCT00971217|Behavioral|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
422401|NCT00971204|Device|CardioFocus HeartLight Endoscopic Ablation System|PVI ablation
422402|NCT00971191|Drug|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
422403|NCT00971178|Drug|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
422404|NCT00971178|Drug|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
422405|NCT00971178|Drug|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
422406|NCT00971165|Drug|losartan|Oral losartan up to 100 mg daily fo 18 months
422407|NCT00971165|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
422408|NCT00971152|Drug|menotropins for injection|comparison of different dosages
422409|NCT00971152|Drug|urofollitropin for injection|comparison of different dosages
422410|NCT00971139|Behavioral|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
422411|NCT00971126|Drug|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).~Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
422412|NCT00971113|Dietary Supplement|sc-FOS and Sideritis euboea extract|"dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days~placebo food: jelly with no sc-FOS and Sideritis euboea"
422413|NCT00971100|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
422414|NCT00971087|Device|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are enrolled from either a screening population or a biopsy population. Both groups are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects recruited in the biopsy population will be imaged on the investigational device prior to their biopsy procedure.
422415|NCT00971074|Drug|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
422416|NCT00971074|Other|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
422417|NCT00971061|Device|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
422418|NCT00971061|Device|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
422419|NCT00971048|Device|HP828-101|Topical test article applied once daily
422420|NCT00971048|Device|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
422421|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
422422|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
422423|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
422424|NCT00971035|Drug|placebo|Subcutaneous repeating dose
422425|NCT00971022|Behavioral|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
422426|NCT00971022|Behavioral|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
422427|NCT00971009|Behavioral|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
422428|NCT00971009|Behavioral|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
422429|NCT00970996|Drug|Temozolomide|250 mg/m^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
422430|NCT00970996|Drug|Abraxane|100 mg/m^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m^2 given on day 5 of each 21-day cycle.
422431|NCT00970996|Drug|Cisplatin|20 mg/m^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
422432|NCT00970996|Biological|Interleukin-2|9 MIU/m^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
422433|NCT00970996|Biological|Interferon alpha 2b|5 MIU/m^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
422434|NCT00970983|Procedure|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
422435|NCT00970983|Procedure|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
422436|NCT00970970|Other|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
422437|NCT00970957|Drug|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
422438|NCT00970957|Drug|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
422439|NCT00970944|Drug|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
422440|NCT00970944|Drug|Placebo|Placebo administered twice daily.
422441|NCT00970931|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
422442|NCT00970931|Drug|placebo|Oral placebo once a day, for 18 months
422443|NCT00970918|Procedure|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
422444|NCT00970918|Biological|Blood sample testing for hs-CRP|one time, blood sample taking
422445|NCT00970905|Drug|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
422446|NCT00970905|Drug|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
422447|NCT00970892|Drug|Warfarin dose titration|Dosage
422448|NCT00970879|Drug|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
422449|NCT00970879|Drug|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
422450|NCT00970866|Dietary Supplement|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
422451|NCT00970866|Dietary Supplement|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
422452|NCT00970866|Dietary Supplement|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.~The LNS products (LNS-P&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
422453|NCT00970853|Behavioral|MOM Program home visiting|Mixed professional home visiting program.
422454|NCT00970853|Other|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
422455|NCT00970840|Dietary Supplement|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
422456|NCT00970827|Procedure|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
422457|NCT00970814|Behavioral|BBCET|11 BBCET sessions
422458|NCT00970814|Behavioral|BBCET|11 BBCET Sessions
422459|NCT00970814|Drug|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
422460|NCT00970814|Drug|Sugar Pill|500mg - 2000mg Once per day 16 weeks
422461|NCT00970788|Behavioral|Video intervention|Video of goals of care
422462|NCT00970775|Drug|AZD2423|oral solution, single dose
422463|NCT00970775|Drug|Placebo|oral solution,single dose
422464|NCT00970762|Drug|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
422465|NCT00970762|Drug|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
422466|NCT00970762|Drug|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
422467|NCT00970762|Drug|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
422468|NCT00970762|Drug|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
422469|NCT00970762|Drug|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
422470|NCT00970762|Drug|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
422471|NCT00970723|Behavioral|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
422472|NCT00970723|Behavioral|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
422473|NCT00970723|Behavioral|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
422474|NCT00970710|Behavioral|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
422475|NCT00970697|Drug|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
422476|NCT00970697|Drug|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
422477|NCT00970684|Biological|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
422478|NCT00970684|Drug|docetaxel|75 mg/m2 on day 1
422479|NCT00970684|Drug|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
422480|NCT00970671|Other|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
422481|NCT00970671|Other|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
422482|NCT00970671|Other|No treatment|No laser treatment
422483|NCT00970658|Drug|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
422484|NCT00970658|Drug|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
422485|NCT00970645|Procedure|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
422486|NCT00970645|Procedure|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
422487|NCT00970632|Drug|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
422488|NCT00970632|Drug|Placebo tablet|Placebo tablet po QD for 12 weeks
422489|NCT00970632|Drug|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
422490|NCT00970632|Drug|Placebo capsule|Placebo capsule po QD for 12 weeks
422491|NCT00970619|Device|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
422492|NCT00970606|Drug|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
422493|NCT00970606|Drug|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
422494|NCT00970593|Drug|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
422495|NCT00970593|Drug|placebo comparator|Group 1 & 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
422496|NCT00970580|Drug|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
422497|NCT00970567|Behavioral|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
422498|NCT00970554|Other|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
422499|NCT00970554|Other|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
422500|NCT00970541|Dietary Supplement|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
422501|NCT00970541|Dietary Supplement|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
422502|NCT00970528|Drug|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
422503|NCT00970528|Drug|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
422504|NCT00970515|Procedure|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
422505|NCT00970515|Procedure|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
422506|NCT00970502|Drug|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
422507|NCT00970489|Drug|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
422508|NCT00970489|Drug|Placebo|Olive Oil capsules
422509|NCT00970450|Drug|Paracetamol|Paracetamol 1 g i.v. once
422510|NCT00970450|Drug|Tropisetron|Tropisetron 5 mg i.v. once
422511|NCT00970450|Drug|Placebo|Saline
422512|NCT00970437|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
422513|NCT00970437|Behavioral|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
422514|NCT00970424|Drug|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
422515|NCT00970424|Drug|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
422516|NCT00970411|Drug|KRN951|Orally once daily administration
422517|NCT00970398|Other|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
422518|NCT00970398|Other|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
422519|NCT00970385|Drug|CHOP21|"CHOP regimen:~cyclophosphamide 750 mg/m2 intravenously (IV) day 1~doxorubicin 50 mg/m2 IV day 1~vincristine 1,4 mg/m2 (maximum 2 mg) day 1~prednisone 100 mg/m2/D from D1 to D5."
422520|NCT00970385|Drug|VIP/ABVD|"VIP regimen:~etoposide 100 mg/m2/D IV from D1 to D3~ifosfamide 1000 mg/m2/D from D1 to D5~cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5~ABVD regimen:~doxorubicin50 mg/m2/D on D1 and D14~bleomycin 10 mg/m2/D~vinblastine 10 mg/m2/D~dacarbazine 375 mg/m2/D"
422521|NCT00970385|Radiation|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
422522|NCT00970359|Biological|AZD6244|"Within 1 week of starting the study: Low iodine diet~The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
422523|NCT00970346|Drug|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
422524|NCT00970333|Drug|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) of [18F]-FEPPA followed by serial PET imaging
422525|NCT00970320|Other|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
422526|NCT00970307|Biological|GSK2202083A vaccine|Intramuscular, three doses
422527|NCT00970307|Biological|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
422528|NCT00970307|Biological|Infanrix hexa™|Intramuscular, three doses
422529|NCT00970307|Biological|Menjugate®|Intramuscular, two doses
422530|NCT00970294|Behavioral|Health Promotion Program|10 week health promotion program 3-4 times per week
422531|NCT00970281|Drug|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
422532|NCT00970281|Drug|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
422533|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
422534|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
422535|NCT00970255|Procedure|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
422536|NCT00970255|Procedure|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
422537|NCT00970229|Drug|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not > 10% of 8 mCi limit)of [123I]MNI-420, followed by SPECT imaging.
422538|NCT00970216|Drug|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
422539|NCT00970203|Biological|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
422540|NCT00970203|Biological|DC1 vaccine|3-5 x 10e6 cells total
422541|NCT00970177|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
422542|NCT00970138|Drug|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent~Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
422543|NCT00970125|Behavioral|video|outline of the goals of care
422544|NCT00970112|Procedure|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
422545|NCT00970099|Behavioral|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
422546|NCT00970099|Behavioral|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
422547|NCT00970086|Drug|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
422548|NCT00970073|Biological|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
422549|NCT00970073|Biological|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
422550|NCT00970073|Drug|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
422551|NCT00970073|Drug|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
422552|NCT00970073|Drug|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
422553|NCT00970060|Behavioral|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
422554|NCT00970021|Dietary Supplement|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
422555|NCT00970021|Dietary Supplement|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
422556|NCT00970008|Other|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
422557|NCT00970008|Other|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
422558|NCT00970008|Other|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
422559|NCT00970008|Other|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
422560|NCT00969982|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
422561|NCT00969982|Drug|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
422562|NCT00969969|Device|Arthrodesis|arthrodesis using screws and/or a plate
422563|NCT00969969|Device|Cartiva|Cartiva Synthetic Cartilage Implant
422564|NCT00969917|Drug|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
422565|NCT00969904|Drug|N-acetylcysteine|600 mg TID for 12 weeks
422566|NCT00969904|Drug|placebo|placebo tablet TID for 12 weeks
422567|NCT00969891|Other|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
422568|NCT00969878|Drug|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
422610|NCT00969475|Device|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
422611|NCT00969462|Drug|Doxorubicin|measurements of serum Doxorubicin levels
422612|NCT00969449|Drug|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
422569|NCT00969878|Other|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
422570|NCT00969852|Drug|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
422571|NCT00969839|Device|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
422572|NCT00969826|Drug|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
422573|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
422574|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
422575|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
422576|NCT00969800|Device|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
422577|NCT00969800|Device|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
422578|NCT00969787|Drug|DWP05195|tablets, oral administration, single and multiple administrations
422579|NCT00969761|Drug|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
422580|NCT00969761|Drug|BI 6727|low to high dose
422581|NCT00969735|Device|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
422582|NCT00969735|Device|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter > 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
422583|NCT00969722|Biological|MAb-3F8|
422584|NCT00969722|Biological|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
422585|NCT00969722|Biological|13-cis-Retinoic Acid|
422586|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
422587|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
422588|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
422589|NCT00969709|Drug|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
422590|NCT00969696|Drug|Placebo|8Mg a day of a sugar pill
422591|NCT00969696|Drug|Galantamine|8mg of Galantamine
422592|NCT00969683|Device|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
422593|NCT00969683|Device|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
422594|NCT00969644|Drug|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
422595|NCT00969644|Drug|Pegvisomant|s.c. injections once daily (10-15 mg/day)
422596|NCT00969631|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
422597|NCT00969631|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
422598|NCT00969618|Drug|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
422599|NCT00969605|Procedure|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
422600|NCT00969592|Drug|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
422601|NCT00969592|Drug|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
422602|NCT00969566|Drug|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
422603|NCT00969553|Drug|BI 6727|Dose level 1
422604|NCT00969540|Device|Active Mattress Cover|Active Mattress Cover
422605|NCT00969540|Device|Placebo Mattress Cover|Placebo Mattress Cover
422606|NCT00969527|Dietary Supplement|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
422607|NCT00969527|Dietary Supplement|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
422608|NCT00969501|Drug|EUFLEXXA|2.5 mL of EUFLEXXA (per injection) x 3 injections
422609|NCT00969488|Other|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.~The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
422613|NCT00969449|Drug|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
422614|NCT00969436|Biological|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
422615|NCT00969436|Biological|Priorix™|Subcutaneous injection
422616|NCT00969436|Biological|Varilrix™|Subcutaneous injection
422617|NCT00969423|Device|5mm videoscope|use of 5mm videoscope
422618|NCT00969423|Device|10mm videoscope|use of 10mm videoscope
422619|NCT00969410|Biological|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
422620|NCT00969397|Drug|Topical Antiangiogenic|Topical Antiangiogenic
422621|NCT00969397|Device|Pulsed Dye Laser|Pulsed Dye Laser
422622|NCT00969384|Behavioral|Active awareness/Lifestyle counseling|"Intervention (active awareness):~In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
422623|NCT00969371|Device|posterior chamber IOL implantation|
422624|NCT00969371|Device|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
422625|NCT00969345|Other|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
422626|NCT00969345|Other|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
422627|NCT00969332|Drug|Omegaven|0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday
422628|NCT00969319|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
422629|NCT00969306|Drug|Chloroquine, A-CQ 100|"Administration:~Orally~Timing: Once daily~Tablets of 100 mg~During or after meals~In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.~Patients should always note date and time of intake on the chloroquine monitoring form."
422630|NCT00969293|Drug|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.~Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.~Duration of Treatment: Single injection with 3 months follow-up."
422631|NCT00969280|Device|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.~According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20*30mm (Dongbang Co., korea) acupuncture needle.~All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
422632|NCT00969280|Device|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.~Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
422633|NCT00969267|Other|ear-acupuncture A|with needle stimulation
422634|NCT00969267|Other|stimulation B|with bread stimulation on ear acupuncture point
422635|NCT00969267|Other|stimulation C|without needle stimulation
422636|NCT00969254|Drug|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pílulas de Lussen®~** Drug B: placebo."
422637|NCT00969254|Drug|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.~* Drug A: Pyridium®~** Drug B: placebo."
422638|NCT00969228|Biological|Rotarix ™|Two oral doses
422639|NCT00969228|Biological|Placebo|Two oral doses
422640|NCT00969215|Device|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
422641|NCT00969202|Radiation|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
422642|NCT00969176|Drug|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
422643|NCT00969163|Drug|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
422644|NCT00969163|Drug|Comparator: placebo|transdermal placebo gel for 6 weeks
422645|NCT00969150|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
422646|NCT00969150|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
422647|NCT00969137|Drug|saline|intravenous saline
422648|NCT00969137|Drug|Nicotine|Intravenous nicotine
422649|NCT00969124|Device|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
422650|NCT00969111|Radiation|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
422651|NCT00969111|Radiation|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
422652|NCT00969111|Radiation|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
422653|NCT00969111|Radiation|Proton to 66.6 CGE|Post-Op Non High Risk
422654|NCT00969085|Drug|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams"
422655|NCT00969085|Behavioral|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
422656|NCT00969085|Other|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
422657|NCT00969072|Drug|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
422658|NCT00969072|Drug|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
422659|NCT00969072|Drug|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
422660|NCT00969059|Drug|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
422661|NCT00969059|Drug|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
422662|NCT00969046|Drug|EPO906 (patupilone)|
422663|NCT00969033|Drug|CS-1008|CS-1008
422664|NCT00969033|Drug|irinotecan|irinotecan
422665|NCT00969020|Procedure|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
422666|NCT00969007|Behavioral|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
422667|NCT00968994|Device|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
422668|NCT00968994|Device|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
422669|NCT00968981|Drug|GDC-0449|Daily oral repeating dose
422670|NCT00968981|Drug|GDC-0449|Three times weekly oral repeating dose
422671|NCT00968981|Drug|GDC-0449|Once weekly oral repeating dose
422672|NCT00968968|Drug|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib was a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
422673|NCT00968968|Biological|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab was a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
422674|NCT00968955|Drug|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
422675|NCT00968942|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
422676|NCT00968942|Drug|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
422677|NCT00968929|Drug|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
422678|NCT00968929|Drug|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
422679|NCT00968916|Drug|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution~Route of administration: intravenous infusion"
422680|NCT00968903|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
422681|NCT00968890|Biological|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
422682|NCT00968890|Biological|Fluarix™|Intramuscular injection, 1 dose
422683|NCT00968890|Biological|Placebo|Intramuscular injection, 1 dose
422684|NCT00968877|Drug|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
422685|NCT00968864|Device|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
422686|NCT00968851|Drug|EVP-6124|Arms: 1
422687|NCT00968851|Drug|Placebo|Arm: 3
422688|NCT00968851|Drug|EVP-6124|Arms: 2
422689|NCT00968838|Procedure|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:~Patients <50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.~Patients >50 years of age are randomized to receive either radiated or non radiated transfusions."
422690|NCT00968825|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
422691|NCT00968825|Drug|Placebo|Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
422692|NCT00968812|Drug|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
422693|NCT00968812|Drug|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
422694|NCT00968812|Drug|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
422695|NCT00968799|Procedure|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
422696|NCT00968799|Procedure|Cytoreduction|"Surgical removal of tumor nodules~including resection of organs infested with tumor"
422697|NCT00968799|Drug|Cisplatin|Cisplatin is applied as chemotherapy during surgery
422698|NCT00968786|Device|Home monitoring|automated measuring devices for patients using at home
422699|NCT00968773|Device|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
422700|NCT00968773|Device|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
422701|NCT00968760|Procedure|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
422702|NCT00968760|Procedure|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
422703|NCT00968760|Procedure|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
422704|NCT00968760|Drug|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10^6 U/m^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
422705|NCT00968760|Drug|Carmustine|300 mg/m^2 IV over 1 hour on Day -6
422706|NCT00968760|Drug|Etoposide|200 mg/m^2 IV over 3 hours every 12 hours on Days -5 to -2
422707|NCT00968760|Drug|Cytarabine|200 mg/m^2 by vein over 1 hour every 12 hours on Days -5 to -2.
422708|NCT00968760|Drug|Melphalan|140 mg/m^2 IV over 30 minutes on Day -1
422709|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
422710|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
422711|NCT00968747|Behavioral|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
422712|NCT00968747|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
422713|NCT00968734|Dietary Supplement|colecalciferol|50.000UI single oral dose
422714|NCT00968708|Drug|Alogliptin|Alogliptin tablets
422715|NCT00968708|Drug|Placebo|Alogliptin placebo matching tablets
422716|NCT00968695|Drug|Albumin|The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
422717|NCT00968682|Biological|trastuzumab|
422718|NCT00968682|Other|laboratory biomarker analysis|
422719|NCT00968682|Procedure|assessment of therapy complications|
422720|NCT00968669|Biological|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
422721|NCT00968669|Biological|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
422722|NCT00968669|Biological|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
422723|NCT00968669|Other|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
422724|NCT00968656|Radiation|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
422725|NCT00968656|Other|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
422726|NCT00968656|Other|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
422727|NCT00968656|Other|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
422728|NCT00968656|Drug|F-18-ISO|Patients receive F-18-ISO-1 i.v.
422729|NCT00968643|Radiation|radiation therapy|Given in multiple fractions or as a single fraction
422730|NCT00968630|Other|Laboratory Biomarker Analysis|Correlative studies
422731|NCT00968630|Procedure|Leukapheresis|Undergo leukapheresis
422732|NCT00968617|Drug|MK2578|MK2578 1.0 mcg/kg/month
422733|NCT00968617|Drug|MK2578|MK2578 2.0 mcg/kg/month
422734|NCT00968617|Drug|MK2578|MK2578 3.6 mcg/kg/month
422735|NCT00968617|Drug|Comparator: darbepoetin alfa|darbepoetin alfa
422736|NCT00968604|Genetic|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
422737|NCT00968591|Drug|Everolimus|
422738|NCT00968578|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
422739|NCT00968578|Drug|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
422740|NCT00968565|Drug|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
422741|NCT00968552|Procedure|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
422742|NCT00968539|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
422743|NCT00968539|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
422744|NCT00968526|Biological|GSK investigational vaccine GSK2340272A|One or two intramuscular injections in the deltoid region of the non-dominant or the dominant arm.
422745|NCT00968513|Behavioral|Brief Intervention|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
422746|NCT00968513|Behavioral|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
422747|NCT00968513|Behavioral|Usual Care|brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
422748|NCT00968500|Behavioral|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.~The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
422749|NCT00968487|Biological|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
422750|NCT00968487|Other|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at −18 °C (−0.4 °F) (or colder) within 6 hours of collection.
422751|NCT00968461|Drug|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
422752|NCT00968448|Behavioral|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
422753|NCT00968448|Behavioral|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
422754|NCT00968435|Other|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
422755|NCT00968422|Drug|ABT-384|3 escalating doses will be administered daily for 21 days
422756|NCT00968422|Drug|Matching placebo to ABT-384|Doses will be administered daily for 21 days
422757|NCT00968409|Radiation|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
422758|NCT00968409|Other|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
422759|NCT00968409|Other|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
422760|NCT00968409|Drug|F18-FFNP|injection of F18-FFNP
422761|NCT00968396|Procedure|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
422762|NCT00968396|Procedure|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
422763|NCT00968396|Drug|Melphalan|100 mg/m^2 IV over 30 minutes daily on Days -2 and -1
422764|NCT00968383|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
422765|NCT00968383|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
422766|NCT00968383|Drug|Statins|Participants will receive statins.
422767|NCT00968383|Drug|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
422768|NCT00968383|Procedure|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
422769|NCT00968370|Other|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
422770|NCT00968370|Other|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
422771|NCT00968357|Drug|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
422772|NCT00968344|Dietary Supplement|Leucine|3-4g Leucine added to daily meals
422773|NCT00968344|Dietary Supplement|Alanine|Powered amino acid
422774|NCT00968331|Drug|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
422775|NCT00968318|Procedure|Excision of strip of deep fascia|operative technique to excise deep fascia.
422776|NCT00968292|Device|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
422777|NCT00968266|Behavioral|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
422778|NCT00968253|Drug|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
422779|NCT00968253|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
422781|NCT00968253|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
422782|NCT00968253|Drug|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
422783|NCT00968253|Drug|Mesna|600 mg/m^2 IV continuous infusion daily for 24 hours days 1-3.
422784|NCT00968253|Drug|Methotrexate|200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 IV over 22 hours day 1.
422785|NCT00968253|Drug|Ara-C (Cytarabine)|3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
422786|NCT00968253|Drug|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
422787|NCT00968253|Drug|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
422788|NCT00968240|Drug|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.~Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
422789|NCT00968227|Biological|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
422790|NCT00968214|Genetic|polymorphism analysis|
422791|NCT00968214|Other|laboratory biomarker analysis|
422792|NCT00968201|Drug|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
422793|NCT00968201|Drug|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
422794|NCT00968188|Behavioral|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
422795|NCT00968188|Behavioral|Information only|Medically fact based HIV information delivered online.
422796|NCT00968175|Procedure|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
422797|NCT00968162|Drug|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
422798|NCT00968149|Drug|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
422799|NCT00968149|Drug|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
422800|NCT00968110|Drug|omalizumab|Dosing table established for omalizumab
422801|NCT00968097|Drug|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
422802|NCT00968071|Drug|Decitabine|20 mg/m^2 IV over an hour and half daily for 5 days.
422803|NCT00968071|Drug|Gemtuzumab Ozogamicin|3 mg/m^2 IV on day 5.
422804|NCT00968058|Procedure|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
422805|NCT00968045|Drug|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
422806|NCT00968032|Device|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
422807|NCT00968019|Device|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
422808|NCT00968006|Drug|Sitagliptin|100 mg once daily for 4 weeks
422809|NCT00967993|Drug|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
422810|NCT00967980|Procedure|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
422811|NCT00967967|Drug|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
422812|NCT00967954|Drug|antiandrogen therapy|
422813|NCT00967954|Drug|releasing hormone agonist therapy|
422814|NCT00967954|Genetic|DNA analysis|
422815|NCT00967954|Genetic|RNA analysis|
422816|NCT00967954|Genetic|comparative genomic hybridization|
422817|NCT00967954|Genetic|gene expression analysis|
422818|NCT00967954|Other|laboratory biomarker analysis|
422819|NCT00967954|Procedure|diffusion-weighted magnetic resonance imaging|
422820|NCT00967954|Procedure|magnetic resonance spectroscopic imaging|
422821|NCT00967941|Drug|Ancef (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
422822|NCT00967941|Drug|Vancomycin and Cefazolin (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
422823|NCT00967941|Drug|Daptomycin and Cefazolin (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
422824|NCT00967928|Drug|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
422825|NCT00967928|Drug|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
422826|NCT00967928|Radiation|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
422947|NCT00967122|Procedure|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
422948|NCT00967109|Other|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
422827|NCT00967915|Procedure|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
422828|NCT00967915|Other|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
422829|NCT00967902|Device|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
422830|NCT00967889|Genetic|gene expression analysis|
422831|NCT00967889|Genetic|protein analysis|
422832|NCT00967889|Other|biologic sample preservation procedure|
422833|NCT00967889|Other|laboratory biomarker analysis|
422834|NCT00967863|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
422835|NCT00967863|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
422836|NCT00967850|Drug|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
422837|NCT00967850|Drug|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
422838|NCT00967837|Procedure|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
422839|NCT00967824|Other|informational intervention|
422840|NCT00967824|Other|questionnaire administration|
422841|NCT00967824|Other|survey administration|
422842|NCT00967811|Drug|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
422843|NCT00967811|Drug|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
422844|NCT00967798|Drug|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
422845|NCT00967785|Drug|Mozobil (TM)|
422846|NCT00967772|Drug|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
422847|NCT00967759|Drug|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
422848|NCT00967759|Drug|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
422849|NCT00967759|Drug|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
422850|NCT00967746|Drug|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
422851|NCT00967746|Drug|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
422852|NCT00967746|Drug|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
422853|NCT00967746|Device|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
422854|NCT00967733|Dietary Supplement|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
422855|NCT00967733|Dietary Supplement|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
422856|NCT00967733|Dietary Supplement|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
422857|NCT00967733|Dietary Supplement|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
422858|NCT00967707|Drug|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Venlafaxine 75 mg once daily is added."
422859|NCT00967707|Drug|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).~Week 7-12: Donepezil 5 mg once daily is added."
422860|NCT00967694|Drug|Nitrous oxide|Nitrous oxide sedation by inhalation
422861|NCT00967681|Dietary Supplement|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
422862|NCT00967681|Dietary Supplement|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
422863|NCT00967668|Behavioral|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
422864|NCT00967668|Behavioral|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
422865|NCT00967655|Biological|panitumumab|
422866|NCT00967655|Drug|capecitabine|
422867|NCT00967655|Drug|irinotecan hydrochloride|
422868|NCT00967655|Procedure|neoadjuvant therapy|
422869|NCT00967655|Procedure|therapeutic conventional surgery|
422870|NCT00967655|Radiation|radiation therapy|
422871|NCT00967642|Drug|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
422949|NCT00967109|Other|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
422872|NCT00967629|Drug|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
422873|NCT00967629|Drug|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
422874|NCT00967616|Drug|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered PO BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
422875|NCT00967616|Drug|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~Irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes~Leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion~5-FU, 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion)"
422876|NCT00967603|Drug|sunitinib|oral sunitinib 37.5 mg daily
422877|NCT00967590|Drug|RO5036505|380mg iv infusion once weekly for 8 weeks
422878|NCT00967590|Drug|placebo|iv infusion once weekly for 8 weeks
422879|NCT00967577|Drug|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
422880|NCT00967564|Other|epidemiologic study|QoL assessment
422881|NCT00967551|Dietary Supplement|Micronutrient Sprinkles with zinc|Daily dose of 1 packet of sprinkles
422882|NCT00967551|Dietary Supplement|Micronutrient sprinkles without zinc|I packet of micronutrient sprinkles without zinc
422883|NCT00967538|Drug|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
422884|NCT00967525|Procedure|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
422885|NCT00967512|Drug|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
422886|NCT00967512|Drug|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
422887|NCT00967512|Drug|idarubicin, cytarabine|idarubicin, cytarabine
422888|NCT00967499|Drug|ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.~Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
422889|NCT00967499|Drug|palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.~Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
422890|NCT00967486|Procedure|Carotid endarterectomy with routine shount|
422891|NCT00967486|Procedure|Carotid endarterectomy with selective shunt|
422892|NCT00967473|Device|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
422893|NCT00967460|Behavioral|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
422894|NCT00967434|Drug|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
422895|NCT00967434|Drug|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
422896|NCT00967434|Drug|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
422897|NCT00967421|Drug|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
422898|NCT00967421|Drug|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
422899|NCT00967421|Other|Placebo drink|Placebo drink containing no alcohol + placebo pill
422900|NCT00967408|Drug|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
422901|NCT00967408|Drug|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
422902|NCT00967408|Other|Rehabilitative treatment|Rehabilitative treatment
422903|NCT00967395|Other|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
422904|NCT00967395|Other|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
422950|NCT00967096|Drug|Rifaximin|Rifaximin for Bone marrow transplant patients
424126|NCT00958672|Other|Endoscopic capsule|Endoscopic capsule
422905|NCT00967382|Drug|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;~dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)~Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
422906|NCT00967369|Drug|Bortezomib|Given IV
422907|NCT00967369|Drug|Carboplatin|Given IV
422908|NCT00967369|Drug|Etoposide|Given IV
422909|NCT00967369|Drug|Ifosfamide|Given IV
422910|NCT00967356|Drug|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
422911|NCT00967356|Drug|Placebo|Oral suspension
422912|NCT00967343|Biological|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
422913|NCT00967330|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
422914|NCT00967330|Drug|irinotecan|125mg/m2 iv every 2 weeks
422915|NCT00967330|Drug|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
422916|NCT00967317|Drug|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.~The medication should be used for a maximum of 3 days when they should return to the doctor."
422917|NCT00967317|Drug|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
422918|NCT00967304|Other|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.~Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
422919|NCT00967291|Drug|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
422920|NCT00967291|Drug|mitomycin C|8 mg/mq on day 1 every 28 days
422921|NCT00967265|Behavioral|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
422922|NCT00967265|Other|Usual care|Usual care
422923|NCT00967252|Drug|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
422924|NCT00967252|Drug|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
422925|NCT00967252|Drug|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
422926|NCT00967252|Drug|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
422927|NCT00967252|Other|Control|No statin being taken
422928|NCT00967239|Genetic|DNA analysis|
422929|NCT00967239|Genetic|polymorphism analysis|
422930|NCT00967239|Other|laboratory biomarker analysis|
422931|NCT00967239|Other|pharmacogenomic studies|
422932|NCT00967226|Drug|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
422933|NCT00967226|Drug|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
422934|NCT00967213|Drug|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
422935|NCT00967200|Other|laboratory biomarker analysis|laboratory biomarker analysis
422936|NCT00967200|Other|pharmacogenomic studies|pharmacogenomic studies
422937|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
422938|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
422939|NCT00967174|Drug|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
422940|NCT00967174|Drug|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
422941|NCT00967174|Drug|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
422942|NCT00967161|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
422943|NCT00967161|Procedure|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
422944|NCT00967148|Drug|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
422945|NCT00967135|Drug|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
422946|NCT00967135|Drug|Placebo|Matching oral placebo twice daily for 5 consecutive days.
422951|NCT00967083|Behavioral|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
422952|NCT00967070|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
422953|NCT00967070|Drug|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
422954|NCT00967057|Drug|asparaginase|Given intramuscularly
422955|NCT00967057|Drug|dexamethasone|Given orally
422956|NCT00967057|Drug|idarubicin|Given IV
422957|NCT00967057|Drug|methotrexate|Given intrathecally
422958|NCT00967057|Drug|mitoxantrone hydrochloride|Given IV
422959|NCT00967057|Drug|pegaspargase|Given intramuscularly
422960|NCT00967057|Drug|vincristine sulfate|Given IV
422961|NCT00967044|Drug|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
422962|NCT00967044|Drug|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
422963|NCT00967031|Drug|capecitabine|
422964|NCT00967031|Drug|lapatinib ditosylate|
422965|NCT00967031|Other|circulating tumor cell analysis|
422966|NCT00967031|Other|laboratory biomarker analysis|
422967|NCT00967018|Drug|Degarelix|
422968|NCT00967005|Drug|N Acetyl Cysteine|N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
422969|NCT00967005|Other|Sugar Pill|placebo control
422970|NCT00966992|Drug|Zoledronic acid|
422971|NCT00966979|Device|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
422972|NCT00966966|Drug|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
422973|NCT00966953|Drug|Fluoride|Brush twice daily
422974|NCT00966953|Drug|Triclosan/Fluoride toothpaste|Brush twice daily
422975|NCT00966953|Drug|Fluoride|Brush twice daily
422976|NCT00966953|Drug|Fluoride|Brush twice daily
422977|NCT00966953|Other|antibacterial plant extract|Brush twice daily
422978|NCT00966940|Drug|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
422979|NCT00966940|Drug|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
422980|NCT00966914|Drug|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
422981|NCT00966914|Drug|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
422982|NCT00966901|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
422983|NCT00966901|Drug|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
422984|NCT00966901|Drug|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
422985|NCT00966901|Radiation|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
422986|NCT00966888|Procedure|standard follow-up care|No intervention
422987|NCT00966888|Radiation|radiation therapy|Chest wall radiotherapy
422988|NCT00966875|Biological|LY2439821|Subcutaneous
422989|NCT00966875|Drug|Placebo|Subcutaneous
422990|NCT00966862|Other|Other: Dietary Fibers|
422991|NCT00966849|Other|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:~An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.~All children under 5 years in the household must be up-to-date with vaccinations.~All children under 5 years must attend a growth monitoring clinic twice per year.~All children 6-17 years in the household attended school at least 90% of days in the last month.~At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
422992|NCT00966849|Other|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
422993|NCT00966849|Other|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
422994|NCT00966849|Other|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
422995|NCT00966836|Drug|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
423109|NCT00965848|Drug|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
422996|NCT00966836|Drug|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
422997|NCT00966836|Drug|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
422998|NCT00966836|Drug|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
422999|NCT00966823|Device|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.~- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
423000|NCT00966810|Procedure|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect > 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
423001|NCT00966784|Other|Dietary Fibers|
423002|NCT00966771|Drug|Copper T380 IUD|copper T 380 IUD
423003|NCT00966771|Drug|Oral levonorgestrel|1.5 mg
423004|NCT00966758|Procedure|Computed Tomography|1 low dose CT scan is taken
423005|NCT00966758|Procedure|Single Photon Emission Computed Tomography|1 SPECT scan is taken
423006|NCT00966745|Drug|milrinone|
423007|NCT00966745|Drug|placebo|
423008|NCT00966732|Behavioral|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
423009|NCT00966719|Other|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
423010|NCT00966706|Drug|capecitabine|Given systemically
423011|NCT00966706|Drug|cisplatin|Given systemically
423012|NCT00966706|Drug|docetaxel|Given systemically
423013|NCT00966706|Drug|epirubicin hydrochloride|Given systemically
423014|NCT00966706|Drug|gemcitabine hydrochloride|Given systemically
423015|NCT00966693|Drug|Dexamethasone|Given PO
423016|NCT00966693|Drug|Lenalidomide|Given PO
423017|NCT00966693|Drug|Thalidomide|Given PO
423018|NCT00966680|Other|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
423019|NCT00966654|Drug|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
423020|NCT00966654|Drug|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
423021|NCT00966641|Drug|Naproxen|Single orally administered dose of 500 mg naproxen
423022|NCT00966641|Drug|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
423023|NCT00966628|Drug|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
423024|NCT00966628|Drug|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
423025|NCT00966615|Other|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
423026|NCT00966615|Other|glucose-based dialysis solution|2-L exchange; three times a day
423027|NCT00966602|Drug|VX-809|VX-809 capsule, once daily for 14 days
423028|NCT00966602|Drug|VX-770|VX-770 tablet, once every 12 hours for 14 days
423029|NCT00966602|Drug|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
423030|NCT00966602|Drug|Placebo|Matching Placebo
423031|NCT00966589|Procedure|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
423032|NCT00966576|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
423033|NCT00966563|Drug|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
423034|NCT00966563|Drug|Placebo|
423035|NCT00966550|Other|Tomato|Tomato with high carb/fat meal
423036|NCT00966550|Other|Non-tomato|Non-tomato with high carb/fat meal
423037|NCT00966524|Procedure|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
423110|NCT00965822|Other|North American ginseng|3 day, once daily, dosing
423111|NCT00965822|Other|Placebo|3 day, once daily dosing
423038|NCT00966511|Procedure|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
423039|NCT00966498|Procedure|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
423040|NCT00966485|Drug|80 mg ASA dosing|
423041|NCT00966485|Drug|500 mg ASA dosing|
423042|NCT00966472|Drug|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
423043|NCT00966459|Procedure|Computed Tomography|1 low-dose CT is taken
423044|NCT00966446|Drug|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
423045|NCT00966446|Drug|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
423046|NCT00966433|Procedure|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
423047|NCT00966433|Device|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
423048|NCT00966433|Device|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
423049|NCT00966420|Device|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
423050|NCT00966381|Other|Exercise and weight loss intervention|randomized control trial, stratified by parity
423051|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
423052|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
423053|NCT00966355|Drug|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
423054|NCT00966355|Drug|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
423055|NCT00966355|Drug|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
423056|NCT00966342|Drug|Fluviral 2009/10|single dose given IM .05 mL
423057|NCT00966329|Drug|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
423058|NCT00966329|Drug|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :~1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)~or ATV/unboosted (in a regimen without tenofovir)~or 1 NNRTI (nevirapine or efavirenz)."
423059|NCT00966316|Drug|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
423060|NCT00966303|Other|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
423061|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
423062|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
423063|NCT00966277|Drug|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
423064|NCT00966264|Drug|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
423065|NCT00966264|Procedure|Hysterectomy|operation
423066|NCT00966251|Drug|CT-011|CT-011
423067|NCT00966238|Biological|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
423068|NCT00966225|Dietary Supplement|LIP-01|comparison of different dosages of natural health product
423069|NCT00966212|Behavioral|parent education|Especially for Daughters audio-cd parent education
423070|NCT00966199|Drug|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
423071|NCT00966186|Procedure|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
423072|NCT00966173|Device|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
423073|NCT00966160|Drug|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
423074|NCT00966160|Drug|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
424127|NCT00958659|Other|laboratory biomarker analysis|Correlative studies
423075|NCT00966147|Other|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
423076|NCT00966134|Other|exposure to high altitude|
423077|NCT00966121|Procedure|endoscopic band ligation|"Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
423078|NCT00966121|Procedure|EBL+Propranolol|"Start with 20 mg b.i.d~Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
423079|NCT00966108|Device|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
423080|NCT00966082|Procedure|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
423081|NCT00966082|Procedure|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
423082|NCT00966069|Other|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
423083|NCT00966069|Other|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
423084|NCT00966056|Drug|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
423085|NCT00966056|Device|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
423086|NCT00966030|Drug|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
423087|NCT00966030|Drug|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
423088|NCT00966004|Drug|YM178|oral
423089|NCT00966004|Drug|Placebo|oral
423090|NCT00966004|Drug|tolterodine|oral
423091|NCT00965991|Drug|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
423092|NCT00965991|Drug|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
423093|NCT00965978|Drug|ONO-5920 / YM529|oral
423094|NCT00965965|Behavioral|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
423095|NCT00965965|Behavioral|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
423096|NCT00965926|Drug|YM178|oral
423097|NCT00965913|Drug|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
423098|NCT00965913|Drug|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
423099|NCT00965913|Drug|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
423100|NCT00965900|Procedure|Endoscopic band ligation|"Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
423101|NCT00965900|Drug|Propranolol|"start with 20 mg of propranolol b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
423102|NCT00965900|Procedure|EBL+Propranolol|"EBL~Perform EBL within 7 days after randomization~Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)~Acid suppression using proton pump inhibitor until eradicated.~After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).~Propranolol~start with 20 mg b.i.d~Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min~After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
423103|NCT00965887|Drug|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
423104|NCT00965887|Drug|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
423105|NCT00965874|Drug|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
423106|NCT00965874|Drug|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
423107|NCT00965874|Drug|Placebos|serum salin
423108|NCT00965861|Other|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
423112|NCT00965809|Drug|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
423113|NCT00965809|Other|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
423114|NCT00965796|Drug|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
423115|NCT00965783|Other|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
423116|NCT00965783|Other|Extension|Bedtime is extended by 2 hours per night for 4 nights
423117|NCT00965770|Device|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
423118|NCT00965757|Drug|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
423119|NCT00965757|Drug|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
423120|NCT00965744|Device|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
423121|NCT00965731|Drug|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
423122|NCT00965731|Drug|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
423123|NCT00965731|Drug|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
423124|NCT00965718|Biological|Activated T lymphocyte|Intravenous dripping of 200 ml (109~2 1010 lymphocytes/60 kg adult) for 1 hour.
423125|NCT00965705|Behavioral|Therapy|Individual Therapy and Group Therapy
423126|NCT00965666|Drug|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
423127|NCT00965653|Drug|folic acid|>/= 5 mg po weekly
423128|NCT00965653|Drug|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
423129|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
423130|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
423131|NCT00965640|Drug|Botulinum Toxin - A injections|
423132|NCT00965614|Other|MCG|Cardiac Arrhythmia,Heart Disease
423133|NCT00965601|Behavioral|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
423134|NCT00965588|Biological|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
423135|NCT00965575|Drug|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects.
423136|NCT00965562|Drug|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
423137|NCT00965562|Drug|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
423138|NCT00965562|Drug|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
423139|NCT00965549|Drug|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
423140|NCT00965549|Drug|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
423141|NCT00965549|Drug|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
423142|NCT00965523|Drug|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
423143|NCT00965510|Behavioral|care coordination|patients receive care coordination to improve their type II diabetes
423144|NCT00965497|Drug|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
423145|NCT00965484|Device|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
423146|NCT00965471|Drug|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
423147|NCT00965471|Drug|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
423148|NCT00965458|Biological|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
423149|NCT00965458|Drug|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
423150|NCT00965432|Drug|STX107|Single dose of an oral suspension
423151|NCT00965419|Drug|Edivoxetine|0.1 mg/kg/day or participant specific known stable dose, rollover participants (LNBJ [No NCT number]) and (LNBF [NCT00922636]), up to 0.3 mg/kg/day, oral, daily for up to 5 years.
423152|NCT00965406|Drug|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
423153|NCT00965393|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
423154|NCT00965393|Drug|Placebo|Systemic infusion of placebo (saline)
423155|NCT00965393|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
423240|NCT00964756|Genetic|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
423156|NCT00965367|Device|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
423157|NCT00965341|Drug|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
423158|NCT00965341|Drug|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
423159|NCT00965328|Procedure|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
423160|NCT00965328|Procedure|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
423161|NCT00965315|Drug|Rosuvastatin,SFC fenofibrate|"Rosuvastatin 10 mg once daily~Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
423162|NCT00965302|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
423163|NCT00965302|Behavioral|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
423164|NCT00965289|Drug|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
423165|NCT00965263|Biological|Cocaine vaccine (TA-CD)|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
423166|NCT00965250|Drug|IMC-12|20 mg/kg intravenously once every three weeks
423167|NCT00965237|Device|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
423168|NCT00965237|Device|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
423169|NCT00965237|Other|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
423170|NCT00965224|Biological|dendritic cell vaccination (active specific immunotherapy)|
423171|NCT00965211|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
423172|NCT00965185|Drug|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
423173|NCT00965185|Drug|Placebo|Placebo
423174|NCT00965172|Other|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
423175|NCT00965172|Other|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
423176|NCT00965146|Device|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
423177|NCT00965133|Other|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
423178|NCT00965120|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
423179|NCT00965120|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
423180|NCT00965120|Drug|Placebo (saline)|Systemic infusion of placebo (saline).
423181|NCT00965107|Drug|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
423182|NCT00965107|Drug|Propofol|Propofol given as a bolus dose of 1 mg/kg.
423183|NCT00965094|Drug|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
423184|NCT00965094|Drug|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
423185|NCT00965094|Drug|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg [day 0 (2 hrs prior to Tx) and day 4 post Tx] to be applied as 10 sec. bolus injection, i.v.
423186|NCT00965094|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
423187|NCT00965094|Drug|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg [prednisone, or equivalent, was used throughout the study period.
423188|NCT00965081|Drug|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
423189|NCT00965081|Drug|Placebo|QD po at the same time each day for 12 weeks
423190|NCT00965068|Other|Cholesterol|
423191|NCT00965055|Drug|Ezetimibe|10 mg
423192|NCT00965055|Drug|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.~Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients~Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.~Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test~Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.~Visit 6: Final cholesterol panel and conclusion of study period"
423193|NCT00965042|Drug|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
423194|NCT00965016|Procedure|hypothermia|Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
423195|NCT00965003|Procedure|MRI scan|Standard of Care
423196|NCT00964990|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
423197|NCT00964990|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
424416|NCT00956306|Drug|Udenafil|100mg Single Oral Dose of Udenafil
423198|NCT00964977|Radiation|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
423199|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
423200|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
423201|NCT00964964|Drug|placebo|Placebo injected s.c. (under the skin) four times weekly
423202|NCT00964951|Biological|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
423203|NCT00964951|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
423204|NCT00964938|Device|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
423205|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
423206|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
423207|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
423208|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
423209|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
423210|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
423211|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
423212|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
423213|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
423214|NCT00964912|Drug|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
423215|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
423216|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
423217|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
423218|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
423219|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
423220|NCT00964886|Drug|benztropine mesylate 0.125 mg daily|benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
423221|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
423222|NCT00964873|Drug|STA-9090 (ganetespib)|Chemotherapy agent
423223|NCT00964860|Device|Glide dental floss|Glide waxed dental floss
423224|NCT00964847|Behavioral|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
423225|NCT00964847|Behavioral|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
423226|NCT00964834|Drug|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
423227|NCT00964834|Drug|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
423228|NCT00964834|Drug|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
423229|NCT00964821|Biological|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
423230|NCT00964821|Other|Immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
423231|NCT00964821|Other|Laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
423232|NCT00964808|Drug|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
423233|NCT00964808|Drug|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg * 2 pr. day until time to discharge from the Hospital or latest at day 12.
423234|NCT00964795|Drug|Intravitreal Aflibercept Injection 2mg|
423235|NCT00964782|Drug|Sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
423236|NCT00964782|Drug|Placebo|Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
423237|NCT00964782|Drug|Sildenafil 2|oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
423238|NCT00964782|Drug|Placebo 2|Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
423239|NCT00964769|Biological|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
423241|NCT00964756|Drug|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
423242|NCT00964743|Drug|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
423243|NCT00964743|Drug|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
423244|NCT00964730|Drug|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
423245|NCT00964730|Drug|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
423246|NCT00964730|Drug|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
423247|NCT00964717|Procedure|real chiropractic|real chiropractic manipulation
423248|NCT00964717|Procedure|Sham Chiropractic|Placebo stimulation using 'activator' thumper
423249|NCT00964704|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
423250|NCT00964704|Drug|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
423251|NCT00964704|Drug|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
423252|NCT00964704|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
423253|NCT00964691|Drug|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
423254|NCT00964691|Drug|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
423255|NCT00964678|Drug|Carvedilol|twice daily oral treatment in escalating dose
423256|NCT00964665|Drug|albinterferon alfa-2b|
423257|NCT00964665|Drug|albinterferon alfa-2b|
423258|NCT00964665|Drug|albinterferon alfa-2b|
423259|NCT00964665|Drug|albinterferon alfa-2b|
423260|NCT00964665|Drug|Pegasys®|
423261|NCT00964652|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
423262|NCT00964639|Drug|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
423263|NCT00964639|Drug|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
423264|NCT00964626|Drug|cisplatin|
423265|NCT00964626|Drug|paclitaxel|
423266|NCT00964600|Procedure|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
423267|NCT00964587|Behavioral|Education + Problem-Solving Training Self-Study|"Education + Problem-Solving Training Self-Study~One session of Literacy-Adapted Diabetes and CVD Risk Education~Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
423268|NCT00964587|Behavioral|Education + Group Problem-Solving Training|"Education + Group Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Group problem-solving training eight, 90-minute sessions"
423269|NCT00964587|Behavioral|Education + Individual Problem-Solving Training|"Education + Individual Problem-Solving Training~One session of the Literacy-Adapted Diabetes and CVD Risk Education~Individual problem-solving training (eight, 60-minute sessions)"
423270|NCT00964587|Behavioral|Usual Care|"Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1~Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
423271|NCT00964574|Drug|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:~APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet~Route of administration:~3-4 subcutaneous injections per day"
423272|NCT00964574|Drug|INSULIN GLARGINE|"Pharmaceutical form:~LANTUS 100U/ml solution for injection in cartridge~Route of administration:~Once daily subcutaneous injection in the evening"
423273|NCT00964561|Drug|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
423274|NCT00964561|Drug|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
423275|NCT00964561|Other|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
423276|NCT00964548|Drug|Dantrolene|1.25 mg/kg IV once over 60 min
423277|NCT00964548|Drug|Dantrolene|2.5 mg/kg IV once over 60 min
423278|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
423279|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
423280|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
423281|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
423282|NCT00964522|Other|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
423283|NCT00964496|Drug|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
423284|NCT00964496|Drug|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
423285|NCT00964483|Behavioral|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
423286|NCT00964483|Behavioral|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
423287|NCT00964470|Device|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
423288|NCT00964457|Drug|cetuximab|cetuximab 500mg per meter square every second week
423289|NCT00964444|Device|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
423290|NCT00964431|Drug|Celecoxib 400 mg|Capsules 2 x 200 mg Single-Dose
423291|NCT00964431|Drug|Placebo|Capsules 2 Single-Dose
423292|NCT00964431|Drug|Indomethacin Test (lower dose)|20-mg single dose
423293|NCT00964431|Drug|Indomethacin Test (upper dose)|40-mg single dose
423294|NCT00964418|Drug|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
423295|NCT00964418|Drug|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
423296|NCT00964405|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist
423297|NCT00964405|Drug|Placebo|Matching placebo
423298|NCT00964392|Procedure|Atrial fibrillation ablation|Radiofrequency ablation
423299|NCT00964379|Procedure|intraperitoneal or extraperitoneal colostomy|creation of colostomy
423300|NCT00964366|Drug|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
423301|NCT00964366|Drug|Dapsone gel|Twice-daily applications of dapsone gel
423302|NCT00964353|Drug|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
423303|NCT00964340|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
423304|NCT00964340|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
423305|NCT00964327|Drug|TMC114|
423306|NCT00964314|Other|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done."
423307|NCT00964301|Other|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.~Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.~School Nurse Asthma Education. School nurses will participate in 2 sessions.~Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
423308|NCT00964301|Other|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
423309|NCT00964288|Drug|GSK1014802 low dose|oral tablet
423310|NCT00964288|Drug|Lidocaine|positive control
423311|NCT00964288|Drug|GSK1014802 high dose|oral tablet
423312|NCT00964288|Drug|Placebo|To match GSK drug and positive control
423313|NCT00964275|Procedure|diagnostic procedure|Standard diagnostic procedures followed
423314|NCT00964275|Radiation|fludeoxyglucose F 18|PET with flueoxyglucose F 18
423315|NCT00964262|Drug|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
423316|NCT00964262|Drug|Placebo|Plcacebo of each doasage, single subcutanoeus injection
423317|NCT00964249|Drug|GW642444|Long acting Beta 2 agonist
423318|NCT00964249|Drug|Placebo|Matching placebo
423319|NCT00964236|Drug|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
423320|NCT00964223|Drug|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
423321|NCT00964223|Drug|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
423322|NCT00964210|Drug|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
423323|NCT00964197|Device|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
423324|NCT00964184|Drug|Metformin|
423325|NCT00964184|Behavioral|Lifestyle modification|
423326|NCT00964171|Drug|efavirenz|
423327|NCT00964171|Procedure|quality-of-life assessment|
424489|NCT00955838|Other|Rehabilitation technique|12 therapy session
423328|NCT00964158|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
423329|NCT00964132|Drug|NRX194204|Once Daily, Oral
423330|NCT00964106|Drug|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
423331|NCT00964106|Drug|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
423332|NCT00964106|Drug|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
423333|NCT00964106|Drug|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
423334|NCT00964106|Drug|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
423335|NCT00964106|Drug|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
423336|NCT00964106|Drug|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
423337|NCT00964106|Drug|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
423338|NCT00964106|Drug|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
423339|NCT00964106|Drug|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
423340|NCT00964106|Drug|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
423341|NCT00964093|Device|Silver Alginate|(Algidex ™)
423342|NCT00964080|Drug|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
423343|NCT00964067|Other|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
423344|NCT00964054|Other|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
423345|NCT00964054|Other|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
423346|NCT00964041|Drug|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
423347|NCT00964041|Drug|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
423348|NCT00964028|Biological|Infanrix™-IPV/Hib|Intramuscular, three doses
423349|NCT00964015|Drug|6% Hydroxyethyl Starch 130/0.4|
423350|NCT00964015|Drug|0.9% Normal Saline|
423351|NCT00964002|Drug|efavirenz|
423352|NCT00963989|Device|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
423353|NCT00963976|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
423354|NCT00963963|Behavioral|Healthy Futures parent education|Multi-year audio CD parent education
423355|NCT00963950|Procedure|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
423356|NCT00963950|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
423357|NCT00963937|Drug|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
423358|NCT00963937|Drug|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
423359|NCT00963937|Drug|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
423360|NCT00963924|Drug|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
423361|NCT00963924|Drug|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
423362|NCT00963924|Behavioral|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
423363|NCT00963911|Other|medical chart review|
423364|NCT00963911|Other|screening questionnaire administration|
423365|NCT00963911|Procedure|comparison of screening methods|
423366|NCT00963911|Procedure|quality-of-life assessment|
423367|NCT00963898|Device|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
423368|NCT00963885|Drug|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
423369|NCT00963885|Drug|Pegasys|180micrograms sc weekly for 24 or 48 weeks
423370|NCT00963885|Drug|Placebo|po for 12 weeks
423371|NCT00963885|Drug|Placebo|po for 24 weeks
423372|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
423373|NCT00963885|Drug|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
423374|NCT00963885|Drug|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
423375|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
423376|NCT00963872|Drug|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
423377|NCT00963872|Drug|fludarabine phosphate|40 mg/m^2 over 1 hour on Days -6 through -2.
423378|NCT00963872|Radiation|Total body irradiation|200 cGy on Day -1
423379|NCT00963872|Biological|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
423380|NCT00963872|Biological|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
423381|NCT00963859|Procedure|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
423382|NCT00963846|Drug|placebo|matching pill placebo
423383|NCT00963846|Drug|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
423384|NCT00963846|Drug|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
423385|NCT00963846|Drug|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
423386|NCT00963833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
423387|NCT00963820|Drug|Ixazomib citrate|Ixazomib citrate capsules
423388|NCT00963807|Drug|Cisplatin|Given IV
423389|NCT00963807|Procedure|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
423390|NCT00963807|Drug|Docetaxel|Given IV
423391|NCT00963807|Drug|FDG|Undergo FDG PET/CT
423392|NCT00963807|Drug|FLT|Undergo FLT PET/CT
423393|NCT00963807|Procedure|PET/CT|Undergo FDG PET/CT and FLT PET/CT
423394|NCT00963807|Procedure|Surgery|Undergo surgery
423395|NCT00963794|Other|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
423396|NCT00963781|Device|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
423397|NCT00963781|Drug|Reduced duration (6 months) DAPT|
423398|NCT00963768|Drug|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
423399|NCT00963768|Drug|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
423400|NCT00963742|Device|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
423401|NCT00963729|Drug|cyclophosphamide|Given IV
423402|NCT00963729|Drug|docetaxel|Given IV
423403|NCT00963729|Drug|epirubicin hydrochloride|Given IV
423404|NCT00963729|Drug|fluorouracil|Given IV
423405|NCT00963729|Drug|letrozole|Given orally
423406|NCT00963716|Device|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
423407|NCT00963716|Device|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
423408|NCT00963703|Drug|Rituximab|Rituximab 1000 mg Intravenously day 1 and day 15
423409|NCT00963690|Device|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
423410|NCT00963690|Procedure|Standard compression|Use standard compression to achieve hemostasis
423411|NCT00963677|Procedure|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
423412|NCT00963664|Drug|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
423413|NCT00963664|Drug|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
423414|NCT00963651|Device|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
423415|NCT00963638|Dietary Supplement|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
423416|NCT00963638|Dietary Supplement|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
423417|NCT00963625|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
423418|NCT00963625|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
423419|NCT00963612|Procedure|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
423420|NCT00963599|Drug|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
423421|NCT00963599|Drug|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
423422|NCT00963599|Drug|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
423423|NCT00963599|Drug|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
423424|NCT00963573|Drug|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
423425|NCT00963573|Drug|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
423426|NCT00963560|Device|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
423427|NCT00963560|Device|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
423428|NCT00963560|Device|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
423472|NCT00963196|Drug|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
423429|NCT00963547|Drug|MK-2206|[Part 1]: MK-2206 tablets will be given starting at a dose of 45 mg QOD and escalated to 60 mg QOD if tolerated, OR starting at a dose of 135 mg QW and escalated to 200 mg QW if tolerated. Dose reduction to 30mg QOD or 90 mg QW may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose (MTD) of MK2206 for both the QOD and QW dosing schedules in combination with trastuzumab. [Part 2] The Part 2 dosing level and schedule of MK2206 will be chosen from the MTD of either the QOD or QW dosing schedules depending on the toxicity profile and preliminary efficacy.
423430|NCT00963547|Biological|Trastuzumab|Trastuzumab will be administered as a 90-minute IV infusion at a loading dose of 8 mg/kg followed by 6 mg/kg q3wk.
423431|NCT00963547|Drug|Lapatinib|Lapatinib tablets will be administered orally QD in doses of 500 mg, 750 mg, or 1000 mg.
423432|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.~Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
423433|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
423434|NCT00963521|Biological|therapeutic autologous dendritic cells|
423435|NCT00963508|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
423436|NCT00963508|Drug|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
423437|NCT00963495|Drug|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
423438|NCT00963482|Behavioral|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra & Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
423439|NCT00963482|Behavioral|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
423440|NCT00963469|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
423441|NCT00963469|Drug|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
423442|NCT00963469|Drug|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
423443|NCT00963443|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
423444|NCT00963443|Drug|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
423445|NCT00963443|Drug|Placebo|Matching Placebo
423446|NCT00963430|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
423447|NCT00963417|Other|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
423448|NCT00963417|Procedure|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
423449|NCT00963404|Radiation|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
423450|NCT00963391|Other|ABHS use|"Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center."
423451|NCT00963365|Drug|AZD6765|Single oral dose and single IV infusion of AZD6765
423452|NCT00963365|Drug|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
423453|NCT00963339|Device|Foresee Home|Home Monitoring
423454|NCT00963326|Other|laboratory biomarker analysis|
423455|NCT00963313|Drug|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
423456|NCT00963300|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
423457|NCT00963300|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
423458|NCT00963300|Procedure|magnetic resonance spectroscopic imaging|
423459|NCT00963300|Procedure|tissue-oxygen-level-dependent functional magnetic resonance imaging|
423460|NCT00963287|Drug|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
423461|NCT00963274|Drug|Bortezomib|Starting dose: 1.3 mg/sq m
423462|NCT00963274|Drug|Romidepsin|Starting dose: 8 mg/sq m
423463|NCT00963261|Behavioral|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
423464|NCT00963235|Biological|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
423465|NCT00963235|Procedure|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
423466|NCT00963222|Drug|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
423467|NCT00963222|Drug|placebo|1 cap placebo/day for 3 month
423468|NCT00963209|Drug|tamoxifen citrate|
423469|NCT00963209|Other|laboratory biomarker analysis|
423470|NCT00963209|Other|pharmacological study|
423471|NCT00963196|Dietary Supplement|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
423665|NCT00961662|Drug|D-Tagatose|powder to be dissolved in water prior to dosage.
423473|NCT00963183|Drug|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
423474|NCT00963183|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
423475|NCT00963157|Drug|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
423476|NCT00963157|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
423477|NCT00963131|Drug|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
423478|NCT00963118|Dietary Supplement|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
423479|NCT00963105|Drug|lenalidomide|"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:~Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily~Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily~Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
423480|NCT00963092|Genetic|DNA analysis|
423481|NCT00963092|Genetic|RNA analysis|
423482|NCT00963092|Genetic|microarray analysis|
423483|NCT00963092|Genetic|protein analysis|
423484|NCT00963092|Other|cytology specimen collection procedure|
423485|NCT00963092|Other|laboratory biomarker analysis|
423486|NCT00963092|Other|questionnaire administration|
423487|NCT00963079|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
423488|NCT00963079|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
423489|NCT00963066|Device|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
423490|NCT00963066|Device|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
423491|NCT00963066|Device|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
423492|NCT00963053|Drug|VA111913 TS and placebo|VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
423493|NCT00963040|Drug|Syntocinon (Oxytocin)|4 actuations in each nostril for a total dose of 32 IU
423494|NCT00963040|Drug|Sterile water|4 actuations in each nostril
423495|NCT00963027|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
423496|NCT00963027|Drug|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
423497|NCT00963001|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
423498|NCT00963001|Other|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
423499|NCT00962988|Drug|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.~Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.~For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.~For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
423500|NCT00962988|Other|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
423501|NCT00962975|Drug|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
423502|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
423503|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
423666|NCT00961649|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
423504|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
423505|NCT00962962|Behavioral|Exercise and Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week~Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
423506|NCT00962949|Drug|Angiotensin II|Angiotensin II infusion for 1 hour
423507|NCT00962936|Drug|CT-011|CT-011
423508|NCT00962923|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
423509|NCT00962910|Other|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
423510|NCT00962897|Procedure|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
423511|NCT00962897|Procedure|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
423512|NCT00962884|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
423513|NCT00962884|Device|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
423514|NCT00962871|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
423515|NCT00962871|Drug|tenofovir|300mg po daily for 2 weeks
423516|NCT00962845|Drug|hydroxychloroquine|200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
423517|NCT00962832|Drug|Placebo|Placebo was supplied as a sterile liquid solution.
423518|NCT00962832|Drug|Rontalizumab|Rontalizumab was supplied as a sterile liquid solution.
423519|NCT00962819|Biological|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
423520|NCT00962806|Behavioral|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
423521|NCT00962806|Behavioral|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
423522|NCT00962780|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
423523|NCT00962780|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
423524|NCT00962780|Procedure|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
423525|NCT00962780|Procedure|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
423526|NCT00962767|Drug|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
423527|NCT00962767|Drug|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
423528|NCT00962754|Procedure|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
423529|NCT00962741|Drug|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
423530|NCT00962728|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
423531|NCT00962728|Device|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
423532|NCT00962715|Biological|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
423533|NCT00962715|Drug|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
423534|NCT00962715|Drug|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
423535|NCT00962702|Device|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
423536|NCT00962663|Drug|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
423537|NCT00962663|Drug|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
423538|NCT00962663|Drug|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA~-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
423539|NCT00962650|Device|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
423540|NCT00962637|Drug|Androxal|12.5 mg once daily
423541|NCT00962637|Drug|Androxal|25 mg once daily
423542|NCT00962637|Drug|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
423543|NCT00962637|Drug|Placebo|1 capsule daily
423544|NCT00962624|Drug|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
423667|NCT00961649|Drug|Brinzolamide ophthalmic suspension, 1%|
423545|NCT00962611|Drug|Copanlisib (Aliqopa, BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
423546|NCT00962598|Drug|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
423547|NCT00962598|Dietary Supplement|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
423548|NCT00962585|Drug|Placebo|
423549|NCT00962585|Drug|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:~S-equol 10 mg BID (20 mg total daily dose)~S-equol 50 mg BID (100 mg total daily dose)~S-equol 150 mg BID (300 mg total daily dose)"
423550|NCT00962572|Behavioral|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
423551|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
423552|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
423553|NCT00962507|Drug|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
423554|NCT00962507|Drug|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
423555|NCT00962507|Other|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
423556|NCT00962507|Other|pharmacological study|Pre-study, day 1 and day 26
423557|NCT00962494|Behavioral|Cancer: Thriving and Surviving Online Workshop|
423558|NCT00962481|Drug|Bimosiamose|
423559|NCT00962481|Drug|Placebo|
423560|NCT00962468|Other|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
423561|NCT00962455|Other|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
423562|NCT00962455|Other|usual practice|Usual practice regarding spirometry execution in family practice
423563|NCT00962442|Drug|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
423564|NCT00962442|Drug|placebo|Glucosé 5% perfusion for 14 days, intravenously
423565|NCT00962429|Drug|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
423566|NCT00962416|Device|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
423567|NCT00962416|Device|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
423568|NCT00962403|Behavioral|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
423569|NCT00962390|Drug|S-equol|10mg S-equol 50mg S-equol, & 150mg S-equol
423570|NCT00962390|Drug|Placebo|Placebo
423571|NCT00962377|Procedure|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
423572|NCT00962377|Procedure|AlloMap Molecular Testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
423573|NCT00962364|Biological|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
423574|NCT00962351|Procedure|Total Hip Replacement|
423575|NCT00962338|Behavioral|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
423576|NCT00962325|Behavioral|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
423577|NCT00962312|Drug|capecitabine|
423578|NCT00962312|Drug|lapatinib ditosylate|
423579|NCT00962299|Drug|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
423580|NCT00962299|Drug|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
423616|NCT00961987|Other|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
423617|NCT00961987|Other|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
423581|NCT00962286|Drug|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.~Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.~In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
423582|NCT00962273|Behavioral|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
423583|NCT00962273|Behavioral|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
423584|NCT00962260|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
423585|NCT00962247|Device|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
423586|NCT00962234|Other|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
423587|NCT00962234|Biological|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
423588|NCT00962234|Procedure|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
423589|NCT00962221|Procedure|laboratory analysis|laboratory analysis
423590|NCT00962208|Device|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
423591|NCT00962208|Device|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
423592|NCT00962195|Dietary Supplement|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
423593|NCT00962182|Drug|STAN1|3-4 capsules/day at meals
423594|NCT00962182|Drug|Placebo enzyme|3-4 capsules/day at meals
423595|NCT00962182|Drug|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
423596|NCT00962169|Other|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
423597|NCT00962169|Other|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
423598|NCT00962156|Drug|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
423599|NCT00962156|Drug|Ringers acetate|Infusion for volume expansion in the ICU
423600|NCT00962143|Device|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
423601|NCT00962143|Procedure|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
423602|NCT00962130|Device|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
423603|NCT00962104|Drug|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
423604|NCT00962104|Drug|Placebo|Taken by mouth, once daily for 10 weeks.
423605|NCT00962091|Drug|Alisertib|Alisertib OS Alisertib PIC Alisertib PIC
423606|NCT00962078|Other|continuous endurance training|at 60 percent of peak Watt
423607|NCT00962078|Other|interval training|at 100 percent of peak Watt
423608|NCT00962065|Drug|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
423609|NCT00962065|Drug|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
423610|NCT00962065|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days
423611|NCT00962039|Drug|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
423612|NCT00962026|Drug|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
423613|NCT00962013|Device|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
423614|NCT00962000|Other|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
423615|NCT00962000|Other|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
423618|NCT00961974|Behavioral|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
423619|NCT00961974|Behavioral|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
423620|NCT00961961|Drug|Lithium / Fluoxetine|Individualized Daily Dosage
423621|NCT00961961|Drug|Lithium / Placebo|Individualized Daily Dosage
423622|NCT00961922|Other|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
423623|NCT00961922|Other|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
423624|NCT00961909|Drug|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
423625|NCT00961909|Drug|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
423626|NCT00961909|Drug|metformin|stable dose
423627|NCT00961909|Drug|placebo|sc once weekly for 4 weeks
423628|NCT00961896|Drug|Vehicle|Placebo cream
423629|NCT00961896|Drug|LDE225 0.25%|
423630|NCT00961896|Drug|LDE225 0.75%|
423631|NCT00961883|Biological|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 ^7 PFU
423632|NCT00961883|Biological|Placebo|Sodium Chloride for injection, delivered intramuscularly
423633|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^10 PFU
423634|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^9 PFU
423635|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^8 PFU
423636|NCT00961870|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
423637|NCT00961857|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
423638|NCT00961857|Drug|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
423639|NCT00961857|Drug|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
423640|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
423641|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
423642|NCT00961857|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
423643|NCT00961844|Biological|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
423644|NCT00961844|Drug|Temozolomide|
423645|NCT00961831|Drug|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
423646|NCT00961831|Drug|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
423647|NCT00961805|Behavioral|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
423648|NCT00961805|Other|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
423649|NCT00961792|Drug|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
423650|NCT00961792|Drug|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
423651|NCT00961792|Drug|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
423652|NCT00961792|Drug|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
423653|NCT00961779|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
423654|NCT00961779|Drug|Placebo|Normal saline infusion
423655|NCT00961766|Drug|BG00010 (Neublastin)|Single dose, weight-based IV administration
423656|NCT00961766|Drug|Placebo|Single dose IV matched placebo
423657|NCT00961753|Drug|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
423658|NCT00961753|Drug|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
423659|NCT00961740|Behavioral|Cognitive Behavioural Therapy|See summary
423660|NCT00961740|Other|Waitlist condition|See Summary
423661|NCT00961727|Other|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; [1] an expert derived, multi-centre validated severity of illness score, [2] an inter-professionally developed documentation record into which the severity of illness score is embedded, [3] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and [4] an educator-developed education-implementation program.
423662|NCT00961714|Device|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
423663|NCT00961675|Drug|FST201 (dexamethasone 0.1% with povidone-iodine 1%)|4gtt BID
423664|NCT00961675|Drug|Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )|4 gtt BID
423670|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
423671|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
423672|NCT00961636|Drug|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
423673|NCT00961636|Drug|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
423674|NCT00961610|Behavioral|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
423675|NCT00961597|Procedure|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
423676|NCT00961597|Procedure|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
423677|NCT00961571|Drug|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
423678|NCT00961558|Procedure|Varicocelectomy|Varicocelectomy
423679|NCT00961532|Drug|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
423680|NCT00961506|Procedure|LESS cholecystectomy|LESS cholecystectomy
423681|NCT00961506|Procedure|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
423682|NCT00961493|Behavioral|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
423683|NCT00961493|Behavioral|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
423684|NCT00961480|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
423685|NCT00961480|Drug|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
423686|NCT00961480|Drug|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
423687|NCT00961480|Drug|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
423688|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
423689|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
423690|NCT00961480|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
423691|NCT00961480|Drug|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
423692|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
423693|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
423694|NCT00961454|Device|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
423695|NCT00961441|Drug|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets~Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
423696|NCT00961415|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
423697|NCT00961415|Drug|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
423698|NCT00961415|Drug|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
423699|NCT00961402|Behavioral|Wellness Control|6-month wellness control
423700|NCT00961402|Behavioral|Exercise Intervention|6 month exercise intervention
423701|NCT00961376|Biological|PBMC re-infusion|Autologous PBMC re-infusion
423702|NCT00961376|Biological|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
423703|NCT00961363|Drug|Sitagliptin|sitagliptin 100 mg per day
423704|NCT00961363|Drug|Placebo|Placebo
423705|NCT00961350|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
423706|NCT00961350|Drug|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
423707|NCT00961337|Biological|Trivalent inactivated influenza vaccine|one dose
423708|NCT00961324|Drug|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
423709|NCT00961324|Drug|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
423710|NCT00961311|Procedure|Percutaneous Coronary Intervention|Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
423711|NCT00961311|Device|Sprinter Legend 1.25mm Balloon Catheter|Balloon Angioplasty
423797|NCT00960687|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
423798|NCT00960687|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
423799|NCT00960674|Procedure|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
423712|NCT00961298|Drug|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
423713|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
423714|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
423715|NCT00961259|Drug|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
423716|NCT00961246|Behavioral|general health information|participants received general health information
423717|NCT00961246|Behavioral|individually-tailored intervention|participants received individually-tailored intervention
423718|NCT00961233|Drug|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
423719|NCT00961233|Drug|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
423720|NCT00961220|Drug|Carmustine|Applied topically
423721|NCT00961220|Other|Laboratory Biomarker Analysis|Correlative studies
423722|NCT00961220|Drug|O6-Benzylguanine|Given IV
423723|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
423724|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
423725|NCT00961194|Drug|Ketamine|"Initial dosage: 250 mg/5 ml~Three doses of ketamine will be tested:~0.35 mg/kg~0.7 mg/kg~1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).~The oral ketamine will be administered in form of syrup."
423726|NCT00961181|Device|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
423727|NCT00961168|Other|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
423728|NCT00961168|Other|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
423729|NCT00961155|Drug|cyklezonid|160 mcg once daily
423730|NCT00961155|Drug|montelukast sodium|5 or 10 mg according to age once daily
423731|NCT00961155|Drug|placebo|fluticasone placebo twice daily, montelukast placebo once daily
423732|NCT00961155|Drug|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
423733|NCT00961142|Drug|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
423734|NCT00961116|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
423735|NCT00961116|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
423736|NCT00961090|Drug|Aminolevulinic Acid|20 mg/kg mixed in 50cc water and taken orally 3 hours prior to surgery
423737|NCT00961077|Drug|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours~every 3 weeks"
423738|NCT00961064|Drug|Eltrombopag|Eltrombopag will be initiated at 50 mg/day (Asians 25 mg/day) and dose adjusted up to 150mg/day based response and safety
423739|NCT00961051|Device|Investigational MPS|Multi-purpose solution
423740|NCT00961051|Device|Opti-Free|Multi-purpose solution
423741|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
423742|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
423743|NCT00961038|Drug|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
423744|NCT00961025|Drug|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg"
423745|NCT00961025|Drug|Placebo|placebo
423746|NCT00961012|Procedure|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
423747|NCT00960999|Radiation|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
423800|NCT00960674|Behavioral|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
423801|NCT00960661|Drug|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
423802|NCT00960661|Drug|insulin lispro|titrated based on pre-meal glucose level; three times a day
423803|NCT00960661|Drug|Metformin|
423804|NCT00960661|Drug|Insulin/ Glargine|
423748|NCT00960999|Radiation|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
423749|NCT00960986|Drug|Duloxetine hydrochloride|po, QD
423750|NCT00960973|Drug|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
423751|NCT00960973|Drug|Placebo|Placebo
423752|NCT00960960|Drug|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
423753|NCT00960960|Drug|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
423754|NCT00960960|Drug|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
423755|NCT00960960|Drug|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
423756|NCT00960960|Drug|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
423757|NCT00960934|Drug|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
423758|NCT00960934|Drug|Placebo|Dose-matched oral placebo to MK-5442
423759|NCT00960934|Dietary Supplement|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
423760|NCT00960934|Dietary Supplement|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
423761|NCT00960921|Drug|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
423762|NCT00960921|Drug|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
423763|NCT00960908|Device|Endeavor Resolute stents|2nd generation ZES
423764|NCT00960908|Device|Endeavor Sprint stent|1st generation ZES
423765|NCT00960882|Drug|DMMET-01|1050.6 mg daily for 30 days
423766|NCT00960869|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
423767|NCT00960869|Drug|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
423768|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
423769|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
423770|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
423771|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
423772|NCT00960843|Device|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
423773|NCT00960843|Other|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
423774|NCT00960830|Drug|mirtazapine|mirtazapine 15 mg daily tablets
423775|NCT00960830|Drug|mirtazapine|15 mg daily
423776|NCT00960817|Drug|Statin, aspirin|
423777|NCT00960817|Drug|Dipyridamole|
423778|NCT00960804|Biological|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
423779|NCT00960804|Biological|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
423780|NCT00960804|Other|Placebo|IV, q 8 weeks, for up to 80 weeks
423781|NCT00960791|Device|AZD1656|Oral single dose
423782|NCT00960778|Drug|nicotine patch (Nicoderm Committed Quitter (CQ), Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
423783|NCT00960778|Other|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
423784|NCT00960752|Drug|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
423785|NCT00960752|Drug|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
423786|NCT00960752|Drug|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
423787|NCT00960739|Drug|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
423788|NCT00960739|Procedure|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
423789|NCT00960739|Radiation|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
423790|NCT00960739|Radiation|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
423791|NCT00960726|Drug|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
423792|NCT00960713|Drug|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
423793|NCT00960700|Device|Visual Acuity|Assessment of visual acuity
423794|NCT00960700|Device|Contrast sensitivity|Assessment of contrast sensitivity
423795|NCT00960700|Device|Reading Speed|Assessment of reading speed
423796|NCT00960700|Procedure|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
423805|NCT00960648|Device|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
423806|NCT00960648|Device|Cypher|Retrospective historical controls that received sirolimus-eluting stent
423807|NCT00960635|Drug|1,25-dihydroxy-vitamin D3 (calcitriol)|
423808|NCT00960635|Drug|placebo|pill without agent
423809|NCT00960622|Drug|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
423810|NCT00960622|Drug|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
423811|NCT00960622|Drug|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
423812|NCT00960609|Procedure|Ultrasound guided liver resection|
423813|NCT00960596|Behavioral|Health promotion and health education for smoking habits|We provide the education to intervention group.
423814|NCT00960583|Other|Exercise program|24 group exercise sessions during 12 weeks
423815|NCT00960583|Other|Routine follow-up|Advice to stay active
423816|NCT00960570|Drug|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
423817|NCT00960570|Drug|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
423818|NCT00960570|Drug|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
423819|NCT00960557|Drug|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
423820|NCT00960544|Drug|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
423821|NCT00960531|Biological|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
423822|NCT00960531|Biological|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
423823|NCT00960531|Biological|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
423824|NCT00960518|Drug|adefovir|adefovir at 10 mg daily for 48 weeks
423825|NCT00960518|Procedure|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
423826|NCT00960505|Other|Alternate day fasting|
423827|NCT00960505|Other|Calorie restriction|
423828|NCT00960505|Other|Control diet|
423829|NCT00960492|Drug|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
423830|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
423831|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
423832|NCT00960492|Radiation|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
423833|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
423834|NCT00960479|Drug|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
423835|NCT00960479|Drug|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
423836|NCT00960466|Behavioral|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
423837|NCT00960466|Behavioral|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
423838|NCT00960453|Drug|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods"
423839|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
423840|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
423841|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
423842|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
423843|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
423844|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
423845|NCT00960427|Drug|systemic chemotherapy|
423846|NCT00960427|Genetic|RNA analysis|
423847|NCT00960427|Genetic|gene expression analysis|
423848|NCT00960427|Genetic|reverse transcriptase-polymerase chain reaction|
423849|NCT00960427|Other|immunohistochemistry staining method|
423850|NCT00960427|Other|laboratory biomarker analysis|
423851|NCT00960427|Procedure|endoscopic biopsy|
423852|NCT00960427|Procedure|neoadjuvant therapy|
423853|NCT00960427|Procedure|sigmoidoscopy|
423854|NCT00960427|Radiation|radiation therapy|
423855|NCT00960414|Behavioral|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detained nutritional education.
423856|NCT00960375|Behavioral|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
423857|NCT00960375|Behavioral|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
423858|NCT00960362|Drug|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
423859|NCT00960362|Drug|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
423860|NCT00960349|Drug|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
423861|NCT00960349|Drug|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
423862|NCT00960349|Drug|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
423863|NCT00960349|Drug|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
423864|NCT00960349|Drug|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
423865|NCT00960336|Drug|pegylated liposomal doxorubicin hydrochloride|
423866|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
423867|NCT00960323|Drug|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
423868|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
423869|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
423870|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
423871|NCT00960297|Drug|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
423872|NCT00960297|Drug|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
423873|NCT00960297|Drug|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
423874|NCT00960284|Drug|capecitabine|Given orally
423875|NCT00960284|Drug|cisplatin|Given IV
423876|NCT00960284|Drug|epirubicin hydrochloride|Given IV
423877|NCT00960284|Drug|fluorouracil|Given IV
423878|NCT00960284|Drug|gemcitabine hydrochloride|Given IV
423879|NCT00960271|Procedure|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
423880|NCT00960258|Drug|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
423881|NCT00960245|Drug|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
423882|NCT00960245|Drug|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
423883|NCT00960232|Drug|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
423884|NCT00960232|Drug|placebo|placebo
423885|NCT00960219|Drug|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
423886|NCT00960219|Drug|placebo|1# BID, oral, for 6 weeks
423887|NCT00960206|Device|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
423888|NCT00960206|Device|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
423889|NCT00960206|Device|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
423890|NCT00960193|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
423891|NCT00960193|Other|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
423892|NCT00960180|Drug|MR1817|
423893|NCT00960180|Drug|Placebo|
423894|NCT00960167|Radiation|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;~Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:~Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
423895|NCT00960154|Device|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
423896|NCT00960154|Procedure|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
423897|NCT00960141|Drug|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
423898|NCT00960141|Drug|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
423899|NCT00960141|Drug|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
423900|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
423901|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
423902|NCT00960115|Biological|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram [mcg]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
423903|NCT00960115|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg/m^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
423904|NCT00960115|Biological|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
423905|NCT00960115|Other|Saline|A single dose of saline (sodium chloride, 9 grams per liter [g/L]) will be administered intravenously, 3 days prior to the start of placebo.
423906|NCT00960102|Device|cochlear implant|Multichannel Nucleus cochlear implant
423907|NCT00960102|Device|hearing aid|Phonak hearing aid
423908|NCT00960089|Device|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
423909|NCT00960076|Drug|Saxagliptin|5mg oral tablet once daily
423910|NCT00960076|Drug|Metformin XR|500mg oral tablet once daily
423911|NCT00960076|Drug|Metformin XR|750mg, 2 tablets once daily
423912|NCT00960063|Drug|Temozolomide|
423913|NCT00960063|Drug|Vincristine|
423914|NCT00960063|Drug|Ifosfamide|
423915|NCT00960063|Drug|Irinotecan|
423916|NCT00960063|Biological|Robatumumab|
423917|NCT00960063|Drug|Doxorubicin|
423918|NCT00960063|Drug|Cyclophosphamide|
423919|NCT00960063|Drug|Etoposide|
423920|NCT00960037|Dietary Supplement|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
423921|NCT00960037|Dietary Supplement|Placebo equivalent|One capsule daily for 8 weeks
423922|NCT00960024|Behavioral|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
423923|NCT00960024|Behavioral|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
423924|NCT00960011|Device|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
423925|NCT00960011|Device|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
423926|NCT00959998|Other|Self-administered Acupressure|
423927|NCT00959985|Device|Compression Sleeve|Worn for a minimum of 12 hours per day
423928|NCT00959985|Device|Short-Stretch Compression Bandage|Worn overnight at least 5 nights of the week
423929|NCT00959972|Drug|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
423930|NCT00959972|Drug|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
423931|NCT00959959|Drug|TOK-001|2 capsules (325 mg each), once per day
423932|NCT00959959|Drug|TOK-001|4 capsules (325 mg each), once per day
423933|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), once per day
423934|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day
423935|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day with supplement
423936|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
423937|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), once per day
423938|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
423939|NCT00959946|Drug|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
423940|NCT00959946|Drug|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
423941|NCT00959933|Drug|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
423942|NCT00959933|Drug|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
423943|NCT00959920|Procedure|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
423944|NCT00959920|Procedure|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
423945|NCT00959907|Drug|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):~Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.~Dysport®: 4 units will be injected in the left or right forehead side.~Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
424027|NCT00959283|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
424028|NCT00959283|Other|Pharmacological Study|Correlative studies
423946|NCT00959894|Drug|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
423947|NCT00959894|Drug|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
423948|NCT00959881|Drug|Donepezil plus placebo|5- and 10-mg tablets, single dose
423949|NCT00959881|Drug|Donepezil|5- and 10-mg tablets, single dose
423950|NCT00959881|Drug|Begacestat|6 x 50-mg capsules, single dose
423951|NCT00959868|Drug|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
423952|NCT00959855|Other|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
423953|NCT00959842|Drug|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
423954|NCT00959829|Other|Music and message|Experimental group: music and message Control group: silence
423955|NCT00959816|Drug|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
423956|NCT00959803|Drug|PF-04447943|3 mg solution, oral single dose.
423957|NCT00959803|Drug|PF-04447943|10 mg solution, oral single dose.
423958|NCT00959803|Drug|PF-04447943|25 mg solution, oral single dose.
423959|NCT00959803|Drug|Placebo|Solution, oral single dose.
423960|NCT00959803|Drug|PF-04447943|25 mg solution, oral twice daily for 7 days.
423961|NCT00959803|Drug|Placebo|Solution, oral twice daily for 7 days.
423962|NCT00959790|Dietary Supplement|Vegetables|200 or 50 grams of vegetables daily for four weeks
423963|NCT00959790|Dietary Supplement|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
423964|NCT00959777|Drug|DA-3031|
423965|NCT00959777|Drug|Filgrastim|
423966|NCT00959764|Drug|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
423967|NCT00959764|Drug|Intranasal Calcitonin|Intranasal Calcitonin Spray
423968|NCT00959764|Drug|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
423969|NCT00959751|Drug|NXN-188|200 mg capsules, 600 mg, PRN
423970|NCT00959751|Drug|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
423971|NCT00959738|Procedure|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
423972|NCT00959738|Procedure|diverting loop ileostomy without rod|diverting loop ileostomy without rod
423973|NCT00959725|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
423974|NCT00959712|Behavioral|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
423975|NCT00959699|Drug|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
423976|NCT00959699|Drug|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
423977|NCT00959699|Drug|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
423978|NCT00959699|Drug|Boceprevir|Boceprevir (800 mg, orally, three times per day)
423979|NCT00959686|Drug|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
423980|NCT00959660|Behavioral|Exercise|walking, treadmill and bicycle exercise
423981|NCT00959660|Dietary Supplement|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
423982|NCT00959660|Behavioral|Diet and exercise|Subjects will be provided meals and instructions for individual food selections and will undergo walking, treadmill and bicycle exercise.
423983|NCT00959660|Other|Attention Control|control group- continue their previously randomized life style
423984|NCT00959647|Drug|Vismodegib|Vismodegib was supplied in capsules.
423985|NCT00959647|Drug|FOLFOX|FOLFOX (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and oxaliplatin [OX]) was supplied as solutions for intravenous administration.
423986|NCT00959647|Drug|FOLFIRI|FOLFIRI (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and irinotecan [IRI]) was supplied as solutions for intravenous administration.
423987|NCT00959647|Drug|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
423988|NCT00959634|Drug|ABT-126|Dose administered twice daily on Study Days 1-10
423989|NCT00959634|Drug|Placebo|Dose administered twice daily on Study Days 1-10
423990|NCT00959621|Drug|Aspirin|ASA 100 mg once daily per os
423991|NCT00959621|Drug|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
423992|NCT00959621|Drug|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
423993|NCT00959608|Behavioral|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
423994|NCT00959608|Behavioral|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
424026|NCT00959296|Device|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
423995|NCT00959595|Drug|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
423996|NCT00959595|Drug|EMLA cream|50g applied according to description of intervention
423997|NCT00959582|Procedure|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
423998|NCT00959569|Drug|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
423999|NCT00959569|Drug|Placebo|normosaline (same ml of the study drug)
424000|NCT00959556|Other|laboratory biomarker analysis|
424001|NCT00959543|Other|MRI|MRI and clinical investigation
424002|NCT00959530|Procedure|lingualized occlusion|occlusal surface arranged by lingualized occlusion
424003|NCT00959530|Procedure|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
424004|NCT00959517|Drug|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
424005|NCT00959517|Drug|sulphadoxine-pyrimethamine (SP)|
424006|NCT00959517|Drug|Chloroquine (CQ)|
424007|NCT00959517|Drug|primaquine (PQ)|
424008|NCT00959478|Behavioral|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
424009|NCT00959465|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
424010|NCT00959452|Behavioral|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
424011|NCT00959439|Drug|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
424012|NCT00959439|Drug|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
424013|NCT00959426|Drug|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
424014|NCT00959426|Drug|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
424015|NCT00959400|Drug|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
424016|NCT00959387|Drug|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
424017|NCT00959387|Radiation|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
424018|NCT00959374|Device|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
424019|NCT00959374|Device|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
424020|NCT00959361|Behavioral|pharmaceutical care|consultation with the pharmacists and usual care
424021|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
424022|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
424023|NCT00959322|Device|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
424024|NCT00959309|Behavioral|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
424025|NCT00959309|Behavioral|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
424029|NCT00959244|Other|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
424030|NCT00959244|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
424031|NCT00959244|Other|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
424032|NCT00959244|Other|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
424033|NCT00959231|Drug|cyclophosphamide|
424034|NCT00959231|Drug|cyclosporine|
424035|NCT00959231|Drug|fludarabine phosphate|
424036|NCT00959231|Drug|mycophenolate mofetil|
424037|NCT00959231|Other|laboratory biomarker analysis|
424038|NCT00959231|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
424039|NCT00959231|Procedure|umbilical cord blood transplantation|
424040|NCT00959231|Radiation|total-body irradiation|
424041|NCT00959218|Drug|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
424042|NCT00959218|Drug|Placebo|oral solution
424043|NCT00959205|Device|CARTO 3D|CARTO (3D Electroanatomic imaging)
424044|NCT00959205|Device|Angiography|Conventional fluoroscopically guided activation mapping
424045|NCT00959192|Biological|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
424046|NCT00959192|Other|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
424047|NCT00959192|Other|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
424048|NCT00959166|Other|PET scan|PET brain scan
424049|NCT00959153|Device|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
424050|NCT00959140|Device|CD3+ T cell depletion|"The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.~Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis."
424051|NCT00959127|Drug|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
424052|NCT00959114|Biological|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
424053|NCT00959114|Biological|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
424054|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
424055|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
424056|NCT00959101|Drug|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
424057|NCT00959101|Drug|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
424058|NCT00959075|Dietary Supplement|Vitamin B1|100 mg Twice a day
424059|NCT00959075|Dietary Supplement|Placebo|Sugar pill
424060|NCT00959062|Drug|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
424061|NCT00959062|Drug|placebo|Preparation visually identical to clonidine.
424062|NCT00959049|Biological|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
424063|NCT00959049|Biological|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
424064|NCT00959036|Drug|ATN-103|10 mg every 4 weeks until week 12
424065|NCT00959036|Drug|ATN-103|10 mg every 8 weeks until week 12
424066|NCT00959036|Drug|ATN-103|30 mg every 4 weeks until week 12
424067|NCT00959036|Drug|ATN-103|80 mg every 4 weeks until week 12
424068|NCT00959036|Drug|ATN-103|80 mg every 8 weeks until week 12
424069|NCT00959036|Drug|Placebo|Placebo every 4 weeks
424070|NCT00959036|Drug|Methotrexate|
424071|NCT00959023|Other|laboratory biomarker analysis|
424072|NCT00959023|Other|medical chart review|
424073|NCT00959023|Other|questionnaire administration|
424074|NCT00959010|Dietary Supplement|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
424075|NCT00959010|Dietary Supplement|Placebo|capsules containing middle chain triglycerides
424076|NCT00958997|Drug|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
424077|NCT00958997|Biological|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
424078|NCT00958971|Drug|TKI258|
424079|NCT00958958|Other|multifaceted strategy|"There are multifaceted Interventions Including~Distribution of educational materials: distribution of published or printed recommendations for clinical care.~Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used~Reminders~Practical training"
424080|NCT00958932|Behavioral|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
424081|NCT00958932|Behavioral|Speech recognition|Automated, speech recognition telephone calls
424082|NCT00958919|Drug|naloxone|10 mg naloxone in 25 ml total volume
424083|NCT00958919|Drug|normal saline|25 ml
424084|NCT00958906|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
424085|NCT00958893|Drug|25 mg Proellex|one 25 mg capsules
424086|NCT00958880|Behavioral|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations~One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
424087|NCT00958880|Drug|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
424088|NCT00958880|Drug|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
424089|NCT00958867|Behavioral|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
424090|NCT00958867|Behavioral|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
424091|NCT00958867|Behavioral|Exercise training (S & R; control)|Six-month, twice-weekly stretch & relax (S & R; control) program
424092|NCT00958854|Drug|cyclophosphamide|
424093|NCT00958854|Drug|fludarabine phosphate|
424094|NCT00958854|Drug|thalidomide|
424095|NCT00958854|Other|laboratory biomarker analysis|
424096|NCT00958841|Drug|pasireotide LAR|Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
424097|NCT00958828|Device|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
424098|NCT00958828|Device|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
424099|NCT00958802|Other|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
424100|NCT00958802|Other|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
424101|NCT00958789|Device|Triathlon TS Knee System|Total knee replacement for revision cases
424102|NCT00958776|Drug|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.~Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
424103|NCT00958776|Drug|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
424104|NCT00958763|Behavioral|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
424105|NCT00958763|Behavioral|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
424106|NCT00958763|Other|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
424107|NCT00958750|Drug|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
424108|NCT00958737|Drug|FOLFOX regimen|Given IV
424109|NCT00958737|Drug|fluorouracil|Given IV
424110|NCT00958737|Drug|leucovorin calcium|Given IV
424111|NCT00958737|Drug|oxaliplatin|Given IV
424112|NCT00958737|Drug|XELOX regimen|
424113|NCT00958737|Drug|Capecitabine|oral
424114|NCT00958724|Drug|Neratinib|
424115|NCT00958724|Drug|Vinorelbine|
424116|NCT00958711|Device|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
424117|NCT00958711|Other|Saline and Gauze|gauze moistened with sterile saline
424118|NCT00958698|Other|Communication Intervention|Ancillary studies
424119|NCT00958698|Other|Educational Intervention|Ancillary studies
424120|NCT00958698|Other|Internet-Based Intervention|Ancillary studies
424121|NCT00958698|Procedure|Psychosocial Assessment and Care|Ancillary studies
424122|NCT00958698|Other|Quality-of-Life Assessment|Ancillary studies
424123|NCT00958698|Other|Questionnaire Administration|Ancillary studies
424124|NCT00958685|Dietary Supplement|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
424125|NCT00958685|Dietary Supplement|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
424128|NCT00958646|Other|Osteopathic Manipulation|Standardized rib raising protocol
424129|NCT00958646|Other|Placebo|Light touch control procedure
424130|NCT00958633|Drug|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.~In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points."
424131|NCT00958633|Drug|Wellbutrin XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.~In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.~The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points."
424132|NCT00958620|Procedure|Shock Wave Therapy|Extracorporal shock-wave therapy
424133|NCT00958607|Behavioral|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care & by telephone during inpatient rehabilitation and community discharge. SSP provides support, information & guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
424134|NCT00958607|Behavioral|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
424135|NCT00958581|Drug|Tranexamic Acid|For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
424136|NCT00958581|Drug|Normal Saline|Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.
424137|NCT00958581|Drug|Epsilon aminocaproic acid|For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
424138|NCT00958568|Drug|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.~Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.~Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
424139|NCT00958568|Drug|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
424140|NCT00958542|Procedure|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
424141|NCT00958529|Dietary Supplement|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
424142|NCT00958516|Drug|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
424143|NCT00958503|Drug|Thiamphenicol|750 and 1500 mg/day;tablets
424144|NCT00958503|Drug|Placebo|Matched tablets without active ingredient
424145|NCT00958490|Other|Walking program|4 week physical activity walking program
424146|NCT00958477|Biological|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
424147|NCT00958464|Procedure|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- [Gd-DTPA2-] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
424148|NCT00958451|Drug|Paricalcitol|"Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;~Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
424149|NCT00958451|Drug|Ergocalciferol|"If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.~If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.~If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
424150|NCT00958438|Drug|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
424151|NCT00958438|Drug|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
424152|NCT00958438|Drug|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
424153|NCT00958425|Device|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
424154|NCT00958425|Device|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
424155|NCT00958412|Drug|Proellex®|one (1) 25 mg capsule daily
424156|NCT00958399|Dietary Supplement|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
424157|NCT00958399|Dietary Supplement|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
424158|NCT00958399|Dietary Supplement|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
424159|NCT00958399|Dietary Supplement|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
424160|NCT00958399|Dietary Supplement|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
424161|NCT00958386|Drug|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.~Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.~Each treatment cycle will have a duration of 14 days."
424162|NCT00958360|Other|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
424163|NCT00958360|Other|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
424164|NCT00958347|Device|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
424165|NCT00958334|Drug|Proellex®|25 mg daily (two 12.5 mg capsules)
424166|NCT00958321|Procedure|computed tomography|
424167|NCT00958321|Radiation|3-dimensional conformal radiation therapy|
424168|NCT00958321|Radiation|fludeoxyglucose F 18|
424169|NCT00958321|Radiation|radiation therapy treatment planning/simulation|
424170|NCT00958308|Other|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
424171|NCT00958308|Other|Placebo|Placebo is devoid of microorganisms.
424172|NCT00958282|Drug|lisdexamfetamine/Behavior Therapy|
424173|NCT00958282|Other|placebo|
424174|NCT00958269|Drug|dutogliptin|100 mg QD
424175|NCT00958269|Drug|dutogliptin|200 mg QD
424176|NCT00958269|Drug|placebo|
424177|NCT00958269|Drug|sitagliptin|25 mg QD
424178|NCT00958269|Drug|sitagliptin|50 mg QD
424179|NCT00958256|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
424180|NCT00958256|Drug|Rituximab|375 mg/m^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
424181|NCT00958256|Drug|Cyclophosphamide|300 mg/m^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
424182|NCT00958256|Drug|Mesna|600 mg/m^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
424183|NCT00958256|Drug|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
424184|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
424185|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
424186|NCT00958243|Biological|Placebo|Placebo
424187|NCT00958230|Device|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
424188|NCT00958217|Behavioral|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
424189|NCT00958217|Behavioral|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
424190|NCT00958204|Procedure|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
424191|NCT00958204|Procedure|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
424192|NCT00958204|Drug|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
424193|NCT00958204|Drug|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
424194|NCT00958191|Device|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
424195|NCT00958178|Drug|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
424196|NCT00958165|Device|CardioFocus EAS-AC|PVI for PAF
424197|NCT00958152|Drug|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
424198|NCT00958152|Drug|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
424199|NCT00958152|Drug|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
424200|NCT00958152|Drug|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
424201|NCT00958139|Other|Permethrin|Permethrin 0.5% treatment of clothing one time
424202|NCT00958139|Other|Placebo|water sprayed on clothing one time
424203|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
424204|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
424205|NCT00958126|Biological|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
424206|NCT00958100|Drug|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
424207|NCT00958100|Drug|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
424292|NCT00957359|Drug|Niacin|Psilocybin and niacin will be administered in identically appearing opaque, size 0 gelatin capsules with approximately 180ml of water. The niacin dose will be 250mg
424208|NCT00958100|Drug|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
424209|NCT00958074|Drug|vorinostat|Given PO
424210|NCT00958074|Other|flow cytometry|correlative study
424211|NCT00958074|Other|laboratory biomarker analysis|correlative study
424212|NCT00958048|Device|non-invasive ventilation|CPAP, BiPAP
424213|NCT00958035|Drug|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
424214|NCT00958035|Drug|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
424215|NCT00958022|Drug|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.~Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin & mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
424216|NCT00958009|Device|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
424217|NCT00957996|Drug|Peramivir|300 mg twice daily
424218|NCT00957996|Drug|Peramivir|600 mg once daily
424219|NCT00957983|Drug|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
424220|NCT00957970|Device|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
424221|NCT00957970|Device|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
424222|NCT00957944|Drug|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
424223|NCT00957931|Procedure|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
424224|NCT00957931|Biological|Mesenchymal Stromal Cells|
424225|NCT00957918|Drug|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
424226|NCT00957918|Other|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
424227|NCT00957905|Drug|Alvocidib Hydrochloride|Given IV
424228|NCT00957905|Drug|Fluorouracil|Given IV
424229|NCT00957905|Drug|Leucovorin Calcium|Given IV
424230|NCT00957905|Drug|Oxaliplatin|Given IV
424231|NCT00957879|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
424232|NCT00957879|Dietary Supplement|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
424233|NCT00957866|Drug|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
424234|NCT00957853|Drug|Cetuximab|First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
424235|NCT00957853|Drug|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
424236|NCT00957853|Procedure|Surgical tumor resection|Surgical tumor resection on Day 10.
424237|NCT00957840|Procedure|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
424238|NCT00957827|Drug|keflex|keflex 500 mg BID 5 days
424239|NCT00957827|Drug|placebo|placebo BID for five days
424240|NCT00957814|Behavioral|Nutritional education|Systematic nutritional orientation program
424241|NCT00957801|Drug|Testosterone injection|100 mg single IM injection
424242|NCT00957801|Drug|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
424243|NCT00957801|Drug|Medrol|Medrol 6 day dose pack with an additional 4mg dose on day 7
424244|NCT00957788|Drug|NST-001|Comparison of different dosages of drug.
424245|NCT00957775|Behavioral|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
424246|NCT00957775|Behavioral|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
424247|NCT00957762|Other|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
424248|NCT00957749|Drug|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
424249|NCT00957736|Genetic|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
424250|NCT00957736|Other|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
424251|NCT00957723|Device|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
424252|NCT00957710|Behavioral|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
424253|NCT00957684|Drug|eslicarbazepine acetate|once-daily oral tablet
424254|NCT00957684|Drug|placebo|once daily placebo comparator
424255|NCT00957671|Drug|Recombinant human growth hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
424256|NCT00957658|Device|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
424257|NCT00957619|Drug|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
424258|NCT00957619|Drug|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
424259|NCT00957606|Procedure|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
424260|NCT00957593|Drug|Oxytocin|Continuation of oxytocin once in active labor
424261|NCT00957593|Drug|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
424262|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
424263|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
424264|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
424265|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
424266|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
424267|NCT00957554|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
424268|NCT00957554|Drug|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
424269|NCT00957541|Device|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
424270|NCT00957528|Drug|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
424271|NCT00957528|Drug|Placebo|Weekly IM injections of sesame oil.
424272|NCT00957502|Device|ENTact™ Septal Stapler|1 year aged septal staples
424273|NCT00957502|Device|ENTact™ Septal Stapler|18 Month Aged Staples
424274|NCT00957489|Other|Dynamax appliance|
424275|NCT00957489|Other|Twin-block appliance|
424276|NCT00957476|Dietary Supplement|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
424277|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 1
424278|NCT00957437|Drug|AZD1305|ER formulation 1, bid for 5 days
424279|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 2
424280|NCT00957424|Behavioral|telephone-based intervention|10-15 minute web-based survey on a computer
424281|NCT00957424|Drug|nicotine replacement therapy|One week supply
424282|NCT00957424|Other|informational intervention|
424283|NCT00957424|Other|internet-based intervention|
424284|NCT00957424|Other|questionnaire administration|Given out week 2, 3 and 4.
424285|NCT00957411|Biological|cetuximab|Given IV
424286|NCT00957411|Drug|cisplatin|Given IV
424287|NCT00957385|Drug|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
424288|NCT00957372|Drug|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
424289|NCT00957372|Drug|placebo (Part I)|once daily placebo comparator
424290|NCT00957372|Drug|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
424291|NCT00957359|Drug|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
424458|NCT00956072|Procedure|therapeutic conventional surgery|Patients undergo surgery
424293|NCT00957346|Drug|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
424294|NCT00957346|Drug|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
424295|NCT00957333|Other|ketamine|N.A.
424296|NCT00957320|Drug|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
424297|NCT00957320|Drug|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
424298|NCT00957268|Drug|Alogliptin|Alogliptin tablets
424299|NCT00957255|Device|OrthoADAPT|soft tissue augmentation device
424300|NCT00957255|Procedure|Standard of care|Standard of care rotator cuff repair
424301|NCT00957242|Drug|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
424302|NCT00957242|Drug|placebo|Oral placebo (1mg or 2.5mg)
424303|NCT00957229|Drug|GDC-0449|capsule, 150 mg, one pill daily, 18 months
424304|NCT00957216|Drug|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
424305|NCT00957216|Drug|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
424306|NCT00957203|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
424307|NCT00957190|Drug|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
424308|NCT00957177|Drug|Pregabalin|300mg pregabalin orally 1 hour before operation
424309|NCT00957177|Drug|Placebo|Placebo
424310|NCT00957164|Behavioral|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
424311|NCT00957164|Behavioral|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
424312|NCT00957164|Behavioral|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
424313|NCT00957151|Drug|Creon|
424314|NCT00957125|Drug|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
424315|NCT00957125|Drug|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
424316|NCT00957125|Drug|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
424317|NCT00957112|Procedure|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
424318|NCT00957112|Procedure|standard follow-up care|Patients receive standard care
424319|NCT00957086|Drug|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
424320|NCT00957086|Drug|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
424321|NCT00957073|Device|Rheos® system|Implant procedure
424322|NCT00957060|Drug|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
424323|NCT00957060|Drug|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
424324|NCT00957047|Drug|eslicarbazepine acetate|oral tablets
424325|NCT00957047|Drug|placebo|once daily placebo comparator
424326|NCT00957047|Drug|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
424327|NCT00957034|Drug|placebo|placebo patch
424328|NCT00957034|Drug|testosterone|300 or 450 micrograms/day transdermal testosterone patch
424329|NCT00957021|Device|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
424330|NCT00957008|Behavioral|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
424331|NCT00957008|Other|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
424377|NCT00956631|Procedure|Interlaminar Decompression|The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
424413|NCT00956332|Biological|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
424332|NCT00957008|Device|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
424333|NCT00956982|Drug|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing < 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
424334|NCT00956969|Behavioral|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
424335|NCT00956969|Behavioral|Relaxation Training|Teaches patients relaxation training
424336|NCT00956956|Drug|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
424337|NCT00956956|Drug|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
424338|NCT00956943|Drug|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
424339|NCT00956943|Drug|placebo|placebo patch
424340|NCT00956930|Radiation|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
424341|NCT00956930|Drug|Doxorubicin|75mg fixed dose
424342|NCT00956917|Device|Akern USA EFG|Impedance measurement device
424343|NCT00956917|Device|RJL Impedance analyzer|Impedance analyzer
424344|NCT00956904|Device|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
424345|NCT00956865|Other|Voucher|Vouchers given to reimburse transportation
424346|NCT00956865|Other|Telephone Call|Telephone reminder calls
424347|NCT00956865|Other|Contact|Contact at senior center to encourage follow up
424348|NCT00956839|Drug|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose~Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose~Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
424349|NCT00956826|Device|Agit Vacuum|With an electrode and a regular vacuum device
424350|NCT00956813|Dietary Supplement|flaxseed|Given orally
424351|NCT00956813|Other|placebo|Given orally
424352|NCT00956800|Other|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
424353|NCT00956800|Other|Normal care|Control group will receive 5 routine office visits in one year
424354|NCT00956787|Drug|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
424355|NCT00956774|Procedure|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
424356|NCT00956774|Procedure|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
424357|NCT00956774|Procedure|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
424358|NCT00956761|Biological|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
424359|NCT00956748|Drug|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
424360|NCT00956748|Drug|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
424361|NCT00956735|Other|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
424362|NCT00956722|Drug|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
424363|NCT00956709|Drug|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
424364|NCT00956709|Drug|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
424365|NCT00956696|Drug|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
424366|NCT00956683|Procedure|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
424367|NCT00956683|Procedure|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
424368|NCT00956670|Other|Quality-of-Life Assessment|Ancillary studies
424369|NCT00956670|Other|Questionnaire Administration|Ancillary studies
424370|NCT00956670|Procedure|Study of High Risk Factors|Undergo lymphedema assessment
424371|NCT00956670|Procedure|Therapeutic Conventional Surgery|Undergo surgery
424372|NCT00956670|Procedure|Therapeutic Laparoscopic Surgery|Undergo surgery
424373|NCT00956670|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
424374|NCT00956657|Behavioral|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
424375|NCT00956644|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
424376|NCT00956644|Drug|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
424378|NCT00956605|Behavioral|Computer attention training systems for children with ADHD|Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
424379|NCT00956592|Device|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
424380|NCT00956592|Device|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
424381|NCT00956566|Behavioral|dietary intervention|dietary counseling, group teaching
424382|NCT00956553|Biological|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
424383|NCT00956553|Biological|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
424384|NCT00956540|Procedure|Deflating tracheal cuff|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
424385|NCT00956540|Procedure|Deflating tracheal cuff 2|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
424386|NCT00956527|Behavioral|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
424387|NCT00956514|Device|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
424388|NCT00956488|Behavioral|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
424389|NCT00956475|Behavioral|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
424390|NCT00956475|Other|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
424391|NCT00956475|Procedure|assessment of therapy complications|questionnaire via telephone
424392|NCT00956475|Procedure|fatigue assessment and management|questionnaire via telephone
424393|NCT00956475|Procedure|psychosocial assessment and care|questionnaire via telephone
424394|NCT00956475|Procedure|quality-of-life assessment|questionnaire via telephone
424395|NCT00956462|Drug|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
424396|NCT00956449|Biological|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
424397|NCT00956436|Drug|BIIB022|IV Q3W
424398|NCT00956436|Drug|Sorafenib|Standard dosing of Sorafenib
424399|NCT00956423|Behavioral|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
424400|NCT00956423|Behavioral|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
424401|NCT00956410|Biological|CAD106|
424402|NCT00956397|Drug|Rifaximin|rifaximin 550 mg TID PO x 10 days
424403|NCT00956397|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
424404|NCT00956397|Drug|Placebo|placebo TID x 10 days
424405|NCT00956384|Procedure|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
424406|NCT00956384|Procedure|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
424407|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
424408|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
424409|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
424410|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
424411|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
424412|NCT00956332|Biological|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
424417|NCT00956293|Drug|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
424418|NCT00956293|Drug|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
424419|NCT00956293|Drug|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
424420|NCT00956293|Drug|Cyclosporin A (CsA)|Dosage was based according to blood level
424421|NCT00956293|Drug|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
424422|NCT00956267|Drug|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
424423|NCT00956267|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
424424|NCT00956254|Drug|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
424425|NCT00956241|Procedure|j-pouch coloanal anastomosis|
424426|NCT00956241|Procedure|side-to-end coloanal anastomosis|
424427|NCT00956228|Radiation|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
424428|NCT00956215|Drug|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
424429|NCT00956215|Drug|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
424430|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
424431|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
424432|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
424433|NCT00956189|Drug|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
424434|NCT00956189|Drug|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
424435|NCT00956176|Drug|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
424436|NCT00956163|Procedure|magnetic resonance imaging|Undergo whole-body MRI
424437|NCT00956163|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
424438|NCT00956163|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
424439|NCT00956163|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
424440|NCT00956163|Radiation|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
424441|NCT00956163|Other|laboratory biomarker analysis|Correlative studies
424442|NCT00956150|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
424443|NCT00956150|Drug|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
424444|NCT00956150|Drug|Placebo|Placebo TID PO x 10 days
424445|NCT00956137|Procedure|Ultrasound guidance|ultrasound imaging
424446|NCT00956137|Procedure|Manual palpation|Manual Palpation of vertebra
424447|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
424448|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
424449|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
424450|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
424451|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
424452|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
424453|NCT00956111|Biological|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
424454|NCT00956098|Drug|oltipraz|60mg bid 90mg qd
424455|NCT00956098|Drug|placebo|
424456|NCT00956085|Drug|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
424457|NCT00956072|Drug|imatinib mesylate|Patients receive imatinib mesylate
424459|NCT00956059|Drug|prednisone, FK506, MMF|1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
424460|NCT00956059|Drug|prednisone|In the initial 16~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
424461|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
424462|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
424463|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
424464|NCT00956020|Biological|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
424465|NCT00956007|Biological|cetuximab|Given IV
424466|NCT00956007|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy.
424467|NCT00955994|Drug|asimadoline|
424468|NCT00955981|Drug|RDEA594|Uricosuric agent for the treatment of gout
424469|NCT00955981|Drug|Placebo|Matching placebo
424470|NCT00955968|Drug|Highly active antiretroviral therapy (HAART)|"A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant."
424471|NCT00955955|Other|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
424472|NCT00955955|Other|Placebo|Inactive substance
424473|NCT00955942|Dietary Supplement|flaxseed|Given orally
424474|NCT00955942|Other|placebo|Given orally
424475|NCT00955929|Drug|Placebo QHS and sildenafil and questionnaires|Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
424476|NCT00955929|Drug|Sildenafil and questionnaire|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
424477|NCT00955929|Drug|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires|Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
424478|NCT00955916|Drug|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
424479|NCT00955916|Drug|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
424480|NCT00955903|Behavioral|Exercise|Participants will participate in supervised exercise sessions
424481|NCT00955903|Behavioral|Reduced Calorie Diet|Participants will follow a reduced calorie diet
424482|NCT00955903|Behavioral|Weight Maintenance Diet|Participants will follow a weight maintenance diet
424483|NCT00955890|Drug|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
424484|NCT00955890|Drug|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
424485|NCT00955877|Drug|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
424486|NCT00955877|Drug|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
424487|NCT00955877|Drug|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
424488|NCT00955851|Other|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
424490|NCT00955825|Drug|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
424491|NCT00955825|Drug|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
424492|NCT00955812|Drug|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
424493|NCT00955799|Drug|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
424494|NCT00955799|Drug|Placebo|Double-blind treatment period of 29 weeks placebo
424495|NCT00955786|Drug|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
424496|NCT00955773|Drug|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
424497|NCT00955760|Drug|Neramexane|Drug-Drug Interaction Study
424498|NCT00955747|Drug|Tagatose|powder; 15 grams three times daily; one year
424499|NCT00955747|Drug|Sugar Substitute Splenda|1.5 g powder tid
424500|NCT00955734|Other|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
424501|NCT00955734|Other|Immobilization|This set of patients will be casted for 6 weeks after surgery.
424502|NCT00955721|Drug|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
424503|NCT00955721|Drug|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
424504|NCT00955721|Drug|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
424505|NCT00955708|Device|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
424506|NCT00955695|Drug|erlotinib hydrochloride|
424507|NCT00955695|Drug|gefitinib|
424508|NCT00955695|Other|questionnaire administration|
424509|NCT00955695|Procedure|quality-of-life assessment|
424510|NCT00955695|Radiation|whole-brain radiation therapy|
424511|NCT00955682|Biological|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
424512|NCT00955682|Biological|Meningitec™|One intramuscular dose (Booster)
424513|NCT00955669|Biological|Symptoms and Objective Examination|5.0*108~5.0*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
424514|NCT00955643|Other|oxygen|
424515|NCT00955643|Other|other|
424516|NCT00955630|Drug|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
424517|NCT00955630|Drug|ranibizumab|prn injections of ranibizumab throughout the study
424518|NCT00955617|Other|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
424519|NCT00955604|Drug|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
424520|NCT00955604|Drug|Group R Rasagiline|At least 2 months of rasagiline
424521|NCT00955604|Drug|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
424522|NCT00955591|Other|Papanicolaou test|
424523|NCT00955578|Procedure|Punch Biopsy|5-6 punch biopsies of affected areas
424524|NCT00955565|Procedure|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
424525|NCT00955565|Procedure|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
424526|NCT00955552|Drug|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
424527|NCT00955552|Drug|Condroflex (Zodiac)|oral capsule of glucosamine sulphate 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
424528|NCT00955539|Device|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
424529|NCT00955539|Device|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
424530|NCT00955526|Drug|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
424531|NCT00955526|Drug|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
424532|NCT00955526|Drug|Placebo|Two placebo tablets once daily for 12 weeks
424533|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
424534|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
424535|NCT00955513|Drug|Placebo|Placebo
424536|NCT00955500|Dietary Supplement|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
424537|NCT00955500|Dietary Supplement|Maltodextrin|30 grams of oral maltodextrin daily
424538|NCT00955487|Drug|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
424539|NCT00955487|Drug|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
424540|NCT00955474|Drug|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
424631|NCT00954785|Drug|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
424541|NCT00955474|Drug|escitalopram|"Active comparator arm:~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
424542|NCT00955474|Drug|Sertraline|"Active comparator arm:~Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.~Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
424543|NCT00955474|Drug|Citalopram|"Active comparator arm:~Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
424544|NCT00955461|Procedure|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
424545|NCT00955461|Procedure|Fractionated Laser treatment|
424546|NCT00955448|Device|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
424547|NCT00955448|Procedure|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
424548|NCT00955435|Drug|bicalutamide|
424549|NCT00955435|Drug|releasing hormone agonist therapy|
424550|NCT00955435|Genetic|protein expression analysis|
424551|NCT00955435|Genetic|proteomic profiling|
424552|NCT00955435|Other|laboratory biomarker analysis|
424553|NCT00955435|Radiation|radiation therapy|
424554|NCT00955409|Drug|ACC-001+ QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
424555|NCT00955409|Drug|ACC-001|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
424556|NCT00955409|Drug|ACC-001 + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
424557|NCT00955396|Drug|GSK1014802|Tablets
424558|NCT00955396|Drug|Placebo|Tablets
424559|NCT00955383|Drug|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
424560|NCT00955383|Drug|Placebo|Matching placebo
424561|NCT00955357|Drug|Lacosamide|"Oral Lacosamide:~Subjects Titration Phase (6 Weeks):~Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid~Maintenance Phase (24 Weeks):~200 mg tablet bid OR 150 mg tablet bid~Taper Phase (1 - 3 Weeks):~50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
424562|NCT00955344|Behavioral|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
424563|NCT00955344|Behavioral|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
424564|NCT00955318|Drug|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
424565|NCT00955305|Biological|Bevacizumab|Given IV
424566|NCT00955305|Drug|Carboplatin|Given IV
424567|NCT00955305|Biological|Cixutumumab|Given IV
424568|NCT00955305|Drug|Paclitaxel|Given IV
424569|NCT00955292|Drug|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
424570|NCT00955279|Drug|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
424571|NCT00955279|Drug|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
424572|NCT00955279|Drug|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
424573|NCT00955266|Drug|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
424574|NCT00955266|Drug|Placebo|Normal saline, 50cc delivered over 5 minutes
424575|NCT00955253|Drug|Guanfacine|2mg oral guanfacine (encapsulated)
424576|NCT00955253|Drug|Placebo|placebo
424577|NCT00955240|Biological|cetuximab|
424578|NCT00955240|Drug|cisplatin|
424579|NCT00955240|Drug|fluorouracil|
424580|NCT00955240|Other|laboratory biomarker analysis|
424581|NCT00955240|Radiation|radiation therapy|
424582|NCT00955227|Dietary Supplement|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
424583|NCT00955227|Drug|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
424584|NCT00955214|Device|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
424585|NCT00955201|Behavioral|Exercise|Structured aerobic exercise (treadmill).
424586|NCT00955201|Behavioral|Exercise|Structured isokinetic strength exercise (dynameter).
424587|NCT00955188|Other|computer-assisted intervention|
424588|NCT00955188|Other|educational intervention|
424589|NCT00955188|Other|medical chart review|
424590|NCT00955175|Radiation|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
424591|NCT00955162|Drug|Buprenorphine (Subutex)|Sublingual tablet
424592|NCT00955162|Drug|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
424593|NCT00955149|Drug|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
424628|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
424629|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
424784|NCT00953576|Drug|hydrocortisone|
424594|NCT00955136|Device|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
424595|NCT00955110|Drug|Oxymorphone ER|15mg or 30mg
424596|NCT00955110|Drug|Oxycodone CR|30mg or 60mg
424597|NCT00955110|Drug|Placebo|The placebo was a sugar pill.
424598|NCT00955110|Drug|Hydromorphone|8 mg
424599|NCT00955097|Drug|Definity®|Definity® injections given both pre-ablation and post-ablation
424600|NCT00955084|Drug|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
424601|NCT00955071|Other|Exercise: LVLI|low volume, low intensity
424602|NCT00955071|Other|Exercise: HVLI|high volume, low intensity
424603|NCT00955071|Other|Exercise: LVHI|low volume, high intensity
424604|NCT00955058|Drug|OCP|Daily For 3 months
424605|NCT00955045|Drug|istradefylline|
424606|NCT00955032|Device|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
424607|NCT00955032|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
424608|NCT00955006|Biological|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
424609|NCT00955006|Biological|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
424610|NCT00954993|Drug|Vaniprevir|Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
424611|NCT00954967|Behavioral|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
424612|NCT00954954|Device|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
424613|NCT00954954|Device|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
424614|NCT00954941|Drug|Ondansetron|8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
424615|NCT00954941|Drug|Aprepitant|125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
424616|NCT00954915|Biological|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
424617|NCT00954902|Dietary Supplement|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
424618|NCT00954902|Behavioral|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
424619|NCT00954902|Other|Placebo antioxidant concentrate|Placebo capsules
424620|NCT00954889|Drug|tamsulosin|Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
424621|NCT00954889|Drug|placebo|(tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
424622|NCT00954876|Drug|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks~Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
424623|NCT00954837|Procedure|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
424624|NCT00954824|Biological|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
424625|NCT00954811|Drug|300IU rec-LH|luteal alternate doses
424626|NCT00954811|Drug|progesterone 600mg|luteal support
424627|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
424630|NCT00954785|Device|Ankle brace|Sports Stirrup ankle brace (Aircast)
424785|NCT00953576|Drug|dutasteride|
424632|NCT00954785|Drug|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
424633|NCT00954759|Procedure|Chiropractic treatment|
424634|NCT00954759|Procedure|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
424635|NCT00954733|Other|Arterial blood draw|One arterial blood draw
424636|NCT00954720|Other|No Intervention|There is no intervention on this trial
424637|NCT00954707|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
424638|NCT00954707|Drug|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
424639|NCT00954694|Device|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
424640|NCT00954681|Drug|quetiapine|Quetiapine treatment from 25 mg daily to 300 mg twice daily
424641|NCT00954668|Procedure|immediate angiography and revascularization|immediate angiography < 2 hours after randomization
424642|NCT00954668|Procedure|early invasive angiography|early invasive angiography 12-72 h after randomization
424643|NCT00954655|Genetic|mutation analysis|
424644|NCT00954655|Genetic|polymorphism analysis|
424645|NCT00954655|Other|laboratory biomarker analysis|
424646|NCT00954642|Drug|bevacizumab|Intravenous repeating dose
424647|NCT00954642|Drug|MNRP1685A|Escalating intravenous dose
424648|NCT00954642|Drug|paclitaxel|Intravenous repeating dose
424649|NCT00954629|Drug|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
424650|NCT00954629|Drug|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
424651|NCT00954603|Drug|quetiapine|25-100 mg
424652|NCT00954603|Drug|haloperidol|0.5-2 mg
424653|NCT00954590|Drug|Dimebon (latrepirdine)|20 mg orally three times daily
424654|NCT00954590|Drug|Placebo|Placebo orally three times daily
424655|NCT00954577|Behavioral|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
424656|NCT00954564|Other|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
424657|NCT00954564|Other|medical chart review|Observational only
424658|NCT00954564|Other|questionnaire administration|Observational only
424659|NCT00954564|Procedure|assessment of therapy complications|Observational only
424660|NCT00954538|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
424661|NCT00954525|Drug|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
424662|NCT00954525|Dietary Supplement|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
424663|NCT00954512|Drug|Carboplatin|
424664|NCT00954512|Drug|Epirubicin|
424665|NCT00954512|Biological|Trastuzumab|
424666|NCT00954512|Drug|Everolimus|
424667|NCT00954512|Drug|Gemcitabine|
424668|NCT00954512|Biological|Robatumumab|In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
424669|NCT00954512|Biological|Cetuximab|
424670|NCT00954512|Drug|Paclitaxel|
424671|NCT00954512|Drug|Cisplatin|
424672|NCT00954512|Drug|5-FU|
424673|NCT00954512|Drug|Erlotinib|
424674|NCT00954512|Drug|Irinotecan|
424675|NCT00954512|Drug|Folinic Acid|
424676|NCT00954499|Behavioral|Tactile stimulation added to Standard care|"Parent rubs the infant's skin near the injection site just before, during and after the injection.~Fast injection technique without aspiration.~Oral sucrose 2 minutes before first injection.~Parent holds infant close."
424677|NCT00954499|Behavioral|Standard care|"Fast injection technique without aspiration.~Oral sucrose 2 minutes before first injection.~Parent holds infant close."
424678|NCT00954486|Drug|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
424679|NCT00954473|Other|laboratory biomarker analysis|Correlative studies
424680|NCT00954460|Drug|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
424681|NCT00954447|Drug|Placebo|Placebo, identical to Linagliptin tablet
424682|NCT00954447|Drug|Linagliptin|intended final marketed dose
424683|NCT00954434|Dietary Supplement|red wine|intake of red wine on a daily basis
424786|NCT00953576|Drug|lapatinib|
424787|NCT00953563|Device|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
424684|NCT00954421|Device|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
424685|NCT00954395|Other|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
424686|NCT00954369|Drug|[F-18]W372|"The individual doses of [F-18]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
424687|NCT00954356|Drug|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
424688|NCT00954356|Drug|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
424689|NCT00954343|Procedure|Extracorporeal Shock Wave|
424690|NCT00954343|Procedure|Extracorporeal Shock Wave|
424691|NCT00954343|Procedure|Extracorporeal Shock Wave|
424692|NCT00954343|Procedure|Extracorporeal Shock Wave|
424693|NCT00954330|Procedure|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
424694|NCT00954330|Device|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
424695|NCT00954317|Procedure|epidural placed low|epidural placed low
424696|NCT00954317|Procedure|high epidural|high epidural
424697|NCT00954304|Drug|HM30181AK 1mg|HM30181AK 1mg tablet
424698|NCT00954304|Drug|HM30181AK 5mg|HM30181AK 5mg tablet
424699|NCT00954304|Drug|HM30181AK 15mg|HM30181AK 15mg tablet
424700|NCT00954304|Drug|HM30181AK 60mg|HM30181AK 60mg tablet
424701|NCT00954304|Drug|Loperamide 2mg|Loperamide 2mg capsule
424702|NCT00954278|Drug|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
424703|NCT00954265|Drug|10000 IU urinary HCG|ovulation triggering
424704|NCT00954265|Drug|250 mcg recombinant HCG|ovulation triggering
424705|NCT00954252|Drug|CHF 5074|1x, oral capsule, single dose
424706|NCT00954252|Drug|placebo|placebo, oral capsule, single dose
424707|NCT00954252|Drug|CHF 5074|2x, oral capsule, single dose
424708|NCT00954252|Drug|CHF 5074|4x, oral capsule, single dose
424709|NCT00954252|Drug|CHF 5074|8x, oral capsule, single dose
424710|NCT00954252|Drug|CHF 5074|16x, oral capsule, single dose
424711|NCT00954252|Drug|CHF 5074|24x, oral capsule, single dose
424712|NCT00954226|Drug|Erlotinib Hydrochloride|Given PO
424713|NCT00954226|Other|Laboratory Biomarker Analysis|Correlative studies
424714|NCT00954213|Behavioral|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
424715|NCT00954200|Drug|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
424716|NCT00954200|Drug|ibuprofen|10mg/kg syrup - single dose
424717|NCT00954187|Drug|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
424718|NCT00954187|Drug|pregabalin|50 mg PO TID
424719|NCT00954174|Drug|Carboplatin|Given IV
424720|NCT00954174|Drug|Ifosfamide|Given IV
424721|NCT00954174|Drug|Paclitaxel|Given IV
424722|NCT00954174|Other|Quality-of-Life Assessment|Ancillary studies
424723|NCT00954161|Other|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
424724|NCT00954161|Other|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
424725|NCT00954148|Procedure|PET/CT|5 visits with PET/CT as only testing
424726|NCT00954148|Procedure|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
424727|NCT00954135|Drug|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
424728|NCT00954135|Drug|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
424729|NCT00954122|Drug|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
424730|NCT00954109|Behavioral|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
424731|NCT00954096|Drug|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
424732|NCT00954083|Behavioral|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
424733|NCT00954083|Behavioral|Routine care|Routine care
424734|NCT00954070|Device|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
424735|NCT00954057|Drug|LIPO-102|intraorbital injection
424736|NCT00954057|Drug|Placebo|intraorbital injection
424737|NCT00954044|Behavioral|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.~Couples will participate in 2 exercise sessions a week for 6 months."
424738|NCT00954044|Behavioral|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
424788|NCT00953550|Drug|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
424739|NCT00954005|Drug|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
424740|NCT00953979|Drug|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
424741|NCT00953966|Other|Genetically modified potatoes|Starch from genetically modified potatoes
424742|NCT00953953|Device|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
424743|NCT00953940|Drug|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
424744|NCT00953927|Biological|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10^8 pfu.
424745|NCT00953927|Biological|Candida Skin Test Antigen|1 test, administered once as a placebo control.
424746|NCT00953914|Drug|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
424747|NCT00953914|Drug|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
424748|NCT00953901|Drug|Fresh Frozen Plasma Transfusion|
424749|NCT00953888|Drug|AZD5069|Single dose of oral solution.
424750|NCT00953888|Drug|Placebo|Single dose of oral solution.
424751|NCT00953862|Drug|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
424752|NCT00953849|Drug|Celecoxib|Celecoxib (400 mg twice daily)
424753|NCT00953849|Drug|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
424754|NCT00953849|Drug|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
424755|NCT00953810|Other|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
424756|NCT00953797|Device|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
424757|NCT00953784|Procedure|standard operating management|As previously described
424758|NCT00953771|Drug|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
424759|NCT00953758|Drug|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
424760|NCT00953745|Drug|Escitalopram|All subjects will begin on escitalopram and placebo for 8 weeks
424761|NCT00953745|Drug|Aripiprazole|Subjects who fail to respond to Escitalopram will continue on Escitalopram and augment with active Aripiprazole.
424762|NCT00953745|Drug|Placebo Capsule|All subjects will begin on escitalopram and placebo capsule for 8 weeks.
424763|NCT00953745|Drug|Placebo Tablet|After 8 weeks, subjects will be given a 2 week supply of escitalopram and placebo tablet.
424764|NCT00953732|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
424765|NCT00953719|Device|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
424766|NCT00953719|Device|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
424767|NCT00953706|Drug|Ivacaftor|Tablet
424768|NCT00953706|Drug|Placebo|Tablet
424769|NCT00953693|Procedure|Biopsy|Skin biopsy
424770|NCT00953680|Drug|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
424771|NCT00953680|Drug|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
424772|NCT00953680|Drug|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
424773|NCT00953667|Drug|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
424774|NCT00953654|Other|Strength Training|6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
424775|NCT00953654|Other|Endurance Training|Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
424776|NCT00953641|Drug|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
424777|NCT00953641|Drug|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
424778|NCT00953628|Drug|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
424779|NCT00953628|Drug|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
424780|NCT00953615|Drug|Thalidomide|Titrate to 400 mg daily for 6 months
424781|NCT00953602|Other|Genetically modified potato|Genetically modified potato
424782|NCT00953589|Drug|ribavirin|Ribavirin - oral administration Subjects with body weight < 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight > 105 kg: 1400 mg/day
424783|NCT00953576|Drug|ketoconazole|
424789|NCT00953550|Drug|Succinylcholine|1 mg/kg
424790|NCT00953537|Drug|capecitabine|
424791|NCT00953537|Other|laboratory biomarker analysis|
424792|NCT00953537|Other|pharmacological study|
424793|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
424794|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
424795|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
424796|NCT00953524|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
424797|NCT00953511|Genetic|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
424798|NCT00953498|Drug|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
424799|NCT00953498|Drug|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
424800|NCT00953485|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
424801|NCT00953472|Drug|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
424802|NCT00953472|Other|no-added salt diet|instruction to reduce salt for one week prior to study
424803|NCT00953459|Drug|sunitinib malate|
424804|NCT00953459|Other|laboratory biomarker analysis|
424805|NCT00953459|Radiation|fludeoxyglucose F 18|
424806|NCT00953446|Procedure|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
424807|NCT00953433|Device|Endoflex tube|Size decided upon gender.
424808|NCT00953433|Device|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
424809|NCT00953420|Drug|Docetaxel|60 mg/m2 IV on Day 1
424810|NCT00953420|Drug|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
424811|NCT00953420|Drug|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
424812|NCT00953420|Biological|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
424813|NCT00953420|Biological|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for > 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC > 2500 cells/ul x 2 days after nadir.
424814|NCT00953407|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
424815|NCT00953407|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
424816|NCT00953407|Device|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
424817|NCT00953407|Device|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
424818|NCT00953407|Device|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
424819|NCT00953394|Drug|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
424820|NCT00953381|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
424821|NCT00953381|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
424822|NCT00953381|Drug|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
424823|NCT00953381|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
424824|NCT00953368|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
424825|NCT00953355|Drug|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
424826|NCT00953355|Drug|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
424827|NCT00953342|Behavioral|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
424828|NCT00953342|Behavioral|Usual care|Standard medical care
424829|NCT00953329|Drug|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
424830|NCT00953316|Other|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
424831|NCT00953303|Drug|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
424832|NCT00953303|Drug|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
424833|NCT00953290|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
424834|NCT00953277|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
424835|NCT00953264|Behavioral|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
424836|NCT00953225|Drug|vitamin D3|4,000 IU daily for one year
424837|NCT00953225|Drug|Placebo daily for one year|Placebo
424838|NCT00953212|Drug|beta blockers|metoprolol 25mg by mouth every 6 hours
424839|NCT00953212|Drug|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
424840|NCT00953212|Drug|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
424841|NCT00953199|Drug|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
424842|NCT00953199|Drug|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
424843|NCT00953186|Device|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
424844|NCT00953186|Device|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
424845|NCT00953173|Device|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
424846|NCT00953160|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
424847|NCT00953147|Drug|Ciclesonide HFA 80 mcg|Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
424848|NCT00953147|Drug|Ciclesonide HFA 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
424849|NCT00953147|Drug|Placebo|Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
424850|NCT00953134|Dietary Supplement|Ferrous fumarate (iron)|60 mg of ferrous fumarate
424851|NCT00953134|Dietary Supplement|folic acid|400 mcg folic acid
424852|NCT00953121|Drug|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
424853|NCT00953108|Drug|quetiapine|300 mg per day
424854|NCT00953108|Drug|escitalopram|escitalopram 10 mg per day
424855|NCT00953095|Behavioral|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
424856|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
424857|NCT00953056|Biological|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
424858|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.~The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
424859|NCT00953056|Biological|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
424860|NCT00953043|Drug|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
424861|NCT00953043|Drug|Placebo|Placebo medication given for three days
424862|NCT00953043|Other|Bowel preparation|Polyethylene glycol-based bowel preparation
424863|NCT00953030|Behavioral|COACH|
424864|NCT00953030|Behavioral|RealAge|
424865|NCT00953017|Drug|Miralax (PEG 3350)|Miralax 255gm bottle
424866|NCT00953017|Drug|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
424867|NCT00953017|Drug|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
424868|NCT00953017|Drug|Golytely (polyethylene glycol)|Golytely 1 gallon
424869|NCT00953004|Dietary Supplement|fiber drink and fiber bread|fiber drink or fiber bread three times daily
424870|NCT00952991|Drug|LAF237 = vildagliptin|
424871|NCT00952978|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
424872|NCT00952978|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
424873|NCT00952952|Drug|Mesalamine|
424874|NCT00952939|Genetic|fluorescence in situ hybridization|At time of surgery
424875|NCT00952939|Other|laboratory biomarker analysis|At time of surgery
424876|NCT00952939|Procedure|fine-needle aspiration|At time of surgery
424877|NCT00952939|Procedure|therapeutic conventional surgery|At time of surgery
424878|NCT00952939|Other|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
424879|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
424880|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
424881|NCT00952913|Drug|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
424882|NCT00952900|Behavioral|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
424883|NCT00952900|Behavioral|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
424884|NCT00952887|Biological|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
424885|NCT00952887|Biological|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
424886|NCT00952861|Drug|Doxycycline|200 mg QD in 5 days
424887|NCT00952861|Drug|Placebo (matching)|Placebo QD i 5 days
424888|NCT00952848|Other|questionnaire administration|Pain Rating Score
424889|NCT00952848|Other|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
424890|NCT00952848|Other|Quality of Life instrument|Uniscale 0-100 scale global quality of life
424891|NCT00952848|Device|MC5-A Scrambler device|Electrical stimulation for 60 minutes
424892|NCT00952835|Other|regular treatment|regular treatment
424893|NCT00952822|Biological|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
424894|NCT00952796|Drug|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
424895|NCT00952796|Drug|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
424896|NCT00952783|Drug|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
424897|NCT00952770|Procedure|transradial coronary intervention|percutaneous coronary intervention with transradial approach
424898|NCT00952731|Drug|oral placebo|Oral placebo taken daily for 4-10 weeks.
424899|NCT00952731|Drug|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
424900|NCT00952731|Drug|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
424901|NCT00952731|Drug|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
424902|NCT00952718|Other|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
424903|NCT00952705|Biological|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
424904|NCT00952705|Biological|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
424905|NCT00952705|Biological|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
424906|NCT00952692|Biological|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.~For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:~One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.~One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
424907|NCT00952692|Drug|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
424908|NCT00952679|Device|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
424909|NCT00952666|Device|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
424910|NCT00952653|Drug|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
424911|NCT00952653|Drug|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
424912|NCT00952640|Dietary Supplement|vitamin A|high dose vitamin A, 200.000 IU
424913|NCT00952627|Dietary Supplement|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
424914|NCT00952627|Dietary Supplement|Placebo|
424915|NCT00952614|Device|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
424916|NCT00952601|Dietary Supplement|Modified Atkins diet|Low carbohydrate diet
424917|NCT00952588|Drug|AZD1152|1200 mg, iv, 7 day infusion
424918|NCT00952588|Drug|LDAC|20 mg, sc, bd, 10 days
424919|NCT00952575|Drug|polyclonal anti-D immunoglobulin|single injection of 300 µg
424920|NCT00952575|Drug|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
424921|NCT00952562|Dietary Supplement|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
424922|NCT00952562|Dietary Supplement|placebo|Empty capsules, 3 capsules per day for 16 weeks
424923|NCT00952549|Procedure|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
424924|NCT00952536|Dietary Supplement|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule
424925|NCT00952536|Dietary Supplement|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable & fruit & placebo capsule
424926|NCT00952536|Dietary Supplement|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
424927|NCT00952523|Drug|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
424928|NCT00952523|Drug|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
424929|NCT00952497|Drug|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
424930|NCT00952484|Biological|asfotase alfa|2 mg/kg subcutaneous injection three times per week for 6 months.
424931|NCT00952484|Biological|asfotase alfa|3 mg/kg subcutaneous injection three times per week for 6 months.
424932|NCT00952471|Other|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
424933|NCT00952458|Device|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
424934|NCT00952445|Drug|T0903131 Besylate|Once daily, oral
424935|NCT00952445|Drug|Placebo|Once daily, oral
424936|NCT00952432|Drug|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
424937|NCT00952432|Procedure|Acupuncture|Acupuncture
424938|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
424939|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
424940|NCT00952419|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
424941|NCT00952406|Other|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
424942|NCT00952393|Drug|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
424943|NCT00952380|Drug|dalteparin|dalteparin subcutaneous injection
424944|NCT00952367|Other|Nasopharyngeal swab|Nasopharyngeal swab
424945|NCT00952341|Drug|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
424946|NCT00952341|Drug|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
424947|NCT00952341|Drug|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
424948|NCT00952341|Drug|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
424949|NCT00952341|Drug|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
424950|NCT00952328|Dietary Supplement|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
424951|NCT00952315|Device|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
424952|NCT00952315|Device|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
424953|NCT00952315|Device|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
424954|NCT00952302|Drug|Iron sucrose|Single intravenous infusion of iron 200 mg
424955|NCT00952302|Drug|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
424956|NCT00952302|Procedure|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
424957|NCT00952302|Drug|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
424958|NCT00952302|Drug|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
424959|NCT00952289|Drug|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
424960|NCT00952289|Drug|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
424961|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
424962|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
424963|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
424964|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
424965|NCT00952276|Biological|Normal saline solution|0.5 mL, Intramuscular on Day 0
424966|NCT00952263|Biological|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
424967|NCT00952250|Behavioral|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
425091|NCT00951431|Drug|Placebo|Placebo in the form of study drug
424968|NCT00952250|Behavioral|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
424969|NCT00952237|Drug|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.~G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
424970|NCT00952237|Drug|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.~Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).~Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
424971|NCT00952224|Other|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
424972|NCT00952211|Device|CPAP|CPAP at therapeutic pressure during nighttime
424973|NCT00952211|Device|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
424974|NCT00952198|Drug|ARRY-403, glucokinase activator; oral|multiple dose, escalating
424975|NCT00952198|Drug|Placebo; oral|matching placebo
424976|NCT00952185|Other|cytology specimen collection procedure|
424977|NCT00952185|Other|fluorescent antibody technique|
424978|NCT00952185|Procedure|assessment of therapy complications|
424979|NCT00952172|Behavioral|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
424980|NCT00952159|Biological|Monitoring seric concentrations of O-demethyl-tramadol and tramadol|The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
424981|NCT00952146|Procedure|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
424982|NCT00952133|Drug|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
424983|NCT00952133|Drug|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
424984|NCT00952120|Device|GSUC|Gauze-based wall suction negative pressure wound therapy
424985|NCT00952120|Device|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
424986|NCT00952107|Device|FLARE imaging system|Testing of operation of imaging system
424987|NCT00952094|Drug|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
424988|NCT00952081|Drug|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
424989|NCT00952068|Drug|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
424990|NCT00952042|Other|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
424991|NCT00952042|Other|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
424992|NCT00952029|Biological|bevacizumab|
424993|NCT00952029|Drug|FOLFIRI regimen|
424994|NCT00952029|Drug|fluorouracil|
424995|NCT00952029|Drug|irinotecan hydrochloride|
424996|NCT00952029|Drug|leucovorin calcium|
424997|NCT00952016|Drug|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
424998|NCT00952003|Drug|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
424999|NCT00951990|Behavioral|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
425000|NCT00951990|Behavioral|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
425001|NCT00951964|Drug|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
425002|NCT00951964|Drug|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
425003|NCT00951951|Procedure|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
425004|NCT00951951|Procedure|Posterior Approach|
425005|NCT00951925|Other|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
425006|NCT00951912|Dietary Supplement|Placebo|10g soy protein isolated per day
425007|NCT00951912|Dietary Supplement|Daidzein|50mg daidzein +10g soy protein isolated per day
425008|NCT00951912|Dietary Supplement|Genistein|50mg genistein +10g soy protein isolated per day
425009|NCT00951899|Drug|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
425010|NCT00951899|Other|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
425011|NCT00951899|Behavioral|Diet|Subjects were instructed to follow a weight maintenance diet (~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
425012|NCT00951899|Drug|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
425013|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
425014|NCT00951873|Drug|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
425015|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
425016|NCT00951860|Other|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
425017|NCT00951847|Drug|oxcarbazepine 300 mg/5 mL oral suspension|
425018|NCT00951834|Drug|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:~Months 1-3: 200 mg EGCG/die (200-0-0 mg)~Months 4-6: 400 mg EGCG/die (200-0-200 mg)~Months 7-9: 600 mg EGCG/die (400-0-200 mg)~Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
425019|NCT00951834|Drug|Placebo|Placebo
425020|NCT00951821|Behavioral|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
425021|NCT00951821|Behavioral|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
425022|NCT00951808|Biological|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
425023|NCT00951808|Behavioral|Standard care|Participants will receive standard care for ACS while in the hospital.
425024|NCT00951782|Device|High frequency TMS|deep TMS HADD coil
425025|NCT00951782|Device|Sham TMS|sham deep TMS HADD coil
425026|NCT00951782|Device|Low frequency TMS|Deep TMS - HADD coil
425027|NCT00951756|Other|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
425028|NCT00951743|Drug|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.~Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.~Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
425029|NCT00951730|Other|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
425030|NCT00951717|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
425031|NCT00951691|Behavioral|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
425032|NCT00951691|Behavioral|Treatment as usual|Standard treatment with physical and occupational therapies
425033|NCT00951678|Other|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
425034|NCT00951665|Drug|paclitaxel|Intravenous repeating dose
425035|NCT00951665|Drug|pertuzumab [Perjeta]|Intravenous repeating dose
425036|NCT00951665|Drug|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
425037|NCT00951665|Drug|paclitaxel|Intravenous escalating dose
425038|NCT00951665|Drug|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
425039|NCT00951652|Behavioral|CBT|
425040|NCT00951652|Other|Interpersonal and emotional processing therapy|
425041|NCT00951652|Behavioral|supportive listening|
425042|NCT00951639|Dietary Supplement|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
425043|NCT00951639|Procedure|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
425044|NCT00951639|Dietary Supplement|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
425045|NCT00951626|Behavioral|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
425046|NCT00951626|Behavioral|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.~For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
425047|NCT00951626|Dietary Supplement|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
425048|NCT00951626|Other|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.~Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
425049|NCT00951626|Other|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
425050|NCT00951626|Procedure|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
425051|NCT00951626|Procedure|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
425052|NCT00951626|Procedure|assessment of therapy complications|Collected throughout the 12 month study period
425053|NCT00951626|Procedure|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
425054|NCT00951626|Procedure|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
425055|NCT00951626|Procedure|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
425056|NCT00951626|Procedure|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
425057|NCT00951613|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
425058|NCT00951600|Drug|oxcarbazepine 300 mg/5mL oral suspension|
425059|NCT00951587|Device|PillCam™ (Capsule Endoscopy)|Medical Device
425060|NCT00951574|Drug|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
425061|NCT00951574|Drug|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
425062|NCT00951561|Device|Vipon|The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
425063|NCT00951561|Drug|Ibuprofen|400 mg daily
425064|NCT00951548|Dietary Supplement|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
425065|NCT00951548|Dietary Supplement|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
425066|NCT00951535|Other|questionnaire administration|
425067|NCT00951535|Procedure|quality-of-life assessment|
425068|NCT00951535|Radiation|image-guided radiation therapy|
425069|NCT00951535|Radiation|intensity-modulated radiation therapy|
425070|NCT00951535|Radiation|radiation therapy treatment planning/simulation|
425071|NCT00951522|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
425072|NCT00951522|Drug|Placebo|Inhaled placebo in sterile saline
425073|NCT00951509|Other|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
425074|NCT00951496|Biological|Bevacizumab|Given IV
425075|NCT00951496|Drug|Carboplatin|Given IV
425076|NCT00951496|Drug|Carboplatin|Given IP
425077|NCT00951496|Drug|Cisplatin|Given IP
425078|NCT00951496|Other|Laboratory Biomarker Analysis|Correlative studies
425079|NCT00951496|Drug|Paclitaxel|Given IV
425080|NCT00951496|Drug|Paclitaxel|Given IP
425081|NCT00951496|Other|Quality-of-Life Assessment|Ancillary studies
425082|NCT00951483|Drug|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
425083|NCT00951470|Other|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
425084|NCT00951470|Other|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.~During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
425085|NCT00951470|Other|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
425086|NCT00951457|Drug|Bendamustine|
425087|NCT00951444|Biological|dalotuzumab|Given IV
425088|NCT00951444|Drug|carboplatin|Given IV
425089|NCT00951444|Drug|gemcitabine hydrochloride|Given IV
425090|NCT00951431|Drug|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
425092|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
425093|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
425094|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
425095|NCT00951392|Drug|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1~Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l~Blood tests"
425096|NCT00951392|Procedure|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :~Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)~Global transcriptome analysis by DNA Chip"
425097|NCT00951392|Device|indirect calorimetry|energy expenditure measurement
425098|NCT00951379|Drug|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
425099|NCT00951379|Other|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
425100|NCT00951379|Other|laboratory biomarker analysis|Correlative studies
425101|NCT00951366|Other|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
425102|NCT00951340|Other|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
425103|NCT00951340|Behavioral|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
425104|NCT00951340|Behavioral|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
425105|NCT00951301|Drug|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
425106|NCT00951301|Drug|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
425107|NCT00951288|Dietary Supplement|Saffron|Saffron 20 mg/day supplementation
425108|NCT00951288|Dietary Supplement|Placebo|Placebo
425109|NCT00951275|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
425110|NCT00951275|Drug|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
425111|NCT00951262|Behavioral|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
425112|NCT00951249|Behavioral|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
425113|NCT00951249|Behavioral|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
425114|NCT00951249|Behavioral|Peer health care system navigators|HIV/STI treatment and other medical and social services
425115|NCT00951249|Behavioral|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
425116|NCT00951236|Drug|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
425117|NCT00951236|Drug|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
425118|NCT00951223|Drug|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
425119|NCT00951210|Biological|PLX-PAD|IM injection
425120|NCT00951197|Other|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
425121|NCT00951184|Behavioral|telephone-based intervention|
425122|NCT00951184|Other|screening questionnaire administration|
425123|NCT00951184|Other|study of socioeconomic and demographic variables|
425124|NCT00951184|Procedure|assessment of therapy complications|
425125|NCT00951184|Procedure|psychosocial assessment and care|
425126|NCT00951171|Procedure|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
425127|NCT00951171|Procedure|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
425128|NCT00951158|Dietary Supplement|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.~CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
425129|NCT00951158|Drug|Conjugated Linoleic Acid|Phase I Dose Escalation Study
425130|NCT00951132|Drug|rosuvastatin|10mg tablets, once daily in three months
425131|NCT00951132|Drug|Placebo|tablet, once daily, three months
425132|NCT00951119|Device|Resperate|device-guided breathing exercises
425133|NCT00951119|Device|Resperate|breathing device without slowing of breathing frequency
425134|NCT00951106|Drug|Pyrimethamine/sulfdoxine (Fansidar)|
425135|NCT00951093|Procedure|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
425136|NCT00951080|Device|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
425137|NCT00951080|Device|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
425138|NCT00951067|Other|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:~exercise~elevate arm~wear an arm compression garment"
425139|NCT00951067|Device|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
425140|NCT00951067|Device|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
425141|NCT00951067|Device|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
425142|NCT00951067|Device|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
425143|NCT00951054|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
425144|NCT00951041|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
425145|NCT00951041|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
425146|NCT00951028|Behavioral|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
425147|NCT00951028|Behavioral|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
425148|NCT00951028|Behavioral|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
425149|NCT00951015|Drug|GSK1349572|investigational HIV-1 integrase inhibitor
425150|NCT00951015|Drug|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
425151|NCT00951002|Procedure|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
425152|NCT00950989|Drug|AMG 827 70 mg|70 mg AMG 827 SC
425153|NCT00950989|Drug|AMG 827 140 mg|140 mg AMG 827 SC
425154|NCT00950989|Drug|AMG 827 210 mg|210 mg AMG 827 SC
425155|NCT00950989|Drug|Placebo|Placebo SC
425156|NCT00950989|Drug|Stable weekly dose of methotrexate|Methotrexate
425157|NCT00950976|Other|citrulline|TID for 5 days
425158|NCT00950976|Other|Lemonade|TID for 5 days
425159|NCT00950963|Behavioral|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
425160|NCT00950963|Other|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
425161|NCT00950950|Drug|Romosozumab|Administered by subcutaneous injection
425162|NCT00950950|Drug|Placebo|Administered by subcutaneous injection
425163|NCT00950924|Device|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
425164|NCT00950924|Device|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
425165|NCT00950911|Drug|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
425166|NCT00950898|Other|decaff|2 mugs of decaffeinated coffee
425167|NCT00950898|Other|caffcoff|2 mugs of caffeinated coffee
425168|NCT00950898|Other|caffeine|2 mugs of hot water containing caffeine
425169|NCT00950898|Other|placebo|2 mugs of hot water
425170|NCT00950885|Biological|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
425171|NCT00950885|Biological|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
425172|NCT00950885|Biological|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
425173|NCT00950872|Device|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
425174|NCT00950859|Drug|GSK1349572 (Cohort I)|50 mg once daily
425175|NCT00950859|Drug|GSK1349572 (Cohort II)|50 mg twice daily
425176|NCT00950846|Drug|Busulfan|"Day -9, -8, -7 and -6~Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses."
425177|NCT00950846|Drug|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
425178|NCT00950846|Drug|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
425179|NCT00950846|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
425180|NCT00950833|Biological|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
425181|NCT00950820|Drug|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.~The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
425182|NCT00950820|Drug|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
425183|NCT00950807|Drug|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
425184|NCT00950807|Drug|Placebo|Inactive/ excipients only
425185|NCT00950807|Drug|GSK573179|GSK573179 investigational drug
425186|NCT00950794|Drug|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
425187|NCT00950794|Drug|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
425188|NCT00950781|Procedure|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
425189|NCT00950768|Procedure|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
425190|NCT00950755|Biological|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
425191|NCT00950742|Drug|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
425192|NCT00950742|Drug|BIBW 2992|Increased dose cohorts from low dose to MTD
425193|NCT00950729|Procedure|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
425194|NCT00950729|Procedure|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
425195|NCT00950729|Procedure|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
425196|NCT00950716|Behavioral|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
425197|NCT00950716|Behavioral|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
425198|NCT00950690|Drug|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
425199|NCT00950677|Drug|Byetta (exenatide)|exenatide 5 mcg subcutaneously
425200|NCT00950677|Drug|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
425201|NCT00950664|Drug|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
425202|NCT00950664|Drug|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
425203|NCT00950651|Drug|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
425204|NCT00950651|Drug|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
425205|NCT00950638|Drug|ARC1905|intravitreal injection
425206|NCT00950625|Drug|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
425207|NCT00950625|Drug|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
425208|NCT00950612|Biological|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
425209|NCT00950612|Biological|Placebo|Intramuscular injection, 2 doses
425210|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
425211|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
425212|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
425213|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
425214|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
425215|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
425216|NCT00950599|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
425217|NCT00950586|Drug|GSK1043702|Oral dose in liquid or tablet formulation
425218|NCT00950586|Drug|Dextromethorphan|30mg Oral dose
425219|NCT00950586|Drug|Placebo|To match GSK1034702
425220|NCT00950547|Device|CARDIOPAT|Cell Saver System at bedside for ICU stay
425221|NCT00950547|Device|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
425505|NCT00948506|Drug|1% topical cidofovir|1% topical cidofovir
425222|NCT00950534|Drug|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
425223|NCT00950534|Drug|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
425224|NCT00950521|Procedure|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
425225|NCT00950521|Drug|convention therapy|antiplatelet
425226|NCT00950508|Procedure|High volume plasma exchange|3 high volume plasma exchanges over 3 days
425227|NCT00950508|Procedure|Standard medical treatment|Standard medical treatment
425228|NCT00950495|Device|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
425229|NCT00950495|Device|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
425230|NCT00950495|Device|placebo|as a placebo, a thin (< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
425231|NCT00950482|Procedure|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
425232|NCT00950482|Other|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
425233|NCT00950482|Other|WC|Waiting Group
425234|NCT00950456|Biological|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
425235|NCT00950443|Device|Acoustic reflection method|Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.
425236|NCT00950443|Device|Acoustic method and breathing/endoscopic evaluation|Endoscopic evaluation done under general anaesthesia.
425237|NCT00950430|Drug|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
425238|NCT00950430|Drug|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
425239|NCT00950430|Drug|Tau (18-F-AV-1451)|"PIB PET scan, Tau PET scan and/or FDG PET scan~Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
425240|NCT00950417|Drug|Nimotuzumab|
425241|NCT00950404|Drug|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
425242|NCT00950404|Drug|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
425243|NCT00950404|Drug|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
425244|NCT00950404|Drug|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
425245|NCT00950391|Drug|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
425246|NCT00950365|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on day 1 every 21 days
425247|NCT00950365|Drug|pemetrexed and erlotinib|pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and erlotinib 150 mg PO once daily on days 2-17 every 21 days
425248|NCT00950352|Drug|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
425249|NCT00950352|Drug|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
425250|NCT00950339|Drug|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
425251|NCT00950339|Drug|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
425252|NCT00950339|Drug|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:~A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).~At the end of each phase- each patient will undergo the following evaluation:~Platelet reactivity"
425253|NCT00950326|Procedure|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
425254|NCT00950326|Procedure|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
425255|NCT00950326|Procedure|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
425256|NCT00950313|Other|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
425257|NCT00950313|Other|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
425258|NCT00950300|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
425259|NCT00950300|Drug|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
425260|NCT00950300|Drug|Docetaxel|Participants will receive docetaxel, 75 mg/m^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
425261|NCT00950300|Drug|Epirubicin|Participants will receive epirubicin, 75 mg/m^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
425262|NCT00950300|Drug|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
425263|NCT00950300|Drug|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
425264|NCT00950287|Device|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
425265|NCT00950274|Drug|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
425266|NCT00950274|Drug|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
425267|NCT00950261|Radiation|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
425268|NCT00950248|Drug|Idebenone|idebenone, lactose monohydrate, microcrystalline cellulose, croscarmellose sodium povidone, magnesium stearate, silicon dioxide, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
425269|NCT00950248|Other|placebo|lactose monohydrate, microcrystalline cellulose, magnesium stearate, film-coat: Opadry II 85F23495 (consisting of: aluminium lake, FD&C yellow #6, macrogol/PEG 3550, polyvinylalcohol, titanium dioxide, talc)
425270|NCT00950235|Behavioral|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
425271|NCT00950235|Other|Usual Care|Standard nutrition counseling from Health Plan
425272|NCT00950222|Drug|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
425273|NCT00950209|Dietary Supplement|saline infusion|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48"
425274|NCT00950209|Other|euglycaemic hyperinsulinic clamp|an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
425275|NCT00950209|Dietary Supplement|infusion of Endolipide and heparin|an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
425276|NCT00950209|Other|hyperglycaemic hyperinsulinic clamp|a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
425277|NCT00950196|Drug|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
425278|NCT00950183|Device|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
425279|NCT00950183|Other|Ice|postoperative cold therapy
425280|NCT00950170|Procedure|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
425281|NCT00950157|Other|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
425282|NCT00950144|Other|medical chart review|
425283|NCT00950144|Other|questionnaire administration|
425284|NCT00950144|Other|study of socioeconomic and demographic variables|
425285|NCT00950144|Procedure|quality-of-life assessment|
425286|NCT00950131|Other|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
425287|NCT00950105|Drug|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
425288|NCT00950092|Device|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
425289|NCT00950079|Drug|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
425290|NCT00950079|Drug|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
425291|NCT00950066|Drug|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
425292|NCT00950066|Drug|Amlodipine|Oral administration of Amlodipine 5mg once a day
425293|NCT00950066|Drug|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
425294|NCT00950066|Drug|Placebo|Oral administration of a placebo once a day
425295|NCT00950053|Procedure|Achilles decompression & debridement|Surgical intervention
425296|NCT00950053|Procedure|Achilles decompression and debridement with FHL transfer|surgical intervention
425297|NCT00950040|Behavioral|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
425298|NCT00950040|Behavioral|General health education|The intervention will consist of information about several general health behaviors.
425299|NCT00950027|Drug|povidone iodine|oropharyngeal decontamination every 4 hours
425300|NCT00950027|Drug|Placebo|oropharyngeal decontamination every 4 hours
425301|NCT00950014|Other|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
425302|NCT00950001|Radiation|Stereotactic Radiosurgery|Undergo SRS
425303|NCT00949988|Drug|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
425304|NCT00949975|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
425305|NCT00949975|Drug|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
425306|NCT00949975|Drug|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
425307|NCT00949975|Drug|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
425308|NCT00949962|Drug|antiandrogen therapy|Given systemically
425309|NCT00949962|Drug|leuprolide acetate|Given subcutaneously
425310|NCT00949962|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
425311|NCT00949949|Drug|everolimus|Given PO
425312|NCT00949949|Drug|gemcitabine hydrochloride|Given IV
425313|NCT00949949|Drug|cisplatin|Given IV
425314|NCT00949936|Device|CAdisc™-L (Total Disc Replacement)|
425315|NCT00949923|Dietary Supplement|tea capsule|3 tea capsules daily for 3 weeks
425316|NCT00949910|Drug|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
425317|NCT00949897|Device|Biofoam|Device
425318|NCT00949897|Other|Iliac Crest Allograft with locked plate|
425319|NCT00949884|Drug|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
425320|NCT00949884|Drug|Placebo|placebo oral tablets once daily for two weeks
425321|NCT00949884|Drug|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
425322|NCT00949871|Other|communication analysis|
425323|NCT00949871|Other|questionnaire administration|
425324|NCT00949871|Procedure|psychosocial assessment and care|
425325|NCT00949871|Procedure|support group therapy|
425326|NCT00949845|Drug|Endotoxin|
425327|NCT00949832|Dietary Supplement|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
425328|NCT00949832|Dietary Supplement|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
425329|NCT00949832|Dietary Supplement|Vitamin D2|50,000 IU given orally once
425330|NCT00949832|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU given orally once
425331|NCT00949819|Other|Active surveillance|Serial, long term data collection and active surveillance
425332|NCT00949806|Drug|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
425333|NCT00949793|Device|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
425334|NCT00949780|Drug|Chloral Hydrate|
425335|NCT00949767|Drug|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
425336|NCT00949767|Drug|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
425337|NCT00949767|Drug|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
425338|NCT00949767|Drug|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
425339|NCT00949767|Drug|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
425340|NCT00949767|Drug|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
425341|NCT00949767|Drug|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
425342|NCT00949767|Drug|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
425343|NCT00949754|Drug|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
425344|NCT00949728|Procedure|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
425345|NCT00949715|Device|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
425346|NCT00949715|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
425347|NCT00949702|Drug|vemurafenib|960 mg b.i.d. continuous oral dosing
425348|NCT00949689|Behavioral|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
425349|NCT00949663|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
425350|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
425351|NCT00949663|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
425352|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
425353|NCT00949650|Drug|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
425354|NCT00949650|Drug|BIBW 2992|BIBW 2992 once daily until progression
425355|NCT00949650|Drug|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
425356|NCT00949637|Behavioral|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
425357|NCT00949637|Behavioral|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
425358|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
425359|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
425360|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
425361|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
425362|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
425363|NCT00949624|Drug|Docetaxel|Intravenous 100 mg/m2 every three weeks
425364|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
425365|NCT00949624|Drug|AG-013736|Oral tablet 5 mg BID continuous
425366|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
425367|NCT00949611|Behavioral|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
425368|NCT00949611|Behavioral|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
425369|NCT00949598|Drug|letrozole|Given orally
425370|NCT00949598|Drug|tamoxifen citrate|Given orally
425371|NCT00949585|Other|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
425372|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
425373|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
425374|NCT00949559|Drug|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
425375|NCT00949546|Drug|etanercept|etanercept 50 mg sc twice weekly
425376|NCT00949533|Drug|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
425377|NCT00949520|Other|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
425378|NCT00949520|Other|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
425379|NCT00949494|Device|Synvisc|intra-articular, 3 weekly injections
425380|NCT00949481|Other|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
425381|NCT00949481|Other|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.~Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
425382|NCT00949455|Drug|lapatinib ditosylate|Given orally
425383|NCT00949455|Other|Placebo|Given orally
425384|NCT00949442|Drug|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
425385|NCT00949442|Drug|Glimepiride|tablets of 1 and 2 mg
425386|NCT00949442|Drug|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
425387|NCT00949390|Behavioral|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
425388|NCT00949377|Drug|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
425389|NCT00949377|Drug|Placebo|Normal saline
425506|NCT00948506|Drug|3% topical cidofovir|3% topical cidofovir
425390|NCT00949364|Drug|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.~If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.~If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
425391|NCT00949351|Drug|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
425392|NCT00949338|Procedure|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
425393|NCT00949325|Drug|temsirolimus plus liposomal doxorubicin|Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
425394|NCT00949312|Genetic|RNA marker analysis of lymph node and primary tumors|
425395|NCT00949312|Genetic|microarray profiling of primary tumors|
425396|NCT00949312|Genetic|reverse transcriptase-polymerase chain reaction of lymph node specimens|
425397|NCT00949312|Other|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
425398|NCT00949312|Procedure|regional lymph node dissection|
425399|NCT00949312|Other|lymph node staining for H&E and pancytokeratin IHC|
425400|NCT00949299|Drug|buprenorphine|intradermal injection
425401|NCT00949273|Procedure|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
425402|NCT00949247|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
425403|NCT00949247|Biological|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
425404|NCT00949247|Drug|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
425405|NCT00949247|Drug|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
425406|NCT00949247|Other|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
425407|NCT00949234|Drug|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:~Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
425408|NCT00949221|Device|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~group 2: intensive strategy using continuous glucose monitoring for 12 months;~group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
425409|NCT00949195|Other|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
425410|NCT00949195|Other|Pulmonary pressure response during exercise|Semi-supine echocardiography test
425411|NCT00949182|Drug|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
425412|NCT00949182|Other|laboratory biomarker analysis|
425413|NCT00949156|Procedure|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
425414|NCT00949143|Other|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
425415|NCT00949143|Other|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
425416|NCT00949130|Drug|NXL103|BID for 7-14 days
425417|NCT00949130|Drug|Linezolid|BID for 7-14 days
425418|NCT00949117|Dietary Supplement|Ensure|Given orally
425419|NCT00949117|Dietary Supplement|PediaSure|Given orally
425420|NCT00949117|Drug|cyproheptadine hydrochloride|Given orally
425421|NCT00949104|Drug|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
425422|NCT00949104|Drug|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
425423|NCT00949091|Drug|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:~TAK-875 25 mg tablets, orally~TAK-875 50 mg tablets, orally~TAK-875 100 mg tablets, orally~TAK-875 200 mg tablets, orally~TAK-875 400 mg tablets, orally~TAK-875 placebo-matching tablets, orally."
425424|NCT00949078|Drug|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
425425|NCT00949065|Biological|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
425426|NCT00949052|Genetic|DNA analysis|
425427|NCT00949052|Genetic|polymorphism analysis|
425428|NCT00949052|Other|laboratory biomarker analysis|
425429|NCT00949052|Other|medical chart review|
425430|NCT00949052|Other|questionnaire administration|
425431|NCT00949052|Procedure|assessment of therapy complications|
425432|NCT00949052|Procedure|evaluation of cancer risk factors|
425433|NCT00949039|Drug|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
425434|NCT00949039|Radiation|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
425435|NCT00949039|Procedure|Surgery|
425436|NCT00949026|Drug|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
425437|NCT00949013|Other|immunohistochemistry staining method|
425438|NCT00949013|Other|laboratory biomarker analysis|
425439|NCT00949000|Device|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
425440|NCT00948987|Drug|Aspirin|325 mg enteric coated single dose p.o.
425441|NCT00948974|Behavioral|Cognitive Therapy|"Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005)."
425442|NCT00948974|Behavioral|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, & Emmelkamp, 2009).
425443|NCT00948961|Biological|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
425444|NCT00948961|Biological|CDX-1401|
425445|NCT00948961|Biological|Resiquimod|
425446|NCT00948961|Biological|poly-ICLC|
425447|NCT00948948|Device|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:~Gel-filled device which is available in smooth surface and textured surface (Siltex®)~Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version~Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
425448|NCT00948935|Drug|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
425449|NCT00948922|Drug|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
425450|NCT00948922|Drug|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes.
425451|NCT00948922|Procedure|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
425452|NCT00948922|Drug|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
425453|NCT00948922|Procedure|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
425454|NCT00948909|Drug|Placebo|Placebo intervention
425455|NCT00948909|Drug|ABT-126|Experimental intervention
425456|NCT00948909|Drug|donepezil|Active comparator intervention
425457|NCT00948896|Drug|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
425458|NCT00948896|Drug|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
425459|NCT00948896|Drug|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
425460|NCT00948870|Drug|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
425461|NCT00948857|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
425462|NCT00948857|Dietary Supplement|Placebo|Blinded placebo
425463|NCT00948844|Device|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
425464|NCT00948831|Biological|Osteocel Plus|biologic
425465|NCT00948818|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
425466|NCT00948818|Drug|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
425467|NCT00948805|Drug|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
425468|NCT00948805|Drug|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
425469|NCT00948792|Procedure|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
425470|NCT00948792|Procedure|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
425471|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
425472|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
425473|NCT00948766|Drug|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm^2 patch which released 4.6 mg/24 h. Patches were changed daily.
425474|NCT00948766|Drug|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm^2 patch which released 9.5 mg/24 h. Patches were changed daily.
425475|NCT00948766|Drug|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm^2 patch which released 13.3 mg/24 h. Patches were changed daily.
425476|NCT00948766|Drug|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
425477|NCT00948753|Drug|Maraviroc|Maraviroc 300 mg bid (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stell-cell infusion.
425478|NCT00948740|Drug|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
425479|NCT00948727|Behavioral|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
425480|NCT00948727|Drug|Cyclosporine (CsA)|Cyclosporine (CsA)
425481|NCT00948714|Behavioral|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
425482|NCT00948714|Behavioral|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
425483|NCT00948714|Other|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
425484|NCT00948701|Behavioral|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
425485|NCT00948688|Radiation|Radiation therapy|Once per day, 5 days a week for 6 weeks
425486|NCT00948688|Drug|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
425487|NCT00948688|Drug|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
425488|NCT00948675|Drug|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
425489|NCT00948675|Drug|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 [maximum possible dose of 900 milligrams (mg)] intravenously infused over 30 minutes.
425490|NCT00948675|Drug|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
425491|NCT00948675|Biological|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
425492|NCT00948662|Drug|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
425493|NCT00948662|Drug|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
425494|NCT00948662|Drug|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
425495|NCT00948649|Drug|Placebo|Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
425496|NCT00948649|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
425497|NCT00948623|Behavioral|physical activity counseling program|
425498|NCT00948623|Behavioral|sham counseling program|
425499|NCT00948610|Drug|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
425500|NCT00948584|Other|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
425501|NCT00948545|Other|Observational study - there is no intervention|Observational study - there is no intervention
425502|NCT00948532|Biological|biologic, Osteocel Plus|Osteocel® Plus
425503|NCT00948519|Device|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
425504|NCT00948519|Device|Laser only|same only without ICG
425507|NCT00948506|Drug|Placebo|topical placebo
425508|NCT00948493|Drug|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
425509|NCT00948480|Biological|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
425510|NCT00948480|Drug|GM-CSF|500 mcg
425511|NCT00948467|Drug|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.~The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
425512|NCT00948441|Drug|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
425513|NCT00948441|Other|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
425514|NCT00948428|Drug|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
425515|NCT00948428|Drug|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
425516|NCT00948428|Drug|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
425517|NCT00948415|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
425518|NCT00948402|Drug|Metformin|metformin 1250 mg three times daily
425519|NCT00948402|Drug|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
425520|NCT00948389|Drug|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
425521|NCT00948389|Drug|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
425522|NCT00948376|Genetic|IFT80 screening|Natural History
425523|NCT00948363|Other|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
425524|NCT00948363|Other|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
425525|NCT00948350|Procedure|awake intubation|two anesthesia techniques
425526|NCT00948337|Behavioral|Brochure of Secondary Cancer Screening|One kind of printed educational material
425527|NCT00948324|Drug|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
425528|NCT00948298|Drug|Vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
425529|NCT00948298|Drug|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
425530|NCT00948285|Procedure|MRI|magnetic resonance imaging (MRI)
425531|NCT00948272|Biological|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
425532|NCT00948272|Biological|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
425533|NCT00948259|Drug|NP031112|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
425534|NCT00948259|Drug|Placebo|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
425535|NCT00948246|Device|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
425536|NCT00948233|Behavioral|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
425537|NCT00948233|Behavioral|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
425538|NCT00948233|Behavioral|Surveys|Computer surveys taken at 4 points throughout the study.
425539|NCT00948220|Drug|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
425540|NCT00948207|Behavioral|My Living Story|"Components include:~1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);~2) Edited transcript is delivered in a word format on...;~3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.~4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
425541|NCT00948207|Behavioral|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
425542|NCT00948194|Drug|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
425543|NCT00948168|Drug|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
425544|NCT00948155|Drug|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
425545|NCT00948142|Drug|CEM-102|600 mg BID oral tablets for 10-14 days
425546|NCT00948142|Drug|Linezolid|600 mg BID oral tablets
425547|NCT00948142|Drug|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
425548|NCT00948129|Other|Laboratory Biomarker Analysis|Correlative studies
425549|NCT00948129|Behavioral|Smoking Cessation Intervention|Undergo standard of care smoking cessation intervention
425550|NCT00948129|Behavioral|Telephone-Based Intervention|Undergo telephone based smoking cessation intervention
425551|NCT00948129|Other|Tobacco Cessation Counseling|Undergo smoking cessation counseling
425552|NCT00948103|Drug|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
425553|NCT00948103|Drug|Oxygen|oxygen
425554|NCT00948090|Drug|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
425555|NCT00948077|Drug|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.~The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.~Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)"
425556|NCT00948064|Drug|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
425557|NCT00948064|Drug|Azacitidine|75 mg/m^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
425558|NCT00948051|Dietary Supplement|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
425559|NCT00948051|Dietary Supplement|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
425560|NCT00948038|Dietary Supplement|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
425561|NCT00948038|Dietary Supplement|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
425562|NCT00948025|Device|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
425563|NCT00948025|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve tissue scaffold at time of surgery.
425564|NCT00947986|Other|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
425565|NCT00947973|Behavioral|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
425566|NCT00947973|Behavioral|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
425567|NCT00947960|Drug|Triheptanoin|1-2 grams triheptanoin (drug)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months.
425568|NCT00947960|Other|Vegetable Oil|1-2 grams vegetable oil (placebo)/kilogram body weight divided into 4 equal doses per day taken with meals and a snack for 6 months followed by 1-2 g triheptanoin (drug)/kilogram body weight for 6 months.
425569|NCT00947947|Behavioral|Tailored Information Program for Safer Sex|Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
425570|NCT00947934|Device|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
425571|NCT00947921|Procedure|Plasty|Restrictive Annuloplasty
425572|NCT00947921|Procedure|Prosthesis|Valve replacement
425573|NCT00947908|Biological|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
425574|NCT00947895|Drug|Methylprednisolone|IV 1000 mg daily for 3 days
425575|NCT00947895|Drug|ACTH|IM ACTH 80 mg/day for 5 days.
425576|NCT00947895|Other|IV placebo|IV placebo (saline) daily for 3 days.
425577|NCT00947895|Other|IM placebo|IM placebo (saline) daily for 5 days.
425578|NCT00947882|Drug|Placebo|Mannitol 50 mg/mL solution
425579|NCT00947882|Drug|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
425580|NCT00947882|Drug|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
425581|NCT00947882|Drug|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
425582|NCT00947856|Drug|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
425583|NCT00947843|Drug|aspirin + pregrel (Clopidogrel resinate)|
425584|NCT00947843|Drug|aspirin + placebo|
425585|NCT00947843|Drug|aspirin + plavix (Clopidogrel bisulfate)|
425586|NCT00947817|Other|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
425587|NCT00947791|Drug|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
425588|NCT00947791|Drug|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
425589|NCT00947778|Other|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
425590|NCT00947778|Other|1 training session|20 sessions of 30 minutes by week during 24 semaines
425780|NCT00946556|Drug|Valacyclovir|1g po od for 2 months
425591|NCT00947765|Biological|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
425592|NCT00947765|Drug|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
425593|NCT00947752|Drug|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
425594|NCT00947752|Drug|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
425595|NCT00947739|Drug|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
425596|NCT00947726|Drug|CeraVe|Using OTC cream on foot twice daily for two weeks.
425597|NCT00947713|Drug|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
425598|NCT00947713|Drug|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
425599|NCT00947700|Behavioral|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
425600|NCT00947687|Drug|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
425601|NCT00947687|Drug|Placebo|
425602|NCT00947674|Device|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
425603|NCT00947661|Drug|SPARC0912|Eye drops, once daily, 12 weeks
425604|NCT00947661|Drug|Reference0912|Eye drops, once daily, 12 weeks
425605|NCT00947648|Other|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
425606|NCT00947648|Other|Cooked Foods|Diet containing only cooked foods.
425607|NCT00947635|Dietary Supplement|Dietary intervention - supplements|Supplement bar & spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
425608|NCT00947622|Device|Transcranial direct current stimulation|Transcranial Direct current stimulation
425609|NCT00947596|Drug|atropine sulfate|dry powder for inhalation
425610|NCT00947596|Drug|atropine sulfate|intramuscular injection
425611|NCT00947583|Biological|Osteocel Plus|biologic
425612|NCT00947570|Behavioral|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
425613|NCT00947557|Drug|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
425614|NCT00947557|Drug|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
425615|NCT00947544|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
425616|NCT00947544|Drug|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
425617|NCT00947531|Drug|Cerebrolysin|
425618|NCT00947531|Drug|0.9% Saline Solution|
425619|NCT00947518|Drug|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
425620|NCT00947518|Drug|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
425621|NCT00947505|Device|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
425622|NCT00947505|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
425623|NCT00947492|Biological|Venous blood sample|Venous blood sample twice a year during 3 years
425624|NCT00947479|Other|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
425625|NCT00947466|Drug|Buprenorphine|Transdermal patch
425626|NCT00947453|Drug|montelukast|montelukast 10 mg once daily for 8 weeks
425627|NCT00947440|Drug|ABT-072|See arm description for more information
425628|NCT00947427|Drug|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
425629|NCT00947427|Drug|Placebo|Placebo subcutaneous injections
425630|NCT00947414|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
425631|NCT00947414|Device|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
425632|NCT00947388|Drug|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
425633|NCT00947388|Biological|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
425634|NCT00947375|Drug|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
425635|NCT00947375|Drug|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
425636|NCT00947362|Other|Electro-thermo-coagulation|
425637|NCT00947362|Drug|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
425638|NCT00947362|Drug|saline|physiological saline
425639|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
425640|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
425641|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
425642|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
425643|NCT00947349|Drug|BI 201335 NA low placebo|Placebo
425644|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
425645|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
425646|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
425647|NCT00947349|Drug|BI 201335 NA low|BI 201335 NA
425648|NCT00947349|Drug|BI 201335 NA high placebo|placebo
425649|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
425650|NCT00947349|Drug|Placebo|
425651|NCT00947336|Drug|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
425652|NCT00947336|Drug|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
425653|NCT00947323|Drug|Simvastatin|simvastatin 20 daily for six months.
425654|NCT00947323|Drug|Placebo|
425655|NCT00947310|Device|Standard ICD programming|Standard ICD programming
425656|NCT00947310|Device|High rate cutoff|Programming of a high rate cutoff
425657|NCT00947310|Device|Long delay|Programming of a prolonged delay
425658|NCT00947297|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
425659|NCT00947284|Drug|nalbuphine plus naloxone|single dose administered intravenously
425660|NCT00947284|Drug|nalbuphine plus saline|single dose administered intravenously
425661|NCT00947284|Drug|naloxone plus saline|single dose administered intravenously
425662|NCT00947271|Behavioral|DVD 1|The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases [STDs]) and improve health
425663|NCT00947271|Behavioral|DVD 2|The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
425664|NCT00947258|Other|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
425665|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
425666|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
425667|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
425668|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
425669|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
425670|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
425671|NCT00947245|Drug|Placebo|Capsules, Oral, Single Dose, One day
425672|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours, 14 days
425673|NCT00947245|Drug|Placebo|Capsules, Oral, Once Daily, 14 days
425674|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
425675|NCT00947232|Behavioral|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
425676|NCT00947232|Behavioral|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
425677|NCT00947219|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
425678|NCT00947219|Device|Control device|Device is used 3 times a week on non-consecutive days
425679|NCT00947206|Behavioral|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
425680|NCT00947206|Behavioral|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
425681|NCT00947193|Drug|Ataluren|Ataluren (PTC124) will be provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren (PTC124) will be taken 3 times per day, with dosing based on the participant's body weight. The dose level for ataluren (PTC124) will be 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days.
425682|NCT00947180|Behavioral|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
425683|NCT00947180|Other|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
425684|NCT00947180|Behavioral|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
425685|NCT00947167|Drug|pertuzumab|840 mg, 420 mg, iv
425686|NCT00947167|Drug|erlotinib|150 mg, PO
425687|NCT00947154|Drug|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
425781|NCT00946556|Drug|Placebo|Placebo po od for 2 months
425688|NCT00947141|Drug|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR >200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
425689|NCT00947141|Other|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
425690|NCT00947141|Drug|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
425691|NCT00947141|Other|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.~Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
425692|NCT00947128|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
425693|NCT00947128|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
425694|NCT00947115|Procedure|Blood sampling|Blood samples will be collected at Years 5, 6, 7, 8, 9 and 10
425695|NCT00947115|Procedure|Cervico-vaginal secretion (CVS) samples|CVS will be collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteer for this procedure.
425696|NCT00947102|Other|Observation|
425697|NCT00947089|Device|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
425698|NCT00947089|Device|iodoform gauze|one iodoform gauze
425699|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
425700|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
425701|NCT00947063|Drug|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
425702|NCT00947063|Drug|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
425703|NCT00947050|Other|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
425704|NCT00947037|Drug|AP-CD/LD|
425705|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
425706|NCT00947024|Drug|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
425707|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
425708|NCT00947011|Drug|Placebo|1 tablet 100 mg once a day
425709|NCT00947011|Drug|Januvia|1 tablet 100 mg once a day
425710|NCT00946998|Drug|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
425711|NCT00946998|Drug|placebo|Placebo tablet will be identical and matched to sertraline tablet.
425712|NCT00946985|Drug|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
425713|NCT00946985|Drug|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
425714|NCT00946972|Drug|JNJ-38431055; Placebo|
425715|NCT00946959|Procedure|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
425716|NCT00946946|Drug|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
425717|NCT00946946|Drug|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
425718|NCT00946946|Drug|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
425719|NCT00946946|Drug|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
425720|NCT00946933|Dietary Supplement|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
425721|NCT00946933|Dietary Supplement|placebo|0.025 g/kg/day of NaCl (sodium chloride)
425722|NCT00946920|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
425723|NCT00946920|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
425724|NCT00946907|Drug|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
425725|NCT00946907|Drug|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
425726|NCT00946894|Procedure|Total thyroidectomy|Total thyroidectomy
425727|NCT00946894|Procedure|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
425728|NCT00946894|Procedure|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
425777|NCT00946582|Behavioral|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
425778|NCT00946569|Drug|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
425729|NCT00946881|Drug|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
425730|NCT00946842|Drug|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
425731|NCT00946842|Drug|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
425732|NCT00946842|Drug|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
425733|NCT00946842|Drug|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
425734|NCT00946842|Drug|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
425735|NCT00946842|Drug|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
425736|NCT00946829|Drug|telmisartan|
425737|NCT00946816|Behavioral|Nutritional Intervention|Nutritional Intervention
425738|NCT00946803|Behavioral|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
425739|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
425740|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
425741|NCT00946777|Other|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
425742|NCT00946764|Drug|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
425743|NCT00946764|Drug|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
425744|NCT00946751|Drug|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
425745|NCT00946751|Drug|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
425746|NCT00946738|Other|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
425747|NCT00946738|Other|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
425748|NCT00946725|Drug|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
425749|NCT00946725|Drug|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
425750|NCT00946712|Biological|Bevacizumab|Given IV
425751|NCT00946712|Drug|Carboplatin|Given IV
425752|NCT00946712|Biological|Cetuximab|Given IV
425753|NCT00946712|Other|Laboratory Biomarker Analysis|Correlative studies
425754|NCT00946712|Drug|Paclitaxel|Given IV
425755|NCT00946699|Biological|MEDI-551|0.1 mg/kg
425756|NCT00946699|Biological|Placebo|0.3 mg/kg
425757|NCT00946699|Biological|MEDI-551|1.0 mg/kg
425758|NCT00946699|Biological|MEDI-551|3.0 mg/kg
425759|NCT00946699|Biological|MEDI-551|10.0 mg/kg
425760|NCT00946699|Other|Placebo|Placebo
425761|NCT00946686|Drug|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
425762|NCT00946686|Drug|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
425763|NCT00946673|Drug|Vorinostat|Orally up to 400 mg
425764|NCT00946673|Procedure|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
425765|NCT00946647|Drug|Panobinostat (LBH589) and 5-Azacytidine|"Each dose of panobinostat should be taken with 240 mL of water. Patients should be instructed to swallow the capsules whole and not chew them.~If the patient forgets to take his/her dose during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next scheduled treatment day. The patient should then continue treatment with the original dosing schedule.~The days when panobinostat and 5-Aza are scheduled together (Day 3 and Day 5 of a treatment cycle), panobinostat should be administered approximately 30 min prior to 5-Aza."
425766|NCT00946647|Drug|5-Azacytidine|
425767|NCT00946634|Drug|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
425768|NCT00946634|Drug|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
425769|NCT00946634|Drug|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
425770|NCT00946621|Drug|Ramipril 10 mg Capsule (Sandoz)|
425771|NCT00946621|Drug|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
425772|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
425773|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
425774|NCT00946608|Drug|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
425775|NCT00946595|Drug|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
425776|NCT00946595|Drug|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
425779|NCT00946569|Drug|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
425782|NCT00946543|Radiation|hypofractionated radiation therapy|
425783|NCT00946543|Radiation|intensity-modulated radiation therapy|
425784|NCT00946530|Device|Bright light|Participants uses bright light
425785|NCT00946530|Device|Control|Participants uses dim light
425786|NCT00946517|Other|Questionnaires|Parenting and behavioral questionnaires
425787|NCT00946504|Drug|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
425788|NCT00946504|Drug|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
425789|NCT00946491|Drug|Haloperidol 10 mg Tablets (Cord Laboratories)|
425790|NCT00946491|Drug|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
425791|NCT00946478|Drug|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
425792|NCT00946478|Other|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.~Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
425793|NCT00946465|Drug|Ramipril 10 Capsule (Sandoz)|
425794|NCT00946465|Drug|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
425795|NCT00946439|Device|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
425796|NCT00946426|Other|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
425797|NCT00946413|Behavioral|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
425798|NCT00946413|Behavioral|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
425799|NCT00946400|Other|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
425800|NCT00946400|Other|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
425801|NCT00946387|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
425802|NCT00946387|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
425803|NCT00946374|Drug|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
425804|NCT00946374|Drug|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( > 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
425805|NCT00946374|Other|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
425806|NCT00946361|Other|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
425807|NCT00946348|Drug|Dronabinol|Dronabinol 10 mg or 15 mg
425808|NCT00946348|Drug|Cannabis|Cannabis cigarette
425809|NCT00946335|Drug|veliparib|Given PO
425810|NCT00946335|Drug|temozolomide|Given PO
425811|NCT00946335|Other|pharmacological study|Correlative studies
425812|NCT00946335|Other|laboratory biomarker analysis|Correlative studies
425813|NCT00946322|Behavioral|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
425814|NCT00946309|Drug|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
425815|NCT00946309|Drug|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
425816|NCT00946296|Drug|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
425817|NCT00946283|Dietary Supplement|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
425818|NCT00946270|Drug|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
425819|NCT00946270|Drug|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
425820|NCT00946270|Drug|CC-4047|3.0 mg capsules daily by mouth day 1 through 21.
425864|NCT00945893|Other|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
425821|NCT00946257|Drug|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
425822|NCT00946205|Procedure|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
425823|NCT00946205|Procedure|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
425824|NCT00946192|Drug|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
425825|NCT00946192|Drug|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
425826|NCT00946192|Dietary Supplement|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
425827|NCT00946179|Biological|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
425828|NCT00946166|Drug|simvastatin|40 mg daily in the evening for a maximum of 14 days
425829|NCT00946166|Drug|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
425830|NCT00946153|Drug|Lenvatinib|In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
425831|NCT00946140|Procedure|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
425832|NCT00946127|Procedure|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
425833|NCT00946127|Procedure|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
425834|NCT00946114|Drug|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
425835|NCT00946114|Drug|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
425836|NCT00946101|Biological|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
425837|NCT00946101|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
425838|NCT00946088|Drug|Progesterone|Progesterone 400 mg per vagina qhs.
425839|NCT00946088|Drug|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate & hydrogenated vegetable oil per vagina qhs.
425840|NCT00946062|Other|orientation and mobility training|orientation and mobility training
425841|NCT00946049|Device|Vicryl Plus|
425842|NCT00946049|Device|Vicryl|
425843|NCT00946036|Drug|Sertraline Hydrochloride|
425844|NCT00946023|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
425845|NCT00946023|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily; Days 3 and 4: 50 mg/kg IV daily
425846|NCT00946023|Radiation|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
425847|NCT00946023|Drug|Tacrolimus|Start on Day 5 through Day 180
425848|NCT00946023|Drug|Mycophenolate Mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
425849|NCT00946023|Drug|Rituximab|Day 30 and every week after for 8 total doses: 375 mg/m^2 IV
425850|NCT00946023|Biological|Allogeneic Bone Marrow Transplant (BMT)|Day 0: Donor bone marrow infusion
425851|NCT00946010|Biological|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
425852|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
425853|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
425854|NCT00945984|Procedure|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
425855|NCT00945971|Other|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
425856|NCT00945958|Drug|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
425857|NCT00945945|Drug|Duloxetine (DLX)|dose daily by mouth
425858|NCT00945945|Drug|Placebo (PLA)|Placebo Comparator daily by mouth
425859|NCT00945932|Drug|GW870086X|Investigational product
425860|NCT00945932|Drug|Placebo|Placebo control
425861|NCT00945919|Drug|Oxymorphone ER|Rapid Opioid rotation/titration
425862|NCT00945906|Biological|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
425863|NCT00945893|Biological|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
425865|NCT00945880|Drug|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
425866|NCT00945854|Other|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
425867|NCT00945854|Other|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
425868|NCT00945841|Biological|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
425869|NCT00945828|Behavioral|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
425870|NCT00945828|Behavioral|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
425871|NCT00945815|Biological|epratuzumab|
425872|NCT00945815|Drug|clofarabine|
425873|NCT00945815|Drug|cytarabine|
425874|NCT00945815|Other|laboratory biomarker analysis|
425875|NCT00945802|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
425876|NCT00945802|Drug|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
425877|NCT00945789|Drug|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
425878|NCT00945789|Procedure|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
425879|NCT00945789|Biological|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
425880|NCT00945776|Behavioral|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
425881|NCT00945776|Behavioral|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
425882|NCT00945776|Behavioral|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
425883|NCT00945763|Drug|N1539|30 mg
425884|NCT00945763|Drug|placebo|tablets
425885|NCT00945763|Drug|N1539|15 mg
425886|NCT00945763|Drug|N1539|60 mg
425887|NCT00945763|Drug|Motrin|400 mg
425888|NCT00945750|Drug|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
425889|NCT00945750|Drug|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
425890|NCT00945737|Dietary Supplement|Soy protein; 25 grams/day|Soy protein
425891|NCT00945737|Dietary Supplement|Control protein|Milk protein
425892|NCT00945724|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate|"Weeks 1-15:~6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days~Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle~IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4&5 of R-CHOP~Weeks 18-22:~• Methotrexate 1.5 g/m2 q14 Days x 2~From Week 24:~• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)"
425893|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
425894|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
425895|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
425896|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
425897|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
425898|NCT00945698|Dietary Supplement|Maize-soy flour|"No food supplement during the primary trial period (6 to 18 months of age)~1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age~Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
425899|NCT00945685|Device|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):~Pulse energy (J);~RF frequency (1MHz);~Pulse duration (30 sec);~Treatment hand piece (skin tightening);"
425900|NCT00945672|Biological|PF-04360365 10 mg/kg|10 mg/kg every 90 days (5 total doses)
425901|NCT00945672|Biological|PF-04360365 7.5 mg/kg|10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
425902|NCT00945672|Drug|placebo|placebo administered every 90 days or monthly to match experimental treatment arms.
425903|NCT00945659|Device|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
425904|NCT00945659|Other|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
425905|NCT00945659|Behavioral|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
425906|NCT00945646|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
425907|NCT00945646|Drug|Vehicle|Instill four times two times a day
425908|NCT00945620|Drug|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
425909|NCT00945620|Drug|placebo|Placebo
425910|NCT00945607|Other|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
425911|NCT00945594|Device|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
425912|NCT00945581|Other|Experimental Nutritional Powder Formula|Powder twice a day
425913|NCT00945581|Other|Placebo comparator|Powder twice a day
425914|NCT00945568|Drug|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
425915|NCT00945555|Drug|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
425916|NCT00945542|Other|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.~Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
425917|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
425918|NCT00945529|Drug|inhaled nitric oxide|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
425919|NCT00945516|Device|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
425920|NCT00945516|Device|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
425921|NCT00945503|Drug|GSK1018921|GSK1018921 is a GT1 recepor antagonist
425922|NCT00945490|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
425923|NCT00945490|Drug|Placebo|Single intraprostatic injection of placebo
425924|NCT00945477|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
425925|NCT00945464|Other|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
425926|NCT00945451|Device|CK|Cyberknife Irradiation
425927|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
425928|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
425929|NCT00945425|Drug|AZD7325|oral capsule, once or twice daily, 7 days
425930|NCT00945425|Drug|Placebo|oral capsule, once or twice daily, 7 days
425931|NCT00945412|Device|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.~No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
425932|NCT00945412|Device|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
425933|NCT00945399|Procedure|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
425934|NCT00945399|Procedure|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
425935|NCT00945373|Drug|calcium dobesilate|2.5% gel
425936|NCT00945373|Procedure|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
425937|NCT00945360|Drug|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
425938|NCT00945347|Drug|Miglustat|Nasal instillation of miglustat
425939|NCT00945347|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
425940|NCT00945334|Drug|Neomycin|500 mg po bid for 14 days
425941|NCT00945334|Drug|Placebo|placebo for 14 days tid
425942|NCT00945334|Drug|Rifaximin|550 mg po tid
425943|NCT00945321|Drug|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
425944|NCT00945321|Drug|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
425945|NCT00945321|Drug|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
425946|NCT00945321|Drug|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
425947|NCT00945308|Drug|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
425948|NCT00945308|Drug|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
425949|NCT00945295|Drug|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
425950|NCT00945295|Other|Rehabilitation Therapy|Rehabilitation therapy
425951|NCT00945282|Drug|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
425952|NCT00945282|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
425953|NCT00945282|Drug|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
425954|NCT00945282|Drug|Placebo|Placebo is a capsule with no drug in it.
425955|NCT00945282|Drug|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
425956|NCT00945269|Biological|therapeutic autologous lymphocytes|Given IV
425957|NCT00945269|Biological|aldesleukin|Given SC
425958|NCT00945269|Biological|denileukin diftitox|Given IV
425959|NCT00945269|Procedure|biopsy|Optional correlative studies
425960|NCT00945269|Other|immunohistochemistry staining method|Correlative studies
425961|NCT00945269|Other|laboratory biomarker analysis|Correlative studies
425962|NCT00945269|Genetic|polymerase chain reaction|Correlative studies
425963|NCT00945256|Other|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
425964|NCT00945256|Drug|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
425965|NCT00945256|Dietary Supplement|Amino Acid Drink|7.5 gram Amino Acid drink
425966|NCT00945243|Device|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
425967|NCT00945230|Procedure|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
425968|NCT00945204|Other|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
425969|NCT00945191|Drug|CS-1008|CS-1008 IV infusion up to 10 mg/kg once every 3 weeks (1 cycle) for 6 cycles
425970|NCT00945191|Drug|paclitaxel|paclitaxel 175 mg/m2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
425971|NCT00945191|Drug|carboplatin|carboplatin (target area under the concentration versus time curve of 6.0 using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
425972|NCT00945178|Drug|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
425973|NCT00945178|Drug|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
425974|NCT00945178|Drug|Naproxen|Tablet, single oral dose, 500mg
425975|NCT00945178|Drug|Placebo for Naproxen|Tablet, single oral dose
425976|NCT00945165|Behavioral|Exercise intervention|various exercise characteristics
425977|NCT00945165|Behavioral|No exercise|No exercise control period
425978|NCT00945152|Drug|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
425979|NCT00945152|Drug|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
425980|NCT00945139|Drug|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
425981|NCT00945139|Drug|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
425982|NCT00945126|Other|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
426081|NCT00944398|Dietary Supplement|Zinc fortified food|Daily consumption
425983|NCT00945113|Behavioral|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
425984|NCT00945100|Device|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
425985|NCT00945100|Device|Eye Patch|2 hours patching daily
425986|NCT00945087|Other|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
425987|NCT00945074|Other|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
425988|NCT00945074|Other|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
425989|NCT00945074|Other|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
425990|NCT00945061|Radiation|intracavitary balloon brachytherapy|Patients undergo brachytherapy
425991|NCT00945061|Radiation|intraoperative radiation therapy|Patients undergo radiotherapy
425992|NCT00945048|Device|electrical velocimetry|determination of cardiac output by electrical velocimetry
425993|NCT00945048|Device|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
425994|NCT00945048|Device|spirometry|spirometry for testing the ventilatory function
425995|NCT00945048|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
425996|NCT00945035|Drug|etoricoxib|Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
425997|NCT00945035|Drug|Comparator: etoricoxib|Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
425998|NCT00945022|Device|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
425999|NCT00945009|Biological|Dactinomycin|Given IV
426000|NCT00945009|Drug|Doxorubicin Hydrochloride|Given IV
426001|NCT00945009|Radiation|Radiation Therapy|Undergo radiation therapy
426002|NCT00945009|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
426003|NCT00945009|Drug|Vincristine Sulfate|Given IV
426004|NCT00944996|Drug|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
426005|NCT00944970|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
426006|NCT00944970|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
426007|NCT00944957|Drug|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
426008|NCT00944957|Drug|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
426009|NCT00944957|Drug|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
426010|NCT00944957|Drug|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
426011|NCT00944944|Behavioral|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
426012|NCT00944944|Behavioral|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
426013|NCT00944931|Device|DC Brain Polarization|
426014|NCT00944918|Drug|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
426015|NCT00944918|Drug|anastrozole|Tablet, oral, once daily until disease progression.
426016|NCT00944918|Drug|exemestane|Tablet, oral, once daily until disease progression.
426017|NCT00944905|Biological|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
426018|NCT00944892|Drug|REGN475|2 Administrations of REGN475 within 24 weeks.
426019|NCT00944892|Other|Placebo|Placebo to match REGN475 doses
426020|NCT00944853|Dietary Supplement|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
426021|NCT00944853|Dietary Supplement|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
426022|NCT00944853|Dietary Supplement|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
426023|NCT00944840|Drug|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
426024|NCT00944840|Drug|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
426025|NCT00944827|Dietary Supplement|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
426026|NCT00944827|Dietary Supplement|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
426027|NCT00944814|Dietary Supplement|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
426028|NCT00944814|Dietary Supplement|LNS without zinc|LNS containing no zinc
426029|NCT00944801|Drug|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
426030|NCT00944788|Other|qi-gong|Physical activity similar to tai-chi
426031|NCT00944775|Behavioral|Exercise training|10-month exercise training program during hemodialysis sessions
426032|NCT00944762|Behavioral|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
426033|NCT00944762|Behavioral|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
426034|NCT00944749|Drug|h-ATG (ATGAM )|
426035|NCT00944749|Drug|Cyclosporine (Gengraf )|
426036|NCT00944736|Dietary Supplement|VSL#3|1 packet BID
426037|NCT00944736|Dietary Supplement|Placebo|1 inactive packet BID
426038|NCT00944723|Dietary Supplement|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
426039|NCT00944723|Dietary Supplement|Zinc supplement|Liquid supplement with zinc
426040|NCT00944723|Dietary Supplement|Non-fortified bread|Daily consumption of non-fortified bread
426041|NCT00944723|Dietary Supplement|Placebo supplement|Daily intake of placebo supplement
426042|NCT00944710|Drug|Atropine|Weekend atropine 1%
426043|NCT00944710|Device|Plano lens|plano lens over the sound eye
426044|NCT00944710|Drug|Atropine|Weekend atropine 1%
426045|NCT00944697|Drug|Oxycodone Naloxone|Oxycodone Naloxone tablets
426046|NCT00944697|Drug|Placebo tablets|Placebo Oxycodone Naloxone tablets
426047|NCT00944684|Drug|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
426048|NCT00944684|Drug|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight <65kg) or 1,200mg (body weight equal or >65kg)
426049|NCT00944671|Drug|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
426050|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
426051|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
426052|NCT00944658|Drug|Apremilast|As per protocol
426053|NCT00944658|Drug|Placebo (sugar pill)|As per protocol
426054|NCT00944645|Drug|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
426055|NCT00944645|Drug|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
426056|NCT00944632|Drug|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
426057|NCT00944632|Drug|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
426058|NCT00944619|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
426059|NCT00944619|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
426060|NCT00944606|Dietary Supplement|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
426061|NCT00944606|Other|Placebo candy|candy gum drops
426062|NCT00944593|Dietary Supplement|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
426063|NCT00944593|Dietary Supplement|Normal Saline|200ml Normal Saline 0.9%
426064|NCT00944580|Biological|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
426065|NCT00944554|Drug|Varenicline|Varenicline given twice a day or five weeks.
426066|NCT00944554|Drug|Placebo|Placebo given twice a day or five weeks.
426067|NCT00944541|Drug|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
426068|NCT00944528|Radiation|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
426069|NCT00944515|Drug|placebo|placebo tablet or syrup 3 days/week
426070|NCT00944515|Drug|azithromycin|azithromycin 3 days/week
426071|NCT00944502|Drug|Dexamethasone|"Group A: Vitatonus DEXA injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group B: Vitatonus DEXA tablets:~1 tablet orally every 8 hours for 10 days.~Group C: Dexamethasone Injectable:~1 ampoule intramuscularly every 3 days for 10 days.~Group D: Dexamethasone tablets:~1 tablet orally every 8 hours for 10 days."
426072|NCT00944476|Procedure|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
426073|NCT00944463|Drug|Gemcitabine+simvastatin|Gemcitabine and simvastatin
426074|NCT00944463|Drug|Gemcitabine+Placebo|Gemcitabine plus Placebo
426075|NCT00944450|Drug|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
426076|NCT00944450|Drug|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets [monohydrate Final Market Image (FMI) form] in one of two treatment periods.
426077|NCT00944437|Device|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
426078|NCT00944437|Device|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
426079|NCT00944424|Drug|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
426080|NCT00944424|Drug|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
426082|NCT00944398|Dietary Supplement|Zinc supplement|Liquid supplement containing zinc sulfate
426083|NCT00944398|Other|Placebo supplement|Liquid placebo supplement
426084|NCT00944398|Dietary Supplement|Non-fortified food|Non-fortified complementary food.
426085|NCT00944385|Drug|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
426086|NCT00944372|Drug|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
426087|NCT00944359|Dietary Supplement|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
426088|NCT00944359|Dietary Supplement|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
426089|NCT00944359|Dietary Supplement|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
426090|NCT00944359|Other|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
426091|NCT00944346|Drug|Metformin HCl|
426092|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
426093|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
426094|NCT00944307|Drug|raltegravir|raltegravir 400mg orally once
426095|NCT00944307|Drug|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
426096|NCT00944294|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
426097|NCT00944294|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
426098|NCT00944281|Dietary Supplement|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
426099|NCT00944281|Dietary Supplement|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
426100|NCT00944281|Dietary Supplement|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
426101|NCT00944281|Dietary Supplement|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
426102|NCT00944268|Drug|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
426103|NCT00944242|Drug|Sertraline|
426104|NCT00944242|Drug|Sertraline Hydrochloride|
426105|NCT00944229|Drug|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
426106|NCT00944229|Drug|Placebo|4 capsules of placebo every 24 hours
426107|NCT00944216|Drug|Salkera Emollient Foam|
426108|NCT00944203|Drug|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
426109|NCT00944190|Behavioral|Self-management intervention|Brief counseling technique, self-management,
426110|NCT00944190|Behavioral|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
426111|NCT00944177|Drug|Metformin HCl|
426112|NCT00944164|Behavioral|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
426113|NCT00944164|Behavioral|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
426114|NCT00944151|Procedure|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
426115|NCT00944138|Behavioral|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
426116|NCT00944125|Device|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
426117|NCT00944125|Device|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
426118|NCT00944112|Biological|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
426119|NCT00944112|Biological|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
426120|NCT00944099|Behavioral|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
426121|NCT00944086|Other|Recruitment Manoeuvre|Recruitment Manoeuvre
426122|NCT00944073|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
426123|NCT00944060|Other|lifestyle intervention|
426124|NCT00944047|Drug|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
426125|NCT00944047|Drug|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
426126|NCT00944047|Drug|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
426127|NCT00944047|Drug|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
426128|NCT00944047|Biological|Growth Factor Support|"All patients will receive pegfilgrastim 6.0 mg sc on Day #2 of each doxorubicin/cyclophosphamide neoadjuvant treatment cycle.~Erythropoetic growth factor support for fatigue/anemia will be allowed at the discretion of the treating physician."
426201|NCT00943709|Biological|insulin glargine recombinant|Given subcutaneously
426129|NCT00944047|Procedure|Surgery|"After completion of neoadjuvant therapy, patients will proceed with either modified radical mastectomy or lumpectomy.~All patients with pretreatment lymph node positive disease and positive sentinel lymph node will undergo complete axillary lymph node dissection."
426130|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
426131|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
426132|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
426133|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
426134|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
426135|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
426136|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
426137|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
426138|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
426139|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
426140|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
426141|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
426142|NCT00944021|Drug|PA-824|50mg
426143|NCT00944021|Drug|PA-824|100mg
426144|NCT00944021|Drug|PA-824|150 mg
426145|NCT00944021|Drug|Rifafour e-275 mg|275 mg
426146|NCT00944021|Drug|PA-824|200 mg
426147|NCT00944008|Drug|DepoCyte|
426148|NCT00943995|Drug|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
426149|NCT00943982|Drug|Interferon Gamma 1-b|
426150|NCT00943969|Procedure|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
426151|NCT00943956|Drug|bicalutamide|
426152|NCT00943956|Drug|everolimus|
426153|NCT00943956|Drug|leuprolide acetate|
426154|NCT00943956|Radiation|external beam radiation therapy|
426155|NCT00943943|Drug|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
426156|NCT00943943|Drug|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
426157|NCT00943943|Drug|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).~Dose Level 0 = 400 mg orally twice daily."
426158|NCT00943930|Drug|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
426159|NCT00943917|Other|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
426160|NCT00943917|Drug|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
426161|NCT00943917|Other|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
426162|NCT00943904|Device|Interstim implant for SNS|stimulates third sacral nerve root
426163|NCT00943891|Procedure|Tumor biopsies|
426164|NCT00943878|Biological|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
426165|NCT00943878|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
426166|NCT00943878|Drug|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
426167|NCT00943865|Behavioral|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
426168|NCT00943865|Behavioral|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
426200|NCT00943722|Biological|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
426169|NCT00943865|Behavioral|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
426170|NCT00943865|Behavioral|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
426171|NCT00943865|Behavioral|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
426172|NCT00943852|Drug|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
426173|NCT00943852|Drug|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
426174|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
426175|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
426176|NCT00943852|Drug|Comparator: Placebo|Single dose placebo only in one of five treatment periods
426177|NCT00943839|Drug|sunitinib malate|
426178|NCT00943839|Other|laboratory biomarker analysis|
426179|NCT00943839|Other|pharmacological study|
426180|NCT00943826|Drug|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
426181|NCT00943826|Drug|Temozolomide|75 mg/m^2 once daily for 6 weeks, followed by 150-200 mg/m^2 once daily on days 1-5 of six 4 week cycles.
426182|NCT00943826|Radiation|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
426183|NCT00943826|Drug|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
426184|NCT00943813|Behavioral|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
426185|NCT00943800|Drug|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
426186|NCT00943800|Procedure|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
426187|NCT00943800|Procedure|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
426188|NCT00943800|Drug|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
426189|NCT00943800|Drug|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
426190|NCT00943787|Procedure|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
426191|NCT00943774|Other|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
426192|NCT00943761|Drug|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
426193|NCT00943761|Drug|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
426194|NCT00943761|Drug|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
426195|NCT00943761|Drug|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (<75 kg or ≥75 kg, respectively), for 48 weeks
426196|NCT00943748|Drug|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
426197|NCT00943748|Drug|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
426198|NCT00943735|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
426199|NCT00943735|Behavioral|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
426202|NCT00943709|Drug|therapeutic insulin|Given subcutaneously
426203|NCT00943696|Dietary Supplement|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
426204|NCT00943683|Drug|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
426205|NCT00943683|Drug|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
426206|NCT00943670|Biological|pertuzumab|Intravenous repeating dose
426207|NCT00943670|Biological|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
426208|NCT00943657|Biological|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
426209|NCT00943644|Device|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
426210|NCT00943644|Device|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
426211|NCT00943631|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
426212|NCT00943618|Drug|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
426213|NCT00943618|Drug|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
426214|NCT00943618|Other|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
426215|NCT00943618|Behavioral|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
426216|NCT00943605|Device|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
426217|NCT00943605|Device|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
426218|NCT00943592|Drug|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
426219|NCT00943592|Drug|Melphalan|Doses ranging from 100 to 140 mg/m2
426220|NCT00943592|Drug|Campath|20mg/d x5
426221|NCT00943592|Procedure|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
426222|NCT00943579|Drug|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
426223|NCT00943566|Drug|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
426224|NCT00943566|Drug|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
426225|NCT00943553|Drug|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day)
426226|NCT00943553|Drug|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day only)
426227|NCT00943540|Drug|raltegravir QD|Raltegravir 800mg QD
426228|NCT00943540|Drug|atazanavir|atazanavir
426229|NCT00943540|Drug|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
426230|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
426231|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
426232|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
426233|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
426234|NCT00943488|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
426235|NCT00943475|Procedure|circumcision|circumcision by plastbell
426236|NCT00943462|Radiation|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2‑Gy fractions, for a total of 30 fractions
426237|NCT00943462|Drug|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
426238|NCT00943449|Drug|4SC-201|oral administration
426239|NCT00943449|Drug|Sorafenib|oral administration
426240|NCT00943436|Other|Exercise Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
426241|NCT00943436|Other|Rest Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
426242|NCT00943423|Radiation|Involved Field Radiotherapy|IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
426243|NCT00943423|Other|No further treatment|
426401|NCT00942214|Drug|Natalizumab|300mg, IV, every 4 weeks
426825|NCT00939367|Drug|'Sanofi-Synthelabo Inc's Ambien® Tablets 10 mg|
426244|NCT00943410|Radiation|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
426245|NCT00943410|Drug|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
426246|NCT00943397|Drug|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
426247|NCT00943397|Drug|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
426248|NCT00943384|Device|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
426249|NCT00943371|Drug|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
426250|NCT00943371|Drug|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
426251|NCT00943358|Biological|MF59 H1N1 vaccine|3.75-7.5ug dose
426252|NCT00943358|Biological|Plain H1N1 vaccine|7.5-15ug
426253|NCT00943345|Drug|indometacin|"capsule for oral consumption~at 22h00 evening before test day: 75 mg~at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms)."
426254|NCT00943332|Procedure|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
426255|NCT00943319|Drug|Busulfan|Daily intravenous dosing to target AVC
426256|NCT00943319|Drug|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
426257|NCT00943319|Drug|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
426258|NCT00943319|Procedure|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
426259|NCT00943306|Drug|lomitapide|5-60 mg po every day
426260|NCT00943293|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
426261|NCT00943293|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
426262|NCT00943293|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
426263|NCT00943267|Drug|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
426264|NCT00943267|Drug|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
426265|NCT00943267|Drug|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
426266|NCT00943267|Procedure|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
426267|NCT00943267|Procedure|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
426268|NCT00943254|Other|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
426269|NCT00943254|Other|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
426270|NCT00943228|Drug|mycophenolate mofetil|High dose 4gms daily
426271|NCT00943202|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
426272|NCT00943202|Biological|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - <36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
426273|NCT00943176|Drug|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
426274|NCT00943150|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
426275|NCT00943150|Procedure|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
426276|NCT00943137|Drug|5-Fluorouracil|"Chemotherapy will be one of the following:~de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.~Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
426277|NCT00943124|Drug|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
426278|NCT00943124|Drug|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
426279|NCT00943124|Drug|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
426499|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
426280|NCT00943111|Drug|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (<) 5 nanogram per milliliter [ng/mL] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.~Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
426281|NCT00943111|Drug|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.~LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was <5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was >=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
426282|NCT00943098|Drug|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
426283|NCT00943098|Drug|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
426284|NCT00943085|Behavioral|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
426285|NCT00943085|Behavioral|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
426286|NCT00943072|Biological|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
426287|NCT00943072|Drug|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
426288|NCT00943059|Drug|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
426289|NCT00943059|Drug|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
426290|NCT00943046|Device|Pacemaker therapy|Implantation of the SIELLO pacemaker leads
426291|NCT00943033|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
426292|NCT00943020|Dietary Supplement|Nutricia PreOp nutritional supplement|nutritional supplement
426293|NCT00943020|Dietary Supplement|Lipid|Drink
426294|NCT00943020|Dietary Supplement|Glutamine|Drink
426295|NCT00943007|Device|Stealth Station|Neuronavigation based on preoperative MRI
426296|NCT00943007|Device|PoleStar N20|Intraoperative MRI guided surgery
426297|NCT00942994|Drug|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)~Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
426298|NCT00942994|Drug|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)~HCTZ capsule (12.5 mg, 25mg)"
426299|NCT00942968|Drug|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
426300|NCT00942903|Device|Provox Xtra HME|Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
426301|NCT00942890|Device|NMES (EMPI 300PV stimulator) plus standard of care|In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
426302|NCT00942890|Behavioral|TMARP standard of care|The usual care is 12 weeks of the Traditional Military Amputee Rehabilitation Program (TMARP). TMARP training starts 1week after surgical closure of the residual limb. Physical Therapy performs Pre-Prosthetic Training for about 6 weeks, preparing for the prosthetic. After pre-prosthetic training, patients are fitted with their prosthetic leg and began post-prosthetic training with PT. The training focus is lower limb prosthetic proficient in ambulation.
426303|NCT00942877|Drug|AZD2171|Cediranib (AZD2171), a VEGF/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with ASPS.
426304|NCT00942864|Drug|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
426305|NCT00942851|Drug|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
426306|NCT00942851|Drug|placebo|topical treatment NOT containing AH-8
426307|NCT00942838|Drug|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
426402|NCT00942201|Drug|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
426447|NCT00941863|Drug|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
426308|NCT00942838|Radiation|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
426309|NCT00942825|Drug|CBP501 + Cisplatin + Pemetrexed|"CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.~Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.~Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
426310|NCT00942825|Drug|Cisplatin + Pemetrexed|"Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).~Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.~Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
426311|NCT00942812|Other|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
426312|NCT00942812|Other|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
426313|NCT00942799|Drug|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
426314|NCT00942799|Drug|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
426315|NCT00942773|Drug|Voriconazole|
426316|NCT00942760|Device|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
426317|NCT00942747|Drug|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
426318|NCT00942734|Drug|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
426319|NCT00942734|Drug|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
426320|NCT00942721|Behavioral|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
426321|NCT00942708|Drug|Fluoxetine|"Total dose How to take:~Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
426322|NCT00942695|Other|1.5PD|average American diet plus 1.5 oz per day pistachios
426323|NCT00942695|Other|3.0PD|average American diet plus 3.0 oz per day pistachios
426324|NCT00942695|Other|control|average American diet without pistachios
426325|NCT00942682|Drug|Sorafenib|Taken orally twice daily
426326|NCT00942682|Drug|RAD001|Taken orally once daily in the morning
426327|NCT00942669|Device|SleepStrip OTC(TM)|self contained SAS screening device
426328|NCT00942656|Other|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
426329|NCT00942656|Other|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
426330|NCT00942656|Other|VA|base diet plus 3.0% energy added from vaccenic acid
426331|NCT00942656|Other|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
426332|NCT00942643|Device|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
426333|NCT00942617|Drug|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
426334|NCT00942604|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
426335|NCT00942604|Drug|Vehicle gel|two day treatment
426336|NCT00942591|Drug|Interferon beta 1b|
426337|NCT00942591|Drug|Atorvastatin|
426338|NCT00942578|Drug|Bevacizumab|15 mg/kg cycle 1 day 1, repeated every 21 days
426339|NCT00942578|Drug|Lenalidomide|Once daily days 1-14 of every 21
426340|NCT00942578|Drug|Docetaxel|75 mg/m^2 intravenous (IV) over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
426341|NCT00942578|Drug|Prednisone|10 mg orally every day
426342|NCT00942565|Drug|tramadol/acetaminophen|
426343|NCT00942565|Drug|acetaminophen|
426344|NCT00942539|Drug|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
426345|NCT00942526|Drug|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
426346|NCT00942526|Other|Water|perioperative gargling with water
426347|NCT00942513|Other|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
426348|NCT00942513|Other|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
426349|NCT00942513|Other|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
426350|NCT00942513|Other|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
426351|NCT00942513|Other|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
426352|NCT00942513|Other|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
426353|NCT00942513|Other|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
426354|NCT00942500|Procedure|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade <2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
426355|NCT00942487|Drug|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
426356|NCT00942487|Drug|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
426357|NCT00942474|Device|Facilitate nerve stimulation lead placement with the nerve access tool|
426358|NCT00942461|Procedure|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
426359|NCT00942461|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
426360|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
426361|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
426362|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
426363|NCT00942448|Other|Placebo s.c.|1 single injection at day of dental surgical extraction
426364|NCT00942435|Drug|YM150|oral
426365|NCT00942435|Procedure|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
426366|NCT00942422|Dietary Supplement|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
426367|NCT00942422|Genetic|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
426368|NCT00942422|Genetic|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
426369|NCT00942422|Other|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
426370|NCT00942409|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
426371|NCT00942396|Device|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
426372|NCT00942370|Device|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:~EMG and MMG Signals of rectus abdominis of the abdomen,~Respiratory flow,~An electrocardiogram (ECG).~These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
426373|NCT00942357|Drug|Carboplatin|Given IV
426374|NCT00942357|Drug|Cisplatin|Given IV
426375|NCT00942357|Radiation|Internal Radiation Therapy|Undergo brachytherapy
426376|NCT00942357|Drug|Paclitaxel|Given IV
426377|NCT00942357|Other|Quality-of-Life Assessment|Ancillary studies
426378|NCT00942357|Radiation|Radiation Therapy|Undergo radiation therapy
426379|NCT00942344|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
426380|NCT00942344|Drug|Amlodipine|amlodipine 5mg, 10mg
426381|NCT00942344|Drug|Losartan|Losartan 50mg, 100mg
426382|NCT00942331|Biological|Bevacizumab|Given IV
426383|NCT00942331|Drug|Cisplatin|Given IV
426384|NCT00942331|Drug|Gemcitabine Hydrochloride|Given IV
426385|NCT00942331|Other|Laboratory Biomarker Analysis|Correlative studies
426386|NCT00942331|Other|Placebo|Given IV
426387|NCT00942318|Drug|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
426388|NCT00942305|Drug|CMX001|CMX001 200mg twice weekly for a total of up to 18 doses.
426389|NCT00942305|Drug|Placebo|Placebo tablets once weekly for a total of up to 11 doses.
426390|NCT00942292|Dietary Supplement|Lipidem- fish oil emulsion BBraun UK|
426391|NCT00942292|Procedure|Digital Contrast MRI scan|
426392|NCT00942266|Drug|fluorouracil|Given IV
426393|NCT00942266|Drug|leucovorin calcium|Given IV
426394|NCT00942266|Drug|vorinostat|Given orally
426395|NCT00942266|Other|pharmacological study|Correlative study
426396|NCT00942253|Other|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
426397|NCT00942240|Drug|ACU-4429|administered orally once a day for 14 days
426398|NCT00942240|Drug|matching placebo tablet|administered orally once a day for 14 days
426399|NCT00942227|Other|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
426400|NCT00942227|Other|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
426403|NCT00942201|Drug|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
426404|NCT00942188|Drug|LY2189102|Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.
426405|NCT00942188|Drug|Placebo|Participants received 2 SC injections weekly for 12 weeks.
426406|NCT00942175|Drug|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
426407|NCT00942175|Drug|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
426408|NCT00942175|Drug|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
426409|NCT00942175|Drug|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
426410|NCT00942175|Drug|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
426411|NCT00942162|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
426412|NCT00942149|Drug|Daptomycin|single dose of 6 mg/kg of daptomycin
426413|NCT00942136|Drug|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
426414|NCT00942136|Drug|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
426415|NCT00942136|Drug|Placebo|Placebo Suspension as a single dose.
426416|NCT00942136|Drug|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
426417|NCT00942110|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
426418|NCT00942097|Drug|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
426419|NCT00942097|Drug|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
426420|NCT00942084|Drug|Acyclovir|"Protocol V2 & up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).~Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."
426421|NCT00942071|Biological|MVA-NP+M1|1. Intradermal injection at 5 x 10^7 pfu at day 0
426422|NCT00942071|Biological|MVA-NP+M1|2.Intramuscular injection at 5 x 10^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10^8 pfu/ml at day 0
426423|NCT00942071|Biological|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
426424|NCT00942058|Other|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
426425|NCT00942045|Biological|Biologic - Osteocel Plus|Osteocel Plus
426426|NCT00942006|Drug|doxycycline|100 mg bid, 14 days
426427|NCT00942006|Drug|ceftriaxone|2g x 1 iv, 14 days
426428|NCT00941993|Device|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
426429|NCT00941980|Biological|Osteocel Plus|biologic
426430|NCT00941967|Drug|gemcitabine hydrochloride|Given IV
426431|NCT00941967|Drug|oxaliplatin|Given IV
426432|NCT00941967|Drug|sorafenib tosylate|Given orally.
426433|NCT00941954|Behavioral|Structured Education|The intervention group will be offered a group−based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self−efficacy, barriers to physical activity and self−regulatory skills based on pedometer use. The programme will employ a person−centred approach to patient education that is based on self−management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5−10 participants by two trained educators and is 3.5 hours long. Brief follow−up counselling will be offered once every 6 months.
426434|NCT00941954|Behavioral|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
426435|NCT00941941|Procedure|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
426436|NCT00941941|Procedure|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
426437|NCT00941928|Drug|Epratuzumab|360 mg/m^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
426438|NCT00941928|Drug|Fludarabine|25 mg/m^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
426439|NCT00941928|Drug|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
426440|NCT00941928|Drug|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
426441|NCT00941928|Procedure|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
426442|NCT00941928|Drug|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
426443|NCT00941915|Radiation|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
426444|NCT00941889|Drug|Saline|0.5 ml
426445|NCT00941889|Drug|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
426446|NCT00941876|Behavioral|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
426448|NCT00941863|Drug|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
426449|NCT00941863|Drug|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
426450|NCT00941863|Drug|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
426451|NCT00941863|Drug|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
426452|NCT00941850|Procedure|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
426453|NCT00941837|Dietary Supplement|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
426454|NCT00941824|Drug|mycophénolate acid|"Day 0 to Day 7, 720 mg twice daily~Day 8 to Day 30, 540 mg twice daily~Day 30 to Day 90, 360 mg twice daily"
426455|NCT00941811|Drug|Imiquimod|Local Imiquimod three times weekly for 16 weeks
426456|NCT00941798|Drug|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
426457|NCT00941798|Drug|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
426458|NCT00941785|Drug|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
426459|NCT00941785|Drug|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
426460|NCT00941772|Other|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
426461|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426462|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426463|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426464|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426465|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426466|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426467|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426468|NCT00941746|Biological|PG110|Single, slow intravenous infusion
426469|NCT00941746|Biological|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
426470|NCT00941733|Device|IN.PACT Amphirion|Balloon Angioplasty
426471|NCT00941733|Device|Standard PTA|Balloon Angioplasty
426472|NCT00941720|Drug|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
426473|NCT00941720|Drug|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
426474|NCT00941720|Procedure|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
426475|NCT00941707|Drug|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
426476|NCT00941707|Drug|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
426477|NCT00941694|Behavioral|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
426478|NCT00941694|Behavioral|placebo group|3 phone calls not related to asthma self-management
426479|NCT00941681|Drug|CK-1827452|50 mg MR CK-1827452 BID for 10 days
426480|NCT00941681|Drug|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
426481|NCT00941681|Drug|CK-1827452|100 mg MR CK-1827452 BID for 10 days
426482|NCT00941668|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
426483|NCT00941668|Drug|sodium monofluorophosphate toothpaste|Twice daily usage
426484|NCT00941655|Drug|Oxaliplatin|"Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.~Systemic chemotherapy - Oxaliplatin 85 mg/m^2 over 120 minutes,"
426485|NCT00941655|Drug|Irinotecan|Irinotecan 165 mg/m^2 IV over 90 minutes
426486|NCT00941655|Drug|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes.~systemic chemotherapy -3200 mg/m^2 continuous intravenous over 48 hours."
426487|NCT00941655|Drug|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m^2 intravenous over 5 minutes.~systemic chemotherapy - 200 mg/m^2 intravenous over 120 minutes."
426488|NCT00941655|Procedure|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.~Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
426489|NCT00941642|Drug|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
426490|NCT00941642|Drug|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
426491|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
426492|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
426493|NCT00941616|Biological|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
426494|NCT00941616|Biological|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
426495|NCT00941603|Drug|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
426496|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
426497|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
426498|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
426500|NCT00941603|Drug|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
426501|NCT00941577|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
426502|NCT00941577|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
426503|NCT00941564|Other|Infant Formula milk based|Consume ad lib
426504|NCT00941564|Other|Infant formula milk based|consume ad lib
426505|NCT00941551|Drug|levothyroxine|levothyroxine 75-125 ug/day
426506|NCT00941551|Drug|no levothyroxine|observation only without prophylactic levothyroxine
426507|NCT00941525|Drug|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
426508|NCT00941499|Drug|HAI Oxaliplatin|140 mg/m^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
426509|NCT00941499|Drug|5-FU|900-1750 mg/m^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
426510|NCT00941499|Drug|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
426511|NCT00941499|Drug|Cetuximab|Loading dose of 250-500mg/m^2 and Maintenance dose of 125-250 mg/m^2 by vein on Day 1 of 21 day cycle.
426512|NCT00941499|Drug|Leucovorin|200 mg/m^2 by vein on Days 1 and 2 of each 21 day cycle.
426513|NCT00941499|Drug|5-FU|300-400 mg/m^2 bolus + 600-1000 mg/m^2 infusion over 22 hours on Days 1-2 of each cycle.
426514|NCT00941499|Drug|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
426515|NCT00941486|Drug|FST-100 (0.1% dexamethasone) Ophthalmic Suspension|A regimen of 2 drops 4 times a day while awake for 5 days.
426516|NCT00941486|Drug|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
426517|NCT00941473|Drug|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
426518|NCT00941460|Drug|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
426519|NCT00941460|Drug|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
426520|NCT00941447|Behavioral|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
426521|NCT00941447|Behavioral|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
426522|NCT00941447|Behavioral|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
426523|NCT00941434|Dietary Supplement|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
426524|NCT00941421|Device|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
426525|NCT00941408|Procedure|Diagnostic tumor core biopsy|
426526|NCT00941395|Other|Survey Administration|Complete surveys
426527|NCT00941382|Drug|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
426528|NCT00941382|Drug|Sibutramine|15 mg per day for 180 days
426529|NCT00941382|Drug|Metformin|Metformin 850 mg per day for 180 days
426530|NCT00941369|Drug|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."
426531|NCT00941356|Dietary Supplement|Bio-K+ CL1285|2 capsules per day before breakfast
426532|NCT00941356|Dietary Supplement|Placebo|2 capsules per day before breakfast
426533|NCT00941343|Drug|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
426534|NCT00941330|Drug|Exemestane|25 mg daily by mouth for 6 to 12 months.
426535|NCT00941330|Drug|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
426536|NCT00941330|Drug|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
426537|NCT00941317|Device|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
426538|NCT00941304|Drug|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
426539|NCT00941304|Drug|Buprenorphine|Single-dose of buprenorphine HCl buccal film
426540|NCT00941304|Drug|Placebo Film|Single-dose of placebo buccal film
426541|NCT00941304|Drug|Placebo Capsule|Single-dose of oral placebo capsule
426542|NCT00941278|Drug|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
426543|NCT00941265|Drug|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
426544|NCT00941265|Drug|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
426545|NCT00941252|Drug|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
426546|NCT00941239|Drug|metformin ER|850mg daily for 30 days
426547|NCT00941239|Drug|metformin|850 mg daily for 30 days
427313|NCT00935805|Drug|Propranolol|40 mg BID
426548|NCT00941213|Device|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
426549|NCT00941213|Device|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
426550|NCT00941200|Biological|Blood collection|
426551|NCT00941187|Other|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
426552|NCT00941174|Drug|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
426553|NCT00941161|Drug|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
426554|NCT00941161|Drug|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
426555|NCT00941161|Drug|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
426556|NCT00941148|Drug|Insulin Glargin|
426557|NCT00941148|Drug|NPH insulin|
426558|NCT00941148|Drug|Insulin detemir|
426559|NCT00941148|Drug|metformin|metformin (2000 mg/day)
426560|NCT00941135|Other|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks~Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
426561|NCT00941122|Device|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
426562|NCT00941109|Drug|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
426563|NCT00941109|Drug|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
426564|NCT00941109|Drug|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
426565|NCT00941109|Drug|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
426566|NCT00941096|Drug|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
426567|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
426568|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
426569|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
426570|NCT00941070|Drug|triapine|Given IV
426571|NCT00941070|Drug|cisplatin|Given IV
426572|NCT00941070|Radiation|external beam radiation therapy|Undergo pelvic external beam radiation therapy
426573|NCT00941070|Procedure|quality-of-life assessment|Ancillary studies
426574|NCT00941070|Other|questionnaire administration|Ancillary studies
426575|NCT00941070|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
426576|NCT00941070|Procedure|positron emission tomography|Undergo FDG-PET/CT
426577|NCT00941070|Procedure|computed tomography|Undergo FDG-PET/CT
426578|NCT00941057|Drug|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
426579|NCT00941057|Drug|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
426580|NCT00941057|Drug|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
426581|NCT00941044|Device|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
426582|NCT00941031|Drug|AIN457|
426583|NCT00941031|Drug|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
426584|NCT00941031|Drug|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
426585|NCT00941031|Drug|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
426586|NCT00941018|Drug|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
426587|NCT00941005|Device|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
426588|NCT00940992|Drug|DER 45 EV|Topical application to face for 12 weeks
426589|NCT00940992|Drug|Vehicle|Topical application to face for 12 weeks
426590|NCT00940979|Procedure|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
426591|NCT00940966|Dietary Supplement|standard ADA diet|standard ADA diet
426592|NCT00940966|Dietary Supplement|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
426593|NCT00940966|Dietary Supplement|low glycemic diet|restricted ketogenic diet
426594|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
426595|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
426596|NCT00940953|Drug|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
426597|NCT00940940|Biological|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
426598|NCT00940940|Biological|Placebo vaccine|0.65 mL subcutaneous
426599|NCT00940927|Drug|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
426600|NCT00940914|Drug|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
426601|NCT00940901|Drug|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
426602|NCT00940901|Other|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
426603|NCT00940888|Device|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
426604|NCT00940875|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
426605|NCT00940875|Drug|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
426606|NCT00940875|Drug|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
426607|NCT00940862|Biological|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
426608|NCT00940862|Device|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
426609|NCT00940862|Other|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:~Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
426610|NCT00940849|Dietary Supplement|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
426611|NCT00940849|Dietary Supplement|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
426612|NCT00940836|Drug|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
426613|NCT00940836|Drug|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
426614|NCT00940836|Drug|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
426615|NCT00940823|Device|Ahmed FP7 Valve|Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
426616|NCT00940823|Device|Baerveldt-350 Tube|Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
426617|NCT00940810|Procedure|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.~Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
426618|NCT00940810|Procedure|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.~Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
426619|NCT00940797|Drug|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
426620|NCT00940797|Drug|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
426621|NCT00940784|Drug|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
426622|NCT00940784|Drug|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
426623|NCT00940784|Drug|Aspirin|81-100 mg qd
426624|NCT00940771|Drug|Boosted Atazanavir|Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.
426625|NCT00940758|Drug|PEP02|Dose escalation: 50-100 mg/m2 biweekly
426626|NCT00940745|Device|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
426627|NCT00940745|Drug|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
426628|NCT00940732|Other|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
426629|NCT00940732|Other|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
426630|NCT00940732|Other|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
426631|NCT00940719|Dietary Supplement|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
426632|NCT00940706|Device|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes~TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
426685|NCT00940394|Behavioral|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
426686|NCT00940394|Other|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
426633|NCT00940706|Other|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.~Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
426634|NCT00940706|Behavioral|Monitoring physical activity|Activity monitoring with accelerometers
426635|NCT00940693|Drug|duloxetine|60 mg capsule once per day for 6 weeks
426636|NCT00940693|Drug|placebo|one capsule of placebo taken one a day for 6 weeks
426637|NCT00940680|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
426638|NCT00940680|Drug|Losartan|losartan 100mg q.d.
426639|NCT00940667|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
426640|NCT00940667|Drug|Amlodipine|amlodipine 5mg q.d.
426641|NCT00940654|Other|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
426642|NCT00940641|Drug|AZD7325|IV Dose
426643|NCT00940641|Drug|AZD7325|oral dose
426644|NCT00940628|Behavioral|Diet and Exercise|mildly hypocaloric diet and physical exercise
426645|NCT00940628|Drug|orlistat [Xenical]|120mg po tid
426646|NCT00940615|Other|aerobic exercise|, participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
426647|NCT00940615|Other|stretching/toning|Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
426648|NCT00940602|Drug|Deferasirox|Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
426649|NCT00940602|Drug|Placebo|Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
426650|NCT00940589|Drug|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
426651|NCT00940589|Drug|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
426652|NCT00940576|Dietary Supplement|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
426653|NCT00940576|Other|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
426654|NCT00940563|Drug|Imatinib|
426655|NCT00940550|Drug|Prolonged-release melatonin|2 mg tablet, once.
426656|NCT00940550|Drug|Temazepam|20 mg capsule, once
426657|NCT00940550|Drug|Zolpidem|10 mg capsule, once
426658|NCT00940550|Drug|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
426659|NCT00940524|Drug|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) *continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) *continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
426660|NCT00940511|Behavioral|Coordinated care|
426661|NCT00940498|Drug|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
426662|NCT00940485|Drug|entecavir|0.5mg po daily for 8 weeks
426663|NCT00940485|Drug|entecavir|0.5mg po daily for 48 weeks
426664|NCT00940485|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
426665|NCT00940472|Drug|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
426666|NCT00940472|Drug|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
426667|NCT00940459|Device|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
426668|NCT00940459|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
426669|NCT00940459|Device|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
426670|NCT00940459|Device|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
426671|NCT00940459|Device|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
426672|NCT00940459|Device|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
426673|NCT00940446|Device|Insorb staples|absorbable staples required for wound closure
426674|NCT00940446|Device|metal staples (Ethicon metal stapler)|wound closure with metal staples
426675|NCT00940433|Procedure|open properitoneal hernia repair|suprapubic retro-inguinal approach
426676|NCT00940433|Procedure|Lechtestien hernia repair|onlay mesh repair
426677|NCT00940433|Procedure|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
426678|NCT00940433|Procedure|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
426679|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
426680|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
426681|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
426682|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
426683|NCT00940407|Device|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
426684|NCT00940394|Behavioral|mutual support group|bi-weekly, 12-session, family-led mutual support group
426687|NCT00940381|Drug|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
426688|NCT00940381|Drug|Cetuximab|Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
426689|NCT00940368|Dietary Supplement|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.~For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.~For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
426690|NCT00940355|Behavioral|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
426691|NCT00940342|Drug|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
426692|NCT00940342|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly for four weeks
426693|NCT00940329|Drug|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
426694|NCT00940329|Drug|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
426695|NCT00940316|Biological|panitumumab|Given intravenously 6mg/kg every 2 weeks
426696|NCT00940316|Drug|erlotinib hydrochloride|Given orally 150mg daily
426697|NCT00940316|Drug|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
426698|NCT00940303|Drug|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
426699|NCT00940303|Drug|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
426700|NCT00940303|Drug|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
426701|NCT00940303|Drug|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
426702|NCT00940303|Drug|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
426703|NCT00940290|Other|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
426704|NCT00940277|Behavioral|Group Counseling|Group counseling
426705|NCT00940264|Procedure|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
426706|NCT00940251|Drug|Mersina|capsule, 3g/day, 3 months
426707|NCT00940238|Drug|Citalopram Hydrobromide|
426708|NCT00940225|Drug|XL184|All subjects receive 100 mg XL184 (supplied at 19.7-, 50-, and 60-mg strength capsules) daily for 12 weeks. Subjects with a partial or complete response will continue daily XL184 administration until disease progression. Subjects with stable disease will be randomized to Arm 2 or 3.
426709|NCT00940225|Drug|Placebo|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 3 will receive capsules of placebo that are size- and color-matched to XL184 administered daily until disease progression. Subjects will be unblinded at disease progression and, if found to be receiving placebo, given the option to receive XL184.
426710|NCT00940225|Drug|XL184|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 2 will continue to receive XL184 (blinded) administered daily until disease progression.
426711|NCT00940225|Drug|XL184|All subjects receive open-label, 100 mg XL184 (supplied at 19.7-, 50-, and 60 mg strength capsules) daily until disease progression.
426712|NCT00940212|Drug|AZD2423|oral, single administration
426713|NCT00940212|Drug|Placebo|oral administration and single dose
426714|NCT00940173|Device|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
426715|NCT00940173|Device|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
426716|NCT00940173|Device|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
426717|NCT00940173|Device|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
426718|NCT00940160|Drug|QAX576|
426719|NCT00940160|Drug|QAX576|
426720|NCT00940160|Drug|QAX576|
426721|NCT00940160|Drug|Placebo|
426722|NCT00940134|Biological|PYY 3-36|0.8 pmol/kg/min x 3 hours
426723|NCT00940134|Biological|GLP-1|1.0 pmol/kg/min x 3 hours
426724|NCT00940134|Biological|saline infusion|saline infusion x 3 hours
426725|NCT00940121|Drug|mirabegron|oral tablet
426726|NCT00940121|Drug|mirabegron|IV solution
426727|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
426728|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
426729|NCT00940095|Drug|Clazosentan 5 m/h|Continuous intravenous infusion of clazosentan (5 mg/h)
426730|NCT00940095|Drug|Clazosentan 15 mg/h|Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)
426731|NCT00940095|Drug|Placebo|Continuous intravenous infusion of placebo-matching clazosentan
426732|NCT00940069|Drug|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.~'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
426733|NCT00940056|Procedure|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
426734|NCT00940056|Drug|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
426823|NCT00939380|Other|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
426735|NCT00940030|Other|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
426736|NCT00940030|Other|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
426737|NCT00940017|Drug|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
426738|NCT00940004|Biological|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
426739|NCT00939991|Drug|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
426740|NCT00939978|Drug|rhEPO|recombinant human erythropoietin(rhEPO)
426741|NCT00939965|Drug|isotretinoin|
426742|NCT00939965|Genetic|DNA analysis|
426743|NCT00939965|Genetic|polymerase chain reaction|
426744|NCT00939965|Other|laboratory biomarker analysis|
426745|NCT00939965|Other|pharmacological study|
426746|NCT00939952|Drug|ertapenem|500 mg IV once
426747|NCT00939939|Drug|sitagliptin|sitagliptin 100 mg/d for 10 weeks
426748|NCT00939939|Drug|glimepiride|glimepiride 1 mg/d for 10 weeks
426749|NCT00939926|Drug|Risperidone|
426750|NCT00939913|Drug|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
426751|NCT00939913|Drug|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
426752|NCT00939900|Drug|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
426753|NCT00939887|Drug|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
426754|NCT00939874|Drug|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
426755|NCT00939861|Procedure|laparoscopy|colorectal resection
426756|NCT00939861|Procedure|laparotomy|colorectal resection
426757|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
426758|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
426759|NCT00939848|Drug|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
426760|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
426761|NCT00939848|Drug|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
426762|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
426763|NCT00939835|Drug|Citalopram Hydrobromide|
426764|NCT00939822|Drug|Simvastatin|40 mg Simvastatin/day
426765|NCT00939822|Drug|Placebo|Matching Placebo
426766|NCT00939809|Biological|Urokinase-Derived Peptide A6|Given SC
426767|NCT00939809|Other|Laboratory Biomarker Analysis|Correlative studies
426768|NCT00939796|Device|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
426769|NCT00939783|Drug|Dimebon|Tablet for oral administration
426770|NCT00939770|Drug|Crizotinib|Given PO
426771|NCT00939770|Other|Laboratory Biomarker Analysis|Correlative studies
426772|NCT00939770|Other|Pharmacological Study|Correlative studies
426773|NCT00939770|Other|Questionnaire Administration|Ancillary studies
426774|NCT00939757|Drug|mirabegron|oral tablet
426775|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
426776|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
426777|NCT00939718|Dietary Supplement|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
426778|NCT00939705|Drug|topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
426779|NCT00939692|Drug|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
426822|NCT00939380|Other|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
426824|NCT00939367|Drug|Zolpidem Tartrate Tablets 10 mg|
426780|NCT00939679|Procedure|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
426781|NCT00939679|Dietary Supplement|low calorie diet (1,000 kcal/day)|"Patients will consume a daily diet composed of:~4 powder diet portions (Cambridge Diets, UK)~plain yogurt (100-125g)~skim milk (1L)~a limited variety of vegetables~The diet will be consumed by both groups for a 10 week period."
426782|NCT00939666|Procedure|Wait&see or TEM with intensive follow-up|Wait&see or TEM with intensive follow-up
426783|NCT00939653|Drug|clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
426784|NCT00939653|Drug|etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
426785|NCT00939653|Drug|cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
426786|NCT00939653|Drug|filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000 x 2 days.
426787|NCT00939653|Drug|cytarabine|Given intrathecally on day 1 at the dose defined by age below. 30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients >3 years of age
426788|NCT00939640|Behavioral|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
426789|NCT00939627|Biological|cetuximab|Given IV
426790|NCT00939627|Other|placebo|Given orally
426791|NCT00939627|Drug|sorafenib tosylate|Given orally
426792|NCT00939627|Other|laboratory biomarker analysis|Correlative studies
426793|NCT00939627|Procedure|quality-of-life assessment|Ancillary studies
426794|NCT00939614|Drug|Lamotrigine|
426795|NCT00939601|Behavioral|Motivational Enhancement Therapy|
426796|NCT00939601|Behavioral|Educational Counseling|
426797|NCT00939588|Drug|Aliskiren/ Valsartan|
426798|NCT00939588|Drug|Telmisartan/ Ramipril|
426799|NCT00939562|Drug|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
426800|NCT00939562|Drug|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
426801|NCT00939549|Drug|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
426802|NCT00939536|Drug|Zolpidem Tartrate Tablets 10 mg|
426803|NCT00939523|Drug|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
426804|NCT00939510|Biological|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
426805|NCT00939510|Drug|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
426806|NCT00939510|Other|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
426807|NCT00939497|Drug|Risperidone|
426808|NCT00939484|Other|Pharmacological Study|Correlative studies
426809|NCT00939484|Drug|Vismodegib|Given PO
426810|NCT00939471|Device|Relieva™ Balloon Sinuplasty™ System|Balloon dilation will be performed using endoscopic equipment with video documentation capability.
426811|NCT00939458|Drug|Lamotrigine|
426812|NCT00939445|Procedure|Online HDF|Online HDF
426813|NCT00939445|Procedure|Short Daily Hemodialysis|Short Daily Hemodialysis
426814|NCT00939419|Other|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
426815|NCT00939419|Other|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
426816|NCT00939419|Other|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
426817|NCT00939406|Device|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
426818|NCT00939393|Device|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
426819|NCT00939393|Device|Balloon Sinuplasty|Balloon dilatation of sinuses
426820|NCT00939380|Behavioral|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
426821|NCT00939380|Other|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
426826|NCT00939341|Drug|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
426827|NCT00939328|Biological|rituximab|
426828|NCT00939328|Drug|bendamustine hydrochloride|
426829|NCT00939289|Device|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
426830|NCT00939276|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
426831|NCT00939276|Drug|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
426832|NCT00939263|Other|assessment of disease activity using the EEsAI|disease activity index
426833|NCT00939250|Behavioral|Diabetes and depression intervention|Disease self management for diabetes and depression
426834|NCT00939250|Behavioral|Diabetes intervention|Disease self management for diabetes
426835|NCT00939237|Drug|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
426836|NCT00939237|Drug|Placebo|
426837|NCT00939224|Device|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
426838|NCT00939211|Drug|AZD9164|Solution for inhalation through nebulization, single dose
426839|NCT00939211|Drug|Tiotropium|Dry powder for inhalation, single dose
426840|NCT00939211|Drug|Placebo|Placebo
426841|NCT00939198|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
426842|NCT00939185|Drug|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
426843|NCT00939172|Drug|TTP607|3.3 mg/m^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
426844|NCT00939159|Drug|LBH589|20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
426845|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
426846|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
426847|NCT00939133|Drug|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
426848|NCT00939133|Drug|vehicle gel|Placebo
426849|NCT00939120|Drug|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
426850|NCT00939120|Drug|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
426851|NCT00939120|Drug|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
426852|NCT00939107|Procedure|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
426853|NCT00939107|Procedure|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
426854|NCT00939094|Drug|AZD2066|Capsule, once daily
426855|NCT00939094|Drug|Placebo|Capsule, once daily
426856|NCT00939081|Behavioral|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
426857|NCT00939081|Behavioral|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
426858|NCT00939068|Drug|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
426859|NCT00939068|Biological|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
426860|NCT00939055|Device|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
426861|NCT00939055|Procedure|Sham procedure|False procedure
426862|NCT00939042|Procedure|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
426863|NCT00939042|Procedure|BMNC therapy|Injection of BMNC after common PCI
426864|NCT00939029|Drug|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
426865|NCT00939029|Drug|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
426866|NCT00939016|Other|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
426867|NCT00939003|Biological|Adalimumab|40 mg every other week up to Week 12
426868|NCT00939003|Biological|Placebo|Placebo every other week up to Week 12
426869|NCT00939003|Biological|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
426870|NCT00938990|Drug|Etomidate|
426871|NCT00938990|Drug|Midazolam|
426872|NCT00938977|Device|CPAP|Before and after effect of treatment with CPAP
426873|NCT00938977|Device|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
426874|NCT00938964|Drug|Lidocaine|Lidocaine versus placebo infusion for 48 hours
426875|NCT00938964|Drug|Placebo|Lidocaine versus placebo infusion for 48 hours
426876|NCT00938951|Other|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
426877|NCT00938938|Other|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
426878|NCT00938925|Procedure|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
426879|NCT00938925|Procedure|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
426880|NCT00938912|Drug|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
426881|NCT00938912|Drug|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).~The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
426882|NCT00938899|Drug|TMC435350; Placebo|
426883|NCT00938886|Drug|Naltrexone|Daily 50 mg naltrexone
426884|NCT00938886|Drug|Placebo|Matched naltrexone placebo
426885|NCT00938873|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
426886|NCT00938860|Drug|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
426887|NCT00938860|Drug|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
426888|NCT00938847|Device|PCI|Stent implantation after acute myocardial infarction
426889|NCT00938834|Other|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
426890|NCT00938821|Procedure|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
426891|NCT00938808|Dietary Supplement|day formula diet|The Cambridge Programme. Formula diet
426892|NCT00938795|Other|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
426893|NCT00938795|Other|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
426894|NCT00938782|Device|Sedline|
426895|NCT00938769|Other|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.~2-hour in-person instruction of home care issues for caregivers of patients with cancer."
426896|NCT00938769|Other|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources"
426897|NCT00938756|Other|diagnostic laboratory biomarker analysis|
426898|NCT00938756|Other|immunoenzyme technique|
426899|NCT00938756|Procedure|magnetic resonance imaging|
426900|NCT00938743|Drug|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
426901|NCT00938730|Drug|YM150|oral
426902|NCT00938730|Drug|Warfarin|oral
426903|NCT00938717|Drug|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
426904|NCT00938704|Drug|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
426905|NCT00938704|Drug|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
426906|NCT00938691|Procedure|Intradermal Suture|
426907|NCT00938691|Procedure|Intradermal Suture|
426908|NCT00938678|Drug|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
426909|NCT00938678|Drug|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
426910|NCT00938665|Device|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
426911|NCT00938652|Drug|gemcitabine/carboplatin|"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)~Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"
426912|NCT00938652|Drug|Iniparib|"Body weight adjusted dose~intravenous infusion (60 ± 10 minutes)"
426913|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
426914|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
426915|NCT00938626|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
427144|NCT00937027|Drug|Aminopterin|oral tablets, 1.0 mg dose, once weekly, two weeks
426916|NCT00938626|Procedure|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
426917|NCT00938626|Procedure|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
426918|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
426919|NCT00938613|Drug|Placebo|nasal spray, one spray per nostril at time 0
426920|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
426921|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
426922|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
426923|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
426924|NCT00938587|Drug|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
426925|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
426926|NCT00938587|Drug|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
426927|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
426928|NCT00938587|Drug|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
426929|NCT00938587|Other|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
426930|NCT00938587|Other|Placebo|Placebo tablet every day for 14 days
426931|NCT00938587|Other|Placebo for PF-04171327|Placebo tablet every day for 14 days
426932|NCT00938574|Drug|Atu027|
426933|NCT00938561|Drug|Inulin|
426934|NCT00938548|Drug|Pregabalin|Pregabalin 75 mg orally
426935|NCT00938548|Drug|Vitamin Complex (placebo)|Vitamin Complex orally
426936|NCT00938535|Behavioral|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
426937|NCT00938522|Drug|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
426938|NCT00938522|Drug|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
426939|NCT00938509|Drug|ibuprofen suppositories|5-10 mg/kg/day-suppositories
426940|NCT00938483|Other|Nutramigen Lipil (Infant formula)|
426941|NCT00938470|Drug|capecitabine|Given PO
426942|NCT00938470|Drug|docetaxel|Given IV
426943|NCT00938470|Drug|fluorouracil|Given IV
426944|NCT00938470|Drug|oxaliplatin|Given IV
426945|NCT00938470|Radiation|radiation therapy|Undergo radiation therapy
426946|NCT00938470|Procedure|therapeutic conventional surgery|Undergo surgery
426947|NCT00938457|Radiation|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
426948|NCT00938457|Procedure|implanted fiducial-based imaging|radiation therapy treatment planning
426949|NCT00938457|Procedure|cone-beam computed tomography|radiation therapy treatment planning
426950|NCT00938431|Drug|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
426951|NCT00938418|Radiation|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
426952|NCT00938405|Drug|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
426953|NCT00938405|Drug|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
426954|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
426955|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
426956|NCT00938379|Drug|20% deet insect repellent|skin-applied repellent lotion
426957|NCT00938379|Drug|placebo control|Identical base formulation of lotion but without any deet active
426958|NCT00938366|Drug|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
426959|NCT00938366|Drug|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
426960|NCT00938353|Drug|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
426961|NCT00938353|Drug|Placebo solution for nebulisation 2 ml|single dose: 4 ml
426962|NCT00938340|Dietary Supplement|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
426963|NCT00938340|Dietary Supplement|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
426964|NCT00938340|Dietary Supplement|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
426965|NCT00938340|Dietary Supplement|Whole walnut|85g whole walnuts, ground, incorporated into inert food carrier
426966|NCT00938327|Biological|Rotarix™|Two doses of oral vaccine.
426967|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
426968|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
426969|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
426970|NCT00938314|Drug|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
426971|NCT00938301|Drug|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
426972|NCT00938301|Drug|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
426973|NCT00938288|Drug|KW-3357|50IU/mL, IV single dose
426974|NCT00938275|Drug|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.~Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
426975|NCT00938262|Drug|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)~Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)~Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
426976|NCT00938249|Dietary Supplement|Monascus Garlic Fermented Extract|
426977|NCT00938249|Dietary Supplement|Placebo|
426978|NCT00938236|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
426979|NCT00938223|Biological|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.~Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.~Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.~All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
426980|NCT00938210|Procedure|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
426981|NCT00938197|Drug|Fimasartan|Fimasartan (1d~7d) Amlodipine (12d~14d) Fimasartan + Amlodipine(15d~21d)
426982|NCT00938197|Drug|Amlodipine|Amlodipine (1d~10d) Amlodipine (25d~27d) Fimasartan + Amlodipine(28d~34d)
426983|NCT00938184|Drug|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
426984|NCT00938184|Drug|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
426985|NCT00938184|Drug|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
426986|NCT00938171|Procedure|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
426987|NCT00938171|Procedure|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
426988|NCT00938158|Biological|albiglutide|single dose of subcutaneously injected albiglutide
426989|NCT00938145|Procedure|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
426990|NCT00938145|Drug|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
426991|NCT00938145|Procedure|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
426992|NCT00938132|Drug|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
426993|NCT00938106|Radiation|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
426994|NCT00938093|Behavioral|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
426995|NCT00938093|Behavioral|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
426996|NCT00938080|Biological|AG013|Mouth rinse once a day for 14 days
426997|NCT00938080|Biological|AG013|Mouth rinse three times a day for 14 days
426998|NCT00938080|Biological|AG013|Mouth rinse six times a day for 14 days
426999|NCT00938080|Other|Placebo|Mouth rinse once a day for 14 days
427000|NCT00938080|Other|Placebo|Mouth rinse three times a day for 14 days
427001|NCT00938080|Other|Placebo|Mouth rinse six times a day for 14 days
427097|NCT00937365|Behavioral|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
427002|NCT00938067|Behavioral|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
427003|NCT00938041|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
427004|NCT00938015|Other|Questionnaire|This is a non-interventional study
427005|NCT00938015|Other|Questionnaire|This is a non-interventional study
427006|NCT00938002|Diagnostic Test|Acceler8 Pheno|
427007|NCT00937989|Other|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
427008|NCT00937989|Other|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
427009|NCT00937989|Other|medical chart review|Baseline, 3, 6 and 9 months after starting the study
427010|NCT00937989|Other|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
427011|NCT00937989|Other|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
427012|NCT00937989|Procedure|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
427013|NCT00937976|Procedure|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
427014|NCT00937963|Dietary Supplement|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
427015|NCT00937950|Other|Gynaecological follow-up|Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.
427016|NCT00937937|Drug|Dinaciclib|Given IV
427017|NCT00937924|Drug|Saline|Saline solution injections
427018|NCT00937924|Drug|Diphenhydramine|Diphenhydramine injections
427019|NCT00937924|Drug|Promethazine|Promethazine
427020|NCT00937911|Drug|YM150|oral
427021|NCT00937898|Dietary Supplement|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
427022|NCT00937898|Dietary Supplement|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
427023|NCT00937885|Behavioral|Implementation of reminiscence|
427024|NCT00937872|Drug|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
427025|NCT00937872|Drug|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
427026|NCT00937859|Drug|SER120|SER120
427027|NCT00937859|Drug|Placebo|Placebo
427028|NCT00937846|Drug|GSK1034702|Single oral 5 mg dose in liquid formulation
427029|NCT00937833|Procedure|Prostatectomy|
427030|NCT00937833|Device|Surgisis Male Sling|
427031|NCT00937820|Drug|YM150|oral
427032|NCT00937807|Drug|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
427033|NCT00937807|Drug|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
427034|NCT00937794|Behavioral|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
427035|NCT00937794|Other|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
427036|NCT00937781|Genetic|RNA analysis|
427037|NCT00937781|Genetic|gene expression analysis|
427038|NCT00937781|Genetic|microarray analysis|
427039|NCT00937781|Genetic|polymerase chain reaction|
427040|NCT00937781|Other|immunohistochemistry staining method|
427041|NCT00937781|Other|laboratory biomarker analysis|
427042|NCT00937768|Drug|Goserelin Acetate|Given SC
427043|NCT00937768|Other|Laboratory Biomarker Analysis|Correlative studies
427044|NCT00937768|Drug|Leuprolide Acetate|Given IM
427045|NCT00937768|Other|Quality-of-Life Assessment|Ancillary studies
427046|NCT00937742|Dietary Supplement|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
427047|NCT00937703|Device|placebo|paper support for glycaemia face to face visit at T4mounths
427048|NCT00937703|Device|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks."
427049|NCT00937703|Device|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
427098|NCT00937365|Procedure|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
427050|NCT00937677|Drug|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
427051|NCT00937664|Drug|AZD7762|solution, intravenous, weekly
427052|NCT00937664|Drug|gemcitabine|intravenous, weekly
427053|NCT00937651|Drug|Placebo|Placebo
427054|NCT00937651|Drug|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
427055|NCT00937651|Drug|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
427056|NCT00937651|Drug|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
427057|NCT00937638|Dietary Supplement|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
427058|NCT00937638|Dietary Supplement|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
427059|NCT00937638|Dietary Supplement|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
427060|NCT00937625|Biological|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
427061|NCT00937612|Radiation|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
427062|NCT00937599|Dietary Supplement|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
427063|NCT00937560|Drug|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
427064|NCT00937560|Drug|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
427065|NCT00937560|Drug|Carboplatin|Carboplatin was supplied locally in commercial batches.
427066|NCT00937534|Drug|Fimasartan|Fimasartan 240mg/day
427067|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation I
427068|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation II
427069|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation III
427070|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation IV
427071|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation V
427072|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation VI
427073|NCT00937521|Biological|Control|Control
427074|NCT00937521|Biological|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
427075|NCT00937508|Behavioral|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
427076|NCT00937508|Drug|varenicline|varenicline (an approved medication for smoking cessation)
427077|NCT00937508|Drug|placebo|sugar pill without any active medication
427078|NCT00937495|Drug|vorinostat|400 mg given PO
427079|NCT00937495|Drug|bortezomib|1.3 mg/m^2 given IV
427080|NCT00937482|Drug|cediranib maleate|Given orally
427081|NCT00937482|Radiation|whole-brain radiation therapy|Undergo whole-brain radiotherapy
427082|NCT00937469|Behavioral|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
427083|NCT00937469|Other|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
427084|NCT00937456|Procedure|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
427085|NCT00937443|Other|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
427086|NCT00937443|Biological|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
427087|NCT00937430|Other|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
427088|NCT00937417|Drug|docetaxel|
427089|NCT00937417|Drug|vandetanib|
427090|NCT00937417|Genetic|proteomic profiling|
427091|NCT00937417|Other|laboratory biomarker analysis|
427092|NCT00937417|Other|pharmacological study|
427093|NCT00937404|Biological|Poliorix|All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.
427094|NCT00937391|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
427095|NCT00937378|Drug|SER120|Nasal Spray, once a day
427096|NCT00937378|Drug|Placebo|Nasal Spray
427099|NCT00937365|Procedure|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
427100|NCT00937352|Drug|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.~1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
427101|NCT00937339|Device|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
427102|NCT00937339|Device|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
427103|NCT00937326|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
427104|NCT00937326|Drug|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
427105|NCT00937313|Other|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
427106|NCT00937300|Biological|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
427107|NCT00937287|Other|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
427108|NCT00937274|Other|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
427109|NCT00937274|Other|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
427110|NCT00937274|Other|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
427111|NCT00937261|Drug|Risperidone|2mg - 8mg per day, for the duration of participation in the study
427112|NCT00937261|Drug|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
427113|NCT00937248|Device|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
427114|NCT00937248|Device|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
427115|NCT00937235|Drug|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
427116|NCT00937235|Behavioral|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
427117|NCT00937235|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
427118|NCT00937222|Dietary Supplement|Peanuts and peanut butter|Peanuts and peanut butter
427119|NCT00937196|Drug|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
427120|NCT00937196|Drug|Histaminum hydrochloricum globuli|
427121|NCT00937183|Biological|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
427122|NCT00937183|Biological|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
427123|NCT00937183|Biological|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
427124|NCT00937170|Device|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
427125|NCT00937170|Device|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
427126|NCT00937170|Device|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
427127|NCT00937157|Drug|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
427128|NCT00937144|Drug|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
427129|NCT00937144|Drug|placebo|
427130|NCT00937131|Drug|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
427131|NCT00937105|Device|lotrafilcon A contact lenses|FDA approved soft contact lenses
427132|NCT00937105|Device|Renu Multiplus|
427133|NCT00937105|Device|Clear Care|
427134|NCT00937092|Drug|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
427135|NCT00937092|Drug|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
427136|NCT00937079|Other|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
427137|NCT00937053|Other|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
427138|NCT00937053|Other|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
427139|NCT00937053|Other|Platelet transfusion|Patients whose platelets fall below 10 x 10*9 will be transfused with platelets
427140|NCT00937040|Drug|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
427141|NCT00937040|Drug|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
427142|NCT00937040|Drug|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
427143|NCT00937040|Drug|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
427145|NCT00937014|Other|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
427146|NCT00937014|Other|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
427147|NCT00937001|Procedure|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
427148|NCT00936988|Drug|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
427149|NCT00936975|Radiation|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
427150|NCT00936962|Biological|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
427151|NCT00936949|Procedure|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
427152|NCT00936949|Procedure|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
427153|NCT00936936|Drug|Gemcitabine|1800 mg/m^2 IV over 3 hours on Days -5 to Day -2.
427154|NCT00936936|Drug|Docetaxel|Docetaxel 300 mg/m^2 IV over 2 hours on Day -5.
427155|NCT00936936|Drug|Melphalan|50 mg/m^2 IV over 15 minutes on Days -4 to Day -2.
427156|NCT00936936|Drug|Carboplatin|"Cycle 1: 333 mg/m^2 IV over 2 hours on Days -4 to -2.~Cycle #2: 300 mg/m^2 IV over 2 hours on Days -6 to -3."
427157|NCT00936936|Drug|Mesna|3,000 mg/m^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
427158|NCT00936936|Drug|Ifosfamide|3,000 mg/m^2 IV over 6 hours on Days -6 to -3
427159|NCT00936936|Drug|Etoposide|200 mg/m^2 IV over 3 hours, every 12 hours on Days -6 to -4.
427160|NCT00936936|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
427161|NCT00936923|Drug|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
427162|NCT00936910|Drug|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome [2 mg/ml]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
427163|NCT00936897|Drug|Ibandronate|Ibandronate 150mg PO QM (tablet)
427164|NCT00936897|Drug|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
427165|NCT00936884|Drug|MOA728|"0.6 ml (12 mg), qod if weight=>62kg;~0.4ml (8 mg), qod if weight between 38 and <62;~0.0075ml/kg (0.15mg/kg), qod if weight between 27 and <38kg; study duration: 2 weeks"
427166|NCT00936884|Drug|MOA728|"0.6 ml, qod if weight=>62kg;~0.4ml, qod if weight between 38 and <62;~0.0075ml/kg, qod if weight between 27 and <38kg; study duration: 2 weeks"
427167|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose
427168|NCT00936871|Drug|Placebo|Placebo single dose
427169|NCT00936871|Drug|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
427170|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
427171|NCT00936871|Drug|Placebo|Placebo single dose
427172|NCT00936871|Drug|Moxifloxacin|Moxifloxacin 400 mg single dose
427173|NCT00936858|Drug|RAD001|Taken orally once a day in the morning
427174|NCT00936832|Drug|FOLFIRI regimen|
427175|NCT00936832|Drug|fluorouracil|
427176|NCT00936832|Drug|irinotecan hydrochloride|
427177|NCT00936832|Drug|leucovorin calcium|
427178|NCT00936832|Drug|sunitinib malate|
427179|NCT00936832|Other|laboratory biomarker analysis|
427180|NCT00936832|Other|pharmacogenomic studies|
427181|NCT00936832|Other|pharmacological study|
427182|NCT00936819|Biological|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
427183|NCT00936819|Biological|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
427184|NCT00936819|Biological|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
427185|NCT00936793|Drug|Darunavir|
427186|NCT00936793|Drug|Ritonavir|
427187|NCT00936793|Drug|Beclomethasone Dipropionate HFA|
427188|NCT00936780|Device|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
427189|NCT00936767|Drug|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
427190|NCT00936767|Drug|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
427191|NCT00936754|Dietary Supplement|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
427192|NCT00936754|Dietary Supplement|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
427193|NCT00936741|Drug|mifepristone|Mifepristone 300 mg to 1200 mg once daily
427194|NCT00936728|Other|therapeutic nutritional supplementation|Given orally
427195|NCT00936728|Dietary Supplement|white wine|Given orally
427196|NCT00936728|Other|questionnaire administration|Ancillary studies
427197|NCT00936715|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
427198|NCT00936702|Drug|carboplatin|Given IV
427199|NCT00936702|Drug|everolimus|Given PO
427200|NCT00936702|Drug|paclitaxel|Given IV
427201|NCT00936689|Procedure|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
427202|NCT00936689|Procedure|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
427203|NCT00936676|Drug|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
427204|NCT00936663|Drug|Placebo|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
427205|NCT00936663|Drug|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
427206|NCT00936650|Drug|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
427207|NCT00936650|Drug|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
427208|NCT00936637|Other|Extensively hydrolyzed infant formula|
427209|NCT00936624|Drug|SOTB07|SOTB07 100mg
427210|NCT00936624|Drug|SOTB07|SOTB07 200mg
427211|NCT00936624|Drug|placebo|placebo
427212|NCT00936624|Drug|montelukast|montelukast 10mg po, bid, 12week
427213|NCT00936611|Drug|LBH589|Orally on Mondays, Wednesdays and Fridays
427214|NCT00936598|Drug|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women = or > 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
427215|NCT00936598|Drug|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
427216|NCT00936585|Other|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
427217|NCT00936572|Procedure|Probiotics (La1, BB536)|
427218|NCT00936572|Biological|probiotics (La1, BB536)|
427219|NCT00936572|Biological|placebo|Maltodoxtrin
427220|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
427221|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
427222|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
427223|NCT00936546|Drug|Rituximab|Mabthera, Rituximab 1000 mg I.V.
427224|NCT00936533|Drug|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
427225|NCT00936533|Drug|Placebo|Placebo preparation without active compound, administered as the active drug.
427226|NCT00936520|Drug|SAR 1118 0.1%|Daily eye drops (twice daily, ~50 microliter [uL] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
427227|NCT00936520|Drug|SAR 1118 1.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
427228|NCT00936520|Drug|SAR 1118 5.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
427229|NCT00936507|Other|Energy Density/Portion Size|
427230|NCT00936494|Procedure|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
427231|NCT00936468|Biological|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
427232|NCT00936442|Drug|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
427233|NCT00936442|Other|Educational materials|Reception of educational material on regular basis.
427234|NCT00936429|Biological|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
427235|NCT00936429|Biological|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
427309|NCT00935805|Drug|Metformin|850 mg TID
427310|NCT00935805|Drug|Glybenclamide|10 mg BID
427311|NCT00935805|Drug|NPH insulin|Variable SC dose
427236|NCT00936416|Procedure|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;~The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
427237|NCT00936403|Drug|NNC126-0083|One single dose administered in four dose levels in an escalating order
427238|NCT00936403|Drug|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
427239|NCT00936390|Drug|bicalutamide|Given orally
427240|NCT00936390|Drug|buserelin|Given subcutaneously or as an injection
427241|NCT00936390|Drug|flutamide|Given orally
427242|NCT00936390|Drug|goserelin acetate|Given subcutaneously or as an injection
427243|NCT00936390|Drug|leuprolide acetate|Given subcutaneously or as an injection
427244|NCT00936390|Drug|triptorelin|Given subcutaneously or as an injection
427245|NCT00936390|Radiation|3-dimensional conformal radiation therapy|Given as external-beam radiation therapy
427246|NCT00936390|Radiation|intensity-modulated radiation therapy|Given as external-beam radiation therapy
427247|NCT00936377|Drug|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
427248|NCT00936377|Other|Placebo|Normal saline for five days.
427249|NCT00936364|Other|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
427250|NCT00936364|Other|Modified fast|Minimal caloric intake on days -2 and -1
427251|NCT00936364|Other|Fasting|Day -1
427252|NCT00936364|Other|Fasting|Days -2 and -1
427253|NCT00936364|Other|Fasting|Days -3, -2, and -1
427254|NCT00936364|Other|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
427255|NCT00936351|Behavioral|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
427256|NCT00936351|Behavioral|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
427257|NCT00936338|Behavioral|splint and joint mobilization self exercise|
427258|NCT00936299|Drug|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
427259|NCT00936286|Device|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
427260|NCT00936260|Drug|alendronate|several duration of treatment
427261|NCT00936247|Drug|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
427262|NCT00936247|Drug|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
427263|NCT00936234|Drug|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
427264|NCT00936221|Drug|AZD6244|oral capsules, 75mg twice daily
427265|NCT00936221|Drug|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
427266|NCT00936221|Drug|Placebo|Placebo
427267|NCT00936195|Drug|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
427268|NCT00936195|Drug|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
427269|NCT00936182|Drug|Fluconazole|Fluconazole daily for 30 days
427270|NCT00936169|Procedure|IVUS optimised DES implantation|Ivus optimised stent implantation
427271|NCT00936169|Procedure|angiographically guided DES implantation|angiographically guided DES implantation
427272|NCT00936156|Drug|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
427273|NCT00936143|Drug|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
427274|NCT00936130|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
427275|NCT00936130|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
427276|NCT00936130|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
427277|NCT00936130|Behavioral|Low Calorie Diet|Low Calorie Diet Program
427278|NCT00936117|Drug|Posaconazole|200 mg (liquid) by mouth 3 times per day.
427279|NCT00936091|Drug|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
427280|NCT00936091|Drug|Placebo|125 children received placebo capsules
427281|NCT00936065|Drug|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
427282|NCT00936065|Drug|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
427283|NCT00936065|Drug|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
427312|NCT00935805|Drug|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
427284|NCT00936052|Other|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
427285|NCT00936039|Behavioral|unloading|2 weeks of unloading of a single leg
427286|NCT00936026|Drug|Neramexane|Drug-Drug Interaction Study
427287|NCT00936013|Drug|oseltamivir|75mg p.o Bid for 5 days
427288|NCT00936013|Drug|oseltamivir and chinese medicinal herbs|oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
427289|NCT00936000|Dietary Supplement|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
427290|NCT00935987|Drug|CYT387|"For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups."
427291|NCT00935961|Drug|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
427292|NCT00935948|Drug|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
427293|NCT00935948|Drug|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
427294|NCT00935922|Dietary Supplement|Flaxseed|Flaxseed omega-3 fatty acids and lignans
427295|NCT00935896|Procedure|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
427296|NCT00935896|Procedure|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
427297|NCT00935896|Other|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
427298|NCT00935883|Drug|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
427299|NCT00935883|Drug|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).~Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.~Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
427300|NCT00935870|Device|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
427301|NCT00935857|Device|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
427302|NCT00935857|Device|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
427303|NCT00935844|Drug|TAK-901|"This study consists of three sequential parts.~Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.~Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
427304|NCT00935831|Drug|GSK1278863A|50mg, 150mg
427305|NCT00935831|Drug|Placebo|matching placebo
427306|NCT00935818|Drug|Varenicline|varenicline - 1 mg bid for 12 weeks
427307|NCT00935818|Drug|placebo|placebo for 12 weeks
427308|NCT00935818|Drug|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
427314|NCT00935805|Drug|Captopril|50 mg TID
427315|NCT00935805|Drug|Amlodipine|10 mg QD
427316|NCT00935792|Drug|alemtuzumab|Given subcutaneously
427317|NCT00935792|Drug|everolimus|Given orally
427318|NCT00935766|Drug|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
427319|NCT00935766|Drug|Placebo|
427320|NCT00935753|Drug|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
427321|NCT00935727|Other|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
427322|NCT00935714|Other|Exercise|
427323|NCT00935714|Other|Exercise|
427324|NCT00935701|Device|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
427325|NCT00935688|Other|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
427326|NCT00935675|Drug|Escitalopram|Escitalopram 10 mg once a day
427327|NCT00935662|Drug|AZD8329|Oral solution, single ascending doses
427328|NCT00935662|Drug|Placebo|Oral solution, placebo
427329|NCT00935649|Device|PinPointe FootLaser|Medical laser
427330|NCT00935623|Biological|Malaria Challenge|Malaria challenge
427331|NCT00935610|Dietary Supplement|Immunocal|20 grams per day of Immunocal for 135 days.
427332|NCT00935610|Dietary Supplement|Casein|20 grams per day for 135 days
427333|NCT00935597|Biological|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
427334|NCT00935584|Behavioral|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
427335|NCT00935571|Drug|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
427336|NCT00935558|Biological|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
427337|NCT00935558|Drug|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
427338|NCT00935545|Biological|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
427339|NCT00935532|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
427340|NCT00935532|Drug|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
427341|NCT00935519|Device|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 5 years follow-up.
427342|NCT00935506|Drug|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
427343|NCT00935506|Drug|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
427344|NCT00935493|Drug|Guanfacine|Guanfacine 0.1 mg po qhs
427345|NCT00935493|Drug|Guanfacine|Guanfacine 0.5 mg po qhs
427346|NCT00935493|Drug|Placebo|Placebo po qhs
427347|NCT00935480|Drug|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
427348|NCT00935480|Drug|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
427349|NCT00935467|Drug|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
427350|NCT00935454|Procedure|Hepatocyte matrix implantation|"First operation:~Removal of liver tissue and biopsy of pancreas~Second operation:~Implantation of hepatocyte matrix implant into small bowel mesentery"
427351|NCT00935441|Behavioral|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
427352|NCT00935441|Behavioral|usual case management|telephone contact with a case manager
427353|NCT00935415|Drug|Montelukast|Montelukast 5 mg
427354|NCT00935415|Drug|Placebo|capsules of matching placebo
427355|NCT00935402|Behavioral|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
427356|NCT00935389|Drug|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
427357|NCT00935376|Behavioral|Sleep Education Program|Treatment as usual.
427358|NCT00935376|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
427359|NCT00935376|Behavioral|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
427360|NCT00935363|Drug|glyburide|single oral dose
427361|NCT00935363|Drug|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
427362|NCT00935363|Drug|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
427363|NCT00935363|Drug|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
427364|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
427365|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|5.0 grams of PGX
427366|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|0 grams of PGX
427367|NCT00935337|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
427368|NCT00935337|Behavioral|Sleep Hygiene|treatment as usual
427369|NCT00935311|Drug|ABT-712 Extended-release|ABT-712 extended-release tablet
427370|NCT00935311|Drug|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
427371|NCT00935311|Drug|Placebo|Placebo tablet
427372|NCT00935298|Drug|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*1 type and CYP3A5*1/*3 type administer 0.15mg/kg/d，CYP3A5*3/*3 type administer 0.08mg/kg/d).
427373|NCT00935272|Device|Restylane®|Restylane® injections in the lips
427374|NCT00935272|Device|Non-Treatment|Non- Treatment
427375|NCT00935259|Drug|Simvastatin|40 mg once daily for 2 weeks
427376|NCT00935259|Drug|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
427377|NCT00935246|Drug|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
427378|NCT00935233|Genetic|DNA analysis|
427379|NCT00935233|Genetic|polymorphism analysis|
427380|NCT00935233|Genetic|protein analysis|
427381|NCT00935233|Other|laboratory biomarker analysis|
427382|NCT00935233|Other|questionnaire administration|
427383|NCT00935233|Other|survey administration|
427384|NCT00935220|Drug|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
427385|NCT00935207|Other|Pediatric Pain Diary|Pain diary designed for pediatric patients
427386|NCT00935194|Drug|oseltamivir|75mg,bid,for 5 days
427387|NCT00935194|Other|blank|no antiviral therapy
427388|NCT00935194|Drug|chinese medicinal herbs|200ml,p.o,qid,for 5 days
427389|NCT00935194|Drug|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
427390|NCT00935181|Behavioral|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
427391|NCT00935168|Drug|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
427392|NCT00935168|Drug|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
427393|NCT00935155|Procedure|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
427394|NCT00935155|Procedure|exercises|Coordination, mobilizing, endurance, strength
427395|NCT00935142|Drug|[18F]VM4-037|Bolus IV injection of [18F]VM4-037
427396|NCT00935129|Device|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
427397|NCT00935129|Device|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
427398|NCT00935116|Drug|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.~G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
427399|NCT00935103|Behavioral|Psychoeducation|
427400|NCT00935090|Device|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
427401|NCT00935077|Other|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
427402|NCT00935077|Other|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
427403|NCT00935077|Other|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
427404|NCT00935064|Drug|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
427405|NCT00935064|Other|Placebo|Placebo orally one tablet once a day for 6 weeks.
427406|NCT00935051|Other|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
427407|NCT00935025|Drug|AZD1305|single and multiple oral doses, extended-release capsule
427408|NCT00935025|Drug|Placebo|single and multiple oral doses, capsule
427409|NCT00935012|Drug|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
427410|NCT00934999|Procedure|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
427411|NCT00934999|Procedure|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
427412|NCT00934986|Other|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :~Stage A patient who does not require a treatment: one sample the day of enrollment.~Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
427413|NCT00934973|Drug|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
427414|NCT00934973|Drug|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
427415|NCT00934973|Drug|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
427416|NCT00934973|Behavioral|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
427417|NCT00934973|Behavioral|No website|No CBT website
427418|NCT00934973|Behavioral|CBT website with minimal support|
427419|NCT00934947|Drug|Propranolol|40 mg
427420|NCT00934947|Drug|Placebo|sugar pill
427421|NCT00934947|Drug|Propanolol|120 mg twice per day
427422|NCT00934934|Other|Normal Saline|Normal Saline
427423|NCT00934934|Drug|anidulafungin|TBA
427424|NCT00934921|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
427425|NCT00934921|Drug|Zofran®|1 x 8 mg ODT
427426|NCT00934908|Dietary Supplement|Green Tea|Green tea capsules taken twice a day.
427427|NCT00934908|Other|Placebo|"Non-active sugar pill."
427428|NCT00934895|Drug|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
427429|NCT00934895|Drug|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
427430|NCT00934882|Drug|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
427431|NCT00934856|Drug|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics [SmPC]).
427432|NCT00934856|Drug|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
427433|NCT00934856|Drug|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
427434|NCT00934843|Drug|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
427435|NCT00934843|Drug|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
427436|NCT00934830|Drug|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
427437|NCT00934830|Other|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
427438|NCT00934817|Drug|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
427439|NCT00934817|Drug|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
427440|NCT00934804|Device|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
427441|NCT00934791|Drug|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
427442|NCT00934791|Drug|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
427443|NCT00934791|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
427444|NCT00934791|Drug|Prednisone|Prednisone tapered to 5 mg/day by day 92
427445|NCT00934778|Procedure|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
427446|NCT00934765|Behavioral|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
427447|NCT00934752|Device|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
427448|NCT00934739|Drug|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
427449|NCT00934739|Drug|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
427450|NCT00934713|Drug|montelukast|montelukast 4mg once per day for 8 weeks period
427451|NCT00934700|Other|Xenon gas|30% Xenon gas inhaled for 24 hours
427452|NCT00934687|Drug|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
427453|NCT00934687|Other|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
427454|NCT00934674|Drug|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella~Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
427455|NCT00934661|Drug|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
427456|NCT00934661|Drug|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
427457|NCT00934648|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
427458|NCT00934648|Drug|methotrexate|10-25mg weekly
427459|NCT00934635|Drug|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 2 hours
427460|NCT00934635|Drug|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 2 hours
427461|NCT00934635|Other|PET Scan|PET Scan
427782|NCT00932217|Drug|filgrastim|subcutaneous filgrastim administration
427462|NCT00934635|Drug|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 24 hours
427463|NCT00934635|Drug|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 2 hours
427464|NCT00934635|Drug|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 2 hours
427465|NCT00934635|Drug|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 24 hours
427466|NCT00934635|Drug|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 24 hours
427467|NCT00934635|Drug|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 24 hours
427468|NCT00934622|Device|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
427469|NCT00934609|Behavioral|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
427470|NCT00934596|Procedure|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV & Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
427471|NCT00934596|Drug|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
427472|NCT00934583|Behavioral|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
427473|NCT00934570|Drug|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
427474|NCT00934570|Drug|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
427475|NCT00934570|Behavioral|Placebo Standard exercise|Standard exercise
427476|NCT00934570|Behavioral|Intensive exercise|Placebo Intensive exercise
427477|NCT00934557|Drug|ATG Fresenius|
427478|NCT00934557|Drug|ATG Fresenius|
427479|NCT00934557|Drug|ATG Fresenius|
427480|NCT00934557|Drug|ATG Fresenius|
427481|NCT00934557|Drug|ATG Fresenius|
427482|NCT00934557|Drug|ATG Fresenius|
427483|NCT00934557|Drug|ATG Fresenius|
427484|NCT00934557|Drug|ATG Fresenius|
427485|NCT00934544|Drug|Ruxolitinib|5 mg tablets packaged as 60-count in high-density polyethylene bottles
427486|NCT00934544|Drug|Best Available Therapy (BAT)|Prescribing and usage per respective package inserts
427487|NCT00934531|Drug|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.~Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.~Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
427488|NCT00934518|Radiation|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
427489|NCT00934518|Drug|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week~Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
427490|NCT00934492|Drug|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
427491|NCT00934492|Drug|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
427492|NCT00934479|Drug|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
427493|NCT00934466|Drug|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
427494|NCT00934466|Drug|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
427495|NCT00934466|Drug|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
427496|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
427497|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
427498|NCT00934453|Biological|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
427499|NCT00934453|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
427500|NCT00934440|Drug|Bevacizumab|"First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."
427573|NCT00933868|Drug|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
427501|NCT00934440|Drug|Azacitidine|"Dose level 1: 35 mg/m2/day for 7 days.~Dose level 2: 55 mg/m2/day for 7 days.~Dose level 3: 75 mg/m2/day for 7 days.~mg/m2/day = dose based on height and weight"
427502|NCT00934427|Drug|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
427503|NCT00934427|Drug|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
427504|NCT00934414|Drug|Technosphere Insulin Inhalation Powder|30U
427505|NCT00934388|Procedure|Pre peritoneal mesh placement|
427506|NCT00934388|Procedure|Laparoscopy|
427507|NCT00934375|Drug|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
427508|NCT00934375|Drug|placebo|
427509|NCT00934362|Drug|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
427510|NCT00934362|Drug|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
427511|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
427512|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
427513|NCT00934323|Drug|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
427514|NCT00934323|Drug|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
427515|NCT00934284|Other|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
427516|NCT00934284|Other|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
427517|NCT00934271|Radiation|fractionated stereotactic radiotherapy|Audit of outcome
427518|NCT00934258|Drug|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
427519|NCT00934258|Genetic|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
427520|NCT00934245|Biological|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
427521|NCT00934245|Biological|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
427522|NCT00934232|Drug|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
427523|NCT00934219|Drug|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
427524|NCT00934206|Behavioral|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
427525|NCT00934193|Drug|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
427526|NCT00934193|Drug|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
427527|NCT00934180|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
427528|NCT00934180|Drug|Zofran®|1 x 8 mg ODT
427529|NCT00934167|Biological|heparin sodium - Hipolabor|5.000 UI/0,25mL
427530|NCT00934167|Biological|Heparin sodium - APP|5.000 USP/mL
427531|NCT00934154|Drug|Thalidomide|100 mg/day continuously for 12 months
427532|NCT00934154|Drug|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
427574|NCT00933868|Drug|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
427533|NCT00934141|Other|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives—to help agencies learn and gather support from each other and from outside experts.
427534|NCT00934141|Other|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
427535|NCT00934141|Other|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
427536|NCT00934141|Other|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
427537|NCT00934128|Device|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
427538|NCT00934128|Device|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
427539|NCT00934102|Device|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
427540|NCT00934102|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
427541|NCT00934102|Device|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
427542|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
427543|NCT00934089|Drug|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
427544|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
427545|NCT00934089|Drug|latanoprost|Topical ocular solution, once-daily for 14 days
427546|NCT00934076|Drug|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.~Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
427547|NCT00934063|Drug|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
427548|NCT00934063|Other|No treatment given|Control group not receiving treatment
427549|NCT00934050|Drug|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks~After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
427550|NCT00934037|Procedure|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
427551|NCT00934037|Other|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
427552|NCT00934024|Drug|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
427553|NCT00934011|Other|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
427554|NCT00934011|Other|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
427555|NCT00933998|Other|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
427556|NCT00933985|Drug|dexrazoxane hydrochloride|Given IV
427557|NCT00933985|Drug|doxorubicin hydrochloride|Given IV
427558|NCT00933985|Drug|obatoclax mesylate|Given IV
427559|NCT00933985|Drug|liposomal vincristine sulfate|Given IV
427560|NCT00933985|Other|pharmacological study|Correlative studies
427561|NCT00933985|Other|laboratory biomarker analysis|Correlative studies
427562|NCT00933972|Drug|RO4998452|20mg po single dose
427563|NCT00933959|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
427564|NCT00933959|Behavioral|Sleep Hygiene|Treatment as usual
427565|NCT00933946|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
427566|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
427567|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
427568|NCT00933920|Drug|Aliskiren|
427569|NCT00933920|Drug|Aliskiren|
427570|NCT00933907|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks
427571|NCT00933894|Drug|Telaprevir; Escitalopram|
427572|NCT00933881|Other|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
427575|NCT00933855|Behavioral|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.~The workshop will follow the approximate time table below:~10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
427576|NCT00933842|Drug|LACTIC ACID(ND)|Treatment duration: 5 weeks
427577|NCT00933829|Procedure|Absorbable Suture Arm|use of irradiated polyglactin 910
427578|NCT00933829|Device|Non-absorbable suture (Prolene)|suture
427579|NCT00933829|Procedure|suture|non-absorable sutures and absorable sutures
427580|NCT00933816|Drug|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
427581|NCT00933790|Drug|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
427582|NCT00933777|Drug|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
427583|NCT00933751|Device|Central vein catheterization|Blood samplings from IVC catheter
427584|NCT00933725|Other|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~One tablet placebo of Tibolone (provided by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.~Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
427585|NCT00933725|Other|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.~Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
427586|NCT00933712|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
427587|NCT00933699|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
427588|NCT00933686|Drug|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
427589|NCT00933686|Drug|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
427590|NCT00933673|Drug|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
427591|NCT00933660|Other|ERC-training by instructor|Standard way of training with an instructor
427592|NCT00933660|Other|Web-based training only|Experimental way of training with a web based training application
427593|NCT00933660|Other|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
427594|NCT00933647|Dietary Supplement|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
427595|NCT00933647|Dietary Supplement|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
427596|NCT00933647|Dietary Supplement|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
427597|NCT00933634|Procedure|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
427598|NCT00933634|Drug|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
427599|NCT00933621|Procedure|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
427600|NCT00933608|Drug|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
427601|NCT00933608|Drug|Placebo|participants will be asked to take 2 tablets per day to match active drug
427602|NCT00933595|Other|Smoking Cessation|"A Motivational Interview session (~40-50 minutes) will be delivered by a trained nurse coordinator.~Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day."
427603|NCT00933582|Drug|JNJ-39439335; Placebo; Naproxen|
427604|NCT00933569|Drug|LACTIC ACID(ND)|treatment period: 21 consecutive days
427605|NCT00933556|Dietary Supplement|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
427606|NCT00933556|Dietary Supplement|sugar pill (placebo)|placebo identical to the active product will be given
427607|NCT00933543|Drug|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
427608|NCT00933543|Drug|Vehicle cream (placebo)|Cream application followed by illumination with red light.
427609|NCT00933543|Procedure|PDT|Photodynamic Therapy - Light dose 37 J/cm2
427610|NCT00933530|Drug|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
427611|NCT00933530|Drug|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
427612|NCT00933517|Drug|vectibix|9mg/kg at D1 of each 21-days cycle
427613|NCT00933517|Drug|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
427614|NCT00933517|Drug|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
427615|NCT00933517|Drug|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
427616|NCT00933517|Drug|docetaxel|100 mg/m2 at D1 of each 21 days cycle
427617|NCT00933504|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks.
427618|NCT00933478|Device|Clay|Small dime sized piece of clay.
427619|NCT00933465|Drug|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
427620|NCT00933465|Drug|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.~Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
427621|NCT00933452|Drug|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
427622|NCT00933452|Drug|duloxetine|15mg, oral administer
427623|NCT00933452|Drug|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
427624|NCT00933439|Drug|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
427625|NCT00933426|Drug|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
427626|NCT00933426|Drug|Paclitaxel|50 mg/m^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
427627|NCT00933413|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
427628|NCT00933400|Procedure|CT Coronary Angiography|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
427629|NCT00933400|Procedure|Traditional, Standard of Care|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
427630|NCT00933387|Drug|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
427631|NCT00933374|Drug|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
427632|NCT00933374|Drug|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
427633|NCT00933361|Drug|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
427634|NCT00933348|Drug|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
427635|NCT00933348|Drug|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
427636|NCT00933335|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
427637|NCT00933322|Dietary Supplement|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
427638|NCT00933322|Dietary Supplement|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
427639|NCT00933322|Dietary Supplement|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
427640|NCT00933309|Drug|Exemestane|25 mg tablets orally once a day
427641|NCT00933309|Drug|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
427642|NCT00933283|Drug|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
427643|NCT00933283|Drug|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
427644|NCT00933270|Device|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
427645|NCT00933257|Drug|LACTIC ACID(ND)|Treatment duration 5 weeks
427646|NCT00933244|Dietary Supplement|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
427647|NCT00933244|Dietary Supplement|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
427648|NCT00933244|Dietary Supplement|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
427649|NCT00933231|Drug|tacrolimus|Standard dose, Oral
427650|NCT00933231|Drug|tacrolimus|Low dose, Oral
427651|NCT00933231|Biological|Simulect|IV
427652|NCT00933231|Drug|Cellcept|Oral
427653|NCT00933231|Drug|Corticosteroids|IV and Oral
427654|NCT00933231|Drug|Ramipril|Oral
427655|NCT00933231|Drug|Irbesartan|Oral
427656|NCT00933218|Dietary Supplement|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
427657|NCT00933218|Dietary Supplement|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
427658|NCT00933205|Drug|Tipranavir|
427659|NCT00933192|Device|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
427660|NCT00933179|Drug|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
427661|NCT00933179|Drug|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
427662|NCT00933166|Device|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
427663|NCT00933153|Dietary Supplement|Ensure Plus|Ensure plus supplement with meals
427664|NCT00933153|Dietary Supplement|Meals on Wheels|Two Meals on Wheels twice daily
427665|NCT00933127|Genetic|DNA analysis|
427666|NCT00933127|Genetic|polymerase chain reaction|
427667|NCT00933127|Genetic|polymorphism analysis|
427668|NCT00933127|Other|laboratory biomarker analysis|
427669|NCT00933114|Procedure|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
427670|NCT00933088|Other|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.~Mothers will be asked to complete data form."
427671|NCT00933075|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
427672|NCT00933062|Drug|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
427673|NCT00933062|Drug|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
427674|NCT00933049|Drug|Amoxicillin|Oral amoxicillin (25mg/kg/dose)for 5 days
427675|NCT00933049|Drug|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
427676|NCT00933049|Drug|Amoxicillin placebo|
427677|NCT00933049|Drug|Cotrimoxazole placebo|
427678|NCT00933036|Device|Crosstrees Pod system for PVA|Minimally invasive spine surgery
427679|NCT00933023|Drug|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
427680|NCT00933023|Drug|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
427681|NCT00932997|Behavioral|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
427682|NCT00932997|Other|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
427683|NCT00932997|Other|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
427684|NCT00932997|Other|questionnaire administration|Baseline and 9 months after enrollment and intervention
427685|NCT00932997|Procedure|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
427686|NCT00932997|Procedure|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
427687|NCT00932984|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
427688|NCT00932971|Drug|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
427689|NCT00932971|Drug|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
427690|NCT00932945|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
427691|NCT00932919|Behavioral|Thought field therapy|5 sessions with Thought field therapy
427692|NCT00932919|Behavioral|Cognitive therapy|12 sessions of Cognitive therapy
427693|NCT00932919|Behavioral|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
427694|NCT00932906|Other|Different self-training methods|Self training with MiniAnne Training Kit
427695|NCT00932906|Other|Standard training|Instructor-based training meeting ERC directions
427696|NCT00932893|Drug|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
427697|NCT00932893|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
427698|NCT00932893|Drug|Docetaxel|Docetaxel, 75 mg/m^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
427699|NCT00932880|Drug|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
427700|NCT00932880|Drug|Norvasc|10 mg dose (Pfizer, USA)
427701|NCT00932867|Drug|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
427702|NCT00932854|Procedure|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
427703|NCT00932841|Other|Placebo|One packet PO daily x 8 weeks.
427704|NCT00932841|Drug|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
427705|NCT00932841|Drug|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
427706|NCT00932828|Drug|Peanut oral immunotherapy|Defatted peanut in flour form to be used as treatment for peanut allergy
427707|NCT00932802|Drug|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
427708|NCT00932776|Device|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
427709|NCT00932776|Device|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
427710|NCT00932763|Drug|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
427711|NCT00932763|Drug|Norvasc|10 mg dose (Pfizer, USA)
427712|NCT00932750|Dietary Supplement|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
427713|NCT00932750|Dietary Supplement|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
427714|NCT00932737|Drug|Placebo|1-5 tablets per episode
427715|NCT00932737|Drug|Placebo|1-5 tablets per episode
427716|NCT00932737|Drug|HBB 20 mg|Active drug, one to five tablets per episode
427717|NCT00932724|Drug|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
427718|NCT00932724|Drug|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
427719|NCT00932711|Behavioral|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
427720|NCT00932698|Drug|Ixazomib|Ixazomib capsules
427721|NCT00932685|Drug|Midazolam|Midazolam 0.5mg/kg
427722|NCT00932685|Device|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
427723|NCT00932672|Behavioral|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
427724|NCT00932659|Device|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
427725|NCT00932646|Drug|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
427726|NCT00932646|Drug|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
427727|NCT00932646|Drug|Placebo|Placebo Respimat once daily and placebo Foradil
427728|NCT00932646|Drug|Foradil|12 mcg twice daily and placebo Respimat
427729|NCT00932620|Drug|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
427730|NCT00932620|Drug|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
427731|NCT00932607|Drug|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.~Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.~Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
427732|NCT00932594|Procedure|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
427733|NCT00932594|Other|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
427734|NCT00932581|Other|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
427735|NCT00932581|Other|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
427736|NCT00932555|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
427737|NCT00932542|Drug|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
427738|NCT00932542|Drug|placebo|placebo
427739|NCT00932542|Drug|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
427740|NCT00932529|Drug|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
427741|NCT00932529|Drug|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
427742|NCT00932529|Drug|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
427743|NCT00932529|Drug|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
427744|NCT00932516|Behavioral|South Beach Diet™ with South Beach Diet™ Products|
427745|NCT00932516|Behavioral|South Beach Diet™|
427746|NCT00932516|Behavioral|Calorie restricted diet with South Beach Diet™ Products|
427747|NCT00932516|Behavioral|Calorie Restricted Diet|
427748|NCT00932503|Device|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
427749|NCT00932490|Behavioral|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
427750|NCT00932477|Drug|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
427751|NCT00932477|Drug|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
427752|NCT00932477|Drug|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
427753|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose under fasted conditions
427754|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
427755|NCT00932451|Drug|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
427756|NCT00932438|Device|LC bead loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan in combination with Fluorouracil, Oxaliplatin, Leucovorin and Avastin alternating on a 2 weekly schedule
427757|NCT00932438|Drug|FOLFOX6 and Avastin|Fluorouracil, Oxaliplatin, Leucovorin and Avastin given biweekly
427758|NCT00932425|Device|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
427759|NCT00932412|Drug|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
427760|NCT00932412|Drug|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
427761|NCT00932386|Drug|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
427762|NCT00932386|Drug|normal saline|0.9% normal saline infusing
427763|NCT00932373|Drug|trastuzumab-MCC-DM1|Intravenous escalating dose
427764|NCT00932360|Device|TENS|Active TENS, Placebo TENS and No Treatment TENS
427765|NCT00932347|Drug|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
427766|NCT00932347|Drug|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
427767|NCT00932334|Behavioral|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
427768|NCT00932334|Behavioral|TALK Standard|Participants receive and educational video and booklet about living kidney donation
427769|NCT00932334|Behavioral|Usual Care|Participants receive their usual care
427770|NCT00932321|Drug|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
427771|NCT00932321|Drug|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
427772|NCT00932308|Dietary Supplement|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
427773|NCT00932308|Dietary Supplement|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
427774|NCT00932295|Other|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
427775|NCT00932295|Other|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
427776|NCT00932295|Other|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
427777|NCT00932295|Other|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
427778|NCT00932282|Drug|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
427779|NCT00932282|Drug|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
427780|NCT00932256|Drug|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
427781|NCT00932230|Other|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
427783|NCT00932217|Drug|lenograstim|subcutaneous lenograstim administration
427784|NCT00932204|Device|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).~The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).~For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
427785|NCT00932191|Procedure|Standard phacoemulsification|Cataract nucleus removal using standard amounts of ultrasound energy
427786|NCT00932191|Procedure|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
427787|NCT00932178|Behavioral|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
427788|NCT00932165|Drug|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
427789|NCT00932152|Drug|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
427790|NCT00932152|Drug|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
427791|NCT00932152|Drug|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
427792|NCT00932152|Drug|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
427793|NCT00932139|Procedure|Electro-acupuncture control|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
427794|NCT00932139|Procedure|Electro-acupuncture test|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heart rate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
427795|NCT00932126|Drug|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
427796|NCT00932113|Drug|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
427797|NCT00932113|Drug|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
427798|NCT00932100|Drug|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
427799|NCT00932100|Drug|Heparin|IV dose per standard of care at the local institution
427800|NCT00932087|Procedure|Blood sample|Blood sample for lipidomic study
427801|NCT00932074|Drug|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
427802|NCT00932061|Other|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
427803|NCT00932061|Other|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.~Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
427804|NCT00932048|Drug|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
427805|NCT00932035|Procedure|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
427806|NCT00932035|Drug|isosulfan blue based lymphatic mapping|
427807|NCT00932035|Procedure|axillary lymph node dissection|Undergo standard axillary lymph node dissection
427808|NCT00932035|Procedure|quality-of-life assessment|Ancillary studies
427809|NCT00932035|Other|Questionnaire administration|Ancillary studies
427810|NCT00932022|Drug|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
427811|NCT00932022|Other|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
427812|NCT00931996|Drug|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
427813|NCT00931957|Drug|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:~Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.~In Arm B:~Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
427814|NCT00931944|Drug|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
427815|NCT00931931|Biological|HSV1716|
427816|NCT00931918|Drug|Bortezomib|Bortezomib IV
427817|NCT00931918|Drug|Rituximab|Rituximab IV
427818|NCT00931918|Drug|Cyclophosphamide|Cyclophosphamide IV
427819|NCT00931918|Drug|Doxorubicin|Doxorubicin IV solution
427820|NCT00931918|Drug|Vincristine|Vincristine IV
427821|NCT00931918|Drug|Prednisone|Prednisone tablet
427822|NCT00931905|Drug|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
427823|NCT00931905|Other|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
427824|NCT00931892|Dietary Supplement|Gluten|3g
427825|NCT00931892|Dietary Supplement|Gluten|10g
427826|NCT00931879|Drug|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients.
427827|NCT00931879|Drug|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
427828|NCT00931866|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
427829|NCT00931866|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
427830|NCT00931853|Drug|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
427831|NCT00931840|Drug|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.~Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
427832|NCT00931827|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
427833|NCT00931827|Drug|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
427834|NCT00931814|Other|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
427835|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
427836|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
427837|NCT00931801|Drug|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
427838|NCT00931788|Drug|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
427839|NCT00931788|Other|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
427840|NCT00931775|Drug|Pindolol|Pill orally administered. 15 mg/day t.i.d.
427841|NCT00931762|Drug|Panobinostat|Panobinostat will be administered orally once a day on Monday, Wednesday and Friday at a fixed dose of 40 mg. A cycle is defined as 28 days of treatment.
427842|NCT00931749|Device|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
427843|NCT00931749|Device|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
427844|NCT00931736|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
427845|NCT00931736|Drug|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
427846|NCT00931723|Drug|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
427847|NCT00931723|Drug|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
427848|NCT00931723|Drug|Placebo|Oral treatment twice daily.
427849|NCT00931710|Drug|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
427850|NCT00931710|Drug|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
427851|NCT00931697|Drug|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
427852|NCT00931697|Drug|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
427853|NCT00931697|Drug|Placebo|Over-encapsulated placebo to maintain blinding
427854|NCT00931671|Other|Exercise training|aerobic exercise training
428145|NCT00929500|Behavioral|MAST program|MAST program: twice a week for 4 months
427855|NCT00931645|Procedure|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
427856|NCT00931645|Procedure|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
427857|NCT00931645|Procedure|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) & cyclophosphamide (300 mg/sqm)
427858|NCT00931632|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
427859|NCT00931632|Drug|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
427860|NCT00931606|Biological|Biological: ACE-011|up to 4 subcutaneous doses of ACE-011 given once every 28 days
427861|NCT00931606|Drug|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
427862|NCT00931593|Device|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):~Subject selection~Obtaining of written informed consent~Visit V1 (day 0):~Fasting subject~Randomization to determine the examination order~Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)~Visit V2 (day 0 + 1 day): Phone contact~Visit V3 (day 0 + 2 to 7 days):~Same as V1~Visit V4 (V3 + 1 day): Phone contact and end of the study"
427863|NCT00931580|Dietary Supplement|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
427864|NCT00931567|Biological|Autologous platelets gel|"Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease."
427865|NCT00931567|Device|Vaselitulle|"application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease."
427866|NCT00931554|Procedure|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
427867|NCT00931541|Drug|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
427868|NCT00931541|Drug|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
427869|NCT00931528|Drug|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
427870|NCT00931528|Other|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
427871|NCT00931515|Device|NuBac|NuBac device implanted at the L4/5 level.
427872|NCT00931515|Device|Prodisc-L|Prodisc-L implanted at the L4/5 level.
427873|NCT00931489|Drug|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
427874|NCT00931476|Drug|somatropin|
427875|NCT00931476|Drug|placebo|
427876|NCT00931463|Drug|raltegravir|400 mg raltegravir tablet taken every 12 hours
427877|NCT00931463|Drug|2N(t)RTI|2N(t)RTIs as prescribed
427878|NCT00931463|Drug|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
427879|NCT00931450|Drug|exemestane|Given orally
427880|NCT00931450|Drug|sunitinib malate|Given orally
427881|NCT00931450|Other|placebo|Given orally
427882|NCT00931437|Dietary Supplement|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
427883|NCT00931424|Procedure|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
427884|NCT00931411|Other|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
427885|NCT00931411|Other|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
427886|NCT00931398|Drug|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
427887|NCT00931398|Drug|Placebo|Matched placebo for all Concerta doses.
427888|NCT00931385|Drug|BI 1744|BI1744 Respimat Med Dose Once Daily
427889|NCT00931385|Drug|bi1744|1744 low dose
427890|NCT00931385|Drug|Placebo|Placebo Respimat and Foradil Placebo
427891|NCT00931385|Drug|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
427892|NCT00931372|Drug|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
427893|NCT00931372|Drug|Placebo|Subcutaneous injection
427894|NCT00931359|Device|DTS-G2 System|Treatment with microwave energy
427895|NCT00931359|Device|DTS System (Sham treatment)|Sham treatment - no energy is delivered
427896|NCT00931346|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
427897|NCT00931346|Drug|Placebo|Placebo
427898|NCT00931333|Procedure|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
427899|NCT00931307|Device|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
427900|NCT00931294|Behavioral|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
428034|NCT00930228|Drug|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
427901|NCT00931294|Behavioral|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
427902|NCT00931281|Drug|ABT-450|capsules, QD or BID, 14 days, ascending doses
427903|NCT00931281|Drug|ritonavir|capsules, QD or BID, 14 days, ascending doses
427904|NCT00931281|Drug|Placebo for ABT-450|capsule, QD or BID, 14 days
427905|NCT00931281|Drug|Placebo for ritonavir|capsule, QD or BID, 14 days
427906|NCT00931268|Device|Macrolane VRF 30|One administration
427907|NCT00931255|Drug|Tacrolimus|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
427908|NCT00931255|Drug|Sirolimus|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
427909|NCT00931242|Drug|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
427910|NCT00931229|Drug|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
427911|NCT00931216|Procedure|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
427912|NCT00931203|Drug|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
427913|NCT00931177|Other|weight|weight and dehydration scores
427914|NCT00931177|Other|weight and dehydration score|weight and dehydration score
427915|NCT00931164|Drug|Sodium Oxybate|dosage is by weight
427916|NCT00931151|Dietary Supplement|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
427917|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
427918|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
427919|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
427920|NCT00931125|Drug|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
427921|NCT00931125|Procedure|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
427922|NCT00931112|Other|individualized exercise training|Lower extremities resistance exercise and bicycle training
427923|NCT00931086|Drug|belimumab|IV 10mg/kg q28days
427924|NCT00931073|Drug|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
427925|NCT00931073|Drug|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
427926|NCT00931073|Drug|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
427927|NCT00931060|Dietary Supplement|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
427928|NCT00931034|Behavioral|South Beach Diet with South Beach Diet Products|
427929|NCT00931034|Behavioral|American Diabetes Association Diabetes Meal Plan|
427930|NCT00931021|Drug|Varenicline (Chantix)|2 mg
427931|NCT00931021|Drug|Nicotine Patch|21 mg
427932|NCT00931008|Drug|SID530, Taxotere|75mg/m2
427933|NCT00930995|Drug|Candesartan|16mg po daily
427934|NCT00930995|Drug|Placebo|once daily
427935|NCT00930982|Drug|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
427936|NCT00930982|Drug|Placebo|Inhalation of matching placebo twice a day
427937|NCT00930969|Device|ICD|Subjects implanted with an ICD.
427938|NCT00930956|Dietary Supplement|Resistant Starch|30 g of carbohydrate per Arm
427939|NCT00930943|Drug|Oxymorphone ER (Opana ER)|40 mg qd twice
427940|NCT00930930|Drug|cisplatin|Given IV
427941|NCT00930930|Drug|everolimus|Given orally
427942|NCT00930930|Drug|paclitaxel|Given IV
427943|NCT00930930|Other|placebo|Given orally
427944|NCT00930930|Procedure|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
427945|NCT00930917|Device|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
427946|NCT00930917|Device|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
427947|NCT00930917|Other|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
427948|NCT00930891|Drug|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
428035|NCT00930215|Drug|D961H|Oral gelatin capsule
428036|NCT00930215|Drug|D961H|Oral HPMC capsule
427949|NCT00930891|Drug|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression~PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
427950|NCT00930891|Drug|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles~PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
427951|NCT00930878|Device|Cardiac Stenting|Drug Eluting stent
427952|NCT00930865|Drug|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
427953|NCT00930865|Drug|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
427954|NCT00930839|Drug|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
427955|NCT00930813|Device|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
427956|NCT00930813|Device|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
427957|NCT00930800|Other|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
427958|NCT00930787|Device|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
427959|NCT00930787|Device|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
427960|NCT00930774|Device|FM system|Frequency modulation assistive device
427961|NCT00930774|Behavioral|Auditory training|Participation in computerized auditory training program for eight weeks
427962|NCT00930761|Behavioral|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
427963|NCT00930748|Device|MR imaging with endorectal coil|MR imaging with endorectal coil
427964|NCT00930748|Device|MRI with endo-rectal coil|MRI with endo-rectal coil
427965|NCT00930722|Drug|quinapril|per label as non interventional study
427966|NCT00930709|Drug|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
427967|NCT00930709|Behavioral|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
427968|NCT00930696|Procedure|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
427969|NCT00930696|Procedure|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
427970|NCT00930683|Drug|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
427971|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
427972|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
427973|NCT00930683|Drug|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
427974|NCT00930683|Drug|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
427975|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
427976|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
427977|NCT00930683|Drug|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
427978|NCT00930683|Drug|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
427979|NCT00930670|Drug|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
427980|NCT00930670|Drug|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
427981|NCT00930670|Drug|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
427982|NCT00930670|Drug|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
427983|NCT00930670|Drug|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
427984|NCT00930670|Drug|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
427985|NCT00930670|Drug|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
427986|NCT00930670|Drug|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
427987|NCT00930644|Drug|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
427988|NCT00930631|Drug|[3H] BMS747158|Single bolus intravenous injection of [3H] BMS747158
427989|NCT00930618|Drug|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
427990|NCT00930618|Drug|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
427991|NCT00930605|Drug|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
427992|NCT00930605|Drug|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
427993|NCT00930579|Drug|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
427994|NCT00930566|Drug|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
427995|NCT00930566|Procedure|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
427996|NCT00930553|Biological|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
427997|NCT00930527|Dietary Supplement|Omega-3 Fatty Acid|4g per day for 3 weeks
427998|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
427999|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 800 mg/m^2 dose level, administered every 2 or 3 months.
428000|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 625 mg/m^2 administered every 2 or 3 months.
428001|NCT00930514|Drug|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m^2) administered every 2 or 3 months.
428002|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 375 mg/m^2 administered every 2 or 3 months.
428003|NCT00930501|Biological|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
428004|NCT00930488|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
428005|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
428006|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
428007|NCT00930462|Device|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
428008|NCT00930449|Other|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.~Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
428009|NCT00930449|Other|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.~Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
428010|NCT00930449|Other|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
428011|NCT00930436|Drug|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
428012|NCT00930410|Procedure|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
428013|NCT00930371|Other|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
428014|NCT00930371|Other|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
428015|NCT00930358|Drug|MEOPA|anaesthetic gaz inhalation
428016|NCT00930358|Drug|general anaesthesia|Anaesthetic intravenous route
428017|NCT00930345|Drug|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).~Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.~At the end of the treatment period patients will be treated at the discretion of the Investigator."
428018|NCT00930332|Drug|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)~Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~OR~Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)~Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
428019|NCT00930332|Other|questionnaire administration|within 48 hours of registration
428020|NCT00930332|Procedure|management of therapy complications|if required
428021|NCT00930319|Other|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
428022|NCT00930306|Drug|AZD2066|12 doses, Given as capsule, 2 mg & 8 mg
428023|NCT00930306|Drug|Caffeine|2 doses, Given as Tablet, 2x50 mg
428024|NCT00930306|Drug|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
428025|NCT00930306|Drug|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
428026|NCT00930306|Drug|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
428027|NCT00930293|Behavioral|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
428028|NCT00930293|Behavioral|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
428029|NCT00930293|Drug|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
428030|NCT00930254|Procedure|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
428031|NCT00930241|Drug|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
428032|NCT00930241|Drug|Prograf®|Prograf® (two daily doses of Tacrolimus)
428033|NCT00930228|Drug|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
428226|NCT00928889|Drug|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
428037|NCT00930202|Drug|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
428038|NCT00930189|Drug|intravitreal injection of ranibizumab|
428039|NCT00930189|Drug|intravitreal injection of triamcinolone|
428040|NCT00930189|Procedure|photodynamic therapy|
428041|NCT00930176|Biological|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
428042|NCT00930163|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
428043|NCT00930163|Drug|placebo|Subcutaneous repeating dose
428044|NCT00930150|Behavioral|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
428045|NCT00930150|Behavioral|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
428046|NCT00930150|Behavioral|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
428047|NCT00930150|Behavioral|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
428048|NCT00930137|Other|isocaloric for week diet|"Consumption of the 2 experimental diets~a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);~a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
428049|NCT00930124|Procedure|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
428050|NCT00930124|Procedure|Distraction osteogenesis|
428051|NCT00930111|Other|2-week rotation|Attending physician is assigned to a 2-week rotation.
428052|NCT00930111|Other|4-week rotation|Attending physician is assigned to a 4-week rotation.
428053|NCT00930098|Drug|clofarabine|
428054|NCT00930085|Other|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
428055|NCT00930072|Drug|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
428056|NCT00930059|Drug|PF-04447943|tablets, 25 mg every 12 hours for 12 wks
428057|NCT00930059|Drug|Placebo|matching placebo tablets, every 12 hours for 12 wks
428058|NCT00930046|Device|Wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
428059|NCT00930046|Device|wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
428060|NCT00930033|Procedure|Nephrectomy|Current surgery
428061|NCT00930033|Other|Sunitinib alone|Sunitinib alone without nephrectomy
428062|NCT00930020|Drug|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
428063|NCT00930020|Drug|Matched placebo|matched placebo (cornstarch) once a day for 5 days
428064|NCT00930007|Other|Blood sampling|Blood sampling for later hormone measurements
428065|NCT00929994|Behavioral|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
428066|NCT00929981|Drug|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
428067|NCT00929968|Biological|Placebo|
428068|NCT00929968|Biological|VAK694|
428069|NCT00929968|Drug|Fluticasone|
428070|NCT00929955|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
428071|NCT00929955|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
428072|NCT00929955|Drug|Placebo|Placebo added to TAU
428073|NCT00929942|Device|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
428074|NCT00929929|Dietary Supplement|L-leucine.|10 g of leucine per day, during 12 weeks.
428075|NCT00929929|Dietary Supplement|Maltodextrin.|10 g of maltodextrin per day, during 12 weeks.
428076|NCT00929929|Behavioral|Exercise program.|Progressive resistance exercise program 4 days a week, during 12 weeks.
428077|NCT00929903|Drug|pazopanib hydrochloride|Given orally
428078|NCT00929903|Other|pharmacological study|Correlative studies
428079|NCT00929890|Behavioral|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
428080|NCT00929890|Behavioral|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
428081|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
428082|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
428083|NCT00929877|Drug|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
428084|NCT00929864|Drug|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
428085|NCT00929864|Drug|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
428086|NCT00929851|Drug|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
428087|NCT00929851|Drug|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
428088|NCT00929838|Behavioral|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
428143|NCT00929526|Procedure|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
428089|NCT00929838|Behavioral|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
428090|NCT00929838|Behavioral|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
428091|NCT00929838|Behavioral|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
428092|NCT00929825|Device|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
428093|NCT00929825|Procedure|TENS|transcutaneous electrical stimulation
428094|NCT00929812|Drug|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
428095|NCT00929812|Drug|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
428096|NCT00929799|Drug|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
428097|NCT00929773|Device|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
428098|NCT00929773|Device|Placebo laser|Inactive laser light.
428099|NCT00929760|Behavioral|specialised renal care|"Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.~Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
428100|NCT00929747|Device|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
428101|NCT00929747|Procedure|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
428102|NCT00929734|Drug|Rosuvastatin|10mg tablets, once daily in three months
428103|NCT00929734|Drug|Placebo|1 tablet, once daily in three months
428104|NCT00929721|Procedure|Blood draw|culture for Streptococcus pneumoniae Frequency-1
428105|NCT00929721|Procedure|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
428106|NCT00929721|Procedure|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
428107|NCT00929721|Procedure|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
428108|NCT00929721|Procedure|sputum|culture for Streptococcus pneumoniae Frequency-1
428109|NCT00929708|Drug|AZD3199|Dry powder for inhalation, o.d., 4 weeks
428110|NCT00929708|Drug|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
428111|NCT00929708|Drug|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
428112|NCT00929695|Drug|prednisone|immunosuppressive drug
428113|NCT00929695|Drug|methylprednisolone|immunosuppressive drug
428114|NCT00929695|Other|questionnaire administration|Ancillary studies
428115|NCT00929682|Drug|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.~Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
428116|NCT00929669|Drug|pasireotide LAR|pasireotide LAR 80 mg IM once a month
428117|NCT00929656|Procedure|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
428118|NCT00929656|Procedure|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
428119|NCT00929656|Procedure|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
428120|NCT00929643|Other|no intervention|success of the initial empiric treatment
428121|NCT00929630|Procedure|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
428122|NCT00929630|Procedure|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
428123|NCT00929630|Procedure|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
428124|NCT00929630|Procedure|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
428125|NCT00929617|Behavioral|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
428126|NCT00929617|Other|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
428127|NCT00929604|Other|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
428128|NCT00929591|Drug|cyclophosphamide|
428129|NCT00929591|Drug|doxorubicin hydrochloride|
428130|NCT00929591|Drug|endocrine therapy|
428131|NCT00929591|Drug|endocrine-modulating drug therapy|
428132|NCT00929591|Drug|fluorouracil|
428133|NCT00929591|Drug|tamoxifen citrate|
428134|NCT00929591|Radiation|brachytherapy|
428135|NCT00929591|Radiation|low-LET electron therapy|
428136|NCT00929591|Radiation|low-LET photon therapy|
428137|NCT00929591|Radiation|radiation therapy|
428138|NCT00929578|Drug|Fluphenazine|Intralesional injection of Fluphenazine
428139|NCT00929578|Drug|Placebo|Intralesional injection of placebo
428140|NCT00929552|Dietary Supplement|Dietary oils (fish, vegetable oil)|6g pr day.
428141|NCT00929539|Drug|JTT-130|Tablets
428142|NCT00929539|Drug|JTT-130 Placebo|Tablets
428144|NCT00929526|Procedure|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
428146|NCT00929487|Device|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
428147|NCT00929487|Other|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
428148|NCT00929487|Device|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
428149|NCT00929474|Device|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
428150|NCT00929474|Device|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
428151|NCT00929461|Drug|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
428152|NCT00929409|Drug|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
428153|NCT00929409|Drug|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
428154|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
428155|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
428156|NCT00929383|Device|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.~The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
428157|NCT00929370|Drug|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
428158|NCT00929357|Drug|DMARDs or Biologics|
428159|NCT00929344|Drug|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
428160|NCT00929344|Drug|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
428161|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
428162|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
428163|NCT00929344|Drug|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
428164|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
428165|NCT00929331|Biological|Fluviral®|Intramuscular injection, one dose
428166|NCT00929318|Procedure|blood sampling|
428167|NCT00929318|Procedure|blood sampling|
428168|NCT00929305|Device|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
428169|NCT00929305|Device|Placebo laser|Inactive laser light
428170|NCT00929292|Other|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
428171|NCT00929292|Other|Modilac 1|Infant formula used for non breastfed children
428172|NCT00929279|Drug|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
428173|NCT00929279|Drug|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
428174|NCT00929266|Biological|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
428175|NCT00929253|Drug|Suboxone|Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks
428176|NCT00929253|Behavioral|CRA|Computer-delivered Community Reinforcement Approach
428177|NCT00929253|Behavioral|Therapy|Therapist-delivered therapy
428178|NCT00929253|Behavioral|CM|Contingency management (vouchers) for providing a drug negative urine sample.
428179|NCT00929240|Drug|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
428180|NCT00929240|Drug|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
428227|NCT00928876|Drug|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
428228|NCT00928876|Drug|Placebo|placebo s/c daily for four weeks
428724|NCT00925548|Drug|sodium chloride (NaCl)|NaCl 9 g/L infusion
428181|NCT00929214|Drug|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:~For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
428182|NCT00929214|Procedure|Local Therapy|"Surgery and/or Radiation Therapy~With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
428183|NCT00929201|Drug|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
428184|NCT00929201|Drug|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
428185|NCT00929201|Drug|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
428186|NCT00929188|Drug|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
428187|NCT00929188|Drug|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
428188|NCT00929175|Device|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
428189|NCT00929175|Device|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
428190|NCT00929162|Drug|ZD4054 Zibotentan|10 mg oral tablets once daily
428191|NCT00929162|Drug|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
428192|NCT00929162|Drug|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
428193|NCT00929162|Drug|Placebo|matching placebo for ZD4054 10 mg
428194|NCT00929136|Biological|USP endotoxin|Continuous intra-arterial infusion
428195|NCT00929123|Procedure|neural mobilization|manual therapy technique known to directly stress the median nerve
428196|NCT00929123|Procedure|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
428197|NCT00929123|Other|healthy controls|People without carpal tunnel syndrome for comparison
428198|NCT00929110|Drug|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
428199|NCT00929110|Drug|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
428200|NCT00929110|Drug|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
428201|NCT00929097|Other|Implementation aids|"Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids~Clinicians receive the guidelines and a risk communication tool, as well as education"
428202|NCT00929097|Other|Control|Dissemination of guidelines
428203|NCT00929084|Other|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
428204|NCT00929071|Device|Evolence|Injectable collagen
428205|NCT00929071|Device|Lidocaine|admix anesthetic
428206|NCT00929071|Drug|topical anesthetic|
428207|NCT00929058|Drug|Bevacizumab|Intra-arterial infusion during 6 minutes
428208|NCT00929045|Drug|Growth Hormone Replacement|
428209|NCT00929032|Radiation|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
428210|NCT00929019|Biological|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
428211|NCT00929006|Drug|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
428212|NCT00929006|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
428213|NCT00928980|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
428214|NCT00928980|Drug|Optimal Medical Care|Therapeutic dose of antidepressant medication
428215|NCT00928967|Drug|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
428216|NCT00928954|Drug|gabapentin|increasing to 1200 mg/day
428217|NCT00928954|Drug|memantine|increasing to 40 mg/day
428218|NCT00928941|Behavioral|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
428219|NCT00928941|Behavioral|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
428220|NCT00928928|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
428221|NCT00928928|Procedure|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
428222|NCT00928915|Drug|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
428223|NCT00928902|Drug|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
428224|NCT00928902|Biological|melanoma vaccine|six melanoma vaccines given over a 6-week period
428225|NCT00928889|Drug|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
428229|NCT00928863|Other|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
428230|NCT00928850|Procedure|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
428231|NCT00928850|Procedure|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
428232|NCT00928850|Procedure|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
428233|NCT00928850|Procedure|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
428234|NCT00928837|Dietary Supplement|Flavocoxid 500 mg|flavonoid mixture
428235|NCT00928837|Drug|Naproxen|non-steroidal anti-inflammatory drug
428236|NCT00928837|Other|Placebo|Placebo
428237|NCT00928837|Other|flavocoxid 250 mg|Medical food product
428238|NCT00928824|Dietary Supplement|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
428239|NCT00928811|Drug|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
428240|NCT00928811|Drug|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
428241|NCT00928798|Drug|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
428242|NCT00928798|Drug|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
428243|NCT00928785|Biological|REPEVAX|1 dose of 0.5 mL at Day 0
428244|NCT00928785|Biological|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
428245|NCT00928772|Device|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
428246|NCT00928772|Drug|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
428247|NCT00928772|Other|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
428248|NCT00928746|Device|Ipratropium bromide|
428249|NCT00928733|Device|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
428250|NCT00928720|Device|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
428251|NCT00928720|Device|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
428252|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
428253|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
428254|NCT00928694|Drug|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
428255|NCT00928694|Drug|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
428256|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
428257|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
428258|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
428259|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
428260|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
428261|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
428262|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
428263|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
428264|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
428265|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
428266|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
428267|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
428268|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
428269|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
428270|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
428271|NCT00928668|Drug|Placebo|Placebo device for comparison
428272|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
428273|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
428274|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
428551|NCT00926926|Drug|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
428275|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
428276|NCT00928655|Drug|acetazolamide|acetazolamide 250mg 1/0/2
428277|NCT00928655|Procedure|nocturnal continuous positive airway pressure|continuous positive airway pressure
428278|NCT00928655|Drug|placebo|placebo capsules
428279|NCT00928642|Drug|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
428280|NCT00928642|Drug|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
428281|NCT00928629|Procedure|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
428282|NCT00928616|Dietary Supplement|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
428283|NCT00928616|Dietary Supplement|margarine (placebo)|non-sterol ester supplemented margarine
428284|NCT00928603|Procedure|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
428285|NCT00928590|Drug|Travoprost/Timolol Maleate Fixed Combination solution|
428286|NCT00928564|Drug|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
428287|NCT00928564|Drug|Placebo|5ml of saline at each block site.
428288|NCT00928551|Drug|vabicaserin|
428289|NCT00928538|Other|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
428290|NCT00928525|Drug|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
428291|NCT00928512|Drug|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
428292|NCT00928512|Drug|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
428293|NCT00928499|Device|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
428294|NCT00928486|Drug|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
428295|NCT00928486|Drug|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
428296|NCT00928473|Behavioral|Weightloss treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
428297|NCT00928460|Procedure|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
428298|NCT00928447|Drug|rHuPH20|ID syringe push bolus injection of rHuPH20. Each injection will be administered once daily for 5 days.
428299|NCT00928447|Drug|Placebo|ID syringe push bolus injection of placebo control. Each injection will be administered once daily for 5 days.
428300|NCT00928434|Drug|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
428301|NCT00928434|Drug|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
428302|NCT00928434|Drug|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
428303|NCT00928421|Drug|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
428304|NCT00928408|Drug|Cinacalcet|
428305|NCT00928395|Device|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
428306|NCT00928356|Procedure|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
428307|NCT00928356|Procedure|Off Pump CABG|Standard of Care Off Pump CABG
428308|NCT00928343|Drug|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
428309|NCT00928343|Drug|Placebo|Matching subcutaneous or oral placebo
428310|NCT00928330|Drug|GDC-0941|Oral repeating dose
428311|NCT00928330|Drug|Trastuzumab|Intravenous repeating dose
428312|NCT00928330|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
428313|NCT00928317|Drug|ART621|3.0mg/kg s.c.
428314|NCT00928317|Drug|ART621|1.5mg/kg s.c.
428315|NCT00928317|Drug|ART621|0.75mg/kg s.c.
428316|NCT00928317|Drug|Placebo|Placebo s.c.
428317|NCT00928304|Drug|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
428318|NCT00928291|Other|procalcitonin|plasma PCT measurement
428319|NCT00928291|Drug|antibiotic therapy|antibiotic therapy use
428320|NCT00928278|Drug|Treatment A|Inhaled, 300/150, single dose
428321|NCT00928278|Drug|Treatment B|Inhaled, 300/150, single dose
428322|NCT00928278|Drug|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
428323|NCT00928278|Drug|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
428355|NCT00928122|Device|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
428725|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
428324|NCT00928265|Device|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.~Accomplishes this by providing coil support at the neck of the aneurysm"
428325|NCT00928252|Drug|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
428326|NCT00928239|Procedure|laparoscopic sacropexy with mid vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
428327|NCT00928239|Procedure|laparoscopic sacropexy with caudal vaginal attachment|"supracervical hysterectomy for uterine prolapse~exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~dissection up to ventrolateral part of the levator ani muscle~Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment~suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
428328|NCT00928226|Radiation|Fractionated Stereotactic Radiosurgery|Standard of care
428329|NCT00928226|Procedure|Surgical resection of the tumor|Standard of care
428330|NCT00928213|Drug|Progesterone|40 units daily admission
428331|NCT00928213|Drug|Low molecular weight Heparin|40-80 mg/day
428332|NCT00928213|Drug|No Drug|no treatment
428333|NCT00928200|Drug|Erwinase|"The dose of Erwinase will be assigned at study entry. The first dose of Erwinase wil be given between Days 3-5 and will continue on a M-W-F schedule for a total of 10 doses.~Erwinase will be administered as a 2-hour intravenous infusion."
428334|NCT00928200|Drug|Vincristine|1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22
428335|NCT00928200|Drug|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14.
428336|NCT00928200|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
428337|NCT00928200|Drug|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
428338|NCT00928200|Drug|Methotrexate|Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
428339|NCT00928200|Drug|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
428340|NCT00928200|Drug|Dexrazoxane|Due to the limited availability of Dexrazoxane (Zinecard®), treatment will be at the discretion of the treating physician. Dose should be 600 mg/m2 as a IV push immediately prior to anthracycline dose (the elapsed time from the beginning of the dexrazoxane dose to the end of the anthracycline infusion should be 30 minutes or less).
428341|NCT00928187|Drug|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
428342|NCT00928187|Drug|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight < 60 kg, 400 mg if weight > 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
428343|NCT00928187|Drug|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
428344|NCT00928174|Drug|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
428345|NCT00928161|Drug|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
428346|NCT00928148|Drug|SPD465|50 or 75 mg once daily for 7 days
428347|NCT00928148|Drug|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
428348|NCT00928148|Drug|Placebo|Once daily for 7 days
428349|NCT00928135|Drug|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
428350|NCT00928135|Drug|Saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
428351|NCT00928122|Device|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
428352|NCT00928122|Device|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
428353|NCT00928122|Device|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
428354|NCT00928122|Device|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
428356|NCT00928109|Behavioral|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
428357|NCT00928109|Behavioral|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
428358|NCT00928083|Drug|OZ439 50mg API capsules|
428359|NCT00928083|Drug|OZ439 200mg API capsules|
428360|NCT00928083|Drug|OZ439 400mg aqueous dispersion|
428361|NCT00928083|Drug|OZ439 800mg aqueous dispersion|
428362|NCT00928083|Drug|OZ439 100mg API capsules|OZ439 100mg (2x50mg API capsules)
428363|NCT00928083|Drug|OZ439 400mg API capsules|OZ439 400mg (2x200mg API capsules)
428364|NCT00928083|Drug|OZ439 1600mg aqueous dispersion|
428365|NCT00928083|Drug|OZ439 800mg API capsules|OZ439 800mg (4x200 API capsules)
428366|NCT00928083|Drug|OZ439 1200mg API capsules|OZ439 1200mg (6x200mg API capsules)
428367|NCT00928083|Drug|Placebo|
428368|NCT00928083|Drug|OZ439 200mg aqueous dispersion|
428369|NCT00928070|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg
428370|NCT00928070|Drug|Placebo|Placebo sham 4 mg and 8 mg
428371|NCT00928057|Device|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
428372|NCT00928057|Device|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
428373|NCT00928057|Device|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
428374|NCT00928018|Drug|Sirolimus|Taken orally for at least 12 months
428375|NCT00928018|Drug|Methotrexate|Given intravenously on the first, third and sixth day after transplant
428376|NCT00928018|Drug|Tacrolimus|Taken orally or given intravenously for at least 6 months
428377|NCT00928018|Drug|Cyclosporine|Taken orally or given intravenously for at least 6 months
428378|NCT00928018|Drug|MMF|Taken orally for about 2 months
428379|NCT00928005|Behavioral|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
428380|NCT00928005|Behavioral|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
428381|NCT00927992|Other|Epidemiological Non interventional|Epidemiological Non interventional
428382|NCT00927979|Drug|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
428383|NCT00927979|Drug|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
428384|NCT00927979|Drug|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
428385|NCT00927966|Drug|RAD001|Taken orally once a day.
428386|NCT00927966|Drug|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
428387|NCT00927953|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
428388|NCT00927953|Biological|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
428389|NCT00927940|Device|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
428390|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428391|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428392|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428393|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428394|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428395|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428396|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428397|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
428398|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
428399|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
428400|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
428401|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
428402|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
428403|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
428404|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
428405|NCT00927914|Drug|Ranirestat|Ranirestat 40 mg tablets
428406|NCT00927914|Drug|Placebo|Placebo tablets
428726|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
428407|NCT00927901|Drug|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
428408|NCT00927901|Drug|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
428409|NCT00927901|Drug|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
428410|NCT00927901|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
428411|NCT00927888|Drug|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
428412|NCT00927888|Drug|Placebo|placebo is identical in appearance in comparison to active drug.
428413|NCT00927875|Drug|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
428414|NCT00927875|Drug|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
428415|NCT00927875|Drug|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, & 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
428416|NCT00927862|Genetic|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
428417|NCT00927862|Genetic|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.~Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
428418|NCT00927862|Other|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients >=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
428419|NCT00927849|Procedure|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
428420|NCT00927849|Drug|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
428421|NCT00927849|Drug|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
428422|NCT00927836|Biological|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
428423|NCT00927836|Drug|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
428424|NCT00927823|Drug|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
428425|NCT00927810|Drug|Canakinumab|
428426|NCT00927797|Drug|Cyclophosphamide, Pentostatin, Rituximab|
428427|NCT00927784|Biological|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
428428|NCT00927784|Drug|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
428429|NCT00927771|Drug|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
428430|NCT00927771|Drug|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
428431|NCT00927758|Drug|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
428432|NCT00927745|Device|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
428433|NCT00927745|Device|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
428434|NCT00927732|Drug|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
428435|NCT00927732|Drug|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
428436|NCT00927719|Biological|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
428437|NCT00927706|Device|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
428478|NCT00927485|Other|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
428438|NCT00927693|Other|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
428439|NCT00927667|Procedure|No Drug|Patients have received primary FVIII prophylaxis (started < 2 years of age)
428440|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - < 6 years of age)
428441|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - < 12 years of age)
428442|NCT00927667|Procedure|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
428443|NCT00927667|Procedure|No Drug|Patients have received on-demand therapy
428444|NCT00927654|Drug|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
428445|NCT00927654|Drug|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
428446|NCT00927641|Drug|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
428447|NCT00927641|Other|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
428448|NCT00927628|Procedure|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
428449|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intracoronary)
428450|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intravenous)
428451|NCT00927602|Drug|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
428452|NCT00927589|Drug|carboplatin|Intravenous repeating dose
428453|NCT00927589|Drug|docetaxel|Intravenous repeating dose
428454|NCT00927589|Drug|trastuzumab|Intravenous repeating dose
428455|NCT00927576|Behavioral|Digit span testing|Testing of short-term verbal memory with digit span
428456|NCT00927576|Behavioral|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
428457|NCT00927576|Behavioral|Finger tapping|Testing motor speed with a finger tapping test.
428458|NCT00927576|Behavioral|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
428459|NCT00927576|Behavioral|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
428460|NCT00927576|Behavioral|Verbal fluency|Evaluating how many words are produced in 90s.
428461|NCT00927576|Behavioral|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
428462|NCT00927576|Behavioral|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
428463|NCT00927576|Behavioral|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
428464|NCT00927576|Behavioral|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
428465|NCT00927563|Drug|Tolcapone|pill, 100-300mg/day for 8 weeks
428466|NCT00927550|Drug|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
428467|NCT00927550|Drug|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
428468|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
428469|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
428470|NCT00927524|Drug|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
428471|NCT00927524|Drug|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
428472|NCT00927511|Drug|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
428473|NCT00927498|Drug|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
428474|NCT00927498|Drug|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
428475|NCT00927485|Drug|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
428476|NCT00927485|Other|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
428477|NCT00927485|Other|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
428479|NCT00927485|Other|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
428480|NCT00927472|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
428481|NCT00927472|Drug|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
428482|NCT00927459|Drug|PRO-040201|Single dose IV infusion
428483|NCT00927459|Drug|Placebo|placebo
428484|NCT00927446|Procedure|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
428485|NCT00927433|Behavioral|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
428486|NCT00927407|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
428487|NCT00927407|Drug|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
428488|NCT00927394|Drug|Aliskiren|Aliskiren 150 mg tablet
428489|NCT00927394|Drug|Valsartan|Valsartan 160 mg capsules
428490|NCT00927394|Drug|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
428491|NCT00927394|Drug|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
428492|NCT00927368|Procedure|ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
428493|NCT00927368|Procedure|ultrasound guidance and needle stimulation|For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
428494|NCT00927368|Procedure|ultrasound guidance and catheter stimulation|The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
428495|NCT00927355|Drug|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
428496|NCT00927355|Drug|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
428497|NCT00927342|Other|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
428498|NCT00927342|Other|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
428499|NCT00927329|Biological|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
428500|NCT00927316|Biological|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).~Placebo arm: Identical procedure but with saline, 30 ml."
428501|NCT00927303|Device|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
428502|NCT00927303|Device|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
428503|NCT00927290|Drug|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
428504|NCT00927290|Drug|Placebo|Placebo 45 mg QD (30 mg QD the first month)
428505|NCT00927277|Device|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
428506|NCT00927277|Device|Erchonia(R) LipoLASER PL|
428507|NCT00927264|Behavioral|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits & 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
428508|NCT00927264|Behavioral|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
428509|NCT00927251|Device|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
428510|NCT00927238|Device|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
428511|NCT00927238|Other|Lumbar fusion surgery|Lumbar fusion surgery
428512|NCT00927225|Drug|ropivacaine 0.2%, 50 mL|
428513|NCT00927225|Drug|normal saline|
428514|NCT00927212|Drug|AS101 ointment|Twice daily topical application
428515|NCT00927199|Dietary Supplement|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
428516|NCT00927199|Dietary Supplement|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
428517|NCT00927199|Dietary Supplement|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
428518|NCT00927186|Drug|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
428519|NCT00927186|Drug|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.~After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
428520|NCT00927173|Device|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
428521|NCT00927173|Device|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
428522|NCT00927147|Radiation|BNCT|Boronophenylalanine infusion followed by neutron irradiation
428523|NCT00927147|Drug|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
428524|NCT00927134|Genetic|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
428525|NCT00927121|Device|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|"The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.~Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.~The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system"
428526|NCT00927108|Other|Progenitor Stem Cell Culture|
428527|NCT00927095|Drug|Continuous OC (EE/DROS)|Continuous EE(20ug)+DROS(3mg) daily for 3 months
428528|NCT00927095|Drug|Intermittent OC (EE/DROS)|Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
428529|NCT00927095|Drug|placebo|daily placebo
428530|NCT00927082|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
428531|NCT00927069|Drug|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
428532|NCT00927069|Drug|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
428533|NCT00927056|Procedure|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
428534|NCT00927043|Other|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
428535|NCT00927030|Drug|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
428536|NCT00927030|Drug|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
428537|NCT00927017|Other|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
428538|NCT00927017|Other|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
428539|NCT00927004|Drug|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
428540|NCT00927004|Drug|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
428541|NCT00926991|Other|No intervention|No intervention; observation only
428542|NCT00926978|Radiation|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.~Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
428543|NCT00926965|Drug|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
428544|NCT00926965|Drug|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
428545|NCT00926965|Drug|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
428546|NCT00926952|Drug|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
428547|NCT00926952|Device|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
428548|NCT00926939|Behavioral|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
428549|NCT00926939|Behavioral|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
428550|NCT00926926|Drug|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
428552|NCT00926900|Drug|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
428553|NCT00926900|Drug|Placebo|Placebo
428554|NCT00926887|Device|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
428555|NCT00926887|Device|Placebo Laser|Inactive light
428556|NCT00926861|Device|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
428557|NCT00926861|Device|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
428558|NCT00926848|Behavioral|Partners Together in Health (PaTH) Intervention|Patients and partners in the PaTH experimental group participated in 18-36 exercise and 18 educational sessions in a structured cardiac rehabilitation program. Patients in the Usual care group also participated in 18-36 exercise and 18 educational sessions; partners, however, only participated in the educational sessions.
428559|NCT00926835|Drug|paroxetine|6 weeks, 20-50mg/day
428560|NCT00926835|Drug|Escitalopram|10-20mg/day for 6 weeks
428561|NCT00926835|Drug|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
428562|NCT00926835|Drug|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
428563|NCT00926835|Drug|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
428564|NCT00926835|Drug|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
428565|NCT00926835|Drug|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
428566|NCT00926835|Drug|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
428567|NCT00926835|Drug|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
428568|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
428569|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
428570|NCT00926796|Drug|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
428571|NCT00926796|Drug|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients >45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
428572|NCT00926796|Drug|Gemifloxacin|One 320 mg tablet administered orally.
428573|NCT00926783|Procedure|CFAE ablation|CFAE ablation (targeted vs. generalized)
428574|NCT00926757|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
428575|NCT00926757|Drug|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
428576|NCT00926744|Behavioral|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
428577|NCT00926731|Drug|AZD1152|Variable dose via a 7-day continuous infusion
428578|NCT00926731|Drug|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
428579|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
428580|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
428581|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
428582|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
428583|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
428584|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
428585|NCT00926705|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
428586|NCT00926705|Drug|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
428587|NCT00926692|Other|Blood draw|Subject will have blood draw.
428588|NCT00926666|Drug|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
428589|NCT00926653|Drug|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
428590|NCT00926640|Drug|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
428591|NCT00926640|Drug|Cisplatin|6 cycles at 60mg/m2 IV on day 2
428592|NCT00926640|Drug|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
428593|NCT00926627|Drug|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)
428594|NCT00926627|Drug|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
428595|NCT00926614|Drug|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
428596|NCT00926614|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
428597|NCT00926588|Drug|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
428598|NCT00926575|Drug|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
428599|NCT00926575|Drug|Placebo|Two tablets QID for 50 days
428600|NCT00926562|Drug|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
428601|NCT00926562|Drug|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
428602|NCT00926549|Device|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
428603|NCT00926536|Device|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
428604|NCT00926536|Device|DSA only|DSA imaging only
428605|NCT00926523|Other|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
428727|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
428606|NCT00926523|Other|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
428607|NCT00926523|Other|Spirometry|To assess subjects lung function
428608|NCT00926523|Other|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
428609|NCT00926510|Behavioral|Language toolkit|Simple toolkit of interactive things to stimulate language.
428610|NCT00926510|Behavioral|Safety counseling|Smoke detector and general safety counseling
428611|NCT00926497|Other|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
428612|NCT00926471|Behavioral|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
428613|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
428614|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
428615|NCT00926419|Biological|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
428616|NCT00926419|Biological|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
428617|NCT00926406|Drug|lead chelation therapy|Patients with lead poisoning (BLL> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL < 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
428618|NCT00926393|Drug|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
428619|NCT00926393|Drug|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
428620|NCT00926380|Drug|denosumab|denosumab: 60 mg SC every 6 months
428621|NCT00926380|Drug|teriparatide|teriparatide: 20 mcg SC QD
428622|NCT00926367|Drug|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
428623|NCT00926367|Drug|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
428624|NCT00926354|Drug|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
428625|NCT00926341|Drug|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
428626|NCT00926341|Drug|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
428627|NCT00926328|Drug|Triclosan, fluoride|Six Month study, brush twice daily
428628|NCT00926328|Drug|Fluoride|twice daily usage
428629|NCT00926315|Drug|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
428630|NCT00926315|Drug|Calcitriol|calcitriol 0.25 mcg PO bid
428631|NCT00926302|Drug|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
428632|NCT00926302|Drug|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
428633|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
428634|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
428635|NCT00926289|Drug|Hydrochlorothiazide|Hydrochlorothiazide25mg
428636|NCT00926276|Procedure|Fundoplication|Fundoplication
428637|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
428638|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
428639|NCT00926263|Biological|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
428640|NCT00926250|Dietary Supplement|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
428641|NCT00926250|Dietary Supplement|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
428642|NCT00926237|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) - ACTIVE|Active rTMS will be targeted according to the following decision tree: 1) to auditory cortex in the superior temporal gyrus opposite the ear with loudest tinnitus; 2) to the same region in the left temporal lobe. Active stimulation will be delivered at 110% of motor threshold (MT) at a frequency of 1 or 10 Hz for a total of 1800 magnetic pulses per session (and a total of 4 sessions per week of active rTMS therapy).
428643|NCT00926237|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) - SHAM|Sham rTMS will be targeted using a commercially available sham coil and delivered to the same site within the temporal lobe as active rTMS and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
428644|NCT00926224|Device|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
428645|NCT00926211|Device|ARTAS™ System|Hair harvest using a computer-assisted system
428646|NCT00926211|Procedure|Manual Hair Harvest|Hair harvesting via the manual technique
428647|NCT00926185|Drug|Lifitegrast|Ophthalmic Solution
428648|NCT00926185|Drug|Placebo|Ophthalmic Solution
428686|NCT00925821|Drug|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
428687|NCT00925808|Behavioral|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
428723|NCT00925548|Drug|cyclophosphamide|300 mg/m^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
428649|NCT00926146|Behavioral|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
428650|NCT00926146|Behavioral|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
428651|NCT00926133|Other|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
428652|NCT00926120|Dietary Supplement|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
428653|NCT00926107|Drug|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
428654|NCT00926081|Behavioral|Supervised exercise training|A standardized supervised exercise training program
428655|NCT00926068|Drug|HO/03/03 10µg|
428656|NCT00926068|Drug|Placebo|
428657|NCT00926055|Drug|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
428658|NCT00926055|Drug|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
428659|NCT00926029|Drug|Fluoride|Brush twice daily
428660|NCT00926029|Drug|Triclosan, fluoride|Brush twice daily
428661|NCT00926029|Other|Metal salt|Brush twice daily
428662|NCT00926016|Drug|Pioglitazone (Actos)|pioglitazone 45 mg a day
428663|NCT00926003|Behavioral|Full Computerized cognitive training|8 weeks of 3 times weekly intervention for 60 min per session with the full titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning
428664|NCT00926003|Behavioral|Limited computerized cognitive training|Locked Captain's Log CCRT that rotates randomly among simplest level of computer cognitive games training. 8 weeks of 3 times weekly intervention for 60 min per session with the non-titrating version of Captain's Log program (3 games for attention, 3 games for visual spatial working memory, 3 games for reasoning/planning).
428665|NCT00925990|Drug|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
428666|NCT00925990|Drug|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
428667|NCT00925990|Drug|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
428668|NCT00925977|Drug|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
428669|NCT00925977|Drug|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
428670|NCT00925951|Device|Wet Cupping|Wet cupping (Seongho trade & company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
428671|NCT00925951|Drug|Acetaminophen|Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
428672|NCT00925938|Drug|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
428673|NCT00925938|Drug|placebo|placebo
428674|NCT00925925|Other|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
428675|NCT00925912|Procedure|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
428676|NCT00925912|Procedure|Perianal block|0.25% bupivacaine injected at perianal region
428677|NCT00925899|Drug|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
428678|NCT00925899|Drug|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
428679|NCT00925886|Procedure|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
428680|NCT00925873|Drug|Active comparator (no fludarabine)|"Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).~The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm~Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
428681|NCT00925873|Drug|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence~Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.~Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.~Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
428682|NCT00925860|Procedure|non positive pressure mechanical ventilatory support|
428683|NCT00925847|Drug|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
428684|NCT00925834|Behavioral|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
428685|NCT00925821|Procedure|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
428688|NCT00925795|Other|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
428689|NCT00925795|Other|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
428690|NCT00925782|Drug|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
428691|NCT00925782|Drug|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
428692|NCT00925769|Drug|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
428693|NCT00925769|Drug|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
428694|NCT00925769|Drug|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
428695|NCT00925756|Drug|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment
428696|NCT00925743|Drug|cabazitaxel (XRP6258)|"administered by IV infusion~in addition to cisplatin treatment"
428697|NCT00925730|Drug|Pimecrolimus|
428698|NCT00925704|Drug|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
428699|NCT00925704|Drug|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
428700|NCT00925704|Drug|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
428701|NCT00925691|Device|RV lead|The RV lead is implanted at the apex or at the interventricular septum
428702|NCT00925678|Drug|DSP-3025|
428703|NCT00925678|Drug|Placebo|
428704|NCT00925665|Device|Glidescope|Patients are to be intubated using the Glidescope technique
428705|NCT00925665|Device|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
428706|NCT00925652|Drug|Bevacizumab|Given intravenously once every 3 weeks for approximately 6 months, then every 6 weeks for additional 1.5 years.
428707|NCT00925652|Drug|Cyclophosphamide|Taken orally once a day for approximately 6 months.
428708|NCT00925652|Drug|Methotrexate|One pill orally twice a day on days 1 and 2 of each week for approximately 6 months.
428709|NCT00925652|Behavioral|Diet Intervention|Series of 13 telephone calls over the course of one-year with a dedicated and trained counselor
428710|NCT00925652|Behavioral|Diet and Exercise Intervention|Counseling targeted toward increasing physical activity and a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
428711|NCT00925639|Drug|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
428712|NCT00925639|Drug|Placebo|Starch pill
428713|NCT00925626|Procedure|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
428714|NCT00925626|Procedure|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
428715|NCT00925613|Device|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.~If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
428716|NCT00925613|Device|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
428717|NCT00925600|Biological|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
428718|NCT00925600|Biological|Placebo|Prefilled syringe for subcutaneous (SC) injection
428719|NCT00925587|Drug|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
428720|NCT00925574|Drug|CNTO 1959; Placebo|
428721|NCT00925548|Biological|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:~Pretreatment (Single Dose) 300 mg/m^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).~Primary treatment phase:~Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* (Week 1 to 8).~Maintenance treatment phase:~Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).~*calculated as mass of lipopeptide (antigen)"
428722|NCT00925548|Biological|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:~Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.~Primary treatment phase:~Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).~Maintenance treatment phase:~Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
428728|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
428729|NCT00925522|Device|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
428730|NCT00925509|Procedure|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.~Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.~Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.~A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
428731|NCT00925483|Procedure|dialysis|different dialysis schedules for each arm
428732|NCT00925457|Other|No Intervention|Neither current domperidone nor current PPI
428733|NCT00925457|Drug|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
428734|NCT00925457|Drug|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
428735|NCT00925444|Device|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
428736|NCT00925444|Device|Stapling|Stapling alon or associated with sealants
428737|NCT00925431|Behavioral|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
428738|NCT00925431|Behavioral|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
428739|NCT00925418|Procedure|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
428740|NCT00925405|Procedure|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
428741|NCT00925405|Procedure|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
428742|NCT00925392|Drug|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
428743|NCT00925392|Drug|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
428744|NCT00925366|Other|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
428745|NCT00925353|Drug|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
428746|NCT00925340|Behavioral|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
428747|NCT00925340|Behavioral|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
428748|NCT00925327|Other|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
428749|NCT00925314|Biological|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
428750|NCT00925301|Drug|migalastat hydrochloride|Oral capsule QOD
428751|NCT00925301|Drug|Placebo|Oral capsule QOD
428752|NCT00925288|Biological|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
428753|NCT00925275|Drug|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
428754|NCT00925262|Behavioral|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
428755|NCT00925262|Behavioral|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
428756|NCT00925262|Behavioral|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
428757|NCT00925210|Procedure|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.~If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
428758|NCT00925197|Other|INR self-testing program|
428759|NCT00925171|Behavioral|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
428760|NCT00925158|Procedure|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
428761|NCT00925145|Procedure|Single Incision Laparoscopic Appendectomy|
428762|NCT00925132|Drug|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.~Decitabine - 6 cohorts with dose escalation.~Panobinostat - 6 cohorts with dose escalation."
428763|NCT00925119|Drug|Atenolol|12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
428885|NCT00924274|Dietary Supplement|sunflower oil|sunflower oil
428764|NCT00925106|Drug|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
428765|NCT00925106|Drug|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
428766|NCT00925106|Drug|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
428767|NCT00925106|Drug|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
428768|NCT00925093|Drug|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
428769|NCT00925093|Drug|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
428770|NCT00925093|Drug|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
428771|NCT00925080|Device|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
428772|NCT00925067|Procedure|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
428773|NCT00925067|Device|lightweight TiMesh|
428774|NCT00925067|Device|lightweight VyproII|
428775|NCT00925067|Device|Heavyweight Marlex|
428776|NCT00925054|Drug|rAvPAL-PEG 0.001 mg/kg|In Part 1, the planned starting dose levels is 0.001 mg/kg
428777|NCT00925054|Drug|rAvPAL-PEG 0.003 mg/kg|In Part 1, the planned starting dose levels is 0.003 mg/kg
428778|NCT00925054|Drug|rAvPAL-PEG 0.01 mg/kg|In Part 1, the planned starting dose levels is 0.01 mg/kg
428779|NCT00925054|Drug|rAvPAL-PEG 0.03 mg/kg|In Part 1, the planned starting dose levels is 0.03 mg/kg
428780|NCT00925054|Drug|rAvPAL-PEG 0.1 mg/kg|In Part 1, the planned starting dose levels is 0.1 mg/kg
428781|NCT00925041|Device|Vedera KXS|one treatment with the Vedera KXS
428782|NCT00925028|Drug|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
428783|NCT00925028|Drug|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
428784|NCT00925015|Biological|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
428785|NCT00925015|Biological|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m^2, followed by subsequent once weekly intravenous infusions of 250 mg/m^2
428786|NCT00925015|Drug|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m^2, once every other week for 42 days
428787|NCT00925015|Biological|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
428788|NCT00925002|Drug|Tafamidis|20 mg oral Fx-1006A daily
428789|NCT00924989|Drug|OSI-906|Administered orally
428790|NCT00924989|Other|Placebo|Matching placebo administered orally
428791|NCT00924976|Behavioral|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
428792|NCT00924963|Device|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
428793|NCT00924963|Device|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
428794|NCT00924963|Drug|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
428795|NCT00924950|Drug|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
428796|NCT00924950|Drug|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
428797|NCT00924937|Behavioral|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; <10% SAT).
428798|NCT00924937|Behavioral|Low Fat Diet|Low fat diet: <30% fat (12% MUFA; 6-8%PUFA; <10% SAT)
428799|NCT00924924|Behavioral|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
428800|NCT00924924|Behavioral|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
428801|NCT00924911|Drug|GSK1322322|Four different formulations of 1000mg of GSK1322322
428802|NCT00924911|Drug|GSK1322322|GSK1322322 1000mg
428803|NCT00924898|Drug|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
428804|NCT00924885|Device|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
428805|NCT00924885|Device|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
428806|NCT00924872|Other|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
428807|NCT00924859|Other|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
428808|NCT00924846|Procedure|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
428809|NCT00924833|Drug|placebo|placebo tablet BID
428810|NCT00924833|Drug|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
428811|NCT00924833|Drug|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
428812|NCT00924820|Drug|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
428813|NCT00924807|Drug|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
428814|NCT00924794|Procedure|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
428815|NCT00924781|Drug|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
428816|NCT00924781|Drug|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
428817|NCT00924781|Drug|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
428818|NCT00924768|Biological|20K EU CCRE|Inhalation of CCRE
428819|NCT00924755|Device|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
428820|NCT00924742|Drug|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
428821|NCT00924729|Drug|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
428822|NCT00924729|Drug|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
428823|NCT00924703|Drug|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
428824|NCT00924690|Other|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
428825|NCT00924690|Other|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
428826|NCT00924677|Procedure|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
428827|NCT00924677|Procedure|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
428828|NCT00924664|Biological|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
428829|NCT00924664|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
428830|NCT00924651|Behavioral|exercise|home based walking and progressive resistance training exercise
428831|NCT00924638|Device|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
428832|NCT00924625|Other|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
428833|NCT00924625|Other|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
428834|NCT00924612|Drug|Oral testosterone undecanoate (containing 300 mg of T)|Single dose administered orally, 30 minutes after the initiation of protocol-defined breakfast or while fasting, in each of the 5 arms.
428835|NCT00924599|Behavioral|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
428836|NCT00924599|Behavioral|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
428837|NCT00924586|Drug|ONO-1101|Placebo for one minute IV
428838|NCT00924586|Drug|ONO-1101|0.125 mg/kg for one minute IV
428839|NCT00924573|Drug|Metformin|oral administration
428840|NCT00924573|Drug|placebo|oral administration
428841|NCT00924573|Drug|Glimepiride (HOE490)|oral administration
428842|NCT00924560|Drug|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.~Take 1 tablet daily"
428843|NCT00924560|Drug|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
428884|NCT00924274|Dietary Supplement|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
428844|NCT00924547|Dietary Supplement|Docosahexanoic Acid Supplement|"The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.~These dosages will be divided BID-TID and will be given for 4 weeks."
428845|NCT00924547|Dietary Supplement|Placebo|Placebo identical to active treatment.
428846|NCT00924534|Drug|Placebo|Placebo
428847|NCT00924534|Drug|SLV337|SLV337 400 mg/day
428848|NCT00924534|Drug|SLV337|SLV337 800 mg/day
428849|NCT00924534|Drug|SLV337|SLV337 1400 mg/day
428850|NCT00924521|Dietary Supplement|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
428851|NCT00924521|Dietary Supplement|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
428852|NCT00924508|Device|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
428853|NCT00924508|Drug|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
428854|NCT00924495|Device|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
428855|NCT00924482|Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
428856|NCT00924469|Drug|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
428857|NCT00924469|Drug|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
428858|NCT00924469|Drug|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
428859|NCT00924456|Behavioral|Transcendental Meditation program|a natural effortless mental technique
428860|NCT00924443|Drug|clofarabine|
428861|NCT00924430|Drug|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
428862|NCT00924430|Drug|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
428863|NCT00924417|Behavioral|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
428864|NCT00924417|Behavioral|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
428865|NCT00924404|Drug|Xylitol|5% solution for sinus rinse
428866|NCT00924404|Drug|Saline|saline for sinus rinse
428867|NCT00924391|Dietary Supplement|phytosterol enhanced soy based beverage|
428868|NCT00924391|Dietary Supplement|1% milk|
428869|NCT00924352|Drug|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level − 1;100 mg QD,Dose Level − 2;70 mg QD.
428870|NCT00924352|Drug|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level − 1;12 mg/m2,Dose Level − 2;12 mg/m2.
428871|NCT00924339|Dietary Supplement|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
428872|NCT00924339|Dietary Supplement|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
428873|NCT00924326|Drug|Fludarabine|Days -5 to -1 (after administration of cyclophosphamide): 25 mg/m^2 intravenous (IV) over 30 minutes
428874|NCT00924326|Drug|Cyclophosphamide|Days -5 to -4: 60mg/kg intravenous (IV) over 60 minutes
428875|NCT00924326|Biological|Anti-cluster of differentiation 19 (CD19)-CAR PBL|"Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) peripheral blood lymphocytes ( PBL).~Day 0 (two to four days after the last dose of fludarabine); Cells will be infused via intravenous (IV) on the Patient Care Unit over 20-30 minutes."
428876|NCT00924326|Drug|Aldesleukin|Day 0: 720,000 IU/kg intravenously (IV) every 8 hours for a maximum of 15 doses.
428877|NCT00924326|Drug|Fludarabine|Days -5 to -3 (after administration of cyclophosphamide): 30 mg/m^2 intravenous (IV) over 30 minutes
428878|NCT00924326|Drug|Cyclophosphamide|Days -5 to -3: 300mg/m^2 intravenous (IV) over 60 minutes
428879|NCT00924313|Drug|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
428880|NCT00924287|Drug|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
428881|NCT00924287|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
428882|NCT00924287|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
428883|NCT00924287|Drug|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
428886|NCT00924261|Other|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
428887|NCT00924261|Other|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
428888|NCT00924248|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
428889|NCT00924222|Drug|Sevoflurane|Sedation with sevoflurane
428890|NCT00924222|Drug|Propofol|Sedation on intensive care unit with propofol
428891|NCT00924209|Drug|Gemcitabine|1250 mg/m^2 dose for two doses on days 1 and 8
428892|NCT00924209|Drug|Cisplatin|80 mg/m^2 on day 1
428893|NCT00924209|Drug|Bevacizumab|7.5 mg/m^2 on day 1 every 21 days for first two cycles only
428894|NCT00924209|Procedure|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
428895|NCT00924209|Drug|Etoposide|100 mg/m^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
428896|NCT00924183|Other|Treatment-as-usual|
428897|NCT00924170|Drug|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
428898|NCT00924170|Drug|Fludarabine|"Days 1-3:~Patients 1-7, 10-14, and >18:25mg/m^2/day Patients 8 - 9:30 mg/m^2/day Patients 15- 17:20 mg/m^2/day"
428899|NCT00924170|Drug|Cyclophosphamide|"Days 1-3:~Patients 1-7, 10 -14, and >18:250 mg/m^2/day Patients 8 - 9:300 mg/m^2/day Patients 15-17:200 mg/m^2/day"
428900|NCT00924157|Dietary Supplement|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
428901|NCT00924157|Other|Placebo|Matching placebo capsules
428902|NCT00924118|Drug|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
428903|NCT00924105|Drug|CYT013-IL1bQb|s.c. injection
428904|NCT00924105|Drug|Placebo|s.c. injection
428905|NCT00924092|Biological|GI-6207 [Recombinant Saccharomyces Cerevisia|
428906|NCT00924092|Drug|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
428907|NCT00924079|Drug|nalbuphine|oral dosage form, 66 mg, single dose
428908|NCT00924066|Drug|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m^2 for a total of 30mg/m^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
428909|NCT00924053|Drug|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
428910|NCT00924053|Drug|Placebo|Placebo capsules to match EGT0001474
428911|NCT00924040|Drug|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
428912|NCT00924027|Radiation|Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
428913|NCT00924014|Drug|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
428914|NCT00924014|Drug|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
428915|NCT00924014|Drug|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
428916|NCT00924001|Drug|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10^9 and 1 x 10^11 lymphocytes) after expansion in interleukin-2 and OKT-3
428917|NCT00924001|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
428918|NCT00924001|Drug|Fludarabine|25 mg/m^2/day intravenously x 5 days
428919|NCT00924001|Drug|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
428920|NCT00923988|Other|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
428921|NCT00923975|Device|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
428922|NCT00923962|Drug|Glucagon like peptide-1|0,1 pmol/kg/min
428923|NCT00923962|Drug|Adenosine|20-40 microgram/minute
428924|NCT00923949|Drug|Pioglitazone|45 mg tablet daily by mouth for six weeks
428925|NCT00923936|Drug|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles.
428926|NCT00923936|Drug|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
428927|NCT00923923|Behavioral|stress|compare levels of stress
428928|NCT00923910|Drug|WT1 Peptide-Pulsed Dendritic Cells|
428929|NCT00923910|Drug|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
428930|NCT00923910|Drug|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
428931|NCT00923910|Drug|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
428932|NCT00923910|Drug|WT1 Peptides|dendritic cell vaccine
428933|NCT00923910|Drug|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
428934|NCT00923910|Drug|Diphenhydramine|Pre-medication
428935|NCT00923910|Drug|Acetaminophen|Pre-medication
428936|NCT00923897|Radiation|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
428937|NCT00923871|Procedure|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
428938|NCT00923845|Drug|Pentostatin|Pentostatin: 2- 4mg/m^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
428939|NCT00923845|Drug|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
428940|NCT00923845|Drug|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
428941|NCT00923845|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
428942|NCT00923845|Procedure|Th2 rapa cells|Th2 rapa cell Transplantation
428943|NCT00923845|Procedure|Donor Lymphocyte Harvest|Apheresis
428944|NCT00923845|Procedure|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
428945|NCT00923845|Procedure|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
428946|NCT00923845|Procedure|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
428947|NCT00923819|Procedure|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
428948|NCT00923819|Behavioral|Standard conservative treatment|Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
428949|NCT00923806|Biological|PG13-CEA_TCR (Anti-CEA TCR PBL)|
428950|NCT00923806|Drug|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
428951|NCT00923793|Device|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
428952|NCT00923793|Device|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
428953|NCT00923741|Drug|Talactoferrin|
428954|NCT00923741|Procedure|Apheresis|
428955|NCT00923728|Drug|AVN944|
428956|NCT00923702|Biological|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants will be randomly allocated in equal numbers to receive either two or three doses of the vaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18. Girls in the two-dose group will receive the vaccine at Day 1 and Day 180, girls in the three-dose group will receive the vaccine at Day 1, Day 60, and Day 180.
428957|NCT00923676|Drug|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
428958|NCT00923676|Drug|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
428959|NCT00923676|Drug|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
428960|NCT00923663|Drug|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
428961|NCT00923637|Drug|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
428962|NCT00923624|Other|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
428963|NCT00923624|Behavioral|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
428964|NCT00923611|Drug|Fimasartan|
428965|NCT00923598|Drug|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
428966|NCT00923572|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
428967|NCT00923559|Other|Treatment as Usual at Child Health Centre|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment may be initiated by the health visitor or the mother. This will be registered at the end-point interview.
428968|NCT00923559|Other|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief whatsoever that the infant understands verbal communication. Rather, the analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
428969|NCT00923533|Drug|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
428970|NCT00923533|Drug|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
428971|NCT00923520|Drug|DMS 612|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 every 21 days until MTD is reached
428972|NCT00923494|Drug|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
428973|NCT00923494|Drug|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
428974|NCT00923494|Drug|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
428975|NCT00923481|Drug|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
428976|NCT00923429|Procedure|Stay-active care|No other treatment than the stay-active care
428977|NCT00923429|Procedure|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
428978|NCT00923429|Procedure|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
428979|NCT00923429|Procedure|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
428980|NCT00923403|Dietary Supplement|plant sterol enriched soymilk|plant sterol enriched soymilk
428981|NCT00923403|Dietary Supplement|control dairy milk|control dairy milk
428982|NCT00923390|Genetic|2G-1 TCR Retroviral Vector-Transduced lyn|
428983|NCT00923390|Drug|Aldesleukin|
428984|NCT00923390|Drug|Cyclophosphamide|
428985|NCT00923390|Drug|Fludarabine|
428986|NCT00923390|Drug|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
428987|NCT00923364|Drug|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg intravenous (IV) (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
428988|NCT00923364|Drug|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m(2) IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
428989|NCT00923364|Procedure|Total Body Irradiation (TBI)|200 centigray (cGy) on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
428990|NCT00923364|Procedure|Allogeneic Hematopoietic Stem Cell (HSC)|stem cell transplant
428991|NCT00923364|Drug|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
428992|NCT00923351|Drug|Tumor Purged/CD25 Depleted Lymphocytes|
428993|NCT00923351|Biological|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
428994|NCT00923351|Drug|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
428995|NCT00923351|Biological|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
428996|NCT00923338|Device|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
428997|NCT00923312|Biological|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
428998|NCT00923299|Drug|cetuximab|Cetuximab at the initial dose of 400 mg/m² (J1S1) as a 2-hour infusion and then at the 250 mg/m² dose as a 1-hour infusion in subsequent weeks.
428999|NCT00923299|Drug|trastuzumab|"Two dose levels of trastuzumab will be evaluated for Phase 1:~Level 1: a loading dose of 3 mg/kg as a 90-minute intravenous infusion at J1S1 and then 1.5 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations;~Level 2: a loading dose of 4 mg/kg as a 90-minute intravenous infusion at J1S1 and then 2 mg/kg as a 30-minute intravenous infusion for all subsequent weekly administrations."
429000|NCT00923273|Drug|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
429001|NCT00923273|Drug|Pemetrexed|
429002|NCT00923273|Drug|Sirolimus|
429003|NCT00923273|Dietary Supplement|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
429004|NCT00923273|Dietary Supplement|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
429005|NCT00923273|Drug|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
429006|NCT00923260|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
429007|NCT00923260|Procedure|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
429008|NCT00923247|Drug|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
429009|NCT00923247|Drug|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
429010|NCT00923234|Drug|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
429011|NCT00923234|Drug|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
429079|NCT00922701|Drug|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
430077|NCT00914966|Biological|C1 inhibitor (human) [C1 INH]|
429012|NCT00923195|Drug|MART-1: 26-35(27L) Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
429013|NCT00923195|Drug|Montanide ISA 51 VG|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
429014|NCT00923195|Drug|gp100:154-162 Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
429015|NCT00923195|Procedure|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
429016|NCT00923195|Drug|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
429017|NCT00923195|Drug|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
429018|NCT00923195|Drug|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
429019|NCT00923195|Genetic|Anti-gp 100:154 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
429020|NCT00923195|Genetic|Anti-MART-1 F5 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).~One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
429021|NCT00923182|Drug|alemtuzumab|
429022|NCT00923169|Drug|Anti-Transforming Growth Factor-beta (GC 1008)|
429023|NCT00923156|Drug|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
429024|NCT00923156|Drug|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
429025|NCT00923156|Drug|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
429026|NCT00923156|Drug|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
429027|NCT00923130|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
429028|NCT00923130|Drug|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
429029|NCT00923117|Drug|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
429030|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
429031|NCT00923091|Drug|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
429032|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
429033|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
429034|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
429035|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
429036|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
429037|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
429038|NCT00923078|Behavioral|Auditory Cognitive Training|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory. Training was administered in a supervised clinical laboratory setting at a frequency of five 60-minute sessions per week over 4 weeks.
429080|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
429081|NCT00922688|Drug|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
429082|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
429039|NCT00923078|Behavioral|Visual Cognitive Training|The program entails five computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and, following our laboratory procedures, calibration testing is repeated every 5th session. Exercises adapt in difficulty to individual performance, giving constant feedback about progress. Each of the five exercises focuses on a distinct process: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view. Training was administered in a supervised clinical laboratory setting at a frequency of five 40-minute sessions per week over 4 weeks.
429040|NCT00923013|Drug|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
429041|NCT00923013|Drug|Rituximab|Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
429042|NCT00923000|Drug|Nalbuphine|Nalbuphine 10mg with oral administration
429043|NCT00923000|Drug|Morphine|Morphine 10mg with oral administration
429044|NCT00923000|Drug|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
429045|NCT00923000|Drug|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
429046|NCT00923000|Drug|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
429047|NCT00922987|Drug|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
429048|NCT00922974|Radiation|External beam radiation therapy|Single fraction dose of 8 Gy external beam radiation therapy
429049|NCT00922974|Radiation|Radiosurgery/SBRT|Single fraction dose image-guided radiosurgery / stereotactic body radiotherapy (SBRT). The phase II component uses 16 Gy. The phase III component allows 16 or 18 Gy as preferred by the treating physician.
429050|NCT00922961|Biological|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
429051|NCT00922961|Procedure|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
429052|NCT00922948|Procedure|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
429053|NCT00922948|Procedure|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
429054|NCT00922935|Device|Cresco|Cresco components loading 10 days post surgery
429055|NCT00922935|Device|Cresco|Cresco loading at 6-8 weeks post surgery
429056|NCT00922935|Device|Straumann components|Straumann components loading 6-8 weeks post surgery
429057|NCT00922909|Behavioral|Simon task|Reaction time task
429058|NCT00922896|Drug|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"Erlotinib 100 mg po q d daily AND~Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8~Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8~Every 3 weeks"
429059|NCT00922883|Drug|Eltrombopag|
429060|NCT00922870|Device|Cascade|Cascade treatment over 48h
429061|NCT00922870|Other|Standard treatment|Standard therapy
429062|NCT00922857|Procedure|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
429063|NCT00922844|Drug|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
429064|NCT00922805|Dietary Supplement|guar gum|guar gum (20 g/l of formula) for one week
429065|NCT00922792|Drug|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
429066|NCT00922792|Drug|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
429067|NCT00922779|Drug|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
429068|NCT00922779|Drug|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
429069|NCT00922766|Drug|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).
429070|NCT00922753|Other|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
429071|NCT00922753|Other|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
429072|NCT00922753|Other|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
429073|NCT00922740|Drug|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
429074|NCT00922740|Drug|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
429075|NCT00922727|Biological|L. reuteri|The oil drops contains 10^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10^8 CFU/ 5 drops and less than 8 x 10^8 CFU/ 5 drops.
429076|NCT00922727|Biological|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops.
429077|NCT00922714|Drug|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
429078|NCT00922714|Drug|saline (placebo)|NaCl 0.9 g/L
429118|NCT00922363|Biological|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
429083|NCT00922675|Procedure|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
429084|NCT00922675|Procedure|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
429085|NCT00922649|Device|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on >2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
429086|NCT00922636|Drug|LY2216684|Taken in tablet form QD po.
429087|NCT00922636|Drug|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
429088|NCT00922636|Drug|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
429089|NCT00922636|Drug|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
429090|NCT00922623|Device|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
429091|NCT00922610|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
429092|NCT00922597|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
429093|NCT00922584|Drug|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
429094|NCT00922571|Procedure|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
429095|NCT00922571|Device|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
429096|NCT00922558|Other|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
429097|NCT00922545|Other|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
429098|NCT00922532|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
429099|NCT00922532|Drug|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
429100|NCT00922519|Other|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 4 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
429101|NCT00922506|Drug|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
429102|NCT00922493|Other|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.~An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
429103|NCT00922480|Drug|Fimasartan|Fimasartan 60 ~ 120mg/po take one tablets once a day
429104|NCT00922480|Drug|Losartan (Control)|Losartan 50 mg ~ 100 mg/po, take one tablets once a day
429105|NCT00922467|Drug|NaCl 9/00|Same volume as in the esmolol group
429106|NCT00922467|Drug|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
429107|NCT00922454|Procedure|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.~EVAR, CTA imaging, 1, 6 12 months post treatment."
429108|NCT00922454|Device|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
429109|NCT00922454|Device|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
429110|NCT00922441|Drug|Fimasartan 60 mg group|Fimasartan 60 mg
429111|NCT00922441|Drug|Fimasartan 120 mg group|Fimasartan 120 mg
429112|NCT00922441|Drug|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
429113|NCT00922402|Procedure|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.~In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
429114|NCT00922389|Procedure|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
429115|NCT00922389|Drug|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
429116|NCT00922389|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
429117|NCT00922376|Device|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
429119|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
429120|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
429121|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
429122|NCT00922350|Other|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
429123|NCT00922350|Other|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
429124|NCT00922350|Other|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
429125|NCT00922350|Other|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
429126|NCT00922337|Device|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
429127|NCT00922324|Drug|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
429128|NCT00922311|Drug|Aliskiren|Titrate from 150 mg daily to 300 mg daily
429129|NCT00922285|Other|psychosocial support for caregiver|6 weekly 60 minute sessions
429130|NCT00922285|Other|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
429131|NCT00922285|Procedure|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
429132|NCT00922285|Procedure|stress management therapy|6 weekly 60 minute sessions
429133|NCT00922272|Drug|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
429134|NCT00922272|Drug|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
429135|NCT00922259|Biological|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
429136|NCT00922246|Device|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
429137|NCT00922233|Drug|levonorgestrel|oral contraceptive pills
429138|NCT00922220|Other|stationary bike|Participants rode a stationary bike for five minutes
429139|NCT00922220|Other|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
429140|NCT00922220|Other|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
429141|NCT00922207|Drug|Adefovir|From week -4 to week 2
429142|NCT00922207|Drug|Entecavir|From week -4 to week 2
429143|NCT00922207|Drug|Placebo|From week -4 to week 2
429144|NCT00922207|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
429145|NCT00922194|Drug|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
429146|NCT00922181|Device|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
429147|NCT00922181|Device|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
429148|NCT00922155|Device|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
429149|NCT00922129|Drug|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
429150|NCT00922129|Drug|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months~Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
429151|NCT00922116|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
429152|NCT00922103|Procedure|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
429153|NCT00922103|Procedure|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
429154|NCT00922077|Behavioral|standard physical therapy program with emphasis on dynamic balance exercises|
429155|NCT00922064|Procedure|ECT|ECT series consisting of 6 to 14 ECTs
429156|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|
429157|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
429158|NCT00922038|Behavioral|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
429159|NCT00922012|Device|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
429160|NCT00921973|Biological|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
429161|NCT00921973|Biological|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
429246|NCT00921258|Procedure|prostate biopsy|"patient of control group will have :~1 prostate biopsy 3 months after diagnostic biopsy~1 prostate biopsy each year during 2 years~1 prostate biopsy each 2 years during 8 years"
429162|NCT00921960|Other|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
429163|NCT00921947|Biological|VAX102|Universal M2e influenza vaccine
429164|NCT00921921|Drug|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
429165|NCT00921921|Drug|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
429166|NCT00921908|Other|2 mBq radioactive technetium diluted in 20 mL saline|
429167|NCT00921895|Device|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
429168|NCT00921882|Procedure|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
429169|NCT00921869|Drug|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
429170|NCT00921856|Other|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
429171|NCT00921843|Drug|Methadone 0.1mg/kg|Subjects will receive methadone as their intraoperative opioid.
429172|NCT00921843|Drug|Methadone 0.2mg/kg|Subjects will receive methadone as their intraoperative opioid.
429173|NCT00921843|Drug|Methadone 0.3mg/kg|Subjects will receive methadone as their intraoperative opioid.
429174|NCT00921843|Drug|Control|Subjects will not receive methadone as their intraoperative opioid.
429175|NCT00921830|Drug|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
429176|NCT00921804|Drug|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
429177|NCT00921804|Drug|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
429178|NCT00921804|Drug|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
429179|NCT00921804|Drug|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
429180|NCT00921791|Device|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
429181|NCT00921791|Device|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
429182|NCT00921791|Behavioral|Pharmaceutical care|consultations with the pharmacists
429183|NCT00921791|Other|Usual care|Consultation with the physician.
429184|NCT00921778|Device|Lapcone|Use of Lapcone during LSH
429185|NCT00921778|Procedure|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
429186|NCT00921765|Drug|Saline|Saline single bolus dose followed by saline single bolus dose iv
429187|NCT00921765|Drug|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
429188|NCT00921765|Drug|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
429189|NCT00921765|Drug|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
429190|NCT00921739|Radiation|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
429191|NCT00921726|Drug|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
429192|NCT00921726|Drug|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
429193|NCT00921713|Other|Oncology Nurse Care Management|
429194|NCT00921713|Other|Patient-centered materials|
429195|NCT00921700|Drug|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
429196|NCT00921700|Drug|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
429197|NCT00921700|Drug|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
429198|NCT00921700|Drug|Placebo|Single oral dose of lactose as placebo in gelatine capsules
429199|NCT00921687|Behavioral|Education only|The education will consist of a lecture and distribution of a CKD reference card.
429200|NCT00921687|Behavioral|Multifactorial intervention|Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
429201|NCT00921674|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
429202|NCT00921661|Drug|AVE0005 (aflibercept)|IV infusion
429203|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
429204|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
429205|NCT00921622|Dietary Supplement|Vitamin D|1000 IU twice daily for up to 10 days
429206|NCT00921622|Dietary Supplement|Vitamin C|500 mg twice daily for up to 10 days
429207|NCT00921609|Diagnostic Test|Oral glucose tolerance test|An oral glucose tolerance test is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
429247|NCT00921245|Drug|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
429248|NCT00921232|Behavioral|Questionnaires|"During a consultation:~3 questionnaires (HADS, FRI, CRA)~and a form for the sociodemographic data"
430078|NCT00914953|Drug|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
429208|NCT00921596|Procedure|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
429209|NCT00921583|Device|Long-term examination|Follow-up dental implants 20 year in function
429210|NCT00921570|Drug|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
429211|NCT00921570|Drug|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
429212|NCT00921557|Drug|Alendronate|Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
429213|NCT00921557|Drug|Placebo|Oral tablet taken once weekly
429214|NCT00921557|Dietary Supplement|Calcium carbonate/vitamin D|Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
429215|NCT00921544|Other|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
429216|NCT00921544|Other|Sterile water|Sterile water administered 2 mins prior to eye exam
429217|NCT00921531|Drug|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE~Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
429218|NCT00921531|Drug|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
429219|NCT00921518|Drug|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
429220|NCT00921518|Drug|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
429221|NCT00921505|Drug|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
429222|NCT00921505|Drug|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
429223|NCT00921505|Drug|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
429224|NCT00921505|Drug|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
429225|NCT00921492|Device|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
429226|NCT00921492|Other|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
429227|NCT00921427|Behavioral|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
429228|NCT00921427|Device|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
429229|NCT00921414|Drug|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
429230|NCT00921414|Other|Watch and wait|No treatment patient follow-up every 2 months during 3 years
429231|NCT00921401|Behavioral|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
429232|NCT00921388|Other|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
429233|NCT00921388|Behavioral|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
429234|NCT00921375|Drug|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
429235|NCT00921349|Procedure|Ligation of varices|all varices are ligated until obliteration
429236|NCT00921349|Drug|Nadolol|Nadolol (beta-blocker)
429237|NCT00921336|Drug|KW-2450|Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
429238|NCT00921323|Behavioral|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
429239|NCT00921323|Behavioral|Control|The control group will be advised to continue to be physically active and record daily steps
429240|NCT00921310|Drug|Pemetrexed|
429241|NCT00921310|Drug|Temsirolimus|
429242|NCT00921297|Procedure|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
429243|NCT00921284|Drug|NaCl 9/00|Same volume as in the dexmedetomidine group
429244|NCT00921284|Drug|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
429245|NCT00921271|Device|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
429249|NCT00921219|Drug|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
429250|NCT00921206|Biological|VAX102|1 ug i.m. compared to 2 ug s.c.
429251|NCT00921193|Device|Radiation Therapy Positioning System (RTPS)|
429252|NCT00921180|Drug|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
429253|NCT00921180|Drug|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
429254|NCT00921167|Drug|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks
429255|NCT00921154|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
429256|NCT00921128|Drug|Muscimol|
429257|NCT00921115|Drug|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
429258|NCT00921115|Drug|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
429259|NCT00921102|Drug|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
429260|NCT00921102|Drug|Morphine|200 µg of a 200 µg/ml solution, intrathecally
429261|NCT00921102|Drug|Isotonic saline solution|"0.9% NaCl solution~0.1 ml, intrathecally in group Control and IV Atropine~0.1 ml, intravenously in group Control and Intrathecal Atropine"
429262|NCT00921102|Drug|Atropine|"100 µg of a 1 mg/ml preservative-free solution~intrathecally in group Intrathecal Atropine~intravenously in group IV Atropine"
429263|NCT00921076|Behavioral|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
429264|NCT00921063|Drug|PD 0332334|250 mg capsule, BID for 4 weeks
429265|NCT00921063|Drug|PD 0332334|100 mg capsule, BID for 4 weeks
429266|NCT00921063|Drug|placebo|0 mg capsule, BID for 4 weeks
429267|NCT00921063|Drug|Alprazolam extended release|1 mg capsule, BID for 4 weeks
429268|NCT00921050|Drug|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
429269|NCT00921050|Drug|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
429270|NCT00921037|Procedure|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
429271|NCT00921024|Drug|CXA-101|intravenous
429272|NCT00921024|Drug|Ceftazidime|intravenous
429273|NCT00920998|Drug|Z-338|oral
429274|NCT00920985|Drug|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
429275|NCT00920985|Drug|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
429276|NCT00920972|Drug|Treatment Plan 1: Stratum 1|Day -50 to -21: Hydroxyurea 30mg/kg PO q day Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
429277|NCT00920972|Drug|Treatment Plan 2: Strata 2, 3, or 4|Day -50 to -21: Hydroxyurea 30mg/kg PO q day… Day -22: Campath-1H 3 mg IV or SQ... Day -21: Campath-1H 10 mg IV or SQ... Day -20: Campath-1H 15 mg IV or SQ... Day -19: Campath-1H 20 mg IV or SQ... Day -8: Fludarabine 30mg/m2 IV... Day -7: Fludarabine 30mg/m2 IV... Day -6: Fludarabine 30mg/m2 IV... Day -5: Fludarabine 30mg/m2 IV... Day -4: Fludarabine 30mg/m2 IV... Day -4: Thiotepa 8mg/kg IV… Day -3: Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
429278|NCT00920972|Drug|GVHD Regimen A: UCB Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +5: Abatacept 10mg/kg IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV
429279|NCT00920972|Drug|GVHD Regimen B: BM Recipients|Day -3: Begin Tacrolimus or cyclosporine Begin MMF Day -1: Abatacept 10mg/kg IV Day +1: Methotrexate 7.5mg/m2 IV Day +3: Methotrexate 7.5mg/m2 IV Day +5: Abatacept 10mg/kg IV Day +6: Methotrexate 7.5mg/m2 IV Day +14: Abatacept 10mg/kg IV Day +28: Abatacept 10mg/kg IV Day +60: Abatacept 10mg/kg IV Day +100: Abatacept 10mg/kg IV Day +180: Abatacept 10mg/kg IV Day +270: Abatacept 10mg/kg IV Day +365: Abatacept 10mg/kg IV
429280|NCT00920959|Drug|FP 100mcg|Once-daily dosing
429281|NCT00920959|Drug|FSC 100/50mcg|Once-daily dosing
429282|NCT00920959|Drug|Placebo|Once-daily dosing
429283|NCT00920946|Drug|Dimebon|20 mg Dimebon orally TID
429284|NCT00920946|Other|Placebo|Orally TID
429285|NCT00920933|Biological|AIN457|
429286|NCT00920933|Other|Placebo|
429287|NCT00920933|Drug|prednisolone|
429288|NCT00920920|Radiation|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
429289|NCT00920907|Biological|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
429290|NCT00920894|Dietary Supplement|plant stanol ester|the effect of plant stanol esters on plasma lipids
429546|NCT00919022|Drug|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
429291|NCT00920881|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
429292|NCT00920868|Drug|dasatinib|dasatinib at 50 mg PO BID)
429293|NCT00920868|Drug|bevacizumab|7.5 mg/kg IV day 1
429294|NCT00920868|Drug|Oxaliplatin|130 mg/m2 IV day 1
429295|NCT00920868|Drug|Capecitabine|850 mg/m2 PO BID on days 1-14
429296|NCT00920855|Drug|bendamustine|"Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.~Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle."
429297|NCT00920855|Drug|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
429298|NCT00920829|Drug|Naltrexone 50 Mg|Naltrexone 25 or 50 mg per titration schedule
429299|NCT00920829|Drug|Placebo|placebo
429300|NCT00920816|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
429301|NCT00920816|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
429302|NCT00920803|Drug|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
429303|NCT00920803|Drug|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
429304|NCT00920790|Biological|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
429305|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 16 weeks
429306|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 8 weeks
429307|NCT00920777|Behavioral|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
429308|NCT00920764|Drug|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
429309|NCT00920764|Drug|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
429310|NCT00920764|Drug|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
429311|NCT00920764|Drug|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
429312|NCT00920751|Procedure|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
429313|NCT00920751|Procedure|Air insufflation|Conventional air insufflation colonoscopy
429314|NCT00920738|Other|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
429315|NCT00920738|Other|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
429316|NCT00920725|Drug|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours~Regular Insulin 0.1units/kg/hr intravenous~Aspart Insulin 0.1 units/kg/hr intravenous"
429317|NCT00920712|Drug|Weiqi decotion|Decoction ,two times a day
429318|NCT00920699|Drug|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
429319|NCT00920686|Drug|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
429320|NCT00920686|Drug|placebo|administered as 3 placebo hard gelatin capsules
429321|NCT00920686|Drug|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
429322|NCT00920673|Procedure|MRI|MRI during 35 to 65 minutes
429323|NCT00920660|Drug|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
429324|NCT00920660|Drug|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
429325|NCT00920660|Drug|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
429326|NCT00920660|Drug|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
429327|NCT00920660|Drug|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
429328|NCT00920660|Drug|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
429617|NCT00918567|Behavioral|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
429329|NCT00920647|Other|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
429330|NCT00920647|Drug|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
429331|NCT00920647|Drug|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
429332|NCT00920647|Drug|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
429333|NCT00920634|Drug|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
429334|NCT00920621|Dietary Supplement|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
429335|NCT00920621|Dietary Supplement|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
429336|NCT00920608|Drug|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
429337|NCT00920608|Drug|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
429338|NCT00920595|Drug|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
429339|NCT00920582|Drug|Teplizumab (MGA031)|IV dosing daily for 14 days times 2 courses
429340|NCT00920582|Drug|Placebo|IV dosing daily for 14 days times 2 courses
429341|NCT00920556|Drug|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
429342|NCT00920556|Drug|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
429343|NCT00920543|Drug|Placebo|Twice daily dosing
429344|NCT00920543|Drug|FP 100mcg|Twice daily dosing
429345|NCT00920543|Drug|FP 500mcg|Twice daily dosing
429346|NCT00920543|Drug|FP 250mcg|Twice daily dosing
429347|NCT00920543|Drug|FSC 100/50mcg|Twice daily dosing
429348|NCT00920543|Drug|FSC 250/50mcg|Twice daily dosing
429349|NCT00920543|Drug|FSC 500/50mcg|Twice daily dosing
429350|NCT00920517|Biological|rDEN2/4delta30(ME) vaccine|10^3 PFU dose
429351|NCT00920517|Biological|Placebo|placebo for rDEN2/4delta30(ME) vaccine
429352|NCT00920504|Behavioral|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
429353|NCT00920504|Other|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
429354|NCT00920491|Biological|biomarker-enhanced disposition decision with proADM|To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
429355|NCT00920478|Other|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
429356|NCT00920478|Other|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
429357|NCT00920465|Drug|mifegyne and cytotec|One day dosage versus two days dosage
429358|NCT00920439|Biological|PoliorixTM|Single dose, intramuscular administration.
429359|NCT00920426|Drug|GSK1265744 30mg|GSK1265744 30 mg
429360|NCT00920426|Drug|Placebo|Placebo to match GSK1265744
429361|NCT00920426|Drug|GSK1265744 5mg|GSK1265744 5mg
429362|NCT00920413|Dietary Supplement|Vitamin C|vitamin C 500mg orally once a day
429363|NCT00920413|Dietary Supplement|placebo|
429364|NCT00920387|Drug|Experimental 200 mcg Lysergic acid diethylamide|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
429365|NCT00920387|Drug|Active Comparator 20 mcg lysergic acid diethylamide|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
429366|NCT00920387|Behavioral|Psychotherapy|Psychotherapy provided by a male and a female psychotherapist
429367|NCT00920374|Biological|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
429710|NCT00917761|Drug|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
429368|NCT00920361|Drug|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
429369|NCT00920335|Other|tumoral sample|Ependymoma tumoral sample
429370|NCT00920322|Device|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
429371|NCT00920322|Device|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
429372|NCT00920309|Drug|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
429373|NCT00920309|Other|Standard of Care-Placebo|
429374|NCT00920296|Drug|GSK1265744|GSK drug
429375|NCT00920283|Device|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
429376|NCT00920283|Device|Driver Cobalt Alloy Coronary Stent|
429377|NCT00920270|Drug|nebulized colistin|nebulized colistin 75 mg every 12 hours
429378|NCT00920270|Drug|antibiotics|conventional parenteral antibiotics
429379|NCT00920257|Drug|GSK2141795|GSK2141795 is an oral AKT inhibitor.
429380|NCT00920244|Procedure|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
429381|NCT00920244|Drug|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
429382|NCT00920244|Drug|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency < 60 beat/min.
429383|NCT00920244|Drug|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
429384|NCT00920244|Device|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
429385|NCT00920231|Device|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
429386|NCT00920231|Device|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
429387|NCT00920218|Biological|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
429388|NCT00920218|Biological|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
429389|NCT00920205|Drug|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
429390|NCT00920192|Drug|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
429391|NCT00920166|Dietary Supplement|Pétunia 1|Infant formula used for non breastfed children
429392|NCT00920166|Dietary Supplement|Regular formula|Infant formula used for non breastfed children
429393|NCT00920153|Biological|bleomycin sulfate|Given IV
429394|NCT00920153|Drug|ABVD regimen|Given IV
429395|NCT00920153|Drug|carmustine|Given IV
429396|NCT00920153|Drug|cisplatin|Given IV
429397|NCT00920153|Drug|cytarabine|Given IV
429398|NCT00920153|Drug|dacarbazine|Given IV
429399|NCT00920153|Drug|dexamethasone|Given orally
429400|NCT00920153|Drug|doxorubicin hydrochloride|Given IV
429401|NCT00920153|Drug|etoposide|Given IV
429402|NCT00920153|Drug|gemcitabine hydrochloride|Given IV
429403|NCT00920153|Drug|ifosfamide|Given IV
429404|NCT00920153|Drug|melphalan|Given IV
429405|NCT00920153|Drug|methylprednisolone|Given IV
429406|NCT00920153|Drug|mitoguazone|Given IV
429407|NCT00920153|Drug|vincristine sulfate|Given IV
429408|NCT00920153|Drug|vindesine|Given IV
429409|NCT00920153|Drug|vinorelbine tartrate|Given IV
429410|NCT00920153|Procedure|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
429411|NCT00920153|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
429412|NCT00920140|Drug|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
429413|NCT00920140|Drug|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
429414|NCT00920127|Dietary Supplement|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.~The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
429415|NCT00920114|Biological|blood sample|
429416|NCT00920101|Drug|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
429417|NCT00920101|Behavioral|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
429418|NCT00920088|Drug|darunavir/ritonavir|DRV/RTV 600/100mg
429419|NCT00920088|Drug|lopinavir/ritonavir|LPV/RTV 400/100mg
429420|NCT00920088|Drug|Midazolam|Midazolam 3mg
429421|NCT00920088|Drug|Dextromethorphan|Dextromethorphan 30mg
429422|NCT00920088|Drug|Flurbiprofen|Flurbiprofen 50mg
429423|NCT00920088|Drug|GSK2248761|NNRTI under investigation
430248|NCT00913848|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
429424|NCT00920075|Drug|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
429425|NCT00920049|Behavioral|Persuasion|
429426|NCT00920036|Device|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
429427|NCT00920023|Drug|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
429428|NCT00920010|Other|biologic sample preservation procedure|
429429|NCT00919997|Genetic|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
429430|NCT00919997|Genetic|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
429431|NCT00919997|Other|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
429432|NCT00919997|Other|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
429433|NCT00919997|Other|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
429434|NCT00919997|Procedure|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
429435|NCT00919984|Drug|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
429436|NCT00919958|Biological|PLX-PAD IM injection|Single treatment; multiple injections
429437|NCT00919945|Other|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
429438|NCT00919945|Other|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
429439|NCT00919932|Behavioral|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
429440|NCT00919932|Device|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
429441|NCT00919919|Drug|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
429442|NCT00919919|Drug|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
429443|NCT00919906|Device|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
429444|NCT00919893|Drug|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
429445|NCT00919893|Drug|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
429446|NCT00919880|Drug|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
429447|NCT00919880|Drug|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
429448|NCT00919867|Drug|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
429449|NCT00919867|Drug|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
429450|NCT00919867|Drug|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
429451|NCT00919854|Drug|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
429452|NCT00919854|Drug|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
429453|NCT00919841|Other|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
429454|NCT00919828|Device|Avivo System|Non invasive external monitoring device
429455|NCT00919815|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
429456|NCT00919815|Drug|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
430717|NCT00910156|Device|Glidescope laryngoscope|glidescope intubation
429457|NCT00919802|Drug|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
429458|NCT00919802|Other|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
429459|NCT00919776|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
429460|NCT00919776|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
429461|NCT00919763|Drug|CD 2027|Topical Ointment; two applications daily, once in the morning and once in the evening for 4 weeks
429462|NCT00919763|Drug|CD 2027 Vehicle|Topical Ointment, two applications daily, once in the morning and once in the evening for 4 weeks
429463|NCT00919750|Other|Cytology Specimen Collection Procedure|Correlative studies
429464|NCT00919737|Drug|NPC-08|Polifeprosan 20 with Carmustine 3.85%
429465|NCT00919711|Drug|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
429466|NCT00919711|Drug|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
429467|NCT00919685|Biological|blood sample|from rest of blood sample collected for other measurements
429468|NCT00919672|Device|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
429469|NCT00919659|Dietary Supplement|parenteral nutrition|25kcal/kg bw with parenteral nutrition
429470|NCT00919633|Drug|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
429471|NCT00919633|Drug|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
429472|NCT00919633|Drug|ribavirin, USP|All patients will receive oral ribavirin
429473|NCT00919633|Device|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
429474|NCT00919620|Behavioral|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
429475|NCT00919607|Drug|quetiapine fumarate extended-release|200mg,oral,single dose
429476|NCT00919607|Drug|quetiapine fumarate extended-release|300mg,oral,single dose
429477|NCT00919594|Behavioral|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
429478|NCT00919594|Behavioral|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
429479|NCT00919555|Drug|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
429480|NCT00919555|Drug|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
429481|NCT00919555|Drug|Placebo|Placebo
429482|NCT00919542|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
429483|NCT00919542|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
429484|NCT00919516|Procedure|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
429485|NCT00919503|Procedure|Allogeneic Bone Marrow Transplantation|Infused IV
429486|NCT00919503|Biological|Anti-Thymocyte Globulin|Given IV
429487|NCT00919503|Drug|Cyclosporine|Given IV or PO
429488|NCT00919503|Drug|Fludarabine Phosphate|Given IV
429489|NCT00919503|Other|Laboratory Biomarker Analysis|Correlative studies
429490|NCT00919503|Drug|Methotrexate|Given IV
429491|NCT00919503|Drug|Mycophenolate Mofetil|Given IV or PO
429492|NCT00919503|Procedure|Peripheral Blood Stem Cell Transplantation|Infused IV
429493|NCT00919503|Drug|Tacrolimus|Given IV or PO
429494|NCT00919503|Radiation|Total-Body Irradiation|Undergo total body irradiation
429495|NCT00919503|Drug|Treosulfan|Given IV
429496|NCT00919503|Procedure|Umbilical Cord Blood Transplantation|Single or double unit umbilical cord blood transplant, infused IV
429497|NCT00919490|Drug|ABT-333|Tablet, see arms for interventional description
429498|NCT00919490|Drug|Placebo|Tablet, see arms for interventional description.
429499|NCT00919464|Device|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
429500|NCT00919464|Device|Compartmental fracture pressure monitoring|
429501|NCT00919464|Device|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
429502|NCT00919451|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
429503|NCT00919438|Device|AVIVO™ Mobile Patient Management System|Non Invasive monitoring device
429504|NCT00919425|Other|biologic sample preservation procedure|
429505|NCT00919399|Drug|Exemestane|25mg a day during 4 months
429506|NCT00919399|Drug|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
429711|NCT00917761|Drug|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
429507|NCT00919373|Procedure|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
429508|NCT00919373|Procedure|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
429509|NCT00919373|Procedure|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
429510|NCT00919360|Procedure|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
429511|NCT00919360|Procedure|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
429512|NCT00919360|Procedure|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
429513|NCT00919360|Procedure|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
429514|NCT00919347|Other|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:~RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;~LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;~SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.~The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):~Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa < 0.1 bpm2.~Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa < 0.5 bpm2 or 0.1 < RFa < 0.5 bpm2.~Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
429515|NCT00919334|Device|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
429516|NCT00919321|Biological|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
429517|NCT00919308|Other|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
429518|NCT00919295|Drug|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
429519|NCT00919295|Drug|placebo|placebo
429520|NCT00919282|Drug|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
429521|NCT00919269|Other|Cytology Specimen Collection Procedure|Correlative studies
429522|NCT00919269|Other|Laboratory Biomarker Analysis|Correlative studies
429523|NCT00919243|Drug|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
429524|NCT00919243|Drug|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
429525|NCT00919230|Drug|Ferrous sulphate tablets|200mg twice daily for four weeks
429526|NCT00919204|Drug|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
429527|NCT00919191|Drug|Tretinoin gel|Tretinoin gel 0.04% used once daily in a split-face model
429528|NCT00919191|Drug|Adapalene and Benzoyl peroxide|Adapalene .1% and Benzoyl peroxide 2.5%
429529|NCT00919178|Biological|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate~Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
429530|NCT00919178|Biological|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo~Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
429531|NCT00919139|Other|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
429532|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
429533|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
429534|NCT00919126|Drug|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
429535|NCT00919113|Drug|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
429536|NCT00919113|Drug|Placebo|The identical buffer used in Uracyst for the same administration
429537|NCT00919100|Device|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
429538|NCT00919100|Other|vapocoolant|venipuncture with vapocoolant spray offered
429539|NCT00919087|Device|Avivo System|Non invasive external monitoring deive
429540|NCT00919074|Procedure|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
429541|NCT00919074|Procedure|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
429542|NCT00919061|Drug|Gemcitabine|Gemcitabine: 800 mg/m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
429543|NCT00919061|Drug|Cisplatin|20 mg /m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
429544|NCT00919061|Drug|Sorafenib|400 mg PO once a day continuously.
429545|NCT00919035|Drug|torisel|Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
429547|NCT00919009|Procedure|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:~Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
429548|NCT00918996|Procedure|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
429549|NCT00918983|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
429550|NCT00918983|Drug|Placebo|Single intraprostatic injection of placebo
429551|NCT00918957|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
429552|NCT00918957|Drug|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
429553|NCT00918944|Other|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~A data entry tool for capturing asthma control data~Standardized documentation templates to facilitate severity classification~Order sets to facilitate ordering controller medications~An asthma care plan that can be supplied to families"
429554|NCT00918944|Other|Intervention|"Three alerts and two reminders will be programmed:~Alert providers to enter asthma severity classification if none is on file~Alert providers to prescribe controller medications for persistent asthma if none on file~Alert providers to complete an asthma care plan if none on file~Remind providers to review the asthma care plan if it is already on file by providing a link to the form~Remind providers that educational content is available on-line by providing a web link"
429555|NCT00918931|Drug|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
429556|NCT00918918|Dietary Supplement|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
429557|NCT00918918|Dietary Supplement|Orange juice|200 mL orange juice
429558|NCT00918905|Device|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.~During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
429559|NCT00918892|Genetic|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
429560|NCT00918892|Other|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
429561|NCT00918892|Other|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
429562|NCT00918879|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
429563|NCT00918879|Drug|Placebo|Oral tablet, once daily for 24 weeks
429564|NCT00918866|Drug|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
429565|NCT00918853|Procedure|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
429566|NCT00918840|Biological|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
429567|NCT00918840|Biological|Placebo|Dextrose/glucose solution
429568|NCT00918840|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
429569|NCT00918814|Drug|LIPO-102|Subcutaneous Injection
429570|NCT00918814|Drug|Placebo|Placebo
429571|NCT00918788|Other|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
429572|NCT00918788|Other|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
429573|NCT00918788|Other|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC).
429574|NCT00918788|Other|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
429575|NCT00918788|Procedure|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
430718|NCT00910156|Device|Macintosh laryngoscope|Macintosh intubation
429576|NCT00918788|Procedure|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
429577|NCT00918788|Procedure|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
429578|NCT00918775|Other|Follow-Up Care|Undergo follow-up
429579|NCT00918775|Other|Laboratory Biomarker Analysis|Correlative studies
429580|NCT00918762|Procedure|assessment of therapy complications|
429581|NCT00918762|Procedure|diagnostic endoscopic surgery|
429582|NCT00918762|Procedure|quality-of-life assessment|
429583|NCT00918762|Procedure|therapeutic conventional surgery|
429584|NCT00918762|Procedure|therapeutic endoscopic surgery|
429585|NCT00918762|Procedure|transoral robotic surgery|
429586|NCT00918762|Procedure|video-assisted surgery|
429587|NCT00918749|Drug|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
429588|NCT00918749|Drug|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
429589|NCT00918749|Drug|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
429590|NCT00918736|Drug|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
429591|NCT00918723|Drug|Fludarabine Phosphate|Given IV
429592|NCT00918723|Drug|Cyclophosphamide|Given IV
429593|NCT00918723|Biological|Rituximab|Given IV
429594|NCT00918723|Drug|Vorinostat|Given PO
429595|NCT00918697|Procedure|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
429596|NCT00918697|Procedure|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
429597|NCT00918684|Drug|Escitalopram|10mg tab daily
429598|NCT00918671|Other|No new specific intervention|No new specific intervention
429599|NCT00918658|Other|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
429600|NCT00918658|Other|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
429601|NCT00918658|Other|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
429602|NCT00918645|Drug|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
429603|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> B -> C. Each of these treatments will be separated by a 7 day washout period.
429604|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> C -> B. Each of these treatments will be separated by a 7 day washout period.
429605|NCT00918632|Drug|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> C -> A. Each of these treatments will be separated by a 7 day washout period.
429606|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> A -> C. Each of these treatments will be separated by a 7 day washout period.
429607|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> A -> B. Each of these treatments will be separated by a 7 day washout period.
429608|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> B -> A. Each of these treatments will be separated by a 7 day washout period.
429609|NCT00918619|Device|Sangustop|Application of Sangustop haemostatic agent on resection area
429610|NCT00918619|Drug|Tachosil|Application of Tachosil fibrin sealant on resection area
429611|NCT00918606|Drug|LIPO-102|LIPO-102
429612|NCT00918593|Drug|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
429613|NCT00918593|Radiation|Radiotherapy|Radiotherapy according to hospital procedures.
429614|NCT00918593|Drug|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
429615|NCT00918580|Biological|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
429616|NCT00918567|Drug|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
429990|NCT00915655|Drug|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
429618|NCT00918554|Drug|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
429619|NCT00918554|Drug|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
429620|NCT00918528|Procedure|Internal urethrotomy|
429621|NCT00918528|Drug|Mitomycin C - local injection|
429622|NCT00918515|Drug|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
429623|NCT00918502|Device|AVIVO system|Non invasive external monitoring device
429624|NCT00918489|Drug|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
429625|NCT00918476|Drug|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
429626|NCT00918463|Drug|dasatinib|100 mg daily dosing
429627|NCT00918450|Drug|ABT-263|"Continuous dosing until disease progression using one of the following formulations:~25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
429628|NCT00918424|Drug|Oxcarbazepine Extended Release|OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
429629|NCT00918411|Drug|Ramosetron|oral
429630|NCT00918411|Drug|Placebo|oral
429631|NCT00918398|Drug|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
429632|NCT00918398|Drug|AZD1981|514 mg oral solution, single dose
429633|NCT00918398|Drug|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
429634|NCT00918398|Drug|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
429635|NCT00918385|Drug|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
429636|NCT00918385|Drug|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
429637|NCT00918346|Drug|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
429638|NCT00918333|Drug|panobinostat|Given PO
429639|NCT00918333|Drug|everolimus|Given PO
429640|NCT00918333|Other|laboratory biomarker analysis|Correlative studies
429641|NCT00918333|Other|pharmacological study|Correlative studies
429642|NCT00918320|Drug|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
429643|NCT00918307|Drug|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
429644|NCT00918307|Drug|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
429645|NCT00918294|Device|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
429646|NCT00918281|Drug|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
429647|NCT00918268|Biological|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
429648|NCT00918255|Biological|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
429649|NCT00918255|Drug|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
429650|NCT00918229|Device|balloon implant|Absorbable perirectal spacer implantation
429651|NCT00918229|Procedure|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
429652|NCT00918216|Genetic|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
429653|NCT00918216|Other|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
429654|NCT00918216|Other|medical chart review|Patients' medical charts are reviewed to obtain clinical information
429655|NCT00918216|Procedure|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
429656|NCT00918216|Procedure|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
429657|NCT00918216|Procedure|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
429658|NCT00918203|Biological|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
429659|NCT00918203|Drug|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
429660|NCT00918203|Drug|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
429661|NCT00918190|Drug|Placebo|Saline
429662|NCT00918190|Drug|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
429663|NCT00918190|Drug|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
429664|NCT00918177|Drug|AP09004|
429665|NCT00918177|Drug|Carbidopa/Levodopa, immediate release|
429666|NCT00918164|Drug|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
429667|NCT00918151|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study
429668|NCT00918138|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
429669|NCT00918138|Drug|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
429670|NCT00918138|Drug|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
429671|NCT00918138|Drug|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
429672|NCT00918138|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
429673|NCT00918099|Procedure|Avaulta mesh|Insertion of a mesh vs conventional repair
429674|NCT00918099|Procedure|Anterior repair|Conventional repair
429675|NCT00918086|Dietary Supplement|Vitamin D pill|Oral tablet taken for 16 weeks
429676|NCT00918086|Dietary Supplement|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
429677|NCT00918060|Drug|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
429678|NCT00918047|Drug|SPN-804O|Open Label study
429679|NCT00918034|Drug|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
429680|NCT00918034|Device|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
429681|NCT00918034|Procedure|Placement|Placement of device in prostate urethra
429682|NCT00918021|Drug|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
429683|NCT00918021|Drug|placebo|placebo
429684|NCT00918008|Genetic|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
429685|NCT00917995|Device|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
429686|NCT00917982|Other|vision therapy|
429687|NCT00917943|Behavioral|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
429688|NCT00917930|Behavioral|physical training|intensive cardiac rehabilitation program
429689|NCT00917917|Behavioral|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.~Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
429690|NCT00917917|Behavioral|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
429691|NCT00917904|Drug|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
429692|NCT00917904|Drug|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
429693|NCT00917891|Drug|dapivirine|"dosage form: vaginal gel~dosage: 1.25mg dapivirine/day~frequency: once daily~duration: 6 weeks"
429694|NCT00917891|Drug|placebo|"dosage form: vaginal gel~frequency: once daily~duration: 6 weeks"
429695|NCT00917878|Dietary Supplement|Milk|500 mL low-fat milk added to high-fat meal
429696|NCT00917878|Dietary Supplement|Protein|Milk protein in 500 mL water added to high-fat meal
429697|NCT00917878|Dietary Supplement|Calcium|Milk calcium in 500 mL water added to high-fat meal
429698|NCT00917878|Dietary Supplement|Control|Lactose in 500 mL water added to high-fat meal
429699|NCT00917865|Drug|anti [18F]FACBC|Anti[18F]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
429700|NCT00917852|Device|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
429701|NCT00917839|Drug|lamotrigine|100 mg, once daily, 12 months
429702|NCT00917826|Drug|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
429703|NCT00917826|Drug|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
429704|NCT00917826|Drug|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
429705|NCT00917813|Drug|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
429706|NCT00917813|Drug|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
429707|NCT00917774|Device|Standard LPS flex TKA|TKA by Standard LPS flex TKA
429708|NCT00917774|Device|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
429709|NCT00917761|Drug|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
429712|NCT00917748|Drug|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
429713|NCT00917748|Drug|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
429714|NCT00917748|Drug|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
429715|NCT00917735|Drug|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
429716|NCT00917735|Other|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
429717|NCT00917709|Other|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with [123I]-iodobenzovesamicol
429718|NCT00917709|Other|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
429719|NCT00917709|Behavioral|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
429720|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
429721|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
429722|NCT00917657|Procedure|Photorefractive keratectomy|
429723|NCT00917644|Drug|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
429724|NCT00917644|Genetic|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
429725|NCT00917631|Procedure|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.~Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.~Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
429726|NCT00917618|Other|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
429727|NCT00917618|Other|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
429728|NCT00917605|Other|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
429729|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
429730|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
429731|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
429732|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
429733|NCT00917566|Device|Airtraq|intubation with airtraq
429734|NCT00917566|Device|Macintoch|use Macintoch laryngoscope for intubation
429735|NCT00917553|Drug|doxycycline monohydrate|50 mg
429736|NCT00917553|Drug|Placebo|Cellulose Placebo Capsule
429737|NCT00917527|Drug|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
429738|NCT00917501|Drug|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
429739|NCT00917501|Drug|Placebo|Placebo given twice a day which will be compared to Omega 3
429740|NCT00917488|Other|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
429741|NCT00917462|Drug|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
429742|NCT00917462|Procedure|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
429743|NCT00917449|Drug|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
429744|NCT00917449|Drug|Placebo|Oral Placebo BID for 18 months
429745|NCT00917436|Drug|Thiocolchicoside|
429851|NCT00916409|Device|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
430075|NCT00914992|Other|Squatting|Squatting
429746|NCT00917410|Behavioral|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.~Remember to take your preventive asthma medication (sent at 8.00 am).~Were you awakened during the night due to your asthma? Answer YES or NO.~How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.~What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
429747|NCT00917397|Drug|Sertraline|varies
429748|NCT00917397|Behavioral|trauma-focused cognitive behavioural therapy|once a week
429749|NCT00917384|Biological|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
429750|NCT00917384|Drug|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
429751|NCT00917384|Other|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
429752|NCT00917358|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
429753|NCT00917345|Drug|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
429754|NCT00917332|Behavioral|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
429755|NCT00917319|Other|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
429756|NCT00917306|Drug|PEP005 Gel|0.05% two day treatment
429757|NCT00917293|Drug|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
429758|NCT00917293|Drug|Placebo|Placebo 2 pills, po bid.
429759|NCT00917267|Drug|exenatide once weekly|2.0mg subcutaneous injection, once a week
429760|NCT00917267|Drug|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
429761|NCT00917254|Drug|YM150|oral
429762|NCT00917254|Drug|Placebo|oral
429763|NCT00917254|Drug|Enoxaparin|injection
429764|NCT00917241|Drug|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
429765|NCT00917241|Drug|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
429766|NCT00917228|Device|recordings with device equipped|
429767|NCT00917228|Device|Control|Recording without device equipped
429768|NCT00917215|Device|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.~For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
429769|NCT00917202|Drug|Methylenblue|
429770|NCT00917189|Behavioral|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
429771|NCT00917176|Device|Occipital nerve stimulation|
429772|NCT00917163|Device|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
429773|NCT00917163|Device|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
429774|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
429775|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
429776|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
429777|NCT00917150|Drug|placebo|oral administration of placebo, once daily for 24months
429778|NCT00917137|Procedure|TBNA + transbronchial lung biopsy + bronchial washing|
429779|NCT00917124|Device|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.~None of the interventions are outside the range of good clinical practice."
429780|NCT00917111|Drug|Nasal CO2|Four times a day for 14 days
429781|NCT00917111|Drug|Inactive Placebo Gas|Placebo
429782|NCT00917098|Behavioral|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
429783|NCT00917098|Behavioral|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
429784|NCT00917085|Behavioral|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
429785|NCT00917072|Behavioral|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
429935|NCT00916019|Other|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
429786|NCT00917072|Behavioral|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
429787|NCT00917072|Behavioral|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
429788|NCT00917059|Drug|Escitalopram|Fixed dose of 10 mg per day
429789|NCT00917059|Drug|Bupropion XL|Fixed dose of 150 mg per day
429790|NCT00917046|Behavioral|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
429791|NCT00917046|Behavioral|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
429792|NCT00917046|Behavioral|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
429793|NCT00917033|Device|GlideScope|Orotracheal intubation
429794|NCT00917033|Device|Macintosh direct laryngoscope|Orotracheal intubation
429795|NCT00917020|Drug|Nasal CO2|As-Needed during the 14 day Treatment Period
429796|NCT00917020|Drug|Inactive Placebo Gas|Placebo
429797|NCT00916994|Device|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
429798|NCT00916981|Procedure|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
429799|NCT00916968|Device|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
429800|NCT00916968|Device|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
429801|NCT00916955|Other|Observation|Observe development of syndrome over time
429802|NCT00916942|Drug|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
429803|NCT00916942|Drug|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
429804|NCT00916929|Device|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
429805|NCT00916916|Other|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
429806|NCT00916890|Drug|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
429807|NCT00916890|Drug|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
429808|NCT00916890|Drug|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
429809|NCT00916890|Drug|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
429810|NCT00916877|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
429811|NCT00916825|Behavioral|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
429812|NCT00916799|Device|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
429813|NCT00916773|Device|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
429814|NCT00916760|Biological|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
429815|NCT00916760|Biological|Placebo|Subcutaneous monthly treatment
429816|NCT00916747|Drug|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
429817|NCT00916734|Procedure|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
429818|NCT00916734|Procedure|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
429819|NCT00916721|Drug|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
429936|NCT00916006|Drug|PEP005 Gel|0.015%, three day treatment
429937|NCT00916006|Drug|Vehicle gel|Vehicle gel, three day treatment
430249|NCT00913848|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
429820|NCT00916721|Drug|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
429821|NCT00916708|Procedure|Intensive/Low-Risk follow up (IA G1; IA G2)|"- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of FU: clinical visit* every 6 months; Pap test every 12 months~* clinical visit with gynecological exploration"
429822|NCT00916708|Procedure|Intensive/High-Risk follow up (≥ IA G3)|"- First 3 years of FU since the end of primary treatment: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months~- In the fourth and fifth years of FU: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months~* clinical visit with gynecological exploration"
429823|NCT00916708|Procedure|Minimalist/Low-Risk follow up (IA G1; IA G2)|"- First 5 years of FU since the end of primary treatment: clinical visit* every 6 months.~* clinical visit with gynecological exploration"
429824|NCT00916708|Procedure|Minimalist/High-Risk follow up (≥ IA G3)|"- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; chest, abdomen, pelvis CT every 12 months~- Since the third to the fifth year of surveillance: clinical visit* every 6 months.~* clinical visit with gynecological exploration"
429825|NCT00916695|Device|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.~Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
429826|NCT00916669|Drug|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
429827|NCT00916669|Drug|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
429828|NCT00916669|Drug|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
429829|NCT00916656|Biological|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
429830|NCT00916656|Biological|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
429831|NCT00916643|Device|HELP Secura (apheresis treatment)|Process is described in Arm (above).
429832|NCT00916630|Drug|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
429833|NCT00916617|Drug|bapineuzumab|5 mg/week subcutaneous bapineuzumab
429834|NCT00916604|Drug|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
429835|NCT00916604|Drug|Placebo|Placebo oral suspension, 8 days treatment
429836|NCT00916578|Radiation|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
429837|NCT00916578|Drug|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
429838|NCT00916552|Drug|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
429839|NCT00916539|Device|Cast that immobilizes the thumb|Cast that immobilizes the thumb
429840|NCT00916539|Device|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
429841|NCT00916526|Procedure|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.~Apply nose clip and subject should be directed to breathe through the mouth~Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)~The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration~At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip~At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)~Insert 5 mg capsule into inhalation device, and proceed as above~Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
429842|NCT00916500|Drug|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
429843|NCT00916487|Dietary Supplement|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
429844|NCT00916474|Drug|telaprevir|
429845|NCT00916461|Drug|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
429846|NCT00916461|Drug|Placebo|Placebo + treatment as usual.
429847|NCT00916448|Drug|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
429848|NCT00916448|Drug|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
429849|NCT00916422|Biological|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
429850|NCT00916422|Biological|Placebo|Subcutaneous monthly treatment
429852|NCT00916409|Drug|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.~Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
429853|NCT00916396|Drug|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
429854|NCT00916396|Drug|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
429855|NCT00916383|Drug|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
429856|NCT00916383|Drug|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
429857|NCT00916370|Device|Core size Xience Prime|Core size includes a range of stent sizes.
429858|NCT00916370|Device|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
429859|NCT00916357|Drug|Humalog|
429860|NCT00916357|Drug|Humulin-R|
429861|NCT00916357|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
429862|NCT00916344|Device|EVIA Pacemaker|patient has standard indication for pacemaker therapy
429863|NCT00916331|Procedure|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
429864|NCT00916331|Procedure|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
429865|NCT00916318|Behavioral|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
429866|NCT00916305|Other|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
429867|NCT00916305|Other|Unmodified audio video|An audio video with unaltered music
429868|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
429869|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
429870|NCT00916279|Device|Lutonix Paclitaxel-Coated Balloon|PTCA
429871|NCT00916266|Procedure|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
429872|NCT00916253|Drug|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
429873|NCT00916253|Drug|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~during 3 days at home~during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
429874|NCT00916240|Behavioral|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
429875|NCT00916240|Behavioral|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
429876|NCT00916227|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
429877|NCT00916214|Other|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
429878|NCT00916201|Drug|URB597|10 mg / d for 5 days, orally
429879|NCT00916201|Drug|intranasal Insulin|160 IU / d for 5 days, intranasal
429880|NCT00916201|Drug|Cannabidiol CR|320 mg / d for 5 days, orally
429881|NCT00916188|Dietary Supplement|Black Tea Extract|Amount/dose depends on Arm assignment.
429882|NCT00916175|Dietary Supplement|P1&P2|"First period (4 weeks) intake food product P1&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from AG&CC group, 4 weeks intake food product P1&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
429883|NCT00916175|Dietary Supplement|P1&CC|"First period (4 weeks) intake food product P1&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from AG&P2 group, 4 weeks intake food product P1&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
429884|NCT00916175|Dietary Supplement|AG&P2|"First period (4 weeks) intake food product AG&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P1&CC group, 4 weeks intake food product AG&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
429885|NCT00916175|Dietary Supplement|AG&CC|"First period (4 weeks) intake food product AG&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet~Second period, cross over from P1&P2 group, 4 weeks intake food product AG&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
429938|NCT00915980|Procedure|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
430898|NCT00908804|Procedure|laparoscopic appendectomy|
429886|NCT00916175|Dietary Supplement|TA (concentrated 5:1 aloe vera gel)|"First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
429887|NCT00916175|Dietary Supplement|P3|"First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.~Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
429888|NCT00916149|Drug|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
429889|NCT00916149|Drug|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:~The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
429890|NCT00916136|Procedure|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
429891|NCT00916123|Drug|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
429892|NCT00916123|Drug|Prednisone|10 mg per day starting on cycle 1, day 1
429893|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
429894|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
429895|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
429896|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
429897|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
429898|NCT00916110|Drug|ATN-103|1.5 mg solution, single subcutaneous injection
429899|NCT00916110|Drug|ATN-103|4 mg solution, single subcutaneous injection
429900|NCT00916110|Drug|ATN-103|10 mg solution, single subcutaneous injection
429901|NCT00916110|Drug|ATN-103|25 mg solution, single subcutaneous injection
429902|NCT00916110|Drug|ATN-103|25 mg solution, single intravenous injection
429903|NCT00916110|Drug|ATN-103|50 mg solution, single subcutaneous injection
429904|NCT00916110|Drug|ATN-103|100 mg solution, single subcutaneous injection
429905|NCT00916110|Drug|ATN-103|200 mg solution, single subcutaneous injection
429906|NCT00916110|Drug|ATN-103|200 mg solution, single intravenous injection
429907|NCT00916097|Drug|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
429908|NCT00916084|Device|Fixed Tongue Appliance|A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
429909|NCT00916084|Device|Fixed Face Mask|An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
429910|NCT00916058|Drug|Bendamustine|30 mg/m^2 given on day 2 of melphalan
429911|NCT00916058|Drug|Melphalan|100 mg/m^2 for 2 days (70 mg/m^2 for patients with Creatinine Clearance <70 ml/min)
429912|NCT00916058|Drug|Bendamustine|60 mg/m^2 given on the 2nd day of melphalan
429913|NCT00916058|Drug|Bendamustine|90 mg/m^2 given on the 2nd day of melphalan
429914|NCT00916058|Drug|Bendamustine|60 mg/m^2 given on the 1st and 2nd day of melphalan
429915|NCT00916058|Drug|Bendamustine|90 mg/m^2 given on the 1st day of melphalan and 60 mg/m^2 given on the 2nd day of melphalan
429916|NCT00916058|Drug|Bendamustine|125 mg/m^2 given on the 1st day of melphalan and 100mg/m^2 given on the 2nd day of melphalan
429917|NCT00916045|Drug|Thiotepa|
429918|NCT00916045|Drug|Fludarabine|
429919|NCT00916045|Drug|Intravenous busulphan|
429920|NCT00916045|Drug|Thymoglobulin|
429921|NCT00916045|Drug|Ciclosporin|
429922|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
429923|NCT00916045|Drug|Fludarabine|
429924|NCT00916045|Drug|Cyclophosphamide|
429925|NCT00916045|Radiation|Radiotherapy|
429926|NCT00916045|Drug|Thymoglobulin|
429927|NCT00916045|Drug|Ciclosporin|
429928|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
429929|NCT00916045|Drug|Fludarabine|
429930|NCT00916045|Drug|Melphalan|
429931|NCT00916045|Drug|Thymoglobulin|
429932|NCT00916045|Drug|Ciclosporin|
429933|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
429934|NCT00916032|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
429939|NCT00915967|Drug|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
429940|NCT00915967|Drug|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
429941|NCT00915954|Diagnostic Test|Oral Glucose Tolerance Test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
429942|NCT00915954|Diagnostic Test|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
429943|NCT00915954|Diagnostic Test|Placebo|Participants will receive a subcutaneous injection of saline followed by a series of blood draws.
429944|NCT00915928|Drug|Perindopril|2,5 mg daily for 3 months
429945|NCT00915928|Drug|Placebo|
429946|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
429947|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
429948|NCT00915902|Drug|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
429949|NCT00915902|Drug|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
429950|NCT00915889|Behavioral|telephone-based intervention|Either 6 or 8 telephone educational sessions
429951|NCT00915889|Other|counseling intervention|counseling and communications studies
429952|NCT00915889|Other|questionnaire administration|Ancillary studies
429953|NCT00915889|Other|study of socioeconomic and demographic variables|Ancillary Studies
429954|NCT00915889|Procedure|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
429955|NCT00915876|Drug|Paricalcitol|paricalcitol 1 mcg QD x 8 weeks
429956|NCT00915876|Drug|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
429957|NCT00915863|Procedure|Billroth-II-type reconstruction|surgical procedure
429958|NCT00915863|Procedure|Isolated Roux-en-Y type reconstruction|surgical procedure
429959|NCT00915850|Drug|DCF|docetaxel, Cisplatin and 5-FU
429960|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
429961|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
429962|NCT00915824|Other|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
429963|NCT00915811|Drug|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
429964|NCT00915811|Drug|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
429965|NCT00915811|Drug|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
429966|NCT00915811|Procedure|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
429967|NCT00915798|Behavioral|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
429968|NCT00915798|Behavioral|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
429969|NCT00915785|Drug|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
429970|NCT00915772|Drug|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
429971|NCT00915772|Drug|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
429972|NCT00915772|Drug|Metformin|Metformin 1000 mg tablet bid
429973|NCT00915759|Device|ProKera|ProKera placed in non-dominant eye after PRK
429974|NCT00915759|Device|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after PRK
429975|NCT00915746|Drug|JNJ-31001074; ketoconazole|
429976|NCT00915733|Drug|cilostazol|100 mg twice daily for at least 1 month
429977|NCT00915733|Drug|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
429978|NCT00915733|Genetic|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19*2 (rs4244285, c. 681G>A, p.P227P), and CYP2C19*3 (rs4986893, c. 636G>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
429979|NCT00915733|Drug|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
429980|NCT00915707|Other|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
429981|NCT00915707|Other|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
429982|NCT00915707|Other|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
429983|NCT00915694|Drug|nelfinavir mesylate|
429984|NCT00915694|Drug|temozolomide|
429985|NCT00915694|Procedure|adjuvant therapy|
429986|NCT00915694|Radiation|radiation therapy|
429987|NCT00915681|Drug|Silibinin|20 mg/kg/day IV
429988|NCT00915668|Drug|JNJ-31001074|
429989|NCT00915655|Drug|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
430311|NCT00913380|Radiation|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
429991|NCT00915655|Drug|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
429992|NCT00915655|Drug|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
429993|NCT00915655|Drug|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
429994|NCT00915629|Dietary Supplement|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
429995|NCT00915616|Drug|Melatonin|
429996|NCT00915603|Drug|Everolimus|Everolimus 10mg PO daily continuously for all 28 days of a cycle
429997|NCT00915603|Drug|Bevacizumab|Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
429998|NCT00915603|Drug|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
429999|NCT00915603|Drug|Placebo|Placebo PO daily continuously for all 28 days of a cycle
430000|NCT00915603|Drug|Bevacizumab|Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
430001|NCT00915603|Drug|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
430002|NCT00915590|Drug|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
430003|NCT00915590|Drug|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
430004|NCT00915577|Drug|Interferon beta-1a|30mcg, IM once-a-week
430005|NCT00915577|Device|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
430006|NCT00915564|Drug|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
430007|NCT00915564|Other|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily [extremes included]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
430008|NCT00915551|Drug|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
430009|NCT00915551|Drug|Vehicle Gel|once daily for 3 consecutive days
430010|NCT00915538|Drug|pMD Symbicort 160/4.5|The subjects will receive Symbicort pMDI 160/4.5 pMDI used in conventional fashion, and have pulmonary function measured over 12 hours. Secondly on another day, they will receive pMDI using a valved holding chamber
430011|NCT00915538|Drug|Symbicort|Symbicort 160/4.5 will be administered first first through a valved holding chamber, and on another day in the conventional fashion. Pulmonary functions will be measured ove r12 hours
430012|NCT00915525|Biological|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
430013|NCT00915512|Drug|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
430014|NCT00915499|Device|VPAP Adapt SV|Comparison of ASV and CPAP modes
430015|NCT00915486|Procedure|Good Standard of Care (GSoC)|Procedural treatment twice per week
430016|NCT00915486|Biological|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
430017|NCT00915486|Biological|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
430018|NCT00915473|Drug|bupivicaine|2.5 mL 0.5% bupivicaine
430019|NCT00915473|Drug|normal saline|2.75 mL normal saline
430020|NCT00915473|Drug|methylprednisolone|0.5 mL 20 mg methylprednisolone
430021|NCT00915473|Drug|lidocaine|0.25 mL 1% lidocaine
430022|NCT00915460|Drug|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
430023|NCT00915434|Drug|JNJ-31001074|
430024|NCT00915421|Procedure|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
430025|NCT00915408|Drug|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
430026|NCT00915408|Drug|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
430027|NCT00915408|Drug|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
430028|NCT00915382|Drug|S-1 and cisplatin|"S-1: 80 mg/m2/day po on Days 1-14~cisplatin: 60 mg/m2 iv on Day 1"
430029|NCT00915382|Drug|S-1 and cisplatin|"S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and~cisplatin: 60 mg/m2 iv on Day 1 or 8"
430030|NCT00915369|Drug|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
430031|NCT00915356|Drug|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
430032|NCT00915356|Drug|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
430033|NCT00915343|Drug|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
430034|NCT00915343|Drug|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
430076|NCT00914979|Device|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
430035|NCT00915330|Procedure|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
430036|NCT00915330|Procedure|TBNA|transbronchial needle aspiration
430037|NCT00915304|Behavioral|The EBMeDS reminders|"Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.~Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months."
430038|NCT00915291|Other|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
430039|NCT00915278|Drug|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
430040|NCT00915265|Other|Multilobed catheter (group CPA)|- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
430041|NCT00915265|Other|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
430042|NCT00915252|Drug|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
430043|NCT00915252|Drug|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5"
430044|NCT00915239|Drug|Pantoprazole|40 mg pantoprazole once daily for 28 days
430045|NCT00915239|Drug|Placebo|identical placebo once daily for 28 days
430046|NCT00915226|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
430047|NCT00915226|Procedure|Squatting|Squatting
430048|NCT00915200|Dietary Supplement|N-acetylcysteine|600 mg orally twice daily for three months
430049|NCT00915200|Dietary Supplement|silibin|480 mg orally twice daily for three months
430050|NCT00915200|Dietary Supplement|high-dose silibin|960 mg orally twice daily for three months
430051|NCT00915200|Dietary Supplement|N-acetylcysteine placebo|excipient orally twice daily for three months
430052|NCT00915200|Dietary Supplement|silibin placebo|excipient orally twice daily for three months
430053|NCT00915187|Drug|CCS/C|Adjuvant to influenza vaccine
430054|NCT00915187|Biological|Influenza Vaccine|Influenza vaccine
430055|NCT00915174|Drug|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
430056|NCT00915148|Other|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
430057|NCT00915135|Drug|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
430058|NCT00915122|Radiation|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
430059|NCT00915083|Drug|Amrubicin|40mg/m^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
430060|NCT00915070|Drug|BQ-123|60 mcg/min, infusion period: 60 min
430061|NCT00915070|Drug|Physiological saline solution|infusion period 60 minutes
430062|NCT00915070|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
430063|NCT00915070|Device|Goldmann Applanation Tonometer|intraocular pressure measurements
430064|NCT00915070|Other|squatting|subjects will perform squatting for 6 minutes while blood flow measurements
430065|NCT00915057|Drug|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
430066|NCT00915031|Device|UroCool|Hypothermia Endorectal Device
430067|NCT00915018|Drug|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
430068|NCT00915018|Drug|Trastuzumab|Trastuzumab - 4 mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
430069|NCT00915018|Drug|Paclitaxel|Paclitaxel - 80 mg/m² IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
430070|NCT00915005|Radiation|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
430071|NCT00915005|Radiation|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.~Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.~Each daily treatment should take about 20-30 minutes to complete."
430072|NCT00915005|Drug|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
430073|NCT00915005|Drug|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
430074|NCT00914992|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
430079|NCT00914940|Drug|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
430080|NCT00914940|Drug|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.~For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.~In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
430081|NCT00914940|Drug|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
430082|NCT00914940|Radiation|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
430083|NCT00914940|Other|Magnetic Affinity Cell Sorting|Device
430084|NCT00914940|Procedure|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
430085|NCT00914940|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
430086|NCT00914940|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
430087|NCT00914927|Drug|Avatrombopag|Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days
430088|NCT00914927|Drug|Avatrombopag|Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
430089|NCT00914927|Drug|Placebo|Placebo or inactive substance once a day for up to 7 days
430090|NCT00914914|Drug|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
430091|NCT00914901|Drug|inhaled salmeterol|Inhalation of 100 micrograms salmeterol in one dose.
430092|NCT00914888|Drug|Tigecycline|"Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
430093|NCT00914888|Drug|Tigecycline|"Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
430094|NCT00914888|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
430095|NCT00914888|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
430096|NCT00914862|Drug|Ramelteon|Ramelteon tablets, orally for one day only.
430097|NCT00914849|Drug|AMD3100|
430098|NCT00914849|Procedure|Leukopheresis|
430099|NCT00914849|Procedure|Stem cell transplant|
430100|NCT00914836|Drug|Betamethasone Sodium Phosphate|1cc:2cc
430101|NCT00914836|Drug|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
430102|NCT00914836|Drug|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
430103|NCT00914823|Drug|kisspeptin 112-121|one or more intravenous doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
430104|NCT00914823|Drug|GnRH|One or more intravenous doses of GnRH
430105|NCT00914810|Dietary Supplement|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
430106|NCT00914810|Dietary Supplement|Placebo|Placebo (sugar pill) daily for 6 weeks
430107|NCT00914797|Drug|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
430108|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
430109|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
430110|NCT00914745|Drug|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
430111|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
430112|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose [2x10^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose] by intradermal (ID) route on Days 0 and 28.
430310|NCT00913380|Radiation|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
430113|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
430114|NCT00914719|Behavioral|Information only|
430115|NCT00914719|Behavioral|Sexual risk reduction intervention|
430116|NCT00914719|Behavioral|sexual risk reduction + alcohol risk reduction component|
430117|NCT00914706|Other|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
430118|NCT00914693|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
430119|NCT00914680|Procedure|magnetic seizure therapy|antidepressant treatment with MST
430120|NCT00914667|Drug|warfarin|Single Dose Warfarin 25 mg on Day 1
430121|NCT00914667|Drug|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
430122|NCT00914654|Drug|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
430123|NCT00914641|Drug|Apixaban IR|immediate release tablet, 10 mg, single dose
430124|NCT00914641|Drug|Apixaban MR1|modified release tablet 1, 10 mg, single dose
430125|NCT00914641|Drug|Apixaban MR2|modified release tablet 2, 10 mg, single dose
430126|NCT00914641|Drug|Apixaban MR3|modified release tablet 3, 10 mg, single dose
430127|NCT00914628|Genetic|HSV-Tk|Infusion of approximately 1±0.2 x 10^7 HSV-Tk genetically modified CD3+ cells/Kg between day +21 and day +49 after haploidentical HCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
430128|NCT00914628|Other|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
430129|NCT00914615|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
430130|NCT00914602|Drug|XP21279|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
430131|NCT00914602|Drug|Sinemet®|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
430132|NCT00914602|Drug|Lodosyn®|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
430133|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
430134|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
430135|NCT00914589|Drug|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
430136|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
430137|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
430138|NCT00914576|Drug|Placebo|2 capsules/day for 14 days
430139|NCT00914576|Drug|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
430140|NCT00914576|Drug|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
430141|NCT00914563|Device|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
430142|NCT00914563|Other|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
430143|NCT00914550|Other|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
430144|NCT00914524|Drug|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
430145|NCT00914511|Drug|avanafil 200mg|single dose tablet of 200mg avanafil
430146|NCT00914511|Drug|avanafil 200mg|single tablet dose of 200mg avanafil
430147|NCT00914498|Drug|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
430148|NCT00914485|Behavioral|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
430149|NCT00914472|Biological|heparin sodium - APP|Heparin 5000 IU / mL
430150|NCT00914472|Biological|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
430151|NCT00914459|Biological|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
430152|NCT00914459|Procedure|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
430153|NCT00914446|Procedure|hepatic biopsies|hepatic biopsies
430154|NCT00914433|Drug|TPI 1100|1 dose only increasing dose
430250|NCT00913835|Biological|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
430155|NCT00914420|Device|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.~The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
430156|NCT00914420|Device|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
430157|NCT00914407|Drug|Oxygen|100% Oxygen inhalation for 30 minutes
430158|NCT00914394|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
430159|NCT00914394|Drug|Phenylephrine|1µg/kg/min, infusion period 20 minutes
430160|NCT00914394|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
430161|NCT00914394|Device|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
430162|NCT00914394|Device|Goldmann applanation tonometer|intraocular pressure measurements
430163|NCT00914394|Device|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
430164|NCT00914381|Behavioral|Behavioral therapy|
430165|NCT00914368|Drug|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
430166|NCT00914355|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
430167|NCT00914329|Drug|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
430168|NCT00914329|Drug|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
430169|NCT00914329|Drug|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
430170|NCT00914316|Drug|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
430171|NCT00914316|Drug|Placebo|twice daily
430172|NCT00914303|Drug|AZD3241|Oral Tablet, Repeated Administration
430173|NCT00914303|Drug|Placebo Tablet|Oral Tablet. Repeated Administration
430174|NCT00914290|Drug|IPX056|IPX056 ER capsule containing 10 mg baclofen
430175|NCT00914290|Drug|Baclofen IR|Encapsulated baclofen tablet 5 mg per capsule
430176|NCT00914290|Drug|Placebo IPX056|Placebo capsule for IPX056
430177|NCT00914290|Drug|Placebo IR|Placebo encapsulated baclofen placebo tablet
430178|NCT00914277|Drug|SAR407899|Oral administration
430179|NCT00914277|Drug|Placebo|Oral administration
430180|NCT00914277|Drug|Sildenafil|Oral administration
430181|NCT00914264|Device|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 & 12 months
430182|NCT00914251|Drug|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
430183|NCT00914251|Drug|Placebo|Administration of oral Placebo, 500 mg/daily
430184|NCT00914238|Behavioral|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
430185|NCT00914238|Behavioral|OPUS 5 years|
430186|NCT00914225|Other|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
430187|NCT00914212|Drug|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
430188|NCT00914212|Drug|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
430189|NCT00914199|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
430190|NCT00914186|Drug|TS022|Lotion
430191|NCT00914186|Drug|Vehicle|Lotion
430192|NCT00914173|Device|Scanlaf Circulator and water bath|Cold Pressor Test
430193|NCT00914173|Device|Medoc TSA 2000|Thermal stimuli pain
430194|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
430195|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
430196|NCT00914160|Drug|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
430197|NCT00914147|Procedure|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
430198|NCT00914134|Drug|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
430199|NCT00914121|Drug|SKI-606|
430200|NCT00914121|Drug|Placebo|
430201|NCT00914121|Drug|Moxifloxacin|
430251|NCT00913835|Drug|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
430252|NCT00913822|Drug|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
430253|NCT00913822|Drug|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
430254|NCT00913809|Drug|Desipramine HCL 100 mg Tablets Cord Laboratories|
430255|NCT00913809|Drug|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
430256|NCT00913796|Drug|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
430202|NCT00914108|Behavioral|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
430203|NCT00914095|Drug|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
430204|NCT00914095|Drug|placebo|tablets of placebo 3 times a day
430205|NCT00914082|Behavioral|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
430206|NCT00914069|Device|RIVS vascular access|Access to peripheral vasculature
430207|NCT00914069|Device|Conventional vascular access|Vascular access using conventional venous access device
430208|NCT00914056|Drug|lactulose|withdrawal of lactulose
430209|NCT00914043|Genetic|gene expression analysis|
430210|NCT00914043|Genetic|microarray analysis|
430211|NCT00914043|Genetic|polymerase chain reaction|
430212|NCT00914043|Genetic|polymorphism analysis|
430213|NCT00914043|Genetic|reverse transcriptase-polymerase chain reaction|
430214|NCT00914043|Other|biologic sample preservation procedure|
430215|NCT00914043|Other|enzyme-linked immunosorbent assay|
430216|NCT00914043|Other|laboratory biomarker analysis|
430217|NCT00914043|Procedure|fatigue assessment and management|
430218|NCT00914030|Other|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
430219|NCT00914017|Drug|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
430220|NCT00914017|Drug|Placebo|sugar pill daily for 1 year
430221|NCT00914004|Drug|Desipramine HCl 50 mg Tablets Cord Laboratories|
430222|NCT00914004|Drug|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
430223|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
430224|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
430225|NCT00913978|Device|Group 1: VitaHeat|Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
430226|NCT00913978|Device|Group 2: Bair Hugger|Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
430227|NCT00913965|Drug|Atenolol Tablets 100 mg (Cord Laboratories)|
430228|NCT00913965|Drug|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
430229|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
430230|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
430231|NCT00913952|Drug|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
430232|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
430233|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
430234|NCT00913926|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
430235|NCT00913913|Biological|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
430236|NCT00913913|Drug|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
430237|NCT00913913|Biological|IL-2|IL-2 18 MiU/m2 CI 5 days
430238|NCT00913913|Biological|IFN|IFN 6 MiU subc TIW
430239|NCT00913900|Biological|autologous CD133+ cells|Intramuscular injection
430240|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
430241|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
430242|NCT00913887|Drug|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
430243|NCT00913874|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
430244|NCT00913874|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
430245|NCT00913861|Behavioral|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
430246|NCT00913861|Drug|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
430247|NCT00913861|Behavioral|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
430257|NCT00913796|Drug|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
430258|NCT00913783|Drug|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
430259|NCT00913783|Drug|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
430260|NCT00913770|Behavioral|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
430261|NCT00913770|Drug|Buprenorphine Initiation|
430262|NCT00913744|Drug|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
430263|NCT00913744|Drug|Sham injection|Sham injection
430264|NCT00913718|Drug|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
430265|NCT00913718|Drug|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
430266|NCT00913705|Drug|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
430267|NCT00913705|Drug|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
430268|NCT00913705|Procedure|Surgery|Surgery
430269|NCT00913692|Drug|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
430270|NCT00913692|Drug|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
430271|NCT00913679|Procedure|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
430272|NCT00913666|Drug|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
430273|NCT00913653|Drug|LCZ696|
430274|NCT00913627|Drug|ibuprofen|
430275|NCT00913627|Drug|ibuprofen|
430276|NCT00913627|Drug|naproxen|
430277|NCT00913627|Drug|Placebo|
430278|NCT00913614|Drug|Eplivanserin (SR46349)|Oral administration
430279|NCT00913601|Device|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
430280|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
430281|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
430282|NCT00913588|Drug|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
430283|NCT00913575|Other|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
430284|NCT00913575|Behavioral|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
430285|NCT00913562|Drug|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
430286|NCT00913562|Drug|Placebo|one tablet a day for 12 weeks
430287|NCT00913549|Drug|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
430288|NCT00913549|Drug|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
430289|NCT00913536|Other|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
430290|NCT00913523|Device|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
430291|NCT00913523|Device|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
430292|NCT00913510|Device|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
430293|NCT00913510|Drug|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
430294|NCT00913497|Drug|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
430295|NCT00913497|Drug|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
430296|NCT00913484|Drug|Disulfiram|Disulfiram 250 mg per day
430297|NCT00913484|Drug|Placebo|Placebo daily
430298|NCT00913471|Other|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.~Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.~Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
430299|NCT00913458|Drug|etanercept|
430300|NCT00913445|Procedure|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
430301|NCT00913432|Drug|masitinib|3 mg/kg/day oral route
430302|NCT00913432|Drug|masitinib|masitinib 6 mg/kg/day oral route
430303|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
430304|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
430305|NCT00913406|Other|Lutein fortification|
430306|NCT00913406|Other|Standard formula|
430307|NCT00913393|Drug|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
430308|NCT00913393|Drug|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
430309|NCT00913393|Drug|Placebo|Placebo IV every 2 weeks for 22 weeks
431245|NCT00906139|Drug|Midazolam|Midazolam dose: 0.1 mg/kg
430312|NCT00913367|Drug|glimepiride + insulin glargine (Amaryl + Lantus)|"Amaryl® 4 mg at breakfast + Lantus® at dinner~The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
430313|NCT00913367|Drug|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner~The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
430314|NCT00913354|Device|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
430315|NCT00913354|Device|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
430316|NCT00913341|Drug|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
430317|NCT00913341|Drug|Alprazolam Tablets, 1 mg (The Upjohn Company)|
430318|NCT00913328|Drug|Montelukast (Singulair)|10 mg tablet once daily
430319|NCT00913328|Drug|Placebo|Oral placebo once daily
430320|NCT00913315|Drug|tolterodine|4 mg of tolterodine ER
430321|NCT00913315|Drug|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
430322|NCT00913315|Drug|placebo|placebo once a day for 8 weeks
430323|NCT00913302|Behavioral|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
430324|NCT00913289|Biological|adipose tissue derived stromal cells|dosage
430325|NCT00913276|Drug|Propofol|
430326|NCT00913276|Drug|Sevoflurane|
430327|NCT00913263|Drug|2-hydroxyflutamide (2-HOF) [Liproca Depot]|Ready made paste including 600 mg 2-HOF for injection as a single dose
430328|NCT00913263|Drug|2-Hydroxyflutamide|The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
430329|NCT00913250|Drug|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
430330|NCT00913250|Drug|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
430331|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
430332|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
430333|NCT00913224|Drug|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
430334|NCT00913224|Drug|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
430335|NCT00913211|Device|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
430336|NCT00913211|Procedure|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
430337|NCT00913211|Procedure|rTMS and Tracking|Combination of rTMS and finger tracking
430338|NCT00913211|Device|Sham rTMS|Sham treatment of rTMS
430339|NCT00913198|Drug|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
430340|NCT00913185|Drug|Acne Free, Proactiv|
430341|NCT00913172|Other|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
430342|NCT00913159|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
430343|NCT00913133|Drug|Desirudin|Desirudin SC 15mg q12h
430344|NCT00913120|Drug|YM150|oral
430345|NCT00913120|Drug|Placebo|oral
430346|NCT00913120|Drug|Enoxaparin|injection
430347|NCT00913107|Drug|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:~50 mg twice daily for 10days, followed by,~100 mg twice daily for the next 10days, followed by,~100 mg thrice daily for the next10 days, followed by,~100 mg four times daily for the final 10 days."
430348|NCT00913107|Drug|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:~150 mg twice daily for 10days, followed by,~200 mg thrice daily for the next 10days, followed by,~300 mg thrice daily for the next 10 days, followed by,~300 mg four times daily for the final 10 days."
430349|NCT00913081|Dietary Supplement|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
430350|NCT00913081|Dietary Supplement|Placebo|Placebo PO one time
430351|NCT00913068|Procedure|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
430352|NCT00913068|Procedure|standard post op pain control|opiates
430353|NCT00913055|Drug|octreotide acetate|subcutaneous implant
430354|NCT00913042|Other|sample blood|"Early culture~Bacterial DNA tests in blood"
430355|NCT00913029|Device|iStent|iStent
430356|NCT00913029|Drug|latanoprost/timolol|Combination latanoprost/timolol
430357|NCT00913003|Drug|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
430358|NCT00913003|Drug|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
430359|NCT00912990|Drug|Cisatracurium|
430360|NCT00912990|Drug|Normal saline|
430361|NCT00912964|Drug|Mirabegron|Mirabegron tablets
430362|NCT00912964|Drug|Placebo|Matching mirabegron placebo tablets.
430363|NCT00912938|Drug|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
430719|NCT00910143|Procedure|conventional rectal surgery|type of rectal surgery before the introduction of TME
430364|NCT00912925|Biological|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
430365|NCT00912925|Biological|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
430366|NCT00912912|Drug|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
430367|NCT00912899|Drug|Noscapine HCl|Escalating doses given twice per day
430368|NCT00912873|Drug|ropivicaine (Psoas compartment block)|Patients will be randomized to one of two groups: ropivicaine 0.1% infusion or ropivicaine 0.4% infusion. The infusion rate will be set at 12mL/hour and 3mL/hour respectively and the outcome measures will be assessed by physical therapy using the described methods.
430369|NCT00912860|Drug|Interferon beta-1a|serum free Avonex given IM once a week
430370|NCT00912821|Drug|6 L dialysate|6 L peritoneal dialysis solution
430371|NCT00912821|Drug|8 L dialysate|8 L peritoneal dialysis solution
430372|NCT00912808|Drug|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
430373|NCT00912808|Drug|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
430374|NCT00912795|Behavioral|SMS Turkey|"6-week smoking cessation program delivered via daily text messages~SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.~Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.~Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages)."
430375|NCT00912782|Drug|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
430376|NCT00912782|Drug|Placebo|Placebo one time per week for 3 weeks
430377|NCT00912756|Drug|cilostazol|200 mg/day BID
430378|NCT00912743|Drug|olaparib|400 mg po bid continuously
430379|NCT00912691|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
430380|NCT00912678|Drug|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
430381|NCT00912678|Drug|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
430382|NCT00912665|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
430383|NCT00912665|Device|Goldmann applanation tonometer|intraocular pressure measurements
430384|NCT00912665|Other|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
430385|NCT00912665|Device|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
430386|NCT00912652|Behavioral|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
430387|NCT00912652|Behavioral|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
430388|NCT00912639|Drug|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
430389|NCT00912626|Behavioral|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
430390|NCT00912613|Other|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
430391|NCT00912600|Other|Intensive Care Unit admission|Intensive Care Unit admission
430392|NCT00912587|Drug|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
430393|NCT00912574|Drug|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
430394|NCT00912574|Drug|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
430395|NCT00912574|Biological|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
430433|NCT00912275|Drug|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
430434|NCT00912262|Drug|Capsaicin Topical Liquid|
430720|NCT00910143|Procedure|total mesorectal excision|total mesorectal excision
430396|NCT00912574|Drug|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.~In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:~1 ml saline~specified dose of GM-CSF in 1 ml saline~an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline~an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
430397|NCT00912561|Behavioral|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
430398|NCT00912548|Drug|goserelin|"Zoladex™ administration:~Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.~Sequence of administration Zoladex depot:~The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).~Dosage:~Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .~Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
430399|NCT00912548|Drug|tamoxifen|"Dose and period of Tamoxifen therapy:~Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.~Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
430400|NCT00912535|Drug|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
430401|NCT00912535|Drug|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
430402|NCT00912522|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
430403|NCT00912509|Drug|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
430404|NCT00912509|Device|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
430405|NCT00912496|Biological|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
430406|NCT00912496|Biological|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal [0.01%(w/v)] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
430407|NCT00912496|Drug|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
430408|NCT00912483|Biological|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
430409|NCT00912483|Biological|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
430410|NCT00912470|Procedure|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye~Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)~Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
430411|NCT00912457|Drug|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
430412|NCT00912457|Drug|placebo|placebo 1 p/day for 28 days
430413|NCT00912444|Drug|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
430414|NCT00912444|Drug|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
430415|NCT00912431|Drug|ABT-126|ABT-126 administered on Day 1 of Period 1
430416|NCT00912431|Drug|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
430417|NCT00912418|Biological|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.~Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
430418|NCT00912405|Device|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
430419|NCT00912392|Drug|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
430420|NCT00912392|Drug|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
430421|NCT00912379|Biological|hemoglobin determination|laboratory and non invasive hemoglobin determinations
430422|NCT00912366|Procedure|Lobectomy|Assessment of VATS versus open surgery.
430423|NCT00912353|Drug|AZD7268|Single Oral
430424|NCT00912353|Drug|Placebo|Single Oral
430425|NCT00912340|Drug|Everolimus|
430426|NCT00912340|Biological|Trastuzumab|
430427|NCT00912327|Biological|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
430428|NCT00912314|Procedure|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
430429|NCT00912301|Drug|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
430430|NCT00912301|Other|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
430431|NCT00912288|Drug|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
430432|NCT00912288|Drug|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
430435|NCT00912249|Behavioral|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
430721|NCT00910117|Drug|nimotuzumab|nimotuzumab 400 mg d1
430436|NCT00912223|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~The conditioning regimen will consist of the following:~Rituxan 375 mg/m^2 on Day -13~Rituxan 1000 mg/m^2 on Days -6, +1, and +8~Fludarabine 30 mg/m^2 on Days -5 to -3~Cyclophosphamide 750 mg/m^2 on Days -5, -4, -3~Day 0 will be the day of the transplant.~The GVHD prophylaxis will consist of the following:~Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.~Methotrexate 5 mg/m^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
430437|NCT00912210|Dietary Supplement|Whey protein isolate|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
430438|NCT00912210|Dietary Supplement|Maltodextrin powder supplement|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
430439|NCT00912197|Dietary Supplement|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
430440|NCT00912197|Dietary Supplement|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
430441|NCT00912184|Device|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
430442|NCT00912184|Device|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
430443|NCT00912171|Drug|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
430444|NCT00912171|Drug|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
430445|NCT00912158|Other|standard therapy (ST)|standard medical therapy
430446|NCT00912158|Device|CPAP|Non-invasive mechanical ventilation (CPAP)
430447|NCT00912158|Device|BIPAP|Non-invasive mechanical ventilation (BIPAP)
430448|NCT00912145|Drug|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
430449|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
430450|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
430451|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
430452|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
430453|NCT00912106|Other|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
430454|NCT00912093|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
430455|NCT00912093|Drug|Placebo|Single subcutaneous injection of matching placebo
430456|NCT00912080|Genetic|genomic signature|genomic signature analysis
430457|NCT00912054|Drug|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
430458|NCT00912054|Drug|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
430459|NCT00912041|Device|Placement of the BrainGate2 sensor(s) into the motor-related cortex|One or two 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex, connected to a percutaneous pedestal. Neural recordings are made at least weekly for a year or more.
430460|NCT00912028|Device|senofilcon A|contact lens
430461|NCT00912028|Device|lotrafilcon B|contact lens
430462|NCT00912028|Device|balafilcon A|contact lens
430463|NCT00912028|Device|methafilcon A|contact lens
430464|NCT00912028|Device|vifilcon A|contact lens
430465|NCT00912015|Drug|Tramadol OAD|
430466|NCT00912015|Drug|Tramadol OAD|
430467|NCT00912015|Drug|Tramadol OAD|
430468|NCT00912015|Drug|Tramadol OAD 100mg|
430469|NCT00912002|Drug|MK-0941|A single dose of 40 mg of [14C]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
430470|NCT00911989|Device|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
430471|NCT00911976|Device|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
430472|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 4 doses once daily or twice daily, 3 days
430473|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
430474|NCT00911963|Biological|peginterferon alfa-2a|subcutaneous injection, 180 μg, once weekly, 48 weeks
430475|NCT00911963|Drug|ribavirin|tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
430476|NCT00911937|Drug|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
430477|NCT00911937|Drug|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
430478|NCT00911924|Device|iStent|Glaukos iStent, medication
430479|NCT00911911|Procedure|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
430480|NCT00911911|Procedure|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
430481|NCT00911911|Procedure|SURGERY|Surgery after neoadjuvant chemotherapy
430482|NCT00911898|Drug|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
430769|NCT00909831|Procedure|autophagy inhibition therapy|
430483|NCT00911885|Behavioral|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
430484|NCT00911872|Device|collagen (EVOLENCE)|injectable collagen
430485|NCT00911859|Drug|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
430486|NCT00911859|Drug|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
430487|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
430488|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
430489|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
430490|NCT00911859|Drug|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
430491|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
430492|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
430493|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
430494|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
430495|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
430496|NCT00911846|Other|interview|interview using questionnaires
430497|NCT00911820|Drug|Bevacizumab|
430498|NCT00911820|Drug|Cisplatin|
430499|NCT00911820|Drug|Irinotecan|
430500|NCT00911820|Device|Docetaxel|
430501|NCT00911807|Drug|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
430502|NCT00911807|Drug|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
430503|NCT00911807|Drug|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.~Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
430504|NCT00911794|Other|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
430505|NCT00911794|Other|Neutral (Sham) Writing|Patients write about neutral subjects
430506|NCT00911781|Other|No intervention|We are only asking for photographs from parents.
430507|NCT00911768|Dietary Supplement|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
430508|NCT00911768|Dietary Supplement|Corn-starch powder with ginseng flavor|"There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.~The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).~Main contents: corn-starch with Panax ginseng flavor"
430509|NCT00911755|Procedure|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
430510|NCT00911755|Procedure|Endotracheal Intubation|
430511|NCT00911742|Drug|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
430512|NCT00911742|Drug|Zytram|1 Zytram 200 mg tablet as a single dose
430513|NCT00911716|Biological|bevacizumab|
430514|NCT00911716|Drug|cyclophosphamide|
430515|NCT00911716|Drug|docetaxel|
430516|NCT00911716|Procedure|adjuvant therapy|
430517|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
430518|NCT00911664|Drug|No supplementation|Control
430519|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
430520|NCT00911651|Drug|Salbutamol|400 µg inhalation once
430521|NCT00911651|Drug|ipratropium bromide|80 µg inhalation once
430522|NCT00911638|Behavioral|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
430598|NCT00911144|Biological|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
430523|NCT00911638|Behavioral|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.~ii) Referral onward to surgeon with a standardized report of clinical findings only"
430524|NCT00911625|Drug|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
430525|NCT00911625|Drug|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
430526|NCT00911612|Drug|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
430527|NCT00911612|Drug|Placebo|Inert capsule matching the study drug, given twice daily
430528|NCT00911599|Diagnostic Test|Blood metal ion levels|Blood and urine will be collected and the levels of cobalt and chromium ions will be tested.
430529|NCT00911586|Drug|Testosterone undecanoate|Oral testosterone undecanoate, twice daily for one month.
430530|NCT00911573|Drug|Tigecycline|50 mg IV every 12 hours up to 14 days
430531|NCT00911573|Drug|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
430532|NCT00911560|Biological|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Pts receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, & 52. Minor schedule adjustments are permitted, as needed. Vaccines must occur a minimum of 6 days apart. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), & continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic & bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood & bone marrow. Phase II treatment schema for patients in 1st CR/VGPR or >2nd CR/VGPR will be the same for the vaccine as in phase I except OPT-821 will be given at a fixed dose of 150 mcg/m2.
430533|NCT00911560|Biological|oral β-glucan|Phase II Patients will be randomized to starting oral β-glucan (40 mg/kg/day) in week 1 or in week 6.
430534|NCT00911547|Drug|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
430535|NCT00911547|Drug|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
430536|NCT00911547|Drug|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
430537|NCT00911547|Drug|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
430538|NCT00911534|Drug|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
430539|NCT00911534|Drug|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
430540|NCT00911521|Drug|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
430541|NCT00911508|Device|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path~Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF~Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System~Bard: Stinger~Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
430542|NCT00911508|Drug|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg~Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
430543|NCT00911495|Drug|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
430544|NCT00911469|Drug|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
430545|NCT00911469|Drug|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
430546|NCT00911456|Procedure|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
430547|NCT00911456|Procedure|Ultrasound Guided Imaging|"Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.~About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals."
430548|NCT00911456|Procedure|3 DUS|3 DUS
430549|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
430550|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
430551|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
430552|NCT00911443|Biological|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
430895|NCT00908817|Drug|triamcinolone acetonide|paste applied over tracheal tube for lubrication
430553|NCT00911443|Drug|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
430554|NCT00911417|Device|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
430555|NCT00911404|Behavioral|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
430556|NCT00911404|Dietary Supplement|High CHO diet|Diet with 55% total calories from carbohydrates.
430557|NCT00911391|Device|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
430558|NCT00911391|Procedure|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
430559|NCT00911378|Procedure|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
430560|NCT00911378|Procedure|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
430561|NCT00911365|Biological|autologous mesenchymal stem cells|"4*107 stem cell (100ml) Intra arterial infusion/ one time, then 4*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-> Total four times"
430562|NCT00911365|Biological|normal saline|saline
430563|NCT00911352|Device|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for > 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
430564|NCT00911339|Drug|Atorvastatin|Atorvastatin 10 mg associated with stent genous
430565|NCT00911339|Drug|Atorvastatin|Atorvastatin 80 mg associated with stent genous
430566|NCT00911326|Drug|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
430567|NCT00911313|Drug|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
430568|NCT00911313|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
430569|NCT00911313|Drug|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
430570|NCT00911300|Drug|fondaparinux|Comparison of different drugs
430571|NCT00911300|Drug|unfractionated heparin|Comparison of different drugs
430572|NCT00911300|Drug|Vitamin-K-Antagonist|Comparison of different drugs
430573|NCT00911287|Drug|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
430574|NCT00911274|Drug|Mycophenolate Mofetil|250 mg Capsule
430575|NCT00911274|Drug|CellCept®|250 mg Capsule
430576|NCT00911261|Drug|Oxymorphone Extended Release|"Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
430577|NCT00911248|Drug|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
430578|NCT00911235|Drug|Fesoterodine|Single 8 mg oral dose of fesoterodine
430579|NCT00911235|Drug|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
430580|NCT00911222|Other|non-interventional|non-interventional
430581|NCT00911209|Behavioral|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
430582|NCT00911196|Other|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
430583|NCT00911183|Biological|filgrastim|Given subcutaneously
430584|NCT00911183|Biological|pegfilgrastim|Given subcutaneously
430585|NCT00911183|Biological|rituximab|Given IV
430586|NCT00911183|Drug|cyclophosphamide|Given IV
430587|NCT00911183|Drug|liposome-encapsulated doxorubicin citrate|Given IV
430588|NCT00911183|Drug|prednisone|Given orally
430589|NCT00911183|Drug|vincristine sulfate|Given IV
430590|NCT00911170|Drug|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
430591|NCT00911170|Drug|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
430592|NCT00911170|Biological|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
430593|NCT00911170|Drug|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:~FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
430594|NCT00911157|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
430595|NCT00911157|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
430596|NCT00911144|Biological|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
430597|NCT00911144|Biological|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
430599|NCT00911131|Device|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
430600|NCT00911131|Procedure|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
430601|NCT00911131|Device|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
430602|NCT00911118|Radiation|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if < 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
430603|NCT00911092|Procedure|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
430604|NCT00911092|Radiation|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
430605|NCT00911092|Drug|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11~Day 1 to day 4: Fluorouracil 1 gr/m²/day~Day 1 or 2: Cisplatin 75 mg/m²"
430606|NCT00911079|Procedure|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
430607|NCT00911079|Radiation|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
430608|NCT00911066|Drug|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:~Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)~Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)~Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)~Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)~Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
430609|NCT00911066|Drug|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
430610|NCT00911053|Drug|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
430611|NCT00911053|Behavioral|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
430612|NCT00911053|Behavioral|Light|Subjects will be exposed to light.
430613|NCT00911027|Drug|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part~One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
430614|NCT00911027|Procedure|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
430615|NCT00911014|Other|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
430616|NCT00911001|Behavioral|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
430617|NCT00910988|Drug|Olanzapine|olanzapine/Zyprexa
430618|NCT00910988|Drug|Ziprasidone|ziprasidone/Geodon
430619|NCT00910975|Drug|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
430620|NCT00910975|Drug|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
430621|NCT00910962|Drug|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
430622|NCT00910962|Drug|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
430623|NCT00910962|Drug|Placebo|Placebo
430624|NCT00910936|Behavioral|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
430625|NCT00910923|Drug|JNJ-38431055|
430626|NCT00910910|Drug|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.~For patients with moderate renal impairment (defined as CrCl ≥ 30 to < 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
430627|NCT00910910|Drug|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
430628|NCT00910897|Drug|Velcade-Dexamethasone|
430629|NCT00910897|Drug|Velcade-Thalidomide-Dexamethasone|
430630|NCT00910884|Other|laboratory biomarker analysis|No supplements are given
430631|NCT00910884|Procedure|therapeutic dietary intervention|Given orally daily for 12 months
430632|NCT00910871|Drug|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
430714|NCT00910182|Procedure|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
431246|NCT00906139|Drug|Fentanyl|Fentanyl dose: 0.05 mg
430633|NCT00910871|Drug|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
430634|NCT00910858|Drug|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
430635|NCT00910858|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
430636|NCT00910845|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
430637|NCT00910845|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
430638|NCT00910832|Drug|Eductyl suppository|one suppository every morning during 21 days
430639|NCT00910832|Drug|Placebo suppository|placebo suppository every morning during 21 days
430640|NCT00910806|Drug|TMC207; nevirapine|
430641|NCT00910793|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
430642|NCT00910780|Drug|Aripiprazole|via oral tablets, everyday
430643|NCT00910780|Drug|Zyprexa|via oral tablets, taken once daily
430644|NCT00910780|Drug|Risperdal|via oral tablets, taken once daily
430645|NCT00910767|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
430646|NCT00910767|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
430647|NCT00910754|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
430648|NCT00910754|Drug|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
430649|NCT00910741|Drug|Nanoplatin (NC-6004) and Gemcitabine|
430650|NCT00910728|Drug|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
430651|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 10 days
430652|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 15 days
430653|NCT00910715|Drug|placebo|control subjects without a history of Lyme borreliosis
430654|NCT00910702|Device|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
430655|NCT00910689|Drug|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
430656|NCT00910689|Drug|Placebo control|Placebo
430657|NCT00910689|Behavioral|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
430658|NCT00910689|Drug|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
430659|NCT00910676|Drug|Diprosone|"Start of treatment: as soon as the EGF-R inhibitors treatment begins~Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~Period of treatment: 8 weeks"
430660|NCT00910663|Drug|Mycophenolate Mofetil|250 mg Capsule
430661|NCT00910663|Drug|CellCept®|250 mg Capsule
430662|NCT00910650|Biological|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
430663|NCT00910650|Drug|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
430664|NCT00910637|Drug|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 13 cycles
430665|NCT00910624|Drug|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
430666|NCT00910624|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
430667|NCT00910624|Drug|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
430668|NCT00910611|Device|Buzzy|"Buzzy, the vibrating cold pack, is pressed by parent or nurse immediately prior to immunizations. The vibration is activated and the device remains in place throughout the procedure, moving locations to complete the 4 shots."
430669|NCT00910598|Drug|glatiramer acetate|20 mg daily s.c. for 1 year
430670|NCT00910585|Behavioral|Coaching, providing social support|Active telephone and in person coaching
430715|NCT00910169|Other|inpatient treatment|Hospitalisation modalities are described but are naturalistic
430716|NCT00910156|Device|Airtraq laryngoscope|Airtraq intubation
430671|NCT00910572|Device|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
430672|NCT00910546|Device|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
430673|NCT00910533|Drug|ceftriaxone|ceftriaxone 2 g od i.v. for 14 days
430674|NCT00910520|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
430675|NCT00910520|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
430676|NCT00910507|Behavioral|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
430677|NCT00910507|Behavioral|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
430678|NCT00910494|Radiation|Photon Radiosurgery System IORT|
430679|NCT00910494|Radiation|Photon Radiosurgery System IORT|
430680|NCT00910481|Device|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
430681|NCT00910468|Procedure|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
430682|NCT00910455|Drug|SRX246|single oral dose of SRX246 capsule
430683|NCT00910455|Drug|Placebo|Single oral dose of placebo capsule
430684|NCT00910442|Dietary Supplement|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
430685|NCT00910429|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
430686|NCT00910416|Drug|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
430687|NCT00910416|Drug|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
430688|NCT00910416|Device|EEG monitoring|simultaneous monitoring with Bis and Neurosense
430689|NCT00910403|Procedure|LASIK|Excimer Laser Ablation using LASIK
430690|NCT00910390|Other|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
430691|NCT00910390|Other|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
430692|NCT00910390|Other|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
430693|NCT00910377|Behavioral|counseling sessions|The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
430694|NCT00910364|Other|Exercise|Exercise
430695|NCT00910351|Drug|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
430696|NCT00910338|Device|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks~Twice a week for the first 4 weeks~Once a week for the next 8 weeks"
430697|NCT00910325|Procedure|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
430698|NCT00910312|Device|Ice-Sense|Ice-Sense Cryoprobe
430699|NCT00910299|Drug|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
430700|NCT00910299|Drug|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
430701|NCT00910286|Other|Pulmonary Ventilator|The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
430702|NCT00910273|Drug|etanercept|etanercept 50 mg/week
430703|NCT00910260|Procedure|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
430704|NCT00910247|Drug|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
430705|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
430706|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
430707|NCT00910234|Drug|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
430708|NCT00910221|Drug|Atorvastatin|Atorvastatin tablet
430709|NCT00910221|Drug|Placebo|Placebo tablet
430710|NCT00910208|Device|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
430711|NCT00910208|Drug|morphine|Intravenous morphine
430712|NCT00910195|Device|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
430713|NCT00910195|Device|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
430722|NCT00910117|Drug|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
430723|NCT00910104|Drug|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
430724|NCT00910091|Drug|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
430725|NCT00910091|Drug|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
430726|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
430727|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
430728|NCT00910065|Drug|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
430729|NCT00910052|Device|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
430730|NCT00910039|Drug|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
430731|NCT00910039|Other|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
430732|NCT00910026|Procedure|low tidal volume ventilation|6 ml/kg tidal volume ventilation
430733|NCT00910026|Procedure|high tidal volume ventilation|12 ml/kg tidal volume ventilation
430734|NCT00910013|Drug|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
430735|NCT00910000|Drug|Vorinostat|
430736|NCT00910000|Drug|Carboplatin|
430737|NCT00910000|Drug|Gemcitabine|
430738|NCT00909987|Drug|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
430739|NCT00909987|Drug|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
430740|NCT00909987|Drug|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
430741|NCT00909987|Radiation|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
430742|NCT00909987|Drug|Capecitabine during all Radiotherapy period|825 mg/m2 bid
430743|NCT00909987|Procedure|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
430744|NCT00909974|Dietary Supplement|UNIMMAP - multiple micronutrients|"Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
430745|NCT00909974|Dietary Supplement|Food supplement enriched with multiple micronutrients|"One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
430746|NCT00909961|Drug|Zoledronic acid|
430747|NCT00909948|Other|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
430748|NCT00909948|Radiation|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
430749|NCT00909935|Drug|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
430750|NCT00909909|Radiation|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
430751|NCT00909909|Radiation|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
430752|NCT00909883|Drug|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
430753|NCT00909883|Drug|Placebo|Placebo injection
430754|NCT00909870|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
430755|NCT00909870|Device|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
430756|NCT00909857|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
430757|NCT00909857|Drug|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
430758|NCT00909857|Drug|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
430759|NCT00909857|Drug|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
430760|NCT00909844|Drug|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
430761|NCT00909831|Drug|hydroxychloroquine|
430762|NCT00909831|Drug|temsirolimus|
430763|NCT00909831|Other|electron microscopy|
430764|NCT00909831|Other|high performance liquid chromatography|
430765|NCT00909831|Other|immunologic technique|
430766|NCT00909831|Other|laboratory biomarker analysis|
430767|NCT00909831|Other|mass spectrometry|
430768|NCT00909831|Other|pharmacological study|
430770|NCT00909818|Radiation|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
430771|NCT00909818|Radiation|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
430772|NCT00909805|Device|cutaneous suture (Surjet)|cutaneous surjet suture
430773|NCT00909805|Device|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
430774|NCT00909792|Device|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
430775|NCT00909792|Device|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
430776|NCT00909779|Drug|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
430777|NCT00909779|Drug|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
430778|NCT00909766|Drug|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
430779|NCT00909766|Drug|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
430780|NCT00909766|Drug|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
430781|NCT00909766|Drug|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
430782|NCT00909766|Drug|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
430783|NCT00909766|Drug|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
430784|NCT00909766|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
430785|NCT00909753|Drug|Ursodiol|Ursodiol Tablets, 500 mg
430786|NCT00909753|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
430787|NCT00909740|Drug|MEGF0444A|Intravenous escalating dose
430788|NCT00909727|Drug|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
430789|NCT00909727|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
430790|NCT00909714|Device|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
430791|NCT00909714|Device|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
430792|NCT00909701|Dietary Supplement|PreOP Booster|1 serving of 400 ml per study arm
430793|NCT00909701|Dietary Supplement|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
430794|NCT00909688|Drug|BLI-489|
430795|NCT00909688|Drug|placebo|
430796|NCT00909662|Procedure|assessment of therapy complications|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
430797|NCT00909662|Procedure|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
430798|NCT00909662|Procedure|fatigue assessment and management|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen~Cognitive Task (2 timed 2-minute tests) with Concomitant EEG~Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS~Borg 15-Category Scale"
430799|NCT00909649|Procedure|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
430800|NCT00909636|Drug|ABT-333|See arm description for more information
430801|NCT00909636|Drug|Placebo|See arm description for more information
430802|NCT00909610|Drug|Ursodiol|Ursodiol Tablets, 500 mg
430803|NCT00909610|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
430804|NCT00909597|Drug|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
430805|NCT00909597|Drug|taspoglutide|10mg sc once weekly
430806|NCT00909597|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
430807|NCT00909584|Drug|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
430808|NCT00909571|Drug|FK506E (modified release tacrolimus)|oral
430809|NCT00909571|Drug|Prograf (tacrolimus)|injection
430810|NCT00909558|Biological|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.~The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
430811|NCT00909545|Drug|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
430812|NCT00909545|Drug|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
430813|NCT00909545|Drug|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
430814|NCT00909545|Drug|Placebo|4 Placebo to Match (PTM) tablets once daily
430815|NCT00909532|Drug|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
430816|NCT00909532|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
430817|NCT00909519|Drug|naproxcinod|naproxcinod 750 mg bid
430818|NCT00909519|Drug|Naproxen|Naproxen 500 mg bid
430819|NCT00909519|Drug|placebo|placebo
430820|NCT00909519|Drug|furosemide|furosemide
430821|NCT00909506|Drug|Placebo|"Control: Receive placebo pill once every evening on 1~2 weeks.~Receive placebo pill in every morning and evening on 3~24 weeks (twice a day)."
430822|NCT00909506|Drug|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3~24 weeks."
430823|NCT00909506|Drug|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3~24 weeks (metformin 500 mg * twice a day = 1000 mg per day)."
430824|NCT00909493|Other|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
430825|NCT00909480|Drug|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
430896|NCT00908817|Drug|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
430826|NCT00909480|Drug|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
430827|NCT00909467|Other|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
430828|NCT00909454|Dietary Supplement|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
430829|NCT00909454|Dietary Supplement|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
430830|NCT00909441|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
430831|NCT00909428|Drug|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
430832|NCT00909402|Drug|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
430833|NCT00909402|Drug|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
430834|NCT00909402|Drug|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
430835|NCT00909389|Drug|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
430836|NCT00909363|Drug|Promacta|"WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests.~they will also have diagnostic blood testing prior to initiating treatment"
430837|NCT00909363|Diagnostic Test|blood drawing in patients with WAS|blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
430838|NCT00909363|Diagnostic Test|blood drawing in healthy controls|blood will be drawn once in healthy children as controls for platelet parameters
430839|NCT00909337|Drug|Bosentan|2x62.5mg for 4 weeks, then 2x125mg
430840|NCT00909324|Drug|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
430841|NCT00909324|Drug|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
430842|NCT00909311|Drug|ABT-450|capsules, QD, 1 dose in each cross-over period
430843|NCT00909311|Drug|ritonavir|capsule, QD, 1 dose in each cross-over period
430844|NCT00909298|Drug|TTP889|300 mg
430845|NCT00909298|Drug|Placebo|Placebo
430846|NCT00909285|Device|TMS stimulation|TMS stimulation and cognitive training
430847|NCT00909285|Device|Sham comparator|Sham comparator
430848|NCT00909285|Behavioral|Cognitive training|TMS stimulation and cognitive training
430849|NCT00909272|Procedure|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
430850|NCT00909272|Procedure|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
430851|NCT00909259|Device|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
430852|NCT00909233|Drug|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
430853|NCT00909220|Behavioral|Behavioral Activation|Behavioral Activation included up to 16 weekly 50 minute psychotherapy sessions using BA (Addis & Martell, 2004; Martell et al., 2001, 2010). Techniques included functional analyses to identify the antecedent and consequential aspects of low mood, and interventions such as monitoring daily activities, assessing pleasure/satisfaction and competence achieved via activities, assigning tasks that induce mastery or pleasure, and reducing skill deficits. Clinicians included postdoctoral fellows in clinical psychology (n = 2) or licensed clinical psychologists (n = 2).
430854|NCT00909207|Behavioral|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
430855|NCT00909194|Behavioral|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
430856|NCT00909181|Drug|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
430857|NCT00909181|Drug|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.~Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
430858|NCT00909168|Drug|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5~ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5~IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5~GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
430859|NCT00909155|Drug|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
430860|NCT00909155|Drug|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
430861|NCT00909142|Drug|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
430862|NCT00909129|Drug|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
430863|NCT00909129|Drug|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
430864|NCT00909116|Procedure|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
430865|NCT00909090|Dietary Supplement|lutein and zeaxanthin supplements|12 mg taken daily for one year
430866|NCT00909090|Drug|Placebo|Placebo
430867|NCT00909077|Drug|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
430868|NCT00909077|Drug|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
430869|NCT00909064|Drug|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
430870|NCT00909051|Drug|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
430871|NCT00909025|Drug|Claudiximab|"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks."
430872|NCT00909012|Dietary Supplement|high oleic sunflower oil|placebo, which does not provide DHA
430873|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
430874|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
430875|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
430876|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
430877|NCT00908986|Drug|Rituximab|375mg/m2 q week x 4; repeated in 6 months
430878|NCT00908960|Drug|Enoxaparin|
430879|NCT00908947|Device|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
430880|NCT00908934|Drug|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
430881|NCT00908934|Drug|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
430882|NCT00908934|Drug|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
430883|NCT00908934|Drug|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
430884|NCT00908921|Drug|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
430885|NCT00908908|Drug|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
430886|NCT00908895|Procedure|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
430887|NCT00908895|Procedure|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
430888|NCT00908882|Behavioral|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
430889|NCT00908869|Drug|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
430890|NCT00908856|Biological|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
430891|NCT00908856|Biological|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
430892|NCT00908856|Drug|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
430893|NCT00908843|Other|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
430894|NCT00908843|Other|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
430897|NCT00908804|Procedure|open appendectomy|
430899|NCT00908791|Drug|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
430900|NCT00908778|Drug|Vitreosolve|intravitreal injection
430901|NCT00908778|Drug|Vitreosolve|intravitreal injection
430902|NCT00908765|Behavioral|Exercise|"High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.~Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
430903|NCT00908752|Drug|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
430904|NCT00908752|Other|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
430905|NCT00908752|Procedure|TACE Therapy|Trans-Arterial Chemo-Embolization Therapy
430906|NCT00908739|Genetic|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
430907|NCT00908739|Other|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
430908|NCT00908739|Other|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
430909|NCT00908726|Drug|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
430910|NCT00908713|Drug|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
430911|NCT00908713|Drug|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
430912|NCT00908700|Procedure|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
430913|NCT00908700|Procedure|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
430914|NCT00908687|Biological|A/H5N1|A/H5N1 Low Dose
430915|NCT00908687|Biological|A/H5N1|A/H5N1 High Dose
430916|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
430917|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch High Dose
430918|NCT00908674|Drug|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).~Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.~Administration period: 12 months."
430919|NCT00908661|Device|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
430920|NCT00908648|Procedure|Narrow Band Imaging|Narrow Band Imaging
430921|NCT00908622|Procedure|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
430922|NCT00908622|Procedure|Cardiac revascularization|Cardiac revascularization
430923|NCT00908596|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
430924|NCT00908583|Drug|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
430925|NCT00908583|Drug|Bortezomib|Patients will receive bortezomib as described in protocol
430926|NCT00908583|Drug|Rituximab|Patients will receive rituximab as described in protocol
430927|NCT00908583|Drug|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
430928|NCT00908570|Drug|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
430929|NCT00908570|Drug|Placebo|Placebo cream
430930|NCT00908557|Other|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
430931|NCT00908557|Other|Control|information based on the classic informed consent document
430932|NCT00908544|Other|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
430933|NCT00908544|Other|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
430934|NCT00908531|Drug|letrozole (Femara)|tablet 2.5 mg daily
430935|NCT00908505|Procedure|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
430936|NCT00908492|Behavioral|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
430982|NCT00908245|Procedure|Preconditioning ischemia|Surgery with a preconditioning ischemia
430983|NCT00908232|Drug|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
430984|NCT00908232|Drug|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
430985|NCT00908232|Drug|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
430937|NCT00908492|Behavioral|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
430938|NCT00908479|Behavioral|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
430939|NCT00908479|Behavioral|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
430940|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
430941|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
430942|NCT00908453|Drug|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
430943|NCT00908440|Behavioral|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
430944|NCT00908427|Procedure|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
430945|NCT00908427|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
430946|NCT00908414|Drug|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
430947|NCT00908414|Drug|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
430948|NCT00908414|Drug|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
430949|NCT00908414|Drug|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
430950|NCT00908414|Drug|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
430951|NCT00908414|Drug|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
430952|NCT00908414|Drug|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
430953|NCT00908414|Drug|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
430954|NCT00908414|Drug|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
430955|NCT00908414|Drug|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
430956|NCT00908414|Drug|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
430957|NCT00908414|Drug|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
430958|NCT00908414|Drug|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
430959|NCT00908414|Drug|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
430960|NCT00908414|Drug|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
430961|NCT00908414|Drug|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
430962|NCT00908414|Drug|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
430963|NCT00908401|Other|Breastmilk|Breastmilk: 0.2 ml
430964|NCT00908401|Other|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
430965|NCT00908388|Device|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
430966|NCT00908375|Drug|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
430967|NCT00908375|Drug|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
430968|NCT00908362|Drug|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
430969|NCT00908362|Drug|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
430970|NCT00908362|Drug|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
430971|NCT00908349|Drug|Oxcarbazepine XR|Open Label Study
430972|NCT00908336|Drug|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
430973|NCT00908336|Drug|Erlotinib|150 mg/day po daily
430974|NCT00908323|Biological|JS7 DNA vaccine|
430975|NCT00908323|Biological|MVA/HIV62 vaccine|
430976|NCT00908310|Drug|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
430977|NCT00908297|Dietary Supplement|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).~Dose escalation:~300 mg for two weeks~600 mg for two weeks~1200 mg for two weeks~1800 mg for final two weeks"
430978|NCT00908284|Behavioral|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
430979|NCT00908284|Behavioral|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
430980|NCT00908271|Drug|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
430981|NCT00908245|Procedure|Control|Surgery without preconditioning surgery
431149|NCT00907036|Biological|donor lymphocytes|
430986|NCT00908232|Drug|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
430987|NCT00908219|Drug|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
430988|NCT00908206|Drug|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
430989|NCT00908193|Device|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
430990|NCT00908193|Procedure|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
430991|NCT00908180|Biological|alemtuzumab|
430992|NCT00908180|Biological|donor lymphocytes|
430993|NCT00908180|Drug|carmustine|
430994|NCT00908180|Drug|cyclosporine|
430995|NCT00908180|Drug|cytarabine|
430996|NCT00908180|Drug|etoposide|
430997|NCT00908180|Drug|melphalan|
430998|NCT00908180|Procedure|allogeneic hematopoietic stem cell transplantation|
430999|NCT00908167|Drug|Sorafenib|Please see detailed description.
431000|NCT00908167|Drug|Cytarabine|Please see Detailed Description.
431001|NCT00908167|Drug|Clofarabine|Please see Detailed Description.
431002|NCT00908154|Drug|Placebo|Tablets to match GSK1014802
431003|NCT00908154|Drug|GSK1014802|Sodium channel blocker
431004|NCT00908141|Biological|sargramostim|Given subcutaneously on varying schedule
431005|NCT00908128|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
431006|NCT00908128|Drug|CellCept®|CellCept® Tablets, 500 mg
431007|NCT00908115|Biological|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
431008|NCT00908102|Other|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
431009|NCT00908102|Other|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
431010|NCT00908102|Other|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
431011|NCT00908102|Other|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
431012|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
431013|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
431014|NCT00908076|Drug|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
431015|NCT00908063|Drug|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
431016|NCT00908063|Drug|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
431017|NCT00908050|Drug|Botulinum toxin type A|"week 1: the patient will undergo the following: a. physical examination; b. sleep questionnaire c. bruxism questionnaire to establish a clinical diagnosis of bruxism; d. headache questionnaire; e. Clinical Global Improvement scale; f. masseter muscle measurement; g. anxiety questionnaire; h. demographic questionnaire;~week 2: The patient undergoes a polysomnogram (sleep study). The patient will spend one night (10:30pm-8:00am or until spontaneous awakening) in a sleep lab. During the sleep study, the following parameters will be recorded: electroencephalogram, electro-oculogram, upper airway resistance, heart rate, muscle activity; upper airway resistance,masseter muscles bilaterally. All recordings are performed using surface electrodes (self-adhesive to the skin), none of them invasive.~Study visit 3 (week 3): Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally."
431018|NCT00908037|Drug|eltrombopag|thrombopoietin receptor agonist
431019|NCT00908037|Drug|Placebo|placebo for comparison
431020|NCT00908024|Drug|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
431021|NCT00908024|Drug|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
431022|NCT00908011|Drug|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
431023|NCT00908011|Drug|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
431024|NCT00907998|Drug|APL180|
431025|NCT00907998|Drug|APL180|
431026|NCT00907998|Drug|Placebo|
431027|NCT00907985|Drug|Placebo|Single dose of placebo will be provided.
431028|NCT00907985|Drug|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
431029|NCT00907985|Drug|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
431030|NCT00907972|Dietary Supplement|Vitamin D3|Vitamin D3
431031|NCT00907972|Other|Placebo|Placebo
431032|NCT00907959|Drug|BZL101|Oral BZL101 20 grams/day (10 grams BID).
431150|NCT00907036|Drug|cyclosporine|
431151|NCT00907036|Drug|fludarabine phosphate|
431152|NCT00907036|Drug|melphalan|
431153|NCT00907036|Procedure|allogeneic hematopoietic stem cell transplantation|
431033|NCT00907946|Procedure|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
431034|NCT00907933|Drug|SB-705498|0.5mg intranasal SB-705498
431035|NCT00907933|Drug|SB-705498|1.5mg intranasal SB-705498
431036|NCT00907933|Drug|SB-705498|3mg intranasal SB-705498
431037|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498
431038|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498
431039|NCT00907933|Drug|Placebo|Placebo '498
431040|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498 for 14 days bid
431041|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498 14 days bid
431042|NCT00907933|Drug|Placebo|Placebo
431043|NCT00907920|Other|laboratory biomarker analysis|Correlative studies
431044|NCT00907907|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
431045|NCT00907907|Drug|CellCept® Tablets|CellCept® Tablets, 500 mg
431046|NCT00907894|Drug|LDT600 (Telbivudine)|LDT600 (Telbivudine)
431047|NCT00907881|Drug|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
431048|NCT00907868|Radiation|partial breast irradiation|Patients undergo radiation tumor bed boost
431049|NCT00907868|Radiation|whole breast irradiation|Patients undergo whole breast irradiation
431050|NCT00907842|Device|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
431051|NCT00907829|Drug|lidocaine|comparison of the effect of the drug to help improve finger function
431052|NCT00907829|Device|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
431053|NCT00907803|Drug|ST-246 400 mg|Capsules, 400 mg daily for 14 days
431054|NCT00907803|Drug|ST-246 600 mg|Capsules, 600 mg daily for 14 days
431055|NCT00907803|Drug|Placebo|Capsules, once daily for 14 days
431056|NCT00907790|Behavioral|Usual Care (Control Group)|
431057|NCT00907790|Behavioral|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
431058|NCT00907777|Biological|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
431059|NCT00907777|Biological|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
431060|NCT00907764|Drug|regadenoson|400 ug, IV
431061|NCT00907751|Drug|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
431062|NCT00907738|Drug|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
431063|NCT00907725|Other|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
431064|NCT00907725|Other|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
431065|NCT00907712|Other|cardiac echo examination|cardiac echo examination - before and after the surgery
431066|NCT00907699|Genetic|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
431067|NCT00907699|Genetic|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
431068|NCT00907699|Genetic|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
431069|NCT00907699|Genetic|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
431070|NCT00907699|Genetic|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
431154|NCT00906997|Procedure|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
431155|NCT00906997|Procedure|Colonoscopy|Every 10 years, with sedation.
431156|NCT00906984|Device|TheraSphere|Given IV
431247|NCT00906126|Drug|Misoprostol|Oral misoprostol
431071|NCT00907699|Genetic|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
431072|NCT00907699|Genetic|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
431073|NCT00907699|Other|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
431074|NCT00907673|Device|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
431075|NCT00907660|Behavioral|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
431076|NCT00907660|Dietary Supplement|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
431077|NCT00907621|Procedure|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
431078|NCT00907608|Drug|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
431079|NCT00907595|Drug|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
431080|NCT00907595|Drug|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
431081|NCT00907582|Procedure|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:~idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
431082|NCT00907569|Radiation|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
431083|NCT00907543|Other|Preoperative treatment of chemotherapy and radiation|Cisplatin + 5FU with concurrent radiation followed by surgery
431084|NCT00907543|Other|Postoperative treatment of chemotherapy and radiation|Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
431085|NCT00907530|Drug|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
431086|NCT00907530|Drug|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
431087|NCT00907517|Drug|MK-8776|IV infusion
431088|NCT00907517|Drug|Cytarabine|IV infusion
431089|NCT00907504|Drug|CP-751,871|CP-751,871 20mg/kg every 3 weeks
431090|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
431091|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
431092|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
431093|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
431094|NCT00907491|Device|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
431095|NCT00907478|Biological|romiplostim|Romiplostim administered by subcutaneous injection
431096|NCT00907452|Drug|melphalan-prednisone-thalidomide|
431097|NCT00907452|Drug|lenalidomide-dexamethasone|
431098|NCT00907426|Drug|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
431099|NCT00907426|Drug|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
431100|NCT00907413|Procedure|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
431101|NCT00907413|Procedure|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
431102|NCT00907400|Drug|PN400|oral tablet
431103|NCT00907400|Drug|Naproxen|oral tablet
431104|NCT00907387|Drug|RT001|Dose A RT001
431105|NCT00907387|Drug|RT001|Dose B RT001
431106|NCT00907387|Other|Placebo|Dose C Placebo
431107|NCT00907374|Drug|benazepril|benazepril 10 mg orally once daily
431108|NCT00907374|Drug|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
431109|NCT00907361|Device|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
431199|NCT00906555|Procedure|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
431200|NCT00906529|Drug|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
431110|NCT00907348|Drug|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14~SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14~THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14~FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
431111|NCT00907335|Drug|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
431112|NCT00907335|Drug|Vehicle control|Color-matched facial gel vehicle control used once daily
431113|NCT00907322|Drug|Dimebon|Oral tablet; 20 mg Dimebon, single dose
431114|NCT00907322|Drug|Dimebon|Oral tablet; 40 mg Dimebon, single dose
431115|NCT00907322|Drug|Dimebon|Oral tablet; 60 mg Dimebon, single dose
431116|NCT00907322|Drug|Dimebon|Oral tablet; placebo, single dose
431117|NCT00907309|Behavioral|iMET|Participants will receive the iMET intervention
431118|NCT00907309|Behavioral|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
431119|NCT00907296|Biological|Romosozumab|Administered by subcutaneous injection
431120|NCT00907296|Drug|Placebo|Administered by subcutaneous injection
431121|NCT00907283|Drug|Deferiprone|15 mg/Kg/twice for 1 year
431122|NCT00907270|Dietary Supplement|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
431123|NCT00907257|Drug|benzoyl peroxide wash|5% benzoyl peroxide wash
431124|NCT00907257|Drug|Tretinoin gel|0.04% tretinoin gel
431125|NCT00907218|Drug|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
431126|NCT00907205|Drug|SF1126|Dose Escalating with 3+ patients in each cohort
431127|NCT00907192|Behavioral|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
431128|NCT00907192|Behavioral|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
431129|NCT00907179|Drug|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).~Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2~Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2~Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2~Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
431130|NCT00907179|Drug|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
431131|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
431132|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
431133|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
431134|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
431135|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
431136|NCT00907153|Dietary Supplement|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
431137|NCT00907153|Drug|Placebo|Placebo by mouth once daily for 12 weeks
431138|NCT00907140|Procedure|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
431139|NCT00907127|Behavioral|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
431140|NCT00907114|Drug|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
431141|NCT00907114|Drug|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
431142|NCT00907101|Drug|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
431143|NCT00907088|Other|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
431144|NCT00907088|Other|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
431145|NCT00907075|Behavioral|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
431146|NCT00907075|Behavioral|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
431147|NCT00907062|Dietary Supplement|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
431148|NCT00907036|Biological|alemtuzumab|
431157|NCT00906971|Other|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
431158|NCT00906945|Drug|G-CSF|
431159|NCT00906945|Drug|Plerixafor|
431160|NCT00906945|Drug|Mitoxantrone|
431161|NCT00906945|Drug|Etoposide|
431162|NCT00906945|Drug|Cytarabine|
431163|NCT00906919|Behavioral|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
431164|NCT00906919|Behavioral|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
431165|NCT00906906|Device|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
431166|NCT00906893|Procedure|18F]-FMISO PET-CT|pretherapy([18F]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe [18F]-FMISO uptake will be used.
431167|NCT00906880|Drug|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
431168|NCT00906867|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
431169|NCT00906867|Procedure|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
431170|NCT00906841|Drug|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
431171|NCT00906828|Drug|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
431172|NCT00906828|Drug|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
431173|NCT00906828|Drug|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
431174|NCT00906802|Procedure|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
431175|NCT00906789|Behavioral|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
431176|NCT00906776|Device|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
431177|NCT00906776|Device|Autogenous bone|Autogenous bone application during periodontal surgery
431178|NCT00906763|Dietary Supplement|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
431179|NCT00906750|Biological|FluMist|FluMist is a live attenuated intranasal influenza vaccine
431180|NCT00906750|Biological|Inactivated influenza vaccine|Inactivated influenza vaccine
431181|NCT00906737|Device|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
431182|NCT00906737|Other|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
431183|NCT00906724|Procedure|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.~Subjects will undergo three month of supervised aerobic exercise."
431184|NCT00906698|Drug|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
431185|NCT00906698|Drug|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
431186|NCT00906698|Drug|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
431187|NCT00906698|Drug|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
431188|NCT00906698|Drug|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
431189|NCT00906698|Drug|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
431190|NCT00906685|Drug|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
431191|NCT00906685|Drug|Sham bevacizumab injection|Sham intravitreal injection
431192|NCT00906672|Device|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
431193|NCT00906672|Procedure|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
431194|NCT00906646|Dietary Supplement|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
431195|NCT00906646|Dietary Supplement|Placebo|Placebo tablets
431196|NCT00906620|Other|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
431197|NCT00906594|Drug|latanoprost|
431198|NCT00906581|Behavioral|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
431201|NCT00906516|Drug|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
431202|NCT00906503|Drug|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
431203|NCT00906503|Procedure|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
431204|NCT00906503|Radiation|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
431205|NCT00906490|Device|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
431206|NCT00906477|Procedure|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
431207|NCT00906451|Drug|Simvastatin|Simvastatin
431208|NCT00906438|Dietary Supplement|2006-RD-05|300 mg daily, once a day for 28 consecutive days
431209|NCT00906438|Dietary Supplement|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
431210|NCT00906425|Device|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
431211|NCT00906399|Drug|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
431212|NCT00906399|Drug|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
431213|NCT00906386|Drug|Varenicline|oral, 1 mg twice daily, 12 weeks
431214|NCT00906386|Drug|placebo|oral, 1 mg twice daily, 12 weeks
431215|NCT00906373|Biological|IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)|intravenous infusions 10 mg/kg on Day 1 of each 3-week cycle
431216|NCT00906373|Biological|IMC-A12 (cixutumumab) - 20 mg/kg|intravenous infusions 20 mg/kg on Day 1 of each 3-week cycle
431217|NCT00906373|Drug|Sorafenib|400 milligrams (mg) twice per day orally
431218|NCT00906360|Drug|sunitinib malate|Given orally or by percutaneous gastrostomy tube
431219|NCT00906360|Other|pharmacological study|Correlative studies
431220|NCT00906360|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
431221|NCT00906360|Biological|cetuximab|Given IV
431222|NCT00906347|Drug|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
431223|NCT00906347|Drug|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
431224|NCT00906334|Drug|ON 01910.Na|The original dosing regimen was 800 mg/m^2 ON 01910.Na.
431225|NCT00906334|Drug|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
431226|NCT00906321|Behavioral|Web-Based Decision Support|
431227|NCT00906308|Drug|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
431228|NCT00906308|Drug|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
431229|NCT00906308|Drug|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
431230|NCT00906295|Other|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
431231|NCT00906295|Other|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
431232|NCT00906282|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
431233|NCT00906282|Drug|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
431234|NCT00906269|Drug|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
431235|NCT00906269|Drug|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
431236|NCT00906256|Drug|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
431237|NCT00906256|Drug|Placebo|Placebo
431238|NCT00906243|Biological|CV9103|CV9103 encodes for 4 prostate specific antigens.
431239|NCT00906204|Biological|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
431240|NCT00906204|Biological|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
431241|NCT00906191|Drug|SAM-531|
431242|NCT00906178|Behavioral|CyberSenga|Internet-based HIV prevention program
431243|NCT00906165|Device|Straumann® Bone Level SLActive Implant (4.1mm diameter)|Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
431244|NCT00906139|Drug|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
431248|NCT00906113|Drug|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
431249|NCT00906113|Drug|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
431250|NCT00906087|Drug|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
431251|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review.
431252|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review
431253|NCT00906061|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
431254|NCT00906048|Drug|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day~Weight < 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
431255|NCT00906035|Drug|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
431256|NCT00906035|Drug|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
431257|NCT00906035|Drug|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
431258|NCT00906022|Device|Astron Pulsar Stent|Stenting with Astron Pulsar
431259|NCT00906022|Device|PTA alone|Balloon angioplasty alone
431260|NCT00905996|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
431261|NCT00905996|Drug|Beta-blocker (propranolol)|
431262|NCT00905983|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
431263|NCT00905957|Procedure|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
431264|NCT00905957|Procedure|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
431265|NCT00905944|Other|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
431266|NCT00905931|Drug|Lycopene|30 mg oral, daily, for 21 days
431267|NCT00905931|Drug|placebo|starch
431268|NCT00905918|Dietary Supplement|vitamin E|Given orally
431269|NCT00905918|Other|laboratory biomarker analysis|All patients undergo biomarker analyses
431270|NCT00905905|Drug|Simvastatin|Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
431271|NCT00905905|Drug|Ezetimibe-Simvastatin|Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
431272|NCT00905892|Dietary Supplement|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
431273|NCT00905879|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
431274|NCT00905866|Other|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
431275|NCT00905853|Procedure|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
431276|NCT00905853|Drug|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.~Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.~Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
431277|NCT00905840|Device|Titanium Zircon implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
431278|NCT00905840|Device|Titanium Grade IV implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.~The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
431279|NCT00905827|Behavioral|CAMS|Collaborative assessment management in suicidality
431280|NCT00905814|Drug|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
431281|NCT00905814|Drug|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
431282|NCT00905801|Other|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
431283|NCT00905788|Procedure|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
431284|NCT00905762|Drug|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
431285|NCT00905762|Drug|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
431286|NCT00905762|Drug|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
431287|NCT00905736|Procedure|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
431288|NCT00905736|Procedure|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
431289|NCT00905723|Drug|estradiol|1 mg daily for 6 months
431290|NCT00905723|Drug|isoflavone|150 mg isoflavone daily for 6 months
431291|NCT00905723|Drug|Placebo|sugar pill daily for six months
431292|NCT00905710|Procedure|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
431293|NCT00905697|Procedure|Living donor lung transplantation|Living donor lung transplantation
431294|NCT00905684|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
431295|NCT00905684|Drug|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
431296|NCT00905671|Device|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
431297|NCT00905658|Dietary Supplement|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
431298|NCT00905658|Procedure|standard follow-up care|Patients undergo standard monitoring
431299|NCT00905645|Device|Silimed Gel-Filled Mammary Implant|
431300|NCT00905632|Drug|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
431301|NCT00905632|Drug|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
431302|NCT00905632|Drug|Placebo + SOC|Placebo tid +SOC
431303|NCT00905632|Drug|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
431304|NCT00905606|Drug|Topiramate Tablets|
431305|NCT00905606|Drug|Topamax® Tablets|
431306|NCT00905593|Drug|Nilotinib|
431307|NCT00905580|Drug|Pregabalin|Pregabalin 150 mg orally
431308|NCT00905580|Drug|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
431309|NCT00905567|Drug|Topiramate 2 x 25 mg tablet|
431310|NCT00905567|Drug|Topamax® Tablet 2 x 25 mg|
431311|NCT00905554|Procedure|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
431312|NCT00905554|Procedure|air insufflation|air insufflation during the insertion phase of colonoscopy
431313|NCT00905541|Drug|simvastatin|40 mg/day
431314|NCT00905541|Drug|simvastatin|80 mg simvastatin acute-on-chronic
431315|NCT00905528|Drug|Telmisartan 80 mg/d|
431316|NCT00905528|Drug|Ramipril 10 mg/d|
431317|NCT00905515|Drug|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
431318|NCT00905515|Drug|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
431319|NCT00905502|Drug|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
431320|NCT00905502|Drug|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
431321|NCT00905489|Drug|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
431322|NCT00905489|Drug|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
431323|NCT00905463|Procedure|Lung transplantation|Lung transplantation
431324|NCT00905450|Drug|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
431325|NCT00905450|Drug|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
431326|NCT00905437|Drug|Placebo|Placebo as an adjunct to standard of care
431327|NCT00905437|Drug|Pregabalin|75 mg BD for 14 days
431328|NCT00905424|Drug|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
431329|NCT00905424|Drug|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
431330|NCT00905411|Behavioral|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.~15 months study."
431331|NCT00905398|Drug|Nilotinib|400mg, Oral, Bid, Daily for three years
431332|NCT00905385|Biological|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
431333|NCT00905372|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
431334|NCT00905372|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
431335|NCT00905359|Procedure|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
431336|NCT00905359|Procedure|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
431337|NCT00905346|Drug|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
431338|NCT00905346|Drug|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
431339|NCT00905346|Other|Applesauce|Applesauce
431340|NCT00905333|Drug|Candesartan (test)|16 mg oral tablet, single dose
431341|NCT00905333|Drug|Felodipine (test)|5 mg oral extended release tablet, single dose
431342|NCT00905333|Drug|Candesartan Cilexetil|16 mg oral tablet, single dose
431343|NCT00905333|Drug|Felodipine|5 mg oral extended release tablet, single dose
431344|NCT00905320|Procedure|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
431345|NCT00905320|Procedure|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
431346|NCT00905307|Drug|OPC-34712|oral, once daily
431347|NCT00905307|Drug|Placebo|Placebo
431348|NCT00905307|Drug|Aripiprazole|oral, once daily
431349|NCT00905294|Other|Blood draws|Observational: blood draws only
431350|NCT00905281|Other|Action Group|"On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary."
431351|NCT00905281|Other|Standard care|No specific intervention
431352|NCT00905268|Drug|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
431353|NCT00905268|Drug|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
431354|NCT00905255|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
431355|NCT00905255|Device|Pen auto-injector|
431356|NCT00905242|Drug|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
431357|NCT00905229|Drug|Phytonadione|2.5 mg po
431358|NCT00905229|Drug|Phytonadione|0.5 mg IV
431359|NCT00905216|Drug|heparin sodium - Bergamo|5.000 UI/mL
431360|NCT00905216|Drug|heparin sodium - APP|5.000 USP
431361|NCT00905203|Other|exercise|exercise training
431362|NCT00905190|Drug|Ondansetron|24 mg one time
431363|NCT00905164|Drug|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
431364|NCT00905164|Drug|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
431365|NCT00905138|Drug|GLPG0259|single ascending doses, oral solution
431366|NCT00905138|Drug|placebo|single dose, oral solution
431367|NCT00905138|Drug|GLPG0259|multiple dose, oral solution, 5 days
431368|NCT00905138|Drug|placebo|oral solution, 5 days
431369|NCT00905125|Biological|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
431370|NCT00905125|Biological|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
431371|NCT00905112|Other|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
431372|NCT00905112|Other|Standard OB Care|Receive standard obstetrical care
431373|NCT00905086|Other|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
431374|NCT00905086|Procedure|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
431375|NCT00905086|Procedure|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
431376|NCT00905086|Procedure|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
431377|NCT00905073|Drug|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
431378|NCT00905060|Biological|HSPPC-96|"Patients will receive 4 weekly injections of HSPPC-96 followed by a 5th vaccine injection on the same day of the start of maintenance temozolomide administered 2 weeks (+ 4 days) following vaccine administration #4 on the same day of the start of maintenance temozolomide (Day 36). Monthly vaccine injections will then begin on day 21 (+/- 7 days) of the first 28 day temozolomide cycle (Day 56 of the study)3 weeks following vaccine administration #5 and will continue every 28 days until depletion of vaccine or progression.~Immune monitoring will be completed pre-operatively, intra-operatively, 48-hours post-surgery, prior to vaccine administration #1, at prior to vaccine administration #5 and at weeks 09, 13, 37 and 53.~The total volume of each vaccine or place provided is 0.47 mL. The total volume that should be administered is 0.4 mL (0.07 mL overage)."
431379|NCT00905047|Drug|XELODA|"XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.~Cycle treatment duration : 21 days"
431380|NCT00905047|Drug|TEGAFUR URACIL - FOLINIC ACID|"Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.~Duration of treatment cycle : 35 days."
431381|NCT00905034|Drug|Methotrexate|200 mg/m^2 by vein on days 1 and 15.
431382|NCT00905034|Drug|Vincristine|1.4 mg/m^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
431383|NCT00905034|Drug|PEG-l-asparaginase|2500 International units/m^2 by vein on days 2 and 16
431384|NCT00905034|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
431385|NCT00905034|Drug|Rituximab|Rituximab 375 mg/m^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
431386|NCT00905021|Drug|Exemestane|Exemestane 25 mg by mouth every day.
431387|NCT00905021|Drug|Sutent|Sunitinib 37.5 mg by mouth every day.
431418|NCT00904813|Radiation|Preoperative radiotherapy|2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
431419|NCT00904800|Drug|AZD0837|tablet, oral, once daily, 1+5 days
431420|NCT00904800|Drug|Placebo|Placebo
431421|NCT00904787|Drug|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
431638|NCT00903071|Behavioral|Real PPL|See above arm description
431639|NCT00903071|Behavioral|Sim PPL|See above arm description
431388|NCT00905008|Procedure|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis <30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
431389|NCT00905008|Device|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
431390|NCT00904995|Drug|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
431391|NCT00904995|Drug|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
431392|NCT00904982|Behavioral|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.~Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
431393|NCT00904982|Device|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
431394|NCT00904969|Device|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
431395|NCT00904969|Device|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
431396|NCT00904943|Drug|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
431397|NCT00904943|Drug|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
431398|NCT00904930|Device|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
431399|NCT00904930|Device|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
431400|NCT00904917|Behavioral|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
431401|NCT00904917|Behavioral|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
431402|NCT00904904|Drug|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
431403|NCT00904904|Drug|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
431404|NCT00904891|Behavioral|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
431405|NCT00904891|Behavioral|Cognitive-behavioral bibliotherapy|"Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good"
431406|NCT00904865|Procedure|SPA cholecystectomy|SPA cholecystectomy
431407|NCT00904865|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
431408|NCT00904852|Drug|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
431409|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
431410|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
431411|NCT00904839|Drug|mFolfox|standard i.v chemotherapy
431412|NCT00904839|Drug|Bevacizumab|100 mg/Kg solution , IV infusion
431413|NCT00904839|Drug|mFolfox 6|IV standard chemotherapy
431414|NCT00904839|Drug|bevacizumab|100 mg/4 ml solution
431415|NCT00904826|Drug|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
431416|NCT00904813|Radiation|Preoperative radiotherapy|5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
431417|NCT00904813|Radiation|Preoperative radiotherapy|5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
431629|NCT00903162|Drug|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
431422|NCT00904761|Other|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
431423|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
431424|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
431425|NCT00904748|Drug|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
431426|NCT00904735|Drug|hydroxyurea|Given orally
431427|NCT00904735|Drug|imatinib mesylate|Given orally
431428|NCT00904722|Drug|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
431429|NCT00904722|Drug|Rituximab|Administered intravenously at the standard dose of 375 mg/m^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
431430|NCT00904709|Drug|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
431431|NCT00904683|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
431432|NCT00904683|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
431433|NCT00904670|Drug|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
431434|NCT00904670|Drug|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
431435|NCT00904670|Drug|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
431436|NCT00904657|Drug|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
431437|NCT00904644|Drug|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
431438|NCT00904631|Device|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
431439|NCT00904618|Procedure|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
431440|NCT00904618|Procedure|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
431441|NCT00904618|Drug|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
431442|NCT00904605|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
431443|NCT00904605|Drug|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
431444|NCT00904592|Drug|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
431445|NCT00904592|Drug|Placebo Comparator|"Control group: Basic therapy ＆ placebo~Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.~placebo,Usage: 4.5g，po，tid"
431446|NCT00904553|Radiation|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
431447|NCT00904540|Drug|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (<6 weeks) LBP, subacute (6 weeks to <3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (>12 months LBP)
431448|NCT00904527|Behavioral|relaxation (Schultz)|Patients have relaxation consultations during 2 months
431449|NCT00904514|Genetic|gene expression analysis|
431450|NCT00904514|Genetic|microarray analysis|
431451|NCT00904514|Genetic|mutation analysis|
431452|NCT00904514|Genetic|polymerase chain reaction|
431453|NCT00904514|Other|flow cytometry|
431454|NCT00904514|Other|immunoenzyme technique|
431455|NCT00904514|Other|laboratory biomarker analysis|
431456|NCT00904501|Procedure|Bone marrow harvest|Implantation of placebo
431457|NCT00904501|Procedure|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
431458|NCT00904488|Drug|Addition of oral Metolazone|Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide
431459|NCT00904488|Drug|Furosemide dose escalation|Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)
431736|NCT00902473|Drug|Topiramate|25mg tablets
431460|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
431461|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
431462|NCT00904462|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
431463|NCT00904462|Drug|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
431464|NCT00904449|Drug|Oxymorphone ER|10mg, 20mg, and 40mg PO
431465|NCT00904436|Drug|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
431466|NCT00904423|Drug|Vitamin D|up to 2400 mg; oral tablet
431467|NCT00904410|Other|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
431468|NCT00904397|Drug|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
431469|NCT00904397|Drug|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
431470|NCT00904358|Diagnostic Test|cross sectional area|
431471|NCT00904345|Drug|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
431472|NCT00904345|Radiation|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
431473|NCT00904319|Other|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
431474|NCT00904306|Dietary Supplement|Sugar Pill|placebo oral tablet taken once per day
431475|NCT00904306|Dietary Supplement|chromium picolinate|1000 ug/day chromium picolinate for 6 months
431476|NCT00904306|Dietary Supplement|chromium picolinate|600 ug/day chromium picolinate
431477|NCT00904293|Other|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
431478|NCT00904293|Other|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
431479|NCT00904280|Drug|Oxymorphone ER|Open label
431480|NCT00904254|Radiation|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
431481|NCT00904241|Other|Cytology Specimen Collection Procedure|Correlative studies
431482|NCT00904241|Other|Laboratory Biomarker Analysis|Correlative studies
431483|NCT00904228|Other|placement of plastic cap during delivery room stabilization|placement of plastic cap during delivery room stabilization
431484|NCT00904228|Other|placement of routine cap during delivery room stabilization|
431485|NCT00904215|Drug|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
431486|NCT00904202|Drug|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
431487|NCT00904202|Drug|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
431488|NCT00904202|Drug|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
431489|NCT00904202|Drug|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
431490|NCT00904202|Drug|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
431491|NCT00904202|Drug|Gabapentin 1800 mg/day + Lidoderm patch|
431492|NCT00904189|Radiation|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
431493|NCT00904176|Drug|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
431494|NCT00904176|Drug|Warfarin|Tablets, Oral, 25 mg, Single Dose
431495|NCT00904176|Drug|Digoxin|Tablets, Oral, 0.25, Single Dose
431496|NCT00904137|Procedure|Cast|
431497|NCT00904137|Procedure|Splint|
431498|NCT00904137|Procedure|Tape|
431499|NCT00904124|Dietary Supplement|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
431500|NCT00904111|Drug|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
431501|NCT00904111|Drug|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
431502|NCT00904098|Drug|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
431503|NCT00904098|Drug|Usual Care|Current treatment used to treat all migraine headaches
431504|NCT00904085|Drug|Oxymorphone IR|5 mg
431505|NCT00904059|Drug|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
431506|NCT00904059|Drug|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
431507|NCT00904059|Drug|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
431508|NCT00904059|Drug|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
431509|NCT00904046|Drug|Pioglitazone|30 mg orally daily for 6 months
431510|NCT00904046|Drug|Placebo|Placebo taken orally once a day for 6 months.
431511|NCT00904033|Drug|Calcitriol|Calcitriol tablet taken once per week.
431512|NCT00904033|Behavioral|Exercise|Exercise consisting of progressive walking and resistance band training
431513|NCT00904033|Dietary Supplement|Multivitamin|
431514|NCT00904020|Drug|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
431515|NCT00904007|Other|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
431516|NCT00903994|Drug|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
431517|NCT00903981|Drug|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
431518|NCT00903981|Drug|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
431519|NCT00903981|Drug|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
431520|NCT00903968|Drug|Plerixafor|
431521|NCT00903968|Drug|bortezomib|
431522|NCT00903968|Drug|Dexamethasone|
431523|NCT00903955|Other|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
431524|NCT00903942|Radiation|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
431525|NCT00903942|Drug|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
431526|NCT00903929|Drug|Eltrombopag|dose escalation
431527|NCT00903890|Other|Survey|Survey asking questions regarding the subjects cardiac and general health.
431528|NCT00903877|Drug|T3|Patients receive T3 in a dose of 25mcg and 50mcg
431529|NCT00903851|Drug|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
431530|NCT00903838|Drug|pardoprunox|1.5 to 12 mg/day
431531|NCT00903838|Drug|pramipexole|0.75-4.5 mg/day
431532|NCT00903825|Procedure|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
431533|NCT00903825|Procedure|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
431534|NCT00903812|Other|No intervention|No intervention as observational study
431535|NCT00903799|Device|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
431536|NCT00903786|Drug|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
431537|NCT00903773|Drug|telaprevir|
431538|NCT00903760|Drug|Decitabine|Decitabine 20 mg/m^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
431539|NCT00903760|Drug|Clofarabine|Clofarabine 10 mg/m^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
431540|NCT00903747|Drug|prucalopride|2-10 mg prucalopride
431541|NCT00903747|Drug|moxifloxacin|400 mg moxifloxacin (Group 2a)
431542|NCT00903747|Drug|placebo|placebo (Group 2b)
431543|NCT00903734|Drug|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
431544|NCT00903721|Drug|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)~Duration: up to 6 months"
431545|NCT00903708|Drug|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
431630|NCT00903162|Drug|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
431631|NCT00903136|Other|questionnaire administration|
431822|NCT00901979|Drug|LCQ908A|
431546|NCT00903695|Drug|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, & acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
431547|NCT00903695|Drug|placebo|placebo comparator
431548|NCT00903682|Drug|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
431549|NCT00903682|Drug|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
431550|NCT00903656|Drug|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
431551|NCT00903643|Other|Physical examination|Physical examination and multiple questionnaires will be administered
431552|NCT00903630|Drug|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
431553|NCT00903630|Drug|liposomal doxorubicin|administered at a fixed dose of 40 mg/m^2 intravenously (IV) on day 1 of each 28 day cycle
431554|NCT00903617|Drug|GSK256073|5 mg for 8 weeks
431555|NCT00903617|Drug|GSK256073|50 mg for 8 weeks
431556|NCT00903617|Drug|GSK256073|150 mg for 8 weeks
431557|NCT00903617|Drug|Placebo|placebo for 8 weeks
431558|NCT00903617|Drug|Niaspan|1500 mg for 8 weeks
431559|NCT00903617|Drug|GSK256073|x mg for 8 weeks based from data from Part A
431560|NCT00903617|Drug|GSK256073|optional dose based on data from Part A
431561|NCT00903604|Drug|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
431562|NCT00903604|Drug|Placebo|Three 10-minutes infusions of isotonic saline solution
431563|NCT00903591|Other|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
431564|NCT00903552|Biological|Influenza VLP Vaccine|
431565|NCT00903552|Biological|Placebo|phosphate-buffered saline (PBS)
431566|NCT00903539|Device|SecurAcath Securement System|Subcutaneous catheter securement system
431567|NCT00903500|Behavioral|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
431568|NCT00903500|Behavioral|Usual care|Usual care
431569|NCT00903474|Other|questionnaire administration|
431570|NCT00903474|Other|study of socioeconomic and demographic variables|
431571|NCT00903474|Procedure|CAM exercise therapy|
431572|NCT00903474|Procedure|psychosocial assessment and care|
431573|NCT00903474|Procedure|quality-of-life assessment|
431574|NCT00903474|Procedure|stress management therapy|
431575|NCT00903461|Biological|EGFR Antisense DNA|"Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule~EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
431576|NCT00903448|Drug|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
431577|NCT00903448|Drug|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
431578|NCT00903435|Other|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
431579|NCT00903422|Drug|eltrombopag olamine|thrombopoietin receptor agonist
431580|NCT00903422|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
431581|NCT00903409|Drug|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) [formerly known as Omacor]
431582|NCT00903396|Drug|palonosetron hydrochloride|Given IV
431583|NCT00903396|Other|placebo|Given IV
431584|NCT00903383|Drug|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
431585|NCT00903383|Drug|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
431586|NCT00903383|Drug|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
431587|NCT00903383|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
431588|NCT00903370|Procedure|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
431632|NCT00903136|Procedure|comparison of screening methods|
431633|NCT00903136|Procedure|diagnostic endoscopic procedure|
431634|NCT00903136|Procedure|esophagogastroduodenoscopy|
431635|NCT00903136|Procedure|tethered capsule endoscopy|
431636|NCT00903110|Drug|Increlex®|Increlex® (mecasermin [rDNA origin] injection), 10 mg/ml solution for injection, 20-120mcg/kg BID or 0,02 to 0,12 mg/kg BID, as prescribed by physician
431637|NCT00903084|Drug|Tenofovir Disoproxil Fumarate|300-mg tablet
431823|NCT00901979|Drug|Placebo|
431589|NCT00903370|Device|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
431590|NCT00903357|Drug|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
431591|NCT00903357|Drug|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
431592|NCT00903344|Drug|Vitamin D3|4000IU vitamin D3 tablet taken daily
431593|NCT00903344|Dietary Supplement|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
431594|NCT00903331|Drug|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
431595|NCT00903331|Drug|Placebo|matching placebo, once daily
431596|NCT00903318|Behavioral|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
431597|NCT00903305|Other|medical chart review|
431598|NCT00903305|Other|questionnaire administration|
431599|NCT00903305|Procedure|fatigue assessment and management|
431600|NCT00903305|Procedure|psychosocial assessment and care|
431601|NCT00903305|Procedure|quality-of-life assessment|
431602|NCT00903292|Drug|erlotinib (Tarceva)|chemotherapy with erlotinib
431603|NCT00903292|Drug|pemetrexed (Alimta)|Chemotherapy with pemetrexed
431604|NCT00903279|Drug|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
431605|NCT00903279|Drug|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
431606|NCT00903266|Behavioral|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
431607|NCT00903266|Behavioral|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
431608|NCT00903253|Drug|LNK-754|
431609|NCT00903227|Drug|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
431610|NCT00903227|Drug|Placebo|1 puff of inhaled Placebo twice a day
431611|NCT00903227|Drug|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
431612|NCT00903227|Drug|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
431613|NCT00903227|Drug|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
431614|NCT00903214|Drug|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
431615|NCT00903214|Genetic|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
431616|NCT00903214|Procedure|axillary lymph node biopsy|
431617|NCT00903214|Procedure|digital image analysis|
431618|NCT00903214|Procedure|needle biopsy|
431619|NCT00903214|Procedure|sentinel lymph node biopsy|
431620|NCT00903214|Procedure|therapeutic conventional surgery|
431621|NCT00903201|Drug|SB656933|20 mg
431622|NCT00903201|Drug|SB656933|50mg
431623|NCT00903201|Drug|Placebo|placebo
431624|NCT00903188|Drug|cyclosporine|"Cyclosporine (Group 1):~basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4~Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.~C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml~Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.~Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.~Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
431625|NCT00903188|Drug|Everolimus|"Everolimus (Group 2):~Basiliximab dose: idem as in group 1~Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.~Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.~Enteric-coated mycophenolate (MPA) dosing idem as group 1.~Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.~Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
431626|NCT00903175|Drug|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
431627|NCT00903175|Drug|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
431628|NCT00903162|Drug|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
431640|NCT00903045|Drug|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
431641|NCT00903045|Drug|Placebo|Identical placebo twice a day
431642|NCT00903032|Behavioral|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
431643|NCT00903032|Behavioral|Usual care|Usual care following ACS hospital discharge.
431644|NCT00903019|Behavioral|Tele-Problem-Solving Therapy|Six sessions of tele-PST
431645|NCT00903019|Behavioral|In-Person PST|Six sessions of in person PST
431646|NCT00903019|Behavioral|Attention control|Six weekly telephone calls
431647|NCT00903006|Drug|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
431648|NCT00903006|Drug|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
431649|NCT00903006|Drug|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
431650|NCT00902993|Drug|AZD1446|Solution, oral single and multiple dose
431651|NCT00902993|Drug|Placebo|Placebo
431652|NCT00902980|Other|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
431653|NCT00902967|Drug|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
431654|NCT00902967|Drug|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
431655|NCT00902954|Drug|anastrozole|anastrozole 1 mg qd
431656|NCT00902954|Drug|letrozole|letrozole 2.5 mg qd
431657|NCT00902954|Drug|exemestane|exemestane 25 mg qd
431658|NCT00902941|Drug|Azilect 1mg|1 mg daily orally for 120 days
431659|NCT00902941|Drug|Placebo|1 mg daily orally for 120 days
431660|NCT00902928|Drug|YM150|oral
431661|NCT00902928|Drug|enoxaparin|SC injection
431662|NCT00902915|Drug|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
431663|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
431664|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
431665|NCT00902876|Device|Mucograft|Collagen Matrix for soft tissue regeneration
431666|NCT00902876|Procedure|Coronally advanced flap (CAF)|
431667|NCT00902863|Behavioral|YOGA|Patients with chronic pain will undergo a six week course of YOGA
431668|NCT00902850|Device|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
431669|NCT00902850|Device|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
431670|NCT00902837|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
431671|NCT00902837|Drug|oxycodone prolonged release tablet|
431672|NCT00902837|Drug|oxycodone naloxone tablet|
431673|NCT00902824|Biological|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10^7 pfu TBC-M4 (IM)
431674|NCT00902824|Biological|TBC-M4|Receive 5x10^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
431675|NCT00902824|Other|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
431676|NCT00902811|Drug|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
431677|NCT00902811|Drug|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
431678|NCT00902811|Drug|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
431679|NCT00902811|Drug|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group <6yrs of age, a subdivision according to weight is made
431680|NCT00902811|Drug|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
431681|NCT00902798|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
431682|NCT00902798|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
431683|NCT00902785|Other|no drug|observational no drug
431684|NCT00902772|Drug|Lorazepam|mg, oral dose
431685|NCT00902772|Drug|AZD7325|mg, oral dose
431686|NCT00902772|Drug|Placebo|
431731|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
431732|NCT00902486|Drug|INCB028050|4 mg capsules QD
431733|NCT00902486|Drug|INCB028050|7 mg capsules QD
431734|NCT00902486|Drug|INCB028050|10 mg capsule QD
431824|NCT00901979|Drug|Sitagliptin|
431687|NCT00902759|Other|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
431688|NCT00902746|Drug|NPC-01|"This study consist of the following steps.~Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.~Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):~After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
431689|NCT00902733|Other|medical chart review|
431690|NCT00902733|Other|questionnaire administration|
431691|NCT00902733|Procedure|fatigue assessment and management|
431692|NCT00902733|Procedure|psychosocial assessment and care|
431693|NCT00902733|Procedure|quality-of-life assessment|
431694|NCT00902720|Other|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
431695|NCT00902707|Drug|Mucinex 1200mg|Compared to Placebo
431696|NCT00902707|Drug|Placebo|Compare to active Mucinex
431697|NCT00902694|Behavioral|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
431698|NCT00902694|Other|Control|group health classes quarterly with topics not related to weight
431699|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
431700|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
431701|NCT00902668|Drug|lovastatin|
431702|NCT00902668|Other|questionnaire administration|
431703|NCT00902668|Procedure|adjuvant therapy|
431704|NCT00902668|Radiation|accelerated partial breast irradiation|
431705|NCT00902668|Radiation|external beam radiation therapy|
431706|NCT00902655|Drug|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
431707|NCT00902642|Behavioral|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
431708|NCT00902629|Procedure|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
431709|NCT00902616|Dietary Supplement|L-arginine|3gm TDS for three months
431710|NCT00902616|Dietary Supplement|Placebo Lactose powder|3gm TDS for 3 months
431711|NCT00902603|Drug|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
431712|NCT00902590|Other|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
431713|NCT00902590|Other|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
431714|NCT00902577|Drug|FMISO|FMISO PET scans
431715|NCT00902577|Other|MRI|Undergo MRI
431716|NCT00902577|Other|PET|Undergo FMISO PET scan
431717|NCT00902577|Other|MRS|
431718|NCT00902564|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
431719|NCT00902538|Drug|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
431720|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
431721|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
431722|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
431723|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
431724|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
431725|NCT00902525|Drug|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
431726|NCT00902512|Drug|Treatment A|Viagra® 100 mg tablet, administered with water single dose
431727|NCT00902512|Drug|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
431728|NCT00902512|Drug|Treatment B|Sildenafil 100 mg CT administered with water single dose
431729|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
431730|NCT00902512|Drug|Treatment C|Sildenafil 100 mg CT administered without water single dose
431735|NCT00902486|Drug|Placebo|Placebo matching INCB028050 QD
431737|NCT00902460|Drug|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
431738|NCT00902460|Drug|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
431739|NCT00902421|Drug|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
431740|NCT00902421|Drug|Antimuscarinics|Antimuscarinics for 3 months
431741|NCT00902408|Dietary Supplement|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
431742|NCT00902395|Drug|Midazolam|Oral midazolam 1.0 mg/kg (maximum 20 mg)
431743|NCT00902395|Behavioral|Protective stabilization|Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
431744|NCT00902395|Drug|Midazolam, ketamine|Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
431745|NCT00902369|Drug|AK106-001616|Part1: Dose escalation Part2: Dose expansion
431746|NCT00902369|Drug|Placebo|
431747|NCT00902369|Drug|Active comparator|
431748|NCT00902356|Drug|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
431749|NCT00902356|Drug|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
431750|NCT00902343|Procedure|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
431751|NCT00902343|Procedure|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
431752|NCT00902330|Procedure|energy-based therapy|Given once a day for 18 weeks
431753|NCT00902330|Procedure|sham intervention|Given once a day for 18 weeks
431754|NCT00902317|Procedure|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
431755|NCT00902317|Procedure|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
431756|NCT00902317|Procedure|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
431757|NCT00902317|Device|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
431758|NCT00902317|Procedure|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
431759|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
431760|NCT00902304|Drug|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
431761|NCT00902304|Drug|Usual care|As directed by investigator
431762|NCT00902304|Drug|Valsartan|Valsartan 160mg per day to 320mg per day orally
431763|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
431764|NCT00902291|Biological|AGS-1C4D4|IV infusion
431765|NCT00902291|Biological|Gemcitabine|IV infusion
431766|NCT00902278|Biological|Flulaval|one 0.5-mL dose via intramuscular injection
431767|NCT00902278|Biological|Fluvirin|one 0.5-mL dose via intramuscular injection
431768|NCT00902278|Biological|Fluzone|one 0.5-mL dose via intramuscular injection
431769|NCT00902278|Biological|Fluarix|one 0.5-mL dose via intramuscular injection
431770|NCT00902278|Biological|Afluria|one 0.5-mL dose via intramuscular injection
431771|NCT00902265|Drug|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
431772|NCT00902252|Device|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
431773|NCT00902252|Device|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
431774|NCT00902252|Device|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
431775|NCT00902226|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
431776|NCT00902213|Behavioral|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
431825|NCT00901979|Drug|metformin|
431777|NCT00902213|Behavioral|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
431778|NCT00902200|Drug|AR-12286|See arms
431779|NCT00902200|Drug|AR-12286 vehicle|See arms
431780|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
431781|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
431782|NCT00902174|Drug|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
431783|NCT00902174|Drug|Placebo|Placebo to imatinib 100 mg film coated tablets
431784|NCT00902161|Drug|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
431785|NCT00902161|Drug|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
431786|NCT00902161|Drug|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
431787|NCT00902148|Device|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
431788|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
431789|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
431790|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
431791|NCT00902122|Drug|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
431792|NCT00902122|Procedure|surgery|removal of thyroid tumor
431793|NCT00902122|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
431794|NCT00902122|Radiation|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
431795|NCT00902109|Device|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
431796|NCT00902109|Device|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
431797|NCT00902109|Device|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
431798|NCT00902083|Drug|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
431799|NCT00902083|Procedure|surgery|remove tumor surgery
431800|NCT00902083|Drug|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
431801|NCT00902083|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
431802|NCT00902070|Drug|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
431803|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
431804|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 3mcg
431805|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 15mcg
431806|NCT00902057|Drug|placebo|saline subcutaneous
431807|NCT00902044|Genetic|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
431808|NCT00902044|Drug|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells~The dose:~>10 kg: 25 mg/m2/day;~<10 kg: 1 mg/kg/day IV over 30 minutes"
431809|NCT00902044|Drug|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days, then fludarabine will be given for the next 5 days, followed by 2 days of rest, then the T cells will be administered~Cyclophosphamide Dose:~30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)~Fludarabine Dose:~>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes"
431810|NCT00902044|Genetic|Autologous CAR Positive T cells|Patient will receive one intravenous injection of autologous CAR T cells at dose level 9C. Further CAR T-cell dose escalation at dose level 9C will be done using the lymphodepletion schema as in dose level 9B.
431811|NCT00902031|Drug|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
431812|NCT00902031|Drug|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
431813|NCT00902018|Drug|Eltrombopag|The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
431814|NCT00902018|Drug|Romiplostim|three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
431815|NCT00902018|Other|healthy controls|single blood draw for all measures included in the intervention arms
431816|NCT00901992|Behavioral|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
431817|NCT00901992|Behavioral|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
431818|NCT00901979|Drug|LCQ908A|
431819|NCT00901979|Drug|LCQ908A|
431820|NCT00901979|Drug|LCQ908A|
431821|NCT00901979|Drug|LCQ908A|
431826|NCT00901940|Biological|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
431827|NCT00901940|Biological|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
431828|NCT00901927|Drug|Bendamustine|Starting dose 90 mg/m^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
431829|NCT00901927|Drug|Mitoxantrone|10 mg/m^2 by vein over 15 minutes on Day 2 of each cycle.
431830|NCT00901927|Drug|Rituximab|375 mg/m^2 by vein over several hours on Day 1 of each cycle.
431831|NCT00901914|Biological|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
431832|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
431833|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
431834|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
431835|NCT00901901|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily
431836|NCT00901901|Drug|Erlotinib (Tarceva)|Erlotinib 150 mg once daily
431837|NCT00901901|Drug|Placebo|Matching erlotinib placebo 150 mg once daily
431838|NCT00901888|Drug|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
431839|NCT00901888|Drug|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
431840|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
431841|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|
431842|NCT00901862|Device|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
431843|NCT00901862|Device|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
431844|NCT00901849|Drug|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
431845|NCT00901836|Radiation|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
431846|NCT00901836|Procedure|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
431847|NCT00901823|Drug|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
431848|NCT00901823|Drug|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
431849|NCT00901810|Device|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
431850|NCT00901810|Device|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
431851|NCT00901797|Procedure|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
431852|NCT00901797|Procedure|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
431853|NCT00901784|Drug|Topiramate|25mg Tablets
431854|NCT00901771|Device|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
431855|NCT00901758|Drug|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
431856|NCT00901758|Drug|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
431857|NCT00901745|Drug|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
431858|NCT00901745|Drug|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
431859|NCT00901732|Device|Caphosol|Oral Mouth Rinse
431860|NCT00901719|Drug|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
431861|NCT00901719|Drug|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
431862|NCT00901719|Drug|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
431863|NCT00901719|Drug|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
431864|NCT00901706|Other|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
431865|NCT00901706|Other|APS usual care|APS usual care consists of social, medical, and legal assistance.
431866|NCT00901693|Drug|AL-46383A Ophthalmic Solution|
431867|NCT00901693|Drug|AL-46383A Ophthalmic Solution Vehicle|
431868|NCT00901654|Biological|ACE527 vaccine|"First cohort: Two doses, each of 3x10^9 cfu of each strain (9x10^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10^10 cfu of each strain (9x10^10 cfu total per dose) administered on Days 0 and Day 21"
431869|NCT00901654|Biological|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
431870|NCT00901641|Device|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
431871|NCT00901628|Drug|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
431872|NCT00901628|Drug|morphine sulfate|10mg intraoperative periarticular injection
431873|NCT00901628|Drug|ketorolac|30 mg intraoperative periarticular injection
431874|NCT00901628|Drug|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
431875|NCT00901628|Drug|cefuroxime|750mg intraoperative periarticular injection
431876|NCT00901615|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
431877|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
431878|NCT00901589|Dietary Supplement|thistle oil|four capsules a day
431879|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
431880|NCT00901589|Dietary Supplement|Thistle oil|Four capsules daily
431881|NCT00901576|Drug|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
431882|NCT00901576|Drug|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
431883|NCT00901576|Drug|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
431884|NCT00901563|Drug|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
431885|NCT00901563|Other|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
431886|NCT00901550|Drug|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
431887|NCT00901550|Drug|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
431888|NCT00901537|Drug|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
431889|NCT00901524|Drug|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
431890|NCT00901511|Drug|GM-CSF [Leukine (Sargramostim)]|"Acute treatment: the PAP subjects will receive inhaled rGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg/24 hours. The acute treatment will be accomplished in 12 weeks, for 7 consecutive days every second week (thus, 6 weeks on and 6 weeks off). For those PAP patients receiving the GM-CSF for the first time (1st and 2nd level treated groups), the treatment will be performed by 1 week run-in, after discharge from the ICU, in the Respiratory Disease Department (during this period PAP patients usually receive e.v. corticosteroids, and oral antibiotics). After the run-in period, the patient is discharged and inhalation treatment will continue at home.~Maintenance treatment: 17 weeks after the WLL (4 weeks after the completion of the acute treatment), the PAP patient will start the maintenance treatment. He/she will receive inhaled GM-CSF at the dose of 250 mcg/daily for 2 consecutive days every 14 days (2 days on and 12 days off) for a period of 6 month"
431891|NCT00901511|Procedure|WLL|Whole lung lavage
431892|NCT00901498|Drug|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
431893|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
431894|NCT00901498|Drug|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
431895|NCT00901498|Drug|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
431896|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
431897|NCT00901485|Device|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
431898|NCT00901485|Device|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
431899|NCT00901459|Device|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
431900|NCT00901459|Device|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
431901|NCT00901459|Device|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
431902|NCT00901446|Device|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
431903|NCT00901433|Device|Personal WheezoMeter|pulmonary sounds analyzer
431974|NCT00900783|Drug|valacyclovir|1 gram, three times a day for seven days
431904|NCT00901420|Procedure|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
431905|NCT00901420|Behavioral|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
431906|NCT00901407|Drug|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
431907|NCT00901407|Drug|placebo|placebo: 1-2 tablets bid; 10 weeks
431908|NCT00901407|Drug|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
431909|NCT00901394|Drug|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.~IV folic acid, 5 mg, single administration over 30 min.~Both diluted in 250 ml normal saline."
431910|NCT00901394|Drug|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
431911|NCT00901394|Other|Placebo|Saline
431912|NCT00901394|Other|oxygen nitrogen|60% air and oxygen mix.
431913|NCT00901381|Drug|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
431914|NCT00901368|Drug|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
431915|NCT00901368|Drug|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
431916|NCT00901342|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
431917|NCT00901329|Device|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
431918|NCT00901329|Device|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
431919|NCT00901316|Procedure|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
431920|NCT00901316|Procedure|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
431921|NCT00901303|Drug|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
431922|NCT00901290|Drug|monophasic oral contraceptive|mg, oral dose
431923|NCT00901290|Drug|AZD7325|mg, oral dose
431924|NCT00901277|Behavioral|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
431925|NCT00901277|Behavioral|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
431926|NCT00901238|Procedure|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
431927|NCT00901225|Drug|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,~if the patient's peripheral CD34+ cell count is < 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.~if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is < 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
431928|NCT00901212|Device|Device programming|6-month period
431929|NCT00901199|Drug|Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)|All subjects will be given Exjade 7 days per week 20-30mg/kg and Deferoxamine 3-7 days per week 50mg/kg. Days per week are dependent on how much iron overload subject has.
431930|NCT00901186|Drug|RFB002|0.5 mg
431931|NCT00901186|Procedure|Laser photocoagulation|
431932|NCT00901160|Procedure|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
431933|NCT00901147|Drug|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
431934|NCT00901121|Device|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
431935|NCT00901121|Device|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
431936|NCT00901108|Procedure|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.~Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
431975|NCT00900783|Drug|FV-100|400 mg, once daily, for seven days
431976|NCT00900783|Drug|FV-100|200 mg, once daily, for seven days
432033|NCT00900432|Other|immunoenzyme technique|
431937|NCT00901108|Procedure|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.~Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
431938|NCT00901095|Behavioral|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
431939|NCT00901082|Behavioral|Relaxation and information session|Relaxation and information session before the medial branch block
431940|NCT00901069|Drug|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2^ Azacitidine 50 mg/m2^ Azacitidine 75 mg/m2^ Azacitidine 100 mg/m2^
431941|NCT00901056|Device|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
431942|NCT00901043|Dietary Supplement|Walnut supplementation|Eight weeks of walnut supplementation
431943|NCT00901043|Dietary Supplement|Ad lib diet|Eight weeks without walnut supplementation
431944|NCT00901030|Procedure|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
431945|NCT00901017|Device|Straumann BoneCeramic|Bone augmentation procedure performed with Bone Ceramic
431946|NCT00901017|Device|Bio-Oss|Bone Augmentation procedure performed with Bio Oss
431947|NCT00900991|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
431948|NCT00900978|Biological|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
431949|NCT00900965|Device|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
431950|NCT00900965|Device|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
431951|NCT00900952|Other|Clinical record review|
431952|NCT00900939|Behavioral|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
431953|NCT00900939|Behavioral|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
431954|NCT00900913|Drug|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
431955|NCT00900900|Dietary Supplement|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
431956|NCT00900900|Dietary Supplement|pregnenolone|one-time 400mg oral dose of pregnenolone
431957|NCT00900900|Drug|Placebo|one-time dose oral dose
431958|NCT00900887|Drug|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
431959|NCT00900887|Drug|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
431960|NCT00900887|Drug|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml~dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
431961|NCT00900874|Drug|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
431962|NCT00900874|Drug|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
431963|NCT00900835|Other|educational intervention|
431964|NCT00900835|Other|questionnaire administration|
431965|NCT00900835|Other|study of socioeconomic and demographic variables|
431966|NCT00900835|Procedure|assessment of therapy complications|
431967|NCT00900835|Procedure|fatigue assessment and management|
431968|NCT00900835|Procedure|quality-of-life assessment|
431969|NCT00900835|Procedure|standard follow-up care|
431970|NCT00900822|Device|Straumann Bone Ceramic|Granules applied once during surgery
431971|NCT00900822|Device|BioOss|Granules that are applied once during surgery
431972|NCT00900809|Biological|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
431973|NCT00900796|Other|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
432098|NCT00900172|Drug|carboplatin|
431977|NCT00900783|Drug|Valacyclovir placebo|three times a day, for seven days
431978|NCT00900783|Drug|FV-100 placebo|once daily, for seven days
431979|NCT00900757|Drug|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
431980|NCT00900744|Drug|Tamoxifen|20 mg daily
431981|NCT00900731|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
431982|NCT00900731|Drug|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
431983|NCT00900731|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
431984|NCT00900731|Drug|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
431985|NCT00900718|Device|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
431986|NCT00900718|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
431987|NCT00900692|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
431988|NCT00900679|Behavioral|telephone-based intervention|
431989|NCT00900679|Other|counseling intervention|
431990|NCT00900679|Other|educational intervention|
431991|NCT00900679|Other|medical chart review|
431992|NCT00900679|Other|questionnaire administration|
431993|NCT00900679|Procedure|psychosocial assessment and care|
431994|NCT00900679|Procedure|quality-of-life assessment|
431995|NCT00900666|Drug|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
431996|NCT00900666|Drug|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
431997|NCT00900653|Drug|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
431998|NCT00900640|Procedure|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
431999|NCT00900627|Drug|AZD8931|Tablet Oral bid
432000|NCT00900627|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
432001|NCT00900627|Drug|Placebo|Oral bid (twice daily)
432002|NCT00900614|Drug|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
432003|NCT00900601|Procedure|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
432004|NCT00900588|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
432005|NCT00900575|Device|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
432006|NCT00900575|Device|Portable Optical Spectrometer|This device is a portable optical spectrometer
432007|NCT00900575|Device|Transvaginal colposcope|
432008|NCT00900562|Drug|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
432009|NCT00900549|Device|CRT on|12 months
432010|NCT00900549|Device|CRT off|12-month
432011|NCT00900536|Genetic|mutation analysis|
432012|NCT00900536|Genetic|polymorphism analysis|
432013|NCT00900536|Genetic|protein expression analysis|
432014|NCT00900536|Other|immunohistochemistry staining method|
432015|NCT00900536|Other|laboratory biomarker analysis|
432016|NCT00900523|Genetic|protein expression analysis|protein expression analysis
432017|NCT00900523|Other|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
432018|NCT00900510|Procedure|Incision and drainage|
432019|NCT00900510|Drug|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
432020|NCT00900510|Drug|Placebo|
432021|NCT00900497|Biological|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
432022|NCT00900484|Other|biologic sample preservation procedure|
432023|NCT00900484|Other|immunohistochemistry staining method|
432024|NCT00900484|Other|laboratory biomarker analysis|
432025|NCT00900471|Other|biologic sample preservation procedure|
432026|NCT00900471|Other|medical chart review|
432027|NCT00900458|Behavioral|Aerobic Exercise training|aerobic exercise training (cycling)
432028|NCT00900445|Drug|Daunorubicin Hydrochloride|Given IV
432029|NCT00900445|Other|Pharmacological Study|Correlative studies
432030|NCT00900445|Drug|Prednisolone|Given orally
432031|NCT00900445|Drug|Prednisone|Given orally
432032|NCT00900445|Drug|Vincristine Sulfate|Given IV
432034|NCT00900432|Other|laboratory biomarker analysis|
432035|NCT00900419|Other|immunohistochemistry staining method|Laboratory test
432036|NCT00900419|Other|laboratory biomarker analysis|Laboratory Test
432037|NCT00900419|Other|sputum cytology|Laboratory Test
432038|NCT00900419|Procedure|biopsy|Laboratory Test
432039|NCT00900406|Genetic|gene expression analysis|blood collection
432040|NCT00900406|Genetic|microarray analysis|Blood collection
432041|NCT00900406|Genetic|polymorphism analysis|Blood collection
432042|NCT00900406|Genetic|proteomic profiling|Blood collection
432043|NCT00900406|Other|flow cytometry|Blood collection
432044|NCT00900406|Other|immunologic technique|Blood collection
432045|NCT00900406|Other|laboratory biomarker analysis|Blood collection
432046|NCT00900406|Procedure|biopsy|Blood collection
432047|NCT00900380|Other|flow cytometry|
432048|NCT00900380|Other|immunological diagnostic method|
432049|NCT00900380|Other|laboratory biomarker analysis|
432050|NCT00900367|Other|high performance liquid chromatography|
432051|NCT00900367|Other|laboratory biomarker analysis|
432052|NCT00900367|Procedure|spectroscopy|
432053|NCT00900354|Genetic|molecular genetic technique|
432054|NCT00900354|Other|mass spectrometry|
432055|NCT00900354|Other|pharmacological study|
432056|NCT00900341|Genetic|DNA analysis|
432057|NCT00900341|Genetic|gene expression analysis|
432058|NCT00900341|Genetic|protein expression analysis|
432059|NCT00900341|Genetic|reverse transcriptase-polymerase chain reaction|
432060|NCT00900341|Genetic|western blotting|
432061|NCT00900341|Other|immunohistochemistry staining method|
432062|NCT00900341|Other|laboratory biomarker analysis|
432063|NCT00900328|Other|laboratory biomarker analysis|Correlative Studies
432064|NCT00900302|Genetic|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
432065|NCT00900302|Other|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
432066|NCT00900302|Other|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
432067|NCT00900302|Procedure|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
432068|NCT00900289|Genetic|DNA methylation analysis|
432069|NCT00900289|Genetic|microarray analysis|
432070|NCT00900289|Genetic|polymerase chain reaction|
432071|NCT00900289|Other|immunohistochemistry staining method|
432072|NCT00900289|Other|laboratory biomarker analysis|
432073|NCT00900276|Other|immunologic technique|
432074|NCT00900276|Other|laboratory biomarker analysis|
432075|NCT00900276|Other|mass spectrometry|
432076|NCT00900263|Genetic|cytogenetic analysis|
432077|NCT00900263|Genetic|microarray analysis|
432078|NCT00900263|Other|biologic sample preservation procedure|
432079|NCT00900263|Other|laboratory biomarker analysis|
432080|NCT00900250|Other|Cytology Specimen Collection Procedure|Correlative studies
432081|NCT00900237|Drug|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
432082|NCT00900237|Drug|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
432083|NCT00900224|Genetic|DNA analysis|
432084|NCT00900224|Genetic|DNA methylation analysis|
432085|NCT00900224|Genetic|gene expression analysis|
432086|NCT00900224|Genetic|mutation analysis|
432087|NCT00900224|Genetic|polymerase chain reaction|
432088|NCT00900224|Genetic|reverse transcriptase-polymerase chain reaction|
432089|NCT00900224|Other|high performance liquid chromatography|
432090|NCT00900224|Other|laboratory biomarker analysis|
432091|NCT00900211|Genetic|microarray analysis|
432092|NCT00900211|Genetic|molecular diagnostic method|
432093|NCT00900211|Other|biologic sample preservation procedure|
432094|NCT00900185|Genetic|mutation analysis|
432095|NCT00900185|Genetic|polymerase chain reaction|
432096|NCT00900185|Genetic|polymorphism analysis|
432097|NCT00900172|Biological|bevacizumab|
432100|NCT00900172|Genetic|gene expression analysis|
432101|NCT00900172|Genetic|polymerase chain reaction|
432102|NCT00900172|Genetic|polymorphism analysis|
432103|NCT00900172|Other|laboratory biomarker analysis|
432104|NCT00900159|Drug|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
432105|NCT00900159|Drug|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
432106|NCT00900146|Drug|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
432107|NCT00900146|Drug|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
432108|NCT00900146|Drug|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
432109|NCT00900133|Other|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
432110|NCT00900133|Other|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
432111|NCT00900107|Procedure|Exercise|
432112|NCT00900094|Genetic|fluorescence in situ hybridization|
432113|NCT00900094|Genetic|polymerase chain reaction|
432114|NCT00900094|Genetic|protein expression analysis|
432115|NCT00900094|Other|immunohistochemistry staining method|
432116|NCT00900094|Other|laboratory biomarker analysis|
432117|NCT00900094|Other|mass spectrometry|
432118|NCT00900081|Other|immunohistochemistry staining method|
432119|NCT00900081|Other|laboratory biomarker analysis|
432120|NCT00900081|Other|medical chart review|
432121|NCT00900068|Other|immunoenzyme technique|
432122|NCT00900068|Other|laboratory biomarker analysis|
432123|NCT00900068|Other|medical chart review|
432124|NCT00900055|Genetic|microarray analysis|
432125|NCT00900055|Genetic|polyacrylamide gel electrophoresis|
432126|NCT00900055|Genetic|polymerase chain reaction|
432127|NCT00900055|Genetic|protein expression analysis|
432128|NCT00900055|Genetic|reverse transcriptase-polymerase chain reaction|
432129|NCT00900055|Genetic|western blotting|
432130|NCT00900055|Other|chromatography|
432131|NCT00900055|Other|high performance liquid chromatography|
432132|NCT00900055|Other|immunoenzyme technique|
432133|NCT00900042|Genetic|DNA ploidy analysis|
432134|NCT00900042|Genetic|DNA stability analysis|
432135|NCT00900042|Genetic|chromosomal translocation analysis|
432136|NCT00900042|Genetic|cytogenetic analysis|
432137|NCT00900042|Other|flow cytometry|
432138|NCT00900042|Other|laboratory biomarker analysis|
432139|NCT00900029|Biological|No HP802 Treatment|
432140|NCT00900029|Other|No HP802 Vehicle Treatment|
432141|NCT00900016|Genetic|protein expression analysis|
432142|NCT00900016|Genetic|western blotting|
432143|NCT00900016|Other|immunohistochemistry staining method|
432144|NCT00900016|Other|immunologic technique|
432145|NCT00900016|Other|laboratory biomarker analysis|
432146|NCT00900003|Genetic|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
432147|NCT00900003|Other|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
432148|NCT00899990|Other|Laboratory Biomarker Analysis|Correlative studies
432149|NCT00899977|Drug|Placebo|Matching placebo
432150|NCT00899977|Drug|TC-5214|
432151|NCT00899964|Behavioral|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
432152|NCT00899951|Drug|fentanyl citrate|
432153|NCT00899951|Other|pharmacological study|
432154|NCT00899912|Genetic|microarray analysis|
432155|NCT00899912|Other|diagnostic laboratory biomarker analysis|
432156|NCT00899899|Genetic|microarray analysis|
432157|NCT00899899|Genetic|reverse transcriptase-polymerase chain reaction|
432158|NCT00899899|Other|laboratory biomarker analysis|
432159|NCT00899873|Genetic|cytogenetic analysis|
432160|NCT00899873|Other|flow cytometry|
432161|NCT00899873|Other|fluorescence activated cell sorting|
432162|NCT00899873|Other|immunoenzyme technique|
432163|NCT00899873|Other|laboratory biomarker analysis|
432164|NCT00899847|Procedure|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.~and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
432165|NCT00899847|Procedure|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
432233|NCT00899600|Other|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
432234|NCT00899587|Drug|enalapril|enalapril 5 mg every night
432295|NCT00899262|Other|immunohistochemistry staining method|
432166|NCT00899847|Drug|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.~Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.~Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
432167|NCT00899847|Drug|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
432168|NCT00899847|Drug|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
432169|NCT00899847|Drug|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
432170|NCT00899847|Radiation|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
432171|NCT00899847|Biological|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
432172|NCT00899847|Drug|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
432173|NCT00899847|Drug|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
432174|NCT00899847|Drug|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
432175|NCT00899847|Drug|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
432176|NCT00899847|Drug|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
432177|NCT00899821|Biological|aldesleukin|
432178|NCT00899821|Biological|recombinant interleukin-12|
432179|NCT00899821|Biological|sargramostim|
432180|NCT00899821|Other|immunologic technique|
432181|NCT00899821|Procedure|biopsy|
432182|NCT00899795|Genetic|cytogenetic analysis|
432183|NCT00899795|Genetic|fluorescence in situ hybridization|
432184|NCT00899795|Other|flow cytometry|
432185|NCT00899795|Procedure|biopsy|
432186|NCT00899782|Other|cytology specimen collection procedure|correlative studies
432187|NCT00899769|Genetic|protein expression analysis|
432188|NCT00899769|Genetic|proteomic profiling|
432189|NCT00899769|Other|immunoenzyme technique|
432190|NCT00899769|Other|laboratory biomarker analysis|
432191|NCT00899769|Other|liquid chromatography|
432192|NCT00899769|Other|mass spectrometry|
432193|NCT00899756|Genetic|molecular diagnostic method|
432194|NCT00899756|Genetic|mutation analysis|
432195|NCT00899743|Genetic|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
432196|NCT00899743|Genetic|western blotting|western blotting
432197|NCT00899743|Other|immunologic technique|immunologic technique
432198|NCT00899743|Other|laboratory biomarker analysis|laboratory biomarker analysis
432199|NCT00899717|Procedure|Occlusal adjustment|modification of occlusal surfaces
432200|NCT00899717|Procedure|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
432201|NCT00899704|Genetic|microarray analysis|
432202|NCT00899704|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
432203|NCT00899704|Other|diagnostic laboratory biomarker analysis|
432204|NCT00899691|Genetic|protein expression analysis|
432205|NCT00899678|Drug|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg~*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
432206|NCT00899678|Drug|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg~*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
432207|NCT00899665|Genetic|fluorescence in situ hybridization|
432208|NCT00899665|Genetic|microarray analysis|
432209|NCT00899665|Genetic|molecular diagnostic method|
432210|NCT00899665|Other|immunohistochemistry staining method|
432211|NCT00899665|Other|laboratory biomarker analysis|
432212|NCT00899665|Procedure|biopsy|
432213|NCT00899665|Procedure|immunoscintigraphy|
432214|NCT00899652|Genetic|Southern blotting|
432215|NCT00899652|Genetic|chromosomal translocation analysis|
432216|NCT00899652|Genetic|cytogenetic analysis|
432217|NCT00899652|Genetic|gene rearrangement analysis|
432218|NCT00899652|Genetic|mutation analysis|
432219|NCT00899626|Genetic|protein analysis|
432220|NCT00899626|Genetic|proteomic profiling|
432221|NCT00899626|Other|biologic sample preservation procedure|
432222|NCT00899626|Other|laboratory biomarker analysis|
432223|NCT00899626|Other|medical chart review|
432224|NCT00899626|Procedure|diagnostic colonoscopy|
432225|NCT00899626|Procedure|diagnostic endoscopic procedure|
432226|NCT00899626|Procedure|diagnostic endoscopic surgery|
432227|NCT00899626|Procedure|diagnostic surgical procedure|
432228|NCT00899626|Procedure|endoscopic surgery|
432229|NCT00899626|Procedure|screening colonoscopy|
432230|NCT00899613|Other|laboratory biomarker analysis|
432231|NCT00899613|Procedure|study of high risk factors|
432232|NCT00899600|Drug|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
432235|NCT00899587|Other|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
432236|NCT00899587|Drug|placebo|
432237|NCT00899574|Drug|Imiquimod|"Each treatment cycle consists of 8 weeks.~Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.~Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
432238|NCT00899548|Genetic|DNA methylation analysis|laboratory analysis
432239|NCT00899548|Genetic|microarray analysis|laboratory analysis
432240|NCT00899548|Genetic|polymerase chain reaction|laboratory analysis
432241|NCT00899548|Other|laboratory biomarker analysis|laboratory analysis
432242|NCT00899535|Genetic|DNA analysis|
432243|NCT00899535|Genetic|RNA analysis|
432244|NCT00899535|Genetic|microarray analysis|
432245|NCT00899535|Genetic|mutation analysis|
432246|NCT00899535|Genetic|polymorphism analysis|
432247|NCT00899522|Other|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
432248|NCT00899522|Procedure|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
432249|NCT00899509|Other|laboratory biomarker analysis|correlative studies
432250|NCT00899496|Other|immunological diagnostic method|
432251|NCT00899496|Other|physiologic testing|
432252|NCT00899483|Drug|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
432253|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
432254|NCT00899470|Drug|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
432255|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
432256|NCT00899470|Drug|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
432257|NCT00899457|Genetic|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
432258|NCT00899457|Other|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
432259|NCT00899457|Other|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
432260|NCT00899457|Procedure|bronchoscopy|Collection of breath condensate.
432261|NCT00899431|Drug|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
432262|NCT00899431|Drug|Fludarabine|30 mg/m^2 intravenously daily on days -5, -4, -3.
432263|NCT00899431|Drug|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8.
432264|NCT00899431|Drug|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
432265|NCT00899431|Procedure|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
432266|NCT00899431|Drug|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
432267|NCT00899431|Drug|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
432268|NCT00899418|Genetic|gene expression analysis|
432269|NCT00899418|Genetic|polymerase chain reaction|
432270|NCT00899418|Genetic|polymorphism analysis|
432271|NCT00899418|Other|immunohistochemistry staining method|
432272|NCT00899392|Other|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
432273|NCT00899379|Drug|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
432274|NCT00899379|Drug|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
432275|NCT00899366|Genetic|microarray analysis|
432276|NCT00899366|Genetic|mutation analysis|
432277|NCT00899366|Other|immunologic technique|
432278|NCT00899353|Dietary Supplement|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
432279|NCT00899340|Genetic|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
432280|NCT00899340|Genetic|microarray analysis|microarray analysis
432281|NCT00899340|Genetic|protein expression analysis|protein expression analysis
432282|NCT00899340|Other|immunohistochemistry staining method|immunohistochemistry staining method
432283|NCT00899340|Other|laboratory biomarker analysis|laboratory biomarker analysis
432284|NCT00899327|Genetic|DNA methylation analysis|
432285|NCT00899327|Genetic|RNA analysis|
432286|NCT00899327|Genetic|cytogenetic analysis|
432287|NCT00899327|Genetic|gene expression analysis|
432288|NCT00899327|Genetic|mutation analysis|
432289|NCT00899327|Genetic|polymerase chain reaction|
432290|NCT00899327|Genetic|protein expression analysis|
432291|NCT00899327|Other|laboratory biomarker analysis|
432292|NCT00899301|Other|biologic sample preservation procedure|Tissue, urine and blood collection.
432293|NCT00899288|Procedure|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
432294|NCT00899275|Other|Cytology Specimen Collection Procedure|Correlative studies
432296|NCT00899262|Other|laboratory biomarker analysis|
432297|NCT00899262|Other|sputum cytology|
432298|NCT00899262|Procedure|Fourier transform infrared spectroscopy|
432299|NCT00899262|Procedure|diagnostic bronchoscopy|
432300|NCT00899223|Other|biologic sample preservation procedure|
432301|NCT00899210|Other|laboratory biomarker analysis|
432302|NCT00899210|Procedure|cryosurgery|
432303|NCT00899210|Procedure|radiofrequency ablation|
432304|NCT00899210|Procedure|therapeutic conventional surgery|
432305|NCT00899197|Drug|tamoxifen citrate|
432306|NCT00899197|Genetic|gene expression analysis|
432307|NCT00899197|Genetic|protein expression analysis|
432308|NCT00899197|Other|immunoenzyme technique|
432309|NCT00899197|Other|laboratory biomarker analysis|
432310|NCT00899184|Genetic|polymorphism analysis|
432311|NCT00899184|Other|laboratory biomarker analysis|
432312|NCT00899171|Genetic|DNA analysis|
432313|NCT00899171|Genetic|DNA methylation analysis|
432314|NCT00899171|Genetic|RNA analysis|
432315|NCT00899171|Genetic|gene expression analysis|
432316|NCT00899171|Genetic|reverse transcriptase-polymerase chain reaction|
432317|NCT00899171|Other|laboratory biomarker analysis|
432318|NCT00899158|Other|immunologic technique|
432319|NCT00899158|Other|laboratory biomarker analysis|
432320|NCT00899158|Procedure|biopsy|
432321|NCT00899145|Other|Laboratory Biomarker Analysis|Correlative studies
432322|NCT00899132|Genetic|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
432323|NCT00899132|Genetic|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
432324|NCT00899132|Other|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
432325|NCT00899119|Procedure|leukapheresis|
432326|NCT00899093|Other|Cytology Specimen Collection Procedure|Correlative studies
432327|NCT00899093|Other|Laboratory Biomarker Analysis|Correlative studies
432328|NCT00899080|Genetic|gene expression analysis|
432329|NCT00899080|Genetic|reverse transcriptase-polymerase chain reaction|
432330|NCT00899080|Other|immunoenzyme technique|
432331|NCT00899080|Other|laboratory biomarker analysis|
432332|NCT00899080|Other|platelet aggregation test|
432333|NCT00899054|Drug|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
432334|NCT00899054|Radiation|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
432335|NCT00899041|Procedure|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
432336|NCT00899028|Genetic|comparative genomic hybridization|
432337|NCT00899028|Genetic|fluorescence in situ hybridization|
432338|NCT00899028|Genetic|gene expression analysis|
432339|NCT00899028|Genetic|microarray analysis|
432340|NCT00899028|Genetic|protein expression analysis|
432341|NCT00899028|Other|immunohistochemistry staining method|
432342|NCT00899028|Other|laboratory biomarker analysis|
432343|NCT00899028|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
432344|NCT00899028|Other|medical chart review|
432345|NCT00899028|Procedure|diagnostic bronchoscopy|
432346|NCT00899015|Other|pharmacological study|
432347|NCT00899002|Genetic|comparative genomic hybridization|Not specified
432348|NCT00899002|Genetic|molecular genetic technique|Not specified
432349|NCT00899002|Genetic|mutation analysis|Not specified
432350|NCT00899002|Genetic|polymerase chain reaction|Not noted
432351|NCT00899002|Genetic|proteomic profiling|not specified
432352|NCT00899002|Other|immunohistochemistry staining method|not noted
432353|NCT00899002|Other|laboratory biomarker analysis|not noted
432354|NCT00899002|Other|mass spectrometry|not noted
432355|NCT00899002|Other|medical chart review|not noted
432356|NCT00898976|Other|immunohistochemistry staining method|
432357|NCT00898976|Other|laboratory biomarker analysis|
432358|NCT00898963|Genetic|gene expression analysis|
432359|NCT00898963|Genetic|microarray analysis|
432360|NCT00898963|Genetic|polymorphism analysis|
432361|NCT00898963|Other|diagnostic laboratory biomarker analysis|
432362|NCT00898963|Other|immunohistochemistry staining method|
432363|NCT00898963|Other|immunologic technique|
432364|NCT00898950|Drug|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
432365|NCT00898950|Drug|Aspirin|300mgs/day orally for 2 weeks
432366|NCT00898950|Drug|Aspirin|aspirin 900mgs QID orally for 2 weeks
432367|NCT00898950|Other|placebo tablet|placebo tablet with lactose and excipients.
432368|NCT00898937|Genetic|microarray analysis|tumor specimen will be assessed by microarray analysis
432435|NCT00898508|Genetic|reverse transcriptase-polymerase chain reaction|
432369|NCT00898937|Procedure|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
432370|NCT00898924|Genetic|molecular diagnostic method|
432371|NCT00898924|Genetic|mutation analysis|
432372|NCT00898911|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
432373|NCT00898898|Other|diagnostic laboratory biomarker analysis|Correlative studies
432374|NCT00898885|Procedure|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
432375|NCT00898872|Other|cryopreservation|
432376|NCT00898846|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
432377|NCT00898833|Other|laboratory biomarker analysis|
432378|NCT00898820|Genetic|gene expression analysis|
432379|NCT00898820|Genetic|polymorphism analysis|
432380|NCT00898820|Genetic|protein expression analysis|
432381|NCT00898807|Drug|citalopram|target dose 30mg daily for 9 weeks
432382|NCT00898807|Drug|placebo|daily for 9 weeks
432383|NCT00898794|Biological|bevacizumab|
432384|NCT00898794|Other|coagulation study|
432385|NCT00898794|Other|laboratory biomarker analysis|
432386|NCT00898794|Other|platelet aggregation test|
432387|NCT00898768|Procedure|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
432388|NCT00898755|Other|Cytology Specimen Collection Procedure|Correlative studies
432389|NCT00898755|Other|Laboratory Biomarker Analysis|Correlative studies
432390|NCT00898742|Genetic|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
432391|NCT00898742|Genetic|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
432392|NCT00898742|Other|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
432393|NCT00898716|Drug|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
432394|NCT00898703|Other|flow cytometry|
432395|NCT00898703|Other|immunoenzyme technique|
432396|NCT00898703|Other|laboratory biomarker analysis|
432397|NCT00898690|Genetic|cytogenetic analysis|
432398|NCT00898690|Genetic|gene expression analysis|
432399|NCT00898690|Genetic|microarray analysis|
432400|NCT00898690|Genetic|mutation analysis|
432401|NCT00898690|Genetic|reverse transcriptase-polymerase chain reaction|
432402|NCT00898690|Other|immunohistochemistry staining method|
432403|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
432404|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
432405|NCT00898677|Drug|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
432406|NCT00898677|Drug|Comparator: Placebo|placebo to rizatriptan
432407|NCT00898664|Genetic|cytogenetic analysis|not specified
432408|NCT00898664|Genetic|gene expression analysis|Not specified
432409|NCT00898664|Genetic|mutation analysis|Not specified
432410|NCT00898664|Genetic|polymerase chain reaction|not specified
432411|NCT00898664|Other|immunohistochemistry staining method|not specified
432412|NCT00898664|Other|laboratory biomarker analysis|not specified
432413|NCT00898638|Other|biologic sample preservation procedure|
432414|NCT00898638|Other|medical chart review|
432415|NCT00898599|Dietary Supplement|Prebiotic|Inulin type fructooligosaccharides
432416|NCT00898599|Dietary Supplement|Placebo|Maltodextrin as placebo
432417|NCT00898573|Drug|lapatinib ditosylate|
432418|NCT00898573|Genetic|fluorescence in situ hybridization|
432419|NCT00898573|Genetic|gene expression analysis|
432420|NCT00898573|Genetic|mutation analysis|
432421|NCT00898573|Genetic|polymerase chain reaction|
432422|NCT00898573|Genetic|reverse transcriptase-polymerase chain reaction|
432423|NCT00898573|Other|cell sorting|
432424|NCT00898573|Other|immunohistochemistry staining method|
432425|NCT00898573|Other|laboratory biomarker analysis|
432426|NCT00898560|Drug|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.~Microginon®: single oral dose on day 14 of treatment period"
432427|NCT00898560|Drug|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
432428|NCT00898547|Other|immunoenzyme technique|
432429|NCT00898547|Other|laboratory biomarker analysis|
432430|NCT00898534|Device|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
432431|NCT00898521|Drug|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area."
432432|NCT00898508|Genetic|gene expression analysis|
432433|NCT00898508|Genetic|mutation analysis|
432434|NCT00898508|Genetic|proteomic profiling|
432436|NCT00898508|Other|fluorescent antibody technique|
432437|NCT00898508|Other|immunohistochemistry staining method|
432438|NCT00898508|Other|laboratory biomarker analysis|
432439|NCT00898508|Other|liquid chromatography|
432440|NCT00898508|Other|mass spectrometry|
432441|NCT00898508|Other|medical chart review|
432442|NCT00898508|Procedure|quality-of-life assessment|
432443|NCT00898495|Genetic|loss of heterozygosity analysis|
432444|NCT00898495|Genetic|polymerase chain reaction|
432445|NCT00898495|Genetic|polymorphism analysis|
432446|NCT00898482|Other|This is a non-intervention study for all groups.|This is a non-intervention study.
432447|NCT00898482|Other|study of socioeconomic and demographic variables|Non-intervention study.
432448|NCT00898469|Genetic|polymorphism analysis|
432449|NCT00898456|Genetic|gene expression analysis|
432450|NCT00898456|Genetic|molecular genetic technique|
432451|NCT00898456|Genetic|polymorphism analysis|
432452|NCT00898456|Genetic|protein expression analysis|
432453|NCT00898456|Other|diagnostic laboratory biomarker analysis|
432454|NCT00898443|Other|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
432455|NCT00898443|Other|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
432456|NCT00898430|Genetic|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
432457|NCT00898430|Genetic|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
432458|NCT00898430|Genetic|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
432459|NCT00898417|Biological|bevacizumab|
432460|NCT00898417|Drug|carboplatin|
432461|NCT00898417|Drug|paclitaxel|
432462|NCT00898417|Genetic|proteomic profiling|
432463|NCT00898417|Other|laboratory biomarker analysis|
432464|NCT00898417|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
432465|NCT00898404|Other|laboratory biomarker analysis|Correlative studies
432466|NCT00898391|Other|laboratory biomarker analysis|Correlative studies
432467|NCT00898391|Genetic|polymerase chain reaction|Correlative studies
432468|NCT00898391|Genetic|polyacrylamide gel electrophoresis|Correlative studies
432469|NCT00898391|Genetic|DNA analysis|Correlative studies
432470|NCT00898378|Genetic|gene expression analysis|gene expression analysis
432471|NCT00898378|Genetic|polymerase chain reaction|polymerase chain reaction
432472|NCT00898378|Genetic|polymorphism analysis|polymorphism analysis
432473|NCT00898378|Genetic|protein expression analysis|protein expression analysis
432474|NCT00898378|Genetic|proteomic profiling|proteomic profiling
432475|NCT00898378|Other|gas chromatography|gas chromatography
432476|NCT00898378|Other|laboratory biomarker analysis|laboratory biomarker analysis
432477|NCT00898378|Other|liquid chromatography|liquid chromatography
432478|NCT00898378|Other|mass spectrometry|mass spectrometry
432479|NCT00898378|Other|questionnaire administration|questionnaire administration
432480|NCT00898365|Other|Cytology Specimen Collection Procedure|Correlative studies
432481|NCT00898365|Other|Laboratory Biomarker Analysis|Correlative studies
432482|NCT00898352|Procedure|regional lymph node dissection|
432483|NCT00898352|Radiation|radiation therapy|
432484|NCT00898326|Other|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
432485|NCT00898313|Genetic|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
432486|NCT00898313|Genetic|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
432487|NCT00898313|Genetic|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
432488|NCT00898313|Other|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
432489|NCT00898313|Procedure|nasal brushing|Using a brush, superficial cells are removed from the nose.
432490|NCT00898313|Procedure|Blood draw|Venous blood will be collected
432491|NCT00898313|Procedure|Urine collection|Subjects will be asked to provide a urine specimen.
432492|NCT00898313|Procedure|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
432493|NCT00898313|Procedure|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
432494|NCT00898313|Procedure|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
432495|NCT00898313|Procedure|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
432496|NCT00898300|Other|biologic sample preservation procedure|
432497|NCT00898300|Procedure|biopsy|
432498|NCT00898287|Drug|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
432569|NCT00897936|Other|diagnostic laboratory biomarker analysis|
432570|NCT00897936|Other|immunologic technique|
432499|NCT00898287|Drug|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
432500|NCT00898274|Other|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
432501|NCT00898274|Other|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
432502|NCT00898261|Genetic|microarray analysis|
432503|NCT00898261|Genetic|reverse transcriptase-polymerase chain reaction|
432504|NCT00898261|Other|flow cytometry|
432505|NCT00898235|Genetic|clonality analysis|analyze clonality
432506|NCT00898235|Genetic|polymerase chain reaction|analyze polymerase chain reaction
432507|NCT00898235|Genetic|protein analysis|analyze protein
432508|NCT00898235|Other|biologic sample preservation procedure|preserve biologic samples
432509|NCT00898235|Other|laboratory biomarker analysis|analyze laboratory biomarkers
432510|NCT00898235|Procedure|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
432511|NCT00898235|Procedure|quality-of-life assessment|assess quality of life at each follow-up for life
432512|NCT00898222|Drug|aspirin|81 mg orally daily for two weeks
432513|NCT00898209|Genetic|protein expression analysis|Blood and exhaled breath condensate will be collected.
432514|NCT00898209|Genetic|proteomic profiling|Blood and exhaled breath condensate will be collected.
432515|NCT00898209|Other|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
432516|NCT00898209|Other|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
432517|NCT00898209|Other|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
432518|NCT00898209|Other|questionnaire administration|Questionnaire will be completed.
432519|NCT00898183|Genetic|gene expression analysis|
432520|NCT00898183|Genetic|polymorphism analysis|
432521|NCT00898170|Procedure|myoma removal|surgical removal of myoma by hysterectomy
432522|NCT00898157|Other|laboratory biomarker analysis|
432523|NCT00898144|Other|Papanicolaou test|
432524|NCT00898144|Other|laboratory biomarker analysis|
432525|NCT00898118|Genetic|polymerase chain reaction|
432526|NCT00898118|Other|flow cytometry|
432527|NCT00898118|Other|laboratory biomarker analysis|
432528|NCT00898118|Procedure|allogeneic hematopoietic stem cell transplantation|
432529|NCT00898092|Genetic|microarray analysis|
432530|NCT00898092|Genetic|molecular genetic technique|
432531|NCT00898092|Genetic|mutation analysis|
432532|NCT00898092|Genetic|polymerase chain reaction|
432533|NCT00898092|Genetic|reverse transcriptase-polymerase chain reaction|
432534|NCT00898092|Other|diagnostic laboratory biomarker analysis|
432535|NCT00898079|Other|Cytology Specimen Collection Procedure|Correlative studies
432536|NCT00898066|Genetic|cytogenetic analysis|marrow and peripheral blood
432537|NCT00898066|Genetic|fluorescence in situ hybridization|marrow and peripheral blood
432538|NCT00898053|Other|laboratory biomarker analysis|Correlative studies
432539|NCT00898040|Genetic|polymorphism analysis|
432540|NCT00898027|Other|laboratory biomarker analysis|laboratory biomarker analysis
432541|NCT00898014|Genetic|fluorescence in situ hybridization|
432542|NCT00898014|Other|immunologic technique|
432543|NCT00898014|Other|laboratory biomarker analysis|
432544|NCT00897988|Genetic|gene expression analysis|
432545|NCT00897988|Genetic|mutation analysis|
432546|NCT00897988|Genetic|polyacrylamide gel electrophoresis|
432547|NCT00897988|Genetic|polymerase chain reaction|
432548|NCT00897988|Genetic|protein expression analysis|
432549|NCT00897988|Genetic|reverse transcriptase-polymerase chain reaction|
432550|NCT00897988|Other|flow cytometry|
432551|NCT00897988|Other|immunoenzyme technique|
432552|NCT00897988|Other|immunologic technique|
432553|NCT00897988|Other|laboratory biomarker analysis|
432554|NCT00897988|Other|pharmacological study|
432555|NCT00897975|Dietary Supplement|red yeast rice|600 mg 3 capsules bid
432556|NCT00897975|Drug|phytosterol|phytosterol 450 mg 2 tabs bid with food
432557|NCT00897975|Behavioral|therapeutic lifestyle program|TLC - 12 weeks
432558|NCT00897975|Drug|placebo|placebo
432559|NCT00897962|Other|Healthy Controls|One blood draw (2 teaspoons)
432560|NCT00897962|Other|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
432561|NCT00897962|Other|Non-cancer medical illness|One blood draw (2 teaspoons)
432562|NCT00897949|Drug|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
432563|NCT00897949|Drug|Comparator: placebo|Placebo to rizatriptan
432564|NCT00897936|Genetic|DNA methylation analysis|
432565|NCT00897936|Genetic|comparative genomic hybridization|
432566|NCT00897936|Genetic|fluorescence in situ hybridization|
432567|NCT00897936|Genetic|microarray analysis|
432568|NCT00897936|Genetic|polymerase chain reaction|
432571|NCT00897923|Procedure|radionuclide imaging|
432572|NCT00897923|Radiation|indium In 111-labeled autologous peripheral blood mononuclear cells|
432573|NCT00897923|Radiation|indium In 111-labeled autologous polymorphonuclear leukocytes|
432574|NCT00897910|Other|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
432575|NCT00897910|Other|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
432576|NCT00897910|Other|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
432577|NCT00897897|Device|Philips MRI-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
432578|NCT00897884|Drug|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
432579|NCT00897871|Drug|carboplatin|
432580|NCT00897871|Drug|cyclophosphamide|
432581|NCT00897871|Drug|etoposide phosphate|
432582|NCT00897871|Genetic|gene expression analysis|
432583|NCT00897871|Genetic|polymorphism analysis|
432584|NCT00897871|Other|pharmacological study|
432585|NCT00897845|Genetic|RNA analysis|
432586|NCT00897845|Genetic|microarray analysis|
432587|NCT00897845|Other|immunohistochemistry staining method|
432588|NCT00897845|Other|laboratory biomarker analysis|
432589|NCT00897832|Other|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
432590|NCT00897819|Genetic|DNA methylation analysis|
432591|NCT00897819|Genetic|loss of heterozygosity analysis|
432592|NCT00897819|Genetic|microsatellite instability analysis|
432593|NCT00897819|Other|laboratory biomarker analysis|
432594|NCT00897806|Genetic|Microarray analysis|
432595|NCT00897806|Other|Laboratory biomarker analysis|
432596|NCT00897793|Procedure|venipuncture|Venipuncture for blood samples. Samples will be tested for TGF-beta.
432597|NCT00897793|Radiation|radiation therapy|Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
432598|NCT00897780|Behavioral|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
432599|NCT00897767|Other|biologic sample preservation procedure|
432600|NCT00897754|Genetic|gene expression analysis|
432601|NCT00897754|Genetic|protein expression analysis|
432602|NCT00897754|Genetic|reverse transcriptase-polymerase chain reaction|
432603|NCT00897754|Other|immunoenzyme technique|
432604|NCT00897754|Other|immunohistochemistry staining method|
432605|NCT00897754|Other|immunologic technique|
432606|NCT00897741|Genetic|microarray analysis|
432607|NCT00897741|Other|laboratory biomarker analysis|
432608|NCT00897728|Other|laboratory biomarker analysis|
432609|NCT00897715|Drug|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
432610|NCT00897715|Drug|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
432611|NCT00897702|Other|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
432612|NCT00897702|Other|immunoenzyme technique|
432613|NCT00897702|Procedure|biopsy|
432614|NCT00897702|Procedure|histopathologic examination|
432615|NCT00897676|Drug|Exendin-(9-39)|100-500pmol/kg/min
432616|NCT00897676|Drug|placebo|placebo (0.9% NaCl)
432617|NCT00897663|Genetic|gene expression analysis|
432618|NCT00897663|Genetic|microarray analysis|
432619|NCT00897663|Genetic|protein expression analysis|
432620|NCT00897663|Other|diagnostic laboratory biomarker analysis|
432621|NCT00897663|Other|immunohistochemistry staining method|
432622|NCT00897650|Genetic|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
432623|NCT00897650|Genetic|Protein expression analysis|Lung tumor tissue will be collected.
432624|NCT00897650|Procedure|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
432625|NCT00897650|Procedure|Blood sample|Patients will be asked for a venous blood sample
432626|NCT00897637|Other|laboratory biomarker analysis|Correlative studies
432627|NCT00897624|Genetic|gene expression analysis|
432628|NCT00897624|Genetic|reverse transcriptase-polymerase chain reaction|
432629|NCT00897624|Other|laboratory biomarker analysis|
432630|NCT00897611|Procedure|DNA methylation analysis|
432631|NCT00897611|Procedure|polymerase chain reaction|
432632|NCT00897611|Procedure|computed tomography|
432633|NCT00897611|Procedure|magnetic resonance imaging|
432634|NCT00897559|Genetic|gene expression analysis|
432635|NCT00897559|Genetic|mutation analysis|
432636|NCT00897559|Genetic|polymorphism analysis|
432637|NCT00897559|Genetic|protein analysis|
432638|NCT00897559|Other|flow cytometry|
432639|NCT00897559|Other|laboratory biomarker analysis|
432640|NCT00897546|Other|laboratory biomarker analysis|
432641|NCT00897533|Genetic|gene mapping|
432642|NCT00897533|Genetic|polymorphism analysis|
432643|NCT00897533|Other|diagnostic laboratory biomarker analysis|
432644|NCT00897533|Other|immunohistochemistry staining method|
432645|NCT00897520|Biological|recombinant interferon alfa|
432646|NCT00897520|Genetic|proteomic profiling|
432647|NCT00897520|Other|immunoenzyme technique|
432648|NCT00897520|Other|laboratory biomarker analysis|
432649|NCT00897507|Genetic|polymorphism analysis|
432650|NCT00897494|Genetic|protein expression analysis|Venous blood collection
432651|NCT00897494|Other|laboratory biomarker analysis|Venous blood collection
432652|NCT00897494|Other|mass spectrometry|Venous blood collection
432653|NCT00897494|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
432654|NCT00897481|Genetic|gene expression analysis|
432655|NCT00897481|Genetic|mutation analysis|
432656|NCT00897481|Other|diagnostic laboratory biomarker analysis|
432657|NCT00897481|Other|immunohistochemistry staining method|
432658|NCT00897481|Procedure|sentinel lymph node biopsy|
432659|NCT00897468|Other|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
432660|NCT00897468|Other|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
432661|NCT00897455|Genetic|DNA analysis|
432662|NCT00897455|Genetic|mutation analysis|
432663|NCT00897455|Genetic|polymorphism analysis|
432664|NCT00897455|Other|laboratory biomarker analysis|
432665|NCT00897455|Procedure|evaluation of cancer risk factors|
432666|NCT00897442|Other|Laboratory Biomarker Analysis|Correlative studies
432667|NCT00897429|Procedure|laboratory biomarker analysis|Correlative studies
432668|NCT00897416|Other|laboratory biomarker analysis|
432669|NCT00897403|Other|biologic sample preservation procedure|
432670|NCT00897403|Procedure|diagnostic colonoscopy|
432671|NCT00897390|Drug|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
432672|NCT00897390|Drug|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
432673|NCT00897390|Drug|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
432674|NCT00897377|Radiation|Radiation therapy|
432675|NCT00897377|Drug|Temozolomide|
432676|NCT00897351|Genetic|mutation analysis|
432677|NCT00897351|Genetic|polymorphism analysis|
432678|NCT00897351|Genetic|protein expression analysis|
432679|NCT00897351|Other|immunohistochemistry staining method|
432680|NCT00897351|Other|laboratory biomarker analysis|
432681|NCT00897338|Other|flow cytometry|laboratory analysis
432682|NCT00897338|Other|fluorescence activated cell sorting|laboratory analysis
432683|NCT00897338|Other|immunohistochemistry staining method|laboratory analysis
432684|NCT00897338|Other|immunologic technique|laboratory analysis
432685|NCT00897338|Other|biomarker analysis|laboratory analysis
432686|NCT00897325|Other|Cytology Specimen Collection Procedure|Correlative studies
432687|NCT00897325|Other|Laboratory Biomarker Analysis|Correlative studies
432688|NCT00897312|Biological|infliximab|Not specified
432689|NCT00897312|Biological|pegylated interferon alfa|not specified
432690|NCT00897312|Biological|ticilimumab|not specified
432691|NCT00897312|Drug|ribavirin|not specified
432692|NCT00897312|Other|high performance liquid chromatography|not specified
432693|NCT00897312|Other|laboratory biomarker analysis|not specified
432694|NCT00897299|Genetic|microarray analysis|
432695|NCT00897299|Genetic|protein expression analysis|
432696|NCT00897299|Other|immunohistochemistry staining method|
432697|NCT00897299|Other|laboratory biomarker analysis|
432698|NCT00897273|Genetic|comparative genomic hybridization|
432699|NCT00897273|Genetic|gene expression analysis|
432700|NCT00897273|Other|study of socioeconomic and demographic variables|
432701|NCT00897273|Procedure|evaluation of cancer risk factors|
432702|NCT00897273|Procedure|study of high risk factors|
432703|NCT00897260|Drug|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.~DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x~Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x~Fludarabine dose adjustment:~70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.~UCB Infusion"
432704|NCT00897260|Radiation|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
432705|NCT00897260|Procedure|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
432706|NCT00897247|Genetic|microarray analysis|
432707|NCT00897247|Genetic|protein expression analysis|
432708|NCT00897247|Genetic|proteomic profiling|
432709|NCT00897247|Other|laboratory biomarker analysis|
432710|NCT00897234|Other|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
432711|NCT00897221|Drug|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
432712|NCT00897221|Drug|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
432713|NCT00897208|Other|high performance liquid chromatography|
432714|NCT00897208|Other|laboratory biomarker analysis|
432715|NCT00897208|Other|mass spectrometry|
432716|NCT00897208|Other|medical chart review|
432717|NCT00897208|Procedure|evaluation of cancer risk factors|
432718|NCT00897182|Genetic|microarray analysis|
432719|NCT00897182|Genetic|polymerase chain reaction|
432720|NCT00897169|Other|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
432721|NCT00897169|Other|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
432722|NCT00897143|Genetic|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
432723|NCT00897143|Genetic|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
432724|NCT00897143|Other|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
432725|NCT00897143|Other|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
432726|NCT00897130|Drug|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
432727|NCT00897117|Genetic|gene expression analysis|Blood and lung tissue collection
432728|NCT00897117|Genetic|microarray analysis|Blood and lung tissue collection
432729|NCT00897117|Genetic|protein expression analysis|Blood and lung tissue collection
432730|NCT00897117|Other|biologic sample preservation procedure|Blood and lung tissue collection
432731|NCT00897117|Other|laboratory biomarker analysis|Blood and lung tissue collection
432732|NCT00897117|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
432733|NCT00897104|Drug|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
432734|NCT00897104|Drug|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
432735|NCT00897104|Drug|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
432736|NCT00897091|Genetic|comparative genomic hybridization|
432737|NCT00897091|Genetic|microarray analysis|
432738|NCT00897091|Genetic|reverse transcriptase-polymerase chain reaction|
432739|NCT00897091|Other|diagnostic laboratory biomarker analysis|
432740|NCT00897078|Other|laboratory biomarker analysis|Not specified
432741|NCT00897078|Other|medical chart review|not specified
432742|NCT00897078|Other|metabolic assessment|not specified
432743|NCT00897078|Other|questionnaire administration|will be obtained at a single clinic visit
432744|NCT00897078|Procedure|assessment of therapy complications|not specified
432745|NCT00897065|Genetic|microarray analysis|
432746|NCT00897065|Genetic|polymerase chain reaction|
432747|NCT00897065|Genetic|protein expression analysis|
432748|NCT00897065|Other|diagnostic laboratory biomarker analysis|
432749|NCT00897065|Other|fluorescent antibody technique|
432750|NCT00897065|Other|immunohistochemistry staining method|
432751|NCT00897065|Other|immunologic technique|
432752|NCT00897052|Genetic|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
432753|NCT00897052|Other|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
432754|NCT00897039|Other|flow cytometry|
432755|NCT00897039|Other|immunohistochemistry staining method|
432756|NCT00897026|Drug|cyclophosphamide|
432757|NCT00897026|Drug|doxorubicin hydrochloride|
432758|NCT00897026|Drug|paclitaxel|
432759|NCT00897026|Genetic|fluorescence in situ hybridization|
432760|NCT00897026|Other|immunohistochemistry staining method|
432761|NCT00896987|Drug|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
432762|NCT00896987|Drug|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg~600 mg) and maintenance for 40 weeks (600 mg)
432763|NCT00896974|Other|Laboratory Biomarker Analysis|Correlative studies
432764|NCT00896974|Other|Pharmacological Study|Correlative studies
432765|NCT00896974|Drug|Retinoid 9cUAB30|Given orally
432766|NCT00896961|Drug|EF5|
432767|NCT00896961|Other|diagnostic laboratory biomarker analysis|
432768|NCT00896961|Other|pharmacological study|
432769|NCT00896948|Genetic|Southern blotting|
432770|NCT00896948|Genetic|TdT-mediated dUTP nick end labeling assay|
432771|NCT00896948|Genetic|gene expression analysis|
432772|NCT00896948|Genetic|protein expression analysis|
432773|NCT00896948|Other|flow cytometry|
432774|NCT00896948|Other|fluorescent antibody technique|
432775|NCT00896948|Other|immunoenzyme technique|
432776|NCT00896948|Other|immunohistochemistry staining method|
432777|NCT00896948|Other|immunologic technique|
432778|NCT00896935|Other|biologic sample preservation procedure|biologic sample preservation procedure
432779|NCT00896922|Genetic|microarray analysis|
432780|NCT00896922|Other|immunohistochemistry staining method|
432781|NCT00896922|Other|laboratory biomarker analysis|
432782|NCT00896909|Genetic|gene expression analysis|
432783|NCT00896909|Genetic|mutation analysis|
432784|NCT00896909|Genetic|polymerase chain reaction|
432785|NCT00896909|Other|diagnostic laboratory biomarker analysis|
432786|NCT00896896|Other|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
432787|NCT00896896|Other|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
432788|NCT00896883|Device|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
432789|NCT00896857|Genetic|RNA analysis|
432790|NCT00896857|Genetic|polymerase chain reaction|
432791|NCT00896857|Genetic|protein expression analysis|
432792|NCT00896857|Genetic|reverse transcriptase-polymerase chain reaction|
432793|NCT00896857|Genetic|western blotting|
432794|NCT00896857|Other|immunoenzyme technique|
432795|NCT00896857|Other|immunohistochemistry staining method|
432796|NCT00896857|Other|laboratory biomarker analysis|
432797|NCT00896857|Procedure|breast duct lavage|
432798|NCT00896844|Behavioral|emotional disclosure|writing about emotional events from the past
432799|NCT00896844|Behavioral|placebo writing|writing about how they spent their time the previous day
432800|NCT00896831|Drug|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
432801|NCT00896831|Drug|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
432802|NCT00896818|Genetic|DNA analysis|
432803|NCT00896818|Genetic|genetic linkage analysis|
432804|NCT00896818|Genetic|loss of heterozygosity analysis|
432805|NCT00896818|Genetic|polymorphism analysis|
432806|NCT00896818|Other|laboratory biomarker analysis|
432807|NCT00896818|Other|medical chart review|
432808|NCT00896818|Other|questionnaire administration|
432809|NCT00896792|Other|counseling intervention|
432810|NCT00896792|Other|questionnaire administration|
432811|NCT00896792|Other|survey administration|
432812|NCT00896792|Procedure|end-of-life treatment/management|
432813|NCT00896792|Procedure|psychosocial assessment and care|
432814|NCT00896779|Drug|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months~Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
432815|NCT00896766|Genetic|loss of heterozygosity analysis|
432816|NCT00896766|Genetic|microarray analysis|
432817|NCT00896766|Genetic|polymorphism analysis|
432818|NCT00896766|Genetic|tumor replication error analysis|
432819|NCT00896740|Genetic|microarray analysis|
432820|NCT00896740|Procedure|biopsy|
432821|NCT00896727|Genetic|gene expression analysis|
432822|NCT00896727|Genetic|protein expression analysis|
432823|NCT00896727|Other|fluorescent antibody technique|
432824|NCT00896727|Other|laboratory biomarker analysis|
432825|NCT00896714|Device|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
432826|NCT00896701|Other|flow cytometry|
432827|NCT00896701|Other|immunologic technique|
432828|NCT00896701|Other|laboratory biomarker analysis|
432829|NCT00896688|Procedure|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
432830|NCT00896675|Other|proteomic profiles|blood samples analysis
432831|NCT00896675|Other|proteomic profiles|blood samples analysis
432832|NCT00896662|Other|immunologic technique|immunologic technique
432833|NCT00896662|Other|laboratory biomarker analysis|laboratory biomarker analysis
432834|NCT00896662|Other|pharmacological study|pharmacological study
432835|NCT00896649|Other|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
432836|NCT00896649|Procedure|digital mammography|standard screening mammogram
432837|NCT00896649|Procedure|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
432838|NCT00896636|Procedure|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
432839|NCT00896636|Other|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
432840|NCT00896623|Genetic|mutation analysis|
432841|NCT00896623|Genetic|polymorphism analysis|
432842|NCT00896623|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
432843|NCT00896597|Drug|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
432844|NCT00896571|Drug|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
432845|NCT00896558|Drug|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
432846|NCT00896558|Drug|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
432847|NCT00896545|Behavioral|5-keys counseling|5-session small group intervention
432848|NCT00896545|Behavioral|Lifestyle counseling|5-session small group behavioral intervention
432849|NCT00896532|Drug|Placebo to Romosozumab|Administered by subcutaneous injection QM or Q3M.
432850|NCT00896532|Drug|Alendronate|Administered orally once a week
432851|NCT00896532|Drug|Teriparatide|Teriparatide 20 μg administered by subcutaneous injection once a day
432852|NCT00896532|Drug|Romosozumab|Administered by subcutaneous injection
432853|NCT00896532|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection Q6M
432854|NCT00896532|Drug|Placebo to Denosumab|Administered by subcutaneous injection Q6M
432855|NCT00896532|Drug|Zoledronic acid|Zoledronic acid 5 mg administered intravenously
432856|NCT00896519|Biological|rituximab|
432857|NCT00896519|Biological|sargramostim|
432858|NCT00896519|Drug|cyclophosphamide|
432859|NCT00896519|Drug|doxorubicin hydrochloride|
432860|NCT00896519|Drug|prednisone|
432861|NCT00896519|Drug|vincristine sulfate|
432862|NCT00896519|Genetic|gene expression analysis|
432863|NCT00896519|Genetic|gene rearrangement analysis|
432864|NCT00896519|Genetic|polymerase chain reaction|
432865|NCT00896519|Other|R-CHOP regimen|
432866|NCT00896519|Other|laboratory biomarker analysis|
432899|NCT00896285|Other|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
432867|NCT00896493|Drug|anti-thymocyte globulin|ATG will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg
432868|NCT00896493|Drug|cyclosporine|5 mg/kg PO or IV
432869|NCT00896493|Radiation|Lymphoid radiation|TLI is administered ten times in 80c- 120c Gy fractions on day -11 through day -7 and day -4 through day -1
432870|NCT00896480|Biological|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
432871|NCT00896467|Other|questionnaire administration|
432872|NCT00896467|Procedure|psychosocial assessment and care|
432873|NCT00896467|Procedure|quality-of-life assessment|
432874|NCT00896454|Drug|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
432875|NCT00896441|Drug|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
432876|NCT00896428|Drug|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
432877|NCT00896428|Drug|Placebo.|1 tablet morning and evening for 12 months
432878|NCT00896402|Drug|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
432879|NCT00896402|Drug|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
432880|NCT00896389|Procedure|Salt loading|Subjects will arrive at the Amish Research Clinics after overnight fasting. After taking height, weight, BP, and body temperature, subjects will receive 2 liters (L) of 0.9% sodium chloride (NaCl) saline over 4 hours while their blood pressure is monitored every 15 minutes. Blood pressure will be taken every 15 minutes during this procedure. Blood and urine samples will be collected from all subjects pre- and post-infusion.
432881|NCT00896389|Drug|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects. After overnight fasting and having their height, weight, and BP measured, subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. Ambulatory blood pressure will be measured and blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will repeat the 7-day HCTZ intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
432882|NCT00896376|Biological|trastuzumab|
432883|NCT00896376|Other|laboratory biomarker analysis|
432884|NCT00896376|Other|pharmacological study|
432885|NCT00896363|Drug|GSK163090 1 mg|Developed for the treatment of Major Depressive Disorder
432886|NCT00896363|Drug|GSK163090 Placebo|Developed for the treatment of Major Depressive Disorder
432887|NCT00896363|Drug|GSK163090 3 mg|Developed for the treatment of Major Depressive Disorder
432888|NCT00896350|Drug|Standard Care Chemoradiation|"External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician."
432889|NCT00896337|Device|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
432890|NCT00896337|Drug|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
432891|NCT00896337|Drug|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
432892|NCT00896324|Behavioral|Cognitive Rehabilitation|The cognitive rehabilitation procedure will involve a curriculum of game-like cognitive exercises designed to facilitate graded practice of EF skills including attention, processing speed, mental flexibility, planning and logic. The exercises will be delivered to participants via a secure, password protected website created specifically for this study by the PI. Subjects will complete a curriculum of cognitive exercises 30 minutes per day, 5 days per week for 6-weeks.
432893|NCT00896324|Behavioral|Active Neurofeedback Training|Neurofeedback training is a type of biofeedback during which the subjects will be trained to improve cognitive function by implementing certain cognitive strategies while receiving feedback of their own brain activity. This is done using an infrared spectroscopy (NIRS) system. NIRS measurements will be performed using an ETG-4000 NIRS system (Hitachi Medical, Tokyo, Japan), at two wavelengths of near-infrared light (695 and 830 nm). Each participant will have 2 or 3 sessions, each lasting approximately 30 minutes.
432894|NCT00896324|Behavioral|Neurofeedback Training (placebo / Sham)|Neurofeedback training: 2-3, 30 min training sessions. For the sham placebo group, fabricated real-time data will be provided to the subject as feedback information hence enabling the subject to view information identical to experimental subjects but without accurate data pertaining to their own brain activation. The technician will be blinded to the subject's treatment condition assignment.
432895|NCT00896311|Drug|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
432896|NCT00896311|Drug|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
432897|NCT00896298|Drug|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
432898|NCT00896298|Drug|Placebo|Sugar pill
432900|NCT00896285|Other|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
432901|NCT00896285|Other|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
432902|NCT00896285|Other|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
432903|NCT00896259|Other|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
432904|NCT00896246|Drug|Klean-Prep®|Four litres of solution administered orally as a divided dose.
432905|NCT00896246|Drug|Moviprep®|Two litres of solution administered orally as a divided dose
432906|NCT00896233|Procedure|MRE|"Part 1: Participants will have a screening visit, followed ~1 month later by two imaging visits over ~14 days. Each imaging visit will consist of two liver MRE scans.~Part 2: Participants will have a screening visit, followed ~1~month later by one imaging visit. The imaging visit will consist~of two liver MRE scans."
432907|NCT00896207|Drug|Akt inhibitor SR13668|Given orally as a single dose
432908|NCT00896194|Behavioral|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
432909|NCT00896194|Behavioral|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
432910|NCT00896181|Drug|docetaxel|Given IV
432911|NCT00896181|Drug|cisplatin|Given IV
432912|NCT00896181|Drug|carboplatin|Given IV
432913|NCT00896181|Drug|fluorouracil|Given IV
432914|NCT00896181|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
432915|NCT00896181|Radiation|intensity-modulated radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
432916|NCT00896168|Drug|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
432917|NCT00896168|Drug|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
432918|NCT00896155|Drug|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
432919|NCT00896155|Radiation|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
432920|NCT00896129|Other|HRQOL Survey Packet|Questionnaires
432921|NCT00896077|Drug|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
432922|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
432923|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
432924|NCT00896051|Drug|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
432925|NCT00896051|Drug|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
432926|NCT00896051|Drug|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
432927|NCT00896051|Drug|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
432928|NCT00896051|Drug|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
432929|NCT00896051|Drug|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
432930|NCT00896038|Drug|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
432931|NCT00896038|Drug|Placebo|Non-active placebo
432932|NCT00896025|Drug|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.~NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.~i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour~ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours~iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours~iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours~v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
432971|NCT00895804|Drug|MDMA|capsule, 1.6 mg/kg body weight, single dose
432933|NCT00896012|Procedure|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
432934|NCT00896012|Drug|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
432935|NCT00896012|Drug|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
432936|NCT00895999|Behavioral|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
432937|NCT00895999|Behavioral|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
432938|NCT00895986|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
432939|NCT00895986|Behavioral|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
432940|NCT00895973|Other|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
432941|NCT00895960|Drug|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
432942|NCT00895960|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
432943|NCT00895960|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
432944|NCT00895947|Drug|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
432945|NCT00895947|Other|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
432946|NCT00895934|Drug|vorinostat|Given orally
432947|NCT00895934|Drug|gemtuzumab ozogamicin|Given intravenously (IV)
432948|NCT00895934|Drug|azacitidine|Given IV or subcutaneously (SC)
432949|NCT00895921|Drug|Olanzapine|Single intramuscular 10-mg dose
432950|NCT00895921|Drug|Aripiprazole|Single intramuscular 9.75-mg dose
432951|NCT00895908|Behavioral|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
432952|NCT00895908|Behavioral|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
432953|NCT00895895|Drug|Placebo|Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
432954|NCT00895895|Drug|SAM-531 1.5 mg|Capsules SAM-531 1.5 mg, once a day during 52 weeks.
432955|NCT00895895|Drug|SAM-531 3.0 mg|Capsules SAM-531 3.0 mg, once a day during 52 weeks.
432956|NCT00895895|Drug|SAM-531 5.0 mg|Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
432957|NCT00895895|Drug|Donepezil|Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
432958|NCT00895882|Drug|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
432959|NCT00895882|Drug|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
432960|NCT00895882|Drug|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
432961|NCT00895882|Drug|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
432962|NCT00895882|Drug|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
432963|NCT00895856|Other|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
432964|NCT00895843|Drug|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
432965|NCT00895843|Drug|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
432966|NCT00895843|Drug|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
432967|NCT00895830|Drug|APD405|IV
432968|NCT00895830|Drug|Placebo|IV
432969|NCT00895817|Drug|Swallowed fluticasone|440 µg twice daily for 8 weeks
432970|NCT00895817|Drug|Esomeprazole|40 mg once daily for 8 weeks
432972|NCT00895804|Drug|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
432973|NCT00895791|Device|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
432974|NCT00895791|Device|culotte stenting (Xience V)|implantation of stent
432975|NCT00895778|Other|Neuromuscular blockade with rocuronium and reversal with sugammadex|
432976|NCT00895752|Drug|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
432977|NCT00895739|Biological|alemtuzumab|
432978|NCT00895739|Drug|cyclosporine|
432979|NCT00895726|Drug|APD209|Oral tablets twice per day for 56 days
432980|NCT00895713|Drug|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
432981|NCT00895700|Behavioral|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
432982|NCT00895687|Drug|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
432983|NCT00895687|Drug|Bortezomib|Beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
432984|NCT00895674|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
432985|NCT00895661|Drug|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
432986|NCT00895648|Drug|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
432987|NCT00895648|Drug|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
432988|NCT00895635|Behavioral|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
432989|NCT00895635|Behavioral|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
432990|NCT00895635|Behavioral|Usual Care|Usual care for PAD
432991|NCT00895622|Radiation|54 Gy radiotherapy|External beam radiation therapy (EBRT) to a total dose of 54 Gy (RBE) in 30 fractions. 1.8 Gy (RBE) daily, 5 fractions per week, excluding weekends. 3D-CRT or IMRT or Proton allowed.
432992|NCT00895622|Radiation|60 Gy radiotherapy|External beam radiation therapy using intensity-modulated radiation therapy (IMRT) to a total dose of 60 Gy in 30 fractions. 2.0 Gy daily, 5 fractions per week, excluding weekends.
432993|NCT00895609|Drug|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:~Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
432994|NCT00895596|Drug|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
432995|NCT00895583|Drug|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
432996|NCT00895583|Drug|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
432997|NCT00895583|Drug|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
432998|NCT00895570|Drug|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
432999|NCT00895570|Drug|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
433000|NCT00895557|Drug|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
433001|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
433002|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
433003|NCT00895531|Drug|Depodur|7.5 mg Depodur via the epidural catheter
433004|NCT00895531|Procedure|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
433005|NCT00895518|Behavioral|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
433006|NCT00895505|Drug|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
433007|NCT00895505|Drug|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
433008|NCT00895479|Procedure|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.~Control arm: graft placement surgery"
433009|NCT00895466|Biological|PEP-223/CoVaccine HT|
433010|NCT00895453|Drug|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
433011|NCT00895453|Drug|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
433113|NCT00894712|Other|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
433202|NCT00893971|Drug|PT001|Inhaled PT001, single dose
433012|NCT00895453|Drug|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
433013|NCT00895414|Drug|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
433014|NCT00895414|Drug|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
433015|NCT00895401|Dietary Supplement|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
433016|NCT00895401|Other|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
433017|NCT00895388|Behavioral|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
433018|NCT00895362|Drug|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
433019|NCT00895362|Drug|Cetuximab|Loading dose of 200 mg/m^2 (maintenance 125 mg/m^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
433020|NCT00895349|Procedure|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
433021|NCT00895349|Procedure|CT Abdomen and Pelvis scan|Pre-treatment scan
433022|NCT00895336|Biological|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
433023|NCT00895323|Other|enzyme-linked immunosorbent assay|
433024|NCT00895323|Other|pharmacological study|
433025|NCT00895323|Procedure|whole-body scintigraphy|
433026|NCT00895323|Radiation|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
433027|NCT00895310|Drug|Ketoconazole|Ketoconazole is taken three times a day by mouth.
433028|NCT00895310|Drug|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
433029|NCT00895297|Drug|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
433030|NCT00895284|Procedure|Robotic hysterectomy|Robotic hysterectomy.
433031|NCT00895284|Procedure|Standard Hysterectomy|Standard hysterectomy.
433032|NCT00895258|Behavioral|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
433033|NCT00895258|Behavioral|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
433034|NCT00895245|Drug|fosaprepitant dimeglumine|Given IV
433035|NCT00895245|Drug|cisplatin|Given IV
433036|NCT00895245|Drug|palonosetron hydrochloride|Given IV
433037|NCT00895245|Drug|dexamethasone|Given IV and orally
433038|NCT00895245|Other|Functional Living Index-Emesis Questionnaire|Ancillary studies
433039|NCT00895245|Behavioral|Emesis Diary|Ancillary studies
433040|NCT00895245|Radiation|Radiotherapy|Undergo radiotherapy
433041|NCT00895232|Drug|Cohort I|
433042|NCT00895232|Drug|Cohort II|
433043|NCT00895232|Drug|Cohort III|
433044|NCT00895219|Other|Breathing re-training|Breathing re-training
433045|NCT00895219|Other|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
433046|NCT00895206|Drug|individual adapted immunosuppression|individual adapted immunosuppression
433047|NCT00895206|Drug|golden standard therapy|golden standard therapy
433048|NCT00895193|Other|Apple pectin|Apple pectin 2000mg
433049|NCT00895193|Drug|Aspirin 325 mg|Aspirin 325 mg
433050|NCT00895193|Other|Placebo|Placebo
433051|NCT00895180|Biological|olaratumab|Given IV
433052|NCT00895180|Biological|ramucirumab|Given IV
433053|NCT00895167|Dietary Supplement|curcumin|one oral dose of 12 caplets = 12 g curcumin
433054|NCT00895154|Behavioral|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
433055|NCT00895154|Behavioral|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
433056|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
433057|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
433058|NCT00895128|Drug|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
433059|NCT00895128|Drug|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
433060|NCT00895115|Dietary Supplement|vitamin E|Given once daily
433061|NCT00895115|Procedure|sham intervention|No supplementation
433062|NCT00895102|Drug|ABT-333 Tablet|See Arm Description for more information.
433063|NCT00895102|Drug|Placebo|See Arm Description for more information.
433064|NCT00895102|Drug|ABT-333 Capsule|See arm description for more information
433065|NCT00895089|Drug|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
433066|NCT00895089|Drug|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
433067|NCT00895076|Drug|dexamethasone|iontophoretic patch and injection
433114|NCT00894712|Device|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
433068|NCT00895063|Behavioral|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
433069|NCT00895050|Other|Review of clinical records|
433070|NCT00895037|Drug|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
433071|NCT00895024|Behavioral|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
433072|NCT00895011|Drug|Placebo|One dose 30 minutes prior to initiation of sexual activity
433073|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
433074|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
433075|NCT00894998|Biological|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
433076|NCT00894998|Biological|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
433077|NCT00894985|Biological|heparin sodium - blausiegel|heparin sodium 5.000UI
433078|NCT00894985|Biological|heparin sodium - APP|heparin sodium 5.000 USP - APP
433079|NCT00894972|Other|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
433080|NCT00894959|Biological|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
433081|NCT00894959|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
433082|NCT00894946|Procedure|Lipiodol + IVF|IVF preceded by lipiodol
433083|NCT00894946|Procedure|IVF|IVF alone
433084|NCT00894933|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
433085|NCT00894920|Dietary Supplement|biotin|capsule approximately 30 mcg daily 21 days
433086|NCT00894920|Dietary Supplement|biotin|capsule 300 mcg daily 21 days
433087|NCT00894907|Other|PiCCO-parameter-guided volume resuscitation|"Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:~ITBI: 850-1000 ml/sqm, if ELWI <=12*ml/kg; ITBI 750-850 ml/sqm, if ELWI >12*ml/kg and/or PaO2:FiO2 <200 (*ELWI<=12ml/kg, if MAP>65mmHg without catecholamines; ELWI<=14ml/kg, if catecholamines required for MAP>65mmHg); SVV<10% (only in controlled ventilation and sinus rhythm); MAP>65mmHg (MAP: Mean Arterial Pressure); IAPP >60mmHg (IAPP: Intra-abdominal Perfusion Pressure)"
433088|NCT00894907|Other|Control-group|"Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.~Main haemodynamic goals: CVP 8-12 mmHg; MAP >65mmHg;IAPP >60mmHg"
433089|NCT00894894|Drug|MP-470|escalating daily doses of amuvatinib
433090|NCT00894894|Drug|amuvatinib (MP-470)|escalating doses of daily amuvatinib
433091|NCT00894881|Procedure|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
433092|NCT00894868|Drug|vildagliptin|
433093|NCT00894868|Drug|placebo of vildagliptin|
433094|NCT00894855|Behavioral|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
433095|NCT00894855|Behavioral|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
433096|NCT00894855|Other|dermatologist skin exam|Full body skin exam.
433097|NCT00894842|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
433098|NCT00894842|Drug|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
433099|NCT00894829|Biological|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
433100|NCT00894829|Biological|heparin sodium - APP|Heparin sodium APP 5.000 USP
433101|NCT00894816|Dietary Supplement|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
433102|NCT00894816|Dietary Supplement|Placebo|Infant cereals without any addition
433103|NCT00894803|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
433104|NCT00894803|Drug|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
433105|NCT00894790|Drug|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
433106|NCT00894790|Drug|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
433107|NCT00894777|Other|Clinical record review|
433108|NCT00894751|Drug|dexmedetomidine|dexmedetomidine general anesthesia for MRI
433109|NCT00894751|Drug|propofol|propofol general anesthesia for MRI
433110|NCT00894738|Procedure|Testing (MRS, US, DEXA, blood tests)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
433111|NCT00894725|Procedure|laparoscopic left colonic resection|laparoscopic colonic resection
433112|NCT00894725|Procedure|open left colonic resection|conventional open colonic resection
433115|NCT00894699|Drug|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
433116|NCT00894699|Drug|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
433117|NCT00894686|Biological|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
433118|NCT00894673|Biological|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
433119|NCT00894673|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
433120|NCT00894660|Drug|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
433121|NCT00894660|Drug|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
433122|NCT00894647|Drug|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
433123|NCT00894647|Drug|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
433124|NCT00894634|Drug|Brompheniramine maleate|
433125|NCT00894621|Drug|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
433126|NCT00894621|Drug|Placebo|
433127|NCT00894608|Drug|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
433128|NCT00894608|Drug|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
433129|NCT00894595|Behavioral|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
433130|NCT00894582|Procedure|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
433131|NCT00894569|Drug|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
433132|NCT00894569|Drug|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
433133|NCT00894556|Drug|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
433134|NCT00894556|Drug|Comparator: Placebo|Placebo to Rizatriptan
433135|NCT00894556|Drug|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
433136|NCT00894543|Drug|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
433137|NCT00894543|Other|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
433138|NCT00894530|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
433139|NCT00894530|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
433140|NCT00894517|Biological|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
433141|NCT00894517|Drug|Placebo (saline)|Saline injected into the prostate on Day 1.
433142|NCT00894504|Drug|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
433143|NCT00894504|Drug|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
433144|NCT00894504|Drug|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
433145|NCT00894478|Procedure|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
433146|NCT00894478|Procedure|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
433147|NCT00894465|Drug|midazolam|Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
433148|NCT00894465|Drug|placebo|Children are randomized to receive a placebo prior to undergoing VCUG
433149|NCT00894439|Drug|BLI-489/Piperacillin|
433150|NCT00894439|Drug|BLI-489|
433151|NCT00894439|Drug|Piperacillin|
433152|NCT00894413|Drug|Tadalafil|20 mg once daily for 10 - 14 days
433153|NCT00894413|Other|Placebo Pill|Placebo
433154|NCT00894400|Procedure|catheter ablation|catheter ablation using radiofrequency energy
433155|NCT00894387|Drug|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
433156|NCT00894387|Drug|Placebo|Placebo
433157|NCT00894374|Drug|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
433158|NCT00894374|Drug|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
433159|NCT00894361|Procedure|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
433160|NCT00894361|Procedure|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
433161|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
433162|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
433163|NCT00894322|Other|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
433164|NCT00894283|Drug|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
433165|NCT00894283|Drug|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
433166|NCT00894270|Procedure|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
433167|NCT00894270|Procedure|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
433168|NCT00894270|Device|Novofine needle|Novofine 5mm needle
433169|NCT00894244|Device|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
433170|NCT00894231|Drug|levocetirizine (Xyzal)|5mg po QD
433171|NCT00894231|Drug|placebo|sugar tablet
433172|NCT00894218|Procedure|Arthroplasty|Hip or knee arthroplasty
433173|NCT00894205|Behavioral|strengthening exercise program|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks."
433174|NCT00894192|Device|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
433175|NCT00894192|Device|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
433176|NCT00894166|Drug|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
433177|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
433178|NCT00894166|Drug|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
433179|NCT00894166|Drug|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
433180|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
433181|NCT00894166|Drug|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
433182|NCT00894166|Drug|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
433183|NCT00894153|Drug|chemotherapy plus p53|chemotherapy plus p53
433184|NCT00894153|Drug|chemotherapy|chemotherapy
433185|NCT00894153|Radiation|radiotherapy|radiotherapy
433186|NCT00894140|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
433187|NCT00894127|Device|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
433188|NCT00894114|Biological|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
433189|NCT00894114|Biological|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
433190|NCT00894101|Drug|[F-18] FLT|10 mCi [F-18] FLT and 10 mCi [F-18] FDG will be used for PET imaging.
433191|NCT00894088|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
433192|NCT00894075|Biological|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
433193|NCT00894062|Device|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
433194|NCT00894062|Device|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
433195|NCT00894049|Drug|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
433196|NCT00894023|Drug|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
433197|NCT00894023|Drug|IV abciximab|IV abciximab + infusion
433198|NCT00894010|Drug|carbamazepine 400mg|
433199|NCT00894010|Drug|levetiracetam 1000mg|
433200|NCT00893997|Biological|PR-1 vaccine|0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
433201|NCT00893984|Drug|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
433203|NCT00893971|Drug|PT005|Inhaled PT005, single dose
433204|NCT00893971|Drug|PT003|Inhaled PT003, single dose
433205|NCT00893971|Drug|PT001 + PT005|Inhaled PT001 + PT005, single dose
433206|NCT00893958|Drug|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
433207|NCT00893945|Drug|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
433208|NCT00893945|Drug|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
433209|NCT00893945|Drug|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
433210|NCT00893919|Drug|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
433211|NCT00893906|Biological|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
433212|NCT00893906|Biological|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
433213|NCT00893880|Drug|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
433214|NCT00893867|Drug|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
433215|NCT00893867|Drug|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
433216|NCT00893854|Drug|Diclophenac|
433217|NCT00893854|Drug|Triamcinolone|
433218|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
433219|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
433220|NCT00893841|Drug|placebo|placebo
433221|NCT00893841|Drug|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
433222|NCT00893802|Other|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
433223|NCT00893789|Drug|Armodafinil|Armodafinil 50 mg/day
433224|NCT00893789|Drug|Armodafinil|Armodafinil 150 mg/day
433225|NCT00893789|Drug|Armodafinil|Armodafinil 250 mg/day
433226|NCT00893789|Other|Placebo|Placebo
433227|NCT00893776|Other|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
433228|NCT00893763|Procedure|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
433229|NCT00893763|Procedure|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
433230|NCT00893750|Behavioral|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
433231|NCT00893750|Behavioral|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
433232|NCT00893750|Behavioral|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
433233|NCT00893737|Drug|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
433234|NCT00893724|Drug|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
433235|NCT00893724|Dietary Supplement|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine [SR] - 1[500mg] tablet bid Tocopherols [200IU], Tocotrienol [10mg], CoQ10 [50mg] - combination capsule bid Sustained Release Niacinamide - 1 [750mg] tablet bid Vitamin C - 1 [1000mg] sustained release tablet bid N-acetyl Cysteine - 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
433236|NCT00893724|Drug|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine [SR] - 1 [500mg] tablet bid Tocopherol [200IU], Tocotrienol [10mg], CoQ10 [50mg] combination capsule bid Sustained Release Niacinamide 1 [750mg] tablet bid Vitamin C 1 [1000mg] sustained release tablet bid N-acetyl Cysteine 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 [50mg] tablet qd
433237|NCT00893711|Other|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
433238|NCT00893711|Other|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
433239|NCT00893711|Dietary Supplement|L.reuteri + Vit D|
433240|NCT00893711|Dietary Supplement|Vit D placebo|
433241|NCT00893698|Procedure|bilateral allotransplantation|bilateral allotransplantation of upper limbs
433242|NCT00893685|Device|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
433243|NCT00893659|Dietary Supplement|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
433244|NCT00893659|Dietary Supplement|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
433245|NCT00893646|Behavioral|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
433352|NCT00892866|Other|Laboratory Biomarker Analysis|Correlative studies
433246|NCT00893620|Device|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
433247|NCT00893607|Drug|NRL001|10mg NRL001 was administered as a slow release suppository
433248|NCT00893594|Drug|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
433249|NCT00893594|Drug|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
433250|NCT00893581|Drug|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
433251|NCT00893581|Drug|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
433252|NCT00893581|Other|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
433253|NCT00893568|Other|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
433254|NCT00893555|Drug|voriconazole|TDM (through level of 2-5mg/L).
433255|NCT00893555|Drug|voriconazole (dosing according to the SPC)|No serum concentrations are determined
433256|NCT00893542|Drug|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
433257|NCT00893529|Dietary Supplement|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
433258|NCT00893529|Dietary Supplement|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
433259|NCT00893516|Biological|CHOP + CD4|
433260|NCT00893516|Drug|CHOP|
433261|NCT00893503|Procedure|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
433262|NCT00893490|Device|Ahmed Glaucoma Valve (AGV)|AGV implantation
433263|NCT00893490|Drug|Mitomycin C (MMC)|3 minute MMC application
433264|NCT00893490|Procedure|amniotic membrane coverage|single layer coverage of amniotic membrane
433265|NCT00893477|Biological|rituximab|
433266|NCT00893477|Biological|sargramostim|
433267|NCT00893477|Genetic|gene expression analysis|
433268|NCT00893477|Genetic|gene rearrangement analysis|
433269|NCT00893477|Genetic|polymerase chain reaction|
433270|NCT00893477|Genetic|polymorphism analysis|
433271|NCT00893477|Other|laboratory biomarker analysis|
433272|NCT00893464|Drug|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
433273|NCT00893451|Drug|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
433274|NCT00893451|Drug|Placebo|Placebo orally twice daily
433275|NCT00893438|Behavioral|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
433276|NCT00893438|Other|Usual care|Usual care treatment for adolescents with CFS
433277|NCT00893425|Drug|ramipril|
433278|NCT00893412|Drug|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
433279|NCT00893412|Procedure|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
433280|NCT00893412|Drug|Placebo|
433281|NCT00893399|Drug|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (> 60 yrs) patients.~Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (> 60 yrs) patients.~For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.~Consolidation 2, 3: no GO"
433282|NCT00893399|Drug|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
433283|NCT00893386|Procedure|LV Lead Extraction|Removal of a LV lead using any tools & techniques.
433284|NCT00893373|Drug|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
433285|NCT00893373|Drug|placebo|Standard AML chemotherapy plus placebo
433286|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
433287|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
433288|NCT00893347|Behavioral|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
433351|NCT00892866|Other|Cytology Specimen Collection Procedure|Correlative studies
433289|NCT00893347|Behavioral|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
433290|NCT00893321|Procedure|Inferior Oblique Muscle Recession and Myectomy|
433291|NCT00893295|Other|informational intervention|
433292|NCT00893295|Other|medical chart review|
433293|NCT00893295|Other|screening questionnaire administration|
433294|NCT00893295|Other|study of socioeconomic and demographic variables|
433295|NCT00893295|Procedure|barium enema injection|
433296|NCT00893295|Procedure|colon imaging study|
433297|NCT00893295|Procedure|screening colonoscopy|
433298|NCT00893295|Procedure|sigmoidoscopy|
433299|NCT00893282|Device|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
433300|NCT00893282|Device|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
433301|NCT00893269|Drug|eszopiclone|Oral capsule at dose recommended for adults
433302|NCT00893269|Drug|Placebo|Participants receive placebo prior to sleep
433303|NCT00893269|Drug|ramelteon|ramelteon
433304|NCT00893269|Drug|zolpidem|zolpidem
433305|NCT00893256|Drug|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
433306|NCT00893256|Drug|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
433307|NCT00893256|Drug|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
433308|NCT00893256|Drug|Placebo|Placebo: once daily
433309|NCT00893230|Dietary Supplement|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
433310|NCT00893230|Dietary Supplement|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
433311|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
433312|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
433313|NCT00893165|Behavioral|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
433314|NCT00893139|Drug|AL-38583 ophthalmic solution 0.05%|
433315|NCT00893139|Drug|AL-38583 ophthalmic solution 0.10%|
433316|NCT00893139|Drug|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
433317|NCT00893126|Procedure|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
433318|NCT00893113|Drug|Placebo|Alfuzosin-matched One tablet once daily
433319|NCT00893113|Drug|Alfuzosin|10 mg once daily
433320|NCT00893100|Drug|Diltiazem|2%,3 times daily
433321|NCT00893087|Device|Triggering mode of the ventilator|10 min of each triggering mode
433322|NCT00893087|Device|Triggering method of the ventilator|Flow triggering
433323|NCT00893087|Device|Triggering method of the ventilator|Pressure triggering
433324|NCT00893087|Device|Triggering method of the ventilator|NAVA triggering
433325|NCT00893074|Drug|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
433326|NCT00893074|Drug|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
433327|NCT00893074|Drug|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
433328|NCT00893074|Drug|Placebo|placebo dronabinol administered 3x/day for 5 days
433329|NCT00893061|Drug|anastrozole|Given orally
433330|NCT00893061|Drug|exemestane|Given orally
433331|NCT00893061|Drug|letrozole|Given orally
433332|NCT00893061|Drug|tamoxifen citrate|Given orally
433333|NCT00893048|Drug|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
433334|NCT00893048|Drug|Placebo Oral Tablet|Placebo
433335|NCT00893009|Drug|Theophylline|100 mg twice a day
433336|NCT00893009|Drug|Placebo|Placebo
433337|NCT00892996|Drug|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
433338|NCT00892996|Drug|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
433339|NCT00892983|Behavioral|FAB|Standard well child care plus 7 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, and 3, 4, 7, 9, 13, and 18 months post-partum.
433340|NCT00892983|Behavioral|Sleep|"Standard well child care plus 2 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), and sleep problem prevention at 3 weeks. A sleep problem intervention starting at 6 months was possible for those indicating their child had a sleep problem at 6 months of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
433341|NCT00892970|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
433342|NCT00892970|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
433343|NCT00892957|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
433344|NCT00892957|Other|Surgical gauze pads|Manual compression with surgical gauze pads
433345|NCT00892944|Drug|AZD2516|Fractionated single oral dose
433346|NCT00892931|Drug|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
433347|NCT00892918|Drug|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
433348|NCT00892892|Drug|Rilmenidine|1 mg Rilmenidine per day versus
433349|NCT00892892|Drug|Nitrendipine|20 mg Nitrendipine per day
433350|NCT00892879|Device|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
433353|NCT00892853|Procedure|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
433354|NCT00892840|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
433355|NCT00892840|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
433356|NCT00892827|Drug|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
433357|NCT00892814|Radiation|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
433358|NCT00892814|Radiation|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
433359|NCT00892801|Drug|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
433360|NCT00892801|Radiation|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
433361|NCT00892788|Behavioral|contingency management|Prize-based contingency management for weight loss
433362|NCT00892788|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
433363|NCT00892775|Biological|Priorix-Tetra (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
433364|NCT00892775|Biological|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
433365|NCT00892762|Drug|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
433366|NCT00892762|Drug|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
433367|NCT00892749|Drug|ASP1585|oral
433368|NCT00892736|Other|Laboratory Biomarker Analysis|Correlative studies
433369|NCT00892736|Other|Pharmacological Study|Correlative studies
433370|NCT00892736|Drug|Veliparib|Given PO
433371|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
433372|NCT00892723|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
433373|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
433374|NCT00892710|Drug|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
433375|NCT00892710|Drug|Bevacizumab|15 mg/kg IV every 21 days
433376|NCT00892710|Drug|Carboplatin|AUC=5 IV every 21 days
433377|NCT00892697|Drug|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
433378|NCT00892697|Drug|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
433379|NCT00892697|Drug|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
433380|NCT00892684|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
433381|NCT00892684|Dietary Supplement|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
433382|NCT00892671|Other|Simulation|simulation of airway management and vascular access
433383|NCT00892658|Drug|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
433384|NCT00892632|Procedure|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
433385|NCT00892619|Procedure|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
433386|NCT00892619|Procedure|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
433387|NCT00892606|Drug|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
433388|NCT00892606|Drug|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
433389|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
433390|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
433391|NCT00892580|Drug|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
433392|NCT00892567|Biological|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
433393|NCT00892554|Dietary Supplement|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
433394|NCT00892554|Dietary Supplement|Corn/soy oil|Capsules taken once daily
433395|NCT00892541|Drug|ER OROS paliperidone|
433396|NCT00892515|Behavioral|exercise intervention|
433397|NCT00892515|Other|counseling intervention|
433398|NCT00892515|Other|gas chromatography|
433399|NCT00892515|Other|immunoenzyme technique|
433400|NCT00892515|Other|immunologic technique|
433401|NCT00892515|Other|laboratory biomarker analysis|
433402|NCT00892515|Other|mass spectrometry|
433403|NCT00892515|Other|physiologic testing|
433404|NCT00892515|Other|questionnaire administration|
433405|NCT00892515|Other|survey administration|
433406|NCT00892515|Procedure|dual x-ray absorptometry|
433407|NCT00892515|Procedure|magnetic resonance imaging|
433408|NCT00892515|Procedure|study of high risk factors|
433409|NCT00892502|Drug|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
433410|NCT00892502|Drug|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
433411|NCT00892489|Drug|ER OROS Paliperidone|
433412|NCT00892476|Dietary Supplement|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:~Amount of feeding Actual Weight < 1000 g Actual Weight < 1000 g~25 ml ¼ tsp 1/8 tsp~50 ml ½ tsp ¼ tsp~100 ml 1 tsp ½ tsp~200 ml 2 tsp 1 tsp"
433413|NCT00892476|Other|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
433414|NCT00892463|Drug|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
433415|NCT00892450|Drug|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
433416|NCT00892437|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
433417|NCT00892437|Drug|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
433418|NCT00892437|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
433419|NCT00892437|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
433420|NCT00892437|Drug|COBI placebo|Placebo to match COBI administered orally once daily
433421|NCT00892437|Drug|RTV placebo|Placebo to match RTV administered orally once daily
433422|NCT00892424|Drug|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
433423|NCT00892398|Drug|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
433424|NCT00892398|Procedure|standard care|standard post-operative care after trabeculectomy with mitomycin C
433425|NCT00892385|Drug|Methoxyamine|For all cycles, TMZ will be given orally for 5 days every 28 days. MX will be given as a single one-hour IV infusion every 28 days. Temozolomide will be administered within 5 minutes following the initiation of methoxyamine.
433426|NCT00892385|Drug|Temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
433427|NCT00892359|Drug|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
433428|NCT00892346|Procedure|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:~Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)~Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
433429|NCT00892320|Drug|ER OROS paliperidone|
433430|NCT00892307|Radiation|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
433431|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
433432|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
433433|NCT00892268|Procedure|acupuncture therapy|Undergo acupuncture
433434|NCT00892268|Procedure|pain therapy|Receive standard care
433435|NCT00892255|Device|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
433436|NCT00892242|Drug|Zoledronic acid|
433437|NCT00892229|Drug|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
433438|NCT00892229|Drug|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
433439|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
433440|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
433441|NCT00892203|Drug|BGG492|
433442|NCT00892203|Drug|Sumatriptan|
433443|NCT00892203|Drug|Placebo|
433444|NCT00892190|Drug|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
433445|NCT00892190|Drug|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
433446|NCT00892177|Biological|bevacizumab|Given intravenously
433447|NCT00892177|Drug|dasatinib|Given orally
433448|NCT00892177|Other|placebo|Given orally
433449|NCT00892164|Device|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
433450|NCT00892164|Device|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
433451|NCT00892151|Device|GLUCOFACTS® Deluxe|Diabetes Data Management Software
433452|NCT00892138|Behavioral|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
433453|NCT00892125|Drug|paliperidone ER; Carbamazepine|
433454|NCT00892112|Drug|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
433455|NCT00892112|Drug|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
433456|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given weekly
433457|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given monthly
433458|NCT00892099|Other|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
433459|NCT00892073|Drug|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
433460|NCT00892073|Drug|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
433461|NCT00892047|Drug|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
433462|NCT00892047|Drug|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
433463|NCT00892021|Drug|NSA-789|
433464|NCT00892021|Drug|Placebo|
433465|NCT00892008|Drug|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
433466|NCT00891995|Device|Closed loop|Closed loop therapy for up to 4 to 6 days
433467|NCT00891995|Device|Home glucose monitoring|Standard diabetes management using a home glucose meter.
433468|NCT00891995|Device|Insulin pump|Insulin pump use for 2 years
433469|NCT00891995|Device|Continuous glucose monitor|Continuous glucose monitor use for 2 years
433470|NCT00891982|Drug|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days~Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
433471|NCT00891982|Drug|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days~Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
433472|NCT00891943|Other|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
433473|NCT00891930|Biological|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
433474|NCT00891930|Biological|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
433475|NCT00891930|Drug|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
433476|NCT00891917|Drug|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
433477|NCT00891904|Biological|cetuximab|Given IV
433478|NCT00891904|Radiation|stereotactic body radiation therapy|Undergoing Radiotherapy
433479|NCT00891878|Drug|capecitabine|Given orally
433480|NCT00891878|Drug|sunitinib malate|Given orally
433481|NCT00891839|Drug|Bendamustine|Bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
433482|NCT00891839|Drug|Rituximab|Patients receive 375 mg/m^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
433483|NCT00891826|Dietary Supplement|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
433484|NCT00891826|Dietary Supplement|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
433485|NCT00891813|Drug|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
433486|NCT00891800|Device|Brachytherapy|SIR-Sphere contains radiation of Y-90.
433487|NCT00891800|Device|SIR-Sphere|Brachytherapy Radiation seeds
433488|NCT00891787|Dietary Supplement|Probiotic Supplement|
433489|NCT00891774|Device|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
433490|NCT00891761|Drug|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
433491|NCT00891761|Drug|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
433492|NCT00891761|Drug|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
433493|NCT00891761|Drug|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
433494|NCT00891761|Drug|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
433495|NCT00891748|Genetic|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
433496|NCT00891735|Drug|Ranibizumab|Sterile solution for intravitreal injection.
433497|NCT00891722|Other|biologic sample preservation procedure|
433498|NCT00891722|Other|laboratory biomarker analysis|
433499|NCT00891722|Other|questionnaire administration|
433500|NCT00891709|Drug|LEO 29102|First-in-man. Healthy volunteers
433501|NCT00891696|Drug|Rapamycin|Single 16-mg oral dose
433502|NCT00891696|Other|Amino acid supplementation|Nutritional drink containing essential amino acids
433503|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
433504|NCT00891696|Drug|Sodium nitroprusside|Variable rate for 3 hours
433505|NCT00891696|Device|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
433506|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
433507|NCT00891683|Drug|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
433508|NCT00891670|Drug|cilostazol|100mg twice daily for at least 1 month
433509|NCT00891670|Drug|clopidogrel|"75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)"
433510|NCT00891670|Drug|aspirin|aspirin 100mg
433511|NCT00891657|Device|SprayShield™|Anti-adhesion barrier
433512|NCT00891644|Other|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.~Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
433513|NCT00891644|Other|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.~When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.~Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
433514|NCT00891644|Other|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
433515|NCT00891631|Behavioral|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
433516|NCT00891631|Behavioral|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
433517|NCT00891618|Other|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
433518|NCT00891605|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
433519|NCT00891605|Drug|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed."
433520|NCT00891592|Biological|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~1xE5 cells/kg~2xE6 cells/kg~3xE7 cells/kg~4xE8 cells/kg"
433521|NCT00891592|Other|Observation Arm|Single infusion of Cord Blood Cells
433522|NCT00891579|Drug|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
433523|NCT00891579|Drug|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
433524|NCT00891566|Procedure|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
433525|NCT00891553|Procedure|DXA|CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
433526|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.5%
433527|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.2%
433528|NCT00891540|Drug|placebo|Isotonic NaCl
433559|NCT00891267|Drug|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
433560|NCT00891267|Drug|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
433529|NCT00891527|Drug|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.~Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
433530|NCT00891514|Behavioral|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
433531|NCT00891514|Behavioral|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
433532|NCT00891501|Procedure|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
433533|NCT00891501|Procedure|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
433534|NCT00891475|Procedure|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
433535|NCT00891475|Procedure|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
433536|NCT00891475|Drug|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
433537|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
433538|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
433539|NCT00891462|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
433540|NCT00891436|Drug|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
433541|NCT00891436|Drug|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
433542|NCT00891423|Drug|Meropenem short infusion|
433543|NCT00891423|Drug|Meropenem extended infusion|
433544|NCT00891397|Drug|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
433545|NCT00891397|Other|Placebo|Sugar pill
433546|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
433547|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
433548|NCT00891371|Drug|lanreotide (Autogel formulation)|Autogel 120mg
433549|NCT00891358|Behavioral|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.~The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
433550|NCT00891345|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
433551|NCT00891332|Drug|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
433552|NCT00891319|Device|Electrical stimulator|"• 12-week intervention~Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home."
433553|NCT00891306|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
433554|NCT00891306|Drug|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
433555|NCT00891306|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
433556|NCT00891306|Drug|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
433557|NCT00891293|Drug|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
433558|NCT00891280|Drug|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
433561|NCT00891267|Drug|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
433562|NCT00891254|Device|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
433563|NCT00891241|Drug|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
433564|NCT00891228|Drug|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
433565|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
433566|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
433567|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
433568|NCT00891202|Drug|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 [active moiety of ET in plasma] trough plasma concentration >=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration <5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
433569|NCT00891202|Drug|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
433570|NCT00891176|Biological|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
433571|NCT00891176|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
433572|NCT00891176|Biological|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
433573|NCT00891176|Biological|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
433574|NCT00891176|Biological|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
433575|NCT00891176|Biological|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
433576|NCT00891176|Biological|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
433577|NCT00891176|Biological|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
433578|NCT00891176|Biological|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
433579|NCT00891163|Drug|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
433580|NCT00891163|Drug|Placebo Patch|placebo
433581|NCT00891150|Drug|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.~Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
433582|NCT00891137|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
433583|NCT00891111|Behavioral|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
433584|NCT00891111|Behavioral|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
433585|NCT00891098|Behavioral|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
433586|NCT00891098|Behavioral|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
433587|NCT00891072|Drug|R-(-)-gossypol acetic acid|Given orally
433588|NCT00891072|Drug|paclitaxel|Given IV
433589|NCT00891072|Drug|carboplatin|Given IV
433590|NCT00891072|Other|pharmacological study|Correlative studies
433591|NCT00891046|Drug|Canakinumab|Canakinumab
433592|NCT00891033|Drug|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
433593|NCT00891033|Drug|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
433594|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous every 4 weeks for 24 weeks
433595|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|4 mg/kg every 4 weeks for 24 weeks
433596|NCT00891020|Drug|Nonbiologic DMARDs of investigator's choice|Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
433597|NCT00891007|Biological|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
433598|NCT00891007|Biological|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
433599|NCT00891007|Biological|Rouvax|Standard measles vaccine, approved in South Africa
433600|NCT00890981|Procedure|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
433601|NCT00890981|Procedure|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
433602|NCT00890981|Biological|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
433603|NCT00890981|Drug|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
433604|NCT00890968|Drug|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
433605|NCT00890968|Drug|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
433606|NCT00890955|Drug|Amrubicin|"Dose Level -1: 20mg/m2~Dose Level 1: 25mg/m2~Dose Level 2: 30mg/m2~Dose Level 3: 35mg/m2~Dose Level 4: 40mg/m2~Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
433607|NCT00890955|Drug|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
433608|NCT00890942|Drug|naloxone|naloxone 0.4mg.(1 ml) intramuscular
433609|NCT00890942|Drug|normal saline|normal saline 1 ml IM
433610|NCT00890929|Drug|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
433611|NCT00890929|Drug|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
433612|NCT00890916|Device|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
433613|NCT00890890|Drug|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
433614|NCT00890890|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
433615|NCT00890877|Drug|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
433616|NCT00890864|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
433617|NCT00890851|Procedure|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
433618|NCT00890838|Dietary Supplement|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
433619|NCT00890825|Drug|AZD6244|oral capsules, 75mg twice daily
433620|NCT00890825|Drug|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
433621|NCT00890825|Drug|Placebo|placebo
433622|NCT00890799|Device|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
433623|NCT00890799|Procedure|surgery|Patient in this group received open surgical repair of pmVSD.
433624|NCT00890786|Drug|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.~High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
433625|NCT00890786|Drug|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.~High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.~Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
433626|NCT00890786|Drug|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.~Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
433627|NCT00890760|Biological|AdCh63 ME-TRAP|5 x 10*10 vp IM
433628|NCT00890760|Biological|MVA ME-TRAP|2 x 10*8 pfu ID
433629|NCT00890760|Other|Sporozoite challenge|Infected mosquito bite
433630|NCT00890760|Biological|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10*10 vp MVA ME-TRAP 2 x 10*8 pfu
433631|NCT00890747|Drug|sunitinib malate|Given PO
433632|NCT00890747|Other|pharmacological study|Correlative studies
433633|NCT00890747|Other|laboratory biomarker analysis|Correlative studies
433634|NCT00890734|Drug|CYT003-QbG10|subcutaneous injection
433635|NCT00890734|Drug|Placebo|subcutaneous injection
433636|NCT00890721|Drug|SKY0402|During the operation, 30cc of SKY0402 are injected into the wound.
433637|NCT00890721|Drug|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
433638|NCT00890708|Drug|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
433750|NCT00889850|Drug|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
434355|NCT00885118|Drug|Placebo|Placebo tablets once a day
433639|NCT00890695|Dietary Supplement|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
433640|NCT00890682|Drug|SKY0402|Local infiltration of 8cc SKY0402
433641|NCT00890682|Drug|Placebo|Local infiltration of 8cc Placebo
433642|NCT00890669|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):~treadmill training with additional body load (A1),~control condition (conventional physical therapy group) (B). and~treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
433643|NCT00890656|Drug|Cyclophosphamide (CTX)|300 mg/m^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
433644|NCT00890656|Drug|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
433645|NCT00890656|Drug|Doxorubicin|50 mg/m^2 by vein (IV) over 24 hours
433646|NCT00890656|Drug|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
433647|NCT00890656|Drug|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
433648|NCT00890656|Drug|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
433649|NCT00890656|Drug|Ara-C|3 gm/m^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
433650|NCT00890656|Drug|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
433651|NCT00890643|Drug|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
433652|NCT00890643|Drug|placebo|placebo
433653|NCT00890630|Procedure|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
433654|NCT00890630|Drug|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
433655|NCT00890617|Procedure|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
433656|NCT00890617|Drug|Prednisone|"Prednisone taken:~20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
433657|NCT00890604|Drug|Acetaminophen|APAP 650mg q4h prn; RTC dosing
433658|NCT00890604|Other|Usual Care|Care per attending physician discretion for fever management
433659|NCT00890604|Drug|Ibuprofen|Ibuprofen 600mg q6h
433660|NCT00890604|Other|Physical Cooling Measures|Fan, Ice Packs
433661|NCT00890604|Device|Cooling Blanket|Water Circulating Cooling Blanket
433662|NCT00890604|Device|Hydrogel Cooling Pads|Application to torso and extremities
433663|NCT00890591|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
433664|NCT00890578|Procedure|adhesive to suture|surgical closure
433665|NCT00890565|Drug|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
433666|NCT00890552|Drug|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
433667|NCT00890552|Drug|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
433668|NCT00890552|Drug|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
433669|NCT00890539|Drug|Methacholine challenge|Clinical and research test used in asthma
433670|NCT00890526|Other|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from ~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
433671|NCT00890526|Other|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
433672|NCT00890526|Other|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
433751|NCT00889837|Drug|Inhaled Loxapine|Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
433752|NCT00889837|Drug|Inhaled Placebo|Staccato Placebo, inhalations x 2 , 10 hours apart
433753|NCT00889824|Device|balance prosthesis|vibrotactile stimulation
433673|NCT00890526|Other|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
433674|NCT00890500|Drug|Fludarabine|30mg/m2/day IV x 6 days
433675|NCT00890500|Drug|Melphalan|100 mg/m2/day IV x 1 day
433676|NCT00890500|Drug|Antithymocyte Globulin|1mg/kg/day x 4 days
433677|NCT00890500|Drug|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
433678|NCT00890500|Drug|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
433679|NCT00890487|Other|hyaluronic acid pill|pill, 220 mg, once a day, three months
433680|NCT00890474|Procedure|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
433681|NCT00890461|Radiation|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
433682|NCT00890448|Other|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
433683|NCT00890435|Other|questionnaire administration|
433684|NCT00890435|Procedure|psychosocial assessment and care|
433685|NCT00890422|Biological|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
433686|NCT00890409|Device|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
433687|NCT00890383|Drug|tetrastarch (Voluven)|Goals directed volume therapy for severe trauma resuscitation
433688|NCT00890370|Procedure|Airway clearance technique|
433689|NCT00890331|Behavioral|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
433690|NCT00890331|Behavioral|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
433691|NCT00890318|Drug|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
433692|NCT00890318|Other|ketoconazole|Tablet, see Arm Description for intervention information.
433693|NCT00890318|Drug|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
433694|NCT00890305|Drug|CT-011|
433695|NCT00890305|Drug|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.~mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
433696|NCT00890292|Drug|JNJ-31001074|
433697|NCT00890279|Drug|Cilnidipine|Cilnidipine up to 20 mg
433698|NCT00890279|Drug|Imidapril|Imidapril up to 10 mg per day
433699|NCT00890266|Procedure|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
433700|NCT00890253|Drug|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
433701|NCT00890253|Drug|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
433702|NCT00890253|Drug|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
433703|NCT00890253|Drug|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
433704|NCT00890240|Drug|JNJ-31001074|
433705|NCT00890227|Procedure|Traditional technique|All level open instrumented posterior spinal fusions
433706|NCT00890227|Procedure|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
433707|NCT00890214|Drug|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
433708|NCT00890214|Drug|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
433754|NCT00889811|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
433709|NCT00890201|Procedure|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:~Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.~Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
433710|NCT00890188|Drug|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
433711|NCT00890175|Drug|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
433712|NCT00890175|Drug|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
433713|NCT00890162|Drug|Epinephrine|
433714|NCT00890162|Drug|Omalizumab (Xolair)|
433715|NCT00890162|Drug|Placebos|
433716|NCT00890149|Drug|Ondansetron|Ondansetron (4ug/kg bid),
433717|NCT00890149|Drug|Placebo|Placebo bid
433718|NCT00890149|Behavioral|BASICS Plus|Brief Alcohol Screening and Intervention for College Students. Brief behavioral intervention to reduce drinking provided to both drug and placebo groups.
433719|NCT00890123|Dietary Supplement|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
433720|NCT00890110|Biological|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
433721|NCT00890097|Drug|AL-8309B Ophthalmic Solution|
433722|NCT00890097|Drug|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
433723|NCT00890084|Drug|Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)|Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
433724|NCT00890071|Other|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
433725|NCT00890045|Device|HeRO Vascular Access Device|HeRO Vascular Access Device
433726|NCT00890045|Device|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
433727|NCT00890032|Biological|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10^6, 5x10^6, and 2x10^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
433728|NCT00890019|Biological|AdCh63 ME-TRAP|"A:Intradermal injection 1x10^8 vp at day 0~A:Intradermal injection 1x10^9 vp at day 0~A:Intradermal injection 1x10^10 vp at day 0~A:Intradermal injection 5x10^10 vp at day 0~5:Intramuscular injection 1x10^10 vp at day 0~6A:Intramuscular injection 5x10^10 vp at day 0~7A: Intramuscular injection 2x10^11 vp at day 0"
433729|NCT00890019|Biological|AdCh63 ME-TRAP; MVA ME-TRAP|"B: AdCh63 ME-TRAP intradermally at dose of 1x10^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 1x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~B: AdCh63 ME-TRAP intradermally at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)~7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)"
433730|NCT00890006|Procedure|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
433731|NCT00889993|Dietary Supplement|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
433732|NCT00889980|Other|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
433733|NCT00889967|Drug|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
433734|NCT00889967|Drug|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
433735|NCT00889967|Drug|Placebo|Placebo once daily by inhalation for 28 days
433736|NCT00889954|Biological|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
433737|NCT00889941|Procedure|LASIK|laser-assisted in situ keratomileusis
433738|NCT00889928|Device|NOTES GEN 1 Toolbox|"Articulating Hook Knife~Articulating Snare~Articulating Needle Knife~Articulating Graspers~Articulating Biopsy Forceps~Steerable Flex Trocar with Rotary Access Needle~Flexible Bipolar Hemostasis Forceps~Flexible Maryland Dissector"
433739|NCT00889915|Drug|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
433740|NCT00889915|Drug|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
433741|NCT00889915|Drug|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
433742|NCT00889915|Drug|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
433743|NCT00889889|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
433744|NCT00889889|Biological|Placebo|Placebo
433745|NCT00889876|Drug|Metformin group|2000 mg/day for one year
433746|NCT00889876|Behavioral|Exercise|3 times/week with a personal coach for one year. Endurance training.
433747|NCT00889863|Drug|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
433748|NCT00889863|Drug|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
433749|NCT00889850|Drug|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
434356|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
433755|NCT00889785|Behavioral|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
433756|NCT00889785|Behavioral|Usual Care|Will receive usual care and monthly phone calls as an active control.
433757|NCT00889733|Drug|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
433758|NCT00889720|Drug|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
433759|NCT00889707|Drug|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
433760|NCT00889707|Drug|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
433761|NCT00889694|Drug|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
433762|NCT00889694|Drug|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
433763|NCT00889694|Drug|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
433764|NCT00889681|Device|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
433765|NCT00889668|Device|GlucoTrack|comparison of different glucose monitoring devices
433766|NCT00889655|Drug|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
433767|NCT00889655|Drug|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
433768|NCT00889642|Device|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
433769|NCT00889642|Device|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
433770|NCT00889629|Drug|Doxercalciferol|Active group receives doxercalciferol (Hectorol) 1mcg
433771|NCT00889629|Drug|placebo|Group 2 receives placebo (dummy bottle with pills resembling doxercalciferol)
433772|NCT00889629|Drug|25-OH Vitamin D3|All groups received cholecalciferol
433773|NCT00889616|Drug|BSAM2/Alhydrogel + CPG 7909|
433774|NCT00889603|Drug|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.~Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
433775|NCT00889590|Drug|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
433776|NCT00889564|Device|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
433777|NCT00889538|Drug|placebo|50 mL of 1/2 normal saline IV
433778|NCT00889538|Drug|glutathione|glutathione 600 mg IV
433779|NCT00889538|Drug|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
433780|NCT00889525|Drug|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
433781|NCT00889512|Drug|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
433782|NCT00889512|Drug|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
433783|NCT00889499|Drug|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
433784|NCT00889499|Drug|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
433785|NCT00889499|Drug|Placebo|NHCL 0,9%
433786|NCT00889486|Drug|TZP-102|
433787|NCT00889486|Drug|Placebo|
433788|NCT00889473|Drug|Larazotide acetate|gelatin capsule
433789|NCT00889473|Drug|Placebo|gelatin capsule
433790|NCT00889473|Dietary Supplement|Gluten 900 mg|gelatin capsule
433791|NCT00889460|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
433792|NCT00889460|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
433793|NCT00889434|Dietary Supplement|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
433794|NCT00889434|Dietary Supplement|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
433795|NCT00889434|Dietary Supplement|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
433796|NCT00889421|Drug|Apremilast|oral dose of 30 mg BID for 6 months
433797|NCT00889408|Biological|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
433798|NCT00889395|Behavioral|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
433799|NCT00889382|Drug|OSI-906|Administered orally
433800|NCT00889382|Drug|Paclitaxel|Administered intravenously
433909|NCT00888472|Procedure|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
433801|NCT00889369|Drug|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
433802|NCT00889356|Drug|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
433803|NCT00889356|Drug|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
433804|NCT00889343|Drug|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
433805|NCT00889343|Drug|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
433806|NCT00889343|Drug|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
433807|NCT00889343|Drug|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
433808|NCT00889343|Drug|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
433809|NCT00889330|Drug|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
433810|NCT00889330|Drug|Placebo|Vehicle without active, one drop in each eye at each of two visits.
433811|NCT00889317|Device|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
433812|NCT00889304|Device|Position HTO system|open wedge high tibial osteotomy
433813|NCT00889265|Device|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
433814|NCT00889252|Device|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
433815|NCT00889252|Device|contact lens|Placebo contact lens
433816|NCT00889239|Other|lithia-disilicate-based crown|all-ceramic crown
433817|NCT00889226|Drug|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
433818|NCT00889226|Drug|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
433819|NCT00889213|Procedure|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
433820|NCT00889213|Procedure|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
433821|NCT00889200|Drug|eszopiclone|6 weeks standard oral therapy
433822|NCT00889187|Radiation|Neoadjuvant Short-Course Photon Radiation|
433823|NCT00889187|Drug|Capecitabine|
433824|NCT00889161|Drug|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
433825|NCT00889148|Drug|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
433826|NCT00889148|Other|Placebo|Half the patients will be randomized to placebo
433827|NCT00889135|Drug|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
433828|NCT00889122|Behavioral|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
433829|NCT00889109|Other|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
433830|NCT00889096|Drug|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
433831|NCT00889096|Drug|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
433832|NCT00889057|Drug|sorafenib|400 mg bid until progression or inacceptable toxicity
433833|NCT00889044|Drug|clopidogrel by chewing|600 mg clopidogrel by chewing
433834|NCT00889044|Drug|Placebo|Placebo p.o
433835|NCT00889031|Other|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
433836|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
433837|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
433838|NCT00889005|Other|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
433839|NCT00888992|Behavioral|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
433840|NCT00888992|Behavioral|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
433841|NCT00888979|Drug|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
433842|NCT00888953|Other|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
433843|NCT00888953|Other|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
433844|NCT00888940|Drug|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
433845|NCT00888940|Drug|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
433846|NCT00888927|Biological|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
433847|NCT00888914|Drug|RT001|RT001
433848|NCT00888914|Drug|RT001|RT001
433849|NCT00888914|Drug|RT001|RT001
433850|NCT00888914|Drug|RT001|RT001
433851|NCT00888914|Other|Vehicle Comparator|Vehicle Comparator
433852|NCT00888901|Drug|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
433853|NCT00888901|Drug|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
433854|NCT00888888|Procedure|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
433855|NCT00888875|Device|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
433856|NCT00888875|Device|ILMA|Insertion after Induction. Insertion of tracheal tube over device
433857|NCT00888862|Drug|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
433858|NCT00888849|Procedure|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
433859|NCT00888849|Procedure|Suturing|Suturing
433860|NCT00888836|Procedure|Bariatric surgery: Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
433861|NCT00888836|Procedure|Bariatric surgery: Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
433862|NCT00888836|Behavioral|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (<30% total fat and <10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
433863|NCT00888823|Radiation|Stereotactic Radiotherapy|Stereotactic Radiotherapy
433864|NCT00888810|Drug|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
433865|NCT00888810|Drug|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
433866|NCT00888797|Drug|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
433867|NCT00888784|Procedure|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
433910|NCT00888459|Drug|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
433911|NCT00888459|Drug|placebo NRT|Placebo nicotine lozenges
433912|NCT00888446|Biological|tgAAC09|
433868|NCT00888784|Drug|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
433869|NCT00888758|Device|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
433870|NCT00888758|Device|everolimus|200 patients with STEMI will be treated with PROMUS DES.
433871|NCT00888745|Drug|placebo|Intravenous and subcutaneous ascending dose
433872|NCT00888745|Drug|PRO283698|Intravenous and subcutaneous ascending dose
433873|NCT00888732|Drug|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
433874|NCT00888719|Drug|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
433875|NCT00888719|Drug|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.~Twice a day, 1 tablet at a time for 12 weeks"
433876|NCT00888719|Drug|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
433877|NCT00888706|Behavioral|Control Condition|The group participated in the usual nursing home activities and routines.
433878|NCT00888706|Behavioral|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
433879|NCT00888706|Behavioral|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
433880|NCT00888706|Behavioral|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
433881|NCT00888693|Drug|ABT-288|See Arm Description for details.
433882|NCT00888693|Drug|Placebo|See Arm Description for details.
433883|NCT00888680|Drug|BGC20-1531|BGC20-1531 administered orally
433884|NCT00888680|Drug|Lactose|Placebo administered orally
433885|NCT00888667|Other|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
433886|NCT00888654|Drug|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
433887|NCT00888654|Procedure|Radical Prosatectomy|
433888|NCT00888641|Procedure|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
433889|NCT00888628|Biological|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
433890|NCT00888628|Drug|Etanercept|Given as induction for islet cell transplant
433891|NCT00888615|Drug|Elesclomol Sodium|Given IV
433892|NCT00888615|Drug|Paclitaxel|Given IV
433893|NCT00888602|Dietary Supplement|3.4 g psyllium|3.4 g psyllium served with meal
433894|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium served with a meal
433895|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium
433896|NCT00888602|Other|Meal|meal
433897|NCT00888550|Procedure|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
433898|NCT00888550|Procedure|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
433899|NCT00888537|Other|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
433900|NCT00888537|Other|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
433901|NCT00888524|Procedure|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
433902|NCT00888524|Procedure|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
433903|NCT00888511|Drug|Tarceva|Tarceva 150 mg/day
433904|NCT00888511|Radiation|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
433905|NCT00888498|Other|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
433906|NCT00888498|Other|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
433907|NCT00888498|Other|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
433908|NCT00888485|Behavioral|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
433913|NCT00888446|Biological|tgAAC09|
433915|NCT00888446|Other|Formulation buffer|Sterile isotonic buffered salt solution
433916|NCT00888433|Device|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
433917|NCT00888420|Other|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
433918|NCT00888407|Behavioral|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
433919|NCT00888407|Behavioral|Nutrition - Small group educational session|Small group session with diet & nutrition focused, topic related resources provided.
433920|NCT00888394|Procedure|chiropody|basic procedure of chiropody in podiatry
433921|NCT00888394|Procedure|basic orthesis|individual basic orthesis of foot
433922|NCT00888394|Procedure|advantage orthesis|advantage orthesis of foot with special material and design
433923|NCT00888394|Procedure|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
433924|NCT00888381|Biological|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
433925|NCT00888368|Procedure|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
433926|NCT00888368|Procedure|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
433927|NCT00888355|Drug|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
433928|NCT00888355|Drug|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
433929|NCT00888342|Drug|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 < 90%. If SpO2 < 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
433930|NCT00888342|Drug|zopiclone|5 mg sedative given approximately 1 hour before sleep
433931|NCT00888342|Other|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
433932|NCT00888329|Drug|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
433933|NCT00888329|Drug|Placebo|Placebo
433934|NCT00888316|Procedure|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
433935|NCT00888316|Procedure|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
433936|NCT00888303|Drug|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
433937|NCT00888303|Drug|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
433938|NCT00888303|Procedure|Thyroidectomy, total or partial|Surgical standard intervention
433939|NCT00888290|Drug|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
433940|NCT00888251|Other|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
433941|NCT00888238|Drug|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
433942|NCT00888238|Drug|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
433943|NCT00888225|Procedure|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
433944|NCT00888225|Procedure|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
433945|NCT00888212|Procedure|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
433946|NCT00888199|Device|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
433947|NCT00888186|Drug|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
433948|NCT00888173|Drug|Brivanib Alaninate|Given PO
433949|NCT00888173|Other|Laboratory Biomarker Analysis|Correlative studies
433950|NCT00888147|Dietary Supplement|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
433951|NCT00888134|Drug|Selumetinib|Given PO
433952|NCT00888108|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
433953|NCT00888108|Drug|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
433954|NCT00888095|Procedure|deep brain stimulation|electrode implantation in either STN or cZI
433955|NCT00888082|Drug|Goserelin acetate|3.6 mg depot injectable preparation
433956|NCT00888069|Drug|CTAP101 Capsules|Single dose oral administration
433957|NCT00888069|Drug|CTAP101 Injection|single IV injection
433958|NCT00888056|Procedure|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
434000|NCT00887653|Drug|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
434357|NCT00885118|Drug|BI 10773|BI 10773 high dose tablets once a day
433959|NCT00888043|Drug|CNTO 95 and avastin|"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab~2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks~1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks~3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks~3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab~20 Recommended Phase II Dose Recommended Phase II Dose"
433960|NCT00888030|Other|there are no interventions currently listed for this study|
433961|NCT00888004|Drug|AFQ056|
433962|NCT00888004|Drug|Placebo|
433963|NCT00887978|Drug|UT-15C SR|treprostinil diolamine sustained release tablets
433964|NCT00887978|Drug|Placebo|
433965|NCT00887965|Drug|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
433966|NCT00887952|Procedure|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
433967|NCT00887952|Procedure|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
433968|NCT00887926|Biological|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
433969|NCT00887913|Device|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
433970|NCT00887900|Procedure|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
433971|NCT00887900|Procedure|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
433972|NCT00887874|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
433973|NCT00887861|Drug|Investigational new drug, company code: BGG492|
433974|NCT00887861|Drug|Placebo|
433975|NCT00887848|Other|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
433976|NCT00887835|Device|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
433977|NCT00887822|Drug|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
433978|NCT00887822|Drug|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
433979|NCT00887822|Drug|Capecitabine|1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
433980|NCT00887822|Drug|Cisplatin|80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
433981|NCT00887809|Drug|gemcitabine|
433982|NCT00887809|Drug|docetaxel|
433983|NCT00887809|Drug|bevacizumab|
433984|NCT00887783|Drug|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
433985|NCT00887783|Radiation|irradiation-66 Gy|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
433986|NCT00887783|Radiation|irradiation-60 Gy|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
433987|NCT00887770|Drug|AZD5672|12 x 50mg tablet, oral, single dose
433988|NCT00887770|Drug|Moxifloxacin|1 x 400mg capsule, oral, single dose
433989|NCT00887770|Drug|placebo|12 x matched to AZD5672 50 mg tablet
433990|NCT00887770|Drug|AZD5672|3 x 50mg tablet, oral. single dose
433991|NCT00887770|Drug|placebo|9 x matched to AZD5672 50mg tablet
433992|NCT00887770|Drug|placebo|1 x matched to Moxifloxacin capsule
433993|NCT00887757|Drug|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
433994|NCT00887757|Drug|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
433995|NCT00887744|Device|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
433996|NCT00887718|Biological|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
433997|NCT00887705|Behavioral|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
433998|NCT00887692|Behavioral|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
433999|NCT00887679|Drug|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
434001|NCT00887640|Drug|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
434002|NCT00887640|Drug|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
434003|NCT00887627|Drug|conivaptan hydrochloride|intravenous
434004|NCT00887614|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
434005|NCT00887601|Drug|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
434006|NCT00887601|Drug|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
434007|NCT00887601|Drug|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
434008|NCT00887601|Drug|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
434009|NCT00887588|Drug|LCZ696|50 mg, 100 mg and 200 mg tablets
434010|NCT00887588|Drug|Valsartan|40 mg, 80 mg and 160 mg tablets
434011|NCT00887588|Drug|Placebo|matching placebo to LCZ696 and Valsartan
434012|NCT00887575|Drug|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
434013|NCT00887575|Drug|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
434014|NCT00887575|Drug|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
434015|NCT00887562|Drug|Idebenone|900 mg/day for 1 month
434016|NCT00887562|Drug|Idebenone|2250 mg/day for 1 month
434017|NCT00887562|Other|Placebo|Placebo - No idebenone
434018|NCT00887549|Drug|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
434019|NCT00887549|Drug|cisplatin|Induction Therapy: 75 mg/m^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
434020|NCT00887536|Drug|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
434021|NCT00887536|Drug|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
434022|NCT00887536|Drug|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
434023|NCT00887536|Drug|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
434024|NCT00887536|Drug|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles [filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.]
434025|NCT00887523|Behavioral|radiation in prone position|radiation in prone position
434026|NCT00887523|Behavioral|radiation in supine position|radiation in supine position
434027|NCT00887510|Drug|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks~Other Names:~HCTZ"
434028|NCT00887510|Drug|Trandolapril|4 mg tablet once daily for 6 weeks
434029|NCT00887497|Procedure|Angioembolization|Angioembolization
434030|NCT00887484|Drug|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
434031|NCT00887484|Drug|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
434032|NCT00887471|Procedure|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
434033|NCT00887458|Drug|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
434034|NCT00887458|Drug|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
434035|NCT00887445|Drug|SLV341|5 - 1000mg once daily
434036|NCT00887445|Drug|placebo|
434037|NCT00887432|Dietary Supplement|Cholecalciferol|Given PO
434038|NCT00887432|Other|Laboratory Biomarker Analysis|Correlative studies
434039|NCT00887432|Other|Patient Observation|
434040|NCT00887432|Drug|Placebo Administration|Given PO
434041|NCT00887432|Other|Quality-of-Life Assessment|Ancillary studies
434042|NCT00887432|Other|Questionnaire Administration|Ancillary studies
434043|NCT00887419|Behavioral|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
434044|NCT00887419|Behavioral|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
434045|NCT00887406|Drug|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
434046|NCT00887406|Drug|GSK961081 3mcg SD|single dose delivered via nebulsier
434358|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
434047|NCT00887406|Drug|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
434048|NCT00887406|Drug|Placebo SD|single dose via nebuliser
434049|NCT00887406|Drug|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
434050|NCT00887406|Drug|GSK961081 200mcg SD|single dose via nebuliser
434051|NCT00887406|Drug|GSK961081 300mcg SD|single dose via nebuliser
434052|NCT00887406|Drug|GSK961081 100mcg RD|repeat dose via nebuliser
434053|NCT00887406|Drug|GSK961081 300mcg RD|repeat dose vai nebuliser
434054|NCT00887406|Drug|Placebo RD|repeat dose via nebuliser
434055|NCT00887393|Other|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (< 15% of total kcaloric intake)
434056|NCT00887393|Other|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
434057|NCT00887380|Drug|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
434058|NCT00887380|Radiation|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
434059|NCT00887380|Drug|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
434060|NCT00887367|Drug|GSK598809|Two 175 mg doses of GSK598809 will be given.
434061|NCT00887367|Other|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
434062|NCT00887354|Drug|Teriparatide|Administered subcutaneously
434063|NCT00887354|Drug|Risedronate|Administered orally
434064|NCT00887354|Drug|Placebo|"Weekly: Administered orally~Daily: Administered subcutaneously"
434065|NCT00887354|Dietary Supplement|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
434066|NCT00887354|Dietary Supplement|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
434067|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
434068|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
434069|NCT00887328|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
434070|NCT00887328|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
434071|NCT00887315|Drug|Docetaxel and cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
434072|NCT00887315|Radiation|Docetaxel and cisplatin Plus Hypofractionated Radiotherapy|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
434073|NCT00887276|Drug|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)~20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes~20 ml physiologic saline solution (placebo) (over 30 min)~20 ml physiologic saline solution (placebo) (over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo~2 capsules Placebo~2 capsules Placebo~Total time of the therapy:at least 7 days, but at most 10 days"
434074|NCT00887276|Drug|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)~following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~2 capsules Amoxicillin (0,5 g)~Total time of the therapy: at least 7 days, but at most 10 days"
434075|NCT00887263|Drug|Budesonide|3 mg TID
434076|NCT00887263|Drug|Placebo|0 mg TID
434077|NCT00887250|Drug|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
434078|NCT00887250|Drug|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
434079|NCT00887250|Drug|Comparator: Placebo|Placebo to Losartan
434080|NCT00887237|Device|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
434081|NCT00887237|Device|Conventional cardiac resynchronization|Conventional cardiac resynchronization
434082|NCT00887224|Drug|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
434083|NCT00887224|Drug|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
434084|NCT00887224|Drug|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
434085|NCT00887211|Device|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
434086|NCT00887211|Device|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
434087|NCT00887198|Drug|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
434088|NCT00887198|Drug|Placebo|4 placebo tablets per day taken orally.
434089|NCT00887198|Drug|Prednisone|5 mg tablet orally twice daily.
434090|NCT00887185|Other|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
434091|NCT00887172|Drug|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
434092|NCT00887172|Drug|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
434093|NCT00887172|Drug|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
434094|NCT00887159|Drug|Cisplatin|Given IV
434095|NCT00887159|Biological|Cixutumumab|Given IV
434096|NCT00887159|Drug|Etoposide|Given IV
434097|NCT00887159|Other|Laboratory Biomarker Analysis|Correlative studies
434098|NCT00887159|Drug|Vismodegib|Given PO
434099|NCT00887146|Drug|concomitant temozolomide (TMZ)|75 mg/m^2, orally daily
434100|NCT00887146|Radiation|radiotherapy|
434101|NCT00887146|Drug|procarbazine|Days 8-21: 60 mg/m^2 orally
434102|NCT00887146|Drug|adjuvant temozolomide (TMZ)|150 or 200 mg/m^2 orally
434103|NCT00887146|Drug|CCNU|Day 1: 110 mg/m^2 orally
434104|NCT00887146|Drug|vincristine|Days 8 and 29: 1.4 mg/m^2 IV
434105|NCT00887120|Drug|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"BW 6-7.9 kg: 1.5 mL oral q 12 hr~BW 8.0-16.9 kg: 2.0 ml oral q 12 hr~BW 17.0-19.9 kg: 2.5 ml oral q 12 hr~BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr~BW 30.0-34.9 kg: 4.0 ml oral q 12 hr~BW > 35 kg: 5.0 ml oral q 12 hr~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
434106|NCT00887120|Drug|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"BW 6-7.9 kg: 1.0 mL oral q 12 hr~BW 8.0-16.9 kg: 1.5 ml oral q 12 hr~BW 17.0-19.9 kg: 1.8 ml oral q 12 hr~BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr~BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr~BW 30.0-34.9 kg: 3.0 ml oral q 12 hr~BW > 35 kg: 3.5 ml oral q 12 h~Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
434107|NCT00887107|Drug|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
434108|NCT00887094|Behavioral|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
434109|NCT00887094|Behavioral|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
434110|NCT00887081|Drug|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
434111|NCT00887068|Drug|Azacitidine|32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
434112|NCT00887055|Device|CRT device|
434113|NCT00887042|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, & -6)
434114|NCT00887029|Drug|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
434115|NCT00887029|Drug|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
434116|NCT00887003|Drug|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
434117|NCT00887003|Drug|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
434118|NCT00887003|Drug|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
434119|NCT00887003|Drug|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
434120|NCT00887003|Drug|Depo-Medrol|80mg Depo-Medrol
434121|NCT00886990|Drug|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
434122|NCT00886990|Drug|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
434123|NCT00886977|Drug|YAM80|Oral administration, 2 to 6 mg, once a day.
434124|NCT00886964|Biological|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
434125|NCT00886964|Biological|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose~Location: left deltoid area x 1 injection~Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
434126|NCT00886951|Drug|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
434127|NCT00886938|Device|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
434128|NCT00886925|Drug|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
434129|NCT00886925|Drug|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
434130|NCT00886912|Other|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
434131|NCT00886912|Other|normoxia|training under normoxic conditions
434132|NCT00886899|Device|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
434133|NCT00886886|Drug|MDMA|125 mg, single dose
434134|NCT00886886|Drug|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
434135|NCT00886886|Drug|Placebo|capsules identical to MDMA or Reboxetine
434136|NCT00886873|Drug|Mifepristone|
434137|NCT00886860|Drug|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
434138|NCT00886860|Drug|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
434139|NCT00886847|Procedure|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
434140|NCT00886834|Drug|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
434141|NCT00886834|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
434142|NCT00886821|Biological|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
434143|NCT00886808|Drug|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
434144|NCT00886795|Drug|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
434145|NCT00886782|Drug|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
434146|NCT00886769|Drug|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
434147|NCT00886769|Drug|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
434148|NCT00886756|Drug|AZD8529|Oral
434149|NCT00886756|Drug|Placebo|Oral
434150|NCT00886743|Drug|oprelvekin|injection, 50 mg/kg, once daily
434151|NCT00886730|Behavioral|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
434152|NCT00886730|Behavioral|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
434153|NCT00886730|Behavioral|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
434154|NCT00886717|Drug|carboplatin|
434155|NCT00886717|Drug|paclitaxel-loaded polymeric micelle|
434156|NCT00886704|Dietary Supplement|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..~Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.~Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
434157|NCT00886704|Dietary Supplement|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
434158|NCT00886691|Biological|Bevacizumab|Given IV
434159|NCT00886691|Drug|Everolimus|Given PO
434160|NCT00886691|Other|Laboratory Biomarker Analysis|Correlative studies
434161|NCT00886691|Other|Placebo|Given PO
434162|NCT00886678|Drug|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
434163|NCT00886678|Drug|carboplatin|AUC=5,IV,q 21 days x 2 cycles
434164|NCT00886678|Radiation|thoracic radiation|66 Gy over 33 fractions
434165|NCT00886665|Drug|placebo|placebo, 4 g, powder, oral, 3 times a day
434166|NCT00886665|Drug|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
434167|NCT00886652|Other|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
434168|NCT00886639|Other|6MWT with oxygen|2 liter per minute as continuous-flow
434169|NCT00886639|Other|6MWT with medical air|2 liters as continuous-flow
434170|NCT00886626|Drug|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
434171|NCT00886613|Biological|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
434172|NCT00886613|Biological|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
434280|NCT00885729|Other|Rehabilitation program|Strength exercises, neuromuscular exercises
434173|NCT00886613|Biological|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
434174|NCT00886613|Other|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
434175|NCT00886613|Other|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
434176|NCT00886600|Drug|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
434177|NCT00886600|Drug|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
434178|NCT00886600|Drug|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
434179|NCT00886587|Device|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
434180|NCT00886587|Device|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
434181|NCT00886574|Drug|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
434182|NCT00886574|Drug|Aspirin|100 mg once a day
434183|NCT00886561|Behavioral|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
434184|NCT00886548|Procedure|Ultrasound performed|Nurse-driven ultrasound performed
434185|NCT00886522|Procedure|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):~i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg~Reduced intensity conditioning regimen (RIC):~Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg~GVHD prophylaxis:~Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
434186|NCT00886509|Biological|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
434187|NCT00886509|Other|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
434188|NCT00886496|Biological|recombinant human mannose-binding lectin|
434189|NCT00886483|Device|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
434190|NCT00886483|Device|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
434191|NCT00886470|Biological|ST266|ST266 is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
434192|NCT00886457|Drug|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
434193|NCT00886444|Drug|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
434194|NCT00886431|Other|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
434195|NCT00886418|Drug|muscle relaxant|muscle relaxant administration throughout anesthesia
434196|NCT00886418|Drug|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
434197|NCT00886405|Drug|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
434198|NCT00886379|Dietary Supplement|Mongolian milk without vitamin D|710ml per day for 49 days
434199|NCT00886379|Dietary Supplement|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
434200|NCT00886379|Dietary Supplement|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
434201|NCT00886379|Dietary Supplement|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
434202|NCT00886379|Dietary Supplement|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
434203|NCT00886379|Dietary Supplement|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
434204|NCT00886366|Drug|AZD6714|Oral single doses a-h suspension
434205|NCT00886366|Drug|Placebo|Oral single doses suspension
434206|NCT00886366|Drug|AZD6714|Oral single doses a-d suspension
434207|NCT00886366|Drug|AZD6714|Oral single doses d and g suspension
434208|NCT00886353|Biological|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
434209|NCT00886353|Other|Placebo|Physiological saline administrated i.v.
434210|NCT00886340|Behavioral|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
434211|NCT00886340|Behavioral|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
434212|NCT00886327|Procedure|Colonic capsule endoscopy|
434213|NCT00886314|Drug|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
434281|NCT00885716|Behavioral|patient training in shared decision making|
434282|NCT00885716|Behavioral|cognitive training|
434214|NCT00886314|Other|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
434215|NCT00886301|Procedure|liver biopsy|liver biopsy
434216|NCT00886275|Drug|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
434217|NCT00886275|Drug|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
434218|NCT00886275|Drug|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
434219|NCT00886262|Drug|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
434220|NCT00886262|Drug|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
434221|NCT00886249|Device|Acrysof IQ|Intraocular lens
434222|NCT00886249|Device|Acrysof Natural IOL|Intraocular Lens
434223|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
434224|NCT00886236|Drug|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
434225|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
434226|NCT00886223|Procedure|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
434227|NCT00886210|Procedure|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
434228|NCT00886210|Procedure|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
434229|NCT00886184|Procedure|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
434230|NCT00886184|Procedure|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
434231|NCT00886171|Behavioral|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
434232|NCT00886171|Behavioral|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
434233|NCT00886145|Device|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.~No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
434234|NCT00886132|Drug|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
434235|NCT00886119|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
434236|NCT00886119|Device|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
434237|NCT00886106|Drug|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
434238|NCT00886106|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
434239|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
434240|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
434241|NCT00886080|Procedure|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
434242|NCT00886067|Drug|AZD1446|Solution, oral, single dose
434243|NCT00886067|Radiation|2-[18F]-F-A85380|iv, single dose
434244|NCT00886041|Procedure|laparoscopy|subjected to laparoscopy
434245|NCT00886041|Other|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
434318|NCT00885404|Drug|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
434246|NCT00886028|Drug|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
434247|NCT00886028|Drug|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
434248|NCT00886015|Device|TT Clamp|trichiasis surgery performed with TT clamp
434249|NCT00886015|Procedure|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
434250|NCT00886002|Drug|Fentanyl; Buprenorphine; Naloxone|
434251|NCT00885989|Drug|SLV338|5 - 1000 mg IV
434252|NCT00885989|Drug|Placebo|Placebo
434253|NCT00885963|Drug|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
434254|NCT00885937|Drug|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
434255|NCT00885937|Drug|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
434256|NCT00885937|Device|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
434257|NCT00885924|Drug|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
434258|NCT00885924|Drug|Placebo|NaCl 0.9%
434259|NCT00885898|Procedure|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
434260|NCT00885898|Procedure|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
434261|NCT00885885|Drug|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle~Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2~5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
434262|NCT00885885|Drug|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.~A cycle of panitumumab is defined as 14 days.~FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:~Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle~Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing~A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1~5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
434263|NCT00885872|Drug|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
434264|NCT00885859|Device|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
434265|NCT00885846|Other|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
434266|NCT00885846|Other|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
434267|NCT00885833|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
434268|NCT00885820|Drug|Tacrolimus|Oral
434269|NCT00885820|Drug|MMF|Oral
434270|NCT00885820|Drug|Corticosteroids (Prednisone)|Oral
434271|NCT00885794|Drug|Ranibizumab|3 intravitreal injection every 5 weeks
434272|NCT00885781|Drug|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
434273|NCT00885768|Procedure|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
434274|NCT00885755|Drug|Standard taxane therapy|As prescribed
434275|NCT00885755|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
434276|NCT00885755|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
434277|NCT00885742|Biological|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.~Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 [NCT00883090]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
434278|NCT00885729|Procedure|stem cells|Stem cells or chondrocytes under a commercial available membrane
434279|NCT00885729|Procedure|Chondrocytes|Implantation of chondrocytes
434283|NCT00885703|Drug|Fluconazole|"Step 1: [For participants randomized to Fluconazole] Induction dose of daily treatment of fluconazole given orally (adjusted according to weight).~Step 2: [For participants randomized to Ampho B only] If participant is intolerant to Ampho B, participant transitions to fluconazole dosage of 400-800mg daily given orally.~Step 3: If participant has a negative culture before week 10, participant transitions to consolidation therapy at dosage of 400mg daily given orally.~Step 4: At week 10, participant transitions to maintenance therapy at dosage of 200mg daily given orally."
434284|NCT00885703|Drug|Amphotericin B|Step 1: [For participants randomized to Ampho B] Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
434285|NCT00885690|Drug|Sertindole|Sertindole 16-24 mg once daily
434286|NCT00885690|Drug|Olanzapine|Olanzapine 10-20 mg
434287|NCT00885677|Device|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.~Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
434288|NCT00885664|Drug|Truvada (tenofovir/emitricitabine)|Tenofovir/emitricitabine fixed dose combination once daily
434289|NCT00885664|Drug|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
434290|NCT00885651|Drug|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
434291|NCT00885651|Drug|Placebo|
434292|NCT00885638|Drug|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
434293|NCT00885638|Drug|placebo|A placebo tablet is given before ingestion of macronutrients
434294|NCT00885625|Biological|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
434295|NCT00885599|Drug|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
434296|NCT00885599|Drug|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
434297|NCT00885599|Drug|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
434298|NCT00885599|Drug|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
434299|NCT00885586|Device|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
434300|NCT00885586|Drug|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
434301|NCT00885586|Procedure|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
434302|NCT00885573|Device|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
434303|NCT00885547|Drug|tripterygium wilfordii (TW)|90 mg/d for 6 months
434304|NCT00885534|Drug|Cisplatin, Vinblastine, Temozolomide|"Patients will receive CVT chemotherapy which consists of the following:~Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1."
434305|NCT00885521|Other|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
434306|NCT00885508|Drug|Lenalidomide|"Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.~Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy~Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse~In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
434307|NCT00885495|Drug|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
434308|NCT00885495|Drug|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
434309|NCT00885482|Drug|Lamiduvine (Epivir)|Epivir 300 mg
434310|NCT00885482|Drug|Atazanavir (Reyataz)|Reyataz 300 mg
434311|NCT00885482|Drug|Ritonavir (Norvir)|Norvir 100 mg
434312|NCT00885456|Behavioral|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
434313|NCT00885456|Behavioral|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
434314|NCT00885443|Drug|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
434315|NCT00885443|Drug|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
434316|NCT00885430|Drug|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
434317|NCT00885417|Drug|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
434319|NCT00885378|Drug|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
434320|NCT00885378|Drug|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
434321|NCT00885365|Drug|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
434322|NCT00885365|Drug|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
434323|NCT00885352|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
434324|NCT00885352|Drug|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
434325|NCT00885352|Drug|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
434326|NCT00885352|Drug|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
434327|NCT00885352|Drug|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
434328|NCT00885326|Drug|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
434329|NCT00885326|Drug|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
434330|NCT00885326|Drug|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
434331|NCT00885313|Drug|DHA250|DHA 250 mg/kg/d
434332|NCT00885313|Drug|DHA500|DHA 500 mg/kg/d
434333|NCT00885313|Drug|PLACEBO|placebo
434334|NCT00885313|Behavioral|Lifestyle intervention|lifestyle intervention [including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity], for 12 months.
434335|NCT00885300|Drug|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
434336|NCT00885300|Drug|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
434337|NCT00885287|Drug|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
434338|NCT00885274|Drug|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
434339|NCT00885274|Drug|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
434340|NCT00885222|Device|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
434341|NCT00885196|Drug|Placebo|
434342|NCT00885196|Drug|AEB071|
434343|NCT00885183|Procedure|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
434344|NCT00885170|Drug|Odanacatib|Odanacatib 50 mg tablets once weekly for 24 months
434345|NCT00885170|Drug|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
434346|NCT00885170|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
434347|NCT00885170|Dietary Supplement|Calcium|Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
434348|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
434349|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
434350|NCT00885144|Dietary Supplement|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
434351|NCT00885144|Dietary Supplement|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
434352|NCT00885144|Dietary Supplement|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
434353|NCT00885144|Dietary Supplement|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
434354|NCT00885118|Drug|Placebo (middle dose)|Placebo tablets once a day
434359|NCT00885118|Drug|Placebo (high dose)|Placebo tablets once a day
434360|NCT00885118|Drug|BI 10773|BI 10773 low dose tablets once a day
434361|NCT00885118|Drug|Placebo (low dose)|Placebo tablets once a day
434362|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
434363|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
434364|NCT00885092|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
434365|NCT00885092|Device|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
434366|NCT00885092|Device|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
434367|NCT00885092|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
434368|NCT00885079|Drug|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
434369|NCT00885079|Drug|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
434370|NCT00885066|Drug|capecitabine|
434371|NCT00885066|Drug|erlotinib hydrochloride|
434372|NCT00885066|Drug|gemcitabine hydrochloride|
434373|NCT00885053|Dietary Supplement|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
434374|NCT00885053|Dietary Supplement|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
434375|NCT00885014|Behavioral|CBT|Telephone cognitive-behavioral therapy
434376|NCT00885014|Behavioral|EAP|Employees Assistance Program
434377|NCT00885001|Procedure|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
434378|NCT00884988|Drug|Lymphomyosot|20 drops X3/day, until discharge
434379|NCT00884988|Drug|Placebo remedy|20 drops X3/day, until discharge
434380|NCT00884962|Device|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
434381|NCT00884949|Drug|BMN 110|"Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:~Weeks 1-12: 0.1 mg/kg/week~Weeks 13-24: 1.0 mg/kg/week~Weeks 25-36: 2.0 mg/kg/week~Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week."
434382|NCT00884910|Device|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
434383|NCT00884897|Drug|Oxytocin|Oxytocin given as 20 IU BID
434384|NCT00884897|Drug|Placebo|Placebo given as 20 IU BID
434385|NCT00884884|Drug|Double Placebo|1 capsule daily
434386|NCT00884884|Drug|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
434387|NCT00884884|Drug|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
434388|NCT00884884|Drug|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
434389|NCT00884884|Drug|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
434390|NCT00884884|Drug|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
434391|NCT00884884|Drug|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
434392|NCT00884884|Drug|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
434393|NCT00884884|Drug|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
434394|NCT00884884|Drug|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
434395|NCT00884871|Procedure|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
434396|NCT00884858|Drug|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
434397|NCT00884845|Drug|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
434398|NCT00884845|Drug|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
434399|NCT00884832|Drug|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
434400|NCT00884832|Drug|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
434401|NCT00884819|Drug|Fenofibrate|fenofibrate 200 mg daily for 6-months
434402|NCT00884819|Other|Placebo|Placebo match for 6 months
434403|NCT00884806|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
434404|NCT00884806|Device|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
434405|NCT00884806|Device|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
434406|NCT00884806|Device|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
434407|NCT00884806|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
434408|NCT00884793|Drug|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
434409|NCT00884793|Drug|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
434471|NCT00884338|Other|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
434410|NCT00884793|Drug|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
434411|NCT00884767|Drug|FOLFOX regimen|
434412|NCT00884767|Drug|fluorouracil|
434413|NCT00884767|Drug|leucovorin calcium|
434414|NCT00884767|Drug|oxaliplatin|
434415|NCT00884767|Genetic|gene expression analysis|
434416|NCT00884767|Genetic|protein expression analysis|
434417|NCT00884767|Genetic|proteomic profiling|
434418|NCT00884767|Other|laboratory biomarker analysis|
434419|NCT00884767|Other|pharmacogenomic studies|
434420|NCT00884754|Device|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
434421|NCT00884741|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimentional conformal radiation therapy
434422|NCT00884741|Biological|Bevacizumab|Given IV
434423|NCT00884741|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
434424|NCT00884741|Other|Laboratory Biomarker Analysis|Correlative studies
434425|NCT00884741|Other|Placebo|Given IV
434426|NCT00884741|Other|Quality-of-Life Assessment|Ancillary studies
434427|NCT00884741|Drug|Temozolomide|Given orally
434428|NCT00884715|Drug|Octreotide|short acting octreotide
434429|NCT00884676|Drug|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:~Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)~Schedule B: Day 1 of each 3-week cycle."
434430|NCT00884676|Drug|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
434431|NCT00884663|Drug|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
434432|NCT00884663|Drug|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
434433|NCT00884663|Drug|placebo|placebo tablets and capsules
434434|NCT00884650|Drug|oral analgesic|per clinical standard of care
434435|NCT00884650|Drug|intravenous analgesic per pump|per clinical standard of care
434436|NCT00884611|Device|Predictive Low Glucose Suspend Algorithm ON|The algorithm uses a Kalman filter-based model to predict whether the sensor glucose level will fall below 80 mg/dL within a given time period and suspends the insulin pump if this event is predicted.
434437|NCT00884611|Device|Predictive Low Glucose Suspend Algorithm OFF|
434438|NCT00884598|Drug|cilengitide|
434439|NCT00884598|Other|pharmacological study|
434440|NCT00884598|Radiation|radiation therapy|
434441|NCT00884585|Drug|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
434442|NCT00884585|Drug|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
434443|NCT00884559|Other|instruction|Debriefing
434444|NCT00884546|Drug|BMS-833923|Capsule, Oral, Once daily, 6 months
434445|NCT00884546|Drug|Lenalidomide|Capsule, Oral, Once daily, 6 months
434446|NCT00884546|Drug|Dexamethasone|Capsule, Oral, Once a week, 6 months
434447|NCT00884546|Drug|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
434448|NCT00884533|Drug|Rosi XR|Rosi XR
434449|NCT00884533|Other|Placebo|Placebo
434450|NCT00884533|Drug|Moxifloxacin|400mg single dose
434451|NCT00884520|Drug|[F-18] VM4-037|"The individual doses of [F-18]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.~The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
434452|NCT00884507|Drug|Placebo|po daily for 24 weeks
434453|NCT00884507|Drug|RO5313534|1mg po daily for 24 weeks
434454|NCT00884507|Drug|RO5313534|5mg po daily for 24 weeks
434455|NCT00884507|Drug|RO5313534|15mg po daily for 24 weeks
434456|NCT00884494|Drug|Ghrelin infusion to assess effects on insulin sensitivity|
434457|NCT00884481|Other|Natalizumab|Participants treated with Tysabri
434458|NCT00884442|Drug|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
434459|NCT00884442|Drug|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
434460|NCT00884429|Procedure|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
434461|NCT00884429|Procedure|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
434462|NCT00884429|Procedure|3-Airway suction|Airway suction
434463|NCT00884416|Drug|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
434464|NCT00884390|Drug|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
434465|NCT00884390|Procedure|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
434466|NCT00884377|Drug|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
434467|NCT00884377|Device|ThermoMed|ThermoMed heat treatment device, one treatment
434468|NCT00884364|Other|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
434469|NCT00884364|Behavioral|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
434470|NCT00884338|Other|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
434578|NCT00883467|Procedure|no preconditioning|no preconditioning
434472|NCT00884325|Drug|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
434473|NCT00884325|Drug|placebo|One tablet taken orally at night for 28 days
434474|NCT00884312|Drug|Carfilzomib|Carfilzomib dose levels ranged from 11 to 27 mg/m² for 2- to 10-minute infusions and 36 to 56 mg/m² for 30-minute infusions. Carfilzomib doses were administered on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Dose level reduction to a minimum dose of 11 mg/m² for toxicity was permitted.
434475|NCT00884299|Dietary Supplement|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
434476|NCT00884286|Drug|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
434477|NCT00884273|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
434478|NCT00884273|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
434479|NCT00884273|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
434480|NCT00884260|Drug|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
434481|NCT00884234|Other|Vehicle Control|Two sequential doses of RT001 or Vehicle Control at Baseline (Day 0) and Week 2
434482|NCT00884234|Drug|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 or Vehicle Control at Baseline (Day 0) and Week 2
434483|NCT00884221|Drug|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
434484|NCT00884221|Drug|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.~NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
434485|NCT00884195|Behavioral|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
434486|NCT00884195|Behavioral|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
434487|NCT00884182|Biological|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
434488|NCT00884169|Drug|M518101|Proper quantity twice a day
434489|NCT00884169|Drug|placebo|Proper quantity twice a day
434490|NCT00884130|Procedure|laparoscopic colorectal resection|
434491|NCT00884130|Procedure|open colorectal resection|
434492|NCT00884117|Drug|Oseltamivir|Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
434493|NCT00884104|Drug|Solifenacin|Oral
434494|NCT00884078|Other|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
434495|NCT00884065|Other|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
434496|NCT00884065|Other|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
434497|NCT00884052|Drug|levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
434498|NCT00884052|Drug|levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
434499|NCT00884039|Drug|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
434500|NCT00884039|Drug|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
434574|NCT00883480|Drug|Docetaxel-Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
434575|NCT00883480|Drug|Gemcitabine-Cisplatin|"Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
434576|NCT00883480|Drug|Erlotinib|Erlotinib 150 mg/day x 21 days
434501|NCT00884026|Device|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
434502|NCT00884026|Device|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
434503|NCT00884000|Drug|Genotropin|
434504|NCT00884000|Drug|Zomacton|
434505|NCT00883974|Behavioral|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
434506|NCT00883961|Other|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
434507|NCT00883948|Behavioral|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
434508|NCT00883948|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
434509|NCT00883935|Drug|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
434510|NCT00883935|Drug|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
434511|NCT00883935|Drug|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
434512|NCT00883935|Drug|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
434513|NCT00883909|Drug|dutasteride|A follow-up study in adult male subjects who have received investigational product
434514|NCT00883896|Other|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
434515|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
434516|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
434517|NCT00883896|Other|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
434518|NCT00883896|Drug|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
434519|NCT00883883|Drug|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
434520|NCT00883883|Drug|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
434521|NCT00883870|Drug|mesenchymal stem cells|Intramuscular injection
434522|NCT00883870|Drug|Plasmalyte A|Intramuscular injection
434523|NCT00883844|Drug|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
434524|NCT00883844|Drug|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
434525|NCT00883831|Procedure|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
434526|NCT00883818|Drug|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
434527|NCT00883805|Biological|Blood draw|Subjects will give blood for analysis of metal ion concentrations
434528|NCT00883805|Radiation|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
434529|NCT00883792|Procedure|Colonoscopy|Once-only colonoscopy screening
434530|NCT00883779|Drug|Placebo|po on days 15-28 of each 4 week cycle until disease progression
434531|NCT00883779|Drug|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
434532|NCT00883779|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
434533|NCT00883779|Drug|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
434534|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days~Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)~Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound~Day before HCG: stop rFSH~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive~(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
434577|NCT00883467|Procedure|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
434535|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5~Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm~Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)~Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO~Day before HCG: stop rFSH + cetrorelix~Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)~Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C~Day 7 after pick-up: ultrasound, patient evaluation.~Day 14 after pick-up: HCG in blood~Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
434536|NCT00883753|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
434537|NCT00883740|Drug|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
434538|NCT00883740|Drug|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
434539|NCT00883727|Drug|Stem cell|IV infusion of stem cells
434540|NCT00883727|Drug|Plasmalyte A|IV infusion
434541|NCT00883714|Other|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
434542|NCT00883714|Other|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
434543|NCT00883688|Drug|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
434544|NCT00883688|Drug|Lapatinib|Pills of 700 mg/m^2/dose given orally 2 times each day.
434545|NCT00883675|Drug|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
434546|NCT00883662|Drug|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
434547|NCT00883649|Dietary Supplement|Hydroeye|2 Capsules BID
434548|NCT00883649|Other|Inactive Capsule|2 Capsules BID
434549|NCT00883636|Other|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
434550|NCT00883636|Other|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
434551|NCT00883636|Other|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
434552|NCT00883623|Drug|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
434553|NCT00883584|Drug|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
434554|NCT00883584|Drug|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
434555|NCT00883571|Procedure|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
434556|NCT00883571|Procedure|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
434557|NCT00883571|Procedure|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
434558|NCT00883558|Drug|Insulin Lispro|
434559|NCT00883558|Drug|regular human insulin|
434560|NCT00883558|Drug|recombinant human hyaluronidase PH20|
434561|NCT00883558|Drug|Insulin glargine|
434562|NCT00883545|Other|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
434563|NCT00883545|Other|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
434564|NCT00883532|Drug|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 < 30% or is extubated
434565|NCT00883532|Drug|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
434566|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
434567|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
434568|NCT00883506|Drug|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
434569|NCT00883506|Drug|Lisinopril 40 mg Tablet under fasting conditions.|
434570|NCT00883506|Drug|Lisinopril 40 mg Tablet under fed conditions.|
434571|NCT00883493|Drug|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
434572|NCT00883493|Drug|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
434573|NCT00883480|Drug|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
434579|NCT00883441|Other|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
434580|NCT00883428|Other|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
434581|NCT00883415|Drug|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
434582|NCT00883402|Procedure|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
434583|NCT00883389|Device|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
434584|NCT00883363|Procedure|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
434585|NCT00883350|Behavioral|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
434586|NCT00883337|Drug|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes~Subcutaneous injection~Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
434587|NCT00883337|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
434588|NCT00883311|Device|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
434589|NCT00883298|Drug|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 & 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 & 5 every 28-day cycle
434590|NCT00883272|Dietary Supplement|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
434591|NCT00883259|Drug|Metformin|850 mg twice daily
434592|NCT00883259|Other|Placebo|Microcristallyne cellulose 1 table twice daily
434593|NCT00883246|Device|SilverHawk & TurboHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
434594|NCT00883233|Drug|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
434595|NCT00883233|Drug|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
434596|NCT00883233|Drug|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
434597|NCT00883233|Drug|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
434598|NCT00883220|Behavioral|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
434599|NCT00883207|Behavioral|Psychotherapy|Narrative and dialogical approach for couples
434600|NCT00883194|Drug|PRF-108|Ropivacaine
434601|NCT00883194|Drug|Placebo|PRF-108 Placebo
434602|NCT00883194|Drug|Ropivacaine|Solution
434603|NCT00883194|Drug|PRF-110|
434604|NCT00883168|Drug|Placebo|Placebo
434605|NCT00883168|Drug|azelastineHcl|azelastine hydrochloride 548 mg
434606|NCT00883168|Drug|fluticasone propionate|fluticasone propionate 200 mcg
434607|NCT00883168|Drug|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
434608|NCT00883155|Drug|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
434609|NCT00883155|Drug|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
434610|NCT00883129|Drug|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
434611|NCT00883129|Drug|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
434612|NCT00883129|Drug|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
434613|NCT00883116|Drug|Ixabepilone|
434614|NCT00883116|Drug|Doxorubicin|
434615|NCT00883116|Drug|Paclitaxel|
434616|NCT00883103|Drug|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
434617|NCT00883103|Drug|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
434618|NCT00883090|Biological|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
434619|NCT00883064|Drug|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
434620|NCT00883064|Drug|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
434669|NCT00882713|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
434621|NCT00883051|Drug|COL-144|Oral application of one dose of either COL-144 50 mg, COL-144 100 mg, COL-144 200 mg, COL-144 400 mg or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
434622|NCT00883051|Drug|Placebo|Placebo
434623|NCT00883038|Other|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
434624|NCT00883038|Other|low-fat vegetarian diet|The low-fat vegetarian diet (~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
434625|NCT00883012|Biological|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:~Active substance:~Split Influenza virus*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms**, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms**, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms** Two doses, one month apart"
434626|NCT00883012|Biological|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
434627|NCT00882999|Drug|LY2127399|Administered via Injection
434628|NCT00882999|Drug|Placebo|Administered via Injection
434629|NCT00882973|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
434630|NCT00882960|Drug|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
434631|NCT00882960|Drug|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
434632|NCT00882947|Drug|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
434633|NCT00882934|Other|Induction to efficient treatment|Informative letters.
434634|NCT00882934|Other|Doubt to the efficacy of treatment|Informative letters.
434635|NCT00882934|Other|Induction to ineffective treatment|Informative letters
434636|NCT00882921|Biological|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
434637|NCT00882908|Drug|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
434638|NCT00882908|Drug|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
434639|NCT00882908|Drug|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
434640|NCT00882908|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
434641|NCT00882895|Procedure|Stem cell infusion|
434642|NCT00882895|Procedure|TLI|
434643|NCT00882895|Drug|Anti-thymocyte globulin|
434644|NCT00882895|Drug|Solumedrol|
434645|NCT00882895|Drug|Tacrolimus|
434646|NCT00882895|Drug|Mycophenolate mofetil|
434647|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
434648|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
434649|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
434650|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
434651|NCT00882869|Drug|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
434652|NCT00882869|Drug|Sorafenib|Sorafenib will be administered at 400 mg BID every day
434653|NCT00882856|Drug|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
434654|NCT00882856|Drug|Placebo|placebo
434655|NCT00882830|Procedure|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
434656|NCT00882817|Other|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
434657|NCT00882804|Drug|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in ~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
434658|NCT00882804|Drug|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
434659|NCT00882778|Drug|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
434660|NCT00882765|Dietary Supplement|genistein|Given orally
434661|NCT00882752|Procedure|molecular analysis|bowel disease
434662|NCT00882739|Drug|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
434663|NCT00882739|Drug|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
434664|NCT00882739|Drug|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
434665|NCT00882726|Drug|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
434666|NCT00882726|Drug|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
434667|NCT00882726|Drug|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
434668|NCT00882726|Drug|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
434670|NCT00882700|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
434671|NCT00882700|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
434672|NCT00882687|Drug|Lifitegrast|Ophthalmic Solution
434673|NCT00882687|Other|Placebo|Ophthalmic Solution
434674|NCT00882674|Drug|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
434675|NCT00882661|Device|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
434676|NCT00882661|Device|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
434677|NCT00882635|Drug|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.~Maintenance dose adjustment for renal insufficiency - creatinine clearance < 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
434678|NCT00882635|Drug|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
434679|NCT00882622|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
434680|NCT00882622|Procedure|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
434681|NCT00882609|Device|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
434682|NCT00882596|Device|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
434683|NCT00882583|Drug|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
434684|NCT00882583|Drug|Dasatinib|Oral Dasatinib Days 8 through 64.
434685|NCT00882583|Drug|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
434686|NCT00882583|Radiation|Radiation Therapy|Standard Radiation Therapy.
434687|NCT00882570|Drug|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
434688|NCT00882570|Drug|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
434689|NCT00882557|Drug|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
434690|NCT00882557|Drug|daptomycin|6 mg/kg administered after a hemodialysis session
434691|NCT00882531|Drug|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
434692|NCT00882531|Drug|placebo|
434693|NCT00882518|Drug|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|200 mg or 300 mg, oral, single dose
434694|NCT00882518|Drug|Chlorpromazine|50 mg, oral, double dose
434695|NCT00882505|Dietary Supplement|vitamin D|Subject will receive vitamin d supplements
434696|NCT00882505|Other|Placebo|Subject will receive a placebo.
434697|NCT00882492|Biological|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
434698|NCT00882492|Biological|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
434699|NCT00882466|Drug|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
434700|NCT00882453|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
434701|NCT00882440|Drug|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
434702|NCT00882440|Drug|Placebo|Placebo capsule to losartan
434703|NCT00882440|Drug|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
434704|NCT00882427|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
434705|NCT00882414|Drug|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
434706|NCT00882414|Drug|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
434707|NCT00882401|Drug|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
434708|NCT00882401|Drug|Placebo|Matching placebo at same dose schedule as ergocalciferol
434709|NCT00882388|Drug|aspirin|aspirin 100 mg qd for 7 days
434710|NCT00882388|Drug|celecoxib|celecoxib 200 mg bid * 7 days
434711|NCT00882388|Drug|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
434712|NCT00882388|Drug|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
434713|NCT00882388|Drug|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
434714|NCT00882375|Drug|Nicotine|Nicotine administered using novel NRT user instructions
434715|NCT00882375|Drug|Placebo|Placebo administered using novel NRT user instructions
434716|NCT00882362|Drug|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
434717|NCT00882323|Drug|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)~fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)~thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
434718|NCT00882310|Drug|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
434719|NCT00882310|Drug|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
434720|NCT00882310|Drug|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
434721|NCT00882297|Procedure|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
434722|NCT00882271|Other|Acupuncture|Ten Acupuncture treatments within six weeks
434723|NCT00882258|Drug|12.5 mg Proellex|12.5 mg Proellex administered orally daily
434724|NCT00882258|Drug|25 mg Proellex|25 mg Proellex administered orally daily
434725|NCT00882258|Drug|Placebo|Administered orally daily
434726|NCT00882245|Other|Vehicle ointment|Topical vehicle cream
434727|NCT00882245|Drug|Ointment|SRD441 Ointment
434728|NCT00882232|Device|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
434729|NCT00882219|Device|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
434730|NCT00882206|Drug|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.~*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
434731|NCT00882206|Drug|decitabine|Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
434732|NCT00882206|Drug|doxorubicin hydrochloride|Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
434733|NCT00882206|Drug|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age <18 years and 400 mg orally every day for >18 years on Days 5-33.
434734|NCT00882206|Drug|methotrexate|**Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
434735|NCT00882206|Drug|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
434736|NCT00882206|Drug|prednisone|40mg/m2/day divided BID (days 5 - 33)
434737|NCT00882206|Drug|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
434738|NCT00882206|Drug|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
434739|NCT00882193|Drug|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
434740|NCT00882193|Drug|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
434741|NCT00882193|Drug|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight < or > 75mg in 2 divided doses
434742|NCT00882180|Drug|ALN-VSP02|IV infusion administered every two weeks
434743|NCT00882167|Other|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
434744|NCT00882154|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
434745|NCT00882154|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
434746|NCT00882141|Behavioral|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
434747|NCT00882141|Behavioral|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
434748|NCT00882115|Drug|Broccoli sprout extract (BSE)|BSE will be ingested by drinking a liquid formula containing 1.25 g BSE in a volume equaling 1 cup daily for 4 consecutive days in the BSE intervention phase.
434749|NCT00882102|Drug|Decitabine|Decitabine 20 mg/m^2 IV over 1-1/2 hours daily for 5 days.
434750|NCT00882102|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m^2 IV on day 5.
434751|NCT00882089|Device|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
434752|NCT00882076|Drug|Clofarabine|For Treatment Clofarabine will be administered on Days 2-6 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Clofarabine will be administered on Days 1-4 at the dose of 20mg/m2 in Cohort 1, 25mg/m2 in Cohort 2 and 30mg/m2 in Cohort 3 and 4 and 10mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
434753|NCT00882076|Drug|Mitoxantrone|For Treatment Mitoxantrone will be administered on Days 1-3 at the dose of 8mg/m2 in Cohort 1, 2, 3 and on Days 1-5 for Cohort 4 and on Days 1-3 8mg/m2 in Cohort 0 (In the event of excessive DLT in Treatment Cohort 1). For Retreatment Mitoxantrone will be administered on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 1, 2 and 3 and on Days 1-4 (4 doses) at the dose of 8mg/m2 in Cohort 4, and on Days 1-2 (2 doses) at the dose of 8mg/m2 in Cohort 0 (In the event of excessive DLT in Retreatment Cohort 1).
434754|NCT00882076|Drug|Etoposide|For Treatment Etoposide will be administered on Days 1-5 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Treatment Cohort 1). For Retreatment Etoposide will be administered on Days 1-4 at the dose of 100mg/m2 in Cohort 1, 2, 3, 4 and Cohort 0 (in the event of excessive DLT in Retreatment Cohort 1).
434755|NCT00882063|Drug|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
434756|NCT00882050|Drug|Exenatide|Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.
434757|NCT00882050|Drug|Exenatide|Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours
434758|NCT00882050|Drug|Placebo|Intravenous Placebo of normal saline solution to be infused at same rate as drug comparator
434759|NCT00882024|Drug|Tranilast|150 mg tranilast tablets, bid, 12 weeks
434760|NCT00882024|Drug|Tranilast|75 mg tablets, bid, 12 weeks
434761|NCT00882024|Drug|Placebo|Placebo tablets, bid, 12 weeks
434762|NCT00882011|Other|Latest generation chemotherapies for T-LBL + transplant|"Standard doses of one of the following chemotherapies:~Holzer~LSA2-L2 modified~Stanford regimen~Hyper CVAD~Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)~Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)~Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
434763|NCT00881998|Procedure|Minimally Invasive Total Hip Arthroplasty|
434764|NCT00881998|Procedure|Conventional Total Hip Arthroplasty|
434765|NCT00881985|Device|continuous positive airway pressure|Use CPAP whenever sleep
434766|NCT00881972|Behavioral|Exercise|walking/running/cycling
434767|NCT00881959|Device|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
434768|NCT00881946|Drug|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
434769|NCT00881933|Other|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, & -2) (if body weight < 10 kg or if age < 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, & -8) total body irradiation (3G on days -1)
434770|NCT00881920|Biological|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10^7 cells/m^2 CAR-Kappa~Group 2: 1x10^8 cells/m^2 CAR-Kappa~Group 3: 2x10^8 cells/m^2 CAR-Kappa"
434771|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
434772|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
434773|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
434774|NCT00881894|Drug|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm^2 patch applied for 24 hours
434775|NCT00881868|Drug|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
434776|NCT00881868|Drug|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
434777|NCT00881855|Drug|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
434778|NCT00881855|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
434779|NCT00881842|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
434780|NCT00881829|Device|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
434781|NCT00881816|Drug|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
434782|NCT00881790|Other|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
434783|NCT00881777|Procedure|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
434784|NCT00881777|Procedure|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
434785|NCT00881764|Procedure|Inguinal hernia surgery|Non-experimental procedure
434786|NCT00881764|Procedure|General anesthesia|Non-experimental procedure/treatment
434787|NCT00881751|Biological|bevacizumab|Given IV
434788|NCT00881751|Drug|erlotinib hydrochloride|Given orally
434789|NCT00881751|Drug|sorafenib tosylate|Given orally
434790|NCT00881738|Drug|Clarithromycin 250 mg Tablets (Geneva, USA)|
434791|NCT00881738|Drug|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
434792|NCT00881725|Drug|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
434793|NCT00881712|Radiation|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
434794|NCT00881712|Radiation|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
434795|NCT00881712|Radiation|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
434796|NCT00881699|Behavioral|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
434887|NCT00881023|Device|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
434797|NCT00881699|Behavioral|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
434798|NCT00881686|Drug|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
434799|NCT00881673|Drug|AL38583 Ophthalmic Solution|Topical ophthalmic
434800|NCT00881673|Drug|Maxidex|Topical ophthalmic
434801|NCT00881673|Drug|Vehicle|AL38583 Vehicle
434802|NCT00881660|Device|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
434803|NCT00881647|Other|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
434804|NCT00881634|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
434805|NCT00881634|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
434806|NCT00881621|Drug|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
434807|NCT00881608|Drug|Placebo|Placebo, 1 capsule daily for five days
434808|NCT00881608|Drug|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
434809|NCT00881595|Drug|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
434810|NCT00881595|Radiation|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
434811|NCT00881595|Procedure|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
434812|NCT00881582|Drug|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 & 4: 48 weeks; genotypes 2 & 3: 24 weeks)
434813|NCT00881569|Drug|CS-7017|CS-7017 tablets twice daily at strength 0.25mg
434814|NCT00881556|Drug|Reduced Intensity Transplant conditioning|"Palifermin (Kepivance®) 60 mcg/kg/day for 6 days~Fludarabine 30 mg/m2 IV x 1 for 6 days~Busulfan 4 mg/kg/day IV divided BID for 4 days~Lorazepam 0.02-0.05 mg/kg for 5 days~Alemtuzumab 20 mg/m2 IV for 5 days~Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days"
434815|NCT00881543|Drug|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
434816|NCT00881530|Drug|BI 10773|BI 10773 high dose once daily
434817|NCT00881530|Drug|Metformin|open label comparator
434818|NCT00881530|Drug|BI 10773|BI 10773 low dose once daily
434819|NCT00881530|Drug|Sitagliptin|open label comparator
434820|NCT00881517|Drug|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
434821|NCT00881517|Drug|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
434822|NCT00881504|Drug|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay > 4 weeks
434823|NCT00881491|Drug|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
434824|NCT00881491|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
434825|NCT00881491|Drug|Mineral Trioxide Aggregate|standard material providing an apical barrier
434826|NCT00881478|Other|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
434827|NCT00881478|Other|Nutrition counseling|Nutrition counseling with registered dietician
434828|NCT00881465|Behavioral|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
434829|NCT00881465|Behavioral|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
434830|NCT00881452|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
434831|NCT00881452|Drug|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
434832|NCT00881439|Drug|Aliskiren|Oral, 300 mg, once daily, 6 months
434833|NCT00881439|Drug|Placebo|Matching Placebo once daily, 6 months
434834|NCT00881426|Drug|Cefprozil 500 mg Tablets (Sandoz GmbH)|
434835|NCT00881426|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
434836|NCT00881413|Drug|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
434931|NCT00880646|Dietary Supplement|Oolong tea containing L-arabinose and indigestible dextrin|
434932|NCT00880646|Dietary Supplement|Oolong tea (Placebo)|
434837|NCT00881413|Drug|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
434838|NCT00881400|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
434839|NCT00881400|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
434840|NCT00881387|Biological|rituximab|Given IV
434841|NCT00881387|Drug|gemcitabine hydrochloride|Given IV
434842|NCT00881387|Drug|vinorelbine ditartrate|Given IV
434843|NCT00881374|Drug|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
434844|NCT00881361|Drug|systemic chemotherapy|
434845|NCT00881361|Procedure|axillary lymph node dissection|
434846|NCT00881361|Procedure|neoadjuvant therapy|
434847|NCT00881361|Procedure|sentinel lymph node biopsy|
434848|NCT00881361|Procedure|therapeutic conventional surgery|
434849|NCT00881361|Procedure|ultrasound imaging|
434850|NCT00881348|Drug|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
434851|NCT00881335|Device|flutter mucus clearance device|five minutes every sessions, three sessions per day
434852|NCT00881322|Dietary Supplement|BC-130 (Gas Defense)|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
434853|NCT00881322|Dietary Supplement|Placebo|"Product Dosing:~Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)~Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule"
434854|NCT00881309|Drug|Tripterygium|TW 90mg/d
434855|NCT00881296|Drug|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
434856|NCT00881296|Drug|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
434857|NCT00881270|Drug|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
434858|NCT00881257|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
434859|NCT00881244|Drug|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
434860|NCT00881231|Drug|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
434861|NCT00881231|Drug|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
434862|NCT00881218|Drug|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
434863|NCT00881205|Drug|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
434864|NCT00881205|Drug|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
434865|NCT00881192|Procedure|IABP|preoperative IABP placement
434866|NCT00881179|Drug|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
434867|NCT00881179|Drug|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
434868|NCT00881166|Drug|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
434869|NCT00881166|Drug|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
434870|NCT00881166|Drug|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
434871|NCT00881166|Drug|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
434872|NCT00881166|Drug|MP-470 + carboplatin/etoposide|Carboplatin IV infustion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100mg/m2 IV infustion over 2 hours on Days 1-3
434873|NCT00881153|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
434874|NCT00881153|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
434875|NCT00881140|Drug|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
434876|NCT00881127|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
434877|NCT00881127|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
434878|NCT00881114|Drug|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
434879|NCT00881114|Drug|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
434880|NCT00881101|Drug|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
434881|NCT00881088|Drug|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
434882|NCT00881088|Drug|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
434883|NCT00881075|Drug|SeeMore(TM)|single dose intravenous injectable
434884|NCT00881062|Drug|Proellex|A single oral dose administered after at least a 10 hour fast
434885|NCT00881049|Drug|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
434886|NCT00881023|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
434933|NCT00880620|Drug|Placebo|Placebo
434888|NCT00881010|Behavioral|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
434889|NCT00881010|Behavioral|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
434890|NCT00880997|Drug|Doxazosin|"Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17."
434891|NCT00880997|Other|Placebo|Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
434892|NCT00880984|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
434893|NCT00880971|Radiation|3D conform radiotherapy|3D conform radiotherapy, 2 Gy per fraction, total 25 fractions (50Gy).
434894|NCT00880958|Dietary Supplement|Mixture of various probiotics and fermentation products|
434895|NCT00880958|Dietary Supplement|Placebo|
434896|NCT00880932|Behavioral|Electronic Alert|
434897|NCT00880919|Drug|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
434898|NCT00880919|Drug|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
434899|NCT00880906|Procedure|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
434900|NCT00880906|Drug|Steroid and Proton Pump Inhibitor Therapy|
434901|NCT00880893|Biological|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
434902|NCT00880893|Biological|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
434903|NCT00880880|Other|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
434904|NCT00880867|Drug|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
434905|NCT00880854|Drug|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15~Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15~Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15~Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
434906|NCT00880841|Drug|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
434907|NCT00880828|Other|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
434908|NCT00880828|Other|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
434909|NCT00880828|Drug|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
434910|NCT00880815|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo ASCT
434911|NCT00880815|Biological|Anti-Thymocyte Globulin|Given IV
434912|NCT00880815|Drug|Bendamustine|Given IV
434913|NCT00880815|Biological|Filgrastim|Given IV
434914|NCT00880815|Drug|Fludarabine|Given IV
434915|NCT00880815|Drug|Methotrexate|Given IV
434916|NCT00880815|Biological|Rituximab|Given IV
434917|NCT00880815|Drug|Tacrolimus|Given IV and PO
434918|NCT00880789|Biological|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
434919|NCT00880763|Drug|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
434920|NCT00880763|Drug|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
434921|NCT00880763|Drug|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
434922|NCT00880763|Drug|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
434923|NCT00880750|Drug|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
434924|NCT00880750|Drug|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
434925|NCT00880724|Device|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
434926|NCT00880698|Biological|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IUs per aggregate dose
434927|NCT00880698|Biological|Placebo|2 mL solution
434928|NCT00880685|Drug|Memantine|10-30mg, daily for 8 weeks
434929|NCT00880672|Drug|dutasteride|5mg, oral, daily, 2-4 weeks
434930|NCT00880659|Behavioral|Soap|Promotion of handwashing with soap
434934|NCT00880620|Drug|IPX066 95 mg LD|IPX066 capsule containing 95 mg LD/23.75 mg CD
434935|NCT00880620|Drug|IPX066 145 mg LD|IPX066 capsule containing 145 mg LD/36.25 mg CD
434936|NCT00880620|Drug|IPX066 195 mg LD|IPX066 capsule containing 195 mg LD/48.75 mg CD
434937|NCT00880620|Drug|IPX066 245 mg LD|IPX066 capsule containing 245 mg LD/61.25 mg CD
434938|NCT00880607|Drug|DepoDur™|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
434939|NCT00880594|Drug|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
434940|NCT00880581|Drug|PF-3512676|18 mg injection
434941|NCT00880581|Radiation|Local radiotherapy|2 gray (2 Gy) on each of Days 1 and 2
434942|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
434943|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
434944|NCT00880542|Drug|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
434945|NCT00880542|Drug|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
434946|NCT00880529|Device|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
434947|NCT00880529|Drug|IV opioid administration|Patient controlled analgesia with IV narcotics
434948|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
434949|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
434950|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
434951|NCT00880490|Drug|Inhaled placebo|single dose, inhaled
434952|NCT00880490|Drug|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
434953|NCT00880477|Biological|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
434954|NCT00880477|Biological|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
434955|NCT00880477|Biological|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
434956|NCT00880464|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
434957|NCT00880412|Drug|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
434958|NCT00880412|Drug|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
434959|NCT00880399|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
434960|NCT00880399|Other|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
434961|NCT00880386|Drug|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
434962|NCT00880373|Drug|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
434963|NCT00880373|Drug|Placebo|Matching placebo three times daily for 4 days
434964|NCT00880373|Drug|Diamorphine or Morphine|Diamorphine or Morphine by PCA
434965|NCT00880360|Drug|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
434966|NCT00880347|Device|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
434967|NCT00880334|Drug|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
434968|NCT00880334|Drug|vandetanib|taken orally once a day, every day
434969|NCT00880334|Drug|Placebo|Taken orally once a day every day
434970|NCT00880321|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
434971|NCT00880321|Drug|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
434972|NCT00880321|Drug|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
434973|NCT00880308|Drug|LDE225|
434974|NCT00880295|Procedure|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
434975|NCT00880295|Procedure|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
434976|NCT00880282|Biological|cixutumumab|Given IV
434977|NCT00880282|Drug|temsirolimus|Given IV
434978|NCT00880282|Other|pharmacological study|Correlative studies
434979|NCT00880282|Other|laboratory biomarker analysis|Correlative studies
434980|NCT00880269|Drug|Panobinostat/LBH589|
434981|NCT00880256|Behavioral|mindfulness-based stress reduction|An 8-week course in mindfulness training
434982|NCT00880243|Drug|GM-CSF|"Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.~Randomiization 2: Consolidation high dose AraC versus consolidation EMA"
434983|NCT00880230|Device|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
434984|NCT00880217|Drug|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
434985|NCT00880217|Drug|Placebo|Placebo capsule once daily for 42 days
434986|NCT00880217|Drug|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
434987|NCT00880217|Drug|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
434988|NCT00880217|Drug|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
434989|NCT00880217|Drug|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
434990|NCT00880204|Behavioral|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
434991|NCT00880191|Drug|dexamethasone|Given orally
434992|NCT00880191|Drug|gabapentin|Given orally
434993|NCT00880191|Other|placebo|Given orally
434994|NCT00880178|Drug|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
434995|NCT00880178|Drug|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
434996|NCT00880165|Device|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
434997|NCT00880152|Behavioral|Mindfulness-based stress reduction|An 8-week course in mindfulness training
434998|NCT00880139|Procedure|Blood sampling|Determination of cytokine plasma levels (ELISA)
434999|NCT00880139|Procedure|Noninvasive measurement of systemic hemodynamics|performed once
435000|NCT00880139|Procedure|Visual acuity assessment|ETDRS charts
435001|NCT00880139|Device|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
435002|NCT00880139|Procedure|Ophthalmic examination and fundus photography|7 + 1 standard fields
435003|NCT00880139|Device|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
435004|NCT00880139|Device|High resolution optical coherence tomography (OCT)|performed once
435005|NCT00880126|Behavioral|Community Development Teams|CDTs bring together counties who are implementing a new practice
435006|NCT00880113|Procedure|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
435007|NCT00880100|Drug|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
435008|NCT00880087|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
435009|NCT00880087|Procedure|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
435010|NCT00880074|Radiation|PET Scan|3 Positron Emission Tomography (PET) scans performed 60-90 minutes after intravenous injection of FLT: 1) within 2 weeks before day 1 of chemotherapy treatment; 2) day 6-7 of chemotherapy treatment; and,3) at end of chemotherapy treatment, day 19-20.
435011|NCT00880074|Drug|FLT|FLT solution is administered through a peripheral intravenous catheter approximately 60 minutes before the PET scan. Dosage of FLT in the range between 1 and 10 mCi.
435012|NCT00880061|Drug|IL13-PE38QQR|
435013|NCT00880048|Drug|orvepitant|neurokinin-1 antagonist
435014|NCT00880048|Other|Placebo|Placebo to match orvepitant 30 mg and 60 mg
435015|NCT00880035|Device|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
435016|NCT00880022|Device|Flexitouch System|( 10 to 30 treatments depending on group assignment)
435017|NCT00880009|Drug|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
435018|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
435019|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
435020|NCT00879996|Drug|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
435021|NCT00879996|Drug|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
435022|NCT00879983|Drug|azithromycin (Zithromax)|"a single dose of azithromycin ER 2g~3-day regimen of azithromycin tablet 500mg"
435023|NCT00879983|Drug|azithromycin (Zithromax)|"3-day regimen of azithromycin tablet 500mg~a single dose of azithromycin ER 2g"
435024|NCT00879970|Drug|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
435025|NCT00879970|Drug|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
435026|NCT00879970|Drug|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
435027|NCT00879970|Dietary Supplement|Vitamin D|Vitamin D factor intervention
435940|NCT00873119|Drug|carboplatin, paclitaxel|
435028|NCT00879970|Dietary Supplement|Placebo|Vitamin D factor intervention
435029|NCT00879957|Drug|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
435030|NCT00879957|Drug|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
435031|NCT00879944|Other|Blood pressure|Blood pressure will be measured once while patient is seated
435032|NCT00879944|Other|Height|Height will be measured in centimeters at the time of enrollment
435033|NCT00879944|Other|Weight|Weight will be measured in kilograms at enrollment
435034|NCT00879944|Other|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
435035|NCT00879944|Other|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
435036|NCT00879931|Drug|Methylprednisolone|Methylprednisolone
435037|NCT00879931|Drug|Placebo|Placebo (NaCl 0.9%)
435038|NCT00879918|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
435039|NCT00879905|Drug|HSP990|
435040|NCT00879892|Drug|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
435041|NCT00879892|Other|Hypothermia|24 hour, target core temperature 33
435042|NCT00879879|Drug|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
435043|NCT00879866|Biological|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
435044|NCT00879853|Behavioral|Interpersonal Therapy|
435045|NCT00879827|Biological|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
435046|NCT00879827|Biological|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
435047|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
435048|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
435049|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
435050|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
435051|NCT00879788|Drug|Ramipril 10mg capsules|
435052|NCT00879775|Drug|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
435053|NCT00879775|Drug|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
435054|NCT00879762|Biological|IMVAMUNE® High Dose|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10^8 TCID50 (5×10^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
435055|NCT00879762|Drug|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
435056|NCT00879762|Biological|IMVAMUNE® Standard Dose|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10^8 tissue culture infectious dose 50 [TCID50] per 0.5 mL dose)
435057|NCT00879749|Biological|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
435058|NCT00879749|Biological|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
435059|NCT00879749|Biological|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
435060|NCT00879749|Biological|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
435061|NCT00879749|Biological|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
435062|NCT00879749|Other|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
435063|NCT00879736|Behavioral|THT PACE Training|Patient training
435064|NCT00879736|Behavioral|THT PACE Training|Patient training
435065|NCT00879736|Other|placebo|
435066|NCT00879723|Dietary Supplement|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.~Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
435067|NCT00879710|Drug|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
435068|NCT00879697|Behavioral|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
435069|NCT00879697|Behavioral|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
435070|NCT00879684|Biological|CVX-060|Weekly, intravenous dose
435071|NCT00879671|Dietary Supplement|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
435072|NCT00879671|Dietary Supplement|placebo|Placebo capsules identical in taste and appearance
435073|NCT00879658|Drug|BAF312|
435074|NCT00879658|Drug|Placebo|
435075|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
435076|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
435077|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
435078|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
435079|NCT00879619|Drug|sunitinib malate|Given PO
435080|NCT00879619|Drug|docetaxel|Given IV
435081|NCT00879619|Drug|prednisone|Given PO
435082|NCT00879606|Drug|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
435083|NCT00879606|Drug|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
435084|NCT00879593|Device|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
435085|NCT00879554|Biological|CVX-045|Weekly, intravenous dose
435086|NCT00879541|Biological|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
435087|NCT00879541|Biological|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
435088|NCT00879541|Biological|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
435089|NCT00879528|Other|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET:~PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
435090|NCT00879528|Other|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.~After the end of salvage therapy, consolidation depends on the outcome of PET~PET positive, the consolidation therapy consists of 2 phases:~phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells~phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.~If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
435091|NCT00879489|Biological|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
435092|NCT00879476|Drug|Ramipril 10mg capsules|
435093|NCT00879463|Procedure|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
435094|NCT00879463|Procedure|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
435095|NCT00879450|Other|Booklet|booklet given to parents for home exercises
435096|NCT00879437|Drug|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
435097|NCT00879437|Drug|Bevacizumab|All patients will receive bevacizumab (10mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
435098|NCT00879437|Radiation|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. the total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
435099|NCT00879424|Dietary Supplement|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
435100|NCT00879424|Dietary Supplement|Placebo|"1000 IU once daily x 1 month~Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
435101|NCT00879411|Drug|Micardis|
435102|NCT00879398|Drug|Toviaz treatment|4 mg starting then can be followed by 8 mg
435103|NCT00879385|Drug|Dacogen™ (decitabine)|"Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs"
435104|NCT00879385|Drug|Vectibix® (panitumumab)|"Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr"
435105|NCT00879372|Drug|tianeptine|tianeptine 12,5mg TID
435106|NCT00879372|Drug|Placebo|Placebo 12.5 mg TID
435107|NCT00879359|Drug|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
435108|NCT00879346|Drug|AZD8931|160mg oral single dose (4 x 40mg tablets)
436928|NCT00866294|Drug|paroxetine IR 20mg tablet|1 tablet once a day
435109|NCT00879333|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
435110|NCT00879333|Drug|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
435111|NCT00879333|Drug|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
435112|NCT00879307|Drug|quetiapine|Use of quetiapine for 16 weeks in acute mania and depression
435113|NCT00879294|Device|Motion sickness wristband|No drugs are involved.
435114|NCT00879294|Dietary Supplement|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
435115|NCT00879281|Behavioral|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
435116|NCT00879268|Device|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
435117|NCT00879255|Behavioral|Cognitive Processing Therapy Group Videoteleconference|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.
435118|NCT00879255|Behavioral|Cognitive Processing Therapy Group In-Person|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
435119|NCT00879242|Drug|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
435120|NCT00879229|Drug|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
435121|NCT00879229|Drug|Placebo|Placebo to match ambrisentan administered orally once daily.
435122|NCT00879216|Drug|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
435123|NCT00879216|Drug|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
435124|NCT00879190|Drug|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
435125|NCT00879190|Drug|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
435126|NCT00879177|Drug|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
435127|NCT00879177|Behavioral|behavioral therapy|confirmed negative smoking status at different time points
435128|NCT00879164|Drug|bupivacaine hydrochloride|
435129|NCT00879164|Other|questionnaire administration|
435130|NCT00879151|Behavioral|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
435131|NCT00879151|Behavioral|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
435132|NCT00879151|Behavioral|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
435133|NCT00879138|Drug|VA106483|
435134|NCT00879138|Drug|Sugar pill|
435135|NCT00879112|Drug|MB07811|Oral
435136|NCT00879112|Drug|Placebo|Oral
435137|NCT00879099|Drug|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
435138|NCT00879099|Drug|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
435139|NCT00879099|Drug|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
435140|NCT00879099|Drug|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
435141|NCT00879086|Drug|eribulin mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m^2 as a 2 - 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
435142|NCT00879086|Drug|ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.~The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
435143|NCT00879073|Drug|Bendamustine|Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
435144|NCT00879060|Drug|spironolactone|spironolactone 50mg daily
435145|NCT00879047|Drug|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
435146|NCT00879047|Drug|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
435147|NCT00879034|Drug|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
435273|NCT00878150|Behavioral|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
435148|NCT00879034|Drug|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
435149|NCT00879034|Drug|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
435150|NCT00879021|Drug|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
435151|NCT00879021|Drug|matching placebo|150 mg by mouth ,twice a day for 49 weeks
435152|NCT00879008|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
435153|NCT00878995|Drug|Placebo Testosterone|Placebo (Saline) Testosterone given IM once per week.
435154|NCT00878995|Drug|Testosterone Enanthate 100 MG/ML|Testosterone Enanthate 100mg/ml given once per week IM.
435155|NCT00878969|Drug|valsartan (ARB)|
435156|NCT00878969|Drug|ramipril (ACE inhibitor)|
435157|NCT00878969|Drug|Placebo|
435158|NCT00878956|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
435159|NCT00878956|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
435160|NCT00878943|Drug|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
435161|NCT00878917|Drug|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
435162|NCT00878904|Drug|epirubicin hydrochloride|
435163|NCT00878904|Drug|panobinostat|
435164|NCT00878904|Genetic|gene expression analysis|
435165|NCT00878904|Genetic|protein expression analysis|
435166|NCT00878904|Genetic|western blotting|
435167|NCT00878904|Other|immunologic technique|
435168|NCT00878904|Other|laboratory biomarker analysis|
435169|NCT00878904|Other|pharmacological study|
435170|NCT00878891|Device|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
435171|NCT00878878|Drug|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
435172|NCT00878878|Drug|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.~Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
435173|NCT00878865|Drug|Alprazolam|1 mg tablet one oral dose
435174|NCT00878865|Drug|Alprazolam|1 mg tablet
435175|NCT00878852|Behavioral|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
435176|NCT00878852|Behavioral|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
435177|NCT00878839|Device|Toric|AcrySof Toric IOL
435178|NCT00878826|Drug|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
435179|NCT00878813|Procedure|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
435180|NCT00878813|Procedure|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
435181|NCT00878800|Drug|PXD101|Administered in combination with doxorubicin (BelDox)
435182|NCT00878800|Drug|Doxorubicin|Administered in combination with PXD101 (BelDox)
435183|NCT00878787|Device|Transcranial magnetic stimulation|
435184|NCT00878774|Biological|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
435185|NCT00878774|Biological|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
435186|NCT00878761|Biological|STX-100|SC, single dose followed by multiple dose
435187|NCT00878748|Drug|Effexor XR|
435188|NCT00878748|Other|Effexor XR discontinue|
435189|NCT00878735|Behavioral|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
435190|NCT00878722|Drug|PXD101|
435191|NCT00878722|Drug|idarubicin|
435192|NCT00878709|Drug|neratinib|
435193|NCT00878709|Other|placebo|
435274|NCT00878150|Behavioral|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
435194|NCT00878696|Procedure|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).~The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.~Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
435195|NCT00878683|Device|silicone catheter boot|silicone device using Dermabond
435196|NCT00878670|Drug|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
435197|NCT00878657|Drug|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
435198|NCT00878657|Radiation|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:~Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
435199|NCT00878644|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
435200|NCT00878644|Other|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
435201|NCT00878631|Drug|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
435202|NCT00878631|Drug|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
435203|NCT00878618|Drug|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
435204|NCT00878618|Drug|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
435205|NCT00878605|Drug|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
435206|NCT00878605|Drug|Placebo|Placebo control
435207|NCT00878592|Behavioral|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
435208|NCT00878579|Device|PDS System|Percutaneous Dynamic Stabilization System
435209|NCT00878579|Device|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
435210|NCT00878566|Other|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
435211|NCT00878566|Other|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
435212|NCT00878553|Drug|placebo|tablet at bedtime
435213|NCT00878553|Drug|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
435214|NCT00878540|Drug|mirtazapine|30 mg mirtazapine once daily for 7 days
435215|NCT00878527|Device|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
435216|NCT00878514|Drug|Alprazolam|Alprazolam 1 mg tablet
435217|NCT00878514|Drug|Xanax|Xanax 1 mg tablet
435218|NCT00878501|Drug|AZD1386|oral, during 4 weeks
435219|NCT00878501|Drug|AZD1386|oral, during 4 weeks
435220|NCT00878501|Drug|Placebo|Oral, during 4 weeks
435221|NCT00878462|Drug|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
435222|NCT00878462|Drug|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
435223|NCT00878462|Drug|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
435224|NCT00878449|Drug|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
435225|NCT00878449|Drug|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
435226|NCT00878436|Drug|Panobinostat|
435227|NCT00878436|Drug|Bicalutamide|
435228|NCT00878423|Drug|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
435312|NCT00877864|Behavioral|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
435229|NCT00878423|Drug|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
435230|NCT00878397|Device|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
435231|NCT00878384|Drug|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of <80bpm and <110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
435232|NCT00878384|Procedure|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
435233|NCT00878371|Drug|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
435234|NCT00878358|Other|Hydrotherapy|
435235|NCT00878358|Other|Physiotherapy|
435236|NCT00878345|Drug|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
435237|NCT00878345|Drug|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.~May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
435238|NCT00878319|Procedure|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using dynamic compression plate
435239|NCT00878319|Other|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
435240|NCT00878306|Drug|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
435241|NCT00878306|Drug|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
435242|NCT00878306|Drug|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
435243|NCT00878306|Drug|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
435244|NCT00878293|Drug|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
435245|NCT00878293|Drug|MS Continus®|60 mg, capsule, once daily
435246|NCT00878293|Drug|Placebo|liquid formulation and capsule, once daily
435247|NCT00878267|Behavioral|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
435248|NCT00878254|Biological|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously (SQ) starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4, per study protocol.
435249|NCT00878254|Drug|Rituximab|Rituximab 375 mg/m^2 intravenously (IV) on Day 1 for 4 Cycles, per study protocol. For study participants achieving complete remission, during maintenance therapy every 6 months for up to three years, per study protocol.
435250|NCT00878254|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m^2 IV on Day 1 and 200 mg/m^2 IV on Days 2 through 5 of Cycles 1 and 3, per study protocol.
435251|NCT00878254|Drug|Cytarabine|Cytarabine 2 grams/m^2 IV on Days 1 and 2 of Cycles 2 and 4, per study protocol.
435252|NCT00878254|Drug|Doxorubicin|Doxorubicin 45 mg/m^2 IV bolus Day 1 of Cycles 1 and 3, per study protocol.
435253|NCT00878254|Drug|Etoposide|Etoposide 60 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
435254|NCT00878254|Drug|Ifosfamide|Ifosfamide 1.5 grams/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
435255|NCT00878254|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is < 0.1 µmol/L during Cycles 1 and 3 per study protocol.
435256|NCT00878254|Drug|Mesna|Mesna 360 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
435257|NCT00878254|Drug|Methotrexate|Methotrexate 1,200 mg/m^2 in 250 mL D5W IV over 1 hour, followed by Methotrexate 3,000 mg/m^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3, per study protocol.
435258|NCT00878254|Drug|Vincristine|Vincristine 1.5 mg/m^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3, per study protocol.
435259|NCT00878241|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
435260|NCT00878228|Drug|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
435261|NCT00878228|Drug|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
435262|NCT00878215|Device|Explorer Liver Image Guided System|
435263|NCT00878215|Device|Explorer Liver Passive Tracking|
435264|NCT00878215|Procedure|Liver surgery|-Standard of care
435265|NCT00878215|Procedure|Liver abalation|-Standard of care
435266|NCT00878202|Device|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
435267|NCT00878189|Drug|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
435268|NCT00878176|Procedure|First stage tined lead procedure|bilateral first stage tined lead placement
435269|NCT00878163|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
435270|NCT00878163|Drug|Erlotinib Hydrochloride|Given PO
435271|NCT00878163|Drug|Gemcitabine Hydrochloride|Given IV
435272|NCT00878163|Drug|Vismodegib|Given PO
437606|NCT00861497|Drug|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
435275|NCT00878137|Device|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
435276|NCT00878124|Dietary Supplement|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
435277|NCT00878124|Other|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
435278|NCT00878111|Drug|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min*~Second cohort: iv q3W 80 mcg/sqm over 120 min*~Third cohort: iv q3W 100 mcg/sqm over 120 min*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min*~* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
435279|NCT00878085|Device|Robot Therapy Device|3x a week for 4 weeks
435280|NCT00878085|Behavioral|Occupational Therapy|3x a week for 4 weeks
435281|NCT00878072|Drug|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
435282|NCT00878046|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
435283|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose, 1 day
435284|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
435285|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
435286|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
435287|NCT00878007|Drug|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
435288|NCT00878007|Behavioral|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness & vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
435289|NCT00878007|Other|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
435290|NCT00877994|Behavioral|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
435291|NCT00877994|Behavioral|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
435292|NCT00877981|Procedure|Minimal invasive Parathyroid surgery|
435293|NCT00877968|Dietary Supplement|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 62.8 g Available CHO: 51.7 g"
435294|NCT00877968|Dietary Supplement|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 67.8 g Available CHO: 52.0 g"
435295|NCT00877968|Dietary Supplement|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 79.8 g Available CHO: 53.1 g"
435296|NCT00877968|Dietary Supplement|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 86 g Available CHO: 51.7 g"
435297|NCT00877968|Dietary Supplement|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion (Dry): 70 g Available CHO: 51.1 g"
435298|NCT00877968|Dietary Supplement|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum~Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
435299|NCT00877968|Dietary Supplement|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g Available CHO: 50 g"
435300|NCT00877968|Dietary Supplement|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate~Portion: 100 g (dry) --> 250 g cooked Available CHO: 52.8 g"
435301|NCT00877955|Drug|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
435302|NCT00877955|Drug|alprazolam sublingual tablet test|0.5 mg tablet, single dose
435303|NCT00877929|Drug|Telmisartan 80|Telmisartan 80 mg
435304|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
435305|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
435306|NCT00877903|Drug|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
435307|NCT00877903|Drug|Placebo|Intravenous infusion of excipients of Prochymal®
435308|NCT00877890|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
435309|NCT00877890|Drug|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
435310|NCT00877877|Procedure|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
435311|NCT00877864|Behavioral|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
435313|NCT00877864|Behavioral|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
435314|NCT00877864|Behavioral|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
435315|NCT00877864|Behavioral|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
435316|NCT00877864|Behavioral|Control|No exercise program provided by the study
435317|NCT00877851|Behavioral|CD-ROM|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the CD−ROM and some instructions on how to navigate around the different sections of the CD−ROM. As a minimum level of use, participants will be asked to use the self−monitoring and goal setting aspects of the CD−ROM on at least a weekly basis.
435318|NCT00877838|Drug|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
435319|NCT00877838|Drug|Placebo|Gelatin capsules resembling the ones containing the active substance
435320|NCT00877825|Procedure|dairy food control diet and high- and low- isoflavone soyfood diets|
435321|NCT00877812|Dietary Supplement|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
435322|NCT00877812|Dietary Supplement|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
435323|NCT00877799|Drug|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
435324|NCT00877799|Drug|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
435325|NCT00877799|Drug|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
435326|NCT00877799|Drug|Placebo|Matched placebo administered the day after surgery (Day 1)
435327|NCT00877799|Drug|Placebo|Matched placebo administered immediately after surgery (Day 0)
435328|NCT00877786|Behavioral|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
435329|NCT00877773|Drug|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
435330|NCT00877760|Drug|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
435331|NCT00877760|Drug|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
435332|NCT00877734|Drug|baclofen|10 mg Baclofen administered tid for 11 weeks
435333|NCT00877734|Drug|placebo|Placebo administered tid for 11 weeks
435334|NCT00877734|Behavioral|BRENDA counseling|
435335|NCT00877721|Device|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
435336|NCT00877695|Behavioral|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
435337|NCT00877682|Procedure|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
435338|NCT00877669|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
435339|NCT00877669|Procedure|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
435340|NCT00877656|Biological|HuMax-CD4|Active treatment
435341|NCT00877643|Other|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
435342|NCT00877643|Other|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
435343|NCT00877617|Behavioral|QOL Questionnaire|Mailed survey.
435344|NCT00877604|Drug|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
435345|NCT00877604|Drug|Placebo|identical placebo by oral route at the same dosing schedule
435346|NCT00877591|Drug|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
435347|NCT00877591|Drug|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
435348|NCT00877591|Drug|Rifampin|600 mg once daily for 15 days total
435349|NCT00877591|Drug|Rifabutin|300 mg once daily for 15 days total
435350|NCT00877591|Drug|Buprenorphine|"FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days~DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days~RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days~RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days"
435351|NCT00877578|Dietary Supplement|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
435352|NCT00877578|Dietary Supplement|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
435353|NCT00877539|Drug|PF-03526299|Inhaled, two doses 4 hours apart
435354|NCT00877539|Drug|Placebo|Inhaled, two doses 4 hours apart
435355|NCT00877539|Drug|Fluticasone propionate|Inhaled
435356|NCT00877526|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
435357|NCT00877513|Behavioral|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
435358|NCT00877500|Other|Best Practice|Receive standard of care
435359|NCT00877500|Drug|Ixabepilone|Given IV
435360|NCT00877487|Drug|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
435361|NCT00877487|Drug|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
435362|NCT00877474|Drug|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
435363|NCT00877448|Biological|Adjuvanted Multimeric-001 250 Mcg|
435364|NCT00877448|Biological|Multimeric-001 250 Mcg|
435365|NCT00877448|Biological|Phosphate Buffered saline|
435366|NCT00877448|Biological|Adjuvanted PBS|
435367|NCT00877448|Biological|Adjuvanted Multimeric-001 500 Mcg|
435368|NCT00877448|Biological|Multimeric-001 500 Mcg|
435369|NCT00877448|Biological|Multimeric-001 125 Mcg|
435370|NCT00877435|Behavioral|Cognitive behavioral therapy (CBT)|
435371|NCT00877422|Dietary Supplement|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
435372|NCT00877409|Drug|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
435373|NCT00877409|Drug|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
435374|NCT00877396|Biological|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
435375|NCT00877396|Biological|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
435376|NCT00877383|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
435377|NCT00877383|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
435378|NCT00877383|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
435379|NCT00877370|Drug|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
435380|NCT00877357|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
435381|NCT00877344|Procedure|Immediate insertion|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
435382|NCT00877344|Procedure|Interval insertion|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
435383|NCT00877331|Behavioral|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
435384|NCT00877318|Device|SCAD information system|Cardiac rehabilitation at home by telemedicine
435385|NCT00877305|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
435386|NCT00877305|Other|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
435387|NCT00877279|Device|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
435388|NCT00877279|Device|Belotero Soft|Dermal Filler
435389|NCT00877266|Procedure|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
435390|NCT00877253|Drug|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
435391|NCT00877253|Drug|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
435392|NCT00877253|Drug|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
435506|NCT00876356|Dietary Supplement|Olive oil|Olive oil 4.5g/day x 12 weeks
435507|NCT00876343|Drug|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
435393|NCT00877240|Behavioral|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
435394|NCT00877227|Drug|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
435395|NCT00877214|Drug|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
435396|NCT00877214|Drug|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
435397|NCT00877201|Drug|CDR2|
435398|NCT00877188|Other|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
435399|NCT00877175|Drug|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
435400|NCT00877162|Behavioral|Controlled crying and routines|Behavioural (teaching and support)
435401|NCT00877149|Drug|telbivudine/LDT600|
435402|NCT00877136|Device|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
435403|NCT00877123|Drug|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
435404|NCT00877123|Drug|Placebo|similar placebo once a month for three consecutive months
435405|NCT00877110|Drug|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
435406|NCT00877097|Drug|Klodronate and Kliogest|
435407|NCT00877097|Procedure|Placebo+ Kliogest|
435408|NCT00877097|Drug|Bonefos|
435409|NCT00877084|Other|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
435410|NCT00877084|Other|Usual care|usual care according to clinical pathway for COPD, No training
435411|NCT00877071|Drug|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
435412|NCT00877058|Behavioral|preventive home visit|
435413|NCT00877058|Behavioral|senior meetings|
435414|NCT00877032|Biological|RN6G|intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
435415|NCT00877032|Biological|Placebo|intravenous, single dose with experimental dose.
435416|NCT00877019|Device|Sonicare elite medium brush head|
435417|NCT00877019|Device|Sonicare elite mini brushhead|
435418|NCT00877019|Device|GABA Elmex sensitive extra soft toothbrush|
435419|NCT00877019|Device|ADA reference toothbrush|
435420|NCT00877006|Drug|bendamustine|
435421|NCT00877006|Drug|rituximab|
435422|NCT00877006|Drug|vincristine|
435423|NCT00877006|Drug|prednisone|
435424|NCT00877006|Drug|cyclophosphamide|
435425|NCT00877006|Drug|doxorubicin|
435426|NCT00876993|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
435427|NCT00876993|Drug|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
435428|NCT00876993|Drug|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
435429|NCT00876980|Device|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
435430|NCT00876967|Device|metallic single use blade|metallic single use blade
435431|NCT00876967|Device|plastic single use blade|plastic single use blade
435432|NCT00876967|Device|metallic reusable blade|metallic reusable blade
435433|NCT00876954|Procedure|Normothermia|Warming without increase in core temperature
435434|NCT00876954|Procedure|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
435435|NCT00876941|Behavioral|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.~Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.~Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.~Contacts, Duration: One, 10-15 minutes.~Communication content delivered to primary care physician: Results of screening and BI.~Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
435436|NCT00876941|Behavioral|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.~Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.~Counselor: Master's level/Doctoral student.~Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.~Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.~Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.~Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
435437|NCT00876941|Behavioral|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
435438|NCT00876928|Drug|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
435439|NCT00876928|Drug|placebo|medium chain triglyceride given once per week
435440|NCT00876915|Drug|dalteparin injection|Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
435441|NCT00876902|Drug|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
435442|NCT00876902|Drug|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
435443|NCT00876889|Drug|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
435444|NCT00876876|Drug|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
435445|NCT00876863|Drug|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 X 10^11 vg
435446|NCT00876863|Procedure|Placebo Surgery|Placebo Surgery
435447|NCT00876850|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
435448|NCT00876850|Drug|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
435449|NCT00876824|Drug|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
435450|NCT00876824|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
435451|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
435452|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
435453|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
435454|NCT00876798|Drug|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
435455|NCT00876798|Drug|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
435456|NCT00876785|Other|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
435457|NCT00876785|Other|wheat bread based breakfast|Reference wheat bread breakfast
435458|NCT00876772|Drug|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
435459|NCT00876759|Radiation|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
435460|NCT00876759|Radiation|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
435461|NCT00876746|Procedure|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
435462|NCT00876720|Device|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
435463|NCT00876720|Device|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
435464|NCT00876707|Device|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
435465|NCT00876707|Device|ReSTOR implant|Implant of multifocal IOL ReSTOR
435466|NCT00876707|Device|ReZoom implant|Implant of multifocal IOL ReZoom
435467|NCT00876694|Drug|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
435468|NCT00876694|Drug|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
435469|NCT00876681|Procedure|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
435470|NCT00876655|Drug|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
435471|NCT00876655|Drug|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
435472|NCT00876642|Drug|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
435473|NCT00876629|Device|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.~The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
435474|NCT00876616|Drug|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
435475|NCT00876616|Drug|Cyclophosphamide|CTX 0.75g/m2 BSA
435476|NCT00876603|Procedure|ACDF|Anterior cervical decompression and fusion
435477|NCT00876603|Procedure|Cervical laminoplasty|Cervical laminoplasty
435478|NCT00876577|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
435479|NCT00876564|Other|Trauma patients|
435480|NCT00876551|Procedure|Endoscopic vacuum assisted closure|"Endoscopic debridement of wound using a regular biopsy forceps.~Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)~Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson & Johnson, St-Stevens-Woluwe, Belgium).~Trimming of the sponge to the specific wound size.~Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)~Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).~Sponge exchange twice a week until wound grounds are clean and closed"
435481|NCT00876538|Drug|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
435482|NCT00876538|Drug|Placebo Control|Placebo Control 2 capsules once day with the noon meal
435483|NCT00876525|Device|Freedom SOLO|The Freedom SOLO heart valve prosthesis is a stentless bioprosthesis manufactured with bovine pericardium.
435484|NCT00876499|Behavioral|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
435485|NCT00876486|Drug|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
435486|NCT00876486|Drug|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
435487|NCT00876473|Procedure|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange~CPAP systems:~Continuous high-flow CPAP with fixed value PEEP valve~Continuous high-flow CPAP with Boussignac valve~Demand flow CPAP supplied by ventilator"
435488|NCT00876460|Drug|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
435489|NCT00876460|Drug|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
435490|NCT00876460|Drug|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
435491|NCT00876460|Drug|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
435492|NCT00876460|Drug|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
435493|NCT00876447|Biological|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
435494|NCT00876447|Biological|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
435495|NCT00876434|Drug|Sirolimus|
435496|NCT00876421|Drug|Placebo|Placebo / 12 weeks
435497|NCT00876421|Drug|Tolterodine|4mg / 12 weeks
435498|NCT00876421|Drug|ONO-8539|low dose / 12 weeks
435499|NCT00876421|Drug|ONO-8539|medium dose / 12 weeks
435500|NCT00876421|Drug|ONO-8539|higher dose / 12 weeks
435501|NCT00876395|Drug|Everolimus|Everolimus was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
435502|NCT00876395|Drug|Placebo|Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
435503|NCT00876395|Drug|Trastuzumab|Trastuzumab, 2 mg/kg weekly was used intravenously.
435504|NCT00876395|Drug|Paclitaxel|Paclitaxel, 80 mg/m2 weekly was used intravenously.
435505|NCT00876356|Dietary Supplement|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
435508|NCT00876343|Drug|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
435509|NCT00876343|Drug|Placebo|administered orally once daily, 6 weeks
435510|NCT00876330|Other|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
435511|NCT00876330|Other|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
435512|NCT00876330|Other|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
435513|NCT00876330|Other|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
435514|NCT00876317|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
435515|NCT00876317|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
435516|NCT00876304|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
435517|NCT00876304|Drug|Placebo|Placebo capsules every 12 hours for 10 days
435518|NCT00876291|Dietary Supplement|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
435519|NCT00876291|Dietary Supplement|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
435520|NCT00876278|Device|*AT.Smart 46LC|Primary implantation of *AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
435521|NCT00876265|Device|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
435522|NCT00876265|Device|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
435523|NCT00876252|Biological|IC43|
435524|NCT00876252|Drug|Placebo|NaCl
435525|NCT00876226|Drug|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.~Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
435526|NCT00876200|Drug|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
435527|NCT00876200|Drug|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.~Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
435528|NCT00876187|Biological|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
435529|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
435530|NCT00876187|Biological|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
435531|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
435532|NCT00876187|Biological|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
435533|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
435534|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
435535|NCT00876187|Drug|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
435536|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
435537|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
435538|NCT00876174|Procedure|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
435539|NCT00876174|Procedure|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
435540|NCT00876161|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
435541|NCT00876161|Drug|Lactose|
435542|NCT00876135|Drug|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
435543|NCT00876122|Drug|GDC-0941|Escalating oral dose
435544|NCT00876109|Drug|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
435545|NCT00876096|Other|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
435546|NCT00876083|Drug|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
435547|NCT00876057|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy
435548|NCT00876057|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
435549|NCT00876044|Drug|aflibercept (AVE0005)|Intravenous route
435550|NCT00876044|Drug|placebo|Intravenous route
437607|NCT00861484|Drug|GSK958108|Coated Tablets 1 mg
435551|NCT00876031|Drug|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
435552|NCT00876018|Other|Nutritional supplement|Fortified nutritional powder
435553|NCT00876018|Other|Placebo|Un-fortified nutritional powder
435554|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
435555|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
435556|NCT00875992|Device|ETN with ASLS|Angle stable locking of ETN using ASLS
435557|NCT00875992|Device|ETN locked with conventional locking bolts|Conventional surgical procedure
435558|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
435559|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
435560|NCT00875979|Drug|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
435561|NCT00875966|Drug|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
435562|NCT00875966|Drug|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
435563|NCT00875953|Procedure|standard neck dissection|standard surgical technique
435564|NCT00875953|Procedure|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
435565|NCT00875940|Other|Diagnostic imaging procedures.|
435566|NCT00875927|Other|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
435567|NCT00875927|Other|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
435568|NCT00875927|Other|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
435569|NCT00875927|Other|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
435570|NCT00875927|Other|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
435571|NCT00875914|Procedure|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
435572|NCT00875901|Radiation|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
435573|NCT00875901|Radiation|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
435574|NCT00875888|Device|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
435575|NCT00875875|Drug|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
435576|NCT00875862|Procedure|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
435577|NCT00875849|Biological|cetuximab|
435578|NCT00875849|Drug|cisplatin|
435579|NCT00875849|Radiation|radiation therapy|
435580|NCT00875836|Drug|Buspirone|Flexible dose, up to 60 mg daily
435581|NCT00875836|Drug|Placebo|Flexible dose, up to 60 mg daily
435582|NCT00875797|Dietary Supplement|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
435583|NCT00875797|Dietary Supplement|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
435584|NCT00875784|Drug|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
435585|NCT00875784|Drug|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
435586|NCT00875784|Drug|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
435587|NCT00875784|Drug|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
435588|NCT00875771|Drug|Capecitabine+Irinotecan+Bevacizumab|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks~Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks~Bevacizumab: 5 mg/kg day 1, every 2 Weeks~Treatment will be given until disease progression or unacceptable toxicity."
435589|NCT00875758|Procedure|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
435590|NCT00875758|Procedure|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
435591|NCT00875745|Drug|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
435592|NCT00875732|Device|Bi Ventricular Pacing|
435593|NCT00875732|Device|Right Ventricular Pacing|
435594|NCT00875719|Device|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
435595|NCT00875719|Device|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
435596|NCT00875706|Behavioral|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
435597|NCT00875693|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
435598|NCT00875680|Device|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
435599|NCT00875667|Drug|Lenalidomide|"For patients with a creatinine clearance of ≥ 60 mL/min: 25 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.~For patients who have a moderate renal insufficiency (creatinine clearance is ≥ 30 mL/min but < 60mL/min: 10 mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15 mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
435600|NCT00875667|Drug|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
435601|NCT00875654|Genetic|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume<100ml) less than 6 weeks after stroke
435602|NCT00875641|Other|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
435603|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
435604|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
435605|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
435606|NCT00875615|Drug|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
435607|NCT00875615|Drug|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
435608|NCT00875615|Drug|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
435609|NCT00875602|Device|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
435610|NCT00875563|Device|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
435611|NCT00875550|Drug|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
435612|NCT00875550|Drug|Midazolam|Rescue medication for sedation according to UMSS scores
435613|NCT00875550|Drug|Fentanyl|Rescue medication for pain based on UMSS scores
435614|NCT00875550|Drug|Morphine|Rescue medication for pain based on UMSS scores.
435615|NCT00875537|Other|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
435616|NCT00875537|Other|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
435617|NCT00875524|Biological|CYD dengue vaccine serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
435618|NCT00875524|Biological|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
435619|NCT00875498|Procedure|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.~80% MT, 20 sessions of 6 minutes, 2 per day"
435620|NCT00875498|Procedure|sham iTBS|iTBS placebo (placebo coil)
435621|NCT00875485|Procedure|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
435622|NCT00875485|Biological|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
435623|NCT00875459|Drug|VIAject™|Subcutaneous injection 25 IU/mL
435624|NCT00875446|Drug|PLACEBO|Placebo
435625|NCT00875446|Drug|GSK1223249|I.V Infusion
435626|NCT00875433|Drug|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
435627|NCT00875420|Drug|RAD1901|10 mg Oral once a day for 28 days.
435628|NCT00875420|Drug|RAD1901|25 mg Oral once a day for 28 days
435629|NCT00875420|Drug|RAD1901|50 mg Oral once a day for 28 days.
435630|NCT00875420|Drug|RAD1901|100 mg Oral once a day for 28 days
435631|NCT00875420|Drug|Placebo|Placebo Oral once a day for 28 days
435632|NCT00875407|Other|Scintigraphy in 123I-IBZM|
435633|NCT00875394|Drug|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
435634|NCT00875394|Drug|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
435635|NCT00875394|Drug|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
435636|NCT00875394|Drug|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
435637|NCT00875368|Drug|maraviroc|maraviroc dose dependent on co-medication
435638|NCT00875368|Drug|Placebo|Placebo drug
435639|NCT00875355|Drug|temozolomide|Given orally
435640|NCT00875355|Radiation|radiation therapy|Patients undergo radiotherapy
435641|NCT00875342|Drug|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
435642|NCT00875342|Other|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
435643|NCT00875316|Drug|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
435644|NCT00875303|Behavioral|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
435645|NCT00875303|Behavioral|Control|Routine primary care.
435646|NCT00875290|Device|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
435647|NCT00875277|Drug|LEO 29102 cream and combination products|Once daily application 6 days a week for 4 weeks
435648|NCT00875264|Drug|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
435649|NCT00875251|Device|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
435650|NCT00875238|Biological|trastuzumab|
435651|NCT00875238|Drug|doxorubicin hydrochloride|
435652|NCT00875238|Genetic|polymorphism analysis|
435653|NCT00875238|Other|laboratory biomarker analysis|
435654|NCT00875238|Other|questionnaire administration|
435655|NCT00875238|Procedure|assessment of therapy complications|
435656|NCT00875238|Procedure|magnetic resonance imaging|
435657|NCT00875225|Behavioral|DVD|Control group will receive usual care DVD from health professionals
435658|NCT00875225|Behavioral|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
435659|NCT00875212|Drug|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
435660|NCT00875212|Drug|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
435661|NCT00875212|Drug|fluoride|use of a dentifrice containing fluoride (1500ppm) only
435662|NCT00875212|Drug|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
435663|NCT00875199|Behavioral|contingency management|Prize-based contingency management for weight loss
435664|NCT00875199|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
435665|NCT00875186|Other|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
435666|NCT00875186|Other|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
435667|NCT00875173|Drug|Selenium|selenium as a drug according to Brazilian regulation laws
435668|NCT00875173|Drug|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
435669|NCT00875160|Drug|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
435670|NCT00875147|Drug|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
435671|NCT00875134|Other|Verbal prompt|Patient hears a voice recording
435672|NCT00875134|Other|Skin Stimulus|Patient receives either a skin stimulus
435673|NCT00875108|Drug|VIAject™|Subcutaneous injection 25 IU/mL
435674|NCT00875082|Drug|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
435675|NCT00875082|Drug|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
435676|NCT00875069|Other|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
435677|NCT00875056|Drug|vorinostat|MK0683 (200 mg capsule) Oral, twice daily (400 mg/day) for Day 1 through 14 of a 21 day cycle
435678|NCT00875030|Drug|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
435679|NCT00875030|Drug|Arsuamoon|single dose 50 mg arsuamoon tablet
435680|NCT00875017|Drug|Lanthanum Carbonate|1 x 1000mg tablet
435681|NCT00875017|Drug|Sevelamer|3 x 800mg tablets
435682|NCT00875004|Biological|epoetin beta|
435683|NCT00875004|Drug|systemic chemotherapy|
435684|NCT00875004|Procedure|quality-of-life assessment|
435685|NCT00874978|Drug|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
435686|NCT00874965|Device|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
435687|NCT00874965|Device|Sham stimulation|30 min; 5 times / week
435688|NCT00874939|Drug|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
435689|NCT00874939|Drug|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
435690|NCT00874939|Drug|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
435691|NCT00874939|Drug|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
435692|NCT00874939|Drug|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
435693|NCT00874926|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
435694|NCT00874913|Device|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
435695|NCT00874900|Other|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
435785|NCT00874237|Drug|Inhaled loxapine|Inhaled Staccato Loxapine 10 mg single dose
435696|NCT00874900|Other|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
435697|NCT00874900|Other|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
435698|NCT00874887|Drug|moxifloxacin 0.5% HCI ophthalmic solution|1 drop in study eye three times a day for 14 days
435699|NCT00874887|Drug|gatifloxacin ophthalmic solution 0.3%|1 drop in study eye four times a day for 14 days
435700|NCT00874874|Drug|sorafenib tosylate|
435701|NCT00874861|Biological|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.~Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical & Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
435702|NCT00874848|Biological|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
435703|NCT00874848|Biological|Cetuximab|initial loading dose of 400 mg/m^2 over 120 min and subsequent doses at 250 mg/m^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
435704|NCT00874848|Drug|Paclitaxel|200 mg/m^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
435705|NCT00874848|Drug|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
435706|NCT00874835|Device|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
435707|NCT00874809|Device|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
435708|NCT00874796|Drug|GS-9450|Taken as one capsule by mouth once daily
435709|NCT00874796|Drug|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
435710|NCT00874770|Drug|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
435711|NCT00874770|Drug|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
435712|NCT00874770|Drug|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
435713|NCT00874770|Drug|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
435714|NCT00874770|Drug|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
435715|NCT00874770|Drug|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
435716|NCT00874744|Drug|Bevacizumab|1.25mg bevacizumab (0.05ml)
435717|NCT00874744|Drug|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
435718|NCT00874731|Drug|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
435719|NCT00874731|Drug|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
435720|NCT00874731|Drug|Placebo|Part 1: A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
435721|NCT00874718|Behavioral|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
435722|NCT00874718|Behavioral|General education|Non-specific educational program for general health.
435723|NCT00874692|Other|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
435724|NCT00874679|Drug|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
435725|NCT00874666|Other|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
435726|NCT00874666|Dietary Supplement|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
435727|NCT00874653|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
435728|NCT00874640|Biological|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
435729|NCT00874627|Other|Milk|sublingual administration of milk
435730|NCT00874627|Other|Milk|placebo
435731|NCT00874614|Radiation|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
435732|NCT00874601|Drug|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
435733|NCT00874588|Biological|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
435734|NCT00874575|Dietary Supplement|Placebo|
435735|NCT00874575|Dietary Supplement|Vitamin D|
435736|NCT00874575|Dietary Supplement|Beta-hydroxy-Beta-methylbutyrate|
435737|NCT00874575|Drug|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
435738|NCT00874562|Drug|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
435739|NCT00874562|Drug|Rapamycin|Taken orally mixed with water or orange juice
435740|NCT00874549|Biological|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
435741|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
435742|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
435743|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
435744|NCT00874536|Dietary Supplement|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
435745|NCT00874536|Dietary Supplement|Placebo|
435746|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
435747|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
435748|NCT00874510|Behavioral|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
435749|NCT00874497|Drug|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
435750|NCT00874497|Drug|placebo|Placebo for 104 weeks (2 years)
435751|NCT00874484|Drug|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
435752|NCT00874458|Procedure|magnetic resonance imaging|
435753|NCT00874458|Procedure|radiomammography|
435754|NCT00874458|Procedure|ultrasound imaging|
435755|NCT00874445|Device|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
435756|NCT00874432|Drug|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
435757|NCT00874432|Drug|lisinopril|1 x 40 mg per day
435758|NCT00874419|Drug|erlotinib|erlotinib 150 mg oral, once a day
435759|NCT00874419|Drug|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
435760|NCT00874406|Drug|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
435761|NCT00874406|Drug|folfox4|folfox4 will be done within 28 days after liver resection
435762|NCT00874393|Drug|Dopamine|Dopamine
435763|NCT00874393|Drug|Hydrocortisone|Hydrocortisone
435764|NCT00874393|Drug|Infusion Placebo|Dextrose (D5W)
435765|NCT00874393|Drug|Syringe Placebo|Normal saline
435766|NCT00874380|Other|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
435767|NCT00874354|Drug|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
435768|NCT00874341|Other|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
435769|NCT00874328|Drug|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
435770|NCT00874328|Drug|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
435771|NCT00874328|Drug|TS-1 (S-1)|TS-1 po D1~D14 q 3 weeks until maximum 6 cycles
435772|NCT00874315|Other|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
435773|NCT00874315|Drug|busulfan|0.8 mg/kg/dose for total of 8 doses.
435774|NCT00874315|Drug|cyclosporine|1.5 mg/kg/dose every 12 hours.
435775|NCT00874315|Drug|fludarabine phosphate|30 mg/m2/day for 5 days.
435776|NCT00874315|Drug|mycophenolate mofetil|15 mg/kg/dose every 8 hours
435777|NCT00874315|Drug|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
435778|NCT00874315|Procedure|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
435779|NCT00874302|Drug|Proellex|One 25mg capsule taken orally once every day.
435780|NCT00874302|Drug|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
435781|NCT00874289|Other|NGAL kit|Kit to test NGAL levels in heart failure patients
435782|NCT00874276|Drug|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
435783|NCT00874276|Genetic|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
435784|NCT00874250|Device|GORE CTAG Device|Endovascular aortic stent-graft
435786|NCT00874237|Drug|Inhaled placebo|Inhaled Staccato placebo single dose
435787|NCT00874237|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg
435788|NCT00874237|Drug|Oral placebo|Oral placebo similar in appearance to moxifloxacin 400 mg
435789|NCT00874224|Procedure|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
435790|NCT00874224|Procedure|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
435791|NCT00874211|Procedure|assessment of therapy complications|By dental and medical assessments.
435792|NCT00874198|Procedure|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system [pressure settings: 30 - 200 mmH20]
435793|NCT00874172|Drug|Rapid optimized analgesic strategy|"Oral treatment :~1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
435794|NCT00874172|Drug|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy~1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
435795|NCT00874159|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
435796|NCT00874146|Genetic|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
435797|NCT00874133|Procedure|Acupuncture|Acupuncture treatment for 12 weeks.
435798|NCT00874133|Drug|Motilium|20 mg motilium thrice daily
435799|NCT00874120|Drug|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
435800|NCT00874120|Drug|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
435801|NCT00874107|Biological|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
435802|NCT00874107|Biological|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
435803|NCT00874107|Drug|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
435804|NCT00874107|Drug|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
435805|NCT00874094|Biological|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
435806|NCT00874068|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
435807|NCT00874068|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
435808|NCT00874042|Drug|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
435809|NCT00874029|Device|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
435810|NCT00874016|Device|Airtraq|Intubation using Airtraq
435811|NCT00874016|Device|Direct Laryngoscopy|Intubation using direct laryngoscopy
435812|NCT00874003|Drug|mirtazapine|oral tablet, 30 mg daily
435813|NCT00874003|Drug|placebo|oral tablet, 1 daily
435814|NCT00873990|Other|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
435815|NCT00873990|Other|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
435816|NCT00873977|Device|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
435817|NCT00873951|Other|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
435818|NCT00873951|Dietary Supplement|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
435819|NCT00873951|Dietary Supplement|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
435820|NCT00873951|Dietary Supplement|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
435821|NCT00873925|Biological|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
435822|NCT00873925|Dietary Supplement|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
435938|NCT00873145|Procedure|HMRS|Modular prosthetic replacement of the humerus and elbow.
435823|NCT00873925|Dietary Supplement|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
435824|NCT00873912|Biological|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
435825|NCT00873912|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
435826|NCT00873899|Device|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
435827|NCT00873886|Drug|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.~A) Subject will take 75 mg of oseltamivir pill by mouth~B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
435828|NCT00873886|Procedure|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
435829|NCT00873860|Other|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
435830|NCT00873860|Biological|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
435831|NCT00873860|Biological|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
435832|NCT00873860|Biological|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
435833|NCT00873834|Drug|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.~A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
435834|NCT00873834|Drug|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
435835|NCT00873821|Drug|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
435836|NCT00873821|Drug|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
435837|NCT00873808|Drug|clodronate disodium|
435838|NCT00873808|Drug|demeclocycline hydrochloride|
435839|NCT00873808|Drug|ibandronate sodium|
435840|NCT00873808|Drug|tetracycline hydrochloride|
435841|NCT00873808|Drug|zoledronic acid|
435842|NCT00873808|Other|laboratory biomarker analysis|
435843|NCT00873808|Procedure|adjuvant therapy|
435844|NCT00873808|Procedure|computed tomography|
435845|NCT00873808|Procedure|dual x-ray absorptiometry|
435846|NCT00873795|Drug|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
435847|NCT00873782|Other|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
435848|NCT00873769|Drug|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
435849|NCT00873756|Drug|FOLFOX regimen|Intravenous repeating dose
435850|NCT00873756|Drug|bevacizumab|Intravenous repeating dose
435851|NCT00873756|Drug|dulanermin|Intravenous repeating dose
435852|NCT00873730|Drug|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
435853|NCT00873730|Drug|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
435854|NCT00873717|Other|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
435855|NCT00873717|Other|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
435856|NCT00873717|Other|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.~associated with control of the administration of dietary prescriptions, incitement to eat."
435857|NCT00873704|Other|supplemental postoperative oxygen|
435858|NCT00873691|Device|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
435859|NCT00873678|Biological|Whole blood sample|Whole blood sample (10 ml)
435860|NCT00873665|Other|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
435861|NCT00873665|Other|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
435862|NCT00873652|Biological|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
435863|NCT00873639|Drug|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
435864|NCT00873639|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
435865|NCT00873626|Drug|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
435866|NCT00873613|Procedure|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
435867|NCT00873600|Drug|chemotherapy|
435868|NCT00873600|Other|medical chart review|
435869|NCT00873600|Other|questionnaire administration|
435870|NCT00873600|Procedure|adjuvant therapy|
435871|NCT00873600|Procedure|assessment of therapy complications|
435872|NCT00873600|Procedure|cognitive assessment|
435873|NCT00873600|Procedure|psychosocial assessment and care|
435874|NCT00873600|Procedure|quality-of-life assessment|
435875|NCT00873587|Procedure|Chest tube pull on inspiration|Pull chest tube on Inspiration
435876|NCT00873587|Procedure|Expiration|Pull chest tube on Expiration
435877|NCT00873574|Biological|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
435878|NCT00873561|Drug|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
435879|NCT00873548|Device|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:~Positioning of the patient~Definition of the CCD-angle~Fracture reduction~Determination of the nail diameter~Incision~Insertion of the device"
435880|NCT00873535|Drug|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
435881|NCT00873535|Drug|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
435882|NCT00873509|Drug|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
435883|NCT00873509|Drug|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
435884|NCT00873509|Drug|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
435885|NCT00873496|Drug|Hydroxychloroquine|
435886|NCT00873483|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 3 cycles
435887|NCT00873470|Procedure|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
435888|NCT00873457|Drug|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
435889|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
435890|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
435891|NCT00873431|Biological|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
435892|NCT00873418|Behavioral|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
435893|NCT00873405|Procedure|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
435894|NCT00873405|Procedure|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
435895|NCT00873392|Drug|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
435896|NCT00873392|Other|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
435897|NCT00873379|Dietary Supplement|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
435898|NCT00873379|Dietary Supplement|placebo|half a white placebo tablet
435899|NCT00873366|Drug|dextromethorphan hydrobromide|
435900|NCT00873366|Drug|tamoxifen citrate|
435901|NCT00873366|Other|high performance liquid chromatography|
435902|NCT00873366|Other|laboratory biomarker analysis|
435903|NCT00873366|Other|pharmacogenomic studies|
435904|NCT00873366|Other|pharmacological study|
435905|NCT00873366|Procedure|fluorescence imaging|
435906|NCT00873353|Drug|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :~capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
435907|NCT00873340|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
435908|NCT00873327|Drug|piperacillin-tazobactam|"6 doses intravenously at the following doses:~Infants <32 weeks gestation at birth < 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6~Infants ≥32 weeks gestation at birth < 14 days PNA 100 mg/kg Q6~≥ 14 days PNA 100 mg/kg Q6"
435909|NCT00873314|Behavioral|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
435910|NCT00873314|Behavioral|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
435911|NCT00873301|Procedure|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
435912|NCT00873288|Other|informational intervention|
435913|NCT00873288|Other|questionnaire administration|
435914|NCT00873275|Biological|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
435915|NCT00873275|Drug|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
435916|NCT00873275|Drug|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
435917|NCT00873275|Drug|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
435918|NCT00873275|Drug|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
435919|NCT00873275|Drug|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
435920|NCT00873275|Genetic|RNA analysis|Analysis on discard tissues
435921|NCT00873275|Genetic|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
435922|NCT00873275|Genetic|polymerase chain reaction|Analysis on discard tissues
435923|NCT00873275|Genetic|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
435924|NCT00873275|Other|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
435925|NCT00873275|Other|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
435926|NCT00873275|Other|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
435927|NCT00873275|Procedure|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
435928|NCT00873262|Drug|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
435929|NCT00873262|Drug|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L~Controls:~Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)~Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:~Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml~Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml~Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
435930|NCT00873236|Biological|bevacizumab|Given IV
435931|NCT00873236|Biological|recombinant interferon alpha-2a|Given SC
435932|NCT00873223|Drug|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
435933|NCT00873223|Drug|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
435934|NCT00873210|Drug|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
435935|NCT00873197|Drug|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).~Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
435936|NCT00873184|Behavioral|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
435937|NCT00873158|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
435939|NCT00873119|Drug|belinostat, carboplatin, paclitaxel|
435941|NCT00873106|Device|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
435942|NCT00873093|Drug|L-asparaginase|Given IM 6000 IU/m2/dose Days 2 and 9
435943|NCT00873093|Drug|doxorubicin hydrochloride|Given IV 60 mg/m2/dose on Day 1
435944|NCT00873093|Drug|therapeutic hydrocortisone|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
435945|NCT00873093|Drug|vincristine sulfate|Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
435946|NCT00873093|Drug|cytarabine|Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
435947|NCT00873093|Drug|prednisone|Given PO or IV 40 mg/m2/day on Days 1-28
435948|NCT00873093|Drug|bortezomib|Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
435949|NCT00873093|Drug|pegaspargase|Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
435950|NCT00873093|Drug|methotrexate|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
435951|NCT00873093|Drug|etoposide phosphate|Given IV 100 mg/m2/dose on Days 1-5
435952|NCT00873093|Drug|cyclophosphamide|Given IV 440 mg/m2/dose on Days 1-5
435953|NCT00873093|Biological|filgrastim|Given IV or SC 5 micrograms/kg/dose Only on Day 6
435954|NCT00873093|Drug|leucovorin calcium|Given PO or IV 15mg/m2/dose q6h x 3 doses
435955|NCT00873093|Other|laboratory biomarker analysis|Correlative studies
435956|NCT00873093|Drug|High Dose MTX|IV 5000 mg/m2/dose Block 2: Day 22
435957|NCT00873067|Procedure|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
435958|NCT00873067|Procedure|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
435959|NCT00873041|Drug|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
435960|NCT00873041|Drug|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
435961|NCT00873028|Other|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
435962|NCT00873015|Drug|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
435963|NCT00873015|Drug|Saline|14 day continuous infusion of a vehicle control infusion
435964|NCT00873002|Drug|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
435965|NCT00873002|Drug|sorafenib tosylate|400 mg PO BID
435966|NCT00872989|Drug|docetaxel|Given IV
435967|NCT00872989|Drug|vandetanib|Given orally
435968|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
435969|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles~Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
435970|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
435971|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles~Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
435972|NCT00872963|Biological|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
435973|NCT00872950|Drug|3,4-DIAMINOPYRIDINE|Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
435974|NCT00872950|Drug|3,4-Diaminopyridine|
435975|NCT00872924|Drug|sumatriptan 100mg|
435976|NCT00872911|Dietary Supplement|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
435977|NCT00872911|Drug|Exercise|progressive exercise training
435978|NCT00872898|Drug|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
435979|NCT00872898|Drug|Placebo|Placebo capsules, once daily, oral administration.
435980|NCT00872885|Drug|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
435981|NCT00872885|Drug|Morphine|60 mg
435982|NCT00872885|Drug|Placebo|single dosage
435983|NCT00872872|Drug|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
435984|NCT00872859|Procedure|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
435985|NCT00872846|Device|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
435986|NCT00872820|Behavioral|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
437608|NCT00861484|Drug|Placebo|Coated tablets
435987|NCT00872820|Behavioral|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
435988|NCT00872807|Behavioral|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.~They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
435989|NCT00872807|Behavioral|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
435990|NCT00872794|Device|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
435991|NCT00872781|Drug|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
435992|NCT00872755|Procedure|Nissen|Laparoscopic Nissen Fundoplication
435993|NCT00872755|Procedure|Gastropexy|posterior gastropexy
435994|NCT00872742|Behavioral|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
435995|NCT00872742|Behavioral|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
435996|NCT00872729|Drug|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.~Duration of Treatment and Dose: Reference Period up to four doses Q6H."
435997|NCT00872729|Drug|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.~Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
435998|NCT00872716|Drug|Quetiapine XR|100 mg single-dose Quetiapine XR
435999|NCT00872716|Other|Placebo|Placebo
436000|NCT00872677|Behavioral|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
436001|NCT00872677|Other|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
436002|NCT00872664|Dietary Supplement|carotenoids|beta-carotene, lycopene, lutein
436003|NCT00872651|Drug|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
436004|NCT00872651|Drug|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
436005|NCT00872638|Procedure|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
436006|NCT00872638|Procedure|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
436007|NCT00872625|Drug|cyclophosphamide|
436008|NCT00872625|Drug|docetaxel|
436009|NCT00872625|Drug|epirubicin hydrochloride|
436010|NCT00872625|Drug|fluorouracil|
436011|NCT00872625|Procedure|neoadjuvant therapy|
436012|NCT00872625|Procedure|therapeutic conventional surgery|
436013|NCT00872625|Radiation|hypofractionated radiation therapy|
436014|NCT00872625|Radiation|image-guided radiation therapy|
436015|NCT00872625|Radiation|radiation therapy|
436016|NCT00872625|Radiation|stereotactic radiosurgery|
436017|NCT00872612|Procedure|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.~EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.~BAL = bronchoalveolar lavage"
436018|NCT00872612|Procedure|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
436019|NCT00872599|Drug|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
436020|NCT00872599|Drug|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
436021|NCT00872586|Drug|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
436022|NCT00872586|Drug|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
436023|NCT00872573|Device|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
436024|NCT00872560|Device|NovoFine® needle 6 mm|
436025|NCT00872560|Device|NovoFine® needle 8 mm|
436026|NCT00872547|Device|DePuy ASR™ Hip System|Resurfacing system
436027|NCT00872547|Device|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
436028|NCT00872534|Drug|acetylsalicylic acid|325mg once a day for 7 days
436029|NCT00872521|Drug|PAD induction|"Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 & 11), Doxorubicin 20 mg/m2 i.v. (D1 & 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 & 12)"
436030|NCT00872482|Drug|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
436031|NCT00872469|Drug|Tranexamic acid|1-2 grams by intravenous injection
436032|NCT00872469|Drug|Placebo [Saline]|Matched to active comparator
436033|NCT00872443|Other|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.~Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
436034|NCT00872430|Other|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
436035|NCT00872430|Other|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
436163|NCT00871572|Drug|Placebo|4 capsules by mouth once daily for 12 weeks
436164|NCT00871559|Drug|REGN421(SAR153192)|
436036|NCT00872417|Drug|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
436037|NCT00872417|Drug|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
436038|NCT00872404|Drug|CP-751,871|20mg/kg/3 weeks
436039|NCT00872391|Radiation|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
436040|NCT00872378|Drug|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
436041|NCT00872378|Drug|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
436042|NCT00872365|Behavioral|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
436043|NCT00872365|Dietary Supplement|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
436044|NCT00872365|Other|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.~Placebo Comparator: Equivalent to placebo (maltodextrin)."
436045|NCT00872352|Procedure|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
436046|NCT00872326|Procedure|Autologous Bone Marrow Mononuclear Cells|Infusion > 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
436047|NCT00872300|Drug|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
436048|NCT00872287|Procedure|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
436049|NCT00872287|Procedure|SILS|Single transumbilical incision laparoscopic cholecystectomy
436050|NCT00872274|Drug|sumatriptan 100mg|
436051|NCT00872248|Procedure|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
436052|NCT00872248|Procedure|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
436053|NCT00872235|Drug|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
436054|NCT00872222|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
436055|NCT00872209|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
436056|NCT00872209|Drug|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
436057|NCT00872196|Drug|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
436058|NCT00872170|Drug|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:~50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
436059|NCT00872157|Drug|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
436060|NCT00872144|Drug|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
436061|NCT00872131|Drug|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
436062|NCT00872118|Behavioral|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
436063|NCT00872118|Behavioral|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
436064|NCT00872105|Procedure|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
436065|NCT00872105|Procedure|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:~Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
436066|NCT00872092|Other|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
436067|NCT00872079|Device|Genomics|Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
436068|NCT00872066|Device|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
436069|NCT00872066|Device|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
436070|NCT00872053|Device|Anklebot|"The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes."
436071|NCT00872053|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
436072|NCT00872040|Other|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
436073|NCT00872027|Drug|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
436074|NCT00872027|Drug|Placebo|Placebo pills for 8 weeks
436075|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
436076|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
436077|NCT00872014|Drug|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort & 10mg/kg cohort
436078|NCT00872001|Drug|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
436079|NCT00872001|Drug|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
436080|NCT00871975|Device|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
436081|NCT00871962|Other|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
436082|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
436083|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
436084|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
436085|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
436086|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
436087|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
436088|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
436089|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
436090|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
436091|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
436092|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
436093|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
436094|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
436095|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
436096|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
436097|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
436098|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
436099|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
436100|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
436101|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
436102|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
436103|NCT00871936|Drug|SLx-4090|SLx-4090
436104|NCT00871936|Other|Placebo|matching tablets
436105|NCT00871936|Drug|Metformin|
436106|NCT00871923|Drug|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
436107|NCT00871923|Radiation|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
436108|NCT00871910|Drug|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
436109|NCT00871910|Drug|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
436110|NCT00871910|Drug|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
436111|NCT00871910|Drug|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
436112|NCT00871910|Drug|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
436113|NCT00871910|Drug|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
436114|NCT00871910|Drug|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
436115|NCT00871884|Behavioral|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
436116|NCT00871884|Behavioral|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
436117|NCT00871884|Behavioral|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
436118|NCT00871871|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
436119|NCT00871871|Drug|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
436120|NCT00871871|Drug|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
436121|NCT00871871|Drug|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
436122|NCT00871858|Drug|anastrozole|Given orally
436123|NCT00871858|Drug|fulvestrant|Given intramuscularly
436124|NCT00871845|Behavioral|Dietary and Lifestyle modification educational sessions|6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
436125|NCT00871819|Device|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
436126|NCT00871806|Drug|Commercial tablet with water|40 mg tablet, given once to each subject
436127|NCT00871806|Drug|ODT #1 without water|40 mg tablet given once to each subject
436128|NCT00871806|Drug|ODT #2 without water|40 mg tablet given once to each subject
436129|NCT00871806|Drug|ODT #1 with water|40 mg tablet given once to each subject
436130|NCT00871806|Drug|ODT #2 with water|40 mg tablet given once to each subject
436131|NCT00871793|Other|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
436132|NCT00871780|Drug|BG00002 (natalizumab)|
436133|NCT00871767|Drug|AZD5672|40 mg tablet (Test formulation)
436134|NCT00871767|Drug|AZD5672|40 mg tablet (Reference formulation)
436135|NCT00871767|Drug|AZD5672|100 mg tablet (Test formulation)
436136|NCT00871767|Drug|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
436137|NCT00871741|Biological|GSK2202083A vaccine|Intramuscular, three doses
436138|NCT00871741|Biological|Infanrix hexa|Intramuscular, three doses
436139|NCT00871741|Biological|Menjugate|Intramuscular, two doses
436140|NCT00871728|Drug|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
436141|NCT00871715|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
436142|NCT00871715|Behavioral|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
436143|NCT00871715|Behavioral|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
436144|NCT00871702|Genetic|CD34-TK75 transduced donor lymphocytes|
436145|NCT00871702|Radiation|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
436146|NCT00871689|Biological|aldesleukin|IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
436147|NCT00871689|Drug|cyclophosphamide|60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
436148|NCT00871689|Drug|fludarabine phosphate|25 mg/m^2 intravenously (IV) over 1 hour on days -7 through -5.
436149|NCT00871689|Procedure|umbilical cord blood transplantation|On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
436150|NCT00871689|Radiation|total-body irradiation|administered on days -5 through -2; 330 cGy daily
436151|NCT00871676|Behavioral|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
436152|NCT00871676|Behavioral|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
436153|NCT00871663|Drug|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
436154|NCT00871650|Other|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
436155|NCT00871650|Other|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
436156|NCT00871650|Other|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
436157|NCT00871624|Drug|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
436158|NCT00871624|Drug|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
436159|NCT00871598|Drug|BTT1023|intravenous, three infusions over three weeks
436160|NCT00871598|Drug|Placebo|intravenous, three infusions over three weeks
436161|NCT00871598|Drug|BTT1023|Test challenge
436162|NCT00871572|Drug|LY2409021|4 capsules by mouth taken once daily for 12 weeks
436165|NCT00871546|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
436166|NCT00871546|Drug|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
436167|NCT00871546|Biological|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
436168|NCT00871533|Drug|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
436169|NCT00871533|Drug|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
436170|NCT00871533|Drug|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
436171|NCT00871533|Drug|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
436172|NCT00871520|Other|no specific interventions|There are no specific interventions in this observational study
436173|NCT00871507|Drug|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
436174|NCT00871507|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
436175|NCT00871507|Drug|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
436176|NCT00871507|Drug|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
436177|NCT00871494|Drug|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
436178|NCT00871481|Biological|ipilimumab|Given IV
436179|NCT00871481|Drug|cyclophosphamide|Given IV
436180|NCT00871481|Procedure|biopsy|Optional correlative studies
436181|NCT00871481|Biological|aldesleukin|Given SC
436182|NCT00871481|Other|immunohistochemistry staining method|Correlative studies
436183|NCT00871481|Genetic|polymerase chain reaction|Correlative studies
436184|NCT00871481|Other|immunoenzyme technique|Correlative studies
436185|NCT00871481|Biological|therapeutic cytotoxic T lymphocytes|Given IV
436186|NCT00871468|Procedure|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
436187|NCT00871468|Procedure|anterior-inferior plate|ORIF clavicle with anterior inferior plate
436188|NCT00871455|Drug|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
436189|NCT00871442|Other|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
436190|NCT00871442|Other|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
436191|NCT00871442|Drug|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
436192|NCT00871429|Other|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.~The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
436193|NCT00871416|Device|NovoFine® needle 6 mm|
436194|NCT00871416|Device|NovoFine® needle 12 mm|
436195|NCT00871403|Drug|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m^2 once every 3 weeks, then pazopanib 800 mg once daily
436196|NCT00871403|Drug|pemetrexed and cisplatin|pemetrexed IV 500 mg/m^2 and cisplatin IV 75 mg/m^2 once every 3 weeks
436197|NCT00871377|Drug|Placebo|corn oil (n-6 fatty acids)
436198|NCT00871377|Drug|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
436199|NCT00871377|Drug|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
436200|NCT00871364|Drug|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
436201|NCT00871364|Drug|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
436202|NCT00871351|Drug|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
436203|NCT00871351|Drug|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
436204|NCT00871351|Drug|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
436205|NCT00871351|Drug|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
436206|NCT00871338|Biological|GSK2197870A|3 doses given at 2, 3 and 4 months of age
436207|NCT00871338|Biological|Prevenar™|3 co-administered doses, intramuscular into right thigh
436208|NCT00871338|Biological|Menitorix™|1 booster dose at 12 months of age
436209|NCT00871338|Biological|Pediacel™|3 doses given at 2, 3 and 4 months of age
436210|NCT00871338|Biological|Menjugate™|2 doses given at 3 and 4 months of age
436211|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
436212|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
436213|NCT00871325|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
436214|NCT00871312|Device|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
436215|NCT00871312|Device|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
436342|NCT00870376|Other|biomarkers|To define a biomarker or combination of overactive bladder syndrome
436456|NCT00869596|Drug|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
436216|NCT00871299|Behavioral|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
436217|NCT00871299|Behavioral|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
436218|NCT00871286|Procedure|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
436219|NCT00871286|Procedure|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
436220|NCT00871273|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
436221|NCT00871260|Drug|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
436222|NCT00871247|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
436223|NCT00871247|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
436224|NCT00871234|Drug|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
436225|NCT00871208|Drug|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
436226|NCT00871208|Drug|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
436227|NCT00871182|Drug|Inhaled PT001|single dose, inhaled
436228|NCT00871182|Drug|Inhaled Placebo|single dose, inhaled
436229|NCT00871182|Drug|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
436230|NCT00871169|Drug|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).~The treatment interval (one cycle) is every 14 days."
436231|NCT00871156|Drug|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
436232|NCT00871156|Drug|Placebo|Placebo
436233|NCT00871143|Behavioral|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
436234|NCT00871143|Behavioral|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
436235|NCT00871130|Procedure|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
436236|NCT00871117|Biological|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
436237|NCT00871117|Biological|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
436238|NCT00871117|Biological|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
436239|NCT00871104|Drug|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
436240|NCT00871104|Drug|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
436241|NCT00871091|Procedure|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
436242|NCT00871091|Procedure|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
436243|NCT00871091|Procedure|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
436244|NCT00871078|Device|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
436245|NCT00871078|Device|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
436246|NCT00871065|Drug|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
436247|NCT00871052|Drug|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
436248|NCT00871039|Drug|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
436249|NCT00871039|Drug|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
436250|NCT00871026|Procedure|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
436251|NCT00871026|Procedure|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
436252|NCT00871013|Drug|Melphalan|"Given by vein, Day 3~First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4~Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2~Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days~Years 2 & 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
436253|NCT00871013|Drug|Velcade|Given by vein, Days 1, 5, 8, 11
436254|NCT00871013|Drug|Thalidomide|Given by mouth at bedtime, Days 5-8
436255|NCT00871013|Drug|Dexamethasone|Given by mouth, once per day Days 5-8
436256|NCT00871013|Drug|Cisplatin|Given by vein, Days 5-8 continuous infusion
436257|NCT00871013|Drug|Adriamycin|Given by vein, days 5-8 continuous infusion
436258|NCT00871013|Drug|Cyclophosphamide|Given by vein days 5-8 continuous infusion
436259|NCT00871013|Drug|Etoposide|Given by vein days 5-8 continuous infusion
436260|NCT00871000|Biological|Boostrix Polio™ 711866|Single dose, intramuscular administration.
436261|NCT00871000|Biological|Priorix Tetra TM 208136|Single dose, subcutaneously.
436262|NCT00871000|Biological|Tetravac TM|Single dose, intramuscular administration.
436263|NCT00870987|Biological|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
436264|NCT00870987|Biological|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
436265|NCT00870974|Drug|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]F-PEB
436266|NCT00870961|Dietary Supplement|cholecalciferol|Given orally
436267|NCT00870961|Other|placebo|Given orally
436268|NCT00870948|Drug|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
436269|NCT00870935|Procedure|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
436270|NCT00870935|Procedure|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
436271|NCT00870922|Procedure|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
436272|NCT00870909|Procedure|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
436273|NCT00870909|Procedure|sham tDCS|sham condition as delivered by the stimulator
436274|NCT00870896|Drug|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
436275|NCT00870883|Drug|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
436276|NCT00870870|Drug|Gemcitabine|"1000 milligrams per square meter (mg/m^2) on Days 1 and 8 of each cycle~[First 6 cycles (18 weeks)]"
436277|NCT00870870|Drug|Cisplatin|"75 mg/m^2 on Day 1 of each cycle~[First 6 cycles (18 weeks)]"
436278|NCT00870870|Biological|IMC-A12 (cixutumumab)|"6 milligrams per kilogram (mg/kg) intravenous (IV) infusion, administered once per week (on Days 1, 8, and 15 of each cycle)~[First 6 cycles (18 weeks)]"
436279|NCT00870870|Biological|Cetuximab|"400 mg/m^2 IV infusion, administered on Day 1 of Cycle 1, 250 mg/m^2 once per week thereafter~[First 6 cycles (18 weeks)]"
436280|NCT00870870|Biological|IMC-A12 (cixutumumab)|"10 mg/kg IV infusion, administered once every 2 weeks~(Maintenance therapy)"
436281|NCT00870870|Biological|Cetuximab|"500 mg/m^2 IV infusion, administered once every 2 weeks~(Maintenance therapy)"
436282|NCT00870870|Drug|Carboplatin|"Area under the curve (AUC) = 5, Day 1 of each cycle~[First 6 cycles (18 weeks)]~*Carboplatin will be replaced by Cisplatin"
436283|NCT00870844|Drug|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
436284|NCT00870844|Drug|Placebo|Vials with solution for IV infusion
436285|NCT00870831|Other|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
436286|NCT00870818|Drug|Teplizumab|No additional drug or placebo will be administered in this study. Blood will be drawn every 6 months after the last visit of the Protege Study for 3 years. Blood will be collected for chemistry, hematology, thyroid function, immunology, serology, autoantibodies, and metabolic function.
436287|NCT00870805|Procedure|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
436288|NCT00870805|Procedure|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
436289|NCT00870805|Procedure|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
436290|NCT00870805|Procedure|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
436291|NCT00870792|Behavioral|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
436292|NCT00870779|Drug|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
436293|NCT00870766|Procedure|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
436294|NCT00870753|Behavioral|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
436295|NCT00870740|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
436296|NCT00870740|Drug|Placebo|Placebo SC injection
436297|NCT00870727|Drug|Aripiprazole oral product|Minimum dose of 2 mg per day to a maximum dose of 20 mg per day over 8-weeks of treatment.
436298|NCT00870727|Drug|Placebo oral capsule|Placebo will be identical in size and appearance to study drug.
436299|NCT00870714|Drug|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
436300|NCT00870714|Drug|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
436301|NCT00870701|Radiation|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
436302|NCT00870701|Other|absence of radiotherapy|absence of radiotherapy
436303|NCT00870688|Drug|sodium valproate|valproate sustained release minitablets, once daily.
436304|NCT00870662|Device|AFS System|AFS System with patient specific flow rate
436305|NCT00870649|Biological|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
436306|NCT00870649|Biological|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
436307|NCT00870636|Drug|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
436308|NCT00870610|Procedure|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
436309|NCT00870597|Procedure|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
436310|NCT00870597|Procedure|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
436311|NCT00870584|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
436312|NCT00870584|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
436313|NCT00870571|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
436314|NCT00870571|Drug|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
436315|NCT00870558|Drug|ethiodized oil|Given as an intra-arterial infusion
436316|NCT00870558|Radiation|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
436317|NCT00870545|Behavioral|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
436318|NCT00870532|Drug|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
436319|NCT00870532|Drug|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
436320|NCT00870519|Drug|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
436321|NCT00870519|Drug|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
436322|NCT00870506|Behavioral|video|5-minute video compared (intervention) to no video and no other intervention (control)
436323|NCT00870493|Drug|Aliskiren|Aliskiren 300 mg daily oral
436324|NCT00870493|Drug|Placebo|starch tablet, 300 mg/day
436325|NCT00870480|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
436326|NCT00870480|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
436327|NCT00870467|Biological|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
436328|NCT00870467|Drug|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
436329|NCT00870467|Biological|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
436330|NCT00870467|Biological|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
436331|NCT00870454|Drug|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
436332|NCT00870454|Drug|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
436333|NCT00870454|Drug|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
436334|NCT00870454|Drug|Placebo|Placebo capsules twice daily
436335|NCT00870441|Drug|ASP2151|Oral
436336|NCT00870441|Drug|Valacyclovir|Oral
436337|NCT00870441|Drug|Placebo|Oral
436338|NCT00870415|Procedure|quality-of-life assessment|
436339|NCT00870415|Procedure|therapeutic conventional surgery|
436340|NCT00870402|Drug|Spironolactone|25 mg per day for 9 months
436341|NCT00870402|Drug|Placebo|Placebo 1 tablet per day for nine months
436343|NCT00870363|Drug|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
436344|NCT00870363|Drug|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
436345|NCT00870363|Drug|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
436346|NCT00870350|Biological|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
436347|NCT00870350|Biological|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
436348|NCT00870337|Drug|everolimus|
436349|NCT00870324|Device|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
436350|NCT00870324|Device|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
436351|NCT00870311|Drug|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
436352|NCT00870298|Drug|Trimethoprim/Sulfamethoxazole and Warfarin|
436353|NCT00870285|Radiation|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
436354|NCT00870272|Drug|Misoprostol|400mcg misoprostol taken sublingually or buccally
436355|NCT00870259|Dietary Supplement|Optifast VLCD|Meal replacement, three times daily for 8 weeks
436356|NCT00870233|Behavioral|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
436357|NCT00870220|Drug|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
436358|NCT00870207|Behavioral|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
436359|NCT00870194|Drug|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
436360|NCT00870194|Drug|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
436361|NCT00870181|Biological|ADV-TK/GCV|gene therapy
436362|NCT00870181|Procedure|Surgery|
436363|NCT00870181|Drug|systemic chemotherapy|
436364|NCT00870168|Drug|chemotherapy|
436365|NCT00870168|Genetic|gene expression analysis|
436366|NCT00870168|Other|laboratory biomarker analysis|
436367|NCT00870168|Procedure|breast biopsy|
436368|NCT00870155|Drug|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
436369|NCT00870142|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
436370|NCT00870142|Drug|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
436371|NCT00870129|Procedure|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
436372|NCT00870116|Radiation|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
436373|NCT00870116|Radiation|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
436374|NCT00870116|Radiation|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
436375|NCT00870103|Drug|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
436376|NCT00870077|Dietary Supplement|ProWHEY 94 CFM, SponserR|3 times 20g per day
436377|NCT00870064|Procedure|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
436378|NCT00870064|Procedure|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
436379|NCT00870051|Device|Endurant Stent Graft|Endurant Stent Graft implantation
436380|NCT00870038|Device|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
436381|NCT00870038|Device|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
436382|NCT00870038|Device|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
436383|NCT00870025|Biological|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
436384|NCT00870025|Biological|placebo|diluent, every 5 days, s.c., 4 doses
436385|NCT00870012|Drug|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
436386|NCT00870012|Other|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
436387|NCT00869999|Drug|Everolimus|Taken orally once daily in the morning
436388|NCT00869999|Drug|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
436389|NCT00869986|Drug|dirucotide|500mg, intravenous, every 6 months for 15 months
436390|NCT00869986|Drug|placebo|intravenous, once every six months for 15 months
436391|NCT00869973|Drug|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
436392|NCT00869973|Drug|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
436393|NCT00869960|Drug|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
436394|NCT00869960|Drug|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
436395|NCT00869960|Drug|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
436396|NCT00869960|Drug|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
436397|NCT00869947|Device|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
436398|NCT00869947|Other|No device|
436399|NCT00869934|Other|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
436400|NCT00869934|Other|Behavior Therapy|Sleep restriction and stimulus control
436401|NCT00869934|Other|Cognitive Therapy|Cognitive restructuring therapy
436402|NCT00869908|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
436403|NCT00869908|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
436404|NCT00869908|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
436405|NCT00869895|Drug|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
436406|NCT00869882|Procedure|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.~The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.~In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.~The end of the procedure is the same as for GPLI."
436407|NCT00869882|Procedure|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.~Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:~Central stenosis: decompression is performed including medial facectomy, laminectomy;~Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;~Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.~Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.~Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.~Bone autograft is placed into this bed."
436408|NCT00869869|Drug|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
436409|NCT00869869|Drug|placebo|placebo
436410|NCT00869856|Drug|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
436411|NCT00869843|Procedure|RF Ablation|
436412|NCT00869830|Other|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
436413|NCT00869804|Behavioral|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
436414|NCT00869804|Behavioral|Attention control|
436415|NCT00869791|Drug|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
436416|NCT00869791|Drug|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
436417|NCT00869778|Biological|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
436418|NCT00869778|Other|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
436419|NCT00869765|Drug|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
436420|NCT00869765|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
436421|NCT00869752|Biological|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
436422|NCT00869752|Drug|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
436423|NCT00869752|Drug|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
436424|NCT00869739|Behavioral|telephone-based intervention|
436425|NCT00869739|Other|educational intervention|
436426|NCT00869739|Other|partner-assisted coping skills training|
436427|NCT00869739|Other|questionnaire administration|
436428|NCT00869739|Procedure|psychosocial assessment and care|
436429|NCT00869739|Procedure|quality-of-life assessment|
436430|NCT00869726|Drug|dirucotide|500mg, intravenous, dosed once every six months for 18 months
436431|NCT00869726|Drug|Placebo|intravenous, once every six months for 18 months
436432|NCT00869713|Biological|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 & 14, & once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer <1:40. Initial non-responders: Individual who has a PRNT80 titer <1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 <1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of <1:40.
436433|NCT00869700|Drug|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine~Trade name: Coartem~Indication: for management of non-severe malaria"
436434|NCT00869687|Device|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
436435|NCT00869674|Procedure|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.~Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
436436|NCT00869661|Drug|Copegus|1000/1200mg po daily for 24 or 48 weeks
436437|NCT00869661|Drug|Copegus|1000/1200mg po daily for 48 weeks
436438|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
436439|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 48 weeks
436440|NCT00869661|Drug|RO5024048|1000mg bid for 24 weeks
436441|NCT00869661|Drug|RO5024048|500mg bid for 12 weeks
436442|NCT00869661|Drug|RO5024048|1000mg bid for 8 weeks
436443|NCT00869661|Drug|RO5024048|1000mg bid for 12 weeks
436444|NCT00869648|Procedure|Extension|After anaesthesia induction the head is placed in extension
436445|NCT00869648|Procedure|Neutral head position|After anaesthesia induction the head is placed in neutral position
436446|NCT00869648|Procedure|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
436447|NCT00869635|Drug|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
436448|NCT00869635|Procedure|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
436449|NCT00869635|Procedure|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
436450|NCT00869622|Drug|Risedronate|35 mgs/week + calcium and vit d
436451|NCT00869622|Drug|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
436452|NCT00869609|Behavioral|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
436453|NCT00869609|Behavioral|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
436454|NCT00869596|Drug|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
436455|NCT00869596|Drug|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
436791|NCT00867100|Drug|Placebo|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
436457|NCT00869596|Drug|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
436458|NCT00869583|Behavioral|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents [METS]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
436459|NCT00869570|Drug|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
436460|NCT00869570|Drug|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
436461|NCT00869570|Radiation|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
436462|NCT00869557|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
436463|NCT00869557|Drug|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
436464|NCT00869531|Other|wholegrain|wholegrain wheat vs. refined wheat products
436465|NCT00869531|Other|refined wheat|refined wheat products
436466|NCT00869518|Drug|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
436467|NCT00869518|Drug|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
436468|NCT00869492|Drug|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
436469|NCT00869492|Drug|nadifloxacine|Nadifloxacine 1% cream twice dailly
436470|NCT00869466|Behavioral|behavioral dietary intervention|
436471|NCT00869466|Behavioral|exercise intervention|
436472|NCT00869466|Other|counseling intervention|
436473|NCT00869466|Other|educational intervention|
436474|NCT00869466|Other|laboratory biomarker analysis|
436475|NCT00869466|Other|questionnaire administration|
436476|NCT00869466|Procedure|quality-of-life assessment|
436477|NCT00869466|Procedure|support group therapy|
436478|NCT00869453|Other|test meal|Mixed meal containing bread, butter, beef
436479|NCT00869453|Other|glucose|administration of a glucose meal
436480|NCT00869453|Other|fat|administration of a lipid meal
436481|NCT00869453|Other|protein|administration of a protein meal
436482|NCT00869453|Other|control|no meal
436483|NCT00869440|Drug|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
436484|NCT00869440|Drug|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
436485|NCT00869427|Drug|vitamin C|vitamin C 1g bid for 1 year
436486|NCT00869414|Drug|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
436487|NCT00869414|Drug|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
436488|NCT00869414|Drug|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
436489|NCT00869401|Drug|dasatinib|Given orally
436490|NCT00869401|Drug|temozolomide|Given orally
436491|NCT00869401|Other|placebo|Given orally
436492|NCT00869401|Radiation|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
436493|NCT00869388|Biological|rBBX-01|
436494|NCT00869375|Device|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
436495|NCT00869362|Other|Diabetes management team|MD evaluation followed by NP education and and medication titration
436496|NCT00869349|Behavioral|IFS|"The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.~Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline."
436497|NCT00869349|Other|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
436498|NCT00869336|Drug|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
436499|NCT00869336|Drug|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
436500|NCT00869336|Drug|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
436501|NCT00869336|Drug|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
436502|NCT00869323|Biological|rituximab|375 mg/m^2 intravenously on Days 1,8, 15 and 22
436503|NCT00869323|Drug|bortezomib|1.3 mg/m^2 intravenous bolus days 1, 8, 15 and 22
436504|NCT00869310|Drug|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
436612|NCT00868491|Drug|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
437761|NCT00860353|Drug|Placebo|Single dose of oral solution
436505|NCT00869310|Drug|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
436506|NCT00869297|Other|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
436507|NCT00869297|Other|Control|Fluids titrated at discretion of anesthesiologist.
436508|NCT00869284|Drug|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
436509|NCT00869284|Procedure|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.~The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
436510|NCT00869271|Procedure|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
436511|NCT00869271|Procedure|Folfox4|"folfox4~Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
436512|NCT00869258|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
436513|NCT00869258|Radiation|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
436514|NCT00869245|Other|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
436515|NCT00869245|Other|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
436516|NCT00869232|Drug|Velcade|1.0mg/m2 days 1, 5, 8, & 11
436517|NCT00869232|Drug|Melphalan|10 mg/m2 day 3
436518|NCT00869232|Drug|Thalidomide|200 mg days 5-8
436519|NCT00869232|Drug|Dexamethasone|40 mg day 5-8
436520|NCT00869232|Drug|Cisplatin|10 mg/m2 day 5-8
436521|NCT00869232|Drug|Adriamycin|10 mg/m2 day 5-8
436522|NCT00869232|Drug|Cyclophosphamide|400 mg/m2 day 5-8
436523|NCT00869232|Drug|Etoposide|40 mg/m2 day 5-8
436524|NCT00869219|Drug|Nevanac|1 drop of NEVANAC at random eye
436525|NCT00869219|Drug|Acular LS|One drop of Acular LS
436526|NCT00869206|Drug|zoledronic acid|Given IV
436527|NCT00869193|Dietary Supplement|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
436528|NCT00869193|Dietary Supplement|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
436529|NCT00869180|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
436530|NCT00869180|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
436531|NCT00869167|Drug|Ramelteon|melatonin agonist
436532|NCT00869154|Behavioral|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
436533|NCT00869154|Behavioral|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
436534|NCT00869141|Drug|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
436535|NCT00869128|Drug|Circadin|2 mg prolonged-release melatonin
436536|NCT00869128|Drug|Placebo|
436537|NCT00869115|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
436538|NCT00869115|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
436539|NCT00869115|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
436540|NCT00869115|Drug|Istaroxime|Placebo continuous i.v. infusion for 24 hours
436541|NCT00869102|Drug|GLP-1|intravenous, 124,5 pmol/kg body weight
436542|NCT00869089|Drug|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
436543|NCT00869076|Other|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
436544|NCT00869076|Other|Usual care|Patient was managed by their primary care physician as usual
436545|NCT00869063|Drug|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
436546|NCT00869063|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
436547|NCT00869050|Drug|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
436548|NCT00869050|Drug|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).~Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles~After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
436613|NCT00868491|Radiation|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
436549|NCT00869037|Drug|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
436550|NCT00869037|Drug|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
436551|NCT00869024|Biological|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
436552|NCT00869011|Other|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
436553|NCT00868998|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
436554|NCT00868985|Drug|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
436555|NCT00868985|Drug|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
436556|NCT00868972|Procedure|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
436557|NCT00868972|Device|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
436558|NCT00868959|Drug|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
436559|NCT00868946|Drug|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.~Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
436560|NCT00868933|Other|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
436561|NCT00868933|Other|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
436562|NCT00868920|Other|patient control of pump|Patient controls sedation pump during colonoscopy.
436563|NCT00868920|Other|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
436564|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
436565|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
436566|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
436567|NCT00868894|Drug|DE-104 medium concentration|Topical ocular application
436568|NCT00868894|Drug|DE-104 high concentration|Topical ocular application
436569|NCT00868894|Drug|Placebo|Topical ocular application
436570|NCT00868894|Drug|0.005% latanoprost|Topical ocular application
436571|NCT00868855|Drug|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
436572|NCT00868829|Device|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
436573|NCT00868816|Drug|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
436574|NCT00868816|Drug|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
436575|NCT00868790|Drug|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
436576|NCT00868790|Drug|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
436577|NCT00868790|Drug|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
436578|NCT00868790|Drug|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
436579|NCT00868777|Procedure|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
436580|NCT00868764|Drug|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
436581|NCT00868751|Biological|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.~Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
436793|NCT00867087|Drug|inotuzumab ozogamicin (CMC-544)|1.8 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
436582|NCT00868738|Dietary Supplement|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
436583|NCT00868725|Other|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
436584|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
436585|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-7
436586|NCT00868699|Drug|Placebo|Placebo Comparator
436587|NCT00868686|Device|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
436588|NCT00868686|Device|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
436589|NCT00868686|Device|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
436590|NCT00868673|Dietary Supplement|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
436591|NCT00868673|Dietary Supplement|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
436592|NCT00868660|Drug|ZP1848|sc. bolus
436593|NCT00868647|Procedure|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
436594|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
436595|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
436596|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
436597|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
436598|NCT00868634|Drug|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
436599|NCT00868608|Drug|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
436600|NCT00868595|Biological|BPX-101|Vaccine
436601|NCT00868595|Drug|AP1903|Activating agent, infusion
436602|NCT00868582|Other|PET scanning in cancer|Collection of institutional practice PET imaging data
436603|NCT00868569|Procedure|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml~folfox4"
436604|NCT00868569|Procedure|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg~folfox4"
436605|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
436606|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
436607|NCT00868530|Biological|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
436608|NCT00868517|Other|True group auricular acupuncture|Received true group auricular acupuncture
436609|NCT00868517|Other|Sham group auricular acupuncture|Received sham auricular acupuncture.
436610|NCT00868517|Other|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
436611|NCT00868504|Other|no intervention|no intervention
436614|NCT00868491|Drug|cetuximab, cisplatin|"cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
436615|NCT00868478|Drug|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
436616|NCT00868465|Drug|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania
436617|NCT00868465|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
436618|NCT00868452|Drug|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
436619|NCT00868452|Drug|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
436620|NCT00868439|Drug|patiromer|Active investigational drug
436621|NCT00868439|Drug|placebo|placebo
436622|NCT00868426|Drug|Budesonide/Formoterol Batch 1|Single, inhaled dose
436623|NCT00868426|Drug|Budesonide/Formoterol Batch 2|Single, inhaled dose
436624|NCT00868426|Drug|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
436625|NCT00868413|Drug|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
436626|NCT00868413|Drug|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
436627|NCT00868413|Drug|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
436628|NCT00868400|Dietary Supplement|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
436629|NCT00868400|Dietary Supplement|flavored water|will be given in doses equal to those of high-carbohydrate beverage
436630|NCT00868387|Other|energy-restricted, CHO-restricted diet|carbohydrate content of the diet < 40% Frequency: daily Duration: 12 months
436631|NCT00868387|Other|energy-restricted, CHO-rich diet|carbohydrate content of diet > 55% Frequency: daily Duration: 12 months
436632|NCT00868374|Drug|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
436633|NCT00868374|Drug|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
436634|NCT00868361|Drug|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
436635|NCT00868348|Drug|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
436636|NCT00868348|Drug|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
436637|NCT00868335|Device|Activ C disc prosthesis|cervical disc prosthesis
436638|NCT00868335|Procedure|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
436639|NCT00868309|Biological|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
436640|NCT00868309|Biological|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
436641|NCT00868296|Drug|pantoprazole|
436642|NCT00868283|Drug|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
436643|NCT00868283|Drug|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
436644|NCT00868231|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
436645|NCT00868231|Drug|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
436646|NCT00868231|Drug|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
436647|NCT00868218|Biological|Influenza vaccine|"Influenza virus strain:~avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
436648|NCT00868205|Dietary Supplement|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
436649|NCT00868192|Drug|Pemetrexed|
436650|NCT00868192|Drug|Bevacizumab|
436651|NCT00868179|Drug|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
436652|NCT00868166|Drug|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
436653|NCT00868166|Drug|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
436654|NCT00868166|Drug|Riluzole|Riluzole given as add-on therapy 50mg bid
436655|NCT00868153|Drug|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
436656|NCT00868140|Drug|pioglitazone|pioglitazone 45 mg
436657|NCT00868140|Drug|Placebo|placebo daily
436658|NCT00868127|Drug|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
436695|NCT00867815|Drug|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
436792|NCT00867100|Drug|140 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
436659|NCT00868127|Drug|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.~Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
436660|NCT00868114|Biological|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
436661|NCT00868101|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
436662|NCT00868088|Procedure|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.~7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.~3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.~6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.~Photographs may be taken at each subject visit."
436663|NCT00868075|Procedure|Chest physiotherapy|Twice daily for 8 weeks
436664|NCT00868075|Procedure|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
436665|NCT00868062|Other|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
436666|NCT00868036|Procedure|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.~Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
436667|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
436668|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
436669|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
436670|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
436671|NCT00868023|Drug|Placebo|Placebo
436672|NCT00868010|Drug|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
436673|NCT00868010|Drug|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
436674|NCT00867997|Other|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
436675|NCT00867997|Other|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
436676|NCT00867997|Other|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
436677|NCT00867984|Other|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
436678|NCT00867984|Other|Usual Care|AV optimization (VTI) only
436679|NCT00867971|Other|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
436680|NCT00867958|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
436681|NCT00867932|Drug|Eculizumab|5 mg/mL solution in 5% Dextrose
436682|NCT00867919|Behavioral|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:~parent-adolescent conflict~adolescent development~support and closeness~behavioral activation~response to adolescent negative affect~relapse prevention~suicide prevention, if necessary"
436683|NCT00867919|Other|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
436684|NCT00867906|Biological|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
436685|NCT00867906|Biological|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
436686|NCT00867880|Drug|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
436687|NCT00867867|Drug|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
436688|NCT00867867|Drug|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
436689|NCT00867867|Drug|Placebo|9.3 mg once per day, 6 days per week, for 9 months
436690|NCT00867854|Other|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
436691|NCT00867841|Procedure|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
436692|NCT00867828|Dietary Supplement|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
436693|NCT00867828|Dietary Supplement|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
436694|NCT00867828|Dietary Supplement|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
436788|NCT00867113|Drug|imatinib mesylate|imatinib mesylate was supplied in 100 and 400 mg tablets
436696|NCT00867802|Behavioral|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
436697|NCT00867789|Drug|Trimethoprim-sulfamethoxazole|10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
436698|NCT00867789|Drug|Sugar pill|10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
436699|NCT00867776|Behavioral|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
436700|NCT00867763|Procedure|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
436701|NCT00867763|Procedure|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
436702|NCT00867750|Device|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
436703|NCT00867750|Drug|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
436704|NCT00867737|Drug|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
436705|NCT00867737|Drug|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks"
436706|NCT00867724|Device|Aer-O-Scope Colonoscopy|Screening Colonoscopy
436707|NCT00867698|Drug|AST-120|AST-120
436708|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
436709|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
436710|NCT00867672|Drug|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
436711|NCT00867672|Drug|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
436712|NCT00867672|Drug|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
436713|NCT00867659|Drug|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
436714|NCT00867607|Drug|MRX-6|b.i.d treatment for 21 days
436715|NCT00867607|Drug|Steroid|b.i.d. 21 days
436716|NCT00867594|Drug|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
436717|NCT00867568|Drug|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
436718|NCT00867555|Dietary Supplement|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
436719|NCT00867542|Other|no intervention|no intervention
436720|NCT00867529|Biological|rituximab|Given IV
436721|NCT00867529|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
436722|NCT00867529|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
436723|NCT00867529|Other|pharmacological study|Correlative studies
436724|NCT00867529|Other|laboratory biomarker analysis|Correlative studies
436725|NCT00867516|Biological|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
436726|NCT00867516|Biological|Infusion without ALD518`|250 cc Normal saline IV over one hour Weeks 1 and 8.
436727|NCT00867503|Drug|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
436728|NCT00867490|Drug|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
436729|NCT00867490|Drug|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
436730|NCT00867490|Drug|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
436731|NCT00867477|Procedure|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
436732|NCT00867477|Behavioral|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
436733|NCT00867477|Procedure|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
436734|NCT00867451|Behavioral|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
436735|NCT00867451|Drug|Melatonin|Body Weight <40mg will be given 3mg at bedtime for two weeks Body Weight >40mg will be given 6 mg at bedtime for two weeks
436736|NCT00867438|Procedure|Sigmoidoscopy|
436789|NCT00867100|Drug|700 mg IV|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
436790|NCT00867100|Drug|350 mg SC|single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
436923|NCT00866307|Drug|mercaptopurine|Given PO
436924|NCT00866307|Drug|thioguanine|Given PO
436737|NCT00867425|Behavioral|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.~Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
436738|NCT00867399|Drug|ABT-126|See arm for details
436739|NCT00867373|Behavioral|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
436740|NCT00867360|Drug|Mifepristone (RU-486)|
436741|NCT00867360|Drug|Placebo|Placebo medication
436742|NCT00867347|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
436743|NCT00867347|Radiation|radiation therapy|Patients undergo radiotherapy
436744|NCT00867334|Drug|Imatinib mesylate and panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
436745|NCT00867334|Drug|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
436746|NCT00867321|Biological|bevacizumab|Given IV
436747|NCT00867321|Drug|sorafenib tosylate|Given orally
436748|NCT00867308|Drug|Lenalidomide 50 mg|
436749|NCT00867308|Drug|Lenalidomide 15 mg|
436750|NCT00867295|Drug|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
436751|NCT00867295|Drug|placebo|placebo
436752|NCT00867282|Drug|Treatment A|PF-00241939 750ug using inhaler A
436753|NCT00867282|Drug|Treatment B|PF-00241939 750ug using inhaler B
436754|NCT00867256|Device|Large Diameter Metal on Metal|
436755|NCT00867230|Drug|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
436756|NCT00867217|Dietary Supplement|High Dose Vitamin D|High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.
436757|NCT00867217|Dietary Supplement|Placebo|Placebo comparator
436758|NCT00867217|Dietary Supplement|Standard Dose Vitamin D3|Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)
436759|NCT00867217|Drug|Letrozole 2.5mg|All subjects received letrozole as standard of care.
436760|NCT00867204|Procedure|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
436761|NCT00867191|Drug|Placebo|Placebo, 1 tablet daily, per os., 15 days
436762|NCT00867191|Drug|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
436763|NCT00867178|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
436764|NCT00867178|Drug|Carboplatin|Given IV
436765|NCT00867178|Drug|Cisplatin|Given IV
436766|NCT00867178|Drug|Cyclophosphamide|Given IV
436767|NCT00867178|Drug|Etoposide Phosphate|Given IV
436768|NCT00867178|Drug|Isotretinoin|Given PO
436769|NCT00867178|Other|Laboratory Biomarker Analysis|Correlative studies
436770|NCT00867178|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
436771|NCT00867178|Drug|Thiotepa|Given IV
436772|NCT00867178|Drug|Vincristine Sulfate|Given IV
436773|NCT00867178|Drug|Vorinostat|Given PO
436774|NCT00867165|Drug|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
436775|NCT00867165|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
436776|NCT00867152|Drug|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
436777|NCT00867152|Drug|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
436778|NCT00867152|Drug|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
436779|NCT00867152|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
436780|NCT00867152|Drug|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
436781|NCT00867139|Drug|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
436782|NCT00867139|Drug|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
436783|NCT00867139|Other|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
436784|NCT00867126|Drug|pioglitazone hydrochloride|
436785|NCT00867126|Other|laboratory biomarker analysis|
436786|NCT00867126|Other|questionnaire administration|
436787|NCT00867126|Procedure|quality-of-life assessment|
436794|NCT00867087|Drug|rituximab|375 mg/m^2 two days before cycle 1 by intravenous infusion; 375 mg/m^2 every 21 days by intravenous infusion, 3 to 6 doses
436795|NCT00867061|Drug|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
436796|NCT00867048|Drug|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
436797|NCT00867035|Drug|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
436798|NCT00867035|Drug|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
436799|NCT00867009|Drug|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
436800|NCT00867009|Drug|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
436801|NCT00867009|Drug|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles~Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
436802|NCT00866996|Drug|Methylphenidate extended-release; Atomoxetine|
436803|NCT00866983|Drug|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
436804|NCT00866970|Biological|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
436805|NCT00866970|Biological|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
436806|NCT00866970|Biological|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
436807|NCT00866970|Biological|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
436808|NCT00866957|Procedure|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
436809|NCT00866944|Drug|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
436810|NCT00866944|Drug|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
436811|NCT00866944|Drug|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
436812|NCT00866918|Drug|arsenic trioxide|Given IV
436813|NCT00866918|Drug|mitoxantrone hydrochloride|Given IV
436814|NCT00866918|Other|diagnostic laboratory biomarker analysis|Correlative studies
436815|NCT00866918|Drug|idarubicin|Given IV
436816|NCT00866918|Drug|tretinoin|Given orally
436817|NCT00866918|Drug|cytarabine|Given IT or IV
436818|NCT00866918|Drug|mercaptopurine tablet|Given orally
436819|NCT00866918|Drug|methotrexate|Given orally
436820|NCT00866905|Drug|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
436821|NCT00866905|Drug|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
436822|NCT00866892|Procedure|Irrigation|irrigation
436823|NCT00866892|Procedure|No irrigation|no irrigation
436824|NCT00866879|Drug|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
436825|NCT00866879|Other|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
436826|NCT00866879|Procedure|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
436827|NCT00866879|Procedure|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
436828|NCT00866879|Procedure|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
436829|NCT00866879|Other|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
436830|NCT00866879|Procedure|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
436831|NCT00866866|Drug|N-Acetyl Cysteine|600 mg PO BID
436832|NCT00866866|Drug|Placebo|1 tab PO BID
436833|NCT00866853|Drug|TMC435|
436834|NCT00866840|Drug|riluzole|100 mg orally twice daily
436835|NCT00866827|Other|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
436836|NCT00866814|Device|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
436837|NCT00866788|Drug|omalizumab|Administered by subcutaneous injection
436838|NCT00866788|Drug|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
436839|NCT00866788|Drug|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
436840|NCT00866788|Drug|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
436841|NCT00866775|Drug|Eslicarbazepine acetate|1600 mg QD
436842|NCT00866775|Drug|Eslicarbazepine acetate|1200 mg QD
436843|NCT00866762|Drug|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
436844|NCT00866749|Drug|Daunorubicin|Starting Dose 25 mg/m^2 by vein weekly
436845|NCT00866749|Drug|Vincristine|Starting Dose 2 mg by vein weekly
436846|NCT00866749|Drug|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
436847|NCT00866749|Drug|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
436848|NCT00866749|Drug|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
436849|NCT00866749|Drug|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
436850|NCT00866749|Drug|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
436851|NCT00866749|Drug|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10~+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
436852|NCT00866749|Drug|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
436853|NCT00866749|Drug|Thioguanine|60 mg/m2 by mouth daily for two weeks
436854|NCT00866736|Drug|dasatinib|100mg QD
436855|NCT00866723|Drug|bevacizumab|
436856|NCT00866710|Other|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
436857|NCT00866697|Drug|Pazopanib|Pazopanib 800 mg tablet daily for 104 weeks (24 months)
436858|NCT00866697|Drug|Placebo|Matching placebo 800 mg tablet daily, for 104 weeks (24 months).
436859|NCT00866684|Drug|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
436860|NCT00866684|Drug|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
436861|NCT00866684|Drug|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
436862|NCT00866684|Drug|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
436863|NCT00866684|Drug|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
436864|NCT00866671|Drug|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
436865|NCT00866658|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
436866|NCT00866658|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
436867|NCT00866658|Device|Pen auto-injector|
436868|NCT00866658|Drug|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
436869|NCT00866658|Drug|Basal Insulin|To be continued at a stable dose.
436870|NCT00866645|Drug|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
436871|NCT00866645|Drug|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
436872|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
436873|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
436874|NCT00866619|Biological|Malaria Vaccine 257049|administered intramuscularly into the left deltoid.
436875|NCT00866619|Biological|Meningococcal C Conjugate Vaccine|administered intramuscularly into the left deltoid.
436876|NCT00866619|Biological|Cell-culture rabies vaccine|administered intramuscularly into the left deltoid.
436877|NCT00866619|Biological|TritanrixHepB/Hib|administered intramuscularly into the left deltoid.
436878|NCT00866619|Biological|Polio Sabin Oral Polio Vaccine (GSK)|administered orally.
436879|NCT00866606|Biological|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
436880|NCT00866593|Drug|Generic Escitalopram|10mg/d or 20mg/d
436881|NCT00866593|Drug|Innovator Escitalopram|10mg/d or 20mg/d
436882|NCT00866580|Biological|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
436883|NCT00866580|Biological|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
436884|NCT00866580|Biological|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
436885|NCT00866554|Drug|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
436925|NCT00866307|Radiation|prophylactic cranial irradiation|Undergo radiation
436926|NCT00866307|Other|laboratory biomarker analysis|Correlative studies
436927|NCT00866294|Drug|paroxetine IR 10mg tablet|1 or 2 tablets once a day
436886|NCT00866554|Drug|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
436887|NCT00866541|Device|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
436888|NCT00866528|Drug|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
436889|NCT00866528|Drug|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
436890|NCT00866515|Drug|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
436891|NCT00866515|Drug|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
436892|NCT00866502|Drug|sNN0031|Continuous ICV infusion for two weeks
436893|NCT00866502|Drug|Placebo|Continous ICV infusion
436894|NCT00866489|Procedure|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
436895|NCT00866476|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
436896|NCT00866476|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
436897|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
436898|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
436899|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
436900|NCT00866450|Dietary Supplement|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
436901|NCT00866450|Dietary Supplement|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
436902|NCT00866437|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.~Hormones:~Progesterone 1mmol/L~Estradiol 1mmol/L~Estrone 3mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
436903|NCT00866437|Drug|Skin test panel|"Hormones:~Progesterone 1mmol/L~Estradiol 1 mmol/L~Estrone 3 mmol/L~Estriol 3mmol/l~Controls:~Saline (NaCl) 0.9%~Ethyl Oleate with 10% Benzyl Alcohol~Histamine phosphate 1mg/ml (epicutaneous- prick test)"
436904|NCT00866424|Procedure|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
436905|NCT00866411|Procedure|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
436906|NCT00866411|Procedure|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
436907|NCT00866385|Drug|AZD8566|Single 6 mg oral solution dose
436908|NCT00866385|Drug|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
436909|NCT00866359|Drug|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
436910|NCT00866359|Drug|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.~Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.~Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
436911|NCT00866346|Biological|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.~Starting infusion dose 1 x 106 nucleated cells/kg."
436912|NCT00866333|Drug|Entinostat|Entinostat tablets
436913|NCT00866320|Drug|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
436914|NCT00866307|Drug|pegaspargase|Given IV
436915|NCT00866307|Drug|cytarabine|Given IT and IV or SC
436916|NCT00866307|Drug|vincristine sulfate|Given IV
436917|NCT00866307|Drug|doxorubicin hydrochloride|Given IV
436918|NCT00866307|Drug|cyclophosphamide|Given IV
436919|NCT00866307|Drug|prednisone|Given IV or PO
436920|NCT00866307|Drug|dexamethasone|Given IV
436921|NCT00866307|Drug|methotrexate|Given IT and PO
436922|NCT00866307|Drug|daunorubicin hydrochloride|Given IV
436929|NCT00866294|Drug|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
436930|NCT00866294|Drug|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
436931|NCT00866294|Drug|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
436932|NCT00866294|Drug|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
436933|NCT00866281|Drug|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
436934|NCT00866268|Device|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
436935|NCT00866268|Device|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
436936|NCT00866255|Device|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
436937|NCT00866242|Biological|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
436938|NCT00866229|Drug|Rosuvastatin|10 mg per day for 12 weeks
436939|NCT00866229|Drug|Simvastatin|20 mg per day
436940|NCT00866216|Drug|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
436941|NCT00866216|Drug|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
436942|NCT00866203|Drug|HDS vs ProMECE/CytaBOM|
436943|NCT00866190|Drug|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
436944|NCT00866190|Drug|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
436945|NCT00866177|Other|Laboratory Biomarker Analysis|Correlative studies
436946|NCT00866177|Drug|Selumetinib|Given orally
436947|NCT00866164|Device|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
436948|NCT00866138|Drug|masitinib (AB1010)|masitinib 9 mg/kg/day per os
436949|NCT00866112|Other|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
436950|NCT00866112|Other|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
436951|NCT00866099|Other|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.~Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
436952|NCT00866086|Other|questionnaire administration|
436953|NCT00866086|Procedure|computed tomography|
436954|NCT00866086|Radiation|radiation therapy treatment planning/simulation|
436955|NCT00866073|Drug|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
436956|NCT00866060|Drug|Memantine|20mg memantine
436957|NCT00866060|Drug|Donepezil|10mg donepezil
436958|NCT00866060|Drug|Placebo donepezil|Placebo donepezil
436959|NCT00866060|Drug|Placebo memantine|Placebo memantine
436960|NCT00866047|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
436961|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
436962|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
436963|NCT00866021|Drug|Lopinavir/ritonavir|NRTI sparing-regimen
436964|NCT00866021|Drug|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
436965|NCT00866008|Drug|Ovarian stimulation|"Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
436966|NCT00865995|Procedure|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
436967|NCT00865982|Drug|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks~followed by resection~and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
436968|NCT00865969|Drug|PXD101|Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of every 3-week cycle
436969|NCT00865956|Behavioral|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
436970|NCT00865956|Other|Case management|Nurse case manager assigned to participant
436971|NCT00865943|Drug|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
436972|NCT00865943|Drug|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
436973|NCT00865917|Drug|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
436974|NCT00865917|Drug|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
436975|NCT00865917|Drug|Placebo|matching appearance
436976|NCT00865904|Drug|VX-809|Capsules
436977|NCT00865904|Drug|Placebo|Placebo matched to VX-809 capsules.
436978|NCT00865891|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
436979|NCT00865891|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
436980|NCT00865878|Drug|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
436981|NCT00865878|Other|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
436982|NCT00865865|Procedure|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
436983|NCT00865865|Procedure|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
436984|NCT00865852|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
436985|NCT00865852|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
436986|NCT00865839|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
436987|NCT00865839|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
436988|NCT00865826|Other|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
436989|NCT00865813|Procedure|Punch Biopsy|"Instillation of anesthetic eye drops.~Asepsis~Placement of surgical cloths and drapes~Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.~Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions~Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
436990|NCT00865774|Behavioral|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
436991|NCT00865774|Behavioral|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
436992|NCT00865761|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
436993|NCT00865761|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under fasting conditions
436994|NCT00865748|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
436995|NCT00865748|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
436996|NCT00865722|Procedure|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
436997|NCT00865709|Drug|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
436998|NCT00865709|Drug|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
436999|NCT00865696|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
437000|NCT00865696|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
437001|NCT00865683|Dietary Supplement|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
437002|NCT00865683|Dietary Supplement|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
437003|NCT00865670|Drug|Azithromycin Monohydrate 600 mg Tablets|
437004|NCT00865670|Drug|Zithromax (azithromycin dihydrate) 600 mg Tablets|
437005|NCT00865657|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
437006|NCT00865657|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under non-fasting conditions
437007|NCT00865644|Drug|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
437008|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
437009|NCT00865631|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
437010|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
437011|NCT00865618|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
437012|NCT00865618|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
437013|NCT00865605|Drug|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
437014|NCT00865605|Drug|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
437015|NCT00865592|Drug|dutogliptin|dutogliptin 400 mg, once daily tablet
437016|NCT00865579|Drug|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).~Trial Medication is to be taken once daily, in the morning."
437017|NCT00865566|Biological|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
437018|NCT00865566|Biological|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
437019|NCT00865566|Biological|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
437020|NCT00865566|Biological|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
437021|NCT00865553|Behavioral|computer-assisted smoking cessation intervention|
437022|NCT00865553|Other|cancer prevention|
437023|NCT00865553|Other|educational intervention|
437024|NCT00865553|Other|survey administration|
437025|NCT00865540|Drug|prednisolone acetate 1%|1 drop every 8h two days before surgery
437026|NCT00865540|Drug|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
437027|NCT00865540|Drug|nepafenac 0.1%|1 drop every 8h two days before surgery
437028|NCT00865540|Drug|methylcellulose 0.5%|1 drop every 8h two days before surgery
437029|NCT00865527|Other|Fecal occult blood test|FOBT
437030|NCT00865527|Procedure|Virtual colonoscopy|computed tomographic colonography
437031|NCT00865527|Procedure|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
437032|NCT00865514|Drug|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
437033|NCT00865514|Genetic|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
437034|NCT00865514|Other|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
437035|NCT00865514|Other|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
437036|NCT00865501|Drug|spironolactone|25mg per oral once daily
437037|NCT00865501|Drug|placebo|placebo
437038|NCT00865488|Biological|ADHEXIL|Adhesions prevention
437039|NCT00865475|Drug|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
437040|NCT00865475|Drug|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
437041|NCT00865462|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
437042|NCT00865462|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
437043|NCT00865449|Drug|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
437044|NCT00865449|Drug|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
437045|NCT00865436|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
437046|NCT00865436|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
437047|NCT00865423|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
437048|NCT00865423|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
437049|NCT00865410|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
437050|NCT00865410|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
437051|NCT00865397|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
437052|NCT00865384|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
437053|NCT00865384|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
437054|NCT00865371|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
437055|NCT00865371|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
437056|NCT00865358|Behavioral|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
437057|NCT00865345|Device|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
437058|NCT00865319|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
437059|NCT00865319|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
437060|NCT00865306|Behavioral|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
437061|NCT00865280|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
437062|NCT00865280|Drug|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
437063|NCT00865267|Drug|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
437064|NCT00865254|Behavioral|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
437065|NCT00865254|Behavioral|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
437066|NCT00865254|Behavioral|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
437067|NCT00865241|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
437068|NCT00865241|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
437069|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
437070|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
437071|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
437072|NCT00865228|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
437073|NCT00865215|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
437074|NCT00865215|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
437075|NCT00865202|Drug|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
437076|NCT00865202|Drug|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
437077|NCT00865189|Drug|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
437078|NCT00865189|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m^2) as a 2-hour IV infusion.
437079|NCT00865189|Drug|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m^2 as a 2-hour infusion.
437080|NCT00865189|Drug|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m^2 as an IV bolus, then at a dose of 600 mg/m^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
437081|NCT00865189|Radiation|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
437082|NCT00865189|Procedure|Surgery|Radical rectal excision based on the TME technique.
437083|NCT00865176|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
437084|NCT00865176|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
437085|NCT00865137|Drug|Tacrolimus, modified release|Oral
437086|NCT00865124|Drug|Spironolactone|25 mg capsule daily for 6 months
437087|NCT00865124|Drug|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
437088|NCT00865124|Other|Placebo|Placebo capsule daily
437089|NCT00865111|Drug|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
437090|NCT00865111|Drug|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
437091|NCT00865098|Drug|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
437092|NCT00865085|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
437093|NCT00865085|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
437094|NCT00865072|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
437095|NCT00865072|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
437096|NCT00865059|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
437097|NCT00865059|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
437098|NCT00865046|Other|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
437099|NCT00865046|Other|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
437100|NCT00865033|Drug|Metformin HCL Tablets, 1000 mg Sandoz|
437101|NCT00865033|Drug|Glucophage 1000 mg|
437102|NCT00865020|Drug|Aliskiren|Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
437103|NCT00865020|Drug|Telmisartan|Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
437104|NCT00865020|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
437105|NCT00865020|Drug|Placebo to Telmisartan|Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
437106|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
437107|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
437108|NCT00864981|Drug|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
437109|NCT00864981|Drug|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
437110|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
437111|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
437112|NCT00864955|Radiation|UVA and UVB irradiation|"4 cutaneous biopsies for Ex-vivo irradiation~Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
437113|NCT00864942|Drug|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
437114|NCT00864942|Drug|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
437115|NCT00864942|Drug|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
437116|NCT00864942|Drug|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
437117|NCT00864916|Drug|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
437118|NCT00864916|Drug|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
437119|NCT00864916|Drug|Placebo|Participants will receive placebo three times per day for 48 weeks.
437120|NCT00864890|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
437121|NCT00864890|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
437122|NCT00864877|Device|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
437123|NCT00864864|Drug|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
437124|NCT00864851|Biological|Replagal|Intravenous (IV) infusion for 12 months
437125|NCT00864838|Drug|Acetazolamide|250 mg 1 hour before intravitreal injection
437126|NCT00864838|Drug|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
437127|NCT00864838|Procedure|Anterior chamber paracentesis|Immediately after bevacizumab injection
437128|NCT00864825|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
437129|NCT00864812|Drug|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
437130|NCT00864812|Drug|tiotropium|COPD patients treated with tiotropium
437131|NCT00864799|Drug|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
437132|NCT00864786|Drug|PF03635659|Inhaled doses of 200 mcgQD
437133|NCT00864786|Drug|PF03635659|Inhaled doses of 600 mcg QD
437134|NCT00864786|Drug|PF03635659|Inhaled doses of 1000 mcg QD
437135|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
437136|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
437137|NCT00864773|Procedure|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
437138|NCT00864760|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
437139|NCT00864760|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
437140|NCT00864747|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
437141|NCT00864747|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
437142|NCT00864734|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
437143|NCT00864734|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
437144|NCT00864721|Drug|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
437145|NCT00864708|Device|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
437146|NCT00864695|Other|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
437147|NCT00864682|Drug|Saline|3.3 mL normal saline
437148|NCT00864682|Drug|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
437149|NCT00864682|Drug|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
437150|NCT00864669|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
437151|NCT00864669|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
437152|NCT00864643|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
437153|NCT00864643|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
437154|NCT00864630|Behavioral|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
437155|NCT00864617|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
437156|NCT00864617|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
437157|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
437158|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
437159|NCT00864591|Procedure|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
437160|NCT00864591|Procedure|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.~Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
437161|NCT00864565|Drug|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
437162|NCT00864565|Drug|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
437163|NCT00864552|Drug|Kogenate (BAY14-2222)|Patients with severe haemophilia A (<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
437164|NCT00864539|Dietary Supplement|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
437165|NCT00864539|Dietary Supplement|plain milk|daily intake of 200 ml plain milk
437166|NCT00864539|Dietary Supplement|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
437167|NCT00864539|Dietary Supplement|plain orange juice|daily intake of 250 ml plain orange juice
437168|NCT00864539|Dietary Supplement|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
437169|NCT00864539|Dietary Supplement|Placebo|daily placebo
437170|NCT00864526|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
437171|NCT00864526|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
437172|NCT00864513|Drug|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
437173|NCT00864500|Drug|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
437174|NCT00864500|Drug|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
437175|NCT00864487|Drug|Neratinib|HKI-272
437176|NCT00864474|Drug|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
437177|NCT00864448|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
437178|NCT00864448|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
437179|NCT00864435|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
437180|NCT00864435|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
437181|NCT00864422|Behavioral|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
437182|NCT00864422|Behavioral|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
437183|NCT00864409|Drug|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
437184|NCT00864409|Drug|saline.9%|Wound infiltration with 170 mL sterile saline
437185|NCT00864396|Drug|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
437186|NCT00864383|Drug|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin < 45 kg 450 mg > 45 kg 600 mg Isoniazid 300 mg Pyrazinamide < 40 kg 25 mg/kg rounded to nearest 500 mg* 40-55 kg 1000 mg > 55 kg - 75 kg 1500 mg > 75 kg 2000 mg Ethambutol < 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg > 55 kg - 75 kg 1200 mg > 75 kg 1600 mg *For pyrazinamide dosing in patients < 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
437187|NCT00864357|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
437188|NCT00864357|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
437189|NCT00864344|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
437190|NCT00864344|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
437191|NCT00864331|Radiation|radiation|39 Gy in 13 daily fractions of 3 Gy
437192|NCT00864331|Other|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
437193|NCT00864331|Drug|Chemotherapy|Chemotherapy given alone
437194|NCT00864331|Other|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
437195|NCT00864318|Drug|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
437196|NCT00864318|Drug|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
437197|NCT00864318|Drug|Carboplatine|"From cycle 3 to cycle 5 :~Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
437198|NCT00864318|Drug|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
437199|NCT00864318|Procedure|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.~At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
437200|NCT00864305|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
437201|NCT00864305|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
437202|NCT00864305|Drug|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
437203|NCT00864279|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
437204|NCT00864279|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
437205|NCT00864266|Drug|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
437206|NCT00864253|Drug|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
437207|NCT00864253|Drug|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
437208|NCT00864240|Drug|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
437209|NCT00864227|Biological|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~Fludarabine: 40 mg/m^2 intravenously (IV) on Days -6, -5, -4, -3, and -2~Cyclophosphamide: 50 mg/kg IV on Day -6~Total body irradiation: 200 centigray (cGy) on Day -1"
437210|NCT00864227|Biological|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:~Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL~MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later~Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.~Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm^3 for three consecutive measurements, each on different days."
437211|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
437212|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
437213|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
437214|NCT00864214|Drug|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
437215|NCT00864201|Drug|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
437216|NCT00864188|Dietary Supplement|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
437217|NCT00864188|Dietary Supplement|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
437218|NCT00864188|Dietary Supplement|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
437219|NCT00864188|Dietary Supplement|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
437220|NCT00864175|Drug|INCB007839|100 mg BID
437221|NCT00864175|Drug|INCB007839|200 mg BID
437222|NCT00864175|Drug|INCB007839|300 mg BID
437223|NCT00864175|Drug|INCB007839|300 mg BID
437224|NCT00864175|Drug|trastuzumab|trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
437225|NCT00864175|Drug|Docetaxel|
437226|NCT00864162|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
437227|NCT00864162|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
437228|NCT00864149|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
437229|NCT00864149|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
437230|NCT00864136|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
437231|NCT00864136|Drug|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
437232|NCT00864136|Drug|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
437233|NCT00864123|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
437234|NCT00864123|Drug|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
437235|NCT00864123|Drug|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
437236|NCT00864110|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
437237|NCT00864110|Radiation|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
437238|NCT00864110|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
437239|NCT00864097|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
437240|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
437241|NCT00864097|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
437242|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
437243|NCT00864097|Biological|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
437244|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
437245|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
437246|NCT00864097|Other|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
437247|NCT00864084|Other|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
437248|NCT00864071|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
437249|NCT00864071|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
437250|NCT00864058|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
437251|NCT00864058|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
437252|NCT00864045|Drug|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
437253|NCT00864045|Drug|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
437254|NCT00864032|Drug|Sorafenib|400mg twice daily
437255|NCT00864019|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
437256|NCT00864019|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
437257|NCT00864006|Drug|Divalproex Sodium|
437258|NCT00864006|Drug|Depakote DR Tablets|
437259|NCT00863980|Drug|Micardis (Telmisartan)|40-80 mg/day oral administration
437260|NCT00863980|Drug|Blopress (Candesartan)|8-12 mg/day oral administration
437261|NCT00863954|Device|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
437262|NCT00863941|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
437263|NCT00863941|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
437264|NCT00863928|Drug|belladonna 16.2 mg and opium 60 mg suppository|belladonna 16.2 mg and opium 60 mg suppository
437265|NCT00863915|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
437266|NCT00863915|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
437267|NCT00863902|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
437268|NCT00863902|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
437269|NCT00863889|Drug|Depomedrol injection|1 cc of Depomedrol 80
437270|NCT00863889|Drug|Lidocaine, Marcaine|4 cc of each local anesthetic
437271|NCT00863863|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
437272|NCT00863863|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
437273|NCT00863850|Drug|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled [14C] bendamustine will be given on day 1 of cycle 1 only.
437274|NCT00863837|Drug|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
437275|NCT00863837|Drug|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
437276|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
437277|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
437278|NCT00863798|Drug|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
437279|NCT00863785|Drug|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
437280|NCT00863772|Biological|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
437281|NCT00863772|Biological|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
437282|NCT00863772|Other|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
437283|NCT00863759|Procedure|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.~Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.~Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
437284|NCT00863746|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
437285|NCT00863746|Drug|Placebo|Placebo - 2 tablets twice daily (BID)
437286|NCT00863733|Drug|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
437287|NCT00863707|Drug|Regadenoson|IV
437288|NCT00863707|Drug|Placebo|IV
437289|NCT00863681|Drug|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
437290|NCT00863668|Drug|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
437291|NCT00863668|Drug|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
437292|NCT00863668|Procedure|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
438788|NCT00852579|Drug|Azithromycin|Daily dose 250mg
437293|NCT00863668|Procedure|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
437294|NCT00863655|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
437295|NCT00863655|Drug|Exemestane|Exemestane 25 mg orally daily.
437296|NCT00863655|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
437297|NCT00863642|Procedure|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
437298|NCT00863642|Procedure|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
437299|NCT00863629|Drug|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
437300|NCT00863616|Device|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
437301|NCT00863603|Other|oxygen|5 Liter/minute by nasal cannula for 6 wks
437302|NCT00863590|Drug|odanacatib|[Intervention Name: odanacatib (Panel A)] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
437303|NCT00863590|Drug|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
437304|NCT00863590|Drug|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
437305|NCT00863590|Drug|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
437306|NCT00863577|Drug|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
437307|NCT00863564|Dietary Supplement|Caseine|
437308|NCT00863564|Dietary Supplement|Cod|
437309|NCT00863564|Dietary Supplement|Gluten|
437310|NCT00863564|Dietary Supplement|Whey Isolate|
437311|NCT00863551|Drug|Trospium Chloride|Extended release, 60 mg, oral daily
437312|NCT00863538|Drug|KPS-0373|
437313|NCT00863525|Drug|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
437314|NCT00863525|Drug|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
437315|NCT00863512|Drug|cisplatin|Given IV
437316|NCT00863512|Drug|docetaxel|Given IV
437317|NCT00863512|Drug|gemcitabine hydrochloride|Given IV
437318|NCT00863512|Drug|pemetrexed disodium|Given IV
437319|NCT00863512|Drug|vinorelbine tartrate|Given IV
437320|NCT00863512|Procedure|standard follow-up care|Standard care
437321|NCT00863499|Drug|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
437322|NCT00863499|Drug|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
437323|NCT00863473|Procedure|Surgical treatment with LCP|
437324|NCT00863460|Radiation|cranial radiotherapy|40 Gy
437325|NCT00863460|Drug|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
437326|NCT00863460|Drug|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58&59 and days79&80
437327|NCT00863434|Drug|clofarabine|Given IV
437328|NCT00863434|Drug|cytarabine|Given IV
437329|NCT00863434|Biological|filgrastim|Given SC
437330|NCT00863395|Procedure|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
437331|NCT00863382|Device|Standard Event Monitor|Standard Event Monitor
437332|NCT00863382|Device|Sleuth Monitor|Implantable Sleuth Recorder
437333|NCT00863369|Biological|rituximab|Given IV
437334|NCT00863369|Drug|bortezomib|Given IV
437335|NCT00863369|Drug|gemcitabine hydrochloride|Given IV
437336|NCT00863369|Other|questionnaire administration|Ancillary studies
437337|NCT00863356|Device|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
437338|NCT00863343|Biological|Public Health Notification|For any H5 positive results, notification of the result to the site's local public health authorities.
438789|NCT00852579|Drug|Placebo|Placebo
437339|NCT00863330|Biological|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
437340|NCT00863317|Drug|montelukast sodium|4mg granules daily for 14 days
437341|NCT00863317|Other|sucrose|table sugar as placebo daily for 14 days
437342|NCT00863304|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
437343|NCT00863304|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
437344|NCT00863304|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
437345|NCT00863304|Other|placebo|placebo to match tanezumab and naproxen dosing
437346|NCT00863291|Drug|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
437347|NCT00863291|Drug|placebo|Placebo in a manner similar to the active comparator
437348|NCT00863278|Procedure|pulsed dye laser treatment|On one side of the face according to Arm placement.
437349|NCT00863278|Drug|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
437350|NCT00863265|Drug|Ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
437351|NCT00863265|Other|Phytosterols + ezetimibe|Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
437352|NCT00863265|Other|Placebo|
437353|NCT00863252|Drug|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
437354|NCT00863252|Drug|angiotensin blockade|Continuation of angiotensin blockade
437355|NCT00863239|Drug|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight < 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight > 85 kg: 1200 mg/day.
437356|NCT00863239|Drug|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
437357|NCT00863239|Drug|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
437358|NCT00863226|Device|Resonator Device|Application of Magnetic Fields Using the Resonator Device
437359|NCT00863213|Procedure|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.~It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
437360|NCT00863213|Drug|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
437361|NCT00863200|Behavioral|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
437362|NCT00863200|Behavioral|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
437363|NCT00863187|Biological|rituximab|b cell depletion
437364|NCT00863174|Drug|SPARC147709|SPARC147709 injection
437365|NCT00863174|Drug|Reference147709|Reference147709 injection
437366|NCT00863161|Drug|AZD3355|capsule, oral, single dose
437367|NCT00863148|Drug|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
437368|NCT00863135|Device|CPAP|continuous positive airways pressure
437369|NCT00863135|Device|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
437370|NCT00863122|Drug|lapatinib|1500 mg lapatinib by mouth per day for 10 days
437371|NCT00863109|Biological|Peginterferon alfa-2b (PEG)|Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
437372|NCT00863109|Drug|Ribavirin (RBV)|Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
437373|NCT00863096|Biological|Gardasil|HPV vaccine
437374|NCT00863083|Behavioral|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
437375|NCT00863057|Drug|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
437376|NCT00863057|Drug|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
437429|NCT00862784|Drug|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
437430|NCT00862758|Drug|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
437377|NCT00863057|Drug|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
437378|NCT00863057|Drug|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
437379|NCT00863044|Procedure|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
437380|NCT00863044|Procedure|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
437381|NCT00863031|Behavioral|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
437382|NCT00863031|Behavioral|Video-viewing|Three sessions of viewing health educational videos.
437383|NCT00863005|Drug|K201|Cream
437384|NCT00863005|Drug|K201|
437385|NCT00862992|Drug|Cariprazine low dose|
437386|NCT00862992|Drug|Cariprazine medium dose|
437387|NCT00862992|Drug|Cariprazine high dose|
437388|NCT00862979|Drug|Everolimus (EVR)|Everolimus 0.25mg, 0.75mg or 1.0mg based on blood levels (5-10 ng/mL)
437389|NCT00862979|Drug|cyclosporine A (CyA)|10 mg, 25 mg, 50 mg or 100 mg capsule according to blood levels for CNI-regimen group. For CNI-free-regimen dispense on month 6 to 9 only
437390|NCT00862979|Drug|tacrolimus (TAC)|0.5 mg, 1 mg, or 5 mg capsule given according to blood levels for CNI-regimen. For CNI-free-regimen give on month 6 to 9 only
437391|NCT00862979|Drug|Enteric coated mycophenolate sodium (EC-MPS)|180 mg or 360 mg tablet dosed 1440-2280 mg per day
437392|NCT00862979|Drug|mycophenolate mofetil (MMF)|250 mg or 500 mg tablets with a dose of 1500-3000 mg per day
437393|NCT00862979|Drug|Corticosteroids|according to local standard: 0.05-0.3 mg/kg of prednisolone or equivalent
437394|NCT00862966|Other|citrate|comparison of different catheter lock solutions
437395|NCT00862966|Other|heparin|comparison of different lock solutions
437396|NCT00862953|Dietary Supplement|Normal protein energy-restricted|Normal protein diet energy restricted
437397|NCT00862953|Dietary Supplement|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
437398|NCT00862940|Drug|Memantine|10 mg tablets twice daily
437399|NCT00862940|Drug|Placebo|Tablets twice daily
437400|NCT00862927|Other|Breath Sample|Breathe into machine measuring carbon monoxide.
437401|NCT00862927|Other|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
437402|NCT00862927|Behavioral|Questionnaire|6 surveys, taking approximately 30 minutes total.
437403|NCT00862927|Behavioral|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
437404|NCT00862901|Device|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
437405|NCT00862888|Drug|PF-00446687|Single 200mg dose as an oral solution
437406|NCT00862888|Drug|Placebo|Placebo for oral solution
437407|NCT00862888|Drug|Placebo|Placebo for tablet
437408|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
437409|NCT00862888|Drug|PF-00446687|Single 125 mg dose as an oral solution
437410|NCT00862888|Drug|PF-00446687|Single 175 mg dose as an oral solution
437411|NCT00862888|Drug|PF-00446687|Single 20 mg dose as an oral solution
437412|NCT00862888|Drug|Placebo|Placebo for oral solution
437413|NCT00862888|Drug|Placebo|Placebo for tablet
437414|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
437415|NCT00862875|Drug|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
437416|NCT00862849|Drug|Insulin Lispro|
437417|NCT00862849|Drug|Regular Human Insulin|
437418|NCT00862849|Drug|rHuPH20|
437419|NCT00862836|Drug|Vandetanib|100mg doses orally, once daily
437420|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
437421|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
437422|NCT00862810|Biological|Received HPV vaccine first|
437423|NCT00862810|Biological|Received concomitant vaccines first|
437424|NCT00862797|Other|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
437425|NCT00862784|Biological|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
437426|NCT00862784|Drug|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
437427|NCT00862784|Drug|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
437428|NCT00862784|Drug|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
437431|NCT00862745|Drug|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
437432|NCT00862745|Drug|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
437433|NCT00862732|Behavioral|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
437434|NCT00862732|Other|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
437435|NCT00862719|Drug|Sitagliptin|600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
437436|NCT00862706|Drug|Telbivudine/LDT600A|Oral once daily
437437|NCT00862693|Drug|Calcitriol|0.5ug/Biw
437438|NCT00862680|Procedure|4-Dimensional Computed Tomography|Undergo 4D PET/CT
437439|NCT00862680|Procedure|4D PET Scan|Undergo 4D PET/CT scan
437440|NCT00862667|Drug|Treatment A|PF-00241939 300ug using Inhaler A
437441|NCT00862667|Drug|Treatment B|PF-00241939 300ug using Inhaler B
437442|NCT00862667|Drug|Treatment C|PF-00241939 300ug using Inhaler C
437443|NCT00862654|Drug|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
437444|NCT00862654|Drug|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
437445|NCT00862654|Drug|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
437446|NCT00862654|Drug|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
437447|NCT00862641|Drug|Regadenoson|IV
437448|NCT00862641|Drug|Placebo|IV
437449|NCT00862628|Drug|Rebamipide|100mg tid, 4 or 8 weeks
437450|NCT00862615|Other|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.~Isotopes are :~(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
437451|NCT00862602|Behavioral|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet & nutrition and prevention.
437452|NCT00862589|Other|GLP-1 infusion|physiological effect of GLP-1
437453|NCT00862563|Drug|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
437454|NCT00862563|Drug|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
437455|NCT00862563|Drug|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
437456|NCT00862563|Drug|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
437457|NCT00862550|Other|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
437458|NCT00862537|Device|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
437459|NCT00862524|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
437460|NCT00862524|Drug|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
437461|NCT00862511|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
437462|NCT00862511|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
437463|NCT00862498|Other|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
437464|NCT00862472|Drug|DuoTrav APS|DuoTrav APS QD AM
437465|NCT00862472|Drug|DuoTrav|DuoTrav QD AM
437466|NCT00862459|Drug|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
437467|NCT00862459|Drug|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
437468|NCT00862459|Drug|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
437469|NCT00862459|Drug|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
437470|NCT00862446|Drug|Omegaven|1 gram/kg/day daily until on feeds
437471|NCT00862433|Drug|Alpha Tocopherol Vitamin E|Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.
437472|NCT00862433|Other|Vitamin C|Oral vitamin C, one gram daily.
437473|NCT00862420|Drug|clopidogrel (SR25990)|oral administration (tablets)
437474|NCT00862420|Drug|ticlopidine|oral administration (tablets)
437475|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
437476|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
437477|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
437478|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
437479|NCT00862381|Drug|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
437480|NCT00862381|Drug|Placebo|NaCl 0.9%
437481|NCT00862368|Behavioral|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
437482|NCT00862368|Behavioral|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
437483|NCT00862368|Behavioral|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
437484|NCT00862355|Drug|SPARC147609|IV infusion
437485|NCT00862355|Drug|Reference147609|IV infusion
437486|NCT00862342|Drug|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
437487|NCT00862329|Dietary Supplement|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
437488|NCT00862329|Dietary Supplement|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
437489|NCT00862329|Dietary Supplement|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
437490|NCT00862329|Dietary Supplement|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
437491|NCT00862316|Device|Oxford Unicompartmental Knee|Knee Arthroplasty
437492|NCT00862303|Biological|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
437493|NCT00862303|Drug|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
437494|NCT00862277|Biological|Menactra®|0.5 mL, Intramuscular (from a previous study)
437495|NCT00862277|Biological|Menomune®|0.5 mL, Intramuscular (from a previous study)
437496|NCT00862264|Drug|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
437497|NCT00862251|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
437498|NCT00862251|Drug|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
437499|NCT00862251|Drug|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
437500|NCT00862251|Drug|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
437501|NCT00862238|Behavioral|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
437502|NCT00862238|Other|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, & C
437503|NCT00862225|Drug|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
437504|NCT00862225|Drug|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
437505|NCT00862225|Drug|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
437506|NCT00862212|Behavioral|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
437558|NCT00861809|Drug|GSK962040 1250 mg|125 mg
437559|NCT00861796|Drug|CYR-101|Experimental arm
437560|NCT00861796|Drug|Placebo|Placebo comparator
437507|NCT00862186|Behavioral|'Fatigue Facts & Fixes'|"'Fatigue Facts & Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
437508|NCT00862160|Device|ROCsafeTM|using minimized perfusion circuit while CABG
437509|NCT00862147|Behavioral|ICDP|Parent training group
437510|NCT00862147|Behavioral|Treatment as usual|Parent and/or child focused interventions
437511|NCT00862134|Drug|PR104|770 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
437512|NCT00862134|Drug|docetaxel|75 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
437513|NCT00862134|Drug|docetaxel|60 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
437514|NCT00862134|Drug|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
437515|NCT00862121|Drug|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
437516|NCT00862121|Drug|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
437517|NCT00862108|Drug|Methylphenidate|mg/kg dose: 0.7~1.2mg/kg PO daily morning intake 8 weeks
437518|NCT00862095|Drug|Placebo|Every month for 3 months
437519|NCT00862095|Drug|Propranolol|target does 80 mg per day for 3 months
437520|NCT00862095|Drug|Amitriptyline|Target does of 50 mg per day for 3 months
437521|NCT00862095|Drug|Topiramate|Target dose 100 mg a day for 3 months
437522|NCT00862082|Drug|PR104 550 mg/m^2 + sorafenib|550 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
437523|NCT00862082|Drug|PR104 770 mg/m^2 + sorafenib|770 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
437524|NCT00862056|Procedure|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
437525|NCT00862043|Drug|Sildenafil Citrate|40 mg t.i.d.
437526|NCT00862043|Drug|Placebo|Placebo t.i.d.
437527|NCT00862030|Procedure|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
437528|NCT00862017|Dietary Supplement|MSg supplementation|
437529|NCT00862017|Dietary Supplement|NaCl supplementation|
437530|NCT00862004|Procedure|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
437531|NCT00861991|Behavioral|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
437532|NCT00861978|Drug|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
437533|NCT00861978|Drug|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
437534|NCT00861965|Biological|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
437535|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
437536|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
437537|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
437538|NCT00861952|Other|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
437539|NCT00861952|Other|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
437540|NCT00861939|Drug|Bupropion HCI 300 mg Extended-Release Tablets EON|
437541|NCT00861939|Drug|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
437542|NCT00861926|Drug|Ventolin|Ventolin : salbutamol sulfate 100µg
437543|NCT00861926|Drug|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
437544|NCT00861913|Other|Laboratory Biomarker Analysis|Correlative studies
437545|NCT00861913|Drug|Pazopanib Hydrochloride|Given orally
437546|NCT00861913|Other|Pharmacological Study|Correlative studies
437547|NCT00861887|Drug|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
437548|NCT00861887|Drug|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
437549|NCT00861874|Drug|Decitabine|20 mg/m2 IV, Days 1-5
437550|NCT00861874|Drug|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
437551|NCT00861861|Drug|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
437552|NCT00861861|Drug|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
437553|NCT00861835|Other|ROSE|rapid on-site evaluation by cytopathology
437554|NCT00861822|Other|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).~In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
437555|NCT00861809|Drug|GSK962040 25 mg|25 mg
437556|NCT00861809|Drug|Placebo|placebo comparator
437557|NCT00861809|Drug|GSK962040 50 mg|50 mg
437561|NCT00861783|Drug|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
437562|NCT00861783|Drug|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.~Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
437563|NCT00861770|Other|Ultrafiltration|Ultrafiltration based on standard of care.
437564|NCT00861770|Other|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
437565|NCT00861757|Drug|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
437566|NCT00861757|Drug|Placebo|PO, QD (30 min after meal) for 12 weeks
437567|NCT00861757|Drug|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
437568|NCT00861744|Biological|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
437569|NCT00861744|Biological|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
437570|NCT00861744|Biological|Varivax®|Subcutaneous injection, one dose
437571|NCT00861744|Biological|Havrix®|Intramuscular injection, one dose
437572|NCT00861744|Biological|Prevnar®|Intramuscular injection, one dose
437573|NCT00861731|Drug|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
437574|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
437575|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
437576|NCT00861718|Drug|AZD7268|Capsule, Oral, QD
437577|NCT00861718|Drug|AZD7268|Capsule, Oral, BID
437578|NCT00861718|Drug|Placebo|Capsule, Oral BID
437579|NCT00861705|Biological|Bevacizumab|Given IV
437580|NCT00861705|Drug|Carboplatin|Given IV
437581|NCT00861705|Drug|Cyclophosphamide|Given IV
437582|NCT00861705|Drug|Doxorubicin Hydrochloride|Given IV
437583|NCT00861705|Other|Laboratory Biomarker Analysis|Correlative studies
437584|NCT00861705|Drug|Paclitaxel|Given IV
437585|NCT00861692|Drug|argatroban|
437586|NCT00861679|Procedure|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:~Number of Cells:~Number of nucleated cells infused exceed 2,5x10*7/kg recipient BW or~Number of nucleated cells collected exceed 3x10*7/kg BW~Number of CD34+ cells infused exceed 2x10*5/kg Recipient BW~GVHD-prophylaxis:~• MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)~• UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.~HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.~If many choices available ABO- major incompatibility should be avoided."
437587|NCT00861666|Behavioral|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.~Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.~Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
437588|NCT00861640|Drug|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
437589|NCT00861640|Drug|Oral Rabeprazole|Oral Rabeprazole 1 bid
437590|NCT00861627|Biological|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
437591|NCT00861627|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
437592|NCT00861627|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
437593|NCT00861614|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
437594|NCT00861614|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
437595|NCT00861601|Drug|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
437596|NCT00861601|Drug|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
437597|NCT00861588|Drug|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
437598|NCT00861588|Drug|placebo|starch placebo
437599|NCT00861562|Drug|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
437600|NCT00861562|Drug|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
437601|NCT00861549|Drug|Phencynonate hydrochloride|2mg/tablet
437602|NCT00861536|Drug|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
437603|NCT00861536|Drug|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
437604|NCT00861523|Drug|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
437609|NCT00861471|Drug|Docetaxel|"One treatment cycle is defined as 21 days.~Docetaxel: 70 mg/m^2 (60 mg/m^2 was tested in Phase I as well), Intravenous, every 21 days."
437610|NCT00861471|Drug|Imatinib Mesylate|"One treatment cycle is defined as 21 days.~Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
437611|NCT00861458|Drug|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
437612|NCT00861445|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
437613|NCT00861445|Other|Placebo|Placebo tablets two times a day for 10 weeks
437614|NCT00861432|Other|additive homeopathic treatment|These patients receive additive homeopathic treatment
437615|NCT00861419|Drug|Sorafenib|Sorafenib 400 mg PO (BID)
437616|NCT00861419|Drug|AMG 706|AMG 706 125 mg PO (QD)
437617|NCT00861419|Drug|AMG 706|AMG 706 75 mg PO (QD)
437618|NCT00861419|Drug|AMG 386|AMG 386 10 mg/kg IV (QW)
437619|NCT00861419|Drug|Sunitinib|Sunitinib 50 mg PO (QD)
437620|NCT00861419|Drug|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
437621|NCT00861419|Drug|AMG 386|AMG 386 3 mg/kg IV (QW)
437622|NCT00861406|Drug|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
437623|NCT00861406|Drug|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
437624|NCT00861393|Behavioral|CBT|12 Session CBT group
437625|NCT00861393|Behavioral|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
437626|NCT00861380|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
437627|NCT00861380|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.~Control 3+1 and Control 2+1 groups, only for children < 12 months of age at the time of first study vaccination."
437628|NCT00861380|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children >= 12 months of age at the time of first study vaccination.
437629|NCT00861367|Drug|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
437630|NCT00861354|Device|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
437631|NCT00861341|Drug|Aspirin|81 mg
437632|NCT00861341|Drug|Pioglitazone|30mg Pioglitazone x1
437633|NCT00861328|Drug|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
437634|NCT00861328|Drug|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
437635|NCT00861315|Drug|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
437636|NCT00861315|Drug|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
437637|NCT00861315|Drug|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
437638|NCT00861315|Drug|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
437639|NCT00861302|Behavioral|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
437640|NCT00861276|Drug|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
437641|NCT00861276|Drug|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
437642|NCT00861263|Device|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
437643|NCT00861250|Drug|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
437644|NCT00861237|Drug|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
437645|NCT00861237|Drug|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
437646|NCT00861224|Other|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
437647|NCT00861211|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
437648|NCT00861211|Drug|Placebo|Placebo comparator
437649|NCT00861198|Other|ERCP as per medical indication|ERCP as per medical indication
437650|NCT00861185|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
437651|NCT00861185|Drug|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
437652|NCT00861172|Procedure|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.~We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.~The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
437653|NCT00861146|Behavioral|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
437654|NCT00861133|Device|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
437655|NCT00861120|Drug|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
437656|NCT00861120|Drug|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
437657|NCT00861107|Biological|AlloStim-7|intradermal injection once a week for 3 weeks
437658|NCT00861107|Procedure|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
437659|NCT00861107|Biological|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
437660|NCT00861107|Biological|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10^8 cell dose and if no toxicity dose escalates to 10^9 cell dose.
437661|NCT00861094|Drug|cisplatin|
437662|NCT00861094|Drug|5-FU|
437663|NCT00861094|Drug|oxaliplatin|
437664|NCT00861094|Radiation|radiation therapy|
437665|NCT00861094|Drug|Folinic Acid|
437666|NCT00861081|Behavioral|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
437667|NCT00861081|Behavioral|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
437668|NCT00861068|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
437669|NCT00861068|Other|Placebo|Placebo tablets two times a day for 10 weeks
437670|NCT00861042|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
437671|NCT00861029|Drug|Pazopanib|Subjects treated with pazopanib
437672|NCT00861029|Other|Placebo for pazopanib|Control for comparison with pazopanib
437673|NCT00861029|Drug|Moxifloxacin|Comparator for pazopanib
437674|NCT00861029|Other|Placebo for moxifloxacin|Placebo for moxifloxacin
437675|NCT00861016|Drug|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
437676|NCT00861003|Device|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
437677|NCT00860990|Other|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
437678|NCT00860977|Drug|valacyclovir|oral valacyclovir 500mg twice daily
437679|NCT00860977|Drug|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
437680|NCT00860964|Drug|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
437681|NCT00860964|Drug|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
437682|NCT00860951|Device|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
437683|NCT00860938|Drug|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
437684|NCT00860925|Drug|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
437685|NCT00860925|Drug|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
437686|NCT00860925|Drug|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
437687|NCT00860925|Drug|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
437688|NCT00860912|Procedure|Collagen Matrix|surgical/reinforcing material
437689|NCT00860899|Drug|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine [Catapres®, Boehringer Ingelheim, Germany], 7 mL of 0.25% levobupivacaine [Chirocaine®, Abbott S.p.A., Italy] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
437690|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
437691|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
437692|NCT00860873|Dietary Supplement|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
437693|NCT00860873|Dietary Supplement|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
437694|NCT00860860|Drug|TF2|TF2: 75-300 mg
437695|NCT00860860|Drug|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
437696|NCT00860847|Dietary Supplement|Aged garlic extract and Coenzyme Q10|AGE (1200 mg) and CoQ10 (120 mg)
437697|NCT00860834|Behavioral|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
437698|NCT00860834|Behavioral|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
437699|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
437700|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
437701|NCT00860808|Drug|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
437702|NCT00860795|Biological|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
437703|NCT00860795|Drug|placebo|placebo 25 ml daily in 2 divided doses for 10 days
437704|NCT00860782|Behavioral|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
437705|NCT00860769|Behavioral|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
437706|NCT00860769|Behavioral|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
437707|NCT00860756|Other|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
437708|NCT00860743|Drug|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
437709|NCT00860730|Device|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
437710|NCT00860717|Procedure|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
437711|NCT00860717|Radiation|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact."
437712|NCT00860704|Drug|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
437713|NCT00860691|Procedure|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
437714|NCT00860691|Procedure|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
437715|NCT00860691|Other|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
437716|NCT00860678|Other|Physical activity|
437717|NCT00860678|Other|no Intervention|
437718|NCT00860652|Radiation|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
437719|NCT00860652|Radiation|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
437720|NCT00860639|Drug|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
437762|NCT00860340|Drug|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
438692|NCT00853203|Behavioral|Questionnaires|Written survey taking about 1 hour.
437721|NCT00860626|Drug|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
437722|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
437723|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
437724|NCT00860613|Other|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
437725|NCT00860600|Drug|PG2|500mg/vial, iv infusion, 3 ~ 5 times/week, 2.5 ~ 3.5 hr/time
437726|NCT00860574|Drug|treosulfan|Given IV
437727|NCT00860574|Drug|fludarabine phosphate|Given IV
437728|NCT00860574|Radiation|total-body irradiation|Low dose starting at 2Gy
437729|NCT00860574|Procedure|peripheral blood stem cell transplantation|Given IV per institutional standard practice
437730|NCT00860574|Drug|tacrolimus|Given IV or PO
437731|NCT00860574|Procedure|allogeneic bone marrow transplantation|Given IV per institutional standard practice
437732|NCT00860574|Procedure|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
437733|NCT00860574|Drug|methotrexate|Given IV
437734|NCT00860548|Drug|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
437735|NCT00860535|Other|Comparator: Biomarker evaluation|"Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a ~3.5 month period.~Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day [qd]), dasatinib (recommended dose 70 mg twice a day [bid]), or nilotinib (recommended dose 400 mg bid).~Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I."
437736|NCT00860522|Drug|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
437737|NCT00860522|Drug|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
437738|NCT00860509|Other|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
437739|NCT00860496|Drug|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
437740|NCT00860496|Drug|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
437741|NCT00860483|Other|observational|PET Scan
437742|NCT00860470|Dietary Supplement|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
437743|NCT00860470|Dietary Supplement|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
437744|NCT00860457|Drug|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
437745|NCT00860457|Drug|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
437746|NCT00860457|Drug|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
437747|NCT00860444|Behavioral|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
437748|NCT00860444|Behavioral|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
437749|NCT00860431|Drug|AST-120|6g/day (3 times a day)
437750|NCT00860418|Behavioral|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
437751|NCT00860418|Behavioral|Standard asthma education|Standard asthma education during 2 home visits.
437752|NCT00860405|Drug|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
437753|NCT00860405|Drug|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
437754|NCT00860392|Drug|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
437755|NCT00860379|Drug|Selenium1|2 ug/kg
437756|NCT00860379|Drug|Selenium2|4 ug/kg
437757|NCT00860379|Drug|Placebo|IV saline as placebo
437758|NCT00860366|Drug|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
437759|NCT00860366|Other|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
437760|NCT00860353|Drug|AZD2551|Single dose of oral solution.
437763|NCT00860314|Procedure|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
437764|NCT00860314|Procedure|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
437765|NCT00860301|Other|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
437766|NCT00860288|Drug|Vildagliptin|
437767|NCT00860288|Drug|Metformin|
437768|NCT00860288|Drug|Placebo|
437769|NCT00860288|Drug|Sitagliptin|
437770|NCT00860275|Drug|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
437771|NCT00860275|Drug|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
437772|NCT00860275|Drug|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
437773|NCT00860275|Drug|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
437774|NCT00860275|Drug|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
437775|NCT00860262|Drug|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
437776|NCT00860262|Drug|telmisartan|telmisartan 80mg for the 8w, no titration required
437777|NCT00860262|Drug|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
437778|NCT00860249|Behavioral|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
437779|NCT00860249|Behavioral|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
437780|NCT00860236|Other|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
437781|NCT00860236|Behavioral|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
437782|NCT00860223|Drug|Digoxin|
437783|NCT00860223|Drug|Neratinib|HKI-272
437784|NCT00860210|Device|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
437785|NCT00860197|Dietary Supplement|Fully torrefied coffee|Fully torrefied coffee
437786|NCT00860197|Dietary Supplement|Partially torrefied coffee|Partially torrefied coffee
437787|NCT00860171|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
437788|NCT00860171|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV
437789|NCT00860171|Other|Laboratory Biomarker Analysis|Correlative studies
437790|NCT00860158|Drug|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
437791|NCT00860158|Drug|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
437792|NCT00860158|Procedure|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
437793|NCT00860145|Procedure|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
437794|NCT00860145|Procedure|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
437795|NCT00860119|Drug|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
437796|NCT00860119|Drug|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
437797|NCT00860106|Other|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
437798|NCT00860093|Other|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
437799|NCT00860093|Drug|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
437887|NCT00859378|Device|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith & Nephew)
438785|NCT00852605|Other|Intermittent Non-Invasive Ventilation|
437800|NCT00860080|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
437801|NCT00860080|Drug|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
437802|NCT00860067|Biological|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
437803|NCT00860067|Biological|FluMist/B/Yamagata|0.2 mL dose at Day 0
437804|NCT00860067|Biological|FluMist/B/Victoria|0.2 mL dose at Day 0
437805|NCT00860054|Dietary Supplement|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
437806|NCT00860041|Behavioral|pain questionnaires|
437807|NCT00860028|Drug|Varenicline|
437808|NCT00860015|Drug|Alimta/Gemcitabine|500 mg/m2 Alimta via IV for 10 minutes, followed by 1000 mg/m2 Gemcitabine via IV for 90 minutes for 14 days. This cycle is repeated for 4 cycles
437809|NCT00859989|Behavioral|behavioral dietary intervention|
437810|NCT00859989|Behavioral|exercise intervention|
437811|NCT00859989|Behavioral|telephone-based intervention|
437812|NCT00859989|Other|counseling intervention|
437813|NCT00859989|Other|educational intervention|
437814|NCT00859989|Other|immunoenzyme technique|
437815|NCT00859989|Other|laboratory biomarker analysis|
437816|NCT00859989|Other|questionnaire administration|
437817|NCT00859989|Other|study of socioeconomic and demographic variables|
437818|NCT00859989|Procedure|evaluation of cancer risk factors|
437819|NCT00859989|Procedure|support group therapy|
437820|NCT00859976|Device|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
437821|NCT00859976|Device|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
437822|NCT00859950|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
437823|NCT00859937|Drug|Dasatinib|Given PO
437824|NCT00859937|Other|Laboratory Biomarker Analysis|Correlative studies
437825|NCT00859911|Dietary Supplement|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
437826|NCT00859898|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
437827|NCT00859898|Drug|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
437828|NCT00859898|Drug|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
437829|NCT00859898|Drug|dapagliflozin matching Placebo|Tablets
437830|NCT00859898|Drug|metformin HCl Modified Release matching Placebo|Tablets
437831|NCT00859885|Drug|Antithrombotic treatment|antiplatelets, anticoagulants
437832|NCT00859885|Device|percutaneous device closure of PFO|umbrella device for PFO closure
437833|NCT00859872|Drug|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
437834|NCT00859872|Drug|haloperidol|haloperidol IM injection (5-20mg/d)
437835|NCT00859859|Device|Vagus Nerve Stimulation|"Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.~Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
437836|NCT00859846|Procedure|Arterial line placement|"The following measures will be collected and compared.~Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.~number of attempts, defined as forward advancements of needle, required to cannulate the artery.~number of separate skin punctures.~number of arteries into which entry is attempted."
437837|NCT00859833|Drug|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
437838|NCT00859833|Drug|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
437839|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
437840|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
437841|NCT00859794|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognitive functions.
437842|NCT00859794|Other|Releasing Data|Subjects in the study will be asked to release data about their surgery, and electrostimulation to the research team for analysis.
437843|NCT00859794|Other|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsych evaluations for analysis.
437844|NCT00859794|Other|Additional electrode implantation|Subjects normally will have anywhere from 100-200 electrodes implanted as part of their surgery. As part of the study, we would implant additional electrodes that are able to record from smaller, more specific parts of the brain to better understand how your brain is wired.
437888|NCT00859378|Device|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
437889|NCT00859365|Procedure|Real Acupuncture|Real acupuncture treatment in real acupuncture points
437845|NCT00859794|Other|Brain stimulation|Subjects may be asked to undergo additional electrical brain stimulation (in addition to what is required for clinical purposes) to map brain function and epileptogenic areas. This may include extended stimulation mapping, low frequency stimulation (CCEPs), and transcranial stimulation.
437846|NCT00859781|Drug|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
437847|NCT00859781|Drug|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
437848|NCT00859781|Drug|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
437849|NCT00859781|Drug|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
437850|NCT00859768|Other|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
437851|NCT00859755|Drug|ARRY-403, glucokinase activator; oral|single dose, escalating
437852|NCT00859755|Drug|Placebo; oral|matching placebo
437853|NCT00859742|Procedure|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
437854|NCT00859729|Biological|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
437855|NCT00859729|Device|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
437856|NCT00859716|Biological|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
437857|NCT00859716|Biological|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
437858|NCT00859703|Drug|Risedronate|35mg oral risedronate once per week for 24 months
437859|NCT00859703|Drug|Placebo|Placebo 35 mg once a week for 24 months
437860|NCT00859664|Other|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
437861|NCT00859651|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.~Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
437862|NCT00859651|Drug|Placebo capsule|Matching placebo capsules
437863|NCT00859638|Behavioral|Physiotherapy|group self-management classes
437864|NCT00859638|Behavioral|Occupational Therapy|group self-management classes
437865|NCT00859638|Behavioral|Capacity Building|workshops and case reviews with primary health care team members
437866|NCT00859625|Procedure|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
437867|NCT00859599|Device|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
437868|NCT00859599|Device|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
437869|NCT00859586|Device|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
437870|NCT00859573|Drug|Modafinil|400 mg/day
437871|NCT00859573|Drug|Placebo|inactive substance
437872|NCT00859547|Biological|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
437873|NCT00859534|Drug|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
437874|NCT00859521|Drug|Levetiracetam|1000 mg Tablet
437875|NCT00859521|Drug|Keppra®|1000 mg Tablet
437876|NCT00859508|Device|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
437877|NCT00859508|Device|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
437878|NCT00859495|Drug|Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)|Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.
437879|NCT00859469|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV infusion for 2 hours
437880|NCT00859469|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes
437881|NCT00859456|Drug|Sunitinib|"Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.~A small molecule, multi-targeted receptor tyrosine kinase inhibitor that selectively targets and intracellularly blocks the signaling pathways of receptor tyrosine kinase (RTKs)."
437882|NCT00859430|Drug|Levetiracetam|1000 mg Tablet
437883|NCT00859430|Drug|Keppra®|1000 mg Tablet
437884|NCT00859417|Procedure|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
437885|NCT00859417|Device|Perigee® prosthesis|Surgical method with Perigee® prosthesis
437886|NCT00859404|Drug|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
437890|NCT00859365|Procedure|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
437891|NCT00859365|Procedure|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
437892|NCT00859352|Drug|AZD1981|oral tablets during 14 consecutive days.
437893|NCT00859352|Drug|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
437894|NCT00859339|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
437895|NCT00859339|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
437896|NCT00859339|Drug|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
437897|NCT00859339|Procedure|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
437898|NCT00859313|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
437899|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
437900|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
437901|NCT00859274|Drug|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
437902|NCT00859261|Procedure|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
437903|NCT00859261|Procedure|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
437904|NCT00859235|Drug|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
437905|NCT00859235|Other|Plain water|Mouth wash prior to procedure
437906|NCT00859222|Drug|LBH589|
437907|NCT00859222|Drug|bevacizumab|
437908|NCT00859196|Drug|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
437909|NCT00859196|Drug|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
437910|NCT00859183|Drug|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
437911|NCT00859183|Drug|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
437912|NCT00859183|Drug|Placebo|Placebo oral
437913|NCT00859170|Device|Accordion device|an antiretropulsion device
437914|NCT00859157|Procedure|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
437915|NCT00859144|Behavioral|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
437916|NCT00859144|Behavioral|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
437917|NCT00859144|Behavioral|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
437918|NCT00859131|Drug|Rabbit Antithymocyte globulin|1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
437919|NCT00859131|Drug|Daclizumab|1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
437920|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
437921|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
437922|NCT00859105|Drug|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
437923|NCT00859105|Drug|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
437924|NCT00859105|Drug|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
437925|NCT00859105|Drug|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
437926|NCT00859092|Dietary Supplement|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
437927|NCT00859079|Drug|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
437928|NCT00859079|Drug|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
437929|NCT00859053|Drug|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
437930|NCT00859040|Drug|SOM230C|Injection in the buttocks every 28 days
437931|NCT00859027|Drug|risedronate|35 mg/week by mouth
437932|NCT00859027|Drug|Placebo risedronate oral tablet|One tablet by mouth every week as directed
437933|NCT00859014|Biological|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
437934|NCT00859001|Drug|FM+R|Fludarabine-Mitoxantrone-Rituximab
437935|NCT00859001|Drug|Zevalin (Ibritumomab Tiuxetan)|
437936|NCT00858988|Drug|Rifaximin|100mg of rifaxin for 7 consecutive days, twice daily
437937|NCT00858988|Drug|Placebo|twice daily for 7 consecutive days
437938|NCT00858975|Procedure|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
437939|NCT00858962|Drug|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
437940|NCT00858936|Drug|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
437941|NCT00858936|Drug|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
437942|NCT00858923|Device|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
437943|NCT00858910|Other|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
437944|NCT00858910|Other|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:~the disease (stroke),~therapy options,~self-help groups and their offers for support,~helping aids for independent living at home."
437945|NCT00858897|Other|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-[3,3-2H2]cysteine
437946|NCT00858897|Drug|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
437947|NCT00858884|Other|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
437948|NCT00858871|Drug|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
437949|NCT00858871|Drug|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
437950|NCT00858871|Drug|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
437951|NCT00858871|Drug|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
437952|NCT00858858|Drug|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
437953|NCT00858845|Drug|Clonidine Patch|A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
437954|NCT00858845|Other|Matching Placebo Patch|A matching placebo patch to be worn for a period of 3 months.
437955|NCT00858832|Drug|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
437956|NCT00858806|Drug|Imatinib|"Intermittent Imatinib administration.~1 week on / 1 week off for the 1st month(weeks 1-4)~2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
437957|NCT00858793|Procedure|PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)|Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
437958|NCT00858780|Drug|Etanercept|50 mg etanercept once weekly + methotrexate
437959|NCT00858780|Drug|Etanercept|25mg etanercept once weekly + methotrexate
437960|NCT00858780|Drug|Placebo|Placebo comparator once weekly + methotrexate
437961|NCT00858767|Dietary Supplement|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
437962|NCT00858767|Dietary Supplement|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
437963|NCT00858767|Dietary Supplement|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
437964|NCT00858754|Drug|methylnaltrexone|
437965|NCT00858754|Drug|placebo|
437966|NCT00858741|Radiation|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
437967|NCT00858741|Radiation|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
437968|NCT00858728|Behavioral|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
437969|NCT00858728|Behavioral|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
437970|NCT00858715|Drug|aspirin|100 mg aspirin
437971|NCT00858715|Drug|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
438819|NCT00852332|Dietary Supplement|Curcumin|
437972|NCT00858702|Drug|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
437973|NCT00858702|Drug|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
437974|NCT00858689|Drug|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
437975|NCT00858676|Drug|acarbose|50mg acarbose 3 times a day PO. duration: one year
437976|NCT00858663|Radiation|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
437977|NCT00858663|Drug|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.~Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.~Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
437978|NCT00858650|Other|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
437979|NCT00858637|Drug|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
437980|NCT00858637|Drug|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
437981|NCT00858637|Drug|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
437982|NCT00858637|Drug|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
437983|NCT00858624|Drug|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
437984|NCT00858611|Drug|VRC-FLUDNA047-00-VP|
437985|NCT00858611|Drug|Flulaval (Registered) Seasonal Influenza Vaccine|
437986|NCT00858572|Drug|STA-9090 (ganetespib)|Chemotherapy agent
437987|NCT00858559|Device|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
437988|NCT00858559|Device|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
437989|NCT00858546|Device|Repetitive transcranial stimulation|Repetitive transcranial stimulation
437990|NCT00858533|Behavioral|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
437991|NCT00858507|Behavioral|RN Brief Intervention|RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
437992|NCT00858507|Behavioral|Social Worker Outreach|Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
437993|NCT00858494|Drug|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
437994|NCT00858481|Drug|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
437995|NCT00858481|Drug|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
437996|NCT00858481|Drug|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
437997|NCT00858481|Drug|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
437998|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
437999|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
438000|NCT00858455|Drug|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
438001|NCT00858455|Drug|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
438002|NCT00858455|Drug|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
438003|NCT00858455|Drug|GSK1349572|A single dose of GSK1349572
438084|NCT00857740|Behavioral|Education|Education about the neurophysiology of pain
438085|NCT00857727|Drug|Dexmedetomidine|Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
438004|NCT00858442|Procedure|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width & length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width & length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
438005|NCT00858429|Drug|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
438006|NCT00858429|Radiation|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
438007|NCT00858416|Device|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
438008|NCT00858416|Device|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
438009|NCT00858403|Drug|Dasatinib|Take tablets of Dasatinib by mouth once a day.
438010|NCT00858390|Dietary Supplement|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
438011|NCT00858377|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
438012|NCT00858377|Drug|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
438013|NCT00858364|Drug|Darbepoetin alfa|Administered subcutaneously once every 3 weeks
438014|NCT00858364|Drug|Placebo|Administered subcutaneously once every 3 weeks
438015|NCT00858351|Behavioral|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
438016|NCT00858351|Behavioral|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
438017|NCT00858338|Procedure|Potentially curative surgery|"Surgery:~Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.~Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
438018|NCT00858338|Drug|Floxuridine (IP)|"Adjuvant IP Chemotherapy:~week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
438019|NCT00858338|Procedure|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:~week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
438020|NCT00858325|Drug|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
438021|NCT00858312|Other|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
438022|NCT00858312|Other|Low Dairy|less than 1 serving of dairy foods per day.
438023|NCT00858299|Drug|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
438024|NCT00858286|Other|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
438025|NCT00858273|Dietary Supplement|Antioxidant supplement|1 capsule daily with dinner
438026|NCT00858273|Other|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
438027|NCT00858273|Drug|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
438028|NCT00858260|Genetic|blood sample|Searching for Klotho variants in DNA
438029|NCT00858247|Dietary Supplement|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
438030|NCT00858234|Drug|vorinostat|MK0683 (400 mg) Oral, once daily treated for Day 1 through 14 of a 21 day cycle
438031|NCT00858234|Drug|bortezomib|bortezomib (1.3 mg/m2 ) intravenous push on Day 1, 4, 8 and 11 of a 21 day cycle
438032|NCT00858208|Drug|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
438033|NCT00858195|Drug|Indomethacin 75mg Extended-Release Capsules, Sandoz|
438034|NCT00858195|Drug|Indocin 75mg SR Capsules|
438035|NCT00858182|Drug|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
438036|NCT00858182|Drug|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
438037|NCT00858156|Drug|BG9928|Oral 75 mg single dose
438038|NCT00858143|Other|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
438086|NCT00857727|Drug|Saline|Given by a continuous infusion
438087|NCT00857714|Drug|lapatinib|1500 mg lapatinib for 14-21 days
438039|NCT00858130|Device|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
438040|NCT00858117|Biological|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
438041|NCT00858117|Biological|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
438042|NCT00858104|Procedure|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
438043|NCT00858065|Behavioral|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
438044|NCT00858065|Behavioral|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
438045|NCT00858052|Device|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
438046|NCT00858026|Other|Breastmilk|Exclusively breastfed babies
438047|NCT00858026|Other|Standard milk|Weaning babies fed with the standard formula
438048|NCT00858026|Other|Fermented milk|Weaning babies fed with the fermented formula
438049|NCT00858013|Drug|Nateglinide|Nateglinide 90~120mg three times a day
438050|NCT00858013|Drug|Glimepiride|Glimepiride 1~2mg once a day
438051|NCT00858000|Other|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
438052|NCT00857987|Drug|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
438053|NCT00857987|Other|Placebo|Vehicle
438054|NCT00857974|Other|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
438055|NCT00857961|Drug|Testosterone MD-Lotion|Administered Topically
438056|NCT00857948|Drug|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
438057|NCT00857948|Drug|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
438058|NCT00857935|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
438059|NCT00857935|Drug|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
438060|NCT00857922|Other|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
438061|NCT00857909|Drug|Amiloride|1 tablet twice a day
438062|NCT00857909|Drug|Spironolactone|1 tablet twice a day
438063|NCT00857909|Drug|Placebo|Placebo
438064|NCT00857909|Drug|Placebo and spironolactone|5mg twice daily
438065|NCT00857909|Drug|Spironolactone|25mg twice daily
438066|NCT00857896|Drug|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
438067|NCT00857883|Drug|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
438068|NCT00857870|Drug|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.~Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.~After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
438069|NCT00857870|Drug|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
438070|NCT00857857|Drug|GW870086X|Investigational product
438071|NCT00857857|Drug|FP|Positive control
438072|NCT00857857|Drug|Placebo|Placebo control
438073|NCT00857831|Dietary Supplement|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
438074|NCT00857818|Drug|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
438075|NCT00857818|Drug|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
438076|NCT00857805|Procedure|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
438077|NCT00857805|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
438078|NCT00857792|Drug|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
438079|NCT00857779|Biological|subcutaneous immunotherapy|7 injections
438080|NCT00857766|Drug|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
438081|NCT00857766|Other|Placebo|COPD subjects-Placebo DISKUS
438082|NCT00857753|Drug|Fentanyl patch 25 ug/nr Sandoz|
438083|NCT00857753|Drug|Duragesic|
438820|NCT00852332|Drug|Taxotere|
438088|NCT00857701|Device|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
438089|NCT00857688|Drug|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
438090|NCT00857688|Other|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
438091|NCT00857675|Drug|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
438092|NCT00857675|Drug|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
438093|NCT00857675|Drug|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
438094|NCT00857662|Device|Onyx|Embolization
438095|NCT00857662|Device|TRUFILL|Embolization
438096|NCT00857649|Drug|Memantine|20 mg Oral Tablets Once Daily
438097|NCT00857649|Drug|Placebo|Oral Tablets Once Daily
438098|NCT00857636|Behavioral|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
438099|NCT00857623|Drug|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
438100|NCT00857623|Drug|Placebo|Capsule, once daily
438101|NCT00857597|Procedure|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
438102|NCT00857597|Drug|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
438103|NCT00857584|Drug|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
438104|NCT00857584|Drug|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
438105|NCT00857584|Drug|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
438106|NCT00857571|Drug|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
438107|NCT00857571|Drug|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
438108|NCT00857571|Drug|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
438109|NCT00857571|Drug|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
438110|NCT00857571|Drug|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
438111|NCT00857571|Drug|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
438112|NCT00857571|Drug|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
438113|NCT00857571|Drug|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
438114|NCT00857571|Drug|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
438115|NCT00857571|Drug|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
438116|NCT00857558|Drug|saxagliptin|orally administration at 1 mg once a day for 12 weeks
438117|NCT00857558|Drug|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
438118|NCT00857558|Drug|saxagliptin|orally administration at 5 mg once a day for 12 weeks
438119|NCT00857558|Drug|placebo|orally administration once a day for 12 weeks
438120|NCT00857545|Other|Laboratory Biomarker Analysis|Correlative studies
438121|NCT00857545|Biological|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
438122|NCT00857545|Biological|Saponin-based Immunoadjuvant OBI-821|Given SC
438123|NCT00857532|Drug|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
438124|NCT00857519|Drug|Melphalan, Carboplatin|Intra-arterial chemotherapy.
438125|NCT00857506|Drug|florbetapir F 18|370 Mega Becquerel (10 mCi)
438126|NCT00857493|Biological|IMVAMUNE|Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
438127|NCT00857493|Biological|IMVAMUNE|One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
438128|NCT00857480|Drug|NRL972|Single intravenous administration of 2 mg NRL972
438129|NCT00857480|Drug|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
438130|NCT00857480|Drug|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
438131|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
438132|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
438133|NCT00857454|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
438134|NCT00857441|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
438135|NCT00857441|Device|Liberté|Bare metal stent
438136|NCT00857441|Device|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
438137|NCT00857441|Device|Taxus|Paclitaxel eluting stent
438138|NCT00857428|Drug|oxymorphone|Tablets
438139|NCT00857428|Drug|Oxymorphone|40 mg tablets
438140|NCT00857415|Drug|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
438141|NCT00857402|Dietary Supplement|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
438142|NCT00857402|Dietary Supplement|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
438143|NCT00857389|Drug|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
438144|NCT00857389|Drug|Clofarabine|40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
438145|NCT00857389|Drug|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.~High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
438146|NCT00857389|Procedure|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
438147|NCT00857389|Drug|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
438148|NCT00857389|Drug|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
438149|NCT00857389|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
438150|NCT00857389|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
438151|NCT00857389|Drug|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
438152|NCT00857389|Drug|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
438153|NCT00857376|Dietary Supplement|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
438154|NCT00857324|Drug|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:~Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses~In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.~Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4~Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
438155|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
438156|NCT00857311|Biological|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
438157|NCT00857311|Biological|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
438158|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
438159|NCT00857298|Behavioral|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be ~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
438160|NCT00857285|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
438161|NCT00857285|Drug|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
438162|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
438163|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
438164|NCT00857259|Drug|Everolimus|5 mg oral tablet
438165|NCT00857259|Drug|Ranibizumab|0.5 mg administered by intravitreal injection
438166|NCT00857246|Drug|Cetuximab|
438167|NCT00857246|Drug|Irinotecan|
438168|NCT00857246|Drug|Cisplatin|
438169|NCT00857246|Procedure|Surgery|
438170|NCT00857246|Drug|5-FU|
438171|NCT00857246|Radiation|Radiation|
438172|NCT00857233|Drug|Memantine|20 mg oral tablets once daily
438173|NCT00857220|Drug|eszopiclone|One 2 mg tablet per day for 12 months
438174|NCT00857220|Drug|eszopiclone|one 3mg tablet per day for 12 months
438175|NCT00857207|Behavioral|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
438176|NCT00857194|Procedure|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
438177|NCT00857194|Procedure|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
438178|NCT00857168|Drug|Testosterone MD-Lotion|
438179|NCT00857155|Other|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
438180|NCT00857142|Drug|oxymorphone hydrochloride|
438181|NCT00857142|Drug|Opana|
438182|NCT00857129|Procedure|Normal Unit|low-risk patients randomised to Normal Unit
438183|NCT00857129|Procedure|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
438184|NCT00857116|Drug|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
438185|NCT00857116|Drug|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
438186|NCT00857103|Behavioral|CHOICE|Use of Choice support system as preparation for patient consultations
438187|NCT00857090|Drug|OMS201|"Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery~Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery"
438188|NCT00857090|Drug|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
438189|NCT00857077|Drug|Sulfadoxine-pyrimethamine|
438190|NCT00857077|Drug|Placebo|
438191|NCT00857051|Other|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
438192|NCT00857051|Other|Film|A DVD addressing common stressors in the early postpartum.
438193|NCT00857038|Drug|Doxycycline|Doxycycline tablets, 100mg daily
438194|NCT00857038|Drug|Placebo|Placebo tablets 100mg
438195|NCT00857025|Biological|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
438196|NCT00857025|Other|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
438197|NCT00857025|Other|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
438198|NCT00857025|Other|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
438199|NCT00856999|Drug|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
438200|NCT00856986|Drug|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
438201|NCT00856986|Drug|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
438202|NCT00856986|Drug|metformin|Metformin tablets, at least 1500 mg/day
438203|NCT00856973|Drug|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
438204|NCT00856973|Drug|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
438205|NCT00856973|Drug|Placebo|1 tablet per day for 12 weeks
438206|NCT00856960|Drug|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
438207|NCT00856960|Drug|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
438208|NCT00856960|Drug|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
438209|NCT00856960|Drug|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
438210|NCT00856960|Drug|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
438211|NCT00856947|Dietary Supplement|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
438212|NCT00856947|Other|Placebo tablet|2 tablets containing no active substance
438213|NCT00856934|Biological|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
438214|NCT00856934|Biological|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
438215|NCT00856934|Other|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
438216|NCT00856908|Drug|AZD1656|Tolerable dose given twice daily
438217|NCT00856908|Drug|Placebo|Tolerable dose given twice daily
438218|NCT00856882|Dietary Supplement|soy protein|
438219|NCT00856882|Dietary Supplement|isoflavones|
438220|NCT00856882|Dietary Supplement|milk protein|
438221|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
438222|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
438223|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
438224|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
438225|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
438226|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
438227|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
438228|NCT00856856|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
438229|NCT00856843|Drug|BLI800|Solution for oral administration prior to colonoscopy
438230|NCT00856843|Drug|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
438279|NCT00856505|Drug|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
438280|NCT00856492|Biological|bevacizumab|Given IV
438281|NCT00856492|Biological|pegfilgrastim|Given subcutaneously
438282|NCT00856492|Drug|cyclophosphamide|Given IV
438283|NCT00856492|Drug|doxorubicin hydrochloride|Given IV
438231|NCT00856830|Drug|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.~All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.~At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
438232|NCT00856817|Drug|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
438233|NCT00856817|Drug|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
438234|NCT00856804|Drug|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
438235|NCT00856791|Drug|ON 01910.Na|
438236|NCT00856778|Device|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
438237|NCT00856765|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
438238|NCT00856765|Device|Bare metal stent|Bare metal stent
438239|NCT00856765|Device|Drug eluting stent|Paclitaxel eluting stent
438240|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
438241|NCT00856752|Drug|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
438242|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
438243|NCT00856726|Drug|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
438244|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
438245|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
438246|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
438247|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
438248|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
438249|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
438250|NCT00856700|Drug|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
438251|NCT00856687|Drug|PF-03893787|Oral, two doses 12 hours apart
438252|NCT00856687|Drug|Placebo|Oral, two doses 12 hours apart
438253|NCT00856687|Drug|Montelukast|Oral, two doses 12 hours apart
438254|NCT00856674|Biological|OPL-CCL2-LPM|"CCL2-LPM~intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg~2 doses one week apart"
438255|NCT00856661|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
438256|NCT00856661|Drug|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
438257|NCT00856648|Device|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
438258|NCT00856635|Drug|Glatiramer Acetate|20 mg injected daily subcutaneously
438259|NCT00856635|Drug|placebo|injected daily subcutaneously
438260|NCT00856622|Drug|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
438261|NCT00856622|Drug|timolol 0.5% ophthalmic solution|one drop in the morning and evening
438262|NCT00856622|Drug|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
438263|NCT00856609|Drug|Byetta (exenatide)|Exenatide is an injectable medication
438264|NCT00856609|Behavioral|Weight loss|Because response to weight loss
438265|NCT00856609|Other|Metabolic Chamber|The subject stays in the small room
438266|NCT00856609|Drug|Placebo|
438267|NCT00856596|Drug|Sertaconazole nitrate cream 2%|Once a day topical cream
438268|NCT00856583|Drug|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
438269|NCT00856583|Drug|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
438270|NCT00856570|Drug|warfarin|Oral
438271|NCT00856570|Drug|YM178|Oral
438272|NCT00856557|Behavioral|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
438273|NCT00856544|Drug|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
438274|NCT00856544|Drug|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
438275|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
438276|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
438277|NCT00856518|Device|EMST|Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
438278|NCT00856518|Device|Sham|The same device just like the EMST but does not provide a load on the target muscle group
438284|NCT00856492|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
438786|NCT00852592|Device|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
438285|NCT00856479|Device|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
438286|NCT00856479|Procedure|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
438287|NCT00856453|Behavioral|Home yoga practice|training for and tracking of patient's practice of yoga at home
438288|NCT00856453|Behavioral|yoga classes|organized out of home classes for yoga
438289|NCT00856440|Drug|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
438290|NCT00856440|Drug|Colyte|Lavage preparation for colonoscopy
438291|NCT00856440|Drug|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
438292|NCT00856427|Radiation|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
438293|NCT00856427|Procedure|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
438294|NCT00856414|Biological|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
438295|NCT00856401|Drug|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
438296|NCT00856388|Drug|fludarabine phosphate|Given IV
438297|NCT00856388|Drug|melphalan|Given IV
438298|NCT00856388|Radiation|total-body irradiation|Undergo total-body irradiation
438299|NCT00856388|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
438300|NCT00856388|Biological|anti-thymocyte globulin|Given IV
438301|NCT00856375|Drug|NKTR-102|IV every 3 weeks
438302|NCT00856375|Drug|irinotecan|IV every 3 weeks
438303|NCT00856362|Drug|Moxidectin|
438304|NCT00856362|Drug|Midazolam|
438305|NCT00856349|Behavioral|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
438306|NCT00856336|Drug|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
438307|NCT00856323|Drug|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
438308|NCT00856323|Behavioral|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
438309|NCT00856310|Biological|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
438310|NCT00856297|Biological|MenACWY-CRM conjugate vaccine|
438311|NCT00856297|Biological|Licensed comparator|
438312|NCT00856284|Drug|Alogliptin|Alogliptin tablets
438313|NCT00856284|Drug|Metformin|Metformin tablets
438314|NCT00856284|Drug|Glipizide|Glipizide tablets
438315|NCT00856271|Drug|olmesartan medoxomil|oral tablets, once daily for 8 weeks
438316|NCT00856271|Drug|losartan potassium|capsules, once daily for 8 weeks
438317|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
438318|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
438319|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
438320|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
438321|NCT00856245|Drug|Rituximab|375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
438322|NCT00856232|Biological|Medical Air|Compressed medical air
438323|NCT00856232|Biological|Oxygen|Medical Oxygen
438324|NCT00856219|Dietary Supplement|Enteral Continuous|Continuous Tube Feeding for 72 hours
438325|NCT00856219|Dietary Supplement|Enteral Intermittent|Intermittent Tube Feedings
438326|NCT00856219|Dietary Supplement|Parenteral Continuous|Parenteral Continuously for 72 hours
438327|NCT00856206|Biological|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
438328|NCT00856206|Other|Placebo|Placebo subcutaneous injection once a week
438329|NCT00856193|Drug|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
438330|NCT00856193|Drug|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
438331|NCT00856180|Drug|Bevacizumab|
438332|NCT00856180|Drug|Cyclophosphamide|
438333|NCT00856167|Drug|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
438334|NCT00856167|Behavioral|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
438335|NCT00856154|Biological|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.~Gag150 RLLNAWVKV~Gag433 FLGKIWPV~Env 67 NIWATHACV~Pol606 KLGKAGYVV~Vpu66 ALVEMGHHV~Vif101 GLADQLIHL~Vif23 SLVKHHMYV~Gag298 KRWIILGLNKIVRMY~gp41 VWGIKQLQARVLAVERYLKD~Padre AKXVAAWTLKAAA"
438336|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
438337|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
438338|NCT00856115|Other|medical chart review|Patient charts are reviewed to obtain medical data.
438466|NCT00855010|Drug|pioglitazone|pioglitazone 45 mg daily
438467|NCT00855010|Drug|placebo|one daily
438339|NCT00856115|Other|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
438340|NCT00856115|Other|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
438341|NCT00856115|Other|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
438342|NCT00856102|Behavioral|Exercise|Home-base walking program
438343|NCT00856102|Behavioral|Control|Usual care
438344|NCT00856089|Drug|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
438345|NCT00856063|Drug|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
438346|NCT00856050|Drug|letrozole|Taken orally once a day continuously
438347|NCT00856037|Drug|Doxorubicin Hydrochloride|Given IV
438348|NCT00856037|Other|Laboratory Biomarker Analysis|Correlative studies
438349|NCT00856037|Other|Quality-of-Life Assessment|Ancillary studies
438350|NCT00856037|Drug|Topotecan Hydrochloride|Given PO
438351|NCT00856024|Biological|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
438352|NCT00856024|Drug|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
438353|NCT00855985|Procedure|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
438354|NCT00855972|Drug|Low Dose Naltrexone|
438355|NCT00855959|Drug|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
438356|NCT00855959|Drug|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
438357|NCT00855933|Device|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (~13% dry weight CPC)
438358|NCT00855920|Drug|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
438359|NCT00855920|Drug|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
438360|NCT00855920|Other|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
438361|NCT00855920|Other|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
438362|NCT00855907|Other|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.~Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
438363|NCT00855894|Drug|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
438364|NCT00855894|Drug|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
438365|NCT00855881|Drug|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
438366|NCT00855868|Drug|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
438367|NCT00855868|Drug|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose [11C]-PIB
438368|NCT00855855|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
438369|NCT00855842|Device|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
438370|NCT00855829|Device|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
438371|NCT00855829|Device|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).~The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.~Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
438372|NCT00855816|Behavioral|Breathing training|relaxation training
438373|NCT00855803|Radiation|radiation|Given in 1 or 5 fractions
438374|NCT00855790|Other|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
438375|NCT00855777|Drug|etoricoxib|etoricoxib 120 mg/day for 3 days
438376|NCT00855777|Drug|ibuprofen|ibuprofen 1,800 mg/day for 3 days
438377|NCT00855764|Drug|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
439232|NCT00849056|Drug|placebo|placebo weekly subcutaneous injection
438378|NCT00855738|Drug|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"Gabapentin: up to 3.600 mg/d~Lamotrigine: up to 400 mg/d~Levetiracetam: up to 3.000 mg/d~Pregabalin: up to 600 mg/d~Oxcarbazepine: up to 2.400 mg/d~Tiagabine: up to 30 mg/d~Topiramate: up to 400 mg/d~Zonisamide: up to 500 mg/d"
438379|NCT00855725|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
438380|NCT00855725|Other|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
438381|NCT00855725|Other|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
438382|NCT00855725|Other|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
438383|NCT00855712|Device|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
438384|NCT00855712|Device|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
438385|NCT00855699|Drug|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
438386|NCT00855686|Drug|Memantine|20mg once daily oral dose
438387|NCT00855686|Drug|Placebo|Daily oral dose
438388|NCT00855673|Device|Intermittent Mechanical Compression|FM220 device
438389|NCT00855673|Drug|Control|Standard medical treatment
438390|NCT00855660|Drug|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
438391|NCT00855660|Drug|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
438392|NCT00855647|Procedure|Hypo-fractionated Radiotherapy|
438393|NCT00855634|Procedure|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
438394|NCT00855634|Procedure|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
438395|NCT00855621|Procedure|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
438396|NCT00855608|Drug|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
438397|NCT00855595|Drug|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
438398|NCT00855595|Drug|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
438399|NCT00855595|Drug|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
438400|NCT00855582|Drug|Tadalafil|tablet once daily by mouth for 12 weeks.
438401|NCT00855582|Drug|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
438402|NCT00855569|Device|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
438403|NCT00855556|Genetic|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:~Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.~Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.~No fasting, activity or medication restrictions are required prior to or following blood collection.~Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
438404|NCT00855530|Drug|amibegron (SR58611A)|oral administration of 300 mg twice daily
438405|NCT00855517|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
438406|NCT00855491|Procedure|Phaco|AcrySof Single-Piece IOL
438407|NCT00855478|Device|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
438408|NCT00855465|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
438409|NCT00855465|Drug|Placebo|Matching Placebo tid orally for 16 weeks
438410|NCT00855452|Procedure|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
438411|NCT00855439|Drug|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
438412|NCT00855439|Drug|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
438413|NCT00855413|Drug|Darunavir|800 mg orally once daily
438414|NCT00855413|Drug|Ritonavir|100 mg orally once daily
438415|NCT00855413|Drug|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
438416|NCT00855400|Procedure|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
438417|NCT00855400|Procedure|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
438418|NCT00855387|Other|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
438419|NCT00855361|Drug|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
438420|NCT00855348|Other|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
438421|NCT00855335|Drug|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
438422|NCT00855335|Drug|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
438423|NCT00855335|Drug|Etravirine|200 mg (1*200 mg/2*100 mg) tablets twice daily up to 12 weeks postpartum.
438424|NCT00855335|Drug|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
438425|NCT00855335|Drug|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
438426|NCT00855322|Other|Gym exercise group intervention|Gym based circuit class
438427|NCT00855322|Other|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
438428|NCT00855322|Other|Control group|No intervention
438429|NCT00855309|Drug|acyclovir sodium|Given IV
438430|NCT00855283|Drug|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
438431|NCT00855283|Drug|IN NEO|40 mg Neostigmine via intranasal administration
438432|NCT00855283|Drug|IN NEO|60 mg Neostigmine via intranasal administration
438433|NCT00855283|Drug|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
438434|NCT00855283|Drug|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
438435|NCT00855270|Drug|Placebo|IV saline will be used as placebo for control
438436|NCT00855270|Drug|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
438437|NCT00855257|Drug|Acid Nicotinique|
438438|NCT00855257|Drug|Placebo|
438439|NCT00855244|Other|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
438440|NCT00855218|Drug|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. [twice daily], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
438441|NCT00855218|Drug|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
438442|NCT00855205|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
438443|NCT00855192|Behavioral|mindful meditation|interpersonal and psycho-educational
438444|NCT00855192|Behavioral|interpersonal therapy|psycho-educational
438445|NCT00855179|Drug|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
438446|NCT00855179|Drug|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
438447|NCT00855166|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
438448|NCT00855166|Drug|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
438449|NCT00855166|Drug|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
438450|NCT00855166|Drug|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
438451|NCT00855153|Other|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
438452|NCT00855153|Drug|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
438453|NCT00855140|Other|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
438454|NCT00855114|Drug|everolimus|5 mg/day x 7 days by mouth
438455|NCT00855114|Procedure|therapeutic conventional surgery|Definitive excision of breast cancer tissue
438456|NCT00855101|Drug|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
438457|NCT00855088|Drug|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
438458|NCT00855088|Drug|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
438459|NCT00855088|Drug|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
438460|NCT00855075|Device|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
438461|NCT00855062|Drug|minocycline|100 mg capsule every 12 hours by mouth
438462|NCT00855062|Drug|minocycline placebo capsule|1 capsule every 12 hours by mouth
438463|NCT00855049|Drug|Acetaminophen|Intranasal acetaminophen administration
438464|NCT00855049|Drug|Acetaminophen|Oral acetaminophen administration
438465|NCT00855036|Other|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
438468|NCT00854984|Behavioral|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
438469|NCT00854971|Biological|TKCell|Biological/Vaccine: TKCell
438470|NCT00854945|Drug|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
438471|NCT00854932|Other|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
438472|NCT00854919|Drug|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
438473|NCT00854919|Behavioral|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
438474|NCT00854893|Device|transcranial direct current stimulation|1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
438475|NCT00854880|Drug|PDC339|
438476|NCT00854880|Drug|Placebo|
438477|NCT00854867|Drug|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
438478|NCT00854867|Drug|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
438479|NCT00854854|Biological|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
438480|NCT00854841|Drug|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.~Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
438481|NCT00854828|Procedure|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
438482|NCT00854828|Other|Non-operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
438483|NCT00854815|Procedure|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
438484|NCT00854815|Procedure|No Irrigation|Suction only using suction/irrigator
438485|NCT00854802|Drug|Debio 025|Debio 025 supplied in soft gel capsules
438486|NCT00854802|Drug|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
438487|NCT00854802|Drug|Ribavirin|Ribavirin supplied in tablets
438488|NCT00854802|Drug|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
438489|NCT00854789|Biological|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
438490|NCT00854776|Drug|lansoprazole|30 mg once daily
438491|NCT00854776|Drug|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
438492|NCT00854763|Drug|olmesartan|olmesartan
438493|NCT00854750|Drug|ACTHAR|SQ weekly injections
438494|NCT00854750|Drug|ACTHAR|SQ weekly injections
438495|NCT00854750|Drug|ACTHAR|SQ weekly injections
438496|NCT00854750|Drug|ACTHAR|SQ weekly injection
438497|NCT00854737|Dietary Supplement|cytidine|cytidine (2g po daily for 4 months)
438498|NCT00854737|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
438499|NCT00854737|Drug|placebo|sugar pill
438500|NCT00854724|Drug|Puerarin, Placebo|400 mg, three times a day for 7 days
438501|NCT00854711|Procedure|inhaled nitric oxide|80 PPM
438502|NCT00854698|Other|exercise training|subjects are asked to exercise 20 or 30 minutes.
438503|NCT00854698|Other|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
438504|NCT00854685|Drug|ART621|3.0mg/kg s.c. - weekly
438505|NCT00854685|Drug|ART621|3.0mg/kg s.c. - fortnightly
438506|NCT00854685|Drug|ART621|1.5mg/kg s.c. - weekly
438507|NCT00854685|Drug|ART621|1.5mg/kg s.c. - fortnightly
438508|NCT00854685|Drug|Placebo|Placebo s.c. - weekly
438509|NCT00854685|Drug|Placebo|Placebo s.c. - fortnightly
438510|NCT00854659|Drug|ABT-102|BID tablets, 7 days of treatment
438511|NCT00854659|Drug|Placebo|BID tablets, 7 days of treatment
438512|NCT00854646|Drug|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
438513|NCT00854633|Drug|Talactoferrin|Enteral, 150 mg/kg twice per day
438514|NCT00854633|Drug|Placebo|Oral, twice per day
438515|NCT00854620|Drug|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
438516|NCT00854607|Other|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
438564|NCT00854139|Radiation|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
438642|NCT00853554|Drug|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
438643|NCT00853554|Drug|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
439233|NCT00849030|Drug|Anastozole (Arimidex)|1mg, orally, once daily
438517|NCT00854594|Behavioral|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
438518|NCT00854581|Biological|PEG-interferon alfa-2b|Administered subcutaneously.
438519|NCT00854581|Biological|Interferon alfa-2b|Administered intravenously.
438520|NCT00854581|Drug|Valproic Acid|Administered orally.
438521|NCT00854581|Drug|Zidovudine|Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
438522|NCT00854568|Drug|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
438523|NCT00854568|Drug|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
438524|NCT00854555|Other|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
438525|NCT00854555|Other|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
438526|NCT00854542|Behavioral|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
438527|NCT00854529|Drug|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
438528|NCT00854516|Procedure|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).~Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
438529|NCT00854503|Drug|Simvastatin|20 mg/day in one oral administration
438530|NCT00854503|Drug|Rosuvastatin|20 mg/day in one oral administration.
438531|NCT00854477|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
438532|NCT00854451|Drug|omeprazole plus amoxicillin|
438533|NCT00854451|Drug|omeprazole plus amoxicillin|
438534|NCT00854451|Drug|omeprazole plus amoxicillin|
438535|NCT00854451|Drug|omeprazole plus amoxicillin|
438536|NCT00854438|Other|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
438537|NCT00854425|Drug|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
438538|NCT00854412|Other|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
438539|NCT00854399|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
438540|NCT00854386|Drug|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
438541|NCT00854386|Drug|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
438542|NCT00854373|Drug|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
438543|NCT00854373|Other|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
438544|NCT00854360|Drug|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
438545|NCT00854360|Drug|Placebo|HFA Vehicle Aerosol
438546|NCT00854321|Drug|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
438547|NCT00854321|Drug|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
438548|NCT00854308|Drug|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
438549|NCT00854308|Drug|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
438550|NCT00854308|Drug|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
438551|NCT00854295|Device|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
438552|NCT00854282|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
438553|NCT00854269|Procedure|surgery|cervical biopsy or specimen of hysterectomy
438554|NCT00854256|Procedure|Canaloplasty|Canaloplasty surgery
438555|NCT00854256|Procedure|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
438556|NCT00854230|Drug|Naltrexone|Naltrexone dose 25-100mg
438557|NCT00854217|Procedure|acute normovolemic hemodilution|
438558|NCT00854204|Drug|TMC114; TMC41629|
438559|NCT00854191|Device|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
438560|NCT00854178|Drug|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
438561|NCT00854152|Drug|GDC-0980|Escalating repeating dose
438562|NCT00854139|Drug|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
438563|NCT00854139|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
438565|NCT00854139|Procedure|Bone marrow transplant from a related donor|• Donor bone marrow (> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is > 60 seconds, the protamine treatment shall be repeated
438566|NCT00854126|Drug|GDC-0980|Escalating repeating dose
438567|NCT00854113|Drug|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
438568|NCT00854113|Drug|Placebo|Placebo to match EGT0001474
438569|NCT00854100|Drug|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
438570|NCT00854100|Drug|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
438571|NCT00854100|Drug|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
438572|NCT00854087|Drug|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
438573|NCT00854087|Drug|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
438574|NCT00854074|Device|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
438575|NCT00854061|Drug|T-Pred|sterile ophthalmic solution
438576|NCT00854061|Drug|Pred Forte|sterile ophthalmic solution
438577|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
438578|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
438579|NCT00854009|Drug|BLI-489|
438580|NCT00854009|Drug|Placebo|
438581|NCT00853996|Drug|acolbifene hydrochloride|Given orally
438582|NCT00853983|Drug|[14C] AZD0530|Solution, Oral, once
438583|NCT00853970|Drug|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
438584|NCT00853970|Drug|Placebo Comparator|sterile ophthalmic solution
438585|NCT00853957|Drug|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
438586|NCT00853957|Drug|Amlodipine|Amlodipine 5 mg titrated to 10mg
438587|NCT00853944|Drug|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
438588|NCT00853931|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
438589|NCT00853918|Other|$20 cash|$20 cash incentive mailed with survey
438590|NCT00853918|Other|$50 cash|$50 cash incentive mailed with survey
438591|NCT00853918|Other|$50 check|$50 check incentive mailed with survey
438592|NCT00853918|Other|$100 check|$100 check incentive mailed with survey
438593|NCT00853905|Drug|Triesence|At end of standard glaucoma surgery and the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure, 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound.
438594|NCT00853905|Drug|balanced salt solution BSS|At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
438595|NCT00853892|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
438596|NCT00853892|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
438597|NCT00853879|Dietary Supplement|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
438598|NCT00853879|Dietary Supplement|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
438599|NCT00853879|Dietary Supplement|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
438600|NCT00853866|Drug|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
438601|NCT00853866|Drug|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
438602|NCT00853866|Device|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
438603|NCT00853866|Device|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
438604|NCT00853853|Device|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
438639|NCT00853580|Device|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
438640|NCT00853567|Drug|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
438641|NCT00853567|Other|placebo|Placebo
438691|NCT00853203|Behavioral|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
438605|NCT00853853|Procedure|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
438606|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
438607|NCT00853840|Drug|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
438608|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
438609|NCT00853840|Drug|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
438610|NCT00853827|Drug|Placebo|Placebo
438611|NCT00853827|Drug|Aliskiren|300 mg
438612|NCT00853814|Behavioral|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
438613|NCT00853801|Behavioral|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.~Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
438614|NCT00853775|Other|No intervention, observational study|
438615|NCT00853762|Drug|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
438616|NCT00853762|Drug|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
438617|NCT00853762|Drug|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
438618|NCT00853762|Drug|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
438619|NCT00853749|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
438620|NCT00853749|Procedure|Blood draw|Collection of 10 mL of blood
438621|NCT00853736|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
438622|NCT00853736|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
438623|NCT00853723|Drug|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
438624|NCT00853723|Drug|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
438625|NCT00853723|Drug|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
438626|NCT00853710|Other|PSA assay|rapid prostate specific antigen assay.
438627|NCT00853697|Other|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.~Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
438628|NCT00853684|Drug|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
438629|NCT00853684|Drug|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
438630|NCT00853671|Other|Adenosine Stress Dual-source CTP|"Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; Iopamidol (IV contrast)- total dose of 150cc; Siemens SOMATOM Definition CT scanner (CT scan radiation) - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)~This is an observational trial, and all patients will undergo the Adenosine Stress Dual-source CTP procedure."
438631|NCT00853658|Drug|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
438632|NCT00853658|Drug|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
438633|NCT00853645|Device|Subcutaneous Implantable Defibrillator (S-ICD) System|
438634|NCT00853632|Device|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
438635|NCT00853619|Other|Service based decision support intervention|Delivering CDS via services
438636|NCT00853606|Drug|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
438637|NCT00853593|Device|Pacing Lead|implant and follow-up of study device
438638|NCT00853580|Drug|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
438644|NCT00853528|Other|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
438645|NCT00853528|Procedure|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
438646|NCT00853528|Procedure|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
438647|NCT00853528|Radiation|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
438648|NCT00853528|Radiation|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
438649|NCT00853515|Other|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
438650|NCT00853502|Drug|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
438651|NCT00853489|Device|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
438652|NCT00853489|Procedure|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
438653|NCT00853463|Behavioral|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
438654|NCT00853450|Drug|AZD6482|Single intravenous infusion during a maximum of 5 hours
438655|NCT00853450|Drug|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
438656|NCT00853450|Drug|ASA|75 mg orally once daily during 7 days in each treatment arm
438657|NCT00853424|Procedure|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
438658|NCT00853424|Other|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
438659|NCT00853411|Drug|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
438660|NCT00853398|Procedure|surgical technique|
438661|NCT00853385|Drug|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
438662|NCT00853385|Drug|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
438663|NCT00853385|Other|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
438664|NCT00853385|Other|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
438665|NCT00853385|Biological|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
438666|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of RCC and will be administered to all subjects.
438667|NCT00853372|Drug|AMG386|10 mg/kg IV QW AMG 386 will be administered until a subject develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
438668|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of RCC and will be administered to all subjects.
438669|NCT00853372|Drug|AMG 386|15 mg/kg IV QW AMG 386 will be administered until a subject develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
438670|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
438671|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
438672|NCT00853333|Drug|dexmedetomidine|
438673|NCT00853333|Drug|midazolam|
438674|NCT00853333|Drug|propofol|
438675|NCT00853320|Drug|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
438676|NCT00853320|Drug|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
438677|NCT00853307|Drug|Alisertib|Alisertib capsules
438678|NCT00853294|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
438679|NCT00853294|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
438680|NCT00853281|Other|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
438681|NCT00853281|Other|Standard vector control measures|Insectice-treated net
438682|NCT00853268|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
438683|NCT00853268|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
438684|NCT00853255|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
438685|NCT00853242|Drug|Placebo|
438686|NCT00853242|Drug|Genz-644470|
438687|NCT00853242|Drug|Sevelamer carbonate|
438688|NCT00853229|Drug|pregabalin|pregabalin 150mg twice daily for 4 weeks
438689|NCT00853216|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
438690|NCT00853216|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
439234|NCT00849030|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
438693|NCT00853203|Other|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
438694|NCT00853203|Behavioral|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
438695|NCT00853203|Behavioral|Written Materials|Written educational materials plus community resource information.
438696|NCT00853190|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
438697|NCT00853190|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
438698|NCT00853177|Procedure|MEOPA inhalation|N2O of 50% and 50% O2
438699|NCT00853177|Procedure|xylocaine|Ampoule-bottle of 20 ml
438700|NCT00853164|Behavioral|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
438701|NCT00853164|Behavioral|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
438702|NCT00853164|Behavioral|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
438703|NCT00853151|Drug|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
438704|NCT00853151|Drug|TT223|subcutaneous injection once a day for 4 weeks
438705|NCT00853151|Drug|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
438706|NCT00853151|Drug|Placebo for TT223|subcutaneous injection once a day for 4 weeks
438707|NCT00853138|Behavioral|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.~The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.~Assignments are incorporated into each module for the participant to work on during the treatment week."
438708|NCT00853125|Biological|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
438709|NCT00853125|Drug|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
438710|NCT00853112|Drug|PF-00489791|tablet form, 1 mg, single dose (Day 1)
438711|NCT00853112|Drug|PF-00489791|tablet form, 2 mg, single dose (Day 1)
438712|NCT00853112|Drug|PF-00489791|tablet form, 4 mg, single dose (Day 1)
438713|NCT00853112|Drug|PF-00489791|tablet form, 10 mg, single dose (Day 1)
438714|NCT00853112|Drug|PF-00489791|tablet form, 20 mg, single dose (Day 1)
438715|NCT00853112|Drug|placebo|tablet form, single dose (Day 1)
438716|NCT00853112|Drug|sildenafil|tablet form, 20 mg, single dose (Day 1)
438717|NCT00853099|Biological|adalimumab|
438718|NCT00853099|Drug|placebo|
438719|NCT00853086|Drug|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
438720|NCT00853073|Drug|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
438721|NCT00853073|Other|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
438722|NCT00853047|Drug|Telotristat etiprate|Telotristat etiprate capsules; orally 3 times daily.
438723|NCT00853047|Drug|Octreotide LAR Depot|A stable-dose octreotide LAR depot therapy; administered subcutaneously once per month.
438724|NCT00853047|Drug|Placebo|Placebo-matching telotristat etiprate capsules; orally 3 times daily.
438725|NCT00853034|Dietary Supplement|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
438726|NCT00853034|Dietary Supplement|AXOS|"arabinoxylan-oligosaccharides (AXOS)~intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
438727|NCT00853021|Biological|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
438728|NCT00853021|Biological|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
438729|NCT00853008|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
438730|NCT00853008|Drug|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
438731|NCT00853008|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
438732|NCT00853008|Drug|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
438733|NCT00853008|Drug|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
438734|NCT00853008|Drug|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
438735|NCT00853008|Drug|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
438736|NCT00853008|Drug|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
438737|NCT00853008|Drug|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
438738|NCT00853008|Drug|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
438739|NCT00853008|Drug|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
438740|NCT00853008|Drug|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
438787|NCT00852592|Device|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
438741|NCT00852995|Biological|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
438742|NCT00852995|Biological|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:~Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
438743|NCT00852982|Behavioral|Exercise|Nordic walking, with walking poles, five hours per week during four months
438744|NCT00852969|Drug|Niacin|1000 mg tablets once per day
438745|NCT00852969|Drug|Active Placebo|100 mg Niacin tablets once per day
438746|NCT00852956|Drug|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:~Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)~On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:~Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
438747|NCT00852930|Procedure|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
438748|NCT00852930|Procedure|laser alone|The intervention is therapist administered laser
438749|NCT00852930|Procedure|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
438750|NCT00852917|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
438751|NCT00852917|Drug|Placebo|One Placebo tablet daily.
438752|NCT00852878|Behavioral|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
438753|NCT00852878|Behavioral|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
438754|NCT00852865|Drug|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4*109 CFU
438755|NCT00852865|Drug|Placebo|1 capsule per day
438756|NCT00852852|Behavioral|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
438757|NCT00852839|Drug|Placebo|Placebo to match oromucosal formulation of 552-02
438758|NCT00852839|Drug|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives.
438759|NCT00852826|Procedure|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
438760|NCT00852826|Procedure|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
438761|NCT00852813|Dietary Supplement|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
438762|NCT00852800|Drug|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
438763|NCT00852800|Drug|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
438764|NCT00852787|Drug|Digoxin immune fab|Intravenously one time
438765|NCT00852787|Drug|Placebo|Intravenously one time
438766|NCT00852761|Drug|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
438767|NCT00852761|Drug|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
438768|NCT00852735|Dietary Supplement|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
438769|NCT00852722|Other|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
438770|NCT00852709|Drug|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
438771|NCT00852709|Drug|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
438772|NCT00852696|Drug|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
438773|NCT00852696|Other|Placebo|Take orally once daily for 9 weeks.
438774|NCT00852683|Drug|Pregabalin|75 mg twice a day
438775|NCT00852683|Drug|Placebo|75 mg twice a day
438776|NCT00852670|Drug|ACT-128800|ACT-128800 administered orally once daily
438777|NCT00852670|Drug|Placebo|Matching placebo capsules administered orally once daily
438778|NCT00852657|Procedure|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
438779|NCT00852657|Procedure|Physiotherapy|According to a rehabilitation program which was established prior to study start.
438780|NCT00852644|Procedure|computed tomography|Standard CT scans
438781|NCT00852644|Radiation|fludeoxyglucose F 18|standard doses with CT scans
438782|NCT00852644|Radiation|hypofractionated radiation therapy|4 doses over 2 weeks
438783|NCT00852644|Radiation|stereotactic radiosurgery|CyberKnife radiosurgery
438784|NCT00852631|Drug|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
438790|NCT00852566|Drug|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
438791|NCT00852566|Drug|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
438792|NCT00852540|Drug|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
438793|NCT00852540|Drug|Linezolid|Adult and adolescent (=>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects <5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
438794|NCT00852514|Device|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
438795|NCT00852501|Other|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
438796|NCT00852488|Procedure|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
438797|NCT00852475|Dietary Supplement|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
438798|NCT00852475|Dietary Supplement|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
438799|NCT00852462|Behavioral|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
438800|NCT00852449|Other|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation > 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity < 13% and no further increases in SV
438801|NCT00852436|Drug|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
438802|NCT00852436|Drug|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
438803|NCT00852423|Drug|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
438804|NCT00852423|Drug|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
438805|NCT00852423|Drug|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
438806|NCT00852423|Drug|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
438807|NCT00852410|Drug|1% lidocaine with 1:100,000 adrenaline|high dose
438808|NCT00852410|Drug|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
438809|NCT00852397|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
438810|NCT00852397|Drug|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
438811|NCT00852397|Other|Placebo|Placebo tablet for 24 weeks
438812|NCT00852384|Procedure|NIPPV and IRM|"non invasive positive pressure support ventilation (NIPPV group)~alveolar recruitment maneuver (IRM group)"
438813|NCT00852371|Drug|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
438814|NCT00852371|Drug|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
438815|NCT00852371|Drug|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
438816|NCT00852371|Drug|placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
438817|NCT00852358|Drug|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
438818|NCT00852345|Drug|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
438821|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
438822|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
438823|NCT00852306|Procedure|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
438824|NCT00852293|Other|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
438825|NCT00852280|Device|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
438826|NCT00852267|Other|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
438827|NCT00852267|Other|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
438828|NCT00852267|Other|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
438829|NCT00852241|Drug|Restalyne|one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
438830|NCT00852241|Drug|Perlane|One syringe of Perlane® (1.0cc) will be used total for both tear trough areas.
438831|NCT00852228|Drug|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
438832|NCT00852228|Drug|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00~Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.~5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.~Treatments will be repeated every 2 weeks."
438833|NCT00852228|Drug|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then~Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then~5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.~Treatments will be repeated every 2 weeks."
438834|NCT00852215|Device|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
438835|NCT00852215|Device|Vision stent|Stenting with VISION coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
438836|NCT00852202|Drug|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
438837|NCT00852202|Drug|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
438838|NCT00852202|Drug|placebo|placebo capsules, oral administration, once daily dosing
438839|NCT00852189|Drug|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
438840|NCT00852189|Drug|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
438841|NCT00852189|Drug|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
438842|NCT00852163|Drug|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
438843|NCT00852137|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
438844|NCT00852137|Drug|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
438845|NCT00852124|Biological|VSL#3|VSL#3 2 times daily
438846|NCT00852124|Biological|VSL#3 or placebo|1 packet 2 x daily of placebo
438847|NCT00852098|Procedure|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
438848|NCT00852098|Procedure|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
438849|NCT00852085|Behavioral|Enhanced community service|Two educational sessions and volunteering at a local community service site
438850|NCT00852085|Behavioral|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
438851|NCT00852072|Procedure|Single-operator cholangioscopy-guided laser lithotripsy|Ability to clear the bile duct of all stones in one ERCP session using laser lithotripsy-based technique, including use of mechanical lithotripsy
438852|NCT00852072|Procedure|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones in one ERCP session using large balloon sphincteroplasty-based technique, including use of mechanical lithotripsy
438853|NCT00852059|Drug|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
438854|NCT00852059|Drug|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
438855|NCT00852046|Drug|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
438900|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
438901|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
438856|NCT00852033|Behavioral|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
438857|NCT00852033|Behavioral|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
438858|NCT00852033|Behavioral|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
438859|NCT00852033|Other|Assessment only|No intervention, assessment only.
438860|NCT00852020|Dietary Supplement|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
438861|NCT00852007|Biological|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
438862|NCT00851981|Other|Placebo|TID
438863|NCT00851981|Dietary Supplement|SAMe|300 mg TID
438864|NCT00851968|Procedure|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
438865|NCT00851968|Procedure|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
438866|NCT00851968|Procedure|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
438867|NCT00851942|Drug|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
438868|NCT00851929|Drug|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
438869|NCT00851916|Radiation|CyberKnife Radiosurgery|CyberKnife Radiosurgery
438870|NCT00851903|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
438871|NCT00851903|Drug|Sitagliptin|Oral administration. 100mg film-coated tablets.
438872|NCT00851903|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
438873|NCT00851890|Drug|ABT-333|50 mg capsules
438874|NCT00851890|Other|Placebo for ABT-333|Capsule
438875|NCT00851890|Drug|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
438876|NCT00851890|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
438877|NCT00851877|Biological|Cetuximab|Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor
438878|NCT00851877|Drug|Cisplatin|Cisplatin is an anti-cancer chemotherapy drug
438879|NCT00851877|Drug|Nab-Paclitaxel|paclitaxel albumin-stabilized nanoparticle formulation
438880|NCT00851877|Radiation|intensity-modulated radiation therapy|intensity-modulated radiation therapy
438881|NCT00851864|Drug|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy."
438882|NCT00851838|Drug|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
438883|NCT00851812|Behavioral|Exercise|Standard care monitoring
438884|NCT00851812|Behavioral|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
438885|NCT00851799|Drug|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).~Other Name: TDF/FTC"
438886|NCT00851799|Drug|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
438887|NCT00851799|Drug|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).~Other Name: ATV"
438888|NCT00851799|Drug|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).~Other Name: RAL"
438889|NCT00851799|Drug|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).~Other Name: RTV"
438890|NCT00851786|Biological|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
438891|NCT00851786|Biological|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
438892|NCT00851773|Drug|semaglutide|0.1 mg once weekly, s.c. injection
438893|NCT00851773|Drug|semaglutide|0.2 mg once weekly, s.c. injection
438894|NCT00851773|Drug|semaglutide|0.4 mg once weekly, s.c. injection
438895|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
438896|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
438897|NCT00851773|Drug|placebo|0.1 mg once weekly, s.c. injection
438898|NCT00851773|Drug|placebo|0.2 mg once weekly, s.c. injection
438899|NCT00851773|Drug|placebo|0.4 mg once weekly, s.c. injection
439117|NCT00850018|Behavioral|Usual care|Participants will receive usual care for the treatment of SCD.
438902|NCT00851760|Procedure|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
438903|NCT00851760|Procedure|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
438904|NCT00851747|Drug|Phosphatidylcholine Deoxycholate|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
438905|NCT00851747|Drug|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
438906|NCT00851734|Drug|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
438907|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
438908|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
438909|NCT00851708|Drug|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
438910|NCT00851682|Device|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
438911|NCT00851669|Behavioral|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
438912|NCT00851669|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
438913|NCT00851643|Biological|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
438914|NCT00851643|Biological|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
438915|NCT00851643|Biological|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
438916|NCT00851643|Biological|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
438917|NCT00851643|Biological|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
438918|NCT00851630|Drug|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
438919|NCT00851617|Device|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
438920|NCT00851591|Drug|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
438921|NCT00851591|Drug|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
438922|NCT00851578|Device|WATCHMAN|WATCHMAN LAA Closure Device
438923|NCT00851565|Procedure|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
438924|NCT00851565|Procedure|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
438925|NCT00851552|Biological|rituximab|Given IV
438926|NCT00851552|Drug|bortezomib|Given IV
438927|NCT00851552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
438928|NCT00851552|Genetic|gene expression analysis|Correlative Study
438929|NCT00851552|Genetic|polymerase chain reaction|Correlative Study
438930|NCT00851552|Genetic|polymorphism analysis|Correlative Study
438931|NCT00851552|Genetic|proteomic profiling|Correlative Study
438932|NCT00851552|Other|flow cytometry|Correlative Study
438933|NCT00851552|Other|laboratory biomarker analysis|Correlative Study
438934|NCT00851539|Behavioral|Video|Behavioral Intervention Video
438935|NCT00851513|Drug|Lidocaine|local anesthetics
438936|NCT00851513|Drug|Depmedrol|local steroids
438937|NCT00851513|Other|physiological serum|important volumes of physiological serum
438938|NCT00851500|Drug|K-604|K-604 is given for 26 weeks
438939|NCT00851500|Other|Placebo|placebo tablets are given for 26 weeks
438940|NCT00851487|Drug|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
438941|NCT00851487|Drug|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
438942|NCT00851461|Drug|Goserelin|Goserelin 10.8 mg SC every 3 months
438943|NCT00851461|Procedure|Electrophysiologic study|Nerve conduction study Electromyogram
438944|NCT00851461|Procedure|tissue biopsy|skin and muscle biopsy before and after treatment every year
438945|NCT00851448|Dietary Supplement|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
438946|NCT00851435|Biological|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
438947|NCT00851409|Drug|Recombinant Human C1 Inhibitor|"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."
438948|NCT00851383|Biological|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
438949|NCT00851383|Biological|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
438950|NCT00851370|Drug|Omalizumab (Xolair)|Bi-weekly
438951|NCT00851370|Drug|Placebo|Bi-Weekly
438952|NCT00851357|Drug|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
438953|NCT00851357|Behavioral|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
438954|NCT00851357|Drug|Placebo|Placebo nicotine patch
438955|NCT00851357|Other|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.~Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
438956|NCT00851344|Drug|GSK835726 (10mg)|GSK835726 (10mg) tablet
438957|NCT00851344|Drug|GSK835726 (50mg)|GSK835726 (50mg) tablet
438958|NCT00851344|Drug|GSK835726 (100mg)|GSK835726 (100mg) tablet
438959|NCT00851344|Drug|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
438960|NCT00851344|Other|Placebo|Placebo to match active
438961|NCT00851331|Genetic|genome analyzes (genetic defects and pathophysiological mechanisms )|
438962|NCT00851318|Drug|Certolizumab pegol|Subcutaneous (SC) injection
438963|NCT00851318|Drug|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
438964|NCT00851305|Device|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
438965|NCT00851305|Device|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
438966|NCT00851292|Device|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
438967|NCT00851279|Device|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
438968|NCT00851266|Biological|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:~1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
438969|NCT00851266|Biological|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
438970|NCT00851253|Radiation|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
438971|NCT00851240|Drug|BTT-1023|intravenous
438972|NCT00851240|Drug|Placebo|Intravenous
438973|NCT00851227|Drug|conivaptan hydrochloride|intravenous
438974|NCT00851214|Device|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
438975|NCT00851201|Behavioral|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
438976|NCT00851201|Behavioral|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
438977|NCT00851188|Behavioral|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
438978|NCT00851188|Behavioral|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
438979|NCT00851188|Other|Waiting list|Waiting list
438980|NCT00851175|Drug|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
438981|NCT00851175|Drug|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
438982|NCT00851162|Biological|Trinity multipotent stem cells|Enough to fill voids which vary in size
438983|NCT00851162|Biological|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
438984|NCT00851149|Device|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
438985|NCT00851136|Drug|bevacizumab|Intravenous repeating dose
438986|NCT00851136|Drug|FOLFOX|Intravenous repeating dose
438987|NCT00851136|Drug|PRO95780|Intravenous repeating dose
439118|NCT00850005|Biological|Intravenous immunoglobulin|2 g/kg divided over five days
438988|NCT00851123|Behavioral|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
438989|NCT00851123|Behavioral|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
438990|NCT00851110|Procedure|stem cell reinfusion|hematopoietic stem cell reinfusion
438991|NCT00851110|Drug|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
438992|NCT00851084|Drug|aflibercept|administration: IV infusion
438993|NCT00851084|Drug|oxaliplatin|administration: IV infusion
438994|NCT00851084|Drug|5-FU|administration: IV infusion
438995|NCT00851084|Drug|Folinic Acid|administration: IV infusion
438996|NCT00851071|Behavioral|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
438997|NCT00851058|Behavioral|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
438998|NCT00851058|Behavioral|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
438999|NCT00851058|Behavioral|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
439000|NCT00851058|Behavioral|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
439001|NCT00851045|Drug|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
439002|NCT00851045|Drug|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
439003|NCT00851045|Drug|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
439004|NCT00851045|Drug|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
439005|NCT00851045|Drug|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
439006|NCT00851045|Drug|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
439007|NCT00851045|Drug|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
439008|NCT00851032|Other|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
439009|NCT00851019|Behavioral|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
439010|NCT00851019|Behavioral|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
439011|NCT00851006|Drug|Creatine Monohydrate|Creapure brand of creatine monohydrate
439012|NCT00850993|Drug|Stannsoporfin|Stannsoporfin administered as a single IM injection
439013|NCT00850993|Other|Placebo|Placebo (sterile saline solution) administered as a single IM injection
439014|NCT00850993|Other|PhotoTherapy (as needed)|PT standard care administered as needed, based on bilirubin levels throughout the treatment period
439015|NCT00850954|Other|Informational Intervention|Receive information on secondhand smoke and supporting smoker in quitting
439016|NCT00850954|Behavioral|Smoking Cessation Intervention|Receive smoking cessation materials based on TTM
439017|NCT00850954|Other|Survey Administration|Ancillary studies
439018|NCT00850941|Behavioral|Questionnaire|Information collection.
439019|NCT00850915|Other|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.~In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.~All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
439020|NCT00850902|Other|High Humidity (HH)|High Humidity Level
439021|NCT00850902|Other|Moderate Humidity|Moderate Humidity Level
439022|NCT00850889|Device|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
439023|NCT00850889|Device|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
439024|NCT00850850|Drug|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
439025|NCT00850850|Drug|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
439026|NCT00850837|Drug|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
439027|NCT00850837|Drug|HEC gel|5 g application of hydroxyethylcellulose gel
439028|NCT00850824|Behavioral|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
439029|NCT00850811|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
439030|NCT00850798|Drug|Intensive glycemic control|Intensive glycemic control
439031|NCT00850798|Drug|Conservative glycemic control|OADs and insulin
439032|NCT00850785|Biological|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
439503|NCT00847171|Other|pharmacological study|
439033|NCT00850772|Dietary Supplement|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
439034|NCT00850759|Device|virtual pedestrian environment|a computer-driven virtual pedestrian environment
439035|NCT00850759|Device|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
439036|NCT00850759|Behavioral|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
439037|NCT00850746|Drug|YM443|Oral
439038|NCT00850746|Drug|Placebo|Oral
439039|NCT00850746|Drug|Moxifloxacin|Oral
439040|NCT00850720|Other|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
439041|NCT00850681|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
439042|NCT00850668|Biological|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
439043|NCT00850642|Drug|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
439044|NCT00850642|Drug|Placebo|"Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
439045|NCT00850629|Behavioral|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
439046|NCT00850629|Behavioral|placebo|no intervention, only follow up
439047|NCT00850616|Biological|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
439048|NCT00850616|Biological|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
439049|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
439050|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
439051|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
439052|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
439053|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
439054|NCT00850590|Drug|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
439055|NCT00850577|Drug|Paclitaxel|Solution, IV, 200 mg/m2, Q21days, 6 cycles
439056|NCT00850577|Drug|Carboplatin|Solution, IV, AUC=6, Q21days, 6 cycles
439057|NCT00850577|Drug|CT-322|Solution, IV, 2 mg/kg, Q7days, Until PD
439058|NCT00850577|Drug|Bevacizumab|Solution, IV, 15 mg/kg, Q21days, Until PD
439059|NCT00850577|Drug|Bevacizumab placebo (ie saline solution)|Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
439060|NCT00850564|Drug|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
439061|NCT00850551|Other|Early Intervention|Twice a week home spirometry and symptom assessment
439062|NCT00850538|Radiation|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
439063|NCT00850538|Procedure|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
439064|NCT00850512|Drug|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
439065|NCT00850512|Drug|Zevalin|12-week safety period for Zevalin
439066|NCT00850499|Drug|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
439067|NCT00850499|Drug|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
439068|NCT00850499|Drug|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
439069|NCT00850486|Device|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
439070|NCT00850473|Diagnostic Test|PET/CT|Patient will have one imaging modality - a Positron Emitting Tomography CT which includes F-18 FDG and heparin/intralipid infusion and Contrast Dye.
439071|NCT00850460|Drug|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
439072|NCT00850460|Drug|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
439073|NCT00850447|Other|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
439074|NCT00850447|Other|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
439075|NCT00850421|Drug|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
439119|NCT00850005|Biological|Normal Saline|Same volume as experimental arm
439120|NCT00849992|Drug|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
439235|NCT00849030|Drug|Anastozole (Arimidex) placebo|1mg, orally, once daily
439076|NCT00850408|Procedure|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
439077|NCT00850395|Drug|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
439078|NCT00850382|Drug|Dasatinib|"Induction cycle(s):~Dasatinib 100 mg QD on days 8-21.~Consolidation Cycles 1, 2, 3, 4:~Patients will receive dasatinib 100 mg QD on days 6-28.~Maintenance therapy:~Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
439079|NCT00850382|Drug|daunorubicin|"Induction cycle(s):~Daunorubicin 60 mg/m2/day administered on days 1 through 3"
439080|NCT00850382|Drug|Cytarabine|"Induction cycle(s):~Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).~Consolidation cycles 1, 2, 3, 4:~Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
439081|NCT00850369|Other|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
439082|NCT00850343|Drug|Certolizumab pegol|Subcutaneous (SC) injection
439083|NCT00850330|Other|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
439084|NCT00850304|Drug|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
439085|NCT00850304|Drug|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
439086|NCT00850278|Other|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
439087|NCT00850265|Device|Volumatic spacer|A spacer is a plastic device to inhaler medication
439088|NCT00850252|Device|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
439089|NCT00850239|Drug|dutogliptin|400 mg
439090|NCT00850239|Drug|placebo|
439091|NCT00850226|Behavioral|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
439092|NCT00850226|Behavioral|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
439093|NCT00850213|Device|Endeavor Resolute Stent|Single implantation
439094|NCT00850200|Radiation|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
439095|NCT00850200|Radiation|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
439096|NCT00850200|Radiation|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
439097|NCT00850187|Biological|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
439098|NCT00850174|Drug|Oxcarbazepine|600 mg Tablet
439099|NCT00850174|Drug|Trileptal®|600 mg Tablet
439100|NCT00850161|Drug|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
439101|NCT00850161|Drug|Nasulin™|100 IU(2 puffs in each nostril)
439102|NCT00850148|Procedure|Anwar|Anwar surgical method
439103|NCT00850148|Procedure|Melles|Melles surgical method
439104|NCT00850135|Device|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
439105|NCT00850122|Drug|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage~≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
439106|NCT00850096|Other|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
439107|NCT00850096|Drug|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
439108|NCT00850070|Drug|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
439109|NCT00850070|Drug|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
439110|NCT00850057|Biological|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
439111|NCT00850044|Drug|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
439112|NCT00850044|Drug|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
439113|NCT00850044|Drug|placebo for ABT-450|capsules, QD, one dose
439114|NCT00850044|Drug|Placebo for ritonavir|capsules, QD, one dose
439115|NCT00850031|Device|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
439116|NCT00850018|Procedure|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
439550|NCT00846885|Drug|Sumatriptan Succinate|100 mg Tablet
439121|NCT00849992|Procedure|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
439122|NCT00849979|Behavioral|Questionnaire|Day 1 MDASI-GI Questionnaire
439123|NCT00849979|Other|Interview|Open-ended, audiotaped interviews
439124|NCT00849966|Drug|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
439125|NCT00849966|Drug|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.~All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
439126|NCT00849940|Device|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
439127|NCT00849901|Drug|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
439128|NCT00849901|Drug|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
439129|NCT00849901|Drug|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
439130|NCT00849888|Biological|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects >4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg & serum free (SF) in other. After first 2 subjects >10% naïve T cells, 3rd receives only SF thymus. After 3rd subject >10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant & thymus biopsy. Followed by immune evaluations.
439131|NCT00849888|Other|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg & serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, >10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject >10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy & skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
439132|NCT00849875|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
439133|NCT00849875|Drug|Dacarbazine|Intravenous administration Chemotherapy
439134|NCT00849862|Drug|Levetiracetam|750 mg Tablet
439135|NCT00849862|Drug|Keppra®|750 mg Tablet
439136|NCT00849823|Behavioral|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
439137|NCT00849823|Behavioral|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
439138|NCT00849810|Drug|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
439139|NCT00849810|Drug|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
439140|NCT00849797|Drug|Oxcarbazepine|600 mg Tablet
439141|NCT00849797|Drug|Trileptal®|600 mg Tablet
439142|NCT00849745|Procedure|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
439143|NCT00849732|Biological|V520|Intentionally Blank
439144|NCT00849732|Biological|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^9 vp/d given at Day 1, Week 4, and Week 26
439145|NCT00849732|Biological|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^10 vp/d given at Day 1, Week 4, and Week 26
439146|NCT00849732|Biological|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
439147|NCT00849719|Drug|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
439189|NCT00849472|Drug|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
439190|NCT00849459|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
439148|NCT00849719|Drug|PCA MO only|When visual analog scale [VAS] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
439149|NCT00849706|Other|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
439150|NCT00849693|Drug|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
439151|NCT00849693|Drug|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
439152|NCT00849693|Drug|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
439153|NCT00849693|Drug|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
439154|NCT00849680|Other|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
439155|NCT00849680|Biological|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
439156|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
439157|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
439158|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
439159|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
439160|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
439161|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
439162|NCT00849680|Biological|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
439163|NCT00849667|Drug|MORAb-003 (farletuzumab)|MORAb-003 1.25 mg/kg infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
439164|NCT00849667|Drug|MORAb-003 (farletuzumab)|MORAb-003 2.5mg/kg infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
439165|NCT00849667|Drug|0.9% Saline|0.9% infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
439166|NCT00849654|Drug|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.~In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
439167|NCT00849615|Drug|Docetaxel|50mg/m2 qd15
439168|NCT00849615|Drug|5-Fluorouracil|2600mg/m2 qd15
439169|NCT00849615|Drug|Oxaliplatin|85mg/m2 qd15
439170|NCT00849615|Drug|folinic acid|200mg/m2 qd15
439171|NCT00849602|Drug|Placebo|Placebo bid for three days
439172|NCT00849602|Drug|Chloroquine|Chloroquine bid for three days
439173|NCT00849589|Behavioral|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
439174|NCT00849589|Behavioral|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
439175|NCT00849576|Drug|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
439176|NCT00849576|Drug|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
439177|NCT00849576|Drug|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
439178|NCT00849576|Drug|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
439179|NCT00849563|Other|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
439180|NCT00849550|Drug|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
439181|NCT00849537|Drug|Triamcinolone|Injection of intravitreal Triamcinolone
439182|NCT00849524|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
439183|NCT00849511|Drug|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
439184|NCT00849485|Drug|Levetiracetam|750 mg Tablet
439185|NCT00849485|Drug|Keppra®|750 mg Tablet
439186|NCT00849472|Drug|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
439187|NCT00849472|Drug|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
439188|NCT00849472|Procedure|surgery|neoadjuvant surgery for breast cancer
439191|NCT00849446|Device|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
439192|NCT00849381|Biological|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
439193|NCT00849368|Drug|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets"
439194|NCT00849355|Drug|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.~Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
439195|NCT00849342|Drug|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
439196|NCT00849329|Drug|lapatinib|1250mg lapatinib
439197|NCT00849329|Drug|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
439198|NCT00849316|Drug|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
439199|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
439200|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
439201|NCT00849290|Biological|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
439202|NCT00849277|Drug|Lactobacillus casei Shirota|
439203|NCT00849264|Drug|chemotherapy with endostar|15mg/d×14d
439204|NCT00849264|Drug|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
439205|NCT00849264|Drug|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
439206|NCT00849251|Drug|cyclophosphamide|Given IV or PO
439207|NCT00849251|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
439208|NCT00849251|Drug|bortezomib|Given IV
439209|NCT00849251|Drug|dexamethasone|Given IV or PO
439210|NCT00849238|Drug|mycophenolate mofetil|
439211|NCT00849212|Drug|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
439212|NCT00849186|Drug|sunitinib malate|oral
439213|NCT00849186|Procedure|neoadjuvant therapy|IV
439214|NCT00849186|Procedure|therapeutic conventional surgery|Surgery
439215|NCT00849160|Drug|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
439216|NCT00849147|Biological|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.~Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2~Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5~Total body irradiation (TBI): 200 centigray (cGy) on Day -1~Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
439217|NCT00849147|Biological|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:~Cy: 50 mg/kg IV on Days 3 and 4~Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL~Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID~Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm^3 for 3 consecutive days"
439218|NCT00849134|Drug|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
439219|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
439220|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
439221|NCT00849108|Drug|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~Doses at rest were to range between 2.9 and 3.4 mCi.~Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~Doses at rest were to range between 1.7 and 2.0 mCi.~Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
439222|NCT00849095|Drug|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
439223|NCT00849095|Drug|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
439224|NCT00849095|Drug|placebo|bid inhaled placebo
439225|NCT00849095|Drug|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
439226|NCT00849082|Drug|cyproterone acetate|
439227|NCT00849082|Drug|goserelin acetate|
439228|NCT00849082|Radiation|radiation therapy|
439229|NCT00849069|Biological|GSK2231395A|3 doses intramuscular injections
439230|NCT00849069|Biological|TwinrixTM|3 doses intramuscular injections
439231|NCT00849056|Biological|albiglutide|albiglutide weekly subcutaneous injection
439236|NCT00849030|Drug|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
439237|NCT00849017|Biological|albiglutide|albiglutide weekly injection
439238|NCT00849017|Biological|albiglutide uptitration|albiglutide uptitration at week 12
439239|NCT00849017|Biological|placebo|matching albiglutide placebo weekly injection
439240|NCT00849004|Other|silicone gel|silicone gel
439241|NCT00849004|Other|silicone sheet|silicone sheet
439242|NCT00849004|Other|paper tape|paper tape
439243|NCT00848991|Drug|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
439244|NCT00848991|Drug|Propofol|evaulation of propofol for emergence from anesthesia
439245|NCT00848978|Behavioral|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity ~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
439246|NCT00848965|Drug|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
439247|NCT00848965|Drug|Placebo|Placebo comparator
439248|NCT00848952|Other|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
439249|NCT00848939|Drug|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
439250|NCT00848939|Drug|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
439251|NCT00848926|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
439252|NCT00848913|Other|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
439253|NCT00848913|Other|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
439254|NCT00848900|Behavioral|Outdoor activity|Adding 1 hour outdoor time into school curricula
439255|NCT00848887|Biological|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
439256|NCT00848874|Behavioral|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
439257|NCT00848861|Drug|propofol (sedation for outpatient colonoscopy)|
439258|NCT00848861|Drug|midazolam plus meperidine (sedation for outpatient colonoscopy)|
439259|NCT00848848|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
439260|NCT00848848|Biological|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
439261|NCT00848848|Biological|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
439262|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
439263|NCT00848848|Biological|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
439264|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
439265|NCT00848848|Biological|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
439266|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
439267|NCT00848848|Biological|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
439268|NCT00848848|Biological|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
439269|NCT00848835|Device|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
439270|NCT00848809|Procedure|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
439271|NCT00848809|Procedure|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
439272|NCT00848796|Drug|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
439273|NCT00848783|Drug|Irinotecan|
439274|NCT00848783|Drug|Cisplatin|
439275|NCT00848783|Procedure|Surgery|
439276|NCT00848783|Drug|Floxuridine|
439277|NCT00848783|Drug|Capecitabine|
439278|NCT00848770|Drug|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).~NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.~NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
439279|NCT00848770|Drug|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
439280|NCT00848770|Drug|manipulation of SAP|Esmolol or NPS or NOR
439281|NCT00848757|Behavioral|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
439282|NCT00848744|Drug|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
439283|NCT00848744|Drug|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
439284|NCT00848731|Drug|nitric oxide|nitric oxide gas is delivered by facemask
439285|NCT00848718|Drug|MK-2206|MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)
439286|NCT00848718|Drug|docetaxel|Administered as an IV infusion on Day 1 of each 21-day cycle
439287|NCT00848718|Drug|erlotinib|Administered daily (QD) PO in each 21-day cycle
439288|NCT00848718|Drug|carboplatin|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
439289|NCT00848718|Drug|paclitaxel|Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle
439290|NCT00848718|Drug|corticosteroid|Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
439291|NCT00848705|Behavioral|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
439292|NCT00848692|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
439293|NCT00848692|Drug|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
439294|NCT00848679|Drug|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
439295|NCT00848679|Drug|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
439296|NCT00848666|Drug|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
439297|NCT00848653|Device|CRT device|market approved CRT device
439298|NCT00848640|Drug|Sorafenib|400 mg twice daily
439299|NCT00848627|Other|Specimen and questionnaires only|Specimen and questionnaires only
439300|NCT00848601|Drug|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
439301|NCT00848575|Device|Flexible Endoscope|
439302|NCT00848562|Drug|Nicorandil|Oral administration of nicorandil (15 mg/day)
439303|NCT00848549|Drug|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
439304|NCT00848549|Drug|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
439305|NCT00848536|Drug|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
439306|NCT00848536|Drug|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
439307|NCT00848523|Drug|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
439308|NCT00848510|Biological|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease [SD], complete response [CR], or partial response [PR]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
439309|NCT00848497|Drug|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
439310|NCT00848497|Other|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
439311|NCT00848497|Drug|Viagra®|Viagra 25mg was the dose given to the patient which he started.
439312|NCT00848484|Drug|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
439313|NCT00848484|Drug|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
439314|NCT00848471|Device|Quark RMR|Quark RMR calorimeter (Cosmed)
439315|NCT00848471|Device|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
439316|NCT00848458|Other|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
439317|NCT00848458|Other|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
439318|NCT00848445|Device|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
439319|NCT00848445|Device|Atrial pacing preference turned on or off|programing changes in the device
439350|NCT00848133|Procedure|mini-midvastus surgical approach for total knee arthroplasty|
439351|NCT00848133|Procedure|mini-subvastus surgical approach for total knee arthroplasty|
439352|NCT00848120|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
439320|NCT00848432|Drug|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
439321|NCT00848419|Drug|Epidural administration of bolus|
439322|NCT00848393|Drug|Fentanyl (High Dose)|Fentanyl (High Dose) 25 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
439323|NCT00848393|Drug|Fentanyl (Low Dose)|Fentanyl (Low Dose) 10 mcg/kg in two divided doses. Half-dose will be given at induction and the second half-dose given prior to incision.
439324|NCT00848393|Drug|Fentanyl (Low Dose) + Dexmedetomidine|Fentanyl (Low Dose) + Dexmedetomidine. Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr. In addition, this group will receive a total of 10 mcg/kg Fentanyl (Low Dose). Half the dose will be given at induction and the second half before incision.
439325|NCT00848367|Behavioral|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
439326|NCT00848354|Biological|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
439327|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
439328|NCT00848354|Drug|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.~Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.~Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
439329|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
439330|NCT00848354|Drug|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
439331|NCT00848341|Device|GUIDANT ICD SYSTEM|
439332|NCT00848328|Biological|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
439333|NCT00848328|Drug|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
439334|NCT00848315|Behavioral|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
439335|NCT00848302|Drug|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
439336|NCT00848289|Behavioral|Interviews|Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
439337|NCT00848263|Procedure|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
439338|NCT00848263|Procedure|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
439339|NCT00848250|Drug|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
439340|NCT00848250|Other|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
439341|NCT00848237|Device|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
439342|NCT00848224|Behavioral|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
439343|NCT00848211|Other|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
439344|NCT00848211|Biological|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
439345|NCT00848211|Biological|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
439346|NCT00848211|Biological|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
439347|NCT00848172|Drug|Octanoic Acid|4mg/kg
439348|NCT00848172|Drug|Placebo|identical capsules
439349|NCT00848146|Procedure|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
439423|NCT00847678|Biological|placebo|
439353|NCT00848107|Drug|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
439354|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
439355|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
439356|NCT00848081|Drug|Tadalafil|5 mg taken by mouth once daily for 12 weeks
439357|NCT00848081|Drug|Placebo|By mouth once daily for 12 weeks
439358|NCT00848068|Other|FID 114657|artificial tears
439359|NCT00848068|Other|OPTIVE Lubricant Eye Drops|artificial tears
439360|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
439361|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
439362|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
439363|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
439364|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
439365|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
439366|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
439367|NCT00848055|Drug|AbGn168 subcutaneous injection|single dose subcutaneous injection
439368|NCT00848042|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
439369|NCT00848029|Biological|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
439370|NCT00848016|Drug|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
439371|NCT00848003|Drug|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
439372|NCT00848003|Drug|Placebo|Strawberry flavored yogurt
439373|NCT00847990|Other|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
439374|NCT00847977|Drug|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
439375|NCT00847977|Drug|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
439376|NCT00847964|Device|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
439377|NCT00847951|Procedure|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
439378|NCT00847938|Drug|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
439379|NCT00847938|Drug|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
439380|NCT00847938|Drug|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
439381|NCT00847925|Drug|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
439382|NCT00847912|Drug|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
439383|NCT00847912|Drug|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
439384|NCT00847899|Drug|AR9281|AR9281 taken in BID dosing regimen for 28 days
439385|NCT00847899|Drug|AR9281|AR9281 taken in TID dosing regimen for 28 days
439386|NCT00847899|Drug|Placebo|Placebo taken in BID dosing regimen for 28 days
439387|NCT00847899|Drug|Placebo|Placebo taken in TID dosing regimen for 28 days
439388|NCT00847886|Drug|LX3305|Daily oral intake of LX3305 for 14 days.
439389|NCT00847886|Drug|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
439390|NCT00847886|Drug|Methotrexate|Once weekly stable-dose methotrexate.
439391|NCT00847873|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
439392|NCT00847873|Behavioral|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
439393|NCT00847860|Drug|Cilostazol|Cilostazol 100 mg bid for 12 months
439394|NCT00847860|Drug|Aspirin|Aspirin 100 mg qd for 12 months
439424|NCT00847678|Biological|Amphotericin B|
439425|NCT00847678|Biological|5 flucytosine|
439426|NCT00847665|Other|repositioning|Turning every 4 or 2 hours
439501|NCT00847171|Other|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
439502|NCT00847171|Other|laboratory biomarker analysis|
439395|NCT00847847|Procedure|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
439396|NCT00847834|Drug|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
439397|NCT00847834|Drug|Irbesartan 150mg|Once a day
439398|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439399|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439400|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439401|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439402|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439403|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439404|NCT00847821|Drug|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439405|NCT00847821|Drug|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
439406|NCT00847808|Drug|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
439407|NCT00847795|Drug|Avotermin|Intradermal administration
439408|NCT00847795|Drug|Placebo|Placebo
439409|NCT00847782|Procedure|Blood draw|1 day
439410|NCT00847769|Other|High velocity, low amplitude stretch|This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
439411|NCT00847769|Other|Slow, mobilization stretch|This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
439412|NCT00847769|Other|Passive Positioning|This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
439413|NCT00847756|Other|questionnaire|Identification of risk factors
439414|NCT00847756|Procedure|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
439415|NCT00847756|Procedure|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
439416|NCT00847756|Procedure|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
439417|NCT00847743|Dietary Supplement|Tart Cherry Juice|8 fl.oz. twice per day
439418|NCT00847730|Device|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an environment that promotes wound healing in chronic and acute wounds
439419|NCT00847717|Procedure|Selective neck dissection|Level IIb preserving neck dissection
439420|NCT00847717|Procedure|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
439421|NCT00847704|Device|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
439422|NCT00847678|Biological|Efungumab (Mycograb)|
439427|NCT00847639|Drug|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.~Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.~The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
439428|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
439429|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
439430|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
439431|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
439432|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
439433|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
439434|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
439435|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
439436|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
439437|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
439438|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
439439|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
439440|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
439441|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
439442|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
439443|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
439444|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
439445|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
439446|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
439447|NCT00847600|Dietary Supplement|Pregnenolone|50 mg, caps.
439448|NCT00847600|Dietary Supplement|Placebo|caps
439449|NCT00847587|Drug|Etonogestrel contraceptive implant|Implant insertion postpartum prior to hospital discharge
439450|NCT00847587|Drug|Etonogestrel contraceptive implant|Standard insertion at 4-8 weeks postpartum
439451|NCT00847574|Behavioral|Moderate-fat|35% of calories from fat
439452|NCT00847574|Behavioral|Lower-fat|20% of calories from fat
439453|NCT00847561|Behavioral|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
439454|NCT00847561|Behavioral|Information Monitoring|Packet providing information on strategies for coping with anxiety
439455|NCT00847548|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
439456|NCT00847548|Behavioral|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
439457|NCT00847535|Biological|autologous muscle cell injection|Injection of autologous muscle cells
439458|NCT00847522|Drug|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
439459|NCT00847509|Drug|[F-18]FLT|The individual doses of [F-18]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
439460|NCT00847496|Device|AWBAT|One-time application of dressing over partial-thickness burns
439461|NCT00847496|Device|Biobrane|One-time application over partial-thickness burns
439462|NCT00847483|Drug|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
439463|NCT00847483|Drug|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
439464|NCT00847483|Drug|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
439465|NCT00847457|Behavioral|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
439466|NCT00847457|Behavioral|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
439497|NCT00847171|Biological|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.~Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
439498|NCT00847171|Drug|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
439467|NCT00847444|Drug|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
439468|NCT00847444|Behavioral|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:~Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
439469|NCT00847418|Drug|esketamine hydrochloride|
439470|NCT00847405|Drug|Sumatriptan Succinate|100 mg Tablets
439471|NCT00847405|Drug|Imitrex®|100 mg Tablet
439472|NCT00847392|Procedure|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
439473|NCT00847379|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner) for up to 96 weeks.
439474|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression. The trial specific intervention is specified in the arms descriptions.
439475|NCT00847366|Drug|Trastuzumab|Trastuzumab was given 6mg/kg i.v. daily or 2 mg/kg i.v. on day 1, 8 and 15.
439476|NCT00847366|Drug|Tamoxifen|Endocrine therapy with tamoxifen will be evaluated in combination with perifosine to determine if the combination overcomes resistance to endocrine therapy .
439477|NCT00847340|Procedure|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
439478|NCT00847327|Behavioral|Parental Support|The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
439479|NCT00847327|Behavioral|Diabetes Education|The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
439480|NCT00847314|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 35yrs in medical practices fulfilling all criteria for documentation.
439481|NCT00847288|Other|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
439482|NCT00847288|Other|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
439483|NCT00847275|Other|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
439484|NCT00847275|Other|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
439485|NCT00847262|Drug|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
439486|NCT00847262|Drug|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
439487|NCT00847249|Drug|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
439488|NCT00847249|Drug|Placebo|Each subject will receive a single-dose.
439489|NCT00847223|Drug|ZARNESTRA (Tipifarnib)|
439490|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
439491|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
439492|NCT00847197|Drug|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
439493|NCT00847197|Drug|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
439494|NCT00847184|Device|Intubation|Intubation using the standard MacIntosh blade
439495|NCT00847184|Device|Airtraq|Intubation with the use of the Airtraq technique
439496|NCT00847171|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:~12 intradermal injections of a divided total dose of 5 x108 cells."
439499|NCT00847171|Other|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
439500|NCT00847171|Other|immunoenzyme technique|
439504|NCT00847171|Procedure|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
439505|NCT00847158|Procedure|phacoemulsification alone|phacoemulsification alone
439506|NCT00847158|Device|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
439507|NCT00847145|Biological|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
439508|NCT00847145|Biological|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
439509|NCT00847145|Biological|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
439510|NCT00847145|Biological|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
439511|NCT00847145|Biological|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
439512|NCT00847145|Biological|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
439513|NCT00847145|Biological|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
439514|NCT00847145|Biological|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
439515|NCT00847132|Behavioral|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
439516|NCT00847132|Behavioral|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
439517|NCT00847119|Biological|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
439518|NCT00847119|Drug|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
439519|NCT00847119|Radiation|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
439520|NCT00847106|Drug|Daclizumab|
439521|NCT00847106|Biological|Dendritic cells|
439522|NCT00847093|Drug|LMX4|One inch every six hours
439523|NCT00847093|Drug|LMX4 Placebo|One inch every six hours
439524|NCT00847080|Drug|Sitagliptin phosphate|Sitagliptin phosphate 100 mg per day per 2 weeks
439525|NCT00847080|Drug|Placebo|Placebo 1 tablet per day per 2 weeks
439526|NCT00847067|Procedure|Paravertebral block|3ml 1% Ropivacaine at each level T1 - T5
439527|NCT00847067|Procedure|Sham injections|Sham injections with Normal Saline
439528|NCT00847054|Drug|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
439529|NCT00847028|Other|glucose 10%|2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
439530|NCT00847028|Other|20% glucose|2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
439531|NCT00847028|Other|glucose 30%|2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
439532|NCT00847028|Other|sterile water|2 minutes prior to the venipuncture, sterile water was administered orally
439533|NCT00847015|Drug|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
439534|NCT00847015|Drug|Gemcitabine|Gemcitabine 1,000 mg/m^2
439535|NCT00847015|Drug|cisplatin|cisplatin 35 mg/m^2 will be administered intravenously on days 1 and 8.
439536|NCT00847002|Device|Standard Wound Care|Standard wound care treatment will include gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
439537|NCT00847002|Device|Flexitouch System with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis. They will be instructed to remove the FarrowWrap during the time they are using Flexitouch. The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
439538|NCT00846989|Drug|RKI983A|RKI983 0.05 % twice daily
439539|NCT00846989|Drug|RKI983A|RKI983 0.1 % twice daily
439540|NCT00846989|Drug|Latanoprost|Latanoprost 0.005 % once a day
439541|NCT00846976|Drug|Bicalutamide|200mg daily
439542|NCT00846963|Drug|Ursodiol|"Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (>33mmol/L) to the resolution of cholestasis (conjugated bilirubin <34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.~If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given."
439543|NCT00846963|Drug|placebo|Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
439544|NCT00846950|Drug|dexchlorpheniramine, lorazepam|
439545|NCT00846937|Dietary Supplement|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
439546|NCT00846924|Device|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
439547|NCT00846924|Device|24-hour Holter|Repeat standard 24-hour Holter Monitor
439548|NCT00846911|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
439549|NCT00846898|Dietary Supplement|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
439551|NCT00846885|Drug|Imitrex®|100 mg Tablet
439552|NCT00846872|Drug|GHRP-3 low dose|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
439553|NCT00846872|Drug|GHRP-3 high dose|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
439554|NCT00846872|Drug|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
439555|NCT00846859|Drug|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
439556|NCT00846859|Drug|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
439557|NCT00846846|Device|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
439558|NCT00846833|Biological|Haploidentical NK cell|"Collection of PBMCs by leukapheresis~CD3+ depletion of apheresis product using CliniMACS®"
439559|NCT00846781|Drug|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
439560|NCT00846768|Drug|BI 1744 CL|
439561|NCT00846755|Drug|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
439562|NCT00846742|Drug|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
439563|NCT00846742|Radiation|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
439564|NCT00846729|Procedure|CT angiogram of the remaining kidney.|
439565|NCT00846729|Procedure|Kidney Function study using Iothalamate & PAH as clearance markers|
439566|NCT00846716|Drug|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
439567|NCT00846716|Drug|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
439568|NCT00846703|Drug|6-mercaptopurine, Methotrexate|"6-mercaptopurine p.o. qd~Methotrexate p.o. qw"
439569|NCT00846703|Drug|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|"(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w~(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d~Go to (1) and (2)"
439570|NCT00846690|Drug|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
439571|NCT00846690|Drug|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
439572|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
439573|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
439574|NCT00846664|Procedure|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
439575|NCT00846651|Other|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
439576|NCT00846651|Other|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
439577|NCT00846651|Drug|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
439578|NCT00846638|Behavioral|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
439579|NCT00846638|Behavioral|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
439580|NCT00846625|Drug|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
439581|NCT00846625|Drug|ranibizumab|Intravitreal injection, 0.5 mg
439582|NCT00846612|Drug|Doxil|1 cycle: 3 weeks; 30 mg/m^2, IV, every cycle
439583|NCT00846612|Drug|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
439584|NCT00846599|Other|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
439585|NCT00846599|Other|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
439586|NCT00846586|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
439587|NCT00846586|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
439588|NCT00846586|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
439589|NCT00846573|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
439590|NCT00846547|Drug|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
439591|NCT00846521|Drug|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
439592|NCT00846508|Drug|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
439593|NCT00846495|Drug|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
439594|NCT00846495|Drug|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
439595|NCT00846482|Drug|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
439596|NCT00846469|Procedure|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
439597|NCT00846469|Other|Control section|Normal emergency room treatment for symptoms of chest pain.
439598|NCT00846456|Biological|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
439599|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
439600|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
439601|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
439602|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
439603|NCT00846430|Drug|Peg-Interferon alpha-2b|age and weight dependant
439604|NCT00846430|Drug|Celecoxib (Celebrex)|age and weight dependant
439605|NCT00846430|Drug|Temozolomide (temodar)|age and weight dependant
439606|NCT00846430|Drug|Vincristine Sulfate (Oncovin)|age and weight dependant
439607|NCT00846391|Drug|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
439608|NCT00846391|Drug|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
439609|NCT00846391|Drug|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.~Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
439610|NCT00846378|Procedure|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
439611|NCT00846378|Procedure|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
439612|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
439613|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
439614|NCT00846365|Drug|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
439615|NCT00846352|Procedure|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
439616|NCT00846339|Drug|Bupropion|bupropion
439617|NCT00846326|Drug|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
439618|NCT00846326|Drug|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
439619|NCT00846313|Other|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
439620|NCT00846300|Behavioral|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
439621|NCT00846287|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
439622|NCT00846287|Drug|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
439623|NCT00846287|Drug|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
439624|NCT00846274|Biological|SK Antithrombin III|
439625|NCT00846261|Device|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
439626|NCT00846248|Dietary Supplement|Chromium|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
439627|NCT00846248|Dietary Supplement|placebo|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
439628|NCT00846235|Other|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
439629|NCT00846222|Procedure|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
439630|NCT00846209|Other|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
439631|NCT00846196|Drug|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
439632|NCT00846196|Drug|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
439633|NCT00846183|Procedure|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
439634|NCT00846170|Drug|co-biotic|give probiotic 2 t/day
439635|NCT00846170|Drug|placebo 2T/day|cross over of patients from study arm to placebo arm
439636|NCT00846157|Biological|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
439637|NCT00846144|Dietary Supplement|copper sulfate|copper sulfate 3mg/d for a period of 6 months
439638|NCT00846131|Drug|Sorafenib|Randomized to Y-90 ± Sorafenib
439639|NCT00846131|Drug|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
439640|NCT00846118|Drug|Pitavastatin|1-4mg/day
439641|NCT00846105|Other|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
439642|NCT00846092|Device|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
439643|NCT00846092|Device|Near-infrared light (NIR)|"Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.~Treatments involve application of the LED-generated light for 80 seconds, twice daily."
439644|NCT00846079|Device|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
439645|NCT00846066|Other|Hands on training|Hands on training by a pediatric dentist on preventive oral health
439646|NCT00846066|Other|Web based training|Web based training alone
439647|NCT00846053|Diagnostic Test|FDG-PET|All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, [18F]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue [18F] FDG uptake. Patlak graphical analysis was used to determine the rate of [18F]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
439648|NCT00846027|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
439649|NCT00846027|Drug|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
439650|NCT00846027|Drug|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
439651|NCT00846014|Drug|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
439652|NCT00846001|Procedure|Coronary artery bypass grafting|Standard coronary surgry according guidelines
439653|NCT00846001|Device|Epicardial implantation of cardiac resynchronization therapy device|During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
439654|NCT00845988|Drug|aripiprazole|dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
439655|NCT00845975|Device|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.~Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
439656|NCT00845975|Device|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
439657|NCT00845962|Drug|chloroprocaine|spinal administration of chloroprocaine 2%, 40 mg (2 mL)
439658|NCT00845962|Drug|bupivacaine|spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
439659|NCT00845936|Drug|Metformin|Metformin 850 mg bid
439660|NCT00845923|Drug|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
439661|NCT00845910|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
439662|NCT00845910|Drug|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
439663|NCT00845910|Drug|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
439706|NCT00845598|Drug|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
439664|NCT00845897|Drug|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
439665|NCT00845897|Drug|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
439666|NCT00845884|Drug|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.~Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.~Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
439667|NCT00845871|Drug|deferasirox:|deferasirox 20mg/kg/day unless on a higher dose at time of study entry. Crushed or dissolved tablets taken once daily with either breakfast,dinner or no meal for 4 months.
439668|NCT00845858|Drug|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
439669|NCT00845858|Drug|Placebo|30 minutes before meals and at bedtime
439670|NCT00845845|Drug|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
439671|NCT00845845|Drug|Placebo|Daily placebo with dietary counseling for 24 weeks.
439672|NCT00845832|Drug|Placebo|iv on days 1 and 15 (Parts 1 and 2)
439673|NCT00845832|Drug|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
439674|NCT00845832|Drug|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
439675|NCT00845819|Drug|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) & nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
439676|NCT00845819|Drug|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.~Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.~For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
439677|NCT00845806|Other|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
439678|NCT00845793|Behavioral|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
439679|NCT00845780|Drug|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
439680|NCT00845767|Procedure|Forearm Vascular Study|"Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min)."
439681|NCT00845754|Drug|ketorolac|15mg IV every6 hours for 4doses
439682|NCT00845754|Drug|saline|15mg IV every 6hrs for 4 doses
439683|NCT00845728|Drug|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
439684|NCT00845728|Drug|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
439685|NCT00845715|Other|Early motion|Early referral to physical therapy for range of motion (2 days post)
439686|NCT00845715|Other|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
439687|NCT00845702|Drug|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
439688|NCT00845702|Other|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
439689|NCT00845689|Drug|placebo|NaCl 0,9 %
439690|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0, 2 %
439691|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0,2 %
439692|NCT00845689|Procedure|Liver resection|Liver resection with Pringle maneuver
439693|NCT00845676|Drug|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
439694|NCT00845663|Drug|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
439695|NCT00845663|Drug|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
439696|NCT00845650|Biological|AIGIV 3.5 mg/kg|AIGIV containing 3.5 mg/kg anti-PA IgG as a single intravenous infusion.
439697|NCT00845650|Biological|Gamunex 90 mg/kg|Gamunex 90 mg/kg total IgG as a single intravenous infusion.
439698|NCT00845650|Biological|AIGIV 7.0 mg/kg|AIGIV containing 7.0 mg/kg anti-PA IgG as a single intravenous infusion.
439699|NCT00845650|Biological|Gamunex 180 mg/kg|Gamunex 180 mg/kg total IgG as a single intravenous infusion.
439700|NCT00845650|Biological|AIGIV 14.0 mg/kg|AIGIV containing 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
439701|NCT00845650|Biological|Gamunex 360 mg/kg|Gamunex 360 mg/kg total IgG as a single intravenous infusion.
439702|NCT00845637|Drug|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
439703|NCT00845637|Drug|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
439704|NCT00845611|Biological|peptide vaccine|peptides emulsified with Montanide ISA51
439705|NCT00845598|Drug|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination~1 squirt in each nostril twice daily"
440351|NCT00840411|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
439707|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
439708|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
439709|NCT00845572|Behavioral|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
439710|NCT00845559|Drug|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
439711|NCT00845546|Drug|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
439712|NCT00845533|Drug|Dihydroartemisinin-Piperaquine|
439713|NCT00845520|Device|Lens implantation +1.00 D postop target|Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
439714|NCT00845520|Device|Lens implantation -1.00 D postop target|Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
439715|NCT00845520|Device|Lens implantation 0.00 D postop target|Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
439716|NCT00845507|Drug|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
439717|NCT00845507|Drug|Placebo|Placebo: Sterile solution in equivalent doses as Exenatide
439718|NCT00845494|Behavioral|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
439719|NCT00845481|Drug|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
439720|NCT00845481|Drug|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
439721|NCT00845481|Drug|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
439722|NCT00845481|Drug|Dermovat ointment|Once daily application 6 days a week for 3 weeks
439723|NCT00845481|Drug|Elocon ointment|Once daily application 6 days a week for 3 weeks
439724|NCT00845481|Drug|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
439725|NCT00845442|Device|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
439726|NCT00845429|Biological|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
439727|NCT00845429|Biological|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
439728|NCT00845429|Biological|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
439729|NCT00845377|Behavioral|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
439730|NCT00845364|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
439731|NCT00845364|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
439732|NCT00845351|Drug|Bexarotene|bexarotene at 300 mg/m2/day
439733|NCT00845338|Drug|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
439734|NCT00845325|Behavioral|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
439735|NCT00845325|Behavioral|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
439736|NCT00845299|Drug|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
439737|NCT00845299|Drug|artificial tears preserved with Benzalkonium Chloride|
439738|NCT00845286|Behavioral|Munich Marathon|42,195 km marathon run
439739|NCT00845273|Drug|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
439740|NCT00845260|Behavioral|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
439741|NCT00845260|Behavioral|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
439742|NCT00845247|Other|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
439743|NCT00845234|Behavioral|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
439744|NCT00845221|Drug|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
439745|NCT00845208|Behavioral|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
439746|NCT00845195|Drug|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
439747|NCT00845195|Drug|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
439748|NCT00845182|Drug|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
439749|NCT00845182|Drug|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
439750|NCT00845182|Drug|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
439751|NCT00845169|Procedure|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
439752|NCT00845156|Dietary Supplement|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
439753|NCT00845130|Biological|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
439754|NCT00845117|Procedure|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
439755|NCT00845104|Drug|fludarabine phosphate|Given IV
439756|NCT00845104|Biological|rituximab|Given IV
439757|NCT00845104|Biological|bevacizumab|Given IV
439758|NCT00845104|Other|laboratory biomarker analysis|Correlative studies
439759|NCT00845104|Other|flow cytometry|Correlative studies
439760|NCT00845104|Genetic|polymerase chain reaction|Correlative studies
439761|NCT00845104|Genetic|fluorescence in situ hybridization|Correlative studies
439762|NCT00845091|Behavioral|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
439763|NCT00845091|Behavioral|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
439764|NCT00845065|Drug|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
439765|NCT00845065|Other|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
439766|NCT00845065|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
439767|NCT00845065|Drug|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing~<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)~>=75 kg, 1200 mg/day PO, divided BID~for 48 weeks"
439768|NCT00845039|Biological|Cetuximab|Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
439769|NCT00845039|Drug|Irinotecan|180 mg/m² every 14 days until disease progression or participant intolerance
439770|NCT00845039|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
439771|NCT00845026|Drug|LY2140023|80mg, oral tablets,twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40mg or a maximum of 160mg.
439772|NCT00845026|Drug|aripiprazole|10mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20mg, 2-10mg oral tablets,once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 30mg (3-10mg oral tablets).
439773|NCT00845026|Drug|olanzapine|10mg dose (2-5mg oral tablets) once every evening, for 3 days. Followed by an increase to 15mg (3-5mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 20mg (4-5mg oral tablets).
439774|NCT00845026|Drug|risperidone|2mg dose, 2-1mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4mg (4-1mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2mg/day or a maximum of 6mg/day (6-1mg tablets).
439775|NCT00845000|Drug|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
439776|NCT00845000|Drug|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
439777|NCT00845000|Drug|Placebo|Placebo capsule, oral, at hour 0 of treatment period
439778|NCT00845000|Drug|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
439779|NCT00845000|Drug|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
439780|NCT00844974|Other|Prevalence|Mood and cognitive assessments
439781|NCT00844961|Behavioral|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
439782|NCT00844922|Drug|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
439783|NCT00844922|Drug|Placebo|Placebo
439784|NCT00844909|Drug|CNTO 136|
439785|NCT00844896|Behavioral|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.~In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
439786|NCT00844896|Behavioral|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.~For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
439787|NCT00844883|Drug|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
439788|NCT00844883|Procedure|LC Bead-TACE|"LC Beads loaded with doxorubicin~Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
439789|NCT00844870|Behavioral|stabilization training|training of arm function with the trunk stabilized
439790|NCT00844870|Behavioral|auditory training group|response to an auditory signal
439791|NCT00844857|Drug|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
439792|NCT00844857|Drug|Placebo|Orally, once daily in the evening for 8 weeks.
439793|NCT00844844|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
439794|NCT00844831|Drug|Lubiprostone|24 mcg bid for 28 days
439795|NCT00844818|Behavioral|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
439796|NCT00844805|Drug|Infliximab|
439797|NCT00844805|Drug|Placebo|
439798|NCT00844805|Drug|Naproxen|
439799|NCT00844792|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
439800|NCT00844792|Drug|Placebo|Twice a day with meals.
439801|NCT00844779|Procedure|Bariatric surgery|Gastric bypass.
439802|NCT00844779|Procedure|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
439803|NCT00844753|Drug|atomoxetine|atomoxetine
439804|NCT00844753|Drug|Placebo|Placebo + parent management treatment
439805|NCT00844753|Behavioral|Parent Management Training|
439806|NCT00844740|Drug|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
439807|NCT00844727|Drug|Rofecoxib|
439808|NCT00844727|Drug|placebo|placebo pills
439809|NCT00844714|Drug|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
439810|NCT00844688|Drug|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease.~The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs.~Withdrawal of consent for any reason."
439811|NCT00844688|Drug|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 & 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
439812|NCT00844675|Drug|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
439813|NCT00844675|Drug|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
439814|NCT00844662|Drug|Fermagate|Film coated tablet 500mg
439815|NCT00844662|Drug|Sevelamer hydrochloride|Tablet 800mg
439816|NCT00844649|Drug|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m^2 administered by intravenous infusion
439817|NCT00844649|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
439818|NCT00844636|Device|Sharp needle|
439819|NCT00844636|Device|Blunt needles|
439820|NCT00844623|Genetic|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
439821|NCT00844597|Drug|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
439822|NCT00844584|Procedure|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
439823|NCT00844571|Other|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
439824|NCT00844558|Other|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
439825|NCT00844558|Other|Control|There is no intervention associated with this arm of the study
439826|NCT00844545|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
439827|NCT00844532|Device|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
440098|NCT00842296|Device|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
439828|NCT00844519|Drug|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
439829|NCT00844519|Drug|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
439830|NCT00844506|Drug|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
439831|NCT00844506|Drug|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
439832|NCT00844493|Biological|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
439833|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
439834|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
439835|NCT00844493|Biological|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
439836|NCT00844480|Drug|zoledronic acid|zoledronic acid, 5mg, iv
439837|NCT00844480|Drug|placebo|iv
439838|NCT00844467|Biological|serotypes and resistance|screening patients with invasive pneumococci
439839|NCT00844454|Procedure|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
439840|NCT00844454|Procedure|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
439841|NCT00844441|Other|medical chart review|
439842|NCT00844441|Other|questionnaire administration|
439843|NCT00844441|Procedure|quality-of-life assessment|
439844|NCT00844428|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
439845|NCT00844415|Drug|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
439846|NCT00844402|Drug|Atorvastatin|oral, 10 mg, daily, 48 weeks
439847|NCT00844389|Device|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
439848|NCT00844389|Device|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
439849|NCT00844376|Drug|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
439850|NCT00844376|Drug|Lipitor|A single dose of 80 mg Lipitor tablet
439851|NCT00844363|Procedure|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
439852|NCT00844350|Drug|letrozole , oxytocin,hCG,clomiphene citrate|
439853|NCT00844337|Drug|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.~The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
439854|NCT00844337|Drug|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
439855|NCT00844337|Drug|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
439856|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
439857|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
439858|NCT00844311|Drug|rFSH|150 iu/day of rFSH
439859|NCT00844311|Drug|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
439860|NCT00844311|Drug|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
439861|NCT00844311|Drug|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
439862|NCT00844298|Drug|Nilotinib+mVPD|"Induction:~Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~Vincristine 2 mg iv push (d1, 8, 15, 22)~Prednisolone 60 mg/m2/day po (d1-28)~Nilotinib 400mg bid/d (d8-)~Consolidation A (cycle1)~Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~Vincristine 2 mg iv (d1, 8)~Prednisolone 60 mg/m2/day po (d1-14)~Nilotinib 400mg bid/d~Consolidation B (cycles 2&4)~Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~Nilotinib 400mg bid/d~Consolidation C (cycles 3&5)~Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~Nilotinib 400mg bid/d~Maintenance~◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~Consider alloHCT"
439863|NCT00844285|Drug|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
439864|NCT00844272|Behavioral|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.~The group leaders are trained in performance of the psycho-education."
440099|NCT00842283|Other|skin tissue sample|skin tissue sample
440100|NCT00842270|Drug|AB1010|3 mg/kg/day
439865|NCT00844246|Other|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
439866|NCT00844246|Other|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
439867|NCT00844233|Device|Irinotecan Bead|Irinotecan eluting bead
439868|NCT00844220|Procedure|CT/MR|CT/MRI-directed clinical management strategy
439869|NCT00844220|Procedure|Catheterization|Standard clinical management directed by conventional coronary angiography
439870|NCT00844207|Drug|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
439871|NCT00844207|Drug|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
439872|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
439873|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
439874|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
439875|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
439876|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
439877|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
439878|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
439879|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
439880|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
439881|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
439882|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
439883|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
439884|NCT00844168|Drug|sorafenib tosylate|Given orally
439885|NCT00844168|Other|laboratory biomarker analysis|Correlative studies
439886|NCT00844155|Drug|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
439887|NCT00844142|Drug|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
439888|NCT00844142|Drug|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
439889|NCT00844116|Device|spirometry|Conventional and telematic spirometry
439890|NCT00844103|Drug|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
439891|NCT00844103|Drug|Placebo|10ml oral solution administered once a day over 10 days.
439892|NCT00844090|Drug|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
439893|NCT00844064|Drug|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.~Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
439894|NCT00844051|Biological|School-based influenza vaccination program|School-based influenza vaccination program
439895|NCT00844025|Behavioral|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
439896|NCT00844012|Drug|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
439897|NCT00844012|Drug|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
439898|NCT00843986|Drug|conivaptan|Premix bag
439899|NCT00843986|Drug|placebo|Premix bag
439900|NCT00843973|Procedure|iliac crest bone graft|iliac crest bone graft procedure
439901|NCT00843973|Procedure|Reamer Irrigator Aspirator|Reamer Irrigator Aspirator (RIA) Procedure
439902|NCT00843960|Behavioral|behavioral adaptation and symptom management|behavioral adaptation and symptom management
439903|NCT00843947|Procedure|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
439940|NCT00843596|Procedure|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
439904|NCT00843934|Drug|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
439905|NCT00843934|Drug|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
439906|NCT00843921|Drug|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
439907|NCT00843908|Device|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
439908|NCT00843908|Device|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
439909|NCT00843895|Biological|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
439910|NCT00843882|Biological|Epoetin Alfa|Given SC
439911|NCT00843882|Other|Laboratory Biomarker Analysis|Correlative studies
439912|NCT00843882|Drug|Lenalidomide|Given PO
439913|NCT00843856|Drug|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
439914|NCT00843856|Drug|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
439915|NCT00843843|Device|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
439916|NCT00843830|Radiation|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
439917|NCT00843830|Biological|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
439918|NCT00843817|Drug|Pulmozyme|Pulmozyme® 2.5mg by inhalation
439919|NCT00843791|Drug|placebo|treatment with placebo for 3 months
439920|NCT00843791|Drug|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
439921|NCT00843778|Biological|Certolizumab Pegol|"200 mg every two weeks~Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 [NCT00674362], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
439922|NCT00843765|Other|acupuncture, massage and basic TCM treatment|"During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.~After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
439923|NCT00843765|Other|rehabilitation and WM basic treatment|"there two steps:~during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education~After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
439924|NCT00843739|Device|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
439925|NCT00843739|Device|sham EMST|Four week sham device training program
439926|NCT00843726|Radiation|stereotactic body radiation therapy|Patients undergo 1 or 3 high-dose fractions
439927|NCT00843713|Drug|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
439928|NCT00843713|Drug|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
439929|NCT00843700|Behavioral|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
439930|NCT00843700|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
439931|NCT00843687|Drug|Risperidone long-acting injectable|
439932|NCT00843661|Drug|ezetimibe|10 mg ezetimibe/day
439933|NCT00843661|Drug|fenofibrate|200 mg fenofibrate/day
439934|NCT00843661|Drug|pravastatin|40 mg pravastatin/day
439935|NCT00843635|Drug|Tadalafil|Given orally
439936|NCT00843635|Other|Placebo|Given orally
439937|NCT00843622|Drug|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
439938|NCT00843622|Other|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
439939|NCT00843609|Device|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
439941|NCT00843570|Drug|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
439942|NCT00843544|Behavioral|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:~Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.~Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice~Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
439943|NCT00843531|Drug|RAD001|5 mg/day PO (oral)
439944|NCT00843531|Drug|erlotinib|100 mg/day (oral)
439945|NCT00843518|Drug|LY451395|3 mg LY451395 orally twice daily for 12 weeks; may have been reduced to 1 mg if participant was unable to tolerate
439946|NCT00843518|Drug|Placebo|Placebo orally twice daily for 12 weeks
439947|NCT00843505|Behavioral|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
439948|NCT00843505|Behavioral|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
439949|NCT00843492|Drug|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg [0.5mL] (1.5 mg [0.3mL] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
439950|NCT00843492|Drug|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
439951|NCT00843466|Other|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:~Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
439952|NCT00843453|Other|blood collection|blood collection
439953|NCT00843453|Drug|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
439954|NCT00843440|Drug|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
439955|NCT00843427|Behavioral|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
439956|NCT00843388|Drug|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
439957|NCT00843388|Drug|placebo tablet|placebo tablet 25 mg OD
439958|NCT00843362|Drug|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
439959|NCT00843362|Drug|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
439960|NCT00843349|Drug|Lanthanum Carbonate|Phosphorus binder
439961|NCT00843349|Other|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
439962|NCT00843349|Drug|LC Placebo|Placebo for Lanthanum Carbonate
439963|NCT00843349|Other|Ad Libitum Diet|Patients continued to eat their usual diet.
439964|NCT00843336|Behavioral|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
439965|NCT00843336|Behavioral|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
439966|NCT00843323|Other|Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device
439967|NCT00843310|Drug|Lenalidomide (Revlimid)|
439968|NCT00843310|Drug|Melphalan|
439969|NCT00843310|Drug|Dexamethasone|
439970|NCT00843297|Device|Coolgard|invasive Cooling via femoral ICY-catheter
439971|NCT00843297|Device|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
439972|NCT00843297|Other|Conventional treatment|Intensive care-treatment without cooling
439973|NCT00843284|Drug|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
439974|NCT00843258|Device|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
439975|NCT00843245|Other|No intervention|No intervention
439976|NCT00843219|Procedure|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
439977|NCT00843193|Drug|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
439978|NCT00843193|Drug|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
439979|NCT00843193|Drug|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
440101|NCT00842270|Drug|AB1010|4,5 mg/kg/day
439980|NCT00843180|Other|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
439981|NCT00843167|Dietary Supplement|broccoli sprout extract|Given orally
439982|NCT00843167|Other|placebo|Given orally
439983|NCT00843154|Drug|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
439984|NCT00843154|Drug|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
439985|NCT00843141|Behavioral|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
439986|NCT00843141|Behavioral|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
439987|NCT00843128|Device|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
439988|NCT00843128|Device|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
439989|NCT00843115|Other|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
439990|NCT00843089|Other|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
439991|NCT00843063|Drug|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
439992|NCT00843050|Drug|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
439993|NCT00843037|Drug|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
439994|NCT00843024|Drug|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
439995|NCT00843024|Drug|Placebo|Placebo to match
439996|NCT00843011|Drug|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
439997|NCT00842998|Drug|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
439998|NCT00842985|Drug|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
439999|NCT00842959|Device|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
440000|NCT00842959|Device|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
440001|NCT00842946|Behavioral|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
440002|NCT00842946|Behavioral|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
440003|NCT00842933|Drug|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
440004|NCT00842933|Drug|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
440005|NCT00842920|Drug|Simvastatin 60 mg|60 mg once daily
440006|NCT00842920|Drug|Placebo|one tablet once daily
440007|NCT00842920|Drug|Simvastatin 20 mg|20 mg once daily
440008|NCT00842907|Drug|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
440009|NCT00842907|Drug|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
440010|NCT00842894|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
440011|NCT00842894|Drug|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
440012|NCT00842881|Device|Healingstone navel belt|6~8hours/day for 3months
440013|NCT00842842|Procedure|tack fixation of mesh|tack fixation of mesh
440014|NCT00842842|Procedure|glue fixation of mesh|glue fixation of mesh
440015|NCT00842829|Drug|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
440016|NCT00842816|Drug|ST101|10 mg; administered once/day
440017|NCT00842816|Drug|ST101|60 mg; administered once/day
440018|NCT00842816|Drug|ST101|120 mg; administered once/day
440019|NCT00842816|Drug|Placebo|placebo tablets to match ST101 tablets
440020|NCT00842803|Drug|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
440054|NCT00842608|Procedure|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
440102|NCT00842270|Drug|AB1010|6 mg/kg/day
440103|NCT00842270|Drug|placebo|matching placebo to AB1010 dosages
440021|NCT00842777|Behavioral|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.~Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.~Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
440022|NCT00842777|Behavioral|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
440023|NCT00842764|Procedure|Holmium: YAG laser|Minimally Invasive Holmium:YAG laser Blepharoplasty
440024|NCT00842751|Drug|First Intervention (7 days)|Acyline 300mcg/kg subcutaneous (days 1, 15 & 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
440025|NCT00842751|Other|First Washout (7 days)|Washout of 7 days between each of the 3 treatment arms
440026|NCT00842751|Drug|Second Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
440027|NCT00842751|Drug|Third Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
440028|NCT00842751|Other|Second wash-out period|Washout of 7 days between each of the 3 treatment arms
440029|NCT00842738|Behavioral|Mindfulness meditation|Mindfulness meditation
440030|NCT00842738|Other|No meditation|Health care services as usual
440031|NCT00842738|Other|Controls|No intervention
440032|NCT00842712|Drug|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
440033|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
440034|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) as intravenous infusion over 2 hours on Day 1.
440035|NCT00842712|Drug|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m^2 as intravenous infusion on Day 1.
440036|NCT00842712|Drug|Cisplatin|Cis will be administered at a dose of 80 mg/m^2 as intravenous infusion on Day 1.
440037|NCT00842712|Drug|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m^2 as intravenous infusion on Days 1 and 8.
440038|NCT00842712|Drug|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m^2 as intravenous infusion on Days 1 and 8.
440039|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
440040|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
440041|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
440042|NCT00842712|Drug|Chemotherapy|Cis 80 mg/m^2 intravenous infusion on Day 1 + Vin 25 mg/m^2 or Cis 75 mg/m^2 intravenous infusion on Day 1 + Gem 1250 mg/m^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
440043|NCT00842686|Drug|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
440044|NCT00842673|Drug|ST101|30 mg; administered once/day
440045|NCT00842673|Drug|ST101|90 mg; administered once/day
440046|NCT00842673|Drug|ST101|180 mg; administered once/day
440047|NCT00842673|Drug|Placebo|placebo to match ST101 tablets
440048|NCT00842660|Drug|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
440049|NCT00842634|Biological|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
440050|NCT00842634|Other|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
440051|NCT00842621|Procedure|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
440052|NCT00842621|Other|Laboratory Studies|"Blood for:~Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,~Serum for:~Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha~Plasma for:~Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1~Urine for:~Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
440053|NCT00842608|Behavioral|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.~Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can & cannot receive Haldol"
440055|NCT00842608|Drug|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
440056|NCT00842608|Procedure|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
440057|NCT00842595|Drug|rituximab|6 courses every 28 days
440058|NCT00842595|Drug|vinorelbine|6 courses every 28 days
440059|NCT00842595|Drug|ifosfamide|6 courses every 28 days
440060|NCT00842595|Drug|Mitoxantrone|6 courses every 28 days
440061|NCT00842595|Drug|Prednisone|6 courses every 28 days
440062|NCT00842582|Drug|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
440063|NCT00842582|Drug|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
440064|NCT00842582|Drug|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
440065|NCT00842556|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
440066|NCT00842556|Drug|Glimepiride|Tablets, Oral, 4 mg, Single Dose
440067|NCT00842556|Drug|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
440068|NCT00842543|Dietary Supplement|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
440069|NCT00842543|Dietary Supplement|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
440070|NCT00842530|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
440071|NCT00842530|Biological|Inactivated rabies virus vaccine|0.5 mL, Subcutaneous
440072|NCT00842530|Biological|Placebo|Sodium chloride 0.9%
440073|NCT00842517|Behavioral|Contingency Management|
440074|NCT00842504|Drug|Micafungin|3 mg/kg IV once over 1 hour
440075|NCT00842491|Drug|endostar, cisplatin, capecitabine|"Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously"
440076|NCT00842491|Drug|capecitabine|"Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally"
440077|NCT00842491|Drug|cisplatin|"Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously"
440078|NCT00842478|Procedure|Toothbrushing|
440079|NCT00842465|Biological|blood collection for hormonal status analysis|for hormonal status analysis
440080|NCT00842465|Procedure|breast Biopsy or surgery|breast Biopsy or surgery
440081|NCT00842465|Genetic|blood collection|blood collection for prlR gene sequencing
440082|NCT00842465|Other|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
440083|NCT00842452|Drug|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
440084|NCT00842452|Other|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
440085|NCT00842439|Behavioral|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
440086|NCT00842439|Dietary Supplement|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
440087|NCT00842426|Behavioral|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
440088|NCT00842426|Behavioral|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
440089|NCT00842400|Drug|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.~metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34~sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39~VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)~2 g (four 500 mg) probenecid tablets on Day 29."
440090|NCT00842361|Drug|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
440091|NCT00842361|Drug|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
440092|NCT00842348|Drug|lanreotide (Autogel formulation)|Autogel 120 mg
440093|NCT00842335|Drug|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
440094|NCT00842322|Behavioral|high fluid intake|fluid intake of 4 litres per day
440095|NCT00842322|Behavioral|normal fluid intake|Fluid intake of 2 litres per day
440096|NCT00842309|Drug|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
440097|NCT00842309|Drug|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
440104|NCT00842257|Drug|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
440105|NCT00842244|Drug|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
440106|NCT00842244|Drug|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
440107|NCT00842244|Drug|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m^2 on day 1.
440108|NCT00842231|Other|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
440109|NCT00842205|Drug|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
440110|NCT00842205|Drug|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
440111|NCT00842192|Drug|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
440112|NCT00842166|Other|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
440113|NCT00842153|Drug|Clobetasol propionate foam|Topical Clobetasol propionate foam
440114|NCT00842153|Drug|Vehicle foam|Vehicle foam does not include the active drug.
440115|NCT00842140|Drug|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
440116|NCT00842140|Drug|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
440117|NCT00842140|Drug|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
440118|NCT00842127|Drug|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
440119|NCT00842114|Biological|R+CVP+IFN|Immunochemotherapy
440120|NCT00842101|Device|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
440121|NCT00842088|Drug|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
440122|NCT00842088|Drug|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
440123|NCT00842075|Drug|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
440124|NCT00842062|Device|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
440125|NCT00842049|Device|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
440126|NCT00842049|Other|No lumbar drain|No lumbar drain
440127|NCT00842036|Behavioral|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
440128|NCT00842036|Behavioral|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
440129|NCT00842036|Behavioral|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
440130|NCT00842023|Drug|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
440131|NCT00842023|Drug|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
440132|NCT00841971|Drug|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
440133|NCT00841971|Drug|Fluconazole|400 mg IV for 21 days
440134|NCT00841958|Procedure|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
440135|NCT00841945|Drug|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
440136|NCT00841945|Drug|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
440137|NCT00841945|Drug|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
440138|NCT00841945|Drug|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
440139|NCT00841945|Procedure|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
440140|NCT00841932|Procedure|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
440141|NCT00841919|Drug|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
440142|NCT00841919|Drug|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
440143|NCT00841919|Drug|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
440144|NCT00841906|Device|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
440145|NCT00841906|Device|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
440146|NCT00841893|Dietary Supplement|Mustard (dijon)|The specific spice added to a brunch meal
440147|NCT00841893|Dietary Supplement|Placebo|Placebo added to a brunch meal
440148|NCT00841880|Drug|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
440149|NCT00841880|Drug|Ramipril|10 mg once a day
440150|NCT00841880|Drug|Ramipril|5mg once a day
440151|NCT00841867|Procedure|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
440152|NCT00841854|Drug|pantoprazole|pantoprazole 40mg bid
440153|NCT00841854|Drug|bismuth|bismuth 300mg qid
440154|NCT00841854|Drug|metronidazole|metronidazole 500mg tid
440155|NCT00841854|Drug|tetracycline|tetracycline 500mg qid
440156|NCT00841841|Drug|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
440157|NCT00841828|Drug|Epirubicin|
440158|NCT00841828|Drug|Cyclophosphamide|
440159|NCT00841828|Drug|Docetaxel|
440160|NCT00841828|Drug|Lapatinib|
440161|NCT00841828|Drug|Trastuzumab|
440162|NCT00841815|Drug|Amlodipine Besylate|10 mg Tablet
440163|NCT00841815|Drug|Norvasc®|10 mg Tablet
440164|NCT00841802|Drug|Prednisone|Prednisone 30mg once daily x 5 days
440165|NCT00841789|Drug|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
440166|NCT00841789|Drug|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
440167|NCT00841776|Drug|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
440168|NCT00841776|Drug|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
440169|NCT00841763|Biological|Placebo|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle.
440170|NCT00841763|Biological|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
440171|NCT00841763|Biological|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
440172|NCT00841763|Biological|Adjuvanted trivalent influenza vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
440173|NCT00841750|Procedure|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
440174|NCT00841750|Procedure|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
440175|NCT00841737|Other|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
440176|NCT00841737|Other|Control Group|In the control group the depression is treated as usual with the conventional treatment.
440177|NCT00841724|Drug|Fludarabine, Busulfan, Thymoglobuline|
440216|NCT00841386|Drug|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
440308|NCT00840749|Radiation|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
440352|NCT00840398|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
440178|NCT00841711|Behavioral|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
440179|NCT00841698|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
440180|NCT00841698|Drug|Paxil®|40 mg Film-Coated Tablet
440181|NCT00841685|Device|Goldlock|Insertion of Goldlock marker
440182|NCT00841685|Device|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
440183|NCT00841685|Device|Visicoil larger size|Insertion of Visicoil, larger size, marker
440184|NCT00841685|Device|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
440185|NCT00841685|Device|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
440186|NCT00841672|Drug|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
440187|NCT00841672|Drug|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
440188|NCT00841659|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
440189|NCT00841659|Drug|Paxil®|40 mg Film-Coated Tablet
440190|NCT00841646|Biological|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
440191|NCT00841633|Drug|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
440192|NCT00841620|Procedure|Haemorrhoidectomy a.m. Milligan|Surgery
440193|NCT00841620|Procedure|Stapled anopexy|Surgery
440194|NCT00841607|Procedure|pancreaticojejunostomy vs pancreaticogastrostomy|
440195|NCT00841594|Drug|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
440196|NCT00841594|Drug|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
440197|NCT00841581|Drug|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
440198|NCT00841568|Drug|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
440199|NCT00841555|Drug|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.~Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
440200|NCT00841555|Radiation|Hypofractionated radiation therapy|Patients will undergo HIMRT
440201|NCT00841555|Radiation|Intensity-modulated radiation therapy|Patients undergo HIMRT
440202|NCT00841542|Drug|Amlodipine Besylate|10 mg Tablet
440203|NCT00841542|Drug|Norvasc®|10 mg Tablet
440204|NCT00841529|Device|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
440205|NCT00841516|Other|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
440206|NCT00841516|Biological|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
440207|NCT00841503|Other|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
440208|NCT00841477|Biological|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
440209|NCT00841477|Behavioral|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
440210|NCT00841451|Drug|Lovaza (Fish Oils)|Double blinded placebo controlled
440211|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
440212|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
440213|NCT00841412|Behavioral|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
440214|NCT00841412|Behavioral|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
440215|NCT00841399|Biological|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
440260|NCT00841139|Drug|Perhexiline|100mg o bd
440261|NCT00841139|Drug|Placebo|1 tablet bd
440350|NCT00840411|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
440217|NCT00841386|Drug|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
440218|NCT00841373|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
440219|NCT00841373|Procedure|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
440220|NCT00841360|Other|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
440221|NCT00841360|Other|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
440222|NCT00841347|Behavioral|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
440223|NCT00841347|Behavioral|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
440224|NCT00841334|Behavioral|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
440225|NCT00841334|Behavioral|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
440226|NCT00841321|Drug|Ginkgo biloba|120 mg orally twice a day for 12 weeks
440227|NCT00841321|Drug|Placebo|One capsule orally twice a day for 12 weeks
440228|NCT00841308|Other|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
440229|NCT00841295|Drug|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
440230|NCT00841295|Drug|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
440231|NCT00841282|Procedure|Colonoscopy for colorectal cancer screening|
440232|NCT00841282|Procedure|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
440233|NCT00841282|Procedure|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
440234|NCT00841269|Drug|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
440235|NCT00841256|Biological|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
440236|NCT00841256|Drug|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
440237|NCT00841243|Dietary Supplement|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
440238|NCT00841230|Drug|Deanxit|Deanxit 1x/day
440239|NCT00841230|Drug|Lactose placebo|Lactose used as placebo
440240|NCT00841217|Drug|GW501516|2.5mg/day
440241|NCT00841217|Drug|placebo pill|
440242|NCT00841204|Drug|sulindac|Given orally
440243|NCT00841204|Other|placebo|Inactive agent
440244|NCT00841204|Other|laboratory biomarker analysis|Correlative studies
440245|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
440246|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
440247|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
440248|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
440249|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
440250|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
440251|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
440252|NCT00841178|Procedure|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
440253|NCT00841178|Procedure|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
440254|NCT00841165|Device|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
440255|NCT00841165|Device|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
440256|NCT00841152|Device|Bioactive glass|Surgical implantation
440257|NCT00841152|Device|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
440258|NCT00841152|Procedure|Autograft|Surgical transplantation from iliac crest
440259|NCT00841152|Procedure|Allograft (frozen femoral head)|Surgical transplantation
440262|NCT00841126|Drug|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
440263|NCT00841126|Drug|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
440264|NCT00841126|Drug|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
440265|NCT00841113|Drug|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
440266|NCT00841113|Drug|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
440267|NCT00841100|Drug|Kuvan|20mg/kg by mouth once daily
440268|NCT00841100|Other|Diet|Phenylalanine-restricted diet (4-10 mg/kg/day phenylalanine) using the prescribed phenylalanine-free medical formula and low protein foods tested with the patients for taste and acceptance to lower blood phenylalanine levels below 600 umol/l.
440269|NCT00841087|Drug|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
440270|NCT00841087|Drug|insulin detemir|Injection subcutaneously at bedtime
440271|NCT00841087|Drug|insulin aspart|Injection subcutaneously immediately before each meal.
440272|NCT00841074|Drug|chlorhexidine|0.12% chlorhexidine mouthwash spray, ~1.3 ml, twice a day.
440273|NCT00841074|Drug|Placebo mouthwash|Placebo mouthwash spray application of ~1.3 ml twice a day.
440274|NCT00841061|Dietary Supplement|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
440275|NCT00841061|Dietary Supplement|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
440276|NCT00841048|Drug|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
440277|NCT00841048|Drug|Placebo|
440278|NCT00841035|Drug|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
440279|NCT00841022|Other|Information with comics|Information of children with comic leaflet
440280|NCT00840996|Drug|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
440281|NCT00840996|Drug|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
440282|NCT00840983|Procedure|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
440283|NCT00840957|Biological|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
440284|NCT00840944|Drug|somatropin|somatropin 0.050 mg/kg/day
440285|NCT00840944|Drug|triptorelin|triptorelin 3.75 mg each month
440286|NCT00840931|Drug|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
440287|NCT00840931|Biological|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
440288|NCT00840918|Drug|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
440289|NCT00840918|Other|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
440290|NCT00840892|Other|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
440291|NCT00840879|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
440292|NCT00840879|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
440293|NCT00840866|Drug|cefprozil|500 mg Tablet
440294|NCT00840866|Drug|Cefzil®|500 mg Tablet
440295|NCT00840853|Genetic|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
440296|NCT00840853|Drug|Benadryl and Tylenol|Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
440297|NCT00840840|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
440298|NCT00840840|Drug|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
440299|NCT00840827|Drug|lenalidomide|Lenalidomide 10mg po daily
440300|NCT00840827|Drug|cyclosporine A|CSA 250mg orally twice daily
440301|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
440302|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
440303|NCT00840788|Procedure|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
440304|NCT00840788|Procedure|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
440305|NCT00840775|Device|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
440306|NCT00840762|Other|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
440307|NCT00840762|Other|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
440309|NCT00840749|Procedure|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
440310|NCT00840736|Procedure|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
440311|NCT00840736|Procedure|vertical banded gastroplasty|vertical banded gastroplasty
440312|NCT00840697|Behavioral|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
440313|NCT00840697|Behavioral|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
440314|NCT00840697|Behavioral|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
440315|NCT00840684|Drug|amsacrine|
440316|NCT00840684|Drug|busulfan|
440317|NCT00840684|Drug|cytarabine|
440318|NCT00840684|Drug|daunorubicin hydrochloride|
440319|NCT00840684|Drug|laromustine|
440320|NCT00840684|Drug|melphalan|
440321|NCT00840684|Drug|mitoxantrone hydrochloride|
440322|NCT00840684|Procedure|allogeneic hematopoietic stem cell transplantation|
440323|NCT00840684|Procedure|autologous hematopoietic stem cell transplantation|
440324|NCT00840671|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
440325|NCT00840671|Drug|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
440326|NCT00840658|Behavioral|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
440327|NCT00840658|Behavioral|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
440328|NCT00840658|Behavioral|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
440329|NCT00840645|Drug|YM178|Oral
440330|NCT00840632|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
440331|NCT00840632|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
440332|NCT00840606|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
440333|NCT00840606|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
440334|NCT00840593|Procedure|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
440335|NCT00840593|Procedure|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
440336|NCT00840580|Drug|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
440337|NCT00840580|Drug|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
440338|NCT00840567|Procedure|Skin biopsy|
440339|NCT00840567|Procedure|Blood draw & sample|
440340|NCT00840554|Other|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
440341|NCT00840554|Other|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
440342|NCT00840528|Other|ozone|0.4 ppm ozone for 2 hours
440343|NCT00840489|Drug|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
440344|NCT00840489|Drug|Colchicine|Colchicine 0.5 mg bd for 24 weeks
440345|NCT00840476|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
440346|NCT00840476|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
440347|NCT00840463|Drug|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
440348|NCT00840463|Other|Placebo|Sugar pill
440349|NCT00840450|Drug|Gleevec/Paclitaxel|"One treatment cycle:~Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.~Paclitaxel: 80 mg/m^2/week intravenously, 3 weeks on, one week off, every 28 days.~After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
440353|NCT00840398|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
440354|NCT00840385|Drug|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
440355|NCT00840372|Procedure|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
440356|NCT00840359|Procedure|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
440357|NCT00840359|Procedure|Cryotherapy|Cryotherapy for 2 times 20 sec
440358|NCT00840346|Drug|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
440359|NCT00840333|Drug|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
440360|NCT00840320|Drug|1278863|15mg, 25mg, 50mg, 150mg
440361|NCT00840320|Drug|Placebo|matching placebo
440362|NCT00840294|Drug|Ciprofloxacin|
440363|NCT00840281|Drug|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
440364|NCT00840281|Drug|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
440365|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
440366|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
440367|NCT00840255|Behavioral|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
440368|NCT00840255|Other|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
440369|NCT00840242|Drug|Nicotine gum|8-12 pieces per day, maximum 24 daily
440370|NCT00840242|Drug|Placebo gum|8-12 pieces per day, maximum 24 daily
440371|NCT00840242|Drug|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
440372|NCT00840242|Drug|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
440373|NCT00840229|Drug|Triamcinolone hexacetonide|20 mg
440374|NCT00840229|Drug|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
440375|NCT00840216|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
440376|NCT00840216|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
440377|NCT00840203|Drug|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
440378|NCT00840203|Drug|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
440379|NCT00840190|Drug|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
440380|NCT00840177|Drug|cytarabine|
440381|NCT00840177|Drug|idarubicin|
440382|NCT00840177|Drug|pravastatin sodium|
440383|NCT00840151|Behavioral|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
440384|NCT00840138|Procedure|Surgical reconstruction|"Hepaticojejunostomy~End-to-end anastomosis~Duct suture over T-tube"
440385|NCT00840125|Drug|erlotinib|150mg tablet daily
440386|NCT00840125|Drug|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
440387|NCT00840112|Dietary Supplement|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
440388|NCT00840099|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
440389|NCT00840099|Drug|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
440390|NCT00840086|Drug|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
440391|NCT00840073|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
440392|NCT00840073|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
440393|NCT00840060|Behavioral|AMALS|Addressing multiple aspects of language simultaneously
440394|NCT00840060|Behavioral|DTA|Discrete Trial Approach
440395|NCT00840047|Drug|Methionine|Intravenous injection
440396|NCT00840034|Drug|LY2216684|Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
440397|NCT00840034|Drug|Placebo|3 tablets PO QD for up to 12 weeks
440398|NCT00840008|Other|Educational intervention|As per detailed protocol.
440399|NCT00839982|Drug|clofarabine|Given PO
440400|NCT00839982|Drug|cytarabine|Given SC
440401|NCT00839969|Procedure|Cystoscopy|Saline cystoscopy under general anaesthesia
440402|NCT00839969|Procedure|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
440403|NCT00839956|Drug|Bortezomib|Given IV
440404|NCT00839956|Drug|Vorinostat|Given PO
440405|NCT00839943|Other|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
440406|NCT00839930|Drug|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
440407|NCT00839930|Drug|Pletal®|1 x 50 mg, single-dose tablet
440408|NCT00839917|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
440409|NCT00839917|Biological|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
440410|NCT00839904|Behavioral|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
440411|NCT00839891|Drug|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
440412|NCT00839878|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
440413|NCT00839865|Drug|herb ointment|a kind of ointment made from herb
440414|NCT00839852|Drug|Cariprazine|Cariprazine was supplied in capsules.
440415|NCT00839839|Procedure|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
440416|NCT00839826|Drug|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
440417|NCT00839826|Drug|Enoxaparin|40 mg bid
440418|NCT00839813|Behavioral|Yoga|10 weeks of a trauma-sensitive yoga class
440419|NCT00839800|Drug|Symbicort Turbuhaler|160/4.5 µg
440420|NCT00839800|Drug|Terbutaline Turbuhaler|0.4 mg
440421|NCT00839787|Drug|Morphine Sulfate|Morphine Sulfate group: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
440422|NCT00839774|Other|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
440423|NCT00839774|Other|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
440424|NCT00839774|Other|White wheat flour|White wheat flour will be administered at 50 g/day
440425|NCT00839761|Dietary Supplement|iron fortified rice|
440426|NCT00839761|Dietary Supplement|iron drops|
440427|NCT00839722|Procedure|embolization|fertility after embolization
440428|NCT00839709|Procedure|blood sampling|peripheral blood draw
440429|NCT00839683|Drug|simvastatin|Tablets, Oral, 20 mg, Single Dose
440430|NCT00839683|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
440431|NCT00839683|Drug|simvastatin|Oral, 40 mg, Single Dose
440432|NCT00839683|Drug|valsartan|Tablets, Oral, 320 mg, Single Dose
440433|NCT00839670|Other|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
440434|NCT00839670|Other|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
440435|NCT00839657|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
440436|NCT00839657|Behavioral|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
440437|NCT00839644|Device|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
440438|NCT00839644|Device|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
440439|NCT00839644|Other|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
440440|NCT00839631|Drug|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
440441|NCT00839605|Drug|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
440442|NCT00839592|Other|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
440443|NCT00839579|Other|1x4 min interval|Aerobic interval training
440444|NCT00839566|Procedure|Ablation|AV-node ablation
440445|NCT00839566|Other|Rate Control|Rate control by drug
440446|NCT00839553|Procedure|Intrapleural Minocycline application|
440447|NCT00839540|Drug|micafungin|100 mg qd by slow IV infusion for 24 h
440448|NCT00839540|Drug|Micafungin|200 mg qd by slow IV infusion for 24 h
440449|NCT00839540|Drug|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
440450|NCT00839527|Drug|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
440451|NCT00839527|Biological|albiglutide|albiglutide weekly subcutaneous injection
440452|NCT00839527|Drug|metformin|metformin
440453|NCT00839527|Drug|glimepiride|glimepiride
440454|NCT00839527|Drug|pioglitazone|pioglitazone
440455|NCT00839527|Drug|placebo to match pioglitazone|pioglitazone matching placebo
440456|NCT00839501|Dietary Supplement|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
440457|NCT00839501|Drug|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
440458|NCT00839488|Drug|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
440459|NCT00839488|Drug|famotidine 20 mg iv|famotidine 20 mg q12h
440460|NCT00839462|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
440461|NCT00839462|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
440462|NCT00839449|Drug|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
440463|NCT00839436|Drug|CYT107|
440464|NCT00839423|Drug|Placebo|capsules, daily, orally
440465|NCT00839423|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
440466|NCT00839423|Drug|Venlafaxine XL|capsules, daily, orally
440467|NCT00839397|Drug|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.~Dosage adjustment will be made at the discretion of the PI or Sub-PI"
440468|NCT00839384|Device|Advisa IPG|Implantable Pulse Generator will be implanted
440469|NCT00839371|Drug|Propofol|i.v. propofol titration until adequate depth of sedation
440470|NCT00839371|Drug|Midazolam|i.v. midazolam titration until adequate depth of sedation
440471|NCT00839358|Drug|albumin|albumine 40 g every 15 days
440472|NCT00839358|Drug|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
440473|NCT00839358|Drug|Placebo|saline solution
440474|NCT00839345|Drug|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
440475|NCT00839332|Drug|LY2603618|
440476|NCT00839332|Drug|Gemcitabine|
440477|NCT00839319|Drug|Acyline|300 ug/kg subcutaneous injections on Day 1.
440478|NCT00839319|Other|placebo hCG (no active ingredient)|placebo hCG
440479|NCT00839319|Drug|hCG (human chorionic gonadotropin)|15 IU subcutaneous injection every other day for 10 days (5 doses)
440480|NCT00839319|Drug|hCG (human chorionic gonadotropin)|60 IU subcutaneous injection
440481|NCT00839319|Drug|hCG (human chorionic gonadotropin)|125 IU subcutaneous injection
440482|NCT00839319|Drug|Testosterone gel|75 mg testosterone gel applied transdermally for 10 days
440483|NCT00839306|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
440484|NCT00839306|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
440485|NCT00839293|Drug|ABT-335|Once, see arm description for more information
440486|NCT00839280|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
440487|NCT00839280|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
440488|NCT00839254|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
440489|NCT00839254|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children < 12 months of age at the time of first study vaccination.
440490|NCT00839254|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children >= 12 months of age at the time of first study vaccination.
440491|NCT00839241|Device|Bellovac ABT|Bellovac ABT (autologous blood)
440492|NCT00839241|Procedure|Allogenic Blood Transfusion|"Transfusion of allogenic (bank) blood."
440493|NCT00839228|Drug|Perhexiline|100mg o bd for 3 months
440494|NCT00839228|Drug|Placebo|Placebo one tablet bd for 3 months
440495|NCT00839202|Other|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
440496|NCT00839189|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
440497|NCT00839176|Drug|RX-10100|Extended-release tablet, 5~15mg, twice day (morning & evening) at least 30 min before meal, 8 weeks
440498|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
440499|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
440500|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
440501|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
440502|NCT00839163|Drug|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
440503|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
440571|NCT00838656|Drug|paclitaxel|Given IV in one of two schedules
440504|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
440505|NCT00839111|Drug|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
440506|NCT00839111|Drug|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
440507|NCT00839098|Other|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
440508|NCT00839098|Other|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction & Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
440509|NCT00839085|Drug|GSE|grape seed extract (100 mg/6h), PO
440510|NCT00839085|Drug|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
440511|NCT00839072|Drug|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
440512|NCT00839072|Drug|Trazodone HCl|300 mg extended-release caplet, single dose
440513|NCT00839059|Drug|lenalidomide|"Dose escalation:~Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.~Duration of the first cycle: 56days, each following cycle will last 28 days"
440514|NCT00839046|Behavioral|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
440515|NCT00839046|Other|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
440516|NCT00839046|Other|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
440517|NCT00839033|Device|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
440518|NCT00839033|Device|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
440519|NCT00839020|Procedure|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
440520|NCT00839020|Procedure|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
440521|NCT00839007|Drug|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
440522|NCT00838994|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
440523|NCT00838981|Drug|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
440524|NCT00838981|Drug|Sugar Pill|placebo, sugar pill will mirror active drug
440525|NCT00838981|Behavioral|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
440526|NCT00838981|Drug|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
440527|NCT00838981|Behavioral|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
440572|NCT00838630|Drug|Cilostazol 100 mg tablets|1 x 100 mg
440573|NCT00838630|Drug|Pletal® 100 mg tablets|1 x 100 mg
440528|NCT00838981|Behavioral|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
440529|NCT00838968|Drug|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
440530|NCT00838955|Drug|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
440531|NCT00838942|Behavioral|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
440532|NCT00838929|Drug|Vorinostat|"All doses given for 3 weeks~Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
440533|NCT00838929|Radiation|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
440534|NCT00838916|Biological|albiglutide|albiglutide weekly injection
440535|NCT00838916|Drug|insulin glargine|insulin glargine
440536|NCT00838903|Biological|albiglutide|albiglutide
440537|NCT00838903|Drug|sitagliptin|sitagliptin
440538|NCT00838903|Drug|glimepiride|Glimepiride
440539|NCT00838903|Drug|metformin|Metformin
440540|NCT00838903|Biological|placebo albiglutide|placebo to match albiglutide
440541|NCT00838903|Drug|placebo sitagliptin|placebo to match sitagliptin
440542|NCT00838903|Drug|placebo glimepiride|placebo to match glimepiride
440543|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
440544|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
440545|NCT00838877|Drug|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
440546|NCT00838877|Drug|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
440547|NCT00838864|Drug|ceftrioxone|500 mg iv q12h for 3 days
440548|NCT00838864|Drug|ceftrioxone|500 mg q12h for 7 days
440549|NCT00838851|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
440550|NCT00838838|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 18yrs in medical practices fulfilling all criteria for documentation.
440551|NCT00838825|Other|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
440552|NCT00838812|Drug|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
440553|NCT00838799|Drug|RGH-896|45 mg TID, capsules, 14 weeks.
440554|NCT00838799|Drug|RGH-896|30 mg TID, capsules, 14 weeks.
440555|NCT00838799|Drug|RGH-896|15 mg TID, capsules, 14 weeks.
440556|NCT00838799|Drug|pregabalin|100 mg, TID, capsules, 14 weeks.
440557|NCT00838799|Drug|placebo|TID, capsules, 14 weeks.
440558|NCT00838773|Behavioral|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
440559|NCT00838773|Behavioral|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
440560|NCT00838773|Behavioral|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
440561|NCT00838760|Drug|TMC558445; TMC310911; Darunavir; Placebo|
440562|NCT00838721|Other|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
440563|NCT00838708|Drug|SRD174 Cream|topical SRD174 Cream
440564|NCT00838708|Other|vehicle cream|topical vehicle cream
440565|NCT00838695|Drug|Phenylephrine|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
440566|NCT00838682|Drug|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
440567|NCT00838682|Drug|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
440568|NCT00838669|Drug|Extended release OROS paliperidone|
440569|NCT00838656|Drug|carboplatin|Given IV in one of two schedules
440570|NCT00838656|Drug|gemcitabine hydrochloride|Given IV in one of two schedules
440574|NCT00838591|Drug|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
440575|NCT00838591|Drug|Placebo|
440576|NCT00838578|Biological|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
440577|NCT00838578|Drug|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
440578|NCT00838565|Drug|Placebo|intravenous infusion on three consecutive months
440579|NCT00838565|Drug|dose level 1|intravenous infusion on three consecutive months
440580|NCT00838565|Drug|dose level 2|intravenous infusion on three consecutive months
440581|NCT00838565|Drug|dose level 3|intravenous infusion on three consecutive months
440582|NCT00838565|Drug|dose level 4|intravenous infusion on 3 consecutive months
440583|NCT00838539|Drug|Neratinib|
440584|NCT00838539|Drug|Temsirolimus|
440585|NCT00838526|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
440586|NCT00838526|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
440587|NCT00838513|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
440588|NCT00838500|Drug|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
440589|NCT00838500|Drug|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
440590|NCT00838487|Other|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
440591|NCT00838487|Other|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
440592|NCT00838474|Other|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
440593|NCT00838461|Drug|HSD-016|
440594|NCT00838461|Drug|placebo|
440595|NCT00838448|Behavioral|Exercise|Exercise performed on a treadmill for 20-30 minutes
440596|NCT00838435|Drug|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
440597|NCT00838396|Drug|XP19986 CR|
440598|NCT00838396|Drug|Placebo for XP19986 CR|
440599|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
440600|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
440601|NCT00838383|Drug|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
440602|NCT00838370|Drug|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD*2A. Patients heterozygous or homozygous mutant for DPYD*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.~In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
440603|NCT00838357|Drug|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
440604|NCT00838344|Other|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
440605|NCT00838331|Biological|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
440606|NCT00838331|Biological|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (< 7 days) and impaired (> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (> 28 days; washed or rejuvenated) RBC transfusions."
440607|NCT00838318|Behavioral|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
440608|NCT00838305|Drug|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
440609|NCT00838305|Drug|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
440610|NCT00838292|Dietary Supplement|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
440611|NCT00838292|Other|nutrition counseling|
440612|NCT00838279|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
440613|NCT00838279|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
440746|NCT00837213|Drug|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
440614|NCT00838266|Drug|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
440615|NCT00838266|Other|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
440616|NCT00838253|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
440617|NCT00838253|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
440618|NCT00838253|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
440619|NCT00838253|Drug|Placebo|Placebo continuous i.v. infusion for 24 hours
440620|NCT00838240|Drug|clofarabine|Given IV
440621|NCT00838240|Drug|cytarabine|Given IV
440622|NCT00838240|Drug|idarubicin|Given IV
440623|NCT00838227|Drug|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
440624|NCT00838214|Drug|budesonide|3mg capsule, 3x per day for 6 months
440625|NCT00838214|Drug|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
440626|NCT00838201|Drug|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
440627|NCT00838188|Other|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
440628|NCT00838175|Procedure|suture mediated closure|Suture mediated closure of femoral venous access
440629|NCT00838162|Drug|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
440630|NCT00838162|Drug|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
440631|NCT00838162|Drug|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
440632|NCT00838162|Drug|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
440633|NCT00838162|Drug|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
440634|NCT00838162|Drug|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
440635|NCT00838149|Dietary Supplement|Glutamine|"Glutamine group :~Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
440636|NCT00838149|Dietary Supplement|Whey protein|"Whey protein group:~Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
440637|NCT00838136|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
440638|NCT00838136|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
440639|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
440640|NCT00838110|Drug|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
440641|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
440642|NCT00838110|Drug|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
440643|NCT00838084|Drug|LY2811376|Oral capsules
440644|NCT00838084|Drug|Placebo|Oral capsules
440645|NCT00838071|Drug|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
440646|NCT00838058|Drug|CE-224,535|one 250mg tablet, once in the morning in fasted state
440647|NCT00838058|Drug|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
440648|NCT00838058|Drug|CE-224,535|4x250mg tablets, once in the morning, in fasted state
440649|NCT00838058|Drug|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
440650|NCT00838058|Drug|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
440651|NCT00838058|Drug|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
440652|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
440653|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
440654|NCT00838045|Device|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch & Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
440655|NCT00838032|Drug|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
440656|NCT00838032|Drug|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
440657|NCT00838019|Procedure|Intrabone administration of umbilical cord blood|Single administration
440658|NCT00838006|Device|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
440659|NCT00838006|Device|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
440660|NCT00838006|Device|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
440661|NCT00837967|Drug|Symbicort Turbuhaler|160/4.5μg for 3 days
440662|NCT00837967|Drug|Terbutaline Turbuhaler|0.4 mg for 3 days
440747|NCT00837213|Drug|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
440663|NCT00837954|Device|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
440664|NCT00837954|Device|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
440665|NCT00837954|Procedure|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
440666|NCT00837941|Drug|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
440667|NCT00837941|Drug|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
440668|NCT00837941|Drug|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
440669|NCT00837928|Drug|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
440670|NCT00837928|Other|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
440671|NCT00837928|Procedure|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
440672|NCT00837928|Radiation|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
440673|NCT00837915|Drug|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
440674|NCT00837902|Drug|Atenolol (β-blocker)|25 mg tablet
440675|NCT00837889|Drug|diuretics, inotropica|
440676|NCT00837876|Drug|Sorafenib|400 mg taken by mouth 1 time per day.
440677|NCT00837876|Drug|Erlotinb|150 mg taken by mouth 1 time per day.
440678|NCT00837863|Drug|Somatropin|ALTU-238 0.3 mg/kg daily
440679|NCT00837863|Drug|Somatropin|ALTU-238 0.6 mg/kg daily
440680|NCT00837863|Drug|Somatropin|ALTU-238 0.9 mg/kg daily
440681|NCT00837863|Drug|Somatropin|Nutropin AQ 0.043 mg/kg daily
440682|NCT00837850|Device|Bone cement 1|Bone cement SmartSet® HV
440683|NCT00837850|Device|Bone cement 2|Bone cement Palacos R
440684|NCT00837837|Drug|Chlorpheniramine|
440685|NCT00837824|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
440686|NCT00837824|Biological|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
440687|NCT00837811|Biological|LY2127399|60 milligrams [(mg) with potential for dose escalation to 120 mg] subcutaneously every 4 weeks for 48 weeks
440688|NCT00837798|Device|CRM Device|Pacemaker, ICD, or CRT device
440689|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally three times a day
440690|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally twice a day
440691|NCT00837772|Device|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
440692|NCT00837772|Device|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
440693|NCT00837759|Drug|Insulin|
440694|NCT00837759|Drug|Lansoprazole|
440695|NCT00837759|Drug|Sitagliptin|
440696|NCT00837759|Biological|Diamyd|
440697|NCT00837759|Drug|GAD65 (Diamyd)|
440698|NCT00837746|Drug|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
440699|NCT00837733|Procedure|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
440700|NCT00837733|Procedure|Endometrial Biopsy|Biopsy catheter
440701|NCT00837707|Drug|aripiprazole|Flexible dose: 5-30 mg/day
440702|NCT00837655|Drug|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of <1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of <1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
440703|NCT00837655|Drug|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration <1.8 mmol/l.
440704|NCT00837642|Diagnostic Test|Transthoracic echocardiography|Full transthoracic echocardiography will be performed.
440705|NCT00837616|Drug|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
440780|NCT00836849|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
442128|NCT00826462|Drug|Naproxen|Naproxen 500 mg bid for 14 days
440706|NCT00837616|Drug|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
440707|NCT00837603|Behavioral|Training|Controlled home ergometer training
440708|NCT00837590|Drug|Chronic salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
440709|NCT00837590|Drug|Acute Salsalate|Subjects will receive a single oral dose of 2 gram of oral salsalate
440710|NCT00837577|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
440711|NCT00837577|Drug|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).~Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
440712|NCT00837577|Drug|Voglibose|"All participants received a stable dose of voglibose, in~accordance with the package insert, throughout the study."
440713|NCT00837564|Other|CBASP psychotherapy|specific psychotherapy for chronic depression
440714|NCT00837564|Drug|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
440715|NCT00837551|Drug|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
440716|NCT00837525|Procedure|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
440717|NCT00837512|Device|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
440718|NCT00837512|Device|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
440719|NCT00837499|Behavioral|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
440720|NCT00837486|Device|Reclaim™ DBS System|
440721|NCT00837473|Device|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
440722|NCT00837460|Other|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
440723|NCT00837447|Device|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
440724|NCT00837447|Device|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
440725|NCT00837434|Drug|Etanercept|50 mg dose of etanercept by subcutaneous injection
440726|NCT00837434|Drug|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
440727|NCT00837382|Behavioral|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
440728|NCT00837382|Behavioral|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
440729|NCT00837369|Drug|Regadenoson|400ug IV bolus injection, single dosage
440730|NCT00837356|Drug|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
440731|NCT00837356|Drug|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
440732|NCT00837343|Drug|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
440733|NCT00837330|Drug|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
440734|NCT00837317|Dietary Supplement|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
440735|NCT00837304|Device|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
440736|NCT00837304|Procedure|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
440737|NCT00837291|Drug|CF101|CF101 tablets 1 mg BID
440738|NCT00837291|Drug|Placebo|Placebo tablets BID
440739|NCT00837265|Biological|Neugranin|Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor)at two dose levels or comparator (pegfilgrastim 6 mg) administered approximately 24 hours following chemotherapy for 4 treatment cycles
440740|NCT00837265|Drug|Pegfilgrastim|6mg
440741|NCT00837265|Drug|Chemotherapy|study treatment was administered 24 hours after initiation of chemotherapy
440742|NCT00837252|Drug|Finasteride|Participants received 5mg of oral finasteride daily for three months.
440743|NCT00837239|Drug|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
440744|NCT00837239|Drug|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
440745|NCT00837239|Drug|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
442365|NCT00824616|Drug|Placebo|Placebo tablets, taken 3 times daily.
440748|NCT00837200|Drug|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
440749|NCT00837187|Drug|Intravenous dexmedetomidine|100 ug
440750|NCT00837187|Drug|Intranasal dexmedetomidine|100 ug
440751|NCT00837174|Drug|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
440752|NCT00837161|Device|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
440753|NCT00837148|Drug|Sorafenib and Dacarbazine|"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.~All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
440754|NCT00837135|Other|Screening|"A. SCREENING~Consent~Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)~Physical Exam, History, Blood Tests~Skin Test (for allergy to saccaromyces cerevisiae) yeast.~Collection of Blood for research~B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)~C. ENROLLMENT INTO ACTIVE PART OF STUDY~Consent~Chemotherapy~GI-4000 Vaccine #1 + Prevnar + Activated T Cells~GI-4000 Vaccine #2~Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
440755|NCT00837135|Biological|GI-4000 Vaccine|"Chemotherapy and Radiation~GI-4000 Vaccine #3~GI-4000 Vaccine #4"
440756|NCT00837135|Biological|GI-4000 Vaccine + Activated T Cells|"Apheresis #2~Chemoradiation~Activated T Cells + GI-4000 Vaccine #3~GI-4000 Vaccine #4"
440757|NCT00837135|Biological|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.~B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
440758|NCT00837109|Behavioral|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
440759|NCT00837109|Behavioral|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
440760|NCT00837096|Device|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
440761|NCT00837096|Device|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
440762|NCT00837070|Procedure|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
440763|NCT00837057|Procedure|crrt|early CRRT (35 ml/kg/h)& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
440764|NCT00837044|Drug|Treximet|Treximet
440765|NCT00837044|Drug|Migraine rescue medication of choice|Migraine rescue medication of choice
440766|NCT00837031|Drug|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
440767|NCT00837031|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
440768|NCT00837018|Other|physical exercise program|45 min, 3times a week
440769|NCT00836953|Biological|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
440770|NCT00836940|Drug|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
440771|NCT00836927|Drug|Ridaforolimus Tablet|Ridaforolimus 10 mg oral tablet
440772|NCT00836927|Drug|Ridaforolimus Intravenous (IV) Infusion|Ridaforolimus IV infusion administered once daily for 5 days every 2 weeks in a 28-day cycle (two 2-week courses equals 1 cycle).
440773|NCT00836914|Drug|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
440774|NCT00836914|Drug|Placebo|Placebo capsules administered orally BID for 7 days
440775|NCT00836901|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
440776|NCT00836901|Drug|Augmentin®|400 mg-57 mg chewable tablet
440777|NCT00836888|Biological|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
440778|NCT00836875|Drug|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.~Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.~Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
440779|NCT00836862|Other|Biologic specimens|Banking of serum, DNA and tissue
440781|NCT00836849|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
440782|NCT00836836|Other|Modified Atkins diet|"Modified Atkins Diet administration~Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~Fats (e.g. cream, butter, oils, ghee) encouraged.~Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~Clear carbohydrate-fluids not restricted.~Calcium and multivitamin supplementation will be provided."
440783|NCT00836823|Drug|Alfuzosin|Alfuzosin 10mg once daily for 12 months
440784|NCT00836810|Drug|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
440785|NCT00836810|Drug|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
440786|NCT00836784|Other|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
440787|NCT00836784|Other|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
440788|NCT00836771|Dietary Supplement|Infant Formula|
440789|NCT00836758|Device|Analysis with AED and manual PSG scoring|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated. Then the events will be analyzed with Automatic Event Detection (AED) and manual PSG scoring.
440790|NCT00836745|Other|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
440791|NCT00836732|Procedure|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
440792|NCT00836719|Drug|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
440793|NCT00836706|Drug|clarithromycin|500 mg Tablet
440794|NCT00836706|Drug|BIAXIN®|500 mg Tablet
440795|NCT00836693|Drug|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
440796|NCT00836693|Drug|placebo|tablet administered orally once a day for 12 weeks.
440797|NCT00836680|Device|Colorectal Stent|"Diagnosis of an internal rectal prolapse:~The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.~An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
440798|NCT00836667|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
440799|NCT00836667|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
440800|NCT00836654|Biological|Catumaxomab (Removab)|Puncture free survival
440801|NCT00836654|Procedure|paracentesis|
440802|NCT00836641|Biological|prevenar|7-valent pneumococcal conjugate vaccine
440803|NCT00836641|Biological|pneumovax|23 valent pneumococcal polysaccharide vaccine
440804|NCT00836628|Drug|Busulfan|
440805|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
440806|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
440807|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, <= 4 mg, Once daily, 7 days
440808|NCT00836602|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
440809|NCT00836589|Device|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
440810|NCT00836576|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
440811|NCT00836576|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
440812|NCT00836550|Behavioral|Video|The participants saw a 6 minute video
440813|NCT00836550|Behavioral|in-person HIV pre-test counseling|
440814|NCT00836537|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
440815|NCT00836537|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
440816|NCT00836524|Procedure|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
440817|NCT00836498|Biological|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
440818|NCT00836498|Biological|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
440819|NCT00836498|Biological|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
440820|NCT00836485|Drug|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
440821|NCT00836485|Drug|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
440822|NCT00836485|Drug|Olopatadine 0.2%|1 gtt/eye on two separate occasions
440823|NCT00836485|Drug|Artificial tears|1 gtt/eye on two separate occasions
440824|NCT00836472|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
440825|NCT00836472|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
440826|NCT00836459|Behavioral|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
440827|NCT00836459|Behavioral|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
440828|NCT00836446|Other|physical activity|physical activity routines 5 times a weeks for 12 weeks.
441009|NCT00835107|Drug|placebo|placebo comparator, oral capsules, BID, for one month
440829|NCT00836433|Behavioral|CONNECT educational intervention|The CONNECT educational intervention is a training program for staff to improve communication with a more dense network of co-workers, in order to improve resident problem-solving. Includes in class sessions, group and individual mapping exercises, self-monitoring of interactions, and individual staff coaching.
440830|NCT00836433|Behavioral|FALLS educational intervention|FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions
440831|NCT00836420|Procedure|no intervention|the value of the clinical use of microdialysis monitoring of the brain
440832|NCT00836407|Drug|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
440833|NCT00836407|Biological|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
440834|NCT00836394|Device|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
440835|NCT00836381|Drug|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
440836|NCT00836381|Drug|Placebo|Identical Placebo once daily
440837|NCT00836368|Dietary Supplement|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
440838|NCT00836355|Drug|Enoxaparin|2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
440839|NCT00836355|Drug|Minocycline|200 mg orally once daily for 5 days
440840|NCT00836329|Behavioral|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
440841|NCT00836329|Behavioral|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
440842|NCT00836316|Drug|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
440843|NCT00836303|Behavioral|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
440844|NCT00836290|Behavioral|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
440845|NCT00836290|Behavioral|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
440846|NCT00836277|Drug|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
440847|NCT00836277|Drug|Irinotecan|125mg/m2 IV Day 1 and Day 8
440848|NCT00836251|Dietary Supplement|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
440849|NCT00836238|Behavioral|Interview|Physical Function and Symptom Assessment Interviews
440850|NCT00836238|Other|Physical Function Tests|3 physical function tests.
440851|NCT00836225|Drug|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg~Placebo: 0.9% sterile saline"
440852|NCT00836212|Drug|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
440853|NCT00836212|Drug|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
440854|NCT00836199|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
440855|NCT00836199|Biological|Placebo vaccine|Placebo vaccine given 6 times over 6 months
440856|NCT00836186|Radiation|radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600cGy. Treatments will be given Monday through Friday.
440857|NCT00836173|Drug|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
440858|NCT00836173|Drug|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
441010|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
442498|NCT00823680|Drug|Placebo|po bid for 4 weeks
440859|NCT00836147|Drug|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
440860|NCT00836147|Drug|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
440861|NCT00836134|Procedure|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
440862|NCT00836134|Procedure|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
440863|NCT00836121|Procedure|right thoracotomy|complete surgical resection
440864|NCT00836108|Behavioral|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
440865|NCT00836095|Device|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
440866|NCT00836095|Device|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
440867|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
440868|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
440869|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
440870|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
440871|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
440872|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
440873|NCT00836069|Drug|No drug name provided by Sponsor; drug referenced as PD 0332334|Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
440874|NCT00836069|Drug|Paroxetine|FDA Approved medication for generalized anxiety disorder, oral tablet, at 20mg, once daily for 8 weeks and then 2 weeks of dose tapering.
440875|NCT00836069|Drug|Placebo|inactive substance, oral tablet, once per day, for 10 weeks.
440876|NCT00836056|Drug|Clindamycin 300 mg capsule|1 x 300 mg
440877|NCT00836056|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
440878|NCT00836043|Drug|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
440879|NCT00836030|Other|No treatment given|No treatment given
440880|NCT00836017|Other|No Intervention|No intervention was administered as part of the study.
440881|NCT00836004|Drug|Clindamycin 300 mg capsule|1 x 300 mg
440882|NCT00836004|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
440883|NCT00835991|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
440884|NCT00835991|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
440885|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
440886|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
440887|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label)
440888|NCT00835965|Drug|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
440889|NCT00835965|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
440890|NCT00835965|Drug|Placebo Dexamethasone|
440891|NCT00835952|Drug|ATX-101|ATX-101 single doses
440892|NCT00835939|Drug|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
440893|NCT00835939|Drug|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
440894|NCT00835939|Procedure|sclerotherapy|
440895|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
440896|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
440897|NCT00835900|Drug|varenicline|variable dosing schedule
440898|NCT00835900|Drug|placebo|placebo
440899|NCT00835887|Dietary Supplement|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
440900|NCT00835874|Drug|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
440901|NCT00835861|Drug|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
440902|NCT00835861|Drug|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values <90 and one hour post prandial values <130.
441011|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
441012|NCT00835081|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
441013|NCT00835081|Drug|DURICEF® capsules 500 mg|1 x 500 mg
440903|NCT00835848|Drug|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
440904|NCT00835848|Drug|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
440905|NCT00835835|Other|Body-weight supported treadmill training +/- Lokomat assistance|walking
440906|NCT00835835|Other|Usual Care - no active intervention|No treatment used for comparison
440907|NCT00835822|Drug|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
440908|NCT00835822|Drug|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
440909|NCT00835796|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
440910|NCT00835796|Drug|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
440911|NCT00835770|Drug|dimethyl fumarate|BG00012 capsules
440912|NCT00835770|Drug|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
440913|NCT00835744|Drug|clomiphene citrate|ovulation induction
440914|NCT00835744|Drug|gonadotropins|ovulation induction
440915|NCT00835731|Drug|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D&E
440916|NCT00835731|Device|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D&E
440917|NCT00835718|Drug|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
440918|NCT00835718|Drug|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
440919|NCT00835718|Drug|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
440920|NCT00835718|Drug|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
440921|NCT00835705|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
440922|NCT00835705|Drug|Augmentin®|400 mg-57 mg chewable tablet
440923|NCT00835692|Drug|Clarithromycin|500 mg Tablet
440924|NCT00835692|Drug|Biaxin®|500 mg Tablet
440925|NCT00835679|Biological|cetuximab|Given IV
440926|NCT00835679|Drug|dasatinib|Given orally
440927|NCT00835679|Procedure|therapeutic conventional surgery|Undergo surgery
440928|NCT00835679|Other|laboratory biomarker analysis|Correlative studies
440929|NCT00835666|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
440930|NCT00835666|Drug|PROSCAR®|1 x 5 mg, single dose fasting
440931|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
440932|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
440933|NCT00835640|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
440934|NCT00835640|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
440935|NCT00835627|Drug|sertraline|flexible dose sertraline
440936|NCT00835627|Behavioral|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
440937|NCT00835627|Other|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
440938|NCT00835627|Other|Standard Care|community care, treatment as usual: routine follow up with existing providers
440939|NCT00835614|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
440940|NCT00835614|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
440941|NCT00835588|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
440942|NCT00835588|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
440943|NCT00835575|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
440944|NCT00835575|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
440945|NCT00835562|Procedure|Non-surgical management|Non-surgical management (physiotherapy and self-training)
440946|NCT00835562|Procedure|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
440947|NCT00835562|Procedure|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
440948|NCT00835549|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
440949|NCT00835549|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
440950|NCT00835536|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
440951|NCT00835536|Drug|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
440952|NCT00835510|Drug|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
440953|NCT00835510|Drug|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
440954|NCT00835510|Drug|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
440955|NCT00835497|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
440956|NCT00835497|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
440957|NCT00835484|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
440958|NCT00835484|Drug|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
441014|NCT00835068|Other|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
440959|NCT00835471|Drug|erlotinib plus docetaxel or pemetrexed|"non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.~squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression."
440960|NCT00835471|Drug|erlotinib|erlotinib 150 mg/day continuously until disease progression
440961|NCT00835458|Procedure|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
440962|NCT00835432|Device|Ossix|Test group
440963|NCT00835432|Device|Biogide|controls
440964|NCT00835419|Drug|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
440965|NCT00835406|Drug|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
440966|NCT00835406|Drug|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
440967|NCT00835393|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
440968|NCT00835393|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
440969|NCT00835380|Biological|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
440970|NCT00835367|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
440971|NCT00835367|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
440972|NCT00835354|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
440973|NCT00835354|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
440974|NCT00835328|Drug|exendin-(9-39)|exendin-(9-39) 1000-30000pmol/kg/min (0.2-6mg/kg/hr) Intravenous infusion over 9 hours
440975|NCT00835328|Other|placebo|normal saline Intravenous infusion over 9 hours
440976|NCT00835302|Procedure|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
440977|NCT00835289|Dietary Supplement|n-3 polyunsaturated fatty acids|Omax3[TM] (Cenestra Health [TM]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
440978|NCT00835289|Other|Placebo|3 capsules of matching corn oil placebo
440979|NCT00835276|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
440980|NCT00835276|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
440981|NCT00835263|Drug|Lamotrigine|200 mg Tablet
440982|NCT00835263|Drug|Lamictal®|200 mg Tablet
440983|NCT00835250|Procedure|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
440984|NCT00835250|Procedure|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
440985|NCT00835237|Biological|Boostrix®|Intramuscular, single dose.
440986|NCT00835237|Biological|Decavac™|Intramuscular, single dose.
440987|NCT00835224|Drug|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
440988|NCT00835224|Drug|Midodrine|To treat low blood pressure.
440989|NCT00835224|Drug|Placebo|A pill with an inactive substance that looks like the study drug.
440990|NCT00835211|Drug|Desmopressin Acetate 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
440991|NCT00835211|Drug|DDAVP® 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
440992|NCT00835198|Drug|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
440993|NCT00835198|Drug|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
440994|NCT00835185|Biological|IMC-11F8 (necitumumab)|IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
440995|NCT00835185|Drug|Oxaliplatin|Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
440996|NCT00835185|Drug|Folinic acid (FA)|FA 400 mg/m² IV infusion bolus injection
440997|NCT00835185|Drug|5-FU|5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
440998|NCT00835172|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
440999|NCT00835172|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
441000|NCT00835159|Drug|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
441001|NCT00835159|Other|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
441002|NCT00835146|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
441003|NCT00835146|Drug|COPEGUS™|1 x 200 mg, single-dose fasting
441004|NCT00835133|Other|biologic sample preservation procedure|one blood sample or saliva sample collection
441005|NCT00835133|Other|medical chart review|confirmation of cancer diagnosis
441006|NCT00835133|Other|survey administration|at baseline enrollment and 12 months post-enrollment
441007|NCT00835120|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
441008|NCT00835107|Drug|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
441015|NCT00835042|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
441016|NCT00835042|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
441017|NCT00835029|Drug|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
441018|NCT00835029|Drug|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
441019|NCT00835016|Behavioral|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
441020|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
441021|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
441022|NCT00834990|Drug|divalproex sodium|delayed-release 500 mg tablet
441023|NCT00834990|Drug|Depakote®|delayed-release 500 mg tablet
441024|NCT00834977|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
441025|NCT00834977|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
441026|NCT00834964|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
441027|NCT00834964|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
441028|NCT00834951|Radiation|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
441029|NCT00834938|Other|No intervention|No intervention
441030|NCT00834925|Drug|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
441031|NCT00834912|Drug|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
441032|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
441033|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
441034|NCT00834899|Drug|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
441035|NCT00834899|Drug|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
441036|NCT00834886|Dietary Supplement|Melatonin|Capsules, 3 mg, once every night
441037|NCT00834886|Other|Bright light|Bright light therapy 10.000 lux by Miljølys AS
441038|NCT00834886|Other|Placebo red light|Red light 400 lux as placebo light
441039|NCT00834886|Other|Placebo capsule|Capsules containing 3 mng rice flour, once every night
441040|NCT00834873|Drug|Carvedilol 25 mg tablets|1 x 25 mg
441041|NCT00834873|Drug|COREG® 25 mg tablets|1 x 25 mg
441042|NCT00834860|Drug|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
441043|NCT00834847|Drug|pravastatin|40 mg tablet
441044|NCT00834847|Drug|Pravachol®|40 mg Tablet
441045|NCT00834834|Drug|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
441046|NCT00834834|Behavioral|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
441047|NCT00834834|Drug|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
441048|NCT00834821|Behavioral|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
441049|NCT00834821|Behavioral|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
441050|NCT00834808|Drug|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
441051|NCT00834795|Drug|Carvedilol 25 mg tablets|1 x 25 mg
441052|NCT00834795|Drug|COREG® 25 mg tablets|1 x 25 mg
441053|NCT00834782|Procedure|IOP measurement|Measuring IOP
441054|NCT00834756|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
441055|NCT00834756|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
441056|NCT00834743|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
441057|NCT00834743|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
441058|NCT00834730|Drug|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
441059|NCT00834717|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
441060|NCT00834717|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
441061|NCT00834704|Drug|PEGPH20|PEGylated recombinant human hyaluronidase
441062|NCT00834678|Drug|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
441063|NCT00834678|Drug|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
441064|NCT00834678|Drug|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
441065|NCT00834665|Biological|hTERT vaccine, GM-CSF, PCV, T cell infusion|hTERT vaccine (multi-peptide vaccine), Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
441066|NCT00834665|Biological|GM-CSF, PCV, T cell infusion|Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF), Prevnar-Pneumococcal Conjugate vaccine (PCV), T cell infusion
441067|NCT00834652|Drug|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
441068|NCT00834652|Drug|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
441069|NCT00834639|Drug|divalproex sodium|delayed-release 500 mg tablet
441070|NCT00834639|Drug|Depakote®|delayed-release 500 mg tablet
441071|NCT00834626|Procedure|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
441072|NCT00834613|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
441073|NCT00834613|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
441074|NCT00834600|Drug|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
441075|NCT00834600|Drug|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
441076|NCT00834587|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
441077|NCT00834587|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
441078|NCT00834574|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
441079|NCT00834574|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
441080|NCT00834561|Drug|Lamotrigine|200 mg Tablet
441081|NCT00834561|Drug|Lamictal®|200 mg Tablet
441082|NCT00834548|Procedure|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
441083|NCT00834535|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
441084|NCT00834535|Drug|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
441085|NCT00834522|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
441086|NCT00834522|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
441087|NCT00834509|Device|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
441088|NCT00834496|Procedure|Liver biopsy|percutaneous liver biopsy
441089|NCT00834483|Device|Knotless suture for wound closure|Angiotech Quill SRS
441090|NCT00834483|Device|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
441091|NCT00834470|Drug|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
441092|NCT00834457|Drug|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
441093|NCT00834457|Drug|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
441094|NCT00834444|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
441095|NCT00834444|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
441096|NCT00834431|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
441097|NCT00834431|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
441098|NCT00834418|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
441099|NCT00834418|Drug|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
441100|NCT00834405|Drug|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
441101|NCT00834405|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
441102|NCT00834392|Behavioral|Exercise|Walking exercise
441103|NCT00834379|Drug|pravastatin sodium|40 mg Tablet
441104|NCT00834379|Drug|Pravachol®|40 mg tablet
441105|NCT00834366|Drug|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
441106|NCT00834353|Drug|ATT|
441107|NCT00834340|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose fasting
441108|NCT00834340|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose fasting
441109|NCT00834327|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
441110|NCT00834314|Procedure|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
441111|NCT00834314|Procedure|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
441112|NCT00834301|Dietary Supplement|Oral Multivitamin|Oral Multivitamin
441113|NCT00834288|Drug|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
441114|NCT00834288|Drug|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
441115|NCT00834275|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
441116|NCT00834275|Drug|DURICEF® capsules 500 mg|1 x 500 mg
441117|NCT00834262|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
441118|NCT00834262|Drug|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
441119|NCT00834262|Drug|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
441120|NCT00834249|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
441121|NCT00834249|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
441122|NCT00834236|Other|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
442499|NCT00823680|Drug|RO5027838|200mg po qd for 4 weeks
441123|NCT00834236|Other|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
441124|NCT00834223|Device|Aquashunt|A shunt which is implanted into the suprachoroidal space.
441125|NCT00834210|Drug|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
441126|NCT00834210|Drug|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
441127|NCT00834197|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
441128|NCT00834197|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
441129|NCT00834184|Drug|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
441130|NCT00834171|Drug|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
441131|NCT00834171|Drug|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
441132|NCT00834158|Procedure|TACE|1 time
441133|NCT00834158|Procedure|PVE|1 time
441134|NCT00834145|Device|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
441135|NCT00834132|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
441136|NCT00834132|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
441137|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
441138|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
441139|NCT00834106|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
441140|NCT00834106|Biological|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
441141|NCT00834093|Biological|Epstein-Barr Virus Specific Immunotherapy|Two infusions given fourteen days apart, with a possible third infusion given 8 weeks later.
441142|NCT00834080|Drug|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
441143|NCT00834067|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
441144|NCT00834067|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
441145|NCT00834054|Procedure|Double-lung transplantation|Double-lung transplanted patients
441146|NCT00834041|Drug|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
441147|NCT00834015|Other|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
441148|NCT00834002|Biological|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
441149|NCT00833989|Drug|GSK249320|I.V. infusion
441150|NCT00833989|Drug|PLACEBO|Placebo
441151|NCT00833976|Drug|Lovaza|4 grams per day
441152|NCT00833963|Drug|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
441153|NCT00833963|Drug|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
441154|NCT00833963|Drug|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
441155|NCT00833950|Device|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
441156|NCT00833937|Drug|Zolpidem 10 mg tablets|1 x 10 mg
441157|NCT00833937|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
441158|NCT00833924|Device|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
441159|NCT00833911|Drug|Tramadol Once A Day|
441160|NCT00833898|Device|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
441161|NCT00833898|Behavioral|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development & application of various stress-mgmt techniques such as effective problem-solving, identifying & challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support & goal setting.
441162|NCT00833885|Device|Masks|Wearing of surgical masks
441163|NCT00833885|Device|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
441164|NCT00833885|Other|Control|General information about virus transmission in households and basic means to prevent it
441165|NCT00833872|Drug|LEO 22811|First-in-man
441166|NCT00833872|Drug|placebo solution|
441167|NCT00833859|Drug|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
441168|NCT00833859|Radiation|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
441169|NCT00833833|Drug|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
441170|NCT00833833|Drug|Dexamethasone|oral dexamethasone
441171|NCT00833833|Drug|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
441172|NCT00833820|Procedure|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
441173|NCT00833820|Procedure|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
441174|NCT00833807|Drug|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.~Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
441175|NCT00833794|Drug|Tramadol Once a day|
441176|NCT00833794|Drug|Placebo|
441177|NCT00833781|Biological|mRNA-transfected autologous dendritic cells|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
441178|NCT00833781|Biological|autologous dendritic cells with no mRNA transfection|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
441179|NCT00833768|Drug|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
441180|NCT00833768|Drug|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
441181|NCT00833755|Drug|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
441182|NCT00833755|Drug|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
441183|NCT00833742|Behavioral|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
441184|NCT00833729|Drug|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
441185|NCT00833716|Drug|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
441186|NCT00833703|Drug|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
441187|NCT00833703|Drug|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
441188|NCT00833690|Drug|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
441189|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
441190|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
441191|NCT00833677|Behavioral|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
441192|NCT00833664|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
441193|NCT00833664|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
441194|NCT00833638|Drug|Placebo|One tablet orally daily
441195|NCT00833638|Drug|Tadalafil|Orally once daily
441196|NCT00833625|Procedure|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
441197|NCT00833625|Other|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
441198|NCT00833612|Device|Counterpulsation with IAB|IABC pre-reperfusion PCI
441199|NCT00833599|Drug|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
441200|NCT00833586|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
441201|NCT00833586|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
441202|NCT00833560|Drug|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
441203|NCT00833560|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
441390|NCT00831987|Biological|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
441204|NCT00833560|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
441205|NCT00833547|Drug|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
441206|NCT00833547|Drug|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
441207|NCT00833534|Biological|rituximab|Given IV
441208|NCT00833534|Drug|lenalidomide|Given orally
441209|NCT00833521|Drug|Zolpidem 10 mg tablets|1 x 10 mg
441210|NCT00833521|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
441211|NCT00833508|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
441212|NCT00833495|Drug|Prednisolone Acetate 0.12% (Pred Mild®)|Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
441213|NCT00833495|Drug|FOV1101-00|This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
441214|NCT00833495|Drug|Prednisolone Acetate 1% (Pred Forte®)|PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
441215|NCT00833495|Drug|Placebo|The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
441216|NCT00833482|Drug|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
441217|NCT00833482|Drug|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
441218|NCT00833482|Drug|Ritonavir|"Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.~Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."
441219|NCT00833469|Drug|Escitalopram|Once daily by mouth
441220|NCT00833443|Drug|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
441221|NCT00833417|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
441222|NCT00833404|Drug|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
441223|NCT00833391|Drug|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
441224|NCT00833378|Drug|Eltrombopag|Eltrombopag 100 mg single oral dose
441225|NCT00833378|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
441226|NCT00833378|Drug|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
441227|NCT00833365|Drug|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
441228|NCT00833365|Drug|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
441229|NCT00833352|Device|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
441230|NCT00833339|Drug|mifepristone|600 mg/day x 1 week
441231|NCT00833339|Drug|placebo|placebo
441232|NCT00833326|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
441233|NCT00833326|Drug|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
441234|NCT00833326|Drug|Prophylactic growth factors; subcutaneous|standard of care
441235|NCT00833313|Other|Atrial biopsy|Biopsy of right atrial free wall
441272|NCT00833001|Device|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
441236|NCT00833300|Drug|Haloperidol|"2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
441237|NCT00833300|Drug|Olanzapine|"2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~Reassess in 24 hours.~Delirium absent - Continue dose for 24 hours then discontinue.~Delirium present - Discontinue current drug therapy and select one of:~Quetiapine up to 100 mg/day~Risperidone up to 6 mg/day~Loxapine up to 50 mg/day~Methotrimeprazine up to 75 mg/day~Reassess in 24 hours.~Delirium absent - Continue for 24 hours then discontinue.~Delirium present - Treatment at discretion of attending physician."
441238|NCT00833274|Behavioral|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
441239|NCT00833261|Drug|cetuximab|cetuximab
441240|NCT00833261|Drug|cisplatin|cisplatin
441241|NCT00833261|Radiation|intensity-modulated radiation therapy|IMRT
441242|NCT00833261|Drug|Nab-Paclitaxel|Nab-Paclitaxel
441243|NCT00833248|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
441244|NCT00833248|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
441245|NCT00833248|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
441246|NCT00833235|Other|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
441247|NCT00833209|Procedure|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
441248|NCT00833209|Procedure|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
441249|NCT00833209|Procedure|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
441250|NCT00833183|Drug|MAL|80 mg/g cream one administration with incubation for 90 minutes
441251|NCT00833157|Drug|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg * 3 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks.
441252|NCT00833157|Drug|ibuprofen|Subjects are administered 600 mg * 2 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks
441253|NCT00833157|Drug|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (*3 weekly) with both legs for 12 weeks
441254|NCT00833131|Radiation|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
441255|NCT00833131|Radiation|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
441256|NCT00833118|Procedure|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
441257|NCT00833105|Device|AMES treatment|The AMES device rotates the fingers-thumb or the wrist in the flexion-extension directions over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that are lengthened by the thumb-finger or hand movement. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
441258|NCT00833092|Dietary Supplement|Sugar Pill|Sugar pill supplementation for 9 weeks
441259|NCT00833092|Dietary Supplement|magnesium|300 milligrams daily for 8 weeks
441260|NCT00833079|Drug|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
441261|NCT00833079|Drug|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
441262|NCT00833079|Drug|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
441263|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
441264|NCT00833066|Biological|Placebo|placebo entero-coated capsules
441265|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
441266|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
441267|NCT00833053|Drug|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
441268|NCT00833053|Drug|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
441269|NCT00833040|Drug|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
441270|NCT00833027|Drug|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
441271|NCT00833014|Device|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
441350|NCT00832286|Drug|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
441273|NCT00832988|Other|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
441274|NCT00832962|Genetic|Genotyping|Whole blood sample
441275|NCT00832962|Other|Usual prophylaxis|Prophylactic anti-RhD
441276|NCT00832923|Behavioral|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
441277|NCT00832897|Procedure|Corneal collagen crosslinking|"The patients will be submitted to corneal collagen crosslinking, that consists:~Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop."
441278|NCT00832884|Drug|Lacosamide|"0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes.~0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes; 1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes; 2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes; 2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes"
441279|NCT00832871|Drug|Mifepristone|Mifepristone 200 mg will be administered orally
441280|NCT00832845|Behavioral|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 24 weeks.
441281|NCT00832845|Behavioral|Treatment as usual (TAU)|Patients will receive their regular treatment for 24 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians. However, in addition to the standard of care, subjects receiving TAU will have 24 weekly 60-minute non-structured meetings, including half-hour lunch break, to control for non-specific factors associated with group therapy.
441282|NCT00832832|Other|Eyelid closure|Eyelid will be closed after eye drop instillation
441283|NCT00832832|Other|No intervention will be assigned|No intervention will be assigned to this arm
441284|NCT00832819|Drug|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
441285|NCT00832819|Drug|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
441286|NCT00832819|Drug|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
441287|NCT00832819|Drug|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
441288|NCT00832806|Behavioral|Extended IVR (integrated voice response technology)|See detailed description
441289|NCT00832806|Drug|Varenicline (Champix)|See detailed description
441290|NCT00832806|Behavioral|IVR treatment|See detailed description
441291|NCT00832780|Radiation|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
441292|NCT00832767|Procedure|SILS™ port laparoscopic cholecystectomy|This interventional arm will have a single incision laparoscopic cholecystectomy procedure.
441293|NCT00832767|Procedure|Four Port Laparoscopic Cholecystectomy|This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
441294|NCT00832754|Device|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
441295|NCT00832754|Other|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
441296|NCT00832728|Other|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
441297|NCT00832728|Device|ELAD®|ELAD therapy
441298|NCT00832715|Procedure|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
441299|NCT00832702|Procedure|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
441300|NCT00832689|Drug|Irinotecan and Gemcitabine|
441301|NCT00832663|Drug|NSAID|Effect of NSAID ingestion on muscle regeneration
441302|NCT00832663|Drug|placebo|receive placebo
441303|NCT00832650|Drug|fesoterodine fumarate|8 mg OD for 14 days
441304|NCT00832650|Drug|placebo|OD for 14 days
441305|NCT00832650|Drug|solifenacin|10 mg OD for 14 days
441306|NCT00832637|Drug|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
441307|NCT00832637|Drug|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
441351|NCT00832273|Device|ELAD®|liver assist system
441352|NCT00832247|Genetic|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
441391|NCT00831974|Drug|masitinib (AB1010)|3 mg/kg/day
441392|NCT00831974|Drug|masitinib (AB1010)|6 mg/kg/day
441308|NCT00832637|Drug|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
441309|NCT00832624|Drug|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
441310|NCT00832611|Device|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
441311|NCT00832598|Radiation|[18F]FACBC PET and [18F]FLT PET imaging|[18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
441312|NCT00832585|Drug|Alefacept|Alefacept 15mg IM every week for 12 weeks
441313|NCT00832572|Drug|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
441314|NCT00832572|Drug|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
441315|NCT00832559|Biological|CVA21|1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
441316|NCT00832546|Drug|Placebo|
441317|NCT00832546|Drug|Oral NGX426 (Powder in solution)|
441318|NCT00832520|Drug|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance < 50% or a bilirubin or transaminases > twice the upper limit of normal will take a 7.5 mg dose.~Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~Dose modifications: None"
441319|NCT00832507|Drug|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
441320|NCT00832507|Drug|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
441321|NCT00832494|Drug|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
441322|NCT00832481|Drug|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
441323|NCT00832481|Drug|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
441324|NCT00832468|Other|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
441325|NCT00832468|Other|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
441326|NCT00832455|Drug|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
441327|NCT00832442|Drug|Beta blocker|as determined by individual study
441328|NCT00832442|Other|Placebo|in addition to usual care
441329|NCT00832429|Procedure|Lymphatic Mapping|SPECT/CT scan following Tc99m-Sulfur colloid injection into eyelid tumor(s) making lymph nodes visible on imaging scan.
441330|NCT00832429|Procedure|SLN Mapping/Biopsy|SLN mapping and biopsy done in OR under general anesthesia. Injection of Tc99m-Sulfur colloid again around eyelid tumor(s) or removed tumor site(s). Lymph nodes visible from injection removed and tested for signs of metastatic disease.
441331|NCT00832429|Drug|Tc99m-Sulfur colloid|On the day of surgery, 0.2-0.3 cc (0.4-0.6 mCi) of Tc99m-Sulfur colloid injected intradermally around the primary lesion approximately one hour prior to the procedure.
441332|NCT00832416|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
441333|NCT00832416|Drug|Placebo|One Placebo tablet daily.
441334|NCT00832403|Other|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
441335|NCT00832390|Drug|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
441336|NCT00832377|Drug|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
441337|NCT00832364|Drug|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
441338|NCT00832364|Drug|Placebo|Placebo capsules
441339|NCT00832364|Biological|Etanercept|Injectable Biologic
441340|NCT00832351|Procedure|Mobilisation|Mobilisation
441341|NCT00832338|Drug|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
441342|NCT00832338|Drug|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
441343|NCT00832325|Behavioral|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
441344|NCT00832325|Behavioral|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
441345|NCT00832325|Behavioral|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
441346|NCT00832312|Other|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
441347|NCT00832312|Other|placebo (saline)|Injection of 1cc of saline into the knee joint
441348|NCT00832299|Drug|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
441349|NCT00832299|Procedure|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
441353|NCT00832234|Drug|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
441354|NCT00832221|Drug|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
441355|NCT00832221|Drug|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
441356|NCT00832221|Drug|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
441357|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
441358|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
441359|NCT00832195|Device|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
441360|NCT00832195|Device|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
441361|NCT00832182|Drug|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
441362|NCT00832182|Drug|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
441363|NCT00832169|Drug|AZD1386|1 dose of oral solution
441364|NCT00832156|Biological|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
441365|NCT00832143|Behavioral|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
441366|NCT00832130|Device|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
441367|NCT00832130|Device|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
441368|NCT00832117|Drug|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
441369|NCT00832117|Drug|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
441370|NCT00832117|Drug|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
441371|NCT00832117|Drug|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
441372|NCT00832091|Drug|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
441373|NCT00832091|Drug|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
441374|NCT00832078|Device|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
441375|NCT00832078|Device|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
441376|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
441377|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
441378|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
441379|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
441380|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
441381|NCT00832039|Drug|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
441382|NCT00832039|Drug|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
441383|NCT00832039|Procedure|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:~Day 4: PCT drop from baseline >=50%: no change in causal therapy; PCT drop from baseline <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.~Day 7, 10, 14: PCT <=1.0 ng/ml: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement >=50%: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
441384|NCT00832026|Device|Trans Nasal Insufflation (TNI) [nasal canula]|"Trans Nasal Insufflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.~By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
441385|NCT00832013|Drug|Propofol|See detailed description
441386|NCT00832013|Drug|Propofol|See detailed description
441387|NCT00832000|Drug|Mexiletine|200 mg three times a day; in pill form
441388|NCT00832000|Drug|Placebo|Placebo three times a day; in pill form
441389|NCT00831987|Biological|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
441393|NCT00831961|Procedure|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
441394|NCT00831948|Genetic|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
441395|NCT00831922|Drug|masitinib (AB1010)|3 mg/kg/day
441396|NCT00831922|Drug|masitinib (AB1010)|6 mg/kg/day
441397|NCT00831896|Biological|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks~Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
441398|NCT00831883|Behavioral|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
441399|NCT00831883|Behavioral|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
441400|NCT00831857|Other|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
441401|NCT00831844|Biological|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
441402|NCT00831844|Other|laboratory biomarker analysis|Correlative studies
441403|NCT00831831|Behavioral|Safety planning|See detailed description
441404|NCT00831792|Drug|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
441405|NCT00831779|Drug|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
441406|NCT00831779|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
441407|NCT00831766|Drug|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
441408|NCT00831766|Drug|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
441409|NCT00831766|Drug|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
441410|NCT00831753|Biological|DTaP IPV HB PRP~T vaccine|0.5 mL, Intramuscular
441411|NCT00831753|Biological|DTaP-HB-IPV and Haemophilus influenzae type b|0.5 mL, Intramuscular
441412|NCT00831740|Other|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
441413|NCT00831740|Other|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
441414|NCT00831727|Behavioral|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
441415|NCT00831727|Behavioral|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
441416|NCT00831714|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
441417|NCT00831714|Drug|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
441418|NCT00831701|Drug|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
441419|NCT00831701|Drug|Placebo|One placebo pill per day for 21 days or until stone expulsion
441420|NCT00831688|Device|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
441421|NCT00831688|Device|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
441422|NCT00831675|Biological|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
441423|NCT00831675|Biological|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
441424|NCT00831662|Drug|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
441425|NCT00831662|Drug|Placebo|One to two drops in each eye QID for 6 weeks
441426|NCT00831649|Drug|natalizumab|
441427|NCT00831636|Drug|CP-4055|D1-5 and D8(+2)-12(+2) q4w
441428|NCT00831636|Drug|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
441429|NCT00831623|Radiation|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
441430|NCT00831623|Radiation|Proton|As above
441431|NCT00831610|Procedure|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
441432|NCT00831610|Procedure|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
441433|NCT00831597|Drug|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
441434|NCT00831597|Drug|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
441435|NCT00831545|Drug|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
441436|NCT00831532|Drug|Dimebon|Dimebon 5mg in healthy controls
442500|NCT00823680|Drug|RO5027838|50mg po bid for 4 weeks
441437|NCT00831532|Drug|Dimebon|Dimebon 5mg in mild hepatic impairment patients
441438|NCT00831532|Drug|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
441439|NCT00831532|Drug|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
441440|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
441441|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
441442|NCT00831506|Drug|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
441443|NCT00831493|Radiation|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
441444|NCT00831493|Drug|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
441445|NCT00831480|Drug|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
441446|NCT00831467|Biological|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
441447|NCT00831441|Drug|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
441448|NCT00831441|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
441449|NCT00831428|Other|no intervention|this is a screening study, not an interventional study
441450|NCT00831415|Drug|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
441451|NCT00831402|Dietary Supplement|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
441452|NCT00831402|Dietary Supplement|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
441453|NCT00831389|Device|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
441454|NCT00831376|Drug|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
441455|NCT00831376|Drug|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
441456|NCT00831376|Drug|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
441457|NCT00831363|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
441458|NCT00831363|Procedure|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
441459|NCT00831350|Drug|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
441460|NCT00831337|Dietary Supplement|VSL3|2 times daily 450 billion live bacteria (in each saschet)
441461|NCT00831311|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
441462|NCT00831311|Biological|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
441463|NCT00831298|Other|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
441464|NCT00831285|Dietary Supplement|food product|food product given at one of six visits
441465|NCT00831272|Drug|naltrexone|50mg/day
441466|NCT00831272|Drug|Placebo|Placebo
441467|NCT00831246|Other|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
441468|NCT00831246|Other|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
441469|NCT00831233|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
441470|NCT00831233|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
441471|NCT00831233|Drug|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
441472|NCT00831194|Behavioral|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
441473|NCT00831181|Drug|5-FU|5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
441474|NCT00831181|Drug|Oxaliplatin|Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
441475|NCT00831181|Drug|leucovorin|Folinic Acid (Leucovorin): 400 mg/m2; 2-hour IV infusion simultaneously with oxaliplatin
441476|NCT00831181|Procedure|mesorectal excision|mesorectal excision
441477|NCT00831168|Behavioral|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
441478|NCT00831155|Drug|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
441479|NCT00831129|Drug|Rosiglitazone|4 mg daily
441480|NCT00831129|Drug|Placebo Rosiglitazone|1 tab daily
441481|NCT00831129|Drug|Simvastatin|40 mg daily
441482|NCT00831116|Device|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
441483|NCT00831103|Drug|EPB-348|Treated over seven days
441484|NCT00831103|Drug|Valacyclovir|Treated over seven days
441485|NCT00831077|Drug|ORM-14540|i.v.
441486|NCT00831077|Drug|ORM-12741|i.v.
441487|NCT00831064|Procedure|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
441488|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
441489|NCT00831051|Drug|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
441490|NCT00831051|Drug|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
441491|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
441492|NCT00831051|Drug|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
441493|NCT00831051|Drug|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
441494|NCT00831038|Procedure|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
441495|NCT00831025|Biological|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
441496|NCT00831025|Biological|Placebo|Placebo for subcutaneous monthly administration
441497|NCT00831012|Biological|rDEN3delta30/31‐7164|A live attenuated, recombinant DEN3 candidate vaccine virus
441498|NCT00830999|Behavioral|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
441499|NCT00830999|Behavioral|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
441500|NCT00830999|Behavioral|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
441501|NCT00830999|Behavioral|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
441502|NCT00830999|Behavioral|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
441503|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
441504|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
441505|NCT00830973|Other|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
441506|NCT00830973|Other|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
441507|NCT00830960|Drug|Prasugrel|Oral, daily, 90 days
441508|NCT00830960|Drug|Clopidogrel|Oral, daily, 90 days
441509|NCT00830947|Device|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
441510|NCT00830947|Device|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
441511|NCT00830934|Procedure|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
441512|NCT00830934|Procedure|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
441513|NCT00830921|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
441514|NCT00830908|Device|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
441515|NCT00830895|Drug|RAD001|RAD001 10mg/day
441516|NCT00830882|Drug|levosalbutamol|2 puffs four times a day for 2 weeks
441517|NCT00830882|Drug|racemic salbutamol|2 puffs four times a day for 2 weeks
441518|NCT00830882|Drug|placebo|2 puffs four times a day for 2 weeks
441519|NCT00830869|Drug|IXAZOMIB|"All participants will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.~The first stage of the study will be initiated at a starting dose of 0.125 mg/m^2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
441520|NCT00830856|Drug|Fluconazole|Fluconazole 800mg po qday
441521|NCT00830856|Drug|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
441522|NCT00830856|Drug|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
441523|NCT00830843|Drug|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
441524|NCT00830843|Drug|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
441525|NCT00830830|Drug|Hyalgan (sodium hyaluronate)|
441526|NCT00830804|Drug|Raltegravir|400 mg tablet taken orally twice daily
441527|NCT00830804|Drug|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
441528|NCT00830791|Drug|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
441529|NCT00830791|Drug|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
441530|NCT00830778|Procedure|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
441531|NCT00830778|Procedure|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
441532|NCT00830765|Drug|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
441533|NCT00830765|Drug|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
441534|NCT00830726|Drug|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
441535|NCT00830726|Procedure|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
441536|NCT00830726|Procedure|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
441537|NCT00830726|Procedure|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
441538|NCT00830713|Procedure|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
441539|NCT00830700|Other|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
441540|NCT00830687|Device|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
441541|NCT00830674|Drug|Placebo|single dose IV or SC administration
441542|NCT00830674|Drug|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
441543|NCT00830661|Procedure|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
441544|NCT00830661|Procedure|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
441545|NCT00830648|Biological|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
441546|NCT00830635|Other|educational intervention|
441547|NCT00830635|Other|informational intervention|
441548|NCT00830635|Other|internet-based intervention|
441549|NCT00830635|Other|questionnaire administration|
441550|NCT00830635|Other|study of socioeconomic and demographic variables|
441551|NCT00830635|Other|survey administration|
441552|NCT00830635|Procedure|psychosocial assessment and care|
441553|NCT00830635|Procedure|quality-of-life assessment|
441554|NCT00830622|Other|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
441555|NCT00830609|Drug|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
441556|NCT00830609|Drug|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks
441557|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 24 weeks
441558|NCT00830609|Drug|ribavirin|ribavirin 800 mg/day for 24 weeks
441559|NCT00830609|Drug|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
441560|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
441561|NCT00830596|Other|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
441562|NCT00830596|Other|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
441563|NCT00830596|Other|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
441564|NCT00830583|Procedure|blood test|There is only a blood test at the beginning.
441565|NCT00830570|Other|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
441566|NCT00830557|Other|medical chart review|baseline, 12 month and 36 months
441567|NCT00830557|Other|survey administration|baseline, 6 month, 12 month
441568|NCT00830557|Other|biospecimen collection|baseline
441569|NCT00830544|Drug|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
441570|NCT00830544|Drug|Chemotherapy|Neoadjuvant chemotherapy
441571|NCT00830544|Drug|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
441572|NCT00830531|Drug|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
441573|NCT00830531|Drug|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
441574|NCT00830518|Drug|Alisertib|Alisertib capsules
441575|NCT00830505|Drug|fluticasone/salmeterol|2 puffs twice a day for 2 weeks
441576|NCT00830505|Drug|fluticasone|2 puffs twice a day for 2 weeks
441577|NCT00830492|Drug|clomiphene citrate|100 mg from cycle day 3 through 7
441578|NCT00830492|Procedure|Ultrasound|cycle day 8
441579|NCT00830492|Drug|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
441580|NCT00830492|Drug|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
441581|NCT00830492|Drug|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
442501|NCT00823680|Drug|RO5093151|400mg po bid for 4 weeks
441582|NCT00830492|Drug|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
441583|NCT00830479|Procedure|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
441584|NCT00830479|Procedure|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
441585|NCT00830466|Drug|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
441586|NCT00830453|Procedure|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
441587|NCT00830440|Device|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
441588|NCT00830440|Behavioral|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
441589|NCT00830427|Drug|PF-00610355|100 mcg, QD, dry powder inhaler
441590|NCT00830427|Drug|PF - 00610355|600 mcg, QD, dry powder inhaler
441591|NCT00830427|Other|Placebo|QD, dry powder inhaler
441592|NCT00830427|Drug|PF - 00610355|300 mcg, QD, dry powder inhaler
441593|NCT00830414|Drug|medroxyprogesterone acetate|IM Injection
441594|NCT00830414|Drug|medroxyprogesterone acetate|IM injection
441595|NCT00830401|Procedure|Treatment of predefined abnormality by hysteroscopic surgery|"Polyp resection with Hysteroscopic scissors or Versapoint~Resection of myoma with Resectoscope Storz or Versapoint~Septum resection with Resectoscope Storz or Versapoint~Resection of adhesions with Hysteroscopic scissors or Versapoint"
441596|NCT00830401|Drug|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
441597|NCT00830388|Drug|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
441598|NCT00830375|Drug|Memantine|10-30mg, by mouth, daily
441599|NCT00830362|Drug|Propranolol|40 mg administered once
441600|NCT00830362|Drug|Placebo|administered once
441601|NCT00830349|Drug|Risperidone|1 mg Tablet
441602|NCT00830349|Drug|Risperidone|1 mg Tablets
441603|NCT00830336|Drug|Azithromycin|Oral Suspension
441604|NCT00830336|Drug|Zithromax®|Oral Suspension
441605|NCT00830323|Drug|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
441606|NCT00830323|Drug|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
441607|NCT00830323|Drug|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
441608|NCT00830310|Behavioral|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
441609|NCT00830310|Behavioral|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
441610|NCT00830310|Behavioral|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
441611|NCT00830310|Behavioral|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
441612|NCT00830297|Drug|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
441613|NCT00830297|Drug|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
441614|NCT00830284|Procedure|Recruitment maneuver|"Three types of maneuvers will be performed.~6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.~6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.~PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
441615|NCT00830271|Device|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
441616|NCT00830271|Device|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
441617|NCT00830258|Drug|Pravastatin sodium 80 mg tablets|1 x 80 mg
441618|NCT00830258|Drug|Pravachol® 80 mg tablets|1 x 80 mg
441619|NCT00830245|Drug|Erlotinib|Erlotinib 150mg/day
441620|NCT00830232|Device|closed-cell stent|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device."
441621|NCT00830232|Device|Open-cell stent|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
441622|NCT00830219|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
441623|NCT00830219|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
441624|NCT00830206|Other|Azithromycin|Oral Suspension
441625|NCT00830206|Drug|Zithromax®|Oral Suspension
441626|NCT00830193|Drug|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
441627|NCT00830193|Drug|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
441628|NCT00830180|Biological|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
441629|NCT00830167|Drug|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
441630|NCT00830167|Drug|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
441631|NCT00830154|Drug|pagoclone|0.30 mg BID, 0.60 mg BID
441632|NCT00830154|Other|placebo|placebo
441633|NCT00830128|Drug|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
441634|NCT00830115|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
441635|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)~Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
441636|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)~Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
441637|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)~Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)~Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
441638|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)~Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)~Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
441639|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)~Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)~Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
441640|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI~Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)~Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)~Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
441641|NCT00830089|Drug|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
441642|NCT00830076|Drug|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
441643|NCT00830076|Drug|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
441644|NCT00830076|Drug|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
441645|NCT00830076|Drug|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
441646|NCT00830063|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
441647|NCT00830063|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
441648|NCT00830063|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
441649|NCT00830063|Other|placebo|placebo to match tanezumab and naproxen dosing
441650|NCT00830050|Drug|Naproxen|500 mg BID 7 days
441651|NCT00830050|Drug|Placebo|BID 7 days
441652|NCT00830037|Drug|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
441653|NCT00830037|Drug|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
441654|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
441655|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
441656|NCT00830011|Behavioral|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
441657|NCT00830011|Other|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
441658|NCT00829998|Drug|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
441659|NCT00829998|Drug|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
441660|NCT00829985|Biological|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
441661|NCT00829985|Biological|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
441662|NCT00829959|Behavioral|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
441663|NCT00829946|Behavioral|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of ~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
441664|NCT00829933|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
441665|NCT00829933|Drug|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
441666|NCT00829907|Drug|ORM-12741|Single dose as a capsule, oral administration
441667|NCT00829894|Drug|Risperidone|1 mg Tablet
441668|NCT00829894|Drug|Risperidone|1 mg Tablet
441669|NCT00829881|Drug|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
441670|NCT00829881|Drug|Placebo Capsule|A single placebo capsule
441671|NCT00829868|Drug|Zaleplon 10 mg Capsules|1 x 10 mg
441672|NCT00829868|Drug|SONATA® 10 mg capsules|1 x 10 mg
441673|NCT00829842|Other|oral hygiene|oral hygiene with 0.12% chlorexidine
441674|NCT00829842|Other|placebo|oral hygiene placebo
441675|NCT00829829|Other|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
441676|NCT00829829|Drug|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
441677|NCT00829829|Drug|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
441678|NCT00829816|Drug|Dimebon|
441679|NCT00829816|Drug|Placebo|
441680|NCT00829803|Device|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
441681|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5mL oral dose
441682|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
441683|NCT00829777|Drug|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:~Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
441684|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
441685|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
441686|NCT00829751|Device|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
441687|NCT00829751|Device|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
441688|NCT00829738|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
441689|NCT00829725|Device|screws-internal fixation|3-4-screws-internal fixation
441690|NCT00829725|Device|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
441691|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
441692|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
441693|NCT00829699|Procedure|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
441694|NCT00829699|Procedure|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
441695|NCT00829699|Procedure|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
441696|NCT00829699|Procedure|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
441697|NCT00829686|Drug|Septra|(800/125) PO BID X 7 days
441698|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
441699|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
441793|NCT00829010|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
441794|NCT00829010|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
441700|NCT00829660|Drug|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
441701|NCT00829660|Drug|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
441702|NCT00829647|Drug|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
441703|NCT00829634|Drug|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
441704|NCT00829634|Drug|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
441705|NCT00829621|Other|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
441706|NCT00829621|Other|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
441707|NCT00829608|Biological|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
441708|NCT00829595|Biological|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
441709|NCT00829582|Drug|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
441710|NCT00829582|Other|placebo|single intravenous infusion
441711|NCT00829569|Dietary Supplement|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
441712|NCT00829556|Device|Integuseal|
441713|NCT00829543|Procedure|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
441714|NCT00829530|Drug|Ramipril 10 mg capsule|1 x 10 mg
441715|NCT00829530|Drug|Altace® 10 mg capsule|1 x 10 mg
441716|NCT00829517|Other|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
441717|NCT00829517|Other|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
441718|NCT00829504|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
441719|NCT00829504|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg
441720|NCT00829491|Behavioral|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
441721|NCT00829478|Behavioral|Decision Aid for Atrial Fibrillation|Single contact educational session
441722|NCT00829478|Other|Usual Care|Usual Care
441723|NCT00829465|Drug|Licartin|Licartin
441724|NCT00829465|Procedure|Transcatheter arterial chemoembolization|TACE
441725|NCT00829452|Drug|Ramipril 10 mg capsule|1 x 10 mg
441726|NCT00829452|Drug|Altace® 10 mg capsule|1 x 10 mg
441727|NCT00829439|Drug|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
441728|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
441729|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
441730|NCT00829413|Drug|SonoVue®|SonoVue (2.4 mL)
441731|NCT00829400|Behavioral|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
441732|NCT00829400|Behavioral|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
441733|NCT00829387|Behavioral|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
441734|NCT00829387|Behavioral|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
441735|NCT00829374|Drug|Dimebon|5 mg orally three times daily
441736|NCT00829374|Drug|Dimebon|20 mg orally three times daily
441737|NCT00829374|Drug|Placebo comparator|Placebo orally three times daily
441738|NCT00829361|Other|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
441739|NCT00829348|Other|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
441740|NCT00829348|Behavioral|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
441795|NCT00829010|Biological|measles|Intramuscular injection, 2 doses
441796|NCT00829010|Biological|Rotarix|Oral, 2 doses
441741|NCT00829335|Procedure|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
441742|NCT00829322|Drug|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
441743|NCT00829322|Drug|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
441744|NCT00829309|Drug|Pravastatin|80 mg Tablet
441745|NCT00829309|Drug|Pravastatin|80 mg Tablets
441746|NCT00829296|Drug|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
441747|NCT00829296|Drug|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
441748|NCT00829283|Behavioral|Behavioral Weight Loss|weekly individual sessions for 6 months
441749|NCT00829283|Behavioral|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
441750|NCT00829283|Drug|Placebo|One pill daily
441751|NCT00829283|Drug|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
441752|NCT00829257|Drug|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
441753|NCT00829257|Drug|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
441754|NCT00829257|Drug|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
441755|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
441756|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
441757|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
441758|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
441759|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
441760|NCT00829218|Other|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
441761|NCT00829218|Other|Placebo diet|Juice with nothing added.
441762|NCT00829205|Biological|filgrastim|
441763|NCT00829205|Biological|rituximab|
441764|NCT00829205|Dietary Supplement|Se-methyl-seleno-L-cysteine|
441765|NCT00829205|Drug|carboplatin|
441766|NCT00829205|Drug|etoposide|
441767|NCT00829205|Drug|ifosfamide|
441768|NCT00829205|Other|laboratory biomarker analysis|
441769|NCT00829205|Other|pharmacological study|
441770|NCT00829192|Drug|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
441771|NCT00829192|Drug|Placebo|Placebo subcutaneous implant administered every 60 days
441772|NCT00829179|Drug|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
441773|NCT00829166|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
441774|NCT00829166|Drug|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
441775|NCT00829166|Drug|Capecitabine|Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
441776|NCT00829153|Device|U Clip|Interuppted nitional clips
441777|NCT00829153|Procedure|Conventional prolene anastomosis|Continuous prolene anastomosis
441778|NCT00829140|Drug|Placebo|
441779|NCT00829140|Drug|Lorcaserin 10mg BID|
441780|NCT00829127|Drug|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
441781|NCT00829127|Drug|Placebo|Oral suspension
441782|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
441783|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
441784|NCT00829088|Drug|AZD2066|1 dose oral solution
441785|NCT00829075|Drug|r-FSH|
441786|NCT00829075|Drug|HP-hMG|
441787|NCT00829075|Drug|r-FSH plus HP-hMG|
441788|NCT00829062|Device|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
441789|NCT00829049|Drug|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
441790|NCT00829049|Drug|Adapalene|1 pea-size amount, QD x 16 weeks
441791|NCT00829036|Device|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
441792|NCT00829023|Other|chlorhexidine gluconate and isopropyl alcohol, iodophor and isopropyl alcohol, povidone-iodine scrub and paint|surgical skin preparation solutions
442743|NCT00822120|Drug|cyclophosphamide|
441797|NCT00829010|Biological|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
441798|NCT00828997|Biological|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
441799|NCT00828984|Drug|macrogol 3350-based oral osmotic laxative|Given PO
441800|NCT00828984|Other|Placebo|Given PO
441801|NCT00828984|Other|Laboratory Biomarker Analysis|Correlative studies
441802|NCT00828971|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
441803|NCT00828971|Drug|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
441804|NCT00828958|Drug|Risperidone long-acting injectable|
441805|NCT00828945|Device|Lipid Self Test|Self test for lipid levels, twice during study period
441806|NCT00828932|Drug|Lorcaserin|
441807|NCT00828919|Drug|axitinib|BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial
441808|NCT00828919|Drug|crizotinib|BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
441809|NCT00828906|Drug|DuoTrav|DuoTrav Eye Drops
441810|NCT00828893|Device|navigation station|navigation station for gestures (carried out under CT) guidance
441811|NCT00828880|Device|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
441812|NCT00828867|Drug|100 mg GSK investigational drug|
441813|NCT00828867|Drug|200 mg GSK investigational drug|
441814|NCT00828867|Drug|400 mg GSK investigational drug|
441815|NCT00828867|Drug|800 mg GSK investigational drug|
441816|NCT00828867|Drug|2000 mg GSK investigational drug|
441817|NCT00828867|Drug|1500 mg GSK investigational drug|
441818|NCT00828867|Drug|800mg fed GSK investigational drug|
441819|NCT00828867|Drug|3000mg GSK investigational drug|
441820|NCT00828867|Drug|4000mg GSK investigational drug|
441821|NCT00828854|Drug|entinostat (SNDX-275)|5 mg PO every week
441822|NCT00828841|Drug|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
441823|NCT00828841|Drug|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
441824|NCT00828841|Drug|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
441825|NCT00828841|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
441826|NCT00828841|Drug|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
441827|NCT00828828|Biological|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
441828|NCT00828815|Drug|TMC125|
441829|NCT00828802|Drug|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
441830|NCT00828789|Drug|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
441831|NCT00828776|Biological|Heparin sodic - Cristália|5000UI/mL
441832|NCT00828776|Biological|heparin - Liquemine (Roche)|5000UI/mL
441833|NCT00828763|Drug|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
441834|NCT00828750|Drug|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
441835|NCT00828737|Drug|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
441836|NCT00828724|Drug|Lorcaserin 10mg|
441837|NCT00828711|Drug|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
441838|NCT00828711|Drug|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
441839|NCT00828711|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
441840|NCT00828698|Other|No intervention|
441841|NCT00828685|Procedure|CRPP|Closed reduction, percutaneous pinning
441842|NCT00828685|Procedure|ORIF|Open reduction, internal fixation
441843|NCT00828672|Drug|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
441844|NCT00828672|Drug|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
441845|NCT00828672|Drug|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
441846|NCT00828672|Radiation|radiotherapy|Total dose 45Gy
441847|NCT00828659|Drug|Placebo|
441848|NCT00828659|Drug|Active Comparator #1|
441849|NCT00828659|Drug|Active Comparator #2|
441850|NCT00828659|Drug|Active Comparator #3|
441851|NCT00828659|Drug|Lorcaserin Dose #1|
441852|NCT00828659|Drug|Lorcaserin Dose #2|
441853|NCT00828659|Drug|Lorcaserin Dose #3|
441854|NCT00828646|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
441855|NCT00828646|Drug|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
441856|NCT00828646|Drug|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
441857|NCT00828646|Drug|Placebo|Capsules, Oral, once daily, 14 days
441858|NCT00828620|Other|Imaging study|PET-CT
441859|NCT00828594|Drug|RAD001|
441860|NCT00828594|Drug|RAD001, sorafenib|
441861|NCT00828581|Drug|lorcaserin|
441862|NCT00828568|Drug|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
441863|NCT00828568|Drug|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
441864|NCT00828568|Drug|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
441865|NCT00828555|Other|Vaccination Program|Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis
441866|NCT00828542|Drug|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
441867|NCT00828542|Drug|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
441868|NCT00828529|Drug|TMC207|
441869|NCT00828516|Other|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
441870|NCT00828503|Drug|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)~MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
441871|NCT00828503|Drug|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
441872|NCT00828490|Behavioral|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
441873|NCT00828490|Behavioral|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
441874|NCT00828490|Behavioral|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
441875|NCT00828477|Drug|Xibrom|Xibrom: two times a day for seven days in the first eye.
441876|NCT00828477|Drug|Nevanac|Nevanac: three times a day for seven days in the second eye.
441877|NCT00828464|Drug|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
441878|NCT00828451|Biological|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
441879|NCT00828438|Drug|Lorcaserin 10mg|
441880|NCT00828412|Device|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
441881|NCT00828412|Drug|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
441882|NCT00828399|Dietary Supplement|Glutamine|Oral glutamine 30g/day
441883|NCT00828399|Dietary Supplement|Whole protein|Oral whole protein 30 g/day
441884|NCT00828386|Procedure|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
441885|NCT00828373|Drug|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
441886|NCT00828373|Drug|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
441887|NCT00828347|Drug|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
441888|NCT00828347|Drug|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
441889|NCT00828334|Device|Transcatheter PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter < 4 mm.
441890|NCT00828321|Drug|Ramipril 10 mg capsule|1 x 10 mg
441891|NCT00828321|Drug|Altace® 10 mg capsule|1 x 10 mg
441892|NCT00828308|Drug|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
441893|NCT00828308|Procedure|Prostatectomy|
441894|NCT00828295|Drug|palonosetron|palonosetron IV 1 mcg/kg
441895|NCT00828295|Drug|palonosetron|palonosetron 3mcg/kg IV
441896|NCT00828282|Drug|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
441897|NCT00828269|Procedure|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.~Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
441898|NCT00828256|Procedure|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
441982|NCT00827658|Procedure|Hypothenar Palm block|"Injection at Hook of the Hamate on Palmar surface~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
442129|NCT00826449|Drug|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
441899|NCT00828243|Drug|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids (palmitate and acetate) and of surfactant-associated proteins (leucine) to infants with neonatal respiratory distress syndrome. We measure with mass spectrometry incorporation of stable isotopically labeled precursors into tracheal aspirates to estimate surfactant phospholipid and protein kinetics.
441900|NCT00828230|Drug|budesonide|One application of 2mg budesonide once daily for 8 weeks
441901|NCT00828230|Drug|Placebo foam|One application of placebo foam once daily for 8 weeks
441902|NCT00828217|Other|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
441903|NCT00828204|Device|single-use autoinjector with a prefilled liquid Avonex syringe|
441904|NCT00828204|Device|Avonex prefilled syringe via manual IM injection|
441905|NCT00828204|Drug|BG9418 (interferon beta-1a)|
441906|NCT00828191|Drug|Progesterone|25 mg, once a day, SC
441907|NCT00828191|Drug|Progesterone|100 mg, twice a day, vaginally
441908|NCT00828178|Drug|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
441909|NCT00828178|Device|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
441910|NCT00828178|Other|corn starch|3 capsules qd for 12weeks
441911|NCT00828165|Drug|ARRY-300, MEK inhibitor; oral|single dose, escalating
441912|NCT00828165|Drug|Placebo|matching placebo
441913|NCT00828152|Behavioral|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
441914|NCT00828152|Behavioral|On line discussion group|Placebo. On line discussion group.
441915|NCT00828139|Biological|ziv-aflibercept|Given IV
441916|NCT00828139|Drug|topotecan hydrochloride|Given IV
441917|NCT00828126|Procedure|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
441918|NCT00828113|Drug|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
441919|NCT00828113|Drug|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
441920|NCT00828113|Behavioral|Individual smoking cessation counseling|Brief (<10 minutes) smoking cessation counseling delivered at clinic visits
441921|NCT00828100|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
441922|NCT00828100|Device|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
441923|NCT00828087|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
441924|NCT00828087|Device|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
441925|NCT00828074|Drug|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
441926|NCT00828074|Drug|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
441927|NCT00828061|Drug|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
441928|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
441929|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
441930|NCT00828035|Procedure|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
441931|NCT00828022|Biological|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
441932|NCT00828009|Biological|bevacizumab|IV
441933|NCT00828009|Biological|Tecemotide|
441934|NCT00828009|Drug|carboplatin|IV
441935|NCT00828009|Drug|cyclophosphamide|IV
441936|NCT00828009|Drug|paclitaxel|IV
441937|NCT00828009|Radiation|radiotherapy|radiotherapy is given 5 days a week for 6½ weeks during concomitant chemoradiotherapy
441938|NCT00827996|Drug|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
441939|NCT00827983|Drug|Progesterone|25 mg, s.c., once à day
441940|NCT00827983|Drug|Progesterone|90 mg, vaginally, once à day
441941|NCT00827970|Behavioral|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
441942|NCT00827957|Device|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
442130|NCT00826449|Drug|Erlotinib|150 mg by mouth daily every 21 day cycle.
441943|NCT00827957|Device|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
441944|NCT00827944|Device|Parietex Progrip|"Surgical technique:~Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
441945|NCT00827944|Device|Low weight polypropylene mesh|"Surgical technique:~Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
441946|NCT00827931|Drug|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
441947|NCT00827931|Procedure|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
441948|NCT00827918|Drug|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
441949|NCT00827918|Drug|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
441950|NCT00827918|Drug|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
441951|NCT00827905|Device|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
441952|NCT00827892|Drug|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
441953|NCT00827892|Drug|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
441954|NCT00827879|Behavioral|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
441955|NCT00827879|Behavioral|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
441956|NCT00827866|Other|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
441957|NCT00827866|Other|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
441958|NCT00827853|Procedure|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
441959|NCT00827853|Procedure|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
441960|NCT00827840|Drug|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
441961|NCT00827840|Drug|Risperidone|1 to 6 mg of risperidone once or twice a day
441962|NCT00827827|Other|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
441963|NCT00827827|Other|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
441964|NCT00827814|Drug|Dutasteride|Dutasteride 0.5 mg od.
441965|NCT00827801|Behavioral|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 & 8.
441966|NCT00827788|Drug|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
441967|NCT00827788|Drug|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
441968|NCT00827775|Drug|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
441969|NCT00827762|Drug|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
441970|NCT00827749|Device|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
441971|NCT00827736|Procedure|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
441972|NCT00827736|Drug|ISDN ointment|application of ISDN 1% ointment 6 times a day
441973|NCT00827736|Drug|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)~Applied to the anoderm six times a day (Botox injection arm)"
441974|NCT00827710|Behavioral|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
441975|NCT00827710|Behavioral|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
441976|NCT00827697|Other|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
441977|NCT00827684|Drug|Irinotecan|
441978|NCT00827684|Drug|Temsirolimus|
441979|NCT00827671|Drug|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
441980|NCT00827671|Radiation|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
441981|NCT00827658|Procedure|Volar Wrist Block|"Injection medial to Flexor Carpi Ulnaris Tendon at volar proximal wrist crease~Local Block - total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)"
442131|NCT00826410|Device|Redon drain|subcutaneous suction drain after laparotomy for two days
442744|NCT00822120|Drug|dacarbazine|
441983|NCT00827632|Drug|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
441984|NCT00827632|Drug|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
441985|NCT00827619|Device|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
441986|NCT00827606|Drug|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
441987|NCT00827593|Behavioral|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
441988|NCT00827593|Behavioral|Weight Watchers|Participants will receive 12 months of Weight Watchers
441989|NCT00827593|Behavioral|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
441990|NCT00827580|Drug|Eniluracil|
441991|NCT00827567|Drug|RAD 001|RAD 001-10 mg by mouth once everyday
441992|NCT00827554|Drug|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
441993|NCT00827554|Procedure|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
441994|NCT00827541|Drug|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
441995|NCT00827528|Procedure|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
441996|NCT00827528|Procedure|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.~Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
441997|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
441998|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
441999|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
442000|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
442001|NCT00827489|Drug|HTC-867|
442002|NCT00827489|Other|Placebo|
442003|NCT00827476|Procedure|ovarian transplantation|ovarian xenotransplantation or in vitro culture
442004|NCT00827463|Biological|dosage of the NFS and iron|a blood test will be made.
442005|NCT00827450|Dietary Supplement|Ctl|Control, isocaloric diet; no coffee
442006|NCT00827450|Dietary Supplement|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
442007|NCT00827450|Dietary Supplement|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
442008|NCT00827450|Dietary Supplement|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
442009|NCT00827450|Dietary Supplement|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
442010|NCT00827437|Other|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
442011|NCT00827424|Behavioral|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
442012|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
442013|NCT00827411|Device|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
442014|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
442015|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
442016|NCT00827411|Drug|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
442017|NCT00827398|Biological|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
442018|NCT00827372|Drug|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
442019|NCT00827359|Drug|Everolimus|Tablet form taken orally once a day
442020|NCT00827346|Drug|Clopidogrel|600 mg now
442021|NCT00827346|Drug|Clopidogrel|600 mg now and 600 mg in 3 hours
442022|NCT00827346|Drug|Clopidogrel|900 mg now
442023|NCT00827346|Drug|Clopidogrel|600 mg now and 300 mg in 3 hours
442024|NCT00827333|Other|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
442025|NCT00827333|Other|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
442026|NCT00827333|Procedure|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
442027|NCT00827333|Procedure|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
442028|NCT00827333|Procedure|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
442029|NCT00827320|Drug|Levetiracetam|1000 mg tablet
442030|NCT00827307|Drug|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
442031|NCT00827307|Drug|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
442032|NCT00827294|Behavioral|Mirror Therapy|The study is an uncontrolled pilot. Subjects receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20 minutes daily. Subjects will complete questionnaires for phantom pain, function, depressive symptoms, anxiety, catastrophizing, and sleep quality at baseline and post treatment at 1 month, 2 months, 3 months, and 6 months. Subjects will keep a diary of their practice and study staff will check in with subjects weekly for the first month, and monthly thereafter.
442033|NCT00827281|Drug|D-cycloserine|Single dosage prior to sessions 3, 4 & 5
442034|NCT00827281|Drug|Placebo|Single dosage prior to sessions 3, 4 & 5
442035|NCT00827268|Behavioral|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
442036|NCT00827255|Drug|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
442037|NCT00827242|Drug|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
442038|NCT00827242|Drug|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
442039|NCT00827229|Device|Labor Monitor|
442040|NCT00827216|Drug|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
442041|NCT00827216|Drug|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
442042|NCT00827203|Drug|Elesclomol Sodium|Chemotherapy agent
442043|NCT00827190|Drug|ILS-920|
442044|NCT00827177|Drug|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.~If < 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
442045|NCT00827164|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
442046|NCT00827164|Behavioral|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
442047|NCT00827151|Drug|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
442048|NCT00827138|Drug|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
442049|NCT00827125|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
442050|NCT00827112|Drug|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
442051|NCT00827112|Drug|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
442052|NCT00827099|Biological|anti-thymocyte globulin|anti-thymocyte globulin
442053|NCT00827099|Drug|fludarabine phosphate|fludarabine phosphate
442054|NCT00827099|Drug|Melphalan|melphalan
442055|NCT00827099|Drug|mycophenolate mofetil|mycophenolate mofetil
442056|NCT00827099|Drug|tacrolimus|tacrolimus
442057|NCT00827099|Procedure|umbilical cord blood transplantation|umbilical cord blood transplantation
442058|NCT00827073|Drug|tetracaine 0.5%|betadine 5%
442059|NCT00827073|Drug|Lidocaine 2% Jelly|Betadine 5%
442120|NCT00826501|Procedure|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
442121|NCT00826488|Device|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
442060|NCT00827047|Procedure|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
442061|NCT00827047|Procedure|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
442062|NCT00827047|Procedure|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
442063|NCT00827034|Drug|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
442064|NCT00827034|Drug|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
442065|NCT00827034|Drug|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
442066|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
442067|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
442068|NCT00827008|Drug|Neramexane mesylate|Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
442069|NCT00826995|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
442070|NCT00826969|Drug|Ciclesonide|320µg Ciclesonide versus Placebo
442071|NCT00826969|Drug|Placebo|Placebo
442072|NCT00826956|Procedure|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
442073|NCT00826943|Drug|Cetirizine|Cetirizine 10 mg tab daily x 7 days
442074|NCT00826943|Drug|Levocetirizine|5 mg tab daily x 7 days
442075|NCT00826943|Drug|Placebo|Placebo tablet daily x 7 days
442076|NCT00826930|Drug|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
442077|NCT00826891|Drug|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).~Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.~Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2~Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
442078|NCT00826878|Drug|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.~Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
442079|NCT00826865|Drug|Levetiracetam|750 mg tablet
442080|NCT00826852|Drug|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
442081|NCT00826839|Drug|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
442082|NCT00826839|Drug|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
442083|NCT00826826|Procedure|Catheter ablation|(Pulmonary vein isolation)
442084|NCT00826826|Drug|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
442085|NCT00826826|Drug|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
442086|NCT00826813|Device|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
442122|NCT00826475|Behavioral|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
442123|NCT00826475|Behavioral|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
442124|NCT00826462|Drug|triamcinolone|Injection with triamcinolone 10 mg at start and at 3 weeks
442125|NCT00826462|Drug|Placebo|Injection with sodium chloride at start and at 3 weeks
442126|NCT00826462|Drug|Lidocaine|10 mg of lidocaine at start and at 3 weeks
442087|NCT00826800|Drug|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
442088|NCT00826787|Drug|Levetiracetam|750 mg tablet
442089|NCT00826774|Behavioral|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
442090|NCT00826774|Behavioral|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
442091|NCT00826774|Behavioral|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
442092|NCT00826761|Dietary Supplement|probiotic|One capsule per meal test (high dose or low dose)
442093|NCT00826761|Dietary Supplement|placebo|1 capsuel every morning
442094|NCT00826748|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
442095|NCT00826735|Behavioral|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
442096|NCT00826722|Drug|Levetiracetam|1000 mg tablet
442097|NCT00826709|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
442098|NCT00826683|Biological|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
442099|NCT00826670|Drug|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days~plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
442100|NCT00826670|Drug|Placebo (Decolonization)|Placebo
442101|NCT00826657|Dietary Supplement|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
442102|NCT00826657|Dietary Supplement|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
442103|NCT00826644|Drug|Belotecan/Cisplatin|Belotecan : 0.5mg/㎡/day for Day 1 to 4, Cisplatin : 60mg/㎡/day for Day 1.
442104|NCT00826644|Drug|Etoposide/Cisplatin|Etoposide : 100mg/㎡/day for Day 1 to 3, Cisplatin : 60mg/㎡/day for Day 1. Repeat next cycle at Day 22.
442105|NCT00826631|Procedure|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
442106|NCT00826618|Drug|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
442107|NCT00826592|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
442108|NCT00826579|Procedure|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
442109|NCT00826579|Procedure|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
442110|NCT00826566|Dietary Supplement|Caffeine|2 times 250 mg caffeine per day
442111|NCT00826566|Dietary Supplement|placebo|2 times 250 mg per day
442112|NCT00826553|Drug|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
442113|NCT00826553|Drug|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
442114|NCT00826540|Drug|sorafenib tosylate|Given orally
442115|NCT00826540|Biological|bevacizumab|Given IV
442116|NCT00826527|Drug|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
442117|NCT00826514|Drug|Tanezumab|Intravenous, 20 mg, single dose.
442118|NCT00826514|Drug|Placebo|Intravenous placebo, single dose
442119|NCT00826501|Procedure|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
442127|NCT00826462|Other|Physiotherapy|12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises
442132|NCT00826397|Procedure|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
442133|NCT00826397|Procedure|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
442134|NCT00826384|Procedure|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
442135|NCT00826371|Drug|ranibizumab 0.5 mg|
442136|NCT00826358|Drug|ABT-143|Once, please see Arm Description for more details.
442137|NCT00826358|Drug|ABT-335|Once, see Arm Description for more detail
442138|NCT00826358|Drug|rosuvastatin|once, see Arm Description for more detail
442139|NCT00826345|Other|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.~- Active"
442140|NCT00826345|Other|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
442141|NCT00826332|Procedure|transabdominal ultrasound|transabdominal ultrasound
442142|NCT00826332|Procedure|transvaginal ultrasound|transvaginal ultrasound
442143|NCT00826306|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
442144|NCT00826293|Procedure|Stabilization belt|Patients receive true stabilization.
442145|NCT00826293|Procedure|Stabilization belt|Patients receive sham stabilization.
442146|NCT00826280|Drug|regadenoson|IV
442147|NCT00826280|Drug|overencapsulated caffeine|oral
442148|NCT00826280|Radiation|technetium|IV
442149|NCT00826280|Drug|placebo|oral
442150|NCT00826267|Drug|lapatinib|lapatinib tablets 1500 mg daily
442151|NCT00826267|Drug|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
442152|NCT00826267|Drug|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
442153|NCT00826254|Drug|Vitamin K|180 micrograms vitamin K daily
442154|NCT00826254|Drug|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo~1 year"
442155|NCT00826241|Drug|Temozolomide|Starting dose 125 mg/m^2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle.
442156|NCT00826241|Drug|Lapatinib|Starting dose 1250 mg daily by mouth.
442157|NCT00826228|Drug|teriparatide|teriparatide 20ug daily sc for 6 months
442158|NCT00826228|Other|weight-bearing|device assisted walking
442159|NCT00826215|Device|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
442160|NCT00826215|Device|Sham laser acupuncture|Sham laser acupuncture
442161|NCT00826202|Drug|D-serine|60 mg/kg/day
442162|NCT00826202|Other|Placebo|Inert Placebo
442163|NCT00826176|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
442164|NCT00826163|Drug|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
442165|NCT00826150|Biological|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.~Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
442166|NCT00826137|Dietary Supplement|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
442167|NCT00826137|Dietary Supplement|Placebo|Placebo is base powder of product with no oligosaccharides.
442168|NCT00826124|Procedure|Epidural steroid injection|Injection based solely on history and physical exam
442169|NCT00826124|Procedure|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
442170|NCT00826124|Procedure|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
442171|NCT00826111|Drug|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
442172|NCT00826111|Drug|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
442173|NCT00826098|Biological|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
442174|NCT00826085|Drug|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.~Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.~All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
442175|NCT00826059|Device|Active Stimulation|SPG stimulation and standard of care
442176|NCT00826059|Device|Sham Stimulation|Sham SPG stimulation and standard of care
442177|NCT00826046|Drug|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
442178|NCT00826020|Drug|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
442179|NCT00825994|Drug|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), PO [by mouth], qd [every day]
442180|NCT00825981|Other|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
442181|NCT00825955|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
442182|NCT00825955|Other|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
442183|NCT00825955|Procedure|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
442184|NCT00825942|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
442185|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
442186|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
442187|NCT00825916|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
442188|NCT00825903|Behavioral|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
442189|NCT00825864|Drug|diclofenac drops|one drop 4 times a day for 3 months
442190|NCT00825864|Drug|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
442191|NCT00825851|Drug|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
442192|NCT00825851|Drug|Placebo patch|
442193|NCT00825851|Behavioral|Smoking cessation|
442194|NCT00825851|Behavioral|Continuous smoking|subjects smoke 20 cigarettes per day
442195|NCT00825838|Dietary Supplement|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
442196|NCT00825838|Dietary Supplement|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
442197|NCT00825825|Drug|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
442198|NCT00825825|Drug|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
442199|NCT00825825|Drug|Placebo|Two weeks of placebo taken orally.
442200|NCT00825812|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
442201|NCT00825812|Drug|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
442202|NCT00825786|Drug|Ropivacaine|ropivacaine (15 ml).
442203|NCT00825786|Drug|Mepivacaine|One syringe will contain mepivacaine (15 ml)
442204|NCT00825773|Device|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
442205|NCT00825760|Drug|Topical PPA904 gel and light|
442206|NCT00825760|Drug|Topical placebo gel plus light|
442207|NCT00825747|Device|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
442208|NCT00825734|Drug|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
442209|NCT00825734|Drug|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m^2)
442210|NCT00825721|Drug|LiquiTears|4 drops applied daily for 360 days
442211|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
442212|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
442213|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
442214|NCT00825708|Device|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
442215|NCT00825708|Device|shamTMS|sham TMS session
442216|NCT00825695|Dietary Supplement|cocoa|two servings of cocoa daily for one month
442217|NCT00825682|Other|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
442218|NCT00825669|Drug|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
442219|NCT00825669|Procedure|Laser ablation|Laser ablation is given to the PVTT.
442220|NCT00825656|Drug|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
442221|NCT00825643|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
442222|NCT00825630|Drug|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
442223|NCT00825630|Drug|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
442224|NCT00825630|Drug|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
442225|NCT00825630|Drug|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
442269|NCT00825201|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
442317|NCT00824967|Other|Training and valuation of the treating personnel|Training and valuation of the treating personnel
442226|NCT00825617|Drug|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
442227|NCT00825604|Procedure|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
442228|NCT00825591|Dietary Supplement|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
442229|NCT00825591|Dietary Supplement|Placebo Comparator|Oral administration before bed. 6 week duration.
442230|NCT00825578|Device|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
442231|NCT00825565|Drug|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
442232|NCT00825552|Drug|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
442233|NCT00825539|Drug|AQW051|
442234|NCT00825539|Drug|Placebo|
442235|NCT00825526|Behavioral|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
442236|NCT00825513|Device|Akreos Toric IOL|Lens implant following cataract surgery
442237|NCT00825513|Device|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
442238|NCT00825500|Drug|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
442239|NCT00825500|Drug|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
442240|NCT00825500|Drug|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
442241|NCT00825487|Drug|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher (cohort 8 and above).
442242|NCT00825474|Other|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
442243|NCT00825448|Procedure|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
442244|NCT00825435|Procedure|Coronary CT Angiogram|Coronary CT Angiogram
442245|NCT00825422|Drug|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
442246|NCT00825396|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
442247|NCT00825383|Other|High Fiber and Moderate Fiber Diets|Dietary
442248|NCT00825370|Drug|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
442249|NCT00825370|Drug|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
442250|NCT00825344|Drug|Etanercept|50 mg subcutaenous preoperatively
442251|NCT00825344|Drug|Saline|Given subcutaneously preoperatively
442252|NCT00825318|Procedure|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
442253|NCT00825305|Biological|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
442254|NCT00825305|Biological|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
442255|NCT00825292|Procedure|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
442256|NCT00825292|Procedure|colon polyp removal|identify and remove polyp
442257|NCT00825292|Procedure|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
442258|NCT00825279|Device|Bare Metal Stent|Stainless steel stent
442259|NCT00825279|Device|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
442260|NCT00825266|Drug|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
442261|NCT00825266|Drug|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
442262|NCT00825253|Drug|biphasic insulin aspart 30|
442263|NCT00825253|Drug|biphasic human insulin 30|
442264|NCT00825240|Behavioral|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
442265|NCT00825227|Drug|Armodafinil 150 mg/day|"150 mg/day armodafinil~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
442266|NCT00825227|Drug|Placebo,|"placebo~concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
442267|NCT00825214|Device|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
442268|NCT00825214|Device|Inactivated zapperclick device|placebo
442270|NCT00825201|Other|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
442271|NCT00825201|Other|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
442272|NCT00825201|Other|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
442273|NCT00825201|Other|laboratory biomarker analysis|Correlative studies
442274|NCT00825188|Drug|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
442275|NCT00825188|Drug|eplerenone|Eplerenone 25-50mg daily x 8 weeks
442276|NCT00825188|Drug|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
442277|NCT00825188|Drug|amlodipine|amlodipine 5-10mg daily for 8 weeks
442278|NCT00825175|Behavioral|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
442279|NCT00825175|Device|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
442280|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
442281|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
442282|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
442283|NCT00825149|Drug|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
442284|NCT00825149|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
442285|NCT00825149|Drug|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
442286|NCT00825149|Drug|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
442287|NCT00825149|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
442288|NCT00825149|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
442289|NCT00825149|Drug|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
442290|NCT00825136|Behavioral|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
442291|NCT00825136|Behavioral|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
442292|NCT00825123|Drug|Ivabradine|Ivabradine 10 mg once
442293|NCT00825123|Drug|Metoprolol|Metoprolol 50 mg once
442294|NCT00825123|Drug|Placebo|Lactose powder
442295|NCT00825097|Procedure|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
442296|NCT00825097|Drug|Botulinum toxin injection|Botulinum toxin type A
442297|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
442298|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
442299|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
442300|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
442301|NCT00825071|Drug|Dexamethasone|8 mg, Intravenous
442302|NCT00825071|Drug|Ondansetron|4 mg, intravenously
442303|NCT00825071|Drug|normal saline|2 ml, intravenously
442304|NCT00825058|Drug|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
442305|NCT00825058|Drug|placebo|oral administration 12 hours intervals
442306|NCT00825058|Drug|paroxetine|oral 20 mg/day
442307|NCT00825045|Drug|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
442308|NCT00825032|Procedure|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
442309|NCT00825032|Procedure|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
442310|NCT00825019|Drug|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
442311|NCT00825019|Drug|placebo|oral administration in 12h intervals
442312|NCT00825019|Drug|paroxetine|oral administration of 20 mg/day
442313|NCT00825006|Device|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.~Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
442314|NCT00824993|Drug|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
442315|NCT00824993|Drug|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months~Vitamin D 400 units by mouth 2 times a day for 12 months"
442316|NCT00824980|Drug|IP10.C8|IP10.C8 Gel 1%
442318|NCT00824954|Procedure|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
442319|NCT00824928|Procedure|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
442320|NCT00824902|Procedure|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
442321|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
442322|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
442323|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
442324|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
442325|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
442326|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
442327|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
442328|NCT00824863|Drug|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
442329|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
442330|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
442331|NCT00824837|Other|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
442332|NCT00824837|Other|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
442333|NCT00824824|Drug|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
442334|NCT00824824|Drug|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
442335|NCT00824811|Drug|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
442336|NCT00824811|Drug|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
442337|NCT00824811|Drug|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.~Week 2: One drop three times a day to both eyes.~Week 3: One drop twice a day to both eyes.~Week 4: One drop once a day to both eyes.~Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
442338|NCT00824785|Drug|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
442339|NCT00824785|Drug|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
442340|NCT00824759|Other|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
442341|NCT00824746|Drug|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
442342|NCT00824733|Drug|Trastuzumab|IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
442343|NCT00824733|Drug|PF03512676|Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
442344|NCT00824733|Other|Correlative Studies|Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
442345|NCT00824720|Drug|High Dose Device|inserted for 14 days
442346|NCT00824720|Drug|Low Dose Device|inserted for 14 days
442347|NCT00824720|Device|Placebo Device|inserted for 14 days
442348|NCT00824707|Drug|Entecavir|Entecavir 0.5mg per day
442349|NCT00824707|Drug|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
442350|NCT00824694|Other|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
442351|NCT00824694|Other|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
442352|NCT00824694|Other|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
442353|NCT00824681|Behavioral|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
442354|NCT00824681|Other|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
442355|NCT00824668|Drug|biphasic insulin aspart 30|
442356|NCT00824668|Drug|insulin glargine|
442357|NCT00824668|Drug|insulin glulisine|
442358|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
442359|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
442360|NCT00824642|Device|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
442361|NCT00824642|Device|placebo|placebo TENS applied prior to exercise
442362|NCT00824629|Procedure|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
442363|NCT00824629|Procedure|Direct embryo transfer procedure|Direct embryo transfer procedure
442364|NCT00824616|Drug|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
442366|NCT00824616|Drug|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
442367|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
442368|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
442369|NCT00824564|Drug|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
442370|NCT00824564|Procedure|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
442371|NCT00824551|Procedure|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
442372|NCT00824551|Other|Standard care|Patient will undergo standard care
442373|NCT00824538|Drug|sunitinib malate|
442374|NCT00824538|Other|flow cytometry|
442375|NCT00824538|Other|immunohistochemistry staining method|
442376|NCT00824538|Other|laboratory biomarker analysis|
442377|NCT00824512|Drug|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
442378|NCT00824512|Drug|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
442379|NCT00824499|Other|Complex regional intervention|"Components of the complex intervention:~Introduction of a program coordinator~Introduction of a self-management education program~Bottom up development of a interdisciplinary care protocol~Support program for the intiation of insulin therapy in primary care~Regional audit"
442380|NCT00824486|Behavioral|Injury prevention education (TIPP)|using TIPP materials
442381|NCT00824486|Behavioral|Injury prevention education (safe home)|using safe home model
442382|NCT00824473|Drug|Placebo|Placebo
442383|NCT00824473|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
442384|NCT00824460|Drug|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
442385|NCT00824460|Drug|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
442386|NCT00824460|Drug|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
442387|NCT00824460|Drug|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
442388|NCT00824460|Drug|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
442389|NCT00824460|Drug|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
442390|NCT00824447|Drug|Oralgen|allergen solution sublingually
442391|NCT00824447|Other|placebo|placebo control
442392|NCT00824434|Device|PROMUS Element™|Drug eluting coronary stent system
442393|NCT00824421|Drug|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
442394|NCT00824421|Drug|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
442395|NCT00824421|Drug|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
442396|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
442397|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
442398|NCT00824408|Drug|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
442399|NCT00824382|Drug|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
442400|NCT00824382|Drug|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
442401|NCT00824382|Drug|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
442402|NCT00824382|Drug|Placebo|2 puffs delivered by the RespimatÂ® inhaler
442403|NCT00824369|Drug|No drug will be administered|No drug will be administered.
442404|NCT00824356|Drug|GSK1004723 (200mg)|Intranasal antihistamine.
442405|NCT00824356|Other|Placebo|Equivalent to GSK1004723 in presentation etc.
442406|NCT00824356|Drug|GSK1004723 (1000mg)|Intranasal antihistamine.
442407|NCT00824343|Drug|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
442408|NCT00824330|Behavioral|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
442409|NCT00824317|Drug|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
442410|NCT00824317|Drug|Placebo|
442411|NCT00824291|Drug|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
442412|NCT00824291|Genetic|Genotyping|CYP2D6 genotyping at randomization
442413|NCT00824265|Drug|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
442414|NCT00824265|Drug|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
442415|NCT00824252|Behavioral|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
442416|NCT00824239|Procedure|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
442417|NCT00824239|Procedure|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
442418|NCT00824226|Dietary Supplement|magnesium|magnesium 350 mg tablets once a day for 3 weeks
442419|NCT00824200|Behavioral|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema.
442420|NCT00824200|Drug|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
442421|NCT00824200|Drug|placebo|tamsulosin placebo
442422|NCT00824200|Behavioral|placebo|placebo behavioral intervention
442423|NCT00824187|Drug|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
442424|NCT00824187|Drug|Placebo|Inert tablet
442425|NCT00824174|Behavioral|Questionnaire|1 questionnaire, about 15-20 minutes.
442426|NCT00824161|Drug|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.~Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
442427|NCT00824148|Device|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
442428|NCT00824148|Other|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
442429|NCT00824135|Drug|Clofarabine|"One dose intravenously every 24 hrs for five days total.~Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
442430|NCT00824135|Procedure|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
442431|NCT00824135|Other|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total~Muromonab-CD3"
442432|NCT00824135|Drug|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
442433|NCT00824135|Drug|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
442434|NCT00824135|Drug|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day~(continue for approximately 2 months or as clinically indicated)"
442435|NCT00824135|Drug|Rituximab|375 mg/m2 intravenous for 1 dose total
442436|NCT00824135|Other|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
442437|NCT00824109|Device|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
442438|NCT00824096|Procedure|Bronchoscopy|The patients in our ICU intubated for > 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3~4 days even with CLV ＜24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
442439|NCT00824070|Drug|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
442440|NCT00824070|Drug|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
442441|NCT00824070|Drug|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
442442|NCT00824057|Drug|AZD6280|oral
442443|NCT00824057|Drug|Midazolam|oral
442444|NCT00824057|Drug|Caffeine|oral
442445|NCT00824044|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
442446|NCT00824044|Drug|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
442447|NCT00824005|Biological|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
442448|NCT00824005|Biological|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
442449|NCT00823992|Drug|placebo|sc once weekly
442450|NCT00823992|Drug|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
442451|NCT00823979|Drug|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
442452|NCT00823979|Drug|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
442453|NCT00823979|Drug|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
442454|NCT00823966|Drug|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
442455|NCT00823953|Drug|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
442456|NCT00823953|Other|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
442457|NCT00823940|Drug|GSK1362885|5 - 100mg of GSK1362885 or placebo
442458|NCT00823940|Drug|GSK1362885|100 - 600mg or placebo
442459|NCT00823940|Drug|Glucagon|0.5mg IV bolus
442460|NCT00823940|Drug|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
442461|NCT00823901|Drug|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
442462|NCT00823901|Drug|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
442463|NCT00823888|Device|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
442464|NCT00823875|Drug|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
442465|NCT00823875|Drug|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
442466|NCT00823875|Drug|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.~Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
442467|NCT00823875|Drug|control group|routine treatment
442468|NCT00823862|Drug|SD-101|Intramuscular (IM)
442469|NCT00823862|Drug|ribavirin|oral, 2 times per day, for 2 months
442470|NCT00823849|Drug|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
442471|NCT00823849|Drug|Probucol|250 mg Bid, PO after breakfast and dinner.
442472|NCT00823849|Drug|Cilostazol+Probucol|
442473|NCT00823849|Other|Control Group|Routine treatment
442474|NCT00823836|Drug|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
442475|NCT00823836|Drug|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.~The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).~Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.~Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.~Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
442476|NCT00823823|Other|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
442477|NCT00823823|Other|Circumferential cast|Circumferential cast will be applied following closed reduction
442478|NCT00823810|Other|PET/CT|18F-FDG PET/CT
442479|NCT00823797|Drug|Bendamustine Hydrochloride|Given IV
442480|NCT00823797|Other|Quality-of-Life Assessment|Ancillary studies
442481|NCT00823784|Procedure|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
442482|NCT00823784|Procedure|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
442483|NCT00823758|Behavioral|Focus Groups|6 to 8 participants per group.
442484|NCT00823758|Behavioral|Personal Interviews|Conducted by phone and audiotaped.
442485|NCT00823745|Drug|[14C]-PF-00868554|solution, single dose
442486|NCT00823732|Other|educational intervention|Undergo individualized interdisciplinary palliative care intervention
442487|NCT00823732|Other|medical chart review|Ancillary studies
442488|NCT00823732|Other|questionnaire administration|Ancillary studies
442489|NCT00823732|Procedure|end-of-life treatment/management|Undergo end-of-life treatment/management
442490|NCT00823732|Procedure|psychosocial assessment and care|Undergo psychosocial assessment and care
442491|NCT00823732|Procedure|quality-of-life assessment|Ancillary studies
442492|NCT00823732|Procedure|management of therapy complications|Undergo management of therapy complications
442493|NCT00823732|Procedure|assessment of therapy complications|Undergo assessment of therapy complications
442494|NCT00823719|Drug|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg~ICE regimen:~ifosfamide + mesna - 5 grams (g)/meters squared (m^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m^2 on days 1, 2 and 3 of dosing cycle."
442495|NCT00823719|Drug|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.~DHAP regimen:~dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m^2 q12 hrs (2 doses) on day 2 of dosing cycle."
442496|NCT00823693|Drug|Bimosiamose Cream|
442497|NCT00823693|Drug|Placebo Cream|
442502|NCT00823680|Drug|RO5093151|10mg po bid for 4 weeks
442503|NCT00823667|Other|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
442504|NCT00823667|Other|medical chart review|Occurs at 1 year post study enrollment
442505|NCT00823667|Other|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
442506|NCT00823667|Procedure|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
442507|NCT00823667|Procedure|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
442508|NCT00823667|Procedure|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
442509|NCT00823654|Other|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment~↓~Tests in the middle of chemotherapy (if applicable):~Blood draw and collection of monthly menstrual calendars ↓~Tests when chemotherapy is over (if applicable):~Blood draw and collection of monthly menstrual calendars~↓~Tests every 4 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire ↓~Tests every 6 months for about 1 year:~Blood draw, collection of monthly menstrual calendars, and questionnaire~↓~Yearly follow-up for about 2 years:~Blood draw collection of monthly menstrual calendars, and questionnaire"
442510|NCT00823654|Other|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent~↓ Register patients at Memorial Sloan-Kettering Cancer Center~↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)~↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires~↓ Year 1 follow up Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires~↓ Optional annual follow-up years 2-5 Blood draw and collection of monthly menstrual calendars /follow-up reproductive and sexual health questionnaires"
442511|NCT00823641|Drug|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
442512|NCT00823628|Drug|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
442513|NCT00823628|Drug|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
442514|NCT00823615|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
442515|NCT00823615|Device|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
442516|NCT00823602|Drug|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
442517|NCT00823602|Drug|suprefact|GnRH agonist, standard protocol
442518|NCT00823589|Other|Blood test and clinical test|Blood test and clinical test
442519|NCT00823576|Drug|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
442520|NCT00823563|Procedure|30 cc blood draw|
442521|NCT00823563|Procedure|Intravascular ultrasound (IVUS)|
442522|NCT00823563|Procedure|Coronary pressure/flow wire testing|
442523|NCT00823563|Procedure|Coronary pressure/flow testing: Acetycholine challenge|
442524|NCT00823563|Procedure|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
442525|NCT00823563|Procedure|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
442526|NCT00823550|Drug|Entecavir|entecavir 0.5 mg QD
442527|NCT00823550|Drug|Lamivudine|lamivudine 100 mg QD
442528|NCT00823537|Procedure|therapeutic electrical stimulation|
442529|NCT00823524|Biological|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
442530|NCT00823498|Behavioral|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
442531|NCT00823498|Behavioral|Interview|Interview with a member of study staff at housing development site.
442532|NCT00823498|Other|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
442533|NCT00823485|Procedure|fibrinolysis in situ|intraventricular injection of actilyse
442534|NCT00823485|Procedure|drainage|drainage
442535|NCT00823472|Drug|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
442536|NCT00823459|Drug|Everolimus|Given PO
442537|NCT00823459|Other|Archival Tissue Analysis|Correlative studies
442538|NCT00823446|Device|Revera Wound Care|Revalesio Part Number MDW0060
442539|NCT00823446|Device|Normal Saline|Sodium Chloride for Irrigation
442540|NCT00823433|Drug|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
442541|NCT00823420|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
442542|NCT00823407|Drug|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
442543|NCT00823407|Drug|Placebo|Subjects will receive a single oral dose of placebo
442544|NCT00823394|Behavioral|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
442545|NCT00823394|Other|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
442546|NCT00823394|Behavioral|Self-help Materials|Information on how to lower risk for developing cancer.
442547|NCT00823381|Dietary Supplement|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
442548|NCT00823381|Other|placebo|one placebo pill taken once a day with breakfast
442549|NCT00823381|Behavioral|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
442550|NCT00823368|Drug|STX209|
442551|NCT00823355|Drug|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
442552|NCT00823355|Drug|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
442553|NCT00823355|Drug|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
442554|NCT00823355|Drug|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
442555|NCT00823342|Drug|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
442556|NCT00823342|Drug|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
442557|NCT00823342|Drug|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
442558|NCT00823329|Device|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
442559|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
442560|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
442561|NCT00823303|Drug|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
442562|NCT00823303|Drug|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
442563|NCT00823290|Drug|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
442564|NCT00823277|Other|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after ~ 1 Year.
442565|NCT00823264|Drug|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
442566|NCT00823251|Device|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
442567|NCT00823238|Drug|ceftazidime and tobramycin|
442568|NCT00823238|Drug|inhaled tobramycin|
442569|NCT00823225|Procedure|standard therapy|wound debridement, moist wound dressing
442570|NCT00823225|Drug|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:~> 2,5g/l 1 000 000 IU, < 2,5g/l 500 000 IU"
442571|NCT00823212|Device|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
442572|NCT00823212|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).
442573|NCT00823212|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
442574|NCT00823212|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
442575|NCT00823199|Drug|Allopurinal|300mg once daily by mouth for four weeks
442576|NCT00823186|Drug|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10~-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
442577|NCT00823173|Biological|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
442578|NCT00823160|Procedure|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
442579|NCT00823160|Procedure|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
442580|NCT00823147|Behavioral|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
442581|NCT00823134|Device|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
442582|NCT00823121|Procedure|freezing embryos by vitrification|vitrification by Cryotop method
442583|NCT00823121|Procedure|fresh embryo transfers|fresh embryo transfers
442584|NCT00823121|Drug|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
442585|NCT00823121|Drug|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
442586|NCT00823121|Drug|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
442587|NCT00823108|Drug|GIK|12 hour infusion of GIK solution
442588|NCT00823095|Drug|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
442589|NCT00823082|Drug|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
442590|NCT00823069|Device|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
442591|NCT00823056|Dietary Supplement|probiotics|placebo
442592|NCT00823056|Dietary Supplement|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
442593|NCT00823043|Drug|timolol hemihydrate|timolol hemihydrate 0.5% solution
442594|NCT00823043|Drug|timolol maleate|timolol maleate in sorbate
442595|NCT00823030|Procedure|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
442596|NCT00823030|Drug|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
442597|NCT00823030|Other|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
442598|NCT00823017|Other|Patient-preferred music|Music of patients' preference
442599|NCT00823017|Other|Relaxation Music|Relaxation music compiled from results of first three stages of study
442600|NCT00823017|Other|Standard Care Environment|Control, no interventions
442601|NCT00823004|Drug|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
442602|NCT00823004|Drug|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
442603|NCT00823004|Drug|GnRH agonist (buserelin)|50 µg SC twice daily
442604|NCT00823004|Drug|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
442605|NCT00823004|Drug|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
442606|NCT00822991|Device|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
442607|NCT00822991|Device|B-mode US|screening by conventional B-mode US every 3-5 months
442608|NCT00822978|Drug|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
442609|NCT00822965|Other|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
442610|NCT00822965|Other|Phone Interviews|2 follow-up phone interviews.
442611|NCT00822965|Behavioral|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
442612|NCT00822926|Drug|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
442613|NCT00822926|Drug|Saline|Subcutaneous injection of saline into scar tissue
442614|NCT00822913|Drug|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
442615|NCT00822900|Drug|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
442616|NCT00822900|Drug|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
442617|NCT00822887|Drug|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
442618|NCT00822887|Radiation|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
442619|NCT00822874|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
442620|NCT00822861|Drug|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
442621|NCT00822861|Drug|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
442622|NCT00822861|Drug|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
442623|NCT00822861|Drug|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
442624|NCT00822848|Drug|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
442625|NCT00822848|Drug|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
442626|NCT00822848|Drug|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
442627|NCT00822848|Other|immunoenzyme technique|
442628|NCT00822848|Other|immunohistochemistry staining method|
442629|NCT00822848|Other|laboratory biomarker analysis|
442630|NCT00822848|Procedure|adjuvant therapy|Preoperative administration has been the preference at our institution.
442631|NCT00822848|Procedure|neoadjuvant therapy|
442632|NCT00822848|Procedure|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
442633|NCT00822848|Radiation|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. *Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
442634|NCT00822835|Biological|ILV-095|
442635|NCT00822835|Biological|Placebo|
442636|NCT00822822|Behavioral|First Questionnaire|Complete questionnaire before completing health history
442637|NCT00822822|Behavioral|Health History|Complete electronic health history
442638|NCT00822822|Behavioral|Second Questionnaire|Complete questionnaire after completing electronic health history
442639|NCT00822809|Drug|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:~10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
442640|NCT00822809|Drug|Prednisolone|25 mg premedication
442641|NCT00822796|Device|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
442745|NCT00822120|Drug|doxorubicin hydrochloride|
442642|NCT00822796|Device|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
442643|NCT00822783|Drug|Omalizumab|
442644|NCT00822783|Drug|Placebo|
442645|NCT00822770|Drug|Plerixafor|"Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.~Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I"
442646|NCT00822770|Drug|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
442647|NCT00822770|Drug|Fludarabine|Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
442648|NCT00822770|Drug|Busulfan|Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
442649|NCT00822770|Procedure|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
442650|NCT00822770|Drug|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
442651|NCT00822757|Biological|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
442652|NCT00822757|Biological|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
442653|NCT00822744|Drug|SSR411298|"Form: capsule~Route: oral administration with food"
442654|NCT00822744|Drug|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)~Route: oral administration with food"
442655|NCT00822744|Drug|Placebo (for SSR411298)|"Form: capsule~Route: oral administration with food"
442656|NCT00822731|Drug|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
442657|NCT00822705|Drug|Placebo tablet|Control arm
442658|NCT00822692|Drug|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
442659|NCT00822692|Drug|placebo|matched placebo 2 pills PO BID x 7 days
442660|NCT00822679|Drug|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
442661|NCT00822679|Other|Placebo|Subjects are given placebo for 3 consecutive nights
442662|NCT00822666|Drug|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
442663|NCT00822653|Device|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
442664|NCT00822640|Device|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
442665|NCT00822627|Drug|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
442666|NCT00822627|Behavioral|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
442667|NCT00822614|Drug|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
442668|NCT00822614|Drug|Opioid|Current optimized BTP treatment
442669|NCT00822601|Device|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
442670|NCT00822601|Device|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
442671|NCT00822588|Device|Sangvia® System|Sangvia® Intra- and Post-op System
442672|NCT00822575|Device|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
442673|NCT00822562|Other|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
442674|NCT00822562|Procedure|surgery|only surgery
442675|NCT00822549|Drug|intravenous morphine titration|intravenous morphine titration
442676|NCT00822536|Drug|Aspirin and Clopidogrel|Aspirin <= 325 mg/j Clopidogrel = 75 mg /j
442677|NCT00822536|Drug|Aspirin|Aspirin : <= 325 mg/j
442678|NCT00822523|Drug|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
442679|NCT00822523|Drug|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
442680|NCT00822523|Drug|Saline|Single Dose, Intramuscular into right EDB muscle
442681|NCT00822510|Behavioral|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
442682|NCT00822510|Behavioral|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
442683|NCT00822497|Behavioral|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
442684|NCT00822497|Behavioral|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
442685|NCT00822484|Biological|ILV-095|
442686|NCT00822484|Other|Placebo|
442687|NCT00822471|Behavioral|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
442688|NCT00822458|Drug|vismodegib|Given orally
442689|NCT00822458|Other|laboratory biomarker analysis|
442690|NCT00822458|Other|pharmacological study|
442691|NCT00822419|Drug|lidocaine|lidocaine cream 5%
442692|NCT00822419|Drug|ketamine|ketamine 5%
442693|NCT00822419|Drug|non-drug cream|will be put on the skin
442694|NCT00822406|Drug|homeopathic medicine|individualized homeopathic medicine
442695|NCT00822406|Drug|placebo|placebo - 6 months
442696|NCT00822393|Drug|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
442697|NCT00822393|Drug|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
442698|NCT00822380|Dietary Supplement|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
442699|NCT00822380|Dietary Supplement|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
442700|NCT00822380|Dietary Supplement|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
442701|NCT00822380|Dietary Supplement|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
442702|NCT00822380|Dietary Supplement|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
442703|NCT00822367|Dietary Supplement|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
442704|NCT00822354|Drug|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
442705|NCT00822341|Drug|TG-0054|0.1, 0.2, 0.4, 0.8, 1.6, and 3.2 mg/kg of TG-0054/placebo via 15 min IV infusion
442706|NCT00822328|Dietary Supplement|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.~Fermented or unfermented milk per 100 ml bottle per day for four week."
442707|NCT00822328|Dietary Supplement|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
442708|NCT00822315|Drug|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
442709|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
442710|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
442711|NCT00822302|Drug|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
442712|NCT00822302|Drug|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
442713|NCT00822263|Drug|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
442714|NCT00822263|Drug|Placebo|Control for study
442715|NCT00822250|Other|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
442716|NCT00822237|Biological|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
442717|NCT00822237|Biological|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
442718|NCT00822237|Biological|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection ~6 weeks apart
442719|NCT00822224|Drug|MEOPA|inhalation of MEOPA during the painful care
442720|NCT00822211|Drug|Vildagliptin 50 mg bid|
442721|NCT00822211|Drug|Vildagliptin 50 mg qd|
442722|NCT00822211|Drug|Placebo|
442723|NCT00822198|Device|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
442724|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
442725|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
442726|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
442727|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
442728|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
442729|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
442730|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
442731|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
442732|NCT00822172|Dietary Supplement|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
442733|NCT00822172|Drug|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.~Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
442734|NCT00822159|Device|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
442735|NCT00822146|Device|CRT|classified
442736|NCT00822133|Drug|lidocaine|lidocaine 5%
442737|NCT00822133|Drug|ketamine|ketamine cream
442738|NCT00822133|Drug|non-active drug cream|will be put on the skin
442739|NCT00822120|Biological|bleomycin sulfate|
442740|NCT00822120|Biological|filgrastim|
442741|NCT00822120|Drug|ABVD regimen|
442742|NCT00822120|Drug|BEACOPP regimen|
442748|NCT00822120|Drug|procarbazine hydrochloride|
442749|NCT00822120|Drug|vinblastine sulfate|
442750|NCT00822120|Drug|vincristine sulfate|
442751|NCT00822107|Drug|Hydrochlorothiazide|50 mg one time
442752|NCT00822094|Drug|CPX-351|
442753|NCT00822094|Drug|Intensive Salvage Therapy|
442754|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
442755|NCT00822081|Drug|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
442756|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
442757|NCT00822081|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
442758|NCT00822068|Device|anodal tDCS|anodal transcranial direct current stimulation
442759|NCT00822068|Device|cathodal tDCS|cathodal transcranial direct current stimulation
442760|NCT00822068|Device|sham stimulation|sham stimulation
442761|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
442762|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
442763|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
442764|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
442765|NCT00822042|Other|Samples and procedures|"Scanner, histomorphometry : at the inclusion and M3 visits~whole blood samples, cytoponction : at the inclusion and M3 visits"
442766|NCT00822029|Drug|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
442767|NCT00822029|Other|PLACEBO|patient receiving one tablet (oral use) placebo by week
442768|NCT00822003|Drug|Oral GLP-1|GLP-1 tablet (2mg)
442769|NCT00822003|Drug|Placebo|Control tablet
442770|NCT00821990|Drug|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
442771|NCT00821990|Other|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
442772|NCT00821977|Drug|Vildagliptin|
442773|NCT00821977|Drug|Vildagliptin|
442774|NCT00821977|Drug|Placebo|
442775|NCT00821964|Drug|imiquimod|Given topically
442776|NCT00821964|Drug|Abraxane|Given IV
442777|NCT00821964|Other|laboratory biomarker analysis|Correlative studies
442778|NCT00821964|Genetic|RNA analysis|Correlative studies
442779|NCT00821964|Other|immunoenzyme technique|Correlative studies
442780|NCT00821951|Drug|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
442781|NCT00821951|Radiation|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
442782|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
442783|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
442784|NCT00821925|Procedure|bone densitometry|All patients do a bone densitometry after the inclusion.
442785|NCT00821912|Drug|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
442786|NCT00821912|Drug|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
442787|NCT00821899|Biological|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
442788|NCT00821886|Drug|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
442789|NCT00821886|Drug|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
442790|NCT00821886|Drug|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
442791|NCT00821873|Other|CR Plug|CR Plug will be placed in the harvest site
442792|NCT00821860|Other|talc|Talc pleurodesis
442793|NCT00821860|Procedure|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
442794|NCT00821860|Procedure|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
442795|NCT00821847|Other|DEXA scan|DEXA scan
442796|NCT00821834|Drug|clopidogrel (SR25990)|"Form: tablets~Route: oral"
442797|NCT00821834|Drug|ticlopidine|"Form: tablets~Route: oral"
442798|NCT00821834|Drug|Placebo|"Form: tablets~Route: oral"
442799|NCT00821821|Drug|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
442800|NCT00821821|Drug|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo"
442801|NCT00821808|Device|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
442838|NCT00821457|Drug|Placebo|Powder for solution for injection
442839|NCT00821457|Drug|Juvista|500ng
442840|NCT00821444|Drug|ziprasidone|40 mg capsule, single dose x 3
442802|NCT00821808|Device|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:~Immediately following device application~1 hour~4 hours~8 hours"
442803|NCT00821795|Drug|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
442804|NCT00821795|Drug|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
442805|NCT00821782|Drug|Levofloxacin; Azithromycin|
442806|NCT00821756|Behavioral|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
442807|NCT00821743|Device|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
442808|NCT00821717|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
442809|NCT00821717|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
442810|NCT00821691|Drug|Amantadin|Amantadin caps
442811|NCT00821691|Drug|Placebo|Placebo caps
442812|NCT00821678|Other|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
442813|NCT00821665|Dietary Supplement|Sucrose consumption|Sucrose
442814|NCT00821665|Dietary Supplement|water consumption|water
442815|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
442816|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
442817|NCT00821639|Behavioral|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
442818|NCT00821626|Device|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
442819|NCT00821626|Other|Control|No rapid flu test
442820|NCT00821600|Drug|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
442821|NCT00821587|Drug|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
442822|NCT00821587|Drug|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
442823|NCT00821574|Drug|Fluvastatin|Fluvastatin: daily 80 mg, oral
442824|NCT00821574|Drug|Valsartan|Valsartan: daily 160 mg, oral
442825|NCT00821574|Drug|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
442826|NCT00821561|Drug|Nexagon®|
442827|NCT00821561|Drug|Nexagon® vehicle|
442828|NCT00821548|Procedure|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
442829|NCT00821535|Drug|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
442830|NCT00821522|Procedure|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
442831|NCT00821509|Behavioral|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
442832|NCT00821509|Behavioral|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
442833|NCT00821496|Drug|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
442834|NCT00821483|Drug|Frovatriptan|2.5mg, qd
442835|NCT00821470|Procedure|core decompression|core decompression procedure only
442836|NCT00821470|Procedure|Bone marrow implantation into the necrotic lesion|
442837|NCT00821457|Drug|Juvista|250ng
442841|NCT00821444|Drug|B16 Fasted|40 mg tablet, single dose X 3
442842|NCT00821444|Drug|B16 Fed|40 mg tablet, single dose X 3
442843|NCT00821431|Device|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:~Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.~Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
442844|NCT00821431|Device|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
442845|NCT00821418|Device|PulseHaler treatment|treatment is for two weeks, 3 times per day
442846|NCT00821418|Device|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
442847|NCT00821392|Drug|Febuxostat|
442848|NCT00821366|Behavioral|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
442849|NCT00821366|Dietary Supplement|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
442850|NCT00821366|Drug|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
442851|NCT00821353|Procedure|RF catheter ablation|RF catheter ablation
442852|NCT00821353|Drug|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
442853|NCT00821340|Genetic|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
442854|NCT00821327|Drug|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.~2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.~3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
442855|NCT00821301|Drug|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
442856|NCT00821288|Behavioral|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
442857|NCT00821288|Behavioral|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
442858|NCT00821275|Procedure|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
442859|NCT00821262|Drug|sevoflurane|
442860|NCT00821262|Drug|propofol|
442861|NCT00821249|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
442862|NCT00821249|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
442863|NCT00821249|Drug|Dexamethasone, steroid; oral|Part 3: standard of care.
442864|NCT00821236|Device|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
442865|NCT00821236|Device|AMO/VISX CustomVue™|Excimer Laser
442866|NCT00821236|Device|LADARVision 4000 excimer laser|Excimer Laser
442867|NCT00821223|Procedure|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
442868|NCT00821223|Procedure|manual small incision surgery|
442869|NCT00821223|Procedure|phacoemulsification|cataract surgery
442870|NCT00821210|Device|Sham CPAP|CPAP with pressure of 3cm H2O
442871|NCT00821210|Device|CPAP of optimal pressure|CPAP of optimal pressure
442872|NCT00821197|Procedure|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
442873|NCT00821197|Procedure|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
442874|NCT00821184|Drug|Vesicare (solifenacin)|5mg po qd
442875|NCT00821184|Behavioral|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
442876|NCT00821158|Drug|Antioxidant|Antioxidant iv bolus
442877|NCT00821158|Other|Placebo|Placebo tablet and iv
442878|NCT00821158|Drug|Anti-inflammatory drug|Anti-inflammatory tablet
442879|NCT00821145|Procedure|conventional surgery|AAA patients operated using a conventional incision
442880|NCT00821145|Procedure|laparoscopic AAA resection|laparoscopic AAA resection
442881|NCT00821145|Procedure|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
442882|NCT00821132|Other|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
442883|NCT00821119|Device|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
442884|NCT00821106|Procedure|Right radial|diagnostic or interventional procedures performed through right transradial approach
442885|NCT00821106|Procedure|left radial|diagnostic or interventional procedures performed through left transradial approach
442886|NCT00821093|Drug|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
442887|NCT00821093|Drug|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
442888|NCT00821093|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
442889|NCT00821093|Drug|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
442890|NCT00821080|Drug|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
442891|NCT00821080|Drug|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
442892|NCT00821067|Dietary Supplement|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
442893|NCT00821067|Dietary Supplement|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
442894|NCT00019539|Drug|bevacizumab|
442895|NCT00019539|Drug|thalidomide|
442896|NCT00821054|Drug|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
442897|NCT00821041|Behavioral|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
442898|NCT00821028|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
442899|NCT00821015|Device|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
442900|NCT00821002|Drug|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
442901|NCT00820989|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
442902|NCT00820976|Drug|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
442903|NCT00820963|Drug|temozolomide|Given orally
442904|NCT00820963|Radiation|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
442905|NCT00820963|Radiation|radiation therapy|Patients undergo standard radiotherapy
442906|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 0.5%
442907|NCT00820950|Drug|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
442908|NCT00820950|Drug|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
442909|NCT00820950|Drug|Placebo cream|Cream applied once or twice daily for 56 days
442910|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.0%
442911|NCT00820950|Drug|Ruxolitinib phosphate cream|Ruxolitinib phosphate cream 1.5%
442912|NCT00820937|Procedure|Single photon emission computed tomography and Magnetic Resonance Imaging|
442913|NCT00820924|Drug|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
442914|NCT00820911|Drug|cyclosporine (reduced exposure) / everolimus|twice daily
442915|NCT00820911|Drug|AEB071 300 mg b.i.d. / everolimus|twice daily
442916|NCT00820911|Drug|AEB071 200 mg b.i.d. / everolimus|twice daily
442917|NCT00820898|Drug|Gemcitabine Hydrochloride|Given IV
442918|NCT00820885|Drug|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
442919|NCT00820885|Drug|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
442920|NCT00820885|Drug|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
442921|NCT00820872|Biological|trastuzumab|
442922|NCT00820872|Drug|carboplatin|
442923|NCT00820872|Drug|docetaxel|
442924|NCT00820872|Drug|lapatinib ditosylate|
442925|NCT00820859|Behavioral|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
442926|NCT00820859|Behavioral|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
442927|NCT00820846|Biological|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
442928|NCT00820846|Biological|Placebo|1 mL of sodium chloride for injection
442929|NCT00820846|Biological|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
442981|NCT00820521|Drug|placebo|
442930|NCT00820833|Other|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
442931|NCT00820833|Other|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
442932|NCT00820820|Biological|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
442933|NCT00820820|Biological|placebo|Vehicle (water for injection), 0.5 ml, once
442934|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
442935|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
442936|NCT00820807|Other|Placebo|oral consumption in beverage
442937|NCT00820794|Drug|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
442938|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
442939|NCT00820794|Drug|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
442940|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
442941|NCT00820781|Procedure|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
442942|NCT00820781|Procedure|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
442943|NCT00820768|Drug|ABI-010|17-AAG and ABI-007
442944|NCT00820755|Drug|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram*hour/milliliter (mg*hr/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
442945|NCT00820755|Drug|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
442946|NCT00820755|Drug|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
442947|NCT00820742|Drug|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
442948|NCT00820716|Other|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
442949|NCT00820703|Drug|Nexagon®|
442950|NCT00820703|Drug|Nexagon® vehicle|
442951|NCT00820690|Drug|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
442952|NCT00820690|Drug|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
442953|NCT00820690|Drug|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
442954|NCT00820690|Procedure|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.~The oncoplastic surgery rate will be reported"
442955|NCT00820677|Behavioral|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
442956|NCT00820664|Drug|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
442957|NCT00820664|Drug|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
442958|NCT00820664|Drug|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
442959|NCT00820651|Dietary Supplement|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
442960|NCT00820651|Other|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with <10% of saturated fatty acids and protein 14%, and exercise)
442961|NCT00820638|Device|myomo e100|use of the myomo e100 in home
442962|NCT00820625|Procedure|pulmonary vein isolation|common pulmonary vein isolation procedure
442963|NCT00820625|Procedure|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
442964|NCT00820612|Drug|Indomethacin|100 mg PR once at the time of ERCP
442965|NCT00820612|Other|Placebo suppositories|2 placebo suppositories at the time of ERCP
442966|NCT00820599|Device|Sapien XT™ transcatheter heart valve and delivery system|
442967|NCT00820586|Procedure|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
442968|NCT00820573|Drug|Sitagliptin|tablet, 100 mg/day, 6 weeks
442969|NCT00820573|Drug|Metformin|tablet, 1000 mg/ bid, 6 weeks
442970|NCT00820573|Drug|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
442971|NCT00820573|Drug|Placebo|Placebo 6 weeks
442972|NCT00820560|Drug|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
442973|NCT00820547|Biological|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
442974|NCT00820547|Drug|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
442975|NCT00820547|Drug|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
442976|NCT00820547|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
442977|NCT00820547|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
442978|NCT00820534|Drug|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
442979|NCT00820534|Drug|Placebo|Placebo every 2 hous during waking hours for 96 hours
442980|NCT00820521|Drug|active|
442982|NCT00820508|Drug|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
442983|NCT00820495|Behavioral|Web + Phone|Web + Phone
442984|NCT00820495|Behavioral|Web Only|Web Only
442985|NCT00820495|Behavioral|Phone Only|Phone Only
442986|NCT00820495|Behavioral|Usual Care|Usual Care
442987|NCT00820482|Drug|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
442988|NCT00820482|Drug|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
442989|NCT00820469|Drug|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
442990|NCT00820469|Drug|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
442991|NCT00820456|Other|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
442992|NCT00820443|Device|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
442993|NCT00820430|Other|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
442994|NCT00820417|Drug|Cetuximab/Gefitinib combination and/or monotherapy|
442995|NCT00820404|Drug|BLI-489|
442996|NCT00820404|Drug|Placebo|
442997|NCT00820391|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
442998|NCT00820391|Behavioral|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
442999|NCT00820378|Other|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
443000|NCT00820365|Drug|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
443001|NCT00820352|Drug|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
443002|NCT00820352|Drug|placebo|placebo twice a day for 12 weeks
443003|NCT00820339|Procedure|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
443004|NCT00820339|Procedure|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
443005|NCT00820326|Drug|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
443006|NCT00820326|Drug|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
443007|NCT00820313|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.~Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.~Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).~Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
443008|NCT00820300|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
443009|NCT00820287|Procedure|Biopsy of testicular tumor|testicular biopsies performed through open surgery
443010|NCT00820274|Procedure|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
443011|NCT00820261|Other|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
443012|NCT00820248|Biological|panitumumab|Given IV
443013|NCT00820248|Drug|cisplatin|Given IV
443014|NCT00820248|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
443015|NCT00820248|Radiation|accelerated radiation therapy|Patients undergo accelerated fractionation radiotherapy
443016|NCT00820248|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
443017|NCT00820235|Device|OsseoSpeed™|OsseoSpeed™ implant
443018|NCT00820235|Device|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
443019|NCT00820235|Device|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
443020|NCT00820222|Drug|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
443021|NCT00820222|Drug|lapatinib|oral medication; daily dose taken once a day
443022|NCT00820222|Drug|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
443023|NCT00820196|Drug|Nexagon®|
443024|NCT00820196|Drug|Nexagon® vehicle|
443025|NCT00820183|Other|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:~Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
443097|NCT00819767|Drug|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
443026|NCT00820170|Drug|Dasatinib and Paclitaxel|"A treatment cycle will consist of 28 days, according to the following schedule:~Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.~The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel."
443027|NCT00820157|Procedure|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
443028|NCT00820157|Procedure|TACE|TACE alone or TACE followed by downstage resection for MNHCC
443029|NCT00820144|Biological|CTB by nasal way|
443030|NCT00820144|Biological|absorption of CTB by oral way|absorption of CTB by oral way
443031|NCT00820144|Biological|absorption of dukoral by oral way|absorption of dukoral by oral way
443032|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
443033|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
443034|NCT00820131|Procedure|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
443035|NCT00820131|Procedure|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
443036|NCT00820118|Drug|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir~Usual dosage recommended :~atazanavir : 300 mg/d~ritonavir : 100 mg/d~abacavir 600 mg and lamivudine 300 mg : once a day~tenofovir 245 mg and emtricitabine 200 mg : once a day"
443037|NCT00820105|Drug|ADX10059|oral administration
443038|NCT00820105|Drug|ADX10059|Oral administration
443039|NCT00820105|Drug|ADX10059|Oral administration
443040|NCT00820105|Drug|ADX10059 Matching Placebo|Oral administration
443041|NCT00820092|Drug|Xerecept 1.0|24 hour infusion
443042|NCT00820092|Drug|Xerecept 2.0|24 hour infusion
443043|NCT00820092|Drug|Xerecept 3.0|24 hour infusion
443044|NCT00820079|Drug|ADX10059|oral administration
443045|NCT00820079|Drug|ADX10059 Matching Placebo|oral administration
443046|NCT00820053|Drug|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
443047|NCT00820027|Drug|Etoricoxib 90 mg|One 90 mg tablet once daily
443048|NCT00820027|Drug|Etoricoxib 120 mg|Two 60 mg tablets once daily
443049|NCT00820027|Drug|Ibuprofen 600 mg|One tablet three times daily
443050|NCT00820027|Drug|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
443051|NCT00820027|Drug|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
443052|NCT00820027|Drug|Matching Placebo for Ibuprofen|One tablet three times daily
443053|NCT00820014|Drug|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
443054|NCT00820001|Behavioral|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
443055|NCT00820001|Behavioral|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
443056|NCT00820001|Other|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
443057|NCT00820001|Other|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
443058|NCT00819988|Drug|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
443059|NCT00819988|Other|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
443060|NCT00819975|Dietary Supplement|Casein|
443061|NCT00819975|Dietary Supplement|Whey Isolate|
443062|NCT00819975|Dietary Supplement|Whey Hydrolysate|
443063|NCT00819975|Dietary Supplement|Alphalact-Albumin|
443064|NCT00819962|Drug|Bupivacaine|Local anesthetic
443065|NCT00819962|Other|TAP|
443093|NCT00819780|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
443094|NCT00819767|Drug|Aliskiren|Aliskiren was supplied in 150 mg tablets.
443095|NCT00819767|Drug|Valsartan|Valsartan was supplied in 160 mg capsules.
443096|NCT00819767|Drug|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
443066|NCT00819949|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
443067|NCT00819936|Procedure|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
443068|NCT00819936|Procedure|backward walking|physiotherapy with use a backward walking type of physiotherapy
443069|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
443070|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
443071|NCT00819910|Drug|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
443072|NCT00819910|Drug|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
443073|NCT00819910|Drug|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
443074|NCT00819910|Drug|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
443075|NCT00819884|Drug|AZD1656|Oral suspension
443076|NCT00819858|Dietary Supplement|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
443077|NCT00819845|Drug|carvedilol|carvedilol vs ramipril
443078|NCT00819845|Drug|ramipril|carvedilol vs ramipril
443079|NCT00819832|Procedure|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
443080|NCT00819832|Procedure|Vertebroplasty|Medical cement will be injected into broken back bone.
443081|NCT00819832|Device|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
443082|NCT00819819|Dietary Supplement|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
443083|NCT00819819|Dietary Supplement|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
443084|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
443085|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
443086|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
443087|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
443088|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
443089|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
443090|NCT00819793|Device|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
443091|NCT00819780|Drug|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
443092|NCT00819780|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
443140|NCT00819416|Drug|5% albumin|5% albumin for the first 7 days of care in the ICU
443098|NCT00819754|Drug|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose~Phase II study - assesses efficacy and safety of IXO with bevacizumab"
443099|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
443100|NCT00819741|Drug|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
443101|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
443102|NCT00819728|Drug|Docetaxel|35mg/m2 IV each week for 4 weeks
443103|NCT00819728|Drug|Irinotecan|50mg/m2 IV each week for 4 weeks
443104|NCT00819702|Other|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
443105|NCT00819676|Other|analysis of exhaled breath by biosensors|
443106|NCT00819676|Other|measurement of exhaled nitric oxide|
443107|NCT00819650|Drug|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na[131I],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
443108|NCT00819637|Drug|arformoterol (RR formoterol)|"Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.~Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses."
443109|NCT00819637|Drug|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
443110|NCT00819637|Drug|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
443111|NCT00819624|Other|Interactive Voice Response System (IVRS)|Telephone based system
443112|NCT00819624|Other|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
443113|NCT00819611|Behavioral|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
443114|NCT00819611|Behavioral|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
443115|NCT00819598|Procedure|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
443116|NCT00819598|Procedure|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
443117|NCT00819585|Drug|Canakinumab|Canakinumab was supplied in glass vials as a lyophilized powder.
443118|NCT00819585|Drug|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
443119|NCT00819585|Drug|Allopurinol|100-300 mg orally once daily for 24 weeks.
443120|NCT00819585|Drug|Placebo Matching Canakinumab|Subcutaneous injection.
443121|NCT00819585|Drug|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
443122|NCT00819572|Biological|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
443123|NCT00819572|Drug|Placebo|
443124|NCT00819559|Radiation|PCRT|Preoperative chemoradiotherapy
443125|NCT00819546|Drug|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
443126|NCT00819546|Drug|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
443127|NCT00819533|Device|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
443128|NCT00819520|Drug|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
443129|NCT00819520|Drug|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
443130|NCT00819507|Drug|Fluocinonide|Fluocinonide 0.1% cream topical daily for two weeks
443131|NCT00819494|Procedure|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
443132|NCT00819481|Device|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
443133|NCT00819468|Drug|Teduglutide|Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
443134|NCT00819455|Behavioral|Experimental|Active Life style modification-motivation by I.T technology
443135|NCT00819455|Behavioral|Control arm (usual care/standard care arm)|Life style modification only once
443136|NCT00819442|Procedure|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
443137|NCT00819429|Dietary Supplement|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
443138|NCT00819429|Behavioral|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
443139|NCT00819429|Other|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
443141|NCT00819416|Drug|Normal Saline|Normal Saline for the first 7 days of care in the ICU
443142|NCT00819403|Drug|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
443143|NCT00819403|Drug|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
443144|NCT00819390|Drug|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
443145|NCT00819390|Drug|Placebo|Taken orally, once daily for 12 weeks.
443146|NCT00819377|Drug|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
443147|NCT00819377|Drug|Normal saline|5 ml normal saline by inhalation over 15 min
443148|NCT00819364|Behavioral|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
443149|NCT00819364|Behavioral|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.~Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.~Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
443150|NCT00819351|Drug|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
443151|NCT00819351|Drug|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
443152|NCT00819338|Dietary Supplement|Efamax|5g daily as capsules for 3 months
443153|NCT00819325|Drug|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
443154|NCT00819325|Drug|oral hypoglycemic agents|sulfonylurea or metformin
443155|NCT00819312|Drug|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
443156|NCT00819299|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
443157|NCT00819286|Device|SternaLock Rigid Fixation Plates|patients will have their sternum closed by rigid fixation using SternaLock Rigid Fixation Plates
443158|NCT00819286|Device|wire (control)|patients will have their sternum closed using wire (stainless steel surgical wire).
443159|NCT00819260|Device|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
443160|NCT00819260|Device|Electrocautery|Electrocautery used to reduce breast on this side
443161|NCT00819247|Drug|Degarelix|Given as a subcutaneous injection.
443162|NCT00819234|Drug|Placebo|placebo pramlintide and placebo metreleptin twice daily
443163|NCT00819234|Drug|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
443164|NCT00819221|Drug|AZD2281|capsules, oral, bd, 2 months
443165|NCT00819221|Drug|liposomal doxorubicin|once every 4 weeks at 40mg/m2
443166|NCT00819208|Behavioral|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
443167|NCT00819208|Other|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
443168|NCT00819208|Other|educational intervention|Once at the beginning of the program
443169|NCT00819208|Other|laboratory biomarker analysis|Every 12 months
443170|NCT00819208|Other|questionnaire administration|Every 6 months
443171|NCT00819208|Other|study of socioeconomic and demographic variables|Every 6 months
443172|NCT00819208|Procedure|fatigue assessment and management|Every 6 months
443173|NCT00819208|Procedure|quality-of-life assessment|Every 6 months
443174|NCT00819208|Other|Educational Intervention|For Arm 2 just once at beginning of program.
443175|NCT00819208|Other|Fitness testing|Objective fitness testing for both arms
443176|NCT00819195|Drug|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
443177|NCT00819182|Behavioral|Paced respiration|Breathing exercise
443178|NCT00819182|Behavioral|Sham comparator: fast shallow breathing|sham breathing exercise
443179|NCT00819169|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
443180|NCT00819169|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
443181|NCT00819156|Drug|degarelix|Degarelix was given as subcutaneous injections.
443182|NCT00819117|Device|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
443183|NCT00819104|Drug|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
443184|NCT00819104|Drug|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
443185|NCT00819104|Drug|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
443186|NCT00819104|Drug|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
443187|NCT00819104|Drug|Amlodipine 5mg|tablet,oral,OD,8 weeks
443188|NCT00819091|Drug|BI 1356|5mg orally (po) tablet qd
443189|NCT00819091|Drug|Placebo|Placebo matching BI 1356 5mg one tablet daily
443190|NCT00819078|Drug|Bupropion|300 mg/d
443191|NCT00819078|Drug|Placebo|no dosage
443228|NCT00818818|Drug|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
443229|NCT00818805|Drug|Olopatadine 0.1%|one drop in one eye
443230|NCT00818805|Drug|Tranilast 0.5%|one drop in one eye
443192|NCT00819065|Drug|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
443193|NCT00819065|Drug|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
443194|NCT00819052|Drug|Nevirapine XR|Nevirapine XR
443195|NCT00819052|Drug|Nevirapine XR|Nevirapine extended release
443196|NCT00819052|Drug|Nevirapine IR|Nevirapine Immediate Release
443197|NCT00819039|Drug|Aprepitant|Aprepitant administered orally or intraveously.
443198|NCT00819039|Drug|Ondansetron|Ondansetron administered intravenously.
443199|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
443200|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
443201|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
443202|NCT00819013|Biological|Saline placebo|0.5 mL, Intramuscular
443203|NCT00819000|Drug|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
443204|NCT00818987|Other|Open reduction internal fixation; reduction and immobilization|
443205|NCT00818961|Biological|alemtuzumab|43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
443206|NCT00818961|Biological|graft-versus-tumor induction therapy|curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
443207|NCT00818961|Biological|rituximab|in patients with Cd20+ malignancies: rituximab 375 mg/m*2 day -13. rituximab 1000 mg/m*2 on days, -6, +1, +8.
443208|NCT00818961|Drug|busulfan|For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
443209|NCT00818961|Drug|cyclophosphamide|750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
443210|NCT00818961|Drug|fludarabine phosphate|For patients with CLL, NHL & HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
443211|NCT00818961|Drug|methotrexate|5 mg/m2 administered on days +1, +3 and +6
443212|NCT00818961|Drug|tacrolimus|0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
443213|NCT00818961|Procedure|allogeneic bone marrow transplantation|Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
443214|NCT00818948|Drug|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
443215|NCT00818935|Dietary Supplement|Low-Intermediate-Glycemic Index diets|
443216|NCT00818935|Dietary Supplement|High GI diet|
443217|NCT00818909|Other|Systane|Systane prescription
443218|NCT00818883|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
443219|NCT00818883|Drug|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.~For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
443220|NCT00818870|Drug|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
443221|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
443222|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
443223|NCT00818857|Behavioral|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
443224|NCT00818857|Behavioral|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
443225|NCT00818844|Drug|Nepafenac 0.1%|NSAID
443226|NCT00818844|Other|BSS|BSS
443227|NCT00818831|Drug|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
443231|NCT00818805|Drug|Placebo (Olopatadine)|one drop in contralateral eye
443232|NCT00818805|Drug|Placebo (Tranilast)|one drop in contralateral eye
443233|NCT00818792|Device|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
443234|NCT00818779|Drug|Aliskiren|150 - 300 mg once daily for 6 weeks
443235|NCT00818779|Drug|Amlodipine|5-10 mg once daily for 6 weeks
443236|NCT00818766|Drug|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
443237|NCT00818766|Drug|Placebo|Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
443238|NCT00818753|Drug|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
443239|NCT00818753|Drug|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
443240|NCT00818753|Drug|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
443241|NCT00818740|Drug|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
443242|NCT00818714|Radiation|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)~Dose Escalation Schema:~Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort~Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3~Continue +1 Gy x 3 until reach MTD"
443243|NCT00818701|Drug|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
443244|NCT00818701|Drug|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
443245|NCT00818688|Procedure|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
443246|NCT00818675|Drug|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
443247|NCT00818675|Drug|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
443248|NCT00818675|Drug|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
443249|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
443250|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
443251|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
443252|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
443253|NCT00818649|Drug|bortezomib|1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
443254|NCT00818649|Drug|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
443255|NCT00818636|Behavioral|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
443256|NCT00818623|Drug|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
443257|NCT00818623|Drug|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
443258|NCT00818623|Drug|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
443259|NCT00818623|Drug|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
443260|NCT00818623|Drug|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
443261|NCT00818623|Drug|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
443262|NCT00818623|Drug|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
443263|NCT00818623|Drug|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
443264|NCT00818610|Drug|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
443265|NCT00818610|Drug|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
443266|NCT00818597|Device|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
443267|NCT00818584|Drug|Micafungin|IV Administration
443268|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
443269|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
443270|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
443271|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
443272|NCT00818558|Biological|ISET Methode|Sampling of blood - ISET Methode
443273|NCT00818545|Drug|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
443274|NCT00818545|Drug|placebo|
443275|NCT00818519|Drug|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
443276|NCT00818519|Drug|Placebo|Inert tablet
443277|NCT00818493|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
443278|NCT00818493|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
443279|NCT00818493|Drug|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
443280|NCT00818480|Drug|YM155|continuous infusion
443281|NCT00818467|Other|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
443282|NCT00818467|Other|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
443283|NCT00818454|Drug|Combivent CFC MDI|
443284|NCT00818454|Drug|Albuterol HFA MDI|
443285|NCT00818454|Drug|Respimat Combivent|
443286|NCT00818441|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
443287|NCT00818441|Drug|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
443288|NCT00818428|Behavioral|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
443289|NCT00818428|Behavioral|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
443290|NCT00818428|Behavioral|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
443291|NCT00818428|Behavioral|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
443292|NCT00818415|Drug|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
443293|NCT00818415|Drug|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
443294|NCT00818389|Drug|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
443295|NCT00818389|Drug|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
443296|NCT00818389|Drug|placebo|an inactive substance
443297|NCT00818376|Other|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
443298|NCT00818363|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER™-Bupivacaine/Once
443299|NCT00818363|Drug|SABER™-Placebo|Injectable Solution; 5.0 mL SABER™-Placebo/Once
443300|NCT00818350|Drug|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
443301|NCT00818337|Drug|Aspirin|Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
443302|NCT00818324|Drug|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
443303|NCT00818311|Device|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
443304|NCT00818298|Drug|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
443305|NCT00818285|Device|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
443306|NCT00818272|Biological|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
443307|NCT00818259|Drug|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
443308|NCT00818259|Drug|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
443309|NCT00818259|Drug|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
443310|NCT00818259|Drug|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
443311|NCT00818259|Drug|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
443312|NCT00818246|Device|Sham light|
443313|NCT00818246|Device|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
443314|NCT00818233|Device|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
443315|NCT00818220|Procedure|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
443316|NCT00818220|Other|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
443317|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
443318|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
443319|NCT00818194|Drug|extended release tacrolimus|oral
443320|NCT00818194|Drug|cyclosporine A microemulsion|oral
443321|NCT00818181|Drug|Biological: AL0206st|
443322|NCT00818168|Biological|Infliximab|"Dosage and infusion intervals were employed in~accordance to the Summary of Product Characteristics (SmPC)"
443323|NCT00818155|Drug|desvenlafaxine succinate SR|desvenlafaxine succinate SR
443324|NCT00818155|Other|Placebo|
443325|NCT00818142|Behavioral|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
443326|NCT00818129|Drug|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
443327|NCT00818129|Drug|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
443328|NCT00818116|Device|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
443329|NCT00818103|Drug|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
443330|NCT00818103|Drug|β-interferon|β-interferon 50ug i.m. qod for 2 years
443331|NCT00818103|Drug|EPO|EPO 10000U i.h. bid for 5 days
443332|NCT00818090|Drug|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
443333|NCT00818077|Other|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
443334|NCT00818064|Drug|anti-IL-20|Single s.c. injection (per dose cohort)
443335|NCT00818064|Drug|placebo|Single s.c. injection (per dose cohort)
443336|NCT00818051|Radiation|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
443337|NCT00818038|Drug|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
443338|NCT00818025|Behavioral|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
443339|NCT00817999|Dietary Supplement|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
443340|NCT00817999|Drug|Clopidogrel 75 mg/day|
443341|NCT00817999|Drug|Clopidogrel 300 mg|
443342|NCT00817986|Drug|Arbaclofen placarbil, 20 mg|tablets
443343|NCT00817986|Drug|Placebo|tablets
443344|NCT00817986|Drug|Arbaclofen placarbil, 30 mg|tablets
443345|NCT00817986|Drug|Arbaclofen placarbil, 40 mg|tablets
443346|NCT00817973|Dietary Supplement|Casein|
443347|NCT00817973|Dietary Supplement|Whey|
443348|NCT00817973|Dietary Supplement|Cod|
443349|NCT00817973|Dietary Supplement|Gluten|
443350|NCT00817960|Drug|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
443351|NCT00817947|Device|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
443352|NCT00817934|Drug|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
443353|NCT00817895|Drug|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
443354|NCT00817895|Drug|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
443355|NCT00817895|Procedure|TACE|All patients will accept TACE one month after tumor was resected.
443356|NCT00817882|Other|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.~Maximum of 25 participants with low back pain"
443357|NCT00817882|Other|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
443358|NCT00817869|Other|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
443359|NCT00817843|Drug|Simvastatin|6 weeks of treatment with simvastatin 80 mg
443360|NCT00817843|Drug|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
443361|NCT00817830|Drug|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
443362|NCT00817817|Device|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
443363|NCT00817817|Device|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
443364|NCT00817804|Device|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
443365|NCT00817791|Device|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
443366|NCT00817778|Drug|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
443685|NCT00815282|Other|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
443367|NCT00817778|Drug|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
443368|NCT00817765|Drug|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
443369|NCT00817765|Drug|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
443370|NCT00817765|Drug|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
443371|NCT00817752|Dietary Supplement|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
443372|NCT00817739|Drug|Leuprorelin|Leuprorelin injection
443373|NCT00817739|Drug|Flutamide|Flutamide tablets
443374|NCT00817713|Drug|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment~Praziquantel 2400mg single dose~Ivermectin 12 mg, single dose~Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months."
443375|NCT00817700|Other|Sleep restriction|Sleep restriction.
443376|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
443377|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
443378|NCT00817661|Dietary Supplement|Vitamin A|10000 IU Vitamin A or placebo per week
443379|NCT00817661|Dietary Supplement|Placebo|10000 IU Vitamin A or placebo per week
443380|NCT00817648|Drug|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
443381|NCT00817648|Drug|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
443382|NCT00817635|Drug|LCI699|
443383|NCT00817635|Drug|Placebo|
443384|NCT00817635|Drug|Eplerenone|
443385|NCT00817622|Dietary Supplement|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
443386|NCT00817609|Drug|Angongniuhuang Pill|7 days of Angongniuhuang Pill
443387|NCT00817609|Drug|placebo|7 days of placebo
443388|NCT00817596|Device|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
443389|NCT00817583|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
443390|NCT00817583|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
443391|NCT00817557|Drug|Loteprednol|Anti-inflammatory
443392|NCT00817557|Other|Rewetter|
443393|NCT00817544|Drug|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
443394|NCT00817531|Drug|Dasatinib|pill form, 100 mg daily
443395|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
443396|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
443397|NCT00817505|Drug|AZD1656|Single dose oral tablet
443398|NCT00817505|Drug|AZD1656|Single dose oral suspension
443399|NCT00817479|Drug|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
443400|NCT00817479|Drug|Placebo|Placebo saline
443401|NCT00817466|Drug|Racemic adrenaline|"For inhalation.~Dosing (as in previous study):~1) 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3~Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
443402|NCT00817466|Drug|Isotonic saline|2ml NaCl 9mg/ml.
443403|NCT00817440|Other|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
443404|NCT00817440|Other|Fasting|3 days of fasting and then the same as arm 1
443405|NCT00817427|Other|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
443406|NCT00817427|Other|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
443407|NCT00817414|Drug|Placebo|
443408|NCT00817414|Drug|LCI699|
443409|NCT00817401|Device|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
443410|NCT00817388|Other|No intervention|No intervention
443411|NCT00817375|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
443412|NCT00817375|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
443413|NCT00817362|Drug|IPI-504|IPI-504 IV infusion 300 mg/m2
443414|NCT00817362|Drug|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
443415|NCT00817336|Drug|D Serine|60 mg/kg/day
443416|NCT00817336|Drug|Placebo|oral
443417|NCT00817323|Procedure|Dietary amino-acid depletion|See detailed description
443454|NCT00817024|Drug|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
443418|NCT00817297|Device|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
443419|NCT00817284|Drug|bevacizumab and Irinotecan and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15.~Irinotecan:~Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
443420|NCT00817284|Drug|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
443421|NCT00817271|Drug|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
443422|NCT00817271|Drug|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
443423|NCT00817258|Drug|cisplatin|Cisplatin 40mg/m2,weekly
443424|NCT00817258|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
443425|NCT00817245|Drug|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
443426|NCT00817232|Device|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
443427|NCT00817219|Drug|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
443428|NCT00817206|Drug|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
443429|NCT00817206|Drug|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
443430|NCT00817193|Behavioral|Physical Activity|Physical Activity program
443431|NCT00817193|Behavioral|Wellness|Wellness program
443432|NCT00817180|Other|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
443433|NCT00817180|Other|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
443434|NCT00817167|Device|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
443435|NCT00817167|Device|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
443436|NCT00817154|Behavioral|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
443437|NCT00817141|Other|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
443438|NCT00817128|Procedure|PEPT|Pain Exposure Physical Therapy
443439|NCT00817128|Procedure|CBO standard|Standard therapy as defined in CBO guideline 2006
443440|NCT00817115|Device|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
443441|NCT00817102|Procedure|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
443442|NCT00817089|Drug|Placebo Oral Tablet|Placebo pill
443443|NCT00817089|Drug|Naltrexone|50 mg of naltrexone prior to challenge session
443444|NCT00817076|Drug|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
443445|NCT00817063|Drug|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
443446|NCT00817063|Drug|Placebo|Patients receive matching placebo for up to 24 weeks
443447|NCT00817050|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
443448|NCT00817050|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
443449|NCT00817037|Drug|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
443450|NCT00817037|Drug|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
443451|NCT00817037|Drug|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
443452|NCT00817024|Drug|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
443453|NCT00817024|Drug|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
444457|NCT00810212|Genetic|PLF with NeoFuse|6 subjects medium dose
443455|NCT00817011|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
443456|NCT00817011|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
443457|NCT00816998|Procedure|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
443458|NCT00816998|Procedure|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
443459|NCT00816985|Procedure|Liposuction|Liposuction is a procedure that involves the removal of fat from deposits beneath the skin using a hollow stainless steel tube with the assistance of a powerful vacuum. Liposuction can be accomplished either with the use of local or general anesthesia.
443460|NCT00816985|Other|Quality of Life Questionnaires|Ratings of 0 to 4, with 0 being Not at ll and 4 being Very Much, regarding how true each statement has been. Statements are in the following categories: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, Additional Concerns.
443461|NCT00816972|Drug|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
443462|NCT00816972|Drug|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
443463|NCT00816972|Drug|Placebo for Desloratadine 2.5 mg|Placebo BID
443464|NCT00816972|Drug|Placebo for Oxybutynin 2.5 mg|Placebo BID
443465|NCT00816959|Drug|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
443466|NCT00816959|Drug|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
443467|NCT00816946|Behavioral|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:~During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI & protection against ARI"
443468|NCT00816933|Procedure|appendectomy|appendectomy according to the number of trocar
443469|NCT00816920|Other|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
443470|NCT00816907|Drug|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
443471|NCT00816907|Drug|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
443472|NCT00816894|Drug|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
443473|NCT00816894|Drug|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
443474|NCT00816881|Device|flutter mucus clearance device|five minutes every session, four sessions per day
443475|NCT00816868|Drug|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
443476|NCT00816855|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
443477|NCT00816829|Drug|Placebo|Fenofibrate-matching placebo tablet
443478|NCT00816829|Drug|Fenofibrate|145 mg NanoCrystal tablet
443479|NCT00816816|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.~concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
443480|NCT00816803|Procedure|Autologous bone marrow transplant|
443481|NCT00816803|Procedure|Physical therapy|
443482|NCT00816790|Drug|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR < 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
443483|NCT00816790|Drug|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
443484|NCT00816777|Procedure|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
443485|NCT00816777|Drug|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
443486|NCT00816764|Biological|AGS-8M4|IV Infusion
443487|NCT00816751|Procedure|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
443488|NCT00816751|Procedure|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
443489|NCT00816751|Drug|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
443490|NCT00816725|Behavioral|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
443491|NCT00816712|Drug|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Testosterone 300 mg, Intramuscular injection."
443492|NCT00816712|Drug|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 & 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Testosterone 100 mg, Intramuscular injection."
443493|NCT00816712|Drug|Comparator: Placebo given by Intramuscular Injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.~Day 1 & 7 - Placebo given as intramuscular injection."
443494|NCT00816699|Other|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
443495|NCT00816686|Biological|AGS-16M18|IV Infusion
443496|NCT00816673|Drug|placebo Circadin|Placebo tabs of Prolonged release melatonin
443497|NCT00816673|Drug|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
443498|NCT00816660|Biological|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
443499|NCT00816660|Biological|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
443500|NCT00816647|Procedure|Patellofemoral stabilizing surgery|Comparison of surgical techniques
443501|NCT00816634|Drug|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.~Chemotherapy regimen (XP):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks~Chemotherapy regimen (XT):~D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
443502|NCT00816621|Behavioral|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
443503|NCT00816621|Behavioral|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
443504|NCT00816595|Biological|bevacizumab|Given IV
443505|NCT00816595|Biological|pegfilgrastim|Given subcutaneously
443506|NCT00816595|Biological|rituximab|Given IV
443507|NCT00816595|Drug|cyclophosphamide|Given IV
443508|NCT00816595|Drug|pentostatin|Given IV
443509|NCT00816582|Procedure|Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline|A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
443510|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - Baseline|A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
443511|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up|A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
443512|NCT00816569|Device|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
443513|NCT00816556|Drug|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
443514|NCT00816556|Drug|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
443515|NCT00816556|Drug|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
443516|NCT00816543|Drug|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
443517|NCT00816543|Drug|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
443518|NCT00816543|Drug|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
443519|NCT00816530|Device|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density > 50% is confirmed by routine digital screening mammography, ABUS will be performed.
443520|NCT00816517|Biological|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
443521|NCT00816504|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
443522|NCT00816491|Device|conventional white light colonoscopy|conventional white light colonoscopy
443523|NCT00816491|Device|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
443524|NCT00816478|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
443525|NCT00816465|Dietary Supplement|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
443526|NCT00816465|Other|Placebo|PO Placebo pill
443527|NCT00816426|Drug|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
443528|NCT00816426|Drug|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
443570|NCT00816283|Genetic|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
444458|NCT00810212|Genetic|PLF with NeoFuse|6 subjects high dose
443529|NCT00816426|Drug|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
443530|NCT00816426|Drug|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
443531|NCT00816426|Drug|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
443532|NCT00816413|Drug|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
443533|NCT00816413|Drug|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
443534|NCT00816413|Drug|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
443535|NCT00816413|Genetic|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
443536|NCT00816413|Genetic|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
443537|NCT00816413|Genetic|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
443538|NCT00816413|Other|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
443539|NCT00816413|Other|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
443540|NCT00816413|Other|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
443541|NCT00816413|Other|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .~Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .~Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.~Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.~Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
443542|NCT00816413|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
443543|NCT00816413|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
443544|NCT00816413|Radiation|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
443545|NCT00816400|Drug|MEDI-575|MEDI-575 as an IV infusion
443546|NCT00816387|Procedure|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
443547|NCT00816387|Procedure|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
443548|NCT00816374|Other|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:~The American Cancer Society~The American Academy of Dermatology~The Skin Cancer Foundation~The pamphlets contain information about ways to reduce risk for skin cancer including:~Sun protection practices~Risk factors for melanoma~Information about what melanoma looks like~How to do skin self-examinations~There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
443569|NCT00816283|Genetic|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
443636|NCT00815698|Procedure|suture|suture for mesh fixation
443549|NCT00816374|Other|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:~Melanoma and skin cancer protection guidelines~The benefits of skin screening practices~Ways to protect yourself from the sun~In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
443550|NCT00816374|Other|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:~knowledge of melanoma~current and past skin cancer screening practices~current and past sun protection practices~attitudes about skin cancer and sun protection~feelings about relative's melanoma diagnosis and treatment"
443551|NCT00816361|Drug|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
443552|NCT00816348|Drug|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
443553|NCT00816335|Procedure|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
443554|NCT00816335|Drug|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
443555|NCT00816335|Procedure|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
443556|NCT00816335|Drug|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
443557|NCT00816335|Procedure|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
443558|NCT00816335|Procedure|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
443559|NCT00816322|Dietary Supplement|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
443560|NCT00816322|Dietary Supplement|Placebo|high oleic oil
443561|NCT00816309|Device|Acapella Physiotherapy|twice daily- around 20 minutes
443562|NCT00816296|Other|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
443563|NCT00816296|Other|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
443564|NCT00816296|Other|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
443565|NCT00816296|Other|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
443566|NCT00816283|Drug|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
443567|NCT00816283|Drug|vorinostat|100 mg orally 2 times per day
443568|NCT00816283|Genetic|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
443571|NCT00816283|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
443572|NCT00816283|Other|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
443573|NCT00816283|Other|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
443574|NCT00816270|Procedure|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
443575|NCT00816244|Drug|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
443576|NCT00816231|Behavioral|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
443577|NCT00816231|Other|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
443578|NCT00816231|Other|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
443579|NCT00816218|Drug|Pioglitazone|pioglitazone, 45 mg daily
443580|NCT00816205|Drug|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:~The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.~The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
443581|NCT00816192|Procedure|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
443582|NCT00816179|Procedure|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
443583|NCT00816166|Device|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
443584|NCT00816166|Drug|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
443585|NCT00816153|Other|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
443586|NCT00816140|Drug|Cravit based triple therapy|"Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
443587|NCT00816140|Drug|Klaricid based triple therapy|"Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
443588|NCT00816127|Drug|Desmopressin|intranasal desmopressin (300μg)
443589|NCT00816127|Biological|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
443590|NCT00816114|Other|Chart Review|Investigator review of MDACC CML patient charts.
443591|NCT00816101|Other|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
443592|NCT00816101|Other|Mepilex® Border Lite|Self-adherent foam dressing
443593|NCT00816101|Device|Adhesive Bandage|Adhesive bandage
443594|NCT00816075|Drug|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
443595|NCT00816062|Device|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
443596|NCT00816049|Drug|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
443597|NCT00816049|Drug|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
443598|NCT00816036|Behavioral|Smoking Cessation Guideline Implementation|"1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
443599|NCT00816023|Drug|ecallantide|infusion administered IV over the duration of the surgical procedure
443600|NCT00816023|Drug|placebo|"solution for IV infusion over the duration of the surgical~>> procedure"
443601|NCT00816010|Behavioral|telephone contact|for lifestyle and compliance counseling
443602|NCT00815997|Procedure|PCI (percutaneous coronary intervention)|PCI will be performed via the radial artery.
443603|NCT00815984|Procedure|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
443637|NCT00815698|Procedure|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
443684|NCT00815295|Drug|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
443604|NCT00815958|Procedure|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
443605|NCT00815958|Procedure|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
443606|NCT00815945|Drug|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
443607|NCT00815945|Drug|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
443608|NCT00815932|Device|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
443609|NCT00815919|Drug|bortezomib|Given intravenously at a dose of 1.3 mg/m^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
443610|NCT00815919|Drug|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
443611|NCT00815906|Drug|SBI-087|IV, Single dose
443612|NCT00815906|Drug|SBI-087|IV, Single dose
443613|NCT00815906|Drug|SBI-087|SC, Single dose
443614|NCT00815906|Drug|SBI-087|SC, Single dose
443615|NCT00815893|Drug|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
443616|NCT00815893|Drug|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
443617|NCT00815893|Drug|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.~The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
443618|NCT00815880|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
443619|NCT00815867|Drug|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin~30000 UI: 4 injections"
443620|NCT00815854|Dietary Supplement|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
443621|NCT00815854|Other|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
443622|NCT00815841|Drug|METHYLPHENIDATE|15-20mg during one of the two sessions
443623|NCT00815828|Other|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
443624|NCT00815815|Behavioral|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
443625|NCT00815789|Behavioral|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
443626|NCT00815776|Device|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
443627|NCT00815776|Device|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
443628|NCT00815776|Other|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
443629|NCT00815763|Drug|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
443630|NCT00815763|Drug|placebo|infusion placebo once a day and continued for 14 day
443631|NCT00815750|Other|Information Gathering|An information gathering phase leading to development of a new decision aid.
443632|NCT00815750|Other|Decision Aid|To test the newly developed decision aid.
443633|NCT00815737|Drug|rhubarb|14 days of rhubarb
443634|NCT00815737|Drug|Placebo|14 days of Placebo
443635|NCT00815724|Behavioral|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
443638|NCT00815685|Drug|Eicosapentaenoic Acid|Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
443639|NCT00815672|Behavioral|Exercise|Progressive walking and resistance exercise treatment
443640|NCT00815659|Drug|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
443641|NCT00815646|Drug|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
443642|NCT00815633|Drug|Alefacept|15mg intramuscular injection weekly for 12 weeks
443643|NCT00815607|Drug|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
443644|NCT00815607|Biological|INXN-3001|Intratumoral injection
443645|NCT00815594|Drug|bevacizumab|0.05ml, 1.25mg
443646|NCT00815581|Device|photorefraction,cycloautorefraction,cycloretinoscopy|
443647|NCT00815568|Drug|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)
443648|NCT00815555|Other|There is no intervention - this is an observational study|
443649|NCT00815542|Device|double balloon catheter|cervical ripening using double balloon catheter
443650|NCT00815542|Drug|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
443651|NCT00815529|Device|Acupuncture, Pak-sham needle|25*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
443652|NCT00815516|Drug|micafungin|Administered by intravenous infusion
443653|NCT00815516|Drug|amphotericin B deoxycholate|Administered by intravenous infusion
443654|NCT00815503|Drug|Ropivacaine|Approved by the Danish Medicines Agency
443655|NCT00815503|Drug|Placebo|Saline
443656|NCT00815490|Device|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
443657|NCT00815477|Behavioral|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
443658|NCT00815477|Behavioral|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
443659|NCT00815464|Device|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
443660|NCT00815451|Dietary Supplement|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
443661|NCT00815451|Dietary Supplement|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
443662|NCT00815438|Procedure|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
443663|NCT00815412|Behavioral|Counseling in use of health care|
443664|NCT00815412|Behavioral|Counseling in diet, exercise|
443665|NCT00815412|Other|Control|
443666|NCT00815399|Drug|Pioglitazone|15-45 mg/die
443667|NCT00815399|Drug|Metformin|500-2000 mg/die
443668|NCT00815386|Device|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
443669|NCT00815373|Drug|Dorzolamide+Timolol Maleate0.5%|Cosopt* b. i. d.
443670|NCT00815373|Drug|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom* QHS
443671|NCT00815360|Drug|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
443672|NCT00815360|Procedure|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
443673|NCT00815360|Drug|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
443674|NCT00815360|Procedure|macular laser|macular laser to areas of retinal thickening or leakage
443675|NCT00815347|Drug|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
443676|NCT00815347|Drug|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
443677|NCT00815334|Procedure|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
443678|NCT00815321|Biological|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
443679|NCT00815308|Drug|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8)
443680|NCT00815308|Drug|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m^2,(Day1 in every week for Weeks 2-8)
443681|NCT00815308|Drug|Cisplatin|Cisplatin,injection,loading dose 20 mg/m^2,(Day1 in every week for Weeks 2-8)
443682|NCT00815308|Radiation|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
443683|NCT00815295|Drug|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
443686|NCT00815269|Drug|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
443687|NCT00815269|Drug|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
443688|NCT00815269|Drug|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
443689|NCT00815269|Drug|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
443690|NCT00815269|Drug|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
443691|NCT00815256|Procedure|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
443692|NCT00815243|Procedure|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
443693|NCT00815243|Procedure|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
443694|NCT00815217|Procedure|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
443695|NCT00815217|Other|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
443696|NCT00815204|Procedure|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
443697|NCT00815204|Procedure|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
443698|NCT00815191|Device|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
443699|NCT00815191|Device|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
443700|NCT00815178|Behavioral|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
443701|NCT00815178|Behavioral|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
443702|NCT00815152|Behavioral|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
443703|NCT00815152|Behavioral|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
443704|NCT00815126|Procedure|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
443705|NCT00815100|Drug|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
443706|NCT00815100|Drug|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
443707|NCT00815087|Device|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
443708|NCT00815087|Behavioral|Exercise home program|Daily exercise training
443709|NCT00815048|Drug|Atropine/Remifentanil|"Atropine 20mcg/kg~Remifentanil 3mcg/kg"
443710|NCT00815048|Drug|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg"
443711|NCT00815035|Drug|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
443712|NCT00815035|Drug|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
443713|NCT00815022|Drug|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
443714|NCT00815009|Behavioral|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
443715|NCT00815009|Behavioral|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
443716|NCT00815009|Behavioral|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
443717|NCT00814983|Procedure|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
443718|NCT00814983|Procedure|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
443719|NCT00814983|Device|Isolex device from Baxter|
443720|NCT00814970|Device|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
443721|NCT00814957|Drug|GSK618334|D3 receptor antagonist
443722|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
443723|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
443724|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
443725|NCT00814944|Drug|Sirolimus|Subconjunctival injection of placebo in each eye.
443726|NCT00814931|Drug|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
443727|NCT00814931|Drug|Placebo|matching oral liquid suspension placebo twice a day for 8 days
443728|NCT00814918|Drug|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
443729|NCT00814918|Drug|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
443730|NCT00814905|Drug|saline|A saline infusion after delivery (one dose)
443731|NCT00814905|Drug|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
443732|NCT00814905|Drug|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
443733|NCT00814905|Drug|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
443734|NCT00814892|Biological|allogeneic tumor cell vaccine|Given intradermally
443735|NCT00814892|Biological|therapeutic autologous dendritic cells|Given intradermally
443736|NCT00814879|Drug|Raltegravir|400 mg BID
443737|NCT00814879|Drug|Atazanavir|300 mg BID
443738|NCT00814879|Other|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
443739|NCT00814866|Drug|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
443740|NCT00814853|Device|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
443741|NCT00814840|Device|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
443742|NCT00814840|Device|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
443743|NCT00814801|Drug|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
443744|NCT00814801|Drug|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
443745|NCT00814801|Drug|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
443746|NCT00814788|Drug|Bicalutamide|50 mg oral tablet daily
443747|NCT00814788|Drug|Everolimus|10 mg oral capsule daily
443748|NCT00814775|Device|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
443749|NCT00814775|Device|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
443750|NCT00814762|Biological|HIV Vaccine 732462|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
443751|NCT00814762|Biological|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
443752|NCT00814749|Procedure|midureteral sling|midureteral sling
443753|NCT00814749|Other|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
443754|NCT00814736|Drug|UK369,003|oral tablet, once a day
443755|NCT00814736|Drug|sildenafil|single oral dose on day 14 or day 17
443756|NCT00814736|Drug|sildenafil matching placebo|single oral dose on day 14 or day 17
443757|NCT00814723|Drug|fluvastatin|80 mg MR, 12 weeks
443758|NCT00814723|Drug|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
443759|NCT00814710|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
443760|NCT00814710|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
443761|NCT00814710|Biological|Hiberix|Intramuscular injection, 3 doses
443762|NCT00814710|Biological|Tritanrix-HepB|Intramuscular injection, 3 doses
443763|NCT00814697|Device|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
443764|NCT00814671|Drug|Rifapentine 450|rifapentine 450 mg
443765|NCT00814671|Drug|Rifapentine 600|rifapentine 600 mg
443766|NCT00814671|Drug|Rifampin|rifampin 600 mg
443767|NCT00814658|Drug|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
443768|NCT00814658|Drug|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
443769|NCT00814658|Drug|Placebo|Matching placebo three times a day (tid).
443770|NCT00814645|Drug|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
443771|NCT00814645|Drug|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
443772|NCT00814632|Drug|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
443773|NCT00814619|Biological|panitumumab|Given IV
443774|NCT00814619|Drug|capecitabine|Given orally
443775|NCT00814619|Procedure|therapeutic conventional surgery|Patients undergo surgical resection
443776|NCT00814619|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
443777|NCT00814606|Drug|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
443778|NCT00814606|Drug|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
443779|NCT00814606|Drug|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
443780|NCT00814593|Biological|lymphokine-activated killer cells|Instilled into the tumor bed cavity
443781|NCT00814593|Drug|polifeprosan 20 with carmustine implant|Intracranial placement
443782|NCT00814580|Drug|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
443783|NCT00814580|Drug|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
443784|NCT00814567|Radiation|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
443785|NCT00814554|Behavioral|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
443786|NCT00814554|Behavioral|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
443787|NCT00814554|Other|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
443788|NCT00814541|Drug|Bortezomib|
443789|NCT00814541|Drug|Doxorubicin|
443790|NCT00814541|Drug|Dexamethasone|
443791|NCT00814528|Drug|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
443792|NCT00814528|Drug|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
443793|NCT00814515|Drug|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
443794|NCT00814515|Drug|NOVA22007|Vehicle
443795|NCT00814502|Drug|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
443796|NCT00814502|Drug|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
443797|NCT00814489|Biological|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
443798|NCT00814489|Biological|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
443799|NCT00814476|Other|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
443800|NCT00814476|Other|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
443801|NCT00814463|Behavioral|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
443802|NCT00814463|Behavioral|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
443803|NCT00814463|Procedure|MRI|MRI done every 3 months for the length of the study.
443804|NCT00814463|Radiation|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
443805|NCT00814450|Device|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
443806|NCT00814424|Device|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
443807|NCT00814424|Device|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
443808|NCT00814411|Behavioral|group family planning counseling|group family planning counseling for gynecological patients with unmet need
443809|NCT00814411|Behavioral|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
443810|NCT00814398|Procedure|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
443811|NCT00814398|Procedure|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
443812|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
443813|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
443814|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
443815|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
443816|NCT00814385|Biological|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
443817|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
443818|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
443819|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
443820|NCT00814385|Biological|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
443821|NCT00814372|Drug|MBX-102|capsule
443822|NCT00814372|Drug|Placebo|matching placebo
443823|NCT00814372|Drug|Actos|over-encapsulated to match MBX-102 and placebo
443824|NCT00814372|Drug|Metformin|greater than or equal to 1500 mg/kg day
443825|NCT00814359|Drug|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.~The concentration of the sucralfate suspension will be 1g/5ml.~Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
443826|NCT00814359|Drug|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
443827|NCT00814346|Drug|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
443828|NCT00814346|Drug|Placebo|Placebo 1 tablet BID
443829|NCT00814333|Drug|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
443830|NCT00814333|Drug|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
443831|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous [SC] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
443832|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.~Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.~Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
443833|NCT00814307|Drug|CP-690,550|5mg CP-690,550 BID PO for 6 months
443834|NCT00814307|Drug|CP-690,550|10 mg CP-690,550 BID PO for 6 months
443835|NCT00814307|Drug|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
443836|NCT00814307|Drug|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
443837|NCT00814294|Drug|placebo|placebo capsule,0 units, QID for 18 weeks
443838|NCT00814294|Drug|Oral HDV-I|Oral HDV-I Caps; 15 U; QID for 18 weeks.
443839|NCT00814294|Drug|Oral HDV-Insulin|Oral HDV-I; Caps; 5 U; QID for 18 weeks.
443840|NCT00814281|Other|placebo|Placebo
443841|NCT00814281|Drug|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
443842|NCT00814268|Drug|Clopidogrel|75mg tablet, oral administration once daily
443843|NCT00814268|Drug|Clopidogrel placebo|Matching tablet, oral administration once daily
443844|NCT00814268|Drug|Aspirin|100mg tablet, oral administration once daily
443845|NCT00814255|Drug|Adalimumab|Adalimumab 24 mg/m^2 (maximum dose 40 mg) sc q 14 days
443846|NCT00814255|Drug|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
443847|NCT00814255|Drug|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
443848|NCT00814242|Procedure|surgical resection|radical resection performed in patinets with HCC.
443849|NCT00814242|Procedure|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
443850|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
443851|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
443852|NCT00814229|Biological|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
443853|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
443854|NCT00814229|Biological|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
443855|NCT00814229|Biological|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
443856|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
443857|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
443858|NCT00814229|Biological|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
443859|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
443860|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
443861|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
443862|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
443863|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
443864|NCT00814216|Drug|QAV680|
443865|NCT00814216|Drug|Matching placebo for QAV680|
443866|NCT00814216|Drug|Fluticasone Propionate|
443867|NCT00814190|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
443868|NCT00814177|Drug|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
443869|NCT00814177|Drug|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
443870|NCT00814164|Drug|clofarabine|IV
443871|NCT00814164|Drug|daunorubicin hydrochloride|IV
443872|NCT00814164|Genetic|cytogenetic analysis|Correlative study
443873|NCT00814164|Genetic|protein expression analysis|Correlative Study
443874|NCT00814164|Other|immunologic technique|Correlative Study
443875|NCT00814164|Other|pharmacological study|Correlative Study
443876|NCT00814151|Other|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
443877|NCT00814138|Drug|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
443878|NCT00814138|Other|Placebo|Weekly
443879|NCT00814125|Drug|Anastrozole (Arimidex)|1mg, orally, once daily
443880|NCT00814125|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
443881|NCT00814125|Drug|Nolvadex placebo|
443882|NCT00814125|Drug|Arimidex placebo|
443883|NCT00814099|Behavioral|Team approach to sedation management|"The team approach to sedation management includes the following:~Team education and consensus on the use of sedatives~Team identification of the patient's trajectory of illness and daily prescription of a sedation goal~A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines~Team feedback on sedation management performance"
443884|NCT00814099|Behavioral|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
443885|NCT00814086|Drug|Paclitaxel|Given IV or intraperitoneally
443886|NCT00814086|Drug|Cisplatin|Given intraperitoneally
443887|NCT00814073|Drug|Masitinib|Masitinib 6 mg/kg/day
443888|NCT00814073|Drug|Placebo|Matching placebo
443889|NCT00814073|Other|Best Supportive Care|Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglicate, antidepressants, leukotriene antagonists, interferon-alpha, 2-CdA, and corticosteroids.
443890|NCT00814060|Drug|neratinib|HKI-272
443891|NCT00814047|Drug|Yohimbine hydrochloride|
443892|NCT00814021|Drug|sunitinib malate|
443893|NCT00814008|Drug|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
443894|NCT00814008|Drug|Glucose|"Glucose:~Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
443895|NCT00813995|Drug|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
443896|NCT00813995|Drug|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
443897|NCT00813982|Device|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
443898|NCT00813982|Device|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
443899|NCT00813969|Biological|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
443900|NCT00813956|Drug|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
443901|NCT00813943|Drug|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
443902|NCT00813943|Drug|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
443903|NCT00813943|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
443904|NCT00813943|Radiation|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
443905|NCT00813930|Behavioral|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
443906|NCT00813917|Drug|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
443907|NCT00813917|Drug|placebo|12 weeks of placebo (double blinded) by mouth twice per day
443908|NCT00813904|Biological|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
443909|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
443910|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
443911|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
443912|NCT00813878|Genetic|protein analysis|protein analysis
443913|NCT00813878|Genetic|protein expression analysis|protein expression analysis
443914|NCT00813878|Genetic|proteomic profiling|proteomic profiling
443915|NCT00813878|Other|diagnostic laboratory biomarker analysis|Performed one time on study
443916|NCT00813878|Other|immunohistochemistry staining method|Performed one time on study
443917|NCT00813878|Other|liquid chromatography|Performed on samples collected one time on study
443918|NCT00813878|Other|mass spectrometry|Performed on samples collected one time on study
443919|NCT00813878|Procedure|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
443920|NCT00813878|Procedure|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
443921|NCT00813878|Procedure|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
443922|NCT00813865|Drug|afegostat tartrate|
443923|NCT00813852|Behavioral|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
443924|NCT00813839|Other|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
443925|NCT00813826|Drug|SLC022|SLC022 150 mg capsule, 900mg daily dose
443926|NCT00813826|Drug|Placebo|Placebo capsule, TID
443999|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
444000|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
444001|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
444002|NCT00813293|Drug|Sorafenib|Short course of sorafenib given orally twice a day prior to RFA
444761|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
443927|NCT00813813|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
443928|NCT00813800|Drug|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
443929|NCT00813774|Biological|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
443930|NCT00813774|Biological|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
443931|NCT00813774|Biological|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
443932|NCT00813761|Device|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
443933|NCT00813761|Device|Proclear contact lens|control contact lens to be worn for entire length of study.
443934|NCT00813761|Device|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
443935|NCT00813761|Device|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
443936|NCT00813748|Drug|Xolair|
443937|NCT00813735|Drug|Eszopiclone|Eszopiclone 2mg daily at bedtime
443938|NCT00813735|Drug|Placebo|Placebo daily at bedtime
443939|NCT00813735|Drug|Escitalopram|Escitalopram 10mg or 20mg
443940|NCT00813722|Behavioral|phone call|patients received or not phone calls to give orientation abou treatment
443941|NCT00813722|Drug|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
443942|NCT00813722|Drug|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
443943|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
443944|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
443945|NCT00813709|Drug|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
443946|NCT00813709|Drug|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
443947|NCT00813696|Drug|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
443948|NCT00813696|Drug|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
443949|NCT00813683|Other|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
443950|NCT00813683|Other|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
443951|NCT00813670|Drug|XPF-001|Single oral dose, or 6 days of repeated oral doses.
443952|NCT00813657|Behavioral|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, ~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (~8 minutes), followed by toning and very light resistance exercises (~20 minutes) and a light intensity cool-down (~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
443953|NCT00813631|Other|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
443954|NCT00813618|Drug|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
443955|NCT00813618|Drug|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
443956|NCT00813618|Drug|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
443957|NCT00813605|Other|FOLFIRI|"Day 1 of each Cycle~Combination Therapy of:~irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
443958|NCT00813605|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
443959|NCT00813605|Other|Placebo|Inactive dummy agent (to maintain blind)
443960|NCT00813605|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
444003|NCT00813293|Procedure|radiofrequency ablation|all patients receive standard of care radiofrequency ablation
444004|NCT00813267|Biological|mesenchymal stem cell infusion|
444005|NCT00813267|Biological|bone marrow mononuclear cell infusion|
443961|NCT00813592|Drug|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
443962|NCT00813566|Radiation|Multi-tracer PET exams of 18F-FDG, 18F-FLT, 11C-ACE, and 15O-H2O|"Baseline: prior to surgery or immediately after surgery and prior to any tumor-directed therapy;~After the initial (~6-8 weeks) chemoradiotherapy;~At the time of MRI-documented recurrence within 2 years (patients with a known primary brain tumor who have previously undergone treatment and have recurred will be eligible for study). The PET scanning will be implemented in two phases: Phase A (separate single-tracer scans with each tracer) will be completed with imaging over two consecutive days and Phase B (where two or more tracers will be imaged in a single scan using rapid multi-tracer PET techniques under development) in one or two imaging sessions according to the best method validated from the Phase A results. The exact order and timing of the multi-tracer exams will vary."
443963|NCT00813553|Dietary Supplement|placebo|daily
443964|NCT00813553|Dietary Supplement|beta-alanine|daily
443965|NCT00813553|Dietary Supplement|beta-alanine|daily
443966|NCT00813540|Behavioral|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
443967|NCT00813540|Other|Usual Care|Usual Care
443968|NCT00813527|Drug|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
443969|NCT00813527|Drug|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
443970|NCT00813514|Genetic|VEGF genotyping|blood sample for gene analysis
443971|NCT00813501|Biological|immunosuppressive therapy|
443972|NCT00813501|Other|immunological diagnostic method|
443973|NCT00813501|Procedure|allogeneic hematopoietic stem cell transplantation|
443974|NCT00813488|Drug|Fentanyl Buccal Tablet|"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."
443975|NCT00813488|Drug|Immediate release oxycodone|"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules)."
443976|NCT00813475|Drug|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
443977|NCT00813475|Drug|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
443978|NCT00813449|Drug|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
443979|NCT00813449|Drug|dacarbazine plus placebo (control group)|dacarbazine plus placebo
443980|NCT00813436|Drug|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
443981|NCT00813436|Drug|Placebo|saline liquid, intranasally administered
443982|NCT00813423|Drug|Hydroxychloroquine|Given PO
443983|NCT00813423|Other|Laboratory Biomarker Analysis|Correlative studies
443984|NCT00813423|Other|Pharmacological Study|Correlative studies
443985|NCT00813423|Drug|Sunitinib Malate|Given PO
443986|NCT00813410|Procedure|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
443987|NCT00813397|Device|Sepraspray|Max. 10g of Sepraspray
443988|NCT00813384|Drug|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c‑Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
443989|NCT00813371|Device|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
443990|NCT00813371|Device|ARDSnet protocol|ARDSnet protocol
443991|NCT00813358|Device|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
443992|NCT00813345|Other|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
443993|NCT00813345|Other|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
443994|NCT00813332|Drug|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
443995|NCT00813332|Drug|Placebo plus Docetaxel|Placebo plus Docetaxel
443996|NCT00813319|Behavioral|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
443997|NCT00813306|Drug|AZD2066|13 mg oral solution, 1 single dose
443998|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
444006|NCT00813254|Behavioral|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
444007|NCT00813241|Drug|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
444008|NCT00813241|Drug|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
444009|NCT00813241|Drug|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
444010|NCT00813241|Drug|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
444011|NCT00813228|Drug|Sitagliptin (Januvia)|
444012|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on saturated fat.
444013|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
444014|NCT00813202|Drug|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
444015|NCT00813189|Device|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
444016|NCT00813176|Device|Double Lumen Endotracheal Tube|
444017|NCT00813176|Device|Arndt Bronchial Blocker|
444018|NCT00813163|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
444019|NCT00813150|Drug|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
444020|NCT00813150|Drug|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
444021|NCT00813150|Drug|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
444022|NCT00813137|Drug|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1~7, D15~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
444023|NCT00813124|Drug|Fludarabine|40 mg/m^2 by vein over 60 minutes on Day -5 through Day -2.
444024|NCT00813124|Drug|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
444025|NCT00813124|Drug|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
444026|NCT00813124|Drug|Azacitidine|Start cycles of 32 mg/m^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
444027|NCT00813124|Procedure|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
444028|NCT00813111|Drug|SKY0402|600mg SKY0402 instilled into breast pocket during surgery
444029|NCT00813111|Drug|Bupivacaine HCl|200mg Bupivacaine HCl instilled into breast pocket during surgery
444030|NCT00813098|Drug|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
444031|NCT00813098|Drug|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
444032|NCT00813098|Drug|Placebo|Matching placebo dosing with daily oral intake
444033|NCT00813085|Other|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
444034|NCT00813072|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
444035|NCT00813072|Drug|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
444036|NCT00813072|Drug|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
444037|NCT00813059|Drug|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
444038|NCT00813046|Biological|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
444039|NCT00813033|Other|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
444040|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
444041|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
444042|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
444043|NCT00813007|Behavioral|Questionnaires|5 Questionnaires at differing times before and after surgery.
444044|NCT00812994|Drug|Escitalopram|SSRI antidepressant
444045|NCT00812994|Drug|Placebo|
444046|NCT00812981|Biological|GSK1562902A|new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
444047|NCT00812981|Biological|GSK1562902A|comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
444048|NCT00812968|Drug|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
444049|NCT00812955|Drug|ABT-143|Once daily for 8 weeks
444050|NCT00812955|Drug|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
444051|NCT00812942|Procedure|colonoscopy|colonoscopy screening
444052|NCT00812942|Procedure|faecal test|faecal occult blood test for screening
444053|NCT00812929|Drug|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
444054|NCT00812929|Drug|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
444055|NCT00812916|Procedure|RF ablation, using specialized CFAE software|RF ablation
444056|NCT00812903|Behavioral|Exercise|Training exercises chosen with background in knowledge of intelligent training
444057|NCT00812890|Device|semi-quantitative pregnancy test|
444058|NCT00812877|Drug|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
444059|NCT00812877|Drug|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
444060|NCT00812864|Drug|Capecitabine|"Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day"
444061|NCT00812851|Drug|Dronabinol|
444062|NCT00812838|Drug|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
444063|NCT00812838|Other|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
444064|NCT00812825|Drug|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
444065|NCT00812825|Drug|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
444066|NCT00812825|Drug|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
444067|NCT00812825|Drug|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
444068|NCT00812825|Drug|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
444069|NCT00812812|Drug|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
444070|NCT00812812|Drug|paroxetine 20mg tablet|1 tablet once a day
444071|NCT00812812|Drug|matched placebo to paroxetine 10mg|2 tablets once a day
444072|NCT00812812|Drug|matched placebo to paroxetine 20mg|1 tablet once a day
444073|NCT00812799|Drug|Oralgen|19.000 BU daily
444074|NCT00812799|Other|placebo control|placebo control
444075|NCT00812786|Drug|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
444076|NCT00812773|Drug|GSK2190915|Investigational Product
444077|NCT00812760|Drug|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
444078|NCT00812747|Other|observation|
444079|NCT00812734|Procedure|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
444080|NCT00812721|Other|Preservative Free Saline|One drop will be instilled into each eye once
444081|NCT00812721|Other|Optive|One drop will be instilled into each eye once
444082|NCT00812721|Other|Refresh Moderate/Severe|One drop will be instilled into each eye once
444083|NCT00812721|Other|Systane|One drop will be instilled into each eye once
444084|NCT00812721|Other|Systane Ultra|One drop will be instilled into each eye once
444085|NCT00812708|Device|Morcher iris diaphragm implantation|Surgical implantation of Morcher iris device(s)
444086|NCT00812695|Device|CPAP|Gold standard treatment for Obstructive sleep apnea
444087|NCT00812682|Drug|Symbicort|
444088|NCT00812669|Biological|pegfilgrastim|
444089|NCT00812669|Biological|rituximab|
444090|NCT00812669|Drug|cyclophosphamide|
444091|NCT00812669|Drug|fludarabine phosphate|
444092|NCT00812669|Genetic|cytogenetic analysis|
444093|NCT00812669|Genetic|fluorescence in situ hybridization|
444094|NCT00812669|Genetic|gene expression analysis|
444095|NCT00812669|Genetic|mutation analysis|
444096|NCT00812669|Genetic|protein expression analysis|
444097|NCT00812669|Other|flow cytometry|
444098|NCT00812669|Other|laboratory biomarker analysis|
444099|NCT00812643|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
444100|NCT00812630|Drug|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
444101|NCT00812617|Dietary Supplement|Mineral water (Hita, Oita, Japan)|
444102|NCT00812617|Dietary Supplement|Mineral water (Aso-gun, Kumamoto, Japan)|
444103|NCT00812604|Drug|Ping On Ointment|Ping On Ointment
444104|NCT00812604|Drug|Vaseline|Placebo
444105|NCT00812591|Procedure|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):~Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.~Hyperinsulinemic euglycemic clamp (CLAMP):~Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
444106|NCT00812578|Drug|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
444107|NCT00812565|Drug|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
444108|NCT00812565|Biological|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
444147|NCT00812266|Drug|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
444148|NCT00812253|Drug|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
444149|NCT00812253|Drug|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
444150|NCT00812240|Drug|Masitinib|Masitinib st 6.0 or 7.5 mg/kg/day, per os
444151|NCT00812240|Drug|Imatinib|imatinib 400 mg or 600 mg per day, per os
444208|NCT00811967|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
444109|NCT00812539|Other|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
444110|NCT00812539|Other|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
444111|NCT00812526|Procedure|Suction cup application|
444112|NCT00812526|Procedure|Squatting|
444113|NCT00812513|Drug|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
444114|NCT00812500|Other|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
444115|NCT00812500|Other|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
444116|NCT00812500|Other|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
444117|NCT00812487|Drug|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
444118|NCT00812487|Drug|Subcutaneous insulin|4 injections of insulin/day
444119|NCT00812461|Drug|Placebo|as-needed use, tablets, orally, 6 months
444120|NCT00812461|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
444121|NCT00812448|Dietary Supplement|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
444122|NCT00812435|Drug|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
444123|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
444124|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
444125|NCT00812422|Drug|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
444126|NCT00812409|Dietary Supplement|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
444127|NCT00812409|Other|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
444128|NCT00812396|Drug|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
444129|NCT00812396|Drug|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
444130|NCT00812396|Drug|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
444131|NCT00812383|Device|RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System|Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
444132|NCT00812370|Drug|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
444133|NCT00812344|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
444134|NCT00812344|Drug|Ketoconazole|tablets, orally, once daily for 3 days
444135|NCT00812344|Drug|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
444136|NCT00812331|Drug|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
444137|NCT00812318|Drug|GSK1265744 10 mg oral solution|GSK1265744
444138|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
444139|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
444140|NCT00812305|Drug|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
444141|NCT00812305|Drug|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
444142|NCT00812292|Drug|TMC278|
444143|NCT00812279|Other|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
444144|NCT00812279|Other|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
444145|NCT00812279|Other|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
444146|NCT00812266|Drug|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
444762|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
444152|NCT00812227|Behavioral|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
444153|NCT00812214|Drug|eszopiclone|3 mg qhs
444154|NCT00812214|Drug|placebo|
444155|NCT00812201|Device|No intervention is used. Collection of signals only.|Device received per standard of care.
444156|NCT00812188|Other|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
444157|NCT00812188|Other|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
444158|NCT00812175|Drug|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
444159|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
444160|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
444161|NCT00812136|Behavioral|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
444162|NCT00812123|Drug|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
444163|NCT00812123|Drug|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
444164|NCT00812123|Drug|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
444165|NCT00812123|Drug|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
444166|NCT00812123|Procedure|Protocol biopsies|protocol kidney biopsies at month one and three
444167|NCT00812110|Drug|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
444168|NCT00812097|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
444169|NCT00812071|Biological|RiVax|vaccine
444170|NCT00812058|Drug|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
444171|NCT00812058|Drug|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
444172|NCT00812045|Drug|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
444173|NCT00812045|Drug|Placebo|
444174|NCT00812032|Drug|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
444175|NCT00812032|Drug|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
444176|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
444177|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
444178|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
444179|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
444180|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
444181|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
444182|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
444183|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
444184|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
444185|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
444186|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
444187|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
444188|NCT00812006|Drug|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
444189|NCT00812006|Drug|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
444190|NCT00811993|Drug|RG1507|Starting dose of >=3mg/kg iv escalating to a maximum dose of <=16mg/kg iv, depending on dosing schedule in each combination treatment arm
444191|NCT00811993|Drug|RO1507|27mg/kg iv, monotherapy
444192|NCT00811993|Drug|bevacizumab [Avastin]|as prescribed
444193|NCT00811993|Drug|capecitabine [Xeloda]|as prescribed
444194|NCT00811993|Drug|carboplatin|as prescribed
444195|NCT00811993|Drug|cetuximab|as prescribed
444196|NCT00811993|Drug|docetaxel|as prescribed
444197|NCT00811993|Drug|erlotinib [Tarceva]|as prescribed
444198|NCT00811993|Drug|etoposide|as prescribed
444199|NCT00811993|Drug|gemcitabine|as prescribed
444200|NCT00811993|Drug|irinotecan|as prescribed
444201|NCT00811993|Drug|mFOLFOX6|as prescribed
444202|NCT00811993|Drug|paclitaxel|as prescribed
444203|NCT00811993|Drug|pemetrexel|as prescribed
444204|NCT00811993|Drug|sorafenib|as prescribed
444205|NCT00811993|Drug|temozolomide|as prescribed
444206|NCT00811993|Drug|trastuzumab [Herceptin]|as prescribed
444207|NCT00811980|Drug|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
444209|NCT00811967|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
444210|NCT00811954|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
444211|NCT00811954|Drug|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
444212|NCT00811954|Drug|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
444213|NCT00811954|Drug|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
444214|NCT00811954|Drug|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
444215|NCT00811941|Drug|Placebo|as-needed use, tablets, orally, 52 weeks
444216|NCT00811941|Drug|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
444217|NCT00811928|Drug|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~3 chemotherapy cycles or~Total treatment duration up to 12 weeks (84 days)"
444218|NCT00811928|Drug|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~3 chemotherapy cycles or~Total treatment duration up to 12 weeks (84 days)"
444219|NCT00811915|Drug|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal~Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
444220|NCT00811902|Drug|Nerispirdine|tablet, oral administration
444221|NCT00811902|Drug|placebo|tablet, oral administration
444222|NCT00811889|Other|Placebo|Placebo
444223|NCT00811889|Drug|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
444224|NCT00811876|Other|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
444225|NCT00811850|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
444226|NCT00811850|Drug|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
444227|NCT00811837|Drug|Midazolam|Intravenous infusion
444228|NCT00811837|Drug|Remifentanil|Intravenous infusion
444229|NCT00811824|Behavioral|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
444230|NCT00811811|Behavioral|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
444231|NCT00811811|Behavioral|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
444232|NCT00811798|Biological|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
444233|NCT00811785|Drug|Copper Histidine|Daily subcutaneous injections for three years
444234|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
444235|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
444236|NCT00811759|Drug|sorafenib tosylate|
444237|NCT00811759|Drug|temozolomide|
444238|NCT00811759|Genetic|gene expression analysis|
444239|NCT00811759|Genetic|mutation analysis|
444240|NCT00811759|Other|laboratory biomarker analysis|
444241|NCT00811759|Other|pharmacological study|
444242|NCT00811759|Procedure|biopsy|
444243|NCT00811746|Drug|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
444244|NCT00811746|Drug|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
444245|NCT00811746|Other|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
444246|NCT00811733|Biological|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
444247|NCT00811720|Drug|Placebo|as-needed use, tablets, orally, 6 months
444248|NCT00811720|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
444249|NCT00811694|Other|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
444250|NCT00811681|Drug|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
444251|NCT00811681|Drug|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
444252|NCT00811668|Device|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
444253|NCT00811668|Device|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
444254|NCT00811655|Procedure|therapeutic conventional surgery|Surgery of a single brain metastasis.
444255|NCT00811655|Radiation|stereotactic radiosurgery|Pre-operative single fraction SRS
444256|NCT00811642|Drug|Posaconazole|400mg BID oral suspension for 12 weeks
444257|NCT00811629|Other|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
444258|NCT00811616|Device|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
444259|NCT00811603|Drug|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
444301|NCT00811369|Drug|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
444763|NCT00808249|Drug|Placebo|2 tablets taken twice a day for 28 days
444260|NCT00811590|Drug|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~directly on the tumor cells by inhibiting tumor cell growth and proliferation~indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
444261|NCT00811577|Drug|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
444262|NCT00811577|Drug|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
444263|NCT00811564|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
444264|NCT00811564|Drug|latanoprost 0.005%|1 drop of study medication taken once daily
444265|NCT00811551|Device|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
444266|NCT00811538|Procedure|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
444267|NCT00811538|Procedure|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
444268|NCT00811525|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.~With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
444269|NCT00811499|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
444270|NCT00811499|Drug|Placebo; oral|matching placebo
444271|NCT00811499|Drug|Placebo; oral|multiple dose, single schedule
444272|NCT00811486|Drug|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
444273|NCT00811473|Drug|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
444274|NCT00811473|Drug|Placebo|Oral treatment once daily in the evening
444275|NCT00811460|Drug|Placebo|sc for 4 days
444276|NCT00811460|Drug|taspoglutide|300micrograms/day sc for 2 days
444277|NCT00811460|Drug|taspoglutide|800 micrograms/day sc for 2 days
444278|NCT00811447|Drug|5-fluorouracil|600 mg/m²/day intravenous
444279|NCT00811447|Drug|Cisplatin|60 mg/m² or 75 mg/m² intravenous
444280|NCT00811447|Drug|Docetaxel|60 mg/m² intravenous
444281|NCT00811434|Drug|Lactulose|1.5cc/kg/day po for three months
444282|NCT00811434|Drug|placebo|1.5 ml sugar water/kg day for three months
444283|NCT00811421|Drug|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
444284|NCT00811421|Drug|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
444285|NCT00811421|Drug|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
444286|NCT00811421|Drug|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
444287|NCT00811421|Drug|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
444288|NCT00811408|Drug|carboplatin|
444289|NCT00811408|Drug|cidofovir|
444290|NCT00811408|Genetic|protein expression analysis|
444291|NCT00811408|Other|laboratory biomarker analysis|
444292|NCT00811408|Radiation|brachytherapy|
444293|NCT00811408|Radiation|radiation therapy|
444294|NCT00811395|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
444295|NCT00811395|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
444296|NCT00811395|Drug|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
444297|NCT00811395|Drug|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
444298|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
444299|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
444300|NCT00811369|Drug|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
445242|NCT00804921|Procedure|anterior chamber paracentesis|
444302|NCT00811356|Drug|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
444303|NCT00811343|Biological|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
444304|NCT00811330|Drug|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
444305|NCT00811317|Device|Closed-loop|Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
444306|NCT00811291|Dietary Supplement|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
444307|NCT00811291|Dietary Supplement|calcium|according to protocol
444308|NCT00811265|Device|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
444309|NCT00811252|Drug|Placebo|capsules; daily; orally
444310|NCT00811252|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
444311|NCT00811252|Drug|Duloxetine|encapsulated tablets; daily; orally
444312|NCT00811239|Drug|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
444313|NCT00811239|Other|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
444314|NCT00811226|Drug|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
444315|NCT00811213|Device|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
444316|NCT00811213|Device|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
444317|NCT00811200|Drug|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
444318|NCT00811200|Drug|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
444319|NCT00811200|Other|sham|at baseline one sham-injection
444320|NCT00811187|Drug|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
444321|NCT00811187|Drug|Normal Saline|5cc Normal Saline injection in each paracervical region
444322|NCT00811174|Drug|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
444323|NCT00811161|Device|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
444324|NCT00811148|Procedure|Tissue Bank|Collection of clinical data and tumor tissue.
444325|NCT00811135|Drug|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
444326|NCT00811135|Drug|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
444327|NCT00811135|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
444328|NCT00811122|Radiation|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
444329|NCT00811122|Radiation|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
444330|NCT00811109|Device|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
444331|NCT00811109|Device|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
444332|NCT00811109|Device|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
444333|NCT00811096|Drug|Tinidazole|2gms, p.o. q.d. for 5 days
444334|NCT00811096|Drug|chloroquine|
444335|NCT00811083|Drug|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
444336|NCT00811070|Drug|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.~SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
444337|NCT00811057|Drug|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
444338|NCT00811057|Drug|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
444339|NCT00811057|Drug|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
444340|NCT00811031|Drug|Taxotere|75 mg/m^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
444341|NCT00811031|Drug|Prednisone|5 mg twice a day by mouth.
444342|NCT00811018|Drug|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
444343|NCT00811005|Radiation|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
444344|NCT00811005|Radiation|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:~Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.~Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
444345|NCT00810992|Behavioral|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
444346|NCT00810992|Behavioral|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
444347|NCT00810979|Drug|SLx-4090|tablet
444348|NCT00810979|Drug|SLx-4090|tablet
444349|NCT00810979|Other|Placebo|matching tablet
444350|NCT00810979|Drug|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
444351|NCT00810953|Drug|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
444352|NCT00810940|Drug|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP < 20 mmHg, then IV 100 ml same schedule for 24 hours
444353|NCT00810940|Drug|mannitol|mannitol plus standard treatment
444354|NCT00810927|Procedure|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
444355|NCT00810927|Procedure|Laser Doppler flowmetry|Measurement of choroidal blood flow
444356|NCT00810927|Procedure|Measurement of intraocular pressure|
444357|NCT00810914|Drug|bupivicaine epidural|bupivicaine continuous epidural infusion
444358|NCT00810914|Drug|bupivicaine epidural infusion patient epidural|bupivicaine
444359|NCT00810914|Drug|bupivicaine|patient controlled anesthesia only
444360|NCT00810901|Behavioral|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
444361|NCT00810901|Behavioral|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
444362|NCT00810888|Drug|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
444363|NCT00810888|Drug|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
444364|NCT00810862|Drug|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
444365|NCT00810862|Other|placebo base cream|apply to affected study area twice daily for 21 days
444366|NCT00810849|Drug|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
444367|NCT00810849|Biological|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
444368|NCT00810836|Drug|BG00012|oral
444369|NCT00810836|Drug|BG00012|Oral
444370|NCT00810836|Drug|placebo|oral placebo
444371|NCT00810810|Biological|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
444372|NCT00810810|Biological|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
444373|NCT00810810|Biological|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
444374|NCT00810797|Drug|exemestane|Given orally
444375|NCT00810797|Other|laboratory biomarker analysis|One year after completion of study treatment
444376|NCT00810797|Procedure|quality-of-life assessment|One year after completion of study treatment
444377|NCT00810797|Other|immunohistochemistry staining method|Correlative studies
444378|NCT00810784|Behavioral|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
444379|NCT00810771|Behavioral|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
444380|NCT00810771|Behavioral|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
444381|NCT00810758|Drug|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
444382|NCT00810758|Drug|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
444383|NCT00810758|Drug|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
444384|NCT00810745|Procedure|starr|stapled transanal rectal resection
444385|NCT00810732|Drug|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
444386|NCT00810732|Drug|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
444387|NCT00810732|Drug|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
444459|NCT00810199|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
444388|NCT00810719|Drug|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
444389|NCT00810719|Drug|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
444390|NCT00810706|Drug|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
444391|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
444392|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
444393|NCT00810693|Drug|Placebo|Matching Placebo tid orally for 12 weeks
444394|NCT00810680|Drug|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
444395|NCT00810667|Drug|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
444396|NCT00810667|Drug|Placebo|twice daily oral dose
444397|NCT00810654|Dietary Supplement|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
444398|NCT00810654|Dietary Supplement|Placebo|Placebo
444399|NCT00810641|Procedure|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
444400|NCT00810641|Procedure|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
444401|NCT00810641|Procedure|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
444402|NCT00810628|Behavioral|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
444403|NCT00810615|Other|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
444404|NCT00810615|Other|Sham treatment|
444405|NCT00810602|Procedure|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen~Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
444406|NCT00810602|Drug|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
444407|NCT00810602|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
444408|NCT00810602|Drug|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.~Dose escalation/ de-escalation~Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher [probably or definitely related to the drug] then vorinostat dose will be escalated to 200 mg PO BID.~If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.~If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
444409|NCT00810589|Drug|Levemir|0,4 IE per kg bodyweight
444410|NCT00810589|Drug|Humalog NPL Insulin|0,4 IE per kg bodyweight
444411|NCT00810576|Drug|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
444412|NCT00810576|Drug|Bortezomib|Dose of 1.3 mg/m^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
444413|NCT00810563|Drug|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
444414|NCT00810563|Drug|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
444415|NCT00810550|Other|Carotid ultrasound|Measurement of intima-media thickness
444416|NCT00810524|Drug|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
444417|NCT00810524|Drug|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
444418|NCT00810524|Drug|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
444419|NCT00810524|Drug|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
444420|NCT00810511|Device|Lotrafilcon A contact lens|Silicone hydrogel contact lens
444421|NCT00810511|Device|Comfilcon A contact lens|Silicone hydrogel contact lens
444422|NCT00810485|Drug|ADX10059|oral administration
444423|NCT00810485|Drug|ADX10059|oral administration
444424|NCT00810485|Drug|ADX10059|oral administration
444425|NCT00810485|Drug|ADX10059 Matching Placebo|oral administration
444452|NCT00810264|Device|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
444453|NCT00810251|Device|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
444454|NCT00810238|Biological|C-Cure|Intraventricular injection
444455|NCT00810212|Procedure|PLF with autograft|6 subjects
444456|NCT00810212|Genetic|PLF with NeoFuse|6 subjects low dose
444426|NCT00810472|Other|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
444427|NCT00810472|Procedure|Penetrating keratoplasty|Corneal transplantation.
444428|NCT00810446|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.~3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
444429|NCT00810433|Procedure|GO-LIF - Guided Oblique Lumbar Interbody Fusion|"All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.~Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.~Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused."
444430|NCT00810407|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
444431|NCT00810394|Drug|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
444432|NCT00810381|Drug|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
444433|NCT00810381|Drug|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
444434|NCT00810381|Drug|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
444435|NCT00810381|Drug|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
444436|NCT00810368|Drug|Carnosine|500mg Carnosine x2 daily
444437|NCT00810368|Drug|Placebo|Microcrystalline cellulose placebo tablets x2 daily
444438|NCT00810355|Behavioral|Support Group|General support and problem solving for work activity
444439|NCT00810355|Behavioral|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
444440|NCT00810355|Behavioral|Cognitive Remediation|Computerized training to enhance cognitive functioning.
444441|NCT00810342|Behavioral|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
444442|NCT00810342|Behavioral|physical activity standard|standard print and website information on how to become more active
444443|NCT00810316|Drug|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
444444|NCT00810316|Drug|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
444445|NCT00810316|Drug|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
444446|NCT00810303|Drug|Ezetrol (ezetimibe) multiple dose|administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
444447|NCT00810303|Drug|Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)
444448|NCT00810303|Drug|Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
444449|NCT00810303|Drug|Sustiva (efavirenz) single dose|administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
444450|NCT00810290|Behavioral|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
444451|NCT00810277|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
445243|NCT00804921|Drug|acetazolamide|
444460|NCT00810199|Drug|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
444461|NCT00810199|Drug|placebo|Placebo matching methotrexate capsule taken orally once a week.
444462|NCT00810173|Behavioral|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
444463|NCT00810160|Dietary Supplement|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
444464|NCT00810160|Dietary Supplement|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
444465|NCT00810160|Dietary Supplement|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
444466|NCT00810160|Dietary Supplement|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
444467|NCT00810147|Drug|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
444468|NCT00810147|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
444469|NCT00810147|Drug|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
444470|NCT00810147|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
444471|NCT00810147|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
444472|NCT00810134|Procedure|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
444473|NCT00810134|Procedure|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
444474|NCT00810121|Drug|ketoprofen 100 mg|100 mg b.i.d. for 5 days
444475|NCT00810121|Drug|ketoprofen|150 mg b.i.d. for 5 days
444476|NCT00810108|Drug|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
444477|NCT00810095|Device|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
444478|NCT00810082|Device|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
444479|NCT00810082|Other|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
444480|NCT00810069|Drug|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
444481|NCT00810069|Drug|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
444482|NCT00810056|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
444483|NCT00810056|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
444484|NCT00810043|Device|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
444485|NCT00810030|Drug|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
444486|NCT00810030|Drug|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:~• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.~The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.~The individual iron deficit will be calculated using the modified formula of Ganzoni.~If the patient's body mass index is >25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height [m] x height [m].~The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.~Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
444487|NCT00810017|Drug|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
444488|NCT00810017|Drug|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
444489|NCT00810004|Drug|Ferinject|Intravenous infusion of iron
444490|NCT00809991|Radiation|hypofractionation|3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). T
444491|NCT00809965|Drug|Rivaroxaban 2.5 mg|One tablet twice daily
444492|NCT00809965|Drug|Rivaroxaban 5 mg|One tablet twice daily
444493|NCT00809965|Drug|Placebo|One placebo tablet twice daily
444494|NCT00809965|Drug|Standard of care|
444495|NCT00809952|Procedure|recombinant FSH|
444496|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
444497|NCT00809939|Drug|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
444498|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
444499|NCT00809939|Drug|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
444500|NCT00809926|Drug|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
444590|NCT00809341|Drug|Doxorubicin|50 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
444501|NCT00809926|Drug|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
444502|NCT00809913|Drug|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
444503|NCT00809900|Dietary Supplement|Experimental|Administration of of 480 mL cranberry juice
444504|NCT00809887|Drug|Micafungin lock therapy|
444505|NCT00809874|Dietary Supplement|Casein|
444506|NCT00809874|Dietary Supplement|Whey Isolate|
444507|NCT00809874|Dietary Supplement|Whey Hydrolysate|
444508|NCT00809874|Dietary Supplement|Alphalact-Albumin|
444509|NCT00809861|Procedure|volar locking plating|open reduction and internal fixation
444510|NCT00809861|Procedure|external immobilisation|closed reduction and external fixation
444511|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
444512|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
444513|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
444514|NCT00809848|Drug|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
444515|NCT00809848|Drug|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
444516|NCT00809835|Drug|Galantamine|Daily 8 mg galantamine capsule
444517|NCT00809835|Behavioral|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
444518|NCT00809822|Drug|NPB-01|Intravenous immunoglobulin
444519|NCT00809822|Drug|Placebo|Physiological saline
444520|NCT00809809|Drug|Zicam (Ionic zinc)|33mmol/l of ionic zinc
444521|NCT00809809|Drug|placebo|placebo swab
444522|NCT00809796|Drug|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
444523|NCT00809783|Biological|tanezumab|Tanezumab 10 mg
444524|NCT00809783|Biological|tanezumab|Tanezumab 5 mg
444525|NCT00809783|Biological|tanezumab|Tanezumab 2.5 mg
444526|NCT00809770|Behavioral|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
444527|NCT00809770|Behavioral|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
444528|NCT00809757|Drug|Levalbuterol|90 ug Levalbuterol (2 actuations)
444529|NCT00809757|Drug|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
444530|NCT00809757|Drug|Placebo|Placebo (2 actuations)
444531|NCT00809744|Drug|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
444532|NCT00809718|Drug|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
444533|NCT00809705|Drug|Placebo|sc once weekly for 12 weeks
444534|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
444535|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 12 weeks
444536|NCT00809692|Procedure|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
444537|NCT00809692|Procedure|new technique for histamine response|laser Dopper technique and genotyping
444538|NCT00809679|Drug|T-62 Dose 1|Capsule dosage form 100 mg bid
444539|NCT00809679|Drug|T-62 Dose 2|Capsule dosage form 200 mg bid
444540|NCT00809679|Other|Placebo|Capsule dosage form placebo bid
444541|NCT00809666|Device|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
444542|NCT00809653|Device|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
444543|NCT00809653|Device|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
444544|NCT00809640|Behavioral|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
444545|NCT00809627|Drug|Caffeine|Caffeine 500 mg IV
444546|NCT00809627|Drug|saline|Normal saline
444547|NCT00809614|Biological|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
444548|NCT00809614|Biological|Placebo|Matching placebo to AIN457
444591|NCT00809341|Drug|Vincristine|1.4 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
444592|NCT00809341|Drug|Prednisone|100 mg/day on Days 1-5 of each cycle as part of R-CHOP.
444593|NCT00809341|Drug|Ifosfamide|2000 mg/m^2/day on Days 1-3 of each cycle as part of R-CHOP.
444594|NCT00809341|Drug|Carboplatin|Given on Day 2 of each cycle as part of R-CHOP. Dosed according to renal function.
444595|NCT00809341|Drug|Etoposide|100 mg/m^2/day on Days 1-3 of each cycle as part of R-CHOP.
444596|NCT00809341|Drug|High-dose cyclophosphamide|50 mg/kg/day on Days 2-5 of HiCy.
445244|NCT00804921|Drug|brimonidine|
444549|NCT00809601|Device|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.~The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.~The first combination will test:~Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)~The second combination will test:~Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)~The third combination will test:~Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)~The fourth combination will test:~Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
444550|NCT00809588|Biological|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
444551|NCT00809575|Other|questionnaire administration|
444552|NCT00809575|Other|fatigue assessment and management|
444553|NCT00809575|Other|observation|
444554|NCT00809575|Other|quality-of-life assessment|
444555|NCT00809562|Drug|Placebo|po daily for 10 days
444556|NCT00809562|Drug|RO4917523|orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
444557|NCT00809549|Drug|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
444558|NCT00809536|Drug|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
444559|NCT00809536|Drug|Metformin|Single, oral, 500 mg of metformin immediate release
444560|NCT00809536|Drug|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
444561|NCT00809536|Drug|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
444562|NCT00809523|Device|Negative Ion Generator|Equivalent exposure to inactivated Negative Ion Generator
444563|NCT00809523|Device|Light-emitting Photodiode light treatment device|Light-emitting Photodiode light treatment device, used for 30 min before 8 am
444564|NCT00809510|Drug|ABT-089|20 mg ABT-089 taken once-daily for 6 months
444565|NCT00809497|Drug|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
444566|NCT00809471|Drug|placebo|30 minutes orally prior to initiation of sexual activity
444567|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
444568|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
444569|NCT00809458|Drug|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
444570|NCT00809445|Behavioral|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
444571|NCT00809445|Behavioral|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
444572|NCT00809445|Behavioral|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
444573|NCT00809432|Device|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
444574|NCT00809432|Other|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
444575|NCT00809419|Device|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
444576|NCT00809393|Drug|tranexamic acid|10 mg/kg
444577|NCT00809393|Drug|tranexamic acid|30 mg/kg
444578|NCT00809380|Behavioral|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
444579|NCT00809380|Behavioral|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
444580|NCT00809367|Other|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
444581|NCT00809354|Drug|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
444582|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
444583|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
444584|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
444585|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
444586|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
444587|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
444588|NCT00809341|Biological|Rituximab|375 mg/m^2 on Day 1 of each cycle as part of R-CHOP or R-ICE. Also given 375 mg/m^2 on Days 1, 30, and 37 as part of HiCy.
444589|NCT00809341|Drug|Cyclophosphamide|750 mg/m^2 on Day 1 of each cycle as part of R-CHOP.
445586|NCT00802373|Drug|Tolterodine|Oral
444597|NCT00809341|Procedure|PET scan|Performed once between Days 16-20 of cycle 3 of R-CHOP.
444598|NCT00809328|Drug|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
444599|NCT00809315|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
444600|NCT00809315|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
444601|NCT00809302|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
444602|NCT00809289|Drug|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
444603|NCT00809289|Drug|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
444604|NCT00809289|Drug|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
444605|NCT00809276|Drug|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days~Fludarabine once a day for 4 days~Bone marrow transplant~Cytoxan two doses"
444606|NCT00809263|Drug|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
444607|NCT00809250|Biological|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
444608|NCT00809237|Drug|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
444609|NCT00809211|Drug|nilotinib|
444610|NCT00809211|Genetic|cytogenetic analysis|
444611|NCT00809211|Genetic|mutation analysis|
444612|NCT00809211|Genetic|polymerase chain reaction|
444613|NCT00809211|Other|pharmacological study|
444614|NCT00809198|Other|Sodium Hyaluronate|
444615|NCT00809198|Other|Carboxymethylcellulose sodium|
444616|NCT00809185|Drug|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
444617|NCT00809185|Other|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
444618|NCT00809185|Procedure|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
444619|NCT00809172|Drug|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
444620|NCT00809172|Drug|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
444621|NCT00809159|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
444622|NCT00809159|Drug|Placebo|Placebo to AIN457
444623|NCT00809146|Drug|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
444624|NCT00809146|Drug|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
444625|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
444626|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
444627|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
444628|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
444629|NCT00809133|Drug|BIBW2992|MTD dose of part A
444630|NCT00809133|Drug|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
444631|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
444632|NCT00809133|Drug|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
444633|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
444634|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
444635|NCT00809120|Device|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
444636|NCT00809107|Drug|HCG|5000IU
444637|NCT00809094|Drug|N-acetylcysteine (NAC)|
444638|NCT00809094|Drug|Placebo|
444639|NCT00809081|Procedure|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1~Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
444640|NCT00809068|Drug|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
444641|NCT00809068|Drug|tibolone|tibolone 2.5 mg daily 23 weeks
444642|NCT00809055|Drug|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
444643|NCT00809042|Drug|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
444644|NCT00809042|Drug|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
444645|NCT00809042|Drug|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
444695|NCT00808691|Other|Critical care|Standard care for each group of patients
444696|NCT00808678|Drug|ABT-143|once, see arm description for more information
444697|NCT00808678|Drug|ABT-335|once, see arm description for more information
444698|NCT00808678|Drug|rosuvastatin|once, see arm description for more detail
444646|NCT00809042|Drug|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
444647|NCT00809029|Other|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
444648|NCT00809016|Radiation|3-dimensional conformal radiation therapy|
444649|NCT00809016|Radiation|fludeoxyglucose F 18|
444650|NCT00809016|Radiation|intensity-modulated radiation therapy|
444651|NCT00808990|Dietary Supplement|BioFemale|BioFemale 6 months.
444652|NCT00808977|Drug|Dersalazine sodium|Dersalazine sodium 2400 mg daily
444653|NCT00808977|Drug|Mesalazine|Mesalazine 2400 mg daily
444654|NCT00808977|Drug|Placebo|Placebo matching active and experimental treatments
444655|NCT00808964|Drug|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
444656|NCT00808951|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
444657|NCT00808951|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
444658|NCT00808938|Device|MST|Magnetic Seizure Therapy
444659|NCT00808925|Other|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
444660|NCT00808912|Drug|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
444661|NCT00808912|Other|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
444662|NCT00808899|Drug|Temsirolimus|Temsirolimus
444663|NCT00808899|Drug|Irinotecan|Irinotecan
444664|NCT00808899|Procedure|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
444665|NCT00808899|Drug|Cyclophosphamide|Cyclophosphamide
444666|NCT00808899|Drug|Doxorubicin|Doxorubicin
444667|NCT00808899|Drug|Etoposide|Etoposide
444668|NCT00808899|Drug|Cisplatin|Cisplatin
444669|NCT00808899|Drug|Topotecan|Topotecan
444670|NCT00808899|Procedure|PBSC|Peripheral Blood Stem Cell Harvest
444671|NCT00808899|Radiation|Radiation Therapy|Radiation Therapy
444672|NCT00808899|Drug|13-cis-retinoic acid|13-cis-retinoic acid
444673|NCT00808873|Other|socio-educational intervention|brief mental health education and 6 follow-up visits
444674|NCT00808860|Dietary Supplement|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
444675|NCT00808860|Dietary Supplement|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
444676|NCT00808834|Device|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
444677|NCT00808834|Device|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
444678|NCT00808808|Biological|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
444679|NCT00808808|Other|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
444680|NCT00808808|Biological|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
444681|NCT00808795|Drug|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
444682|NCT00808795|Drug|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
444683|NCT00808782|Device|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
444684|NCT00808782|Device|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
444685|NCT00808769|Drug|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
444686|NCT00808769|Drug|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
444687|NCT00808756|Dietary Supplement|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
444688|NCT00808756|Other|Standard infant formula.|Standard infant formula.
444689|NCT00808743|Drug|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
444690|NCT00808743|Drug|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
444691|NCT00808743|Drug|Placebo|"Placebo: orally, 6 months, dosage based on body weight:~below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
444692|NCT00808730|Procedure|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
444693|NCT00808717|Drug|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
444694|NCT00808704|Drug|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
444699|NCT00808665|Drug|Dexmedetomidine|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
444700|NCT00808665|Drug|0.9% Saline|Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
444701|NCT00808652|Other|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.~Study Phases:~Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.~NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
444702|NCT00808639|Drug|Methotrexate|intravenously 30mg/m2 over 30 minutes
444703|NCT00808639|Drug|Doxorubicin|intravenously 30mg/ms over 15 minutes
444704|NCT00808639|Drug|vinblastine|intravenously 3mg/m2 over 30 minutes
444705|NCT00808639|Drug|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
444706|NCT00808639|Drug|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
444707|NCT00808626|Drug|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
444708|NCT00808613|Device|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
444709|NCT00808613|Device|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
444710|NCT00808600|Behavioral|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.~Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
444711|NCT00808600|Behavioral|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
444712|NCT00808600|Behavioral|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
444713|NCT00808600|Behavioral|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
444714|NCT00808574|Behavioral|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
444715|NCT00808561|Other|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
444716|NCT00808561|Other|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
444717|NCT00808548|Other|counseling, emotional support|
444718|NCT00808548|Other|emotional support|emotional support during the interview
444719|NCT00808548|Other|emotional support|emotional supporting during the interview
444720|NCT00808535|Procedure|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
444760|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
444721|NCT00808522|Drug|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
444722|NCT00808509|Biological|adalimumab|40 mg every other week via subcutaneous injection
444723|NCT00808509|Drug|methotrexate|At least 10 mg/week administered orally or subcutaneously
444724|NCT00808496|Other|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).~MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
444725|NCT00808496|Other|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.~Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
444726|NCT00808496|Other|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
444727|NCT00808483|Other|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
444728|NCT00808470|Drug|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
444729|NCT00808470|Other|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
444730|NCT00808444|Biological|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
444731|NCT00808444|Biological|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
444732|NCT00808444|Biological|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
444733|NCT00808444|Biological|Rotarix|Oral, 2 doses
444734|NCT00808431|Behavioral|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
444735|NCT00808418|Drug|Elesclomol Sodium|Chemotherapy agent
444736|NCT00808418|Drug|Docetaxel|Chemotherapy agent
444737|NCT00808405|Drug|acyclovir|400mg taken orally three times daily for 5 days
444738|NCT00808405|Drug|matching placebo|matching placebo taken orally three times daily for 5 days.
444739|NCT00808392|Biological|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
444740|NCT00808392|Biological|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
444741|NCT00808379|Drug|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
444742|NCT00808379|Radiation|Additional Radiation boost to the primary tumor volume|15-20Gy
444743|NCT00808366|Drug|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
444744|NCT00808366|Drug|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
444745|NCT00808340|Device|balafilcon A|multifocal contact lens
444746|NCT00808340|Device|senofilcon A production|multifocal contact lens
444747|NCT00808340|Device|senofilcon A test|multifocal contact lens
444748|NCT00808327|Drug|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
444749|NCT00808327|Drug|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
444750|NCT00808314|Drug|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
444751|NCT00808314|Drug|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
444752|NCT00808301|Other|Gluten-free products|Gluten-free bakery products containing oatmeal.
444753|NCT00808288|Drug|PF-00610355|oral, inhaled, dry powder, 600ug, OD
444754|NCT00808288|Drug|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
444755|NCT00808288|Drug|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
444756|NCT00808288|Drug|Placebo|oral, inhaled, dry powder, placebo, OD
444757|NCT00808288|Drug|Salmeterol|salmeterol, 50ug, BID
444758|NCT00808275|Dietary Supplement|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
444759|NCT00808262|Biological|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
444764|NCT00808236|Device|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
444765|NCT00808236|Other|Control|Advanced cardiac life support according to American Heart Association & European Resuscitation Council 2005 Guidelines
444766|NCT00808223|Biological|alefacept|IM injection
444767|NCT00808210|Drug|infliximab|Intravenous repeating dose
444768|NCT00808210|Drug|methotrexate|Oral or parenteral repeating dose
444769|NCT00808210|Drug|methylprednisolone|Intravenous repeating dose
444770|NCT00808210|Drug|ocrelizumab|Intravenous repeating dose
444771|NCT00808210|Drug|sham|Intravenous repeating dose
444772|NCT00808197|Procedure|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
444773|NCT00808184|Drug|CPT-11, Raltegravir (Isentress®), Midazolam|
444774|NCT00808171|Drug|Livopan|Inhalation of oxygen and nitrous oxide 50%
444775|NCT00808171|Drug|Livopan|equimolar mixture of N2O/O2
444776|NCT00808171|Drug|EMLA|Lidocaine-prilocain cream
444777|NCT00808145|Drug|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
444778|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
444779|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
444780|NCT00808132|Drug|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
444781|NCT00808132|Drug|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
444782|NCT00808132|Drug|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
444783|NCT00808119|Drug|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
444784|NCT00808093|Drug|GSK256073|GSK256073 100 mg study drug
444785|NCT00808080|Biological|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
444786|NCT00808067|Drug|dabigatran dose 1|dabigatran high dose twice daily
444787|NCT00808067|Drug|dabigatran dose 2|dabigatran low dose twice daily
444788|NCT00808054|Drug|EMLA|0.5g topical EMLA
444789|NCT00808041|Device|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
444790|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
444791|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
444792|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
444793|NCT00808028|Other|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
444794|NCT00808015|Drug|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
444795|NCT00808002|Drug|Raltegravir|Raltegravir 400 mg every 12 hours
444796|NCT00808002|Drug|Maraviroc|Maraviroc 300 mg every 12 hours
444797|NCT00808002|Drug|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
444798|NCT00807989|Drug|Carbamazepine|
444799|NCT00807989|Drug|Lamotrigine/Valproate|
444800|NCT00807963|Drug|rHuPH20|recombinant human hyaluronidase PH20 injection
444801|NCT00807963|Drug|zoledronic acid|subcutaneous injection
444802|NCT00807950|Drug|Simvastatin|
444803|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
444804|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
444805|NCT00807937|Drug|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
444806|NCT00807937|Drug|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
444807|NCT00807911|Drug|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
444808|NCT00807911|Drug|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
444809|NCT00807885|Drug|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
444810|NCT00807872|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
444811|NCT00807859|Drug|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
444812|NCT00807859|Drug|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
444813|NCT00807859|Drug|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
444814|NCT00807859|Drug|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
444815|NCT00807846|Drug|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
444816|NCT00807846|Drug|Naproxen|Naproxen 7.5 mg/kg PO BID [maximum of 500 mg BID] for 6 weeks
444817|NCT00807807|Dietary Supplement|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
444818|NCT00807807|Drug|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
444819|NCT00807794|Drug|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
444820|NCT00807794|Drug|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
444821|NCT00807794|Drug|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
444822|NCT00807794|Drug|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
444823|NCT00807794|Drug|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
444824|NCT00807781|Biological|Mammaglobin-A DNA vaccine|
444825|NCT00807768|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
444826|NCT00807768|Drug|Carboplatin|Given IV
444827|NCT00807768|Radiation|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
444828|NCT00807768|Radiation|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
444829|NCT00807768|Other|Laboratory Biomarker Analysis|Correlative studies
444830|NCT00807768|Drug|Paclitaxel|Given IV
444831|NCT00807768|Other|Quality-of-Life Assessment|Ancillary studies
444832|NCT00807768|Other|Questionnaire Administration|Ancillary studies
444833|NCT00807755|Drug|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
444834|NCT00807755|Drug|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
444835|NCT00807755|Drug|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
444836|NCT00807742|Drug|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, 14mg patch for 2 weeks, 7mg patch for 2 weeks. This is supplemental intervention provided to all.
444837|NCT00807742|Behavioral|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
444838|NCT00807742|Behavioral|Contingency Management|Condition provides contingent monetary reinforcement for smoking reductions (first 5 days) then for smoking abstinence (subsequent 14 days). Expired carbon monoxide (CO) levels will be the basis for determining reductions and abstinence.
444839|NCT00807742|Behavioral|Non-Contingent Reinforcement|Controls for effects of receiving payments, providing daily breath samples for CO level, and degree of interaction between patient and research staff. NR will allow them to earn an amount which is matched in amount to the expected average earned in CM contingent only on providing breath samples independent of the CO level attained.
444840|NCT00807729|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
444841|NCT00807729|Procedure|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
444842|NCT00807716|Other|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
444843|NCT00807716|Other|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
444844|NCT00807703|Procedure|Select Stim|Select Stim: see summary
444845|NCT00807690|Drug|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
444846|NCT00807677|Drug|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
444847|NCT00807664|Device|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
444848|NCT00807664|Device|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
444849|NCT00807651|Procedure|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
444850|NCT00807651|Drug|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
444851|NCT00807625|Drug|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
444852|NCT00807625|Device|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
444853|NCT00807612|Biological|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
444854|NCT00807612|Biological|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
444855|NCT00807612|Drug|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
444945|NCT00807053|Drug|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
444946|NCT00807053|Drug|Placebo|Placebo
444856|NCT00807612|Biological|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
444857|NCT00807612|Drug|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
444858|NCT00807599|Procedure|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.~On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
444859|NCT00807599|Drug|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
444860|NCT00807586|Drug|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
444861|NCT00807586|Drug|Placebo|Normal saline (1.6 cc)
444862|NCT00807573|Drug|Paclitaxel|Day 1: Paclitaxel (90 mg/m^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m^2 over 60 minutes)
444863|NCT00807573|Drug|Pemetrexed|Day 1: Pemetrexed (500 mg/m^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
444864|NCT00807573|Drug|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
444865|NCT00807560|Behavioral|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
444866|NCT00807560|Behavioral|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
444867|NCT00807547|Biological|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
444868|NCT00807534|Drug|ipratropium bromide|ipratropium bromide nebulization
444869|NCT00807534|Drug|placebo|placebo nebulization
444870|NCT00807534|Behavioral|constant rate step test|nebulization of 500ug
444871|NCT00807534|Behavioral|constant rate shuttle walk test|nebulization of 500ug
444872|NCT00807521|Drug|Dexamethasone|Single high dose bolus of dexamethasone before surgery
444873|NCT00807521|Drug|Placebo|Placebo for dexamethasone
444874|NCT00807508|Dietary Supplement|placebo|wheat meal capsules with each main meal
444875|NCT00807508|Dietary Supplement|leucine|daily leucine capsules with each main meal
444876|NCT00807495|Drug|Alisertib|Alisertib capsules
444877|NCT00807456|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
444878|NCT00807443|Drug|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp & Dohme. A dose of 400 mg will be administered every 12 hours
444879|NCT00807430|Device|Grindcare (Active)|Active treatment
444880|NCT00807430|Device|Grindcare (Placebo - the device is not activated)|Placebo treatment
444881|NCT00807404|Procedure|histopathologic examination|
444882|NCT00807404|Procedure|optical coherence tomography|
444883|NCT00807391|Procedure|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
444884|NCT00807378|Other|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
444885|NCT00807365|Drug|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, & 5:00 AM for 6 months.
444886|NCT00807339|Radiation|Stereotactic radiation|Dose escalation three consecutive treatments
444887|NCT00807339|Device|CyberKnife Robotic Radiosurgery System|
444888|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
444889|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
444890|NCT00807326|Drug|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
444891|NCT00807300|Radiation|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
444892|NCT00807300|Procedure|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
444893|NCT00807287|Procedure|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
444894|NCT00807287|Procedure|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
444947|NCT00807040|Procedure|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
444984|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
444895|NCT00807261|Drug|Gemcitabine and Docetaxel|"Drug and schedule~Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)~Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days~Dose modification~Treatment should be delayed if the ANC<1,500/ mm3, or if the platelet count <75,000/mm3 on the first day of the next cycle.~Gemcitabine & docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.~Patients with response or no change will receive 2 additional cycles."
444896|NCT00807248|Drug|Escitalopram placebo|Once daily before bedtime for 8 weeks
444897|NCT00807248|Drug|Gaboxadol placebo|Once daily before bedtime for 8 weeks
444898|NCT00807248|Drug|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
444899|NCT00807248|Drug|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
444900|NCT00807248|Drug|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
444901|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
444902|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
444903|NCT00807222|Drug|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
444904|NCT00807209|Drug|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
444905|NCT00807209|Drug|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
444906|NCT00807209|Drug|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
444907|NCT00807209|Drug|Fentanyl via PCA|Fentanyl via PCA
444908|NCT00807209|Drug|Bupivacaine via epidural|Bupivacaine via epidural
444909|NCT00807196|Drug|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
444910|NCT00807196|Drug|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
444911|NCT00807196|Drug|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
444912|NCT00807196|Drug|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
444913|NCT00807196|Other|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
444914|NCT00807183|Other|woodstove|installation of new EPA-certified woodstove
444915|NCT00807183|Other|inactive air filter|air filter units without filter in place
444916|NCT00807183|Other|Active air filter|air filter units correctly operating
444917|NCT00807170|Drug|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
444918|NCT00807170|Radiation|Whole Brain Radiotherapy (WBRT)|
444919|NCT00807170|Drug|ZD6474|200 mg as a once daily oral dose, 21 days
444920|NCT00807170|Drug|ZD6474|300 mg as a once daily oral dose, 21 days
444921|NCT00807157|Dietary Supplement|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
444922|NCT00807157|Dietary Supplement|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
444923|NCT00807144|Drug|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
444924|NCT00807144|Drug|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
444925|NCT00807131|Behavioral|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
444926|NCT00807131|Behavioral|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
444927|NCT00807131|Behavioral|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
444928|NCT00807131|Behavioral|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
444929|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
444930|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
444931|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
444932|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
444933|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
444934|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
444935|NCT00807105|Device|H-coil dTMS|treatment with deep TMS stimulation.
444936|NCT00807092|Drug|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
444937|NCT00807092|Drug|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
444938|NCT00807092|Drug|metformin|Metformin dose must remain the same as that used prior to the trial.
444939|NCT00807079|Drug|carboplatin|
444940|NCT00807079|Drug|topotecan hydrochloride|
444941|NCT00807066|Drug|Gefitinib|Gefitinib 250 mg/day
444942|NCT00807066|Drug|Platinum|Platinum based chemotherapy with cycles every 21 days
444943|NCT00807053|Drug|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
444944|NCT00807053|Drug|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
444948|NCT00807040|Procedure|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
444949|NCT00807027|Drug|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention~Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
444950|NCT00807014|Drug|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
444951|NCT00807014|Drug|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
444952|NCT00807001|Drug|IDX184|oral dose, active or placebo
444953|NCT00806988|Procedure|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:~All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.~The heart will be arrested with cardioplegia.~A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
444954|NCT00806988|Procedure|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
444955|NCT00806975|Device|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
444956|NCT00806962|Drug|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
444957|NCT00806962|Device|placebo|intranasal, puff of air, 2 doses, 21 days apart
444958|NCT00806962|Biological|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
444959|NCT00806962|Biological|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
444960|NCT00806936|Drug|human insulin|Any kind of human insulin administered at the discretion of the physician
444961|NCT00806936|Drug|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
444962|NCT00806923|Drug|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
444963|NCT00806923|Drug|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
444964|NCT00806923|Drug|Placebo|iv on day 1 of each 3 week cycle until disease progression
444965|NCT00806923|Drug|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
444966|NCT00806923|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
444967|NCT00806910|Drug|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
444968|NCT00806910|Other|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
444969|NCT00806897|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
444970|NCT00806884|Other|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
444971|NCT00806884|Other|Control group measurements|None other than control group measurements
444972|NCT00806871|Drug|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use~1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
444973|NCT00806871|Drug|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.~2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
444974|NCT00806871|Drug|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use~1 ml 10 mg Lidocaine + 2 ml saline"
444975|NCT00806858|Device|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
444976|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
444977|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
444978|NCT00806819|Drug|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
444979|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
444980|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
444981|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
444982|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
444983|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
444985|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
444986|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
444987|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
444988|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
444989|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
444990|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
444991|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
444992|NCT00806806|Drug|SKY0402|Local administration of SKY0402 followed by noxious stimulus
444993|NCT00806806|Drug|Placebo|Local administration of Placebo followed by noxious stimuli
444994|NCT00806780|Procedure|on table cholangiography|x-ray imaging of common bile duct
444995|NCT00806767|Biological|therapeutic immune globulin|
444996|NCT00806767|Drug|busulfan|
444997|NCT00806767|Drug|fludarabine phosphate|
444998|NCT00806767|Procedure|allogeneic hematopoietic stem cell transplantation|
444999|NCT00806754|Drug|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
445000|NCT00806754|Drug|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
445001|NCT00806741|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
445002|NCT00806741|Drug|Phenylephrine|1μg/kg/min, infusion period 20 minutes
445003|NCT00806741|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
445004|NCT00806741|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
445005|NCT00806741|Device|Goldmann applanation tonometer|intraocular pressure measurements
445006|NCT00806741|Other|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
445007|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
445008|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
445009|NCT00806689|Procedure|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
445010|NCT00806689|Device|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
445011|NCT00806676|Drug|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
445012|NCT00806663|Drug|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
445013|NCT00806650|Genetic|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
445014|NCT00806650|Genetic|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
445015|NCT00806650|Diagnostic Test|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
445016|NCT00806650|Other|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
445017|NCT00806650|Other|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
445018|NCT00806637|Procedure|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
445019|NCT00806637|Procedure|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
445020|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
445021|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
445022|NCT00806624|Drug|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
445023|NCT00806611|Procedure|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
445024|NCT00806598|Drug|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days~Aplastic anemia patients receive 3.5 mg/kg/day for 5 days~MDS patients <55 years receive 3.5 mg/kg/day for 5 days~MDS patients >55 years receive 2.5 mg/kg/day for 5 days"
445240|NCT00804934|Drug|Lucentis|0.5mg Lucentis every four months
445025|NCT00806598|Drug|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
445026|NCT00806598|Drug|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
445027|NCT00806598|Drug|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
445028|NCT00806585|Drug|MK-0736|
445029|NCT00806585|Drug|Comparator: Placebo|
445030|NCT00806585|Drug|Comparator: HCTZ|
445031|NCT00806572|Drug|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
445032|NCT00806559|Other|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
445033|NCT00806559|Other|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
445034|NCT00806546|Drug|NP101|NP101 study patch four hour application
445035|NCT00806533|Drug|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
445036|NCT00806507|Procedure|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
445037|NCT00806507|Procedure|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
445038|NCT00806494|Drug|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
445039|NCT00806481|Drug|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
445040|NCT00806481|Drug|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
445041|NCT00806468|Drug|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
445042|NCT00806442|Drug|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
445043|NCT00806442|Dietary Supplement|Corn Oil|9 g/day of corn oil
445044|NCT00806429|Procedure|transvaginal appendectomy|patient undergoes transvaginal appendectomy
445045|NCT00806416|Drug|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
445046|NCT00806416|Drug|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
445047|NCT00806416|Dietary Supplement|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
445048|NCT00806403|Drug|reteplase 10+10 U|comparison to primary PCI
445049|NCT00806403|Procedure|primary PCI|comparison to thrombolysis
445050|NCT00806390|Drug|Metoprolol|Metroprolol tartrate titrated up
445051|NCT00806351|Drug|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
445052|NCT00806351|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
445053|NCT00806338|Drug|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
445054|NCT00806338|Drug|Placebo|
445055|NCT00806299|Drug|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
445056|NCT00806299|Drug|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
445057|NCT00806299|Drug|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
445058|NCT00806286|Drug|CS7017 tablets|CS7017 tablets, strength 0.25mg, two tablets, two times daily for twenty-five to thirty months
445059|NCT00806286|Drug|Paclitaxel|IV, 200mg/m2, once every three weeks for up to 18 weeks
445060|NCT00806286|Drug|Carboplatin|IV, AUC of 6, once every three weeks for up to 18 weeks
445061|NCT00806286|Drug|Placebo Tablets|Placebo tablets matching CS-7017 tablets
445062|NCT00806273|Device|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
445063|NCT00806273|Device|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
445064|NCT00806260|Drug|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
445065|NCT00806260|Drug|Placebo|Placebo daily for 4 weeks
445066|NCT00806260|Other|Alcohol|
445067|NCT00806260|Other|alcohol placebo|fruit juice
445068|NCT00806247|Drug|tapentadol HCl|
445069|NCT00806234|Drug|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
445070|NCT00806234|Drug|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
445071|NCT00806234|Drug|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
445072|NCT00806221|Drug|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
445073|NCT00806208|Drug|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
445241|NCT00804921|Drug|bevacizumab|
445074|NCT00806208|Drug|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
445075|NCT00806208|Drug|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
445076|NCT00806208|Drug|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
445077|NCT00806208|Other|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
445078|NCT00806195|Biological|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
445079|NCT00806195|Biological|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
445080|NCT00806195|Biological|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
445081|NCT00806195|Biological|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
445082|NCT00806195|Biological|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
445083|NCT00806195|Biological|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
445084|NCT00806195|Biological|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
445085|NCT00806195|Biological|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
445086|NCT00806169|Drug|triamcinolone and bevacizumab|
445087|NCT00806156|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
445088|NCT00806156|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
445089|NCT00806143|Device|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.~In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
445090|NCT00806143|Device|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
445091|NCT00806117|Radiation|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks~Lateral: 2 cm lateral to the bony margin of the pelvis~Superior: Between L5 and S1~Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
445092|NCT00806117|Other|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
445093|NCT00806117|Other|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135~175mg/m2 over 3 hours Cisplatin 60~75mg/m2
445094|NCT00806104|Dietary Supplement|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
445095|NCT00806104|Dietary Supplement|Maltodextrins|Dietary supplementation for 4 weeks
445096|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
445097|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
445098|NCT00806065|Drug|ENMD-2076|Oral capsules, once daily in 28-day cycles
445099|NCT00806039|Other|Early Renal Involvement|Renal Consultation
445100|NCT00806026|Drug|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
445101|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
445102|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
445103|NCT00806026|Drug|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
445104|NCT00806026|Drug|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
445105|NCT00806026|Drug|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
445106|NCT00805974|Biological|Biological examinations (blood and urinary).|
445107|NCT00805961|Radiation|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
445108|NCT00805961|Drug|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
445109|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
445110|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
445111|NCT00805961|Drug|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
445112|NCT00805948|Device|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aortic aneurysms using the Talent Thoracic Stent Graft System.
445113|NCT00805935|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
445114|NCT00805935|Drug|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
445115|NCT00805935|Drug|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
445116|NCT00805935|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
445117|NCT00805935|Drug|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
445118|NCT00805922|Other|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
445119|NCT00805909|Drug|NI-0401|5 daily infusions with escalating doses of NI-0401
445120|NCT00805896|Drug|Songyou|4g/pack
445121|NCT00805896|Drug|placebo|4g/pack
445122|NCT00805883|Procedure|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
445123|NCT00805870|Drug|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
445124|NCT00805870|Drug|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
445125|NCT00805857|Drug|Tipranavir|
445126|NCT00805831|Device|HDH|sutureless vascular anastomosis
445127|NCT00805818|Drug|NNZ-2566|"Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
445128|NCT00805818|Drug|Placebo|Sodium Chloride 0.9% Injection
445129|NCT00805805|Drug|Tetrathiomolybdate|120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
445130|NCT00805805|Other|Placebo|Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
445131|NCT00805792|Drug|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
445132|NCT00805779|Device|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
445133|NCT00805766|Drug|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
445134|NCT00805753|Drug|ACTH|comparison of different dosages of drug
445135|NCT00805740|Drug|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
445136|NCT00805740|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
445137|NCT00805701|Drug|avodart|0.5 avodart once daily for 13 weeks
445138|NCT00805701|Drug|Placebo|placebo
445139|NCT00805688|Behavioral|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
445140|NCT00805688|Procedure|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
445141|NCT00805688|Device|Pedometer|Worn daily to measure physical activity.
445142|NCT00805675|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
445143|NCT00805675|Drug|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
445144|NCT00805675|Drug|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
445145|NCT00805662|Drug|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
445146|NCT00805649|Procedure|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
445147|NCT00805649|Procedure|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
445148|NCT00805649|Drug|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
445149|NCT00805649|Drug|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
445150|NCT00805649|Procedure|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
445151|NCT00805649|Drug|triamcincolone|intravitreal injection of 8 mg triamcincolone
445152|NCT00805636|Drug|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|[18F]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for [18F]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of [18F]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
445153|NCT00805636|Radiation|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
445154|NCT00805636|Procedure|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of [18F]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
445155|NCT00805623|Dietary Supplement|sucrose|1 cc of sucrose 33.5% with or without pacifier
445156|NCT00805610|Biological|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
445157|NCT00805597|Radiation|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
445158|NCT00805597|Radiation|no radiation|no radiotherapy
445159|NCT00805584|Drug|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
445160|NCT00805558|Drug|moxifloxacin|400 mg moxifloxacin once daily for 7 days
445161|NCT00805558|Drug|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
445162|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
445163|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
445164|NCT00805532|Behavioral|Behavioral Activation treatment|Behavioral Activation (BA) is a present-focused psychotherapy based on behavioral theory and principles of change, that aims to re-engage individuals with meaningful and pleasurable life activities by targeting and problem-solving patterns of avoidance. It is well-established as a treatment for depression and has been modified for the current study to address PTSD-related problems.
445165|NCT00805532|Other|Treatment as Usual|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
445166|NCT00805519|Drug|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
445167|NCT00805519|Drug|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
445168|NCT00805519|Drug|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
445169|NCT00805519|Drug|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
445170|NCT00805493|Drug|Riluzole|
445171|NCT00805480|Drug|AIN457|AIN457 was administered intravenously.
445172|NCT00805480|Drug|Placebo|Matching placebo to AIN457 was administered intravenously.
445173|NCT00805467|Drug|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
445174|NCT00805454|Drug|OPC-34712|Single oral dose, 0.5 to 25 mg
445175|NCT00805441|Drug|LY686017|50 milligrams (mg) daily by oral route for 12 weeks
445176|NCT00805441|Drug|Placebo|Daily by oral route for 12 weeks
445177|NCT00805415|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
445178|NCT00805415|Drug|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
445179|NCT00805402|Other|flow cytometry|flow cytometry
445180|NCT00805389|Biological|Engerix-B™|2 doses intramuscular injections
445181|NCT00805389|Biological|Fendrix™|2 doses intramuscular injections
445182|NCT00805389|Biological|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
445183|NCT00805389|Biological|HBsAg (Booster injection)|Single dose intramuscular injection
445184|NCT00805376|Drug|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
445185|NCT00805376|Procedure|Tumor Removal|Surgical Tumor Resection
445186|NCT00805350|Drug|Eplivanserin|one 5 mg tablet once a day
445187|NCT00805350|Drug|Placebo|Placebo of Eplivanserin one tablet once a day
445188|NCT00805337|Device|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
445189|NCT00805324|Drug|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
445190|NCT00805311|Procedure|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
445191|NCT00805311|Drug|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
445192|NCT00805298|Drug|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
445193|NCT00805298|Drug|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
445194|NCT00805298|Drug|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
445195|NCT00805298|Drug|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
445196|NCT00805285|Drug|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
445197|NCT00805272|Other|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
445198|NCT00805259|Behavioral|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
445199|NCT00805233|Drug|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
445200|NCT00805233|Drug|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
445201|NCT00805220|Other|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
445202|NCT00805207|Drug|Progesterone|Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.
445203|NCT00805207|Drug|testosterone|Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
445204|NCT00805207|Drug|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.
445205|NCT00805207|Device|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.
445206|NCT00805207|Drug|Estrogen|Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.
445207|NCT00805207|Other|Control|No treatment with studies performed 31 to 72 days apart
445208|NCT00805194|Drug|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
445209|NCT00805194|Drug|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
445210|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
445211|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
445212|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
445213|NCT00805142|Drug|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
445214|NCT00805129|Drug|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
445215|NCT00805116|Dietary Supplement|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
445216|NCT00805116|Dietary Supplement|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
445217|NCT00805103|Radiation|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
445218|NCT00805090|Drug|Sporanox|200 mg
445219|NCT00805090|Drug|Diclofenac Sodium|37.5 mg
445220|NCT00805077|Procedure|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
445221|NCT00805077|Other|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
445222|NCT00805064|Drug|triamcinolone and bevacizumab|
445223|NCT00805038|Behavioral|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
445224|NCT00805038|Behavioral|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
445225|NCT00805025|Drug|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
445226|NCT00805012|Drug|docetaxel+CDDP|docetaxel+CDDP
445227|NCT00805012|Drug|docetaxel+S-1|docetaxel+S-1
445228|NCT00804999|Drug|Clear Care|neutralized Clear Care
445229|NCT00804999|Drug|ReNu|overnight soak in solution
445230|NCT00804999|Drug|OPTI-FREE|overnight soak in solution
445231|NCT00804986|Drug|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
445232|NCT00804986|Drug|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
445233|NCT00804973|Drug|LY2590443|200mg as 4-50 mg capsules, oral, once
445234|NCT00804973|Drug|Placebo injection|saline solution, injection, once
445235|NCT00804973|Drug|Sumatriptan|6mg injection (0.5mL of 12mg/mL solution), once
445236|NCT00804973|Drug|Placebo capsule|4 capsules, once
445237|NCT00804960|Drug|Letrozole|1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
445238|NCT00804960|Drug|Std IVF Protocol|2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
445239|NCT00804947|Drug|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
445245|NCT00804908|Drug|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
445246|NCT00804908|Drug|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
445247|NCT00804908|Other|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
445248|NCT00804895|Drug|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
445249|NCT00804895|Drug|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
445250|NCT00804895|Drug|Verapamil|standard prophylactic treatment
445251|NCT00804869|Device|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
445252|NCT00804869|Device|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
445253|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
445254|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
445255|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
445256|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
445257|NCT00804843|Drug|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
445258|NCT00804843|Drug|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
445259|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
445260|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
445261|NCT00804830|Drug|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
445262|NCT00804817|Behavioral|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
445263|NCT00804817|Behavioral|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.~The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
445264|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
445265|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
445266|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
445267|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
445268|NCT00804791|Other|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
445269|NCT00804791|Other|Unisol 4 Saline Solution|saline solution for irrigating the cornea
445270|NCT00804765|Other|Therapeutic education|Intensive training individual and collective teaching
445271|NCT00804765|Other|Follow-up|classical follow-up with two individual consultations
445272|NCT00804752|Drug|Adding vitamin D|Adding 1000IU/Vitamin D daily
445273|NCT00804752|Drug|Vitamin D|Addition of 1000IU/day Vitamin D
445274|NCT00804739|Other|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
445275|NCT00804726|Device|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
445276|NCT00804713|Drug|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
445277|NCT00804713|Drug|TST|Administer TB Skin test (TST)
445278|NCT00804713|Other|QFT|Perform QFT TB test
445279|NCT00804713|Other|T-spot|Perform T-Spot TB test
445280|NCT00804700|Behavioral|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
445281|NCT00804687|Other|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
445282|NCT00804687|Drug|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
445283|NCT00804687|Drug|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
445284|NCT00804674|Drug|bupivacain|
445285|NCT00804674|Drug|placebo|
445286|NCT00804661|Device|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
445287|NCT00804648|Drug|Timolol Maleate in Sorbate|0.5%
445288|NCT00804648|Drug|Timolol hemihydrate|0.5%
445289|NCT00804648|Drug|Timolol maleate gel forming solution|0.5%
445290|NCT00804622|Drug|telbivudine|daily oral administration,600mg,over 12 weeks
445291|NCT00804622|Drug|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
445292|NCT00804622|Drug|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
445293|NCT00804609|Drug|DepoDur following epidural lidocaine|"All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.~Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration."
445294|NCT00804609|Drug|DepoDur following spinal anesthetic|"Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.~Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug."
445295|NCT00804596|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
445296|NCT00804570|Drug|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
445297|NCT00804570|Drug|placebo|once daily, orally, 16 weeks
445298|NCT00804544|Device|SPECT/CT|SPECT/Low-Dose MultiSclice CT
445299|NCT00804531|Drug|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
445300|NCT00804531|Drug|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
445301|NCT00804518|Other|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at ~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
445302|NCT00804505|Device|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
445303|NCT00804505|Device|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
445304|NCT00804492|Behavioral|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
445305|NCT00804479|Other|No intervention.|
445306|NCT00804466|Device|OncoE6|HPV oncoprotein assay
445307|NCT00804466|Device|EVA System|low-cost colposcope
445308|NCT00804453|Device|Cartridge blood set|Once a week
445309|NCT00804453|Device|Standard blood line|Once a week
445310|NCT00804440|Drug|Ibuprofen Tablets, 800 mg|
445311|NCT00804427|Dietary Supplement|Fish oil (90% triglycerides)|
445312|NCT00804427|Dietary Supplement|Fish oil (60% triglycerides)|
445313|NCT00804427|Dietary Supplement|Fish oil (ethyl esters)|
445314|NCT00804427|Dietary Supplement|Soy oil|
445315|NCT00804414|Drug|SBG|Solution for topical use
445316|NCT00804414|Drug|Placebo Comparator|Solutin for topical use
445317|NCT00804401|Drug|Naproxen Tablets, 500 mg|
445318|NCT00804388|Procedure|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
445319|NCT00804375|Drug|2PX|cutaneous solution to be applied twice daily for 84 days
445320|NCT00804375|Drug|Placebo|cutaneous solution to be applied twice daily for 84 days
445321|NCT00804349|Device|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
445322|NCT00804336|Drug|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
445323|NCT00804336|Drug|RAD001|Given orally once a day
445324|NCT00804323|Procedure|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
445325|NCT00804310|Drug|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
445326|NCT00804310|Drug|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
445327|NCT00804297|Drug|Octreotide (drug)|
445328|NCT00804284|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
445329|NCT00804284|Biological|Other DTap Vaccines|0.5 mL, Intramuscular
445330|NCT00804271|Drug|memantine|memantine tablets, OD, 12 weeks
445331|NCT00804258|Drug|intraperitoneal chemotherapy|
445332|NCT00804258|Other|educational intervention|
445333|NCT00804258|Other|medical chart review|
445334|NCT00804258|Other|questionnaire administration|
445335|NCT00804258|Procedure|assessment of therapy complications|
445336|NCT00804258|Procedure|end-of-life treatment/management|
445337|NCT00804258|Procedure|psychosocial assessment and care|
445338|NCT00804258|Procedure|quality-of-life assessment|
445339|NCT00804245|Procedure|needle biopsy|Biopsy of positive findings found on CT scan
445340|NCT00804245|Drug|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
445341|NCT00804232|Behavioral|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
445342|NCT00804219|Biological|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
445343|NCT00804206|Drug|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
445344|NCT00804206|Drug|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
445345|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension|topical suspension
445346|NCT00804193|Drug|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
445347|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
445348|NCT00804180|Behavioral|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
445349|NCT00804154|Drug|Intrathecal Resiniferatoxin|phase I, single-site, non-randomized, open-label, dose- escalation study to determine the safety and efficacy of IT RTX in subjects with severe refractory pain due to advanced malignancy
445350|NCT00804141|Drug|N-methylnaltrexone bromide (MOA-728)|MOA-728 will be administered as per the dose and schedule specified in the arm.
445351|NCT00804128|Procedure|contrast-enhanced magnetic resonance imaging|
445352|NCT00804115|Drug|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
445353|NCT00804102|Device|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
445354|NCT00804102|Device|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
445355|NCT00804089|Procedure|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
445356|NCT00804089|Procedure|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
445357|NCT00804089|Procedure|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
445358|NCT00804076|Biological|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
445359|NCT00804063|Procedure|drawing blood sample|fasting blood sample
445360|NCT00804050|Drug|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
445361|NCT00804050|Drug|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
445362|NCT00804037|Procedure|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
445363|NCT00804024|Device|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
445364|NCT00804011|Other|ATC|Automatic tube compensation
445365|NCT00804011|Other|PSV|Pressure support ventilation
445366|NCT00803985|Procedure|Total Extraperitoneal repair (TEP)|Operation for primary inguinal hernias i men
445367|NCT00803985|Procedure|Lichtenstein|Operation for primary inguinal hernias i men
445368|NCT00803972|Drug|rHuPH20|recombinant human hyaluronidase PH20
445369|NCT00803972|Drug|Insulin Human Injection|injection
445370|NCT00803972|Drug|Insulin Lispro Injection|injection
445371|NCT00803959|Other|Office evaluation|Office evaluation
445372|NCT00803959|Other|UDS|Urodynamics
445373|NCT00803946|Drug|Ibuprofen Tablets, 800 mg|
445374|NCT00803933|Drug|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
445375|NCT00803933|Drug|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
445376|NCT00803907|Drug|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
445377|NCT00803894|Drug|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
445378|NCT00803894|Drug|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
445379|NCT00803894|Drug|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
445380|NCT00803881|Other|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
445381|NCT00803868|Drug|varenicline|up to 1mg po bid for 9 weeks
445382|NCT00803868|Drug|placebo|placebo matching study drug up to 1mg po bid
445383|NCT00803855|Drug|AZD1446|oral, single dose
445633|NCT00802061|Behavioral|Sleeping position in glaucoma patient|
445384|NCT00803842|Drug|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
445385|NCT00803829|Other|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
445386|NCT00803816|Drug|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
445387|NCT00803803|Drug|Pilocarpine Concentration|Varying concentration 0.5 to 8%
445388|NCT00803803|Drug|Pilocarpine Frequency|1 to 4 times daily
445389|NCT00803790|Drug|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
445390|NCT00803790|Drug|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
445391|NCT00803790|Dietary Supplement|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
445392|NCT00803777|Device|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
445393|NCT00803764|Drug|Naproxen Tablets, 500 mg|
445394|NCT00803751|Device|Truview EVO2 laryngoscope|will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
445395|NCT00803751|Device|Macintosh laryngoscope|Intubation using the traditional Macintosh laryngoscope
445396|NCT00803738|Drug|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
445397|NCT00803738|Drug|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
445398|NCT00803725|Drug|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
445399|NCT00803725|Drug|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
445400|NCT00803712|Drug|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
445401|NCT00803712|Drug|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
445402|NCT00803699|Dietary Supplement|placebo|daily placebo capsules for 12 months
445403|NCT00803699|Dietary Supplement|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
445404|NCT00803686|Drug|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
445405|NCT00803686|Drug|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
445406|NCT00803686|Drug|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
445407|NCT00803686|Drug|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
445408|NCT00803673|Drug|100mcg|100mcg '719
445409|NCT00803673|Drug|500mcg|500mcg '719
445410|NCT00803673|Drug|1000mcg|1000mcg '719
445411|NCT00803673|Drug|Placebo|Placebo '719
445412|NCT00803647|Biological|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
445413|NCT00803647|Drug|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
445414|NCT00803647|Drug|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
445415|NCT00803647|Drug|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
445416|NCT00803634|Drug|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
445417|NCT00803634|Drug|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
445418|NCT00803621|Other|Toxoplasma PCR assay|Toxoplasma PCR assay
445419|NCT00803608|Device|TrueContour® Insole|Novel designed insole
445420|NCT00803608|Device|Current standard of care insole|Current Medicare approved A5513 insole
445421|NCT00803595|Drug|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
445422|NCT00803595|Drug|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
445423|NCT00803595|Drug|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
445424|NCT00803582|Procedure|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
445425|NCT00803582|Procedure|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
445426|NCT00803569|Biological|ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine|The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.
445427|NCT00803569|Biological|Sargramostim|The GM-CSF sargramostim is administered at a dose of 100 μg SC.
445428|NCT00803556|Drug|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
445429|NCT00803556|Drug|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
445430|NCT00803556|Drug|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
445431|NCT00803543|Drug|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
445432|NCT00803543|Drug|Placebo|Dosage: Two tablets once a day for 24 weeks
445433|NCT00803530|Drug|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.~The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
445434|NCT00803504|Procedure|ocular blood flow measurement|
445435|NCT00803491|Other|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
445436|NCT00803491|Other|Traditional rheumatology care.|Individually base.
445437|NCT00803478|Procedure|LASIK|
445438|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
445439|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
445440|NCT00803452|Drug|doxycycline|Oral doxycycline 100mg bid
445441|NCT00803452|Drug|azithromycin|topical 1% azithromycin daily to eye
445442|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
445443|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
445444|NCT00803426|Procedure|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
445445|NCT00803413|Behavioral|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
445446|NCT00803413|Behavioral|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
445447|NCT00803413|Behavioral|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
445448|NCT00803413|Behavioral|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
445449|NCT00803400|Drug|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.~Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
445450|NCT00803400|Drug|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine the functional capacity expressed in Metabolic Equivalents of Task (METs), and their maximum heart rates to standardize the future exercise indication.~Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.~At the same time they have to follow a protocolized aerobic exercise plan for this study 3 times a week for 12 weeks.~The type of selected exercise consists of a rapid walk (both in not inclined treadmill or natural courses) for 30 minutes divided in stages.~After each stage the patient has to control his own heart frequency that has to be maintained between 50 and 75% of their maximum not to turn to an anaerobic condition, according to the American Cardiological Association."
445451|NCT00803387|Drug|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
445799|NCT00801138|Drug|ropivacaine|30 ml 0.5% ropivacaine
445452|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
445453|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
445454|NCT00803374|Drug|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
445455|NCT00803374|Drug|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
445456|NCT00803374|Drug|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
445457|NCT00803374|Drug|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
445458|NCT00803361|Drug|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
445459|NCT00803361|Drug|Placebo|placebo capsules, oral, once a day for 15 weeks
445460|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
445461|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
445462|NCT00803348|Drug|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
445463|NCT00803335|Drug|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
445464|NCT00803335|Drug|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
445465|NCT00803309|Drug|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
445466|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
445467|NCT00803309|Drug|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
445468|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
445469|NCT00803296|Other|Oral glucose tolerance test (OGTT)|
445470|NCT00803296|Other|Isoglycemic intravenous glucose infusion|
445471|NCT00803283|Drug|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
445472|NCT00803283|Drug|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
445473|NCT00803270|Drug|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
445474|NCT00803270|Procedure|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
445475|NCT00803257|Other|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
445476|NCT00803244|Drug|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
445477|NCT00803244|Drug|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
445478|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
445479|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
445480|NCT00803205|Drug|Ataluren (PTC124)|Ataluren PO
445481|NCT00803205|Drug|Placebo|Placebo PO
445482|NCT00803192|Drug|Famotidine Tablets, 40 mg|
445483|NCT00803179|Drug|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
445484|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
445485|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
445486|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
445487|NCT00803153|Procedure|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
445488|NCT00803140|Procedure|Cautery vs Active Control Arm (Scalpel)|"Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.~A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.~The closure will be standardized."
445489|NCT00803127|Device|vs-sense|detection swab
445490|NCT00803114|Drug|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
445491|NCT00803114|Drug|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
445492|NCT00803101|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
445493|NCT00803101|Biological|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
445494|NCT00803088|Device|The Alair System|Treatment of airways with the Alair System
445495|NCT00803075|Device|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
445496|NCT00803062|Biological|Bevacizumab|Given IV
445497|NCT00803062|Drug|Cisplatin|Given IV
445498|NCT00803062|Other|Laboratory Biomarker Analysis|Correlative studies
445499|NCT00803062|Drug|Paclitaxel|Given IV
445500|NCT00803062|Other|Quality-of-Life Assessment|Ancillary studies
445501|NCT00803062|Other|Questionnaire Administration|Ancillary studies
445502|NCT00803062|Drug|Topotecan Hydrochloride|Given IV
445503|NCT00803049|Drug|Teriflunomide (HMR1726)|Tablet, oral administration QD.
445504|NCT00803023|Drug|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
445505|NCT00803023|Drug|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
445506|NCT00803023|Drug|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
445507|NCT00803023|Drug|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
445508|NCT00803010|Drug|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
445509|NCT00803010|Drug|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
445510|NCT00803010|Drug|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
445511|NCT00802997|Device|Sinergy|radiofrequency denervation
445512|NCT00802997|Device|Placebo sham|sham procedure
445513|NCT00802984|Device|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
445514|NCT00802971|Dietary Supplement|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
445515|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
445516|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
445517|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
445518|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
445519|NCT00802932|Device|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
445520|NCT00802932|Device|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
445521|NCT00802919|Drug|Varenicline|Varenicline 1-2 mg/day
445522|NCT00802919|Drug|Placebo for varenicline|Placebo
445523|NCT00802906|Device|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
445524|NCT00802906|Drug|bevacizumab|1.5 mg initial intravitreal injection
445525|NCT00802893|Drug|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
445526|NCT00802893|Other|Placebo|placebo given BID for entire length of study
445527|NCT00802880|Drug|Dacarbazine|
445528|NCT00802867|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
445529|NCT00802841|Drug|nilotinib|Supplied as 200 mg tablets
445530|NCT00802841|Drug|imatinib|Supplied as 100 mg and 400 mg tablets
445531|NCT00802828|Drug|Famotidine Tablets, 40 mg|
445532|NCT00802815|Drug|Etanercept|50 milligrams subcutaneously every week
445533|NCT00802802|Drug|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
445534|NCT00802802|Drug|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
445535|NCT00802776|Procedure|Femtosecond laser assisted keratoplasty|
445536|NCT00802776|Procedure|PKP|
445537|NCT00802763|Device|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
445538|NCT00802737|Drug|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
445539|NCT00802724|Behavioral|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
445540|NCT00802724|Behavioral|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
445541|NCT00802711|Radiation|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
445542|NCT00802711|Radiation|brachytherapy|Given twice a day for 10 fractions
445543|NCT00802698|Device|Transcorneal electric stimulation|central artery occlusion
445544|NCT00802698|Device|Transcorneal stimulation|new waveform
445545|NCT00802698|Device|transcorneal electric stimulation|Novel waveform central artery occlusion
445546|NCT00802685|Drug|Early ibuprofen|"IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen."
445547|NCT00802685|Other|Late ibuprofen expectant group (placebo)|"Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
445548|NCT00802672|Drug|Ciclopirox Olamine Cream|topical cream
445549|NCT00802672|Drug|Loprox Cream 0.77%|topical cream
445550|NCT00802672|Drug|Placebo|topical cream
445551|NCT00802659|Radiation|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
445552|NCT00802646|Drug|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
445553|NCT00802646|Drug|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
445554|NCT00802633|Device|Stapling device during radical cystectomy|Hemostasis
445555|NCT00802633|Device|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
445556|NCT00802620|Procedure|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
445557|NCT00802594|Drug|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
445558|NCT00802581|Procedure|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
445559|NCT00802581|Procedure|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
445560|NCT00802568|Biological|anti-thymocyte globulin|
445561|NCT00802568|Drug|busulfan|
445562|NCT00802568|Drug|fludarabine phosphate|
445563|NCT00802568|Procedure|allogeneic bone marrow transplantation|
445564|NCT00802568|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
445565|NCT00802555|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
445566|NCT00802529|Drug|Methylprednisolone|2 transtympanic injections at interval of two weeks.
445567|NCT00802529|Drug|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
445568|NCT00802516|Dietary Supplement|stanol ester|enriched margarine
445569|NCT00802516|Dietary Supplement|sterol ester|enriched margarine
445570|NCT00802516|Dietary Supplement|No intervention|placebo margarine
445571|NCT00802503|Dietary Supplement|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line.
445572|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
445573|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
445574|NCT00802477|Procedure|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
445575|NCT00802477|Procedure|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
445576|NCT00802464|Biological|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
445577|NCT00802464|Biological|Placebo|2 vaccinations at Months 0 and 2 with placebo
445578|NCT00802451|Drug|Mesalamine|
445579|NCT00802438|Biological|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
445580|NCT00802425|Drug|AM-111|single intratympanic injection
445581|NCT00802425|Drug|placebo|single intratympanic injection
445582|NCT00802412|Drug|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
445583|NCT00802412|Drug|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
445584|NCT00802399|Procedure|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
445585|NCT00802373|Drug|Solifenacin succinate|oral
445587|NCT00802360|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
445588|NCT00802360|Drug|Progestrone vaginal insert|100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
445589|NCT00802360|Drug|follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
445590|NCT00802360|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
445591|NCT00802360|Drug|Ganirelix|Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
445592|NCT00802347|Drug|I5NP|"Single IV injection of I5NP~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
445593|NCT00802347|Drug|Saline|"Single IV injection of saline~Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg~Part B: 10.0 mg/kg"
445594|NCT00802334|Drug|generic lopinavir/ritonavir|"Screening visit~• Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available~Baseline visit~• (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician~Week 4~Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)~Clinical, safety and laboratory assessment~Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
445595|NCT00802321|Drug|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
445596|NCT00802308|Drug|Morphine sulphate|Extended release tablet combined with alcohol or water
445597|NCT00802295|Drug|Gonadotrophins|Administration of standard ovarian stimulation protocol
445598|NCT00802295|Drug|Low dosis Gonadotrophin|
445599|NCT00802282|Drug|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
445600|NCT00802282|Behavioral|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
445601|NCT00802282|Behavioral|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
445602|NCT00802269|Procedure|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
445603|NCT00802256|Procedure|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
445604|NCT00802243|Drug|leflunomide|
445605|NCT00802230|Drug|Terbutaline Infusion|
445606|NCT00802217|Drug|Civamide|5 mg liquid filled softgel capsules
445607|NCT00802217|Drug|Civamide|5 mg x 2 liquid softgel capsules
445608|NCT00802204|Radiation|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride [18F] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.~Completed at baseline and post-VLCD"
445609|NCT00802204|Procedure|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
445610|NCT00802204|Procedure|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
445611|NCT00802204|Behavioral|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
445612|NCT00802204|Other|Caloric Restriction|Obese participants only complete a short-term (~10days) very low calorie diet
445613|NCT00802165|Device|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
445614|NCT00802165|Device|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
445615|NCT00802152|Other|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
445616|NCT00802139|Drug|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
445617|NCT00802139|Drug|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
445618|NCT00802126|Drug|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
445619|NCT00802113|Drug|Fludarabine|Fludarabine 30 mg/m2 x 5 days
445620|NCT00802113|Drug|Busulfan|Busulfan 3.2 mg/kg/day x 2 days
445621|NCT00802113|Drug|Anti-Thymocyte Globulin|Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days
445622|NCT00802100|Drug|Olanzapine|Daily tablets of 10 to 30 mg
445623|NCT00802100|Drug|Perphenazine|Daily tablets of 8 to 24 mg
445624|NCT00802100|Drug|Aripiprazole|Daily tablets of 10 to 30 mg
445625|NCT00802100|Drug|Metformin|Daily tablets of 850 to 2550 mg
445626|NCT00802100|Drug|Simvastatin|Daily tablets of 20 to 40 mg
445627|NCT00802100|Drug|Benztropine|Daily tablets of 1 to 2 mg
445628|NCT00802087|Drug|hydrocodone|Extended Release tablet
445629|NCT00802087|Drug|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
445630|NCT00802074|Drug|Raltegravir|400mg BID
445631|NCT00802074|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
445632|NCT00802074|Drug|Ritonavir|100 mg BID or QD
445634|NCT00802048|Drug|Local anesthetic (Ropivacaine)|Local anesthetic infusion
445635|NCT00802048|Drug|Saline|Saline serum infusion
445636|NCT00802035|Drug|Baclofen IR|30 mg; single dose
445637|NCT00802035|Drug|Baclofen ER|30 mg; single dose
445638|NCT00802022|Device|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
445639|NCT00802009|Drug|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
445640|NCT00802009|Drug|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
445641|NCT00801983|Device|Alternative Keyboard|Subjects use either a typical or alternative keyboard
445642|NCT00801970|Behavioral|Psychological Treatment|15 weekly therapy sessions.
445643|NCT00801970|Behavioral|Group Therapy|3 months of weekly group therapy sessions.
445644|NCT00801957|Drug|tacrolimus ointment 0.03%|topical application
445645|NCT00801957|Drug|hydrocortisone acetate ointment 1%|topical application
445646|NCT00801957|Drug|hydrocortisone butyrate ointment 0.1%|topical application
445647|NCT00801957|Biological|Meningitec|im injection
445648|NCT00801957|Biological|AC VAX|im injection
445649|NCT00801944|Drug|Solifenacin succinate|oral
445650|NCT00801944|Drug|Placebo|oral
445651|NCT00801931|Drug|Alemtuzumab|Each dose of alemtuzumab is to be diluted in 5% dextrose in water (D5W) or normal saling (NS) (maximum concentration: 0.3 mg/mL) for intravenous (IV) infusion over two hours.
445652|NCT00801931|Radiation|Total Body Irradiation|
445653|NCT00801931|Drug|Melphalan|Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
445654|NCT00801931|Drug|Busulfan|(Busulfex) will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
445655|NCT00801931|Drug|Phenytoin|Fosphenytoin can be administered in D5W or 0.9% sodium chloride to a final concentration ranging from 1.5 to 25 mg PE/ml at a rate of 1-3 mg phenytoin sodium equivalents (PE)/kg/min up to 50-150 mg PE/minute.
445656|NCT00801931|Drug|Fludarabine|Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
445657|NCT00801931|Drug|Cyclophosphamide|Cyclophosphamide should be infused over one hour. The drug can be diluted in D5W, NS, or other solutions (100-250 mL) to a maximum concentration of 20 mg/mL.
445658|NCT00801931|Drug|Horse Antithymocyte Globulin|Horse Antithymocyte Globulin (ATG [horse]) will be diluted in 0.9% sodium chloride or 0.45% sodium chloride for IV infusion (through an inline filter with pore size of 0.2 micrometer) to a concentration of 1-4 mg/ml and infused through a central venous catheter over 8 hours in Regimen E.
445659|NCT00801931|Drug|Rabbit Antithymocyte Globulin|Rabbit Anti-Thymocyte Globulin (rabbit ATG) will be diluted in 0.9% sodium chloride or D5W for IV infusion (through an in-line filter with pore size of 0.22 micrometer) to a concentration of 0.5 mg/ml and infused through a central venous catheter over 8 hours for all doses on Days -4, -3, -2, and -1 in Regimens A, B, D and F.
445660|NCT00801931|Drug|Thiotepa|Thiotepa should be diluted in NS (1-5 mg/ml) and infused over 2 hrs on Days -8, -4. IV fluids should be at maintenance rate (1500 ml/m2).
445661|NCT00801918|Drug|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
445662|NCT00801918|Drug|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
445663|NCT00801905|Drug|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
445664|NCT00801905|Other|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
445665|NCT00801892|Device|Continuous Positive Airway Pressure (CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
445666|NCT00801892|Device|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Mask worn over nose to splint open the airway with positive pressure to prevent the subject from holding their breath (apneas).
445667|NCT00801879|Drug|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
445668|NCT00801879|Drug|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
445669|NCT00801866|Drug|Bevacizumab|Intravitreal administration
445670|NCT00801866|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation
445671|NCT00801853|Drug|Aerovant|Aerovant 1mg bid (dry powder)
445672|NCT00801853|Drug|Aerovant|Aerovant 3mg bid (dry powder)
445673|NCT00801853|Drug|Aerovant|Aerovant 10mg bid (dry powder)
445674|NCT00801853|Other|placebo|placebo control (dry powder)
445675|NCT00801827|Drug|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
445676|NCT00801814|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
445677|NCT00801814|Dietary Supplement|PolyGlycopleX (PG)|5.0 grams of PGX
445678|NCT00801814|Dietary Supplement|PolyGlycopleX|7.5 grams of PGX
445679|NCT00801814|Dietary Supplement|Control|0g of PGX
445680|NCT00801814|Dietary Supplement|Second Control|0g of PGX
445731|NCT00801463|Drug|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
445732|NCT00801450|Drug|Triamcinolone acetonide|4 mg
445733|NCT00801450|Drug|Triamcinolone acetonide|40 mg
445734|NCT00801437|Drug|Xalacom|Xalacom 1 drop into the affected eye daily
445800|NCT00801138|Drug|Bupivacaine|30 ml 0.5% bupivacaine
445801|NCT00801125|Drug|natalizumab|
445681|NCT00801801|Drug|Docetaxel + Sorafenib|Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
445682|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
445683|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
445684|NCT00801762|Device|Fibered confocal microscope|
445685|NCT00801749|Behavioral|sleep|
445686|NCT00801736|Drug|Cisplatin, Paclitaxel|"Cisplatin 75mg/m2, Day 1~Paclitaxel 175mg/m2, Day 1"
445687|NCT00801723|Drug|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
445688|NCT00801723|Drug|Placebo Tablet|Placebo Tablet once daily.
445689|NCT00801710|Device|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.~Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
445690|NCT00801697|Biological|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
445691|NCT00801697|Biological|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
445692|NCT00801697|Biological|rAd35|VRC-HIVADV027-00-VP 1 x 10^10 PU administered as 1 mL
445693|NCT00801697|Biological|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
445694|NCT00801697|Biological|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
445695|NCT00801697|Biological|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
445696|NCT00801684|Drug|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
445697|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
445698|NCT00801684|Drug|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
445699|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
445700|NCT00801684|Drug|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
445701|NCT00801671|Procedure|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
445702|NCT00801658|Device|selective Laser Trabeculoplasty (SLT)|
445703|NCT00801645|Behavioral|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
445704|NCT00801632|Procedure|Kidney Transplantation|Surgical transplantation of donor kidney
445705|NCT00801632|Procedure|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
445706|NCT00801632|Biological|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
445707|NCT00801632|Drug|cyclophosphamide|60 mg/kg infusion on days -5, -4
445708|NCT00801632|Biological|rituximab|375 mg/m^2 infusion on days -7, -2, 5, and 12
445709|NCT00801632|Drug|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
445710|NCT00801632|Drug|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
445711|NCT00801632|Radiation|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
445712|NCT00801606|Drug|Zinc|Zinc 20 mg/day
445713|NCT00801606|Drug|Micronutrient without zinc|Multimineral 2 RDA
445714|NCT00801606|Drug|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
445715|NCT00801606|Drug|Placebo|Placebo
445716|NCT00801593|Procedure|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
445717|NCT00801580|Drug|doxorubicin liposomal|"Cyclophosphamide~Mesna~Methotrexate~Doxorubicin liposomal~Vincristine~Dexamethasone~Rituximab~Cytarabine"
445718|NCT00801567|Device|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
445719|NCT00801528|Drug|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
445720|NCT00801515|Drug|Maraviroc|150 mg twice per day
445721|NCT00801502|Dietary Supplement|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
445722|NCT00801502|Other|Control|No change to habitual diet from week 20 of pregnancy until giving birth
445723|NCT00801489|Drug|Cytarabine|Given IV
445724|NCT00801489|Drug|Decitabine|Given IV
445725|NCT00801489|Biological|Filgrastim-sndz|Given SC
445726|NCT00801489|Drug|Fludarabine Phosphate|Given IV
445727|NCT00801489|Drug|Gemtuzumab Ozogamicin|Given IV
445728|NCT00801489|Drug|Idarubicin|Given IV
445729|NCT00801489|Other|Laboratory Biomarker Analysis|Correlative studies
445730|NCT00801476|Procedure|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
445735|NCT00801424|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
445736|NCT00801411|Drug|cyclophosphamide|Given IV
445737|NCT00801411|Drug|docetaxel|Given IV
445738|NCT00801411|Drug|doxorubicin hydrochloride|Given IV
445739|NCT00801398|Drug|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
445740|NCT00801385|Drug|erlotinib hydrochloride|
445741|NCT00801385|Drug|sorafenib tosylate|
445742|NCT00801385|Genetic|DNA analysis|
445743|NCT00801385|Genetic|mutation analysis|
445744|NCT00801385|Genetic|polymerase chain reaction|
445745|NCT00801385|Genetic|protein analysis|
445746|NCT00801385|Genetic|protein expression analysis|
445747|NCT00801385|Other|immunohistochemistry staining method|
445748|NCT00801385|Other|laboratory biomarker analysis|
445749|NCT00801359|Procedure|Phacoemulsification|
445750|NCT00801359|Drug|BSSPlus solution|
445751|NCT00801359|Drug|Lactated Ringer's solution|
445752|NCT00801346|Other|laboratory biomarker analysis|
445753|NCT00801346|Other|metabolic assessment|
445754|NCT00801346|Other|questionnaire administration|
445755|NCT00801346|Procedure|assessment of therapy complications|
445756|NCT00801346|Procedure|fatigue assessment and management|
445757|NCT00801346|Procedure|quality-of-life assessment|
445758|NCT00801320|Procedure|Tumor collection|Tumor collected at the time of planned surgery
445759|NCT00801307|Device|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
445760|NCT00801294|Drug|BIBF 1120 and BIBW 2992|
445761|NCT00801281|Drug|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
445762|NCT00801281|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
445763|NCT00801281|Drug|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
445764|NCT00801281|Drug|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
445765|NCT00801281|Drug|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
445766|NCT00801281|Drug|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
445767|NCT00801268|Drug|tripterygium wilfordii|TW，60mg/d
445768|NCT00801268|Drug|Emodin|100mg/d
445769|NCT00801255|Drug|RO5024048|500mg po bid/100mg po q8h for 7 days
445770|NCT00801255|Drug|danoprevir|500mg po bid/100mg po q8h for 14 days
445771|NCT00801255|Drug|danoprevir|1000mg po bid/100mg po q8h for 14 days\n500mg po bid/200mg po q8h for 14 days
445772|NCT00801255|Drug|danoprevir|1000mg po bid/200mg po q8h for 14 days
445773|NCT00801255|Drug|danoprevir|1000mg/600mg po twice daily for 14 days
445774|NCT00801255|Drug|danoprevir|1000mg/900mg po twice daily for 14 days
445775|NCT00801242|Drug|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
445776|NCT00801229|Drug|Vyvanse|Vyvanse 30, 50, or 70 mg daily
445777|NCT00801229|Drug|Placebo|Placebo 30, 50, 70 mg daily
445778|NCT00801216|Drug|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
445779|NCT00801203|Drug|IRCT|Up to two administrations of the IRCT during a single cough testing session
445780|NCT00801190|Other|HES (130/0.4)|33 ml/kg i.v. during surgery
445781|NCT00801190|Other|Ringer's Lactate|33 ml/kg i.v.
445782|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
445783|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
445784|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
445785|NCT00801177|Biological|IMC-11F8 I.V.|"Cohort 4~600 mg I.V."
445786|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
445787|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
445788|NCT00801177|Biological|IMC-11F8|"Cohort 1~100 mg I.V."
445789|NCT00801177|Biological|IMC-11F8|"Cohort 2~200 mg I.V."
445790|NCT00801177|Biological|IMC-11F8|"Cohort 3~400 mg I.V."
445791|NCT00801177|Biological|IMC-11F8|"Cohort 4~600 mg I.V."
445792|NCT00801177|Biological|IMC-11F8|"Cohort 5~800 mg I.V."
445793|NCT00801177|Biological|IMC-11F8|"Cohort 6~1000 mg I.V."
445794|NCT00801164|Drug|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
445795|NCT00801164|Drug|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
445796|NCT00801151|Drug|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.~Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).~Patients may receive a maximum of 6 cycles of study medication."
445797|NCT00801138|Drug|saline|2 ml 0.9% saline (placebo)
445798|NCT00801138|Drug|Dexamethasone|dexamethasone 8 mg (2 ml)
445802|NCT00801099|Drug|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
445803|NCT00801086|Drug|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
445804|NCT00801086|Drug|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
445805|NCT00801073|Procedure|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
445806|NCT00801060|Drug|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
445807|NCT00801060|Drug|FCR|Dosage, schedule, and duration in the protocol
445808|NCT00801047|Drug|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
445809|NCT00801047|Drug|Remifentanil|40-50 mic per 1-2 min via PCA
445810|NCT00801034|Drug|Calcium|tablets, 1 tablet 2 times per day in 28 days
445811|NCT00801034|Drug|Potassium|Tablets, 5 tablets 2 times per day for 28 days
445812|NCT00801021|Drug|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
445813|NCT00801008|Behavioral|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
445814|NCT00800995|Dietary Supplement|SOD|
445815|NCT00800995|Dietary Supplement|Sham|
445816|NCT00800982|Procedure|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
445817|NCT00800982|Drug|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
445818|NCT00800969|Procedure|FDG-PET-CT|Radiologic standard procedure
445819|NCT00800956|Drug|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi [14C]-esreboxetine
445820|NCT00800943|Biological|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
445821|NCT00800930|Biological|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
445822|NCT00800930|Biological|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
445823|NCT00800917|Drug|Temsirolimus|25 mg weekly IV
445824|NCT00800917|Drug|Bevacizumab|10 mg/kg every 2 weeks
445825|NCT00800865|Other|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
445826|NCT00800865|Other|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
445827|NCT00800839|Drug|Busulfan|Starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
445828|NCT00800839|Drug|Fludarabine|Dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
445829|NCT00800839|Drug|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
445830|NCT00800826|Drug|dexmedetomidine|
445831|NCT00800813|Behavioral|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.~After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
445832|NCT00800800|Drug|Rosuvastatin|40 mg, oral, single dose
445833|NCT00800800|Drug|Placebo|oral, single dose
445834|NCT00800787|Biological|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.~Dosage will be according to each patients body weight, as follow:~< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly"
445835|NCT00800774|Procedure|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
445836|NCT00800761|Drug|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
445837|NCT00800761|Drug|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
445838|NCT00800748|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
445839|NCT00800748|Drug|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
445840|NCT00800735|Drug|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
445841|NCT00800735|Drug|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing < 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
445842|NCT00800722|Drug|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
445843|NCT00800709|Drug|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
445844|NCT00800696|Procedure|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
445845|NCT00800683|Drug|BI 1356|BI 1356 dosed once daily
445846|NCT00800683|Drug|placebo|placebo matching BI 1356 taken once daily
445847|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
445848|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
445849|NCT00800657|Procedure|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
445850|NCT00800657|Procedure|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
445851|NCT00800644|Procedure|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.~Blood (about 1 tablespoon) will be drawn to test for bone turnover."
445852|NCT00800618|Drug|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
445853|NCT00800618|Drug|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
445854|NCT00800618|Drug|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
445855|NCT00800618|Drug|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
445856|NCT00800618|Drug|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
445857|NCT00800605|Biological|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
445858|NCT00800605|Biological|Placebo: Phosphate-buffered saline|Single intramuscular injection
445859|NCT00800592|Drug|sildenafil|10 mg sildenafil bolus
445860|NCT00800579|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
445861|NCT00800579|Drug|Placebo|Inhaled volume-matched placebo in sterile saline
445862|NCT00800566|Drug|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
445863|NCT00800553|Drug|donepezil|5mg o.m. p.o. for approx. 2 weeks
445864|NCT00800553|Drug|Placebo|5mg of placebo for approx. 2 weeks
445865|NCT00800540|Drug|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
445866|NCT00800540|Drug|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
445867|NCT00800527|Drug|Gabapentin|Gabapentin 800 mg one a day up to 30 day
445868|NCT00800527|Drug|Diclofenac|Diclofenac 75 mg one a day up to 30 day
445869|NCT00800514|Drug|amantadine|amantadine twice daily
445870|NCT00800514|Drug|amantadine|amantadine 100 mg twice daily
445871|NCT00800501|Drug|sNN0029|Continuous ICV infusion at one of three dose levels
445872|NCT00800501|Drug|Placebo|Continuous ICV infusion
445873|NCT00800475|Drug|Gemfibrozil Tablets|
445874|NCT00800462|Drug|Oxybutynin Cl|15 mg qd for 3 months
445875|NCT00800462|Drug|Trospium Cl|20mg bid for 3 months
445876|NCT00800462|Drug|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
445877|NCT00800436|Drug|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
445878|NCT00800423|Drug|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops~1 drop twice a day for 1 month in the operated eye"
445879|NCT00800423|Drug|Timolol maleate 0.5%|"timolol maleate 0.5% drops~1 drop twice a day for 1 month in the operated eye"
445880|NCT00800410|Behavioral|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
445881|NCT00800384|Device|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
445882|NCT00800371|Procedure|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
445883|NCT00800358|Drug|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
445884|NCT00800358|Drug|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
445885|NCT00800345|Drug|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
445886|NCT00800345|Drug|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
445887|NCT00800332|Drug|CYT003-QbG10|subcutaneous injection
445888|NCT00800332|Drug|Placebo|subcutaneous injection
445889|NCT00800319|Drug|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
445890|NCT00800319|Drug|Placebo|Volume matched placebo; oral solution; single dose
445891|NCT00800306|Drug|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
445944|NCT00799916|Drug|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
445892|NCT00800306|Drug|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
445893|NCT00800293|Drug|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
445894|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
445895|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
445896|NCT00800280|Drug|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
445897|NCT00800267|Drug|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
445898|NCT00800267|Drug|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
445899|NCT00800267|Drug|timolol 0.5%|one drop in the morning and evening
445900|NCT00800254|Device|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
445901|NCT00800254|Other|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
445902|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
445903|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
445904|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
445905|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
445906|NCT00800202|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
445907|NCT00800202|Drug|carboplatin|AUC6 iv every 3 weeks for 6 cycles
445908|NCT00800202|Drug|erlotinib [Tarceva]|150mg/day po
445909|NCT00800202|Drug|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
445910|NCT00800189|Radiation|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
445911|NCT00800176|Drug|Placebo|po daily for 12 weeks
445912|NCT00800176|Drug|RO4998452|2.5mg po daily for 12 weeks
445913|NCT00800176|Drug|RO4998452|5mg po daily for 12 weeks
445914|NCT00800176|Drug|RO4998452|10mg po daily for 12 weeks
445915|NCT00800176|Drug|RO4998452|20mg po daily for 12 weeks
445916|NCT00800176|Drug|RO4998452|40mg po daily for 12 weeks
445917|NCT00800163|Other|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
445918|NCT00800150|Drug|fludarabine phosphate|
445919|NCT00800150|Drug|melphalan|
445920|NCT00800150|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
445921|NCT00800150|Radiation|intensity-modulated radiation therapy|
445922|NCT00800150|Radiation|tomotherapy|
445923|NCT00800150|Radiation|total marrow irradiation|
445924|NCT00800150|Radiation|total nodal irradiation|
445925|NCT00800137|Drug|low molecular weight heparin or unfractionated heparin|"For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.~Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.~Last dose given in the morning(ie. > 24 hours)of the day prior to the procedure.~Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.~Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery."
445926|NCT00800137|Drug|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be < 3.0
445927|NCT00800124|Procedure|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
445928|NCT00800111|Procedure|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
445929|NCT00800098|Drug|herbal topical cream|
445930|NCT00800085|Drug|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
445931|NCT00800072|Device|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
445932|NCT00800059|Radiation|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
445933|NCT00800046|Device|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
445934|NCT00800033|Behavioral|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
445935|NCT00800033|Dietary Supplement|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
445936|NCT00800007|Drug|ANZ-521|3x10^7 cfu or 3x10^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
445937|NCT00800007|Drug|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
445938|NCT00799968|Drug|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
445939|NCT00799968|Drug|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
445940|NCT00799955|Procedure|Placebo block|100 micrograms of spinal morphine
445941|NCT00799955|Procedure|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
445942|NCT00799942|Drug|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
445943|NCT00799929|Other|in vitro fertilization (IVF/ICSI)|
445945|NCT00799916|Drug|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
445946|NCT00799903|Drug|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
445947|NCT00799903|Drug|Placebo|Placebo administered in addition to standard therapy
445948|NCT00799890|Drug|Sunphenon EGCG|200-800mg (1-4 capsules)
445949|NCT00799890|Drug|Placebo|1-4 capsules
445950|NCT00799864|Drug|Rilpivirine|Patients will receive rilpivirine tablet 25 milligram or adjusted dose orally once daily for 240 weeks.
445951|NCT00799864|Drug|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
445952|NCT00799864|Drug|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
445953|NCT00799864|Drug|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
445954|NCT00799864|Drug|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
445955|NCT00799864|Drug|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
445956|NCT00799851|Device|Variceal band ligation|
445957|NCT00799851|Drug|cyanoacrylate injection|cyanoacrylate injection
445958|NCT00799838|Drug|Ketoprofen|"Formulation: oral solution 20mg/mL~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
445959|NCT00799838|Drug|Placebo (for Ketoprofen)|"Formulation: oral solution~Route of administration: oral~Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
445960|NCT00799838|Drug|Amoxicillin|"Formulation: suspension 125mg/5 mL~Route of administration: oral~Dose regimen: 20-40mg/Kg/day administered t.i.d"
445961|NCT00799825|Biological|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
445962|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
445963|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
445964|NCT00799812|Drug|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
445965|NCT00799812|Other|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
445966|NCT00799812|Other|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
445967|NCT00799799|Biological|NK cells|NK cells infusion after immunosuppressive chemotherapy
445968|NCT00799786|Behavioral|Building Better Caregivers Online Workshop|
445969|NCT00799773|Drug|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
445970|NCT00799773|Procedure|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
445971|NCT00799773|Drug|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
445972|NCT00799760|Drug|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
445973|NCT00799760|Drug|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
445974|NCT00799760|Drug|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
445975|NCT00799747|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
445976|NCT00799747|Drug|Placebo|placebo
445977|NCT00799734|Drug|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
445978|NCT00799708|Drug|Comparator: placebo|placebo capsule once daily for 7 days.
445979|NCT00799708|Drug|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
445980|NCT00799695|Behavioral|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
445981|NCT00799682|Drug|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
445982|NCT00799682|Drug|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
445983|NCT00799669|Behavioral|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
445984|NCT00799669|Other|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
445985|NCT00799669|Other|preventive intervention|
445986|NCT00799669|Other|questionnaire administration|
445987|NCT00799656|Drug|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
445988|NCT00799656|Drug|placebo|oral administration once daily for 28 days
445989|NCT00799643|Drug|Salsalate|Salsalate 3.5 g/d orally, divided dosing
445990|NCT00799643|Drug|Salsalate Placebo|
445991|NCT00799630|Dietary Supplement|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
445992|NCT00799617|Drug|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
445993|NCT00799617|Drug|Placebo|Testosterone levels will be measured at regular intervals.
445994|NCT00799604|Drug|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
445995|NCT00799591|Other|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
445996|NCT00799578|Drug|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
445997|NCT00799565|Genetic|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.~This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
445998|NCT00799552|Drug|RX-10045|RX-10045 eye drop
445999|NCT00799552|Drug|Placebo|Placebo eye drop
446000|NCT00799539|Drug|bortezomib|From cycles 1-4, 1.3mg/m^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
446001|NCT00799539|Drug|bortezomib|From cycles 5-9, 1.3mg/m^2 on days 1, 8, 22, and 29 of each 6-week cycle
446002|NCT00799539|Drug|melphalan|9 mg/m^2 once daily on days 1-4 of each 6-week cycle
446003|NCT00799539|Drug|prednisone|60 mg/m^2 once daily on days 1-4 of each 6-week cycle
446004|NCT00799526|Procedure|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
446005|NCT00799526|Procedure|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
446006|NCT00799513|Drug|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
446007|NCT00799500|Other|Screening|Weekly vaginal pH
446008|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
446009|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
446010|NCT00799461|Other|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
446011|NCT00799461|Other|questionnaire administration|Completion of questions in an online format
446012|NCT00799461|Procedure|psychosocial assessment and care|Assessment and care of psychosocial aspects
446013|NCT00799461|Procedure|assessment of therapy complications|Evaluation of complications of treatment
446014|NCT00799461|Procedure|management of therapy complications|Managing therapy complications
446015|NCT00799461|Procedure|fatigue assessment and management|Assessing and managing fatigue
446016|NCT00799461|Other|counseling intervention|Counseling provided via telephone
446017|NCT00799448|Drug|repaglinide|
446018|NCT00799448|Drug|biphasic human insulin 30|
446019|NCT00799448|Drug|insulin NPH|
446020|NCT00799435|Drug|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
446021|NCT00799422|Device|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
446022|NCT00799422|Device|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
446023|NCT00799422|Device|Clear Care|Commercially marketed contact lens solution for contact lens care
446024|NCT00799422|Device|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
446025|NCT00799409|Drug|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
446026|NCT00799409|Drug|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
446027|NCT00799396|Drug|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
446028|NCT00799396|Drug|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
446029|NCT00799383|Drug|Calcium and Vitamin D|Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
446030|NCT00799383|Other|Placebo|
446031|NCT00799370|Procedure|Early weight bearing|Weight bearing performed immediately after surgery
446032|NCT00799370|Procedure|Delayed weight bearing|Weight bearing performed 2 months after surgery
446033|NCT00799344|Device|Catania Stent|coronary stent implantation
446034|NCT00799331|Drug|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
446035|NCT00799331|Drug|placebo|Oral suspension.
446036|NCT00799292|Drug|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
446037|NCT00799279|Behavioral|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
446038|NCT00799279|Behavioral|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
446039|NCT00799266|Drug|Zoledronic acid|intravenous infusion
446040|NCT00799266|Drug|Placebo|intravenous infusion
446041|NCT00799240|Drug|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
446042|NCT00799240|Drug|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
446043|NCT00799227|Drug|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
446044|NCT00799214|Drug|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
446045|NCT00799214|Drug|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
446046|NCT00799214|Drug|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
446047|NCT00799201|Drug|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
446048|NCT00799188|Drug|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
446049|NCT00799175|Drug|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
446050|NCT00799175|Drug|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
446051|NCT00799162|Other|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
446052|NCT00799149|Drug|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
446053|NCT00799136|Drug|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
446054|NCT00799110|Drug|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
446055|NCT00799110|Biological|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
446056|NCT00799110|Drug|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
446057|NCT00799084|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
446058|NCT00799084|Behavioral|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
446059|NCT00799071|Drug|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
446060|NCT00799058|Drug|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
446061|NCT00799058|Drug|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
446062|NCT00799058|Drug|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
446063|NCT00799045|Drug|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
446064|NCT00799032|Device|PCI|coronary stent implantation
446065|NCT00799006|Drug|Placebo|Subjects will be given placebo or PF-04620110
446066|NCT00799006|Drug|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
446067|NCT00798993|Other|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
446068|NCT00798993|Drug|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
446069|NCT00798993|Other|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
446070|NCT00798980|Drug|Mirena (BAY86-5028)|Nulliparous Women
446071|NCT00798967|Drug|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
446072|NCT00798967|Drug|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
446073|NCT00798954|Device|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
446074|NCT00798954|Device|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
446075|NCT00798941|Behavioral|mouth care|mouth spray, mouth swab, moisturizer
446076|NCT00798941|Behavioral|pain intervention|music and massage
446077|NCT00798915|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
446078|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
446079|NCT00798915|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
446191|NCT00798265|Behavioral|Survey|Administration of on-line risk behavior and knowledge survey
446080|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
446081|NCT00798902|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
446082|NCT00798902|Other|Iliac crest autograft|autograft
446083|NCT00798889|Drug|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
446084|NCT00798876|Dietary Supplement|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
446085|NCT00798876|Dietary Supplement|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
446086|NCT00798876|Dietary Supplement|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
446087|NCT00798876|Dietary Supplement|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
446088|NCT00798876|Other|Medical Examination|Subjects will have a routine medical exam.
446089|NCT00798876|Other|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
446090|NCT00798876|Other|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
446091|NCT00798876|Procedure|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
446092|NCT00798863|Procedure|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
446093|NCT00798850|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull & East Yorshire Yospitals NHS Trust.
446094|NCT00798850|Procedure|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.~Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).~Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)~Station 2-Exercise bicycles~Station 3-Knee extensions with weights(2kg beanbag)~Station 4-Heel raises~Station 5-Knee bends(Alternating legs after 10 bends)~Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.~This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
446095|NCT00798850|Procedure|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
446096|NCT00798837|Radiation|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.~Doses of radiotherapy are as follows:~The prescription dose will be 73.7 Gy in 28 fractions~A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
446097|NCT00798824|Procedure|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
446098|NCT00798824|Procedure|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
446099|NCT00798824|Device|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
446100|NCT00798824|Device|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
446101|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery -> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
446102|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
446103|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
446104|NCT00798798|Device|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
446105|NCT00798785|Drug|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
446144|NCT00798538|Other|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
446238|NCT00797966|Drug|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
446106|NCT00798785|Drug|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
446107|NCT00798785|Drug|ATG-basilixumab-MMF-TAC|"First transplantation:~ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.~Second transplantation:~Basilixumab:~the day before the second transplantation followed by 4days after transplantation.~Tacrolimus levels for 2 years between 8-10 ng/ml.~At year 2: randomization:~group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
446108|NCT00798785|Procedure|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:~In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels >= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
446109|NCT00798772|Dietary Supplement|Micronutrients and antioxidants|8 capsules twice daily for two years
446110|NCT00798772|Dietary Supplement|Multivitamins and minerals|8 capsules twice daily for two years
446111|NCT00798759|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
446112|NCT00798759|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
446113|NCT00798746|Behavioral|Telephone Questionnaire|Ten questions regarding symptoms of reflux
446114|NCT00798720|Drug|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
446115|NCT00798720|Drug|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
446116|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
446117|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
446118|NCT00798707|Drug|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
446119|NCT00798694|Drug|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
446120|NCT00798694|Drug|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
446121|NCT00798681|Dietary Supplement|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
446122|NCT00798681|Other|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
446123|NCT00798681|Other|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
446124|NCT00798668|Dietary Supplement|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
446125|NCT00798668|Dietary Supplement|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
446126|NCT00798655|Drug|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.~The panitumumab dose will be calculated based on the subject's actual weekly body weight"
446127|NCT00798655|Drug|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
446128|NCT00798655|Radiation|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.~Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
446129|NCT00798642|Behavioral|Hypnotherapy|8 weeks of gut-directed hypnotherapy
446130|NCT00798642|Behavioral|Standard care|8 weeks of standard of care
446131|NCT00798642|Behavioral|Mind Body Therapy|8 weeks of mind-body therapy
446132|NCT00798629|Biological|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
446133|NCT00798616|Drug|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
446134|NCT00798616|Drug|placebo|oral or IV placebo
446135|NCT00798603|Biological|bevacizumab|
446136|NCT00798603|Drug|carboplatin|
446137|NCT00798603|Drug|pemetrexed disodium|
446138|NCT00798590|Drug|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
446139|NCT00798590|Drug|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
446140|NCT00798577|Drug|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
446141|NCT00798577|Drug|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
446142|NCT00798551|Behavioral|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
446143|NCT00798538|Other|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
446190|NCT00798265|Biological|Gardisil|.5 mL dose injected IM at 0 2 and 6 months
446336|NCT00797056|Drug|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
446145|NCT00798525|Drug|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of > 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
446146|NCT00798525|Drug|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine < 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
446147|NCT00798512|Device|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.~For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
446148|NCT00798499|Other|Laboratory variables|1 visit
446149|NCT00798486|Device|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
446150|NCT00798473|Drug|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
446151|NCT00798473|Other|IV saline infusion|
446152|NCT00798460|Drug|adefovir|adefovir 10mg
446153|NCT00798460|Drug|clevudine|clevudine 30mg
446154|NCT00798460|Drug|lamivudine|lamivudine 100mg
446155|NCT00798447|Drug|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
446156|NCT00798447|Drug|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
446157|NCT00798434|Drug|Placebo|placebo administered orally in the morning or evening.
446158|NCT00798434|Drug|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
446159|NCT00798408|Dietary Supplement|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
446160|NCT00798408|Dietary Supplement|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
446161|NCT00798395|Drug|Org 50081|1.5 mg on day 1-7
446162|NCT00798395|Drug|Org 50081|4.5 mg on Day 1-7
446163|NCT00798395|Drug|Placebo|Once daily on Day 1-7
446164|NCT00798395|Drug|zopiclone|Single dose of 7.5 mg
446165|NCT00798382|Other|soy protein formula|ad lib for 0-35 days of age
446166|NCT00798382|Other|Commercially available soy formula|ad lib for 0-35 days of age
446167|NCT00798382|Other|Soy formula experimental #2|ad lib for 0-35 days of age
446168|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
446169|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
446170|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
446171|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
446172|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
446173|NCT00798369|Drug|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
446174|NCT00798356|Other|Yoga training|Yoga training for 12 weeks
446175|NCT00798343|Biological|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
446176|NCT00798343|Biological|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
446177|NCT00798317|Drug|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
446178|NCT00798317|Drug|Placebo|Intravitreal injection placebo.
446179|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
446180|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
446181|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
446182|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
446183|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
446184|NCT00798291|Other|Ad lib diet and Control placebo|one packet with water two times a day
446185|NCT00798291|Other|Ad lib diet and An 777|one packet with water two times a day
446186|NCT00798291|Other|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
446187|NCT00798291|Other|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
446188|NCT00798278|Drug|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
446189|NCT00798278|Procedure|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
446383|NCT00796796|Drug|Temsirolimus|
446192|NCT00798252|Drug|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
446193|NCT00798252|Drug|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
446194|NCT00798252|Drug|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
446195|NCT00798252|Drug|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
446196|NCT00798252|Drug|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
446197|NCT00798252|Drug|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
446198|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
446199|NCT00798239|Other|Iliac crest autograft|autograft
446200|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
446201|NCT00798226|Dietary Supplement|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 og gestation to 1 week after delivery
446202|NCT00798226|Dietary Supplement|olive oil|Oral intake of 4 capsules (1 g) daily from 26 weeks of gestation to 1 week after delivery
446203|NCT00798213|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
446204|NCT00798213|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
446205|NCT00798200|Other|Exercise program|All exercise programs will include endurance and strength exercises.
446206|NCT00798187|Behavioral|Group Meetings|10 weekly group meetings lasting 2 hours.
446207|NCT00798187|Behavioral|Questionnaire|Surveys
446208|NCT00798174|Device|Standard configuration vs. azygos coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
446209|NCT00798161|Drug|BI 1356|BI 1356 high dose tablet, once daily
446210|NCT00798161|Drug|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
446211|NCT00798161|Drug|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
446212|NCT00798161|Drug|Metformin|Metformin 500 mg tablet, twice daily
446213|NCT00798161|Drug|metformin|metformin 1000 mg tablet, twice daily
446214|NCT00798161|Drug|matching placebo|matching placebo
446215|NCT00798148|Drug|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
446216|NCT00798135|Drug|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
446217|NCT00798122|Procedure|Intravascular ultrasound|intravascular ultrasound
446218|NCT00798122|Procedure|MRI|cardiac MRI
446219|NCT00798109|Behavioral|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
446220|NCT00798109|Behavioral|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
446221|NCT00798096|Drug|Fostamatinib Disodium|200 mg PO BID
446222|NCT00798083|Drug|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
446223|NCT00798070|Drug|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
446224|NCT00798070|Drug|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
446225|NCT00798044|Behavioral|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
446226|NCT00798044|Behavioral|Patient Feedback|Weekly feedback reports provided to counselors
446227|NCT00798031|Device|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
446228|NCT00798031|Device|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.~A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
446229|NCT00798031|Device|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
446230|NCT00798018|Drug|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
446231|NCT00798018|Drug|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
446232|NCT00798018|Drug|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
446233|NCT00798018|Drug|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
446234|NCT00798005|Drug|XRP0038 (NV1FGF)|
446235|NCT00797992|Drug|Injection|Intravitreal injection of 1.25 mg bevacizumab
446236|NCT00797979|Device|Skull Grip bone fixation|Skull Grip bone fixation
446237|NCT00797979|Device|sutures|Standard skull bon flap fixation, sutures
446239|NCT00797966|Drug|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
446240|NCT00797966|Drug|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
446241|NCT00797953|Drug|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
446242|NCT00797940|Drug|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
446243|NCT00797927|Drug|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
446244|NCT00797927|Other|no intervention|keep the original conventional antipsychotic agent for 28 days
446245|NCT00797901|Other|Collaborative Care|
446246|NCT00797888|Behavioral|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
446247|NCT00797875|Procedure|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
446248|NCT00797875|Procedure|passive stretching|passive stretching x 5 repetitions continue 3 days
446249|NCT00797862|Drug|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
446250|NCT00797862|Drug|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
446251|NCT00797862|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
446252|NCT00797849|Device|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
446253|NCT00797849|Device|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
446254|NCT00797836|Procedure|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response~Health Personnel Hospitals, General Occupational Diseases/*epidemiology/*statistics & numerical data Occupational Exposure/*statistics & numerical data~Tuberculosis/*diagnosis/*epidemiology/prevention & control Immunologic Tests/methods/*standards Disease Transmission, Horizontal/*statistics & numerical data Patient Isolation~Tuberculin Test/standards/*methods Immunoassay/methods/*standards T-Lymphocytes/immunology Interferon Type II/*blood/*analysis~*Reagent Kits, Diagnostic~Mass Screening/*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/*methods"
446255|NCT00797823|Drug|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
446256|NCT00797823|Drug|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
446257|NCT00797823|Drug|Placebo|Saline solution 0.9%
446258|NCT00797810|Drug|Rituximab|
446259|NCT00797797|Drug|No Treatment Added|No added treatment
446260|NCT00797797|Drug|Milnacipran Added|Milnacipran 100 mg/d added
446261|NCT00797784|Drug|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
446262|NCT00797771|Device|"Adi Insulin pump"|insulin delivery will be defined by the physician
446263|NCT00797758|Other|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
446264|NCT00797745|Biological|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
446265|NCT00797745|Drug|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
446266|NCT00797745|Drug|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
446267|NCT00797745|Drug|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
446268|NCT00797732|Device|Acupuncture|
446269|NCT00797719|Other|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
446270|NCT00797706|Drug|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
446271|NCT00797693|Drug|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
446272|NCT00797680|Other|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
446273|NCT00797680|Other|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
446274|NCT00797667|Drug|Telcagepant 140 mg|
446275|NCT00797667|Drug|Telcagepant 280 mg|
446276|NCT00797667|Drug|140 mg telcagepant placebo|
446277|NCT00797667|Drug|280 mg telcagepant placebo|
446278|NCT00797654|Behavioral|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
446279|NCT00797654|Behavioral|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
446280|NCT00797628|Behavioral|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
446281|NCT00797628|Behavioral|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
446282|NCT00797615|Behavioral|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
446283|NCT00797615|Behavioral|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
446284|NCT00797589|Drug|HES|20ml/kg as prime fluid
446285|NCT00797589|Drug|Ringer lactate|
446286|NCT00797563|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
446287|NCT00797550|Biological|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
446288|NCT00797550|Procedure|Autologous bone graft|
446289|NCT00797537|Procedure|Echography|Echography
446290|NCT00797511|Biological|TdcP-IPV vaccine|0.5 mL, Intramuscular
446291|NCT00797498|Other|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
446292|NCT00797485|Biological|bevacizumab|Given IV
446293|NCT00797485|Drug|capecitabine|Given orally
446294|NCT00797485|Drug|fluorouracil|Given IV
446295|NCT00797485|Drug|irinotecan hydrochloride|Given IV
446296|NCT00797485|Drug|leucovorin calcium|Given IV
446297|NCT00797472|Drug|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
446298|NCT00797472|Drug|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
446299|NCT00797459|Device|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
446300|NCT00797420|Drug|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
446301|NCT00797420|Drug|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
446302|NCT00797407|Dietary Supplement|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
446303|NCT00797394|Dietary Supplement|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
446304|NCT00797394|Dietary Supplement|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
446305|NCT00797368|Other|Manual Therapy and Exercise|Manual Therapy and Exercise
446306|NCT00797368|Other|Home exercises|Home exercises
446307|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
446308|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
446309|NCT00797342|Drug|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
446310|NCT00797329|Other|chart review|"cholesterol~cognitive profiles~violent behavior"
446311|NCT00797316|Drug|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
446312|NCT00797316|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
446313|NCT00797303|Drug|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
446314|NCT00797277|Drug|IM olanzapine|10mg olanzapine IM
446315|NCT00797277|Drug|IM haloperidol plus lorazepam|IM 5 mg haloperidol plus IM 2 mg lorazepam
446316|NCT00797264|Drug|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
446317|NCT00797264|Drug|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
446318|NCT00797264|Drug|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
446319|NCT00797251|Procedure|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
446320|NCT00797225|Drug|Leuprorelin Acetate Depot|Leuprorelin acetate depot injection 3.75 mg administered as an intramuscular injection
446321|NCT00797225|Drug|Elagolix|Elagolix tablets administered orally
446322|NCT00797225|Drug|Placebo to Elagolix|Placebo tablet administered orally
446323|NCT00797225|Drug|Placebo to Leuprorelin Acetate|Saline solution administered as an intramuscular injection
446324|NCT00797212|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
446325|NCT00797186|Other|Intensive risk factor management|Aggressive medical and lifestyle therapy.
446326|NCT00797160|Drug|propofol|2mg/Kg IV in bolus before tracheal intubation
446327|NCT00797121|Procedure|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
446328|NCT00797108|Drug|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
446329|NCT00797108|Drug|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
446330|NCT00797108|Drug|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
446331|NCT00797082|Device|MRI|MRI = Myocardial Perfusion Stress
446332|NCT00797082|Device|MPS|MPS = Myocardial Perfusion Scintigraphy
446333|NCT00797069|Other|standard nutritional product (medical food)|once during crossover
446334|NCT00797069|Other|nutritional product for diabetes (medical food)|once during crossover
446335|NCT00797069|Other|diabetes specific experimental nutritional product (medical food)|once during crossover
446337|NCT00797056|Drug|Placebo|Saline SQ daily for 10 days
446338|NCT00797056|Drug|Aspirin|Aspirin 75 mg/day for 14 days
446339|NCT00797056|Drug|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
446340|NCT00797030|Drug|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
446341|NCT00797030|Drug|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
446342|NCT00797017|Drug|fentanyl|Infection, starting with 12mcg/h (flexible dose)
446343|NCT00797017|Drug|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
446344|NCT00797017|Drug|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
446345|NCT00797017|Drug|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
446346|NCT00797017|Drug|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
446347|NCT00797017|Drug|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
446348|NCT00797017|Drug|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
446349|NCT00796991|Drug|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
446350|NCT00796991|Drug|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
446351|NCT00796991|Drug|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
446352|NCT00796991|Drug|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
446353|NCT00796978|Biological|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
446354|NCT00796978|Other|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
446355|NCT00796978|Procedure|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
446356|NCT00796978|Procedure|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
446357|NCT00796965|Drug|AZD7268|Solution/Capsule, Oral, once daily
446358|NCT00796965|Drug|Placebo|
446359|NCT00796952|Behavioral|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
446360|NCT00796952|Behavioral|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
446361|NCT00796952|Behavioral|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
446362|NCT00796939|Device|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
446363|NCT00796939|Device|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
446364|NCT00796926|Drug|Systane Ultra eyedrops|Four times a day
446365|NCT00796926|Drug|Refresh eye drops|Four times a day
446366|NCT00796913|Other|Stop medication|Stop medication Stop medication + se supplement
446367|NCT00796900|Drug|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
446368|NCT00796900|Drug|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
446369|NCT00796887|Drug|Extended-Release Niacin|500mg tablet once daily
446370|NCT00796887|Drug|Extended-Release Niacin|1000mg tablet once daily
446371|NCT00796887|Drug|Placebo|Placebo tablet once daily
446372|NCT00796874|Other|active surveillance|Correlative Study
446373|NCT00796874|Other|imaging biomarker analysis|Correlative Study
446374|NCT00796874|Procedure|biopsy|Tissue Removal
446375|NCT00796874|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
446376|NCT00796874|Procedure|magnetic resonance imaging|Radiolical Medical Imaging
446377|NCT00796874|Procedure|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
446378|NCT00796861|Drug|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
446379|NCT00796848|Device|Navigator Continuous Glucose Monitor|
446380|NCT00796835|Drug|ER OROS Paliperidone|
446381|NCT00796822|Drug|Pentoxifylline|400 mg three times a day for 8 weeks
446382|NCT00796822|Drug|Placebo|One pill three times a day for 8 weeks
446384|NCT00796796|Radiation|Radiation therapy|
446385|NCT00796783|Drug|Cushing's syndrome confirmation|
446386|NCT00796770|Biological|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.~At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:~two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks~an opportunistic infection~a CDC class C-defining event (defined in appendix 2)~a serious non-AIDS defining event.~Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
446387|NCT00796757|Drug|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
446388|NCT00796757|Drug|interferon alfa-2a|3 MIU sc t.i.w.
446389|NCT00796744|Drug|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
446390|NCT00796731|Drug|SAR3419|administered by intravenous infusion
446391|NCT00796718|Radiation|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
446392|NCT00796718|Drug|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m^2) orally twice daily for 5 weeks.
446393|NCT00796705|Drug|Adalimumab|40 mg injection of adalimumab administered subcutaneously
446394|NCT00796705|Drug|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
446395|NCT00796705|Drug|Etanercept|50 mg dimeric fusion protein administered subcutaneously
446396|NCT00796692|Drug|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
446397|NCT00796692|Drug|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
446398|NCT00796679|Drug|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH <500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
446399|NCT00796666|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
446400|NCT00796666|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
446401|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
446402|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
446403|NCT00796653|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
446404|NCT00796653|Drug|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
446405|NCT00796640|Drug|ER Paliperidone|
446406|NCT00796627|Genetic|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
446407|NCT00796627|Other|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
446408|NCT00796614|Drug|tamsulosin hydrochloride|Oral
446409|NCT00796614|Drug|Placebo|Oral
446410|NCT00796601|Drug|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
446411|NCT00796601|Drug|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
446412|NCT00796588|Other|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
446413|NCT00796575|Drug|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
446414|NCT00796575|Drug|placebo tablets|placebo tablets matching active
446415|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
446416|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
446417|NCT00796562|Drug|Busulfan|Participant will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis (in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
446418|NCT00796562|Drug|Cyclophosphamide|Patient will receive Cy by IV once a day for 2 days.
446419|NCT00796562|Radiation|Total body irradiation|Patients will receive TBI once a day for 4 days.
446420|NCT00796549|Drug|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
446421|NCT00796536|Behavioral|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
446422|NCT00796536|Behavioral|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
446423|NCT00796523|Behavioral|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
446424|NCT00796523|Behavioral|control videotape|a videotape with general newborn care instructions
446425|NCT00796510|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
446426|NCT00796510|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
446427|NCT00796497|Drug|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
446428|NCT00796484|Drug|XL888|Administered orally
446429|NCT00796471|Drug|Paliperidone ER|
446430|NCT00796458|Drug|docetaxel|Given IV
446431|NCT00796458|Drug|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
446432|NCT00796445|Drug|GSK 2132231A|IM solution, a course of 13 injections administered over 27 months
446433|NCT00796445|Drug|Placebo|IM solution, a course of 13 injections administered over 27 months
446434|NCT00796432|Drug|OROS paliperidone|
446435|NCT00796419|Drug|5% human albumin|Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
446436|NCT00796419|Drug|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
446437|NCT00796393|Dietary Supplement|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
446438|NCT00796393|Dietary Supplement|Starch of potato|1 pill per day for 12 weeks
446439|NCT00796380|Drug|Xingnaojing|injection
446440|NCT00796367|Drug|VI-0521|7.5 mg phentermine and 46 mg topiramate
446441|NCT00796367|Drug|Placebo|placebo
446442|NCT00796367|Drug|VI-0521|15 mg phentermine and 92 mg topiramate
446443|NCT00796354|Drug|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
446444|NCT00796354|Drug|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
446445|NCT00796341|Procedure|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
446446|NCT00796328|Drug|Phenylephrine infusion|Up-down, biased coin design
446447|NCT00796315|Drug|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
446448|NCT00796302|Drug|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily."
446449|NCT00796302|Drug|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
446450|NCT00796302|Behavioral|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
446451|NCT00796302|Drug|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
446452|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
446453|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
446454|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
446455|NCT00796289|Drug|clomiphene citrate|Oral, 50 mg daily for 5 days
446456|NCT00796289|Drug|placebo clomiphene citrate|oral, taken for 5 days
446457|NCT00796289|Drug|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
446458|NCT00796276|Drug|IR OROS paliperidone and ER OROS paliperidone|
446459|NCT00796263|Drug|HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily~Dolutegravir(DTG) 50 mg orally once daily"
446460|NCT00796250|Biological|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
446461|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
446462|NCT00796250|Drug|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
446463|NCT00796250|Drug|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
446464|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
446465|NCT00796250|Biological|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
446466|NCT00796237|Device|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
446467|NCT00796237|Other|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
446468|NCT00796224|Drug|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
446469|NCT00796224|Drug|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
446470|NCT00796211|Drug|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
446471|NCT00796211|Drug|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
446472|NCT00796211|Drug|Nortriptyline|0.1% nortriptyline HCl topical cream
446473|NCT00796211|Drug|Calcipotriol|0.005% calcipotriol topical cream
446474|NCT00796211|Other|Placebo|Vehicle of CRx-197 topical cream (placebo)
446475|NCT00796198|Drug|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
446476|NCT00796198|Drug|Xalatan|Xalatan ophthalmic solution one drop at 10pm
446477|NCT00796185|Drug|Paliperidone ER|
446478|NCT00796172|Behavioral|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
446479|NCT00796172|Behavioral|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
446480|NCT00796159|Drug|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
446481|NCT00796133|Drug|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
446482|NCT00796120|Drug|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
446483|NCT00796120|Drug|Doxorubicin|Doxorubicin 60 or 75 mg/m^2 will be given intravenously every 3 weeks until disease progression.
446484|NCT00796120|Drug|Ifosfamide|Ifosfamide 6 to 9 g/m^2 will be given intravenously every 3 weeks until disease progression.
446485|NCT00796107|Drug|RG1507|16mg/kg iv every 3 weeks
446486|NCT00796107|Drug|letrozole|2.5mg po daily
446487|NCT00796094|Other|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
446488|NCT00796081|Drug|ER OROS paliperidone, paliperidone ER|
446489|NCT00796068|Drug|Cyclosporine|Given IV or PO
446490|NCT00796068|Drug|Fludarabine Phosphate|Given IV
446491|NCT00796068|Other|Laboratory Biomarker Analysis|Correlative studies
446492|NCT00796068|Drug|Mycophenolate Mofetil|Given IV
446493|NCT00796068|Radiation|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
446494|NCT00796068|Drug|Treosulfan|Given IV
446495|NCT00796068|Procedure|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
446496|NCT00796055|Drug|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
446497|NCT00796042|Other|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
446498|NCT00796042|Other|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
446499|NCT00796029|Drug|14C-paliperidone|
446500|NCT00796003|Drug|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
446501|NCT00796003|Drug|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
446502|NCT00795977|Biological|dendritic cells, OK-432|Single Group Assignment
446503|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
446504|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
446505|NCT00795951|Biological|T.R.U.E. Test|48 hour application of 28 allergens and negative control
446506|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
446507|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
446508|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
446509|NCT00795925|Drug|propiverine hydrochloride|"coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
446510|NCT00795912|Drug|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
446511|NCT00795899|Drug|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d~Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
446512|NCT00795886|Drug|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
446513|NCT00795860|Behavioral|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
446514|NCT00795860|Behavioral|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
446515|NCT00795847|Drug|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
446516|NCT00795834|Dietary Supplement|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
446517|NCT00795834|Dietary Supplement|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0~250ml twice daily for 1 month (56 doses)"
446518|NCT00795821|Drug|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
446519|NCT00795821|Drug|Placebo|Dose: 3 tablets QD for 10 weeks
446520|NCT00795808|Drug|Metformin|500mg tds for 6 months
446521|NCT00795808|Drug|Placebo|One tablet tds for 6 months
446522|NCT00795808|Drug|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
446523|NCT00795808|Drug|Metformin|500mg tds for 6 months
446524|NCT00795808|Drug|Clomiphene|Ovulatory dose for 6 months
446525|NCT00795795|Procedure|Preimplantation Genetic Screening|Preimplantation Genetic Screening
446526|NCT00795795|Procedure|IVF without PGS|IVF without PGS
446527|NCT00795782|Procedure|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
446528|NCT00795769|Drug|ondansetron|Given IV
446529|NCT00795769|Other|survey administration|Correlative studies
446530|NCT00795769|Procedure|management of therapy complications|Ondansetron IV
446531|NCT00795756|Drug|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
446532|NCT00795756|Drug|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
446533|NCT00795730|Drug|NSA-789|
446534|NCT00795730|Other|placebo|
446535|NCT00795717|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
446536|NCT00795717|Drug|Placebo|2 capsules given twice daily
446537|NCT00795704|Drug|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
446538|NCT00795704|Drug|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
446539|NCT00795691|Behavioral|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
446540|NCT00795691|Behavioral|low-fat diet|low-fat diet in patients with type 2 diabetes
446541|NCT00795678|Drug|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
446542|NCT00795678|Drug|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
446615|NCT00795171|Drug|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
446616|NCT00795171|Drug|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
446617|NCT00795158|Drug|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
446543|NCT00795678|Drug|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
446544|NCT00795678|Drug|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
446545|NCT00795678|Drug|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
446546|NCT00795678|Drug|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
446547|NCT00795678|Drug|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
446548|NCT00795678|Drug|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
446549|NCT00795665|Drug|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
446550|NCT00795665|Drug|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
446551|NCT00795652|Behavioral|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
446552|NCT00795639|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
446553|NCT00795639|Drug|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
446554|NCT00795626|Behavioral|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
446555|NCT00795613|Drug|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
446556|NCT00795613|Drug|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
446557|NCT00795600|Drug|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
446558|NCT00795600|Drug|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
446559|NCT00795587|Drug|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
446560|NCT00795574|Drug|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
446561|NCT00795574|Drug|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
446562|NCT00795561|Procedure|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
446563|NCT00795561|Procedure|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
446564|NCT00795548|Drug|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.~DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
446565|NCT00795522|Drug|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
446618|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
446619|NCT00795145|Drug|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
446566|NCT00795509|Drug|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
446567|NCT00795496|Procedure|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
446568|NCT00795496|Procedure|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
446569|NCT00795496|Procedure|Serum IgE blood testing|One blood test to measure total serum IgE
446570|NCT00795496|Procedure|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
446571|NCT00795483|Drug|Zoledronic acid|Zoledronic Acid 5mg/year
446572|NCT00795483|Behavioral|Lifestyle modifications|Lifestyle modifications
446573|NCT00795483|Drug|Zoledronic acid|Zoledronic acid (5mg/2years)
446574|NCT00795470|Drug|Antimicrobial|Appropriate antimicrobial based on urine culture results
446575|NCT00795470|Device|Catheter change|Change urine catheter
446576|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
446577|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
446578|NCT00795444|Drug|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
446579|NCT00795418|Biological|Placebo|Placebo comparator
446580|NCT00795418|Biological|CAD106|
446581|NCT00795405|Behavioral|Exposure to sporting events|Exposure to sporting events
446582|NCT00795405|Behavioral|No exposure to sporting events|No exposure to sporting events
446583|NCT00795392|Other|ASA scale|ASA scale evaluation before operation
446584|NCT00795392|Other|Full-scale psychological assessment|Full-scale psychological evaluation before operation
446585|NCT00795379|Behavioral|Interoceptive Exposure|Exposure to internal stimuli.
446586|NCT00795366|Drug|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
446587|NCT00795366|Drug|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
446588|NCT00795353|Drug|Amevive exposure|Commercial alefacept prescribed by Physician
446589|NCT00795340|Drug|carboplatin|Given IV
446590|NCT00795340|Drug|cediranib maleate|Given orally
446591|NCT00795340|Drug|paclitaxel|Given IV
446592|NCT00795340|Other|placebo|Given orally
446593|NCT00795327|Device|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
446594|NCT00795314|Drug|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
446595|NCT00795314|Drug|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
446596|NCT00795301|Drug|Capecitabine, Cetuximab, Oxaliplatin|
446597|NCT00795288|Drug|Simvastatin, 80 mg/day for 21 days|Active treatment group
446598|NCT00795288|Drug|placebo|Control group
446599|NCT00795275|Drug|Januvia (sitagliptin phosphate)|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
446600|NCT00795262|Drug|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
446601|NCT00795262|Drug|accupril, placebo|accupril 40 mg
446602|NCT00795262|Drug|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
446603|NCT00795249|Behavioral|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
446604|NCT00795236|Drug|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
446605|NCT00795223|Drug|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
446606|NCT00795223|Drug|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
446607|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
446608|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
446609|NCT00795210|Drug|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
446610|NCT00795210|Drug|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
446611|NCT00795184|Device|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.~Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.~Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.~After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
446612|NCT00795184|Device|HDWLE|
446613|NCT00795184|Device|pCLE|
446614|NCT00795171|Drug|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
446620|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
446621|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
446622|NCT00795145|Drug|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
446623|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
446624|NCT00795145|Drug|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
446625|NCT00795132|Drug|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
446626|NCT00795132|Drug|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of~1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
446627|NCT00795132|Drug|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
446628|NCT00795132|Drug|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G~1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
446629|NCT00795132|Drug|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
446630|NCT00795119|Device|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
446631|NCT00795106|Drug|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
446632|NCT00795106|Drug|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
446633|NCT00795080|Procedure|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
446634|NCT00795054|Other|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
446635|NCT00795028|Other|Standard Care for people after hip fracture|
446636|NCT00795028|Other|Standard Care + exercise intervention|
446637|NCT00795015|Drug|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
446638|NCT00795015|Drug|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
446639|NCT00795002|Drug|alvocidib|Given IV
446640|NCT00795002|Drug|mitoxantrone hydrochloride|Given IV
446641|NCT00795002|Drug|cytarabine|Given IV
446642|NCT00795002|Other|pharmacological study|Correlative studies
446643|NCT00795002|Other|laboratory biomarker analysis|Correlative studies
446644|NCT00794989|Dietary Supplement|Ground Flaxseed|Given orally
446645|NCT00794989|Other|No Intervention|Participants randomized to Arm 2 do not receive any intervention
446646|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (low dose)|
446647|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (high dose)|
446648|NCT00794976|Drug|Dexamethasone Passive Patch|
446649|NCT00794976|Drug|Placebo Patch|
446650|NCT00794963|Drug|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
446651|NCT00794963|Other|As selected by community physician|As selected by community physician
446652|NCT00794950|Drug|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.~Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
446653|NCT00794924|Dietary Supplement|VSL#3|one sachet per day, for 45 consecutive days
446654|NCT00794924|Dietary Supplement|placebo|one sachet per day, for 45 consecutive days
446655|NCT00794911|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
446656|NCT00794911|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
446657|NCT00794898|Biological|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
446658|NCT00794885|Drug|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
446659|NCT00794885|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
446660|NCT00794872|Other|blood sampling|
446661|NCT00794859|Drug|Sorafenib|400mg twice daily
446662|NCT00794846|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
446663|NCT00794846|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
446664|NCT00794820|Drug|Fludarabine Phosphate|25 mg/m^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
446665|NCT00794820|Drug|Cyclophosphamide|250 mg/m^2 by vein over 60 minutes daily for 3 days (days 2-4)
446666|NCT00794820|Drug|Rituximab|375 mg/m^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m^2 on days 2-3
446667|NCT00794807|Drug|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
446668|NCT00794794|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
446669|NCT00794794|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
446670|NCT00794781|Drug|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
446671|NCT00794768|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
446672|NCT00794768|Drug|fexofenadine|Allegra 180 mg daily x 7 days
446673|NCT00794755|Dietary Supplement|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
446674|NCT00794755|Dietary Supplement|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
446675|NCT00794716|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
446676|NCT00794703|Drug|micafungin (Mycamine)|Intravenous
446677|NCT00794703|Drug|itraconazole|oral
446678|NCT00794690|Drug|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
446679|NCT00794677|Drug|ezetimibe|Blinded study medication (ezetimibe 10 mg or matching placebo in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
446680|NCT00794664|Drug|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
446681|NCT00794664|Drug|Placebo|1 mL weekly subcutaneous injections for 26 weeks
446682|NCT00794638|Drug|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
446683|NCT00794638|Drug|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
446684|NCT00794625|Drug|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
446685|NCT00794625|Drug|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
446686|NCT00794625|Drug|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
446687|NCT00794625|Drug|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
446688|NCT00794625|Behavioral|Behavioral family counseling|Weekly behavioral counseling with a therapist
446689|NCT00794612|Drug|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
446690|NCT00794599|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
446691|NCT00794599|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
446692|NCT00794586|Drug|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
446693|NCT00794586|Drug|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
446694|NCT00794573|Drug|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
446695|NCT00794573|Other|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
446696|NCT00794560|Behavioral|patient education|"Possible, individualized interventions:~Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material~Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)~Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom~First self-injection under control of a specially trained pharmacist"
446697|NCT00794547|Drug|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
446698|NCT00794547|Drug|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
446699|NCT00794508|Biological|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
446700|NCT00794495|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
446701|NCT00794495|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
446702|NCT00794482|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
446703|NCT00794469|Other|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
446704|NCT00794456|Drug|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
446705|NCT00794456|Drug|Valeriana|1 tablet PO twice a day
446706|NCT00794443|Drug|YM529 / ONO-5920|Oral
446707|NCT00794430|Drug|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
446708|NCT00794430|Drug|Placebo|Capsule, bid, for 13 weeks
446709|NCT00794417|Biological|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
446710|NCT00794417|Biological|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
446711|NCT00794417|Biological|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
446712|NCT00794391|Behavioral|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
446713|NCT00794391|Behavioral|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
446714|NCT00794378|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
446715|NCT00794378|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
446716|NCT00794365|Drug|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
446717|NCT00794339|Drug|64Cu-ATSM|
446718|NCT00794339|Radiation|FDG|
446719|NCT00794326|Drug|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
446720|NCT00794313|Drug|Amantadine 300 mg|Amantadine, 300 mg, capsule, three times a day, two weeks
446721|NCT00794313|Drug|Topiramate|Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
446722|NCT00794313|Drug|Sugar Pill|sugar pill, capsule, three times a day, 2 weeks
446723|NCT00794300|Device|second magnetic resonance imaging scan|
446724|NCT00794287|Other|Taking blood samples|No intervention is done. Only blood samples are taken.
446725|NCT00794274|Drug|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
446726|NCT00794261|Drug|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
446727|NCT00794261|Drug|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
446728|NCT00794248|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
446729|NCT00794248|Drug|fexofenadine|Allegra 180 mg daily x 7 days
446730|NCT00794235|Drug|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.~DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
446731|NCT00794222|Device|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
447117|NCT00791336|Drug|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
446732|NCT00794209|Drug|i.v fentanyl, AeroLEF|"i.v fentanyl~5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)~5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)~5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)~3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device."
446733|NCT00794196|Behavioral|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
446734|NCT00794183|Device|CRT device settings|Comparision of A-V delay settings
446735|NCT00794170|Behavioral|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
446736|NCT00794157|Drug|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
446737|NCT00794157|Drug|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
446738|NCT00794157|Drug|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
446739|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
446740|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
446741|NCT00794131|Biological|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
446742|NCT00794118|Other|As per clinical practice|As per clinical practice
446743|NCT00794092|Drug|Sinerem administration|Single dose
446744|NCT00794079|Dietary Supplement|omega-3 fatty acids|4 grams per day for 8 weeks
446745|NCT00794079|Dietary Supplement|corn oil|4 grams per day for 8 weeks
446746|NCT00794066|Procedure|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
446747|NCT00794053|Procedure|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
446748|NCT00794040|Drug|Add-on citalopram following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
446749|NCT00794040|Drug|Add-on placebo following optimized methylphenidate|After optimized treatment with methylphenidate, those who meet threshold for chronic irritability are randomized to add-on citalopram or placebo
446750|NCT00794027|Behavioral|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
446751|NCT00794027|Behavioral|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
446752|NCT00794014|Procedure|Conservative strategy|"Main vessel stenting was performed.~Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow <3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) >75% in LM subgroup.~Side branch stenting was performed if TIMI flow <3 in the Side branch after ballooning in non-LM subgroup, and DS >50% or dissection in the Side branch after ballooning in LM subgroup."
446753|NCT00794014|Procedure|Aggressive strategy|"Main vessel was performed.~Side branch ballooning and kissing ballooning were done if DS >75% in the side branch after main vessel stenting in non-LM subgroup, and DS >50% in LM subgroup.~Side branch stenting was performed if DS >50% in the side branch after ballooning in non-LM subgroup, and DS >30% or dissection in the side branch after ballooning in LM subgroup."
446754|NCT00794001|Behavioral|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
446755|NCT00793988|Procedure|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.~The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
446756|NCT00793988|Procedure|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
446757|NCT00793975|Biological|IMC-1121B|"Cohort 1~2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
446758|NCT00793975|Biological|1121B|"Cohort 2~4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
446759|NCT00793975|Biological|1121B|"Cohort 3~6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
446760|NCT00793975|Biological|1121B|"Cohort 4~8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
446761|NCT00793975|Biological|1121B|"Cohort 5~10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
446762|NCT00793975|Biological|1121B|"Cohort 6~13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
446763|NCT00793975|Biological|1121B|"Cohort 7~16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
446764|NCT00793962|Radiation|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
446765|NCT00793962|Radiation|conventional fractionation radiotherapy|50Gy/25/f/5w
447272|NCT00790309|Procedure|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
446766|NCT00793923|Drug|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
446767|NCT00793923|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
446768|NCT00793910|Drug|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
446769|NCT00793910|Drug|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
446770|NCT00793897|Drug|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
446771|NCT00793897|Drug|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
446772|NCT00793897|Drug|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
446773|NCT00793871|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
446774|NCT00793858|Drug|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
446775|NCT00793845|Drug|Cyclophosphamide|First HDCT
446776|NCT00793845|Drug|Etoposide|First HDCT
446777|NCT00793845|Drug|Carboplatin|First HDCT
446778|NCT00793845|Drug|Thiotepa|Second HDCT
446779|NCT00793845|Drug|Melphalan|Second HDCT
446780|NCT00793845|Radiation|Total body irradiation|Second HDCT
446781|NCT00793832|Behavioral|supervised exercise|supervised exercise
446782|NCT00793832|Behavioral|Diet advice|Diet Advice
446783|NCT00793819|Drug|silodosin|α1-adrenergic antagonist
446784|NCT00793806|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
446785|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
446786|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
446787|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
446788|NCT00793793|Drug|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
446789|NCT00793793|Drug|Placebo|
446790|NCT00793780|Drug|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
446791|NCT00793780|Other|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
446792|NCT00793767|Drug|erythropoietin|bolus of 400 IU/kg
446793|NCT00793767|Drug|placebo (saline)|i.v
446794|NCT00793754|Drug|Aspirin|100 mg / day for 8 weeks
446795|NCT00793754|Drug|Atorvastatin|40 mg / day for 8 weeks
446796|NCT00793754|Drug|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
446797|NCT00793741|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
446798|NCT00793728|Procedure|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
446799|NCT00793715|Procedure|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
446800|NCT00793715|Procedure|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
446801|NCT00793702|Biological|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
446802|NCT00793676|Other|spirometry|
446803|NCT00793676|Other|blood test|
446804|NCT00793663|Drug|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
446805|NCT00793663|Drug|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
446806|NCT00793663|Drug|Dexamethasone|Intravenous use, 4 mg, single shot
446807|NCT00793663|Drug|NaCl|Intravenous use; single shot
446808|NCT00793663|Drug|Ondansetron|Intravenous use; 4 mg; single shot
446809|NCT00793663|Drug|NaCl|Intravenous use; single shot
446810|NCT00793650|Drug|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
446811|NCT00793650|Drug|Melphalan|"All patients received melphalan (100 mg/m^2/day × 2; days~−3 and −2), for a total dose of 200 mg/m^2."
446812|NCT00793650|Procedure|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
446813|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
446814|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
446815|NCT00793624|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
446816|NCT00793624|Drug|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
446817|NCT00793624|Drug|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
446818|NCT00793611|Behavioral|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
446819|NCT00793611|Other|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
446820|NCT00793598|Drug|Placebo|Placebo Cohort 3A placebo once weekly for a total of 5 doses Cohort 4A placebo twice weekly for a total of nine doses Cohort 4B placebo once or twice weekly Cohort 4C placebo once or twice weekly
446821|NCT00793598|Drug|CMX001|Cohort 3A 40mg CMX001 once weekly for a total of 5 doses Cohort 4A 100mg CMX001 twice weekly for a total of nine doses Cohort 4B 200mg CMX001 once or twice weekly Cohort 4C 300mg CMX001 once or twice weekly
446822|NCT00793585|Drug|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level < 6mg/dl , the dosage changed to 200mg/d.
446823|NCT00793585|Other|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
446824|NCT00793572|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
446825|NCT00793572|Drug|Bortezomib|Given SC
446826|NCT00793572|Drug|Cyclosporine|Given IV
446827|NCT00793572|Drug|Cyclosporine|Given PO
446828|NCT00793572|Drug|Fludarabine Phosphate|Given IV
446829|NCT00793572|Other|Laboratory Biomarker Analysis|Correlative studies
446830|NCT00793572|Drug|Melphalan|Given IV
446831|NCT00793572|Drug|Mycophenolate Mofetil|Given PO
446832|NCT00793572|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
446833|NCT00793572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
446834|NCT00793572|Procedure|Syngeneic Bone Marrow Transplantation|Undergo transplantation
446835|NCT00793572|Radiation|Total-Body Irradiation|Undergo radiotherapy
446836|NCT00793559|Drug|terlipressin|1 mg of terlipressin one time only
446837|NCT00793559|Drug|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
446838|NCT00793546|Drug|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
446839|NCT00793546|Drug|exemestane|25 mg tablet once daily
446840|NCT00793546|Drug|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
446841|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
446842|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
446843|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
446844|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
446845|NCT00793507|Other|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
446846|NCT00793494|Other|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
446847|NCT00793494|Other|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
446848|NCT00793481|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
446849|NCT00793468|Drug|GSK598809|GSK598809 once daily for 12 weeks
446850|NCT00793468|Drug|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
446851|NCT00793468|Drug|Placebo|Placebo once daily for 12 weeks
446852|NCT00793455|Behavioral|Educational outreach|Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
446853|NCT00793442|Diagnostic Test|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
446854|NCT00793429|Drug|Prucalopride|
446855|NCT00793429|Other|Placebo|
446856|NCT00793416|Device|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
446857|NCT00793403|Other|As per routinary clinical care|As per routine clinical care
446858|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
446859|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
446860|NCT00793364|Dietary Supplement|Stanol ester spread|Stanol ester spread 20 g every day
446861|NCT00793364|Dietary Supplement|Placebo spread|Placebo spread 20 g every day
446862|NCT00793364|Dietary Supplement|Mediterranean Diet|Mediterranean Diet every day
446863|NCT00793351|Procedure|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme~Enrollment - Pre-RIST treatment - RIST~4 cycles of conventional chemotherapy will be given prior to RIST.~Surgery will be done whenever possible prior to RIST.~Local radiotherapy will be applied whenever possible prior to RIST.~topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.~Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
446864|NCT00793338|Drug|Sildenafil|Sildenafil 20mg three times a day for 3 months.
446948|NCT00792870|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
446865|NCT00793325|Drug|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
446866|NCT00793299|Behavioral|Video Illness Narrative|video
446867|NCT00793286|Procedure|Mesh fixation by staples|Mesh fixation by staples
446868|NCT00793286|Procedure|Mesh fixation by glue|Mesh fixation by glue
446869|NCT00793273|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
446870|NCT00793260|Behavioral|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.~The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.~The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
446871|NCT00793260|Behavioral|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
446872|NCT00793247|Drug|PRU-PLA-PRU-PLA|
446873|NCT00793247|Drug|PLA-PRU-PLA-PRU|
446874|NCT00793247|Drug|PLA-PRU-PRU-PLA|
446875|NCT00793247|Drug|PRU-PLA-PLA-PRU|
446876|NCT00793234|Drug|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
446877|NCT00793234|Drug|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
446878|NCT00793221|Device|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
446879|NCT00793221|Device|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
446880|NCT00793208|Biological|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.~Subjects will have immunizations administered at 4 different sites for each vaccination as follows:~Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
446881|NCT00793195|Drug|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
446882|NCT00793195|Drug|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
446883|NCT00793182|Drug|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
446884|NCT00793182|Drug|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
446885|NCT00793169|Procedure|Blood Draw|Serum levels were measured
446886|NCT00793156|Drug|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
446887|NCT00793156|Drug|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
446888|NCT00793156|Other|Placebo|Placebo daily dose
446889|NCT00793130|Dietary Supplement|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
446890|NCT00793117|Procedure|packing|packing in middle meatus for duration of 5 day
446891|NCT00793104|Procedure|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
446892|NCT00793091|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
446893|NCT00793091|Drug|Placebo|4 drops applied daily for 120 days
446894|NCT00793065|Other|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
446895|NCT00793065|Other|Medical Home redesign|Implementation of NCQA Level III Medical Home
446896|NCT00793052|Drug|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
446897|NCT00793026|Drug|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
446949|NCT00792857|Drug|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
446898|NCT00793013|Device|Volume-Cycled Assist-Control (AC) mode|"Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40%~Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min~Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2~Inspiratory to Expiratory ratio set at 1:1 to 1:3~If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased~Mgmt of PEEP will be conducted as per the ARDSnet Protocol~Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%~Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
446899|NCT00793013|Device|Airway Pressure Release Ventilation (APRV) mode|"Ventilation uses Drager Model X1~Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels~Time periods for the high & low pressure levels can be set independently~Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume~Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min~Spontaneous frequency will be targeted for 6 to 18 breaths/per min~If spontaneous breathing is achieved,level of sedation will be decreased~If spontaneous respirations are >20 breaths/min, sedation will be increased~If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
446900|NCT00793000|Drug|PF-04287881|75 mg oral dose (prepared solution) given once
446901|NCT00793000|Drug|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
446902|NCT00793000|Drug|PF-04287881|150 mg oral dose (prepared solution) given once
446903|NCT00793000|Drug|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
446904|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
446905|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
446906|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
446907|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
446908|NCT00793000|Drug|PF-04287881|1000 mg oral dose (prepared solution) given once
446909|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
446910|NCT00793000|Drug|PF-04287881|1250 mg oral dose (prepared solution) given once
446911|NCT00793000|Drug|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
446912|NCT00793000|Drug|PF-04287881|1500 mg oral dose (prepared solution) given once
446913|NCT00793000|Drug|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
446914|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
446915|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
446916|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
446917|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
446918|NCT00793000|Drug|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
446919|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
446920|NCT00792974|Behavioral|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.~This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
446921|NCT00792961|Device|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
446922|NCT00792948|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
446923|NCT00792948|Drug|Cyclophosphamide|Given IV
446924|NCT00792948|Drug|Cytarabine|Given IT
446925|NCT00792948|Drug|Dasatinib|Given PO
446926|NCT00792948|Drug|Dexamethasone|Given IV or PO
446927|NCT00792948|Drug|Doxorubicin Hydrochloride|Given IV
446928|NCT00792948|Drug|Etoposide|Given IV
446929|NCT00792948|Biological|Filgrastim|Given SC
446930|NCT00792948|Other|Laboratory Biomarker Analysis|Correlative studies
446931|NCT00792948|Drug|Leucovorin Calcium|Given IV
446932|NCT00792948|Drug|Methotrexate|Given IV or IT
446933|NCT00792948|Drug|Methylprednisolone|Given IV
446934|NCT00792948|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
446935|NCT00792948|Drug|Prednisone|Given PO
446936|NCT00792948|Drug|Sirolimus|Given PO
446937|NCT00792948|Drug|Tacrolimus|Given IV
446938|NCT00792948|Radiation|Total-Body Irradiation|Undergo TBI
446939|NCT00792948|Drug|Vincristine Sulfate|Given IV
446940|NCT00792935|Drug|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
446941|NCT00792935|Drug|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
446942|NCT00792935|Drug|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin [(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)], the participant should remain on the same metformin dose throughout the study.
446943|NCT00792922|Drug|Azithromycin|Comparison of community coverage rate
446944|NCT00792922|Drug|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is >5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
446945|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
446946|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
446947|NCT00792896|Behavioral|family conference|family conference
447063|NCT00791895|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme
446950|NCT00792857|Drug|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
446951|NCT00792844|Dietary Supplement|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
446952|NCT00792844|Dietary Supplement|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
446953|NCT00792831|Drug|ITF2357|Histone-Deacetylase Inhibitor
446954|NCT00792818|Drug|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
446955|NCT00792818|Drug|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
446956|NCT00792805|Drug|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
446957|NCT00792805|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
446958|NCT00792805|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
446959|NCT00792792|Device|Modulated Imaging|Modulated Imaging Spectroscopy
446960|NCT00792779|Drug|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
446961|NCT00792766|Drug|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
446962|NCT00792753|Device|Medtronic Endeavor Coronary Stent System|coronary stent implantation
446963|NCT00792753|Device|DESyne BD Novolimus Stent System|coronary stent implantation
446964|NCT00792753|Device|DESyne Novolimus Stent System|coronary stent implantation
446965|NCT00792740|Drug|ITF2357|ITF2357 will be supplied as hard gelatin capsules for oral administration at the dose strength of 50 mg.
446966|NCT00792740|Drug|Placebo capsules|Placebo will be supplied as matching capsules for oral administration with the same outer appearance
446967|NCT00792727|Drug|ketoprofen Patch|2 topical patches applied once daily for 28 days
446968|NCT00792727|Other|Placebo Patch|2 topical placebo patches applied once daily for 28 days
446969|NCT00792714|Drug|Mannitol|400mg twice daily for 7 days
446970|NCT00792701|Drug|cisplatin|Given IV
446971|NCT00792701|Drug|gemcitabine hydrochloride|Given IV
446972|NCT00792688|Drug|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
446973|NCT00792688|Drug|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
446974|NCT00792688|Drug|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
446975|NCT00792675|Other|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
446976|NCT00792662|Drug|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
446977|NCT00792662|Drug|Placebo|Standard inactive pill.
446978|NCT00792636|Drug|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
446979|NCT00792636|Drug|sumatriptan tablet|sumatriptan 85mg
446980|NCT00792636|Drug|naproxen sodium tablet|Naproxen sodium 500mg
446981|NCT00792623|Biological|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
446982|NCT00792610|Biological|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
446983|NCT00792584|Drug|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
446984|NCT00792584|Drug|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
446985|NCT00792571|Drug|Beraprost Sodium Modified Release|
446986|NCT00792558|Drug|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
446987|NCT00792532|Procedure|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
446988|NCT00792532|Device|DBS electrodes|Deep brain stimulation (DBS) electrodes
446989|NCT00792519|Behavioral|HIV support group|group support
446990|NCT00792519|Behavioral|CBT|group cognitive behavioral treatment
446991|NCT00792506|Drug|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to end of treatment. The patient had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
446992|NCT00792493|Drug|ORM-12741|Alternating panel multiple dose escalation
446993|NCT00792480|Behavioral|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.~At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
446994|NCT00792467|Drug|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
447273|NCT00790296|Drug|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
446995|NCT00792454|Behavioral|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.~Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.~Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
446996|NCT00792441|Device|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
446997|NCT00792428|Device|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
446998|NCT00792428|Device|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
446999|NCT00792389|Other|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
447000|NCT00792389|Other|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
447001|NCT00792376|Drug|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
447002|NCT00792376|Drug|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
447003|NCT00792363|Drug|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
447004|NCT00792363|Drug|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
447005|NCT00792350|Drug|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
447006|NCT00792337|Drug|simvastatin|10 mg per oral once daily for 8 weeks
447007|NCT00792337|Drug|B1-6-12|1 table per day for 8 weeks
447008|NCT00792324|Drug|Etravirine|Four 100mg tablets daily for 12-24 weeks
447009|NCT00792324|Drug|Efavirenz|One 600mg tablet daily
447010|NCT00792311|Procedure|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
447011|NCT00792298|Drug|Suvorexant|oral tablet taken before bedtime
447012|NCT00792298|Drug|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
447013|NCT00792285|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
447014|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
447015|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
447016|NCT00792233|Other|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
447017|NCT00792220|Procedure|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
447018|NCT00792220|Procedure|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
447019|NCT00792207|Other|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
447020|NCT00792207|Other|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
447021|NCT00792194|Other|Exercise training|"Subjects will be randomised in two groups:~a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.~a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
447022|NCT00792181|Drug|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
447023|NCT00792181|Other|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
447064|NCT00791882|Behavioral|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
447065|NCT00791856|Drug|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
447066|NCT00791856|Drug|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
447024|NCT00792168|Drug|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
447025|NCT00792168|Other|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
447026|NCT00792142|Drug|bortezomib|Given IV
447027|NCT00792142|Drug|dexamethasone|Given orally
447028|NCT00792142|Drug|melphalan|Given IV
447029|NCT00792142|Drug|thalidomide|Given orally
447030|NCT00792142|Genetic|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
447031|NCT00792142|Genetic|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
447032|NCT00792142|Other|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
447033|NCT00792142|Other|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
447034|NCT00792142|Procedure|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
447035|NCT00792142|Procedure|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
447036|NCT00792129|Device|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.~The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
447037|NCT00792116|Behavioral|Gum Chewing|
447038|NCT00792103|Drug|NP101|NP101 study patch 4 hour application
447039|NCT00792090|Other|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
447040|NCT00792090|Other|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
447041|NCT00792077|Drug|Lenalidomide|5 mg daily for 56 days.
447042|NCT00792051|Biological|Inactivated influenza vaccine|0.5ml intramuscular single dose
447043|NCT00792051|Biological|Saline|0.5ml intramuscular, one dose
447044|NCT00792025|Drug|sunitinib malate|
447045|NCT00792012|Radiation|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
447046|NCT00792012|Drug|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
447047|NCT00791999|Drug|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
447048|NCT00791999|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
447049|NCT00791999|Drug|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
447050|NCT00791999|Drug|Placebo of CDP870|given every 2 weeks until Week22 (SC)
447051|NCT00791986|Device|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.~LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
447052|NCT00791973|Drug|fluticasone furoate|2 puffs in each nostril once daily for 1 week
447053|NCT00791973|Drug|Placebo|2 puffs in each nostril once daily for 1 week
447054|NCT00791960|Drug|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
447055|NCT00791960|Other|Placebo|single dose, 10 mL normal saline, IV
447056|NCT00791947|Drug|CHOEP + G-CSF followed by BEAM|"CHOEP:~Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5~BEAM:~Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
447057|NCT00791934|Device|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
447058|NCT00791921|Drug|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
447059|NCT00791921|Drug|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
447060|NCT00791908|Procedure|Electrodessication|Treatment applied to a third of the torso at each study visit.
447061|NCT00791908|Procedure|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
447062|NCT00791908|Procedure|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
447274|NCT00790296|Drug|Placebo|Saline
447067|NCT00791843|Drug|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
447068|NCT00791830|Drug|Irbesartan|Tablets, 300 mg * 1 daily, 1 year
447069|NCT00791830|Drug|Placebo matching irbesartan 150 mg|Tablets, 300 mg * 1 daily, 1 year
447070|NCT00791817|Drug|PG-760564|200 mg capsule, single dose,fasted when dosed, duration is 4 days
447071|NCT00791817|Drug|PG-760564|200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
447072|NCT00791804|Drug|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~for nebulized administration as required by the patient.~Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
447073|NCT00791791|Procedure|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
447074|NCT00791778|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
447075|NCT00791778|Drug|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
447076|NCT00791765|Biological|Etanercept|Etanercept for subcutaneous injection.
447077|NCT00791765|Biological|Placebo|Placebo for subcutaneous injection.
447078|NCT00791752|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
447079|NCT00791752|Drug|Placebo|Placebo
447080|NCT00791739|Drug|trazodone, pregabalin|"phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability~phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
447081|NCT00791713|Drug|Paliperidone ER|
447082|NCT00791700|Drug|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
447083|NCT00791661|Drug|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
447084|NCT00791661|Drug|Placebo|Matching placebo to MK-1006 in a single oral dose
447085|NCT00791648|Drug|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.~Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
447086|NCT00791648|Drug|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.~Aim 2 control: placebo the day of cardiac surgery and postop day 1."
447087|NCT00791635|Behavioral|Questionnaires|11 Questionnaires
447088|NCT00791622|Drug|Paliperidone ER|
447089|NCT00791596|Other|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
447090|NCT00791570|Biological|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
447091|NCT00791557|Drug|Infliximab|IV drug given at weeks 1,2,14,22
447092|NCT00791544|Drug|AVE1642|intravenous infusion
447093|NCT00791544|Drug|sorafenib|oral intake
447094|NCT00791544|Drug|erlotinib|oral intake
447095|NCT00791531|Drug|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
447096|NCT00791518|Drug|No intervention|No intervention
447097|NCT00791505|Drug|ciprofloxacin|1500 mg a day for 10 days
447098|NCT00791505|Drug|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
447099|NCT00791492|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
447100|NCT00791479|Drug|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
447101|NCT00791479|Drug|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
447102|NCT00791466|Dietary Supplement|Placebo|Daily placebo supplementation from enrolment <14 wk of gestation until delivery
447103|NCT00791466|Dietary Supplement|Iodine|Daily supplementation with 200 µg iodine from enrolment <14 wk of gestation until delivery
447104|NCT00791453|Behavioral|Education|Patients will receive literacy appropriate health information.
447105|NCT00791440|Behavioral|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
447106|NCT00791440|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
447107|NCT00791427|Drug|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
447108|NCT00791401|Drug|ER OROS Paliperidone|
447109|NCT00791388|Drug|Placebo|oral capsule, 2x/day for 14 days
447110|NCT00791388|Drug|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
447111|NCT00791388|Drug|PG-760564|oral capsule, 100mg, 2x/day for 14 days
447112|NCT00791388|Drug|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
447113|NCT00791388|Drug|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
447114|NCT00791375|Behavioral|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
447115|NCT00791362|Other|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
447116|NCT00791349|Drug|Immediate release (IR) Paliperidone|
447324|NCT00789984|Device|noncontact specular microscopy|
447118|NCT00791323|Drug|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
447119|NCT00791323|Drug|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
447120|NCT00791310|Drug|Flucis|FDG injected i.v
447121|NCT00791297|Drug|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
447122|NCT00791284|Drug|Intermediate release (IR) Paliperidone|
447123|NCT00791271|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
447124|NCT00791271|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
447125|NCT00791258|Drug|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
447126|NCT00791258|Drug|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
447127|NCT00791245|Biological|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
447128|NCT00791232|Drug|extended-release (ER) OROS paliperidone|
447129|NCT00791219|Drug|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
447130|NCT00791219|Drug|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
447131|NCT00791219|Drug|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
447132|NCT00791206|Procedure|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
447133|NCT00791206|Procedure|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
447134|NCT00791193|Drug|Paliperidone ER|
447135|NCT00791167|Drug|Paliperidone ER|
447136|NCT00791154|Drug|AMG 479|AMG 479 is administered to subjects
447137|NCT00791154|Drug|Etoposide|Etoposide is administered to subjects
447138|NCT00791154|Drug|Placebo|Placebo is administered with Carboplatin and Etoposide
447139|NCT00791154|Drug|AMG 102|AMG 102 is administered to subjects
447140|NCT00791154|Drug|Carboplatin|Carboplatin is administered to some subjects in combination
447141|NCT00791154|Drug|Cisplatin|Cisplatin is administered to some subjects in combination
447142|NCT00791141|Drug|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
447143|NCT00791128|Device|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
447144|NCT00791115|Procedure|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
447145|NCT00791102|Drug|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
447146|NCT00791102|Drug|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
447147|NCT00791089|Drug|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
447148|NCT00791089|Drug|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
447149|NCT00791089|Other|placebo|Control group will receive placebo before & after ablation.
447150|NCT00791076|Drug|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
447151|NCT00791076|Drug|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
447152|NCT00791063|Other|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
447153|NCT00791050|Device|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
447154|NCT00791037|Biological|HER-2/neu peptide vaccine|Given ID
447155|NCT00791037|Procedure|leukapheresis|Undergo leukapheresis
447156|NCT00791037|Biological|ex vivo-expanded HER2-specific T cells|Given IV
447157|NCT00791037|Drug|cyclophosphamide|Given IV
447158|NCT00791037|Biological|sargramostim|Given ID
447159|NCT00791037|Other|laboratory biomarker analysis|Correlative study
447160|NCT00791024|Drug|CRC-Pharma 001|50 mg
447161|NCT00791024|Drug|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
447162|NCT00791011|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
447163|NCT00791011|Other|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
447164|NCT00791011|Other|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
447165|NCT00790998|Drug|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
447166|NCT00790998|Drug|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
447167|NCT00790985|Dietary Supplement|flavocoxid|medical food
447168|NCT00790985|Drug|Naproxen|antiinflammatory drug
447169|NCT00790972|Drug|Sinofresh|two sprays in each nostril three times daily for one week
447170|NCT00790972|Drug|Placebo|two sprays in each nostril three times daily for one week
447209|NCT00790699|Device|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
447511|NCT00788671|Other|Quality-of-Life Assessment|Ancillary studies
447171|NCT00790959|Behavioral|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours~The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
447172|NCT00790959|Other|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.~For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
447173|NCT00790946|Drug|Valsartan|Valsartan 80 to 160 mg
447174|NCT00790933|Drug|Vedolizumab|Vedolizumab intravenous infusion
447175|NCT00790920|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
447176|NCT00790920|Drug|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
447177|NCT00790907|Drug|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein [GP] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) [maximum two additional bolus doses]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
447178|NCT00790907|Drug|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
447179|NCT00790907|Drug|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
447180|NCT00790894|Drug|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
447181|NCT00790894|Drug|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
447182|NCT00790881|Drug|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
447183|NCT00790881|Drug|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
447184|NCT00790868|Drug|d-cycloserine|50mg
447185|NCT00790868|Drug|placebo|50mg
447186|NCT00790855|Drug|Bendamustine|Starting dose of 50 mg/m^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
447187|NCT00790842|Drug|Lenalidomide|Given by mouth days 1-21 of a 28-day cycle. There is a 7 day rest (days 22-28). Continue until disease progression or unacceptable toxicity.
447188|NCT00790842|Drug|Dexamethasone|40 mg given by mouth days 1, 8, 15 and 22 of a 28-day cycle. Continue until disease progression or unacceptable toxicity.
447189|NCT00790842|Drug|Anticoagulants|Anticoagulation consisted of aspirin at either 81 mg/day or 325 mg/day at the physician's discretion. Heparin, low molecular weight heparin, or coumadin could be used if the patient was intolerant to aspirin.
447190|NCT00790829|Drug|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
447191|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
447192|NCT00790816|Drug|Lapatinib|Lapatinib monotherapy
447193|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
447194|NCT00790803|Drug|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
447195|NCT00790790|Drug|Placebo|LY545694 placebo BID po for 5 weeks
447196|NCT00790790|Drug|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
447197|NCT00790790|Drug|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
447198|NCT00790777|Drug|Paliperidone ER|
447199|NCT00790764|Biological|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
447200|NCT00790764|Other|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
447201|NCT00790751|Drug|placebo|30 minutes orally prior to initiation of sexual activity
447202|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
447203|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
447204|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
447205|NCT00790738|Drug|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
447206|NCT00790738|Drug|placebo|placebo
447207|NCT00790725|Other|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
447208|NCT00790725|Other|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
447271|NCT00790309|Procedure|Weight loss surgery|Weight loss surgery
447210|NCT00790699|Other|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
447211|NCT00790686|Procedure|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
447212|NCT00790673|Drug|CF 102|Oral capsules
447213|NCT00790673|Drug|Placebo|Matching placebo capsules
447214|NCT00790660|Drug|ASP1941|Oral
447215|NCT00790660|Drug|Placebo|Oral
447216|NCT00790647|Biological|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
447217|NCT00790647|Drug|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
447218|NCT00790647|Drug|melphalan|100 mg/m2/dose D -2, D -1
447219|NCT00790647|Procedure|Stem Cell Infusion|infusion of previously collected autologous stem cells
447220|NCT00790608|Drug|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
447221|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
447222|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
447223|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
447224|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
447225|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
447226|NCT00790582|Drug|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
447227|NCT00790569|Drug|nicotine|Given transdermally and orally
447228|NCT00790569|Drug|varenicline|Given orally
447229|NCT00790569|Other|placebo|Given orally
447230|NCT00790556|Drug|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
447231|NCT00790556|Drug|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
447232|NCT00790530|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
447233|NCT00790530|Other|Usual Care|Usual Care
447234|NCT00790517|Behavioral|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
447235|NCT00790491|Behavioral|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
447236|NCT00790478|Dietary Supplement|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
447237|NCT00790478|Other|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
447238|NCT00790465|Dietary Supplement|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
447239|NCT00790465|Dietary Supplement|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
447240|NCT00790452|Drug|Aspirin|325 mg daily by mouth
447241|NCT00790452|Drug|Placebo|Tablet daily by mouth
447242|NCT00790439|Drug|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
447243|NCT00790439|Drug|Heparin|Anticoagulant
447244|NCT00790439|Drug|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
447245|NCT00790439|Drug|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
447246|NCT00790439|Drug|Tacrolimus|Calcineurin inhibitor
447247|NCT00790439|Drug|Cyclosporine|Calcineurin inhibitor, immunosuppressant
447248|NCT00790439|Drug|Daclizumab|Monoclonal IL-2 receptor blocker
447249|NCT00790439|Drug|Basiliximab|Monoclonal IL-2 receptor blocker
447250|NCT00790439|Biological|Allogeneic Pancreatic Islet Cells|
447251|NCT00790426|Drug|TKI258|
447252|NCT00790413|Drug|iodine I 131 metaiodobenzylguanidine|
447253|NCT00790413|Drug|Fludarabine|
447254|NCT00790413|Drug|Thiotepa|
447255|NCT00790413|Procedure|T-cell depletion|
447256|NCT00790413|Procedure|Haploidentical stem cell transplantation|
447257|NCT00790413|Procedure|Donor Lymphocyte Infusion|
447258|NCT00790413|Drug|Rituximab|
447259|NCT00790413|Procedure|Co-transplantation of mesenchymal stem cells|
447260|NCT00790400|Drug|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
447261|NCT00790400|Drug|Everolimus Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
447262|NCT00790387|Drug|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
447263|NCT00790387|Drug|Tirofiban|
447264|NCT00790387|Drug|unfractionated heparin|
447265|NCT00790374|Drug|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
447266|NCT00790374|Drug|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
447267|NCT00790374|Drug|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
447268|NCT00790335|Drug|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
447269|NCT00790322|Drug|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
447270|NCT00790322|Other|Placebo|Solution for oral use
447275|NCT00790283|Device|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.~Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
447276|NCT00790270|Drug|Cyclobenzaprine|5 mg orally every 8 hours as needed
447277|NCT00790270|Drug|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
447278|NCT00790270|Drug|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
447279|NCT00790257|Device|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
447280|NCT00790244|Drug|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
447281|NCT00790244|Drug|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
447282|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
447283|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.~(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
447284|NCT00790231|Device|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
447285|NCT00790218|Drug|CF102|CF102 capsules twice daily by mouth
447286|NCT00790205|Drug|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
447287|NCT00790205|Drug|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
447288|NCT00790192|Drug|Lurasidone|Lurasidone 80 mg tablets
447289|NCT00790192|Drug|Lurasidone|Lurasidone 4 40 mg tablets
447290|NCT00790192|Drug|Quetiapine XR|Quetiapine XR 600mg
447291|NCT00790192|Drug|Placebo|Matching Placebo to Lurasidone or Quetiapine
447292|NCT00790179|Procedure|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
447293|NCT00790166|Device|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
447294|NCT00790166|Device|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
447295|NCT00790166|Device|CPAP + No added humidity|ambient humidity
447296|NCT00790153|Drug|Insulin|Insulin infusion given during 3 hours at one occasion.
447297|NCT00790153|Drug|AZD1656|Single dose oral suspension given at one occasion.
447298|NCT00790140|Dietary Supplement|Prosure|This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
447299|NCT00790140|Dietary Supplement|Ensure Plus|This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
447300|NCT00790127|Drug|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
447301|NCT00790127|Drug|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
447302|NCT00790114|Drug|AZD7325|Oral, day 1-12
447303|NCT00790114|Drug|Midazolam|single dose, twice during treatment
447304|NCT00790114|Drug|Caffeine|single dose, twice during treatment
447305|NCT00790101|Drug|Risedronate|
447306|NCT00790101|Drug|Raloxifene|
447307|NCT00790101|Other|Placebo|
447308|NCT00790075|Drug|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was >30 minutes.
447309|NCT00790062|Drug|Oxytocin|See arms
447310|NCT00790049|Drug|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
447311|NCT00790049|Drug|Placebo; oral|matching placebo
447312|NCT00790036|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
447313|NCT00790036|Drug|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
447314|NCT00790023|Drug|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
447315|NCT00790023|Drug|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
447316|NCT00790023|Drug|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
447317|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
447318|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
447319|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
447320|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
447321|NCT00789997|Drug|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
447322|NCT00789997|Drug|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
447323|NCT00789997|Drug|levofloxacin|Levofloxacin 750 mg daily for 10 days.
447325|NCT00789971|Drug|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
447326|NCT00789971|Drug|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
447327|NCT00789958|Drug|capecitabine|"Adjuvant chemotherapy: 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
447328|NCT00789958|Drug|gemcitabine hydrochloride|1000 mg/m^2, IV, Days 1 & 8 of each cycle
447329|NCT00789958|Radiation|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
447330|NCT00789958|Radiation|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
447331|NCT00789945|Other|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
447332|NCT00789945|Other|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
447333|NCT00789932|Behavioral|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
447334|NCT00789932|Behavioral|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
447335|NCT00789919|Procedure|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
447336|NCT00789893|Device|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis & assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st & 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, & the 2nd will be one month ± 2 weeks from last day of radiation.
447337|NCT00789880|Drug|Vitamin D3|Administration of oral vitamin D3 at 4000IU
447338|NCT00789880|Drug|Placebo|Administration of oral Vitamin D3 placebo
447339|NCT00789867|Drug|pGM169/GL67A|Plasmid expressing the human CFTR gene complexed with cationic lipid 67 and helper lipids: 10 ml nebulised and 1 ml nasal administration (n=3) and 20 ml nebulised and 2 ml nasal (n=24)
447340|NCT00789854|Drug|Quetiapine XR|300 mg once daily (od)
447341|NCT00789854|Drug|Lithium carbonate|900 mg once daily (od)
447342|NCT00789854|Drug|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
447343|NCT00789841|Device|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
447344|NCT00789828|Drug|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
447345|NCT00789828|Drug|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
447346|NCT00789815|Device|Bispectral index guide propofol infusion|"Induction:~Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.~Maintenance:~Propofol infusion (3~12 mg/kg/hour) to maintain BIS around 65~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
447347|NCT00789815|Drug|Clinical-judged midazolam administration|"Induction:~Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S* 2~3.~Maintenance:~Midazolam: 2 mg/ 2min prn to keep OAA/S* 2~3 or if intolerance of procedure. Alfentanil as study arm.~*Observer's assessment of alertness/sedation (OAA/S):~Class 5: Responds readily to name spoken in normal tone.~Class 4: Lethargic response to name called in normal tone.~Class 3: Responds only to name called loudly.~Class 2: Responds only to shaking.~Class 1: No response to shaking."
447348|NCT00789802|Drug|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
447349|NCT00789802|Drug|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
447350|NCT00789802|Drug|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
447351|NCT00789776|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
447352|NCT00789776|Drug|Cyclophosphamide|Given IV
447353|NCT00789776|Drug|Fludarabine Phosphate|Given IV
447354|NCT00789776|Other|Laboratory Biomarker Analysis|Correlative studies
447355|NCT00789776|Drug|Mycophenolate Mofetil|Given PO
447356|NCT00789776|Biological|Natural Killer Cell Therapy|Given IV
447357|NCT00789776|Drug|Tacrolimus|Given IV or PO
447358|NCT00789776|Radiation|Total-Body Irradiation|Undergo total-body irradiation
447359|NCT00789763|Drug|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
447360|NCT00789763|Radiation|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
447361|NCT00789763|Drug|Sorafenib|200-800 mg/day p.o. during 5 weeks
447362|NCT00789750|Drug|Colesevelam|Colesevelam 625 mg tablets
447363|NCT00789750|Drug|Placebo|Placebo tablets appearing to be colesevelam
447364|NCT00789750|Drug|Pioglitazone|30 mg or 45 mg pioglitazone therapy
447365|NCT00789737|Drug|Welchol|Welchol 625mg tablets
447366|NCT00789737|Drug|Placebo|placebo
447367|NCT00789724|Drug|Anakinra|100 mg daily subcutaneous injection for 14 days
447368|NCT00789724|Drug|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
447369|NCT00789711|Drug|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
447370|NCT00789711|Drug|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
447371|NCT00789698|Drug|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
447372|NCT00789698|Drug|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
447373|NCT00789685|Drug|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
447374|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
447375|NCT00789672|Device|patching|2 hours daily patching
447376|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
447377|NCT00789659|Other|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
447378|NCT00789646|Procedure|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
447379|NCT00789646|Procedure|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
447380|NCT00789633|Drug|Masitinib|Masitinib at 9 mg/kg/day given orally twice daily
447381|NCT00789633|Drug|Placebo|Matching placebo given orally twice daily
447382|NCT00789633|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 by intravenous infusion
447383|NCT00789620|Drug|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
447384|NCT00789620|Drug|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
447385|NCT00789607|Device|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
447386|NCT00789607|Device|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
447387|NCT00789594|Behavioral|laboratory monitoring alerts|laboratory monitoring alerts
447388|NCT00789594|Behavioral|Result management module|Result management module
447389|NCT00789581|Drug|Doxorubicin|Doxorubicin 60 mg/m2
447390|NCT00789581|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2
447391|NCT00789581|Drug|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
447392|NCT00789581|Drug|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
447393|NCT00789568|Drug|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
447394|NCT00789568|Drug|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
447395|NCT00789555|Drug|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
447396|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
447397|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
447398|NCT00789542|Device|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
447399|NCT00789542|Other|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
447400|NCT00789529|Device|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
447401|NCT00789529|Device|ReNu MultiPlus®|soft contact lens disinfecting solution
447402|NCT00789503|Dietary Supplement|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
447403|NCT00789490|Dietary Supplement|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
447404|NCT00789490|Dietary Supplement|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
447405|NCT00789477|Procedure|Laser Photocoagulation|laser every 16 weeks as needed
447406|NCT00789477|Drug|Intravitreal Aflibercept Injection|
447407|NCT00789464|Dietary Supplement|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
447408|NCT00789464|Drug|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
447409|NCT00789451|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
447410|NCT00789425|Dietary Supplement|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.~A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
447411|NCT00789425|Dietary Supplement|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
447412|NCT00789399|Drug|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
447413|NCT00789399|Other|Placebo|subcutaneous equivolume isotonic saline
447414|NCT00789386|Drug|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
447415|NCT00789386|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
447416|NCT00789373|Drug|Pemetrexed|Induction therapy: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
447417|NCT00789373|Drug|Cisplatin|Induction therapy: Cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles
447418|NCT00789373|Drug|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
447419|NCT00789373|Drug|Pemetrexed|Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
447420|NCT00789373|Other|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
447421|NCT00789360|Drug|Inhaled Placebo|Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
447422|NCT00789360|Drug|Inhaled Loxapine|Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
447423|NCT00789321|Drug|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
447424|NCT00789321|Drug|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
447425|NCT00789308|Drug|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
447426|NCT00789308|Drug|Heparin|Anticoagulation
447427|NCT00789308|Drug|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
447428|NCT00789308|Drug|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
447429|NCT00789308|Drug|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
447430|NCT00789308|Drug|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
447431|NCT00789308|Drug|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
447432|NCT00789308|Drug|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
447433|NCT00789308|Drug|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
447434|NCT00789295|Other|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
447435|NCT00789282|Other|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
447436|NCT00789282|Other|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
447437|NCT00789282|Other|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.~Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
447438|NCT00789269|Drug|rhubarb|14 days of rhubarb
447439|NCT00789269|Drug|placebo|14 days of placebo
447440|NCT00789256|Drug|Melphalan|Melphalan: 2mg orally, once daily
447441|NCT00789256|Drug|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
447442|NCT00789256|Drug|Melphalan and bortezomib|
447443|NCT00789243|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
447444|NCT00789230|Procedure|primary suture closure|primary suture closure of hernia
447445|NCT00789230|Device|mesh enforced closure|mesh enforced closure of hernia
447446|NCT00789217|Procedure|Immediate skin test|Intradermal test with immediate reading
447447|NCT00789204|Other|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
447448|NCT00789204|Other|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
447449|NCT00789191|Drug|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
447450|NCT00789191|Drug|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
447451|NCT00789191|Drug|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
447452|NCT00789191|Drug|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
447453|NCT00789165|Drug|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
447454|NCT00789165|Drug|no therapy|No therapy; this is not a placebo-controlled trial
447455|NCT00789152|Drug|desloratadine|desloratadine 5 mg daily x 8 days
447456|NCT00789152|Drug|levocetirizine|levocetirizine 5 mg daily x 8 days
447457|NCT00789139|Device|ICM Implantation|Sub cutaneous implantation of the ICM
447458|NCT00789126|Drug|VX-509|
447459|NCT00789113|Drug|Extended Release Lamotrigine|
447460|NCT00789087|Procedure|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
447461|NCT00789087|Procedure|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
447462|NCT00789074|Drug|Varenicline|Varenicline 1mg twice daily
447463|NCT00789074|Drug|Placebo|Placebo 1mg BD
447464|NCT00789061|Drug|Proton pump inhibitor|One dosage/day/year
447465|NCT00789048|Other|radiograph|One radiograph with the patient lying on his contralateral side
447466|NCT00789035|Drug|BI 10773|
447467|NCT00789035|Drug|placebo|
447468|NCT00789035|Drug|metformin|
447469|NCT00788996|Behavioral|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
447470|NCT00788970|Behavioral|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
447471|NCT00788957|Drug|Panitumumab|Panitumumab for intravenous infusion
447472|NCT00788957|Drug|Ganitumab|Ganitumab for intravenous infusion
447473|NCT00788957|Drug|Rilotumumab|Rilotumumab for intravenous infusion
447474|NCT00788957|Drug|Placebo|Placebo intravenous infusion
447475|NCT00788944|Procedure|blood draw|Test Article was not provided to subjects for this study.
447476|NCT00788931|Drug|IV LBH589|
447477|NCT00788931|Drug|Oral LBH589|
447478|NCT00788931|Drug|trastuzumab|
447479|NCT00788931|Drug|paclitaxel|
447480|NCT00788918|Drug|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
447481|NCT00788905|Device|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
447482|NCT00788892|Drug|CPX-351|
447483|NCT00788892|Drug|Cytarabine|
447484|NCT00788892|Drug|Daunorubicin|
447485|NCT00788879|Behavioral|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
447486|NCT00788879|Behavioral|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).~Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
447487|NCT00788866|Dietary Supplement|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
447488|NCT00788866|Dietary Supplement|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
447489|NCT00788853|Other|No treatment given|No treatment is given
447490|NCT00788840|Drug|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
447491|NCT00788840|Drug|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
447492|NCT00788827|Biological|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
447493|NCT00788814|Behavioral|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
447494|NCT00788801|Drug|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
447495|NCT00788788|Drug|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
447496|NCT00788775|Drug|Nilotinib|
447497|NCT00788749|Drug|Prednisolone|tablets 25 mg/day
447498|NCT00788749|Drug|Placebo|tablets once daily
447499|NCT00788749|Other|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
447500|NCT00788749|Other|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
447501|NCT00788723|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
447502|NCT00788710|Drug|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
447503|NCT00788710|Drug|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
447504|NCT00788710|Drug|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
447505|NCT00788697|Drug|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
447506|NCT00788697|Other|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
447507|NCT00788684|Drug|rituximab|IV infusion once weekly for four doses
447508|NCT00788684|Drug|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
447509|NCT00788671|Other|Laboratory Biomarker Analysis|Correlative studies
447510|NCT00788671|Device|Levonorgestrel-Releasing Intrauterine System|Undergo placement of a levonorgestrel-releasing intrauterine system
447512|NCT00788658|Behavioral|Diet modifications|Diet consultation
447513|NCT00788658|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
447514|NCT00788645|Behavioral|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
447515|NCT00788645|Behavioral|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
447516|NCT00788632|Behavioral|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
447517|NCT00788632|Behavioral|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
447518|NCT00788632|Behavioral|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
447519|NCT00788619|Procedure|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
447520|NCT00788619|Procedure|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
447521|NCT00788606|Drug|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
447522|NCT00788593|Drug|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
447523|NCT00788593|Drug|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
447524|NCT00788593|Drug|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
447525|NCT00788580|Drug|pazopanib hydrochloride|
447526|NCT00788580|Drug|temsirolimus|
447527|NCT00788580|Procedure|immunoenzyme technique|
447528|NCT00788580|Procedure|laboratory biomarker analysis|
447529|NCT00788580|Procedure|pharmacological study|
447530|NCT00788567|Drug|mycophenolate mofetil|1
447531|NCT00788554|Procedure|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
447532|NCT00788554|Procedure|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
447533|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
447534|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
447535|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
447536|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
447537|NCT00788541|Other|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
447538|NCT00788528|Drug|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
447539|NCT00788515|Drug|Volinanserin (M100907)|2 mg tablets QD
447540|NCT00788515|Drug|Lormetazepam|1 mg tablets (overencapsulated) QD
447541|NCT00788502|Behavioral|Healing Touch|
447542|NCT00788502|Behavioral|Desensitization Therapy|
447543|NCT00788502|Behavioral|Standard Care|
447544|NCT00788476|Other|Survey|"Survey packets to adult (>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
447545|NCT00788463|Drug|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
447546|NCT00788463|Drug|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
447547|NCT00788424|Drug|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
447548|NCT00788398|Procedure|Saline Solution|Irrigation with Saline
447549|NCT00788398|Procedure|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
447550|NCT00788398|Procedure|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
447551|NCT00788398|Procedure|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.~Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
448164|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposures.
447552|NCT00788398|Procedure|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.~Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
447553|NCT00788385|Device|ShuntCheck test|
447554|NCT00788372|Drug|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
447555|NCT00788346|Behavioral|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
447556|NCT00788346|Behavioral|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
447557|NCT00788333|Drug|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
447558|NCT00788333|Drug|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
447559|NCT00788320|Drug|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
447560|NCT00788320|Drug|Placebo|Placebo three times a week for 8 weeks
447561|NCT00788307|Biological|Ad5-CMV-NIS|
447562|NCT00788307|Drug|liothyronine sodium|
447563|NCT00788307|Genetic|reverse transcriptase-polymerase chain reaction|
447564|NCT00788307|Other|laboratory biomarker analysis|
447565|NCT00788307|Radiation|iodine I 131|
447566|NCT00788294|Biological|tanezumab|Drug solution given intravenously only once at dose of 10 mg
447567|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
447568|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
447569|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
447570|NCT00788281|Procedure|laparoscopic surgery|surgery would be performed by laparoscope
447571|NCT00788281|Procedure|open surgery|surgery would be performed by traditional surgery.
447572|NCT00788255|Drug|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
447573|NCT00788255|Drug|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
447574|NCT00788255|Drug|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
447575|NCT00788242|Drug|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
447576|NCT00788242|Drug|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
447577|NCT00788229|Drug|AT01|eye drop for 12 weeks
447578|NCT00788229|Drug|AT02|eye drop for 12 weeks
447579|NCT00788229|Drug|AT03|eye drop for 12 weeks
447580|NCT00788229|Drug|AT04|eye drop for 12 weeks
447581|NCT00788216|Other|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
447582|NCT00788190|Procedure|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
447583|NCT00788190|Other|Conservative Management|Conservative management of Distal Radius Fractures
447584|NCT00788177|Drug|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
447585|NCT00788164|Biological|TA-HPV|Given intramuscularly
447586|NCT00788164|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
447587|NCT00788164|Drug|imiquimod|Given topically
447588|NCT00788151|Biological|CYD Dengue Vaccine Serotypes 1, 2, 3, and 4|0.5 mL, Subcutaneous (SC)
447589|NCT00788151|Biological|Pneumococcal polysaccharide vaccine|0.5 mL, SC
447590|NCT00788138|Dietary Supplement|Vitamin D3|250,000 IU of vitamin D3
447591|NCT00788138|Dietary Supplement|Placebo|Matching Placebo
447592|NCT00788125|Drug|carboplatin|
447593|NCT00788125|Drug|dasatinib|
447594|NCT00788125|Drug|etoposide phosphate|
447595|NCT00788125|Drug|ifosfamide|
447596|NCT00788125|Genetic|microarray analysis|
447597|NCT00788125|Genetic|western blotting|
447598|NCT00788125|Other|immunohistochemistry staining method|
447599|NCT00788125|Other|laboratory biomarker analysis|
447600|NCT00788125|Procedure|therapeutic conventional surgery|
447601|NCT00788125|Radiation|radiation therapy|
447602|NCT00788112|Drug|vorinostat|
447603|NCT00788112|Genetic|protein expression analysis|
447604|NCT00788112|Other|immunohistochemistry staining method|
447605|NCT00788112|Other|laboratory biomarker analysis|
447606|NCT00788112|Procedure|neoadjuvant therapy|
447607|NCT00788112|Procedure|therapeutic conventional surgery|
447608|NCT00788099|Drug|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
447835|NCT00786188|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
447609|NCT00788099|Drug|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
447610|NCT00788073|Drug|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
447611|NCT00788073|Drug|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
447612|NCT00788060|Drug|Everolimus (RAD001)|5mg per day, continuously
447613|NCT00788060|Drug|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
447614|NCT00788047|Drug|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
447615|NCT00788047|Drug|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
447616|NCT00788034|Drug|Lu AA21004|5 or 10 mg/day
447617|NCT00788034|Drug|Placebo|Once daily
447618|NCT00788008|Drug|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
447619|NCT00787982|Device|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
447620|NCT00787969|Biological|rituximab|Give IV
447621|NCT00787969|Drug|cladribine|Give IV
447622|NCT00787969|Drug|temsirolimus|Give IV
447623|NCT00787969|Biological|Filgrastim|Give SC
447624|NCT00787969|Biological|Pegfilgrastim|
447625|NCT00787956|Behavioral|Internet Chronic Disease Self-Management Program (ICDSMP)|
447626|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
447627|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
447628|NCT00787930|Drug|Valproic Acid|Tablets, 250mg-3000mg
447629|NCT00787917|Drug|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
447630|NCT00787917|Drug|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
447631|NCT00787917|Drug|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
447632|NCT00787891|Drug|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
447633|NCT00787891|Drug|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
447634|NCT00787878|Drug|somatropin|SGA previously treated with Norditropin®
447635|NCT00787878|Drug|No treatment given|Untreated SGA
447636|NCT00787878|Drug|No treatment given|AGA (Average gestational age)
447637|NCT00787852|Drug|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily~Maintenance x 2 years*"
447638|NCT00787852|Drug|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36~Dasatinib is to be taken 1x daily~50 mg daily 100 mg daily~70 mg daily 100 mg daily~100 mg daily 100 mg daily Maintenance x 2 years*"
447639|NCT00787839|Other|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
447640|NCT00787839|Other|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
447641|NCT00787826|Biological|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
447642|NCT00787813|Drug|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
447643|NCT00787813|Drug|Placebo|
447644|NCT00787800|Device|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
447645|NCT00787800|Device|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.~VT/VF detection and therapies with discrimination criteria for single chamber device."
447646|NCT00787787|Drug|sunitinib malate|Given PO
447647|NCT00787787|Drug|capecitabine|Given PO
447648|NCT00787774|Drug|resume raltegravir|resume raltegravir after 16 weeks of stopping
447667|NCT00787670|Other|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
447668|NCT00787670|Procedure|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
447669|NCT00787670|Other|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
447649|NCT00787761|Biological|anti-thymocyte globulin|"Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains > 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.~Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.~Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration."
447650|NCT00787761|Drug|busulfan|"Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses."
447651|NCT00787761|Drug|cyclophosphamide|"Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.~The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.~Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.~Each dose will be infused over 1-2 hr (depending on the total volume)."
447652|NCT00787761|Drug|fludarabine phosphate|"Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes."
447653|NCT00787761|Drug|methotrexate|"Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.~Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.~Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.~Administer via slow IV push."
447654|NCT00787761|Drug|tacrolimus|"Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F)."
447655|NCT00787761|Procedure|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem & Seattle, RICT has been used to treat hematologic & solid malignancies with related & unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute & chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
447656|NCT00787735|Behavioral|Counseling compliance|Rates of attendance to call counseling session over specific time points
447657|NCT00787722|Procedure|Hematopoietic Stem Cell Transplantation|Infusion of participant's own stem cells
447658|NCT00787722|Drug|Cyclophosphamide|A medication used as chemotherapy and to suppress the immune system
447659|NCT00787722|Drug|G-CSF|A glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream
447660|NCT00787722|Drug|rATG|A rabbit polyclonal antibody to lymphocytes
447661|NCT00787722|Drug|Mesna|A medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder
447662|NCT00787722|Drug|Rituximab|Monoclonal antibody therapy used to treat certain autoimmune diseases and types of cancer
447663|NCT00787722|Drug|Methylprednisolone|A corticosteroid medication used to suppress the immune system and decrease inflammation
447664|NCT00787709|Behavioral|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
447665|NCT00787696|Behavioral|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
447666|NCT00787683|Device|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
447788|NCT00786539|Device|Diffuse Optical Spectroscopy|mitochondria
447670|NCT00787657|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
447671|NCT00787644|Drug|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
447672|NCT00787644|Drug|Placebo|Matching placebo (inert tablet)
447673|NCT00787618|Drug|50 mg Proellex|Single dose
447674|NCT00787605|Drug|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
447675|NCT00787605|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
447676|NCT00787605|Drug|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
447677|NCT00787579|Device|Bifocal spectacles|+1.50D bifocal spectacles
447678|NCT00787579|Device|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
447679|NCT00787566|Drug|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
447680|NCT00787553|Drug|cefazolin|2.0 g, IV, 2 hours before surgery
447681|NCT00787553|Drug|tinidazole|2.0 g orally, 12 hours before surgery
447682|NCT00787553|Drug|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
447683|NCT00787527|Drug|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
447684|NCT00787527|Drug|Cyclophosphamide|750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
447685|NCT00787527|Drug|Doxorubicin|50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
447686|NCT00787527|Drug|Vincristine|1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
447687|NCT00787527|Drug|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
447688|NCT00787501|Drug|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI < 2) and tolerability is adequate. Nonresponse at week 10 (CGI < 2) will be cause for medication switch or augmentation.
447689|NCT00787501|Behavioral|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
447690|NCT00787488|Device|Hyperthermia|Every 3 weeks
447691|NCT00787475|Other|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
447692|NCT00787462|Drug|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
447693|NCT00787462|Drug|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
447694|NCT00787436|Drug|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
447695|NCT00787410|Drug|ZD1839|250mg tablet, once daily, orally administered
447696|NCT00787397|Behavioral|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
447697|NCT00787384|Drug|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
447698|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
447699|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
447700|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
447701|NCT00787358|Drug|ZT-031|80 ul subcutaneous injection per day
447702|NCT00787358|Other|placebo|80 ul daily subcutaneous injection of vehicle only
447703|NCT00787345|Other|simulation based training|simulation based training in aseptic techniques that included specified AT categories
447704|NCT00787332|Drug|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
447705|NCT00787319|Other|no intervention|Outpatients with age-related macular degeneration (AMD)
447833|NCT00786201|Drug|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
447706|NCT00787306|Behavioral|Active risk factor surveillance|Cardiovascular risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
447707|NCT00787293|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
447708|NCT00787280|Behavioral|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
447709|NCT00787280|Behavioral|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
447710|NCT00787267|Drug|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
447711|NCT00787254|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
447712|NCT00787254|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
447713|NCT00787215|Other|observational: no treatment involved|observational: no treatment involved
447714|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
447715|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
447716|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
447717|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
447718|NCT00787202|Other|placebo|Administration via oral route twice daily for the duration of treatment
447719|NCT00787189|Device|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
447720|NCT00787189|Device|Placebo Laser|inactive low level laser light therapy with no therapeutic output
447721|NCT00787176|Procedure|Lactated Ringers bolus of 1000 ml|Lactated Ringers bolus of 1000 ml initiated at patient positioning for epidural placement
447722|NCT00787176|Procedure|No additional fluid|Regular maintenance infusion of Lactated Ringers @ 125 ml/hr; no additional fluids
447723|NCT00787176|Procedure|Routine oxytocin|per regular oxytocin protocols
447724|NCT00787176|Procedure|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes after initiation of labor analgesia
447725|NCT00787163|Procedure|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
447726|NCT00787150|Drug|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
447727|NCT00787150|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
447728|NCT00787150|Drug|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
447729|NCT00787137|Drug|PG102|A single intravenous infusion
447730|NCT00787137|Drug|Placebo comparator|Phosphate-buffered saline
447731|NCT00787111|Drug|Fluoxetine (prozac)|Formulation: ODT
447732|NCT00787098|Other|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
447733|NCT00787072|Drug|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
447734|NCT00787072|Drug|Placebo|Oral suspension
447735|NCT00787059|Drug|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10^9 vp to 10^12 vp in 5 dose groups
447736|NCT00787059|Drug|Sucrose (3%)|
447737|NCT00787033|Drug|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
447738|NCT00787007|Drug|S-equol|capsule, oral, single dose
447739|NCT00787007|Drug|Placebo|capsule, oral, single dose
447740|NCT00786994|Drug|Oleogel-S10 100 mg/g|topical use once or twice daily
447741|NCT00786994|Drug|Placebo (petroleum jelly)|topical use once or twice daily
447742|NCT00786981|Other|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
447743|NCT00786981|Other|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
447744|NCT00786968|Drug|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
447745|NCT00786942|Procedure|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
447746|NCT00786942|Procedure|higi tibial osteotomy|the gap of the tibia is unfilled
447747|NCT00786929|Procedure|Catheter drainage|
447748|NCT00786929|Drug|Conservative treatment|
447749|NCT00786916|Drug|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
447834|NCT00786201|Drug|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
447836|NCT00786188|Drug|Sugar pill|Subjects will receive a sugar pill.
447750|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
447751|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
447752|NCT00786890|Other|observational, no intervention needed|observational, no intervention needed
447753|NCT00786877|Other|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
447754|NCT00786877|Other|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
447755|NCT00786864|Other|exercise programme|Specific low back pain exercise programme for children
447756|NCT00786851|Drug|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
447757|NCT00786838|Drug|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
447758|NCT00786838|Drug|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
447759|NCT00786825|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
447760|NCT00786812|Drug|Nilotinib|
447761|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega~1 mg of omega-3 fatty acid 2 times per day"
447762|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form~1 packet two times per day"
447763|NCT00786760|Other|Cohort: 3000 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
447764|NCT00786760|Other|Pilot study: 150 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
447765|NCT00786747|Behavioral|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
447766|NCT00786747|Behavioral|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
447767|NCT00786734|Drug|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
447768|NCT00786734|Drug|Pitavastatin|4mg daily for 28 days after PCI
447769|NCT00786721|Device|Diffuse Optical Spectroscopy|muscle properties scanning
447770|NCT00786695|Drug|esomeprazole|esomeprazole (40 mg o d) for 14 days
447771|NCT00786695|Drug|Placebo|Identical looking Placebo, same regimen, for 14 days
447772|NCT00786682|Drug|docetaxel|
447773|NCT00786682|Drug|hydroxychloroquine|
447774|NCT00786669|Drug|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
447775|NCT00786669|Drug|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
447776|NCT00786669|Drug|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
447777|NCT00786669|Drug|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
447778|NCT00786669|Drug|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
447779|NCT00786643|Drug|5-Fluorouracil|5-FU bolus was administered at 400mg/m^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
447780|NCT00786643|Drug|Leucovorin (LV)|Leucovorin 200mg/m^2 was administered over 2 hours on day 1 and day 2 of each cycle.
447781|NCT00786643|Drug|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
447782|NCT00786643|Drug|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
447783|NCT00786630|Behavioral|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
447784|NCT00786630|Behavioral|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
447785|NCT00786565|Device|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
447786|NCT00786565|Device|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
447787|NCT00786552|Drug|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
447789|NCT00786513|Other|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
447790|NCT00786513|Other|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
447791|NCT00786500|Dietary Supplement|Gynostemma pentaphyllum tea|3 grams twice daily, orally
447792|NCT00786500|Dietary Supplement|Placebo tea|3 grams twice daily, orally
447793|NCT00786487|Drug|20% lipid infusion|1.5 ml/min for 6 hours
447794|NCT00786487|Drug|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
447795|NCT00786474|Drug|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
447796|NCT00786474|Drug|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
447797|NCT00786461|Procedure|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
447798|NCT00786461|Procedure|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
447799|NCT00786448|Drug|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
447800|NCT00786422|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
447801|NCT00786409|Biological|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
447802|NCT00786396|Behavioral|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
447803|NCT00786383|Biological|IMC-1121B|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
447804|NCT00786383|Biological|1121B|"Cohort 2~8mg/kg I.V., once every other week for 4 weeks"
447805|NCT00786383|Biological|1121B|"Cohort 3~10 mg/kg I.V., once every other week for 4 weeks"
447806|NCT00786383|Biological|1121B|"Cohort 4~15 mg/kg I.V., once every 3 weeks for 6 weeks"
447807|NCT00786383|Biological|1121B|"Cohort 5~20 mg/kg I.V., once every 3 weeks for 6 weeks"
447808|NCT00786370|Drug|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
447809|NCT00786370|Drug|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
447810|NCT00786370|Drug|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
447811|NCT00786357|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
447812|NCT00786357|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
447813|NCT00786344|Behavioral|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.~Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
447814|NCT00786331|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
447815|NCT00786331|Drug|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
447816|NCT00786318|Drug|ziprasidone|ziprasidone 20mg IM
447817|NCT00786318|Drug|Standard therapy|Haldol 5mg/ Ativan 2mg IM
447818|NCT00786305|Drug|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
447819|NCT00786305|Drug|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
447820|NCT00786292|Other|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
447821|NCT00786279|Other|ethanol|15 gm ethanol daily for 6 months
447822|NCT00786279|Other|Ethanol-free beverage|0 grams ethanol daily for 6 months.
447823|NCT00786266|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
447824|NCT00786266|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
447825|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
447826|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
447827|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
447828|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
447829|NCT00786214|Other|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
447830|NCT00786214|Other|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
447831|NCT00786201|Drug|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
447832|NCT00786201|Drug|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
447837|NCT00786162|Other|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
447838|NCT00786162|Other|BP cuff at workplace|Provided BP cuff for communal use at the worksite
447839|NCT00786149|Other|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
447840|NCT00786149|Other|Varenicline without counseling|Brief advice, one time during initial session
447841|NCT00786136|Drug|rosuvastatin|rosuvastatin
447842|NCT00786123|Dietary Supplement|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
447843|NCT00786123|Dietary Supplement|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
447844|NCT00786110|Drug|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
447845|NCT00786110|Drug|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
447846|NCT00786097|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
447847|NCT00786058|Drug|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
447848|NCT00786045|Other|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
447849|NCT00786032|Device|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
447850|NCT00786019|Behavioral|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
447851|NCT00786019|Drug|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 grams of Vitamin C per kilogram fat-free mass per 100 milliliters (mL) of normal saline administered; Subjects will receive a bolus of 100mL Vitamin C solution given at 5ml/minute over 20 minutes followed by a drip-infusion given at 1.7ml/minute."
447852|NCT00786006|Drug|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
447853|NCT00786006|Drug|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
447854|NCT00785993|Other|Vitrification of oocytes for IVF treatment|
447855|NCT00785993|Other|Protocolary IVF treatment with fresh donor oocytes|
447856|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
447857|NCT00785980|Drug|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
447858|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
447859|NCT00785967|Biological|Various vaccines|VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
447860|NCT00785954|Drug|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
447861|NCT00785941|Biological|IMC-A12|"Cohort 1~6 mg/kg I.V., once every other week for 4 weeks"
447862|NCT00785941|Biological|IMC-A12|"Cohort 2~10 mg/kg I.V., once every other week for 4 weeks"
447863|NCT00785941|Biological|IMC-A12|"Cohort 3~15 mg/kg I.V., once every other week for 4 weeks"
447864|NCT00785941|Biological|IMC-A12|"Cohort 4~21 mg/kg I.V., once every other week for 4 weeks"
447865|NCT00785941|Biological|IMC-A12|"Cohort 5~27 mg/kg I.V., once every other week for 4 weeks"
447866|NCT00785928|Biological|LY2127399|Administered SC every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
447867|NCT00785928|Drug|Placebo|Administered subcutaneously (SC) every 4 weeks over a 24-week period (Weeks 0, 4, 8, 12, 16, and 20).
447868|NCT00785915|Drug|AZD6765|single administration and once daily for 5 days
447869|NCT00785915|Drug|Placebo|single administration and once daily for 5 days
447870|NCT00785902|Device|AtriCure Bipolar System|
447871|NCT00785889|Procedure|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
447872|NCT00785876|Other|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.~Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
447873|NCT00785863|Other|Placebo|Placebo IV before placebo infusion
447874|NCT00785863|Drug|Remifentanil|placebo IV and remifentanil infusion
447875|NCT00785863|Drug|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
447876|NCT00785863|Drug|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
447877|NCT00785850|Drug|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
447878|NCT00785837|Other|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
447879|NCT00785811|Drug|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
447880|NCT00785811|Drug|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
447881|NCT00785798|Drug|Vorinostat|200mg to 400 mg twice daily on days 1-7
447882|NCT00785798|Drug|Pegylated Liposomal Doxorubicin (PLD), Doxil|IV 30mg/m2 on day 3 of a 21-day cycle
447883|NCT00785785|Drug|Nilotinib (AMN107)|
447884|NCT00785785|Drug|imatinib (STI571)|
447885|NCT00785772|Drug|Gabapentin|100-200mg once a day
447886|NCT00785772|Drug|Gabapentin|200-500mg once a day
447887|NCT00785772|Drug|Gabapentin|400-1000mg (200-500 mg twice a day)
447888|NCT00785759|Drug|AH110690 (18F) Injection|All subjects will receive an I.V. dose of [18F]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of [18F]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
447889|NCT00785746|Other|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
447890|NCT00785720|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
447891|NCT00785694|Drug|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
447892|NCT00785681|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
447893|NCT00785668|Drug|AER 001|10 mg dry powder administered using a handheld device
447894|NCT00785655|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
447895|NCT00785642|Drug|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
447896|NCT00785629|Drug|Calcium acetate|
447897|NCT00785629|Drug|Lanthanum Carbonate|
447898|NCT00785629|Drug|Sevelamer Carbonate|
447899|NCT00785629|Drug|Placebo|
447900|NCT00785616|Other|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
447901|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
447902|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
447903|NCT00785603|Drug|Paroxetine|tablets of 20 mg paroxetine
447904|NCT00785603|Drug|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
447905|NCT00785603|Drug|Tramadol|Capsules of 50 mg tramadol
447906|NCT00785590|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
447907|NCT00785577|Drug|Placebo|"LY545694 placebo BID po for 5 weeks~Pregabalin placebo capsules TID po for 6 weeks"
447908|NCT00785577|Drug|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6~LY545694 placebo BID po for 5 weeks"
447909|NCT00785577|Drug|LY545694 21 mg|"LY545694 21 mg BID po for 1 week~Pregabalin placebo TID po for 6 weeks"
447910|NCT00785577|Drug|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.~Pregabalin placebo TID po for 6 weeks."
447911|NCT00785577|Drug|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks~Pregabalin placebo TID po for 6 weeks"
447912|NCT00785551|Drug|quinine sulfate|2 x 324mg given in one dose to healthy subjects
447913|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
447914|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
447915|NCT00785538|Biological|IMC-A12|"Cohort 1~3 milligrams/kilogram (mg/kg), I.V. once a week, for 4 weeks, followed by a 2-week observation period."
447916|NCT00785538|Biological|IMC-A12|"Cohort 2~6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
447917|NCT00785538|Biological|IMC-A12|"Cohort 3~10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
447918|NCT00785538|Biological|IMC-A12|"Cohort 4~15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
447919|NCT00785538|Biological|IMC-A12|"Cohort 5~21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
447920|NCT00785538|Biological|IMC-A12|"Cohort 6~27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2-week observation period."
447921|NCT00785525|Drug|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
447922|NCT00785512|Drug|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
447923|NCT00785512|Drug|Placebo|Matching placebo tablets, oral administration
447924|NCT00785499|Behavioral|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
447925|NCT00785486|Drug|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
447926|NCT00785486|Drug|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
447927|NCT00785486|Drug|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
447928|NCT00785473|Dietary Supplement|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
447929|NCT00785473|Dietary Supplement|calcium carbonate|calcium carbonate 500 mg daily for 2 years
447930|NCT00785460|Drug|Benfotiamine|
448022|NCT00784745|Drug|Dexamethasone|2mg morning and night for 5 days.
448023|NCT00784732|Drug|QAV680|
448024|NCT00784732|Drug|QAV680|
448025|NCT00784732|Drug|Mometasone Furoate|
447931|NCT00785447|Other|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
447932|NCT00785434|Drug|escitalopram|Dose ranging up to 50mg
447933|NCT00785421|Drug|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
447934|NCT00785421|Drug|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
447935|NCT00785421|Drug|only chemotherapy|observation, no treatment with LMWH
447936|NCT00785408|Drug|AC2307|subcutaneous, twice daily, low dose
447937|NCT00785408|Drug|placebo|subcutaneous, twice daily, low dose
447938|NCT00785408|Drug|AC2307|subcutaneous, twice daily, middle dose
447939|NCT00785408|Drug|placebo|subcutaneous, twice daily, middle dose
447940|NCT00785408|Drug|AC2307|subcutaneous, twice daily, high dose
447941|NCT00785408|Drug|placebo|subcutaneous, twice daily, high dose
447942|NCT00785395|Drug|Oxytocin infusion|Up-down dosing determination
447943|NCT00785382|Drug|Placebo|Lactulose Placebo
447944|NCT00785382|Drug|Pregabalin 150 mg|150 mg Q12H x 2 doses
447945|NCT00785369|Device|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
447946|NCT00785356|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
447947|NCT00785356|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
447948|NCT00785356|Drug|Placebo|Placebo, 2 capsules daily for 3 months
447949|NCT00785343|Device|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
447950|NCT00785343|Procedure|Conventional Therapy|Occupational therapy that is the current standard of care
447951|NCT00785330|Drug|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
447952|NCT00785330|Drug|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
447953|NCT00785317|Drug|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
447954|NCT00785291|Biological|Bevacizumab|Given IV
447955|NCT00785291|Drug|Ixabepilone|Given IV
447956|NCT00785291|Other|Laboratory Biomarker Analysis|Correlative studies
447957|NCT00785291|Drug|Nab-paclitaxel|Given IV
447958|NCT00785291|Drug|Paclitaxel|Given IV
447959|NCT00785291|Other|Questionnaire Administration|Ancillary studies
447960|NCT00785265|Behavioral|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
447961|NCT00785265|Behavioral|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
447962|NCT00785252|Device|Powered Intraosseous device (EZIO)|EZIO
447963|NCT00785252|Device|standard central line|placement of a central line
447964|NCT00785226|Drug|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
447965|NCT00785226|Drug|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
447966|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
447967|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
447968|NCT00785213|Drug|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
447969|NCT00785200|Other|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
447970|NCT00785200|Other|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
447971|NCT00785187|Device|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
447972|NCT00785174|Device|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
447973|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
447974|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
447975|NCT00785161|Device|Penumbra System|Mechanical Thrombectomy in acute stroke
447976|NCT00785148|Drug|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
447977|NCT00785135|Device|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
447978|NCT00785135|Device|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
448026|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
447979|NCT00785122|Drug|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
447980|NCT00785122|Drug|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
447981|NCT00785109|Dietary Supplement|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
447982|NCT00785096|Other|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
447983|NCT00785083|Drug|FTY720|
447984|NCT00785083|Drug|Placebo|
447985|NCT00785044|Drug|I-123 mIBG|This was an observational study. Participants were previously dosed in separate study.
447986|NCT00785031|Other|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
447987|NCT00785018|Drug|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
447988|NCT00785018|Drug|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
447989|NCT00784992|Procedure|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.~Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
447990|NCT00784979|Drug|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
447991|NCT00784966|Drug|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
447992|NCT00784966|Drug|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
447993|NCT00784940|Drug|Anastrozole|1mg, orally, once daily
447994|NCT00784940|Drug|Tamoxifen|20mg, orally, once daily
447995|NCT00784927|Biological|rituximab|
447996|NCT00784927|Drug|cyclophosphamide|
447997|NCT00784927|Drug|dexamethasone|
447998|NCT00784927|Drug|lenalidomide|
447999|NCT00784914|Drug|temsirolimus|Receive temsirolimus IV
448000|NCT00784914|Other|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
448001|NCT00784914|Other|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
448002|NCT00784888|Other|Aromatase inhibitors|non-interventional study
448003|NCT00784875|Drug|LY2624803|1 mg, oral capsule, once nightly before bedtime
448004|NCT00784875|Drug|LY2624803|3 mg, oral capsule, once nightly before bedtime
448005|NCT00784875|Drug|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
448006|NCT00784875|Drug|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
448007|NCT00784862|Drug|Anastrozole|1mg, orally, once daily
448008|NCT00784862|Drug|Tamoxifen|20mg, orally, once daily
448009|NCT00784849|Drug|Methylene blue|1 mC1
448010|NCT00784836|Drug|BG9418 (interferon beta 1-a)|
448011|NCT00784823|Drug|Bortezomib|"Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line~Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1~Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
448012|NCT00784823|Drug|Melphalan|"Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour~Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration~The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period~Melphalan will be given as a single dose (not split over 2 or more days)~Dosing will be based body surface area calculated using actual body weight"
448013|NCT00784810|Drug|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
448014|NCT00784810|Drug|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
448015|NCT00784797|Drug|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
448016|NCT00784797|Drug|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
448017|NCT00784784|Biological|Fluviral|One dose
448018|NCT00784784|Drug|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
448019|NCT00784771|Behavioral|Hypnotherapeutic Olfactory Conditioning (HOC)|
448020|NCT00784758|Device|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
448021|NCT00784758|Device|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
448027|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
448028|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
448029|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
448030|NCT00784719|Drug|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
448031|NCT00784719|Drug|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
448032|NCT00784706|Other|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
448033|NCT00784706|Other|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
448034|NCT00784706|Other|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
448035|NCT00784693|Biological|Tanezumab|15 mg IV single dose
448036|NCT00784693|Drug|Placebo|Placebo IV single dose
448037|NCT00784680|Drug|Anastrozole|1mg, orally, once daily
448038|NCT00784680|Drug|Tamoxifen|20mg, orally, once daily
448039|NCT00784667|Drug|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
448040|NCT00784667|Drug|Erlotinib|100mg orally daily continuously
448041|NCT00784654|Drug|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
448042|NCT00784654|Drug|Placebo|Placebo capsule once per day (double-blind period)
448043|NCT00784615|Procedure|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
448044|NCT00784589|Drug|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
448045|NCT00784589|Drug|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
448046|NCT00784563|Behavioral|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age[Goldberg, Elliot, and Kuehl1988] and reduced by 20% in participants who used beta-blockers.[Wonisch et al. 2003] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
448047|NCT00784563|Behavioral|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking [Wisloff et al. 2007].
448048|NCT00784550|Drug|Tiotropium Bromide|Long-acting muscarinic antagonist
448049|NCT00784550|Drug|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
448050|NCT00784537|Drug|ABVD|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)"
448051|NCT00784537|Drug|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
448052|NCT00784524|Biological|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
448053|NCT00784524|Biological|aldesleukin|Subcutaneous aldesleukin (10 x 10^6 International Units) will be given on day 7 and day 8 after each LMI injection.
448054|NCT00784511|Dietary Supplement|cholecalciferol|4000 IU/d
448055|NCT00784511|Other|microcrystalline cellulose|1/d
448056|NCT00784498|Drug|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
448057|NCT00784498|Drug|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
448058|NCT00784485|Drug|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
448059|NCT00784472|Drug|oxycodone|intravenous according to patients weight, pn.
448060|NCT00784472|Drug|morphine|intravenous administration according to patients weight, pn.
448061|NCT00784459|Drug|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
448062|NCT00784459|Drug|Placebo|Treatment with Placebo, IV
448117|NCT00784017|Drug|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
448118|NCT00784017|Drug|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
448063|NCT00784446|Drug|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22.~Dose level II:~Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg~Repeat on day 22."
448064|NCT00784433|Dietary Supplement|alcohol|150 cc
448065|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
448066|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
448067|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
448068|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
448069|NCT00784407|Device|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
448070|NCT00784394|Drug|diindolylmethane|Given PO
448071|NCT00784394|Other|placebo|Given PO
448072|NCT00784394|Other|pharmacological study|Correlative studies
448073|NCT00784394|Other|laboratory biomarker analysis|Correlative studies
448074|NCT00784394|Other|quality-of-life assessment|Ancillary studies
448075|NCT00784381|Device|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
448076|NCT00784368|Drug|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
448077|NCT00784368|Drug|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
448078|NCT00784355|Procedure|Laparoscopic cholecystectomy|Surgery
448079|NCT00784329|Device|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
448080|NCT00784316|Drug|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
448081|NCT00784303|Drug|Lenvatinib (DTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily, or 10 mg lenvatinib orally twice daily (20 mg total). Out of 58 participants in the DTC cohort, 56 participants received 24 mg lenvatinib once daily and 2 participants received 10 mg lenvatinib twice daily (total 20 mg daily), given continuously in 28-day treatment cycles.
448082|NCT00784303|Drug|Lenvatinib (MTC Cohort)|24 mg lenvatinib (two 10 mg tablets and one 4 mg tablet) given orally, once daily given continuously in 28-day treatment cycles.
448083|NCT00784290|Drug|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
448084|NCT00784277|Drug|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
448085|NCT00784277|Drug|oxycodone IR|10mg for 14 days
448086|NCT00784277|Drug|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
448087|NCT00784277|Drug|Tapentadol IR (CG5503)|50mg for 14 days
448088|NCT00784277|Drug|Tapentadol IR (CG5503)|75mg for 14 days
448089|NCT00784277|Drug|placebo|1 capsule for 14 days
448090|NCT00784277|Drug|placebo|Tablets and capsules 2 x a day for 28 days
448091|NCT00784238|Drug|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
448092|NCT00784225|Drug|selenium|200 mcg daily for 7-12 years
448093|NCT00784225|Drug|vitamin E|400 IU daily by mouth for 7-12 years
448094|NCT00784225|Drug|vitamin E placebo|daily for 7-12 years
448095|NCT00784225|Drug|selenium placebo|daily for 7-12 years
448096|NCT00784212|Drug|BGG492|
448097|NCT00784212|Drug|BGG492|
448098|NCT00784212|Drug|Placebo|
448099|NCT00784186|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
448100|NCT00784186|Drug|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
448101|NCT00784186|Drug|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
448102|NCT00784160|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
448103|NCT00784147|Drug|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
448104|NCT00784147|Drug|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
448105|NCT00784134|Drug|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
448106|NCT00784134|Other|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
448107|NCT00784121|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
448108|NCT00784108|Device|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
448109|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
448110|NCT00784095|Other|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
448111|NCT00784095|Other|Attention Control|Subjects will listen to a non-guided relaxation CD.
448112|NCT00784082|Drug|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
448113|NCT00784069|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
448114|NCT00784056|Drug|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
448115|NCT00784043|Device|Cochlear Implant|Bilateral Implantation in children
448116|NCT00784030|Other|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
448119|NCT00784004|Other|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:~Breathing in through the nose only and out through the mouth only~Breathing in through the mouth only and out through the nose only~Breathing in and out through the nose only~Breathing in and out through the mouth only"
448120|NCT00783978|Other|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
448121|NCT00783965|Drug|tazarotene|Applied to the skin
448122|NCT00783965|Other|placebo|Applied to the skin
448123|NCT00783952|Device|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.~Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
448124|NCT00783952|Device|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
448125|NCT00783939|Drug|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
448126|NCT00783926|Biological|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
448127|NCT00783913|Other|Visumotor Upper Extremity Training|Control
448128|NCT00783913|Other|Anodal/Sham tDCS|Condition
448129|NCT00783900|Other|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
448130|NCT00783887|Other|Blood sample|Blood sample of 5 ml
448131|NCT00783861|Drug|Lactic Acid|Lactic Acid (Dermacyd Femina)
448132|NCT00783835|Drug|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
448133|NCT00783822|Other|RGCT|rapid genetic counseling and testing
448134|NCT00783796|Device|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
448135|NCT00783757|Device|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
448136|NCT00783744|Drug|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
448137|NCT00783744|Drug|Glimepiride|Glimepiride 3 or 4 mg
448138|NCT00783744|Drug|Metformin|At least 850 mg od
448139|NCT00783744|Drug|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
448140|NCT00783731|Drug|Low dose midazolam|
448141|NCT00783718|Drug|vedolizumab|Vedolizumab for intravenous infusion
448142|NCT00783718|Other|Placebo|Placebo intravenous infusion
448143|NCT00783705|Other|placebo|Given orally
448144|NCT00783705|Drug|inositol|Given orally
448145|NCT00783692|Drug|vedolizumab|Vedolizumab for intravenous infusion
448146|NCT00783692|Other|Placebo|Placebo intravenous infusion
448147|NCT00783679|Device|NICO device|"Measurement of cardiac output and simultaneous blood sampling.~The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
448148|NCT00783666|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
448149|NCT00783653|Drug|Sunitinib|25 mg or 37,5 mg daily dose until DLT
448150|NCT00783640|Drug|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
448151|NCT00783627|Procedure|Angiography|Angiography done at the J1 visit
448152|NCT00783614|Drug|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
448153|NCT00783614|Drug|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
448154|NCT00783601|Drug|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
448155|NCT00783601|Drug|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
448156|NCT00783601|Drug|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
448157|NCT00783601|Drug|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
448158|NCT00783588|Biological|ISF35|Subjects participating in this study will receive up to two doses of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
448159|NCT00783562|Other|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
448160|NCT00783562|Other|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
448161|NCT00783549|Drug|an undetermined dose of GSK1292263|GSK investigational product or placebo
448162|NCT00783549|Drug|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
448163|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
448165|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
448166|NCT00783536|Drug|Etanercept + Methotrexate|
448167|NCT00783536|Drug|DMARDS|
448168|NCT00783523|Drug|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
448169|NCT00783510|Biological|adalimumab|As prescribed by treating physician
448170|NCT00783510|Drug|Methotrexate|As prescribed by treating physician
448171|NCT00783484|Drug|PF-03716539|PF-03716539 10 mg oral solution, single dose
448172|NCT00783484|Drug|PF-03716539|PF-03716539 25 mg oral solution, single dose
448173|NCT00783484|Drug|PF-03716539|PF-03716539 3 mg oral solution, single dose
448174|NCT00783484|Other|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
448175|NCT00783484|Drug|PF-03716539|PF-03716539 100 mg oral solution, single dose
448176|NCT00783484|Drug|PF-03716539|PF-03716539 200 mg oral solution, single dose
448177|NCT00783484|Drug|PF-03716539|PF-03716539 50 mg oral solution, single dose
448178|NCT00783484|Other|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
448179|NCT00783484|Drug|Midazolam|Midazolam 1 mg IV, single dose
448180|NCT00783484|Drug|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
448181|NCT00783484|Drug|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
448182|NCT00783484|Drug|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
448183|NCT00783484|Drug|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
448184|NCT00783484|Drug|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
448185|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
448186|NCT00783484|Drug|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
448187|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
448188|NCT00783471|Drug|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
448189|NCT00783471|Drug|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
448190|NCT00783458|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
448191|NCT00783458|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
448192|NCT00783445|Behavioral|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
448193|NCT00783445|Behavioral|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
448194|NCT00783432|Drug|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
448195|NCT00783432|Drug|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
448196|NCT00783406|Drug|PF-00610355|dry powder inhaler, 1472 mcg, single dose
448197|NCT00783406|Drug|PF-00610355|dry powder inhaler, 736 mcg, single dose
448198|NCT00783406|Drug|PF-00610355|dry powder inhaler, 368 mcg, single dose
448199|NCT00783406|Drug|Placebo|Placebo
448200|NCT00783393|Drug|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
448201|NCT00783380|Biological|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
448202|NCT00783380|Biological|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
448203|NCT00783367|Drug|lenalidomide-low dose dexamethasone plus rituximab|Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study; Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study; rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
448204|NCT00783367|Drug|Lenalidomide + Rituximab|
448205|NCT00783354|Drug|desloratadine|"Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months."
448206|NCT00783354|Drug|desloratadine|"Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months."
448207|NCT00783341|Drug|GAP-134|
448208|NCT00783341|Drug|placebo|
448209|NCT00783328|Drug|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
448210|NCT00783315|Behavioral|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
448211|NCT00783315|Behavioral|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
448212|NCT00783315|Behavioral|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
448213|NCT00783289|Biological|MEDI-563|25,50-mg MEDI-563 injections
448214|NCT00783289|Other|Placebo|Placebo SC injections
448215|NCT00783276|Drug|SYN115|100 mg single dose
448216|NCT00783276|Drug|PLACEBO|PLACEBO
448217|NCT00783263|Drug|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
448218|NCT00783263|Drug|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
448219|NCT00783263|Drug|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
448220|NCT00783263|Drug|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
448221|NCT00783250|Drug|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
448222|NCT00783250|Drug|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
448223|NCT00783237|Drug|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
448224|NCT00783237|Drug|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
448225|NCT00783224|Drug|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
448226|NCT00783224|Drug|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
448227|NCT00783224|Drug|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
448228|NCT00783224|Drug|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
448229|NCT00783211|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
448230|NCT00783211|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
448231|NCT00783211|Drug|placebo|placebo, once daily for 15 days
448232|NCT00783198|Biological|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
448233|NCT00783198|Biological|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
448234|NCT00783198|Biological|Placebo|matching placebo sublingual tablets administered once daily
448235|NCT00783185|Behavioral|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
448236|NCT00783185|Behavioral|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
448237|NCT00783172|Drug|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
448238|NCT00783172|Biological|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
448239|NCT00783159|Procedure|Power Training|Power training, Vitamin D substitution
448240|NCT00783159|Procedure|Strength Training|Strength training, Vitamin D substitution
448241|NCT00783159|Other|Control|Vitamin D substitution, Lifestyle consultation
448242|NCT00783146|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
448243|NCT00783146|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
448244|NCT00783146|Drug|placebo|placebo, once daily for 15 days
448245|NCT00783133|Drug|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
448246|NCT00783133|Drug|fexofenadine|Allegra 180 mg daily x 7 days
448247|NCT00783120|Other|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
448248|NCT00783120|Other|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
448249|NCT00783107|Drug|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
448250|NCT00783107|Drug|Placebo|
448251|NCT00783094|Drug|Tadalafil 2.5 mg|oral, daily
448252|NCT00783094|Drug|Tadalafil 5 mg|oral, daily
448253|NCT00783094|Drug|Placebo|oral, daily
448254|NCT00783081|Drug|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
448255|NCT00783081|Drug|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
448256|NCT00783081|Drug|Placebo|Placebo BID for 26 weeks.
448257|NCT00783068|Drug|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
448258|NCT00783068|Drug|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
448259|NCT00783068|Drug|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
448260|NCT00783055|Other|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
448261|NCT00783042|Drug|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
448262|NCT00783042|Drug|Placebo|Tablet, oral, once daily for 1 month (double blind)
448263|NCT00783016|Drug|Morphine|
448264|NCT00783003|Drug|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
448265|NCT00783003|Drug|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
448266|NCT00783003|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
448267|NCT00783003|Drug|Placebo|Matching placebo.
448268|NCT00782990|Procedure|Surgical treatment: TVT|
448269|NCT00782990|Procedure|Surgical treatment: colposuspension|
448270|NCT00782977|Other|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
448271|NCT00782951|Drug|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
448272|NCT00782951|Drug|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
448273|NCT00782951|Drug|Placebo|single IV dose of placebo after dental impaction surgery
448274|NCT00782925|Other|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
448275|NCT00782925|Other|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
448276|NCT00782925|Other|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
448277|NCT00782847|Behavioral|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
448278|NCT00782834|Drug|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
448279|NCT00782821|Drug|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
448280|NCT00782821|Drug|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
448281|NCT00782821|Drug|Rituxan|Given via IV per group assignment.
448282|NCT00782795|Drug|Pioglitazone|Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.
448283|NCT00782795|Drug|Placebo|
448284|NCT00782769|Drug|Oxybutinyn Vaginal Ring 4mg|
448285|NCT00782769|Drug|Oxybutinyn Vaginal Ring 6mg|
448286|NCT00782756|Other|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.~Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.~Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
448287|NCT00782717|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
448288|NCT00782717|Other|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
448289|NCT00782717|Drug|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
448290|NCT00782691|Other|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
448291|NCT00782665|Procedure|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
448292|NCT00782652|Drug|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
448293|NCT00782652|Drug|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
448294|NCT00782639|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
448295|NCT00782639|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
448296|NCT00782626|Drug|everolimus|
448297|NCT00782613|Drug|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
448298|NCT00782613|Drug|Placebo|Placebo in a cream formulation
448299|NCT00782600|Drug|suspension IR|50 mg IR suspension once daily for one day
448300|NCT00782600|Drug|CR 1|50 mg shorter release CR once daily for one day
448301|NCT00782600|Drug|CR 2|50 mg medium release CR once daily for one day
448302|NCT00782600|Drug|CR 3|longer release SR formulation once daily for one day
448303|NCT00782587|Drug|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
448304|NCT00782574|Drug|AZD2281|Capsule Oral bid
448305|NCT00782574|Drug|Cisplatin|IV every 3 weeks
448306|NCT00782561|Drug|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
448307|NCT00782548|Drug|morphine sulfate sustained-release capsules|Capsules, 30 mg
448308|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
448309|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
448310|NCT00782535|Drug|Placebo|Inhaled solution, single dose of placebo
448311|NCT00782522|Procedure|Eccentric training program|Eccentric training program
448312|NCT00782522|Procedure|Traditional training program|Traditional training program
448313|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
448314|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
448315|NCT00782509|Drug|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
448316|NCT00782496|Device|Education + new meter|Diabetes education and a new meter with basic features
448317|NCT00782496|Device|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
448318|NCT00782483|Device|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
448319|NCT00782483|Device|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
448320|NCT00782483|Device|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
448321|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
448322|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
448323|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
448324|NCT00782457|Procedure|RECTAL CANCER RESECTION|
448325|NCT00782444|Procedure|Computer navigated knee replacement|Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
448326|NCT00782444|Procedure|Conventional knee replacement|Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
448327|NCT00782431|Biological|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
448328|NCT00782431|Biological|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
448329|NCT00782418|Drug|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
448330|NCT00782418|Drug|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
448331|NCT00782418|Drug|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
448332|NCT00782405|Drug|quetiapine|XR, 150-300mg
448333|NCT00782405|Drug|mirtazapine|30-45 mg
448334|NCT00782379|Drug|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
448335|NCT00782379|Drug|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
448336|NCT00782379|Drug|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
448337|NCT00782379|Drug|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
448338|NCT00782379|Drug|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
448339|NCT00782379|Procedure|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
448340|NCT00782379|Procedure|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
448341|NCT00782366|Genetic|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
448342|NCT00782353|Drug|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
448343|NCT00782353|Drug|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
448344|NCT00782353|Drug|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
448345|NCT00782340|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
448346|NCT00782340|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
448347|NCT00782327|Drug|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
448348|NCT00782327|Drug|Placebo|Daily placebo capsule
448349|NCT00782301|Drug|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
448350|NCT00782301|Drug|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
448351|NCT00782288|Drug|digitoxin|0.05mg tabs, once daily for 28 days
448352|NCT00782288|Drug|digitoxin|0.1mg pills, once daily for 28 days.
448353|NCT00782288|Other|placebo|pill taken once daily for 28 days
448354|NCT00782275|Drug|bevacizumab|
448355|NCT00782275|Drug|temsirolimus|
448356|NCT00782262|Dietary Supplement|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
448357|NCT00782249|Device|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
448358|NCT00782249|Device|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
448359|NCT00782249|Device|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
448360|NCT00782236|Device|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
448361|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
448362|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
448363|NCT00782210|Drug|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
448364|NCT00782197|Device|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
448365|NCT00782197|Device|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
448366|NCT00782184|Drug|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
448367|NCT00782184|Drug|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
448368|NCT00782184|Drug|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
448369|NCT00782171|Device|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.~Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.~In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
448370|NCT00782145|Other|educational intervention|
448371|NCT00782145|Other|informational intervention|
448372|NCT00782145|Other|internet-based intervention|
448373|NCT00782145|Other|questionnaire administration|
448374|NCT00782145|Other|study of socioeconomic and demographic variables|
448375|NCT00782145|Other|survey administration|
448376|NCT00782145|Procedure|psychosocial assessment and care|
448377|NCT00782145|Procedure|quality-of-life assessment|
448378|NCT00782145|Procedure|standard follow-up care|
448379|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
448380|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|"IV infusion of IGIV, 10% to determine pharmacokinetics~Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
448381|NCT00782093|Drug|volociximab|volociximab intravitreal injection
448382|NCT00782080|Drug|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
448383|NCT00782080|Drug|Placebo|Placebo
448384|NCT00782067|Drug|Midostaurin (PKC412)|Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
448385|NCT00782054|Other|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
448386|NCT00782054|Other|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
448387|NCT00782041|Drug|Oxaliplatin|85 mg/m²
448388|NCT00782041|Drug|5-FluoroUracil|2,000 mg/m²
448389|NCT00782041|Drug|Folinic acid|20 mg/m²
448390|NCT00782028|Other|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
448391|NCT00782028|Other|Standard Care|
448392|NCT00782015|Dietary Supplement|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
448393|NCT00782015|Dietary Supplement|Placebo Comparator:|NCEP Step 2 diet
448394|NCT00782002|Biological|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
448395|NCT00781976|Drug|AZD7295|700mg per day maximum
448396|NCT00781976|Drug|Placebo|matched placebo
448397|NCT00781963|Behavioral|Manual-based cognitive behavioral therapy for insomnia|Manual-based CBT-I provided in 5 individual or group sessions by a non-clinician sleep coach.
448398|NCT00781963|Behavioral|Non-directive sleep education|Manual-based non-directive sleep education provided in 5 group sessions by a health educator.
448399|NCT00781950|Dietary Supplement|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
448400|NCT00781950|Dietary Supplement|Placebo|Wheat and Mixed Dietary Oils
448401|NCT00781937|Drug|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
448402|NCT00781937|Drug|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
448403|NCT00781924|Procedure|biopsy|ultrasound guided biopsy of tumors.
448404|NCT00781911|Biological|Cixutumumab|Participants will receive cixutumumab IV 10 mg/kg over 1 hour every 2 weeks. Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
448405|NCT00781911|Drug|depot octreotide|Participants must be receiving depot octreotide at the time of enrolling into the study. Participants on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
448406|NCT00781898|Drug|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
448407|NCT00781898|Other|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
448408|NCT00781885|Drug|Beraprost sodium modified release|Tablets 60mcg
448409|NCT00781872|Biological|injection of autologous stem cells|60 milion cells intrathecally and 20 milion intravenously
448410|NCT00781859|Drug|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
448411|NCT00781859|Drug|Placebo|Placebo intravitreal injection
448412|NCT00781846|Drug|ridaforolimus|oral tablets, daily for 5 days/week
448413|NCT00781846|Drug|bevacizumab|IV infusion
448414|NCT00781833|Device|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
448415|NCT00781820|Drug|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
448416|NCT00781820|Drug|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
448417|NCT00781807|Other|multi-module rehabilitation program|"The multi-module rehabilitation program includes:~Nutrition management~Home-based ergometer training program~Psychosocial support"
448418|NCT00781794|Drug|NSA-789 at 2 different doses|
448419|NCT00781781|Drug|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
448420|NCT00781768|Drug|Standard PO (Zofran + Dexamethason)|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
448421|NCT00781768|Drug|Aprepitant (MK-869) + Standard PO|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
448422|NCT00781755|Drug|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
448423|NCT00781755|Behavioral|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
448424|NCT00781742|Drug|AZD6765|IV once per dosing day, multiple times during the treatment period
448425|NCT00781742|Drug|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
448426|NCT00781729|Behavioral|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
448427|NCT00781729|Behavioral|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
448428|NCT00781716|Device|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
448429|NCT00781703|Other|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
448430|NCT00781690|Device|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
448431|NCT00781664|Other|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
448432|NCT00781664|Drug|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
448433|NCT00781664|Drug|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
448434|NCT00781664|Other|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
448435|NCT00781664|Drug|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
448436|NCT00781664|Drug|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
448437|NCT00781664|Drug|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
448438|NCT00781664|Drug|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
448439|NCT00781664|Other|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
448440|NCT00781638|Device|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
448441|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
448442|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
448527|NCT00780910|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
448443|NCT00781625|Dietary Supplement|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
448444|NCT00781612|Drug|Docetaxel|Docetaxel will be administered as per local prescribing information.
448445|NCT00781612|Drug|Paclitaxel|Paclitaxel will be administered as per local prescribing information.
448446|NCT00781612|Drug|Pertuzumab|Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
448447|NCT00781612|Drug|Trastuzumab|Trastuzumab will be administered as per local prescribing information.
448448|NCT00781612|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
448449|NCT00781612|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg by IV infusion every three weeks (Q3W)
448450|NCT00781599|Drug|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
448451|NCT00781599|Behavioral|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
448452|NCT00781599|Behavioral|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
448453|NCT00781586|Dietary Supplement|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
448454|NCT00781586|Drug|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
448455|NCT00781586|Drug|Placebo|Placebo 1 tablet at 1st visit
448456|NCT00781573|Drug|Clopidogrel|Clopidogrel, 75 mg QD, for one year
448457|NCT00781547|Drug|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
448458|NCT00781534|Drug|Ginseng|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
448459|NCT00781534|Drug|Ginseng|
448460|NCT00781534|Drug|ginsenoside RE|active metabolite of ginseng
448461|NCT00781534|Dietary Supplement|Placebo (sugar pill)|placebo group
448462|NCT00781521|Drug|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
448463|NCT00781508|Drug|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
448464|NCT00781508|Other|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
448465|NCT00781495|Device|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
448466|NCT00781482|Drug|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
448467|NCT00781456|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
448468|NCT00781456|Drug|Placebo|1 tablet daily to match experimental arm
448469|NCT00781443|Drug|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
448470|NCT00781443|Drug|placebo|Repeating subcutaneous injection
448471|NCT00781430|Drug|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
448472|NCT00781417|Dietary Supplement|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
448473|NCT00781417|Other|Placebo|Matching Placebo
448474|NCT00781404|Drug|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
448475|NCT00781391|Drug|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
448476|NCT00781391|Drug|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
448477|NCT00781391|Drug|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
448478|NCT00781391|Drug|placebo warfarin|placebo warfarin
448479|NCT00781391|Drug|placebo edoxaban|placebo edoxaban
448480|NCT00781378|Drug|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
448481|NCT00781378|Drug|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
448482|NCT00781365|Other|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
448483|NCT00781352|Drug|nitrous oxide|65% nitrous oxide administered during surgery
448484|NCT00781352|Drug|nitrogen|Nitrogen administration during surgery
448485|NCT00781339|Drug|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
448486|NCT00781326|Drug|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
448487|NCT00781326|Drug|Placebo|Placebo will be given in doses matching those of nimodipine.
448528|NCT00780884|Device|acupuncture|16 sessions of acupuncture treatment, twice a week.
448529|NCT00780858|Drug|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
448488|NCT00781300|Drug|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
448489|NCT00781300|Drug|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
448490|NCT00781287|Drug|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
448491|NCT00781287|Drug|Raltegravir|400 mg BID PO
448492|NCT00781274|Drug|MP-424|750 mg every 8 hours for 12 weeks
448493|NCT00781274|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
448494|NCT00781274|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
448495|NCT00781261|Drug|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
448496|NCT00781261|Drug|Placebo|Subjects in the control group will receive a placebo drug for a similar period
448497|NCT00781248|Device|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
448498|NCT00781209|Procedure|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.~Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:~Maximum Tumor Diameter:<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
448499|NCT00781196|Drug|folic acid|capsule 0.5 mg once a day
448500|NCT00781196|Drug|placebo|capsule, once a day
448501|NCT00781183|Other|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
448502|NCT00781170|Procedure|allogeneic hematopoietic SCT|
448503|NCT00781157|Drug|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
448504|NCT00781131|Drug|Pregabalin|pregabalin 75 or 150 mg
448505|NCT00781131|Drug|Placebo|lactulose placebo
448506|NCT00781118|Device|Guardian System|There is no intervention in this study. The device is a diagnostic only.
448507|NCT00781105|Drug|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
448508|NCT00781092|Other|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
448509|NCT00781092|Other|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
448510|NCT00781079|Behavioral|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
448511|NCT00781066|Procedure|Controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~Gently hold the cord and wait until the uterus is well contracted again;~With the next contraction, repeat CCT with counter-pressure."
448512|NCT00781066|Procedure|No controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
448513|NCT00781053|Drug|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
448514|NCT00781040|Other|Severe sepsis vs. non-severe sepsis|To compare these two groups
448515|NCT00781027|Procedure|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
448516|NCT00781001|Drug|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
448517|NCT00780988|Biological|Autologous tumor cell + CpG vaccine|
448518|NCT00780988|Procedure|Autologous hematopoietic and immune cell rescue (transplantation)|
448519|NCT00780975|Drug|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
448520|NCT00780962|Drug|N-Acetylcysteine (NAC)|"Experimental:~Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours."
448521|NCT00780962|Drug|0.9% Sodium-chloride|"Placebo:~Before CT: 500 cc 0.9% Sodium-chloride~After CT: NS at 67 cc/hour for up to 24 hours."
448522|NCT00780949|Other|intestinal biopsies|intestinal biopsies during routine endoscopy
448523|NCT00780936|Procedure|femoral nerve block|
448524|NCT00780923|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
448525|NCT00780910|Drug|MP-424|750 mg every 8 hours for 12 weeks
448526|NCT00780910|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
448530|NCT00780832|Behavioral|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
448531|NCT00780832|Drug|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
448532|NCT00780819|Device|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
448533|NCT00780806|Biological|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
448534|NCT00780806|Procedure|Blood draw|Blood draw
448535|NCT00780793|Drug|progressive spacing of TNF-blocker injections|"Experimental arm~Progressive spacing of TNF-blocker injections according to the following algorithm :~if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1~if DAS28 > 2.6 and DAS28 change ≤ 0.6: continue at step N~if DAS28 > 2.6 and DAS28 change > 0.6 : return to step N-1 (relapse as defined by the European expert consensus).~Step 0 (inclusion) :~Adalimumab 40 mg / 14 days~Etanercept 50 mg / 7 days~Step 1 :~Adalimumab 40 mg / 21 days~Etanercept 50 mg / 10 days~Step 2 :~Adalimumab 40 mg / 28 days~Etanercept 50 mg / 14 days~Step 3 :~Adalimumab 40 mg / 42 days~Etanercept 50 mg / 21 days~Step 4 :~TNF-blocker stop"
448536|NCT00780793|Drug|DMARD maintenance|DMARD maintenance
448537|NCT00780780|Drug|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
448538|NCT00780780|Drug|triamcinolone intravitreal injection|triamcinolone intravitreal injection
448539|NCT00780767|Device|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
448540|NCT00780754|Drug|dutasteride|0.5mg
448541|NCT00780754|Procedure|prostate biopsy|prostate biopsy
448542|NCT00780741|Procedure|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
448543|NCT00780741|Procedure|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
448544|NCT00780728|Drug|Sildenafil|
448545|NCT00780715|Drug|Gliclazide MR|30mg daily increased to 60mg if HbA1c > 7% at 3 months
448546|NCT00780715|Drug|Sitagliptin|Sitagliptin 100mg daily for 6 months
448547|NCT00780715|Drug|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c >7% at 3 months. 6 months duration
448548|NCT00780715|Drug|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
448549|NCT00780702|Drug|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
448550|NCT00780702|Drug|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
448551|NCT00780676|Drug|Dasatinib|100 mg tablet by mouth daily
448552|NCT00780676|Drug|AZD6244|75 mg by mouth twice daily.
448553|NCT00780663|Drug|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
448554|NCT00780650|Drug|Atomoxetine|80 mg oral dose, once per day for 6 weeks
448555|NCT00780650|Drug|Placebo|80 mg dose once per day for 6 weeks
448556|NCT00780637|Drug|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
448557|NCT00780624|Device|NIPPV|Ventilator is Bird VIP.
448558|NCT00780624|Device|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
448559|NCT00780624|Device|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
448560|NCT00780598|Drug|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:~120 mg for 6 months once daily, OR~240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months~In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
448561|NCT00780585|Drug|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
448562|NCT00780572|Behavioral|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
448563|NCT00780559|Behavioral|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
448564|NCT00780559|Behavioral|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
448565|NCT00780520|Dietary Supplement|alanine-glutamine infusion|
448566|NCT00780494|Drug|bevacizumab|Intravenous 15 mg/kg
448567|NCT00780494|Drug|carboplatin|AUC 6, Intravenously Day 1 every 21 days
448568|NCT00780494|Drug|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
448569|NCT00780481|Drug|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
448570|NCT00780468|Behavioral|Existing diet plan|
448571|NCT00780468|Behavioral|New diet plan|
448572|NCT00780455|Drug|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
448573|NCT00780455|Drug|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
448574|NCT00780442|Drug|D-cycloserine|50 mg DCS
448575|NCT00780442|Drug|Placebo|Placebo
448576|NCT00780416|Drug|MP-424|750 mg every 8 hours for 12 weeks
448577|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
448578|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
448579|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
448580|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
448581|NCT00780403|Drug|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
448582|NCT00780403|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
448583|NCT00780390|Other|Autonomic Function Assessment|
448584|NCT00780377|Drug|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
448585|NCT00780351|Device|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
448586|NCT00780338|Other|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
448587|NCT00780325|Drug|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
448588|NCT00780325|Drug|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
448589|NCT00780325|Drug|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
448590|NCT00780325|Drug|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
448591|NCT00780325|Drug|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
448592|NCT00780325|Drug|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
448593|NCT00780312|Other|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
448594|NCT00780299|Device|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
448595|NCT00780299|Procedure|CVVH|hemofiltration intermittent dialysis
448596|NCT00780286|Device|Polymer based lubricating liquid|5 mls of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
448597|NCT00780286|Device|Moi-Stir|2 sprays (0.35 mL) of the radiolabeled commercial device. A blend of Water, sorbitol, carboxymethylcellulose, sodium, methylparaben, propylparaben, potassium chloride, dibasic sodium phosphate, calcium chloride, magnesium chloride, sodium chloride, flavor.
448598|NCT00780273|Device|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
448599|NCT00780273|Device|Biomet 3i Prevail Implants|
448600|NCT00780260|Behavioral|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
448601|NCT00780234|Procedure|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
448602|NCT00780234|Procedure|quantitative high resolution CT scan|High resolution CT scan of the chest
448603|NCT00780234|Drug|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-~activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
448604|NCT00780208|Drug|Daytrana (methylphenidate patch)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
448605|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
448606|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
448607|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
448608|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
448609|NCT00780182|Drug|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
448610|NCT00780169|Drug|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan~sorafenib starting dose 400 mg/day~irinotecan starting dose 80 mg/m2 on day 1"
448611|NCT00780143|Drug|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
448612|NCT00780130|Other|No Intervention|male & female college students ages 20 to 50, asymptomatic normals
448613|NCT00780104|Drug|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
448691|NCT00779467|Drug|fentanyl|fentanyl 2 mcg/ml
448814|NCT00778479|Device|Sepraspray|Max. 10g of Sepraspray
448614|NCT00780104|Drug|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
448615|NCT00780091|Other|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
448616|NCT00780091|Other|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
448617|NCT00780078|Procedure|extubation|extubation failure in patients intubated orotracheally
448618|NCT00780052|Drug|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
448619|NCT00780039|Drug|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
448620|NCT00780039|Drug|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
448621|NCT00780026|Drug|insulin|bolus or infusion 80 to 110 mg/dl
448622|NCT00780013|Drug|metformin hydrochloride liquid 500 mg per 5 mL|
448623|NCT00780000|Drug|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
448624|NCT00779987|Drug|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
448625|NCT00779987|Drug|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
448626|NCT00779974|Other|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
448627|NCT00779961|Procedure|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
448628|NCT00779961|Procedure|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
448629|NCT00779935|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
448630|NCT00779922|Drug|lenalidomide|
448631|NCT00779909|Drug|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
448632|NCT00779909|Other|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
448633|NCT00779896|Drug|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
448634|NCT00779883|Biological|ISF35|Subjects participating in this study will receive a single dose of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells.
448635|NCT00779870|Other|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
448636|NCT00779857|Device|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
448637|NCT00779844|Procedure|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
448638|NCT00779844|Procedure|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
448639|NCT00779831|Drug|120 mg Pseudoephedrine hydrochloride extended release tablets|
448640|NCT00779818|Device|Electrical acupuncture|Treatment by electrical acupuncture
448641|NCT00779818|Device|Laser|Treatment by laser
448642|NCT00779805|Drug|Pseudoephedrine hydrochloride 120 mg ER tablets|
448643|NCT00779792|Drug|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
448644|NCT00779792|Drug|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
448645|NCT00779792|Drug|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
448646|NCT00779792|Drug|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
448647|NCT00779792|Drug|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
448648|NCT00779779|Biological|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
448649|NCT00779766|Biological|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
448650|NCT00779766|Biological|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
448651|NCT00779753|Dietary Supplement|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
448652|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
448653|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
448654|NCT00779727|Procedure|Placement of drainages|
448655|NCT00779714|Drug|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
448656|NCT00779714|Drug|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
448657|NCT00779714|Drug|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
448658|NCT00779701|Drug|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
448659|NCT00779688|Device|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
448660|NCT00779675|Biological|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
448661|NCT00779649|Other|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.~Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
448662|NCT00779649|Other|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.~Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
448663|NCT00779636|Drug|Desloratadine|Desloratadine 10 mg daily x 28 days
448664|NCT00779636|Drug|Placebo|Placebo daily x 28 days
448665|NCT00779610|Procedure|Vibration with flexion|Vibration with forearm flexion (active contraction)
448666|NCT00779610|Procedure|Vibration without flexion|Vibration without forearm flexion (passive)
448667|NCT00779597|Behavioral|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
448668|NCT00779584|Drug|MK-8776|IV infusion
448669|NCT00779584|Drug|Gemcitabine|IV infusion
448670|NCT00779571|Behavioral|Crispbread|8 week low calorie diet
448671|NCT00779558|Drug|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
448672|NCT00779558|Drug|Placebo infusion|Infusion of normal saline
448673|NCT00779545|Drug|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
448674|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
448675|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
448676|NCT00779545|Drug|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
448677|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
448678|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
448679|NCT00779532|Drug|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
448680|NCT00779532|Drug|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
448681|NCT00779532|Drug|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
448682|NCT00779532|Drug|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
448683|NCT00779519|Drug|TTP435|
448684|NCT00779519|Drug|Placebo|
448685|NCT00779506|Drug|Quetiapine Fumarate XR|oral, once daily, flexible dose
448686|NCT00779493|Dietary Supplement|curcumin|curcumin 900mg twice daily by mouth
448687|NCT00779493|Dietary Supplement|placebo|placebo capsule to simulate 900mg curcumin capsule
448688|NCT00779480|Drug|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
448689|NCT00779467|Drug|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
448690|NCT00779467|Drug|Bupivacaine|
448692|NCT00779454|Drug|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
448693|NCT00779454|Drug|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
448694|NCT00779441|Drug|Zolpidem 10mg tablets|
448695|NCT00779428|Drug|Tanespimycin|"Solution, IV~This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
448696|NCT00779402|Other|Control|Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
448697|NCT00779402|Biological|Sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
448698|NCT00779389|Drug|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
448699|NCT00779389|Drug|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
448700|NCT00779389|Drug|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
448701|NCT00779389|Drug|Placebo|Placebo for 14-21 days.
448702|NCT00779389|Drug|Erlotinib|Erlotinib 150 mg for 14-21 days.
448703|NCT00779376|Drug|Zidovudine 300mg tablets|
448704|NCT00779363|Device|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
448705|NCT00779350|Drug|sertraline 100 mg tablets|
448706|NCT00779337|Biological|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
448707|NCT00779324|Drug|Amantadine Hydrochloride|100 mg every morning and noon
448708|NCT00779324|Drug|Placebo|one placebo tablet every morning and 12 Noon
448709|NCT00779311|Drug|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
448710|NCT00779311|Drug|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
448711|NCT00779311|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
448712|NCT00779285|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
448713|NCT00779259|Drug|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
448714|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
448715|NCT00779259|Drug|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
448716|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
448717|NCT00779246|Other|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
448718|NCT00779246|Drug|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
448719|NCT00779246|Other|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
448720|NCT00779233|Drug|Zidovudine tablets 300 mg|
448721|NCT00779220|Drug|placebo|Intravenous repeating dose
448722|NCT00779220|Drug|methotrexate|Oral repeating dose
448723|NCT00779220|Drug|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
448724|NCT00779220|Drug|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
448725|NCT00779220|Drug|ocrelizumab 500mg|Intravenous repeating dose (500mg)
448726|NCT00779207|Behavioral|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
448727|NCT00779207|Behavioral|weight loss|10 percent weight loss through diet and behavioral modification
448728|NCT00779194|Drug|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
448729|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a high total daily dose
448730|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
448731|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a low total daily dose
448732|NCT00779181|Drug|Placebo|Placebo taken three times a day
448733|NCT00779168|Drug|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
448734|NCT00779168|Other|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
448735|NCT00779168|Other|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
448736|NCT00779168|Other|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
448737|NCT00779168|Other|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
448738|NCT00779168|Other|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
448739|NCT00779155|Device|The Resonator|active magnetic field therapy
448740|NCT00779155|Device|The Resonator control|inactive magnetic field therapy with placebo fields
448741|NCT00779142|Drug|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
448742|NCT00779129|Drug|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
448743|NCT00779129|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
448744|NCT00779116|Drug|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
448745|NCT00779116|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
448746|NCT00779103|Drug|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
448747|NCT00779090|Procedure|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
448748|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
448749|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
448750|NCT00779051|Drug|Zolpidem 10mg tablets|
448751|NCT00779038|Drug|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
448752|NCT00779025|Device|PD-F-5254|Female Personal Lubricant (MINE)
448753|NCT00779025|Device|10855-096|Male Personal Lubricant (YOURS)
448754|NCT00779012|Biological|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
448755|NCT00778999|Drug|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
448756|NCT00778986|Device|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
448757|NCT00778973|Drug|sertraline 100 mg tablets|
448758|NCT00778960|Behavioral|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
448759|NCT00778960|Behavioral|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
448760|NCT00778960|Behavioral|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
448761|NCT00778960|Behavioral|Sitting Quietly|"The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily."
448762|NCT00778947|Procedure|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
448763|NCT00778947|Procedure|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
448764|NCT00778934|Other|Intimate Health Gel|Intimate Health Gel
448765|NCT00778921|Drug|Amlodipine 10 mg|Amlodipine 10 mg
448766|NCT00778921|Drug|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
448767|NCT00778921|Drug|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
448768|NCT00778908|Radiation|Late-course accelerated hyperfractionated IMRT|"IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
448769|NCT00778908|Drug|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
448813|NCT00778505|Drug|Remifentanil|manual administration according bispectral index values
448770|NCT00778908|Radiation|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
448771|NCT00778895|Biological|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
448772|NCT00778895|Biological|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
448773|NCT00778882|Drug|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
448774|NCT00778869|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
448775|NCT00778856|Procedure|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
448776|NCT00778843|Dietary Supplement|Viusid|Viusid, three oral sachets daily during 24 weeks
448777|NCT00778843|Other|Placebo|Placebo three oral sachets daily during 24 weeks
448778|NCT00778830|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
448779|NCT00778830|Drug|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
448780|NCT00778830|Drug|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
448781|NCT00778817|Biological|IMC-A12|Given IV
448782|NCT00778817|Drug|mitotane|Given orally
448783|NCT00778804|Behavioral|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
448784|NCT00778791|Drug|metformin HC1 750 mg extended-release tablets|
448785|NCT00778778|Drug|cefprozil 500mg tablets|
448786|NCT00778765|Drug|400 mg Gabapentin Capsules|
448787|NCT00778752|Drug|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.~If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.~If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
448788|NCT00778739|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
448789|NCT00778726|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
448790|NCT00778713|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
448791|NCT00778700|Drug|Ruxolitinib Phosphate Cream|0.5% phosphate cream
448792|NCT00778700|Drug|Placebo Cream|Cream with no active drug
448793|NCT00778700|Drug|Ruxolitinib Phosphate Cream|1.0% phosphate cream
448794|NCT00778700|Drug|Ruxolitinib Phosphate Cream|1.5% phosphate cream
448795|NCT00778674|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
448796|NCT00778661|Drug|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
448797|NCT00778648|Dietary Supplement|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).~Subjects will take four capsules of Juice Plus+® daily."
448798|NCT00778648|Dietary Supplement|Placebo|Four capsules of placebo daily.
448799|NCT00778622|Drug|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
448800|NCT00778609|Drug|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
448801|NCT00778609|Drug|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
448802|NCT00778596|Drug|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
448803|NCT00778596|Drug|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
448804|NCT00778583|Drug|Nitrofurantoin 100 mg capsules|
448805|NCT00778557|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
448806|NCT00778544|Drug|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
448807|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
448808|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
448809|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
448810|NCT00778505|Drug|Propofol|closed-loop administration using bispectral index as the controller
448811|NCT00778505|Drug|remifentanil|closed-loop administration using bispectral index as the controller
448812|NCT00778505|Drug|Propofol|manual administration according bispectral index values
448815|NCT00778466|Drug|metformin hydrochloride 1000 mg tablets|
448816|NCT00778453|Other|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
448817|NCT00778453|Other|Hospital-based BIT|bilateral symmetric, repetitive arm training
448818|NCT00778453|Other|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
448819|NCT00778453|Other|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
448820|NCT00778453|Other|Home-based BAT|bilateral symmetric, repetitive arm training
448821|NCT00778453|Other|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
448822|NCT00778427|Drug|metformin hydrochloride 1000 mg tablets|
448823|NCT00778414|Drug|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
448824|NCT00778401|Drug|Gabapentin tablets 800 mg|
448825|NCT00778388|Biological|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
448826|NCT00778388|Drug|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
448827|NCT00778375|Drug|Clofarabine|20 mg/m^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
448828|NCT00778375|Drug|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
448829|NCT00778375|Drug|Decitabine|20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
448830|NCT00778349|Drug|Metformin solution 100 mg/mL|
448831|NCT00778323|Procedure|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
448832|NCT00778310|Drug|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
448833|NCT00778310|Drug|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
448834|NCT00778297|Biological|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
448835|NCT00778297|Biological|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
448836|NCT00778284|Drug|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
448837|NCT00778271|Drug|Gabapentin 400mg capsules|
448838|NCT00778258|Biological|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
448839|NCT00778258|Biological|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
448840|NCT00778245|Drug|cefprozil 500mg tablets|
448841|NCT00778232|Drug|Gabapentin tablets 800 mg|
448842|NCT00778219|Device|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
448843|NCT00778206|Drug|Kuvan|"After the baby is born, follow-up assessments will be requested for six months. If Kuvan is taken by the mother during and/or after pregnancy, blood samples will be requested from the mother and the baby.~If the mother is lactating and taking Kuvan, breast milk samples will be requested."
448844|NCT00778193|Drug|Naproxen|1 tablet 500mg BID for 8 days
448845|NCT00778193|Drug|Aspirin|1 tablet 81mg QD for 8 days
448846|NCT00778193|Drug|Celecoxib|1 capsule 200mg QD for 8 days
448847|NCT00778193|Drug|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
448848|NCT00778193|Drug|Placebo|1 capsule BID for 8 days
448849|NCT00778180|Drug|furosemide 80 mg tablets|
448850|NCT00778167|Biological|cixutumumab|Given IV
448851|NCT00778167|Drug|erlotinib hydrochloride|Given PO
448852|NCT00778167|Other|laboratory biomarker analysis|Correlative studies
448853|NCT00778141|Drug|metformin HC1 750 mg extended-release tablets|
448854|NCT00778128|Drug|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
448855|NCT00778128|Drug|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
448856|NCT00778115|Drug|Loperamide HCl 2 mg and simethicone 125 mg tablets|
448857|NCT00778102|Drug|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
448858|NCT00778102|Drug|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
448859|NCT00778102|Drug|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
448860|NCT00778102|Drug|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
448861|NCT00778102|Drug|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
448862|NCT00778102|Drug|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
450974|NCT00762515|Drug|Fluoride|Brush two times daily for 6 weeks
448863|NCT00778102|Drug|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
448864|NCT00778102|Drug|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
448865|NCT00778089|Device|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
448866|NCT00778076|Device|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
448867|NCT00778076|Device|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
448868|NCT00778063|Drug|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
448869|NCT00778063|Drug|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
448870|NCT00778050|Drug|Amoxicillin 600mg|
448871|NCT00778037|Drug|Cyclobenzaprine hydrochloride 10 mg tablet|
448872|NCT00778024|Drug|fluoxetine HCL 40 mg capsules|
448873|NCT00778011|Drug|Ondansetron|dosage
448874|NCT00778011|Drug|Ondansetron|4 mg
448875|NCT00778011|Drug|Metoclopramide|10 mg IV
448876|NCT00777998|Procedure|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> 2 months later: Melphalan plus allogeneic PBSCT~-> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)~-> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10^6 (MRD) or 5 x 10^5 (MUD) CD3+ cells per kg BW)~-> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)~-> Further DLI depending on MRD-measurement"
448877|NCT00777998|Procedure|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"*Multiple myeloma~-> Induction Therapy (max. 8 cycles)~-> Registration of patient, stem cell mobilization, start of donor search~-> Melphalan (200mg/qm) plus autologous PBSCT~-> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT~-> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
448878|NCT00777985|Drug|bosentan|62.5 mg b.i.d for 4 weeks
448879|NCT00777985|Device|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
448880|NCT00777972|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
448881|NCT00777959|Drug|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
448882|NCT00777959|Drug|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
448883|NCT00777959|Drug|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
448884|NCT00777946|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
448885|NCT00777946|Drug|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
448886|NCT00777946|Drug|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
448887|NCT00777946|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
448888|NCT00777946|Drug|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
448889|NCT00777933|Drug|tacrolimus|
448890|NCT00777933|Drug|cyclosporine|
448891|NCT00777920|Drug|Ambrisentan|Ambrisentan tablet administered orally once daily
448892|NCT00777907|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
448893|NCT00777907|Device|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
448894|NCT00777894|Radiation|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
448895|NCT00777894|Radiation|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
448966|NCT00777491|Procedure|Post-Induction Chemoradiotherapy Endoscopic Response Evaluation|Urine cytology, cystoscopy, tumor site transurethral biopsy, and bimanual examination after biopsy.
448967|NCT00777491|Drug|adjuvant gemcitabine|1000 mg/m^2 administered intravenously over 30-60 minutes (preferably 30 minutes) on days 1 and 8 of each 21-day cycle for four cycles.
448896|NCT00777894|Radiation|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.~Phase I: Dose finding according to the following escalation table:~Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)~(3 patients) 27 x 2 Gy = 54 Gy~(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy~(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy~(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy~Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
448897|NCT00777868|Drug|Low Strength IDP-108|Topical application once a day for 9 months
448898|NCT00777868|Drug|High Strength IDP-108|Topical application once a day for 9 months
448899|NCT00777868|Drug|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
448900|NCT00777868|Drug|Vehicle|Topical application once a day for 9 months
448901|NCT00777855|Drug|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
448902|NCT00777855|Drug|warfarin|warfarin 7.5mg po x 1
448903|NCT00777842|Device|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
448904|NCT00777829|Drug|Low-dose sodium oxybate|Participants will receive one dose of 2.5 g before each nap.
448905|NCT00777829|Drug|High-dose sodium oxybate|Participants will receive one dose of 3 g before each nap.
448906|NCT00777829|Drug|Low-dose zolpidem|Participants will receive one dose of 5 mg before each nap.
448907|NCT00777829|Drug|High-dose zolpidem|Participants will receive one dose of 10 mg before each nap.
448908|NCT00777829|Drug|Placebo|Participants will receive a dose of placebo before each nap.
448909|NCT00777816|Drug|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
448910|NCT00777816|Drug|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
448911|NCT00777803|Drug|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
448912|NCT00777803|Drug|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
448913|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
448914|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
448915|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
448916|NCT00777777|Device|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
448917|NCT00777764|Drug|Cohort I|"In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were in SWFI."
448918|NCT00777764|Drug|Cohort 2|"In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.~For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.~Dilutions of omalizumab and its excipients were made in saline."
448919|NCT00777738|Drug|BORTEZOMIB|"Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).~For responding patients : up to 6 cycles~For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
448920|NCT00777725|Device|FibroScan|Liver scan, similar to an ultrasound.
448921|NCT00777712|Other|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
448922|NCT00777699|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
448923|NCT00777699|Drug|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
448924|NCT00777686|Procedure|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
448968|NCT00777491|Drug|adjuvant cisplatin|70 mg/m^2 administered as a sixty-minute infusion on day 1 of each 21-day cycle for four cycles.
449056|NCT00776724|Drug|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
449242|NCT00775229|Drug|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
448925|NCT00777673|Drug|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:~nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.~Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.~Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.~After completion of the above regimen, patients will receive:~Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.~Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.~Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.~Patients will then proceed with:~- Surgery including axillary staging~A minimum of 4 weeks post operatively, patient will receive:~- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
448926|NCT00777647|Other|Sugar-sweetened soft drink|One litre a day for six months.
448927|NCT00777647|Other|Aspartame-sweetened soft drink|One litre a day for six months.
448928|NCT00777647|Other|Semi-skimmed milk|One litre a day for six months
448929|NCT00777647|Other|Water|One litre a day for six months.
448930|NCT00777634|Other|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
448931|NCT00777621|Other|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
448932|NCT00777621|Other|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
448933|NCT00777621|Other|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
448934|NCT00777608|Drug|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
448935|NCT00777608|Drug|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.~Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
448936|NCT00777608|Drug|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
448937|NCT00777608|Drug|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
448938|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
448939|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
448940|NCT00777595|Drug|Placebo|Inhaled solution, single dose of placebo
448941|NCT00777595|Drug|Moxifloxacin|Tablet, oral, 400mg, single dose
448942|NCT00777582|Drug|AZD2281|Oral single dose formulation
448943|NCT00777569|Drug|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
448944|NCT00777569|Drug|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
448945|NCT00777569|Drug|Nicotine Lozenge|4 mg nicotine lozenge
448946|NCT00777556|Drug|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
448947|NCT00777543|Other|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
448948|NCT00777543|Dietary Supplement|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
448949|NCT00777543|Dietary Supplement|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
448950|NCT00777530|Drug|Bosutinib (SKI-606)|
448951|NCT00777517|Drug|Lipitor|A single dose of 10 mg Lipitor tablet
448952|NCT00777517|Drug|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
448953|NCT00777504|Drug|usage oral angiogenesis inhibitor|see under 'study arms'
448954|NCT00777504|Drug|stop oral angiogenesis inhibitor|see under 'study arms'
448955|NCT00777491|Drug|induction cisplatin|15 mg/m^2 administered as a 60-minute infusion on days 1,2,3,8,9,10,15,16,17.
448956|NCT00777491|Drug|induction 5-fluorouracil|400mg/m^2 administered as a 24-hour infusion on days 1,2,3, and 15,16,17.
448957|NCT00777491|Drug|induction gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15, 18, 22, 25.
448958|NCT00777491|Radiation|Induction BID radiation therapy|Twice daily (BID) on days 1-5,8-12,15-17. The first daily treatment consists of 1.6 Gy delivered to the pelvis. The second fraction consists of 1.5 Gy to the bladder for the first 5 treatment days. Then, 1.5 Gy is delivered to bladder tumor volume as the second treatment for the remaining 8 treatment days. The bladder tumor volume receives a total of 40.3 Gy.
448959|NCT00777491|Radiation|Induction QD radiation therapy|Once daily (QD) on days (1-5,8-12,15-19,22-26). For the first 10 treatment days, 2 Gy is delivered to the pelvis. Then, 2 Gy is delivered to the bladder for the next 4 treatment days, followed by 2 Gy to the bladder tumor volume for the remaining 6 treatment days. The bladder tumor volume receives a total of 40 Gy.
448960|NCT00777491|Radiation|Consolidation BID radiation therapy|Twice daily (BID) for 8 days on days 1,2,3,4,5,8,9,10 of consolidation. 1.5 Gy per fraction for a total of 24 Gy delivered to the pelvis.
448961|NCT00777491|Radiation|Consolidation QD radiation therapy|Once daily (QD) pelvic radiation therapy for 12 days on days 1-5,8-12,15-16 of consolidation. 2 Gy per fraction for a total of 24 Gy delivered to the pelvis.
448962|NCT00777491|Drug|consolidation gemcitabine|27 mg/m^2 administered as a 30-minute infusion on days 1, 4, 8, 11, 15 of consolidation.
448963|NCT00777491|Drug|consolidation 5-fluorouracil|400 mg/m^2 administered as a 24-hour infusion on days 1, 2, 3 and 8, 9, 10 of consolidation.
448964|NCT00777491|Drug|consolidation cisplatin|15 mg/m^2 administered as a sixty-minute infusion on days 1, 2, 8, 9 of consolidation.
448965|NCT00777491|Procedure|radical cystectomy|Operable patients who have a pT1 or worse tumor response on re-evaluation following initial transurethral resection and induction chemoradiotherapy will have a radical cystectomy 3-8 weeks following the post-induction response evaluation.
449097|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
448969|NCT00777478|Drug|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
448970|NCT00777439|Drug|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
448971|NCT00777413|Drug|Minocycline 100mg Tablets|
448972|NCT00777400|Drug|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
448973|NCT00777387|Procedure|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
448974|NCT00777387|Procedure|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
448975|NCT00777374|Drug|Patch|epicutaneous application of allergen patch
448976|NCT00777374|Drug|Placebo patch|epicutanoeus application of a placebo patch
448977|NCT00777361|Drug|AZD3480|Iv single dose, 4-hour infusion of 25 mg
448978|NCT00777361|Drug|AZD3480|Oral solution single dose of 50 mg
448979|NCT00777348|Drug|Combination DSCG and Reproterol|1:
448980|NCT00777335|Drug|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
448981|NCT00777335|Drug|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
448982|NCT00777322|Procedure|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15−30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross−linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
448983|NCT00777309|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
448984|NCT00777309|Drug|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
448985|NCT00777309|Drug|Placebo|The placebo is provided as a capsule
448986|NCT00777296|Drug|ARIKACE™|Study start date is before Jan 18, 2017.
448987|NCT00777296|Drug|Placebo|Study start date is before Jan 18, 2017.
448988|NCT00777270|Procedure|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
448989|NCT00777270|Procedure|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
448990|NCT00777257|Biological|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
448991|NCT00777257|Biological|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
448992|NCT00777257|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
448993|NCT00777244|Drug|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
448994|NCT00777231|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
448995|NCT00777218|Drug|propranolol|standard pediatric doses, based on body weight
448996|NCT00777218|Drug|zonisamide|standard pediatric dosages, based on body weight
448997|NCT00777218|Drug|topiramate|standard pediatric dosages, based on body weight
448998|NCT00777205|Behavioral|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
448999|NCT00777205|Behavioral|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
449000|NCT00777192|Behavioral|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
449001|NCT00777179|Drug|Vandetanib|Tablet, oral, daily
449002|NCT00777179|Drug|Placebo|Placebo
449003|NCT00777166|Drug|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
449004|NCT00777166|Drug|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
449005|NCT00777153|Drug|Cediranib|30 mg/day, oral, until progression
449006|NCT00777153|Drug|Cediranib|20 mg/day, oral, until progression
449007|NCT00777153|Drug|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
449008|NCT00777153|Drug|Placebo Cediranib|Oral, until progression
449009|NCT00777140|Drug|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.~Bolus + 72h perfusion of saline solution for the placebo group."
449054|NCT00776763|Drug|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
449010|NCT00777127|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
449011|NCT00777127|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
449012|NCT00777114|Drug|bortezomib, tositumomab|"0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
449013|NCT00777101|Drug|Neratinib|Tablets 240 mg orally once per day until disease progression or unacceptable toxicity
449014|NCT00777101|Drug|Lapatinib|Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.
449015|NCT00777101|Drug|Capecitabine|Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
449016|NCT00777088|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
449017|NCT00777075|Drug|L-arginine|
449018|NCT00777075|Drug|Placebo|
449019|NCT00777062|Drug|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
449020|NCT00777062|Drug|Placebo|Placebo injection at the start of weeks 2 and 6.
449021|NCT00777049|Drug|Panobinostat|Hard gelatine capsule - 5mg and 20mg
449022|NCT00777036|Drug|Dasatinib|
449023|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
449024|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
449025|NCT00777023|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
449026|NCT00777010|Other|Ketogenic diet|carbohydrate restricted diet
449027|NCT00777010|Other|Healthy high carbohydrate diet|higher carbohydrate diet
449028|NCT00776997|Device|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
449029|NCT00776984|Drug|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
449030|NCT00776984|Drug|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
449031|NCT00776971|Other|Sugar-sweetened soft drink|500mL as a preload drink
449032|NCT00776971|Other|Aspartame-sweetened soft drink|500mL as a preload drink
449033|NCT00776971|Other|Semi-skimmed milk|500mL as a preload drink
449034|NCT00776971|Other|Water|500mL as a preload drink
449035|NCT00776958|Other|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
449036|NCT00776919|Drug|clindamycin / benzoyl peroxide gel|Once a day application to the face
449037|NCT00776919|Drug|clindamycin gel|Once a day application to the face
449038|NCT00776919|Drug|BPO gel|Once a day application to the face
449039|NCT00776919|Drug|vehicle gel|Once a day application to the face
449040|NCT00776906|Device|Advance® 18PTX® Balloon Catheter|
449041|NCT00776906|Device|Advance® 18LP Balloon Catheter|
449042|NCT00776880|Other|ASA scale|ASA scale evaluation before operation
449043|NCT00776880|Other|PPS scale|PPS scale evaluation before operation
449044|NCT00776867|Drug|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
449045|NCT00776854|Device|Noveon laser|870 and 930nm wavelengths
449046|NCT00776841|Drug|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
449047|NCT00776841|Drug|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
449048|NCT00776841|Drug|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
449049|NCT00776828|Drug|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
449050|NCT00776802|Drug|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
449051|NCT00776802|Drug|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
449052|NCT00776789|Other|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
449053|NCT00776789|Other|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
449055|NCT00776750|Biological|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
449057|NCT00776724|Drug|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.~Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.~Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.~Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.~Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
449058|NCT00776711|Drug|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
449059|NCT00776711|Drug|VRC-AViDNA036-00-VP|
449060|NCT00776698|Drug|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
449061|NCT00776698|Drug|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
449062|NCT00776698|Drug|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
449063|NCT00776685|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
449064|NCT00776672|Drug|Fosinopril 40mg Tablets|
449065|NCT00776659|Other|Aromasin|Non-Interventional study design.
449066|NCT00776646|Drug|hydrochlorothiazide 50 mg tablet|
449067|NCT00776633|Drug|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
449068|NCT00776633|Drug|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
449069|NCT00776633|Drug|oral anticoagulation|
449070|NCT00776620|Drug|Glimepiride 1mg Tablets|
449071|NCT00776607|Drug|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
449072|NCT00776607|Drug|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
449073|NCT00776594|Drug|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
449074|NCT00776594|Drug|bicalutamide|50mg orally daily for 6 months
449075|NCT00776594|Drug|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
449076|NCT00776581|Procedure|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
449077|NCT00776581|Procedure|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
449078|NCT00776581|Procedure|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
449079|NCT00776581|Procedure|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
449080|NCT00776568|Procedure|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
449081|NCT00776568|Drug|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
449082|NCT00776555|Drug|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
449083|NCT00776555|Drug|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
449084|NCT00776542|Drug|Minocycline 100mg Tablets|
449085|NCT00776529|Other|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
449086|NCT00776529|Other|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
449087|NCT00776516|Drug|mirabegron|oral
449088|NCT00776516|Drug|rifampin|oral
449089|NCT00776503|Drug|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
449090|NCT00776490|Drug|Glimepiride 1mg Tablets|
449091|NCT00776477|Drug|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
449092|NCT00776477|Drug|aspirin|aspirin 100mg daily
449093|NCT00776464|Device|Noveon laser|Two wavelenghts of light
449094|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
449095|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
449096|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
449243|NCT00775229|Drug|Placebo|pill, by mouth, daily
449098|NCT00776425|Drug|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
449099|NCT00776399|Device|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
449100|NCT00776373|Drug|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
449101|NCT00776360|Drug|oxytocin|80mIE/min as continuous infusion for 70 minutes
449102|NCT00776360|Drug|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
449103|NCT00776347|Drug|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
449104|NCT00776347|Drug|Donepezil|
449105|NCT00776334|Drug|Fosinopril 40mg Tablets|
449106|NCT00776321|Drug|Eprotirome|
449107|NCT00776321|Drug|Placebo|
449108|NCT00776295|Biological|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes|Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
449109|NCT00776282|Drug|loratadine 10 mg orally disintegrating|
449110|NCT00776269|Procedure|argon laser and radiofrequency|
449111|NCT00776256|Dietary Supplement|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
449112|NCT00776230|Biological|IC51|6 mcg im. at day 0 and day 28
449113|NCT00776217|Drug|loratadine 10 mg orally disintegrating tablets|
449114|NCT00776204|Device|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
449115|NCT00776204|Device|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
449116|NCT00776204|Device|Taxus Libertè|Taxus Libertè stent placed in coronary artery
449117|NCT00776191|Drug|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
449118|NCT00776191|Drug|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
449119|NCT00776165|Biological|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
449120|NCT00776165|Biological|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
449121|NCT00776139|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
449122|NCT00776126|Device|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
449123|NCT00776113|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
449124|NCT00776100|Other|clinical observation|Patients undergo observation for 6 weeks.
449125|NCT00776100|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
449126|NCT00776087|Device|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
449127|NCT00776087|Device|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
449128|NCT00776074|Drug|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
449129|NCT00776074|Drug|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
449130|NCT00776035|Procedure|PET (positron Emission Tomography)|this is a diagnostic scan that requires the injection of radioactive tracers into an IV placed in the arm.
449131|NCT00776035|Procedure|Echocardiogram|an ultrasound of the heart
449132|NCT00776035|Procedure|VO2 peak test|walking on a treadmill during which you will breath in and out through a tube
449133|NCT00776035|Procedure|Body composition Study|a scan of your entire body measuring Body Mass Index, fat percentage etc...
449134|NCT00776035|Radiation|15O water|radioactive tracer used to study blood flow during the PET scan
449135|NCT00776035|Radiation|11C Acetate|radioactive tracer that helps study heart metabolism
449136|NCT00776035|Radiation|11C Palmitate|radioactive tracer used to study fatty acid usage in the heart
449137|NCT00776035|Radiation|11C Glucose|radioactive tracer usde to study glucose usage in the heart
449138|NCT00776022|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
449139|NCT00776009|Drug|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
449140|NCT00776009|Drug|Placebo|Placebo Comparator
449141|NCT00775996|Drug|Clorazepate Dipotassium 15mg Tablets|
449142|NCT00775983|Device|laminaria|place device in cervix for dilation
449143|NCT00775983|Device|Dilapan-S|Place in cervix for dilation.
449144|NCT00775970|Behavioral|walking activity|
449145|NCT00775957|Procedure|FLT-PET scan|imaging scan
449146|NCT00775957|Procedure|FDG-PET scan|imaging scan
449147|NCT00775944|Behavioral|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
449148|NCT00775944|Behavioral|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
449149|NCT00775944|Drug|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
449150|NCT00775931|Procedure|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
449151|NCT00775931|Drug|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
449152|NCT00775931|Radiation|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
449153|NCT00775931|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
449154|NCT00775931|Drug|Busulfan|patients<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
449155|NCT00775931|Drug|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
449156|NCT00775931|Procedure|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
449157|NCT00775918|Drug|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
449158|NCT00775905|Drug|amlodipine 10 mg tablet|
449159|NCT00775892|Device|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
449160|NCT00775879|Drug|Induction with Sevoflurane|
449161|NCT00775866|Procedure|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
449162|NCT00775840|Drug|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
449163|NCT00775840|Drug|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
449164|NCT00775827|Drug|fenofibrate 160 mg tablets|
449165|NCT00775814|Drug|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
449166|NCT00775814|Drug|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
449167|NCT00775801|Device|FLD|Artificial lumbar disc
449168|NCT00775801|Device|Control|Artificial lumbar disc
449169|NCT00775788|Procedure|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
449170|NCT00775762|Drug|aspirin|Aspirin (75-100 mg)die for three months
449171|NCT00775762|Drug|clopidogrel|Clopidogrel (75mg) die for three months
449172|NCT00775762|Drug|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
449173|NCT00775749|Drug|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
449174|NCT00775749|Drug|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
449175|NCT00775736|Drug|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
449176|NCT00775736|Drug|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
449177|NCT00775736|Drug|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
449178|NCT00775710|Device|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
449179|NCT00775697|Drug|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
449180|NCT00775697|Drug|Montelukast|montelukast 4 mg day for 4 weeks
449181|NCT00775684|Drug|Exenatide|Exenatide (Byetta®)—5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
449182|NCT00775684|Drug|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
449183|NCT00775684|Drug|Glimepiride|Glimepiride (Amaryl®)—0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
449184|NCT00775671|Drug|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
449185|NCT00775671|Drug|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
449186|NCT00775671|Drug|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
449187|NCT00775658|Drug|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
449188|NCT00775658|Drug|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
449189|NCT00775645|Dietary Supplement|acetyl-L-carnitine hydrochloride|Given orally
449190|NCT00775645|Other|placebo|Given orally
449191|NCT00775632|Drug|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
449192|NCT00775632|Drug|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
449193|NCT00775619|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
449194|NCT00775606|Drug|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
449195|NCT00775606|Drug|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
449196|NCT00775593|Drug|clofarabine|"Patients will receive one course of low-dose Clofarabine in combination with Temsirolimus (CloTor regimen) for remission induction.~Induction therapy~- Clofarabine 20 mg/m2/day, administered by iv infusion over 1 hour on days 1 through 5"
449197|NCT00775593|Drug|temsirolimus|"Those who achieve morphologic CR and morphologic CRi will receive maintenance treatment with Temsirolimus monthly for 12 months, or until relapse.~Those who achieve a PR will receive one additional course of CloTor and, if a CR/CRi is obtained, maintenance treatment with Temsirolimus as above.~Induction therapy:~- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1, 8 and 15.~Maintenance therapy:~- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1 and 8 of each month for 12 months, or until relapse."
449198|NCT00775580|Drug|Atenolol 100mg Tablets|
449199|NCT00775567|Dietary Supplement|Fructose powder|30g in 250ml water twice a day
449200|NCT00775554|Other|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
449201|NCT00775554|Other|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
449202|NCT00775541|Dietary Supplement|Vitamin C|One IV infusion of 2 gm vitamin C
449203|NCT00775528|Drug|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
449204|NCT00775515|Procedure|laparoscopic prostatectomy|laparoscopic prostatectomy
449205|NCT00775502|Drug|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
449206|NCT00775489|Drug|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
449207|NCT00775489|Drug|Saline|control group will receive normal saline inhaler
449208|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, 1.2 g twice daily
449209|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, 2.4 g twice daily
449210|NCT00775476|Drug|Placebo|2.4 g of placebo (sugar) twice daily
449211|NCT00775463|Drug|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
449212|NCT00775463|Drug|placebo|
449213|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
449214|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
449215|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
449216|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
449217|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
449218|NCT00775437|Drug|Adalimumab|Adalimumab solution for injection for subcutaneous use.
449219|NCT00775424|Biological|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
449220|NCT00775424|Biological|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
449221|NCT00775424|Biological|PLACEBO|PLACEBO
449222|NCT00775424|Biological|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
449223|NCT00775411|Drug|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
449224|NCT00775411|Biological|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
449225|NCT00775385|Drug|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
449226|NCT00775385|Drug|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~ERCC1 high : no treatment~ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
449227|NCT00775372|Drug|Clarithromycin 250mg/5mL|
449228|NCT00775359|Drug|Fenofibrate 160 mg tablets|
449229|NCT00775333|Procedure|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
449230|NCT00775320|Procedure|FLT-PET scan|Imaging test
449231|NCT00775307|Drug|PAZOPANIB|400 mg/day (24 weeks)
449232|NCT00775307|Drug|Placebo|Placebo 400 mg/day (24 weeks)
449233|NCT00775294|Drug|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
449234|NCT00775268|Procedure|Biopsy|Biopsy taken
449235|NCT00775268|Radiation|Fluordeoxyglucose F 18|Undergo scans
449236|NCT00775268|Other|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
449237|NCT00775268|Procedure|computed tomography|Undergo scans
449238|NCT00775268|Procedure|fine-needle aspiration|sample collected
449239|NCT00775255|Drug|clarithromycin 250 mg/5 mL powder for oral suspension|
449240|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
449241|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
449244|NCT00775216|Behavioral|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
449245|NCT00775203|Drug|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
449246|NCT00775203|Drug|Placebo|
449247|NCT00775190|Drug|ortho tricyclen|brand name oral contraceptive
449248|NCT00775190|Drug|Trinessa|generic oral contraceptive
449249|NCT00775177|Drug|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
449250|NCT00775164|Drug|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
449251|NCT00775164|Drug|Metformin|Metformin XR; 1000 mg once daily
449252|NCT00775151|Drug|amlodipine 10 mg tablet|
449253|NCT00775138|Drug|280 mg Arikayce™|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
449254|NCT00775138|Drug|Matching Placebo for Cohort 1|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
449255|NCT00775138|Drug|560 mg Arikayce™|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
449256|NCT00775138|Drug|Matching Placebo for Cohort 2|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
449257|NCT00775125|Drug|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
449258|NCT00775112|Device|pillow|use of pillow for lumbar punctures
449259|NCT00775099|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
449260|NCT00775099|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
449261|NCT00775086|Drug|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
449262|NCT00775073|Drug|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
449263|NCT00775047|Other|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
449264|NCT00775047|Other|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
449265|NCT00775034|Drug|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
449266|NCT00775034|Procedure|Drainage|Mesh repair for open incisional hernia repair with drainage
449267|NCT00775021|Device|etafilcon A|Contact Lens
449268|NCT00775021|Device|nelfilcon A|Contact Lens
449269|NCT00775008|Behavioral|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
449270|NCT00774995|Biological|EngerixTM-B|Intramuscular injection, one dose.
449271|NCT00774982|Drug|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
449272|NCT00774982|Drug|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
449273|NCT00774969|Drug|Metronidazole|Metronidazole 10% ointment three times a day 7 days
449274|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
449275|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
449276|NCT00774943|Drug|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
449277|NCT00774930|Drug|Lanreotide|deep s.c. injection, 120 mg, every 4 weeks (±3 days).
449278|NCT00774930|Drug|Placebo|deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
449279|NCT00774917|Device|Numen|Numen Co-Cr coronary stent implant
449280|NCT00774904|Drug|Losartan|Angiotensin II Type 1 Receptor Blockers
449281|NCT00774878|Drug|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
449282|NCT00774878|Drug|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
449283|NCT00774865|Procedure|MIBI and CTA|Rest and Stress MIBI and CT Angiography
449284|NCT00774852|Drug|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
449285|NCT00774852|Drug|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
449286|NCT00774852|Drug|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
449287|NCT00774852|Drug|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
449288|NCT00774852|Drug|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
449289|NCT00774852|Drug|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
449290|NCT00774839|Behavioral|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
449367|NCT00774280|Drug|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
449291|NCT00774826|Drug|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
449292|NCT00774826|Drug|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
449293|NCT00774826|Drug|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
449294|NCT00774813|Device|Nexalin 1.3mA Device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of placebo antidepressant"
449295|NCT00774813|Device|Nexalin 15mA device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a placebo antidepressant"
449296|NCT00774813|Drug|placebo device and Citalopram|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)~Daily receipt of a a SSRI (Citalopram or similar)"
449297|NCT00774800|Drug|Humalog|
449298|NCT00774800|Drug|Humulin-R|
449299|NCT00774800|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
449300|NCT00774800|Other|Liquid meal|
449301|NCT00774787|Drug|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
449302|NCT00774774|Device|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
449303|NCT00774774|Device|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor~Masks will not be worn:~during the night,~when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
449304|NCT00774761|Drug|fluticasone propionate/formoterol fumarate|inhalation suspension
449305|NCT00774761|Drug|fluticasone propionate|inhalation suspension
449306|NCT00774761|Drug|formoterol fumarate|inhalation solution
449307|NCT00774748|Device|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
449308|NCT00774735|Drug|GSK1349572|30 mg given in combination with lopinavir/ritonavir
449309|NCT00774735|Drug|GSK1349572|30 mg in combination with darunavir/ritonavir
449310|NCT00774722|Drug|Metronidazole|10% ointment, three times daily for 14 days
449311|NCT00774696|Drug|clarithromycin 500mg tablets|
449312|NCT00774683|Drug|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
449313|NCT00774644|Drug|Clarithromycin 500mg|
449314|NCT00774631|Procedure|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:~Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 [6, 48]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
449315|NCT00774631|Procedure|local recommendations and guidelines|"Investigational procedure:~This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.~Controls will receive standard care and will be also be deeply sedated for 48 hours."
449316|NCT00774618|Device|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
449317|NCT00774605|Drug|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
449318|NCT00774605|Drug|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
449319|NCT00774592|Behavioral|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
449320|NCT00774592|Behavioral|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
449321|NCT00774592|Behavioral|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
449322|NCT00774592|Behavioral|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
449323|NCT00774592|Behavioral|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
449324|NCT00774592|Behavioral|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
449325|NCT00774566|Procedure|PV-Isolation RF|Radiofrequency
449326|NCT00774566|Procedure|PV-Isolation Cryo|Cryo-Balloon
449327|NCT00774553|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
449328|NCT00774553|Drug|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
449329|NCT00774540|Drug|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
449330|NCT00774540|Drug|Placebo|Saline
449520|NCT00772954|Biological|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
449331|NCT00774527|Drug|Cyclophosphamide-fludarabine-anti thymocyte globulin|"Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.~Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).~Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
449332|NCT00774514|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
449333|NCT00774501|Procedure|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.~Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.~The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
449334|NCT00774488|Other|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
449335|NCT00774475|Drug|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
449336|NCT00774475|Drug|doubled therapy|clopidogrel 150 mg/day
449337|NCT00774462|Drug|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
449338|NCT00774436|Procedure|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
449339|NCT00774423|Drug|Riluzole|50 mg per day during 24 months
449340|NCT00774397|Drug|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
449341|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
449342|NCT00774397|Drug|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
449343|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
449344|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
449345|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
449346|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
449347|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
449348|NCT00774397|Drug|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
449349|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
449350|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
449351|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
449352|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
449353|NCT00774397|Drug|Placebo|Placebo
449354|NCT00774384|Biological|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
449355|NCT00774371|Behavioral|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
449356|NCT00774358|Drug|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
449357|NCT00774345|Drug|Lenalidomide|Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
449358|NCT00774345|Drug|Placebo|Placebo capsules given orally on days 1 - 28 of a 28 day cycle
449359|NCT00774332|Drug|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
449360|NCT00774319|Radiation|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.~100 mg/m2 cisplatin iv on day 1, 22 and 43"
449361|NCT00774319|Radiation|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
449362|NCT00774306|Drug|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
449363|NCT00774306|Drug|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
449364|NCT00774306|Drug|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
449365|NCT00774293|Drug|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
449366|NCT00774293|Drug|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
449368|NCT00774267|Drug|BZA 20 mg/CE 0.45 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
449369|NCT00774267|Drug|BZA 20 mg/CE 0.625 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
449370|NCT00774267|Drug|Raloxifene 60 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
449371|NCT00774267|Drug|Placebo|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
449372|NCT00774254|Behavioral|A|Intervention
449373|NCT00774254|Behavioral|B|Intervention
449374|NCT00774241|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
449375|NCT00774241|Drug|docetaxel|75mg/m2 every 3 weeks for 18 weeks
449376|NCT00774228|Device|I-ZIP Ocular Bandage|
449377|NCT00774228|Device|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
449378|NCT00774202|Drug|Rituxan, Cyclophosphamide, Vincristine, Prednisone|'Rituximab, Cyclophosphamide, Vincristine, Prednisone interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first infusions of C and V and oral P, and the following 3 rituximab infusions will be given on the same day as the 3 cycles of C, V, and P.
449379|NCT00774202|Drug|Higher Dose of Rituximab|rituximab 750mg/m2 (twice the standard dose of 375mg/m2) will be given weekly for 4 weeks. Premedication and infusion rate escalation will be exactly the same as for standard dose rituximab. The additional dose will thus run at 400ml/hr.
449380|NCT00774189|Drug|clarithromycin 250 mg tablets|
449381|NCT00774163|Biological|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
449382|NCT00774163|Other|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
449383|NCT00774150|Behavioral|Cognitive Behavioral Therapy|16 sessions of CBT
449384|NCT00774150|Behavioral|Client Centered Therapy|16 sessions of CCT
449385|NCT00774124|Other|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
449386|NCT00774124|Other|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
449387|NCT00774111|Drug|GSK1349572|GSK1349572 50 mg in combination with Etravirine
449388|NCT00774098|Drug|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
449389|NCT00774098|Drug|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
449390|NCT00774098|Dietary Supplement|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
449391|NCT00774098|Drug|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
449392|NCT00774085|Other|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
449393|NCT00774072|Drug|Tobramycin (Gernebcin®)|1 ml / day in each nostril
449394|NCT00774059|Device|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
449395|NCT00774046|Drug|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5~Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
449396|NCT00774046|Drug|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
449397|NCT00774046|Drug|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
449398|NCT00774033|Device|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
449399|NCT00774033|Procedure|classic skin grafts|classic skin grafts used for the treatment of acute burn
449400|NCT00774020|Drug|Zoledronic acid|5mg, i.v. single dose
449401|NCT00774007|Drug|mesalazine|
449402|NCT00774007|Drug|placebo|
449403|NCT00773994|Other|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
449404|NCT00773981|Procedure|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
449405|NCT00773968|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
449406|NCT00773955|Drug|R-(-)-gossypol acetic acid|Given orally
449407|NCT00773955|Other|pharmacological study|Correlative studies
449408|NCT00773955|Other|laboratory biomarker analysis|Correlative studies
449560|NCT00772603|Drug|1200mg SPN-804|two active tablets and two non-active tablets, all identical
449561|NCT00772590|Drug|Raltegravir|Tablets, 400mg, twice daily
449409|NCT00773942|Behavioral|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
449410|NCT00773942|Behavioral|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
449411|NCT00773929|Drug|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.~Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
449412|NCT00773916|Drug|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
449413|NCT00773890|Drug|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
449414|NCT00773890|Drug|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
449415|NCT00773851|Procedure|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
449416|NCT00773851|Procedure|mesh fixation by staples|mesh fixation by staples
449417|NCT00773838|Drug|vorinostat (HDAC inhibitor)|Four 100 mg vorinostat capsules once daily by mouth on days 1-14 of each 21 day treatment cycle. Up to 18 months of treatment.
449418|NCT00773838|Drug|bortezomib|bortezomib 1.3 mg/m2 by IV on days 1, 4, 8, and 11 of each 21-day treatment cycle. Total treatment is up to 18 months.
449419|NCT00773838|Drug|dexamethasone|Five 4 mg Dexamethasone tablets by mouth on days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if disease progression is observed after 2 treatment cycles if no change to disease is observed after 4 treatment cycles .
449420|NCT00773812|Drug|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
449421|NCT00773812|Drug|placebo|One pill is taken once daily.
449422|NCT00773786|Drug|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
449423|NCT00773786|Drug|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
449424|NCT00773773|Other|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
449425|NCT00773760|Other|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
449426|NCT00773747|Drug|vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.
449427|NCT00773747|Drug|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
449428|NCT00773747|Drug|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.
449429|NCT00773734|Drug|Apremilast 10mg|
449430|NCT00773734|Drug|Apremilast 20mg|
449431|NCT00773734|Drug|Apremilast 30 mg|
449432|NCT00773734|Drug|Placebo|
449433|NCT00773734|Drug|Apremilast 30mg|
449434|NCT00773734|Drug|Apremilast 20mg|
449435|NCT00773708|Drug|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
449436|NCT00773695|Drug|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
449437|NCT00773695|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
449438|NCT00773695|Drug|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
449439|NCT00773695|Drug|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
449440|NCT00773695|Drug|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
449441|NCT00773695|Drug|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m^2 as IV infusion every week for 12 weeks.
449442|NCT00773695|Drug|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
449443|NCT00773682|Other|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
449444|NCT00773656|Other|Whole blood sample|70 ml per patient for collection of biological sample
449445|NCT00773643|Other|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
449446|NCT00773630|Drug|Cilostazol|100 mg Cilostazol
449447|NCT00773617|Behavioral|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
449448|NCT00773617|Behavioral|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
449449|NCT00773604|Device|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
449562|NCT00772590|Drug|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
449563|NCT00772590|Other|raltegravir placebo|One tablet, twice daily
449450|NCT00773591|Drug|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.~Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
449451|NCT00773578|Device|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
449452|NCT00773578|Device|Measurement of biomarkers of nasal inflammation|Nasal lavage
449453|NCT00773565|Dietary Supplement|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
449454|NCT00773552|Drug|solifenacin succinate|5mg PO Qday x 90 days
449455|NCT00773552|Drug|placebo|1 tab PO Qday x 90 days
449456|NCT00773539|Procedure|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
449457|NCT00773539|Procedure|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
449458|NCT00773539|Procedure|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
449459|NCT00773526|Drug|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
449460|NCT00773513|Drug|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
449461|NCT00773513|Drug|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
449462|NCT00773513|Drug|Epoetin Beta|Epoetin beta will be administered as per approved label.
449463|NCT00773513|Drug|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
449464|NCT00773500|Other|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
449465|NCT00773487|Other|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
449466|NCT00773474|Drug|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
449467|NCT00773461|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
449468|NCT00773461|Drug|Placebo|iv every 4 weeks for 24 weeks
449469|NCT00773448|Device|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
449470|NCT00773448|Other|Limited Malignancy Screening|"1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)~In women, a pap smear/pelvic examination (if > 18 and < 70 years old and not performed during the past year),a mammogram (> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (>40 years old) will be performed if not conducted in the past year."
449471|NCT00773435|Biological|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
449472|NCT00773435|Other|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
449473|NCT00773422|Drug|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
449474|NCT00773422|Drug|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
449475|NCT00773422|Drug|placebo|placebo
449476|NCT00773383|Drug|RG1507|iv 9mg/kg weekly
449477|NCT00773383|Drug|erlotinib [Tarceva]|150mg oral daily
449478|NCT00773370|Behavioral|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
449479|NCT00773370|Behavioral|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
449480|NCT00773357|Drug|guanfacine|3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
449481|NCT00773357|Drug|placebo|placebo
449482|NCT00773357|Drug|Carvedilol|50 mg/day titrated to stead state. The starting dose is 12.5 mg/day for day 1, followed by 25 mg/day for days 2-3, followed by 50 mg from days 4 to the end of the study.
449483|NCT00773344|Drug|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT~This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
449484|NCT00773331|Drug|epoetin beta|As prescribed
449485|NCT00773331|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
449486|NCT00773318|Procedure|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
449487|NCT00773292|Drug|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
449488|NCT00773279|Device|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
449489|NCT00773279|Device|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
449490|NCT00773253|Drug|Botulinum toxin A|All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
449491|NCT00773240|Drug|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
449492|NCT00773240|Drug|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
449493|NCT00773227|Procedure|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
449494|NCT00773214|Behavioral|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
449495|NCT00773201|Drug|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
449496|NCT00773188|Drug|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
449497|NCT00773188|Drug|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
449498|NCT00773188|Drug|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
449499|NCT00773175|Drug|recombinant human hyaluronidase|150 Units in 1 mL
449500|NCT00773162|Drug|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
449501|NCT00773162|Drug|Sugar Pill|Sugar pill to match seroquel
449502|NCT00773149|Drug|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
449503|NCT00773136|Drug|Bimatoprost Suspension|see prior
449504|NCT00773110|Drug|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
449505|NCT00773110|Drug|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
449506|NCT00773097|Biological|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
449507|NCT00773084|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
449508|NCT00773071|Device|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
449509|NCT00773058|Drug|hydrocortisone|hydrocortisone 100mg q8h
449510|NCT00773058|Drug|placebo|normal saline 100ml q8h
449511|NCT00773045|Other|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
449512|NCT00773019|Device|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
449513|NCT00772980|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
449514|NCT00772980|Drug|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
449515|NCT00772967|Drug|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
449516|NCT00772967|Drug|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
449517|NCT00772967|Drug|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
449518|NCT00772954|Biological|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
449519|NCT00772954|Biological|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
449848|NCT00770614|Drug|Placebo|Placebo
449521|NCT00772941|Drug|Varenicline|"Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows.~The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
449522|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
449523|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
449524|NCT00772915|Drug|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression.~If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.~If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
449525|NCT00772915|Drug|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.~Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
449526|NCT00772902|Drug|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
449527|NCT00772902|Drug|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
449528|NCT00772889|Biological|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
449529|NCT00772889|Biological|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
449530|NCT00772876|Drug|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
449531|NCT00772863|Drug|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
449532|NCT00772837|Drug|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
449533|NCT00772837|Drug|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
449534|NCT00772824|Dietary Supplement|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
449535|NCT00772824|Dietary Supplement|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
449536|NCT00772811|Drug|Flu-Mel|"Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~Melphalan will be administered following the completion of Fludarabine infusion at day -2."
449537|NCT00772798|Drug|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
449538|NCT00772785|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
449539|NCT00772772|Drug|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
449540|NCT00772759|Drug|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
449541|NCT00772759|Drug|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
449542|NCT00772720|Drug|raltegravir|raltegravir 400 mg BID for 7 days
449543|NCT00772720|Drug|Placebo|Placebo BID for 7 days
449544|NCT00772707|Device|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI‐FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
449545|NCT00772707|Device|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
449546|NCT00772694|Drug|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
449547|NCT00772681|Drug|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
449548|NCT00772668|Drug|Rituximab|Administered intravenously during induction and maintenance therapy per protocol.
449549|NCT00772668|Drug|Bortezomib|Administered intravenously per protocol.
449550|NCT00772668|Drug|Cyclophosphamide|Administered intravenously per protocol.
449551|NCT00772668|Drug|Prednisone|Administered orally (PO) per protocol.
449552|NCT00772655|Drug|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 [if platelets are below 150000/µl only 11 MBq/kg are administered).
449553|NCT00772655|Drug|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
449554|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
449555|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
449556|NCT00772616|Drug|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
449557|NCT00772616|Drug|Sufentanil|dosage according to usual criteria
449558|NCT00772603|Drug|Placebo|Non-active tablet identical to study drug tablets
449559|NCT00772603|Drug|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
449564|NCT00772590|Other|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
449565|NCT00772590|Drug|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
449566|NCT00772577|Drug|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
449567|NCT00772577|Drug|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
449568|NCT00772564|Drug|Atorvastatin|Oral Atorvastatin
449569|NCT00772551|Drug|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
449570|NCT00772551|Drug|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
449571|NCT00772538|Drug|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
449572|NCT00772538|Drug|placebo|Matching placebo
449573|NCT00772525|Drug|Nerispirdine|"form: tablet~Route: oral"
449574|NCT00772525|Drug|Placebo|"form: tablet~Route: oral"
449575|NCT00772512|Drug|PF-04802540|5 mg capsule, single dose
449576|NCT00772512|Drug|PF-04802540|15 mg capsule, single dose
449577|NCT00772512|Drug|Placebo|Placebo capsule, single dose
449578|NCT00772499|Drug|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
449579|NCT00772499|Drug|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
449580|NCT00772486|Biological|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
449581|NCT00772473|Other|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
449582|NCT00772460|Device|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
449583|NCT00772447|Drug|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
449584|NCT00772447|Drug|Vancomycin|"Vancomycin - 1g per 12 hrs, for 7-14 days~Or switch to~Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:~- 1 g every 6 hours or 2 g every 8 hours"
449585|NCT00772421|Device|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
449586|NCT00772395|Drug|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
449587|NCT00772395|Drug|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
449588|NCT00772382|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
449589|NCT00772356|Device|Accu-Chek Spirit Insulin Pump|
449590|NCT00772356|Device|Comparator insulin pump|
449591|NCT00772343|Biological|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
449592|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
449593|NCT00772343|Biological|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
449594|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
449595|NCT00772330|Device|Glaucoma Drainage Device|Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye
449596|NCT00772317|Device|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
449597|NCT00772304|Drug|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
449598|NCT00772291|Drug|pregabalin|pregabalin 150-600mg/day during 8 weeks
449599|NCT00772291|Drug|placebo|placebo drug during 8 weeks
449600|NCT00772278|Procedure|carotid artery stenting|carotid artery angiography, angioplasty and stenting
449601|NCT00772278|Procedure|carotid endarterectomy|open surgery including endarterectomy
449602|NCT00772265|Biological|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
449603|NCT00772265|Biological|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
449604|NCT00772252|Other|liver support treatment|plasma exchange for liver support treatment
449605|NCT00772239|Device|Rotation thromboelastometry (ROTEM)|Coagulation measurement
449606|NCT00772239|Procedure|Standard coagulation managment procedure|Standard coagulation managment procedure
449607|NCT00772226|Device|music pillow|according to randomisation patients will receive with/without music.
449608|NCT00772226|Device|pillow without music|According to randomisation patients will receive a pillow with/without music
449609|NCT00772213|Procedure|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
449610|NCT00772200|Procedure|Cognitive Assessment|Complete COG Standard Neuropsychological and Behavioral Battery
449611|NCT00772200|Other|Quality-of-Life Assessment|Ancillary studies
449612|NCT00772187|Drug|morphine|Single dose: 0.1-0.5 mg
449613|NCT00772187|Drug|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
449614|NCT00772187|Drug|general anesthesia (fentanyl)|general anesthesia alone
449615|NCT00772174|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
449616|NCT00772174|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
449849|NCT00770601|Drug|Canakinumab|
449617|NCT00772161|Drug|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
449618|NCT00772148|Drug|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
449619|NCT00772148|Drug|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.~Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
449620|NCT00772135|Drug|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
449621|NCT00772122|Drug|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
449622|NCT00772122|Drug|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
449623|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
449624|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
449625|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
449626|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
449627|NCT00772096|Drug|n-3 fatty acids|
449628|NCT00772083|Behavioral|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
449629|NCT00772083|Behavioral|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
449630|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
449631|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
449632|NCT00772057|Drug|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
449633|NCT00772057|Drug|Placebo|Placebo tablets given two times daily.
449634|NCT00772044|Device|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
449635|NCT00772044|Device|Sham Device|Sham device will be applied
449636|NCT00772031|Drug|propranolol LA|Propranolol LA up to 240 mg/day
449637|NCT00772031|Drug|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
449638|NCT00772031|Drug|placebo|an inactive substance
449639|NCT00772005|Drug|armodafinil|150 mg/day armodafinil
449640|NCT00772005|Drug|placebo|placebo
449641|NCT00772005|Drug|armodafinil|200 mg/day armodafinil
449642|NCT00772005|Drug|armodafinil|250 mg/day armodafinil
449643|NCT00771992|Procedure|Bronchoscopy|Bronchoscopy with segmental allergen challenge
449644|NCT00771979|Drug|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
449645|NCT00771979|Drug|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
449646|NCT00771966|Procedure|Standard therapy|Standard therapy
449647|NCT00771966|Procedure|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
449648|NCT00771953|Drug|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
449649|NCT00771953|Drug|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
449650|NCT00771953|Drug|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
449651|NCT00771940|Drug|Ghrelin|Solvent, cont. infusion
449652|NCT00771927|Drug|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
449653|NCT00771914|Drug|Aspirin|Aspirin 81mg tablet
449654|NCT00771914|Drug|Lovaza|Lovaza 4 grams
449655|NCT00771914|Drug|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
449656|NCT00771914|Other|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
449657|NCT00771901|Drug|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
449658|NCT00771901|Other|placebo|7 pills daily for 4 weeks
449659|NCT00771901|Drug|sodium phenylbutyrate|20g/day for four weeks.
449660|NCT00771888|Drug|lanreotide|lanreotide
449661|NCT00771875|Drug|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
449662|NCT00771875|Drug|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
449663|NCT00771875|Drug|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
449664|NCT00771875|Drug|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
449665|NCT00771875|Drug|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
449666|NCT00771875|Drug|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
449667|NCT00771862|Procedure|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
449668|NCT00771849|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
449669|NCT00771849|Biological|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
449670|NCT00771823|Drug|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
449671|NCT00771823|Drug|Maraviroc|"Placebo twice daily for the first 14 days of the study.~Maraviroc 300 mg twice daily for the last 14 days of the study."
449672|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 100 ug/kg
449673|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 300 ug/kg
449674|NCT00771810|Drug|Placebo|Once daily subcutaneous injection of placebo
449675|NCT00771797|Dietary Supplement|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
449676|NCT00771797|Dietary Supplement|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
449677|NCT00771771|Other|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
449678|NCT00771771|Other|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
449679|NCT00771758|Drug|oxycodone IR|maximum daily dose 450 mg
449680|NCT00771758|Drug|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
449681|NCT00771758|Drug|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
449682|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
449683|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
449684|NCT00771732|Device|light therapy|6 minute light therapy
449685|NCT00771732|Device|light therapy|combination of wavelengths
449686|NCT00771719|Drug|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
449687|NCT00771706|Drug|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
449688|NCT00771706|Drug|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
449689|NCT00771693|Drug|Insulin aspart (Novorapid®)|a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
449690|NCT00771680|Drug|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
449691|NCT00771680|Drug|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
449692|NCT00771680|Drug|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
449693|NCT00771667|Drug|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
449694|NCT00771667|Drug|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
449695|NCT00771667|Drug|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
449696|NCT00771667|Drug|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
449697|NCT00771667|Drug|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
449698|NCT00771667|Drug|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
449699|NCT00771667|Drug|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
449700|NCT00771667|Drug|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
449701|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
449702|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
449703|NCT00771654|Drug|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
449704|NCT00771654|Other|Placebo|daily for one year
449705|NCT00771641|Procedure|conventional surgery|
449706|NCT00771641|Radiation|low-LET cobalt-60 gamma ray therapy|
449707|NCT00771641|Radiation|low-LET electron therapy|
449708|NCT00771641|Radiation|low-LET photon therapy|
449709|NCT00771641|Radiation|radiation therapy|
449710|NCT00771628|Device|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
449711|NCT00771628|Device|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
449712|NCT00771615|Biological|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
449713|NCT00771602|Drug|Rituximab|375 mg/m^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
449714|NCT00771602|Drug|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
449715|NCT00771589|Device|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
449716|NCT00771563|Drug|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
449717|NCT00771563|Drug|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
449718|NCT00771537|Behavioral|Message Sidedness|There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
449719|NCT00771524|Drug|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
449720|NCT00771511|Drug|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
449721|NCT00771511|Drug|Placebo|Only lidocaine gel will be appled to the cervix
449722|NCT00771498|Drug|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
449723|NCT00771485|Drug|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
449724|NCT00771485|Drug|Marketed Bowel Cleanser|Marketed bowel cleanser
449725|NCT00771472|Drug|vorinostat|Parts I & II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
449726|NCT00771459|Drug|Ropivacaine 0.5 %|Local infiltration analgesia
449727|NCT00771459|Drug|Isotonic NaCl|Local infiltration analgesia
449728|NCT00771446|Biological|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
449729|NCT00771446|Other|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
449730|NCT00771433|Biological|filgrastim|Given subcutaneously
449731|NCT00771420|Drug|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
449732|NCT00771420|Drug|CAM-3001|Dosed at 0.1mg/kg.
449733|NCT00771420|Drug|CAM-3001|Dosed at 0.3mg/kg
449734|NCT00771420|Drug|CAM-3001|Dosed at 1.0 mg/kg.
449735|NCT00771420|Drug|CAM-3001|Dosed at 3.0 mg/kg.
449736|NCT00771420|Drug|CAM-3001|Dosed at 10 mg/kg.
449737|NCT00771420|Other|Placebo|Active: Placebo 5:1 for arms 2-6
449738|NCT00771407|Device|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
449739|NCT00771407|Other|Standard ostomy creation|Ostomy will be created as routinely performed
449740|NCT00771394|Drug|Tamsulosin hydrochloride|oral
449741|NCT00771394|Drug|Solifenacin succinate|oral
449742|NCT00771381|Drug|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
449743|NCT00771381|Drug|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
449744|NCT00771368|Drug|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
449745|NCT00771342|Drug|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
449746|NCT00771342|Drug|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
449747|NCT00771329|Drug|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
449748|NCT00771329|Other|Placebo (sterile normal saline)|Single IV dose of Placebo
449749|NCT00771316|Drug|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
449750|NCT00771316|Drug|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
449751|NCT00771303|Other|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
449752|NCT00771290|Procedure|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
449753|NCT00771277|Behavioral|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
449754|NCT00771264|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
449755|NCT00771251|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
449756|NCT00771251|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
449757|NCT00771238|Device|P500 Mattress|Study mattress
449758|NCT00771225|Procedure|fascial repair|surgery to treat genital prolapse with fascia repair
449759|NCT00771225|Procedure|mesh repair|surgery to genital prolapse with mesh
449760|NCT00771212|Other|Observational pain control study|Observational pain control study
449761|NCT00771199|Drug|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
449762|NCT00771173|Drug|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
449763|NCT00771173|Other|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
449764|NCT00771160|Drug|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
449765|NCT00771147|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
449766|NCT00771134|Drug|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
449767|NCT00771134|Drug|Placebo|B.I.D. for 8 weeks
449768|NCT00771134|Drug|Quetiapine|300mg/day for 8 weeks
449769|NCT00771121|Drug|urea/lactic acid|new emulsion type
449770|NCT00771121|Drug|Placebo|only emulsion base
449771|NCT00771108|Behavioral|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
449772|NCT00771095|Behavioral|podcasting|
449773|NCT00771056|Drug|Hydroxychloroquine|400mg by mouth daily x 1 year
449774|NCT00771043|Drug|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
449775|NCT00771030|Drug|AMG 827|Five treatment dose levels in Part A with AMG 827 and one dose level in Part B with AMG 827
449776|NCT00771030|Other|Placebo|Five treatment dose levels in Part A with placebo and one dose level in Part B with placebo
449777|NCT00771017|Biological|GVAX prostate cancer vaccine|Given intradermally
449778|NCT00771017|Drug|bicalutamide|Given orally
449779|NCT00771017|Drug|goserelin|Given intramuscularly
449780|NCT00771017|Drug|leuprolide acetate|Given intramuscularly
449781|NCT00771004|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
449782|NCT00771004|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
449783|NCT00770991|Drug|Black raspberry (BRB) Slurry|20 grams BRB Slurry
449784|NCT00770991|Drug|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
449785|NCT00770991|Drug|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
449786|NCT00770978|Drug|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
449787|NCT00770978|Drug|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
449788|NCT00770965|Biological|AIN457|
449789|NCT00770965|Biological|Placebo|
449790|NCT00770952|Drug|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
449791|NCT00770952|Drug|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
449792|NCT00770939|Device|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
449793|NCT00770926|Behavioral|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
449794|NCT00770913|Drug|E3810|20 mg taken orally, once a day for 8 weeks.
449795|NCT00770913|Drug|E3810|10 mg, taken orally, twice a day for 8 weeks.
449796|NCT00770913|Drug|E3810|20 mg taken orally, twice a day for 8 weeks.
449797|NCT00770900|Drug|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.~Children aged 2-5 years took 4mg tablet of montelukast~Children aged 6-15 years took 5mg tablet of montelukast~Children >15 years took 10mg tablet of montelukast"
449798|NCT00770900|Drug|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
449799|NCT00770887|Procedure|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
449800|NCT00770874|Drug|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
449801|NCT00770874|Drug|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
449802|NCT00770861|Drug|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
449803|NCT00770861|Drug|Placebo|Matching placebo tablets, oral administration
449804|NCT00770848|Drug|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
449805|NCT00770848|Drug|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
449806|NCT00770848|Drug|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
449807|NCT00770848|Drug|Placebo|Placebo
449808|NCT00770848|Drug|Prednisone|5 mg orally BID
449809|NCT00770835|Drug|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
451818|NCT00756080|Drug|citrulline|0.06 G/kg three times/day during 7 days
449810|NCT00770835|Drug|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
449811|NCT00770822|Device|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
449812|NCT00770822|Device|Brachytherapy|Standard of care
449813|NCT00770809|Other|Laboratory Biomarker Analysis|Correlative studies
449814|NCT00770809|Drug|Lapatinib Ditosylate|Given PO
449815|NCT00770809|Drug|Paclitaxel|Given IV
449816|NCT00770809|Biological|Trastuzumab|Given IV
449817|NCT00770796|Drug|Atorvastatin|80 mg die
449818|NCT00770796|Drug|Placebo|
449819|NCT00770783|Device|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
449820|NCT00770783|Device|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
449821|NCT00770770|Drug|Fluocinolone Acetonide|0.2 µg/day
449822|NCT00770770|Drug|Fluocinolone Acetonide|0.5 µg/day
449823|NCT00770757|Drug|CC-4047|
449824|NCT00770744|Drug|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
449825|NCT00770744|Drug|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
449826|NCT00770731|Drug|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
449827|NCT00770731|Drug|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
449828|NCT00770731|Drug|Velcade (Bortezomib)|Starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
449829|NCT00770718|Drug|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
449830|NCT00770718|Drug|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
449831|NCT00770718|Biological|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
449832|NCT00770705|Drug|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
449833|NCT00770705|Other|Standard surgical approach|Historical controls
449834|NCT00770692|Drug|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
449835|NCT00770692|Drug|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
449836|NCT00770692|Drug|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
449837|NCT00770692|Drug|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
449838|NCT00770679|Drug|lipitor|80 mg everyday (QD) for 3 weeks
449839|NCT00770666|Drug|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
449840|NCT00770666|Drug|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
449841|NCT00770653|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
449842|NCT00770653|Drug|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
449843|NCT00770640|Drug|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
449844|NCT00770640|Drug|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
449845|NCT00770627|Dietary Supplement|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
449846|NCT00770614|Drug|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
449847|NCT00770614|Drug|Isotonic saline|0.9% sodium chloride
449850|NCT00770588|Drug|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
449851|NCT00770588|Drug|Placebo|To match Gefitinib
449852|NCT00770575|Drug|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
449853|NCT00770575|Drug|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
449854|NCT00770562|Drug|rituximab|
449855|NCT00770562|Drug|Dexamethasone|
449856|NCT00770536|Drug|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
449857|NCT00770536|Drug|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
449858|NCT00770536|Drug|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
449859|NCT00770536|Drug|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
449860|NCT00770510|Drug|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
449861|NCT00770510|Drug|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
449862|NCT00770510|Drug|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
449863|NCT00770510|Drug|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
449864|NCT00770510|Drug|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
449865|NCT00770497|Drug|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
449866|NCT00770497|Drug|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
449867|NCT00770497|Drug|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:~Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
449868|NCT00770484|Drug|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
449869|NCT00770484|Drug|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
449870|NCT00770471|Drug|temozolomide|
449871|NCT00770471|Drug|veliparib|
449872|NCT00770471|Genetic|DNA methylation analysis|
449873|NCT00770471|Genetic|gene expression analysis|
449874|NCT00770471|Genetic|mutation analysis|
449875|NCT00770471|Genetic|proteomic profiling|
449876|NCT00770471|Other|high performance liquid chromatography|
449877|NCT00770471|Other|immunoenzyme technique|
449878|NCT00770471|Other|laboratory biomarker analysis|
449879|NCT00770471|Other|mass spectrometry|
449880|NCT00770471|Other|pharmacogenomic studies|
449881|NCT00770471|Other|pharmacological study|
449882|NCT00770471|Procedure|adjuvant therapy|
449883|NCT00770471|Radiation|radiation therapy|
449884|NCT00770445|Drug|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
449885|NCT00770445|Drug|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
449886|NCT00770445|Drug|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
449887|NCT00770432|Drug|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
449888|NCT00770432|Other|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
449889|NCT00770419|Other|medical chart review|
449890|NCT00770419|Other|questionnaire administration|
449891|NCT00770419|Procedure|psychosocial assessment and care|
449892|NCT00770406|Drug|botulinum toxin type A|100 or 200 units intravesically
449932|NCT00770133|Drug|Ketotifen/naphazoline|One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
449933|NCT00770133|Drug|Naphazoline|One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
449934|NCT00770133|Drug|Ketotifen|One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
449935|NCT00770133|Drug|Vehicle|One drop of vehicle ophthalmic solution at visit 3 and visit 4.
449936|NCT00770120|Drug|everolimus|
449893|NCT00770393|Procedure|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
449894|NCT00770393|Procedure|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
449895|NCT00770380|Behavioral|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
449896|NCT00770380|Other|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
449897|NCT00770367|Drug|Pioglitazone then Placebo|Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
449898|NCT00770367|Drug|Placebo then Pioglitazone|Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
449899|NCT00770354|Drug|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
449900|NCT00770354|Drug|Letrozole|Daily 2.5 mg oral letrozole tablet
449901|NCT00770341|Drug|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
449902|NCT00770341|Drug|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
449903|NCT00770341|Drug|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
449904|NCT00770328|Drug|Pentoxifylline|400mg PO TID x 8 weeks
449905|NCT00770328|Drug|Placebo|PO TID x 8 weeks
449906|NCT00770315|Biological|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
449907|NCT00770315|Biological|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
449908|NCT00770302|Drug|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
449909|NCT00770289|Other|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
449910|NCT00770263|Drug|Erlotinib|
449911|NCT00770263|Drug|Temsirolimus|
449912|NCT00770237|Behavioral|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
449913|NCT00770237|Behavioral|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
449914|NCT00770224|Biological|rituximab|
449915|NCT00770224|Biological|tositumomab|
449916|NCT00770224|Drug|cyclophosphamide|
449917|NCT00770224|Drug|doxorubicin|
449918|NCT00770224|Drug|prednisone|
449919|NCT00770224|Drug|vincristine|
449920|NCT00770224|Radiation|tositumomab|
449921|NCT00770211|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
449922|NCT00770211|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
449923|NCT00770185|Drug|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
449924|NCT00770185|Genetic|gene expression analysis|
449925|NCT00770185|Other|immunohistochemistry staining method|
449926|NCT00770185|Other|laboratory biomarker analysis|
449927|NCT00770172|Biological|filgrastim|Given subcutaneously
449928|NCT00770159|Drug|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
449929|NCT00770159|Drug|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
449930|NCT00770146|Drug|Mipomersen sodium|200 mg/mL
449931|NCT00770146|Drug|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
449937|NCT00770107|Drug|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
449938|NCT00770107|Drug|Placebo|Placebo, once daily, for a duration of 4 weeks
449939|NCT00770094|Device|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
449940|NCT00770094|Device|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
449941|NCT00770094|Device|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
449942|NCT00770081|Drug|vildagliptin|50mg qd
449943|NCT00770081|Drug|sitagliptin|25mg qd
449944|NCT00770055|Other|medical chart review|
449945|NCT00770055|Other|questionnaire administration|
449946|NCT00770055|Other|survey administration|
449947|NCT00770055|Procedure|psychosocial assessment and care|
449948|NCT00770042|Drug|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
449949|NCT00770042|Drug|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
449950|NCT00770042|Drug|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
449951|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 8
449952|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 6
449953|NCT00770042|Drug|Avanafil|Avanafil 200mg Days 1 and 6
449954|NCT00770029|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
449955|NCT00770029|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
449956|NCT00770016|Drug|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
449957|NCT00770003|Drug|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
449958|NCT00770003|Drug|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
449959|NCT00769990|Dietary Supplement|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
449960|NCT00769990|Radiation|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
449961|NCT00769964|Drug|VA111913 TS / placebo|
449962|NCT00769951|Other|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
449963|NCT00769951|Other|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
449964|NCT00769951|Procedure|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
449965|NCT00769951|Procedure|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
449966|NCT00769951|Procedure|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
449967|NCT00769938|Device|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
449968|NCT00769925|Behavioral|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
449969|NCT00769925|Behavioral|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
449970|NCT00769912|Drug|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
449971|NCT00769912|Drug|Placebo (air)|Placebo administration during the intervention
449972|NCT00769899|Drug|AZD7325|Capsule for oral, single dose
449973|NCT00769899|Drug|Placebo|Placebo capsule for oral, single dose
449974|NCT00769886|Drug|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
449975|NCT00769886|Drug|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
449976|NCT00769886|Drug|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
449977|NCT00769886|Drug|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
449978|NCT00769873|Drug|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days
449979|NCT00769860|Drug|Arimoclomol|Arimoclomol 100 mg TID for 4 months
449980|NCT00769860|Other|Placebo|Placebo for 4 months
449981|NCT00769847|Procedure|Endoscopic strip craniectomy|Surgery
449982|NCT00769821|Other|questionnaire administration|
449983|NCT00769821|Procedure|assessment of therapy complications|
449984|NCT00769821|Procedure|bioimpedance spectroscopy|
449985|NCT00769821|Procedure|quality-of-life assessment|
449986|NCT00769795|Drug|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
449987|NCT00769795|Drug|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
449988|NCT00769795|Drug|Goserelin|10.8 mg subcutaneous once
449989|NCT00769782|Procedure|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
449990|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
449991|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
449992|NCT00769717|Behavioral|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
449993|NCT00769717|Behavioral|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
449994|NCT00769704|Biological|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
449995|NCT00769704|Biological|GM-CSF|125 µg/m² subcutaneous injection
449996|NCT00769678|Device|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
449997|NCT00769665|Other|Systane Ultra|Re-wetting ocular eye drop
449998|NCT00769665|Other|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
449999|NCT00769652|Behavioral|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
450000|NCT00769652|Behavioral|Standard Care|"Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during & after treatment."
450001|NCT00769626|Other|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
450002|NCT00769626|Other|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
450003|NCT00769613|Biological|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
450004|NCT00769613|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
450005|NCT00769613|Biological|therapeutic allogeneic lymphocytes|
450006|NCT00769613|Genetic|polymerase chain reaction|
450007|NCT00769613|Other|flow cytometry|
450008|NCT00769613|Other|immunological diagnostic method|
450009|NCT00769613|Other|laboratory biomarker analysis|
450010|NCT00769600|Drug|Itraconazole|Itraconazole 200 mg once daily
450011|NCT00769600|Drug|Pemetrexed|Pemetrexed every 21 days.
450012|NCT00769587|Drug|thalidomide|
450013|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
450014|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
450015|NCT00769561|Behavioral|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
452208|NCT00753207|Other|biomarker analysis|
450016|NCT00769561|Device|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
450017|NCT00769548|Drug|flutamide|Drug used for TAS.
450018|NCT00769548|Drug|goserelin acetate|Drug used for TAS.
450019|NCT00769548|Radiation|low-LET photon therapy|radiation therapy
450020|NCT00769535|Genetic|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
450021|NCT00769522|Biological|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"
450022|NCT00769522|Drug|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
450023|NCT00769522|Drug|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
450024|NCT00769522|Drug|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
450025|NCT00769509|Other|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
450026|NCT00769509|Other|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
450027|NCT00769496|Drug|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
450028|NCT00769483|Drug|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
450029|NCT00769483|Drug|Gemcitabine|1000 mg/m^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
450030|NCT00769483|Drug|Erlotinib|100 mg by mouth daily.
450031|NCT00769470|Biological|trastuzumab|Given IV
450032|NCT00769470|Drug|carboplatin|Given IV
450033|NCT00769470|Drug|docetaxel|Given IV
450034|NCT00769470|Drug|lapatinib ditosylate|Given orally
450035|NCT00769457|Device|Access Arm|Active OptiVol-System with CareAlert via CareLink
450036|NCT00769431|Other|educational intervention|
450037|NCT00769431|Other|study of socioeconomic and demographic variables|
450038|NCT00769418|Drug|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days."
450039|NCT00769418|Drug|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.~Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.~Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.~Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.~Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.~Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.~Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
450040|NCT00769405|Drug|fluorouracil|Given IV
450041|NCT00769405|Drug|leucovorin calcium|Given IV
450042|NCT00769405|Drug|oxaliplatin|Given during surgery
450043|NCT00769405|Procedure|hyperthermia treatment|Given intraperitoneally during surgery
450044|NCT00769392|Drug|Proparacaine Ophthalmic|Drops of Proparacaine on the eye, administered as described in the package insert
450045|NCT00769392|Drug|Tetracaine Ophthalmic|Drops of Tetracaine on the eye, administered as described in the package insert
450046|NCT00769392|Drug|Lidocaine 4%|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
450047|NCT00769392|Drug|Lidocaine 2% Injectable Solution|A subconjunctival injection of Lidocaine 2%
450048|NCT00769379|Other|Laboratory Biomarker Analysis|Correlative studies
450049|NCT00769379|Biological|Trastuzumab|Given IV
450050|NCT00769379|Radiation|Whole Breast Irradiation|Undergo standard whole breast irradiation
450051|NCT00769366|Behavioral|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
450052|NCT00769366|Drug|Medical therapy|Optimal medical therapy after Acute myocardial infarction
450053|NCT00769353|Behavioral|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
450054|NCT00769353|Behavioral|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
450055|NCT00769327|Drug|imatinib mesylate|
450056|NCT00769327|Drug|nilotinib|
450057|NCT00769327|Genetic|cytogenetic analysis|
450058|NCT00769327|Genetic|fluorescence in situ hybridization|
450059|NCT00769327|Genetic|microarray analysis|
450060|NCT00769327|Genetic|mutation analysis|
450061|NCT00769327|Genetic|polymerase chain reaction|
450062|NCT00769327|Genetic|polymorphism analysis|
450063|NCT00769327|Other|laboratory biomarker analysis|
450064|NCT00769314|Drug|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
450065|NCT00769314|Drug|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
450066|NCT00769288|Drug|2'-F-ara-deoxyuridine|Given IV
450067|NCT00769288|Other|positron emission tomography|Correlative studies
450068|NCT00769288|Other|laboratory biomarker analysis|Correlative studies
450069|NCT00769288|Other|pharmacological study|Correlative studies
450070|NCT00769288|Other|pharmacogenomic studies|Correlative studies
450071|NCT00769262|Other|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
450072|NCT00769262|Other|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
450073|NCT00769249|Other|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
450074|NCT00769249|Other|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
450075|NCT00769249|Procedure|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
450076|NCT00769236|Other|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
450077|NCT00769236|Other|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
450078|NCT00769236|Other|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
450079|NCT00769223|Other|medical chart review|
450080|NCT00769223|Other|questionnaire administration|
450081|NCT00769223|Procedure|quality-of-life assessment|
450082|NCT00769223|Radiation|brachytherapy|
450083|NCT00769223|Radiation|radiation therapy|
450084|NCT00769210|Drug|Simvastatin|Simvastatin 40 mg tablet
450085|NCT00769184|Drug|Corticosteroid|"One side of body:~clobetasol: 2 applications / day along with LCD application 2 applications/day"
450086|NCT00769184|Other|Placebo|"One side of body:~Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
450087|NCT00769184|Drug|LCD|"One side of body:~LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
450088|NCT00769171|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
450089|NCT00769171|Drug|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
450090|NCT00769158|Drug|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
450091|NCT00769158|Other|Placebo|Placebo Comparator
450092|NCT00769145|Drug|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
450093|NCT00769132|Drug|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
450094|NCT00769132|Drug|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
450095|NCT00769132|Drug|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
450096|NCT00769132|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
450097|NCT00769119|Drug|AZD9668|2 x 30 mg, oral tablet, twice daily for 28 days
450098|NCT00769119|Drug|Placebo|2 x Matched placebo, oral tablet, twice daily for 28 days
450099|NCT00769106|Biological|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
450100|NCT00769093|Drug|Ferumoxytol|2 mg/kg
450101|NCT00769067|Drug|Erlotinib|Continuous oral dosing at 150 mg daily.
450102|NCT00769067|Drug|PF-00299804|Continuous oral dosing at 45mg daily
450103|NCT00769054|Drug|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
450104|NCT00769054|Drug|Isotonic NaCl|Local Infiltration with NaCl
450105|NCT00769041|Drug|moxifloxacin|400mg
450106|NCT00769041|Drug|avanafil|100mg single dose
450107|NCT00769041|Drug|avanafil|800mg single dose
450108|NCT00769041|Drug|sugar pill|single dose
450109|NCT00769028|Drug|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
450110|NCT00769028|Drug|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
450111|NCT00769015|Behavioral|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
450112|NCT00769015|Behavioral|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
450113|NCT00769002|Biological|FluShield, FluMist|Flu vaccine
450114|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
450115|NCT00768989|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
450116|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
450117|NCT00768989|Drug|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
450118|NCT00768989|Drug|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
450119|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
450120|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
450121|NCT00768950|Procedure|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
450122|NCT00768950|Procedure|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
450123|NCT00768937|Drug|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
450124|NCT00768937|Procedure|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
450125|NCT00768911|Drug|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
450150|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
450126|NCT00768911|Drug|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
450127|NCT00768911|Procedure|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
450128|NCT00768898|Other|2.5/5.0/10.0 ÂµL lissamine green|vital stain solution
450129|NCT00768885|Device|PureVision 1|Currently marketed PureVision soft contact lens.
450130|NCT00768885|Device|PureVision 2|Alternate design soft contact lens.
450131|NCT00768859|Drug|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
450132|NCT00768846|Device|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
450133|NCT00768846|Device|Xience V Stent|Everolimus-eluting Xience V Stent
450134|NCT00768820|Drug|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
450135|NCT00768807|Device|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
450136|NCT00768794|Dietary Supplement|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.~The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
450137|NCT00768794|Dietary Supplement|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
450138|NCT00768781|Behavioral|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
450139|NCT00768781|Behavioral|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
450140|NCT00768781|Behavioral|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
450141|NCT00768768|Other|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
450142|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
450143|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
450144|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
450145|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel~Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.~Two different drug applicators to be tested on each subject~Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design~Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
450146|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po
450147|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
450148|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
450149|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
450151|NCT00768742|Device|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
450152|NCT00768729|Drug|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
450153|NCT00768729|Drug|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
450154|NCT00768716|Drug|Acetaminophen|2 x 500 mg by mouth once
450155|NCT00768703|Device|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
450156|NCT00768690|Drug|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
450157|NCT00768690|Drug|ketoconazole|Tablet, see arms for intervention description
450158|NCT00768690|Drug|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
450159|NCT00768677|Drug|topiramate|
450160|NCT00768664|Drug|PF-00299804|45 mg by continuous oral dosing
450161|NCT00768651|Drug|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
450162|NCT00768651|Drug|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
450163|NCT00768638|Drug|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
450164|NCT00768638|Drug|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
450165|NCT00768612|Drug|SCA-136 50mg/day|
450166|NCT00768612|Drug|SCA-136 150 mg/day|
450167|NCT00768612|Drug|SCA-136 300mg/day|
450168|NCT00768612|Drug|Risperidone 4mg/day|
450169|NCT00768599|Drug|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
450170|NCT00768599|Drug|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
450171|NCT00768599|Drug|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
450172|NCT00768573|Drug|sildenafil|Oral suspension of sildenafil.
450173|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
450174|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
450175|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
450176|NCT00768521|Drug|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose tolterodine tartrate 4 mg capsule"
450177|NCT00768521|Drug|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days~Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days~Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
450178|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
450179|NCT00768508|Drug|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
450180|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
450181|NCT00768508|Other|Placebo + Cognitive Behavioral Therapy|Placebo comparator
450182|NCT00768482|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
450183|NCT00768482|Drug|Sublingual Buprenorphine|16 mg/day, QD
450184|NCT00768469|Drug|Neratinib|Administered orally, continuous, once daily.
450185|NCT00768469|Drug|Paclitaxel|Administered IV, on days 1, 8, 15 of 28 day cycle.
450186|NCT00768456|Drug|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
450187|NCT00768456|Drug|Isotonic NaCl|Local Infiltration with NaCl
450188|NCT00768430|Drug|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
450189|NCT00768430|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
450190|NCT00768417|Behavioral|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
450191|NCT00768417|Behavioral|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
450192|NCT00768417|Behavioral|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
450193|NCT00768404|Drug|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
450194|NCT00768391|Biological|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
450195|NCT00768378|Device|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
450288|NCT00767559|Drug|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
450196|NCT00768352|Other|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
450197|NCT00768339|Drug|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.~Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.~Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
450198|NCT00768326|Drug|Zicronapine|"Study Part A:~3mg; orally, film-coated tablets, once daily, 8 weeks"
450199|NCT00768326|Drug|Zicronapine|"Study Part B:~5mg; orally, film-coated tablets, once daily, 8 weeks"
450200|NCT00768326|Drug|Zicronapine|"Study Part C:~7mg; orally, film-coated tablets, once daily, 8 weeks"
450201|NCT00768326|Drug|Zicronapine|"Study Part D:~2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
450202|NCT00768326|Drug|Zicronapine|"Study Part E:~2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
450203|NCT00768326|Drug|Placebo|"Study Part A, B, C, D and E:~Placebo; orally, film-coated tablets, once daily, 8 weeks"
450204|NCT00768313|Device|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
450205|NCT00768313|Device|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
450206|NCT00768300|Drug|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
450207|NCT00768300|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
450208|NCT00768287|Biological|IB1001|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa; Study Part 2: Non-randomized, open-label evaluation of prophylaxis and on demand IB1001; Surgical Sub-study: Open-label evaluation of IB1001 during major surgery
450209|NCT00768287|Biological|nonacog alfa|Study Part 1: Randomized, double-blind, cross-over study with IB1001 and nonacog alfa
450210|NCT00768274|Drug|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
450211|NCT00768274|Drug|Placebo|Placebo twice daily (b.i.d.) for 28 days
450212|NCT00768261|Drug|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
450213|NCT00768261|Drug|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
450214|NCT00768248|Drug|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
450215|NCT00768248|Drug|normal saline (placebo)|the basal rate will be set at 7 mL/h
450216|NCT00768235|Other|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
450217|NCT00768222|Device|silk suture|skin closure
450218|NCT00768222|Device|VICRYL* Plus suture|skin closure
450219|NCT00768209|Drug|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
450220|NCT00768183|Other|KADIAN + Ethanol|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
450221|NCT00768183|Other|KADIAN + Water|Capsules 100mg + 240 mL in 4 shots of 60 mL
450222|NCT00768183|Other|morphine sulfate IR oral solution + water|Solution 20mg/5mL, 235 mL of water in 1 shot of 55 mL (+ 5mL IR morphine) + 3 shots of 60 mL of water
450223|NCT00768170|Drug|MK0633|MK0633 (50 mg) Oral, single dose
450224|NCT00768157|Drug|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
450225|NCT00768157|Procedure|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
450226|NCT00768144|Drug|Sunitinib|
450227|NCT00768131|Drug|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
450228|NCT00768131|Drug|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
450229|NCT00768131|Drug|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
450230|NCT00768118|Dietary Supplement|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
450231|NCT00768118|Genetic|electrophoretic mobility shift assay|
450232|NCT00768118|Other|laboratory biomarker analysis|
450233|NCT00768105|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
450234|NCT00768105|Drug|Placebo|Dosing to match AZD1656
450235|NCT00768079|Other|Placebo|Placebo on Study Day 0 (3mL vials filled with 1.2 mL solution of 10mM histidine, 300 mM glycine, 0.02% polysorbate 20, pH 6.0.)
450236|NCT00768079|Biological|MEDI-563|0.3 mg/kg IV MEDI-563 on Study Day 0
450237|NCT00768079|Biological|MEDI-563|1.0 mg/kg IV MEDI-563 on Study Day 0
450238|NCT00768066|Biological|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
450289|NCT00767559|Drug|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
452209|NCT00753207|Other|immunohistochemistry staining method|
450239|NCT00768066|Biological|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
450240|NCT00768066|Biological|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
450241|NCT00768053|Drug|Etanercept|Etanercept 50 mg once a week
450242|NCT00768040|Drug|Aliskiren|300 mg once daily
450243|NCT00768040|Drug|Placebo|Matching placebo once daily
450244|NCT00767988|Dietary Supplement|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
450245|NCT00767988|Other|Placebo|Capsule once daily at approximately the same time each day for 6 months.
450246|NCT00767975|Drug|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
450247|NCT00767975|Drug|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
450248|NCT00767962|Other|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
450249|NCT00767962|Other|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
450250|NCT00767949|Biological|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
450251|NCT00767897|Drug|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
450252|NCT00767871|Drug|Lexapro|12 week treatment with lexapro
450253|NCT00767845|Other|questionnaire/survey administration|
450254|NCT00767819|Drug|Everolimus|2.5 and 5 mg tablets taken orally and starting dose was 10 mg daily for all patients
450255|NCT00767806|Drug|Duloxetine|60 mg orally once daily for 12 weeks
450256|NCT00767806|Drug|Placebo|Placebo once daily orally for 12 weeks
450257|NCT00767793|Drug|Placebo|One drop in each eye every 12 hours for seven days
450258|NCT00767793|Drug|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
450259|NCT00767793|Drug|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
450260|NCT00767793|Drug|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
450261|NCT00767780|Device|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
450262|NCT00767767|Drug|Placebos|IV Saline infusion for 2 hours.
450263|NCT00767767|Drug|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
450264|NCT00767767|Drug|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
450265|NCT00767767|Drug|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
450266|NCT00767767|Drug|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
450267|NCT00767754|Drug|Paxil CR|12 week treatment of Paxil(20-40mg)
450268|NCT00767741|Device|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
450269|NCT00767728|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
450270|NCT00767728|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
450271|NCT00767715|Drug|olanzapine|physician determined dose, oral, daily, 5 months
450272|NCT00767715|Drug|haloperidol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
450273|NCT00767715|Drug|zuclopentixol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
450274|NCT00767689|Drug|vitamin b6|vitamin b6 100 mg po daily
450275|NCT00767689|Drug|placebo|placebo is given in the placebo arm
450276|NCT00767676|Device|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
450277|NCT00767663|Drug|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
450278|NCT00767663|Drug|placebo|placebo twice daily, minimal three days pretreatment
450279|NCT00767637|Drug|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
450280|NCT00767624|Drug|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
450281|NCT00767624|Behavioral|Desensitization Therapy for Insomnia|
450282|NCT00767624|Behavioral|Cognitive Behavioral Therapy for Insomnia|
450283|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
450284|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
450285|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
450286|NCT00767572|Drug|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
450287|NCT00767572|Drug|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
450290|NCT00767559|Drug|warfarin|"Fixed Low Dose warfarin~1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
450291|NCT00767546|Drug|Botulinum toxin|60- 100 units Local injection to the rash area
450292|NCT00767520|Drug|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
450293|NCT00767520|Drug|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
450294|NCT00767507|Drug|cangrelor|
450295|NCT00767507|Other|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
450296|NCT00767494|Drug|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
450297|NCT00767494|Drug|Azopt|Eye Drop Suspension, 1 drop BID
450298|NCT00767494|Drug|Travatan|Eye Drop Solution, 1 drop BID
450299|NCT00767481|Drug|Travoprost/Brinzolamide|Eye drop suspension, once daily
450300|NCT00767481|Drug|Cosopt|Eye drop solution, one drop BID
450301|NCT00767468|Drug|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
450302|NCT00767455|Device|HP828-101|21 day patches
450303|NCT00767429|Device|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
450304|NCT00767416|Biological|MEDI-559|Cohort 1 (5 to <24 months): N=80 MEDI-559 at 10^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
450305|NCT00767416|Other|Placebo|Cohort 1 (5 to < 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
450306|NCT00767403|Behavioral|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
450307|NCT00767403|Behavioral|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
450308|NCT00767403|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
450309|NCT00767390|Device|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
450310|NCT00767377|Drug|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
450311|NCT00767364|Biological|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
450312|NCT00767338|Behavioral|Timed intercourse|Timed intercourse
450313|NCT00767338|Procedure|Microsurgical varicocelectomy|Microsurgical varicocelectomy
450314|NCT00767338|Procedure|Intrauterine insemination|Intrauterine insemination
450315|NCT00767325|Drug|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
450316|NCT00767325|Drug|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
450317|NCT00767299|Drug|arzoxifene|20 mg, QD, PO,24 weeks
450318|NCT00767299|Drug|Placebo|QD, PO, 24 weeks
450319|NCT00767286|Drug|flutamide|
450320|NCT00767286|Drug|goserelin acetate|
450321|NCT00767286|Radiation|low-LET cobalt-60 gamma ray therapy|
450322|NCT00767286|Radiation|low-LET photon therapy|
450323|NCT00767273|Procedure|PET Scan|
450324|NCT00767273|Drug|FLT|
450325|NCT00767273|Drug|FDG|
450326|NCT00767260|Drug|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
450327|NCT00767260|Drug|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
450328|NCT00767260|Device|HOT|Hyperbaric Oxygen Therapy
450329|NCT00767260|Drug|SMT|hypoglycemic drugs or exogenous insulin
450330|NCT00767234|Procedure|Observation|Standard of Care
450331|NCT00767221|Drug|Budesonide|8 mg PL-56 once daily for six months
450332|NCT00767208|Other|oral glucose load|oral ingestion of 13C labeled glucose
450333|NCT00767182|Other|blood sample|biological markers evaluated : D-Dimer, sEPCR
450334|NCT00767169|Device|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
450335|NCT00767156|Other|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
450336|NCT00767156|Other|Base cream|The subjects use the base cream on the face, twice per day
450337|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
450371|NCT00766870|Drug|Placebo|Per oral doses, twice daily as capsules during 10 weeks
450338|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
450339|NCT00767117|Drug|Etravirine; Lopinavir; Ritonavir|
450340|NCT00767104|Other|Silk like Pillowcase|sleep on silk-like pillowcase each night
450341|NCT00767104|Other|Cotton Pillowcase|Sleep on placebo cotton pillowcase each night
450342|NCT00767091|Drug|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
450343|NCT00767091|Drug|placebo|transdermal patch of placebo
450344|NCT00767065|Radiation|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate <70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
450345|NCT00767065|Other|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
450346|NCT00767052|Drug|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
450347|NCT00767052|Drug|Placebo|Placebo tablet matching to the active in multiple dose part.
450348|NCT00767052|Drug|AZD1236|75mg single dose will be administered in relative bioavailability part.
450349|NCT00767052|Drug|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
450350|NCT00767039|Drug|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
450351|NCT00767039|Drug|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
450352|NCT00767026|Behavioral|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
450353|NCT00767026|Behavioral|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
450354|NCT00767013|Other|DSCT, TTE|One assessment each
450355|NCT00767000|Drug|MK-0941|MK-0941 tablets three times daily
450356|NCT00767000|Drug|Comparator: Placebo|Matching placebo to MK-0941 three times daily
450357|NCT00767000|Biological|Lantus|Lantus injection once daily
450358|NCT00767000|Drug|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
450359|NCT00766974|Device|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
450360|NCT00766974|Device|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
450361|NCT00766961|Procedure|Trans-catheter arterial embolization|Trans-catheter arterial embolization
450362|NCT00766961|Procedure|Surgery|Surgery
450363|NCT00766948|Other|There is no intervention, this is a biorepository.|There are no interventions in this study.
450364|NCT00766909|Drug|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
450365|NCT00766909|Drug|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.~For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
450366|NCT00766909|Other|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.~For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
450367|NCT00766896|Drug|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
450368|NCT00766883|Behavioral|Problem Solving Education|
450369|NCT00766870|Drug|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
450370|NCT00766870|Drug|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
450372|NCT00766857|Drug|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
450373|NCT00766857|Drug|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
450374|NCT00766844|Device|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
450375|NCT00766831|Drug|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram [mg] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
450376|NCT00766818|Drug|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
450377|NCT00766805|Drug|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
450378|NCT00766805|Other|EVL alone|
450379|NCT00766792|Procedure|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
450380|NCT00766792|Procedure|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
450381|NCT00766779|Procedure|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
450382|NCT00766779|Drug|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
450383|NCT00766766|Behavioral|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
450384|NCT00766766|Behavioral|Telephone Coaching Sessions|Telephone Coaching Sessions
450385|NCT00766766|Behavioral|Physician Feedback Letter|Physician Feedback Letter
450386|NCT00766753|Biological|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
450387|NCT00766753|Biological|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
450388|NCT00766753|Biological|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
450389|NCT00766740|Device|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
450390|NCT00766740|Device|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
450391|NCT00766714|Device|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
450392|NCT00766714|Device|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
450393|NCT00766701|Procedure|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
450394|NCT00766688|Drug|AVE5530|"one tablet in the evening with dinner~in addition to high doses of statin treatment"
450395|NCT00766688|Drug|Placebo|"one tablet in the evening with dinner~in addition to high doses of statin treatment"
450396|NCT00766675|Drug|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
450397|NCT00766675|Drug|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
450398|NCT00766662|Drug|Sulfadoxine pyrimethamine|
450399|NCT00766649|Drug|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
450400|NCT00766636|Drug|Gemcitabine|"Arm A:~1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.~Arm B:~400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day."
450401|NCT00766636|Radiation|Radiation Therapy|1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.
450402|NCT00766636|Drug|Erlotinib|100 mg daily by mouth on days 1-42.
450403|NCT00766636|Procedure|Surgery|Surgical removal of the pancreas and duodenum
450404|NCT00766623|Dietary Supplement|high fat meal|milkshake containing 95g fat
450405|NCT00766623|Dietary Supplement|control meal|milkshake comparable with a normal breakfast
450531|NCT00765700|Drug|Topical Ketoprofen 10% Cream|Topical Administration
450532|NCT00765700|Drug|Topical Placebo Cream|Topical Administration
450406|NCT00766597|Drug|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
450407|NCT00766584|Other|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
450408|NCT00766545|Drug|cilostazol|oral tablet 100 mg, twice daily, over 1 year
450409|NCT00766545|Drug|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
450410|NCT00766532|Drug|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
450411|NCT00766519|Other|volume optimization|"Fluid management:~basal fluid administration = 5 ml/kg/h lactated Ringer's solution~+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery~hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is > 10%"
450412|NCT00766519|Other|standard volume administration|"Fluid management:~basal fluid administration = 5 ml/kg/h lactated Ringer's solution~hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
450413|NCT00766506|Device|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
450414|NCT00766506|Device|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
450415|NCT00766493|Device|GORE® Embolic Filter|Embolic protection during carotid stenting
450416|NCT00766480|Drug|cisplatin|Given IV
450417|NCT00766480|Drug|fluorouracil|Given IV
450418|NCT00766480|Radiation|radiation therapy|Patients undergo radiotherapy
450419|NCT00766467|Drug|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
450420|NCT00766467|Other|Placebo|Placebo taken once a day in the morning
450421|NCT00766454|Genetic|DNA analysis|
450422|NCT00766454|Genetic|mutation analysis|
450423|NCT00766454|Genetic|polymorphism analysis|
450424|NCT00766454|Other|laboratory biomarker analysis|
450425|NCT00766454|Other|medical chart review|
450426|NCT00766454|Other|questionnaire administration|
450427|NCT00766454|Procedure|evaluation of cancer risk factors|
450428|NCT00766441|Drug|Sitagliptin|tablet, 100mg, once daily, 4 weeks
450429|NCT00766441|Drug|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
450430|NCT00766415|Drug|AZD1981|Oral tablet, twice daily, 4 weeks treatment
450431|NCT00766415|Drug|Placebo|Placebo
450432|NCT00766402|Drug|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
450433|NCT00766402|Drug|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
450434|NCT00766376|Device|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
450435|NCT00766363|Drug|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
450436|NCT00766363|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
450437|NCT00766363|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
450438|NCT00766363|Drug|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
450439|NCT00766363|Drug|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
450440|NCT00766363|Drug|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
450441|NCT00766350|Drug|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
450442|NCT00766350|Drug|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
450443|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
450444|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
450445|NCT00766337|Drug|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
450446|NCT00766324|Drug|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
450447|NCT00766324|Drug|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
450448|NCT00766311|Other|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
450449|NCT00766311|Other|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
450533|NCT00765687|Drug|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
450534|NCT00765674|Drug|Aliskiren|150 and 300 mg tablets
450450|NCT00766311|Other|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
450451|NCT00766311|Other|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
450452|NCT00766311|Other|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
450453|NCT00766311|Other|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
450454|NCT00766311|Other|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
450455|NCT00766298|Behavioral|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
450456|NCT00766298|Behavioral|Weight Loss|The reduction of kcal/day through implementation of low fat diet
450457|NCT00766298|Behavioral|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.~Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
450458|NCT00766285|Biological|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
450459|NCT00766285|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
450460|NCT00766272|Device|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
450461|NCT00766246|Drug|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
450462|NCT00766246|Drug|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
450463|NCT00766246|Drug|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
450464|NCT00766233|Other|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
450465|NCT00766220|Drug|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
450466|NCT00766220|Drug|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
450467|NCT00766220|Drug|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
450468|NCT00766207|Other|Clinical decision support|multi-faceted decision support
450469|NCT00766207|Other|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
450470|NCT00766181|Behavioral|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
450471|NCT00766168|Other|HDS HI 1.54; pahrifocon A|Contact Lens
450472|NCT00766168|Device|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
450473|NCT00766155|Drug|capecitabine|Given orally
450474|NCT00766155|Drug|oxaliplatin|Given IV
450475|NCT00766142|Biological|cetuximab|
450476|NCT00766142|Drug|fluorouracil|
450477|NCT00766142|Drug|leucovorin calcium|
450478|NCT00766142|Drug|oxaliplatin|
450479|NCT00766142|Procedure|adjuvant therapy|
450480|NCT00766142|Procedure|therapeutic conventional surgery|
450481|NCT00766129|Device|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
450482|NCT00766129|Device|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
450483|NCT00766116|Drug|5-Azacitidine|Given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit.
450484|NCT00766116|Drug|Gemtuzumab ozogamicin|Mylotarg given 2 times over 2 weeks
450485|NCT00766103|Other|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
450486|NCT00766090|Drug|GW685698X|Inhaled Corticosteroid
450487|NCT00766064|Drug|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:~Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily*, Week 6: fixed dose,~*Criteria to increase the dose from 3 mg to 6 mg daily are 1] absence of any side effects, 2] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
450535|NCT00765674|Drug|Amlodipine|5 and 10 mg capsules
450536|NCT00765674|Drug|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
450537|NCT00765674|Drug|Placebo|tablet
450538|NCT00765674|Drug|Placebo|capsules
450579|NCT00765323|Drug|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
450488|NCT00766051|Other|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
450489|NCT00766038|Drug|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
450490|NCT00766038|Drug|Placebo|SC injection daily
450491|NCT00766025|Drug|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
450492|NCT00766012|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
450493|NCT00766012|Drug|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
450494|NCT00765999|Drug|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
450495|NCT00765986|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
450496|NCT00765986|Other|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
450497|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
450498|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
450499|NCT00765947|Drug|Aliskiren|Aliskiren 150 or 300 mg
450500|NCT00765947|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
450501|NCT00765947|Drug|Amlodipine|Amlodipine 5 or 10 mg
450502|NCT00765934|Drug|Rapydan|lidocaine / tetracaine 70/70 mg patch
450503|NCT00765921|Drug|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
450504|NCT00765908|Device|Angioplasty balloon|90 second balloon inflation x 2
450505|NCT00765908|Device|Angioplasty balloon|30 seconds or less balloon inflations x 2
450506|NCT00765895|Drug|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
450507|NCT00765895|Drug|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
450508|NCT00765882|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
450509|NCT00765882|Drug|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
450510|NCT00765882|Drug|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
450511|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
450512|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
450513|NCT00765869|Other|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
450514|NCT00765856|Drug|Oxymorphone IR - Opioid|Opana IR 5mg tablet
450515|NCT00765843|Device|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
450516|NCT00765830|Drug|vildagliptin|50mg qd
450517|NCT00765830|Drug|Placebo|qd
450518|NCT00765817|Drug|placebo|subcutaneous injection, twice a day
450519|NCT00765817|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
450520|NCT00765804|Drug|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
450521|NCT00765804|Drug|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
450522|NCT00765791|Procedure|Selective Neck Dissection Including Level IIB|Level IIB is dissected
450523|NCT00765791|Procedure|Selective Neck Dissection Excluding Level IIB|Level IIB is not dissected
450524|NCT00765765|Drug|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
450525|NCT00765765|Drug|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
450526|NCT00765739|Other|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
450527|NCT00765739|Other|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
450528|NCT00765726|Biological|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
450529|NCT00765726|Procedure|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
450530|NCT00765713|Device|Nasal continuous positive airway pressure|Nocturnal
450539|NCT00765661|Drug|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other Names:~Tacrolimus modified-release"
450540|NCT00765661|Drug|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.~Other name: tacrolimus"
450541|NCT00765648|Drug|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
450542|NCT00765648|Drug|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
450543|NCT00765635|Drug|drops intilation (Taponoto ® )|four drops, unique doses
450544|NCT00765635|Drug|drops intilation (Otocerum®)|four drops, unique doses
450545|NCT00765635|Drug|drops intilation (Placebo)|Placebo
450546|NCT00765596|Other|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
450547|NCT00765583|Drug|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
450548|NCT00765570|Radiation|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
450549|NCT00765570|Radiation|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
450550|NCT00765570|Radiation|Standard radiation|15 Standard radiation treatments
450551|NCT00765570|Radiation|Standard radiation|standard radiation treatment
450552|NCT00765557|Drug|Miralax|Every subject will be given one bottle of the laxative/placebo, and depending on the patient's weight, will be instructed to take 1-3 tsps (.75 gm/kg) of the medication daily.
450553|NCT00765544|Device|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
450554|NCT00765544|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
450555|NCT00765531|Radiation|Radiological testing|Bone mineral density
450556|NCT00765531|Genetic|Pediatric Urologic DNA and History Repository|"All Stone Forming Patients and their families will undergo one of two groups of testing:~Testing 1 - Involves completing an in-patient evaluation at UT Southwestern for patients with hypercalciuria and their families.~Testing 2 - Involves completing a simple out-patient evaluation for patients with or without hypercalciuria and their family members."
450557|NCT00765518|Biological|Ixmyelocel-T|CRCs will be administered via direct injection into the heart muscle.
450558|NCT00765518|Other|Standard of Care|Because the eligible patients had no other cardiac surgery or percutaneous cardiac interventions that were likely to produce clinical improvement, SOC was limited to pharmacologic therapy, heart transplant, or ventricular assist device therapy.
450559|NCT00765505|Behavioral|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
450560|NCT00765505|Behavioral|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
450561|NCT00765492|Drug|AZD8529|oral
450562|NCT00765492|Drug|Placebo|oral
450563|NCT00765479|Dietary Supplement|soy protein isolate|Given orally
450564|NCT00765479|Other|placebo|Given orally
450565|NCT00765466|Drug|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
450566|NCT00765453|Other|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
450567|NCT00765453|Other|Placebo infusion|Placebo infusion
450568|NCT00765440|Dietary Supplement|therapeutic nutritional supplementation|Given orally
450569|NCT00765440|Other|placebo|Given orally
450570|NCT00765427|Drug|QLT091001|7-day repeated dose
450571|NCT00765414|Biological|Myozyme|30 mg/kg qow f and 40 mg/kg qow
450572|NCT00765388|Device|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
450573|NCT00765388|Device|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
450574|NCT00765375|Drug|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
450575|NCT00765375|Drug|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
450576|NCT00765362|Device|Encore Mobile-Bearing Knee|Used for primary total knee replacement
450577|NCT00765336|Drug|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
450578|NCT00765336|Drug|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
452210|NCT00753207|Other|liquid chromatography|
450580|NCT00765323|Drug|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range ~10-40 mg every 28 days)
450581|NCT00765310|Dietary Supplement|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
450582|NCT00765310|Dietary Supplement|Placebo|two capsules once daily in morning on empty stomach
450583|NCT00765297|Device|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
450584|NCT00765297|Device|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
450585|NCT00765271|Drug|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
450586|NCT00765271|Drug|Darunavir/ritonavir|"Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
450587|NCT00765271|Drug|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
450588|NCT00765245|Drug|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
450589|NCT00765245|Drug|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
450590|NCT00765245|Drug|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
450591|NCT00765232|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
450592|NCT00765232|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
450593|NCT00765219|Behavioral|CBT|10-12 weekly sessions of CBT in person or over the telephone.
450594|NCT00765219|Other|Usual Care|Treatment as usual provided by participants' physician(s)
450595|NCT00765206|Drug|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
450596|NCT00765206|Drug|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
450597|NCT00765193|Other|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
450598|NCT00765180|Device|TRE vs. NBI|TRE NBI
450599|NCT00765167|Drug|Fluoride|Brush half mouth twice daily for four days
450600|NCT00765167|Drug|Triclosan|Brush half mouth daily for four days
450601|NCT00765167|Drug|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
450602|NCT00765167|Drug|Fluoride|Brush half mouth daily for four days
450603|NCT00765154|Drug|darunavir|two 400mg tablets (800mg) once daily
450604|NCT00765154|Drug|ritonavir|one 100mg capsule once daily
450605|NCT00765128|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
450606|NCT00765128|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
450607|NCT00765115|Drug|LY450139|
450608|NCT00765115|Drug|placebo|
450609|NCT00765102|Drug|Bortezomib|"Bortezomib was administered at a dose of 1.0 mg/m^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.~Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
450610|NCT00765102|Drug|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m^2.
450611|NCT00765089|Procedure|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
450612|NCT00765076|Biological|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
450613|NCT00765076|Biological|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
450614|NCT00765063|Drug|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
450615|NCT00765050|Biological|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
450616|NCT00765037|Device|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
450617|NCT00765024|Drug|Ivermectin|single dose of 200 mcg/kg
450618|NCT00765024|Drug|ivermectin|two single dose of 200mcg/kg in 2 weeks
450619|NCT00765024|Drug|Albendazole|Albendazole 7 days
450620|NCT00765011|Drug|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
450621|NCT00765011|Procedure|H&N surgery|Rescue surgery
450622|NCT00764998|Biological|Fluviral|
450623|NCT00764972|Drug|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);~sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
450711|NCT00764361|Drug|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
452211|NCT00753207|Other|mass spectrometry|
450624|NCT00764959|Device|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
450625|NCT00764946|Drug|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
450626|NCT00764933|Behavioral|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
450627|NCT00764933|Other|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
450628|NCT00764920|Device|non-invasive imaging modalities for assessment of skin|skin imaging
450629|NCT00764907|Drug|asparaginase|Given IV during reinduction
450630|NCT00764907|Drug|cyclophosphamide|Given IV during reinduction
450631|NCT00764907|Drug|cytarabine|Given IV during reinduction
450632|NCT00764907|Drug|daunorubicin hydrochloride|Given IV during reinduction
450633|NCT00764907|Drug|dexamethasone|Given IV or orally during reinduction
450634|NCT00764907|Drug|doxorubicin hydrochloride|Given IV during reinduction
450635|NCT00764907|Drug|etoposide|Given IV during reinduction
450636|NCT00764907|Drug|ifosfamide|Given IV during reinduction
450637|NCT00764907|Drug|leucovorin calcium|Given IV during reinduction
450638|NCT00764907|Drug|mercaptopurine|Given orally during reinduction
450639|NCT00764907|Drug|methotrexate|Given orally during reinduction
450640|NCT00764907|Drug|prednisone|Given intrathecally during reinduction
450641|NCT00764907|Drug|thioguanine|Given orally during reinduction
450642|NCT00764907|Drug|vincristine sulfate|Given IV during reinduction
450643|NCT00764907|Drug|vindesine|Given IV during reinduction
450644|NCT00764894|Device|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
450645|NCT00764881|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
450646|NCT00764881|Drug|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
450647|NCT00764881|Drug|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
450648|NCT00764868|Drug|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
450649|NCT00764855|Procedure|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.~The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.~The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
450650|NCT00764842|Device|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
450651|NCT00764816|Other|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
450652|NCT00764816|Other|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
450653|NCT00764803|Device|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
450654|NCT00764803|Device|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
450655|NCT00764790|Biological|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
450656|NCT00764790|Biological|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
450657|NCT00764777|Device|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
450658|NCT00764764|Procedure|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
450659|NCT00764764|Procedure|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
450660|NCT00764751|Drug|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
450661|NCT00764751|Drug|Dovonex® cream|Twice daily application
450662|NCT00764751|Drug|Cream vehicle|Twice daily application
450663|NCT00764738|Device|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.~Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.~Multifocal ERG done at the same monthly visits as the microperimetry."
450664|NCT00764725|Drug|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
450665|NCT00764725|Biological|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
450712|NCT00764361|Drug|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
450713|NCT00764348|Other|no treatment|
450714|NCT00764335|Procedure|total hip arthroplasty one side|unilateral total hip arthroplasty
450715|NCT00764335|Procedure|total hip arthroplasty both sides|bilateral total hip arthroplasty
450666|NCT00764712|Drug|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
450667|NCT00764699|Drug|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
450668|NCT00764686|Other|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
450669|NCT00764686|Other|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
450670|NCT00764673|Device|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
450671|NCT00764660|Drug|SCH 900435|tablets
450672|NCT00764660|Drug|Placebo|tablets
450673|NCT00764647|Behavioral|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
450674|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
450675|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
450676|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
450677|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
450678|NCT00764621|Procedure|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
450679|NCT00764621|Procedure|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
450680|NCT00764621|Procedure|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
450681|NCT00764595|Drug|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
450682|NCT00764582|Drug|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 1: 30 minutes prior to surgery~Group 2: 1 hour prior to surgery~Group 3: 2 hours prior to surgery~Group 4: 4 hours prior to surgery"
450683|NCT00764582|Drug|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.~Group 5: 30 minutes prior to surgery~Group 6: 1 hour prior to surgery~Group 7: 2 hours prior to surgery~Group 8: 4 hours prior to surgery"
450684|NCT00764569|Device|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
450685|NCT00764556|Drug|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
450686|NCT00764543|Device|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
450687|NCT00764530|Device|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
450688|NCT00764530|Device|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
450689|NCT00764517|Drug|Cladribine|Given IV
450690|NCT00764517|Other|Laboratory Biomarker Analysis|Correlative studies
450691|NCT00764517|Biological|Rituximab|Given IV
450692|NCT00764517|Drug|Vorinostat|Given PO
450693|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
450694|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
450695|NCT00764478|Drug|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
450696|NCT00764478|Drug|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
450697|NCT00764478|Drug|Placebo|placebo sublingual tablet, administered BID for 21 days
450698|NCT00764465|Drug|Maraviroc|300 mg BID
450699|NCT00764465|Drug|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
450700|NCT00764465|Drug|Ritonavir|100 mg BID, 100 mg QD
450701|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
450702|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
450703|NCT00764426|Drug|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
450704|NCT00764426|Drug|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
450705|NCT00764413|Drug|methylprednisolone|1 gram intravenous a day for 3 days
450706|NCT00764413|Drug|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
450707|NCT00764400|Behavioral|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
450708|NCT00764387|Drug|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
450709|NCT00764387|Drug|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
450710|NCT00764374|Drug|YM443|oral
450716|NCT00764322|Drug|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
450717|NCT00764322|Genetic|gene expression analysis|Genetic analysis of blood sample.
450718|NCT00764322|Other|pharmacogenomic studies|Genetic analysis of blood sample.
450719|NCT00764322|Other|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
450720|NCT00764322|Procedure|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
450721|NCT00764309|Drug|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
450722|NCT00764296|Other|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
450723|NCT00764296|Other|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
450724|NCT00764283|Device|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
450725|NCT00764283|Device|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
450726|NCT00764283|Device|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
450727|NCT00764270|Dietary Supplement|R-alpha lipoic acid|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
450728|NCT00764257|Device|PREVELLE Shape|
450729|NCT00764257|Device|Restylane|
450730|NCT00764244|Procedure|Vitrectomy|Vitrectomy
450731|NCT00764244|Drug|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
450732|NCT00764244|Procedure|Laser photocoagulation|Laser photocoagulation
450733|NCT00764231|Behavioral|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
450734|NCT00764231|Behavioral|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
450735|NCT00764218|Device|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
450736|NCT00764218|Other|No positive airway pressure treatment|No treatment
450737|NCT00764192|Procedure|blood sample|blood sample before and after a single HD
450738|NCT00764192|Procedure|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
450739|NCT00764179|Other|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
450740|NCT00764179|Other|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
450741|NCT00764166|Drug|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:~To D1 of every cycle in the dose of 70 mg/m²,~Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).~Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
450742|NCT00764166|Drug|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
450743|NCT00764153|Procedure|Bipolar hemiarthroplasty|Lateral approach. FWB.
450744|NCT00764153|Procedure|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
450745|NCT00764140|Biological|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
450746|NCT00764114|Drug|antibiotic|6 or 12 weeks
450747|NCT00764101|Behavioral|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
450748|NCT00764075|Device|Beutel TM|application of BeutelTM
450749|NCT00764075|Other|standard|standard procedure will be applied but no Beutel TM software
450750|NCT00764075|Device|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
450751|NCT00764062|Drug|Amoxicillin|Amoxicillin :drug
450752|NCT00764049|Device|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
450753|NCT00764036|Drug|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
450754|NCT00764010|Dietary Supplement|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
450755|NCT00764010|Dietary Supplement|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
450756|NCT00764010|Dietary Supplement|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
450757|NCT00763997|Drug|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
450758|NCT00763997|Drug|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
450759|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
450760|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
450761|NCT00763997|Drug|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
450887|NCT00763113|Device|Vanguard PS Knee|Vanguard PS Knee
450762|NCT00763997|Other|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
450763|NCT00763984|Behavioral|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
450764|NCT00763984|Behavioral|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
450765|NCT00763971|Drug|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
450766|NCT00763971|Drug|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
450767|NCT00763971|Drug|Placebo|Placebo capsule once per day (Overencapsulated)
450768|NCT00763958|Drug|Placebo|Placebo to match buprenorphine administered for 3 months
450769|NCT00763958|Drug|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
450770|NCT00763945|Other|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
450771|NCT00763932|Biological|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
450772|NCT00763919|Behavioral|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
450773|NCT00763919|Behavioral|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
450774|NCT00763919|Behavioral|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
450775|NCT00763919|Behavioral|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
450776|NCT00763906|Device|norepinephrine infused at the clinician's discretion|
450777|NCT00763906|Device|norepinephrine infused under computerized fuzzy logic control|
450778|NCT00763893|Drug|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
450779|NCT00763893|Drug|Losartan|50 mg/day if < weight 50 kg 100 mg/day if weight > 50 kg
450780|NCT00763880|Drug|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
450781|NCT00763880|Drug|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
450782|NCT00763867|Drug|Placebo|
450783|NCT00763867|Drug|Sildenafil|
450784|NCT00763841|Device|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
450785|NCT00763841|Device|Sham|
450786|NCT00763828|Device|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
450787|NCT00763815|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
450788|NCT00763815|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
450789|NCT00763815|Device|Pen auto-injector|
450790|NCT00763815|Drug|Pioglitazone|Dose to be kept stable.
450791|NCT00763815|Drug|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
450792|NCT00763789|Other|local anaesthesia and remifentanil sedation|
450793|NCT00763789|Other|total intravenous anaesthesia|
450794|NCT00763776|Device|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
450795|NCT00763776|Device|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
450796|NCT00763763|Drug|Imatinib mesylate|imatinib 600 mg/day for 2 years
450797|NCT00763763|Drug|Interferon|45 micrograms per week during 2 years
450798|NCT00763763|Drug|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
450799|NCT00763763|Drug|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
450800|NCT00763750|Drug|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
450801|NCT00763737|Procedure|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-31+6 weeks and removal at 34-34+6 wks
450802|NCT00763711|Device|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
450803|NCT00763698|Device|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
450804|NCT00763685|Drug|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
450805|NCT00763672|Other|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
450806|NCT00763672|Other|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
450807|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
450808|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
450809|NCT00763659|Dietary Supplement|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
450810|NCT00763646|Drug|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
450811|NCT00763633|Drug|vitamin B6|high dose of vitamin B6
450812|NCT00763633|Drug|vitamin B6|low vitamin B6
450813|NCT00763620|Device|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
450814|NCT00763607|Genetic|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
450815|NCT00763594|Behavioral|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
450816|NCT00763594|Behavioral|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
450817|NCT00763568|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
450818|NCT00763568|Biological|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
450819|NCT00763555|Drug|CD 2027|3 µg/g Oily Spray, twice a day for 8 weeks
450820|NCT00763555|Drug|Vehicle (placebo)|placebo spray, twice a day for 8 weeks
450821|NCT00763542|Behavioral|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
450822|NCT00763542|Behavioral|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
450823|NCT00763529|Drug|Mometasone|Mometasone furoate cream 0.1% applied once daily
450824|NCT00763529|Drug|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
450825|NCT00763516|Radiation|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only~Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks~Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation~Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
450826|NCT00763503|Drug|CD 2027|3µg/g Oily Spray
450827|NCT00763490|Procedure|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
450828|NCT00763490|Drug|Flu/Bu4 conditioning regimen|"Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2~Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2"
450829|NCT00763490|Radiation|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
450830|NCT00763490|Drug|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
450831|NCT00763490|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) < 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.~MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued."
450832|NCT00763477|Biological|ghrelin|subcutaneous injection
450833|NCT00763464|Procedure|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
450834|NCT00763464|Procedure|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
450835|NCT00763451|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
450836|NCT00763451|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
450837|NCT00763451|Device|Pen auto-injector|
450838|NCT00763451|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
450839|NCT00763438|Drug|Sertindole|Flexible dose
450840|NCT00763425|Procedure|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
450841|NCT00763425|Procedure|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
450842|NCT00763412|Drug|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
450888|NCT00763113|Device|Vanguard CR Knee|Vanguard CR Knee
450975|NCT00762502|Device|senofilcon A toric contact lens|soft contact lens
450843|NCT00763412|Drug|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
450844|NCT00763399|Dietary Supplement|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10^8CFU/day
450845|NCT00763386|Device|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
450846|NCT00763386|Device|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
450847|NCT00763373|Other|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
450848|NCT00763360|Device|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
450849|NCT00763360|Drug|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
450850|NCT00763360|Drug|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
450851|NCT00763347|Drug|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
450852|NCT00763347|Drug|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
450853|NCT00763347|Drug|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
450854|NCT00763347|Drug|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
450855|NCT00763347|Drug|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
450856|NCT00763347|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
450857|NCT00763321|Drug|ABT-712|ABT-712 extended-release tablet
450858|NCT00763321|Drug|Placebo|Placebo tablet
450859|NCT00763308|Behavioral|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
450860|NCT00763295|Other|T-Spot.TB test|diagnostic test
450861|NCT00763282|Behavioral|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
450862|NCT00763282|Behavioral|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
450863|NCT00763282|Behavioral|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
450864|NCT00763269|Drug|Triclosan, Silicon dioxide, fluoride|Brush twice daily
450865|NCT00763269|Drug|Triclosan, fluoride|Brush twice daily
450866|NCT00763256|Drug|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
450867|NCT00763256|Drug|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
450868|NCT00763243|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
450869|NCT00763230|Device|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
450870|NCT00763204|Drug|AN2728 Cream, 2%|
450871|NCT00763204|Drug|AN2728 Cream, 1%|
450872|NCT00763204|Drug|AN2728 Cream, 0.3%|
450873|NCT00763204|Drug|AN2728 Cream Vehicle|
450874|NCT00763204|Drug|Betnesol®-V Creme, 0.1%|
450875|NCT00763191|Other|examination of ocular movements|
450876|NCT00763191|Other|MATTIS test|
450877|NCT00763191|Other|UPDRS test|
450878|NCT00763191|Other|CRST test|
450879|NCT00763178|Drug|Duloxetine|"Dosage given according to the following schedule:~Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
450880|NCT00763165|Drug|Triclosan|Brush twice daily
450881|NCT00763165|Drug|Fluoride|Brush twice daily
450882|NCT00763165|Drug|Fluoride|Brush twice daily
450883|NCT00763152|Other|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
450884|NCT00763139|Drug|Pioglitazone|45 mg by mouth once a day for 8 weeks
450885|NCT00763139|Drug|Placebo|By mouth once a day for 8 weeks
450886|NCT00763126|Behavioral|stress level|Stress levels
450889|NCT00763087|Behavioral|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
450890|NCT00763087|Behavioral|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
450891|NCT00763087|Behavioral|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
450892|NCT00763074|Behavioral|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.~----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30~35kcal/day"
450893|NCT00763074|Behavioral|Diet restriction|"Education for diet and exercise every 2 weeks~----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
450894|NCT00763074|Behavioral|Exercise|"Education for diet and exercise every 2 weeks~----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
450895|NCT00763074|Behavioral|Diet and exercise|"Education for diet and exercise every 2 weeks~----------- Exercise education like as exercise group and diet education like as diet group"
450896|NCT00763061|Drug|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo & 9 PM
450897|NCT00763061|Drug|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM & 9 PM
450898|NCT00763048|Drug|Fluoride|Brush twice daily for 6 weeks
450899|NCT00763048|Drug|Fluoride, triclosan|Brush twice daily
450900|NCT00763035|Drug|Regadenoson|Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
450901|NCT00763035|Drug|Dobutamine|Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
450902|NCT00763022|Drug|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
450903|NCT00763022|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
450904|NCT00763022|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
450905|NCT00763009|Drug|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
450906|NCT00762996|Device|etafilcon A|contact lens
450907|NCT00762996|Device|omafilcon A|contact lens
450908|NCT00762983|Drug|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.~Claritin Dry Syrup 1%: For pediatric patients aged 3 to < 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.~The observation period will not be specified."
450909|NCT00762970|Device|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
450910|NCT00762970|Device|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
450911|NCT00762970|Device|Control Lens|Spectacle Lenses.
450912|NCT00762957|Drug|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
450913|NCT00762957|Drug|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
450914|NCT00762957|Drug|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
450915|NCT00762931|Device|Resolve Stimulator and Proximity Lead|An electrical neurostimulation signal will be applied to the neck via subcutaneous lead placement for vagal nerve stimulation
450916|NCT00762918|Dietary Supplement|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
450917|NCT00762905|Device|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
450918|NCT00762905|Device|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
450919|NCT00762892|Drug|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
450920|NCT00762892|Drug|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
450921|NCT00762853|Drug|Fluoride|Brush half mouth once with assigned study treatment
450922|NCT00762853|Drug|Fluoride and triclosan|Brush half mouth once with assigned study treatment
450923|NCT00762840|Device|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
450924|NCT00762840|Procedure|Conventional endodontic procedure|Standard root canal treatment
450971|NCT00762528|Drug|Sodium monofluorophosphate toothpaste|Twice daily usage
450972|NCT00762515|Drug|Fluoride|Brush teeth two times daily for 6 weeks
450973|NCT00762515|Drug|Triclosan|Brush two times daily for 6 weeks
450925|NCT00762814|Device|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
450926|NCT00762788|Device|senofilcon A|1 week extended wear contact lens
450927|NCT00762788|Device|lotrafilcon A|1 week extended wear contact lens
450928|NCT00762788|Device|lotrafilcon B|1 week extended wear contact lens
450929|NCT00762788|Device|balafilcon A|1 week extended wear contact lens
450930|NCT00762788|Device|comfilcon A|1 week extended wear contact lens
450931|NCT00762788|Device|etafilcon A|1 week extended wear contact lens
450932|NCT00762775|Dietary Supplement|Calcium and vitamin D supplementation|Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
450933|NCT00762762|Drug|Triclosan and fluoride|Brush twice daily
450934|NCT00762762|Drug|Fluoride|swished twice daily
450935|NCT00762749|Drug|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
450936|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
450937|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
450938|NCT00762736|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
450939|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
450940|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
450941|NCT00762736|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
450942|NCT00762723|Device|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
450943|NCT00762710|Drug|Prazosin medication|"Form: Prazosin will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
450944|NCT00762710|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.~Dosing: 9 AM, 3 PM, 9 PM~Days 1-2: 0 mg, 0 mg, 1 mg~Days 3-4: 1 mg, 1 mg, 1 mg~Days 5-7: 2 mg, 2 mg, 2 mg~Day 8-10: 2 mg, 2 mg, 6 mg~Day 11-14: 4 mg, 4 mg, 6 mg~Day 15-84: 4 mg, 4 mg, 8 mg"
450945|NCT00762684|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
450946|NCT00762684|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
450947|NCT00762671|Drug|Ebselen|150 mg BID for 2 weeks
450948|NCT00762671|Drug|Placebo|Placebo 1 po BID for 2 weeks
450949|NCT00762658|Drug|AN2728 Ointment, 5%|
450950|NCT00762658|Drug|AN2728 Ointment, 2%|
450951|NCT00762658|Drug|AN2728 Ointment, 0.5%|
450952|NCT00762658|Drug|AN2728 Ointment Vehicle|
450953|NCT00762658|Drug|Betnesol®-V Creme, 0.1%|
450954|NCT00762658|Drug|Protopic® Ointment, 0.1 %|
450955|NCT00762645|Drug|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
450956|NCT00762645|Drug|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
450957|NCT00762632|Drug|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
450958|NCT00762632|Drug|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
450959|NCT00762619|Drug|Fluoride|Brush twice daily
450960|NCT00762619|Drug|Triclosan, fluoride|Brush twice daily
450961|NCT00762606|Procedure|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
450962|NCT00762606|Procedure|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
450963|NCT00762593|Device|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
450964|NCT00762593|Device|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
450965|NCT00762567|Drug|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
450966|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section.
450967|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
450968|NCT00762554|Drug|Fentanyl|Epidural fentanyl infusion started after epidural lidocaine or spinal bupivacaine used for the cesarean section.
450969|NCT00762541|Device|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
450970|NCT00762528|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
450976|NCT00762502|Device|balafilcon A toric contact lens|soft contact lens
450977|NCT00762489|Other|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
450978|NCT00762476|Drug|3804-250A|"topical product~apply 2 pumps~apply at least every 4 hours or after hand washing"
450979|NCT00762476|Drug|3804-291|"topical~apply 2 pumps~apply at least every 4 hours or after hand washing"
450980|NCT00762463|Drug|Celecoxib|capsule, 200 mg QD, 6-12 weeks
450981|NCT00762463|Drug|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
450982|NCT00762450|Drug|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
450983|NCT00762450|Drug|fluoride|Rinse 3 times daily with assigned toothpaste slurry
450984|NCT00762450|Drug|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
450985|NCT00762437|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
450986|NCT00762424|Drug|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
450987|NCT00762424|Drug|placebo|cornstarch
450988|NCT00762411|Drug|LY450139|Administered orally once daily.
450989|NCT00762411|Drug|Placebo|Administered orally once daily.
450990|NCT00762398|Device|Masimo hemoglobin-meter|Placing a probe on the finger
450991|NCT00762398|Biological|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
450992|NCT00762385|Device|galyfilcon A|galyfilcon A
450993|NCT00762385|Device|comfilcon A|comfilcon A
450994|NCT00762372|Drug|desflurane|volatile liquid for inhalation
450995|NCT00762372|Drug|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
450996|NCT00762372|Drug|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
450997|NCT00762359|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
450998|NCT00762359|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
450999|NCT00762346|Drug|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
451000|NCT00762320|Drug|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
451001|NCT00762307|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
451002|NCT00762281|Device|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
451003|NCT00762268|Drug|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
451004|NCT00762268|Drug|Placebo|
451005|NCT00762255|Drug|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
451006|NCT00762255|Drug|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
451007|NCT00762255|Drug|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
451008|NCT00762242|Procedure|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)~Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.~Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
451009|NCT00762229|Drug|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
451010|NCT00762229|Drug|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
451011|NCT00762216|Device|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
451012|NCT00762190|Drug|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
451013|NCT00762190|Drug|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
451014|NCT00762177|Drug|Fluoride|Brush twice a day for 14 days
451015|NCT00762177|Drug|Fluoride, Triclosan|Brush twice daily for 14 days
451016|NCT00762177|Drug|Stannous Fluoride|Brush twice daily for 14 days
451017|NCT00762164|Drug|Vytorin|Vytorin 10/80 split into 4
451018|NCT00762164|Drug|Simvastatin|Simvastatin 20 milligrams
451019|NCT00762151|Other|Negative Control (Regular Toothpaste)|Regular Toothpaste
451020|NCT00762151|Other|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
451021|NCT00762151|Drug|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
451022|NCT00762138|Device|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:~Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
451023|NCT00762125|Behavioral|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
451069|NCT00761761|Other|Placebo|
451543|NCT00758264|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
451024|NCT00762125|Behavioral|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
451025|NCT00762125|Behavioral|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
451026|NCT00762112|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
451027|NCT00762099|Drug|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
451028|NCT00762099|Drug|Placebo|Placebo/sugar tabs will look identical to active drug.
451029|NCT00762086|Device|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
451030|NCT00762086|Other|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
451031|NCT00762073|Drug|budesonide|oral suspension
451032|NCT00762073|Drug|placebo|oral suspension matching budesonide
451033|NCT00762060|Device|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
451034|NCT00762060|Drug|Patient controlled analgesia|IV opioids delivered via PCA
451035|NCT00762047|Device|Durasphere FI|Durasphere Injection
451036|NCT00762047|Device|Sham|Sham injection with anesthesia
451037|NCT00762034|Drug|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
451038|NCT00762034|Drug|Pemetrexed|Maintenance therapy 500 mg/m^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
451039|NCT00762034|Drug|Paclitaxel|Induction therapy 200 mg/m^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
451040|NCT00762034|Drug|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
451041|NCT00762034|Biological|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
451042|NCT00762034|Biological|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
451043|NCT00762021|Device|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
451044|NCT00762021|Device|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
451045|NCT00761995|Drug|Azopt|topical eye drop dosed 1 drop 3 times daily
451046|NCT00761995|Drug|Cosopt|topical eye drop dosed 1 drop 2 times daily
451047|NCT00761982|Procedure|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
451048|NCT00761969|Other|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
451049|NCT00761956|Device|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
451050|NCT00761956|Device|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
451051|NCT00761930|Drug|Fluoride|Brush twice daily
451052|NCT00761930|Drug|Triclosan and fluoride|Brush twice daily
451053|NCT00761930|Drug|Herbal Ingredient and fluoride|Brush twice daily
451054|NCT00761917|Device|Tear Film Analyzer|tear film images
451055|NCT00761904|Behavioral|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
451056|NCT00761891|Other|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
451057|NCT00761878|Procedure|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
451058|NCT00761865|Device|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
451059|NCT00761852|Drug|Ruboxistaurin|32 mg daily for 2 weeks
451060|NCT00761852|Drug|Placebo|1 tab po QD for 2 weeks
451061|NCT00761839|Behavioral|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
451062|NCT00761839|Behavioral|Control group|Patients in the control group will receive usual counseling for self-management.
451063|NCT00761826|Device|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
451064|NCT00761813|Device|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
451065|NCT00761813|Device|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
451066|NCT00761800|Drug|Lactic acid|
451067|NCT00761774|Drug|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
451068|NCT00761761|Drug|Sensoril|
451070|NCT00761748|Device|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.~The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
451071|NCT00761748|Device|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
451072|NCT00761735|Biological|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
451073|NCT00761735|Drug|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
451074|NCT00761722|Drug|azacitidine|"Arm 1:~Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.~Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.~Arm 2:~All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
451075|NCT00761709|Drug|AL-39256 Ophthalmic Suspension, 1%|
451076|NCT00761709|Drug|Latanoprost Ophthalmic Solution, 0.005%|
451077|NCT00761709|Drug|Vehicle|Inactive ingredients used as a placebo comparator
451078|NCT00761696|Drug|IPI-926|Oral daily dosing
451079|NCT00761670|Drug|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
451080|NCT00761657|Drug|FG-4592|FG-4592 1.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
451081|NCT00761657|Drug|FG-4592|FG-4592 1.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
451082|NCT00761657|Drug|FG-4592|FG-4592 2.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
451083|NCT00761657|Drug|FG-4592|FG-4592 2.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
451084|NCT00761657|Drug|FG-4592|FG-4592 3.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
451085|NCT00761657|Drug|FG-4592|Placebo Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
451086|NCT00761657|Drug|FG-4592|FG-4592 0.7 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
451087|NCT00761644|Drug|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.
451088|NCT00761644|Drug|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
451089|NCT00761644|Drug|Temsirolimus|Days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
451090|NCT00761631|Biological|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
451091|NCT00761618|Procedure|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
451092|NCT00761618|Procedure|IPC Placement|IPC placed in chest cavity to drain excess fluid
451093|NCT00761618|Radiation|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
451094|NCT00761605|Drug|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
451095|NCT00761592|Biological|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
451096|NCT00761592|Biological|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
451097|NCT00761579|Drug|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
451098|NCT00761566|Other|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
451099|NCT00761566|Other|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
451100|NCT00761553|Other|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
451101|NCT00761553|Dietary Supplement|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
451102|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
451103|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
451104|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
451105|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
452212|NCT00753181|Other|Nutritional Formula|nutritional shake daily
451106|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
451107|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
451108|NCT00761527|Drug|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;~Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:~Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg [milligrams] of desloratadine)~Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)~Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
451109|NCT00761514|Drug|Humira (adalimumab)|40 mg eow
451110|NCT00761501|Drug|PN400|Oral
451111|NCT00761501|Drug|Naproxen (Proxen S)|Oral
451112|NCT00761501|Drug|Naproxen (Naprosyn E)|Oral
451113|NCT00761488|Device|AcrySof® Toric IOL|Implanted into the study eye
451114|NCT00761475|Procedure|mesh supported closure|onlay mesh supported closure midline laparotomy
451115|NCT00761475|Procedure|primary closure|primary closure of the midline
451116|NCT00761475|Procedure|mesh supported closure|sublay mesh supported closure midline laparotomy
451117|NCT00761462|Drug|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
451118|NCT00761462|Drug|Non-quinolone antibiotic|Common used dose and route
451119|NCT00761449|Drug|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
451120|NCT00761436|Biological|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
451121|NCT00761423|Biological|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
451122|NCT00761423|Biological|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
451123|NCT00761410|Device|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
451124|NCT00761397|Behavioral|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
451125|NCT00761397|Behavioral|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
451126|NCT00761397|Other|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
451127|NCT00761397|Other|Questionnaire|Day 1 of study, 10 weeks after starting study, & 12 months after starting study
451128|NCT00761384|Drug|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
451129|NCT00761371|Drug|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
451130|NCT00761358|Drug|Z-338|Oral
451131|NCT00761358|Drug|Placebo|Oral
451132|NCT00761345|Drug|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
451133|NCT00761345|Drug|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
451134|NCT00761345|Radiation|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
451135|NCT00761332|Drug|teriparatide|treatment will be prescribed according to usual standard of care
451136|NCT00761332|Drug|antiresorptives|treatment will be prescribed according to usual standard of care
451137|NCT00761319|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
451138|NCT00761319|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
451139|NCT00761306|Drug|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
451140|NCT00761280|Drug|trabedersen|
451141|NCT00761280|Drug|temozolomide|
451142|NCT00761280|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
451143|NCT00761280|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
451144|NCT00761280|Drug|carmustine|
451145|NCT00761280|Drug|lomustine|
451146|NCT00761267|Drug|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).~Maximum treatment duration with anidulafungin is 35 days."
451147|NCT00761267|Drug|Fluconazole|Subjects may be switched to oral fluconazole [6-12 mg/kg/day (not to exceed 800mg/day] provided they meet specified criteria. Maximum total treatment duration is 49 days.
451148|NCT00761254|Drug|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
451149|NCT00761241|Drug|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
451150|NCT00761241|Biological|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
451151|NCT00761241|Radiation|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
451152|NCT00761241|Procedure|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
451153|NCT00761228|Drug|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
451154|NCT00761228|Drug|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
451155|NCT00761215|Drug|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
451156|NCT00761215|Drug|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
451157|NCT00761215|Drug|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
451158|NCT00761202|Drug|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
451159|NCT00761202|Drug|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
451160|NCT00761189|Drug|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
451161|NCT00761176|Device|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
451162|NCT00761163|Other|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
451163|NCT00761163|Other|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
451164|NCT00761163|Other|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
451165|NCT00761150|Drug|ABT-712|ABT-712 extended-release tablet
451166|NCT00761150|Drug|Placebo|Placebo tablet
451167|NCT00761137|Drug|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
451168|NCT00761137|Drug|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
451169|NCT00761137|Drug|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
451170|NCT00761137|Drug|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
451171|NCT00761124|Behavioral|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
451172|NCT00761124|Behavioral|Printed Material|General prostate cancer pamphlet
451173|NCT00761111|Behavioral|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
451174|NCT00761098|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
451175|NCT00761098|Drug|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
451176|NCT00761085|Drug|Morphine|Standard of care for pain management of acute episode of pain
451177|NCT00761085|Drug|Methadone|Methadone given to compare to standard of care for pain management
451178|NCT00761059|Drug|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
451179|NCT00761059|Drug|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
451180|NCT00761033|Behavioral|music|
451181|NCT00761020|Drug|Mefloquine|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
451182|NCT00761020|Other|Control|No Intervention
451183|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
451184|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
451185|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
451186|NCT00761007|Drug|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
451187|NCT00760994|Behavioral|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert & Forsyth, 2005; Hayes, Strosahl, & Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, & Barlow, 2004).
451188|NCT00760994|Behavioral|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
451189|NCT00760994|Other|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
451190|NCT00760981|Drug|Imatinib|
451191|NCT00760968|Drug|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
452213|NCT00753181|Other|Usual diet|usual dietary habits
451192|NCT00760968|Drug|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
451193|NCT00760955|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
451194|NCT00760955|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
451195|NCT00760955|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
451196|NCT00760955|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
451197|NCT00760942|Dietary Supplement|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
451198|NCT00760942|Dietary Supplement|Similac human milk fortifier|Powdered human milk fortifier.
451199|NCT00760929|Drug|Placebo|iv 9mg/kg weekly
451200|NCT00760929|Drug|Placebo|iv 16mg/kg every 3 weeks
451201|NCT00760929|Drug|RG1507|iv 9mg/kg weekly
451202|NCT00760929|Drug|RG1507|iv 16mg/kg every 3 weeks
451203|NCT00760929|Drug|erlotinib [Tarceva]|150mg oral daily
451204|NCT00760916|Drug|UT-15C 1 mg|UT-15C 1 mg
451205|NCT00760916|Drug|UT-15C 0.25 mg|UT-15C 0.25 mg
451206|NCT00760916|Drug|UT-15C 5 mg|UT-15C 5 mg
451207|NCT00760916|Drug|Placebo|Placebo
451208|NCT00760903|Other|Conventional MRI of the brain|
451209|NCT00760903|Other|MR spectroscopy (MRS)|
451210|NCT00760903|Other|MR Diffusion Tensor Imaging (DTI)|
451211|NCT00760890|Dietary Supplement|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
451212|NCT00760890|Dietary Supplement|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
451213|NCT00760877|Drug|Nilotinib|Supplied in 200 mg capsules
451214|NCT00760877|Drug|Imatinib|Supplied in 100 mg and 400 mg capsules
451215|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
451216|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
451217|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
451218|NCT00760864|Drug|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
451219|NCT00760851|Other|probiotic strain Bb-12|10^9 CFU Bb-12 per 4 oz yogurt
451220|NCT00760851|Other|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
451221|NCT00760838|Drug|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
451222|NCT00760838|Drug|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
451223|NCT00760825|Biological|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
451224|NCT00760812|Behavioral|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
451225|NCT00760812|Behavioral|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
451226|NCT00760799|Procedure|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
451227|NCT00760786|Drug|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
451228|NCT00760786|Drug|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
451229|NCT00760786|Drug|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
451230|NCT00760786|Drug|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
451231|NCT00760773|Drug|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
451232|NCT00760773|Drug|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
451233|NCT00760773|Drug|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
451234|NCT00760760|Drug|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
451235|NCT00760760|Drug|control|equivalent amount of fat as butter
451236|NCT00760747|Drug|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
451237|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
451544|NCT00758264|Biological|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
451238|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
451239|NCT00760721|Behavioral|Educational Small Group Session|1 hour small group health-related discussion
451240|NCT00760695|Drug|dronabinol|tablets, twice daily, for 4 weeks
451241|NCT00760695|Drug|placebo|tablets, twice daily, for 4 weeks
451242|NCT00760682|Procedure|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
451243|NCT00760669|Drug|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
451244|NCT00760669|Drug|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
451245|NCT00760630|Device|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
451246|NCT00760617|Biological|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
451247|NCT00760617|Biological|Fluarix|Intramuscular (IM) administration, 1 dose
451248|NCT00760604|Procedure|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
451249|NCT00760578|Drug|Placebo|Once daily, oral
451250|NCT00760578|Drug|Pioglitazone|Once daily, oral
451251|NCT00760578|Drug|MSDC-0160 90 mg|Once daily, oral
451252|NCT00760578|Drug|MSDC-0160 220 mg|Once daily, oral
451253|NCT00760565|Drug|RO4905417|3mg/kg iv every 28 days for 3 infusions
451254|NCT00760565|Drug|RO4905417|20mg/kg iv every 28 days for 3 infusions
451255|NCT00760565|Drug|RO4905417|7mg/kg iv every 28 days for 3 infusions
451256|NCT00760565|Drug|placebo|3mg/kg iv every 28 days for 3 infusions
451257|NCT00760565|Drug|placebo|7mg/kg iv every 28 days for 3 infusions
451258|NCT00760565|Drug|placebo|20mg/kg iv every 28 days for 3 infusions
451259|NCT00760552|Other|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
451260|NCT00760552|Other|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, & possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
451261|NCT00760552|Other|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
451262|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
451263|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
451264|NCT00760526|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
451265|NCT00760526|Device|Home blood glucose monitor|Home monitoring 3 or more times a day
451266|NCT00760513|Drug|OMACOR|4 grammes daily, oral capsule
451267|NCT00760513|Drug|Placebo oral capsule|4 grammes daily, oral capsule (olive oil)
451268|NCT00760500|Other|Nasopharyngeal Swab|Nasopharyngeal Swab
451269|NCT00760487|Device|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
451270|NCT00760474|Drug|Pregabalin, then placebo|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
451271|NCT00760474|Drug|Placebo, then pregabalin|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
451272|NCT00760461|Drug|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
451273|NCT00760448|Drug|insulin detemir|
451274|NCT00760448|Drug|insulin NPH|
451275|NCT00760435|Drug|Infliximab|5 mg/kg IV over 2 hours once
451276|NCT00760435|Drug|Placebo|Placebo (same volume as active drug)
451277|NCT00760422|Device|NIR|Thermometer
451278|NCT00760396|Drug|VGX-1027|Subjects will
451430|NCT00759109|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
451279|NCT00760383|Dietary Supplement|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
451280|NCT00760383|Dietary Supplement|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
451281|NCT00760370|Drug|Zoledronic Acid|4 mg intravenous (iv), one treatment
451282|NCT00760344|Drug|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
451283|NCT00760344|Drug|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
451284|NCT00760344|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
451285|NCT00760344|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
451286|NCT00760344|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
451287|NCT00760344|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
451288|NCT00760318|Drug|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
451289|NCT00760305|Behavioral|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
451290|NCT00760279|Drug|Azithromycin|
451291|NCT00760266|Drug|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
451292|NCT00760266|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
451293|NCT00760227|Other|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
451294|NCT00760227|Other|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
451295|NCT00760227|Other|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
451296|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
451297|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
451298|NCT00760214|Drug|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
451299|NCT00760188|Device|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
451300|NCT00760175|Biological|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
451301|NCT00760149|Drug|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
451302|NCT00760136|Procedure|Computed Tomography|CT imaging of bilateral knee
451303|NCT00760123|Other|Early Physical Therapy and Educational strategy|"Experimental group:~physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.~Other: control group: only the educational strategy"
451304|NCT00760110|Device|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
451305|NCT00760097|Device|Transcranial direct stimulation|sessions of 20 minutes each
451306|NCT00760084|Drug|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
451307|NCT00760058|Device|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
451308|NCT00760058|Device|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
451309|NCT00760058|Device|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
451310|NCT00760045|Drug|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
451311|NCT00760045|Drug|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
451312|NCT00760032|Drug|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
451313|NCT00760032|Drug|Placebo|Placebo capsules, one capsule per day during four weeks.
451314|NCT00760019|Drug|salsalate|1.5 grams orally 3 times daily
451315|NCT00760019|Drug|placebo|matching placebo
451540|NCT00758290|Drug|Fluoride/triclosan|Brush daily for 3 weeks
451316|NCT00760006|Drug|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
451317|NCT00760006|Other|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
451318|NCT00759993|Drug|chromium piccolinate|1000mg tab
451319|NCT00759993|Drug|placebo for chromium piccolinate|
451320|NCT00759967|Procedure|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
451321|NCT00759967|Procedure|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
451322|NCT00759954|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
451323|NCT00759954|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
451324|NCT00759941|Drug|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
451325|NCT00759941|Drug|Placebo eye drops|One drop three times a day in both eyes for 3 months
451326|NCT00759941|Drug|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
451327|NCT00759928|Drug|Erlotinib|150 mg once daily by mouth
451328|NCT00759928|Drug|Sorafenib|400 mg twice daily by mouth
451329|NCT00759915|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
451330|NCT00759915|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
451331|NCT00759902|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
451332|NCT00759902|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
451333|NCT00759876|Drug|Ataluren|Oral powder in a sachet taken 3 times per day with dosing based on subject body weight. Doses are 20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner.
451334|NCT00759863|Behavioral|Lifezig|Personalized Reminiscence Video
451335|NCT00759850|Device|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
451336|NCT00759837|Drug|Bosutinib|
451337|NCT00759824|Drug|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
451338|NCT00759811|Drug|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
451339|NCT00759811|Drug|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.~All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
451340|NCT00759798|Drug|Fludarabine|25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
451341|NCT00759798|Drug|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
451342|NCT00759798|Drug|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
451343|NCT00759785|Drug|dalotuzumab (MK0646)|Single intravenous infusion
451344|NCT00759772|Drug|Placebo|sc daily for 6 months
451345|NCT00759772|Drug|Teriparatide|20 mcg sc daily for 6 months
451346|NCT00759759|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
451347|NCT00759759|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
451348|NCT00759746|Behavioral|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
451349|NCT00759746|Behavioral|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
451350|NCT00759746|Behavioral|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
451351|NCT00759733|Procedure|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
451352|NCT00759733|Procedure|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
451353|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
451354|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
451355|NCT00759720|Drug|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
451356|NCT00759707|Drug|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein [arterial] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
451357|NCT00759681|Device|ArterX Surgical Sealant|Apply at the suture site.
451358|NCT00759681|Device|Gelfoam and Thrombin|Apply at the suture site.
451359|NCT00759668|Device|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
451360|NCT00759668|Device|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
451361|NCT00759655|Biological|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
451362|NCT00759642|Drug|lapatinib|lapatinib 1500 mg PO daily
451363|NCT00759629|Other|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
451364|NCT00759629|Other|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
451365|NCT00759616|Device|Oxford Partial Knee|Oxford Partial Knee
451366|NCT00759603|Drug|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
451367|NCT00759603|Drug|Rituximab|Dose of 375 mg/m^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
451368|NCT00759590|Procedure|CT scan and Pressure volume curve|CT scan
451369|NCT00759577|Drug|Solifenacin|5mg and 10 mg, oral once daily
451370|NCT00759564|Drug|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
451371|NCT00759551|Drug|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
451372|NCT00759551|Drug|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
451373|NCT00759551|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
451374|NCT00759551|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
451375|NCT00759551|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
451376|NCT00759551|Drug|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
451377|NCT00759551|Drug|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
451378|NCT00759525|Drug|Glycyrrhetic Acid|130 mg daily for fourteen days
451379|NCT00759525|Drug|Placebo|Placebo daily for fourteen days
451380|NCT00759512|Other|Therapeutic Touch|
451381|NCT00759473|Drug|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
451382|NCT00759473|Drug|Placebo|
451383|NCT00759460|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
451384|NCT00759460|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
451385|NCT00759447|Device|Genesis and Gemini|3 dimensional breast mammography system
451386|NCT00759447|Device|Investigational 3D Mammography system|3 dimensional breast mammography system
451541|NCT00758277|Drug|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
451387|NCT00759434|Procedure|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
451388|NCT00759434|Procedure|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
451389|NCT00759421|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
451390|NCT00759421|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
451391|NCT00759408|Drug|BQ-123|6-120 µg/min
451392|NCT00759395|Drug|AZD2327|Tablet, Oral, Daily
451393|NCT00759395|Drug|Placebo|Tablet, Oral, Daily
451394|NCT00759369|Other|Water prescription|Water prescription in 12 to 16 equally divided doses
451395|NCT00759356|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
451396|NCT00759356|Drug|KADIAN|2 x 100 mg, single-dose capsule
451397|NCT00759330|Drug|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
451398|NCT00759330|Drug|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
451399|NCT00759330|Drug|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
451400|NCT00759330|Drug|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
451401|NCT00759317|Drug|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
451402|NCT00759291|Drug|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
451403|NCT00759291|Drug|Placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
451404|NCT00759278|Procedure|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
451405|NCT00759265|Other|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).~During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
451406|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
451407|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
451408|NCT00759226|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
451409|NCT00759226|Drug|Cisplatin|Cisplatin 30 mg/m2 (90 min)
451410|NCT00759226|Drug|5-FU|5-FU 750 mg/m2 (24h CI)
451411|NCT00759226|Drug|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
451412|NCT00759200|Drug|alb-interferon alfa 2b|900 mcg every 4 weeks
451413|NCT00759200|Drug|alb-interferon alfa 2b|1200 mcg every 4 weeks
451414|NCT00759200|Drug|alb-interferon alfa 2b|1500 mcg every 4 weeks
451415|NCT00759200|Drug|alb-interferon alfa 2b|1800 mcg every 4 weeks
451416|NCT00759200|Drug|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
451417|NCT00759187|Drug|Fluoride|Brush twice daily
451418|NCT00759187|Drug|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
451419|NCT00759187|Drug|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
451420|NCT00759174|Drug|No intervention|No intervention occurs in this observational study.
451421|NCT00759161|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
451422|NCT00759161|Drug|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
451423|NCT00759148|Drug|Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%|Eye drops
451424|NCT00759148|Other|Moxifloxacin AF Vehicle|Inactive ingredients used as a placebo for masking purposes
451425|NCT00759135|Drug|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
451426|NCT00759135|Drug|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
451427|NCT00759135|Drug|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
451428|NCT00759122|Drug|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
451429|NCT00759122|Drug|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
451431|NCT00759109|Other|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
451432|NCT00759096|Device|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
451433|NCT00759083|Drug|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
451434|NCT00759070|Drug|Tenofovir + emtricitabine + efavirenz|"Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily"
451435|NCT00759070|Drug|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
451436|NCT00759057|Device|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
451437|NCT00759031|Drug|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
451438|NCT00759031|Drug|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
451439|NCT00759018|Biological|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
451440|NCT00759005|Drug|propranolol and cortisol|
451441|NCT00758966|Drug|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
451442|NCT00758966|Drug|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
451443|NCT00758966|Drug|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
451444|NCT00758953|Drug|Danazol Once Weekly|semi-solid
451445|NCT00758953|Drug|Danazol Twice Weekly|semi-solid
451446|NCT00758953|Drug|Placebo Once Weekly|semi-solid
451447|NCT00758953|Drug|Placebo Twice Weekly|semi-solid
451448|NCT00758940|Device|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
451449|NCT00758927|Drug|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
451450|NCT00758927|Drug|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
451451|NCT00758914|Dietary Supplement|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
451452|NCT00758901|Device|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
451453|NCT00758888|Procedure|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
451454|NCT00758888|Procedure|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
451455|NCT00758888|Other|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
451456|NCT00758862|Drug|2% TD1414 Cream|Application 3 times daily for 7 days
451457|NCT00758849|Drug|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
451458|NCT00758849|Drug|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
451459|NCT00758836|Drug|placebo|
451460|NCT00758836|Drug|ibuprofen|
451461|NCT00758836|Drug|acetominophen|
451462|NCT00758836|Drug|telcagepant|
451463|NCT00758823|Device|Paranix|pediculicide product
451464|NCT00758797|Other|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
451465|NCT00758784|Drug|Refresh Tears|sterile ophthalmic solution
451466|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
451467|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
451468|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
451469|NCT00758745|Device|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
451470|NCT00758745|Device|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
451471|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
451472|NCT00758732|Drug|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
451473|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
451474|NCT00758732|Drug|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
451475|NCT00758706|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
451476|NCT00758706|Drug|Placebo|Dosing to match AZD1236
451477|NCT00758693|Drug|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
451478|NCT00758693|Drug|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
451479|NCT00758680|Drug|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
451480|NCT00758680|Drug|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
451542|NCT00758277|Drug|Placebo|Sugar Pill
451481|NCT00758667|Drug|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
451482|NCT00758641|Device|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
451483|NCT00758641|Drug|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
451484|NCT00758628|Drug|Bromefenac|Bromfenac BID 3 months
451485|NCT00758628|Drug|Blink|Blink BID for 3 months
451486|NCT00758615|Behavioral|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
451487|NCT00758602|Drug|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
451488|NCT00758602|Drug|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
451489|NCT00758602|Drug|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
451490|NCT00758602|Drug|corticosteroids|According to center's practice
451491|NCT00758589|Drug|AZD1981|Oral tablet, 50 mg twice daily
451492|NCT00758589|Drug|AZD1981|Oral tablet, 400 mg twice daily
451493|NCT00758589|Drug|AZD1981|Oral tablet, 1000 mg twice daily
451494|NCT00758589|Drug|Placebo|
451495|NCT00758576|Device|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
451496|NCT00758563|Drug|Fluoride|Brush twice daily
451497|NCT00758563|Drug|Triclosan/Fluoride|Brush twice daily
451498|NCT00758550|Device|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
451499|NCT00758550|Device|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
451500|NCT00758524|Drug|LCI699|
451501|NCT00758524|Drug|Eplerenone|
451502|NCT00758524|Drug|Placebo|Placebo
451503|NCT00758511|Procedure|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
451504|NCT00758511|Procedure|facilitated tucking|facilitated tucking before, during and after heel stick
451505|NCT00758511|Procedure|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
451506|NCT00758498|Drug|armodafinil|50 mg/day orally, once daily in the morning for 3 days
451507|NCT00758498|Drug|armodafinil|150 mg/day orally, once daily in the morning for 3 days
451508|NCT00758498|Drug|placebo|placebo tablets, once daily in the morning for 3 days
451509|NCT00758485|Drug|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
451510|NCT00758485|Drug|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
451511|NCT00758472|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
451512|NCT00758459|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
451513|NCT00758459|Drug|Placebo|Dosing to match AZD1236
451514|NCT00758446|Drug|BLX-028914|50 mg capsules, p.o, daily, 14 days
451515|NCT00758446|Drug|BLX-028914|15 mg capsules, p.o, daily, 14 days
451516|NCT00758446|Drug|placebo|capsules, p.o, daily, 14 days
451517|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
451518|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
451519|NCT00758433|Drug|Placebo patch|Placebo patch q.d. 24 hours for 7 days
451520|NCT00758420|Drug|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
451521|NCT00758420|Drug|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
451522|NCT00758407|Drug|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
451523|NCT00758407|Drug|Placebo|dosage according to an individual titration schedule
451524|NCT00758394|Drug|Fluoride|Brush two times a day for 4 days.
451525|NCT00758394|Drug|Triclosan/Fluoride|Brush two times daily for 4 days
451526|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
451527|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
451528|NCT00758381|Drug|Sorafenib 400 mg po bid, continuously|"NEXAVAR*112CPR RIV 200MG~Titolare AIC:~BAYER SpA~Numero di AIC dell'IMP:~037154010"
451529|NCT00758381|Drug|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
451530|NCT00758368|Drug|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
451531|NCT00758342|Drug|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
451532|NCT00758342|Drug|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
451533|NCT00758329|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
451534|NCT00758316|Other|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
451535|NCT00758316|Procedure|Thoracoscopy|Talc poudrage
451536|NCT00758303|Drug|Low Dose TRIA-662|One Capsule 3 times a day
451537|NCT00758303|Drug|High Dose TRIA-662|3 Capsules 3 times daily
451538|NCT00758303|Drug|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
451539|NCT00758290|Drug|Triclosan/Fluoride|Brush twice daily for 3 weeks
451545|NCT00758238|Other|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
451546|NCT00758225|Drug|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients > 45 kg: 900 mg/day (2 tablets 3 times a day)
451547|NCT00758212|Biological|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
451548|NCT00758199|Drug|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
451549|NCT00758199|Drug|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
451550|NCT00758199|Drug|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
451551|NCT00758186|Procedure|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
451552|NCT00758186|Procedure|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
451553|NCT00758173|Genetic|polymorphism analysis|
451554|NCT00758173|Other|laboratory biomarker analysis|
451555|NCT00758173|Other|questionnaire administration|
451556|NCT00758160|Drug|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
451557|NCT00758147|Device|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
451558|NCT00758134|Drug|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
451559|NCT00758121|Device|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
451560|NCT00758082|Device|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
451561|NCT00758082|Device|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
451562|NCT00758069|Drug|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
451563|NCT00758069|Drug|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
451564|NCT00758069|Drug|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
451565|NCT00758056|Genetic|polymorphism analysis|
451566|NCT00758056|Other|laboratory biomarker analysis|
451567|NCT00758056|Other|questionnaire administration|
451568|NCT00758043|Drug|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
451569|NCT00758043|Drug|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
451570|NCT00758043|Biological|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
451571|NCT00758030|Drug|Paliperidone ER OROS|
451572|NCT00758017|Other|Acupuncture 1|Application of individualised acupuncture
451573|NCT00758017|Other|Acupuncture 2|Application of standardised acupuncture
451574|NCT00758004|Drug|Atorvastatin|A single dose of 80 mg atrovastatin tablet
451575|NCT00758004|Drug|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
451576|NCT00757991|Genetic|polymorphism analysis|
451577|NCT00757991|Other|laboratory biomarker analysis|
451578|NCT00757991|Other|questionnaire administration|
451579|NCT00757978|Drug|memantine|memantine 10mg twice a day
451580|NCT00757978|Drug|placebo|1 capsule of placebo twice a day
451581|NCT00757965|Genetic|polymorphism analysis|
451582|NCT00757965|Other|laboratory biomarker analysis|
451583|NCT00757965|Other|questionnaire administration|
451584|NCT00757952|Other|Fourier transform ion cyclotron resonance mass spectrometry|
451585|NCT00757952|Other|chromatography|
451586|NCT00757952|Other|diagnostic laboratory biomarker analysis|
451587|NCT00757952|Other|questionnaire administration|
451588|NCT00757939|Other|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
451589|NCT00757939|Other|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
451590|NCT00757926|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
451591|NCT00757926|Other|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
451592|NCT00757913|Dietary Supplement|n-3 enriched nutrition|
451593|NCT00757900|Biological|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
451594|NCT00757887|Biological|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
451595|NCT00757874|Drug|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
451596|NCT00757874|Drug|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
451597|NCT00757848|Drug|AZD9668|60 mg, oral tablet, twice daily for 28 days
451598|NCT00757848|Drug|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
451599|NCT00757835|Drug|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
451600|NCT00757835|Drug|latanoprost/timolol fixed combination drops|once in the evening
451601|NCT00757822|Drug|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
451602|NCT00757822|Drug|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
451603|NCT00757809|Drug|neratinib|HKI-272
451604|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
451605|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
451606|NCT00757783|Drug|darunavir|800 mg tablet once daily for 48 weeks
451607|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
451608|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
451609|NCT00757783|Drug|atazanavir|300 mg capsule once daily for 48 weeks
451610|NCT00757770|Biological|Rotarix|Two oral doses.
451611|NCT00757770|Biological|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
451612|NCT00757757|Drug|MCS110|Anti-M-CSF antibody
451613|NCT00757744|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
451614|NCT00757744|Behavioral|Drug counseling|individual drug counseling
451615|NCT00757731|Drug|milnacipran|hard capsule
451616|NCT00757731|Drug|Placebo|hard capsule
451617|NCT00757718|Device|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
451618|NCT00757718|Device|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
451619|NCT00757705|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
451620|NCT00757692|Drug|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
451621|NCT00757692|Drug|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
451622|NCT00757679|Drug|Milnacipran|capsules
451623|NCT00757679|Drug|Placebo|capsules
451624|NCT00757666|Device|Rate adaptive pacemaker|Accelerometer sensor
451625|NCT00757666|Device|Rate adaptive pacemaker|Minute ventilation sensor
451626|NCT00757653|Device|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
451627|NCT00757653|Device|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
451628|NCT00757653|Device|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
451629|NCT00757640|Procedure|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
451630|NCT00757627|Drug|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
451631|NCT00757614|Genetic|DNA analysis|
451632|NCT00757614|Genetic|polymorphism analysis|
451633|NCT00757614|Other|laboratory biomarker analysis|
451634|NCT00757614|Other|questionnaire administration|
451635|NCT00757601|Drug|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.~Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
451636|NCT00757601|Drug|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.~Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg~Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.~Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.~There will a 7-day interval between each dose"
451637|NCT00757588|Drug|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
451638|NCT00757588|Drug|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
451639|NCT00757562|Drug|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects >=2 to <6 years, 2.5 mg (5 mL) for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
451640|NCT00757562|Drug|Placebo|placebo syrup: 2.5 mL for subjects >=2 to <6 years, 5 mL for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
451641|NCT00757549|Biological|cetuximab|
451642|NCT00757549|Drug|cisplatin|
451643|NCT00757549|Genetic|TdT-mediated dUTP nick end labeling assay|
451644|NCT00757549|Other|3'-deoxy-3'-[18F]fluorothymidine|
451645|NCT00757549|Other|immunohistochemistry staining method|
451646|NCT00757549|Other|laboratory biomarker analysis|
451647|NCT00757549|Radiation|fludeoxyglucose F 18|
451648|NCT00757549|Radiation|radiation therapy|
451649|NCT00757536|Procedure|Encircling Band|ppVE and encircling band
451650|NCT00757536|Procedure|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
451651|NCT00757523|Drug|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
451652|NCT00757523|Drug|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
451653|NCT00757497|Behavioral|Electrical Polarization|
451654|NCT00757471|Procedure|Brillant Blue|Membrane Peeling with Brillant Blue
451655|NCT00757471|Procedure|Indocyanine Green|Membrane Peeling with indocyanine Green
451656|NCT00757458|Drug|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
451657|NCT00757458|Other|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
451658|NCT00757458|Other|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
451659|NCT00757458|Other|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
451660|NCT00757419|Drug|AZD3355|capsules, oral, single or twice daily dose
451661|NCT00757419|Drug|Placebo|To match dosing of AZD3355
451662|NCT00757393|Dietary Supplement|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
451663|NCT00757393|Drug|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
451664|NCT00757380|Procedure|Trypan Blue|Membranepeeling with TB
451665|NCT00757380|Procedure|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
451666|NCT00757367|Drug|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
451667|NCT00757354|Procedure|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
451668|NCT00757341|Drug|SKI-606|
451669|NCT00757315|Device|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
451670|NCT00757315|Drug|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
451671|NCT00757302|Device|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).~Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
451672|NCT00757289|Biological|PRP Injection|PRP Injection
451673|NCT00757289|Biological|Corticosteroid Injection|Corticosteroid Injection
451674|NCT00757263|Genetic|polymorphism analysis|
451675|NCT00757263|Other|laboratory biomarker analysis|
451676|NCT00757263|Other|questionnaire administration|
451677|NCT00757250|Drug|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
451678|NCT00757237|Drug|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
451679|NCT00757237|Drug|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
451680|NCT00757224|Behavioral|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
451681|NCT00757211|Genetic|polymorphism analysis|
451682|NCT00757211|Other|laboratory biomarker analysis|
451683|NCT00757211|Other|questionnaire administration|
451684|NCT00757198|Drug|remifentanil|remifentanil infusion
451685|NCT00757198|Drug|remifentanil|remifentanil infusion
451686|NCT00757185|Drug|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
451687|NCT00757185|Drug|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
451688|NCT00757172|Biological|panitumumab|
451689|NCT00757172|Drug|cisplatin|
451690|NCT00757172|Drug|docetaxel|
451691|NCT00757172|Procedure|neoadjuvant therapy|
451692|NCT00757172|Procedure|therapeutic conventional surgery|
451693|NCT00757172|Radiation|radiation therapy|
451694|NCT00757159|Device|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
451695|NCT00757159|Device|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
451776|NCT00756418|Drug|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
452340|NCT00752232|Other|PBS|IM injection, Day 1, month 3, 6, 9, 12
451696|NCT00757133|Procedure|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
451697|NCT00757133|Procedure|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
451698|NCT00757107|Device|Taperloc Microplasty|primary total hip arthroplasty
451699|NCT00757107|Device|Taperloc standard|primary total hip arthroplasty
451700|NCT00757081|Drug|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
451701|NCT00757068|Behavioral|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
451702|NCT00757068|Behavioral|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
451703|NCT00757055|Drug|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate < 60 bpm.
451704|NCT00757055|Drug|Placebo|No active treatment given
451705|NCT00757042|Drug|AMG 157|Part A (healthy subjects): 6 subcutaneous (SC) cohorts and 2 intravenous (IV) cohorts receiving a single dose of either AMG 157 (dose escalating by cohort) or placebo. Part B (subjects with moderate to severe atopic dermatitis):two cohorts receiving a single dose (SC or IV; dose to be determined) of AMG 157 or placebo.
451706|NCT00757029|Genetic|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
451707|NCT00757016|Drug|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
451708|NCT00757016|Drug|Saline solution|Saline solution
451709|NCT00757003|Device|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
451710|NCT00756990|Drug|Depot Naltrexone|228mg of injectable naltrexone
451711|NCT00756977|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
451712|NCT00756977|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
451713|NCT00756964|Drug|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
451714|NCT00756964|Drug|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
451715|NCT00756951|Drug|Placebo|Placebo
451716|NCT00756951|Drug|SCV-07|0.02 mg/kg
451717|NCT00756951|Drug|SCV-07|0.10 mg/kg
451718|NCT00756938|Drug|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
451719|NCT00756925|Drug|Acthrel|1 ug/kg, i.v., 1 minute
451720|NCT00756912|Drug|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
451721|NCT00756886|Drug|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
451722|NCT00756886|Drug|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
451723|NCT00756873|Drug|Administration of placebo|Placebo qd orally day 0-14
451724|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
451725|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
451726|NCT00756860|Drug|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
451727|NCT00756860|Drug|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
451728|NCT00756847|Drug|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
451729|NCT00756847|Drug|paclitaxel|Intravenous injection dosed once every three weeks
451730|NCT00756847|Drug|carboplatin|Intravenous injection dosed once every three weeks
451731|NCT00756795|Behavioral|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.~Structured Interview will be conducted at baseline and post-intervention.~Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.~All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
451732|NCT00756782|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
451733|NCT00756782|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
451734|NCT00756756|Drug|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
451735|NCT00756756|Drug|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
451736|NCT00756743|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
451737|NCT00756743|Drug|Placebo|Placebo capsules q12 hours for 10 days
451738|NCT00756730|Drug|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
451739|NCT00756730|Drug|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
451740|NCT00756717|Drug|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
451741|NCT00756704|Behavioral|Smoking cessation guideline implementation|"a tutorial on brief cessation counseling for ED nurses and physicians~use of an ED algorithm that includes recommended tobacco counseling items~fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy~group feedback to ED staff"
451742|NCT00756691|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
451743|NCT00756678|Drug|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days`
451744|NCT00756678|Drug|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
451745|NCT00756652|Device|Mentor Silicone Gel-Filled Breast Implants|
451746|NCT00756652|Device|Saline Breast Implants|
451747|NCT00756639|Radiation|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
451748|NCT00756639|Other|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
451749|NCT00756626|Behavioral|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
451750|NCT00756600|Drug|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
451751|NCT00756600|Drug|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
451752|NCT00756587|Device|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
451753|NCT00756587|Device|Bottle Feeding|receiving all feeding by bottle
451754|NCT00756574|Device|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
451755|NCT00756574|Device|N95 mask|N95 mask worn for patients with febrile respiratory illness
451756|NCT00756548|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
451757|NCT00756548|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
451758|NCT00756535|Procedure|Exercise training|Group-based exercise training 5 days a week during hospitalization
451759|NCT00756535|Procedure|usual treatment and rehabilitation|usual treatment and rehabilitation
451760|NCT00756522|Other|There is no intervention. Study is observational.|There is no intervention. Study is observational.
451761|NCT00756509|Drug|Nilotinib|800 mg/d orally
451762|NCT00756470|Drug|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
451763|NCT00756470|Drug|Paclitaxel|80 mg/m^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
451764|NCT00756470|Drug|5-Fluorouracil (5-FU)|500 mg/m^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
451765|NCT00756470|Drug|Epirubicin|75 mg/m^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
451766|NCT00756470|Drug|Cyclophosphamide|500 mg/m^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
451767|NCT00756457|Device|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
451768|NCT00756457|Other|Strengthening exercises|"Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up."
451769|NCT00756457|Other|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
451770|NCT00756444|Drug|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
451771|NCT00756444|Drug|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
451772|NCT00756444|Drug|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
451773|NCT00756431|Device|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
451774|NCT00756431|Device|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
451775|NCT00756418|Drug|montelukast|montelukast 5 mg QD 4-weeks.
451777|NCT00756405|Behavioral|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
451778|NCT00756405|Dietary Supplement|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
451779|NCT00756405|Dietary Supplement|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
451780|NCT00756392|Procedure|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
451781|NCT00756379|Other|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
451782|NCT00756366|Other|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
451783|NCT00756366|Other|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
451784|NCT00756366|Other|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
451785|NCT00756340|Drug|Bevacizumab|"Bevacizumab IV every 2 weeks~Dose Level 0- 8 mg/kg~Dose Level 1 (starting dose)- 10 mg/kg~Dose Level 2- 10 mg/kg"
451786|NCT00756340|Drug|Everolimus|"Everolimus~Dose Level 0- 4 mg/m2~Dose level 1 (starting dose)- 4 mg/m2~Dose Level 2- 5 mg/m2"
451787|NCT00756314|Behavioral|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
451788|NCT00756301|Other|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
451789|NCT00756288|Procedure|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
451790|NCT00756288|Procedure|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
451791|NCT00756275|Drug|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
451792|NCT00756275|Drug|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
451793|NCT00756275|Behavioral|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
451794|NCT00756262|Biological|Lactobacillus GG or Culturelle|Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10^10 bacteria
451795|NCT00756249|Drug|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
451796|NCT00756249|Drug|Placebo|Vials with solution for IV infusion
451797|NCT00756236|Drug|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
451798|NCT00756236|Drug|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
451799|NCT00756236|Drug|P-Group|0.9%NaCl dispensed in 60ml & 5ml syringes
451800|NCT00756223|Drug|Arm A|Dose escalation Arm A (4 weeks)
451801|NCT00756223|Drug|Arm B|Dose escalation Arm B (3 weeks)
451802|NCT00756210|Other|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
451803|NCT00756197|Device|Cryo Spray Ablation Group 1|Cryo Spray Ablation
451804|NCT00756197|Device|Cryo Spray Ablation Group 2|cryo spray ablation
451805|NCT00756184|Device|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
451806|NCT00756184|Device|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
451807|NCT00756171|Drug|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
451808|NCT00756171|Drug|placebo|2 times 3 625mg tablets daily
451809|NCT00756145|Procedure|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
451810|NCT00756145|Procedure|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
451811|NCT00756145|Procedure|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
451812|NCT00756106|Drug|temozolomide|chemotherapy
451813|NCT00756106|Other|imaging biomarker analysis|MRI
451814|NCT00756093|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
451815|NCT00756093|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
451816|NCT00756093|Other|Blink Tears|Blink Tears one drop each eye one time
451817|NCT00756093|Other|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
451819|NCT00756080|Drug|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
451820|NCT00756067|Biological|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
451821|NCT00756067|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
451822|NCT00756041|Drug|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
451823|NCT00756028|Drug|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
451824|NCT00756028|Drug|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
451825|NCT00756015|Other|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
451826|NCT00756015|Other|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
451827|NCT00756002|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
451828|NCT00756002|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
451829|NCT00755989|Drug|morphine topical gel|morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay
451830|NCT00755989|Drug|placebo|topical gel without morphine
451831|NCT00755976|Drug|epirubicin hydrochloride|
451832|NCT00755976|Drug|sulindac|
451833|NCT00755976|Other|immunologic technique|
451834|NCT00755963|Drug|estradiol valerate|Progynova® 21; 2mg/d
451835|NCT00755963|Drug|micronized progesterone|Utrogestan®; 200mg/d
451836|NCT00755963|Drug|placebo|maltodextrin
451837|NCT00755950|Dietary Supplement|Silymarin|280 mg three times daily for four weeks
451838|NCT00755950|Dietary Supplement|Silymarin|420 mg three times daily for four weeks
451839|NCT00755950|Other|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
451840|NCT00755937|Other|Data collection post infusion|
451841|NCT00755924|Dietary Supplement|Vinegar|Apple cider vinegar 2 TBlsp/day
451842|NCT00755924|Other|Placebo|Water placebo colored with balsamic vinegar
451843|NCT00755911|Biological|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
451844|NCT00755911|Device|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
451845|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
451846|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
451847|NCT00755885|Drug|abiraterone acetate|
451848|NCT00755885|Other|laboratory biomarker analysis|
451849|NCT00755885|Other|pharmacogenomic studies|
451850|NCT00755872|Drug|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
451851|NCT00755872|Drug|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
451852|NCT00755872|Drug|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
451853|NCT00755872|Drug|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
451854|NCT00755859|Drug|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
451855|NCT00755859|Drug|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
451856|NCT00755846|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
451857|NCT00755846|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
451858|NCT00755846|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
451859|NCT00755846|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
451860|NCT00755846|Drug|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
451861|NCT00755846|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
451862|NCT00755833|Drug|biphasic insulin aspart 50|Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
451863|NCT00755820|Behavioral|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
451864|NCT00755820|Behavioral|Exposure Therapy + Placebo|Exposure therapy with placebo medication
451865|NCT00755820|Behavioral|Supportive Psychotherapy|Supportive psychotherapy
451902|NCT00755534|Drug|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
451903|NCT00755521|Drug|etoricoxib|"Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg"
451866|NCT00755807|Drug|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
451867|NCT00755807|Drug|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams [mg] QD for 12 weeks).
451868|NCT00755794|Drug|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
451869|NCT00755781|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
451870|NCT00755768|Behavioral|additional review by dietician|
451871|NCT00755755|Drug|PGL4001 (ulipristal) and iron|tablets
451872|NCT00755755|Drug|PGL4001 matching placebo and iron|tablets
451873|NCT00755755|Drug|PGL4001 (ulipristal) and iron|Tablets
451874|NCT00755742|Other|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):~i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.~ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).~iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
451875|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
451876|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
451877|NCT00755716|Drug|Placebo (sugar pill)|patients receive
451878|NCT00755716|Drug|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
451879|NCT00755716|Drug|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
451880|NCT00755703|Biological|Pandemic Influenza Vaccine|Undetermined
451881|NCT00755703|Biological|Placebo|
451882|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
451883|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
451884|NCT00755690|Behavioral|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
451885|NCT00755677|Other|Pulses|subjects consume 1 pulse food daily for eight weeks
451886|NCT00755664|Dietary Supplement|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
451887|NCT00755651|Procedure|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
451888|NCT00755638|Biological|ACE-031|single subcutaneous dose of ACE-031
451889|NCT00755599|Procedure|no-stirrup vaginal examination|Vaginal speculum examination done with feet on table extender.
451890|NCT00755599|Procedure|Vaginal speculum examination done with stirrups.|Speculum examination done with feet in stirrups.
451891|NCT00755586|Procedure|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 * 10e8 cells in the m. biceps brachii.
451892|NCT00755586|Procedure|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 * 10e8 cells in the m. biceps brachii.
451893|NCT00755586|Procedure|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
451894|NCT00755573|Drug|Pregabalin|Pregabalin 300 mg - 600 mg BID
451895|NCT00755573|Drug|placebo|Regime as described for pregabalin
451896|NCT00755560|Drug|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
451897|NCT00755560|Drug|Placebo|Placebo BID for 15 days
451898|NCT00755547|Other|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
451899|NCT00755534|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
451900|NCT00755534|Drug|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
451901|NCT00755534|Drug|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
451904|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
451905|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
451906|NCT00755508|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
451907|NCT00755508|Drug|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
451908|NCT00755508|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
451909|NCT00755495|Drug|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
451910|NCT00755495|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
451911|NCT00755495|Drug|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
451912|NCT00755495|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
451913|NCT00755482|Drug|Aquamin F|
451914|NCT00755482|Drug|Placebo (maltodextran)|
451915|NCT00755469|Procedure|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
451916|NCT00755456|Drug|PD solution containing glucose|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
451917|NCT00755456|Drug|PD solution containing glucose and L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
451918|NCT00755443|Device|Drug eluting stent|Drug eluting stent implantation
451919|NCT00755443|Device|Bare metal stent|
451920|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
451921|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
451922|NCT00755417|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
451923|NCT00755404|Drug|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
451924|NCT00755404|Drug|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
451925|NCT00755391|Behavioral|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
451926|NCT00755391|Behavioral|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
451927|NCT00755378|Drug|AZD8529|Oral
451928|NCT00755378|Drug|Placebo|Oral
451929|NCT00755352|Drug|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
451930|NCT00755352|Drug|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
451931|NCT00755326|Drug|HLXL|Three daily dosages will be investigated. The lowest dosage condition will be 6 capsules (2,400 mg) daily, followed by an escalation to the 10 capsule condition (4,000 mg), and then to the 14 capsule (5,600 mg) condition. Participants will be treated for 6 weeks
451932|NCT00755313|Biological|trastuzumab|
451933|NCT00755313|Drug|aromatase inhibition therapy|
451934|NCT00755313|Drug|carboplatin|
451935|NCT00755313|Drug|cyclophosphamide|
451936|NCT00755313|Drug|docetaxel|
451937|NCT00755313|Drug|doxorubicin hydrochloride|
451938|NCT00755313|Other|metabolic assessment|
451939|NCT00755313|Other|questionnaire administration|
451940|NCT00755313|Other|study of socioeconomic and demographic variables|
451941|NCT00755313|Procedure|cognitive assessment|
451942|NCT00755313|Procedure|positron emission tomography|
451943|NCT00755313|Radiation|fludeoxyglucose F 18|
451944|NCT00755300|Procedure|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
451945|NCT00755287|Drug|insulin glargine|starting dose 10 IU daily
451946|NCT00755287|Drug|metformin|As prescribed
451947|NCT00755287|Drug|taspoglutide|10 mg once weekly
451948|NCT00755287|Drug|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
451949|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
451950|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
451951|NCT00755261|Drug|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
451952|NCT00755261|Drug|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
451953|NCT00755248|Procedure|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
451954|NCT00755235|Other|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
451955|NCT00755222|Biological|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
451956|NCT00755222|Biological|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
451957|NCT00755209|Drug|tranexamic acid|Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
451958|NCT00755196|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
451959|NCT00755196|Drug|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
451960|NCT00755183|Drug|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
451961|NCT00755183|Drug|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
451962|NCT00755170|Drug|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
451963|NCT00755170|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
451964|NCT00755157|Drug|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
451965|NCT00755157|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
451966|NCT00755144|Device|LCS Knee|Cementless total knee arthroplasty with LCS Knee
451967|NCT00755144|Device|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
451968|NCT00755131|Other|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
451969|NCT00755118|Drug|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
451970|NCT00755118|Drug|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
451971|NCT00755118|Drug|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
451972|NCT00755118|Drug|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
451973|NCT00755118|Drug|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
451974|NCT00755118|Drug|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
451975|NCT00755092|Behavioral|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
451976|NCT00755092|Behavioral|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
451977|NCT00755079|Drug|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
451978|NCT00755079|Drug|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
451979|NCT00755066|Drug|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
451980|NCT00755066|Drug|Placebo|Placebo intranasal spray
451981|NCT00755053|Drug|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
451982|NCT00755053|Drug|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
451983|NCT00755040|Drug|cyclosporine ophthalmic emulsion|Given as eye drops
451984|NCT00755040|Other|placebo|Given as eye drops
451985|NCT00755027|Drug|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
451986|NCT00755014|Other|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
451987|NCT00755001|Device|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
451988|NCT00755001|Device|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
451989|NCT00754988|Drug|Metformin|As prescribed
451990|NCT00754988|Drug|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
451991|NCT00754988|Drug|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
451992|NCT00754988|Drug|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
451993|NCT00754988|Drug|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
451994|NCT00754975|Device|JACTAX LD DES|Drug Eluting Stent
451995|NCT00754975|Device|TAXUS™ Libertè™ DES|Drug Eluting Stent
451996|NCT00754962|Drug|protriptyline|10 mg tablet
452337|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
451997|NCT00754949|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
451998|NCT00754949|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
451999|NCT00754949|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
452000|NCT00754936|Drug|Escitalopram|20 mg by mouth daily
452001|NCT00754923|Drug|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
452002|NCT00754910|Drug|porfimer sodium|Given IV
452003|NCT00754910|Procedure|bronchoscopy|Patients undergo bronchoscopy
452004|NCT00754884|Drug|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
452005|NCT00754884|Drug|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
452006|NCT00754871|Drug|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
452007|NCT00754871|Drug|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
452008|NCT00754871|Drug|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
452009|NCT00754871|Drug|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
452010|NCT00754858|Drug|belotecan hydrochloride|
452011|NCT00754858|Drug|cisplatin|
452012|NCT00754845|Drug|letrozole|Given orally
452013|NCT00754845|Other|placebo|Given orally
452014|NCT00754832|Drug|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
452015|NCT00754832|Drug|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
452016|NCT00754819|Drug|Colchicine|1mg once daily
452017|NCT00754819|Drug|Placebo|1 capsule daily
452018|NCT00754793|Drug|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
452019|NCT00754793|Drug|placebo|inactive comparator; titrated as per protocol over 12 weeks
452020|NCT00754780|Drug|Pirfenidone|Capsule 800 mg TID, oral
452021|NCT00754767|Drug|L-carnitine L-tartrate|Given orally
452022|NCT00754767|Other|placebo|Given orally
452023|NCT00754754|Procedure|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
452024|NCT00754741|Behavioral|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
452025|NCT00754741|Behavioral|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
452026|NCT00754728|Device|JACTAX DES|Drug Eluting Stent
452027|NCT00754715|Drug|AZD2516|Solution administered once orally
452028|NCT00754715|Drug|Placebo|Solution administered only once
452029|NCT00754702|Drug|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
452030|NCT00754702|Drug|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
452031|NCT00754689|Drug|Rimonabant|Tablet, oral administration
452032|NCT00754689|Drug|Metformin|Tablet, oral administration
452033|NCT00754689|Drug|placebo|Tablet, oral administration
452034|NCT00754663|Behavioral|exercise training|walking training at least 3 times a week
452035|NCT00754650|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
452036|NCT00754624|Drug|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
452037|NCT00754585|Device|Logic Back Grahl Duo Back Model DB11‐01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
452038|NCT00754572|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
452039|NCT00754572|Drug|methotrexate|10-25mg oral or parenteral weekly.
452040|NCT00754559|Drug|Tocilizumab|8mg/kg iv every 4 weeks
452041|NCT00754546|Drug|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
452042|NCT00754546|Drug|Placebo: Normal Saline|Normal saline was nebulized.
452043|NCT00754546|Other|Treadmill Exercise|
452044|NCT00754546|Other|Cycle Exercise|
452045|NCT00754533|Other|Continuous versus interval training|Influence of different exercise training programs
452046|NCT00754520|Device|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
452047|NCT00754520|Device|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
452048|NCT00754507|Drug|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
452049|NCT00754507|Drug|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
452050|NCT00754494|Drug|erlotinib hydrochloride|Given PO
452051|NCT00754494|Other|placebo|Given PO
452052|NCT00754494|Other|laboratory biomarker analysis|Correlative studies
452338|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
452053|NCT00754481|Other|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) will be maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who are hypothermic (temperature < 35 ºC) when randomized to the normothermia group will be rewarmed slowly using the servo-controlled mattress. Patients who are hyperthermic following randomization to the normothermia group will be actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers will be administered as needed intravenously in both groups of patients to prevent shivering.
452054|NCT00754481|Other|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) will be cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe will be placed in the esophagus and its position confirmed using a chest radiograph. Patients will be placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reaches 34.0ºC, the ice and second cooling blanket will be removed and esophageal temperature will be maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO will be cooled using the extracorporeal circuit cooling-device. Rewarming will be done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC is reached. Thereafter temperature will be recorded but not controlled by surface cooling.
452055|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
452056|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
452057|NCT00754455|Biological|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
452058|NCT00754455|Biological|Placebo|Placebo as a single injection of 0.5 mL.
452059|NCT00754442|Drug|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
452060|NCT00754429|Drug|losartan|losartan 50mg qd for 30 weeks.
452061|NCT00754429|Drug|amlodipine|amlodipine 5 mg q.d for 30 weeks.
452062|NCT00754403|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
452063|NCT00754403|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
452064|NCT00754390|Dietary Supplement|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
452065|NCT00754390|Dietary Supplement|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
452066|NCT00754390|Dietary Supplement|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
452067|NCT00754390|Dietary Supplement|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
452068|NCT00754377|Other|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
452069|NCT00754364|Drug|Pemetrexed/Carboplatin|"Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day."
452070|NCT00754364|Drug|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
452071|NCT00754351|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
452072|NCT00754351|Drug|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
452073|NCT00754351|Drug|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
452074|NCT00754338|Drug|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
452075|NCT00754338|Drug|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
452076|NCT00754338|Drug|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
452077|NCT00754325|Drug|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
452078|NCT00754325|Drug|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
452079|NCT00754312|Drug|SNDX-275|
452080|NCT00754286|Other|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
452081|NCT00754286|Other|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
452082|NCT00754273|Other|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
452083|NCT00754260|Behavioral|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
452084|NCT00754247|Drug|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
452085|NCT00754247|Drug|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
452086|NCT00754247|Drug|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
452087|NCT00754234|Behavioral|My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7|Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
452088|NCT00754221|Drug|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
452089|NCT00754208|Drug|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
452090|NCT00754195|Other|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
452091|NCT00754182|Device|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
452092|NCT00754182|Device|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
452093|NCT00754156|Device|ABRA Abdominal Closure System|ABRA Abdominal Closure System
452094|NCT00754156|Device|V.A.C. Therapy|V.A.C. Therapy Alone
452095|NCT00754156|Device|KCI ABThera|KCI ABThera
452096|NCT00754143|Drug|FG-3019|Placebo every 2 weeks IV for all infusions
452097|NCT00754143|Drug|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
452098|NCT00754143|Drug|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
452099|NCT00754130|Drug|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
452100|NCT00754130|Drug|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
452101|NCT00754104|Drug|ABT-869|0.25 mg/kg. daily.
452102|NCT00754104|Drug|Tarceva|150mg, daily.
452103|NCT00754091|Device|Polymer based lubricating liquid|three sprays of radiolabeled polymer blend of carboxymethylcellulose, polyoxyl 40 stearate, and polyethylene oxide that coats and protects the mucus membrane
452104|NCT00754078|Radiation|Tomotherapy|30 fractions of tomotherapy treatment
452105|NCT00754065|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
452106|NCT00754065|Drug|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
452107|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
452108|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All participants will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
452109|NCT00754052|Drug|Placebo|All participants will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
452110|NCT00754039|Drug|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
452111|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
452112|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
452113|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
452114|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
452115|NCT00754013|Drug|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.~All doses will be administered orally."
452116|NCT00754013|Drug|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.~All doses will be administered orally."
452117|NCT00754000|Other|Observation|AE monitoring and EPIC QOL survey
452118|NCT00753987|Drug|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
452119|NCT00753961|Other|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
452120|NCT00753961|Other|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
452121|NCT00753948|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
452122|NCT00753935|Drug|enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
452123|NCT00753935|Drug|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
452163|NCT00753636|Drug|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
452164|NCT00753623|Drug|Ramelteon|ramelteon (8 mg)
452165|NCT00753623|Drug|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
452166|NCT00753597|Drug|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
452124|NCT00753922|Device|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
452125|NCT00753909|Drug|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
452126|NCT00753909|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
452127|NCT00753909|Drug|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
452128|NCT00753896|Drug|exenatide|subcutaneous injection, 2.0mcg, once weekly
452129|NCT00753883|Drug|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
452130|NCT00753883|Drug|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
452131|NCT00753870|Biological|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
452132|NCT00753857|Other|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
452133|NCT00753857|Other|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
452134|NCT00753844|Biological|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
452135|NCT00753831|Procedure|Aurosling|Silicon rod to be used in frontalis suspension surgery
452136|NCT00753818|Other|DHA and ARA|various levels of DHA and ARA
452137|NCT00753818|Other|Control|
452138|NCT00753805|Dietary Supplement|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
452139|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
452140|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
452141|NCT00753792|Drug|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
452142|NCT00753779|Drug|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
452143|NCT00753779|Drug|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
452144|NCT00753766|Other|Multifactorial Intervention|
452145|NCT00753740|Drug|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
452146|NCT00753740|Drug|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
452147|NCT00753740|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
452148|NCT00753727|Drug|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
452149|NCT00753727|Radiation|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
452150|NCT00753714|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452151|NCT00753714|Drug|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452152|NCT00753714|Drug|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452153|NCT00753688|Drug|PAZOPANIB|800 mg once daily orally
452154|NCT00753688|Drug|Placebo|matching placebo 800 mg once daily orally
452155|NCT00753675|Drug|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452156|NCT00753675|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452157|NCT00753675|Drug|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452158|NCT00753675|Drug|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452159|NCT00753662|Device|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
452160|NCT00753662|Device|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
452161|NCT00753662|Device|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
452162|NCT00753649|Biological|Infanrix™ hexa|Intramuscular, three doses
452167|NCT00753571|Drug|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd*9months Arms: 1 Drug: blank capsules 6 capsules po Qd*9months~Arms: 2"
452168|NCT00753558|Drug|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel.~Arm #2: Oral placebo solutions, placebo buccal gel."
452169|NCT00753545|Drug|AZD2281|Oral 400mg bid
452170|NCT00753545|Drug|matching placebo|matching placebo bid
452171|NCT00753532|Dietary Supplement|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort received either 200 mg softgels of Palm Vitamin E (tocotrienols) or placebo taken orally twice a day.
452172|NCT00753519|Device|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
452173|NCT00753519|Device|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
452174|NCT00753506|Dietary Supplement|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
452175|NCT00753506|Dietary Supplement|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
452176|NCT00753493|Drug|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
452177|NCT00753480|Drug|D4064A|
452178|NCT00753467|Drug|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
452179|NCT00753467|Drug|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
452180|NCT00753467|Drug|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
452181|NCT00753454|Drug|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 & Week 4, followed by 200 mg every 2 weeks).
452182|NCT00753441|Procedure|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
452183|NCT00753441|Procedure|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
452184|NCT00753428|Other|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.~Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
452185|NCT00753415|Biological|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10^9 vector genomes/mL) or a HD (1 x 10^11 vector genomes/mL).
452186|NCT00753415|Biological|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
452187|NCT00753402|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
452188|NCT00753402|Biological|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes/Epinephrine 30mcg/kg/min
452189|NCT00753389|Other|None (anesthesia)|anesthesia
452190|NCT00753363|Other|Weight Loss|6 months of weight loss
452191|NCT00753363|Other|Aerobic Exercise Training|6 months of aerobic exercise training
452192|NCT00753350|Device|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
452193|NCT00753337|Device|Assurant® Cobalt Iliac Stent System|Iliac Stenting
452194|NCT00753324|Drug|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
452195|NCT00753311|Drug|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
452196|NCT00753298|Device|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
452197|NCT00753298|Device|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
452198|NCT00753285|Device|Renal Denervation|
452199|NCT00753272|Biological|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
452200|NCT00753272|Biological|Fluarix TM|IM administration, two times one annual dose
452201|NCT00753259|Other|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
452202|NCT00753259|Other|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
452203|NCT00753246|Drug|nimotuzumab|monoclonal antibody
452204|NCT00753220|Biological|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8 cells"
452205|NCT00753220|Drug|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
452206|NCT00753207|Drug|epirubicin hydrochloride|
452207|NCT00753207|Drug|lapatinib ditosylate|
452214|NCT00753181|Other|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
452215|NCT00753168|Drug|OT-730 ophthalmic solution|one eye drop twice daily
452216|NCT00753168|Drug|timolol maleate ophthalmic solution|one eye drop twice daily
452217|NCT00753168|Drug|OT-730 placebo|one eye drop twice daily
452218|NCT00753155|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
452219|NCT00753142|Drug|Intralipid 20%|Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
452220|NCT00753142|Drug|Glucose infusion|Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m^2/min for 20 hours.
452221|NCT00753129|Procedure|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
452222|NCT00753116|Device|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
452223|NCT00753103|Biological|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
452224|NCT00753103|Drug|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
452225|NCT00753103|Drug|Prednisolone|Daily oral 1mg/kg tapered over 12 months
452226|NCT00753103|Drug|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
452227|NCT00753103|Procedure|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine > 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
452228|NCT00753103|Drug|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
452229|NCT00753103|Drug|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
452230|NCT00753090|Device|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
452231|NCT00753090|Device|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
452232|NCT00753064|Drug|Antiscorpion venom serum(AScVS).|"AScVS therapy group~If the score is 5 and if the patient belongs to pediatric group(>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.~According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:~Vials of AScVS Composite score Child Adult 5-10 2 4 > 10-15 3 6 >15- 21 4 8"
452233|NCT00753064|Drug|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
452234|NCT00753064|Drug|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
452235|NCT00753051|Drug|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
452236|NCT00753051|Drug|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
452237|NCT00753038|Biological|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
452238|NCT00753038|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
452239|NCT00753038|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
452240|NCT00753025|Procedure|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.~Arm TNC receives injection of total nucleated cells into ischemic muscle"
452241|NCT00753025|Procedure|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
452242|NCT00753025|Procedure|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
452243|NCT00753012|Drug|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
452244|NCT00752999|Drug|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
452245|NCT00752999|Drug|Placebo|Placebo tablet, oral, twice-a-day
452246|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452247|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452248|NCT00752986|Drug|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
452249|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
452250|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
452251|NCT00752973|Drug|MALG (malathion) Treatment|MALG applied for 30 minutes
452252|NCT00752947|Drug|moxifloxacin|Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
452253|NCT00752947|Drug|levofloxacin|Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
452254|NCT00752947|Drug|metronidazole|metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
452339|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
452255|NCT00752934|Drug|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.~For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.~For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.~Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
452256|NCT00752934|Drug|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
452257|NCT00752921|Drug|etoricoxib|120 mg
452258|NCT00752921|Drug|placebo|placebo
452259|NCT00752895|Dietary Supplement|American ginseng|Given orally
452260|NCT00752895|Dietary Supplement|Placebo|Given orally
452261|NCT00752882|Drug|ceftazidime|
452262|NCT00752869|Drug|dutasteride|0.5mg by mouth one time per day for 1 year
452263|NCT00752869|Drug|placebo|one tablet per day for 1 year
452264|NCT00752856|Drug|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
452265|NCT00752856|Drug|Atripla|Atripla 1 tab once a day
452266|NCT00752843|Drug|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
452267|NCT00752830|Drug|AZD0328|Oral capsule, single dose
452268|NCT00752817|Other|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
452269|NCT00752817|Other|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
452270|NCT00752804|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
452271|NCT00752804|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
452272|NCT00752804|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
452273|NCT00752791|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
452274|NCT00752778|Other|pet-scan FDG-F18|
452275|NCT00752739|Dietary Supplement|selenium|Given orally
452276|NCT00752739|Other|placebo|Given orally
452277|NCT00752726|Drug|Orlistat|Weight loss treatment
452278|NCT00752726|Drug|Placebo|Inactive
452279|NCT00752713|Procedure|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
452280|NCT00752700|Other|Conventional resistance training|Conventional resistance training program (CRT)
452281|NCT00752700|Other|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
452282|NCT00752687|Drug|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
452283|NCT00752687|Drug|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
452284|NCT00752674|Other|Neuromuscular balance|
452285|NCT00752661|Drug|Tramadol Hydrochloride; JNS013|
452286|NCT00752648|Drug|TMC435350|
452287|NCT00752635|Drug|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
452288|NCT00752622|Biological|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
452289|NCT00752622|Biological|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
452290|NCT00752622|Biological|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
452291|NCT00752609|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
452292|NCT00752596|Drug|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
452293|NCT00752583|Procedure|Peritoneal dialysis|Blood, urine and dialysate sampling
452294|NCT00752583|Procedure|Haemodialysis|Blood, urine and dialysate sampling
452295|NCT00752570|Drug|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
452296|NCT00752570|Drug|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
452297|NCT00752570|Drug|FOLFIRI|"Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.~FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.~FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest."
452298|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
452299|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
452300|NCT00752557|Drug|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
452301|NCT00752544|Drug|TMC435350|
452302|NCT00752531|Behavioral|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
452303|NCT00752518|Drug|bortezomib|
452304|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
452305|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
452306|NCT00752492|Other|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
452307|NCT00752479|Biological|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy~Mesenchymal cells infusion.~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
452308|NCT00752479|Drug|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy~Induction therapy:~Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).~Maintenance therapy:~Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
452309|NCT00752466|Drug|Topiramate; flunarizine|
452310|NCT00752453|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
452311|NCT00752453|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
452312|NCT00752453|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
452313|NCT00752440|Other|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
452314|NCT00752427|Drug|Paliperidone ER OROS®|
452315|NCT00752414|Drug|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
452316|NCT00752414|Drug|Placebo|same frequency as MP-376
452317|NCT00752401|Drug|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels >2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
452318|NCT00752401|Drug|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
452319|NCT00752375|Drug|Trimethoprim Sulfamethoxazole|"Children >3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.~Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.~Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
452320|NCT00752375|Drug|placebo|"Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age~Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age~Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
452321|NCT00752362|Device|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
452322|NCT00752362|Device|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
452323|NCT00752362|Device|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
452324|NCT00752349|Procedure|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
452325|NCT00752336|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
452326|NCT00752323|Drug|aminolevulinic acid|Given orally
452327|NCT00752310|Drug|Darunavir|
452328|NCT00752297|Drug|Preservative-free Saline|Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
452329|NCT00752297|Drug|Mentor Purified Toxin|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
452330|NCT00752284|Procedure|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
452331|NCT00752284|Procedure|Total Excision|Total excision of lower third molar
452332|NCT00752258|Drug|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
452333|NCT00752245|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
452334|NCT00752245|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
452335|NCT00752245|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
452336|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
452341|NCT00752219|Drug|ceftazidime/NXL104 + metronidazole|IV TID
452342|NCT00752219|Drug|meropenem|IV TID
452343|NCT00752206|Drug|Saracatinib|Oral Agent
452344|NCT00752206|Drug|Placebo|Oral Agent
452345|NCT00752193|Other|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
452346|NCT00752193|Other|Placebo|Placebo in combination with antibiotic therapy
452347|NCT00752180|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
452348|NCT00752180|Biological|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
452349|NCT00752154|Drug|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
452350|NCT00752141|Drug|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
452351|NCT00752141|Drug|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
452352|NCT00752141|Other|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
452353|NCT00752128|Device|Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation
452354|NCT00752115|Drug|sildenafil|50mg, day1,8 and 15 in each cycle
452355|NCT00752115|Drug|placebo|1 tab, day 1,8 and 15 in each cycle.
452356|NCT00752115|Drug|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
452357|NCT00752115|Drug|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
452358|NCT00752102|Drug|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
452359|NCT00752102|Drug|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
452360|NCT00752089|Drug|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
452361|NCT00752089|Drug|NaF/KNO3 Dentifrice|Experimental toothpaste
452362|NCT00752089|Drug|NaF Dentifrice|Active comparator
452363|NCT00752089|Other|Placebo Dentifrice|Placebo comparator
452364|NCT00752076|Other|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
452365|NCT00752063|Drug|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
452366|NCT00752050|Drug|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
452367|NCT00752050|Drug|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
452368|NCT00752037|Drug|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
452369|NCT00752024|Device|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
452370|NCT00752024|Drug|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
452371|NCT00752011|Drug|TAS-106|Starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
452372|NCT00752011|Drug|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
452373|NCT00751998|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
452374|NCT00751985|Other|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
452375|NCT00751985|Other|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.~The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.~Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
452376|NCT00751985|Other|Control|The participant is being informed about their allocation to the control group.
452377|NCT00751972|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
452378|NCT00751959|Drug|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
452379|NCT00751959|Drug|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
452380|NCT00751946|Behavioral|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.~TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis & Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
452381|NCT00751946|Behavioral|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, & Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
452382|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.~One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
452383|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
452384|NCT00751933|Dietary Supplement|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
452385|NCT00751933|Other|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
452386|NCT00751920|Procedure|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
452387|NCT00751907|Drug|atorvastatin|40mg daily for 4 months
452388|NCT00751907|Drug|Placebo|Matching placebo daily for 4 months
452389|NCT00751894|Drug|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
452390|NCT00751881|Drug|Placebo|"Film-coated tablet~Oral administration"
452391|NCT00751881|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
452392|NCT00751868|Drug|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
452393|NCT00751855|Behavioral|Prolonged Exposure therapy|10 weekly sessions
452394|NCT00751855|Drug|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
452395|NCT00751855|Drug|placebo|placebo
452396|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
452397|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
452398|NCT00751842|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
452399|NCT00751829|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
452400|NCT00751829|Drug|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
452401|NCT00751816|Drug|systemic chemotherapy|Not specified
452402|NCT00751816|Other|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
452403|NCT00751816|Procedure|adjuvant therapy|not specified
452404|NCT00751816|Procedure|management of therapy complications|not specified
452405|NCT00751816|Procedure|musculoskeletal complications management/prevention|Not specified
452406|NCT00751816|Procedure|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
452407|NCT00751816|Radiation|radiation therapy|not specified
452408|NCT00751803|Drug|BI 44370 TA Low Dose|
452409|NCT00751803|Drug|Eletriptan|
452410|NCT00751803|Drug|Placebo|
452411|NCT00751803|Drug|BI 44370 TA Medium Dose|
452412|NCT00751790|Drug|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
452413|NCT00751777|Biological|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
452414|NCT00751777|Biological|Placebo|Travelers' Diarrhea Vaccine System
452415|NCT00751764|Drug|Moxidectin|
452416|NCT00751751|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
452417|NCT00751751|Drug|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
452418|NCT00751738|Drug|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
452419|NCT00751712|Device|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
452420|NCT00751699|Drug|Asacol|Asacol tablets, 6 tablets per day at 7 am for 7 days
452421|NCT00751699|Drug|Asacol|Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
452422|NCT00751699|Drug|Lialda|Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
452423|NCT00751686|Procedure|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
452424|NCT00751686|Other|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
452425|NCT00751660|Other|laboratory biomarker analysis|
452426|NCT00751660|Other|screening questionnaire administration|
452427|NCT00751660|Procedure|bronchoscopic and lung imaging studies|
452428|NCT00751660|Procedure|computed tomography|
452429|NCT00751660|Procedure|endoscopic biopsy|
452430|NCT00751660|Procedure|quality-of-life assessment|
452431|NCT00751647|Other|Physical Therapy|Treatment
452432|NCT00751634|Device|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
452433|NCT00751621|Biological|IgPro20|
452434|NCT00751608|Drug|APL180|
452435|NCT00751608|Drug|APL180|
452436|NCT00751608|Drug|Placebo|
452437|NCT00751595|Biological|Tat protein|Biologically active recombinant Tat protein
452438|NCT00751582|Dietary Supplement|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
452439|NCT00751582|Behavioral|Nutrition education|Nutrition education for children for three months
452440|NCT00751582|Other|Control Group|No Nutrition Education
452441|NCT00751569|Other|blood donation|obtaining cord blood
452442|NCT00751556|Drug|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
452443|NCT00751556|Drug|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
452444|NCT00751543|Radiation|CT, radiation therapy|Computed tomography (CT) is the mainstay for evaluating lung cancer. The advance of multi-row detector CT (MDCT) provides volumetric acquisition within a breath hold, and enables detailed evaluation of tissue and organ perfusion with excellent resolution
452445|NCT00751530|Drug|raltegravir|New combination ART incorporating raltegravir with other ARVs.
452446|NCT00751517|Drug|Methotrexate|
452447|NCT00751517|Drug|Cyclophosphamide|
452448|NCT00751504|Drug|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
452449|NCT00751491|Drug|Adenosin|Intracoronary Adenosin 50 microg;
452450|NCT00751491|Other|placebo|no intervention
452451|NCT00751491|Drug|Clopidogrel|Clopidogrel 300/600 mg
452452|NCT00751478|Drug|ALO-01|ALO-01 capsules
452453|NCT00751478|Drug|MSIR|immediate release morphine sulfate
452454|NCT00751478|Drug|Placebo|Placebo
452455|NCT00751465|Behavioral|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
452456|NCT00751465|Behavioral|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
452457|NCT00751413|Drug|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
452458|NCT00751400|Drug|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
452459|NCT00751374|Drug|gentamicin|topical gentamicin cream on daily basis
452460|NCT00751374|Drug|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
452461|NCT00751361|Device|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
452462|NCT00751348|Biological|PriorixTM|Subcutaneous administration in left upper arm
452463|NCT00751348|Biological|VarilrixTM|Subcutaneous administration in right upper arm
452464|NCT00751348|Biological|Priorix-Tetra®|Subcutaneous injection in left upper arm
452465|NCT00751335|Device|Heated breathing tube (CPAP with ThermoSmart)|heated humidification with a heated breathing tube.
452466|NCT00751335|Device|Non heated breathing tube (CPAP with conventional humidification)|Heated humidification without a heated breathing tube
452467|NCT00751322|Other|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
452468|NCT00751322|Other|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
452469|NCT00751309|Other|Non-interventional|Post-transplantation observational study
452470|NCT00751296|Drug|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
452471|NCT00751283|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
452472|NCT00751270|Biological|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
452580|NCT00750386|Drug|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
452473|NCT00751270|Drug|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
452474|NCT00751257|Drug|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
452475|NCT00751257|Drug|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
452476|NCT00751244|Behavioral|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
452477|NCT00751244|Behavioral|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
452478|NCT00751244|Other|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
452479|NCT00751231|Drug|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
452480|NCT00751231|Drug|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
452481|NCT00751218|Drug|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
452482|NCT00751218|Drug|placebo|placebo, once daily for 28 days
452483|NCT00751218|Drug|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
452484|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
452485|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
452486|NCT00751192|Device|HIV-testing motivational videos|
452487|NCT00751192|Device|Standard public health text|
452488|NCT00751179|Drug|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
452489|NCT00751179|Drug|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
452490|NCT00751179|Drug|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
452491|NCT00751166|Drug|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
452492|NCT00751166|Drug|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
452493|NCT00751166|Drug|placebo|placebo once daily for 28 days
452494|NCT00751153|Drug|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
452495|NCT00751140|Procedure|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
452496|NCT00751127|Drug|PhXA41|One drop in the affected eye once daily for six months.
452497|NCT00751127|Drug|timolol|One drop in the affected eye twice daily for six months.
452498|NCT00751114|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
452499|NCT00751114|Drug|Sitagliptin|Oral administration. 100 mg film-coated tablets.
452500|NCT00751114|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
452501|NCT00751101|Drug|nicotine|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
452502|NCT00751088|Procedure|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
452535|NCT00750815|Drug|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
452536|NCT00750815|Drug|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
452537|NCT00750802|Drug|AZD6280|10mg Capsule, oral, single-dose
452538|NCT00750802|Drug|AZD6280|40mg Capsule, oral, single-dose
452539|NCT00750802|Drug|Lorazepam|2mg tablet, oral single-dose
452503|NCT00751088|Procedure|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
452504|NCT00751088|Procedure|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
452505|NCT00751088|Procedure|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
452506|NCT00751075|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
452507|NCT00751075|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
452508|NCT00751075|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
452509|NCT00751075|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
452510|NCT00751062|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
452511|NCT00751062|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
452512|NCT00751049|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
452513|NCT00751049|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
452514|NCT00751036|Drug|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
452515|NCT00751036|Drug|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
452516|NCT00751023|Drug|Modafinil|400 mg daily for four weeks
452517|NCT00751023|Drug|Placebo|Placebo 2 tablets daily for 4 weeks
452518|NCT00750997|Drug|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
452519|NCT00750984|Procedure|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
452520|NCT00750984|Procedure|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
452521|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
452522|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
452523|NCT00750971|Procedure|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
452524|NCT00750958|Procedure|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
452525|NCT00750945|Other|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
452526|NCT00750945|Other|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
452527|NCT00750945|Other|Home program|Home walking program 6 days/wk x 4 weeks
452528|NCT00750919|Drug|esmirtazapine|
452529|NCT00750893|Biological|Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe)|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine.
452530|NCT00750880|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
452531|NCT00750867|Drug|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
452532|NCT00750854|Dietary Supplement|NEM Formulation X|see Treatment Arms
452533|NCT00750854|Dietary Supplement|NEM Formulation Y|see Treatment Arms
452534|NCT00750841|Drug|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
452540|NCT00750802|Drug|Placebo|
452926|NCT00747565|Device|CeeOn 911A monofocal IOL|Monofocal Control IOL
452541|NCT00750789|Dietary Supplement|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
452542|NCT00750763|Drug|Colonlytely|Bowel preparation
452543|NCT00750763|Drug|Picolax/Picoprep|Bowel preparation
452544|NCT00750763|Drug|Fleet|Bowel preparation
452545|NCT00750750|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
452546|NCT00750750|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
452547|NCT00750750|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
452548|NCT00750750|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
452549|NCT00750737|Drug|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
452550|NCT00750737|Drug|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
452551|NCT00750724|Drug|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
452552|NCT00750724|Drug|normal saline,2 ml., intraarticular weekly for 5 weeks|
452553|NCT00750711|Procedure|Radiofrequency ablation for atrial flutter by catheters|
452554|NCT00750698|Drug|SNDX-275|SNDX-275 (10 mg fixed dose PO Q2W) on days 1 and 15 of a 28-day cycle for up to 6 cycles
452555|NCT00750698|Drug|erlotinib|erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
452556|NCT00750685|Device|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
452557|NCT00750659|Drug|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
452558|NCT00750646|Device|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
452559|NCT00750633|Drug|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
452560|NCT00750633|Drug|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
452561|NCT00750633|Drug|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
452562|NCT00750633|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
452563|NCT00750620|Drug|YM178|oral
452564|NCT00750581|Drug|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
452565|NCT00750555|Drug|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
452566|NCT00750529|Drug|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
452567|NCT00750503|Behavioral|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
452568|NCT00750477|Dietary Supplement|NEM|see Treatment Arms
452569|NCT00750477|Dietary Supplement|Placebo|Placebo comparator containing inactives
452570|NCT00750451|Drug|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
452571|NCT00750451|Drug|crinone 8% gel|routine luteal phase support with progesterone gel
452572|NCT00750438|Dietary Supplement|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
452573|NCT00750438|Dietary Supplement|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
452574|NCT00750438|Dietary Supplement|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
452575|NCT00750425|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
452576|NCT00750412|Behavioral|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
452577|NCT00750399|Drug|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
452578|NCT00750399|Drug|ranibizumab|intravitreal ranibizumab 0.5 mg
452579|NCT00750386|Drug|Paclitaxel|175 mg/m2, I.V, every 2 weeks
452581|NCT00750373|Procedure|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
452582|NCT00750360|Biological|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
452583|NCT00750347|Drug|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
452584|NCT00750334|Drug|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
452585|NCT00750334|Drug|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
452586|NCT00750308|Drug|Ramipril|Ramipril 10 mg per day for three weeks
452587|NCT00750308|Drug|Tadalafil|tadalafil 10 mg every other day for three weeks
452588|NCT00750308|Drug|placebo|placebo matching ramipril
452589|NCT00750308|Drug|placebo|placebo matching tadalafil
452590|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
452591|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
452592|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
452593|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
452594|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
452595|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
452596|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
452597|NCT00750282|Drug|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
452598|NCT00750269|Radiation|SBRT 40.0 Gy|SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
452599|NCT00750269|Radiation|SBRT 42.5 Gy|SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
452600|NCT00750269|Radiation|SBRT 45.0 Gy|SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
452601|NCT00750269|Radiation|SBRT 47.5 Gy|SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
452602|NCT00750269|Radiation|SBRT 50.0 Gy|SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
452603|NCT00750269|Radiation|SBRT 52.5 Gy|SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
452604|NCT00750269|Radiation|SBRT 55.0 Gy|SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
452605|NCT00750269|Radiation|SBRT 57.5 Gy|SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
452606|NCT00750269|Radiation|SBRT 60.0 Gy|SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
452607|NCT00750256|Drug|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
452608|NCT00750243|Drug|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
452609|NCT00750243|Drug|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
452610|NCT00750230|Dietary Supplement|NEM|see Treatment Arm
452611|NCT00750217|Drug|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.~Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
452612|NCT00750204|Device|APRV|"APRV Protocol~Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used~Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).~Respiratory rate (RR) to equal 60-65% of RR on conventional MV.~P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.~Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).~If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
452613|NCT00750204|Device|Conventional MV|Low tidal-volume mechanical ventilation
452614|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
452615|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
452616|NCT00750178|Drug|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days"
452617|NCT00750165|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
452618|NCT00750152|Drug|NAFT-500|topical cream application up to 4 weeks
452619|NCT00750152|Drug|Placebo|placebo cream applied for up to 4 weeks
452620|NCT00750139|Drug|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
452621|NCT00750139|Drug|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
452622|NCT00750139|Drug|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
452623|NCT00750139|Drug|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
452664|NCT00749788|Drug|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
452624|NCT00750126|Drug|Fludarabine, Busulfan, Thymoglobulin|"study :~acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation~the effectiveness of the protocol on tumor response~overall survival"
452625|NCT00750113|Drug|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
452626|NCT00750113|Drug|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
452627|NCT00750113|Drug|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
452628|NCT00750100|Drug|human chorionic gonadotropin|hCG 200IU in the late follicular phase
452629|NCT00750100|Drug|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
452630|NCT00750061|Drug|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.~The course of medication is 6 weeks."
452631|NCT00750061|Drug|Placebo|Matching placebo
452632|NCT00750048|Drug|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
452633|NCT00750035|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
452634|NCT00750035|Procedure|Subtotal abdominal hysterectomy|
452635|NCT00750022|Behavioral|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
452636|NCT00750022|Behavioral|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
452637|NCT00750009|Other|educational intervention|Patients receive a tailored intervention or generic information
452638|NCT00749996|Device|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
452639|NCT00749996|Procedure|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
452640|NCT00749983|Dietary Supplement|Creatine supplementation|
452641|NCT00749983|Dietary Supplement|Dextrose supplementation|
452642|NCT00749957|Biological|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
452643|NCT00749944|Drug|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
452644|NCT00749944|Drug|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
452645|NCT00749931|Device|MarginProbe|Device use to assess margin status of the excised specimen surface.
452646|NCT00749931|Procedure|Lumpectomy|Standard of care lumpectomy procedure
452647|NCT00749918|Dietary Supplement|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
452648|NCT00749905|Other|low fiber diet|Low fiber diet for 5 days prior to colon capsule
452649|NCT00749905|Other|regular diet|Regular diet until 1 day before colon capsule
452650|NCT00749892|Drug|Erlotinib Hydrochloride|Given PO
452651|NCT00749879|Drug|Proellex|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
452652|NCT00749866|Drug|Gentamicin|Nebulised 80mg twice daily
452653|NCT00749866|Drug|Saline|Nebulised 4mls 0.9% Saline twice daily
452654|NCT00749853|Drug|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
452655|NCT00749853|Drug|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
452656|NCT00749840|Behavioral|Questionnaire|Questionnaire taking 60-90 minutes.
452657|NCT00749827|Drug|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
452658|NCT00749827|Drug|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
452659|NCT00749814|Dietary Supplement|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
452660|NCT00749814|Other|Placebo tablets|Placebo
452661|NCT00749801|Drug|Nattokinase|2 capsules in the morning and before bed-time daily
452662|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
452663|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
453017|NCT00746811|Drug|Placebo|4 grams/day - 4 one gram capsules
452665|NCT00749775|Drug|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
452666|NCT00749749|Drug|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
452667|NCT00749749|Drug|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
452668|NCT00749736|Dietary Supplement|cholecalciferol|"4000 IU of cholecalciferol per day~15 patients will be enrolled in each arm."
452669|NCT00749736|Dietary Supplement|doxercalciferol|1 mcg of doxercalciferol per day
452670|NCT00749736|Dietary Supplement|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.~15 patients will be enrolled in each arm."
452671|NCT00749723|Drug|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
452672|NCT00749723|Drug|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
452673|NCT00749723|Drug|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
452674|NCT00749723|Drug|thiotepa, carboplatin, etoposide|high dose chemotherapy followed by to autologous stem cell transplantation
452675|NCT00749723|Drug|temozolomide, thiotepa|high dose chemotherapy followed by autologous stem cell transplantation
452676|NCT00749723|Procedure|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
452677|NCT00749723|Drug|intraventricular etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (>3m to <3y 0.7 mg; >3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
452678|NCT00749723|Drug|trofosfamide, etoposide|maintenance therapy: trofosfamide and etoposide: 100 mg/m²/d and 25 mg/m²/d, respectively, for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
452679|NCT00749710|Procedure|clopidogrel|ORIF - surgical treatment
452680|NCT00749710|Procedure|no antiaggregant therapy|ORIF - surgical treatment
452681|NCT00749697|Other|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
452682|NCT00749684|Biological|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
452683|NCT00749671|Device|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
452684|NCT00749671|Other|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
452685|NCT00749658|Drug|Bupropion SR|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
452686|NCT00749658|Drug|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
452687|NCT00749645|Drug|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
452688|NCT00749645|Drug|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
452689|NCT00749632|Drug|oxybutynin|low dose oxybutynin administered daily
452690|NCT00749632|Drug|oxybutynin|middle dose oxybutynin administered daily
452691|NCT00749632|Drug|oxybutynin|high dose oxybutynin administered daily
452692|NCT00749619|Other|Catheter Lock Solution Taurolidine and Citrate|
452693|NCT00749619|Other|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
452694|NCT00749619|Other|Catheter Lock Solution : Heparin|
452695|NCT00749606|Behavioral|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
452696|NCT00749606|Behavioral|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
452697|NCT00749580|Drug|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA <75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
452698|NCT00749567|Drug|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
452699|NCT00749567|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
452700|NCT00749554|Device|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
452701|NCT00749554|Device|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
452702|NCT00749515|Drug|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.
452703|NCT00749515|Drug|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
452704|NCT00749515|Radiation|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
452705|NCT00749502|Drug|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
452706|NCT00749489|Procedure|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
452707|NCT00749476|Biological|Factor IX recovery|
452708|NCT00749463|Drug|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
452709|NCT00749463|Drug|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
452710|NCT00749450|Drug|capecitabine|Given orally
452711|NCT00749450|Drug|fluorouracil|Given IV
452712|NCT00749450|Drug|oxaliplatin|Given IV
452713|NCT00749437|Radiation|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
452714|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
452715|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
452716|NCT00749411|Drug|Placebo|matching placebo
452717|NCT00749411|Drug|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
452718|NCT00749398|Biological|Infliximab|According to local country regulations.
452719|NCT00749385|Drug|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
452720|NCT00749385|Drug|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
452721|NCT00749385|Drug|EC naproxen|Enteric-coated naproxen tablet (500mg)
452722|NCT00749385|Drug|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
452723|NCT00749372|Other|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
452724|NCT00749359|Drug|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
452725|NCT00749346|Device|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
452726|NCT00749333|Drug|AZD8566|solution. Specific dose will be selected by the safety review committee
452727|NCT00749333|Drug|Placebo|Single 10ml oral solution.
452728|NCT00749320|Other|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
452729|NCT00749307|Dietary Supplement|Docosahexaenoic acid (DHA)|
452730|NCT00749307|Dietary Supplement|Placebo|
452731|NCT00749268|Device|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
452732|NCT00749268|Device|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
452733|NCT00749242|Other|orthopedic brace|antalgic drugs and orthopedic brace
452734|NCT00749242|Device|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
452735|NCT00749229|Device|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
452736|NCT00749216|Drug|Solanezumab|
452737|NCT00749203|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
452738|NCT00749203|Drug|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
452739|NCT00749190|Drug|BI 10773|
452740|NCT00749190|Drug|placebo|
452741|NCT00749190|Drug|sitagliptin|
452742|NCT00749177|Other|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
452743|NCT00749164|Procedure|MSC transplantation|1-2X10^6 MSC per kg
452744|NCT00749151|Behavioral|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
452745|NCT00749138|Drug|tamoxifen|giving drug tamoxifen
452746|NCT00749125|Drug|Lexapro|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
452747|NCT00749112|Drug|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
452748|NCT00749099|Drug|pancrelipase|"The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
452749|NCT00749099|Drug|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
453441|NCT00743366|Drug|Placebo oral capsule|
452750|NCT00749086|Device|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
452751|NCT00749086|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
452752|NCT00749073|Device|Minimally Invasive Lumbar Decompression (MILD™)|The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
452753|NCT00749060|Other|conventional treatment|with our without brace
452754|NCT00749060|Procedure|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
452755|NCT00749060|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
452756|NCT00749047|Drug|Pioglitazone|15-45 mg/day
452757|NCT00749034|Biological|VPM1002|live vaccine
452758|NCT00749034|Biological|BCG|commercially available live vaccine BCG
452759|NCT00749021|Drug|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
452760|NCT00749021|Drug|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
452761|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
452762|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
452763|NCT00748982|Drug|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
452764|NCT00748982|Drug|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
452765|NCT00748969|Drug|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
452766|NCT00748956|Drug|Low dose NPY|50nmol, administered intranasally
452767|NCT00748956|Drug|High dose NPY|100nmol administered intranasally
452768|NCT00748956|Drug|Placebo|placebo comparator (0nmol)) administered intranasally
452769|NCT00748943|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
452770|NCT00748930|Other|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
452771|NCT00748904|Drug|Rifaximin|400 mg orally
452772|NCT00748904|Drug|Lactulose|20 grams titrate to 2-3 bowel movements in one day
452773|NCT00748891|Drug|Recentin (Cediranib)|30mg once daily, oral dose
452774|NCT00748865|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
452775|NCT00748865|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
452776|NCT00748852|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
452777|NCT00748826|Biological|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of~Infliximab therapy with additional infusions of 5 mg/kg at week 2"
452778|NCT00748813|Biological|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
452779|NCT00748800|Behavioral|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
452780|NCT00748800|Behavioral|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
452781|NCT00748787|Drug|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
452782|NCT00748787|Drug|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
452783|NCT00748774|Behavioral|Questionnaire|Two questionnaires taking about 10 minutes to complete.
452784|NCT00748761|Behavioral|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
452785|NCT00748761|Behavioral|Waitlist|Contact waitlist weekly for 12 weeks
452786|NCT00748748|Biological|Culturelle|10^10 Lactobacillus rhamnosus GG per capsule
452787|NCT00748735|Procedure|Implantation of a cardiac resynchronization therapy device|
452788|NCT00748735|Procedure|Echocardiography (myocardial deformation imaging)|
452789|NCT00748722|Device|CT Angiography|Injection of contrast material (iodine)
452790|NCT00748709|Drug|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
452791|NCT00748696|Dietary Supplement|Fortimel Extra®|260kcal and 20g protein per day
452792|NCT00748696|Other|resistance training|3 sessions of resistance training per week
452793|NCT00748696|Other|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
452794|NCT00748683|Other|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
453965|NCT00739791|Procedure|therapeutic dietary intervention|
452795|NCT00748670|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
452796|NCT00748657|Biological|Bevacizumab|Given IV
452797|NCT00748657|Other|Laboratory Biomarker Analysis|Correlative studies
452798|NCT00748644|Drug|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
452799|NCT00748644|Drug|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.~All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
452800|NCT00748631|Device|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
452801|NCT00748618|Dietary Supplement|vitamin D3|10,000 I.U./wk of vitamin D3 orally for 6 months
452802|NCT00748618|Dietary Supplement|vitamin D3|50,000 I.U./wk of vitamin D3 orally for 6 months
452803|NCT00748605|Drug|S-2367 Placebo|Four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet for 6 weeks) and RCD (reduced calorie diet for 54 weeks) for a total of 60 weeks
452804|NCT00748605|Drug|S-2367 1600 mg q.d. 54 Weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD for a total of 54 weeks
452805|NCT00748605|Drug|S-2367 1600 mg q.d. 60 weeks|Four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD for a total of 60 weeks
452806|NCT00748605|Other|LCD (low calorie diet)|A low calorie diet was utilized during the first 6 weeks of the study
452807|NCT00748605|Other|RCD (reduced calorie diet)|A reduced calorie diet was used during the last 54 weeks for the study
452808|NCT00748592|Drug|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
452809|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
452810|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
452811|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
452812|NCT00748579|Drug|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
452813|NCT00748579|Drug|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
452814|NCT00748566|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
452815|NCT00748553|Drug|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
452816|NCT00748553|Drug|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
452817|NCT00748540|Device|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
452818|NCT00748527|Drug|carboplatin|Given IV
452819|NCT00748527|Drug|decitabine|Given IV
452820|NCT00748501|Drug|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
452821|NCT00748488|Other|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.~Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
452822|NCT00748488|Other|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
452823|NCT00748475|Behavioral|Neurofeedback|
452824|NCT00748462|Device|Fractional CO2 Laser|"the treatment settings:~Pulse duration : 5 to 7ms depending on skin reaction~Spot Density: 49 MTZ/cm2 (Low density)~Power: 15 W = (75 - 105) mJ/MTZ"
452825|NCT00748449|Procedure|Colonoscopy|1 Colonoscopy
452826|NCT00748449|Procedure|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
452827|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
452828|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
452829|NCT00748436|Drug|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
452830|NCT00748423|Drug|Nitric Oxide|NO in inhalation for 3 days
452831|NCT00748423|Drug|Placebo|Placebo in inhalation for 3 days
452832|NCT00748410|Drug|SB-656933|7 days repeat dose
452833|NCT00748397|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
452834|NCT00748371|Drug|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
452835|NCT00748371|Drug|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
452836|NCT00748371|Drug|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
452837|NCT00748358|Drug|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
452884|NCT00748059|Procedure|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
452838|NCT00748345|Drug|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
452839|NCT00748332|Dietary Supplement|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
452840|NCT00748332|Dietary Supplement|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
452841|NCT00748319|Other|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
452842|NCT00748306|Drug|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
452843|NCT00748306|Drug|Placebo|Matching Intervention Drug
452844|NCT00748293|Other|Low-residue diet|Commercialized (not yet marketed)low-residue diet
452845|NCT00748280|Procedure|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
452846|NCT00748280|Procedure|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
452847|NCT00748267|Other|questionnaire administration|
452848|NCT00748267|Procedure|hypnotherapy|
452849|NCT00748267|Procedure|therapeutic conventional surgery|
452850|NCT00748254|Procedure|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on finger joints with any of the scanning methods described above.
452851|NCT00748254|Procedure|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on finger joints with any of the scanning methods described above.
452852|NCT00748241|Device|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
452853|NCT00748228|Dietary Supplement|dietary sodium|10 mEq/day
452854|NCT00748228|Dietary Supplement|dietary sodium|300 mEq/day
452855|NCT00748228|Dietary Supplement|dietary sodium|150 mEq/day dietary sodium
452856|NCT00748215|Drug|calcium aluminosilicate anti-diarrheal|Given orally
452857|NCT00748215|Other|placebo|Given orally
452858|NCT00748202|Drug|C1-Esterase Inhibitor|1000 I.E.
452859|NCT00748189|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
452860|NCT00748189|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
452861|NCT00748176|Procedure|spinal anesthesia|spinal anesthesia with bupivacaine
452862|NCT00748163|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
452863|NCT00748163|Drug|sunitinib malate|
452864|NCT00748150|Biological|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
452865|NCT00748137|Device|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
452866|NCT00748137|Other|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
452867|NCT00748124|Device|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
452868|NCT00748124|Procedure|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
452869|NCT00748111|Other|Blood sample|Blood sample and thrombus sample
452870|NCT00748098|Drug|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
452871|NCT00748098|Drug|Placebo|Placebo
452872|NCT00748085|Device|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
452873|NCT00748072|Drug|DDAVP|0.3 mcg/kg subcutaneous
452874|NCT00748072|Drug|saline solution|saline solution 1 ml subcutaneous
452875|NCT00748059|Procedure|Standing or upright tilt|stand upright or tilt table test
452876|NCT00748059|Procedure|Microneurography|Recording from sympathetic nerve
452877|NCT00748059|Procedure|QSweat|quantitative sweat testing
452878|NCT00748059|Device|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
452879|NCT00748059|Drug|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing~phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
452880|NCT00748059|Drug|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing~clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
452881|NCT00748059|Procedure|BodPod|Determination of body composition
452882|NCT00748059|Procedure|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:~0.5% proparacaine (Alcaine, Allergan, Inc)~Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)~0.5%, 1% tropicamide (Mydriacyl, Alcon)~Over-the-counter preservative-free artificial tears~0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)~1% cyclopentolate hydrochloride (Alcon)"
452883|NCT00748059|Procedure|Sleep study|Recording of sleep pattern overnight
452885|NCT00748059|Procedure|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
452886|NCT00748059|Procedure|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
452887|NCT00748059|Procedure|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
452888|NCT00748046|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
452889|NCT00748020|Procedure|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
452890|NCT00748020|Procedure|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
452891|NCT00748007|Drug|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
452892|NCT00747981|Procedure|Thoracic CT Scan|Perform a CT Scan and an endoscopy
452893|NCT00747968|Drug|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol*kg-1*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
452894|NCT00747942|Behavioral|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
452895|NCT00747929|Drug|S-2367 Placebo|four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
452896|NCT00747929|Drug|S-2367 800 mg|two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
452897|NCT00747929|Drug|S-2367 1600 mg|four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
452898|NCT00747929|Other|Reduced Calorie Diet|A diet with restricted calorie content
452899|NCT00747916|Device|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
452900|NCT00747903|Drug|aminolevulinic acid hydrochloride|
452901|NCT00747890|Procedure|Modified tonsillectomy|"Tonsillectomy~Uvulectomy~Soft palatal resection~Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
452902|NCT00747890|Other|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
452903|NCT00747877|Drug|cyclophosphamide|Given orally
452904|NCT00747877|Drug|melphalan|Given IV
452905|NCT00747877|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
452906|NCT00747838|Procedure|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
452907|NCT00747825|Drug|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
452908|NCT00747812|Device|Precision|Implantable Neurostimulator
452909|NCT00747799|Drug|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~Sorafenib 400 mg bid per daily . Every 21-day cycles.~Cisplatin 80 mg/m2 day d1, every 21 days cycle.~5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
452910|NCT00747773|Device|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
452911|NCT00747747|Biological|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
452912|NCT00747747|Device|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
452913|NCT00747734|Drug|MNRP1685A|Escalating intravenous dose
452914|NCT00747721|Drug|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
452915|NCT00747708|Drug|Granulocyte-colony stimulating factor|5 days subcutaneous injection
452916|NCT00747708|Procedure|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
452917|NCT00747708|Procedure|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
452918|NCT00747695|Drug|Rabeprazole sodium|
452919|NCT00747669|Drug|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
452920|NCT00747643|Drug|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
452921|NCT00747643|Drug|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
452922|NCT00747630|Other|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
452923|NCT00747617|Drug|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
452924|NCT00747604|Biological|mecasermin [rDNA origin] injection|As prescribed by the physician.
452925|NCT00747565|Device|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
452927|NCT00747539|Drug|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
452928|NCT00747526|Drug|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
452929|NCT00747526|Drug|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
452930|NCT00747513|Behavioral|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
452931|NCT00747487|Drug|Idebenone|Idebenone 900 mg/day
452932|NCT00747487|Drug|Placebo|Placebo
452933|NCT00747474|Drug|Lipotecan|Lipotecan IV day 1, 8, 15
452934|NCT00747461|Device|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
452935|NCT00747435|Device|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
452936|NCT00747422|Device|Ulthera™ System|ultrasound treatment
452937|NCT00747409|Drug|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
452938|NCT00747409|Drug|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
452939|NCT00747396|Other|Foster Care Placement|A group of children living in institutions in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and trained in Romanian. Before placement, foster parents visited their children to begin developing a relationship with the child. Hired foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occurring weekly for several months after placement of the child, then biweekly and later monthly. Foster parents were invited to participate in a support group organized by social workers. Project social workers consulted weekly with US staff experienced in dealing with young children in foster care.
452940|NCT00747383|Drug|Glimepiride|3mg oral tablet.
452941|NCT00747383|Drug|Sitagliptin|100mg oral tablet.
452942|NCT00747370|Procedure|movement of midurethra, bladder neck, cervix and rectum|
452943|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
452944|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
452945|NCT00747344|Drug|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
452946|NCT00747344|Drug|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
452947|NCT00747344|Drug|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
452948|NCT00747344|Drug|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
452949|NCT00747331|Drug|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
452950|NCT00747331|Drug|Placebo|"Intravenous infusion (saline)~Infused at the same rate (ml/h) as the experimental drug"
452951|NCT00747318|Drug|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
452952|NCT00747305|Drug|sunitinib malate|
452953|NCT00747305|Genetic|gene expression analysis|
452954|NCT00747305|Genetic|reverse transcriptase-polymerase chain reaction|
452955|NCT00747305|Genetic|western blotting|
452956|NCT00747305|Other|immunohistochemistry staining method|
452957|NCT00747305|Other|laboratory biomarker analysis|
452958|NCT00747305|Procedure|adjuvant therapy|
452959|NCT00747305|Procedure|neoadjuvant therapy|
452960|NCT00747305|Procedure|therapeutic conventional surgery|
452961|NCT00747292|Procedure|epidural|Patients in this limb receive epidural analgesia
452962|NCT00747292|Procedure|PCA|Patients in this limb receive a PCA for their pain control
452963|NCT00747292|Procedure|Spinal|Patients in limb will receive spinal analgesia
452964|NCT00747279|Other|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
452965|NCT00747279|Drug|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
452966|NCT00747253|Device|AutoLITT system|laser treatment with the AutoLITT system
452967|NCT00747227|Device|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
452968|NCT00747227|Device|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
452969|NCT00747214|Drug|CRx-102|
452970|NCT00747214|Drug|Placebo|
452971|NCT00747214|Drug|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
452972|NCT00747201|Behavioral|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
452973|NCT00747201|Behavioral|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
452974|NCT00747188|Behavioral|PBL|
452975|NCT00747175|Drug|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
452976|NCT00747175|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
452977|NCT00747162|Device|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
452978|NCT00747162|Device|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
452979|NCT00747149|Drug|Rosuvastatin|Oral
452980|NCT00747123|Biological|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
452981|NCT00747123|Biological|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
452982|NCT00747110|Drug|budesonide|3x 3mg budesonide capsules once daily
452983|NCT00747110|Drug|mesalazine|3x 1000mg mesalazine onc daily
452984|NCT00747097|Drug|gemcitabine + cetuximab|gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
452985|NCT00747084|Procedure|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
452986|NCT00747071|Drug|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
452987|NCT00747058|Drug|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
452988|NCT00747058|Drug|Placebo|Placebo
452989|NCT00747045|Other|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
452990|NCT00747032|Drug|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
452991|NCT00747032|Drug|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
452992|NCT00747019|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.
452993|NCT00747019|Behavioral|Physical Exercise (PE)|The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
452994|NCT00747006|Drug|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
452995|NCT00747006|Drug|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
452996|NCT00746993|Other|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
452997|NCT00746980|Drug|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
452998|NCT00746967|Drug|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
452999|NCT00746954|Drug|Acetazolamide|Cabonic Anhydrase inhibitor
453000|NCT00746954|Drug|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
453001|NCT00746941|Drug|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
453002|NCT00746928|Other|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
453003|NCT00746915|Device|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
453004|NCT00746902|Device|nCPAP|Active nCPAP
453005|NCT00746889|Drug|triamcinolone acetonide|single intraarticular injection of 40 mg of triamcinolone acetonide
453006|NCT00746889|Drug|saline|Single intraarticular injection of 1 ml of 0.9% saline
453007|NCT00746876|Device|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
453008|NCT00746876|Device|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
453009|NCT00746863|Drug|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
453010|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
453011|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
453012|NCT00746837|Drug|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
453013|NCT00746837|Drug|AZD5672|50 mg od, 12 days
453014|NCT00746837|Drug|AZD5672|150mg od, 12 days
453015|NCT00746824|Drug|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
453016|NCT00746811|Drug|P-OM3|4 grams/day - 4 one gram capsules
453018|NCT00746798|Biological|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
453019|NCT00746798|Biological|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
453020|NCT00746798|Biological|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
453021|NCT00746798|Biological|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
453022|NCT00746785|Drug|2.5 mg Olanzapine|2.5 mg
453023|NCT00746785|Drug|5mg Olanzapine|5 mg
453024|NCT00746785|Drug|placebo|placebo
453025|NCT00746772|Drug|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
453026|NCT00746772|Drug|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
453027|NCT00746759|Device|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
453028|NCT00746746|Biological|HyperAcute vaccine|1.8 mL weekly
453029|NCT00746746|Drug|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
453030|NCT00746733|Drug|Lisdexamfetamine Dimesylate|50mg capsule
453031|NCT00746733|Drug|Adderall XR (mixed salts amphetamine)|20mg capsule
453032|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
453033|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
453034|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
453035|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
453036|NCT00746707|Device|1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate|adhesive of perineal tears
453037|NCT00746707|Procedure|3. traditional suturing with vicryl rapid 2X0|suturing of perineal tears grade one with vicryl rapid 2X0
453038|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
453039|NCT00746681|Drug|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
453040|NCT00746681|Drug|Placebo|Placebo, Oral, twice daily for 4 weeks
453041|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
453042|NCT00746681|Drug|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
453043|NCT00746668|Behavioral|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.~This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
453044|NCT00746668|Behavioral|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
453045|NCT00746668|Behavioral|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation [RSVP]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
453046|NCT00746655|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
453047|NCT00746655|Procedure|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
453048|NCT00746642|Device|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
453085|NCT00746343|Behavioral|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
453086|NCT00746330|Drug|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
453609|NCT00742274|Device|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
453049|NCT00746629|Behavioral|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
453050|NCT00746616|Device|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
453051|NCT00746603|Drug|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
453052|NCT00746590|Drug|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
453053|NCT00746577|Other|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
453054|NCT00746564|Device|SJM Confirm|All patients in this study will receive the SJM Confirm device.
453055|NCT00746551|Drug|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
453056|NCT00746551|Drug|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
453057|NCT00746538|Device|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
453058|NCT00746525|Other|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
453059|NCT00746525|Other|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
453060|NCT00746525|Other|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
453061|NCT00746512|Drug|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
453062|NCT00746512|Drug|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
453063|NCT00746512|Drug|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
453064|NCT00746512|Drug|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
453065|NCT00746499|Drug|Raltegravir|400mg raltegravir BID x 7 days
453066|NCT00746486|Drug|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
453067|NCT00746486|Drug|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
453068|NCT00746460|Behavioral|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
453069|NCT00746447|Drug|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
453070|NCT00746447|Drug|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
453071|NCT00746447|Drug|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
453072|NCT00746434|Drug|Roflumilast cream|Roflumilast cream 0.5%
453073|NCT00746434|Drug|Placebo cream|Placebo cream
453074|NCT00746421|Drug|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
453075|NCT00746421|Drug|Placebo|200mg, 300mg or 400mg
453076|NCT00746408|Other|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
453077|NCT00746395|Drug|Lubiprostone|24 mcg oral administration
453078|NCT00746395|Drug|Placebo|Oral administration
453079|NCT00746382|Drug|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
453080|NCT00746382|Drug|Placebo cream|Placebo cream
453081|NCT00746369|Behavioral|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
453082|NCT00746356|Device|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
453083|NCT00746356|Device|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
453084|NCT00746343|Behavioral|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
453967|NCT00739778|Other|food vehicle blank|water blank
453087|NCT00746330|Drug|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
453088|NCT00746330|Drug|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
453089|NCT00746330|Drug|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
453090|NCT00746330|Drug|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
453091|NCT00746317|Drug|GC33|IV administration at 4 escalating dose levels.
453092|NCT00746291|Other|6 min walk test, Step climbing|walking for 6 minute and climbing steps
453093|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
453094|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
453095|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
453096|NCT00746265|Behavioral|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
453097|NCT00746252|Drug|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
453098|NCT00746252|Drug|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
453099|NCT00746239|Drug|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
453100|NCT00746239|Drug|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
453101|NCT00746226|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10^9 CFU of a combination of L. acidophilus and B. lactis
453102|NCT00746226|Biological|Placebo|"Microcrystalline cellulose~As capsule which could be opened"
453103|NCT00746200|Procedure|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
453104|NCT00746200|Procedure|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
453105|NCT00746187|Device|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
453106|NCT00746187|Device|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
453107|NCT00746174|Drug|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
453108|NCT00746174|Drug|Placebo|Placebo 1 tablet PO daily for 16 weeks
453109|NCT00746161|Procedure|Reconstruction after total gastrectomy|Roux-en-Y
453110|NCT00746161|Procedure|Reconstruction after total gastrectomy|double tract reconstruction
453111|NCT00746148|Other|Reflexology|10 weekly sessions of 45 minutes each
453112|NCT00746135|Device|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
453113|NCT00746122|Procedure|Open repair|Standard treatment of emergency open surgery
453114|NCT00746122|Procedure|EVAR|Emergency endovascular aneurysm repair
453115|NCT00746109|Procedure|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
453116|NCT00746109|Procedure|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
453117|NCT00746096|Drug|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
453118|NCT00746096|Drug|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
453119|NCT00746083|Behavioral|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
453120|NCT00746070|Other|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
453121|NCT00746057|Biological|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
453122|NCT00746031|Drug|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
453123|NCT00746031|Drug|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
453124|NCT00746018|Device|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
453125|NCT00746005|Dietary Supplement|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
453126|NCT00746005|Dietary Supplement|placebo, sunflower oil|3 g of sunflower oil
453127|NCT00745992|Other|Blood drawn (lab data)|"Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated~Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
453128|NCT00745953|Drug|Valsartan|Valsartan 320mg PO daily for 8 months
453129|NCT00745953|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
453270|NCT00744536|Drug|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
453130|NCT00745940|Behavioral|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
453131|NCT00745927|Other|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
453132|NCT00745914|Drug|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
453133|NCT00745914|Drug|Placebo comparator|Placebo comparator
453134|NCT00745901|Drug|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
453135|NCT00745888|Other|Chemiluminescence Analyzer|measure reactive oxygen species
453136|NCT00745875|Drug|ZD4054|10mg oral tablet, once daily
453137|NCT00745875|Drug|Pemetrexed|500mg2/m IV infusion
453138|NCT00745875|Drug|Placebo|10mg oral tablet, once daily
453139|NCT00745862|Behavioral|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
453140|NCT00745849|Drug|esomeprazole|40mg by mouth twice daily
453141|NCT00745849|Drug|placebo|
453142|NCT00745836|Drug|statin|
453143|NCT00745823|Drug|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
453144|NCT00745823|Drug|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
453145|NCT00745823|Drug|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
453146|NCT00745810|Other|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
453147|NCT00745797|Radiation|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
453148|NCT00745784|Behavioral|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
453149|NCT00745771|Drug|Diractin|
453150|NCT00745771|Drug|Diractin|
453151|NCT00745745|Device|Device Implantation|ICD lead implantation
453152|NCT00745732|Drug|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
453153|NCT00745732|Radiation|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.~Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
453154|NCT00745719|Procedure|parathyroidectomy|total parathyroidectomy with forearm autografting
453155|NCT00745706|Device|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
453156|NCT00745693|Drug|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
453157|NCT00745693|Drug|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
453158|NCT00745667|Procedure|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
453159|NCT00745667|Procedure|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
453160|NCT00745615|Drug|Laquinimod|Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.
453161|NCT00745615|Drug|Placebo|Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
453162|NCT00745602|Procedure|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
453163|NCT00745589|Drug|sevelamer hydrochloride|First-line high dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
453164|NCT00745576|Drug|SAM-531|
453165|NCT00745563|Device|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
453166|NCT00745550|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
453167|NCT00745537|Other|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
453168|NCT00745511|Drug|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
453169|NCT00745511|Drug|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
453170|NCT00745498|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
453171|NCT00745485|Drug|zoledronic acid|
453172|NCT00745459|Drug|NPO-11|20 mL NPO-11
453173|NCT00745446|Procedure|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
453174|NCT00745433|Drug|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
453175|NCT00745433|Drug|metformin|Start dose and frequency at the discretion of the physician following clinical practice
453176|NCT00745420|Biological|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.~Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively~Fludarabine: 30 mg/m^2/day IV on Days -8 through -4~Melphalan: 140 mg/m^2 IV on Day -3~Rest on Days -2 and -1~Transplant occurs on Day 0~GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
453177|NCT00745407|Drug|fenofibrate|
453178|NCT00745381|Other|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
453179|NCT00745368|Drug|Raltegravir|400 mg tablets twice daily during duration of trial
453180|NCT00745355|Behavioral|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
453181|NCT00745342|Behavioral|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
453182|NCT00745329|Other|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
453183|NCT00745316|Drug|Tonapofylline|Oral Tonapofylline - 2 capsules bid
453184|NCT00745316|Drug|Placebo|Oral placebo - 2 capsules bid
453185|NCT00745303|Procedure|Tai Chi Cuan|Tai Chi Cuan training for 3 months
453186|NCT00745290|Drug|Bupivacaine HCl|200 mg bupivacaine HCl
453187|NCT00745290|Drug|SKY0402|600 mg SKY0402 (study drug).
453188|NCT00745264|Drug|Diractin|100 mg Ketoprofen to 2 joints
453189|NCT00745264|Drug|Diractin|400 mg ketoprofen to 4 joints
453190|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
453191|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
453192|NCT00745251|Drug|VI-0521|15 mg Phentermine and 92 mg Topiramate
453193|NCT00745251|Drug|placebo|placebo
453194|NCT00745238|Other|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
453195|NCT00745225|Drug|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
453196|NCT00745225|Drug|placebo comparator|1 capsule daily, 96 weeks.
453197|NCT00745199|Drug|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
453198|NCT00745199|Drug|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
453199|NCT00745186|Drug|Glucagen|0.2 mg or 1 mg Glucagen single injection
453200|NCT00745186|Drug|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
453201|NCT00745173|Drug|Premarin|
453202|NCT00745160|Other|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
453203|NCT00745147|Drug|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
453204|NCT00745147|Drug|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
453205|NCT00745134|Drug|Capecitabine|Given PO
453206|NCT00745134|Dietary Supplement|Curcumin|Given PO
453207|NCT00745134|Other|Laboratory Biomarker Analysis|Correlative studies
453208|NCT00745134|Other|Pharmacological Study|Optional correlative studies
453209|NCT00745134|Other|Placebo|Given PO
453210|NCT00745134|Other|Quality-of-Life Assessment|Ancillary studies
453211|NCT00745134|Radiation|Radiation Therapy|Undergo radiation therapy
453212|NCT00745121|Device|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
453213|NCT00745108|Drug|tibolone|oral 1.25 mg tablet, once daily, for 2 years
453214|NCT00745108|Drug|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
453215|NCT00745108|Drug|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
453216|NCT00745095|Drug|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
453217|NCT00745069|Drug|tapentadol HCl|
453218|NCT00745043|Drug|bronchodilator response|
453219|NCT00745030|Drug|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
453220|NCT00745030|Drug|Placebo|Placebo 8 mg tablets
453221|NCT00745017|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
453222|NCT00745017|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
453400|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
453223|NCT00745017|Drug|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
453224|NCT00745004|Drug|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
453225|NCT00745004|Drug|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
453226|NCT00744991|Drug|Enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
453227|NCT00744978|Drug|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
453228|NCT00744978|Drug|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
453229|NCT00744965|Drug|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
453230|NCT00744965|Drug|Placebo|Sham dose adjustments of the placebo will be made.
453231|NCT00744939|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
453232|NCT00744926|Drug|placebo|sc, once weekly
453233|NCT00744926|Drug|taspoglutide|10mg sc, once weekly
453234|NCT00744926|Drug|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
453235|NCT00744913|Drug|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
453236|NCT00744913|Other|Counselling|Women in this arm of the study will receive standard counseling only.
453237|NCT00744900|Drug|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
453238|NCT00744887|Drug|Darunavir|
453239|NCT00744874|Procedure|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
453240|NCT00744861|Device|Low Intensity Pulsed Ultrasound|
453241|NCT00744861|Device|Sham|
453242|NCT00744848|Drug|Bupivacaine HCl|100 mg Bupivacaine HCl
453243|NCT00744848|Drug|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
453244|NCT00744835|Procedure|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
453245|NCT00744809|Drug|TMC278; Moxifloxacin; Efavirenz|
453246|NCT00744796|Procedure|DSEAK|Endothelial Keratoplasty
453247|NCT00744770|Drug|TMC278|
453248|NCT00744757|Drug|Decitabine|Decitabine 20 mg per m^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
453249|NCT00744744|Other|informational intervention|Patient educational information
453250|NCT00744744|Other|questionnaire administration|Survey
453251|NCT00744744|Procedure|management of therapy complications|Survey
453252|NCT00744744|Procedure|psychosocial assessment and care|Survey
453253|NCT00744744|Procedure|quality-of-life assessment|Survey
453254|NCT00744731|Drug|placebo|placebo for 1 week
453255|NCT00744731|Drug|carisbamate|400 mg/day to 1,200 mg per day
453256|NCT00744718|Drug|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
453257|NCT00744718|Drug|Carboplatin|Carboplatin AUC 5 every 5 weeks
453258|NCT00744692|Biological|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
453259|NCT00744692|Drug|Reduced Intensity Conditioning|
453260|NCT00744679|Drug|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
453261|NCT00744666|Drug|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
453262|NCT00744653|Procedure|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
453263|NCT00744640|Drug|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
453264|NCT00744627|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
453265|NCT00744627|Drug|Placebo|Vortioxetine placebo-matching capsules
453266|NCT00744614|Procedure|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
453267|NCT00744562|Drug|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
453268|NCT00744549|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
453269|NCT00744549|Drug|Placebo|Twice a day with meals.
453271|NCT00744523|Device|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
453272|NCT00744510|Other|Reflexology|10 weekly sessions of 45 minutes each
453273|NCT00744497|Drug|Placebo|
453274|NCT00744497|Drug|Dasatinib|
453275|NCT00744497|Drug|Docetaxel|
453276|NCT00744497|Drug|Prednisone|
453277|NCT00744484|Behavioral|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
453278|NCT00744484|Behavioral|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
453279|NCT00744471|Biological|tanezumab|Tanezumab 10 mg IV every 8 weeks
453280|NCT00744471|Biological|tanezumab|Tanezumab 5mg IV every 8 weeks
453281|NCT00744471|Biological|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
453282|NCT00744471|Biological|Placebo|Placebo to match tanezumab IV every 8 weeks
453283|NCT00744458|Other|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
453284|NCT00744458|Other|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
453285|NCT00744458|Other|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
453286|NCT00744445|Drug|r-HuEPO|r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
453287|NCT00744419|Drug|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose [0.4 mg/kg (< 44 wks PMA) or 0.8 mg/kg (44 wks to < 1 yr)] and the last 6 subjects in each age group will receive high dose [0.8 mg/kg(< 44 wks PMA) or 1.6 mg/kg(44 wks to < 1 yr)]
453288|NCT00744406|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
453289|NCT00744406|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
453290|NCT00744406|Drug|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
453291|NCT00744393|Drug|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
453292|NCT00744393|Drug|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
453293|NCT00744380|Drug|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
453294|NCT00744380|Drug|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
453295|NCT00744367|Drug|metformin|>1500 mg/day or maximum tolerated dose (MTD)
453296|NCT00744367|Drug|pioglitazone|>= 30 mg/day
453297|NCT00744367|Drug|placebo|sc once weekly
453298|NCT00744367|Drug|taspoglutide|10 mg sc once weekly;
453299|NCT00744367|Drug|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
453300|NCT00744354|Drug|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
453301|NCT00744354|Drug|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
453302|NCT00744354|Drug|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
453303|NCT00744341|Drug|SLV320|1.25mg i.v. bid
453304|NCT00744341|Drug|SLV320|3.75mg i.v. bid
453305|NCT00744341|Drug|SLV320|7.5mg i.v. bid
453306|NCT00744341|Drug|SLV320|15.0mg i.v. bid
453307|NCT00744341|Drug|Placebo|
453308|NCT00744328|Drug|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
453309|NCT00744328|Drug|Sertraline|Sertraline dose will range from 50 - 200 mg/day
453310|NCT00744328|Other|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
453311|NCT00744315|Procedure|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
453401|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
453312|NCT00744302|Drug|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
453313|NCT00744289|Other|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
453314|NCT00744276|Drug|danazol|danazol applied topically once per day for 4 treatment cycles
453315|NCT00744276|Drug|Placebo|placebo topically applied once daily for 4 treatment cycles
453316|NCT00744263|Biological|VACCINE: placebo|0.5 mL, single intra-muscular injection
453317|NCT00744263|Biological|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
453318|NCT00744250|Drug|Pancrelipase|PANCRECARB MS-16
453319|NCT00744237|Drug|Nebivolol|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration~Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration~Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration~Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration"
453320|NCT00744237|Drug|Metoprolol ER|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration~Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration~Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration~Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration"
453321|NCT00744237|Drug|HCTZ|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration~HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration"
453322|NCT00744224|Drug|Placebo|Single dose of placebo with saline infusion
453323|NCT00744224|Drug|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
453324|NCT00744224|Drug|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
453325|NCT00744211|Drug|1mg/kg sitaxsentan sodium|1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
453326|NCT00744211|Drug|2mg/kg sitaxsentan sodium|2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
453327|NCT00744211|Other|Vehicle|Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
453328|NCT00744198|Procedure|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
453329|NCT00744198|Procedure|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
453330|NCT00744198|Procedure|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
453331|NCT00744185|Drug|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
453332|NCT00744185|Drug|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
453333|NCT00744172|Procedure|laparoscopy|laparoscopic hysterectomy
453334|NCT00744172|Procedure|vaginal|vaginal hysterectomy
453335|NCT00744172|Procedure|abdominal|abdominal hysterectomy
453336|NCT00744146|Biological|Protexia|Single 50 mg IM dose
453337|NCT00744146|Biological|Protexia|Single 100 mg dose
453338|NCT00744146|Biological|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
453339|NCT00744146|Biological|Protexia|Single 500 mg dose, IM
453340|NCT00744146|Biological|Protexia|Single 750 mg dose, IM
453341|NCT00744133|Biological|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
453342|NCT00744107|Device|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
453343|NCT00744094|Dietary Supplement|protein drink|250 ml protein hydrolysate solution
453344|NCT00744094|Behavioral|Resistance training|12 weeks resistance training, 3 days per week
453345|NCT00744081|Drug|Glivec|
453346|NCT00744081|Drug|Mitoxantrone|
453347|NCT00744081|Drug|Topotecan|
453348|NCT00744081|Drug|AraC|
453349|NCT00744068|Behavioral|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
453350|NCT00744055|Drug|Prazosin|prazosin (16mg/day) 2 times a day
453351|NCT00744055|Drug|Placebo|Placebo
453352|NCT00744042|Biological|asfotase alfa|
453353|NCT00744029|Behavioral|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
453354|NCT00744016|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
453355|NCT00744016|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
453356|NCT00743990|Other|Ointment containing camphor, eucalyptus oil, and menthol|One time use
453357|NCT00743990|Other|Petroleum jelly|One time use
453358|NCT00743977|Drug|Phenazopyridine HCl|100mg tablet in fasting state
453359|NCT00743964|Drug|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
453360|NCT00743964|Drug|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
453397|NCT00743704|Other|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
453398|NCT00743691|Other|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
453361|NCT00743951|Behavioral|1 Patient decision aid|"Patients will receive:~i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.~iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.~iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
453362|NCT00743951|Behavioral|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.~ii) Referral to the surgeon with a standardized report of their clinical findings."
453363|NCT00743938|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
453364|NCT00743938|Drug|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
453365|NCT00743925|Drug|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
453366|NCT00743912|Drug|rifaximin|550 mg TID
453367|NCT00743899|Procedure|The aggressive group|Stents were implanted in lesions with diameter stenosis >50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis >50% and RD ≥2.0 mm and <2.25 mm.
453368|NCT00743899|Procedure|The conservative group|Stenting was performed only in lesions with diameter stenosis >70% and reference diameter (RD) ≥2.25 mm
453369|NCT00743886|Biological|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
453370|NCT00743886|Drug|saline|injection of 6 cc of saline into injured area
453371|NCT00743873|Biological|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
453372|NCT00743873|Drug|placebo|injection of 6 cc of saline into injured area
453373|NCT00743860|Drug|darapladib|experimental drug
453374|NCT00743847|Drug|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
453375|NCT00743847|Drug|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
453376|NCT00743847|Drug|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
453377|NCT00743834|Drug|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
453378|NCT00743834|Behavioral|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
453379|NCT00743808|Other|quality improvement|3-phase quality improvement intervention
453380|NCT00743795|Drug|placebo|oral BID
453381|NCT00743795|Drug|GS-9190|40 mg oral BID
453382|NCT00743795|Drug|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
453383|NCT00743795|Drug|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
453384|NCT00743782|Drug|Synthetic Human Parathyroid Hormone 1-34|
453385|NCT00743769|Drug|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
453386|NCT00743769|Other|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
453387|NCT00743756|Dietary Supplement|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
453388|NCT00743756|Dietary Supplement|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
453389|NCT00743756|Behavioral|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
453390|NCT00743743|Dietary Supplement|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
453391|NCT00743743|Dietary Supplement|placebo|1 capsule of placebo daily for 52 weeks
453392|NCT00743730|Other|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
453393|NCT00743730|Other|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
453394|NCT00743730|Other|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.~Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
453395|NCT00743717|Device|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
453396|NCT00743717|Device|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
453399|NCT00743678|Drug|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
453440|NCT00743366|Drug|Quetiapine|200 mg/day
453402|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
453403|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
453404|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
453405|NCT00743639|Procedure|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.~Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10[7] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
453406|NCT00743626|Other|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
453407|NCT00743613|Behavioral|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
453408|NCT00743613|Procedure|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
453409|NCT00743600|Other|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
453410|NCT00743600|Other|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
453411|NCT00743587|Drug|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
453412|NCT00743587|Drug|Oxycodone|Oral, 1 x 20mg controlled-release tablets
453413|NCT00743587|Drug|Tramadol|Oral, 2 x 50mg immediate release capsules
453414|NCT00743587|Drug|Naproxen|Oral, 1 x 500mg enteric-coated
453415|NCT00743574|Dietary Supplement|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
453416|NCT00743574|Drug|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
453417|NCT00743574|Dietary Supplement|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
453418|NCT00743574|Dietary Supplement|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
453419|NCT00743561|Device|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
453420|NCT00743561|Device|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
453421|NCT00743548|Device|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
453422|NCT00743548|Device|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
453423|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
453424|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.~Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
453425|NCT00743522|Device|ICD/ CRT-D|Cardiac device
453426|NCT00743509|Drug|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.~Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
453427|NCT00743496|Biological|Anti-GD2 antibody|Anti-GD2 antibody
453428|NCT00743483|Drug|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
453429|NCT00743470|Drug|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
453430|NCT00743470|Drug|rifabutin|rifabutin capsule; see arms for intervention description
453431|NCT00743457|Device|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
453432|NCT00743444|Drug|AZD3355|65 mg capsules, oral, 3 single doses
453433|NCT00743444|Drug|Placebo|capsules, oral, 3 single doses
453434|NCT00743431|Drug|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
453435|NCT00743418|Device|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
453436|NCT00743405|Drug|GSK1034702|Oral or liquid
453437|NCT00743405|Drug|Placebo|To match GSK1034702
453438|NCT00743379|Drug|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
453439|NCT00743366|Drug|Marijuana|0,6.2% THC
453442|NCT00743353|Drug|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
453443|NCT00743340|Drug|Emtricitabine|6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
453444|NCT00743327|Drug|Pioglitazone|45mg capsule, once daily for 1 year
453445|NCT00743314|Other|screening questionnaire administration|
453446|NCT00743314|Procedure|computed tomography|
453447|NCT00743314|Procedure|lymphoscintigraphy|
453448|NCT00743314|Procedure|single photon emission computed tomography|
453449|NCT00743314|Radiation|intensity-modulated radiation therapy|
453450|NCT00743314|Radiation|technetium Tc 99m sulfur colloid|
453451|NCT00743301|Other|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
453452|NCT00743288|Drug|Melphalan|Same as above
453453|NCT00743288|Drug|Panobinostat|
453454|NCT00743275|Biological|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
453455|NCT00743262|Device|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
453456|NCT00743249|Device|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
453457|NCT00743249|Device|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
453458|NCT00743236|Procedure|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
453459|NCT00743236|Procedure|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
453460|NCT00743223|Other|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
453461|NCT00743210|Drug|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
453462|NCT00743210|Drug|Placebo|Placebo, 3 grams once per day for 3 weeks.
453463|NCT00743197|Drug|Aspirin|Aspirin 81 mg daily
453464|NCT00743197|Drug|Lisinopril|Lisinopril 10 mg every night
453465|NCT00743197|Drug|Simvastatin|Simvastatin 20 mg every night
453466|NCT00743197|Drug|Lovaza|Lovaza 1 gram daily
453467|NCT00743197|Behavioral|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
453468|NCT00743184|Drug|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
453469|NCT00743184|Drug|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution
453470|NCT00743145|Drug|Inactive Marijuana (0% THC)|Marijuana cigarette containing 0% THC
453471|NCT00743145|Drug|Active Marijuana (5.5% THC)|Marijuana cigarette containing 5.5% THC
453472|NCT00743145|Drug|Active Marijuana (6.2% THC)|Marijuana cigarette containing 6.2% THC
453473|NCT00743145|Drug|Naltrexone|Naltrexone (12mg/70kg)
453474|NCT00743145|Drug|Placebo naltrexone|Naltrexone (0mg)
453475|NCT00743119|Drug|Placebo capsules|Placebo capsules
453476|NCT00743119|Drug|Inactive marijuana (0% THC)|Inactive marijuana cigarettes (0% THC) provided by NIDA
453477|NCT00743119|Drug|Low dose Dronabinol|Dronabinol 10mg
453478|NCT00743119|Drug|High dose Dronabinol|Dronabinol 20mg
453479|NCT00743119|Drug|Low THC marijuana|marijuana cigarettes (1.98% THC) provided by NIDA
453480|NCT00743119|Drug|High THC marijuana|Marijuana cigarettes (3.56% THC) provided by NIDA
453481|NCT00743106|Drug|Fenoldopam|Fenoldopam (0.1 ~g/kg/min)started during surgery and lasting for a total of 24 hours
453482|NCT00743106|Drug|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
453483|NCT00743093|Drug|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
453484|NCT00743093|Drug|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
453485|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).~Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
453486|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).~Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
453487|NCT00743067|Drug|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
453658|NCT00741884|Drug|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
453659|NCT00741884|Drug|Placebo|Placebo BID for 7 weeks
453488|NCT00743041|Behavioral|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
453489|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
453490|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
453491|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
453492|NCT00743015|Drug|BI 44370 TA tablet|
453493|NCT00743002|Drug|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
453494|NCT00743002|Drug|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
453495|NCT00742989|Other|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
453496|NCT00742989|Other|Sham OLT|Therapeutic massage performed
453497|NCT00742976|Drug|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
453498|NCT00742976|Drug|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
453499|NCT00742963|Drug|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.~Dose escalation dose levels:~Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
453500|NCT00742950|Procedure|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
453501|NCT00742950|Procedure|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
453502|NCT00742950|Procedure|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
453503|NCT00742937|Dietary Supplement|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
453504|NCT00742937|Dietary Supplement|Placebo|second capsule with vitamin E, eight days after delivery.
453505|NCT00742924|Drug|cisplatin|Given IV
453506|NCT00742924|Drug|dexrazoxane hydrochloride|Given IV
453507|NCT00742924|Drug|doxorubicin hydrochloride|Given IV
453508|NCT00742924|Drug|etoposide|Given IV
453509|NCT00742924|Drug|ifosfamide|Given IV
453510|NCT00742924|Drug|leucovorin calcium|Given IV or orally
453511|NCT00742924|Drug|methotrexate|Given IV
453512|NCT00742924|Drug|zoledronic acid|Given IV
453513|NCT00742924|Procedure|adjuvant therapy|
453514|NCT00742924|Procedure|neoadjuvant therapy|
453515|NCT00742924|Procedure|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
453516|NCT00742924|Biological|filgrastim|Given SC
453517|NCT00742924|Drug|Mesna|Given IV
453518|NCT00742911|Drug|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.~Patients must not consume beverages containing alcohol while taking disulfiram."
453519|NCT00742911|Drug|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.~Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.~Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
453520|NCT00742898|Other|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
453521|NCT00742885|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
453522|NCT00742872|Drug|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
453523|NCT00742872|Drug|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
453524|NCT00742859|Drug|betrixaban|orally, once daily for at least 3 months
453525|NCT00742859|Drug|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
453526|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint~Intra-articular injection with local anesthetic and steroid"
453527|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space~Local anesthetic and steroid in to the subacromial space"
453528|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection"
453529|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection"
453530|NCT00742833|Drug|KUC-7483|
453531|NCT00742833|Drug|Placebo|
453532|NCT00742820|Drug|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
453533|NCT00742820|Drug|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
453660|NCT00741871|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
453534|NCT00742820|Dietary Supplement|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
453535|NCT00742807|Drug|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
453536|NCT00742807|Drug|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
453537|NCT00742794|Other|Observation|Observation of sting frequency
453538|NCT00742781|Dietary Supplement|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
453539|NCT00742768|Dietary Supplement|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
453540|NCT00742768|Dietary Supplement|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
453541|NCT00742755|Behavioral|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
453542|NCT00742742|Behavioral|healthy life style education|healthy life style education
453543|NCT00742729|Behavioral|Arm 1|Educational small group session with free FOBT kit
453544|NCT00742729|Behavioral|Arm 2|Educational small group session with no FOBT kit
453545|NCT00742729|Behavioral|Arm 3|Educational small group session, exercise
453546|NCT00742716|Drug|CTA018 Injection|Comparison of different dosages of drug
453547|NCT00742703|Other|Mineralized water|
453548|NCT00742703|Other|Low mineralized water|
453549|NCT00742690|Drug|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
453550|NCT00742690|Drug|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
453551|NCT00742677|Procedure|nutritional support|Given orally
453552|NCT00742664|Behavioral|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
453553|NCT00742664|Behavioral|Wait-list control|The subject will not receive active treatment during this interval.
453554|NCT00742638|Drug|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
453555|NCT00742638|Drug|Sodium valproate|Sodium valproate tablet 200 mg
453556|NCT00742625|Drug|daunorubicin hydrochloride|Given IV
453557|NCT00742625|Drug|cytarabine|Given IV
453558|NCT00742625|Drug|bortezomib|Given IV
453559|NCT00742612|Drug|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
453560|NCT00742612|Drug|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
453561|NCT00742599|Drug|NPO-11|20 ml NPO-11
453562|NCT00742599|Drug|Placebo|20 ml NPO-11(Placebo)
453563|NCT00742573|Drug|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
453564|NCT00742573|Behavioral|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
453565|NCT00742560|Biological|elotuzumab|Humanized Anti-CS1 Monoclonal IgG1 Antibody (HuLuc63) administered as an intravenous infusion once a week during Cycles 1 and 2, and every other week beginning with Cycle 3.
453566|NCT00742560|Drug|lenalidomide|Lenalidomide 25 mg administered orally once daily on Days 1 to 21 of each 28-day cycle
453567|NCT00742560|Drug|dexamethasone oral|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
453568|NCT00742560|Drug|dexamethasone injection|Dexamethasone 40 mg administered orally once weekly; during weeks when elotuzumab is also administered, dexamethasone was administered as a split dose (28 mg orally and 8 mg intravenously)
453569|NCT00742547|Other|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
453661|NCT00741858|Procedure|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
453662|NCT00741858|Procedure|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
453570|NCT00742534|Drug|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
453571|NCT00742521|Procedure|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
453572|NCT00742521|Procedure|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
453573|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
453574|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
453575|NCT00742508|Drug|SK&F-105517-D 10 mg capsule|1 capsule once a day
453576|NCT00742508|Drug|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
453577|NCT00742508|Drug|SK&F-105517-D 20 mg capsule|1 capsule once a day
453578|NCT00742508|Drug|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
453579|NCT00742508|Drug|Carvedilol-IR 10 mg tablet|1 tablet twice a day
453580|NCT00742495|Drug|Forodesine|PK study
453581|NCT00742482|Drug|HL 10|Freeze dried HL 10
453582|NCT00742469|Drug|Rifaximin|
453583|NCT00742469|Drug|Placebo|
453584|NCT00742456|Dietary Supplement|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
453585|NCT00742456|Dietary Supplement|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
453586|NCT00742443|Drug|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
453587|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
453588|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
453589|NCT00742430|Procedure|PCI|percutaneous coronary intervention in stable coronary artery disease
453590|NCT00742417|Biological|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:~three weeks of intensive treatment with two plasma exchanges per week~six weeks of maintenance treatment with one weekly plasma exchange~three months of maintenance treatment with one plasma exchange every two weeks"
453591|NCT00742417|Other|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
453592|NCT00742404|Drug|bortezomib|
453593|NCT00742404|Drug|dexamethasone|
453594|NCT00742404|Drug|pegylated liposomal doxorubicin hydrochloride|
453595|NCT00742404|Genetic|protein analysis|
453596|NCT00742404|Other|immunologic technique|
453597|NCT00742391|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
453598|NCT00742391|Drug|Vehicle gel|two day treatment
453599|NCT00742365|Device|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
453600|NCT00742365|Device|Red light placebo|One hour of exposure to red light.
453601|NCT00742339|Drug|Terlipressin plus albumin|The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
453602|NCT00742339|Drug|Midodrine plus octreotide plus human albumin|Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
453603|NCT00742326|Drug|Pioglitazone|45 mg/daily
453604|NCT00742326|Drug|Placebo|one capsule daily
453605|NCT00742313|Biological|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
453606|NCT00742300|Procedure|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
453607|NCT00742287|Dietary Supplement|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
453608|NCT00742287|Dietary Supplement|Placebo|placebo
453610|NCT00742274|Other|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
453611|NCT00742261|Drug|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
453612|NCT00742248|Drug|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
453613|NCT00742248|Drug|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
453614|NCT00742248|Drug|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
453615|NCT00742235|Drug|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
453616|NCT00742222|Radiation|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
453617|NCT00742222|Radiation|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
453618|NCT00742209|Drug|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
453619|NCT00742209|Drug|Placebo|Placebo-control
453620|NCT00742183|Device|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
453621|NCT00742183|Device|Silvadene|Silvadene - dressing changes every day, more frequently if needed
453622|NCT00742170|Device|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
453623|NCT00742157|Drug|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
453624|NCT00742144|Drug|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
453625|NCT00742131|Drug|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid [5 milligrams/milliliter] or 1000 milligrams of GSK1363089 in 50 milliliters liquid [20 milligrams/milliliter]) or as solid capsules of 20, 100, and/or 200 milligrams.
453626|NCT00742118|Procedure|Colic biopsies|colic biopsies and analysis
453627|NCT00742105|Drug|BGT226|
453628|NCT00742092|Drug|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
453629|NCT00742092|Drug|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
453630|NCT00742079|Drug|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
453631|NCT00742079|Behavioral|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
453632|NCT00742066|Drug|Irbesartan|Single dose 600mg orally
453633|NCT00742066|Drug|Felodipine|single dose 10mg Felodipine ER
453634|NCT00742066|Drug|Placebo|Single dose tablet orally
453635|NCT00742053|Device|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
453636|NCT00742040|Drug|Captopril|A rapid 3-day up-titration protocol
453637|NCT00742040|Drug|Captopril|A slower 9-day up-titration protocol
453638|NCT00742027|Drug|Panobinostat|Oral 40 mg/dose, three times per week, every week dosing on a 21-day cycle
453639|NCT00742014|Drug|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
453640|NCT00742001|Biological|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
453641|NCT00741988|Drug|Ixabepilone|ixabepilone 30 mg/m2
453642|NCT00741988|Drug|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
453643|NCT00741988|Drug|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
453644|NCT00741975|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
453645|NCT00741975|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
453646|NCT00741962|Dietary Supplement|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
453647|NCT00741962|Dietary Supplement|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
453648|NCT00741949|Drug|Propofol|Sedation in TCI with propofol
453649|NCT00741949|Drug|Placebo|Isotonic saline solution infusion
453650|NCT00741936|Drug|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
453651|NCT00741936|Drug|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
453652|NCT00741923|Other|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
453653|NCT00741910|Drug|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
453654|NCT00741897|Drug|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
453655|NCT00741884|Drug|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
453656|NCT00741884|Drug|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
453657|NCT00741884|Drug|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
453663|NCT00741845|Drug|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
453664|NCT00741832|Device|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.~The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.~Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
453665|NCT00741832|Other|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
453666|NCT00741819|Drug|Inhaled treprostinil|
453667|NCT00741806|Biological|GHB04L1|single dose intranasal administration of GHB04L1
453668|NCT00741806|Other|Placebo|SPGN buffer
453669|NCT00741780|Drug|Placebo|
453670|NCT00741780|Drug|plerixafor|
453671|NCT00741780|Drug|granulocyte colony-stimulating factor (G-CSF)|
453672|NCT00741767|Drug|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
453673|NCT00741754|Other|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
453674|NCT00741741|Drug|TMC278|
453675|NCT00741728|Other|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
453676|NCT00741715|Drug|AVE5530|oral administration once daily in the evening with dinner
453677|NCT00741715|Drug|atorvastatin|oral administration once daily in the evening with dinner
453678|NCT00741715|Drug|placebo|oral administration once daily in the evening with dinner
453679|NCT00741702|Other|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP >=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP>=13/80 mm Hg, increase verapamil to 240 mg/d
453680|NCT00741689|Drug|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
453681|NCT00741676|Procedure|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
453682|NCT00741676|Procedure|open distal gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
453683|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
453684|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
453685|NCT00741650|Behavioral|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
453686|NCT00741650|Behavioral|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.~In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.~In addition,"
453687|NCT00741637|Biological|CholeraGarde®|"Live attenuated oral Cholera vaccine~Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
453688|NCT00741637|Biological|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
453689|NCT00741624|Other|Bandage|one application for one week
453690|NCT00741611|Device|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
453691|NCT00741611|Drug|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
453692|NCT00741598|Drug|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
453693|NCT00741598|Drug|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
453694|NCT00741585|Drug|Any antihypertensive medication alone or in combination|All drugs on awakening
453695|NCT00741585|Drug|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
453696|NCT00741585|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
453697|NCT00741559|Device|magnetoencephalography|MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
453874|NCT00740415|Drug|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
453698|NCT00741559|Device|Positron emission tomography (PET)|An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
453699|NCT00741559|Device|Magnetic resonance imaging|MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
453700|NCT00741546|Procedure|Cardiac Surgery|Cardiac Surgery
453701|NCT00741520|Device|CPAP|Control - no treatment
453702|NCT00741520|Device|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
453703|NCT00741507|Behavioral|Alcohol drinking|Never drinking of alcohol
453704|NCT00741507|Behavioral|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
453705|NCT00741507|Behavioral|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
453706|NCT00741507|Behavioral|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
453707|NCT00741507|Behavioral|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
453708|NCT00741494|Device|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
453709|NCT00741481|Procedure|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
453710|NCT00741468|Drug|Proellex|2, 25 mg Proellex capsules administered daily
453711|NCT00741468|Drug|CYP1A2 probe|Caffeine (200 mg)
453712|NCT00741468|Drug|CYP2C9 probe|Tolbutamide (250 mg)
453713|NCT00741468|Drug|CYP2C19 probe|Omeprazole (20 mg)
453714|NCT00741468|Drug|CYP2D6 probe|Dextromethorphan (30 mg)
453715|NCT00741468|Drug|CYP3A4 probe|Midazolam (2mg)
453716|NCT00741455|Procedure|Stem Cell Transplant|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be > 5 x 106 CD34+cells/kg of recipient.~Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.~Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
453717|NCT00741455|Drug|G-CSF|10 mcg/kg/day on days 5, 6, and 7
453718|NCT00741455|Drug|Fludarabine|25 mg/m2/d IV over 30 minutes on days -6 to -2
453719|NCT00741455|Drug|cyclophosphamide|1 g/m2/d IV on days -3 and -2
453720|NCT00741455|Drug|Cyclosporine|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
453721|NCT00741455|Drug|Methotrexate|used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml
453722|NCT00741442|Drug|RDEA806|Uricosuric agent for the treatment of gout
453723|NCT00741442|Drug|Placebo|Matching Placebo.
453724|NCT00741429|Drug|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
453725|NCT00741429|Drug|Comparator|Subjects previously treated with other anti-diabetic medications
453726|NCT00741403|Drug|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
453727|NCT00741390|Device|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
453728|NCT00741390|Device|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
453729|NCT00741390|Device|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
453730|NCT00741390|Device|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
453731|NCT00741390|Device|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
453732|NCT00741377|Drug|BHQ880|
453733|NCT00741377|Drug|Zoledronic acid|
453734|NCT00741364|Dietary Supplement|vitamin D3 (cholecalciferol)|liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
453735|NCT00741351|Drug|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
453736|NCT00741351|Drug|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
453737|NCT00741351|Drug|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
453738|NCT00741338|Biological|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
453739|NCT00741338|Drug|Cyclosporine A (CsA)|Orally three times daily.
453740|NCT00741338|Drug|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
453741|NCT00741325|Drug|granulocyte colony-stimulating factor (G-CSF)|
453742|NCT00741325|Drug|plerixafor|
453743|NCT00741325|Drug|Placebo|
453875|NCT00740389|Drug|TMC125|
453966|NCT00739778|Other|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
453744|NCT00741312|Behavioral|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.~The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
453745|NCT00741312|Behavioral|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
453746|NCT00741286|Drug|Aspirin|Asprin (100mg) plus placebo
453747|NCT00741286|Drug|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
453748|NCT00741273|Drug|Proellex|Proellex 25 mg capsule, single dose
453749|NCT00741260|Drug|Neratinib|Neratinib orally once daily continually
453750|NCT00741260|Drug|Capecitabine|Capecitabine orally on days 1-14 of each 21 day cycle
453751|NCT00741247|Procedure|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
453752|NCT00741234|Drug|SB939|SB939 taken orally in a 4-week cycle.
453753|NCT00741234|Drug|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
453754|NCT00741221|Drug|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
453755|NCT00741221|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
453756|NCT00741208|Dietary Supplement|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
453757|NCT00741195|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
453758|NCT00741195|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
453759|NCT00741182|Drug|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
453760|NCT00741169|Drug|TMC435350|200 mg taken by mouth once daily for 7 days
453761|NCT00741169|Drug|Rifampin|600 mg taken by mouth once daily for 7 days
453762|NCT00741169|Drug|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
453763|NCT00741156|Drug|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
453764|NCT00741143|Other|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
453765|NCT00741117|Procedure|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
453766|NCT00741117|Procedure|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
453767|NCT00741117|Procedure|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
453768|NCT00741104|Drug|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
453769|NCT00741091|Device|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
453770|NCT00741091|Device|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
453771|NCT00741078|Drug|statin, amlodipine|
453772|NCT00741065|Procedure|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
453773|NCT00741052|Drug|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
453774|NCT00741052|Drug|Azithromycin|1 gm Azithromycin single dose
453775|NCT00741039|Biological|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients >65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
453776|NCT00741039|Biological|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
453777|NCT00741026|Drug|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
453778|NCT00741026|Drug|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
453779|NCT00741013|Drug|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
453780|NCT00741013|Drug|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
453781|NCT00741013|Drug|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
453782|NCT00741013|Biological|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
453783|NCT00741000|Procedure|Cervical Stairstep|Cervical low force mobilization procedure.
453784|NCT00740987|Device|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
453785|NCT00740961|Behavioral|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
453786|NCT00740961|Drug|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
453787|NCT00740961|Other|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
453788|NCT00740961|Other|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
453789|NCT00740961|Other|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
453790|NCT00740961|Procedure|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
453791|NCT00740961|Procedure|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
453792|NCT00740948|Drug|Rituximab (mabthera) Injection|2 * 1g of Rituximab at the 1st day and at the 14th day.
453793|NCT00740948|Drug|Placebo: NaCl 0.9% or Glucose 5%|2* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
453794|NCT00740935|Biological|Rotateq vaccine|"Vaccination against rotavirus~Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose."
453795|NCT00740922|Drug|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
453796|NCT00740909|Behavioral|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
453797|NCT00740896|Behavioral|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
453798|NCT00740896|Behavioral|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
453799|NCT00740883|Drug|warfarin|18 months of warfarin therapy, once daily
453800|NCT00740883|Drug|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
453801|NCT00740870|Device|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
453802|NCT00740857|Drug|placebo|2 placebo gels capsules delivered as a single dose.
453803|NCT00740857|Drug|ibuprofen Formulation 1|2 marketed ibuprofen gels
453804|NCT00740857|Drug|ibuprofen Formulation 2|2 marketed ibuprofen gels
453805|NCT00740844|Device|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
453806|NCT00740831|Drug|PGL4001|tablets
453807|NCT00740831|Drug|leuprorelin|solution for injection
453808|NCT00740818|Other|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
453809|NCT00740818|Procedure|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
453810|NCT00740818|Procedure|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
453811|NCT00740805|Drug|Cyclophosphamide|Given IV
453812|NCT00740805|Drug|Doxorubicin Hydrochloride|Given IV
453813|NCT00740805|Other|Laboratory Biomarker Analysis|Correlative studies
453814|NCT00740805|Other|Pharmacological Study|Correlative studies
453815|NCT00740805|Drug|Veliparib|Given PO
453816|NCT00740792|Drug|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
453817|NCT00740792|Drug|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
453818|NCT00740792|Drug|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
453819|NCT00740792|Drug|placebo|placebo one spray per nostril BID
453820|NCT00740779|Drug|Silodosin 8 mg|Silodosin 8 mg daily
453821|NCT00740779|Drug|Placebo|Placebo
453822|NCT00740779|Drug|Silodosin 4 mg|Silodosin 4 mg daily
453876|NCT00740376|Device|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
453823|NCT00740766|Behavioral|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.~The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.~All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
453824|NCT00740753|Device|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
453825|NCT00740727|Drug|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
453826|NCT00740727|Procedure|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
453827|NCT00740714|Drug|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
453828|NCT00740714|Drug|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
453829|NCT00740701|Device|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
453830|NCT00740688|Procedure|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
453831|NCT00740688|Procedure|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
453832|NCT00740675|Other|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:~Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.~Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).~Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
453833|NCT00740662|Procedure|Distal gastric bypass|Distal gastric bypass
453834|NCT00740649|Drug|HSD-016|
453835|NCT00740649|Drug|placebo|
453836|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
453837|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
453838|NCT00740623|Drug|Carisbamate|800 mg/day for 14 weeks
453839|NCT00740623|Drug|placebo|placebo for 14 weeks
453840|NCT00740623|Drug|Carisbamate|1,200 mg/day for 14 weeks
453841|NCT00740610|Drug|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
453842|NCT00740610|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
453843|NCT00740597|Genetic|gene expression analysis|
453844|NCT00740597|Genetic|polymerase chain reaction|
453845|NCT00740597|Genetic|western blotting|
453846|NCT00740597|Procedure|neoadjuvant therapy|
453847|NCT00740597|Procedure|therapeutic conventional surgery|
453848|NCT00740597|Radiation|intensity-modulated radiation therapy|
453849|NCT00740584|Drug|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
453850|NCT00740571|Drug|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
453851|NCT00740571|Drug|pregabalin|Strategy in which patient starts with pregabalin
453852|NCT00740558|Procedure|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
453853|NCT00740558|Procedure|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
453854|NCT00740545|Drug|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
453855|NCT00740545|Drug|placebo|Women inject ourselves every days with placebo
453856|NCT00740532|Genetic|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
453857|NCT00740519|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
453858|NCT00740506|Behavioral|Frequency of Intercourse|
453859|NCT00740493|Drug|warfarin|18 months of warfarin therapy
453860|NCT00740493|Drug|placebo of warfarin|18 months of placebo of warfarin therapy
453861|NCT00740467|Biological|anti-thymocyte globulin|
453862|NCT00740467|Drug|busulfan|
453863|NCT00740467|Drug|cyclophosphamide|
453864|NCT00740467|Drug|cyclosporine|
453865|NCT00740467|Drug|fludarabine phosphate|
453866|NCT00740467|Drug|mycophenolate mofetil|
453867|NCT00740467|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
453868|NCT00740454|Other|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
453869|NCT00740441|Drug|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
453870|NCT00740428|Procedure|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
453871|NCT00740415|Biological|rituximab|Rituximab, 375 mg/m2 Intraveinous
453872|NCT00740415|Drug|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
453873|NCT00740415|Drug|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
453877|NCT00740376|Device|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
453878|NCT00740363|Drug|sitagliptin|Once daily sitagliptin. If GFR>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
453879|NCT00740363|Drug|placebo|No active sitagliptin treatment for 4 weeks
453880|NCT00740350|Procedure|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
453881|NCT00740324|Drug|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
453882|NCT00740324|Drug|NPO-11|NPO-11 after administration of NPO-11
453883|NCT00740324|Drug|NPO-11|1 mg glucagons after administration of NPO-11
453884|NCT00740311|Device|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
453885|NCT00740298|Other|sucrose|sweet taste
453886|NCT00740298|Other|warmth|warmth
453887|NCT00740285|Drug|Lidocaine 2% without vessel constrictor|"first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
453888|NCT00740285|Other|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
453889|NCT00740272|Procedure|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
453890|NCT00740272|Procedure|Pacemaker implantation|regular pacemaker implantation
453891|NCT00740259|Drug|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
453892|NCT00740246|Drug|VIT-45|
453893|NCT00740207|Drug|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
453894|NCT00740207|Drug|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
453895|NCT00740194|Drug|Aromatase inhibition|Letrozole
453896|NCT00740194|Drug|Estradiol|Dermestril
453897|NCT00740181|Drug|chemotherapy|
453898|NCT00740168|Drug|bevacizumab treatment|single infusion 10 mg/kg
453899|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
453900|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
453901|NCT00740155|Biological|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
453902|NCT00740155|Biological|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
453903|NCT00740155|Biological|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
453904|NCT00740142|Drug|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
453905|NCT00740142|Drug|placebo and lactulose|placebo 3 times a day for 7 days
453906|NCT00740129|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
453907|NCT00740116|Drug|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to scin incision at surgery
453908|NCT00740116|Drug|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before scin incision at surgery.
453909|NCT00740103|Drug|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
453910|NCT00740090|Drug|AMA1-C1/Alhydrogel plus CPG 7909|
453911|NCT00740077|Other|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
453912|NCT00740064|Drug|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
453913|NCT00740051|Drug|Linagliptin|5mg once daily
453914|NCT00740051|Drug|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
453915|NCT00740051|Drug|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
453916|NCT00740038|Behavioral|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, & provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
453917|NCT00740038|Behavioral|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
453918|NCT00740038|Behavioral|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
453919|NCT00740038|Behavioral|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
453920|NCT00740012|Other|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
453964|NCT00739791|Procedure|support group therapy|
453921|NCT00740012|Other|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
453922|NCT00740012|Other|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
453923|NCT00740012|Other|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
453924|NCT00740012|Other|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
453925|NCT00740012|Other|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
453926|NCT00739999|Drug|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
453927|NCT00739999|Drug|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
453928|NCT00739986|Drug|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
453929|NCT00739986|Drug|Semapimod|Semapimod 60 mg IV x 3 days
453930|NCT00739986|Drug|Placebo|placebo IV x 3 days
453931|NCT00739973|Drug|Placebo|
453932|NCT00739973|Drug|Aliskiren 150 mg tablet|
453933|NCT00739973|Drug|Aliskiren 300 mg tablet|
453934|NCT00739973|Drug|Amlodipine 5 mg capsule|
453935|NCT00739973|Drug|Amlodipine 10 mg capsule|
453936|NCT00739973|Drug|Aliskiren/amlodipine 150/5 mg tablet|
453937|NCT00739973|Drug|Aliskiren/amlodipine 150/10 mg tablet|
453938|NCT00739973|Drug|Aliskiren/amlodipine 300/5 mg tablet|
453939|NCT00739973|Drug|Aliskiren/amlodipine 300/10 mg tablet|
453940|NCT00739960|Drug|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
453941|NCT00739947|Other|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
453942|NCT00739934|Drug|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)"
453943|NCT00739921|Procedure|Nasal swab under endoscopic guidance|"After the application of pontocaine and neosynephrine spray, the following will be done:~A small sponge applicator will be used to swab the inside of your mouth for saliva collection~A blood sample (6cc - one tube) will be collected~A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)~Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you~You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well~The samples will be refrigerated and analyzed using PCR to detect and speciate fungus."
453944|NCT00739908|Drug|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
453945|NCT00739908|Drug|Placebo|Six capsules administered three times a day for six weeks.
453946|NCT00739895|Procedure|Cardiac magnetic Resonance study|follow-up studies
453947|NCT00739895|Procedure|Blood testing|Blood sample tested for myocardial biomarkers
453948|NCT00739882|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
453949|NCT00739882|Drug|Placebo|Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
453950|NCT00739856|Procedure|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
453951|NCT00739830|Drug|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
453952|NCT00739830|Drug|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
453953|NCT00739830|Drug|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
453954|NCT00739791|Behavioral|exercise intervention|
453955|NCT00739791|Genetic|gene expression analysis|
453956|NCT00739791|Genetic|polymerase chain reaction|
453957|NCT00739791|Genetic|proteomic profiling|
453958|NCT00739791|Genetic|reverse transcriptase-polymerase chain reaction|
453959|NCT00739791|Other|laboratory biomarker analysis|
453960|NCT00739791|Other|medical chart review|
453961|NCT00739791|Other|questionnaire administration|
453962|NCT00739791|Procedure|psychosocial assessment and care|
453963|NCT00739791|Procedure|quality-of-life assessment|
453968|NCT00739778|Other|food - sweetener, positive control|4.7% sucrose in water
453969|NCT00739778|Other|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
453970|NCT00739765|Behavioral|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
453971|NCT00739765|Behavioral|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
453972|NCT00739765|Behavioral|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
453973|NCT00739752|Behavioral|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
453974|NCT00739752|Behavioral|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
453975|NCT00739752|Behavioral|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
453976|NCT00739752|Behavioral|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
453977|NCT00739752|Behavioral|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
453978|NCT00739752|Behavioral|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
453979|NCT00739739|Drug|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
453980|NCT00739739|Drug|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
453981|NCT00739739|Drug|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
453982|NCT00739713|Dietary Supplement|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
453983|NCT00739713|Dietary Supplement|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
453984|NCT00739687|Drug|ALT-711|200 mg tablet BID for 9 months.
453985|NCT00739687|Drug|Placebo|200 mg tablet BID for 9 months.
453986|NCT00739674|Drug|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:~Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:~Losartan 50 mg~Losartan 100 mg~Losartan 100 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 25 mg~Losartan 100 mg/HCTZ 25 mg + CCB~Patients with severe hypertension:~Losartan 50 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 12.5 mg~Losartan 100 mg/HCTZ 25 mg~Losartan 100 mg/HCTZ 25 mg + CCB~Losartan 100 mg/HCTZ 25 mg + increasing CCB"
453987|NCT00739674|Behavioral|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension [DASH]) including:~Healthy diet~Reduction in sodium intake to less than 2300 mmol/day~Low alcohol consumption (less than 2 standard drinks/day)"
453988|NCT00739661|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
453989|NCT00739661|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
453990|NCT00739648|Drug|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
453991|NCT00739648|Drug|Placebo|same frequency as study drug using the same method of delivery
453992|NCT00739635|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
453993|NCT00739635|Drug|Placebo|Double-blind treatment period of 17 weeks placebo
453994|NCT00739622|Drug|TMC278|
453995|NCT00739609|Drug|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
453996|NCT00739596|Drug|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
453997|NCT00739596|Drug|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
453998|NCT00739583|Drug|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
453999|NCT00739583|Drug|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
454000|NCT00739570|Device|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
454001|NCT00739544|Other|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
454002|NCT00739531|Device|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
454003|NCT00739518|Procedure|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
454004|NCT00739505|Biological|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:~Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
454005|NCT00739505|Biological|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
454006|NCT00739492|Behavioral|financial incentives|financial incentives based on attaining weight loss goals
454007|NCT00739479|Dietary Supplement|Weight Loss|Participants will reduce their total dietary intake by ~800 kcal/day. ~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of ~700 kcal/day.
454008|NCT00739466|Drug|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
454009|NCT00739466|Drug|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
454010|NCT00739466|Drug|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
454011|NCT00739453|Drug|OSI-906|administered orally
454012|NCT00739453|Drug|erlotinib|administered orally
454013|NCT00739440|Biological|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
454014|NCT00739414|Drug|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
454015|NCT00739401|Device|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
454016|NCT00739388|Drug|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
454017|NCT00739375|Procedure|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
454018|NCT00739362|Behavioral|Behavioral Weight Loss Treatment|
454019|NCT00739362|Procedure|Transcranial Direct Current Stimulation (TDCS)|
454020|NCT00739362|Device|Transcranial Direct Current Stimulation (TDCS)|
454021|NCT00739362|Behavioral|Appetite Control|
454022|NCT00739362|Procedure|Appetite Control|
454023|NCT00739362|Device|Weight Control|
454024|NCT00739362|Behavioral|Weight Loss|
454025|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
454026|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
454027|NCT00739349|Drug|vehicle/placebo|vehicle/placebo
454028|NCT00739336|Behavioral|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
454029|NCT00739310|Device|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
454030|NCT00739297|Drug|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
454031|NCT00739297|Drug|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
454032|NCT00739284|Device|nephrostomy tube and ureteral stent|
454033|NCT00739271|Other|Early feeding|
454034|NCT00739271|Other|late feeding after bowel sounds return|Traditional method
454035|NCT00739232|Drug|HSD-016|
454036|NCT00739232|Other|placebo|
454037|NCT00739219|Device|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
454038|NCT00739206|Drug|SAR97276A|Dose based on body weight
454039|NCT00739193|Drug|amiodarone|
454040|NCT00739180|Other|Control|Standard care control (no exercise)
454041|NCT00739180|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
454042|NCT00739180|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
454043|NCT00739141|Other|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
454044|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
454045|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
454046|NCT00739115|Other|Heliox gas|Heliox gas used in conjunction with nasal CPAP
454047|NCT00739102|Device|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
454048|NCT00739076|Behavioral|Virtual Reality|Using Virtual Reality for pain control
454049|NCT00739063|Drug|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
454050|NCT00739050|Drug|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
454051|NCT00739050|Drug|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
454052|NCT00739037|Drug|Placebo|
454053|NCT00739037|Drug|PAZ-417|
454054|NCT00739024|Drug|Ramelteon|8 mg tablet, oral, once daily
454055|NCT00739024|Drug|Placebo|Placebo tablet, oral, once daily
454136|NCT00738413|Drug|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
454056|NCT00739011|Device|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
454057|NCT00738998|Behavioral|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
454058|NCT00738998|Other|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
454059|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
454060|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
454061|NCT00738972|Drug|valsartan|80 mg valsartan. Duration: 12 months. Tablets
454062|NCT00738972|Drug|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
454063|NCT00738972|Drug|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
454064|NCT00738972|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
454065|NCT00738959|Drug|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
454066|NCT00738946|Drug|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
454067|NCT00738933|Dietary Supplement|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
454068|NCT00738933|Dietary Supplement|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
454069|NCT00738933|Dietary Supplement|placebo|Margarine product without plant stanol or sterol esters
454070|NCT00738920|Behavioral|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
454071|NCT00738920|Behavioral|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
454072|NCT00738920|Behavioral|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
454073|NCT00738894|Device|Septal Occluder Device|PFO closure with study septal occluder device
454074|NCT00738894|Drug|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
454075|NCT00738881|Drug|Erlotinib Hydrochloride|Given PO
454076|NCT00738881|Drug|Pemetrexed Disodium|Given IV
454077|NCT00738868|Biological|cetuximab|
454078|NCT00738868|Radiation|stereotactic body radiation therapy|
454079|NCT00738855|Other|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
454080|NCT00738855|Other|Nothing per os|A nasogastric tube
454081|NCT00738842|Drug|AZD6140|Oral tablets taken bid for 5 days
454082|NCT00738842|Drug|Placebo to match AZD6140|Oral tablets taken bid for 5 days
454083|NCT00738829|Drug|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
454084|NCT00738829|Drug|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
454085|NCT00738829|Biological|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
454086|NCT00738816|Other|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
454087|NCT00738803|Procedure|Total hip replacement|Total hip replacement typically preformed for hip arthritis
454088|NCT00738790|Radiation|Short course of radiotherapy|5 x 5 Gy plus boost 4 Gy
454089|NCT00738790|Radiation|Radiochemotherapy|28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
454090|NCT00738777|Drug|Anastrozole|1 mg,QD,PO
454091|NCT00738777|Drug|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
454092|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
454093|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
454094|NCT00738764|Biological|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
454095|NCT00738751|Drug|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
454137|NCT00738400|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
454138|NCT00738400|Drug|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
454139|NCT00738387|Drug|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
454140|NCT00738387|Drug|Placebo|Placebo i.v. on day 1 of each 21 day cycle
454096|NCT00738751|Drug|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
454097|NCT00738738|Drug|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
454098|NCT00738712|Procedure|MRI Magnetic Resonance Imaging|MRI
454099|NCT00738699|Drug|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
454100|NCT00738699|Drug|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
454101|NCT00738699|Drug|Paclitaxel|
454102|NCT00738686|Device|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
454103|NCT00738673|Drug|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
454104|NCT00738660|Drug|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
454105|NCT00738647|Procedure|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
454106|NCT00738634|Behavioral|Self-motivated physical activity|"Components:~Physical activity education in the form of a brief booklet (double sided A4 page).~Physical activity motivation tips (one sided A4 page).~Pedometer~Monitoring chart~Online presentation of common obstacles and ways to overcome these obstacles"
454107|NCT00738634|Behavioral|Nutrition|"Components:~Nutrition education booklet (Double-sided A4 page)~Nutrition motivation tips (single-sided A4 page)~Nutrition monitoring chart~Online presentation of common obstacles and ways to overcome these obstacles"
454108|NCT00738634|Behavioral|Physical activity researcher contact|"Behavioral: Self-motivated physical activity~Components:~Physical activity education in the form of a brief booklet (double sided A4 page).~Physical activity motivation tips (one sided A4 page).~Pedometer~Monitoring chart~Online presentation of common obstacles and ways to overcome these obstacles"
454109|NCT00738621|Drug|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
454110|NCT00738621|Drug|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
454111|NCT00738595|Drug|EVT 302|EVT 302 5 mg once daily
454112|NCT00738595|Drug|Placebo|Placebo to match EVT 302, 5 mg
454113|NCT00738595|Drug|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
454114|NCT00738595|Drug|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
454115|NCT00738582|Drug|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
454116|NCT00738582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
454117|NCT00738582|Drug|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
454118|NCT00738569|Drug|Raltegravir|Raltegravir 400 mg PO BID for 12 months
454119|NCT00738556|Device|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
454120|NCT00738543|Other|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
454121|NCT00738530|Drug|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
454122|NCT00738530|Drug|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
454123|NCT00738530|Drug|Placebo|IV every 2 weeks
454124|NCT00738517|Device|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
454125|NCT00738478|Device|nasogastric tube|insertion of nasogastric tube for 2 days after operation
454126|NCT00738478|Device|without nasogastric tube|without nasogastric tube after operation
454127|NCT00738452|Other|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
454128|NCT00738452|Other|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
454129|NCT00738452|Procedure|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
454130|NCT00738452|Procedure|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
454131|NCT00738452|Radiation|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
454132|NCT00738452|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
454133|NCT00738426|Device|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
454134|NCT00738426|Device|Sham device|non-therapeutic light energy output
454135|NCT00738413|Drug|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
454141|NCT00738387|Drug|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
454142|NCT00738374|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
454143|NCT00738374|Drug|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
454144|NCT00738361|Drug|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
454145|NCT00738348|Drug|sivelstat|sivelstat sodiumhydrate
454146|NCT00738348|Drug|glucose|glucose
454147|NCT00738335|Drug|erlotinib hydrochloride|
454148|NCT00738335|Other|immunoenzyme technique|
454149|NCT00738335|Other|laboratory biomarker analysis|
454150|NCT00738335|Other|liquid chromatography|
454151|NCT00738335|Other|mass spectrometry|
454152|NCT00738335|Other|pharmacological study|
454153|NCT00738335|Radiation|stereotactic radiosurgery|
454154|NCT00738322|Drug|AZD1305|Solution for iv infusion, single dose
454155|NCT00738322|Drug|Placebo|NaCl solution for iv infusion, single dose
454156|NCT00738296|Drug|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
454157|NCT00738296|Drug|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
454158|NCT00738296|Drug|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
454159|NCT00738257|Drug|Pamidronate|
454160|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
454161|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
454162|NCT00738218|Other|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
454163|NCT00738192|Drug|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
454164|NCT00738192|Drug|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
454165|NCT00738192|Drug|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
454166|NCT00738179|Device|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
454167|NCT00738179|Other|Standard care|Standard care of cardiovascular risk factors
454168|NCT00738166|Other|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
454169|NCT00738166|Other|Diet (organic or conventional)|organic or conventional diet
454170|NCT00738153|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
454171|NCT00738140|Behavioral|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
454172|NCT00738127|Procedure|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
454173|NCT00738101|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
454174|NCT00738088|Drug|gliclazide|Gliclazide 80mg bd for 6 weeks
454175|NCT00738075|Device|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
454176|NCT00738062|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
454177|NCT00738062|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
454178|NCT00738049|Drug|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
454179|NCT00738023|Drug|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
454180|NCT00738023|Drug|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
454181|NCT00738023|Drug|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
454182|NCT00738010|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
454183|NCT00738010|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
454184|NCT00738010|Behavioral|Control|Voluntary quadriceps muscle contractions.
454185|NCT00737997|Drug|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
454186|NCT00737997|Other|Saline|10 ml saline alone
454187|NCT00737984|Procedure|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
454188|NCT00737971|Drug|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
454189|NCT00737971|Drug|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
454190|NCT00737971|Drug|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
454191|NCT00737932|Drug|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
454192|NCT00737932|Other|placebo|Matching placebo for 8 weeks of treatment
454193|NCT00737919|Dietary Supplement|Plant Stanol|Plant stanols in margarines daily 2 grams
454194|NCT00737919|Dietary Supplement|Plant Sterol|Plant sterols in margarines daily 2 grams
454195|NCT00737906|Procedure|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
454196|NCT00737893|Drug|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
454197|NCT00737893|Drug|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
454198|NCT00737880|Other|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
454199|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
454200|NCT00737867|Drug|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
454201|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
454202|NCT00737867|Drug|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert`s formula)
454203|NCT00737854|Procedure|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
454204|NCT00737841|Drug|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
454205|NCT00737841|Drug|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
454206|NCT00737828|Other|Perioperative care pathway guided by CPX results|"AT > 11ml/min/kg no myocardial ischaemia or Ve/VO2 <35 - Level 1 Ward Care~AT > 11ml/min/kg with myocardial ischaemia or Ve/VO2 >35 - Level 2/3 (ITU) Critical Care Unit~AT <11mls/min/kg - Level 2/3 Critical Care Unit~AT <8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
454207|NCT00737815|Dietary Supplement|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
454208|NCT00737815|Other|Placebo|Inactive placebo pill
454209|NCT00737789|Drug|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
454210|NCT00737789|Drug|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
454211|NCT00737776|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
454212|NCT00737763|Drug|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
454213|NCT00737763|Drug|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
454214|NCT00737750|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
454215|NCT00737750|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
454216|NCT00737750|Behavioral|Control|Voluntary quadriceps muscle contractions.
454217|NCT00737737|Drug|MS Contin|
454218|NCT00737737|Drug|Placebo|
454219|NCT00737724|Drug|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
454220|NCT00737724|Drug|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
454221|NCT00737711|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
454222|NCT00737698|Other|Exercise|Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
454223|NCT00737698|Other|Repetitive magnetic stimulation|Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
454224|NCT00737685|Drug|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 & -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 & -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 & -1)
454225|NCT00737672|Device|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
454226|NCT00737672|Procedure|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
454227|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg*h\L) measured on Days 7,14,Months 1,3,6 and 12.
454228|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
454229|NCT00737646|Behavioral|Usual care|No intervention will be conducted in this arm of the study.
454309|NCT00736996|Behavioral|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
454310|NCT00736983|Drug|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
454311|NCT00736983|Drug|ciprofloxacin|12 weeks; daily 2 x 500mg
454359|NCT00736645|Dietary Supplement|selenomethionine|Given orally
454360|NCT00736645|Drug|finasteride|Given orally
454230|NCT00737646|Behavioral|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
454231|NCT00737646|Behavioral|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
454232|NCT00737633|Drug|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
454233|NCT00737620|Procedure|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
454234|NCT00737594|Drug|Placebo|Matching placebo capsules for oral administration
454235|NCT00737594|Drug|Cobiprostone|Cobiprostone capsules for oral administration
454236|NCT00737568|Drug|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
454237|NCT00737568|Drug|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
454238|NCT00737568|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
454239|NCT00737568|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
454240|NCT00737555|Drug|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
454241|NCT00737542|Drug|lidocaine|
454242|NCT00737542|Drug|NACL 0.9%|
454243|NCT00737529|Drug|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
454244|NCT00737516|Biological|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
454245|NCT00737503|Biological|Rotavirus Vaccine (ROTARIX)|Rotavirus Vaccine two doses four weeks apart
454246|NCT00737490|Other|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm~Using one of the FDA approved St. Jude devices, depending on MD preference."
454247|NCT00737490|Other|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.~Using one of the FDA approved St. Jude devices, depending on MD preference."
454248|NCT00737477|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
454249|NCT00737464|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
454250|NCT00737451|Behavioral|blood sampling|blood sampling 10ml from the study subjects
454251|NCT00737438|Drug|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.~Patients with a good metabolic response (eg. > 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).~Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
454252|NCT00737425|Device|PainShield|
454253|NCT00737425|Device|Sham PainShield|
454254|NCT00737412|Other|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
454255|NCT00737412|Other|Placebo|Matching capsules devoid of microorganisms
454256|NCT00737399|Behavioral|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
454257|NCT00737373|Drug|Docetaxel|50mg/m2 qd15
454258|NCT00737373|Drug|5-Fluorouracil|2600mg/m2 qd15
454259|NCT00737373|Drug|Oxaliplatin|85mg/m2 qd15
454260|NCT00737373|Drug|folinic acid|200mg/m2 qd15
454261|NCT00737360|Drug|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
454262|NCT00737347|Behavioral|Lifestyle modification|lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
454263|NCT00737334|Device|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.~All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
454264|NCT00737321|Procedure|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
454265|NCT00737308|Other|ceramic crown|Zirconia
454312|NCT00736970|Drug|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
454313|NCT00736970|Drug|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
454266|NCT00737295|Procedure|CCK Injection and Ultrasound|"All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:~If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.~An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder."
454267|NCT00737282|Drug|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
454268|NCT00737282|Drug|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
454269|NCT00737256|Drug|Aripiprazole|15-30 mg
454270|NCT00737256|Drug|Perphenazine|8-16 mg
454271|NCT00737243|Drug|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
454272|NCT00737243|Drug|Carboplatin|AUC 6.0 IV Day 1
454273|NCT00737243|Drug|Bevacizumab|15 mg/kg IV infusion Day 1
454274|NCT00737243|Drug|Erlotinib|150 mg PO
454275|NCT00737243|Other|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
454276|NCT00737230|Other|educational intervention|
454277|NCT00737230|Other|questionnaire administration|
454278|NCT00737230|Procedure|assessment of therapy complications|
454279|NCT00737230|Procedure|gastrointestinal complications management/prevention|
454280|NCT00737230|Procedure|management of therapy complications|
454281|NCT00737230|Procedure|quality-of-life assessment|
454282|NCT00737217|Behavioral|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
454283|NCT00737204|Drug|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
454284|NCT00737204|Drug|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
454285|NCT00737191|Drug|olanzapine|Given orally
454286|NCT00737191|Other|placebo|Given orally
454287|NCT00737178|Device|CuT380A|Comparison of different timing of IUD insertion
454288|NCT00737165|Behavioral|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:~Building support networks for suicide prevention and mental health promotion in public health system~Primary prevention of suicide and suicide related behaviors~Secondary prevention of suicide and suicide related behaviors~Tertiary prevention; after care for suicide survivors~Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders~Suicide prevention targeting for people with work-related problems"
454289|NCT00737165|Behavioral|Suicide prevention program as usual|Usual suicide prevention program
454290|NCT00737152|Other|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
454291|NCT00737139|Procedure|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
454292|NCT00737139|Procedure|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
454293|NCT00737126|Drug|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
454294|NCT00737126|Drug|Placebo|Administration of an oral placebo pill
454295|NCT00737113|Drug|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of ~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
454296|NCT00737100|Drug|Placebo Respimat|patient to receive placebo matching active drug once daily
454297|NCT00737100|Drug|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
454298|NCT00737100|Drug|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
454299|NCT00737087|Device|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
454300|NCT00737061|Device|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
454301|NCT00737048|Drug|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
454302|NCT00737048|Drug|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
454303|NCT00737048|Drug|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
454304|NCT00737048|Drug|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
454305|NCT00737035|Behavioral|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
454306|NCT00737035|Behavioral|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
454307|NCT00736996|Drug|Pioglitazone|30 - 45mg tablet daily for 6 months
454308|NCT00736996|Drug|Placebo|Matching tablet daily for 6 months
454358|NCT00736658|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
454314|NCT00736957|Drug|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
454315|NCT00736944|Drug|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
454316|NCT00736944|Drug|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
454317|NCT00736944|Drug|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
454318|NCT00736944|Drug|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
454319|NCT00736944|Drug|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
454320|NCT00736944|Radiation|Radiation (Post induction)|Monday-Friday, weeks 1-7
454321|NCT00736944|Drug|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
454322|NCT00736944|Drug|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
454323|NCT00736931|Drug|Brivaracetam|Brivaracetam 10 mg tablets
454324|NCT00736931|Drug|levetiracetam|500mg tablets
454325|NCT00736931|Drug|lorazepam|lorazepam 2 mg over encapsulated tablets
454326|NCT00736931|Other|placebo|placebo capsules
454327|NCT00736918|Behavioral|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
454328|NCT00736918|Other|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
454329|NCT00736905|Drug|TMC278|
454330|NCT00736879|Drug|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
454331|NCT00736879|Drug|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
454332|NCT00736866|Drug|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
454333|NCT00736866|Drug|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
454334|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
454335|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
454336|NCT00736853|Drug|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
454337|NCT00736840|Device|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
454338|NCT00736814|Drug|carboplatin|Given intravenously
454339|NCT00736814|Drug|docetaxel|Given intravenously
454340|NCT00736814|Drug|gemcitabine hydrochloride|Given intravenously
454341|NCT00736814|Drug|vinorelbine tartrate|Given intravenously
454342|NCT00736801|Drug|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
454343|NCT00736788|Drug|AZD1704|single dose oral suspension, 4 different dose levels
454344|NCT00736788|Drug|Placebo|single dose oral suspension
454345|NCT00736775|Drug|anti-Abeta|Intravenous single and multiple doses
454346|NCT00736775|Drug|placebo|Intravenous single and multiple doses
454347|NCT00736762|Other|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
454348|NCT00736749|Procedure|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
454349|NCT00736749|Other|Questionnaire Administration|Complete patient response form and Health Status Update Form
454350|NCT00736736|Other|Additional Hip Muscle Strengthening to Leg Press Exercise|
454351|NCT00736736|Other|Leg Press Exercise|
454352|NCT00736710|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
454353|NCT00736710|Procedure|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
454354|NCT00736697|Drug|moxidectin|
454355|NCT00736684|Device|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
454356|NCT00736684|Device|Gamma Nail 3TM (Gamma3)|intramedullary nailing
454357|NCT00736658|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
454361|NCT00736645|Other|placebo|Given orally
454362|NCT00736632|Drug|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
454363|NCT00736632|Drug|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
454364|NCT00736619|Other|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.~The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
454365|NCT00736606|Drug|simvastatin|One single dose of 40mg
454366|NCT00736606|Drug|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
454367|NCT00736593|Drug|Nexagon™ or Nexagon™ vehicle|
454368|NCT00736580|Other|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
454369|NCT00736580|Other|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
454370|NCT00736541|Drug|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
454371|NCT00736528|Drug|PF-04447943|05 mg BID for 14 days
454372|NCT00736528|Drug|PF-04447943|15 mg BID for 14 days
454373|NCT00736528|Drug|PF-04447943|45mg BID for 14 days
454374|NCT00736528|Drug|Placebo|Placebo for 14 days
454375|NCT00736515|Drug|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
454376|NCT00736515|Drug|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
454377|NCT00736489|Drug|AZD3199|Dry powder for inhalation, single dose
454378|NCT00736489|Drug|Formoterol|Dry powder for inhalation, single dose
454379|NCT00736489|Drug|Placebo|Dry powder for inhalation, single dose
454380|NCT00736476|Biological|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
454381|NCT00736476|Biological|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
454382|NCT00736463|Drug|Simvastatin|One arm of randomized crossover
454383|NCT00736463|Drug|Atorvastatin 80 mg|Second arm of randomized crossover
454384|NCT00736450|Biological|oblimersen sodium|Given IV
454385|NCT00736450|Biological|rituximab|Given IV
454386|NCT00736450|Drug|cyclophosphamide|Given IV
454387|NCT00736450|Drug|doxorubicin hydrochloride|Given IV
454388|NCT00736450|Drug|vincristine sulfate|Given IV
454389|NCT00736450|Drug|prednisone|Given orally
454390|NCT00736450|Procedure|biopsy|Correlative studies
454391|NCT00736450|Genetic|microarray analysis|Correlative studies
454392|NCT00736450|Other|immunohistochemistry staining method|Correlative studies
454393|NCT00736450|Genetic|gene expression analysis|Correlative studies
454394|NCT00736450|Genetic|cytogenetic analysis|Correlative studies
454395|NCT00736437|Drug|ME-609|Cream applied topically 6 times daily over the UVR exposed area
454396|NCT00736437|Drug|Vehicle|Treatment applied 6 times daily over the UVR exposed area
454397|NCT00736424|Device|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
454398|NCT00736411|Procedure|acupuncture|16 treatments over 8 weeks
454399|NCT00736411|Procedure|IVF|one 4 week IVF cycle
454400|NCT00736398|Procedure|Spinal fusion|Spinal fusion
454401|NCT00736385|Drug|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
454402|NCT00736385|Drug|Placebo|placebo 2000 mg daily for 12 months
454403|NCT00736372|Drug|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
454404|NCT00736346|Behavioral|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
454405|NCT00736346|Behavioral|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
454406|NCT00736346|Drug|paroxetine|40 mg die, for 6 months
454407|NCT00736333|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m^2, given for up to 6 cycles
454408|NCT00736320|Drug|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
454409|NCT00736320|Radiation|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
454410|NCT00736307|Procedure|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
454411|NCT00736294|Drug|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
454412|NCT00736294|Drug|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
454413|NCT00736281|Other|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
454414|NCT00736268|Behavioral|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
454415|NCT00736268|Other|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
454416|NCT00736255|Drug|Transdermal Nicotine Patch|All subjects will lreceive transdermal nicotine patch during beginning at Visit 0 (quit smoke date). The dose will be tapered down from 21 mg to 14mg after week 1,vthen to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
454417|NCT00736255|Drug|Lis-dexamphetamine (Vyvanse)|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week.
454418|NCT00736255|Drug|Placebo|Subjects on this arm will receive matching placebo, along with Nicotine Replacement Therapy.
454419|NCT00736242|Biological|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
454420|NCT00736242|Drug|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
454421|NCT00736229|Drug|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
454422|NCT00736216|Other|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases [STDs], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
454423|NCT00736190|Drug|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
454424|NCT00736177|Procedure|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
454425|NCT00736177|Procedure|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
454426|NCT00736164|Dietary Supplement|selenomethionine|Given orally
454427|NCT00736164|Other|placebo|Given orally
454428|NCT00736151|Drug|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
454429|NCT00736138|Procedure|training and pellots|training and pellots
454430|NCT00736125|Device|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
454431|NCT00736125|Device|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
454432|NCT00736112|Other|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
454433|NCT00736112|Procedure|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
454434|NCT00736112|Procedure|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
454435|NCT00736099|Drug|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
454436|NCT00736099|Drug|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
454437|NCT00736086|Device|Vessel Closure (StarClose™)|
454438|NCT00736073|Drug|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
454439|NCT00736073|Drug|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
454440|NCT00736060|Other|Observational|Summary of clinical and laboratory data
454441|NCT00736047|Biological|NIC002|
454442|NCT00736047|Biological|Placebo|
454443|NCT00736034|Dietary Supplement|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
454444|NCT00736021|Drug|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
454445|NCT00736008|Other|Observational|Data summary only
454446|NCT00735995|Behavioral|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
454447|NCT00735995|Behavioral|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
454448|NCT00735969|Drug|Peginterferon|
454449|NCT00735969|Drug|Ribavirin|
454450|NCT00735956|Behavioral|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
454451|NCT00735943|Other|No intervention|No intervention
454452|NCT00735930|Drug|Alvocidib Hydrochloride|Given IV
454453|NCT00735930|Drug|Lenalidomide|Given PO
454454|NCT00735930|Other|Pharmacological Study|Correlative studies
454455|NCT00735930|Other|Laboratory Biomarker Analysis|Correlative studies
454456|NCT00735917|Drug|saracatinib|Given PO
454457|NCT00735917|Other|pharmacogenomic studies|Optional correlative studies
454458|NCT00735917|Other|pharmacological study|Optional correlative studies
454459|NCT00735917|Procedure|positron emission tomography|Optional correlative studies
454460|NCT00735917|Radiation|fludeoxyglucose F 18|Optional correlative studies
454461|NCT00735917|Other|laboratory biomarker analysis|Optional correlative studies
454462|NCT00735904|Drug|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
454463|NCT00735904|Drug|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
454464|NCT00735904|Drug|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
454465|NCT00735878|Drug|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
454466|NCT00735865|Procedure|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin & tarsal/inferior fornix conjunctiva obtained & plated according to protocol
454467|NCT00735865|Procedure|Punctal Plug, Punctal thermocauterization|"Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.~This group ONLY, cultures will be obtained of the lid margin & conjunctiva/inferior fornix of BOTH eyes"
454468|NCT00735865|Procedure|Silicone plug or thermodynamic hydrophobic acrylic plug|"Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.~In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes"
454469|NCT00735865|Other|Previous subjects with Punctal occlusion|"Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.~Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol."
454470|NCT00735852|Drug|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
454471|NCT00735839|Biological|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
454472|NCT00735839|Biological|Placebo|Saline placebo (0.5 ml) single injection on Day 1
454473|NCT00735826|Drug|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
454474|NCT00735813|Device|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
454475|NCT00735813|Device|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
454476|NCT00735800|Behavioral|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
454477|NCT00735800|Behavioral|Telephone Support|Supportive telephone counseling about caregiving
454478|NCT00735787|Biological|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
454479|NCT00735787|Biological|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
454480|NCT00735774|Drug|11C-ORM-13070|Single dose of i.v. solution
454481|NCT00735761|Drug|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
454482|NCT00735761|Drug|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
454483|NCT00735748|Drug|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
454484|NCT00735748|Drug|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
454485|NCT00735735|Other|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
454486|NCT00735722|Device|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
454487|NCT00735709|Drug|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
454488|NCT00735709|Drug|Placebo|Vortioxetine placebo-matching capsules
454489|NCT00735696|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
454490|NCT00735696|Drug|Paclitaxel|200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
454491|NCT00735696|Drug|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
454492|NCT00735683|Drug|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
454493|NCT00735683|Drug|Placebo|includes diet, physical activity, and lifestyle modification
454494|NCT00735670|Drug|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
454495|NCT00735670|Other|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
454496|NCT00735657|Device|needle|Peribulbar blockade with standard (25 mm) needle
454497|NCT00735657|Device|needle|Peribulbar blockade with short (12.5 mm) needle
454498|NCT00735657|Procedure|Pars Plana Vitrectomy|Peribulbar block
454499|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
454500|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
454501|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
454502|NCT00735644|Biological|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
454503|NCT00735644|Biological|Hepatitis A vaccine|0.5 mL, Intramuscular
454504|NCT00735631|Device|SISO model-based predictive closed-loop system|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
454505|NCT00735618|Other|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
454506|NCT00735605|Other|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
454507|NCT00735605|Procedure|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
454508|NCT00735605|Other|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
454509|NCT00735592|Other|Observational|Retrospective data obtained from electronic files
454510|NCT00735553|Drug|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
454511|NCT00735553|Drug|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
454512|NCT00735553|Drug|Placebo|Two placebo capsules orally daily for up to four months
454513|NCT00735540|Other|Observational|Data summary only
454514|NCT00735527|Drug|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
454515|NCT00735527|Drug|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
454516|NCT00735514|Behavioral|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
454517|NCT00735514|Other|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
454518|NCT00735514|Procedure|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
454519|NCT00735514|Procedure|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
454520|NCT00735514|Procedure|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
454521|NCT00735501|Drug|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
454522|NCT00735488|Other|Observational|Summary of data
454523|NCT00735475|Biological|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
454524|NCT00735475|Biological|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
454525|NCT00735462|Drug|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
454526|NCT00735462|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
454527|NCT00735462|Drug|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
454528|NCT00735449|Drug|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
454529|NCT00735449|Drug|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
454530|NCT00735449|Drug|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
454531|NCT00735436|Drug|Gliadel/Avastin/CPT-11|
454532|NCT00735423|Device|No intervention|IDE used for outcome measurement not intervention
454533|NCT00735410|Biological|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
454534|NCT00735397|Drug|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
454535|NCT00735371|Drug|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
454536|NCT00735371|Drug|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
454537|NCT00735371|Drug|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
454538|NCT00735371|Drug|Placebo|Placebo will be identical to test product.
454539|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
454540|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
454541|NCT00735345|Drug|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
454542|NCT00735345|Drug|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
454543|NCT00735345|Drug|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
454544|NCT00735345|Biological|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
454545|NCT00735345|Radiation|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
454546|NCT00735332|Drug|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
454547|NCT00735319|Device|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
454548|NCT00735306|Drug|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
454549|NCT00735306|Drug|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
454550|NCT00735306|Radiation|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
454551|NCT00735293|Device|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
454552|NCT00735280|Drug|unfractionated heparin|bolus of 100 U/kg of unfractionated heparin
454553|NCT00735267|Drug|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
454554|NCT00735254|Device|pulsed dye laser|patient will have scar treated with pulsed dye laser
454555|NCT00735254|Device|Affirm Laser|patient will have scar treated with Affirm laser
454556|NCT00735254|Device|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
454557|NCT00735254|Other|Placebo|patient will receive no treatment
454558|NCT00735241|Device|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
454559|NCT00735241|Drug|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
454560|NCT00735241|Drug|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
454561|NCT00735241|Drug|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
454562|NCT00735228|Device|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
454563|NCT00735189|Other|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
454564|NCT00735189|Other|usual care|patient receives usual anticoagulation care from their regular primary care physician
454565|NCT00735176|Procedure|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
454566|NCT00735176|Procedure|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
454567|NCT00735163|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
454568|NCT00735150|Behavioral|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
454569|NCT00735137|Device|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
454570|NCT00735124|Drug|Gabapentin|1200 mg single dose gabapentin
454571|NCT00735124|Other|placebo|Injection of placebo/sham
454572|NCT00735111|Other|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
454573|NCT00735098|Other|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
454574|NCT00735098|Other|strength training exercise|strength training exercise, 3 times per week for 8 weeks
454575|NCT00735098|Other|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
454576|NCT00735098|Other|Control group|8 week control group
454577|NCT00735085|Drug|SLV334|1000mg SLV334 as a single dose
454578|NCT00735085|Drug|SLV334|1000mg SLV334 b.i.d. for one day
454579|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for one day
454580|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for three days
454581|NCT00735085|Drug|Placebo|SLV334 Placebo arm
454582|NCT00735072|Drug|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
454583|NCT00735072|Drug|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
454584|NCT00735059|Device|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, > 3 hours
454585|NCT00735059|Device|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, > 3 hours
454586|NCT00735046|Behavioral|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
454587|NCT00735046|Other|Control|Patients and proxies who are assigned to treatment as usual
454588|NCT00735033|Other|Physiotherapy with Swiss Ball|
454589|NCT00735020|Biological|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
454590|NCT00735020|Biological|Influenza Vaccine|1 dose of Influenza Vaccine
454591|NCT00735007|Drug|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
454592|NCT00734994|Device|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
454593|NCT00734994|Drug|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
454594|NCT00734968|Drug|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
454595|NCT00734968|Other|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
454596|NCT00734955|Device|49-channel optical spectrometer|
454597|NCT00734942|Other|support service|"professional partners for communication~befriending with other families concerned~information and education (about illness, symptoms, first aid, caring)~free-time activities and time out~homework assistance~administrative advise~support for everyday life"
454598|NCT00734929|Drug|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
454599|NCT00734929|Drug|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
454600|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
454601|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
454602|NCT00734916|Dietary Supplement|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
454603|NCT00734903|Behavioral|A Woman's Path to Recovery|WPR is a gender-specific therapy model for women with substance use disorder. It uses A Woman's Addiction Workbook to provide education and coping skills. In this trial it was conducted in 12 weekly individual sessions.
454604|NCT00734903|Behavioral|12-Step Facilitation|12SF is an evidence-based therapy designed to facilitate early recovery from substance addiction. It is an individual model consisting of 12 sessions that use the principles of 12-step groups such as Alcoholics Anonymous, and strongly emphasizes participation in those. In this trial the model was conducted weekly.
454605|NCT00734890|Biological|bevacizumab|
454606|NCT00734890|Drug|vandetanib|
454607|NCT00734890|Other|laboratory biomarker analysis|
454608|NCT00734890|Other|pharmacological study|
454609|NCT00734877|Drug|M-VTD-PACE|2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
454610|NCT00734877|Drug|TT3-LITE Regimen (L-TT3)|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
454611|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
454612|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
454613|NCT00734851|Drug|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
454614|NCT00734851|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
454615|NCT00734851|Radiation|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
454616|NCT00734838|Device|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
454617|NCT00734825|Other|Omnipaque|oral contrast for CT scan
454618|NCT00734812|Procedure|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
454619|NCT00734812|Procedure|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
454620|NCT00734799|Behavioral|Sleep Intervention for PTSD (SIP).|"Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress."
454621|NCT00734786|Other|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
454622|NCT00734773|Biological|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
454623|NCT00734773|Drug|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
454624|NCT00734773|Drug|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
454625|NCT00734773|Drug|Motexafin gadolinium|"Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).~For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.~During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
454626|NCT00734773|Drug|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
454627|NCT00734773|Drug|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
454628|NCT00734773|Radiation|Radiation therapy|Given at weeks 11 through 16.
454629|NCT00734760|Behavioral|education|face-to-face education and counseling intervention
454630|NCT00734747|Device|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
454631|NCT00734734|Biological|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
454632|NCT00734721|Behavioral|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
454633|NCT00734708|Drug|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
454634|NCT00734708|Drug|Placebo|Control
454635|NCT00734695|Dietary Supplement|vitamin c|Subconjunctival daily or bid
454636|NCT00734695|Dietary Supplement|vitamin c|topical and systemic
454637|NCT00734695|Dietary Supplement|vitamin c|topical systemic
454638|NCT00734682|Drug|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m^2 (wild type) or 60 mg/m^2 IV q3 weeks.
454639|NCT00734669|Drug|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
454640|NCT00734656|Drug|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
454641|NCT00734656|Drug|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
454642|NCT00734656|Drug|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
454643|NCT00734656|Drug|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
454644|NCT00734630|Drug|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily~Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
454645|NCT00734630|Drug|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
454646|NCT00734617|Drug|Nicotine Patch|"Groups 1 & 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day~Groups 2 & 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
454647|NCT00734604|Drug|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
454648|NCT00734604|Drug|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
454649|NCT00734604|Drug|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
454650|NCT00734591|Drug|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
454651|NCT00734591|Other|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.~Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
454652|NCT00734578|Drug|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
454653|NCT00734578|Drug|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
454654|NCT00734578|Drug|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
454655|NCT00734565|Biological|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
454795|NCT00733668|Drug|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
455345|NCT00729729|Drug|PCA|PO, 700mg, once
454656|NCT00734552|Dietary Supplement|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.~Low Protein Diet: Diet contain protein 0.8g/kg/d."
454657|NCT00734552|Dietary Supplement|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
454658|NCT00734539|Drug|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
454659|NCT00734539|Drug|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
454660|NCT00734526|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.~Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
454661|NCT00734526|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
454662|NCT00734526|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.~Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.~Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
454663|NCT00734513|Behavioral|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
454664|NCT00734513|Behavioral|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
454665|NCT00734500|Drug|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
454666|NCT00734474|Drug|LY2189265|
454667|NCT00734474|Drug|Sitagliptin|
454668|NCT00734474|Drug|Placebo solution|
454669|NCT00734474|Drug|Placebo tablet|
454670|NCT00734474|Drug|Metformin|
454671|NCT00734461|Drug|oxycodone and naltrexone|"tablets containing 20 mg or 40 mg oxycodone~/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone"
454672|NCT00734448|Dietary Supplement|myo-inositol|2 g twice a day until delivery
454673|NCT00734435|Drug|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
454674|NCT00734435|Drug|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
454675|NCT00734422|Behavioral|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
454676|NCT00734409|Device|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
454677|NCT00734396|Procedure|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
454678|NCT00734383|Drug|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
454679|NCT00734383|Drug|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
454680|NCT00734370|Behavioral|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Virtual reality Exposure to agoraphobic situations and interoceptive exposure~Relapse prevention"
454681|NCT00734370|Behavioral|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of~Psycho-education, breathing training and cognitive restructuring~Standard exposure in vivo to agoraphobic situations and interoceptive exposure~Relapse prevention (according to the protocol of Craske & Barlow)"
454682|NCT00734357|Procedure|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
454683|NCT00734344|Drug|Raltegravir|Raltegravir 400 mg. BID
454684|NCT00734344|Drug|Efavirenz|600 mg once daily
454685|NCT00734344|Drug|Emtricitibine|200mg once daily
454686|NCT00734344|Drug|Tenofovir disoproxil once daily|300mg once daily
454687|NCT00734344|Drug|Tenofovir disoproxil twice daily|300mg twice daily
454688|NCT00734318|Drug|Flutiform 250/10 micrograms|
454689|NCT00734318|Drug|Flutiform 50/5 micrograms|
454690|NCT00734318|Drug|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
454691|NCT00734318|Drug|Flixotide pMDI 250 micrograms|
454692|NCT00734305|Drug|MM-121|Dose escalation Frequency - once weekly
454693|NCT00734292|Drug|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)"
454694|NCT00734292|Other|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"
454695|NCT00734292|Other|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"
454696|NCT00734279|Drug|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
454697|NCT00734279|Drug|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
454698|NCT00734279|Drug|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
454699|NCT00734279|Drug|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
454700|NCT00734253|Drug|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
454701|NCT00734253|Drug|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
454702|NCT00734253|Drug|Placebo|Placebo capsules taken twice a day for 1-year
454703|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, single dose
454704|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
454705|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, single dose
454706|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
454707|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
454708|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, single dose
454709|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, single dose
454710|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, single dose
454711|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, single-dose
454712|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
454713|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
454714|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
454715|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
454716|NCT00734240|Drug|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
454717|NCT00734240|Drug|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
454718|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
454719|NCT00734227|Procedure|Emergency portacaval shunt|
454720|NCT00734227|Other|Emergency TIPS|
454721|NCT00734214|Drug|0.9% NaCl|"Intravenous Fluid~Isotonic Parenteral Fluid"
454722|NCT00734214|Drug|0.45%NaCl|"Intravenous Fluid~Hypotonic Parenteral Fluid"
454723|NCT00734201|Drug|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
454724|NCT00734188|Drug|PTI-6D2|monoclonal antibody
454725|NCT00734175|Biological|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
454726|NCT00734162|Drug|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet once daily
454727|NCT00734162|Drug|Placebo|TDF placebo tablet once daily
454728|NCT00734149|Drug|Bortezomib|
454729|NCT00734149|Drug|Melphalan|
454730|NCT00734149|Drug|Prednisone|
454731|NCT00734136|Procedure|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).~Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.~Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
454732|NCT00734136|Procedure|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
454733|NCT00734123|Drug|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
454734|NCT00734123|Drug|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
454735|NCT00734123|Drug|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
454736|NCT00734123|Drug|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.~Drugs will be prescribed as the standard clinical care"
454737|NCT00734110|Device|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
454738|NCT00734097|Drug|Esomeprazole 40 mg|Once a day
454739|NCT00734097|Procedure|Physical Exam|every visit
454740|NCT00734097|Other|Quality of Life Questionnaires|every visit
454741|NCT00734097|Procedure|pregnancy test, if applicable|as needed
454742|NCT00734084|Device|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
454743|NCT00734071|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
454744|NCT00734071|Drug|Placebo|Vortioxetine placebo-matching capsules
454796|NCT00733642|Biological|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
455346|NCT00729729|Drug|PCA|PO, 1000mg, once
454745|NCT00734058|Device|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
454746|NCT00734032|Drug|SB480848 40mg EC Tablet|1 tablet once a day
454747|NCT00734032|Drug|SB480848 80mg EC Tablet|1 tablet once a day
454748|NCT00734032|Drug|SB480848 160mg EC Tablet|1 tablet once a day
454749|NCT00734032|Drug|SB480848 Placebo Tablet|1 tablet once a day
454750|NCT00734019|Device|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
454751|NCT00733993|Drug|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
454752|NCT00733993|Drug|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
454753|NCT00733993|Drug|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
454754|NCT00733993|Drug|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
454755|NCT00733980|Drug|GSK561679|GSK561679
454756|NCT00733980|Other|Placebo|Placebo
454757|NCT00733967|Drug|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
454758|NCT00733967|Drug|Placebo|Matching oral placebo capsules as control.
454759|NCT00733954|Drug|clobetasol propionate spray|Apply twice daily
454760|NCT00733954|Drug|clobetasol propionate ointment|Apply twice daily
454761|NCT00733941|Behavioral|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
454762|NCT00733941|Behavioral|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
454763|NCT00733928|Device|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
454764|NCT00733928|Device|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
454765|NCT00733915|Device|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
454766|NCT00733902|Biological|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
454767|NCT00733902|Biological|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
454768|NCT00733902|Biological|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
454769|NCT00733902|Biological|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
454770|NCT00733889|Drug|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:~3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.~Radio-chemotherapy plus cetuximab:~The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).~Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
454771|NCT00733876|Biological|Multipotent Stromal Cells|Post-operative administration of MSC
454772|NCT00733876|Biological|Administration of MSC|Dose escalation protocol
454773|NCT00733863|Biological|Placebo|
454774|NCT00733863|Biological|CAD106|
454775|NCT00733850|Drug|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
454776|NCT00733850|Drug|Gemcitabine|Intravenous repeating dose
454777|NCT00733837|Other|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
454778|NCT00733824|Drug|AMD3100|
454779|NCT00733824|Drug|G-CSF|
454780|NCT00733824|Procedure|Apheresis|
454781|NCT00733811|Drug|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
454782|NCT00733811|Drug|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
454783|NCT00733798|Drug|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
454784|NCT00733785|Drug|Rosiglitazone XR|Rosiglitazone extended release formulation
454785|NCT00733772|Dietary Supplement|flaxseed|30 grams/day of flaxseed for 12 weeks
454786|NCT00733772|Behavioral|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
454787|NCT00733746|Drug|erlotinib hydrochloride|oral administration
454788|NCT00733746|Drug|gemcitabine hydrochloride|Intravenous administration
454789|NCT00733746|Procedure|therapeutic conventional surgery|
454790|NCT00733733|Drug|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
454791|NCT00733720|Drug|Suboxone|4/1mg, 8/2mg 16/4mg
454792|NCT00733707|Behavioral|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
454793|NCT00733694|Device|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
454794|NCT00733681|Device|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
454797|NCT00733642|Biological|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
454798|NCT00733642|Biological|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
454799|NCT00733642|Biological|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
454800|NCT00733616|Drug|DOX: Docetaxel, oxaliplatin, Capecitabine|"Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1~Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1~Capecitabine 625 mg/m2, bid, oral, continuous~6 cycles, every 3 weeks~Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
454801|NCT00733603|Other|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
454802|NCT00733603|Other|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
454803|NCT00733577|Drug|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
454804|NCT00733564|Drug|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
454805|NCT00733564|Drug|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
454806|NCT00733564|Drug|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
454807|NCT00733551|Drug|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
454808|NCT00733551|Drug|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
454809|NCT00733538|Drug|zometa|patients receiving treatment during their follow-up
454810|NCT00733525|Behavioral|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
454811|NCT00733525|Drug|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
454812|NCT00733525|Behavioral|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
454813|NCT00733512|Device|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
454814|NCT00733499|Device|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
454815|NCT00733499|Device|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
454816|NCT00733486|Device|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
454817|NCT00733473|Drug|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
454818|NCT00733473|Drug|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
454819|NCT00733460|Drug|BFPET|
454820|NCT00733447|Device|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
454821|NCT00733434|Drug|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
454822|NCT00733434|Other|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
454823|NCT00733421|Drug|etoricoxib|90 mg once daily
454824|NCT00733421|Drug|tramadol|100 mg twice daily
454825|NCT00733408|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
454826|NCT00733408|Biological|bevacizumab|Given IV
454827|NCT00733408|Drug|erlotinib hydrochloride|Given PO
454828|NCT00733395|Dietary Supplement|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
454829|NCT00733395|Dietary Supplement|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
454830|NCT00733382|Drug|dexamethazone|injection form, 8 miligram, injected once
454831|NCT00733369|Device|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
454832|NCT00733369|Device|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
454833|NCT00733356|Drug|Vyvanse|Subjects will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subjects will take their prescribed dose once a day in the morning with breakfast.
454834|NCT00733343|Device|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
454835|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
454836|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
454837|NCT00733317|Drug|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
454838|NCT00733317|Drug|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
454839|NCT00733304|Drug|Pazopanib|5 mg/ml TID, 2 mg/ml TID or 5 mg/ml QD
454840|NCT00733291|Device|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
454841|NCT00733291|Device|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
454842|NCT00733291|Device|FID 107027 solution|Commercially marketed solution for contact lens disinfection
454843|NCT00733278|Device|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
454844|NCT00733265|Drug|AZD6140|single oral dose
454845|NCT00733252|Procedure|bronchoscopic and lung imaging studies|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
454846|NCT00733252|Procedure|diagnostic bronchoscopy|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
454847|NCT00733252|Procedure|histopathologic examination|All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
454848|NCT00733252|Procedure|optical coherence tomography|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
454849|NCT00733239|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
454850|NCT00733226|Drug|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
454851|NCT00733226|Drug|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
454852|NCT00733200|Procedure|Minor or Major Liver Resection|
454853|NCT00733187|Drug|ABT-869|0.25 mg/kg
454854|NCT00733174|Drug|Rosiglitazone|tablet
454855|NCT00733174|Drug|Placebo|
454856|NCT00733161|Other|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
454857|NCT00733161|Other|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
454858|NCT00733148|Drug|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
454859|NCT00733135|Device|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
454860|NCT00733122|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
454861|NCT00733109|Procedure|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
454862|NCT00733109|Other|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
454863|NCT00733096|Drug|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
454864|NCT00733096|Drug|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
454865|NCT00733096|Drug|normal saline|Two transforaminal epidural saline injections, two weeks apart
454866|NCT00733083|Drug|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
454867|NCT00733083|Drug|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
454868|NCT00733083|Drug|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
454869|NCT00733083|Drug|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
454870|NCT00733070|Device|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
454871|NCT00733057|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
454872|NCT00733057|Drug|Placebo (200 mg/day)|
454873|NCT00733044|Behavioral|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
454874|NCT00733044|Other|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
454875|NCT00733031|Drug|AZD6918|liquid suspension, daily, oral dose
454876|NCT00733031|Drug|gemcitabine|intravenous, doses are on an intermittent schedule
454877|NCT00733031|Drug|pemetrexed|intravenous, dose administered every 21-days
454878|NCT00733018|Behavioral|"Western versus balanced macro nutrient diet composition"|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
454879|NCT00733005|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
454880|NCT00733005|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
454881|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
454882|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
454883|NCT00732979|Procedure|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
455125|NCT00731302|Drug|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
454884|NCT00732979|Procedure|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
454885|NCT00732966|Drug|losartan|with losartan 50 mg once daily for one month
454886|NCT00732966|Drug|valsartan|valsartan 160 mg once daily
454887|NCT00732953|Device|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
454888|NCT00732953|Device|Genous stent implantation|Genous stent implantation
454889|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
454890|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
454891|NCT00732927|Drug|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
454892|NCT00732927|Drug|aspirin|tablets, 100 mg for 3 months
454893|NCT00732914|Drug|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
454894|NCT00732914|Drug|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
454895|NCT00732901|Drug|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
454896|NCT00732901|Drug|Placebo|Once daily days 1-28
454897|NCT00732888|Drug|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
454898|NCT00732888|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
454899|NCT00732875|Biological|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
454900|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
454901|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
454902|NCT00732849|Drug|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
454903|NCT00732836|Drug|HAI Abraxane|Escalating doses (beginning dose 180 mg/m^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
454904|NCT00732836|Procedure|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
454905|NCT00732836|Drug|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
454906|NCT00732823|Device|Placebo - No device worn|
454907|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454908|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454909|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454910|NCT00732810|Drug|SCH 727965|SCH 727965 50 mg/m^2 IV on Day 1 of each 21 day cycle until disease progression.
454911|NCT00732810|Drug|Capecitabine|Capecitabine 1250 mg/m^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
454912|NCT00732810|Drug|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
454913|NCT00732797|Behavioral|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
454914|NCT00732797|Behavioral|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
454915|NCT00732784|Drug|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
454916|NCT00732784|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
454917|NCT00732771|Drug|LCI699|
454918|NCT00732758|Dietary Supplement|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
454919|NCT00732758|Dietary Supplement|Placebo Tablet|Placebo Tablet once daily for 6 months
454920|NCT00732745|Drug|docetaxel|Given IV
454921|NCT00732745|Drug|oxaliplatin|Given IV
454922|NCT00732745|Drug|vandetanib|Given orally
454923|NCT00732745|Other|placebo|Given orally
454924|NCT00732732|Dietary Supplement|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
454925|NCT00732732|Other|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
454926|NCT00732719|Device|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
454927|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454928|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454929|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454930|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454931|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454932|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
454933|NCT00732706|Procedure|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
454934|NCT00732706|Procedure|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
454935|NCT00732693|Drug|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
454936|NCT00732693|Drug|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
454937|NCT00732680|Drug|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
454938|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
454939|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
454940|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
454941|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
454942|NCT00732641|Drug|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
454943|NCT00732628|Device|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
454944|NCT00732615|Drug|Placebo|Placebo for subcutaneous injection
454945|NCT00732615|Drug|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
454946|NCT00732602|Other|GIP-infusion|
454947|NCT00732602|Other|Sodium-chloride|
454948|NCT00732602|Other|GLP-2 infusion|
454949|NCT00732589|Drug|1% xylocaine|10 cc. of 1%xylocaine, once a week
454950|NCT00732589|Other|ultrasound|ultrasound at shoulder area about 10 mins.
454951|NCT00732576|Dietary Supplement|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
454952|NCT00732576|Dietary Supplement|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
454953|NCT00732576|Dietary Supplement|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
454954|NCT00732563|Drug|chemotherapy|Given IV and Orally
454955|NCT00732563|Procedure|lymphadenectomy|Removal of lymph nodes
454956|NCT00732563|Procedure|neoadjuvant therapy|Tumor reduction
454957|NCT00732563|Procedure|quality-of-life assessment|Correlative Study
454958|NCT00732563|Procedure|therapeutic conventional surgery|Treatment for cancer
454959|NCT00732563|Procedure|thoracic surgical procedure|removal of tissue
454960|NCT00732563|Radiation|fludeoxyglucose F 18|given IV
454961|NCT00732563|Radiation|radiation therapy|undergoing radiotherapy
454962|NCT00732550|Procedure|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
454963|NCT00732550|Procedure|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
454964|NCT00732537|Drug|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If >5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If > 5% drop in oxygen saturation or >5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
454965|NCT00732537|Drug|Oxygen (>90% by hood) - standard therapy|"Oxygen (>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
454966|NCT00732524|Drug|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
454967|NCT00732524|Drug|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
454968|NCT00732511|Drug|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
454969|NCT00732511|Drug|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
454970|NCT00732498|Drug|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
454971|NCT00732498|Drug|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
454972|NCT00732498|Drug|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
454973|NCT00732498|Drug|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
454974|NCT00732498|Drug|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
454975|NCT00732498|Drug|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
455092|NCT00731614|Behavioral|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
454976|NCT00732498|Drug|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from >/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
454977|NCT00732485|Drug|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
454978|NCT00732485|Drug|placebo|Placebo, sugar pill, from admission to 6 months post burn
454979|NCT00732472|Drug|GSK573719|7 day repeat dose
454980|NCT00732459|Device|Electro-acupuncture preconditioning|electro-acupuncture
454981|NCT00732446|Drug|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
454982|NCT00732446|Drug|Moxifloxacin|moxifloxacin 0,5% qid and
454983|NCT00732446|Drug|Dexamethasone|dexamethasone 0,1% qid
454984|NCT00732433|Procedure|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
454985|NCT00732420|Drug|topotecan|Topoisomerase I inhibition.
454986|NCT00732420|Drug|pazopanib|Tyrosine kinase inhibitor
454987|NCT00732407|Drug|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
454988|NCT00732407|Drug|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
454989|NCT00732394|Other|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.~MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
454990|NCT00732381|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
454991|NCT00732381|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
454992|NCT00732368|Drug|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
454993|NCT00732355|Device|Syph-Check POC|Rapid membrane test for syphilis antibodies
454994|NCT00732342|Behavioral|Contingency Management|Prizes given for targeted behavior of abstinence
454995|NCT00732329|Behavioral|Occupational Therapy|"optimized home Based Occupational Therapy including:~diagnostic assessment~patient-centered definition of targets involving the care giver~occupational therapy"
454996|NCT00732316|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
454997|NCT00732316|Procedure|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
454998|NCT00732303|Drug|Pemetrexed|Pemetrexed (Alimta) 500mg/^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
454999|NCT00732303|Radiation|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
455000|NCT00732290|Drug|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
455001|NCT00732290|Drug|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
455002|NCT00732277|Drug|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
455003|NCT00732251|Drug|Allopurinol|Allopurinol: 300-600 mg/day over a 24 month period
455004|NCT00732238|Other|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
455005|NCT00732238|Other|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
455006|NCT00732225|Device|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
455007|NCT00732225|Device|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
455008|NCT00732225|Device|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
455009|NCT00732225|Device|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
455010|NCT00732225|Device|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
455011|NCT00732212|Device|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
455124|NCT00731315|Other|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
455012|NCT00732212|Other|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage & visual cues for risk stratification and completion of endoscopic treatment.
455013|NCT00732199|Other|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
455014|NCT00732186|Biological|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
455015|NCT00732173|Behavioral|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
455016|NCT00732173|Behavioral|exercise intervention|Undergo SUCCEED lifestyle intervention
455017|NCT00732173|Other|counseling intervention|Undergo SUCCEED lifestyle intervention
455018|NCT00732173|Other|educational intervention|Receive information
455019|NCT00732173|Other|survey administration|Undergo SUCCEED lifestyle intervention
455020|NCT00732160|Drug|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
455021|NCT00732160|Drug|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
455022|NCT00732160|Other|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
455023|NCT00732160|Other|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
455024|NCT00732147|Drug|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
455025|NCT00732147|Drug|Placebo|120 micrograms given subcutaneously before each meal x 3.
455026|NCT00732121|Drug|Sitagliptin|100 mg daily for 4 weeks
455027|NCT00732121|Drug|Placebo|Placebo
455028|NCT00732108|Drug|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
455029|NCT00732108|Drug|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
455030|NCT00732095|Behavioral|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
455031|NCT00732082|Drug|Gemcitabine|
455032|NCT00732082|Biological|LAG-3|
455033|NCT00732069|Drug|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
455034|NCT00732069|Drug|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
455035|NCT00732069|Drug|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
455036|NCT00732056|Drug|GRN163L|25% dose escalation infused over 2 hours weekly
455037|NCT00732043|Dietary Supplement|pomegranate extract|8 oz per day, 48 months
455038|NCT00732043|Dietary Supplement|pomegranate juice|8 oz per day, 48 months
455039|NCT00732043|Dietary Supplement|placebo|8 oz per day, 48 months
455040|NCT00732030|Device|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
455041|NCT00732017|Device|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
455042|NCT00732017|Device|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
455043|NCT00732017|Other|standard physical therapy treatment|"Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
455044|NCT00732004|Device|Silicone Hydrogel Contact Lenses|
455045|NCT00732004|Device|1x PMBH preserved MPS|
455046|NCT00732004|Device|1x Polyquad/Aldox MPS|
455047|NCT00731991|Other|ART|ART to the levator scapulae.
455048|NCT00731991|Other|PNF|PNF to the levator scapulae.
455049|NCT00731991|Other|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
455050|NCT00731978|Procedure|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
455388|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
455051|NCT00731965|Biological|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
455052|NCT00731952|Drug|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
455053|NCT00731939|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
455054|NCT00731926|Dietary Supplement|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
455055|NCT00731926|Dietary Supplement|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
455056|NCT00731926|Other|placebo|twice a day for 1 month
455057|NCT00731913|Other|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
455058|NCT00731887|Procedure|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
455059|NCT00731874|Drug|Tacrolimus|Dosed to achieve target trough concentrations.
455060|NCT00731861|Drug|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
455061|NCT00731848|Dietary Supplement|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
455062|NCT00731835|Procedure|Endovascular Revascularization|"angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or~stent placement~atherectomy"
455063|NCT00731822|Drug|GW685698/GW642444|GW685698/GW642444
455064|NCT00731809|Radiation|FDG PET CT|FDG PET CT
455065|NCT00731796|Device|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
455066|NCT00731783|Drug|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
455067|NCT00731783|Drug|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
455068|NCT00731783|Behavioral|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:~Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.~Use liquid(pour or pump) soaps instead of bar soaps.~Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.~Do not share personal care items such as razors and brushes.~Wash all sheets and towels in hot water. Wash sheets every week.~Use towels and wash cloths only once before washing and do not share."
455069|NCT00731770|Drug|Advair 250|1 puff bid inhaled
455070|NCT00731770|Drug|Placebo- matched|1 puff bid inhaled
455071|NCT00731770|Drug|Placebo|Placebo 1 puff bid inhaled
455072|NCT00731770|Drug|Advair 250 - matched|i puff bid inhaled
455073|NCT00731757|Drug|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
455074|NCT00731744|Procedure|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
455075|NCT00731731|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
455076|NCT00731731|Procedure|Cognitive Assessment|Ancillary studies
455077|NCT00731731|Other|Laboratory Biomarker Analysis|Correlative studies
455078|NCT00731731|Drug|Temozolomide|Given PO
455079|NCT00731731|Drug|Vorinostat|Given PO
455080|NCT00731718|Device|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
455081|NCT00731705|Procedure|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
455082|NCT00731692|Drug|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
455083|NCT00731692|Drug|Placebo|Matching placebo capsules were administered orally once daily
455084|NCT00731679|Drug|Rifaximin|
455085|NCT00731679|Drug|Placebo|
455086|NCT00731666|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
455087|NCT00731653|Drug|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
455088|NCT00731640|Device|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
455089|NCT00731627|Drug|placebo|one tablet a day for up to 21 days
455090|NCT00731627|Drug|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
455091|NCT00731614|Behavioral|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
455093|NCT00731614|Behavioral|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
455094|NCT00731601|Drug|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
455095|NCT00731601|Drug|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
455096|NCT00731588|Biological|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns ~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
455097|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
455098|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
455099|NCT00731575|Drug|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
455100|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
455101|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
455102|NCT00731549|Drug|Aripiprazole IM Depot|300mg or 400mg
455103|NCT00731536|Other|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
455104|NCT00731523|Drug|fingolimod (FTY720)|
455105|NCT00731510|Dietary Supplement|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
455106|NCT00731510|Dietary Supplement|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
455107|NCT00731497|Device|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
455108|NCT00731471|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
455109|NCT00731458|Device|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
455110|NCT00731445|Drug|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
455111|NCT00731432|Drug|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
455112|NCT00731432|Drug|Placebo Patch|Identical in shape and texture to treatment patch
455113|NCT00731419|Device|SEMS|Comparing plastic and metal stents
455114|NCT00731393|Biological|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
455115|NCT00731393|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
455116|NCT00731380|Drug|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
455117|NCT00731367|Device|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
455118|NCT00731367|Device|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
455119|NCT00731354|Device|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
455120|NCT00731354|Device|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
455121|NCT00731341|Procedure|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
455122|NCT00731328|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
455123|NCT00731315|Other|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
455126|NCT00731289|Drug|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
455127|NCT00731289|Drug|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)~antiinflammatory intervention"
455128|NCT00731276|Drug|irinotecan hydrochloride|
455129|NCT00731276|Other|pharmacogenomic studies|
455130|NCT00731276|Other|pharmacological study|
455131|NCT00731263|Drug|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
455132|NCT00731250|Drug|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
455133|NCT00731250|Drug|Placebo|Subjects will be administered SB-705498 matching placebo tablets
455134|NCT00731250|Other|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
455135|NCT00731224|Drug|Rivastigmine transdermal patch|
455136|NCT00731211|Drug|Pazopanib|800 mg of pazopanib orally each day continuously
455137|NCT00731198|Drug|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
455138|NCT00731198|Drug|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
455139|NCT00731185|Drug|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
455140|NCT00731185|Drug|Placebo|
455141|NCT00731172|Drug|glatiramer acetate|20 mg daily subcutaneous injection through week 12
455142|NCT00731172|Drug|placebo|subcutaneous daiky injection through week 12
455143|NCT00731159|Biological|sperm capacitation|sperm capacitation measured at Bar Ilan University
455144|NCT00731159|Other|biologic|sperm synthesis of G-actine to F-actine
455145|NCT00731159|Other|sperm capacitation|sperm synthesis of G-actine to F-actine
455146|NCT00731146|Other|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
455147|NCT00731146|Other|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
455148|NCT00731133|Drug|Disulfiram|250 mg/day
455149|NCT00731120|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
455150|NCT00731120|Drug|Placebo|Vortioxetine placebo-matching capsules
455151|NCT00731107|Procedure|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
455152|NCT00731107|Procedure|laparoscopic surgery|Veress Needle laparoscopic entry
455153|NCT00731094|Behavioral|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
455154|NCT00731068|Biological|PRGF|injection of 6cc into injured area of tendon
455155|NCT00731068|Biological|placebo|injection of 6 cc of saline into injured area
455156|NCT00731055|Drug|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
455157|NCT00731055|Drug|Placebo|1 dose of placebo
455158|NCT00731042|Drug|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
455159|NCT00731042|Drug|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
455160|NCT00731029|Biological|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
455161|NCT00731029|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
455162|NCT00731016|Drug|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily~Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :~injection 1, S1: 0.0125 mg/kg of zoledronic acid~injection 2, S6: 0.025 mg/kg of zoledronic acid~injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
455163|NCT00731003|Drug|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
455164|NCT00731003|Other|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
455165|NCT00731003|Other|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
455166|NCT00731003|Drug|Placebo capsule|Placebo for 5-HTP
455167|NCT00730990|Other|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
455168|NCT00730990|Drug|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
455169|NCT00730990|Drug|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
455170|NCT00730990|Drug|PET Scan with PF-03654746|"Part 2 of the study will have 3 possible interventions:~1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg)."
455171|NCT00730977|Drug|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
455389|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
455172|NCT00730964|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.~The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .~The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
455173|NCT00730951|Dietary Supplement|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
455174|NCT00730951|Dietary Supplement|Corn Starch|500mg Capsulated Corn Starch
455175|NCT00730938|Drug|cefuroxime|intracameral cefuroxime 0.1 ml
455176|NCT00730938|Drug|Saline placebo|0.1 ml of Ringers lactate
455177|NCT00730925|Drug|BIBW2992|tablet BIBW high dose
455178|NCT00730925|Drug|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
455179|NCT00730912|Drug|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
455180|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
455181|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
455182|NCT00730886|Device|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
455183|NCT00730886|Procedure|Myomectomy|Invasive surgical procedure for fibroid removal
455184|NCT00730873|Device|Continuous positive airway pressure|
455185|NCT00730860|Procedure|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
455186|NCT00730860|Procedure|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
455187|NCT00730847|Biological|Cervarix|Three doses of Cervarix administered intramuscularly in the deltoid region, according to a 0, 1, 6-month vaccination schedule.
455188|NCT00730834|Device|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
455189|NCT00730821|Drug|BIBW 2992|
455190|NCT00730821|Drug|BIBF 1120|
455191|NCT00730808|Dietary Supplement|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
455192|NCT00730795|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
455193|NCT00730782|Biological|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
455194|NCT00730769|Drug|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
455195|NCT00730756|Drug|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
455196|NCT00730756|Other|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
455197|NCT00730743|Procedure|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
455198|NCT00730730|Device|Complete SE Iliac Stent|Iliac stenting
455199|NCT00730730|Device|Complete SE Iliac Stent|Self-expanding stent
455200|NCT00730717|Drug|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
455201|NCT00730717|Drug|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
455202|NCT00730691|Drug|Placebo|Placebo-matching capsules
455203|NCT00730691|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
455204|NCT00730691|Drug|Duloxetine|Overencapsulated duloxetine capsules
455205|NCT00730665|Drug|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
455206|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
455207|NCT00730665|Drug|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
455208|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
455209|NCT00730665|Drug|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
455210|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
455211|NCT00730665|Drug|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
455212|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
455213|NCT00730665|Other|Placebo|Capsule, Placebo, every 12 hours (twice a day)
455390|NCT00729508|Biological|Cat-PAD|Placebo
455391|NCT00729495|Drug|celecoxib|dose form
455214|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
455215|NCT00730652|Biological|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
455216|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
455217|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
455218|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
455219|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
455220|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
455221|NCT00730626|Dietary Supplement|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
455222|NCT00730626|Dietary Supplement|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
455223|NCT00730626|Dietary Supplement|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
455224|NCT00730613|Biological|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
455225|NCT00730613|Genetic|gene expression analysis|At the time of excess pathology samples documenting response/relapse
455226|NCT00730613|Other|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
455227|NCT00730600|Procedure|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
455228|NCT00730574|Dietary Supplement|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
455229|NCT00730561|Biological|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
455230|NCT00730548|Behavioral|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
455231|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
455232|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
455233|NCT00730535|Drug|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
455234|NCT00730522|Drug|CPP-109 vigabatrin|tablets, bid for 12 weeks
455235|NCT00730522|Drug|Matching Placebo|tablets, bid, 12 weeks
455236|NCT00730509|Dietary Supplement|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
455237|NCT00730496|Procedure|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
455238|NCT00730483|Drug|PVA microporous hydrospheres/doxorubicin hydrochloride|
455239|NCT00730470|Drug|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
455240|NCT00730457|Biological|VAX125|Single intramuscular dose
455241|NCT00730444|Drug|Iobenguane I 123 Injection|1-10 mCi administered intravenously
455242|NCT00730431|Drug|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
455243|NCT00730431|Drug|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
455244|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
455245|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
455246|NCT00730405|Drug|Albaconazole 100mg|Albaconazole for 36 weeks
455247|NCT00730405|Drug|Albaconazole 200mg|Albaconazole for 36 weeks
455248|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 36 weeks
455249|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
455250|NCT00730405|Drug|Placebo 400 mg|Placebo for 36 weeks
455251|NCT00730392|Drug|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
455252|NCT00730392|Drug|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
455253|NCT00730379|Drug|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
455254|NCT00730366|Drug|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
455255|NCT00730366|Drug|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
455256|NCT00730353|Drug|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
455257|NCT00730353|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
455343|NCT00729742|Drug|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
455344|NCT00729729|Drug|PCA|Placebo tablet, once
455258|NCT00730340|Procedure|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
455259|NCT00730340|Procedure|Tonsillectomy with open fossa|SOP for a tonsillectomy.
455260|NCT00730327|Device|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
455261|NCT00730327|Other|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
455262|NCT00730314|Procedure|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
455263|NCT00730301|Procedure|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
455264|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
455265|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
455266|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
455267|NCT00730275|Drug|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
455268|NCT00730275|Drug|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
455269|NCT00730262|Drug|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
455270|NCT00730249|Drug|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
455271|NCT00730249|Drug|Placebo|twice daily according to an individual titration schedule
455272|NCT00730236|Drug|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
455273|NCT00730223|Drug|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
455274|NCT00730210|Drug|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
455275|NCT00730210|Drug|b:placebo|100 microgram placebo subcutaneous a day for 6 months
455276|NCT00730197|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
455277|NCT00730197|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
455278|NCT00730184|Dietary Supplement|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
455279|NCT00730184|Dietary Supplement|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
455280|NCT00730171|Drug|Linaclotide|Linaclotide capsules, oral, once daily each morning at least 30 minutes before breakfast for the duration of the study.
455281|NCT00730158|Drug|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, at a dose of 1,800 mg, twice a day.
455282|NCT00730158|Drug|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, at a dose of 215 mg/m².
455283|NCT00730158|Drug|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
455284|NCT00730145|Drug|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
455285|NCT00730132|Drug|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
455286|NCT00730132|Drug|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
455287|NCT00730093|Dietary Supplement|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
455288|NCT00730080|Drug|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
455289|NCT00730067|Drug|sildenafil|Sildenafil 50 mg three times daily
455290|NCT00730067|Drug|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
455291|NCT00730054|Drug|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
455292|NCT00730041|Device|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
455293|NCT00730041|Device|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
455294|NCT00730028|Drug|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child > 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child < 40 kg dose). Study drug will be administered for 10 days.
455295|NCT00730028|Other|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
455296|NCT00730028|Drug|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
455297|NCT00730015|Drug|Matching Placebo|Oral, once daily
455298|NCT00730015|Drug|Linaclotide|Oral, once daily
455299|NCT00730002|Procedure|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
455300|NCT00730002|Procedure|Magnetic resonance imaging|MR spectroscopy
455301|NCT00730002|Procedure|MRA|MRA of the brain
455302|NCT00730002|Procedure|MRA|
455303|NCT00730002|Procedure|diffusion Imaging|MRA of the Brain
455304|NCT00730002|Procedure|perfusion imaging.|MRA of the brain
455305|NCT00729989|Procedure|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
455306|NCT00729976|Drug|Ibuprofen suppository|5-10mg/Kg of ibuprofen
455307|NCT00729976|Drug|Ibuprofen Suspension|5-10mg/Kg
455308|NCT00729963|Drug|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
455309|NCT00729963|Device|CPAP|
455310|NCT00729950|Biological|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
455311|NCT00729937|Drug|Cephalexin|500 mg, four times per day.
455312|NCT00729937|Drug|Clindamycin|300 mg, four times per day.
455313|NCT00729937|Other|Placebo|Placebo tablet administered orally.
455314|NCT00729937|Drug|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
455315|NCT00729924|Drug|Raltegravir|400mg orally every 12 hours for 7 days
455316|NCT00729911|Procedure|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
455317|NCT00729911|Drug|Amiodarone|Taken orally on a daily basis.
455318|NCT00729898|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
455319|NCT00729885|Device|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
455320|NCT00729885|Device|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
455321|NCT00729872|Biological|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
455322|NCT00729872|Other|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
455323|NCT00729859|Drug|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
455324|NCT00729859|Drug|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
455325|NCT00729859|Drug|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
455326|NCT00729846|Drug|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
455327|NCT00729846|Device|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence [600mW/cm2].
455328|NCT00729846|Device|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2].
455329|NCT00729833|Drug|CP-751,871|CP-751,871 IV, every 3 weeks
455330|NCT00729833|Drug|Sunitinib|Sunitinib - daily dosing
455331|NCT00729807|Drug|pentamidine|
455332|NCT00729794|Drug|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
455333|NCT00729794|Drug|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
455334|NCT00729781|Device|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
455335|NCT00729768|Drug|basiliximab|2 intravenous doses
455336|NCT00729768|Drug|efalizumab|Subcutaneous repeating dose
455337|NCT00729768|Drug|mycophenolate mofetil|Oral repeating dose
455338|NCT00729768|Drug|corticosteroids|Repeating doses
455339|NCT00729768|Drug|cyclosporine|Oral repeating dose
455340|NCT00729755|Dietary Supplement|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
455341|NCT00729755|Dietary Supplement|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
455342|NCT00729742|Drug|Comparator: erlotinib + dalotuzumab|"Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.~Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.~Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib."
455347|NCT00729716|Biological|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
455348|NCT00729716|Procedure|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
455349|NCT00729703|Device|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
455350|NCT00729703|Device|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
455351|NCT00729690|Drug|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.~Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.~Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
455352|NCT00729690|Drug|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
455353|NCT00729690|Drug|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
455354|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
455355|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
455356|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
455357|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
455358|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
455359|NCT00729651|Drug|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
455360|NCT00729651|Drug|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
455361|NCT00729651|Dietary Supplement|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
455362|NCT00729638|Drug|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
455363|NCT00729638|Drug|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
455364|NCT00729625|Device|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
455365|NCT00729612|Drug|carboplatin|
455366|NCT00729612|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
455367|NCT00729612|Genetic|protein expression analysis|
455368|NCT00729612|Other|immunoenzyme technique|
455369|NCT00729612|Other|immunohistochemistry staining method|
455370|NCT00729612|Other|laboratory biomarker analysis|
455371|NCT00729599|Drug|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
455372|NCT00729586|Other|Laboratory Biomarker Analysis|Correlative studies
455373|NCT00729586|Drug|Megestrol Acetate|Given PO
455374|NCT00729586|Drug|Tamoxifen Citrate|Given PO
455375|NCT00729586|Drug|Temsirolimus|Given IV
455376|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
455377|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
455378|NCT00729573|Drug|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
455379|NCT00729573|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
455380|NCT00729560|Drug|Flutamide|250 mg twice daily for 4 weeks
455381|NCT00729560|Drug|Placebo|Placebo twice daily for 4 weeks
455382|NCT00729547|Behavioral|Neurofeedback|enhance relative activity level of left frontal activity
455383|NCT00729547|Behavioral|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
455384|NCT00729521|Other|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
455385|NCT00729521|Other|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
455386|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
455387|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
455392|NCT00729482|Drug|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
455393|NCT00729469|Drug|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
455394|NCT00729469|Drug|Placebo|oral dose of placebo,1 tablet/day, for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12) plus Non-hormonal vaginal lubricant as needed
455395|NCT00729456|Other|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
455396|NCT00729443|Drug|AZD3241|single oral dose
455397|NCT00729443|Drug|Placebo|
455398|NCT00729430|Drug|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
455399|NCT00729430|Drug|Placebo|Placebo tablets taken orally once per day for 6 months
455400|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
455401|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
455402|NCT00729391|Behavioral|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
455403|NCT00729391|Behavioral|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
455404|NCT00729391|Behavioral|VCT Only|Participants in this group will receive VCT only.
455405|NCT00729378|Other|Skeletal loading|Impact activities, 3 times per week, increasing the number of jumps (up to 40) and increasing height (from 6 inches to 24 inches per repetition) over the initial 8-weeks (2 months). New activities will be introduced approximately every 2-3 months in order to continually stress the skeleton over 2 years.
455406|NCT00729365|Drug|Ramipril|"ACE inhibitor known as Ramipril~Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
455407|NCT00729365|Drug|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
455408|NCT00729365|Drug|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
455409|NCT00729339|Drug|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
455410|NCT00729339|Drug|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
455411|NCT00729326|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
455412|NCT00729326|Drug|sitagliptin|oral administration (100mg), once a day in the morning
455413|NCT00729326|Drug|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
455414|NCT00729326|Drug|placebo|oral administration (100mg), once a day in the morning
455415|NCT00729313|Drug|Lanreotide microparticles|
455416|NCT00729313|Drug|Placebo|
455417|NCT00729300|Drug|placebo|placebo daily
455418|NCT00729300|Drug|disulfiram|250mg daily
455419|NCT00729287|Dietary Supplement|selenium|Given orally
455420|NCT00729287|Other|placebo|Given orally
455421|NCT00729274|Drug|normal saline solution|Two 4ml nebulizations with 30 minute interval
455422|NCT00729261|Procedure|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
455423|NCT00729261|Procedure|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
455424|NCT00729235|Device|Ovatio CRT 6750|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
455425|NCT00729235|Device|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
455426|NCT00729222|Drug|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
455427|NCT00729222|Drug|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
455428|NCT00729209|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
455429|NCT00729209|Drug|Placebo; oral|matching placebo
455430|NCT00729196|Behavioral|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
455431|NCT00729183|Drug|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
455432|NCT00729183|Drug|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
455433|NCT00729183|Drug|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
455434|NCT00729183|Drug|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to ~1200 mg total) for 24 months.
455435|NCT00729170|Dietary Supplement|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
455436|NCT00729157|Radiation|Fludeoxyglucose F-18|Correlative studies
455437|NCT00729157|Other|Laboratory Biomarker Analysis|Correlative studies
455438|NCT00729157|Other|Pharmacological Study|Correlative studies
455439|NCT00729157|Procedure|Positron Emission Tomography|Correlative studies
455440|NCT00729157|Biological|Ziv-Aflibercept|Given IV
455441|NCT00729131|Drug|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
455442|NCT00729118|Drug|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
455846|NCT00725842|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
455443|NCT00729118|Drug|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
455444|NCT00729079|Behavioral|DPP|"The primary outcome measure is weight loss with a goal of 7% of initial weight.~Secondary outcomes are adherence to behavior changes:~Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~Fat intake less than 25% and saturated fat less than 10%~Fiber intake of at least 25 grams per day~Fasting blood sugar < 100 mg/dL~Absence of tobacco use"
455445|NCT00729079|Behavioral|DPP|"The primary outcome measure is weight loss with a goal of 7% of initial weight.~Secondary outcomes are adherence to behavior changes:~Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week~Fat intake less than 25% and saturated fat less than 10%~Fiber intake of at least 25 grams per day~Fasting blood sugar < 100 mg/dL~Absence of tobacco use"
455446|NCT00729053|Drug|IMO-2055|immunostimulatory oligonucleotide
455447|NCT00729040|Behavioral|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
455448|NCT00729027|Drug|25 mg/day AVE5530|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
455449|NCT00729027|Drug|50 mg/day AVE5530|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
455450|NCT00729027|Drug|placebo|"one tablet in the evening with dinner~in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
455451|NCT00729001|Biological|Human Rotavirus Vaccine - two different formulations|Two oral doses
455452|NCT00729001|Biological|Prevnar|Three-dose intramuscular injection (US subjects only)
455453|NCT00729001|Biological|IPOL|Two-dose intramuscular injection (US subjects only)
455454|NCT00729001|Biological|Infanrix|Three-dose intramuscular injection (US subjects only)
455455|NCT00729001|Biological|OmniHIB|Three-dose intramuscular injection (US subjects only)
455456|NCT00729001|Biological|Pentacel|Three-dose intramuscular injection (Canada only)
455457|NCT00728988|Drug|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
455458|NCT00728988|Drug|Atorvastatin|40mg daily after PCI for 30 days.
455459|NCT00728949|Biological|IMC-A12 (cixutumumab)|10 mg/kg I.V.
455460|NCT00728949|Drug|tamoxifen|Daily 20 mg, oral
455461|NCT00728949|Drug|Anastrozole|Daily 1 mg, oral
455462|NCT00728949|Drug|Letrozole|Daily 2.5 mg, oral
455463|NCT00728949|Drug|Exemestane|Daily 25 mg, oral
455464|NCT00728949|Drug|Fulvestrant|Monthly 250 mg, intramuscularly
455465|NCT00728936|Drug|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
455466|NCT00728936|Drug|Saline placebo|saline placebo given subcutaneously
455467|NCT00728923|Drug|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
455468|NCT00728910|Drug|Atorvastatin|10 mg QD for 4 weeks
455469|NCT00728910|Drug|ABT335|135 mg QD added to atorvastatin for 8 weeks
455470|NCT00728910|Drug|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
455471|NCT00728897|Drug|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
455472|NCT00728897|Drug|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
455473|NCT00728871|Procedure|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
455474|NCT00728845|Biological|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
455475|NCT00728845|Drug|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
455476|NCT00728845|Drug|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
455477|NCT00728845|Drug|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
455478|NCT00728832|Drug|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
455479|NCT00728819|Device|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
455480|NCT00728819|Device|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
455481|NCT00728793|Drug|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
455482|NCT00728780|Drug|ABT-143|once
455483|NCT00728780|Drug|ABT-335 and rosuvastatin|once
455484|NCT00728767|Other|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.~The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.~The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.~Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
455485|NCT00728767|Other|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
455486|NCT00728754|Device|Dental implant Osseotite Prevail|Root form titanium dental implant
455487|NCT00728754|Device|Dental implant Osseotite|root form titanium dental implant
455488|NCT00728728|Drug|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
455489|NCT00728728|Dietary Supplement|Placebo|Placebo
455490|NCT00728715|Drug|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
455491|NCT00728715|Drug|High dose of budesonide|1600 mcg/d of budesonide
455492|NCT00728715|Drug|A|medium dose of budesonide-formoterol
455493|NCT00728715|Drug|B|High Dose Inhaled Budesonide
455494|NCT00728689|Drug|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
455495|NCT00728689|Drug|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
455496|NCT00728663|Biological|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
455497|NCT00728663|Drug|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle~--- for max. 24 weeks or until progression or unacceptable toxicity ---"
455498|NCT00728637|Behavioral|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
455499|NCT00728637|Behavioral|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
455500|NCT00728611|Biological|PRGF|intra auricular injection 6mg
455501|NCT00728611|Drug|hyaluronic acid|20 mg / 2 ml
455502|NCT00728611|Drug|placebo|physiological water 3cc + lidocain 3cc
455503|NCT00728585|Drug|Palifermin|Given IV
455504|NCT00728585|Other|Placebo|Given IV
455505|NCT00728572|Procedure|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
455506|NCT00728572|Other|Surface EMG|Surface EMG only, no intervention
455507|NCT00728572|Procedure|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
455508|NCT00728559|Drug|bupivacain 0.5%|trocar site injection
455509|NCT00728546|Drug|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
455510|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
455511|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
455512|NCT00728520|Drug|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
455513|NCT00728507|Drug|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects <= 45kg and 450mg for those >45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
455514|NCT00728507|Drug|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
455515|NCT00728494|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
455516|NCT00728494|Drug|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
455517|NCT00728494|Behavioral|Patient Assistance Program|"The patient assistance program includes the following:~Training by physicians or specialized nurses.~Informational materials based on the To beat HCV program.~Management of specific side effects."
455518|NCT00728481|Drug|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
455519|NCT00728481|Drug|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
455520|NCT00728468|Drug|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
455521|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
455522|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
455523|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
455524|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
455525|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
455526|NCT00728455|Drug|placebo|Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
455847|NCT00725829|Drug|simvastatin|Simvastatin 40mg/d
455848|NCT00725829|Drug|ezetimibe|ezetimibe 10mg/d
455527|NCT00728455|Drug|placebo|Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
455528|NCT00728455|Drug|placebo|Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
455529|NCT00728455|Drug|placebo|Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
455530|NCT00728455|Drug|placebo|Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
455531|NCT00728442|Device|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
455532|NCT00728429|Behavioral|exercise intervention|24 week program of exercise
455533|NCT00728416|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
455534|NCT00728416|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
455535|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
455536|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
455537|NCT00728403|Dietary Supplement|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
455538|NCT00728390|Drug|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
455539|NCT00728377|Behavioral|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
455540|NCT00728377|Behavioral|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
455541|NCT00728351|Drug|vildagliptin + metformin|
455542|NCT00728351|Drug|metformin|1000 bid metformin
455543|NCT00728338|Dietary Supplement|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
455544|NCT00728338|Dietary Supplement|Olive oil|7.5 g olive oil/day
455545|NCT00728325|Behavioral|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
455546|NCT00728325|Behavioral|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
455547|NCT00728312|Drug|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
455548|NCT00728312|Drug|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
455549|NCT00728299|Drug|PomWonderful Juice|8 oz per day each day for 78 weeks
455550|NCT00728299|Drug|Placebo juice|8 oz per day for 78 weeks
455551|NCT00728273|Dietary Supplement|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).~The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
455552|NCT00728260|Biological|None administered in this study|N/A in this study
455553|NCT00728247|Procedure|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
455554|NCT00728234|Device|aEEG recording|weekly recordings with aEEG
455555|NCT00728221|Dietary Supplement|Korean Red Ginseng|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: whole root in capsules (3g)"
455849|NCT00725829|Drug|placebo|placebo
455556|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total ginsenoside fraction in capsules"
455557|NCT00728221|Dietary Supplement|Cornstarch|Placebo
455558|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax Ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.~Dosage form: total polysaccharide fraction (panaxans) in capsules"
455559|NCT00728208|Drug|GSK372475|1.5mg for 28 days
455560|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
455561|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
455562|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
455563|NCT00728195|Drug|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
455564|NCT00728195|Drug|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
455565|NCT00728182|Drug|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
455566|NCT00728182|Drug|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
455567|NCT00728156|Drug|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
455568|NCT00728156|Drug|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
455569|NCT00728143|Dietary Supplement|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
455570|NCT00728130|Procedure|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
455571|NCT00728117|Other|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
455572|NCT00728117|Other|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
455573|NCT00728091|Drug|Satavaptan|tablets
455574|NCT00728091|Drug|placebo|tablets
455575|NCT00728078|Drug|thalidomide|thalidomide 50mg tid for 6 months
455576|NCT00728065|Dietary Supplement|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
455577|NCT00728065|Dietary Supplement|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
455578|NCT00728065|Dietary Supplement|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
455579|NCT00728065|Dietary Supplement|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
455580|NCT00728065|Dietary Supplement|Rice milk|Rice milk containing 50g of available carbohydrates
455581|NCT00728065|Dietary Supplement|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
455582|NCT00728065|Dietary Supplement|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
455583|NCT00728065|Dietary Supplement|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
455584|NCT00728052|Drug|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
455585|NCT00728052|Drug|Placebo|Placebo capsules will be administered orally with water.
455586|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
455587|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
455588|NCT00728000|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
455589|NCT00728000|Drug|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
455590|NCT00728000|Drug|Erlotinib|100mg/day PO on days 1-14 and 15-28
455591|NCT00727987|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
455592|NCT00727987|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
455593|NCT00727987|Drug|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
455594|NCT00727961|Drug|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
455595|NCT00727948|Drug|Aspirin|325 mg tablets, once daily for 45 days
455596|NCT00727935|Drug|Lidocaïne|
455597|NCT00727935|Drug|Ropivacaïne|
455598|NCT00727935|Drug|Placebo|
455599|NCT00727922|Drug|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
455600|NCT00727909|Device|Hearing Aid Treatments|"Hearing aid treatments:~Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
455601|NCT00727896|Behavioral|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
455602|NCT00727896|Drug|Diabetes Treatment|Life style modification and drug therapy
456177|NCT00723242|Drug|Viraferon-peg and Rebetol|
455603|NCT00727870|Device|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
455604|NCT00727870|Device|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
455605|NCT00727870|Device|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
455606|NCT00727857|Drug|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
455607|NCT00727857|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
455608|NCT00727857|Drug|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
455609|NCT00727844|Drug|Immediate Start Linezolid|
455610|NCT00727844|Drug|Delayed Start Linezolid|
455611|NCT00727831|Drug|glucarpidase|
455612|NCT00727831|Drug|leucovorin calcium|
455613|NCT00727831|Drug|methotrexate|
455614|NCT00727831|Other|laboratory biomarker analysis|
455615|NCT00727831|Procedure|quality-of-life assessment|
455616|NCT00727831|Radiation|radiation therapy|
455617|NCT00727818|Device|guided bone regeneration|
455618|NCT00727792|Procedure|MRI -Clinical|MRI done is standard of care
455619|NCT00727792|Procedure|MRI-Research|MRI includes extra sequences
455620|NCT00727779|Behavioral|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
455621|NCT00727766|Drug|Clofarabine|
455622|NCT00727753|Drug|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
455623|NCT00727753|Drug|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
455624|NCT00727753|Other|No treatment|No treatment
455625|NCT00727740|Drug|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
455626|NCT00727740|Drug|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
455627|NCT00727727|Drug|Piribedil|
455628|NCT00727701|Behavioral|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
455629|NCT00727675|Behavioral|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
455630|NCT00727662|Other|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
455631|NCT00727662|Other|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
455632|NCT00727649|Drug|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
455633|NCT00727649|Drug|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
455634|NCT00727636|Biological|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
455635|NCT00727597|Drug|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~To resolve a Grade 3 or 4 Adverse Event~The subject experienced a virologic failure (as defined in section 3.6.2)~The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
455636|NCT00727597|Drug|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)~The intervention may be switched for the following reasons:~To resolve a Grade 3 or 4 Adverse Event~The subject experienced a virologic failure (as defined in section 3.6.2)~The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue~The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
455637|NCT00727584|Radiation|radiation therapy|Patients undergo external beam radiotherapy
455638|NCT00727571|Other|Observations|This is a non-interventional, observational study; no investigational product is being used
455639|NCT00727558|Device|nelfilcon A|spherical soft contact lens
455640|NCT00727558|Device|narafilcon A|spherical soft contact lens
455641|NCT00727545|Other|iron bisglycine chelate|
455642|NCT00727545|Other|placebo|
455643|NCT00727532|Drug|Sorafenib|400mg by mouth twice daily for 28 consecutive days
455644|NCT00727519|Dietary Supplement|Pomegranate juice|
455645|NCT00727519|Dietary Supplement|Placebo|
455646|NCT00727506|Drug|BIBW 2992|BIBW 2992 once daily
455647|NCT00727506|Drug|TMZ|TMZ 21/28
455648|NCT00727506|Drug|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
455649|NCT00727493|Drug|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
455650|NCT00727493|Drug|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
455651|NCT00727480|Procedure|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
455652|NCT00727467|Device|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
455653|NCT00727454|Device|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
455654|NCT00727454|Device|No treatment|No treatment
455655|NCT00727441|Biological|GVAX pancreatic cancer vaccine|Given intradermally
455656|NCT00727441|Drug|cyclophosphamide|Given IV (Arm B), given orally (Arm C)
455657|NCT00727428|Biological|FluLaval® TF|One IM injection.
455658|NCT00727415|Drug|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
455659|NCT00727415|Drug|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
455660|NCT00727415|Drug|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).~In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
455661|NCT00727389|Behavioral|Physiotherapy|Exercise two days a week for six month
455662|NCT00727363|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
455663|NCT00727363|Dietary Supplement|Placebo|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
455664|NCT00727350|Radiation|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
455665|NCT00727337|Behavioral|LACE-computer|Computerized Auditory Training
455666|NCT00727337|Behavioral|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
455667|NCT00727337|Behavioral|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
455668|NCT00727337|Behavioral|Lace-DVD|DVD based Auditory Training
455669|NCT00727324|Drug|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
455670|NCT00727311|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
455671|NCT00727311|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
455672|NCT00727298|Biological|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
455673|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
455674|NCT00727272|Drug|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
455675|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
455676|NCT00727259|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
455677|NCT00727259|Drug|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
455678|NCT00727246|Drug|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
455679|NCT00727246|Drug|Placebo|Treatment with placebo for 6 weeks
455680|NCT00727233|Drug|Nexavar (BAY 43-9006) (Sorafenib)|
455681|NCT00727233|Drug|Toxicity, Pharmacokinetics|
455682|NCT00727233|Drug|Pharmacodynamics|
455683|NCT00727233|Drug|Radiographic Evaluation|
455684|NCT00727233|Drug|QOL assessment, Neuropsychological|
455685|NCT00727233|Drug|Bony Toxicity|
455686|NCT00727207|Drug|everolimus|
455687|NCT00727194|Drug|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
455688|NCT00727194|Drug|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
455689|NCT00727181|Device|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
455690|NCT00727155|Behavioral|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
455691|NCT00727142|Procedure|Surgical treatment|Insertion of a functioning shunt
455692|NCT00727129|Drug|Divigel|
455693|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
455850|NCT00725803|Drug|GS-9450|GS-9450 capsules administered orally once daily
455851|NCT00725803|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
455694|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
455695|NCT00727103|Drug|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
455696|NCT00727103|Drug|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
455697|NCT00727090|Drug|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
455698|NCT00727077|Biological|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
455699|NCT00727077|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
455700|NCT00727064|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
455701|NCT00727064|Drug|Venlafaxine Extended Release (VEN ER)|
455702|NCT00727038|Drug|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
455703|NCT00727025|Device|wound closure device (Steri-Strip™)|wound closure with steri-strip S
455704|NCT00727012|Device|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
455705|NCT00726999|Drug|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
455706|NCT00726999|Drug|Placebo|
455707|NCT00726999|Drug|Morphine|Administered as needed
455708|NCT00726986|Drug|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
455709|NCT00726986|Drug|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
455710|NCT00726986|Drug|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
455711|NCT00726973|Drug|Ranibizumab|Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness >100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
455712|NCT00726973|Drug|Ranibizumab monotherapy|3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
455713|NCT00726960|Drug|aprepitant|Oral, 125 mg once daily for one week
455714|NCT00726960|Drug|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
455715|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Acute DVT
455716|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Chronic DVT
455717|NCT00726934|Other|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
455718|NCT00726934|Other|Neutropenic Diet|"The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:~Avoid raw vegetables and fruit (Oranges and bananas are okay.)~Avoid take-out foods and fast foods and fountain drinks.~Avoid aged cheese (blue, Roquefort, Brie).~Cook all produce to well done. Eggs must be hard-boiled.~Avoid deli meats.~No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.~No well water~No yogurt"
455719|NCT00726908|Dietary Supplement|Low carbohydrate|43% CHO
455720|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
455721|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
455722|NCT00726882|Procedure|Blood sample collection only|Approximately monthly collection of blood samples.
455723|NCT00726882|Drug|ABT-333|Previous treatment in prior ABT-333 studies.
455724|NCT00726869|Drug|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8.
455725|NCT00726856|Drug|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
455726|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
455727|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
455728|NCT00726830|Drug|methadone hydrochloride|Given orally
455729|NCT00726830|Drug|morphine sulfate|Given orally
455730|NCT00726830|Drug|oxycodone hydrochloride|Given orally
455731|NCT00726817|Drug|Butyrate|
455732|NCT00726804|Drug|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
455931|NCT00725023|Device|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
455733|NCT00726791|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
455734|NCT00726752|Drug|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
455735|NCT00726739|Biological|aldesleukin|IL-2 Alone - administer 10 x 10^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
455736|NCT00726739|Biological|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI [1 x 10^7, 5-μm silica spheres]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
455737|NCT00726726|Drug|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
455738|NCT00726726|Drug|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
455739|NCT00726726|Drug|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
455740|NCT00726713|Other|Metanx (a medical food)|Metanx one tablet twice a day
455741|NCT00726713|Other|Metanx placebo|Metanx placebo one tablet twice a day
455742|NCT00726700|Biological|pegfilgrastim|Given subcutaneously
455743|NCT00726700|Biological|rituximab|Given IV
455744|NCT00726700|Drug|cyclophosphamide|Given IV
455745|NCT00726700|Drug|doxorubicin hydrochloride|Given IV
455746|NCT00726700|Drug|prednisone|Given orally
455747|NCT00726700|Drug|vincristine sulfate|Given IV
455748|NCT00726687|Drug|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
455749|NCT00726687|Drug|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
455750|NCT00726648|Drug|CDP323|50mg capsules, 100mg bid for 4 weeks
455751|NCT00726648|Drug|CDP323|250mg capsules, 500mg bid for 4 weeks
455752|NCT00726648|Drug|CDP323|250mg capsules, 1000mg bid for 4 weeks
455753|NCT00726648|Drug|CDP323|250mg capsules, 1000mg daily for 4 weeks
455754|NCT00726648|Drug|Placebo|placebo capsules for 4 weeks
455755|NCT00726635|Behavioral|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
455756|NCT00726635|Other|Control group|A one hour conversation with a nurse
455757|NCT00726635|Other|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
455758|NCT00726622|Procedure|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
455759|NCT00726622|Procedure|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
455760|NCT00726609|Drug|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
455761|NCT00726596|Drug|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
455762|NCT00726583|Drug|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
455763|NCT00726570|Device|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
455764|NCT00726570|Drug|Dalteparin|"2500 UI qd if ≤ 50 kg body weight~5000 UI qd if > 50 kg"
455765|NCT00726570|Procedure|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~Patient admission (before SCD start)~40-60 min after admission~Morning after surgery"
455766|NCT00726557|Biological|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
455767|NCT00726557|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
455768|NCT00726544|Drug|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
455769|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
455932|NCT00725023|Device|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
456017|NCT00724360|Drug|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
455770|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
455771|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
455772|NCT00726531|Behavioral|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
455773|NCT00726531|Behavioral|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
455774|NCT00726531|Other|Treatment As Usual|Treatment as usual by the general practitioner
455775|NCT00726505|Drug|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
455776|NCT00726492|Other|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
455777|NCT00726492|Other|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
455778|NCT00726479|Drug|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
455779|NCT00726466|Drug|Efalizumab, Ranibizumab|
455780|NCT00726453|Device|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
455781|NCT00726440|Device|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
455782|NCT00726440|Device|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
455783|NCT00726440|Device|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
455784|NCT00726427|Drug|AZD1656|Dose escalation to achieve maximum tolerated dose
455785|NCT00726427|Drug|AZD1656|Oral single dose
455786|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
455787|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
455788|NCT00726401|Drug|COLD-fX|200mg BID for 4 weeks
455789|NCT00726401|Drug|Placebo|200mg BID for 4 weeks
455790|NCT00726388|Drug|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
455791|NCT00726375|Drug|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
455792|NCT00726349|Other|No intervention|Observational study.
455793|NCT00726336|Drug|GSK1349572 and tenofovir|
455794|NCT00726323|Drug|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
455795|NCT00726310|Device|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
455796|NCT00726271|Dietary Supplement|light olive oil, fish oil capsules, flax seed oil capsules|fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
455797|NCT00726258|Drug|ketamine|ketamine with various concentrations
455798|NCT00726258|Drug|placebo|physiological serum
455799|NCT00726245|Biological|PRGF|3-6mg IM (to area of muscle tear)
455800|NCT00726245|Biological|Placebo|3cc IM of physiological saline
455801|NCT00726232|Drug|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
455802|NCT00726219|Other|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
455803|NCT00726206|Other|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
455804|NCT00726193|Device|OsteoGen|OsteoGen Implatable stimulator
455805|NCT00726180|Drug|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
455806|NCT00726167|Device|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
455981|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
456178|NCT00723229|Drug|acyclovir|Acyclovir 400 mg PO BID for 28 days
455807|NCT00726154|Behavioral|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
455808|NCT00726154|Behavioral|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
455809|NCT00726141|Behavioral|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
455810|NCT00726128|Device|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF
455811|NCT00726115|Drug|SAM-531|
455812|NCT00726115|Drug|placebo|
455813|NCT00726102|Other|Meat|2 0z of locally available meat per day
455814|NCT00726102|Other|Cereal|Daily provision of cereal to infants from 6-18 mos
455815|NCT00726102|Other|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
455816|NCT00726076|Behavioral|WebEase|"Computer-based epilepsy self-management program~The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
455817|NCT00726076|Behavioral|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
455818|NCT00726063|Device|Nanotite dental implant|Nanotite root form titanium dental implant
455819|NCT00726063|Device|Osseotite dental implant|Osseotite Root form titanium dental implant
455820|NCT00726037|Drug|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
455821|NCT00726011|Biological|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
455822|NCT00725985|Drug|Cladribine|Cladribine tablets will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the initial treatment period (ITP) of 96 weeks or until CDMS conversion, whichever occur first
455823|NCT00725985|Drug|Cladribine|Cladribine tablets will be administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occur first
455824|NCT00725985|Drug|Placebo|Placebo matched to cladribine tablets will be administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occur first
455825|NCT00725985|Drug|Rebif® new formulation (RNF)|Participants who will convert to CDMS during ITP will enter in open-label maintenance period (OLMP) and receive RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who will convert to CDMS during long-term follow-up (LTFU) period, will also receive RNF subcutaneously at a dose of 44 mcg three times a week
455826|NCT00725972|Other|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
455827|NCT00725972|Procedure|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
455828|NCT00725959|Behavioral|Online social networking HIV prevention|messages about HIV posted in online social networking sites
455829|NCT00725946|Drug|Iodine-124|
455830|NCT00725946|Radiation|PET/CT with Iodine-124|
455831|NCT00725933|Drug|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
455832|NCT00725920|Drug|Topiramate|patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
455833|NCT00725920|Drug|placebo control group|initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
455834|NCT00725907|Biological|PGRF|injection of 6cc into injured area
455835|NCT00725907|Biological|placebo saline|injection of 6cc into injured area
455836|NCT00725894|Device|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
455837|NCT00725881|Drug|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
455838|NCT00725881|Drug|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
455839|NCT00725868|Other|Data private hospitals, angioplasty, sampling of blood|"Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency~coronary angioplasty~Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
455840|NCT00725855|Drug|MEM 3454|1 mg dose
455841|NCT00725855|Drug|MEM 3454|5 mg dose
455842|NCT00725855|Drug|MEM 3454|15 mg dose
455843|NCT00725855|Drug|MEM 3454|50 mg dose
455844|NCT00725855|Drug|Placebo for MEM 3454|Placebo dose
455845|NCT00725842|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
455852|NCT00725790|Drug|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
455853|NCT00725790|Drug|Placebo|"10 mg placebo on demand treatment for first 4 weeks.~A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.~A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
455854|NCT00725777|Drug|artemether-lumefantrine|Standard artemether-lumefantrine treatment
455855|NCT00725764|Drug|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
455856|NCT00725751|Biological|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
455857|NCT00725751|Drug|Ribavirin|Ribavirin administered according to European labeling.
455858|NCT00725738|Genetic|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
455859|NCT00725725|Behavioral|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
455860|NCT00725725|Drug|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
455861|NCT00725725|Drug|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
455862|NCT00725725|Drug|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
455863|NCT00725712|Drug|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
455864|NCT00725686|Drug|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
455865|NCT00725634|Biological|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
455866|NCT00725634|Biological|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
455867|NCT00725621|Biological|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
455868|NCT00725608|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
455869|NCT00725582|Drug|IMA-026|
455870|NCT00725582|Other|Placebo|
455871|NCT00725569|Drug|Bellis perennis and Staphysagria (C6)|homeopathic remedy
455872|NCT00725569|Drug|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
455873|NCT00725569|Drug|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
455874|NCT00725556|Other|Speech Therapy|Speech Therapy
455875|NCT00725543|Biological|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
455876|NCT00725530|Device|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
455877|NCT00725530|Device|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
455878|NCT00725517|Drug|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
455879|NCT00725504|Drug|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
455880|NCT00725491|Drug|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
455881|NCT00725491|Drug|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 <= 50 pg/ml (<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
455882|NCT00725478|Drug|Piribedil|
455883|NCT00725452|Biological|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
455884|NCT00725439|Drug|Talarozole|Oral Dose 1.0 mg once daily
455885|NCT00725426|Drug|Bosutinib|
455886|NCT00725413|Drug|etonogestrel implant (Implanon)|subdermal etonogestrel implant
455887|NCT00725400|Other|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
456179|NCT00723216|Drug|enoxaparin|20 mg twice a day
456180|NCT00723216|Other|Physical prophylaxis|
455888|NCT00725400|Procedure|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
455889|NCT00725374|Drug|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
455890|NCT00725374|Drug|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
455891|NCT00725361|Drug|Ambrisentan|
455892|NCT00725348|Drug|Talarozole|1.0 mg oral dose per day
455893|NCT00725335|Procedure|curative resection without Pringle|Radical excision of liver cancer without the procedure of pringle manoeuvre
455894|NCT00725335|Procedure|curative resection with Pringle manoeuvre|curative resection liver cancer under pringle manoeuvre
455895|NCT00725322|Drug|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
455896|NCT00725322|Drug|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
455897|NCT00725296|Biological|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
455898|NCT00725283|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|Intramuscular administration
455899|NCT00725270|Drug|Mifepristone|600 mg of mifepristone
455900|NCT00725270|Drug|Placebo Oral Tablet|Placebo comparator
455901|NCT00725257|Other|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
455902|NCT00725257|Other|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
455903|NCT00725244|Device|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
455904|NCT00725244|Device|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
455905|NCT00725231|Biological|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
455906|NCT00725231|Drug|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
455907|NCT00725218|Drug|Saline|Saline 5 ml injection 10 min prior to propofol administration.
455908|NCT00725218|Drug|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
455909|NCT00725205|Biological|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms [mcg]/killogram [kg]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
455910|NCT00725205|Drug|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
455911|NCT00725192|Behavioral|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
455912|NCT00725192|Behavioral|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
455913|NCT00725166|Other|Skeletal muscle aging|"W1 - Blood test~Maximal voluntary contraction of quadriceps~Hydrostatic weighing~W2 - Maximal metabolic test using a cycloergometer~W3 - Muscular biopsy"
455914|NCT00725153|Device|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
455915|NCT00725153|Device|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
455916|NCT00725127|Drug|aspirin|100 mg/day upon awakening for five years
455917|NCT00725127|Drug|aspirin|100 mg/day at bedtime for five years
455918|NCT00725114|Biological|Tetrodotoxin|30 µg twice daily for 4 days
455919|NCT00725114|Biological|Placebo|2 mL subcutaneous injection twice daily for 4 days
455920|NCT00725101|Drug|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
455921|NCT00725088|Behavioral|Exercise training|Exercise training
455922|NCT00725075|Drug|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
455923|NCT00725075|Drug|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
455924|NCT00725075|Drug|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
455925|NCT00725062|Biological|CD4+CD25+ regulatory T cells|Cohort 1 will receive 3 x 10^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10^7 CD4+CD25 cells/kg
455926|NCT00725062|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
455927|NCT00725049|Device|Dental Implant (Nanotite)|Root form titanium dental implant
455928|NCT00725036|Drug|inhaled human insulin|
455929|NCT00725036|Drug|insulin aspart|
455930|NCT00725036|Drug|insulin NPH|
455933|NCT00725010|Drug|Temozolomide|Temozolomide will be administered orally at 75 mg/m^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m^2 to 200 mg/m^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
455934|NCT00725010|Radiation|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
455935|NCT00724997|Biological|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
455936|NCT00724984|Drug|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).~Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
455937|NCT00724971|Drug|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
455938|NCT00724971|Drug|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
455939|NCT00724958|Biological|Infliximab|Not specified in the protocol.
455940|NCT00724945|Device|balafilcon A|multifocal contact lens
455941|NCT00724945|Device|senofilcon A|multifocal contact lens
455942|NCT00724932|Drug|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
455943|NCT00724932|Drug|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
455944|NCT00724932|Drug|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
455945|NCT00724932|Drug|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
455946|NCT00724906|Drug|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
455947|NCT00724893|Biological|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
455948|NCT00724893|Drug|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
455949|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
455950|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
455951|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
455952|NCT00724867|Biological|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV over one hour every 28 days
455953|NCT00724867|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days
455954|NCT00724854|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
455955|NCT00724854|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
455956|NCT00724841|Drug|Obatoclax Mesylate|Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
455957|NCT00724841|Drug|Temozolomide|
455958|NCT00724815|Drug|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
455959|NCT00724815|Drug|Placebo|NP101 Placebo iontophoretic transdermal patch
455960|NCT00724802|Dietary Supplement|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
455961|NCT00724802|Drug|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
455962|NCT00724789|Drug|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
455963|NCT00724789|Drug|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
455964|NCT00724776|Biological|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
455965|NCT00724763|Device|acupuncture|to Liv 3 and PE 9.
455966|NCT00724763|Device|sham needle treatment|needle not in meridian area
455967|NCT00724750|Device|Gauze suction (G-SUC)|Negative pressure wound therapy
455968|NCT00724750|Device|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
455969|NCT00724737|Procedure|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
455970|NCT00724737|Procedure|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
455971|NCT00724724|Drug|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
455972|NCT00724724|Drug|Aspirin|Aspirin 100mg Qd for 1 year
455973|NCT00724711|Drug|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
455974|NCT00724711|Drug|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
455975|NCT00724698|Drug|Desloratadine|Desloratadine 5 mg once daily
455976|NCT00724685|Drug|Naropeine (Ropivacaine)|
455977|NCT00724685|Drug|Placebo|saline
455978|NCT00724672|Drug|etanercept|etanercept 50 mg subcutaneously once weekly
455979|NCT00724672|Drug|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
455980|NCT00724672|Drug|adalimumab|adalimumab 40 mg subcutaneously biweekly
455982|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
455983|NCT00724646|Other|Survey|3 individual surveys
455984|NCT00724646|Other|Focus group|Focus group discussions facilitated by a psychologist
455985|NCT00724633|Other|Lowering the dialysate sodium|Please see above
455986|NCT00724620|Biological|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
455987|NCT00724620|Drug|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
455988|NCT00724594|Drug|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
455989|NCT00724594|Drug|Control|Saline was given in the same volume, at the same timing as NAC infusions
455990|NCT00724581|Drug|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
455991|NCT00724568|Drug|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
455992|NCT00724568|Drug|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
455993|NCT00724568|Drug|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
455994|NCT00724568|Drug|Doxil|Patients will be treated with Doxil on day 4.
455995|NCT00724542|Drug|Voglibose tablets|0.2mg Tid
455996|NCT00724529|Biological|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
455997|NCT00724516|Device|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
455998|NCT00724503|Device|SIR-Spheres yttrium-90 microspheres|"SIR-Spheres microspheres (yttrium-90 [Y-90] labelled resin microspheres), hepatic artery injection administered on Day 3 or 4 of cycle 1.~mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
455999|NCT00724503|Drug|Systemic chemotherapy (FOLFOX)|"mFOLFOX6 administered on Day 1 and at the start of each cycle every 14 days: 85 or 60 mg/m2 oxaliplatin by 2-hour intravenous (IV) infusion + 200 mg/m2 leucovorin by 2-hour IV infusion + 400 mg/m2 5-fluorouracil (5-FU) by IV bolus + 2.4 g/m2 5-FU by 46-hour continuous IV infusion.~Treatment with the biologic agent bevacizumab, if part of standard practice at the participating institution, was permitted at the discretion of the treating Investigator.~In the event that leucovorin was not available, use of levofolinic acid (the active S enantiomer) was acceptable at half the dose of the racemic leucovorin i.e. 100 mg/m2."
456000|NCT00724490|Procedure|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
456001|NCT00724477|Drug|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
456002|NCT00724464|Biological|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
456003|NCT00724464|Drug|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
456004|NCT00724451|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
456005|NCT00724451|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
456006|NCT00724451|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
456007|NCT00724425|Drug|IPI-493|Capsules, Multiple Schedules
456008|NCT00724412|Other|Systane|Dry Eye relief eye drops
456009|NCT00724412|Other|Optive|Dry Eye relief eye drops
456010|NCT00724399|Behavioral|Survey on womens health Issues.|Cardiovascular health.
456011|NCT00724386|Drug|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
456012|NCT00724386|Drug|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
456013|NCT00724386|Drug|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).~For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
456014|NCT00724386|Radiation|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
456015|NCT00724373|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
456016|NCT00724373|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
456181|NCT00723203|Drug|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
456018|NCT00724347|Behavioral|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
456019|NCT00724334|Drug|SAR302503 (TG101348)|orally administered, once a day
456020|NCT00724321|Drug|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
456021|NCT00724308|Other|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
456022|NCT00724308|Other|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
456023|NCT00724295|Drug|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
456024|NCT00724295|Drug|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
456025|NCT00724282|Drug|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
456026|NCT00724282|Drug|Placebo|Placebo by mouth daily at bedtime for 9 days
456027|NCT00724269|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
456028|NCT00724269|Device|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
456029|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
456030|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
456031|NCT00724243|Drug|Infliximab|Infliximab given in accordance with the local summary of product characteristics
456032|NCT00724230|Drug|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling~Subcutaneous injection once weekly for 24 weeks."
456033|NCT00724230|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
456034|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
456035|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
456036|NCT00724204|Dietary Supplement|follow on formula without probiotics|A follow on formula without probiotics
456037|NCT00724204|Dietary Supplement|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
456038|NCT00724191|Procedure|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
456039|NCT00724178|Dietary Supplement|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
456040|NCT00724165|Behavioral|Intervention|Culturally-modified, individually tailored physical activity print materials
456041|NCT00724165|Behavioral|Control|Bilingual health education booklets
456042|NCT00724152|Behavioral|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
456043|NCT00724152|Behavioral|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
456044|NCT00724139|Device|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
456045|NCT00724126|Drug|Rifaximin|
456046|NCT00724126|Drug|Placebo|
456047|NCT00724113|Procedure|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
456048|NCT00724113|Procedure|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
456049|NCT00724100|Drug|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
456050|NCT00724087|Other|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
456051|NCT00724087|Other|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
456052|NCT00724074|Device|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
456053|NCT00724074|Device|Usual Care|Usual Care
456054|NCT00724061|Biological|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
456090|NCT00723879|Behavioral|Patient assistance program|"Patient assistance programs will be classified as follows:~medications, including psychiatric medications (antidepressants);~other interventions, including nurse telephone calls and nurse support in the office: and~educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
456055|NCT00724061|Other|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
456056|NCT00724061|Other|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
456057|NCT00724048|Drug|ACR16 10 mg|ACR16 capsules: 10mg twice daily
456058|NCT00724048|Drug|ACR16 22.5 mg|ACR16 capsules: 22.5mg twice daily
456059|NCT00724048|Drug|ACR16 45 mg|ACR16 capsules: 45mg twice daily
456060|NCT00724048|Other|Placebo|Placebo capsules
456061|NCT00724035|Drug|Midazolam|"Procedural sedation before the execution of the block.~0.03 mg/kg iv bolus"
456062|NCT00724035|Drug|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
456063|NCT00724035|Drug|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
456064|NCT00724035|Procedure|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
456065|NCT00724035|Procedure|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
456066|NCT00724035|Procedure|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
456067|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
456068|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
456069|NCT00724022|Drug|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
456070|NCT00724009|Drug|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
456071|NCT00723996|Behavioral|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
456072|NCT00723983|Drug|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
456073|NCT00723983|Drug|NP101 Study Patch|NP101 study patch 4 hour application
456074|NCT00723970|Drug|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
456075|NCT00723957|Drug|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m^2
456076|NCT00723957|Drug|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m^2
456077|NCT00723957|Drug|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
456078|NCT00723944|Device|Osseotite Certain Prevail|Root form titanium dental implant
456079|NCT00723944|Device|Osseotite Certain|Dental implant without the lateralized design
456080|NCT00723931|Biological|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
456081|NCT00723918|Drug|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
456082|NCT00723918|Drug|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
456083|NCT00723918|Drug|SAB placebo|an inactive substance
456084|NCT00723918|Drug|Methadone placebo|Methadone placebo
456085|NCT00723892|Biological|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg^kg^week
456086|NCT00723892|Drug|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg^day
456087|NCT00723892|Behavioral|Psychotherapy support program|Each site has implemented a psychotherapy support program.
456088|NCT00723879|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
456089|NCT00723879|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
456091|NCT00723866|Other|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
456092|NCT00723866|Other|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
456093|NCT00723853|Behavioral|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.~During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
456094|NCT00723853|Behavioral|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
456095|NCT00723840|Other|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
456096|NCT00723827|Drug|Temozolomide|Administration of temozolomide based on the product labeling.
456097|NCT00723827|Radiation|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
456098|NCT00723801|Drug|Atenolol|Atenolol 50mg PO QD
456099|NCT00723801|Drug|Losartan|Losartan 100mg PO QD
456100|NCT00723788|Device|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
456101|NCT00723775|Drug|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
456102|NCT00723762|Procedure|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
456103|NCT00723749|Drug|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine & 0.5 mg naloxone and 8 mg buprenorphine & 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
456104|NCT00723736|Drug|Desloratadine|2.5 ml (1.25 mg) once daily
456105|NCT00723723|Drug|Statin|Statin
456106|NCT00723710|Biological|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
456107|NCT00723697|Drug|buprenorphine|0.4, 2, or 8 mg sublingual tablets
456108|NCT00723684|Other|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).~In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
456109|NCT00723684|Other|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
456110|NCT00723671|Procedure|MRI|
456111|NCT00723658|Biological|rituximab|
456112|NCT00723658|Drug|bortezomib|
456113|NCT00723658|Drug|carmustine|
456114|NCT00723658|Drug|cisplatin|
456115|NCT00723658|Drug|cyclophosphamide|
456116|NCT00723658|Drug|cytarabine|
456117|NCT00723658|Drug|dexamethasone|
456118|NCT00723658|Drug|doxorubicin hydrochloride|
456119|NCT00723658|Drug|etoposide|
456120|NCT00723658|Drug|melphalan|
456121|NCT00723658|Drug|thalidomide|
456122|NCT00723658|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
456123|NCT00723658|Procedure|peripheral blood stem cell transplantation|
456124|NCT00723632|Biological|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
456125|NCT00723632|Drug|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants <65 kg, 1000 mg/day for participants >65 to <85 kg, and 1200 mg/day for participants >=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
456126|NCT00723606|Drug|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
456127|NCT00723606|Drug|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
456128|NCT00723580|Drug|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
456175|NCT00723255|Biological|bevacizumab|Given IV
456176|NCT00723255|Drug|temsirolimus|Given IV
456129|NCT00723554|Drug|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
456130|NCT00723554|Drug|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.~Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
456131|NCT00723541|Procedure|Computer aided analysis of breast lesions|Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
456132|NCT00723528|Drug|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
456133|NCT00723528|Drug|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
456134|NCT00723528|Drug|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
456135|NCT00723528|Drug|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
456136|NCT00723528|Drug|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
456137|NCT00723528|Drug|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
456138|NCT00723528|Drug|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
456139|NCT00723515|Drug|sodium fluoride|sodium fluoride 5%
456140|NCT00723515|Drug|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
456141|NCT00723502|Drug|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
456142|NCT00723502|Drug|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
456143|NCT00723489|Biological|Live Yellow Fever Vaccine (YFV-17D)|
456144|NCT00723489|Drug|YFV-17D Placebo|
456145|NCT00723476|Behavioral|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
456146|NCT00723476|Behavioral|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
456147|NCT00723463|Procedure|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
456148|NCT00723450|Drug|lamictal|Flexible Dosing
456149|NCT00723437|Drug|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
456150|NCT00723424|Drug|AZD5672|50 mg, for 13 days
456151|NCT00723424|Drug|Digoxin|0.5mg dose
456152|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
456153|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
456154|NCT00723411|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
456155|NCT00723398|Dietary Supplement|Lovaza 4gm oral|Dietary supplement; Take 4 mg oral capsules daily
456156|NCT00723398|Drug|Raloxifene 60 Mg Oral Tablet|60 mg orally every day for two years
456157|NCT00723398|Drug|Raloxifene 30 Mg Oral Tablet|30 mg orally daily for two years
456158|NCT00723398|Drug|Lovaza 4gm & Raloxifene 30mg|Lovaza 4gm and Raloxifene 30 Mg orally once per day for 2 years
456159|NCT00723385|Dietary Supplement|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
456160|NCT00723385|Other|Placebo|Administration of placebo for 12 weeks with repeated D measurements
456161|NCT00723359|Drug|BT062|biologic
456162|NCT00723346|Biological|GRASPA|50 UI/Kg
456163|NCT00723346|Biological|GRASPA|100 UI/Kg
456164|NCT00723346|Biological|GRASPA|150 UI/Kg
456165|NCT00723346|Drug|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
456166|NCT00723333|Procedure|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
456167|NCT00723320|Drug|Atorvastatin|atorvastatin 10mg/d
456168|NCT00723320|Behavioral|Aggressive lifestyle intervention|aggressive lifestyle intervention
456169|NCT00723307|Drug|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
456170|NCT00723307|Drug|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
456171|NCT00723294|Procedure|cryosurgery|
456172|NCT00723294|Procedure|therapeutic conventional surgery|
456173|NCT00723268|Drug|Prednisolone|5MG Prednisolone per day for 3 months
456174|NCT00723268|Drug|Colchicine|0.5 MG Colchicine per day for 3 months
456182|NCT00723203|Genetic|gene expression analysis|Day 1 and day 28 samples
456183|NCT00723203|Genetic|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
456184|NCT00723203|Other|laboratory biomarker analysis|Day 1 and day 28 samples
456185|NCT00723190|Drug|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
456186|NCT00723177|Drug|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
456187|NCT00723177|Drug|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
456188|NCT00723164|Drug|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
456189|NCT00723164|Drug|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
456190|NCT00723151|Behavioral|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
456191|NCT00723125|Drug|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
456192|NCT00723125|Drug|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
456193|NCT00723125|Drug|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
456194|NCT00723099|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
456195|NCT00723099|Drug|Cyclophosphamide|Given IV
456196|NCT00723099|Drug|Cyclosporine|Given IV
456197|NCT00723099|Drug|Fludarabine Phosphate|Given IV
456198|NCT00723099|Other|Laboratory Biomarker Analysis|Correlative studies
456199|NCT00723099|Drug|Mycophenolate Mofetil|Given IV or PO
456200|NCT00723099|Radiation|Total-Body Irradiation|Undergo TBI
456201|NCT00723099|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
456202|NCT00723086|Drug|docetaxel (XRP6976)|combined treatment with prednisolone
456203|NCT00723060|Drug|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
456204|NCT00723047|Procedure|Fibrin glue injection in fistula|
456205|NCT00723021|Drug|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
456206|NCT00723021|Drug|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
456207|NCT00723021|Drug|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
456208|NCT00723021|Drug|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
456209|NCT00723021|Drug|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
456210|NCT00723008|Device|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
456211|NCT00722995|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
456212|NCT00722995|Procedure|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
456213|NCT00722969|Drug|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
456214|NCT00722956|Drug|AZD5672|100 mg once daily, 10 days
456215|NCT00722956|Drug|atorvastatin|one single dose of 40 mg on day 10
456216|NCT00722943|Other|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
456217|NCT00722943|Other|no intervention|The infant will not be touched by the therapist.
456218|NCT00722930|Drug|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
456219|NCT00722917|Drug|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
456220|NCT00722917|Drug|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
456221|NCT00722917|Drug|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
456222|NCT00722917|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
456223|NCT00722917|Drug|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
456224|NCT00722891|Device|Purevision Lenses with ReNu Multiplus|Purevision lenses using ReNu Multiplus lens solution for 28 days
456225|NCT00722891|Device|Purevision Lenses with Optifree RepleniSH|Purevision lenses using Optifree RepleniSH lens solution for 28 days
456226|NCT00722865|Drug|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
456227|NCT00722852|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
456228|NCT00722852|Drug|Placebo|100 mg (b.i.d.)
456229|NCT00722839|Biological|PADRE-CMV fusion peptide vaccine|Given subcutaneously
456230|NCT00722839|Biological|tetanus-CMV fusion peptide vaccine|Given subcutaneously
456231|NCT00722839|Drug|agatolimod sodium|Given subcutaneously
456232|NCT00722813|Other|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
456233|NCT00722800|Drug|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
456234|NCT00722800|Drug|Placebo|1 tablet daily for 24 weeks
456235|NCT00722774|Biological|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
456236|NCT00722761|Drug|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
456237|NCT00722761|Drug|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
456238|NCT00722735|Drug|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
456239|NCT00722735|Drug|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
456240|NCT00722722|Drug|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
456241|NCT00722709|Drug|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.~At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
456242|NCT00722709|Drug|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.~At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
456243|NCT00722696|Other|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
456244|NCT00722683|Procedure|Ultrasound Imaging with Contrast|"An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.~The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times."
456245|NCT00722670|Behavioral|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
456246|NCT00722670|Behavioral|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
456247|NCT00722644|Behavioral|Cognitive Behavioral Stress Management|
456248|NCT00722631|Drug|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
456249|NCT00722631|Drug|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
456250|NCT00722618|Behavioral|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
456251|NCT00722618|Other|Written materials|2 written materials available on public website
456252|NCT00722605|Procedure|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~For all scans, an external monitor will be used to record your breathing.~If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
456253|NCT00722592|Drug|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
456254|NCT00722592|Drug|pegylated liposomal doxorubicin (PLD)|50 mg/m^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
456255|NCT00722592|Other|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
456256|NCT00722579|Device|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
456257|NCT00722566|Drug|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
456258|NCT00722566|Drug|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
456259|NCT00722553|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).~Initial dose: 190 mg/m2~Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
456260|NCT00722553|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
456261|NCT00722553|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
456262|NCT00722540|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
456263|NCT00722540|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
456264|NCT00722540|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
456265|NCT00722540|Drug|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
456266|NCT00722540|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
456267|NCT00722540|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
456268|NCT00722540|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
456269|NCT00722540|Drug|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
456270|NCT00722540|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
456271|NCT00722540|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
456350|NCT00721955|Drug|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
456351|NCT00721929|Procedure|MRI|Magnetic Resonance Imaging
456272|NCT00722514|Behavioral|patient education|"complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~Patient education 6 x 90 Minutes"
456273|NCT00722514|Behavioral|Standard Care|"complex individual antiinflammatory rehabilitation program during inpatient~complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally~further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
456274|NCT00722501|Drug|ERB-257|
456275|NCT00722501|Other|placebo|
456276|NCT00722488|Drug|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
456277|NCT00722475|Drug|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
456278|NCT00722475|Drug|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
456279|NCT00722462|Procedure|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
456280|NCT00722462|Procedure|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
456281|NCT00722436|Drug|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
456282|NCT00722436|Drug|saline|Placebo
456283|NCT00722423|Behavioral|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
456284|NCT00722423|Behavioral|Usual Care Model|
456285|NCT00722410|Dietary Supplement|VSL#3|A probiotic preparation.
456286|NCT00722410|Drug|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
456287|NCT00722384|Drug|bevasiranib|
456288|NCT00722384|Drug|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
456289|NCT00722371|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
456290|NCT00722371|Drug|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
456291|NCT00722371|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
456292|NCT00722371|Drug|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
456293|NCT00722371|Drug|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
456294|NCT00722358|Drug|BMS-650032|"Capsule, Oral, Q12h, 3/5 days~Panel 1: 200 mg~Panel 2: 400 mg~Panel 3: 600 mg"
456295|NCT00722358|Drug|Placebo|"Capsule, Oral, Q 12h, 3/5 days~Panel 1: matching placebo~Panel 2: matching placebo~Panel 3: matching placebo"
456296|NCT00722345|Behavioral|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
456297|NCT00722345|Behavioral|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current & past activities; 2) reviewing the pros & cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
456298|NCT00722332|Biological|HepaGam B|Hepatitis B Immunoglobulin
456299|NCT00722306|Drug|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
456300|NCT00722293|Drug|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
456301|NCT00722293|Drug|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
456302|NCT00722293|Drug|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
456352|NCT00721916|Drug|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
456524|NCT00720720|Dietary Supplement|placebo margarine|
456588|NCT00720356|Drug|bevacizumab|10mg/kg administered intravenously every 2 weeks
456303|NCT00722280|Procedure|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
456304|NCT00722228|Biological|Autologous or Allogeneic tumor cells|Five vaccine doses, injected subcutaneously at 3-week intervals. Each dose is composed of irradiated and DNP-conjugated tumor cells.
456305|NCT00722215|Drug|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
456306|NCT00722215|Drug|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
456307|NCT00722215|Drug|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
456308|NCT00722202|Drug|ERB-257|
456309|NCT00722202|Other|placebo|
456310|NCT00722176|Drug|BL-1020|10 mg
456311|NCT00722176|Drug|BL-1020 10-30 mg|BL-1020 10-30 mg
456312|NCT00722176|Drug|risperidone|risperidone
456313|NCT00722163|Other|Cognitive Behavioural Therapy|
456314|NCT00722163|Other|befriending|
456315|NCT00722150|Drug|Artesunate|2 mg/kg/day x 7 days
456316|NCT00722150|Drug|Artesunate|4 mg/kg/day x 7 days
456317|NCT00722150|Drug|Artesunate|6 mg/kg/day x 7 days
456318|NCT00722137|Drug|Rituximab 375 mg/m^2|Intravenous rituximab 375 mg/m^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.
456319|NCT00722137|Drug|Cyclophosphamide 750 mg/m^2|Intravenous cyclophosphamide 750 mg/m^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
456320|NCT00722137|Drug|Doxorubicin 50 mg/m^2|Intravenous doxorubicin 50 mg/m^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles
456321|NCT00722137|Drug|VELCADE 1.3 mg/m^2|Intravenous VELCADE 1.3 mg/m^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles
456322|NCT00722137|Drug|Prednisone 100 mg/m^2|Oral prednisone 100 mg/m^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles
456323|NCT00722137|Drug|Vincristine 1.4 mg/m^2|Intravenous vincristine 1.4 mg/m^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
456324|NCT00722124|Drug|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
456325|NCT00722124|Drug|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
456326|NCT00722124|Other|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
456327|NCT00722111|Device|lingual press|lingual press (high-intensity, oral, non-swallowing)
456328|NCT00722111|Behavioral|effortful swallowing|effortful swallowing (high-intensity swallowing)
456329|NCT00722111|Behavioral|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
456330|NCT00722111|Behavioral|non-oral sham (control) exercise|non-oral sham (control) exercise
456331|NCT00722098|Biological|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
456332|NCT00722098|Biological|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
456333|NCT00722072|Drug|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
456334|NCT00722072|Drug|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
456335|NCT00722059|Procedure|Breast Tomosynthesis|3D breast imaging
456336|NCT00722046|Biological|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
456337|NCT00722046|Biological|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
456338|NCT00722046|Biological|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
456339|NCT00722046|Drug|Placebo|Placebo every 60 days (10 doses total)
456340|NCT00722046|Biological|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
456341|NCT00722046|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
456342|NCT00722033|Drug|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
456343|NCT00722020|Device|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
456344|NCT00722007|Device|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
456345|NCT00721994|Device|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
456346|NCT00721968|Device|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
456347|NCT00721968|Procedure|cataract surgery alone|Cataract surgery alone
456348|NCT00721955|Drug|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
456349|NCT00721955|Drug|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
456353|NCT00721916|Drug|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
456354|NCT00721903|Procedure|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
456355|NCT00721903|Procedure|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
456356|NCT00721890|Dietary Supplement|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
456357|NCT00721877|Drug|resveratrol|Given orally
456358|NCT00721877|Other|pharmacological study|Correlative studies
456359|NCT00721877|Other|laboratory biomarker analysis|Correlative studies
456360|NCT00721825|Drug|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
456361|NCT00721825|Drug|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
456362|NCT00721812|Drug|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
456363|NCT00721799|Drug|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
456364|NCT00721786|Behavioral|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
456365|NCT00721773|Drug|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
456366|NCT00721773|Drug|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
456367|NCT00721773|Drug|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
456368|NCT00721773|Drug|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
456369|NCT00721760|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
456370|NCT00721760|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
456371|NCT00721760|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
456372|NCT00721747|Drug|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
456373|NCT00721734|Drug|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
456374|NCT00721721|Behavioral|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
456375|NCT00721721|Behavioral|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
456376|NCT00721721|Dietary Supplement|Potassium Supplementation|60 mmol potassium supplement
456377|NCT00721708|Dietary Supplement|pure carnosine|one time dose of pure carnosine (450 mg)
456378|NCT00721708|Other|Beef|one time dose, 150 g of beef
456379|NCT00721708|Other|Chicken|One time dose, 150g of chicken breast
456380|NCT00721708|Other|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
456381|NCT00721695|Drug|OMS302|OMS302 Irrigation Solution
456382|NCT00721695|Drug|OMS302-PE|OMS302-PE HCI Irrigation Solution
456383|NCT00721695|Drug|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
456384|NCT00721669|Drug|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
456385|NCT00721656|Drug|Placebo|
456386|NCT00721656|Drug|KLS-0611|
456387|NCT00721643|Dietary Supplement|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
456388|NCT00721643|Dietary Supplement|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
456389|NCT00721630|Drug|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
456390|NCT00721617|Other|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
456391|NCT00721617|Other|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
456392|NCT00721617|Other|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
456393|NCT00721604|Drug|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
456452|NCT00721240|Drug|montelukast|5mg montelukast once daily for 12 weeks
456587|NCT00720369|Drug|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
456394|NCT00721578|Drug|voriconazole|Patients must have received (in the Intensive Care Unit [ICU] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
456395|NCT00721565|Behavioral|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
456396|NCT00721552|Drug|Sitagliptin 100 mg|28 days administration of 100 mg daily
456397|NCT00721552|Drug|Prednisolone 30 mg|14 days administration of 30 mg daily
456398|NCT00721552|Drug|Sitagliptin-placebo|28 days administration once daily
456399|NCT00721552|Drug|Prednisolone-placebo|14 days administration once daily
456400|NCT00721539|Device|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
456401|NCT00721539|Procedure|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
456402|NCT00721526|Drug|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
456403|NCT00721513|Biological|cetuximab|
456404|NCT00721513|Drug|cisplatin|
456405|NCT00721513|Drug|docetaxel|
456406|NCT00721513|Drug|fluorouracil|
456407|NCT00721513|Procedure|computed tomography|
456408|NCT00721513|Procedure|positron emission tomography|
456409|NCT00721513|Procedure|quality-of-life assessment|
456410|NCT00721513|Radiation|3-dimensional conformal radiation therapy|
456411|NCT00721513|Radiation|intensity-modulated radiation therapy|
456412|NCT00721500|Device|etafilcon A|contact lens
456413|NCT00721500|Device|narafilcon A|contact lens
456414|NCT00721487|Drug|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
456415|NCT00721474|Drug|Bosutinib|Bosutinib fasting
456416|NCT00721474|Drug|Bosutinib|Bosutinib fed
456417|NCT00721461|Biological|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
456418|NCT00721448|Drug|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
456419|NCT00721448|Drug|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
456420|NCT00721435|Procedure|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis & ultrasound imaging for scanning masses or healthy breast tissue
456421|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
456422|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
456423|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
456424|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
456425|NCT00721409|Drug|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
456426|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
456427|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
456428|NCT00721396|Biological|rMenB+OMV NZ|
456429|NCT00721396|Biological|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
456430|NCT00721396|Biological|Pneumococcal vaccine|
456431|NCT00721383|Behavioral|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
456432|NCT00721383|Behavioral|CSBI|Caregiver skill-building
456433|NCT00721370|Device|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
456434|NCT00721357|Behavioral|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
456435|NCT00721357|Other|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
456436|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
456437|NCT00721344|Drug|Moxifloxacin|Tablets 400mg
456438|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
456439|NCT00721344|Drug|Placebo|Placebo cartridges
456440|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
456441|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
456442|NCT00721331|Drug|nortriptyline HCl|Topical
456443|NCT00721331|Drug|mometasone furoate|Topical
456444|NCT00721331|Drug|Active ingredient free vehicle cream of CRx-197|Topical
456445|NCT00721305|Drug|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
456446|NCT00721305|Other|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
456447|NCT00721279|Drug|Sifrol® (pramipexole dihydrochloride)|
456448|NCT00721266|Drug|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
456449|NCT00721253|Device|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
456450|NCT00721253|Device|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
456451|NCT00721253|Device|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
456453|NCT00721227|Procedure|Reduction Gastroplasty|"Subjects will undergo reduction gastroplasty by gastric plication~Subjects are followed for 12 months to evaluate outcomes and potential complications."
456454|NCT00721214|Drug|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
456455|NCT00721201|Drug|Mifepristone|Use of mifepristone 200mg bd for 8 weeks
456456|NCT00721188|Drug|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
456457|NCT00721175|Device|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
456458|NCT00721175|Device|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
456459|NCT00721162|Biological|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
456460|NCT00721149|Device|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
456461|NCT00721136|Drug|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
456462|NCT00721136|Drug|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
456463|NCT00721136|Drug|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
456464|NCT00721123|Drug|Tocilizumab|Tocilizumab (myeloma receptor antibody [MRA]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
456465|NCT00721110|Drug|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
456466|NCT00721110|Drug|Placebo|Placebo boluses and infusions will be substituted
456467|NCT00721110|Drug|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
456468|NCT00721110|Drug|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
456469|NCT00721097|Other|spirometry, and blood taken|each month during one year
456470|NCT00721071|Drug|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
456471|NCT00721058|Other|CT-scan|A pre-operative CT-scan will be made
456472|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
456473|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
456474|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
456475|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
456476|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
456477|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
456478|NCT00721032|Procedure|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
456479|NCT00721032|Drug|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:~current dose -> new dose 100 once daily (QD) -> 200 QD; 200 QD -> 400 QD; 300 QD -> 600 QD; 400 QD -> 600 QD"
456480|NCT00721019|Other|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
456481|NCT00721019|Other|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
456482|NCT00721006|Biological|MESENDO|40 subcutaneous injections of biological product
456483|NCT00721006|Biological|Placebo|40 subcutaneous injections of placebo
456484|NCT00720967|Procedure|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
456485|NCT00720967|Procedure|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP >75 mmHg, CVP > 12 mmHg, Htc > 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at ~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
456522|NCT00720733|Behavioral|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning & Purpose.
456523|NCT00720720|Dietary Supplement|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
456486|NCT00720967|Procedure|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs < 75 kg, and 4 hours if > 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
456487|NCT00720954|Procedure|Ct-guided pleural needle biopsy|Biopsy of pleura
456488|NCT00720954|Procedure|Thoracoscopy|Biopsy of pleura
456489|NCT00720941|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
456490|NCT00720941|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
456491|NCT00720928|Drug|flucinolone acetonide|Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
456492|NCT00720915|Other|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
456493|NCT00720915|Other|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
456494|NCT00720902|Procedure|Blood draws|Subjects will have serum cardiovascular markers assessed
456495|NCT00720902|Drug|Growth hormone releasing hormone (GHRH) and arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
456496|NCT00720902|Procedure|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
456497|NCT00720902|Procedure|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
456498|NCT00720902|Procedure|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
456499|NCT00720876|Biological|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
456500|NCT00720876|Drug|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
456501|NCT00720850|Drug|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
456502|NCT00720837|Procedure|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
456503|NCT00720824|Behavioral|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
456504|NCT00720824|Behavioral|Office routine|Standard vaccine administration
456505|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
456506|NCT00720811|Drug|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
456507|NCT00720811|Drug|paracetamol|paracetamol 500mg tablet <36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
456508|NCT00720811|Device|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
456509|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
456510|NCT00720798|Drug|Tocilizumab|For participants weighing > 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
456511|NCT00720798|Drug|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
456512|NCT00720798|Drug|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
456513|NCT00720798|Drug|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
456514|NCT00720785|Drug|NK cells +CliniMACs CD3 and CD56 systems|Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
456515|NCT00720785|Biological|NK cells|NK Cell Infusion
456516|NCT00720772|Drug|25% intravenous (IV) sodium thiosulfate|50 ml IV drip twice/week post hemodialysis
456517|NCT00720759|Drug|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
456518|NCT00720759|Behavioral|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
456519|NCT00720759|Drug|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
456520|NCT00720759|Behavioral|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
456521|NCT00720733|Behavioral|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
456525|NCT00720707|Procedure|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
456526|NCT00720707|Procedure|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
456527|NCT00720694|Device|Duolith SD1|
456528|NCT00720694|Device|Sham Duolith SD1|
456529|NCT00720668|Procedure|radiofrequency ablation|radiofrequency ablation for HCC
456530|NCT00720655|Other|Dietary intervention|Fatty fish at least 4 meals per week.
456531|NCT00720655|Other|Dietary intervention|Lean fish at least 4 meals per week.
456532|NCT00720655|Other|Dietary intervention|Control diet with lean meat and chicken.
456533|NCT00720629|Drug|Visilizumab|3 mg/m^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
456534|NCT00720629|Drug|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
456535|NCT00720629|Drug|Methotrexate|15 mg/m^2 intravenously (IV) on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
456536|NCT00720629|Drug|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
456537|NCT00720629|Drug|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
456538|NCT00720629|Drug|Methotrexate|15 mg/m^2 IV on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
456539|NCT00720616|Drug|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
456540|NCT00720603|Drug|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
456541|NCT00720590|Drug|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
456542|NCT00720590|Drug|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
456543|NCT00720590|Drug|Placebo|Daily dose of placebo for 4 weeks
456544|NCT00720577|Drug|Simvastatin|40 Mg. tablet, 1 tablet daily
456545|NCT00720577|Drug|Losartan|50 mg., tablets, 1 tablet once daily
456546|NCT00720577|Drug|Pioglitazone|30 mg, tablet, 1 tablet once daily
456547|NCT00720564|Drug|arsenic trioxide|
456548|NCT00720564|Drug|temozolomide|
456549|NCT00720564|Procedure|adjuvant therapy|
456550|NCT00720564|Radiation|intensity-modulated radiation therapy|
456551|NCT00720564|Radiation|radiation therapy|
456552|NCT00720551|Other|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
456553|NCT00720538|Drug|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
456554|NCT00720538|Drug|placebo|placebo capsules
456555|NCT00720512|Biological|bevacizumab|Given IV
456556|NCT00720512|Drug|fluorouracil|Given IV
456557|NCT00720512|Drug|irinotecan hydrochloride|Given IV
456558|NCT00720512|Drug|leucovorin calcium|Given IV
456559|NCT00720512|Drug|oxaliplatin|Given IV
456560|NCT00720499|Drug|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
456561|NCT00720499|Device|Respimat® Inhaler|
456562|NCT00720486|Behavioral|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
456563|NCT00720486|Behavioral|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
456564|NCT00720473|Drug|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
456565|NCT00720447|Biological|alemtuzumab|
456566|NCT00720447|Biological|donor lymphocytes|
456567|NCT00720447|Drug|carmustine|
456568|NCT00720447|Drug|cytarabine|
456569|NCT00720447|Drug|etoposide|
456570|NCT00720447|Drug|melphalan|
456571|NCT00720447|Procedure|allogeneic bone marrow transplantation|
456572|NCT00720447|Procedure|peripheral blood stem cell transplantation|
456573|NCT00720434|Drug|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
456574|NCT00720434|Drug|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
456575|NCT00720434|Drug|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
456576|NCT00720434|Drug|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
456577|NCT00720421|Drug|AZD7325|AZD7325 10 mg oral 2 capsules
456578|NCT00720421|Drug|AZD7325|AZD7325 1 mg oral 2 capsules
456579|NCT00720421|Drug|AZD7325|AZD7325 Placebo oral 2 capsules
456580|NCT00720421|Drug|Lorazepam|Lorazepam 1 mg oral 2 tablets
456581|NCT00720421|Drug|Lorazepam|Lorazepam Placebo oral 2 tablets
456582|NCT00720408|Drug|Prograf-XL|oral
456583|NCT00720408|Drug|Prograf|oral
456584|NCT00720408|Drug|MMF|oral
456585|NCT00720382|Drug|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
456586|NCT00720382|Drug|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
456589|NCT00720356|Drug|erlotinib hydrochloride|150 mg/daily orally
456590|NCT00720343|Drug|Choline|Oral Choline 20 grams before surgery
456591|NCT00720343|Drug|Placebo|Gelatin Capsule
456592|NCT00720330|Drug|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
456593|NCT00720330|Drug|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
456594|NCT00720330|Other|placebo|placebo
456595|NCT00720304|Drug|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
456596|NCT00720304|Drug|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
456597|NCT00720304|Genetic|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
456598|NCT00720304|Genetic|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
456599|NCT00720304|Other|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
456600|NCT00720304|Other|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
456601|NCT00720304|Other|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
456602|NCT00720304|Other|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
456603|NCT00720304|Procedure|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
456604|NCT00720304|Radiation|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
456605|NCT00720304|Radiation|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
456606|NCT00720291|Drug|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
456607|NCT00720291|Drug|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
456608|NCT00720278|Drug|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
456609|NCT00720278|Drug|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
456610|NCT00720278|Drug|Placebo|0 mcg Placebo daily
456611|NCT00720265|Drug|Prograf|oral
456612|NCT00720265|Drug|MR4|oral
456613|NCT00720252|Device|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
456614|NCT00720239|Other|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:~Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.~Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.~Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
456615|NCT00720226|Drug|Losartan|Losartan 100 mg daily
456616|NCT00720226|Drug|Placebo|Placebo pill daily
456617|NCT00720213|Device|Respironics BiPAP autoSV2|Respironics BiPAP autoSV2 is an Auto Servo Ventilation Device. This will be used on a randomized night.
456618|NCT00720213|Device|Respironics BiPAP autoSV3|Respironics BiPAP autoSV3 is an Auto Servo Ventilation Device. This will be used on a randomized night.
456619|NCT00720200|Behavioral|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
456620|NCT00720200|Behavioral|Usual Care|Family Members receiving usual care/clinical interaction
456621|NCT00720174|Biological|Cixutumumab|Given IV
456622|NCT00720174|Drug|Doxorubicin Hydrochloride|Given IV
456623|NCT00720174|Other|Laboratory Biomarker Analysis|Correlative studies
456624|NCT00720161|Drug|Metformin|daily 850 mg
456625|NCT00720161|Drug|placebo|placebo
456626|NCT00720148|Drug|Sunitinib and Bortezomib|50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops
456627|NCT00720135|Biological|DI-Leu16-IL2 immunocytokine|Given IV
456628|NCT00720135|Biological|rituximab|Given IV
456629|NCT00720135|Other|flow cytometry|Correlative studies
456630|NCT00720135|Other|immunohistochemistry staining method|Correlative studies
456631|NCT00720135|Other|pharmacological study|Correlative studies
456632|NCT00720135|Other|laboratory biomarker analysis|Correlative studies
456633|NCT00720135|Other|enzyme-linked immunosorbent assay|Correlative studies
456634|NCT00720135|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
456635|NCT00720122|Drug|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
456636|NCT00720109|Drug|Asparaginase|Given IT
456637|NCT00720109|Drug|Cyclophosphamide|Given IV
456638|NCT00720109|Drug|Cytarabine|Given IT or IV
456639|NCT00720109|Drug|Dasatinib|Given PO
456640|NCT00720109|Drug|Daunorubicin Hydrochloride|Given IV
456641|NCT00720109|Drug|Dexamethasone|Given IV or PO
456642|NCT00720109|Drug|Etoposide|Given IV
456643|NCT00720109|Biological|Filgrastim|Given IV or SC
456644|NCT00720109|Drug|Hydrocortisone Sodium Succinate|Given IT
456645|NCT00720109|Drug|Ifosfamide|Given IV
456646|NCT00720109|Other|Laboratory Biomarker Analysis|Correlative studies
456647|NCT00720109|Drug|Leucovorin Calcium|Given IV or PO
456648|NCT00720109|Drug|Mercaptopurine|Given PO
456649|NCT00720109|Drug|Methotrexate|Given IT, PO, or IV
456650|NCT00720109|Drug|Methylprednisolone|Given IV
456651|NCT00720109|Drug|Pegaspargase|Given IM
456652|NCT00720109|Drug|Prednisone|Given PO or IV
456653|NCT00720109|Radiation|Radiation Therapy|Some patients undergo cranial RT
456654|NCT00720109|Drug|Vincristine Sulfate|Given IV
456655|NCT00720096|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
456656|NCT00720096|Drug|Topotecan|"Topotecan (daily x 5 days of a 21 day cycle)~Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
456657|NCT00720083|Drug|cisplatin|Given IV
456658|NCT00720083|Drug|vandetanib|Given orally
456659|NCT00720083|Radiation|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
456660|NCT00720070|Procedure|positron emission tomography/computed tomography|Patients undergo PET/CT scan
456661|NCT00720070|Procedure|therapeutic conventional surgery|Patients undergo neck dissection
456662|NCT00720057|Drug|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
456663|NCT00720057|Drug|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
456664|NCT00720031|Biological|autologous Melan-A/MART-1 specific CTL clones|"By using patients' blood, several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient, 3 to 6 months after collecting blood sample. During this production period of the T cell clone, the patient will be treated with deticene at the dose of 250mg/m2/j by IV for 4 days each month.~After each T cell clone infusion (J1), the patient will receive IFN-α at the dose of 9 M/U 3 times a week for 4 weeks and Interleukin-2 at the dose of 9 M/U from Day 1 to day 5 and from Day 8 to Day 12."
456665|NCT00720018|Drug|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
456666|NCT00720005|Device|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
456667|NCT00719992|Procedure|coronary angiography|effect of level of HS-CRP
456668|NCT00719979|Behavioral|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
456669|NCT00719979|Behavioral|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
456670|NCT00719979|Behavioral|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
456671|NCT00719966|Drug|anastrozole|Patients receive aromatase inhibition therapy.
456672|NCT00719966|Drug|exemestane|Patients receive aromatase inhibition therapy.
456673|NCT00719966|Drug|letrozole|Patients receive aromatase inhibition therapy.
456674|NCT00719966|Procedure|assessment of therapy complications|Endothelial function is measured
456675|NCT00719953|Dietary Supplement|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
456676|NCT00719940|Behavioral|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
456677|NCT00719940|Other|Waiting group|No intervention
456678|NCT00719927|Behavioral|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
456679|NCT00719914|Drug|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
456680|NCT00719914|Drug|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
456681|NCT00719914|Drug|normal saline|Intra-coronary injection, weight based, of normal saline.
456682|NCT00719901|Drug|obatoclax mesylate|Given IV
456683|NCT00719901|Drug|bortezomib|Given IV
456684|NCT00719901|Other|laboratory biomarker analysis|Correlative studies
456685|NCT00719888|Drug|Cyclophosphamide|Given IV
456686|NCT00719888|Drug|Cyclosporine|Given IV and PO
456687|NCT00719888|Procedure|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
456688|NCT00719888|Drug|Fludarabine|Given IV
456689|NCT00719888|Other|Laboratory Biomarker Analysis|Correlative studies
456690|NCT00719888|Drug|Mycophenolate Mofetil|Given IV and PO
456691|NCT00719888|Radiation|Total-Body Irradiation|Undergo high-dose or moderate-intensity TBI
456692|NCT00719888|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
456693|NCT00719888|Drug|Thiotepa|Given IV
456694|NCT00719875|Drug|Vorinostat|BID days -7, 1-7 and 15-21, 200 mg
456695|NCT00719862|Drug|Placebo nasal spray|Placebo
456696|NCT00719862|Drug|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
456697|NCT00719849|Biological|anti-thymocyte globulin|30mg/Kg Days -6 to -4
456698|NCT00719849|Drug|cyclophosphamide|50 mg/Kg Day -6
456699|NCT00719849|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
456700|NCT00719849|Drug|fludarabine phosphate|40mg/m2 Days -6 to -2
456701|NCT00719849|Drug|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
456702|NCT00719849|Procedure|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
456703|NCT00719849|Radiation|total body irradiation|200 cGy Day -1
456704|NCT00719836|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
456705|NCT00719823|Drug|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
456706|NCT00719810|Drug|delafloxacin|300 mg intravenous every 12 hours
456707|NCT00719810|Drug|delafloxacin|450 mg intravenous every 12 hours
456708|NCT00719810|Drug|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
456709|NCT00719797|Biological|bevacizumab|Given IV
456710|NCT00719797|Drug|fluorouracil|Given IV
456711|NCT00719797|Drug|irinotecan hydrochloride|Given IV
456712|NCT00719797|Drug|leucovorin calcium|Given IV
456713|NCT00719797|Drug|oxaliplatin|Given IV
456714|NCT00719784|Device|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
456715|NCT00719771|Device|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
456716|NCT00719758|Drug|TRK-100STP (BERASUS LA)|oral
456717|NCT00719758|Drug|AST-120 (Kremezin®)|oral
456718|NCT00719745|Drug|Prograf|oral
456719|NCT00719745|Drug|MR4|oral
456720|NCT00719732|Device|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
456721|NCT00719706|Drug|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
456722|NCT00719706|Drug|Placebo|Placebo
456723|NCT00719693|Drug|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
456724|NCT00719693|Drug|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
456725|NCT00719680|Biological|IgPro20|
456726|NCT00719667|Other|coronary artery bypass grafting|on pump off pump
456727|NCT00719641|Procedure|Colonoscopy|
456728|NCT00719641|Device|Segmental Stiffening Wire|
456729|NCT00719602|Drug|Lamivudine|Taken orally twice daily
456730|NCT00719602|Drug|Lopinavir/Ritonavir|Taken orally twice daily
456731|NCT00719602|Drug|Nevirapine|Taken orally twice daily
456732|NCT00719602|Drug|Zidovudine|Taken orally twice daily
456733|NCT00719576|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation via mini-arthrotomy
456734|NCT00719576|Procedure|Microfracture|Microfracture performed by arthroscopic surgery
456735|NCT00719563|Drug|American ginseng|Given orally
456736|NCT00719563|Other|placebo|Given orally
456737|NCT00719550|Drug|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
456738|NCT00719550|Drug|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
456739|NCT00719550|Drug|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
456740|NCT00719550|Drug|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
456741|NCT00719550|Drug|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
456742|NCT00719537|Drug|Aspirin|Aspirin 81 mg once a day
456743|NCT00719537|Drug|Placebo Oral Tablet|Placebo 1 tab Daily
456744|NCT00719537|Drug|Progesterone|Oral Progesterone 200 mg Twice Daily
456745|NCT00719524|Drug|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
456746|NCT00719511|Drug|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
456747|NCT00719511|Drug|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
456748|NCT00719511|Drug|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
456749|NCT00719511|Drug|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
456750|NCT00719498|Drug|Epo-alpha|
456751|NCT00719485|Other|Educational program|Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
456793|NCT00719212|Biological|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
456794|NCT00719199|Drug|IMO-2055|SC weekly injections
456930|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
456752|NCT00719472|Drug|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
456753|NCT00719472|Drug|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
456754|NCT00719472|Drug|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
456755|NCT00719472|Drug|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
456756|NCT00719459|Drug|Iron Sucrose|Venofer 20 mg/mL
456757|NCT00719459|Drug|Iron Sucrose|Iron sucrose 20 mg/mL
456758|NCT00719433|Device|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
456759|NCT00719433|Other|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
456760|NCT00719420|Drug|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
456761|NCT00719420|Drug|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
456762|NCT00719407|Drug|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
456763|NCT00719394|Drug|GSI 136|
456764|NCT00719394|Drug|placebo|
456765|NCT00719381|Drug|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
456766|NCT00719355|Behavioral|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
456767|NCT00719355|Behavioral|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
456768|NCT00719342|Drug|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
456769|NCT00719342|Other|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
456770|NCT00719329|Drug|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
456771|NCT00719329|Behavioral|Dry Cord Care|Educational messages regarding clean cord care
456772|NCT00719316|Drug|Aliskiren|Aliskiren 300mg per day for 6 weeks
456773|NCT00719303|Behavioral|Behavioral Dietary Intervention|Receive dietary intervention
456774|NCT00719303|Behavioral|Compliance Monitoring|Complete daily fat gram and step diaries
456775|NCT00719303|Other|Counseling|Undergo face-to-face and telephone counseling
456776|NCT00719303|Other|Educational Intervention|Receive educational materials
456777|NCT00719303|Behavioral|Exercise Intervention|Undergo physical activity intervention
456778|NCT00719303|Other|Laboratory Biomarker Analysis|Correlative studies
456779|NCT00719303|Other|Quality-of-Life Assessment|Ancillary studies
456780|NCT00719303|Other|Questionnaire Administration|Ancillary studies
456781|NCT00719290|Procedure|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
456782|NCT00719290|Procedure|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
456783|NCT00719277|Device|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
456784|NCT00719264|Drug|RAD001(everolimus)|10 mg qd
456785|NCT00719264|Drug|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
456786|NCT00719264|Drug|bevacizumab|10 mg/kg every 2 weeks
456787|NCT00719251|Device|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
456788|NCT00719251|Device|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
456789|NCT00719251|Other|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
456790|NCT00719238|Behavioral|Nutrition plus education|Nutritional instruction in small groups plus education
456791|NCT00719238|Behavioral|Education only|Educational video and pamphlets
456792|NCT00719225|Drug|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
456841|NCT00718874|Other|Dietary|modification of macronutrient content
456795|NCT00719199|Drug|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
456796|NCT00719199|Drug|FOLFIRI|Given day 1 of each cycle
456797|NCT00719186|Drug|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
456798|NCT00719186|Drug|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
456799|NCT00719173|Drug|aprepitant|Given orally
456800|NCT00719173|Drug|cyclophosphamide|Given IV
456801|NCT00719173|Other|placebo|Given orally
456802|NCT00719160|Drug|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
456803|NCT00719160|Drug|Placebo|Placebo 20 mg twice a day for 9 days
456804|NCT00719147|Procedure|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
456805|NCT00719147|Other|Functional Status and Symptom Questionnaire|Questionnaire
456806|NCT00719134|Drug|Maxalt|anti-migraine drug
456807|NCT00719134|Drug|placebo pill|placebo pills
456808|NCT00719134|Drug|placebo pills|placebo pills
456809|NCT00719121|Drug|Talarozole|Topical Application (20 mg)
456810|NCT00719121|Drug|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
456811|NCT00719108|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
456812|NCT00719108|Biological|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
456813|NCT00719095|Drug|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
456814|NCT00719095|Behavioral|Behavioral therapy|
456815|NCT00719056|Drug|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
456816|NCT00719056|Drug|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
456817|NCT00719043|Biological|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
456818|NCT00719043|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
456819|NCT00719043|Biological|Placebo|Administered as an intramuscular (IM) injection
456820|NCT00719030|Dietary Supplement|Pomegranate pill|Pomegranate extract pill
456821|NCT00719030|Dietary Supplement|Pomegranate pill placebo|Pomegranate pill placebo
456822|NCT00719017|Procedure|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
456823|NCT00719017|Radiation|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
456824|NCT00719017|Procedure|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
456825|NCT00719004|Procedure|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
456826|NCT00718991|Device|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
456827|NCT00718978|Procedure|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
456828|NCT00718965|Drug|AVE5530|one tablet in the evening with dinner
456829|NCT00718965|Drug|Placebo|one tablet in the evening with dinner
456830|NCT00718952|Drug|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
456831|NCT00718952|Drug|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
456832|NCT00718952|Drug|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
456833|NCT00718939|Device|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
456834|NCT00718913|Drug|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
456835|NCT00718913|Drug|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
456836|NCT00718913|Drug|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
456837|NCT00718913|Radiation|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
456838|NCT00718913|Drug|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
456839|NCT00718887|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
456840|NCT00718887|Drug|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
456844|NCT00718848|Procedure|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
456845|NCT00718848|Procedure|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
456846|NCT00718835|Behavioral|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
456847|NCT00718822|Other|oxygen concentration in the culture atmosphere|
456848|NCT00718809|Drug|saracatinib|Given orally
456849|NCT00718796|Other|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
456850|NCT00718796|Other|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
456851|NCT00718783|Other|Tissue samples taken from retinoblastoma|Tissue banking
456852|NCT00718783|Other|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
456853|NCT00718770|Drug|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
456854|NCT00718757|Drug|Dexamethasone|5 doses given on Days 6-10
456855|NCT00718757|Drug|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
456856|NCT00718757|Drug|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8~* Patients < 1 year of age or < 10kg in weight: Vincristine 0.05 mg/kg"
456857|NCT00718744|Other|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
456858|NCT00718731|Drug|GSI-136|
456859|NCT00718731|Other|Placebo|
456860|NCT00718718|Drug|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
456861|NCT00718718|Drug|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
456862|NCT00718718|Drug|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
456863|NCT00718718|Drug|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
456864|NCT00718718|Drug|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
456865|NCT00718705|Drug|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
456866|NCT00718705|Drug|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
456867|NCT00718692|Drug|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
456868|NCT00718679|Drug|IVN201|Intralymphativ injection of the study drug
456869|NCT00718679|Drug|Placebo|
456870|NCT00718666|Biological|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
456871|NCT00718653|Dietary Supplement|Lutein|Lutein (12 mg/d)
456872|NCT00718653|Dietary Supplement|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
456873|NCT00718640|Drug|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
456874|NCT00718640|Drug|Bortezomib|Bortezomib 1.3 milligram per meter^2 (mg/m^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
456875|NCT00718627|Biological|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
456876|NCT00718614|Procedure|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
456877|NCT00718601|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
456878|NCT00718588|Drug|MTRX1011A|Subcutaneous and intravenous single and repeating dose
456879|NCT00718575|Procedure|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
456880|NCT00718562|Drug|AMN107|
456881|NCT00718549|Drug|Cladribine|Cladribine will be adminiatered at a dose of 0.12 mg/kg/day as IV infusion on Days 2-4 of each 28-day cycle during induction phase.
456882|NCT00718549|Drug|Cyclophosphamide|Cyclophosphamide will be administred at a dose of 250 mg/m^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
456883|NCT00718549|Drug|Rituximab|Rituximab will be administered at a dose of 375 mg/m^2 as IV infusion on Day 1 of Cycle 1 and at a dose of 500 mg/m^2 as IV infusion on Day 1 of Cycles 2-6 during induction phase. Rituximab will be administered at a dose of 375 mg/m^2 as IV infusion on Day 1 of each 12-week cycle during maintenance phase.
456884|NCT00718536|Drug|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
456885|NCT00718523|Drug|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
456886|NCT00718523|Drug|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
456887|NCT00718510|Drug|L-Arginine|3 grams, twice daily, oral administration
456931|NCT00718133|Device|Spirometry (Pony spirometer)|Spirometry at rest
456932|NCT00718120|Biological|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
456888|NCT00718484|Drug|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
456889|NCT00718484|Drug|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
456890|NCT00718471|Drug|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
456891|NCT00718471|Drug|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
456892|NCT00718432|Behavioral|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
456893|NCT00718432|Behavioral|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
456894|NCT00718432|Behavioral|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
456895|NCT00718419|Drug|Enzastaurin|Enzastaurin: Cycle 1 Day 1 only: 3, 125-mg tablets three times on Day 1 (Day 1 total dose = 1125 mg) Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally BID (500 mg total per day) Cycle length (all cycles): 28 Days Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression.
456896|NCT00718406|Drug|Metoprolol|
456897|NCT00718406|Drug|metoprolol plus morphine|
456898|NCT00718380|Drug|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
456899|NCT00718354|Drug|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
456900|NCT00718354|Drug|Standard Chemotherapy|Investigator's discretion
456901|NCT00718341|Drug|AF056|
456902|NCT00718341|Drug|Placebo|
456903|NCT00718328|Drug|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
456904|NCT00718328|Drug|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
456905|NCT00718315|Drug|erlotinib [Tarceva]|150mg po daily
456906|NCT00718315|Drug|fusidic acid [Verutex]|topical, daily for 30 days.
456907|NCT00718315|Drug|erythromycin [Eritex]|topical, daily for 30 days.
456908|NCT00718315|Drug|Fisiogel|topical, daily for 30 days
456909|NCT00718302|Device|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
456910|NCT00718302|Device|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
456911|NCT00718289|Other|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
456912|NCT00718289|Other|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
456913|NCT00718276|Drug|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
456914|NCT00718276|Dietary Supplement|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
456915|NCT00718250|Biological|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
456916|NCT00718250|Biological|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
456917|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
456918|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
456919|NCT00718237|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
456920|NCT00718237|Biological|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
456921|NCT00718224|Drug|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
456922|NCT00718224|Drug|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe~Subcutaneous injection"
456923|NCT00718224|Drug|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
456924|NCT00718185|Procedure|Obtain blood specimens|Obtain blood samples at multiple timepoints.
456925|NCT00718172|Procedure|Liver Biopsy|
456926|NCT00718172|Drug|Peginterferon &amp; Ribavirin for Hepatitis C|
456927|NCT00718172|Drug|Pre-treatment Ribavirin|
456928|NCT00718159|Drug|LY573636-sodium|Individualized dose is dependent on participant's height, weight, gender and is adjusted to target a specific exposure range corrected for a participant's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for acute myeloid leukemia (AML) and Day 1 of a 28-day cycle for essential thrombocythemia (ET) for at least one cycle. A participant may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
456929|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
456933|NCT00718094|Drug|Polyphenon E®|Oral capsules
456934|NCT00718094|Drug|Placebo Oral Tablet|Oral tablet: placebo
456935|NCT00718081|Drug|Oral sufentanil|Oral dosage of sufentanil
456936|NCT00718081|Drug|Placebo|Oral dosage of placebo
456937|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
456938|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
456939|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
456940|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
456941|NCT00717990|Drug|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
456942|NCT00717990|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
456943|NCT00717990|Drug|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
456944|NCT00717977|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
456945|NCT00717951|Drug|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
456946|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
456947|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
456948|NCT00717925|Drug|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
456949|NCT00717912|Other|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
456950|NCT00717912|Other|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
456951|NCT00717912|Other|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
456952|NCT00717899|Device|Spirometry (Pony spirometer)|Spirometry at rest
456953|NCT00717886|Radiation|isosulfan blue dye|"At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience."
456954|NCT00717873|Device|Airway clearance Device|Provided by the Vest Airway clearance system
456955|NCT00717860|Drug|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
456956|NCT00717860|Drug|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
456957|NCT00717834|Biological|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
456958|NCT00717821|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120 micrograms or 200 micrograms iv or sc (starting dose)
456959|NCT00717821|Drug|Epoetin beta or darbepoetin alfa|As prescribed
456960|NCT00717808|Drug|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
456961|NCT00717808|Drug|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
456962|NCT00717795|Behavioral|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
456963|NCT00717795|Behavioral|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
456964|NCT00717782|Procedure|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
456965|NCT00717782|Procedure|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
456966|NCT00717769|Drug|SUN13834|Daily oral doses, low dose, for 28 days of SUN13834
456967|NCT00717769|Drug|Placebo|Daily oral doses, placebo, for 28 days of SUN13834
456968|NCT00717756|Drug|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
456969|NCT00717730|Dietary Supplement|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
456970|NCT00717730|Dietary Supplement|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
456971|NCT00717730|Dietary Supplement|Placebo|Placebo with no active ingredients
456972|NCT00717730|Dietary Supplement|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
456973|NCT00717717|Behavioral|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
456974|NCT00717704|Drug|ixabepilone|by vein once every 3 weeks
456975|NCT00717704|Drug|Dasatinib|by mouth once daily
456976|NCT00717691|Device|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
456977|NCT00717691|Other|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
456978|NCT00717678|Drug|Prograf-XL|oral
456979|NCT00717678|Drug|Prograf|oral
456980|NCT00717678|Drug|MMF|oral
456981|NCT00717665|Device|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
456982|NCT00717665|Other|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
456983|NCT00717652|Drug|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
456984|NCT00717652|Drug|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
456985|NCT00717639|Procedure|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
456986|NCT00717626|Drug|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is < 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
456987|NCT00717600|Dietary Supplement|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
456988|NCT00717587|Drug|motexafin gadolinium|
456989|NCT00717587|Drug|sunitinib malate|
456990|NCT00717587|Genetic|comparative genomic hybridization|
456991|NCT00717587|Genetic|gene expression analysis|
456992|NCT00717587|Genetic|mutation analysis|
456993|NCT00717587|Genetic|polymorphism analysis|
456994|NCT00717587|Other|immunohistochemistry staining method|
456995|NCT00717587|Other|iodine I-124 girentuximab|
456996|NCT00717587|Other|laboratory biomarker analysis|
456997|NCT00717587|Other|pharmacological study|
456998|NCT00717587|Procedure|adjuvant therapy|
456999|NCT00717587|Procedure|neoadjuvant therapy|
457000|NCT00717587|Procedure|therapeutic conventional surgery|
457001|NCT00717574|Drug|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
457002|NCT00717574|Drug|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
457003|NCT00717561|Drug|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
457004|NCT00717561|Drug|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
457005|NCT00717548|Behavioral|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
457006|NCT00717535|Other|cryopreservation|
457007|NCT00717535|Other|questionnaire administration|
457008|NCT00717535|Other|study of socioeconomic and demographic variables|
457009|NCT00717522|Drug|Pomalidomide|
457010|NCT00717496|Other|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
457011|NCT00717470|Drug|Prograf®|oral
457012|NCT00717470|Drug|Advagraf®|oral
457013|NCT00717470|Drug|Mycophenolate Mofetil|oral
457014|NCT00717470|Drug|Simulect|oral
457015|NCT00717470|Drug|methylprednisolone / prednisone|oral
457016|NCT00717457|Drug|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
457017|NCT00717457|Drug|taspoglutide|10mg once weekly
457018|NCT00717457|Drug|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
457019|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy~prizes awarded for target behaviors"
457065|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
457020|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities~prizes awarded for target behaviors"
457021|NCT00717431|Procedure|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
457022|NCT00717418|Drug|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
457023|NCT00717405|Drug|Standard chemotherapy|As prescribed
457024|NCT00717405|Drug|bevacizumab [Avastin]|15mg/kg iv 3 weekly in cycles 1-8
457025|NCT00717405|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
457026|NCT00717379|Drug|Tacrolimus|oral
457027|NCT00717379|Drug|Mycophenolate Mofetil|oral
457028|NCT00717379|Drug|Methylprednisolone or equivalent|oral
457029|NCT00717379|Drug|Prednisone|oral
457030|NCT00717366|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
457031|NCT00717340|Drug|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):~Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.~Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.~Paclitaxel: Phase 1b study and Phase 2a study:~All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
457032|NCT00717327|Other|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
457033|NCT00717314|Drug|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
457034|NCT00717314|Drug|CNI (50%)|50% reduction from BL
457035|NCT00717314|Drug|CNI (≥75%)|≥75% reduction from BL
457036|NCT00717288|Drug|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
457037|NCT00717288|Drug|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
457038|NCT00717288|Drug|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
457039|NCT00717275|Drug|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
457040|NCT00717262|Drug|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
457041|NCT00717262|Drug|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
457042|NCT00717249|Device|galyifilcon A control lens|Marketed daily wear contact lens
457043|NCT00717249|Device|galyfilcon A with a silver additive|Investigational daily wear contact lens
457044|NCT00717236|Drug|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
457045|NCT00717236|Other|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
457046|NCT00717210|Drug|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
457047|NCT00717210|Radiation|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
457048|NCT00717197|Drug|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
457049|NCT00717184|Drug|Interleukin, NK cells|
457050|NCT00717171|Device|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
457051|NCT00717171|Device|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
457052|NCT00717158|Behavioral|Usual medical care|
457053|NCT00717158|Behavioral|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
457054|NCT00717145|Drug|risedronate|one risedronate 20 mg DR tablet
457055|NCT00717145|Drug|risedronate|One risedronate 20 mg DR tablet
457056|NCT00717145|Drug|risedronate|One risedronate 35 mg DR tablet
457057|NCT00717145|Drug|risedronate|One risedronate 35 mg IR tablet
457058|NCT00717132|Behavioral|Individual Behavior Modification|Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
457059|NCT00717132|Behavioral|Family-based behavior modification|Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
457060|NCT00717093|Drug|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
457061|NCT00717093|Drug|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
457062|NCT00717080|Procedure|IOL surgery|IOL surgery using capsular tension ring (AURORING)
457063|NCT00717080|Procedure|IOL surgery|IOL surgery without CTR
457064|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
457066|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
457067|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
457068|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
457069|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
457070|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
457071|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
457072|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
457073|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
457074|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
457075|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
457076|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
457077|NCT00717054|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
457078|NCT00717054|Drug|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
457079|NCT00716989|Biological|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
457080|NCT00716976|Drug|sodium thiosulfate|Given IV
457081|NCT00716976|Procedure|examination|Patients undergo audiological assessments periodically
457082|NCT00716963|Drug|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
457083|NCT00716963|Drug|budesonide 400 mcg|budesonide 400 mcg
457084|NCT00716963|Other|Placebo|Placebo
457085|NCT00716950|Drug|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
457086|NCT00716950|Drug|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
457087|NCT00716937|Procedure|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
457088|NCT00716937|Procedure|laying open|laying open the site of excision of sinus or cyst without any flap
457089|NCT00716924|Drug|Clopidogrel|300 mg
457090|NCT00716924|Drug|Clopidogrel|600 mg
457091|NCT00716911|Drug|ganciclovir|
457092|NCT00716911|Genetic|polymerase chain reaction|
457093|NCT00716911|Other|flow cytometry|
457094|NCT00716911|Other|immunologic technique|
457095|NCT00716911|Procedure|allogeneic bone marrow transplantation|
457096|NCT00716911|Procedure|allogeneic hematopoietic stem cell transplantation|
457097|NCT00716911|Procedure|assessment of therapy complications|
457098|NCT00716911|Procedure|peripheral blood stem cell transplantation|
457099|NCT00716872|Behavioral|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
457100|NCT00716872|Behavioral|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
457101|NCT00716859|Drug|Timolol|Timolol 0.5% dosed twice-daily
457102|NCT00716859|Drug|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
457103|NCT00716846|Drug|simvastatin|10mg, 2 weeks
457104|NCT00716846|Drug|atorvastatin|10mg
457105|NCT00716846|Drug|pitavastatin|2mg
457106|NCT00716833|Drug|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
457107|NCT00716833|Drug|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
457108|NCT00716820|Drug|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
457109|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
457110|NCT00716807|Drug|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
457111|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
457112|NCT00716807|Drug|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
457113|NCT00716794|Drug|HE3235|HE3235 will be administered orally in 28 day cycles.
457114|NCT00716768|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
457115|NCT00716768|Procedure|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
457116|NCT00716755|Drug|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, [11C]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
457117|NCT00716742|Drug|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
457118|NCT00716716|Drug|rFIXFc|As specified in the treatment arm
457119|NCT00716703|Other|CT Scan using IV contrast alone|CT scan using IV contrast alone
457120|NCT00716690|Procedure|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
457121|NCT00716664|Other|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
457122|NCT00716664|Other|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
457123|NCT00716651|Drug|mepolizumab|750 mg mepolizumab iv q4wk until week 32
457124|NCT00716638|Behavioral|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
457125|NCT00716638|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
457126|NCT00716625|Drug|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition."
457127|NCT00716612|Drug|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
457128|NCT00716612|Drug|Placebo control|po Placebo QD
457129|NCT00716599|Device|training in use of rapid diagnostic tests (RDTs) for malaria|training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
457130|NCT00716586|Drug|dorzolamide|2% dorzolamide- 1 Gtt TID
457131|NCT00716573|Drug|everolimus|0,75 mg bid, 24 months
457132|NCT00716547|Drug|ketoprofen in Diractin®|50 mg (b.i.d.)
457133|NCT00716547|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
457134|NCT00716547|Drug|Placebo|b.i.d.
457135|NCT00716547|Drug|celecoxib|100 mg (b.i.d.)
457136|NCT00716534|Drug|ABT-869|12.5 mg ABT-869
457137|NCT00716534|Drug|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
457138|NCT00716534|Drug|ABT-869|7.5 mg ABT-869
457139|NCT00716534|Drug|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
457140|NCT00716534|Drug|Paclitaxel|Paclitaxel (200 mg/m2)
457141|NCT00716521|Drug|placebo|single oral dose placebo
457142|NCT00716521|Drug|zolpidem|single oral dose, 5 mg zolpidem
457143|NCT00716521|Drug|zolpidem|single oral dose, 10 mg zolpidem
457144|NCT00716508|Procedure|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
457145|NCT00716508|Procedure|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
457146|NCT00716495|Biological|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
457147|NCT00716469|Drug|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
457148|NCT00716456|Drug|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
457149|NCT00716443|Drug|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
457150|NCT00716443|Drug|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
457151|NCT00716430|Behavioral|Quality Improvement Programme|Quality Improvement training programme
457152|NCT00716417|Drug|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
457153|NCT00716417|Drug|BIBW 2992|low to high dose, daily
457154|NCT00716404|Device|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
457155|NCT00716391|Other|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
457156|NCT00716391|Other|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
457157|NCT00716378|Behavioral|Teen Passenger Presence|
457158|NCT00716365|Device|HemCon bandage|5 cm X 5 cm
457159|NCT00716352|Behavioral|Educational intervention programme|
457160|NCT00716339|Behavioral|motivation|
457161|NCT00716326|Device|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
457162|NCT00716326|Device|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.~Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
457163|NCT00716274|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
457164|NCT00716274|Drug|Placebo|oral, daily, for 16 weeks
457165|NCT00716261|Device|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
457166|NCT00716248|Drug|bucillamine|bucillamine 100 mg, twice a day
457167|NCT00716248|Drug|methotrexate|methotrexate 6 mg or more per week
457168|NCT00716183|Biological|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
457169|NCT00716183|Biological|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
457170|NCT00716183|Biological|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
457171|NCT00716183|Drug|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
457172|NCT00716170|Biological|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)~Day B: Isoglycemic intravenous (iv) glucose infusion~Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)~Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)~Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)~Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
457173|NCT00716144|Drug|Talarozole|Oral Capsule Once Daily
457174|NCT00716105|Other|Standard infant formula|From 3 to 12 months of age. As per standard requirement
457175|NCT00716105|Other|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
457176|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
457177|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
457178|NCT00716092|Drug|Sitagliptin|100 mg once daily for 28 days
457179|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
457180|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
457181|NCT00716092|Drug|Linagliptin|5mg once daily for 28 days
457182|NCT00716079|Other|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
457183|NCT00716066|Biological|Anti-Thymocyte Globulin|Given IV
457184|NCT00716066|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic peripheral blood stem cell transplantation
457185|NCT00716066|Drug|Carmustine|Given IV
457186|NCT00716066|Drug|Cytarabine|Given IV
457187|NCT00716066|Drug|Etoposide|Given IV
457188|NCT00716066|Other|Laboratory Biomarker Analysis|Correlative studies
457189|NCT00716066|Drug|Melphalan|Given IV
457190|NCT00716066|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic peripheral blood stem cell transplantation
457191|NCT00716066|Drug|Prednisone|Given PO
457192|NCT00716066|Procedure|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
457193|NCT00716053|Drug|BLVR|BLVR 20 mL
457194|NCT00716040|Behavioral|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
457195|NCT00716040|Other|Usual care|The control group will be submitted to the usual care of the health service
457196|NCT00716027|Behavioral|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
457197|NCT00716027|Behavioral|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
457198|NCT00716014|Drug|TD101|TD101 is injection into a callus on the bottom of one of the patient's feet
457199|NCT00716014|Drug|Normal saline (placebo)|A normal saline solution (placebo) is injected into one of the patient's feet.
457200|NCT00716001|Drug|N-acetylcysteine|
457201|NCT00715988|Drug|Methadone HCl Inject 10 mg/ml (will require dilution)|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
457202|NCT00715988|Drug|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
457203|NCT00715975|Drug|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
457204|NCT00715975|Drug|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
457309|NCT00715273|Drug|Placebo Niacin|Placebo niacin each day
457205|NCT00715962|Behavioral|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
457206|NCT00715962|Other|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
457207|NCT00715962|Other|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
457208|NCT00715949|Other|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
457209|NCT00715936|Behavioral|Control|
457210|NCT00715936|Behavioral|ECD|
457211|NCT00715936|Behavioral|Enhanced Nutrition|
457212|NCT00715923|Other|Modified consent form|modified consent form used
457213|NCT00715923|Other|Standard consent form|standard consent form used
457214|NCT00715910|Biological|Nimenrix|One dose, as intramuscular injection
457215|NCT00715910|Procedure|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
457216|NCT00715897|Procedure|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
457217|NCT00715884|Device|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
457218|NCT00715884|Device|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
457219|NCT00715871|Drug|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
457220|NCT00715871|Device|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
457221|NCT00715858|Drug|doxycycline|capsule, 100 mg, b.i.d., 12 months
457222|NCT00715858|Drug|rifampin|capsule, 300 mg, od, 12 months
457223|NCT00715858|Drug|placebo|placebo matched to rifampin; placebo matched to doxycycline
457224|NCT00715845|Procedure|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
457225|NCT00715832|Biological|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
457226|NCT00715806|Device|Open MRI scanner.|Imaging in an Open MRI scanner.
457227|NCT00715806|Device|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
457228|NCT00715793|Drug|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
457229|NCT00715793|Drug|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
457230|NCT00715793|Procedure|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
457231|NCT00715780|Drug|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
457232|NCT00715780|Drug|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
457233|NCT00715780|Drug|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
457234|NCT00715780|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
457235|NCT00715780|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
457236|NCT00715780|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
457275|NCT00715546|Procedure|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
457303|NCT00715299|Behavioral|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
457304|NCT00715286|Other|timing of surgery|Surgery is followed by chemotherapy
457237|NCT00715767|Behavioral|Assessment|"Cognitive Assessment:~Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:~Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).~Survey Instrument for Barriers to Acute Medicine Education:~A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
457238|NCT00715741|Other|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
457239|NCT00715741|Other|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
457240|NCT00715741|Other|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 >0.9 with 3-5 cm water PEEP
457241|NCT00715741|Other|FiO2 >0.9 without PEEP|FiO2 >0.9 without PEEP
457242|NCT00715728|Device|Intraoperative warming with Bair Hugger forced air system|Intraoperative warming with Bair Hugger forced air system
457243|NCT00715728|Device|Intraoperative warming with Hotdog resistive heating system|Intraoperative warming with Hotdog resistive heating system
457244|NCT00715715|Drug|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
457245|NCT00715702|Drug|AZD5672|100 mg oral single dose
457246|NCT00715689|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
457247|NCT00715689|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
457248|NCT00715689|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
457249|NCT00715689|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
457250|NCT00715689|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
457251|NCT00715689|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
457252|NCT00715689|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
457253|NCT00715689|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
457254|NCT00715676|Drug|Placebo|oral, once daily
457255|NCT00715676|Drug|DP001|oral, once daily
457256|NCT00715663|Drug|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
457257|NCT00715650|Behavioral|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
457258|NCT00715650|Behavioral|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
457259|NCT00715637|Drug|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
457260|NCT00715637|Drug|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
457261|NCT00715624|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
457262|NCT00715624|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
457263|NCT00715624|Drug|Basal Insulin|Dose to be kept stable.
457264|NCT00715624|Drug|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
457265|NCT00715624|Device|Pen auto-injector|
457266|NCT00715611|Procedure|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
457267|NCT00715611|Drug|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
457268|NCT00715611|Radiation|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
457269|NCT00715585|Behavioral|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
457270|NCT00715585|Behavioral|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
457271|NCT00715585|Behavioral|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
457272|NCT00715572|Drug|thyroxine|monotherapy with thyroxine
457273|NCT00715572|Drug|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
457274|NCT00715559|Drug|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
457276|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single—pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post—training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
457277|NCT00715520|Drug|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.~The order in which Carbidopa-Levodopa is given will be randomized per participant."
457278|NCT00715520|Drug|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.~The order in which Methylphenidate is given will be randomized per participant."
457279|NCT00715520|Drug|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.~The order in which Amphetamine Sulfate is given will be randomized per participant."
457280|NCT00715520|Drug|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant."
457281|NCT00715520|Other|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
457282|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
457283|NCT00715507|Device|medication monitor|the medication monitor will aid in expertise and decision-making.
457284|NCT00715494|Behavioral|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
457285|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
457286|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
457287|NCT00715455|Drug|Unfractionated Heparin|Heparin will be administered per standard of care at sites
457288|NCT00715442|Drug|Sunitinib|50 mg by mouth daily for 28 consecutive days
457289|NCT00715442|Procedure|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
457290|NCT00715429|Drug|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
457291|NCT00715429|Drug|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
457292|NCT00715416|Device|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
457293|NCT00715416|Procedure|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
457294|NCT00715403|Drug|BIBF 1120|
457295|NCT00715377|Drug|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
457296|NCT00715364|Drug|NTx™-265: rhCG, then rEPO|"rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then~rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
457297|NCT00715364|Drug|Saline Placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then~Saline IV, on Day 7, 8, and 9 of study participation"
457298|NCT00715351|Drug|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
457299|NCT00715351|Drug|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
457300|NCT00715325|Device|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
457301|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
457302|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
457305|NCT00715286|Other|timing of surgery|Chemotherapy is followed by surgery
457306|NCT00715273|Drug|Atorvastatin|10 to 80 mg of atorvastatin each day
457307|NCT00715273|Drug|Niacin|2000 mg of niacin each day
457308|NCT00715273|Drug|Colesevelam|3.8 g of colesevelam each day
457310|NCT00715273|Drug|Placebo Colesevelam|Placebo colesevelam each day
457311|NCT00715234|Other|Reminder/recall notices for vaccines|"Receive a generic letter reminding them to make an appointment to get vaccines.~Receive a computer-generated telephone message at 1 week post initial letter.~Receive a computer-generated telephone message at 2 months post initial letter.~Receive a letter at 3 months post initial letter."
457312|NCT00715208|Drug|rituximab|
457313|NCT00715208|Drug|cyclophosphamide|
457314|NCT00715208|Drug|doxorubicin|
457315|NCT00715208|Drug|VELCADE|
457316|NCT00715208|Drug|prednisone|
457317|NCT00715195|Behavioral|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
457318|NCT00715182|Drug|TKI258|
457319|NCT00715169|Drug|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
457320|NCT00715169|Other|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
457321|NCT00715143|Device|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
457322|NCT00715130|Behavioral|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
457323|NCT00715117|Drug|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
457324|NCT00715117|Other|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
457325|NCT00715104|Biological|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
457326|NCT00715104|Biological|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
457327|NCT00715091|Drug|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
457328|NCT00715091|Drug|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
457329|NCT00715078|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
457330|NCT00715065|Procedure|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting ~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
457331|NCT00715052|Procedure|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
457332|NCT00715039|Drug|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
457333|NCT00715039|Drug|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
457334|NCT00715039|Drug|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
457335|NCT00715026|Device|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
457336|NCT00715013|Drug|Patupilone|Patupilone
457337|NCT00715000|Procedure|Oral rehydration therapy|oral rehydration solution
457338|NCT00715000|Procedure|classical hydration via intravenous infusion|intravenous infusion
457339|NCT00714974|Device|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
457340|NCT00714961|Drug|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
457341|NCT00714961|Drug|Placebo|plus acetylsalicylic acid (ASA)
457342|NCT00714948|Drug|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) > 2.1), after consultation with the Principal Investigator.
457343|NCT00714935|Behavioral|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
457344|NCT00714935|Behavioral|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke~The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
457345|NCT00714922|Procedure|PRK|Laser refractive surgery
457346|NCT00714922|Procedure|SBK|Laser refractive surgery
457347|NCT00714896|Behavioral|Stepped-Care|"stage-based expert system written intervention at baseline and 3 months~in-person stage appropriate counseling at baseline and 3 months~telephone counseling sessions at weeks 2,4 and 8,~as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study~optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
457348|NCT00714896|Behavioral|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
457349|NCT00714883|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
457350|NCT00714870|Behavioral|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
457351|NCT00714857|Drug|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
457352|NCT00714831|Behavioral|Physical activity intervention|3-months physical activity intervention
457353|NCT00714831|Behavioral|Health educational program|Health education sessions and stretching sessions
457354|NCT00714818|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
457355|NCT00714818|Behavioral|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
457356|NCT00714779|Drug|Fluoxetine|20-40 mg / day orally
457357|NCT00714779|Behavioral|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
457358|NCT00714766|Procedure|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
457359|NCT00714753|Radiation|brachytherapy|
457360|NCT00714753|Radiation|hypofractionated radiation therapy|
457361|NCT00714753|Radiation|image-guided radiation therapy|
457362|NCT00714753|Radiation|intensity-modulated radiation therapy|
457363|NCT00714740|Drug|acetazolamide|acetazolamide 2 times 250mg per day
457364|NCT00714727|Procedure|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
457365|NCT00714714|Drug|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
457366|NCT00714714|Drug|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
457367|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
457368|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
457369|NCT00714688|Drug|Placebo|2xplacebo once daily for 13 weeks
457370|NCT00714675|Dietary Supplement|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
457371|NCT00714675|Dietary Supplement|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
457372|NCT00714662|Device|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
457373|NCT00714649|Drug|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
457374|NCT00714623|Device|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
457375|NCT00714597|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
457376|NCT00714597|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
457377|NCT00714584|Drug|Naltrexone HCl.|
457378|NCT00714571|Behavioral|Mnemonic strategy training (MST)|
457379|NCT00714571|Behavioral|Repeated exposure (XP)|
457380|NCT00714571|Behavioral|Subtracting Cues training|
457381|NCT00714558|Drug|Fentanyl citrate; Naltrexone; Naloxone|
457382|NCT00714545|Radiation|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
457383|NCT00714532|Behavioral|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
457384|NCT00714532|Behavioral|Enhanced Expert System|"The intervention consists of 3 components:~Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months~scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention~telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials~a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
457385|NCT00714519|Drug|Xenaderm® Ointment|Topical, BID or as needed
457386|NCT00714519|Drug|Placebo Comparator|Topical, BID or as needed
457387|NCT00714506|Behavioral|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
457388|NCT00714506|Other|Physical activity control|physical activity plus successful aging health education
457389|NCT00714493|Biological|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
457390|NCT00714480|Drug|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
457391|NCT00714480|Drug|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
457392|NCT00714480|Drug|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
457393|NCT00714467|Behavioral|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
457394|NCT00714467|Behavioral|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
457395|NCT00714454|Other|APS Topical Lotion|
457396|NCT00714454|Other|Placebo|
457397|NCT00714441|Behavioral|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
457398|NCT00714441|Behavioral|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
457399|NCT00714441|Behavioral|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
457400|NCT00714415|Drug|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
457401|NCT00714376|Drug|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
457402|NCT00714363|Procedure|LASIK|Refractive surgery
457403|NCT00714363|Procedure|SBK|Refractive surgery
457404|NCT00714350|Behavioral|New ICU Display Visualization|
457405|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
457406|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
457407|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
457408|NCT00714311|Behavioral|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
457409|NCT00714311|Behavioral|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
457410|NCT00714298|Other|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
457411|NCT00714285|Biological|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
457412|NCT00714285|Biological|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
457413|NCT00714259|Drug|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
457414|NCT00714259|Radiation|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
457415|NCT00714259|Other|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.
457416|NCT00714246|Drug|Bortezomib|Dose escalation using traditional Phase I - 3 x 3 design to establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
457417|NCT00714246|Drug|Carboplatin|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
457418|NCT00714246|Drug|Docetaxel|Establish MTD of bortezomib when administered in combination with carboplatin and docetaxel
457419|NCT00714233|Drug|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
457420|NCT00714233|Drug|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
457421|NCT00714233|Behavioral|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
457422|NCT00714233|Drug|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
457423|NCT00714207|Behavioral|NOT program|Students in this arm of the study received the reformatted NOT intervention
457424|NCT00714207|Behavioral|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
457425|NCT00714207|Behavioral|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
457505|NCT00713674|Drug|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
457426|NCT00714207|Behavioral|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
457427|NCT00714194|Procedure|Normal continuous sedation|Normal continuous sedation.
457428|NCT00714194|Other|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
457429|NCT00714181|Drug|hydroxychloroquine|
457430|NCT00714181|Drug|temozolomide|
457431|NCT00714181|Genetic|TdT-mediated dUTP nick end labeling assay|
457432|NCT00714181|Genetic|western blotting|
457433|NCT00714181|Other|electron microscopy|
457434|NCT00714181|Other|high performance liquid chromatography|
457435|NCT00714181|Other|immunoenzyme technique|
457436|NCT00714181|Other|immunohistochemistry staining method|
457437|NCT00714181|Other|laboratory biomarker analysis|
457438|NCT00714181|Other|mass spectrometry|
457439|NCT00714181|Other|pharmacological study|
457440|NCT00714168|Behavioral|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
457441|NCT00714168|Behavioral|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
457442|NCT00714155|Other|Questionnaires, Physical Examination|Questionnaires, Physical Examination
457443|NCT00714142|Drug|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
457444|NCT00714142|Drug|15O-water|10-20 mCi, IV
457445|NCT00714142|Procedure|Positron Emission Tomography|PET Scan
457446|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
457447|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
457448|NCT00714116|Drug|SBI-087|Single IV or SC dose of SBI-087
457449|NCT00714103|Drug|8-Chloro-Adenosine|45 mg/m^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
457450|NCT00714090|Other|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.~active rTMS : 5 sessions per week for 2 to 6 weeks"
457451|NCT00714090|Other|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
457452|NCT00714090|Other|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
457453|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
457454|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
457455|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
457456|NCT00714051|Behavioral|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
457457|NCT00714051|Behavioral|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
457458|NCT00714025|Drug|RAD001|RAD001 10mg, daily, PO
457459|NCT00714012|Other|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
457460|NCT00713999|Drug|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
457461|NCT00713986|Procedure|Water 2mL PO 2 minutes prior to intra-muscular injection|Sterile Water 2mL PO - single dose
457462|NCT00713986|Procedure|skin-to-skin contact|neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.
457463|NCT00713986|Procedure|Glucose 25% 2 mL PO 2 minutes prior to injection|Glucose 25% 2mL PO - single dose
457464|NCT00713986|Procedure|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.|neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
457465|NCT00713947|Drug|during one week for the active treatments|during one week for the active treatments placebo during 25 weeks
457466|NCT00713947|Drug|Pantoprazole|6 months at 20 mg
457467|NCT00713947|Drug|Placebo Formula 515|26 weeks, one tablet per day
457468|NCT00713934|Biological|CD133|portal vein infusion of CD133+ cells
457469|NCT00713934|Biological|BM-MNC|portal vein infusion of BM-MNC
457470|NCT00713921|Drug|Fesoterodine Oral Product|After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
457548|NCT00713336|Drug|ZD4054|ZD4054 10mg Tablet
457549|NCT00713336|Drug|Moxifloxacin|400 mg capsule
457471|NCT00713895|Behavioral|Expert System|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
457472|NCT00713895|Behavioral|Standard Self-Help|standard smoking cessation self-help manual
457473|NCT00713856|Procedure|Custom PRK with iris registration|PRK
457474|NCT00713856|Procedure|Conventional PRK|PRK
457475|NCT00713843|Other|Manual Therapy Utrecht|Manual Therapy (6 weeks).
457476|NCT00713843|Other|Physical Therapy|Physical Therapy (six weeks).
457477|NCT00713830|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
457478|NCT00713830|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
457479|NCT00713830|Device|Pen auto-injector|
457480|NCT00713830|Drug|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
457481|NCT00713830|Drug|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day [except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea]) up to the end of treatment.
457482|NCT00713817|Drug|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
457483|NCT00713817|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
457484|NCT00713804|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
457485|NCT00713804|Behavioral|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
457486|NCT00713791|Drug|ZD4054|Treatment period 1: 10mg oral solution
457487|NCT00713791|Drug|ZD4054|Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
457488|NCT00713791|Drug|ZD4054|Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
457489|NCT00713791|Drug|ZD4054|Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
457490|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
457491|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
457492|NCT00713778|Procedure|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
457493|NCT00713765|Drug|AZD3480|18 total doses of 40 mg, on days 1-18
457494|NCT00713765|Drug|Donepezil|One single dose of mg on day 5
457495|NCT00713739|Drug|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
457496|NCT00713739|Drug|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
457497|NCT00713739|Drug|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
457498|NCT00713739|Drug|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
457499|NCT00713726|Drug|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
457500|NCT00713726|Drug|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
457501|NCT00713713|Procedure|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
457502|NCT00713700|Device|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
457503|NCT00713687|Drug|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"Photodynamic therapy (PDT) after successful drainage:~Photosan® 2 mg/kg i.v. 48 hrs before laser activation~9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~iteration every 14 days~afterwards 4 weeks intermission~Iteration of 1. and 2. in case of good compatibility"
457504|NCT00713674|Other|Theraworx|Theraworx swab intranasal BID for 5 days
457506|NCT00713661|Drug|TachoSil®|"Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy."
457507|NCT00713648|Drug|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
457508|NCT00713622|Drug|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
457509|NCT00713622|Drug|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
457510|NCT00713609|Drug|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
457511|NCT00713609|Drug|Clindamycin gel|1% clindamycin phosphate applied topically once a day
457512|NCT00713609|Drug|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
457513|NCT00713609|Drug|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
457514|NCT00713609|Drug|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
457515|NCT00713596|Drug|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
457516|NCT00713596|Procedure|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
457517|NCT00713596|Procedure|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
457518|NCT00713596|Procedure|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
457519|NCT00713596|Other|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
457520|NCT00713583|Drug|levodopa|800mg levodopa and 200mg carbidopa per day
457521|NCT00713583|Drug|Placebo|Placebo
457522|NCT00713583|Behavioral|Cognitive Behavioral Therapy|Participants received individual cognitive behavioral therapy (CBT) in 50-minute weekly sessions. These sessions were manual-driven and based on the relapse prevention model proposed by Marlatt and Gordon (1985). Trained masters-level therapists, under the supervision of senior therapists and the principal investigator, worked with participants to teach them how to recognize and cope with risky situations that could influence their cocaine use through self-monitoring of situational craving and drug use stimuli, coping skills training, and lifestyle modifications.
457523|NCT00713583|Behavioral|Contingency Management|An abstinence-based contingency management (CM) procedure was used. Participants earned vouchers according to the reward schedule recommended by Budney and Higgins (1998), beginning at $2.50 for the first cocaine-negative urine. For each consecutive cocaine-negative urine, voucher values increased by $1.25 with a $10 bonus given for provision of three consecutive cocaine-negative urines within a week. A cocaine-positive urine or failure to provide a scheduled urine sample resulted in a reset of the schedule to the initial value of $2.50. After provision of five negative urines, the voucher returned to the value prior to the reset. Participants were able to redeem their vouchers for small amounts of cash (≤$25) or gift cards for goods and services.
457524|NCT00713557|Device|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
457525|NCT00713557|Drug|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
457526|NCT00713544|Drug|AZD5672|20 mg oral, once daily
457527|NCT00713544|Drug|Etanercept|50 mg, subcutaneous injection, weekly
457528|NCT00713544|Drug|Placebo|placebo, oral, once daily
457529|NCT00713544|Drug|AZD5672|50 mg oral, once daily
457530|NCT00713544|Drug|AZD5672|100 mg oral, once daily
457531|NCT00713544|Drug|AZD5672|150 mg oral, once daily
457532|NCT00713518|Drug|0.5 mg ranibizumab|
457533|NCT00713518|Drug|3 mg PF-04523655|
457534|NCT00713518|Drug|1 mg PF-04523655|
457535|NCT00713505|Other|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
457536|NCT00713505|Procedure|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
457537|NCT00713492|Drug|Alcohol|human laboratory alcohol consumption.
457538|NCT00713479|Drug|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
457539|NCT00713479|Drug|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
457540|NCT00713440|Other|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.~Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.~Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days"
457541|NCT00713427|Device|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
457542|NCT00713401|Drug|Tecadenoson|Tecadenoson administered intravenously (i.v.)
457543|NCT00713401|Drug|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
457544|NCT00713362|Procedure|Video-assisted thoracoscopic surgery|VATS for bullectomy and mechanical pleurodesis
457545|NCT00713362|Procedure|chest tube drainage|Chest tube drainage for pneumothroax
457546|NCT00713349|Drug|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
457547|NCT00713349|Other|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
457550|NCT00713336|Drug|ZD4054 Placebo|3 tablets
457551|NCT00713336|Drug|Moxifloxacin placebo|1 capsule
457552|NCT00713336|Drug|ZD4054 Placebo|2 tablets
457553|NCT00713336|Drug|ZD4054|30mg tablet
457554|NCT00713336|Drug|ZD4054|10mg tablet
457555|NCT00713323|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
457556|NCT00713310|Drug|Asacol 400 mg|"High dose:~17-<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
457557|NCT00713310|Drug|Asacol 400 mg|"Low dose:~17-<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
457558|NCT00713297|Behavioral|satisfaction questionnaire|Satisfaction questionnaire
457559|NCT00713284|Drug|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
457560|NCT00713271|Drug|AZD3199|"Low dose~Dry powder for inhalation, o.d., 1+12 days"
457561|NCT00713271|Drug|Placebo|
457562|NCT00713271|Drug|AZD3199|"intermediate dose~Dry powder for inhalation, o.d., 1+12 days"
457563|NCT00713271|Drug|AZD3199|"high dose~Dry powder for inhalation, o.d., 1+12 days"
457564|NCT00713258|Drug|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
457565|NCT00713258|Drug|Alendronate|70 mg alendronate weekly
457566|NCT00713219|Radiation|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
457567|NCT00713206|Device|Dental Implant (Osseotite)|Root form titanium dental implant
457568|NCT00713193|Drug|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
457569|NCT00713193|Drug|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
457570|NCT00713180|Procedure|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
457571|NCT00713167|Drug|Grape Seed Extract (Vitagrape)|"Drug {Each Containing: Grape Seed Extract100 mg +...}~1 capsule twice daily for 2 months"
457572|NCT00713167|Drug|Placebo of Grape Seed Extract|"Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}~1 capsule twice daily for 2 months"
457573|NCT00713154|Drug|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
457574|NCT00713154|Drug|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
457575|NCT00713115|Procedure|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
457576|NCT00713076|Other|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
457577|NCT00713063|Behavioral|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
457578|NCT00713063|Behavioral|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
457579|NCT00713050|Behavioral|Imitate Therapy|Imitation-based computer therapy
457580|NCT00713037|Procedure|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
457581|NCT00713011|Drug|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
457582|NCT00713011|Drug|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
457583|NCT00712985|Drug|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
457584|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
457585|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
457586|NCT00712933|Drug|belimumab|"Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
457587|NCT00712920|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
457588|NCT00712920|Drug|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
457589|NCT00712920|Drug|Placebo|Placebo
457590|NCT00712907|Dietary Supplement|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
457591|NCT00712907|Dietary Supplement|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
457642|NCT00712660|Other|no intervention|Treatment as usual
457717|NCT00712127|Other|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
457592|NCT00712907|Other|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.~Dosage reference: Strenn K 1997"
457593|NCT00712894|Drug|Diltiazem|Intracoronary Infusion 400-2000ug
457594|NCT00712894|Drug|Verapamil|Intracoronary Infusion 200-1000ug
457595|NCT00712894|Drug|Nitroglycerin|Intracoronary Infusion 200-1000ug
457596|NCT00712881|Drug|MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles|MYOCET® (60 mg/m2) and cyclophosphamide (600 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (6 mg/kg) once every 3 weeks for 4 cycles (MCH→TH).
457597|NCT00712881|Drug|Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles|Free doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) once every 3 weeks for 4 cycles (AC→TH).
457598|NCT00712868|Drug|Lactic acid|Once a day
457599|NCT00712855|Biological|mapatumumab|3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
457600|NCT00712855|Drug|sorafenib|400 mg orally, twice a day continuously in each cycle
457601|NCT00712842|Other|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
457602|NCT00712829|Drug|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
457603|NCT00712829|Drug|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
457604|NCT00712816|Device|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
457605|NCT00712816|Other|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
457606|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^3 dose of rDEN3-3'D4delta30 vaccine.
457607|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^5 dose of rDEN3-3'D4delta30 vaccine.
457608|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^1 dose of rDEN3-3'D4delta30 vaccine.
457609|NCT00712790|Drug|Sorafenib|Tablet, 400mg orally, twice daily
457610|NCT00712790|Radiation|SIR-Spheres|one time treatment and capped at 3.0 Gbq
457611|NCT00712777|Drug|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
457612|NCT00712764|Drug|Adenosine|
457613|NCT00712764|Drug|Placebo|
457614|NCT00712751|Behavioral|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
457615|NCT00712751|Behavioral|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
457616|NCT00712738|Drug|Nifedipine|
457617|NCT00712738|Procedure|Phlebotomy|
457618|NCT00712738|Procedure|Urinalysis|
457619|NCT00712738|Procedure|Echocardiogram|
457620|NCT00712738|Procedure|Electrocardiogram|
457621|NCT00712725|Drug|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
457622|NCT00712725|Drug|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
457623|NCT00712725|Drug|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
457624|NCT00712725|Drug|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
457625|NCT00712725|Drug|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
457626|NCT00712725|Drug|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
457627|NCT00712725|Drug|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
457628|NCT00712712|Drug|acetaminophen|
457629|NCT00712712|Drug|morphine sulfate|
457630|NCT00712712|Other|questionnaire administration|
457631|NCT00712712|Procedure|quality-of-life assessment|
457632|NCT00712712|Procedure|radiofrequency ablation|
457633|NCT00712699|Drug|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
457634|NCT00712699|Drug|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
457635|NCT00712686|Drug|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
457636|NCT00712686|Drug|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
457637|NCT00712673|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
457638|NCT00712673|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
457639|NCT00712673|Device|Pen auto-injector|
457640|NCT00712673|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
457641|NCT00712660|Drug|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
457643|NCT00712647|Drug|Beta Carotene and Retinol|"Pilot participants (ppts):~Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol~Vanguard & Efficacy ppts:~Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol"
457644|NCT00712647|Other|Placebo|Two placebos, one each/day
457645|NCT00712634|Biological|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
457646|NCT00712621|Behavioral|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
457647|NCT00712621|Behavioral|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
457648|NCT00712608|Other|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
457649|NCT00712608|Other|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
457650|NCT00712608|Other|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
457651|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
457652|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
457653|NCT00712582|Drug|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
457654|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
457655|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.~Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
457656|NCT00712569|Behavioral|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
457657|NCT00712569|Behavioral|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
457658|NCT00712569|Behavioral|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
457659|NCT00712556|Radiation|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
457660|NCT00712543|Drug|lactulose (Kristalose®)|Crystals to be dissolved in water and taken as prescribed.
457661|NCT00712543|Drug|liquid lactulose|Liquid to be taken as prescribed.
457662|NCT00712530|Biological|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
457663|NCT00712530|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
457664|NCT00712517|Drug|propofol|propofol anesthesia 3-5mg/kg
457665|NCT00712517|Drug|sevoflurane|sevoflurane anesthesia
457666|NCT00712504|Drug|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
457667|NCT00712504|Drug|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
457668|NCT00712491|Drug|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
457669|NCT00712491|Drug|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
457670|NCT00712478|Drug|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
457671|NCT00712465|Drug|AZD1305|Extended Release tablet, repeated administration
457672|NCT00712465|Drug|Digoxin|Tablet, repeated administration
457673|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
457674|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
458215|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
457675|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
457676|NCT00712439|Drug|Gabapentin Extended Release tablets|
457677|NCT00712439|Drug|Placebo|
457678|NCT00712426|Drug|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
457679|NCT00712426|Drug|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
457680|NCT00712413|Drug|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
457681|NCT00712400|Drug|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
457682|NCT00712400|Drug|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
457683|NCT00712387|Behavioral|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
457684|NCT00712374|Drug|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season~Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
457685|NCT00712361|Device|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
457686|NCT00712348|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
457687|NCT00712335|Drug|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
457688|NCT00712335|Drug|Montelukast|PO 10 mg QHS for 3 weeks
457689|NCT00712335|Drug|Salmeterol|DPI 50mg BID for 3 weeks
457690|NCT00712322|Drug|Darifenacin|(0.030 mg/kg/day)
457691|NCT00712322|Drug|Darifenacin|(0.0625 mg/kg/day)
457692|NCT00712322|Drug|Darifenacin|(0.125 mg/kg/day)
457693|NCT00712322|Drug|Darifenacin|(0.250 mg/kg/day)
457694|NCT00712309|Device|Lifestent|Stent for endovascular treatment of popliteal artery lesions
457695|NCT00712309|Device|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
457696|NCT00712296|Drug|ASHMI|6 capsules orally twice a day
457697|NCT00712296|Drug|ASHMI|2 capsules orally twice a day
457698|NCT00712296|Drug|Placebo|Placebo 6 capsules twice a day
457699|NCT00712283|Drug|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
457700|NCT00712270|Drug|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
457701|NCT00712270|Drug|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
457702|NCT00712257|Device|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
457703|NCT00712244|Device|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
457704|NCT00712244|Device|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
457705|NCT00712244|Device|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
457706|NCT00712244|Device|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
457707|NCT00712218|Procedure|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
457708|NCT00712218|Procedure|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions [24, ].
457709|NCT00712205|Drug|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
457710|NCT00712205|Drug|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
457711|NCT00712192|Procedure|coronary artery bypass grafting|patient with coroary artery diseases underwent coronary artery bypass grafting surgery
457712|NCT00712166|Drug|AZLI 75 mg three times daily (TID)|
457713|NCT00712166|Drug|Placebo three times daily (TID)|
457714|NCT00712140|Biological|trastuzumab|Given IV
457715|NCT00712140|Drug|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
457716|NCT00712127|Other|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
457718|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
457719|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
457720|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
457721|NCT00712101|Drug|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
457722|NCT00712101|Drug|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
457723|NCT00712088|Behavioral|Project ICARE|Group-level intervention (Project ICARE)
457724|NCT00712088|Behavioral|HCT|Offer of HIV counseling and testing
457725|NCT00712075|Behavioral|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
457726|NCT00712075|Behavioral|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
457727|NCT00712075|Behavioral|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
457728|NCT00712062|Drug|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
457729|NCT00712049|Drug|simvastatin|simvastatin 40 mg
457730|NCT00712049|Drug|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
457731|NCT00712036|Behavioral|Interim|Methadone maintenance with emergency counseling only for up to 4 months
457732|NCT00712036|Behavioral|Comprehensive|Methadone treatment with counseling as usual
457733|NCT00712036|Behavioral|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
457734|NCT00712023|Device|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress~1=circulating-water mattress"
457735|NCT00712010|Other|Whey protein native|Whey protein native against the 6 other arms
457736|NCT00712010|Other|Whey protein microgels|Whey protein microgels versus the six other arms
457737|NCT00712010|Other|Hydrolyzed whey protein|versus the six other arms
457738|NCT00712010|Other|Casein native|versus the six other arms
457739|NCT00712010|Other|Hydrolyzed casein|versus the six other arms
457740|NCT00712010|Other|Total milk protein native|versus the six other arms
457741|NCT00712010|Other|Hydrolyzed milk protein|versus the six other arms
457742|NCT00711997|Biological|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
457743|NCT00711984|Device|Herkulink renal artery Stent|renal artery stent
457744|NCT00711984|Other|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
457745|NCT00711971|Drug|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
457746|NCT00711971|Drug|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
457747|NCT00711971|Drug|placebo|control arm
457748|NCT00711958|Drug|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
457749|NCT00711958|Drug|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
457750|NCT00711919|Drug|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin~Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
457751|NCT00711919|Drug|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
457752|NCT00711906|Drug|Cotrimoxazole|Cotrimoxazole
457753|NCT00711906|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
457754|NCT00711893|Device|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
457755|NCT00711880|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
457756|NCT00711880|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
457757|NCT00711867|Device|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
457758|NCT00711867|Device|Bair Hugger|Arizant Bair Hugger temperature management system.
457759|NCT00711854|Drug|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
457760|NCT00711854|Drug|Linezolid|Linezolid (600 mg IV or PO twice daily)
457761|NCT00711854|Drug|Rifampicin|Rifampicin (600 mg IV or PO once daily)
457762|NCT00711841|Drug|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
457763|NCT00711841|Drug|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
457764|NCT00711841|Drug|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
457765|NCT00711828|Drug|Bortezomib|Given IV
457766|NCT00711828|Biological|Rituximab|Given IV
457767|NCT00711828|Drug|Cyclophosphamide|Given PO
457768|NCT00711828|Drug|Dexamethasone|Given PO
457769|NCT00711828|Other|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
457976|NCT00710099|Drug|nitroprussiate iontophoresis|nitroprussiate iontophoresis
457770|NCT00711828|Other|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
457771|NCT00711802|Drug|Daptomycin|
457772|NCT00711802|Drug|Standard of Care (SOC)|
457773|NCT00711789|Drug|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
457774|NCT00711789|Drug|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
457775|NCT00711776|Drug|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
457776|NCT00711776|Drug|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
457777|NCT00711711|Other|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
457778|NCT00711711|Other|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
457779|NCT00711698|Procedure|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
457780|NCT00711698|Drug|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
457781|NCT00711685|Procedure|coronary artery bypass grafting via midline sternotomy|
457782|NCT00711646|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
457783|NCT00711646|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
457784|NCT00711633|Dietary Supplement|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
457785|NCT00711633|Dietary Supplement|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
457786|NCT00711620|Drug|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
457787|NCT00711607|Drug|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
457788|NCT00711594|Drug|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
457789|NCT00711594|Drug|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
457790|NCT00711594|Drug|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
457791|NCT00711594|Drug|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
457792|NCT00711581|Device|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
457793|NCT00711568|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
457794|NCT00711568|Procedure|Sham rTMS|20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
457795|NCT00711568|Device|Repetitive Transcranial Magnetic Stimulator|Repetitive Transcranial Magnetic Stimulator
457796|NCT00711555|Drug|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.~FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.~FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
457797|NCT00711542|Biological|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
457798|NCT00711542|Biological|placebo medium|intracoronary infusion of placebo medium
457799|NCT00711529|Behavioral|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
457800|NCT00711529|Drug|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
457801|NCT00711516|Drug|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
457802|NCT00711516|Drug|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
457803|NCT00711503|Drug|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
457804|NCT00711503|Drug|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
457805|NCT00711490|Drug|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
457806|NCT00711477|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
457807|NCT00711477|Drug|Placebo|
457808|NCT00711477|Other|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
457809|NCT00711464|Drug|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
457810|NCT00711451|Behavioral|Manual removal|Manual removal of placenta during cesarean delivery
457811|NCT00711451|Procedure|Expressed removal|Surgeon will perform an expressed delivery of the placenta
457812|NCT00711438|Behavioral|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
457813|NCT00711438|Behavioral|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
457814|NCT00711425|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
457815|NCT00711412|Drug|Induction Therapy - Capecitabine|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
457816|NCT00711412|Drug|Induction Therapy - Oxaliplatin|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
457817|NCT00711412|Drug|Combination Therapy - Capecitabine|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
457818|NCT00711412|Drug|Combination Therapy - Oxaliplatin|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
457819|NCT00711412|Radiation|Combination Therapy - Radiation|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
457820|NCT00711412|Procedure|Evaluation for response and surgery|Four to eight weeks following the completion of therapy subjects will undergo evaluation for response and surgical resection.
457821|NCT00711399|Device|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
457822|NCT00711386|Drug|GSK706769|50mg, 100mg, 200mg, or 400mg
457823|NCT00711386|Other|Placebo|Placebo
457824|NCT00711373|Procedure|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
457825|NCT00711360|Device|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
457826|NCT00711347|Device|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
457827|NCT00711347|Device|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
457828|NCT00711308|Drug|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
457829|NCT00711308|Drug|acenocoumarol|acenocoumarol for 6 months
457830|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
457831|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
457832|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
457833|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
457834|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
457835|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
457836|NCT00711269|Drug|Placebo|
457837|NCT00711269|Drug|Risperidone|
457838|NCT00711256|Other|sunscreen MATAS sunlotion SPF 8|
457839|NCT00711256|Radiation|UVB light|duration 4 times 1 minute radiation on the trunk.
457840|NCT00711243|Drug|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
457841|NCT00711243|Drug|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
457842|NCT00711243|Drug|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
457843|NCT00711230|Biological|DermaVir|
457844|NCT00711230|Biological|Placebo|glucose/dextrose
457845|NCT00711217|Other|Medical Food|twice daily
457846|NCT00711217|Other|Drink mix calorically similar to experimental product|twice daily
457847|NCT00711204|Drug|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
457848|NCT00711191|Biological|monoclonal antibody|CP-870,893 intravenous administration [IV] on day 3 of 4-week cycles
457849|NCT00711191|Drug|chemotherapy|gemcitabine 1000 mg/m^2 intravenous administration [IV] q week [wk]x3 of 4-week cycles
457850|NCT00711178|Procedure|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
457851|NCT00711165|Drug|Placebo|2 puffs, qd
457852|NCT00711165|Drug|Mometasone Furoate|400 mcg, qd for 8 weeks
458216|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
457853|NCT00711152|Other|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
457854|NCT00711152|Other|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
457855|NCT00711126|Drug|GW642444|2.5mcg IV
457856|NCT00711126|Drug|GW642444|5mcg IV
457857|NCT00711126|Drug|GW642444|10mcg IV
457858|NCT00711126|Drug|GW642444|100mcg inhaled
457859|NCT00711126|Drug|GW642444|20mcg IV
457860|NCT00711126|Drug|GW642444|500mcg oral
457861|NCT00711113|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
457862|NCT00711100|Other|Camel Snus|All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
457863|NCT00711100|Other|Marlboro Snus|All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
457864|NCT00711100|Other|Stonewall|All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
457865|NCT00711100|Other|Ariva|All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
457866|NCT00711100|Other|General Snus|All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
457867|NCT00711087|Drug|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
457868|NCT00711087|Other|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
457869|NCT00711074|Drug|AZD5672|single dose 200mg aqueous solution
457870|NCT00711048|Drug|AZD1386|oral, single dose
457871|NCT00711048|Drug|Placebo|Oral solution, single dose
457872|NCT00711035|Biological|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
457873|NCT00711022|Device|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
457874|NCT00711009|Drug|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
457875|NCT00711009|Drug|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
457876|NCT00711009|Drug|raltegravir (RAL)|RAL 400 mg BID
457877|NCT00710983|Biological|Oral polio vaccine|
457878|NCT00710970|Drug|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
457879|NCT00710944|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
457880|NCT00710931|Device|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
457881|NCT00710905|Device|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
457882|NCT00710892|Biological|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.~Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
457883|NCT00710879|Device|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
457884|NCT00710866|Biological|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
457885|NCT00710853|Other|YiRen Qi gong|One hour weekly class for 8 week duration
457886|NCT00710853|Other|Tai Chi|One hour weekly class for 8 week duration
457887|NCT00710853|Other|Hatha yoga|One hour weekly class for 8 week duration
457888|NCT00710840|Procedure|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
457889|NCT00710840|Procedure|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
457890|NCT00710827|Drug|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
457891|NCT00710827|Drug|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
457892|NCT00710814|Drug|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
457893|NCT00710814|Other|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
457894|NCT00710788|Drug|sevelamer phosphate-binders|1600 mg/day for 2 years
457895|NCT00710788|Drug|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
457896|NCT00710775|Procedure|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
457897|NCT00710762|Drug|BIBF1120|
457898|NCT00710762|Drug|Placebo|
457899|NCT00710749|Device|Disposable device|Disposable urine flow meter
457900|NCT00710749|Device|Digital device|Digital urine flowmeter
457901|NCT00710749|Device|Clinic flow measurement|Clinic gold standard flow measurement
457902|NCT00710736|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
457903|NCT00710736|Drug|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
457904|NCT00710723|Procedure|vitrification|Vitrification using Hemi-straw carrier system.
457905|NCT00710710|Drug|BI 2536|
457906|NCT00710697|Drug|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
457907|NCT00710684|Drug|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
457908|NCT00710684|Drug|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
457909|NCT00710684|Drug|Placebo|Placebo added to existing donepezil
457910|NCT00710684|Drug|donepezil 5-10mg|existing donepezil treatment
457911|NCT00710658|Behavioral|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.~Patients in the control group received usual care"
457912|NCT00710645|Device|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
457913|NCT00710632|Other|laboratory biomarker analysis|
457914|NCT00710632|Other|physiologic testing|
457915|NCT00710632|Other|questionnaire administration|
457916|NCT00710632|Procedure|management of therapy complications|
457917|NCT00710619|Drug|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
457918|NCT00710619|Drug|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
457919|NCT00710606|Drug|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
457920|NCT00710606|Drug|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
457921|NCT00710593|Biological|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
457922|NCT00710580|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
457923|NCT00710580|Biological|etanercept|SQ injection 50 mg BIW
457924|NCT00710580|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
457925|NCT00710567|Device|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanted in using open heart surgery
457926|NCT00710554|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
457927|NCT00710554|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
457928|NCT00710541|Device|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
457929|NCT00710528|Drug|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
457930|NCT00710515|Drug|AZD6244|75mg
457931|NCT00710502|Procedure|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
457932|NCT00710502|Procedure|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
457933|NCT00710476|Procedure|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
457934|NCT00710463|Device|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
457935|NCT00710437|Drug|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
457936|NCT00710424|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
458024|NCT00709735|Drug|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
457937|NCT00710424|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
457938|NCT00710398|Behavioral|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
457939|NCT00710398|Behavioral|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.~Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
457940|NCT00710385|Drug|Heroin|Heroin (25 mg)
457941|NCT00710385|Drug|Naloxone|.4 mg
457942|NCT00710385|Drug|Low Bup Dose|4 and 8 mg
457943|NCT00710385|Drug|High Bup Dose|8mg and 16 mg
457944|NCT00710385|Drug|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
457945|NCT00710385|Drug|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
457946|NCT00710385|Drug|Placebo (PCB)|Placebo control administration
457947|NCT00710372|Biological|CYT006-AngQb|s.c. injection
457948|NCT00710359|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
457949|NCT00710333|Drug|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
457950|NCT00710333|Drug|placebo|placebo
457951|NCT00710320|Procedure|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:~the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
457952|NCT00710307|Procedure|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
457953|NCT00710307|Genetic|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
457954|NCT00710294|Device|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.~Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
457955|NCT00710281|Radiation|Additional scan time on standard MR angiography|"Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography~Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements~Arms:"
457956|NCT00710268|Drug|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
457957|NCT00710268|Drug|Bevacizumab|IV administration10 mg/kg every 14 days
457958|NCT00710255|Procedure|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
457959|NCT00710242|Drug|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
457960|NCT00710242|Drug|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
457961|NCT00710229|Drug|Ranibizumab|intravitreal injection
457962|NCT00710229|Drug|Bevacizumab|intravitreal injection
457963|NCT00710216|Drug|Lamivudine|100 mg/day
457964|NCT00710216|Drug|Telbivudine|600 mg/day
457965|NCT00710203|Device|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
457966|NCT00710203|Procedure|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
457967|NCT00710203|Procedure|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
457968|NCT00710203|Other|No treatment|A fourth lesion will not be treated and will serve as a control.
457969|NCT00710190|Device|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
457970|NCT00710164|Drug|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
457971|NCT00710164|Drug|Placebo|14 days of Placebo
457972|NCT00710138|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
457973|NCT00710125|Drug|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
457974|NCT00710112|Genetic|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
457975|NCT00710099|Drug|sildenafil|systemic absorption of sildenafil
457977|NCT00710086|Drug|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
457978|NCT00710086|Drug|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
457979|NCT00710073|Device|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
457980|NCT00710060|Behavioral|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
457981|NCT00710060|Behavioral|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
457982|NCT00710047|Drug|ZD4054|one single 10mg dose
457983|NCT00710034|Other|Oral tobacco|Snus
457984|NCT00710034|Drug|Nicotine Gum|4 mg Nicotine gum
457985|NCT00710021|Drug|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
457986|NCT00710021|Drug|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
457987|NCT00710008|Other|exercise training|3 bouts of exercise at 90%RCP during one week
457988|NCT00709995|Drug|Enzastaurin|Administered orally
457989|NCT00709995|Drug|Sunitinib|Administered orally
457990|NCT00709995|Drug|Placebo|Administered orally
457991|NCT00709982|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
457992|NCT00709969|Drug|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - < 10kg (BWG 1) = 6 doses of 1 tablet / 10 - < 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
457993|NCT00709956|Drug|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
457994|NCT00709956|Drug|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
457995|NCT00709930|Device|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
457996|NCT00709930|Device|Placebo magnetic field generator|Placebo device with no magnetic fields
457997|NCT00709917|Drug|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
457998|NCT00709904|Drug|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
457999|NCT00709904|Drug|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection once daily"
458000|NCT00709904|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection once daily"
458001|NCT00709891|Device|cobas® 4800 HPV Test|
458002|NCT00709878|Procedure|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
458003|NCT00709865|Drug|tonapofylline|IV
458004|NCT00709865|Drug|Placebo|IV
458005|NCT00709852|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
458006|NCT00709852|Drug|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
458007|NCT00709839|Drug|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
458008|NCT00709839|Drug|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
458009|NCT00709826|Drug|gemcitabine|Gemcitabine: per package insert.
458010|NCT00709826|Drug|placebo|placebo: 100 mg tablets, 400 mg/day
458011|NCT00709826|Drug|Erlotinib|Erlotinib - per package insert.
458012|NCT00709826|Drug|apricoxib|apricoxib: 100mg tablets, given orally
458013|NCT00709813|Behavioral|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
458014|NCT00709800|Biological|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
458015|NCT00709800|Biological|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
458016|NCT00709800|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
458017|NCT00709800|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
458018|NCT00709800|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
458019|NCT00709787|Other|Usual Care|Normal care for hypertensive patients with risk factors for CHD
458020|NCT00709774|Device|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
458021|NCT00709761|Drug|Lapatinib/nab-Paclitaxel|This was an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Subjects were to receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
458022|NCT00709748|Device|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
458023|NCT00709748|Device|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
458025|NCT00709735|Drug|Placebo|Placebo (matching propranolol) short-acting and long-acting capsules
458026|NCT00709722|Drug|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
458027|NCT00709709|Procedure|multislice coronary scan|multislice coronary scan
458028|NCT00709696|Drug|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
458029|NCT00709696|Drug|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
458030|NCT00709683|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
458031|NCT00709670|Procedure|MSCT and stress echocardiography|tests MSCT and stress echocardiography
458032|NCT00709657|Drug|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
458033|NCT00709644|Drug|Norgestimate; Ethinyl Estradiol; Folic acid.|
458034|NCT00709618|Drug|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
458035|NCT00709605|Drug|VRC-HIVADV014-00-VP|
458036|NCT00709592|Biological|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
458037|NCT00709592|Radiation|Total-Body Irradiation|Undergo TBI
458038|NCT00709592|Procedure|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
458039|NCT00709592|Drug|Tacrolimus|Given PO
458040|NCT00709592|Drug|Mycophenolate Mofetil|Given PO
458041|NCT00709579|Drug|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
458042|NCT00709579|Drug|Placebo|placebo
458043|NCT00709566|Behavioral|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
458044|NCT00709566|Behavioral|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
458045|NCT00709553|Drug|midazolam|
458046|NCT00709553|Drug|ZD4054|ZD4054 10 mg od
458047|NCT00709540|Biological|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
458048|NCT00709527|Drug|ARC1905|intravitreal injection
458049|NCT00709514|Drug|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
458050|NCT00709514|Drug|Placebo|Placebo
458051|NCT00709501|Behavioral|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
458052|NCT00709501|Behavioral|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
458053|NCT00709488|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
458054|NCT00709488|Procedure|Placement of device in prostate urethra|Placement of device in prostate urethra
458055|NCT00709488|Device|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
458056|NCT00709475|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
458057|NCT00709462|Biological|CDX1307|
458058|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
458059|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
458060|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
458061|NCT00709436|Drug|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
458062|NCT00709436|Drug|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
458063|NCT00709423|Drug|Moxaverine|
458064|NCT00709423|Drug|Moxaverin 150mg|intravenous administration
458065|NCT00709423|Drug|NaCl|intravenous administration
458066|NCT00709410|Biological|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
458067|NCT00709397|Other|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
458068|NCT00709384|Procedure|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
458069|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
458070|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
458071|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
458072|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
458073|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
458074|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
458075|NCT00709358|Other|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.~Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
458076|NCT00709358|Other|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
458077|NCT00709345|Behavioral|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
458078|NCT00709345|Behavioral|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
458079|NCT00709332|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
458080|NCT00709306|Device|UV-Detect Photos|UV-Detect Photos
458081|NCT00709306|Behavioral|Motivational Interviewing|Motivational Interviewing
458082|NCT00709306|Behavioral|Education|Education
458083|NCT00709293|Drug|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
458084|NCT00709293|Drug|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
458085|NCT00709280|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
458086|NCT00709280|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
458087|NCT00709267|Drug|Folic acid|
458088|NCT00709254|Drug|i.v. fentanyl|single dose, 200 ug
458089|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
458090|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
458091|NCT00709228|Drug|PegIntron|1.5 ug/kg/week
458092|NCT00709228|Drug|Rebetol|800-1200 mg/day
458093|NCT00709215|Drug|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
458094|NCT00709202|Drug|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID (BID = 2 times a day)..
458095|NCT00709202|Drug|Placebo Oral Tablet|
458096|NCT00709189|Drug|Norgestimate/Ehinyl Estradiol; Folic acid.|
458097|NCT00709176|Behavioral|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
458098|NCT00709176|Behavioral|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
458099|NCT00709163|Drug|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
458100|NCT00709163|Drug|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
458101|NCT00709150|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
458102|NCT00709150|Behavioral|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
458103|NCT00709137|Drug|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
458104|NCT00709137|Drug|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
458217|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
458105|NCT00709124|Device|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
458106|NCT00709124|Device|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
458107|NCT00709111|Drug|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
458108|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
458109|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
458110|NCT00709072|Behavioral|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
458111|NCT00709059|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
458112|NCT00709059|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg: 800 mg; 65 - 85 kg: 1000 mg; >85 kg: 1200 mg) orally for 48 weeks
458113|NCT00709046|Drug|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
458114|NCT00709046|Drug|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
458115|NCT00709033|Biological|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
458116|NCT00709020|Drug|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
458117|NCT00709020|Other|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
458118|NCT00709020|Other|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
458119|NCT00709020|Other|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
458120|NCT00709020|Other|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
458121|NCT00709020|Other|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
458122|NCT00709020|Other|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
458123|NCT00709007|Behavioral|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
458124|NCT00709007|Behavioral|SAT|Participants take their HIV medications by themselves.
458125|NCT00708994|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.~Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.~Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
458126|NCT00708994|Drug|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
458127|NCT00708981|Other|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:~Elements of multifactorial intervention:~BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.~Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.~Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.~Patient enhanced self-management provided by combined diabetes-renal education curriculum.~Behavior and social intervention~Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
458128|NCT00708968|Behavioral|FOCUS Program|Supportive, educative sessions with patients and spouses.
458129|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
458130|NCT00708942|Drug|Placebo|Placebo suppository, for 3-7 hours application
458131|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
458132|NCT00708942|Drug|Placebo|Placebo ointment for 5 hours application
458133|NCT00708929|Procedure|Squatting|Squatting for 6 minutes
458134|NCT00708916|Drug|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
458135|NCT00708903|Drug|neratinib|HKI-272
458136|NCT00708903|Other|Placebo|Placebo
458137|NCT00708903|Drug|Moxifloxacin|
458177|NCT00708526|Device|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
458178|NCT00708500|Drug|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
458138|NCT00708890|Behavioral|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
458139|NCT00708877|Procedure|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
458140|NCT00708851|Other|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day~NB-UVB Phototherapy: 3 light sessions / week"
458141|NCT00708851|Device|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
458142|NCT00708812|Drug|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
458143|NCT00708812|Drug|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
458144|NCT00708799|Other|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
458145|NCT00708786|Device|ICD|Ventricular arrhythmia treatment
458146|NCT00708786|Device|CRT-D|Ventricular arrhythmia treatment
458147|NCT00708773|Drug|Irinotecan|"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."
458148|NCT00708760|Behavioral|paper based training|read selected material, test skills learned in simulator lab
458149|NCT00708760|Behavioral|web based training|read and view selected web based material, test skills learned in simulator lab
458150|NCT00708747|Drug|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
458151|NCT00708747|Drug|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
458152|NCT00708734|Behavioral|functional exercise training|twice weekly group sessions for 5 weeks
458153|NCT00708721|Drug|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
458154|NCT00708708|Drug|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
458155|NCT00708695|Behavioral|Nurse Home Visiting|Visits from nurses from mid-pregnancy to child age 2 years.
458156|NCT00708682|Biological|13-valent pneumococcal conjugate vaccine|
458157|NCT00708669|Device|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
458158|NCT00708669|Device|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
458159|NCT00708656|Drug|mesalazine (Asacol®)|800 mg tablets
458160|NCT00708643|Device|Habitual Silicone Hydrogel Contact Lens|contact lens
458161|NCT00708643|Device|narafilcon A|contact lens
458162|NCT00708630|Behavioral|Extended information on side effects|More detailed information on possible side effects of vaccine
458163|NCT00708604|Procedure|Islet Transplantation|Islet Transplantation
458164|NCT00708604|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
458165|NCT00708591|Drug|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
458166|NCT00708591|Drug|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
458167|NCT00708578|Drug|Glimepiride|Once a day before breakfast
458168|NCT00708578|Drug|Metformin|After breakfast and supper
458169|NCT00708578|Drug|Insulin Glargine|Injection in the morning
458170|NCT00708565|Drug|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
458171|NCT00708552|Drug|SB-742457|investigational drug
458172|NCT00708552|Drug|Donepezil|comparator
458173|NCT00708552|Drug|Placebo|comparator
458174|NCT00708539|Drug|progesterone|90 mg, vaginal, once daily
458175|NCT00708539|Drug|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
458176|NCT00708526|Other|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
458179|NCT00708500|Biological|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
458180|NCT00708500|Drug|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
458181|NCT00708500|Drug|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
458182|NCT00708487|Other|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
458183|NCT00708474|Device|OsseoFit™ Porous Tissue Matrix™|Bone void filler
458184|NCT00708461|Behavioral|weight gain prevention|"Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.~Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.~Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.~Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices."
458185|NCT00708448|Radiation|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
458186|NCT00708448|Drug|Erlotinib|150 mg/day
458187|NCT00708448|Drug|Bevacizumab|15mg/kg q 21 days
458188|NCT00708435|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
458189|NCT00708435|Biological|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
458190|NCT00708422|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
458191|NCT00708422|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
458192|NCT00708409|Procedure|Cardiac valve surgery|Different autograft implantation techniques.
458193|NCT00708396|Drug|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
458194|NCT00708383|Other|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
458195|NCT00708383|Other|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
458196|NCT00708370|Other|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
458197|NCT00708370|Other|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
458198|NCT00708357|Drug|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
458199|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
458200|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
458201|NCT00708331|Device|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
458202|NCT00708318|Drug|i.v. fentanyl and AeroLEF|"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).~Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."
458203|NCT00708305|Drug|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
458204|NCT00708305|Drug|Placebo|Fluoride free toothpaste (0ppmF)
458205|NCT00708292|Drug|AUY922|
458206|NCT00708292|Drug|Bortezomib|
458207|NCT00708292|Drug|Dexamethasone|
458208|NCT00708279|Procedure|Osteopathic manipulation|Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
458209|NCT00708266|Device|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
458210|NCT00708266|Dietary Supplement|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
458211|NCT00708266|Other|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
458212|NCT00708253|Device|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
458213|NCT00708253|Device|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
458214|NCT00708240|Drug|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
458218|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
458219|NCT00708201|Drug|Alvimopan|
458220|NCT00708201|Drug|Placebo|
458221|NCT00708188|Device|Multidetector raw CT|Multidetector raw CT
458222|NCT00708175|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
458223|NCT00708175|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
458224|NCT00708162|Drug|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
458225|NCT00708162|Drug|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
458226|NCT00708162|Drug|EVG placebo|Placebo to match elvitegravir administered orally once daily
458227|NCT00708162|Drug|RAL placebo|RAL placebo administered orally twice daily.
458228|NCT00708162|Drug|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
458229|NCT00708149|Drug|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
458230|NCT00708149|Drug|placebo|takepron placebo
458231|NCT00708136|Behavioral|water based training program to improve balance|
458232|NCT00708123|Drug|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
458233|NCT00708123|Drug|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
458234|NCT00708110|Drug|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
458235|NCT00708110|Drug|Placebo|Placebo is a tablet with no drug in it.
458236|NCT00708097|Drug|NaF|Fluoride
458237|NCT00708097|Drug|Placebo|Placebo
458238|NCT00708097|Drug|NaMFP|Fluoride
458239|NCT00708084|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
458240|NCT00708084|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
458241|NCT00708071|Biological|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
458242|NCT00708045|Procedure|Imaging assessments|FDG-PET scans, functional MRI (fMRI) scans, Neuropsychological Testing
458243|NCT00708032|Device|spectacles|habitual spectacles
458244|NCT00708032|Device|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
458245|NCT00708019|Behavioral|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls [total time 12.3 hours]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls [8.0 hours]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
458246|NCT00708006|Drug|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
458247|NCT00707993|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
458248|NCT00707993|Drug|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
458249|NCT00707980|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
458250|NCT00707967|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
458251|NCT00707967|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
458252|NCT00707967|Biological|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
458253|NCT00707954|Drug|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
458254|NCT00707954|Drug|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
458255|NCT00707941|Drug|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows:~1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
458256|NCT00707941|Drug|Placebo|"Children < 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)~Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days~≥ 40 75 mg PO BID 6.25"
458257|NCT00707928|Drug|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
458258|NCT00707928|Other|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
458409|NCT00706797|Drug|etanercept (EnbrelTM)|
458410|NCT00706797|Drug|methotrexate|
458259|NCT00707915|Drug|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.~All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
458260|NCT00707902|Drug|chlorhexidine/lidocaine|
458261|NCT00707902|Drug|echinacea/sage|
458262|NCT00707889|Drug|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
458263|NCT00707889|Drug|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
458264|NCT00707889|Drug|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
458265|NCT00707889|Drug|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
458266|NCT00707889|Drug|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
458267|NCT00707889|Drug|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
458268|NCT00707876|Drug|ferumoxytol|Dose 1 versus non-contrast MRA
458269|NCT00707876|Drug|ferumoxytol|Dose 2 versus non-contrast MRA
458270|NCT00707876|Drug|ferumoxytol|Dose 3 versus non-contrast MRA
458271|NCT00707863|Drug|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
458272|NCT00707850|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
458273|NCT00707837|Other|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
458274|NCT00707837|Other|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
458275|NCT00707824|Drug|nalbuphine|nalbuphine 5 mg epidural
458276|NCT00707824|Drug|nalbuphine|nalbuphine 10 mg epidural
458277|NCT00707824|Other|NSS|NSS
458278|NCT00707798|Biological|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
458279|NCT00707798|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
458280|NCT00707785|Dietary Supplement|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
458281|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
458282|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
458283|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|"Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.~1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses~3°day: Prednisone 2 mg/kg/d in 2 doses~4ºday: Prednisone 1 mg/kg/d in 2 doses~5ºday: Prednisone 0.5 mg/kg/d in 2 doses~6ºday: Prednisone 0.25 mg/kg/d in 2 doses~7ºday: Stop Prednisone"
458284|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|"Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day~10°days after Tx: 2 mg/kg/d~Day 11 - 20: 1 mg/kg/d~Day 21 - 30: 0.5 mg/kg/d~Day 31 - 60: 0.3 mg/k/d~Week 8 - 12: 0.25 mg/k/d~Week 12 - 16: 0.20 mg/k/d~Week 16 - 20: 0.15 mg/k/d~Month 6 - 12: 0.10 - 0.12 mg/k/d"
458285|NCT00707746|Drug|mipomersen|
458286|NCT00707746|Drug|placebo|
458287|NCT00707720|Device|TERIS procedure|The implantation of the restrictive implant
458288|NCT00707707|Drug|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
458289|NCT00707707|Drug|Paclitaxel|Intravenous infusion over 1 hour
458290|NCT00707681|Drug|MS-20|4 ml/vial
458291|NCT00707681|Drug|Placebo|4ml/vial
458292|NCT00707655|Drug|Zalutumumab|Eight weekly infusions
458293|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)] given one month apart
458294|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)] given one month apart
458295|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)] given one month apart
458296|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg)] given one month apart
458297|NCT00707616|Other|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
458298|NCT00707590|Drug|BMS-767778 or Placebo|
458299|NCT00707577|Behavioral|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
458300|NCT00707564|Device|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
458301|NCT00707564|Device|Gauze with pressure|Gauze with pressure
458302|NCT00707551|Drug|Ketoconazole|Tablet, administered as repeated doses.
458303|NCT00707551|Drug|Verapamil|Extended Release tablet, administered as repeated doses.
458304|NCT00707551|Drug|AZD1305|Extended Release tablet, administered as a single dose.
458305|NCT00707538|Drug|BMS747158|2 IV injection of ~11 mCi (total) F-18 labeled compound
458306|NCT00707525|Procedure|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
458307|NCT00707512|Drug|natalizumab|Administered as specified in the TOUCH Prescribing Program
458308|NCT00707499|Drug|BMS747158|Single dose administration.
458309|NCT00707486|Device|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
458310|NCT00707486|Device|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
458311|NCT00707473|Drug|Carboplatin|Given IV
458312|NCT00707473|Other|Chemoradiotherapy|Undergo chemoradiotherapy
458313|NCT00707473|Drug|Cisplatin|Given IV
458314|NCT00707473|Procedure|Definitive Surgical Resection|Undergo surgery
458315|NCT00707473|Drug|Docetaxel|Given IV
458316|NCT00707473|Drug|Fluorouracil|Given IV
458317|NCT00707473|Procedure|Quality-of-Life Assessment|Correlative studies
458318|NCT00707473|Radiation|Radiation Therapy|Undergo radiation therapy
458319|NCT00707460|Behavioral|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.~All groups are exposed to nutrition education on serving size and portion size."
458320|NCT00707447|Behavioral|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
458321|NCT00707447|Behavioral|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
458322|NCT00707434|Device|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
458323|NCT00707421|Drug|ketorolac acetate|
458324|NCT00707421|Drug|fluorometholone|
458325|NCT00707421|Drug|artificial lacrimal tears|
458326|NCT00707408|Drug|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
458327|NCT00707382|Genetic|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
458328|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
458329|NCT00707382|Other|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
458330|NCT00707369|Drug|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
458331|NCT00707369|Drug|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
458332|NCT00707356|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
458333|NCT00707343|Radiation|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-[F-18]fluorothymidine, [F-18]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
458334|NCT00707330|Drug|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
458335|NCT00707304|Drug|Talactoferrin|Oral, 1.5 grams twice per day
458336|NCT00707304|Drug|Placebo|Oral, twice per day
458337|NCT00707278|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
458338|NCT00707278|Drug|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
458339|NCT00707278|Drug|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
458340|NCT00707265|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|"The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.~The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used."
458411|NCT00706784|Drug|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
458412|NCT00706771|Drug|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
458341|NCT00707265|Device|Autograft/CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
458342|NCT00707252|Drug|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
458343|NCT00707252|Drug|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
458344|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
458345|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
458346|NCT00707239|Drug|imipenem/cilastatin|Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
458347|NCT00707213|Procedure|Imaging study (FDG-PET/CT scan)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar ([18F]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
458348|NCT00707187|Drug|Cialis|35 pills of study medication (20 mg)
458349|NCT00707174|Drug|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
458350|NCT00707174|Drug|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
458351|NCT00707161|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
458352|NCT00707161|Drug|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
458353|NCT00707161|Procedure|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
458354|NCT00707148|Drug|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
458355|NCT00707148|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
458356|NCT00707135|Drug|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
458357|NCT00707122|Other|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
458358|NCT00707122|Other|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
458359|NCT00707083|Drug|dexamethasone|Given oral
458360|NCT00707083|Drug|mercaptopurine|Given orally
458361|NCT00707083|Drug|methotrexate|Given orally
458362|NCT00707083|Drug|vincristine sulfate|Given IV
458363|NCT00707070|Drug|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
458364|NCT00707070|Drug|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
458365|NCT00707057|Drug|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
458413|NCT00706771|Drug|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
458366|NCT00707057|Drug|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
458367|NCT00707044|Procedure|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
458368|NCT00707044|Procedure|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
458369|NCT00707031|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
458370|NCT00707031|Device|Pen auto-injector|
458371|NCT00707031|Drug|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
458372|NCT00707031|Device|Prefilled pen injector|
458373|NCT00707031|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
458374|NCT00707018|Device|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
458375|NCT00707018|Device|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
458376|NCT00706992|Biological|ALVAC-MART-1 vaccine|Given subcutaneously
458377|NCT00706992|Biological|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
458378|NCT00706992|Biological|Aldesleukin|Given subcutaneously
458379|NCT00706992|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
458380|NCT00706992|Biological|incomplete Freund's adjuvant|Given subcutaneously
458381|NCT00706979|Other|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
458382|NCT00706979|Behavioral|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
458383|NCT00706966|Drug|dutasteride|6 months of dutasteride 3.5 mg daily
458384|NCT00706953|Drug|bortezomib; pegylated liposomal doxorubicin|1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
458385|NCT00706927|Drug|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
458386|NCT00706927|Drug|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
458387|NCT00706914|Drug|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
458388|NCT00706914|Drug|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
458389|NCT00706914|Drug|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
458390|NCT00706914|Drug|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
458391|NCT00706901|Behavioral|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller & Rollnick 2013) and based on a manualized protocol (Martino & Santa Ana 2013; Santa Ana & Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
458392|NCT00706901|Behavioral|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
458393|NCT00706901|Behavioral|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
458394|NCT00706888|Dietary Supplement|Vitamins B6, B9 and B12 and polyphenols|
458395|NCT00706888|Dietary Supplement|placebo|
458396|NCT00706875|Behavioral|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~In person at the medical appointment~Over the telephone~Mailed with self-addressed return envelope and prepaid postage~E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
458397|NCT00706875|Behavioral|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~In person at the medical appointment~Over the telephone~Mailed with self-addressed return envelope and prepaid postage~E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
458398|NCT00706862|Drug|Talactoferrin|Oral, 1.5 grams twice per day
458399|NCT00706862|Drug|Placebo|Oral, twice per day
458400|NCT00706849|Drug|mipomersen sodium|200 mg /mL
458401|NCT00706849|Drug|placebo|1 mL matching placebo
458402|NCT00706836|Drug|Pregabalin 50mg|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
458403|NCT00706836|Drug|Pregabalin 200 MG|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
458404|NCT00706836|Drug|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
458405|NCT00706823|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
458406|NCT00706823|Device|Laryngeal Mask Airway-Unique|supra-glottic airway device
458407|NCT00706810|Drug|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
458408|NCT00706810|Drug|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
458414|NCT00706758|Behavioral|IBS school|Structured patient group education
458415|NCT00706758|Behavioral|IBS-guidebook|Written information - IBS-guidebook
458416|NCT00706745|Dietary Supplement|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
458417|NCT00706745|Dietary Supplement|placebo|identical placebo capsules.
458418|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
458419|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
458420|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
458421|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
458422|NCT00706719|Drug|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
458423|NCT00706719|Drug|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
458424|NCT00706706|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
458425|NCT00706693|Dietary Supplement|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
458426|NCT00706693|Dietary Supplement|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
458427|NCT00706693|Dietary Supplement|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
458428|NCT00706680|Drug|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
458429|NCT00706667|Drug|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
458430|NCT00706654|Drug|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
458431|NCT00706654|Drug|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
458432|NCT00706654|Drug|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
458433|NCT00706654|Drug|Placebo depot|Placebo depot was supplied in lyophilized vials.
458434|NCT00706654|Drug|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
458435|NCT00706641|Drug|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
458436|NCT00706641|Procedure|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
458437|NCT00706628|Drug|BIBF 1120|
458438|NCT00706628|Drug|BIBW 2992|
458439|NCT00706628|Drug|Sequential BIBF 1120 + BIBW 2992|
458440|NCT00706615|Biological|Ad-sig-hMUC-1/ecdCD40L vaccine|
458441|NCT00706589|Drug|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
458442|NCT00706589|Drug|placebo|Initial dose: 2mg, Maximum dose:20mg
458443|NCT00706576|Drug|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
458444|NCT00706563|Biological|Fluarix™|Single intramuscular dose on Day 0
458445|NCT00706550|Biological|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
458446|NCT00706550|Biological|Placebo|Placebo
458447|NCT00706537|Drug|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
458448|NCT00706537|Drug|Placebo|Placebo as two tablets once daily for three weeks
458449|NCT00706511|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
458450|NCT00706498|Drug|BI 2536|
458451|NCT00706485|Device|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
458452|NCT00706459|Device|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
458453|NCT00706446|Drug|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
458487|NCT00706147|Drug|Arimoclomol|Drug: Arimoclomol capsules given three times per day
458488|NCT00706147|Drug|Placebo|Drug: Placebo capsules given three times per day
458454|NCT00706446|Drug|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
458455|NCT00706446|Drug|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
458456|NCT00706446|Drug|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
458457|NCT00706446|Drug|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
458458|NCT00706433|Drug|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
458459|NCT00706433|Other|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
458460|NCT00706420|Procedure|Islet Transplantation + Immunosuppression|Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
458461|NCT00706420|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
458462|NCT00706407|Device|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
458463|NCT00706394|Device|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
458464|NCT00706381|Drug|Sincalide|
458465|NCT00706381|Drug|Ursodiol Acid|
458466|NCT00706381|Procedure|High Fat/Low Fat Diet|
458467|NCT00706368|Device|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
458468|NCT00706355|Drug|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
458469|NCT00706342|Drug|Fostamatinib Disodium / R935788|R935788 tablets
458470|NCT00706329|Device|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
458471|NCT00706316|Biological|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:~Dose level I: 5 x 107 cells/m2~Dose level II: 1 x 108 cells/m2~Dose level III: 2 x 108 cells/m2"
458472|NCT00706303|Behavioral|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
458473|NCT00706290|Behavioral|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
458474|NCT00706277|Drug|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
458475|NCT00706277|Drug|propofol|propofol 2mg
458476|NCT00706277|Drug|remifentanil|remifentanil 0,25mcg/kg/hour
458477|NCT00706277|Drug|fentanyl|fentanyl 100mcg
458478|NCT00706277|Drug|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
458479|NCT00706264|Device|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
458480|NCT00706251|Device|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
458481|NCT00706238|Biological|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
458482|NCT00706225|Drug|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
458483|NCT00706199|Procedure|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
458484|NCT00706186|Drug|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
458485|NCT00706173|Drug|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
458486|NCT00706173|Drug|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
458489|NCT00706134|Drug|Placebo|Placebo tablet taken once daily in the morning with a light meal.
458490|NCT00706134|Drug|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
458491|NCT00706134|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
458492|NCT00706134|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
458493|NCT00706121|Drug|Vitamin E|400 IU daily by mouth for 7 - 12 years
458494|NCT00706121|Drug|Selenium|200 mcg daily for 7 - 12 years
458495|NCT00706121|Drug|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
458496|NCT00706121|Drug|selenium placebo|1 pill by mouth daily for 7 - 12 years
458497|NCT00706108|Behavioral|Observational study|Observational (descriptive) study of technical and non-technical performance
458498|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m^2 for normal hepatic function.
458499|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m^2 for mild hepatic impairment (Child-Pugh A)
458500|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m^2 for moderate hepatic impairment (Child-Pugh B)
458501|NCT00706069|Drug|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
458502|NCT00706069|Drug|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
458503|NCT00706030|Drug|neratinib|
458504|NCT00706030|Drug|vinorelbine|
458505|NCT00706017|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
458506|NCT00706004|Drug|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
458507|NCT00705991|Procedure|ROTEM|
458508|NCT00705978|Drug|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
458509|NCT00705978|Drug|Placebo|placebo
458510|NCT00705965|Behavioral|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
458511|NCT00705965|Behavioral|Information session|One information session about living with heart disease.
458512|NCT00705965|Other|Usual cardiological care|Usual cardiological care
458513|NCT00705952|Other|Lifestyle intervention|Diet, exercise and behavioural change intervention.
458514|NCT00705939|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
458515|NCT00705926|Drug|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
458516|NCT00705926|Other|No treatment|Participants in this group will not receive treatment at this stage of their infection.
458517|NCT00705913|Device|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
458518|NCT00705913|Device|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
458519|NCT00705900|Drug|LCD|2 applications / day for 12 weeks
458520|NCT00705900|Drug|calcipotriol|2 applications / day for 12 weeks
458521|NCT00705887|Behavioral|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
458522|NCT00705874|Drug|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
458523|NCT00705874|Drug|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
458524|NCT00705874|Drug|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
458525|NCT00705874|Drug|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
458526|NCT00705874|Drug|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
458527|NCT00705874|Drug|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
458528|NCT00705874|Drug|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
458529|NCT00705861|Drug|Placebo|Placebo as a substitute of SK3530 100mg
458530|NCT00705861|Drug|SK3530|SK3530 100mg
458531|NCT00705835|Biological|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
458532|NCT00705822|Drug|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.~Combination of these 3 drugs every 3 weeks"
458533|NCT00705822|Drug|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
458534|NCT00705796|Drug|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
458535|NCT00705796|Drug|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
458868|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
458536|NCT00705783|Drug|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
458537|NCT00705783|Drug|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
458538|NCT00705770|Drug|Anecortave Acetate|"Low dose~Sustained release depot suspension"
458539|NCT00705770|Drug|Anecortave Acetate|"Middle dose~Sustained release depot suspension"
458540|NCT00705770|Drug|Anecortave Acetate|"High dose~Sustained release depot suspension"
458541|NCT00705770|Drug|Placebo|Placebo treatment with vehicle
458542|NCT00705757|Drug|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
458543|NCT00705757|Drug|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
458544|NCT00705757|Drug|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
458545|NCT00705744|Drug|Lactic acid (Dermacyd Femina)|
458546|NCT00705718|Device|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
458547|NCT00705705|Behavioral|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
458548|NCT00705705|Behavioral|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
458549|NCT00705692|Drug|Levamisole|
458550|NCT00705692|Drug|Placebo|
458551|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
458552|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
458553|NCT00705679|Drug|Tenofovir disoproxil fumarate|300 mg tablet
458554|NCT00705679|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet
458555|NCT00705679|Drug|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
458556|NCT00705679|Drug|Tenofovir placebo|placebo gel
458557|NCT00705666|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
458558|NCT00705666|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
458559|NCT00705653|Drug|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
458560|NCT00705640|Biological|incomplete Freund's adjuvant|Given subcutaneously and intradermally
458561|NCT00705640|Biological|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
458562|NCT00705640|Biological|tetanus toxoid helper peptide|Given subcutaneously and intradermally
458563|NCT00705640|Procedure|biopsy|Patients undergo surgical biopsy at replicate vaccine site
458564|NCT00705627|Drug|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
458565|NCT00705614|Biological|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
458566|NCT00705601|Procedure|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
458567|NCT00705588|Drug|Tadalafil|Orally, titrated to maximum 20mg od
458568|NCT00705588|Drug|Vardenafil|Orally, titrated to 10 mg bid
458569|NCT00705575|Drug|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
458570|NCT00705575|Drug|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
458571|NCT00705562|Other|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
458572|NCT00705549|Drug|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
458573|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
458574|NCT00705549|Drug|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
458575|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
458576|NCT00705549|Drug|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
458577|NCT00705549|Drug|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
458578|NCT00705536|Drug|Humalog|
458579|NCT00705536|Drug|Humulin-R|
458580|NCT00705536|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
458581|NCT00705523|Drug|varenicline|1.0 mg BID for 12 weeks
458582|NCT00705523|Drug|placebo|BID 12 weeks
458583|NCT00705510|Drug|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
458584|NCT00705497|Procedure|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
458585|NCT00705484|Biological|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
458586|NCT00705484|Drug|Standard Therapy|The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
458587|NCT00705471|Biological|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
458588|NCT00705458|Procedure|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
458589|NCT00705458|Procedure|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
458590|NCT00705445|Dietary Supplement|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
458591|NCT00705445|Dietary Supplement|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
458592|NCT00705445|Other|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
458593|NCT00705432|Biological|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
458594|NCT00705432|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
458595|NCT00705432|Drug|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
458596|NCT00705432|Drug|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
458597|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
458598|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
458599|NCT00705419|Drug|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
458600|NCT00705419|Drug|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
458601|NCT00705406|Drug|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
458602|NCT00705406|Drug|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
458603|NCT00705380|Behavioral|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
458604|NCT00705380|Behavioral|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
458605|NCT00705367|Drug|Placebo|Infusion, Intravenous, single dose, Day 1
458606|NCT00705367|Drug|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
458607|NCT00705367|Drug|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
458608|NCT00705354|Drug|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
458609|NCT00705354|Procedure|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
458610|NCT00705341|Drug|fluticasone|Inhaled corticosteroid approved for treatment of asthma
458611|NCT00705328|Behavioral|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
458612|NCT00705328|Behavioral|Recreation Coordination Model (REC)|Recreation coordination service delivery
458613|NCT00705328|Behavioral|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
458614|NCT00705315|Drug|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
458615|NCT00705315|Drug|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
458616|NCT00705315|Drug|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
458617|NCT00705302|Behavioral|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
458618|NCT00705302|Behavioral|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
458619|NCT00705289|Biological|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
458620|NCT00705276|Drug|Lactic acid (Dermacyd Femina Delicata)|
458621|NCT00705263|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
458622|NCT00705263|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
458869|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
458623|NCT00705250|Drug|bendamustine hcl|Patients will receive bendamustine 120mg/m^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is > 1000/ul and the platelet count is > 75,000/ul.
458624|NCT00705237|Procedure|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
458625|NCT00705224|Biological|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous~injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
458626|NCT00705224|Drug|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.~The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the~morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.~The Sponsor did not provide formal drug supply."
458627|NCT00705211|Drug|Ezetimibe|Ezetimibe, 10-mg tablets,
458628|NCT00705211|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
458629|NCT00705198|Drug|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
458630|NCT00705198|Drug|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules."
458631|NCT00705198|Radiation|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
458632|NCT00705172|Drug|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
458633|NCT00705159|Drug|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
458634|NCT00705159|Drug|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
458635|NCT00705159|Drug|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
458636|NCT00705159|Drug|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
458637|NCT00705146|Device|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
458638|NCT00705146|Device|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
458639|NCT00705133|Drug|Treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min every 1-3 days as tolerated
458640|NCT00705120|Other|Bone Marrow Cell Transplantation|
458641|NCT00705120|Radiation|Irradiation, Total Body|
458642|NCT00705120|Drug|Cyclophosphamide|
458643|NCT00705120|Drug|Cyclosporin|
458644|NCT00705120|Procedure|Mesenchymal Stem Cell Transplantation|
458645|NCT00705120|Drug|Busulfan|
458646|NCT00705107|Biological|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
458647|NCT00705107|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
458648|NCT00705081|Drug|ezetimibe|10 mg once daily
458649|NCT00705081|Drug|statin|
458650|NCT00705042|Drug|Etanercept|
458651|NCT00705016|Drug|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
458652|NCT00705016|Drug|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
458653|NCT00705016|Drug|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m^2) as infusion (initial starting dose of 400 mg/m^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
458654|NCT00705016|Drug|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
458655|NCT00705016|Drug|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
458656|NCT00705003|Drug|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
458657|NCT00705003|Drug|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
458658|NCT00705003|Drug|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
458659|NCT00704990|Dietary Supplement|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
458660|NCT00704977|Procedure|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.~Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.~Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.~Wound closure by by technique described in each arm.~Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.~Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.~Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
458661|NCT00704964|Biological|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
458662|NCT00704964|Drug|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
458663|NCT00704951|Drug|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:~Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
458664|NCT00704938|Biological|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
458665|NCT00704938|Biological|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10^8 cells to 5 x 10^10 cells.
458666|NCT00704938|Biological|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
458667|NCT00704938|Biological|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
458668|NCT00704938|Drug|cyclophosphamide|60mg/kg/day (Days-7,-6)
458669|NCT00704938|Drug|fludarabine phosphate|25mg/m^2 (Days -5, -4, -3, -2, and -1)
458670|NCT00704925|Drug|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
458671|NCT00704912|Drug|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
458672|NCT00704912|Drug|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
458673|NCT00704912|Drug|Combination of treatments|Medications will be administered as described for the other 2 arms.
458674|NCT00704899|Procedure|Physiotherapy|Structured exercise regimen
458675|NCT00704899|Drug|Amitryptiline|Amitryptiline 25mg once daily
458676|NCT00704886|Other|video|video of dementia
458677|NCT00704860|Other|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.~doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
458678|NCT00704847|Drug|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
458679|NCT00704847|Drug|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
458680|NCT00704834|Other|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
458681|NCT00704821|Drug|PTC299|Oral
458682|NCT00704821|Drug|Docetaxel|Intravenous infusion
458683|NCT00704808|Procedure|Primary surgical treatment|Primary surgery for tumor resection.
458684|NCT00704808|Radiation|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
458685|NCT00704808|Drug|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
458686|NCT00704795|Other|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
458687|NCT00704795|Other|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
458688|NCT00704782|Drug|dimebon|
458870|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
458689|NCT00704769|Drug|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
458690|NCT00704756|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
458691|NCT00704756|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg : 800 mg, 65 - 85 kg : 1000 mg, >85 kg : 1200 mg) orally for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
458692|NCT00704743|Device|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
458693|NCT00704743|Device|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
458694|NCT00704743|Device|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
458695|NCT00704730|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
458696|NCT00704730|Drug|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
458697|NCT00704717|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
458698|NCT00704717|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
458699|NCT00704704|Drug|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
458700|NCT00704691|Drug|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
458701|NCT00704678|Drug|SBR759|1g tid
458702|NCT00704678|Drug|Sevelamer HCl|1.6 g tid
458703|NCT00704678|Drug|Sevelamer HCl|1.5 g tid
458704|NCT00704678|Drug|Sevelamer HCl|0.8 g tid
458705|NCT00704665|Drug|Relaxin|10 ug/kg/day or 25 ug/kg/day
458706|NCT00704665|Drug|Relaxin|Placebo
458707|NCT00704639|Drug|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
458708|NCT00704639|Drug|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
458709|NCT00704639|Radiation|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
458710|NCT00704626|Other|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
458711|NCT00704626|Other|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
458712|NCT00704600|Drug|nelfinavir|"Phase I:~take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days~day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~day 0: PET-CT~Phase II:~take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days~day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample~day 7 biopsy~day 7, 21 and week 15 :PET-CT + perfusion CT"
458713|NCT00704574|Drug|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
458714|NCT00704561|Device|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
458715|NCT00704561|Device|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
458716|NCT00704561|Device|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
458717|NCT00704561|Device|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
458718|NCT00704548|Drug|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
458719|NCT00704548|Drug|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
458720|NCT00704535|Drug|Ezetimibe|1 tablet of 10 mg once daily
458721|NCT00704522|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
458722|NCT00704522|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
458723|NCT00704522|Behavioral|Patient assistance program|"Assistance programs will be classified as follows:~Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)~Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).~In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
458724|NCT00704509|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
458725|NCT00704509|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
458726|NCT00704509|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
458727|NCT00704496|Drug|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
458728|NCT00704483|Drug|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
458729|NCT00704483|Drug|Sevelamer HCl|0.8 g tid
458730|NCT00704483|Drug|SBR759|1.5 g tid
458731|NCT00704483|Drug|Sevelamer HCl|1.6 g tid
458732|NCT00704470|Other|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
458733|NCT00704470|Other|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
458734|NCT00704444|Drug|Ezetimibe|Ezetimibe, 10-mg tablets
458778|NCT00704093|Device|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
458735|NCT00704444|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
458736|NCT00704431|Drug|SB-480848 (darapladib)|160 mg darapladib
458737|NCT00704418|Drug|Bromfenac|sterile ophthalmic solution
458738|NCT00704418|Drug|Placebo|sterile ophthalmic solution
458739|NCT00704405|Drug|Vaniprevir|Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
458740|NCT00704405|Drug|Pegylated Interferon (Peg-IFN)|Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
458741|NCT00704405|Drug|Ribavirin (RBV)|Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing <=75 kg and 1200 mg for participants weighing >75 kg.
458742|NCT00704405|Drug|Placebo (PBO)|Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
458743|NCT00704392|Drug|XL647|Tablets supplied at 50-mg strength administered orally daily
458744|NCT00704392|Drug|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
458745|NCT00704379|Drug|Placebo|an inactive substance
458746|NCT00704379|Drug|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
458747|NCT00704366|Drug|AZD0530|oral, tablet, once daily, dose will be variable
458748|NCT00704353|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
458749|NCT00704353|Drug|Standard Medical Care (SMC)|Per product label
458750|NCT00704340|Device|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
458751|NCT00704340|Other|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
458752|NCT00704314|Drug|Simvastatin|80 mg Simvastatin daily for 8 weeks
458753|NCT00704314|Drug|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
458754|NCT00704301|Drug|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
458755|NCT00704301|Drug|Placebo|Placebo, 2 times a day
458756|NCT00704288|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
458757|NCT00704275|Drug|0.05% cyclosporin eye drop|bid dosage for 4 months
458758|NCT00704262|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
458759|NCT00704249|Drug|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
458760|NCT00704249|Drug|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
458761|NCT00704236|Drug|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
458762|NCT00704236|Drug|Placebo|
458763|NCT00704223|Drug|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
458764|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
458765|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
458766|NCT00704184|Drug|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
458767|NCT00704184|Drug|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
458768|NCT00704184|Drug|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
458769|NCT00704184|Drug|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
458770|NCT00704171|Procedure|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
458771|NCT00704171|Device|PleuraSeal Lung Sealant System|
458772|NCT00704158|Drug|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
458773|NCT00704145|Device|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
458774|NCT00704132|Drug|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
458775|NCT00704132|Drug|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
458776|NCT00704119|Drug|RhuDex®|"Treatment A.1: 31.65 mg RhuDex® once N=12~Treatment A.2: 63.33 mg RhuDex® once N=12~Treatment A.3: 126.63 mg RhuDex® once N=12~Treatment A.4: 253.26 mg RhuDex® once N=12~Treatment B.1: 31.65 mg RhuDex® once N=12~Treatment B.2: selected dose of RhuDex® once N=12~Treatment C: selected dose of RhuDex® once N=12~Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
458777|NCT00704106|Drug|Entecavir|0.5 or 1 mg dose qd
458779|NCT00704080|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
458780|NCT00704080|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
458781|NCT00704067|Behavioral|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
458782|NCT00704067|Behavioral|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
458783|NCT00704054|Drug|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
458784|NCT00704028|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
458785|NCT00704028|Drug|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
458786|NCT00704015|Behavioral|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
458787|NCT00704002|Procedure|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
458788|NCT00704002|Procedure|conservative treatment|conservative treatment with 2-finger splint for one week
458789|NCT00703989|Dietary Supplement|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
458790|NCT00703976|Drug|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
458791|NCT00703976|Drug|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
458792|NCT00703976|Drug|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
458793|NCT00703976|Radiation|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
458794|NCT00703963|Device|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
458795|NCT00703963|Other|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
458796|NCT00703950|Procedure|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
458797|NCT00703950|Procedure|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
458798|NCT00703937|Drug|Ferric Carboxymaltose (FCM)|
458799|NCT00703937|Drug|Standard Medical Care (SMC) for the treatment of IDA|
458800|NCT00703924|Drug|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
458801|NCT00703924|Drug|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
458802|NCT00703911|Drug|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
458803|NCT00703898|Drug|nevirapine|200 mg/day twice a day
458804|NCT00703885|Drug|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
458805|NCT00703885|Drug|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
458806|NCT00703885|Drug|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan~Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
458807|NCT00703872|Drug|Oral HDV-Interferon + ribavarin|Naive pateints
458808|NCT00703872|Drug|Injectable HDV-Interferon + ribavarin|Nonresponders
458809|NCT00703859|Drug|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
458810|NCT00703846|Drug|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
458811|NCT00703833|Drug|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
458812|NCT00703833|Drug|Placebo (unspecified)|matching placebo
458813|NCT00703820|Drug|Cytarabine|See Detailed Description
458814|NCT00703820|Drug|Daunorubicin|See Detailed Description
458815|NCT00703820|Drug|Etoposide|See Detailed Description
458816|NCT00703820|Drug|Clofarabine|See Detailed Description
458817|NCT00703820|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
458818|NCT00703807|Drug|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
458819|NCT00703807|Drug|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
458820|NCT00703794|Device|The AXIUM Progressive Coil System|Embolization of aneurysm
458821|NCT00703781|Drug|bromfenac ophthalmic solution|sterile ophthalmic solution
458822|NCT00703781|Drug|placebo|sterile ophthalmic solution
458823|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
458824|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
458825|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
458826|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
458827|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
458828|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
458829|NCT00703755|Drug|Placebo|Placebo
458830|NCT00703742|Drug|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
458831|NCT00703729|Device|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
458832|NCT00703729|Other|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
458833|NCT00703703|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
458834|NCT00703703|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
458835|NCT00703703|Drug|Placebo|Placebo tablet once daily
458836|NCT00703690|Drug|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
458837|NCT00703690|Drug|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
458838|NCT00703690|Drug|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
458839|NCT00703677|Drug|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
458840|NCT00703664|Drug|Bortezomib|Bortezomib: 1.3 mg/m^2/d IV days 1, 4, 8, and 11.
458841|NCT00703664|Other|Laboratory Biomarker Analysis|Correlative studies
458842|NCT00703664|Drug|Vorinostat|Vorinostat: 400 mg (total daily dose as a single dose) days 1-5 and 8-12.
458843|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
458844|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
458845|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
458846|NCT00703638|Drug|cisplatin|Cisplatin administered intravenously, 75 mg/m^2 over 1-2 hours on day 1 of a 21 day cycle
458847|NCT00703638|Drug|pemetrexed disodium|Pemetrexed 500 mg/m^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
458848|NCT00703638|Drug|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
458849|NCT00703625|Drug|Temsirolimus|
458850|NCT00703625|Drug|Docetaxel|
458851|NCT00703612|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
458852|NCT00703599|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
458853|NCT00703586|Drug|Maraviroc|"ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc."
458854|NCT00703573|Drug|S-777469 400 mg|S-777469 400 mg BID
458855|NCT00703573|Drug|S-777469 800 mg|S-777469 800 mg BID
458856|NCT00703573|Drug|Placebo|Placebo BID
458857|NCT00703547|Drug|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
458858|NCT00703547|Drug|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
458859|NCT00703547|Drug|Placebo|Placebo tablets and capsules will be provided to subjects.
458860|NCT00703534|Drug|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
458861|NCT00703534|Drug|Placebo|capsule. administered as a single dose twice daily for 4 weeks
458862|NCT00703534|Drug|Gelusil®|Chewable tablets taken as needed
458863|NCT00703521|Biological|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
458864|NCT00703508|Drug|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
458865|NCT00703495|Device|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
458866|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
458867|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
458871|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
458872|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
458873|NCT00703469|Drug|MDX1106-02|Single dose
458874|NCT00703469|Drug|Placebo|Placebo single dose
458875|NCT00703456|Behavioral|Balance Training|balance training three days per week for 4 weeks during single limb standing
458876|NCT00703430|Drug|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
458877|NCT00703417|Device|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
458878|NCT00703417|Device|Computed Tomography|CT scan of the lower back and hip
458879|NCT00703417|Device|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
458880|NCT00703391|Drug|AZD9668|30mg oral tablets twice daily (bid) for 14 days
458881|NCT00703391|Drug|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
458882|NCT00703378|Drug|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
458883|NCT00703365|Drug|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
458884|NCT00703352|Drug|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
458885|NCT00703339|Drug|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose~Dose:~Cohort 1: dosed at 3 breaths (18 mcg)~Cohort 2: dosed at 6 breaths (36 mcg)~Cohort 3: dosed at 9 breaths (54 mcg)~Cohort 4: dosed at 12 breaths (72 mcg)~The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
458886|NCT00703326|Biological|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
458887|NCT00703326|Drug|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
458888|NCT00703326|Other|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
458889|NCT00703313|Drug|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
458890|NCT00703313|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
458891|NCT00703313|Drug|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
458892|NCT00703300|Drug|bortezomib|Given IV
458893|NCT00703300|Drug|decitabine|Given IV
458894|NCT00703300|Other|pharmacological study|Correlative studies
458895|NCT00703300|Other|laboratory biomarker analysis|Optional correlative studies
458896|NCT00703287|Other|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
458897|NCT00703287|Other|Physiotherapy|Generic physiotherapy
458898|NCT00703274|Behavioral|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
458899|NCT00703261|Drug|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
458900|NCT00703261|Drug|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
458901|NCT00703248|Procedure|Osteopathic Manipulative Treatments|"opening the thoracic inlet~pectoral traction for 1 minute bilaterally~rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine ]~thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally~abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
458902|NCT00703235|Drug|Bevacizumab|
458903|NCT00703222|Biological|SJNB-JF-IL2 and SJNB-JF-Lptn|SJNB-JF-IL2 and SJNB-JF-Lptn cells are each dosed at 1x10e7 cells/m2/vaccination.
458904|NCT00703222|Biological|SKNLP|"Dose Level 1: 1x10e6 cells/m2/vaccination~Dose Level 2: 1x10e7 cells/m2/vaccination"
458905|NCT00703209|Procedure|Nerve Decompression|"Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression."
458906|NCT00703196|Dietary Supplement|folic acid|Given orally once daily
458907|NCT00703196|Other|placebo|Given orally once daily
458908|NCT00703183|Drug|ACU-4429|administered as a single dose, orally
458909|NCT00703183|Drug|matching placebo|administered as a single dose, orally
458910|NCT00703170|Drug|Temsirolimus|
458911|NCT00703170|Drug|Pegylated liposomal doxorubicin|
458912|NCT00703157|Procedure|Catheter Ablation|Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
458913|NCT00703157|Procedure|Surgical Ablation|patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
458914|NCT00703144|Drug|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
458915|NCT00703144|Procedure|Pharmacokinetic|
458916|NCT00703131|Device|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
458917|NCT00703118|Drug|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
458918|NCT00703118|Drug|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
458919|NCT00703118|Drug|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
458920|NCT00703118|Drug|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
458921|NCT00703105|Biological|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate or tumor peptides and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
458922|NCT00703092|Drug|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
458923|NCT00703079|Drug|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
458924|NCT00703079|Procedure|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
458925|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
458926|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
458927|NCT00703066|Biological|Rabies vaccine|3 doses of Rabies vaccine
458928|NCT00703053|Biological|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
458929|NCT00703053|Biological|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
458930|NCT00703014|Drug|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
458931|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
458932|NCT00703014|Drug|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
458933|NCT00703014|Drug|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
458934|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
458935|NCT00703014|Drug|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
458936|NCT00703014|Biological|hCG|In the Base Trial P05787, when 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
458937|NCT00703014|Biological|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
458938|NCT00703001|Behavioral|Educational Intervention|students in this arm will receive several oral health educational modules in class
458939|NCT00703001|Behavioral|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
458940|NCT00702988|Drug|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
458941|NCT00702988|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
458942|NCT00702975|Drug|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
458943|NCT00702962|Drug|Vorinostat, Carboplatin, Etoposide|"Study originally a Phase I standard dose escalation of the study medication Vorinostat with sequential cohorts of 3-6 participants entered to 3 dose levels (200mg, 300mg, 400mg). Dose escalation stopped after participant 1 on dose level 2 due to recently published research identifying an appropriate dosing regimen. A set dose was then to be administered to all subsequent participants. This regimen (a cycle) consisted of Vorinostat on Day 1 through Day 4, Carboplatin AUC 6 on Day 3, and Etoposide 100 mg/m2 on Day 3 through Day 5. Treatment cycles were repeated every 21 days (3 weeks) for 4 cycles total."
458944|NCT00702949|Drug|pregabalin|Given orally
458945|NCT00702949|Other|placebo|Given orally
458946|NCT00702936|Drug|TELMISARTAN|80 mg daily
458947|NCT00702936|Drug|RAMIPRIL|5 mg daily
458948|NCT00702923|Drug|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
458949|NCT00702923|Drug|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
458950|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
458951|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
458952|NCT00702923|Drug|Bicalutamide, CP-675,206|"Final Dose Level:~Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112~At month 9, if evidence of PSA progression:~Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
458953|NCT00702910|Drug|Placebo|comparator
458954|NCT00702910|Drug|GW642444|investigational drug or placebo
458955|NCT00702910|Drug|Magnesium Stearate|Magnesium Stearate
458956|NCT00702884|Drug|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
458957|NCT00702871|Drug|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
458958|NCT00702871|Drug|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
458959|NCT00702858|Drug|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
458960|NCT00702858|Drug|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
458961|NCT00702845|Drug|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
458962|NCT00702845|Drug|recFSH (follitropin beta)|150 IU recFSH SC injection
458963|NCT00702845|Drug|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
458964|NCT00702845|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
458965|NCT00702845|Biological|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
458966|NCT00702845|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
458967|NCT00702845|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
458968|NCT00702845|Biological|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
458969|NCT00702832|Behavioral|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
458970|NCT00702832|Other|standard treatment|treatment as usual
458971|NCT00702819|Drug|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
458972|NCT00702806|Drug|Org 36286|Intra-abdominal injection of Org 36286
458973|NCT00702806|Drug|Puregon®|Subcutaneous Puregon® 150 IU
458974|NCT00702806|Drug|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
458975|NCT00702806|Drug|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
458976|NCT00702793|Drug|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
458977|NCT00702780|Drug|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
458978|NCT00702780|Drug|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
458979|NCT00702767|Drug|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
458980|NCT00702754|Biological|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
458981|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
458982|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
458983|NCT00702741|Drug|Placebo|Intra-articular injection of Hyaluronan
458984|NCT00702728|Drug|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
458985|NCT00702728|Drug|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
458986|NCT00702715|Drug|sugammadex|"Each subject will receive an~intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After~this dose, maintenance doses of 0.1 - 0.2 mg.kg-1~rocuronium may be given. In case of maintenance dosing, the target depth of~neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC."
458987|NCT00702702|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
458988|NCT00702702|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
458989|NCT00702702|Drug|Placebo|Placebo, 2 capsules daily for 3 months
458990|NCT00702689|Drug|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.~Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
458991|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
458992|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
458993|NCT00702650|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
458994|NCT00702637|Drug|Modafinil|
458995|NCT00702624|Drug|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
458996|NCT00702624|Biological|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
458997|NCT00702624|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
458998|NCT00702624|Biological|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
458999|NCT00702624|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
459000|NCT00702624|Drug|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
459001|NCT00702624|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
459002|NCT00702624|Biological|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
459121|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
459231|NCT00700921|Drug|Placebo|One capsule, once daily
459003|NCT00702611|Device|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
459004|NCT00702598|Behavioral|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
459005|NCT00702598|Behavioral|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
459006|NCT00702585|Drug|Org 36286|Org 36286 single-dose subcutaneous injection
459007|NCT00702585|Drug|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
459008|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which <2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
459009|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
459010|NCT00702546|Drug|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
459011|NCT00702546|Biological|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
459012|NCT00702546|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
459013|NCT00702546|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
459014|NCT00702546|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
459015|NCT00702546|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
459016|NCT00702546|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
459017|NCT00702546|Biological|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
459018|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
459019|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
459020|NCT00702520|Drug|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
459021|NCT00702520|Biological|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
459022|NCT00702520|Biological|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
459023|NCT00702507|Drug|0.25 % Miconazole Nitrate Ointment|Topical Application
459024|NCT00702494|Biological|TB-403|Multiple IV
459025|NCT00702481|Drug|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
459026|NCT00702481|Drug|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
459027|NCT00702481|Radiation|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
459028|NCT00702468|Drug|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
459029|NCT00702468|Drug|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
459030|NCT00702455|Behavioral|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
459031|NCT00702455|Behavioral|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
459032|NCT00702442|Drug|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
459033|NCT00702442|Drug|Saline solution|Saline solution administrated i.v 30 min prior surgery
459034|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
459035|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
459066|NCT00702273|Drug|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
459036|NCT00702416|Procedure|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.~A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.~At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
459037|NCT00702416|Procedure|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.~A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.~An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought~Injection of the local anesthetic will start with a visible motor response at a current <0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
459038|NCT00702416|Drug|Ropivacaine|"Block induction [1% (wt/vol) solution]:~20 ml (200 mg)~Postoperative analgesia [0.2% (wt/vol) solution]:~Background infusion: 4 ml/h (8 mg/h)~Incremental on-demand dose: 2 ml (4 mg)~Lockout time: 15 min"
459039|NCT00702416|Drug|Paracetamol|1 g iv q8h
459040|NCT00702416|Drug|Morphine|5 mg im prn q1h (in the postoperative period)
459041|NCT00702416|Drug|Fentanyl|50 µg iv prn (in the intraoperative period)
459042|NCT00702416|Procedure|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.~The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
459043|NCT00702403|Drug|nilotinib|Given PO
459044|NCT00702403|Drug|imatinib mesylate|Given PO
459045|NCT00702403|Other|pharmacological study|Correlative studies
459046|NCT00702377|Other|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
459047|NCT00702377|Other|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
459048|NCT00702364|Drug|atomoxetine|
459049|NCT00702364|Drug|placebo|
459050|NCT00702351|Drug|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
459051|NCT00702338|Drug|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
459052|NCT00702338|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
459053|NCT00702338|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
459054|NCT00702338|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
459055|NCT00702325|Drug|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
459056|NCT00702325|Drug|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
459057|NCT00702312|Behavioral|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
459058|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
459059|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
459060|NCT00702299|Drug|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
459061|NCT00702299|Drug|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
459062|NCT00702299|Drug|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
459063|NCT00702299|Other|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
459064|NCT00702273|Drug|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
459065|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
459119|NCT00701883|Drug|Atorvastatin|2 capsules, once daily for 8 weeks
459120|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
459067|NCT00702273|Drug|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
459068|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
459069|NCT00702273|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
459070|NCT00702273|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
459071|NCT00702273|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
459072|NCT00702260|Drug|Ramipril|10 mg capsule
459073|NCT00702247|Procedure|Hematopoietic Stem Cell Transplantation|
459074|NCT00702234|Biological|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
459075|NCT00702234|Biological|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
459076|NCT00702234|Biological|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
459077|NCT00702234|Biological|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
459078|NCT00702234|Drug|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
459079|NCT00702221|Biological|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
459080|NCT00702221|Biological|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
459081|NCT00702208|Device|Delphi Screener|Self-sampling device for cervical vaginal lavage
459082|NCT00702195|Drug|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
459083|NCT00702195|Drug|Placebo|single dose of placebo (administered under protocol 38805)
459084|NCT00702195|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
459085|NCT00702182|Drug|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
459086|NCT00702182|Drug|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
459087|NCT00702182|Drug|Erlotinib|Daily Oral Erlotinib 100 mg
459088|NCT00702156|Drug|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
459089|NCT00702156|Drug|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
459090|NCT00702143|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
459091|NCT00702130|Drug|Pravastatin|pravastatin 40mg per os once daily
459092|NCT00702117|Drug|flecainide|2 mg/kg iv in 10 minutes
459093|NCT00702117|Drug|ajmaline|1 mg/kg iv in 10 minutes
459094|NCT00702117|Drug|procainamide|10 mg/kg iv in 10 minutes
459095|NCT00702104|Other|survey administration|
459096|NCT00702091|Drug|Ramipril|10 mg capsule
459097|NCT00702078|Behavioral|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
459098|NCT00702078|Behavioral|usual care|follow-up according to todays best practice
459099|NCT00702052|Drug|RAD001|
459100|NCT00702039|Other|No Music|No music will be played in patients in arm 2 of the study.
459101|NCT00702039|Other|Music Therapy|Classical music being played during intravitreal injection.
459102|NCT00702026|Dietary Supplement|multispecies probiotic (Ecologic 801)|once daily, 5 gram [10e9 cfu/gram]
459103|NCT00702026|Dietary Supplement|Placebo|once daily, 5 gram [10e9 cfu/gram]
459104|NCT00701987|Drug|ALS-357|Topical application of ALS-357
459105|NCT00701974|Biological|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
459106|NCT00701974|Biological|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
459107|NCT00701961|Drug|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
459108|NCT00701935|Drug|placebo|subcutaneous injection, twice a day
459109|NCT00701935|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
459110|NCT00701909|Drug|morphine plus saline|During the first wound care procedure, some patients will receive morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS), according to randomization, while other patients will receive morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg
459111|NCT00701909|Drug|morphine plus ketamine|Patients who received morphine 0.1 mg/kg (maximum dose of 8 mg)plus saline during the first wound care procedure will now receive ketamine 0.25 mg/kg IV plus morphine 0.05 mg/kg
459112|NCT00701896|Drug|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
459113|NCT00701896|Drug|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
459114|NCT00701896|Other|Biological Control|No treatment intervention only information and procedures.
459115|NCT00701896|Behavioral|Motivational Interview|60 minute one-on-one Interview
459116|NCT00701883|Drug|Placebo|2 capsules, once a day for 8 weeks
459117|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
459118|NCT00701883|Drug|MBX-8025|2 capsule, once daily for 8 weeks
459122|NCT00701870|Drug|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
459123|NCT00701857|Drug|cisplatin|Standard weekly dose
459124|NCT00701857|Drug|Pemetrexed|Biweekly pemetrexed dose escalation
459125|NCT00701857|Radiation|radiation therapy|Weekly standard dose radiation therapy
459126|NCT00701844|Behavioral|Writing A (Experimental informative writing)|Experimental informative writing
459127|NCT00701844|Behavioral|Writing B (Experimental noninformative writing)|Experimental noninformative writing
459128|NCT00701844|Behavioral|Writing C (Control informative writing)|Control informative writing
459129|NCT00701844|Behavioral|Writing D (Control noninformative writing)|Control noninformative writing
459130|NCT00701831|Drug|Insulin glargine|The dose is titrated according to patient needs
459131|NCT00701805|Drug|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
459132|NCT00701792|Procedure|liver transplantation|liver transplantation
459133|NCT00701792|Other|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
459134|NCT00701779|Drug|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
459135|NCT00701766|Drug|BI 2536|
459136|NCT00701740|Drug|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
459137|NCT00701740|Drug|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
459138|NCT00701727|Drug|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
459139|NCT00701727|Drug|Placebo|1 tablet, once a day, for 7 weeks
459140|NCT00701714|Drug|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
459141|NCT00701714|Drug|ERYPO|Solution for injection (s.c.)
459142|NCT00701701|Biological|Myozyme (alglucosidase alfa)|Myozyme: Intravenous (IV) infusion of 20 mg/kg every other week (qow); Cyclophosphamide: 250 mg/m2 IV every 4 wks after Myozyme infusion for 6 months
459143|NCT00701701|Biological|Myozyme (alglucosidase alfa)|Myozyme: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m2 IV weekly beginning the day after MZ infusion for 4 weeks (an optional additional 2nd cycle may be administered at the discretion of the investigator); Methotrexate: 15mg/m2 subcutaneous every other week on the day after Myozyme infusion for 6 months
459144|NCT00701688|Drug|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
459145|NCT00701675|Drug|sertraline 50 mg daily|50 mg daily
459146|NCT00701675|Drug|sertraline 100 mg daily|100 mg daily
459147|NCT00701675|Drug|Placebo 50 or 100 mg|50mg or 100mg matching placebo
459148|NCT00701662|Biological|Vivaglobin|
459149|NCT00701649|Biological|CYT006-AngQb|s.c.
459150|NCT00701649|Biological|Placebo|s.c.
459151|NCT00701636|Drug|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
459152|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
459153|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
459154|NCT00701623|Drug|folder water|patients will receive the application of folder water directly on the injured area
459155|NCT00701597|Drug|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
459156|NCT00701571|Procedure|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
459157|NCT00701558|Drug|Erlotinib|150 mg po daily
459158|NCT00701558|Drug|Gemcitabine|1000 mg/m^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
459159|NCT00701532|Drug|Modafinil and PET (brain imaging)|duration 90 days
459160|NCT00701532|Drug|placebo|duration 90 days
459161|NCT00701506|Device|Patterned Electrical Neuromuscular Stimulation|"20-minute session, to each affected knee, 3 times per week for 12 weeks.~PENS for 20 minutes:~Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).~Minimal twitch for 5 minutes.~Moderate to strong, but well-tolerated twitch contractions for 15 minutes.~Electrodes placed on quadriceps and hamstrings"
459162|NCT00701506|Device|Placebo PENS|"20-minute session, to each affected knee, 3 times per week for 12 weeks.~Placebo PENS for 20 minutes:~Electrodes placed on quadriceps and hamstrings."
459163|NCT00701493|Drug|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
459164|NCT00701480|Other|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
459165|NCT00701480|Other|marketed skin cleanser|face washing 2-3 times/day
459166|NCT00701454|Other|No intervention|No intervention
459167|NCT00701428|Drug|Losartan|Losartan 50 mg daily during 6 + 6 weeks
459168|NCT00701428|Other|CPAP|CPAP during the second 6 week-period
459169|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
459170|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
459171|NCT00701389|Drug|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
459172|NCT00701389|Drug|sumatriptan|single oral dose of 100 mg sumatriptan
459173|NCT00701389|Drug|sumatriptan placebo|single oral dose
459230|NCT00700921|Drug|Lovastatin|40mg po once daily
459174|NCT00701389|Drug|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
459175|NCT00701376|Other|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
459176|NCT00701363|Drug|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
459177|NCT00701337|Drug|oestradiol|oestradiol 2 mg oral route 30 days
459178|NCT00701337|Drug|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
459179|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
459180|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 1)
459181|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 15)
459182|NCT00701311|Drug|CC-10004|CC-10004 20 mg per day
459183|NCT00701298|Biological|peginterferon alfa-2b|Given SC
459184|NCT00701298|Drug|decitabine|Given IV
459185|NCT00701298|Other|laboratory biomarker analysis|Correlative studies
459186|NCT00701285|Drug|pitavastatin|pitavastatin 4mg once daily
459187|NCT00701285|Drug|pravastatin|pravastatin 10mg once daily
459188|NCT00701259|Drug|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
459189|NCT00701259|Drug|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
459190|NCT00701259|Drug|placebo|
459191|NCT00701246|Drug|ferrous sulfate|
459192|NCT00701246|Drug|folic acid|
459193|NCT00701246|Drug|placebo (folic acid)|
459194|NCT00701233|Drug|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
459195|NCT00701233|Drug|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
459196|NCT00701220|Drug|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
459197|NCT00701207|Drug|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
459198|NCT00701194|Behavioral|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
459199|NCT00701181|Procedure|Laser Treatment|Necessity of laser treatment is assessed every three months.
459200|NCT00701181|Drug|PF-04523655 high|3 mg intravitreal injection
459201|NCT00701181|Drug|PF-04523655 middle|1 mg intravitreal injection
459202|NCT00701181|Drug|PF-04523655 low|0.4 mg intravitreal injection
459203|NCT00701168|Device|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
459204|NCT00701155|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
459205|NCT00701142|Biological|Haemocomplettan® P|Single intravenous infusion
459206|NCT00701142|Biological|Saline solution|Single intravenous infusion
459207|NCT00701129|Biological|Alglucosidase Alfa|Administered as IV infusion.
459208|NCT00701129|Drug|Methotrexate|Administered subcutaneously.
459209|NCT00701129|Drug|Rituximab|Administered as IV infusion.
459210|NCT00701103|Drug|Dalotuzumab|IV infusion
459211|NCT00701090|Drug|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
459212|NCT00701090|Drug|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
459213|NCT00701090|Drug|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
459214|NCT00701077|Drug|3,4-Di-amino-Pyridine|a single 20 mg dosing
459215|NCT00701077|Drug|placebo|placebo
459216|NCT00701064|Other|Bright Light Exposure|Administered via bright light box
459217|NCT00701064|Other|Negative Ion Generator|Administered via Negative Ion Generatore
459218|NCT00701051|Behavioral|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
459219|NCT00701051|Behavioral|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
459220|NCT00701038|Device|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
459221|NCT00701012|Procedure|preservation of nerve fibers around IMA|low ligation
459222|NCT00701012|Procedure|resection of nerve fibers around IMA|high ligation
459223|NCT00700999|Drug|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
459224|NCT00700986|Drug|AZD9056|Oral tablet, 800mg, one single administration
459225|NCT00700986|Drug|Placebo|Single dose
459226|NCT00700973|Behavioral|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
459227|NCT00700973|Other|Usual care|Substance use disorder usual care
459228|NCT00700960|Drug|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
459229|NCT00700947|Drug|Beta-blocker therapy (TOPROL-XL® )|Patients who are asymptomatic with normal left ventricular systolic function and wish to be medically treated for severe primary mitral regurgitation with Beta-blocker.
459232|NCT00700908|Behavioral|automated telephone intervention vs. usual care|
459233|NCT00700895|Drug|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
459234|NCT00700882|Drug|dasatinib|
459235|NCT00700882|Other|laboratory biomarker analysis|
459236|NCT00700869|Procedure|mechanical ventilation|mechanical ventilation
459237|NCT00700856|Drug|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
459238|NCT00700856|Drug|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
459239|NCT00700830|Drug|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
459240|NCT00700817|Drug|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
459241|NCT00700817|Drug|sitagliptin|Tablets, 100 mg daily
459242|NCT00700817|Drug|metformin|Tablets, minimum 1500 mg daily
459243|NCT00700817|Drug|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
459244|NCT00700804|Behavioral|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
459245|NCT00700804|Behavioral|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
459246|NCT00700791|Dietary Supplement|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
459247|NCT00700791|Device|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
459248|NCT00700791|Other|Placebo|Oral Placebo
459249|NCT00700791|Other|Placebo Cream|Topical Placebo Cream
459250|NCT00700778|Biological|recombinant human chorionic gonadotropin|
459251|NCT00700778|Genetic|microarray analysis|
459252|NCT00700778|Other|immunohistochemistry staining method|
459253|NCT00700778|Other|laboratory biomarker analysis|
459254|NCT00700778|Procedure|needle biopsy|
459255|NCT00700765|Drug|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
459256|NCT00700752|Device|senofilcon A|silicone hydrogel contact lens
459257|NCT00700752|Device|balafilcon A|silicone hydrogel contact lens
459258|NCT00700739|Device|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
459259|NCT00700739|Device|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
459260|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
459261|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
459262|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
459263|NCT00700700|Device|Active Cardiac Resynchronization Therapy (CRT)|"Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~Insync Sentry 7298 & 7299~Concerto C174 ASK (Most frequently implanted)~Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~Contak Renewal 4 H190 & H199~Contak Renewal 3 H127~Devices by ELA/Sorin:~1. Ovatio CRT 6750"
459264|NCT00700687|Drug|PA32540|aspirin/omeprazole
459265|NCT00700687|Drug|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
459266|NCT00700687|Drug|aspirin and [NSAID]|aspirin and [NSAID]
459267|NCT00700661|Drug|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
459268|NCT00700661|Drug|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
459269|NCT00700648|Drug|insulin aspart|Intravenous NovoRapid dose & frequency as decided by treating physician
459270|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
459271|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
459272|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
459273|NCT00700622|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
459274|NCT00700622|Drug|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
459275|NCT00700622|Drug|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
459276|NCT00700609|Behavioral|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
459277|NCT00700596|Drug|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
459278|NCT00700596|Drug|Placebo|Control or Placebo SA (30 % ethanolic solution)
459279|NCT00700583|Drug|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
459280|NCT00700570|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
459281|NCT00700570|Drug|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
459282|NCT00700570|Drug|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
459283|NCT00700557|Dietary Supplement|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
459284|NCT00700557|Dietary Supplement|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
459285|NCT00700544|Drug|chemotherapy treatment (see arm) + norethandrolone|"oral form~Dosage:~10 mg in patients with a weight < 60 kgs 20 mg in patients with a weight > 60 kgs frequency: every day Duration: 2 years"
459286|NCT00700544|Drug|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
459328|NCT00700271|Drug|Amlodipine|5 mg or 10 mg tablets.
459287|NCT00700531|Device|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
459288|NCT00700531|Procedure|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
459289|NCT00700518|Drug|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
459290|NCT00700518|Drug|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
459291|NCT00700518|Drug|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
459292|NCT00700518|Drug|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
459293|NCT00700518|Drug|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
459294|NCT00700505|Device|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding."
459295|NCT00700492|Drug|progesterone|vaginal capsules 3X200mg daily
459296|NCT00700479|Drug|aldosterone|4 hour infusion
459297|NCT00700479|Dietary Supplement|low or high sodium diet|
459298|NCT00700479|Drug|placebo|placebo
459299|NCT00700466|Drug|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
459300|NCT00700453|Behavioral|Control group with no video game play|Subjects will abstain from all video game play during study participation.
459301|NCT00700453|Behavioral|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
459302|NCT00700453|Behavioral|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
459303|NCT00700453|Behavioral|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
459304|NCT00700440|Drug|C225 (cetuximab)|one week before and then weekly during radiotherapy
459305|NCT00700427|Drug|atomoxetine hydrochloride|Oral 40-100 mg/day
459306|NCT00700427|Drug|Placebo|Oral delivery of matching placebo
459307|NCT00700401|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
459308|NCT00700401|Drug|ribavirin [Copegus]|800mg po daily for 24 weeks
459309|NCT00700388|Device|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
459310|NCT00700388|Procedure|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
459311|NCT00700375|Drug|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
459312|NCT00700375|Drug|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
459313|NCT00700362|Procedure|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
459314|NCT00700362|Procedure|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
459315|NCT00700349|Other|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
459316|NCT00700336|Drug|pemetrexed, cisplatin and CBP501|"CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
459317|NCT00700336|Drug|pemetrexed and cisplatin|"Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
459318|NCT00700323|Dietary Supplement|PS-Omega3 conjugate supplementation|
459319|NCT00700323|Dietary Supplement|placebo|
459320|NCT00700310|Drug|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
459321|NCT00700310|Drug|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
459322|NCT00700310|Drug|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
459323|NCT00700310|Drug|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
459324|NCT00700297|Drug|Colchicine|100 mg Colchicine per day for 4 months
459325|NCT00700297|Drug|Placebo|One tablet placebo per day for 4 months
459326|NCT00700284|Drug|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
459327|NCT00700284|Drug|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
459329|NCT00700271|Drug|Valsartan|160 mg capsules.
459330|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
459331|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
459332|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
459333|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
459334|NCT00700258|Drug|Axitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
459335|NCT00700245|Behavioral|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
459336|NCT00700245|Behavioral|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
459337|NCT00700245|Behavioral|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
459338|NCT00700206|Drug|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.~Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
459339|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
459340|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
459341|NCT00700180|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
459342|NCT00700180|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
459343|NCT00700180|Drug|Carboplatin-based chemotherapy|As prescribed
459344|NCT00700167|Biological|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
459345|NCT00700154|Procedure|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
459346|NCT00700128|Drug|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
459347|NCT00700128|Drug|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
459348|NCT00700128|Drug|placebo|placebo
459349|NCT00700115|Drug|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
459350|NCT00700115|Drug|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
459351|NCT00700102|Drug|Chemotherapy|As prescribed
459352|NCT00700102|Drug|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
459353|NCT00700089|Behavioral|Assertive intervention|8-20 assertive contacts after suicide attempt
459354|NCT00700089|Other|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
459355|NCT00700076|Drug|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
459356|NCT00700076|Drug|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
459357|NCT00700063|Drug|PEP005 Topical Gel|0.005%, two days treatment
459358|NCT00700063|Drug|PEP005 Topical Gel|0.01%, two days treatment
459359|NCT00700063|Drug|PEP005 Topical Gel|0.015%, two days treatment
459360|NCT00700063|Drug|Vehicle gel|two days treatment
459361|NCT00700063|Drug|PEP005 Topical Gel|0.005%, three days treatment
459362|NCT00700063|Drug|PEP005 Topical Gel|0.01%, three days treatment
459363|NCT00700063|Drug|PEP005 Topical Gel|0.015%, three days treatment
459364|NCT00700063|Drug|Vehicle gel|three days treatment
459365|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 1 (females with cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, she will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
459413|NCT00699660|Behavioral|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
459414|NCT00699660|Behavioral|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
459366|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 2 (females without cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, she will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
459367|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 3 (males with cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, he will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
459368|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 4 (males without cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, he will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
459369|NCT00700037|Drug|high-dose atorvastatin|20mg/day
459370|NCT00700037|Drug|low-dose atorvastatin|5mg/day
459371|NCT00700024|Drug|Testim|50 mg/dose7day
459372|NCT00700024|Behavioral|Strength training|three times a week
459373|NCT00700024|Drug|placebo|placebo
459374|NCT00700011|Drug|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
459375|NCT00700011|Drug|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
459376|NCT00699998|Drug|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
459377|NCT00699998|Drug|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
459378|NCT00699998|Drug|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
459379|NCT00699972|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
459380|NCT00699972|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
459381|NCT00699972|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
459382|NCT00699946|Drug|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
459383|NCT00699946|Drug|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
459384|NCT00699933|Other|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
459385|NCT00699920|Drug|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
459386|NCT00699920|Drug|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
459387|NCT00699907|Drug|flutamide|Patients receive oral flutamide (125 MG/DAY) once daily for 6 weeks in the absence of unacceptable toxicity.
459388|NCT00699894|Drug|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
459389|NCT00699894|Drug|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
459390|NCT00699881|Drug|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
459391|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
459392|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
459393|NCT00699842|Drug|Lenalidomide|"Dose Level Lenalidomide Schedule~15mg/day for d1-21 out of 28 days~20mg/day for d1-21 out of 28 days~25mg/day for d1-21 out of 28 days"
459394|NCT00699816|Biological|Immuncell-LC|Activated T lymphocyte
459395|NCT00699803|Drug|T-PRED|sterile ophthalmic solution at the first time point
459396|NCT00699803|Drug|T-PRED|sterile ophthalmic solution at the second time point
459397|NCT00699803|Drug|Pred Forte|sterile ophthalmic solution at the first time point
459398|NCT00699803|Drug|Pred Forte|sterile ophthalmic solution at the second time point
459399|NCT00699790|Drug|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
459400|NCT00699790|Drug|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
459401|NCT00699777|Drug|Risedronate|1 risedronate 150 mg tablet administered orally
459402|NCT00699777|Drug|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
459403|NCT00699764|Biological|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
459404|NCT00699764|Biological|Placebo injection|Intramuscular injection, 3 doses
459405|NCT00699751|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
459406|NCT00699751|Drug|Placebo|Isotonic saline 6 IV administrations separated by 4 weeks intervals.
459407|NCT00699751|Drug|Best standard of care (BSoC)|Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
459408|NCT00699738|Behavioral|Breastfeeding|Breastfeeding
459409|NCT00699738|Behavioral|Bottlefeeding|Bottlefeeding
459410|NCT00699712|Drug|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
459411|NCT00699686|Drug|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
459412|NCT00699686|Drug|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
459415|NCT00699634|Drug|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
459416|NCT00699621|Biological|platelets|Four units of fresh platelets will be infused immediately
459417|NCT00699608|Drug|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
459418|NCT00699582|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
459419|NCT00699582|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
459420|NCT00699582|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
459421|NCT00699569|Dietary Supplement|hyperimmune colostrum|hyperimmune colostrum
459422|NCT00699569|Dietary Supplement|Placebo|
459423|NCT00699556|Drug|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
459424|NCT00699556|Drug|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
459425|NCT00699556|Drug|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
459426|NCT00699543|Device|Coroflex Please stent implantation|Use Coroflex Please stent in the treatment of coronary stenosis
459427|NCT00699543|Device|Taxus stent implantation|Use Taxus stent in the treatment of coronary stenosis
459428|NCT00699530|Other|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
459429|NCT00699517|Drug|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
459430|NCT00699517|Drug|Placebo|I.V. infusion followed by administration of cisplatin
459431|NCT00699504|Drug|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
459432|NCT00699504|Drug|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
459433|NCT00699504|Drug|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
459434|NCT00699504|Drug|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
459435|NCT00699504|Drug|placebo|placebo IV and oral
459436|NCT00699491|Biological|Cixutumumab|Given IV
459437|NCT00699491|Other|Laboratory Biomarker Analysis|Correlative studies
459438|NCT00699491|Other|Pharmacological Study|Correlative studies
459439|NCT00699491|Drug|Temsirolimus|Given IV
459440|NCT00699478|Drug|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
459441|NCT00699465|Drug|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
459442|NCT00699465|Drug|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
459443|NCT00699452|Drug|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
459444|NCT00699452|Drug|placebo|placebo
459445|NCT00699439|Other|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
459446|NCT00699426|Drug|nexium|40 mg once daily is tested together with Yoghurt
459447|NCT00699426|Drug|nexium|nexium and placebo are tested
459448|NCT00699426|Dietary Supplement|Yoghurt|Yoghurt
459449|NCT00699426|Drug|placebo+placebo|placebo and placebo are tested.
459450|NCT00699413|Drug|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
459451|NCT00699413|Drug|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.~Active and inactive supplements will be identical in appearance and taste."
459452|NCT00699387|Drug|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
459453|NCT00699374|Drug|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
459454|NCT00699374|Drug|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
459455|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg I.V.
459456|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
459509|NCT00698932|Drug|Placebo|oral tablet, once daily for 24 weeks
459593|NCT00698230|Drug|INCB013739|INCB013739 15 mg QD tablet
459457|NCT00699348|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
459458|NCT00699335|Drug|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
459459|NCT00699322|Drug|Sitagliptin|100mg P.O. per day for 1month
459460|NCT00699322|Drug|Glimepiride|2mg P.O. per day for 1 month
459461|NCT00699296|Drug|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
459462|NCT00699283|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
459463|NCT00699283|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
459464|NCT00699244|Procedure|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
459465|NCT00699244|Procedure|Central placement of local anesthesia|Central placement of local anesthesia
459466|NCT00699231|Biological|HBV-MPL vaccine 208129|IM injection
459467|NCT00699231|Biological|Engerix™-B|IM injection
459468|NCT00699218|Device|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
459469|NCT00699192|Drug|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
459470|NCT00699192|Drug|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
459471|NCT00699192|Drug|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
459472|NCT00699192|Drug|Placebo|1 capsule placebo to match valsartan orally once daily
459473|NCT00699179|Drug|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
459474|NCT00699166|Drug|DNK333|25 mg and 100 mg oral doses, each taken twice daily
459475|NCT00699153|Drug|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
459476|NCT00699153|Drug|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
459477|NCT00699140|Biological|IGIV3I Grifols|Immune Globulin Intravenous (Human)
459478|NCT00699127|Behavioral|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
459479|NCT00699114|Drug|Placebo|Lactose as powder in gelatine capsules, single dose
459480|NCT00699114|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
459481|NCT00699114|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
459482|NCT00699114|Drug|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
459483|NCT00699114|Drug|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
459484|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
459485|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
459486|NCT00699101|Device|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
459487|NCT00699062|Drug|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
459488|NCT00699062|Drug|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
459489|NCT00699049|Drug|Alpha blocker|oral
459490|NCT00699049|Drug|placebo|oral
459491|NCT00699049|Drug|solifenacin|oral
459492|NCT00699036|Drug|avandia|4 mg twice daily
459493|NCT00699036|Drug|metformin|500 mg twice daily for 48 weeks
459494|NCT00699036|Drug|losartan|losartan 50 mg once daily
459495|NCT00699023|Drug|ezetimibe tablets|ezetimibe tablets 10 mg/die
459496|NCT00699023|Drug|simvastatin tablets|simvastatin tablets 20 mg/die
459497|NCT00699023|Drug|placebo|placebo
459498|NCT00699010|Drug|Acurox 5/30mg taken first|followed by oxycodone 5mg with 48 hour washout
459499|NCT00699010|Drug|Oxycodone 5mg taken first|followed by Acurox 5/30mg with 48 hour washout
459500|NCT00698997|Behavioral|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.~Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
459501|NCT00698997|Behavioral|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
459502|NCT00698984|Dietary Supplement|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
459503|NCT00698984|Dietary Supplement|Placebo|2 capsules per day over a period of 6 months
459504|NCT00698958|Procedure|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
459505|NCT00698958|Procedure|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
459506|NCT00698945|Drug|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
459507|NCT00698945|Drug|Alphagan|Alphagan: two drops a day for 28 days
459508|NCT00698932|Drug|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
459510|NCT00698919|Other|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision."
459511|NCT00698906|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
459512|NCT00698906|Biological|Engerix™-B|3-dose intramuscular injection
459513|NCT00698893|Biological|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
459514|NCT00698880|Procedure|Right hepatic vein embolization|Embolization of the right hepatic vein
459515|NCT00698854|Device|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
459516|NCT00698854|Device|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
459517|NCT00698841|Drug|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m^2 over 60 minutes.
459518|NCT00698828|Drug|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
459519|NCT00698828|Drug|SUN11031|Twice daily subcutaneous injections of SUN11031 for 12 weeks.
459520|NCT00698815|Other|Laboratory Biomarker Analysis|Correlative studies
459521|NCT00698815|Drug|Pemetrexed Disodium|Given IV
459522|NCT00698815|Drug|Sunitinib Malate|Given PO
459523|NCT00698802|Drug|EX1000|Treat-to-target titration scheme, s.c. injection
459524|NCT00698802|Drug|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
459525|NCT00698789|Drug|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
459526|NCT00698789|Drug|INCB019602|20 mg in AM with placebo administration in PM
459527|NCT00698789|Drug|INCB019602|5 mg in PM with placebo administration in AM
459528|NCT00698789|Drug|INCB019602|20 mg in PM with placebo administration in AM
459529|NCT00698789|Drug|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
459530|NCT00698789|Drug|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
459531|NCT00698789|Drug|Metformin|Stable dose metformin monotherapy
459532|NCT00698776|Drug|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
459533|NCT00698776|Biological|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
459534|NCT00698763|Drug|Levosimendan|from 0.125 mg to 2 mg in escalating doses
459535|NCT00698763|Drug|Placebo|Placebo capsules are identical in appearance to active capsules
459536|NCT00698724|Drug|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
459537|NCT00698724|Drug|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
459538|NCT00698711|Biological|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.~After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
459539|NCT00698685|Drug|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
459540|NCT00698685|Biological|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
459541|NCT00698685|Procedure|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
459542|NCT00698672|Device|charnley OGEE|charnley OGEE
459543|NCT00698672|Device|Spectron Reflection CoCr|Spectron Reflection CoCr
459544|NCT00698672|Device|Spectron XLPE CoCr|Spectron XLPE CoCr
459545|NCT00698672|Device|Spectron Reflection Oxinium|Spectron Reflection Oxinium
459546|NCT00698672|Device|Spectron XLPE CoCR|Spectron XLPE CoCR
459547|NCT00698646|Drug|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
459548|NCT00698646|Drug|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
459549|NCT00698646|Drug|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
459550|NCT00698607|Device|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
459551|NCT00698607|Device|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
459552|NCT00698607|Drug|6-month clopidogrel therapy|Use clopidogrel for 6 months
459553|NCT00698607|Drug|12-month clopidogrel therapy|Use clopidogrel for 12 months
459554|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
459555|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
459591|NCT00698243|Drug|OSI-027|Administered orally
459592|NCT00698230|Drug|INCB013739|INCB013739 5 mg QD tablet
459556|NCT00698594|Biological|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
459557|NCT00698581|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
459558|NCT00698581|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
459559|NCT00698568|Biological|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
459560|NCT00698568|Biological|Placebo|Intramuscular injection, 3 doses
459561|NCT00698555|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
459562|NCT00698555|Biological|Engerix™-B|3-dose intramuscular injection
459563|NCT00698529|Behavioral|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
459564|NCT00698529|Behavioral|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
459565|NCT00698529|Behavioral|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
459566|NCT00698516|Drug|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
459567|NCT00698490|Biological|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
459568|NCT00698490|Biological|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
459569|NCT00698464|Drug|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
459570|NCT00698451|Drug|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
459571|NCT00698438|Device|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.~X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.~XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.~XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.~XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
459572|NCT00698438|Procedure|Trabeculectomy|standard trabeculectomy
459573|NCT00698425|Other|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
459574|NCT00698425|Drug|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
459575|NCT00698412|Device|Cane|This group use the cane every day since the baseline
459576|NCT00698386|Dietary Supplement|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
459577|NCT00698386|Dietary Supplement|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
459578|NCT00698347|Device|M2a-Magnum™ Hip System|
459579|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
459580|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
459581|NCT00698321|Behavioral|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
459582|NCT00698321|Behavioral|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
459583|NCT00698282|Drug|AZD1981|Oral tablet, 250 mg single dose
459584|NCT00698282|Drug|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
459585|NCT00698282|Drug|Placebo|
459586|NCT00698269|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
459587|NCT00698269|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
459588|NCT00698269|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
459589|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
459590|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
459594|NCT00698230|Drug|INCB013739|INCB013739 50 mg QD tablet
459595|NCT00698230|Drug|INCB013739|INCB013739 100 mg QD tablet
459596|NCT00698230|Drug|INCB013739|INCB013739 200 mg QD
459597|NCT00698230|Drug|Placebo comparator matching INCB013739|Orally once daily tablet
459598|NCT00698230|Drug|Metformin|
459599|NCT00698204|Drug|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
459600|NCT00698204|Drug|placebo|Subject was asked to take placebo each day that radiation therapy was given.
459601|NCT00698191|Biological|Allogeneic MSC (AlloMSC)|"Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
459602|NCT00698178|Other|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
459603|NCT00698139|Device|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
459604|NCT00698126|Drug|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
459605|NCT00698126|Drug|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
459606|NCT00698113|Procedure|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.~Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
459607|NCT00698113|Other|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
459608|NCT00698100|Biological|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
459609|NCT00698100|Biological|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
459610|NCT00698087|Biological|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
459611|NCT00698087|Biological|Engerix™-B|Intramuscular injection, 2 or 3 doses
459612|NCT00698074|Device|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
459613|NCT00698061|Biological|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
459614|NCT00698061|Biological|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
459615|NCT00698035|Drug|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
459616|NCT00698035|Drug|Estring|2mg ring inserted vaginally once every 12 weeks
459617|NCT00698022|Drug|risperidone|daily risperidone plus mifepristone for 28 days
459618|NCT00698022|Drug|risperidone matched placebo|risperidone-matched placebo plus mifepristone daily for 28 days
459619|NCT00698022|Drug|risperidone-matched placebo|daily risperidone-matched placebo plus mifepristone for 28 days
459620|NCT00698022|Drug|Mifepristone-matched placebo|daily mifepristone-matched placebo for 28 days
459621|NCT00698009|Drug|Fludarabine|25 mg/m^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
459622|NCT00698009|Drug|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
459623|NCT00698009|Biological|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
459624|NCT00698009|Drug|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
459625|NCT00698009|Drug|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:~For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
459626|NCT00697996|Drug|Rituximab for transplant rejection|
459627|NCT00697970|Biological|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
459628|NCT00697970|Biological|Engerix™-B|Intramuscular injection, 3 doses
459629|NCT00697957|Behavioral|Exercise|Progressive impact exercise
459630|NCT00697944|Drug|Amphotericine in liposome (Ambisome®)|2 IV infusions separated by one week 10 mg/kg per injection
459631|NCT00697931|Biological|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
459632|NCT00697931|Biological|Engerix™-B|Intramuscular injection, 3 doses
459633|NCT00697918|Drug|RWJ-333369|100 mg to 400 mg twice daily
459634|NCT00697905|Drug|Gemcitabine|Intravenous administration on days 1, 8 of a 21-day cycle
459635|NCT00697905|Drug|Carboplatin|Intravenous following Gemcitabine infusion on day 1
459636|NCT00697905|Drug|Cisplatin|Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle
459637|NCT00697905|Drug|5-fluorouracil (5-FU)|Intravenous infusion on day 2 to day 5
459638|NCT00697892|Drug|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
459639|NCT00697892|Drug|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
459640|NCT00697892|Drug|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
459641|NCT00697879|Drug|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
459642|NCT00697866|Biological|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
459643|NCT00697866|Biological|Engerix™-B|3-dose intramuscular injection
459644|NCT00697853|Biological|Engerix™-B|3-dose intramuscular injection
459645|NCT00697853|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
459646|NCT00697840|Biological|Engerix™-B|Intramuscular injection, 2 doses
459647|NCT00697840|Biological|HBV-MPL 208129|Intramuscular injection, 2 doses
459648|NCT00697840|Biological|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
459649|NCT00697827|Device|Interspinous Spacer device|Device: In-Space
459650|NCT00697827|Device|Interspinous Process Distraction Device|Device: X STOP
459651|NCT00697814|Drug|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
459652|NCT00697801|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
459653|NCT00697801|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
459654|NCT00697801|Drug|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
459655|NCT00697788|Drug|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
459656|NCT00697775|Biological|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
459657|NCT00697775|Biological|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
459658|NCT00697775|Biological|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
459659|NCT00697762|Drug|RWJ-333369|200 mg tablet twice daily for 12 weeks
459660|NCT00697762|Drug|RWJ-333369|100 mg tablet twice daily for 12 weeks
459661|NCT00697762|Drug|Placebo|Placebo tablet twice daily for 12 weeks
459662|NCT00697749|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
459663|NCT00697749|Biological|Engerix™-B|3-dose intramuscular injection
459664|NCT00697736|Procedure|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
459665|NCT00697723|Procedure|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
459666|NCT00697710|Drug|50 mg S-777469|S-777469, 50 mg BID
459667|NCT00697710|Drug|200 mg S-777469|S-777469, 200 mg BID
459668|NCT00697710|Drug|800 mg S-777469|S-777469, 800 mg BID
459669|NCT00697710|Drug|Placebo|Matching Placebo
459670|NCT00697697|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
459671|NCT00697697|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
459672|NCT00697684|Drug|Antithymocyte Globulin|
459673|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
459674|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
459675|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
459676|NCT00697671|Other|NK Cell Infusion|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
459677|NCT00697671|Biological|Immunotherapy|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
459678|NCT00697671|Device|Miltenyi Biotec CliniMACS device|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
459679|NCT00697671|Drug|Interleukin-2 (IL-2)|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
459680|NCT00697671|Drug|Clofarabine|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
459681|NCT00697671|Drug|Cyclophosphamide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
459682|NCT00697671|Drug|Etoposide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
459683|NCT00697658|Drug|Paliperidone ER|6 mg tablet once daily, variable treatment length.
459684|NCT00697645|Device|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
459685|NCT00697645|Device|Brainsway Deep TMS|Deep TMS applied over the motor strip
459686|NCT00697632|Drug|MGCD265|Oral daily administration without interruption
459687|NCT00697619|Drug|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
459688|NCT00697606|Device|Seprafilm®|Seprafilm® placed at time of primary cesarean
459689|NCT00697606|Other|Control|no Seprafilm® used at primary cesarean
459690|NCT00697593|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
459691|NCT00697580|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
459692|NCT00697580|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
459693|NCT00697580|Behavioral|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
459694|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
459695|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
459696|NCT00697554|Biological|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
459697|NCT00697554|Biological|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
459698|NCT00697541|Drug|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
459699|NCT00697541|Drug|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
459700|NCT00697541|Drug|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
459701|NCT00697541|Drug|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
459702|NCT00697515|Drug|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
459703|NCT00697515|Drug|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
459704|NCT00697502|Drug|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.~Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
459705|NCT00697489|Procedure|correction of POP plus preventive continence procedure|
459706|NCT00697489|Procedure|POP surgery followed by eventual incontinence procedure|
459707|NCT00697476|Drug|topotecan, vorinostat|"Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.~Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal."
459708|NCT00697463|Drug|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily
459709|NCT00697450|Drug|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
459710|NCT00697437|Drug|Docetaxel|70mg q3wx 1 dose
459711|NCT00697437|Drug|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
459712|NCT00697424|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
459713|NCT00697398|Other|Transcranial stimulation|Stimulation to white
459714|NCT00697398|Other|Transcranial stimulation|Repetitive transcranial magnetic stimulation (rTMS)
459715|NCT00697385|Drug|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
459716|NCT00697372|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
459717|NCT00697372|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
459718|NCT00697359|Device|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
459719|NCT00697346|Drug|Alisertib|Alisertib (MLN8237) PIC or ECT
459720|NCT00697333|Procedure|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
459721|NCT00697320|Drug|eptacog alfa (activated)|"A NON INTERVENTIONAL OBSERVATIONAL STUDY:~Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation"
459722|NCT00697294|Dietary Supplement|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
459723|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 1"
459724|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 2"
459725|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 3"
459726|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days~Dose level 4"
459727|NCT00697281|Drug|Placebo|"Tablets twice daily for 8 days~Dose level 5"
459728|NCT00697255|Drug|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
459729|NCT00697255|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
459730|NCT00697255|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
459731|NCT00697255|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
459732|NCT00697242|Biological|Engerix™-B|Intramuscular injection, 3 doses
459733|NCT00697242|Biological|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
459734|NCT00697229|Biological|Engerix™-B|Intramuscular injection, 1 or 3 doses
459735|NCT00697229|Biological|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
459736|NCT00697216|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
459737|NCT00697216|Biological|Engerix™-B|3-dose intramuscular injection
459738|NCT00697203|Drug|Placebo|po daily for 12 weeks
459739|NCT00697203|Drug|Pravastatin|40mg po daily for 12 weeks
459740|NCT00697203|Drug|dalceptrapib|300mg po daily for 12 weeks
459741|NCT00697203|Drug|dalceptrapib|600mg po daily for 12 weeks
459742|NCT00697203|Drug|dalceptrapib|900mg po daily for 12 weeks
459743|NCT00697190|Device|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
459744|NCT00697190|Device|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
459745|NCT00697164|Drug|Placebo|Saline Admission, day 1, day 2 3 days
459746|NCT00697164|Drug|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
459747|NCT00697151|Drug|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
459748|NCT00697151|Drug|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
459749|NCT00697138|Drug|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
459750|NCT00697125|Biological|Engerix™-B|Intramuscular injection, 3 doses
459751|NCT00697125|Biological|HBV-MPL vaccine (208129)|
459752|NCT00697125|Biological|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
459753|NCT00697112|Drug|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
459754|NCT00697099|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
459755|NCT00697099|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
459756|NCT00697099|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component~Subcutaneous injection"
459757|NCT00697086|Drug|Dronedarone (SR33589)|
459758|NCT00697086|Drug|Placebo|
459759|NCT00697073|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
459760|NCT00697060|Drug|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
459761|NCT00697047|Behavioral|Automated Mailing|Usual Care plus Automated mailing
459762|NCT00697047|Behavioral|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
459763|NCT00697047|Behavioral|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
459764|NCT00697034|Drug|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
459765|NCT00697021|Drug|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
459766|NCT00697021|Drug|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
459767|NCT00696995|Drug|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
459768|NCT00696982|Drug|sitagliptin|sitagliptin 100 mg once daily for 3 months
459769|NCT00696982|Drug|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
459770|NCT00696969|Drug|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
459771|NCT00696969|Drug|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
459772|NCT00696969|Drug|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
459773|NCT00696969|Drug|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
459774|NCT00696956|Device|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
459775|NCT00696956|Device|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
459776|NCT00696943|Drug|([18F]-ML-10)|[18F]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of [18F]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
459777|NCT00696930|Drug|90Y-SMT487|
459778|NCT00696917|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
459779|NCT00696917|Biological|Engerix™-B|3-dose intramuscular injection
459780|NCT00696904|Drug|ABT-333|Capsule, see arms for intervention description
459781|NCT00696904|Drug|Placebo|Capsule, see arms for intervention description
459782|NCT00696891|Biological|HBV-MPL vaccine|3-dose intramuscular injection
459783|NCT00696891|Biological|Engerix™-B|3-dose intramuscular injection
459784|NCT00696878|Drug|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
459785|NCT00696878|Biological|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
459786|NCT00696878|Biological|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
459787|NCT00696878|Biological|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
459788|NCT00696878|Drug|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
459789|NCT00696865|Drug|AZD2624|oral suspension, 3 doses
459790|NCT00696865|Drug|Placebo|
459791|NCT00696852|Behavioral|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
459792|NCT00696852|Behavioral|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
459793|NCT00696852|Behavioral|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
459794|NCT00696839|Behavioral|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
459795|NCT00696826|Drug|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
459796|NCT00696800|Drug|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
459797|NCT00696800|Biological|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
459798|NCT00696800|Drug|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
459799|NCT00696800|Drug|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
459800|NCT00696800|Biological|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
459801|NCT00696800|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
459802|NCT00696800|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
459803|NCT00696800|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
459804|NCT00696787|Drug|Desvenlafaxine Sustained Release (DVS SR)|
459805|NCT00696787|Drug|Lyrica® (Pregabalin)|
459806|NCT00696787|Drug|Placebo|
459807|NCT00696774|Drug|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.~Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
459808|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
459809|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
459810|NCT00696761|Drug|alfuzosin|10mg, once daily, 12 months
459811|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
459812|NCT00696748|Drug|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
459813|NCT00696748|Drug|Placebo|Placebo 4 mL intramuscular
459814|NCT00696735|Procedure|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
459815|NCT00696735|Procedure|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
459816|NCT00696722|Drug|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second~4 day treatment"
459817|NCT00696722|Drug|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second~4 day treatment"
459818|NCT00696709|Biological|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered ~30 days apart
459819|NCT00696709|Biological|Comparator: Placebo|Placebo; 4-dose regimen administered ~30 days apart.
459820|NCT00696696|Drug|Gemcitabine|1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
459821|NCT00696696|Drug|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
459822|NCT00696696|Drug|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
459823|NCT00696683|Other|None, this is an observational study|
459824|NCT00696657|Drug|semaglutide|0.1 mg, once weekly, s.c. injection
459825|NCT00696657|Drug|semaglutide|0.2 mg, once weekly, s.c. injection
459826|NCT00696657|Drug|semaglutide|0.4 mg, once weekly, s.c. injection
459827|NCT00696657|Drug|semaglutide|0.8 mg, once weekly, s.c. injection
459828|NCT00696657|Drug|semaglutide|0.8 mg with titration, once weekly, s.c. injection
459829|NCT00696657|Drug|semaglutide|1.6 mg with titration, once weekly, s.c. injection
459830|NCT00696657|Drug|placebo|0.1 mg, once weekly, s.c. injection
459831|NCT00696657|Drug|placebo|0.2 mg, once weekly, s.c. injection
459832|NCT00696657|Drug|placebo|0.4 mg, once weekly, s.c. injection
459833|NCT00696657|Drug|placebo|0.8 mg with titration, once weekly, s.c. injection
459834|NCT00696657|Drug|placebo|1.6 mg, once weekly, s.c. injection
459835|NCT00696657|Drug|liraglutide|1.2 mg with titration, once daily, s.c. injection
459836|NCT00696657|Drug|liraglutide|1.8 mg with titration, once daily, s.c. injection
459837|NCT00696644|Drug|Teriparatide|20 mcg daily subcutaneous for 18 months.
459838|NCT00696631|Drug|Dronedarone (SR33589)|oral administration
459839|NCT00696631|Drug|Placebo|oral administration
459840|NCT00696618|Drug|Fleet Enema|hyper-osmolar preparation
459841|NCT00696618|Drug|tap water enema|hypo-osmolar preparation
459842|NCT00696618|Drug|Normosol-R enema|iso-osmolar preparation
459843|NCT00696592|Drug|Bevacizumab (Avastin), Verteporfin (Visudyne)|
459844|NCT00696579|Drug|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
459845|NCT00696579|Drug|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
459846|NCT00696566|Drug|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days~Rifampicin: 300 mg b.d. for up to 28 days"
459847|NCT00696553|Other|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
459848|NCT00696553|Behavioral|Nutrition plus Exercise|Nutrition plus Exercise
459849|NCT00696540|Drug|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
459850|NCT00696540|Drug|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
459851|NCT00696514|Dietary Supplement|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
459852|NCT00696514|Dietary Supplement|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
459853|NCT00696488|Drug|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
459854|NCT00696475|Drug|Diazoxide choline|
459855|NCT00696475|Drug|Diazoxide choline|
459856|NCT00696475|Drug|Diazoxide choline|
459857|NCT00696475|Drug|Placebo|
459858|NCT00696462|Device|forced-air warming|forced-air warming device
459859|NCT00696449|Drug|Adapalene|All Subjects will treat the face once daily in the evening.
459894|NCT00696215|Drug|placebo|Placebo 1 mg once a day
459860|NCT00696449|Behavioral|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
459861|NCT00696449|Behavioral|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
459862|NCT00696449|Behavioral|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
459863|NCT00696449|Behavioral|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
459864|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.~Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
459865|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.~Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
459866|NCT00696436|Drug|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.~Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
459867|NCT00696436|Drug|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.~Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
459868|NCT00696436|Drug|Placebo|Matching placebo, orally, once daily for up to six weeks.
459869|NCT00696423|Biological|Infanrix™|Intramuscular injection, one dose
459870|NCT00696423|Biological|Hiberix™|Intramuscular injection, one dose
459871|NCT00696410|Drug|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels ~10-12.
459872|NCT00696384|Drug|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and <130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.~Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
459873|NCT00696384|Drug|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
459874|NCT00696384|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
459875|NCT00696358|Radiation|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
459876|NCT00696358|Radiation|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
459877|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
459878|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
459879|NCT00696332|Other|placebo|capsules, placebo, 3 times a day, for 52 weeks
459880|NCT00696319|Other|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
459881|NCT00696319|Other|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
459882|NCT00696293|Drug|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
459883|NCT00696280|Behavioral|Functional Living Index - Emesis|
459884|NCT00696254|Behavioral|Nerve excitability measurement|
459885|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
459886|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
459887|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
459888|NCT00696241|Drug|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
459889|NCT00696241|Drug|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
459890|NCT00696228|Dietary Supplement|Placebo|Placebo
459891|NCT00696228|Dietary Supplement|MUFA|MUFA
459892|NCT00696228|Dietary Supplement|PUFA|PUFA
459893|NCT00696228|Dietary Supplement|SFA|SFA
459896|NCT00696202|Drug|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
459897|NCT00696176|Drug|STAT 3 DECOY|single administration to a head and neck tumor
459898|NCT00696163|Drug|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
459899|NCT00696150|Procedure|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
459900|NCT00696150|Procedure|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
459901|NCT00696150|Procedure|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
459902|NCT00696137|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
459903|NCT00696124|Biological|VM202 2mg|2mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
459904|NCT00696124|Biological|VM202 4mg|4mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
459905|NCT00696124|Biological|VM202 8mg|8mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
459906|NCT00696124|Biological|VM202 16mg|16mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
459907|NCT00696111|Drug|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
459908|NCT00696111|Drug|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
459909|NCT00696111|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
459910|NCT00696098|Other|sodium butyrate|1 enema (60 ml) once daily containing 100mM
459911|NCT00696098|Other|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
459912|NCT00696085|Behavioral|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
459913|NCT00696072|Drug|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
459914|NCT00696072|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
459915|NCT00696059|Drug|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
459916|NCT00696046|Procedure|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical & steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
459917|NCT00696033|Drug|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
459918|NCT00696033|Drug|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
459919|NCT00696033|Drug|placebo|lorazépam placebo or Diazépam placebo
459920|NCT00696020|Drug|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
459921|NCT00696020|Drug|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
459922|NCT00696020|Device|Respimat® Inhaler|
459923|NCT00696007|Drug|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
459924|NCT00696007|Other|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
459925|NCT00695994|Drug|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
459926|NCT00695994|Drug|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.~Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.~Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.~Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
459927|NCT00695981|Procedure|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
459928|NCT00695981|Procedure|Conservative treatment|Physiotherapy according to a standardized protocol
459929|NCT00695955|Drug|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
459981|NCT00695409|Drug|cytarabine|Given IV
459930|NCT00695955|Drug|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
459931|NCT00695929|Drug|Levosimendan|Intravenous injection
459932|NCT00695929|Drug|Milrinone|Intravenous injection
459933|NCT00695916|Procedure|Breast MRI|
459934|NCT00695903|Drug|daptomycin|daptomycin 10 mg/kg IV every 24 hours
459935|NCT00695903|Drug|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
459936|NCT00695877|Biological|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
459937|NCT00695864|Drug|Ondansetron and Placebo crossover|
459938|NCT00695851|Drug|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
459939|NCT00695851|Drug|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
459940|NCT00695825|Dietary Supplement|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
459941|NCT00695825|Dietary Supplement|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
459942|NCT00695786|Drug|Lenalidomide|Given PO
459943|NCT00695786|Biological|Rituximab|Given IV
459944|NCT00695747|Procedure|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
459945|NCT00695708|Behavioral|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
459946|NCT00695708|Behavioral|Cogpack|Computer-aided cognitive program for cognitive abilities
459947|NCT00695682|Drug|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
459948|NCT00695669|Biological|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
459949|NCT00695643|Drug|Mesalazine|3 g per day
459950|NCT00695643|Drug|Placebo|0 g per day
459951|NCT00695630|Drug|Flumazenil|2 mL, 0.2 mg SM
459952|NCT00695630|Drug|Placebo|2 mL sterile saline SM
459953|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
459954|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
459955|NCT00695604|Drug|Placebo|Placebo via MDI.
459956|NCT00695604|Drug|Fluticasone|Fluticasone MDI.
459957|NCT00695591|Other|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
459958|NCT00695578|Drug|Biafine|Apply to wounds 3 times daily for 4 weeks: ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
459959|NCT00695578|Drug|Polysporin|over the counter Polysporin ointment 3 times daily for 4 weeks to wounds
459960|NCT00695565|Drug|Placebo Gel|TID x 12 weeks
459961|NCT00695565|Drug|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
459962|NCT00695552|Behavioral|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
459963|NCT00695552|Behavioral|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
459964|NCT00695526|Dietary Supplement|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
459965|NCT00695513|Dietary Supplement|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
459966|NCT00695500|Drug|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
459967|NCT00695500|Drug|Placebo|Placebo tablets, 0 mg per day for 3 weeks
459968|NCT00695487|Drug|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
459969|NCT00695461|Dietary Supplement|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
459970|NCT00695461|Dietary Supplement|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
459971|NCT00695448|Drug|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
459972|NCT00695435|Drug|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
459973|NCT00695435|Drug|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
459974|NCT00695435|Drug|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
459975|NCT00695422|Genetic|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
459976|NCT00695422|Other|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
459977|NCT00695422|Other|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
459978|NCT00695422|Procedure|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
459979|NCT00695409|Biological|rituximab|Given IV
459980|NCT00695409|Drug|carmustine|Given IV
459984|NCT00695409|Procedure|ASCT|Undergo autologous peripheral blood stem cell transplant
459985|NCT00695409|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
459986|NCT00695396|Drug|Placebo|Matching volume 2 mLfor 48 weeks
459987|NCT00695396|Drug|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
459988|NCT00695396|Drug|Placebo|Matching volume 1 mL for 48 weeks
459989|NCT00695396|Drug|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
459990|NCT00695383|Behavioral|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
459991|NCT00695383|Behavioral|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
459992|NCT00695370|Drug|Pegfilgrastim (drug)|
459993|NCT00695344|Drug|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
459994|NCT00695344|Drug|azathioprine or mycophenolate mofetil|2 times per day during 2 years
459995|NCT00695331|Drug|Misoprostol|Titrated Misoprostol Solution
459996|NCT00695331|Drug|Oxytocin|Titrated Intravenous Oxytocin
459997|NCT00695318|Drug|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
459998|NCT00695318|Drug|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
459999|NCT00695305|Drug|rilapladib|250 mg oral dose once daily
460000|NCT00695305|Drug|placebo|placebo
460001|NCT00695305|Other|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
460002|NCT00695292|Drug|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
460003|NCT00695292|Drug|Carboplatin|carboplatin AUC=4 on Day 1
460004|NCT00695292|Drug|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
460005|NCT00695279|Procedure|Venipuncture|Blood draw
460006|NCT00695253|Device|Endoluminal treatment of abdominal aortic aneurysms using the Medtronic/Talent Stent Graft|Stent-graft for AAA
460007|NCT00695240|Device|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
460008|NCT00695227|Diagnostic Test|Screening for Barrett's Esophagus|
460009|NCT00695214|Drug|Propofol sedation|Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
460010|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
460011|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
460012|NCT00695188|Drug|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
460013|NCT00695188|Drug|methotrexate|25 mg oral administration
460014|NCT00695162|Other|quiet|no noise
460015|NCT00695162|Other|non-speech noise|noise without speech
460016|NCT00695162|Other|speech noise|noise with speech present
460017|NCT00695149|Procedure|Transplantation of bone marrow stromal cell|
460018|NCT00695136|Drug|Donepezil hydrochloride|
460019|NCT00695136|Behavioral|Increase REM sleep percentage|
460020|NCT00695110|Drug|Testosterone undecanoate (TU)|300 mg T equivalents BID for 7 days
460021|NCT00695110|Drug|TU + testosterone enanthate (TE)|400 mg T equivalents BID for 7 days
460022|NCT00695110|Drug|Testosterone undecanoate (TU)|200 mg T equivalents BID for 8 days; pharmacokinetics determined when oral TU administered with and without food.
460023|NCT00695110|Drug|TU + testosterone enanthate (TE)|300 mg T equivalents BID for 7 days
460024|NCT00695097|Drug|Rituximab|Rituximab infusion on Day 1 and Day 15
460025|NCT00695097|Drug|No Rituximab|No Rituximab
460026|NCT00695084|Behavioral|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
460027|NCT00695071|Drug|Itraconazole|Oral
460028|NCT00695058|Device|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.~In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).~A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.~In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
460029|NCT00695045|Drug|intra thecal morphine|100 mcg intrathecal morphine given once .
460030|NCT00695045|Drug|intra thecal morphine|200 mcg intrathecal morphine given once
460031|NCT00695045|Drug|intra thecal morphine|300 mcg intrathecal morphine given once
460032|NCT00695032|Drug|cisplatin|
460033|NCT00695032|Drug|ifosfamide|
460034|NCT00695032|Other|laboratory biomarker analysis|
460035|NCT00695019|Drug|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
460036|NCT00695019|Drug|placebo lozenges|200 mg matching placebo lozenges
460037|NCT00695006|Other|Sham Traction|Traction <5lbs
460038|NCT00695006|Other|Traction|Standard supine intermittent traction
460039|NCT00694993|Drug|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
460040|NCT00694993|Drug|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
460041|NCT00694980|Drug|placebo|Intravenous and subcutaneous escalating doses
460042|NCT00694980|Drug|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
460043|NCT00694967|Procedure|McDonald cerclage placement|Transcervical McDonald cerclage placement
460044|NCT00694967|Drug|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
460045|NCT00694954|Device|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.~Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
460046|NCT00694954|Other|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
460047|NCT00694941|Drug|ONO-2506PO|1200mg QD / 5 years
460048|NCT00694928|Drug|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
460049|NCT00694928|Drug|butoconazole nitrate|semi-solid, single dose
460050|NCT00694915|Biological|Mycobacterium w|Immunomodulator
460051|NCT00694915|Biological|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
460052|NCT00694902|Drug|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
460053|NCT00694902|Drug|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
460054|NCT00694889|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
460055|NCT00694889|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
460056|NCT00694863|Drug|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
460057|NCT00694850|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
460058|NCT00694837|Drug|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
460059|NCT00694811|Behavioral|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
460060|NCT00694798|Biological|Mycobacterium w|Immunomodulator
460061|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.~Group NT3"
460062|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.~Group T3"
460063|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.~Group NT6"
460064|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.~Group T6"
460065|NCT00694772|Procedure|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
460066|NCT00694772|Procedure|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
460067|NCT00694759|Drug|pioglitazone|30 mg for 2 weeks, then 45 mg daily
460068|NCT00694759|Drug|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
460069|NCT00694759|Drug|placebo|capsule twice daily
460070|NCT00694746|Drug|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
460071|NCT00694746|Drug|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
460072|NCT00694733|Drug|Placebo injection|Normal saline injection IM monthly for 4 months
460073|NCT00694733|Drug|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
460074|NCT00694733|Drug|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
460075|NCT00694733|Drug|placebo|Placebo Cream 1ml applied twice daily for four months
460076|NCT00694733|Drug|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
460077|NCT00694720|Drug|AVE0657|capsules once a day at bedtime
460078|NCT00694720|Drug|placebo|capsules once a day at bedtime
460079|NCT00694707|Drug|Placebo|Placebo was supplied in capsules.
460080|NCT00694707|Drug|Cariprazine|Cariprazine was supplied in capsules
460081|NCT00694707|Drug|Risperidone|Risperidone was supplied in capsules
460338|NCT00692757|Drug|Iodopovidone|Iodopovidone
460082|NCT00694694|Drug|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
460083|NCT00694694|Drug|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.~For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
460084|NCT00694681|Behavioral|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
460085|NCT00694668|Behavioral|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
460086|NCT00694668|Behavioral|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
460087|NCT00694655|Biological|Yellow fever vaccine|YFV will be given as injection
460088|NCT00694642|Biological|Selected CD 133+ cells|Endothelial progenitor cell CD 133
460089|NCT00694629|Drug|rifampin|tablet, 10 mg/kg, daily, 8 weeks
460090|NCT00694629|Drug|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
460091|NCT00694629|Drug|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
460092|NCT00694629|Drug|rifapentine|20 mg/kg, daily, 8 weeks
460093|NCT00694616|Device|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
460094|NCT00694616|Device|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
460095|NCT00694603|Drug|Cetuximab|Given intravenously once per week.
460096|NCT00694590|Drug|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
460097|NCT00694577|Radiation|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
460098|NCT00694577|Radiation|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
460099|NCT00694577|Radiation|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
460100|NCT00694564|Drug|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
460101|NCT00694551|Biological|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
460102|NCT00694551|Drug|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
460103|NCT00694538|Device|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
460104|NCT00694512|Dietary Supplement|Low fat diet|20% fat diet
460105|NCT00694512|Dietary Supplement|High fat diet|40% fat diet
460106|NCT00694512|Dietary Supplement|MCT diet|Medium chain triglyceride diet
460107|NCT00694473|Device|Freestyle Navigator|Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
460108|NCT00694460|Biological|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
460109|NCT00694460|Biological|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
460110|NCT00694460|Biological|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
460111|NCT00694460|Biological|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
460112|NCT00694460|Biological|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
460113|NCT00694447|Procedure|Acupuncture|
460114|NCT00694408|Drug|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
460115|NCT00694408|Other|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
460116|NCT00694382|Drug|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
460117|NCT00694382|Drug|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component~Subcutaneous injection"
460118|NCT00694369|Drug|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
460119|NCT00694369|Drug|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
460120|NCT00694369|Drug|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
460121|NCT00694369|Drug|Comparator: placebo|matching placebo over three Days
460122|NCT00694356|Biological|Dalotuzumab|IV infusion
460123|NCT00694343|Drug|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
460124|NCT00694343|Drug|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
460125|NCT00694330|Biological|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
460126|NCT00694317|Drug|Zaleplon|Short term treatment of insomnia
460127|NCT00694304|Drug|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
460128|NCT00694291|Drug|Sorafenib|400 mg orally twice daily
460129|NCT00694291|Drug|Placebo|Matching Placebo
460130|NCT00694265|Procedure|Decompression|Surgical decompression of the median nerve
460131|NCT00694265|Procedure|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
460132|NCT00694252|Drug|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
460133|NCT00694239|Behavioral|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
460134|NCT00694226|Behavioral|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
460135|NCT00694226|Behavioral|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
460136|NCT00694213|Biological|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
460137|NCT00694213|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
460138|NCT00694213|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
460139|NCT00694213|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
460140|NCT00694200|Drug|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
460141|NCT00694200|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
460142|NCT00694187|Drug|Zaleplon|
460143|NCT00694174|Drug|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
460144|NCT00694174|Drug|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
460145|NCT00694161|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
460146|NCT00694148|Drug|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins~Detailed described in study protocol"
460147|NCT00694135|Drug|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
460148|NCT00694135|Drug|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
460149|NCT00694135|Drug|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
460150|NCT00694135|Drug|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
460151|NCT00694122|Drug|Lantus (glargine)|Described in Arm Description
460152|NCT00694109|Drug|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
460153|NCT00694096|Drug|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.~Imaging studies include:~FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
460154|NCT00694083|Drug|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
460155|NCT00694057|Drug|HE3286|HE3286 10 mg per day (5 mg BID)
460156|NCT00694057|Drug|Placebo|Placebo capsules BID
460157|NCT00694044|Drug|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
460158|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
460159|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
460160|NCT00694044|Drug|Placebo|Placebo for 21 days
460161|NCT00694031|Procedure|Hemodialysis|3 times per week
460162|NCT00694031|Procedure|On-line hemodiafiltration|3 times per week
460163|NCT00694018|Other|Education and standard care|Educational program for individuals with chronic back pain.
460164|NCT00694018|Behavioral|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
460165|NCT00694005|Procedure|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
460166|NCT00694005|Procedure|"without kissing balloon angioplasty leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
460167|NCT00693992|Other|Laboratory Biomarker Analysis|Correlative studies
460168|NCT00693992|Other|Placebo|Given PO
460169|NCT00693992|Other|Quality-of-Life Assessment|Ancillary studies
460170|NCT00693992|Drug|Sunitinib Malate|Given PO
460171|NCT00693979|Device|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
460172|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
460173|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
460174|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
460175|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
460176|NCT00693940|Behavioral|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
460177|NCT00693940|Other|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
460178|NCT00693927|Procedure|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).~Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
460179|NCT00693927|Procedure|CD8-depleted PBSC after nonmyeloablative conditioning|
460180|NCT00693914|Behavioral|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
460181|NCT00693901|Behavioral|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
460182|NCT00693901|Behavioral|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
460183|NCT00693888|Behavioral|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
460184|NCT00693862|Drug|levodopa, carbidopa, entacapone|
460185|NCT00693862|Drug|levodopa, carbidopa|
460186|NCT00693849|Drug|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
460187|NCT00693849|Drug|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
460188|NCT00693849|Drug|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
460189|NCT00693836|Genetic|genetic linkage analysis|
460190|NCT00693836|Genetic|loss of heterozygosity analysis|
460191|NCT00693836|Genetic|mutation analysis|
460192|NCT00693836|Genetic|polymerase chain reaction|
460193|NCT00693836|Genetic|polymorphism analysis|
460194|NCT00693836|Other|biologic sample preservation procedure|
460195|NCT00693836|Other|medical chart review|
460196|NCT00693836|Other|questionnaire administration|
460197|NCT00693836|Procedure|evaluation of cancer risk factors|
460198|NCT00693823|Procedure|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
460199|NCT00693823|Device|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
460200|NCT00693784|Biological|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
460201|NCT00693771|Drug|Insulin Glargine|Once daily and up-titrate accordingly
460202|NCT00693758|Drug|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
460203|NCT00693758|Other|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
460204|NCT00693758|Other|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
460205|NCT00693758|Device|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
460206|NCT00693758|Device|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
460207|NCT00693732|Drug|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
460208|NCT00693732|Behavioral|Quantitative sensory testing|Rectal Distention Stimulation
460209|NCT00693719|Drug|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
460210|NCT00693719|Drug|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
460211|NCT00693706|Biological|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
460212|NCT00693706|Biological|Fluarix|IM injection on Day 0
460213|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
460214|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
460215|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
460216|NCT00693680|Dietary Supplement|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
460217|NCT00693680|Dietary Supplement|Placebo|placebo + imipramine (100-200mg/day)
460218|NCT00693667|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
460219|NCT00693654|Drug|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
460220|NCT00693654|Drug|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
460221|NCT00693641|Other|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
460222|NCT00693641|Other|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
460223|NCT00693628|Device|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
460224|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
460225|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
460226|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
460227|NCT00693602|Drug|Erwinase|Chemotherapy
460228|NCT00693589|Drug|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
460229|NCT00693576|Drug|simvastatin|20 mg simvastatin daily
460230|NCT00693563|Behavioral|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
460231|NCT00693550|Other|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
460232|NCT00693537|Behavioral|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
460233|NCT00693524|Drug|tacrolimus|oral
460234|NCT00693524|Drug|Anti-IL2R AB|i.v.
460235|NCT00693524|Drug|Mycophenolate mofetil|oral
460236|NCT00693524|Drug|prednisone|oral
460237|NCT00693511|Behavioral|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
460238|NCT00693511|Behavioral|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
460239|NCT00693498|Biological|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
460240|NCT00693498|Biological|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
460241|NCT00693485|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
460242|NCT00693485|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
460243|NCT00693485|Drug|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
460244|NCT00693472|Drug|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
460245|NCT00693472|Drug|Placebo|Matching placebo capsule administered orally every 12 hours
460246|NCT00693472|Drug|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.~Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
460247|NCT00693472|Drug|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
460248|NCT00693459|Device|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
460249|NCT00693446|Drug|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.~The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.~The dose of sirolimus will be administrated once a day."
460250|NCT00693446|Drug|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.~The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.~Patients receive also rATG , mycophenolate mofetil and corticosteroids."
460251|NCT00693433|Drug|dexamethasone|Given orally
460252|NCT00693433|Drug|temsirolimus|Given IV
460253|NCT00693433|Other|laboratory biomarker analysis|Correlative studies
460254|NCT00693420|Drug|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
460255|NCT00693420|Drug|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
460256|NCT00693407|Procedure|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS >30 is reported.
460257|NCT00693381|Drug|Tacrolimus|oral
460258|NCT00693381|Drug|Mycophenolate Mofetil|oral
460259|NCT00693381|Drug|methylprednisolone and prednisone|IV and oral
460260|NCT00693355|Other|Sodium butyrate|sodium butyrate
460261|NCT00693355|Other|NaCl|NaCl
460262|NCT00693342|Biological|immunological adjuvant OPT-821|Given subcutaneously
460263|NCT00693342|Biological|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
460264|NCT00693316|Drug|ORM-12741|Alternating panel single dose escalation.
460265|NCT00693303|Behavioral|Handwriting Training using My Scrivener|Subjects received 20 minutes of training per week which included writing letters and words with the My Scivener device.
460266|NCT00693290|Other|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
460267|NCT00693264|Dietary Supplement|Hoodia Gordonii|750 mg capsule will be taken one time
460268|NCT00693264|Dietary Supplement|Placebo|Placebo capsule to be taken one time
460269|NCT00693251|Procedure|Crush technique|Crush technique
460270|NCT00693251|Procedure|provisional T stenting|Provisional T stenting
460271|NCT00693238|Radiation|Low Risk Proton Radiation|
460272|NCT00693238|Radiation|Intermediate Risk Proton Radiation|
460273|NCT00693225|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
460274|NCT00693212|Drug|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
460275|NCT00693212|Drug|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
460276|NCT00693212|Drug|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
460277|NCT00693199|Drug|amlodipine|amlodipine 5mg once daily for 28 days
460278|NCT00693199|Drug|terazosin|terazosin 2 mg once daily for 28 days
460279|NCT00693199|Drug|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
460280|NCT00693186|Biological|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
460281|NCT00693186|Biological|Engerix B® 10 µg / 0.5 mL|10 µg
460282|NCT00693160|Drug|ketorolac|single intrathecal injection of ketorolac 2 mg
460283|NCT00693160|Drug|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
460284|NCT00693160|Drug|remifentanil|All subjects will receive a remifentanil infusion
460285|NCT00693160|Drug|Capsaicin|Topical capsaicin pain model utilized for each subject
460286|NCT00693147|Procedure|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
460287|NCT00693121|Drug|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
460288|NCT00693121|Drug|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
460289|NCT00693108|Drug|Transdermal testosterone|
460290|NCT00693095|Biological|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
460291|NCT00693095|Biological|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
460339|NCT00692731|Dietary Supplement|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
460292|NCT00693082|Dietary Supplement|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
460293|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
460294|NCT00693069|Drug|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
460295|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
460296|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
460297|NCT00693056|Drug|Placebo|Placebo (w/o API)
460298|NCT00693056|Drug|RX-10100 5mg|5 mg/dose of RX-10100
460299|NCT00693056|Drug|RX-10100 10mg|10 mg/dose of RX-10100
460300|NCT00693056|Drug|RX-10100 15mg|15 mg/dose of RX-10100
460301|NCT00693043|Drug|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
460302|NCT00693030|Device|sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)|comparison of multiple drug eluting stents
460303|NCT00693030|Device|paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)|comparison of multiple drug eluting coronary stents
460304|NCT00693030|Device|zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)|comparison of multiple drug eluting coronary stents
460305|NCT00693030|Device|Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)|comparison of DES in overlap vs BMS in overlap
460306|NCT00693017|Drug|Zonisamide|"50-400 mg capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
460307|NCT00693017|Drug|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.~Maximum study duration 28 weeks comprising:~Baseline Period (Week -8 to Week 0): no treatment~Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)~Down Titration Period (4 Weeks)"
460308|NCT00693004|Drug|PRX-03140|
460309|NCT00693004|Drug|Donepezil|
460310|NCT00693004|Drug|Placebo|
460311|NCT00692978|Drug|Fluticasone Propionate|Dose 50 micrograms (total dose), Monodisperse aerosol with diofferemt particle size of drug (1.5, 3.0, 6.0 microns), inhaled
460312|NCT00692978|Drug|Fluticasone Propionate|Inhaled, Metered dose inhaler, 250 micrograms dose (total dose)
460313|NCT00692952|Drug|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
460314|NCT00692952|Drug|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
460315|NCT00692939|Biological|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
460316|NCT00692939|Drug|Alemtuzumab|Transplant conditioning
460317|NCT00692939|Drug|ATG|Transplant conditioning
460318|NCT00692939|Drug|Melphalan|Transplant conditioning
460319|NCT00692939|Drug|Thiotepa|Transplant conditioning
460320|NCT00692939|Drug|Rituximab|Transplant conditioning
460321|NCT00692939|Drug|Cyclophosphamide|Mobilization
460322|NCT00692939|Drug|G-CSF|Mobilization
460323|NCT00692939|Drug|Mesna|Mobilization
460324|NCT00692926|Biological|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
460325|NCT00692913|Drug|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
460326|NCT00692913|Dietary Supplement|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg~calcium supplement) daily for 52 weeks (unless the patient's dietary intake of~calcium exceeds 1000 mg per day)."
460327|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
460328|NCT00692900|Drug|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
460329|NCT00692900|Drug|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
460330|NCT00692887|Device|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
460331|NCT00692848|Other|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
460332|NCT00692835|Procedure|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
460333|NCT00692835|Procedure|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
460334|NCT00692796|Other|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
460335|NCT00692770|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
460336|NCT00692770|Drug|Placebo|Placebo 2 tablets twice daily (BID)
460337|NCT00692757|Drug|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
460340|NCT00692731|Other|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
460341|NCT00692718|Drug|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
460342|NCT00692705|Drug|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
460343|NCT00692705|Drug|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
460344|NCT00692692|Procedure|DermaMatrix|experimental group with DermaMatrix acellular dermis over tissue expanders in addition to skin/soft tissue and muscle to allow for more natural appearing breast and prevention of complications
460345|NCT00692692|Procedure|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care using skin/soft tissue and muscle coverage of tissue expander for breast reconstruction after mastectomy without acellular dermal matrix
460346|NCT00692653|Behavioral|P4|Tailored online decision support system for prostate cancer treatment decision making
460347|NCT00692640|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
460348|NCT00692640|Drug|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
460349|NCT00692614|Drug|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
460350|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
460351|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
460352|NCT00692601|Dietary Supplement|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
460353|NCT00692575|Behavioral|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
460354|NCT00692575|Other|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
460355|NCT00692562|Procedure|simultaneous islet-kidney transplantation|
460356|NCT00692549|Device|ultrasound|
460357|NCT00692536|Behavioral|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
460358|NCT00692536|Behavioral|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
460359|NCT00692523|Other|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
460360|NCT00692523|Other|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
460361|NCT00692510|Drug|AZD3480|Capsule, oral, dose once daily, 7 days
460362|NCT00692510|Drug|Placebo|Capsule, oral, dose once daily, 7 days
460363|NCT00692510|Drug|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:~CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)~single dose of mix"
460364|NCT00692497|Behavioral|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
460365|NCT00692484|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
460366|NCT00692484|Drug|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
460367|NCT00692471|Device|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
460368|NCT00692458|Drug|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
460369|NCT00692458|Drug|Comparator: placebo|placebo; oral, once daily for approximately 60 months
460370|NCT00692445|Drug|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
460371|NCT00692445|Drug|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
460372|NCT00692419|Behavioral|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
460373|NCT00692419|Behavioral|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
460374|NCT00692406|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
460375|NCT00692393|Procedure|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
460376|NCT00692393|Procedure|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
460377|NCT00692380|Radiation|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
460536|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|High Dose- 100g bar
460537|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
460378|NCT00692367|Behavioral|Physical Activity|1. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
460379|NCT00692354|Drug|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
460380|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
460381|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
460382|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
460383|NCT00692328|Behavioral|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
460384|NCT00692315|Drug|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
460385|NCT00692302|Behavioral|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
460386|NCT00692302|Behavioral|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
460387|NCT00692276|Device|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
460388|NCT00692276|Device|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
460389|NCT00692263|Drug|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
460390|NCT00692263|Drug|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
460391|NCT00692263|Drug|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
460392|NCT00692250|Drug|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
460393|NCT00692237|Drug|Sildenafil|100 mg daily (3 capsules/day)
460394|NCT00692237|Drug|Placebo|Placebo 100 mg (3 capsules/day)
460395|NCT00692224|Drug|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
460396|NCT00692224|Drug|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
460397|NCT00692211|Other|Mailed fecal occult blood tests|Stool blood test
460398|NCT00692211|Other|Mailed fecal immunochemical tests|Stool blood test
460399|NCT00692198|Drug|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
460400|NCT00692185|Drug|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
460401|NCT00692185|Drug|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
460402|NCT00692172|Drug|Alefacept|intramuscular injection (IM)
460403|NCT00692159|Drug|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
460404|NCT00692146|Drug|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
460405|NCT00692146|Drug|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
460406|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
460407|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
460408|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
460409|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
460410|NCT00692120|Dietary Supplement|Placebo|oral placebo capsule once daily for 12 months
460411|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
460412|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
460413|NCT00692094|Biological|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
460414|NCT00692094|Biological|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
460415|NCT00692094|Biological|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
460416|NCT00692094|Biological|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
460417|NCT00692081|Behavioral|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
460418|NCT00692081|Behavioral|Special vocational training|as provided in German special centres for vocational training
460419|NCT00692055|Drug|PN400|naproxen 375 mg / esomeprazole 20 mg
460420|NCT00692055|Drug|Naproxen|naproxen 375 mg
460421|NCT00692042|Drug|AZD1704|One dose, by mouth
460422|NCT00692016|Drug|Naproxen sodium|Administered under fasting condition
460423|NCT00692016|Drug|Naproxen sodium|Administered under fed condition
460424|NCT00692003|Drug|Zonisamide|"25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
462081|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
460425|NCT00692003|Drug|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)"
460426|NCT00691990|Procedure|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
460427|NCT00691977|Radiation|Radiation Therapy followed by prostatectomy|Radiation Therapy
460428|NCT00691964|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
460429|NCT00691964|Biological|etanercept|SQ injection 50 mg BIW
460430|NCT00691964|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
460431|NCT00691951|Drug|budesonide and budesonide/formoterol|
460432|NCT00691938|Drug|LBH589|
460433|NCT00691938|Drug|Decitabine|
460434|NCT00691912|Drug|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
460435|NCT00691912|Drug|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
460436|NCT00691899|Drug|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
460437|NCT00691899|Drug|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
460438|NCT00691886|Drug|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
460439|NCT00691873|Drug|Placebo|placebo
460440|NCT00691873|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
460441|NCT00691860|Device|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
460442|NCT00691860|Procedure|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
460443|NCT00691834|Biological|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
460444|NCT00691834|Biological|Placebo|Plasma and culture medium (10 ml)
460445|NCT00691821|Other|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
460446|NCT00691821|Device|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
460447|NCT00691808|Drug|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
460448|NCT00691808|Drug|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
460449|NCT00691808|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
460450|NCT00691795|Drug|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
460451|NCT00691782|Other|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
460452|NCT00691756|Procedure|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
460453|NCT00691756|Procedure|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
460454|NCT00691730|Other|laboratory biomarker analysis|Correlative studies
460455|NCT00691730|Other|pharmacological study|Correlative studies
460456|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
460457|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
460458|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
460459|NCT00691717|Other|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
460460|NCT00691704|Drug|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
460461|NCT00691704|Drug|Sequential Maintenance Therapy|"Subjects who achieve >partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved > stable disease (SD) from maintenance (per discussion with physician):~325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
460538|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|High dose: 100g bar
460539|NCT00691249|Dietary Supplement|Shredded Wheat|70g bar
460540|NCT00691236|Drug|Zoledronic acid|4mg IV 3 weekly for 6 doses
460541|NCT00691236|Drug|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
460462|NCT00691691|Radiation|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
460463|NCT00691678|Drug|Chondroitin|400mg chondroitin TID for twenty-four weeks
460464|NCT00691678|Drug|Glucosamine|500mg glucosamine TID for twenty-four weeks
460465|NCT00691665|Drug|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
460466|NCT00691665|Drug|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
460467|NCT00691652|Biological|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
460468|NCT00691652|Drug|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
460469|NCT00691652|Genetic|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
460470|NCT00691652|Genetic|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
460471|NCT00691652|Genetic|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals << 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
460472|NCT00691652|Genetic|polymerase chain reaction|
460473|NCT00691652|Other|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
460474|NCT00691652|Other|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
460475|NCT00691639|Other|Blood Collection Only|Blood Collection Only
460476|NCT00691626|Behavioral|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
460477|NCT00691626|Behavioral|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
460478|NCT00691613|Drug|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
460479|NCT00691613|Drug|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
460480|NCT00691600|Drug|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
460481|NCT00691600|Drug|Placebo|Placebo caps or suspension every 12 hours for 10 days
460482|NCT00691600|Other|Observational Unit Short Stay|Patients with abscesses greater that 5cm to 10cm randomized to Observational Short Stay unit for up to 23 hrs.
460483|NCT00691600|Other|Hospitalization|Patients with abscesses 5-10cm may be randomized to inpatient treatment
460484|NCT00691587|Biological|KB001|Single low-dose, administered intravenously
460485|NCT00691587|Biological|KB001|Single high-dose, administered intravenously
460486|NCT00691587|Biological|Placebo|Placebo single-dose, administered intravenously
460487|NCT00691574|Dietary Supplement|Melatonin|up to 3 mg, daily, for up to 1 year
460488|NCT00691574|Device|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
460489|NCT00691561|Behavioral|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
460599|NCT00690872|Other|fluorescence activated cell sorting|
460600|NCT00690872|Other|immunoenzyme technique|
460601|NCT00690846|Drug|adalimumab|40 mg weekly adalimumab injection.
462082|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
460490|NCT00691548|Drug|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.~On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.~Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
460491|NCT00691522|Drug|Xerecept|
460492|NCT00691509|Genetic|gene expression analysis|
460493|NCT00691509|Genetic|polymorphism analysis|
460494|NCT00691509|Other|high performance liquid chromatography|
460495|NCT00691509|Other|laboratory biomarker analysis|
460496|NCT00691509|Other|mass spectrometry|
460497|NCT00691509|Other|questionnaire administration|
460498|NCT00691496|Behavioral|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
460499|NCT00691483|Drug|placebo|placebo tablet taken orally twice daily for 12 weeks
460500|NCT00691483|Drug|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
460501|NCT00691470|Drug|ATI-5923|Dose Adjusted based on INR.
460502|NCT00691470|Drug|Coumadin (warfarin)|Dose adjusted based on INR.
460503|NCT00691457|Device|Opti-Free contact lens solution|Solution
460504|NCT00691457|Device|ReNu Multiplus contact lens solution|Solution
460505|NCT00691457|Device|Clear Care contact lens solution|Solution
460506|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 0.5 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
460507|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 10 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
460508|NCT00691444|Biological|Melatonin|"Subjects will be given up to 20 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
460509|NCT00691431|Device|LASIK|
460510|NCT00691418|Dietary Supplement|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
460511|NCT00691418|Dietary Supplement|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
460512|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
460513|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
460514|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
460515|NCT00691405|Drug|Placebo|Placebo inhalation solution BID
460516|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
460517|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
460518|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
460519|NCT00691405|Drug|Placebo|Placebo inhalation solution QD
460520|NCT00691392|Drug|Linezolid|Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
460521|NCT00691392|Drug|Microcrystalline Methylcellulose - Placebo|The placebo will be over-encapsulated microcrystalline methylcellulose
460522|NCT00691379|Drug|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
460523|NCT00691379|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
460524|NCT00691379|Drug|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
460525|NCT00691327|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
460526|NCT00691314|Device|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:~Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent~Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .~Arms: 1"
460527|NCT00691314|Drug|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
460528|NCT00691301|Drug|cisplatin|Cisplatin as an IV infusion at less than 1 mg/min over less than 4 hours at a dose of
460529|NCT00691301|Drug|pemetrexed disodium|
460530|NCT00691288|Drug|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
460531|NCT00691288|Drug|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
460532|NCT00691275|Drug|Ondansetron|
460533|NCT00691275|Drug|Saline|
460534|NCT00691262|Drug|tacrolimus ointment|transdermal
460535|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|Low Dose- 70g bar
460542|NCT00691210|Drug|Vorinostat|"Dose escalation scheme (400 mg)~Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
460543|NCT00691210|Drug|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)~Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
460544|NCT00691210|Drug|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)~Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
460545|NCT00691197|Device|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
460546|NCT00691197|Device|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
460547|NCT00691184|Drug|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
460548|NCT00691184|Drug|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
460549|NCT00691184|Drug|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
460550|NCT00691184|Drug|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
460551|NCT00691158|Drug|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
460552|NCT00691158|Drug|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
460553|NCT00691158|Drug|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
460554|NCT00691158|Drug|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
460555|NCT00691145|Drug|tacrolimus ointment|transdermal
460556|NCT00691132|Drug|phenethyl isothiocyanate|Given orally
460557|NCT00691132|Other|placebo|Given orally
460558|NCT00691119|Behavioral|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
460559|NCT00691119|Other|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
460560|NCT00691093|Drug|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
460561|NCT00691067|Drug|mifepristone|200 mg po per day x 6 weeks
460562|NCT00691067|Drug|Placebos|placebo
460563|NCT00691054|Drug|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
460564|NCT00691041|Behavioral|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
460565|NCT00691028|Drug|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
460566|NCT00691028|Drug|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
460567|NCT00691028|Drug|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
460568|NCT00691015|Biological|rituximab|Given IV
460569|NCT00691015|Drug|busulfan|Given IV
460570|NCT00691015|Drug|carmustine|Given IV
460571|NCT00691015|Drug|cyclophosphamide|Given IV
460572|NCT00691015|Drug|cytarabine|Given IV
460573|NCT00691015|Drug|etoposide|Given IV
460574|NCT00691015|Drug|fludarabine phosphate|Given IV
460575|NCT00691015|Drug|melphalan|Given IV
460576|NCT00691015|Radiation|total body irradiation (TBI)|Given once or twice daily
460577|NCT00691015|Drug|anti-thymocyte globulin IV|Given IV
460578|NCT00691002|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
460579|NCT00690976|Behavioral|Proyecto SOL|Group intervention
460580|NCT00690976|Behavioral|HCT|Offer of HIV counseling and testing
460581|NCT00690963|Procedure|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
460582|NCT00690950|Drug|Dutasteride|0.5mg capsule, taken once daily for 12 months
460583|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
460584|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
460585|NCT00690937|Drug|Colesevelam Cholestagel|Drug comparator
460586|NCT00690937|Drug|Placebo|Placebo
460587|NCT00690937|Drug|Placebo|Placebo
460588|NCT00690924|Drug|calcitriol|Oral
460589|NCT00690924|Other|laboratory biomarker analysis|Correlative Study
460590|NCT00690924|Other|pharmacological study|Correlative Study
460591|NCT00690911|Drug|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
460592|NCT00690898|Drug|Lanreotide autogel 120 mg|12 months
460593|NCT00690885|Drug|interferon-alpha lozenges|150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
460594|NCT00690885|Drug|placebo lozenges|matching placebo lozenges
460595|NCT00690872|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
460596|NCT00690872|Drug|carboplatin|
460597|NCT00690872|Drug|gemcitabine hydrochloride|
460598|NCT00690872|Genetic|polymerase chain reaction|
460602|NCT00690833|Drug|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
460603|NCT00690820|Drug|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
460604|NCT00690820|Drug|Placebo Comparator|Placebo
460605|NCT00690807|Drug|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
460606|NCT00690794|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
460607|NCT00690794|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
460608|NCT00690781|Dietary Supplement|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
460609|NCT00690781|Dietary Supplement|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
460610|NCT00690781|Dietary Supplement|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
460611|NCT00690781|Dietary Supplement|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
460612|NCT00690768|Drug|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
460613|NCT00690768|Procedure|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
460614|NCT00690729|Behavioral|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
460615|NCT00690729|Behavioral|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
460616|NCT00690716|Drug|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
460617|NCT00690716|Drug|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
460618|NCT00690703|Device|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
460619|NCT00690690|Behavioral|Video (group-delivered video-based intervention)|group-delivered video-based intervention
460620|NCT00690690|Behavioral|HCT|Offer of HIV counseling and testing
460621|NCT00690677|Drug|LBH589|"LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.~The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study."
460622|NCT00690651|Procedure|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
460623|NCT00690651|Procedure|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
460624|NCT00690638|Drug|PHX1149T|200 mg
460625|NCT00690638|Drug|PHX1149T|400 mg
460626|NCT00690638|Drug|Placebo|Placebo
460627|NCT00690625|Drug|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
460628|NCT00690625|Drug|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
460629|NCT00690612|Drug|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
460630|NCT00690573|Biological|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
460631|NCT00690560|Biological|rituximab|
460632|NCT00690560|Drug|cyclophosphamide|
460633|NCT00690560|Drug|doxorubicin hydrochloride|
460634|NCT00690560|Drug|prednisone|
460635|NCT00690560|Drug|vincristine sulfate|
460636|NCT00690560|Radiation|yttrium Y 90 ibritumomab tiuxetan|
460637|NCT00690547|Other|muscle activation|activation of the muscle quadriceps femoris
460638|NCT00690534|Drug|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
460639|NCT00690534|Drug|L-NMMA|variable rate for 3 hours
460640|NCT00690534|Drug|Sodium Nitroprusside|variable rate for 3 hours
460641|NCT00690534|Other|mixed meal|mixed meal
460642|NCT00690521|Drug|metolazone or hydrochlorothiazide|The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
460643|NCT00690508|Procedure|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
460644|NCT00690495|Drug|Propofol|Propofol (drug), intravenous, induction of anesthesia
460645|NCT00690495|Drug|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
460646|NCT00690482|Drug|AZD1981|Oral tablet, twice daily
460647|NCT00690482|Drug|Placebo|Placebo Oral tablet, twice daily
460648|NCT00690469|Other|Laboratory Biomarker Analysis|Correlative studies
460649|NCT00690469|Other|Questionnaire Administration|Ancillary studies
460650|NCT00690456|Drug|Rimonabant|Tablet, oral administration
460651|NCT00690456|Drug|Placebo (for Rimonabant)|Tablet, oral administration
460652|NCT00690456|Drug|Metformin|Metformin continued at stable dose as background therapy
460653|NCT00690443|Drug|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
460654|NCT00690443|Drug|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
460655|NCT00690430|Drug|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
460656|NCT00690430|Drug|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
460657|NCT00690417|Dietary Supplement|Cholecalciferol (vitamin D3)|low calorie (~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
460658|NCT00690404|Drug|AZD2066|single oral dose
460659|NCT00690378|Drug|NXL104/ceftazidime|125mg/500mg TID
460660|NCT00690378|Drug|Imipenem/Cilastatin|4 x daily
460661|NCT00690352|Behavioral|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
460662|NCT00690339|Device|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
460663|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity"
460664|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire"
460665|NCT00690313|Drug|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
460666|NCT00690300|Drug|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
460667|NCT00690300|Drug|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
460668|NCT00690287|Drug|AZD6370|Oral single doses a+b+c, o.d., suspension
460669|NCT00690287|Drug|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
460670|NCT00690287|Drug|Placebo|Placebo
460671|NCT00690274|Drug|BF2.649|up to 20mg per day
460672|NCT00690274|Drug|Placebo|up to 20mg per day
460673|NCT00690235|Drug|Pramlintide|180mg subcutaneous injections, twice daily
460674|NCT00690235|Drug|Placebo|180mg subcutaneous injections, twice daily
460675|NCT00690222|Procedure|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
460676|NCT00690209|Procedure|Autologous bone marrow derived stem cells myocardial transplantation|
460677|NCT00690196|Behavioral|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
460678|NCT00690196|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
460679|NCT00690170|Drug|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
460680|NCT00690170|Drug|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
460681|NCT00690170|Drug|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
460682|NCT00690170|Drug|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.~13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
460683|NCT00690144|Device|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
460783|NCT00689520|Drug|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
460784|NCT00689520|Drug|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
460785|NCT00689507|Biological|LY2127399|monoclonal antibody
460684|NCT00690131|Behavioral|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
460685|NCT00690118|Drug|pioglitazone|45 mg/day, 18 months
460686|NCT00690118|Drug|placebo|once daily, 18 months
460687|NCT00690105|Drug|tacrolimus 0.1%|ointment
460688|NCT00690105|Drug|fluticasone 0.005 %|ointment
460689|NCT00690092|Biological|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
460690|NCT00690079|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol*h/L
460691|NCT00690079|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
460692|NCT00690066|Drug|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
460693|NCT00690066|Drug|Placebo|Intravenous infusion of excipients of PROCHYMAL®
460694|NCT00690053|Procedure|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
460695|NCT00690040|Device|Foley catheter|Single balloon catheter
460696|NCT00690040|Device|Atad catheter|Double balloon catheter
460697|NCT00690027|Procedure|Emergency portacaval shunt|
460698|NCT00690027|Procedure|Emergency and long-term endoscopic sclerotherapy|
460699|NCT00690014|Drug|probenecid|500 mg q 6 hrs
460700|NCT00689988|Behavioral|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
460701|NCT00689975|Behavioral|behavioral dietary intervention|
460702|NCT00689975|Behavioral|exercise intervention|
460703|NCT00689975|Other|counseling intervention|
460704|NCT00689975|Other|flow cytometry|
460705|NCT00689975|Other|immunoenzyme technique|
460706|NCT00689975|Other|laboratory biomarker analysis|
460707|NCT00689975|Procedure|complementary or alternative medicine procedure|
460708|NCT00689975|Procedure|standard follow-up care|
460709|NCT00689962|Device|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
460710|NCT00689962|Device|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
460711|NCT00689949|Dietary Supplement|folic acid|0.4 mg of folic acid per day
460712|NCT00689936|Drug|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
460713|NCT00689936|Drug|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
460714|NCT00689936|Drug|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
460715|NCT00689897|Procedure|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
460716|NCT00689897|Procedure|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
460717|NCT00689884|Drug|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
460718|NCT00689871|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
460719|NCT00689858|Drug|Cilostazol, Ginkgo biloba and placebo|dosing time
460720|NCT00689845|Biological|bleomycin sulfate|Given IV
460721|NCT00689845|Biological|filgrastim|Given subcutaneously
460722|NCT00689845|Biological|rituximab|given IV
460723|NCT00689845|Drug|cyclophosphamide|Given IV
460724|NCT00689845|Drug|cytarabine|Given subcutaneously
460725|NCT00689845|Drug|doxorubicin hydrochloride|Given IV
460726|NCT00689845|Drug|etoposide phosphate|Given IV
460727|NCT00689845|Drug|ifosfamide|Given IV
460728|NCT00689845|Drug|methotrexate|Given IV
460729|NCT00689845|Drug|prednisolone|Given orally
460730|NCT00689845|Drug|prednisone|Given orally
460731|NCT00689845|Drug|vincristine sulfate|Given IV
460732|NCT00689845|Drug|vindesine|Given IV
460733|NCT00689832|Drug|Tacrolimus 0.03%|ointment
460734|NCT00689832|Drug|Fluticasone 0.005%|ointment
460735|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460736|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460737|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460738|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460739|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460740|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460741|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460742|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460743|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460786|NCT00689494|Other|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
460787|NCT00689481|Drug|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
460788|NCT00689481|Drug|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
460744|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
460745|NCT00689806|Drug|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not > 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
460746|NCT00689806|Drug|Placebo|Placebo by mouth once daily for weeks 1-4.
460747|NCT00689793|Drug|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
460748|NCT00689793|Drug|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
460749|NCT00689780|Drug|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
460750|NCT00689780|Drug|Midazolam|Oral solution given orally once daily on day -1 and day 14
460751|NCT00689767|Device|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
460752|NCT00689767|Device|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
460753|NCT00689754|Procedure|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
460754|NCT00689741|Biological|Cervarix|3 doses of IM injection
460755|NCT00689741|Biological|placebo|3 doses of IM injection of Al(OH)3 placebo
460756|NCT00689728|Biological|LY2127399|LY2127399 will be administered as a single IV infusion over 30 minutes.
460757|NCT00689728|Drug|Placebo|Placebo will be administered as a single IV infusion over 30 minutes.
460758|NCT00689715|Procedure|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
460759|NCT00689702|Drug|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).~Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.~Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
460760|NCT00689689|Device|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
460761|NCT00689689|Device|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
460762|NCT00689663|Procedure|Laparoscopic cholecystectomy|Randomized to three arm.
460763|NCT00689650|Device|1540 nm fractional laser|
460764|NCT00689637|Drug|AZD3480|AZD3480 capsules qd, 12 days
460765|NCT00689637|Drug|Placebo|Placebo capsules qd, 12 days
460766|NCT00689637|Drug|Warfarin|Warfarin: single dose on day 6
460767|NCT00689624|Drug|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
460768|NCT00689624|Drug|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
460769|NCT00689624|Drug|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
460770|NCT00689624|Drug|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
460771|NCT00689624|Drug|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
460772|NCT00689611|Drug|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
460773|NCT00689611|Drug|Placebo|Placebo
460774|NCT00689598|Drug|Spironolactone|25 mg po qd 25 mg po bid
460775|NCT00689598|Drug|Placebo|Spironolactone 25 mg po qd
460776|NCT00689585|Drug|Placebo|250mg matching placebo capsules
460777|NCT00689585|Drug|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
460778|NCT00689572|Drug|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
460779|NCT00689572|Drug|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
460780|NCT00689559|Drug|AZD3480|AZD3480 capsules qd, oral, 22 days
460781|NCT00689559|Drug|Placebo|Placebo qd, 12 days
460782|NCT00689559|Drug|Aripiprazole|single dose on day 5
460789|NCT00689468|Procedure|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
460790|NCT00689468|Dietary Supplement|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
460791|NCT00689468|Procedure|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
460792|NCT00689468|Dietary Supplement|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
460793|NCT00689442|Drug|JTT-705 600 mg and atorvastatin 20 mg|"JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment~Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
460794|NCT00689442|Drug|Placebo and atorvastatin 20 mg|"Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
460795|NCT00689416|Drug|rosuvastatin|40 mg, tablet, once daily for 3 months.
460796|NCT00689416|Drug|placebo|40 mg, tablet, once daily for 3 months
460797|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
460798|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
460799|NCT00689390|Biological|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
460800|NCT00689390|Biological|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
460801|NCT00689390|Biological|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
460802|NCT00689390|Drug|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
460803|NCT00689390|Other|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
460804|NCT00689351|Biological|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
460805|NCT00689351|Biological|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
460806|NCT00689338|Drug|Anidulafungin|Anidulafungin Intravenous Administration
460807|NCT00689338|Drug|Fluconazole|Oral Administration of Fluconazole
460808|NCT00689338|Drug|Voriconazole|Oral Administration of Voriconazole
460809|NCT00689312|Drug|Enfalyte|Each patient will receive one 250 ml dose.
460810|NCT00689312|Drug|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
460811|NCT00689312|Drug|Pedialyte|Each patient will receive one 250 ml dose.
460812|NCT00689299|Biological|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
460813|NCT00689299|Biological|Placebo|Placebo Sublingual Drops
460814|NCT00689286|Device|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.~In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
460815|NCT00689273|Drug|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
460816|NCT00689273|Drug|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
460817|NCT00689260|Device|easypod|Subjects is aware that the device records injection information that can be viewed by user
460818|NCT00689260|Device|easypod|Subjects is not aware that the device records injection information that can be viewed by user
460819|NCT00689247|Drug|AZD1305|oral solution, single dose
460820|NCT00689247|Drug|AZD1305|iv infusion, single dose
460821|NCT00689234|Procedure|diaphragm plication 6 months after inclusion|thoracotomy
460822|NCT00689234|Procedure|diaphragm plication at time of inclusion|thoracotomy
460823|NCT00689221|Drug|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
460824|NCT00689221|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
460960|NCT00688272|Drug|Placebo|Given QD x 6 days
460825|NCT00689221|Radiation|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
460826|NCT00689208|Drug|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
460827|NCT00689208|Drug|Physostigmine|0,12ug/kg/min
460828|NCT00689208|Drug|Placebo Sodium|
460829|NCT00689195|Dietary Supplement|Curcumin powder|oral capsules containing the investigational agent
460830|NCT00689195|Dietary Supplement|Ashwagandha extract|4.5% extract of ashwagandha
460831|NCT00689182|Procedure|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
460832|NCT00689169|Drug|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
460833|NCT00689169|Procedure|ASCT|ASCT : D0
460834|NCT00689169|Drug|Rituximab|Rituximab 250 mg/m² :D-21 D-14
460835|NCT00689156|Drug|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
460836|NCT00689156|Drug|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
460837|NCT00689143|Drug|sargramostim|
460838|NCT00689117|Drug|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
460839|NCT00689117|Drug|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
460840|NCT00689117|Drug|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
460841|NCT00689117|Drug|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
460842|NCT00689104|Drug|Mirabegron|Tablets
460843|NCT00689104|Drug|Tolterodine|Capsules
460844|NCT00689104|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
460845|NCT00689104|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
460846|NCT00689091|Device|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
460847|NCT00689091|Device|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
460848|NCT00689078|Drug|Prednisolone Acetate 1%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
460849|NCT00689078|Drug|Prednisolone Acetate 0.12%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
460850|NCT00689078|Drug|Loteprednol Etabonate 0.2%|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
460851|NCT00689078|Drug|Placebo|One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
460852|NCT00689065|Drug|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
460853|NCT00689052|Drug|pramipexole ER|
460854|NCT00689052|Drug|placebo|
460855|NCT00689039|Drug|AZD1305|ER tablet, administered as single and repeated doses.
460856|NCT00689039|Drug|Placebo|Tablet, administered as single and repeated doses.
460857|NCT00689026|Drug|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
460858|NCT00689026|Other|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
460859|NCT00689013|Other|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
460860|NCT00689013|Other|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
460861|NCT00689013|Other|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
460862|NCT00689000|Drug|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort~Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
460863|NCT00688987|Drug|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
460864|NCT00688987|Dietary Supplement|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
460865|NCT00688974|Procedure|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
460866|NCT00688974|Procedure|Adjustable gastric band|Laparoscopic adjustable gastric band
460867|NCT00688961|Drug|Aspirin|generic aspirin
460868|NCT00688961|Drug|omega-3 acid ethyl esters|4, 1 g capsules q.d.
460869|NCT00688948|Drug|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
460870|NCT00688935|Biological|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
460871|NCT00688922|Drug|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
460872|NCT00688909|Drug|letrozole|2.5 mg daily by mouth for 6 months
460873|NCT00688896|Drug|JTT-705 600 mg and pravastatin 40 mg|"JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
460874|NCT00688896|Drug|JTT-705 300 mg and pravastatin 40 mg|"JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment~Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments~Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
460875|NCT00688896|Drug|Placebo and pravastatin 40 mg|"Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
460876|NCT00688883|Drug|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
460877|NCT00688870|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
460878|NCT00688870|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
460879|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
460880|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
460881|NCT00688844|Drug|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
460882|NCT00688831|Drug|AZD1305|Solution for iv infusion , single dose
460883|NCT00688831|Drug|Placebo|NaCl solution for iv infusion, single dose
460884|NCT00688818|Drug|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
460885|NCT00688818|Drug|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
460886|NCT00688805|Drug|Propranolol|40 mg given as a single oral administration in an opaque capsule
460887|NCT00688805|Drug|Placebo|matching capsule containing no active medication
460888|NCT00688779|Drug|AZD8848|Concentrate for nasal spray,solution 60 mg/g
460889|NCT00688779|Drug|Placebo|
460890|NCT00688766|Drug|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
460891|NCT00688766|Drug|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
460892|NCT00688766|Other|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
460893|NCT00688753|Drug|RAD001|
460894|NCT00688740|Drug|Docetaxel|intravenous
460895|NCT00688740|Drug|5-fluorouracil|intravenous
460896|NCT00688740|Drug|Doxorubicin|intravenous
460897|NCT00688740|Drug|Cyclophosphamide|intravenous
460898|NCT00688727|Behavioral|CBT|CBT, up to 12 sessions.
460899|NCT00688727|Behavioral|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
460900|NCT00688714|Drug|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
460901|NCT00688714|Drug|Placebo|
460902|NCT00688701|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
460903|NCT00688701|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
460904|NCT00688701|Device|Pen auto-injector|
460905|NCT00688688|Drug|Mirabegron|Tablets
460906|NCT00688688|Drug|Tolterodine|Extended release capsules
460907|NCT00688688|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
460908|NCT00688688|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
460909|NCT00688662|Procedure|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
460910|NCT00688662|Procedure|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
460911|NCT00688649|Dietary Supplement|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
460912|NCT00688649|Dietary Supplement|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
460913|NCT00688636|Drug|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
460914|NCT00688636|Drug|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
460915|NCT00688623|Drug|Everolimus|Everolimus 5 mg tablets were supplied in blister packs
460961|NCT00688259|Behavioral|Supportive Therapy (ST)|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
460962|NCT00688259|Behavioral|Cognitive Behavioral Therapy for Psychosis (CBTp)|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
461006|NCT00687947|Drug|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
460916|NCT00688610|Other|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.~B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
460917|NCT00688597|Drug|Duvoglustat|Powder in a bottle for dissolution in water for oral administration
460918|NCT00688584|Behavioral|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
460919|NCT00688584|Behavioral|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
460920|NCT00688571|Device|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
460921|NCT00688558|Drug|JTT-705 600 mg and simvastatin 40 mg|"JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment~Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments"
460922|NCT00688558|Drug|Placebo and simvastatin 40 mg|"Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments~Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
460923|NCT00688545|Drug|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
460924|NCT00688545|Drug|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
460925|NCT00688519|Drug|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
460926|NCT00688519|Drug|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
460927|NCT00688506|Device|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
460928|NCT00688506|Device|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
460929|NCT00688493|Drug|Dapagliflozin|3 x 50 mg tablets, single oral dose
460930|NCT00688493|Drug|Dapagliflozin|2 x 10 mg capsules, single oral dose
460931|NCT00688493|Drug|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
460932|NCT00688493|Drug|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
460933|NCT00688480|Drug|Placebo|1 capsule, orally for 9 months
460934|NCT00688480|Drug|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
460935|NCT00688467|Drug|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
460936|NCT00688467|Drug|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
460937|NCT00688441|Drug|Nasal CO2|Twice daily during the 14 day Treatment Period
460938|NCT00688441|Drug|Placebo|Use of the study drug dispenser at the same frequency as the active arm
460939|NCT00688428|Drug|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
460940|NCT00688428|Drug|Esomeprazole|40mg capsule, administered as a single dose
460941|NCT00688428|Drug|ASA|325mg tablet, administered as a single oral dose
460942|NCT00688415|Drug|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
460943|NCT00688402|Drug|AZD3355|Single dose
460944|NCT00688389|Other|case/control|case: infected dengue fever people control:healthy people
460945|NCT00688376|Drug|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.~During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
460946|NCT00688376|Drug|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.~During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
460947|NCT00688363|Procedure|weekly blood glucose profile|once daily self-control of urinary-glucose
460948|NCT00688363|Procedure|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
460949|NCT00688363|Procedure|no blood-glucose self-control|once daily self-control of urinary-glucose
460950|NCT00688350|Behavioral|Behavioral feedback|The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
460951|NCT00688324|Drug|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
460952|NCT00688311|Dietary Supplement|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10^10 each) combined with 4 types of dietary fiber (2.5g each).
460953|NCT00688311|Dietary Supplement|Placebo|Placebo
460954|NCT00688298|Device|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
460955|NCT00688298|Device|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
460956|NCT00688285|Other|automated clinical alerts|automated clinical alerts in the electronic medical record
460957|NCT00688285|Other|provider education|PCP education session on CKD
460958|NCT00688272|Drug|Ciprofloxacin|Given 500mg BID x 6 days
460959|NCT00688272|Drug|Eltrombopag|Given QD x 6 days
460963|NCT00688246|Other|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture [Lønning 2005]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk [Looker 2000]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
460964|NCT00688246|Procedure|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
460965|NCT00688233|Device|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
460966|NCT00688207|Drug|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
460967|NCT00688194|Drug|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
460968|NCT00688194|Drug|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
460969|NCT00688194|Drug|fulvestrant|Given intramuscularly
460970|NCT00688194|Drug|lapatinib ditosylate|Given orally
460971|NCT00688194|Drug|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
460972|NCT00688194|Other|placebo|Given orally
460973|NCT00688181|Device|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
460974|NCT00688168|Behavioral|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
460975|NCT00688168|Behavioral|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
460976|NCT00688168|Behavioral|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
460977|NCT00688155|Behavioral|Physical Activity Training|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
460978|NCT00688155|Behavioral|Cognitive Training|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
460979|NCT00688155|Behavioral|Healthy Aging Education|One 1-hour lecture each week for 3 months, then monthly.
460980|NCT00688129|Behavioral|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
460981|NCT00688116|Drug|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., [Monday, Thursday] or [Tuesday, Friday]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
460982|NCT00688103|Drug|ETN Alone|etanercept (25 mg, twice/week, s.c.)
460983|NCT00688103|Drug|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
460984|NCT00688090|Biological|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
460985|NCT00688090|Biological|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
460986|NCT00688077|Drug|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
460987|NCT00688077|Drug|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
460988|NCT00688064|Drug|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
460989|NCT00688064|Drug|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
460990|NCT00688051|Other|My Life with CF game|Play the game My Life with CF
460991|NCT00688038|Procedure|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
460992|NCT00688038|Procedure|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
460993|NCT00688012|Drug|SPC3649|
460994|NCT00687999|Drug|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
460995|NCT00687986|Radiation|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
460996|NCT00687986|Procedure|primary surgery|an anatomical surgical resection with lymph node dissection
460997|NCT00687973|Drug|Valsartan/amlodipine 80/5 mg tablets|
460998|NCT00687973|Drug|Amlodipine 5 mg capsules|
460999|NCT00687973|Drug|Amlodipine 10 mg capsules|
461000|NCT00687973|Drug|Atenolol 50 mg tablets|
461001|NCT00687973|Drug|Atenolol 100 mg tablets|
461002|NCT00687960|Dietary Supplement|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
461003|NCT00687960|Dietary Supplement|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
461004|NCT00687960|Dietary Supplement|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
461005|NCT00687960|Dietary Supplement|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
461007|NCT00687934|Drug|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
461008|NCT00687908|Drug|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
461009|NCT00687908|Drug|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
461010|NCT00687895|Procedure|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm~The content of the package included~description of signs and symptoms of malaria disease~history taking relevant to malaria and physical examination~identification of danger signs and severe illness for referral~appropriate treatment~counseling patients on the use of drugs.~Malaria microscopy. contents~make thick blood smears from patients with fever and stain with Giemsa~identify and count malaria parasites~maintain the microscope and store blood slides."
461011|NCT00687882|Other|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
461012|NCT00687882|Other|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
461013|NCT00687882|Other|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
461014|NCT00687882|Other|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
461015|NCT00687869|Behavioral|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
461016|NCT00687869|Behavioral|Case management|Usual stroke aftercare plus patient-information-notes
461017|NCT00687856|Procedure|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
461018|NCT00687843|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
461019|NCT00687843|Drug|Krestin (PSK)|3 g, PO from day 1 to day 336
461020|NCT00687830|Drug|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
461021|NCT00687830|Drug|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
461022|NCT00687817|Drug|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
461023|NCT00687804|Drug|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
461024|NCT00687804|Procedure|Laser|Laser photocoagulation treatment
461025|NCT00687804|Procedure|Sham laser|Sham to laser procedure.
461026|NCT00687804|Drug|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
461027|NCT00687791|Device|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
461028|NCT00687765|Drug|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
461029|NCT00687739|Drug|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
461030|NCT00687739|Drug|Estradiol Transdermal|0.075 mg patch per day for 5 months
461031|NCT00687739|Behavioral|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
461032|NCT00687726|Behavioral|Standing balance exercise|Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
461033|NCT00687726|Behavioral|Isometric knee extension exercise|Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
461034|NCT00687713|Drug|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
461035|NCT00687713|Other|Placebo|Placebo
461036|NCT00687700|Drug|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
461037|NCT00687700|Drug|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
461038|NCT00687700|Drug|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
461039|NCT00687700|Drug|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
461040|NCT00687687|Drug|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
461041|NCT00687687|Drug|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
461042|NCT00687687|Drug|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
461043|NCT00687674|Drug|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
461044|NCT00687674|Drug|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM & 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
461223|NCT00686517|Drug|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
461224|NCT00686504|Drug|AZD2066|single dose of oral dose, 3 times per subject
461045|NCT00687674|Drug|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
461046|NCT00687661|Drug|Bisphosphonate|35mg given orally once weekly for 24 months
461047|NCT00687661|Drug|Placebo|identical placebo pill once weekly for 24 months
461048|NCT00687648|Drug|anastrozole|Given as previously prescribed
461049|NCT00687648|Drug|cyclophosphamide|Given by mouth
461050|NCT00687648|Drug|exemestane|Given as previously prescribed
461051|NCT00687648|Drug|letrozole|Given as previously prescribed
461052|NCT00687648|Drug|methotrexate|Given by mouth
461053|NCT00687648|Drug|prednisolone|Given by mouth
461054|NCT00687622|Drug|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
461055|NCT00687609|Drug|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
461056|NCT00687596|Drug|TAC-101|Patients randomized to TAC 101 will receive TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle will be repeated every 21 days.
461057|NCT00687596|Drug|Placebo|Patients randomized to placebo will receive 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
461058|NCT00687570|Dietary Supplement|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg*dag-1, seven days before surgery
461059|NCT00687570|Drug|Laxabon®|Laxabon® 4 litres starting the day before surgery
461060|NCT00687544|Biological|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
461061|NCT00687544|Drug|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is <65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is >85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
461062|NCT00687531|Drug|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
461063|NCT00687518|Drug|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
461064|NCT00687518|Drug|Placebo|Intravenous injection of equivalent volume of saline serum
461065|NCT00687505|Drug|FP-1039|Intravenous weekly administration
461066|NCT00687466|Drug|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour."
461067|NCT00687453|Drug|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
461068|NCT00687453|Drug|NPH twice-daily|Addition of morning NPH to bedtime NPH
461069|NCT00687440|Drug|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks~Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
461070|NCT00687440|Drug|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
461071|NCT00687440|Drug|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
461072|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|"Group A:~Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.~Treatment will focus on the patient's needs and in accordance with the physicians requests.~Three months post initial treatment re-assessment will be conducted."
461073|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
461074|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
461075|NCT00687401|Biological|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
461076|NCT00687388|Drug|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
461077|NCT00687388|Drug|celecoxib|200mg daily for 8 weeks
461078|NCT00687388|Drug|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
461079|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
461080|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
461081|NCT00687362|Biological|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
461082|NCT00687349|Behavioral|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
461083|NCT00687336|Other|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
461084|NCT00687336|Other|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
461085|NCT00687323|Drug|temozolomide|
461086|NCT00687310|Behavioral|Educational intervention|Tailored asthma education based on needs assessment
461087|NCT00687297|Drug|vandetanib induction|100 mg daily by mouth
461088|NCT00687297|Drug|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
461089|NCT00687297|Drug|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
461090|NCT00687297|Drug|Placebo|
461091|NCT00687297|Drug|Vandetanib maintenance|300 mg daily by mouth
461092|NCT00687284|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
461093|NCT00687271|Drug|MK-6213|MK-6213 160 mg for 4 weeks.
461094|NCT00687271|Drug|Atorvastatin calcium|atorvastatin calcium 20mg for 4 weeks.
461095|NCT00687271|Drug|Placebo for MK-6312 160 mg|
461096|NCT00687271|Drug|Placebo for Atorvastatin 20 mg|
461097|NCT00687258|Device|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
461098|NCT00687258|Device|APS-U (Asahi Polysulfone APS)|PS Polysulfone dialyser without vitamin E alpha-tocopherol
461099|NCT00687245|Drug|esomeprazole magnesium|capsules, oral, qd, one day
461100|NCT00687232|Drug|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
461101|NCT00687232|Drug|Placebo|
461102|NCT00687219|Biological|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
461103|NCT00687219|Drug|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and <14g/dL; treatment duration is 48 weeks
461104|NCT00687206|Drug|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
461105|NCT00687193|Drug|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
461106|NCT00687193|Drug|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
461107|NCT00687193|Drug|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
461108|NCT00687193|Drug|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
461109|NCT00687193|Drug|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
461110|NCT00687193|Drug|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
461111|NCT00687180|Drug|Treatment with mycophenolat mofetil|
461112|NCT00687180|Drug|Treatment with azathioprin|
461113|NCT00687167|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
461114|NCT00687167|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
461115|NCT00687154|Procedure|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
461116|NCT00687154|Procedure|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
461117|NCT00687141|Drug|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
461118|NCT00687141|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
461119|NCT00687128|Behavioral|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
461120|NCT00687128|Behavioral|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
461121|NCT00687128|Behavioral|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
461122|NCT00687115|Behavioral|Weight Loss|liquid diet at 50% of weight maintaining intake
461123|NCT00687115|Behavioral|Overfeeding|Overfeeding at 150% of weight maintaining intake
461124|NCT00687115|Behavioral|Overfeeding Low Pro|Overfeeding 150% of normal intake at <5% protein
461125|NCT00687102|Drug|tamoxifen|oral tamoxifen plus placebo daily for 5 years
461126|NCT00687102|Drug|raloxifene|oral raloxifene plus placebo daily for 5 years
461127|NCT00687089|Other|Sexual, cognitive functional tests and measurement weight|
461128|NCT00687076|Drug|Ezetimibe|Daily dose of 10 mg of Ezetimibe
461129|NCT00687076|Drug|Niaspan|Daily dose of 1500 mg of Niaspan
461130|NCT00687076|Drug|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
461131|NCT00687076|Behavioral|Standard care|Standard of medical care for PAD
461132|NCT00687076|Drug|Aspirin|Daily dose of 325 mg of aspirin
461133|NCT00687076|Drug|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
461134|NCT00687076|Drug|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
461135|NCT00687076|Drug|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
461136|NCT00687076|Procedure|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
461137|NCT00687063|Drug|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
461936|NCT00681356|Drug|Placebo Comparator|Direct instillation into the surgical site
461138|NCT00687050|Dietary Supplement|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
461139|NCT00687050|Dietary Supplement|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
461140|NCT00687037|Drug|Cetylpyridinium chloride|
461141|NCT00687024|Procedure|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
461142|NCT00687024|Procedure|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
461143|NCT00687024|Procedure|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
461144|NCT00687011|Drug|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
461145|NCT00686998|Drug|AZD2624|Oral Suspension
461146|NCT00686998|Drug|Olanzapine|PO BID
461147|NCT00686998|Drug|Placebo|
461148|NCT00686985|Drug|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
461149|NCT00686972|Drug|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
461150|NCT00686959|Drug|Pemetrexed|infusion over 10 minutes
461151|NCT00686959|Drug|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
461152|NCT00686959|Drug|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
461153|NCT00686959|Drug|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
461154|NCT00686959|Drug|Paclitaxel|administered as a 3-hour infusion
461155|NCT00686959|Drug|Carboplatin|administered per local practice guidelines over 30 minutes
461156|NCT00686959|Radiation|Thoracic Radiation Therapy (TRT)|
461157|NCT00686933|Drug|ABT-089|Subjects will take up to 80 mg daily for 24 months
461158|NCT00686920|Drug|Rifaximin|Oral
461159|NCT00686907|Drug|Melatonin|Dose range: 0.01 mg - 20 mg, daily, up to 5 years (based on each subject's circadian rhythms and response to the dose).
461160|NCT00686894|Procedure|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
461161|NCT00686894|Drug|Infliximab|"5 mg/kg~IV~Frequency : weeks 0,2,6"
461162|NCT00686881|Biological|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
461163|NCT00686881|Drug|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
461164|NCT00686868|Other|placebo|placebo
461165|NCT00686868|Drug|ofatumumab|fully human anti-CD20 monoclonal antibody
461166|NCT00686855|Drug|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
461167|NCT00686855|Drug|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
461168|NCT00686842|Drug|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
461169|NCT00686842|Genetic|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
461170|NCT00686842|Genetic|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
461171|NCT00686842|Genetic|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
461172|NCT00686842|Other|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
461173|NCT00686842|Other|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
461174|NCT00686842|Other|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
461175|NCT00686842|Procedure|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
461176|NCT00686829|Drug|Vicriviroc maleate|30 mg tablet for once daily oral administration until vicriviroc becomes commercially available.
461177|NCT00686816|Dietary Supplement|Low calorie diet|low calorie diet
461178|NCT00686816|Dietary Supplement|Olestra|low calorie Olestra diet
461179|NCT00686803|Drug|PL3994|Study drug
461180|NCT00686803|Drug|Placebo|Placebo
461181|NCT00686790|Biological|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
461182|NCT00686777|Biological|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
461183|NCT00686777|Drug|Ribavirin|Ribavirin 400 mg/day orally
461225|NCT00686504|Drug|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
461310|NCT00685906|Drug|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
461184|NCT00686764|Other|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.~We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
461185|NCT00686751|Drug|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
461186|NCT00686725|Drug|Temozolomide|
461187|NCT00686725|Radiation|Radiotherapy|
461188|NCT00686712|Drug|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings <120 mg/dL)
461189|NCT00686712|Drug|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings <120 mg/dL)
461190|NCT00686712|Drug|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses <120 mg/dL)
461191|NCT00686699|Drug|Preladenant|capsules
461192|NCT00686699|Drug|Placebo|capsules
461193|NCT00686686|Biological|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
461194|NCT00686673|Behavioral|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
461195|NCT00686673|Behavioral|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
461196|NCT00686660|Behavioral|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
461197|NCT00686660|Behavioral|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training."
461198|NCT00686660|Behavioral|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
461199|NCT00686660|Behavioral|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community."
461200|NCT00686647|Device|AngioSculpt® Scoring Balloon Catheter|Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion
461201|NCT00686647|Device|AngioSculpt Scoring Balloon Catheter|Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device
461202|NCT00686634|Drug|Sitagliptin|Sitagliptin 100 mg by mouth once daily
461203|NCT00686621|Drug|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
461204|NCT00686608|Dietary Supplement|glucose|0.3mg/kg of glucose
461205|NCT00686608|Dietary Supplement|fructose|fructose IV bolus
461206|NCT00686608|Dietary Supplement|saline|IV saline
461207|NCT00686595|Biological|Infliximab|Infliximab 5 mg/kg IV infusion.
461208|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
461209|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
461210|NCT00686582|Procedure|Blood Draw Only|
461211|NCT00686556|Drug|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
461212|NCT00686556|Drug|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of >200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
461213|NCT00686556|Drug|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
461214|NCT00686556|Drug|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients <40 kg, 3 gm/day for patients >40 kg.
461215|NCT00686556|Radiation|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
461216|NCT00686556|Procedure|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
461217|NCT00686556|Biological|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10^9/L for 3 consecutive days.
461218|NCT00686556|Biological|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10^8 nucleated cells/kg recipient weight, minimum 3x10^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
461219|NCT00686543|Drug|Posaconazole|Posaconazole will be used for prophylaxis
461220|NCT00686530|Procedure|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
461221|NCT00686530|Procedure|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
461222|NCT00686517|Biological|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
461226|NCT00686478|Drug|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
461227|NCT00686465|Other|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
461228|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg on alternate weeks
461229|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg every other week
461230|NCT00686426|Dietary Supplement|Dairy Foods|Adequate dairy (> 3 standard daily servings)
461231|NCT00686426|Dietary Supplement|Dairy Foods|< 1 standard dairy serving/day
461232|NCT00686413|Drug|AZD3480|single dose, oral
461233|NCT00686413|Radiation|2-[18F]-F-A85380|Single dose, IV
461234|NCT00686400|Other|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
461235|NCT00686374|Biological|Adalimumab|Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed < 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
461236|NCT00686361|Drug|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
461237|NCT00686335|Drug|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
461238|NCT00686335|Drug|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
461239|NCT00686322|Drug|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
461240|NCT00686296|Other|Taliderm™|taliderm™ dressing application once
461241|NCT00686296|Other|Taliderm™|Taliderm™ dressing application up to three applications
461242|NCT00686296|Other|standard wet to dry dressing with gauze|wet to dry dressing standard of care
461243|NCT00686283|Behavioral|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
461244|NCT00686270|Drug|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
461245|NCT00686257|Device|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
461246|NCT00686257|Device|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
461247|NCT00686244|Other|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).~Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
461248|NCT00686231|Drug|Nitroglycerin|1 inch of Nitroglycerin vs 2 inches of Nitroglycerin
461249|NCT00686231|Drug|Placebo|Sorbolene cream
461250|NCT00686231|Drug|Lidocaine|Visit 2 lidocaine 1 inch + best dose Nitro vs Placebo + lidocaine
461251|NCT00686218|Drug|imatinib mesylate|Given orally
461252|NCT00686218|Drug|panobinostat|Given orally
461253|NCT00686218|Genetic|polymerase chain reaction|Testing
461254|NCT00686218|Genetic|protein expression analysis|Testing
461255|NCT00686218|Genetic|western blotting|Testing
461256|NCT00686218|Other|flow cytometry|Testing
461257|NCT00686218|Other|laboratory biomarker analysis|Testing
461258|NCT00686218|Other|pharmacological study|Testing
461259|NCT00686205|Device|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
461260|NCT00686192|Dietary Supplement|Calcium Carbonate|1500 mg per day
461261|NCT00686179|Drug|AZD3480|Capsule, oral, single dose, 6 days
461262|NCT00686179|Drug|Moxifloxacin|Capsule(encapsulated), oral, single dose
461263|NCT00686179|Drug|PLACEBO|Capsule, oral, single dose
461264|NCT00686166|Biological|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m^2, IV, Day 1; Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29~Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78"
461265|NCT00686166|Drug|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)~Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)"
461266|NCT00686166|Drug|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29~Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78"
461267|NCT00686166|Procedure|therapeutic surgical procedure|Surgical resection
461268|NCT00686166|Radiation|radiation therapy|IMRT (intensity-modulated radiation therapy)
461269|NCT00686140|Drug|celecoxib|400mg/day, twice a day, 12 weeks
461270|NCT00686140|Drug|Placebo|twice a day, 12 weeks
461271|NCT00686127|Drug|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
461272|NCT00686127|Drug|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
461273|NCT00686114|Drug|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
461274|NCT00686114|Drug|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
461275|NCT00686114|Drug|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
461276|NCT00686114|Radiation|Radiotherapy|Enlarged field radiotherapy
461277|NCT00686114|Radiation|Radiotherapy|Conventional field radiotherapy
461278|NCT00686088|Drug|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
461279|NCT00686075|Biological|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
461280|NCT00686075|Other|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
461281|NCT00686075|Biological|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
461282|NCT00686075|Other|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
461283|NCT00686075|Biological|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
461284|NCT00686075|Other|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
461285|NCT00686075|Biological|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
461286|NCT00686075|Other|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
461287|NCT00686075|Biological|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
461288|NCT00686075|Other|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
461289|NCT00686062|Other|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
461290|NCT00686062|Other|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
461291|NCT00686036|Drug|vandetanib|300 mg orally, once daily for up to 18 months
461292|NCT00686036|Drug|Placebo|
461293|NCT00686023|Procedure|internal fixation (DHS - richard nail)|internal fixation
461294|NCT00686023|Procedure|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
461295|NCT00686010|Drug|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
461296|NCT00686010|Drug|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
461297|NCT00686010|Drug|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
461298|NCT00686010|Drug|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
461299|NCT00685971|Dietary Supplement|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
461300|NCT00685971|Dietary Supplement|placebo|5 drops once daily for 12 weeks
461301|NCT00685958|Drug|enoxaparin (XRP4563)|14 days of treatment
461302|NCT00685945|Drug|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
461303|NCT00685945|Drug|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
461304|NCT00685945|Drug|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
461305|NCT00685945|Drug|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
461306|NCT00685932|Device|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
461307|NCT00685919|Drug|Carbidopa|200 mg every 6 hours for 5 doses given orally
461308|NCT00685919|Drug|Placebo|every 6 hours for 5 doses, given orally, and matching Intervention 1
461309|NCT00685906|Drug|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
461311|NCT00685893|Behavioral|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
461312|NCT00685893|Behavioral|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
461313|NCT00685893|Behavioral|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
461314|NCT00685893|Behavioral|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
461315|NCT00685893|Behavioral|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
461316|NCT00685880|Drug|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
461317|NCT00685880|Drug|Betamethasone|CELESTONE® SOLUSPAN® * (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
461318|NCT00685867|Other|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
461319|NCT00685867|Behavioral|Hand hygiene promotion|"Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~Isolation precautions according to the hospitals' capacity and strategy~Additional basic infection control interventions (if necessary)"
461320|NCT00685854|Drug|Ranibizumab|
461321|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
461322|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
461323|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
461324|NCT00685841|Drug|Salmeterol MDI|Salmeterol MDI 42 mcg BID
461325|NCT00685841|Drug|Placebo|Placebo BID MDI
461326|NCT00685828|Drug|imatinib mesylate|By mouth
461327|NCT00685815|Drug|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
461328|NCT00685815|Drug|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
461329|NCT00685802|Drug|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
461330|NCT00685802|Drug|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
461331|NCT00685789|Device|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
461332|NCT00685789|Device|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
461333|NCT00685776|Drug|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
461334|NCT00685776|Drug|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
461335|NCT00685763|Radiation|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .~Chemotherapy:~Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
461336|NCT00685750|Procedure|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
461337|NCT00685737|Drug|1-MNA|Capsule
461338|NCT00685737|Drug|Placebo|Capsule
461339|NCT00685724|Behavioral|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
461340|NCT00685724|Behavioral|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
461341|NCT00685711|Biological|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
461342|NCT00685698|Drug|TG-873870 (Nemonoxacin)|750 mg
461343|NCT00685685|Drug|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
461344|NCT00685685|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
461345|NCT00685672|Drug|adrenalin|adrenalin 2 microgram pr ml placebo
461346|NCT00685672|Drug|placebo|Saline instead of adrenaline in the epidural mixture
461347|NCT00685659|Other|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
461348|NCT00685659|Other|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
461349|NCT00685659|Other|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
461350|NCT00685646|Drug|antiandrogen therapy|Up to 24 courses of therapy
461351|NCT00685646|Drug|zoledronic acid|Up to 24 courses of therapy
461352|NCT00685633|Drug|bicalutamide|Given orally
461353|NCT00685633|Drug|enzastaurin hydrochloride|Given orally
461354|NCT00685620|Behavioral|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
461355|NCT00685607|Drug|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
461356|NCT00685607|Drug|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
461357|NCT00685594|Drug|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
461358|NCT00685594|Drug|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
461359|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
461360|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
461361|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
461362|NCT00685568|Drug|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
461363|NCT00685568|Other|placebo|Orally, twice daily for 3 months
461364|NCT00685555|Behavioral|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
461365|NCT00685555|Behavioral|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
461366|NCT00685542|Drug|diacerein|Diacerein 50mg bid
461367|NCT00685542|Drug|placebo|placebo
461368|NCT00685529|Drug|Racemic formoterol|12 µg of racemic formoterol fumarate BID
461369|NCT00685529|Drug|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
461370|NCT00685529|Drug|Racemic formoterol|24 µg of racemic formoterol fumarate BID
461371|NCT00685516|Dietary Supplement|green tea|6 cups of green tea daily for 2-8 weeks
461372|NCT00685516|Dietary Supplement|placebo|6 cups of water daily for 2-8 weeks
461373|NCT00685516|Dietary Supplement|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
461374|NCT00685503|Drug|Ranibizumab|
461375|NCT00685490|Procedure|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
461376|NCT00685477|Drug|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
461377|NCT00685477|Drug|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
461378|NCT00685477|Drug|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
461379|NCT00685477|Drug|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
461380|NCT00685477|Drug|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
461381|NCT00685477|Drug|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
461382|NCT00685464|Drug|Abciximab|Intravenous.
461383|NCT00685464|Drug|Abciximab|Intracoronary
461384|NCT00685451|Behavioral|Cognitive Behavioral Therapy (CBT)|
461385|NCT00685425|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~Arm #A~Xopenex HFA MDI"
461386|NCT00685425|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~Arm #B~Proventil HFA MDI"
461387|NCT00685412|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
461388|NCT00685399|Drug|AIN457|AIN457 subcutaneous dose
461389|NCT00685399|Drug|AIN 457|AIN457 low dose (i.v)
461390|NCT00685399|Drug|AIN457|AIN457 high dose (i.v)
461391|NCT00685386|Other|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
461392|NCT00685386|Other|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
461393|NCT00685373|Drug|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
461394|NCT00685360|Drug|OPC-67683|100 mg BID will be administered as two 50 mg tablets together with two matching placebo tablets for a total of four tablets administered twice a day (total daily dose of OPC-67683 is 200 mg) for 56 days. .
461395|NCT00685360|Drug|OPC-67683|200 mg BID will be administered as four 50 mg tablets administered twice a day for (total daily dose of OPC-67683 is 400 mg) 56 days.
461396|NCT00685360|Drug|Placebo|Placebo will be administered as four 50 mg tablets matching the OPC-67683 tablets administered twice a day for 56 days
461397|NCT00685347|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~Arm #A~Xopenex HFA MDI"
461398|NCT00685347|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~Arm #B~Proventil HFA MDI"
461399|NCT00685334|Drug|Olanzapine|Participants will take olanzapine daily for 12 weeks.
461400|NCT00685334|Drug|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
461401|NCT00685321|Device|H1 deep TMS coil|20 daily deep rTMS treatment
461402|NCT00685321|Device|Sham|inactive treatment
461403|NCT00685308|Procedure|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.~All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
461404|NCT00685295|Drug|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
461405|NCT00685295|Drug|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
461406|NCT00685295|Drug|Oxycodone|Oxycodone 5/325 mg tablet
461407|NCT00685282|Behavioral|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
461408|NCT00685269|Drug|Eszopiclone|Eszopiclone 3 mg QD
461409|NCT00685269|Drug|Placebo|Placebo tablet
461410|NCT00685256|Other|counseling intervention|subjects and parents will receive genetic counseling
461411|NCT00685256|Other|educational intervention|subjects and parents will receive education re: genetic testing
461412|NCT00685256|Other|survey administration|surveys will be administered to subjects and parents
461413|NCT00685256|Behavioral|psychosocial assessment and care|psychosocial assessment and counseling will be provided
461414|NCT00685256|Behavioral|supportive care|parents and children will be provided with supportive care
461415|NCT00685243|Procedure|Laser treatment|Fraxel and pulsed dye laser
461416|NCT00685230|Biological|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
461417|NCT00685230|Other|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
461418|NCT00685217|Procedure|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
461419|NCT00685217|Procedure|TVT (Gynecare)|Sling procedure for stress urinary incontinence
461420|NCT00685204|Drug|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
461421|NCT00685191|Drug|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
461422|NCT00685178|Drug|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.~capsules are administered from week 4 through 25 of the trial"
461423|NCT00685178|Behavioral|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
461424|NCT00685178|Drug|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
461425|NCT00685165|Drug|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
461426|NCT00685165|Drug|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
461427|NCT00685152|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
461428|NCT00685139|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
461429|NCT00685139|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
461430|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
461431|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
461432|NCT00685126|Drug|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
461433|NCT00685113|Drug|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
461434|NCT00685113|Drug|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
461435|NCT00685113|Drug|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
461436|NCT00685100|Other|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
461437|NCT00685074|Behavioral|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
461438|NCT00685074|Behavioral|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
461439|NCT00685061|Drug|Thymoglobulin|Induction
461440|NCT00685061|Drug|Campath-1H|Induction
461441|NCT00685061|Drug|Daclizumab|Induction
461442|NCT00685048|Behavioral|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
461443|NCT00685048|Behavioral|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
461444|NCT00685048|Behavioral|four 50-minute individual therapy sessions of MET & CBT|MET & CBT
461445|NCT00685035|Device|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
461446|NCT00685035|Device|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
461447|NCT00685022|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~Arm #A~Xopenex HFA MDI, albuterol HFA MDI"
461448|NCT00685022|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~Arm #B~albuterol HFA MDI, Xopenex HFA MDI"
461449|NCT00685009|Drug|Estrogen hormone therapy|Estrogen pill daily
461450|NCT00685009|Drug|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
461451|NCT00685009|Drug|Placebo|Placebo pill daily
461452|NCT00684996|Drug|etaracizumab|Given IV
461453|NCT00684996|Biological|bevacizumab|Given IV
461454|NCT00684983|Drug|Capecitabine|Given PO
461455|NCT00684983|Biological|Cixutumumab|Given IV
461456|NCT00684983|Drug|Lapatinib|Given PO
461457|NCT00684983|Drug|Lapatinib Ditosylate|Given PO
461458|NCT00684983|Other|Quality-of-Life Assessment|Ancillary studies
461459|NCT00684970|Drug|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
461460|NCT00684957|Drug|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
461461|NCT00684957|Drug|Recombinant human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
461462|NCT00684944|Drug|TRx0014|Gelatin capsule, tid
461463|NCT00684931|Other|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
461464|NCT00684918|Drug|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
461465|NCT00684905|Drug|bicalutamide|
461466|NCT00684905|Drug|leuprolide acetate|
461467|NCT00684905|Procedure|adjuvant therapy|
461468|NCT00684905|Procedure|neoadjuvant therapy|
461469|NCT00684905|Procedure|quality-of-life assessment|
461470|NCT00684905|Radiation|brachytherapy|
461471|NCT00684892|Device|Chartis System|Assessment of airway flow and pressure
461472|NCT00684866|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
461473|NCT00684866|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
461474|NCT00684853|Drug|bevacizumab|1.25 mg of bevacizumab intravitreal
461475|NCT00684853|Drug|vetaporfin|full fluence of vetaporfin
461476|NCT00684827|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~Arm #A~Xopenex HFA MDI, Pirbuterol HFA MDI"
461477|NCT00684827|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~Arm #B~Pirbuterol HFA MDI, Xopenex HFA MDI"
461478|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
461479|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
461480|NCT00684801|Other|questionnaire administration|Patients complete questionnaires.
461481|NCT00684801|Procedure|quality-of-life assessment|Patients undergo quality-of-life assessments.
461517|NCT00684515|Drug|Aspirin 75-150 mg|oral tablets; once daily for 60 days
461482|NCT00684788|Combination Product|employment-based reinforcement|"Participants in the Work Plus Naltrexone Contingency condition were required to take scheduled doses of depot naltrexone to work and earn wages."
461483|NCT00684775|Combination Product|Work Plus Naltrexone Contingency|"Vivitrol, an extended-release depot formulation of naltrexone, was used. Participants were offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) were randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition earned access to working and earning salary by taking depot naltrexone injections once per month."
461484|NCT00684762|Drug|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
461485|NCT00684762|Drug|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
461486|NCT00684723|Drug|Lovastatin 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
461487|NCT00684723|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
461488|NCT00684710|Drug|PAZ-417|
461489|NCT00684710|Drug|Placebo|
461490|NCT00684697|Dietary Supplement|iron|High, intermediate and low iron dosage orally for 2 months
461491|NCT00684684|Device|Chartis System|Assessment of airway flow and pressure
461492|NCT00684671|Biological|Twinrix|Intramuscular injection, single dose in left deltoid.
461493|NCT00684671|Biological|Engerix-B|Intramuscular injection, single dose in left deltoid.
461494|NCT00684671|Biological|Havrix|Intramuscular injection, single dose in right deltoid.
461495|NCT00684671|Biological|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
461496|NCT00684671|Biological|Vaqta|Intramuscular injection, single dose in right deltoid.
461497|NCT00684658|Behavioral|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
461498|NCT00684658|Behavioral|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
461499|NCT00684645|Drug|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
461500|NCT00684632|Drug|Placebo|Placebo
461501|NCT00684632|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
461502|NCT00684619|Drug|Nelarabine|1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
461503|NCT00684606|Drug|Oxytocin IV|5 miu/1000ml Glu/Saline
461504|NCT00684593|Drug|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
461505|NCT00684593|Other|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
461506|NCT00684580|Other|Data Collection|Continuing review of outcomes and late toxicities
461507|NCT00684567|Radiation|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
461508|NCT00684567|Drug|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
461509|NCT00684554|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
461510|NCT00684541|Behavioral|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
461511|NCT00684541|Behavioral|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
461512|NCT00684528|Drug|Metformin 1500 mg daily|500 mg thrice daily
461513|NCT00684528|Drug|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
461514|NCT00684515|Drug|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
461515|NCT00684515|Drug|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
461516|NCT00684515|Drug|Placebo|oral tablets; once daily for 60 days
462083|NCT00680290|Procedure|Exercise|Exercise x 8 weeks
461518|NCT00684502|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
461519|NCT00684502|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
461520|NCT00684489|Drug|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
461521|NCT00684489|Drug|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
461522|NCT00684476|Drug|venom immunotherapy|
461523|NCT00684463|Drug|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
461524|NCT00684450|Procedure|Titration protamine|10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
461525|NCT00684450|Drug|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
461526|NCT00684437|Behavioral|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
461527|NCT00684437|Behavioral|Questionnaire|Questionnaires taking 15-30 minutes to complete.
461528|NCT00684424|Other|Non-Interventional Study|Observational Only
461529|NCT00684411|Drug|Imatinib mesylate|
461530|NCT00684385|Drug|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H&NC will take two tablets at each dose administration.
461531|NCT00684372|Drug|leflunomide|"Screening: If BK viremia (BK PCR >10 000 copies/ml in serum) i. Reduced immunosuppression~MMF / AZA withdrawal~CNI reduction~Tacrolimus 5 ng/ml in serum~Cyclosporin 100 ng/ml in serum~Prednisolone to maintenance level~If effective => continue~Stable renal function (P-Krea)~>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis~Negative PCR at > 3 months after diagnosis~If failure => add leflunomide~Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy~<50% reduction in PCR at 4 weeks after diagnosis~Positive PCR at >3 months after diagnosis~Leflunomide dosing:~ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)~Starting at 20 mgx1 PO daily~Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 >40 ug/ml"
461532|NCT00684346|Other|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
461533|NCT00684333|Device|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
461534|NCT00684320|Behavioral|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
461535|NCT00684320|Behavioral|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
461536|NCT00684307|Drug|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
461537|NCT00684307|Drug|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
461538|NCT00684307|Drug|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
461539|NCT00684294|Biological|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10^7 cells/ injection or TAG Vaccine 2.5 X 10^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
461540|NCT00684281|Other|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
461541|NCT00684281|Other|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
461542|NCT00684268|Drug|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days~sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
461543|NCT00684268|Drug|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
461544|NCT00684255|Procedure|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
461545|NCT00684255|Drug|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
461546|NCT00684255|Drug|Busulfan|Busulfan 3.2 mg/kg Days _8, -7, -6, -5
461547|NCT00684255|Drug|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
461548|NCT00684242|Drug|Lenalidomide|10 mg by mouth daily
461549|NCT00684229|Procedure|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
461550|NCT00684229|Drug|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
461551|NCT00684216|Drug|capecitabine|200 mg, BID, PO, QD until progression of disease
461552|NCT00684216|Drug|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
461553|NCT00684203|Drug|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
461554|NCT00684203|Drug|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
461555|NCT00684203|Drug|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
461556|NCT00684203|Drug|Clopidogrel|100 mg two or three times daily for 60 days.
461557|NCT00684190|Drug|AZD3355|150 mg bid, oral, 7 days
461558|NCT00684190|Drug|Esomeprazole|40 mg od, oral, 7 days
461559|NCT00684177|Drug|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
461560|NCT00684177|Drug|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
461561|NCT00684164|Drug|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
461562|NCT00684164|Other|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
461563|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
461564|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
461565|NCT00684125|Device|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
461566|NCT00684125|Device|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
461567|NCT00684112|Drug|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
461568|NCT00684112|Drug|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
461569|NCT00684099|Drug|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
461570|NCT00684099|Drug|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
461571|NCT00684086|Behavioral|Diabetes Self Management Program|
461572|NCT00684073|Drug|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
461573|NCT00684073|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
461574|NCT00684060|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
461575|NCT00684060|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
461576|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
461577|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
461578|NCT00684047|Procedure|Manual Compression|Manual Compression. Primary Part (II)
461579|NCT00684034|Other|Sampling of blood|A sampling of blood will be made
461580|NCT00684034|Other|Sampling of blood|A sampling of bood will be made before the dialysis
461581|NCT00684034|Other|Sampling of blood|A sampling of blood will be made.
461582|NCT00684021|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
461583|NCT00684021|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
461584|NCT00684008|Drug|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
461585|NCT00684008|Drug|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
461586|NCT00683995|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
461587|NCT00683982|Drug|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
461588|NCT00683982|Drug|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
461589|NCT00683982|Other|Oral hydration solutions|Oral hydration solutions as needed
461590|NCT00683969|Drug|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
461591|NCT00683969|Drug|placebo|po bid for 36 weeks
461592|NCT00683956|Device|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
461593|NCT00683956|Drug|Propofol|
461594|NCT00683943|Drug|Lithium Carbonate|
461664|NCT00683462|Drug|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
461595|NCT00683930|Drug|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
461596|NCT00683930|Drug|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
461597|NCT00683930|Drug|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
461598|NCT00683917|Drug|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
461599|NCT00683917|Drug|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
461600|NCT00683917|Drug|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
461601|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
461602|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
461603|NCT00683891|Drug|FazaClo (clozapine, USP) ODT|
461604|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
461605|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
461606|NCT00683878|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
461607|NCT00683878|Drug|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
461608|NCT00683865|Drug|Ofloxacin|Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
461609|NCT00683865|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg po od for 14 days
461610|NCT00683852|Drug|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
461611|NCT00683852|Drug|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
461612|NCT00683852|Drug|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
461613|NCT00683839|Behavioral|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
461614|NCT00683826|Dietary Supplement|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
461615|NCT00683826|Other|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
461616|NCT00683826|Dietary Supplement|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
461617|NCT00683813|Behavioral|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
461618|NCT00683800|Drug|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
461619|NCT00683800|Drug|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
461620|NCT00683787|Drug|docetaxel|Given IV once every 3 weeks
461621|NCT00683787|Drug|vandetanib|Oral vandetanib once daily
461622|NCT00683774|Drug|diazoxide|100mg orally three times per day for 10 days
461665|NCT00683449|Drug|Dose Group 1|IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
461666|NCT00683449|Drug|MN-221 placebo|i.v. infusion of placebo for 15 minutes
461667|NCT00683449|Drug|Dose Group 2|i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
461623|NCT00683761|Drug|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
461624|NCT00683735|Drug|Sitagliptin|100 mg once daily in the morning
461625|NCT00683735|Drug|Metformin|up to 2000 mg/day
461626|NCT00683735|Drug|Placebo|500mg 1-0-0-0
461627|NCT00683735|Drug|Placebo|100mg 1-0-0-0
461628|NCT00683722|Drug|PROCHYMAL™|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
461629|NCT00683722|Drug|Placebo|Intravenous infusion of excipient of PROCHYMAL™
461630|NCT00683709|Behavioral|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
461631|NCT00683709|Behavioral|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
461632|NCT00683696|Device|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
461633|NCT00683683|Behavioral|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
461634|NCT00683670|Drug|cyclophosphamide|
461635|NCT00683670|Biological|Mature dendritic cell vaccine|
461636|NCT00683657|Drug|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
461637|NCT00683657|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
461638|NCT00683644|Drug|Zinc|Zinc taken once daily
461639|NCT00683644|Drug|Placebo oral capsule|Placebo capsules taken once daily
461640|NCT00683631|Radiation|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
461641|NCT00683618|Drug|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
461642|NCT00683618|Drug|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
461643|NCT00683592|Drug|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
461644|NCT00683592|Drug|placebo|placebo
461645|NCT00683579|Drug|Early Treatment with HAART|HAART with possibility of de-intensification
461646|NCT00683579|Other|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
461647|NCT00683579|Drug|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA >100,000 copies/ml
461648|NCT00683566|Procedure|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
461649|NCT00683553|Drug|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
461650|NCT00683553|Drug|Placebo|Single IV injection of saline
461651|NCT00683527|Drug|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
461652|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :~50 mg/m2 oral vinorelbine d1, d8, d15~20 mg/m2/d cisplatin from d1 to d4"
461653|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :~60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2~80 mg/m2 cisplatin d1"
461654|NCT00683501|Drug|DNB-001|four dosages of DNB-001, one placebo dosage
461655|NCT00683488|Behavioral|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
461656|NCT00683488|Behavioral|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.~Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.~Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.~Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
461657|NCT00683488|Behavioral|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
461658|NCT00683475|Biological|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
461659|NCT00683475|Drug|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m^2) or until there is evidence of disease progression, death, or intolerable toxicity.
461660|NCT00683475|Drug|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
461661|NCT00683475|Biological|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
461662|NCT00683462|Drug|Placebo|
461663|NCT00683462|Drug|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
461668|NCT00683449|Drug|Dose Group 3|i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
461669|NCT00683436|Drug|Adipiplon|bilayer tablets 6 mg
461670|NCT00683436|Drug|Placebo|Placebo
461671|NCT00683436|Drug|Ambien CR|Ambien CR 12.5 mg
461672|NCT00683436|Drug|Adipiplon|bilayer tablets 9 mg
461673|NCT00683423|Drug|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
461674|NCT00683423|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
461675|NCT00683410|Biological|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
461676|NCT00683397|Other|Blood sampling|Screening of thrombophilia
461677|NCT00683384|Drug|Etanercept (Enbrel)|
461678|NCT00683371|Procedure|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
461679|NCT00683371|Procedure|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
461680|NCT00683358|Biological|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
461681|NCT00683345|Drug|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
461682|NCT00683345|Drug|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
461683|NCT00683332|Drug|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
461684|NCT00683319|Drug|carboplatin|
461685|NCT00683319|Drug|cisplatin|
461686|NCT00683319|Drug|cyclophosphamide|
461687|NCT00683319|Drug|methotrexate|
461688|NCT00683319|Drug|vincristine sulfate|
461689|NCT00683319|Procedure|adjuvant therapy|
461690|NCT00683319|Procedure|cognitive assessment|
461691|NCT00683319|Procedure|magnetic resonance imaging|
461692|NCT00683319|Procedure|magnetic resonance spectroscopic imaging|
461693|NCT00683319|Procedure|quality-of-life assessment|
461694|NCT00683306|Drug|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
461695|NCT00683293|Procedure|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
461696|NCT00683293|Procedure|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
461697|NCT00683280|Behavioral|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
461698|NCT00683280|Other|Standard of Care|varenicline (smoking cessation medication) 0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
461699|NCT00683280|Other|Standard of Care|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
461700|NCT00683267|Drug|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
461701|NCT00683267|Drug|Placebo|One dose administered by direct instillation into the surgical site
461702|NCT00683241|Biological|DCVac-L|Subjects will receive three doses of intradermal vaccination with ~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
461703|NCT00683228|Behavioral|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
461704|NCT00683202|Drug|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
461705|NCT00683202|Drug|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
461706|NCT00683189|Drug|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
461707|NCT00683176|Drug|Choline Fenofibrate|135 mg
461708|NCT00683176|Drug|Placebo|Placebo
461709|NCT00683163|Drug|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
461710|NCT00683163|Drug|Ibandronate|150mg by mouth once monthly
461711|NCT00683163|Other|Placebo injection|Daily injections as placebo for PTS 1-84
461712|NCT00683163|Other|Placebo pills|Monthly pills as placebo for oral ibandronate
461713|NCT00683150|Other|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
461714|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
461715|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
461716|NCT00683137|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
461896|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
461717|NCT00683124|Drug|Losartan and nebivolol|"Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations"
461718|NCT00683124|Drug|Losartan|Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
461719|NCT00683124|Drug|Nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
461720|NCT00683111|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
461721|NCT00683111|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
461722|NCT00683085|Biological|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
461723|NCT00683059|Drug|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
461724|NCT00683046|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
461725|NCT00683046|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
461726|NCT00683046|Drug|Stem cells|Stem cell infusion on day 0.
461727|NCT00683046|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
461728|NCT00683033|Behavioral|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
461729|NCT00683033|Behavioral|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
461730|NCT00683020|Behavioral|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.~For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
461731|NCT00683007|Other|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
461732|NCT00683007|Other|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
461733|NCT00682994|Behavioral|Interview|Interview lasting about 5-10 minutes.
461734|NCT00682994|Behavioral|Questionnaire|Questionnaires taking 20-30 minutes to complete.
461735|NCT00682981|Drug|Obatoclax|IV Infusions for 3 consecutive days of either 3-hours, 2 hours duration
461736|NCT00682981|Drug|Carboplatin/etoposide|Carboplatin/etoposide combination
461737|NCT00682955|Drug|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
461738|NCT00682955|Drug|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
461739|NCT00682929|Drug|Inhaled Cannabis|Participants will be instructed to smoke one cannabis cigarette, daily for 7 weeks.
461740|NCT00682929|Drug|Oral THC|Participants will be instructed to take two 5 mg dronabinol tablets two hours prior to the inhaled medication, daily for 7 weeks.
461741|NCT00682929|Drug|Oral Placebo|Participants will be instructed to take two placebo tablets two hours prior to the inhaled medication, daily for 7 weeks.
461742|NCT00682929|Drug|Inhaled placebo|Participants will be instructed to smoke one placebo cigarette, daily for 7 weeks.
461743|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
461744|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
461745|NCT00682903|Device|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
461746|NCT00682890|Drug|placebo|placebo birth control pill daily
461747|NCT00682890|Drug|metformin|2000 mg per day for 3 months daily birth control pill
461748|NCT00682851|Device|OSOM Trichomonas Rapid Test|Rapid test run using vaginal discharge collected via a cotton swab
461749|NCT00682851|Device|OSOM BVBlue Test|Rapid test run using vaginal discharge collected using a cotton swab
461750|NCT00682838|Behavioral|Self-management|Self-management
461751|NCT00682838|Behavioral|Telemonitored care|Telemonitored care
461752|NCT00682825|Behavioral|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
461753|NCT00682825|Behavioral|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
461754|NCT00682812|Other|2 cervical takings and 2 sampling of blood|"2 cervical takings~2 sampling of blood before and after the total hysterectomy"
461755|NCT00682812|Other|2 cervical takings and 2 sampling of blood|"cervical taking during the cervical conization~2 sampling of blood before and after the intervention"
461756|NCT00682812|Other|2 cervical takings and 2 sampling of blood|"cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation~2 sampling of blood before and after the intervention"
461757|NCT00682786|Drug|5FU|
461758|NCT00682786|Radiation|Radiation|
461759|NCT00682786|Procedure|Surgery of resectable lesions|
461760|NCT00682786|Drug|Irinotecan|
461761|NCT00682773|Other|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
461762|NCT00682760|Drug|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
461763|NCT00682747|Drug|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
461764|NCT00682734|Drug|metoclopramide|metoclopramide 20 mg
461765|NCT00682734|Drug|metoclopramide|metoclopramide 40 mg
461766|NCT00682734|Drug|metoclopramide|metoclopramide 10 mg
461767|NCT00682734|Drug|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
461768|NCT00682721|Drug|Placebo|Matching placebo two pills once daily
461769|NCT00682721|Drug|Valacyclovir|1 gram daily x number of days active in the study
461770|NCT00682708|Dietary Supplement|PlumpyNut|
461771|NCT00682708|Dietary Supplement|PlumpyDoz|
461772|NCT00682682|Other|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
461773|NCT00682682|Other|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
461774|NCT00682669|Behavioral|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
461775|NCT00682669|Behavioral|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
461776|NCT00682656|Drug|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
461777|NCT00682656|Drug|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
461778|NCT00682643|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray
461779|NCT00682643|Drug|vehicle placebo nasal spray|placebo
461780|NCT00682630|Drug|pyronaridine artesunate|720:240 mg of the reference tablet formulation; wash out period of 43 days; 720:240 mg of the to-be-marketed formulation; wash out period of 43 days
461781|NCT00682617|Behavioral|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
461782|NCT00682617|Behavioral|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
461783|NCT00682578|Drug|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
461784|NCT00682578|Drug|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
461785|NCT00682565|Drug|CK-1827452 24mg and 6 mg iv infusion|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
461786|NCT00682565|Drug|CK-1827452 12.5mg capsule|12.5mg oral immediate release capsule
461787|NCT00682565|Drug|CK-1827452 48 mg and 11 mg iv infusion|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
461788|NCT00682565|Drug|CK-1827452 25mg capsule|25mg oral immediate release capsule
461789|NCT00682565|Drug|Placebo iv infusion|Matching placebo iv infusion
461790|NCT00682565|Drug|Placebo capsule|Matching placebo oral immediate release capsule
461791|NCT00682552|Procedure|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
461792|NCT00682539|Drug|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
461897|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
461793|NCT00682539|Drug|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
461794|NCT00682539|Drug|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
461795|NCT00682539|Procedure|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
461796|NCT00682526|Device|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
461797|NCT00682500|Drug|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
461798|NCT00682500|Drug|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
461799|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
461800|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
461801|NCT00682474|Behavioral|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
461802|NCT00682474|Behavioral|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
461803|NCT00682461|Drug|Nicotine|Marketed nicotine replacement therapy formulation
461804|NCT00682461|Drug|Nicotine|Nicotine prototype
461805|NCT00682448|Drug|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
461806|NCT00682448|Drug|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
461807|NCT00682435|Drug|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
461808|NCT00682409|Other|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
461809|NCT00682383|Drug|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
461810|NCT00682370|Drug|saline solution|intravenous infusion, single dose
461811|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~0.3 mg/kg heme arginate"
461812|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~1 mg/kg heme arginate"
461813|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose~3 mg/kg heme arginate"
461814|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
461815|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
461816|NCT00682357|Drug|Placebo and Lidocaine|Placebo and lidocaine 20 mg
461817|NCT00682344|Drug|Levobupivacaïne|1,75mg/kg
461818|NCT00682318|Drug|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;~Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;~Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
461819|NCT00682318|Dietary Supplement|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
461820|NCT00682318|Dietary Supplement|Ethanol|"Part 1 & Part 1.1:~Dose of 0.9 g/kg body weight 98% alcohol solution~Part 2a:~Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution~Part 2b, Part 3:~Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
461821|NCT00682318|Dietary Supplement|Omega-3 polyunsaturated fatty acids|"Part 2b:~Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;~Part 3:~Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
461822|NCT00682318|Dietary Supplement|Omega-6 polyunsaturated fatty acid|"Part 2b:~Control omega-6 fatty acid alimentary diet (<130 mg/day EPA/DHA)"
461898|NCT00681668|Drug|Quetiapine|150-800 mg, oral, twice a day (bid)
461823|NCT00682305|Procedure|Hematopoietic stem cell transplantation|"conditioning regimen:~day -7: 12g/m^2 Treosulfan~day -6: 12g/m^2 Treosulfan~day -5: 12g/m^2 Treosulfan~day -4: 30mg/kg BW Etoposide~day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~day -1: 20mg/kg ATG Fresenius (OPTIONAL)~day 0: SCT"
461824|NCT00682292|Drug|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
461825|NCT00682292|Drug|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
461826|NCT00682279|Drug|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
461827|NCT00682266|Behavioral|intensity controlled interval training (AIT)|4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
461828|NCT00682266|Behavioral|Multidisciplinary approach (MTG)|exercise, dietary and psychological advice, twice a month for 12 months
461829|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - single-session
461830|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - multi-session
461831|NCT00682240|Procedure|laser treatment with PASCAL®|grid / focal laser treatment
461832|NCT00682240|Procedure|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
461833|NCT00682227|Biological|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
461834|NCT00682214|Drug|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
461835|NCT00682214|Drug|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
461836|NCT00682188|Behavioral|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
461837|NCT00682188|Behavioral|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
461838|NCT00682175|Other|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
461839|NCT00682162|Device|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
461840|NCT00682162|Device|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
461841|NCT00682149|Dietary Supplement|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
461842|NCT00682136|Procedure|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
461843|NCT00682123|Dietary Supplement|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.~The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
461844|NCT00682097|Drug|RO4998452|Escalating oral doses
461845|NCT00682097|Drug|placebo|Oral doses
461846|NCT00682084|Procedure|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
461847|NCT00682058|Other|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
461848|NCT00682032|Dietary Supplement|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
461849|NCT00682019|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
461850|NCT00682019|Drug|Placebo|matching placebo
461851|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
461852|NCT00682006|Other|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
461853|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
461854|NCT00681993|Other|Standard Dose Dense Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
461855|NCT00681993|Other|Standard Doxorubucin and Cyclophosphamide|4 cycles of Standard Dose Doxorubucin and Cyclophosphamide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
461856|NCT00681993|Other|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
461857|NCT00681993|Other|Standard Docetaxel, Doxorubucin and Cyclophosphamide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
461858|NCT00681993|Other|Standard Docetaxel and Cyclophosphamide|4 cycles of Standard Docetaxel and Cyclophosphamide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
461859|NCT00681980|Drug|Valproic acid|15 mg/kg/day
461860|NCT00681980|Drug|costicosteroids|metypredsolone 1 g/day
461861|NCT00681980|Drug|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
461862|NCT00681967|Drug|Gefitinib|250 mg; oral
461863|NCT00681967|Drug|Gefitinib|250mg; oral
461864|NCT00681941|Drug|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
461865|NCT00681928|Drug|anastrozole|As determined by the subject's physician
461866|NCT00681928|Drug|letrozole|As determined by the subject's physician
461867|NCT00681928|Other|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
461868|NCT00681928|Procedure|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
461869|NCT00681928|Procedure|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
461870|NCT00681915|Drug|AZD7325|Oral
461871|NCT00681902|Drug|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
461872|NCT00681902|Drug|Placebo|Jet saline
461873|NCT00681889|Drug|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
461874|NCT00681876|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
461875|NCT00681876|Drug|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
461876|NCT00681876|Drug|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
461877|NCT00681863|Drug|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
461878|NCT00681863|Drug|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
461879|NCT00681863|Drug|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
461880|NCT00681863|Drug|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
461881|NCT00681863|Drug|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
461882|NCT00681824|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
461883|NCT00681824|Procedure|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
461884|NCT00681811|Drug|HGT-1111|Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
461885|NCT00681798|Drug|Vandetanib|100mg/300mg
461886|NCT00681785|Drug|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
461887|NCT00681772|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
461888|NCT00681746|Drug|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
461889|NCT00681746|Drug|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
461890|NCT00681733|Drug|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
461891|NCT00681733|Drug|Pioglitazone|30 mg OD
461892|NCT00681733|Drug|Pentoxifylline|1200 mg/d
461893|NCT00681720|Drug|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
461894|NCT00681720|Drug|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
461895|NCT00681694|Radiation|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
461899|NCT00681655|Drug|Alcohol|Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).
461900|NCT00681655|Drug|Placebo|Placebo (saline vehicle) infused for 2.8 hour long session.
461901|NCT00681629|Drug|Quetiapine XR|400-800 mg, oral, bid
461902|NCT00681629|Other|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
461903|NCT00681616|Device|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement & Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
461904|NCT00681616|Device|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
461905|NCT00681616|Device|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
461906|NCT00681603|Drug|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
461907|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|400 IU daily (low dose)
461908|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|2000 IU daily (high dose)
461909|NCT00681577|Biological|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
461910|NCT00681564|Procedure|One-Stage Full-Mouth Disinfection|"Scaling and root planing, four quadrants in one session~Tongue brushing with a 1% chlorhexidine gel (1 minute)~Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)~Subgingival chlorhexidine (1%) irrigation in all pockets~Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention~Basic oral hygiene instructions~Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
461911|NCT00681564|Procedure|Periodontal care|"Basic oral hygiene instructions~Supragingival plaque removal"
461912|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
461913|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
461914|NCT00681538|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
461915|NCT00681538|Drug|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
461916|NCT00681525|Drug|ABT-335|One ABT-335 135 mg capsule QD for 10 days
461917|NCT00681525|Drug|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
461918|NCT00681525|Drug|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
461919|NCT00681512|Dietary Supplement|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.~The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.~All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
461920|NCT00681486|Drug|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
461921|NCT00681486|Drug|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
461922|NCT00681473|Radiation|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
461923|NCT00681460|Drug|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
461924|NCT00681460|Drug|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
461925|NCT00681447|Procedure|Lumbar Interlaminar Epidural|"Lumbar interlaminar epidural injections under fluoroscopy~Epidural tray and needle~Drugs:~0.5% Xylocaine and non-particulate Celestone"
461926|NCT00681447|Procedure|Lumbar Interlaminar Epidural injection|"Lumbar interlaminar epidural injections under fluoroscopy~Epidural tray and needle~Drugs:~0.5% Xylocaine and non-particulate Celestone"
461927|NCT00681434|Behavioral|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
461928|NCT00681434|Behavioral|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
461929|NCT00681421|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
461930|NCT00681408|Drug|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
461931|NCT00681408|Drug|Placebo|Fish oil placebo pills
461932|NCT00681395|Drug|ABT-143|once daily for 6 days
461933|NCT00681395|Drug|ABT-335|once daily for six days
461934|NCT00681395|Drug|Rosuvastatin|Once daily for 6 days
461935|NCT00681356|Drug|4975, 15 and 5 mg|Direct instillation into the surgical site
461937|NCT00681356|Drug|4975 - 5 mg|Direct instillation into the surgical site
461938|NCT00681343|Drug|Thymoglobulin|Induction
461939|NCT00681343|Drug|Campath-1H|Induction
461940|NCT00681343|Drug|Daclizumab|Induction
461941|NCT00681330|Biological|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
461942|NCT00681317|Drug|AZD6280|oral
461943|NCT00681304|Other|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
461944|NCT00681291|Device|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
461945|NCT00681291|Device|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
461946|NCT00681265|Drug|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
461947|NCT00681265|Drug|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
461948|NCT00681252|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
461949|NCT00681239|Dietary Supplement|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
461950|NCT00681226|Drug|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
461951|NCT00681213|Drug|Tacrolimus/Sirolimus|
461952|NCT00681213|Drug|Tacrolimus/MMF|
461953|NCT00681213|Drug|Neoral/Sirolimus|
461954|NCT00681200|Behavioral|Enhanced health education|health education and social support
461955|NCT00681200|Behavioral|Transcendental Meditation program|The TM program plus didactic-based health education classes
461956|NCT00681187|Drug|lanreotide (Autogel formulation)|90 mg or 120 mg once every 28th day
461957|NCT00681174|Drug|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
461958|NCT00681174|Drug|oxycodone|20 mg p.o. 1 h before the start of anesthesia
461959|NCT00681174|Procedure|Paravertebral block|"Three injections of 0.5% ropivacaine, 5 ml each~Injections at the T5, T6 and T7 levels~A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper."
461960|NCT00681174|Drug|Propofol|"Plasma concentration target-controlled infusion based on bispectral index values~Acceptable range of concentrations: 2-4 µg/mL~Target bispectral index values: 40-60~Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)"
461961|NCT00681174|Drug|Remifentanil|"50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min~Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)~Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.~Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)"
461962|NCT00681174|Drug|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
461963|NCT00681174|Drug|Morphine|"Patient-controlled intravenous infusion pump (IV-PCA).~50 mg morphine in 50 ml saline solution (1 mg/ml)~Incremental dose: 1 mg~Lock-out time: 8 min~Limit: 40 mg in 4 h~Background infusion: none"
461964|NCT00681161|Other|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
461965|NCT00681148|Drug|Botox injection|Intraprostatic injection of Botox (100 units for < 30 cc prostate; 200 units for > 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
461966|NCT00681148|Drug|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
461967|NCT00681135|Device|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
461968|NCT00681135|Device|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
461969|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
461970|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
461971|NCT00681109|Drug|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
461972|NCT00681109|Drug|Placebo|custom eye drop to be applied three times a day in both eyes for three months
461973|NCT00681109|Drug|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
461974|NCT00681083|Device|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
461975|NCT00681083|Device|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
461976|NCT00681070|Other|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
461977|NCT00681070|Other|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
461978|NCT00681044|Biological|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
461979|NCT00681044|Drug|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
461980|NCT00681044|Procedure|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
461981|NCT00681031|Biological|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
461982|NCT00681018|Other|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
461983|NCT00681018|Other|Powder human milk fortifier|Powder human milk fortifier added to human milk
461984|NCT00681005|Drug|rabeprazole|20 mg bid for 14 days
461985|NCT00681005|Drug|pantoprazole|pantoprazole 40 mg bid
461986|NCT00680992|Drug|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
461987|NCT00680979|Behavioral|Interpersonal Psychotherapy|
461988|NCT00680979|Behavioral|Health Education|
461989|NCT00680966|Behavioral|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
461990|NCT00680953|Drug|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
461991|NCT00680953|Drug|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
461992|NCT00680953|Drug|Alendronate sodium hydrate|Oral tablet once a week for 24 months
461993|NCT00680940|Drug|Paclitaxel & Cisplatin|Chemotherapeutic agent
461994|NCT00680940|Biological|Mycobacterium w.|Immunomodulator
461995|NCT00680927|Other|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
461996|NCT00680914|Biological|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
461997|NCT00680914|Biological|Prevenar|3 doses administered intramuscularly.
461998|NCT00680914|Biological|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
461999|NCT00680901|Drug|Lapatinib|5 pills at 250mg each once daily
462000|NCT00680901|Drug|Placebo|5 pills once daily
462001|NCT00680901|Drug|Capecitabine|1700mg/m2/day in two daily doses
462002|NCT00680901|Drug|Oxaliplatin|130mg/m2 on day 1
462003|NCT00680875|Behavioral|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
462004|NCT00680836|Drug|Placebo|orally two times per day for 14 days
462005|NCT00680836|Drug|Rifaximin|550 mg orally two times per day for 14 days
462006|NCT00680823|Drug|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
462007|NCT00680823|Drug|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
462008|NCT00680797|Drug|Testosterone|Testosterone gel
462009|NCT00680797|Drug|Estrogen|Estrogen patch
462010|NCT00680784|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
462011|NCT00680784|Other|Placebo Patch|Placebo Patch
462012|NCT00680758|Drug|cisplatin|"Dose Level: -3 20mg/m2/week 3-6 patients~Dose Level: -2 20mg/m2/week 3-6 patients~Dose Level: -1 25mg/m2/week 3-6 patients~Dose Level: 1 25mg/m2/week 3-6 patients~Dose Level: 2 25mg/m2/week 3-6 patients~Dose Level: 3 25mg/m2/week 3-6 patients"
462013|NCT00680758|Drug|everolimus|"Dose Level: -3 20mg/m2/week 3-6 patients~Dose Level: -2 20mg/m2/week 3-6 patients~Dose Level: -1 20mg/m2/week 3-6 patients~Dose Level: 1 20mg/m2/week 3-6 patients~Dose Level: 2 25mg/m2/week 3-6 patients~Dose Level: 3 30mg/m2/week 3-6 patients"
462014|NCT00680758|Drug|paclitaxel|"Dose Level: -3 65mg/m2/week 3-6 patients~Dose Level: -2 70mg/m2/week 3-6 patients~Dose Level: -1 70mg/m2/week 3-6 patients~Dose Level: 1 80mg/m2/week 3-6 patients~Dose Level: 2 80mg/m2/week 3-6 patients~Dose Level: 3 80mg/m2/week 3-6 patients"
462015|NCT00680745|Drug|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
462016|NCT00680745|Drug|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
462017|NCT00680745|Drug|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
462018|NCT00680745|Drug|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
462019|NCT00680745|Drug|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
462020|NCT00680732|Dietary Supplement|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
462021|NCT00680732|Dietary Supplement|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
462022|NCT00680732|Drug|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
462023|NCT00680732|Drug|Sulphadoxyne-pyrimethamine (SP)|Tablets
462024|NCT00680719|Behavioral|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
462025|NCT00680719|Behavioral|IBFT|Integrated Behavioral and Family Therapy (IBFT).
462026|NCT00680706|Drug|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
462027|NCT00680706|Drug|Placebo|D5W (50 ml)
462028|NCT00680693|Behavioral|Mindfulness training|8 weekly 2-hour classes
462029|NCT00680693|Behavioral|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
462030|NCT00680680|Drug|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
462031|NCT00680667|Biological|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
462032|NCT00680654|Drug|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
462033|NCT00680641|Drug|Simvastatin|40mg of Simvastatin once daily
462034|NCT00680641|Drug|Placebo|40mg of placebo once daily
462078|NCT00680316|Drug|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
462079|NCT00680316|Drug|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
462080|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
462035|NCT00680628|Drug|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.~Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: <60Kg=30mg; ≥60Kg to <70Kg=35mg; ≥70Kg to <80Kg=40mg; ≥80Kg to <90Kg=45mg; ≥90Kg=50mg"
462036|NCT00680628|Drug|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
462037|NCT00680615|Behavioral|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
462038|NCT00680615|Behavioral|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
462039|NCT00680602|Behavioral|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
462040|NCT00680602|Drug|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
462041|NCT00680589|Biological|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
462042|NCT00680576|Behavioral|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
462043|NCT00680576|Behavioral|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
462044|NCT00680563|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
462045|NCT00680537|Procedure|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
462046|NCT00680524|Other|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
462047|NCT00680511|Behavioral|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
462048|NCT00680511|Behavioral|Functional Family Therapy (FFT)|FFT
462049|NCT00680498|Drug|Ranibizumab|Ranibizumab 0.5 mg
462050|NCT00680498|Drug|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
462051|NCT00680485|Drug|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
462052|NCT00680472|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
462053|NCT00680472|Other|Placebo Patch|Treatment with Placebo Patch
462054|NCT00680459|Drug|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
462055|NCT00680459|Drug|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
462056|NCT00680446|Drug|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
462057|NCT00680433|Drug|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
462058|NCT00680433|Drug|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
462059|NCT00680420|Procedure|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
462060|NCT00680407|Other|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
462061|NCT00680407|Drug|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
462062|NCT00680407|Drug|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
462063|NCT00680394|Drug|mifepristone|200 mg mifepristone
462064|NCT00680394|Drug|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
462065|NCT00680394|Drug|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
462066|NCT00680381|Behavioral|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
462067|NCT00680381|Behavioral|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
462068|NCT00680381|Behavioral|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
462069|NCT00680355|Dietary Supplement|golden rice|An acute dose of cooked golden rice containing ~ 1 mg of ß-carotene
462070|NCT00680355|Dietary Supplement|corn oil 0g|0 g of corn oil in the golden rice meal
462071|NCT00680355|Dietary Supplement|corn oil 10g|10g corn oil in the golden rice meal
462072|NCT00680355|Dietary Supplement|coren oil 5 g|golden rice meal with 5 g corn oil
462073|NCT00680342|Drug|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
462074|NCT00680342|Drug|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
462075|NCT00680342|Other|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
462076|NCT00680329|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
462077|NCT00680329|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
462084|NCT00680277|Dietary Supplement|spirulina ß-carotene|an acute dose of spirulina up to 5 g
462085|NCT00680277|Dietary Supplement|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
462086|NCT00680238|Drug|Human derived FSH|Customized for each patient
462087|NCT00680225|Drug|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
462088|NCT00680212|Dietary Supplement|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
462089|NCT00680212|Dietary Supplement|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
462090|NCT00680186|Drug|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
462091|NCT00680186|Drug|Dabigatran etexilate|150mg bid
462092|NCT00680173|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
462093|NCT00680160|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
462094|NCT00680147|Behavioral|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
462095|NCT00680134|Drug|AN2690|AN2690 1% Solution, once daily for 180 days
462096|NCT00680134|Drug|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
462097|NCT00680121|Drug|Benfotiamine|Benfotiamine 600 mg
462098|NCT00680121|Drug|Placebo|Placebo
462099|NCT00680108|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
462100|NCT00680095|Drug|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
462101|NCT00680095|Drug|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
462102|NCT00680095|Drug|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
462103|NCT00680095|Other|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
462104|NCT00680095|Other|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
462105|NCT00680069|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
462106|NCT00680056|Drug|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
462107|NCT00680056|Drug|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
462108|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
462109|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
462110|NCT00680043|Drug|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
462111|NCT00680017|Drug|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
462112|NCT00680017|Drug|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
462113|NCT00679991|Drug|PRT-201|Applied topically to AVF during surgery
462114|NCT00679991|Drug|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
462115|NCT00679965|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
462116|NCT00679965|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
462117|NCT00679965|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
462118|NCT00679965|Drug|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
462119|NCT00679952|Procedure|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
462120|NCT00679952|Procedure|natural drainage of pancreatic duct|Natural drainage group
462121|NCT00679939|Drug|Rosiglitazone|up to 8mg/day
462122|NCT00679939|Drug|Metformin|up to 2000mg/day
462123|NCT00679926|Drug|Lopinavir/ritonavir and tenofovir|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
462124|NCT00679913|Procedure|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
462125|NCT00679913|Procedure|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
462126|NCT00679900|Drug|eplivanserin (SR46349)|5 mg/day
462127|NCT00679900|Drug|lormetazepam|1 mg/day
462128|NCT00679887|Procedure|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
462129|NCT00679874|Other|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
462130|NCT00679861|Behavioral|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
462215|NCT00679276|Procedure|Prolift|surgical repair of vaginal prolapse
462489|NCT00677300|Drug|Darunavir|800 mg P.O. (orally) once daily
462131|NCT00679861|Behavioral|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
462132|NCT00679848|Device|RS2 (RESTORe Suturing System)|Suturing in stomach
462133|NCT00679835|Drug|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
462134|NCT00679796|Procedure|Varicella (chickenpox) lesion sampling|
462135|NCT00679783|Drug|AZD2281|PARP inhibitor
462136|NCT00679770|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
462137|NCT00679770|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
462138|NCT00679770|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
462139|NCT00679770|Drug|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
462140|NCT00679744|Drug|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
462141|NCT00679731|Drug|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
462142|NCT00679731|Drug|Methotrexate|5.0 to 25 mg weekly
462143|NCT00679718|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
462144|NCT00679705|Drug|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
462145|NCT00679705|Drug|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
462146|NCT00679705|Drug|Placebo|Glucose 5%, IV
462147|NCT00679679|Drug|Metformin|Metformin 750 mg BID for 4 months
462148|NCT00679679|Drug|Placebo|Diet counseling and exercise
462149|NCT00679666|Drug|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
462150|NCT00679666|Drug|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
462151|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
462152|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
462153|NCT00679653|Drug|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
462154|NCT00679653|Drug|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
462155|NCT00679653|Drug|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
462156|NCT00679640|Drug|Candesartan|Oral tablets
462157|NCT00679627|Drug|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
462158|NCT00679627|Drug|Placebo|Matching placebo
462159|NCT00679614|Drug|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
462160|NCT00679614|Drug|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
462161|NCT00679614|Drug|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
462162|NCT00679601|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
462163|NCT00679588|Drug|Semuloparin Sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
462164|NCT00679588|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe~Subcutaneous injection"
462165|NCT00679588|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
462166|NCT00679562|Drug|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
462167|NCT00679562|Other|Distilled water|Application of patches containing distilled water for 24 hours
462168|NCT00679549|Device|CPAP Therapy|CPAP therapy is provided as an inpatient.
462169|NCT00679536|Drug|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
462170|NCT00679536|Drug|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m^2/day.
462171|NCT00679536|Drug|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
462172|NCT00679536|Radiation|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
462173|NCT00679523|Drug|AN2690 Solution, 5.0%|Once daily application for 180 days
462174|NCT00679523|Drug|AN2690 Solution, 7.5%|Once daily application for 180 days
462175|NCT00679510|Drug|rosuvastatin|tablet 10 mgs once daily
462176|NCT00679510|Drug|placebo|placebo
462177|NCT00679497|Biological|MVA-B|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)~-~ 1 x 10e8 pfu/ml~3 immunisations at week 0, 4 and 16"
462178|NCT00679497|Biological|Placebo|-3 immunisations at week 0, 4 and 16
462179|NCT00679484|Drug|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
462180|NCT00679484|Drug|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
462181|NCT00679458|Drug|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
462182|NCT00679458|Drug|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
462183|NCT00679445|Device|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
462184|NCT00679432|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
462185|NCT00679432|Drug|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
462186|NCT00679432|Drug|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
462187|NCT00679432|Drug|Placebo|Placebo
462188|NCT00679432|Drug|Asacol® 400 mg|2400 mg/day, 400 mg tablets
462189|NCT00679406|Behavioral|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
462190|NCT00679393|Procedure|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
462191|NCT00679393|Procedure|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
462192|NCT00679380|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
462193|NCT00679380|Drug|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
462194|NCT00679380|Drug|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
462195|NCT00679380|Drug|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
462196|NCT00679380|Drug|Placebo|Placebo
462197|NCT00679367|Drug|dexamethasone|40 mg once weekly
462198|NCT00679367|Drug|lenalidomide|10 mg/day D1-21
462199|NCT00679367|Drug|melphalan|5 mg/m2 D1-4
462200|NCT00679354|Drug|cilengitide|Given IV
462201|NCT00679354|Other|laboratory biomarker analysis|Correlative studies
462202|NCT00679354|Other|pharmacological study|Correlative studies
462203|NCT00679341|Drug|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
462204|NCT00679341|Drug|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
462205|NCT00679341|Drug|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
462206|NCT00679328|Device|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
462207|NCT00679315|Drug|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
462208|NCT00679315|Drug|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
462209|NCT00679302|Drug|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
462210|NCT00679302|Drug|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
462211|NCT00679289|Drug|HDI|20 MU/m^2 IV QD for 5 days/week for 4 weeks, then 10 MU/m^2 SC 3 days/week until disease progression
462212|NCT00679289|Drug|KW2871|5 mg/m^2 IV every 2 weeks until disease progression
462213|NCT00679289|Drug|KW2871|10 mg/m^2 IV every 2 weeks until disease progression
462214|NCT00679289|Drug|KW2871|20 mg/m^2 IV every 2 weeks until disease progression
462216|NCT00679263|Drug|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
462217|NCT00679263|Drug|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
462218|NCT00679263|Drug|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
462219|NCT00679250|Drug|levocetirizine|5 mg once nightly before visit
462220|NCT00679250|Drug|placebo to levocetirizine|1 tablet once nightly before visit
462221|NCT00679237|Behavioral|smoking cessation|NRT and varenicline
462222|NCT00679237|Drug|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
462223|NCT00679237|Drug|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
462224|NCT00679237|Behavioral|training|daily walking
462225|NCT00679237|Biological|influenza vaccine|vaccine (FLuarix, Influvac etc)
462226|NCT00679237|Drug|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
462227|NCT00679237|Behavioral|weight reduction|diet tips
462228|NCT00679224|Drug|ambrisentan|ambrisentan
462229|NCT00679211|Drug|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
462230|NCT00679198|Behavioral|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.~Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
462231|NCT00679185|Behavioral|expressive writing|four non-emotional writing assignments
462232|NCT00679172|Biological|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
462233|NCT00679172|Biological|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
462234|NCT00679172|Biological|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
462235|NCT00679172|Biological|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
462236|NCT00679172|Other|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
462237|NCT00679159|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
462238|NCT00679159|Biological|Prevenar|Streptococcus pneumoniae vaccine
462239|NCT00679146|Drug|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
462240|NCT00679146|Drug|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
462241|NCT00679133|Drug|MGCD265|Oral daily administration; 7 days on / 7 days off
462242|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
462243|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
462244|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
462245|NCT00679107|Device|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
462246|NCT00679094|Drug|Bowman-Birk inhibitor concentrate|Given orally
462247|NCT00679094|Other|placebo|Given orally
462248|NCT00679094|Other|pharmacological study|Correlative studies
462249|NCT00679094|Other|laboratory biomarker analysis|Correlative studies
462250|NCT00679081|Device|CelTx|Single application; split-mouth design
462251|NCT00679081|Other|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
462252|NCT00679068|Drug|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
462253|NCT00679055|Drug|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
462254|NCT00679055|Drug|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
462255|NCT00679042|Drug|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:~Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
462256|NCT00679029|Drug|doxorubicin hydrochloride|Given IV
462257|NCT00679029|Drug|cyclophosphamide|Given IV
462258|NCT00679029|Biological|bevacizumab|Given IV
462259|NCT00679029|Drug|paclitaxel|Given IV
462260|NCT00679029|Drug|gemcitabine hydrochloride|Given IV
462261|NCT00679029|Other|laboratory biomarker analysis|Correlative studies
462262|NCT00679029|Biological|pegfilgrastim|Given subcutaneously
462263|NCT00679003|Behavioral|SLCBT|Social learning and cognitive behavioral therapy
462264|NCT00679003|Behavioral|ES|Education and support (information about nutrition and gastrointestinal system)
462265|NCT00678990|Procedure|Transplantation of islets with heparin coating|Transplantation of islets with heparin coating
462266|NCT00678977|Drug|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
462267|NCT00678977|Drug|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
462268|NCT00678977|Drug|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
462269|NCT00678964|Drug|Erlotinib|Erlotinib 150 mg, p.o., once daily
462270|NCT00678964|Drug|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
462271|NCT00678938|Behavioral|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
462272|NCT00678938|Behavioral|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
462273|NCT00678925|Dietary Supplement|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
462274|NCT00678925|Dietary Supplement|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
462275|NCT00678912|Device|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
462276|NCT00678899|Device|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
462277|NCT00678886|Biological|otelixizumab infusion plus physician determined standard of care|infusion
462278|NCT00678886|Biological|placebo infusion plus physician determined standard of care|infusion
462279|NCT00678873|Procedure|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
462280|NCT00678847|Device|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
462281|NCT00678847|Device|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
462282|NCT00678834|Dietary Supplement|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
462283|NCT00678834|Dietary Supplement|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
462284|NCT00678834|Dietary Supplement|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
462285|NCT00678821|Other|Aerobic exercise|Supervised aerobic exercise and educational lectures for 10 weeks
462286|NCT00678795|Drug|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
462287|NCT00678795|Drug|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
462288|NCT00678782|Drug|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
462289|NCT00678782|Drug|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
462290|NCT00678769|Drug|Cixutumumab|Given IV
462291|NCT00678769|Other|Laboratory Biomarker Analysis|Correlative studies
462292|NCT00678769|Other|Pharmacological Study|Correlative studies
462293|NCT00678769|Drug|Temsirolimus|Given IV
462294|NCT00678756|Drug|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
462295|NCT00678756|Radiation|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
462296|NCT00678743|Drug|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
462297|NCT00678730|Drug|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
462298|NCT00678717|Procedure|Autonomic Evaluation|Orthostatic vital signs will be determined by measuring heart rate (HR) and brachial blood pressure (BP) during a tilt table test. The degree of vagal mediated sinus arrhythmia will be assessed during controlled breathing (5 seconds inhalation and 5 seconds exhalation during 90 seconds), and the sinus arrhythmia parameters will be calculated as the difference and ratio of the longest to the shortest RR interval. The sympathetic response during breath hold will be measured. Responses of BP, HR, MSNA will be acquired during Valsalva maneuver. The valsalva ratio of heart rate will be calculated from the maximum of heart rate during or shortly after straining and the minimal depressed heart rate in the overshoot phase IV. Blood pressure and MSNA increase during isometric handgrip maintained at 30% of maximal voluntary contraction for five minutes will be determined. The blood pressure and MSNA response will be measured during cold pressor test with the hand in ice water for 1 minute.
462299|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
462300|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
462301|NCT00678704|Drug|Placebo|Placebo tablet prior to intercourse on demand
462302|NCT00678691|Drug|armodafinil|50-250mg/d
462303|NCT00678691|Drug|placebo|matching placebo
462304|NCT00678678|Device|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
462305|NCT00678678|Device|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
462306|NCT00678652|Biological|10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
462307|NCT00678652|Biological|25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
462308|NCT00678652|Biological|50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
462309|NCT00678652|Biological|75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine|75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
462310|NCT00678639|Other|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
462311|NCT00678626|Drug|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
462312|NCT00678626|Drug|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
462313|NCT00678613|Drug|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
462314|NCT00678613|Drug|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
462315|NCT00678600|Other|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
462316|NCT00678600|Other|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
462317|NCT00678587|Drug|Eltrombopag|75 mg, once daily, oral
462318|NCT00678587|Drug|Placebo|placebo, once daily, oral
462319|NCT00678574|Drug|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
462320|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
462321|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
462322|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
462323|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
462324|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
462325|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
462326|NCT00678561|Drug|Placebo Vehicle|Topical treatment once daily for 28 days
462327|NCT00678561|Drug|Placebo Vehicle|Topical treatment twice daily for 28 days
462328|NCT00678548|Behavioral|Pleasant guided imagery|CD with pleasant guided imagery
462329|NCT00678548|Behavioral|Pain diary|Filling out a pain diary
462330|NCT00678535|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
462331|NCT00678535|Drug|Capecitabine|Capecitabine 1000 mg/m^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
462332|NCT00678535|Drug|Cisplatin|Cisplatin 80 mg/m^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
462333|NCT00678522|Drug|Atorvastatin|80 mg atorvastatin daily on two following days
462334|NCT00678509|Biological|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
462335|NCT00678496|Other|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
462336|NCT00678496|Other|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
462337|NCT00678483|Drug|rimonabant (SR141716)|once daily
462338|NCT00678470|Drug|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
462339|NCT00678457|Drug|Ondansetron|ondansetron (4 μg/kg b.i.d.)
462340|NCT00678457|Drug|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
462341|NCT00678457|Drug|Placebo|placebo
462342|NCT00678444|Other|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
462343|NCT00678431|Dietary Supplement|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
462344|NCT00678431|Dietary Supplement|Placebo|Liquid placebo
462345|NCT00678418|Drug|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
462346|NCT00678418|Drug|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
462347|NCT00678405|Behavioral|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer & non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
462348|NCT00678405|Behavioral|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
462349|NCT00678392|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosing
462350|NCT00678392|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing
462351|NCT00678379|Drug|lidocaine (1%) + bupivacaine (0.5%)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~B - lidocaine (1%) + bupivacaine (0.5%)"
462352|NCT00678379|Drug|Normal saline|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~A - normal saline"
462353|NCT00678379|Drug|Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.~C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)"
462354|NCT00678366|Procedure|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
462355|NCT00678366|Procedure|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
462356|NCT00678340|Device|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
462357|NCT00678340|Device|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
462358|NCT00678327|Biological|bleomycin sulfate|Given IV
462359|NCT00678327|Biological|filgrastim|Given subcutaneously
462360|NCT00678327|Biological|pegfilgrastim|Given subcutaneously
462361|NCT00678327|Drug|cyclophosphamide|Given IV
462362|NCT00678327|Drug|dacarbazine|Given IV
462363|NCT00678327|Drug|doxorubicin hydrochloride|Given IV
462364|NCT00678327|Drug|etoposide|Given IV
462365|NCT00678327|Drug|prednisolone|Given orally
462366|NCT00678327|Drug|procarbazine hydrochloride|Given orally
462367|NCT00678327|Drug|vinblastine sulfate|Given IV
462368|NCT00678327|Drug|vincristine sulfate|Given IV
462369|NCT00678314|Drug|Ropivacaine 0.2%|10 ml
462370|NCT00678314|Drug|Ropivacaine 0.75%|3 ml
462371|NCT00678314|Drug|Normal saline|10 ml
462372|NCT00678301|Biological|GSK Biologicals' Synflorix™|3 IM doses.
462373|NCT00678301|Biological|GSK Biologicals' Polio Sabin™|3 oral doses
462374|NCT00678301|Biological|GSK Biologicals' Zilbrix™ Hib|3 IM doses.
462375|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
462376|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
462377|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
462378|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
462379|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
462380|NCT00678249|Procedure|PTA|Percutaneous Transluminal Angioplasty
462381|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
462382|NCT00678236|Other|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
462383|NCT00678236|Other|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
462384|NCT00678210|Drug|CP-690,550|tablets, 2 mg BID for 12 weeks
462385|NCT00678210|Drug|CP-690,550|tablets, 5 mg BID for 12 weeks
462386|NCT00678210|Drug|CP-690,550|tablets, 15 mg BID for 12 weeks
462387|NCT00678210|Drug|Placebo|tablets, BID for 12 weeks
462388|NCT00678197|Other|Access Intervention|
462389|NCT00678197|Other|Bonus/Pay-for-Performance Intervention|
462390|NCT00678184|Drug|Atorvastatin|80 mg atorvastatin on two following days each
462391|NCT00678171|Device|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
462392|NCT00678158|Radiation|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
462393|NCT00678145|Drug|naloxone|Administering naloxone on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
462394|NCT00678145|Dietary Supplement|fructose|Administering fructose on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
462395|NCT00678145|Behavioral|exercise|Administering exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
462396|NCT00678145|Drug|Morphine sulfate|Administering morphine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
462397|NCT00678145|Drug|Epinephrine|Administering epinephrine on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
462398|NCT00678132|Drug|AZD 2281|
462399|NCT00678132|Drug|Cisplatin|
462400|NCT00678132|Drug|Gemcitabine|
462401|NCT00678119|Biological|AGS-003|Dendritic cell Immunotherapeutic
462402|NCT00678119|Drug|Sunitinib|An approved drug for the treatment of RCC
462403|NCT00678106|Drug|Dalbavancin|Subjects weighing > 60 Kg: 1 gram IV single dose Subjects weighing < 60 Kg: 15 mg/Kg IV
462404|NCT00678093|Other|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
462405|NCT00678080|Drug|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
462406|NCT00678080|Drug|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
462407|NCT00678067|Dietary Supplement|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
462408|NCT00678067|Dietary Supplement|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
462409|NCT00678067|Dietary Supplement|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
462410|NCT00678067|Other|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake <30% of total calories, Saturated fat intake <10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
462411|NCT00678054|Drug|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
462412|NCT00678041|Drug|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
462413|NCT00678041|Drug|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
462414|NCT00678015|Drug|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
462415|NCT00677989|Procedure|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
462416|NCT00677989|Procedure|Open appendectomy|open appendectomy: did appendectomy by laparotomy
462417|NCT00677963|Drug|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
462418|NCT00677950|Procedure|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
462419|NCT00677937|Behavioral|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
462420|NCT00677924|Drug|Zalutumumab|Solution for infusion
462421|NCT00677911|Behavioral|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
462422|NCT00677898|Behavioral|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
462423|NCT00677898|Behavioral|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
462424|NCT00677872|Drug|PRX-08066|
462425|NCT00677859|Biological|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
462426|NCT00677859|Biological|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
462427|NCT00677833|Drug|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (~30 mg/kg) + chloroquine (~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
462428|NCT00677833|Drug|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
462429|NCT00677820|Biological|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
462430|NCT00677820|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
462431|NCT00677807|Drug|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
462432|NCT00677807|Drug|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
462433|NCT00677794|Drug|Clear fluids|Clear fluids only after lunch.
462434|NCT00677794|Drug|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
462435|NCT00677794|Drug|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
462436|NCT00677768|Other|No intervention|Sample collection
462437|NCT00677755|Drug|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
462438|NCT00677755|Drug|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
462439|NCT00677742|Other|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
462440|NCT00677742|Other|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
462441|NCT00677729|Drug|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
462442|NCT00677729|Drug|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
462443|NCT00677716|Drug|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
462444|NCT00677703|Other|Daily Text Messages|"Text message reminders to take oral contraception daily:~Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors."
462445|NCT00677690|Other|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
462488|NCT00677300|Drug|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
462446|NCT00677690|Other|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
462447|NCT00677677|Biological|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
462448|NCT00677664|Drug|Glatiramer acetate (Copaxone)|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
462449|NCT00677664|Drug|Mannitol|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
462450|NCT00677651|Procedure|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
462451|NCT00677651|Procedure|Blood sample|Blood will be sampled from an IV line
462452|NCT00677651|Radiation|CT Scan|Single image at the level of the liver
462453|NCT00677651|Radiation|DEXA|Whole body scan
462454|NCT00677638|Device|Ventor Embracer|Implantation of Ventor Embracer
462455|NCT00677612|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
462456|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
462457|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
462458|NCT00677586|Procedure|simultaneous resection of liver metastasis and the colorectal primary tumor|simultaneous resection of liver metastasis and the colorectal primary tumor
462459|NCT00677586|Procedure|staged resection of liver metastasis and the colorectal primary tumor|Patients received resection of the colorectal tumor. 1 months later received resection of liver metastasis
462460|NCT00677573|Drug|Fostimon|450 IU for 4 days then adjusted
462461|NCT00677534|Drug|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
462462|NCT00677521|Drug|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
462463|NCT00677495|Dietary Supplement|Gluten-free diet|Gluten-free diet
462464|NCT00677469|Drug|Cholestyramine|2 grams BID
462465|NCT00677469|Drug|Cholestyramine|1 gram BID
462466|NCT00677469|Drug|Placebo powder|1 gram BID
462467|NCT00677456|Procedure|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
462468|NCT00677456|Procedure|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
462469|NCT00677456|Procedure|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
462470|NCT00677456|Procedure|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
462471|NCT00677443|Drug|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
462472|NCT00677443|Drug|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
462473|NCT00677430|Behavioral|Questionnaire|A brief questionnaire packet will be completed.
462474|NCT00677430|Procedure|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
462475|NCT00677404|Biological|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
462476|NCT00677391|Drug|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
462477|NCT00677391|Drug|Placebo|Capsules, once daily
462478|NCT00677365|Drug|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
462479|NCT00677365|Drug|Placebo|same frequency as study drug using the same nebulizer
462480|NCT00677352|Drug|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
462481|NCT00677352|Drug|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
462482|NCT00677339|Drug|L-arginine|L-arginine 6g orally daily
462483|NCT00677339|Drug|Vitamin D|Cholecalciferol 50000 IU once monthly orally
462484|NCT00677339|Drug|Placebo L-arginine|placebo L-arginine once daily
462485|NCT00677339|Drug|Placebo Vitamin D|placebo vitamin D orally once monthly
462486|NCT00677326|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
462487|NCT00677313|Drug|metreleptin|metreleptin injection
462490|NCT00677300|Drug|Ritonavir|100mg once daily
462491|NCT00677300|Drug|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
462492|NCT00677287|Biological|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
462493|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
462494|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
462495|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
462496|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
462497|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
462498|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
462499|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
462500|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
462501|NCT00677261|Procedure|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
462502|NCT00677261|Procedure|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
462503|NCT00677261|Procedure|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
462504|NCT00677248|Drug|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
462505|NCT00677248|Drug|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
462506|NCT00677235|Device|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
462507|NCT00677235|Procedure|PTA|Treatment of stenoses with PTA only
462508|NCT00677222|Biological|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
462509|NCT00677209|Biological|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
462510|NCT00677196|Device|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
462511|NCT00677196|Device|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
462512|NCT00677170|Drug|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
462513|NCT00677144|Drug|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
462514|NCT00677144|Drug|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
462515|NCT00677131|Other|Reading the package insert of the drug|package insert of the drug
462516|NCT00677131|Other|Reading the education information provided by the Pharmacy of NTUH|education information
462517|NCT00677131|Other|Oral education provided by the pharmacist|Oral education provided by the pharmacist
462518|NCT00677118|Drug|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
462519|NCT00677118|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
462520|NCT00677105|Drug|JNJ-26481585|
462521|NCT00677092|Drug|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
462522|NCT00677079|Drug|Iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
462523|NCT00677066|Procedure|Home oxygen therapy|Administer oxygen at home or in hospital
462524|NCT00677053|Drug|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
462525|NCT00677053|Drug|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
462526|NCT00677053|Drug|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
462527|NCT00677053|Drug|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
462528|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
462529|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
462530|NCT00677053|Drug|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
462531|NCT00677053|Drug|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
462532|NCT00677053|Drug|Placebo|Stages I, II & III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
462533|NCT00677027|Other|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
462534|NCT00677027|Other|placebo|Placebo
462535|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
462536|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
462537|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
462538|NCT00677001|Drug|R306465|
462539|NCT00676975|Drug|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.~The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
462540|NCT00676975|Drug|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
462541|NCT00676962|Behavioral|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
462542|NCT00676949|Biological|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
462543|NCT00676936|Drug|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
462544|NCT00676936|Drug|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
462545|NCT00676910|Drug|JNJ-26854165|
462546|NCT00676897|Drug|Simvastatin|Simvastatin 40mg PO or NGT
462547|NCT00676897|Drug|Placebo|Corn Starch
462548|NCT00676884|Drug|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
462549|NCT00676884|Drug|placebo|1.5 mL s.c. b.i.d.
462550|NCT00676871|Drug|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
462551|NCT00676871|Drug|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
462552|NCT00676871|Drug|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
462553|NCT00676871|Drug|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
462554|NCT00676871|Drug|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
462555|NCT00676871|Drug|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
462556|NCT00676871|Drug|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
462557|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
462558|NCT00676845|Drug|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
462559|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
462560|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
462561|NCT00676832|Drug|Placebo|Placebo solid capsule dosage form administered orally once daily.
462562|NCT00676832|Drug|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
462563|NCT00676819|Drug|insulin aspart|
462564|NCT00676819|Drug|human insulin|
462565|NCT00676806|Biological|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.
462566|NCT00676806|Biological|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
462567|NCT00676793|Drug|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
462568|NCT00676780|Drug|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
462569|NCT00676767|Dietary Supplement|Resistant Starch Type 4|
462570|NCT00676767|Dietary Supplement|Dextrose|
462571|NCT00676767|Dietary Supplement|Puffed wheat|
462572|NCT00676754|Procedure|Statens Serum Institut RT23 2TU tuberculin|
462573|NCT00676741|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
462574|NCT00676741|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
462575|NCT00676741|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
462671|NCT00676013|Biological|AlloDerm|Application of AlloDerm over full thickness burn following excision
462672|NCT00676013|Procedure|Skin Biopsy|Tissue Biopsy of study sites (AlloDerm, Integra, Homograft, Autograft only)
462576|NCT00676728|Drug|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
462577|NCT00676715|Drug|Placebo|Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
462578|NCT00676715|Drug|Ocrelizumab|Two infusion of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
462579|NCT00676715|Drug|Ocrelizumab|Ocrelizumab 1000 mg IV infusions was administered on cycle 1 Day 1.
462580|NCT00676715|Drug|Ocrelizumab|Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
462581|NCT00676715|Drug|Avonex|Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
462582|NCT00676702|Dietary Supplement|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
462583|NCT00676702|Drug|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
462584|NCT00676689|Device|SAPIEN Transcatheter Valve Implantation|Device Implantation
462585|NCT00676676|Drug|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
462586|NCT00676663|Drug|entinostat|Entinostat 5 mg tablet orally once per week
462587|NCT00676663|Drug|exemestane|Exemestane 25 mg tablet orally once daily
462588|NCT00676663|Drug|Placebo|Placebo-matching entinostat tablet orally once per week
462589|NCT00676650|Drug|Prednisone|5 mg BID, oral
462590|NCT00676650|Drug|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
462591|NCT00676650|Drug|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
462592|NCT00676650|Drug|Prednisone|5 mg BID, oral
462593|NCT00676637|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
462594|NCT00676637|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
462595|NCT00676585|Drug|Normal Saline|Normal Saline
462596|NCT00676585|Drug|Hydrocortisone|Hydrocortisone 100mg
462597|NCT00676572|Other|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
462598|NCT00676559|Drug|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
462599|NCT00676559|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
462600|NCT00676533|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
462601|NCT00676520|Device|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
462602|NCT00676507|Biological|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
462603|NCT00676507|Other|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
462604|NCT00676494|Device|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
462605|NCT00676481|Behavioral|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
462606|NCT00676468|Other|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
462607|NCT00676468|Other|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
462608|NCT00676468|Other|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
462609|NCT00676442|Drug|PN400|naproxen/esomeprazole
462610|NCT00676429|Drug|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
462611|NCT00676429|Drug|Placebo|Placebo as oral solution, individually titrated
462612|NCT00676416|Drug|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
462613|NCT00676403|Drug|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
462614|NCT00676403|Drug|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
462615|NCT00676403|Drug|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
462616|NCT00676403|Drug|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
462617|NCT00676403|Drug|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
462618|NCT00676403|Drug|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
462619|NCT00676390|Other|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
462620|NCT00676377|Drug|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
462621|NCT00676377|Drug|Saline|Saline Placebo
462622|NCT00676364|Drug|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
462623|NCT00676364|Drug|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
462710|NCT00675740|Drug|rosiglitazone|tablets 4 mg daily
462624|NCT00676351|Procedure|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
462625|NCT00676338|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
462626|NCT00676338|Drug|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
462627|NCT00676338|Drug|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
462628|NCT00676338|Drug|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
462629|NCT00676325|Procedure|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
462630|NCT00676325|Device|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
462631|NCT00676325|Procedure|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
462632|NCT00676312|Drug|PTH134|
462633|NCT00676299|Drug|JNJ-26483327|
462634|NCT00676286|Procedure|3T MR Imaging|3TR Imaging
462635|NCT00676286|Procedure|C-Choline PET Scanning|C-Choline PET Scanning
462636|NCT00676286|Procedure|Gene Rearrangement|Gene Rearrangement
462637|NCT00676273|Device|TVT-Obturator (TVT-O)|sub urethral sling
462638|NCT00676273|Device|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
462639|NCT00676260|Drug|Pioglitazone|Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
462640|NCT00676260|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
462641|NCT00676234|Drug|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
462642|NCT00676221|Drug|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.~Cellcept 1000mg bid = Myfortic 720mg bid"
462643|NCT00676208|Behavioral|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
462644|NCT00676195|Drug|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:~Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
462645|NCT00676182|Other|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
462646|NCT00676156|Drug|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
462647|NCT00676156|Drug|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
462648|NCT00676156|Drug|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
462649|NCT00676143|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
462650|NCT00676143|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
462651|NCT00676130|Drug|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily~20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily~25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily~29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily~60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily~> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
462652|NCT00676130|Drug|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:~15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily~20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily~25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily~29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily~60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily~> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
462653|NCT00676117|Drug|Esomeprazole (D961H)|20mg
462654|NCT00676117|Drug|Loxoprofen|60mg tablet
462655|NCT00676104|Device|CoolSystems Discrete Cerebral Hypothermia System|The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
462656|NCT00676091|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
462657|NCT00676091|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
462658|NCT00676052|Drug|GSK233705 12.5mcg|Once daily via dry powder inhaler
462659|NCT00676052|Drug|GSK233705 25mcg|once daily via dry powder inhaler
462660|NCT00676052|Drug|GSK233705 50mcg|Once daily via dry powder inhaler
462661|NCT00676052|Drug|GSK233705 100mcg|Once daily via dry powder inhaler
462662|NCT00676052|Drug|GSK233705 200mcg|Once daily via dry powder inhaler
462663|NCT00676052|Drug|Placebo|Once daily via dry powder imhaler
462664|NCT00676039|Drug|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
462665|NCT00676039|Drug|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
462666|NCT00676039|Drug|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
462667|NCT00676039|Drug|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
462668|NCT00676026|Drug|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
462669|NCT00676026|Drug|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
462670|NCT00676026|Drug|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
462673|NCT00676013|Biological|Integra|Application of skin substitute over full thickness burn following excision.
462674|NCT00676013|Biological|Autograft|Application of autograft over full thickness burn injury following excision of burn wound.
462675|NCT00676013|Biological|Homograft|Application of homograft skin over full thickness burn injury following excision of burn wound.
462676|NCT00676000|Procedure|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
462677|NCT00676000|Procedure|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
462678|NCT00675987|Drug|losartan|losartan 100 mg tablets 1 tab po QD
462679|NCT00675987|Drug|Placebo control|Placebo 1 po QD
462680|NCT00675974|Device|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
462681|NCT00675974|Device|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
462682|NCT00675961|Behavioral|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
462683|NCT00675961|Drug|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
462684|NCT00675961|Other|BCI + Naltrexone|Combination of the two previous interventions
462685|NCT00675961|Behavioral|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
462686|NCT00675948|Drug|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
462687|NCT00675948|Drug|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
462688|NCT00675935|Other|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
462689|NCT00675922|Drug|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
462690|NCT00675909|Drug|Aerosolized Intranasal midazolam|"Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg."
462691|NCT00675909|Drug|Aerosolized Buccal Midazolam|"0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth."
462692|NCT00675909|Drug|Oral midazolam|oral midazolam 0.5mg/kg
462693|NCT00675896|Drug|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
462694|NCT00675896|Drug|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
462695|NCT00675870|Drug|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
462696|NCT00675857|Drug|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
462697|NCT00675857|Other|placebo|Dosage: 4 capsules BID for 26 weeks
462698|NCT00675844|Drug|elvucitabine|10 mg elvucitabine daily as part of an ART regimen
462699|NCT00675831|Device|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
462700|NCT00675818|Device|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
462701|NCT00675818|Device|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
462702|NCT00675805|Device|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
462703|NCT00675805|Device|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
462704|NCT00675792|Drug|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
462705|NCT00675792|Drug|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
462706|NCT00675792|Drug|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
462707|NCT00675779|Drug|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
462708|NCT00675779|Drug|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
462709|NCT00675753|Genetic|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
462711|NCT00675740|Behavioral|physical exercise|stationary bike 5-6 times a week
462712|NCT00675740|Other|control|control without intervention
462713|NCT00675727|Biological|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
462714|NCT00675714|Procedure|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
462715|NCT00675714|Procedure|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
462716|NCT00675714|Procedure|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
462717|NCT00675714|Drug|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
462718|NCT00675714|Drug|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
462719|NCT00675714|Drug|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
462720|NCT00675714|Drug|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
462721|NCT00675714|Drug|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
462722|NCT00675714|Drug|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
462723|NCT00675714|Drug|Placebo|placebo to be given once a day for up to two years post burn injury.
462724|NCT00675714|Behavioral|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
462725|NCT00675714|Behavioral|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
462726|NCT00675701|Drug|placebo|capsules
462727|NCT00675701|Drug|lixivaptan|capsules
462728|NCT00675701|Drug|moxifloxacin|tablets
462729|NCT00675688|Drug|Bazedoxifene/Conjugate Estrogens (CE)|
462730|NCT00675688|Drug|Raloxifene|
462731|NCT00675688|Drug|Placebo|
462732|NCT00675675|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
462733|NCT00675675|Behavioral|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
462734|NCT00675662|Behavioral|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
462735|NCT00675662|Behavioral|waiting list control|waiting list control
462736|NCT00675649|Biological|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
462737|NCT00675649|Biological|placebo|placebo sc injection every 4 weeks from week 0 to week 20
462738|NCT00675636|Other|study of socioeconomic and demographic variables|database, no intervention
462739|NCT00675636|Procedure|evaluation of cancer risk factors|database, no intervention
462740|NCT00675636|Procedure|study of high risk factors|database, no intervention
462741|NCT00675623|Drug|Dimebon|Dimebon, 5 mg orally three times daily for six months
462742|NCT00675623|Drug|Dimebon|Dimebon 20 mg orally three times daily for six months
462743|NCT00675623|Drug|Placebo|Placebo three times daily for six months
462744|NCT00675610|Behavioral|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
462745|NCT00675597|Drug|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
462746|NCT00675584|Drug|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
462747|NCT00675584|Drug|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
462748|NCT00675558|Procedure|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.~MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.~All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) & fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
462749|NCT00675558|Procedure|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
462750|NCT00675545|Drug|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
463020|NCT00673465|Drug|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
462751|NCT00675532|Behavioral|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
462752|NCT00675532|Behavioral|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
462753|NCT00675519|Behavioral|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
462754|NCT00675506|Drug|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
462755|NCT00675506|Drug|Placebo|2-mg sub-cutaneous injections once daily for 12 months
462756|NCT00675493|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
462757|NCT00675480|Procedure|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
462758|NCT00675480|Procedure|Primary angioplasty|Standard primary angioplasty with stent implantation
462759|NCT00675467|Behavioral|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
462760|NCT00675467|Behavioral|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
462761|NCT00675441|Drug|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
462762|NCT00675428|Drug|BG00002 (natalizumab)|
462763|NCT00675415|Diagnostic Test|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
462764|NCT00675402|Other|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
462765|NCT00675389|Behavioral|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for ~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
462766|NCT00675389|Behavioral|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
462767|NCT00675363|Procedure|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
462768|NCT00675363|Procedure|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
462769|NCT00675350|Drug|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
462770|NCT00675337|Procedure|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
462771|NCT00675337|Procedure|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
462772|NCT00675324|Drug|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
462773|NCT00675324|Dietary Supplement|Fresubin Energy drink|30 kcal/kg*day five days before colonoscopy
462774|NCT00675311|Behavioral|DM-Standard|Device/t+ Medical Diabetes Management System
462775|NCT00675311|Behavioral|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
462776|NCT00675285|Drug|montelukast sodium|one tablet 5 mg once/day for 4 weeks
462777|NCT00675285|Drug|placebo|one tablet 5 mg once/day for 4 weeks
462778|NCT00675272|Drug|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
462779|NCT00675272|Drug|sodium chloride|sodium chloride every 6 hours iv
462780|NCT00675259|Drug|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days [1 cycle] for 5 cycles
462781|NCT00675259|Drug|carboplatin|AUC 2 IV on days 1, 8, and 15
462782|NCT00675259|Drug|nab-paclitaxel|100 mg/M2 IV
462783|NCT00675259|Procedure|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
462784|NCT00675259|Drug|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
463161|NCT00672620|Drug|Placebo|Placebo-matching capsules
462785|NCT00675246|Drug|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
462786|NCT00675233|Drug|HPPH|Given IV
462787|NCT00675233|Procedure|laser therapy|Escalating light doses with 665 nm light
462788|NCT00675220|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
462789|NCT00675207|Drug|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
462790|NCT00675207|Drug|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
462791|NCT00675207|Drug|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
462792|NCT00675194|Drug|Cisplatin, Irinotecan, Capecitabine|
462793|NCT00675181|Drug|Melatonin|5mg per os
462794|NCT00675181|Drug|Placebo|per os
462795|NCT00675168|Radiation|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
462796|NCT00675155|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
462797|NCT00675142|Procedure|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
462798|NCT00675129|Behavioral|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.~The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
462799|NCT00675129|Behavioral|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
462800|NCT00675116|Drug|GW823296|
462801|NCT00675103|Drug|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
462802|NCT00675090|Drug|GSK239512|GSK239512 oral tablets once a day
462803|NCT00675090|Drug|Placebo|Placebo tablets to match once a day
462804|NCT00675077|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
462805|NCT00675064|Drug|GSK369796|Anti-malarial
462806|NCT00675064|Drug|Placebo|Placebo matching GSK369796
462807|NCT00675038|Procedure|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2* MRI
462808|NCT00675025|Drug|Donepezil Hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
462809|NCT00675012|Drug|NGR-hTNF|iv 0.8 or 45 mcg/sqm q3W
462810|NCT00675012|Drug|Oxaliplatin|iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
462811|NCT00675012|Drug|capecitabine|orally 825 mg/sqm 2qDx14
462812|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
462813|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
462814|NCT00674999|Drug|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
462815|NCT00674986|Device|Accu-Chek 360° View Blood Glucose Analysis Tool|
462816|NCT00674986|Device|Accu-Chek Aviva Glucose Meter|
462817|NCT00674973|Drug|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
462818|NCT00674973|Drug|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
462819|NCT00674960|Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
462820|NCT00674947|Drug|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
462821|NCT00674934|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
462822|NCT00674921|Drug|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
462823|NCT00674921|Drug|Placebo|starch, magnesium stearate, sodium lauryl sulphate
462824|NCT00674908|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
462825|NCT00674908|Biological|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
462826|NCT00674895|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
462827|NCT00674882|Other|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
462828|NCT00674869|Other|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
462829|NCT00674856|Drug|naproxcinod|750mg
462830|NCT00674843|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
462831|NCT00674830|Behavioral|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
462832|NCT00674830|Behavioral|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
462833|NCT00674830|Behavioral|placebo|usual care
462834|NCT00674817|Drug|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
462835|NCT00674817|Drug|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
462836|NCT00674791|Biological|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
462837|NCT00674778|Procedure|Any percutaneous cardiovascular procedure|
462838|NCT00674765|Drug|Seroquel|400 mg/day
462839|NCT00674765|Drug|Placebo|400 mg/day
462840|NCT00674752|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
462841|NCT00674752|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
462842|NCT00674752|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
462843|NCT00674739|Drug|Imiquimod|daily topical application for up to 8 weeks
462844|NCT00674739|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
462845|NCT00674739|Drug|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
462846|NCT00674726|Other|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
462847|NCT00674713|Other|Acupuncture|
462848|NCT00674713|Drug|Ondansetron|
462849|NCT00674713|Drug|Physiological saline solution|
462850|NCT00674713|Other|Sham acupuncture|
462851|NCT00674713|Drug|Ondansetron|
462852|NCT00674713|Other|Acupuncture at P6 point|
462853|NCT00674713|Drug|Physiological saline solution|
462854|NCT00674713|Other|Sham acupuncture|
462855|NCT00674700|Drug|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
462856|NCT00674700|Drug|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
462857|NCT00674700|Drug|Placebo tablet|One sublingual tablet daily for one year
462858|NCT00674687|Drug|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
462859|NCT00674687|Drug|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
462860|NCT00674674|Drug|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.~The Induction period is the first 4 weeks of therapy."
462861|NCT00674674|Drug|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
462862|NCT00674674|Drug|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
462863|NCT00674661|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
462864|NCT00674661|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
462865|NCT00674648|Biological|CMV-Peptide-Specific T cells|"In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).~The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose."
462866|NCT00674635|Drug|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
462867|NCT00674635|Drug|Placebo|matching placebo
462868|NCT00674622|Drug|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
462869|NCT00674622|Procedure|Placebo|Saline/lidocaine
462870|NCT00674609|Drug|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
462871|NCT00674609|Drug|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
462872|NCT00674609|Drug|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
462873|NCT00674596|Drug|ramipril|ramipril 10 mg/day during 3 months
462874|NCT00674583|Biological|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
462875|NCT00674583|Biological|Menjugate|Intramuscular administration, 1 dose
462876|NCT00674570|Drug|Hydrocortisone|25 mg/oral one hour prior to extinction task
462877|NCT00674570|Drug|D-Cycloserine|50 mg/oral one hour prior to extinction task
462878|NCT00674570|Drug|Placebo|One hour prior to extinction task
462879|NCT00674557|Drug|SOD1 inhibitor ATN-224|
462880|NCT00674557|Drug|exemestane|
462881|NCT00674557|Genetic|protein expression analysis|
462882|NCT00674557|Genetic|proteomic profiling|
462883|NCT00674557|Other|laboratory biomarker analysis|
462884|NCT00674557|Other|pharmacological study|
462885|NCT00674544|Behavioral|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
462886|NCT00674531|Procedure|Artery resection|Artery resection
462887|NCT00674518|Behavioral|One on one counseling|Motivational Interviewing
462888|NCT00674518|Behavioral|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
462889|NCT00674518|Behavioral|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
462890|NCT00674505|Device|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
462891|NCT00674479|Drug|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
462892|NCT00674466|Drug|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
462893|NCT00674466|Drug|Placebo|twice-a-week
462894|NCT00674453|Drug|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
462895|NCT00674453|Other|Placebo|Matching placebo tablet given once daily for 2 years
462896|NCT00674440|Drug|F-DOPA|0.08-0.16 mCi/kg once
462897|NCT00674440|Radiation|PET scan|
462898|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
462899|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
462900|NCT00674414|Biological|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
462901|NCT00674414|Drug|everolimus|Oral everolimus once daily
462902|NCT00674414|Procedure|therapeutic conventional surgery|Patients undergo surgery
462903|NCT00674401|Procedure|Radiofrequency catheter ablation|"In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:~Empirical pulmonary vein antrum circumferential isolation, or~High frequency sites ablation in the LA~In case of Persistent AF, patients will be randomized into one of 2 in the study:~Empirical circumferential PV antrum isolation w/out roof line, or~A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
462904|NCT00674375|Other|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
462905|NCT00674362|Biological|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
462906|NCT00674362|Biological|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
462907|NCT00674349|Procedure|surgery|staging surgery
462908|NCT00674336|Procedure|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
462909|NCT00674323|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, light application of 50 J/cm^2 to the study eye was begun 15 minutes after the start of infusion.
462910|NCT00674323|Drug|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
462911|NCT00674310|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
462912|NCT00674297|Drug|Fluvastatin|Fluvastatin 40 mg daily for 3 months
462913|NCT00674258|Biological|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
462914|NCT00674245|Drug|Pantoprazole|40 mg once daily for 4 weeks
462915|NCT00674245|Drug|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
462916|NCT00674245|Drug|placebo|40 mg once daily for 4 weeks
462917|NCT00674232|Drug|600 mcg misoprostol|single dose of misoprostol taken orally
462918|NCT00674232|Procedure|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
462919|NCT00674219|Drug|Memantine|Namenda 10mg BID for 12 weeks
462920|NCT00674206|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
462921|NCT00674206|Drug|Oxaliplatin|Oxaliplatin 100mg/m^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
462922|NCT00674193|Other|pharmacological study|Correlative studies
462923|NCT00674193|Other|laboratory biomarker analysis|Correlative studies
462924|NCT00674180|Behavioral|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
462925|NCT00674180|Behavioral|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
462926|NCT00674180|Behavioral|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
462927|NCT00674167|Drug|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
462928|NCT00674167|Drug|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
462929|NCT00674167|Drug|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
462930|NCT00674154|Drug|Cholecalciferol|2800 IE daily in 52 weeks
462931|NCT00674141|Drug|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
462932|NCT00674128|Device|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
462933|NCT00674128|Device|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
462934|NCT00674115|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
462935|NCT00674115|Drug|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
462936|NCT00674115|Drug|sodium bicarbonate|Sodium bicarbonate. Single dose.
462937|NCT00674102|Drug|ASA404|
462938|NCT00674089|Dietary Supplement|Vitamin A|Vitamin A 50,000 IU
462939|NCT00674089|Dietary Supplement|Placebo|Vitamin A Placebo
462940|NCT00674063|Drug|alefacept|IV
462941|NCT00674050|Drug|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
462942|NCT00674050|Drug|Albuterol (Salbutamol)|2 puff= 200ug total dose
462943|NCT00674050|Drug|Fluticasone|2 puffs= 500ug total dose
462944|NCT00674037|Other|monetary incentive|75 euros for each patient included
462945|NCT00674024|Drug|Pazopanib|
462946|NCT00674024|Drug|Pazopanib (GW786034)(GW786034)|
462947|NCT00674011|Drug|Bevacizumab|Given as part of standard of care or another research protocol
462948|NCT00673998|Device|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
462949|NCT00673985|Other|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
462950|NCT00673985|Device|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
462951|NCT00673972|Radiation|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.~Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
462952|NCT00673959|Other|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
462953|NCT00673959|Other|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
462954|NCT00673946|Other|True saturation values displayed|Physicians will be presented with real saturations.
462955|NCT00673946|Other|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
462956|NCT00673933|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
462957|NCT00673920|Drug|methotrexate|Oral or parenteral repeating dose
462958|NCT00673920|Drug|ocrelizumab|Intravenous repeating dose
462959|NCT00673920|Drug|placebo|Intravenous repeating dose
462960|NCT00673907|Other|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
462961|NCT00673894|Drug|Sitagliptin|Glutamine 30g +sitagliptin 100mg
462962|NCT00673894|Drug|Placebo|Glutamine 30g +placebo (matching sitagliptin 100 mg)
462963|NCT00673881|Drug|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
462964|NCT00673868|Biological|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
462965|NCT00673855|Other|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
462966|NCT00673855|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
462967|NCT00673842|Device|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved (in each geography) single chamber or dual chamber implantable cardioverter defibrillator (ICD)
462968|NCT00673842|Other|Usual care|Usual post-MI care
462969|NCT00673829|Biological|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
462970|NCT00673829|Biological|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
462971|NCT00673816|Drug|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
462972|NCT00673803|Procedure|cataract surgery|cataract surgery with implantation of an IOL
462973|NCT00673790|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration
462974|NCT00673790|Drug|HCTZ|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration.
462975|NCT00673790|Drug|Placebo|Placebo
462976|NCT00673777|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
462977|NCT00673764|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
462978|NCT00673764|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
462979|NCT00673751|Drug|GLP-2|450 nmol subcutaneous
462980|NCT00673751|Drug|Placebo|
463021|NCT00673465|Drug|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
463022|NCT00673465|Drug|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
463023|NCT00673452|Drug|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
463024|NCT00673452|Drug|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
462981|NCT00673738|Drug|Cetuximab|"Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.~Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
462982|NCT00673738|Radiation|Conformal Thoracic Radiotherapy (CTRT)|"Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.~Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC >1,000 and platelets >75,000) required. Patient may be delayed for a max. of 2 weeks. If > 2 week delay occurs, patient will come off study."
462983|NCT00673725|Drug|Locobase® REPAIR|emollient
462984|NCT00673712|Device|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
462985|NCT00673712|Drug|Opioid based analgesia|"Opioid Analgesic agents delivered by:~PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
462986|NCT00673699|Procedure|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
462987|NCT00673686|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
462988|NCT00673686|Drug|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
462989|NCT00673673|Drug|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
462990|NCT00673673|Drug|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
462991|NCT00673660|Behavioral|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
462992|NCT00673647|Behavioral|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
462993|NCT00673634|Procedure|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
462994|NCT00673634|Procedure|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
462995|NCT00673621|Drug|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
462996|NCT00673621|Drug|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
462997|NCT00673621|Drug|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
462998|NCT00673608|Drug|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
462999|NCT00673595|Drug|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
463000|NCT00673595|Drug|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
463001|NCT00673582|Drug|Rosuvastatin|10 mg/day rosuvastatin
463002|NCT00673582|Drug|Placebo|Placebo, 10 mg a day for 96 weeks
463003|NCT00673569|Drug|erlotinib hydrochloride|
463004|NCT00673569|Genetic|gene expression analysis|
463005|NCT00673569|Genetic|protein expression analysis|
463006|NCT00673569|Other|immunoenzyme technique|
463007|NCT00673569|Other|immunologic technique|
463008|NCT00673569|Other|laboratory biomarker analysis|
463009|NCT00673569|Procedure|needle biopsy|
463010|NCT00673556|Drug|alefacept|Intramuscular (IM)
463011|NCT00673556|Drug|placebo|Intramuscular (IM)
463012|NCT00673530|Behavioral|evidence based clinical nutrition concept|The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
463013|NCT00673530|Behavioral|care as usual|Unchanged treatment of hospital patients without interference by the study.
463014|NCT00673504|Drug|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
463015|NCT00673504|Drug|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
463016|NCT00673491|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
463017|NCT00673478|Drug|Tiotropium+Salmeterol|
463018|NCT00673478|Drug|Salmeterol|
463019|NCT00673478|Drug|Tiotropium|
463025|NCT00673439|Drug|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
463026|NCT00673439|Drug|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
463027|NCT00673426|Biological|Enoxaparin sodic|
463028|NCT00673400|Procedure|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
463029|NCT00673387|Drug|pramlintide acetate|subcutaneous injection, twice a day
463030|NCT00673387|Drug|metreleptin|subcutaneous injection, twice a day
463031|NCT00673387|Drug|placebo-P|subcutaneous injection, twice a day
463032|NCT00673387|Drug|placebo-M|subcutaneous injection, twice a day
463033|NCT00673374|Device|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
463034|NCT00673361|Drug|Concurrent decrescendo biochemotherapy regimen|"Temozolomide: 200mg/m^2, daily, PO, days 1-4~Vinblastine: 1.5mg/m^2, daily, IV, days 1-4~Cisplatin: 20mg/m^2, daily IV, days 1-4~IL (interleukin)-2: - 18 milli-International unit (MIU)/m^2, IVCI (intravenous continual infusion), day 1~9 MIU/m^2, IVCI, day 2~4.5 MIU/m^2, IVCI, days 3 & 4~Interferon (IFN) alpha: 5 MIU/m^2, daily, SC (subcutaneously), days 1-5~5-day inpatient regimen, to be repeated every 21 days"
463035|NCT00673361|Drug|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
463036|NCT00673335|Drug|letrozole|
463037|NCT00673335|Drug|Placebo|
463038|NCT00673322|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
463039|NCT00673309|Procedure|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
463040|NCT00673309|Procedure|Stable Isotope Infusion study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
463041|NCT00673309|Procedure|Radiology testing: DEXA, K+ counter, ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
463042|NCT00673309|Drug|IGF-1|Administration of randomized drug daily throughout hospitalization to 95% wound healing
463043|NCT00673309|Drug|Insulin|Insulin IV administered continuously to maintain serum glucose between 80-110 throughout hospitalization until wounds are 95% healed.
463044|NCT00673309|Drug|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
463045|NCT00673309|Drug|Propranolol|Propranolol to be given daily to decrease HR and BP throughout hospitalization until 95% wound healing.
463046|NCT00673309|Drug|Clonidine|Clonidine administered daily throughout hospitalization until 95% wound healing to decrease HR, BP, and anxiety.
463047|NCT00673309|Drug|Ketoconazole|Ketoconazole administered PO every 12 hours throughout hospitalization until 95% wound healing.
463048|NCT00673309|Drug|Dehydroepiandrosterone-sulfate|The hormone Dehydroepiandrosterone-sulfate will be given daily until 95% wound healing.
463049|NCT00673309|Drug|Fenofibrate|Fenofibrate administered daily until 95% wound healing.
463050|NCT00673309|Drug|Metformin|metformin to be administered daily throughout hospitalization until 95% wound healing.
463051|NCT00673309|Drug|Byetta|Byetta administered daily throughout hospitalization until 95% wound healing.
463052|NCT00673309|Drug|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
463053|NCT00673309|Drug|Pioglitazone|Pioglitazone administered daily throughout hospitalization until 95% wound healing
463054|NCT00673296|Drug|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
463055|NCT00673283|Device|bi-plane chest radiography|Bi-plane radiography of the thorax
463056|NCT00673270|Drug|Fludrocortisone|50 µg of fludrocortisone per os
463057|NCT00673270|Drug|Hydrocortisone|50 mg of intravenous hydrocortisone
463058|NCT00673270|Drug|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
463059|NCT00673270|Drug|Placebo of Hydrocortisone|2 ml of isotonic saline solution
463060|NCT00673257|Drug|daunorubicin hydrochloride|Given IV
463061|NCT00673257|Other|pharmacological study|pharmacological studies
463062|NCT00673257|Procedure|dual x-ray absorptimetry|
463063|NCT00673244|Drug|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
463064|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
463065|NCT00673231|Drug|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
463066|NCT00673231|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
463067|NCT00673231|Drug|Placebo|Placebo
463068|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
463158|NCT00672633|Drug|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
463340|NCT00671424|Drug|Hydrochlorothiazide (HCTZ)|
463069|NCT00673231|Drug|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
463070|NCT00673218|Drug|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
463071|NCT00673218|Drug|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
463072|NCT00673205|Drug|Bicalutamide|150mg p.o. daily
463073|NCT00673205|Drug|Placebo|
463074|NCT00673192|Procedure|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
463075|NCT00673179|Drug|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m^2.
463076|NCT00673179|Drug|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m^2/day for 2 days continuous infusion.
463077|NCT00673179|Drug|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m^2, max 20 gm over 4 hours.
463078|NCT00673179|Drug|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
463079|NCT00673179|Drug|Dexrazoxane|Dose 900 mg/m^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
463080|NCT00673179|Drug|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2. Dose 2.8 grams m^2/day.
463081|NCT00673179|Behavioral|Questionnaire|Questionnaires to be completed on 5 different days during the study.
463082|NCT00673179|Drug|Gemcitabine|IV over 1 hour, every other week.
463083|NCT00673179|Drug|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
463084|NCT00673179|Procedure|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
463085|NCT00673179|Drug|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2/day.
463086|NCT00673166|Procedure|Staff incentive & supervision|Control & management of funds for incentive of staff; supervision
463087|NCT00673166|Behavioral|Staff motivation|Supervision, control of funds
463088|NCT00673153|Drug|gemtuzumab ozogamicin|Given IV
463089|NCT00673153|Drug|vorinostat|Given orally
463090|NCT00673153|Other|laboratory biomarker analysis|Correlative studies
463091|NCT00673140|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
463092|NCT00673140|Radiation|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
463093|NCT00673127|Drug|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
463094|NCT00673114|Biological|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
463095|NCT00673088|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
463096|NCT00673075|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
463097|NCT00673075|Drug|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
463098|NCT00673062|Drug|SCH 900538|(4X50mg Capsules)
463099|NCT00673062|Drug|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
463100|NCT00673062|Drug|Placebo Capsules|Placebo
463101|NCT00673049|Drug|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
463102|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
463103|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
463104|NCT00673036|Other|Blood sample|60 ml of whole blood
463105|NCT00673023|Other|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
463106|NCT00673010|Radiation|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
463107|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
463108|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
463109|NCT00672984|Drug|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
463110|NCT00672984|Drug|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
463111|NCT00672984|Drug|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
463159|NCT00672620|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
463160|NCT00672620|Drug|Duloxetine|Duloxetine capsules
463112|NCT00672971|Other|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
463113|NCT00672971|Other|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
463114|NCT00672958|Drug|Vortioxetine|Encapsulated immediate-release tablets.
463115|NCT00672958|Drug|Placebo|Vortioxetine placebo-matching capsules.
463116|NCT00672945|Drug|PRX-03140|
463117|NCT00672945|Drug|Placebo|
463118|NCT00672932|Drug|raltegravir|400 mg two times daily for three months
463119|NCT00672919|Drug|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
463120|NCT00672906|Behavioral|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
463121|NCT00672906|Behavioral|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
463122|NCT00672893|Other|Vibration Response Imaging|12 seconds of recording lung sounds
463123|NCT00672880|Behavioral|Self-System Therapy|12 sessions of structured Self-System Therapy
463124|NCT00672880|Behavioral|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
463125|NCT00672880|Other|Standard Care|Study participants continue with their usual medical care, no changes.
463126|NCT00672867|Drug|Clevudine|30mg
463127|NCT00672867|Drug|Adefovir dipivoxil|10mg
463128|NCT00672854|Drug|ClinOleic 20% Intravenous Emulsion|ClinOleic 20% is a lipid emulsion containing a mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%) corresponding to an essential fatty acid intake of approximately 20% of the total fatty acids intake.
463129|NCT00672854|Drug|Intralipid, 20% Intravenous Emulsion|It is made up of 20% Soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection
463130|NCT00672841|Drug|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
463131|NCT00672841|Drug|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
463132|NCT00672828|Behavioral|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
463133|NCT00672828|Behavioral|Interactive computer intervention|
463134|NCT00672802|Drug|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
463135|NCT00672789|Behavioral|Blood smear education|education at baseline and three month follow-up
463136|NCT00672789|Other|standard education|standard education
463137|NCT00672776|Drug|paroxetine|
463138|NCT00672776|Drug|placebo|
463139|NCT00672763|Drug|Colecalciferol D3 (Vigantol Oil)|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
463140|NCT00672763|Drug|Medium chain triglycerides|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;~Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;~Migliol Oil 5ml oral fortnightly (2 doses)"
463141|NCT00672737|Drug|Remifentanil|Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
463142|NCT00672737|Procedure|Cold pain threshold and tolerance|Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
463143|NCT00672737|Device|Heat pain threshold and tolerance|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
463144|NCT00672737|Procedure|Polysomnography|All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
463145|NCT00672724|Drug|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
463146|NCT00672724|Drug|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
463147|NCT00672698|Procedure|SURGERY|ELECTIVE SURGICAL PROCEDURES
463148|NCT00672685|Dietary Supplement|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
463149|NCT00672685|Behavioral|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
463150|NCT00672685|Drug|Placebo|OMEGA-3 placebo
463151|NCT00672672|Biological|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
463152|NCT00672659|Drug|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
463153|NCT00672659|Drug|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
463154|NCT00672646|Drug|AZD1386|95mg, oral solution, single dose
463155|NCT00672646|Drug|Naproxen|500mg, capsule, single dose
463156|NCT00672646|Drug|Placebo|AZD1386 Placebo oral solution
463157|NCT00672633|Drug|Lovaza|Lovaza , 4 grams/day orally for 6 months
463162|NCT00672607|Drug|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
463163|NCT00672607|Drug|Placebo|Placebo
463164|NCT00672594|Drug|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
463165|NCT00672581|Drug|ZD4054|10mg, Oral tablet, single dose
463166|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
463167|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
463168|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
463169|NCT00672568|Drug|Placebo|Solution, single dose, injection
463170|NCT00672555|Procedure|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
463171|NCT00672542|Biological|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
463172|NCT00672529|Dietary Supplement|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.~Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
463173|NCT00672490|Drug|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.~Tablets"
463174|NCT00672490|Drug|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
463175|NCT00672477|Drug|Methylnaltrexone|
463176|NCT00672477|Drug|Placebo|
463177|NCT00672464|Drug|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
463178|NCT00672464|Drug|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
463179|NCT00672464|Drug|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
463180|NCT00672451|Dietary Supplement|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
463181|NCT00672451|Dietary Supplement|placebo|placebo titrated up to 6 pills daily as patient tolerates
463182|NCT00672438|Drug|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
463183|NCT00672438|Other|Saline placebo infusion|Intravenous infusion of normal saline
463184|NCT00672412|Drug|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
463185|NCT00672412|Drug|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
463186|NCT00672412|Drug|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
463187|NCT00672412|Drug|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
463188|NCT00672399|Drug|exenatide|Subcutaneously injected, 10 mcg, single doses
463189|NCT00672399|Drug|Moxifloxacin|oral, 400 mg tablet, single doses
463190|NCT00672399|Drug|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
463191|NCT00672386|Drug|JNJ16269110|5 mg twice daily for 12 weeks
463192|NCT00672386|Drug|JNJ16269110|10 mg twice daily for 12 weeks
463193|NCT00672386|Drug|JNJ16269110|15 mg twice daily for 12 weeks
463194|NCT00672386|Drug|Placebo|twice daily for 12 weeks
463195|NCT00672386|Drug|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
463196|NCT00672386|Other|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
463197|NCT00672373|Drug|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
463198|NCT00672373|Drug|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
463199|NCT00672360|Dietary Supplement|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
463200|NCT00672360|Dietary Supplement|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
463201|NCT00672347|Drug|Clonidine|1 mcg/kg
463202|NCT00672347|Drug|Morphine|20 mcg/kg
463203|NCT00672347|Drug|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg~clonidine 1 mcg/kg~morphine 20 mcg/kg"
463204|NCT00672347|Drug|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
463205|NCT00672334|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
463206|NCT00672334|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
463207|NCT00672321|Genetic|gene expression analysis|
463208|NCT00672321|Genetic|mutation analysis|
463209|NCT00672321|Genetic|polymorphism analysis|
463210|NCT00672321|Other|laboratory biomarker analysis|
463211|NCT00672321|Other|questionnaire administration|
463212|NCT00672308|Other|Benefiber|
463213|NCT00672308|Other|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
463214|NCT00672308|Other|Benefiber with ORS|
463215|NCT00672308|Other|Benefiber with ORS|
463216|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
463217|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
463218|NCT00672295|Drug|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.~Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m^2) IV infused over 3 hours on day #1 of each cycle.~Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.~All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
463219|NCT00672282|Drug|Bicalutamide|150mg p.o. daily
463220|NCT00672282|Drug|Placebo|
463221|NCT00672256|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
463222|NCT00672243|Drug|Erlotinib + sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
463223|NCT00672230|Dietary Supplement|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
463224|NCT00672217|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
463225|NCT00672217|Behavioral|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
463226|NCT00672204|Biological|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
463227|NCT00672204|Drug|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
463228|NCT00672204|Drug|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
463229|NCT00672204|Drug|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
463230|NCT00672191|Biological|AGS-004|HIV-1 Immune Therapy
463231|NCT00672178|Radiation|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
463232|NCT00672165|Biological|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
463233|NCT00672152|Biological|WT1 derived peptides|"WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:~WT peptide #1: HLA-A2 restricted: RMFPNAPYL~WT peptide #2: HLA-A24 restricted: CMTWNQMNL~WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
463234|NCT00672139|Drug|Methylnaltrexone bromide|
463235|NCT00672113|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
463236|NCT00672113|Drug|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
463237|NCT00672100|Drug|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
463238|NCT00672100|Drug|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
463239|NCT00672100|Drug|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
463240|NCT00672087|Genetic|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
463241|NCT00672074|Drug|Ipamorelin|IV
463242|NCT00672074|Drug|placebo|IV
463243|NCT00672061|Drug|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
463244|NCT00672048|Other|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
463245|NCT00672048|Other|Continuing Education Course|Annual standard continuing education
463246|NCT00672048|Other|Continuing education|Annual standard continuing education materials
463247|NCT00672035|Biological|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
463248|NCT00672022|Drug|Zavesca (Miglustat)|
463249|NCT00672009|Drug|Ixabepilone|Ixabepilone 35 mg/m^2 intravenously over 3 hours every 21 days for 4 cycles.
463250|NCT00671996|Drug|Mangafodipir|"Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy."
463251|NCT00671996|Drug|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
463252|NCT00671983|Procedure|Neurocognitive Testing|
463253|NCT00671970|Drug|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs & 500 mg/day for pts on EIAEDs.~It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
463254|NCT00671944|Other|Low protein diet|Low protein diet for 6.5 weeks
463255|NCT00671931|Drug|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
463256|NCT00671931|Drug|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
463257|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
463258|NCT00671931|Drug|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
463259|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
463260|NCT00671918|Drug|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
463261|NCT00671905|Procedure|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
463262|NCT00671905|Procedure|PV isolation|Circumferential PV isolation
463263|NCT00671892|Biological|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU"
463264|NCT00671879|Drug|Carisoprodol SR 700 mg|700 mg twice daily tablet
463265|NCT00671879|Drug|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
463266|NCT00671879|Drug|Placebo|placebo tablet
463267|NCT00671853|Drug|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
463268|NCT00671853|Drug|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
463269|NCT00671827|Behavioral|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
463270|NCT00671814|Drug|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
463271|NCT00671814|Drug|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
463272|NCT00671814|Drug|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
463273|NCT00671801|Drug|Irinotecan|200 mg/m^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
463274|NCT00671801|Drug|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
463275|NCT00671788|Drug|Dasatinib|Given orally
463276|NCT00671788|Other|Laboratory Biomarker Analysis|Correlative studies
463277|NCT00671749|Drug|adapalene gel, 0.3%|Applied once daily at bedtime
463278|NCT00671749|Drug|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
463279|NCT00671736|Drug|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
463280|NCT00671736|Drug|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
463281|NCT00671723|Drug|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
463282|NCT00671723|Drug|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
463283|NCT00671723|Drug|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
463284|NCT00671710|Drug|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
463285|NCT00671697|Drug|Arsenic Trioxide|
463286|NCT00671697|Drug|Decitabine|
463337|NCT00671463|Procedure|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
463338|NCT00671437|Procedure|FDG-PET/CT|
463339|NCT00671437|Drug|Cetuximab|
463287|NCT00671684|Procedure|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
463288|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
463289|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
463290|NCT00671658|Drug|Rituximab|375 mg/m2 by vein
463291|NCT00671658|Drug|Cyclophosphamide (CTX)|300 mg/m2 by vein
463292|NCT00671658|Drug|Doxorubicin|50 mg/m2 by vein
463293|NCT00671658|Drug|Vincristine|2 mg by vein
463294|NCT00671658|Drug|Dexamethasone|40 mg by vein or by mouth (P.O.)
463295|NCT00671658|Drug|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7~200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
463296|NCT00671658|Drug|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7~3 gm/m2 by vein for Courses 2,4,6,8"
463297|NCT00671658|Drug|G-CSF|10 ug/kg subcutaneous injection
463298|NCT00671658|Drug|Mesna|600 mg/m2 a day by vein
463299|NCT00671658|Drug|Pegylated asparaginase|2000 International units/m2 by vein
463300|NCT00671658|Drug|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
463301|NCT00671658|Drug|Solumedrol|40 mg by vein for Courses 2,4,6,8
463302|NCT00671645|Drug|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
463303|NCT00671632|Drug|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:~Ramelteon 16 mg, tablets, orally, one day only;~Ramelteon 80 mg, tablets, orally, one day only;~Ramelteon 160 mg, tablets, orally, one day only;~Triazolam 0.25 mg, capsules, orally, one day only;~Triazolam 0.50 mg, capsules, orally, one day only;~Triazolam 0.75 mg, capsules, orally, one day only;~Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;~Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
463304|NCT00671619|Drug|ESBA105|eye drops
463305|NCT00671606|Procedure|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
463306|NCT00671593|Biological|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,~1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
463307|NCT00671593|Biological|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
463308|NCT00671580|Drug|PZ-601|750 mg
463309|NCT00671580|Drug|PZ-601|1000 mg
463310|NCT00671580|Drug|Standard of Care|as directed
463311|NCT00671567|Drug|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
463312|NCT00671567|Drug|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
463313|NCT00671567|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
463314|NCT00671554|Biological|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
463315|NCT00671541|Drug|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
463316|NCT00671541|Drug|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
463317|NCT00671528|Drug|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
463318|NCT00671528|Drug|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
463319|NCT00671528|Drug|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
463320|NCT00671515|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
463321|NCT00671502|Drug|Carisoprodol SR|700 mg twice daily
463322|NCT00671502|Drug|Carisoprodol SR|500 mg twice daily
463323|NCT00671502|Drug|Placebo|Placebo tablet
463324|NCT00671489|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
463325|NCT00671476|Drug|pegylated liposomal doxorubicin hydrochloride|
463326|NCT00671476|Genetic|DNA methylation analysis|
463327|NCT00671476|Genetic|TdT-mediated dUTP nick end labeling assay|
463328|NCT00671476|Genetic|fluorescence in situ hybridization|
463329|NCT00671476|Genetic|loss of heterozygosity analysis|
463330|NCT00671476|Genetic|polymerase chain reaction|
463331|NCT00671476|Other|immunoenzyme technique|
463332|NCT00671476|Other|immunohistochemistry staining method|
463333|NCT00671476|Other|laboratory biomarker analysis|
463334|NCT00671476|Procedure|breast duct lavage|
463335|NCT00671476|Procedure|neoadjuvant therapy|
463336|NCT00671476|Procedure|therapeutic conventional surgery|
463341|NCT00671424|Drug|Remogliflozin etabonate (GSK189075)|
463342|NCT00671424|Drug|Furosemide|
463343|NCT00671411|Drug|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings & Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 & 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings & energy w/i FDA guidelines. This will only be performed while imaging the kidney."
463344|NCT00671398|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
463345|NCT00671398|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
463346|NCT00671398|Drug|Placebo|Ramelteon placebo-matching tablets, orally for one night only
463347|NCT00671372|Drug|FOLFIRI regimen|Intravenous repeating dose
463348|NCT00671372|Drug|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
463349|NCT00671372|Drug|cetuximab|Intravenous repeating dose
463350|NCT00671372|Drug|dulanermin|Intravenous repeating dose
463351|NCT00671372|Drug|irinotecan|Intravenous repeating dose
463352|NCT00671359|Drug|TR-701 600mg|TR-701 600mg
463353|NCT00671333|Procedure|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
463354|NCT00671333|Procedure|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
463355|NCT00671320|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
463356|NCT00671320|Drug|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
463357|NCT00671307|Drug|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
463358|NCT00671307|Drug|Placebo|Vehicle control given as IV infusion over 1 hour
463359|NCT00671294|Drug|Ramelteon and Placebo (9 possible combinations total)|"Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights"
463360|NCT00671281|Drug|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
463361|NCT00671281|Drug|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
463362|NCT00671268|Biological|AL0704rP|strict subcutaneous
463363|NCT00671268|Biological|Placebo|strict subcutaneous
463364|NCT00671255|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
463365|NCT00671255|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
463366|NCT00671255|Drug|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
463367|NCT00671216|Drug|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
463368|NCT00671216|Drug|GW642444|Subjects will receive 50 mcg once daily as a single dose
463369|NCT00671216|Drug|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
463370|NCT00671216|Drug|Placebo|Placebo matching study medication will be inhaled by subjects
463371|NCT00671203|Procedure|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
463372|NCT00671190|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
463373|NCT00671190|Drug|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
463374|NCT00671190|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
463375|NCT00671190|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
463376|NCT00671190|Drug|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
463377|NCT00671177|Procedure|water immersion colonoscopy|instillation of 300cc of water in the rectum
463378|NCT00671177|Procedure|standard air colonoscopy|air instillation in colon for visualization
463379|NCT00671151|Drug|Theophylline|Theophylline 100 mg bid for 3 months
463380|NCT00671138|Biological|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
463381|NCT00671138|Other|Sham inoculation|A diluted amount of McIlhenny & Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
463382|NCT00671125|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
463383|NCT00671125|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
463384|NCT00671125|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
463506|NCT00670358|Drug|doxorubicin hydrochloride|
463507|NCT00670358|Drug|lenalidomide|
463385|NCT00671112|Drug|Bortezomib|"Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.~The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line."
463386|NCT00671112|Drug|Everolimus|Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
463387|NCT00671099|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
463388|NCT00671099|Dietary Supplement|Placebo|Placebo
463389|NCT00671086|Drug|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
463390|NCT00671086|Drug|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
463391|NCT00671073|Drug|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
463392|NCT00671073|Drug|Placebo|Placebo, oral administration, once daily for 12 weeks
463393|NCT00671073|Drug|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
463394|NCT00671073|Drug|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
463395|NCT00671060|Drug|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
463396|NCT00671060|Drug|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
463397|NCT00671047|Other|non-interventional|SLE nature history observational
463398|NCT00671034|Drug|calaspargase pegol|Given IV
463399|NCT00671034|Drug|calaspargase pegol|Given IV
463400|NCT00671034|Drug|Pegaspargase|Given IV
463401|NCT00671034|Drug|DOXOrubicin Hydrochloride|Given IV
463402|NCT00671034|Drug|Cytarabine|Given IV, IT, or SC
463403|NCT00671034|Drug|Prednisone|Given IV or PO
463404|NCT00671034|Drug|methotrexate|Given IV, IT, or PO
463405|NCT00671034|Drug|cyclophosphamide|Given IV
463406|NCT00671034|Drug|mercaptopurine tablet|Given PO
463407|NCT00671034|Drug|Dexamethasone|Given PO or IV
463408|NCT00671034|Drug|thioguanine|Given PO
463409|NCT00671034|Drug|DAUNOrubicin Hydrochloride|Given IV
463410|NCT00671034|Drug|vincristine sulfate|Given IV
463411|NCT00671034|Radiation|radiation therapy|Some patients undergo RT
463412|NCT00671034|Other|laboratory biomarker analysis|Correlative studies
463413|NCT00671034|Other|pharmacological study|Correlative studies
463414|NCT00671021|Other|Platelet aggregation|Platelet aggregation TxA2 formation
463415|NCT00671008|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
463416|NCT00671008|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
463417|NCT00670995|Behavioral|Interactive Tobacco Education|Increase perceived behavioral control (self-efficacy) Decrease willingness to use tobacco Decrease intentions to use tobacco
463418|NCT00670982|Drug|bevacizumab|Given intravenously every 2 weeks
463419|NCT00670982|Drug|vinorelbine|Given intravenously once a week
463420|NCT00670982|Drug|trastuzumab|Given intravenously once a week
463421|NCT00670956|Drug|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
463422|NCT00670956|Drug|Placebo|PLACEBO: IM x 2 doses 24 hours apart
463423|NCT00670943|Other|Platelet function testing|
463424|NCT00670930|Drug|omalizumab at a dose of 0.016mg/kg/IU/mL|
463425|NCT00670930|Drug|Placebo|
463426|NCT00670917|Other|questionnaire administration|
463427|NCT00670917|Procedure|acupressure therapy|
463428|NCT00670917|Procedure|biopsy|
463429|NCT00670917|Procedure|bone marrow aspiration|
463430|NCT00670917|Procedure|pain therapy|
463431|NCT00670904|Other|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
463432|NCT00670904|Other|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
463433|NCT00670891|Procedure|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International~Air or Gas Embolus~Decompression Illness~Carbon Monoxide poising~Clostridial Myonecrosis (Gas Gangrene)~Necrotizing Fasciitis~Crush Injury (Compartment syndromes)~Selected Problem Wounds~Compromised Skin Flaps or Grafts~Refractory Osteomyelitis~Exceptional Anemia due to Blood loss~Osteoradionecrosis~Thermal Burns and Radiation Tissue Damage~Diabetic Wounds~Intra-Cranial Abscess~Brain Injury and other Head Trauma~Cerebral Palsy~High Altitude Sickness~Lyme disease"
463434|NCT00670878|Drug|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
463508|NCT00670358|Drug|prednisone|
463509|NCT00670358|Drug|vincristine sulfate|
463435|NCT00670878|Drug|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
463436|NCT00670865|Other|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
463437|NCT00670852|Procedure|X-rays and CT scan|CT Scan x-rays
463438|NCT00670839|Biological|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
463439|NCT00670839|Biological|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
463440|NCT00670826|Device|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand & forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
463441|NCT00670826|Device|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
463442|NCT00670813|Drug|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
463443|NCT00670813|Drug|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
463444|NCT00670800|Drug|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
463445|NCT00670787|Drug|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
463446|NCT00670774|Drug|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.~Patients will be given 900 mg of eculizumab on Day 1 post-transplant.~Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant~At week 4, patients will be assessed for B cell flow cytometry cross match (FCXM). Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FCXM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.~In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
463447|NCT00670761|Drug|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
463448|NCT00670761|Procedure|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
463449|NCT00670748|Biological|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
463450|NCT00670748|Drug|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
463451|NCT00670748|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
463452|NCT00670748|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
463453|NCT00670748|Biological|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
463454|NCT00670722|Drug|insulin aspart|Intervention at the discretion of the physician
463455|NCT00670722|Drug|insulin detemir|Intervention at the discretion of the physician
463456|NCT00670722|Drug|biphasic insulin aspart 30|Intervention at the discretion of the physician
463457|NCT00670696|Drug|Rapydan|Topical anaesthetic plaster
463458|NCT00670696|Drug|tetracaine gel|Topical tetracaine gel
463459|NCT00670683|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
463460|NCT00670670|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
463461|NCT00670670|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
463462|NCT00670657|Drug|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
463463|NCT00670644|Other|questionnaire administration|Completed self-report form
463464|NCT00670644|Other|survey administration|Completed self-report form-other
463465|NCT00670644|Procedure|quality-of-life assessment|Completed self-report form qol
463499|NCT00670410|Drug|Fludarabine|Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients < 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
463500|NCT00670397|Drug|HPPH|IV
463501|NCT00670384|Biological|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
463466|NCT00670631|Combination Product|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.~Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.~Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.~Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 & 15-18 every cycle.~Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
463467|NCT00670618|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
463468|NCT00670618|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
463469|NCT00670618|Device|Fluoride (Elmex Medical Gel)|Fluoride
463470|NCT00670605|Other|medical chart review|
463471|NCT00670605|Other|study of socioeconomic and demographic variables|
463472|NCT00670592|Drug|HCD122|
463473|NCT00670566|Drug|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
463474|NCT00670553|Drug|panobinostat|
463475|NCT00670540|Other|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
463476|NCT00670527|Procedure|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the [18F]Fluorocholine PET/CT scan. [18F]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.~The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
463477|NCT00670514|Behavioral|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
463478|NCT00670514|Behavioral|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
463479|NCT00670501|Drug|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
463480|NCT00670501|Drug|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
463481|NCT00670501|Drug|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
463482|NCT00670501|Drug|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
463483|NCT00670501|Drug|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
463484|NCT00670488|Drug|MK-2206|MK-2206 administered as an oral formulation in rising dose levels on a QOD schedule (30 mg, 60 mg, 75 mg, and 90 mg) or QW schedule (90 mg, 135 mg, 200 mg, 250 mg, and 300 mg) in repeating 4 week cycles, depending upon allocation.
463485|NCT00670475|Drug|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
463486|NCT00670475|Dietary Supplement|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
463487|NCT00670462|Behavioral|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
463488|NCT00670462|Behavioral|Maintenance-Tailored Treatment (MTT)|
463489|NCT00670449|Drug|Fingolimod|Fingolimod was supplied in capsules.
463490|NCT00670436|Device|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
463491|NCT00670436|Device|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
463492|NCT00670423|Drug|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
463493|NCT00670423|Drug|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
463494|NCT00670423|Drug|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:~Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3~Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3~Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
463495|NCT00670410|Procedure|Related donor transplant|Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
463496|NCT00670410|Procedure|Cord blood transplant|Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
463497|NCT00670410|Drug|Busulfan|Busulfan (Busulfex) [4mg/kg/dose for patients < 4 years; 3.2 mg/kg/dose for patients > 4 years] will be given IV in 0.9% sodium chloride or D5W to a final concentration > 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.
463498|NCT00670410|Drug|Thymoglobulin|Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.
463502|NCT00670384|Biological|Placebo|Sublingual drops
463503|NCT00670358|Biological|pegfilgrastim|
463510|NCT00670358|Genetic|polymorphism analysis|
463511|NCT00670358|Other|laboratory biomarker analysis|
463512|NCT00670345|Drug|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
463513|NCT00670345|Drug|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
463514|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
463515|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
463516|NCT00670319|Drug|Placebo|Placebo one tab orally per day
463517|NCT00670306|Drug|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
463518|NCT00670293|Radiation|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
463519|NCT00670293|Drug|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
463520|NCT00670293|Procedure|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
463521|NCT00670280|Behavioral|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
463522|NCT00670280|Behavioral|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
463523|NCT00670280|Behavioral|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
463524|NCT00670267|Drug|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
463525|NCT00670254|Drug|Placebo|Application is identical to experimental arm
463526|NCT00670254|Drug|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
463527|NCT00670241|Drug|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
463528|NCT00670241|Drug|LEO 80185 vehicle|Once daily application
463529|NCT00670241|Drug|Tacalcitol ointment|Once daily application
463530|NCT00670228|Drug|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
463531|NCT00670228|Drug|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
463532|NCT00670228|Drug|Standard Therapy|Standard insulin therapy titrated to blood sugar control
463533|NCT00670215|Drug|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
463534|NCT00670215|Drug|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
463535|NCT00670202|Drug|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
463536|NCT00670202|Drug|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
463537|NCT00670189|Drug|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
463538|NCT00670176|Behavioral|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
463539|NCT00670163|Behavioral|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
463540|NCT00670163|Behavioral|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
463541|NCT00670163|Behavioral|Standard Care|Standard care will consist of usual care for STIs.
463542|NCT00670150|Drug|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
463543|NCT00670150|Drug|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
463544|NCT00670124|Device|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
463545|NCT00670111|Device|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
463546|NCT00670098|Procedure|Bariatric surgery|patients receive either gastric bypass or lap-band
463547|NCT00670098|Behavioral|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
463548|NCT00670059|Genetic|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
463549|NCT00670059|Genetic|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
463550|NCT00670046|Drug|valproic acid|given orally
463551|NCT00670046|Other|standard of care follow-up|participant follow the standard of care for patient with metastatic prostate cancer
463552|NCT00670033|Drug|Travoprost ophthalmic solution (new formulation)|
463553|NCT00670033|Drug|Travoprost ophthalmic solution, 0.004%|
463554|NCT00670033|Drug|Vehicle|Inactive ingredients used as a placebo
463555|NCT00670020|Procedure|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
463556|NCT00670007|Biological|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
463557|NCT00669994|Drug|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
463558|NCT00669981|Behavioral|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
463559|NCT00669955|Drug|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
463560|NCT00669955|Drug|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
463561|NCT00669942|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
463562|NCT00669942|Drug|Placebo|Placebo to AIN457
463563|NCT00669916|Biological|AIN457|single infusion of 3 mg/kg
463564|NCT00669916|Drug|Placebo|single infusion of placebo
463565|NCT00669903|Drug|AZD0328|
463566|NCT00669903|Drug|Placebo|
463567|NCT00669890|Drug|Gemtuzumab Ozogamicin|Dose Escalation
463568|NCT00669890|Drug|Busulfan|Conditioning Regimen
463569|NCT00669890|Drug|Cyclophosphamide|Conditioning Regimen
463570|NCT00669890|Drug|Thymoglobulin|(Unrelated Donors only)
463571|NCT00669890|Drug|Tacrolimus|GVHD Prophylaxis
463572|NCT00669890|Drug|Mycophenolate Mofetil|GVHD Prophylaxis
463573|NCT00669890|Drug|Methotrexate|GVHD Prophylaxis
463574|NCT00669877|Drug|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
463575|NCT00669877|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
463576|NCT00669877|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
463577|NCT00669877|Drug|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
463578|NCT00669877|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
463579|NCT00669877|Drug|G-CSF|10 mcg/kg
463580|NCT00669877|Drug|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
463581|NCT00669877|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
463582|NCT00669864|Drug|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
463583|NCT00669864|Drug|metformin|Tablets, 1000 - 2000 mg daily
463584|NCT00669851|Drug|AI-700|
463585|NCT00669825|Drug|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
463586|NCT00669825|Drug|Placebo|Placebo to be administered via intragastric tube
463587|NCT00669812|Drug|carmustine|
463588|NCT00669812|Drug|cyclophosphamide|
463589|NCT00669812|Drug|cytarabine|
463590|NCT00669812|Drug|doxorubicin hydrochloride|
463591|NCT00669812|Drug|epirubicin hydrochloride|
463592|NCT00669812|Drug|etoposide|
463593|NCT00669812|Drug|ifosfamide|
463594|NCT00669812|Drug|melphalan|
463595|NCT00669812|Drug|methotrexate|
463596|NCT00669812|Drug|prednisolone|
463597|NCT00669812|Drug|vincristine sulfate|
463598|NCT00669812|Procedure|autologous hematopoietic stem cell transplantation|
463599|NCT00669812|Procedure|biopsy|
463600|NCT00669812|Procedure|peripheral blood stem cell transplantation|
463601|NCT00669799|Drug|gentamyacin|topical internasal
463602|NCT00669799|Drug|gentamyacin|intranasal
463603|NCT00669786|Drug|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
463604|NCT00669773|Drug|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
463605|NCT00669773|Drug|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
463606|NCT00669760|Other|non-interventional study|does not apply
463607|NCT00669747|Drug|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 & 15
463608|NCT00669747|Drug|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
463609|NCT00669747|Drug|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
463610|NCT00669734|Biological|Falimarev|Given intratumorally or SC
463611|NCT00669734|Biological|Inalimarev|Given SC
463612|NCT00669734|Other|Laboratory Biomarker Analysis|Correlative studies
463613|NCT00669734|Biological|Sargramostim|Given SC
463614|NCT00669721|Drug|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
463615|NCT00669721|Drug|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
463616|NCT00669708|Device|cooling compound (ph5 Eucerin)|application twice daily to the skin
463617|NCT00669695|Drug|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
463618|NCT00669695|Other|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
463619|NCT00669695|Other|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
463620|NCT00669682|Other|Congestive heart failure|Spontaneous occurrence of fluid overload.
463621|NCT00669669|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
463622|NCT00669669|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
463623|NCT00669669|Drug|Carmustine|Given IV
463624|NCT00669669|Biological|Filgrastim|Given SC
463625|NCT00669669|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
463626|NCT00669669|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
463627|NCT00669669|Other|Laboratory Biomarker Analysis|Correlative studies
463628|NCT00669669|Drug|O6-Benzylguanine|Given IV
463629|NCT00669669|Drug|Plerixafor|Given SC
463630|NCT00669669|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
463631|NCT00669669|Drug|Temozolomide|Given PO
463632|NCT00669656|Drug|Prostate Health Cocktail|3 capsules daily PO up 12 months
463633|NCT00669643|Drug|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;~Children: 6 doses;~1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
463634|NCT00669643|Drug|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 6 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
463635|NCT00669643|Drug|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;~Children: 12 doses;~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
463636|NCT00669643|Drug|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses~1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine~Children: 6 doses~1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
463637|NCT00669630|Behavioral|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
463638|NCT00669617|Drug|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
463639|NCT00669617|Drug|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
463640|NCT00669617|Drug|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
463641|NCT00669617|Drug|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
463642|NCT00669617|Drug|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
463643|NCT00669617|Drug|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
463644|NCT00669591|Drug|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
463645|NCT00669578|Drug|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
463646|NCT00669565|Drug|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
463647|NCT00669552|Procedure|Percutaneous coronary intervention|PCI previously electively scheduled.
463648|NCT00669526|Behavioral|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
463649|NCT00669526|Behavioral|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
463650|NCT00669513|Behavioral|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
463651|NCT00669500|Behavioral|Lifestyle intervention|Alive!TM web-based, 12 week lifestyle intervention sent via NutritionQuest.
463652|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
463653|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
463654|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
463655|NCT00669474|Procedure|Suction curettage|Suction curettage
463656|NCT00669474|Drug|Treatment with Botox|Treatment with Botox
463657|NCT00669461|Drug|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
463658|NCT00669448|Behavioral|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
463659|NCT00669435|Drug|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months~tablets; 20 mg; od; 6 months"
463660|NCT00669435|Drug|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months~tablets; 20 mg; od; 6 months"
463661|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
463662|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
463663|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
463664|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
463665|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
463666|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of Placebo IV
463667|NCT00669396|Drug|Copper T380 IUD|Copper T380 IUD
463668|NCT00669396|Drug|levonorgestrel|1.5 mg
463669|NCT00669383|Drug|betamethasone|12 mg IM q 24 hours x 2 doses
463670|NCT00669383|Drug|placebo|Placebo IM q 24 hours x 2 doses
463671|NCT00669370|Drug|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
463672|NCT00669357|Device|Abiocor Implantable Replacement Heart|Replacement of heart
463673|NCT00669344|Drug|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
463674|NCT00669344|Drug|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
463675|NCT00669331|Drug|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
463676|NCT00669331|Drug|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
463677|NCT00669318|Biological|alemtuzumab|
463678|NCT00669318|Biological|rituximab|
463679|NCT00669318|Drug|pentostatin|
463680|NCT00669318|Drug|sargramostim|
463681|NCT00669292|Biological|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
463682|NCT00669279|Drug|Carvedilol CR|Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
463683|NCT00669279|Drug|Atenolol|Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
463684|NCT00669253|Procedure|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
463685|NCT00669253|Procedure|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
463686|NCT00669253|Procedure|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
463687|NCT00669240|Drug|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
463688|NCT00669227|Other|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
463689|NCT00669227|Other|placebo suspension|intracoronary administration at the same day as cell aspiration
463690|NCT00669214|Drug|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
463691|NCT00669214|Drug|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
463692|NCT00669188|Other|Information absent|Control information - carrier test results only
463693|NCT00669188|Other|Information|Information about genetic risk for virtual patient
463694|NCT00669162|Drug|Docetaxel|20mg/m2 IV weekly for 7 weeks
463695|NCT00669162|Radiation|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
463696|NCT00669162|Drug|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
463697|NCT00669149|Drug|clopidogrel + aspirin|
463698|NCT00669149|Drug|heparin + clopidogrel + aspirin|
463699|NCT00669149|Drug|enoxaparin + clopidogrel + aspirin|
463700|NCT00669149|Drug|bivalirudin + clopidogrel + aspirin|
463701|NCT00669136|Drug|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
463702|NCT00669123|Drug|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
463703|NCT00669123|Drug|Placebo|
463704|NCT00669110|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"tablet~subjects randomly assigned to 10-200 mg/day by age group~6 month treatment period(~182 days)"
463705|NCT00669097|Drug|TKI258|
463744|NCT00668720|Device|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
463745|NCT00668707|Dietary Supplement|melatonin|20 mgs ingested nightly
463706|NCT00669071|Drug|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
463707|NCT00669071|Drug|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
463708|NCT00669058|Drug|Lactic acid (Dermacid)|
463709|NCT00669032|Device|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
463710|NCT00669032|Other|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
463711|NCT00669019|Drug|saracatinib|
463712|NCT00668993|Behavioral|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
463713|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
463714|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
463715|NCT00668954|Dietary Supplement|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
463716|NCT00668954|Dietary Supplement|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
463717|NCT00668941|Drug|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
463718|NCT00668941|Drug|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
463719|NCT00668941|Dietary Supplement|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
463720|NCT00668941|Dietary Supplement|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
463721|NCT00668928|Other|Polyphenols (flavon-3-ol monomers and oligomers)|Flavanols
463722|NCT00668902|Drug|[13C]Pantoprazole|[13C]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
463723|NCT00668889|Drug|Lactic acid (Dermacid)|
463724|NCT00668876|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
463725|NCT00668876|Dietary Supplement|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
463726|NCT00668876|Dietary Supplement|Parenteral nutrition|Parenteral nutrition
463727|NCT00668863|Drug|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
463728|NCT00668863|Drug|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
463729|NCT00668850|Drug|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
463730|NCT00668850|Drug|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
463731|NCT00668837|Drug|Paliperidone|
463732|NCT00668824|Drug|Vasovist|
463733|NCT00668811|Drug|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
463734|NCT00668785|Drug|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
463735|NCT00668772|Drug|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
463736|NCT00668772|Drug|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
463737|NCT00668772|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
463738|NCT00668772|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
463739|NCT00668772|Drug|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
463740|NCT00668759|Drug|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
463741|NCT00668759|Drug|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
463742|NCT00668746|Drug|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
463743|NCT00668720|Device|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
463892|NCT00667641|Drug|paclitaxel|Starting dose level 40mg/m2
463746|NCT00668707|Dietary Supplement|placebo|similar to experimental in all ways except for lack of active ingredient
463747|NCT00668694|Behavioral|Stimulation|Stimulation given to the child by mother
463748|NCT00668681|Device|EndoRefix|
463749|NCT00668668|Drug|Lactic acid (Dermacid)|
463750|NCT00668655|Drug|Metronidazole Gel|Topical, Once daily for 2 weeks
463751|NCT00668642|Drug|Dutasteride|0.5 mg capsule given orally on daily basis
463752|NCT00668642|Drug|Placebo|Identical placebo
463753|NCT00668629|Drug|Lactic acid (Dermacid)|
463754|NCT00668616|Drug|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
463755|NCT00668616|Drug|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
463756|NCT00668603|Drug|17-b-estradiol|2mg oral daily for 6 months
463757|NCT00668603|Drug|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
463758|NCT00668603|Drug|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
463759|NCT00668603|Drug|placebo pill + gel|placebo daily for 6 months
463760|NCT00668590|Behavioral|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
463761|NCT00668590|Behavioral|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
463762|NCT00668577|Drug|Lactic acid (Dermacid)|
463763|NCT00668564|Procedure|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
463764|NCT00668564|Drug|Cyclophosphamide|"Days before Transplant Drug Frequency~4 Cyclophosphamide Once, given over 2 hours~3 Cyclophosphamide Once, given over 2 hours~2 Cyclophosphamide Once, given over 2 hours~1 Cyclophosphamide Once, given over 2 hours"
463765|NCT00668564|Drug|Campath-1H|"Days before Transplant Drug Frequency~12 Campath-1H Once, given over 2 hours~11 Campath-1H Once, given over 2 hours~10 Campath-1H Once, given over 2 hours"
463766|NCT00668564|Drug|Busulfan|"Days before Transplant Drug Frequency~9 Busulfan Four times per day~8 Busulfan Four times per day~7 Busulfan Four times per day~6 Busulfan Four times per day"
463767|NCT00668538|Drug|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
463768|NCT00668525|Drug|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
463769|NCT00668525|Drug|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
463770|NCT00668525|Drug|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
463771|NCT00668512|Biological|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
463772|NCT00668499|Drug|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
463773|NCT00668486|Drug|Lactic acid (Dermacid)|
463774|NCT00668460|Drug|Lactic acid (Dermacid)|
463775|NCT00668447|Dietary Supplement|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
463776|NCT00668447|Dietary Supplement|Control protein|20 grams of powder mixed in beverages or food daily for one year
463777|NCT00668447|Dietary Supplement|Novasoy isoflavones|3 tablets daily for one year
463778|NCT00668447|Dietary Supplement|Placebo tablets|3 tablets daily for one year
463779|NCT00668434|Drug|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
463780|NCT00668434|Drug|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
463781|NCT00668421|Drug|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
463782|NCT00668408|Other|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
463783|NCT00668408|Other|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :~Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)~Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)~Beta-blockers~Diuretics~Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics~Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).~The treatment of the deseases will follow the international guidelines."
463784|NCT00668395|Drug|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
463785|NCT00668382|Biological|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
463786|NCT00668369|Procedure|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
463787|NCT00668356|Drug|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
463788|NCT00668356|Drug|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
463789|NCT00668343|Drug|simvastatin|40 mg/ day
463790|NCT00668343|Drug|placebo|80 mg /day
463791|NCT00668330|Drug|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
463792|NCT00668330|Drug|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
463793|NCT00668317|Drug|Omeprazole|20 mg BD tablet 8 weeks duration
463794|NCT00668317|Drug|Ranitidine|300 mg od nocte tablet 8weeks duration
463795|NCT00668304|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
463796|NCT00668278|Device|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
463797|NCT00668278|Device|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
463798|NCT00668278|Other|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
463799|NCT00668265|Drug|Quetiapine|Dosage is 50 - 300 mg, once daily, at bedtime.
463800|NCT00668239|Drug|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
463801|NCT00668239|Procedure|laser therapy|pan fotocoaglulation by laser therapy
463802|NCT00668226|Drug|Lactic acid (Dermacid)|
463803|NCT00668200|Drug|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
463804|NCT00668200|Dietary Supplement|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
463805|NCT00668200|Dietary Supplement|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
463806|NCT00668174|Behavioral|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
463807|NCT00668161|Behavioral|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
463808|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/PNET~10 milligrams per kilogram (mg/kg) intravenous (IV) infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
463809|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
463810|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Leiomyosarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
463811|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Adipocytic sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
463812|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Synovial sarcoma~10 mg/kg IV infusion every two weeks.~A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
463813|NCT00668135|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
463814|NCT00668135|Drug|Placebo|Matching placebo
463815|NCT00668122|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
463816|NCT00668122|Drug|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
463817|NCT00668109|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
463818|NCT00668109|Drug|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
463819|NCT00668096|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
463820|NCT00668096|Drug|Placebo|Matching Placebo
463821|NCT00668070|Drug|ASP9831|Oral
463822|NCT00668070|Drug|Placebo|Oral
463823|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
463824|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
463825|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
463826|NCT00668057|Drug|Placebo|5 mg matching placebo
463827|NCT00668057|Drug|Placebo|10 mg matching placebo
463828|NCT00668057|Drug|Placebo|20 mg matching placebo
463829|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv BID
463830|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv TID
463831|NCT00668031|Drug|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
463832|NCT00668031|Drug|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
463833|NCT00668018|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
463834|NCT00668005|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
463835|NCT00668005|Drug|Placebo|Matching placebo
463836|NCT00667992|Drug|Budesonide HFA|standard daily inhaled dose
463837|NCT00667992|Drug|Budesonide CFC|standard daily inhaled dose
463838|NCT00667979|Drug|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
463839|NCT00667979|Drug|Placebo|Matching placebo
463840|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
463841|NCT00667966|Drug|Placebo|10/20 mg placebo in sequence in respective arm
463842|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
463843|NCT00667953|Drug|Gleevec + Temozolomide|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle. Gleevec (600 mg) daily.
463844|NCT00667940|Behavioral|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
463845|NCT00667927|Drug|Busulfan|See Detailed Description section for description of treatment plan.
463846|NCT00667927|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
463847|NCT00667927|Drug|Mesna|See Detailed Description section for description of treatment plan.
463848|NCT00667914|Procedure|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
463849|NCT00667914|Procedure|Orthopedic care as usual|treatment in ordinary orthopedic unit
463850|NCT00667901|Drug|riluzole|
463851|NCT00667901|Genetic|protein expression analysis|
463852|NCT00667901|Genetic|reverse transcriptase-polymerase chain reaction|
463853|NCT00667901|Genetic|western blotting|
463854|NCT00667901|Other|immunohistochemistry staining method|
463855|NCT00667901|Other|laboratory biomarker analysis|
463856|NCT00667901|Other|pharmacological study|
463857|NCT00667901|Procedure|neoadjuvant therapy|
463858|NCT00667901|Procedure|therapeutic conventional surgery|
463859|NCT00667888|Radiation|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
463860|NCT00667888|Radiation|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
463861|NCT00667875|Drug|Placebo|placebo
463862|NCT00667875|Drug|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
463863|NCT00667875|Drug|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
463864|NCT00667862|Drug|Panobinostat|
463865|NCT00667849|Device|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
463866|NCT00667849|Device|Sham|sham device identical to active device with the exception of administration of ultrasound
463867|NCT00667823|Drug|Macitentan|Tablet, oral administration, 10 mg dose once daily
463868|NCT00667810|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
463869|NCT00667810|Drug|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
463870|NCT00667810|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
463871|NCT00667797|Drug|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
463872|NCT00667797|Drug|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
463873|NCT00667784|Behavioral|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
463874|NCT00667771|Drug|Naltrexone|
463875|NCT00667758|Drug|Cetrorelix|3-5 mg s.c. on days 1-5
463876|NCT00667758|Drug|Placebo|3-5 ml NaCl s.c. on days 1-5
463877|NCT00667745|Drug|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
463878|NCT00667745|Drug|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
463879|NCT00667732|Drug|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
463880|NCT00667732|Drug|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
463881|NCT00667719|Drug|aliskiren /amlodipine/hydrochlorothiazide|1x aliskiren/amlodipine/hydrochlorothiazide
463882|NCT00667706|Procedure|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
463883|NCT00667706|Procedure|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of <50, and >50, respectively.
463884|NCT00667693|Device|Macintosh laryngoscope|Intubation with Macintosh laryngoscope
463885|NCT00667693|Device|Pentax AWS|Intubation with Pentax AWS
463886|NCT00667680|Device|Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator|real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
463887|NCT00667667|Device|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
463888|NCT00667667|Device|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
463889|NCT00667667|Behavioral|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
463890|NCT00667654|Drug|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
463891|NCT00667641|Drug|bortezomib|Starting dose level 0.70mg/m2
463893|NCT00667628|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
463894|NCT00667628|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
463895|NCT00667615|Drug|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
463896|NCT00667602|Biological|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
463897|NCT00667602|Biological|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
463898|NCT00667602|Biological|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
463899|NCT00667602|Biological|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
463900|NCT00667602|Biological|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
463901|NCT00667589|Drug|urea 40% cream|urea 40% cream applied twice per day to affected areas
463902|NCT00667589|Drug|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
463903|NCT00667589|Drug|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
463904|NCT00667589|Drug|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
463905|NCT00667576|Drug|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
463906|NCT00667576|Drug|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
463907|NCT00667563|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
463908|NCT00667563|Genetic|DNA analysis|Weeks 0, 2, 10, 26, and 52.
463909|NCT00667563|Genetic|polymerase chain reaction|Screening, week 36, and week 52.
463910|NCT00667563|Other|cytology specimen collection procedure|Screening, week 36, and week 52.
463911|NCT00667563|Procedure|colposcopic biopsy|Screening, week 36, and week 52.
463912|NCT00667537|Drug|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
463913|NCT00667511|Device|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
463914|NCT00667498|Drug|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
463915|NCT00667498|Drug|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
463916|NCT00667485|Drug|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
463917|NCT00667485|Drug|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
463918|NCT00667485|Drug|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
463919|NCT00667472|Drug|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
463920|NCT00667472|Device|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
463921|NCT00667459|Device|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
463922|NCT00667459|Device|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
463923|NCT00667446|Drug|Leuprolide Acetate 3 Month Depot|
463924|NCT00667433|Drug|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
463925|NCT00667420|Drug|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
463926|NCT00667407|Drug|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.~Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
463927|NCT00667407|Drug|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.~Period II: TID for 3 days then PRN to TID for 7 days"
463928|NCT00667394|Biological|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
463929|NCT00667394|Drug|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
463930|NCT00667394|Procedure|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
464078|NCT00666640|Device|CT scan of hip|Computed Tomography scan
463931|NCT00667381|Device|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
463932|NCT00667368|Drug|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
463933|NCT00667355|Biological|adalimumab|40 mg or 80 mg every other week, subcutaneous
463934|NCT00667342|Biological|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
463935|NCT00667342|Drug|Cisplatin|Given IV.
463936|NCT00667342|Drug|Doxorubicin|Given IV.
463937|NCT00667342|Drug|Methotrexate|Given IV.
463938|NCT00667342|Drug|Ifosfamide|Given IV.
463939|NCT00667342|Drug|etoposide|Given IV.
463940|NCT00667342|Procedure|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
463941|NCT00667342|Radiation|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
463942|NCT00667329|Drug|2CdA|1.5 mg/m^2 subcutaneous injection three times daily x 7 days.
463943|NCT00667329|Drug|Cyclophosphamide|40 mg/m^2 PO twice daily x 7 days.
463944|NCT00667329|Drug|Rituximab|375 mg/m^2 IV once weekly x 4 weeks.
463945|NCT00667316|Behavioral|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
463946|NCT00667303|Other|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
463947|NCT00667303|Other|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
463948|NCT00667303|Other|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
463949|NCT00667290|Behavioral|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
463950|NCT00667277|Drug|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
463951|NCT00667264|Procedure|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
463952|NCT00667251|Biological|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
463953|NCT00667251|Drug|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
463954|NCT00667251|Drug|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
463955|NCT00667251|Drug|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
463956|NCT00667238|Behavioral|Questionnaire|
463957|NCT00667225|Drug|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
463958|NCT00667225|Drug|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
463959|NCT00667212|Behavioral|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
463960|NCT00667212|Behavioral|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
463961|NCT00667199|Drug|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
463962|NCT00667186|Other|Targeted Screening|Selection method for screening is based on risk
463963|NCT00667186|Other|Routine Screening|Selection method for screening is not based on risk
463964|NCT00667173|Drug|IDP-115|Topical application for 12 weeks
463965|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
463966|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
463967|NCT00667160|Drug|tacrolimus ointment|topical
463968|NCT00667160|Drug|pimecrolimus cream|topical
463969|NCT00667147|Drug|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
463970|NCT00667147|Drug|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
463971|NCT00667121|Drug|citalopram hydrobromide|
463972|NCT00667121|Drug|escitalopram oxalate|
463973|NCT00667121|Drug|gabapentin|
463974|NCT00667121|Drug|sertraline hydrochloride|
463975|NCT00667121|Drug|tamoxifen citrate|
463976|NCT00667121|Drug|venlafaxine|
463977|NCT00667121|Genetic|molecular genetic technique|
463978|NCT00667121|Other|high performance liquid chromatography|
463979|NCT00667121|Other|laboratory biomarker analysis|
463980|NCT00667121|Other|pharmacological study|
463981|NCT00667121|Procedure|adjuvant therapy|
463982|NCT00667108|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
463983|NCT00667108|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
463984|NCT00667108|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
463985|NCT00667095|Drug|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
463986|NCT00667095|Drug|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
463987|NCT00667082|Drug|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle~Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
463988|NCT00667069|Drug|triptorelin|
463989|NCT00667069|Procedure|adjuvant therapy|
463990|NCT00667069|Radiation|3-dimensional conformal radiation therapy|
463991|NCT00667056|Drug|tacrolimus ointment|topical
463992|NCT00667056|Drug|placebo ointment|topical
463993|NCT00667043|Drug|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
463994|NCT00667043|Drug|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
463995|NCT00667030|Behavioral|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
463996|NCT00667017|Biological|RFT5-dgA immunotoxin|
463997|NCT00667017|Other|fluorescence activated cell sorting|
463998|NCT00667017|Other|immunohistochemistry staining method|
463999|NCT00667004|Drug|ecabet ophthalmic solution|sterile ophthalmic solution
464000|NCT00667004|Drug|placebo|sterile ophthalmic solution
464001|NCT00666991|Drug|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
464002|NCT00666978|Behavioral|smoking cessation intervention|
464003|NCT00666978|Drug|bupropion hydrochloride|
464004|NCT00666978|Genetic|gene expression analysis|
464005|NCT00666978|Genetic|polymerase chain reaction|
464006|NCT00666978|Other|counseling intervention|
464007|NCT00666978|Other|educational intervention|
464008|NCT00666978|Procedure|psychosocial assessment and care|
464009|NCT00666965|Drug|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
464010|NCT00666952|Other|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
464011|NCT00666952|Other|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
464012|NCT00666939|Drug|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
464013|NCT00666939|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
464014|NCT00666939|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
464015|NCT00666926|Drug|PF00562271|125 mg twice daily [BID] with food, tablet
464016|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
464017|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
464018|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
464019|NCT00666913|Other|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
464020|NCT00666900|Drug|Low Strength IDP-107|Once a day for 12 weeks
464021|NCT00666900|Drug|High Strength IDP-107|Once a day for 12 weeks
464022|NCT00666900|Drug|Placebo Comparator|Once a day for 12 weeks
464023|NCT00666887|Drug|Minocycline|100 mg twice daily to be taken for up to 2 years
464024|NCT00666887|Drug|Placebo|placebo twice daily for 2 years
464025|NCT00666874|Behavioral|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
464026|NCT00666874|Behavioral|Control - general information|General information about healthy food choices and exercise
464027|NCT00666848|Drug|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
464028|NCT00666848|Drug|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
464029|NCT00666848|Drug|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
464030|NCT00666848|Drug|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
464031|NCT00666835|Drug|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
464032|NCT00666835|Drug|ERYPO®, Janssen-Cilag|Solution for i.v. injection
464033|NCT00666822|Behavioral|compliance monitoring|To examine the relationship between adherence to endocrine therapy and variables from the Health Belief Model (i.e., perceived risk, barriers to and benefits of adherence, and cues to action such as physician recommendation) as well as measures of patient's perceptions of patient- and family-centered care in women with estrogen receptor-positive stage I-IIIA breast cancer.
464034|NCT00666822|Other|medical chart review|Patient's medical records are reviewed for information about the time since diagnosis, tumor characteristics, treatment, and comorbidity.
464079|NCT00666627|Drug|Ibandronate|once monthly
464080|NCT00666627|Drug|Risedronate|Risedronate 35mg once weekly
464035|NCT00666822|Other|questionnaire administration|Patients complete a 15 minute questionnaire on-line or by mail comprising questions of demographic and medical variables (i.e., age, race/ethnicity, marital and educational status, and medication side effects) as well as health beliefs and selected aspects of patient- and family-centered care. Data collected from the questionnaire will be stored in an Excel database.
464036|NCT00666809|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
464037|NCT00666809|Drug|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
464038|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
464039|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
464040|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
464041|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
464042|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
464043|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
464044|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
464045|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
464046|NCT00666783|Drug|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
464047|NCT00666783|Drug|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
464048|NCT00666770|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
464049|NCT00666770|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
464050|NCT00666770|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
464051|NCT00666757|Drug|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
464052|NCT00666757|Drug|fluoxetine|20-80 mgs orally daily for 12 weeks
464053|NCT00666757|Drug|citalopram|20-40 mgs orally daily for 12 weeks
464054|NCT00666757|Drug|paroxetine|20-50 mgs orally daily for 12 weeks
464055|NCT00666757|Drug|sertraline|50-200 mgs orally daily for 12 weeks
464056|NCT00666744|Other|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
464057|NCT00666731|Other|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
464058|NCT00666731|Other|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
464059|NCT00666731|Other|study of socioeconomic and demographic variables|Repository
464060|NCT00666731|Procedure|Excess human biological tissue|Tissue procurement.
464061|NCT00666731|Procedure|quality-of-life assessment|Cancer care.
464062|NCT00666718|Drug|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
464063|NCT00666718|Drug|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
464064|NCT00666718|Drug|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
464065|NCT00666705|Drug|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
464066|NCT00666705|Drug|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
464067|NCT00666705|Drug|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
464068|NCT00666705|Drug|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
464069|NCT00666692|Drug|M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab|Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
464070|NCT00666679|Drug|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
464071|NCT00666679|Drug|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
464072|NCT00666679|Drug|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
464073|NCT00666666|Drug|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
464074|NCT00666666|Drug|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
464075|NCT00666666|Other|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
464076|NCT00666653|Drug|pramipexole|
464077|NCT00666640|Device|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
464081|NCT00666627|Drug|Alendronate|Alendronate 70mg once weekly
464082|NCT00666614|Other|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
464083|NCT00666614|Other|Normal Hospital Environment|Normal Hospital Environment
464084|NCT00666601|Drug|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
464085|NCT00666601|Drug|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
464086|NCT00666588|Drug|idarubicin|Given IV
464087|NCT00666588|Drug|cytarabine|Given IV or IT
464088|NCT00666588|Drug|bortezomib|Given IV
464089|NCT00666588|Drug|etoposide|Given IV
464090|NCT00666588|Other|laboratory biomarker analysis|Correlative studies
464091|NCT00666575|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
464092|NCT00666575|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
464093|NCT00666562|Dietary Supplement|Defined Green Tea Catechin Extract|Given orally
464094|NCT00666562|Other|Laboratory Biomarker Analysis|Correlative studies
464095|NCT00666562|Other|Pharmacological Study|Correlative studies
464096|NCT00666562|Drug|Placebo|Given orally
464097|NCT00666562|Procedure|Therapeutic Conventional Surgery|Undergo surgery
464098|NCT00666536|Drug|valsartan and amlodipine|
464099|NCT00666536|Drug|valsartan and amlodipine|
464100|NCT00666523|Dietary Supplement|phytalgic|3/day
464101|NCT00666523|Dietary Supplement|placebo|3/Day
464102|NCT00666497|Drug|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
464103|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
464104|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
464105|NCT00666484|Drug|cyclophosphamide|
464106|NCT00666484|Drug|doxorubicin hydrochloride|
464107|NCT00666484|Drug|etoposide|
464108|NCT00666484|Drug|prednisolone|
464109|NCT00666484|Drug|procarbazine hydrochloride|
464110|NCT00666484|Drug|vincristine sulfate|
464111|NCT00666484|Radiation|radiation therapy|
464112|NCT00666471|Procedure|MICE|MICE
464113|NCT00666471|Procedure|SPA ligation|SPA ligation
464114|NCT00666458|Drug|saxagliptin|tablet, per oral, once daily
464115|NCT00666458|Drug|sitagliptin|capsule, per oral, once daily
464116|NCT00666432|Other|This is an observational study model that is family based|This is an observational study model that is family based
464117|NCT00666419|Other|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
464118|NCT00666406|Drug|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
464119|NCT00666406|Drug|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
464120|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
464121|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
464122|NCT00666380|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
464123|NCT00666367|Drug|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
464124|NCT00666367|Drug|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
464125|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
464126|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
464127|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
464128|NCT00666341|Drug|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
464129|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
464130|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
464131|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
464132|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
464133|NCT00666328|Drug|clevidipine|"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
464134|NCT00666302|Drug|tacrolimus ointment|topical
464135|NCT00666302|Drug|pimecrolimus cream|topical
464178|NCT00665964|Device|N2Vac polethylene|conventional polyethylene
464179|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
464136|NCT00666276|Drug|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.~Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
464137|NCT00666263|Biological|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
464138|NCT00666263|Biological|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
464139|NCT00666250|Dietary Supplement|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
464140|NCT00666237|Procedure|Tube shunt surgery|350mm2 Baerveldt glaucoma implant
464141|NCT00666237|Procedure|Trabeculectomy with mitomycin C|Mitomycin C 0.4 mg/ml for 2 minutes
464142|NCT00666224|Drug|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
464143|NCT00666224|Drug|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
464144|NCT00666224|Drug|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
464145|NCT00666211|Other|educational intervention|Participants will be educated on pain management.
464146|NCT00666211|Other|Titrated pain management|Pain will be Monitored and Medication Titrated
464147|NCT00666211|Other|questionnaire administration|Participants will be given questionnaires to complete.
464148|NCT00666198|Drug|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.~Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
464149|NCT00666185|Drug|Micafungin|IV
464150|NCT00666185|Drug|Fluconazole|IV
464151|NCT00666172|Behavioral|Exercise|
464152|NCT00666172|Behavioral|Weight Loss|
464153|NCT00666159|Drug|tacrolimus ointment|topical
464154|NCT00666159|Drug|pimecrolimus cream|topical
464155|NCT00666133|Device|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
464156|NCT00666120|Other|Enfamil LIPIL with iron|cow's milk based infant formula
464157|NCT00666120|Other|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
464158|NCT00666107|Biological|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
464159|NCT00666094|Behavioral|Endurance training|supervised endurance training. Three sessions per week in three months.
464160|NCT00666094|Behavioral|strength training|Supervised strength training. Three sessions per week in three months.
464161|NCT00666081|Drug|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
464162|NCT00666068|Other|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
464163|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
464164|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
464165|NCT00666055|Drug|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).~Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
464166|NCT00666042|Drug|Vigamox - administration in spray form|Vigamox will be administered in a spray form
464167|NCT00666042|Drug|Vigamox eye drops|Vigamox eye drops
464168|NCT00666029|Drug|atorvastatin|40 m.g. o.d. tablets for 6 months
464169|NCT00666029|Drug|placebo|Placebo
464170|NCT00666016|Drug|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
464171|NCT00665990|Drug|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
464172|NCT00665990|Drug|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
464173|NCT00665990|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
464174|NCT00665977|Drug|Thermosmart & placebo|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
464175|NCT00665977|Drug|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
464176|NCT00665977|Device|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
464177|NCT00665964|Device|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
464180|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
464181|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
464182|NCT00665938|Other|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics"
464183|NCT00665925|Drug|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
464184|NCT00665925|Drug|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
464185|NCT00665925|Drug|Placebo|Placebo, orally, either once a day, or twice a day
464186|NCT00665912|Procedure|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
464187|NCT00665912|Procedure|Standard post-lobectomy wound care|Standard post-lobectomy wound care
464188|NCT00665899|Behavioral|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
464189|NCT00665899|Behavioral|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
464190|NCT00665886|Device|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
464191|NCT00665886|Device|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
464192|NCT00665873|Device|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
464193|NCT00665873|Drug|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
464194|NCT00665860|Dietary Supplement|Placebo|Three pills per day for two years
464195|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
464196|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
464197|NCT00665847|Drug|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
464198|NCT00665847|Drug|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir [LPV], darunavir [DRV], atazanavir [ATV] or saquinavir [SQV]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N[t]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
464199|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
464200|NCT00665834|Drug|placebo|placebo 20 mg from day 0 to (maximum) day 6
464201|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
464202|NCT00665834|Drug|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
464203|NCT00665821|Behavioral|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
464204|NCT00665821|Behavioral|General health education|General health education: a booklet describing general norms for maintaining good health
464205|NCT00665808|Drug|insulin detemir|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
464206|NCT00665808|Drug|isophane human insulin|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
464207|NCT00665782|Other|laboratory biomarker analysis|
464208|NCT00665782|Other|questionnaire administration|
464209|NCT00665782|Other|study of socioeconomic and demographic variables|
464210|NCT00665782|Procedure|assessment of therapy complications|
464211|NCT00665782|Procedure|psychosocial assessment and care|
464212|NCT00665782|Procedure|therapeutic conventional surgery|
464213|NCT00665769|Other|Hypercapnia|transcutaenous CO2 50-60 mm Hg
464214|NCT00665769|Other|Normocapnia|transcutaneous CO2 35-45 mm Hg
464215|NCT00665756|Procedure|second Trabeculectomy|second trabeculectomy with mitomycin-c
464216|NCT00665756|Procedure|Ahmed Implant|Ahmed silicone drainage device
464217|NCT00665743|Drug|PN400|naproxen 500 mg /esomeprazole 20 mg
464218|NCT00665743|Drug|naproxen|naproxen 500 mg tablet
464219|NCT00665743|Drug|naproxen|naproxen 500 mg
464220|NCT00665730|Device|Sepraspray|
464221|NCT00665717|Drug|Pravastatin|40 mg tablet; QD; 4 days
464222|NCT00665717|Drug|Raltegravir|400mg tablet; BD 4 days
464223|NCT00665717|Drug|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
464224|NCT00665704|Behavioral|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
464225|NCT00665691|Other|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
464226|NCT00665678|Drug|paroxetine|treatment for three months with paroxetine
464227|NCT00665678|Drug|placebo|treatment for three months with placebo
464228|NCT00665665|Drug|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
464229|NCT00665665|Drug|placebo|Placebo for s.c. injection
464230|NCT00665665|Drug|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
464231|NCT00665665|Drug|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
464585|NCT00663221|Dietary Supplement|placebo|
464232|NCT00665665|Drug|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
464233|NCT00665652|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
464234|NCT00665639|Drug|micafungin|IV
464235|NCT00665639|Drug|caspofungin|IV
464236|NCT00665626|Drug|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
464237|NCT00665626|Drug|Placebo|Placebo, orally, twice-a-day
464238|NCT00665600|Drug|Levalbuterol HCl|Levalbuterol 0.63 TID
464239|NCT00665600|Drug|Levalbuterol HCl|Levabuterol 1.25 mg TID
464240|NCT00665600|Drug|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
464241|NCT00665600|Drug|Placebo|Placebo TID
464242|NCT00665587|Procedure|Cox-MAZE III|Maze procedure according to standards of the department
464243|NCT00665574|Other|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
464244|NCT00665561|Drug|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
464245|NCT00665561|Drug|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
464246|NCT00665548|Radiation|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
464247|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
464248|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
464249|NCT00665522|Drug|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
464250|NCT00665522|Drug|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
464251|NCT00665509|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
464252|NCT00665496|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
464253|NCT00665496|Drug|Placebo|Matching Placebo
464254|NCT00665483|Other|Skin Prick Test|Skin Prick Test
464255|NCT00665470|Drug|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).~Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
464256|NCT00665457|Biological|filgrastim|
464257|NCT00665457|Drug|capecitabine|
464258|NCT00665457|Drug|celecoxib|
464259|NCT00665457|Drug|cyclophosphamide|
464260|NCT00665457|Drug|docetaxel|
464261|NCT00665457|Drug|doxorubicin hydrochloride|
464262|NCT00665457|Genetic|gene expression analysis|
464263|NCT00665457|Genetic|polymorphism analysis|
464264|NCT00665457|Genetic|protein expression analysis|
464265|NCT00665457|Genetic|reverse transcriptase-polymerase chain reaction|
464266|NCT00665457|Other|imaging biomarker analysis|
464267|NCT00665457|Other|immunohistochemistry staining method|
464268|NCT00665457|Other|laboratory biomarker analysis|
464269|NCT00665457|Other|pharmacogenomic studies|
464270|NCT00665457|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
464271|NCT00665457|Procedure|needle biopsy|
464272|NCT00665457|Procedure|neoadjuvant therapy|
464273|NCT00665457|Procedure|radiomammography|
464274|NCT00665457|Procedure|ultrasound imaging|
464275|NCT00665444|Drug|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
464276|NCT00665431|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
464277|NCT00665431|Drug|celebrex|200 mg celecoxib qd
464278|NCT00665431|Other|Placebo|sugar pill bid
464279|NCT00665431|Drug|Rescue Antacid|Antacid Tablets
464280|NCT00665418|Drug|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
464281|NCT00665405|Radiation|CT scan|Thoracic CT scan
464282|NCT00665392|Drug|cisplatin|75 mg/m², day 1. 3 cycles
464283|NCT00665392|Drug|docetaxel|75 mg/m² Day 1. 3 cycles
464284|NCT00665392|Drug|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
464285|NCT00665392|Drug|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
464286|NCT00665379|Other|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
464287|NCT00665379|Other|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
464288|NCT00665366|Drug|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
464289|NCT00665366|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
464290|NCT00665366|Drug|Lithium|Participant's ongoing dose
464291|NCT00665366|Drug|Valproate|Participant's ongoing dose
464292|NCT00665353|Drug|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
464293|NCT00665353|Drug|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
464294|NCT00665353|Drug|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
464295|NCT00665340|Drug|Placebo|Matching placebo
464296|NCT00665340|Drug|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
464297|NCT00665327|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
464298|NCT00665327|Drug|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
464299|NCT00665314|Drug|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
464300|NCT00665314|Drug|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
464301|NCT00665262|Drug|tramacet|2 tablets every 6 hours for 5 days
464302|NCT00665249|Behavioral|Motivational Interviewing|See MotivationalInterviewing.org
464303|NCT00665249|Behavioral|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
464304|NCT00665249|Other|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
464305|NCT00665236|Other|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
464306|NCT00665236|Procedure|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
464307|NCT00665223|Drug|ACR16|45 mg capsules Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
464308|NCT00665223|Drug|Placebo|Placebo capsules. Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
464309|NCT00665197|Radiation|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
464310|NCT00665197|Radiation|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
464311|NCT00665184|Behavioral|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
464312|NCT00665184|Behavioral|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
464313|NCT00665158|Behavioral|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
464314|NCT00665158|Behavioral|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
464315|NCT00665145|Drug|SB-509|Active drug
464316|NCT00665145|Drug|SB-509|Active drug
464317|NCT00665145|Drug|Placebo|Placebo
464318|NCT00665145|Drug|SB-509|Active drug
464319|NCT00665132|Device|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
464320|NCT00665119|Drug|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
464321|NCT00665119|Drug|placebo|NaCl 0.9 %
464322|NCT00665106|Drug|"NOVA63035 Corticosteroid"|Single injection in the study eye
464323|NCT00665093|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
464324|NCT00665093|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
464325|NCT00665054|Drug|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
464326|NCT00665054|Drug|Placebo|Matching placebo tablets orally prior to sexual activity
464327|NCT00665041|Drug|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral."
464328|NCT00665002|Biological|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
464329|NCT00665002|Drug|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
464330|NCT00665002|Drug|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
464331|NCT00664976|Procedure|Electroconvulsive therapy|Electroconvulsive therapy
464332|NCT00664976|Other|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
464333|NCT00664963|Device|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
464334|NCT00664963|Device|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
464335|NCT00664950|Device|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
464336|NCT00664950|Device|IntertAn IM nail|interTAN IM nail
464586|NCT00663208|Drug|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
464337|NCT00664937|Drug|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
464338|NCT00664937|Drug|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
464339|NCT00664911|Other|chemotherapy|
464340|NCT00664898|Drug|bortezomib|Escalating intravenous repeating dose
464341|NCT00664898|Drug|SGN-40|Escalating intravenous repeating dose
464342|NCT00664885|Other|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
464343|NCT00664872|Other|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
464344|NCT00664872|Behavioral|case management|
464345|NCT00664859|Drug|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
464346|NCT00664846|Drug|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
464347|NCT00664846|Drug|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
464348|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
464349|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
464350|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
464351|NCT00664833|Other|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
464352|NCT00664820|Dietary Supplement|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
464353|NCT00664794|Procedure|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
464354|NCT00664794|Procedure|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
464355|NCT00664781|Drug|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
464356|NCT00664781|Genetic|protein expression analysis|
464357|NCT00664781|Genetic|western blotting|
464358|NCT00664781|Other|immunohistochemistry staining method|
464359|NCT00664781|Other|liquid chromatography|
464360|NCT00664781|Other|mass spectrometry|
464361|NCT00664781|Other|pharmacological study|
464362|NCT00664768|Dietary Supplement|Neocate Infant|minimum of 8 fl. oz daily
464363|NCT00664768|Dietary Supplement|new Neocate|minimum of 8 fl oz daily
464364|NCT00664755|Drug|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID~Varenicline is taken for a duration of 4 weeks in this study."
464365|NCT00664755|Device|transdermal nicotine patch|"Weeks 0-3: 21mg patch~Transdermal nicotine patch is used for a duration of 3 weeks in this study."
464366|NCT00664742|Drug|Fluvastatin XL®|Fluvastatin extended release 80 mg
464367|NCT00664729|Behavioral|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
464368|NCT00664729|Behavioral|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
464369|NCT00664729|Behavioral|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
464370|NCT00664716|Biological|Baminercept alfa 1|experimental - one dose level
464371|NCT00664716|Biological|Placebo|Placebo comparator
464372|NCT00664716|Biological|Baminercept alfa 2|experimental - second dose level
464373|NCT00664716|Biological|Baminercept alfa 3|experimental - third dose level
464374|NCT00664716|Biological|Baminercept alfa 4|experimental - fourth dose level
464375|NCT00664716|Biological|Baminercept alfa 5|experimental - fifth dose level
464376|NCT00664703|Drug|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
464377|NCT00664703|Drug|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
464378|NCT00664703|Drug|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
464379|NCT00664690|Drug|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
464380|NCT00664690|Drug|placebo|placebo given preop and BID postop
464587|NCT00663208|Drug|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
464381|NCT00664677|Drug|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
464382|NCT00664664|Drug|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
464383|NCT00664664|Drug|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
464384|NCT00664664|Drug|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
464385|NCT00664638|Device|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
464386|NCT00664625|Drug|BMS-791325|Capsules, Oral, Once Daily, Single Dose
464387|NCT00664625|Drug|Placebo|Capsules, Oral, Once Daily, Single Dose
464388|NCT00664612|Device|AirTraq|Laryngoscopy with AirTraq
464389|NCT00664599|Drug|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
464390|NCT00664599|Drug|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
464391|NCT00664586|Drug|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
464392|NCT00664573|Biological|Baminercept alfa (BG9924)|dosage administered as per Biogen-Idec protocol
464393|NCT00664560|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
464394|NCT00664560|Drug|celebrex|200 mg celecoxib qd
464395|NCT00664560|Drug|Placebo|sugar pill bid
464396|NCT00664560|Drug|Rescue Antacid|Antacid Tablets
464397|NCT00664547|Behavioral|Diet Weight Loss|
464398|NCT00664547|Behavioral|Exercise Weight Loss|
464399|NCT00664547|Behavioral|Exercise Without Weight Loss|
464400|NCT00664534|Drug|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
464401|NCT00664534|Drug|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
464402|NCT00664521|Biological|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
464403|NCT00664521|Drug|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
464404|NCT00664521|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
464405|NCT00664508|Procedure|Motion analysis|Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach
464406|NCT00664495|Behavioral|Diet Weight Loss|
464407|NCT00664495|Behavioral|Exercise Weight Loss|
464408|NCT00664495|Behavioral|Exercise Without Weight Loss|
464409|NCT00664482|Biological|AGS-006|Autologous Therapy for Pancreatic Cancer
464410|NCT00664469|Drug|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
464411|NCT00664469|Drug|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
464412|NCT00664469|Drug|Comparator: Atorvastatin|Atorvastatin 20, 40 & 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
464413|NCT00664469|Drug|Comparator: Rosuvastatin|Rosuvastatin 10, 20 & 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
464414|NCT00664456|Drug|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
464415|NCT00664456|Drug|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
464416|NCT00664456|Radiation|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
464417|NCT00664443|Behavioral|Dispatch-assisted CPR Instructions|Pre and post assessment of bystander CPR frequency and impact on victim survival related to Dispatch-assisted CPR Instructions given since 2004
464418|NCT00664430|Drug|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
464419|NCT00664430|Drug|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
464420|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
464421|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
464422|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
464423|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
464424|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
464425|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
464426|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
464427|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
464428|NCT00664417|Biological|Physiological saline|0.5 mL, IM, 2 injections
464429|NCT00664404|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
464430|NCT00664391|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
464431|NCT00664378|Drug|CYT997|Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
464588|NCT00663195|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
464589|NCT00663182|Drug|Entecavir|Entecavir 0.5 mg/d
464432|NCT00664365|Drug|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
464433|NCT00664365|Drug|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
464434|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
464435|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
464436|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
464437|NCT00664352|Drug|Mannose-6-Phophate (Juvidex)|"300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.~300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
464438|NCT00664352|Drug|Placebo|"100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.~Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site."
464439|NCT00664339|Biological|Flu Vaccine|Single dose of Flu vaccine by year (1)
464440|NCT00664339|Other|Conventional medical therapy for heart failure|According with the international guidelines
464441|NCT00664326|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
464442|NCT00664313|Drug|Linezolid|600 mg po daily for 112 doses (16 weeks)
464443|NCT00664313|Drug|Placebo|Placebo given daily for 112 doses (16 weeks)
464444|NCT00664300|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
464445|NCT00664287|Drug|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
464446|NCT00664287|Drug|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
464447|NCT00664274|Behavioral|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
464448|NCT00664274|Genetic|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
464449|NCT00664261|Behavioral|smoking cessation intervention|
464450|NCT00664261|Other|cancer prevention|
464451|NCT00664261|Other|counseling intervention|
464452|NCT00664261|Other|educational intervention|
464453|NCT00664261|Other|laboratory biomarker analysis|
464454|NCT00664261|Other|questionnaire administration|
464455|NCT00664261|Other|survey administration|
464456|NCT00664261|Procedure|study of high risk factors|
464457|NCT00664248|Drug|IDP-110|Topical application for 12 weeks
464458|NCT00664248|Drug|Clindamycin|Topical application for 12 weeks
464459|NCT00664248|Drug|Benzoyl peroxide|Topical application for 12 weeks
464460|NCT00664248|Drug|Vehicle|Topical application for 12 weeks
464461|NCT00664222|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
464462|NCT00664209|Drug|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
464463|NCT00664209|Drug|placebo|placebo therapy
464464|NCT00664196|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
464465|NCT00664183|Drug|Vitreosolve|Intravitreal injection
464466|NCT00664170|Drug|ANX-514|75 mg/m^2
464467|NCT00664170|Drug|docetaxel|75 mg/m^2
464468|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
464469|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
464470|NCT00664144|Drug|Rasburicase (SR29142)|
464471|NCT00664131|Other|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
464472|NCT00664118|Procedure|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
464473|NCT00664118|Procedure|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
464474|NCT00664105|Drug|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
464475|NCT00664105|Drug|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.~Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
464476|NCT00664105|Radiation|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
464477|NCT00664092|Other|Residential|living in a democratic, resident-run setting
464478|NCT00664092|Other|Residential|Professionally-run substance abuse recovery setting
464479|NCT00664079|Other|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
464480|NCT00664066|Drug|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
464481|NCT00664053|Dietary Supplement|DHEA|50mg daily for 6 months
464482|NCT00664053|Behavioral|Yoga|2 sessions per week for 6 months
464483|NCT00664053|Dietary Supplement|Placebo|Placebo supplement every day for 6 months
464484|NCT00664053|Behavioral|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
464485|NCT00664040|Other|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
464486|NCT00664040|Other|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
464487|NCT00664040|Other|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
464488|NCT00664040|Other|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
464489|NCT00664027|Drug|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
464490|NCT00664014|Drug|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
464491|NCT00664014|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
464492|NCT00664001|Dietary Supplement|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
464493|NCT00664001|Dietary Supplement|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
464494|NCT00663988|Procedure|human transplantation|Allograft composite tissue transplantation. procedure. medication
464495|NCT00663975|Drug|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
464496|NCT00663962|Drug|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.~PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
464497|NCT00663962|Drug|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
464498|NCT00663949|Drug|Captopril|25 mg captopril tablet q8h
464499|NCT00663949|Drug|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
464500|NCT00663936|Drug|T-817MA|224 mg T-817 MA once daily
464501|NCT00663936|Drug|Placebo|Placebo once daily
464502|NCT00663923|Procedure|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
464590|NCT00663169|Biological|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
464591|NCT00663169|Drug|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
464592|NCT00663169|Other|placebo matching canakinumab|5% glucose in water intravenous infusion.
464503|NCT00663910|Drug|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
464504|NCT00663910|Procedure|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
464505|NCT00663910|Procedure|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
464506|NCT00663910|Procedure|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
464507|NCT00663897|Drug|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
464508|NCT00663897|Drug|mosapride|mosapride, 5 mg, thrice daily for 14 days
464509|NCT00663884|Drug|Mitiglinide|mitiglinide 10mg three times a day before a meal
464510|NCT00663884|Drug|Voglibose|voglibose 0.2mg three times a day before a meal
464511|NCT00663871|Dietary Supplement|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
464512|NCT00663871|Dietary Supplement|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
464513|NCT00663858|Drug|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
464514|NCT00663858|Drug|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
464515|NCT00663858|Other|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
464516|NCT00663845|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
464517|NCT00663845|Drug|Placebo|Matching placebo
464518|NCT00663832|Drug|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2~i.v. docetaxel 75 or 60 mg/m2~oral prednisone 5mg bid.~LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
464519|NCT00663819|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
464520|NCT00663819|Procedure|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
464521|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
464522|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
464523|NCT00663793|Drug|Acyline|300 mcg/kg
464524|NCT00663793|Drug|Testosterone|"24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
464525|NCT00663793|Drug|Finasteride|1 mg PO once daily [day -2 to day 12) 14 days total
464526|NCT00663767|Drug|Placebo; oral|dose 1, dose 2
464527|NCT00663767|Drug|Placebo; oral|dose 1
464528|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
464529|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
464530|NCT00663767|Drug|Celecoxib, COX-2 inhibitor; oral|dose 1
464531|NCT00663767|Drug|Placebo; oral|dose 2
464532|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
464533|NCT00663754|Behavioral|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
464534|NCT00663754|Behavioral|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
464535|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
464536|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
464537|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
464538|NCT00663728|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
464539|NCT00663728|Drug|Placebo|Matching placebo
464540|NCT00663715|Other|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
464541|NCT00663702|Drug|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
464542|NCT00663689|Drug|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
464593|NCT00663169|Other|placebo matching dexamethasone|Placebo intravenous infusion.
464594|NCT00663156|Procedure|breast implants|patients will have breast augmentation using implants
464595|NCT00663156|Procedure|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
464543|NCT00663663|Behavioral|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
464544|NCT00663663|Behavioral|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
464545|NCT00663650|Procedure|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
464546|NCT00663650|Procedure|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
464547|NCT00663637|Device|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
464548|NCT00663624|Drug|aspart insulin|subcutaneous aspart insulin every 2 hours
464549|NCT00663624|Drug|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
464550|NCT00663611|Drug|Norditropin|A polypeptide hormone of recombinant DNA origin.
464551|NCT00663611|Drug|Placebo|
464552|NCT00663598|Drug|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
464553|NCT00663585|Behavioral|Vipassana Meditation|12 day retreat where participants learn to meditate
464554|NCT00663559|Drug|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
464555|NCT00663533|Device|Vas-X|mechanical vasectomy device
464556|NCT00663481|Drug|CoFactor|
464557|NCT00663481|Drug|Leucovorin|
464558|NCT00663455|Drug|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
464559|NCT00663442|Drug|OROS methylphenidate|18, 36, 54 mg
464560|NCT00663429|Drug|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
464561|NCT00663416|Drug|NTx™-265: rhCG, then rEPO|"rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then~rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
464562|NCT00663416|Drug|Saline placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then~Saline IV, on Day 7, 8, and 9 of study participation"
464563|NCT00663403|Drug|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
464564|NCT00663390|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
464565|NCT00663377|Drug|losartan|losartan 50-100mg for 16 weeks
464566|NCT00663364|Drug|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
464567|NCT00663351|Device|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
464568|NCT00663351|Device|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
464569|NCT00663338|Drug|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
464570|NCT00663325|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
464571|NCT00663312|Behavioral|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
464572|NCT00663299|Device|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
464573|NCT00663286|Drug|IDP-110|Topical application for 12 weeks
464574|NCT00663286|Drug|Clindamycin|Topical application for 12 weeks
464575|NCT00663286|Drug|Benzoyl peroxide|Topical application for 12 weeks
464576|NCT00663286|Drug|Vehicle|Topical application for 12 weeks
464577|NCT00663273|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
464578|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
464579|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
464580|NCT00663260|Drug|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
464581|NCT00663247|Device|Mesalazine|3 grams daily for 3 months
464582|NCT00663247|Drug|Placebo|3 grams daily for 3 months
464583|NCT00663234|Drug|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
464584|NCT00663221|Dietary Supplement|Anthocyans, Calcium and Vitamin D|
464596|NCT00663143|Procedure|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
464597|NCT00663130|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
464598|NCT00663130|Drug|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
464599|NCT00663117|Drug|Naltrexone-HCl|naltrexone 4.5 mg
464600|NCT00663117|Drug|Placebo|Placebo
464601|NCT00663104|Behavioral|exercise|exercise: 3 joint sessions/week for 12 months
464602|NCT00663104|Behavioral|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
464603|NCT00663104|Behavioral|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
464604|NCT00663091|Drug|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
464605|NCT00663091|Drug|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
464606|NCT00663091|Drug|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
464607|NCT00663078|Behavioral|Brief CBT Group therapy|CBT based therapy also expert patient programme
464608|NCT00663065|Drug|PAZ-417|
464609|NCT00663052|Drug|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
464610|NCT00663052|Drug|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
464611|NCT00663039|Drug|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
464612|NCT00663039|Drug|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
464613|NCT00663026|Drug|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
464614|NCT00663026|Drug|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
464615|NCT00663026|Drug|placebo|Placebo subcutaneous injection once per week for 6 months
464616|NCT00663013|Other|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
464617|NCT00662987|Drug|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
464618|NCT00662987|Drug|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
464619|NCT00662974|Other|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
464620|NCT00662974|Other|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
464621|NCT00662961|Procedure|Periosteum|Periosteum fixation
464622|NCT00662961|Procedure|Bone|Bone tunnel fixation
464623|NCT00662948|Drug|Rituximab|375 mg/m2 every 8 weeks during 24 months
464624|NCT00662948|Drug|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
464625|NCT00662935|Procedure|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
464626|NCT00662909|Drug|Mirabegron|Oral
464627|NCT00662909|Drug|Placebo|Oral
464628|NCT00662896|Drug|naproxcinod 375 mg bid|naproxcinod 375 mg bid
464629|NCT00662896|Drug|naproxcinod 750 mg bid|naproxcinod 750 mg bid
464630|NCT00662896|Drug|naproxen 250 mg bid|naproxen 250 mg bid
464631|NCT00662896|Drug|naproxen 500 mg bid|naproxen 500 mg bid
464632|NCT00662896|Drug|ibuprofen 600 mg tid|ibuprofen 600 mg tid
464633|NCT00662883|Drug|PMI-150 (intranasal ketamine HCl); mometasone furoate|"1 dose PMI-150 (intranasal ketamine HCl); day 1~mometasone furoate, daily; days 2-15~1 dose PMI-150 (intranasal ketamine HCl); day 15"
464634|NCT00662870|Biological|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
464635|NCT00662870|Biological|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
464636|NCT00662857|Drug|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
464637|NCT00662857|Drug|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
464638|NCT00662857|Drug|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
464639|NCT00662844|Dietary Supplement|vitamin D3|Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
464640|NCT00662831|Drug|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
464641|NCT00662831|Drug|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
464642|NCT00662818|Drug|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
464643|NCT00662818|Drug|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
464644|NCT00662818|Drug|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
464645|NCT00662818|Drug|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
464646|NCT00662805|Drug|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
464647|NCT00662792|Drug|Tiotropium plus Salmeterol|
464648|NCT00662792|Drug|Tiotropium|
464649|NCT00662792|Drug|Salmeterol|
464650|NCT00662779|Drug|arformoterol|15 mcg arformoterol nebulizer
464651|NCT00662779|Drug|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
464652|NCT00662779|Drug|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
464653|NCT00662766|Dietary Supplement|black currant seed press residue|Black currant seed press residue, baked into bread
464654|NCT00662766|Dietary Supplement|Bread without black currant seed press residues|Same bread but without seeds
464655|NCT00662766|Dietary Supplement|Baseline data|No supplement was administered.
464656|NCT00662753|Device|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
464657|NCT00662753|Other|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
464658|NCT00662740|Drug|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
464659|NCT00662740|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
464660|NCT00662740|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
464661|NCT00662740|Drug|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
464662|NCT00662740|Drug|Tiotropium|Tiotropium
464663|NCT00662727|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
464664|NCT00662727|Device|Placebo|Placebo
464665|NCT00662714|Drug|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
464666|NCT00662714|Drug|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
464667|NCT00662701|Procedure|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
464668|NCT00662701|Procedure|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
464669|NCT00662688|Drug|daltéparine|
464670|NCT00662688|Drug|Chemotherapy at the investigator's discretion|
464671|NCT00662675|Drug|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
464672|NCT00662675|Drug|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
464673|NCT00662662|Behavioral|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
464674|NCT00662649|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
464675|NCT00662649|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
464676|NCT00662636|Drug|dasatinib|Given orally
464677|NCT00662636|Drug|lapatinib ditosylate|Given orally
464678|NCT00662636|Other|pharmacological study|Correlative study (cohort II only)
464679|NCT00662636|Other|laboratory biomarker analysis|Correlative study (cohort II only)
464680|NCT00662623|Behavioral|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
464681|NCT00662623|Behavioral|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
464682|NCT00662610|Drug|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
464683|NCT00662610|Drug|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
464684|NCT00662597|Drug|ASA404|
464685|NCT00662597|Drug|Placebo|
464686|NCT00662597|Drug|carboplatin|
464687|NCT00662597|Drug|Paclitaxel|
464688|NCT00662584|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
464689|NCT00662571|Drug|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
464690|NCT00662558|Drug|celecoxib|200 mg capsules BID for 6 weeks
464691|NCT00662558|Drug|tramadol HCL|50 mg capsules QID for 6 weeks
464692|NCT00662545|Drug|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
464693|NCT00662545|Drug|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
464694|NCT00662532|Drug|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
464695|NCT00662519|Drug|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
464696|NCT00662519|Drug|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
464697|NCT00662519|Dietary Supplement|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
464698|NCT00662519|Other|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
464699|NCT00662519|Other|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
464700|NCT00662506|Drug|Cediranib Maleate|Given PO
464701|NCT00662506|Procedure|Diffusion Tensor Imaging|Undergo DTI
464702|NCT00662506|Procedure|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
464703|NCT00662506|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
464704|NCT00662506|Radiation|Fludeoxyglucose F-18|Undergo 18 FDG PET
464705|NCT00662506|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
464706|NCT00662506|Other|Laboratory Biomarker Analysis|Correlative studies
464707|NCT00662506|Procedure|Perfusion Magnetic Resonance Imaging|Undergo PWI
464708|NCT00662506|Procedure|Positron Emission Tomography|Undergo 18 F FDG-PET
464709|NCT00662506|Drug|Temozolomide|Given PO
464710|NCT00662493|Behavioral|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
464711|NCT00662493|Behavioral|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
464712|NCT00662480|Procedure|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
464713|NCT00662467|Drug|aspirin + clopidogrel|Dual therapy
464714|NCT00662467|Drug|aspirin + clopidogrel + warfarin|Triple therapy
464715|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
464716|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
464717|NCT00662441|Drug|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
464718|NCT00662428|Other|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
464719|NCT00662428|Other|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
464720|NCT00662415|Device|mirror-box treatment|15 minutes daily for 4 weeks
464721|NCT00662415|Behavioral|observation|observation
464722|NCT00662402|Other|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
464723|NCT00662389|Device|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
464724|NCT00662376|Dietary Supplement|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
464725|NCT00662363|Drug|Lubiprostone|24 µg po BID given with meals for 6 days
464726|NCT00662363|Drug|Senna|2 tabs daily for 6 days
464727|NCT00662350|Device|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
464728|NCT00662337|Drug|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
464729|NCT00662324|Behavioral|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.~The focus group to last from 60 to 90 minutes."
464730|NCT00662324|Behavioral|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.~We expect the focus group to last from 60 to 90 minutes."
464731|NCT00662324|Behavioral|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.~During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.~Expect the focus group to last from 60 to 90 minutes."
464732|NCT00662311|Drug|vorinostat|Given PO
464733|NCT00662311|Drug|paclitaxel|Given IV
464734|NCT00662311|Radiation|radiation therapy|Undergo radiation therapy
464735|NCT00662298|Drug|prednisolone|40mg of prednisolone once a day for 14 days
464736|NCT00662285|Dietary Supplement|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
464737|NCT00662272|Biological|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
464738|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
464739|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
464740|NCT00662259|Drug|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
464741|NCT00662259|Drug|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
464742|NCT00662246|Radiation|respiratory gated proton beam radiotherapy|- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
464743|NCT00662233|Drug|cyclophosphamide|
464744|NCT00662233|Drug|doxorubicin hydrochloride|
464745|NCT00662233|Drug|etoposide|
464746|NCT00662233|Drug|ifosfamide|
464747|NCT00662233|Drug|vincristine sulfate|
464748|NCT00662233|Procedure|adjuvant therapy|
464749|NCT00662233|Procedure|neoadjuvant therapy|
464750|NCT00662233|Procedure|therapeutic conventional surgery|
464751|NCT00662233|Radiation|brachytherapy|
464752|NCT00662233|Radiation|intraoperative radiation therapy|
464753|NCT00662233|Radiation|radiation therapy|
464754|NCT00662220|Drug|ribavirin|25-29 mg/kg/day
464755|NCT00662220|Drug|ribavirin|12-15 mg/kg/day
464756|NCT00662207|Device|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
464757|NCT00662207|Procedure|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
464758|NCT00662155|Drug|Zolpidem|sedative-hypnotic
464759|NCT00662155|Drug|Placebos|Placebo
464760|NCT00662142|Dietary Supplement|docosahexaenoic acid|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
464761|NCT00662129|Biological|bevacizumab|
464762|NCT00662129|Drug|gemcitabine hydrochloride|
464763|NCT00662129|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
464764|NCT00662116|Drug|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
464765|NCT00662116|Drug|placebo|placebo tablets - two tablets taken twice daily
464766|NCT00662103|Behavioral|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.~Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
464767|NCT00662103|Other|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health & Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
464768|NCT00662103|Other|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
464769|NCT00662103|Other|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
464770|NCT00662103|Procedure|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
464771|NCT00662103|Procedure|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
464772|NCT00662103|Procedure|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
464773|NCT00662103|Procedure|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
464774|NCT00662077|Drug|Ibandronate|Ibandronate endovenous 3 mg every 3 months
464775|NCT00662077|Behavioral|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
464776|NCT00662038|Drug|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
464777|NCT00662025|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
464778|NCT00662025|Drug|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
464779|NCT00662012|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
464780|NCT00661999|Biological|darbepoetin alfa|Given by injection
464781|NCT00661999|Dietary Supplement|ferrous sulfate|Given by mouth
464782|NCT00661999|Drug|sodium ferric gluconate complex in sucrose|Given by IV
464783|NCT00661999|Other|placebo|Given by mouth
464784|NCT00661986|Dietary Supplement|dark chocolate 6 g/day|dark chocolate 6 g/day
464785|NCT00661986|Dietary Supplement|dark chocolate 25 g/day|dark chocolate 25 g/day
464786|NCT00661973|Drug|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
464787|NCT00661960|Drug|raltegravir|400mg tablet twice daily by mouth for nine months
464788|NCT00661960|Drug|efavirenz|600mg capsule once daily by mouth without regard to food
464789|NCT00661947|Other|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
464790|NCT00661921|Biological|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
464791|NCT00661921|Biological|Placebo|AMG 108 volume matching placebo
464792|NCT00661895|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
464793|NCT00661895|Drug|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
464794|NCT00661895|Drug|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
464795|NCT00661895|Drug|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
464796|NCT00661895|Drug|Metoprolol tartrate|50 mg tablets & 100 mg tablets
464797|NCT00661895|Drug|Atenolol|50 mg tablet
464798|NCT00661895|Drug|Valsartan|80 mg tablets & 160 mg tablet
464799|NCT00661895|Drug|Doxazosin|4 mg tablets
464800|NCT00661895|Drug|Clonidine|0.2 mg tablets
464801|NCT00661895|Drug|Hydralazine|50 mg tablets
464802|NCT00661895|Drug|Metoprolol succinate|50 mg tablet & 100 mg tablet
464803|NCT00661895|Drug|Amlodipine|5 mg tablets & 10 mg tablets
464804|NCT00661882|Other|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
464805|NCT00661882|Other|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
464806|NCT00661882|Other|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
464807|NCT00661882|Procedure|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
464808|NCT00661869|Other|Wellness Program|36 weeks of educational and supportive interventions
464809|NCT00661856|Dietary Supplement|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
464810|NCT00661843|Other|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
464811|NCT00661830|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
464812|NCT00661830|Drug|Placebo|Placebo
464813|NCT00661830|Drug|Sorafenib|Sorafenib 400 mg bid orally continuously
464814|NCT00661817|Behavioral|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
464815|NCT00661817|Behavioral|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
464816|NCT00661791|Behavioral|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
464817|NCT00661791|Behavioral|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
464818|NCT00661778|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
464819|NCT00661778|Drug|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
464820|NCT00661778|Drug|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
464821|NCT00661765|Drug|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
464822|NCT00661765|Drug|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
464823|NCT00661752|Device|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
464824|NCT00661752|Device|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
464825|NCT00661739|Drug|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
464826|NCT00661726|Drug|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
464827|NCT00661713|Biological|rMenB+OMV NZ|
464828|NCT00661713|Biological|Placebo|
464829|NCT00661700|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
464830|NCT00661700|Drug|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
464831|NCT00661687|Device|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
464832|NCT00661687|Device|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
464833|NCT00661674|Drug|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
464834|NCT00661674|Drug|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
464835|NCT00661674|Other|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:~Placebo saline IV and sugar pill~0.75 mg Palonosetron IV and sugar pill~0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
464836|NCT00661661|Drug|CP-690,550|5 mg BID up to 10 mg BID until launch
464837|NCT00661648|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
464838|NCT00661635|Drug|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
464839|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
464840|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
464841|NCT00661622|Drug|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
464842|NCT00661622|Procedure|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
464843|NCT00661609|Drug|AZD4877|Intravenous (IV)25mg/weekly
464844|NCT00661596|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg, 10 mg and 20 mg one hour prior to sexual intercourse
464845|NCT00661596|Drug|Placebo|Matching placebo
464846|NCT00661583|Drug|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
464847|NCT00661583|Drug|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
464848|NCT00661583|Drug|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
464849|NCT00661570|Device|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
464850|NCT00661557|Biological|Meningococcal vaccine GSK134612 (Nimenrix)|one dose, as intramuscular injection
464851|NCT00661544|Drug|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
464852|NCT00661544|Drug|Melphalan|Dose Levels 1, 2, & 3: 100 mg/m2 IV Days -4, -3.
464853|NCT00661544|Drug|Ascorbic Acid|Dose Levels 1, 2, & 3: 1000 mg IV Days -9 to -3.
464854|NCT00661531|Drug|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
464855|NCT00661531|Drug|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
464856|NCT00661505|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
464857|NCT00661492|Drug|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
464858|NCT00661492|Drug|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
464859|NCT00661479|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
464860|NCT00661479|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
464861|NCT00661479|Drug|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
464862|NCT00661479|Other|Sham (no implant)|Sham in the fellow eye on Day 1.
464863|NCT00661466|Drug|Bupivacaine Collagen Sponge|
464864|NCT00661466|Drug|Placebo|placebo
464865|NCT00661453|Drug|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
464866|NCT00661440|Drug|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
464867|NCT00661427|Biological|cetuximab|Cetuximab 500 mg/m^2 IV over 2 hours every other week
464868|NCT00661427|Biological|cetuximab|Cetuximab 750 mg/m^2 IV over 3 hours every other week
464970|NCT00660673|Device|CADD-Legacy® 1400 ambulatory infusion pump|pump
464869|NCT00661414|Biological|ASONEP (sonepcizumab/LT1009)|"ASONEP [sonepcizumab/LT1009] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.~The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
464870|NCT00661401|Biological|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
464871|NCT00661388|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
464872|NCT00661375|Drug|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
464873|NCT00661362|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
464874|NCT00661362|Drug|Placebo|oral tablet, once daily for 24 weeks
464875|NCT00661362|Drug|Metformin|oral tablet, once daily for 24 weeks
464876|NCT00661349|Drug|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
464877|NCT00661349|Drug|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
464878|NCT00661336|Drug|buthionine sulfoximine|
464879|NCT00661336|Drug|melphalan|
464880|NCT00661336|Genetic|microarray analysis|
464881|NCT00661336|Other|high performance liquid chromatography|
464882|NCT00661336|Other|laboratory biomarker analysis|
464883|NCT00661336|Other|pharmacological study|
464884|NCT00661336|Procedure|biopsy|
464885|NCT00661310|Other|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
464886|NCT00661297|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
464887|NCT00661297|Drug|Placebo|Matching placebo
464888|NCT00661271|Behavioral|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice, with one retreat session.
464889|NCT00661271|Behavioral|Healthy topics|8 week health education program with one retreat session
464890|NCT00661258|Behavioral|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
464891|NCT00661245|Device|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
464892|NCT00661245|Device|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
464893|NCT00661219|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
464894|NCT00661219|Drug|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
464895|NCT00661206|Drug|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
464896|NCT00661206|Drug|Placebo|Patients randomized in this group will receive placebo for 6 months.
464897|NCT00661193|Drug|carboplatin|given IV
464898|NCT00661193|Drug|erlotinib hydrochloride|given orally
464899|NCT00661193|Drug|paclitaxel|given IV
464900|NCT00661180|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
464901|NCT00661167|Drug|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
464902|NCT00661154|Drug|Bevacizumab|2-12microCi IV injection
464903|NCT00661141|Drug|Antizol|
464904|NCT00661141|Drug|Placebo|
464905|NCT00661141|Other|Ethanol|oral dose of ethanol (0.5 g/kg)
464906|NCT00661115|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
464907|NCT00661115|Drug|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
464908|NCT00661102|Drug|Corticosteroids|As prescribed
464909|NCT00661102|Drug|Placebo|As prescribed
464910|NCT00661102|Drug|capecitabine [Xeloda]|As prescribed
464911|NCT00661102|Drug|dexpantenol [Bepantol]|As prescribed
464912|NCT00661089|Drug|Botulinum Toxin Type A - OnabotulinumtoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
464913|NCT00661089|Drug|Placebo (Saline)|Equivalent volume of saline without study drug injected into the pectoralis major. Teres major was also injected if tone noted in the shoulder extensors.
464914|NCT00661076|Drug|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
464915|NCT00661076|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
464916|NCT00661063|Drug|ketamine|ketamine 150 mcg/g bid
464917|NCT00661063|Drug|vehicle gel|bid - 12 weeks
464918|NCT00661063|Drug|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
464919|NCT00661063|Drug|clonidine gel 1%|bid 12 weeks
464920|NCT00661050|Procedure|Alternative Medicine|
464921|NCT00661050|Procedure|Tai Chi instruction and class participation or walking exercise and sitting meditation|
464922|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
464923|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
464924|NCT00661024|Procedure|intraoperative RLN visualization|intraoperative RLN visualization
464925|NCT00661024|Procedure|intraoperative neuromonitoring of the RLN|IONM
464926|NCT00661011|Procedure|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
464927|NCT00660998|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
464928|NCT00660998|Drug|Placebo|Matching placebo
464929|NCT00660985|Drug|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
464930|NCT00660985|Drug|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
464931|NCT00660972|Drug|Raltegravir|400 mg tablet taken orally twice daily
464932|NCT00660972|Drug|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
464933|NCT00660959|Drug|lixivaptan|oral capsule
464934|NCT00660959|Drug|placebo|oral capsule
464935|NCT00660933|Drug|Iron sucrose|Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
464936|NCT00660933|Drug|NaCl|NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
464937|NCT00660920|Drug|Ponatinib|Comparison of different dosages of drug given orally once per day.
464938|NCT00660907|Drug|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
464939|NCT00660907|Drug|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
464940|NCT00660907|Drug|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
464941|NCT00660894|Drug|folinate calcium|
464942|NCT00660894|Drug|tegafur-uracil|
464943|NCT00660894|Drug|tegafur-gimeracil-oteracil potassium|
464944|NCT00660881|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
464945|NCT00660868|Drug|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
464946|NCT00660855|Drug|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
464947|NCT00660842|Procedure|carboplatin|AUC 6 IV day 1 every 21 days
464948|NCT00660842|Drug|paclitaxel|175 mg/m2 IV day 1 every 21 days
464949|NCT00660842|Drug|carboplatin|AUC 2 IV every week
464950|NCT00660842|Drug|paclitaxel|60mg/m2 IV every week
464951|NCT00660829|Drug|Placebo|Placebo
464952|NCT00660829|Drug|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
464953|NCT00660816|Drug|erlotinib hydrochloride|Given orally once daily on days 2-19.
464954|NCT00660816|Drug|pemetrexed disodium|Given IV over 10 minutes on day 1
464955|NCT00660816|Drug|docetaxel|IV over 60 minutes on day 1.
464956|NCT00660803|Drug|Fulvestrant|
464957|NCT00660777|Behavioral|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
464958|NCT00660777|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
464959|NCT00660764|Drug|Rosuvastatin|Oral
464960|NCT00660751|Drug|Duloxetine|SNRIs
464961|NCT00660725|Drug|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
464962|NCT00660725|Drug|Gemcitabine|30-minute IV infusion of 1000 mg/m^2 gemcitabine on Day 1 of each 14-day cycle.
464963|NCT00660725|Drug|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m^2 oxaliplatin on Day 1 of each 14-day cycle.
464964|NCT00660699|Drug|Gemcitabine|
464965|NCT00660699|Drug|Docetaxel|
464966|NCT00660699|Radiation|Radiation|
464967|NCT00660686|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
464968|NCT00660686|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
464969|NCT00660673|Drug|Levodopa-carbidopa intestinal gel|should be kept within a range of 0.5-10 ml/hour (10-200 mg levodopa/hour) and is usually 2-6 ml/hour (40-120 mg levodopa/hour);
464971|NCT00660660|Drug|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
464972|NCT00660660|Drug|Placebo|once daily
464973|NCT00660647|Drug|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
464974|NCT00660647|Drug|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
464975|NCT00660634|Procedure|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
464976|NCT00660621|Drug|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).~No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
464977|NCT00660595|Drug|Quetiapine|Oral administration
464978|NCT00660595|Drug|Risperidone|Oral administration
464979|NCT00660582|Drug|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
464980|NCT00660582|Drug|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
464981|NCT00660543|Drug|Gadolinium|Given IV
464982|NCT00660543|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
464983|NCT00660543|Other|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
464984|NCT00660543|Other|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
464985|NCT00660543|Other|Diffusion Weighted Imaging|Undergo DWI
464986|NCT00660543|Other|MRI-Based Angiogram|Undergo TOF MR angiography
464987|NCT00660530|Drug|Lanthanum carbonate|Lanthanum carbonate 1 g to be chewed, three times daily with meals
464988|NCT00660530|Drug|Lanthanum carbonate|Lanthanum carbonate 1 g crushed into a fine powder, three times daily with meal
464989|NCT00660517|Drug|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
464990|NCT00660517|Drug|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
464991|NCT00660517|Drug|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
464992|NCT00660517|Drug|placebo|placebo nasal spray one spray per nostril two times a day
464993|NCT00660504|Drug|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
464994|NCT00660504|Drug|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
464995|NCT00660491|Other|exercise training|moderate intensity exercise group, and high intensity exercise group
464996|NCT00660478|Device|Endeavor|Comparison of two different drug eluting coronary stents
464997|NCT00660478|Device|Cypher Select|Comparison of two different drug eluting coronary stents
464998|NCT00660452|Drug|Staloral|Sublingual immunotherapy with Staloral dust mites solution
464999|NCT00660439|Behavioral|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
465000|NCT00660426|Drug|Oxaliplatin|
465001|NCT00660426|Drug|Gemcitabine|
465002|NCT00660426|Drug|Capecitabine|
465003|NCT00660413|Device|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
465004|NCT00660400|Drug|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
465005|NCT00660400|Procedure|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.~Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.~The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.~All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
465006|NCT00660387|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
465007|NCT00660387|Drug|Placebo Gel|
465008|NCT00660387|Drug|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
465009|NCT00660387|Drug|Placebo (PBO) oral capsules|
465010|NCT00660387|Device|CADD-Legacy® 1400 ambulatory infusion pump|
465011|NCT00660387|Device|PEG tube|percutaneous endoscopic gastrostomy tube
465012|NCT00660387|Device|J-tube|jejunal tube
465013|NCT00660374|Drug|insulin NPH|"Soft-treat-to-target dose titration scheme, injection s.c."
465014|NCT00660374|Drug|EX1000|"Soft-treat-to-target dose titration scheme, injection s.c."
465015|NCT00660348|Drug|morphine sulfate|This is morphine given in the traditional methods.
465016|NCT00660348|Device|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
465017|NCT00660335|Drug|RG1068 (synthetic human secretin)|Single-dose, IV infusion
465018|NCT00660322|Behavioral|Telephone Asthma Program|"The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:~Using asthma controller medications as prescribed~Having and Asthma Action Plan available to all who may need it.~Using asthma rescue medications with the child's first symptoms.~Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year."
465019|NCT00660309|Drug|Aliskiren|Aliskiren 300 mg tablets
465020|NCT00660309|Drug|Irbesartan|Irbesartan 300 mg tablets
465021|NCT00660309|Drug|Captopril|Captopril 25 mg tablet
465022|NCT00660296|Other|Air insufflation use in colonoscopy|Air insufflation for colonic distension
465023|NCT00660296|Other|CO2 use in colonoscopy|Co2 insufflation for colonic distension
465024|NCT00660283|Drug|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.~7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
465025|NCT00660270|Procedure|Pancreatic Surgery|
465026|NCT00660270|Radiation|Radiation therapy|
465027|NCT00660270|Drug|Cisplatin|
465028|NCT00660270|Drug|5-FU|
465029|NCT00660270|Drug|Alpha-interferon|
465030|NCT00660270|Drug|Gemcitabine|
465031|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
465032|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
465033|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
465034|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
465035|NCT00660244|Drug|anastrozole|Oral
465036|NCT00660231|Drug|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
465037|NCT00660231|Drug|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
465038|NCT00660218|Drug|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
465039|NCT00660218|Biological|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
465040|NCT00660218|Radiation|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
465041|NCT00660192|Drug|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
465042|NCT00660192|Other|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
465043|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
465044|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
465045|NCT00660179|Drug|placebo|Matching placebo, once daily
465046|NCT00660166|Biological|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
465047|NCT00660153|Drug|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):~Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.~Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
465048|NCT00660140|Drug|Gemcitabine|
465049|NCT00660140|Drug|Carboplatin|
465050|NCT00660101|Biological|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
465051|NCT00660088|Other|Ketasyn|10g for 7 days, 20g for 7 or 14 days
465052|NCT00660075|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
465053|NCT00660075|Drug|Placebo|Placebo for 6 weeks
465054|NCT00660062|Drug|escitalopram|10 mg daily
465055|NCT00660062|Drug|escitalopram|20 mg daily dosage
465056|NCT00660062|Drug|escitalopram|30 mg daily dosage
465057|NCT00660062|Drug|nortriptyline|100 mg daily dosage
465058|NCT00660049|Device|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
465059|NCT00660049|Other|SNaP|Daily use
465060|NCT00660049|Other|SNaP|Daily application per protocol
465061|NCT00660036|Drug|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m^2, 6 mg/m^2 or 9 mg/m^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
465062|NCT00660036|Drug|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
465063|NCT00660036|Drug|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
465064|NCT00660023|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
465110|NCT00659659|Drug|MEDI-563|1.0 mg/kg IV: MEDI-563
465065|NCT00660010|Drug|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
465066|NCT00659997|Drug|Albendazole|Single oral dose of 400mg
465067|NCT00659997|Drug|Levamisole|Single oral dose of 2.5mg/kg
465068|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg [3.7 MBq/kg] (minimum dose 1mCi [37MBq] but not to exceed 5 mCi [185 MBq]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
465069|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed > 23 Gy to the kidneys, > 30 Gy to the liver, or > 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
465070|NCT00659971|Drug|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
465071|NCT00659958|Drug|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
465072|NCT00659945|Drug|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
465073|NCT00659945|Drug|Ondansetron plus placebo|Ondansetron plus placebo
465074|NCT00659932|Behavioral|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
465075|NCT00659932|Behavioral|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
465076|NCT00659919|Drug|Placebo|
465077|NCT00659919|Drug|Trazodone|
465078|NCT00659906|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
465079|NCT00659906|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
465080|NCT00659893|Drug|PEP005 Topical gel|0.05%, two day dose
465081|NCT00659880|Other|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
465082|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
465083|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
465084|NCT00659854|Dietary Supplement|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
465085|NCT00659854|Dietary Supplement|milk based formula|Babies will be given a milk based formula for 12 weeks
465086|NCT00659841|Drug|Ciclesonide|200µg Ciclesonide versus placebo
465087|NCT00659841|Drug|Placebo|placebo
465088|NCT00659828|Drug|Recombinant methionyl human leptin|recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
465089|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
465090|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
465091|NCT00659802|Drug|HMPL-004|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day), 600 mg (3 x 200 mg t.i.d. or placebo.
465092|NCT00659802|Drug|Placebo|Placebo
465093|NCT00659789|Drug|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
465094|NCT00659789|Drug|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
465095|NCT00659776|Drug|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
465096|NCT00659763|Other|Exclusion diagnosis|"Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.~3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy"
465097|NCT00659763|Other|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
465098|NCT00659750|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
465099|NCT00659750|Drug|Placebo|placebo
465100|NCT00659737|Drug|Aprepitant|40mg tablet
465101|NCT00659737|Drug|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
465102|NCT00659711|Drug|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
465103|NCT00659711|Drug|Placebo|will be placed on a placebo for 12 weeks.
465104|NCT00659698|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
465105|NCT00659685|Drug|Ondansetron|ODT, single-dose, fasting
465106|NCT00659685|Drug|Zofran ODT|
465107|NCT00659672|Dietary Supplement|Whey Protein|40 grams per day Whey Protein
465108|NCT00659672|Dietary Supplement|Soy Protein|40 grams per day soy protein
465109|NCT00659672|Dietary Supplement|Control (carbohydrate)|40 grams per day maltodextrin
465111|NCT00659659|Drug|MEDI-563|100 mg, 200 mg SC
465112|NCT00659659|Other|Placebo Comp.|Placebo SC
465113|NCT00659659|Other|Placebo|Placebo as a single IV infusion (Certain number of subjects)
465114|NCT00659646|Drug|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
465115|NCT00659646|Drug|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
465116|NCT00659633|Drug|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
465117|NCT00659620|Biological|mesenchymal stem cell|transplantation of mesenchymal stem cell
465118|NCT00659594|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
465119|NCT00659594|Drug|Placebo|placebo
465120|NCT00659581|Drug|Telmisartan|Oral administration
465121|NCT00659568|Drug|metformin hydrochloride|
465122|NCT00659568|Drug|temsirolimus|
465123|NCT00659555|Drug|pazopanib eye drops|Pazopanib will be administered as eye drop solution via topical ocular route. Pazopanib eye drops will be available as white, colorless solution.
465124|NCT00659555|Drug|Ketoconozole tablets|Ketoconozole will be administered as tablets via oral route. Ketoconozole tablets will be present as white, rounded, scored tablets
465125|NCT00659542|Procedure|cyanoacrylate glue|1 ml glue
465126|NCT00659529|Drug|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
465127|NCT00659503|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
465128|NCT00659503|Drug|Placebo|placebo
465129|NCT00659490|Drug|AZD1940|800ug oral administration
465130|NCT00659490|Drug|Naproxen|500mg oral administration
465131|NCT00659490|Drug|Placebo|Placebo given pre-surgery
465132|NCT00659477|Drug|insulin glargine|once daily
465133|NCT00659451|Drug|Losartan|tablets; 50, 100 mg; od; 12 months
465134|NCT00659451|Drug|Amlodipine|tablets; 5, 10 mg; od; 12 months
465135|NCT00659438|Drug|ZD6474 (Vandetanib)|300mg orally, once daily
465136|NCT00659438|Drug|Bicalutamide|150mg orally, once daily
465137|NCT00659438|Drug|Placebo|orally, once daily
465138|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465139|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465140|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465141|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465142|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465143|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465144|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465145|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
465146|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
465147|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
465148|NCT00659412|Drug|Alefacept|Intramuscular
465149|NCT00659412|Drug|Methotrexate|Oral
465150|NCT00659412|Drug|Placebo|Intramuscular
465151|NCT00659399|Drug|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
465152|NCT00659386|Drug|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
465153|NCT00659373|Drug|Tamoxifen|
465154|NCT00659373|Drug|triptorelin|
465155|NCT00659373|Drug|Exemestane|
465156|NCT00659360|Drug|saracatinib|Given orally
465157|NCT00659347|Drug|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
465158|NCT00659347|Drug|Placebo|Capsules,25 mg,BID,6weeks
465159|NCT00659334|Drug|Ferumoxtran-10 (Combidex)|2.6 mg/kg
465160|NCT00659334|Procedure|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
465161|NCT00659321|Drug|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
465162|NCT00659321|Drug|placebo|16 weeks treatment with placebo
465408|NCT00657540|Drug|Saline|50 mL of saline infused over 10 minutes
465163|NCT00659308|Procedure|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
465164|NCT00659308|Procedure|anterior stromal puncture|the other group is submitted to anterior stromal puncture
465165|NCT00659295|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
465166|NCT00659282|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
465167|NCT00659269|Dietary Supplement|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
465168|NCT00659269|Dietary Supplement|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
465169|NCT00659269|Drug|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)~Ranges of cumulative doses (in mg/m2) are:~paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
465170|NCT00659243|Drug|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
465171|NCT00659243|Drug|Placebo|One week treatment
465172|NCT00659230|Drug|Nepicastat|100-800mg
465173|NCT00659230|Drug|Placebo|100-800mg placebo
465174|NCT00659217|Biological|mesenchymal stem cell|Autologous MSC transplantation
465175|NCT00659204|Drug|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
465176|NCT00659204|Drug|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
465177|NCT00659191|Drug|GSK1265744|
465178|NCT00659178|Drug|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
465179|NCT00659165|Drug|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
465180|NCT00659165|Drug|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
465181|NCT00659126|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
465182|NCT00659126|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
465183|NCT00659126|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
465184|NCT00659126|Drug|Ferumoxytol|Given IV
465185|NCT00659126|Drug|Gadolinium|Given IV
465186|NCT00659126|Procedure|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
465187|NCT00659126|Procedure|Susceptibility Weighted Imaging|Undergo SWI
465188|NCT00659113|Drug|cisplatin|
465189|NCT00659113|Drug|tegafur-gimeracil-oteracil potassium|
465190|NCT00659113|Other|cytology specimen collection procedure|
465191|NCT00659113|Procedure|endoscopic biopsy|
465192|NCT00659100|Drug|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
465193|NCT00659087|Procedure|Femoral Block|Those receiving femoral block postoperatively
465194|NCT00659087|Other|Usual Care|Those receiving only usual pain management postoperatively
465195|NCT00659074|Drug|Ondansetron|ODT, single-dose, fasting
465196|NCT00659074|Drug|Zofran|ODT, single-dose, fasting
465197|NCT00659061|Dietary Supplement|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).~Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
465198|NCT00659061|Behavioral|Nutrition education|Nutrition education will be provided by LHWs as per their regular routine monthly door to door community services
465199|NCT00659048|Drug|Ciclesonide|Ciclesonide 200µg versus Placebo
465200|NCT00659048|Drug|Placebo|placebo
465201|NCT00659022|Procedure|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
465202|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
465203|NCT00659022|Drug|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
465204|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
465205|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
465206|NCT00659009|Other|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
465207|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
465208|NCT00658996|Device|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
465209|NCT00658996|Device|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
465210|NCT00658983|Other|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
465211|NCT00658983|Other|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
465212|NCT00658970|Drug|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
465213|NCT00658957|Drug|gentamicin-collagen sponge|5 × 5 cm sponge
465214|NCT00658957|Drug|placebo collagen sponge|5 × 5 cm sponge
465215|NCT00658931|Drug|Drug treatment with Cymbalta|Drug treatment with Cymbalta
465216|NCT00658918|Drug|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
465217|NCT00658918|Drug|Placebo|placebo
465218|NCT00658905|Drug|rhBSSL|0.15 g/L rhBSSL added to infant formula; one week treatment
465219|NCT00658905|Drug|Placebo|One week treatment
465220|NCT00658892|Biological|B7-DC cross-linking antibody rHIgM12B7|
465221|NCT00658892|Other|flow cytometry|
465222|NCT00658892|Other|immunologic technique|
465223|NCT00658892|Other|laboratory biomarker analysis|
465224|NCT00658879|Drug|Somavert (Pegvisomant)|"Somavert (Pegvisomant) 10, 15 or 20mg powder and solvent for solution for injection.~Dosage, Frequency : According to Japanese LPD.~Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
465225|NCT00658866|Procedure|Microdialysis|PK measurements with microdialysis
465226|NCT00658853|Behavioral|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
465227|NCT00658840|Drug|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
465228|NCT00658840|Radiation|Localization, simulation and immobilization|"Radiation dose and planning~Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.~Dose prescription : 90% isodose volume of prescribed dose encompassed PTV~The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
465229|NCT00658827|Other|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
465230|NCT00658814|Drug|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
465231|NCT00658814|Drug|Gemtuzumab Ozogamicin|Given IV
465232|NCT00658801|Radiation|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:~Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.~Group 2: 5cm <Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
465233|NCT00658788|Drug|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
465234|NCT00658788|Drug|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
465235|NCT00658775|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
465236|NCT00658775|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
465237|NCT00658762|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper
465238|NCT00658762|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper
465239|NCT00658762|Drug|paroxetine|Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper
465240|NCT00658762|Drug|Placebo|Capsules, oral, BID, 8 weeks, with 2 week taper
465241|NCT00658749|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
465242|NCT00658749|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
465243|NCT00658736|Drug|Triamcinolone|Injection of bupivacaine and triamcinolone
465244|NCT00658736|Drug|Bupivicaine alone|Injection of bupivacaine
465245|NCT00658723|Drug|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
465246|NCT00658723|Device|SURGICEL™|Absorbable hemostat
465247|NCT00658710|Behavioral|physical therapy sessions|two physical therapy sessions per week for two months
465248|NCT00658697|Drug|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
465249|NCT00658697|Drug|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
465250|NCT00658697|Drug|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
465251|NCT00658697|Drug|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
465252|NCT00658684|Drug|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
465253|NCT00658671|Drug|ENMD-2076|Capsules, daily dosing in 28 day cycles
465254|NCT00658658|Biological|Panitumumab|Panitumumab administered by intravenous infusion
465255|NCT00658645|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
465256|NCT00658645|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
465257|NCT00658645|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
465258|NCT00658632|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
465259|NCT00658632|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
465260|NCT00658619|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
465261|NCT00658619|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
465262|NCT00658619|Other|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
465263|NCT00658606|Drug|alefacept|IM
465264|NCT00658606|Procedure|Narrow Band UVB Phototherapy|UVB Phototherapy
465265|NCT00658593|Drug|capecitabine|
465266|NCT00658593|Drug|gemcitabine hydrochloride|
465267|NCT00658593|Procedure|quality-of-life assessment|
465268|NCT00658580|Drug|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
465269|NCT00658580|Drug|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks~Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks~Etoposide 100 mg/m² days 1-3, every 3 weeks"
465409|NCT00657527|Drug|Rosuvastatin|
465270|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
465271|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
465272|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
465273|NCT00658554|Drug|ARQ 197|Treatment with ARQ 197
465274|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
465275|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
465276|NCT00658528|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
465277|NCT00658528|Drug|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
465278|NCT00658515|Drug|Dalcetrapib (RO4607381)|600mg po daily
465279|NCT00658515|Drug|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
465280|NCT00658515|Drug|Placebo|po daily
465281|NCT00658489|Behavioral|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
465282|NCT00658476|Dietary Supplement|Fish Oil|Omega-3 fatty acid supplements.
465283|NCT00658476|Behavioral|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
465284|NCT00658476|Other|Placebo|
465285|NCT00658463|Drug|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
465286|NCT00658463|Drug|Placebo|Placebo
465287|NCT00658450|Behavioral|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.~Children will complete these tasks in 16 session for 8 weeks."
465288|NCT00658437|Drug|CY-503|solution for subcutaneous injection, 350 ng twice weekly
465289|NCT00658411|Drug|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
465290|NCT00658398|Behavioral|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
465291|NCT00658385|Genetic|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected."
465292|NCT00658372|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
465293|NCT00658372|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
465294|NCT00658372|Drug|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
465295|NCT00658372|Drug|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
465296|NCT00658359|Drug|Cyclosporine|Standard of care
465297|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
465298|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
465299|NCT00658346|Drug|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
465300|NCT00658346|Drug|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :~If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)~If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)~If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
465301|NCT00658333|Drug|Enteric-coated Mycophenolate Acid (EC-MPA)|
465302|NCT00658333|Drug|Mycophenolate Mofetil (MMF)|
465303|NCT00658333|Drug|Placebo MMF|
465304|NCT00658333|Drug|Placebo EC-MPA|
465305|NCT00658320|Drug|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
465306|NCT00658320|Drug|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
465307|NCT00658320|Drug|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
465308|NCT00658320|Drug|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
465309|NCT00658320|Drug|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
465310|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
465311|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
465312|NCT00658307|Device|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
465313|NCT00658294|Other|Stop treatment|
465314|NCT00658281|Procedure|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
465315|NCT00658281|Procedure|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
465316|NCT00658268|Drug|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
465317|NCT00658268|Drug|Placebo|10 ml, single dose mixed in bone graft at operation
465318|NCT00658255|Drug|budesonide/formoterol|
465319|NCT00658255|Drug|formoterol|
465320|NCT00658229|Behavioral|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
465321|NCT00658203|Device|New Living CHF|PEA CRT optimization
465322|NCT00658203|Device|New Living CHF|Standard optimized CRT.
465323|NCT00658177|Drug|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
465324|NCT00658177|Drug|Placebo|Matching placebo
465325|NCT00658164|Other|Iron depletion treatment|Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
465326|NCT00658138|Device|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
465327|NCT00658138|Device|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
465328|NCT00658125|Procedure|Bilateral fornix DBS implantation,|Fornix DBS for Alzheimer Disease
465329|NCT00658112|Drug|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
465330|NCT00658099|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
465331|NCT00658099|Drug|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
465332|NCT00658086|Drug|ALN-RSV01|administered by nebulization once daily for 3 days
465333|NCT00658086|Drug|normal saline|administered by nebulization once daily for 3 days
465334|NCT00658073|Procedure|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
465335|NCT00658073|Procedure|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
465336|NCT00658047|Drug|CH-1504|Comparison of different doses of CH-1504
465337|NCT00658047|Drug|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
465338|NCT00658034|Procedure|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
465339|NCT00658034|Procedure|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.~Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
465340|NCT00658021|Drug|Placebo|Subcutaneous injection, twice a day
465341|NCT00658021|Drug|Exenatide|Subcutaneous injection, 5 µg, twice a day
465342|NCT00658021|Drug|Exenatide|Subcutaneous injection,10 µg, twice a day
465343|NCT00658008|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
465344|NCT00658008|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
465345|NCT00658008|Drug|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
465346|NCT00658008|Drug|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
465347|NCT00658008|Drug|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
465348|NCT00657995|Device|Artificial Pancreas (STG-22)|safe tool
465349|NCT00657982|Drug|RAD001|10mg BID
465350|NCT00657956|Device|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
465351|NCT00657943|Drug|metformin|metformin tablets 2 g x 2
465352|NCT00657943|Drug|insulin detemir|insulin as requested
465353|NCT00657943|Drug|insulin aspart + insulin aspart protamin|insulin as requested
465354|NCT00657943|Drug|Insulin aspart|insulin as requested
465355|NCT00657930|Drug|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
465356|NCT00657917|Drug|Paromomycin +Gentamicin topical cream|WR297,396 for treatment of patients with parasitologically confirmed, primarily ulcerative, Old World CL, who had either failed pentavalent antimony treatment, or who where ineligible for pentavalent antimony therapy.
465357|NCT00657904|Drug|Bicalutamide|150mg daily
465358|NCT00657904|Drug|Placebo|once daily
465359|NCT00657891|Drug|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
465360|NCT00657891|Drug|Placebo|Placebo Injection
465361|NCT00657878|Drug|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
465362|NCT00657878|Drug|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
465363|NCT00657878|Drug|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
465364|NCT00657878|Drug|Topotecan|dosing and schedule according to Institutional guidelines
465365|NCT00657878|Drug|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
465366|NCT00657865|Drug|ramipril|oral intake
465367|NCT00657865|Drug|placebo|placebo
465368|NCT00657852|Drug|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
465369|NCT00657852|Drug|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
465370|NCT00657839|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
465371|NCT00657839|Drug|Placebo|Matching placebo
465372|NCT00657826|Device|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
465373|NCT00657813|Drug|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
465374|NCT00657800|Behavioral|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
465375|NCT00657774|Drug|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
465376|NCT00657774|Drug|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
465377|NCT00657774|Drug|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
465378|NCT00657774|Drug|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
465379|NCT00657761|Drug|Enfuvirtide|90 mg/12h sc for 7 days
465380|NCT00657761|Drug|Placebo|0.9% saline solution/12h sc for 7 days
465381|NCT00657748|Drug|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
465382|NCT00657735|Device|H-Coil deep TMS|20 daily deep rTMS treatments
465383|NCT00657735|Device|sham|inactive treatment
465384|NCT00657722|Other|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
465385|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
465386|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
465387|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
465388|NCT00657709|Biological|Infanrix Hexa|Routine vaccination
465389|NCT00657709|Biological|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
465390|NCT00657709|Biological|Prevenar|Routine vaccination
465391|NCT00657683|Biological|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
465392|NCT00657683|Biological|Placebo|1 dose of placebo
465393|NCT00657670|Device|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
465394|NCT00657670|Device|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
465395|NCT00657657|Biological|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
465396|NCT00657644|Drug|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
465397|NCT00657631|Behavioral|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl & Wilson, 1999)."
465398|NCT00657618|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
465399|NCT00657605|Drug|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
465400|NCT00657579|Drug|DE-104 ophthalmic solution, low concentration|
465401|NCT00657579|Drug|DE-104 ophthalmic solution, medium concentration|
465402|NCT00657579|Drug|DE-104 ophthalmic solution, high concentration|
465403|NCT00657579|Drug|DE-104 vehicle|
465404|NCT00657566|Other|duration of antibiotics|4 +/- 1 days of antibiotics
465405|NCT00657566|Other|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
465406|NCT00657553|Drug|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
465407|NCT00657540|Drug|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
465410|NCT00657527|Behavioral|Cholesterol lowering diet|
465411|NCT00657514|Drug|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
465412|NCT00657514|Drug|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
465413|NCT00657501|Drug|testosterone gel|once daily transdermal gel, 300 mcg
465414|NCT00657501|Drug|placebo gel|once daily transdermal placebo gel
465415|NCT00657488|Drug|Thalidomide|Thalidomide 100mg/day or 400 mg/day at bed time during one year
465416|NCT00657475|Drug|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
465417|NCT00657475|Drug|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
465418|NCT00657462|Other|Reminders|Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
465419|NCT00657449|Drug|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
465420|NCT00657449|Drug|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
465421|NCT00657423|Drug|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
465422|NCT00657423|Drug|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
465423|NCT00657410|Drug|dexamethasone|
465424|NCT00657410|Drug|prednisone|
465425|NCT00657410|Procedure|quality-of-life assessment|
465426|NCT00657397|Drug|Methadone|Methadone sirup once daily
465427|NCT00657384|Drug|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
465428|NCT00657384|Drug|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
465429|NCT00657371|Device|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
465430|NCT00657358|Drug|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
465431|NCT00657332|Procedure|blood sample draw|
465432|NCT00657332|Procedure|urine sample|
465433|NCT00657319|Drug|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
465434|NCT00657306|Drug|hydrocortisone|50 mg/6 h per day
465435|NCT00657306|Drug|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
465436|NCT00657293|Behavioral|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
465437|NCT00657293|Behavioral|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
465438|NCT00657280|Drug|Sitagliptin|No one is blinded to the treatments.
465439|NCT00657267|Drug|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
465440|NCT00657254|Drug|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
465441|NCT00657241|Drug|carvedilol|Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).
465442|NCT00657241|Drug|valsartan|Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)
465443|NCT00657228|Drug|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.~To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
465444|NCT00657228|Drug|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
465445|NCT00657202|Drug|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
465446|NCT00657189|Drug|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
465447|NCT00657189|Drug|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
465448|NCT00657189|Drug|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
465449|NCT00657189|Drug|MEDI-545|100 mg every week × 13 doses
465450|NCT00657189|Drug|Placebo|SC Placebo every week × 13 doses
465451|NCT00657176|Drug|OPB-31121|"100mg tablet~oral administration, Qd"
465452|NCT00657163|Drug|fluoxetine|fluoxetine per os 20 mg daily
465453|NCT00657163|Drug|placebo|placebo per os daily
465454|NCT00657150|Drug|Enoxaparin|40 mg once daily
465455|NCT00657150|Drug|Dabigatran etexilate|220 mg once daily
465456|NCT00657137|Drug|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
465457|NCT00657137|Drug|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day~lapatinib: per package insert~capecitabine: per package insert"
465458|NCT00657124|Dietary Supplement|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
465459|NCT00657124|Dietary Supplement|Placebo|placebo
465460|NCT00657111|Drug|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
465461|NCT00657111|Other|Placebo|placebo capsules containing 25 mg lactose
465462|NCT00657059|Drug|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( < 5 g NaCl/day), and then given a stable dose (150mg ~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
465463|NCT00657059|Drug|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
465464|NCT00657059|Drug|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt ＜ 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
465465|NCT00657046|Drug|Droxidopa|Capsules containing 200 mg droxidopa
465466|NCT00657046|Drug|Placebo|Capsules with mannitol substituted for droxidopa
465467|NCT00657033|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
465468|NCT00657033|Drug|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
465469|NCT00657020|Drug|Nicotine|Nicotine lozenge containing 4 mg of nicotine
465470|NCT00657020|Drug|Placebo|Placebo lozenge
465471|NCT00657007|Biological|belimumab|"1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
465472|NCT00657007|Biological|belimumab|"4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
465473|NCT00657007|Biological|belimumab|"10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
465474|NCT00657007|Biological|belimumab|"20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
465475|NCT00657007|Biological|Placebo|"IV (in the vein) on Day 0 (Cohorts 1-4).~IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
465476|NCT00656994|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
465477|NCT00656994|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
465478|NCT00656981|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
465479|NCT00656981|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
465480|NCT00656968|Drug|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
465481|NCT00656968|Drug|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
465482|NCT00656942|Device|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
465483|NCT00656929|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
465484|NCT00656929|Other|Placebo|Placebo tablets
465485|NCT00656916|Drug|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
465486|NCT00656890|Biological|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
465487|NCT00656890|Biological|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
465488|NCT00656864|Drug|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
465489|NCT00656864|Drug|Placebo|placebo
465490|NCT00656851|Drug|Pioglitazone|30mg/day for 16 weeks
465491|NCT00656851|Behavioral|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
465492|NCT00656838|Behavioral|Patients receives letter, phone call, office visit, educational materials|Behavioral
465493|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 100 μg/mL
465494|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 200 μg/mL
465495|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 300 μg/mL
465496|NCT00656825|Drug|Placebo|Placebo will be randomly given to 4 subjects in each panel
465497|NCT00656812|Drug|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
465498|NCT00656812|Drug|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
465499|NCT00656799|Drug|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
465500|NCT00656799|Drug|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
465501|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
465502|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
465503|NCT00656773|Drug|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
465504|NCT00656773|Drug|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
465505|NCT00656760|Other|PET/CT|PET/CT is being performed on all patients in the study.
465506|NCT00656747|Drug|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
465507|NCT00656747|Drug|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
465508|NCT00656734|Biological|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
465509|NCT00656721|Device|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.~In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
465510|NCT00656708|Other|Kerlix AMD gauze|Use Kerlix AMD gauze as the wound dressing for the entire burn unit
465511|NCT00656695|Drug|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
465512|NCT00656695|Drug|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
465513|NCT00656682|Behavioral|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
465514|NCT00656682|Behavioral|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
465515|NCT00656669|Drug|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
465516|NCT00656669|Drug|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
465517|NCT00656669|Drug|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
465518|NCT00656656|Drug|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks~Rituximab: 1000 mg i.v. given twice at a 2-week interval~Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks~Azathioprine: 2.5 mg/kg body weight daily p.o."
465519|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
465520|NCT00656643|Drug|Placebo|Two subconjunctival injections of placebo.
465521|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
465522|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
465523|NCT00656630|Drug|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
465524|NCT00656630|Drug|Naltrexone|50mg capsule, Once daily, 1 week duration
465525|NCT00656630|Drug|Placebo|Matched placebo capsule, 1 week duration
465526|NCT00656617|Drug|Idarubicin|12 mg/m^2 IV over 1 hour daily for 3 days (days 4 to 6)
465527|NCT00656617|Drug|Cytarabine|1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
465528|NCT00656617|Drug|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
465529|NCT00656604|Genetic|proteomic profiling|at the time of each procedure.
465530|NCT00656604|Procedure|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
465531|NCT00656604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
465532|NCT00656604|Procedure|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
465533|NCT00656604|Procedure|magnetic resonance spectroscopy|Prior to initiation of treatment
465534|NCT00656591|Drug|Methotrexate|Methotrexate
465535|NCT00656578|Drug|4975|Single dose, solution
465536|NCT00656578|Drug|Placebo|Single dose, solution
465537|NCT00656552|Drug|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
465538|NCT00656539|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
465539|NCT00656526|Drug|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
465540|NCT00656526|Drug|Lidocaine|0.5 cc %2 lidocaine,single injection
465541|NCT00656513|Drug|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
465542|NCT00656513|Procedure|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
465543|NCT00656500|Behavioral|Standard brief advice|Brief general assistance with smoking cessation
465544|NCT00656500|Behavioral|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
465545|NCT00656487|Drug|rimonabant|double blind, placebo controlled, single 90 mg dose
465546|NCT00656487|Drug|placebo|matched placebo
465547|NCT00656474|Drug|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
465548|NCT00656474|Drug|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
465549|NCT00656461|Drug|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
465674|NCT00655590|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
465550|NCT00656448|Drug|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
465551|NCT00656435|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
465552|NCT00656422|Drug|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
465553|NCT00656422|Drug|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
465554|NCT00656409|Drug|Conjugated pneumococcal vaccine (Prevenar)|
465555|NCT00656396|Device|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
465556|NCT00656396|Procedure|Control Intervention|Standard care
465557|NCT00656383|Other|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
465558|NCT00656383|Other|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
465559|NCT00656370|Drug|recombinant human hyaluronidase|150 Units in 1mL
465560|NCT00656357|Drug|SYN117 Placebo|Placebo
465561|NCT00656357|Drug|SYN117 80 mg|SYN117 80 mg
465562|NCT00656357|Drug|SYN117 160 mg|SYN117 160 mg
465563|NCT00656357|Drug|Cocaine 10mg|IV Cocaine 10mg
465564|NCT00656357|Drug|Cocaine 20mg|IV Cocaine 20mg
465565|NCT00656357|Drug|Cocaine 40mg|IV Cocaine 40mg
465566|NCT00656357|Drug|Saline|IV Cocaine Placebo
465567|NCT00656344|Other|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
465568|NCT00656331|Drug|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
465569|NCT00656318|Other|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
465570|NCT00656305|Device|ExAblate MRfFUS|MR guided focused ultrasound.
465571|NCT00656305|Device|Sham|sham comparator
465572|NCT00656292|Drug|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
465573|NCT00656292|Drug|Placebo|1 pill po/NG every day x 6 days
465574|NCT00656279|Behavioral|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
465575|NCT00656266|Drug|MMF (Cellcept)|
465576|NCT00656266|Drug|placebo|
465577|NCT00656253|Drug|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
465578|NCT00656253|Drug|Placebo|12 months period of placebo plus 1 month period without placebo
465579|NCT00656240|Drug|DE-104 ophthalmic solution|
465580|NCT00656240|Drug|DE-104 vehicle|
465581|NCT00656227|Drug|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
465582|NCT00656214|Drug|Lycopene|08 mg/day in two divided dosage
465583|NCT00656214|Drug|Placebo|Two divided dosage
465584|NCT00656201|Drug|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
465585|NCT00656201|Drug|Intramuscular Progesterone|Progesterone—50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
465586|NCT00656188|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
465587|NCT00656188|Drug|Placebo|Matching placebo
465588|NCT00656175|Drug|raltegravir|raltegravir
465589|NCT00656149|Procedure|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
465590|NCT00656149|Procedure|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
465591|NCT00656136|Drug|placebo|Patients receive placebo once daily
465592|NCT00656136|Drug|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
465593|NCT00656123|Biological|Colon GVAX|Dose escalation: 1.4x10^8 to 7x10^8 cells administered in up to 15 intradermal injections on Day 2 of Cycles 1-4
465594|NCT00656123|Drug|cyclophosphamide|200 mg/m^2 administered IV on Day 1 of Cycles 1-4
465595|NCT00656110|Drug|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
465596|NCT00656110|Drug|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
465597|NCT00656097|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
465598|NCT00656097|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
465675|NCT00655590|Drug|Sildenafil|100 mg daily dosing
465599|NCT00656097|Biological|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
465600|NCT00656084|Drug|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar-->Novantrone-->Rituxan.
465601|NCT00656084|Drug|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
465602|NCT00656084|Drug|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:~Gemzar-->Novantrone-->Rituxan."
465603|NCT00656058|Drug|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
465604|NCT00656045|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
465605|NCT00656045|Behavioral|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
465606|NCT00656045|Behavioral|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
465607|NCT00656032|Other|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
465608|NCT00656032|Other|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
465609|NCT00656019|Drug|Vitamin D|0, 2000, 4000, and 6000 IU per day orally
465610|NCT00656006|Drug|Albuferon|
465611|NCT00656006|Drug|Ribavirin|
465612|NCT00655993|Drug|simvastatin|40 mg po daily
465613|NCT00655980|Drug|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
465614|NCT00655980|Drug|Nitrous oxide and placebo|
465615|NCT00655980|Other|standard of care|
465616|NCT00655967|Drug|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.~Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
465617|NCT00655967|Drug|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
465618|NCT00655954|Procedure|Induced sputum|Used Ultrasonic nebuliser
465619|NCT00655941|Behavioral|Dietary instruction|Weekly instruction by dieticians
465620|NCT00655941|Other|Exercise|Supervised exercise in groups
465621|NCT00655928|Drug|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
465622|NCT00655928|Drug|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
465623|NCT00655915|Other|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
465624|NCT00655902|Dietary Supplement|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
465625|NCT00655902|Dietary Supplement|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
465626|NCT00655889|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of biopsy from palate~Papillary priming procedure~Seven injection treatments to target sites~Performance of study assessments (investigator and subject)"
465627|NCT00655876|Drug|cetuximab|Weekly with external beam radiation therapy for a total of six doses. The initial dose of cetuximab is 400 mg/m^2 intravenously administered over 120 minutes on day 1, followed by weekly infusions of 250 mg/m^2 intravenously over 60 minutes on days 8, 15, 22, 29, and 36. The infusion rate of cetuximab must never exceed 5 mL/min.
465628|NCT00655876|Drug|cisplatin|Weekly with external beam radiation therapy for a total of six doses. Patients receive 25 mg/m^2 as an intravenous infusion over 30-60 minutes on days 1, 8, 15, 22, 29 and 36.
465629|NCT00655876|Drug|paclitaxel|Weekly with external beam radiation therapy for a total of six doses. Patients receive 50 mg/m^2 as an intravenous infusion over 1 hour on days 1, 8, 15, 22, 29 and 36.
465630|NCT00655876|Radiation|radiation therapy|1.8 Gy daily for 28 days (over 5-6 weeks) for a total dose of 50.4 Gy.
465631|NCT00655863|Drug|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
465632|NCT00655863|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
465633|NCT00655863|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
465634|NCT00655850|Drug|Paclitaxel|"Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:~Dexamethasone 20mg, intravenously (IV)~Diphenhydramine 50 mg IV~Ranitidine 50 mg IV~Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.~The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)~Paclitaxel Dose Levels:~Dose Level 1 ________80 mg/m2/weekly~Dose Level -1 ________70 mg/m2/weekly"
465676|NCT00655590|Drug|Placebo|Matching placebos
465677|NCT00655577|Behavioral|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
465881|NCT00654160|Drug|irinotecan hydrochloride|
465882|NCT00654160|Drug|leucovorin calcium|
465883|NCT00654160|Other|pharmacogenomic studies|
465884|NCT00654160|Other|pharmacological study|
465635|NCT00655850|Drug|Gemcitabine|"Premedication~Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.~Prior to receiving paclitaxel chemotherapy~Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.~The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.~Gemcitabine Dose Levels:~Dose Level 2 ________300 mg/m2/weekly~Dose Level 1 ________200 mg/m2/weekly~Dose Level -1 ________150 mg/m2/weekly"
465636|NCT00655850|Biological|Avastin|"The dose of Avastin is 10 mg/kg IV every 2 weeks~It will be administered following the administration of chemotherapy~The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.~It should not be administered or mixed with dextrose solutions."
465637|NCT00655837|Drug|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
465638|NCT00655837|Drug|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
465639|NCT00655837|Drug|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
465640|NCT00655824|Drug|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
465641|NCT00655811|Drug|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
465642|NCT00655811|Drug|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
465643|NCT00655798|Dietary Supplement|Placebo|plain yogurt and capsules containing cellulose
465644|NCT00655798|Dietary Supplement|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
465645|NCT00655798|Dietary Supplement|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
465646|NCT00655798|Dietary Supplement|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
465647|NCT00655785|Biological|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
465648|NCT00655785|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
465649|NCT00655772|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
465650|NCT00655746|Drug|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
465651|NCT00655733|Drug|HMPL004|HMPL004 1200mg/d
465652|NCT00655733|Drug|Placebo|Placebo
465653|NCT00655720|Other|infant formula|"hydrolyzed infant formula without probiotics~hydrolyzed infant formula with probiotics~hydrolyzed infant formula with probiotics"
465654|NCT00655707|Biological|Autologous Expanded CD34+ Haemopoietic cells|"Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.~Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells"
465655|NCT00655694|Procedure|sputum, blood, urine, exhaled breath, lung function|
465656|NCT00655681|Drug|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children < 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
465657|NCT00655681|Other|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
465658|NCT00655668|Drug|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
465659|NCT00655655|Drug|everolimus|Given orally
465660|NCT00655655|Drug|vatalanib|Given orally
465661|NCT00655655|Other|pharmacological study|Correlative study (Cohort IIA only)
465662|NCT00655655|Other|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
465663|NCT00655655|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
465664|NCT00655655|Procedure|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
465665|NCT00655642|Drug|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
465666|NCT00655642|Drug|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
465667|NCT00655642|Drug|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
465668|NCT00655642|Drug|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
465669|NCT00655629|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
465670|NCT00655629|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
465671|NCT00655616|Drug|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
465672|NCT00655616|Drug|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast~Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
465673|NCT00655603|Other|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
465678|NCT00655564|Drug|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.~Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
465679|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
465680|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
465681|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
465682|NCT00655538|Drug|Placebo|po daily for 36 weeks
465683|NCT00655538|Drug|dalcetrapib|600mg po daily for 36 weeks
465684|NCT00655525|Dietary Supplement|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
465685|NCT00655525|Dietary Supplement|placebo|placebo administered orally every day for 3 months
465686|NCT00655512|Drug|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
465687|NCT00655512|Drug|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
465688|NCT00655512|Drug|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
465689|NCT00655512|Drug|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
465690|NCT00655512|Drug|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
465691|NCT00655499|Biological|panitumumab|
465692|NCT00655499|Drug|irinotecan hydrochloride|
465693|NCT00655499|Genetic|chromogenic in situ hybridization|
465694|NCT00655499|Genetic|fluorescence in situ hybridization|
465695|NCT00655499|Genetic|gene expression analysis|
465696|NCT00655499|Other|laboratory biomarker analysis|
465697|NCT00655486|Drug|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
465698|NCT00655473|Drug|Dalcetrapib (RO4607381)|600mg po daily for 24 months
465699|NCT00655473|Drug|Placebo|po daily for 24 months
465700|NCT00655460|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
465701|NCT00655421|Other|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
465702|NCT00655421|Device|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
465703|NCT00655421|Other|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
465704|NCT00655408|Drug|elemental iron|Iron supplementation.
465705|NCT00655395|Drug|Laromustine (VNP40101M) and Ara-C|"Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.~Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
465706|NCT00655369|Drug|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
465707|NCT00655369|Drug|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
465708|NCT00655369|Drug|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
465709|NCT00655369|Drug|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
465710|NCT00655369|Drug|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
465711|NCT00655369|Drug|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
465712|NCT00655356|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
465713|NCT00655356|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
465714|NCT00655343|Drug|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution~20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
465715|NCT00655330|Drug|Valsartan|Valsartan (160mg/day)
465716|NCT00655330|Drug|Placebo|Placebo
465717|NCT00655330|Drug|Probucol|Probucol (750mg/day)
465718|NCT00655317|Other|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
465719|NCT00655317|Other|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
465720|NCT00655304|Device|Prometheus (R) liver support dialysis|6-8 hours of dialysis
465721|NCT00655304|Device|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
465722|NCT00655291|Drug|XP20B|
465723|NCT00655291|Drug|Placebo|
465724|NCT00655278|Drug|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
465725|NCT00655265|Drug|Colesevelam hydrochloride film-coated tablets|tablets
465726|NCT00655265|Drug|Placebo|Tablets
465727|NCT00655252|Drug|Everolimus|
465815|NCT00654641|Procedure|Negative pressure wound closure|Applying negative pressure to primary wound closure
465816|NCT00654641|Procedure|Standard wound closure|Standard wound closure
465728|NCT00655239|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
465729|NCT00655239|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
465730|NCT00655226|Behavioral|Hepatitis C educational support groups|Hepatitis C educational support groups
465731|NCT00655226|Behavioral|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
465732|NCT00655213|Device|Symphony D 2450|
465733|NCT00655213|Device|Symphony DR 2550|
465734|NCT00655200|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
465735|NCT00655187|Other|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
465736|NCT00655187|Procedure|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
465737|NCT00655174|Drug|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
465738|NCT00655174|Drug|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
465739|NCT00655174|Drug|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
465740|NCT00655161|Biological|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
465741|NCT00655148|Biological|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
465742|NCT00655148|Biological|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
465743|NCT00655135|Drug|LDP-02|Each patient in arms 2 & 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
465744|NCT00655135|Drug|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
465745|NCT00655122|Drug|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
465746|NCT00655122|Drug|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
465747|NCT00655109|Drug|Olopatadine|Ophthalmic solution
465748|NCT00655109|Drug|Fluticasone|Nasal spray
465749|NCT00655109|Drug|Saline|Nasal spray
465750|NCT00655109|Drug|Artificial tears|Ophthalmic Solution
465751|NCT00655083|Drug|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
465752|NCT00655083|Drug|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
465753|NCT00655070|Device|Timi3 Transthoracic ultrasound|Low frequency ultrasound over the chest using Timi3 ultrasound device
465754|NCT00655057|Drug|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
465755|NCT00655057|Behavioral|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
465756|NCT00655057|Procedure|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using [99mTc]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
465757|NCT00655044|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
465758|NCT00655031|Dietary Supplement|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
465759|NCT00655031|Dietary Supplement|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
465760|NCT00655018|Dietary Supplement|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
465761|NCT00655018|Dietary Supplement|Placebo|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
465762|NCT00655005|Other|questionnaire administration|Newly diagnosed HNC patients
465763|NCT00655005|Procedure|quality-of-life assessment|following treatment
465764|NCT00654992|Drug|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
465765|NCT00654992|Drug|Normal Saline|300 IU/kg of normal saline intravenously before surgery
465766|NCT00654979|Device|SafeFlo IVC Filter|SafeFlo IVC Filter
465767|NCT00654966|Drug|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
465768|NCT00654966|Drug|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
465817|NCT00654628|Drug|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
465885|NCT00654147|Drug|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
465769|NCT00654953|Drug|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
465770|NCT00654953|Drug|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
465771|NCT00654953|Drug|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
465772|NCT00654940|Drug|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
465773|NCT00654940|Drug|Placebo|Oral, matched capsules, BID
465774|NCT00654927|Drug|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
465775|NCT00654914|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
465776|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
465777|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
465778|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
465779|NCT00654901|Biological|Infanrix Hexa™|0.5 mL, Intramuscular
465780|NCT00654888|Procedure|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
465781|NCT00654888|Drug|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
465782|NCT00654875|Drug|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
465783|NCT00654875|Drug|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
465784|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
465785|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
465786|NCT00654849|Procedure|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
465787|NCT00654849|Procedure|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
465788|NCT00654836|Biological|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
465789|NCT00654836|Drug|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
465790|NCT00654836|Drug|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
465791|NCT00654810|Behavioral|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
465792|NCT00654797|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
465793|NCT00654784|Drug|idebenone|idebenone 450 mg/day (150 mg three times a day)
465794|NCT00654784|Drug|placebo|
465795|NCT00654771|Other|urine collection|clean catch urine collection and catheterized urine collection
465796|NCT00654758|Drug|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
465797|NCT00654745|Drug|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
465798|NCT00654745|Drug|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
465799|NCT00654745|Drug|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
465800|NCT00654732|Drug|Bleomycin|Given IV
465801|NCT00654732|Drug|Dacarbazine|Given IV
465802|NCT00654732|Drug|Doxorubicin Hydrochloride|Given IV
465803|NCT00654732|Biological|Rituximab|Given IV
465804|NCT00654732|Drug|Vinblastine|Given IV
465805|NCT00654719|Dietary Supplement|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
465806|NCT00654719|Dietary Supplement|Placebo|Nutritional supplementation containing only 12 kcal/day
465807|NCT00654706|Drug|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
465808|NCT00654706|Drug|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
465809|NCT00654693|Other|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
465810|NCT00654680|Drug|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
465811|NCT00654680|Drug|Placebo|Matching placebo
465812|NCT00654667|Drug|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
465813|NCT00654667|Drug|Resveratrol|
465814|NCT00654654|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm biopsies~Two injection treatments of facial wrinkles and creases~Conduct of study assessments"
465878|NCT00654173|Drug|Simvastatin|
465818|NCT00654615|Device|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
465819|NCT00654615|Procedure|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
465820|NCT00654602|Drug|Rosuvastatin|
465821|NCT00654602|Behavioral|Maintenance of specific diet|
465822|NCT00654589|Drug|Deferasirox|
465823|NCT00654576|Drug|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
465824|NCT00654576|Behavioral|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
465825|NCT00654550|Drug|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
465826|NCT00654537|Drug|Rosuvastatin|
465827|NCT00654537|Drug|Atorvastatin|
465828|NCT00654537|Drug|Pravastatin|
465829|NCT00654537|Drug|Simvastatin|
465830|NCT00654524|Drug|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.& Livial 1.25-2.5mg p.o. q.d.) if needed.
465831|NCT00654511|Drug|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
465832|NCT00654511|Drug|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
465833|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
465834|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
465835|NCT00654498|Drug|Pramipexole|
465836|NCT00654498|Drug|Placebo|
465837|NCT00654485|Drug|Rosuvastatin|
465838|NCT00654485|Drug|Atorvastatin|
465839|NCT00654459|Dietary Supplement|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
465840|NCT00654446|Drug|Rosuvastatin|
465841|NCT00654446|Drug|Simvastatin|
465842|NCT00654433|Biological|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
465843|NCT00654420|Drug|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
465844|NCT00654420|Drug|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
465845|NCT00654407|Drug|Rosuvastatin|
465846|NCT00654407|Drug|Atorvastatin|
465847|NCT00654407|Drug|Simvastatin|
465848|NCT00654394|Drug|Rosuvastatin|
465849|NCT00654381|Drug|BI 1356|5 mg/daily
465850|NCT00654381|Drug|BI 1356|10 mg/daily
465851|NCT00654381|Drug|voglibose placebo|three times daily
465852|NCT00654381|Drug|BI 1356 placebo|once daily
465853|NCT00654381|Drug|voglibose|0.6 mg/daily
465854|NCT00654368|Biological|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
465855|NCT00654368|Drug|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
465856|NCT00654355|Drug|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
465857|NCT00654342|Procedure|Intraoperative injection (in vivo)|Intraoperative injection
465858|NCT00654342|Procedure|Postoperative injection (ex vivo)|postoperative injection
465859|NCT00654329|Drug|Saline|Normal saline, given intranasally
465860|NCT00654329|Drug|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
465861|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
465862|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
465863|NCT00654316|Biological|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
465864|NCT00654303|Drug|Rosuvastatin|
465865|NCT00654290|Drug|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
465866|NCT00654290|Drug|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
465867|NCT00654290|Drug|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
465868|NCT00654277|Drug|Ondansetron|ODT, 8 mg, single-dose
465869|NCT00654277|Drug|Zofran|ODT, 8 mg, fasting conditions
465870|NCT00654264|Procedure|Water immersion|Subjects will sit in tub for four hours.
465871|NCT00654238|Drug|sorafenib|400mg PO BID daily
465872|NCT00654225|Drug|Rosuvastatin|
465873|NCT00654225|Drug|Atorvastatin|
465874|NCT00654212|Procedure|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
465875|NCT00654212|Procedure|open approach|emergency open surgery
465876|NCT00654186|Drug|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
465877|NCT00654173|Drug|Rosuvastatin|
465886|NCT00654147|Drug|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
465887|NCT00654134|Biological|Clinical Center Reference Endotoxin|20,000 EU inhaled
465888|NCT00654121|Drug|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
465889|NCT00654108|Drug|Ciprofloxacin 500 mg|500 milligrams(mg) will be administered orally twice daily for 5 days.
465890|NCT00654108|Biological|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10^7; 1 X 10^8; 1 X 10^9; and 1 X 10^10.
465891|NCT00654108|Drug|Placebo|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
465892|NCT00654095|Drug|Ezetimibe|Ezetimibe 10 mg once daily
465893|NCT00654095|Drug|atorvastatin|atorvastatin 20 mg once daily
465894|NCT00654082|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
465895|NCT00654082|Drug|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
465896|NCT00654069|Drug|Placebo|2 tablets every 6 hours for 48 hours
465897|NCT00654069|Drug|Acurox 5/30 mg|2 tablets every 6 hours for 48 hours
465898|NCT00654069|Drug|Acurox 7.5/30|2 tablets every 6 hours for 48 hours
465899|NCT00654056|Drug|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
465900|NCT00654043|Drug|Torsemide|tablets, 20 Mg, single-dose
465901|NCT00654043|Drug|Demadex|Tablets, 20 mg, single-dose
465902|NCT00654030|Drug|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
465903|NCT00654017|Drug|placebo|Placebo comparator to be given per protocol.
465904|NCT00654017|Drug|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
465905|NCT00653991|Behavioral|SOLVE-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
465906|NCT00653978|Procedure|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
465907|NCT00653978|Procedure|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
465908|NCT00653965|Drug|Rosuvastatin|
465909|NCT00653965|Drug|Atorvastatin|
465910|NCT00653952|Drug|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
465911|NCT00653952|Drug|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
465912|NCT00653939|Drug|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
465913|NCT00653939|Drug|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
465914|NCT00653939|Drug|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
465915|NCT00653939|Drug|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
465916|NCT00653926|Drug|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
465917|NCT00653926|Drug|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
465918|NCT00653913|Drug|SCH 58235|SCH 58235 10 mg (once daily)
465919|NCT00653913|Drug|pitavastatin|Pitavastatin 2 mg (once daily)
465920|NCT00653887|Other|Biofeedback|4 sessions of biofeedback one session each week
465921|NCT00653887|Other|Placebo|4 sessions, one each week, of discussion about anorectal disease
465922|NCT00653874|Device|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
465923|NCT00653874|Procedure|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
465924|NCT00653874|Other|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
465925|NCT00653861|Device|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
465926|NCT00653861|Device|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
465927|NCT00653848|Drug|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
465928|NCT00653835|Drug|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
465929|NCT00653835|Drug|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
465930|NCT00653822|Drug|alefacept|IC and SC
465931|NCT00653822|Drug|placebo|IV and SC
465932|NCT00653796|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
465933|NCT00653796|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
465934|NCT00653770|Biological|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10^7 pfu)
465935|NCT00653770|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10^7 pfu)
465936|NCT00653757|Drug|goserelin acetate|
465937|NCT00653757|Drug|leuprolide acetate|
465938|NCT00653757|Radiation|image-guided radiation therapy|
465939|NCT00653757|Radiation|intensity-modulated radiation therapy|
465940|NCT00653744|Drug|Rosuvastatin|
465941|NCT00653744|Drug|Atorvastatin|
465942|NCT00653731|Behavioral|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
465943|NCT00653731|Behavioral|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
465944|NCT00653731|Behavioral|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
465945|NCT00653731|Behavioral|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
465946|NCT00653705|Other|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
465947|NCT00653705|Other|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
465948|NCT00653679|Other|exercise|1 hour of endurance or resistance exercise
465949|NCT00653666|Other|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is < 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
465950|NCT00653640|Procedure|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
465951|NCT00653640|Procedure|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
465952|NCT00653627|Biological|BCG|Mycobacterium bovis Bacille Calmette-Guerin
465953|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
465954|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
465955|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
465956|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
465957|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
465958|NCT00653614|Drug|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
465959|NCT00653614|Drug|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
465960|NCT00653614|Drug|Placebo|Placebo administration in each arm
465961|NCT00653588|Drug|Rosuvastatin|40mg
465962|NCT00653588|Drug|Atorvastatin|80mg
465963|NCT00653575|Behavioral|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
465964|NCT00653575|Behavioral|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
465965|NCT00653562|Drug|zolpidem|Oral
465966|NCT00653549|Drug|Torsemide|Tablets, 20 mg, single-dose
465967|NCT00653549|Drug|Demadex|tablets, 20 mg, single-dose
465968|NCT00653536|Device|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
465969|NCT00653523|Drug|Ezetimibe|Ezetimibe 10 mg once daily
465970|NCT00653523|Drug|Simvastatin|Simvastatin 20 mg daily
465971|NCT00653510|Drug|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
465972|NCT00653497|Behavioral|Aquatic exercise|"Arthritis Foundation Aquatics Program~community-based aquatic exercise program~participants asked to attend 2 classes per week for 20 weeks~each class 45-60 minutes in duration"
465973|NCT00653484|Behavioral|Physical Activity|
465974|NCT00653484|Behavioral|Energy Restriction|
465975|NCT00653484|Behavioral|Physical Activity and Energy Restriction|
465976|NCT00653471|Device|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
465977|NCT00653471|Device|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
465978|NCT00653471|Device|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
465979|NCT00653458|Drug|Ondansetron|ODT, 8 mg, single-dose, fed conditions
465980|NCT00653458|Drug|Zofran|ODT, 8 mg, single-dose, under fed conditions
465981|NCT00653445|Drug|Rosuvastatin|40mg
465982|NCT00653445|Drug|Ezetimibe|10mg
465983|NCT00653432|Device|MONOVISC|Intra-articular injection
465984|NCT00653419|Drug|buspirone HCl|Tablets, 30 mg, single-dose
465985|NCT00653419|Drug|Buspar|Tablets, 30 mg, single-dose
465986|NCT00653406|Drug|Risperidone long acting injectable|
465987|NCT00653393|Drug|Tranylcypromine|Tablets, 10 mg, single-dose
465988|NCT00653393|Drug|Parnate|Tablets, 10 mg, single-dose
465989|NCT00653380|Drug|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
465990|NCT00653380|Drug|Monodox|Capsules, 100 mg, single-dose
465991|NCT00653367|Procedure|Nerve section|Intercostal nerve is divided during surgery
465992|NCT00653354|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
466114|NCT00652704|Drug|Doxycycline Monohydrate|Capsules, 100 mg, fasting
466115|NCT00652691|Biological|filgrastim|
465993|NCT00653354|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
465994|NCT00653354|Drug|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
465995|NCT00653341|Drug|insulin glargine|
465996|NCT00653341|Drug|NPH human insulin|
465997|NCT00653328|Drug|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
465998|NCT00653328|Drug|doxil|50 mg/m2 intravenously every 28 days
465999|NCT00653315|Drug|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
466000|NCT00653315|Drug|Ultracet|Tablets, 37.5mg/325mg
466001|NCT00653302|Drug|Lantus (insulin glargine) + Glucophage (Metformin)|
466002|NCT00653276|Drug|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
466003|NCT00653276|Drug|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
466004|NCT00653250|Drug|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
466005|NCT00653250|Procedure|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
466006|NCT00653250|Procedure|therapeutic conventional surgery|surgery to remove the lung tumor
466007|NCT00653237|Device|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
466008|NCT00653224|Drug|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
466009|NCT00653224|Drug|placebo|0 mg daily (matching oral tablet) for 14 days
466010|NCT00653198|Other|No intervention|
466011|NCT00653185|Drug|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
466012|NCT00653185|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
466013|NCT00653185|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
466014|NCT00653185|Drug|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
466015|NCT00653185|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
466016|NCT00653172|Drug|NXL103|600mg orally twice daily
466017|NCT00653172|Drug|comparator|comparator twice daily
466018|NCT00653172|Drug|NXL103|500mg orally twice daily
466019|NCT00653159|Device|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
466020|NCT00653159|Device|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
466021|NCT00653146|Behavioral|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
466022|NCT00653146|Behavioral|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
466023|NCT00653133|Device|Ultrasound imaging|Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic
466024|NCT00653133|Device|Peripheral nerve stimulator|either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
466025|NCT00653120|Drug|Propranolol|ER capsules, 160 mg, single-dose
466026|NCT00653120|Drug|Inderal-LA|ER capsules, 160 mg, single-dose
466027|NCT00653107|Procedure|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
466028|NCT00653107|Radiation|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
466029|NCT00653107|Radiation|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
466030|NCT00653094|Device|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
466031|NCT00653081|Procedure|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
466032|NCT00653081|Procedure|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
466033|NCT00653068|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
466034|NCT00653068|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC rescue
466035|NCT00653068|Drug|Carboplatin|Given IV
466036|NCT00653068|Drug|Cisplatin|Given IV
466037|NCT00653068|Drug|Cyclophosphamide|Given IV
466038|NCT00653068|Drug|Etoposide|Given IV
466039|NCT00653068|Biological|Filgrastim|Given IV or SC
466040|NCT00653068|Other|Laboratory Biomarker Analysis|Correlative studies
466041|NCT00653068|Drug|Leucovorin Calcium|Given IV or PO
466042|NCT00653068|Drug|Methotrexate|Given IV
466043|NCT00653068|Drug|Thiotepa|Given IV
466044|NCT00653068|Drug|Vincristine Sulfate|Given IV
466045|NCT00653055|Drug|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
466046|NCT00653055|Drug|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
466047|NCT00653042|Drug|Nesiritide|
466048|NCT00653016|Drug|norelgestromin; ethinyl estradiol|
466049|NCT00653003|Drug|Leflunomide|tablets, 20mg, single-dose
466050|NCT00653003|Drug|ARAVA|Tablets, 20mg, single-dose
466116|NCT00652691|Drug|carboplatin|
466117|NCT00652691|Drug|cyclophosphamide|
466118|NCT00652691|Drug|topotecan hydrochloride|
466051|NCT00652977|Procedure|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
466052|NCT00652977|Procedure|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
466053|NCT00652964|Device|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
466054|NCT00652951|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
466055|NCT00652951|Biological|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
466056|NCT00652951|Biological|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
466057|NCT00652951|Biological|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
466058|NCT00652938|Biological|HPV Vaccine (GSK580299) Cervarix TM|IM administration
466059|NCT00652938|Biological|Engerix B|IM administration
466060|NCT00652925|Drug|Celecoxib|Higher dose, 6 mg/kg/dose BID
466061|NCT00652925|Drug|Celecoxib|Active drug at lower dose
466062|NCT00652925|Drug|Naproxen|Control comparator, 15 mg/kg/dy target dose
466063|NCT00652912|Drug|Clonazepam|ODT, 1 mg
466064|NCT00652912|Drug|Klonopin Wafers|ODT, 1 mg
466065|NCT00652899|Biological|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
466066|NCT00652899|Drug|Cyclophosphamide|60 mg/m^2 on Days 4 and 5 preceding natural killer cell infusion.
466067|NCT00652899|Drug|Fludarabine phosphate|25 mg/m^2 on Days 6 through 2 preceding natural killer cell infusion.
466068|NCT00652899|Radiation|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
466069|NCT00652899|Biological|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 * 10^7/kg
466070|NCT00652899|Biological|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
466071|NCT00652886|Drug|Oxandrolone|Tablets, 10mg, single-dose
466072|NCT00652886|Drug|Oxandrin|tablets, 10mg, single-dose
466073|NCT00652873|Drug|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
466074|NCT00652873|Drug|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
466075|NCT00652860|Biological|aerosol sargramostim|
466076|NCT00652860|Biological|sargramostim|
466077|NCT00652860|Drug|cisplatin|
466078|NCT00652860|Drug|doxorubicin hydrochloride|
466079|NCT00652860|Drug|ifosfamide|
466080|NCT00652860|Drug|mitomycin C|
466081|NCT00652860|Other|flow cytometry|
466082|NCT00652860|Other|immunological diagnostic method|
466083|NCT00652860|Other|laboratory biomarker analysis|
466084|NCT00652860|Procedure|adjuvant therapy|
466085|NCT00652860|Procedure|multimodality therapy|
466086|NCT00652860|Procedure|neoadjuvant therapy|
466087|NCT00652860|Procedure|therapeutic conventional surgery|
466088|NCT00652860|Radiation|intraoperative radiation therapy|
466089|NCT00652860|Radiation|selective external radiation therapy|
466090|NCT00652847|Drug|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
466091|NCT00652847|Drug|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
466092|NCT00652834|Procedure|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
466093|NCT00652834|Drug|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
466094|NCT00652821|Drug|Tramadol/ APAP|Tablets 37.5mg /325mg
466095|NCT00652821|Drug|Ultracet|Tablets, 37.5mg/325mg
466096|NCT00652808|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
466097|NCT00652808|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
466098|NCT00652795|Drug|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
466099|NCT00652795|Drug|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
466100|NCT00652782|Drug|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
466101|NCT00652782|Drug|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
466102|NCT00652769|Procedure|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
466103|NCT00652769|Procedure|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
466104|NCT00652756|Device|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
466105|NCT00652756|Other|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
466106|NCT00652743|Biological|Pandemic influenza vaccine GSK1562902A|IM administration
466107|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
466108|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
466109|NCT00652730|Drug|Buspar|Tablets, 30 mg, single-dose, fed conditions
466110|NCT00652717|Drug|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
466111|NCT00652717|Drug|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
466112|NCT00652704|Drug|Doxycycline monohydrate|Capsules, 100 mg, fed
466113|NCT00652704|Drug|Monodox|Capsules, 100 mg, fed
466119|NCT00652691|Procedure|autologous hematopoietic stem cell transplantation|
466120|NCT00652691|Procedure|peripheral blood stem cell transplantation|
466121|NCT00652665|Drug|Leflunomide|Tablets, 20mg, single-dose
466122|NCT00652665|Drug|ARAVA|Tablets, 20mg,single-dose
466123|NCT00652652|Drug|nesiritide, furosemide|
466124|NCT00652639|Drug|Clonazepam|Tablets, 1 mg, single-dose
466125|NCT00652639|Drug|Klonopin|tablets, 1 mg, single-dose
466126|NCT00652626|Drug|azacitidine|
466127|NCT00652613|Radiation|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
466128|NCT00652613|Radiation|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
466129|NCT00652600|Drug|Propranolol|ER Capsules, 160 mg, single-dose
466130|NCT00652600|Drug|Inderal-LA|ER Capsules, 160 mg, single-dose
466131|NCT00652587|Procedure|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
466132|NCT00652587|Procedure|hepatectomy|hepatectomy alone
466133|NCT00652574|Drug|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
466134|NCT00652561|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
466135|NCT00652522|Device|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
466136|NCT00652522|Procedure|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
466137|NCT00652522|Other|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
466138|NCT00652509|Behavioral|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
466139|NCT00652509|Behavioral|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
466140|NCT00652496|Drug|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
466141|NCT00652496|Drug|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
466142|NCT00652496|Drug|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
466143|NCT00652496|Drug|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
466144|NCT00652496|Drug|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
466145|NCT00652483|Drug|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
466146|NCT00652483|Drug|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
466147|NCT00652470|Procedure|Endoscopic Third Ventriculostomy|A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
466148|NCT00652470|Procedure|CSF Shunt Insertion|The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
466149|NCT00652457|Drug|Memantine|10 mg BID x 3 months
466150|NCT00652444|Drug|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
466151|NCT00652444|Drug|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
466152|NCT00652444|Drug|Placebo (Unspecified)|Matching ezetimibe placebo
466153|NCT00652431|Drug|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
466154|NCT00652431|Drug|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
466155|NCT00652431|Drug|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
466156|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
466157|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
466158|NCT00652405|Dietary Supplement|alcohol|250 ml of white wine (13% vol; ~25 gram of alcohol per day)
466159|NCT00652405|Dietary Supplement|Placebo|250 ml of mineral water (Brand name: Vittel)
466160|NCT00652392|Drug|budesonide/formoterol|
466161|NCT00652392|Drug|budesonide and placebo|
466162|NCT00652379|Drug|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
466163|NCT00652379|Drug|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
466164|NCT00652366|Drug|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
466165|NCT00652366|Drug|Erlotinib, standard dose|100mg, PO, once daily
466166|NCT00652366|Drug|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
466243|NCT00651794|Behavioral|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
466167|NCT00652353|Other|44-55-66-PM|"The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.~44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar"
466168|NCT00652353|Other|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
466169|NCT00652340|Drug|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day~erlotinib: per package insert"
466170|NCT00652340|Drug|erlotinib/placebo|"erlotinib: per package insert~placebo: 100 mg tablets, 400 mg/day"
466171|NCT00652327|Drug|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
466172|NCT00652327|Drug|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
466173|NCT00652314|Device|Thrombi-Gel|Applicaton of Hemostatic product during surgery
466174|NCT00652301|Drug|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
466175|NCT00652301|Drug|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
466176|NCT00652301|Drug|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
466177|NCT00652288|Drug|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
466178|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given separately
466179|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
466180|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given separately
466181|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
466182|NCT00652275|Biological|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
466183|NCT00652275|Biological|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
466184|NCT00652262|Drug|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
466185|NCT00652236|Other|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
466186|NCT00652223|Biological|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
466187|NCT00652210|Other|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
466188|NCT00652184|Drug|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
466189|NCT00652184|Drug|placebo|placebo cream and placebo valaciclovir
466190|NCT00652184|Drug|valaciclovir|active valaciclovir
466191|NCT00652171|Drug|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
466192|NCT00652171|Dietary Supplement|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
466193|NCT00652158|Drug|MLN8054|"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"
466194|NCT00652145|Drug|mesalamine|Increase dose by 2.4gm per day over baseline dose
466195|NCT00652132|Drug|cisplatin|
466196|NCT00652132|Drug|sodium thiosulfate|
466197|NCT00652119|Drug|Paclitaxel|Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.
466198|NCT00652119|Drug|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
466199|NCT00652119|Drug|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
466200|NCT00652106|Drug|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
466201|NCT00652106|Drug|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
466202|NCT00652106|Drug|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
466203|NCT00652093|Drug|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
466204|NCT00652093|Drug|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
466205|NCT00652093|Drug|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
466206|NCT00652093|Drug|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
466207|NCT00652093|Drug|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
466244|NCT00651794|Behavioral|Skills practice with low-fidelity mannequin|
466719|NCT00648622|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
466208|NCT00652093|Drug|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
466209|NCT00652080|Drug|API 31510|Topical Cream; 3% active; AM & PM application
466210|NCT00652054|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
466211|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
466212|NCT00652041|Drug|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is <Grade 2, dose should be increased to 200 mg/24 h. in day 15
466213|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
466214|NCT00652028|Drug|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
466215|NCT00652002|Drug|budesonide/formoterol|
466216|NCT00652002|Drug|budesonide|
466217|NCT00652002|Drug|formoterol|
466218|NCT00651989|Other|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
466219|NCT00651976|Drug|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
466220|NCT00651976|Other|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
466221|NCT00651976|Procedure|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
466222|NCT00651963|Drug|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose."
466223|NCT00651937|Drug|Melphalan|100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
466224|NCT00651937|Procedure|Stem Cell Infusion|"Stem Cell Infusion is Day 0.~Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 CD34/kg On Day 0~High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0."
466225|NCT00651937|Behavioral|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
466226|NCT00651937|Drug|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
466227|NCT00651937|Procedure|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
466228|NCT00651924|Behavioral|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
466229|NCT00651911|Drug|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
466230|NCT00651885|Drug|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
466231|NCT00651885|Drug|Placebo|Placebo
466232|NCT00651859|Drug|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
466233|NCT00651859|Drug|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
466234|NCT00651859|Drug|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
466235|NCT00651846|Drug|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
466236|NCT00651846|Drug|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
466237|NCT00651833|Drug|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
466238|NCT00651820|Drug|Collagenase Santyl|"Dermatome-induced skin wounds treated with drug active.~Each subject serves as his own control receiving both treatments in parallel."
466239|NCT00651820|Drug|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
466240|NCT00651807|Drug|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
466241|NCT00651807|Drug|Placebo|Every day one tablet up to 8 weeks
466242|NCT00651794|Behavioral|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
466290|NCT00651534|Drug|Ronacaleret|
466245|NCT00651794|Behavioral|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
466246|NCT00651781|Drug|Bortezomib|2 times per week of Velcade administration.
466247|NCT00651768|Drug|budesonide/formoterol|
466248|NCT00651768|Drug|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg & budesonide HFA pMDI 4 X 160mcg
466249|NCT00651755|Drug|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
466250|NCT00651755|Drug|Cyclophosphamide|750 mg/m^2 By Vein On Day 1
466251|NCT00651755|Drug|Doxorubicin|25 mg/m^2 By Vein Over 48 Hours On Days 1-2
466252|NCT00651755|Drug|Vincristine|2 mg By Vein On Day 1
466253|NCT00651755|Drug|Prednisone|100 mg PO for 5 Days
466254|NCT00651755|Drug|Rituximab|375 mg/m^2 By Vein On Day 1.
466255|NCT00651755|Drug|Ondansetron|8 mg daily for 2 days
466256|NCT00651742|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
466257|NCT00651729|Biological|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
466258|NCT00651716|Other|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
466259|NCT00651716|Other|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
466260|NCT00651716|Other|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
466261|NCT00651703|Biological|CYT004-MelQbG10 + Montanide|
466262|NCT00651703|Biological|CYT004-MelQbG10 + Montanide + Imiquimod|
466263|NCT00651703|Biological|CYT004-MelQbG10 + Imiquimod|
466264|NCT00651703|Biological|CYT004-MelQbG10 intra nodal injection|
466265|NCT00651690|Biological|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
466266|NCT00651690|Biological|Placebo|Saline injection on Day 0
466267|NCT00651677|Procedure|HAL proctectomy|Hand-assisted laparoscopic proctectomy
466268|NCT00651677|Procedure|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
466269|NCT00651677|Procedure|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
466270|NCT00651677|Procedure|SL Proctectomy|Straight laparoscopic proctectomy
466271|NCT00651664|Drug|alisertib|Alisertib (MLN8237) capsules
466272|NCT00651651|Drug|budesonide/formoterol|
466273|NCT00651651|Drug|budesonide|
466274|NCT00651651|Drug|formoterol|
466275|NCT00651638|Drug|Treatment with ARQ 197|Treatment with ARQ 197
466276|NCT00651625|Device|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
466277|NCT00651625|Device|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
466278|NCT00651612|Drug|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
466279|NCT00651612|Drug|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
466280|NCT00651599|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
466281|NCT00651599|Drug|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
466282|NCT00651586|Drug|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
466283|NCT00651586|Drug|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
466284|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 24%|transfusion
466285|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 28%|transfusion
466286|NCT00651560|Drug|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
466287|NCT00651547|Drug|budesonide/formoterol|
466288|NCT00651547|Drug|budesonide|
466289|NCT00651547|Drug|formoterol|
466291|NCT00651508|Drug|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
466292|NCT00651495|Behavioral|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
466293|NCT00651482|Drug|Everolimus|
466294|NCT00651482|Drug|Bevacizumab|
466295|NCT00651469|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
466296|NCT00651469|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
466297|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin)|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
466298|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)~Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)~Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
466299|NCT00651443|Drug|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
466300|NCT00651417|Dietary Supplement|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
466301|NCT00651417|Dietary Supplement|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
466302|NCT00651404|Drug|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
466303|NCT00651404|Drug|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
466304|NCT00651391|Drug|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
466305|NCT00651391|Drug|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
466306|NCT00651391|Drug|Placebo|oral placebo once daily in the evening for 12 weeks
466307|NCT00651378|Drug|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
466308|NCT00651378|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
466309|NCT00651378|Drug|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
466310|NCT00651365|Drug|JNJ-38877605|
466311|NCT00651352|Drug|4 mg nicotine lozenge|marketed formulation
466312|NCT00651352|Drug|2 mg nicotine lozenge|marketed formulation
466313|NCT00651352|Drug|2 mg nicotine prototype|2 mg
466314|NCT00651352|Drug|4 mg nicotine prototype|4 mg
466315|NCT00651339|Drug|botox|botox injection
466316|NCT00651326|Drug|bicalutamide|
466317|NCT00651326|Drug|buserelin|
466318|NCT00651326|Drug|flutamide|
466319|NCT00651326|Drug|goserelin|
466320|NCT00651326|Drug|leuprolide acetate|
466321|NCT00651326|Procedure|neoadjuvant therapy|
466322|NCT00651326|Procedure|quality-of-life assessment|
466323|NCT00651326|Radiation|radiation therapy|"46 Gy in 23 fractions over < 5 weeks.~Boost:~24-28 Gy in 12-14 fractions over < 3 weeks"
466324|NCT00651326|Drug|Docetaxel|
466325|NCT00651313|Drug|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
466326|NCT00651313|Drug|Placebo|Placebo vaginal gel administered once daily for 4 days
466327|NCT00651300|Drug|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
466328|NCT00651300|Drug|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
466329|NCT00651287|Drug|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
466330|NCT00651287|Drug|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
466331|NCT00651287|Drug|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
466332|NCT00651274|Drug|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
466333|NCT00651274|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
466334|NCT00651261|Drug|cytarabine|Given IV
466335|NCT00651261|Drug|daunorubicin|Given IV
466336|NCT00651261|Drug|midostaurin|Given orally
466337|NCT00651261|Other|placebo|Given orally
466338|NCT00651261|Drug|dexamethasone acetate|ocular medication administration
466339|NCT00651235|Drug|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.~Losartan is 100 mg/day for adult and 50 mg/day for children."
466340|NCT00651235|Drug|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
466341|NCT00651222|Other|No intervention was required|Death records were reviewed, therefore, there was no intervention
466394|NCT00650819|Drug|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
466395|NCT00650806|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
466342|NCT00651209|Drug|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
466343|NCT00651183|Drug|Pramipexole immediate release|
466344|NCT00651157|Biological|wild-type reovirus|Given IV: Administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
466345|NCT00651144|Drug|Ezetimibe + Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
466346|NCT00651144|Drug|Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
466347|NCT00651144|Drug|Placebo|oral tablets; two ezetimibe placebo once daily for 14 days
466348|NCT00651144|Drug|Ezetimibe|oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
466349|NCT00651131|Drug|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
466350|NCT00651118|Drug|Placebo|placebo
466351|NCT00651118|Drug|azelastine Hcl|azelastine Hcl 548 mcg
466352|NCT00651118|Drug|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
466353|NCT00651118|Drug|fluticasone propionate|fluticasone propionate 200 mcg
466354|NCT00651105|Drug|Vildagliptin|
466355|NCT00651105|Drug|Placebo|
466356|NCT00651092|Procedure|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
466357|NCT00651092|Procedure|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
466358|NCT00651079|Drug|GSK1247303|
466359|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
466360|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
466361|NCT00651053|Device|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
466362|NCT00651040|Drug|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
466363|NCT00651040|Drug|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
466364|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class A
466365|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class B
466366|NCT00651027|Drug|PF-868554|200 mg, healthy volunteers
466367|NCT00651014|Drug|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
466368|NCT00651014|Drug|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
466369|NCT00650988|Procedure|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
466370|NCT00650975|Device|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
466371|NCT00650975|Device|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
466372|NCT00650962|Other|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
466373|NCT00650962|Other|Rhythm analysis|Rhythm analysis as soon as AED is ready
466374|NCT00650949|Drug|CYT997|Escalating doses (100mg/m^2 to 150mg/m^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
466375|NCT00650949|Drug|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
466376|NCT00650936|Device|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
466377|NCT00650923|Drug|ziv-aflibercept|Given IV
466378|NCT00650923|Procedure|radiation therapy|Undergo RT
466379|NCT00650923|Drug|temozolomide|Given PO
466380|NCT00650923|Procedure|pharmacological study|Correlative studies
466381|NCT00650923|Procedure|laboratory biomarker analysis|Correlative studies
466382|NCT00650910|Drug|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
466383|NCT00650910|Drug|Digoxin|0.5mg on Days 1 and 9
466384|NCT00650897|Drug|Escitalopram|10-20 mg once daily
466385|NCT00650884|Device|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
466386|NCT00650871|Drug|GW679769|
466387|NCT00650871|Drug|Placebo|
466388|NCT00650858|Drug|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
466389|NCT00650845|Drug|Dotarem®-enhanced MRI|Single IV administration before MRI exam
466390|NCT00650845|Other|non-enhanced MRI|non injected MRI
466391|NCT00650832|Drug|TMC114; darunavir; Prezista|
466392|NCT00650819|Drug|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
466393|NCT00650819|Drug|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
466396|NCT00650806|Drug|Placebo|One matching placebo capsule orally once daily for 12 weeks.
466397|NCT00650793|Drug|Extended Release OROS® Paliperidone|
466398|NCT00650767|Drug|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
466399|NCT00650767|Drug|Placebo; oral|matching placebo
466400|NCT00650754|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
466401|NCT00650754|Other|Placebo|Placebo
466402|NCT00650728|Procedure|placing gastric tube|
466403|NCT00650715|Device|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
466404|NCT00650715|Device|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
466405|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
466406|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
466407|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
466408|NCT00650689|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
466409|NCT00650689|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
466410|NCT00650663|Drug|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
466411|NCT00650663|Drug|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
466412|NCT00650637|Drug|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
466413|NCT00650637|Drug|nelfinavir|1250 mg twice a day
466414|NCT00650637|Drug|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
466415|NCT00650637|Drug|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
466416|NCT00650637|Other|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
466417|NCT00650637|Drug|nelfinavir|nelfinavir 1250 mg twice a day
466418|NCT00650637|Drug|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
466419|NCT00650624|Drug|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
466420|NCT00650624|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
466421|NCT00650624|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
466422|NCT00650624|Drug|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
466423|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
466424|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.~Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
466425|NCT00650598|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
466426|NCT00650598|Drug|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
466427|NCT00650585|Behavioral|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
466428|NCT00650572|Drug|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
466429|NCT00650559|Procedure|Chest wall enlargement|Widening sternotomy
466430|NCT00650546|Drug|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
466431|NCT00650533|Drug|Glimepiride Tablets 1 mg|1mg, single dose fed
466432|NCT00650533|Drug|Amaryl® Tablets 1 mg|1mg, single dose fed
466433|NCT00650520|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
466434|NCT00650520|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
466489|NCT00650169|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
466490|NCT00650169|Drug|Plavix® Tablets 75 mg|75mg, single dose fed
466491|NCT00650156|Biological|adalimumab|40 mg single sc dose
466492|NCT00650156|Biological|adalimumab|80 mg single sc dose
466435|NCT00650507|Procedure|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
466436|NCT00650507|Procedure|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
466437|NCT00650494|Drug|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
466438|NCT00650494|Drug|Valtrex® 1000 mg|1000mg, single dose fed
466439|NCT00650481|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
466440|NCT00650481|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
466441|NCT00650468|Drug|tacrolimus|Oral
466442|NCT00650468|Drug|CellCept|IV or Oral
466443|NCT00650468|Drug|steroids (methylprednisone or prednisone)|IV or Oral
466444|NCT00650455|Drug|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
466445|NCT00650455|Drug|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
466446|NCT00650455|Drug|placebo|placebo tablet every morning and capsule every evening for 12 weeks
466447|NCT00650442|Drug|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
466448|NCT00650442|Drug|Estradiol Transdermal System Placebo - Current Adhesive|single application
466449|NCT00650429|Drug|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
466450|NCT00650416|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
466451|NCT00650416|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
466452|NCT00650403|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
466453|NCT00650403|Drug|Paxil® 40 mg Tablet|40mg, single dose fed
466454|NCT00650390|Biological|adalimumab|40 mg adalimumab every other week
466455|NCT00650377|Drug|Finasteride Tablets 5 mg|5mg, single dose fed
466456|NCT00650377|Drug|Proscar® Tablets 5 mg|5mg, single dose fed
466457|NCT00650364|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
466458|NCT00650364|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fasting
466459|NCT00650351|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
466460|NCT00650351|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
466461|NCT00650338|Drug|DE-104 ophthalmic solution, low concentration|Topical ocular application
466462|NCT00650338|Drug|DE-104 ophthalmic solution, medium concentration|Topical ocular application
466463|NCT00650338|Drug|DE-104 ophthalmic solution, high concentration|Topical ocular application
466464|NCT00650338|Drug|Placebo|placebo
466465|NCT00650338|Drug|0.005% latanoprost|Topical ocular application
466466|NCT00650325|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fasting
466467|NCT00650325|Drug|Zoloft® Tablets 100 mg|100mg, single dose fasting
466468|NCT00650312|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
466469|NCT00650312|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
466470|NCT00650299|Drug|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
466471|NCT00650299|Drug|Xanax XR® Tablets 3 mg|3mg, single dose fed
466472|NCT00650286|Drug|Modafinil Tablets 200 mg|200mg, single dose fed
466473|NCT00650286|Drug|Provigil® Tablets 200 mg|200mg, single dose fed
466474|NCT00650273|Drug|Azithromycin Tablets 600 mg|600mg, single dose fasting
466475|NCT00650273|Drug|Zithromax® Tablets 600 mg|600mg, single dose fasting
466476|NCT00650260|Device|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
466477|NCT00650260|Device|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
466478|NCT00650247|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fed
466479|NCT00650247|Drug|Imitrex® Tablets 100 mg|100mg, single dose fed
466480|NCT00650234|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
466481|NCT00650234|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
466482|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release oral tablet
466483|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release tablet
466484|NCT00650208|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
466485|NCT00650208|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
466486|NCT00650195|Drug|Metolazone Tablets 10 mg|10mg, single dose fasting
466487|NCT00650195|Drug|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
466488|NCT00650182|Drug|fentanyl; naltrexone|
466493|NCT00650143|Drug|Lenograstim (GRANOCYTE)=GCSF|10 µg/kg/d s.c. for 5 days divided in two dosages per day
466494|NCT00650143|Drug|Sitagliptin (Januvia)|100 mg p.o. per day for 28 days
466495|NCT00650143|Drug|Sodium Chloride (NaCl) 0.9 %|applied s.c. twice a day for 5 days
466496|NCT00650143|Drug|Gelatin|One capsule p.o. per day for 28 days
466497|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
466498|NCT00650117|Drug|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
466499|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
466500|NCT00650117|Drug|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
466501|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
466502|NCT00650117|Drug|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
466503|NCT00650104|Drug|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
466504|NCT00650091|Drug|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
466505|NCT00650091|Drug|Placebo|Participants will receive placebo each day.
466506|NCT00650078|Drug|MR prednisone|1 x 5 mg daily
466507|NCT00650078|Drug|Placebo|1x daily
466508|NCT00650065|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
466509|NCT00650065|Drug|Zyrtec® Tablets 10 mg|10mg, single dose fasting
466510|NCT00650052|Drug|Zonisamide Capsules 100 mg|100mg, single dose fasting
466511|NCT00650052|Drug|Zonegran® Capsules 100 mg|100mg, single dose fasting
466512|NCT00650039|Drug|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
466513|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
466514|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
466515|NCT00650026|Biological|adalimumab|40 mg adalimumab every other week
466516|NCT00650013|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
466517|NCT00650013|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
466518|NCT00650000|Drug|Modafinil Tablets 200 mg|200mg, single dose fasting
466519|NCT00650000|Drug|Provigil® Tablets 200 mg|200mg, single dose fasting
466520|NCT00649987|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
466521|NCT00649987|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
466522|NCT00649974|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
466523|NCT00649974|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
466524|NCT00649961|Drug|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.~Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
466525|NCT00649948|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
466526|NCT00649948|Drug|Glucophage XR 500 mg|500mg, single dose fed
466527|NCT00649935|Drug|Azithromycin Tablets 600 mg|600mg, single dose fed
466528|NCT00649935|Drug|Zithromax® Tablets 600 mg|600mg, single dose fed
466529|NCT00649922|Biological|adalimumab|80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
466530|NCT00649922|Biological|placebo|2 injections Day 1, 1 injection Days 15 and 29
466531|NCT00649922|Biological|adalimumab|40 mg adalimumab every other week
466532|NCT00649896|Drug|Mylan Estradiol Transdermal System 0.025 mg/day|
466533|NCT00649896|Drug|Climara® Transdermal System 0.025 mg/day|
466534|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
466535|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
466536|NCT00649870|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
466537|NCT00649870|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fed
466538|NCT00649857|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
466539|NCT00649857|Drug|Zyrtec® 10 mg|10mg, single dose fed
466540|NCT00649844|Drug|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
466541|NCT00649844|Drug|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
466542|NCT00649831|Drug|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
466543|NCT00649831|Drug|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
466544|NCT00649818|Drug|Lorazepam Tablets 2 mg|2mg, single dose fasting
466545|NCT00649818|Drug|Ativan Tablets 2 mg|2mg, single dose fasting
466546|NCT00649805|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
466547|NCT00649805|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
466548|NCT00649792|Drug|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
466549|NCT00649779|Drug|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
466550|NCT00649779|Drug|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
466551|NCT00649766|Behavioral|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
466552|NCT00649766|Behavioral|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
466553|NCT00649753|Procedure|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
466554|NCT00649753|Procedure|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
466555|NCT00649753|Procedure|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
466556|NCT00649740|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
466557|NCT00649740|Drug|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
466558|NCT00649727|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
466559|NCT00649727|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
466560|NCT00649714|Drug|Zonisamide Capsules 100 mg|100mg, single dose fed
466561|NCT00649714|Drug|Zonegran® Capsules 100 mg|100mg, single dose fed
466562|NCT00649701|Behavioral|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
466563|NCT00649701|Behavioral|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
466564|NCT00649701|Behavioral|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
466565|NCT00649701|Behavioral|Both Videos|Morning After and Talking About HIV videos
466566|NCT00649688|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
466567|NCT00649688|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
466568|NCT00649675|Drug|Meloxicam Tablets 15 mg|15mg, single dose fed
466569|NCT00649675|Drug|Mobic® Tablets 15 mg|15mg, single dose fed
466570|NCT00649662|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fasting
466571|NCT00649662|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fasting
466572|NCT00649649|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
466573|NCT00649649|Drug|Accupril® Tablets 40 mg|40mg, single dose fed
466574|NCT00649636|Drug|Fluoxetine Capsules 40 mg|40mg, single dose fasting
466575|NCT00649636|Drug|Prozac Pulvules 40 mg|40mg, single dose fasting
466576|NCT00649623|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
466577|NCT00649623|Drug|Benicar® Tablets 40 mg|40mg, single dose fasting
466578|NCT00649610|Drug|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
466579|NCT00649610|Drug|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
466580|NCT00649597|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
466581|NCT00649597|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
466582|NCT00649584|Drug|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
466583|NCT00649584|Drug|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
466584|NCT00649571|Drug|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
466585|NCT00649571|Drug|Adoxa Tablets 100 mg|100mg, single dose fasting
466586|NCT00649558|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
466587|NCT00649558|Drug|Actos® Tablets 45 mg|45mg, single dose fasting
466588|NCT00649545|Biological|adalimumab|40 mg every other week
466589|NCT00649532|Drug|Ondansetron Tablets 24 mg|24mg, single dose fasting
466590|NCT00649532|Drug|Zofran® Tablets 24 mg|24mg, single dose fasting
466591|NCT00649519|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
466592|NCT00649519|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
466593|NCT00649506|Drug|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
466594|NCT00649506|Drug|Macrodantin® 100 mg Capsules|100mg, single dose fed
466595|NCT00649493|Drug|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
466596|NCT00649493|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
466597|NCT00649480|Drug|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
466598|NCT00649480|Drug|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
466599|NCT00649467|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
466600|NCT00649467|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
466601|NCT00649454|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
466602|NCT00649454|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
466603|NCT00649441|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
466604|NCT00649441|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
466605|NCT00649428|Biological|Autologous Human Fibroblast (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
466606|NCT00649428|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Three injection visits administered 5 ± 1 weeks apart on each side of the face."
466607|NCT00649415|Drug|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
466608|NCT00649415|Drug|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
466609|NCT00649402|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
466610|NCT00649402|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
466611|NCT00649389|Drug|Olmesartan medoxomil|40mg olmesartan medoxomil
466612|NCT00649389|Drug|Amlodipine|Amlodipine 10mg
466613|NCT00649389|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
466614|NCT00649376|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fasting
466615|NCT00649376|Drug|Allegra® Tablets 180 mg|180mg, single dose fasting
466616|NCT00649363|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
466617|NCT00649363|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
466618|NCT00649350|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
466619|NCT00649350|Drug|Glucophage XR 750 mg|750mg, single dose fed
466620|NCT00649337|Procedure|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.~The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
466621|NCT00649324|Drug|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
466622|NCT00649324|Drug|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
466623|NCT00649311|Drug|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
466624|NCT00649311|Drug|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
466625|NCT00649298|Procedure|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
466626|NCT00649285|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
466627|NCT00649285|Drug|Macrobid® Capsules 100 mg|100mg, single dose fed
466628|NCT00649272|Drug|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
466629|NCT00649272|Drug|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
466630|NCT00649259|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
466631|NCT00649259|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
466632|NCT00649233|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
466633|NCT00649233|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
466634|NCT00649220|Drug|Memantine|memantine tablets, twice a day (bid), for 20 weeks
466635|NCT00649207|Drug|ABT-888|Oral Capsules
466636|NCT00649207|Radiation|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
466637|NCT00649194|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
466638|NCT00649194|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
466639|NCT00649181|Drug|Metolazone Tablets 5 mg|2x5mg, single dose fasting
466640|NCT00649181|Drug|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
466641|NCT00649168|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
466642|NCT00649168|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
466643|NCT00649155|Drug|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
466644|NCT00649155|Drug|Cipro® XR Tablets (500 mg|500mg, single dose fasting
466645|NCT00649142|Procedure|Open sutured mesh repair|Open sutured mesh repair
466646|NCT00649142|Procedure|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
466647|NCT00649129|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
466648|NCT00649129|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
466649|NCT00649116|Drug|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
466650|NCT00649116|Drug|Lopressor® Tablets 100 mg|100mg, single dose fed
466651|NCT00649103|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
466652|NCT00649103|Drug|Accupril® Tablets 40 mg|40mg, single dose fasting
466653|NCT00649090|Drug|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
466654|NCT00649077|Drug|Meloxicam Tablets 15 mg|15mg, single dose fasting
466655|NCT00649077|Drug|Mobic® Tablets 15 mg|15mg, single dose fasting
466656|NCT00649064|Drug|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
466657|NCT00649051|Drug|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
466658|NCT00649051|Drug|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
466659|NCT00649038|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
466660|NCT00649038|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
466661|NCT00649025|Drug|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
466662|NCT00649025|Drug|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
466663|NCT00649025|Drug|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
466664|NCT00649012|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
466665|NCT00649012|Drug|Actos® Tablets 45 mg|45mg, single dose fed
466666|NCT00648999|Drug|lopinavir/ritonavir|lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
466667|NCT00648986|Drug|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
466668|NCT00648973|Drug|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules~Twice daily: one pseudoephedrine-matching placebo tablet"
466669|NCT00648973|Drug|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule~Twice daily: one pseudoephedrine-matching placebo tablet"
466670|NCT00648973|Drug|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules~Twice daily: one pseudoephedrine 120 mg tablet"
466671|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
466672|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral dose
466673|NCT00648947|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
466674|NCT00648947|Drug|Plavix® Tablets 75 mg|75mg, single dose fasting
466675|NCT00648934|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
466676|NCT00648934|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
466677|NCT00648921|Drug|Olanzapine Tablets 5 mg|5mg, single dose fasting
466678|NCT00648921|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fasting
466679|NCT00648908|Drug|Fampridine-SR|Tablets, 10 mg, BID
466680|NCT00648895|Drug|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
466681|NCT00648895|Drug|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
466682|NCT00648882|Drug|LEVOTHYROXINE SODIUM TABLETS,|2x300mcg, single dose fasting
466683|NCT00648882|Drug|SYNTHROID® 300 mcg Tablets|2x300mcg, single dose fasting
466684|NCT00648869|Drug|metformin tablet, metformin gum|500 mg, 250 mg
466685|NCT00648856|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
466686|NCT00648856|Drug|Zoloft® Tablets 100 mg|100mg, single dose fed
466687|NCT00648843|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
466688|NCT00648843|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
466689|NCT00648830|Procedure|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
466690|NCT00648830|Drug|Clarithromycin|single-dose 250 mg immediate-release oral tablets
466691|NCT00648817|Drug|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
466692|NCT00648817|Drug|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
466693|NCT00648804|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
466694|NCT00648804|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fed
466695|NCT00648791|Drug|Finasteride Tablets 5 mg|5mg, single dose fasting
466696|NCT00648791|Drug|Proscar Tablets 5 mg|5mg, single dose fasting
466697|NCT00648778|Drug|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
466698|NCT00648778|Drug|Loxitane® Capsules 25 mg|25mg, single dose fasting
466699|NCT00648765|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
466700|NCT00648765|Drug|Agrylin® Capsules 1 mg|1mg, single dose fed
466701|NCT00648739|Drug|Samalizumab|Samalizumab is a humanized anti-CD200 monoclonal antibody.
466702|NCT00648726|Drug|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
466703|NCT00648726|Drug|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
466704|NCT00648726|Drug|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
466705|NCT00648713|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
466706|NCT00648713|Drug|Lamisil® Tablets 250 mg|250mg, single dose fed
466707|NCT00648700|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
466708|NCT00648700|Drug|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
466709|NCT00648687|Behavioral|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
466710|NCT00648674|Device|Apligraf|Applied at Day 0, possible re-application at Week 6
466711|NCT00648661|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
466712|NCT00648661|Drug|Lexapro® Tablets 20 mg|20mg, single dose fed
466713|NCT00648648|Drug|MK-1775|MK-1775 administered as an oral formulation as either monotherapy or in combination with either gemcitabine, cisplatin, or carboplatin.
466714|NCT00648648|Drug|gemcitabine|Gemcitabine administered at 1000 mg/m^2 by IV infusion in a 28-day cycle.
466715|NCT00648648|Drug|cisplatin|Cisplatin administered at 75 mg/m^2 by IV infusion in a 21-day cycle.
466716|NCT00648648|Drug|carboplatin|Carboplatin administered at AUC/time curve of 5 mg/min/mL (AUC5) by IV infusion in a 21-day cycle.
466717|NCT00648635|Behavioral|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
466718|NCT00648622|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
466720|NCT00648609|Other|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
466721|NCT00648609|Other|Standard of care|Usual care for COPD patients
466722|NCT00648596|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
466723|NCT00648596|Drug|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
466724|NCT00648583|Drug|Ondansetron Tablets 24 mg|24mg, single dose fed
466725|NCT00648583|Drug|Zofran® Tablets 24 mg|24mg, single dose fed
466726|NCT00648570|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
466727|NCT00648570|Drug|Lexapro® Tablets (20 mg|20mg, single dose fasting
466728|NCT00648557|Drug|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
466729|NCT00648557|Drug|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
466730|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablet
466731|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablets
466732|NCT00648531|Drug|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
466733|NCT00648531|Drug|Colazal® Capsules 750 mg|3x750mg, single dose fasting
466734|NCT00648518|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
466735|NCT00648518|Drug|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
466736|NCT00648505|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
466737|NCT00648505|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
466738|NCT00648492|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
466739|NCT00648492|Drug|Glucophage® XR 500 mg|500mg, single dose fed
466740|NCT00648479|Device|The Guiding Star|
466741|NCT00648479|Device|fluoroscopy (OEC 9800 - General Electric)|
466742|NCT00648466|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
466743|NCT00648466|Drug|Imitrex® Tablets 100 mg|100mg, single dose fasting
466744|NCT00648453|Drug|Clopidogrel (Plavix)|
466745|NCT00648440|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
466746|NCT00648440|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
466747|NCT00648427|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
466748|NCT00648427|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
466749|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
466750|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
466751|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
466752|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
466753|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
466754|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
466755|NCT00648401|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
466756|NCT00648401|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
466757|NCT00648388|Drug|Cilostazol Tablets 100 mg|100mg, single dose fasting
466758|NCT00648388|Drug|Pletal® Tablets 100 mg|100 single dose fasting
466759|NCT00648375|Drug|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
466760|NCT00648375|Drug|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
466761|NCT00648375|Behavioral|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
466762|NCT00648362|Drug|Glimepiride Tablets 1 mg|1mg, single dose fasting
466763|NCT00648362|Drug|Amaryl® Tablets 1 mg|1mg, single dose fasting
466764|NCT00648349|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
466765|NCT00648349|Drug|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
466766|NCT00648336|Drug|Mercaptopurine 50 mg|50mg, single dose fasting
466767|NCT00648336|Drug|Purinethol® Tablets 50 mg|50mg, single dose fasting
466768|NCT00648323|Drug|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
466769|NCT00648310|Drug|Tolterodine 4 mg|
466770|NCT00648310|Drug|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
466771|NCT00648297|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
466772|NCT00648297|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
466773|NCT00648271|Drug|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
466774|NCT00648271|Drug|Lopressor® Tablets 50 mg|1x50mg, single dose fed
466775|NCT00648258|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
466776|NCT00648258|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
466777|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
466778|NCT00648245|Drug|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
466779|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
466780|NCT00648245|Drug|Placebo|Placebo given once daily for 21 days by nebulizer
466781|NCT00648245|Drug|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
466782|NCT00648232|Behavioral|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
466783|NCT00648232|Behavioral|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
466784|NCT00648232|Behavioral|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
466785|NCT00648232|Behavioral|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
466786|NCT00648219|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
466787|NCT00648219|Drug|Benicar® Tablets 40 mg|40mg, single dose fed
466788|NCT00648193|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
466789|NCT00648193|Drug|Paxil® 40 mg Table|40mg, single dose fasting
466790|NCT00648180|Drug|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
466791|NCT00648180|Drug|Adoxa Tablets 100 mg|100mg, single dose fed
466792|NCT00648167|Drug|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
466793|NCT00648154|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
466794|NCT00648154|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fed
466795|NCT00648141|Drug|Celecoxib|200 mg oral capsule once daily for 12 weeks
466796|NCT00648141|Drug|Celecoxib|200 mg oral capsule twice daily for 12 weeks
466797|NCT00648141|Drug|Diclofenac|75 mg oral capsule twice daily for 12 weeks
466798|NCT00648128|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
466799|NCT00648128|Drug|Clarithromycin|single-dose 500 mg immediate-release oral dose`
466800|NCT00648115|Other|Basic Vocational Services|Vocational services
466801|NCT00648115|Other|Self-Study|Veteran receives self-study resources
466802|NCT00648115|Other|Group Program|Veteran participates in group vocational program
466803|NCT00648102|Biological|CDX-1307|
466804|NCT00648089|Drug|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
466805|NCT00648076|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
466806|NCT00648076|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fed
466807|NCT00648063|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
466808|NCT00648063|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
466809|NCT00648050|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
466810|NCT00648050|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
466811|NCT00648037|Drug|Rituximab|Rituximab 375 mg/m^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is > 200 cells/ul or a maximum of 6 doses have been given.
466812|NCT00648024|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
466813|NCT00648024|Drug|Agrylin® Capsules 1 mg|1mg, single dose fasting
466814|NCT00648011|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
466815|NCT00648011|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
466816|NCT00647998|Drug|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
466817|NCT00647998|Other|Standard care|
466818|NCT00647985|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fed
466819|NCT00647985|Drug|Allegra® Tablets 180 mg|180mg, single dose fed
466820|NCT00647972|Drug|Olanzapine Tablets 20 mg|20mg, single dose fasting
466821|NCT00647972|Drug|Zyprexa® Tablets 20 mg|20mg, single dose fasting
466822|NCT00647959|Drug|Doxycycline Tablets, 150mg|150mg, single dose fasting
466823|NCT00647959|Drug|Adoxa Tablets 150 mg|150mg, single dose fasting
466824|NCT00647946|Drug|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
466825|NCT00647946|Drug|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
466826|NCT00647933|Drug|Org 36286|Subcutaneous Org 36286
466827|NCT00647933|Drug|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
466828|NCT00647920|Biological|adalimumab|40 mg adalimumab sc, every other week
466829|NCT00647920|Biological|placebo|placebo sc, every other week
466830|NCT00647907|Drug|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
466831|NCT00647894|Drug|Alprazolam Extended-Release Tablets 1 mg|
466832|NCT00647894|Drug|Xanax XR Tablets 1 mg|
466833|NCT00647881|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
466834|NCT00647881|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fed
466835|NCT00647868|Drug|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
466836|NCT00647855|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
466837|NCT00647855|Drug|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
466838|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
466839|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h|single application
466840|NCT00647829|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
466841|NCT00647829|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
466842|NCT00647829|Drug|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
466843|NCT00647816|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fasting
466844|NCT00647816|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fasting
466845|NCT00647790|Procedure|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
466846|NCT00647777|Drug|Olanzapine Tablets 5 mg|5mg, single dose fed
466847|NCT00647777|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fed
466848|NCT00647764|Drug|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
466849|NCT00647751|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
466850|NCT00647751|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fed
466851|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablets
466852|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablet
466853|NCT00647725|Procedure|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
466854|NCT00647725|Procedure|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
466855|NCT00647712|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
466856|NCT00647712|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fasting
466857|NCT00647699|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
466858|NCT00647699|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
466859|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
466860|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h|single application
466861|NCT00647673|Drug|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
466862|NCT00647673|Drug|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
466863|NCT00647660|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
466864|NCT00647660|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
466865|NCT00647647|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
466866|NCT00647647|Drug|Lamisil® Tablets 250 mg|250mg, single dose fasting
466867|NCT00647634|Drug|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
466868|NCT00647634|Drug|Xanax XR® Tablets (3 mg|3mg, single dose fasting
466869|NCT00647621|Drug|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
466870|NCT00647621|Drug|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
466871|NCT00647608|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
466872|NCT00647608|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fed
466873|NCT00647595|Behavioral|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
466874|NCT00647582|Procedure|adjuvant therapy|
466875|NCT00647582|Procedure|therapeutic conventional surgery|
466876|NCT00647582|Radiation|intraoperative radiation therapy|
466877|NCT00647582|Radiation|radiation therapy|
466878|NCT00647569|Procedure|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
466879|NCT00647569|Procedure|Conventional facial closure|The abdominal facia is closed with with continuous running suture
466880|NCT00647556|Drug|adapalene gel, 0.3%|applied topically once daily in the evening
466881|NCT00647556|Drug|tretinoin 0.05% emollient cream|applied topically once daily in the evening
466882|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
466883|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
466884|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
466885|NCT00647530|Biological|panitumumab|
466886|NCT00647530|Drug|capecitabine|
466887|NCT00647530|Drug|fluorouracil|
466888|NCT00647530|Drug|oxaliplatin|
466889|NCT00647517|Drug|Ultracet|"For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.~For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day."
466890|NCT00647491|Biological|adalimumab|20 mg sc eow
466891|NCT00647491|Biological|adalimumab|40 mg sc eow
466892|NCT00647491|Biological|adalimumab|80 mg sc eow
466893|NCT00647491|Biological|placebo|placebo sc eow
466894|NCT00647465|Drug|vaccine|IFNalpha 2b
466895|NCT00647465|Drug|Placebo|Placebo
466896|NCT00647452|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
466897|NCT00647426|Drug|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
466898|NCT00647413|Behavioral|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.~The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
466899|NCT00647400|Biological|adalimumab|Adalimumab 40 mg every other week, subcutaneous
466900|NCT00647400|Biological|adalimumab|Adalimumab 80 mg every other week, subcutaneous
466901|NCT00647387|Device|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
466902|NCT00647374|Other|this is an observational study|
466903|NCT00647361|Device|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
466904|NCT00647348|Drug|Simvastatin|80mg simvastatin oral once daily for 24 months
466905|NCT00647348|Drug|Placebo|Oral placebo tablet once daily for 24 months
466906|NCT00647322|Other|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
466907|NCT00647322|Procedure|No drug change|No change in anti-epileptic treatment
466908|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 12.5 mg twice daily for 12 weeks
466909|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 37.5 mg twice daily for 12 weeks
466910|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 75 mg twice daily for 12 weeks
466911|NCT00647296|Drug|Placebo|Placebo oral tablet (2 tabs twice daily) for 12 weeks
466912|NCT00647283|Procedure|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
466913|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
466914|NCT00647270|Drug|Placebo|Pre-filled syringe. See arm for more detail
466915|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
466916|NCT00647257|Drug|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
466917|NCT00647257|Drug|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
466918|NCT00647244|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
466919|NCT00647244|Drug|Abacavir|Abacavir 300 mg oral tablet twice daily
466920|NCT00647231|Drug|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
466921|NCT00647231|Other|Placebo Patch|Treatment with placebo patch
466922|NCT00647218|Drug|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
466923|NCT00647218|Drug|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
466924|NCT00647218|Procedure|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
466925|NCT00647218|Radiation|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
466926|NCT00647218|Drug|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
466927|NCT00647205|Device|QuantiFERON TB Gold In-Tube|
466928|NCT00647205|Device|T-SPOT.TB®|
466929|NCT00647192|Drug|Eplerenone|50 mg per day
466930|NCT00647192|Drug|Placebo|50 mg per day
466931|NCT00647179|Procedure|Transsphenoidal adenomectomy|Surgery
466932|NCT00647166|Drug|corticosteroid and azathioprine|"Corticosteroid 1 mg/kg/day with a conventional decrease dose~Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
466933|NCT00647166|Drug|corticosteroid and placebo|"Corticosteroid 1 mg/kg/day with a conventional decrease dose~Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
466934|NCT00647153|Other|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
466935|NCT00647153|Procedure|single photon emission computed tomography|One day post infusion
466936|NCT00647153|Radiation|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
466937|NCT00647140|Other|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
466938|NCT00647127|Drug|Buprenorphine|Buprenorphine: 20microg/h
466939|NCT00647127|Drug|Fentanyl|Fentanyl: 25microg/h
466940|NCT00647127|Drug|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
466941|NCT00647114|Biological|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
466942|NCT00647114|Biological|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
466943|NCT00647101|Drug|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
466944|NCT00647075|Dietary Supplement|Yunzhi extract|3.5 g/day
466945|NCT00647075|Dietary Supplement|Placebo|Placebo (starch)
466946|NCT00647049|Drug|methotrexate|8000mg/m2 i.v., max. 2 cycles
466947|NCT00647049|Drug|Rituximab|375mg/m2, max. 8 times
466948|NCT00647049|Drug|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
466949|NCT00647049|Drug|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
466950|NCT00647049|Drug|Carmustin|400mg/m2 i.v. for 1 day
466951|NCT00647036|Dietary Supplement|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
466952|NCT00647036|Drug|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
466953|NCT00647023|Drug|metformin|1000 mg metformin x 2 daily during 8 months
466954|NCT00646984|Drug|Standard continuous antiretroviral therapy|
466955|NCT00646984|Drug|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
466956|NCT00646984|Drug|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
466957|NCT00646971|Device|CPAP device|for 4 weeks
466958|NCT00646971|Device|Placebo device|for 4 weeks
466959|NCT00646958|Drug|Radezolid|450mg PO QD
466960|NCT00646958|Drug|Radezolid|450mg PO BID
466961|NCT00646958|Drug|Linezolid|600mg PO BID
466962|NCT00646945|Drug|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
466963|NCT00646945|Drug|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
466964|NCT00646932|Drug|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
466965|NCT00646932|Drug|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
466966|NCT00646932|Drug|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
466967|NCT00646932|Drug|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
466968|NCT00646919|Procedure|Nose swab|
466969|NCT00646906|Drug|Aspirin first|Subjects will receive 81 mg aspirin at approximately 8 am followed by 1000 or 2000 mg acetaminophen at approximately 10 am during this intervention phase.
466970|NCT00646906|Drug|Aspirin last|Subjects will receive 1000 or 2000 mg acetaminophen at approximately 8am followed by 81 mg aspirin at approximately 10 am during this intervention phase.
466971|NCT00646906|Drug|Acetaminophen|The data will be handled the same as Part A.
466972|NCT00646893|Procedure|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
466973|NCT00646880|Drug|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
466974|NCT00646880|Drug|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
466975|NCT00646867|Device|Tetrix|Twice daily topical application
466976|NCT00646867|Device|Placebo|Twice daily topical application
466977|NCT00646854|Drug|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
466978|NCT00646854|Drug|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
466979|NCT00646841|Drug|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
466980|NCT00646815|Drug|growth hormone (genotropin)|Dosage regulation will follow the local recommendations of GHD treatment
466981|NCT00646802|Drug|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
466982|NCT00646802|Drug|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
466983|NCT00646789|Drug|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
466984|NCT00646776|Drug|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
466985|NCT00646776|Drug|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days~Rifabutin (150 mg, 2x/wk)~Atazanavir (300 mg, once daily)~Ritonavir (100 mg, once daily)"
466986|NCT00646763|Drug|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
466987|NCT00646763|Drug|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
466988|NCT00646750|Drug|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
466989|NCT00646737|Drug|Mycophenolate sodium|Mycophenolate sodium
466990|NCT00646724|Biological|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
466991|NCT00646711|Drug|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
466992|NCT00646711|Drug|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
466993|NCT00646685|Procedure|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
466994|NCT00646685|Procedure|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
466995|NCT00646659|Biological|cetuximab|
466996|NCT00646659|Drug|carboplatin|
466997|NCT00646659|Drug|cisplatin|
466998|NCT00646659|Drug|docetaxel|
466999|NCT00646659|Drug|fluorouracil|
467000|NCT00646659|Genetic|fluorescence in situ hybridization|
467001|NCT00646659|Genetic|molecular genetic technique|
467002|NCT00646659|Genetic|reverse transcriptase-polymerase chain reaction|
467003|NCT00646659|Other|immunoenzyme technique|
467004|NCT00646659|Other|immunohistochemistry staining method|
467005|NCT00646659|Other|laboratory biomarker analysis|
467006|NCT00646659|Procedure|biopsy|
467007|NCT00646659|Radiation|3-dimensional conformal radiation therapy|
467008|NCT00646659|Radiation|intensity-modulated radiation therapy|
467009|NCT00646646|Drug|propofol|sedative
467010|NCT00646646|Drug|dexmedetomidine|Sedative
467011|NCT00646646|Drug|Midazolam|sedative
467012|NCT00646646|Drug|saline placebo|saline placebo
467013|NCT00646633|Procedure|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
467014|NCT00646620|Drug|budesonide/formoterol (Symbicort)|
467015|NCT00646620|Drug|fluticasone/salmeterol (Advair Diskus)|
467016|NCT00646620|Drug|albuterol (Ventolin)|
467017|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
467018|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
467019|NCT00646594|Drug|budesonide/formoterol (Symbicort)|
467020|NCT00646594|Drug|fluticasone/salmeterol (Advair)|
467021|NCT00646581|Drug|Placebo|Placebo
467022|NCT00646581|Drug|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
467023|NCT00646568|Drug|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
467024|NCT00646542|Drug|Vildagliptin|
467025|NCT00646542|Drug|Placebo|
467026|NCT00646529|Drug|budesonide/formoterol (Symbicort)|
467027|NCT00646529|Drug|budesonide (Pulmicort)|
467028|NCT00646516|Drug|budesonide/formoterol (Symbicort)|
467029|NCT00646503|Drug|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
467030|NCT00646477|Device|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:~in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.~in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
467031|NCT00646451|Drug|pregabalin|75 mg bid to 300 mg bid based on per subject tolerability
467032|NCT00646451|Drug|placebo capsules|up to 4 capsules bid as tolerated
467033|NCT00646438|Drug|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.~Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.~For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
467034|NCT00646425|Drug|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
467035|NCT00646425|Drug|Placebo|Placebo to match basiliximab
467036|NCT00646412|Device|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
467037|NCT00646399|Drug|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
467038|NCT00646399|Drug|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
467039|NCT00646386|Drug|adalimumab|40 mg eow Week 0 - Week 24
467040|NCT00646386|Drug|placebo for adalimumab|40 mg eow Week 0 - Week 24
467041|NCT00646373|Other|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
467042|NCT00646360|Dietary Supplement|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
467043|NCT00646360|Dietary Supplement|Placebo|2 tablets daily during pregnancy
467044|NCT00646347|Other|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.~Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
467045|NCT00646347|Device|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;~NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.~The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.~The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
467046|NCT00646334|Device|Mesh Implantation|An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.
467047|NCT00646334|Device|Mesh Implantation|Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
467048|NCT00646321|Drug|budesonide/formoterol (Symbicort)|
467049|NCT00646321|Drug|budesonide|
467050|NCT00646295|Device|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
467051|NCT00646282|Drug|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH <300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
467052|NCT00646269|Behavioral|Standard intervention protocol|The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
467053|NCT00646269|Behavioral|Standard intervention protocol + Cognitive training therapy|"Cognitive training therapy is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving…) related to activities of daily living is realized at each session."
467054|NCT00646269|Behavioral|Standard intervention protocol + Reminiscence therapy|"Reminiscence therapy is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session."
467055|NCT00646269|Behavioral|"Standard intervention protocol + Made-to-measure program"|"The made to measure program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies (Cognitive training therapy or Reminiscence therapy) the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs."
467056|NCT00646256|Behavioral|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
467057|NCT00646230|Drug|fenretinide|
467058|NCT00646230|Other|high performance liquid chromatography|
467059|NCT00646230|Other|pharmacological study|
467060|NCT00646217|Behavioral|Self Care Talk|6 weekly telephone sessions
467061|NCT00646204|Drug|Memantine|10 mg bid
467062|NCT00646204|Drug|placebo|2 tabs bid
467063|NCT00646191|Drug|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
467064|NCT00646191|Drug|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
467065|NCT00646191|Drug|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
467066|NCT00646178|Drug|adalimumab|40 mg adalimumab eow Week 0 - Week 12
467067|NCT00646178|Drug|placebo for adalimumab|placebo eow Week 0 - Week 12
467068|NCT00646165|Drug|Forodesine|
467069|NCT00646152|Drug|Poly-ICLC|
467070|NCT00646139|Drug|Src kinase inhibitor KX2-391|
467071|NCT00646139|Other|immunoenzyme technique|
467072|NCT00646139|Other|pharmacological study|
467073|NCT00646126|Drug|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
467074|NCT00646126|Drug|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
467075|NCT00646113|Device|OsseoSpeed™ TX 3.0S|OsseoSpeed™ TX 3.0 mm diameter
467076|NCT00646100|Procedure|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
467077|NCT00646087|Drug|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
467078|NCT00646087|Drug|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
467079|NCT00646074|Behavioral|Self-Care Talk|6 conversational sessions
467080|NCT00646061|Drug|buscopan|
467081|NCT00646048|Device|TriVascular Stent-Graft System|TriVascular Stent-Graft System
467082|NCT00646035|Drug|paricalcitol capsules|baseline iPTH/60
467083|NCT00646009|Drug|budesonide/formoterol|
467084|NCT00646009|Drug|fluticasone/salmeterol|
467085|NCT00646009|Drug|albuterol|
467086|NCT00645996|Dietary Supplement|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
467087|NCT00645996|Dietary Supplement|Cornflor|Cornflour 2 gram daily
467088|NCT00645983|Dietary Supplement|Chamomile Extract|220 mg - 1100 mg daily
467089|NCT00645983|Other|Placebo|1 to 5 capsules daily
467090|NCT00645957|Procedure|penrose drain|incision and drainage of the infection with placement of a penrose drain
467091|NCT00645957|Procedure|red rubber drain|incision and drainage of infection and placement of a red rubber drain
467092|NCT00645944|Drug|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
467093|NCT00645944|Drug|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
467094|NCT00645931|Behavioral|protein and calorie controlled diet and self-hypnotic relaxation|daily
467095|NCT00645918|Drug|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
467096|NCT00645918|Drug|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
467097|NCT00645918|Drug|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
467098|NCT00645905|Drug|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
467099|NCT00645905|Drug|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
467100|NCT00645892|Drug|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
467101|NCT00645892|Drug|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
467102|NCT00645879|Drug|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
467103|NCT00645879|Drug|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
467104|NCT00645879|Drug|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
467105|NCT00645866|Drug|capecitabine|
467106|NCT00645866|Drug|docetaxel|
467107|NCT00645866|Drug|epirubicin hydrochloride|
467108|NCT00645866|Other|laboratory biomarker analysis|
467109|NCT00645866|Other|pharmacogenomic studies|
467110|NCT00645866|Procedure|biopsy|
467111|NCT00645866|Procedure|neoadjuvant therapy|
467112|NCT00645866|Procedure|therapeutic surgical procedure|
467113|NCT00645853|Drug|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
467114|NCT00645853|Drug|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
467115|NCT00645840|Drug|Anakinra|Patients will receive daily anakinra therapy for 28 days
467116|NCT00645827|Other|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
467117|NCT00645827|Other|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
467118|NCT00645814|Drug|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
467119|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
467120|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
467121|NCT00645801|Drug|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
467122|NCT00645801|Drug|Placebo|Amitiza Placebo
467123|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
467124|NCT00645788|Drug|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
467125|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
467126|NCT00645788|Drug|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
467127|NCT00645775|Dietary Supplement|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
467128|NCT00645762|Device|RS-Series Rhinosinusitis Treatment System|Single arm
467129|NCT00645762|Device|FinESS Balloon|
467130|NCT00645749|Biological|Helminth ova|2500 ova per dose (liquid form)
467131|NCT00645736|Other|No intervention|No intervention
467132|NCT00645723|Drug|Colistin|intravenous colistin and nebulized colistin
467133|NCT00645723|Drug|Colistin and saline solution|intravenous colistin and nebulized saline solution
467134|NCT00645710|Drug|gemcitabine hydrochloride|Given IV
467135|NCT00645710|Drug|floxuridine|Given via hepatic arterial infusion
467136|NCT00645710|Genetic|proteomic profiling|Correlative studies
467137|NCT00645710|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
467138|NCT00645710|Other|liquid chromatography|Correlative studies
467139|NCT00645710|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
467140|NCT00645710|Other|laboratory biomarker analysis|Correlative studies
467141|NCT00645710|Other|mass spectrometry|Correlative studies
467142|NCT00645710|Other|pharmacological study|Correlative studies
467143|NCT00645684|Procedure|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
467144|NCT00645671|Drug|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
467145|NCT00645671|Drug|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
467146|NCT00645658|Drug|Testim (1% testosterone gel)|Subjects apply contents of gel packet to skin daily.
467147|NCT00645632|Drug|cisplatin|
467148|NCT00645632|Drug|doxorubicin hydrochloride|
467149|NCT00645632|Drug|ifosfamide|
467150|NCT00645632|Drug|methotrexate|
467151|NCT00645632|Procedure|adjuvant therapy|
467152|NCT00645632|Procedure|neoadjuvant therapy|
467153|NCT00645632|Procedure|therapeutic conventional surgery|
467154|NCT00645606|Biological|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
467155|NCT00645593|Drug|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
467156|NCT00645593|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
467157|NCT00645593|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
467158|NCT00645580|Drug|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
467159|NCT00645567|Device|Unassisted Manual Transfer|No device assistance
467160|NCT00645567|Device|Standard Transfer Board|Flat surface board
467161|NCT00645567|Device|Glide n' Go|Flip down power lift chair
467162|NCT00645567|Device|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
467163|NCT00645567|Device|Ryno lift|Lift for the wheelchair
467164|NCT00645554|Drug|Galantamine oral solution|
467165|NCT00645541|Procedure|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
467166|NCT00645528|Other|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
467167|NCT00645515|Drug|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
467168|NCT00645515|Drug|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
467169|NCT00645502|Drug|risperidone|
467170|NCT00645489|Behavioral|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
467171|NCT00645489|Other|wait list|Wait list
467172|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
467173|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 alone
467174|NCT00645450|Drug|Propranolol|Weekly doses of short and long acting propranolol (Inderal, Inderal LA, Hemangeol, Inderal XL) following recollection of traumatic memory
467175|NCT00645450|Drug|Placebo|Weekly doses of placebo (inactive pill) following recollection of traumatic memory
467176|NCT00645437|Drug|Levofloxacin|
467177|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
467178|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
467179|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
467180|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
467181|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
467182|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
467183|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
467184|NCT00645398|Drug|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
467185|NCT00645398|Drug|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
467186|NCT00645398|Drug|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
467187|NCT00645398|Drug|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
467188|NCT00645385|Other|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.~Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
467189|NCT00645372|Drug|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
467190|NCT00645372|Drug|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
467191|NCT00645359|Procedure|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
467192|NCT00645346|Biological|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
467193|NCT00645346|Biological|Placebo|Subjects will receive one dose of placebo
467194|NCT00645333|Drug|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
467195|NCT00645320|Drug|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
467196|NCT00645307|Drug|Extended Release OROS® Paliperidone|
467197|NCT00645294|Drug|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
467198|NCT00645294|Drug|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
467199|NCT00645294|Drug|Adefovir Dipivoxil|ADV 10 mg on Day 1
467200|NCT00645281|Drug|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
467201|NCT00645268|Drug|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
467202|NCT00645268|Drug|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
467203|NCT00645268|Drug|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
467204|NCT00645255|Drug|placebo|placebo one capsule daily
467205|NCT00645255|Drug|sibutramine or placebo|one capsule daily
467206|NCT00645242|Drug|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
467207|NCT00645229|Drug|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
467208|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 alone for 21 days
467209|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
467210|NCT00645203|Drug|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
467211|NCT00645190|Drug|Galantamine HBr|
467212|NCT00645177|Drug|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
467213|NCT00645177|Drug|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
467214|NCT00645177|Drug|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
467215|NCT00645164|Other|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
467216|NCT00645164|Drug|Xenaderm|20 mg under Finn chambers
467217|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
467218|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
467219|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
467220|NCT00645138|Procedure|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
467221|NCT00645138|Procedure|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
467222|NCT00645125|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
467223|NCT00645125|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
467224|NCT00645112|Drug|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
467225|NCT00645112|Drug|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
467226|NCT00645099|Drug|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
467227|NCT00645099|Drug|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
467228|NCT00645086|Drug|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
467275|NCT00644774|Drug|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
467229|NCT00645086|Drug|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
467230|NCT00645073|Drug|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
467231|NCT00645073|Drug|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
467232|NCT00645060|Other|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
467233|NCT00645060|Other|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
467234|NCT00645060|Procedure|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
467235|NCT00645060|Procedure|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
467236|NCT00645060|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
467237|NCT00645047|Behavioral|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
467238|NCT00645047|Behavioral|In-Person CBT|In-Person Provision Of Cognitive Therapy
467239|NCT00645034|Drug|placebo|placebo by mouth as a single dose
467240|NCT00645034|Drug|sildenafil|sildenafil 100 mg by mouth as a single dose
467241|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
467242|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
467243|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
467244|NCT00644995|Behavioral|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
467245|NCT00644995|Behavioral|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
467246|NCT00644982|Drug|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
467247|NCT00644982|Drug|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
467248|NCT00644969|Drug|placebo|Randomization 2:1 treatment to placebo
467249|NCT00644969|Drug|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
467250|NCT00644956|Drug|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
467251|NCT00644956|Drug|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
467252|NCT00644943|Drug|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
467253|NCT00644943|Drug|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
467254|NCT00644930|Device|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
467255|NCT00644930|Device|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist—control or synchronized intermittent mandatory ventilation (SIMV) mode.
467256|NCT00644917|Drug|Xenaderm|20mg under Finn chambers
467257|NCT00644917|Drug|Placebo|20mg under Finn chambers
467258|NCT00644904|Dietary Supplement|Vitamin D3|
467259|NCT00644904|Dietary Supplement|Vitamin D3|
467260|NCT00644891|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
467261|NCT00644891|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
467262|NCT00644878|Drug|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
467263|NCT00644852|Other|Retrospective chart review study|Retrospective study chart review long acting risperidone
467264|NCT00644839|Drug|CP-945,598|Administration of CP-945,598 alone in period 1
467265|NCT00644839|Drug|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
467266|NCT00644826|Behavioral|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
467267|NCT00644813|Other|Scapular with glenoid neck fractures|
467268|NCT00644800|Drug|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
467269|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
467270|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
467271|NCT00644787|Drug|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
467272|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
467273|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
467274|NCT00644774|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
467276|NCT00644761|Drug|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
467277|NCT00644748|Drug|gabapentin|"Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
467278|NCT00644735|Drug|Esomeprazole|
467279|NCT00644735|Drug|Lansoprazole|
467280|NCT00644722|Device|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
467281|NCT00644722|Device|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
467282|NCT00644709|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
467283|NCT00644696|Drug|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
467284|NCT00644670|Drug|Atorvastatin|In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
467285|NCT00644670|Drug|Atorvastatin|In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
467286|NCT00644657|Drug|Clopidogrel|All subjects will receive a 300 mg loading dose
467287|NCT00644644|Other|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
467288|NCT00644631|Drug|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
467289|NCT00644631|Drug|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
467290|NCT00644618|Drug|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
467291|NCT00644618|Other|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
467292|NCT00644605|Drug|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
467293|NCT00644605|Drug|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
467294|NCT00644605|Drug|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
467295|NCT00644605|Drug|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
467296|NCT00644592|Drug|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
467297|NCT00644592|Drug|Fenofibrate|160 mg/day orally for 4 weeks
467298|NCT00644579|Drug|bLAC|bLAC high and low dose and placebo
467299|NCT00644579|Drug|Placebo|Placebo
467300|NCT00644566|Other|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
467301|NCT00644553|Drug|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
467302|NCT00644553|Drug|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
467303|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
467304|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.~Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.~Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
467305|NCT00644527|Other|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
467306|NCT00644527|Other|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
467452|NCT00643591|Other|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
467532|NCT00643032|Procedure|Perioperative administration near the nerve|
467307|NCT00644514|Biological|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
467308|NCT00644501|Drug|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
467309|NCT00644488|Drug|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
467310|NCT00644475|Drug|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
467311|NCT00644475|Drug|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
467312|NCT00644462|Device|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
467313|NCT00644449|Other|placebo|placebo
467314|NCT00644449|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
467315|NCT00644449|Other|placebo|placebo
467316|NCT00644449|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
467317|NCT00644436|Device|Tetrix|single topical application
467318|NCT00644436|Device|Tetrix|Single topical application
467319|NCT00644423|Drug|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
467320|NCT00644423|Drug|Placebo|Matching Placebo
467321|NCT00644410|Biological|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
467322|NCT00644410|Biological|Saline|12 injection with 0.2 ml saline
467323|NCT00644397|Device|95-degree Angled Blade Plate|
467324|NCT00644397|Device|4.5mm Condylar Locking Plate|
467325|NCT00644384|Drug|acitretin|
467326|NCT00644384|Genetic|gene expression analysis|
467327|NCT00644384|Genetic|northern blotting|
467328|NCT00644384|Genetic|polymerase chain reaction|
467329|NCT00644384|Genetic|protein expression analysis|
467330|NCT00644384|Other|laboratory biomarker analysis|
467331|NCT00644371|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen~Rituximab, 250 mg/m2 on days -21 and -14.~Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.~Chemotherapy:~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.~Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:~Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.~Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.~Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
467332|NCT00644358|Drug|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
467333|NCT00644332|Drug|Ranolazine|Oral dosage form.
467334|NCT00644319|Drug|ibuprofen|
467335|NCT00644319|Drug|morphine sulfate|
467336|NCT00644319|Procedure|management of therapy complications|
467337|NCT00644319|Procedure|pleurodesis|
467338|NCT00644306|Drug|Thalidomide|100 mg/day continuously for 18 months
467339|NCT00644306|Drug|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
467340|NCT00644306|Drug|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
467341|NCT00644293|Drug|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
467342|NCT00644293|Drug|placebo|placebo
467343|NCT00644293|Drug|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
467344|NCT00644293|Drug|placebo|placebo
467345|NCT00644280|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
467346|NCT00644267|Behavioral|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
467347|NCT00644254|Procedure|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
467348|NCT00644241|Biological|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
467349|NCT00644241|Procedure|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
467350|NCT00644228|Drug|Bortezomib|Given IV
467351|NCT00644228|Drug|Dexamethasone|Given PO
467352|NCT00644228|Other|Laboratory Biomarker Analysis|Optional correlative studies
467353|NCT00644228|Drug|Lenalidomide|Given PO
467354|NCT00644215|Drug|5-FU and Mitomycin|"5-FU injection 5mg~Mitomycin drop 0.02%"
467355|NCT00644202|Behavioral|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
467356|NCT00644202|Behavioral|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
467357|NCT00644202|Behavioral|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
467358|NCT00644189|Drug|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
467359|NCT00644176|Drug|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
467360|NCT00644176|Other|placebo|placebo
467361|NCT00644176|Drug|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
467362|NCT00644176|Other|placebo|placebo
467363|NCT00644163|Behavioral|Eban HIV/STD Risk Reduction Intervention|The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
469216|NCT00631189|Drug|Atorvastatin|10mg oral
467364|NCT00644163|Behavioral|Eban Health Promotion Intervention|The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
467365|NCT00644150|Behavioral|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
467366|NCT00644150|Drug|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
467367|NCT00644150|Behavioral|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
467368|NCT00644137|Drug|pregabalin|Help stop smoking
467369|NCT00644137|Other|cigarettes|help stop smoking with study medication
467370|NCT00644124|Drug|aflibercept|in combination with standard treatment R-CHOP
467371|NCT00644111|Drug|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
467372|NCT00644111|Drug|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
467373|NCT00644098|Dietary Supplement|soluble fibre complex and medium chain triglycerides|
467374|NCT00644098|Dietary Supplement|cellulose and soybean oil|
467375|NCT00644085|Drug|aspirin|oral administration of aspirin 100 mg
467376|NCT00644085|Drug|placebo|oral administration of placebo
467377|NCT00644072|Drug|SNX-5422|
467378|NCT00644059|Biological|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
467379|NCT00644059|Biological|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
467380|NCT00644059|Biological|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"Meningococcal vaccine: two IM injections~Tick-borne encephalitis vaccine: two IM injections"
467381|NCT00644046|Behavioral|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
467382|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
467383|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
467384|NCT00644033|Drug|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
467385|NCT00644020|Drug|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
467386|NCT00644007|Drug|Placebo|Placebo as a substitute of SK3530 100mg
467387|NCT00644007|Drug|SK3530|SK3530 100 mg
467388|NCT00643994|Radiation|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
467389|NCT00643981|Biological|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
467390|NCT00643968|Drug|EFV+TDF|
467391|NCT00643968|Drug|EFV+3TC+TDF|
467392|NCT00643955|Other|muscle strength|muscle strength
467393|NCT00643942|Other|No intervention required|
467394|NCT00643929|Drug|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
467395|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
467396|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
467397|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
467398|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
467399|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
467400|NCT00643916|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to <6 years of age)
467401|NCT00643903|Behavioral|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
467402|NCT00643903|Behavioral|Standard care|Participants will receive standard of care for HIV infections.
467453|NCT00643578|Drug|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
467403|NCT00643903|Behavioral|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
467404|NCT00643890|Genetic|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10^12 vector genomes in 35 uL.
467405|NCT00643877|Procedure|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
467406|NCT00643877|Procedure|surgery|radical surgery only
467407|NCT00643864|Behavioral|mirror training|"Training will be performed one-on-one by an investigator in a quiet room, one hour a day, five days a week, for four weeks. Attendance will be recorded. The mirror-box apparatus consists of an 18 x 24 vertical mirror secured in the center of a wooden platform. During training, the mirror-box will be placed on a table in front of the subject so that the mirror is perpendicular to the chest, slightly lateral of midline. Subjects will be asked to attend to the mirror reflection of their unaffected hand performing a series of tasks, while keeping their affected limb still. At the end of the four week training period, posttests will be administered by the same Occupational Therapist who performed the pretests."
467408|NCT00643851|Drug|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
467409|NCT00643851|Drug|Metformin XR|Tablets, Oral, Once daily, 24 weeks
467410|NCT00643838|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
467411|NCT00643825|Drug|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
467412|NCT00643825|Drug|Temozolomide|Observation till Progression then rechallenging with TMZ
467413|NCT00643812|Other|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
467414|NCT00643812|Other|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
467415|NCT00643799|Drug|Celecoxib|200 mg oral capsule once daily for 6 months
467416|NCT00643799|Drug|Naproxen|500 mg oral capsule twice daily for 6 months
467417|NCT00643799|Drug|Placebo|Matched oral placebo for 6 months
467418|NCT00643786|Drug|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
467419|NCT00643786|Drug|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
467420|NCT00643773|Dietary Supplement|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
467421|NCT00643773|Dietary Supplement|Wheat flour|Wheat flour
467422|NCT00643760|Drug|Placebo|placebo
467423|NCT00643760|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
467424|NCT00643760|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
467425|NCT00643760|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
467426|NCT00643760|Drug|Pregabalin|pregabalin 300mg/day
467427|NCT00643747|Biological|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
467428|NCT00643734|Drug|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
467429|NCT00643734|Other|placebo|placebo
467430|NCT00643734|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
467431|NCT00643734|Other|placebo|placebo
467432|NCT00643721|Other|dehydration|dehydration to 3% and 5% loss of total body water
467433|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
467434|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
467435|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
467436|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
467437|NCT00643695|Behavioral|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
467438|NCT00643695|Other|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
467439|NCT00643682|Other|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
467440|NCT00643669|Drug|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
467441|NCT00643656|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
467442|NCT00643656|Drug|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
467443|NCT00643643|Drug|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
467444|NCT00643643|Drug|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
467445|NCT00643643|Drug|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
467446|NCT00643643|Drug|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
467447|NCT00643643|Other|Placebo|Matching placebo oral tablet twice daily for 10 days
467448|NCT00643630|Device|Tetrix|Twice daily topical application
467449|NCT00643630|Device|Tetrix|Twice daily topical application
467450|NCT00643617|Radiation|CyberKnife Stereotactic Radiosurgery|38 Gy delivered in 4 fractions of 9.5 Gy per fraction
467451|NCT00643604|Drug|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
467454|NCT00643578|Drug|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
467455|NCT00643578|Device|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
467456|NCT00643565|Drug|Standard chemotherapy|As prescribed
467457|NCT00643565|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
467458|NCT00643539|Drug|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
467459|NCT00643539|Drug|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
467460|NCT00643526|Device|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
467461|NCT00643500|Drug|Levetiracetam|
467462|NCT00643487|Procedure|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
467463|NCT00643474|Device|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
467464|NCT00643474|Device|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
467465|NCT00643461|Device|Adhesive A|Applied per manufacturer's instructions.
467466|NCT00643461|Device|Adhesive B|Applied per manufacturer's instructions.
467467|NCT00643461|Device|Adhesive C|Applied per manufacturer's instructions.
467468|NCT00643448|Drug|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
467469|NCT00643448|Drug|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
467470|NCT00643448|Drug|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
467471|NCT00643435|Behavioral|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
467472|NCT00643435|Behavioral|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
467473|NCT00643422|Device|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
467474|NCT00643409|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
467475|NCT00643409|Other|placebo|placebo
467476|NCT00643409|Drug|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
467477|NCT00643409|Other|placebo|placebo
467478|NCT00643396|Radiation|thoracic radiotherapy|
467479|NCT00643383|Drug|Combination drug (Acetaminophen + Tramadol)|
467480|NCT00643383|Drug|Placebo|
467481|NCT00643370|Other|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
467482|NCT00643357|Drug|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
467483|NCT00643357|Drug|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
467484|NCT00643344|Behavioral|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
467485|NCT00643331|Behavioral|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
467486|NCT00643318|Radiation|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as < 2 cm from carina and < 2 cm from right and left mainstem bronchus and/or < 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)~Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
467487|NCT00643305|Behavioral|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
467488|NCT00643305|Behavioral|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
467489|NCT00643292|Drug|amoxicillin/clavulanate postassium (Augmentin ES-600)|amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
467490|NCT00643292|Drug|azithromycin SR|azithromycin SR 60 mg/kg x 1 dose
467528|NCT00643045|Drug|Safinamide|
467529|NCT00643045|Drug|Safinamide|
467530|NCT00643045|Drug|Placebo|
467531|NCT00643032|Procedure|Transcutaneous iliohypogastric|
467491|NCT00643279|Device|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead. The implantable hemodynamic monitoring device captures intracardiac hemodynamic information about the patient including trended right ventricular (RV) and estimated pulmonary arterial (PA) pressures, heart rate and activity data. The IHM device does not provide therapy, but rather provides intracardiac diagnostic information about the patient which the physician can utilize to manage the patient and the patients heart failure.
467492|NCT00643279|Other|Standard of Care|Surgical implantation of chronic ambulatory implantable hemodynamic monitoring (IHM) device and intracardiac pressure sensing lead, but physician and patient access to the intracardiac information provided by the device is restricted until the end of the randomized period of the study, at 6 months. Patients and patients heart failure are managed conventionally per standard of care.
467493|NCT00643266|Behavioral|Recollection Training|"Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session."
467494|NCT00643266|Behavioral|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
467495|NCT00643253|Behavioral|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
467496|NCT00643240|Radiation|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
467497|NCT00643240|Radiation|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
467498|NCT00643227|Drug|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
467499|NCT00643227|Drug|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
467500|NCT00643214|Device|Tetrix|Twice daily topical application
467501|NCT00643214|Device|Tetrix|Twice daily topical application
467502|NCT00643201|Drug|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
467503|NCT00643201|Drug|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
467504|NCT00643201|Drug|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
467505|NCT00643201|Drug|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
467506|NCT00643201|Drug|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
467507|NCT00643201|Drug|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
467508|NCT00643188|Procedure|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
467509|NCT00643188|Other|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
467510|NCT00643175|Behavioral|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
467511|NCT00643162|Drug|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
467512|NCT00643162|Behavioral|Light touch|Light touch twice a week, for 8 weeks
467513|NCT00643162|Behavioral|Massage|Massage twice a week, for 8 weeks.
467514|NCT00643149|Drug|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
467515|NCT00643149|Drug|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
467516|NCT00643136|Drug|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
467517|NCT00643136|Drug|Placebo|Matching placebo capsules twice daily for 28 days
467518|NCT00643123|Drug|Allopurinol|300-600 mg/day over a 6 week period
467519|NCT00643123|Other|Placebo|Inactive substance
467520|NCT00643110|Drug|D50 glucose|D50 glucose would be administered, if necessary.
467521|NCT00643097|Biological|PEP-3 vaccine|Given intradermally
467522|NCT00643097|Biological|sargramostim|Given intradermally
467523|NCT00643097|Drug|Temozolomide|Standard of care chemotherapy
467524|NCT00643084|Procedure|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
467525|NCT00643084|Procedure|standard bowel preparation|standard bowel preparation
467526|NCT00643071|Drug|Tacrolimus|Oral
467527|NCT00643058|Biological|LPS endotoxin|"Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated~High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated~Diluent Challenge: 3 X Sterile saline inhalation (2 ml)"
467533|NCT00643019|Behavioral|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
467534|NCT00643019|Other|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
467535|NCT00643006|Behavioral|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
467536|NCT00643006|Behavioral|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
467537|NCT00642993|Drug|SCH 497079|100 mg capsule administered orally
467538|NCT00642993|Drug|Placebo|Placebo capsules matching SCH 497079 administered orally
467539|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
467540|NCT00642980|Drug|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
467541|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
467542|NCT00642967|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|s.c. every 4 weeks (starting dose based on previous ESA therapy)
467543|NCT00642954|Drug|Comparator: vorinostat|"Dose escalation study. Level 1: 300 mg q.d. vorinostat p.o. for 14 days. Level 2,3, 4 & 5: 400 mg q.d. vorinostat p.o. for 14 days. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.~Participants who do not have disease progression and who continue to meet the eligibility criteria after the 8 cycles will be offered continued treatment at the same dose level and schedule."
467544|NCT00642954|Drug|Comparator: lenalidomide|Dose escalation study. Level 1 & 2: 10 mg q.d. lenalidomide p.o. for 21 days. Level 3: 15 mg q.d. lenalidomide p.o. for 21 days. Level 4: 20 mg q.d. lenalidomide p.o. for 21 days. Level 5: 25 mg q.d. lenalidomide p.o. for 21 days. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
467545|NCT00642954|Drug|Comparator: dexamethasone|Dose escalation study. 40 mg q.d. Dexamethasone p.o. will be given in each level on days 1, 8, 15, and 22 of each treatment cycle. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
467546|NCT00642941|Drug|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
467547|NCT00642928|Drug|Placebo|1 capsule per day during 4 weeks
467548|NCT00642928|Drug|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
467549|NCT00642928|Drug|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
467550|NCT00642928|Drug|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
467551|NCT00642928|Drug|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
467552|NCT00642915|Drug|Lantus, Amaryl|
467553|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
467554|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
467555|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
467556|NCT00642902|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
467557|NCT00642889|Drug|Safinamide|
467558|NCT00642889|Drug|Safinamide|
467559|NCT00642889|Drug|Placebo|
467560|NCT00642876|Device|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
467561|NCT00642876|Device|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
467562|NCT00642863|Dietary Supplement|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
467563|NCT00642863|Dietary Supplement|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
467564|NCT00642863|Dietary Supplement|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
467565|NCT00642850|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
467566|NCT00642837|Drug|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
467567|NCT00642837|Drug|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
467568|NCT00642837|Drug|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
467569|NCT00642837|Drug|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
467570|NCT00642837|Drug|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
467571|NCT00642837|Drug|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
467572|NCT00642837|Drug|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
467573|NCT00642837|Drug|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
467574|NCT00642837|Drug|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
467575|NCT00642837|Drug|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
467576|NCT00642824|Drug|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
467577|NCT00642824|Drug|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
467578|NCT00642811|Drug|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
467579|NCT00642811|Drug|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
467580|NCT00642811|Drug|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
467581|NCT00642798|Drug|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
467582|NCT00642772|Other|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
467583|NCT00642759|Drug|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
467584|NCT00642759|Drug|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
467585|NCT00642759|Drug|Bevacizumab|IV infusion
467586|NCT00642746|Drug|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.~Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
467587|NCT00642746|Drug|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
467588|NCT00642746|Drug|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
467589|NCT00642746|Drug|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
467590|NCT00642746|Drug|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
467591|NCT00642733|Drug|erlotinib [Tarceva]|100mg po daily
467592|NCT00642733|Drug|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
467593|NCT00642720|Drug|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
467594|NCT00642707|Drug|PRO 140 (humanized monoclonal antibody to CCR5)|
467595|NCT00642707|Drug|Placebo Comparator|
467596|NCT00642694|Drug|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
467597|NCT00642694|Drug|Ramelteon|Ramelteon 8 mg qd
467598|NCT00642694|Other|Placebo|Matching placebo qd
467599|NCT00642681|Drug|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
467600|NCT00642668|Drug|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
467601|NCT00642655|Drug|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
467602|NCT00642642|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
467603|NCT00642642|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.~Administration of 3 study treatments administered 14 ± 7 days apart."
467604|NCT00642629|Drug|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
467605|NCT00642629|Drug|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
467606|NCT00642616|Drug|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
467607|NCT00642616|Drug|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
467608|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
467609|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
467610|NCT00642603|Drug|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
467611|NCT00642603|Drug|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
467612|NCT00642603|Drug|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
467613|NCT00642577|Drug|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
467614|NCT00642577|Drug|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
467615|NCT00642577|Drug|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
467616|NCT00642577|Drug|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
467617|NCT00642564|Other|Observational study in Epileptic Patients|Observation study in Epileptic Patients with Migraine and Headache
467618|NCT00642551|Dietary Supplement|menaquinone-7|180 µg menaquinone-7 daily for three years
467619|NCT00642551|Dietary Supplement|placebo|1 placebo capsule daily for three years
467620|NCT00642538|Drug|MKC253 Inhalation Powder|Inhalation Powder, prandial
467621|NCT00642538|Drug|Technosphere Inhalation Powder|Inhalation Powder, prandial
467622|NCT00642538|Drug|subcutaneous injection|10µg Exenatide, prandial
467623|NCT00642525|Procedure|Contrast swallow radiography, endoscopy|Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
467624|NCT00642512|Drug|dronabinol|10 - 20 mg
467625|NCT00642512|Drug|ondansetron|8 - 16 mg
467626|NCT00642512|Drug|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
467627|NCT00642512|Drug|placebo|placebo
467628|NCT00642499|Drug|Dronabinol|2.5 mg to 40 mg
467629|NCT00642499|Drug|Placebo|placebo
467669|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
467630|NCT00642486|Other|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
467631|NCT00642486|Other|Standard polysomnography (PSG)|laboratory-based testing
467632|NCT00642473|Drug|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
467633|NCT00642473|Drug|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
467634|NCT00642473|Other|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
467635|NCT00642460|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (patients>=30kg) or 12mg/kg (patients <30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
467636|NCT00642460|Drug|Placebo|iv every 2 weeks for 12 weeks
467637|NCT00642460|Drug|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
467638|NCT00642460|Drug|methotrexate|as prescribed
467639|NCT00642460|Drug|corticosteroids|orally, as prescribed
467640|NCT00642447|Drug|helium:oxygen mixture|
467641|NCT00642434|Drug|carvedilol|variable
467642|NCT00642434|Drug|metoprolol|variable
467643|NCT00642421|Drug|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
467644|NCT00642421|Drug|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
467645|NCT00642408|Dietary Supplement|Multiple micronutrient supplements (MMN)|Iron and folic acid: iron 60 mg and folic acid 400µg
467646|NCT00642408|Dietary Supplement|IFA|Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
467647|NCT00642395|Drug|Bortezomib|bortezomib-Melphalan
467648|NCT00642382|Device|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
467649|NCT00642382|Device|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
467650|NCT00642369|Drug|quetiapine fumarate|600-750mg/day
467651|NCT00642369|Drug|haloperidol|6-40mg/day
467652|NCT00642356|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
467653|NCT00642356|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
467654|NCT00642343|Behavioral|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
467655|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
467656|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
467657|NCT00642343|Behavioral|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
467658|NCT00642330|Drug|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
467659|NCT00642330|Drug|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
467660|NCT00642317|Behavioral|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
467661|NCT00642304|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
467662|NCT00642291|Drug|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
467663|NCT00642291|Drug|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
467664|NCT00642278|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
467665|NCT00642278|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
467666|NCT00642278|Drug|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
467667|NCT00642265|Procedure|osteosynthesis|operative treatment
467668|NCT00642265|Other|sling|conservative treatment
467822|NCT00641173|Drug|placebo|treatment with placebo
467670|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
467671|NCT00642239|Drug|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
467672|NCT00642239|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
467673|NCT00642226|Procedure|Grid Laser|ETDRS Grid Laser
467674|NCT00642226|Procedure|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
467675|NCT00642200|Procedure|Lichtenstein hernioplasty|
467676|NCT00642200|Procedure|Laparoscopic TEP|
467677|NCT00642187|Drug|budesonide|
467678|NCT00642187|Drug|Placebo|
467679|NCT00642174|Drug|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
467680|NCT00642174|Drug|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
467681|NCT00642161|Drug|budesonide|
467682|NCT00642148|Drug|GW856553|Active tablet
467683|NCT00642148|Drug|Placebo|Placebo tablet and inhaler
467684|NCT00642148|Drug|Seretide|Active comparator inhaler
467685|NCT00642135|Drug|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
467686|NCT00642135|Drug|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
467687|NCT00642122|Drug|Budesonide|0.5mg once daily
467688|NCT00642122|Drug|Budesonide|1mg once daily
467689|NCT00642122|Drug|Budesonide|1mg twice daily
467690|NCT00642122|Drug|Budesonide|2mg once daily
467691|NCT00642122|Drug|Budesonide|4.00mcg twice daily
467692|NCT00642109|Procedure|midurethral sling procedure|quality of life, voiding dysfunction
467693|NCT00642096|Drug|Metoprolol Succinate|
467694|NCT00642096|Drug|Hydrochlorothiazide|
467695|NCT00642083|Device|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
467696|NCT00642057|Drug|tetrabenazine|25 mg titrated to optimal dose per patient
467697|NCT00642044|Procedure|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
467698|NCT00642031|Drug|Triciribine|15 mg/m^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
467699|NCT00642018|Drug|docetaxel|Docetaxel 75 milligrams per square meter (mg/m²) intravenously on Day 1 of a 21-day cycle. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
467700|NCT00642018|Drug|LY2181308 sodium|LY2181308 sodium (referred to as LY2181308 throughout this record) administered weekly plus docetaxel 75 mg/m² intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
467701|NCT00642018|Drug|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
467702|NCT00642005|Procedure|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
467703|NCT00642005|Procedure|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
467704|NCT00641979|Drug|budesonide|Current product
467705|NCT00641979|Device|Budesonide|New type device
467706|NCT00641979|Drug|Placebo|
467707|NCT00641953|Drug|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
467708|NCT00641953|Drug|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
467709|NCT00641953|Drug|Placebo|0.5 g topically BID to each foot for 4 weeks
467710|NCT00641940|Behavioral|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
467711|NCT00641940|Behavioral|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
467712|NCT00641927|Drug|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
467713|NCT00641927|Drug|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
467714|NCT00641914|Drug|budesonide|
467715|NCT00641914|Drug|Placebo|
467716|NCT00641901|Behavioral|counseling|"The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.~Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.~First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires."
467717|NCT00641875|Procedure|Nocturnal Hemodialysis|
467718|NCT00641862|Dietary Supplement|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
467719|NCT00641862|Other|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
467720|NCT00641849|Behavioral|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
467823|NCT00641160|Drug|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
467721|NCT00641849|Behavioral|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
467722|NCT00641836|Procedure|Transplantation of autologous endothelial progenitor cells|
467723|NCT00641810|Behavioral|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
467724|NCT00641797|Drug|Meclizine|medication administration 25mg PO one time
467725|NCT00641797|Other|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
467726|NCT00641797|Drug|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
467727|NCT00641797|Drug|Diphenhydramine|25 - 50mg PO/IV once prn
467728|NCT00641797|Drug|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
467729|NCT00641784|Drug|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
467730|NCT00641784|Drug|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
467731|NCT00641771|Drug|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
467732|NCT00641771|Drug|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
467733|NCT00641758|Drug|Pycnogenol|Pycnogenol 100mg twice daily
467734|NCT00641758|Drug|Placebo|Placebo 100mg twice daily
467735|NCT00641745|Drug|Lurasidone HCl|40 - 120mg per day
467736|NCT00641745|Drug|Risperidone|Risperidone
467737|NCT00641732|Drug|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
467738|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
467739|NCT00641732|Drug|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
467740|NCT00641732|Drug|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
467741|NCT00641732|Drug|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
467742|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
467743|NCT00641732|Drug|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
467744|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
467745|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
467746|NCT00641706|Drug|vorinostat|Given orally
467747|NCT00641706|Procedure|therapeutic conventional surgery|Patient undergoes surgery
467748|NCT00641706|Drug|bortezomib|Given IV
467749|NCT00641693|Drug|Budesonide|16mg Nasal Spray
467750|NCT00641693|Drug|Budesonide|32mg Nasal Spray
467751|NCT00641693|Drug|Budesonide|64mg Nasal Spray
467752|NCT00641693|Drug|Placebo|
467753|NCT00641680|Drug|Budesonide|
467754|NCT00641680|Drug|Fluticasone propionate|
467755|NCT00641680|Drug|Placebo|
467756|NCT00641667|Drug|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
467757|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
467758|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
467759|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
467760|NCT00641641|Drug|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
467761|NCT00641628|Procedure|mastectomy|
467762|NCT00641615|Biological|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
467763|NCT00641602|Drug|Esomeprazole|40mg once daily
467764|NCT00641602|Drug|Lansoprazole|30mg once daily
467765|NCT00641589|Drug|epoetin alfa|
467766|NCT00641576|Device|ACE CONNECT Endosseous dental implant|"Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.~Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration."
467767|NCT00641563|Drug|Dexmedetomidine|Infusion of dexmedetomidine
467768|NCT00641563|Drug|Midazolam|Midazolam infusion
467769|NCT00641563|Drug|Remifentanil|Infusion of remifentanil
467770|NCT00641550|Other|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
467771|NCT00641537|Drug|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
467772|NCT00641537|Drug|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
469271|NCT00630799|Drug|leuprolide acetate|17 mg i.m.
467773|NCT00641537|Drug|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
467774|NCT00641537|Drug|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
467775|NCT00641537|Drug|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
467776|NCT00641524|Procedure|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
467777|NCT00641511|Drug|SYN117 (nepicastat)|120 mg per day
467778|NCT00641511|Drug|Placebo comparator|once per day placebo capsules
467779|NCT00641498|Behavioral|Psychotherapy|Individual supportive
467780|NCT00641472|Drug|Budesonide inhalation suspension|0.5mg
467781|NCT00641472|Drug|Montelukast Sodium|4mg or 5mg
467782|NCT00641459|Other|Observational BPSD treatment study|Observational BPSD treatment study
467783|NCT00641446|Drug|budesonide|
467784|NCT00641446|Drug|varicella zoster virus|
467785|NCT00641433|Device|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
467786|NCT00641433|Drug|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
467787|NCT00641420|Procedure|Fractionated Laser Resurfacing|
467788|NCT00641407|Drug|NPL insulin|Starting dose 10 IU bedtime and then titration
467789|NCT00641407|Drug|Insulin glargine|10 IU bedtime and then titration
467790|NCT00641394|Behavioral|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
467791|NCT00641394|Behavioral|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
467792|NCT00641381|Drug|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
467793|NCT00641381|Drug|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
467794|NCT00641381|Drug|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
467795|NCT00641381|Other|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
467796|NCT00641381|Procedure|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
467797|NCT00641381|Procedure|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
467798|NCT00641368|Behavioral|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
467799|NCT00641368|Other|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
467800|NCT00641355|Procedure|No intervention|No intervention
467801|NCT00641342|Device|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
467802|NCT00641329|Drug|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
467803|NCT00641329|Drug|Placebo|Matching placebo tablets
467804|NCT00641316|Procedure|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
467805|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
467806|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
467807|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
467808|NCT00641303|Procedure|acupuncture therapy|Given weekly for 8 sessions
467809|NCT00641303|Procedure|sham intervention|Given weekly for 8 sessions
467810|NCT00641290|Device|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
467811|NCT00641264|Drug|Omeprazole|
467812|NCT00641264|Behavioral|Quality of Life questionnaire|
467813|NCT00641251|Other|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
467814|NCT00641251|Other|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
467815|NCT00641238|Device|Radiofrequency ablation|Radiofrequency ablation
467816|NCT00641225|Drug|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
467817|NCT00641212|Drug|Budesonide|
467818|NCT00641212|Drug|Placebo|
467819|NCT00641199|Other|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
467820|NCT00641186|Drug|sodium oxybate|4.5 to 9.0 grams per night
467821|NCT00641173|Drug|paroxetine|treatment with SSRI paroxetine
467824|NCT00641160|Drug|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
467825|NCT00641160|Drug|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
467826|NCT00641147|Drug|Curcumin|Given PO
467827|NCT00641147|Other|Laboratory Biomarker Analysis|Correlative studies
467828|NCT00641147|Other|Placebo|Given PO
467829|NCT00641134|Other|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
467830|NCT00641108|Drug|ADAM SPECT plus Cognitive Therapy|
467831|NCT00641108|Drug|ADAM SPECT plus No Therapy|
467832|NCT00641095|Biological|rituximab|concentrate for solution for infusion
467833|NCT00641095|Drug|Cyclophosphamide|Tablets
467834|NCT00641095|Drug|Fludarabine|Film coated tablet
467835|NCT00641082|Drug|Clevudine|30mg for 48 weeks
467836|NCT00641082|Drug|Adefovir dipivoxil|10mg for 48 weeks
467837|NCT00641069|Device|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
467838|NCT00641056|Drug|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
467839|NCT00641056|Drug|Insulin Glargine|subcutaneous injection, variable dose, QD
467840|NCT00641043|Drug|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
467841|NCT00641043|Drug|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
467842|NCT00641030|Drug|clofarabine|Administered at the appropriate dose level(dose level one = 30 mg/m2, dose level two and three = 40 mg/m2)on days -9 to day -5 from transplant
467843|NCT00641030|Drug|melphalan|Administered at the appropriate dose level (dose level one and two = 100 mg/m2, dose level three = 140 mg/m2) on day -4 from transplant
467844|NCT00641030|Genetic|gene expression analysis|Peripheral blood draw on day -9 and day -4 prior to transplant
467845|NCT00641030|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood draw on day -9 and day -4 prior to transplant
467846|NCT00641030|Other|flow cytometry|Bone marrow aspirate and biopsy to confirm diagnosis prior to transplant, day -9 pre-transplant, day 30 post-transplant, day 100 post-transplant, 6 months post-transplant, one year post-transplant, then yearly through year 5 post-transplant
467847|NCT00641030|Other|laboratory biomarker analysis|Peripheral blood draw day -9 or earlier pre-transplant, day 14 post-transplant, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, 6 months and one year post-transplant.
467848|NCT00641030|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of allogeneic hematopoietic stem cells on day 0 of transplant
467849|NCT00641017|Biological|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
467850|NCT00641017|Biological|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
467851|NCT00641004|Drug|Rebamipide and Esomeprazole|"Rebamipide 100mg TID for 12 weeks~Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks"
467852|NCT00640991|Drug|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
467853|NCT00640978|Drug|RAD001|30 mg orally weekly for 4 weeks
467854|NCT00640978|Drug|Erlotinib|150 mg by mouth daily for 28 Days
467855|NCT00640965|Drug|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
467856|NCT00640965|Drug|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
467857|NCT00640952|Drug|acamprosate|333 mg 2 tabs tid
467858|NCT00640939|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
467859|NCT00640939|Drug|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
467860|NCT00640926|Drug|Radezolid|300 mg/day, orally for 7-10 days
467861|NCT00640926|Drug|Radezolid|450 mg/day orally for 7-10 days
467862|NCT00640926|Drug|Radezolid|900 mg/day orally for 7-10 days
467863|NCT00640913|Procedure|Reversal of defunctioning stoma|Reversal of defunctioning stoma
467864|NCT00640900|Behavioral|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
467865|NCT00640900|Behavioral|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
467866|NCT00640887|Drug|rifabutin in combination with efavirenz|"Ia. arm 1a:~D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);~Ib. arm 1b:~D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);"
467867|NCT00640887|Drug|rifabutin in combination with nevirapine|"IIa. arm 2a:~D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);~IIb. arm 2b :~D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);"
467868|NCT00640887|Drug|rifabutin in combination with lopinavir/ritonavir|"IIIa. arm 3a :~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);~IIIb. arm 3b:~D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks)."
467869|NCT00640861|Biological|CpG oligodeoxynucleotide|
467870|NCT00640861|Biological|HER-2/neu peptide vaccine|
467871|NCT00640861|Biological|MUC-1 peptide vaccine|
467872|NCT00640861|Biological|incomplete Freund's adjuvant|
467873|NCT00640861|Biological|sargramostim|
467874|NCT00640861|Other|immunoenzyme technique|
467875|NCT00640861|Other|immunologic technique|
467876|NCT00640848|Drug|almorexant|1 dose of 400 mg in two treatment sequences
467877|NCT00640848|Drug|almorexant|1 dose of 200 mg in two treatment sequences
467878|NCT00640848|Drug|almorexant|1 dose of 100 mg in two treatment sequences
467879|NCT00640848|Drug|almorexant|1 dose of 50 mg mg in two treatment sequences
467880|NCT00640848|Drug|almorexant|1 dose of 1000 mg in two treatment sequences
467881|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
467882|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
467883|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
467884|NCT00640822|Drug|Tacalcitol Ointment|Once daily application for up to 8 weeks
467885|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
467886|NCT00640809|Drug|Celecoxib|200 mg oral capsule twice daily for 2 weeks
467887|NCT00640809|Other|Placebo|Matched placebo for 2 weeks
467888|NCT00640809|Drug|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
467889|NCT00640796|Procedure|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
467890|NCT00640796|Drug|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
467891|NCT00640796|Device|CliniMACS|Cell selection system based on magnetic-activated cell sorting
467892|NCT00640783|Behavioral|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
467893|NCT00640783|Behavioral|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, <30%).
467894|NCT00640770|Device|balloon angioplasty|balloon angioplasty
467895|NCT00640770|Device|drug eluting stent|Cypher Select+ Coronary or Infrapopliteal Stent
467896|NCT00640757|Dietary Supplement|Methionine deficient diet|Hominex with a low protein diet
467897|NCT00640757|Dietary Supplement|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
467898|NCT00640744|Drug|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
467899|NCT00640731|Device|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
467900|NCT00640705|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
467901|NCT00640705|Drug|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
467902|NCT00640679|Drug|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
467903|NCT00640679|Drug|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
467904|NCT00640666|Behavioral|Exercise Behavior Change|Multidisciplinary
467905|NCT00640653|Behavioral|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
467906|NCT00640653|Behavioral|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
467907|NCT00640653|Behavioral|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
467908|NCT00640653|Behavioral|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
467909|NCT00640653|Behavioral|Health promotion control intervention|"Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention."
467910|NCT00640640|Device|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
467911|NCT00640640|Drug|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
467912|NCT00640640|Drug|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
467913|NCT00640627|Drug|Celecoxib|200 mg oral capsule once daily for 6 weeks
467914|NCT00640627|Drug|Placebo|Matched oral placebo for 6 weeks
467915|NCT00640614|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
467982|NCT00640120|Device|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
467916|NCT00640601|Drug|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
467917|NCT00640588|Drug|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
467918|NCT00640588|Drug|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
467919|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
467920|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
467921|NCT00640562|Drug|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
467922|NCT00640562|Drug|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
467923|NCT00640549|Drug|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
467924|NCT00640549|Drug|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
467925|NCT00640523|Drug|forodesine HCl|2 x 100mg capsules daily
467926|NCT00640510|Drug|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
467927|NCT00640510|Drug|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
467928|NCT00640497|Biological|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
467929|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning~(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
467930|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning~(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
467931|NCT00640484|Drug|placebo|"placebo once a day, in the morning~(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
467932|NCT00640484|Drug|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening~(1 blister of Serevent Diskus BID)"
467933|NCT00640471|Biological|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
467934|NCT00640471|Drug|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
467935|NCT00640458|Drug|Sildenafil 100 mg|
467936|NCT00640458|Drug|Placebo|
467937|NCT00640445|Behavioral|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
467938|NCT00640445|Behavioral|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
467939|NCT00640432|Drug|Diclofenac|75 mg oral capsule twice daily for 7 days
467940|NCT00640432|Drug|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
467941|NCT00640419|Drug|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
467942|NCT00640419|Drug|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
467943|NCT00640406|Device|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
467944|NCT00640406|Drug|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
467945|NCT00640393|Drug|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
467946|NCT00640393|Device|nbUVB|
467947|NCT00640380|Other|Nerve stimulation|CPVB with NS
467948|NCT00640380|Other|Loss of resistance to air|CPVB with LOR
467949|NCT00640367|Other|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
467950|NCT00640367|Drug|Alteplase IV|intravenous recombinant tissue plasminogen activator
468030|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
467951|NCT00640354|Device|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
467952|NCT00640354|Device|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
467953|NCT00640341|Device|PureVision Contact Lens|contact lens for daily wear
467954|NCT00640341|Device|Acuvue Oasys Contact Lens|contact lens for daily wear
467955|NCT00640341|Device|O2Optix Contact lens|contact lens for daily wear
467956|NCT00640328|Drug|Ofatumumab 100|100mg
467957|NCT00640328|Drug|Ofatumumab 300|300mg
467958|NCT00640328|Drug|Ofatumumab 700|700mg
467959|NCT00640328|Drug|Placebo|matching placebo
467960|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
467961|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
467962|NCT00640289|Drug|Fibrogammin P|Prophylaxis treatment
467963|NCT00640276|Drug|pitavastatin|Pitavastatin 2mg daily once
467964|NCT00640276|Behavioral|Lifestyle Modification|conducting mainly exercises and diet
467965|NCT00640263|Drug|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
467966|NCT00640263|Drug|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.~The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
467967|NCT00640250|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2~Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
467968|NCT00640237|Dietary Supplement|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
467969|NCT00640224|Drug|rosiglitazone|4 mg daily for 6 months
467970|NCT00640224|Drug|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
467971|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
467972|NCT00640198|Behavioral|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
467973|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
467974|NCT00640198|Drug|placebo|Placebo
467975|NCT00640185|Drug|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
467976|NCT00640185|Drug|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
467977|NCT00640159|Drug|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
467978|NCT00640146|Drug|Methylnaltrexone bromide|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
467979|NCT00640146|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
467980|NCT00640133|Device|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
467981|NCT00640133|Device|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
467983|NCT00640094|Drug|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
467984|NCT00640081|Biological|cetuximab|
467985|NCT00640081|Drug|capecitabine|
467986|NCT00640081|Drug|fluorouracil|
467987|NCT00640081|Drug|leucovorin calcium|
467988|NCT00640081|Drug|oxaliplatin|
467989|NCT00640081|Other|immunohistochemistry staining method|
467990|NCT00640081|Other|laboratory biomarker analysis|
467991|NCT00640055|Other|Coordinator|Coordinator (non-physician) assigned cause of death
467992|NCT00640055|Other|Physician-assigned cause of death|Physician (gold standard) cause of death
467993|NCT00640042|Drug|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
467994|NCT00640029|Procedure|Arthrodesis|"posterior,~anterior,~circumference approach"
467995|NCT00640029|Device|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"SYNTHES : PRODISC-C® , PRODISC-L®~LDR : Mobi-C®, Mobidisc®~MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®~SCIENT'X : DISCOCERV®"
467996|NCT00640016|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
467997|NCT00640016|Biological|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
467998|NCT00640016|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
467999|NCT00640016|Other|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
468000|NCT00640003|Drug|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
468001|NCT00640003|Drug|Placebo|placebo drug
468002|NCT00639990|Other|PEEP|Application of positive end expiratory pressure
468003|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
468004|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
468005|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
468006|NCT00639977|Other|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
468007|NCT00639977|Other|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
468008|NCT00639964|Other|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
468009|NCT00639964|Other|diet questionnaire|questions about nutrition before and during pregnancy
468010|NCT00639964|Other|umbilical cord blood collect|collected at the delivery
468011|NCT00639964|Other|placenta collect|collected at the delivery
468012|NCT00639951|Biological|A|20 vials up front in a Single Dose of Antivipmyn
468013|NCT00639951|Biological|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
468014|NCT00639938|Drug|Nevirapine|200 mg Nevirapine tablet
468015|NCT00639938|Drug|HIV immune globulin solution|5% intravenous HIV immune globulin solution
468016|NCT00639925|Biological|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
468017|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
468018|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
468019|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
468020|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
468021|NCT00639899|Procedure|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
468022|NCT00639873|Drug|Artesunate|2 or 4 mg/kg/day for 7 days
468023|NCT00639873|Drug|quinine-doxycycline|quinine-doxycycline for 7 days
468024|NCT00639860|Device|OSSIX-Plus|resorbable collagen membrane
468025|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
468026|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
468027|NCT00639834|Biological|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
468028|NCT00639808|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
468029|NCT00639808|Drug|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
468070|NCT00639496|Drug|n-acetylcysteine|600 mg x 3, for 12 months
468071|NCT00639496|Drug|placebo|Placebo
468031|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
468032|NCT00639782|Device|On-X Heart valve replacement|On-X Heart valve replacement
468033|NCT00639782|Device|SJM Heart valve replacement|SJM Heart valve replacement
468034|NCT00639769|Drug|cisplatin|Starting dose 30 mg/m2 Dose level -1 20 mg/m2
468035|NCT00639769|Drug|irinotecan hydrochloride|50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
468036|NCT00639756|Drug|Allopurinol|Allopurinol 300 mg
468037|NCT00639756|Drug|Placebo|Placebo given for 2 weeks
468038|NCT00639743|Drug|placebo ( group B)|placebo ( group B)
468039|NCT00639743|Drug|tenecteplase (group A)|tenecteplase (group A)
468040|NCT00639730|Dietary Supplement|modified Atkins diet|High fat, low carbohydrate diet
468041|NCT00639717|Procedure|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
468042|NCT00639717|Drug|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
468043|NCT00639717|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
468044|NCT00639717|Drug|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
468045|NCT00639717|Drug|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped."
468046|NCT00639691|Biological|omalizumab|sc
468047|NCT00639678|Drug|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
468048|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
468049|NCT00639678|Drug|placebo|40 mg/kg placebo, single dose (day 0), Group 4
468050|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
468051|NCT00639665|Other|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
468052|NCT00639652|Procedure|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
468053|NCT00639652|Procedure|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
468054|NCT00639639|Biological|tetanus toxoid|Given by injection
468055|NCT00639639|Biological|therapeutic autologous dendritic cells|Given intradermally
468056|NCT00639639|Biological|therapeutic autologous lymphocytes|Given IV
468057|NCT00639626|Drug|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
468058|NCT00639613|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
468059|NCT00639613|Other|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
468060|NCT00639600|Procedure|human pancreatic islet transplantation|human pancreatic islet transplantation
468061|NCT00639587|Drug|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
468062|NCT00639587|Drug|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
468063|NCT00639574|Drug|Néfopam|"There are two groups :~a group N : néfopam~a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
468064|NCT00639561|Dietary Supplement|10 g of fibres per day|10 g of fibres per day
468065|NCT00639561|Dietary Supplement|40 g of fibres per day|40g of fibres per day
468066|NCT00639522|Drug|Liposomal paclitaxel and capecitabine|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
468067|NCT00639509|Biological|cixutumumab|Given IV
468068|NCT00639509|Procedure|computed tomography|Undergo contrast-enhanced computed tomography
468069|NCT00639509|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
468072|NCT00639483|Drug|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
468073|NCT00639483|Drug|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
468074|NCT00639470|Other|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
468075|NCT00639457|Drug|Pioglitazone|Oral 30mg/day for 16 weeks
468076|NCT00639457|Behavioral|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
468077|NCT00639444|Dietary Supplement|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
468078|NCT00639431|Behavioral|direct observation|direct observation of another person's foot moving
468079|NCT00639431|Behavioral|mental visualization|mentally imagining moving one's phantom foot/feet
468080|NCT00639418|Biological|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
468081|NCT00639392|Drug|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
468082|NCT00639392|Drug|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
468083|NCT00639379|Device|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
468084|NCT00639379|Device|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
468085|NCT00639366|Biological|trastuzumab|
468086|NCT00639366|Drug|chemotherapy|
468087|NCT00639366|Radiation|radiation therapy|
468088|NCT00639353|Device|senofilcon A toric soft contact lens|contact lens
468089|NCT00639353|Device|senofilcon A sphere soft contact lens|contact lens
468090|NCT00639327|Drug|S-1 + irinotecan|Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
468091|NCT00639327|Drug|irinotecan|Irinotecan 150mg/m2 iv on day one every two weeks until PD
468092|NCT00639314|Procedure|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
468093|NCT00639314|Procedure|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
468094|NCT00639301|Behavioral|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
468095|NCT00639288|Other|modified CPT-C|modified CPT-C
468096|NCT00639262|Drug|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
468097|NCT00639262|Drug|Temozolomide|For Cohort 2 - Gliomas only.
468098|NCT00639262|Radiation|Radiotherapy|Radiation Therapy (XRT)
468099|NCT00639249|Drug|placebo|Oral administration
468100|NCT00639249|Drug|SA4503 Low|Oral administration
468101|NCT00639249|Drug|SA4503 High|Oral administration
468102|NCT00639236|Other|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
468103|NCT00639223|Dietary Supplement|Red Yeast Rice|Four 600mg capsules twice daily for 12 weeks
468104|NCT00639223|Drug|Pravastatin|One 20mg capsule twice daily for 12 weeks
468105|NCT00639223|Behavioral|Lifestyle modification program|Weekly sessions each lasting 3 1/2 hours for 12 weeks
468106|NCT00639210|Other|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
468107|NCT00639197|Procedure|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
468108|NCT00639197|Procedure|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
468109|NCT00639184|Other|Early intervention counseling|Bi-monthly home visits by counselor
468110|NCT00639184|Other|Health education counseling|World Health Education health education counseling program at home visits,twice per month
468111|NCT00639158|Drug|ABT-335|135 mg capsule, daily, 12 weeks
468112|NCT00639158|Drug|placebo|placebo capsule, daily, 12 weeks
468113|NCT00639158|Drug|atorvastatin|40 mg, tablet, daily, 12 weeks
468114|NCT00639158|Drug|ezetimibe|10 mg capsule, daily, 12 weeks
468115|NCT00639119|Drug|Ropinirole|8 + 8 weeks cross-over placebo controlled
468116|NCT00639106|Procedure|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
468117|NCT00639106|Procedure|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
468118|NCT00639093|Behavioral|psychoeducational / motivational combined with crushing|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
468165|NCT00638781|Drug|Desmoteplase|Desmoteplase 90 µg/kg BW
468166|NCT00638781|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW
468167|NCT00638781|Drug|Placebo|Placebo
468119|NCT00639093|Behavioral|psychoeducational / motivational combined with control|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).~During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
468120|NCT00639080|Other|Stop lipid lowering therapy (statin)|Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
468121|NCT00639067|Device|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
468122|NCT00639054|Procedure|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
468123|NCT00639054|Procedure|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
468124|NCT00639041|Dietary Supplement|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
468125|NCT00639041|Dietary Supplement|Placebo|dairy products without special oils
468126|NCT00639028|Other|Ankle echography|Ankle echography
468127|NCT00639028|Other|Ankle echography + stress radiography|Ankle echography + stress radiography
468128|NCT00639028|Other|stress radiography|ankle stress radiography
468129|NCT00639015|Drug|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
468130|NCT00639015|Drug|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
468131|NCT00639002|Drug|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
468132|NCT00639002|Drug|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
468133|NCT00638989|Biological|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
468134|NCT00638989|Biological|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
468135|NCT00638989|Biological|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
468136|NCT00638976|Drug|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
468137|NCT00638976|Drug|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
468138|NCT00638963|Drug|temozolomide|Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles
468139|NCT00638950|Dietary Supplement|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
468140|NCT00638950|Dietary Supplement|Placebo|The placebo products were commercial dairy products with comparable fat contents.
468141|NCT00638937|Drug|saracatinib|Given PO
468142|NCT00638924|Other|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
468143|NCT00638898|Drug|busulfan|Given IV
468144|NCT00638898|Drug|melphalan|Given IV
468145|NCT00638898|Drug|topotecan hydrochloride|Given IV
468146|NCT00638898|Other|laboratory biomarker analysis|Correlative studies
468147|NCT00638898|Biological|filgrastim|Given IV or subcutaneously
468148|NCT00638898|Procedure|autologous hematopoietic stem cell transplantation|Undergo transplantation
468149|NCT00638898|Other|pharmacological study|Correlative studies
468150|NCT00638898|Procedure|autologous bone marrow transplantation|Undergo transplantation
468151|NCT00638872|Drug|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
468152|NCT00638872|Other|0.9% NaCl|same as PDRN
468153|NCT00638859|Drug|Telithromycin (HMR3647)|
468154|NCT00638846|Device|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
468155|NCT00638846|Device|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
468156|NCT00638833|Drug|Memantine|Memantine 30 mg/day (20-10-0)
468157|NCT00638833|Drug|Placebo|Placebo pills
468158|NCT00638820|Procedure|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
468159|NCT00638820|Drug|Campath, Busulfan, Clofarabine|"12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours~11 Campath-1H 0.3 mg/kg intravenously over 2 hours~10 Campath-1H 0.3 mg/kg intravenously over 2 hours~9 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~8 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours~7 Rest~6 Clofarabine 40 mg/m2 intravenously over 2 hours~5 Clofarabine 40 mg/m2 intravenously over 2 hours~4 Clofarabine 40 mg/m2 intravenously over 2 hours~3 Clofarabine 40 mg/m2 intravenously over 2 hours~2 Clofarabine 40 mg/m2 intravenously over 2 hours"
468160|NCT00638820|Procedure|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
468161|NCT00638807|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
468162|NCT00638807|Other|Placebo|Matched oral placebo for 6 weeks
468163|NCT00638794|Device|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
468164|NCT00638781|Drug|Desmoteplase|Desmoteplase 62.5 µg/kg BW
468168|NCT00638768|Other|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
468169|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
468170|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
468171|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
468172|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
468173|NCT00638742|Drug|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
468174|NCT00638729|Drug|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
468175|NCT00638729|Drug|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
468176|NCT00638729|Drug|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
468177|NCT00638716|Drug|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
468178|NCT00638716|Drug|Placebo|Placebo
468179|NCT00638703|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU Oxalobacter formigenes twice daily for 24 weeks
468180|NCT00638703|Drug|Placebo|placebo
468181|NCT00638690|Drug|Placebo|Four tablets once daily until disease progression
468182|NCT00638690|Drug|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
468183|NCT00638690|Drug|Prednisone/prednisolone|5 mg twice daily until disease progression
468184|NCT00638677|Dietary Supplement|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
468185|NCT00638677|Dietary Supplement|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
468186|NCT00638677|Dietary Supplement|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
468187|NCT00638651|Device|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
468188|NCT00638651|Drug|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
468189|NCT00638638|Drug|Abciximab|"Abciximab: 0.25 mg/Kg bolus~Abciximab placebo bolus~Abciximab infusion 10 µg/Kg/min"
468190|NCT00638638|Drug|Abciximab placebo|"Abciximab placebo Bolus~Abciximab: 0.25 mg/Kg bolus~Abciximab infusion 10 µg/Kg/min"
468191|NCT00638612|Biological|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
468192|NCT00638612|Drug|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
468193|NCT00638599|Device|LMA®|LMA® is placed after anesthesia induction and removed after the operation
468194|NCT00638599|Device|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
468195|NCT00638560|Dietary Supplement|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
468196|NCT00638560|Dietary Supplement|Antioxidant treatment|no treatment
468197|NCT00638547|Drug|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.~Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
468198|NCT00638534|Drug|Telithromycin (HMR3647)|
468199|NCT00638508|Drug|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
468200|NCT00638508|Drug|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
468201|NCT00638495|Drug|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
468202|NCT00638495|Drug|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
468203|NCT00638482|Drug|Hydrochlorothiazide|Hydrochlorothiazide
468204|NCT00638469|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
468205|NCT00638469|Other|No treatment|no UV exposure
468206|NCT00638456|Drug|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
468207|NCT00638456|Drug|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
468208|NCT00638443|Drug|Pregabalin|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
468209|NCT00638443|Drug|Diphenhydramine|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
468210|NCT00638417|Behavioral|Maximal strength training|maximal dynamic strength training from 1 week after the operation, 5 training bouts a week for 4 weeks. The regimen consisted of 2 exercises, leg press and hip abduction, that included 4 series of 5RM involving the operated leg only. 5RM corresponds to approximately 85% of 1RM. When the patients managed to perform 6RM, the load was increased by 5kg. The series were separated by resting periods of 2 minutes.
468261|NCT00637988|Drug|Aspirin|
468262|NCT00637988|Drug|Rofecoxib|25mg once daily
468263|NCT00637975|Drug|oxycodone|"Arm A - 20 mg/day~Arm B - increasing dose startnig at 20 mg/day~For 15 days or until unacceptable toxicity develops."
469272|NCT00630786|Drug|Panitumumab|Administered by intravenous infusion
468211|NCT00638417|Behavioral|conventional rehabilitation|conventional rehabilitation program: inpatient treatment in a rehabilitation center. Individual sling exercise therapy in hip abduction/adduction, hip flexion/extension, exercises with low resistance (>12-15 repetitions37), or no resistance and exercises performed in water when sutures had been removed. Each session lasted 1 hour and was performed 5 days a week for 4 weeks.
468212|NCT00638391|Drug|Anastrozole|
468213|NCT00638378|Drug|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
468214|NCT00638365|Biological|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
468215|NCT00638365|Other|Placebo|Placebo single-dose administered intravenously
468216|NCT00638326|Drug|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
468217|NCT00638326|Drug|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
468218|NCT00638313|Biological|Placebo|Subjects will be given either Placebo or PF-04603629.
468219|NCT00638313|Biological|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
468220|NCT00638300|Device|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
468221|NCT00638300|Other|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
468222|NCT00638300|Other|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
468223|NCT00638274|Procedure|Air|3 mls used for identifying epidural space
468224|NCT00638274|Procedure|Saline|3 mls of saline used to identify epidural space
468225|NCT00638261|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
468226|NCT00638248|Drug|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
468227|NCT00638248|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
468228|NCT00638248|Drug|Placebo|Placebo i.v. bolus
468229|NCT00638235|Device|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
468230|NCT00638235|Device|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
468231|NCT00638235|Device|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
468232|NCT00638235|Device|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
468233|NCT00638235|Device|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
468234|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
468235|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
468236|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
468237|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
468238|NCT00638222|Other|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
468239|NCT00638209|Drug|Human insulin|
468240|NCT00638209|Drug|Saline|
468241|NCT00638196|Drug|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
468242|NCT00638170|Biological|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
468243|NCT00638170|Biological|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
468244|NCT00638157|Drug|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
468245|NCT00638157|Drug|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
468246|NCT00638131|Drug|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
468247|NCT00638118|Drug|Fexofenadine|
468248|NCT00638092|Drug|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
468249|NCT00638092|Drug|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
468250|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
468251|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
468252|NCT00638066|Drug|botulinum toxin|500 units of botulinum toxin for the second arm
468253|NCT00638066|Drug|botulinum toxin A|250 units of botulinum toxin A once
468254|NCT00638053|Genetic|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
468255|NCT00638027|Drug|placebo|matched tablets bid
468256|NCT00638027|Drug|memantine|10 mg bid
468257|NCT00638014|Device|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
468258|NCT00638014|Device|Conventional wire closure|Conventional wire closure of sternum
468259|NCT00638001|Device|custom-molded insoles and custom-molded shoes|"custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy~custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
468260|NCT00637988|Drug|Esomeprazole|40mg twice daily
468264|NCT00637975|Drug|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day~Arm B - pregabalin 50 mg/day~For 15 days or until unacceptable toxicity develops."
468265|NCT00637962|Biological|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
468266|NCT00637962|Biological|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
468267|NCT00637949|Device|lumiracoxib|400 mg once daily, oral over 6 weeks
468268|NCT00637949|Drug|rofecoxib|25 mg, oral, daily over 6 weeks
468269|NCT00637936|Drug|Oxygen|Inspiratory fraction during anaesthesia
468270|NCT00637923|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
468271|NCT00637923|Drug|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
468272|NCT00637923|Biological|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
468273|NCT00637923|Drug|Ribavirin|Weight-based ribavirin for 48 weeks.
468274|NCT00637910|Drug|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
468275|NCT00637910|Drug|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
468276|NCT00637897|Drug|docetaxel|
468277|NCT00637897|Drug|ixabepilone|
468278|NCT00637897|Drug|paclitaxel|
468279|NCT00637897|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
468280|NCT00637897|Drug|paricalcitol|
468281|NCT00637884|Drug|Fexofenadine HCl|
468282|NCT00637871|Drug|Casodex|150mg once daily
468283|NCT00637871|Drug|Tamoxifen|
468284|NCT00637858|Dietary Supplement|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
468285|NCT00637858|Dietary Supplement|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
468286|NCT00637858|Dietary Supplement|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
468287|NCT00637858|Dietary Supplement|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
468288|NCT00637858|Other|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
468289|NCT00637845|Drug|Esomeprazole Magnesium|40mg once daily
468290|NCT00637845|Drug|Lansoprazole|30mg twice daily
468291|NCT00637832|Biological|rituximab|
468292|NCT00637832|Drug|cyclophosphamide|
468293|NCT00637832|Drug|doxorubicin hydrochloride|
468294|NCT00637832|Drug|prednisolone|
468295|NCT00637832|Drug|vincristine sulfate|
468296|NCT00637832|Radiation|yttrium Y 90 ibritumomab tiuxetan|
468297|NCT00637819|Drug|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
468298|NCT00637806|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
468299|NCT00637806|Drug|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
468300|NCT00637806|Drug|Placebo|Placebo oral suspension, 5 mL once daily
468301|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
468302|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
468303|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
468304|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
468305|NCT00637780|Drug|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
468306|NCT00637767|Drug|melphalan|
468307|NCT00637767|Procedure|autologous hematopoietic stem cell transplantation|
468308|NCT00637767|Radiation|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
468309|NCT00637741|Device|Everflex 200|
468310|NCT00637728|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
468311|NCT00637728|Drug|Placebo|Placebo oral suspension, 5 mL once daily
468312|NCT00637715|Drug|Alfuzosin|
468313|NCT00637702|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
468314|NCT00637676|Procedure|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
468315|NCT00637676|Procedure|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
468316|NCT00637663|Drug|Entecavir|entecavir 0.5 mg QD
468317|NCT00637663|Drug|Lamivudine|lamivudine 100 mg QD
468318|NCT00637650|Procedure|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
468319|NCT00637650|Procedure|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
468320|NCT00637637|Drug|indinavir sulfate|
468321|NCT00637637|Drug|ritonavir|
468322|NCT00637637|Radiation|radiation therapy|
468323|NCT00637624|Drug|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
468324|NCT00637624|Drug|Placebo|Placebo once every 3 weeks intravenous saline fluid
468326|NCT00637598|Radiation|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
468327|NCT00637585|Drug|Fexofenadine|
468328|NCT00637572|Drug|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
468329|NCT00637572|Drug|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
468330|NCT00637559|Drug|Esomeprazole Magnesium|
468331|NCT00637546|Other|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
468332|NCT00637533|Procedure|Lumbar sympathetic block with Botulinum Toxin type A|
468333|NCT00637507|Other|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., >10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 >150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
468334|NCT00637494|Drug|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
468335|NCT00637494|Drug|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
468336|NCT00637481|Drug|atorvastatin calcium|Given orally
468337|NCT00637481|Other|laboratory biomarker analysis|Correlative studies
468338|NCT00637468|Drug|Intravenous injection of heparin|
468339|NCT00637468|Drug|Intravenous injection of acetazolamide|
468340|NCT00637468|Procedure|Local intra-arterial fibrinolysis|
468341|NCT00637468|Procedure|Globe massage|
468342|NCT00637468|Drug|Topical use of beta-blocker|
468343|NCT00637468|Drug|Isovolaemic haemodilution|
468344|NCT00637468|Drug|Acetylsalicylic acid|
468345|NCT00637455|Drug|fexofenadine HCl|
468346|NCT00637442|Drug|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
468347|NCT00637416|Drug|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
468348|NCT00637416|Other|Placebo|placebo taken by mouth daily for 3 months
468349|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr >80 mL/min)
468350|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
468351|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - <50 mL/min)
468352|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr <30 mL/min and not on hemodialysis)
468353|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
468354|NCT00637390|Drug|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
468355|NCT00637377|Drug|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
468356|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
468357|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
468358|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
468359|NCT00637364|Procedure|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).~The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
468360|NCT00637351|Procedure|Blood sample|One blood sample will be collected at the time of screening for subjects
468361|NCT00637351|Procedure|Urine sample|One urine sample will be collected at the time of screening for subjects
469273|NCT00630786|Drug|Conatumumab|Administered by intravenous infusion
468362|NCT00637338|Biological|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
468363|NCT00637338|Biological|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
468364|NCT00637325|Drug|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
468365|NCT00637312|Device|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
468366|NCT00637312|Device|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
468367|NCT00637299|Other|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
468368|NCT00637299|Other|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
468369|NCT00637286|Drug|Zolmitriptan|5mg Nasal Spray
468370|NCT00637273|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
468371|NCT00637273|Drug|sitagliptin|oral tablet, 100mg, once a day
468372|NCT00637273|Drug|pioglitazone|oral tablet, 45mg, once a day
468373|NCT00637273|Drug|placebo tablet|oral tablet, once a day
468374|NCT00637273|Drug|placebo once weekly|subcutaneous injection, once a week
468375|NCT00637260|Device|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
468376|NCT00637260|Device|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
468377|NCT00637247|Drug|imexon in combination with gemcitabine|875 mg/m^2 imexon IV + 1000 mg/m^2 gemcitabine IV
468378|NCT00637247|Drug|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m^2 gemcitabine IV
468379|NCT00637234|Drug|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
468380|NCT00637234|Drug|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
468381|NCT00637221|Drug|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
468382|NCT00637208|Procedure|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
468383|NCT00637195|Biological|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
468384|NCT00637195|Biological|Engerix™|Intramuscular administration, 4 doses.
468385|NCT00637182|Drug|Anastrozole|
468386|NCT00637169|Other|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
468387|NCT00637156|Device|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
468388|NCT00637156|Device|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
468389|NCT00637143|Drug|Tacrolimus|Oral
468390|NCT00637143|Drug|Cyclosporine|Oral
468391|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0008%|
468392|NCT00637130|Drug|Travoprost ophthalmic solution, 0.001%|
468393|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0012%|
468394|NCT00637130|Drug|TRAVATAN|
468395|NCT00637130|Other|Vehicle|
468396|NCT00637117|Biological|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
468397|NCT00637104|Device|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
468398|NCT00637104|Device|Vision Co-Cr stent implant|Implant of the Vision stent
468399|NCT00637091|Drug|Cetuximab, irinotecan|cetuximab, irinotecan
468400|NCT00637078|Other|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
468401|NCT00637065|Drug|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
468402|NCT00637065|Drug|Placebo|Placebo tables - identical to active drug but without the active ingredient -
468403|NCT00637052|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
468404|NCT00637039|Drug|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
468405|NCT00637026|Drug|Gefitinib|Iressa
468406|NCT00637013|Procedure|Acromioplasty|Arthroscopic or open acromioplasty
468407|NCT00637013|Procedure|Physiotherapy|Physiotherapy according to a standardized protocol
468408|NCT00637000|Drug|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
468409|NCT00637000|Drug|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
468410|NCT00637000|Drug|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
468411|NCT00636987|Device|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
468412|NCT00636974|Procedure|Combined spinal epidural anaesthesia|
468413|NCT00636961|Drug|Indacaterol 300μg|300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
468414|NCT00636961|Drug|Placebo|Matching placebo devices and hard gelatin capsules
468415|NCT00636935|Drug|Antibiotics only|Antibiotic only for treatment for mild (pO2 > 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
468416|NCT00636935|Drug|Antibiotics + Corticosteroids|Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
468417|NCT00636935|Drug|Corticosteroids + antibiotics|Drugs will be prescribed per standard of care for patients with PCP and pO2 < 70mmHg.
468418|NCT00636922|Drug|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
468419|NCT00636909|Drug|Cyclophosphamide|preparative cytoreduction
468420|NCT00636909|Drug|fludarabine|preparative cytoreduction
468421|NCT00636909|Drug|cyclosporine|immunosuppressive therapy
468422|NCT00636909|Drug|methotrexate|immunosuppressive therapy
468423|NCT00636909|Biological|G-CSF|foster engraftment
468424|NCT00636896|Drug|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
468425|NCT00636896|Drug|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
468426|NCT00636883|Drug|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
468427|NCT00636870|Drug|Fexofenadine|
468428|NCT00636857|Procedure|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
468429|NCT00636857|Procedure|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
468430|NCT00636831|Drug|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
468431|NCT00636818|Drug|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
468432|NCT00636805|Drug|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
468433|NCT00636792|Drug|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
468434|NCT00636792|Drug|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
468435|NCT00636792|Drug|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
468436|NCT00636766|Drug|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
468437|NCT00636766|Drug|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
468438|NCT00636766|Drug|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
468439|NCT00636766|Drug|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
468440|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
468441|NCT00636740|Drug|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
468442|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
468443|NCT00636727|Procedure|arthrocentesis|Irrigate the TMJ with lactated ringers
468444|NCT00636727|Procedure|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
468445|NCT00636727|Procedure|arthroplasty|The disc will be surgically repositioned with open surgery
468446|NCT00636714|Behavioral|Nursing judgement|Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
469326|NCT00630435|Drug|Premarin®/MPA formulation A|
468447|NCT00636714|Behavioral|Nomogram|A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
468448|NCT00636701|Device|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
468449|NCT00636688|Behavioral|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
468450|NCT00636688|Behavioral|Control - general information|General information about healthy food choices and exercise
468451|NCT00636675|Behavioral|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:~In-House Falls Coordinator training on content and falls processes.~Case-based modules about fall prevention and tailored for various team members.~Academic Detailing in which researcher consults with staff regarding challenging residents with falls.~Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.~Toolbox: Handbook of useful measures and worksheets."
468452|NCT00636675|Behavioral|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:~In-class learning sessions introduce interaction strategies.~Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.~Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
468453|NCT00636662|Other|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
468454|NCT00636649|Drug|Escitalopram|10-20 mg
468455|NCT00636649|Drug|Placebo|Placebo
468456|NCT00636636|Drug|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
468457|NCT00636636|Drug|Placebo|Once daily; 300 mg and 600 mg tablets
468458|NCT00636623|Other|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
468459|NCT00636623|Other|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
468460|NCT00636610|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
468461|NCT00636610|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
468462|NCT00636610|Drug|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
468463|NCT00636610|Drug|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
468464|NCT00636610|Drug|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then fluorouracil 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
468465|NCT00636584|Drug|sodium nitroprusside|sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
468466|NCT00636584|Drug|placebo|placebo
468467|NCT00636571|Behavioral|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
468468|NCT00636558|Drug|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
468469|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
468470|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
468471|NCT00636519|Biological|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
468472|NCT00636519|Biological|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
468473|NCT00636506|Device|AMS 700 IPP with MS Pump|AMS 700 Series Inflatable Penile Prosthesis with MS Pump
468474|NCT00636493|Device|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
468475|NCT00636480|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
468476|NCT00636480|Drug|ChloraPrep One Step|Administer topically
468477|NCT00636480|Drug|Sterile saline|0.9% NaCl solution
468478|NCT00636467|Other|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
468479|NCT00636454|Behavioral|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
468480|NCT00636454|Other|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
468481|NCT00636441|Drug|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
468482|NCT00636428|Drug|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
468483|NCT00636415|Drug|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
468484|NCT00636402|Procedure|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
468485|NCT00636402|Procedure|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
468486|NCT00636389|Device|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
468487|NCT00636389|Device|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
468488|NCT00636376|Procedure|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
468489|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
468490|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
468491|NCT00636363|Device|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
468492|NCT00636350|Dietary Supplement|Pepper|pepper carotenoids as meals
468493|NCT00636337|Behavioral|Attention Training|Computer program training for attention difficulties.
468494|NCT00636337|Behavioral|Placebo|Comparison computer program
468495|NCT00636324|Device|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
468496|NCT00636324|Device|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
468497|NCT00636311|Drug|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
468498|NCT00636311|Drug|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
468499|NCT00636298|Drug|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly~Bevacizumab - 10 mg/kg every 2 weeks"
468500|NCT00636285|Drug|Placebo|Placebo
468501|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
468502|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
468503|NCT00636259|Drug|Bicalutamide (Casodex)|150mg
468504|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg [S,S]-reboxetine for 5 and one half weeks.
468505|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg [S,S]-reboxetine for 5 and one half weeks.
468506|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
468507|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
468508|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks.
468509|NCT00636246|Drug|Placebo|Tablets, orally once per day for 8 weeks
468510|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks
468511|NCT00636246|Drug|[S,S]-reboxetine monotherapy|Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
468512|NCT00636207|Drug|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
468513|NCT00636207|Drug|Placebo|Placebo dry powder inhaler
468514|NCT00636194|Device|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
468515|NCT00636194|Device|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
468516|NCT00636181|Device|Auto AFlex|Positive pressure therapy treatment
468517|NCT00636181|Device|Auto CPAP|Positive pressure therapy treatment
468518|NCT00636181|Device|CPAP|Positive pressure therapy treatment
468519|NCT00636168|Drug|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
468520|NCT00636168|Drug|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
468521|NCT00636155|Drug|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
468522|NCT00636155|Drug|Rituximab|375 mg/m2 on day 2
468523|NCT00636155|Drug|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
468524|NCT00636155|Drug|Fludarabine|25 mg/m2 on days 2, 3, and 4
468525|NCT00636142|Biological|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
468526|NCT00636129|Behavioral|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
468527|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
468528|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
468529|NCT00636116|Biological|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
468608|NCT00635531|Other|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
468530|NCT00636103|Drug|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
468531|NCT00636103|Other|Placebo|"Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months"
468532|NCT00636077|Device|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
468533|NCT00636077|Device|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
468534|NCT00636077|Device|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
468535|NCT00636077|Device|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
468536|NCT00636064|Drug|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
468537|NCT00636064|Drug|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
468538|NCT00636064|Other|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
468539|NCT00636038|Dietary Supplement|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
468540|NCT00636012|Procedure|verum acupuncture|acupuncture at St36 and Pe6
468541|NCT00636012|Procedure|sham acupuncture|superficial needling at sham points
468542|NCT00635999|Behavioral|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
468543|NCT00635999|Other|Cognitive therapy (CT)|CT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CT will include 14 weekly sessions.
468544|NCT00635999|Behavioral|Cognitive-Behavioral Therapy|Includes all of the techniques in the other 2 interventions.
468545|NCT00635986|Drug|Fentanyl|100 mcg Fentanyl intravenous or epidural route
468546|NCT00635973|Drug|Gefitinib (Iressa)|Iressa
468547|NCT00635960|Drug|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
468548|NCT00635960|Drug|Placebo|Same as for Growth hormone group
468549|NCT00635947|Other|isotonic solution|1.5 L- during 2-4hours
468550|NCT00635947|Other|water|1.5 L- during 2-4hours
468551|NCT00635947|Other|water|200mL- during 2-4hours
468552|NCT00635934|Device|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
468553|NCT00635921|Drug|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
468554|NCT00635921|Drug|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
468555|NCT00635895|Other|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
468556|NCT00635882|Drug|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
468557|NCT00635882|Drug|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
468558|NCT00635882|Drug|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
468559|NCT00635882|Drug|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
468560|NCT00635882|Drug|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
468561|NCT00635882|Drug|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
468689|NCT00635024|Drug|melphalan|16 mg/m^2
468562|NCT00635869|Behavioral|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
468563|NCT00635869|Behavioral|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
468564|NCT00635869|Behavioral|Placebo|didactic education sessions on physical assessment
468565|NCT00635856|Drug|Gefitinib|Iressa
468566|NCT00635843|Device|MAVERICK™ Disc|The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
468567|NCT00635843|Device|LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft|The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
468568|NCT00635830|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
468569|NCT00635817|Drug|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
468570|NCT00635817|Drug|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
468571|NCT00635804|Drug|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
468572|NCT00635804|Drug|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
468573|NCT00635791|Drug|Sorafenib|Given by mouth
468574|NCT00635791|Drug|Vorinostat|Given by mouth
468575|NCT00635778|Drug|dalotuzumab|Administered as an IV infusion over one to two hours
468576|NCT00635765|Drug|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
468577|NCT00635752|Other|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
468578|NCT00635752|Other|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
468579|NCT00635739|Dietary Supplement|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
468580|NCT00635739|Dietary Supplement|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
468581|NCT00635726|Drug|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
468582|NCT00635726|Drug|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
468583|NCT00635726|Drug|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
468584|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
468585|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
468586|NCT00635726|Drug|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
468587|NCT00635713|Drug|Fulvestrant|125mg
468588|NCT00635713|Drug|Anastrozole|ARIMIDEX
468589|NCT00635713|Drug|Fulvestrant|250mg
468590|NCT00635700|Drug|ziprasidone|20-160 mg/d
468591|NCT00635700|Drug|placebo|placebo
468592|NCT00635687|Device|Fibroscan|transient elastography measure - Liver stiffness
468593|NCT00635674|Device|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
468594|NCT00635648|Drug|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
468595|NCT00635635|Behavioral|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
468596|NCT00635635|Behavioral|Music Audio|Music only audio to be listened to 5x per week
468597|NCT00635622|Drug|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
468598|NCT00635622|Drug|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
468599|NCT00635609|Drug|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
468600|NCT00635609|Drug|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
468601|NCT00635596|Biological|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
468602|NCT00635583|Other|Increased Dairy Consumption|"3 additional servings of dairy (two of which must be milk or yogurt)~8 oz milk~6 oz yogurt~1.5 oz cheese"
468603|NCT00635570|Drug|Ortho Tri-cyclen Lo|Low dose oral contraceptive
468604|NCT00635570|Device|NuvaRing|Contraceptive vaginal ring
468605|NCT00635557|Drug|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
468606|NCT00635544|Other|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
468607|NCT00635544|Other|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
468690|NCT00635011|Behavioral|psychotherapy|Cognitive Behavioral therapy
468609|NCT00635531|Drug|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
468610|NCT00635518|Behavioral|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
468611|NCT00635505|Drug|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
468612|NCT00635505|Drug|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
468613|NCT00635505|Drug|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
468614|NCT00635492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
468615|NCT00635492|Drug|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
468616|NCT00635479|Device|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
468617|NCT00635479|Other|Gauze dressing|Gauze dressing for surgical incision
468618|NCT00635466|Procedure|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (<8 cm).
468619|NCT00635453|Behavioral|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
468620|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
468621|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
468622|NCT00635427|Biological|VPRIV®|Intravenous infusion, every other week (EOW)
468623|NCT00635414|Drug|Esomeprazole|40mg oral
468624|NCT00635414|Drug|Esomeprazole|15 minute intravenous infusion
468625|NCT00635401|Drug|Varenicline|0.5 mg BID for 7 weeks
468626|NCT00635388|Other|Placebo|oral, placebo, once/day for 12 weeks
468627|NCT00635388|Other|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
468628|NCT00635388|Other|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
468629|NCT00635375|Device|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
468630|NCT00635375|Device|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
468631|NCT00635375|Device|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
468632|NCT00635375|Device|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
468633|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
468634|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
468635|NCT00635349|Drug|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
468636|NCT00635349|Drug|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
468637|NCT00635349|Drug|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam [7.5 mg or 15 mg once daily] or aceclofenac [100 mg twice daily]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
468638|NCT00635336|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
468639|NCT00635323|Drug|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
468640|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
468641|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
468642|NCT00635297|Procedure|Percutaneous vertebroplasty|PMMA injection 3-10 milliliter in each treated vertebrae
468643|NCT00635284|Drug|ABI-009|nab-rapamycin
468691|NCT00634998|Dietary Supplement|Vitamin C|1000mg Vitamin C capsules orally twice daily
468644|NCT00635258|Drug|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
468645|NCT00635258|Drug|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
468646|NCT00635245|Biological|figitumumab|
468647|NCT00635245|Other|imaging biomarker analysis|
468648|NCT00635245|Other|laboratory biomarker analysis|
468649|NCT00635245|Other|pharmacological study|
468650|NCT00635245|Procedure|conventional surgery|
468651|NCT00635245|Procedure|magnetic resonance spectroscopic imaging|
468652|NCT00635245|Procedure|neoadjuvant therapy|
468653|NCT00635232|Drug|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
468654|NCT00635232|Drug|placebo|placebo capsules once daily for 12 weeks
468655|NCT00635232|Drug|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
468656|NCT00635232|Drug|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
468657|NCT00635232|Drug|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
468658|NCT00635219|Drug|Placebo|capsules; daily; orally
468659|NCT00635219|Drug|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
468660|NCT00635219|Drug|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
468661|NCT00635219|Drug|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
468662|NCT00635219|Drug|Duloxetine|60 mg/day; encapsulated capsules; orally
468663|NCT00635206|Device|BiPap auto with Fi Flex|"MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)~MaxIPAP = 25 cm H2O~MinPS = 2 cm H2O (cannot be adjusted)~MaxPS = 8 cm H2O~Bi-Flex setting of 3"
468664|NCT00635206|Device|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
468665|NCT00635193|Drug|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
468666|NCT00635193|Drug|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
468667|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
468668|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
468669|NCT00635180|Behavioral|isometric exercise|
468670|NCT00635167|Drug|Contrast Enhanced-Transrectal Ultrasound|Drug Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline [Visit 2]); week 5 (middle of treatment [Visit 3]); week 10 (end of treatment [Visit 4]); week 18 (2 months after end of EBRT [Visit 5]); week 26 (4 months after end of EBRT [Visit 6]); and week 36 (6 months after end of EBRT [Visit 7]).
468671|NCT00635154|Biological|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
468672|NCT00635154|Drug|Dexamethasone acetate|"Low dose - 20 mg/week~High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
468673|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
468674|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
468675|NCT00635128|Biological|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
468676|NCT00635115|Device|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
468677|NCT00635115|Device|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
468678|NCT00635102|Drug|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
468679|NCT00635102|Drug|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
468680|NCT00635102|Drug|Placebo D-Cycloserine PO and Glycine IV|
468681|NCT00635102|Drug|D-Cycloserine PO and placebo Glycine IV|
468682|NCT00635089|Drug|reslizumab|
468683|NCT00635076|Other|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
468684|NCT00635076|Drug|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
468685|NCT00635063|Drug|AD 923|
468686|NCT00635050|Drug|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.~Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
468687|NCT00635037|Drug|bupivacaine and acupuncture|"trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.~acupuncture twice a week"
468688|NCT00635024|Biological|anti-thymocyte globulin|2.5 mg/kg
468692|NCT00634998|Dietary Supplement|Placebo|1000mg Placebo capsules orally twice daily for 90 days
468693|NCT00634985|Drug|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet >2 hours from first dose if migraine reoccurred within 24 hours of achieving response
468694|NCT00634972|Drug|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
468695|NCT00634972|Drug|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
468696|NCT00634972|Drug|placebo|
468697|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
468698|NCT00634959|Drug|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
468699|NCT00634959|Drug|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
468700|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
468701|NCT00634959|Other|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
468702|NCT00634946|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
468703|NCT00634946|Drug|Placebo|Placebo is administrated into the nucleus pulposus of an intervertebral disc.
468704|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
468705|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
468706|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
468707|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
468708|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
468709|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
468710|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
468711|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
468712|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
468713|NCT00634920|Drug|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
468714|NCT00634920|Drug|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
468715|NCT00634920|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
468716|NCT00634920|Drug|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
468717|NCT00634920|Drug|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
468718|NCT00634907|Genetic|Pharmacogenetic-based warfarin dosing|"Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
468719|NCT00634907|Other|Usual care warfarin dosing|"For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.~NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
468720|NCT00634894|Drug|Femara|2.5 mg by mouth daily x 12 weeks
468721|NCT00634894|Drug|Placebo|Placebo capsule by mouth daily x 12 weeks
468722|NCT00634881|Biological|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion~Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
468723|NCT00634881|Biological|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously~Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration~Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)~Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
468724|NCT00634868|Other|Qray light therapy device|The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
468725|NCT00634868|Device|Qray light therapy device-Sham|non curative light- the device emits the same broad light, but with very low intensity
468726|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
468727|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
468728|NCT00634829|Drug|albuterol (Armstrong Albuterol HFA)|2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
468729|NCT00634829|Drug|Albuterol Sulfate (Provenetil-HFA)|2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
468730|NCT00634829|Drug|Placebo-HFA|Placebo containing HFA propellant without active drug substance
468731|NCT00634816|Radiation|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
468732|NCT00634803|Behavioral|CBT|Cognitive behavioral therapy
468733|NCT00634803|Drug|Buprenorphine|buprenorphine/naloxone
468734|NCT00634803|Other|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
468735|NCT00634803|Other|Physician Management|Brief physician counseling
468736|NCT00634790|Drug|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
468737|NCT00634777|Other|pet scan|pet scan
468738|NCT00634751|Drug|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
468739|NCT00634751|Drug|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
468740|NCT00634751|Drug|Sorafenib|"Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).~Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length~Sorafenib 200 mg BID Oral Daily Every 28 days~If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.~Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length~Sorafenib 400 mg BID Oral Daily Every 28 days"
468741|NCT00634738|Procedure|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
468742|NCT00634725|Drug|capecitabine|
468743|NCT00634725|Drug|erlotinib hydrochloride|
468744|NCT00634725|Drug|gemcitabine hydrochloride|
468745|NCT00634725|Other|laboratory biomarker analysis|
468746|NCT00634725|Radiation|radiation therapy|
468747|NCT00634712|Drug|Candesartan|
468748|NCT00634712|Drug|Placebo|
468749|NCT00634699|Procedure|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
468750|NCT00634686|Dietary Supplement|DHA/EPA|1.2 gram capsule daily for 6 months
468751|NCT00634686|Dietary Supplement|Placebo capsule|daily for 6 months
468752|NCT00634686|Dietary Supplement|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
468753|NCT00634673|Other|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
468754|NCT00634660|Drug|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
468755|NCT00634647|Drug|Satraplatin|80 mg/m^2 days 1-5 of every 35 day cycle
468756|NCT00634647|Drug|prednisone|5 mg twice daily every 35 days
468757|NCT00634634|Drug|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
468758|NCT00634634|Drug|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
468759|NCT00634621|Drug|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
468760|NCT00634608|Other|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
468761|NCT00634595|Drug|E10A|E10A 1*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
468762|NCT00634595|Drug|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
468763|NCT00634595|Drug|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
468764|NCT00634582|Drug|paricalcitol|
468765|NCT00634582|Other|immunoenzyme technique|
468766|NCT00634582|Other|laboratory biomarker analysis|
468767|NCT00634582|Procedure|dual x-ray absorptometry|
468768|NCT00634582|Procedure|quality-of-life assessment|
468769|NCT00634569|Biological|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
468770|NCT00634556|Drug|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
468771|NCT00634556|Drug|placebo|normal saline
468895|NCT00633750|Genetic|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
468772|NCT00634543|Drug|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
468773|NCT00634543|Drug|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
468774|NCT00634530|Behavioral|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
468775|NCT00634517|Drug|Armstrong Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
468776|NCT00634517|Drug|Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
468777|NCT00634504|Drug|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
468778|NCT00634504|Drug|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
468779|NCT00634491|Drug|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
468780|NCT00634491|Drug|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
468781|NCT00634491|Drug|normal salin|1 cc/kg/hr 6 hour before and after angiography
468782|NCT00634478|Radiation|Pre-lemniscal Radiation Deep Brain Stimulation|
468783|NCT00634465|Device|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
468784|NCT00634452|Biological|MDX-1401|IV weekly for 4 weeks
468785|NCT00634439|Drug|atomoxetine|
468786|NCT00634439|Drug|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
468787|NCT00634439|Other|No intervention (general population)|
468788|NCT00634426|Procedure|Surgical excision of the metastatic process|Surgical excision of the metastatic process
468789|NCT00634426|Radiation|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
468790|NCT00634413|Drug|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
468791|NCT00634413|Drug|Placebo|Inhaled matching placebo administered twice daily for 28 days
468792|NCT00634413|Drug|Budesonide|Inhaled budesonide twice daily for 28 days
468793|NCT00634400|Drug|Candesartan|
468794|NCT00634400|Drug|Placebo|
468795|NCT00634387|Dietary Supplement|Anthocyans|Anthocyans
468796|NCT00634387|Other|placebo|
468797|NCT00634387|Dietary Supplement|Anthocyans|
468798|NCT00634374|Device|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
468799|NCT00634361|Drug|ethyl-eicosapentaenoic acid|2 mg per day
468800|NCT00634348|Drug|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
468801|NCT00634348|Drug|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
468802|NCT00634322|Drug|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
468803|NCT00634322|Drug|leucovorin|IV or po given every 6 hours
468804|NCT00634309|Drug|Candesartan|
468805|NCT00634309|Drug|Placebo|
468806|NCT00634296|Other|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
468807|NCT00634283|Drug|venlafaxine|venlafaxine IR 150mg
468808|NCT00634270|Drug|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
468809|NCT00634257|Behavioral|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
468810|NCT00634244|Drug|alvocidib|Given IV
468811|NCT00634244|Drug|mitoxantrone hydrochloride|Given IV
468812|NCT00634244|Drug|carboplatin|Given IV
468813|NCT00634244|Drug|cytarabine|Given IV
468814|NCT00634244|Drug|sirolimus|Given PO
468815|NCT00634244|Drug|etoposide|Given IV
468816|NCT00634244|Drug|topotecan hydrochloride|Given IV
468817|NCT00634231|Biological|AdV-tk|
468818|NCT00634231|Drug|valacyclovir|
468819|NCT00634231|Radiation|Radiation|
468820|NCT00634218|Behavioral|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
468821|NCT00634218|Behavioral|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
468822|NCT00634218|Behavioral|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
468823|NCT00634218|Behavioral|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
468824|NCT00634205|Drug|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
468825|NCT00634192|Drug|tobramycin|1x300mg/d inhaled
468826|NCT00634192|Drug|tobramycin|2x300mg/d inhaled
468827|NCT00634179|Drug|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
468828|NCT00634179|Biological|Rituximab|Rituximab 375 mg/m²
468829|NCT00634179|Drug|Doxorubicin|Doxorubicin 50 mg/m²
468830|NCT00634179|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m²
468831|NCT00634179|Drug|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
468832|NCT00634179|Drug|Prednisone|Prednisone 100 mg/day given orally on days 1-5
468833|NCT00634166|Drug|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
468834|NCT00634166|Drug|Topical Antimicrobial/Antifungal Medications|Various topical antimicrobials and antifungals.
468835|NCT00634153|Other|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
468836|NCT00634140|Drug|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
468837|NCT00634140|Drug|Placebo|placebo for 4-6 weeks
468838|NCT00634114|Drug|Esomeprazole|10mg once daily oral administration
468839|NCT00634114|Drug|Esomeprazole|20mg once daily oral administration
468840|NCT00634114|Drug|Omeprazole|10mg once daily oral administration
468841|NCT00634101|Device|nelfilcon A|contact lens
468842|NCT00634101|Device|narafilcon A|contact lens
468843|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
468844|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
468845|NCT00634088|Drug|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
468846|NCT00634088|Drug|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
468847|NCT00634075|Drug|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
468848|NCT00634075|Drug|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
468849|NCT00634062|Drug|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
468850|NCT00634062|Drug|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
468851|NCT00634049|Drug|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
468852|NCT00634036|Drug|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
468853|NCT00634036|Drug|placebo|matching placebo (inert tablet)
468854|NCT00634010|Drug|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
468855|NCT00634010|Drug|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
468856|NCT00633997|Drug|Vildagliptin|50 mg orally twice daily for 10 days (last dose morning of day 10)
468857|NCT00633997|Drug|Vildagliptin|
469053|NCT00632541|Other|Imaging|Imaging every third cycle
468858|NCT00633984|Behavioral|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
468859|NCT00633984|Drug|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
468860|NCT00633984|Drug|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
468861|NCT00633971|Other|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
468862|NCT00633958|Other|[18F]-Fluorothymidine|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
468863|NCT00633945|Drug|Lenalidomide|
468864|NCT00633932|Drug|Esomeprazole|20mg once daily
468865|NCT00633932|Drug|Esomeprazole|40 mg once daily
468866|NCT00633932|Drug|Omeprazole|20mg once daily
468867|NCT00633919|Biological|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
468868|NCT00633919|Biological|Placebo|Sublingual immunotherapy once daily for 2 years
468869|NCT00633919|Drug|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
468870|NCT00633919|Drug|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
468871|NCT00633919|Drug|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
468872|NCT00633919|Drug|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
468873|NCT00633919|Drug|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
468874|NCT00633906|Behavioral|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
468875|NCT00633906|Behavioral|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
468876|NCT00633893|Drug|Apixaban|Tablets, Oral, twice daily, 12 months
468877|NCT00633893|Drug|Placebo|Tablets, Oral, twice daily, 12 months
468878|NCT00633880|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
468879|NCT00633880|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
468880|NCT00633867|Device|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
468881|NCT00633867|Device|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
468882|NCT00633854|Procedure|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
468883|NCT00633841|Biological|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
468884|NCT00633828|Behavioral|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
468885|NCT00633815|Other|Supine positioning|Subjects underwent exercise testing on a stationary bicycle in the supine position
468886|NCT00633815|Other|Upright positioning|Subjects underwent exercise testing on a stationary bicycle in the upright position
468887|NCT00633802|Drug|Risperidone|1 mg/d risperidone for 10 weeks or placebo
468888|NCT00633789|Drug|brivanib|Tablets, Oral, 800 mg, once daily, until progression
468889|NCT00633789|Drug|Placebo|Tablets, Oral, 0 mg, once daily, until progression
468890|NCT00633776|Drug|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
468891|NCT00633763|Drug|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
468892|NCT00633763|Drug|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
468893|NCT00633750|Drug|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
468894|NCT00633750|Genetic|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
468896|NCT00633750|Other|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
468897|NCT00633750|Other|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
468898|NCT00633750|Other|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
468899|NCT00633750|Other|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
468900|NCT00633750|Other|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
468901|NCT00633750|Procedure|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
468902|NCT00633737|Behavioral|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
468903|NCT00633724|Biological|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
468904|NCT00633711|Device|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment."
468905|NCT00633711|Device|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment."
468906|NCT00633698|Drug|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
468907|NCT00633698|Drug|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
468908|NCT00633685|Drug|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
468909|NCT00633685|Drug|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
468910|NCT00633672|Drug|Esomeprazole|20mg Oral tablet once daily
468911|NCT00633672|Drug|Ranitidine|150mg oral twice daily
468912|NCT00633672|Drug|Esomeprazole|40mg oral tablet once daily
468913|NCT00633659|Drug|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
468914|NCT00633659|Drug|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
468915|NCT00633646|Dietary Supplement|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
468916|NCT00633633|Other|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
468917|NCT00633633|Behavioral|Exercise Training|Exercise training 3 times a week.
468918|NCT00633633|Behavioral|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
468919|NCT00633620|Device|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
468920|NCT00633607|Other|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
468921|NCT00633594|Drug|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1~Same for DL-1."
468922|NCT00633594|Drug|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11~Same for DL-1."
468923|NCT00633594|Drug|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest~DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest~DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest~DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
468924|NCT00633581|Dietary Supplement|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
468925|NCT00633581|Dietary Supplement|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
468926|NCT00633568|Drug|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
468927|NCT00633568|Drug|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
468928|NCT00633542|Drug|thalidomide|100 mg/day orally until progression or severe toxicity
468929|NCT00633542|Drug|interferon alpha|3 MU 3 times a week until progression or severe toxicity
468930|NCT00633529|Drug|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
468931|NCT00633516|Device|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
468932|NCT00633490|Drug|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
468933|NCT00633477|Drug|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
468934|NCT00633477|Drug|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
469054|NCT00632528|Drug|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
469055|NCT00632528|Drug|Medicinal air|Administration of medical air during postoperative physical therapy
469327|NCT00630435|Drug|Premarin®/MPA formulation B|
468935|NCT00633464|Drug|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.~Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
468936|NCT00633464|Drug|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.~Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.~Cetuximab 400 mg/m^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
468937|NCT00633451|Other|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
468938|NCT00633451|Other|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
468939|NCT00633438|Other|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
468940|NCT00633438|Drug|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
468941|NCT00633425|Drug|GLIMEPIRIDE|
468942|NCT00633412|Drug|Esomeprazole|20mg oral daily
468943|NCT00633412|Drug|Ranitidine|150mg oral twice daily
468944|NCT00633412|Drug|Esomeprazole|40mg oral tablet daily
468945|NCT00633399|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
468946|NCT00633399|Drug|Placebo|"0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo."
468947|NCT00633386|Drug|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
468948|NCT00633386|Other|Placebo|Matched placebo
468949|NCT00633373|Drug|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
468950|NCT00633360|Drug|Drospirenone and ethinyl estradiol|Once daily by mouth
468951|NCT00633360|Drug|Placebo|Once daily by mouth
468952|NCT00633347|Drug|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
468953|NCT00633347|Drug|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
468954|NCT00633334|Other|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
468955|NCT00633321|Biological|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
468956|NCT00633321|Biological|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
468957|NCT00633308|Device|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
468958|NCT00633295|Drug|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
468959|NCT00633282|Behavioral|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment~activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50－70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
468960|NCT00633282|Drug|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
468961|NCT00633282|Drug|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
468962|NCT00633269|Drug|AZD2281|100mg Oral Dose
468963|NCT00633256|Drug|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
468964|NCT00633256|Drug|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
468965|NCT00633243|Procedure|Modified Directly Observed Therapy (mDOT)|
468966|NCT00633243|Procedure|Self-Administered Therapy (SAT)|
468967|NCT00633230|Drug|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
468968|NCT00633230|Other|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
468969|NCT00633217|Drug|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
468970|NCT00633217|Drug|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
468971|NCT00633204|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
468972|NCT00633191|Drug|Anti-pseudomonas IgY gargle|Gargle (solution), > 5FKU, every night after toothbrushing, life-long
469056|NCT00632515|Behavioral|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
469057|NCT00632502|Drug|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
468973|NCT00633178|Behavioral|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
468974|NCT00633178|Behavioral|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
468975|NCT00633165|Drug|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
468976|NCT00633152|Drug|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
468977|NCT00633152|Drug|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
468978|NCT00633152|Drug|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
468979|NCT00633139|Biological|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
468980|NCT00633126|Drug|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
468981|NCT00633113|Procedure|MPPA|- Medial Parapatellar Arthrotomy
468982|NCT00633113|Procedure|SV|- Subvastus Technique
468983|NCT00633087|Drug|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
468984|NCT00633074|Biological|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
468985|NCT00633074|Biological|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
468986|NCT00633061|Drug|Enoxaparin|Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children >2 months and 1.5 mg/kg every 12 hours for infants <2 months. Duration of treatment is 6 weeks.
468987|NCT00633048|Drug|NSA-789|
468988|NCT00633048|Drug|placebo|
468989|NCT00633035|Drug|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
468990|NCT00633035|Drug|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
468991|NCT00633022|Drug|LOSMAPIMOD 7.5 MG|GW856553 tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised GW856553X active substance. Tablets are available containing 7.5 mg of GW856553X and are packed into high-density polyethylene (HDPE) bottles.
468992|NCT00633022|Drug|Placebo|Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
468993|NCT00633009|Biological|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
468994|NCT00633009|Biological|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
468995|NCT00632996|Other|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
468996|NCT00632970|Drug|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
468997|NCT00632970|Drug|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
468998|NCT00632970|Drug|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
468999|NCT00632957|Dietary Supplement|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
469000|NCT00632957|Dietary Supplement|Placebo|corn/soybean oil capsules 1g/three times daily
469001|NCT00632931|Drug|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
469002|NCT00632931|Drug|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
469003|NCT00632866|Drug|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
469004|NCT00632866|Drug|Placebo|Placebo : 2cp/ day since 24 weeks
469005|NCT00632853|Radiation|Standard Radiation Dose Therapy|45 Gy
469006|NCT00632853|Drug|cisplatin|IV
469007|NCT00632853|Drug|etoposide|IV
469008|NCT00632853|Radiation|High Radiation Dose Therapy|70 Gy
469009|NCT00632853|Drug|carboplatin|IV
469010|NCT00632840|Drug|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
469011|NCT00632827|Drug|REGIMEN|Induction chemotherapy
469012|NCT00632827|Drug|REGIMEN B|Induction Chemotherapy
469013|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
469058|NCT00632502|Drug|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
469328|NCT00630435|Drug|Premarin®/MPA formulation C|
469014|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
469015|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for patients in this group
469016|NCT00632801|Other|chewing gum|The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
469017|NCT00632788|Other|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
469018|NCT00632775|Drug|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
469019|NCT00632775|Drug|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:~100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
469020|NCT00632762|Drug|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
469021|NCT00632749|Drug|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
469022|NCT00632749|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
469023|NCT00632749|Drug|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
469024|NCT00632749|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
469025|NCT00632736|Drug|Ropinirole XL (formerly CR)|
469026|NCT00632723|Drug|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
469027|NCT00632710|Other|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
469028|NCT00632710|Other|phototherapy placebo|disconnected laser (same device - experimental group)
469029|NCT00632697|Drug|pentoxifylline|800 mg daily for six months
469030|NCT00632697|Drug|placebo|
469031|NCT00632684|Behavioral|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
469032|NCT00632684|Behavioral|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
469033|NCT00632645|Drug|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
469034|NCT00632645|Drug|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
469035|NCT00632645|Drug|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
469036|NCT00632632|Drug|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
469037|NCT00632632|Other|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
469038|NCT00632619|Behavioral|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
469039|NCT00632619|Drug|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
469040|NCT00632619|Behavioral|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
469041|NCT00632606|Drug|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
469042|NCT00632606|Drug|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
469043|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
469044|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
469045|NCT00632580|Drug|intraarticular injection with ropivacaine|
469046|NCT00632580|Drug|extraarticular injection with ropivacaine|
469047|NCT00632567|Procedure|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
469048|NCT00632567|Procedure|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
469049|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for three months|period of treatment
469050|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for six months|period of therapy
469051|NCT00632541|Drug|Sorafenib|Sorafenib 200mg po daily
469052|NCT00632541|Drug|Bevacizumab|"Bevacizumab 5mg/kg every other week~1 Cycle = 4 weeks"
469059|NCT00632502|Drug|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
469060|NCT00632489|Drug|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
469061|NCT00632489|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
469062|NCT00632489|Drug|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
469063|NCT00632476|Other|Placebo|Placebo capsule once a day
469064|NCT00632476|Dietary Supplement|Vitamin C|A 500-mg vitamin C capsule once a day
469065|NCT00632463|Biological|RI-001|Dose 1
469066|NCT00632463|Biological|RI-001|Dose 2
469067|NCT00632463|Biological|RI-001|Placebo
469068|NCT00632437|Procedure|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
469069|NCT00632424|Drug|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
469070|NCT00632411|Drug|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.~Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.~Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.~The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
469071|NCT00632411|Behavioral|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.~Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.~Phone session 3 will focus on the first days after the quit date.~Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.~Phone session 5 will focus on short-term relapse prevention.~Phone session 6 will focus on long-term relapse prevention."
469072|NCT00632398|Behavioral|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
469073|NCT00632398|Behavioral|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
469074|NCT00632385|Drug|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose
469075|NCT00632372|Device|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
469076|NCT00632372|Device|HeartPOD™ System|Left atrial pressure monitoring.
469077|NCT00632359|Drug|Lenalidomide|10 mg daily given for 12 months
469078|NCT00632333|Biological|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
469079|NCT00632294|Procedure|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
469080|NCT00632281|Radiation|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
469081|NCT00632268|Drug|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
469082|NCT00632255|Drug|Imatinib|Conventional therapy with imatinib
469083|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
469084|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
469085|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
469086|NCT00632242|Drug|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
469087|NCT00632242|Drug|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
469088|NCT00632229|Drug|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
469089|NCT00632229|Drug|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
469090|NCT00632216|Drug|Risedronate Sodium|
469091|NCT00632203|Drug|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
469092|NCT00632190|Other|fluorophotometry|
469093|NCT00632190|Procedure|colposcopic biopsy|
469094|NCT00632190|Procedure|colposcopy|
469095|NCT00632190|Procedure|light-scattering spectroscopy|
469096|NCT00632138|Behavioral|exercise intervention|
469097|NCT00632138|Other|questionnaire administration|
469098|NCT00632138|Procedure|biofeedback|
469099|NCT00632138|Procedure|management of therapy complications|
469100|NCT00632138|Procedure|psychosocial assessment and care|
469101|NCT00632138|Procedure|quality-of-life assessment|
469102|NCT00632125|Drug|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
469103|NCT00632099|Drug|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
469104|NCT00632099|Drug|Placebo|matched placebo
469105|NCT00632086|Drug|PA32540|
469106|NCT00632086|Drug|aspirin component of PA32540|The 325 mg aspirin component of PA32540
469107|NCT00632086|Drug|Ecotrin|325 mg Ecotrin
469108|NCT00632073|Drug|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
469109|NCT00632060|Procedure|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
469110|NCT00632047|Other|active surveillance|
469111|NCT00632047|Other|educational intervention|
469112|NCT00632047|Procedure|examination|
469113|NCT00632047|Procedure|long-term screening|
469114|NCT00632034|Other|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
469115|NCT00632021|Behavioral|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
469116|NCT00632008|Drug|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
469117|NCT00632008|Drug|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
469118|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
469119|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
469120|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
469121|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
469122|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
469123|NCT00631995|Dietary Supplement|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
469124|NCT00631982|Procedure|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
469125|NCT00631969|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
469126|NCT00631969|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
469127|NCT00631943|Drug|Pregabalin (Lyrica)|Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
469128|NCT00631917|Drug|Aliskiren|Aliskiren 300 mg once a day
469129|NCT00631917|Drug|Ramipril|Ramipril 10 mg once a day
469130|NCT00631917|Other|Placebo to Ramipril|Placebo capsules to match ramipril.
469131|NCT00631917|Other|Placebo to Aliskiren|Placebo tablets to match aliskiren.
469132|NCT00631878|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
469133|NCT00631865|Biological|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
469134|NCT00631852|Drug|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
469135|NCT00631839|Radiation|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies >=6MV.
469136|NCT00631813|Drug|Prucalopride|0.5 mg bid
469137|NCT00631813|Drug|Prucalopride|1 mg bid
469138|NCT00631813|Drug|Prucalopride|2 mg bid
469139|NCT00631813|Drug|Placebo|bid
469140|NCT00631800|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
469141|NCT00631774|Dietary Supplement|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
469142|NCT00631761|Other|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
469143|NCT00631761|Other|no intervention (usual resident activities)|usual activities
469186|NCT00631397|Device|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
469187|NCT00631384|Behavioral|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
469188|NCT00631384|Behavioral|Individual VCT|Women to receive individual VCT
469144|NCT00631748|Drug|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
469145|NCT00631748|Drug|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
469146|NCT00631748|Behavioral|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
469147|NCT00631722|Drug|Quatiapine Fumarate|600-750mg/day
469148|NCT00631722|Drug|Haloperidol|12-20mg/day
469149|NCT00631709|Other|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
469150|NCT00631696|Drug|Pregabalin|pregabalin 600 mg given twice a day
469151|NCT00631696|Drug|Placebo|Placebo
469152|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|15 Gy in one treatment
469153|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
469154|NCT00631657|Drug|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
469155|NCT00631657|Drug|Placebo|One placebo tablet once a day
469156|NCT00631631|Drug|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
469157|NCT00631618|Drug|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
469158|NCT00631592|Drug|GSK1349572|
469159|NCT00631579|Drug|Rasburicase (SR29142)|
469160|NCT00631566|Drug|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).~pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.~Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
469161|NCT00631566|Drug|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
469162|NCT00631553|Drug|perflutren lipid microspheres|1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
469163|NCT00631540|Device|Formula Balloon-Expandable Stent|renal artery stenting
469164|NCT00631527|Drug|Leuprolide|Injections given through a needle in the muscle every 3 months.
469165|NCT00631527|Drug|Goserelin|Subcutaneous injections given once every 3 months.
469166|NCT00631527|Drug|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
469167|NCT00631527|Drug|Casodex|Once a day by mouth for 2 weeks.
469168|NCT00631527|Radiation|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
469169|NCT00631514|Drug|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
469170|NCT00631514|Drug|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
469171|NCT00631514|Drug|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
469172|NCT00631501|Drug|Placebo|
469173|NCT00631501|Drug|Doxycycline|
469174|NCT00631488|Drug|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
469175|NCT00631488|Drug|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
469176|NCT00631488|Drug|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
469177|NCT00631488|Drug|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
469178|NCT00631488|Drug|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
469179|NCT00631488|Drug|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
469180|NCT00631475|Drug|Bosentan|"For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs < 90 lbs.)"
469181|NCT00631462|Drug|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
469182|NCT00631449|Drug|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
469183|NCT00631449|Drug|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
469184|NCT00631410|Drug|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
469185|NCT00631410|Drug|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
469189|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
469190|NCT00631371|Drug|Temsirolimus|Temsirolimus 25 mg IV weekly
469191|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
469192|NCT00631371|Drug|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
469193|NCT00631358|Drug|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
469194|NCT00631358|Other|No treatment|Healthy normal control group receiving no treatment
469195|NCT00631345|Behavioral|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
469196|NCT00631345|Other|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
469197|NCT00631345|Behavioral|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
469198|NCT00631345|Behavioral|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
469199|NCT00631319|Drug|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
469200|NCT00631319|Drug|Placebo|Placebo
469201|NCT00631293|Dietary Supplement|lactisole|administration of lactisole followed by placebo
469202|NCT00631293|Other|placebo|administration of placebo followed by lactisole
469203|NCT00631280|Behavioral|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
469204|NCT00631280|Behavioral|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
469205|NCT00631267|Procedure|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
469206|NCT00631267|Procedure|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
469207|NCT00631254|Procedure|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.~Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
469208|NCT00631254|Procedure|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.~Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
469209|NCT00631241|Procedure|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
469210|NCT00631241|Procedure|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
469211|NCT00631228|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
469212|NCT00631215|Procedure|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
469213|NCT00631202|Drug|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
469214|NCT00631189|Drug|Rosuvastatin|5mg oral
469215|NCT00631189|Drug|Pravastatin|40mg oral
469217|NCT00631176|Behavioral|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
469218|NCT00631163|Drug|Deferasirox (ICL670)|The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
469219|NCT00631150|Drug|Levetiracetam (Keppra)|
469220|NCT00631137|Drug|testosterone gel applied to skin|Application of testosterone gel
469221|NCT00631137|Dietary Supplement|whey powder protein|
469222|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
469223|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
469224|NCT00631111|Drug|effervescent ibuprofen tablets|
469225|NCT00631111|Drug|effervescent Aspirin plus Vitamin C tablets|
469226|NCT00631111|Drug|ibuprofen tablets|
469227|NCT00631111|Drug|placebo|
469228|NCT00631098|Procedure|venous cannulation|External jugular and cubital vein cannulation
469229|NCT00631085|Drug|gamma tocopherol|Maxi Gamma softgels 1200mg QD
469230|NCT00631072|Biological|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
469231|NCT00631072|Drug|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
469232|NCT00631059|Other|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
469233|NCT00631046|Dietary Supplement|Fish Oil|Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
469234|NCT00631046|Dietary Supplement|Sunflower Oil|Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
469235|NCT00631033|Drug|Placebo|
469236|NCT00631033|Drug|Diazoxide|
469237|NCT00631033|Drug|Metformin + Diazoxide|
469238|NCT00631020|Behavioral|CBME|6 weeks of once a week one-on-one CBME
469239|NCT00631020|Drug|Optional NRT|NicoDerm CQ nicotine transdermal patch
469240|NCT00631007|Drug|INT131 besylate|Once-daily, oral
469241|NCT00631007|Drug|Pioglitazone HCl|Once-daily, oral
469242|NCT00631007|Drug|Placebo|Once-daily, oral
469243|NCT00630994|Drug|Dacogen|
469244|NCT00630981|Behavioral|Psychotherapy|Specific psychotherapy for dissociative disorders
469245|NCT00630981|Drug|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
469246|NCT00630968|Drug|Levetiracetam (Keppra)|
469247|NCT00630955|Drug|memantine|Memantine 20 mg once per day for 7 days
469248|NCT00630955|Drug|Memantine|Memantine 40 mg once per day for 7 days
469249|NCT00630955|Drug|Placebo|Placebo once per day for 7 days
469250|NCT00630942|Drug|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
469251|NCT00630929|Drug|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
469252|NCT00630929|Drug|Placebo|Matched placebo orally for 6 weeks
469253|NCT00630929|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
469254|NCT00630916|Device|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
469255|NCT00630903|Drug|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
469256|NCT00630903|Drug|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
469257|NCT00630890|Radiation|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
469258|NCT00630877|Drug|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
469259|NCT00630877|Drug|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
469260|NCT00630877|Drug|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
469261|NCT00630877|Drug|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
469262|NCT00630864|Drug|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
469263|NCT00630851|Drug|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
469264|NCT00630851|Drug|Placebo|Matching placebo tablets orally once daily for 6 months
469265|NCT00630838|Drug|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.~E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
469266|NCT00630838|Drug|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
469267|NCT00630825|Drug|LY2189265|
469268|NCT00630825|Drug|Placebo|
469269|NCT00630812|Drug|inhaled mannitol|400 mg BD for 26 + 26 weeks
469270|NCT00630812|Drug|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
469274|NCT00630760|Drug|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
469275|NCT00630747|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
469276|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
469277|NCT00630734|Drug|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
469278|NCT00630734|Drug|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
469279|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
469280|NCT00630734|Other|Washout|Washout (no medication) on days 5-11.
469281|NCT00630721|Other|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
469282|NCT00630708|Drug|Benazepril|20 mg per day
469283|NCT00630708|Drug|Losartan|100 mg per day
469284|NCT00630708|Drug|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
469285|NCT00630695|Drug|Lanreotide LP 90|Lanreotide LP 90
469286|NCT00630695|Drug|Placebo lanreotide|Placebo
469287|NCT00630682|Drug|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
469288|NCT00630682|Drug|Placebo|9 weeks of placebo 60mg capsules QD.
469289|NCT00630669|Procedure|Rubber band ligation|placing rubber bands around the internal hemorrhoids
469290|NCT00630669|Procedure|Bipolar coagulation|using electricity to cauterize
469291|NCT00630656|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
469292|NCT00630656|Drug|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
469293|NCT00630643|Biological|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
469294|NCT00630643|Drug|Placebo|Placebo
469295|NCT00630630|Drug|Levetiracetam|
469296|NCT00630630|Other|Placebo|
469297|NCT00630617|Behavioral|Diet, Physical activity, Physical inactivity|Community based participatory research design
469298|NCT00630591|Behavioral|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
469299|NCT00630591|Behavioral|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
469300|NCT00630591|Behavioral|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
469301|NCT00630578|Behavioral|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
469302|NCT00630565|Biological|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
469303|NCT00630565|Drug|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
469304|NCT00630565|Drug|cyclophosphamide|4 gm/m^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
469305|NCT00630565|Drug|dexamethasone|20 mg/m^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
469306|NCT00630565|Drug|etoposide|300 mg/m^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
469307|NCT00630565|Procedure|bone marrow transplantation|Day 0 infusion of bone marrow cells
469308|NCT00630565|Procedure|hematopoietic stem cell transplantation|Stem cell infusion (>48 hours after the last dose of cyclophosphamide)
469309|NCT00630565|Procedure|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
469310|NCT00630565|Radiation|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
469311|NCT00630552|Other|Placebo|Inactive dummy of AMG 655.
469312|NCT00630552|Drug|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
469313|NCT00630552|Drug|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
469314|NCT00630539|Drug|Placebo|1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
469315|NCT00630539|Drug|Ospemifene 5 mg|1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
469316|NCT00630539|Drug|Ospemifene 15 mg|1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
469317|NCT00630539|Drug|Ospemifene 30 mg|1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
469318|NCT00630513|Drug|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
469319|NCT00630513|Drug|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
469320|NCT00630500|Drug|Memantine|Tablets, 5 or 10 mg, twice daily
469321|NCT00630500|Drug|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
469322|NCT00630487|Drug|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
469323|NCT00630487|Drug|Somatropin|Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
469324|NCT00630474|Drug|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
469325|NCT00630461|Biological|Clinical Center Reference Endotoxin|single inhalation challenge
469329|NCT00630435|Drug|Premarin®/MPA currently marketed product|
469330|NCT00630409|Drug|Gemcitabine|800 mg IV day 1 and 8
469331|NCT00630409|Drug|Doxil|24 mg/m2 every 21 days IV
469332|NCT00630396|Drug|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.~Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.~Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.~Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
469333|NCT00630383|Biological|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
469334|NCT00630383|Other|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
469335|NCT00630370|Drug|Placebo|2 Placebo tablets, TID, orally, 58 days
469336|NCT00630370|Drug|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
469337|NCT00630370|Drug|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
469338|NCT00630370|Drug|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
469339|NCT00630357|Drug|Levetiracetam (Keppra)|
469340|NCT00630344|Drug|RAD001|
469341|NCT00630344|Drug|Bicalutamide|
469342|NCT00630331|Biological|Cell culture-derived influenza vaccine|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
469343|NCT00630331|Biological|Egg-derived influenza virus vaccine|One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
469344|NCT00630331|Biological|Placebo|One dose (0.5 mL) of phosphate buffered solution.
469345|NCT00630318|Device|MRI|15-20 minutes MR imaging
469346|NCT00630305|Device|alphafilcon A toric|Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
469347|NCT00630305|Device|lotrafilcon B toric|Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
469348|NCT00630305|Device|senofilcon A toric|Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
469349|NCT00630292|Other|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
469350|NCT00630279|Drug|Placebo|Placebo
469351|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
469352|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
469353|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
469354|NCT00630266|Device|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
469355|NCT00630253|Biological|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
469356|NCT00630253|Drug|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
469357|NCT00630253|Drug|Fludarabine|35 mg/m^2 intravenously (IV) on days -6 through -2.
469358|NCT00630253|Procedure|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
469359|NCT00630253|Drug|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
469360|NCT00630253|Drug|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count > or = 2.5 x 10^9/L
469361|NCT00630253|Drug|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
469362|NCT00630253|Drug|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
469363|NCT00630227|Biological|Biologic Lung Volume Reduction|20 mL Hydrogel
469364|NCT00630214|Dietary Supplement|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
469365|NCT00630214|Dietary Supplement|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
469366|NCT00630201|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
469367|NCT00630188|Other|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
469368|NCT00630188|Other|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
469369|NCT00630175|Drug|zolpidem-MR (modified release)|
469370|NCT00630175|Drug|zolpidem (SL800750)|
469371|NCT00630175|Drug|placebo|
469372|NCT00630162|Genetic|amoeba|
469373|NCT00630149|Drug|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
469374|NCT00630136|Behavioral|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
469375|NCT00630110|Drug|docetaxel|docetaxel (75 mg/m2)
469376|NCT00630110|Drug|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
469377|NCT00630097|Drug|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
469378|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
469379|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
469380|NCT00630058|Drug|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
469381|NCT00630058|Drug|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
469382|NCT00630045|Drug|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
469383|NCT00630045|Procedure|resection of liver metastasis|surgery with the aim of R0 resection
469384|NCT00630032|Drug|cyclophosphamide|500 mg/m² every 3 weeks
469385|NCT00630032|Drug|Docetaxel|100 mg/m² every 3 weeks
469386|NCT00630032|Drug|epirubicin hydrochloride|100 mg/m² every 3 weeks
469387|NCT00630032|Drug|fluorouracil|500 mg/m² every 3 weeks
469388|NCT00630032|Drug|ixabepilone|40 mg/m² every 3 weeks
469389|NCT00630019|Drug|1.5% levofloxacin ophthalmic solution|Topical application
469390|NCT00630019|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
469391|NCT00630006|Genetic|TNF-alpha and IL-10|
469392|NCT00629993|Behavioral|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
469393|NCT00629980|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
469394|NCT00629967|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
469395|NCT00629967|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
469396|NCT00629941|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
469397|NCT00629928|Drug|Esomeprazole|20mg oral capsule daily
469398|NCT00629928|Drug|Esomeprazole|40mg oral capsule daily
469399|NCT00629928|Drug|Placebo|
469400|NCT00629889|Drug|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
469401|NCT00629889|Drug|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.~Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
469402|NCT00629876|Drug|Peginesatide|"Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.~Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen."
469403|NCT00629863|Drug|cisplatin|
469404|NCT00629863|Drug|fluorouracil|
469405|NCT00629863|Other|questionnaire administration|
469406|NCT00629863|Procedure|diagnostic endoscopic procedure|
469407|NCT00629863|Procedure|neoadjuvant therapy|
469408|NCT00629863|Procedure|quality-of-life assessment|
469409|NCT00629863|Procedure|therapeutic conventional surgery|
469410|NCT00629863|Procedure|therapeutic endoscopic surgery|
469411|NCT00629863|Procedure|ultrasound imaging|
469412|NCT00629863|Radiation|radiation therapy|
469413|NCT00629863|Radiation|radioisotope therapy|
469414|NCT00629850|Device|Powerlung Performer|Inspiratory/Expiratory muscle trainer
469415|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 [13mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
469416|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 [22mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
469417|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 [13mg of liposomes/kg]
469418|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 [22mg of liposomes/kg]
469419|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
469420|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
469421|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
469422|NCT00629811|Drug|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:~Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)~Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)~Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
469547|NCT00628953|Drug|Placebo|40mg twice a day
469423|NCT00629811|Drug|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.~Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.~Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
469424|NCT00629798|Drug|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients > or = to 4 years of age or 1.0 mg/kg IV for patients < 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
469425|NCT00629772|Drug|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
469426|NCT00629772|Drug|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
469427|NCT00629759|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
469428|NCT00629746|Device|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system~The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor~A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.~The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.~The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
469429|NCT00629733|Drug|RO-14|
469430|NCT00629720|Drug|alfuzosin (SL770499)|
469431|NCT00629707|Other|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
469432|NCT00629694|Procedure|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
469433|NCT00629694|Procedure|A-M|adenoidectomy and myringotomy alone
469434|NCT00629681|Drug|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
469435|NCT00629668|Genetic|TNF-alpha and HBV genotype|
469436|NCT00629668|Other|TNF-alpha and HBV genotypes|
469437|NCT00629655|Other|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type~sensory stimulation: electric or tactile stimulation"
469438|NCT00629642|Drug|Solifenacin Succinate|Oral, 10mg
469439|NCT00629642|Drug|Solifenacin Succinate|Oral, 5mg
469440|NCT00629642|Drug|Oxybutynin Hydrochloride|Oral, 15mg
469441|NCT00629642|Drug|Placebo|Oral
469442|NCT00629629|Behavioral|Dietary Advice|
469443|NCT00629616|Drug|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
469444|NCT00629616|Drug|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
469445|NCT00629603|Genetic|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
469446|NCT00629603|Genetic|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
469447|NCT00629603|Genetic|cytokine polymorphism|fibrosis-relating cytokine polymorphism
469448|NCT00629590|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~12 days
469449|NCT00629577|Genetic|microarray analysis|
469450|NCT00629577|Other|flow cytometry|
469451|NCT00629577|Procedure|biopsy|
469452|NCT00629577|Procedure|colposcopy|
469453|NCT00629564|Drug|Esomeprazole|20mg oral
469454|NCT00629564|Drug|Esomeprazole|15 minute intravenous infusion
469455|NCT00629551|Drug|saredutant (SR48968)|oral administration,capsules
469456|NCT00629551|Drug|paroxetine|oral administration, capsules
469457|NCT00629551|Drug|placebo|oral administration, capsules
469458|NCT00629538|Procedure|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
469459|NCT00629525|Drug|RAD001|RAD001 at a dose of 10 mg PO daily
469460|NCT00629512|Drug|Esomeprazole|20mg oral daily
469461|NCT00629512|Drug|Esomeprazole|40mg oral daily
469462|NCT00629512|Drug|Placebo|
469463|NCT00629499|Drug|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
469464|NCT00629499|Drug|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
469465|NCT00629499|Drug|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
469466|NCT00629486|Genetic|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
469467|NCT00629473|Drug|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
469468|NCT00629473|Drug|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
469469|NCT00629473|Drug|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
469470|NCT00629447|Drug|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
469471|NCT00629434|Other|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
469472|NCT00629434|Other|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
469473|NCT00629395|Behavioral|Captain's Log Computer Program|12 Computer Program
469474|NCT00629382|Device|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
469475|NCT00629382|Other|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
469476|NCT00629369|Device|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
469477|NCT00629356|Genetic|dengue fever|
469478|NCT00629343|Drug|Azacitidine In Combination With Temozolomide|mg, oral
469479|NCT00629330|Behavioral|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
469480|NCT00629317|Other|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
469481|NCT00629317|Drug|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
469482|NCT00629304|Device|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
469483|NCT00629304|Device|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
469484|NCT00629304|Device|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
469485|NCT00629278|Biological|trastuzumab|
469486|NCT00629278|Drug|aromatase inhibition therapy|
469487|NCT00629278|Drug|cyclophosphamide|
469488|NCT00629278|Drug|docetaxel|
469489|NCT00629278|Drug|doxorubicin hydrochloride|
469490|NCT00629278|Drug|epirubicin hydrochloride|
469491|NCT00629278|Drug|fluorouracil|
469492|NCT00629278|Drug|paclitaxel|
469493|NCT00629278|Drug|releasing hormone agonist therapy|
469494|NCT00629278|Drug|tamoxifen citrate|
469495|NCT00629278|Procedure|adjuvant therapy|
469496|NCT00629278|Radiation|radiation therapy|
469497|NCT00629265|Device|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
469498|NCT00629252|Drug|Sertindole|oral 12-20 mg/day
469499|NCT00629252|Drug|Risperidone|oral 2-6mg / day
469500|NCT00629239|Drug|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
469501|NCT00629239|Drug|Placebo|
469502|NCT00629226|Biological|cetuximab|Given IV
469503|NCT00629226|Drug|bortezomib|Given IV
469504|NCT00629226|Drug|cisplatin|Given IV
469505|NCT00629226|Radiation|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
469506|NCT00629213|Drug|acarbose|
469507|NCT00629213|Drug|placebo|
469508|NCT00629200|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
469509|NCT00629200|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
469510|NCT00629187|Drug|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
469511|NCT00629174|Behavioral|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
469512|NCT00629174|Behavioral|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
469513|NCT00629161|Drug|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
469514|NCT00629161|Drug|placebo|12 months period of placebo plus 1 month period without placebo
469515|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
469516|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
469517|NCT00629135|Drug|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
469542|NCT00628992|Other|Cycloergometer training|Muscular rehabilitation of the leg
469543|NCT00628992|Other|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
469544|NCT00628979|Behavioral|CBT|cognitive- behavioral treatment for panic disorder.
469545|NCT00628966|Device|LifeVest|The LifeVest is a non-invasive, wearable defibrillator vest that detects and treats arrhythmias.
469518|NCT00629122|Drug|Tacrolimus (Arm B)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
469519|NCT00629122|Drug|Clotrimazole Troche|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and clotrimazole troche x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, clotrimazole); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and clotrimazole troche x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subject by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
469520|NCT00629122|Drug|Tacrolimus (Arm A)|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
469521|NCT00629122|Drug|Nystatin Suspension|Study day 1 (9a): Initiate sublingual (SL) tacrolimus and nystatin suspension x 5 doses; Study day 3 (9a): Collection of pharmacokinetic parameters around the 5th SL tacrolimus dose; Study day 3 (9p): Start washout period, no drug administration (tacrolimus, nystatin); Study day 5 (9p): End washout period; Study day 6 (9a): Initiate oral tacrolimus and nystatin suspension x 5 doses; Study day 8 (9a): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose; Study day 15: Contact subjects by telephone to assess for any adverse effects. To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8).
469522|NCT00629096|Procedure|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
469523|NCT00629083|Device|Bulkamid|Bulking injection with Bulkamid injection device
469524|NCT00629083|Device|Contigen|Transurethral bulking injection
469525|NCT00629070|Other|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
469526|NCT00629070|Other|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
469527|NCT00629057|Biological|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
469528|NCT00629057|Biological|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
469529|NCT00629057|Biological|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
469530|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
469531|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
469532|NCT00629044|Biological|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
469533|NCT00629031|Drug|Paromomycin|11 mg/kg for 14 days
469534|NCT00629031|Drug|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
469535|NCT00629018|Biological|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
469536|NCT00629018|Drug|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
469537|NCT00629018|Biological|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
469538|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
469539|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
469540|NCT00628992|Other|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
469541|NCT00628992|Other|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
469546|NCT00628953|Drug|Esomeprazole|40mg twice a day
469548|NCT00628940|Radiation|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
469549|NCT00628914|Drug|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
469550|NCT00628914|Drug|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
469551|NCT00628914|Drug|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
469552|NCT00628901|Procedure|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
469553|NCT00628901|Device|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
469554|NCT00628901|Device|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
469555|NCT00628888|Behavioral|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
469556|NCT00628862|Drug|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
469557|NCT00628862|Drug|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
469558|NCT00628862|Drug|Turbuhaler® placebo|placebo inhaled twice daily
469559|NCT00628836|Device|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.~Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.~If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
469560|NCT00628823|Dietary Supplement|Gluten-free diet|Gluten containing foods removed from diet
469561|NCT00628810|Biological|bevacizumab|
469562|NCT00628810|Drug|fluorouracil|
469563|NCT00628810|Drug|irinotecan hydrochloride|
469564|NCT00628810|Drug|leucovorin calcium|
469565|NCT00628797|Radiation|UVA1|intraindividual half body irradiation
469566|NCT00628797|Other|UVA1|60 J/cm2 at least 36 tx
469567|NCT00628784|Procedure|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
469568|NCT00628784|Procedure|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
469569|NCT00628771|Behavioral|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
469570|NCT00628771|Behavioral|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
469571|NCT00628758|Drug|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
469572|NCT00628758|Drug|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
469573|NCT00628745|Other|None. Observational Study.|
469574|NCT00628732|Drug|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
469575|NCT00628719|Drug|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
469576|NCT00628719|Drug|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
469577|NCT00628706|Drug|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
469578|NCT00628680|Device|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
469579|NCT00628680|Drug|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
469580|NCT00628667|Drug|Esomeprazole|40mg orally twice daily
469581|NCT00628667|Drug|Placebo|
469582|NCT00628628|Drug|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
469583|NCT00628628|Drug|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
469584|NCT00628602|Device|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
469585|NCT00628589|Drug|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
469586|NCT00628589|Drug|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
469587|NCT00628589|Drug|Inhaled placebo|Inhaled placebo
469588|NCT00628576|Drug|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
469589|NCT00628576|Drug|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
469590|NCT00628550|Drug|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
469591|NCT00628550|Drug|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
469592|NCT00628537|Device|BION stimulation|"BION™ Experimental Group~The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.~Surface Stimulation Group~Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.~Control Group with conservative therapy (Range of motion exercises)~The research participant is instructed in self-administered, standard range of motion stretching exercises."
469593|NCT00628511|Device|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
469594|NCT00628498|Drug|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
469595|NCT00628498|Drug|Defibrotide|
469596|NCT00628485|Device|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
469597|NCT00628485|Device|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
469598|NCT00628485|Device|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
469599|NCT00628472|Drug|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
469600|NCT00628459|Dietary Supplement|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
469601|NCT00628433|Drug|Placebo|Placebo
469602|NCT00628433|Drug|HE3286|daily for 28 days
469603|NCT00628420|Drug|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
469604|NCT00628420|Drug|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
469605|NCT00628420|Drug|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
469606|NCT00628394|Drug|Atomoxetine|40mg 2po qam
469607|NCT00628394|Drug|Placebo|40mg 2po qam
469608|NCT00628381|Dietary Supplement|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
469609|NCT00628381|Dietary Supplement|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
469610|NCT00628368|Genetic|gene expression analysis|
469611|NCT00628368|Genetic|mutation analysis|
469612|NCT00628368|Genetic|polymorphism analysis|
469613|NCT00628368|Other|laboratory biomarker analysis|
469614|NCT00628368|Procedure|biopsy|
469615|NCT00628368|Procedure|endoscopic biopsy|
469616|NCT00628355|Drug|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
469617|NCT00628355|Procedure|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
469618|NCT00628342|Drug|Esomeprazole|20mg Oral tablet once daily
469619|NCT00628342|Drug|Esomeprazole|40mg Oral tablet once daily
469620|NCT00628342|Drug|Placebo|Oral once daily
469621|NCT00628316|Dietary Supplement|caffeine|caffeine daily intake will be reduced form 150 ml per day
469622|NCT00628303|Biological|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
469623|NCT00628303|Other|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
469624|NCT00628290|Drug|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
469625|NCT00628290|Drug|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
469626|NCT00628277|Behavioral|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
469627|NCT00628277|Behavioral|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
469628|NCT00628264|Drug|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
469629|NCT00628264|Drug|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
469630|NCT00628251|Drug|AZD2281|400mg Oral twice daily
469631|NCT00628251|Drug|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
469632|NCT00628251|Drug|AZD2281|200mg oral twice daily
469633|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
469634|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
469635|NCT00628225|Behavioral|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
469636|NCT00628225|Behavioral|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
469637|NCT00628212|Drug|Teneligliptin 10mg|
469638|NCT00628212|Drug|Teneligliptin 20 mg|
469639|NCT00628212|Drug|Teneligliptin 40 mg|
469640|NCT00628212|Drug|Placebo|
469641|NCT00628199|Procedure|Improving the scientific process of human cell reprogramming|
469642|NCT00628186|Device|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
469643|NCT00628186|Device|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
469644|NCT00628173|Procedure|AGV implantation|
469645|NCT00628160|Drug|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
469646|NCT00628160|Drug|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
469647|NCT00628147|Device|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
469648|NCT00628134|Drug|calfactant|single inhaled dose by nebulizer
469649|NCT00628134|Drug|isotonic saline|single inhaled dose by nebulizer
469650|NCT00628121|Drug|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
469651|NCT00628108|Drug|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
469652|NCT00628108|Other|Placebo|Placebo oral liquid once a day for two weeks
469653|NCT00628095|Drug|CE-224,535|500 mg po BID
469654|NCT00628095|Drug|Placebo|no active ingredient
469655|NCT00628056|Drug|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
469656|NCT00628043|Drug|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
469657|NCT00628043|Drug|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
469658|NCT00628030|Behavioral|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
469659|NCT00628030|Other|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
469660|NCT00628017|Dietary Supplement|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
469661|NCT00628004|Device|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
469662|NCT00628004|Device|Local best practice|"N/A - since intervention is local best practice"
469663|NCT00627991|Drug|Valsartan|
469664|NCT00627978|Drug|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
469665|NCT00627965|Drug|Sildenafil citrate|50mg tds
469666|NCT00627965|Drug|Placebo|Placebo tds
469667|NCT00627952|Drug|amlodipine 10 mg|amlodipine 10 mg once daily
469668|NCT00627952|Drug|manidipine 20 mg|manidipine 20 mg once daily
469669|NCT00627952|Drug|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
469670|NCT00627952|Drug|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
469671|NCT00627926|Biological|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
469672|NCT00627926|Drug|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
469673|NCT00627926|Drug|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
469674|NCT00627926|Other|Placebo|Telaprevir matching placebo
469675|NCT00627913|Procedure|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
469676|NCT00627913|Procedure|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
469677|NCT00627900|Device|bare metal stent|implantation of a bare metal stent
469678|NCT00627900|Device|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
469679|NCT00627887|Procedure|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
469680|NCT00627887|Drug|venlafaxine|extended release target dose of 300mg/day duration of one year
469681|NCT00627887|Drug|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
469682|NCT00627874|Device|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
469683|NCT00627861|Drug|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
469684|NCT00627861|Drug|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
469685|NCT00627848|Drug|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
469686|NCT00627835|Drug|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
469687|NCT00627835|Drug|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
469688|NCT00627835|Drug|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
469689|NCT00627835|Drug|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
469690|NCT00627835|Drug|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
469691|NCT00627809|Drug|Streptokinase|intracoronary infusion, 250.000 Units
469692|NCT00627809|Procedure|primary percutaneous coronary intervention|balloon catheter, stent
469693|NCT00627796|Drug|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were < 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels <1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
469694|NCT00627783|Other|a bicycle exercise test|
469695|NCT00627770|Device|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
469696|NCT00627744|Drug|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
469697|NCT00627731|Drug|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
469698|NCT00627731|Drug|prednisolone (PSL)|PSL 40 mg per day for 10 days
469699|NCT00627718|Device|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
469700|NCT00627705|Drug|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
469701|NCT00627705|Other|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks~Entire intervention lasts for 12 weeks (drug administration is continuous)."
469702|NCT00627692|Drug|Prucalopride|0.5 mg o.d.
469703|NCT00627692|Other|Placebo|o.d.
469704|NCT00627692|Drug|Prucalopride|1 mg o.d.
469705|NCT00627692|Drug|Prucalopride|2 mg o.d.
469706|NCT00627692|Drug|Prucalopride|4 mg o.d.
469707|NCT00627679|Drug|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
469708|NCT00627679|Drug|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
469709|NCT00627679|Drug|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
469710|NCT00627679|Drug|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
469711|NCT00627666|Biological|anti-thymocyte globulin|
469712|NCT00627666|Drug|busulfan|
469713|NCT00627666|Drug|fludarabine phosphate|
469714|NCT00627666|Drug|leucovorin calcium|
469715|NCT00627666|Drug|methotrexate|
469716|NCT00627666|Procedure|allogeneic bone marrow transplantation|
469717|NCT00627666|Procedure|allogeneic hematopoietic stem cell transplantation|
469718|NCT00627666|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
469719|NCT00627653|Drug|fenofibrate|148mg daily for 30 days
469720|NCT00627640|Drug|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
469721|NCT00627640|Drug|Matching Placebo|Matching Placebo
469722|NCT00627627|Drug|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
469723|NCT00627614|Other|breast imaging study|"1. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.~2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
469724|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
469725|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
469726|NCT00627575|Drug|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
469727|NCT00627575|Drug|atorvastatin|Atorvastatin will available as 40 mg tablets.
469728|NCT00627575|Drug|phenytoin|Phenytoin will available as 100 mg capsules.
469729|NCT00627562|Device|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
469730|NCT00627549|Procedure|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
469731|NCT00627549|Procedure|Conventional surgery (anterior repair)|Anterior repair surgery
469732|NCT00627536|Drug|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
469733|NCT00627536|Drug|Placebo|Matched to avotermin dosage strength
469734|NCT00627523|Drug|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
469735|NCT00627523|Drug|Control-no treatment|Control-no treatment
469736|NCT00627510|Other|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
469737|NCT00627497|Procedure|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
469738|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
469739|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
469740|NCT00627497|Device|Fusion|Posterolateral Interbody Fusion
469741|NCT00627484|Procedure|Gastric bypass|NOTE: the surgery is not paid for by the study
469742|NCT00627484|Procedure|Gastric banding|NOTE: the surgery is not paid for by the study
469743|NCT00627484|Procedure|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
469744|NCT00627484|Behavioral|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
469745|NCT00627471|Drug|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
469746|NCT00627471|Drug|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.~For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
469747|NCT00627458|Biological|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
469748|NCT00627445|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
469749|NCT00627445|Drug|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
469750|NCT00627445|Drug|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
469751|NCT00627432|Drug|gemcitabine hydrochloride|
469752|NCT00627432|Drug|oxaliplatin|
469753|NCT00627419|Drug|IPI-504|Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
469754|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
469755|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
469756|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
469757|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
469758|NCT00627393|Drug|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
469759|NCT00627393|Biological|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10^10 per collection (or proportionately less for participants less than 30 kg in weight).
469760|NCT00627393|Drug|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
469761|NCT00627393|Device|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
469762|NCT00627380|Behavioral|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
469763|NCT00627380|Other|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
469764|NCT00627367|Drug|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
469765|NCT00627367|Drug|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
469766|NCT00627354|Drug|etoposide|
469767|NCT00627354|Drug|mitoxantrone hydrochloride|
469768|NCT00627354|Drug|prednisone|
469769|NCT00627354|Drug|vinorelbine tartrate|
469770|NCT00627341|Behavioral|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
469771|NCT00627341|Behavioral|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
469772|NCT00627315|Procedure|Gastric bypass|NOTE: Surgery will not be paid by the study
469773|NCT00627315|Procedure|Gastric banding|NOTE: Surgery will not be paid by the study
469774|NCT00627302|Drug|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
469775|NCT00627302|Drug|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
469776|NCT00627276|Dietary Supplement|omega-3 fatty acid|Oral, 3 times daily
469777|NCT00627276|Other|placebo|Oral, 3 times daily
469778|NCT00627263|Behavioral|Stress reduction treatment (SRT) program|The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
469779|NCT00627250|Drug|Amantadine|Amantadine 100 mg every morning and 12 noon
469780|NCT00627237|Behavioral|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
469781|NCT00627237|Behavioral|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
469782|NCT00627211|Procedure|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
469783|NCT00627185|Behavioral|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
469784|NCT00627185|Other|No intervention arm|
469785|NCT00627159|Other|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
469786|NCT00627159|Other|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
469787|NCT00627146|Drug|ChAgly CD3|6 days treatment 8mg/d intravenous
469788|NCT00627146|Drug|Placebo|6 days
469789|NCT00627133|Drug|levetiracetam|2 gram iv load, 500mg bid
469790|NCT00627120|Drug|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
469791|NCT00627107|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
469792|NCT00627094|Device|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
469793|NCT00627094|Device|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
469794|NCT00627081|Drug|remifentanil|dosage
469795|NCT00627055|Drug|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
469796|NCT00627055|Drug|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
469797|NCT00627042|Biological|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
469798|NCT00627029|Behavioral|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
469799|NCT00627016|Drug|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
469800|NCT00627016|Drug|Placebo|1 capsule, orally, once daily for 4 weeks
469801|NCT00627003|Drug|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
469802|NCT00627003|Other|Placebo|Placebo oral tablets administered daily for 5 weeks
469803|NCT00626990|Drug|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
469804|NCT00626990|Genetic|DNA methylation analysis|MGMT methylation status is used for stratification at randomization.
469805|NCT00626990|Other|laboratory biomarker analysis|Prognostic factor analyses
469806|NCT00626990|Procedure|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
469807|NCT00626990|Procedure|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
469808|NCT00626990|Radiation|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
469809|NCT00626977|Drug|ropivacaine|15 ml of ropivacaine 0.125% peridural once
469810|NCT00626977|Drug|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
469811|NCT00626964|Procedure|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
469812|NCT00626964|Behavioral|Conservative Treatment:|Intensive Lifestyle Intervention Program
469813|NCT00626951|Device|LMA Supreme|Extraglottic airway devices
469814|NCT00626951|Device|LMA ProSeal|
469815|NCT00626925|Drug|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
469816|NCT00626925|Drug|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
469817|NCT00626912|Procedure|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
469818|NCT00626886|Drug|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
469819|NCT00626886|Drug|placebo collagen sponge|collagen
469820|NCT00626873|Drug|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
469821|NCT00626873|Other|medical chart review|
469822|NCT00626860|Biological|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
469823|NCT00626834|Drug|Vigabatrin|Dose 1 BID
469824|NCT00626834|Drug|Vigabatrin|Dose 2 BID
469825|NCT00626834|Drug|Vigabatrin|Dose 3 BID
469826|NCT00626834|Drug|Matching placebo|Matching placebo BID
469827|NCT00626821|Device|SenSura|Real life assessment of SenSura
469828|NCT00626808|Drug|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
469829|NCT00626795|Drug|TD1414 2% cream|BID 7 days
469830|NCT00626795|Drug|TD1414 2% cream|TID 7 days
469831|NCT00626795|Drug|Bactroban® (mupirocin) 2% cream|BID 7 days
469832|NCT00626782|Drug|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
469833|NCT00626782|Drug|Mitomycin (MMC)|Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
469834|NCT00626769|Dietary Supplement|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
469835|NCT00626769|Dietary Supplement|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
469836|NCT00626756|Device|LiDCO technology|non invasive monitoring of cardiac output
469837|NCT00626743|Drug|SK3530 100mg, Placebo, Amlodipine|
469838|NCT00626730|Procedure|adjuvant therapy|
469839|NCT00626730|Radiation|radiation therapy|
469840|NCT00626717|Procedure|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
469841|NCT00626717|Procedure|Sham treatment|Fluorescein eye drops. Exposure with blue light
469842|NCT00626704|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
469843|NCT00626704|Other|Placebo|Inactive dummy AMG 655 (to maintain blind)
469844|NCT00626704|Drug|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
469845|NCT00626691|Behavioral|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
469846|NCT00626678|Drug|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
469895|NCT00626340|Drug|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
469954|NCT00625989|Drug|Aeroallergen|
469847|NCT00626678|Drug|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
469848|NCT00626678|Drug|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
469849|NCT00626665|Drug|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
469850|NCT00626652|Drug|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
469851|NCT00626639|Drug|Placebo|Administered by intravenous (IV) bolus injection
469852|NCT00626639|Drug|palifermin|Administered by intravenous (IV) bolus injection
469853|NCT00626639|Radiation|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation [one fraction per day])
469854|NCT00626639|Drug|Cisplatin|100 mg/m^2 intravenously (IV) on days 1, 22 and 43.
469855|NCT00626626|Drug|Clofar, Cyclophos, Alemtuzumab|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
469856|NCT00626626|Drug|Clofar, Cyclophos,Alemtuzumab(Ph II)|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
469857|NCT00626613|Drug|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
469858|NCT00626600|Drug|Oxycodone Hydrochloride|
469859|NCT00626587|Device|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
469860|NCT00626574|Drug|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
469861|NCT00626574|Drug|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
469862|NCT00626561|Drug|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
469863|NCT00626561|Drug|Paclitaxel|60 mg/m^2 IV weekly on days 1, 8, 15, and 22.
469864|NCT00626548|Drug|ZD4054|10 mg once daily oral dose
469865|NCT00626548|Drug|Palcebo|Matching Plcebo oral tablet once daily
469866|NCT00626535|Drug|Esomeprazole|20mg Oral Once Daily
469867|NCT00626535|Drug|Matching placebo|Oral Once Daily
469868|NCT00626522|Drug|Aclidinium bromide and formoterol|once daily
469869|NCT00626522|Drug|Aclidinium bromide and formoterol placebo|once daily
469870|NCT00626509|Drug|sunitinib malate|
469871|NCT00626509|Procedure|adjuvant therapy|
469872|NCT00626509|Procedure|neoadjuvant therapy|
469873|NCT00626509|Procedure|therapeutic conventional surgery|
469874|NCT00626483|Biological|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10^7) is being assessed.
469875|NCT00626483|Drug|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
469876|NCT00626470|Procedure|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
469877|NCT00626457|Behavioral|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
469878|NCT00626444|Drug|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
469879|NCT00626431|Drug|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
469880|NCT00626431|Drug|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
469881|NCT00626418|Drug|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
469882|NCT00626418|Drug|Placebo|Placebo tablets
469883|NCT00626405|Biological|bevacizumab|Given IV over 30-90 minutes
469884|NCT00626405|Drug|carboplatin|Given IV over 30 minutes
469885|NCT00626405|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
469886|NCT00626405|Drug|temozolomide|Oral temozolomide on days 1-5
469887|NCT00626392|Drug|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
469888|NCT00626392|Drug|aspirin (ASA)|325 mg tablets administered once daily
469889|NCT00626392|Drug|aspirin placebo (ASA Pbo)|Tablets administered once daily
469890|NCT00626366|Radiation|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
469891|NCT00626366|Drug|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
469892|NCT00626366|Drug|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
469893|NCT00626353|Other|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
469894|NCT00626353|Other|Standard care|Standard care during hospital stay and in the municipality after discharge
469896|NCT00626340|Drug|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
469897|NCT00626340|Drug|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
469898|NCT00626340|Drug|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
469899|NCT00626327|Biological|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
469900|NCT00626327|Biological|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
469901|NCT00626327|Biological|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
469902|NCT00626314|Biological|myoblast|autologous myoblast
469903|NCT00626314|Biological|sham|sham injection procedure
469904|NCT00626301|Drug|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
469905|NCT00626288|Drug|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
469906|NCT00626288|Drug|Placebo|Placebo cpr, t.i.d. 12 weeks
469907|NCT00626275|Drug|ADL5859|
469908|NCT00626275|Drug|Naproxen|
469909|NCT00626275|Drug|Placebo|
469910|NCT00626275|Drug|ADL5859|
469911|NCT00626275|Drug|Placebo|
469912|NCT00626262|Drug|Esomeprazole|Oral and Intravenous
469913|NCT00626249|Drug|Technosphere Inhalation Powder|Technosphere Inhalation Powder
469914|NCT00626236|Drug|SPN-810|capsule taken three times a day
469915|NCT00626236|Drug|SPN-810|capsule taken TID
469916|NCT00626236|Drug|SPN-810|capsule taken TID
469917|NCT00626236|Drug|SPN-810|capsule taken TID
469918|NCT00626223|Drug|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
469919|NCT00626223|Drug|folic acid|5 mg per day of oral folic acid
469920|NCT00626210|Drug|modafinil|100-400 mg daily for 4 weeks
469921|NCT00626197|Drug|corticosteroids|Intravenous and oral repeating dose
469922|NCT00626197|Drug|cyclophosphamide|Intravenous repeating dose
469923|NCT00626197|Drug|mycophenolate mofetil|oral repeating dose
469924|NCT00626197|Drug|ocrelizumab|Intravenous repeating dose
469925|NCT00626197|Drug|placebo|Intravenous repeating dose
469926|NCT00626184|Drug|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
469927|NCT00626171|Procedure|Allergen Challenge|Allergen challenge
469928|NCT00626158|Drug|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
469929|NCT00626158|Drug|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
469930|NCT00626145|Procedure|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
469931|NCT00626145|Procedure|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
469932|NCT00626132|Dietary Supplement|Eucommia|two capsules three times a day orally for 2 weeks
469933|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 2 - placebo with exemestane or fulvestrant
469934|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 3 - roll over to open-label AMG 479 with exemestane or fulvestrant
469935|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 1 - AMG 479 administered with exemestane or fulvestrant
469936|NCT00626093|Device|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).~Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
469937|NCT00626080|Drug|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
469938|NCT00626080|Drug|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
469939|NCT00626067|Device|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
469940|NCT00626067|Device|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
469941|NCT00626067|Device|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
469942|NCT00626054|Drug|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
469943|NCT00626054|Drug|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
469944|NCT00626041|Other|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
469945|NCT00626028|Drug|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent®
469946|NCT00626028|Drug|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent®
469947|NCT00626028|Drug|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
469948|NCT00626015|Biological|PEP-3-KLH conjugate vaccine|Given intradermally
469949|NCT00626015|Biological|daclizumab|Given IV
469950|NCT00626015|Drug|temozolomide|Given by mouth.
469951|NCT00626015|Other|placebo|Given IV
469952|NCT00626015|Biological|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
469953|NCT00626002|Drug|ABT-874|100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
469955|NCT00625976|Behavioral|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
469956|NCT00625976|Behavioral|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
469957|NCT00625950|Procedure|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
469958|NCT00625937|Drug|cisplatin|
469959|NCT00625937|Drug|docetaxel|
469960|NCT00625937|Drug|tegafur-gimeracil-oteracil potassium|
469961|NCT00625937|Radiation|radiation therapy|
469962|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
469963|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
469964|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
469965|NCT00625911|Drug|morphine|intravenous patient controlled analgesia, standard protocol
469966|NCT00625911|Drug|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
469967|NCT00625898|Drug|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B~100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
469968|NCT00625898|Drug|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B~First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
469969|NCT00625898|Drug|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
469970|NCT00625898|Drug|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B~15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
469971|NCT00625898|Drug|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
469972|NCT00625898|Drug|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
469973|NCT00625898|Drug|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
469974|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
469975|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
469976|NCT00625859|Drug|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
469977|NCT00625859|Drug|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
469978|NCT00625859|Drug|Placebo|Placebo tablets will be given to subjects.
469979|NCT00625846|Other|Laboratory Biomarker Analysis|Correlative studies
469980|NCT00625846|Drug|Pazopanib Hydrochloride|Given PO
469981|NCT00625833|Drug|Placebo|Oral tablet once a day dosing for 10 weeks.
469982|NCT00625833|Drug|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
469983|NCT00625820|Drug|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
469984|NCT00625820|Dietary Supplement|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
469985|NCT00625807|Behavioral|RR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing relaxation
469986|NCT00625807|Behavioral|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week for 1.5 hours. Participants will be asked to perform stress reduction techniques each night for 20 minutes throughout the entire 8-week course. Stress reduction techniques use meditative techniques that focus primarily on inducing mindfulness
469987|NCT00625794|Drug|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
469988|NCT00625794|Behavioral|Smoking cessation counseling|8 weeks or counseling
469989|NCT00625781|Drug|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
469990|NCT00625768|Drug|AS1409|Study drug
469991|NCT00625755|Biological|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
469992|NCT00625742|Behavioral|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
469993|NCT00625742|Behavioral|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
469994|NCT00625742|Drug|Melatonin|20 mg by mouth (PO) Daily
469995|NCT00625742|Dietary Supplement|Juven|90 calories of Juven, twice a day.
469996|NCT00625742|Drug|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted.
469997|NCT00625742|Drug|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
469998|NCT00625729|Biological|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
470573|NCT00621894|Drug|Placebo|Placebo
469999|NCT00625729|Biological|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10^7 cells/kg).
470000|NCT00625729|Biological|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m^2
470001|NCT00625729|Drug|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
470002|NCT00625729|Drug|fludarabine phosphate|Day -6 through day -2, 25 mg/m^2 intravenous (IV)
470003|NCT00625703|Drug|Linezolid|"Pharmacokinetics~daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
470004|NCT00625690|Other|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
470005|NCT00625690|Procedure|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
470006|NCT00625690|Procedure|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
470007|NCT00625690|Procedure|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
470008|NCT00625677|Biological|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
470009|NCT00625677|Biological|Menjugate (Meningococcal C conjugate vaccine)|Dosage
470010|NCT00625664|Drug|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
470011|NCT00625664|Drug|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
470012|NCT00625664|Drug|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
470013|NCT00625651|Drug|Placebo|Inactive dummy AMG 655 (to maintain blind)
470014|NCT00625651|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
470015|NCT00625651|Drug|Modified FOLFOX6|Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)] administered by intravenous infusion once every 14 days (+3 days)
470016|NCT00625651|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
470017|NCT00625638|Behavioral|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
470018|NCT00625638|Other|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
470019|NCT00625625|Drug|isosulfan blue|
470020|NCT00625625|Genetic|polymerase chain reaction|
470021|NCT00625625|Other|diagnostic laboratory biomarker analysis|
470022|NCT00625625|Other|immunohistochemistry staining method|
470023|NCT00625625|Procedure|diagnostic lymphadenectomy|
470024|NCT00625625|Procedure|therapeutic conventional surgery|
470025|NCT00625625|Procedure|therapeutic lymphadenectomy|
470026|NCT00625612|Drug|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
470027|NCT00625612|Drug|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
470028|NCT00625599|Other|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
470029|NCT00625586|Biological|RAV12 plus gemcitabine|"Initial dose of gemcitabine plus RAV12 at 0.375 mg/kg qw escalated to 0.75 mg/kg qw.~During the efficacy segment, 63 pts were to be treated with gemcitabine 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days plus RAV12 at Maximum Tolerated Dose (MTD) iv days 1; 4 or 5; 8, 11 or 12; and 15, 18 or 19 of each 28-day cycle until progression."
470030|NCT00625573|Drug|Abraxane|100mg/m2 every week X's 3
470031|NCT00625560|Drug|Entecavir|entecavir 1.0 mg QD
470032|NCT00625560|Drug|Lamivudine|lamivudine 100 mg QD
470033|NCT00625547|Drug|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
470034|NCT00625547|Drug|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
470189|NCT00624546|Drug|Prevacid Solutabs|BID Prevacid Solutabs
470190|NCT00624546|Procedure|Antireflux surgery|Lap Nissen
470035|NCT00625534|Procedure|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
470036|NCT00625534|Procedure|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
470037|NCT00625521|Drug|ASF 1096 0.5 % cream applied twice daily|
470038|NCT00625521|Drug|Cream vehicle for ASF 1096 cream applied twice daily|
470039|NCT00625495|Drug|Esomeprazole|40mg Intravenous infusion over 3 minutes
470040|NCT00625495|Drug|Esomeprazole|40mg Oral
470041|NCT00625482|Biological|OPV|
470042|NCT00625482|Biological|OPV plus BCG|
470043|NCT00625482|Biological|OPV|
470044|NCT00625482|Biological|OPV plus BCG|
470045|NCT00625469|Drug|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
470046|NCT00625456|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10^5 pfu/kg to 3 x 10^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
470047|NCT00625443|Drug|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
470048|NCT00625443|Drug|Open Label (Avatrombopag tablets)|"Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
470049|NCT00625443|Drug|Blinded (Avatrombopoag tablets)|"Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months"
470050|NCT00625430|Biological|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.~Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.~If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.~Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
470051|NCT00625417|Procedure|breast biopsy|
470052|NCT00625417|Procedure|histopathologic examination|
470053|NCT00625417|Procedure|light-scattering spectroscopy|
470054|NCT00625417|Procedure|therapeutic conventional surgery|
470055|NCT00625404|Drug|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
470056|NCT00625404|Other|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
470057|NCT00625391|Drug|Placebo|500 mg medicinal starch pills daily
470058|NCT00625391|Drug|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
470059|NCT00625391|Drug|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
470060|NCT00625391|Drug|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
470061|NCT00625378|Drug|Sorafenib (Nexavar, BAY43-9006)|
470062|NCT00625365|Drug|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
470063|NCT00625352|Drug|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
470064|NCT00625339|Drug|Entecavir|entecavir 0.5 mg QD
470065|NCT00625339|Drug|Lamivudine|lamivudine 100 mg QD
470066|NCT00625326|Drug|COL-121|75 µg/g COL-121 Ointment
470067|NCT00625326|Drug|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
470068|NCT00625326|Drug|Placebo|Placebo
470069|NCT00625326|Drug|COL-121|150 µg/g COL-121 Ointment
470070|NCT00625326|Drug|COL-121|300 µg/g COL-121 Ointment
470071|NCT00625313|Device|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
470072|NCT00625300|Device|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
470073|NCT00625300|Device|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
470074|NCT00625274|Drug|Esomeprazole|40mg Oral
470075|NCT00625274|Drug|Lansoprazole|30mg Oral
470076|NCT00625274|Drug|Pantoprazole|40mg Oral
470077|NCT00625261|Other|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
470078|NCT00625248|Drug|Antithrombotics|With or without or discontinuted use of Antithrombotics
470079|NCT00625235|Dietary Supplement|VLED followed by a high protein or high carbohydrate diet|
470080|NCT00625222|Procedure|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
470081|NCT00625209|Drug|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
470082|NCT00625209|Drug|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
470083|NCT00625209|Drug|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
470084|NCT00625209|Drug|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
470085|NCT00625196|Drug|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
470086|NCT00625196|Drug|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
470087|NCT00625196|Drug|Vilanterol|Vilanterol will be available as dry powder inhaler.
470088|NCT00625196|Drug|Placebo|Placebo will be supplied as dry powder inhaler.
470089|NCT00625183|Dietary Supplement|selenomethionine|
470090|NCT00625183|Drug|capecitabine|
470091|NCT00625183|Drug|oxaliplatin|
470092|NCT00625183|Other|laboratory biomarker analysis|
470093|NCT00625183|Other|pharmacological study|
470094|NCT00625183|Procedure|adjuvant therapy|
470095|NCT00625183|Procedure|neoadjuvant therapy|
470096|NCT00625183|Procedure|therapeutic conventional surgery|
470097|NCT00625183|Radiation|radiation therapy|
470098|NCT00625170|Drug|olanzapine|olanzapine 10 mg/day for 8 days
470099|NCT00625170|Drug|Haloperidol|haloperidol 3 mg/day for 8 days
470100|NCT00625157|Drug|ASF 1096 0.5 % cream|
470101|NCT00625157|Drug|ASF 1096 placebo cream|
470102|NCT00625131|Drug|Nicotine|Delivered through transdermal nicotine patch
470103|NCT00625131|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
470104|NCT00625131|Drug|Bupropion Sustained Release (SR)|Antidepressant
470105|NCT00625131|Drug|Placebo patch|Pre-treatment placebo transdermal patch
470106|NCT00625105|Behavioral|Biofeedback|
470107|NCT00625092|Drug|fluorouracil|Post-operative day 1 and day 2, 600mg/m^2 intraperitoneal (IP) held for 23 hours
470108|NCT00625092|Drug|leucovorin calcium|Day 0 200 mg/m^2 intraperitoneal held for 2 hours
470109|NCT00625092|Drug|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m^2
470110|NCT00625092|Procedure|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
470111|NCT00625079|Drug|sildenafil|the dose of sildenafil will be 20mg three times per day (orally)
470112|NCT00625066|Other|biologic sample preservation procedure|
470113|NCT00625066|Other|cytology specimen collection procedure|
470114|NCT00625066|Other|medical chart review|
470115|NCT00625066|Other|questionnaire administration|
470116|NCT00625066|Other|survey administration|
470117|NCT00625066|Procedure|biopsy|
470118|NCT00625066|Procedure|evaluation of cancer risk factors|
470119|NCT00625066|Procedure|screening colonoscopy|
470120|NCT00625053|Procedure|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
470121|NCT00625053|Procedure|Open midline incisional hernia repair|"Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
470122|NCT00625040|Other|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water~Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT~Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water~Gastric Emptying Rate: Paracetamol absorption test."
470123|NCT00625027|Other|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
470124|NCT00625014|Drug|Haloperidol|Haloperidol 3 mg/day for 8 days
470125|NCT00624988|Procedure|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
470126|NCT00624975|Biological|Peru-15 Vaccine|up to 1 x 10^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
470127|NCT00624975|Biological|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
470128|NCT00624962|Dietary Supplement|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
470129|NCT00624962|Dietary Supplement|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
470130|NCT00624936|Drug|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
470240|NCT00624299|Drug|Botox|Botox injection (100 ius) per muscle
470131|NCT00624936|Drug|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
470132|NCT00624923|Drug|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
470133|NCT00624923|Drug|Placebo|Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
470134|NCT00624910|Drug|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
470135|NCT00624910|Drug|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
470136|NCT00624871|Drug|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
470137|NCT00624871|Drug|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
470138|NCT00624871|Drug|Placebo|
470139|NCT00624858|Drug|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise"
470140|NCT00624845|Drug|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
470141|NCT00624845|Drug|Vehicle|Maximum of 6 bags of vehicle irrigation solution
470142|NCT00624832|Drug|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
470143|NCT00624832|Drug|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
470144|NCT00624819|Biological|GSK1024805A|No vaccination in this trial
470145|NCT00624819|Biological|Prevenar|No vaccination in this trial
470146|NCT00624806|Behavioral|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
470147|NCT00624806|Behavioral|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
470148|NCT00624793|Other|Acupuncture|Standard Acup point protocol for treating nausea
470149|NCT00624793|Other|Individualized Acup based on TCM diagnosis|Acup
470150|NCT00624793|Other|Sham Acup|Sham Acup - Non-Active
470151|NCT00624780|Drug|Pregabalin|Pregabalin 150-300 mg given twice a day
470152|NCT00624780|Drug|Lorazepam|Lorazepam 3-4 mg given twice a day
470153|NCT00624780|Drug|Pregabalin|Pregabalin 450-600 mg given twice a day
470154|NCT00624780|Drug|Placebo|Placebo
470155|NCT00624767|Drug|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
470156|NCT00624767|Drug|NovoLog|NovoLog at doses up to 30 IU
470157|NCT00624754|Drug|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
470158|NCT00624754|Drug|lactose|Lactose 2 puffs b.i.d for 1 month
470159|NCT00624741|Drug|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
470160|NCT00624728|Radiation|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).~Specific activity of 18FLT will be more than 37 GBq/µmol (>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (> 95%) via HPLC technique and thin layer chromatography.~18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.~PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
470161|NCT00624715|Drug|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
470162|NCT00624715|Drug|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
470163|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
470164|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
470165|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
470166|NCT00624702|Drug|Placebo|
470167|NCT00624689|Dietary Supplement|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
470168|NCT00624676|Drug|Lipo Hydroxy Acid|Twice a day
470169|NCT00624676|Drug|5% benzoyl peroxide gel|Once a day
470170|NCT00624663|Drug|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
470238|NCT00624312|Drug|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit~Day of surgery - injection of 60,000 IU of Procrit"
470239|NCT00624312|Drug|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo~Day of surgery - injection with 60,000 IU of placebo"
470171|NCT00624650|Drug|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour~Initiation:~Continuous IV furosemide at 3mg/hour or last known protocol specified dose~Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal~Do not exceed 30mg/hour~Furosemide Bolus:~If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows~By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour~Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
470172|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP<8 or measured PaOP <12mmHg in addition to concurrent urine output of <0.5 ml/kg/hr
470173|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.~Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases > 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map < 60 or who are on vasopressors that also have a measured GEDI less than goal"
470174|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
470175|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)~Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.~Vasopressin - 0.04 international units/hour~Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.~Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.~Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.~In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of < 60"
470176|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.~Used in patients with a measured cardiac index < 2.5"
470177|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.~Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.~If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
470178|NCT00624650|Other|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.~EVLW arm: Patients with a MAP > 60 and off vasopressors for >12 hours, as well as patients with a measured cardiac index >2.5 that also have a measured GEDI > goal."
470179|NCT00624650|Drug|Diuresis (furosemide) part II|"Withhold furosemide if:~Significant hypokalemia (K+ <= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists~Dialysis dependence~Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF~More than 800mg has been given in less then 24 hours~Creatinine increases > 1.5 mg/dl in any 24 hour period"
470180|NCT00624650|Procedure|Dialysis|"Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.~CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.~EVLW arm: Fluid balance as per algorithm~When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
470181|NCT00624637|Other|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
470182|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
470183|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
470184|NCT00624598|Behavioral|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
470185|NCT00624585|Drug|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE~Dose Level and Dose of dasatinib:~Starting dose (1-8 weeks)= 100 mg orally (po) daily~+1 (<8 weeks if no PR and well tolerated) = 150 mg po daily~DOSE MODIFICATION OF DASATINIB~Dose Level and Dose of dasatinib:~Starting dose = 100 mg po daily~-1 = 70 mg po daily~-2 = 50 mg po daily~OR~Dose Level and Dose of dasatinib:~Starting dose = 150 mg po daily~-1 = 120 mg po daily~-2 = 90 mg po daily~-3 = 50 mg po daily"
470186|NCT00624572|Drug|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
470187|NCT00624559|Drug|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
470188|NCT00624559|Other|Placebo|Placebo pill taken twice per day on each day of the diet
471449|NCT00616161|Drug|Placebo|Placebo
470191|NCT00624533|Behavioral|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
470192|NCT00624533|Behavioral|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.~Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
470193|NCT00624520|Behavioral|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
470194|NCT00624520|Other|Patient Education|"10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease."
470195|NCT00624494|Device|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
470196|NCT00624494|Device|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
470197|NCT00624481|Drug|Teriparatide|20ug subcutaneous injection daily for 24 weeks
470198|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
470199|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
470200|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
470201|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
470202|NCT00624468|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
470203|NCT00624468|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
470204|NCT00624455|Drug|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
470205|NCT00624455|Drug|Placebo|Placebo
470206|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.125 mg/kg/hr followed by 1 hour at 0.0625 mg/kg/hr
470207|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 1 hour at 0.125 mg/kg/hr
470208|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 1 hour at 0.25 mg/kg/hr
470209|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.75 mg/kg/hr followed by 1 hour at 0.375 mg/kg/hr
470210|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 1 hour at 0.5 mg/kg/hr
470211|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 1 hour at 0.125 mg/kg/hr followed by 22 hours at 0.025 mg/kg/hr
470212|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 1 hour at 0.25 mg/kg/hr followed by 22 hours at 0.05 mg/kg/hr
470213|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 1 hour at 0.5 mg/kg/hr followed by 22 hours at 0.1 mg/kg/hr
470214|NCT00624442|Drug|Placebo|I.V. infusion for 2 hours
470215|NCT00624442|Drug|Placebo|I.V. infusion for 24 hours
470216|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0mg/kg/hr followed 1 hour at 0.5mg/kg/hr followed by 70 hours at 0.1mg/kg/hr
470217|NCT00624442|Drug|Placebo|I.V. infusion for 72 hours
470218|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.75 mg/kg/hr followed 1 hour at 0.5mg/kg/hr followed by 70 hours at 0.1 mg/kg/hr
470219|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 23 hours at 0.025 mg/kg/hr
470220|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 23 hours at 0.05 mg/kg/hr
470221|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 23 hours at 0.1 mg/kg/hr
470222|NCT00624429|Drug|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
470223|NCT00624416|Drug|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
470224|NCT00624403|Device|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
470225|NCT00624403|Device|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
470226|NCT00624390|Device|Sepraspray|
470227|NCT00624377|Drug|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
470228|NCT00624364|Drug|biphasic insulin aspart|
470229|NCT00624364|Drug|metformin|
470230|NCT00624351|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
470231|NCT00624351|Other|Placebo|Phosphate-buffered Saline (PBS) infusion.
470232|NCT00624338|Drug|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
470233|NCT00624338|Drug|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
470234|NCT00624338|Other|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
470235|NCT00624325|Drug|interferon alfa-2b|12 MU daily continuously subcutaneous
470236|NCT00624325|Drug|interferon alfa-2b|9 MU daily continuously subcutaneous
470237|NCT00624325|Drug|interferon alfa-2b|6 MU daily continuously subcutaneous
470241|NCT00624299|Other|Saline|Saline injection
470242|NCT00624286|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
470243|NCT00624286|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
470244|NCT00624273|Drug|Sildenafil therapy|oral use
470245|NCT00624260|Other|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
470246|NCT00624260|Other|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
470247|NCT00624247|Other|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
470248|NCT00624234|Behavioral|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
470249|NCT00624234|Behavioral|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
470250|NCT00624221|Procedure|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
470251|NCT00624208|Drug|droperidol and saline|droperidol 20 mcg.kg-1 and saline
470252|NCT00624208|Drug|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
470253|NCT00624208|Drug|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
470254|NCT00624208|Drug|saline and saline|saline and saline
470255|NCT00624195|Drug|FDA Approved Antiretroviral Therapy (see list below)|"Combinations of FDA approved antiretroviral agents:~Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress~Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
470256|NCT00624182|Biological|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
470257|NCT00624182|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
470258|NCT00624169|Procedure|An optimized perioperative course|A number of interventions before, during and after surgery
470259|NCT00624156|Behavioral|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
470260|NCT00624156|Behavioral|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
470261|NCT00624143|Drug|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
470262|NCT00624130|Drug|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
470263|NCT00624130|Drug|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
470264|NCT00624117|Behavioral|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
470265|NCT00624104|Dietary Supplement|Food (fat free meal)|Fat free meal (40% of REE)
470266|NCT00624091|Procedure|Cardiac surgery|Cardiac surgery within 48 hours of randomization
470267|NCT00624091|Procedure|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
470268|NCT00624078|Drug|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
470269|NCT00624065|Drug|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
470270|NCT00624065|Drug|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
470271|NCT00624052|Drug|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
470272|NCT00624052|Drug|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
470273|NCT00624039|Other|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
470274|NCT00624026|Drug|Memantine-HCl|20 mg per day (once daily)
470275|NCT00624013|Drug|sertraline|50 mg up to 100 mg daily for 6 months
473166|NCT00603252|Biological|Engerix-B|
470276|NCT00624013|Drug|Placebo|50 mg up to 100 mg daily for 6 months
470277|NCT00624000|Drug|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
470278|NCT00623987|Drug|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
470279|NCT00623974|Drug|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
470280|NCT00623974|Drug|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
470281|NCT00623974|Drug|Calcitriol|0.25 micrograms PO Every 12 Hours
470282|NCT00623948|Device|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
470283|NCT00623935|Drug|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
470284|NCT00623935|Drug|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
470285|NCT00623935|Radiation|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
470286|NCT00623935|Procedure|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
470287|NCT00623922|Behavioral|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
470288|NCT00623909|Device|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
470289|NCT00623883|Procedure|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
470290|NCT00623883|Procedure|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
470291|NCT00623870|Drug|RO5045337|Multiple ascending doses
470292|NCT00623857|Dietary Supplement|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
470293|NCT00623857|Dietary Supplement|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
470294|NCT00623857|Dietary Supplement|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
470295|NCT00623857|Dietary Supplement|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
470296|NCT00623844|Behavioral|physical activity|activity program at kindergarten 5 * 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
470297|NCT00623831|Biological|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
470298|NCT00623805|Drug|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
470299|NCT00623805|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
470300|NCT00623805|Drug|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
470301|NCT00623792|Behavioral|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
470302|NCT00623779|Drug|AZD0837|ER formulation
470303|NCT00623779|Drug|Aspirin|Oral form
470304|NCT00623766|Drug|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
470305|NCT00623766|Drug|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
470306|NCT00623766|Drug|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
470307|NCT00623766|Drug|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
470308|NCT00623766|Drug|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
470309|NCT00623766|Drug|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
470310|NCT00623766|Drug|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
470311|NCT00623766|Drug|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
470312|NCT00623766|Drug|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
470313|NCT00623766|Drug|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
470361|NCT00623402|Drug|Sorafenib|2x 400 mg orally per day (4 tablets)
470362|NCT00623402|Drug|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
470403|NCT00623090|Behavioral|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
470314|NCT00623753|Biological|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
470315|NCT00623740|Drug|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
470316|NCT00623740|Drug|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
470317|NCT00623727|Biological|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
470318|NCT00623727|Biological|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
470319|NCT00623714|Drug|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
470320|NCT00623714|Drug|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
470321|NCT00623701|Biological|Allerslit forte|sublingual placebo preparation, daily
470322|NCT00623701|Biological|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
470323|NCT00623688|Device|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
470324|NCT00623688|Device|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
470325|NCT00623675|Dietary Supplement|Mineralox C|Mineralox C 2 capsules three times a day.
470326|NCT00623662|Other|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
470327|NCT00623662|Other|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
470328|NCT00623649|Drug|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
470329|NCT00623649|Drug|Placebo|Dose escalation study with a full review of all safety data following each cohort.
470330|NCT00623636|Drug|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
470331|NCT00623636|Drug|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
470332|NCT00623623|Procedure|primary PCI|Standard primary PCI
470333|NCT00623623|Drug|enoxaparin|Adjunctive treatment
470334|NCT00623623|Procedure|catheterisation|Routine or rescue coronary intervention
470335|NCT00623623|Drug|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
470336|NCT00623623|Drug|clopidogrel|Adjunctive treatment
470337|NCT00623610|Procedure|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
470338|NCT00623597|Drug|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
470339|NCT00623597|Drug|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
470340|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
470341|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
470342|NCT00623571|Other|Treatment of elderly patients in a GMW|
470343|NCT00623571|Other|Treatment of elderly patients in GHHS|
470344|NCT00623558|Drug|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
470345|NCT00623558|Drug|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
470346|NCT00623558|Drug|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
470347|NCT00623545|Drug|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
470348|NCT00623532|Behavioral|Mind-body exercises|
470349|NCT00623532|Behavioral|Adapted Tai-chi|
470350|NCT00623506|Drug|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:~Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
470351|NCT00623506|Drug|Placebo|"Placebo for two weeks (placebo lead in), then:~Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
470352|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
470353|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
470354|NCT00623467|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
470355|NCT00623454|Behavioral|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
470356|NCT00623441|Device|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
470357|NCT00623428|Drug|peginterferon alfa-2a|
470358|NCT00623428|Drug|Ribavirin|
470359|NCT00623415|Drug|Flupirtine|300 mg daily (divided in two doses)
470360|NCT00623415|Drug|Placebo|twice daily
473167|NCT00603252|Biological|Havrix|
470363|NCT00623389|Device|IST-16 (16-channel implanted stimulator-telemeter)|Pre-surgical exercise with surface electrical stimulation, surgery including electrode insertion and IST-16 stimulator/telemeter implantation, exercise and physical therapy with the implanted system, functional training and laboratory assessment of clinical and technical performance.
470364|NCT00623376|Drug|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
470365|NCT00623376|Drug|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
470366|NCT00623363|Drug|piclozotan|piclozotan, IV
470367|NCT00623363|Drug|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline)
470368|NCT00623350|Other|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
470369|NCT00623350|Other|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
470370|NCT00623337|Behavioral|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy & 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify & refer sick babies
470371|NCT00623324|Drug|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
470372|NCT00623324|Drug|Placebo|Placebo tablets to match the number of active tablets
470373|NCT00623298|Behavioral|Narrative Exposure Therapy|
470374|NCT00623298|Behavioral|group IPT|
470375|NCT00623298|Other|6 months-baseline|
470376|NCT00623285|Drug|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
470377|NCT00623285|Drug|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
470378|NCT00623272|Other|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
470379|NCT00623259|Biological|MVA-mBN120B|
470380|NCT00623246|Behavioral|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
470381|NCT00623246|Behavioral|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
470382|NCT00623233|Drug|Gemcitabine|Gemcitabine 2500 mg/m^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
470383|NCT00623233|Drug|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event [AE], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)~Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
470384|NCT00623220|Other|N2O|EMONO
470385|NCT00623220|Other|oxygen|oxygen
470386|NCT00623207|Drug|Atropine|I.V Atropine 0.5mg up to 2 mg
470387|NCT00623194|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
470388|NCT00623194|Drug|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
470389|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
470390|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
470391|NCT00623168|Drug|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
470392|NCT00623155|Drug|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
470393|NCT00623142|Drug|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
470394|NCT00623129|Other|questionnaire administration|
470395|NCT00623129|Procedure|electroacupuncture therapy|
470396|NCT00623129|Procedure|management of therapy complications|
470397|NCT00623129|Procedure|quality-of-life assessment|
470398|NCT00623116|Drug|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
470399|NCT00623103|Drug|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
470400|NCT00623103|Drug|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm^2/day delivering 9.5 mg over a 24 hour period.
470401|NCT00623090|Behavioral|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
470402|NCT00623090|Behavioral|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
470404|NCT00623077|Biological|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm^2.~Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
470405|NCT00623077|Drug|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age),every 6 hours on Days -8 through -6.
470406|NCT00623077|Drug|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m^2/day intravenous (IV) over 1 hour for 5 days.
470407|NCT00623077|Drug|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day intravenous (IV) over 1 hour on for 5 days.
470408|NCT00623077|Drug|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m^2 intravenous (IV) over 30 min on Days -5 through -4.
470409|NCT00623077|Drug|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m^2 intravenously (IV) over 2 hrs on Days -3 through -2.
470410|NCT00623077|Procedure|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
470411|NCT00623077|Radiation|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy~/minute (instantaneous dose rate)."
470412|NCT00623077|Radiation|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
470413|NCT00623077|Drug|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day divided in every 6 hrs dosing for 5 days.
470414|NCT00623077|Radiation|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
470415|NCT00623064|Drug|cisplatin|
470416|NCT00623064|Drug|gemcitabine hydrochloride|
470417|NCT00623064|Drug|lapatinib ditosylate|
470418|NCT00623064|Other|pharmacological study|
470419|NCT00623051|Procedure|Male Circumcision|
470420|NCT00623025|Drug|Creon 25000|6 to 9 capsules Creon 25000 per day
470421|NCT00623025|Drug|Placebo|6 to 9 capsules placebo per day
470422|NCT00623012|Drug|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
470423|NCT00623012|Drug|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
470424|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
470425|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
470426|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
470427|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
470428|NCT00622973|Other|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
470429|NCT00622973|Other|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
470430|NCT00622960|Other|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
470431|NCT00622960|Other|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
470432|NCT00622947|Procedure|right temporal low frequency (1 hz) rTMS|Right temporal low frequency (1 hz) rTMS.
470433|NCT00622947|Procedure|Sham-rTMS|The coil is angled 90 degrees away from the scalp
470434|NCT00622934|Drug|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
470435|NCT00622934|Drug|placebo|placebo
470436|NCT00622921|Behavioral|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
470437|NCT00622908|Drug|ISV-403|0.6% TID, 5 days
470438|NCT00622908|Drug|Vehicle|Vehicle of ISV-403 TID, 5 days
470439|NCT00622895|Drug|fludarabine phosphate|Given IV
470440|NCT00622895|Drug|Mycophenolic Acid|Given PO
470441|NCT00622895|Drug|tacrolimus|Given PO
470442|NCT00622895|Radiation|total-body irradiation|Undergo TBI
470443|NCT00622895|Procedure|bone marrow transplantation|Undergo transplantation
470444|NCT00622895|Procedure|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
470445|NCT00622895|Procedure|quality-of-life assessment|Ancillary studies
470446|NCT00622895|Other|laboratory biomarker analysis|Correlative studies
470447|NCT00622895|Other|flow cytometry|Correlative studies
470448|NCT00622895|Procedure|biopsy|Punch biopsy of skin involved with scleroderma
470569|NCT00621920|Drug|FM-601|Dose-escalation, split dosage, liquid
473168|NCT00603252|Biological|HBVAXPRO|
470449|NCT00622882|Other|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
470450|NCT00622869|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
470451|NCT00622869|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
470452|NCT00622869|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
470453|NCT00622869|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
470454|NCT00622869|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
470455|NCT00622869|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
470456|NCT00622856|Behavioral|psychological intervention|Psychological intervention
470457|NCT00622856|Behavioral|Diabetes education|5 sessions with diabetes nurse
470458|NCT00622843|Biological|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:~2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
470459|NCT00622843|Biological|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
470460|NCT00622830|Drug|SB-480848 (Darapladib)|
470461|NCT00622817|Drug|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
470462|NCT00622817|Drug|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
470463|NCT00622804|Procedure|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
470464|NCT00622804|Procedure|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
470465|NCT00622804|Procedure|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
470466|NCT00622765|Drug|placebo|Placebo capsule twice daily
470467|NCT00622765|Drug|R256918|5 mg capsule twice daily
470468|NCT00622765|Drug|R256918|10 mg capsule twice daily
470469|NCT00622765|Drug|R256918|15 mg capsule twice daily
470470|NCT00622752|Drug|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
470471|NCT00622752|Drug|placebo|2 X placebo tablets to match EVT 302 5 mg
470472|NCT00622752|Drug|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
470473|NCT00622752|Device|NRT placebo|Medically inert plaster cut to match the NRT plaster
470474|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
470475|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
470476|NCT00622726|Drug|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
470477|NCT00622726|Procedure|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
470570|NCT00621907|Drug|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
470571|NCT00621907|Drug|sodium chloride|sodium chloride : 0,9% 30 ml
470478|NCT00622713|Drug|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm^2.
470479|NCT00622700|Drug|Teriflunomide|Film-coated tablet Oral administration
470480|NCT00622700|Drug|Placebo|Film-coated tablet Oral administration
470481|NCT00622687|Drug|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
470482|NCT00622687|Drug|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
470483|NCT00622687|Drug|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
470484|NCT00622674|Biological|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
470485|NCT00622674|Drug|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
470486|NCT00622661|Other|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
470487|NCT00622661|Other|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
470488|NCT00622648|Drug|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
470489|NCT00622648|Drug|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
470490|NCT00622635|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
470491|NCT00622635|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
470492|NCT00622635|Drug|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
470493|NCT00622622|Biological|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
470494|NCT00622609|Drug|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
470495|NCT00622609|Drug|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
470496|NCT00622596|Other|Mobile Access|Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
470497|NCT00622570|Drug|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
470498|NCT00622570|Drug|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion"
470499|NCT00622531|Device|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
470500|NCT00622531|Other|hidden BNP value|no intervention
470501|NCT00622518|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
470502|NCT00622505|Drug|zoledronic acid|4 mg either 4 or 12 weeks for 96 weeks
470503|NCT00622492|Other|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
470504|NCT00622479|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
470505|NCT00622466|Drug|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
470506|NCT00622466|Drug|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
470507|NCT00622453|Other|Screening|Electrocardiography Blood Test
470508|NCT00622440|Drug|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
470509|NCT00622440|Drug|Placebo|Placebo twice daily for 48 weeks.
470510|NCT00622427|Drug|Ramelteon|8 mg tablets every night for 2 weeks
470511|NCT00622427|Drug|Placebo|placebo tablets for every night for 2 weeks
470512|NCT00622414|Biological|ziv-aflibercept|Given IV
470513|NCT00622401|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
470514|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 30ng/kg
470515|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 100ng/kg
470516|NCT00622388|Drug|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
470517|NCT00622375|Drug|mesalamine|encapsulated mesalamine granules
470518|NCT00622362|Biological|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
470519|NCT00622362|Biological|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
470520|NCT00622362|Biological|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
470521|NCT00622349|Drug|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
470522|NCT00622349|Drug|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
470523|NCT00622349|Drug|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
470524|NCT00622336|Drug|CC-5013|Oral 25mg daily on Days 1-21 every 28 days.
470525|NCT00622336|Drug|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
470572|NCT00621894|Drug|LGD-4665|LGD-4665 Thrombopoietin mimetic
470526|NCT00622310|Behavioral|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (~6.8 kg) during the 6 month intervention.
470527|NCT00622284|Drug|Placebo identical to BI 1356 5mg|Placebo tablet once daily
470528|NCT00622284|Drug|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
470529|NCT00622284|Drug|BI 1356|5mg, once daily in the morning for 104 weeks
470530|NCT00622284|Drug|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
470531|NCT00622271|Behavioral|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
470532|NCT00622258|Drug|Everolmus|
470533|NCT00622245|Drug|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
470534|NCT00622245|Drug|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
470535|NCT00622245|Drug|Placebo|per oral doses, twice daily as capsules during 13 weeks
470536|NCT00622232|Genetic|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
470537|NCT00622219|Other|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
470538|NCT00622206|Drug|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
470539|NCT00622193|Drug|anamorelin HCl|50 mg tablet
470540|NCT00622193|Drug|anamorelin HCl|100 mg tablet
470541|NCT00622193|Drug|placebo|placebo tablet
470542|NCT00622180|Device|NBUVB|NBUVB hand foot box
470543|NCT00622180|Device|Monochromacitc Excimer light|Treatment with Monochromacitc Excimer light
470544|NCT00622167|Device|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
470545|NCT00622167|Device|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
470546|NCT00622141|Drug|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
470547|NCT00622128|Behavioral|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
470548|NCT00622115|Drug|Enoxaparin|
470549|NCT00622102|Behavioral|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
470550|NCT00622102|Behavioral|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
470551|NCT00622089|Drug|DIO-902|150mg DIO-902 + 10mg atorvastatin
470552|NCT00622089|Drug|DIO-902|300mg dose once per day for 24 weeks
470553|NCT00622089|Drug|DIO-902|450mg dose once per day for 24 weeks
470554|NCT00622076|Procedure|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
470555|NCT00622063|Drug|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
470556|NCT00622050|Behavioral|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
470557|NCT00622050|Behavioral|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
470558|NCT00622037|Drug|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
470559|NCT00622037|Drug|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
470560|NCT00622011|Drug|Risperidone and Zolpidem for delirium|try risperidone or zolpidem in the treatment of delirium
470561|NCT00621998|Drug|risperidone|0.5-6 mg/day
470562|NCT00621998|Drug|olanzapine|2.5-20 mg/day
470563|NCT00621985|Drug|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
470564|NCT00621985|Drug|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
470565|NCT00621959|Drug|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
470566|NCT00621959|Drug|placebo|0mg (matching oral tablet)for 14 days
470567|NCT00621946|Drug|Placebo|Placebo Matching Escitalopram
470568|NCT00621946|Drug|Escitalopram|Active Escitalopram
470574|NCT00621881|Drug|naproxcinod|750 mg bid
470575|NCT00621868|Drug|ipragliflozin|Oral
470576|NCT00621868|Drug|Placebo|Oral
470577|NCT00621855|Drug|placebo|matched placebo
470578|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
470579|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
470580|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
470581|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
470582|NCT00621842|Drug|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
470583|NCT00621842|Drug|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.~Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
470584|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
470585|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
470586|NCT00621816|Drug|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
470587|NCT00621816|Drug|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
470588|NCT00621803|Drug|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
470589|NCT00621790|Drug|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
470590|NCT00621790|Drug|placebo|placebo
470591|NCT00621777|Drug|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
470592|NCT00621777|Drug|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.~In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
470593|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
470594|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
470595|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
470596|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
470597|NCT00621751|Drug|Carbamazepine|800 mg daily
470598|NCT00621751|Drug|Placebo|Placebo
470599|NCT00621725|Drug|AZD2171|Oral dose
470600|NCT00621712|Device|GamCath® central venous catheter|choice of catheter type
470601|NCT00621712|Device|GamCath Dolphin® Protect central venous catheter|choice of catheter type
470602|NCT00621699|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
470603|NCT00621699|Drug|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
470604|NCT00621699|Drug|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
470605|NCT00621686|Biological|bevacizumab|
470606|NCT00621686|Drug|sorafenib tosylate|
470607|NCT00621673|Drug|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
470608|NCT00621660|Procedure|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
470609|NCT00621660|Procedure|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
470610|NCT00621647|Drug|Quetiapine Fumarate|
470611|NCT00621647|Drug|Quetiapine Fumarate|
470612|NCT00621647|Drug|Placebo|
470613|NCT00621634|Dietary Supplement|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
470614|NCT00621634|Dietary Supplement|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
470615|NCT00621621|Device|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
470616|NCT00621608|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
470617|NCT00621608|Procedure|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
470618|NCT00621595|Dietary Supplement|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
470619|NCT00621569|Behavioral|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
470620|NCT00621569|Behavioral|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
470621|NCT00621556|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
470622|NCT00621543|Device|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
470623|NCT00621530|Drug|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
470624|NCT00621530|Drug|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
470625|NCT00621517|Drug|Bupropion|Partipants will receive 150 mg bupropion per night
470626|NCT00621517|Drug|Placebo|1 capsule nightly for six weeks
470627|NCT00621504|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
470628|NCT00621504|Drug|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
470629|NCT00621504|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
470630|NCT00621504|Drug|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
470631|NCT00621491|Drug|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
470632|NCT00621478|Drug|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.~The medication will be administered as a slow IV push."
470633|NCT00621465|Behavioral|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
470634|NCT00621465|Behavioral|Usual care|Usual care will include the standard aftercare and community care services.
470635|NCT00621452|Biological|therapeutic autologous lymphocytes|Given IV
470636|NCT00621452|Drug|cyclophosphamide|Given IV
470637|NCT00621452|Biological|aldesleukin|Given subcutaneously
470638|NCT00621452|Genetic|polymerase chain reaction|Correlative studies
470639|NCT00621452|Genetic|gene rearrangement analysis|Correlative studies
470640|NCT00621452|Procedure|lymph node biopsy|Optional correlative studies
470641|NCT00621452|Biological|genetically engineered lymphocyte therapy|Receive genetically modified T cells
470642|NCT00621452|Procedure|bone marrow aspiration|Optional correlative studies
470643|NCT00621452|Other|flow cytometry|Correlative studies
470644|NCT00621452|Other|laboratory biomarker analysis|Correlative studies
470645|NCT00621452|Other|enzyme-linked immunosorbent assay|Correlative studies
470646|NCT00621439|Drug|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
470647|NCT00621439|Drug|Placebo|Patients will receive placebo.
470705|NCT00621049|Drug|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:~Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1~Docetaxel should be administered before carboplatin.~Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
470648|NCT00621400|Drug|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
470649|NCT00621400|Drug|Melphalan|0,18mg/Kg/day from day 1- 4
470650|NCT00621400|Drug|Dexamethasone|40mg/day from day 1- 4.
470651|NCT00621387|Drug|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
470652|NCT00621387|Drug|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
470653|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
470654|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT)|"One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain."
470655|NCT00621374|Behavioral|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
470656|NCT00621374|Behavioral|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
470657|NCT00621361|Drug|AZD2171|Oral
470658|NCT00621361|Drug|Etoposide|Intravenous
470659|NCT00621361|Drug|Cisplatin|Intravenous
470660|NCT00621348|Drug|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
470661|NCT00621348|Drug|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
470662|NCT00621348|Drug|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
470663|NCT00621322|Biological|GSK Biologicals' AS01B adjuvant|Intramuscular injection, 2 doses
470664|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1|Intramuscular injection, 2 doses
470665|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2|Intramuscular injection, 2 doses
470666|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3|Intramuscular injection, 2 doses
470667|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1|Intramuscular injection, 2 doses
470668|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2|Intramuscular injection, 2 doses
470669|NCT00621309|Drug|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
470670|NCT00621309|Dietary Supplement|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
470671|NCT00621309|Dietary Supplement|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
470672|NCT00621296|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
470673|NCT00621283|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
470674|NCT00621270|Drug|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
470675|NCT00621257|Dietary Supplement|ergocalciferol|8000 units/ml
470676|NCT00621257|Dietary Supplement|Cholecalciferol|400 units per drop
470677|NCT00621244|Drug|LBH589|
470678|NCT00621231|Dietary Supplement|Placebo|Placebo
470679|NCT00621231|Dietary Supplement|Protein|30 E% from protein
470680|NCT00621218|Drug|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
470681|NCT00621218|Drug|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
470682|NCT00621205|Behavioral|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
470706|NCT00621036|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
470707|NCT00621036|Biological|sargramostim|
470683|NCT00621192|Drug|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.~20 mg/kg every 12 hours in infants <32 weeks GA and PNA < 2 weeks 20 mg/kg every 8 hours in infants <32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA < 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
470684|NCT00621179|Drug|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
470685|NCT00621179|Drug|Leuprolide acetate|leuprolide acetate 20 mcg subcutaneously twice daily for two days or 0.5 mg daily for 7 days prior to initiation of controlled ovarian stimulation
470686|NCT00621179|Drug|leuprolide acetate|Leuprolide acetate 20 mcg subcutaneously twice daily or 0.5 mg subcutaneously once daily prior to initiation of gonadotropin stimulation
470687|NCT00621166|Drug|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.~Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
470688|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
470689|NCT00621153|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
470690|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
470691|NCT00621140|Drug|linagliptin|active
470692|NCT00621140|Drug|placebo|placebo
470693|NCT00621114|Device|GamCath® central venous catheter|Choice of central venous catheter type
470694|NCT00621114|Device|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
470695|NCT00621101|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
470696|NCT00621101|Drug|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
470697|NCT00621101|Drug|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
470698|NCT00621088|Procedure|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
470699|NCT00621075|Other|Pulmonary Arterial Hypertension - Lung Perfusion Scans|Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
470700|NCT00621062|Procedure|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
470701|NCT00621062|Procedure|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
470702|NCT00621062|Procedure|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
470703|NCT00621062|Procedure|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
470704|NCT00621049|Drug|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1~Docetaxel should be administered before carboplatin.~After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:~Maintenance Treatment for patients in Cohort A:~Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily~Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
470708|NCT00621036|Drug|methotrexate|
470709|NCT00621036|Drug|thiotepa|
470710|NCT00621036|Radiation|radiation therapy|
470711|NCT00621023|Drug|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
470712|NCT00621010|Drug|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
470713|NCT00620997|Drug|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
470714|NCT00620997|Drug|saline drops|saline drops continuously PRN for up to 7 days
470715|NCT00620971|Drug|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
470716|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
470717|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
470718|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
470719|NCT00620971|Drug|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
470720|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
470721|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
470722|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
470723|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
470724|NCT00620958|Behavioral|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
470725|NCT00620958|Behavioral|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
470726|NCT00620958|Behavioral|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
470727|NCT00620945|Drug|Phenoxybenzamine|"Use of Phenoxybenzamine:~Loading dose given at the time of going on CPB:~For patients with obstructing lesions on systemic side:~0.25 mg/kg dose in the bypass circuit~None intravenous~For patients without obstructing left sided lesions:~0.5 mg/kg in the bypass circuit~0.5 mg/kg I.V. at cannulation~Maintenance dose given in the post-operative period:~0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours~0.3 mg/kg P.O. every 8 hours for next 24 hours~0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop~Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group"
470728|NCT00620932|Behavioral|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
470729|NCT00620919|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
470730|NCT00620906|Procedure|Manipulation|HVLA manipulation to Sacroiliac Joint
470731|NCT00620893|Drug|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
470732|NCT00620893|Drug|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
470733|NCT00620880|Behavioral|Blood sample|
470734|NCT00620867|Drug|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
470735|NCT00620867|Drug|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
470736|NCT00620867|Other|placebo|matched placebo orally for 6 weeks
470737|NCT00620854|Drug|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
470738|NCT00620854|Drug|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
470739|NCT00620854|Drug|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
470740|NCT00620854|Drug|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
470741|NCT00620841|Other|genotyping|Restriction fragment lenght polymorphisms
470742|NCT00620828|Other|Placebo saline injection|20 cc of sterile, injectable saline
470743|NCT00620828|Drug|Ropivicaine 0.5%|Ropivicaine
470744|NCT00620815|Biological|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
470745|NCT00620815|Biological|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
470746|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
470881|NCT00619918|Drug|Nebulized 3% saline|4 ml inhaled q8h
470747|NCT00620815|Biological|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
470748|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
470749|NCT00620815|Biological|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
470750|NCT00620802|Drug|CGT-2168|(CGT-2168, one capsule each daily)
470751|NCT00620802|Drug|Plavix|(clopidogrel, 75 mg)
470752|NCT00620789|Drug|Escitalopram + CBT-I|"Escitalopram, 10 mg daily for the duration of the study (6 months)~CBT-I, four biweekly sessions during eight week Treatment phase."
470753|NCT00620789|Behavioral|CBT-I plus placebo antidepressant medication|"CBT-I, 4 biweekly sessions, eight week Treatment phase.~Placebo,daily for duration of study(6 months)."
470754|NCT00620789|Drug|Escitalopram|"Escitalopram, 10 mg daily for the duration of the study (6 months)~SH, four biweekly sessions during eight week Treatment phase"
470755|NCT00620776|Behavioral|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
470756|NCT00620776|Drug|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
470757|NCT00620763|Other|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
470758|NCT00620763|Other|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
470759|NCT00620750|Drug|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
470760|NCT00620737|Biological|Autologous Human Fibroblasts (Isolagen TherapyTM)|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
470761|NCT00620737|Biological|Placebo|"Collection of skin biopsy.~Administration of 2 study injections~Performance of various study assessments during clinic visits"
470762|NCT00620724|Drug|Placebo|Placebo three times daily
470763|NCT00620724|Drug|Nifedipine|20 mg of slow-release Nifedipine three times daily
470764|NCT00620711|Device|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
470765|NCT00620685|Drug|Placebo|Tablet, once daily for 4 weeks
470766|NCT00620685|Drug|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
470767|NCT00620685|Drug|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
470768|NCT00620672|Dietary Supplement|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
470769|NCT00620672|Dietary Supplement|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
470770|NCT00620659|Drug|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
470771|NCT00620659|Drug|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
470772|NCT00620659|Drug|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
470773|NCT00620646|Drug|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
470774|NCT00620646|Drug|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
470775|NCT00620633|Biological|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
470776|NCT00620620|Drug|Inhaled placebo|Inhaled Staccato Placebo
470777|NCT00620620|Drug|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
470778|NCT00620620|Drug|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
470779|NCT00620620|Drug|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
470780|NCT00620620|Drug|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
470781|NCT00620607|Drug|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
470782|NCT00620594|Drug|BEZ235|
470783|NCT00620581|Drug|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
470784|NCT00620568|Drug|SLV-313 SR|sustained release tablets taken once daily for 14 days
470785|NCT00620555|Drug|gabapentin|Orally administered gabapentin
470786|NCT00620542|Drug|Rosuvastatin|capsule, oral, once daily
470787|NCT00620542|Drug|Atorvastatin|capsule, oral, one daily
470788|NCT00620529|Dietary Supplement|Ocean Nutrition 2050|1000mg capsules, 4 capsules/day for 8 weeks
470789|NCT00620529|Dietary Supplement|Olive oil capsules|Olive oil capsules, 4 per day for 8 weeks
470790|NCT00620503|Drug|Proellex 25 mg formulation A|One Proellex 25 mg formulation A capsule
470791|NCT00620503|Drug|Proellex 25 mg formulation B|One 25 mg Proellex capsule formulation B administered both fed and fasted
470792|NCT00620490|Drug|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
470793|NCT00620490|Other|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
470794|NCT00620477|Drug|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
470795|NCT00620477|Drug|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
470796|NCT00620464|Drug|Radiopaque Implanon|Radiopaque rod for 3 years
470797|NCT00620464|Drug|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
470798|NCT00620451|Drug|larazotide acetate|gelatin capsule
470799|NCT00620451|Drug|placebo|gelatin capsule
470800|NCT00620438|Drug|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
470801|NCT00620438|Drug|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
470802|NCT00620438|Drug|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
470803|NCT00620425|Drug|Sumatriptan|injection
470804|NCT00620412|Dietary Supplement|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10^10 LGG organisms.
470805|NCT00620412|Dietary Supplement|placebo control|2 capsules by mouth twice a day for 28 days
470806|NCT00620412|Biological|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
470807|NCT00620399|Other|lumbar corset|
470808|NCT00620386|Device|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
470809|NCT00620386|Device|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
470810|NCT00620373|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
470811|NCT00620373|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
470812|NCT00620373|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
470813|NCT00620360|Dietary Supplement|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
470814|NCT00620360|Dietary Supplement|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
470815|NCT00620347|Drug|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
470816|NCT00620321|Drug|LY2181308 sodium|750 milligrams (mg) is administered as a 3-hour intravenous infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 (28 days) and Days 1, 8, 15, 22 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
470817|NCT00620321|Drug|cytarabine|1.5 grams per square meter (g/m²) will be administered as a 4-hour intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
470818|NCT00620321|Drug|idarubicin|12 milligrams per square meter (mg/m²) will be administered as a 30-minute intravenous infusion on Days 3, 4, 5 of Cycle 1 (28 days) and on Days 1, 2, 3 of Cycle 2 (28 days) until disease progression or unacceptable toxicity develops.
470819|NCT00620308|Drug|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
470820|NCT00620308|Drug|Placebo|Dextrose 5% in water (the vehicle)
470821|NCT00620295|Drug|bortezomib|Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
470822|NCT00620295|Drug|gemcitabine hydrochloride|Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m^2) on day 1 and day 8 of a 21 day cycle.
470823|NCT00620282|Drug|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
470824|NCT00620282|Drug|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
470825|NCT00620282|Drug|glimepiride|Tablets, 1 - 4 mg daily
470826|NCT00620269|Drug|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
470827|NCT00620269|Drug|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
470828|NCT00620269|Drug|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 & 8 every 3 weeks X 2 cycles
470829|NCT00620269|Radiation|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
470830|NCT00620256|Drug|AL-37807 ophthalmic suspension, 0.1%|
470831|NCT00620256|Drug|Timolol gel forming solution, 0.5%|
470832|NCT00620256|Other|AL-37807 ophthalmic solution vehicle|
470833|NCT00620256|Drug|Latanoprost ophthalmic solution|
470834|NCT00620243|Procedure|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
470835|NCT00620230|Drug|NVP-VAK694|
470836|NCT00620230|Drug|NVP-VAK694|
473169|NCT00603252|Biological|Vaqta|
470837|NCT00620217|Genetic|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
470838|NCT00620204|Drug|atorvastatin|atorvastatin 40mg qd for 1 year
470839|NCT00620191|Drug|metformin|metformin 1000 mg twice a day titrated from 500 mg once a day
470840|NCT00620191|Drug|placebo|placebo identical to metformin 2 tablets twice a day titrated from one table once a day
470841|NCT00620178|Drug|Candesartan Cilexetil|oral once daily dose
470842|NCT00620178|Drug|Losartan|once daily oral dose
470843|NCT00620165|Drug|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
470844|NCT00620165|Drug|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
470845|NCT00620152|Behavioral|1|Low glycemic load diet by telephone counseling
470846|NCT00620152|Behavioral|2|Low fat diet by telephone counseling
470847|NCT00620139|Biological|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
470848|NCT00620126|Other|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
470849|NCT00620126|Other|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
470850|NCT00620113|Drug|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
470851|NCT00620113|Dietary Supplement|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
470852|NCT00620113|Dietary Supplement|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
470853|NCT00620113|Drug|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
470854|NCT00620100|Drug|Docetaxel|
470855|NCT00620087|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
470856|NCT00620087|Procedure|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
470857|NCT00620074|Drug|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
470858|NCT00620074|Drug|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
470859|NCT00620061|Drug|Lubiprostone|24 mcg capsules twice daily (BID) for 9 months
470860|NCT00620048|Biological|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
470861|NCT00620035|Drug|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
470862|NCT00620022|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
470863|NCT00620022|Drug|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
470864|NCT00620009|Behavioral|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
470865|NCT00619996|Drug|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously~Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
470866|NCT00619996|Drug|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
470867|NCT00619983|Drug|donepezil|Group 1: Will receive donepezil 5mg once a day
470868|NCT00619983|Drug|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
470869|NCT00619983|Drug|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
470870|NCT00619983|Drug|placebo|Group 4: Will receive placebo pills
470871|NCT00619983|Drug|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
470872|NCT00619970|Procedure|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
470873|NCT00619970|Drug|xifaxan|xifaxan 550mg TID x10days
470874|NCT00619970|Drug|placebo|placebo TID x 10days
470875|NCT00619970|Procedure|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
470876|NCT00619957|Drug|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
470877|NCT00619957|Drug|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
470878|NCT00619944|Drug|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
470879|NCT00619944|Drug|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
470880|NCT00619931|Drug|APD791|APD791 or matching placebo in escalating doses
473822|NCT00598793|Drug|metformin|
470882|NCT00619918|Drug|Placebo|normal saline
470883|NCT00619905|Drug|ACZ885|
470884|NCT00619905|Drug|ACZ885|
470885|NCT00619892|Drug|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
470886|NCT00619892|Drug|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
470887|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
470888|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:~For children >/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.~For children < 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.~Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols*min for the 16 doses.~Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.~Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.~Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
470889|NCT00619879|Other|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
470890|NCT00619879|Radiation|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.~Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) < 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:~Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count~Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
470891|NCT00619866|Drug|Elagolix|Elagolix tablets administered orally
470892|NCT00619866|Drug|placebo|Placebo tablet administered orally
470893|NCT00619853|Behavioral|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
470894|NCT00619853|Behavioral|treatment approach - HABIT|HABIT-2 months, 2Hr per day
470895|NCT00619840|Drug|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
470896|NCT00619840|Drug|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
470897|NCT00619827|Drug|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
470898|NCT00619827|Drug|Placebo tablet|Placebo tablet once daily during four months
470899|NCT00619814|Procedure|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
470900|NCT00619801|Drug|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
470901|NCT00619801|Drug|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
470902|NCT00619788|Device|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
470903|NCT00619775|Device|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
470904|NCT00619762|Device|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
470905|NCT00619749|Dietary Supplement|juice rich in polyphenols|juice during 2 weeks
470906|NCT00619749|Dietary Supplement|juice poor in polyphenols|juice during 2 weeks
470907|NCT00619736|Drug|NSA-789|
470908|NCT00619736|Other|Placebo|
470909|NCT00619723|Drug|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
470910|NCT00619723|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
470911|NCT00619723|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
470912|NCT00619710|Drug|Meropenem|Intravenous
470913|NCT00619710|Drug|Imipenem-cilastatin|Intravenous
470914|NCT00619697|Drug|biphasic insulin aspart|
470915|NCT00619697|Drug|insulin glargine|
470916|NCT00619697|Drug|metformin|
470917|NCT00619697|Drug|glimepiride|
470918|NCT00619684|Drug|lenalidomide|Given PO
470919|NCT00619671|Drug|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
470920|NCT00619658|Other|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
470921|NCT00619645|Drug|busulfan|
470922|NCT00619645|Drug|cyclosporine|
470923|NCT00619645|Drug|fludarabine phosphate|
470924|NCT00619645|Drug|mycophenolate mofetil|
470925|NCT00619645|Procedure|allogeneic hematopoietic stem cell transplantation|
470926|NCT00619645|Procedure|peripheral blood stem cell transplantation|
470927|NCT00619632|Behavioral|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
470928|NCT00619632|Behavioral|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
470929|NCT00619632|Behavioral|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
470930|NCT00619619|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
470931|NCT00619606|Device|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
470932|NCT00619606|Device|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
470933|NCT00619606|Device|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
470934|NCT00619606|Device|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
470935|NCT00619593|Other|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"Assessment of general health status (weight, BP, NYHA)~Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)~Echocardiography (LVEF, LVEDD, mitral regurgitation)~Non-invasive ischemia evaluation~Coronary angiography (if indicated by ischemia evaluation)~Upgrade to CRT, if indicated~Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)~24 hrs ECG Holter (Heart rate variability)~Further treatment (if applicable)~Changes in ICD settings, or medication"
470936|NCT00619593|Other|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
470937|NCT00619567|Behavioral|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
470938|NCT00619541|Drug|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
470939|NCT00619541|Drug|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
470940|NCT00619528|Biological|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
470941|NCT00619515|Other|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
470942|NCT00619515|Procedure|implanted fiducial-based imaging|Undergo fiducial placement imaging
470943|NCT00619515|Radiation|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
470944|NCT00619502|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
470945|NCT00619489|Drug|vedolizumab|Vedolizumab for intravenous (IV) infusion
470946|NCT00619476|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
470947|NCT00619476|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
470948|NCT00619476|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
470949|NCT00619476|Drug|Placebo|placebo
470950|NCT00619463|Behavioral|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
470951|NCT00619463|Behavioral|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
470952|NCT00619450|Other|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
470953|NCT00619424|Drug|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
470954|NCT00619424|Drug|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
470955|NCT00619424|Drug|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
470956|NCT00619411|Behavioral|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
470957|NCT00619398|Drug|Prograf|Oral
470958|NCT00619398|Drug|FK506MR capsule|Oral
470959|NCT00619385|Drug|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
470960|NCT00619372|Drug|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
470961|NCT00619372|Drug|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
470962|NCT00619372|Drug|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
470963|NCT00619372|Drug|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
470964|NCT00619372|Drug|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
470965|NCT00619372|Drug|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
470966|NCT00619359|Drug|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
470967|NCT00619359|Drug|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
471057|NCT00618774|Drug|telmisartan40/amlodipine5|
470968|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
470969|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
470970|NCT00619359|Drug|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
470971|NCT00619346|Drug|Placebo|Placebo tablets, BID X 14 days
470972|NCT00619346|Drug|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
470973|NCT00619333|Drug|follitropin and lutropin|follitropin and lutropin
470974|NCT00619320|Behavioral|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
470975|NCT00619307|Drug|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
470976|NCT00619307|Drug|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
470977|NCT00619268|Drug|Temsirolimus|25 mg once per week administered intravenously
470978|NCT00619268|Drug|Bevacizumab|10 mg/kg * 1 time /2 weeks administered intravenously
470979|NCT00619268|Drug|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
470980|NCT00619268|Drug|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
470981|NCT00619255|Behavioral|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
470982|NCT00619242|Drug|sorafenib|2 tablets with water by mouth twice a day for two weeks.
470983|NCT00619229|Drug|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
470984|NCT00619229|Other|Placebo|Placebo/d i.v. for 15 days
470985|NCT00619216|Drug|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
470986|NCT00619203|Drug|Glycerol and paracetamol|"glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses~paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7"
470987|NCT00619203|Drug|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
470988|NCT00619203|Drug|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
470989|NCT00619203|Drug|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
470990|NCT00619203|Drug|Placebo|2 placebos, one po, one suppository
470991|NCT00619203|Drug|Paracetamol and glycerol|"35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol~1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses"
470992|NCT00619203|Drug|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
470993|NCT00619190|Drug|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
470994|NCT00619164|Drug|E5555|E5555, 50 mg (tablet), taken orally, once a day.
470995|NCT00619164|Drug|E5555|E5555, 100 mg (tablet), taken orally, once a day.
470996|NCT00619164|Drug|E5555|E5555, 200 mg (tablet), taken orally, once a day.
470997|NCT00619164|Drug|Placebo|Placebo tablet taken orally, once a day.
470998|NCT00619151|Device|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
470999|NCT00619151|Device|Regent|Implant of the St. Jude Medical Regent mechanical valve
471000|NCT00619138|Behavioral|individual cognitive-behavioural therapy|1 session per week for 12 weeks
471001|NCT00619138|Behavioral|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
471002|NCT00619125|Other|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
471003|NCT00619112|Drug|temozolomide|single arm study
471004|NCT00619099|Drug|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
471005|NCT00619099|Drug|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
471006|NCT00619086|Drug|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
471007|NCT00619086|Drug|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
471008|NCT00619073|Drug|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
471009|NCT00619073|Drug|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
471010|NCT00619073|Drug|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
471058|NCT00618774|Drug|telmisartan80/amlodipine5|
471011|NCT00619060|Drug|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
471012|NCT00619060|Drug|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
471013|NCT00619034|Drug|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
471014|NCT00619034|Drug|Diclofenac|dicolfenac eyedrops twice daily i one eye
471015|NCT00619034|Drug|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
471016|NCT00619021|Drug|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m^2, 800 mg/m^2, 1000 mg/m^2, 1200 mg/m^2
471017|NCT00619008|Other|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
471018|NCT00619008|Other|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
471019|NCT00619008|Other|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
471020|NCT00618995|Drug|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
471021|NCT00618995|Drug|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
471022|NCT00618995|Drug|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
471023|NCT00618995|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
471024|NCT00618982|Drug|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
471025|NCT00618969|Other|haploidentical allogeneic PBSC transp|"Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days~Day -3: IV melphalan 100 mg/m2 as a single dose~Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days~Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight"
471026|NCT00618956|Drug|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily [BID]), oral administration.
471027|NCT00618956|Drug|Placebo|Placebo
471028|NCT00618943|Behavioral|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
471029|NCT00618930|Drug|Moviprep®|use of Moviprep®
471030|NCT00618930|Drug|Fleet|Use of Fleet
471031|NCT00618917|Genetic|MnSOD|15 ml of a liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL. This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
471032|NCT00618904|Dietary Supplement|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
471033|NCT00618904|Dietary Supplement|Placebo|Placebo administered bid for 6 weeks.
471034|NCT00618878|Procedure|Electroacupuncture|twice a week for 26 treatments in total
471035|NCT00618878|Procedure|Laser Therapy|twice a week for a total of 26 treatments
471036|NCT00618865|Dietary Supplement|Omega-3 fatty acids|
471037|NCT00618852|Drug|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
471038|NCT00618852|Drug|Saline|1 mg/kg by intravenous bolus injection
471039|NCT00618839|Biological|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
471040|NCT00618839|Procedure|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
471041|NCT00618826|Drug|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
471042|NCT00618826|Drug|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
471043|NCT00618826|Drug|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
471044|NCT00618813|Other|radiation therapy|Undergo radiation therapy
471045|NCT00618813|Other|therapeutic conventional surgery|Undergo surgery
471046|NCT00618813|Drug|etoposide|Given IV
471047|NCT00618813|Drug|ifosfamide|Given IV
471048|NCT00618813|Drug|doxorubicin hydrochloride|Given IV
471049|NCT00618813|Drug|cyclophosphamide|Given IV
471050|NCT00618813|Drug|vincristine sulfate|Given IV
471051|NCT00618813|Drug|topotecan hydrochloride|Given IV
471052|NCT00618813|Biological|filgrastim|Given SC
471053|NCT00618800|Behavioral|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
471054|NCT00618800|Other|Written Materials|Participants receive written information about falls prevention.
471055|NCT00618787|Device|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
471056|NCT00618787|Device|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
473823|NCT00598793|Drug|pioglitazone|
471059|NCT00618761|Other|hyperglycemic clamp test|hyperglycemic clamp test
471060|NCT00618748|Drug|Olanzapine|5-20 mg/day, oral, daily
471061|NCT00618735|Drug|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
471062|NCT00618735|Drug|BIIB021|Twice daily dosing
471063|NCT00618722|Drug|Deoxycholic Acid Injection|
471064|NCT00618722|Drug|Placebo|
471065|NCT00618709|Drug|ATX-101|ATX-101 single dose
471066|NCT00618696|Biological|anti-CD45 monoclonal antibody AHN-12|150 mg/m^2 cold antibody at Day 0
471067|NCT00618696|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m^2
471068|NCT00618683|Procedure|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
471069|NCT00618670|Behavioral|Walking Exercise|Three times per week for 3 months
471070|NCT00618670|Behavioral|Control--Resistance Training|Three times per week for 3 months
471071|NCT00618657|Drug|Carboplatin|Given IV
471072|NCT00618657|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
471073|NCT00618657|Drug|bevacizumab|Given IV
471074|NCT00618657|Drug|trastuzumab|Given IV
471075|NCT00618657|Procedure|magnetic resonance imaging|Optional correlative studies
471076|NCT00618657|Procedure|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
471077|NCT00618644|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection
471078|NCT00618631|Drug|Nicotine|
471079|NCT00618631|Drug|Carfentanil|
471080|NCT00618618|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
471081|NCT00618618|Drug|Placebo|
471082|NCT00618605|Biological|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
471083|NCT00618592|Dietary Supplement|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
471084|NCT00618579|Drug|LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects|Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
471085|NCT00618566|Behavioral|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
471086|NCT00618553|Other|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
471087|NCT00618553|Behavioral|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
471088|NCT00618540|Biological|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
471089|NCT00618540|Drug|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age <12 months)
471090|NCT00618540|Drug|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age <12 months)
471091|NCT00618540|Procedure|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
471092|NCT00618527|Drug|mycophenolate mofetil (Cellcept)|1 gram po, bid
471093|NCT00618527|Drug|human interferon beta 1a (Rebif)|44mcg sq injection every other day
471094|NCT00618514|Device|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
471095|NCT00618514|Device|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
471096|NCT00618501|Drug|cytarabine|
471097|NCT00618501|Drug|daunorubicin hydrochloride|
471098|NCT00618501|Drug|etoposide|
471099|NCT00618501|Drug|imatinib mesylate|
471100|NCT00618501|Drug|leucovorin calcium|
471101|NCT00618501|Drug|methotrexate|
471102|NCT00618501|Drug|prednisolone|
471103|NCT00618501|Drug|therapeutic hydrocortisone|
471104|NCT00618501|Drug|vincristine sulfate|
471105|NCT00618501|Procedure|allogeneic hematopoietic stem cell transplantation|
471106|NCT00618488|Dietary Supplement|Probiotic BB12 - Bifidobacterium lactis|Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks
471107|NCT00618488|Dietary Supplement|Placebo|Placebo administered once a day for 6 weeks
471108|NCT00618475|Behavioral|Cognitive behavioral therapy|"10 sessions~1 hour per week"
471109|NCT00618462|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
471110|NCT00618462|Behavioral|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
471111|NCT00618462|Behavioral|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
471112|NCT00618462|Behavioral|Case management|Case management will assist participants in obtaining additional services from the community as needed.
471113|NCT00618462|Behavioral|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
471114|NCT00618449|Drug|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 & Day 30 for a total of 2 doses.
471115|NCT00618449|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
471116|NCT00618436|Drug|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
471117|NCT00618436|Drug|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
471118|NCT00618423|Drug|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
471119|NCT00618423|Drug|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
471120|NCT00618410|Device|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
471121|NCT00618410|Other|Placebo|Nasal placebo
471122|NCT00618397|Drug|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
471123|NCT00618384|Drug|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
471124|NCT00618371|Drug|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
471125|NCT00618358|Device|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
471126|NCT00618358|Other|Gelfoam/Thrombin|
471127|NCT00618345|Drug|everolimus|
471128|NCT00618345|Genetic|DNA analysis|
471129|NCT00618345|Genetic|protein analysis|
471130|NCT00618345|Genetic|western blotting|
471131|NCT00618345|Other|flow cytometry|
471132|NCT00618345|Other|laboratory biomarker analysis|
471133|NCT00618345|Procedure|biopsy|
471134|NCT00618332|Drug|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
471135|NCT00618332|Drug|placebo|2 puffs in each nostril once a day for 2 weeks
471136|NCT00618319|Drug|BIIB021|Dose, schedule, and duration specified in protocol
471137|NCT00618293|Drug|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
471138|NCT00618293|Other|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
471139|NCT00618280|Drug|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
471140|NCT00618254|Drug|Granisetron|
471141|NCT00618241|Drug|lamotrigine|100 mg
471142|NCT00618241|Drug|Raltegravir|400 mg BD
471143|NCT00618228|Drug|Balsalazide|
471144|NCT00618215|Behavioral|peer group educational implementation strategy|"Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice"
471145|NCT00618202|Drug|Balsalazide|
471146|NCT00618176|Drug|Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W>60Kg)125mg bid (W<60Kg) Nevirapine (NVP) 200mg bid
471147|NCT00618176|Drug|Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)|Stavudine (d4T) 30mg bid (W>60Kg)20mg bid (W<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
471148|NCT00618176|Drug|Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
471149|NCT00618163|Drug|Meloxicam|
471150|NCT00618150|Behavioral|Patient education|An educational program: Three lessons spaced over 2 weeks.
471151|NCT00618124|Drug|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
471152|NCT00618111|Drug|Granisetron|
471153|NCT00618098|Biological|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was < 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
471154|NCT00618098|Biological|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of < 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was < 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
471155|NCT00618085|Behavioral|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
471156|NCT00618085|Other|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
471157|NCT00618072|Drug|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
471158|NCT00618059|Drug|Pilocarpine|
471159|NCT00618046|Drug|Oxcarbazepine|
471160|NCT00618033|Procedure|Hemodialysis|varying concentration of glucose in dialysate
471161|NCT00618020|Device|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
471162|NCT00618007|Drug|PF-00734200 30 mg QD|30 mg QD
471163|NCT00618007|Drug|PF-00734200 20 mg QD|20 mg QD
471164|NCT00618007|Drug|Placebo|Placebo
471165|NCT00617994|Drug|Ruxolitinib|Ruxolitinib 1.5% cream BID for 28 days
471166|NCT00617981|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
471167|NCT00617981|Drug|5% Dextrose Solution|Single 30 minute intravenous infusion
471168|NCT00617968|Drug|DOCETAXEL|
471169|NCT00617955|Drug|Aprotinin|compare outcomes of Aprotinin versus Amicar
471170|NCT00617955|Drug|Amicar|compare outcomes of Aprotinin versus Amicar
471171|NCT00617942|Drug|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14~Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
471172|NCT00617942|Drug|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
471173|NCT00617942|Drug|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
471174|NCT00617942|Drug|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
471175|NCT00617929|Biological|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
471176|NCT00617929|Biological|rituximab|administered 375 mg/m^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
471177|NCT00617929|Drug|clofarabine|administered 30 mg/m^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
471178|NCT00617929|Procedure|stem cell transplantation|administered on Day 0 per institutional guidelines.
471179|NCT00617903|Drug|Azelaic acid|15% foam to be applied topically twice daily
471180|NCT00617903|Drug|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
471181|NCT00617890|Biological|robatumumab|Robatumumab IV every two weeks until disease progression.
471182|NCT00617877|Drug|losartan potassium|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
471183|NCT00617877|Drug|Comparator: Hydrochlorothiazide|Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
471184|NCT00617864|Drug|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
471185|NCT00617864|Drug|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
471186|NCT00617851|Biological|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
471187|NCT00617851|Biological|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
471188|NCT00617851|Biological|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
471189|NCT00617851|Biological|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
471190|NCT00617851|Biological|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
471191|NCT00617838|Other|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
471192|NCT00617825|Other|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
471193|NCT00617812|Biological|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
471194|NCT00617799|Biological|aldesleukin|
471195|NCT00617799|Genetic|gene expression analysis|
471196|NCT00617799|Genetic|mutation analysis|
471197|NCT00617799|Other|flow cytometry|
471198|NCT00617786|Procedure|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
471199|NCT00617773|Biological|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
471200|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
471201|NCT00617760|Biological|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
471202|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
471203|NCT00617747|Drug|Zolmitriptan|5mg Nasal Spray
471204|NCT00617747|Drug|Placebo|
471205|NCT00617734|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 milligrams per kilogram (mg/kg) over one hour every two weeks. A cycle is defined as four weeks of therapy. Participants will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
471409|NCT00616538|Device|Epiceram(r)|Topical barrier repair emulsion cream
471410|NCT00616538|Drug|Fluticasone Propionate 0.05%|Topical mid-strength steroid
471206|NCT00617734|Biological|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 milligrams per square meter (mg/m^2) over two hours. This sequence will be repeated every two weeks. Participants will continue on study until evidence of progressive disease or unacceptable toxicity develops.
471207|NCT00617721|Other|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
471208|NCT00617708|Biological|cixutumumab|Given IV
471209|NCT00617708|Drug|erlotinib hydrochloride|Given PO
471210|NCT00617708|Drug|gemcitabine hydrochloride|Given IV
471211|NCT00617695|Drug|Zolmitriptan|5mg nasal spray
471212|NCT00617695|Drug|Placebo|
471213|NCT00617682|Biological|PNCRM9|0.5 mL IM at 30-35 wks gestation
471214|NCT00617682|Biological|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
471215|NCT00617669|Drug|Docetaxel|intravenous infusion given every three weeks
471216|NCT00617669|Drug|ZD4054|10 mg oral once daily dose
471217|NCT00617669|Drug|Placebo|placebo oral tablet once daily
471218|NCT00617656|Drug|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
471219|NCT00617656|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
471220|NCT00617656|Drug|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
471221|NCT00617656|Drug|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
471222|NCT00617643|Drug|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
471223|NCT00617643|Drug|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
471224|NCT00617617|Dietary Supplement|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
471225|NCT00617617|Other|Placebo|Control Group - Control Group participants will receive an identical placebo.
471226|NCT00617604|Drug|Alefacept|IV and subcutaneous injection
471227|NCT00617604|Drug|placebo|IV and subcutaneous injection
471228|NCT00617604|Drug|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
471229|NCT00617604|Drug|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
471230|NCT00617604|Drug|Steroids|"Methylprednisolone or equivalent:~Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus~Prednisone or equivalent:~Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
471231|NCT00617591|Drug|Lenalidomide|25 mg orally on days 1-21
471232|NCT00617591|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated)
471233|NCT00617591|Drug|Dexamethasone|40 mg orally on days on 1-4
471234|NCT00617578|Device|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
471235|NCT00617578|Device|ATP One Shot OFF|Standard defibrillation shock delivery
471236|NCT00617565|Drug|biphasic insulin aspart|
471237|NCT00617565|Drug|biphasic human insulin|
471238|NCT00617552|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
471239|NCT00617552|Drug|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
471240|NCT00617552|Drug|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
471241|NCT00617552|Drug|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
471242|NCT00617552|Drug|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
471243|NCT00617552|Drug|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
471244|NCT00617552|Drug|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
471245|NCT00617552|Drug|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
471246|NCT00617539|Drug|irinotecan hydrochloride|
471247|NCT00617539|Drug|temozolomide|
471248|NCT00617526|Drug|RDEA806 400 mg|
471249|NCT00617526|Drug|Placebo|Placebo
471250|NCT00617526|Drug|RDEA806 1000 mg|
471251|NCT00617526|Drug|RDEA806 600 mg|
471252|NCT00617526|Drug|RDEA806 800 mg|
471253|NCT00617513|Drug|Prucalopride|0.5 mg once daily
471254|NCT00617513|Other|Placebo|o.d.
471255|NCT00617513|Drug|Prucalopride|1 mg o.d.
471256|NCT00617513|Drug|Prucalopride|2 mg o.d.
471257|NCT00617500|Other|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
471258|NCT00617500|Other|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
471259|NCT00617500|Other|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
471260|NCT00617500|Drug|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
471261|NCT00617474|Drug|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
471262|NCT00617474|Drug|Placebo|placebo
471263|NCT00617461|Drug|GEn 1200mg/day|1200mg/day gabapentin enacarbil
471264|NCT00617461|Drug|GEn 3600mg/day|3600mg/day gabapentin enacarbil
471265|NCT00617448|Procedure|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
471450|NCT00616148|Drug|YKP3089|Oral dosage form
471451|NCT00616148|Drug|Placebo|
471266|NCT00617448|Procedure|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
471267|NCT00617448|Procedure|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
471268|NCT00617448|Procedure|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
471269|NCT00617435|Dietary Supplement|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
471270|NCT00617435|Dietary Supplement|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
471271|NCT00617435|Dietary Supplement|control diet|Mixed of different oil
471272|NCT00617409|Drug|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
471273|NCT00617409|Biological|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
471274|NCT00617409|Drug|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
471275|NCT00617396|Drug|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
471276|NCT00617370|Drug|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
471277|NCT00617357|Device|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
471278|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5555 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
471279|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine , 5553 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
471280|NCT00617344|Biological|Tetravalent CYD Dengue Vaccine, 4444 formulation|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
471281|NCT00617331|Biological|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
471282|NCT00617318|Dietary Supplement|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
471283|NCT00617318|Dietary Supplement|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
471284|NCT00617305|Drug|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
471285|NCT00617305|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
471286|NCT00617305|Drug|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
471287|NCT00617305|Drug|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
471288|NCT00617279|Device|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
471289|NCT00617279|Procedure|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
471290|NCT00617266|Other|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
471291|NCT00617266|Other|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
471292|NCT00617266|Other|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
471489|NCT00615810|Drug|Atripla|Open label once daily for oral administration to be taken on an empty stomach
471293|NCT00617266|Other|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
471294|NCT00617253|Drug|recombinant interleukin-21|3 mcg/kg, s.c. injection
471295|NCT00617253|Drug|sunitinib|Hard gelatine capsules, 12.5 mg
471296|NCT00617253|Drug|recombinant interleukin-21|10 mcg/kg, s.c. injection
471297|NCT00617253|Drug|recombinant interleukin-21|30 mcg/kg, s.c. injection
471298|NCT00617253|Drug|recombinant interleukin-21|100 mcg/kg, s.c. injection
471299|NCT00617240|Drug|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
471300|NCT00617240|Drug|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
471301|NCT00617201|Drug|atomoxetine|Once daily oral dosing
471302|NCT00617201|Drug|placebo|Once daily oral dosing - matched placebo
471303|NCT00617188|Drug|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
471304|NCT00617175|Device|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
471305|NCT00617175|Device|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
471306|NCT00617149|Behavioral|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
471307|NCT00617136|Device|Intraoperative warming (Bair Hugger)|Intraoperative warming
471308|NCT00617136|Device|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
471309|NCT00617136|Device|Intraoperative warming (HotDog)|Intraoperative warming
471310|NCT00617123|Drug|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
471311|NCT00617123|Drug|Placebo|matching placebo oral tablet
471312|NCT00617110|Other|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
471313|NCT00617110|Other|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
471314|NCT00617097|Drug|lidocaine|paracervical block with lidocaine
471315|NCT00617097|Drug|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
471316|NCT00617084|Device|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
471317|NCT00617084|Device|Abbott Xience V|Abbott Xience V
471318|NCT00617071|Other|medical chart review|
471319|NCT00617071|Other|survey administration|
471320|NCT00617071|Procedure|fecal occult blood test|
471321|NCT00617071|Procedure|screening colonoscopy|
471322|NCT00617058|Drug|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
471323|NCT00617058|Behavioral|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
471324|NCT00617045|Drug|duloxetine|"Total treatment period is 12 weeks~30mg po qd times 1 week~60mg po qd times 11 weeks"
471325|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
471326|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
471327|NCT00617032|Genetic|tgAAC94 placebo|Single dose
471328|NCT00616993|Drug|Difluprednate|Difluprednate
471329|NCT00616993|Other|Placebo|Vehicle
471330|NCT00616980|Biological|CD34-positive cells|
471331|NCT00616980|Biological|CD34-positive cells|
471332|NCT00616980|Biological|Saline and 5% autologous plasma|
471333|NCT00616967|Drug|carboplatin|Given IV
471334|NCT00616967|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
471335|NCT00616967|Drug|vorinostat|Given orally
471336|NCT00616967|Other|placebo|Given orally
471337|NCT00616954|Drug|ATG-F|ATG-f
471338|NCT00616941|Biological|NY-ESO-1 OLP4|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of 5% dextrose in water (D5W) and administered subcutaneously as a single injection.
471339|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) was diluted in 0.5 mL of D5W, mixed with 0.5 mL of Montanide, and administered subcutaneously as a single injection.
471340|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1.0 mg of NY-ESO-1 OLP4 (0.25 mg of each overlapping peptide) and 1.4 mg of poly-ICLC were emulsified in 1.0 mL of Montanide and administered subcutaneously as two injections.
471341|NCT00616928|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
471342|NCT00616928|Biological|Placebo|Two intramuscular injections at Days 0 and 21.
471343|NCT00616915|Drug|Wellbutrin XL|Wellbutrin XL 300mg daily
471344|NCT00616902|Drug|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
471345|NCT00616902|Drug|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
471346|NCT00616889|Drug|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
471411|NCT00616512|Procedure|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
471412|NCT00616499|Drug|gefitinib|
471413|NCT00616499|Procedure|neoadjuvant therapy|
471414|NCT00616499|Procedure|therapeutic conventional surgery|
471347|NCT00616876|Drug|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
471348|NCT00616876|Dietary Supplement|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
471349|NCT00616863|Drug|Oxcarbazepine|
471350|NCT00616850|Procedure|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
471351|NCT00616850|Drug|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
471352|NCT00616850|Other|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
471353|NCT00616837|Other|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
471354|NCT00616837|Other|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
471355|NCT00616824|Procedure|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
471356|NCT00616824|Procedure|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
471357|NCT00616811|Drug|vildagliptin|
471358|NCT00616811|Drug|Sitagliptin|
471359|NCT00616798|Drug|RO4917838|10mg po daily
471360|NCT00616798|Drug|RO4917838|30mg po daily
471361|NCT00616798|Drug|RO4917838|60mg po daily
471362|NCT00616798|Drug|Placebo|po daily
471363|NCT00616798|Drug|Standard antipsychotic therapy|As prescribed
471364|NCT00616785|Drug|cisplatin|
471365|NCT00616785|Drug|etoposide|
471366|NCT00616785|Drug|irinotecan hydrochloride|
471367|NCT00616785|Radiation|radiation therapy|
471368|NCT00616772|Drug|ABT-335|Capsule
471369|NCT00616772|Drug|Placebo|Capsule
471370|NCT00616772|Other|Atorvastatin|Capsule
471371|NCT00616759|Procedure|electroconvulsive therapy|electroconvulsive therapy as usual
471372|NCT00616759|Procedure|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
471373|NCT00616759|Drug|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
471374|NCT00616746|Drug|Nicotine|1.0 microg/kg/min IV x 10 minutes
471375|NCT00616746|Drug|Ethanol|IV
471376|NCT00616733|Drug|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
471377|NCT00616733|Drug|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
471378|NCT00616733|Drug|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
471379|NCT00616720|Biological|aldesleukin|
471380|NCT00616720|Biological|idiotype-pulsed autologous dendritic cell vaccine APC8020|
471381|NCT00616720|Biological|recombinant interferon gamma|
471382|NCT00616720|Genetic|polymerase chain reaction|
471383|NCT00616720|Genetic|reverse transcriptase-polymerase chain reaction|
471384|NCT00616720|Other|flow cytometry|
471385|NCT00616720|Other|laboratory biomarker analysis|
471386|NCT00616694|Drug|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
471387|NCT00616681|Drug|Oxcarbazepine|
471388|NCT00616668|Device|Air- Limb|
471389|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
471390|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
471391|NCT00616655|Drug|Placebo|Placebo total daily dose 0.9 mg
471392|NCT00616642|Drug|rosiglitazone maleate|Given orally
471393|NCT00616629|Drug|AZD1305|Intravenous infusion
471394|NCT00616616|Procedure|single incision laparoscopic surgery|Surgery will be performed with ine laparoscopic incision
471395|NCT00616603|Drug|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
471396|NCT00616603|Drug|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
471397|NCT00616603|Drug|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
471398|NCT00616603|Drug|Normal Saline|2ml of normal saline given once intravenously.
471399|NCT00616590|Other|medical chart review|
471400|NCT00616590|Other|questionnaire administration|
471401|NCT00616590|Procedure|fatigue assessment and management|
471402|NCT00616590|Procedure|quality-of-life assessment|
471403|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
471404|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
471405|NCT00616577|Drug|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
471406|NCT00616564|Drug|GM-CSF|Concomitant Priming with GM-CSF
471407|NCT00616551|Drug|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
471408|NCT00616551|Drug|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
471415|NCT00616486|Device|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
471416|NCT00616486|Device|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
471417|NCT00616460|Drug|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT < 250
471418|NCT00616447|Device|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
471419|NCT00616447|Device|placebo sham|Sham treatment will mimic active treatment mentioned above.
471420|NCT00616434|Drug|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
471421|NCT00616434|Drug|Placebo|Placebo IM injection, self-administered per protocol.
471422|NCT00616421|Biological|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
471423|NCT00616421|Biological|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
471424|NCT00616421|Biological|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
471425|NCT00616408|Drug|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
471426|NCT00616395|Device|No intervention|
471427|NCT00616382|Drug|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
471428|NCT00616382|Drug|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
471429|NCT00616343|Drug|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
471430|NCT00616330|Drug|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
471431|NCT00616330|Drug|clindamycin phosphate|semi solid, single dose
471432|NCT00616330|Drug|butoconazole nitrate|semi solid, single dose
471433|NCT00616304|Drug|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
471434|NCT00616304|Other|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
471435|NCT00616291|Biological|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
471436|NCT00616265|Device|CPAP|Pressure device on airway to maintain it open
471437|NCT00616239|Drug|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
471438|NCT00616239|Drug|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
471439|NCT00616213|Biological|filgrastim|filgrastim will be administered at a standard dose and schedule
471440|NCT00616213|Drug|PR104|PR104 is administered intravenously once every 21 days
471441|NCT00616213|Other|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
471442|NCT00616200|Other|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
471443|NCT00616187|Drug|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
471444|NCT00616187|Drug|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
471445|NCT00616174|Procedure|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
471446|NCT00616161|Drug|Istaroxime|0.5 microgram/kg/min IV for 6 hours
471447|NCT00616161|Drug|Istaroxime|1.0 microgram/kg/min IV for 6 hours
471448|NCT00616161|Drug|Istaroxime|1.5 microgram/kg/min IV for 6 hours
471452|NCT00616135|Procedure|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
471453|NCT00616122|Drug|cyclophosphamide|
471454|NCT00616122|Drug|methotrexate|
471455|NCT00616122|Drug|sunitinib malate|
471456|NCT00616122|Other|laboratory biomarker analysis|
471457|NCT00616109|Drug|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
471458|NCT00616096|Procedure|immunoadsorption|"First cycle: week 1, day 1-5~Second cycle: week 5, day 1-5"
471459|NCT00616070|Drug|Difluprednate|Difluprednate
471460|NCT00616070|Other|Placebo|Vehicle
471461|NCT00616057|Dietary Supplement|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
471462|NCT00616057|Dietary Supplement|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
471463|NCT00616044|Procedure|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
471464|NCT00616044|Procedure|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
471465|NCT00616044|Procedure|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
471466|NCT00616031|Drug|carboplatin|
471467|NCT00616031|Drug|nitroglycerin|
471468|NCT00616031|Drug|paclitaxel|
471469|NCT00616018|Drug|acetaminophen|4 g/day for 10 consecutive days
471470|NCT00616005|Drug|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle & every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, & 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
471471|NCT00615992|Drug|Tiotropium|
471472|NCT00615979|Device|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
471473|NCT00615966|Drug|Diannexin|single dose, 200 µg/kg IV
471474|NCT00615966|Drug|Placebo|Single dose, IV
471475|NCT00615966|Drug|Diannexin|Single dose, 400 µg/kg IV
471476|NCT00615940|Drug|WX-671|capsules taken per os once daily until progression or toxicity
471477|NCT00615940|Drug|placebo|capsule taken per os once daily until progression or toxicity
471478|NCT00615927|Drug|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant & must be taken in sitting position; mini of 2hrs should be allowed between last drug intake & going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.~Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 & continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
471479|NCT00615901|Drug|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
471480|NCT00615888|Procedure|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
471481|NCT00615888|Procedure|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
471482|NCT00615875|Drug|naproxen|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
471483|NCT00615875|Drug|placebo|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
471484|NCT00615862|Other|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
471485|NCT00615849|Procedure|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
471486|NCT00615836|Drug|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
471487|NCT00615823|Drug|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
471488|NCT00615823|Drug|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
473897|NCT00598078|Other|Placebo|Dose 3
471490|NCT00615810|Drug|Kivexa plus Sustiva|Open label once daily for oral administration
471491|NCT00615797|Biological|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
471492|NCT00615797|Drug|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
471493|NCT00615784|Drug|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
471494|NCT00615771|Procedure|Day 3 embryo transfer|Standard of care
471495|NCT00615771|Procedure|Day 2 embryo transfer|Embryos are transferred 1 day prior to standard of care
471496|NCT00615758|Drug|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
471497|NCT00615745|Drug|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
471498|NCT00615732|Procedure|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
471499|NCT00615732|Procedure|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
471500|NCT00615706|Other|No intervention|no intervention
471501|NCT00615693|Drug|AEB071|
471502|NCT00615667|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
471503|NCT00615654|Other|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
471504|NCT00615615|Drug|Levetiracetam|
471505|NCT00615602|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
471506|NCT00615602|Drug|Trastuzumab|Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
471507|NCT00615602|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
471508|NCT00615602|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
471509|NCT00615602|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
471510|NCT00615602|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
471511|NCT00615602|Drug|Trastuzumab|Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
471512|NCT00615589|Drug|Fludarabine/Busulfan x 4 days|"Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.~Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.~The Fludarabine shall be administered prior to the Busulfan each day."
471513|NCT00615589|Procedure|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
471514|NCT00615576|Drug|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
471515|NCT00615576|Drug|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
471516|NCT00615563|Behavioral|NO BI Drug administered|
471517|NCT00615550|Drug|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
471518|NCT00615550|Drug|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
471519|NCT00615537|Procedure|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
471520|NCT00615524|Drug|exemestane and pazopanib|
471521|NCT00615511|Dietary Supplement|placebo pregnenolone|Sugar pill, taken twice a day
471522|NCT00615511|Dietary Supplement|pregnenolone|500mg in tablet form taken orally twice a day
471523|NCT00615472|Drug|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
471524|NCT00615472|Drug|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
471525|NCT00615472|Drug|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
471526|NCT00615459|Drug|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
471527|NCT00615459|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
471528|NCT00615459|Drug|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
475572|NCT00583154|Drug|BLI-801|Dose 2
471529|NCT00615446|Drug|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
471530|NCT00615433|Drug|Lurasidone|120mg/day
471531|NCT00615433|Drug|Olanzapine|15mg/day
471532|NCT00615433|Drug|Placebo comparator|Placebor Comparator
471533|NCT00615433|Drug|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
471534|NCT00615420|Dietary Supplement|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
471535|NCT00615420|Dietary Supplement|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
471536|NCT00615394|Procedure|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
471537|NCT00615381|Drug|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
471538|NCT00615368|Drug|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
471539|NCT00615368|Drug|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
471540|NCT00615355|Radiation|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
471541|NCT00615355|Device|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
471542|NCT00615316|Drug|Guaraná|Guaraná extract 75mg/day
471543|NCT00615316|Drug|Placebo|Placebo 1tab/d
471544|NCT00615303|Drug|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
471545|NCT00615303|Drug|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
471546|NCT00615290|Drug|tipranavir|
471547|NCT00615277|Dietary Supplement|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
471548|NCT00615264|Drug|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
471549|NCT00615264|Drug|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
471550|NCT00615251|Drug|DR-2011|Progesterone vaginal ring for approximately 10 weeks
471551|NCT00615251|Drug|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
471552|NCT00615238|Behavioral|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
471553|NCT00615238|Behavioral|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
471554|NCT00615238|Behavioral|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
471555|NCT00615225|Procedure|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
471556|NCT00615212|Drug|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
471557|NCT00615212|Drug|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
471558|NCT00615212|Drug|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
471559|NCT00615212|Drug|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
471560|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
471561|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
471562|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
471563|NCT00615199|Drug|Placebo|administration via oral route twice daily
471564|NCT00615186|Drug|Neuradiab + Radiotherapy + Temozolomide|"Prior Surgery~Rickham Catheter placement 99mTc-DTPA Flow Study~Neuradiab Dosimetry Study~Neuradiab Therapeutic Dose Administration~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
471598|NCT00614965|Drug|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
471599|NCT00614965|Drug|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
471600|NCT00614965|Drug|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
471601|NCT00614952|Device|PSG (polysomnography)|POLYSOMNOGRAPHY
471565|NCT00615186|Drug|Radiation Therapy + Temozolomide|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)~Radiation Therapy (XRT) + Temozolomide:~XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks~Post-Radiation Temozolomide Therapy:~Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
471566|NCT00615173|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
471567|NCT00615173|Drug|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
471568|NCT00615160|Drug|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
471569|NCT00615160|Drug|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
471570|NCT00615147|Procedure|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
471571|NCT00615134|Drug|enfuvirtide [Fuzeon]|90mg sc bid
471572|NCT00615134|Drug|Optimized background ARV therapy|As prescribed
471573|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
471574|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
471575|NCT00615095|Other|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
471576|NCT00615082|Behavioral|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
471577|NCT00615082|Behavioral|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
471578|NCT00615069|Device|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
471579|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous [IV] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
471580|NCT00615056|Drug|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous [IV] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
471581|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
471582|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion [IV] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
471583|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
471584|NCT00615056|Drug|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
471585|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous infusion [IV] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
471586|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
471587|NCT00615043|Procedure|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
471588|NCT00615030|Drug|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
471589|NCT00615030|Drug|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
471590|NCT00615030|Drug|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
471591|NCT00615030|Drug|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
471592|NCT00615017|Drug|AZD9773 (CytoFab)|intravenous infusions
471593|NCT00615017|Other|Placebo|Placebo
471594|NCT00614991|Drug|Raltegravir|400mg BID
471595|NCT00614991|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
471596|NCT00614991|Drug|Ritonavir|100 mg BID or QD
471597|NCT00614978|Drug|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
475573|NCT00583154|Drug|BLI-801|Dose 3
471602|NCT00614952|Other|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
471603|NCT00614939|Drug|Saxagliptin|2.5 mg once daily oral dose
471604|NCT00614939|Drug|Placebo|Placebo
471605|NCT00614926|Drug|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
471606|NCT00614926|Drug|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
471607|NCT00614913|Radiation|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
471608|NCT00614874|Drug|rosiglitazone|2mg, 4mg, 8mg
471609|NCT00614861|Other|Non-cancer pain management survey|Non-cancer pain management survey
471610|NCT00614848|Device|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
471611|NCT00614835|Drug|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
471612|NCT00614822|Drug|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
471613|NCT00614809|Drug|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
471614|NCT00614796|Behavioral|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
471615|NCT00614770|Procedure|standard of care colonoscopy|"Standard White Light Colonoscopy~one exam per patient"
471616|NCT00614770|Procedure|colonoscopy|"Narrow Band Imaging Colonoscopy~one exam per patient"
471617|NCT00614770|Procedure|standard of care colonoscopy|"High Definition White Light Colonoscopy~one exam per patient"
471618|NCT00614757|Drug|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
471619|NCT00614757|Drug|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
471620|NCT00614744|Procedure|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
471621|NCT00614744|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
471622|NCT00614731|Biological|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
471623|NCT00614705|Drug|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
471624|NCT00614705|Drug|Placebo|oral capsule form, once daily for 28 days
471625|NCT00614679|Drug|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
471626|NCT00614666|Drug|nikkomycin Z|"Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.~50 mg BID (n=8) vs placebo capsule BID (n=2)~250 mg BID (n=8) vs Placebo capsule BID (n=2)~500 mg BID (n=8) vs Placebo capsule BID (n=2)~750 mg TID (n=8) vs Placebo capsule TID (n=2)~At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.~Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization."
471627|NCT00614653|Drug|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
471628|NCT00614653|Drug|Erlotinib|100 mg by mouth Once Daily on days with radiation.
471629|NCT00614653|Drug|Capecitabine|400 mg/m^2 PO Twice Daily on days with radiation.
471630|NCT00614653|Radiation|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
471631|NCT00614640|Biological|DermaVir patch|DNA Vaccine
471632|NCT00614640|Biological|Placebo patch|10% dextrose (D-glucose) solution
471633|NCT00614614|Biological|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
471634|NCT00614614|Biological|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
471635|NCT00614614|Biological|Infanrix®|One dose as intramuscular injection
471636|NCT00614614|Biological|ActHIB®|Three doses in the priming phase as intramuscular injection
471637|NCT00614614|Biological|Pediarix®|Three doses in the priming phase as intramuscular injection
471638|NCT00614601|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
471639|NCT00614588|Device|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
471640|NCT00614562|Device|Neurally adjusted ventilatory assist (NAVA)|NAVA for 72 hours
471641|NCT00614536|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
471642|NCT00614523|Drug|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
471643|NCT00614523|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
471644|NCT00614510|Device|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
471758|NCT00613626|Drug|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
471645|NCT00614484|Radiation|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
471646|NCT00614484|Drug|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
471647|NCT00614484|Drug|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
471648|NCT00614471|Drug|Entecavir|0.5mg po daily for 24 weeks
471649|NCT00614471|Drug|Entecavir|0.5mg po daily from week 13 to week 36
471650|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
471651|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
471652|NCT00614458|Drug|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
471653|NCT00614445|Drug|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
471654|NCT00614445|Drug|Placebo|2 to 4 tablets daily titrated according to the protocol
471655|NCT00614419|Device|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
471656|NCT00614419|Device|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
471657|NCT00614406|Drug|Celebrex|One 400mg tablet daily.
471658|NCT00614406|Drug|Placebo|One tablet daily.
471659|NCT00614393|Biological|dalotuzumab|IV infusion
471660|NCT00614393|Drug|irinotecan hydrochloride|IV infusion
471661|NCT00614393|Biological|cetuximab|IV infusion
471662|NCT00614393|Drug|placebo|IV infusion
471663|NCT00614380|Drug|telmisartan/amlodipine 40/5 mg fixed combination|
471664|NCT00614380|Drug|telmisartan/amlodipine 80/5 mg fixed combination|
471665|NCT00614354|Drug|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
471666|NCT00614341|Device|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
471667|NCT00614328|Drug|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
471668|NCT00614315|Device|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
471669|NCT00614302|Drug|TPV|
471670|NCT00614289|Device|Epikeia Coatings|Topical skin coating
471671|NCT00614276|Behavioral|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
471672|NCT00614276|Behavioral|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
471673|NCT00614276|Behavioral|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
471674|NCT00614276|Behavioral|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
471675|NCT00614250|Drug|AVE0657|capsules once a day at bedtime
471676|NCT00614250|Drug|placebo|capsules once a day at bedtime
471677|NCT00614224|Behavioral|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
471678|NCT00614211|Procedure|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
471679|NCT00614211|Procedure|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
471680|NCT00614198|Other|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
471681|NCT00614172|Radiation|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
471682|NCT00614159|Drug|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
471683|NCT00614159|Drug|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
471684|NCT00614146|Device|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
471685|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
471686|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
471759|NCT00613626|Drug|Placebo|Matched placebo oral daily
471687|NCT00614133|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
471688|NCT00614133|Other|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
471689|NCT00614120|Drug|liraglutide|0.6 mg/day, s.c. (under the skin) injection
471690|NCT00614120|Drug|placebo|Glimepiride placebo, capsules
471691|NCT00614120|Drug|liraglutide|1.2 mg/day, s.c. (under the skin) injection
471692|NCT00614120|Drug|liraglutide|1.8 mg/day, s.c. (under the skin) injection
471693|NCT00614120|Drug|glimepiride|Capsules, 4.0 mg/day
471694|NCT00614120|Drug|metformin|Tablets, 1.5-2.0 g/day
471695|NCT00614120|Drug|placebo|Liraglutide placebo, s.c. (under the skin) injection
471696|NCT00614081|Device|Contrast-enhanced dynamic MRI|
471697|NCT00614068|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
471698|NCT00614068|Behavioral|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
471699|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
471700|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
471701|NCT00614055|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
471702|NCT00614055|Drug|metformin|Tablets, 1500-2000 mg/day
471703|NCT00614042|Drug|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
471704|NCT00614029|Device|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
471705|NCT00614016|Drug|Sodium ST20|single administration of oral dosage form
471706|NCT00614003|Behavioral|Decision support skills building Intervention|Decision support skills
471707|NCT00613964|Drug|Carperitide heart failure therapy|carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
471708|NCT00613964|Drug|Standard heart failure therapy|Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
471709|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
471710|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
471711|NCT00613951|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
471712|NCT00613951|Drug|metformin|Tablets, 1500-2000 mg/daily
471713|NCT00613938|Drug|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
471714|NCT00613938|Drug|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
471715|NCT00613938|Drug|oxycodone|10mg capsule q4-6 hrs for 3 days
471716|NCT00613938|Drug|placebo|1 capsule q4-6 hrs for 3 days
471717|NCT00613925|Device|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
471718|NCT00613925|Device|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
471719|NCT00613912|Other|Magnetic Resonance Imaging|"Morphological sequences~Arterial Spin Labelling (Perfusion)~Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
471720|NCT00613899|Other|telesurveillance|A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
471721|NCT00613886|Device|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
471722|NCT00613886|Behavioral|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
471723|NCT00613873|Procedure|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
471724|NCT00613860|Device|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
471725|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
471760|NCT00613626|Drug|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
471761|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
471726|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
471727|NCT00613834|Drug|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
471728|NCT00613834|Drug|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
471729|NCT00613821|Drug|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
471730|NCT00613821|Drug|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
471731|NCT00613808|Drug|Nitric Oxide 200ppm Group B|200 ppm, 8hrs / day for 6 weeks
471732|NCT00613795|Dietary Supplement|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
471733|NCT00613795|Dietary Supplement|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
471734|NCT00613782|Drug|Reandron 1000|1000mg at 0,6,18,30 weeks
471735|NCT00613782|Drug|placebo|placebo injection 0,6.18.30 weeks
471736|NCT00613769|Drug|trimethoprim-sulfamethoxazole + metronidazole|trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
471737|NCT00613769|Drug|cefuroxime and metronidazole|cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
471738|NCT00613743|Drug|mouth wash with morphine|morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
471739|NCT00613743|Drug|placebo|placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
471740|NCT00613730|Drug|Gemcitabine|Intravenous administration
471741|NCT00613730|Drug|panitumumab|Intravenous administration
471742|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
471743|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
471744|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
471745|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.~Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
471746|NCT00613691|Drug|SPI-1620|SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
471747|NCT00613678|Behavioral|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
471748|NCT00613678|Behavioral|Education|The health education program is based on educational materials from the Arthritis Foundation.
471749|NCT00613665|Biological|helicobacter pylori vaccine|Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
471750|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
471751|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
471752|NCT00613665|Biological|helicobacter pylori vaccine|Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
471753|NCT00613665|Biological|Placebo|Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
471754|NCT00613665|Biological|helicobacter pylori vaccine|Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
471755|NCT00613665|Biological|helicobacter pylori vaccine|Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
471756|NCT00613652|Drug|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
471757|NCT00613626|Drug|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
471762|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
471763|NCT00613600|Dietary Supplement|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
471764|NCT00613600|Dietary Supplement|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
471765|NCT00613574|Drug|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
471766|NCT00613561|Drug|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
471767|NCT00613548|Procedure|CABG alone|CABG alone
471768|NCT00613548|Procedure|CABG + Mitral repair|CABG + Mitral repair
471769|NCT00613535|Device|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
471770|NCT00613535|Device|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
471771|NCT00613535|Procedure|Lavage debridement|Remove loose chondral fragments
471772|NCT00613535|Device|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
471773|NCT00613535|Device|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
471774|NCT00613522|Other|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale > 2.~Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).~Controls will be evaluated at 3 months using a phone interview"
471775|NCT00613509|Biological|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
471776|NCT00613509|Biological|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
471777|NCT00613496|Drug|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
471778|NCT00613496|Drug|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
471779|NCT00613470|Drug|citalopram and escitalopram|"escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.~citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
471780|NCT00613457|Drug|dexamethasone|10 mg/sqm/day from for 21 days
471781|NCT00613457|Drug|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
471782|NCT00613457|Drug|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
471783|NCT00613457|Drug|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
471784|NCT00613457|Drug|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
471785|NCT00613457|Drug|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
471786|NCT00613457|Drug|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
471787|NCT00613457|Drug|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
471788|NCT00613457|Drug|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
471789|NCT00613457|Drug|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
471790|NCT00613457|Drug|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
471791|NCT00613457|Drug|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
471792|NCT00613457|Drug|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
471793|NCT00613457|Drug|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
471794|NCT00613457|Drug|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
471795|NCT00613444|Device|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
471796|NCT00613431|Drug|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
471797|NCT00613431|Drug|Placebo|Some subjects will receive matching placebo instead of CS-8080.
471798|NCT00613418|Device|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
471799|NCT00613405|Other|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
471800|NCT00613405|Other|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
471801|NCT00613392|Dietary Supplement|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
471802|NCT00613392|Dietary Supplement|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
471803|NCT00613379|Drug|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
471804|NCT00613379|Drug|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
471805|NCT00613379|Drug|Placebo|PBO, one IV dose (N=10)
471806|NCT00613366|Drug|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
471807|NCT00613366|Dietary Supplement|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
471808|NCT00613353|Other|Behavioral|Participants will be asked to wear an accelerometer
471809|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
471810|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
471811|NCT00613327|Drug|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
471812|NCT00613288|Drug|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.~The four days will include treatment on the examination day, Day 1 with:~Placebo (hypogonadism after leuprorelide injection)~Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).~Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).~No treatment."
471813|NCT00613275|Other|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
471814|NCT00613262|Other|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
471815|NCT00613249|Drug|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
471816|NCT00613249|Drug|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
471817|NCT00613249|Drug|HEC-based Placebo Gel|intravaginal gel, dosed daily
471818|NCT00613223|Drug|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 & 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
471819|NCT00613197|Drug|Epanova|4g/day in divided doses
471820|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
471821|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
471822|NCT00613171|Drug|STI571|STI571 tablets taken orally once a day
471823|NCT00613145|Drug|Capecitabine and Sorafenib|"During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle."
471824|NCT00613145|Drug|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
471825|NCT00613132|Drug|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort & will be increased to 600 mg po/day & then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 & hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
471826|NCT00613106|Drug|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
471827|NCT00613106|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
471828|NCT00613093|Drug|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).~BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
471829|NCT00613080|Drug|capecitabine|1650 mg/m^2/day orally 5 days/week during radiotherapy.
471830|NCT00613080|Drug|oxaliplatin|
471831|NCT00613080|Procedure|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
471832|NCT00613080|Radiation|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
471833|NCT00613080|Drug|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m^2, IV continuous infusion over 46 hours, day 1."
471834|NCT00613067|Drug|escitalopram|"Start with escitalopram 10mg~According to patient's symptoms, stay on 10mg or increase up to 20mg~Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages~Length of washout period will be at least 2 weeks for any psychotropic drugs"
471873|NCT00612716|Drug|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
472011|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
471835|NCT00613054|Drug|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate & hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs & 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate & that such doses are safe & well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.~Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety & pharmacokinetic parameters as required.~Treatment cycle is defined as daily administration of Zactima + imatinib mesylate & hydroxyurea for 28 days for purpose of scheduling evaluations."
471836|NCT00613041|Procedure|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
471837|NCT00613028|Drug|Temo + Avastin|Patients have progressed/had gr3/> toxicity related to etoposide, with no had progression/gr 3/> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
471838|NCT00613028|Drug|VP-16 + Avastin|Patients have progressed/had gr3/> toxicity related to temozolomide, but have not progressed/gr3/> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
471839|NCT00613015|Drug|Guanfacine|
471840|NCT00613015|Drug|Modafinil|
471841|NCT00613015|Drug|Placebo|
471842|NCT00613002|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
471843|NCT00613002|Drug|placebo gel|once daily transdermal placebo gel
471844|NCT00612989|Drug|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.~Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle & every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.~Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar & continue fasting 2 hrs after administration of each Temodar dose."
471845|NCT00612963|Drug|Frio Oral Rinse|Prescription Mouth Rinse
471846|NCT00612950|Drug|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
471847|NCT00612950|Drug|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
471848|NCT00612950|Drug|Saline|continuous infusion of Saline for 120 min
471849|NCT00612924|Device|Anaconda Stent Graft System|Endovascular device
471850|NCT00612924|Device|Anaconda ONE-LOK Stent Graft System|Endovascular device
471851|NCT00612911|Other|Cell therapy|bone marrow mononuclear cell
471852|NCT00612898|Drug|apricitabine|800mg BID apricitabine orally for 48 weeks
471853|NCT00612898|Drug|lamivudine|150mg BID lamivudine orally for 48 weeks
471854|NCT00612872|Drug|[123I]CLINDE|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
471855|NCT00612859|Drug|levetiracetam|
471856|NCT00612846|Procedure|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
471857|NCT00612846|Procedure|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
471858|NCT00612833|Procedure|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
471859|NCT00612820|Drug|GSK256066|200mcg bd,
471860|NCT00612820|Drug|fluticasone propionate|200mcg od,100mcg bd
471861|NCT00612807|Behavioral|Weekly marital therapy|Weekly marital therapy for 6 months.
471862|NCT00612807|Drug|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).~SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)~SNRIs (e.g., venlafaxine)~Bupropion SR (achieve dose of at least 150 mg BID)~Mirtazapine~Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)~Lithium augmentation~MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
471863|NCT00612794|Drug|exenatide once weekly|subcutaneous injection, once weekly
471864|NCT00612794|Drug|placebo|subcutaneous injection, once weekly
471865|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
471866|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
471867|NCT00612768|Biological|TRUE Test allergens Fragrance Mix and Thimerosol|"Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose~Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone~Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin~Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin~Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
471868|NCT00612755|Drug|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
471869|NCT00612742|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
471870|NCT00612742|Drug|placebo gel|once daily transdermal placebo gel
471871|NCT00612729|Procedure|Polylens Y30 intraocular lens|cataract surgery
471872|NCT00612729|Procedure|Orange Series Model PC 440 Y intraocular lens|cataract surgery
471874|NCT00612716|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
471875|NCT00612716|Biological|Stem cell infusion|Infused on Day 0
471876|NCT00612716|Radiation|Total body irradiation|165 cGy morning and evening on days -4 through -1.
471877|NCT00612703|Drug|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
471878|NCT00612690|Behavioral|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
471879|NCT00612690|Behavioral|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
471880|NCT00612677|Drug|Oxaliplatin|Dose Regimen: 120 mg/m^2 on Days 1 every 21 days
471881|NCT00612677|Drug|Pemetrexed|Dose Regimen: 500 mg/m^2 on Days 1 every 21 days
471882|NCT00612664|Drug|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
471883|NCT00612651|Drug|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated & escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle & escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning & evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 & 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
471884|NCT00612638|Drug|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 & 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
471885|NCT00612625|Drug|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
471886|NCT00612625|Drug|Saline|continuous infusion of saline
471887|NCT00612612|Drug|obatoclax mesylate|Given IV
471888|NCT00612612|Drug|fludarabine phosphate|Given IV
471889|NCT00612612|Biological|rituximab|Given IV
471890|NCT00612612|Other|laboratory biomarker analysis|Correlative study
471891|NCT00612599|Drug|biphasic insulin aspart|
471892|NCT00612586|Drug|Enzastaurin|1125 mg loading dose, then 250 mg twice daily, oral(up to 1 yr or until progressive disease)
471893|NCT00612586|Drug|Placebo|oral, daily (up to 1 yr or until progressive disease)
471894|NCT00612586|Drug|Leucovorin|400 mg/m2 IV, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
471895|NCT00612586|Drug|5-FU|400 mg/m2 bolus then 2400 mg/m2 IV over 46 hours, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
471896|NCT00612586|Drug|Bevacizumab|5 mg/kg IV, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
471897|NCT00612573|Drug|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
471898|NCT00612573|Drug|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
471899|NCT00612573|Drug|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
471900|NCT00612573|Drug|Placebo|Placebo, 12 weeks
471901|NCT00612560|Drug|Anastrozole|1 mg per day
471902|NCT00612560|Dietary Supplement|flaxseed|25 g per day ground
471903|NCT00612560|Drug|Placebo|Placebo pill 1 per day
471904|NCT00612547|Drug|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:~Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
471905|NCT00612534|Drug|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
471906|NCT00612534|Drug|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
471907|NCT00612534|Drug|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
471908|NCT00612534|Drug|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
471909|NCT00612521|Drug|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
471910|NCT00612508|Drug|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
471911|NCT00612508|Drug|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
471912|NCT00612495|Drug|oxaliplatin, 5 FU|"Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.~5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks."
472012|NCT00611806|Dietary Supplement|Folic Acid|Folic acid 2mg po daily
475574|NCT00583154|Drug|BLI-801|Dose 4
471913|NCT00612482|Other|drug prevention curriculum|"Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes."
471914|NCT00612469|Drug|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
471915|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
471916|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
471917|NCT00612469|Drug|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
471918|NCT00612456|Drug|Pazopanib|Pazopanib eye drops formulation
471919|NCT00612443|Behavioral|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
471920|NCT00612443|Behavioral|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
471921|NCT00612430|Drug|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG & 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data & order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
471922|NCT00612417|Drug|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
471923|NCT00612391|Procedure|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
471924|NCT00612391|Procedure|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
471925|NCT00612378|Device|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
471926|NCT00612352|Drug|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
471927|NCT00612339|Drug|Avastin and Temozolomide|This is Phase II study with the combination of Avastin & Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin & Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI & repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy & requests discontinuation, patients will receive up to 4 cycles of Avastin & Temozolomide, then proceed with standard XRT therapy, & future therapy after 4 cycles will be at discretion of patient & treating physicians.
471928|NCT00612326|Procedure|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
471929|NCT00612313|Drug|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
471959|NCT00612144|Drug|Glimepiride/metformin fixed combination|"Amaryl M 1/250mg~4/1000mg bid for 12~26 weeks~Maintenance dose for 10 weeks after 2~14 weeks of dose titration~Dose titration according to titration algorithm based on daily mean SMBG"
476656|NCT00574496|Drug|ifosfamide|
471930|NCT00612313|Behavioral|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
471931|NCT00612300|Behavioral|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
471932|NCT00612300|Behavioral|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.~A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
471933|NCT00612287|Drug|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
471934|NCT00612274|Drug|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
471935|NCT00612274|Drug|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
471936|NCT00612274|Drug|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
471937|NCT00612261|Procedure|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
471938|NCT00612261|Procedure|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
471939|NCT00612248|Other|Splint|Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
471940|NCT00612235|Drug|Lamotrigine|Subjects had at least 3 months on a stable dosage of lamotrigine monotherapy.
471941|NCT00612235|Drug|Levetiracetam|Subjects had at least 3 months on a stable dosage of levetiracetam monotherapy.
471942|NCT00612235|Drug|Carbamazepine|Subjects had at least 3 months on a stable dosage of carbamazepine monotherapy.
471943|NCT00612235|Other|No Intervention|No intervention was given
471944|NCT00612222|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
471945|NCT00612222|Biological|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
471946|NCT00612222|Biological|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
471947|NCT00612222|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
471948|NCT00612222|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
471949|NCT00612209|Drug|ARQ 197|Treatment with ARQ 197
471950|NCT00612196|Drug|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
471951|NCT00612196|Drug|Placebo|
471952|NCT00612183|Drug|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
471953|NCT00612170|Drug|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
471954|NCT00612170|Drug|Placebo|0 mg oral tablet once a day dosing
471955|NCT00612170|Drug|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
471956|NCT00612170|Drug|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
471957|NCT00612157|Drug|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
471958|NCT00612157|Drug|Placebo control|Matching placebo
472010|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
471960|NCT00612144|Drug|Metformin HCl|"Metformin HCl 500mg~1250mg bid for 12~26 weeks~Maintenance dose for 10 weeks after 2~14 weeks of dose titration~Dose titration according to titration algorithm based on daily mean SMBG"
471961|NCT00612118|Drug|GSK256066|200mcg bd
471962|NCT00612118|Drug|azelastine hydrochloride|140mcg
471963|NCT00612105|Drug|Retigabine|150mg/day up to 900mg/day
471964|NCT00612105|Drug|Placebo|daily
471965|NCT00612092|Radiation|Spiral image acquisition|standard spiral scan protocol
471966|NCT00612092|Radiation|sequential image acquisition|sequential CT scan protocol
471967|NCT00612079|Drug|Sertindole|oral 3 x 4mg
471968|NCT00612079|Drug|Placebo|3 x 4mg Placebo
471969|NCT00612066|Drug|rosiglitazone maleate|
471970|NCT00612040|Drug|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
471971|NCT00612040|Drug|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
471972|NCT00612040|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
471973|NCT00612040|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
471974|NCT00612014|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
471975|NCT00612014|Drug|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
471976|NCT00612014|Drug|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
471977|NCT00612014|Drug|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
471978|NCT00612014|Drug|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
471979|NCT00612014|Drug|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days"
471980|NCT00612001|Biological|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
471981|NCT00611988|Behavioral|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
471982|NCT00611988|Other|Control group|Attention control group will receive routine follow-up phone calls
471983|NCT00611975|Drug|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
471984|NCT00611975|Drug|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
471985|NCT00611962|Drug|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient~Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
471986|NCT00611949|Other|Geranium oil|2 applications of topical oil per week for 2 weeks
471987|NCT00611936|Drug|Placebo|Placebo
471988|NCT00611936|Drug|Atomoxetine|20mg maximum of d-amphetamine
471989|NCT00611923|Drug|Flutamide|Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
471990|NCT00611923|Drug|Placebo|Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
471991|NCT00611910|Device|sirolimus-eluting stent|due to randomization Cypher stent will be implanted
471992|NCT00611910|Device|paclitaxel-eluting stent|due to randomization Taxus stent will be implanted
471993|NCT00611910|Device|biodegradable-polymer-based sirolimus-eluting stent|due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted
471994|NCT00611910|Device|bare metal stents|Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
471995|NCT00611897|Drug|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
471996|NCT00611897|Drug|placebo and ketamine|placebo N-acetylcysteine
471997|NCT00611884|Drug|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
471998|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
471999|NCT00611884|Drug|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
472000|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
472001|NCT00611884|Drug|metformin|Tablets, 1500-2000 mg/day
472002|NCT00611871|Drug|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
472003|NCT00611871|Drug|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
472004|NCT00611858|Drug|Cetuximab|
472005|NCT00611858|Drug|5-Fluorouracil|
472006|NCT00611858|Radiation|Radiation|
472007|NCT00611845|Drug|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
472008|NCT00611832|Behavioral|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
472009|NCT00611832|Behavioral|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
472013|NCT00611806|Dietary Supplement|B12|B12 400 micrograms po daily
472014|NCT00611806|Other|Placebo|1 capsule po daily
472015|NCT00611793|Drug|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
472016|NCT00611780|Radiation|tube voltage|standard 120 kV
472017|NCT00611780|Radiation|tube voltage|reduced voltage of 100 kV
472018|NCT00611767|Drug|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
472019|NCT00611767|Drug|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
472020|NCT00611754|Drug|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
472021|NCT00611741|Drug|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
472022|NCT00611728|Drug|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 & 1/2 hrs on 1st day of each cycle & then again on days 14 & 28.~Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 & continue daily for 4 wks by mouth.~Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height & weight. Irinotecan will be given intravenously over 90 min on days 1, 14 & 28 of 6wk cycle.~You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, & then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, & then within 1 week prior to completion of every other cycle."
472023|NCT00611715|Drug|erlotinib hydrochloride|OSI-774 150 mg/day
472024|NCT00611715|Drug|letrozole|Letrozole 2.5 mg/day
472025|NCT00611715|Genetic|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
472026|NCT00611715|Other|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
472027|NCT00611715|Other|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
472028|NCT00611702|Procedure|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
472029|NCT00611689|Drug|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in < 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
472030|NCT00611676|Drug|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
472031|NCT00611663|Biological|Prevenar® and Pneumo23®|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
472032|NCT00611663|Biological|Placebo, Pneumo23®|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
472033|NCT00611650|Drug|defined green tea catechin extract|Given orally
472034|NCT00611650|Other|placebo|Given orally
472035|NCT00611637|Biological|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
472036|NCT00611624|Radiation|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
472037|NCT00611611|Biological|fluzone|once
472038|NCT00611611|Biological|pneumovax|once
472039|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
472040|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
472041|NCT00611585|Device|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
472042|NCT00611572|Drug|iomazenil|Given as IV infusion
472043|NCT00611572|Drug|iomazenil|saline IV infusion
472044|NCT00611559|Biological|Infanrix™ penta|Subjects received a booster dose
472045|NCT00611559|Biological|Infanrix™ hexa|Subjects received a booster dose
472046|NCT00611546|Other|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
472047|NCT00611546|Other|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
472048|NCT00611533|Drug|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
472049|NCT00611533|Drug|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
472050|NCT00611507|Drug|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
472051|NCT00611494|Drug|MMF|Gradual optimization of drug dosage, as clinically tolerated.
472052|NCT00611494|Drug|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
472053|NCT00611481|Behavioral|Tai Chi|a set of pre-designed Tai Chi Movements
472054|NCT00611481|Behavioral|Strength training|Lower-extremity strength training exercises
472055|NCT00611481|Behavioral|Low-Impact Exercise Control|a set of chair-based low-impact exercises
472056|NCT00611468|Drug|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
472057|NCT00611468|Drug|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
472058|NCT00611455|Drug|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
472059|NCT00611455|Drug|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
472060|NCT00611442|Drug|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
472061|NCT00611442|Drug|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
472062|NCT00611429|Behavioral|Counseling sessions|The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
472063|NCT00611429|Behavioral|Group workshop|During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
472064|NCT00611416|Dietary Supplement|green tea|different catechin combinations
472065|NCT00611416|Dietary Supplement|Mix of catechins and caffeine|3 tablet a day
472066|NCT00611416|Dietary Supplement|EGCG|3 tablets a day
472067|NCT00611416|Dietary Supplement|EGC|3 tablets a day
472068|NCT00611416|Dietary Supplement|Caffeine|3 tablets a day
472069|NCT00611416|Dietary Supplement|Placebo|3 tablets a day
472070|NCT00611403|Drug|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
472071|NCT00611403|Drug|Artificial Tears REFRESH ENDURA®|REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
472072|NCT00611390|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
472073|NCT00611390|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
472074|NCT00611364|Other|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
472075|NCT00611364|Other|education meetings|This group only participed of education meeting (every fifteen days)
472076|NCT00611351|Biological|anti-thymocyte globulin|
472077|NCT00611351|Drug|busulfan|
472078|NCT00611351|Drug|cyclophosphamide|
472079|NCT00611351|Drug|mycophenolate mofetil|
472080|NCT00611351|Drug|tacrolimus|
472081|NCT00611351|Genetic|polymerase chain reaction|
472082|NCT00611351|Genetic|polymorphism analysis|
472083|NCT00611351|Other|flow cytometry|
472084|NCT00611351|Other|laboratory biomarker analysis|
472085|NCT00611351|Other|pharmacogenomic studies|
472086|NCT00611351|Other|pharmacological study|
472087|NCT00611351|Procedure|allogeneic bone marrow transplantation|
472088|NCT00611351|Procedure|allogeneic hematopoietic stem cell transplantation|
472089|NCT00611351|Procedure|peripheral blood stem cell transplantation|
472090|NCT00611338|Behavioral|HIV Skills-based Prevention|
472091|NCT00611325|Drug|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
472092|NCT00611325|Drug|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, & 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs & 2.5 mg/m2 for patients taking EIAEDs.
472093|NCT00611312|Behavioral|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
472094|NCT00611299|Dietary Supplement|BB-12 and CRL 431|
472095|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
472096|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
472097|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
472098|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
472188|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
472189|NCT00610675|Drug|Org 50081|One tablet daily
472099|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
472100|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
472101|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
472102|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
472103|NCT00611273|Device|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
472104|NCT00611260|Behavioral|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
472105|NCT00611260|Other|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
472106|NCT00611247|Drug|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.~Induction (both arms) 200 mg/m2/day temozolomide"
472107|NCT00611221|Procedure|Massage|Massage therapy by an RMT during labour
472108|NCT00611221|Procedure|Massage|Massage by anyone else, eg. husband, nurse, doula
472109|NCT00611208|Biological|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
472110|NCT00611195|Drug|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
472111|NCT00611169|Drug|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
472112|NCT00611156|Dietary Supplement|ginger|added to a brunch meal
472113|NCT00611156|Dietary Supplement|black pepper|Added to a brunch meal
472114|NCT00611156|Dietary Supplement|horseradish|Added to a brunch meal
472115|NCT00611156|Dietary Supplement|mustard|Added to a brunch meal
472116|NCT00611156|Dietary Supplement|placebo|Added to a bruch meal
472117|NCT00611143|Drug|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
472118|NCT00611130|Drug|vigabatrin|Tablets twice a day for 9 weeks
472119|NCT00611130|Drug|placebo|tablets twice daily for 9 weeks
472120|NCT00611117|Other|Physical Activity Level|High vs. low physical activity during a high fat diet consumption.
472121|NCT00611104|Dietary Supplement|standardized freeze-dried table grape powder|
472122|NCT00611104|Other|laboratory biomarker analysis|
472123|NCT00611104|Other|pharmacological study|
472124|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
472125|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
472126|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
472127|NCT00611065|Device|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
472128|NCT00611052|Behavioral|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
472129|NCT00611052|Behavioral|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
472130|NCT00611052|Other|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
472131|NCT00611039|Drug|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
472132|NCT00611039|Drug|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
472133|NCT00611026|Drug|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
472134|NCT00611026|Drug|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
472135|NCT00611026|Drug|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
472136|NCT00611013|Device|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
472137|NCT00611000|Dietary Supplement|folic acid|
472138|NCT00611000|Genetic|DNA methylation analysis|
472139|NCT00611000|Genetic|gene expression analysis|
472140|NCT00611000|Genetic|microarray analysis|
472141|NCT00611000|Genetic|polymorphism analysis|
472142|NCT00611000|Other|laboratory biomarker analysis|
472143|NCT00610987|Drug|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
472144|NCT00610987|Drug|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
472145|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
472146|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
472147|NCT00610948|Biological|panitumumab|Given IV
472148|NCT00610948|Drug|everolimus|Given orally
472149|NCT00610948|Drug|fluorouracil|Given IV
472150|NCT00610948|Drug|leucovorin calcium|Given IV
472151|NCT00610948|Drug|oxaliplatin|Given IV
472152|NCT00610935|Drug|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
472153|NCT00610935|Drug|Placebo|Single intramuscular injection
472154|NCT00610922|Dietary Supplement|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
472155|NCT00610909|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
472156|NCT00610909|Drug|Placebo|Placebo
472157|NCT00610883|Drug|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
472158|NCT00610870|Drug|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
472159|NCT00610857|Drug|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.~Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.~Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
472160|NCT00610844|Procedure|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
472161|NCT00610831|Device|DIRECTVIEW CR Mammography|4 views screening mammogram
472162|NCT00610818|Other|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
472163|NCT00610805|Other|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
472164|NCT00610805|Other|Usual Care|Participants will receive usual care per their primary care physician.
472165|NCT00610792|Drug|bortezomib|1.3 mg/m2 on Days 1, 4, 8 & 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
472166|NCT00610792|Drug|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
472167|NCT00610779|Dietary Supplement|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
472168|NCT00610779|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
472169|NCT00610753|Behavioral|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
472170|NCT00610753|Behavioral|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
472171|NCT00610740|Drug|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
472172|NCT00610740|Procedure|therapeutic conventional surgery|hysterectomy
472173|NCT00610727|Drug|Prochlorperazine 0.5 mg IV over 5 sec|IV Prochlorperazine for bioavailability
472174|NCT00610727|Drug|Inhaled prochlorperazine 0.625 mg|Inhaled Staccato Prochlorperazine 0.625 mg
472175|NCT00610727|Drug|Inhaled prochlorperazine 1.25 mg|Inhaled Staccato Prochlorperazine 1.25 mg
472176|NCT00610727|Drug|Inhaled prochlorperazine 2.5 mg|Inhaled Staccato Prochlorperazine 2.5 mg
472177|NCT00610727|Drug|Inhaled prochlorperazine 5 mg|InhaledStaccato Prochlorperazine 5 mg
472178|NCT00610727|Drug|Inhaled prochlorperazine 10 mg|InhaledStaccato Prochlorperazine 10 mg
472179|NCT00610727|Drug|Inhaled placebo|Inhaled Staccato Placebo (0 mg)
472180|NCT00610727|Drug|Prochlorperazine 10 mg IV over 5 sec|Prochlorperazine 10 mg IV over 5 sec for patient qualification
472181|NCT00610714|Drug|AZD0530|oral once daily dose
472182|NCT00610714|Drug|Carboplatin|intravenous injection
472183|NCT00610714|Drug|Paclitaxel|intravenous infusion
472184|NCT00610701|Device|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
472185|NCT00610701|Device|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
472186|NCT00610688|Drug|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
472187|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
472471|NCT00608738|Procedure|assessment of therapy complications|
472190|NCT00610649|Drug|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
472191|NCT00610649|Drug|Placebo|Orally administered matching placebo capsules.
472192|NCT00610636|Procedure|Hepatic resection|Hepatic resection
472193|NCT00610623|Drug|azithromycin|300 mg/day, IV from day 1 to 20
472194|NCT00610623|Drug|placebo|once per day, IV from day 1 to 20
472195|NCT00610610|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
472196|NCT00610610|Drug|Placebo|Same shape Placebo
472197|NCT00610584|Procedure|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
472198|NCT00610584|Procedure|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
472199|NCT00610584|Drug|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
472200|NCT00610571|Drug|Oral Topotecan and Temodar|"Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.~Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose."
472201|NCT00610558|Device|Arm 1: Juvenile Myoclonic Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
472202|NCT00610558|Device|Arm 2: Frontal Lobe Epilepsy|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
472203|NCT00610558|Device|Arm 3: Normal Controls|Positron emission tomography (PET) fluorodeoxyglucose (FDG) (10 mCi) and MRI
472204|NCT00610545|Drug|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
472205|NCT00610545|Drug|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
472206|NCT00610532|Drug|phenytoin|intravenous phenytoin (15 mg/kg) single dose
472207|NCT00610532|Drug|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
472208|NCT00610519|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
472209|NCT00610519|Dietary Supplement|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
472210|NCT00610506|Drug|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
472211|NCT00610493|Drug|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
472212|NCT00610493|Drug|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
472213|NCT00610493|Procedure|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
472214|NCT00610493|Procedure|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
472215|NCT00610493|Procedure|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
472216|NCT00610480|Drug|Optive|Instillation of Optive followed by Evaporametry assessment at 30 and 60 minutes
472217|NCT00610480|Drug|Systane|Instillation of Systane followed by Evaporametry assessment at 30 and 60 minutes
472218|NCT00610480|Drug|Systane|
472219|NCT00610467|Device|combined optical and MR imaging|MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
472220|NCT00610454|Drug|Levetiracetam|
472221|NCT00610441|Drug|MK-8777|
472222|NCT00610441|Drug|Placebo|
472223|NCT00610428|Drug|Staccato Placebo|Inhaled Staccato Placebo
472224|NCT00610428|Drug|Staccato Prochlorperazine 5 mg|Inhaled Prochlorperazine 5 mg
472225|NCT00610428|Drug|Staccato Prochlorperazine 10 mg|Inhaled Prochlorperazine10 mg
472226|NCT00610415|Procedure|tumor biopsy|
472227|NCT00610402|Other|blood sample tear drop sample|blood sample tear drop sample
472228|NCT00610389|Biological|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
472229|NCT00610376|Behavioral|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
472230|NCT00610376|Behavioral|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
472231|NCT00610363|Biological|Rilonacept|Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
472232|NCT00610363|Other|Placebo (for Rilonacept)|Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
472233|NCT00610350|Drug|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
472234|NCT00610350|Drug|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
472235|NCT00610337|Drug|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
472236|NCT00610337|Procedure|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
476844|NCT00573222|Drug|Symbicort|
472237|NCT00610324|Drug|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
472238|NCT00610324|Drug|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
472239|NCT00610311|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
472240|NCT00610311|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
472241|NCT00610311|Biological|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
472242|NCT00610311|Biological|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL)
472243|NCT00610311|Biological|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10^8 cells will be given.
472244|NCT00610298|Device|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
472245|NCT00610285|Other|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
472246|NCT00610272|Radiation|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
472247|NCT00610272|Radiation|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
472248|NCT00610272|Radiation|Radiotherapy|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
472249|NCT00610272|Radiation|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
472250|NCT00610259|Behavioral|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
472251|NCT00610259|Other|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
472252|NCT00610246|Drug|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
472253|NCT00610233|Procedure|deep brain stimulation ON|deep brain stimulation in the ON state
472254|NCT00610233|Procedure|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
472255|NCT00610220|Device|Fiberglass short arm cast|Cast will be applied for a 4-week period
472256|NCT00610220|Device|Prefabricated wrist splint|Splint will be applied for a 4-week period
472257|NCT00610207|Device|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
472258|NCT00610194|Drug|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
472259|NCT00610181|Procedure|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
472260|NCT00610168|Biological|Boostrix TM|Single booster dose of vaccine
472261|NCT00610155|Drug|Placebo|BID
472262|NCT00610155|Drug|Pregabalin|Dose 75 mg titrated to 150 mg, bid
472263|NCT00610155|Drug|Tramadol SR|Dose 50mg titrated to 200 mg, bid
472264|NCT00610142|Drug|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
472265|NCT00610142|Drug|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
472266|NCT00610129|Drug|MK-0646|MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
472267|NCT00610116|Device|Electronic Repositioning|Change of pacing vectors for CRT pacing
472268|NCT00610103|Drug|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
472269|NCT00610090|Device|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
472270|NCT00610077|Drug|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
472271|NCT00610077|Drug|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
472272|NCT00610064|Radiation|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
472273|NCT00610064|Radiation|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
472274|NCT00610051|Drug|Alprostadil|central venous access continuous delivery with 2.5ng/kg/min
472275|NCT00610038|Drug|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
472276|NCT00610025|Procedure|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
476925|NCT00572585|Drug|AEB071|
472277|NCT00609999|Drug|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
472278|NCT00609986|Drug|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.~After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.~Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
472279|NCT00609986|Drug|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.~The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.~Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
472280|NCT00609973|Drug|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
472281|NCT00609973|Drug|Placebo|Placebo bid for 6 months
472282|NCT00609960|Behavioral|clowns present|clowns present during the proccess of induction of anesthesia
472283|NCT00609960|Drug|midazolam|midazolam
472284|NCT00609947|Device|Endeavor Zotarolimus-Eluting Coronary Stent|
472285|NCT00609934|Drug|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
472286|NCT00609934|Radiation|external beam radiotherapy|3000cGy in 10 fractions
472287|NCT00609921|Drug|ARQ197|treatment
472288|NCT00609908|Procedure|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
472289|NCT00609908|Procedure|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
472290|NCT00609908|Procedure|serial excision|as much scar as possible is excised, whereafter the wound is closed
472291|NCT00609908|Procedure|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
472292|NCT00609895|Drug|INSULIN GLARGINE|
472293|NCT00609882|Other|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
472294|NCT00609882|Other|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
472295|NCT00609869|Drug|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
472296|NCT00609869|Drug|Rituximab|Rituximab was administered at 375 mg/m^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
472297|NCT00609856|Drug|pioglitazone|tablet, 30 mg, once daily, 26 weeks
472298|NCT00609856|Drug|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
472299|NCT00609843|Other|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
472300|NCT00609830|Behavioral|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
472301|NCT00609830|Behavioral|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
472302|NCT00609830|Behavioral|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
472303|NCT00609830|Behavioral|No Information|Participants received no informational materials.
472304|NCT00609817|Drug|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
472305|NCT00609817|Drug|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
472306|NCT00609804|Drug|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
472307|NCT00609804|Drug|Erlotinib|Erlotinib 150 mg once daily by mouth
472308|NCT00609791|Drug|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
472426|NCT00609063|Drug|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
472309|NCT00609791|Other|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
472310|NCT00609791|Other|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
472311|NCT00609791|Other|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
472312|NCT00609791|Other|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
472313|NCT00609791|Procedure|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
472314|NCT00609791|Procedure|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
472315|NCT00609778|Device|LUCAS|Mechanical chest compression
472316|NCT00609778|Other|Conventional manual resuscitation method|Manual compression
472317|NCT00609765|Drug|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
472318|NCT00609765|Drug|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m^2 iv bolus daily days 1-5
472319|NCT00609765|Drug|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m^2 iv bolus day 1
472320|NCT00609765|Drug|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
472321|NCT00609765|Drug|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
472322|NCT00609765|Drug|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
472323|NCT00609752|Drug|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
472324|NCT00609752|Dietary Supplement|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
472325|NCT00609739|Drug|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients >40 kg with normal renal function (creatinine <1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
472326|NCT00609739|Drug|cytarabine|3000 mg/m^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m^2/day) on days -9 through -4.
472327|NCT00609739|Drug|filgrastim|Patients with absolute neutrophil count (ANC) <0.2 x 10^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
472328|NCT00609739|Drug|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m^2 IV on days +3, +6, and +11.
472329|NCT00609739|Drug|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
472330|NCT00609739|Drug|mitoxantrone hydrochloride|10 mg/m^2 over 30 minutes intravenously (IV) on days -9 through -7.
472331|NCT00609739|Procedure|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 >10^8/kg recipient weight. Infused on Day 0.
472332|NCT00609739|Procedure|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
472333|NCT00609739|Drug|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
472334|NCT00609713|Behavioral|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
472335|NCT00609713|Other|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
472336|NCT00609687|Procedure|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.~Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
472337|NCT00609674|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
472338|NCT00609674|Drug|Placebo|Placebo
472339|NCT00609648|Behavioral|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
472340|NCT00609648|Behavioral|Pamphlet|A pamphlet reassuring patients about dental injections.
472341|NCT00609622|Drug|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
472342|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
472343|NCT00609622|Drug|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
472344|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
472345|NCT00609609|Procedure|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
472346|NCT00609609|Drug|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
472347|NCT00609596|Drug|GI198745|
472348|NCT00609570|Dietary Supplement|NanoGreens|fruits and vegetables
472349|NCT00609570|Dietary Supplement|Whey protein|Whey
472350|NCT00609570|Dietary Supplement|Calcium pills|CA
472351|NCT00609557|Drug|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
472352|NCT00609544|Drug|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
472353|NCT00609531|Drug|Citalopram|Pill, 5-20mg once a day for twelve weeks
472354|NCT00609531|Drug|Placebo|Placebo pill once a day for twelve weeks
472355|NCT00609518|Drug|pemetrexed|500 mg/m^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
472356|NCT00609518|Dietary Supplement|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
472357|NCT00609518|Dietary Supplement|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
472358|NCT00609518|Dietary Supplement|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
472359|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
472360|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
472361|NCT00609505|Other|Telemedicine|Telemedicine genetic counseling
472362|NCT00609505|Other|Face-to-Face|Face-to-face genetic counseling
472363|NCT00609492|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
472364|NCT00609492|Biological|Infanrix™-IPV/Hib|Single dose, intramuscular injection
472365|NCT00609479|Procedure|Osteosynthesis|"Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.~Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12."
472366|NCT00609466|Drug|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
472367|NCT00609466|Drug|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
472368|NCT00609466|Drug|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
472369|NCT00609453|Behavioral|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
472370|NCT00609440|Other|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
472371|NCT00609427|Behavioral|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
472372|NCT00609427|Behavioral|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
472373|NCT00609401|Drug|Nexavar (Sorafenib)|400 mg bid
472374|NCT00609401|Drug|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
472375|NCT00609388|Drug|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
472376|NCT00609388|Other|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
472377|NCT00609375|Drug|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
472378|NCT00609375|Drug|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
472379|NCT00609362|Drug|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
472380|NCT00609362|Drug|Placebo pill|One encapsulated placebo pill a day for 14 weeks
472427|NCT00609063|Drug|Placebo|Placebo capsules taken daily for 6 months
472472|NCT00608738|Procedure|management of therapy complications|
472473|NCT00608725|Radiation|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
472381|NCT00609349|Device|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)~right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
472382|NCT00609336|Drug|gemcitabine hydrochloride|Given IV
472383|NCT00609336|Drug|docetaxel|Given IV
472384|NCT00609336|Drug|capecitabine|Given PO
472385|NCT00609336|Radiation|intensity-modulated radiation therapy|Undergo IMRT
472386|NCT00609336|Drug|oxaliplatin|Given IV
472387|NCT00609336|Procedure|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
472388|NCT00609336|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
472389|NCT00609336|Other|laboratory biomarker analysis|Correlative studies
472390|NCT00609323|Drug|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
472391|NCT00609323|Drug|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
472392|NCT00609310|Dietary Supplement|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
472393|NCT00609297|Other|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
472394|NCT00609297|Other|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
472395|NCT00609297|Other|survey administration|Given to patient and caregivers throughout the study
472396|NCT00609284|Drug|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
472397|NCT00609284|Drug|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
472398|NCT00609284|Radiation|Radiotherapy|70 Gy in 7 weeks
472399|NCT00609271|Behavioral|low carbohydrate diet|<40 grams carbohydrate/day
472400|NCT00609271|Behavioral|low fat diet|<30% fat, <7% saturated fat
472401|NCT00609245|Drug|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
472402|NCT00609245|Drug|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
472403|NCT00609219|Biological|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs~Group One:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 2 x 10^7 cells/m2~Group Two:~Day 0 - 2 x 10^7 cells/m2 Day 14 - 1 x 10^8 cells/m2~Group Three:~Day 0 - 1 x 10^8 cells/m2 Day 14 - 2 x 10^8 cells/m2"
472404|NCT00609193|Drug|lithium|standard clinical care
472405|NCT00609193|Drug|quetiapine|standard clinical care
472406|NCT00609180|Behavioral|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
472407|NCT00609180|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
472408|NCT00609180|Dietary Supplement|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
472409|NCT00609180|Dietary Supplement|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
472410|NCT00609167|Drug|bortezomib|"First 33 patients: 1.3 mg/m^2 IV Days 1, 4, 8 & 11~Remaining 30 patients: 1.5 mg/m^2 IV Days 1, 8, 15 & 22"
472411|NCT00609167|Drug|cyclophosphamide|300mg/m^2 PO days 1, 8, 15 & 22
472412|NCT00609167|Drug|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20~Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
472413|NCT00609154|Drug|glucagon like peptide-1|GLP-1 1 pmole/kg/min
472414|NCT00609154|Drug|glucose control|glucose without GLP-1
472415|NCT00609141|Biological|cixutumumab|Given IV
472416|NCT00609141|Other|pharmacological study|Correlative studies
472417|NCT00609141|Other|laboratory biomarker analysis|Correlative studies
472418|NCT00609128|Drug|olopatadine|olopatadine one drop in one eye for one week
472419|NCT00609115|Device|AMES device|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
472420|NCT00609115|Device|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
472421|NCT00609115|Device|AMES device|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
472422|NCT00609102|Drug|Placebo|one capsule BID
472423|NCT00609102|Drug|n-aceylcysteine|450 mgm BID
472424|NCT00609089|Behavioral|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
472425|NCT00609089|Behavioral|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
472428|NCT00609050|Behavioral|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
472429|NCT00609050|Behavioral|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
472430|NCT00609050|Behavioral|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
472431|NCT00609011|Drug|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
472432|NCT00608985|Drug|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
472433|NCT00608985|Drug|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
472434|NCT00608985|Drug|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
472435|NCT00608985|Drug|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
472436|NCT00608972|Drug|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
472437|NCT00608972|Drug|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
472438|NCT00608972|Drug|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
472439|NCT00608959|Drug|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).~In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
472440|NCT00608959|Drug|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.~Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
472441|NCT00608946|Dietary Supplement|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
472442|NCT00608946|Dietary Supplement|placebo|placebo
472443|NCT00608933|Other|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
472444|NCT00608933|Other|questionnaire administration|Patients complete questionnaires
472445|NCT00608920|Other|Single Photon Emission Computed Tomography (SPECT)|
472446|NCT00608907|Drug|bortezomib|1.3 mg/m^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
472447|NCT00608907|Drug|bortezomib, rifampicin|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
472448|NCT00608907|Drug|bortezomib, dexamethasone|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
472449|NCT00608894|Drug|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
472450|NCT00608894|Drug|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
472451|NCT00608881|Drug|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
472452|NCT00608881|Other|placebo|an inactive substance
472453|NCT00608868|Drug|Gefitinib|Gefitinib tablet 250mg once daily orally
472454|NCT00608855|Other|questionnaire administration|
472455|NCT00608855|Procedure|cryosurgery|
472456|NCT00608855|Procedure|pain therapy|
472457|NCT00608855|Procedure|quality-of-life assessment|
472458|NCT00608842|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
472459|NCT00608842|Drug|Placebo|Matching vehicle placebo administered via intralipomal injection.
472460|NCT00608829|Device|GORE TAG® Thoracic Endoprosthesis|Implant
472461|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
472462|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
472463|NCT00608803|Drug|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
472464|NCT00608790|Drug|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
472465|NCT00608790|Drug|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
472466|NCT00608777|Drug|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
472467|NCT00608751|Radiation|IMRT|
472468|NCT00608738|Other|informational intervention|
472469|NCT00608738|Other|medical chart review|
472470|NCT00608738|Other|questionnaire administration|
472474|NCT00608725|Procedure|QSweat|Quantitative Sweat Testing
472475|NCT00608725|Drug|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
472476|NCT00608712|Drug|Esomeprazole|Esomeprazole 20mg oral tablet
472477|NCT00608699|Drug|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
472478|NCT00608686|Dietary Supplement|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
472479|NCT00608673|Drug|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
472480|NCT00608673|Drug|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
472481|NCT00608660|Other|acupuncture|staging acupuncture
472482|NCT00608660|Other|acupuncture and moxibustion|staging acupuncture and moxibustion
472483|NCT00608660|Other|electroacupuncture|staging electroacupuncture
472484|NCT00608660|Other|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
472485|NCT00608660|Other|acupuncture|non-staging acupuncture
472486|NCT00608634|Drug|perillyl alcohol|Applied as topical cream
472487|NCT00608634|Other|placebo|Applied as topical cream
472488|NCT00608595|Drug|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
472489|NCT00608595|Genetic|gene expression analysis|not noted
472490|NCT00608595|Genetic|protein expression analysis|Not noted
472491|NCT00608595|Other|immunohistochemistry staining method|not noted
472492|NCT00608595|Other|laboratory biomarker analysis|not noted
472493|NCT00608595|Other|mass spectrometry|Not specified
472494|NCT00608595|Procedure|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
472495|NCT00608595|Procedure|neoadjuvant therapy|not noted
472496|NCT00608595|Procedure|therapeutic conventional surgery|not noted
472497|NCT00608582|Device|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
472498|NCT00608569|Drug|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
472499|NCT00608569|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
472500|NCT00608569|Drug|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
472501|NCT00608569|Drug|Zidovudine|300-mg tablet taken orally twice daily
472502|NCT00608569|Drug|Emtricitabine|200-mg tablet taken orally once daily
472503|NCT00608543|Drug|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
472504|NCT00608530|Behavioral|Cognitive Behavioral Therapy-Psychologist-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a psychologist
472505|NCT00608530|Behavioral|Supportive Psychotherapy-Psychologist-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was administered by a psychologist
472506|NCT00608530|Behavioral|Cognitive Behavioral Therapy Nurse-Delivered|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms; treatment was delivered by a nurse
472507|NCT00608530|Behavioral|Supportive Psychotherapy-Nurse-Delivered|Supportive Psychotherapy was based on Rogerian Therapy techniques. Rogerian Therapy encourages self-identification of goals and solutions using a supportive but not didactic approach; it was delivered by a nurse
472508|NCT00608517|Biological|anti-thymocyte globulin|Given IV
472509|NCT00608517|Drug|cyclophosphamide|Given IV
472510|NCT00608517|Drug|fludarabine phosphate|Given IV
472511|NCT00608517|Drug|methylprednisolone|Given IV
472512|NCT00608517|Radiation|total-body irradiation|Given daily for 1-4 days
472513|NCT00608491|Drug|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
472514|NCT00608491|Device|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
472515|NCT00608465|Drug|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
472516|NCT00608465|Drug|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
472517|NCT00608452|Other|Symptom Assessment Scale|"Memorial Symptom Assessment Scale~History and neurologic examination"
472518|NCT00608439|Drug|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
472519|NCT00608439|Other|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
472520|NCT00608426|Behavioral|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
472521|NCT00608400|Dietary Supplement|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
472554|NCT00608075|Drug|lithium|600 mg - 1800 mg per day
472522|NCT00608387|Behavioral|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
472523|NCT00608374|Drug|chlorambucil|
472524|NCT00608374|Drug|fludarabine phosphate|
472525|NCT00608374|Procedure|quality-of-life assessment|
472526|NCT00608361|Drug|Dasatinib|Given PO
472527|NCT00608361|Other|Pharmacological Study|Correlative studies
472528|NCT00608348|Procedure|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
472529|NCT00608348|Procedure|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
472530|NCT00608335|Drug|Micafungin|IV
472531|NCT00608322|Drug|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
472532|NCT00608322|Other|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
472533|NCT00608244|Drug|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.~LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.~Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
472534|NCT00608244|Drug|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
472535|NCT00608231|Drug|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
472536|NCT00608231|Drug|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
472537|NCT00608218|Drug|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
472538|NCT00608205|Drug|cisplatin|Given IV
472539|NCT00608205|Drug|fluorouracil|Given IV
472540|NCT00608205|Radiation|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
472541|NCT00608192|Behavioral|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
472542|NCT00608192|Behavioral|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
472543|NCT00608179|Drug|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
472544|NCT00608179|Drug|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
472545|NCT00608179|Other|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
472546|NCT00608179|Other|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
472547|NCT00608140|Procedure|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
472548|NCT00608140|Drug|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
472549|NCT00608127|Device|LupusorbTM|Single treatment
472550|NCT00608101|Drug|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
472551|NCT00608101|Drug|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
472552|NCT00608088|Behavioral|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
472553|NCT00608088|Behavioral|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
472555|NCT00608075|Drug|Lithium|600 - 1800 mg
472556|NCT00608062|Drug|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
472557|NCT00608062|Drug|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
472558|NCT00608062|Drug|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
472559|NCT00608049|Behavioral|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
472560|NCT00608049|Behavioral|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
472561|NCT00608049|Behavioral|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
472562|NCT00608049|Behavioral|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
472563|NCT00608023|Drug|Tesamorelin|
472564|NCT00608023|Drug|Placebo for Tesamorelin|
472565|NCT00608010|Procedure|Vitrification|Embryos were vitrified according to a previously described technique
472566|NCT00608010|Procedure|Slow freezing|Embryos were frozen with slow freezing technique
472567|NCT00607997|Drug|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
472568|NCT00607984|Drug|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
472569|NCT00607971|Drug|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
472570|NCT00607958|Drug|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
472571|NCT00607945|Drug|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
472572|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
472573|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
472574|NCT00607932|Behavioral|behavioral dietary intervention|Not specified
472575|NCT00607932|Dietary Supplement|Brassica vegetable|Not specified
472576|NCT00607932|Drug|indole-3-carbinol|follow up at 2,4,6 months post baseline.
472577|NCT00607932|Other|counseling intervention|2, 4, 6 months post baseline
472578|NCT00607932|Other|medical chart review|2,4,6 months post baseline
472579|NCT00607932|Other|questionnaire administration|not specified
472580|NCT00607932|Procedure|adjuvant therapy|not specified
472581|NCT00607919|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
472582|NCT00607919|Drug|Placebo|oral, daily, for 16 weeks
472583|NCT00607906|Drug|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
472584|NCT00607906|Drug|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
472585|NCT00607906|Drug|Placebo|Subjects will also receive placebo capsules.
472586|NCT00607893|Device|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
472587|NCT00607893|Device|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
472588|NCT00607880|Procedure|vascular access device placement|
472589|NCT00607867|Other|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
472590|NCT00607867|Other|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
472591|NCT00607854|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.~Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
472592|NCT00607841|Drug|Ispinesib|10 mg/m2 dose as a 1-hour intravenous infusion.
472593|NCT00607841|Drug|Ispinesib|12 mg/m2 dose as a 1-hour intravenous infusion.
472594|NCT00607841|Drug|Ispinesib|14 mg/m2 dose as a 1-hour intravenous infusion.
472595|NCT00607828|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
472596|NCT00607815|Behavioral|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
472641|NCT00607412|Behavioral|12-step based supportive therapy|supportive psychotherapy based on 12-step model
472642|NCT00607399|Drug|SGX523 Capsules|This is a dose escalation study
472643|NCT00607386|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
476926|NCT00572585|Drug|Placebo|
472597|NCT00607815|Behavioral|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
472598|NCT00607802|Biological|leukocyte therapy|
472599|NCT00607802|Genetic|polymerase chain reaction|
472600|NCT00607789|Drug|Duloxetine|30 mg/day - 120 mg/day
472601|NCT00607789|Drug|Placebo|identical to study drug
472602|NCT00607776|Drug|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
472603|NCT00607776|Drug|Systane|Drops
472604|NCT00607763|Drug|Micafungin (Mycamine)|IV
472605|NCT00607750|Drug|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
472606|NCT00607750|Drug|Placebo|Placebo eyedrops, BID, 48 weeks
472607|NCT00607737|Drug|insulin detemir|3 cutaneous injections
472608|NCT00607737|Drug|saline|3 cutaneous injections
472609|NCT00607724|Drug|GDC-0449|
472610|NCT00607711|Drug|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
472611|NCT00607685|Drug|5 Fluorouracil with hyaluronic acid|Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
472612|NCT00607685|Drug|5 Fluorouracil|Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
472613|NCT00607672|Drug|Placebo|Placebo
472614|NCT00607672|Drug|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
472615|NCT00607672|Drug|Candesartan|Candesartan 16mg/d
472616|NCT00607659|Other|No intervention, only observational|No intervention, only observational
472617|NCT00607646|Drug|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
472618|NCT00607646|Drug|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
472619|NCT00607620|Behavioral|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
472620|NCT00607607|Drug|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
472621|NCT00607594|Drug|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
472622|NCT00607581|Drug|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
472623|NCT00607581|Drug|lenalidomide|lenalidomide: 15 mg orally on days 1-21
472624|NCT00607581|Drug|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
472625|NCT00607568|Drug|Atomoxetine|"atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
472626|NCT00607555|Device|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
472627|NCT00607542|Drug|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
472628|NCT00607529|Other|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
472629|NCT00607516|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
472630|NCT00607516|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
472631|NCT00607503|Drug|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.~Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.~The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
472632|NCT00607490|Behavioral|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
472633|NCT00607490|Behavioral|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
472634|NCT00607477|Drug|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
472635|NCT00607477|Drug|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
472636|NCT00607464|Device|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
472637|NCT00607451|Drug|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
472638|NCT00607438|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
472639|NCT00607438|Drug|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
472640|NCT00607412|Behavioral|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
473324|NCT00602277|Other|Laboratory Biomarker Analysis|Correlative studies
472644|NCT00607373|Drug|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
472645|NCT00607373|Drug|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
472646|NCT00607360|Behavioral|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
472647|NCT00607347|Other|Glucose|Oral Glucose Tolerance Test
472648|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
472649|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
472650|NCT00607321|Device|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
472651|NCT00607308|Biological|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
472652|NCT00607308|Biological|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
472653|NCT00607308|Biological|PF-04360365|Single dose of 1 mg/kg IV on Day 1
472654|NCT00607308|Biological|PF-04360365|Single dose of 5 mg/kg IV on Day 1
472655|NCT00607308|Drug|Placebo|Single dose of placebo IV on Day 1
472656|NCT00607308|Biological|PF-04360365|Single dose of 10 mg/kg IV on Day 1
472657|NCT00607295|Drug|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
472658|NCT00607282|Drug|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
472659|NCT00607269|Behavioral|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).~Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol <0.05) urine sample."
472660|NCT00607256|Drug|[S,S]-reboxetine|S_S reboxetine dosed daily.
472661|NCT00607243|Biological|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
472662|NCT00607230|Biological|BCG|BCG vaccination at 0 and 4 weeks
472663|NCT00607230|Biological|Saline|Saline vaccination at 0 and 4 weeks
472664|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
472665|NCT00607217|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
472666|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
472667|NCT00607178|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
472668|NCT00607178|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
472669|NCT00607152|Drug|Rasburicase|0.20mg/kg per day IV
472670|NCT00607152|Drug|Allopurinol|100mg tablets
472671|NCT00607126|Device|Lokomat|locomotor training using body weight support on a treadmill
472672|NCT00607126|Procedure|resistive training|resistive training using theraband and/or weights
472673|NCT00607113|Drug|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
472674|NCT00607113|Drug|RAD001|10 mg By Mouth Daily For 21 Days
472675|NCT00607087|Drug|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
472676|NCT00607087|Drug|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
472677|NCT00607087|Drug|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
472678|NCT00607074|Drug|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
472679|NCT00607074|Drug|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
472680|NCT00607074|Drug|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
472681|NCT00607061|Procedure|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
472682|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
472683|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
472684|NCT00607035|Drug|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
472685|NCT00607035|Drug|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
472686|NCT00607022|Device|dental implant|Dental implant stability measured with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement.
472687|NCT00607009|Behavioral|ALIVE|ALIVE email-based behavioral program based on the participants selected intervention - physical activity, fats/sugars or fruits/vegetabls
472688|NCT00606996|Behavioral|Group interpersonal psychotherapy (IPT-G)|
472689|NCT00606996|Behavioral|Psychoeducation on co-occurring disorders (PSYCHOED)|
472690|NCT00606983|Drug|Tamsulosin|oral administration of Tamsulosin
472691|NCT00606970|Dietary Supplement|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
472692|NCT00606970|Dietary Supplement|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
472693|NCT00606957|Dietary Supplement|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
472694|NCT00606944|Behavioral|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
472695|NCT00606931|Device|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
472696|NCT00606905|Biological|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
472697|NCT00606905|Other|normal saline|equivalent volume of normal saline
472698|NCT00606892|Drug|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
472699|NCT00606892|Drug|Placebo|Sugar Pill
472700|NCT00606892|Drug|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
472701|NCT00606879|Drug|SGX523 Capsules|This is a dose escalation study
472702|NCT00606866|Drug|placebo|Placebo for four weeks
472703|NCT00606866|Drug|Sorafenib|Sorafenib 200 mg twice daily
472704|NCT00606866|Drug|Sorafenib|Sorafenib, 400 mg twice daily
472705|NCT00606853|Behavioral|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
472706|NCT00606840|Behavioral|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
472707|NCT00606840|Behavioral|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
472708|NCT00606827|Drug|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
472709|NCT00606827|Drug|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
472710|NCT00606814|Drug|IPI-504, docetaxel|"IPI-504 administered IV at a dose of 300mg/m2~Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
472711|NCT00606801|Drug|Galantamine|Galantamine 8 mg/day
472712|NCT00606801|Drug|placebo|sugar pill
472713|NCT00606788|Device|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
472714|NCT00606788|Procedure|Conventional weaning|Patients received physician-directed non-protocolized weaning
472715|NCT00606775|Drug|Carvedilol|2.5-5mg/day
472716|NCT00606762|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
472717|NCT00606749|Drug|KC706|300 mg once daily (QD) for 12 weeks.
472718|NCT00606723|Biological|Hematopoietic stem cells from bone marrow or peripheral blood|> = 2 x 10*8 nucleated cells (WBC)/kg body weight of the recipient or rather > = 4 x 10*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
472719|NCT00606710|Device|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
472720|NCT00606697|Drug|GR205171|10 milligrams (mg)
472721|NCT00606697|Drug|GW597599|15 mg
472722|NCT00606684|Drug|GW642444 6.25|GW642444 6.25
472723|NCT00606684|Drug|GW642444 3mcg|once daily
472724|NCT00606684|Drug|GW642444 12.5mcg|GW642444 12.5mcg
472725|NCT00606684|Drug|GW642444 25mcg|GW642444 25mcg
472726|NCT00606684|Drug|GW642444 50mcg|GW642444 50mcg
472727|NCT00606684|Other|placebo|placebo
472728|NCT00606658|Procedure|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
472729|NCT00606645|Biological|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
472730|NCT00606632|Drug|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
472731|NCT00606632|Procedure|CT|contrast enhanced CT scan
472732|NCT00606619|Other|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
472733|NCT00606619|Other|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
472734|NCT00606606|Other|Clinical Decision Support|
472735|NCT00606593|Drug|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472736|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472737|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472738|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472739|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
473325|NCT00602277|Biological|Wild-type Reovirus|
472740|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472741|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472742|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472743|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472744|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
472745|NCT00606580|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
472746|NCT00606580|Drug|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
472747|NCT00606580|Drug|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
472748|NCT00606567|Other|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
472749|NCT00606554|Device|Computer-assisted weaning program|Closed-loop, knowledge-based, computer-assisted wean program initiated at the start of ventilator weaning.
472750|NCT00606554|Behavioral|Standard of Care weaning|Evidence-based standard of care weaning process.
472751|NCT00606541|Drug|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
472752|NCT00606541|Drug|Placebo|Placebo
472753|NCT00606528|Other|No intervention|None. This is an observational study.
472754|NCT00606515|Drug|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
472755|NCT00606515|Drug|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
472756|NCT00606502|Drug|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.~Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.~Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
472757|NCT00606502|Drug|Erlotinib|"150 mg orally in tablet form~Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
472758|NCT00606502|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
472759|NCT00606502|Dietary Supplement|Folic Acid|"1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
472760|NCT00606489|Drug|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
472761|NCT00606489|Drug|Placebo|Placebo
472762|NCT00606476|Drug|Bapineuzumab (AAB-001)|IV q13w
472763|NCT00606463|Device|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
472764|NCT00606450|Drug|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
472765|NCT00606450|Drug|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
472766|NCT00606450|Drug|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
472767|NCT00606437|Procedure|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
472768|NCT00606424|Drug|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
472769|NCT00606411|Drug|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
472770|NCT00606398|Procedure|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
472771|NCT00606385|Procedure|Liver resection|Laparoscopic or Open hepatectomy
472772|NCT00606372|Procedure|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
472773|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
472774|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
472775|NCT00606346|Biological|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
472776|NCT00606346|Drug|No Biologics|Treatments will be prescribed according to investigator judgement.
472777|NCT00606333|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
472778|NCT00606333|Device|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
472779|NCT00606320|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
472780|NCT00606307|Drug|ITF2357|50 mg b.i.d. PO every day
472781|NCT00606294|Radiation|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
472782|NCT00606294|Device|18F-FMISO PET scan|
472783|NCT00606294|Device|MRI|
472784|NCT00606294|Device|FDG PET/CT scan|
472785|NCT00606281|Drug|Aripiprazole|oral, 24mg/day
472786|NCT00606281|Drug|placebo|oral, 0mg(4tablets)/day
472787|NCT00606268|Drug|Micafungin|IV
472788|NCT00606242|Drug|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
472789|NCT00606229|Drug|Aripiprazole|oral, 24mg/day
472790|NCT00606216|Procedure|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
472791|NCT00606216|Procedure|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
472792|NCT00606216|Procedure|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
472793|NCT00606203|Drug|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
472794|NCT00606203|Drug|placebo|placebo
472795|NCT00606190|Procedure|Retrograde brain perfusion|observational
472796|NCT00606190|Procedure|Antegrade brain perfusion|observational
472797|NCT00606177|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
472798|NCT00606177|Drug|placebo|oral, 0mg(4tablets)/day
472799|NCT00606164|Drug|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
472800|NCT00606164|Drug|Placebo|A single one-hour intravenous infusion of placebo on Day 1
472801|NCT00606138|Drug|ranibizumab|One 0.5 mg intravitreal injection
472802|NCT00606138|Procedure|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
472803|NCT00606125|Drug|Nexavar (Sorafenib, BAY43-9006)|The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
472804|NCT00606112|Drug|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
472805|NCT00606099|Drug|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
472806|NCT00606099|Drug|adefovir dipivoxil|Active Comparator
472807|NCT00606086|Drug|GI-5005|40YU, subcutaneous
472808|NCT00606086|Drug|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
472809|NCT00606073|Other|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
472810|NCT00606060|Drug|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
472811|NCT00606047|Radiation|Magnetic resonance imaging (MRI)|Participation in this study will involve patients coming to the hospital after regular work hours for an MRI of the hip joints.
472812|NCT00606034|Drug|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
472813|NCT00606021|Drug|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
472989|NCT00604643|Device|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
472814|NCT00606021|Drug|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
472815|NCT00606008|Drug|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
472816|NCT00605995|Drug|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
472817|NCT00605982|Procedure|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
472818|NCT00605969|Procedure|Motion analysis|Motion analysis and CT
472819|NCT00605969|Procedure|Motion analysis|Motion analysis and CT
472820|NCT00605956|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
472821|NCT00605956|Drug|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
472822|NCT00605956|Drug|Blank Patch|Blank Patch
472823|NCT00605930|Dietary Supplement|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
472824|NCT00605930|Dietary Supplement|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
472825|NCT00605917|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
472826|NCT00605904|Drug|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
472827|NCT00605904|Drug|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
472828|NCT00605904|Drug|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
472829|NCT00605904|Drug|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
472830|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
472831|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning~(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
472832|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning~(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
472833|NCT00605891|Drug|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
472834|NCT00605891|Drug|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
472835|NCT00605865|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
472836|NCT00605852|Drug|GSK835726|GSK835726 will be available in single dose and repeat dose formulations.
472837|NCT00605852|Drug|Placebo|Placebo will be given to subjects.
472838|NCT00605839|Device|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
472839|NCT00605839|Device|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
472840|NCT00605839|Other|Usual Care|This intervention was usual care, without either device.
472841|NCT00605826|Device|NASHA/Dx Injectable Gel|Injection of 4 x 1ml of NASHA/Dx Gel
472842|NCT00605826|Device|Sham Injection|Sham injection
472843|NCT00605813|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
472844|NCT00605800|Other|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
472845|NCT00605800|Other|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
472846|NCT00605787|Drug|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
472847|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
472848|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
472849|NCT00605761|Drug|SB656933|50 mg treatment
472850|NCT00605761|Drug|SB656933|150 mg treatment
472851|NCT00605748|Procedure|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
473326|NCT00602251|Drug|Terbinafine|
472852|NCT00605748|Procedure|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
472853|NCT00605735|Drug|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
472854|NCT00605735|Drug|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
472855|NCT00605722|Drug|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
472856|NCT00605722|Drug|erlotinib (Tarceva)|150 mg orally (po) daily.
472857|NCT00605709|Drug|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
472858|NCT00605696|Drug|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
472859|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
472860|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
472861|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
472862|NCT00605670|Behavioral|questionnaires|patients will fill out two questionnaires post surgery
472863|NCT00605670|Behavioral|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
472864|NCT00605657|Drug|Valproic Acid|Oral administration of valproic acid
472865|NCT00605657|Procedure|CT Scan|CT scans were done before and after treating the patient with valproic acid
472866|NCT00605657|Procedure|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
472867|NCT00605644|Drug|MOA-728|Oral Capsules
472868|NCT00605644|Drug|Placebo|Placebo
472869|NCT00605631|Device|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
472870|NCT00605618|Drug|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
472871|NCT00605605|Drug|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
472872|NCT00605592|Procedure|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
472873|NCT00605566|Drug|Sorafenib|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
472874|NCT00605566|Drug|Cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
472875|NCT00605553|Drug|Placebo|"Placebo oral capsules~Placebo for 7 days"
472876|NCT00605553|Drug|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
472877|NCT00605514|Drug|VRC-EBODNA023-00-VP|
472878|NCT00605514|Drug|VRC-MARDNA025-00-VP|
472879|NCT00605488|Procedure|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
472880|NCT00605475|Drug|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
472881|NCT00605475|Drug|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
472882|NCT00605475|Drug|Metformin|Participants continued on their stable daily dose of metformin throughout the study
472883|NCT00605449|Drug|GSK376501|
472884|NCT00605436|Behavioral|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
472885|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
472886|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
472887|NCT00605410|Drug|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
472888|NCT00605410|Drug|placebo|Matched placebo
472889|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
473327|NCT00602225|Drug|clofarabine|Given IV
472890|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
472891|NCT00605384|Drug|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
472892|NCT00605384|Drug|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
472893|NCT00605371|Drug|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
472894|NCT00605371|Drug|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
472895|NCT00605358|Behavioral|Open Door intervention|"Open Door intervention subjects will:~receive an evaluation~receive a referral to a local mental health provider~identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
472896|NCT00605345|Drug|Darbepoetin alfa|As prescribed
472897|NCT00605345|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
472898|NCT00605332|Device|inferior vena cava filter|Crux Biomedical IVC Filter
472899|NCT00605319|Drug|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
472900|NCT00605306|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
472901|NCT00605306|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
472902|NCT00605293|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
472903|NCT00605293|Drug|Epoetin alfa|As prescribed
472904|NCT00605280|Drug|Standard of Care|Clinicians decision to use optional laser therapy.
472905|NCT00605280|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
472906|NCT00605267|Drug|Tamoxifen|20 mg once daily oral dose
472907|NCT00605267|Drug|Anastrazole (Arimidex)|1 mg once daily oral dose
472908|NCT00605267|Drug|Goserelin acetate (Zoladex)|3.6mg/month depot injection
472909|NCT00605241|Drug|GSK598809|Drug
472910|NCT00605228|Drug|MOVIPREP|2L Drug
472911|NCT00605228|Drug|COLOPEG|4L Drug
472912|NCT00605215|Drug|laquinimod|0.6 mg oral once daily for 24 months
472913|NCT00605215|Drug|placebo|oral placebo once daily for 24 months
472914|NCT00605215|Drug|Interferon β-1a (Avonex®)|Interferon β-1a (Avonex®) 30 mcg IM once weekly for 24 months
472915|NCT00605202|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
472916|NCT00605202|Dietary Supplement|Licorice|Licorice candy 32 grams a day for 14 days.
472917|NCT00605189|Device|Powered Suction Pump (VAC Freedom)|continuous foam based negative pressure wound therapy
472918|NCT00605189|Device|Powered Suction Pump|continuous gauze based negative pressure wound therapy
472919|NCT00605189|Device|MWT|moist wound therapy
472920|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
472921|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
472922|NCT00605176|Drug|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
472923|NCT00605150|Radiation|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
472924|NCT00605137|Drug|insulin detemir|
472925|NCT00605137|Drug|insulin NPH|
472926|NCT00605124|Other|Knee muscle exercises|Home exercises three times a week, control every three months
472927|NCT00605111|Drug|biphasic insulin aspart|
472928|NCT00605098|Drug|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
472929|NCT00605098|Drug|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
472930|NCT00605085|Biological|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
472931|NCT00605085|Biological|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
472932|NCT00605072|Drug|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
472933|NCT00605072|Drug|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
472934|NCT00605072|Drug|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
472935|NCT00605072|Drug|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
472936|NCT00605072|Drug|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
472937|NCT00605059|Drug|[123I]AV94|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
472938|NCT00605046|Drug|SPECT scan|AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
472939|NCT00605033|Drug|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
472940|NCT00605033|Drug|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
472941|NCT00605020|Drug|insulin detemir|
472942|NCT00605020|Drug|insulin aspart|
472943|NCT00605020|Device|biphasic insulin aspart|
472944|NCT00604981|Behavioral|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
472945|NCT00604981|Behavioral|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
472946|NCT00604968|Drug|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
472947|NCT00604955|Drug|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
472948|NCT00604942|Procedure|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
472949|NCT00604942|Procedure|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
472950|NCT00604942|Drug|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
472951|NCT00604942|Drug|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
472952|NCT00604929|Dietary Supplement|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
472953|NCT00604916|Other|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
472954|NCT00604916|Other|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
472955|NCT00604903|Device|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
472956|NCT00604890|Drug|API 31510 3% Topical Cream|Topical treatment 3% active cream applied to the lesion
472957|NCT00604890|Drug|API 31510 1.5% Topical Cream|Topical treatment 1.5% active cream applied to the lesion
472958|NCT00604890|Other|Placebo|Topical treatment placebo applied to the lesion
472959|NCT00604877|Behavioral|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
472960|NCT00604877|Behavioral|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
472961|NCT00604864|Drug|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
472962|NCT00604864|Drug|placebo|Placebo
472963|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
472964|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
472965|NCT00604825|Drug|Other: Placebo|
472966|NCT00604825|Drug|GSK232802|
472967|NCT00604825|Drug|PREMARIN|
472968|NCT00604812|Drug|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
472969|NCT00604812|Drug|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
472970|NCT00604812|Drug|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
472971|NCT00604812|Drug|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
472972|NCT00604799|Device|Talent Thoracic Stent Graft|TEVAR
472973|NCT00604786|Drug|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
472974|NCT00604786|Drug|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
472975|NCT00604760|Drug|MEM 3454|Capsule 5 mg once a day
472976|NCT00604760|Drug|MEM 3454|Capsule 15 mg once a day
472977|NCT00604760|Drug|MEM 3454|Capsule 50 mg once a day
472978|NCT00604760|Drug|Placebo for MEM 3454|Capsule once a day
472979|NCT00604747|Other|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
472980|NCT00604734|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
472981|NCT00604721|Drug|selumetinib|Given orally
472982|NCT00604721|Other|pharmacological study|
472983|NCT00604708|Biological|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
472984|NCT00604708|Biological|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
472985|NCT00604695|Drug|Tenecteplase|Intracoronary injection of IV tenecteplase.
472986|NCT00604695|Drug|Sterile Saline|Intracoronary injection of IV sterile saline
472987|NCT00604682|Drug|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
472988|NCT00604656|Drug|insulin aspart|
477499|NCT00568321|Drug|RN624|200 mcg/kg
472990|NCT00604630|Drug|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
472991|NCT00604630|Drug|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
472992|NCT00604617|Procedure|Interferon-Gamma Release Assay|IGRAs
472993|NCT00604617|Drug|RT-23|TST - tuberculin skin test
472994|NCT00604604|Behavioral|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
472995|NCT00604591|Drug|Tolcapone|200 mg by mouth three times a day
472996|NCT00604591|Drug|Placebo|200 mg by mouth three times a day
472997|NCT00604578|Drug|Pioglitazone Hydrochloride|
472998|NCT00604565|Drug|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
472999|NCT00604565|Other|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
473000|NCT00604552|Device|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
473001|NCT00604539|Drug|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
473002|NCT00604539|Drug|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
473003|NCT00604526|Radiation|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|"Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL~*After 1 year, will follow up with doctor about every 6 months."
473004|NCT00604513|Other|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun & Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
473005|NCT00604513|Other|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
473006|NCT00604500|Drug|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
473007|NCT00604487|Device|ARD (Atad Ripener Device)|Atad double balloon ripener device
473008|NCT00604487|Device|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
473009|NCT00604487|Device|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
473010|NCT00604474|Device|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
473011|NCT00604461|Drug|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
473012|NCT00604448|Other|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
473013|NCT00604448|Other|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
473014|NCT00604435|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
473015|NCT00604435|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
473016|NCT00604409|Radiation|SIRT|Undergo SIRT
473017|NCT00604409|Drug|capecitabine|Given PO
473018|NCT00604396|Drug|insulin detemir|
473019|NCT00604396|Drug|insulin NPH|
473020|NCT00604383|Drug|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
473021|NCT00604383|Drug|placebo|1 tablet, orally, daily, up to 42 months
473022|NCT00604357|Drug|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)~MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)~Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)~Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
473023|NCT00604344|Drug|insulin detemir|
473024|NCT00604344|Drug|insulin NPH|
473025|NCT00604331|Drug|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
473063|NCT00603967|Procedure|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
473170|NCT00603239|Drug|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
473026|NCT00604318|Drug|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
473027|NCT00604305|Device|Acrysof|Monofocal IOL
473028|NCT00604305|Device|Acuity's AIOL|Accommodating IOL
473029|NCT00604279|Drug|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
473030|NCT00604279|Drug|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
473031|NCT00604253|Drug|insulin detemir|
473032|NCT00604253|Drug|insulin NPH|
473033|NCT00604227|Other|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
473034|NCT00604214|Drug|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
473035|NCT00604214|Drug|Placebo|0.9% sodium chloride, intravenous, 96 hours
473036|NCT00604201|Biological|Umbilical Cord Blood|unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
473037|NCT00604188|Drug|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
473038|NCT00604188|Drug|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
473039|NCT00604175|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
473040|NCT00604162|Device|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
473041|NCT00604162|Procedure|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
473042|NCT00604136|Biological|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
473043|NCT00604123|Drug|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
473044|NCT00604123|Drug|Placebo|Placebo nasal spray twice daily for 2 weeks.
473045|NCT00604110|Other|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF<45%), is hemodynamically favourable.
473046|NCT00604097|Behavioral|Attachment-Based Family Therapy|12-16 week family-based therapy
473047|NCT00604097|Behavioral|Enhanced Usual Care|Rapid referral to community outpatient care with weekly monitoring of symptoms by study team
473048|NCT00604084|Drug|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
473049|NCT00604084|Drug|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
473050|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
473051|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
473052|NCT00604045|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
473053|NCT00604045|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
473054|NCT00604032|Drug|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
473055|NCT00604019|Drug|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
473056|NCT00604019|Drug|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
473057|NCT00604006|Drug|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
473058|NCT00604006|Drug|Placebo|Placebo (lactose in capsules for blinding) once daily
473059|NCT00603993|Biological|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
473060|NCT00603980|Drug|alprazolam|Staccato Alprazolam, single dose
473061|NCT00603980|Drug|alprazolam|oral, immediate release
473062|NCT00603980|Drug|placebo|Staccato placebo + oral placebo
473165|NCT00603252|Biological|Twinrix|
473064|NCT00603967|Procedure|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
473065|NCT00603967|Behavioral|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months~Cognitive tests - baseline, 6 months, 12 months~Depression assessment - baseline, 6 months, 12 months~Dietary calcium intake questionnaire - baseline"
473066|NCT00603954|Drug|Conditioning regimen TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
473067|NCT00603954|Drug|Conditioning regimen II (TLI 8 Gy + ATG [Thymoglobulin])|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
473068|NCT00603941|Drug|CS7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.25, 0.35, and 0.50mg BID. At Phase 2, CS-7017 will be administered at the RP2D. Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
473069|NCT00603941|Drug|Paclitaxel|
473070|NCT00603915|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) day 1 and day 8
473071|NCT00603915|Drug|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m^2 (Cisplatin) intravenous (IV) day 1
473072|NCT00603915|Drug|erlotinib|150mg daily (post GC therapy)
473073|NCT00603902|Drug|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
473074|NCT00603902|Drug|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
473075|NCT00603902|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
473076|NCT00603889|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
473077|NCT00603876|Dietary Supplement|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
473078|NCT00603863|Biological|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
473079|NCT00603850|Device|ForeseeHome|human factor
473080|NCT00603837|Device|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
473081|NCT00603837|Device|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
473082|NCT00603824|Drug|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg
473083|NCT00603824|Drug|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
473084|NCT00603811|Biological|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
473085|NCT00603811|Biological|Placebo|Placebo
473086|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
473087|NCT00603798|Drug|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
473088|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
473089|NCT00603785|Drug|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive placebo treatment for 6 months.
473090|NCT00603785|Drug|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
473091|NCT00603772|Drug|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
473092|NCT00603759|Drug|celecoxib|100 mg qid
473093|NCT00603759|Drug|placebo|1 cap qid
473094|NCT00603746|Drug|GW685698X|GW685698X
473095|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
473096|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet
473097|NCT00603720|Drug|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
473098|NCT00603720|Drug|L-Arginine|aids in nitric oxide production
473099|NCT00603720|Drug|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
473100|NCT00603681|Drug|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
473101|NCT00603681|Drug|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
473102|NCT00603668|Biological|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
473103|NCT00603655|Other|Low glycemic load diet|Low glycemic load diet
473104|NCT00603655|Other|High glycemic load diet|High glycemic load diet
473105|NCT00603642|Drug|Placebo|Subcutaneously administered, once a week, for 12 weeks
473106|NCT00603642|Drug|AMG 531|Subcutaneously administered, once a week, for 12 weeks
473107|NCT00603616|Drug|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
473108|NCT00603616|Drug|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
473109|NCT00603603|Other|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
473110|NCT00603603|Other|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
473111|NCT00603590|Drug|Polypill|Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
473112|NCT00603590|Drug|Placebo drug|Inactive tablet Once a day Identical in appearance to intervention drug
473113|NCT00603577|Drug|Placebo|Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
473114|NCT00603577|Drug|Xaliproden|1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
473115|NCT00603564|Procedure|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
473116|NCT00603538|Drug|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
473117|NCT00603525|Drug|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
473118|NCT00603525|Drug|Placebo|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
473119|NCT00603512|Drug|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
473120|NCT00603512|Drug|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
473121|NCT00603512|Drug|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
473122|NCT00603512|Drug|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
473123|NCT00603512|Drug|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
473124|NCT00603499|Dietary Supplement|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
473125|NCT00603499|Other|Placebo|Subjects in the control group received inert placebo once per day during 4 months
473126|NCT00603486|Device|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
473127|NCT00603473|Drug|gabapentin|Orally administered gabapentin
473128|NCT00603460|Biological|DCVax-L and T Cells|"Arm A~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~End of study visit~Arm B~Optional DCVax-L prior to chemotherapy~Apheresis~Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)~Infusion of activated T cells~DCVax-L vaccine~Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks~End of study visit"
473129|NCT00603447|Drug|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
473130|NCT00603447|Drug|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
473131|NCT00603447|Drug|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
473132|NCT00603434|Drug|OROS-MPH|18 mg bid on days 1 and 2
473133|NCT00603434|Drug|OROS-MPH|27mg bid on days 3 and 4
473134|NCT00603434|Drug|OROS-MPH|35 mg bid on days 5-9
473135|NCT00603421|Other|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
473136|NCT00603421|Other|treatment as usual|Treatment as usual
473137|NCT00603408|Drug|Cisplatin|
473138|NCT00603408|Radiation|Radiation Therapy|
473139|NCT00603408|Procedure|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
473140|NCT00603395|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
473141|NCT00603382|Drug|GW685698X|GW685698X
473142|NCT00603382|Drug|Placebo|placebo comparator
473143|NCT00603369|Behavioral|group intervention|13-session intervention
473144|NCT00603369|Behavioral|group intervention|2-session intervention
473145|NCT00603356|Drug|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
473146|NCT00603343|Drug|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
473147|NCT00603343|Drug|placebo|placebo corresponding to body weight
473148|NCT00603330|Biological|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
473149|NCT00603317|Drug|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
473150|NCT00603317|Drug|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
473151|NCT00603304|Drug|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
473152|NCT00603304|Drug|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
473153|NCT00603304|Drug|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
473154|NCT00603304|Drug|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
473155|NCT00603304|Drug|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
473156|NCT00603304|Drug|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
473157|NCT00603291|Drug|Lorcaserin 10 mg once daily (QD)|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
473158|NCT00603291|Drug|Lorcaserin 10 mg twice a day (BID)|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
473159|NCT00603291|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
473160|NCT00603278|Drug|GW685698X|GW685698X
473161|NCT00603278|Drug|placebo|placebo
473162|NCT00603265|Drug|ADL5859|
473163|NCT00603265|Drug|Duloxetine|
473164|NCT00603265|Drug|Placebo|
473171|NCT00603239|Drug|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
473172|NCT00603213|Procedure|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.~Echocardiogram is an ultrasound of the heart."
473173|NCT00603187|Drug|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
473174|NCT00603174|Device|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
473175|NCT00603135|Drug|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
473176|NCT00603122|Behavioral|ascent protocol|ascent protocol for the two groups has different acclimatization time
473177|NCT00603109|Drug|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
473178|NCT00603109|Drug|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
473179|NCT00603096|Device|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
473180|NCT00603083|Drug|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
473181|NCT00603083|Drug|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
473182|NCT00603070|Other|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
473183|NCT00603070|Other|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
473184|NCT00603044|Drug|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
473185|NCT00603031|Other|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
473186|NCT00603031|Other|NaCl|infusion with NaCl for 120 minutes as placebo-arm
473187|NCT00603031|Other|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
473188|NCT00603018|Drug|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
473189|NCT00603005|Device|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
473190|NCT00602979|Device|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
473191|NCT00602979|Device|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
473192|NCT00602979|Device|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
473193|NCT00602979|Device|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
473194|NCT00602979|Device|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
473195|NCT00602953|Other|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
473196|NCT00602940|Procedure|Acupuncture|12 treatments over 8 weeks
473197|NCT00602940|Procedure|Sham Acupuncture|12 treatments over 8 weeks
473198|NCT00602927|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
473199|NCT00602927|Drug|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
473200|NCT00602914|Device|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
473201|NCT00602914|Device|MicronJet|MicronJet, Intradermal Injection
473202|NCT00602901|Other|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
473203|NCT00602901|Other|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
473204|NCT00602901|Drug|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
473205|NCT00602862|Drug|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
473206|NCT00602862|Drug|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
473207|NCT00602862|Drug|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
473208|NCT00602849|Drug|Sertraline|
473209|NCT00602836|Biological|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m^2 by IV on day 2 Cycle 2-6: 375 mg/m^2 by IV on day 1 (every 21 days)
473210|NCT00602836|Drug|Cyclophosphamide|600 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
473211|NCT00602836|Drug|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
473212|NCT00602836|Drug|Pentostatin|2 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
473213|NCT00602797|Drug|Paclitaxel|Given IV
473214|NCT00602797|Other|Quality-of-Life Assessment|Ancillary studies
473215|NCT00602797|Other|Questionnaire Administration|Ancillary studies
473216|NCT00602797|Drug|Vinorelbine Tartrate|Given IV
473217|NCT00602784|Biological|IC41|
473218|NCT00602771|Drug|tipifarnib|Given orally
473219|NCT00602771|Drug|etoposide|Given orally
473220|NCT00602758|Behavioral|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
473328|NCT00602225|Drug|cytarabine|Given IV
473221|NCT00602758|Behavioral|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
473222|NCT00602745|Drug|S-1|oral administration
473223|NCT00602745|Drug|5-Fluorouracil|intravenous bolus
473224|NCT00602732|Behavioral|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
473225|NCT00602732|Behavioral|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
473226|NCT00602719|Drug|Zolpidem|
473227|NCT00602706|Biological|sargramostim|
473228|NCT00602706|Drug|melphalan|
473229|NCT00602706|Procedure|autologous hematopoietic stem cell transplantation|
473230|NCT00602706|Procedure|peripheral blood stem cell transplantation|
473231|NCT00602706|Radiation|samarium Sm 153 lexidronam pentasodium|
473232|NCT00602693|Biological|umbilical cord blood transplantation|Infusion of umbilical cord blood
473233|NCT00602693|Drug|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
473234|NCT00602693|Drug|fludarabine phosphate|40 mg/m^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
473235|NCT00602693|Drug|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
473236|NCT00602693|Radiation|Total body irradiation|200 cGy on Day -1
473237|NCT00602693|Biological|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10^5 Treg/kg.
473238|NCT00602693|Drug|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
473239|NCT00602680|Drug|SSR180711C|duration of treatment: 4 weeks
473240|NCT00602680|Drug|donepezil|duration of treatment: 4 weeks
473241|NCT00602680|Drug|placebo|duration of treatment: 4 weeks
473242|NCT00602667|Drug|Induction Chemotherapy|All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
473243|NCT00602667|Drug|Low-Risk Therapy|Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
473244|NCT00602667|Drug|High-Risk Therapy|High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
473245|NCT00602667|Drug|Intermediate-Risk Therapy|"Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan."
473246|NCT00602641|Other|Laboratory Biomarker Analysis|Optional correlative studies
473247|NCT00602641|Drug|Lenalidomide|Given PO
473248|NCT00602641|Drug|Melphalan|Given PO
473249|NCT00602641|Drug|Prednisone|Given PO
473250|NCT00602641|Other|Quality-of-Life Assessment|Ancillary studies
473251|NCT00602641|Drug|Thalidomide|Given PO
473252|NCT00602628|Other|questionnaire administration|
473253|NCT00602628|Procedure|adjuvant therapy|
473254|NCT00602628|Procedure|biopsy|
473255|NCT00602628|Procedure|computed tomography|
473256|NCT00602628|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
473257|NCT00602628|Procedure|magnetic resonance imaging|
473258|NCT00602628|Procedure|therapeutic conventional surgery|
473259|NCT00602628|Procedure|ultrasound imaging|
473260|NCT00602628|Radiation|radiation therapy|
473261|NCT00602615|Drug|Torsemide|
473262|NCT00602602|Biological|bevacizumab|
473263|NCT00602602|Drug|fluorouracil|
473264|NCT00602602|Drug|gemcitabine hydrochloride|
473265|NCT00602602|Drug|oxaliplatin|
473266|NCT00602602|Other|immunohistochemistry staining method|
473267|NCT00602602|Other|laboratory biomarker analysis|
473268|NCT00602602|Procedure|conventional surgery|
473269|NCT00602602|Procedure|endoscopic biopsy|
473270|NCT00602602|Procedure|laparoscopy|
473271|NCT00602602|Radiation|radiation therapy|
473272|NCT00602589|Drug|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
473273|NCT00602576|Drug|sorafenib tosylate|Given orally
473274|NCT00602576|Drug|temozolomide|Given orally
473323|NCT00602290|Drug|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
477500|NCT00568321|Drug|Placebo|placebo
473275|NCT00602563|Behavioral|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
473276|NCT00602563|Behavioral|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
473277|NCT00602563|Behavioral|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
473278|NCT00602563|Behavioral|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
473279|NCT00602550|Drug|Zidovudine|
473280|NCT00602537|Drug|Venlafaxine|75 to 375 mg
473281|NCT00602537|Drug|Lithium Carbonate|300 to 2400 mg
473282|NCT00602524|Drug|Pilocarpine|
473283|NCT00602511|Drug|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles~Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
473284|NCT00602511|Drug|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day~Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
473285|NCT00602498|Drug|Clarithromycin|
473286|NCT00602485|Other|Action Control Education|30 minute educational intervnetion
473287|NCT00602472|Drug|linagliptin|active
473288|NCT00602472|Drug|placebo|placebo to linagliptin 5 mg
473289|NCT00602459|Drug|Cyclophosphamide|Given IV
473290|NCT00602459|Drug|Fludarabine Phosphate|Given IV or PO
473291|NCT00602459|Other|Laboratory Biomarker Analysis|Correlative studies
473292|NCT00602459|Drug|Lenalidomide|Given PO
473293|NCT00602459|Biological|Rituximab|Given IV
473294|NCT00602446|Drug|deferasirox|20 mg/kg once daily orally for 6 months
473295|NCT00602420|Drug|naproxen|Oral naproxen twice daily for 5-8 days.
473296|NCT00602420|Other|placebo|Oral placebo twice daily for 5-8 days.
473297|NCT00602407|Drug|Cilostazol|
473298|NCT00602394|Drug|Lithium|
473299|NCT00602381|Drug|Lithium|
473300|NCT00602368|Other|histological technique|
473301|NCT00602368|Other|laboratory biomarker analysis|
473302|NCT00602368|Procedure|colposcopic biopsy|
473303|NCT00602368|Procedure|colposcopy|
473304|NCT00602368|Procedure|light-scattering spectroscopy|
473305|NCT00602368|Procedure|loop electrosurgical excision procedure|
473306|NCT00602355|Drug|Sertraline|"Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care."
473307|NCT00602355|Drug|Placebo|"Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline."
473308|NCT00602355|Behavioral|Interpersonal psychotherapy (IPT)|IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
473309|NCT00602355|Behavioral|Clinical management|Clinical management includes treatment as usual for those receiving medication for depression.
473310|NCT00602355|Behavioral|Mothercrafting|Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
473311|NCT00602342|Drug|Terbinafine|
473312|NCT00602329|Biological|bevacizumab|Given IV
473313|NCT00602329|Drug|fluorouracil|Given IV
473314|NCT00602329|Drug|leucovorin calcium|Given IV
473315|NCT00602329|Drug|oxaliplatin|Given IV
473316|NCT00602316|Drug|gadolinium-chelate|
473317|NCT00602316|Procedure|conventional surgery|
473318|NCT00602316|Procedure|magnetic resonance imaging|
473319|NCT00602316|Procedure|magnetic resonance spectroscopic imaging|
473320|NCT00602303|Drug|Torsemide|
473321|NCT00602290|Drug|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were > 2 until treatment completion.
473322|NCT00602290|Drug|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
477605|NCT00567567|Drug|Thiotepa|Given IV
473329|NCT00602225|Biological|filgrastim|Given subcutaneously
473330|NCT00602212|Behavioral|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
473331|NCT00602212|Behavioral|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
473332|NCT00602199|Drug|ABT-510|
473333|NCT00602199|Other|immunoenzyme technique|
473334|NCT00602199|Other|immunohistochemistry staining method|
473335|NCT00602199|Other|laboratory biomarker analysis|
473336|NCT00602199|Other|pharmacological study|
473337|NCT00602199|Procedure|biopsy|
473338|NCT00602186|Drug|tamsolusin|0.4 mg /day
473339|NCT00602186|Drug|prazosin|1 mg/day
473340|NCT00602173|Drug|Cilostazol|
473341|NCT00602160|Drug|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.~Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
473342|NCT00602147|Other|laboratory biomarker analysis|Blood or cheek cells wil be collected.
473343|NCT00602134|Drug|6-Mercaptopurine|
473344|NCT00602108|Procedure|adjuvant therapy|
473345|NCT00602108|Procedure|conventional surgery|
473346|NCT00602108|Radiation|hypofractionated radiation therapy|
473347|NCT00602108|Radiation|intraoperative radiation therapy|
473348|NCT00602095|Drug|misoprostol|0.025mg tablet vaginally every 4 hour until progress
473349|NCT00602095|Drug|dinoprostone|2mg vaginal gel every 6 hours until progress
473350|NCT00602095|Device|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
473351|NCT00602082|Drug|capecitabine|
473352|NCT00602082|Drug|cisplatin|
473353|NCT00602082|Drug|streptozocin|
473354|NCT00602082|Genetic|DNA analysis|
473355|NCT00602082|Genetic|RNA analysis|
473356|NCT00602082|Genetic|protein analysis|
473357|NCT00602082|Genetic|proteomic profiling|
473358|NCT00602082|Other|laboratory biomarker analysis|
473359|NCT00602069|Behavioral|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
473360|NCT00602069|Behavioral|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
473361|NCT00602056|Other|Redesigned immunization card|A low cost nad simplified redesigned immunization card
473362|NCT00602056|Other|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
473363|NCT00602056|Other|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
473364|NCT00602043|Radiation|F-18 16 alpha-fluoroestradiol|Undergo [^18F] FES PET
473365|NCT00602043|Radiation|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
473366|NCT00602043|Procedure|positron emission tomography|Undergo [^18F] FES PET
473367|NCT00602043|Procedure|positron emission tomography|Undergo standard clinical FDG PET/CT
473368|NCT00602043|Procedure|computed tomography|Undergo standard clinical FDG PET/CT
473369|NCT00602043|Other|laboratory biomarker analysis|Correlative studies
473370|NCT00602030|Drug|entinostat|"Dose cohort 1: SNDX-275 5mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)~Dose cohort 2: SNDX-275 10mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)"
473371|NCT00602030|Drug|SNDX-275|entinostat 5mg or 10mg (determined by Lead in study findings) on days 1 and 15 of a 28-day cycle until progression or unacceptable toxicity develops; maximum of 6 cycles
473372|NCT00602030|Drug|erlotinib|erlotinib 150mg PO QD
473373|NCT00602017|Drug|Amlodipine|
473374|NCT00602004|Drug|losartan|losartan 50 mg a day
473375|NCT00601991|Biological|VEGF Trap|Drug under investigation
473376|NCT00601991|Procedure|Bone marrow biopsy|To determine response to treatment
473377|NCT00601991|Procedure|bone marrow aspiration|To determine response to treatment
473378|NCT00601991|Procedure|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
473379|NCT00601978|Drug|carbidopa/levodopa|
473380|NCT00601978|Drug|Carbidopa/Levodopa/Entacapone|
473381|NCT00601965|Drug|Escitalopram|20 mg daily oral escitalopram
473382|NCT00601965|Drug|Placebo|Placebo pill of daily oral escitalopram
473383|NCT00601965|Behavioral|Cognitive behavioral therapy (CBT)|16 weekly 1-hour sessions
473384|NCT00601952|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
473385|NCT00601952|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
473490|NCT00601393|Other|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
473678|NCT00599989|Radiation|proton beam radiation therapy|
479581|NCT00553345|Drug|vitamin E|
473386|NCT00601939|Behavioral|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
473387|NCT00601939|Behavioral|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
473388|NCT00601926|Biological|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
473389|NCT00601913|Drug|erlotinib hydrochloride|
473390|NCT00601913|Genetic|protein analysis|
473391|NCT00601913|Genetic|western blotting|
473392|NCT00601913|Other|immunohistochemistry staining method|
473393|NCT00601913|Other|laboratory biomarker analysis|
473394|NCT00601913|Other|liquid chromatography|
473395|NCT00601913|Other|mass spectrometry|
473396|NCT00601913|Procedure|neoadjuvant therapy|
473397|NCT00601913|Procedure|therapeutic conventional surgery|
473398|NCT00601900|Biological|Bevacizumab|Given IV
473399|NCT00601900|Other|Laboratory Biomarker Analysis|Correlative studies
473400|NCT00601900|Drug|Letrozole|Given PO
473401|NCT00601900|Other|Questionnaire Administration|Ancillary studies
473402|NCT00601900|Drug|Tamoxifen Citrate|Given PO
473403|NCT00601887|Drug|Meloxicam|
473404|NCT00601874|Drug|Pilocarpine|
473405|NCT00601861|Drug|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
473406|NCT00601848|Drug|chemotherapy|
473407|NCT00601848|Drug|porfimer sodium|
473408|NCT00601848|Other|immunohistochemistry staining method|
473409|NCT00601848|Other|laboratory biomarker analysis|
473410|NCT00601848|Procedure|spectroscopy|
473411|NCT00601848|Procedure|therapeutic conventional surgery|
473412|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
473413|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
473414|NCT00601822|Behavioral|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
473415|NCT00601822|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
473416|NCT00601809|Other|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
473417|NCT00601809|Drug|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
473418|NCT00601796|Biological|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
473419|NCT00601796|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
473420|NCT00601796|Drug|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
473421|NCT00601770|Biological|IC41|injection
473422|NCT00601757|Behavioral|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
473423|NCT00601757|Behavioral|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
473424|NCT00601744|Behavioral|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours~Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)~Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
473425|NCT00601744|Behavioral|Questionnaire|5-10 minute questionnaire to be completed after the interview.
473426|NCT00601731|Biological|MenACWY-CRM197|Blood test, 40-months and 60-months children
473427|NCT00601731|Biological|Blood test|Blood test, 40-months and 60-months children
473428|NCT00601718|Drug|vorinostat|Given PO
473429|NCT00601718|Biological|rituximab|Given IV
473430|NCT00601718|Drug|ifosfamide|Given IV
473431|NCT00601718|Drug|carboplatin|Given IV
473432|NCT00601718|Drug|etoposide|Given IV
473433|NCT00601718|Other|pharmacological study|Correlative studies
473434|NCT00601718|Other|laboratory biomarker analysis|Correlative studies
473435|NCT00601718|Genetic|gene expression analysis|Correlative studies
473436|NCT00601705|Drug|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
473437|NCT00601705|Drug|epirubicin hydrochloride|50 mg/m2 IV bolus
473438|NCT00601705|Drug|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
473439|NCT00601705|Drug|oxaliplatin|130 mg/m2 IV infusion over 2 hours
473539|NCT00601003|Drug|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
473440|NCT00601705|Procedure|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
473441|NCT00601705|Procedure|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).~Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
473442|NCT00601692|Drug|cisplatin|Given IV
473443|NCT00601692|Drug|docetaxel|Given IV
473444|NCT00601692|Drug|irinotecan hydrochloride|Given IV
473445|NCT00601692|Radiation|radiation therapy|Given 5 days a week for 3 weeks
473446|NCT00601679|Other|NT-proBNP guided care|knowledge of NT-proBNP results
473447|NCT00601666|Drug|Zolpidem|
473448|NCT00601653|Behavioral|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
473449|NCT00601653|Behavioral|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
473450|NCT00601640|Drug|Diclofenac Na gel|Given topically twice daily on days 1-90
473451|NCT00601640|Drug|Eflornithine HCL ointment|Given topically twice daily on days 1-90
473452|NCT00601627|Biological|panitumumab|
473453|NCT00601627|Drug|capecitabine|
473454|NCT00601627|Drug|fluorouracil|
473455|NCT00601627|Drug|gemcitabine hydrochloride|
473456|NCT00601627|Radiation|radiation therapy|
473457|NCT00601614|Drug|temozolomide|
473458|NCT00601614|Drug|vandetanib|
473459|NCT00601614|Other|immunoenzyme technique|
473460|NCT00601614|Other|laboratory biomarker analysis|
473461|NCT00601588|Drug|Sertraline|
473462|NCT00601575|Drug|Lithium|
473463|NCT00601562|Drug|Zidovudine|
473464|NCT00601549|Procedure|Laparoscopic surgery|Laparoscopic surgery
473465|NCT00601549|Procedure|Traditional open surgery|Open surgery
473466|NCT00601536|Drug|Lithium|
473467|NCT00601523|Drug|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
473468|NCT00601523|Drug|Pramipexole|ER 0.375-4,5 mg
473469|NCT00601510|Drug|capecitabine|
473470|NCT00601510|Drug|cisplatin|
473471|NCT00601510|Drug|imatinib mesylate|
473472|NCT00601497|Device|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
473473|NCT00601484|Drug|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
473474|NCT00601484|Drug|Placebo|placebo IV, single dose
473475|NCT00601471|Other|proximal tibiofibular manipulation|proximal tibiofibular manipulation
473476|NCT00601471|Other|distal tibiofibular manipulation|distal tibiofibular manipulation
473477|NCT00601471|Other|no intervention|no intervention / control
473478|NCT00601458|Drug|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
473479|NCT00601458|Drug|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
473480|NCT00601458|Drug|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
473481|NCT00601445|Behavioral|Amount of sleep and wake|4 groups with different patterns of sleep and wake
473482|NCT00601432|Drug|levofloxacin oral solution|
473483|NCT00601419|Drug|Somatropin|"Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration."
473484|NCT00601406|Genetic|gene expression analysis|
473485|NCT00601406|Genetic|gene rearrangement analysis|
473486|NCT00601406|Genetic|polymorphism analysis|
473487|NCT00601406|Other|laboratory biomarker analysis|
473488|NCT00601406|Radiation|radiation therapy|
473489|NCT00601393|Behavioral|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
473724|NCT00599638|Drug|Placebo|Placebo
473491|NCT00601367|Drug|flibanserin flexible dose|"Initial dosage:~Patients were to take one 50 mg flibanserin tablet in the evening.~Subsequent dosage titrations:~Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.~Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.~Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
473492|NCT00601354|Behavioral|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
473493|NCT00601354|Drug|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
473494|NCT00601341|Other|lumbosacral joint manipulation|lumbosacral joint manipulation
473495|NCT00601341|Other|lumbar passive range of motion|lumbar passive range of motion
473496|NCT00601341|Other|No active intervention|Lie on exam table for 3 minutes
473497|NCT00601328|Drug|Calcitriol|
473498|NCT00601315|Drug|Clarithromycin|
473499|NCT00601302|Drug|Amlodipine|
473500|NCT00601289|Drug|temozolomide|
473501|NCT00601289|Genetic|DNA methylation analysis|
473502|NCT00601289|Genetic|microarray analysis|
473503|NCT00601289|Genetic|protein expression analysis|
473504|NCT00601289|Genetic|proteomic profiling|
473505|NCT00601289|Other|laboratory biomarker analysis|
473506|NCT00601276|Drug|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
473507|NCT00601276|Drug|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
473508|NCT00601263|Drug|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
473509|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
473510|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
473511|NCT00601237|Behavioral|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
473512|NCT00601237|Behavioral|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
473513|NCT00601224|Behavioral|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
473514|NCT00601224|Behavioral|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
473515|NCT00601211|Drug|Pilocarpine|
473516|NCT00601198|Drug|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
473517|NCT00601185|Procedure|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
473518|NCT00601172|Drug|Casopitant|Experimental NK-1 receptor antagonist
473519|NCT00601172|Drug|Dexamethasone|Standard antiemetics
473520|NCT00601172|Drug|Placebo|Placebo to match IV casopitant
473521|NCT00601172|Drug|Ondansetron|Standard antiemetics
473522|NCT00601159|Drug|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
473523|NCT00601146|Procedure|chest computed tomography scan|Once a year for three years
473524|NCT00601133|Other|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back~Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
473525|NCT00601133|Other|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
473526|NCT00601133|Behavioral|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
473527|NCT00601133|Behavioral|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
473528|NCT00601120|Procedure|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
473529|NCT00601107|Drug|Doxercalciferol|
473530|NCT00601107|Drug|Placebo|
473531|NCT00601094|Biological|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
473532|NCT00601068|Other|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
473533|NCT00601055|Behavioral|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
473534|NCT00601055|Behavioral|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
473535|NCT00601042|Other|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
473536|NCT00601042|Other|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
473537|NCT00601016|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
473538|NCT00601003|Drug|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
480683|NCT00546143|Drug|Omalizumab|
473540|NCT00601003|Drug|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
473541|NCT00600990|Drug|GW597599|
473542|NCT00600977|Drug|Doxorubicine|9mg/m² J1 J4 2 COURSES
473543|NCT00600977|Drug|Doxorubicine pegylated|40 MG/M² J1 2 courses
473544|NCT00600964|Drug|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
473545|NCT00600964|Drug|GX15-070MS|GX15-070MS at various doses and schedules
473546|NCT00600938|Drug|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
473547|NCT00600938|Drug|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
473548|NCT00600938|Drug|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
473549|NCT00600938|Drug|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
473550|NCT00600938|Drug|Deferasirox|
473551|NCT00600938|Drug|Deferoxamine|
473552|NCT00600925|Drug|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
473553|NCT00600912|Drug|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
473554|NCT00600912|Drug|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
473555|NCT00600899|Procedure|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
473556|NCT00600899|Procedure|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
473557|NCT00600886|Drug|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
473558|NCT00600886|Drug|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
473559|NCT00600873|Drug|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
473560|NCT00600860|Other|No interventions|Only registration of clinical practice
473561|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 20mg
473562|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 5 mg
473563|NCT00600847|Drug|placebo|single dose for 7 days, oral
473564|NCT00600821|Drug|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
473565|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
473566|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
473567|NCT00600821|Drug|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
473568|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
473569|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
473570|NCT00600808|Drug|BPLG-003|
473571|NCT00600795|Other|CSF collection|CSF collection at time of VPS insertion
473572|NCT00600782|Biological|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
473573|NCT00600769|Drug|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
473574|NCT00600756|Drug|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
473575|NCT00600756|Drug|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
473576|NCT00600743|Drug|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
473577|NCT00600743|Behavioral|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
473578|NCT00600743|Behavioral|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
473579|NCT00600743|Drug|Placebo|Drug one trial vs placebo
473580|NCT00600730|Procedure|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
473581|NCT00600730|Procedure|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
473582|NCT00600704|Procedure|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
473583|NCT00600704|Procedure|Free fluid infusion|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
473584|NCT00600691|Drug|Finasteride|one tablet (5mg) of finasteride
473585|NCT00600678|Dietary Supplement|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
473586|NCT00600665|Behavioral|PAINReportIt|A pain assessment data collection tool
473587|NCT00600665|Behavioral|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
473588|NCT00600665|Behavioral|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
473589|NCT00600639|Device|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
473633|NCT00600340|Biological|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
473590|NCT00600639|Drug|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
473591|NCT00600639|Drug|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
473592|NCT00600626|Drug|biphasic insulin aspart|
473593|NCT00600626|Drug|insulin NPH|
473594|NCT00600626|Drug|insulin aspart|
473595|NCT00600613|Radiation|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
473596|NCT00600600|Drug|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
473597|NCT00600587|Drug|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
473598|NCT00600587|Drug|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
473599|NCT00600574|Other|physical therapy|weekly pool physiotherapy with muscle stretching
473600|NCT00600574|Other|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
473601|NCT00600561|Behavioral|MBSR|Mindfulness-Based Stress Reduction Intervention
473602|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
473603|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
473604|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
473605|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
473606|NCT00600535|Drug|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
473607|NCT00600535|Drug|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
473608|NCT00600535|Drug|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
473609|NCT00600535|Drug|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
473610|NCT00600535|Drug|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
473611|NCT00600535|Drug|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
473612|NCT00600535|Drug|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
473613|NCT00600522|Procedure|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:~Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.~Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.~Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
473614|NCT00600509|Drug|Levetiracetam|
473615|NCT00600496|Drug|AZD6244|twice daily oral dose
473616|NCT00600496|Drug|Dacarbazine|intravenous infusion
473617|NCT00600496|Drug|Erlotinib|daily oral dose
473618|NCT00600496|Drug|Docetaxel|intravenous infusion
473619|NCT00600496|Drug|Temsirolimus|intravenous infusion
473620|NCT00600483|Drug|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
473621|NCT00600470|Behavioral|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
473622|NCT00600470|Behavioral|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
473623|NCT00600457|Device|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
473624|NCT00600444|Procedure|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
473625|NCT00600444|Procedure|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
473626|NCT00600405|Drug|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
473627|NCT00600405|Drug|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
473628|NCT00600379|Device|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
473629|NCT00600366|Drug|biphasic insulin aspart|
473630|NCT00600353|Drug|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
473631|NCT00600353|Drug|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
473632|NCT00600353|Drug|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
473676|NCT00599989|Radiation|brachytherapy|
473677|NCT00599989|Radiation|intracavitary balloon brachytherapy|
473634|NCT00600340|Biological|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
473635|NCT00600327|Device|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
473636|NCT00600327|Device|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
473637|NCT00600301|Drug|Triamcinolone Acetonide and Bevacizumab|
473638|NCT00600288|Drug|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
473639|NCT00600288|Drug|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
473640|NCT00600275|Drug|BGT226|
473641|NCT00600262|Drug|intravitreal bevacizumab|
473642|NCT00600249|Drug|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
473643|NCT00600249|Drug|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
473644|NCT00600236|Procedure|blood sample|
473645|NCT00600223|Behavioral|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
473646|NCT00600210|Drug|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
473647|NCT00600210|Drug|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
473648|NCT00600210|Radiation|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.~Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
473649|NCT00600197|Behavioral|back school|A kind of educational program for low back pain
473650|NCT00600171|Drug|GW642444M|GW642444M
473651|NCT00600171|Drug|Placebo|Placebo mulit-dose dry powder inhaler
473652|NCT00600158|Drug|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
473653|NCT00600158|Drug|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients > 70 kg)
473654|NCT00600145|Drug|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
473655|NCT00600145|Other|Placebo|Placebo
473656|NCT00600119|Drug|placebo|placebo, oral, once daily (QD)
473657|NCT00600119|Drug|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
473658|NCT00600106|Drug|1/10 NA/EE|Hormone replacement therapy with 1 mg norethindrone/10 mcg thinyl estradiol (1/10 NA/EE)
473659|NCT00600106|Drug|Placebo|1 mg placebo
473660|NCT00600093|Drug|Amantadine|IV Amantadine 200mg *1/d at the beginning of surgery and 24 hours following surgery
473661|NCT00600080|Device|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
473662|NCT00600080|Device|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
473663|NCT00600067|Drug|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
473664|NCT00600067|Drug|Placebo|Oral placebo capsules, once daily, 28 weeks
473665|NCT00600054|Biological|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
473666|NCT00600041|Drug|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
473667|NCT00600041|Drug|Placebo|Identical infusion manner like experimental arm
473668|NCT00600028|Drug|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
473669|NCT00600028|Drug|Placebo|Placebo 50-100 mg by mouth per day
473670|NCT00600015|Drug|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
473671|NCT00600015|Drug|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
473672|NCT00600002|Biological|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
473673|NCT00599989|Procedure|adjuvant therapy|
473674|NCT00599989|Procedure|conventional surgery|
473675|NCT00599989|Radiation|3-dimensional conformal radiation therapy|
473679|NCT00599976|Procedure|Pulmonary vein isolation|Pulmonary vein isolation
473680|NCT00599963|Drug|paricalcitol|paricalcitol 1 mg/day
473681|NCT00599950|Drug|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
473682|NCT00599937|Drug|ATRA|early introduction of ATRA
473683|NCT00599937|Drug|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
473684|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
473685|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
473686|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
473687|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
473688|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
473689|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
473690|NCT00599924|Drug|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
473691|NCT00599911|Drug|Lu AA24530|per oral, once daily for 6 weeks
473692|NCT00599911|Drug|Duloxetine|per oral, once daily for 6 weeks
473693|NCT00599911|Drug|Placebo|per oral, once daily for 6 weeks
473694|NCT00599898|Drug|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
473695|NCT00599898|Drug|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
473696|NCT00599885|Drug|telmisartan|telmisartan 40-80mg once per day for 8 months
473697|NCT00599885|Drug|valsartan|valsartan 80-160mg once per day for 8 months
473698|NCT00599872|Biological|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
473699|NCT00599872|Biological|Placebo|Placebo, sublingual oral
473700|NCT00599859|Dietary Supplement|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
473701|NCT00599859|Dietary Supplement|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
473702|NCT00599833|Biological|cetuximab|
473703|NCT00599833|Radiation|3-dimensional conformal radiation therapy|
473704|NCT00599820|Drug|Intravitreal Bevacizumab|
473705|NCT00599807|Dietary Supplement|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
473706|NCT00599781|Genetic|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
473707|NCT00599768|Other|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
473708|NCT00599755|Radiation|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
473709|NCT00599755|Drug|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
473710|NCT00599742|Behavioral|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
473711|NCT00599742|Behavioral|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
473712|NCT00599716|Drug|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
473713|NCT00599716|Drug|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
473714|NCT00599703|Other|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
473715|NCT00599690|Procedure|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
473716|NCT00599677|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
473717|NCT00599677|Drug|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
473718|NCT00599664|Drug|OMS201|OMS201 irrigation solution during surgery
473719|NCT00599664|Drug|Vehicle|Vehicle irrigation solution during surgery
473720|NCT00599651|Device|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
473721|NCT00599651|Other|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
473722|NCT00599638|Drug|pregabalin|75mg bid titrating to 150mg bid on day 4
473723|NCT00599638|Drug|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
473725|NCT00599625|Drug|Pravastatin|80mg administered daily for 6 consecutive weeks
473726|NCT00599612|Drug|GW856553|A dose of 10mg GW856553 containing 50µCi of [14C]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
473727|NCT00599599|Behavioral|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
473728|NCT00599586|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
473729|NCT00599573|Drug|ondansetron|Ondansetron 4mg BID for six weeks
473730|NCT00599560|Genetic|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
473731|NCT00599547|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
473732|NCT00599534|Drug|Montelukast|4 mg oral tablets
473733|NCT00599534|Drug|Placebo|5mg tablets
473734|NCT00599521|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
473735|NCT00599521|Drug|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
473736|NCT00599508|Dietary Supplement|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
473737|NCT00599508|Dietary Supplement|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
473738|NCT00599508|Dietary Supplement|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
473739|NCT00599508|Dietary Supplement|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
473740|NCT00599508|Dietary Supplement|berry placebo powder|berry placebo powder administered daily for 16 weeks
473741|NCT00599495|Procedure|allogeneic HSCT|dose-reduced conditioning regimen
473742|NCT00599482|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
473743|NCT00599469|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
473744|NCT00599456|Dietary Supplement|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
473745|NCT00599456|Dietary Supplement|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
473746|NCT00599443|Biological|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
473747|NCT00599443|Biological|Placebo Comparator|0.5 mL im, single dose
473748|NCT00599430|Dietary Supplement|Placebo|Inert excipient
473749|NCT00599430|Dietary Supplement|Lactobacillus acidophilus NCFM|1e10 CFU/day
473750|NCT00599430|Dietary Supplement|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
473751|NCT00599417|Drug|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
473752|NCT00599417|Drug|placebo|placebo controlled
473753|NCT00599404|Drug|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
473754|NCT00599391|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
473755|NCT00599378|Behavioral|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
473756|NCT00599365|Other|Pharmacy care arm|"The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.~You will need to give a complete list of medications to the pharmacist.~You will need to describe how you take these medications.~The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.~The pharmacist will give you a medication schedule, and other papers about your medications."
473757|NCT00599352|Dietary Supplement|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
473758|NCT00599326|Drug|Deferasirox|250 mg of deferasirox once daily for 6 months
473759|NCT00599313|Drug|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
473760|NCT00599287|Drug|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
473761|NCT00599287|Drug|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
473762|NCT00599287|Drug|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
473763|NCT00599274|Drug|Interferon beta-1a|injection once a week
473764|NCT00599274|Drug|Interferon beta-1a|injection three times a week
473765|NCT00599261|Procedure|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
473766|NCT00599248|Biological|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
473767|NCT00599248|Biological|Placebo|Placebo control (DMEM)
473768|NCT00599235|Drug|sildenafil|50mg 3 times daily for 7 days
473769|NCT00599235|Drug|hydralazine|25mg 3 times daily for 7 days
473770|NCT00599235|Drug|placebo|3 times daily for 7 days
473771|NCT00599222|Biological|ranibizumab|0.5 mg intravitreal injection
473772|NCT00599222|Procedure|TTT|Transpupillary thermotherapy (TTT)
473773|NCT00599222|Procedure|Sham TTT|Sham Transpupillary thermotherapy (TTT)
473774|NCT00599209|Other|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
473818|NCT00598806|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
473819|NCT00598806|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
473820|NCT00598793|Drug|biphasic insulin aspart|
473821|NCT00598793|Drug|insulin glargine|
473775|NCT00599196|Drug|Rotigotine|"Rotigotine trans-dermal patches, once daily:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.~After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
473776|NCT00599183|Other|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
473777|NCT00599170|Drug|Rituximab|375 mg/m2 IV
473778|NCT00599144|Procedure|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
473779|NCT00599144|Procedure|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
473780|NCT00599144|Procedure|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
473781|NCT00599131|Drug|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a < 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, > 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
473782|NCT00599131|Drug|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
473783|NCT00599131|Drug|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
473784|NCT00599131|Drug|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
473785|NCT00599105|Procedure|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
473786|NCT00599079|Drug|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
473787|NCT00599066|Device|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
473788|NCT00599053|Drug|Azithromycin|10 mg/kg IV per dose given for 10 days
473789|NCT00599040|Behavioral|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
473790|NCT00599040|Behavioral|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
473791|NCT00599040|Behavioral|Dairy diet|participants are given a high dairy, reduced calorie diet
473792|NCT00599027|Drug|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
473793|NCT00599027|Drug|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
473794|NCT00599001|Drug|SD-101|Single subcutaneous escalating dose
473795|NCT00599001|Drug|placebo|placebo
473796|NCT00598988|Procedure|traditional Chinese acupuncture|10 treatments over 6 weeks
473797|NCT00598988|Other|standard medical care|standard care as provided by primary physician
473798|NCT00598975|Drug|NKTR-102 + Cetuximab|Drug: NKTR-102 + Cetuximab
473799|NCT00598962|Drug|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
473800|NCT00598962|Drug|Rifabutin/rifampin|
473801|NCT00598936|Device|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
473802|NCT00598923|Drug|topiramate|100 mg twice per day for 3 months
473803|NCT00598923|Drug|topiramate|100 twice per day for 6 days after loading dose of phenytoin
473804|NCT00598923|Drug|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
473805|NCT00598910|Drug|Omacor|n-3 PUFA
473806|NCT00598910|Drug|Placebo|Placebo
473807|NCT00598897|Drug|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
473808|NCT00598884|Behavioral|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
473809|NCT00598871|Drug|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
473810|NCT00598871|Other|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
473811|NCT00598858|Drug|Docetaxel|Given IV
473812|NCT00598858|Drug|Prednisone|Given PO
473813|NCT00598845|Procedure|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
473814|NCT00598832|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
473815|NCT00598832|Drug|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
473816|NCT00598819|Device|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
473817|NCT00598806|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
473824|NCT00598741|Other|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.~MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
473825|NCT00598728|Behavioral|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
473826|NCT00598715|Device|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
473827|NCT00598715|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
473828|NCT00598702|Drug|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
473829|NCT00598689|Drug|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
473830|NCT00598676|Device|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
473831|NCT00598676|Device|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
473832|NCT00598676|Device|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
473833|NCT00598663|Device|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
473834|NCT00598663|Device|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
473835|NCT00598650|Drug|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
473836|NCT00598637|Device|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
473837|NCT00598637|Device|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
473838|NCT00598624|Drug|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
473839|NCT00598611|Drug|desloratadine|singel dose, oral, 20 mg
473840|NCT00598611|Drug|desloratadine|single dose, oral, 5 mg
473841|NCT00598585|Drug|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
473842|NCT00598585|Drug|Placebo|Placebo pills 3X/day for 6 weeks
473843|NCT00598572|Drug|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
473844|NCT00598559|Drug|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
473845|NCT00598546|Behavioral|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
473846|NCT00598533|Device|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
473847|NCT00598533|Device|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
473848|NCT00598507|Drug|ZK-EPO|Participants were treated with 16 mg/m^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
473849|NCT00598481|Genetic|Gene Therapy|Infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with Busulphan
473850|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
473851|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
473852|NCT00598442|Drug|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
473853|NCT00598429|Drug|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
473854|NCT00598416|Behavioral|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
473855|NCT00598403|Drug|cefditoren pivoxil|400 mg, oral, single dose during 3 days
473856|NCT00598403|Drug|Ciprofloxacin|250 mg, oral, twice a day for 3 days
473857|NCT00598390|Drug|[11C]MePPEP|
473858|NCT00598377|Drug|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
473859|NCT00598338|Drug|Prucalopride|4 mg o.d.
473860|NCT00598338|Other|Placebo|o.d.
480980|NCT00544271|Biological|BOOSTRIX|
473861|NCT00598325|Biological|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
473862|NCT00598312|Drug|Leuprolide Acetate for Injectable Suspension|Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product
473863|NCT00598299|Procedure|venous puncture|venous puncture
473864|NCT00598299|Other|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
473865|NCT00598286|Drug|[18F]FMPEP-d2|
473866|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
473867|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
473868|NCT00598273|Drug|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
473869|NCT00598260|Procedure|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
473870|NCT00598247|Drug|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
473871|NCT00598234|Drug|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
473872|NCT00598208|Drug|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
473873|NCT00598208|Drug|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
473874|NCT00598195|Drug|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
473875|NCT00598169|Biological|rituximab|375mg/m2 on Day 1
473876|NCT00598169|Drug|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
473877|NCT00598169|Drug|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x [creatinine clearance + 25]; the maximum dose of carboplatin is 750 mg.~Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
473878|NCT00598169|Drug|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
473879|NCT00598169|Drug|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
473880|NCT00598169|Drug|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.~Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
473881|NCT00598169|Genetic|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
473882|NCT00598169|Genetic|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
473883|NCT00598156|Drug|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
473884|NCT00598156|Drug|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
473885|NCT00598143|Behavioral|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
473886|NCT00598143|Behavioral|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
473887|NCT00598130|Biological|Fleece|Fibrin Patch
473888|NCT00598117|Behavioral|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)~Initial QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)~Follow up QOL form~FACT-E, PAR, Symptom Assessment Scale, MDSS"
473889|NCT00598104|Drug|QAX576|
473890|NCT00598104|Drug|Placebo|
473891|NCT00598091|Drug|gemcitabine|1000mg/m2, Days 1, 8, 15
473892|NCT00598091|Drug|dasatinib|50mg, PO, QD
473893|NCT00598091|Drug|gemcitabine|1000mg/m2, days 1, 8, 15
473894|NCT00598091|Drug|dasatinib|50mg, PO, BID
473895|NCT00598078|Drug|Sodium Oxybate|Dose 1
473896|NCT00598078|Drug|Sodium Oxybate|Dose 2
473898|NCT00598065|Other|PET/CT|Synchronized PET/CT Imaging
473899|NCT00598052|Drug|Escitalopram|10mg/day
473900|NCT00598026|Other|Tele- follow-up|Remote transmission to the implantation centre every 3 months
473901|NCT00598026|Other|Conventional follow-up|Visits at the implantation centre every 3 months
473902|NCT00598013|Drug|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
473903|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
473904|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.~Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
473905|NCT00597974|Procedure|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
473906|NCT00597974|Device|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson & Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson & Johnson), Wallstent® (Boston Scientific Medi-Tech)
473907|NCT00597974|Other|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
473908|NCT00597974|Procedure|Angiography|(non-experimental) Coronary angiography
473909|NCT00597948|Behavioral|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
473910|NCT00597935|Procedure|SSLF|sacrospinous ligament fixation (SSLF)
473911|NCT00597935|Procedure|ULS|uterosacral vaginal vault ligament suspension (ULS)
473912|NCT00597935|Behavioral|PMT|Pelvic muscle training and exercises (PMT)
473913|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
473914|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
473915|NCT00597909|Drug|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
473916|NCT00597896|Drug|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
473917|NCT00597870|Device|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
473918|NCT00597857|Drug|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
473919|NCT00597857|Drug|placebo|receipt of a placebo pill for 16 days
473920|NCT00597844|Other|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
473921|NCT00597844|Other|undergo voice evaluation and fMRI prior|in approximately one month and six months
473922|NCT00597818|Drug|Cobiprostone|6 mcg and 12 mcg capsules
473923|NCT00597818|Drug|Placebo|0 mcg capsules
473924|NCT00597805|Behavioral|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
473925|NCT00597792|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
473926|NCT00597779|Device|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
473927|NCT00597766|Drug|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
473928|NCT00597766|Drug|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
473929|NCT00597766|Drug|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
473930|NCT00597766|Drug|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
473931|NCT00597753|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
473962|NCT00597506|Drug|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
474060|NCT00596674|Other|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
473932|NCT00597753|Drug|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
473933|NCT00597727|Drug|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
473934|NCT00597727|Drug|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
473935|NCT00597714|Drug|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
473936|NCT00597701|Drug|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
473937|NCT00597701|Drug|Placebo|Placebo
473938|NCT00597701|Drug|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
473939|NCT00597688|Drug|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
473940|NCT00597688|Drug|Placebo gel|Oral mucosal application of placebo gel
473941|NCT00597675|Biological|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
473942|NCT00597675|Biological|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
473943|NCT00597662|Device|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
473944|NCT00597662|Device|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
473945|NCT00597649|Drug|Bicifadine|SR dosage form of 400 mg bid or tid for one year
473946|NCT00597636|Behavioral|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
473947|NCT00597636|Behavioral|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
473948|NCT00597623|Other|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
473949|NCT00597623|Other|Placebo|syringes under cutaneous vol = 8 ml
473950|NCT00597610|Other|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
473951|NCT00597597|Drug|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
473952|NCT00597584|Drug|peginesatide|"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
473953|NCT00597584|Drug|Epoetin alfa or Epoetin beta|"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.~The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
473954|NCT00597558|Drug|Egg white protein|Egg white protein powder
473955|NCT00597545|Procedure|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
473956|NCT00597545|Device|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
473957|NCT00597532|Dietary Supplement|Soy|soy (soy protein supplementation 50 grams/day)
473958|NCT00597532|Dietary Supplement|Milk|placebo (milk protein supplementation 50 grams/day)
473959|NCT00597519|Drug|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.~Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).~Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
473960|NCT00597519|Procedure|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
473961|NCT00597506|Drug|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
473963|NCT00597493|Drug|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
473964|NCT00597480|Drug|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
473965|NCT00597480|Drug|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
473966|NCT00597467|Device|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
473967|NCT00597467|Device|Acuvue 2 Soft Contact Lens|Control device
473968|NCT00597454|Other|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
473969|NCT00597441|Biological|Thymic Transplantation for Recipients of UCB transplant|Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
473970|NCT00597428|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
473971|NCT00597428|Drug|Placebo|0 mcg capsules twice daily (BID)
473972|NCT00597415|Drug|celecoxib|celecoxib 200mg
473973|NCT00597415|Drug|placebo|placebo
473974|NCT00597402|Drug|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
473975|NCT00597402|Drug|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
473976|NCT00597402|Radiation|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
473977|NCT00597402|Drug|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
473978|NCT00597389|Drug|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
473979|NCT00597376|Other|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
473980|NCT00597376|Other|Cerefolin NAC placebo|Placebo tablet once a day
473981|NCT00597363|Device|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH & Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
473982|NCT00597363|Other|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
473983|NCT00597350|Dietary Supplement|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
473984|NCT00597337|Behavioral|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
473985|NCT00597324|Procedure|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
473986|NCT00597311|Radiation|radiotherapy|"Short term radiotherapy 5x5 Gy during 5 days~Chemoradiotherapy 50 Gy + 5Fu/Lv"
473987|NCT00597298|Device|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
473988|NCT00597298|Device|sham threshold|non-training physical activity
473989|NCT00597272|Biological|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
473990|NCT00597259|Drug|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
473991|NCT00597259|Drug|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
474055|NCT00596700|Device|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.~An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
474056|NCT00596687|Drug|Insulin glargine|Insulin glargine once daily SQ
474057|NCT00596687|Drug|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
474103|NCT00596310|Other|CT|Screening CT
473992|NCT00597246|Drug|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
473993|NCT00597246|Other|PET Scan|GE Advance PET scanner for sequential body imaging
473994|NCT00597233|Drug|insulin aspart|
473995|NCT00597233|Drug|soluble human insulin|
473996|NCT00597233|Drug|insulin NPH|
473997|NCT00597220|Dietary Supplement|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
473998|NCT00597220|Drug|Placebo|Placebo
473999|NCT00597207|Device|AutoPulse|Mechanical device that provides chest compression
474000|NCT00597207|Other|Manual|Manual chest compression
474001|NCT00597194|Procedure|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
474002|NCT00597181|Procedure|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
474003|NCT00597181|Procedure|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
474004|NCT00597142|Device|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:~Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery~Lesion length ≤15mm~Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen~RVD 4.0-7.0mm"
474005|NCT00597129|Biological|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
474006|NCT00597116|Drug|Vinorelbine|
474007|NCT00597116|Drug|Vandetanib|once daily oral dose
474008|NCT00597103|Other|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
474009|NCT00597103|Other|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
474010|NCT00597103|Other|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
474011|NCT00597077|Other|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
474012|NCT00597077|Other|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
474013|NCT00597064|Drug|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
474014|NCT00597051|Drug|ARD-0403|
474015|NCT00597038|Drug|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.~Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m^2.~Arm B/Phase II Potential Dose Levels.~MTD1: Dasatinib 70 mg; DTIC 1000 mg/m^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m^2."
474016|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
474017|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
474018|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
474019|NCT00597012|Procedure|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
474020|NCT00597012|Other|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
474021|NCT00597012|Other|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
474022|NCT00596999|Procedure|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
474023|NCT00596986|Drug|Duloxetine|Duloxetine 30mg up to 120mg per day.
474024|NCT00596986|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
474025|NCT00596973|Procedure|Surgical Treatment|Ileal transposition with sleeve gastrectomy
474026|NCT00596960|Behavioral|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
474027|NCT00596960|Behavioral|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
474028|NCT00596947|Drug|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
474058|NCT00596687|Drug|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
474059|NCT00596674|Behavioral|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
474219|NCT00595140|Drug|combination with somatostatin analogue octreotide|s.c., 100µg, one time
474029|NCT00596947|Drug|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
474030|NCT00596947|Drug|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
474031|NCT00596947|Drug|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
474032|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
474033|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
474034|NCT00596934|Drug|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
474035|NCT00596895|Dietary Supplement|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
474036|NCT00596882|Other|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
474037|NCT00596882|Other|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
474038|NCT00596856|Behavioral|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
474039|NCT00596843|Behavioral|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
474040|NCT00596843|Behavioral|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
474041|NCT00596830|Drug|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
474042|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
474043|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
474044|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
474045|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
474046|NCT00596817|Drug|Placebo|capsules, daily, orally
474047|NCT00596817|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
474048|NCT00596804|Drug|veltuzumab|once weekly intravenous dosing for 4 weeks
474049|NCT00596791|Drug|tafluprost|prostaglandine analoque
474050|NCT00596778|Other|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
474051|NCT00596765|Behavioral|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
474052|NCT00596752|Drug|Alprostadil|"Active Substance: Prostaglandin E1~Pharmaceutical Form: solution for infusion~Concentration: 40 μg b.d.~Route of Administration: intravenous infusion"
474053|NCT00596752|Other|Placebo|"Active Substance: Lactose~Pharmaceutical Form: solution for infusion~Concentration: 40 μg b.d.~Route of Administration: intravenous infusion"
474054|NCT00596726|Device|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
474061|NCT00596661|Device|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
474062|NCT00596648|Drug|XL184|Capsules administered orally daily
474063|NCT00596648|Drug|erlotinib|Tablets administered orally daily.
474064|NCT00596635|Dietary Supplement|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
474065|NCT00596635|Dietary Supplement|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
474066|NCT00596622|Drug|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
474067|NCT00596609|Drug|Intrathecal Morphine|"In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.~In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
474068|NCT00596596|Drug|prucalopride|0,5 mg once daily
474069|NCT00596596|Drug|prucalopride|1 mg once daily
474070|NCT00596596|Drug|2 mg prucalopride|2 mg once daily
474071|NCT00596596|Drug|4 mg prucalopride|4 mg once daily
474072|NCT00596596|Other|Placebo|placebo once daily
474073|NCT00596583|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
474074|NCT00596583|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
474075|NCT00596570|Procedure|PCI|Percutaneous coronary interventiom
474076|NCT00596557|Drug|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
474077|NCT00596544|Behavioral|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
474078|NCT00596544|Behavioral|questionnaires|Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
474079|NCT00596531|Drug|Acamprosate|Oral administration, 666 mg, tid, for 4 months
474080|NCT00596531|Drug|Placebo|Oral administration of 2 pills, tid, for 4 months
474081|NCT00596518|Drug|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
474082|NCT00596492|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
474083|NCT00596492|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
474084|NCT00596479|Drug|Filgrastim (rG-CSF)|
474085|NCT00596466|Drug|pregabalin|pregabalin
474086|NCT00596453|Drug|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
474087|NCT00596453|Drug|Placebo|Placebo twice a day for 14 days
474088|NCT00596440|Drug|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
474089|NCT00596427|Drug|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
474090|NCT00596427|Drug|Placebo|Placebo tablets: 3 tablets twice per day
474091|NCT00596414|Procedure|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
474092|NCT00596414|Drug|placebo|
474093|NCT00596414|Drug|midazolam|
474094|NCT00596414|Drug|midazolam + pethidine|
474095|NCT00596375|Procedure|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
474096|NCT00596375|Drug|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
474097|NCT00596362|Drug|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
474098|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
474099|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
474100|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
474101|NCT00596336|Drug|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
474102|NCT00596336|Drug|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
474104|NCT00596297|Drug|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
474105|NCT00596297|Procedure|pars plana vitrectomy|4 weeks after baseline
474106|NCT00596284|Behavioral|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
474107|NCT00596284|Behavioral|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
474108|NCT00596271|Biological|IC51|
474109|NCT00596271|Biological|HAVRIX|
474110|NCT00596271|Other|Placebo|
474111|NCT00596258|Drug|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
474112|NCT00596245|Drug|MT400|MT 400, naproxen sodium 550mg
474113|NCT00596219|Drug|celecoxib|celecoxib
474114|NCT00596206|Drug|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
474115|NCT00596180|Drug|HBOT|total body exposure to greater than atmospheric pressure oxygen
474116|NCT00596167|Drug|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
474117|NCT00596154|Other|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.~On day 2 you will be admitted to the hospital and will receive 3 other drugs:~Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.~Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
474118|NCT00596141|Device|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
474119|NCT00596128|Behavioral|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
474120|NCT00596115|Drug|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
474121|NCT00596102|Biological|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
474122|NCT00596076|Behavioral|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.~A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
474123|NCT00596063|Biological|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
474124|NCT00596063|Biological|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
474125|NCT00596050|Drug|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
474126|NCT00596050|Drug|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
474127|NCT00596037|Drug|Growth hormone - LB03002|
474128|NCT00596024|Dietary Supplement|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
474129|NCT00596024|Dietary Supplement|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
474130|NCT00596011|Drug|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
474131|NCT00596011|Drug|Placebo|Matching placebo BID
474132|NCT00595985|Drug|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
474133|NCT00595972|Drug|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
474134|NCT00595959|Device|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
474135|NCT00595946|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
474136|NCT00595946|Drug|Placebo|0 mcg capsules twice daily (BID)
474137|NCT00595933|Other|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
474138|NCT00595933|Other|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
474139|NCT00595933|Other|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
474140|NCT00595933|Other|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
474141|NCT00595933|Drug|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
474142|NCT00595933|Drug|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
474143|NCT00595920|Biological|Tovaxin|2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
474144|NCT00595881|Device|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
480981|NCT00544271|Biological|HAVRIX|
474145|NCT00595868|Drug|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
474146|NCT00595868|Drug|Placebo|same as Varenicline arm
474147|NCT00595855|Procedure|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis
474148|NCT00595855|Procedure|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
474149|NCT00595829|Drug|XL019|XL019 capsules administered orally
474150|NCT00595816|Other|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
474151|NCT00595790|Biological|IC51|
474152|NCT00595777|Behavioral|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
474153|NCT00595764|Behavioral|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
474154|NCT00595764|Behavioral|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
474155|NCT00595738|Other|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
474156|NCT00595725|Other|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
474157|NCT00595712|Procedure|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
474158|NCT00595712|Procedure|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
474159|NCT00595699|Drug|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
474160|NCT00595699|Drug|placebo|Placebo
474161|NCT00595686|Drug|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
474162|NCT00595673|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
474163|NCT00595660|Procedure|FNA - fine needle aspiration|Fine Needle aspiration
474164|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
474165|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
474166|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
474167|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
474168|NCT00595647|Device|Drug eluting stent|Implantation of stent
474169|NCT00595647|Device|Bare metal stent|Implantation of stent
474170|NCT00595621|Device|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
474171|NCT00595608|Drug|Sterimar Spray|Post-op nasal spray, three times a day
474172|NCT00595608|Drug|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
474173|NCT00595582|Dietary Supplement|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
474174|NCT00595569|Behavioral|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
474175|NCT00595556|Drug|zonisamide|flexible dosages of 100-500mg/day
474176|NCT00595556|Drug|Placebo|Placebo
474177|NCT00595543|Drug|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
474178|NCT00595543|Drug|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
474179|NCT00595543|Drug|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
474180|NCT00595530|Drug|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.~Dosing Regimen:~Patients begin the ketamine infusion at 0.05 mg/kg/hr.~4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:~patient's pain has not improved to an acceptable level~side effects remain acceptable~4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr~4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour~Maximum dose of ketamine is limited to 300 mg per 24 hrs~Patient may receive ketamine up to 72 hrs after initiation."
474181|NCT00595517|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
474182|NCT00595504|Drug|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
474183|NCT00595504|Drug|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
474220|NCT00595140|Drug|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
474221|NCT00595127|Drug|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
474222|NCT00595127|Drug|Fludarabine|Fludarabine (30mg/m^2/day x 5 days)
474223|NCT00595127|Radiation|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
474224|NCT00595101|Drug|PF-03187207|
474225|NCT00595101|Drug|Latanoprost 0.005%|
474904|NCT00589186|Other|immunoenzyme technique|
474184|NCT00595491|Biological|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
474185|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
474186|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
474187|NCT00595465|Biological|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
474188|NCT00595426|Drug|YM150|Oral
474189|NCT00595426|Drug|Warfarin|Oral
474190|NCT00595413|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
474191|NCT00595413|Drug|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
474192|NCT00595413|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
474193|NCT00595413|Biological|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
474194|NCT00595387|Other|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
474195|NCT00595387|Other|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
474196|NCT00595374|Drug|insulin detemir|
474197|NCT00595374|Drug|insulin NPH|
474198|NCT00595374|Drug|insulin aspart|
474199|NCT00595361|Drug|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
474200|NCT00595335|Drug|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
474201|NCT00595335|Drug|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
474202|NCT00595335|Drug|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
474203|NCT00595322|Other|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains < 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
474204|NCT00595309|Biological|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
474205|NCT00595296|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
474206|NCT00595283|Behavioral|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
474207|NCT00595283|Behavioral|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
474208|NCT00595270|Biological|IC51|
474209|NCT00595257|Device|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
474210|NCT00595244|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
474211|NCT00595231|Drug|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
474212|NCT00595231|Drug|Placebo|0 mg tablets
474213|NCT00595218|Behavioral|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
474214|NCT00595218|Other|Patient Preference Results|Knowledge of Patient Preference Results
474215|NCT00595205|Other|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
474216|NCT00595166|Device|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
474217|NCT00595153|Drug|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
474218|NCT00595140|Drug|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
474226|NCT00595101|Drug|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
474227|NCT00595101|Drug|Latanoprost Vehicle|
474228|NCT00595088|Biological|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
474229|NCT00595075|Drug|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
474230|NCT00595075|Drug|placebo|placebo identical in appearance to active experimental drug x 1 dose
474231|NCT00595062|Radiation|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
474232|NCT00595049|Drug|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
474233|NCT00595023|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
474234|NCT00595010|Behavioral|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
474235|NCT00594997|Behavioral|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
474236|NCT00594997|Behavioral|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
474237|NCT00594984|Drug|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
474238|NCT00594984|Drug|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
474239|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
474240|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
474241|NCT00594984|Drug|Brivanib Placebo|Oral, tablet, QD, until progression
474242|NCT00594971|Other|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
474243|NCT00594971|Other|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
474244|NCT00594958|Biological|IC51|6 mcg, intramuscularly [i.m.], 0.5 mL
474245|NCT00594945|Drug|Clonazepam|1 Dose
474246|NCT00594932|Drug|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
474247|NCT00594932|Other|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant)"
474248|NCT00594932|Drug|Mycophenolate mofetil|Please see the Arm Description
474249|NCT00594906|Drug|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
474250|NCT00594906|Drug|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
474251|NCT00594893|Procedure|Mini Incision Approach|Mini Incision Approach
474252|NCT00594893|Procedure|2 Incision Approach|2 Incision Approach
474253|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
474254|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
474255|NCT00594867|Drug|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
474256|NCT00594867|Drug|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
474257|NCT00594867|Drug|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
474258|NCT00594854|Drug|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
474259|NCT00594854|Drug|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
474260|NCT00594841|Procedure|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:~Anatomic reduction of the AC joint~Definitive fixation with a hook plate and screws"
474261|NCT00594841|Other|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
474262|NCT00594828|Device|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
474263|NCT00594828|Device|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
474264|NCT00594815|Drug|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
474265|NCT00594789|Other|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
474266|NCT00594776|Device|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
474267|NCT00594737|Drug|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
474268|NCT00594724|Procedure|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
474269|NCT00594698|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
474270|NCT00594659|Behavioral|Psychotherapy|Nine session treatment
474271|NCT00594659|Behavioral|Computerized Psychotherapy|Nine session computer delivered treatment
474272|NCT00594659|Behavioral|Motivational enhancement therapy|Two session treatment
474273|NCT00594646|Drug|TRUVADA + raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
474274|NCT00594633|Other|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
474275|NCT00594620|Dietary Supplement|Flav-ein capsules|Soy/isoflavone supplementation
474276|NCT00594620|Drug|Placebo|Placebo
474277|NCT00594607|Device|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
474278|NCT00594607|Device|Fx8 (Fresenius)|Polysulphone dialysis membrane
474279|NCT00594594|Other|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
474280|NCT00594581|Drug|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
474281|NCT00594568|Drug|LY450139|Administered orally once daily
474282|NCT00594568|Drug|Placebo|Administered orally once daily
474283|NCT00594555|Drug|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
474284|NCT00594555|Drug|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2~Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2~G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
474285|NCT00594542|Drug|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
474286|NCT00594529|Procedure|Surgery|Liver resection for metastatic liver lesions
474287|NCT00594516|Drug|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
474288|NCT00594516|Drug|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
474289|NCT00594516|Drug|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
474290|NCT00594503|Drug|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
474291|NCT00594477|Radiation|IMRT|
474292|NCT00594464|Drug|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;~Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;~One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
474293|NCT00594438|Device|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
474294|NCT00594438|Device|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
474295|NCT00594425|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
474296|NCT00594412|Procedure|Diagnostic Radiology: 1H-MRS of the liver|
474437|NCT00593255|Drug|insulin aspart|
474297|NCT00594399|Behavioral|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
474298|NCT00594386|Drug|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
474299|NCT00594373|Drug|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
474300|NCT00594373|Drug|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
474301|NCT00594360|Behavioral|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
474302|NCT00594347|Biological|Pneumo 23|Vaccine (Pneumo 23)
474303|NCT00594347|Biological|Prevnar|Vaccine (Prevnar)
474304|NCT00594334|Drug|Risedronate|Weekly Risedronate
474305|NCT00594321|Device|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
474306|NCT00594321|Device|standard vertebroplasty|standard vertebroplasty
474307|NCT00594308|Drug|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
474308|NCT00594308|Drug|Fludarabine|25mg/m2/day for 5 consecutive days
474309|NCT00594308|Drug|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
474310|NCT00594308|Drug|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
474311|NCT00594308|Drug|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
474312|NCT00594282|Device|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
474313|NCT00594269|Drug|Risperidone|Discontinuation
474314|NCT00594269|Drug|Escitalopram|Discontinuation
474315|NCT00594269|Drug|Citalopram|Discontinuation
474316|NCT00594269|Drug|Sertraline|Discontinuation
474317|NCT00594269|Drug|Paroxetine|Discontinuation
474318|NCT00594256|Drug|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
474319|NCT00594243|Behavioral|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
474320|NCT00594243|Other|Wait-list control|No treatment given.
474321|NCT00594230|Drug|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
474322|NCT00594217|Drug|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
474323|NCT00594217|Other|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
474324|NCT00594204|Drug|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
474325|NCT00594204|Drug|Placebo|matching placebo 1 tablet twice a day for 12 weeks
474326|NCT00594191|Drug|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
474327|NCT00594191|Drug|Placebo|Placebo with the same characteristics of the drug and at the same dose
474328|NCT00594178|Device|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
474329|NCT00594165|Drug|Rotigotine|"Rotigotine trans-dermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~During the first year:~The maximum Rotigotine dose allowed is 6 mg/24 hours.~After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
474330|NCT00594152|Drug|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
474331|NCT00594139|Biological|Autologous neobladder construct|provision of an autologous neo-bladder construct
474332|NCT00594126|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
474333|NCT00594113|Other|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
474334|NCT00594113|Other|Touch screen intervention|Touch screen intervention
474335|NCT00594100|Device|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
474336|NCT00594087|Drug|eszopiclone|eszopiclone 2mg or 3mg at bedtime
474337|NCT00594087|Other|placebo|2 mg or 3 mg at bedtime
474338|NCT00594074|Other|white wine|3.25 ounces of white wine twice a day with lunch and dinner
474339|NCT00594061|Device|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
474340|NCT00594048|Device|Resperate|Use of the device 15 minutes a day for 9 weeks
474341|NCT00594048|Device|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
474342|NCT00594035|Device|Spinal Sealant System|
474343|NCT00594035|Device|Standard of care|Standard of care: devices intended to provide a watertight closure
474344|NCT00594022|Device|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
474345|NCT00594022|Device|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
474346|NCT00594009|Device|Venovenous CO2 Removal (VVCO2R) in COPD|Patients who meet criteria will be placed on an extracorporeal circuit consisting of an oxygenator, centrifugal pump, tubing and indwelling double lumen venous catheter for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
474347|NCT00593996|Other|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
474348|NCT00593983|Behavioral|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
474349|NCT00593983|Behavioral|Time-matched health education|Health education and standard of care treatment
474350|NCT00593957|Drug|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
474351|NCT00593957|Drug|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
474352|NCT00593944|Biological|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
474353|NCT00593931|Other|fMRI|Functional Magnetic Resonance Imaging without contrast
474354|NCT00593905|Drug|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
474355|NCT00593905|Drug|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
474356|NCT00593879|Drug|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
474357|NCT00593866|Radiation|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
474358|NCT00593866|Drug|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
474359|NCT00593853|Drug|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
474360|NCT00593853|Drug|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
474361|NCT00593840|Radiation|Intensity modulated radiation therapy|
474362|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
474363|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
474364|NCT00593814|Device|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
474365|NCT00593801|Drug|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
474366|NCT00593801|Drug|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
474367|NCT00593775|Procedure|assisted hatching|assisted hatching with laser
474368|NCT00593749|Behavioral|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
474369|NCT00593749|Behavioral|Control|control group in study
474370|NCT00593736|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
474371|NCT00593736|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
474372|NCT00593736|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
474373|NCT00593736|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
474374|NCT00593723|Radiation|IMRT|
474375|NCT00593710|Drug|Losartan|Losartan (25mg OD)
474376|NCT00593710|Drug|Atenolol|Atenolol (25-50mg OD)
474377|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)"
474378|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
474379|NCT00593684|Device|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
474380|NCT00593671|Procedure|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
474438|NCT00593255|Drug|insulin NPH|
474381|NCT00593658|Drug|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
474382|NCT00593645|Drug|Clofarabine|
474383|NCT00593645|Drug|Cytarabine|
474384|NCT00593645|Drug|Thymoglobulin|
474385|NCT00593645|Procedure|Stem cell infusion|
474386|NCT00593632|Dietary Supplement|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
474387|NCT00593619|Drug|Iron dextran|300mg in 250cc normal saline given over 2 hours
474388|NCT00593619|Drug|Iron sucrose|300mg in 250cc normal saline given over 2 hours
474389|NCT00593606|Drug|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
474390|NCT00593580|Drug|placebo|placebo
474391|NCT00593580|Drug|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
474392|NCT00593567|Drug|gentamicin-collagen sponge|Inserted daily into open ulcer
474393|NCT00593567|Drug|Levofloxacin|750mg oral levofloxacin daily
474394|NCT00593554|Radiation|Total Body Irradiation|8 Gy on Day -9
474395|NCT00593554|Drug|Thiotepa|5 mg/kg/d on Day -8 to -7
474396|NCT00593554|Drug|Fludarabine|40 mg/m2/d on Day -6 to -3
474397|NCT00593554|Biological|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
474398|NCT00593554|Drug|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
474399|NCT00593528|Device|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
474400|NCT00593528|Device|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
474401|NCT00593528|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
474402|NCT00593515|Behavioral|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
474403|NCT00593515|Behavioral|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
474404|NCT00593502|Drug|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; > 40 kg, 75 mg twice daily, for 5 days
474405|NCT00593502|Drug|placebo|The dosage of placebo will be similar to the active drug
474406|NCT00593489|Other|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
474407|NCT00593476|Other|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
474408|NCT00593476|Other|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
474409|NCT00593463|Drug|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
474410|NCT00593463|Drug|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
474411|NCT00593463|Drug|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
474412|NCT00593463|Drug|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
474413|NCT00593463|Drug|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
474414|NCT00593463|Drug|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
474415|NCT00593463|Drug|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
474416|NCT00593463|Device|Saline|Saline: I.M. injection may possibly be given
474417|NCT00593463|Drug|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
474418|NCT00593450|Drug|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
474419|NCT00593450|Drug|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
474420|NCT00593424|Other|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
474421|NCT00593424|Other|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
474422|NCT00593385|Device|iCAST covered stent|Iliac stent implantation
474423|NCT00593372|Behavioral|Spaced Retrieval Training|Increasing time to remember important information.
474424|NCT00593346|Radiation|brachytherapy|brachytherapy (radioactive implants)
474425|NCT00593333|Device|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
474426|NCT00593333|Device|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
474427|NCT00593320|Radiation|Stereotactic Radiosurgery|
474428|NCT00593307|Other|high GI|high GI and high carb breakfast
474429|NCT00593307|Other|Low GI|low GI, high carb breakfast
474430|NCT00593307|Other|Low GI Low Carb|low GI low carb breakfast
474431|NCT00593307|Other|High GI Low carb|high GI low carb breakfast
474432|NCT00593294|Behavioral|Physical exercise|45 minutes each day for three times/week for 6 months
474433|NCT00593294|Drug|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
474434|NCT00593294|Dietary Supplement|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
474435|NCT00593281|Drug|Hylenex|Add Hylenex to SC injection of Morphine
474436|NCT00593255|Drug|soluble human insulin|
474439|NCT00593242|Biological|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
474440|NCT00593242|Other|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
474441|NCT00593216|Device|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
474442|NCT00593190|Drug|Gas SF6 (Sulfur Hexafluoride)|ONCE
474443|NCT00593177|Drug|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
474444|NCT00593164|Device|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
474445|NCT00593164|Device|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
474446|NCT00593151|Other|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
474447|NCT00593151|Biological|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
474448|NCT00593138|Drug|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
474449|NCT00593125|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
474450|NCT00593112|Drug|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
474451|NCT00593112|Other|No intervention|No intervention
474452|NCT00593099|Drug|Bupropion|BUP [as the intermediate-release (IR) formulation] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg [as BUP SR formulation] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
474453|NCT00593099|Drug|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
474454|NCT00593086|Procedure|Pain management|Pain mamagement for burn care procedures.
474455|NCT00593086|Other|Standard of care/no virtual reality game|no intervention for standard of care
474456|NCT00593073|Behavioral|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
474457|NCT00593073|Behavioral|General Reminder Message|General CRC health education message and reminder to get screened.
474458|NCT00593060|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
474459|NCT00593060|Drug|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
474460|NCT00593047|Drug|KB2115|tablet formulation given once daily for 12 weeks
474461|NCT00593008|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
474462|NCT00593008|Drug|Gemcitabine|Given intravenously every other week of each 28-day cycle.
474463|NCT00592995|Drug|Creatine monohydrate|10 to 30 grams daily
474464|NCT00592995|Drug|Placebo|10 to 30 grams daily
474465|NCT00592969|Drug|metformin|
474466|NCT00592969|Drug|biphasic insulin aspart|
474467|NCT00592943|Drug|armodafinil|tablet, taken by mouth, once each study day
474468|NCT00592930|Drug|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
474469|NCT00592930|Drug|placebo|
474470|NCT00592917|Dietary Supplement|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
474471|NCT00592904|Drug|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
474472|NCT00592891|Drug|Hyperbaric oxygen therapy|Total body pressurized oxygen
474473|NCT00592852|Drug|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
474474|NCT00592839|Drug|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
474475|NCT00592839|Drug|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
474476|NCT00592813|Behavioral|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.~Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
474477|NCT00592813|Behavioral|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
474478|NCT00592774|Drug|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
474479|NCT00592774|Drug|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
474480|NCT00592761|Behavioral|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
474481|NCT00592748|Radiation|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
474482|NCT00592735|Procedure|laparoscopic gastric banding|standard surgical procedure
474483|NCT00592683|Drug|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
474484|NCT00592683|Dietary Supplement|fish oil|1600mg (4 capsules) daily for 12 weeks
474485|NCT00592683|Drug|Placebo|Placebo
474486|NCT00592670|Drug|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
474487|NCT00592670|Drug|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
474488|NCT00592644|Procedure|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
474489|NCT00592644|Procedure|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
474490|NCT00592631|Device|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
474491|NCT00592631|Device|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
474492|NCT00592618|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
474493|NCT00592592|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
474494|NCT00592579|Drug|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
474495|NCT00592566|Drug|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
474496|NCT00592553|Drug|PTC124 High Dose|PTC124 High Dose - 20-, 20-, 40-mg/kg dose level
474497|NCT00592553|Drug|PTC124 Low Dose|PTC124 Low Dose - 10-, 10-, 20 mg/kg dose level
474498|NCT00592553|Drug|Placebo|Placebo
474499|NCT00592540|Procedure|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
474500|NCT00592527|Drug|insulin detemir|
474501|NCT00592501|Radiation|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
474502|NCT00592501|Drug|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
474503|NCT00592501|Drug|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
474504|NCT00592488|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
474505|NCT00592475|Drug|conivaptan|IV
474506|NCT00592475|Drug|Placebo|IV
474507|NCT00592462|Procedure|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
474508|NCT00592449|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
474509|NCT00592449|Behavioral|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
474510|NCT00592423|Other|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
474511|NCT00592410|Drug|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
474512|NCT00592397|Other|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
474513|NCT00592384|Drug|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
474514|NCT00592384|Drug|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
474515|NCT00592358|Drug|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
474516|NCT00592345|Radiation|Proton Beam Radiation|Administered over a period of 12 weeks.
474517|NCT00592345|Radiation|Photon Beam Radiation|Administered over a period of 12 weeks.
474518|NCT00592345|Radiation|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
474519|NCT00592332|Drug|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
474520|NCT00592332|Other|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
474521|NCT00592319|Drug|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
474522|NCT00592319|Device|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
474523|NCT00592319|Procedure|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
474524|NCT00592306|Drug|thymoglobulin (intraoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
474525|NCT00592306|Drug|thymoglobulin (postoperative)|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
474526|NCT00592293|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
474527|NCT00592280|Device|Two-Layer Method pancreas preservation system|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
474528|NCT00592241|Device|"Adi Insulin Pump Usability"|no intervention
474529|NCT00592228|Device|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,~FFR group: if FFR<0.75~Routine DES group"
474530|NCT00592215|Drug|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
474531|NCT00592202|Device|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
474532|NCT00592189|Procedure|blood draw|blood collection
474533|NCT00592176|Drug|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
474534|NCT00592163|Drug|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (>8 hours between doses) for 3 weeks followed by 1 week of rest
474535|NCT00592150|Drug|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
474536|NCT00592150|Drug|Placebo|Placebo infusion for 3 hours
474537|NCT00592137|Dietary Supplement|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
474538|NCT00592137|Dietary Supplement|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
474539|NCT00592137|Dietary Supplement|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
474540|NCT00592124|Drug|Tenofovir disoproxil fumarate|300 mg tablet daily
474541|NCT00592124|Drug|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
474542|NCT00592111|Drug|COPP/ABV|4 courses of COPP/ABV hybrid
474543|NCT00592111|Drug|COPP/ABV|6 courses of COPP/ABV hybrid
474544|NCT00592111|Drug|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
474545|NCT00592098|Drug|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
474546|NCT00592098|Drug|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
474547|NCT00592085|Behavioral|Questionnaires|Participants will use a computer to complete a series of questionnaires.
474548|NCT00592085|Behavioral|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
474549|NCT00592085|Behavioral|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
474550|NCT00592072|Dietary Supplement|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
474551|NCT00592072|Other|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
474552|NCT00592046|Drug|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
474553|NCT00592033|Other|oxygen from a portable concentrator|2 l/minute during exercise
474554|NCT00592020|Procedure|Short Transverse Incision|Short Transverse Incision for kidney transplantation
474555|NCT00592020|Procedure|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
474556|NCT00592007|Drug|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
474557|NCT00591994|Drug|piribedil|50 mg once a day, after lunch 3 month therapy
474558|NCT00591981|Behavioral|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
474559|NCT00591968|Device|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
474687|NCT00590863|Drug|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
474560|NCT00591942|Device|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inclusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
474561|NCT00591929|Other|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
474562|NCT00591916|Drug|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
474563|NCT00591916|Procedure|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
474564|NCT00591916|Procedure|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
474565|NCT00591890|Drug|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
474566|NCT00591877|Procedure|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.~The acupoints that will be used are:~ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.~PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.~CV-12: 4 finger breadths superior to the umbilicus."
474567|NCT00591877|Procedure|Sham Acupuncture|"The acupoints for SAC are:~LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.~GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.~UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
474568|NCT00591877|Other|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
474569|NCT00591864|Device|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
474570|NCT00591851|Drug|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|No Intervention
474571|NCT00591838|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
474572|NCT00591825|Drug|D-cycloserine|D-cycloserine
474573|NCT00591825|Drug|Placebo|Placebo
474574|NCT00591812|Device|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
474575|NCT00591799|Device|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
474576|NCT00591786|Drug|Sugammadex|After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered.
474577|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
474578|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
474579|NCT00591773|Drug|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
474580|NCT00591760|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
474581|NCT00591747|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
474582|NCT00591747|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
474583|NCT00591734|Drug|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
474584|NCT00591734|Drug|Everolimus|10 mg by mouth daily
474613|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
474688|NCT00590850|Device|ORIF with Plate and Screws|ORIF with plate and screws
480982|NCT00544258|Drug|PEP005|
474585|NCT00591721|Behavioral|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
474586|NCT00591708|Dietary Supplement|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
474587|NCT00591708|Dietary Supplement|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
474588|NCT00591695|Procedure|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
474589|NCT00591695|Procedure|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
474590|NCT00591682|Drug|MSX-122|"Dosage form = capsule~Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)~If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.~If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.~If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
474591|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
474592|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
474593|NCT00591643|Procedure|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
474594|NCT00591643|Radiation|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
474595|NCT00591630|Drug|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
474596|NCT00591630|Drug|Carmustine|300 mg/m^2 by vein.
474597|NCT00591630|Drug|Etoposide|200 mg/m^2 by vein every 12 hours.
474598|NCT00591630|Drug|Cytarabine|200 mg/m^2 by vein every 12 hours.
474599|NCT00591630|Drug|Melphalan|140 mg/m^2 by vein.
474600|NCT00591630|Drug|Rituximab|"Arm 1, Arm 2 = 250 mg/m^2 by vein;~Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;~Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
474601|NCT00591630|Procedure|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
474602|NCT00591617|Other|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
474603|NCT00591604|Drug|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
474604|NCT00591591|Device|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
474605|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
474606|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
474607|NCT00591578|Drug|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
474608|NCT00591565|Drug|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
474609|NCT00591552|Device|Harmonic ACE23P Scalpel|Lymph node dissection
474610|NCT00591552|Device|Electrocautery|
474611|NCT00591539|Procedure|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
474612|NCT00591526|Drug|Arac|Ommit ARAC in the chemotherapy
474614|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
474615|NCT00591487|Drug|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
474616|NCT00591474|Dietary Supplement|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
474617|NCT00591474|Dietary Supplement|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
474618|NCT00591448|Other|Virtual Reality (VR)|See above
474619|NCT00591435|Other|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
474620|NCT00591422|Drug|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (>36 hours between doses) for 3 weeks with 1 week rest.
474621|NCT00591409|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
474622|NCT00591409|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of placebo IV was administered"
474623|NCT00591396|Drug|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
474624|NCT00591383|Drug|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
474625|NCT00591383|Drug|erlotinib|erlotinib taken at 150 mg every morning with food.
474626|NCT00591370|Drug|Temozolomide (TMZ)|One group treatment study
474627|NCT00591357|Drug|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
474628|NCT00591357|Drug|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
474629|NCT00591344|Behavioral|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
474630|NCT00591344|Behavioral|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
474631|NCT00591331|Drug|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
474632|NCT00591331|Drug|placebo|
474633|NCT00591318|Drug|ceftriaxone|2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
474634|NCT00591318|Drug|Normal Saline|50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
474635|NCT00591305|Dietary Supplement|diindolylmethane (DIM)|3-month DIM
474636|NCT00591305|Device|585 nm pulsed dye laser|once-time PDL
474637|NCT00591292|Drug|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
474638|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
474639|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
474640|NCT00591266|Drug|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
474641|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
474642|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
474643|NCT00591253|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
474644|NCT00591227|Drug|insulins aspart and detemir|insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER. If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.
474645|NCT00591214|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
474646|NCT00591201|Drug|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
474647|NCT00591201|Drug|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
474648|NCT00591188|Drug|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
474649|NCT00591175|Behavioral|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
474650|NCT00591175|Behavioral|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
474689|NCT00590850|Device|Pin Fixation|Clavicle fixation with clavicle pin
483339|NCT00527033|Drug|YM178|Oral
474651|NCT00591175|Behavioral|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
474652|NCT00591162|Drug|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
474653|NCT00591162|Radiation|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
474654|NCT00591162|Procedure|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
474655|NCT00591149|Drug|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
474656|NCT00591149|Drug|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
474657|NCT00591149|Drug|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
474658|NCT00591136|Drug|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
474659|NCT00591123|Drug|FOLFOX and Erlotinib|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions, after which 5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home. All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
474660|NCT00591110|Behavioral|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
474661|NCT00591110|Behavioral|Social-contact control|Participants receive an engaging informational session on a non-health related topic
474662|NCT00591084|Drug|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
474663|NCT00591084|Drug|placebo|infusion placebo (group B)once a day and continued for 14 days
474664|NCT00591084|Drug|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
474665|NCT00591071|Other|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
474666|NCT00591071|Other|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
474667|NCT00591058|Drug|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
474668|NCT00591045|Drug|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
474669|NCT00591019|Drug|Modafinil|200 mg/day, morning dose
474670|NCT00591019|Other|Placebo|Sugar pill once per day in the morning.
474671|NCT00591006|Drug|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
474672|NCT00591006|Drug|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
474673|NCT00591006|Drug|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
474674|NCT00590993|Other|MRI and MRSI|Compare treatment impact when using MRI and MRSI
474675|NCT00590967|Radiation|IMRT extended field external beam radiation therapy|
474676|NCT00590967|Radiation|Brachytherapy|
474677|NCT00590967|Drug|Cisplatin|
474678|NCT00590954|Drug|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.~In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
474679|NCT00590941|Procedure|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
474680|NCT00590928|Drug|esomeprazole|40mg once daily
474681|NCT00590928|Drug|ranitidine|50mg every h hours
474682|NCT00590915|Drug|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.~NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
474683|NCT00590902|Drug|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
474684|NCT00590889|Device|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
474685|NCT00590863|Drug|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
474686|NCT00590863|Drug|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
474725|NCT00590538|Drug|Placebo|The placebo is given to match the active comparator for four days.
474690|NCT00590837|Drug|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.~Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.~Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
474691|NCT00590824|Drug|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
474692|NCT00590824|Drug|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
474693|NCT00590798|Behavioral|Walking|Patient will walk within 30 minutes of vascular closure system procedure
474694|NCT00590785|Drug|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
474695|NCT00590785|Drug|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
474696|NCT00590785|Drug|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
474697|NCT00590785|Drug|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
474698|NCT00590785|Drug|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
474699|NCT00590772|Drug|montelukast|10 mg po each day (compared to placebo for 2 weeks)
474700|NCT00590772|Drug|placebo|placebo for 2 weeks
474701|NCT00590759|Device|GORE TAG® Thoracic Endoprosthesis|implant
474702|NCT00590720|Biological|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
474703|NCT00590720|Other|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
474704|NCT00590707|Device|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
474705|NCT00590707|Device|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
474706|NCT00590694|Drug|ranibizumab|0.5mg injection monthly according to protocol for one year
474707|NCT00590681|Drug|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
474708|NCT00590668|Diagnostic Test|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
474709|NCT00590655|Behavioral|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
474710|NCT00590655|Behavioral|weight loss programme|
474711|NCT00590629|Drug|Niaspan|1500 mg Niaspan for 16 weeks
474712|NCT00590616|Procedure|transthoracic examination|observational transthoracic examination
474713|NCT00590603|Drug|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I~Loading:~Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
474714|NCT00590590|Drug|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
474715|NCT00590590|Drug|lidocaine|semi solid, twice weekly for 4 months
474716|NCT00590590|Drug|placebo|semi solid, twice weekly for 4 months
474717|NCT00590577|Drug|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
474718|NCT00590577|Drug|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
474719|NCT00590577|Drug|Placebo|Placebo i.m. Days 1, 8, 36, 64
474720|NCT00590577|Drug|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
474721|NCT00590564|Drug|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
474722|NCT00590551|Other|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
474723|NCT00590538|Drug|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
474724|NCT00590538|Drug|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
483340|NCT00527033|Drug|Placebo|Oral
474726|NCT00590525|Procedure|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
474727|NCT00590512|Dietary Supplement|High sodium|
474728|NCT00590512|Dietary Supplement|Low sodium|
474729|NCT00590473|Device|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
474730|NCT00590460|Biological|CAMPATH-1H|Given intravenous on days -8, -7, and -6
474731|NCT00590460|Biological|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2~dose is 400 micrograms/kg"
474732|NCT00590460|Drug|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4~Dose is 30 mg/m2"
474733|NCT00590460|Procedure|Stem cell infusion|Stem cells are infused on day 0
474734|NCT00590447|Drug|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
474735|NCT00590447|Drug|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
474736|NCT00590408|Dietary Supplement|coenzyme Q10|60mg capsule twice daily for 12 weeks
474737|NCT00590408|Dietary Supplement|matching placebo|matching placebo capsule twice daily for 12 weeks
474738|NCT00590395|Drug|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
474739|NCT00590382|Device|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
474740|NCT00590369|Device|KCI -VAC|Negative pressure wound therapy device
474741|NCT00590369|Device|Versatile One (EZCare)|Negative pressure wound therapy device
474742|NCT00590356|Device|StarClose®|Closure device for femoral artery suture site occlusion
474743|NCT00590356|Device|AngioSeal®|Closure device for femoral artery suture site occlusion
474744|NCT00590343|Drug|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
474745|NCT00590317|Drug|Prochlorperazine|Patients receiving Prochlorperazine
474746|NCT00590317|Drug|Ondansetron|Patients receiving Ondansetron
474747|NCT00590278|Drug|Tomudex|
474748|NCT00590278|Procedure|Radiotherapy|
474749|NCT00590278|Procedure|Haematology|
474750|NCT00590278|Procedure|Biochemistry|
474751|NCT00590265|Device|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
474752|NCT00590265|Device|Northern Light Technology (SADelite lamp) Dim light-therapy|<100 lux for 30 minutes
474753|NCT00590226|Drug|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
474754|NCT00590226|Drug|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
474755|NCT00590213|Drug|Casodex 150mg|
474756|NCT00590213|Procedure|Radiotherapy|
474757|NCT00590213|Procedure|Haematology|
474758|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
474759|NCT00590187|Drug|sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
474760|NCT00590187|Drug|sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
474761|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
474762|NCT00590187|Drug|sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
474763|NCT00590187|Drug|sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
474764|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
474765|NCT00590187|Drug|sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
474766|NCT00590187|Drug|sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
474767|NCT00590174|Drug|Aspirin|stopping clopidogrel at 1 year after DES implantation
474768|NCT00590174|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
474769|NCT00590161|Drug|pentoxifylline (PTX)|400 mg PO tid
474770|NCT00590161|Drug|placebo|placebo tid
474771|NCT00590135|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
474772|NCT00590122|Drug|Parcopa|at subjects current stable dose of comparator
474773|NCT00590122|Drug|carbidopa-levodopa|at subjects current stable dose
474774|NCT00590109|Other|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
474775|NCT00590109|Other|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
474776|NCT00590083|Biological|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.~One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
474777|NCT00590070|Drug|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
474778|NCT00590070|Drug|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
474779|NCT00590070|Drug|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
474780|NCT00590044|Drug|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
474781|NCT00590044|Drug|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
474782|NCT00590031|Drug|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
474783|NCT00590031|Drug|Irinotecan|Irinotecan will be given 65 mg/m2
474784|NCT00590031|Radiation|External Beam Radiation Therapy|will be delivered with multiple (>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
474785|NCT00590018|Drug|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --> 25mg/m2/day) over 5 days intravenously.
474786|NCT00590018|Drug|Placebo|Placebo for 5 days intravenously.
474787|NCT00589992|Drug|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
474788|NCT00589979|Drug|Lidoderm (Lidocaine 5% Patch)|Topical Patch
474789|NCT00589979|Drug|Placebo Patch|Topical Patch
474790|NCT00589966|Behavioral|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
474791|NCT00589966|Behavioral|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
474792|NCT00589953|Drug|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.~The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
474793|NCT00589953|Drug|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
474794|NCT00589927|Drug|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
474795|NCT00589927|Drug|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
474796|NCT00589914|Drug|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
474797|NCT00589914|Drug|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
474798|NCT00589901|Drug|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14"
474799|NCT00589888|Drug|Intralipid 20% @ 20cc/hour|In this arm subjects received Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting
474800|NCT00589888|Drug|Intralipid 20%@ 40cc/hour|In this arm subjects received Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours. In this arm subjects will receive Intralipid 20% Intravenous IV continuous infusion at 20cc/hour for 8 hours. The 20% intralipid solution is a long-chain triglyceride emulsion composed of 50% polyunsaturated fatty acids, 26% monounsaturated fatty acids, and 19% saturated fatty acids. During the intralipid infusion studies, subjects remained fasting.
474801|NCT00589888|Drug|Normal Saline|In this arm subjects received 0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours.
474802|NCT00589888|Dietary Supplement|32-gram oral fat load|In this arm subjects received oral liquid fat load prepared by the General Clinical Research Center (GCRC) at baseline and every 2 hours for 6 hours. Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
474803|NCT00589888|Dietary Supplement|64-gram oral fat load|In this arm subjects received 60-gram oral fat load intake at baseline and every 2 hours for 6 hours prepared by the General Clinical Research Center (GCRC). Participants received fat with Free Fatty Acids (FFA) composed of 33% polyunsaturated fatty acids, 34% monounsaturated fatty acids, and 22% saturated fatty acids. The oral fat load in either low or high dose was given in four equally divided doses at 0, 2, 4, and 6 h.
474804|NCT00589875|Biological|AdV-tk|Single dose of 3x10e11 vector particles of AdV-tk delivered to the tumor bed after resection on day 0.
474805|NCT00589875|Drug|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
474806|NCT00589862|Drug|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
474807|NCT00589849|Procedure|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
474808|NCT00589823|Drug|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
474809|NCT00589823|Drug|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
474810|NCT00589797|Device|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
474811|NCT00589797|Device|ProDisc-L Total Disc Replacement or Charité Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
474812|NCT00589784|Drug|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
474813|NCT00589771|Drug|Saccharomyces boulardii|"Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~Ispaghula husk 1 Tsf daily after dinner for six weeks"
474814|NCT00589771|Drug|Placebo|"Cap Placebo TDS for six weeks~Ispaghula husk 1 Tsf daily after dinner for six weeks"
474815|NCT00589758|Diagnostic Test|Echocardiography|2D and 3D echocardiography
474816|NCT00589758|Other|Biomarker evaluation|Blood and urine collected
474859|NCT00589537|Procedure|quality-of-life assessment|
474905|NCT00589186|Other|laboratory biomarker analysis|
483433|NCT00526318|Drug|vindesine|
474817|NCT00589745|Other|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
474818|NCT00589732|Drug|Valsartan|Valsartan 160mg per day
474819|NCT00589706|Drug|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
474820|NCT00589693|Drug|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
474821|NCT00589693|Drug|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
474822|NCT00589693|Drug|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
474823|NCT00589667|Drug|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.~Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.~For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
474824|NCT00589654|Other|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
474825|NCT00589641|Behavioral|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
474826|NCT00589641|Behavioral|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
474827|NCT00589628|Drug|infliximab|5mg/kg/dose IV at 4 week intervals
474828|NCT00589628|Drug|infliximab|10mg/kg/dose IV at 4 week intervals
474829|NCT00589615|Behavioral|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
474830|NCT00589602|Procedure|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be >0.5 x 105 but <1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be >2 x 106 cells/kg.
474831|NCT00589602|Procedure|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
474832|NCT00589602|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
474833|NCT00589602|Radiation|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
474834|NCT00589589|Device|Endo Tool|Computer tool to help achieve glucose control
474835|NCT00589563|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
474836|NCT00589563|Drug|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
474837|NCT00589563|Drug|etoposide|60mg/kg on day -4 from stem cell transplant
474838|NCT00589563|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
474839|NCT00589563|Drug|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
474840|NCT00589563|Drug|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
474841|NCT00589563|Drug|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
474842|NCT00589563|Drug|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
474843|NCT00589563|Procedure|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
474844|NCT00589563|Procedure|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
474845|NCT00589563|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
474846|NCT00589563|Procedure|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
474847|NCT00589563|Radiation|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
474848|NCT00589550|Biological|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
474849|NCT00589550|Drug|Sorafenib|
474850|NCT00589550|Genetic|gene expression analysis|
474851|NCT00589550|Genetic|polymerase chain reaction|
474852|NCT00589550|Genetic|reverse transcriptase-polymerase chain reaction|
474853|NCT00589550|Other|flow cytometry|
474854|NCT00589550|Other|immunoenzyme technique|
474855|NCT00589550|Other|laboratory biomarker analysis|
474856|NCT00589537|Other|questionnaire administration|
474857|NCT00589537|Procedure|computed tomography|
474858|NCT00589537|Procedure|magnetic resonance imaging|
474860|NCT00589524|Device|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
474861|NCT00589498|Dietary Supplement|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
474862|NCT00589485|Device|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
474863|NCT00589485|Device|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
474864|NCT00589472|Drug|Bicalutamide|Given PO
474865|NCT00589472|Drug|Goserelin Acetate|Given SC
474866|NCT00589472|Other|Laboratory Biomarker Analysis|Correlative studies
474867|NCT00589472|Drug|Leuprolide Acetate|Given IM
474868|NCT00589472|Procedure|Therapeutic Conventional Surgery|Undergo radical prostatectomy
474869|NCT00589472|Drug|Vorinostat|Given PO
474870|NCT00589446|Device|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
474871|NCT00589420|Drug|docetaxel|
474872|NCT00589420|Drug|sorafenib tosylate|
474873|NCT00589394|Biological|pneumococcal vaccination (Pneumovax)|pneumovax was given
474874|NCT00589381|Drug|fenretinide lipid matrix|
474875|NCT00589368|Behavioral|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
474876|NCT00589329|Drug|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
474877|NCT00589329|Drug|placebo|IV and pill placebo
474878|NCT00589316|Procedure|Allogeneic Bone Marrow Transplantation|Given via central line
474879|NCT00589316|Drug|Cyclophosphamide|Given IV
474880|NCT00589316|Drug|Fludarabine Phosphate|Given IV
474881|NCT00589316|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
474882|NCT00589316|Other|Laboratory Biomarker Analysis|Correlative studies
474883|NCT00589316|Drug|Mycophenolate Mofetil|Given IV or PO
474884|NCT00589316|Drug|Tacrolimus|Given IV or PO
474885|NCT00589316|Radiation|Total-Body Irradiation|Undergo TBI
474886|NCT00589303|Drug|FDA approved rate and rhythm control drugs|"Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~metoprolol~atenolol~carvedilol~Calcium Channel Blocker:~verapamil~diltiazem~Rhythm Control:~procainamide~quinidine~disopyramide~propafenone~flecainide~sotalol~dofetilide~amiodarone"
474887|NCT00589303|Device|AV Node ablation and device implant|"Pacing Systems:~Enpusle Premarket Approval Number (PMA#) P980035~EnRhythm PMA# P980035~Adapta PMA# P980035~Cardiac Resynchronization Therapy (CRT) Pacing Systems:~- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031~Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:~EnTrust PMA# P980016~Virtuoso PMA# P980016~ICD CRT Pacing Systems:~InSync Maximo PMA# P980016~InSync Sentry PMA# P890003~Concerto PMA# P980016"
474888|NCT00589290|Drug|Belinostat (PDX101)|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
474889|NCT00589277|Behavioral|"Yale coaching"|Novel messages for quitting smoking
474890|NCT00589277|Behavioral|Standard care|Standard messages for quitting smoking
474891|NCT00589264|Dietary Supplement|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
474892|NCT00589264|Dietary Supplement|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
474893|NCT00589251|Other|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.~Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
474894|NCT00589238|Drug|carboplatin|
474895|NCT00589238|Drug|cyclophosphamide|
474896|NCT00589238|Drug|doxorubicin hydrochloride|
474897|NCT00589238|Drug|paclitaxel|
474898|NCT00589225|Genetic|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
474899|NCT00589212|Device|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
474900|NCT00589199|Procedure|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
474901|NCT00589186|Biological|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
474902|NCT00589186|Drug|celecoxib|
474903|NCT00589186|Other|flow cytometry|
474906|NCT00589173|Behavioral|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
474907|NCT00589173|Behavioral|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
474908|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
474909|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
474910|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
474911|NCT00589134|Dietary Supplement|Gatorade Endurance Formula|carbohydrate electrolyte beverage
474912|NCT00589134|Other|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
474913|NCT00589121|Drug|Chemotherapy|Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
474914|NCT00589121|Radiation|Radiation therapy|Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
474915|NCT00589121|Procedure|Surgery|Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
474916|NCT00589108|Device|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
474917|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
474918|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
474919|NCT00589095|Other|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
474920|NCT00589082|Drug|DaunoXome|
474921|NCT00589082|Drug|Daunorubicine|
474922|NCT00589056|Drug|cisplatin|
474923|NCT00589056|Drug|etoposide|
474924|NCT00589056|Drug|nelfinavir mesylate|
474925|NCT00589056|Genetic|protein expression analysis|
474926|NCT00589056|Other|immunohistochemistry staining method|
474927|NCT00589056|Other|laboratory biomarker analysis|
474928|NCT00589056|Procedure|biopsy|
474929|NCT00589056|Radiation|radiation therapy|
474930|NCT00589030|Radiation|brachytherapy|The target dose of TheraSphere® is 80-150Gy
474931|NCT00589030|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
474932|NCT00588991|Drug|Carboplatin|Given IV
474933|NCT00588991|Other|Laboratory Biomarker Analysis|Correlative study
474934|NCT00588991|Drug|Topotecan Hydrochloride|Given IV
474935|NCT00588991|Drug|Veliparib|Given orally
474936|NCT00588978|Behavioral|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
474937|NCT00588965|Drug|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
474938|NCT00588965|Drug|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
474939|NCT00588952|Drug|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
474940|NCT00588939|Device|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
474941|NCT00588926|Drug|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
474942|NCT00588913|Biological|aldesleukin|
474943|NCT00588913|Biological|therapeutic autologous lymphocytes|
474944|NCT00588913|Drug|zoledronic acid|
474945|NCT00588900|Drug|cediranib maleate|
474946|NCT00588900|Drug|irinotecan hydrochloride|
474947|NCT00588887|Device|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
474948|NCT00588887|Device|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
474949|NCT00588861|Device|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
474950|NCT00588861|Device|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
474951|NCT00588848|Device|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
474952|NCT00588848|Device|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
474953|NCT00588835|Drug|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
474954|NCT00588835|Drug|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
474955|NCT00588822|Biological|Rituximab|Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
474956|NCT00588809|Drug|selumetinib|Given PO
474957|NCT00588783|Device|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
474958|NCT00588783|Device|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
474959|NCT00588770|Biological|Bevacizumab|Given IV
474960|NCT00588770|Drug|Carboplatin|Given IV
474961|NCT00588770|Drug|Cisplatin|Given IV
474962|NCT00588770|Drug|Docetaxel|Given IV
474963|NCT00588770|Drug|Fluorouracil|Given IV
474964|NCT00588757|Device|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
474965|NCT00588757|Device|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
474966|NCT00588731|Drug|Cannabidiol|Active Cannabidiol daily over 6 weeks
474967|NCT00588731|Drug|Placebo|Placebo
474968|NCT00588705|Behavioral|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
474969|NCT00588692|Device|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
474970|NCT00588679|Other|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
474971|NCT00588666|Drug|Bevacizumab|
474972|NCT00588666|Drug|Carboplatin|
474973|NCT00588666|Drug|Gemcitabine|
474974|NCT00588653|Device|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
474975|NCT00588640|Drug|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
474976|NCT00588640|Drug|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
474977|NCT00588640|Drug|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
474978|NCT00588588|Procedure|Bronchoscopy|Bronchoscopy procedure
474979|NCT00588588|Procedure|Clinical pulmonary infection score (CPIS)|Calculate CPIS
474980|NCT00588536|Drug|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
474981|NCT00588536|Drug|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
474982|NCT00588536|Drug|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
474983|NCT00588523|Drug|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
474984|NCT00588510|Other|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
474985|NCT00588497|Procedure|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
474986|NCT00588497|Radiation|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
474987|NCT00588497|Procedure|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
474988|NCT00588497|Radiation|Hysterosalpingogram|Performed 3 months after micro-inserts placement
474989|NCT00588471|Drug|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
474990|NCT00588471|Drug|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
474991|NCT00588458|Procedure|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
475021|NCT00588133|Drug|tranexamic acid|"Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr~Renal Insufficiency (normal loading dose and prime dose):~Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = >6.6: reduce infusion to 1.5 mg/kg/hr"
475022|NCT00588133|Drug|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
475045|NCT00587860|Drug|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
475309|NCT00585533|Drug|Erlotinib (Tarceva)|Erlotinib
474992|NCT00588445|Drug|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.~Patients who have had at least a minor response to gefitinib therapy preoperatively (> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.~Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
474993|NCT00588419|Behavioral|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
474994|NCT00588406|Drug|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
474995|NCT00588406|Drug|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
474996|NCT00588406|Drug|Ipratropium bromide|2.5 mg, one dose
474997|NCT00588406|Drug|Prednisone|60mg PO
474998|NCT00588393|Drug|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
474999|NCT00588380|Drug|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
475000|NCT00588367|Device|Mayo Interactive Breath Hold Monitor|Biofeedback device
475001|NCT00588354|Drug|Clonidine|200 or 400 micrograms clonidine
475002|NCT00588354|Drug|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
475003|NCT00588354|Drug|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
475004|NCT00588341|Drug|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.~Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.~After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
475005|NCT00588328|Device|PET/CT scan|PET/CT scans
475006|NCT00588302|Drug|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
475007|NCT00588276|Radiation|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three *IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
475008|NCT00588250|Other|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
475009|NCT00588237|Drug|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
475010|NCT00588224|Other|3D ultrasound|measurement of stomach volume by 3D ultrasound
475011|NCT00588211|Behavioral|Interviews|45-minute individual interviews after the conclusion of their dental appointment
475012|NCT00588211|Behavioral|focus group|A focus group of the preliminary cancer-related risk perception item pool.
475013|NCT00588211|Behavioral|Survey|Quantitative item analysis of the final item pool.
475014|NCT00588211|Behavioral|Survey|A second confirmatory factor analysis.
475015|NCT00588185|Drug|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
475016|NCT00588172|Drug|Metformin|1000mg bid for 1 week
475017|NCT00588159|Drug|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
475018|NCT00588159|Drug|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
475019|NCT00588146|Drug|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
475020|NCT00588146|Other|Standard care|Standard care
486446|NCT00503906|Drug|Gemcitabine|
475023|NCT00588120|Drug|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.~Take one capsule by mouth for one day."
475024|NCT00588107|Other|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
475025|NCT00588107|Behavioral|print materials|tailored print materials designed to aid in smoking reduction and cessation
475026|NCT00588094|Drug|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.~Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.~For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is > 100kg. Leukapheresis will continue."
475027|NCT00588081|Behavioral|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
475028|NCT00588068|Other|Tumor and Marrow Markers|Tumor and Marrow Markers
475029|NCT00588042|Device|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
475030|NCT00588042|Device|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
475031|NCT00588016|Drug|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
475032|NCT00588003|Drug|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
475033|NCT00588003|Other|Placebo|No medication before surgery
475034|NCT00587990|Biological|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 10^7 cells. The injections will be administered following completion of CABG surgery.
475035|NCT00587990|Genetic|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
475036|NCT00587990|Biological|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 10^8 cells. The injections will be administered following completion of CABG surgery.
475037|NCT00587964|Radiation|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.~A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
475038|NCT00587925|Other|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
475039|NCT00587899|Procedure|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
475040|NCT00587886|Behavioral|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
475041|NCT00587886|Behavioral|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.~We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
475042|NCT00587873|Drug|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
475043|NCT00587873|Drug|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
475044|NCT00587873|Drug|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
486447|NCT00503906|Drug|Abraxane|
475046|NCT00587860|Drug|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
475047|NCT00587847|Drug|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
475048|NCT00587834|Device|Gintuit|Application of Gintuit at Day 0 to the gingival bed
475049|NCT00587834|Other|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
475050|NCT00587821|Other|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
475051|NCT00587808|Procedure|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
475052|NCT00587795|Device|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
475053|NCT00587795|Other|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
475054|NCT00587769|Drug|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
475055|NCT00587756|Procedure|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
475056|NCT00587730|Device|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
475057|NCT00587717|Drug|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
475058|NCT00587717|Drug|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
475059|NCT00587704|Procedure|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
475060|NCT00587704|Procedure|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
475061|NCT00587691|Biological|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
475062|NCT00587678|Drug|Simvastatin|40mg each night
475063|NCT00587678|Drug|Ezetimibe|10mg daily
475064|NCT00587678|Drug|Simvastatin/Ezetimibe|40mg/10mg each night
475065|NCT00587665|Drug|ketamine|Single IV dose of 0.1 mg/kg of ketamine
475066|NCT00587665|Drug|Placebo|Saline given of equal volume to drug
475067|NCT00587639|Device|rTMS Treatment|Active rTMS treatment.
475068|NCT00587626|Device|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
475069|NCT00587626|Device|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
475070|NCT00587600|Procedure|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
475071|NCT00587600|Procedure|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
475072|NCT00587587|Device|Apligraf|Application at Day 0, potential re-application at Week 4
475073|NCT00587587|Other|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
475074|NCT00587561|Behavioral|Social Cognition Interaction Training|manualized group therapy
475075|NCT00587561|Behavioral|WLC|wait-list control for 6 months, followed by the experimental group therapy
475076|NCT00587548|Other|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
475077|NCT00587522|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
475078|NCT00587496|Drug|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
475079|NCT00587496|Drug|placebo|lactose placebo capsule, six per day for 30 days
475080|NCT00587496|Drug|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
475081|NCT00587483|Drug|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
475082|NCT00587483|Drug|Amiodarone|300 mg
475083|NCT00587483|Drug|Placebo|Saline
475084|NCT00587470|Drug|Candesartan|Maximum vasodilation.
475085|NCT00587470|Drug|atacand|maximum vasodilation
475086|NCT00587470|Drug|Placebo|Placebo
475087|NCT00587457|Drug|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
475088|NCT00587457|Drug|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
475089|NCT00587457|Drug|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
475310|NCT00585520|Drug|Progesterone|200mg BID for 5 days
475090|NCT00587444|Drug|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is < 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is>480 seconds
475091|NCT00587444|Drug|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is <600 seconds anytime during CPB
475092|NCT00587444|Drug|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.~All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
475093|NCT00587431|Drug|GnRh (Leuprolide)|Leuprolide LUPRON
475094|NCT00587431|Drug|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
475095|NCT00587431|Drug|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
475096|NCT00587418|Dietary Supplement|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
475097|NCT00587418|Dietary Supplement|Placebo|Placebo powder 9.2g bid for 7 days
475098|NCT00587405|Procedure|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.~A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
475099|NCT00587405|Procedure|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
475100|NCT00587392|Device|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
475101|NCT00587379|Drug|Atorvastatin|40 mg atorvastatin pill daily
475102|NCT00587379|Drug|placebo|40 mg pill per day
475103|NCT00587353|Other|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
475104|NCT00587327|Drug|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
475105|NCT00587327|Drug|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
475106|NCT00587327|Drug|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
475107|NCT00587314|Other|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
475108|NCT00587301|Device|Lap-Band|Obesity and adolescents
475109|NCT00587288|Biological|Reslizumab|
475110|NCT00587288|Other|Saline|
475111|NCT00587275|Drug|AST-120|Oral, sachet, 2 grams daily for 4 weeks
475112|NCT00587275|Drug|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
475113|NCT00587249|Biological|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
475114|NCT00587249|Biological|Alhydrogel|Aluminum hydroxide gel.
475115|NCT00587223|Device|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
475116|NCT00587223|Other|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
475117|NCT00587171|Device|Patching|2 hours daily patching
475118|NCT00587171|Procedure|Near activities|30 minutes daily near activities at home
475119|NCT00587171|Procedure|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
475120|NCT00587171|Procedure|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
475121|NCT00587158|Drug|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
475122|NCT00587158|Other|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
475123|NCT00587145|Drug|S-1,Docetaxel|"S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
475124|NCT00587132|Drug|Synthetic Human Secretin|0.2mcg/kg one time dose.
475125|NCT00587119|Drug|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
475126|NCT00587093|Other|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
475127|NCT00587067|Drug|FLOXURIDINE|"[0.16* mg/kg/day X 30 ml] / pump flow rate~* If the patient is >25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
475128|NCT00587054|Drug|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.~Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
475129|NCT00587041|Dietary Supplement|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
475130|NCT00587041|Dietary Supplement|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
475131|NCT00587041|Other|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
475132|NCT00587015|Drug|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
475133|NCT00587002|Procedure|IVUS|Intravascular ultrasound with virtual histology
475134|NCT00586989|Procedure|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
475135|NCT00586976|Drug|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
475136|NCT00586976|Drug|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
475137|NCT00586937|Behavioral|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
475138|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 5 microgram per kilogram (mcg/kg) moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
475139|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
475140|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
475141|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
475142|NCT00586924|Drug|CAT 8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
475143|NCT00586924|Drug|Moxetumomab Pasudotox (CAT 8015)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.
475144|NCT00586911|Drug|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
475145|NCT00586911|Drug|Identical Placebo|Placebo
475146|NCT00586898|Drug|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
475147|NCT00586898|Drug|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
475148|NCT00586898|Drug|Bicalutamide|A pure nonsteroidal antiandrogen
475149|NCT00586898|Drug|Testosterone transdermal gel|an androgenic anabolic steroid
475150|NCT00586898|Drug|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
475151|NCT00586885|Drug|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
475186|NCT00586612|Biological|Infanrix™ IPV|Intramuscular injection, 1 dose in the Booster study.
475187|NCT00586599|Other|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
475311|NCT00585520|Drug|Placebo|Placebo
475366|NCT00585039|Drug|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
475152|NCT00586859|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
475153|NCT00586846|Drug|Cisplatin|Cisplatin 120 mg/m^2
475154|NCT00586846|Drug|Doxorubicin|75mg/m^2
475155|NCT00586846|Drug|Methotrexate|Methotrexate 12g/m^2
475156|NCT00586833|Procedure|O2 consumption max bike test|Single visit exercise study
475157|NCT00586820|Drug|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
475158|NCT00586820|Drug|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
475159|NCT00586807|Other|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
475160|NCT00586794|Drug|Sildenafil|3x per day 20 mg TID
475161|NCT00586794|Drug|Placebo|3x per day, 20 mg TID
475162|NCT00586781|Device|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
475163|NCT00586755|Procedure|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
475164|NCT00586742|Procedure|labral repair|labral repair with suture anchors
475165|NCT00586742|Procedure|biceps tenodesis|biceps tenodesis with suture anchor
475166|NCT00586742|Procedure|diagnostic arthroscopy|diagnostic arthroscopy
475167|NCT00586729|Device|Vashe|Antimicrobial irrigant
475168|NCT00586729|Drug|Mafenide acetate|Antimicrobial solution
475169|NCT00586716|Drug|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
475170|NCT00586703|Device|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
475171|NCT00586690|Device|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
475172|NCT00586690|Procedure|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
475173|NCT00586677|Behavioral|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
475174|NCT00586677|Behavioral|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
475175|NCT00586677|Behavioral|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
475176|NCT00586664|Drug|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
475177|NCT00586664|Drug|placebo comparator|sterile ophthalmic solution
475178|NCT00586664|Drug|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
475179|NCT00586651|Drug|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
475180|NCT00586638|Behavioral|Video game based training|36 one-hour sessions over 12 weeks
475181|NCT00586625|Drug|Bepreve|One drop, both eyes, twice a day
475182|NCT00586625|Drug|Placebo|One drop, both eyes, twice a day
475183|NCT00586612|Biological|Menitorix™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
475184|NCT00586612|Biological|Infanrix™ penta|Intramuscular injection, 3 doses in the primary study
475185|NCT00586612|Biological|Prevenar™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
475367|NCT00585026|Device|D-28 bifocal lenses and frame|
475188|NCT00586586|Behavioral|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
475189|NCT00586573|Drug|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
475190|NCT00586560|Drug|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).~Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
475191|NCT00586547|Drug|Ara-C|"Day -8,-7,-6, and-5:~(3g/m2) IV every 12 hours for 6 doses"
475192|NCT00586547|Drug|Cyclophosphamide|"Days -7 and -6:~Intravenous 45mg/kg"
475193|NCT00586547|Drug|Mesna|(45mg/kg, divided into 5 doses) administered 15 minutes prior to each dose of cyclophosphamide and 3, 6, 9 and 12 hours after each dose of cyclophosphamide.
475194|NCT00586547|Biological|Campath 1H|"Days -3,-2, and -1:~Intravenous, according to age and weight."
475195|NCT00586547|Radiation|TBI|"Days -4,-3,-2, and-1:~Total dose 14.0 Gy will be delivered in 8 fractions of 1.75 Gy in two fractions. The dose rate will be 10cGy/min."
475196|NCT00586547|Procedure|Stem Cells Infusion|once
475197|NCT00586547|Procedure|T-cell Infusion|"30 Days after stem cell infusion~Patients will be entered starting at level 1, according to the following doses:~Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)."
475198|NCT00586534|Behavioral|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
475199|NCT00586534|Behavioral|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
475200|NCT00586521|Drug|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
475201|NCT00586508|Drug|enzastaurin|1125 mg loading dose then 500 or 875 mg, oral, daily, 4 week cycles with patients evaluated after each cycle. The dose difference is for patients who are on enzyme-inducing antiepileptic drugs versus non-enzyme inducing antiepileptic drugs.
475202|NCT00586508|Drug|bevacizumab|10mg/kg, IV, every 2 weeks, patients are evaluated after each cycle
475203|NCT00586495|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
475204|NCT00586482|Drug|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
475205|NCT00586482|Drug|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
475206|NCT00586482|Behavioral|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
475207|NCT00586469|Biological|Fluviral|One dose, Intramuscular injection
475208|NCT00586443|Drug|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab~3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks~2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks~1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks~3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD* RPTD* RPTD* 3b 10 RPTD** RPTD** RPTD**~Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. **Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
475209|NCT00586430|Drug|lorazepam|single 2 mg dose of lorazepam
475210|NCT00586430|Drug|placebo|single dose of placebo
475211|NCT00586417|Other|punch biopsy|skin biopsies
475212|NCT00586391|Genetic|CD19CAR-28-zeta T cells|"Intravenous injection~Dose Level 1:~CD19CAR-28zeta - 2x10^7 cells/m^2~Dose Level 2:~CD19CAR-28zeta - 1 x10^8 cells/m^2~Dose Level 3:~CD19CAR-28zeta - 2x10^8 cells/m^2"
475213|NCT00586391|Drug|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
475214|NCT00586378|Device|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
475215|NCT00586365|Drug|Naproxen|500 mg Naproxen twice a day for two weeks
475216|NCT00586352|Other|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
475217|NCT00586339|Biological|Cervarix|Intramuscular injection, 3 doses
475218|NCT00586339|Biological|Placebo Control|Intramuscular injection, 3 doses
475219|NCT00586326|Device|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
475220|NCT00586313|Device|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
475221|NCT00586313|Procedure|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
475255|NCT00586066|Drug|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
475256|NCT00586066|Drug|Placebo|Inactive comparator. Placebo-matching memantine tablet.
475257|NCT00586040|Procedure|tissue bonding|application of rose bengal and treatment with green light
475222|NCT00586300|Other|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
475223|NCT00586300|Behavioral|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
475224|NCT00586300|Other|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
475225|NCT00586287|Other|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
475226|NCT00586287|Other|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
475227|NCT00586287|Drug|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
475228|NCT00586274|Procedure|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
475229|NCT00586274|Drug|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m^2
475230|NCT00586274|Biological|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are > 1000/ul.~Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)"
475231|NCT00586274|Biological|Campath 1h|10 mg iv over 4 hours day-8 through day-6
475232|NCT00586274|Biological|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
475233|NCT00586261|Drug|Pioglitazone|Pioglitazone 30 mg daily for 6 months
475234|NCT00586261|Drug|Placebo|Placebo 30 mg daily for 6 months
475235|NCT00586261|Drug|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
475236|NCT00586222|Dietary Supplement|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
475237|NCT00586222|Other|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
475238|NCT00586209|Drug|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (>66.7 kg)
475239|NCT00586209|Drug|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
475240|NCT00586196|Drug|donepezil|5 mg each day for 30 days
475241|NCT00586196|Drug|Placebo|Encapsulated cornstarch One capsule daily for 30 days
475242|NCT00586183|Procedure|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
475243|NCT00586170|Device|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
475244|NCT00586170|Device|Placebo Device|10 hours of treatment per day for up to 24 weeks
475245|NCT00586170|Procedure|Surgery|Open Reduction and Internal Fixation of the nonunion site
475246|NCT00586157|Drug|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
475247|NCT00586157|Drug|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
475248|NCT00586131|Drug|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
475249|NCT00586131|Drug|Sodium citrate/citratic acid|dictated by pH
475250|NCT00586118|Drug|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
475251|NCT00586118|Drug|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
475252|NCT00586105|Drug|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
475253|NCT00586092|Drug|bevacizumab, ABT-510|"Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days*~Stage 2 (RPTD) ABT-510: X mg SC BID**, bevacizumab: Y mg/kg IV every 14 days**~Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.~*Both agents begin on Day 1 of Cycle 1.~**At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
475254|NCT00586079|Procedure|Deep brain stimulation surgery.|Deep brain stimulation surgery.
475258|NCT00586040|Procedure|sutures|interrupted superficial sutures
475365|NCT00585052|Drug|Lovastatin|Lovastatin, 80 mg, po, daily will be self-administered by the subject.
475259|NCT00586014|Procedure|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
475260|NCT00586001|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|Cognitive-behavioral treatment in development for emotional disorders
475261|NCT00585988|Device|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
475262|NCT00585988|Device|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
475263|NCT00585975|Drug|bromfenac ophthalmic solution|sterile opthalmic solution
475264|NCT00585962|Radiation|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
475265|NCT00585949|Procedure|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
475266|NCT00585923|Device|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
475267|NCT00585923|Device|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
475268|NCT00585910|Drug|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
475269|NCT00585897|Behavioral|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
475270|NCT00585871|Drug|clonidine|0.1 mg tid
475271|NCT00585871|Drug|metoprolol|25 mg tid
475272|NCT00585845|Biological|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.
475273|NCT00585832|Behavioral|DASH-4-Teens|24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
475274|NCT00585832|Other|Routine Care|individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
475275|NCT00585819|Procedure|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
475276|NCT00585819|Procedure|Freebreathing in Body fix mold|Freebreathing in Body fix mold
475277|NCT00585793|Drug|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
475278|NCT00585780|Drug|Prazosin|three week dose titration schedule at the start of study with the full dose schedule of 5.0mg in the morning, 5.0mg at 3pm, and 11.0mg at bedtime for 8 weeks and then a 5-day taper in week 12.
475279|NCT00585780|Drug|placebo|placebo
475280|NCT00585754|Drug|Guanfacine|1.5mg BID
475281|NCT00585754|Drug|Placebo|placebo
475282|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
475283|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
475284|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
475285|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
475286|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
475287|NCT00585728|Procedure|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
475288|NCT00585715|Device|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
475289|NCT00585689|Drug|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
475290|NCT00585689|Drug|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
475291|NCT00585689|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
475292|NCT00585689|Procedure|Radical Cystectomy|
475293|NCT00585650|Biological|Etanercept|Subcutaneous injections 50 mg Etanercept will occur twice weekly over a 12-week treatment period.
475294|NCT00585650|Other|Placebo injections|Placebo injections twice weekly for 12 weeks.
475295|NCT00585637|Drug|Vitamin D|Taken orally every day for three months
475296|NCT00585637|Dietary Supplement|Placebo|Placebo pill taken once daily for 3 month
475297|NCT00585624|Dietary Supplement|Impact Advanced Recovery|Nutritional supplement
475298|NCT00585624|Dietary Supplement|No supplement|No supplement
475299|NCT00585611|Drug|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
475300|NCT00585611|Other|placebo|placebo
475301|NCT00585598|Other|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
475302|NCT00585585|Drug|betahistine dihydrochloride|oral, 50-300 mg, daily
475303|NCT00585559|Drug|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
475304|NCT00585559|Drug|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
475305|NCT00585559|Drug|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
475306|NCT00585559|Drug|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
475307|NCT00585559|Drug|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
475308|NCT00585546|Drug|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
475312|NCT00585507|Drug|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
475313|NCT00585481|Procedure|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).~Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
475314|NCT00585481|Procedure|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
475315|NCT00585468|Drug|Myfortic|Myfortic 720 mg orally twice daily
475316|NCT00585455|Drug|sertraline|open label 25-50 mg daily as tolerated
475317|NCT00585442|Drug|calcitriol|1.0 mcg daily
475318|NCT00585442|Drug|Placebo|Placebo
475319|NCT00585416|Drug|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
475320|NCT00585390|Dietary Supplement|Omega-3 Fatty Acids|"Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams~Docosahexaenoic acid fish oil concentrate at 1.6 grams"
475321|NCT00585390|Other|Olive oil placebo|Olive oil capsules, 8 capsules per day
475322|NCT00585390|Dietary Supplement|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
475323|NCT00585390|Drug|Placebo|Olive oil capsule
475324|NCT00585377|Drug|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
475325|NCT00585351|Drug|Ranitidine|50 mg single dose injection of Ranitidine
475326|NCT00585351|Drug|Placebo|50 mg single dose injection of normal saline (placebo)
475327|NCT00585351|Other|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
475328|NCT00585351|Other|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
475329|NCT00585338|Device|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
475330|NCT00585325|Drug|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
475331|NCT00585325|Other|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
475332|NCT00585312|Drug|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
475333|NCT00585312|Drug|Placebo|Masked, placebo comparator
475334|NCT00585299|Other|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
475335|NCT00585299|Other|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
475336|NCT00585286|Device|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
475337|NCT00585260|Drug|mannitol|indirect mannitol challenge
475338|NCT00585247|Drug|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
475339|NCT00585247|Other|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
475340|NCT00585234|Other|Digital Photography|Digital Photography
475341|NCT00585221|Drug|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
475342|NCT00585221|Drug|Imatinib|Continue imatinib until progression.
475343|NCT00585208|Drug|Ramelteon|Ramelteon 8mg daily
475344|NCT00585208|Drug|Placebo|matching placebo for ramelteon 8mg daily
475345|NCT00585195|Drug|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
475346|NCT00585195|Drug|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
475347|NCT00585195|Drug|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
475348|NCT00585182|Drug|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
475349|NCT00585169|Drug|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
475350|NCT00585156|Drug|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
475351|NCT00585143|Drug|ABT-335|45 mg once daily for 10 consecutive days
475352|NCT00585143|Drug|Rosuvastatin|10 mg once daily for 10 days
475353|NCT00585117|Procedure|PET-imaging with CuATSM|imaging with CuATSM
475354|NCT00585117|Procedure|PET Imaging|Imaging with CuATSM
475355|NCT00585117|Procedure|PET CuATSM|Imaging with CuATSM
475356|NCT00585117|Procedure|PET imaging|imaging with CuATSM
475357|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
475358|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
475359|NCT00585104|Drug|levosimendan|10-minute infusion
475360|NCT00585091|Drug|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
475361|NCT00585078|Drug|Capecitabine|
475362|NCT00585078|Drug|Oxaliplatin|
475363|NCT00585065|Other|Cardiac Resynchronization Therapy|Cardiac Resynchronization Therapy
475364|NCT00585052|Drug|Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly
475368|NCT00585026|Device|Progressive addition computer lenses and frame|
475369|NCT00585013|Drug|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
475370|NCT00585000|Drug|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
475371|NCT00584987|Drug|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
475372|NCT00584987|Drug|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
475373|NCT00584987|Drug|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
475374|NCT00584987|Drug|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
475375|NCT00584974|Drug|SEP-225289|0.5 mg SEP-225289
475376|NCT00584974|Drug|SEP-225289|2.0 mg SEP-225289
475377|NCT00584974|Drug|Venlafaxine|150 mg Venlafaxine
475378|NCT00584974|Drug|placebo|Placebo
475379|NCT00584961|Other|non-interventional|non-interventional
475380|NCT00584948|Drug|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
475381|NCT00584948|Drug|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
475382|NCT00584935|Drug|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
475383|NCT00584922|Procedure|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
475384|NCT00584909|Drug|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
475385|NCT00584896|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
475386|NCT00584883|Drug|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
475387|NCT00584870|Drug|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
475388|NCT00584870|Drug|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
475389|NCT00584870|Drug|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
475390|NCT00584857|Drug|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
475391|NCT00584844|Biological|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (< 1:20).
475392|NCT00584831|Device|senofilcon A|toric contact lens
475393|NCT00584831|Device|balafilcon A|toric contact lens
475394|NCT00584831|Device|omafilcon A|toric contact lens
475395|NCT00584831|Device|lotrafilcon B|toric contact lens
475396|NCT00584818|Drug|PB127 for Injectable Suspension|"Stages 1 & 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.~Stage 3 - will utilize infusion rate and dose established in Stages 1 & 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
475397|NCT00584805|Biological|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is < 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
475398|NCT00584779|Drug|Gabapentin|CLcr:14-5 mL/min
475399|NCT00584779|Drug|Gabapentin|CLcr: 29-15 mL/min
475400|NCT00584779|Drug|Gabapentin|Hemodialysis
475401|NCT00584779|Drug|Gabapentin|CLcr: 29-30 mL/min
475402|NCT00584766|Procedure|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
475403|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
475404|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
475405|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
475406|NCT00584740|Drug|AIN457|10 mg/kg
475407|NCT00584740|Drug|Placebo|Matching placebo to AIN457
475408|NCT00584727|Device|senofilcon A toric contact lens|contact lens
475409|NCT00584727|Device|alphafilcon A toric|contact lens
475410|NCT00584727|Device|etafilcon A sphere|contact lens
475411|NCT00584701|Drug|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
475412|NCT00584688|Drug|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
475413|NCT00584675|Device|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
475414|NCT00584662|Drug|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
475415|NCT00584649|Procedure|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
475416|NCT00584636|Drug|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
475417|NCT00584610|Device|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
475418|NCT00584610|Device|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
475419|NCT00584597|Drug|Saline|Saline Control
475420|NCT00584597|Drug|Traumeel S|Traumeel S 1 mL
475421|NCT00584597|Drug|Traumeel S|Traumeel S 2mL
475422|NCT00584597|Drug|Traumeel S|Traumeel S 3mL
475423|NCT00584584|Drug|QAX576|
475424|NCT00584584|Drug|Placebo|
475425|NCT00584571|Procedure|Sensory Adaptation Training|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
475426|NCT00584571|Drug|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
475427|NCT00584558|Procedure|Catheter Ablation|Catheter Ablation of arrhythmias
475428|NCT00584532|Drug|Placebo|10 Placebo Capsules taken orally every day.
475429|NCT00584532|Drug|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
475430|NCT00584519|Other|non-interventional|non-interventional
475431|NCT00584493|Drug|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma~Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
475432|NCT00584480|Other|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
475433|NCT00584454|Biological|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
475434|NCT00584428|Procedure|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
475435|NCT00584415|Device|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
475436|NCT00584402|Drug|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
475437|NCT00584389|Drug|rimonabant|20mg/d (oral) once daily for 12 weeks
475438|NCT00584389|Behavioral|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
475439|NCT00584376|Drug|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
475440|NCT00584376|Drug|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
475441|NCT00584350|Other|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
475442|NCT00584350|Other|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
475443|NCT00584350|Other|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
475444|NCT00584324|Combination Product|BIS 40|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
475519|NCT00583661|Device|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
475520|NCT00583648|Other|Urinanlysis|sending a Urine sample to the laboratory for processing
475521|NCT00583622|Drug|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
475522|NCT00583622|Drug|Carboplatin|333 mg/m^2 by vein over 2 hours for 3 Days
475523|NCT00583622|Drug|Docetaxel|300 mg/m^2 by vein over 2 hours for 1 Day
475445|NCT00584324|Combination Product|BIS 60|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.~Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.~Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.~Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.~Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
475446|NCT00584311|Other|MRI and Ultrasound|MRI and US of the joint
475447|NCT00584298|Drug|SMS995|
475448|NCT00584298|Drug|Placebo|
475449|NCT00584259|Other|Coffee|3 cups of coffee over a 24 hour period
475450|NCT00584246|Drug|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
475451|NCT00584246|Drug|Placebo|50 - 150 mg po qhs for 2 months
475452|NCT00584233|Device|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
475453|NCT00584220|Device|senofilcon A toric|contact lens
475454|NCT00584220|Device|alphafilcon A toric|contact lens
475455|NCT00584207|Procedure|radiofrequency ablation|Intraoperative RFA of uterine fibroids
475456|NCT00584194|Biological|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
475457|NCT00584168|Drug|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
475458|NCT00584168|Drug|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
475459|NCT00584155|Drug|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
475460|NCT00584155|Drug|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
475461|NCT00584142|Behavioral|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
475462|NCT00584129|Other|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
475463|NCT00584129|Other|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
475464|NCT00584103|Device|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
475465|NCT00584103|Device|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
475466|NCT00584090|Drug|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
475467|NCT00584090|Drug|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
475468|NCT00584064|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
475469|NCT00584038|Behavioral|educational instruction and phone follow-up|Educational instruction and phone follow-up.
475470|NCT00584038|Behavioral|educational instruction in clinic|Educational instruction in clinic.
475471|NCT00584025|Drug|levetiracetam|100 - 500mg IV q 15 min
475472|NCT00584025|Drug|Placebo|Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
475473|NCT00584012|Drug|Lovastatin|Given PO
475474|NCT00584012|Drug|Docetaxel|Given IV
475475|NCT00583999|Other|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
475476|NCT00583986|Drug|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
475477|NCT00583947|Drug|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
475478|NCT00583947|Drug|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
475479|NCT00583908|Device|senofilcon A|toric contact lens
475480|NCT00583908|Device|balafilcon A toric|toric contact lens
475481|NCT00583908|Device|lotrafilcon B toric|toric contact lens
475482|NCT00583908|Device|omafilcon A|toric contact lens
475483|NCT00583895|Drug|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
475484|NCT00583895|Drug|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
475485|NCT00583882|Other|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
475524|NCT00583622|Drug|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
475525|NCT00583622|Drug|Melphalan|50 mg/m^2 by vein over 15 minutes for 3 Days
475486|NCT00583869|Drug|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
475487|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
475488|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.~Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
475489|NCT00583843|Procedure|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
475490|NCT00583830|Biological|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
475491|NCT00583830|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
475492|NCT00583830|Drug|Paclitaxel|200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle
475493|NCT00583830|Drug|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
475494|NCT00583817|Device|Endovascular stent-graft implantation|Endovascular repair of aorta
475495|NCT00583804|Device|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
475496|NCT00583791|Device|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
475497|NCT00583778|Drug|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
475498|NCT00583765|Drug|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
475499|NCT00583752|Biological|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
475500|NCT00583739|Behavioral|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
475501|NCT00583726|Behavioral|motivational interviewing|telephone counseling
475502|NCT00583726|Behavioral|written materials only|dietary guidance materials and pedometers
475503|NCT00583713|Drug|BLI-800|BLI-800 oral solution (two doses)
475504|NCT00583700|Drug|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
475505|NCT00583700|Drug|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
475506|NCT00583687|Device|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
475507|NCT00583687|Other|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
475508|NCT00583687|Other|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
475509|NCT00583687|Device|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
475510|NCT00583674|Drug|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475511|NCT00583674|Drug|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475512|NCT00583674|Drug|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475513|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475514|NCT00583674|Drug|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475515|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475516|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475517|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475518|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
475526|NCT00583622|Procedure|Stem Cell Transplant|"Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest~Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
475527|NCT00583609|Drug|PEG3350|PEG3350
475528|NCT00583596|Device|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
475529|NCT00583596|Other|Objective Performance Criteria|Compare results of device closure to objective performance criteria
475530|NCT00583583|Device|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
475531|NCT00583570|Behavioral|dietary education|dietary education
475532|NCT00583557|Drug|belimumab|IV 10mg/kg Q28 days
475533|NCT00583544|Drug|TC-2216|Multiple ascending dose groups will be explored.
475534|NCT00583531|Drug|AST-120|Oral, 2 grams TID in sachets for 4 weeks
475535|NCT00583518|Drug|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
475536|NCT00583505|Device|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
475537|NCT00583492|Biological|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
475538|NCT00583492|Radiation|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
475539|NCT00583479|Other|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
475540|NCT00583479|Other|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
475541|NCT00583466|Drug|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
475542|NCT00583466|Drug|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
475543|NCT00583466|Drug|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
475544|NCT00583453|Drug|Celecoxib|"Celecoxib 200 mg capsule~capsule the night before surgery~capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
475545|NCT00583453|Drug|Placebo|"Placebo capsule~capsule the night before surgery~capsules the morning of surgery~1 capsule the night of surgery~1 capsule twice daily for 10 days immediately after the surgery"
475546|NCT00583440|Behavioral|12-step facilitation|12 weekly individual 12-step facilitation sessions
475547|NCT00583440|Behavioral|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
475548|NCT00583427|Drug|Sulodexide|200 mg per day in an oral gelcap form
475549|NCT00583414|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
475550|NCT00583401|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
475551|NCT00583388|Dietary Supplement|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
475552|NCT00583388|Device|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
475553|NCT00583375|Device|Augment® Bone Graft|Augment® Bone Graft
475554|NCT00583375|Procedure|Standard of Care|Autologous Bone Graft
475555|NCT00583362|Biological|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
475556|NCT00583349|Drug|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
475557|NCT00583336|Device|ShuntCheck|Thermal dilution test for CSF flow
475558|NCT00583323|Drug|Lomotil|Orally 10ml of Lomotil
475559|NCT00583323|Other|Normal saline|10 ml orally
475560|NCT00583310|Behavioral|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
475561|NCT00583271|Drug|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
475562|NCT00583271|Drug|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
475563|NCT00583258|Drug|Alfuzosin (Xatral)|10 mg PO once a day
475564|NCT00583258|Drug|Placebo Alfuzosin|10 mg PO once a day
475565|NCT00583245|Other|Gait Training|Gait training with physical therapist 2/week for 3 months
475566|NCT00583232|Drug|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
475567|NCT00583219|Drug|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
475568|NCT00583219|Drug|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
475569|NCT00583193|Drug|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
475570|NCT00583180|Drug|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
475571|NCT00583154|Drug|BLI-801|Dose 1
475575|NCT00583128|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
475576|NCT00583128|Drug|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
475577|NCT00583115|Drug|Gleevec|260 mg/M2/day, given once daily by mouth
475578|NCT00583102|Drug|Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.
475579|NCT00583102|Drug|Lovastatin|Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
475580|NCT00583076|Drug|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
475581|NCT00583063|Drug|sunitinib|25 mg daily (oral dosing)
475582|NCT00583063|Drug|rapamycin|4 mg daily (oral dosing)
475583|NCT00583050|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
475584|NCT00583037|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
475585|NCT00583024|Biological|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
475586|NCT00583011|Drug|Local anesthesia - lidocaine|Local anesthesia: 2 cc of 1% Lidocaine
475587|NCT00583011|Drug|Placebo Group|Placebo Group: 2cc Normal Saline
475588|NCT00582998|Procedure|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
475589|NCT00582998|Device|Vacuum Assisted Closure Device|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
475590|NCT00582985|Drug|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
475591|NCT00582972|Drug|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
475592|NCT00582959|Other|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
475593|NCT00582946|Device|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
475594|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
475595|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
475596|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.~The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
475597|NCT00582920|Radiation|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
475598|NCT00582907|Drug|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
475599|NCT00582907|Drug|Placebo|placebo by subcutaneous injection weekly for 3 months
475600|NCT00582894|Drug|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
475601|NCT00582868|Device|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
475602|NCT00582868|Other|CSF|analysis of CSF for cleaved tau protein
475603|NCT00582868|Other|Whole blood|Analysis of whole blood for cleaved-tau protein
475604|NCT00582855|Drug|AQW051|
475605|NCT00582855|Drug|Placebo|
476010|NCT00579137|Drug|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2"
475606|NCT00582842|Behavioral|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
475607|NCT00582842|Behavioral|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
475608|NCT00582829|Other|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
475609|NCT00582829|Other|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
475610|NCT00582829|Other|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
475611|NCT00582816|Device|Clinimacs Cell Separation System|Depletion of T-cells
475612|NCT00582816|Drug|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
475613|NCT00582816|Other|DLI|NK Cell selected DLI
475614|NCT00582790|Drug|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
475615|NCT00582790|Drug|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
475616|NCT00582777|Behavioral|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
475617|NCT00582777|Behavioral|HS DOSING|Take your usual BP meds at bed time
475618|NCT00582777|Drug|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
475619|NCT00582764|Other|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
475620|NCT00582738|Drug|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
475621|NCT00582738|Drug|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
475622|NCT00582725|Drug|R-CHOP+GM-CSF|addition of GM-CSF
475623|NCT00582712|Drug|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
475624|NCT00582699|Behavioral|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
475625|NCT00582686|Procedure|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
475626|NCT00582686|Procedure|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
475627|NCT00582673|Drug|AFQ056|
475628|NCT00582673|Drug|Placebo|
475629|NCT00582660|Drug|Celecoxib|400 mg twice a day for 7 days prior to surgery
475630|NCT00582660|Drug|Placebo|one tablet of placebo will be given for 7 days prior to surgery
475631|NCT00582634|Drug|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
475632|NCT00582608|Drug|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein]
475633|NCT00582608|Drug|8H9|administration of 50mg/1.73m^2 of unlabeled 8H9.
475634|NCT00582582|Drug|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
475635|NCT00582582|Drug|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
475636|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
475637|NCT00582556|Drug|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
475638|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
475639|NCT00582543|Other|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
475640|NCT00582530|Other|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
475641|NCT00582517|Device|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
475642|NCT00582517|Procedure|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
475643|NCT00582504|Biological|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
475644|NCT00582491|Drug|Modafinil|Modafinil 400mg orally every day for 16 days
475645|NCT00582491|Drug|Placebo|Placebo orally everyday for 16 days
475646|NCT00582478|Behavioral|questionnaires|Participants will be followed regularly at 3, 6, 12, and 18-month intervals
475647|NCT00582452|Other|Telephone survey|Telephone survey
475648|NCT00582439|Device|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
475649|NCT00582426|Drug|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
475650|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
475651|NCT00582413|Behavioral|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
475652|NCT00582400|Drug|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.~The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
475653|NCT00582387|Genetic|specimen samples|blood, urine and tissue
475654|NCT00582387|Behavioral|questionnaires|
475655|NCT00582361|Procedure|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
475656|NCT00582361|Device|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
475657|NCT00582309|Procedure|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.~Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
475658|NCT00582309|Procedure|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving >80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
475659|NCT00582309|Procedure|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
475660|NCT00582296|Behavioral|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
475661|NCT00582296|Behavioral|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
475662|NCT00582283|Drug|I124-NM404|I-124-NM404
475663|NCT00582257|Behavioral|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
475664|NCT00582244|Behavioral|CBT and relaxation|Group A: CBT and relaxation.
475665|NCT00582244|Behavioral|Physical activity|Group B: Physical exercise program.
475666|NCT00582244|Behavioral|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
475667|NCT00582244|Other|Control group|Waiting list control group
475668|NCT00582231|Other|Questionnaires.|Questionnaires.
475669|NCT00582205|Drug|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
475670|NCT00582192|Other|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
475671|NCT00582179|Procedure|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
475672|NCT00582179|Device|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
475673|NCT00582166|Drug|Ibritumomab Tiuxetan (Zevalin) + Rituximab|Subjects will receive the Ibritumomab Tiuxetan (Zevalin) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
475674|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
475675|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
475676|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
475677|NCT00582114|Drug|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
475678|NCT00582114|Drug|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
475679|NCT00582101|Behavioral|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
475680|NCT00582101|Behavioral|General Health Promotion|7 hour one-day workshop on general health promotion topics
475681|NCT00582088|Biological|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer <1:20.
475682|NCT00582075|Drug|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
475683|NCT00582062|Other|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
475684|NCT00582036|Drug|Regular Insulin|Use of sliding scale insulin as per Appendix 1
475685|NCT00582036|Device|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
475686|NCT00582010|Drug|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
475687|NCT00582010|Drug|nitrogen gas|inhaled
475688|NCT00581997|Drug|QAX576|
475689|NCT00581997|Drug|Placebo|
475690|NCT00581971|Drug|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
475691|NCT00581971|Drug|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
475692|NCT00581971|Drug|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
475693|NCT00581971|Radiation|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
475694|NCT00581958|Other|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
487228|NCT00498238|Drug|Levothyroxine|
475695|NCT00581945|Drug|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
475696|NCT00581945|Drug|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
475697|NCT00581919|Drug|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
475698|NCT00581906|Radiation|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) & group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite & will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st & 2nd weeks of treatment & the 2nd intra-treatment DCE-MRI is recommended between the 3rd & 4th weeks of treatment.
475699|NCT00581893|Drug|Phenytoin|Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
475700|NCT00581880|Behavioral|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
475701|NCT00581867|Drug|Insulin Aspart|40IU insulin aspart applied intranasally
475702|NCT00581867|Drug|Placebo|Placebo
475703|NCT00581854|Drug|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
475704|NCT00581841|Other|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
475705|NCT00581828|Drug|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
475706|NCT00581815|Device|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
475707|NCT00581815|Device|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
475708|NCT00581789|Drug|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
475709|NCT00581776|Drug|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
475710|NCT00581776|Drug|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
475711|NCT00581776|Drug|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
475712|NCT00581776|Drug|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
475713|NCT00581776|Drug|Vincristine|1 mg administered by IV on day 3 of each cycle.
475714|NCT00581776|Drug|Dexamethasone|40 mg orally on days 1-4 of each cycle.
475715|NCT00581750|Other|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
475716|NCT00581724|Behavioral|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
475717|NCT00581711|Other|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
475718|NCT00581711|Other|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
475719|NCT00581711|Other|1-part intervention|Provision of feedback on otitis media quality indicators
475720|NCT00581685|Drug|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
475721|NCT00581672|Behavioral|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
475722|NCT00581646|Behavioral|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
475723|NCT00581633|Other|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
475724|NCT00581620|Biological|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
475725|NCT00581607|Drug|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
475726|NCT00581607|Drug|Placebo|Placebo twice a day
475727|NCT00581607|Drug|Bosentan|drug given for 16 weeks
475728|NCT00581607|Drug|Placebo|placebo
475766|NCT00581256|Radiation|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
476045|NCT00578929|Drug|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
475729|NCT00581594|Procedure|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
475730|NCT00581594|Procedure|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
475731|NCT00581568|Other|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
475732|NCT00581555|Drug|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
475733|NCT00581555|Other|Placebo|Randomized to placebo during taper of ciclosporin
475734|NCT00581542|Drug|moxifloxacin|1-2 drops three times a day for 8-10 days.
475735|NCT00581542|Drug|polytrim|1-2 drops four times a day for 8-10 days.
475736|NCT00581529|Radiation|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
475737|NCT00581503|Device|diagnostic|oct imaging
475738|NCT00581477|Drug|droxidopa|up to 300mg four times daily
475739|NCT00581477|Drug|placebo|same frequency as experimental medication
475740|NCT00581477|Drug|alpha-methyldopa|up to 250mg two times daily
475741|NCT00581477|Drug|carbidopa|up to 25mg four times daily
475742|NCT00581477|Drug|metyrosine|up to 1000mg three times daily
475743|NCT00581477|Drug|levodopa|up to 250mg three times daily
475744|NCT00581477|Drug|atomoxetine|up to 40mg twice daily
475745|NCT00581477|Drug|metoclopramide|up to 10mg four times daily
475746|NCT00581464|Behavioral|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
475747|NCT00581464|Behavioral|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
475748|NCT00581451|Drug|bifeprunox|oral tablet once daily
475749|NCT00581425|Biological|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
475750|NCT00581399|Device|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
475751|NCT00581399|Device|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
475752|NCT00581386|Device|LTS-D|supra-glottic airway device
475753|NCT00581386|Device|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
475754|NCT00581386|Device|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
475755|NCT00581373|Other|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
475756|NCT00581360|Drug|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
475757|NCT00581347|Other|outreach services|Tracking/reminder/recall/home visit strategy.
475758|NCT00581334|Procedure|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
475759|NCT00581321|Dietary Supplement|water|water 500 ml x 1
475760|NCT00581308|Device|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
475761|NCT00581295|Device|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
475762|NCT00581282|Radiation|PET scan|positron emission tomography PET scan
475763|NCT00581282|Other|fMRI|functional magnetic resonance imaging fMRI
475764|NCT00581269|Behavioral|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
475765|NCT00581269|Dietary Supplement|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
476011|NCT00579137|Biological|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg"
475767|NCT00581256|Radiation|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
475768|NCT00581243|Drug|SLV-313 SR|sustained relase tablets taken once daily for 14 days
475769|NCT00581230|Device|Laryngoscopy with RAMP|inflatable positioning ramp
475770|NCT00581230|Device|Laryngoscopy without RAMP|Laryngoscopy without RAMP
475771|NCT00581217|Other|Aquacel Ag|Aquacel Ag will be applied to one donor site.
475772|NCT00581217|Other|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
475773|NCT00581204|Device|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
475774|NCT00581191|Drug|SLV-351|SLV-351 capsules taken once
475775|NCT00581165|Drug|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
475776|NCT00581139|Behavioral|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
475777|NCT00581139|Drug|Midazolam|0.5 mg/kg oral midazolam
475778|NCT00581139|Behavioral|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
475779|NCT00581139|Other|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
475780|NCT00581126|Drug|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
475781|NCT00581113|Radiation|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
475782|NCT00581100|Drug|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
475783|NCT00581087|Drug|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
475784|NCT00581087|Drug|Placebo|Treatment : 200 mg/day hard gelatine capsule
475785|NCT00581074|Behavioral|diet (grapefruit or grapefruit juice)|weight loss diet
475786|NCT00581061|Drug|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
475787|NCT00581048|Drug|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
475788|NCT00581035|Biological|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
475789|NCT00581035|Biological|Prevenar|1 dose at 2,3.5,6 and 12 months
475790|NCT00581035|Biological|Meningitec|1 dose at 2,6 and 12 months
475791|NCT00581022|Procedure|Polysomnography|Overnight Sleep Study
475792|NCT00581009|Other|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
475793|NCT00581009|Drug|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
475794|NCT00581009|Radiation|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
475795|NCT00580996|Other|water high dose|water 16 oz PO x 1
475796|NCT00580996|Other|water tiny dose|water 1 oz PO x 1
475797|NCT00580983|Radiation|IMRT|
475798|NCT00580983|Drug|Paclitaxel|
475799|NCT00580983|Drug|Carboplatin|
475800|NCT00580983|Drug|Cisplatin|
475801|NCT00580983|Drug|5-Fluorouracil|
475802|NCT00580970|Drug|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
475803|NCT00580957|Drug|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
475804|NCT00580957|Drug|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
475805|NCT00580944|Procedure|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
475806|NCT00580931|Drug|Nicotinamide|1500 mg twice a day for 6 months
475807|NCT00580931|Drug|Enduramide placebo|1 tab twice a day
475808|NCT00580918|Other|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
475809|NCT00580905|Drug|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
475810|NCT00580905|Drug|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
476012|NCT00579137|Procedure|Stem cell infusion|stem cells are infused on day 0
476013|NCT00579124|Device|CliniMACs|T and B Cell depletion
475811|NCT00580905|Drug|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
475812|NCT00580892|Device|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
475813|NCT00580866|Device|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
475814|NCT00580853|Drug|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
475815|NCT00580853|Drug|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
475816|NCT00580853|Drug|Placebo|Placebo
475817|NCT00580840|Drug|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
475818|NCT00580840|Drug|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
475819|NCT00580840|Other|Placebo|placebo (saline) administered as two injections every 2 weeks
475820|NCT00580827|Drug|Placebo|Matched placebo.
475821|NCT00580827|Drug|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
475822|NCT00580827|Drug|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
475823|NCT00580827|Drug|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
475824|NCT00580814|Drug|Methylphenidate|Methylphenidate
475825|NCT00580801|Drug|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
475826|NCT00580801|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
475827|NCT00580801|Drug|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
475828|NCT00580801|Drug|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
475829|NCT00580788|Drug|PTHrP (1-36)|IND # 49,175
475830|NCT00580762|Procedure|Roux-en-y gastric bypass (RYGB)|
475831|NCT00580749|Procedure|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
475832|NCT00580749|Procedure|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
475833|NCT00580736|Device|Optical Clearing|Optical Clearing
475834|NCT00580723|Other|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
475835|NCT00580684|Biological|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
475836|NCT00580671|Behavioral|MET/CBT|Weekly Individual Counseling Sessions
475837|NCT00580671|Behavioral|CM|Abstinence-based incentives delivered contingent on drug-negative urine test results.
475838|NCT00580671|Behavioral|BPT|Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
475839|NCT00580658|Device|Medtronic Activa Gpi|Activa Therapy, Gpi
475840|NCT00580645|Drug|varenicline|2mg/day or 1mg/day with 1-week medication lead-in period.
475841|NCT00580645|Drug|placebo|placebo
475842|NCT00580619|Other|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
475843|NCT00580619|Other|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
475844|NCT00580619|Drug|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
475845|NCT00580619|Drug|methyldopa|Aldomet oral twice a day for 12 weeks
475846|NCT00580606|Drug|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
475847|NCT00580606|Drug|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
475848|NCT00580593|Device|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
475849|NCT00580593|Other|sham-NIPPV|a sham-device
475850|NCT00580580|Drug|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
475851|NCT00580580|Drug|Definity|intravenous injection at 0.05-0.20 mL
475852|NCT00580580|Drug|PESDA|intravenous injections dosage 0.05-0.20 mL
475853|NCT00580541|Behavioral|variety|variety and nonvariety
475854|NCT00580528|Behavioral|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
475855|NCT00580528|Behavioral|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
476009|NCT00579137|Biological|Campath -1H|"Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients >15 kg to 30 kg the dose 5 mg; for patients > 30 kg the dose is 10 mg"
475856|NCT00580515|Behavioral|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
475857|NCT00580515|Behavioral|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
475858|NCT00580515|Behavioral|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
475859|NCT00580502|Device|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m^2
475860|NCT00580489|Drug|either fentanyl or morphine|either morphine 4mg IV or fentanyl 50mcg IV
475861|NCT00580450|Drug|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
475862|NCT00580437|Procedure|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
475863|NCT00580424|Drug|Norethindrone|Norethindrone 0.35 mg orally daily
475864|NCT00580398|Behavioral|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
475865|NCT00580398|Drug|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
475866|NCT00580385|Other|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
475867|NCT00580372|Drug|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
475868|NCT00580372|Drug|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
475869|NCT00580372|Procedure|Hemopoietic stem cell procurement|Collection target = 10 x 10^6 cells/kg
475870|NCT00580372|Drug|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
475871|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
475872|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
475873|NCT00580372|Drug|Maintenance|3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse
475874|NCT00580359|Drug|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
475875|NCT00580346|Device|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
475876|NCT00580333|Drug|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
475877|NCT00580333|Drug|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
475878|NCT00580333|Drug|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
475879|NCT00580333|Drug|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
475880|NCT00580333|Drug|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
475881|NCT00580320|Drug|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
475882|NCT00580307|Procedure|Septoplasty|Surgical straightening of nasal septum
475883|NCT00580307|Procedure|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
475884|NCT00580294|Drug|Oxymorphone|IV PO
475885|NCT00580281|Other|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
475886|NCT00580242|Drug|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
475887|NCT00580242|Drug|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
475888|NCT00580242|Drug|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
475889|NCT00580242|Drug|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
475890|NCT00580229|Drug|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
475891|NCT00580216|Drug|Idrabiotaparinux sodium|"Pre-filled syringes containing:~0.5 mL for the 3.0 mg dosage;~0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
475892|NCT00580216|Drug|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
475893|NCT00580216|Drug|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:~0.5 mL for the 3.0 mg dosage;~0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);~0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).~Subcutaneous injection"
475894|NCT00580216|Drug|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
475895|NCT00580216|Drug|Avidin|"Vial containing 105 mg of lyophilized powder for dilution~Intravenous infusion for 30 minutes"
475896|NCT00580216|Drug|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution~Intravenous infusion for 30 minutes"
475897|NCT00580190|Drug|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
475898|NCT00580190|Other|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
475899|NCT00580190|Drug|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
475900|NCT00580177|Procedure|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
475901|NCT00580177|Procedure|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
475902|NCT00580177|Procedure|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
475903|NCT00580151|Drug|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
475904|NCT00580151|Drug|placebo|1 dose every 6 hours
475905|NCT00580125|Drug|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
475906|NCT00580125|Other|Placebo|Placebo, oral capsule, once daily for 21 days
475907|NCT00580125|Drug|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
475908|NCT00580125|Drug|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
475909|NCT00580125|Drug|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
475910|NCT00580112|Drug|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
475911|NCT00580112|Drug|Trabectedin|Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
475912|NCT00580099|Other|assisted exercise|4 weeks of passive range of motion exercise
475913|NCT00580099|Other|cuddle|cuddle infant for 20 minutes
475914|NCT00580086|Other|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
475915|NCT00580073|Drug|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
475916|NCT00580073|Drug|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
475917|NCT00580060|Biological|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
475918|NCT00580047|Drug|Zoledronic Acid|4mg IV Annually
475919|NCT00580047|Combination Product|Calcium with vitamin D|1200 mg Calcium with 800 International Units of vitamin D
475920|NCT00580047|Drug|Alendronate|70mg weekly
475921|NCT00580034|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
475922|NCT00580034|Procedure|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
475923|NCT00580021|Other|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
475924|NCT00579995|Drug|Oral N-Acetylcysteine|600 mg
475925|NCT00579995|Drug|Intravenous Sodium Bicarbonate|3mL/kg/hr for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
475926|NCT00579982|Drug|Lamotrigine|Experimental formulation
475927|NCT00579969|Drug|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
475928|NCT00579969|Drug|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
475929|NCT00579956|Drug|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
475930|NCT00579956|Drug|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
487280|NCT00497692|Drug|Lactoserum|
475931|NCT00579917|Behavioral|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
475932|NCT00579917|Behavioral|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
475933|NCT00579904|Dietary Supplement|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
475934|NCT00579904|Dietary Supplement|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
475935|NCT00579878|Drug|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
475936|NCT00579878|Drug|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:~dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.~Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
475937|NCT00579878|Drug|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
475938|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
475939|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
475940|NCT00579852|Procedure|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
475941|NCT00579839|Procedure|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
475942|NCT00579839|Procedure|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
475943|NCT00579826|Drug|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
475944|NCT00579826|Drug|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
475945|NCT00579813|Drug|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
475946|NCT00579800|Procedure|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
475947|NCT00579774|Other|Low AGE Diet|Diet
475948|NCT00579774|Other|Regular Diet|Diet
475949|NCT00579709|Biological|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained <4000/cumm Csa weaned over 8 weeks. If T cell >4,000/cumm, Csa held at 180-300ng/ml.~Thymus tissue, donor, & mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.~Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
475950|NCT00579683|Other|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
475951|NCT00579670|Drug|Ziprasidone|Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
475952|NCT00579657|Other|control diet, supported by dietary supplement twice daily|control diet, see above
475953|NCT00579657|Other|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
475954|NCT00579657|Other|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
475955|NCT00579657|Other|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
475976|NCT00579527|Drug|Daclizumab|A single dose of Daclizumab 1 mg/kg IV may be given. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before thymus transplantation. If Daclizumab is not given before thymus transplantation, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after thymus transplantation.
475956|NCT00579644|Drug|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:~1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.~3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.~4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
475957|NCT00579644|Drug|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.~2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.~4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.~6, 8 and 10 month evaluations:~If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.~If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
475958|NCT00579631|Behavioral|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
475959|NCT00579618|Other|Saliva or Blood samples|Extracting sample of saliva or blood only once.
475960|NCT00579605|Behavioral|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
475961|NCT00579592|Drug|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
475962|NCT00579579|Behavioral|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
475963|NCT00579566|Other|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
475964|NCT00579553|Drug|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
475965|NCT00579553|Drug|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
475966|NCT00579540|Dietary Supplement|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
475967|NCT00579540|Dietary Supplement|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
475968|NCT00579540|Dietary Supplement|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
475969|NCT00579527|Biological|Thymus Tissue for Transplantation|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and donor's biological mother are screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue if transplanted into the subject's quadriceps. Two to three months post thymus transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
475970|NCT00579527|Other|Thymus Tissue and Parental Parathyroid Transplantation|If the recipient has hypoparathyroidism, and is eligible, the subject may receive both a thymus and parathyroid transplant. If the subject is not eligible the subject will receive only a thymus transplant. For parathyroid transplant, parental parathyroid donors screened. If both parents met criteria, parathyroid harvested from the parent who shares the most HLA alleles with the thymus donor. Parathyroid harvest is done under general anesthesia. One parathyroid gland is minced and placed in quadriceps muscle of 1 leg; there is no dose. No biopsy is done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
475971|NCT00579527|Procedure|Blood Draw|Biological Mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab amy be done.
475972|NCT00579527|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV prior to thymus or thymus and parathyroid transplantation. Each dose is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to thymus or thymus and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
475973|NCT00579527|Drug|Cyclosporine|Csa may be given every 8 to 12 hours orally or IV before and after thymus transplantation or thymus and parathyroid transplantation. The Csa dose is dependant on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol.
475974|NCT00579527|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 to 12 hours orally or IV before and after the thymus transplant or the thymus/parathyroid transplant. FK506 dose is dependent on the T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
475975|NCT00579527|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and after thymus or thymus/parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Steroids are weaned as per protocol.
476008|NCT00579189|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
475977|NCT00579527|Drug|Mycophenolate mofetil|Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after thymus transplantation. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after thymus transplantation or continued for up to six months after thymus transplantation.
475978|NCT00579514|Genetic|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
475979|NCT00579501|Drug|Trabectedin|Trabectedin 1.5 mg/m^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
475980|NCT00579501|Drug|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
475981|NCT00579475|Drug|Mifegyne|tablets, 50 mg every other day
475982|NCT00579475|Drug|placebo|
475983|NCT00579462|Other|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
475984|NCT00579449|Behavioral|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
475985|NCT00579449|Behavioral|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
475986|NCT00579436|Drug|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
475987|NCT00579436|Drug|placebo|4 inert capsules daily by mouth for 12 weeks.
475988|NCT00579423|Biological|QS21|"Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.~Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.~Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
475989|NCT00579384|Drug|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
475990|NCT00579384|Drug|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
475991|NCT00579371|Drug|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
475992|NCT00579345|Biological|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
475993|NCT00579345|Biological|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
475994|NCT00579345|Biological|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV_a administered.
475995|NCT00579345|Biological|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
475996|NCT00579332|Dietary Supplement|brassica intervention|diet and phyto-chemical intervention
475997|NCT00579280|Drug|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
475998|NCT00579280|Drug|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
475999|NCT00579280|Drug|placebo|placebo
476000|NCT00579267|Other|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
476001|NCT00579254|Drug|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
476002|NCT00579241|Procedure|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
476003|NCT00579215|Behavioral|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
476004|NCT00579215|Behavioral|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
476005|NCT00579202|Device|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
476006|NCT00579189|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
476007|NCT00579189|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
476187|NCT00578071|Radiation|Radiation Therapy (RT)|Daily for 6 weeks
476014|NCT00579111|Drug|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
476015|NCT00579111|Drug|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
476016|NCT00579111|Drug|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
476017|NCT00579111|Procedure|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
476018|NCT00579111|Drug|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
476019|NCT00579098|Drug|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
476020|NCT00579098|Drug|Placebo|Placebo tablet taken by mouth once daily for 90 days
476021|NCT00579085|Drug|Ketamine|IV Ketamine .35mg/kg times ten days.
476022|NCT00579085|Other|IV NSS|Placebo inactive ingredients
476023|NCT00579085|Other|Normal Saline|"INFUSION PLAN:~All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
476024|NCT00579072|Behavioral|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
476025|NCT00579072|Behavioral|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
476026|NCT00579072|Device|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup or Longitudinal Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline for the Comparison Androgen Ablation Subgroup. The fMRI will be performed at the follow-up time point for the Longitudinal Androgen Ablation Subgroup. The fMRI will be performed at baseline for the No Androgen Ablation Subgroup; if the fMRI can not be completed at baseline (due to participant schedule conflict, lack of fMRI availability, staff schedule conflict, etc.), then the scan will be conducted at the follow-up time point if possible.
476027|NCT00579059|Device|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
476028|NCT00579059|Device|Regular Maxim® Knee System|Used for total knee replacements
476029|NCT00579046|Drug|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).~Frequency: every week for 2 months: 8 injections"
476030|NCT00579033|Other|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
476031|NCT00579033|Other|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
476032|NCT00579020|Drug|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
476033|NCT00579020|Drug|Moxifloxacin ophthalmic solution 0.5%|
476034|NCT00579020|Drug|Dexamethasone phosphate solution, 0.1%|
476035|NCT00579007|Behavioral|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
476036|NCT00578994|Device|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
476037|NCT00578981|Behavioral|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
476038|NCT00578968|Drug|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
476039|NCT00578968|Drug|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
476040|NCT00578955|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
476041|NCT00578955|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
476042|NCT00578955|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
476043|NCT00578942|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
476044|NCT00578929|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
476046|NCT00578916|Drug|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
476047|NCT00578903|Drug|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
476048|NCT00578903|Drug|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
476049|NCT00578903|Radiation|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
476050|NCT00578903|Drug|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
476051|NCT00578903|Drug|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
476052|NCT00578903|Procedure|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10^6 CD 34+ cells/kg should be collected, with a target of 10 X 10^6/kg.
476053|NCT00578890|Procedure|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
476054|NCT00578877|Device|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
476055|NCT00578877|Combination Product|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
476056|NCT00578877|Combination Product|Buffer Gel|Buffer Gel
476057|NCT00578864|Drug|Protracted Oral Etoposide|"IV Cisplatin and Oral Protracted Etoposide for induction~Induction chemotherapy will consist of five cycles 21 days apart. Cycles 1, 2 and 4 will be IV cisplatin and etoposide. Patients on the phase II window will receive the first two cycles of chemo with IV cisplatin and oral protracted etoposide. If their tumor responds with a CR, VGPR or PR, it will be repeated during cycle 4. If their tumor does not respond cycle 4 will include bolus etoposide~Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4~Day 1 - 5~Hour 0: Etoposide 50 mg/m2 po daily~Hours 1 to 7: Cisplatin 40 mg/m2~Day 6 - 14~Etoposide 50 mg/m2 po once daily"
476058|NCT00578864|Drug|Adriamycin and Cyclophosphamide|"Induction chemotherapy will consist of 5 cycles given 21 days apart. Cycle 3 and 5 will be adriamycin and cyclophosphamide.~Day 1 and 2~Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if < 12 kg) with Mesna 400 mg/m2 (13 mg/kg if < 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr~Hours 6 to 6.25: Adriamycin 37.5 mg/m2 (1.25 mg/kg if < 12 kg) IV over 15 minutes"
476059|NCT00578864|Drug|IV Cisplatin and IV Bolus Etoposide|"Induction chemotherapy will consist of five cycles of chemotherapy given 21 days apart. The 1st, 2nd and 4th cycles will the IV Cisplatin and Etoposide. Patients ineligible to participate on the phase II window will receive IV bolus etoposide during cycles 1, 2 and 4.~Cisplatin with Bolus IV Etoposide~Day 1~Hours 0 to 6: Cisplatin 40 mg/m2~Days 2, 3, 4:~Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2~Day 5:~Hours 0 to 6: Cisplatin 40 mg/m2"
476060|NCT00578851|Device|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
476061|NCT00578838|Other|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
476062|NCT00578838|Other|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
476063|NCT00578825|Drug|Lopinavir / Ritonavir plus Ribavirin|
476064|NCT00578812|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
476065|NCT00578812|Device|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
476066|NCT00578799|Dietary Supplement|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
476067|NCT00578799|Dietary Supplement|placebo|placebo capsules (potato starch
476068|NCT00578786|Drug|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
476069|NCT00578773|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
476070|NCT00578773|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
476071|NCT00578773|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
476072|NCT00578760|Drug|aspirin|325mg ASA OD for the duration of the cisplatin
476073|NCT00578760|Drug|placebo|OD for course of cisplatin chemotherapy
476074|NCT00578734|Drug|Lucinactant|Slow intra-tracheal instillation
476075|NCT00578734|Other|Sham Comparator|Slow intra-tracheal instillation
476076|NCT00578721|Drug|Aspirin|325 mg taken daily with an arginine-restricted diet
476077|NCT00578708|Device|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
476078|NCT00578695|Drug|lixivaptan|Oral Capsule
476079|NCT00578695|Drug|Placebo|Oral Capsule
476080|NCT00578682|Biological|MEDI-557|Single IV dose of 3 mg/kg
476081|NCT00578682|Biological|MEDI-557|Single IV dose of 15 mg/kg
476082|NCT00578682|Biological|MEDI-557|Single IV dose of 30 mg/kg
476083|NCT00578682|Biological|MEDI-557|Single IV dose of 0.3 mg/kg
476084|NCT00578669|Drug|Fluoxetine|20mg once daily for 16 weeks
476085|NCT00578669|Drug|Dextrose|Once daily for 16 weeks
476086|NCT00578656|Dietary Supplement|Baked Milk|Extensively heated milk
476087|NCT00578643|Drug|Busulfan|"Days -9 through -6~1 mg/kg initially (based on weight)"
476657|NCT00574496|Drug|mechlorethamine hydrochloride|
476088|NCT00578643|Biological|Alemtuzumab|"Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg"
476089|NCT00578643|Drug|Cyclophosphamide|"Days -5 through -2~50 mg/kg"
476090|NCT00578643|Drug|Fludarabine|"Day -5 through Day -2~30 mg/m^2"
476091|NCT00578643|Drug|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
476092|NCT00578643|Procedure|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10^8/kg recipient weight; for cord blood ≥ 3 X 10^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10^/kg CD34+ cells.
476093|NCT00578630|Other|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
476094|NCT00578617|Drug|Rate Control|Metoprolol 50-100mg
476095|NCT00578617|Device|Ablation Therapy|
476096|NCT00578617|Drug|Rate Control|Atenolol 50-100mg,
476097|NCT00578617|Drug|Rate control|Propranolol 40-80mg
476098|NCT00578617|Drug|Rate control|Acebutolol 200mg
476099|NCT00578617|Drug|Rate control|Carvedilol 6.25mg
476100|NCT00578617|Drug|Rate Control|Diltiazem 180-240mg
476101|NCT00578617|Drug|Rate Control|Verapamil 180-240mg
476102|NCT00578617|Drug|Rate Control|Digoxin 0.125mg
476103|NCT00578617|Drug|Rhythm Control|Propafenone 450mg
476104|NCT00578617|Drug|Rhythm control|Flecainide 200mg
476105|NCT00578617|Drug|Rhythm control|Sotalol 240mg
476106|NCT00578617|Drug|Rhythm control|Dofetilide 500mcg
476107|NCT00578617|Drug|Rhythm control|Amiodarone 200mg
476108|NCT00578617|Drug|Rhythm control|Quinidine 600-900mg
476109|NCT00578604|Device|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
476110|NCT00578591|Drug|Rituximab|"Rituximab 375 mg/m^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).~Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
476111|NCT00578578|Dietary Supplement|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
476112|NCT00578565|Drug|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
476113|NCT00578552|Drug|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
476114|NCT00578552|Drug|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
476115|NCT00578552|Drug|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
476116|NCT00578539|Drug|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
476117|NCT00578539|Drug|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
476118|NCT00578539|Drug|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
476119|NCT00578539|Radiation|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
476120|NCT00578539|Biological|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
476121|NCT00578539|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
476122|NCT00578526|Drug|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
476123|NCT00578526|Drug|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
476124|NCT00578500|Procedure|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
476125|NCT00578474|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
476126|NCT00578474|Drug|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
476127|NCT00578474|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
476128|NCT00578461|Drug|Ara C|3000 mg/m^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
476129|NCT00578461|Drug|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
476130|NCT00578461|Drug|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
476131|NCT00578461|Radiation|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
476132|NCT00578448|Drug|Belatacept|IV infusion
476133|NCT00578435|Procedure|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
476134|NCT00578422|Other|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
476135|NCT00578422|Procedure|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
476136|NCT00578396|Dietary Supplement|grapes|1 pound of seedless red grapes
476137|NCT00578396|Dietary Supplement|grapes|2/3 lb/day fresh red grapes
476138|NCT00578396|Dietary Supplement|grapes|1/3 lb/day fresh red grapes
476139|NCT00578383|Device|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
476140|NCT00578370|Drug|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
476141|NCT00578370|Drug|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
476142|NCT00578370|Drug|0.1% betamethasone|Solution 200µl once a day (26 days)
476143|NCT00578370|Drug|0.005% calcipotriol|Solution 200µl once a day (26 days)
476144|NCT00578370|Drug|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
476145|NCT00578357|Behavioral|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
476146|NCT00578344|Drug|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
476147|NCT00578344|Biological|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
476148|NCT00578344|Drug|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
476149|NCT00578331|Drug|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
476150|NCT00578331|Drug|Placebo Nasal Spray|2 sprays each nostril twice daily
476151|NCT00578318|Behavioral|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
476152|NCT00578305|Biological|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
476153|NCT00578305|Drug|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
476154|NCT00578305|Drug|Methylprednisolone|
476155|NCT00578305|Drug|Methotrexate|
476156|NCT00578305|Drug|Folic acid or folate|
476157|NCT00578292|Drug|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg~Days -9 through -6"
476158|NCT00578292|Drug|Fludarabine|30mg/m2 Day -5 through Day -2
476159|NCT00578292|Drug|Campath 1H|Per institutional guidelines Days -5 through -2
476160|NCT00578292|Drug|Cyclophosphamide|50 mg/kg Days -5 through -2
476161|NCT00578292|Drug|MESNA|10 mg/kg x 5 Days -5 through -2
476162|NCT00578279|Drug|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
476163|NCT00578266|Drug|Cyclophosphamide,Campath IH and TBI|"DAY 5 TREATMENT~6 5 CYTOXAN 50 mg/kg WITH MESNA~5 CYTOXAN 50 mg/kg WITH MESNA;~4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg~3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;~2 TBI; CAMPATH; TACROLIMUS~1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)"
476164|NCT00578227|Biological|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
476165|NCT00578227|Biological|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
476166|NCT00578214|Drug|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
476167|NCT00578214|Other|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
476168|NCT00578214|Drug|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
476169|NCT00578214|Drug|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
476170|NCT00578201|Drug|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
476171|NCT00578175|Biological|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
476172|NCT00578175|Biological|ProQuad®|One subcutaneous injection.
476173|NCT00578175|Biological|Havrix®|Two intramuscular injections.
476174|NCT00578175|Biological|Prevnar®|One intramuscular injection.
476175|NCT00578162|Behavioral|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
476176|NCT00578149|Drug|Bevacizumab|
476177|NCT00578149|Drug|Carboplatin|
476178|NCT00578149|Drug|Paclitaxel|
476179|NCT00578136|Drug|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
476180|NCT00578123|Behavioral|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
476181|NCT00578110|Device|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
476182|NCT00578097|Biological|Botulinum toxin type A|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
476183|NCT00578097|Drug|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
476184|NCT00578071|Drug|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
476185|NCT00578071|Drug|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
476186|NCT00578071|Drug|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
476188|NCT00578058|Other|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
476189|NCT00578045|Procedure|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
476190|NCT00578032|Behavioral|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
476191|NCT00578019|Procedure|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith & Nephew supracondylar nail.
476192|NCT00578019|Procedure|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
476193|NCT00578006|Behavioral|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
476194|NCT00578006|Behavioral|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
476195|NCT00577993|Drug|Fludarabine|Group 1= 25 mg/m^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
476196|NCT00577993|Drug|Novantrone|Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.
476197|NCT00577993|Drug|Decadron|Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
476198|NCT00577993|Drug|Rituximab|Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.
476199|NCT00577993|Drug|Interferon|Group 1 = After Completion of Fludarabine, Novantrone, & Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine & Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.
476200|NCT00577993|Drug|Doxorubicin|25 mg/m^2 IV Days 2 & 3 of 1st Sequence.
476201|NCT00577993|Drug|Vincristine|.7 mg/m^2 IV Days 2 & 3 of 1st Sequence; 1.4 mg/m^2 IV Day 2 of 3rd Sequence.
476202|NCT00577993|Drug|Bleomycin|5 unit/m^2 IV Days 2 & 3 of 1st Sequence.
476203|NCT00577993|Drug|Cyclophosphamide|750 mg/m^2 IV Day 2 of 1st Sequence.
476204|NCT00577993|Drug|Etoposide|40 mg/m^2 IV Days 1 through 4 of 2nd Sequence.
476205|NCT00577993|Drug|Cisplatin|25 mg/m^2 IV Days 1 through 4 of 2nd Sequence
476206|NCT00577993|Drug|Ara-C|1.5 gm/m^2 IV Day 5 of 2nd Sequence.
476207|NCT00577993|Drug|Methyl-Prednisolone|500 mg IV Days 1 through 5 of 2nd Sequence.
476208|NCT00577993|Drug|Procarbazine|100 mg/m^2 PO Days 2 through 11 of 3rd Sequence.
476209|NCT00577993|Drug|Prednisone|100 mg PO Days 1 through 5 of 3rd Sequence.
476210|NCT00577980|Drug|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
476211|NCT00577967|Drug|Gabapentin|
476212|NCT00577954|Procedure|Multimodal MRI|Multimodal MRI
476213|NCT00577915|Other|Radiology/MRI scan|MRI spectroscopy
476214|NCT00577902|Other|Observation|Head and neck cancer patients receiving chemoradiation
476215|NCT00577889|Drug|gemcitabine hydrochloride|750 mg/m2 Given IV
476216|NCT00577889|Drug|tanespimycin|154 mg/m2 Given IV
476217|NCT00577876|Procedure|Trimix Injection with Doppler Ultrasound|"In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion."
476218|NCT00577863|Drug|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
476219|NCT00577850|Drug|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
476220|NCT00577850|Drug|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
476221|NCT00577837|Drug|risedronate|tablet, 5 mg risedronate daily for 6 months
476222|NCT00577837|Drug|risedronate|tablet, 100 mg risedronate monthly for 6 months
476223|NCT00577837|Drug|risedronate|tablet, 150 mg risedronate monthly for 6 months
476224|NCT00577837|Drug|experimental|tablet, 200 mg risedronate monthly for 6 months
476225|NCT00577824|Drug|exenatide|subcutaneous injection, 5mcg, twice a day
476226|NCT00577824|Drug|exenatide|subcutaneous injection, 10mcg, twice a day
476227|NCT00577824|Drug|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
476228|NCT00577798|Drug|doxorubicin hydrochloride|Standard therapy for patients undergoing chemotherapy for their non-Hogdkin's lyphoma and Hogdkin's lymphoma
476269|NCT00577473|Drug|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
476270|NCT00577460|Drug|Pramipexole|Pramipexole ER 0.375 -4.5 mg
476229|NCT00577798|Procedure|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake).
476230|NCT00577785|Other|tissue procurement|No intervention. Tissue procurement study.
476231|NCT00577772|Drug|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
476232|NCT00577772|Device|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
476233|NCT00577772|Procedure|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
476234|NCT00577759|Other|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
476235|NCT00577759|Other|Passive Intervention|Provision of tools to help with referrals to community resources
476236|NCT00577759|Other|No intervention|No intervention
476237|NCT00577720|Drug|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
476238|NCT00577720|Drug|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
476239|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
476240|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
476241|NCT00577707|Drug|erlotinib|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
476242|NCT00577707|Drug|Pemetrexed|pemetrexed 500 mg/m^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
476243|NCT00577707|Drug|Cisplatin|cisplatin 75 mg/m^2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment.
476244|NCT00577707|Procedure|Resection|
476245|NCT00577694|Drug|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
476246|NCT00577694|Drug|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
476247|NCT00577681|Drug|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
476248|NCT00577668|Drug|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
476249|NCT00577655|Drug|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
476250|NCT00577655|Drug|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
476251|NCT00577655|Drug|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
476252|NCT00577642|Drug|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
476253|NCT00577629|Drug|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
476254|NCT00577629|Drug|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
476255|NCT00577629|Drug|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
476256|NCT00577629|Drug|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
476257|NCT00577629|Drug|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
476258|NCT00577629|Drug|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
476259|NCT00577616|Procedure|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
476260|NCT00577603|Procedure|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
476261|NCT00577603|Other|no intervention|
476262|NCT00577590|Drug|Metformin|Metformin is taken alone
476263|NCT00577590|Drug|Rosiglitazone|Rosiglitizone is taken with Metformin
476264|NCT00577590|Drug|Lovaza|Lovaza is taken with Metformin
476265|NCT00577577|Drug|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
476266|NCT00577577|Drug|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
476267|NCT00577512|Drug|DTPACE|"Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~Thalidomide 200 mg by mouth (PO) Days 1-7~Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~Adriamycin 15 mg/m2 Days 1-4~Cyclophosphamide 600 mg/m2 Days 1-4~Etoposide 60 mg/m2 Days 1-4"
476268|NCT00577473|Drug|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
476658|NCT00574496|Drug|melphalan|
476271|NCT00577460|Drug|Placebo|Placebo tablets identical to Pramipexole ER tablets
476272|NCT00577447|Dietary Supplement|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
476273|NCT00577447|Dietary Supplement|Placebo|Placebo capsule containing corn and soybean oil
476274|NCT00577421|Drug|risedronate|5 mg tablet of risedronate once a day for 2 years
476275|NCT00577408|Drug|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
476276|NCT00577408|Drug|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
476277|NCT00577395|Drug|placebo|oral tablet once a month for 12 months
476278|NCT00577395|Drug|risedronate|tablet, 150 mg once a month for 12 months
476279|NCT00577382|Drug|Sunitinib|
476280|NCT00577369|Other|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
476281|NCT00577356|Drug|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
476282|NCT00577356|Biological|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
476283|NCT00577330|Dietary Supplement|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
476284|NCT00577317|Procedure|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
476285|NCT00577317|Procedure|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
476286|NCT00577317|Other|Quality-of-Life Assessment|Ancillary studies
476287|NCT00577304|Drug|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
476288|NCT00577304|Drug|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
476289|NCT00577278|Biological|rituximab|Given IV
476290|NCT00577278|Drug|fludarabine phosphate|Given IV
476291|NCT00577278|Drug|melphalan|Given IV
476292|NCT00577278|Drug|sirolimus|Given PO
476293|NCT00577278|Drug|tacrolimus|Given PO or IV
476294|NCT00577278|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
476295|NCT00577278|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
476296|NCT00577278|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
476297|NCT00577278|Other|laboratory biomarker analysis|Correlative Studies
476298|NCT00577200|Drug|Midazolam|Midazolam
476299|NCT00577200|Drug|Sufentanil|Sufentanil
476300|NCT00577200|Drug|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
476301|NCT00577187|Device|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
476302|NCT00577161|Drug|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
476303|NCT00577161|Drug|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
476304|NCT00577148|Drug|Rimonabant|Tablet, oral administration
476305|NCT00577148|Drug|Placebo (for Rimonabant)|Tablet, oral administration
476306|NCT00577135|Drug|Furosemide-Q12 hour bolus|Q12 hours bolus
476307|NCT00577135|Drug|Furosemide-Continuous Infusion|Continuous infusion
476308|NCT00577135|Drug|Furosemide-Low Intensification|1x oral dose
476309|NCT00577135|Drug|Furosemide-High Intensification|2.5x oral dose
476310|NCT00577122|Drug|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
476311|NCT00577122|Drug|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
476312|NCT00577109|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
476313|NCT00577109|Drug|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
476314|NCT00577109|Drug|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
476315|NCT00577109|Drug|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
476316|NCT00577109|Drug|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
476317|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
476318|NCT00577096|Behavioral|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
476319|NCT00577096|Biological|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
476320|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
476321|NCT00577096|Drug|Thalidomide|Fifty percent of the participants received 400 mg daily
476322|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
476323|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
476324|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
476325|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
476326|NCT00577096|Drug|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
476327|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
476328|NCT00577096|Drug|Thalidomide|Fifty percent of participants received 400 mg daily
476329|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
476330|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
476331|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
476332|NCT00577083|Device|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
476333|NCT00577070|Device|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
476334|NCT00577057|Procedure|Conventional Radiotherapy|
476335|NCT00577057|Procedure|Accelerated Radiotherapy|
476336|NCT00577057|Drug|Cisplatin|
476337|NCT00577057|Drug|5-fluorouracil|
476338|NCT00577057|Drug|Capecitabine|
476339|NCT00577031|Drug|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
476340|NCT00577031|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
476341|NCT00577031|Drug|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
476342|NCT00577018|Drug|Prucalopride|4 mg o.d.
476343|NCT00577018|Drug|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
476344|NCT00577018|Other|Placebo|o.d.
476345|NCT00577005|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
476346|NCT00577005|Drug|Placebo|
476347|NCT00576979|Drug|cyclophosphamide|Given IV
476348|NCT00576979|Drug|etoposide|Given IV
476349|NCT00576979|Procedure|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
476350|NCT00576979|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
476351|NCT00576979|Procedure|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
476352|NCT00576979|Radiation|intensity-modulated radiation therapy|Undergo IMRT
476353|NCT00576979|Radiation|tomotherapy|Undergo IMRT using helical tomotherapy
476354|NCT00576940|Drug|Reconvan|isocaloric, immunomodulating entral diet
476355|NCT00576940|Drug|Peptisorb|isocaloric, isopeptic standard diet
476356|NCT00576927|Drug|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
476357|NCT00576927|Drug|Placebo|
476358|NCT00576914|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
476359|NCT00576901|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
476360|NCT00576901|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
476361|NCT00576901|Drug|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
476362|NCT00576888|Other|no intervention|no intervention - observational only
476363|NCT00576862|Drug|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
476364|NCT00576849|Drug|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
476365|NCT00576849|Drug|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
476366|NCT00576849|Drug|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
476659|NCT00574496|Drug|methotrexate|
476660|NCT00574496|Drug|mycophenolate mofetil|
476367|NCT00576836|Biological|Thymus Tissue for Transplantation|Thymus tissue (from unrelated donor), donor, and donor's mother screened for safety. Thymus transplantation done under general anesthesia. Thymus transplanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not >18 grams/m2 body surface area (1.0 grams/kg body weight). At time of transplant, skin biopsy obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy done to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples.
476368|NCT00576836|Other|Parathyroid Tissue for Transplantation|Parental parathyroid donors screened for eligibility and transplant safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most HLA alleles with thymus donor. Parathyroid harvest & transplant preferably done at same time as thymus transplant. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of thymus transplant.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced & placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
476369|NCT00576823|Drug|Alfuzosin|"Dose: 0.2 mg/kg/day~Route: oral"
476370|NCT00576810|Drug|sodium picosulphate|
476371|NCT00576784|Drug|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
476372|NCT00576771|Procedure|PSV|Pressure Support Ventilation
476373|NCT00576771|Procedure|NAVA|Neurally Adjusted Ventilatory Assist
476374|NCT00576771|Procedure|patient-controlled|assisted controlled MV through a button
476375|NCT00576758|Drug|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
476376|NCT00576758|Drug|rituximab|375 mg/m^2 rituximab IV infusion once a week for 4 weeks.
476377|NCT00576745|Procedure|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
476378|NCT00576745|Device|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
476379|NCT00576732|Drug|Placebo|Oral solution qd or bid for 6 weeks
476380|NCT00576732|Drug|Risperidone high dose|Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
476381|NCT00576732|Drug|Risperidone low dose|Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
476382|NCT00576719|Behavioral|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
476383|NCT00576719|Behavioral|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
476384|NCT00576719|Other|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
476385|NCT00576706|Drug|Rebamipide|Rebamipide 100㎎, 12 weeks
476386|NCT00576706|Drug|Misoprostol|Misoprostol 200㎍ 12 weeks
476387|NCT00576693|Device|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
476388|NCT00576693|Other|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
476389|NCT00576680|Drug|RAD001|Given orally once a day
476390|NCT00576680|Drug|Temozolomide|Taken orally once a day for one week followed by a one-week break period
476391|NCT00576667|Drug|Rimonabant|Tablet, oral administration
476392|NCT00576667|Drug|Placebo (for Rimonabant)|Tablet, oral administration
476393|NCT00576654|Drug|Irinotecan Hydrochloride|Given IV
476394|NCT00576654|Other|Laboratory Biomarker Analysis|Correlative studies
476395|NCT00576654|Other|Pharmacological Study|Correlative studies
476396|NCT00576654|Drug|Veliparib|Given PO
476397|NCT00576641|Biological|autologous dendritic cells|
476398|NCT00576628|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
476399|NCT00576615|Drug|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
476400|NCT00576615|Drug|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
476401|NCT00576602|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
476402|NCT00576602|Drug|Supportive treatment|As prescribed
476403|NCT00576589|Drug|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
476404|NCT00576589|Drug|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
476405|NCT00576576|Drug|Atorvastatin|Atorvastatin 80 mg a day
476406|NCT00576563|Drug|FDG|contrast medium
476407|NCT00576550|Drug|Urea|Urea cream applied twice daily up to six months
476408|NCT00576550|Drug|betamethasone valerate|Application once daily for two weeks
476409|NCT00576550|Drug|betamethasone valerate|Application twice daily for two weeks
476410|NCT00576537|Biological|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
476411|NCT00576524|Device|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
476412|NCT00576524|Device|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
476413|NCT00576511|Drug|prucalopride|4 mg o.d.
476414|NCT00576511|Drug|placebo|Placebo o.d.
476415|NCT00576498|Other|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.~Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
476416|NCT00576498|Other|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
476417|NCT00576485|Procedure|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
476418|NCT00576472|Drug|Methylphenidate|Please see detailed description for dosing information and study design.
476419|NCT00576459|Drug|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
476420|NCT00576459|Drug|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
476421|NCT00576459|Procedure|standard of care laser photocoagulation|standard of care laser photocoagulation
476422|NCT00576446|Biological|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
476423|NCT00576433|Drug|Methotrexate|As prescribed
476424|NCT00576433|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
476425|NCT00576420|Biological|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
476426|NCT00576420|Biological|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
476427|NCT00576420|Procedure|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
476428|NCT00576407|Biological|Thymus Tissue for Transplantation|Thymus transplantation is done using allogeneic cultured postnatal tissue from unrelated donors. Thymus tissue, the donor, & donor's mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were transplanted into the recipient's quadriceps. Dose was number of grams of transplanted tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of transplantation, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-transplant, subjects followed by routine research immune evaluations, using blood samples for approximately 2 years.
476429|NCT00576394|Drug|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
476430|NCT00576394|Drug|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
476431|NCT00576381|Drug|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
476432|NCT00576368|Drug|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
476433|NCT00576355|Behavioral|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
476434|NCT00576355|Behavioral|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
476435|NCT00576342|Drug|AL-3862+timolol ophthalmic suspension|
476436|NCT00576342|Drug|Dorzolamide+timolol ophthalmic solution|
476437|NCT00576329|Drug|Ketorolac|Topical use before surgery
476438|NCT00576316|Drug|Symbicort Turbuhaler 160/4.5|
476439|NCT00576303|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
476440|NCT00576277|Drug|AV411|
476441|NCT00576251|Drug|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
476442|NCT00576251|Drug|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
476443|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
476444|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
476445|NCT00576238|Drug|urea|Topical application twice daily for up to 6 months
476446|NCT00576225|Drug|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
476447|NCT00576225|Drug|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
476448|NCT00576212|Behavioral|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
476449|NCT00576199|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
476450|NCT00576199|Procedure|Transarterial chemoembolisation (TACE)|"TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.~Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE."
476451|NCT00576173|Drug|tramadol hydrochloride; acetaminophen|
476452|NCT00576160|Behavioral|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
476453|NCT00576147|Device|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
476454|NCT00576134|Device|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
476455|NCT00576108|Drug|KD7040 Topical Gel|KD7040 topical gel
476456|NCT00576108|Drug|Placebo gel|Placebo gel
476457|NCT00576082|Other|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
476458|NCT00576069|Drug|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
476459|NCT00576069|Drug|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
476460|NCT00576069|Drug|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group"
476461|NCT00576069|Drug|Prednisone|0-15 mg daily as needed
476462|NCT00576056|Drug|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
476463|NCT00576056|Drug|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
476464|NCT00576043|Procedure|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
476465|NCT00576030|Other|hab cof with water|habitual coffee drinker provided with water
476466|NCT00576030|Other|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
476467|NCT00576030|Other|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
476468|NCT00576030|Other|non-hab cof with water|non-habitual coffee drinkers given water
476469|NCT00576030|Other|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
476470|NCT00576030|Other|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
476471|NCT00576017|Drug|Fentanyl-TTS|
476472|NCT00576004|Procedure|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
476473|NCT00575991|Dietary Supplement|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
476474|NCT00575978|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
476475|NCT00575965|Drug|Simvastatin|Oral tablets taken daily
476476|NCT00575952|Drug|Cisplatin|Given IV or IP
476477|NCT00575952|Drug|Doxorubicin Hydrochloride|Given IV
476478|NCT00575952|Biological|Filgrastim|Given SC
476479|NCT00575952|Drug|Paclitaxel|Given IV or IP
476480|NCT00575952|Biological|Pegfilgrastim|Given SC
476481|NCT00575926|Drug|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
476482|NCT00575913|Drug|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
476483|NCT00575900|Behavioral|dietary intervention|12 weeks of dietary intervention
476484|NCT00575887|Drug|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
476485|NCT00575874|Drug|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
476486|NCT00575874|Drug|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
476487|NCT00575874|Drug|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
476488|NCT00575874|Drug|pioglitazone HCl|30 mg capsules once daily for 12 weeks
476489|NCT00575874|Drug|placebo|matching tablets or capsule once daily for 12 weeks
476490|NCT00575861|Drug|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
476661|NCT00574496|Drug|prednisone|
476662|NCT00574496|Drug|procarbazine hydrochloride|
476491|NCT00575848|Dietary Supplement|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
476492|NCT00575848|Dietary Supplement|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
476493|NCT00575835|Dietary Supplement|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
476494|NCT00575835|Dietary Supplement|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
476495|NCT00575822|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
476496|NCT00575822|Device|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
476497|NCT00575809|Other|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
476498|NCT00575796|Drug|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
476499|NCT00575744|Procedure|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
476500|NCT00575731|Behavioral|Weight management strategies|
476501|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement Therapy. questionaires|"brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status."
476502|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
476503|NCT00575679|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
476504|NCT00575666|Drug|Insulin or Placebo|intranasal, 40IU, 4 times daily
476505|NCT00575640|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
476506|NCT00575627|Drug|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
476507|NCT00575614|Drug|prucalopride|1 mg o.d.
476508|NCT00575614|Drug|placebo|o.d.
476509|NCT00575601|Drug|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
476510|NCT00575588|Drug|Metformin|open-label metformin
476511|NCT00575588|Drug|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
476512|NCT00575588|Drug|Saxagliptin|Saxagliptin 5 mg tablets
476513|NCT00575575|Behavioral|cognitive behavior therapy|cognitive behavior therapy once a week
476514|NCT00575562|Drug|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
476515|NCT00575549|Other|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
476572|NCT00575120|Other|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
476516|NCT00575536|Procedure|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
476517|NCT00575523|Drug|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
476518|NCT00575523|Drug|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
476519|NCT00575510|Behavioral|Intervention|Multiple component intervention based in the unified theory of behavior
476520|NCT00575510|Behavioral|Active control|Partial intervention (full intervention minus cultural-specific component)
476521|NCT00575497|Procedure|More frequent hemodialysis|Six Day per week short daily hemodialysis
476522|NCT00575497|Procedure|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
476523|NCT00575497|Procedure|More frequent hemodialysis|Every other day short daily hemodialysis
476524|NCT00575497|Procedure|More frequent hemodialysis|Every other night hemodialysis
476525|NCT00575497|Procedure|More frequent hemodialysis|5 days per week short daily hemodialysis
476526|NCT00575497|Procedure|More frequent hemodialysis|5 nights per week hemodialysis
476527|NCT00575497|Procedure|Conventional Hemodialysis|3 days per week short daily hemodialysis
476528|NCT00575484|Drug|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium </=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
476529|NCT00575484|Drug|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
476530|NCT00575471|Drug|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
476531|NCT00575471|Drug|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
476532|NCT00575471|Drug|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
476533|NCT00575471|Drug|Placebo|Matching placebo tablets once daily for 12 weeks
476534|NCT00575432|Radiation|diffusion MRI|diffusion MRI
476535|NCT00575432|Radiation|BOLD MRI|BOLD MRI
476536|NCT00575432|Other|Clinical Outcome|Clinical outcome
476537|NCT00575419|Drug|N-acetylcysteine|"Dose Level 1: 150 mg/kg/day~Dose Level 2: 300 mg/kg/day~Dose Level 3: 600 mg/kg/day~Dose Level 4: 900 mg/kg/day~Dose Level 5: 1200 mg/kg/day"
476538|NCT00575406|Drug|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
476539|NCT00575406|Drug|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
476540|NCT00575406|Drug|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
476541|NCT00575406|Drug|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
476542|NCT00575406|Drug|Vincristin|i.v., 2mg, d1 of each treatment cycle
476543|NCT00575406|Drug|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
476544|NCT00575393|Drug|gold sodium thiomalate|
476545|NCT00575393|Genetic|gene expression analysis|
476546|NCT00575393|Other|fluorine F 18 fluorothymidine|
476547|NCT00575393|Other|mass spectrometry|
476548|NCT00575393|Other|pharmacological study|
476549|NCT00575380|Drug|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
476550|NCT00575380|Drug|Vigamox Eye Drops|One drop three times a day for seven days
476551|NCT00575367|Drug|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
476552|NCT00575367|Drug|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
476553|NCT00575354|Drug|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
476554|NCT00575354|Drug|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
476555|NCT00575341|Drug|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
476556|NCT00575341|Drug|placebo|placebo, oral, once daily
476557|NCT00575328|Drug|Maca Root|3g/day of Maca Root for 12 weeks
476558|NCT00575328|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks
476559|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
476560|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
476561|NCT00575250|Behavioral|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
476562|NCT00575250|Behavioral|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
476563|NCT00575237|Procedure|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
476564|NCT00575224|Drug|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
476565|NCT00575198|Other|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
476566|NCT00575198|Other|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
476567|NCT00575185|Drug|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
476568|NCT00575185|Drug|placebo|Placebo tablets orally twice daily for 21 days.
476569|NCT00575159|Drug|GSK189075|investigational drug
476570|NCT00575159|Drug|placebo|placebo comparator
476571|NCT00575146|Dietary Supplement|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
489335|NCT00482248|Drug|Omalizumab|
476573|NCT00575107|Other|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
476574|NCT00575107|Other|Exercise|Standard training of leg extension
476575|NCT00575094|Drug|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
476576|NCT00575081|Device|Stereotactic brain procedures|Stereotactic brain procedures
476577|NCT00575068|Drug|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A & II-B - Dosage start at the MTD (up to 375 mg/m2)
476578|NCT00575055|Drug|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
476579|NCT00575055|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
476580|NCT00575055|Drug|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
476581|NCT00575042|Drug|Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)|160 mg per day for 1 year
476582|NCT00575029|Drug|megestrol acetate|600 mg by mouth daily
476583|NCT00575016|Biological|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U > Week 12; injection into the detrusor
476584|NCT00575016|Biological|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
476585|NCT00575016|Biological|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
476586|NCT00575016|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
476587|NCT00575003|Drug|CYT003-QbG10|6 subcutaneous injections
476588|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
476589|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.~Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
476590|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.~Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
476591|NCT00574964|Other|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
476592|NCT00574951|Drug|motesanib diphosphate|
476593|NCT00574925|Drug|Esomeprazole|
476594|NCT00574912|Drug|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
476595|NCT00574912|Drug|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
476596|NCT00574912|Drug|Insulin Glargine 1.0 u/kg body wt SC|
476597|NCT00574912|Drug|Insulin Glargine 1.5 u/kg body wt SC|
476598|NCT00574912|Drug|Insulin Glargine 2.0 u/kg body wt SC|
476599|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
476600|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.~Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
476601|NCT00574886|Biological|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
476602|NCT00574873|Drug|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
476603|NCT00574873|Drug|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
476604|NCT00574860|Drug|EN3285|Oral rinse
476605|NCT00574860|Drug|Placebo|Oral rinse
476606|NCT00574860|Other|Standard of care|This will be the therapy most commonly used the the institution treating the patient
476607|NCT00574847|Drug|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
476608|NCT00574847|Drug|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
476609|NCT00574834|Drug|Ramipril|Ramipril 20 mg once daily for 6 months
476610|NCT00574834|Drug|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
476611|NCT00574834|Drug|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
476651|NCT00574509|Radiation|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
476652|NCT00574496|Drug|cyclophosphamide|
476653|NCT00574496|Drug|cyclosporine|
476612|NCT00574808|Other|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
476613|NCT00574795|Biological|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
476614|NCT00574769|Drug|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m^2 every 21 days"
476615|NCT00574756|Drug|ranolazine|extended release 500 mg twice a day for two weeks
476616|NCT00574743|Drug|Enteric-coated Mycophenolate Sodium|
476617|NCT00574730|Drug|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.~Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
476618|NCT00574730|Drug|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
476619|NCT00574717|Procedure|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
476620|NCT00574704|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
476621|NCT00574704|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
476622|NCT00574704|Drug|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
476623|NCT00574704|Drug|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
476624|NCT00574691|Device|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
476625|NCT00574678|Other|Tear collection|"A tear sample (~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
476626|NCT00574665|Other|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
476627|NCT00574652|Drug|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
476628|NCT00574639|Drug|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
476629|NCT00574639|Drug|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
476630|NCT00574626|Procedure|PBSCT|Peripheral Blood Stem Cell Transplant
476631|NCT00574626|Procedure|Bone Marrow Transplant|Bone Marrow Transplant
476632|NCT00574613|Drug|P144|Cream 0,3 ml once a day (3 months)
476633|NCT00574613|Drug|placebo|Cream 0,3 ml once a day (3 months)
476634|NCT00574600|Biological|SAAVI DNA-C2 vaccine|DNA vaccine
476635|NCT00574600|Biological|SAAVI MVA-C vaccine|Boost vaccine
476636|NCT00574600|Biological|Placebo|Placebo vaccine
476637|NCT00574587|Drug|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
476638|NCT00574587|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
476639|NCT00574587|Drug|Trastuzumab|Part A: Trastuzumab 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
476640|NCT00574587|Drug|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
476641|NCT00574587|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
476642|NCT00574587|Procedure|Mastectomy or Lumpectomy|Surgical excision of tumor from breast
476643|NCT00574587|Drug|Post surgery therapy (Trastuzumab)|Part D: After Surgical intervention Post Protocol Therapy- Trastuzumab 8 mg/kg as a loading dose, then 6 mg/kg every 3 weeks for a total of 14 doses
476644|NCT00574574|Dietary Supplement|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
476645|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
476646|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
476647|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
476648|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
476649|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
476650|NCT00574522|Radiation|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
476654|NCT00574496|Drug|fludarabine phosphate|
476655|NCT00574496|Drug|gemcitabine hydrochloride|
476663|NCT00574496|Drug|vincristine sulfate|
476664|NCT00574496|Drug|vinorelbine tartrate|
476665|NCT00574496|Procedure|allogeneic bone marrow transplantation|
476666|NCT00574496|Procedure|allogeneic hematopoietic stem cell transplantation|
476667|NCT00574496|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
476668|NCT00574496|Procedure|peripheral blood stem cell transplantation|
476669|NCT00574496|Procedure|umbilical cord blood transplantation|
476670|NCT00574496|Radiation|total-body irradiation|
476671|NCT00574483|Drug|quinacrine|100 mg day
476672|NCT00574470|Drug|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
476673|NCT00574457|Other|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
476674|NCT00574444|Procedure|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
476675|NCT00574431|Other|Data Collection|Collection of patient data before implementation of a nutritional management protocol
476676|NCT00574431|Other|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
476677|NCT00574418|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
476678|NCT00574405|Drug|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
476679|NCT00574405|Device|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
476680|NCT00574392|Device|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
476681|NCT00574379|Drug|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
476682|NCT00574379|Drug|Placebo|Placebo tablets twice daily for 14 days
476683|NCT00574366|Drug|erlotinib|"Levels:~1 Erlotinib 50 mg/d~2 Erlotinib 50 mg/d~1 Erlotinib 100 mg/d~2 Erlotinib 100 mg/d~3 Erlotinib 150 mg/d~4 Erlotinib 150 mg/d"
476684|NCT00574366|Drug|RAD001|"Levels~minus 1: RAD001 2.5 mg/d~minus 2: RAD001 2.5 every other day~RAD001 2.5 mg per day~RAD001 5 mg per day~RAD001 10 mg per day~RAD001 10 mg per day"
476685|NCT00574353|Radiation|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
476686|NCT00574340|Other|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
476687|NCT00574314|Other|No Intervention|Participants will be consented.
476688|NCT00574301|Procedure|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
476689|NCT00574288|Drug|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
476690|NCT00574288|Drug|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
476691|NCT00574288|Other|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
476692|NCT00574288|Other|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
476693|NCT00574275|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
476694|NCT00574275|Drug|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
476695|NCT00574275|Drug|Gemcitabine|1000 mg/m^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
476696|NCT00574249|Biological|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
476697|NCT00574249|Drug|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
476698|NCT00574249|Drug|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
476699|NCT00574236|Drug|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
476700|NCT00574223|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
476701|NCT00574223|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
476702|NCT00574210|Drug|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
476703|NCT00574210|Drug|Placebo|Placebo Tablets administered twice per day
476704|NCT00574197|Drug|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
476705|NCT00574171|Drug|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
476706|NCT00574171|Drug|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
476707|NCT00574145|Procedure|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
476708|NCT00574145|Procedure|fatigue assessment and management|duration
476709|NCT00574145|Procedure|psychosocial assessment and care|duration
476710|NCT00574145|Procedure|quality-of-life assessment|duration
476711|NCT00574145|Procedure|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
476712|NCT00574132|Drug|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
476713|NCT00574132|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
476714|NCT00574132|Drug|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
476715|NCT00574119|Drug|spironolactone|spironolactone 50 mg daily for 6 months
476716|NCT00574106|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
476717|NCT00574093|Drug|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
476718|NCT00574080|Drug|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
476719|NCT00574080|Drug|Induction/Consolidation Dexamethasone|40 mg Days 1-4
476720|NCT00574080|Drug|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
476721|NCT00574080|Drug|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
476722|NCT00574080|Drug|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
476723|NCT00574080|Drug|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
476724|NCT00574080|Drug|Induction Pegfilgrastim|6 mg Days 6 and 13
476725|NCT00574080|Drug|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
476726|NCT00574080|Drug|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
476727|NCT00574080|Drug|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
476728|NCT00574080|Drug|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
476729|NCT00574080|Drug|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
476730|NCT00574080|Drug|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
476731|NCT00574080|Drug|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
476732|NCT00574080|Procedure|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
476733|NCT00574080|Drug|Transplant 2 Carmustine|300 mg/m2 Day -5
476734|NCT00574080|Drug|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
476735|NCT00574080|Drug|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
476736|NCT00574080|Drug|Transplant 2 Melphalan|140 mg/m2 Day -1
476737|NCT00574080|Drug|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
476738|NCT00574080|Drug|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
476739|NCT00574080|Drug|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
476740|NCT00574067|Drug|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
476741|NCT00574067|Drug|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
476742|NCT00574067|Drug|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
476799|NCT00573599|Drug|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
476800|NCT00573586|Device|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
476743|NCT00574067|Drug|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
476744|NCT00574054|Radiation|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
476745|NCT00574041|Drug|Interferon beta-1a|injected, once a week
476746|NCT00574015|Drug|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
476747|NCT00574015|Drug|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
476748|NCT00573989|Drug|erlotinib hydrochloride|
476749|NCT00573989|Drug|pemetrexed disodium|
476750|NCT00573989|Procedure|quality-of-life assessment|
476751|NCT00573989|Radiation|intensity-modulated radiation therapy|
476752|NCT00573963|Drug|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
476753|NCT00573963|Drug|saline solution|2 injections of 20mL plain saline solution - one on each side.
476754|NCT00573950|Drug|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
476755|NCT00573950|Drug|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
476756|NCT00573937|Drug|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
476757|NCT00573937|Drug|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
476758|NCT00573924|Drug|Proton pump inhibitor (lansoprazole)|"120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
476759|NCT00573911|Procedure|Endoscopy and pH study|endoscopy and PH study done one time
476760|NCT00573885|Drug|defined green tea catechin extract|Given orally
476761|NCT00573885|Other|placebo|Given orally
476762|NCT00573872|Radiation|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions~Phase II: 9-24 GY in 1 fraction"
476763|NCT00573859|Drug|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
476764|NCT00573859|Drug|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
476765|NCT00573833|Other|questionnaire administration|
476766|NCT00573833|Procedure|quality-of-life assessment|
476767|NCT00573833|Radiation|brachytherapy|
476768|NCT00573820|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
476769|NCT00573807|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
476770|NCT00573794|Biological|adalimumab|adalimumab prefilled syringes administered as subcutaneous injection EW or EOW
476771|NCT00573781|Dietary Supplement|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
476772|NCT00573781|Dietary Supplement|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
476773|NCT00573781|Dietary Supplement|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
476774|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
476775|NCT00573768|Drug|Placebo|Vehicle 2 times daily
476776|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
476777|NCT00573755|Drug|anastrozole|given orally
476778|NCT00573755|Drug|exemestane|given orally
476779|NCT00573755|Drug|letrozole|given orally
476780|NCT00573755|Drug|sorafenib tosylate|given orally
476781|NCT00573755|Other|placebo|given orally
476782|NCT00573742|Drug|Candesartan Cilexeotil 16mg|
476783|NCT00573729|Other|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
476784|NCT00573729|Other|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
476785|NCT00573703|Procedure|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
476786|NCT00573703|Procedure|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
476787|NCT00573690|Drug|carboplatin|Given IV
476788|NCT00573690|Drug|cisplatin|Given IV
476789|NCT00573690|Drug|etoposide|Given IV
476790|NCT00573690|Drug|pemetrexed disodium|Given IV
476791|NCT00573690|Drug|sorafenib tosylate|Given orally
476792|NCT00573664|Drug|Gabapentin|single oral dose of 600mg gabapentin
476793|NCT00573664|Other|lactose|Single dose
476794|NCT00573651|Other|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
476795|NCT00573638|Device|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
476796|NCT00573612|Behavioral|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
476797|NCT00573612|Behavioral|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
476798|NCT00573599|Drug|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
476801|NCT00573573|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
476802|NCT00573560|Device|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
476803|NCT00573547|Drug|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
476804|NCT00573534|Drug|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
476805|NCT00573508|Drug|Placebo|Oral Administration
476806|NCT00573508|Drug|Solifenacin Succinate|Oral Administration
476807|NCT00573495|Biological|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
476808|NCT00573482|Behavioral|REDE|"The intervention group received the education in REDE techniques.~The intervention in this study comprised four components:~Four group education sessions to introduce the REDE principles of eating;~Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;~Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.~Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
476809|NCT00573482|Behavioral|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
476810|NCT00573469|Drug|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
476811|NCT00573469|Drug|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
476812|NCT00573469|Drug|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
476813|NCT00573456|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
476814|NCT00573443|Drug|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
476815|NCT00573443|Drug|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
476816|NCT00573443|Drug|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
476817|NCT00573430|Drug|Candesartan Cilexetil|8 mg oral once daily dose
476818|NCT00573430|Drug|Candesartan Cilexetil|16 mg oral once daily dose
476819|NCT00573430|Drug|Candesartan Cilexetil 32mg|32 mg oral once daily dose
476820|NCT00573417|Drug|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
476821|NCT00573417|Drug|Placebo|
476822|NCT00573404|Drug|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
476823|NCT00573404|Drug|sunitinib malate|Not specified
476824|NCT00573404|Other|pharmacological study|Not specified
476825|NCT00573391|Drug|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles~Thalidomide - By Mouth Days 1-28~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
476826|NCT00573391|Drug|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11~Yr 1: Every 28-35 days-12 cycles~Yr 2: Every 8-10 weeks- 6 cycles"
476827|NCT00573378|Drug|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
476828|NCT00573365|Device|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
476829|NCT00573365|Radiation|Radiation|Weekly radiation treatment
476830|NCT00573365|Radiation|Radiation|Weekly radiation treatment
476831|NCT00573352|Radiation|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
476832|NCT00573339|Other|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
476833|NCT00573326|Drug|Imatinib|200 mg p.o. once a day for 6 months
476834|NCT00573313|Drug|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
476835|NCT00573313|Drug|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
476836|NCT00573300|Procedure|Phlebotomy|Single blood draw
476837|NCT00573287|Drug|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
476838|NCT00573287|Drug|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
476839|NCT00573274|Device|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
476840|NCT00573261|Drug|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
476841|NCT00573261|Drug|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
476842|NCT00573248|Drug|Nicotine|"21 mg nicotine patches for smokers for 2 days~7 mg nicotine patches for nonsmokers for 2 days"
476843|NCT00573248|Other|Placebo|Placebo Patch
476845|NCT00573209|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
476846|NCT00573196|Radiation|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
476847|NCT00573183|Behavioral|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
476848|NCT00573183|Behavioral|Treatment as Usual|
476849|NCT00573170|Drug|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)
476850|NCT00573170|Drug|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]
476851|NCT00573170|Drug|placebo|placebo
476852|NCT00573157|Drug|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
476853|NCT00573157|Drug|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
476854|NCT00573157|Drug|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
476855|NCT00573157|Drug|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
476856|NCT00573144|Drug|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
476857|NCT00573144|Drug|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
476858|NCT00573131|Drug|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
476859|NCT00573131|Drug|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
476860|NCT00573131|Drug|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
476861|NCT00573131|Radiation|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
476862|NCT00573131|Procedure|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
476863|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
476864|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
476865|NCT00573066|Drug|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
476866|NCT00573053|Other|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
476867|NCT00573053|Other|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
476868|NCT00573027|Procedure|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
476869|NCT00573014|Other|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
476870|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
476871|NCT00573001|Drug|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
476872|NCT00573001|Drug|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
476873|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
476874|NCT00572975|Other|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.~in breakfast shake x1"
476875|NCT00572962|Procedure|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
476876|NCT00572936|Drug|Latanoprost|prostaglandin
476877|NCT00572936|Drug|Dorzolamide|carbonic anhydrase inhibitor
476878|NCT00572936|Drug|Timolol|beta blocker
476879|NCT00572910|Biological|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
476880|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA~Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
476881|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA~Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
476882|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA~Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
476883|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA~Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
489336|NCT00482235|Drug|MK0359|
476884|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA~Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
476885|NCT00572897|Drug|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:~Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)~Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 [given over 6 hours], and 2 mg/kg on days -2 and -1 [given over 4 hours])"
476886|NCT00572884|Other|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
476887|NCT00572871|Other|plyometric exercise|single bout of plyometric exercise
476888|NCT00572871|Other|resistance exercise|single bout of resistance exercise
476889|NCT00572871|Other|No exercise|Will not do any exercise
476890|NCT00572858|Procedure|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
476891|NCT00572858|Genetic|Blood test|Blood test for genetic testing
476892|NCT00572858|Procedure|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
476893|NCT00572858|Procedure|Saliva test|Saliva test for cotisol levels
476894|NCT00572845|Other|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
476895|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
476896|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
476897|NCT00572819|Drug|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
476898|NCT00572819|Drug|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
476899|NCT00572806|Drug|insulin aspart|
476900|NCT00572767|Drug|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
476901|NCT00572767|Other|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.~The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
476902|NCT00572754|Procedure|Circumcision|Circumcision by tying a ligature around the foreskin.
476903|NCT00572741|Dietary Supplement|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
476904|NCT00572741|Dietary Supplement|Placebo|cellulose
476905|NCT00572741|Dietary Supplement|folate|Folinic acid: Dose: 400 µg twice a day (BID)
476906|NCT00572741|Dietary Supplement|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
476907|NCT00572741|Dietary Supplement|vitamin C|Vitamin C 500 mg
476908|NCT00572741|Dietary Supplement|cod liver oil|Cod liver oil 1/2 teaspoon
476909|NCT00572741|Dietary Supplement|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
476910|NCT00572741|Dietary Supplement|carnitine|Acetyl L-Carnitine Dose: 250 mg
476911|NCT00572728|Procedure|CT|Undergo 18F-FLT PET/CT
476912|NCT00572728|Drug|18F-FLT|Undergo 18F-FLT PET/CT
476913|NCT00572728|Procedure|PET|Undergo 18F-FLT PET/CT
476914|NCT00572702|Procedure|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
476915|NCT00572702|Procedure|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
476916|NCT00572689|Drug|Exenatide|10 microgram injected sub-cutaneously once
476917|NCT00572689|Genetic|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
476918|NCT00572663|Drug|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
476919|NCT00572650|Drug|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
476920|NCT00572637|Drug|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
476921|NCT00572624|Behavioral|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
476922|NCT00572624|Procedure|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
476923|NCT00572611|Drug|[14C]-bilastine|Single oral dose of 20 mg [14C]-bilastine. 1 capsule. 1 day dosing only
476924|NCT00572598|Drug|4- [F-18] fluoropaclitaxel|4- [F-18] fluoropaclitaxel, <84 micrograms, <10 mCi, IV followed by PET/CT imaging
476927|NCT00572572|Drug|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
476928|NCT00572572|Drug|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
476929|NCT00572559|Drug|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
476930|NCT00572559|Drug|Linezolid|600 mg every 12 hours (intravenously [IV] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
476931|NCT00572533|Other|ESA Dose Adjustment per standard Anemia Management Protocol|Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
476932|NCT00572533|Other|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"|"Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm"
476933|NCT00572520|Behavioral|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
476934|NCT00572520|Behavioral|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
476935|NCT00572520|Behavioral|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
476936|NCT00572507|Device|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
476937|NCT00572494|Device|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
476938|NCT00572494|Device|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
476939|NCT00572481|Procedure|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
476940|NCT00572468|Drug|Simvastatin|40 mg of simvastatin
476941|NCT00572468|Other|Placebo|placebo
476942|NCT00572455|Drug|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
476943|NCT00572455|Drug|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
476944|NCT00572455|Drug|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
476945|NCT00572455|Drug|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
476946|NCT00572455|Drug|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
476947|NCT00572455|Drug|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
476948|NCT00572455|Drug|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
476949|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
476950|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
476951|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
476952|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
476953|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
476954|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
476955|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
476956|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
476957|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
476958|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
476959|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
476960|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
476961|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
476962|NCT00572455|Drug|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
476963|NCT00572429|Dietary Supplement|l-carnitine|3 gram daily dose
476964|NCT00572416|Behavioral|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
476965|NCT00572416|Behavioral|Healthy Eating Control|Equal time and attention and information about healthy eating
489337|NCT00482222|Biological|cetuximab|
476966|NCT00572390|Drug|oestrogen|Cyclic oestrogen substitution therapy
476967|NCT00572377|Drug|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
476968|NCT00572377|Drug|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
476969|NCT00572364|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
476970|NCT00572351|Other|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
476971|NCT00572351|Other|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
476972|NCT00572338|Other|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
476973|NCT00572312|Drug|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
476974|NCT00572299|Drug|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
476975|NCT00572260|Drug|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
476976|NCT00572247|Behavioral|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
476977|NCT00572234|Drug|bupropion SR|12 week course of bupropion SR 150 mg, BID
476978|NCT00572221|Behavioral|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
476979|NCT00572221|Behavioral|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
476980|NCT00572208|Drug|Gabapentin group|"Gabapentin group:~Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)~st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)~th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
476981|NCT00572195|Device|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. Patients with epilepsy treated with responsive direct-brain stimulation with the RNS System typically receive less than 6 minutes of stimulation a day.
476982|NCT00572182|Drug|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
476983|NCT00572169|Drug|Velcade|Will be given in central venous catheter
476984|NCT00572169|Drug|Thalidomide|Capsule taken by mouth
476985|NCT00572169|Drug|Dexamethasone|A pill taken by mouth
476986|NCT00572169|Drug|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
476987|NCT00572169|Drug|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
476988|NCT00572169|Drug|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
476989|NCT00572169|Drug|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
476990|NCT00572156|Drug|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
476991|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
476992|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
476993|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
476994|NCT00572143|Other|ca coli follow-up by GP|patients randomized to follow up by GP
476995|NCT00572130|Genetic|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
476996|NCT00572130|Genetic|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
476997|NCT00572117|Drug|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
476998|NCT00572104|Other|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
476999|NCT00572104|Other|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
477033|NCT00571883|Procedure|therapeutic conventional surgery|
489338|NCT00482222|Drug|capecitabine|
477000|NCT00572091|Device|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
477001|NCT00572078|Drug|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
477002|NCT00572065|Drug|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
477003|NCT00572065|Drug|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
477004|NCT00572052|Device|NovoFine® needle 6 mm|
477005|NCT00572052|Device|Ultra-Fine needle 12.7 mm|
477006|NCT00572039|Behavioral|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
477007|NCT00572039|Behavioral|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
477008|NCT00572026|Drug|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
477009|NCT00572013|Drug|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
477010|NCT00572013|Drug|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
477011|NCT00572013|Procedure|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
477012|NCT00572000|Biological|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
477013|NCT00571987|Device|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
477014|NCT00571974|Device|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
477015|NCT00571974|Drug|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
477016|NCT00571974|Procedure|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
477017|NCT00571961|Drug|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
477018|NCT00571961|Drug|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
477019|NCT00571961|Other|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
477020|NCT00571948|Other|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.~The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
477021|NCT00571948|Other|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
477022|NCT00571935|Drug|insulin aspart|
477023|NCT00571935|Drug|soluble human insulin|
477024|NCT00571922|Drug|Acamprosate|2 gr/day (333 mg, TID)
477025|NCT00571922|Drug|placebo|matching placebo
477026|NCT00571909|Procedure|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
477027|NCT00571896|Drug|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
477028|NCT00571896|Drug|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
477029|NCT00571883|Other|questionnaire administration|
477030|NCT00571883|Procedure|psychosocial assessment and care|
477031|NCT00571883|Procedure|quality-of-life assessment|
477032|NCT00571883|Procedure|regional lymph node dissection|
477034|NCT00571870|Drug|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
477035|NCT00571844|Behavioral|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
477036|NCT00571844|Behavioral|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
477037|NCT00571831|Procedure|intraocular lens implantation|Intraocular lens implantation
477038|NCT00571818|Procedure|Oral glucose tolerance test|test done over 2 hours
477039|NCT00571818|Procedure|IV Glucose Tolerance Test|Done over 4 hours
477040|NCT00571805|Drug|varencline|2.0 mg/day varencline (1.0 mg BID)
477041|NCT00571805|Drug|placebo|matching placebo
477042|NCT00571779|Device|AtriCure Bipolar System|
477043|NCT00571766|Drug|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
477044|NCT00571766|Drug|Placebo|Placebo 2 g twice a day for 14 weeks
477045|NCT00571753|Drug|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
477046|NCT00571753|Drug|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
477047|NCT00571740|Biological|bevacizumab|Given IV
477048|NCT00571740|Biological|cetuximab|Given IV
477049|NCT00571740|Drug|fluorouracil|Given IV
477050|NCT00571740|Drug|leucovorin calcium|Given IV
477051|NCT00571740|Drug|oxaliplatin|Given IV
477052|NCT00571727|Drug|mecasermin|injections BID of rhIGF-1, mecasermin
477053|NCT00571714|Drug|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
477054|NCT00571714|Drug|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
477055|NCT00571701|Drug|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight >25 kg
477056|NCT00571701|Drug|placebo|similar appearing capsules containing inert ingredients
477057|NCT00571688|Drug|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score > 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
477058|NCT00571688|Drug|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
477059|NCT00571675|Drug|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
477060|NCT00571675|Drug|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
477061|NCT00571662|Drug|Pentostatin|4 mg/m^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
477062|NCT00571662|Radiation|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
477063|NCT00571662|Drug|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
477064|NCT00571662|Drug|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
477065|NCT00571662|Drug|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
477066|NCT00571649|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
477067|NCT00571649|Drug|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
477068|NCT00571649|Drug|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
477069|NCT00571649|Drug|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
477070|NCT00571636|Drug|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is > 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
477071|NCT00571636|Drug|5% glucose solution|ev continuous infusion
477072|NCT00571623|Other|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
477073|NCT00571610|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
477074|NCT00571584|Drug|activated recombinant human factor VII|
477075|NCT00571571|Behavioral|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
477076|NCT00571571|Behavioral|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
477077|NCT00571558|Drug|aminolevulinic acid hydrochloride|Given PO
477078|NCT00571558|Drug|photodynamic therapy|Undergo photodynamic therapy
477079|NCT00571558|Other|laboratory biomarker analysis|Correlative studies
477080|NCT00571545|Behavioral|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
477081|NCT00571545|Behavioral|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
477082|NCT00571519|Drug|Rivoglitazone HCl|0.5 mg tablets
477083|NCT00571519|Drug|rivoglitazone HCl|1.0 mg tablets
477084|NCT00571519|Drug|rivoglitazone HCl|1.5 mg tablets
477085|NCT00571519|Drug|placebo|placebo tablets matching rivoglitazone tablets
477086|NCT00571519|Drug|pioglitazone HCl|15 mg tablets
477087|NCT00571519|Drug|pioglitazone HCl|30 mg tablets
477088|NCT00571519|Drug|pioglitazone HCl 45 mg|45 mg tablets
477089|NCT00571519|Drug|placebo|placebo capsules for pioglitazone
477090|NCT00571519|Drug|metformin|Oral tablets. Rescue medication.
477091|NCT00571506|Drug|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
477092|NCT00571506|Drug|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
477093|NCT00571493|Drug|Bortezomib|Patients will receive bortezomib in four dose cohorts ( .8. 1.0, 1.3, 1.5 mg/m²). Patients will receive bortezomib on days -11, -8, -5, and -2 before infusion of autologous stem cells.
477094|NCT00571493|Drug|BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)|"All study patients will receive BEAM per the standard institution protocol:~BCNU (carmustine): 300 mg/m²on day -5 etoposide 100 mg/m² twice daily on days -5, -4, -3, and -2 cytarabine 100 mg/m² twice daily on days -5, -4, -3, -2 melphalan: 140 mg/m² on day -1 before infusion of autologous stem cells."
477095|NCT00571480|Other|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
477096|NCT00571480|Other|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
477097|NCT00571480|Other|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
477098|NCT00571467|Drug|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:~Cohort 1: 0.075 mcg/kg~Cohort 2: 0.15 mcg/kg~Cohort 3: 0.30 mcg/kg"
477099|NCT00571454|Behavioral|telephone depression care management|"1 call per week for first 4 weeks~1 call every other week for next 8 weeks"
477100|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
477101|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
477102|NCT00571428|Drug|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
477103|NCT00571402|Behavioral|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
477104|NCT00571402|Behavioral|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
477105|NCT00571376|Other|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
477106|NCT00571363|Procedure|standard surgery|excision with 4 mm margins
477107|NCT00571363|Procedure|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
477108|NCT00571350|Procedure|tvt-o operation|transvaginal tention free obturator tape
477109|NCT00571350|Procedure|tvt o operation|transobturator vaginal tape insertion
477110|NCT00571337|Drug|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
477111|NCT00571324|Drug|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
477112|NCT00571324|Other|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
477113|NCT00571298|Procedure|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
477114|NCT00571298|Drug|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
477115|NCT00571298|Drug|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
477116|NCT00571298|Drug|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
477117|NCT00571298|Drug|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
477118|NCT00571298|Procedure|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
477119|NCT00571285|Dietary Supplement|Vitamin D3|600 IU Vitamin D3 capsule daily
477120|NCT00571285|Dietary Supplement|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
477121|NCT00571285|Dietary Supplement|Placebo|Placebo capsule given once a week
477122|NCT00571259|Drug|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
477123|NCT00571259|Drug|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
477124|NCT00571246|Drug|lamotrigine and topiramate|lamotrigine (250 mg/day) 2 times a day, topiramate (250mg/day) 2 times a day, placebo
477125|NCT00571220|Procedure|gastric bypass surgery|weight loss bariatric surgery
477126|NCT00571220|Other|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
477127|NCT00571207|Device|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
477128|NCT00571207|Behavioral|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
477129|NCT00571194|Drug|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study"
477130|NCT00571181|Device|Closed-loop system|Automatic delivery of propofol and remifentanil
477131|NCT00571181|Device|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
477132|NCT00571168|Drug|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
477133|NCT00571168|Drug|Placebo|Placebo capsules on day 1-4
477134|NCT00571155|Drug|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
477135|NCT00571142|Procedure|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
477136|NCT00571142|Procedure|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
477137|NCT00571129|Procedure|DCR|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.~In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
477138|NCT00571116|Drug|Disulfiram|Given PO
477139|NCT00571116|Drug|Arsenic trioxide|Given IV
477140|NCT00571103|Drug|acamprosate|Two 333mg tablets taken three times daily.
477141|NCT00571090|Procedure|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
477142|NCT00571077|Device|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
477143|NCT00571064|Drug|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
477144|NCT00571051|Behavioral|Mindfulness Based Stress Reduction|8 week course in mindfulness training
477145|NCT00571038|Behavioral|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
477146|NCT00571038|Behavioral|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
477147|NCT00571025|Behavioral|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
477148|NCT00570999|Drug|Palifermin|60 mg/kg/day
477149|NCT00570999|Other|Placebo|1,2 mL once daily
477150|NCT00570986|Drug|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
477151|NCT00570986|Biological|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
477152|NCT00570986|Biological|ABT-874|100mg every 12 weeks.
477153|NCT00570973|Procedure|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
477154|NCT00570973|Procedure|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
477155|NCT00570960|Drug|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
477156|NCT00570960|Biological|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
477157|NCT00570947|Other|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
477158|NCT00570934|Dietary Supplement|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
477159|NCT00570934|Dietary Supplement|Calcium|1 gm calcium as calcium carbonate
477160|NCT00570934|Dietary Supplement|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
477161|NCT00570934|Drug|Placebo|Placebo
477162|NCT00570921|Drug|Everolimus|Everolimus tablets, two-5 mg tablets a day
477163|NCT00570921|Drug|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
477164|NCT00570908|Drug|sunitinib|Sutent
477165|NCT00570908|Drug|capecitabine|concurrently
477166|NCT00570908|Radiation|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
477167|NCT00570895|Dietary Supplement|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.~Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.~Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
477168|NCT00570882|Drug|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
477169|NCT00570882|Drug|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
477170|NCT00570869|Other|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
477171|NCT00570856|Drug|Folic acid|Folic acid 5 mg/day
477172|NCT00570856|Drug|Placebo|Placebo similar to the folic acid tablets, 1/day
477173|NCT00570843|Drug|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
477174|NCT00570843|Drug|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
477175|NCT00570830|Device|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
477176|NCT00570817|Other|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
477177|NCT00570804|Behavioral|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
477178|NCT00570804|Behavioral|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
477179|NCT00570791|Device|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
477180|NCT00570778|Drug|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
477181|NCT00570778|Drug|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
477182|NCT00570778|Drug|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
477183|NCT00570765|Drug|Placebo|Placebo
477184|NCT00570765|Drug|INT-747|10 mg po qd
477185|NCT00570765|Drug|INT-747|50 mg po qd
477186|NCT00570752|Other|Placebo|
477187|NCT00570752|Drug|BMS-582949|
477188|NCT00570752|Drug|Atorvastatin|
477189|NCT00570752|Drug|Statin|
477190|NCT00570739|Drug|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
477191|NCT00570739|Drug|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
477192|NCT00570739|Drug|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
477193|NCT00570739|Drug|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
477194|NCT00570726|Drug|Ranibizumab (Lucentis)|
477195|NCT00570713|Drug|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
477196|NCT00570713|Drug|Placebo|As per package insert.
477197|NCT00570713|Drug|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
477198|NCT00570700|Drug|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
477199|NCT00570687|Drug|Technosphere Insulin|Inhalation 15U/30U
477200|NCT00570674|Drug|Abraxane|
477201|NCT00570674|Drug|Erbitux|
477202|NCT00570674|Drug|Carboplatin|
477203|NCT00570674|Radiation|Intensity Modulated Radiation Therapy|
477204|NCT00570661|Drug|ITF2357|ITF2357 will be supplied as hard gelatine capsule for oral administration at the dose strengths of 7.5, 10, 12.5, 15, 20 and 50 mg, identifiable by different colours. The dose of 1.5 mg/kg/day will be achieved by administration, at 12-hour interval, of an appropriate number of capsules of definite strength(s) as specified here below
477205|NCT00570648|Drug|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
477206|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
477207|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
477208|NCT00570622|Drug|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
477209|NCT00570622|Drug|Placebo|Patients receive placebo once a day orally for 9 days
477210|NCT00570609|Other|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
477211|NCT00570570|Procedure|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
477212|NCT00570570|Other|conventional physiotherapy|trice a week during 6 weeks
477213|NCT00570557|Other|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
477214|NCT00570544|Drug|tiotropium|18ug capsule daily for 30 days
477215|NCT00570531|Drug|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
477216|NCT00570531|Drug|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
477217|NCT00570531|Drug|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
477218|NCT00570531|Drug|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
477219|NCT00570531|Radiation|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
477220|NCT00570531|Procedure|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
477221|NCT00570505|Device|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
477222|NCT00570492|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
477223|NCT00570492|Drug|Placebo nasal spray|Placebo nasal spray
477224|NCT00570479|Drug|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
477225|NCT00570466|Behavioral|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
477226|NCT00570466|Behavioral|Web and DVD knowledge|Web and DVD based knowledge games
477227|NCT00570440|Drug|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
477228|NCT00570427|Behavioral|Problem Solving Therapy (PST)|Counseling
477229|NCT00570427|Behavioral|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
477230|NCT00570414|Device|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
477231|NCT00570414|Device|Endotracheal tube|Airway management by the use of endotracheal tube
477232|NCT00570401|Drug|dasatinib|
477233|NCT00570388|Drug|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
477234|NCT00570375|Drug|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
477235|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
477236|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
477237|NCT00570349|Drug|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
477238|NCT00570336|Drug|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
477239|NCT00570336|Other|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
477240|NCT00570323|Drug|Arimidex|Aromatase inhibitors
477241|NCT00570323|Drug|Faslodex|Hormone Receptor
477242|NCT00570310|Drug|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
477243|NCT00570310|Drug|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
477244|NCT00570284|Drug|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
477245|NCT00570271|Other|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
477246|NCT00570271|Other|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
477247|NCT00570271|Other|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
477248|NCT00570271|Other|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
477249|NCT00570271|Other|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
477250|NCT00570271|Other|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
477251|NCT00570258|Drug|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
477252|NCT00570258|Drug|erlotinib|150 mg PO QD
477253|NCT00570258|Drug|Fulvestrant|250 mg IM Q 4 weeks
477254|NCT00570258|Drug|Placebo|Placebo 150 mg PO QD
477255|NCT00570245|Drug|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
477256|NCT00570245|Drug|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
477257|NCT00570232|Drug|Erlotinib|150 mg per day by mouth for 12 months
477258|NCT00570219|Drug|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
477259|NCT00570206|Behavioral|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
477260|NCT00570193|Drug|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
477261|NCT00570193|Drug|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
477262|NCT00570180|Drug|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
477263|NCT00570167|Procedure|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
477264|NCT00570167|Procedure|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
477265|NCT00570141|Device|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
477266|NCT00570128|Drug|Donepezil hydrochloride|Oral liquid.
477267|NCT00570128|Drug|Placebo|Oral liquid.
477268|NCT00570102|Dietary Supplement|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
477269|NCT00570102|Dietary Supplement|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
477270|NCT00570089|Drug|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
477271|NCT00570089|Drug|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
477272|NCT00570063|Drug|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
477273|NCT00570063|Drug|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
477274|NCT00570050|Drug|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
477275|NCT00570050|Drug|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
477276|NCT00570037|Biological|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
477277|NCT00570024|Procedure|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
477278|NCT00570024|Procedure|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
477279|NCT00570011|Drug|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
477280|NCT00570011|Drug|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
477281|NCT00569998|Device|NovoPen™ 4|
477282|NCT00569998|Device|NovoPen® 3|
477283|NCT00569985|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
477284|NCT00569985|Drug|carmustine|Given IV
477285|NCT00569985|Drug|cyclophosphamide|Given IV
477286|NCT00569985|Drug|etoposide|Given IV
477287|NCT00569985|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
477288|NCT00569972|Drug|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
477289|NCT00569972|Drug|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
477290|NCT00569972|Drug|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
477291|NCT00569972|Drug|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
477292|NCT00569972|Drug|Placebo|Matched oral placebo for weeks 2-7.
477293|NCT00569959|Other|fasting 12+ hours|fasting 12+ hours
477294|NCT00569959|Other|Non-fasting|Non-fasting
477295|NCT00569946|Drug|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.~Number of cycles: until progression or unacceptable toxicity develops."
477296|NCT00569933|Behavioral|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
477297|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
477298|NCT00569920|Drug|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
477299|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
477300|NCT00569894|Biological|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
477301|NCT00569894|Biological|TIV (Injection)|One or two injections of TIV depending on previous status.
477302|NCT00569894|Other|Unvaccinated Control|no vaccine
477303|NCT00569881|Drug|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
477304|NCT00569868|Drug|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000."
477305|NCT00569855|Drug|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
477306|NCT00569829|Behavioral|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
477307|NCT00569816|Drug|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
477308|NCT00569803|Drug|belatacept|single dose, 116 days
477309|NCT00569803|Drug|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
477310|NCT00569790|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
477311|NCT00569777|Device|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
477312|NCT00569777|Device|Placebo Lens|contact lens without drug
477313|NCT00569751|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
477314|NCT00569738|Procedure|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
477315|NCT00569712|Drug|budesonide/formoterol fumarate dihydrate inhalation aerosol|
477316|NCT00569712|Genetic|DNA methylation analysis|
477317|NCT00569712|Genetic|comparative genomic hybridization|
477318|NCT00569712|Genetic|microarray analysis|
477319|NCT00569712|Other|bronchoalveolar lavage|
477320|NCT00569712|Other|immunoenzyme technique|
477321|NCT00569712|Other|laboratory biomarker analysis|
477322|NCT00569712|Procedure|bronchoscopy|
477323|NCT00569699|Drug|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25 m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
477324|NCT00569686|Drug|lovaza|lovaza 4 gm po daily
477325|NCT00569686|Drug|placebo|placebo
477326|NCT00569673|Biological|filgrastim|
477327|NCT00569673|Biological|pegfilgrastim|
477328|NCT00569673|Drug|docetaxel|
477329|NCT00569673|Drug|trabectedin|
477330|NCT00569660|Drug|Azacitidine|75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle)
477331|NCT00569647|Device|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
477332|NCT00569647|Device|Placebo|no use of device
477333|NCT00569634|Procedure|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always < 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
477334|NCT00569621|Drug|Moxaverine|intravenous administration
477335|NCT00569621|Drug|physiological saline|intravenous administration
477336|NCT00569608|Other|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
477337|NCT00569595|Behavioral|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
477338|NCT00569595|Behavioral|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
477339|NCT00569582|Drug|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
477340|NCT00569569|Drug|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
477341|NCT00569556|Other|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
477342|NCT00569543|Other|high performance liquid chromatography|urine analysis
477388|NCT00569140|Drug|E10030|Intravitreal injection
477343|NCT00569543|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
477344|NCT00569543|Other|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
477345|NCT00569543|Other|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
477346|NCT00569530|Drug|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
477347|NCT00569530|Drug|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
477348|NCT00569517|Behavioral|CBT|6-CBT based sesions
477349|NCT00569517|Other|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
477350|NCT00569491|Device|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
477351|NCT00569478|Other|rehabilitation|Nursing consultations and physical training
477352|NCT00569465|Drug|Arginine|1200 mg, once a day
477353|NCT00569465|Drug|Acetylcysteine|600 mg twice a day
477354|NCT00569465|Drug|Placebo|3 vials a day
477355|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|One basal rate
477356|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|Multiple basal rates
477357|NCT00569439|Drug|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
477358|NCT00569439|Drug|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
477359|NCT00569439|Drug|NS|Normal Saline solution at 125 cc/hr
477360|NCT00569426|Device|NovoFine® needle 6 mm|
477361|NCT00569426|Device|NovoFine® needle 8 mm|
477362|NCT00569400|Drug|human insulin|
477363|NCT00569387|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
477364|NCT00569374|Drug|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
477365|NCT00569361|Procedure|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
477366|NCT00569335|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).~Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
477367|NCT00569322|Procedure|BG Test|
477368|NCT00569309|Biological|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
477369|NCT00569309|Other|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
477370|NCT00569309|Other|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
477371|NCT00569296|Biological|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
477372|NCT00569296|Biological|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
477373|NCT00569296|Biological|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
477374|NCT00569283|Biological|therapeutic allogeneic lymphocytes|
477375|NCT00569270|Drug|Placebo|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
477376|NCT00569257|Drug|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
477377|NCT00569244|Drug|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
477378|NCT00569244|Drug|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
477379|NCT00569231|Drug|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
477380|NCT00569192|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
477381|NCT00569192|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
477382|NCT00569192|Drug|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
477383|NCT00569179|Device|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
477384|NCT00569166|Behavioral|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
477385|NCT00569166|Behavioral|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
477386|NCT00569166|Behavioral|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
477387|NCT00569153|Drug|TAK-700|"Phase 1 portion of study:~TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.~Phase 2 portion of study:~Patients will receive one of 4 treatments:~TAK-700 at 300 mg twice/day~TAK-700 at 400 mg and 5 mg prednisone twice/day~TAK-700 at 600 mg and 5 mg prednisone twice/day~TAK-700 at 600 mg once/day in the morning"
477389|NCT00569127|Biological|Bevacizumab|Given IV
477390|NCT00569127|Other|Laboratory Biomarker Analysis|Correlative studies
477391|NCT00569127|Drug|Octreotide Acetate|Given IM
477392|NCT00569127|Biological|Recombinant Interferon Alfa-2b|Given SC
477393|NCT00569114|Drug|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
477394|NCT00569101|Drug|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg ~0.02 mg/kg + prednisolone tapering
477395|NCT00569088|Drug|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).~Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
477396|NCT00569088|Drug|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
477397|NCT00569075|Other|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
477398|NCT00569062|Drug|GW856553X|GW856553X 7.5mg BID for 6 weeks
477399|NCT00569062|Other|Placebo|Placebo to match GW856553X
477400|NCT00569049|Procedure|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
477401|NCT00569036|Drug|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
477402|NCT00569023|Dietary Supplement|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.~Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
477403|NCT00569010|Drug|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days
477404|NCT00569010|Drug|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days~Arms 3 and 4 at High-dose = 1 g/m^2 Daily CIV for 4 days (age<65 years) or 3 days (age>=65 years)"
477405|NCT00568997|Drug|Pimecrolimus|Pimecrolimus 1% cream
477406|NCT00568984|Drug|repaglinide|
477407|NCT00568984|Drug|metformin|
477408|NCT00568984|Drug|glicazide|
477409|NCT00568971|Drug|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
477410|NCT00568958|Behavioral|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
477411|NCT00568958|Drug|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
477412|NCT00568958|Drug|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
477413|NCT00568945|Drug|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
477414|NCT00568893|Drug|drotrecogin alfa (activated)|
477415|NCT00568880|Drug|bortezomib|
477416|NCT00568880|Drug|hydroxychloroquine|
477417|NCT00568880|Other|immunologic technique|
477418|NCT00568880|Other|laboratory biomarker analysis|
477419|NCT00568880|Other|mass spectrometry|
477420|NCT00568880|Other|pharmacological study|
477421|NCT00568880|Procedure|biopsy|
477422|NCT00568854|Biological|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
477423|NCT00568841|Drug|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
477424|NCT00568841|Procedure|FDG-/FLT-PET|
477425|NCT00568815|Drug|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
477426|NCT00568802|Drug|Hydroxyurea|
477427|NCT00568802|Drug|Placebo to match hydroxyurea|
477428|NCT00568789|Drug|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3~Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3~Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
477429|NCT00568776|Drug|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
477430|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
477431|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
477432|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
477433|NCT00568763|Biological|sargramostim|
477434|NCT00568763|Other|immunoenzyme technique|
477435|NCT00568763|Other|immunohistochemistry staining method|
477436|NCT00568763|Other|immunologic technique|
477437|NCT00568763|Other|laboratory biomarker analysis|
477438|NCT00568763|Procedure|biopsy|
477439|NCT00568763|Procedure|cryosurgery|
477440|NCT00568763|Procedure|radiofrequency ablation|
477441|NCT00568750|Drug|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
477442|NCT00568737|Drug|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
477443|NCT00568737|Drug|Placebo|0.9% sodium chloride
477444|NCT00568711|Drug|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
477445|NCT00568711|Drug|rifampin|a 5-day course of daily 600-mg doses of rifampin
477446|NCT00568698|Drug|Hydroxyurea|
477447|NCT00568698|Drug|Placebo to match hydroxyurea|
477448|NCT00568685|Drug|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
477449|NCT00568685|Drug|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
477450|NCT00568685|Drug|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.~Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
477451|NCT00568672|Drug|Olanzapine|Olanzapine 5 mg / day for 6 months
477452|NCT00568659|Procedure|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
477453|NCT00568646|Drug|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
477454|NCT00568633|Procedure|Allogeneic HSCT|Allogeneic, 5+ of 6 HLA-matched PBSC transplant from sibling, mobilized to target of 5 x 10e6 CD34+ cells/kg and < 7 x 10e8 CD3+ cells/kg.
477455|NCT00568633|Drug|Anti-thymocyte globulin (ATG)|1.5 mg/kg for 5 days by IV
477456|NCT00568633|Drug|Cyclosporine (CSP)|6.25 mg/kg twice daily oral
477457|NCT00568633|Drug|Mycophenolate mofetil (MMF)|15 mg/kg twice daily oral
477458|NCT00568633|Radiation|Total lymphoid irradiation (TLI)|80 cGy/fraction radiotherapy in 10 fractions.
477459|NCT00568633|Drug|Methylprednisolone sodium succinate|1.0 mg/kg for 5 days by IV
477460|NCT00568633|Drug|Best standard care|"Intervention consist of:~Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~Autologous transplantation~Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~Umbilical cord blood transplantation~Haploidentical transplantation"
477461|NCT00568620|Procedure|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
477462|NCT00568620|Procedure|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
477463|NCT00568607|Drug|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
477464|NCT00568594|Drug|APL180|
477465|NCT00568594|Drug|Placebo|
477466|NCT00568568|Drug|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
477467|NCT00568555|Drug|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
477468|NCT00568555|Drug|Placebo - sugar pill|Placebo pill once daily
477469|NCT00568542|Drug|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
477470|NCT00568542|Drug|placebo|35 I.E. kg body weight placebo to erythropoetin beta
477471|NCT00568529|Drug|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
477472|NCT00568516|Drug|ASP3550|subcutaneous administration
477473|NCT00568503|Drug|QAX028|
477474|NCT00568503|Drug|Placebo|
477475|NCT00568503|Drug|Tiotropium bromide|
477476|NCT00568503|Drug|QAX028|
477477|NCT00568503|Drug|QAX028|
477478|NCT00568490|Procedure|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
477479|NCT00568490|Procedure|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
477480|NCT00568477|Drug|MabThera|"Rituximab (MabThera):~375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
477481|NCT00568464|Drug|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
477482|NCT00568451|Drug|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
477483|NCT00568451|Drug|paclitaxel|100mg/m^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
477484|NCT00568451|Drug|temozolomide|150mg/m^2 at cycle 1, 200mg/m^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
477485|NCT00568412|Device|Zarzenda|Topical cream, applied twice daily for three weeks
477486|NCT00568412|Drug|Elidel|1% cream, applied topically twice daily for three weeks
477487|NCT00568399|Drug|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
477488|NCT00568386|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
477489|NCT00568386|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
477490|NCT00568373|Device|Enterra Gastric Pacemaker|Gastric Pacemaker
477491|NCT00568360|Device|Oximeter|
477492|NCT00568347|Drug|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
477493|NCT00568347|Drug|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
477494|NCT00568347|Drug|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
477495|NCT00568347|Drug|Salmeterol|salmeterol 50mcg bid X 3months
477496|NCT00568347|Drug|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
477497|NCT00568334|Biological|Varilrix (inactivated varicella vaccine)|subcutaneously injection
477498|NCT00568321|Drug|RN624|50 mcg/kg
477501|NCT00568308|Drug|PI-88|160mg subcutaneous injection
477502|NCT00568308|Drug|placebo|matched placebo
477503|NCT00568295|Drug|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
477504|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
477505|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
477506|NCT00568282|Procedure|phlebotomy|Standard of care
477507|NCT00568269|Procedure|Open repair|Open repair is according to the Lichtenstein technique
477508|NCT00568269|Procedure|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
477509|NCT00568256|Behavioral|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
477510|NCT00568230|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
477511|NCT00568217|Drug|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature > 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still < 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature < 38 degree Celsius
477512|NCT00568204|Device|Mexyn-A|Atomised topical self-chilled pressurised spray
477513|NCT00568178|Drug|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:~Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed <50 kg)~or 100 mg/day (if the patient weighed ≥50 kg).~Losartan Use During the Treatment Extension Phase:~Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
477514|NCT00568178|Other|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
477515|NCT00568178|Drug|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
477516|NCT00568178|Other|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
477517|NCT00568178|Other|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
477518|NCT00568178|Drug|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
477519|NCT00568165|Procedure|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
477520|NCT00568165|Procedure|Standard care|Standard care
477521|NCT00568152|Dietary Supplement|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
477522|NCT00568152|Dietary Supplement|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
477523|NCT00568152|Drug|Aspirin|75mg dispersable aspirin taken daily for 14 days
477524|NCT00568126|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
477525|NCT00568126|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks
477526|NCT00568113|Drug|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.~Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
477527|NCT00568100|Procedure|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
477528|NCT00568087|Drug|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
477529|NCT00568087|Drug|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
477530|NCT00568074|Drug|repaglinide|
477531|NCT00568074|Drug|Glurenorm®|
477532|NCT00568074|Drug|Glucobay®|
477533|NCT00568061|Drug|Nitric Oxide|Nitric oxide for inhalation
477534|NCT00568061|Drug|Placebo|Nitrogen gas (placebo) for inhalation
477535|NCT00568048|Biological|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
477536|NCT00568048|Drug|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
477537|NCT00568035|Drug|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
477538|NCT00568022|Drug|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m^2, once every 3 weeks, up to 6 cycles
477539|NCT00568022|Drug|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m^2, twice daily for 2 weeks, one week off, up to 6 cycles
477540|NCT00568009|Drug|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
477606|NCT00567567|Drug|Topotecan Hydrochloride|Given IV
477541|NCT00567996|Drug|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
477542|NCT00567996|Drug|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
477543|NCT00567996|Drug|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
477544|NCT00567996|Drug|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
477545|NCT00567983|Drug|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
477546|NCT00567983|Drug|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
477547|NCT00567970|Procedure|quality-of-life assessment|
477548|NCT00567970|Radiation|stereotactic body radiation therapy|
477549|NCT00567957|Drug|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
477550|NCT00567957|Drug|Saline|same volume iv bolus before induction followed by same volume infusion
477551|NCT00567944|Device|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
477552|NCT00567931|Drug|1-methyl-d-tryptophan|Given orally
477553|NCT00567931|Other|pharmacological study|Correlative studies
477554|NCT00567931|Other|laboratory biomarker analysis|Correlative studies
477555|NCT00567918|Drug|FK506|Ophthalmic suspension
477556|NCT00567905|Dietary Supplement|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
477557|NCT00567892|Device|rTMS|"Stimulation Settings:~Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
477558|NCT00567879|Drug|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
477559|NCT00567879|Drug|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
477560|NCT00567866|Drug|Quetiapine|50 or 100 mg of quetiapine orally
477561|NCT00567853|Device|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
477562|NCT00567840|Drug|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
477563|NCT00567814|Drug|Metyrapone|Twice daily
477564|NCT00567814|Drug|Oxazepam|Twice Daily
477565|NCT00567814|Drug|Placebo|Twice daily
477566|NCT00567801|Procedure|conventional embolectomy/thrombectomy|
477567|NCT00567801|Procedure|embolectomy/thrombectomy with controlled reperfusion|
477568|NCT00567788|Drug|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
477569|NCT00567788|Drug|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
477570|NCT00567775|Drug|human insulin|
477571|NCT00567775|Drug|inhaled human insulin|
477572|NCT00567762|Drug|FK506|Opthalmic suspension
477573|NCT00567762|Drug|placebo|placebo eye drops
477574|NCT00567736|Drug|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
477575|NCT00567736|Drug|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
477576|NCT00567710|Drug|BL - 1020|10 mg/day
477577|NCT00567710|Drug|BL - 1020|BL 1020 20-30 mg/day
477578|NCT00567710|Drug|Placebo|Capsules
477579|NCT00567710|Drug|Risperidone|Capsules
477580|NCT00567697|Drug|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
477581|NCT00567697|Drug|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
477582|NCT00567684|Other|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
477583|NCT00567684|Other|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
477584|NCT00567671|Procedure|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
477585|NCT00567671|Procedure|Sham comparator|Sham treatment
477586|NCT00567658|Drug|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
477587|NCT00567606|Other|risedronate, calcium/vit D, strength weight training|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine. G2 group receives the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
477588|NCT00567593|Drug|Rosiglitazone|8mg tablet once a day for 14 days
477589|NCT00567580|Drug|bicalutamide|Oral, daily
477590|NCT00567580|Drug|flutamide|Oral, daily
477591|NCT00567580|Radiation|radiation therapy|Once daily, 5 days a week
477592|NCT00567567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
477593|NCT00567567|Drug|Carboplatin|Given IV
477594|NCT00567567|Drug|Cisplatin|Given IV
477595|NCT00567567|Drug|Cyclophosphamide|Given IV
477596|NCT00567567|Drug|Doxorubicin Hydrochloride|Given IV
477597|NCT00567567|Drug|Etoposide|Given IV
477598|NCT00567567|Radiation|External Beam Radiation Therapy|Undergo EBRT
477599|NCT00567567|Biological|Filgrastim|Given IV or SC
477600|NCT00567567|Drug|Isotretinoin|Given orally
477601|NCT00567567|Other|Laboratory Biomarker Analysis|Correlative studies
477602|NCT00567567|Drug|Melphalan|Given IV
477603|NCT00567567|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
477604|NCT00567567|Other|Pharmacological Study|Correlative studies
477607|NCT00567567|Drug|Vincristine Sulfate Liposome|Given IV
477608|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel|
477609|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
477610|NCT00567554|Drug|paclitaxel|
477611|NCT00567554|Drug|paclitaxel + everolimus (RAD001)|
477612|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
477613|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + lapatinib|
477614|NCT00567541|Device|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
477615|NCT00567528|Drug|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
477616|NCT00567528|Drug|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
477617|NCT00567515|Device|AtriCure LAA Exclusion System|Placement of clip of LAA.
477618|NCT00567489|Drug|Physioneal|Physioneal 40 or Physioneal 35
477619|NCT00567489|Drug|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
477620|NCT00567489|Drug|Extraneal|7.5% Icodextrin
477621|NCT00567489|Drug|Nutrineal|Amino Acids 1.1%
477622|NCT00567476|Drug|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
477623|NCT00567476|Drug|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
477624|NCT00567476|Drug|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
477625|NCT00567476|Drug|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
477626|NCT00567463|Device|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
477627|NCT00567450|Drug|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
477628|NCT00567450|Drug|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
477629|NCT00567437|Other|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
477630|NCT00567424|Drug|GW273225|
477631|NCT00567411|Drug|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
477632|NCT00567411|Drug|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
477633|NCT00567398|Drug|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
477634|NCT00567398|Drug|Physioneal|Physioneal 40 or Physioneal 35
477635|NCT00567398|Drug|Extraneal|Extraneal - 7.5% Icodextrin
477636|NCT00567398|Drug|Nutrineal|Nutrineal - 1.1% Amino Acids
477637|NCT00567385|Drug|somatropin|
477638|NCT00567372|Drug|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
477639|NCT00567359|Drug|Erlotinib|Oral drug taken daily around the same time. Starting dose is 150mg once daily.
477640|NCT00567346|Drug|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
477641|NCT00567346|Drug|grass pollen extract|Patients will receive matching placebo sublingually
477642|NCT00567333|Other|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
477643|NCT00567333|Other|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
477644|NCT00567320|Drug|Varenicline|Varenicline up to 2 mg a day
477645|NCT00567320|Drug|Sugar pill or Placebo|Placebo
477646|NCT00567307|Drug|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
477647|NCT00567307|Other|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
477648|NCT00567294|Behavioral|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
477649|NCT00567294|Behavioral|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
477650|NCT00567294|Behavioral|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
477689|NCT00567008|Drug|placebo|placebo BID for 8 weeks
477690|NCT00566995|Drug|ZACTIMA (Vandetanib) (ZD6474)|
477691|NCT00566982|Drug|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
477692|NCT00566982|Drug|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
477651|NCT00567281|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
477652|NCT00567281|Device|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
477653|NCT00567268|Drug|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.~Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).~Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
477654|NCT00567255|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
477655|NCT00567255|Drug|Placebo|
477656|NCT00567255|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
477657|NCT00567242|Behavioral|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
477658|NCT00567242|Behavioral|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
477659|NCT00567229|Biological|rituximab|
477660|NCT00567229|Drug|lenalidomide|
477661|NCT00567229|Genetic|microarray analysis|
477662|NCT00567229|Other|flow cytometry|
477663|NCT00567229|Other|laboratory biomarker analysis|
477664|NCT00567216|Drug|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
477665|NCT00567203|Drug|PF-3463275|PF-3463275 10mg
477666|NCT00567203|Drug|PF-3463275|PF-3463275 25mg
477667|NCT00567203|Drug|Placebo|Placebo
477668|NCT00567190|Drug|Pertuzumab|Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) Q3W on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg Q3W on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
477669|NCT00567190|Drug|Placebo|Pertuzumab matching placebo will be administered intravenously.
477670|NCT00567190|Drug|Trastuzumab|Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) Q3W on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg Q3W on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
477671|NCT00567190|Drug|Docetaxel|Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m^2) Q3W on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) Q3W on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
477672|NCT00567177|Drug|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
477673|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
477674|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
477675|NCT00567164|Drug|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
477676|NCT00567112|Drug|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
477677|NCT00567112|Drug|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
477678|NCT00567112|Drug|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
477679|NCT00567112|Drug|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
477680|NCT00567099|Drug|Aripiprzole|"Dosage form, dosage, frequency and duration:~Aripiprazole 5-30 mg tabs po qday x 3 months"
477681|NCT00567086|Drug|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
477682|NCT00567073|Biological|alglucosidase alpha|
477683|NCT00567073|Other|No Treatment|
477684|NCT00567060|Drug|Piracetam|
477685|NCT00567047|Drug|vildagliptin|
477686|NCT00567034|Drug|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
477687|NCT00567034|Drug|placebo|lactose placebo, 1 capsule every day for 12 weeks
477688|NCT00567008|Drug|varenicline|1.0 mg BID for 8 weeks
489339|NCT00482222|Drug|fluorouracil|
477693|NCT00566969|Drug|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
477694|NCT00566969|Drug|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
477695|NCT00566969|Drug|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
477696|NCT00566956|Procedure|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
477697|NCT00566943|Device|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
477698|NCT00566943|Procedure|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
477699|NCT00566930|Other|spinal manipulation|Monthly cervical spinal manipulation
477700|NCT00566930|Other|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
477701|NCT00566917|Procedure|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
477702|NCT00566917|Procedure|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
477703|NCT00566904|Drug|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
477704|NCT00566904|Drug|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
477705|NCT00566904|Other|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
477706|NCT00566891|Drug|tirofiban|tirofiban high dose bolus 25µ/Kg
477707|NCT00566891|Drug|Clopidogrel|
477708|NCT00566878|Biological|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
477709|NCT00566865|Drug|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
477710|NCT00566865|Drug|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
477711|NCT00566852|Drug|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
477712|NCT00566852|Other|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
477713|NCT00566852|Radiation|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
477714|NCT00566839|Procedure|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
477715|NCT00566839|Procedure|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
477716|NCT00566826|Behavioral|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
477717|NCT00566826|Behavioral|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
477718|NCT00566813|Drug|Islet Cell Transplant|1-3 allogeneic islet transplants; two doses of basiliximab 20 mg iv.; sirolimus po trough levels 10-15 ng/ml X 3 months, then 7-10 ng/ml; tacrolimus po trough levels 3-6 ng/ml
477719|NCT00566813|Drug|Islet Cell Transplant plus|1-3 allogeneic Islets of Langerhans transplantations; two doses of basiliximab 20 mg iv.; sirolimus po daily to maintatin serum levels 12-15 ng/mL for 3 months, and 7-10 ng/mL thereafter; tacrolimus po twice daily to maintain serum levels 3-6 ng/mL; etanercept 50 mg IV before islet transplant, 25 mg subcutaneously post-transplant days 3, 7, 10; exenatide subcutaneously 5 mcg pre-transplant and twice daily for I week, then increased to 10-mcg twice daily for 6 months after the last islet transplant.
477720|NCT00566800|Drug|erlotinib hydrochloride|
477721|NCT00566800|Other|laboratory biomarker analysis|
477722|NCT00566800|Procedure|biopsy|
477723|NCT00566787|Device|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
477724|NCT00566774|Other|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
477725|NCT00566774|Other|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
477726|NCT00566761|Drug|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
477727|NCT00566735|Drug|Razadyne|The starting dose of study medication is 4 mg twice a day
477728|NCT00566735|Drug|Placebo|4 mg, 2 times a day
477729|NCT00566722|Biological|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
477730|NCT00566709|Procedure|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
477731|NCT00566696|Device|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
477732|NCT00566696|Procedure|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
477733|NCT00566696|Drug|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477734|NCT00566696|Drug|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477735|NCT00566696|Drug|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477736|NCT00566696|Drug|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477737|NCT00566696|Drug|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477738|NCT00566696|Drug|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
477739|NCT00566696|Drug|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477740|NCT00566696|Drug|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477741|NCT00566696|Drug|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
477742|NCT00566696|Drug|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
477743|NCT00566683|Drug|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
477744|NCT00566683|Drug|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
477745|NCT00566657|Biological|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid~Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
477746|NCT00566657|Biological|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo~Route: IM injection of 2.5 mL in the ischemic leg to be treated"
477747|NCT00566644|Device|levonorgestrel-releasing intrauterine system|
477748|NCT00566644|Other|questionnaire administration|
477749|NCT00566644|Procedure|observation|
477750|NCT00566631|Drug|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
477751|NCT00566618|Drug|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
477752|NCT00566618|Drug|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
477753|NCT00566605|Procedure|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty [IEK])
477754|NCT00566605|Procedure|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
477755|NCT00566592|Other|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
477756|NCT00566592|Other|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
477757|NCT00566592|Other|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
477758|NCT00566592|Other|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
477759|NCT00566579|Procedure|Cryotherapy|Double freezing technique
477760|NCT00566566|Other|sample without DNA|family history, anthropometric measurements and blood sampling
477761|NCT00566553|Dietary Supplement|Grape Seed Extract|200 mg dose daily for 12 weeks.
477762|NCT00566553|Dietary Supplement|Grape Seed Extract|400 mg dose daily for 12 weeks.
477763|NCT00566553|Dietary Supplement|Grape Seed Extract|600 mg dose daily for 12 weeks.
477764|NCT00566553|Dietary Supplement|Grape Seed Extract|800 mg dose daily for 12 weeks.
477765|NCT00566540|Drug|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
477766|NCT00566540|Drug|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
477767|NCT00566540|Radiation|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
477768|NCT00566540|Procedure|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
477769|NCT00566527|Biological|ProQuad® manufactured with recombinant Human Albumin (rHA)|A 2-dose regimen of ProQuad® (0.5 mL per dose) given via subcutaneous injection into the deltoid muscle at a 3-month interval. Each dose contains measles virus Enders' Edmonston strain (live attenuated), mumps virus Jeryl Lynn™ (Level B) strain (live attenuated), rubella virus Wistar RA 27 or 3 strain (live attenuated), and varicella virus Oka or Merck strain (live attenuated).
477770|NCT00566514|Dietary Supplement|D-ribose|5 grams administered orally TID
477771|NCT00566514|Other|dextrose|5 grams orally TID
477772|NCT00566501|Drug|23 mg SR in Study 326|Patients will receive 23 mg donepezil SR orally, once daily for 12 months.
477773|NCT00566501|Drug|10 mg IR in Study 326|Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.
477774|NCT00566488|Biological|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, & parental parathyroid donor screened for transplant safety. Depending on T cell phenotype & function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre & post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis & graft rejection.
477775|NCT00566475|Other|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
477776|NCT00566462|Drug|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
477777|NCT00566462|Drug|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
477778|NCT00566449|Drug|Placebo|one dose daily for 4 weeks
477779|NCT00566449|Drug|JNJ-31001074|10 mg daily for 4 weeks
477780|NCT00566449|Drug|JNJ-31001074|30 mg daily for 4 weeks
477781|NCT00566436|Procedure|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
477782|NCT00566436|Procedure|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
477783|NCT00566423|Other|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
477784|NCT00566410|Drug|Dichloroacetate|Continuous daily oral dosage (bid).
477785|NCT00566397|Drug|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
477786|NCT00566397|Drug|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
477787|NCT00566397|Drug|Placebo|Placebo
477788|NCT00566384|Drug|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
477789|NCT00566384|Drug|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
477790|NCT00566371|Drug|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
477791|NCT00566371|Drug|placebo|placebo
477792|NCT00566358|Procedure|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
477793|NCT00566345|Biological|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
477794|NCT00566345|Biological|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
477795|NCT00566332|Drug|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
477796|NCT00566332|Drug|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
477797|NCT00566319|Behavioral|PREPARE with pedometer|Structured educational programme with pedometer use
477798|NCT00566319|Behavioral|PREPARE|Structured educational programme
477799|NCT00566306|Other|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
477800|NCT00566280|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
477801|NCT00566267|Drug|simvastatin 20 mg/ezetimibe|see protocol
477802|NCT00566254|Drug|Zonisamide|8mg/kg per day for approximately 24 weeks.
477803|NCT00566254|Drug|Placebo|
477804|NCT00566241|Drug|recombinant human IGF-1|rhIGF-1
477805|NCT00566241|Drug|Placebo|Placebo
477806|NCT00566228|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
477807|NCT00566228|Procedure|leukapheresis|Stem cells collected
477808|NCT00566215|Procedure|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.~Additionally, total omentectomy is performed."
477809|NCT00566215|Procedure|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
477810|NCT00566202|Drug|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
477811|NCT00566202|Drug|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
477812|NCT00566202|Drug|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
477813|NCT00566189|Procedure|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
477814|NCT00566176|Device|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
477815|NCT00566150|Drug|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
477816|NCT00566150|Drug|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
477817|NCT00566124|Drug|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
477818|NCT00566124|Drug|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
477819|NCT00566124|Drug|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
477820|NCT00566111|Drug|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
477821|NCT00566111|Drug|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
477822|NCT00566098|Biological|MILs|
477823|NCT00566098|Drug|Melphalan|
477824|NCT00566098|Biological|PCV13|
477825|NCT00566085|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
477826|NCT00566072|Behavioral|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
477827|NCT00566046|Drug|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
477828|NCT00566046|Drug|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
477829|NCT00566033|Behavioral|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
477830|NCT00566020|Drug|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
477831|NCT00566007|Procedure|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
477832|NCT00566007|Drug|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
477833|NCT00566007|Drug|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
477834|NCT00565994|Procedure|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
477835|NCT00565981|Drug|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
477836|NCT00565981|Drug|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
477837|NCT00565968|Drug|melphalan|
477838|NCT00565968|Drug|sorafenib tosylate|
477839|NCT00565968|Genetic|gene expression analysis|
477840|NCT00565968|Genetic|protein expression analysis|
477841|NCT00565968|Genetic|western blotting|
477842|NCT00565968|Other|pharmacological study|
477843|NCT00565955|Drug|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:~5-12 years: 5 mg chewable tablet of montelukast; > 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
477844|NCT00565955|Drug|Placebo|The patients will receive placebo tablets.
477845|NCT00565942|Procedure|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
477846|NCT00565942|Procedure|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
477847|NCT00565929|Drug|Placebo|Sterile saline (0.9%).
477848|NCT00565929|Biological|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10^7 or 1X10^8 TCID 50.
477849|NCT00565916|Drug|Estrogen|"Estrogen only plus placebo: estradiol topical patch 0.3 mg placed on the lower abdomen for 3 days plus an oral placebo.~Other procedures: heart metabolism tests which includes a positron-emission tomography (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO)."
477850|NCT00565916|Drug|Progesterone|Estrogen plus progesterone: estradiol with oral progesterone (Prometrium, 200 mg/day) for 3 days, instead of placebo. Progesterone therapy involves taking a daily oral pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
489340|NCT00482222|Drug|leucovorin calcium|
477851|NCT00565916|Drug|Placebo|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
477852|NCT00565890|Drug|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
477853|NCT00565877|Other|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
477854|NCT00565864|Drug|L-thyroxine (L-T4)|L-thyroxine (L-T4) is the intervention for each arm/group. In each arm/group, the dose of L-T4 is adjusted to achieve TSH levels in the randomly assigned arm. L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
477855|NCT00565851|Biological|Bevacizumab|Given IV
477856|NCT00565851|Drug|Carboplatin|Given IV
477857|NCT00565851|Drug|Docetaxel|Given IV
477858|NCT00565851|Drug|Gemcitabine Hydrochloride|Given IV
477859|NCT00565851|Other|Laboratory Biomarker Analysis|Correlative studies
477860|NCT00565851|Drug|Paclitaxel|Given IV
477861|NCT00565851|Other|Quality-of-Life Assessment|Ancillary studies
477862|NCT00565838|Procedure|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
477863|NCT00565812|Drug|SD-6010|200 mg tablets once a day for 2 years
477864|NCT00565812|Drug|SD-6010|50 mg tablets once a day for 2 years
477865|NCT00565812|Drug|Placebo|Placebo tablets once a day for 2 years
477866|NCT00565799|Procedure|Omentectomy|Removing the omentum
477867|NCT00565799|Other|No intervention|Only LAGB without Omentectomy
477868|NCT00565786|Device|ArCom® Polyethylene|Argon packaged compression molded polyethylene
477869|NCT00565786|Device|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
477870|NCT00565773|Drug|Belatacept|Belatacept will be given as an IV infusion of 10mg /kg over 30 minutes. This will be repeated on study days 4 and 8 (prior to bone marrow infusion in the first group of subjects) and 15 then every 2 weeks for 5 additional doses. After week 24, belatacept will be given at a dose of 5 mg/kg once every 4 weeks indefinitely.
477871|NCT00565773|Drug|Belatacept|Belatacept will be given as an IV infusion at 10mg/kg over 30 minutes on the day of transplantation. This dose will be repeated on study days 4, 8, and 15, then every 2 weeks for 5 additional doses. After week 24, belatacept will be given as an infusion of 5 mg/kg once every 4 weeks indefinitely.
477872|NCT00565773|Drug|Alemtuzumab|All patients will receive a single dose of 30 mgs. on the day of transplantation.
477873|NCT00565773|Other|donor bone marrow|"The bone marrow was given as an IV infusion over 3 hours on postoperative day 7 (study day 8) in the initial group of 20 randomized subjects. The formulated dose was 1 x 10(8th power) unfractionated nucleated cells/kg recipient ideal body weight.~A proposed total of forty patients will be enrolled in this study. Enrollment was reopened December of 2012 to include 20 additional living or deceased donor kidney recipients.~Half of the first group of 20 recipients were randomized to receive a single donor bone marrow infusion. Half did not receive the infusion. Donor bone marrow infusion in the second group of 20 subjects has been eliminated."
477874|NCT00565760|Drug|Q8003|Capsules
477875|NCT00565760|Drug|Placebo|Capsules
477876|NCT00565747|Device|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
477877|NCT00565747|Device|Control culture|The same standard culture medium, but without any additions (ready-to-use)
477878|NCT00565721|Drug|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
477879|NCT00565708|Other|placebo|Placebo Comparator
477880|NCT00565708|Drug|Acetylsalicylic acid|Adjuvant Therapy
477881|NCT00565695|Device|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
477882|NCT00565682|Drug|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
477883|NCT00565669|Drug|Cyclosporin A Restasis®|
477884|NCT00565669|Drug|Blink tears|blink tears to be used twice a day
477885|NCT00565669|Drug|Systane|systane to be used twice a day
477886|NCT00565656|Drug|BEVACIZUMAB|Administration of Bevacizumab
477887|NCT00565643|Device|modified sodium hyaluronic acid and carboxymethylcellulose|Adhesion barrier applied at the time of initial cesarean delivery
477888|NCT00565643|Device|Placebo|Routine abdominal closure without placement of adhesion barrier
477889|NCT00565630|Device|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
477890|NCT00565617|Device|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
477891|NCT00565604|Device|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
477892|NCT00565591|Drug|Albuterol sulfate|Single dose dry powder by inhalation
477893|NCT00565565|Drug|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
477894|NCT00565552|Drug|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
477895|NCT00565539|Drug|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
477896|NCT00565513|Procedure|blood test|cord blood and maternal milk test
477897|NCT00565500|Drug|celecoxib|celecoxib capsules 200 mg bid for 1 week
477898|NCT00565500|Drug|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
477899|NCT00565500|Drug|placebo|placebo capsules tid for 1 week
477900|NCT00565487|Drug|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication & will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine & Tarceva is continued daily until the completeness of the radiation or toxicity.
477901|NCT00565474|Drug|Fluvastatin|Graft vasculopathy
477902|NCT00565461|Biological|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
477903|NCT00565448|Drug|docetaxel|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
489341|NCT00482222|Drug|oxaliplatin|
477904|NCT00565448|Drug|cisplatin|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
477905|NCT00565448|Drug|5-fluorouracil|"Pharmaceutical form:solution for infusion~Route of administration:intravenous"
477906|NCT00565422|Drug|Escitalopram|10 mg/day
477907|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
477908|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
477909|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
477910|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
477911|NCT00565409|Drug|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
477912|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.~If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
477913|NCT00565396|Drug|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
477914|NCT00565383|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural
477915|NCT00565383|Procedure|Intravenous fentanyl (50mcg)|Intravenous fentanyl
477916|NCT00565370|Drug|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
477917|NCT00565357|Device|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
477918|NCT00565357|Other|Control|Standard care in the neonatal intensive care unit
477919|NCT00565331|Drug|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
477920|NCT00565331|Drug|Placebo|saline solution
477921|NCT00565318|Drug|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
477922|NCT00565318|Drug|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
477923|NCT00565305|Behavioral|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
477924|NCT00565305|Radiation|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
477925|NCT00565292|Drug|MK0859|
477926|NCT00565279|Drug|ASF1057|Twice daily, topical
477927|NCT00565279|Drug|ASF1057|Twice daily, Topical
477928|NCT00565266|Drug|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
477929|NCT00565266|Drug|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
477930|NCT00565266|Drug|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
477931|NCT00565253|Drug|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
477932|NCT00565240|Drug|Marvelon|oral contraceptive
477933|NCT00565240|Drug|Nuvaring|contraceptive vaginal ring
477934|NCT00565240|Drug|Letrozole|Aromatase Inhibitors
477935|NCT00565227|Drug|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
477936|NCT00565227|Drug|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
477937|NCT00565214|Dietary Supplement|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
477938|NCT00565214|Dietary Supplement|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
477939|NCT00565201|Drug|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
477940|NCT00565201|Drug|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
477941|NCT00565188|Drug|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
477942|NCT00565175|Drug|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
477943|NCT00565175|Drug|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
478029|NCT00564512|Biological|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
477944|NCT00565162|Drug|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
477945|NCT00565149|Behavioral|PROOF|dietary overfeeding with high, low or normal protein content
477946|NCT00565136|Device|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
477947|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
477948|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
477949|NCT00565110|Behavioral|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
477950|NCT00565097|Drug|Placebo|
477951|NCT00565097|Drug|Lanreotide|
477952|NCT00565084|Drug|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
477953|NCT00565084|Drug|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
477954|NCT00565071|Device|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
477955|NCT00565058|Biological|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
477956|NCT00565045|Device|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups~• 6-week intervention~Home exercise, daily~Exercise (at home) 2 sessions/day~A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest~A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions~Lab therapy, 2x/week~Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
477957|NCT00565019|Drug|Triamcinolone Acetonide|"Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.~Doses will range from 60-120 mg depending on extent of the disease.~Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.~PI will determine the dosages. Estimates will be made based on the following:~Size of nodule/cord: 1-2 cm2, dosage 20-40 mg~Size of nodule/cord: 2-6 cm2, dosage 40-80 mg~Size of nodule/cord: 6-10 cm2, dosage 80-100 mg~Size of nodule/cord: >10 cm2, dosage 100-120 mg"
477958|NCT00565006|Drug|MK0859|
477959|NCT00564993|Drug|Dobutamin|10&20 µg/kg/min
477960|NCT00564980|Procedure|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
477961|NCT00564980|Procedure|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
477962|NCT00564967|Behavioral|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
477963|NCT00564967|Behavioral|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
477964|NCT00564954|Drug|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
477965|NCT00564954|Drug|Placebo|orally once a day for 7 days
477966|NCT00564941|Drug|deferasirox|
477967|NCT00564928|Drug|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
477968|NCT00564915|Dietary Supplement|Ketogenic diet|Ketogenic diet
477969|NCT00564902|Drug|3R 3'R Zeaxanthin|8 mg per day during 12 months
477970|NCT00564902|Dietary Supplement|Lutein|9 mg of Lutein during 12 months
477971|NCT00564902|Dietary Supplement|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
477972|NCT00564889|Drug|cyclophosphamide|300 mg/m^2 days 1, 8 & 15 of a 28 day cycle taken orally with food
477973|NCT00564889|Drug|dexamethasone|40 mg weekly taken orally
477974|NCT00564889|Drug|lenalidomide|15 mg daily days 1-21 of a 28 day cycle taken orally with food
477975|NCT00564876|Drug|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
477976|NCT00564863|Biological|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
477977|NCT00564850|Drug|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|One intra muscular injection at day 1 and month 3.
477978|NCT00564837|Procedure|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
478030|NCT00564512|Biological|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
477979|NCT00564837|Procedure|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
477980|NCT00564824|Drug|Caffeine|Caffeine 200 mg tablet
477981|NCT00564824|Drug|Placebo|Placebo pills
477982|NCT00564811|Dietary Supplement|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
477983|NCT00564785|Drug|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
477984|NCT00564785|Other|Placebo patch|placebo patch applied 20 minutes prior to epidural
477985|NCT00564772|Drug|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
477986|NCT00564759|Drug|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
477987|NCT00564746|Drug|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"[14C] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) [14C] SB-681323 in dextrose and water for injection on the day prior to dosing.~For a 10 milligram/50 microcurie oral dose of [14C]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter [14C] SB-681323 oral solution will be dosed."
477988|NCT00564733|Drug|carboplatin|Given IV
477989|NCT00564733|Drug|docetaxel|Given IV
477990|NCT00564733|Drug|gemcitabine hydrochloride|Given IV
477991|NCT00564733|Drug|paclitaxel|Given IV
477992|NCT00564733|Procedure|computed tomography|Undergo FDG PET/CT
477993|NCT00564733|Procedure|positron emission tomography|Undergo FDG PET/CT
477994|NCT00564733|Radiation|fludeoxyglucose F 18|Given IV
477995|NCT00564733|Other|imaging biomarker analysis|Correlative studies
477996|NCT00564720|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
477997|NCT00564720|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
477998|NCT00564720|Drug|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
477999|NCT00564720|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
478000|NCT00564707|Behavioral|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
478001|NCT00564707|Procedure|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
478002|NCT00564694|Procedure|psychosocial assessment and care|
478003|NCT00564694|Procedure|quality-of-life assessment|
478004|NCT00564681|Biological|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
478005|NCT00564681|Biological|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
478006|NCT00564681|Drug|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
478007|NCT00564668|Drug|biphasic insulin aspart|
478008|NCT00564655|Procedure|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
478009|NCT00564655|Procedure|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
478010|NCT00564642|Drug|N Acetylcysteine|1200 mg, BD, 2weeks
478011|NCT00564629|Drug|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
478012|NCT00564629|Drug|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
478013|NCT00564629|Biological|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
478014|NCT00564616|Device|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
478015|NCT00564603|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
478016|NCT00564603|Other|0.9% Saline|Saline, in same volume of 2mL
478017|NCT00564590|Drug|Melatonin|4 mg of Melatonin once a day for 3 months
478018|NCT00564590|Other|omeprazole|omeprazole 20 mg once a day
478019|NCT00564590|Drug|Placebo|Placebo once a day
478020|NCT00564577|Biological|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
478021|NCT00564564|Drug|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
478022|NCT00564564|Drug|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
478023|NCT00564551|Behavioral|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
478024|NCT00564551|Behavioral|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
478025|NCT00564538|Drug|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
478026|NCT00564538|Drug|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
478027|NCT00564525|Drug|Amitriptyline|Medication taken for 4 weeks
478028|NCT00564525|Drug|Placebo|Medication taken for 4 weeks
489716|NCT00479440|Drug|SAM-315|
478031|NCT00564512|Drug|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
478032|NCT00564512|Drug|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
478033|NCT00564486|Drug|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
478034|NCT00564486|Drug|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
478035|NCT00564486|Drug|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
478036|NCT00564486|Drug|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
478037|NCT00564473|Behavioral|questionnaire|"questionnaire of demographic and medical data, use of and attituded toward herbal medicine.~Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
478038|NCT00564460|Drug|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
478039|NCT00564460|Drug|Placebo|Placebo once daily for 8 weeks
478040|NCT00564447|Drug|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
478041|NCT00564447|Drug|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
478042|NCT00564421|Drug|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
478043|NCT00564421|Other|placebo nasal spray|2 sprays in each nostril, dosed twice a day
478044|NCT00564421|Drug|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
478045|NCT00564421|Drug|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
478046|NCT00564421|Drug|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
478047|NCT00564408|Drug|Carbachol|3 microgram per kg bodyweight infused intravenously
478048|NCT00564395|Drug|Insulin Detemir mixed with RAI injection|Insulin Detemir mixed with RAI injection is given twice daily as subcutaneous injection
478049|NCT00564395|Drug|Insulin Detemir and RAI injection|Insulin detemir and RAI are given as separate injections, twice daily as subcutaneous injection
478050|NCT00564382|Procedure|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
478051|NCT00564369|Other|CDC HIV testing recommendations|Current vs. prior CDC recommendations
478052|NCT00564356|Procedure|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
478053|NCT00564343|Other|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
478054|NCT00564330|Drug|Esomeprazole|20mg bid
478055|NCT00564330|Drug|Placebo|Placebo bid
478056|NCT00564317|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
478057|NCT00564317|Behavioral|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
478058|NCT00564291|Other|Examination with an OCT device|
478059|NCT00564278|Drug|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
478060|NCT00564278|Behavioral|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
478061|NCT00564265|Other|Observation|Not applied
478062|NCT00564252|Drug|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
478063|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
478064|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions
478065|NCT00564226|Drug|SSR240600C|oral administration
478066|NCT00564226|Drug|tolterodine|oral administration
478067|NCT00564226|Drug|placebo|oral administration
478068|NCT00564213|Drug|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
478069|NCT00564200|Drug|Bortezomib|"PREACONDICIONAMIENTO:~2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~- Day -2: Velcade~POSTRANSPLANTATION:~2 cycles of 21 days : Velcade days 1, 8 and 15~5 cycles of 56 days : Velcade days 1, 8 and 15"
478070|NCT00564200|Drug|dexamethasone|"PREACONDICIONAMIENTO:~- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
478071|NCT00564200|Drug|Fludarabine|"ACONDICIONAMIENTO:~- Days -9 al -5: Fludarabine"
478072|NCT00564200|Drug|Melphalan|"ACONDICIONAMIENTO:~- Days -4 and -3: Melphalan."
478073|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
478074|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets~Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:~• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
478075|NCT00564174|Drug|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
478076|NCT00564174|Drug|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
478077|NCT00564148|Drug|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
478078|NCT00564135|Procedure|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
478079|NCT00564122|Device|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
478080|NCT00564122|Other|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
478081|NCT00564109|Procedure|retrospective Observation|retrospective Observation
478082|NCT00564096|Device|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
478083|NCT00564096|Device|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
478084|NCT00564083|Procedure|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
478085|NCT00564070|Behavioral|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
478086|NCT00564070|Behavioral|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
478087|NCT00564057|Drug|candesartan|tablet 8-16 mg once daily, one year
478088|NCT00564057|Drug|lercanidipine|tablets 10-20 mg once daily, one year
478089|NCT00564044|Procedure|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm*5mm*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
478090|NCT00564031|Drug|Femanest|2mg/day
478091|NCT00564031|Drug|gestapuran|5mg/day
478092|NCT00564031|Drug|placebo|daily
478093|NCT00564031|Drug|Femanest plus Gestapuran|combined daily
478094|NCT00564018|Drug|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
478095|NCT00564018|Drug|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
478096|NCT00564018|Drug|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
478097|NCT00564005|Other|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
478098|NCT00564005|Other|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
478099|NCT00564005|Other|Combined therapy (CT)|combined different treatment approaches
478100|NCT00564005|Behavioral|Control intervention|Conventional treatment program
478101|NCT00563992|Drug|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
478102|NCT00563992|Drug|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
478103|NCT00563979|Dietary Supplement|VitaluxPlus®|1 tablet daily
478104|NCT00563979|Dietary Supplement|Omega 3|1 tablet daily
478105|NCT00563953|Drug|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
478106|NCT00563927|Procedure|Conventional RT|
478107|NCT00563927|Drug|Cisplatin|
478108|NCT00563927|Drug|5-fluorouracil|
478109|NCT00563914|Drug|ferroquine (SSR97193)|associated with artesunate
478110|NCT00563914|Drug|amodiaquine|associated with artesunate
478111|NCT00563888|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
478112|NCT00563875|Drug|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
478113|NCT00563862|Procedure|Conventional RT|
478114|NCT00563862|Procedure|Accelerated RT|
478115|NCT00563862|Drug|Cisplatin|
478116|NCT00563862|Drug|5-fluorouracil|
478117|NCT00563849|Drug|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
478118|NCT00563836|Drug|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
478119|NCT00563823|Drug|vatalanib|
478120|NCT00563810|Drug|MYO-029|
478121|NCT00563797|Drug|Mecamylamine|mecamylamine 10mg/day for 12 weeks
478122|NCT00563797|Drug|Placebo|Placebo pill
478123|NCT00563784|Drug|Erlotinib|150 mg by mouth daily for 7 Weeks
478124|NCT00563784|Drug|Carboplatin|2 AUC by vein weekly for 7 Weeks
478125|NCT00563784|Drug|Paclitaxel|45 mg/m^2 by vein weekly for 7 Weeks
478126|NCT00563784|Radiation|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
478127|NCT00563771|Drug|Rasburicase|
478128|NCT00563758|Drug|tegaserod|
478129|NCT00563745|Device|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
478130|NCT00563732|Drug|Lecozotan|
478131|NCT00563706|Drug|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
478132|NCT00563706|Drug|risperidone|
478133|NCT00563706|Other|placebo|
478134|NCT00563693|Device|ASV|Adaptive servo ventilator
478135|NCT00563693|Other|without Autoset CS2|without Autoset CS2
478192|NCT00563290|Other|laboratory biomarker analysis|Correlative studies
478136|NCT00563680|Drug|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand‑dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
478137|NCT00563667|Procedure|pterygium excision|
478138|NCT00563654|Drug|Alfuzosin GITS (Xatral XL)|
478139|NCT00563641|Other|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
478140|NCT00563641|Other|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
478141|NCT00563628|Device|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
478142|NCT00563615|Drug|Tegaserod|
478143|NCT00563602|Other|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:~1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
478144|NCT00563589|Drug|mycophenolate mofetil, methotrexate, cyclosporin|
478145|NCT00563589|Drug|Methotrexate and cyclosporin|
478146|NCT00563576|Drug|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.~Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
478147|NCT00563576|Drug|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
478148|NCT00563563|Drug|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
478149|NCT00563563|Behavioral|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
478150|NCT00563537|Radiation|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
478151|NCT00563524|Drug|ILV-094|SC and IV administration on days 1, 14, 28, and 42
478152|NCT00563511|Procedure|adherence intervention|
478153|NCT00563511|Procedure|intervention without adherence advice|
478154|NCT00563511|Procedure|control|
478155|NCT00563498|Drug|Glutamine|
478156|NCT00563485|Drug|Doxazosin GITS (Cardura XL)|
478157|NCT00563485|Drug|Terazosin (Hytrin)|
478158|NCT00563472|Drug|estetrol|10 mg orally per day for 28 days
478159|NCT00563472|Drug|estetrol|20 mg orally per day for 28 days
478160|NCT00563472|Drug|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
478161|NCT00563472|Drug|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
478162|NCT00563459|Drug|carisbamate|400-1200 mg/day for 12 months
478163|NCT00563459|Drug|topiramate|200-400mg/day for 12 months
478164|NCT00563459|Drug|levetiracetam|1000-3000mg/day for 12 months
478165|NCT00563446|Drug|Darbepoetin alfa|
478166|NCT00563433|Drug|ofloxacin|400 mg twice a day for 14 days
478167|NCT00563433|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
478168|NCT00563420|Procedure|Bronchoscopy|
478169|NCT00563394|Drug|ofloxacin|400 mg twice a day for 14 days
478170|NCT00563394|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
478171|NCT00563381|Drug|Tiotropium bromide|18 mcg/daily
478172|NCT00563381|Drug|Salmeterol|100 mcg/daily
478173|NCT00563381|Drug|Placebo Salmeterol|Placebo identical to Salmeterol device
478174|NCT00563381|Drug|Placebo Tiotropium|Placebo identical to Tiotropium device
478175|NCT00563368|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
478176|NCT00563368|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
478177|NCT00563368|Drug|topiramate|topiramate 46 mg, po once daily
478178|NCT00563368|Drug|topiramate|topiramate 92 mg, po once daily
478179|NCT00563368|Drug|phentermine|phentermine 7.5 mg, po once daily
478180|NCT00563368|Drug|phentermine|phentermine 15 mg, po once daily
478181|NCT00563368|Drug|VI-0521|placebo, po once daily
478182|NCT00563355|Drug|erythropoietin|
478183|NCT00563342|Drug|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
478184|NCT00563329|Procedure|Reduction Intervention + Adherence Intervention|
478185|NCT00563329|Behavioral|Reduction Intervention|
478186|NCT00563329|Procedure|control|
478187|NCT00563316|Drug|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
478188|NCT00563316|Drug|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
478189|NCT00563303|Drug|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
478190|NCT00563303|Drug|NaCl|48mL from Day 1 to Day 6
478191|NCT00563290|Drug|dasatinib|Given PO
478193|NCT00563277|Procedure|combined pterygium and cataract operation|
478194|NCT00563277|Procedure|pterygium excision followed by cataract operation|
478195|NCT00563264|Behavioral|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).~The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
478196|NCT00563251|Drug|Azithromycin|
478197|NCT00563251|Drug|Placebo tablet|
478198|NCT00563238|Drug|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
478199|NCT00563225|Drug|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
478200|NCT00563212|Drug|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
478201|NCT00563199|Behavioral|nurse-delivered stage-matched smoking cessation counseling|
478202|NCT00563186|Other|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance (80%) of private rooms, absence of shared bathrooms, absence of curtains)
478203|NCT00563173|Drug|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
478204|NCT00563160|Drug|gemcitabine, carboplatin|
478205|NCT00563160|Procedure|surgery|
478206|NCT00563147|Drug|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
478207|NCT00563134|Drug|GR270774|
478208|NCT00563121|Procedure|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
478209|NCT00563108|Drug|Basiliximab|
478210|NCT00563108|Drug|Placebo|
478211|NCT00563095|Procedure|Transcatheter Arterial Chemoembolization (TACE)|
478212|NCT00563095|Procedure|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
478213|NCT00563069|Drug|Midazolam|
478214|NCT00563056|Drug|Flutiform|
478215|NCT00563056|Drug|Flixotide plus Foradil|
478216|NCT00563043|Procedure|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
478217|NCT00563017|Drug|Long-acting Risperidone microspheres injection|
478218|NCT00563004|Dietary Supplement|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
478219|NCT00563004|Dietary Supplement|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
478220|NCT00562991|Device|measurement of exhaled NO is used to guide treatment|exhaled NO
478221|NCT00562978|Biological|filgrastim|
478222|NCT00562978|Drug|cyclophosphamide|
478223|NCT00562978|Drug|etoposide|
478224|NCT00562978|Procedure|autologous hematopoietic stem cell transplantation|
478225|NCT00562978|Procedure|peripheral blood stem cell transplantation|
478226|NCT00562978|Radiation|yttrium Y 90 ibritumomab tiuxetan|
478227|NCT00562965|Drug|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
478228|NCT00562965|Drug|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
478229|NCT00562965|Drug|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
478230|NCT00562965|Drug|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
478231|NCT00562965|Drug|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
478232|NCT00562965|Drug|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
478233|NCT00562965|Drug|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
478234|NCT00562965|Drug|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
478235|NCT00562965|Drug|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
478236|NCT00562952|Drug|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
478237|NCT00562952|Drug|placebo|no intervention
478238|NCT00562939|Biological|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
478239|NCT00562939|Biological|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
478240|NCT00562926|Procedure|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
478241|NCT00562913|Drug|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
478242|NCT00562900|Procedure|robotic assisted cholecystectomy|robotic assisted cholecystectomy
478243|NCT00562900|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
478244|NCT00562887|Biological|Placebo|every 4 weeks, IV
478245|NCT00562887|Biological|ABT-874|400 mg IV every 4 weeks
478246|NCT00562887|Biological|ABT-874|700 mg IV every 4 weeks
478247|NCT00562874|Dietary Supplement|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
478248|NCT00562874|Dietary Supplement|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
478288|NCT00562575|Drug|Placebo|
478783|NCT00559221|Drug|FLAG+IDA|Fludarabine, cytarabine, G-CSF
478249|NCT00562874|Dietary Supplement|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
478250|NCT00562861|Drug|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
478251|NCT00562861|Drug|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
478252|NCT00562848|Drug|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
478253|NCT00562848|Drug|Placebo|Subjects will receive placebo.
478254|NCT00562835|Drug|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25*‡ 0.25 mg/kg/day; Days 26 to 28*‡ 0.125 mg/kg/day~*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
478255|NCT00562835|Other|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc [prednisolone + diluting fluid], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
478256|NCT00562822|Procedure|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
478257|NCT00562822|Other|Physical and medical therapy|Treatment with physical and medical therapy alone
478258|NCT00562809|Drug|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
478259|NCT00562783|Drug|Vitaliver|
478260|NCT00562783|Drug|Placebo|
478261|NCT00562770|Drug|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
478262|NCT00562770|Drug|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
478263|NCT00562744|Other|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
478264|NCT00562731|Drug|ARD-0403|Daily transdermal ARD-0403
478265|NCT00562718|Drug|capecitabine|
478266|NCT00562718|Procedure|adjuvant therapy|
478267|NCT00562718|Radiation|radiation therapy|
478268|NCT00562705|Behavioral|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
478269|NCT00562705|Behavioral|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
478270|NCT00562692|Drug|Nesiritide|Nesiritide 4 hour infusion
478271|NCT00562692|Drug|Placebo|Placebo infusion
478272|NCT00562679|Other|There is no intervention|
478273|NCT00562666|Other|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
478274|NCT00562640|Biological|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
478275|NCT00562640|Biological|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
478276|NCT00562640|Drug|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
478277|NCT00562640|Other|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
478278|NCT00562627|Drug|ropivacaine|intraoperative and 1. postoperative day
478279|NCT00562627|Drug|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
478280|NCT00562627|Drug|ketorolac|intraoperative and 1. postoperative day
478281|NCT00562627|Drug|morphine|intraoperative
478282|NCT00562627|Drug|fentanyl|continuous postoperatively
478283|NCT00562627|Drug|bupivacaine|continuous postoperatively
478284|NCT00562614|Drug|SLx-2101|
478285|NCT00562588|Drug|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
478286|NCT00562588|Drug|ASA 100 mg qd|
478287|NCT00562575|Drug|SLx-4090|
478289|NCT00562562|Other|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
478290|NCT00562549|Drug|SLx-2101|
478291|NCT00562536|Procedure|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
478292|NCT00562523|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
478293|NCT00562510|Drug|Raltegravir|Raltegravir 400 mg BID added to stable HAART
478294|NCT00562510|Drug|Placebo|Placebo BID added to stable HAART
478295|NCT00562497|Drug|Prochymal|Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the active treatment group will receive Prochymal™ at 2 x 106 hMSC/kg per infusion.
478296|NCT00562497|Other|Placebo|Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the non active treatment group will receive placebo (excipient, less cells). It is recommended that all subjects receive all six infusions. The discontinuation of investigational agent is allowed for GVHD worsening with subsequent need for salvage therapy. All infusions must be given at least 3 days apart.
478297|NCT00562484|Biological|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
478298|NCT00562484|Biological|Placebo|Placebo
478299|NCT00562471|Other|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
478300|NCT00562471|Other|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
478301|NCT00562458|Drug|anastrozole|
478302|NCT00562432|Device|Plexisyl-AF|Plexisyl-AF implants
478303|NCT00562432|Other|No Treatment|CABG without the experimental treatment
478304|NCT00562419|Drug|CT-322|IV solution, weekly
478305|NCT00562419|Drug|irinotecan hydrochloride|IV solution, biweekly
478306|NCT00562406|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
478307|NCT00562406|Procedure|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
478308|NCT00562393|Other|Nutritional|Overfeeding high fat diet for 28 days
478309|NCT00562380|Biological|ganitumab|
478310|NCT00562380|Other|laboratory biomarker analysis|
478311|NCT00562380|Other|pharmacological study|
478312|NCT00562380|Procedure|biopsy|
478313|NCT00562367|Drug|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
478314|NCT00562354|Biological|13vPnC|13vPnC for both stratum
478315|NCT00562341|Other|Bariatric Surgery|one time lapb-band gastric bypass surgery
478316|NCT00562328|Biological|Alemtuzumab|"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."
478317|NCT00562328|Biological|Rituximab|"Weeks 2-5:~375 mg/m^2 by IV once weekly"
478318|NCT00562328|Biological|Sargramostim|"Week 1-6:~250 mcg subcutaneously three time as week"
478319|NCT00562315|Drug|FACBC|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
478320|NCT00562315|Other|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
478321|NCT00562302|Device|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
478322|NCT00562289|Drug|aspirin|during the follow up
478323|NCT00562289|Drug|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
478324|NCT00562289|Device|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
478325|NCT00562276|Procedure|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
478326|NCT00562263|Behavioral|Lifestyle modification|Dietary modification and regular physical activity
478327|NCT00562250|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
478328|NCT00562250|Drug|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
478329|NCT00562250|Drug|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
478330|NCT00562237|Biological|S205 placebo|2 i.m. injections per subject (0.5 mL each)
478331|NCT00562237|Biological|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
478332|NCT00562237|Biological|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
478333|NCT00562237|Biological|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
478334|NCT00562237|Biological|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
478335|NCT00562237|Biological|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
478336|NCT00562237|Biological|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
478421|NCT00561704|Drug|losartan|losartan, 100mg daily,
478422|NCT00561691|Drug|nimotuzumab|monoclonal antibody
478463|NCT00561353|Drug|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
478337|NCT00562224|Drug|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
478338|NCT00562211|Drug|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
478339|NCT00562211|Drug|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
478340|NCT00562198|Drug|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
478341|NCT00562198|Drug|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
478342|NCT00562185|Drug|carboplatin|
478343|NCT00562185|Drug|doxorubicin hydrochloride|
478344|NCT00562172|Drug|Insulin glargine|Once daily in the morning
478345|NCT00562172|Drug|Glimepiride|Once daily in the morning
478346|NCT00562172|Drug|Metformin|At least 1000 mg/day
478347|NCT00562159|Drug|Placebo|Placebo sublingual tablet
478348|NCT00562159|Biological|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units [BAU] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
478349|NCT00562159|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
478350|NCT00562159|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
478351|NCT00562159|Drug|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
478352|NCT00562159|Drug|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day~(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
478353|NCT00562159|Drug|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
478354|NCT00562159|Drug|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
478355|NCT00562159|Drug|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
478356|NCT00562146|Procedure|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
478357|NCT00562133|Drug|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
478358|NCT00562133|Drug|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
478359|NCT00562120|Drug|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
478360|NCT00562120|Drug|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
478361|NCT00562120|Drug|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
478362|NCT00562120|Drug|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
478363|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
478364|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
478365|NCT00562094|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
478366|NCT00562081|Behavioral|Education|24/7 access to a Certified Asthma Educator
478367|NCT00562081|Behavioral|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
478368|NCT00562068|Biological|alemtuzumab|
478369|NCT00562068|Drug|cyclophosphamide|
478370|NCT00562068|Drug|doxorubicin hydrochloride|
478371|NCT00562068|Drug|prednisolone|
478372|NCT00562068|Drug|vincristine sulfate|
478373|NCT00562068|Genetic|polymerase chain reaction|
478374|NCT00562068|Other|flow cytometry|
478375|NCT00562068|Other|laboratory biomarker analysis|
478376|NCT00562068|Other|pharmacological study|
478377|NCT00562055|Drug|Atomoxetine|
478378|NCT00562055|Drug|PNU-165442G; [S,S]-reboxetine|
478379|NCT00562029|Procedure|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
478380|NCT00562016|Device|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
478381|NCT00562016|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
478382|NCT00562003|Procedure|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
478423|NCT00561678|Drug|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
478784|NCT00559195|Biological|epoetin beta|
478383|NCT00562003|Drug|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.~The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
478384|NCT00561990|Drug|Nimotuzumab|
478385|NCT00561977|Behavioral|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
478386|NCT00561977|Behavioral|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
478387|NCT00561977|Behavioral|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
478388|NCT00561964|Drug|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
478389|NCT00561964|Drug|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
478390|NCT00561951|Drug|fesoterodine fumarate|8mg tablets OD for 12 weeks
478391|NCT00561951|Drug|Placebo|Corresponding placebo tablets OD for 12 weeks
478392|NCT00561951|Drug|fesoterodine fumarate|4mg tablets OD for 12 weeks
478393|NCT00561938|Procedure|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
478394|NCT00561938|Procedure|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
478395|NCT00561925|Drug|nevirapine IR|200 mg BID
478396|NCT00561925|Drug|nevirapine XR|400 mg QD
478397|NCT00561912|Drug|Decitabine|15 mg/m^2 IV Daily over one hour for 5 days
478398|NCT00561912|Drug|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
478399|NCT00561899|Drug|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
478400|NCT00561899|Drug|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
478401|NCT00561899|Drug|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
478402|NCT00561886|Drug|Formoterol|One inhalation of 24µg Formoterol
478403|NCT00561860|Device|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
478404|NCT00561834|Drug|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
478405|NCT00561821|Drug|Esmirtazapine|one tablet daily
478406|NCT00561821|Drug|Placebo|one tablet daily
478407|NCT00561808|Other|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
478408|NCT00561795|Drug|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
478409|NCT00561795|Drug|carboplatin|IV over one hour every 3 weeks of 6 cycles
478410|NCT00561795|Drug|paclitaxel|IV 175 mg/m^2 given over 3 hours on day one of a 21 day cycle for six cycles
478411|NCT00561769|Drug|Norditropin pen|12 IU per day
478412|NCT00561756|Biological|plasmid DNA vaccine therapy|
478413|NCT00561756|Other|flow cytometry|
478414|NCT00561756|Other|immunoenzyme technique|
478415|NCT00561743|Drug|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
478416|NCT00561730|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
478417|NCT00561717|Drug|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
478418|NCT00561717|Drug|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
478419|NCT00561717|Drug|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
478420|NCT00561717|Drug|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
478424|NCT00561678|Drug|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
478425|NCT00561652|Behavioral|Education & Exercise|Education & Exercise
478426|NCT00561652|Procedure|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education & Exercise)
478427|NCT00561626|Dietary Supplement|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
478428|NCT00561626|Dietary Supplement|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
478429|NCT00561613|Other|SILCS and lubricant|
478430|NCT00561613|Other|SILCS and spermicide|
478431|NCT00561600|Device|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
478432|NCT00561600|Device|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
478433|NCT00561587|Drug|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
478434|NCT00561574|Drug|Esmirtazapine|One tablet daily
478435|NCT00561561|Behavioral|Acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
478436|NCT00561548|Procedure|rectosigmoïdal biopsies|rectosigmoïdal biopsies
478437|NCT00561535|Dietary Supplement|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
478438|NCT00561535|Dietary Supplement|placebo (starch)|Once daily
478439|NCT00561522|Drug|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
478440|NCT00561522|Other|No other preventive treatment|No other preventive treatment
478441|NCT00561509|Drug|SSRIs|Use within normal clinical practice
478442|NCT00561509|Drug|Dual antidepressants|Use within clinical practice
478443|NCT00561496|Drug|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
478444|NCT00561470|Drug|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
478445|NCT00561470|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
478446|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
478447|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1~The FOLFIRI regimen included:~180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:~5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:~5-FU 2400 mg/m² continuous IV infusion over 46-hours"
478448|NCT00561457|Device|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
478449|NCT00561444|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
478450|NCT00561431|Device|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
478451|NCT00561431|Device|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
478452|NCT00561418|Drug|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
478453|NCT00561418|Other|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
478454|NCT00561405|Behavioral|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
478455|NCT00561405|Behavioral|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
478456|NCT00561392|Drug|Rivastigmine 5 and 10 cm^2 patch|
478457|NCT00561379|Drug|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
478458|NCT00561379|Drug|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
478459|NCT00561366|Drug|Placebo|Placebo t.i.d.
478460|NCT00561366|Drug|Arimoclomol|capsule, 400 mg t.i.d.
478461|NCT00561353|Drug|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
478462|NCT00561353|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
478464|NCT00561353|Drug|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
478465|NCT00561340|Dietary Supplement|Pediasure|50% will be randomized to pediasure with nutritional counseling
478466|NCT00561340|Behavioral|Nutritional counseling|50% randomized to nutritional counseling only
478467|NCT00561327|Drug|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
478468|NCT00561314|Other|questionnaire administration|
478469|NCT00561314|Procedure|biopsy|
478470|NCT00561314|Procedure|high-intensity focused ultrasound ablation|
478471|NCT00561314|Procedure|magnetic resonance imaging|
478472|NCT00561314|Procedure|quality-of-life assessment|
478473|NCT00561301|Drug|GemDOx|gemcitabine oxliplatin
478474|NCT00561288|Drug|acetaminophen|2 x 1000 mg doses per day
478475|NCT00561288|Other|cornstarch|2 x 1000 mg cornstarch per day
478476|NCT00561275|Biological|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
478477|NCT00561262|Other|questionnaire administration|
478478|NCT00561262|Procedure|high-intensity focused ultrasound ablation|
478479|NCT00561262|Procedure|quality-of-life assessment|
478480|NCT00561249|Procedure|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
478481|NCT00561223|Drug|iloprost Inhalation|inhale 2.5 mg, repeat times one
478482|NCT00561223|Drug|iloprost|inhaled 2.5 mg, repeat times one
478483|NCT00561210|Dietary Supplement|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
478484|NCT00561210|Dietary Supplement|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
478485|NCT00561197|Drug|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
478486|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
478487|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
478488|NCT00561171|Drug|SPP635|oral once daily
478489|NCT00561158|Behavioral|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.~The group sessions included are:~Rate Your Plate: determining high fat foods~Label Reading: reading food labels~Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income~Recipe Modification: preparing old recipes in new ways to reduce fat~Eating Out: order healthier fast foods~Coping with High Risk Situations: coping with situations in which these new habits may be threatened~Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:~Substituting fat-modified foods for high fat foods~Avoiding fat as a seasoning or flavoring~Avoiding fried foods~Modifying meat~Replacing high fat foods with fruits, vegetables, grains and breads"
478490|NCT00561145|Other|Energy restriction period|The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
478491|NCT00561132|Dietary Supplement|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
478492|NCT00561132|Other|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (<50 mg) twice daily for a period of 4 weeks
478493|NCT00561119|Drug|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 & 8~Paclitaxel 175 mg/m2 i.v. day 1~repeat every 3 weeks"
478494|NCT00561106|Drug|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
478495|NCT00561106|Drug|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
478496|NCT00561093|Drug|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
478497|NCT00561093|Dietary Supplement|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
478498|NCT00561093|Dietary Supplement|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
478499|NCT00561093|Drug|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
478500|NCT00561093|Dietary Supplement|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
478501|NCT00561093|Dietary Supplement|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
478502|NCT00561080|Biological|Zostavax|
478503|NCT00561067|Drug|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
478540|NCT00560755|Biological|ProQuad®|ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
478504|NCT00561067|Drug|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
478505|NCT00561054|Drug|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
478506|NCT00561041|Behavioral|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
478507|NCT00561041|Behavioral|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
478508|NCT00561028|Other|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
478509|NCT00561015|Drug|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
478510|NCT00561015|Drug|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
478511|NCT00561015|Drug|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
478512|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
478513|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
478514|NCT00560976|Drug|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
478515|NCT00560963|Drug|everolimus|
478516|NCT00560950|Biological|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
478517|NCT00560937|Drug|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
478518|NCT00560937|Drug|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
478519|NCT00560924|Drug|estradiol, 25 mcg|
478520|NCT00560911|Behavioral|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.~After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
478521|NCT00560911|Behavioral|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session~During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
478522|NCT00560898|Drug|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
478523|NCT00560898|Drug|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
478524|NCT00560898|Drug|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
478525|NCT00560898|Drug|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
478526|NCT00560885|Device|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
478527|NCT00560872|Device|remote magnetic catheter navigation|use of the Stereotaxis system
478528|NCT00560872|Procedure|cavotricuspid isthmus ablation|conventional (manual) approach
478529|NCT00560859|Procedure|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
478530|NCT00560859|Other|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
478531|NCT00560846|Dietary Supplement|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
478532|NCT00560846|Dietary Supplement|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
478533|NCT00560833|Drug|esmirtazapine|
478534|NCT00560833|Drug|Placebo|
478535|NCT00560820|Drug|Deferasirox|30 mg/kg/day
478536|NCT00560807|Procedure|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
478537|NCT00560794|Biological|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
478538|NCT00560781|Drug|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
478539|NCT00560768|Device|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:~A right ventricular defibrillation lead~In case of use of a dual chamber ICD a right atrial pacing lead~A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.~Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
478541|NCT00560742|Procedure|Control|Coronary artery bypass grafting without bone marrow cells injection
489821|NCT00478543|Drug|Furosemide|
478542|NCT00560742|Procedure|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
478543|NCT00560742|Procedure|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
478544|NCT00560729|Dietary Supplement|Renutryl 500|
478545|NCT00560729|Dietary Supplement|Generique|
478546|NCT00560729|Dietary Supplement|Generique + Renutryl 500|
478547|NCT00560716|Drug|CYC116|Dose escalation of CYC116
478548|NCT00560703|Drug|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
478549|NCT00560703|Drug|placebo|sugar capsule
478550|NCT00560690|Drug|Metformin|500 mg oral three times a day for 6 months
478551|NCT00560690|Drug|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
478552|NCT00560690|Drug|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
478553|NCT00560664|Procedure|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
478554|NCT00560664|Procedure|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
478555|NCT00560651|Procedure|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
478556|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|TID
478557|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|QID
478558|NCT00560638|Drug|vehicle of loteprednol etabonate|TID or BID according to the randomization
478559|NCT00560612|Drug|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
478560|NCT00560612|Drug|Placebo|Placebo: same as paroxetine (active comparator)
478561|NCT00560599|Drug|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
478562|NCT00560599|Behavioral|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
478563|NCT00560599|Drug|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.~Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.~Environmental cleaning with topical ethanol and laundering of clothes and linen."
478564|NCT00560586|Drug|Budesonide|1 puff each nostril (32 micrograms) at bedtime
478565|NCT00560586|Drug|placebo|1 puff each nostril at bedtime
478566|NCT00560573|Drug|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
478567|NCT00560573|Drug|Cisplatin|"Cisplatin 75* mg/m2 or 80* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.~* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
478568|NCT00560573|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
478569|NCT00560573|Drug|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
478570|NCT00560560|Biological|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
478571|NCT00560547|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
478572|NCT00560534|Procedure|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
478573|NCT00560521|Behavioral|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
478574|NCT00560508|Drug|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
478575|NCT00560508|Drug|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
478576|NCT00560495|Drug|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
478577|NCT00560495|Other|immunoenzyme technique|
478578|NCT00560495|Other|laboratory biomarker analysis|
478579|NCT00560495|Radiation|Tc 99m sestamibi|
478580|NCT00560495|Radiation|radiation therapy|once daily, 5 days a week, for 6-7 weeks
478581|NCT00560482|Drug|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
478582|NCT00560482|Drug|Placebo|Identical appearing gelatin capsules containing placebo
478583|NCT00560469|Other|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
478584|NCT00560456|Other|Chronic sleep restriction and driving simulator|"One night of normal sleep~Driving simulator~Night 1: night of total sleep deprivation~Night 2: night of sleep recovery~Night 1 to 5: nights of sleep restriction~Driving simulator after night 1 to 5~Night 6: night of sleep recovery~Driving simulator"
478585|NCT00560443|Drug|ketorolac|0,5 mg/kg per os one time
478586|NCT00560443|Drug|tramadol|2,5 mg/ kg per os in one dose
478587|NCT00560430|Drug|telmisartan|80 mg per day, orally, weeks 1-14
478588|NCT00560430|Drug|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
478589|NCT00560430|Drug|placebo|placebo; orally weeks 1-14
478590|NCT00560417|Drug|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
478591|NCT00560417|Drug|Insulin Glargine|Administered subcutaneously once a day at bedtime
478592|NCT00560404|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
478593|NCT00560404|Drug|Epoetin alfa|As prescribed
478594|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
478595|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
478596|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
478597|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
478598|NCT00560391|Drug|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
478599|NCT00560378|Drug|Tacrolimus ointment 0.1%|Topical
478600|NCT00560365|Other|laboratory biomarker analysis|
478601|NCT00560365|Procedure|computed tomography|
478602|NCT00560365|Procedure|magnetic resonance imaging|
478603|NCT00560365|Procedure|quality-of-life assessment|
478604|NCT00560352|Drug|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
478605|NCT00560352|Drug|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m^2 QD, 1.3 mg/m^2 QD
478606|NCT00560352|Drug|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
478607|NCT00560326|Drug|Tacrolimus Ointment 0.03%|Once or twice daily topical application
478608|NCT00560313|Biological|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
478609|NCT00560313|Biological|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
478610|NCT00560300|Drug|1 alpha D2|Vitamin D sterol
478611|NCT00560300|Drug|1,25 dihydroxy vitamin D3|Active vitamin D sterol
478612|NCT00560300|Drug|Sevelamer HCl|Phosphate binder
478613|NCT00560300|Drug|Calcium Carbonate|Phosphate binder
478614|NCT00560287|Device|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
478615|NCT00560287|Device|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
478616|NCT00560274|Drug|Pegasys|As prescribed
478617|NCT00560274|Drug|Ribavirin|As prescribed
478618|NCT00560274|Drug|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
478619|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
478620|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
478621|NCT00560235|Drug|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
478622|NCT00560222|Dietary Supplement|bovine lactoferrin|1gm of lactoferrin will be given each day
478623|NCT00560222|Dietary Supplement|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
478624|NCT00560209|Drug|ONO-1101|placebo for 1 minute IV
478625|NCT00560209|Drug|ONO-1101|0.06 mg/kg for 1 minute IV
478626|NCT00560209|Drug|ONO-1101|0.125 mg/kg for 1 minute IV
478627|NCT00560196|Other|Observation|N.A.
478628|NCT00560183|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
478629|NCT00560183|Drug|Placebo|Capsules
478630|NCT00560170|Drug|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
478631|NCT00560170|Drug|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
478632|NCT00560157|Dietary Supplement|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
478633|NCT00560144|Drug|RG1507|3mg/kg iv weekly
478634|NCT00560144|Drug|RG1507|9mg/kg iv weekly
478635|NCT00560144|Drug|RG1507|Pharmacokinetic-derived dose, <=16mg/kg iv weekly
478636|NCT00560118|Drug|fotemustine|
478637|NCT00560118|Genetic|gene expression analysis|
478638|NCT00560118|Genetic|polymerase chain reaction|
478639|NCT00560105|Device|Lung Flute|8 weeks home use, twice daily
478640|NCT00560105|Device|Acapella|8 weeks home use, twice daily
478641|NCT00560092|Drug|intrathecal magnesium sulfate|intrathecal magnesium sulfate
478642|NCT00560079|Drug|Allopurinol|Allopurinol 600mg/day bid for 28 days
478643|NCT00560079|Drug|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
478644|NCT00560079|Drug|Placebo|Placebo
478645|NCT00560066|Biological|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
478646|NCT00560066|Biological|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
478647|NCT00560053|Drug|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.~VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
490143|NCT00475969|Drug|duloxetine|
478648|NCT00560053|Procedure|Autologous Transplantation|"Autologous Transplantation :~BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
478649|NCT00560053|Drug|Maintenance|"At 3 months of transplantation or with >1.500 neutrophiles/ > 75.000 platelets mm 3 .~Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
478650|NCT00560053|Procedure|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
478651|NCT00560053|Procedure|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
478652|NCT00560027|Other|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
478653|NCT00560014|Dietary Supplement|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
478654|NCT00560014|Dietary Supplement|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
478655|NCT00560001|Behavioral|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
478656|NCT00559988|Drug|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
478657|NCT00559988|Drug|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.~OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
478658|NCT00559975|Biological|Subunit influenza vaccine|0.5 mL single dose vaccine
478659|NCT00559975|Biological|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
478660|NCT00559975|Biological|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
478661|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
478662|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
478663|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
478664|NCT00559962|Drug|placebo|3 capsules each evening for each 4-week period
478665|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
478666|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
478667|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
478668|NCT00559962|Drug|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
478669|NCT00559962|Drug|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
478670|NCT00559962|Drug|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
478671|NCT00559949|Other|Laboratory Biomarker Analysis|Correlative studies
478672|NCT00559949|Drug|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
478673|NCT00559936|Drug|Topical Avastin 1%|Avastin (bevacizumab) 1%
478674|NCT00559910|Drug|PH-797804|PH-797804 at four dose levels
478675|NCT00559910|Drug|Placebo|Placebo
478676|NCT00559897|Other|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
478677|NCT00559897|Procedure|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
478678|NCT00559884|Drug|GSK189075 (Modified and immediate release formulations)|
478679|NCT00559871|Drug|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
478680|NCT00559858|Dietary Supplement|pyridoxine hydrochloride|
478681|NCT00559858|Other|placebo|
478682|NCT00559858|Procedure|quality-of-life assessment|
478683|NCT00559845|Drug|5-fluorouracil|600 milligrams per meter squared (mg/m^2) as an intravenous (i.v.) bolus over ≤15 minutes every 3 weeks for 4 cycles.
478684|NCT00559845|Drug|Epidoxorubicin|90 mg/m^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
478685|NCT00559845|Drug|Cyclophosphamide|600 mg/m^2 as an i.v. infusion over 1 hour every 3 weeks for 4 cycles.
478686|NCT00559845|Drug|Paclitaxel|Paclitaxel was administered at 80 mg/m^2 i.v. over 1 hour weekly for 12 weeks.
478687|NCT00559845|Biological|Bevacizumab|Bevacizumab was administered at 10 milligrams per kilogram (mg/kg) i.v. every 2 weeks for 6 cycles.
478688|NCT00559832|Other|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
478689|NCT00559819|Drug|placebo|Placebo (orange juice), same volume as alcohol
478690|NCT00559819|Drug|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
478740|NCT00559494|Drug|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
478785|NCT00559195|Procedure|quality-of-life assessment|
478691|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
478692|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
478693|NCT00559780|Behavioral|Resistance training|12 weeks of resistance training (3/week)
478694|NCT00559780|Behavioral|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
478695|NCT00559780|Behavioral|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
478696|NCT00559754|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
478697|NCT00559754|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
478698|NCT00559754|Drug|Standard chemotherapy|As prescribed
478699|NCT00559741|Biological|cetuximab|
478700|NCT00559741|Drug|fluorouracil|
478701|NCT00559741|Drug|irinotecan hydrochloride|
478702|NCT00559741|Drug|leucovorin calcium|
478703|NCT00559741|Other|pharmacological study|
478704|NCT00559715|Drug|bevacizumab|1.25 mg intravitreally monthly/on demand
478705|NCT00559715|Drug|ranibizumab|0.5 mg intravitreally monthly/on demand
478706|NCT00559702|Drug|natalizumab|natalizumab
478707|NCT00559702|Other|standard of care|standard of care as determined by the Investigator and Treating Neurologist
478708|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
478709|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
478710|NCT00559676|Drug|capecitabine|
478711|NCT00559676|Drug|fluorouracil|
478712|NCT00559676|Drug|irinotecan hydrochloride|
478713|NCT00559676|Drug|leucovorin calcium|
478714|NCT00559676|Drug|oxaliplatin|
478715|NCT00559676|Other|laboratory biomarker analysis|
478716|NCT00559676|Other|pharmacological study|
478717|NCT00559663|Dietary Supplement|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.~After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
478718|NCT00559663|Dietary Supplement|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.~After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).~Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
478719|NCT00559650|Drug|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
478720|NCT00559650|Drug|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
478721|NCT00559637|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
478722|NCT00559624|Drug|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
478723|NCT00559611|Procedure|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
478724|NCT00559611|Procedure|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
478725|NCT00559598|Genetic|proteomic profiling|
478726|NCT00559598|Other|medical chart review|
478727|NCT00559585|Drug|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
478728|NCT00559585|Drug|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).~500mg (for body weight up to 60 kg)~750 mg (body weight between 61 and 100 kg)~1g (body weight above 100 kg)infusions"
478729|NCT00559572|Behavioral|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
478730|NCT00559572|Other|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
478731|NCT00559559|Device|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
478732|NCT00559559|Procedure|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
478733|NCT00559546|Drug|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
478734|NCT00559533|Drug|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
478735|NCT00559520|Dietary Supplement|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
478736|NCT00559520|Dietary Supplement|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
478737|NCT00559507|Drug|saracatinib|
478738|NCT00559507|Other|laboratory biomarker analysis|Correlative studies
478739|NCT00559494|Drug|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
478741|NCT00559494|Procedure|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
478742|NCT00559494|Procedure|SCPP control|maintenance of Mean arterial pressure of >65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
478743|NCT00559481|Drug|dexamethasone|
478744|NCT00559481|Drug|ketoconazole|
478745|NCT00559481|Drug|therapeutic hydrocortisone|
478746|NCT00559481|Procedure|pharmacological study|
478747|NCT00559468|Drug|Sugammadex|Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
478748|NCT00559468|Drug|Rocuronium|Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
478749|NCT00559468|Drug|Sevoflurane|Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
478750|NCT00559468|Drug|Propofol|Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
478751|NCT00559455|Drug|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
478752|NCT00559455|Drug|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
478753|NCT00559455|Drug|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
478754|NCT00559442|Other|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
478755|NCT00559429|Drug|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
478756|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
478757|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
478758|NCT00559429|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
478759|NCT00559416|Drug|Cell Transfer|
478760|NCT00559403|Behavioral|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
478761|NCT00559403|Behavioral|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
478762|NCT00559377|Other|18F-fluoromisonidazole|Undergo ^18F FMISO PET scan
478763|NCT00559377|Radiation|fluorodeoxyglucose F 18|Undergo ^18F FDG PET scan
478764|NCT00559377|Procedure|positron emission tomography|Undergo ^18F-FMISO and ^18F FDG PET scan
478765|NCT00559377|Other|tissue oxygen measurement|Undergo ^18 F FMISO PET and ^18F FDG PET
478766|NCT00559364|Drug|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
478767|NCT00559364|Drug|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
478768|NCT00559364|Drug|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
478769|NCT00559364|Drug|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
478770|NCT00559351|Procedure|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
478771|NCT00559351|Drug|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
478772|NCT00559351|Radiation|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
478773|NCT00559338|Drug|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
478774|NCT00559338|Drug|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
478775|NCT00559312|Drug|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
478776|NCT00559312|Drug|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
478777|NCT00559299|Drug|GSK163090|
478778|NCT00559286|Drug|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
478779|NCT00559273|Drug|Methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg SC monthly, starting dose
478780|NCT00559273|Drug|Darbepoetin alfa|0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
478781|NCT00559260|Device|Passive monitoring with pulse-oximetry, NIBP and ECG|
478782|NCT00559247|Drug|BMS-650032 or Placebo|Oral, Once daily, Single Dose
490144|NCT00475969|Drug|placebo|
478786|NCT00559182|Drug|Comparator: MK-8033|"MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at ~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed."
478787|NCT00559182|Drug|Comparator: MK-8033 +/- omeprazole|"Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended."
478788|NCT00559169|Drug|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
478789|NCT00559156|Dietary Supplement|arginine/omega-3 fatty acids/nucleotides oral supplement|
478790|NCT00559156|Drug|cisplatin|
478791|NCT00559156|Procedure|adjuvant therapy|
478792|NCT00559156|Radiation|radiation therapy|
478793|NCT00559143|Other|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
478794|NCT00559130|Device|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
478795|NCT00559117|Drug|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
478796|NCT00559104|Drug|carmustine|Unique to the Carmustine in Conditioning arm
478797|NCT00559104|Drug|cyclophosphamide|Used in Both Arms
478798|NCT00559104|Drug|etoposide|Used in Both Arms
478799|NCT00559104|Procedure|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
478800|NCT00559104|Procedure|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
478801|NCT00559104|Radiation|total-body irradiation|Unique to the Radiation in Conditioning Arm
478802|NCT00559104|Drug|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
478803|NCT00559091|Drug|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
478804|NCT00559078|Other|Interview|Hour-long, qualitative, phone interview
478805|NCT00559052|Drug|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
478806|NCT00559039|Other|questionnaire administration|
478807|NCT00559039|Procedure|evaluation of cancer risk factors|
478808|NCT00559026|Biological|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
478809|NCT00559026|Other|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
478810|NCT00559013|Device|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
478811|NCT00559000|Behavioral|KIDNET|Narrative Exposure Therapy for Children
478812|NCT00558987|Behavioral|Discipline Video|"The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.~A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
478813|NCT00558987|Behavioral|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
478814|NCT00558961|Drug|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
478815|NCT00558935|Dietary Supplement|Red Wine|20g alcohol daily/red wine for 4 weeks
478816|NCT00558922|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
478817|NCT00558909|Drug|BI 44847|
478818|NCT00558909|Drug|placebo for BI 44847|
478819|NCT00558896|Drug|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
478820|NCT00558896|Drug|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
478821|NCT00558883|Drug|acarbose|oral application
478822|NCT00558870|Drug|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
478823|NCT00558870|Drug|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)~Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
478824|NCT00558857|Device|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
478825|NCT00558844|Drug|Arikayce™ 560 mg|"Arikayce™ at 560 mg~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
478826|NCT00558844|Drug|Placebo for 560 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
478827|NCT00558844|Drug|Arikayce™ 70 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
478828|NCT00558844|Drug|Arikayce™ 140 mg|Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
478829|NCT00558844|Drug|Placebo for 70 mg / 140 mg|"Matching placebo~Subjects will be randomly assigned to study drug dose of of Arikayce™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 1:1:1 allocation between Arikayce™ and placebo. They will be blinded whether they receive Arikayce™ or Placebo Study subjects will receive Arikayce™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer."
478830|NCT00558831|Drug|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
478831|NCT00558831|Drug|Moisturizing Lotion|
478832|NCT00558818|Drug|Clevudine|clevudine 30 mg qd
478833|NCT00558805|Behavioral|FISP + Usual Care|
478834|NCT00558805|Behavioral|Usual Care|
478835|NCT00558792|Drug|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
478836|NCT00558792|Drug|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
478837|NCT00558792|Drug|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
478838|NCT00558779|Procedure|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
478839|NCT00558779|Procedure|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
478840|NCT00558753|Drug|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
478841|NCT00558753|Drug|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
478842|NCT00558740|Other|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
478843|NCT00558727|Drug|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
478844|NCT00558701|Device|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
478845|NCT00558701|Device|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
478846|NCT00558688|Procedure|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
478847|NCT00558675|Biological|AlloStim|single intravenous infusion of 1 x 10^9 AlloStim cells
478848|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7
478849|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14
478850|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21
478851|NCT00558662|Device|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
478852|NCT00558662|Device|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
478853|NCT00558649|Biological|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
478854|NCT00558636|Drug|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
478855|NCT00558636|Drug|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
478856|NCT00558623|Dietary Supplement|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
478857|NCT00558584|Device|protein A immunoadsorption|protein-A immunoadsorption and i.v. IgG substitution
478858|NCT00558584|Device|pseudo-immunoadsorption|pseudo-immunoadsorption followed by an intravenous infusion without IgG
478859|NCT00558571|Drug|BI 10773 low dose|
478860|NCT00558571|Drug|placebo to BI 10773|
478861|NCT00558571|Drug|BI 10773 medium dose|
478862|NCT00558571|Drug|BI 10773 high dose|
478863|NCT00558558|Drug|Haelan|4 oz orally twice daily for 8 Weeks
478864|NCT00558545|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
478865|NCT00558532|Procedure|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
478866|NCT00558519|Drug|cyclophosphamide|
478867|NCT00558519|Drug|cytarabine|
478868|NCT00558519|Drug|daunorubicin hydrochloride|
478869|NCT00558519|Drug|dexamethasone|
478870|NCT00558519|Drug|doxorubicin hydrochloride|
478871|NCT00558519|Drug|mercaptopurine|
478872|NCT00558519|Drug|methotrexate|
478873|NCT00558519|Drug|pegaspargase|
478874|NCT00558519|Drug|thioguanine|
478875|NCT00558519|Drug|vincristine sulfate|
478876|NCT00558519|Radiation|radiation therapy|
478877|NCT00558506|Drug|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
478878|NCT00558493|Drug|Clevudine|clevudine 30 mg qd for 24 seeks
478879|NCT00558480|Drug|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
478880|NCT00558480|Drug|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
478881|NCT00558467|Drug|pramipexole immediate release (IR)|
478882|NCT00558467|Drug|Placebo|
478883|NCT00558454|Drug|Iron|Ferrous succinate mixture
478884|NCT00558441|Device|IVMRI|Intra Vascular Magnetic Resonance Imaging
478885|NCT00558428|Drug|fixed dose combination of telmisartan+amlodipine|
478886|NCT00558428|Drug|amlodipine|
478887|NCT00558402|Behavioral|Meditation|meditation class 1/week for 8 weeks
478888|NCT00558402|Behavioral|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
478889|NCT00558402|Behavioral|Respite only|Respite care 90 mins per week for 8 weeks
478890|NCT00558376|Drug|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
478891|NCT00558376|Drug|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
478892|NCT00558363|Drug|Avodart|0.5 mg administered orally once daily
478893|NCT00558363|Other|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
478894|NCT00558337|Drug|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
478895|NCT00558324|Procedure|LASIK|Mechanical microkeratome Hansatome 160 microns
478896|NCT00558324|Procedure|LASIK|Mechanical microkeratome K 3000 130 microns
478897|NCT00558324|Procedure|LASIK|Femtoseconds laser 100 microns
478898|NCT00558311|Drug|clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h for the duration of the treatment
478899|NCT00558311|Drug|placebo|Placebo administered by continuous infusion at 5 mg/h for the duration of the treatment.
478900|NCT00558298|Drug|risperidone|
478901|NCT00558285|Drug|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
478902|NCT00558285|Drug|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
478903|NCT00558285|Drug|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
478904|NCT00558285|Drug|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
478905|NCT00558272|Drug|AZD0530|Daily oral dose
478906|NCT00558272|Drug|Zoledronic Acid|
478907|NCT00558259|Drug|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
478908|NCT00558259|Drug|matching placebo twice daily (BID)|Matching placebo BID
478909|NCT00558246|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
478910|NCT00558246|Device|Suture|Topical Suturing
478911|NCT00558233|Behavioral|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
478912|NCT00558233|Behavioral|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
478913|NCT00558220|Procedure|immunotherapy|"Given together with induction chemotherapy:~Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
478914|NCT00558220|Procedure|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.~3 cycles consisting of combination treatment of above mentioned drugs are given."
478915|NCT00558220|Procedure|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.~Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.~Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are >20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
478916|NCT00558220|Procedure|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.~Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
478917|NCT00558220|Procedure|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
478956|NCT00557973|Drug|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
478957|NCT00557960|Drug|Mixed salts of a single-entity amphetamine|
478958|NCT00557960|Drug|Atomoxetine hydrochloride|
478918|NCT00558220|Radiation|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
478919|NCT00558207|Drug|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
478920|NCT00558207|Drug|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
478921|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
478922|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
478923|NCT00558181|Drug|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
478924|NCT00558155|Drug|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
478925|NCT00558155|Drug|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
478926|NCT00558155|Drug|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
478927|NCT00558155|Drug|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
478928|NCT00558142|Drug|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
478929|NCT00558142|Drug|Visipaque 320|100mls IV dose as single dose
478930|NCT00558142|Drug|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
478931|NCT00558129|Device|X-STOP®|Surgical implantation of X-STOP IPD device
478932|NCT00558129|Procedure|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
478933|NCT00558116|Device|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
478934|NCT00558103|Drug|lapatinib|Oral administration
478935|NCT00558103|Drug|Pazopanib|Oral administration
478936|NCT00558090|Drug|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
478937|NCT00558077|Drug|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
478938|NCT00558077|Procedure|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
478939|NCT00558064|Drug|telmisartan+amlodipine|
478940|NCT00558064|Drug|amlodipine|
478941|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
478942|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
478943|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
478944|NCT00558038|Drug|AST-120|AST-120
478945|NCT00558038|Drug|lactulose|lactulose
478946|NCT00558025|Drug|Pramipexole Extended Release|
478947|NCT00558025|Drug|Pramipexole Immediate Release|
478948|NCT00558012|Drug|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
478949|NCT00558012|Dietary Supplement|Vitamin D 800 IU/daily|Daily divided dose
478950|NCT00558012|Dietary Supplement|Calcium 1200 mg/daily|supplement plus diet
478951|NCT00557999|Other|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
478952|NCT00557986|Procedure|Primary surgery|Primary breast surgery before systemic therapy
478953|NCT00557973|Drug|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
478954|NCT00557973|Drug|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
478955|NCT00557973|Drug|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
478959|NCT00557947|Device|Suture|intradermal and topical suturing
479189|NCT00556218|Behavioral|No Meditation|No meditation; usual care.
478960|NCT00557947|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
478961|NCT00557934|Other|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
478962|NCT00557921|Drug|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
478963|NCT00557921|Drug|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
478964|NCT00557908|Drug|VWF/FVIII products|"Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)~Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.~Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses"
478965|NCT00557882|Device|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
478966|NCT00557856|Drug|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
478967|NCT00557843|Drug|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
478968|NCT00557843|Drug|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
478969|NCT00557830|Drug|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
478970|NCT00557830|Drug|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
478971|NCT00557817|Drug|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to > 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases < 13 g/dL. If the Hb decreases to < 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
478972|NCT00557817|Drug|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin > 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS > 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation < 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
478973|NCT00557804|Device|MUSE clinical system|non-invasive external monitoring device
478974|NCT00557791|Drug|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
478975|NCT00557791|Drug|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
478976|NCT00557752|Device|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
478977|NCT00557739|Drug|mometasone furoate|Topical 0.1% mometasone furoate
478978|NCT00557739|Drug|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
478979|NCT00557739|Drug|Vehicle (placebo)|Topical placebo
478980|NCT00557713|Drug|bevacizumab|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)~-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))~-Surgery (6-8 weeks after last bevacizumab dose)~-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
478981|NCT00557700|Drug|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
478982|NCT00557700|Drug|Administration of placebo|Administration of placebo
478983|NCT00557661|Drug|CD-NP|24 hr intravenous infusion
478984|NCT00557648|Behavioral|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
478985|NCT00557648|Behavioral|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
478986|NCT00557635|Procedure|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
478987|NCT00557622|Drug|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
478988|NCT00557622|Other|placebo|placebo
478989|NCT00557609|Drug|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
478990|NCT00557596|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
478991|NCT00557583|Drug|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
490487|NCT00473213|Drug|Interferon Beta 1|
478992|NCT00557557|Drug|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
478993|NCT00557557|Drug|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
478994|NCT00557544|Drug|metoclopramide|metoclopramide 0,15 mg/kg
478995|NCT00557544|Drug|placebo|placebo per os
478996|NCT00557544|Drug|ketoprofen|ketoprofen 1 mg/Kg
478997|NCT00557531|Device|BL-1040|2 mL of BL-1040
478998|NCT00557518|Drug|Alagebrium|200 mg bid
478999|NCT00557518|Drug|Placebo|bid
479000|NCT00557505|Drug|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
479001|NCT00557492|Drug|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
479002|NCT00557492|Drug|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
479003|NCT00557492|Radiation|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
479004|NCT00557466|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
479005|NCT00557466|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
479006|NCT00557466|Drug|placebo to indacaterol|Placebo TWISTHALER® device
479007|NCT00557466|Drug|placebo to formoterol|Placebo AEROLIZER® device
479008|NCT00557466|Drug|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
479009|NCT00557453|Drug|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
479010|NCT00557453|Drug|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
479011|NCT00557440|Drug|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
479012|NCT00557440|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
479013|NCT00557440|Drug|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
479014|NCT00557440|Drug|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
479015|NCT00557427|Drug|hypericum|250mg tablets twice daily for 8 weeks
479016|NCT00557427|Drug|fluoxetine|20mg - 40mg daily for 8 weeks
479017|NCT00557401|Drug|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
479018|NCT00557401|Drug|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
479019|NCT00557401|Drug|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
479020|NCT00557401|Drug|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
479021|NCT00557401|Drug|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
479022|NCT00557388|Dietary Supplement|Protein/Amino Acids|Casein Whey Leucine
479023|NCT00557388|Other|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
479024|NCT00557362|Drug|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
479025|NCT00557362|Drug|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.~One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
479026|NCT00557362|Procedure|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
479027|NCT00557349|Drug|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
479028|NCT00557349|Drug|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
479029|NCT00557336|Drug|somatropin|
479030|NCT00557323|Drug|Lanthanum carbonate|
479031|NCT00557310|Drug|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
479032|NCT00557284|Drug|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
479033|NCT00557284|Drug|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
479034|NCT00557245|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
479035|NCT00557245|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
479036|NCT00557245|Drug|Placebo|Placebo TDF & Placebo FTC/TDF, 1 tablet each daily.
479037|NCT00557232|Drug|bevacizumab|1.25mg/month
479038|NCT00557219|Drug|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
490697|NCT00471289|Device|PTA|PTA
479039|NCT00557219|Drug|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
479040|NCT00557219|Drug|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
479041|NCT00557206|Drug|Oxaliplatin and Docetaxel|"Chemotherapy~Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
479042|NCT00557193|Drug|Asparaginase|Given IV, IM, or PO
479043|NCT00557193|Drug|Cyclophosphamide|Given IV
479044|NCT00557193|Drug|Cytarabine|Given IV or IT
479045|NCT00557193|Drug|Daunorubicin Hydrochloride|Given IV
479046|NCT00557193|Drug|Dexamethasone|Given IV or PO
479047|NCT00557193|Drug|Etoposide|Given IV
479048|NCT00557193|Biological|Filgrastim|Given IV or SC
479049|NCT00557193|Other|Laboratory Biomarker Analysis|Correlative studies
479050|NCT00557193|Drug|Lestaurtinib|Given PO
479051|NCT00557193|Drug|Leucovorin Calcium|Given IV
479052|NCT00557193|Drug|Mercaptopurine|Given PO
479053|NCT00557193|Drug|Methotrexate|Given IV, IT, or PO
479054|NCT00557193|Drug|Methylprednisolone|Given IV
479055|NCT00557193|Drug|Pegaspargase|Given IM
479056|NCT00557193|Other|Pharmacological Study|Correlative studies
479057|NCT00557193|Drug|Prednisone|Given PO
479058|NCT00557193|Drug|Therapeutic Hydrocortisone|Given IT
479059|NCT00557193|Drug|Vincristine Sulfate|Given IV
479060|NCT00557180|Drug|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
479061|NCT00557180|Drug|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
479062|NCT00557180|Drug|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
479063|NCT00557154|Device|ultrasound|ultrasound used to identify target vein
479064|NCT00557154|Device|standard technique for venipuncture|routine equipment
479065|NCT00557128|Drug|COREG CR and lisinopril (FDC)|
479066|NCT00557115|Other|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
479067|NCT00557102|Biological|cetuximab|
479068|NCT00557102|Biological|filgrastim|
479069|NCT00557102|Drug|fluorouracil|
479070|NCT00557102|Drug|irinotecan hydrochloride|
479071|NCT00557102|Drug|leucovorin calcium|
479072|NCT00557089|Drug|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
479073|NCT00557089|Other|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
479074|NCT00557076|Behavioral|Familiar Auditory Sensory Training|Patient is provided with customized recordings of stories told by people well known to the patient at least 1 year prior to injury. The stories represent specific events experienced by both the patient and the storyteller. Patients received FAST for 10 minutes 4 times per day, with at least 2 hours in between, for 6 week.
479075|NCT00557076|Behavioral|Sham Auditory Sensory Training|The sham intervention is zero minutes of Familiar Auditory Sensory Training. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
479076|NCT00557050|Other|Training|10-week eccentric hamstring muscle training
479077|NCT00557037|Drug|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
479078|NCT00557024|Procedure|RFA|radiofrequency ablation
479079|NCT00557024|Procedure|radiotherapy after RFA|radiotherapy after RFA
479080|NCT00557011|Drug|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
479081|NCT00557011|Drug|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
479082|NCT00557011|Drug|Placebo|Placebo capsule taken once daily in the morning
479083|NCT00556998|Drug|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
479084|NCT00556972|Device|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
479085|NCT00556959|Drug|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
479086|NCT00556959|Drug|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
479087|NCT00556959|Drug|placebo|placebo tablets for 8 weeks
479088|NCT00556946|Drug|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
479089|NCT00556933|Drug|rabbit anti-thymocyte globulin|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
479090|NCT00556933|Drug|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
479185|NCT00556257|Drug|Cyclosporine|Standard of care
492166|NCT00459758|Device|Hans unit|
479091|NCT00556933|Drug|rabbit anti-thymocyte globulin|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
479092|NCT00556933|Drug|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
479093|NCT00556933|Drug|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
479094|NCT00556920|Drug|COREG CR|
479095|NCT00556907|Radiation|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
479096|NCT00556907|Device|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
479097|NCT00556894|Drug|CF101|orally q12h
479098|NCT00556894|Drug|Placebo|orally q12h
479099|NCT00556868|Other|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
479100|NCT00556855|Other|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
479101|NCT00556855|Other|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
479102|NCT00556842|Device|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
479103|NCT00556842|Device|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
479104|NCT00556816|Behavioral|on demand clinic|Outpatient on demand clinic
479105|NCT00556816|Behavioral|Control|conventional outpatient clinic
479106|NCT00556803|Procedure|radiofrequency ablation|radiofrequency ablation
479107|NCT00556803|Procedure|TACE after RFA|TACE after RFA within one month
479108|NCT00556790|Procedure|Standard Care|standard fluid regime, delayed feeding
479109|NCT00556790|Procedure|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
479110|NCT00556777|Procedure|axillary lymph node dissection|
479111|NCT00556777|Procedure|conventional surgery|
479112|NCT00556777|Procedure|sentinel lymph node biopsy|
479113|NCT00556777|Radiation|intraoperative radiation therapy|
479114|NCT00556764|Drug|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
479115|NCT00556764|Drug|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
479116|NCT00556738|Procedure|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
479117|NCT00556738|Procedure|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
479118|NCT00556712|Drug|erlotinib [Tarceva]|150mg po daily
479119|NCT00556712|Drug|Placebo|po daily
479120|NCT00556699|Drug|rituximab|Escalating intravenous repeating dose
479121|NCT00556699|Drug|SGN-40|Escalating intravenous repeating dose
479122|NCT00556673|Drug|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
479123|NCT00556673|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
479124|NCT00556673|Drug|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
479125|NCT00556660|Drug|[123I] AV-151|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
479126|NCT00556647|Procedure|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
479127|NCT00556647|Procedure|conventional diagnosis|out-patient diagnosis
479128|NCT00556634|Drug|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)"
479129|NCT00556621|Drug|cisplatin|
479130|NCT00556621|Drug|gemcitabine hydrochloride|
479131|NCT00556621|Procedure|biopsy|
479132|NCT00556621|Procedure|cystoscopy|
479133|NCT00556621|Procedure|therapeutic conventional surgery|
479134|NCT00556621|Radiation|radiation therapy|
479135|NCT00556608|Device|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
479136|NCT00556608|Device|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
479137|NCT00556595|Procedure|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
479138|NCT00556595|Procedure|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
479139|NCT00556569|Other|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
479186|NCT00556257|Drug|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
479187|NCT00556244|Procedure|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
479188|NCT00556218|Behavioral|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
479140|NCT00556543|Device|U-plate fracture repair system|All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
479141|NCT00556504|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
479142|NCT00556504|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
479143|NCT00556504|Drug|Ribavirin|conventional treatment of Hepatitis C
479144|NCT00556504|Drug|Placebo|Placebo, without acting ingredient.
479145|NCT00556491|Drug|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
479146|NCT00556491|Drug|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
479147|NCT00556478|Drug|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
479148|NCT00556478|Drug|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.~Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.~During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.~During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
479149|NCT00556465|Drug|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
479150|NCT00556452|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)~1st dose level: 20 mg/m2/day x 5 days~2nd dose level: 30 mg/m2/day x 5 days~3rd dose level: 40 mg/m2/day x 5 days~Busulfan IV 3.2 mg/kg daily x 4 days"
479151|NCT00556452|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
479152|NCT00556452|Radiation|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
479153|NCT00556439|Drug|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~Participants weighing less than 60kg will receive 500mg of abatacept.~Participants weighing 60 to 100kg will receive 750mg of abatacept.~Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept."
479154|NCT00556439|Drug|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
479155|NCT00556426|Device|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
479156|NCT00556413|Biological|cetuximab|
479157|NCT00556413|Drug|fluorouracil|
479158|NCT00556413|Drug|irinotecan hydrochloride|
479159|NCT00556413|Drug|leucovorin calcium|
479160|NCT00556413|Drug|oxaliplatin|
479161|NCT00556400|Drug|Lo-Ovral Oral Contraceptive Pills|
479162|NCT00556400|Drug|Placebo - sugar pill|
479163|NCT00556387|Drug|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
479164|NCT00556387|Drug|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
479165|NCT00556374|Drug|Placebo|
479166|NCT00556374|Biological|Denosumab|Administered as a subcutaneous injection
479167|NCT00556374|Drug|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
479168|NCT00556374|Drug|Zoledronic Acid|5 mg zoledronic acid administered at a constant infusion rate
479169|NCT00556374|Other|Standard of Care|Standard of care (SoC) as recommended by the treating physician, depending on individual factors such as bone density, lifestyle recommendations by the Investigator such as diet, physical activities and sun exposure, as well as local treatment standards.
479170|NCT00556361|Drug|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
479171|NCT00556361|Drug|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
479172|NCT00556348|Drug|bevacizumab|1.25mg
479173|NCT00556335|Procedure|manual aspiration|air aspiration
479174|NCT00556335|Procedure|conventional drainage|drainage, pneumocath
479175|NCT00556322|Drug|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
479176|NCT00556322|Drug|erlotinib [Tarceva]|150mg po daily
479177|NCT00556309|Device|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
479178|NCT00556296|Drug|NRP104|NRP104 30mg capsule once daily in a.m.
479179|NCT00556296|Drug|NRP104|NRP104 50mg capsule once daily in a.m.
479180|NCT00556296|Drug|NRp104|NRP104 70mg capsule once daily in a.m.
479181|NCT00556296|Drug|Placebo|Placebo
479182|NCT00556283|Device|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
479183|NCT00556283|Behavioral|Biofeedback|electromyographic-based treatment sessions
479184|NCT00556270|Drug|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
479190|NCT00556205|Drug|Sunitinib|Sunitinib orally once daily
479191|NCT00556205|Drug|Bevacizumab|Intravenously every 14 days
479192|NCT00556192|Drug|rituximab|"Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.~A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.~Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
479193|NCT00556179|Drug|Lactoserum (Dermacyd Femina®)|Once a day during three months
479194|NCT00556166|Device|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.~The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
479195|NCT00556153|Drug|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
479196|NCT00556140|Drug|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
479197|NCT00556127|Drug|Rituximab|375 mg/m2 on day 1
479198|NCT00556127|Drug|Epirubicin|110 mg/m2 on day 3
479199|NCT00556127|Drug|Cyclophosphamide|1200 mg/m2 on day 3
479200|NCT00556127|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
479201|NCT00556127|Drug|Prednisone|40 mg/m2 from day 1 to 5
479202|NCT00556127|Drug|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
479203|NCT00556127|Drug|Mitoxantrone|8 mg/m2 for 3-day
479204|NCT00556127|Drug|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
479205|NCT00556127|Drug|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
479206|NCT00556127|Drug|Carmustine BCNU|300 mg/m2 on day -7
479207|NCT00556127|Drug|Etoposide|100 mg/m2/12 hours
479208|NCT00556127|Drug|Melphalan|140 mg/m2 on day -2
479209|NCT00556127|Radiation|Radiotherapy|Involved Field Radiotherapy (IF-RT)
479210|NCT00556127|Procedure|PBSC reinfusion|ASCT
479211|NCT00556114|Device|Optical Coherence Tomography|Optical Coherence Tomography
479212|NCT00556101|Procedure|Whole body magnetic resonance angiography|
479213|NCT00556088|Drug|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
479214|NCT00556075|Drug|Proellex 25 mg|1 capsule daily for 4 months
479215|NCT00556075|Drug|Placebo|1 capsule daily for 4 months
479216|NCT00556075|Drug|Proellex 50 mg|2 capsules daily for 4 months
479217|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
479218|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
479219|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
479220|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
479221|NCT00556049|Drug|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
479222|NCT00556049|Drug|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
479223|NCT00556023|Drug|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
479224|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
479225|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
479226|NCT00555997|Drug|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
479227|NCT00555984|Drug|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
479228|NCT00555984|Drug|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
479229|NCT00555971|Drug|Omalizumab|Subjects randomized to Omalizumab prior to aspirin desensitization
479230|NCT00555971|Drug|placebo|Subjects randomized to Placebo prior to aspirin desensitization
479231|NCT00555958|Device|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
479232|NCT00555945|Procedure|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
479233|NCT00555945|Procedure|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
479234|NCT00555932|Procedure|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
479235|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
479236|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
479237|NCT00555906|Drug|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
479238|NCT00555906|Drug|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
479239|NCT00555906|Drug|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
479240|NCT00555893|Drug|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:~for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
479241|NCT00555893|Drug|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
479242|NCT00555880|Drug|Midodrine hydrochloride|one dose, 10-30mg, given orally
479243|NCT00555880|Drug|Placebo|Placebo
479244|NCT00555867|Drug|Anastrozole|oral
479245|NCT00555854|Behavioral|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
479246|NCT00555841|Drug|ALC and Placebo|ALC and Placebo
479247|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
479248|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
479249|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
479250|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
479251|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
479252|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
479253|NCT00555802|Other|exercise|exercise
479254|NCT00555789|Drug|AEB071|200mg oral b.i.d.
479255|NCT00555789|Drug|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
479256|NCT00555776|Drug|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
479257|NCT00555776|Drug|placebo|placebo is given with the same definition as Gabapentin
479258|NCT00555763|Device|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
479259|NCT00555750|Drug|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
479260|NCT00555750|Drug|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
479261|NCT00555737|Device|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
479262|NCT00555724|Drug|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
479263|NCT00555711|Device|Modulated Imaging|Modulated Imaging
479264|NCT00555698|Device|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
479265|NCT00555685|Drug|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
479266|NCT00555685|Drug|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
479267|NCT00555672|Drug|5-fluorouracil|5- fluorouracil is given as 4000 mg/m^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
479268|NCT00555672|Drug|cisplatin|Cisplatin is given 80 mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
479269|NCT00555672|Drug|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
479270|NCT00555646|Drug|PH-10 (rose bengal disodium 0.001%)|"PH-10 with 544 nm LED light illumination~OR~PH-10 with ambient light exposure"
479271|NCT00555646|Drug|Control|No treatment control.
479272|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
479273|NCT00555620|Drug|oxaliplatin|Oxaliplatin is given 110mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
479274|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
479275|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
479276|NCT00555620|Drug|cisplatin|Cisplatin is given 80mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
479277|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
479278|NCT00555607|Drug|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
479279|NCT00555594|Drug|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
479280|NCT00555581|Drug|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
479281|NCT00555568|Behavioral|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
479282|NCT00555568|Behavioral|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
479283|NCT00555555|Biological|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
479284|NCT00555542|Drug|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
479285|NCT00555529|Procedure|radial artery applanation tonometry (RAAP)|non-invasive tonometry
479286|NCT00555516|Other|EW02|"Name: EW02~Dosage form: capsule.~Dose(s): 350mg per capsule, 2 capsule tid.~Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
479287|NCT00555490|Dietary Supplement|Soy protein|35 % of protein from soy protein for 4-years
479288|NCT00555477|Drug|anastrozole|1 mg tablet by mouth once a day
479289|NCT00555464|Drug|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
479290|NCT00555464|Drug|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
479291|NCT00555451|Drug|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.~HE3286 5 mg or placebo QD for 28 days;~HE3286 10 mg (5 mg BID) or placebo BID for 28 days~HE3286 20 mg (10 mg BID) or placebo BID for 28 days~HE3286 40 mg (20 mg BID) or placebo BID for 28 days~HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days~HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
479292|NCT00555438|Drug|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
479293|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
479294|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
479295|NCT00555412|Drug|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
479296|NCT00555412|Drug|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
479297|NCT00555412|Drug|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
479298|NCT00555412|Drug|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
479299|NCT00555399|Drug|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.~Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
479300|NCT00555399|Drug|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 2: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.~Phase I/Arm 3: Level -II = 100 mg/m^2/day PO x 21 days; Level -I = 100 mg/m^2/day PO x 21 days; Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days."
479301|NCT00555399|Procedure|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
479302|NCT00555399|Drug|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.~Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
479303|NCT00555386|Dietary Supplement|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
479304|NCT00555373|Drug|Sirolimus|"Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.~Sirolimus (Rapamune®):~At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
479305|NCT00555360|Behavioral|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
479306|NCT00555360|Behavioral|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
479307|NCT00555347|Drug|Armodafinil|Dosage 150-250 mg
479308|NCT00555347|Drug|Placebo|Placebo
479309|NCT00555334|Procedure|RFA|radiofrequency ablation
479310|NCT00555334|Drug|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
479311|NCT00555321|Drug|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term [ST]), in accordance with local practice and the package insert, 4 years (Long-Term Extension [LTE])
479312|NCT00555321|Drug|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
479313|NCT00555321|Drug|Belatacept More Intensive (MI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.~After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension [LTE])"
479314|NCT00555321|Drug|Belatacept Less Intensive (LI)|"Intravenous (IV),~10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.~After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
479315|NCT00555321|Drug|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term [ST]), ≤ 1 g/day, 4 years (Long-term extension [LTE])
479316|NCT00555308|Other|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
479317|NCT00555282|Device|central venous catheter|coated central venous catheter
479318|NCT00555282|Device|central venous catheter|standard central venous catheter
479319|NCT00555256|Drug|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
479320|NCT00555243|Procedure|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
479321|NCT00555243|Procedure|Traditional Surgical Education|Traditional surgical teaching (no simulator)
479322|NCT00555230|Drug|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
479323|NCT00555230|Drug|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
479324|NCT00555217|Drug|losartan|50 or 100mg/day
479325|NCT00555217|Drug|lisinopril|10, 20 or 40 mg/day
479326|NCT00555204|Drug|ABT-089|10 mg - capsules once daily for 12 weeks
479327|NCT00555204|Drug|ABT-089|5 mg - capsules once daily for 12 weeks
479328|NCT00555204|Drug|ABT-089|15 mg - capsules once daily for 12 weeks
479329|NCT00555204|Drug|ABT-089|20 mg - capsules once daily for 12 weeks
479330|NCT00555204|Drug|ABT-089|30 mg - capsules once daily for 12 weeks
479331|NCT00555204|Drug|ABT-089|35 mg - capsules once daily for 12 weeks
479332|NCT00555204|Drug|placebo|placebo - capsules once daily for 12 weeks
479333|NCT00555191|Behavioral|diet restriction|each meal should contain less than 2 gm fructose
479334|NCT00555165|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
479335|NCT00555152|Other|Laboratory Biomarker Analysis|Correlative studies
479336|NCT00555152|Drug|Lapatinib Ditosylate|Given PO
479337|NCT00555152|Other|Placebo|Given PO
479338|NCT00555139|Drug|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
479339|NCT00555139|Drug|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
479340|NCT00555139|Drug|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
479341|NCT00555139|Drug|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
479342|NCT00555126|Device|Forced Air Warming|Warming after Randomization
479343|NCT00555126|Device|Warming with endovascular catheter + forced air warming|Warming after Randomization
479344|NCT00555100|Drug|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
479345|NCT00555100|Drug|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
479346|NCT00555087|Drug|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
479347|NCT00555074|Drug|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
479348|NCT00555074|Drug|Placebo|Placebo, BID, oral route during 6 weeks
479349|NCT00555061|Drug|Retapamulin Ointment, 1%|1% Ointment
479350|NCT00555048|Biological|alemtuzumab|
479351|NCT00555048|Drug|busulfan|
479352|NCT00555048|Drug|cyclophosphamide|
479353|NCT00555048|Drug|methotrexate|
479354|NCT00555048|Drug|tacrolimus|
479355|NCT00555048|Procedure|allogeneic hematopoietic stem cell transplantation|
479356|NCT00555048|Procedure|peripheral blood stem cell transplantation|
479357|NCT00555035|Drug|GSK1349572|
479358|NCT00555022|Drug|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
479359|NCT00555022|Drug|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
479360|NCT00555022|Drug|Placebo|Subjects will receive placebo.
479361|NCT00555009|Drug|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
479362|NCT00555009|Drug|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
479363|NCT00554996|Device|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
479364|NCT00554983|Biological|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
479365|NCT00554983|Biological|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
479366|NCT00554970|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
479367|NCT00554970|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
479368|NCT00554970|Drug|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
479369|NCT00554970|Drug|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
479370|NCT00554944|Procedure|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
479371|NCT00554918|Drug|docetaxel|
479372|NCT00554918|Drug|prednisolone|
479373|NCT00554918|Drug|zoledronic acid|
479374|NCT00554918|Procedure|quality-of-life assessment|
479375|NCT00554918|Radiation|strontium chloride Sr 89|
479376|NCT00554905|Procedure|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
479377|NCT00554905|Procedure|TACE|TACE first, then RFA within 2 weeks
479378|NCT00554892|Procedure|bowel preparation|oral laxatives, retrograde enemas
479379|NCT00554892|Procedure|no preparation bowel|no preparation bowel
479380|NCT00554879|Procedure|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
479381|NCT00554879|Procedure|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
479382|NCT00554866|Other|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.~Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
479383|NCT00554853|Drug|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
479384|NCT00554853|Drug|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
479385|NCT00554840|Drug|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
479386|NCT00554840|Drug|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
479387|NCT00554827|Drug|Pralatrexate Injection|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
479388|NCT00554827|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
479389|NCT00554827|Dietary Supplement|Folic Acid|"1 mg orally~Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.~Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
479390|NCT00554814|Drug|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
479391|NCT00554814|Drug|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
479392|NCT00554814|Drug|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
479393|NCT00554801|Procedure|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
479394|NCT00554788|Procedure|Autologous Bone Marrow Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
479395|NCT00554788|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
479396|NCT00554788|Drug|Carboplatin|Given IV
479397|NCT00554788|Drug|Cisplatin|Given IV
479398|NCT00554788|Drug|Cyclophosphamide|Given IV
479399|NCT00554788|Drug|Etoposide|Given IV
479400|NCT00554788|Biological|Filgrastim|Given SC
479401|NCT00554788|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell or bone marrow transplant
479402|NCT00554788|Radiation|Radiation Therapy|Undergo radiotherapy
479403|NCT00554788|Drug|Thiotepa|Given IV
479404|NCT00554788|Drug|Vincristine Sulfate|Given IV
479405|NCT00554775|Drug|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
479406|NCT00554775|Drug|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
479407|NCT00554762|Drug|GW842166X|Administer
479408|NCT00554749|Behavioral|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
479409|NCT00554736|Biological|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
479410|NCT00554723|Drug|NeuroAid|4 capsules 3 times daily, for three months
479411|NCT00554723|Drug|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
479412|NCT00554710|Drug|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
479413|NCT00554710|Drug|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
479414|NCT00554671|Other|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
479415|NCT00554671|Behavioral|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
479416|NCT00554671|Behavioral|Group support|Peer support are provided in the group setting
479417|NCT00554671|Behavioral|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
479418|NCT00554658|Drug|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
479419|NCT00554645|Behavioral|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
479420|NCT00554645|Other|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
479421|NCT00554632|Drug|Ethinyl estradiol and norgestimate|Oral contraceptive
479422|NCT00554632|Drug|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
479423|NCT00554619|Drug|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
479424|NCT00554606|Drug|ACZ885|ACZ885
479425|NCT00554580|Procedure|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:~stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
479426|NCT00554580|Procedure|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :~Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.~Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.~As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
479427|NCT00554567|Behavioral|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
479428|NCT00554541|Other|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
479429|NCT00554528|Device|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy~stage 2: location of the medial axis~stage 3: centering pin~stage 4: installation of the caspar spacer~stage 5: total discectomy~stage 6: parallel distraction~stage 7: depth measurement~stage 8: trial implant~stage 9: assembly~stage 10: implant insertion~stage 11: anchorage optimization"
479430|NCT00554528|Procedure|arthrodesis - cervical disk surgery|discectomy and arthrodesis
479431|NCT00554515|Drug|HD IL2|
479432|NCT00554502|Drug|supportive therapy with: ACE-inhibitor / ARB / Statin|"Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).~ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)~Other antihypertensive medications depending on the clinical decision and following current guidelines.~Statin therapy~Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
479433|NCT00554502|Drug|supportive and immunosuppressive therapy|"supportive therapy as outlined above~depending on GFR:~methylprednisolone and prednisolone~cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone~Concomitant medication with the immunosuppressive treatment following current clinical practice"
479434|NCT00554489|Behavioral|exercise intervention|participation in physical activity intervention program weeks 2 through 5
479435|NCT00554476|Drug|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
479436|NCT00554463|Drug|Filgrastim|5 mcg/kg/day IV (intravenous) days 4-13 and days 25-34 for a total of 20 doses.
479437|NCT00554463|Drug|Pegfilgrastim|6 mg via subcutaneous injection days 46 and 67
479438|NCT00554463|Drug|Etoposide|Concurrent: 120 mg/m^2, IV on days 1-3 and days 22-24. Adjuvant: 120 mg/m^2, IV on days 43-45 and days 65-66.
479439|NCT00554463|Drug|Cisplatin|Concurrent: 60 mg/m^2, IV on days 1 and 22. Adjuvant: 60 mg/m^2, IV on days 43 and 64.
479440|NCT00554463|Radiation|radiation therapy|A total of 61.2 Gy in 5 weeks: Once-daily 1.8 Gy fractions for 15 fractions over 3 weeks beginning on day 1 of chemotherapy, then twice-daily 1.8 Gy fractions for 10 fractions over 2 weeks.
479441|NCT00554450|Drug|Dapagliflozin|Tablets, Oral, once daily
479484|NCT00554099|Drug|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
479485|NCT00554086|Drug|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
479582|NCT00553345|Procedure|chemoprevention|
479583|NCT00553332|Drug|selumetinib|Given orally
479442|NCT00554437|Behavioral|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
479443|NCT00554424|Drug|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
479444|NCT00554424|Drug|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
479445|NCT00554398|Drug|MK-0518 400mg twice a day|Raltegravir, MK-0518
479446|NCT00554385|Drug|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
479447|NCT00554372|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
479448|NCT00554359|Drug|I5NP (a small interfering RNA)|Single IV injection of experimental drug
479449|NCT00554359|Drug|placebo|Single IV injection of saline
479450|NCT00554346|Drug|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
479451|NCT00554333|Biological|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
479452|NCT00554333|Biological|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
479453|NCT00554320|Procedure|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
479454|NCT00554320|Procedure|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
479455|NCT00554307|Device|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
479456|NCT00554294|Behavioral|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
479457|NCT00554281|Device|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
479458|NCT00554268|Drug|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
479459|NCT00554255|Drug|SB751689|
479460|NCT00554242|Dietary Supplement|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
479461|NCT00554229|Drug|ZD4054|ZD4054 10 mg oral tablet once daily
479462|NCT00554229|Drug|Placebo|Matching placebo oral tablet once daily
479463|NCT00554216|Drug|VI-0521|3.75 mg phentermine/23 mg topiramate
479464|NCT00554216|Drug|VI-0521|15 mg phentermine/92 mg topiramate
479465|NCT00554216|Drug|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
479466|NCT00554203|Drug|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
479467|NCT00554190|Device|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
479468|NCT00554190|Device|Merogel Injectable|Bioresorbable hyaluronic acid product
479469|NCT00554177|Drug|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
479470|NCT00554177|Drug|Placebo|2 doses of 1200mg, administered 2-3 days apart
479471|NCT00554164|Drug|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
479472|NCT00554164|Drug|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
479473|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
479474|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
479475|NCT00554151|Device|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
479476|NCT00554138|Drug|placebo|1 dd for 7-10 days
479477|NCT00554138|Drug|rosuvastatin|1 dd 20 mg for 7-10 days
479478|NCT00554125|Drug|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
479479|NCT00554112|Behavioral|Exercise|Exercise
479480|NCT00554099|Drug|Mesalamine|6 - 400 mg tablets once daily
479481|NCT00554099|Drug|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
479482|NCT00554099|Drug|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
479483|NCT00554099|Other|Dietary Advice|Dietary advice
479538|NCT00553631|Biological|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
479486|NCT00554047|Other|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
479487|NCT00554047|Other|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
479488|NCT00554034|Drug|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
479489|NCT00554008|Procedure|laparoscopic appendectomy|appendix removal via scope
479490|NCT00554008|Procedure|open appendectomy|open operation for removal of appendix
479491|NCT00553995|Drug|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
479492|NCT00553995|Drug|Placebo|
479493|NCT00553982|Procedure|Patellar component|Resurfacing with onlay technique
479494|NCT00553982|Procedure|No patellar component|Trimming of osteophytes when appropriate
479495|NCT00553969|Drug|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
479496|NCT00553969|Drug|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
479497|NCT00553969|Drug|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
479498|NCT00553969|Drug|placebo and placebo|capsule once daily for 9 months; dosage unknown
479499|NCT00553956|Behavioral|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
479500|NCT00553943|Drug|Rituximab|375 mg/m2 D1
479501|NCT00553943|Drug|Cytarabine|50 mg D3
479502|NCT00553930|Drug|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
479503|NCT00553930|Drug|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of >= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
479504|NCT00553904|Dietary Supplement|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
479505|NCT00553891|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
479506|NCT00553891|Drug|placebo nasal spray|One spray in each nostril once daily for 3 months.
479507|NCT00553878|Drug|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
479508|NCT00553865|Drug|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
479509|NCT00553852|Drug|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
479510|NCT00553839|Drug|ketamine hydrochloride|Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
479511|NCT00553813|Drug|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
479512|NCT00553800|Drug|bevacizumab|
479513|NCT00553800|Drug|Erlotinib|
479514|NCT00553787|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
479515|NCT00553787|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
479516|NCT00553787|Drug|VI-0521|placebo
479517|NCT00553774|Dietary Supplement|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
479518|NCT00553774|Other|Placebo|Placebo (BD 21 - 28 Days)
479519|NCT00553761|Device|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
479520|NCT00553748|Drug|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
479521|NCT00553735|Drug|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
479522|NCT00553735|Drug|Arificial Tear|Artificial Tear - three times a day for 18 months.
479523|NCT00553722|Drug|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
479524|NCT00553722|Drug|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
479525|NCT00553709|Drug|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
479526|NCT00553696|Drug|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
479527|NCT00553696|Drug|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
479528|NCT00553696|Drug|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
479529|NCT00553683|Drug|cyclophosphamide|
479530|NCT00553683|Drug|poly ICLC|
479531|NCT00553683|Procedure|hepatic artery embolization|
479532|NCT00553683|Radiation|3-dimensional conformal radiation therapy|
479533|NCT00553657|Drug|DETROL LA (drug)|
479534|NCT00553644|Drug|Bortezomib|Given IV
479535|NCT00553644|Other|Laboratory Biomarker Analysis|Correlative studies
479536|NCT00553644|Drug|Lenalidomide|Given PO
479537|NCT00553631|Biological|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
479539|NCT00553618|Drug|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.~Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
479540|NCT00553605|Drug|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
479541|NCT00553605|Drug|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
479542|NCT00553592|Drug|Bicifadine|600mg/day
479543|NCT00553592|Drug|Bicifadine|placebo tablet
479544|NCT00553592|Drug|Bicifadine|1200 mg
479545|NCT00553566|Procedure|medical chart review|
479546|NCT00553566|Procedure|questionnaire administration|
479547|NCT00553566|Procedure|study of socioeconomic and demographic variables|
479548|NCT00553553|Drug|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
479549|NCT00553553|Drug|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram~Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
479550|NCT00553540|Device|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
479551|NCT00553527|Procedure|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
479552|NCT00553514|Drug|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
479553|NCT00553514|Drug|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
479554|NCT00553514|Drug|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
479555|NCT00553514|Drug|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
479556|NCT00553514|Drug|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
479557|NCT00553514|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to [=<] 3 follicles with a mean diameter of greater than or equal to [>=] 14 millimeter [mm], and one or two of these follicles with a diameter of >= 17 mm).
479558|NCT00553501|Biological|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, & 36: 360mg/sq m IV
479559|NCT00553501|Biological|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, & 36: 375mg/sq m IV
479560|NCT00553488|Drug|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
479561|NCT00553488|Drug|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
479562|NCT00553475|Drug|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
479563|NCT00553475|Drug|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
479564|NCT00553475|Drug|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
479565|NCT00553462|Drug|carboplatin|
479566|NCT00553462|Drug|erlotinib hydrochloride|
479567|NCT00553462|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
479568|NCT00553462|Radiation|radiation therapy|
479569|NCT00553449|Drug|rabeprazole|
479570|NCT00553436|Device|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
479571|NCT00553423|Drug|Lactulose|Lactulose 30 ml q6h for 48 hrs
479572|NCT00553423|Drug|Placebo|Placebo 30 ml q6hrly for 48 hrs
479573|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
479574|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
479575|NCT00553371|Other|biomarker analysis|
479576|NCT00553371|Procedure|computed tomography|
479577|NCT00553358|Drug|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
479578|NCT00553358|Biological|Trastuzumab|Therapeutic Monoclonal Antibody
479579|NCT00553358|Drug|Paclitaxel|antimicrotubule agent
479580|NCT00553345|Drug|selenium|
479584|NCT00553332|Other|laboratory biomarker analysis|Correlative studies
479585|NCT00553319|Drug|Placebo|Placebo group
479586|NCT00553319|Drug|Adderall-XR|Adderall-XR 60mg/day
479587|NCT00553319|Drug|Adderall-XR|Adderall-XR 80mg/day
479588|NCT00553306|Biological|therapeutic autologous lymphocytes|Given IV
479589|NCT00553306|Biological|aldesleukin|Given subcutaneously
479590|NCT00553306|Drug|cyclophosphamide|Given IV
479591|NCT00553306|Procedure|biopsy|Optional correlative studies
479592|NCT00553306|Other|immunohistochemistry staining method|Optional correlative studies
479593|NCT00553306|Other|flow cytometry|Correlative studies
479594|NCT00553306|Genetic|polymerase chain reaction|Correlative studies
479595|NCT00553293|Drug|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
479596|NCT00553293|Drug|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
479597|NCT00553280|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
479598|NCT00553267|Drug|fixed dose combination of telmisartan+amlodipine|
479599|NCT00553267|Drug|amlodipine|
479600|NCT00553254|Drug|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
479601|NCT00553228|Biological|Tdap|0.5 mL IM once at visit #2
479602|NCT00553228|Biological|Td|0.5 mL IM once at visit #2
479603|NCT00553215|Procedure|quality-of-life assessment|
479604|NCT00553215|Procedure|questionnaire administration|
479605|NCT00553202|Biological|anti-thymocyte globulin|Given IV
479606|NCT00553202|Drug|busulfan|Given IV
479607|NCT00553202|Drug|cyclophosphamide|Given IV
479608|NCT00553202|Drug|cyclosporine|Given IV or orally
479609|NCT00553202|Drug|methotrexate|Given IV
479610|NCT00553202|Drug|methylprednisolone|Given IV
479611|NCT00553202|Drug|tacrolimus|Given IV
479612|NCT00553202|Other|laboratory biomarker analysis|Correlative studies
479613|NCT00553202|Other|pharmacological study|Correlative studies
479614|NCT00553202|Procedure|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
479615|NCT00553202|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
479616|NCT00553189|Drug|ABT-888|
479617|NCT00553189|Drug|Topotecan|
479618|NCT00553176|Other|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
479619|NCT00553163|Behavioral|Gut focussed hypnotherapy|Gut focussed hypnotherapy
479620|NCT00553163|Behavioral|Control educational sessions|Control educational sessions
479621|NCT00553150|Drug|everolimus|
479622|NCT00553150|Drug|temozolomide|
479623|NCT00553150|Radiation|radiation|
479624|NCT00553137|Drug|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
479625|NCT00553137|Drug|fluconazole|150 mg fluconazole tablets once daily for 14 days
479626|NCT00553124|Drug|selenium|
479627|NCT00553124|Drug|vitamin E|
479628|NCT00553124|Procedure|biopsy|
479629|NCT00553124|Procedure|chemoprevention|
479630|NCT00553124|Procedure|cryopreservation|
479631|NCT00553124|Procedure|cytology specimen collection procedure|
479632|NCT00553124|Procedure|diagnostic procedure|
479633|NCT00553124|Procedure|gene expression analysis|
479634|NCT00553124|Procedure|immunohistochemistry staining method|
479635|NCT00553124|Procedure|laboratory biomarker analysis|
479636|NCT00553124|Procedure|medical chart review|
479637|NCT00553124|Procedure|mutation analysis|
479638|NCT00553124|Procedure|polymerase chain reaction|
479639|NCT00553124|Procedure|quality-of-life assessment|
479640|NCT00553124|Procedure|questionnaire administration|
479641|NCT00553124|Procedure|study of socioeconomic and demographic variables|
479642|NCT00553111|Other|educational video|educational video
479643|NCT00553098|Biological|Alemtuzumab|Given IV
479644|NCT00553098|Procedure|Allogeneic Bone Marrow Transplantation|Undergo HCT
479645|NCT00553098|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
479646|NCT00553098|Drug|Cyclosporine|Given PO or IV
479647|NCT00553098|Drug|Fludarabine Phosphate|Given IV
479648|NCT00553098|Other|Laboratory Biomarker Analysis|Correlative study
479649|NCT00553098|Drug|Mycophenolate Mofetil|Given PO or IV
479650|NCT00553098|Radiation|Total-Body Irradiation|Undergo low dose TBI
479651|NCT00553072|Drug|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
479652|NCT00553072|Drug|Normal saline|1 ml/kg/dose
479653|NCT00553059|Drug|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
479654|NCT00553059|Drug|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
479655|NCT00553059|Drug|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
479656|NCT00553059|Other|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
479657|NCT00553046|Other|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
479658|NCT00553033|Procedure|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
479659|NCT00553020|Drug|Insulin glargine|"Lantus (commercial formulation, Reference):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)~NPH-insulin (Protaphan) (Test):~10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
479660|NCT00553007|Procedure|Periodontal therapy|Normal periodontal therapy is performed.
479661|NCT00552994|Device|Cypher Select plus|Drug eluting stent
479662|NCT00552994|Device|Xience V stent|Drug eluting stent
479663|NCT00552981|Procedure|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
479664|NCT00552981|Procedure|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
479665|NCT00552942|Procedure|laparoscopic gastric bypass plus omentectomy|
479666|NCT00552929|Drug|Sugammadex|"After induction of anesthesia an intubation dose of a neuromuscular blocking agent (NMBA) was administered IV: either 0.9 mg/kg rocuronium (arms 1-5) or 0.1 mg/kg vecuronium (arms 6-10). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex (0.5 to 8.0 mg/kg) IV was administered."
479667|NCT00552916|Device|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
479668|NCT00552916|Device|Compex Motion Stimulator|'False' FES
479669|NCT00552903|Behavioral|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
479670|NCT00552890|Other|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
479671|NCT00552890|Other|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
479672|NCT00552877|Device|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
479673|NCT00552864|Drug|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
479674|NCT00552864|Drug|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
479675|NCT00552851|Drug|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
479676|NCT00552838|Behavioral|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
479677|NCT00552812|Device|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
479678|NCT00552799|Drug|Penicillin VK|Biconcave tablet 250mg oral, b.d.
479679|NCT00552799|Other|placebo|biconcave tablet matching active comparator as much as possible in size and shape
479680|NCT00552786|Drug|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
479681|NCT00552786|Drug|glucose|1 gm glucose capsule
479682|NCT00552773|Drug|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
479683|NCT00552760|Drug|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
479684|NCT00552760|Drug|Placebo|one tablet at bedtime for up to 6 months
479685|NCT00552747|Drug|fenofibrate|fenofibrate 160 mg capsules qd
479686|NCT00552747|Drug|placebo|capsules placebo
479687|NCT00552734|Device|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
479688|NCT00552721|Other|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
479689|NCT00552721|Other|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
479690|NCT00552708|Drug|COREG CR|
479691|NCT00552708|Drug|Lisinopril|
479692|NCT00552695|Device|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
479693|NCT00552695|Device|Placebo|Placebo patch identical in appearance to Synera
479694|NCT00552682|Drug|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
479695|NCT00552669|Drug|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
479696|NCT00552669|Device|Drug Eluting stent|Any Drug eluting stent
479697|NCT00552656|Device|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
479698|NCT00552643|Device|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
479699|NCT00552643|Device|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
479700|NCT00552630|Device|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
479701|NCT00552630|Drug|placebo|placebo with same characteristics as drug
479738|NCT00552305|Drug|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
479899|NCT00551265|Biological|Oregovomab|Given IV
479702|NCT00552617|Drug|Sugammadex|"After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered"
479703|NCT00552617|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered"
479704|NCT00552617|Drug|Rocuronium|"After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary."
479705|NCT00552617|Drug|Vecuronium|After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
479706|NCT00552604|Drug|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
479707|NCT00552604|Drug|Placebo|Matching placebo capsules, twice daily
479708|NCT00552591|Behavioral|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
479709|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
479710|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
479711|NCT00552565|Drug|Rezular 15mg|Oral Tablets
479712|NCT00552565|Drug|Placebo|placebo
479713|NCT00552565|Drug|Rezular|Rezular 37.5mg 3xday up to 12 weeks
479714|NCT00552565|Drug|Rezular|Rezular 75mg 3xday up to 12 weeks
479715|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
479716|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
479717|NCT00552539|Other|'educational video'|'educational video'
479718|NCT00552526|Dietary Supplement|Ketogenic diet|Ketogenic diet is a very strict high fat diet
479719|NCT00552526|Drug|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
479720|NCT00552513|Procedure|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (and within 24 hours of randomisation).
479721|NCT00552513|Procedure|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
479722|NCT00552500|Drug|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
479723|NCT00552487|Drug|synacthen|1 µg synacthen in the vein
479724|NCT00552474|Device|Libra Deep Brain Stimulation System|Active DBS Therapy
479725|NCT00552474|Device|Libra Deep Brain Stimulation System|Implanted system but no stimulation
479726|NCT00552461|Drug|rituximab|IV, 1000 mg, two weeks, 2 times
479727|NCT00552448|Device|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
479728|NCT00552435|Device|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
479729|NCT00552422|Drug|domperidone|10mg orally four times per day
479730|NCT00552409|Dietary Supplement|Cholecalciferol|2000 IU by mouth daily for one year
479731|NCT00552409|Dietary Supplement|Placebo|One softgel daily for one year
479732|NCT00552396|Drug|Anti-KIR (1-7F9)|human monoclonal antibody
479733|NCT00552383|Procedure|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff [this includes 3 of the investigators], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
479734|NCT00552370|Drug|Lantus®|
479735|NCT00552344|Biological|Cimzia|"Active substance: Certolizumab Pegol~Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe~Concentration: 200 mg/ml~Route of Administration: Subcutaneous use"
479736|NCT00552331|Device|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
479737|NCT00552331|Device|LISS|treatment of distal femur fractures with less invasive stabilization systems
479739|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
479740|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
479741|NCT00552266|Drug|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
479742|NCT00552253|Drug|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1~0.3 mU/L. It will be discontinued for 3 months. Then
479743|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
479744|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
479745|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
479746|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
479747|NCT00552240|Drug|Nevirapine 200 mg BID|200 mg BID
479748|NCT00552240|Drug|Atazanavir 300 mg|300 mg QD
479749|NCT00552240|Drug|Ritonavir 100 mg|100 mg QD
479750|NCT00552227|Drug|ruboxistaurin|oral 32 mg daily
479751|NCT00552227|Other|placebo|placebo
479752|NCT00552214|Device|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
479753|NCT00552201|Drug|Tacrolimus|Administration Twice a day after adjustment to blood level
479754|NCT00552188|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 24 weeks
479755|NCT00552188|Drug|Placebo|oral dosing, 1 time daily for 24 weeks
479756|NCT00552175|Drug|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
479757|NCT00552175|Drug|placebo|placebo taken orally every day
479758|NCT00552175|Drug|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
479759|NCT00552162|Procedure|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
479760|NCT00552162|Procedure|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
479761|NCT00552149|Drug|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
479762|NCT00552136|Procedure|Ankle Arthroplasty|
479763|NCT00552136|Procedure|Ankle Arthrodesis|
479764|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
479765|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
479766|NCT00552110|Drug|mometasone furoate nasal spray (MFNS) once daily|MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
479767|NCT00552110|Drug|oxymetazoline nasal spray (OXY) twice daily|OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
479768|NCT00552110|Drug|Placebo|Matching placebo to MFNS given every morning and every evening x 2 weeks.
479769|NCT00552097|Drug|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
479770|NCT00552097|Drug|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
479771|NCT00552084|Drug|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
479772|NCT00552084|Drug|Placebo|Placebo supplements will be taken daily for 24 weeks.
479773|NCT00552071|Drug|Octreotide LAR 30 MG Injection|Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
479774|NCT00552058|Biological|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
479775|NCT00552058|Other|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
479776|NCT00552032|Drug|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
479777|NCT00552032|Drug|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
479778|NCT00552006|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.~NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
479779|NCT00552006|Behavioral|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.~AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
479780|NCT00551993|Procedure|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
479781|NCT00551993|Procedure|Laparoscopic Sacral Colpopexy|Standard laparoscopy
479782|NCT00551980|Behavioral|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
492167|NCT00459745|Drug|Pravafen|
479783|NCT00551967|Procedure|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
479784|NCT00551954|Drug|acarbose|100 mg (tablets) t.i.d.
479785|NCT00551954|Drug|placebo|one tablet t.i.d.
479786|NCT00551941|Procedure|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
479787|NCT00551941|Procedure|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
479788|NCT00551928|Drug|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
479789|NCT00551928|Drug|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
479790|NCT00551928|Drug|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
479791|NCT00551928|Drug|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
479792|NCT00551915|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
479793|NCT00551915|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
479794|NCT00551915|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
479795|NCT00551915|Biological|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
479796|NCT00551915|Biological|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
479797|NCT00551902|Procedure|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
479798|NCT00551902|Procedure|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
479799|NCT00551889|Drug|celecoxib|
479800|NCT00551889|Drug|cyclophosphamide|
479801|NCT00551889|Other|laboratory biomarker analysis|
479802|NCT00551876|Drug|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
479803|NCT00551876|Drug|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
479804|NCT00551863|Behavioral|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
479805|NCT00551850|Drug|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
479806|NCT00551824|Drug|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
479807|NCT00551811|Drug|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
479808|NCT00551811|Drug|Placebo|Placebo tablets will be intended to be administered orally.
479809|NCT00551798|Procedure|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
479810|NCT00551772|Drug|SB-742457|
479811|NCT00551759|Drug|5-Fluorouracil|given IV
479812|NCT00551759|Drug|Oxaliplatin|given IV
479813|NCT00551759|Drug|Cetuximab|given IV
479814|NCT00551759|Drug|Docetaxel|given IV
479815|NCT00551759|Procedure|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
479816|NCT00551759|Radiation|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
479817|NCT00551746|Dietary Supplement|Purple Grape Juice|Grape Juice
479818|NCT00551733|Drug|carboplatin|Given IV
479819|NCT00551733|Drug|paclitaxel|Given IV
479820|NCT00551733|Drug|paclitaxel poliglumex|Given IV
479821|NCT00551720|Behavioral|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
479822|NCT00551720|Behavioral|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
479823|NCT00551707|Drug|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
479824|NCT00551707|Drug|prednisolone|prednisolone (2.7 mg)
479825|NCT00551707|Drug|dipyridamole|dipyridamole 360 mg
479826|NCT00551707|Drug|placebo|placebo
479827|NCT00551707|Drug|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
479828|NCT00551694|Drug|GSK256073A tablets|
479829|NCT00551681|Device|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
479830|NCT00551681|Device|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
479831|NCT00551668|Procedure|proximal patellar surgery|Initial proximal patellar surgery
479832|NCT00551668|Procedure|Nonoperative|Nonoperative without surgery
479833|NCT00551642|Drug|Nitric Oxide for inhalation|inhaled nitric oxide given at 5 parts per million (ppm) for 7-21 days
479834|NCT00551642|Drug|Nitrogen|nitrogen gas given at 5ppm for 7-21 days
479835|NCT00551629|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
479836|NCT00551629|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
479837|NCT00551629|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
479838|NCT00551629|Biological|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
479839|NCT00551616|Drug|CDB-2914|Single dose
479840|NCT00551616|Drug|Levonorgestrel|Single dose
479841|NCT00551603|Drug|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
479842|NCT00551603|Drug|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
479843|NCT00551590|Drug|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
479844|NCT00551590|Drug|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
479845|NCT00551590|Drug|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
492168|NCT00459745|Drug|Pravastatin|
479846|NCT00551590|Drug|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
479847|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
479848|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
479849|NCT00551564|Drug|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
479850|NCT00551551|Other|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
479851|NCT00551551|Other|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
479852|NCT00551538|Drug|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
479853|NCT00551538|Drug|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
479854|NCT00551525|Radiation|Radiotherapy|3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
479855|NCT00551525|Drug|Samarium 153|Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
479856|NCT00551512|Drug|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
479857|NCT00551499|Device|CRT + AOP|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
479858|NCT00551486|Procedure|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
479859|NCT00551473|Drug|Lavoltidine|
479860|NCT00551460|Drug|arsenic trioxide|
479861|NCT00551460|Drug|gemtuzumab ozogamicin|
479862|NCT00551460|Drug|mercaptopurine|
479863|NCT00551460|Drug|methotrexate|
479864|NCT00551460|Drug|tretinoin|
479865|NCT00551447|Drug|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
479866|NCT00551447|Drug|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
479867|NCT00551447|Drug|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
479868|NCT00551434|Dietary Supplement|Creatine|Creatine 21 g daily
479869|NCT00551434|Dietary Supplement|L-arginine and creatine|L-arginine
479870|NCT00551434|Dietary Supplement|l-arginine|l-arginine 9 g daily
479871|NCT00551434|Dietary Supplement|placebo, double|placebo
479872|NCT00551421|Biological|pertuzumab|Given IV
479873|NCT00551421|Biological|cetuximab|Given IV
479874|NCT00551421|Drug|irinotecan hydrochloride|Given IV
479875|NCT00551421|Other|immunohistochemistry staining method|Correlative study
479876|NCT00551421|Other|fluorescence in situ hybridization|Correlative study
479877|NCT00551421|Other|gene expression analysis|Correlative study
479878|NCT00551421|Other|mutation analysis|Correlative study
479879|NCT00551421|Other|polymerase chain reaction|Correlative study
479880|NCT00551421|Other|laboratory biomarker analysis|Correlative study
479881|NCT00551395|Procedure|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
479882|NCT00551395|Procedure|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
479883|NCT00551382|Drug|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
479884|NCT00551382|Drug|Placebo|Look alike tablets or granules 1 per day for 12 weeks
479885|NCT00551369|Radiation|SBRT|SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
479886|NCT00551356|Drug|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
479887|NCT00551356|Drug|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
479888|NCT00551343|Drug|Exenatide|10ug Exenatide single s.c. injection
479889|NCT00551330|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily
479890|NCT00551330|Drug|Placebo|One tablet of placebo once daily
479891|NCT00551317|Drug|Darapladib (SB480848)|
479892|NCT00551304|Device|Ardian Catheter|
479893|NCT00551291|Drug|Mycophenolate mofetil|1 gm twice daily orally until end of study.
479894|NCT00551291|Drug|Prednisone|10 mg/day orally until end of study.
479895|NCT00551291|Drug|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
479896|NCT00551278|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|"For in vitro diagnostic use only.~The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra‑operative or post-operative decision to remove additional lymph nodes.~Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required."
479897|NCT00551265|Drug|Cyclophosphamide|Given IV
479898|NCT00551265|Procedure|Laboratory Biomarker Analysis|Correlative studies
479900|NCT00551252|Drug|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
479901|NCT00551239|Biological|rituximab|Given IV
479902|NCT00551239|Drug|fludarabine phosphate|Given IV
479903|NCT00551239|Drug|pixantrone dimaleate|Given IV
479904|NCT00551213|Biological|Robatumumab|
479905|NCT00551213|Drug|Irinotecan|
479906|NCT00551213|Biological|Cetuximab|
479907|NCT00551213|Drug|Capecitabine|
479908|NCT00551213|Drug|FOLFOX|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
479909|NCT00551213|Drug|CAPEOX/XELOX|Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
479910|NCT00551213|Drug|FOLFIRI|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
479911|NCT00551200|Drug|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
479912|NCT00551200|Drug|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
479913|NCT00551187|Biological|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
479914|NCT00551187|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
479915|NCT00551187|Biological|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
479916|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
479917|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
479918|NCT00551161|Drug|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
479919|NCT00551148|Drug|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
479920|NCT00551148|Drug|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
479921|NCT00551148|Drug|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
479922|NCT00551148|Drug|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
479923|NCT00551148|Other|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
479924|NCT00551135|Drug|Pregabalin|150 mg BID
479925|NCT00551135|Drug|placebo|Placebo
479926|NCT00551135|Drug|Pregabalin|75 mg BID
479927|NCT00551135|Drug|Pregabalin|25 mg BID
479928|NCT00551122|Biological|filgrastim|
479929|NCT00551122|Biological|lenograstim|
479930|NCT00551122|Biological|pegfilgrastim|
479931|NCT00551122|Drug|cisplatin|
479932|NCT00551122|Drug|gemcitabine hydrochloride|
479933|NCT00551122|Drug|ifosfamide|
479934|NCT00551122|Drug|paclitaxel|
479935|NCT00551109|Drug|placebo|placebo, oral administration, once daily for 8 weeks
479936|NCT00551109|Drug|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
479937|NCT00551109|Drug|SA4503 High|High dose, oral administration, once daily for 8 weeks
479938|NCT00551096|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
479939|NCT00551096|Drug|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
479940|NCT00551096|Drug|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
479941|NCT00551083|Other|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
479942|NCT00551083|Other|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
479943|NCT00551070|Other|Laboratory Biomarker Analysis|Correlative studies
479944|NCT00551070|Other|Pharmacological Study|Correlative studies
479945|NCT00551070|Drug|Selumetinib|Given PO
479946|NCT00551070|Drug|Selumetinib Sulfate|Given PO
479947|NCT00551057|Behavioral|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
479948|NCT00551044|Drug|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
480407|NCT00548067|Drug|Valsartan/amlodipine|
479949|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
479950|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
479951|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
479952|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
479953|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
479954|NCT00551018|Drug|Vicriviroc|one 30 mg tablet QD
479955|NCT00551018|Drug|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
479956|NCT00551005|Drug|celecoxib|
479957|NCT00551005|Drug|etoposide|
479958|NCT00551005|Other|immunoenzyme technique|
479959|NCT00551005|Other|laboratory biomarker analysis|
479960|NCT00550992|Biological|anti-thymocyte globulin|
479961|NCT00550992|Drug|asparaginase|
479962|NCT00550992|Drug|busulfan|
479963|NCT00550992|Drug|cyclophosphamide|
479964|NCT00550992|Drug|cyclosporine|
479965|NCT00550992|Drug|cytarabine|
479966|NCT00550992|Drug|daunorubicin hydrochloride|
479967|NCT00550992|Drug|etoposide|
479968|NCT00550992|Drug|leucovorin calcium|
479969|NCT00550992|Drug|melphalan|
479970|NCT00550992|Drug|mercaptopurine|
479971|NCT00550992|Drug|methotrexate|
479972|NCT00550992|Drug|mitoxantrone hydrochloride|
479973|NCT00550992|Drug|pegaspargase|
479974|NCT00550992|Drug|prednisolone|
479975|NCT00550992|Drug|prednisone|
479976|NCT00550992|Drug|therapeutic hydrocortisone|
479977|NCT00550992|Drug|thioguanine|
479978|NCT00550992|Drug|vincristine sulfate|
479979|NCT00550992|Procedure|allogeneic bone marrow transplantation|
479980|NCT00550992|Procedure|allogeneic hematopoietic stem cell transplantation|
479981|NCT00550992|Procedure|umbilical cord blood transplantation|
479982|NCT00550966|Behavioral|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
479983|NCT00550953|Drug|telmisartan+amlodipine|
479984|NCT00550953|Drug|telmisartan|
479985|NCT00550927|Biological|bevacizumab|
479986|NCT00550927|Drug|enzastaurin hydrochloride|
479987|NCT00550927|Other|diagnostic laboratory biomarker analysis|
479988|NCT00550927|Other|pharmacological study|
479989|NCT00550901|Drug|cisplatin|
479990|NCT00550901|Drug|dexrazoxane hydrochloride|
479991|NCT00550901|Other|high performance liquid chromatography|
479992|NCT00550901|Other|laboratory biomarker analysis|
479993|NCT00550901|Other|mass spectrometry|
479994|NCT00550901|Other|pharmacological study|
479995|NCT00550888|Procedure|suture techniques|
479996|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
479997|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
479998|NCT00550875|Biological|placebo|Sublingual. 2 drops/daily 2 years
479999|NCT00550862|Drug|INT-747|Once a day (QD) by mouth (PO)
480000|NCT00550862|Drug|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
480001|NCT00550862|Drug|Placebo|Placebo
480002|NCT00550849|Drug|RTA 402|5 mg oral capsules
480003|NCT00550849|Drug|RTA 402|25 mg oral capsules
480004|NCT00550849|Drug|RTA 402|50 mg oral capsules
480005|NCT00550836|Biological|panitumumab|Given IV
480006|NCT00550836|Drug|erlotinib hydrochloride|Given orally
480007|NCT00550836|Drug|gemcitabine hydrochloride|Given IV
480008|NCT00550823|Device|Cardiac CT 0BRILLIANT 64|Cardiac CT
480009|NCT00550810|Drug|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
480010|NCT00550797|Biological|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
480011|NCT00550797|Biological|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
480012|NCT00550784|Biological|filgrastim|
480013|NCT00550784|Drug|cisplatin|
480014|NCT00550784|Drug|cyclophosphamide|
480015|NCT00550784|Drug|melphalan|
480016|NCT00550784|Drug|paclitaxel|
480017|NCT00550784|Drug|topotecan hydrochloride|
480018|NCT00550784|Genetic|TdT-mediated dUTP nick end labeling assay|
480019|NCT00550784|Genetic|gene expression analysis|
480020|NCT00550784|Other|immunohistochemistry staining method|
480021|NCT00550784|Other|pharmacological study|
480022|NCT00550784|Procedure|peripheral blood stem cell transplantation|
480023|NCT00550771|Drug|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m^2 IV push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
480024|NCT00550771|Drug|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
480025|NCT00550758|Drug|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
480026|NCT00550758|Device|spirometry|spirometry
480027|NCT00550745|Biological|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
480028|NCT00550745|Biological|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
480029|NCT00550732|Drug|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
480030|NCT00550693|Device|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
480031|NCT00550680|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
480032|NCT00550654|Other|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
480033|NCT00550654|Radiation|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
480034|NCT00550654|Radiation|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
480035|NCT00550654|Radiation|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
480036|NCT00550654|Radiation|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
480037|NCT00550641|Other|physical therapy|physical therapy in warm pool performing stretching
480038|NCT00550641|Other|physical therapy|physical therapy in warm pool performing Ai Chi
480039|NCT00550628|Genetic|DNA methylation analysis|
480040|NCT00550628|Genetic|fluorescence in situ hybridization|
480041|NCT00550628|Genetic|gene expression analysis|
480042|NCT00550628|Genetic|polymerase chain reaction|
480043|NCT00550628|Genetic|protein expression analysis|
480044|NCT00550628|Genetic|reverse transcriptase-polymerase chain reaction|
480045|NCT00550628|Other|diagnostic laboratory biomarker analysis|
480046|NCT00550628|Other|immunoenzyme technique|
480047|NCT00550628|Other|immunohistochemistry staining method|
480048|NCT00550628|Procedure|biopsy|
480049|NCT00550628|Procedure|therapeutic conventional surgery|
480050|NCT00550628|Radiation|fludeoxyglucose F 18|
480051|NCT00550615|Drug|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.~There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:~Dose cohort # 1 will be 100 mg per day Dose cohort # 2 will be 150 mg per day Dose cohort # 3 will be 200 mg per day~The MTD will be determined in the Phase I portion of this trial."
480052|NCT00550615|Drug|Dasatinib Maximum Tolerated Dose|An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I.
480053|NCT00550589|Drug|cidofovir|1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
480054|NCT00550589|Genetic|DNA methylation analysis|formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
480055|NCT00550589|Genetic|gene expression analysis|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
480056|NCT00550589|Genetic|polymerase chain reaction|performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
480057|NCT00550589|Procedure|biopsy|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
480058|NCT00550589|Procedure|histopathologic examination|Evaluated at baseline and 6 weeks after treatment discontinuation
480059|NCT00550576|Drug|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
480060|NCT00550563|Dietary Supplement|cholecalciferol|Oral
480061|NCT00550563|Genetic|polymerase chain reaction|companion study
480062|NCT00550563|Genetic|polymorphism analysis|companion study
480063|NCT00550563|Genetic|protein expression analysis|companion study
480064|NCT00550563|Genetic|reverse transcriptase-polymerase chain reaction|companion study
480065|NCT00550563|Genetic|western blotting|companion study
480066|NCT00550563|Other|high performance liquid chromatography|companion study
480067|NCT00550563|Other|laboratory biomarker analysis|companion study
480068|NCT00550563|Other|pharmacological study|companion study
480069|NCT00550563|Procedure|adjuvant therapy|Additional therapy
480070|NCT00550563|Procedure|immunoscintigraphy|additional testing
480071|NCT00550550|Drug|Placebo|Placebo sublingual tablet, once daily
480072|NCT00550550|Biological|SCH 697243|Grass sublingual tablet, once daily
480073|NCT00550550|Drug|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to <6 years of age and at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
480074|NCT00550550|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
480075|NCT00550550|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
480112|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
480076|NCT00550550|Drug|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to <12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to <18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
480077|NCT00550550|Drug|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to <18 years with asthma symptoms .
480078|NCT00550550|Drug|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to <18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
480079|NCT00550550|Drug|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
480080|NCT00550537|Drug|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
480081|NCT00550537|Drug|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
480082|NCT00550537|Drug|erlotinib hydrochloride|150 mg taken by mouth daily
480083|NCT00550537|Drug|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
480084|NCT00550537|Genetic|gene expression analysis|Blood and tissue collection.
480085|NCT00550537|Genetic|protein expression analysis|Blood and tissue collection.
480086|NCT00550537|Genetic|proteomic profiling|Blood and tissue collection.
480087|NCT00550537|Other|laboratory biomarker analysis|Blood and tissue collection.
480088|NCT00550524|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
480089|NCT00550511|Radiation|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
480090|NCT00550498|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
480091|NCT00550485|Drug|escitalopram|escitalopram 4 mg
480092|NCT00550472|Dietary Supplement|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
480093|NCT00550459|Drug|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
480094|NCT00550459|Drug|Placebo|Placebo tablet given once daily for 21 days
480095|NCT00550446|Drug|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
480096|NCT00550446|Drug|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
480097|NCT00550446|Drug|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
480098|NCT00550446|Drug|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
480099|NCT00550446|Drug|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
480100|NCT00550446|Drug|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
480101|NCT00550446|Drug|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
480102|NCT00550433|Device|Bazedoxifene/Conjugated Estrogens|
480103|NCT00550420|Drug|Rosiglitazone XR|experimental drug
480104|NCT00550407|Drug|lamotrigine|lamotrigine 100mg/day or 200mg/day
480105|NCT00550407|Drug|Placebo|placebo once daily
480106|NCT00550394|Drug|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
480107|NCT00550394|Drug|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:~open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1~Dosing Schedule and Titration of Topiramate:~All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.~Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
480108|NCT00550381|Drug|HKI-357|Single-dose capsule
480109|NCT00550368|Biological|Biological intervention: Enteropathogenic E. coli|5x10^8 or 1x10^9 organisms of EPEC were administered to all participants.
480110|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
480111|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
480113|NCT00550355|Drug|Placebo|3 doses of Placebo administered over 12 weeks
480114|NCT00550342|Drug|rituximab|375 mg/m2 intravenously for 4 doses
480115|NCT00550329|Drug|Glipizide GITS|
480116|NCT00550303|Drug|bazedoxifene/conjugated estrogens combination|
480117|NCT00550290|Drug|Cefazolin PostOperatively|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
480118|NCT00550290|Drug|Cefazolin Preoperatively|Patients in active comparator arm will receive an initial pre-operative 2 gram does of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV will be used.
480119|NCT00550277|Drug|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
480120|NCT00550264|Other|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
480121|NCT00550251|Device|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
480122|NCT00550251|Device|Placebo wristbands|Elasticated wrist bands without active bead.
480123|NCT00550238|Drug|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
480124|NCT00550225|Drug|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
480125|NCT00550225|Drug|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
480126|NCT00550212|Drug|neratinib|HKI-272, Single-dose capsule and solution
480127|NCT00550199|Drug|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
480128|NCT00550186|Other|placebo|
480129|NCT00550186|Drug|Ringers Lactate|
480130|NCT00550186|Drug|HaemoHES 6%|
480131|NCT00550173|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
480132|NCT00550173|Drug|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
480133|NCT00550160|Drug|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.~Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
480134|NCT00550147|Drug|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:~Visit 2 dose of 18 mg QAM~Visit 3 dose of 36mg QAM~Visit 4 dose of 54mg QAM."
480135|NCT00550147|Drug|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).~Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)~Visit 5 dose of 25mg BID~Visit 6 dose of 50mg BID~Visit 7 dose of 100mg BID~Visit 8 dose of 200mg BID~Visit 9 dose of 300mg BID~Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
480136|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
480137|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
480138|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
480139|NCT00550121|Drug|vitamin C|
480140|NCT00550121|Drug|placebo|
480141|NCT00550108|Other|Ethanol lavage|Ethanol lavage of pancreatic cysts.
480142|NCT00550095|Drug|valsartan|
480143|NCT00550056|Behavioral|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
480144|NCT00550056|Behavioral|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
480145|NCT00550043|Drug|INCB018424|
480146|NCT00550043|Drug|Placebo|
480147|NCT00550030|Radiation|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
480148|NCT00550030|Other|No treatment|no UV exposure
480149|NCT00550017|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
480150|NCT00550004|Drug|RP101|190 mg oral tablet
480151|NCT00550004|Drug|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
480152|NCT00549978|Drug|Cilostazol|cilostazol, then cilostazol/probucol
480153|NCT00549978|Drug|Probucol|Probucol probucol/ cilostazol
480154|NCT00549965|Drug|Risedronate Sodium|
480155|NCT00549952|Other|no intervention study|
480156|NCT00549939|Drug|Alfuzosin|"Form: solution or tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
480157|NCT00549939|Drug|Placebo|"Form: matching solution or matching tablet according to age~Route: oral~Dose: daily dose adjusted to body weight"
480158|NCT00549926|Drug|Fluvastatin|
480159|NCT00549926|Drug|Pravastatin|
480160|NCT00549926|Drug|Pitavastatin|
480161|NCT00549926|Drug|Atorvastatin|
480162|NCT00549913|Genetic|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
480163|NCT00549913|Procedure|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
480164|NCT00549900|Biological|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
480165|NCT00549887|Drug|Analog or Human Insulin|prescribed in accordance with usual clinical practice
480166|NCT00549874|Drug|Rosiglitazone|oral 8 mg/once daily for 6 months
480167|NCT00549874|Drug|Glyburide|20 mg/ once daily for 6 months
480168|NCT00549861|Procedure|Cardiac Magnetic Resonance study|Cardiac MRI study
480169|NCT00549848|Drug|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
480170|NCT00549848|Drug|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
480171|NCT00549835|Procedure|Real Acupuncture|
480172|NCT00549835|Procedure|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.~All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
480173|NCT00549822|Drug|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
480174|NCT00549809|Procedure|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
480175|NCT00549796|Other|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
480176|NCT00549783|Biological|Botulinum Toxin Type A 900kD|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
480177|NCT00549783|Biological|Placebo|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.~First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
480178|NCT00549770|Drug|LCZ696|
480179|NCT00549770|Drug|Valsartan|
480180|NCT00549770|Drug|AHU377|
480181|NCT00549770|Drug|Placebo|
480182|NCT00549757|Drug|Aliskiren|Aliskiren 150 mg film-coated tablets
480183|NCT00549757|Drug|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
480184|NCT00549744|Drug|GSK256066|
480185|NCT00549718|Drug|Lurasidone HCl|Once daily
480186|NCT00549692|Drug|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
480187|NCT00549679|Drug|GSK256066|PDE4 inhibitor
480188|NCT00549679|Drug|Placebo|Placebo
480189|NCT00549666|Drug|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
480190|NCT00549666|Drug|Placebo 40 mg|Placebo 40 mg once daily during treatment period
480191|NCT00549666|Drug|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
480192|NCT00549653|Drug|GW856553|
480193|NCT00549640|Drug|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
480194|NCT00549640|Drug|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
480195|NCT00549627|Device|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
480196|NCT00549614|Drug|acipimox|capsule, 250 mg, 4 times daily for 28 days
480197|NCT00549614|Drug|placebo|capsule, 250 mg, 4 times daily for 28 days
480198|NCT00549601|Drug|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
480199|NCT00549601|Drug|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
480200|NCT00549601|Drug|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
480201|NCT00549588|Other|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
480682|NCT00546143|Drug|Omalizumab|
480202|NCT00549588|Other|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
480203|NCT00549588|Other|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
480204|NCT00549588|Other|Intervention: none (only UV)|n.a.
480205|NCT00549575|Drug|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
480206|NCT00549575|Drug|Placebo|After double blind randomization, patients received a placebo.
480207|NCT00549562|Drug|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
480208|NCT00549549|Drug|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
480209|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
480210|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
480211|NCT00549549|Drug|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
480212|NCT00549536|Dietary Supplement|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
480213|NCT00549523|Drug|Placebo|Capsules containing 0 mg bid (placebo)
480214|NCT00549523|Drug|Low Dose|Capsules containing 400 mg bid of L. frutescens.
480215|NCT00549523|Drug|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
480216|NCT00549523|Drug|High Dose|Capsules containing 1200 mg bid of L. frutescens.
480217|NCT00549510|Drug|COREG CR and lisinopril (FDC)|
480218|NCT00549497|Drug|GW870086X|
480219|NCT00549471|Other|physiotherapy|CG children will undergo a program of intensive physiotherapy
480220|NCT00549471|Other|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
480221|NCT00549458|Behavioral|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
480222|NCT00549458|Procedure|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
480223|NCT00549445|Drug|Azithromycin|250 mg daily
480224|NCT00549445|Drug|Placebo|Daily
480225|NCT00549432|Device|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
480226|NCT00549419|Drug|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
480227|NCT00549419|Drug|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
480228|NCT00549419|Drug|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
480229|NCT00549406|Procedure|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
480230|NCT00549406|Procedure|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
480231|NCT00549406|Procedure|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
480232|NCT00549393|Drug|2% Chlorhexidine gluconate cloth|Daily bathing
480233|NCT00549380|Device|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
480234|NCT00549367|Behavioral|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
480235|NCT00549354|Device|Endoluminal Graft|
480236|NCT00549341|Drug|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
480237|NCT00549341|Other|Physiologic saline|Single injection.
480238|NCT00549328|Drug|Pazopanib (GW786034)|Pazopanib monotherapy
480239|NCT00549315|Device|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
480240|NCT00549302|Drug|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
480401|NCT00548106|Dietary Supplement|partially hydrolyzed whey|Total infant feeding by study formula.
480402|NCT00548106|Dietary Supplement|Nan HA|Total infant diet by study formula.
480241|NCT00549302|Drug|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
480242|NCT00549289|Drug|cyclosporine A|
480243|NCT00549263|Drug|SB797620|
480244|NCT00549237|Dietary Supplement|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
480245|NCT00549237|Other|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
480246|NCT00549211|Drug|GSK557296|
480247|NCT00549198|Drug|Abacavir/lamivudine and efavirenz|
480248|NCT00549198|Drug|Tenofovir/Emtricitabine and efavirenz|
480249|NCT00549185|Drug|SAR3419|Intravenous infusion
480250|NCT00549172|Procedure|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
480251|NCT00549172|Procedure|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
480252|NCT00549159|Device|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
480253|NCT00549159|Device|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
480254|NCT00549146|Drug|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
480255|NCT00549146|Drug|fluticasone propionate DISKUS 500mcg|
480256|NCT00549133|Drug|Irbesartan|
480257|NCT00549120|Drug|Propranolol|40 mg tablets
480258|NCT00549120|Drug|Salbutamol|Metered dose inhaler (600 μg)
480259|NCT00549120|Drug|Ipratropium|Metered dose inhaler (40 μg)
480260|NCT00549120|Drug|Placebo|Placebo for propranolol tablets
480261|NCT00549107|Drug|Levosimendan|
480262|NCT00549107|Drug|Milrinone|
480263|NCT00549081|Dietary Supplement|DHEA|oral DHEA tablets 75 mg daily
480264|NCT00549068|Drug|Risedronate Sodium (Actonel)|
480265|NCT00549055|Drug|Macugen|Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
480266|NCT00549042|Drug|OROS hydromorphone|hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets
480267|NCT00549042|Drug|Placebo|Placebo
480268|NCT00549029|Genetic|DNA|withdraw 5~10mL blood from vein only once during the whole design
480269|NCT00549016|Device|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
480270|NCT00549003|Device|Rapid Diagnostic Test for P. falciparum malaria|
480271|NCT00548990|Behavioral|cardiovascular exercise training|
480272|NCT00548990|Behavioral|flexibility/balance control|
480273|NCT00548977|Other|Drawing blood to study genetic polymorphism|
480274|NCT00548964|Drug|Lithium|600-900mg of Li carbonate
480275|NCT00548964|Drug|Ketamine|0.5mg/kg of ketamine
480276|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
480277|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
480278|NCT00548951|Other|Control|Receive no sessions in a Snoezelen Room.
480279|NCT00548938|Drug|Gliadel wafer|Implanted at surgery
480280|NCT00548938|Drug|Temozolomide|During External Beam Radiation
480281|NCT00548938|Radiation|External Beam Radiation Therapy|60 Gy
480282|NCT00548925|Drug|ABT-894|6 mg BID tablets, 8 weeks of treatment
480283|NCT00548925|Drug|placebo|BID tablets, 8 weeks of treatment
480284|NCT00548912|Drug|Spironolactone|
480285|NCT00548899|Drug|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
480286|NCT00548886|Drug|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
480287|NCT00548860|Drug|Ferric Carboxymaltose|
480288|NCT00548860|Drug|Standard Medical Care (SMC)|
480289|NCT00548847|Biological|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
480290|NCT00548847|Biological|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
480291|NCT00548834|Drug|CDP870|
480292|NCT00548821|Drug|Cisplatin|
480293|NCT00548808|Drug|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
480294|NCT00548808|Drug|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
480295|NCT00548808|Drug|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
480296|NCT00548782|Other|Paleolithic diet|diet
480297|NCT00548782|Other|ADA ( American Diabetes Association) recommended diet|diet
480403|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
480404|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
480298|NCT00548769|Drug|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
480299|NCT00548769|Drug|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
480300|NCT00548769|Drug|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
480301|NCT00548769|Drug|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
480302|NCT00548756|Procedure|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
480303|NCT00548756|Other|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
480304|NCT00548756|Behavioral|Questionnaire|Questionnaire taking 40 minutes to complete.
480305|NCT00548743|Behavioral|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
480306|NCT00548743|Behavioral|Usual care|usual care for identification and management of postpartum depression
480307|NCT00548730|Procedure|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
480308|NCT00548717|Drug|Sirolimus|
480309|NCT00548717|Drug|Mycophenolate mofetil|
480310|NCT00548717|Drug|Bortezomib|
480311|NCT00548704|Drug|Dexrazoxane|
480312|NCT00548691|Drug|Ferric Carboxymaltose|
480313|NCT00548691|Drug|Standard Medical Care (SMC)|
480314|NCT00548678|Drug|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
480315|NCT00548678|Drug|ketorolac|intravenous ketorolac
480316|NCT00548678|Drug|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
480317|NCT00548678|Drug|aspirin|oral aspirin
480318|NCT00548665|Device|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
480319|NCT00548665|Behavioral|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
480320|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
480321|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
480322|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
480323|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
480324|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
480325|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
480326|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
480327|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
480328|NCT00548639|Other|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
480329|NCT00548639|Other|Control Pamphlet|ADA Diabetes Sheet
480330|NCT00548626|Procedure|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
480331|NCT00548626|Procedure|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
480332|NCT00548613|Biological|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
480333|NCT00548613|Biological|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
480334|NCT00548600|Procedure|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
480335|NCT00548600|Radiation|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
480336|NCT00548587|Drug|E5555|
480337|NCT00548587|Drug|Placebo|
480338|NCT00548574|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
480339|NCT00548574|Drug|Mesalazine|
480340|NCT00548561|Drug|Dexrazoxane|
480341|NCT00548548|Drug|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
480342|NCT00548548|Drug|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
480343|NCT00548548|Drug|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
480344|NCT00548548|Drug|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
480405|NCT00548080|Drug|MK0991, caspofungin acetate / Duration of Treatment:|
480406|NCT00548067|Drug|Valsartan/hydrochlorothiazide (HCTZ)|
480345|NCT00548548|Drug|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
480346|NCT00548535|Procedure|Reliability of complication assessment|
480347|NCT00548509|Drug|Menatetrenone (Vitamin K2)|
480348|NCT00548496|Drug|SB-751689|SB-751689
480349|NCT00548496|Other|Placebo|Placebo to match
480350|NCT00548483|Drug|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
480351|NCT00548470|Drug|Varenicline|Varenicline 1-2 mg/day
480352|NCT00548444|Biological|MVA85A|Vaccine. Dose: 1 x 10^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
480353|NCT00548444|Other|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
480354|NCT00548431|Drug|6-mercaptopurine|Standard dose 25 mg/m^2/day. Can be increased up to 75 mg/m^2/day if the myelosuppression is acceptable (ANC>0.5 T-count >50)
480355|NCT00548418|Drug|Topotecan|
480356|NCT00548418|Drug|Cisplatin|
480357|NCT00548418|Drug|Bevacizumab|
480358|NCT00548405|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
480359|NCT00548405|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
480360|NCT00548405|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
480361|NCT00548379|Drug|vitamin D|vitamin D 100,000 units once in 3 months
480362|NCT00548379|Drug|placebo|olive oil 1ml
480363|NCT00548366|Other|Sodium restriction|4 gram sodium diet
480364|NCT00548366|Other|Sodium restriction|2 gram sodium diet
480365|NCT00548353|Drug|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
480366|NCT00548353|Drug|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
480367|NCT00548340|Drug|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
480368|NCT00548340|Drug|Placebo|Placebo capsules, PO daily for five weeks
480369|NCT00548340|Drug|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
480370|NCT00548327|Drug|Atomoxetine|Comparison between Atomoxetine and Placebo
480371|NCT00548327|Procedure|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
480372|NCT00548327|Procedure|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
480373|NCT00548327|Drug|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
480374|NCT00548314|Other|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
480375|NCT00548314|Procedure|Split skin graft|
480376|NCT00548314|Device|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
480377|NCT00548301|Drug|cyclosporine|
480378|NCT00548288|Drug|pamidronate|
480379|NCT00548275|Behavioral|Enhanced Sexual Risk Management|management of sexual risk
480380|NCT00548275|Behavioral|Standard Sexual Risk Management|management of sexual risk
480381|NCT00548262|Drug|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
480382|NCT00548262|Drug|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if <40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if <40 kg body weight).
480383|NCT00548249|Device|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
480384|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
480385|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
480386|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
480387|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
480388|NCT00548236|Behavioral|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
480389|NCT00548223|Drug|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid*1year
480390|NCT00548223|Drug|placebo|Capsule, 0.18g, 2#, Bid*1year
480391|NCT00548197|Drug|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
480392|NCT00548184|Drug|Lapatinib|Monoclonal Antibody
480393|NCT00548184|Drug|Trastuzumab|Monoclonal Antibody
480394|NCT00548184|Drug|Endocrine|Hormonal Therapy
480395|NCT00548171|Biological|Boostrix™|Intramuscular injection, 1 dose
480396|NCT00548145|Drug|Pitavastatin|2 mg by orally/day Duration: 12 months
480397|NCT00548145|Drug|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
480398|NCT00548132|Device|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
480399|NCT00548119|Biological|NeoCart|autologous tissue implant
480400|NCT00548119|Procedure|microfracture|microfracture
480408|NCT00548067|Drug|Amlodipine/hydrochlorothiazide(HCTZ)|
480409|NCT00548067|Drug|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
480410|NCT00548054|Biological|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
480411|NCT00548054|Biological|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
480412|NCT00548041|Other|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
480413|NCT00548015|Behavioral|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
480414|NCT00548002|Drug|trovafloxacin and levofloxacin|Trovafloxacin: <60 kg 200 mg iv/orally once daily and >60 kg 300 mg iv/orally once daily Levofloxacin: < 60 kg 500 mg iv/orally once daily and >60 kg 500 mg iv/orally bid
480415|NCT00547989|Drug|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
480416|NCT00547989|Drug|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
480417|NCT00547989|Drug|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
480418|NCT00547976|Drug|[C-11]PBR28|
480419|NCT00547963|Behavioral|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
480420|NCT00547950|Drug|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid*1year.
480421|NCT00547937|Device|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
480422|NCT00547924|Behavioral|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
480423|NCT00547911|Drug|Droxidopa|
480424|NCT00547911|Drug|Carbidopa|
480425|NCT00547911|Drug|Entacapone|
480426|NCT00547898|Drug|Crofelemer 125 mg|Crofelemer 125 mg
480427|NCT00547898|Drug|Crofelemer 250 mg|Crofelemer 250 mg
480428|NCT00547898|Drug|Crofelemer 500 mg|Crofelemer 500 mg
480429|NCT00547898|Drug|Placebo|Placebo
480430|NCT00547885|Drug|Dihydrocodeine|"Group 1: 2* 60 mg dihydrocodeine long acting + up to four placebo short action~Group 2: 3* 60 mg dihydrocodeine long acting + up to six placebo short action~Group 3: 4* 60 mg dihydrocodeine long acting + up to eight placebo short action~Group 4: 2 placebo for long acting + up to 4*30 mg dihydrocodeine short acting~Group 5: 3 placebo for long acting + up to 6*30 mg dihydrocodeine short acting~Group 6: 3 placebo for long acting + up to 8*30 mg dihydrocodeine short acting"
480431|NCT00547872|Procedure|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
480432|NCT00547846|Drug|PDC-748|
480433|NCT00547820|Other|placebo|
480434|NCT00547820|Device|Urinary sensor|
480435|NCT00547807|Other|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
480436|NCT00547807|Other|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
480437|NCT00547781|Procedure|PGD|
480438|NCT00547768|Drug|Fexofenadine HCI|
480439|NCT00547742|Procedure|PET/CT Scan|
480440|NCT00547742|Procedure|phlebotomy|
480441|NCT00547729|Device|HeartPOD™ System|HeartPOD™ device automatically measures left heart pressures throughout the day.
480442|NCT00547716|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
480443|NCT00547716|Drug|Placebo comparator|
480444|NCT00547703|Drug|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
480445|NCT00547703|Drug|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
480446|NCT00547690|Other|Acupuncture and Strengthening|Acupuncture and strengthening
480447|NCT00547690|Other|Strengthening Alone|Strengthening training program
480448|NCT00547677|Radiation|stereotactic radiosurgery|
480449|NCT00547664|Drug|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
480450|NCT00547664|Other|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
480451|NCT00547651|Drug|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
480452|NCT00547651|Drug|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
480453|NCT00547638|Device|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
480454|NCT00547638|Device|cyanoacrylate|Topical Skin Adhesive
480455|NCT00547625|Drug|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
480456|NCT00547625|Drug|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
480457|NCT00547612|Other|high performance liquid chromatography|
480458|NCT00547612|Other|pharmacological study|
480459|NCT00547612|Radiation|[18F]-labeled substance P antagonist receptor quantifier|
480460|NCT00547599|Drug|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
480461|NCT00547586|Drug|N-methylnaltrexone bromide (MOA-728)|Oral
480462|NCT00547586|Other|placebo|placebo
480463|NCT00547573|Drug|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
480464|NCT00547573|Drug|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
480465|NCT00547573|Drug|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
480466|NCT00547560|Drug|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
480467|NCT00547547|Dietary Supplement|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
480468|NCT00547547|Drug|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
480469|NCT00547547|Drug|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
480470|NCT00547534|Drug|bortezomib|1.3 mg/m^2 on days 1, 4, 8, 11
480471|NCT00547534|Drug|bendamustine|90 mg/m^2 days 1 and 4
480472|NCT00547534|Drug|rituximab|375 mg/m^2 day 1
480473|NCT00547521|Drug|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
480474|NCT00547521|Drug|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
480475|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
480476|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
480477|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
480478|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
480479|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
480480|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
480481|NCT00547495|Drug|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
480482|NCT00547495|Drug|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
480483|NCT00547495|Drug|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
480484|NCT00547495|Drug|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
480485|NCT00547482|Device|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
480486|NCT00547469|Drug|DDP733|
480487|NCT00547456|Drug|Oxygen|Oxygen 2-3L Nasal cannula
480488|NCT00547443|Drug|carboplatin|Given IV
480489|NCT00547443|Drug|paclitaxel|Given IV
480490|NCT00547443|Drug|sorafenib tosylate|Given orally
480491|NCT00547443|Radiation|radiation therapy|Given 5 days a week for 7.5 weeks
480492|NCT00547417|Drug|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
480493|NCT00547404|Drug|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
480494|NCT00547391|Procedure|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
480495|NCT00547391|Other|no intervention|No intervention (controls). Follow up started from the day of randomization.
480496|NCT00547378|Device|InterStim|
480497|NCT00547378|Drug|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
480498|NCT00547365|Biological|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
480499|NCT00547352|Drug|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
480500|NCT00547352|Drug|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
480501|NCT00547339|Radiation|stereotactic body radiation therapy|
480502|NCT00547326|Procedure|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
480503|NCT00547326|Procedure|Treatment with placebo|Treatment with placebo
480504|NCT00547300|Drug|Metoprolol ER|Metoprolol ER once daily, oral administration
480505|NCT00547300|Drug|Nebivolol|Nebivolol once daily, oral administration
480506|NCT00547287|Drug|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
480507|NCT00547287|Drug|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
480508|NCT00547274|Drug|MK0767|
480509|NCT00547261|Drug|SSR97225|every 3 weeks
480510|NCT00547248|Biological|Synflorix|Intramuscular injection, 1 dose
480511|NCT00547248|Biological|Tritanrix-HepB|Intramuscular injection, 1 dose
480512|NCT00547248|Biological|Hiberix|Reconstituted with Tritanrix-Hep B before injection
480513|NCT00547248|Biological|Polio Sabin|Oral, 1 dose
480514|NCT00547248|Biological|Poliorix|Intramuscular injection, 1 dose
480515|NCT00547248|Biological|Prevenar (Wyeth)|Intramuscular injection, 1 dose
480516|NCT00547235|Biological|therapeutic allogeneic lymphocytes|
480517|NCT00547235|Procedure|allogeneic bone marrow transplantation|
480518|NCT00547235|Radiation|total-body irradiation|
480519|NCT00547209|Drug|air|60% air combined with 40% oxygen for ventilation
480520|NCT00547209|Drug|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
480521|NCT00547196|Biological|filgrastim|
480522|NCT00547196|Drug|busulfan|
480523|NCT00547196|Drug|cyclophosphamide|
480524|NCT00547196|Drug|cyclosporine|
480525|NCT00547196|Drug|fludarabine phosphate|
480526|NCT00547196|Drug|melphalan|
480527|NCT00547196|Drug|mycophenolate mofetil|
480528|NCT00547196|Procedure|allogeneic hematopoietic stem cell transplantation|
480529|NCT00547196|Procedure|umbilical cord blood transplantation|
480530|NCT00547196|Radiation|total-body irradiation|
480531|NCT00547183|Drug|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
480532|NCT00547183|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
480533|NCT00547183|Drug|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
480534|NCT00547170|Drug|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
480535|NCT00547170|Drug|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
480536|NCT00547157|Drug|Panitumumab|Arm 2 consists of panitmumab plus RT
480537|NCT00547157|Drug|Cisplatin|Cisplatin
480538|NCT00547144|Drug|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
480539|NCT00547144|Procedure|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
480540|NCT00547131|Drug|temozolomide|
480541|NCT00547131|Other|laboratory biomarker analysis|
480542|NCT00547131|Other|liquid chromatography|
480543|NCT00547131|Other|mass spectrometry|
480544|NCT00547131|Other|pharmacological study|
480545|NCT00547131|Procedure|conventional surgery|
480546|NCT00547131|Radiation|stereotactic radiosurgery|
480547|NCT00547118|Drug|Rimonabant|One 20 mg tablet given 1 time per day for 112 days.
480548|NCT00547118|Drug|Placebo|One placebo tablet given 1 time per day for 112 days.
480549|NCT00547105|Drug|Erlotinib|Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
480550|NCT00547105|Radiation|SBRT|SBRT is a treatment method to deliver a high dose of radiation to the target, utilizing either a single dose or a small number of fractions with a high degree of precision within the body
480551|NCT00547092|Drug|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
480552|NCT00547092|Drug|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
480553|NCT00547066|Biological|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
480554|NCT00547053|Drug|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
480555|NCT00547040|Other|no intervention|no intervention
480556|NCT00547027|Behavioral|print-based physical activity intervention|individually-based, print-based physical activity intervention
480557|NCT00547027|Behavioral|usual care|print-based materials of nutritional information
480558|NCT00547014|Drug|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
480559|NCT00547014|Drug|52364 3 mg|3 mg capsule single dose administered orally as a single dose
480560|NCT00547014|Drug|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
480561|NCT00547014|Drug|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
480562|NCT00547014|Drug|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
480563|NCT00547014|Drug|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
480564|NCT00547014|Drug|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
480565|NCT00547001|Drug|Estradiol|1mg during stabilization & then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
480566|NCT00546988|Biological|allogeneic stem cell transplant|
480567|NCT00546975|Dietary Supplement|Resource Support®|
480568|NCT00546975|Dietary Supplement|Resource Protein®|
480569|NCT00546975|Dietary Supplement|Placebo|
480570|NCT00546949|Procedure|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
480571|NCT00546949|Procedure|Interspinous Process Decompression (IPD)|Interspinous device
480572|NCT00546936|Drug|ranibizumab|0.5mg ranibizumab
480573|NCT00546936|Drug|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
480574|NCT00546923|Drug|Venlafaxine XR|
480575|NCT00546910|Drug|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
480576|NCT00546910|Drug|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
480577|NCT00546897|Drug|Lenalidomide|
480578|NCT00546884|Behavioral|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
480579|NCT00546884|Behavioral|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
480580|NCT00546871|Drug|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
480581|NCT00546858|Other|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
480582|NCT00546845|Device|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
480583|NCT00546845|Device|Use of self-expanding Expert stent|Nitinol stent
480584|NCT00546832|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
480585|NCT00546832|Drug|celecoxib|
480586|NCT00546832|Other|placebo|
480587|NCT00546819|Biological|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
480588|NCT00546819|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
480589|NCT00546806|Other|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
480590|NCT00546793|Biological|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
480591|NCT00546780|Drug|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
480592|NCT00546780|Drug|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
480593|NCT00546767|Behavioral|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
480594|NCT00546767|Behavioral|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
480595|NCT00546767|Behavioral|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
480596|NCT00546767|Behavioral|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
480597|NCT00546754|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
480598|NCT00546754|Drug|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
480599|NCT00546741|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
480600|NCT00546741|Drug|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
480601|NCT00546741|Drug|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose~Dapagliflozin: 20 mg~Metformin: 1000 mg"
480602|NCT00546728|Drug|Exenatide|exenatide 10 mcg twice daily
480603|NCT00546728|Drug|Metformin|metformin 500 twice daily
480604|NCT00546715|Drug|Daclatasvir|Oral Solution, Oral, Single Dose
480605|NCT00546715|Drug|Placebo|Oral Solution, Oral, Single Dose
480606|NCT00546702|Drug|Insuline Glulisine|
480607|NCT00546676|Drug|Telithromycin|
480608|NCT00546663|Drug|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.~A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).~To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
480609|NCT00546650|Drug|Sumatriptan succinate|NP101 iontophoretic transdermal system
480610|NCT00546650|Drug|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
480611|NCT00546637|Drug|Fesoterodine|Fesoterodine 4mg or 8mg
480612|NCT00546637|Drug|Placebo|Placebo
480613|NCT00546624|Drug|MK0777|
480614|NCT00546611|Drug|PEP005|
480615|NCT00546598|Device|Total hip replacement/arthroplasty|Hip replacement
480616|NCT00546598|Device|Hip replacement/arthroplasty|Hip replacement
480617|NCT00546585|Biological|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
480618|NCT00546585|Drug|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
480619|NCT00546572|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
480620|NCT00546572|Biological|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
480621|NCT00546559|Drug|statins (simvastatin, pravastatin)|
480622|NCT00546546|Drug|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
480623|NCT00546533|Drug|Etanercept|
480624|NCT00546520|Drug|Ciclesonide|
480625|NCT00546507|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
480626|NCT00546507|Drug|celecoxib|
480627|NCT00546507|Other|placebo|
480628|NCT00546494|Drug|Effexor® (Venlafaxine)|
480629|NCT00546481|Drug|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
480630|NCT00546481|Drug|Epoetin|As prescribed, iv, 3 times weekly
480631|NCT00546468|Procedure|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
480632|NCT00546468|Procedure|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
480633|NCT00546455|Drug|Fenretinide|200 mg/day
480634|NCT00546455|Drug|Placebo|2 capsules/day
480635|NCT00546442|Drug|Metformine|850-2550 mg/daily for 48 weeks
480636|NCT00546442|Other|Placebo of metformine|850-2550 mg/daily for 48 weeks
480637|NCT00546429|Device|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
480638|NCT00546403|Drug|Modafinil|Adjunctive treatment with titrated dose of modafinil
480639|NCT00546403|Drug|Placebo|Adjunctive treatment with placebo
480640|NCT00546390|Device|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
480641|NCT00546377|Biological|filgrastim|
480642|NCT00546377|Biological|pegfilgrastim|
480643|NCT00546377|Biological|rituximab|
480644|NCT00546377|Biological|sargramostim|
480645|NCT00546377|Drug|cyclophosphamide|
480646|NCT00546377|Drug|mitoxantrone hydrochloride|
480647|NCT00546377|Drug|pentostatin|
480648|NCT00546377|Genetic|fluorescence in situ hybridization|
480649|NCT00546377|Genetic|gene rearrangement analysis|
480650|NCT00546377|Genetic|polymerase chain reaction|
480651|NCT00546377|Genetic|protein expression analysis|
480652|NCT00546377|Other|flow cytometry|
480653|NCT00546377|Procedure|biopsy|
480654|NCT00546364|Drug|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
480655|NCT00546364|Drug|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
480656|NCT00546364|Drug|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
480657|NCT00546351|Drug|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
480658|NCT00546325|Drug|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
480659|NCT00546325|Drug|Placebo|Matching placebo tablets. Once daily before breakfast
480660|NCT00546312|Device|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
480661|NCT00546299|Drug|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
480662|NCT00546286|Drug|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
480663|NCT00546286|Drug|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
480664|NCT00546273|Biological|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
480665|NCT00546273|Biological|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
480666|NCT00546273|Biological|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
480667|NCT00546273|Biological|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
480668|NCT00546273|Biological|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
480669|NCT00546260|Drug|placebo|administration of iv bolus prior to angiography
480670|NCT00546260|Drug|PRT060128 Potassium|administration of iv bolus prior to angiography
480671|NCT00546247|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
480672|NCT00546234|Drug|tiotropium|18 mcg daily via Handihaler
480673|NCT00546234|Drug|long acting beta agonist|Turbohaler, 6 & 12 mcg
480674|NCT00546221|Behavioral|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
480675|NCT00546221|Behavioral|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
480676|NCT00546169|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
480677|NCT00546156|Drug|Doxorubicin|Standard chemotherapy regimen
480678|NCT00546156|Drug|Cyclophosphamide|Standard chemotherapy regimen
480679|NCT00546156|Drug|Paclitaxel|Standard chemotherapy regimen
480680|NCT00546156|Drug|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
480681|NCT00546143|Drug|Omalizumab|
480684|NCT00546130|Drug|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
480685|NCT00546130|Drug|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
480686|NCT00546130|Drug|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
480687|NCT00546117|Drug|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing >30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
480688|NCT00546117|Drug|placebo|Placebo Solutab in 15 and 30 mg dosages.
480689|NCT00546104|Drug|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
480690|NCT00546078|Biological|Cervarix™|Intramuscular injection, one or three doses
480691|NCT00546065|Drug|esomeprazole treatment|concomitant esomeprazole treatment
480692|NCT00546052|Drug|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
480693|NCT00546039|Drug|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
480694|NCT00546039|Drug|Placebo|Capsule
480695|NCT00546026|Other|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
480696|NCT00546000|Drug|Fluticasone propionate 0.05% lotion|Daily applications
480697|NCT00545987|Device|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
480698|NCT00545987|Device|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
480699|NCT00545974|Drug|memantine|memantine 10mg BID
480700|NCT00545974|Drug|Placebo pill|Placebo pill BID
480701|NCT00545961|Drug|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
480702|NCT00545961|Drug|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
480703|NCT00545948|Drug|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
480704|NCT00545948|Drug|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
480705|NCT00545935|Drug|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
480706|NCT00545935|Drug|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
480707|NCT00545935|Drug|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
480708|NCT00545922|Behavioral|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
480709|NCT00545922|Behavioral|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
480710|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
480711|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
480712|NCT00545896|Procedure|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
480713|NCT00545870|Drug|bevacizumab|intravitreal application
480714|NCT00545870|Drug|Ranibizumab|intravitreal application
480715|NCT00545857|Drug|pioglitazone|Pioglitazone daily; dose varies with size
480716|NCT00545857|Drug|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
480717|NCT00545844|Drug|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
480718|NCT00545831|Device|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
480719|NCT00545831|Device|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
480720|NCT00545818|Device|OsseoSpeed™|OsseoSpeed™ implant, length: 6 mm
480721|NCT00545818|Device|OsseoSpeed™|OsseoSpeed™ implant, length: 11 mm
480722|NCT00545805|Procedure|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
480723|NCT00545805|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
480724|NCT00545792|Drug|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
480725|NCT00545779|Drug|Ibandronate|150 mg orally once monthly for 6 months
480726|NCT00545766|Drug|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
480727|NCT00545753|Drug|Spinosad|10 minute topical application product, following by a complete rinse off.
480728|NCT00545753|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
480729|NCT00545753|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
480730|NCT00545740|Drug|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
480731|NCT00545740|Drug|SPD476 (2.4 g)|2.4g SPD476 QD orally
480732|NCT00545740|Drug|SPD476 (4.8 g)|4.8g SPD476 QD orally
480733|NCT00545740|Drug|Placebo|QD orally
480734|NCT00545727|Behavioral|Diet|Whole-foods, low glycemic index diet
480735|NCT00545727|Other|Standard diet|Standard diet meeting American Diabetes Association guidelines
480736|NCT00545714|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
480737|NCT00545714|Drug|Fludarabine|Fludarabine 25 mg/m^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
480738|NCT00545714|Drug|Rituximab|Rituximab 375 mg/m^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
480739|NCT00545701|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
480740|NCT00545688|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
480741|NCT00545688|Drug|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
480742|NCT00545688|Drug|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
480743|NCT00545675|Drug|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
480744|NCT00545675|Drug|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
480745|NCT00545662|Drug|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
480746|NCT00545662|Drug|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
480747|NCT00545649|Behavioral|Exercise and education|
480748|NCT00545649|Behavioral|Education|
480749|NCT00545636|Other|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
480750|NCT00545623|Procedure|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
480751|NCT00545623|Behavioral|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
480752|NCT00545623|Other|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
480753|NCT00545597|Drug|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
480754|NCT00545584|Drug|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
480755|NCT00545584|Behavioral|Comparator: Diet|Diet
480756|NCT00545584|Behavioral|Comparator: Physical Activity|Physical Activity
480757|NCT00545571|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
480758|NCT00545558|Drug|Efavirenz|600 mg tablet taken orally daily
480759|NCT00545558|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
480760|NCT00545545|Biological|Safety and efficacy of escalating doses|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
480761|NCT00545545|Biological|Safety and efficacy of escalating doses.|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
480762|NCT00545532|Drug|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days
480763|NCT00545532|Other|placebo|Placebo matched to oseltamivir po twice daily for 10 days
480764|NCT00545519|Drug|thymoglobulin|
480765|NCT00545506|Device|conventional bandage|
480766|NCT00545506|Device|warming bandage|
480767|NCT00545493|Drug|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
480768|NCT00545493|Drug|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
480769|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
480770|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
480771|NCT00545467|Drug|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
480772|NCT00545454|Drug|SSR150106|
480773|NCT00545454|Drug|Placebos|
480774|NCT00545441|Device|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
480775|NCT00545441|Device|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
480776|NCT00545428|Procedure|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
480777|NCT00545415|Dietary Supplement|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
480778|NCT00545415|Dietary Supplement|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
480779|NCT00545415|Dietary Supplement|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
480829|NCT00545129|Drug|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
480903|NCT00544687|Drug|mometasone furoate|topical mometasone furoate
480780|NCT00545415|Dietary Supplement|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
480781|NCT00545415|Dietary Supplement|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
480782|NCT00545415|Dietary Supplement|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.~Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
480783|NCT00545402|Drug|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
480784|NCT00545402|Drug|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
480785|NCT00545402|Drug|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
480786|NCT00545402|Drug|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
480787|NCT00545402|Drug|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
480788|NCT00545389|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
480789|NCT00545376|Procedure|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
480790|NCT00545376|Procedure|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
480791|NCT00545376|Other|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
480792|NCT00545363|Drug|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
480793|NCT00545350|Other|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.~The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
480794|NCT00545337|Drug|Insuline glulisine|
480795|NCT00545324|Drug|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
480796|NCT00545324|Drug|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
480797|NCT00545311|Drug|NVA237|
480798|NCT00545311|Drug|NVA237|
480799|NCT00545311|Drug|NVA237|
480800|NCT00545311|Drug|NVA237|
480801|NCT00545311|Drug|Placebo|
480802|NCT00545298|Drug|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
480803|NCT00545298|Drug|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
480804|NCT00545285|Procedure|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
480805|NCT00545272|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
480806|NCT00545272|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
480807|NCT00545272|Drug|placebo to indacaterol|Placebo TWISTHALER® device
480808|NCT00545272|Drug|placebo to formoterol|Placebo AEROLIZER® device
480809|NCT00545272|Drug|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
480810|NCT00545259|Drug|AEB071|
480811|NCT00545246|Drug|aflibercept (AVE0005)|intravenous infusion
480812|NCT00545246|Drug|docetaxel|intravenous infusion
480813|NCT00545233|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
480814|NCT00545233|Drug|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
480815|NCT00545233|Drug|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
480816|NCT00545220|Behavioral|problem-solving training|
480817|NCT00545220|Behavioral|sham intervention|
480818|NCT00545207|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
480819|NCT00545207|Drug|Placebo|po monthly for 2 years
480820|NCT00545194|Drug|Prostaglandin E2|
480821|NCT00545181|Drug|Vaginal acidifying gel (RepHresh)|"placement of vaginal acidifying gel into vagina to restore normal vaginal pH."
480822|NCT00545181|Drug|Metronidazole control|oral metronidazole therapy alone
480823|NCT00545168|Drug|Spinosad|10 minute topical application of product, followed by a complete rinse off.
480824|NCT00545168|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
480825|NCT00545168|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
480826|NCT00545142|Drug|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
480827|NCT00545142|Drug|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
480828|NCT00545129|Drug|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
480979|NCT00544271|Biological|INFANRIX|
480830|NCT00545116|Other|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
480831|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
480832|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 2.4g administered Once Daily (QD)
480833|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 4.8g administered Once Daily (QD)
480834|NCT00545103|Drug|Placebo|Placebo administered Once Daily (QD)
480835|NCT00545090|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
480836|NCT00545077|Drug|Letrozole|
480837|NCT00545077|Drug|Bevacizumab|
480838|NCT00545077|Drug|Fulvestrant|
480839|NCT00545064|Drug|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
480840|NCT00545051|Drug|Placebo|po monthly for 12 months
480841|NCT00545051|Drug|ibandronate|150mg po monthly for 12 months
480842|NCT00545025|Biological|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
480843|NCT00545025|Biological|Fluarix™|Single dose, Intramuscular injection
480844|NCT00545012|Drug|Levetiracetam|
480845|NCT00544999|Drug|cytarabine|
480846|NCT00544999|Drug|daunorubicin hydrochloride|
480847|NCT00544999|Drug|everolimus|
480848|NCT00544999|Other|laboratory biomarker analysis|
480849|NCT00544999|Other|pharmacological study|
480850|NCT00544986|Drug|Anastrozole|
480851|NCT00544960|Drug|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
480852|NCT00544960|Drug|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
480853|NCT00544934|Drug|GLY-230|125, 250 0r 375 mg bid for 14 days
480854|NCT00544934|Other|Placebo|No drug administered
480855|NCT00544921|Drug|GLY-230|
480856|NCT00544921|Other|Placebo|No drug administered
480857|NCT00544908|Drug|dasatinib|
480858|NCT00544908|Other|immunoenzyme technique|
480859|NCT00544908|Other|immunohistochemistry staining method|
480860|NCT00544908|Other|laboratory biomarker analysis|
480861|NCT00544908|Procedure|quality-of-life assessment|
480862|NCT00544882|Drug|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
480863|NCT00544882|Drug|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
480864|NCT00544882|Drug|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
480865|NCT00544869|Drug|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
480866|NCT00544856|Behavioral|complex cognitive training|
480867|NCT00544830|Drug|Bicalutamide|Given PO
480868|NCT00544830|Drug|Goserelin Acetate|Given SC
480869|NCT00544830|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
480870|NCT00544830|Other|Laboratory Biomarker Analysis|Correlative studies
480871|NCT00544830|Drug|Leuprolide Acetate|Given via injection
480872|NCT00544817|Radiation|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
480873|NCT00544817|Drug|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily~In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
480874|NCT00544817|Drug|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
480875|NCT00544804|Drug|lapatinib ditosylate|
480876|NCT00544804|Genetic|gene expression analysis|
480877|NCT00544804|Other|diagnostic laboratory biomarker analysis|
480878|NCT00544791|Drug|melatonin|5 mg, oral, daily dose for 6 months
480879|NCT00544791|Drug|placebo like melatonin tablets|
480880|NCT00544778|Biological|filgrastim|
480881|NCT00544778|Drug|dexrazoxane hydrochloride|
480882|NCT00544778|Drug|doxorubicin hydrochloride|
480883|NCT00544778|Drug|ifosfamide|
480884|NCT00544778|Drug|irinotecan hydrochloride|
480885|NCT00544778|Genetic|protein expression analysis|
480886|NCT00544778|Other|immunoenzyme technique|
480887|NCT00544778|Procedure|adjuvant therapy|
480888|NCT00544778|Procedure|conventional surgery|
480889|NCT00544778|Procedure|neoadjuvant therapy|
480890|NCT00544778|Radiation|radiation therapy|
480891|NCT00544765|Drug|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
480892|NCT00544765|Drug|NX|Vinorelbine 25 mg/m² as a < 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
480893|NCT00544752|Other|16|indoor temperature of 16 degrees celcius
480894|NCT00544752|Other|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
480895|NCT00544752|Other|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
480896|NCT00544726|Behavioral|Physical training|
480897|NCT00544726|Behavioral|No training|
480898|NCT00544713|Drug|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
480899|NCT00544713|Drug|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
480900|NCT00544700|Biological|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
480901|NCT00544700|Other|no maintenance|No treatment until progression
480902|NCT00544687|Drug|CRx-191|topical (mometasone furoate + nortriptyline HCl)
480904|NCT00544687|Drug|nortriptyline HCl|topical nortriptyline HCl
480905|NCT00544687|Drug|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
480906|NCT00544687|Drug|Vehicle|topical (placebo)
480907|NCT00544674|Drug|PR104|administered at a dose of 1100 mg/m^2 by intravenous infusion over 1 hour and repeated every three weeks
480908|NCT00544674|Other|F-18-fluoromisonidazole|administered intravenously prior to PET scan
480909|NCT00544648|Drug|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
480910|NCT00544648|Drug|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
480911|NCT00544648|Radiation|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
480912|NCT00544635|Device|no intervention|no intervention
480913|NCT00544635|Device|light|scars will be treated with light
480914|NCT00544622|Procedure|structured therapeutic chain of stroke treatment|
480915|NCT00544609|Drug|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
480916|NCT00544609|Procedure|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
480917|NCT00544596|Drug|R-(-)-gossypol acetic acid|Given orally
480918|NCT00544596|Drug|cisplatin|Given IV
480919|NCT00544596|Drug|etoposide|Given IV
480920|NCT00544583|Procedure|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
480921|NCT00544583|Procedure|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
480922|NCT00544570|Biological|filgrastim|
480923|NCT00544570|Drug|carmustine|
480924|NCT00544570|Drug|cyclophosphamide|
480925|NCT00544570|Drug|etoposide|
480926|NCT00544570|Drug|melphalan|
480927|NCT00544570|Procedure|autologous hematopoietic stem cell transplantation|
480928|NCT00544570|Procedure|peripheral blood stem cell transplantation|
480929|NCT00544570|Radiation|radiation therapy|
480930|NCT00544570|Radiation|total-body irradiation|
480931|NCT00544557|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
480932|NCT00544544|Drug|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
480933|NCT00544518|Drug|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
480934|NCT00544518|Drug|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
480935|NCT00544505|Drug|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
480936|NCT00544492|Device|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
480937|NCT00544466|Drug|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
480938|NCT00544466|Drug|melphalan|140 mg/m2 day -2 prior to transplant
480939|NCT00544466|Procedure|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
480940|NCT00544466|Radiation|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
480941|NCT00544453|Drug|[123I] MNI-308|Injection of [123I] MNI-308 and SPECT scanning
480942|NCT00544440|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
480943|NCT00544440|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
480944|NCT00544427|Device|Optical coherence tomography|Optical coherence tomography imaging
480945|NCT00544414|Drug|cisplatin|
480946|NCT00544414|Drug|docetaxel|
480947|NCT00544414|Drug|fluorouracil|
480948|NCT00544414|Drug|gemcitabine hydrochloride|
480949|NCT00544414|Drug|leucovorin calcium|
480950|NCT00544414|Genetic|gene expression analysis|
480951|NCT00544414|Genetic|protein expression analysis|
480952|NCT00544414|Other|laboratory biomarker analysis|
480953|NCT00544414|Procedure|adjuvant therapy|
480954|NCT00544414|Procedure|biopsy|
480955|NCT00544414|Procedure|conventional surgery|
480956|NCT00544414|Procedure|neoadjuvant therapy|
480957|NCT00544414|Procedure|quality-of-life assessment|
480958|NCT00544414|Radiation|radiation therapy|
480959|NCT00544401|Other|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
480960|NCT00544388|Drug|levocetirizine dihydrochloride|
480961|NCT00544375|Device|Optical measurement|Optical measurement neonatal tissues
480962|NCT00544362|Biological|cetuximab|
480963|NCT00544362|Drug|cisplatin|
480964|NCT00544362|Drug|fluorouracil|
480965|NCT00544362|Procedure|conventional surgery|
480966|NCT00544349|Biological|cetuximab|
480967|NCT00544349|Drug|fluorouracil|
480968|NCT00544349|Drug|leucovorin calcium|
480969|NCT00544349|Drug|oxaliplatin|
480970|NCT00544336|Other|questionnaire administration|no intervention
480971|NCT00544336|Other|survey administration|no intervention
480972|NCT00544336|Procedure|quality-of-life assessment|no intervention
480973|NCT00544323|Device|oral implant|
480974|NCT00544310|Biological|Anti adhesion agent|Adhesions prevention
480975|NCT00544297|Drug|PEP005 gel|Two day application, 0.05%
480976|NCT00544284|Drug|bortezomib|
480977|NCT00544284|Drug|temozolomide|
480978|NCT00544284|Other|pharmacological study|
480983|NCT00544245|Behavioral|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
480984|NCT00544232|Drug|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
480985|NCT00544232|Drug|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF~+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
480986|NCT00544219|Biological|rituximab|375 mg/m2 i.v. per cycle
480987|NCT00544219|Drug|cyclophosphamide|750 mg/m2 i.v. per cycle
480988|NCT00544219|Drug|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
480989|NCT00544219|Drug|prednisone|100 mg/day p.o. per cycle
480990|NCT00544219|Drug|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
480991|NCT00544219|Procedure|positron emission tomography|PET Scan during treatment
480992|NCT00544206|Other|standard enteral feeding product|16 hrs daily x 5 days
480993|NCT00544206|Other|Diabetes specific feeding product|16 hrs daily for 5 days
480994|NCT00544193|Drug|gemcitabine hydrochloride|
480995|NCT00544193|Genetic|polymerase chain reaction|
480996|NCT00544193|Other|immunohistochemistry staining method|
480997|NCT00544193|Procedure|conventional surgery|
480998|NCT00544193|Radiation|intraoperative radiation therapy|
480999|NCT00544193|Radiation|radiation therapy|
481000|NCT00544180|Drug|Risedronate|
481001|NCT00544167|Drug|Doxorubicin|
481002|NCT00544167|Drug|Cyclophosphamide|
481003|NCT00544167|Drug|Paclitaxel|
481004|NCT00544167|Drug|Sorafenib|
481005|NCT00544154|Drug|CDP870|
481006|NCT00544128|Drug|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
481007|NCT00544128|Drug|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
481008|NCT00544115|Drug|busulfan|
481009|NCT00544115|Drug|cyclophosphamide|
481010|NCT00544115|Drug|cyclosporine|
481011|NCT00544115|Drug|etoposide|
481012|NCT00544115|Drug|fludarabine phosphate|
481013|NCT00544115|Drug|melphalan|
481014|NCT00544115|Drug|methotrexate|
481015|NCT00544115|Drug|mycophenolate mofetil|
481016|NCT00544115|Drug|sirolimus|
481017|NCT00544115|Drug|tacrolimus|
481018|NCT00544115|Procedure|allogeneic hematopoietic stem cell transplantation|
481019|NCT00544115|Procedure|peripheral blood stem cell transplantation|
481020|NCT00544115|Radiation|total-body irradiation|
481021|NCT00544076|Drug|sildenafil citrate|Given orally
481022|NCT00544076|Drug|alprostadil|Given intraurethrally
481023|NCT00544076|Procedure|robotic-assisted laparoscopic surgery|Undergo prostatectomy
481024|NCT00544076|Procedure|quality-of-life assessment|Ancillary studies
481025|NCT00544076|Other|questionnaire administration|Ancillary studies
481026|NCT00544063|Drug|irinotecan hydrochloride|
481027|NCT00544063|Drug|oxaliplatin|
481028|NCT00544050|Drug|Levetiracetam|
481029|NCT00544037|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
481030|NCT00544011|Biological|bevacizumab|
481031|NCT00544011|Drug|capecitabine|
481032|NCT00544011|Drug|fluorouracil|
481033|NCT00544011|Drug|irinotecan hydrochloride|
481034|NCT00544011|Other|diagnostic laboratory biomarker analysis|
481035|NCT00543998|Device|Optical Measurement transillumination|Optical Measurement of sinus
481036|NCT00543985|Procedure|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
481037|NCT00543972|Drug|AVE9633|Intravenous Infusion
481038|NCT00543959|Drug|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
481039|NCT00543959|Drug|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
481040|NCT00543959|Drug|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
481041|NCT00543946|Drug|GAP-134|24-Hour IV infusion, SAD
481042|NCT00543933|Drug|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
481043|NCT00543920|Drug|MK0777|
481044|NCT00543881|Device|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
481045|NCT00543881|Device|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
481046|NCT00543868|Drug|MK0782|
481047|NCT00543855|Drug|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
481048|NCT00543855|Drug|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
481049|NCT00543855|Drug|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).~Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).~Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
481050|NCT00543855|Drug|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.~Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
481051|NCT00543842|Drug|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
481052|NCT00543842|Drug|Capecitabine|Starting Dose 650 mg/m^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
481053|NCT00543842|Drug|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
481054|NCT00543842|Radiation|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
481055|NCT00543842|Procedure|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
481056|NCT00543829|Drug|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
481057|NCT00543829|Drug|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
481058|NCT00543816|Drug|MK0767|
481059|NCT00543790|Drug|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
481060|NCT00543777|Diagnostic Test|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
481061|NCT00543777|Diagnostic Test|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
481062|NCT00543764|Other|pathway|Comparison of pre and post pathway
481063|NCT00543751|Drug|MK0767|
481064|NCT00543738|Drug|MK0767|
481065|NCT00543725|Drug|TMC278|25 mg tablet once daily for 96 weeks
481066|NCT00543725|Drug|efavirenz|600 mg tablet once daily for 96 weeks
481067|NCT00543712|Drug|PRO95780|Intravenous repeating dose
481068|NCT00543686|Drug|Montelukast|Intake of Montelukast
481069|NCT00543686|Drug|Fluticasone|Intake of Fluticasone
481070|NCT00543673|Other|Milk based formula A|feed as per HCP directions
481071|NCT00543673|Other|#2 Standard formula|Feed as per HCP directions
481072|NCT00543673|Other|#3 Human Milk|Feed as per HCP directions
481073|NCT00543673|Other|Milk based formula C|Feed as per HCP direction
481074|NCT00543660|Procedure|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
481075|NCT00543647|Drug|Fenofibrate 160 mg tablet|
481076|NCT00543647|Drug|Placebo|
481077|NCT00543634|Drug|Premarin/MPA|0.625 mg/2.5 mg X4
481078|NCT00543634|Drug|Premarin/MPA|0.625 mg/5 mg X 2
481079|NCT00543634|Drug|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
481080|NCT00543621|Other|daily enteral nutritional product and/or behavioral changes|
481081|NCT00543608|Drug|iclaprim|
481082|NCT00543608|Drug|vancomycin|
481083|NCT00543595|Drug|MK0916|
481084|NCT00543582|Drug|MGCD0103 and Azacitidine|"In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.~In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops."
481085|NCT00543569|Drug|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
481086|NCT00543569|Drug|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
481087|NCT00543569|Drug|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
481088|NCT00543569|Drug|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
481089|NCT00543569|Drug|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
481090|NCT00543556|Drug|MK0767|
481091|NCT00543543|Biological|Comparator: GARDASIL|GARDASIL (quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
481092|NCT00543543|Biological|Experimental: V503|V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
481093|NCT00543530|Drug|MK0831|
481094|NCT00543517|Drug|MK0767|
481095|NCT00543504|Drug|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
481096|NCT00543504|Drug|Sorafenib|200 mg By Mouth Daily for 28 Days
481097|NCT00543504|Drug|Erlotinib|50 mg By Mouth Daily for 28 Days.
481153|NCT00543062|Drug|Inhaled placebo|Inhaled Staccato placebo (0 mg)
481098|NCT00543504|Drug|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
481099|NCT00543504|Drug|Lapatinib|250 mg By Mouth Daily for 21 Days.
481100|NCT00543504|Drug|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
481101|NCT00543504|Drug|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
481102|NCT00543491|Drug|MK0767|
481103|NCT00543478|Drug|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
481104|NCT00543478|Drug|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
481105|NCT00543465|Drug|MK0782|
481106|NCT00543452|Other|Oxygen|4 liters of oxygen a minute
481107|NCT00543452|Other|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
481108|NCT00543439|Biological|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
481109|NCT00543439|Biological|Moroctocog alfa (AF-CC)|"Routine prophylaxis crossover:~45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
481110|NCT00543426|Drug|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
481111|NCT00543426|Drug|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
481112|NCT00543413|Drug|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
481113|NCT00543413|Drug|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
481114|NCT00543413|Drug|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
481115|NCT00543400|Drug|M118|intravenous (IV) infusion
481116|NCT00543400|Drug|Unfractionated Heparin|IV infusion
481117|NCT00543387|Drug|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
481118|NCT00543387|Drug|docetaxel|Docetaxel will be administered intravenously (I.V.) at a dose of 60 mg/m^2 Q12H during the first 2 days of each 21-day cycle.
481119|NCT00543374|Drug|Placebo|Placebo
481120|NCT00543374|Drug|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
481121|NCT00543361|Drug|MK0767|Duration of Treatment: 52 Weeks
481122|NCT00543361|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
481123|NCT00543361|Drug|Comparator: metformin|Duration of Treatment: 52 Weeks
481124|NCT00543348|Procedure|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
481125|NCT00543348|Procedure|HIGH PRESSURE BALLOON|
481126|NCT00543335|Drug|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
481127|NCT00543335|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
481128|NCT00543309|Drug|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
481129|NCT00543309|Drug|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
481130|NCT00543309|Drug|placebo|Placebo bolus on CPB, then placebo infusion
481131|NCT00543296|Drug|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
481132|NCT00543270|Device|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
481133|NCT00543270|Procedure|Open Surgery|Open surgical abdominal aortic aneurysm repair
481134|NCT00543257|Other|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
481135|NCT00543257|Other|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
481136|NCT00543244|Drug|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: < 75 kg 1000 mg/day, >=75 kg 1200 mg/day; genotype 2: 800 mg/day)~HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
481137|NCT00543231|Drug|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
481138|NCT00543218|Drug|teriparatide 20 micrograms/day subcutaneous|
481139|NCT00543218|Drug|calcitonin 100 IU/day subcutaneous|
481140|NCT00543205|Drug|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
481141|NCT00543179|Drug|Somatuline (Lanreotide Autogel®)|
481142|NCT00543166|Drug|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
481143|NCT00543153|Behavioral|Interview|Interview lasting approximately 30-45 minutes.
481144|NCT00543140|Device|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
481145|NCT00543127|Drug|Fulvestrant|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
481146|NCT00543127|Drug|Anastrozole|1 mg oral Anastrozole per day during 5 years.
481147|NCT00543114|Drug|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
481148|NCT00543114|Drug|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
481149|NCT00543114|Drug|Rituximab|Given intravenously on Day 1 of each 28 day cycle
481150|NCT00543101|Drug|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
481151|NCT00543101|Drug|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
481152|NCT00543075|Drug|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
481154|NCT00543062|Drug|Oral placebo|Oral placebo (identical to 400 mg moxifloxacin)
481155|NCT00543062|Drug|Inhaled prochlorperazine 5 mg|Staccato prochlorperazine 5 mg, single dose
481156|NCT00543062|Drug|Inhaled prochlorperazine 10 mg|Inhaled prochlorperazine 10 mg, single dose
481157|NCT00543062|Drug|Oral moxifloxacin|Oral moxifloxacin 400 mg, si/ngle dose
481158|NCT00543049|Drug|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
481159|NCT00543049|Drug|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
481160|NCT00543036|Device|H-Coil deep TMS|
481161|NCT00543023|Drug|teriparatide 20 micrograms/day subcutaneous|
481162|NCT00543023|Drug|salmon calcitonin 100 IU/day subcutaneous|
481163|NCT00543010|Drug|MK0767|
481164|NCT00542997|Biological|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
481165|NCT00542984|Drug|teriparatide 20 micrograms/day subcutaneous|
481166|NCT00542984|Drug|salmon calcitonin 100 IU/day subcutaneous|
481167|NCT00542971|Drug|Idarubicin|12 mg/m^2 IV over 1 hour daily (days 1-3)
481168|NCT00542971|Drug|Sorafenib|Starting dose 400 mg by mouth for 7 days
481169|NCT00542971|Drug|Ara-C|1.5 g/m^2 IV over 24 hours daily (days 1-4)
481170|NCT00542958|Drug|NK012|9.0, 12.0, 16.0, 21.0, 28.0 mg/m^2, and to be determined. Intravenous infusion
481171|NCT00542945|Device|ICD|Implantation of an ICD
481172|NCT00542945|Other|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
481173|NCT00542932|Other|Exercise|"Watched Film A (promotional film)~Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
481174|NCT00542919|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
481175|NCT00542906|Other|localization|localization of the several types of somatosensory stimuli
481176|NCT00542893|Drug|Genasense® (G3139, oblimersen sodium)|
481177|NCT00542893|Drug|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
481178|NCT00542893|Drug|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
481179|NCT00542880|Drug|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
481180|NCT00542880|Drug|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
481181|NCT00542854|Device|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
481182|NCT00542841|Procedure|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
481183|NCT00542828|Biological|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
481184|NCT00542815|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
481185|NCT00542815|Drug|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
481186|NCT00542802|Drug|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
481187|NCT00542802|Drug|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
481188|NCT00542789|Drug|Esomeprazole|20mg once daily oral
481189|NCT00542789|Drug|Placebo|once daily oral
481190|NCT00542776|Other|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
481191|NCT00542763|Drug|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
481192|NCT00542750|Drug|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
481193|NCT00542737|Behavioral|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
481194|NCT00542724|Drug|VIAject™|Dosage as individually required
481195|NCT00542724|Drug|Regular Human Insulin|Dosage as individually required
481196|NCT00542711|Drug|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
481197|NCT00542698|Behavioral|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
481198|NCT00542685|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
481199|NCT00542685|Drug|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
481200|NCT00542685|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
481201|NCT00542685|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
482223|NCT00535561|Drug|Ferrous sulfate tablets 325 mg, po, TID|
481202|NCT00542646|Procedure|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
481203|NCT00542633|Drug|VIAject™|Dosage as individually required
481204|NCT00542633|Drug|Regular Human Insulin|Dosage as individually required
481205|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
481206|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
481207|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
481208|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
481209|NCT00542607|Drug|levocetirizine dihydrochloride|
481210|NCT00542581|Device|The Acrysof toric SN60T3 IOL|Intraocular Lens
481211|NCT00542568|Biological|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
481212|NCT00542555|Drug|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
481213|NCT00542555|Drug|Naproxcinod 375 mg|
481214|NCT00542555|Drug|Naproxen|
481215|NCT00542555|Drug|Naproxcinod 750 mg|
481216|NCT00542542|Procedure|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
481217|NCT00542542|Drug|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
481218|NCT00542542|Drug|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
481219|NCT00542542|Drug|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
481220|NCT00542542|Drug|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
481221|NCT00542529|Biological|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
481222|NCT00542516|Drug|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
481223|NCT00542516|Drug|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
481224|NCT00542490|Radiation|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
481225|NCT00542464|Biological|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
481226|NCT00542451|Drug|Paclitaxel|Every week for 12 weeks
481227|NCT00542451|Drug|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
481228|NCT00542438|Behavioral|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
481229|NCT00542438|Behavioral|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
481230|NCT00542425|Drug|teriparatide|teriparatide 20 µg subcutaneous daily
481231|NCT00542425|Drug|Placebo|Placebo subcutaneous daily
481232|NCT00542425|Drug|BA058 20 µg|BA058 20 µg subcutaneous daily
481233|NCT00542425|Drug|BA058 40 µg|BA058 40 µg subcutaneous daily
481234|NCT00542425|Drug|BA058 80 µg|BA058 80 µg subcutaneous daily
481235|NCT00542412|Drug|Riluzole|
481236|NCT00542399|Drug|Levemir (insulin detemir)|Levemir once a day
481237|NCT00542399|Drug|Levemir twice a day|Levemir twice a day
481238|NCT00542386|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
481239|NCT00542386|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
481240|NCT00542373|Other|Cytology Specimen Collection Procedure|Undergo oral tissue collection
481241|NCT00542373|Procedure|Diagnostic Microscopy|Mouth tissue examined microscopically for cytologic features
481242|NCT00542373|Procedure|Diagnostic Procedure|Undergo standard white light headlamp oral examination
481243|NCT00542373|Procedure|Fluorescence Imaging|Undergo widefield fluorescent and reflectance imaging
481244|NCT00542373|Procedure|Fluorescence Spectroscopy|Undergo point fluorescent spectroscopy
481245|NCT00542360|Behavioral|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
481246|NCT00542347|Drug|Esomeprazole first|"esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
481247|NCT00542347|Drug|Generic omeprazole first|"generic omeprazole 20mg po once per day for 7 days~24hr pH study on day 7~followed by washout for 7 days~esomeprazole 20mg po once per day for 7 days~24hr pH study on day 7"
481248|NCT00542321|Other|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
481249|NCT00542321|Device|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
481250|NCT00542308|Drug|Zalutumumab|Individual dose titration weekly i.v. doses
481251|NCT00542295|Drug|alverine citrate and simeticone|
481252|NCT00542295|Drug|placebo|
481253|NCT00542269|Drug|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
481254|NCT00542269|Drug|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
481255|NCT00542269|Drug|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
481256|NCT00542256|Device|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
481257|NCT00542256|Device|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
481258|NCT00542243|Drug|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
481259|NCT00542243|Drug|Placebo|Placebo will be given once a day for 6 months.
481260|NCT00542217|Biological|Imprime PGG|
481261|NCT00542204|Behavioral|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
481262|NCT00542191|Drug|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
481263|NCT00542191|Procedure|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
481264|NCT00542191|Radiation|Radiotherapy|Standard of care RADIATION THERAPY as indicated
481265|NCT00542178|Drug|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
481266|NCT00542178|Drug|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
481267|NCT00542178|Drug|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
481268|NCT00542178|Drug|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
481269|NCT00542178|Drug|Fenofibrate|Blinded fenofibrate
481270|NCT00542178|Drug|Simvastatin|Simvastatin 20-40 mg/d
481271|NCT00542178|Drug|Placebo|Placebo
481272|NCT00542165|Drug|Alfuzosin|
481273|NCT00542152|Drug|CYCLOSPORINE VS INFLIXIMAB|"Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.~Infliximab 5mg/kg at weeks 0, 2 and 6"
481274|NCT00542139|Drug|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
481275|NCT00542139|Drug|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
481276|NCT00542126|Drug|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
481277|NCT00542113|Behavioral|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
481278|NCT00542113|Behavioral|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
481279|NCT00542113|Behavioral|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
481280|NCT00542100|Device|PCMRI|
481281|NCT00542087|Drug|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
481282|NCT00542087|Drug|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
481283|NCT00542074|Other|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
481284|NCT00542074|Other|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
481285|NCT00542061|Device|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
481286|NCT00542048|Drug|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
481287|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
481288|NCT00542035|Drug|Placebo; oral|dose 1, dose 2
481289|NCT00542035|Drug|Placebo; oral|dose 1
481290|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
481291|NCT00542022|Drug|MK0812 / Duration of Treatment: 12 Weeks|
481292|NCT00542022|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
481293|NCT00542009|Drug|CE-326,597 100 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
481294|NCT00542009|Drug|CE-326,597 50 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
481295|NCT00542009|Drug|CE-326,597 25 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
481296|NCT00542009|Drug|Placebo|Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
481297|NCT00542009|Drug|CE-326,597 5mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
481298|NCT00541996|Drug|vabicaserin|
481299|NCT00541983|Drug|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
481300|NCT00541983|Drug|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
481301|NCT00541970|Biological|Cervarix|Intramuscular injection, different dosing /schedule
481302|NCT00541970|Drug|Placebo|Intramuscular injection, different dosing /schedule
481303|NCT00541957|Behavioral|behavior therapy|10 sessions over 4 months
481304|NCT00541957|Drug|Medication prescribed by PCP|Can include any antidepressant medication
481305|NCT00541931|Drug|Dietary Supplement: LifePak Nano|Daily use
481306|NCT00541918|Drug|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
481307|NCT00541918|Drug|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
481308|NCT00541905|Drug|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
481309|NCT00541892|Other|Medium with no human serum albumine added|See above
481310|NCT00541892|Other|Conventional medium|See above
481311|NCT00541879|Behavioral|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
481312|NCT00541879|Other|comparison|
481313|NCT00541866|Drug|Voreloxin injection and cytarabine|"Dose-escalation Phase~Schedule A: vosaroxin injection (dose-escalation from 10 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion of 400 mg/m2/day × 5 days)~Schedule B: vosaroxin injection (dose-escalation from 70 to 90 mg/m2) on Days 1 and 4 in combination with cytarabine (2-hour intravenous [IV] infusion of 1 g/m2/day × 5 days)~Expansion Phase The MTD determined in the dose-escalation phase was used in the expansion phase.~Schedule A: 80 mg/m2 vosaroxin on Days 1 and 4 in combination with cytarabine (24-hour CIV infusion at 400 mg/m2/day × 5 days)~Schedule B: 90 mg/m2 vosaroxin (dose-escalation) on Days 1 and 4 in combination with cytarabine (2 hour IV infusion at 1 g/m2/day × 5 days)"
481314|NCT00541853|Drug|Candesartan|Candesartan upto 8mg
481315|NCT00541853|Drug|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
481316|NCT00541853|Drug|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
481317|NCT00541840|Drug|Sorafenib|"Phase I:~Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .~Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration~Phase II:~Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
481318|NCT00541814|Drug|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
481319|NCT00541801|Device|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
481320|NCT00541788|Other|Administration of Common Sage|Administration of Common Sage
481321|NCT00541775|Drug|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
481322|NCT00541775|Drug|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
481323|NCT00541775|Drug|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
481324|NCT00541775|Drug|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
481325|NCT00541762|Dietary Supplement|Fat perfusion to the small intestine|"Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine~Orlistat perfused to the small intestine~DEXLOX as CCK-1 receptor antagonist"
481326|NCT00541749|Drug|rhuMAb IFNalpha|Intravenous repeating dose
481327|NCT00541736|Drug|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
481328|NCT00541723|Drug|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
481329|NCT00541723|Drug|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
481330|NCT00541710|Dietary Supplement|genistein|pills of 27 mg, twice per day for 12 months
481331|NCT00541710|Dietary Supplement|placebo|sugar pills twice per day for 12 months
481332|NCT00541697|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
481333|NCT00541697|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
481334|NCT00541684|Drug|MK0954, /Duration of Treatment : 16 Weeks|
481335|NCT00541684|Drug|Comparator : atenolol /Duration of Treatment : 16 Weeks|
481336|NCT00541671|Drug|Saline|10 c of saline
481337|NCT00541671|Drug|Phenergan|Physician ordered dose
481338|NCT00541658|Drug|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
481339|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
481340|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
481341|NCT00541606|Other|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
481342|NCT00541606|Other|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
481343|NCT00541593|Procedure|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
481344|NCT00541567|Drug|ibipinabant|oral, tablet, once daily
481345|NCT00541554|Drug|Abilify (aripiprazole)|
481346|NCT00541541|Procedure|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
481347|NCT00541515|Device|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
481348|NCT00541489|Drug|Naproxcinod|750 mg, bid
481349|NCT00541489|Drug|Naproxen|500 mg, bid
481350|NCT00541489|Drug|Placebo|bid
481351|NCT00541463|Drug|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
481352|NCT00541463|Drug|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
481353|NCT00541450|Drug|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
481354|NCT00541450|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
481355|NCT00541450|Drug|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
481356|NCT00541450|Drug|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
481357|NCT00541450|Drug|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
481358|NCT00541450|Drug|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
481359|NCT00541424|Procedure|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
481360|NCT00541411|Drug|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
481361|NCT00541398|Behavioral|Implementation of guideline|Outreach visits with interactive education for health staff
481362|NCT00541385|Drug|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
481363|NCT00541385|Drug|arthemeter lumefantrine|"Artemether 20 mg and lumefantrine 120 mg fixed dose combination, 6 dose regimen 120 mg artemether and 720 mg lumefantrine total (Novartis).~The posology is twice daily for 3 consecutive days 1 tablet for patients weighing ≥5 kg to <15 kg, 2 tablets for patients weighing ≥15 to <25 kg."
481364|NCT00541372|Device|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
481365|NCT00541359|Drug|bortezomib|Given IV
481366|NCT00541359|Drug|topotecan hydrochloride|Given IV
481367|NCT00541359|Other|immunohistochemistry staining method|Correlative studies
481368|NCT00541359|Other|pharmacological study|Correlative studies
481369|NCT00541346|Drug|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
481370|NCT00541333|Drug|Copaxone Injection|
481371|NCT00541320|Drug|GW813893|
481372|NCT00541307|Device|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
481373|NCT00541281|Drug|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
481374|NCT00541281|Drug|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
481375|NCT00541281|Drug|prednisone|2x5 mg a day
481376|NCT00541268|Device|ICD|Intracardioverter defibrillators from 2 different manufacturers
481377|NCT00541268|Other|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
481378|NCT00541242|Drug|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
481379|NCT00541242|Drug|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
481380|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
481381|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
481382|NCT00541229|Drug|Comparator: Placebo|sitagliptin 100 mg & 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
481383|NCT00541216|Drug|Ephedrine|
481384|NCT00541190|Other|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
481385|NCT00541177|Drug|atropine|0.25% atropine
481386|NCT00541177|Drug|tropicamide|0.5% tropicamide
481387|NCT00541164|Drug|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
481388|NCT00541164|Dietary Supplement|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
481389|NCT00541151|Device|MiniArc|sling system
481390|NCT00541138|Drug|carboplatin|CBDCA AUC=3
481391|NCT00541138|Drug|tamoxifen citrate|Tamoxifen 100mg bid
481392|NCT00541138|Drug|topotecan hydrochloride|Topotecan 0.75 g/m2/d
481549|NCT00540215|Other|Glucagonlike peptide|450 nmol native form, synthetic
481393|NCT00541138|Other|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
481394|NCT00541125|Biological|bevacizumab|
481395|NCT00541125|Biological|filgrastim|
481396|NCT00541125|Drug|fluorouracil|
481397|NCT00541125|Drug|irinotecan hydrochloride|
481398|NCT00541125|Drug|leucovorin calcium|
481399|NCT00541112|Biological|cetuximab|
481400|NCT00541112|Drug|capecitabine|
481401|NCT00541112|Drug|fluorouracil|
481402|NCT00541112|Drug|leucovorin calcium|
481403|NCT00541112|Drug|oxaliplatin|
481404|NCT00541112|Procedure|adjuvant therapy|
481405|NCT00541112|Procedure|conventional surgery|
481406|NCT00541112|Procedure|neoadjuvant therapy|
481407|NCT00541112|Radiation|radiation therapy|
481408|NCT00541099|Biological|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
481409|NCT00541099|Drug|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
481410|NCT00541086|Drug|anastrozole|1 mg per day, orally
481411|NCT00541086|Drug|exemestane|25 mg per day, orally
481412|NCT00541086|Drug|letrozole|2.5 mg per day, orally
481413|NCT00541086|Drug|tamoxifen citrate|20 mg per day, orally
481414|NCT00541073|Dietary Supplement|vitamin B12|
481415|NCT00541073|Drug|cisplatin|
481416|NCT00541073|Drug|pemetrexed disodium|
481417|NCT00541073|Genetic|gene expression analysis|
481418|NCT00541073|Other|laboratory biomarker analysis|
481419|NCT00541073|Other|pharmacological study|
481420|NCT00541060|Genetic|mutation|a mutation of a gene coding
481421|NCT00541047|Drug|bicalutamide|
481422|NCT00541047|Drug|goserelin acetate|
481423|NCT00541047|Drug|leuprolide acetate|
481424|NCT00541047|Procedure|adjuvant therapy|
481425|NCT00541047|Procedure|quality-of-life assessment|
481426|NCT00541047|Radiation|radiation therapy|
481427|NCT00541034|Biological|rituximab|
481428|NCT00541034|Drug|cyclophosphamide|
481429|NCT00541034|Drug|pentostatin|
481430|NCT00541021|Drug|gemcitabine hydrochloride|
481431|NCT00541021|Drug|sorafenib tosylate|
481432|NCT00541008|Drug|sunitinib malate|
481433|NCT00540995|Drug|busulfan|Given IV
481434|NCT00540995|Drug|etoposide|Given IV
481435|NCT00540995|Radiation|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
481436|NCT00540995|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
481437|NCT00540995|Procedure|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
481438|NCT00540995|Procedure|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
481439|NCT00540995|Radiation|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
481440|NCT00540982|Drug|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
481441|NCT00540982|Drug|lidocaine|1 mg/kg will be administered to determine metabolic capacity
481442|NCT00540982|Drug|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
481443|NCT00540982|Other|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
481444|NCT00540982|Other|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
481445|NCT00540982|Other|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
481446|NCT00540982|Other|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
481447|NCT00540982|Other|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
481448|NCT00540969|Procedure|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
481449|NCT00540969|Radiation|radiation therapy|Patients undergo radiotherapy for 1 week
481450|NCT00540956|Drug|cytarabine|
481451|NCT00540956|Other|laboratory biomarker analysis|
481452|NCT00540943|Drug|Pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
481453|NCT00540943|Drug|Cetuximab|"Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline"
481454|NCT00540943|Drug|Irinotecan|Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
481455|NCT00540930|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
481456|NCT00540917|Procedure|cooling spray during laser treatment|skin temperature measurement
481457|NCT00540904|Drug|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
481458|NCT00540904|Drug|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
481459|NCT00540891|Drug|ALFUZOSIN|
481460|NCT00540878|Drug|SB-751689 oral tablets (400 mg)|
481461|NCT00540865|Behavioral|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
481550|NCT00540202|Drug|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
481551|NCT00540202|Drug|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
481462|NCT00540865|Behavioral|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
481463|NCT00540852|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
481464|NCT00540839|Drug|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
481465|NCT00540839|Drug|Placebo to montelukast|Placebo OG or CT
481466|NCT00540839|Drug|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
481467|NCT00540839|Drug|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
481468|NCT00540826|Drug|Atomoxetine|in-label use
481469|NCT00540826|Drug|stimulants (any approved ADHD medication)|in-label use
481470|NCT00540813|Device|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
481471|NCT00540800|Drug|docetaxel|given in combination with epirubicin or capecitabine
481472|NCT00540800|Drug|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
481473|NCT00540800|Drug|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
481474|NCT00540787|Device|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
481475|NCT00540787|Drug|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
481476|NCT00540787|Device|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
481477|NCT00540774|Device|detection of oral pathology|detection of oral pathology
481478|NCT00540761|Device|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
481479|NCT00540748|Drug|oxytocin|5 U i.v. during surgical abortion
481480|NCT00540735|Procedure|photodynamic therapy|
481481|NCT00540722|Drug|R-(-)-gossypol acetic acid|Given PO
481482|NCT00540722|Other|laboratory biomarker analysis|Correlative studies
481483|NCT00540709|Drug|Insulin Glargine|
481484|NCT00540696|Drug|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.~Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
481485|NCT00540683|Device|Diffuse Optical Spectroscopy|Muscle properties
481486|NCT00540670|Drug|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
481487|NCT00540670|Drug|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
481488|NCT00540670|Drug|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
481489|NCT00540670|Drug|Placebo|Placebo (tablet) taken orally, once a day.
481490|NCT00540657|Drug|CCX282-B|250mg capsule, twice daily, 13 weeks
481491|NCT00540657|Drug|Placebo|Placebo capsule, twice daily, 13 weeks
481492|NCT00540644|Drug|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
481493|NCT00540644|Drug|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
481494|NCT00540644|Drug|Prednisone|50 mg p.o. Q.O.D.
481495|NCT00540631|Biological|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~to be det. A 0.1 100 TU~7 (+7) days later A 0.2 200 TU~7 (+7) days later A 0.4 400 TU~7 (+7) days later A 0.6 600 TU~7 (+7) days later B 0.1 1000 TU~7 (+7) days later B 0.2 2000 TU~7 (+7) days later B 0.4 4000 TU~7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection~to be det. A 0.1 100 TU~7 (+7) days later A 0.2 200 TU~7 (+7) days later A 0.4 400 TU~7 (+7) days later A 0.6 600 TU~7 (+7) days later B 0.1 1000 TU~7 (+7) days later B 0.2 2000 TU~7 (+7) days later B 0.4 4000 TU~7 (+7) days later B 0.6 6000 TU~Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
481496|NCT00540618|Drug|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
481497|NCT00540618|Other|Placebo|
481498|NCT00540618|Drug|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
481499|NCT00540618|Drug|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
481500|NCT00540605|Drug|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
481501|NCT00540592|Biological|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
481502|NCT00540592|Biological|Fluarix|Single dose, Intramuscular injection
481503|NCT00540579|Drug|Pomalidomide|Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
481504|NCT00540579|Drug|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
481505|NCT00540566|Device|Optical Biopsy imaging|Optical Biopsy imaging
481506|NCT00540553|Drug|placebo|
481507|NCT00540553|Drug|GSK971086|
481508|NCT00540540|Device|Diffuse Optical Spectroscopy|Breast properties scanning
481552|NCT00540189|Procedure|Initial appendectomy|
481553|NCT00540189|Procedure|Interval appendectomy|
481554|NCT00540176|Drug|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
481555|NCT00540150|Biological|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
481556|NCT00540137|Drug|nevirapine|400mg once daily
482361|NCT00534495|Biological|Rilonacept|2.2 mg/kg subcutaneously
481509|NCT00540527|Drug|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
481510|NCT00540527|Drug|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
481511|NCT00540514|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
481512|NCT00540514|Drug|Paclitaxel|Administered by intravenous infusion.
481513|NCT00540514|Drug|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate [GFR] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
481514|NCT00540501|Drug|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.~Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.~Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
481515|NCT00540488|Other|Adult enteral formula|
481516|NCT00540462|Procedure|gastric bypass|
481517|NCT00540462|Procedure|sleeve gastrectomy|
481518|NCT00540449|Drug|TMC278|25 mg tablet once daily for 96 weeks
481519|NCT00540449|Drug|Efavirenz|600mg once daily for 96 weeks
481520|NCT00540436|Drug|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
481521|NCT00540423|Drug|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
481522|NCT00540423|Drug|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
481523|NCT00540423|Drug|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
481524|NCT00540423|Drug|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
481525|NCT00540410|Drug|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
481526|NCT00540410|Drug|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days"
481527|NCT00540397|Drug|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
481528|NCT00540384|Drug|Placebo|Placebo
481529|NCT00540384|Drug|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
481530|NCT00540371|Other|Port wine stain Birthmark|Port wine stain Birthmark
481531|NCT00540358|Drug|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
481532|NCT00540358|Drug|iniparib|"Body weight adjusted dose~1 hour intravenous infusion"
481533|NCT00540345|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
481534|NCT00540345|Drug|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
481535|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
481536|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
481537|NCT00540332|Drug|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
481538|NCT00540332|Drug|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
481539|NCT00540319|Behavioral|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
481540|NCT00540306|Device|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
481541|NCT00540293|Drug|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
481542|NCT00540280|Radiation|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
481543|NCT00540267|Other|No Intervention|No Intervention
481544|NCT00540254|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
481545|NCT00540254|Other|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
481546|NCT00540241|Drug|Pemetrexed|in-label use
481547|NCT00540228|Biological|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
481548|NCT00540228|Biological|Fluarix™|Single dose, Intramuscular injection
481557|NCT00540137|Drug|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
481558|NCT00540124|Drug|Tadalafil|5 mg once a day
481559|NCT00540124|Drug|Placebo|once a day
481560|NCT00540124|Drug|Tamsulosin|0.2 mg once a day
481561|NCT00540111|Dietary Supplement|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
481562|NCT00540098|Drug|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
481563|NCT00540098|Drug|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
481564|NCT00540098|Drug|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
481565|NCT00540098|Drug|Placebo + relaxation|placebo pill once daily + regular relaxation training
481566|NCT00540085|Drug|Rocuronium|0.6 mg/kg given intravenously before intubation
481567|NCT00540072|Drug|daptomycin|
481568|NCT00540046|Device|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
481569|NCT00540033|Dietary Supplement|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
481570|NCT00540033|Dietary Supplement|infloran|Study group was fed with infloran [Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)] and Bifidobacteria bifidum [(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)]; Laboratorio Farmaceutico S.I.T S.r.I ITALY] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
481571|NCT00540020|Other|Rehabilitation|
481572|NCT00540007|Drug|Lenalidomide|
481573|NCT00539994|Drug|retapamulin|200mg BID retapamulin 3 days
481574|NCT00539994|Drug|Retapamulin|200mg BID retapamulin 5 days
481575|NCT00539994|Drug|Placebo|200mg BID placebo 5 days
481576|NCT00539981|Biological|Influenza Vaccine, recombinant hemagglutinin, FluBlok|0.5mL dose for IM injection
481577|NCT00539968|Drug|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2~Lonafarnib: 150-375 mg PO BID"
481578|NCT00539955|Behavioral|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
481579|NCT00539955|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
481580|NCT00539942|Drug|Arixtra (fondaparinux sodium)|Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
481581|NCT00539942|Device|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
481582|NCT00539929|Drug|E6201 0.005%|
481583|NCT00539929|Drug|E6201 0.01%|
481584|NCT00539929|Drug|E6201 0.03%|
481585|NCT00539929|Drug|Placebo|
481586|NCT00539916|Behavioral|Regular orange juice consumption|600 mL /day.
481587|NCT00539903|Behavioral|Physical activity (PA) and immigrants|
481588|NCT00539890|Drug|Technosphere Insulin|
481589|NCT00539877|Drug|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.~If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
481590|NCT00539864|Biological|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
481591|NCT00539864|Biological|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
481592|NCT00539838|Drug|Prednisone|Oral repeating dose
481593|NCT00539838|Drug|immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
481594|NCT00539838|Drug|methylprednisolone|Intravenous repeating dose
481595|NCT00539838|Drug|ocrelizumab|Intravenous repeating dose
481596|NCT00539838|Drug|placebo|Intravenous repeating dose
481597|NCT00539825|Drug|GSK704838|
481598|NCT00539812|Behavioral|Standard Care|Standard 40 hour state mandated batterer intervention program
481599|NCT00539812|Behavioral|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
481600|NCT00539799|Drug|prednisolone|5 - 7.5 mg/day
481601|NCT00539799|Drug|Placebo|Matched placebo to prednisolone
481602|NCT00539786|Drug|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
481603|NCT00539773|Drug|BCG, Interferon|Chemotherapy
481604|NCT00539760|Drug|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
481605|NCT00539760|Drug|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
481606|NCT00539734|Drug|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
481607|NCT00539721|Drug|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
481608|NCT00539721|Drug|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
481609|NCT00539721|Drug|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
481610|NCT00539721|Drug|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
481611|NCT00539721|Drug|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
481612|NCT00539721|Drug|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
481613|NCT00539708|Procedure|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
492169|NCT00459745|Drug|Fenofibrate|
481614|NCT00539695|Biological|IL-2|"IL2 Administration:~Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed >grade I side effects to IL-2 and has not developed >grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection."
481615|NCT00539669|Drug|Docetaxel|
481616|NCT00539656|Biological|Ex vivo expansion of cord blood|Day 0: the expanded cell product will be infused to patient; Day +1: A second, unexpanded, cord blood product will be infused
481617|NCT00539643|Device|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
481618|NCT00539643|Other|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
481619|NCT00539630|Drug|Docetaxel|
481620|NCT00539617|Drug|erlotinib|Tarceva single agent therapy: 150 mg/day PO
481621|NCT00539617|Drug|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
481622|NCT00539617|Drug|leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
481623|NCT00539617|Drug|oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
481624|NCT00539604|Procedure|MDCT and Coronary Angiography|
481625|NCT00539591|Drug|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
481626|NCT00539591|Drug|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
481627|NCT00539591|Drug|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
481628|NCT00539578|Drug|MK0777|Duration of Treatment: 4 weeks
481629|NCT00539578|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
481630|NCT00539565|Drug|prednisolone|"2 mg/kg /day from post-op day 7 - day 21~1 mg/kg /day from post-op day 22 - day 30"
481631|NCT00539565|Drug|placebo|
481632|NCT00539539|Other|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
481633|NCT00539526|Drug|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
481634|NCT00539526|Drug|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
481635|NCT00539526|Drug|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
481636|NCT00539513|Drug|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
481637|NCT00539513|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
481638|NCT00539500|Drug|Carboplatin|Carboplatin by vein over 24 hours for 4 days, dosing as determined at day 1.
481639|NCT00539500|Drug|Etoposide|300 mg/m^2 by vein over 24 hours for 4 days
481640|NCT00539500|Drug|Melphalan|70 mg/m^2 Intravenous Bolus for 3 Days
481641|NCT00539500|Procedure|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10^8 TNC cells/kg CD133+ selected) on Day 0.
481642|NCT00539500|Device|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
481643|NCT00539474|Procedure|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
481644|NCT00539448|Drug|insulin glargine|in combination with insulin Glulisine as bolus regimen
481645|NCT00539448|Drug|insulin glulisine|in combination with insulin Glargine as bolus regimen
481646|NCT00539435|Procedure|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
481647|NCT00539422|Genetic|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
481648|NCT00539409|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
481649|NCT00539396|Drug|Technosphere Insulin|
481650|NCT00539383|Drug|ANG1005|IV infusion once every 21 days
481651|NCT00539357|Device|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
481652|NCT00539344|Drug|ANG1005|IV infusion once every 21 days
481653|NCT00539331|Drug|AZD2171|oral tablet
481654|NCT00539331|Drug|Paclitaxel|intravenous infusion
481655|NCT00539331|Drug|Carboplatin|intravenous injection
481656|NCT00539318|Procedure|Blood drawing|Once when enroll in study
481657|NCT00539305|Drug|testosterone gel|50-100mg applied topically daily for six months
481658|NCT00539305|Drug|placebo gel|applied topically daily for six months
481659|NCT00539292|Procedure|Primary placement of a spring-loaded silo|
481660|NCT00539292|Procedure|Primary Closure|primary closure of abdomen
481661|NCT00539279|Behavioral|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
481705|NCT00538928|Other|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
494565|NCT00441571|Drug|177Lu-CYT-500|
481662|NCT00539279|Behavioral|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
481663|NCT00539266|Biological|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
481664|NCT00539266|Biological|placebo|40 IM injections (calf muscle) of placebo suspension
481665|NCT00539253|Drug|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
481666|NCT00539240|Drug|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
481667|NCT00539240|Drug|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast & Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
481668|NCT00539240|Drug|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
481669|NCT00539227|Procedure|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
481670|NCT00539227|Behavioral|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
481671|NCT00539201|Drug|GSK706769|
481672|NCT00539188|Drug|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
481673|NCT00539188|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
481674|NCT00539175|Device|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
481675|NCT00539175|Device|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
481676|NCT00539162|Behavioral|Questionnaire|Questionnaires completed at baseline and during each follow up visit.
481677|NCT00539149|Drug|Amoxycillin|50 mg/kg/day twice daily
481678|NCT00539149|Drug|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
481679|NCT00539136|Drug|GSK561679 tablet or solution|
481680|NCT00539123|Behavioral|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
481681|NCT00539123|Behavioral|abstinence-contingent take-home buprenorphine (ACB)|Patients achieving heroin abstinence receive take-home doses of buprenorphine
481682|NCT00539123|Behavioral|Physician Management (PM)|medically focused advice and brief counseling
481683|NCT00539110|Drug|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
481684|NCT00539110|Drug|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
481685|NCT00539097|Dietary Supplement|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
481686|NCT00539084|Device|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
481687|NCT00539071|Drug|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
481688|NCT00539071|Drug|long acting injectable risperidone|Study dose remains 50 mg for the length of the study.
481689|NCT00539071|Drug|long acting injectable risperidone|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
481690|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
481691|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
481692|NCT00539019|Other|calories measured 5x following wound healing|measure REE at various time points postburn
481693|NCT00539006|Drug|FPNS|fluticasone propionate nasal spray
481694|NCT00539006|Drug|FFNS|fluticasone furoate nasal spray
481695|NCT00539006|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
481696|NCT00539006|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
481697|NCT00538993|Behavioral|Stage based counseling|
481698|NCT00538980|Drug|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
481699|NCT00538967|Drug|doxycycline|2 weeks once daily
481700|NCT00538954|Drug|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
481701|NCT00538954|Dietary Supplement|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
481702|NCT00538954|Other|Standard ERAS group|
481703|NCT00538941|Dietary Supplement|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
481704|NCT00538941|Dietary Supplement|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
495296|NCT00436566|Other|fluorophotometry|
481706|NCT00538915|Biological|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% [Immune Globulin Intravenous (Human), 10%] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
481707|NCT00538902|Biological|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
481708|NCT00538902|Biological|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
481709|NCT00538902|Biological|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
481710|NCT00538889|Drug|Lecozotan SR|
481711|NCT00538889|Drug|Citalopram|
481712|NCT00538876|Drug|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
481713|NCT00538863|Drug|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
481714|NCT00538850|Drug|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
481715|NCT00538850|Drug|Placebo|Matching placebo to fentanyl sublingual spray.
481716|NCT00538824|Drug|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
481717|NCT00538824|Drug|thalidomide|"Cycles 1-4~• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
481718|NCT00538824|Drug|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.~After completing 4 cycles:~Patients who demonstrate disease progression at any time will be taken off study.~Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.~Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.~Maintenance therapy will consist of:~• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of < 40cc/min*"
481719|NCT00538811|Drug|interferon alpha-2b, ribavirin, interferon-gamma,|
481720|NCT00538811|Drug|interferon alpha-2b, ribavirin, amantadine|
481721|NCT00538798|Drug|[18F]SP203|
481722|NCT00538785|Biological|Motavizumab|15 mg/kg IM administered at monthly intervals
481723|NCT00538785|Biological|Palivizumab|15 mg/kg IM administered at monthly intervals
481724|NCT00538772|Other|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
481725|NCT00538759|Device|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
481726|NCT00538759|Other|Sham Control|
481727|NCT00538746|Device|BIPAP|
481728|NCT00538746|Device|PSV|
481729|NCT00538746|Device|PSV + CPAP|
481730|NCT00538733|Drug|thalomid|"Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
481731|NCT00538733|Drug|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)~During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)~During Maintenance Phase~• 25 mg daily for days 1-21 out of a 28 day cycle"
481732|NCT00538733|Drug|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)"
481733|NCT00538733|Drug|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During BiRD Phase:~• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)~During Maintenance Phase~• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
481734|NCT00538720|Drug|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
481735|NCT00538720|Device|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
481736|NCT00538707|Behavioral|2-minute Bondet test|2-minute Bondet test
481737|NCT00538694|Drug|daptomycin|
481738|NCT00538681|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
481739|NCT00538681|Drug|pemetrexed|500 mg/m2, IV, q 21 days, six 21 day cycles
481740|NCT00538681|Drug|cisplatin|75 mg/m2, IV, q 21 days, six 21 day cycles
481741|NCT00538681|Drug|placebo|oral, daily
481742|NCT00538668|Drug|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
481743|NCT00538655|Drug|modafinil|400mg vs. 200mg (PO) daily
481744|NCT00538642|Drug|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
481745|NCT00538629|Other|no intervention|No intervention
481746|NCT00538616|Drug|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
481747|NCT00538616|Drug|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
481748|NCT00538603|Drug|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
481749|NCT00538603|Drug|Paclitaxel & Carboplatin|Chemotherapy
481750|NCT00538590|Device|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
481751|NCT00538590|Drug|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
481752|NCT00538564|Drug|tadalafil|10mg oral tablets taken 3 times a week for 2 months
481753|NCT00538564|Drug|placebo|Placebo tablets taken orally 3 times a week for 2 months
481754|NCT00538551|Other|Database|Database
481755|NCT00538538|Drug|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
481756|NCT00538538|Drug|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
481757|NCT00538525|Drug|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
481758|NCT00538512|Biological|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
481759|NCT00538512|Biological|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
481760|NCT00538512|Other|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
481761|NCT00538499|Drug|Fentanyl citrate|
481762|NCT00538499|Drug|Bupivacaine hydrocloride|
481763|NCT00538499|Procedure|videothoracoscopy|
481764|NCT00538486|Drug|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
481765|NCT00538486|Drug|Telmisartan|Telmisartan 80mg 1/d
481766|NCT00538486|Drug|Candesartan|Candesartan 8mg daily
481767|NCT00538486|Drug|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
481768|NCT00538486|Drug|Amlodipine|Amlodipine 5mg 1/d
481769|NCT00538486|Drug|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
481770|NCT00538473|Biological|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
481771|NCT00538473|Biological|Fluarix™|Single dose, intramuscular injection
481772|NCT00538447|Other|Database|data base for CML
481773|NCT00538434|Biological|Reslizumab|
481774|NCT00538434|Other|Saline|
481775|NCT00538421|Drug|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
481776|NCT00538421|Drug|Sevoflurane|0,7-1,5 MAC
481777|NCT00538408|Procedure|Whole body magnetic resonance angiography (dotarem)|
481778|NCT00538408|Device|Whole body magnetic resonance angiography (vasovist)|
481779|NCT00538395|Drug|Adriamycin, Taxol and Cytoxan|Chemotherapy
481780|NCT00538382|Drug|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
481781|NCT00538369|Other|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
481782|NCT00538369|Device|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
481783|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
481784|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
481785|NCT00538343|Drug|berubicin hydrochloride (RTA 744)|
481786|NCT00538330|Drug|Tamoxifen|Tamoxifen
481787|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
481788|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
481789|NCT00538304|Drug|bimatoprost eye drops|1 drop in each eye daily for 1 month
481790|NCT00538304|Drug|placebo|1 drop in each eye daily for 1 month
481791|NCT00538291|Biological|cetuximab|
481792|NCT00538291|Drug|capecitabine|
481793|NCT00538291|Genetic|gene expression analysis|
481794|NCT00538291|Genetic|microarray analysis|
481795|NCT00538291|Genetic|polymorphism analysis|
481796|NCT00538291|Genetic|reverse transcriptase-polymerase chain reaction|
481797|NCT00538291|Other|immunohistochemistry staining method|
481798|NCT00538278|Other|Database|database
481799|NCT00538265|Drug|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
481800|NCT00538265|Drug|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)"
481801|NCT00538265|Drug|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
481802|NCT00538239|Drug|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
481803|NCT00538239|Drug|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
481804|NCT00538226|Device|External Electric Muscle Stimulation|
481805|NCT00538213|Biological|Fluarix™|Single dose, Intramuscular injection
481806|NCT00538213|Biological|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
481807|NCT00538200|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
481808|NCT00538200|Other|Dietary Advice|Standard dietary advice
481809|NCT00538187|Drug|obatoclax mesylate|Given IV
481810|NCT00538187|Drug|bortezomib|Given IV
481811|NCT00538187|Other|laboratory biomarker analysis|correlative study
481812|NCT00538187|Other|pharmacological study|correlative study
481813|NCT00538174|Drug|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
481814|NCT00538174|Drug|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
481815|NCT00538161|Other|Ventilation strategy|
481816|NCT00538148|Drug|Telithromycin|
481817|NCT00538135|Behavioral|Cognitive Behavioural Therapy|
481818|NCT00538135|Other|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
481819|NCT00538122|Device|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.~From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
481820|NCT00538109|Drug|Glivec®/Gleevec®|Chemotherapy
481821|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
481822|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
481823|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
481824|NCT00538083|Other|Chocolate|74 grams of single dose solid dark chocolate versus placebo
481825|NCT00538083|Other|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
481826|NCT00538083|Other|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, & placebo given for six weeks
481827|NCT00538070|Dietary Supplement|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
481828|NCT00538057|Drug|GW685698X & GW642444M|study drug
481829|NCT00538044|Drug|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
481830|NCT00538031|Drug|cyclophosphamide|Given orally
481831|NCT00538031|Drug|celecoxib|Given orally
481832|NCT00538018|Drug|Telithromycin|
481833|NCT00538005|Biological|bevacizumab|
481834|NCT00538005|Drug|oxaliplatin|
481835|NCT00538005|Drug|sorafenib tosylate|
481836|NCT00537992|Procedure|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
481837|NCT00537979|Drug|Paricalcitol injection|Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
481838|NCT00537979|Drug|Paricalcitol capsules|Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
481839|NCT00537966|Drug|Dolutegravir|In this arm patients with primary HIV-1 infection are treated with standard antiretroviral combination therapy (only drugs that have been approved by Swiss Medic)
481840|NCT00537966|Drug|Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate|standard dosage
481841|NCT00537966|Drug|Raltegravir|standard dosage
481842|NCT00537966|Drug|Darunavir|standard dosage
482524|NCT00533377|Drug|CP-533,536|Active study drug
481843|NCT00537966|Drug|Ritonavir|used only as booster for the protease inhibitors that are prescribed in this study according to standard boosting
481844|NCT00537966|Drug|Rilpivirine|standard dosage
481845|NCT00537966|Drug|Lamivudine|standard dosage
481846|NCT00537966|Drug|tenofovir|standard dosage
481847|NCT00537966|Drug|Emtricitabine|standard dosage
481848|NCT00537966|Drug|Abacavir|standard dosage
481849|NCT00537953|Drug|Miltefosine , meglumine antimoniate|
481850|NCT00537940|Drug|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
481851|NCT00537940|Drug|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
481852|NCT00537927|Procedure|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
481853|NCT00537914|Drug|Somatropin|Infant, Small for Gestational Age, Omnitrope®/Somatropin, rhGH,
481854|NCT00537901|Radiation|First-Line Bevacizumab and Chemotherapy|Chemotherapy
481855|NCT00537901|Drug|Bevacizumab|Chemotherapy
481856|NCT00537888|Drug|fluconazole|Intravenous or oral 400 md/d
481857|NCT00537875|Dietary Supplement|Ginger|Capsule, 1000 mg, BID, 3 days
481858|NCT00537875|Dietary Supplement|Placebo|Capsule, 1000 mg, BID, 3 days
481859|NCT00537862|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
481860|NCT00537849|Device|Sonablate 500(SB-500)|
481861|NCT00537836|Drug|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
481862|NCT00537836|Drug|Placebo|Placebo, once daily p.o. over 8 weeks
481863|NCT00537836|Drug|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
481864|NCT00537823|Drug|Cetuximab|
481865|NCT00537823|Drug|Bevacizumab|
481866|NCT00537823|Drug|Leucovorin|
481867|NCT00537823|Drug|Oxaliplatin|
481868|NCT00537823|Drug|Fluorouracil|
481869|NCT00537810|Drug|Sibutramine|15 mg daily
481870|NCT00537810|Drug|Placebo|Daily
481871|NCT00537810|Behavioral|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
481872|NCT00537810|Behavioral|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
481873|NCT00537797|Other|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
481874|NCT00537784|Biological|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
481875|NCT00537784|Biological|no injection|
481876|NCT00537771|Drug|Anastrozole|1 mg once daily oral dose
481877|NCT00537771|Drug|Tamoxifen|20 mg once daily oral dose
481878|NCT00537758|Behavioral|Cognitive Behavior Therapy|
481879|NCT00537758|Behavioral|CBT and BWL|
481880|NCT00537758|Behavioral|Behavioral Weight Loss Treatment|
481881|NCT00537745|Drug|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
481882|NCT00537745|Other|Medication Management Therapy|Medication Management Therapy once a month.
481883|NCT00537732|Drug|omeprazole|20 mg daily
481884|NCT00537732|Drug|omeprazole|20 vs. 60 mg daily, genotype dependent
481885|NCT00537719|Drug|GSK716155|albiglutide subcutaneous injection
481886|NCT00537719|Drug|Placebo|placebo injection
481887|NCT00537693|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
481888|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients > 45 kg/99 lbs: idebenone 900 mg/day
481889|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
481890|NCT00537680|Drug|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
481891|NCT00537667|Drug|anakinra|anakinra
481892|NCT00537667|Drug|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
481893|NCT00537654|Drug|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
481894|NCT00537654|Drug|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
481895|NCT00537654|Drug|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
481896|NCT00537654|Drug|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
481897|NCT00537615|Drug|PD 0332334|
481898|NCT00537602|Drug|miglustat|
481899|NCT00537602|Drug|placebo|
481900|NCT00537589|Procedure|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
481901|NCT00537576|Drug|LACTIN-V|Arm 1: 5.0 x 10^8 cfu/dose 1x/day x 5 days total intravaginal. Arm 2: 1.0 x 10^9 cfu/dose 1x/day x 5 days total intravaginal. Arm 3: 2.0 x 10^9 cfu/dose 1x/day x 5 days total intravaginal. Arm 4: placebo 1x/day x 5 days total intravaginal.
481902|NCT00537563|Drug|Telithromycin|
481903|NCT00537550|Drug|Vincristine|Steroids pre-treatment
481904|NCT00537550|Drug|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
481905|NCT00537537|Drug|Telbivudine|
481906|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
481907|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
481908|NCT00537511|Drug|Pomalidomide|
481909|NCT00537511|Drug|Cisplatin|
481910|NCT00537511|Drug|Etoposide|
481911|NCT00537498|Drug|Urokinase|"Daily intravenous application of urokinase over 30 minutes~Dosage:~If plasma fibrinogen is > 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is < 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is < 1,6g/l treatment must be stopped and continued after rising up to >2g/l"
481912|NCT00537485|Drug|SPM 962|transdermal application, 1 time per day
481913|NCT00537485|Drug|placebo|transdermal application, 1 time per day
481914|NCT00537472|Drug|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
481915|NCT00537472|Drug|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
481916|NCT00537459|Drug|16448|
481917|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
481918|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
481919|NCT00537433|Other|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.~Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
481920|NCT00537420|Drug|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
481921|NCT00537420|Drug|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
481922|NCT00537420|Drug|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
481923|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
481924|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
481925|NCT00537420|Drug|Sibutramine|Sibutramine will be taken once daily with or without food
481926|NCT00537407|Drug|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
481927|NCT00537407|Drug|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
481928|NCT00537407|Drug|Ribavirin|Ribavirin supplied as 200 mg tablets
481929|NCT00537394|Drug|Enfuvirtide|90mg subcutaneously twice daily
481930|NCT00537394|Drug|Raltegravir|400 mg twice daily
481931|NCT00537394|Drug|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
481932|NCT00537394|Drug|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
481933|NCT00537394|Drug|Etravirine|Two 100-mg tablets twice daily
481934|NCT00537394|Drug|Maraviroc|Dosage dependent on regimen in which maraviroc is included
481935|NCT00537381|Drug|Docetaxel|Docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks.
481936|NCT00537381|Drug|Prednisone|Prednisone 5 mg orally twice daily.
481937|NCT00537381|Biological|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
481938|NCT00537381|Drug|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
481939|NCT00537368|Drug|CNTO 888|
481940|NCT00537355|Biological|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
481941|NCT00537355|Drug|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
481942|NCT00537342|Biological|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
481943|NCT00537329|Drug|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
481944|NCT00537316|Biological|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
481945|NCT00537316|Drug|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
481946|NCT00537316|Drug|Placebo to Azathioprine|Placebo to AZA tablet orally every day
481947|NCT00537316|Drug|Placebo infusion|Placebo to IFX intravenous (IV) infusion
481948|NCT00537303|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
481949|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
481950|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
481951|NCT00537290|Drug|Rituximab|Rituximab 1000mg IV on Days 0 and 15
481952|NCT00537277|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
481953|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
481954|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
481955|NCT00537251|Drug|Insulin glargine|
481956|NCT00537238|Drug|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
482016|NCT00536939|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, until progressive disease
481957|NCT00537238|Drug|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
481958|NCT00537225|Behavioral|exercise|tailored multifactor CVD risk reduction
481959|NCT00537212|Other|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
481960|NCT00537212|Other|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
481961|NCT00537212|Other|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
481962|NCT00537199|Other|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
481963|NCT00537199|Drug|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
481964|NCT00537186|Drug|Iron oligosaccharide|
481965|NCT00537173|Procedure|Core Biopsy|biopsy
481966|NCT00537173|Procedure|Blood Collection|Blood/serum sample
481967|NCT00537173|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
481968|NCT00537173|Drug|Avastin|Avastin 10 mg/kg IV, day 1 and 15
481969|NCT00537160|Behavioral|Behavior modification, Nutrition Education, Exercise|
481970|NCT00537147|Biological|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
481971|NCT00537147|Biological|Placebo|Placebo for WN/DEN4delta30 vaccine
481972|NCT00537134|Device|Embolization, coiling|Endovascular embolization with platinum coils
481973|NCT00537121|Drug|fluorouracil|Given IV
481974|NCT00537121|Drug|irinotecan hydrochloride|Given IV
481975|NCT00537121|Drug|leucovorin calcium|Given IV
481976|NCT00537121|Drug|vorinostat|Taken Orally
481977|NCT00537121|Other|pharmacological study|Correlative Study
481978|NCT00537108|Behavioral|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support & skills-building for school continuation, higher education, and job readiness.
481979|NCT00537095|Drug|Vandetanib|300 mg oral once daily oral dose
481980|NCT00537095|Other|Placebo|
481981|NCT00537082|Drug|FTY720|Administered orally once daily for 6 months
481982|NCT00537082|Drug|Placebo|Administered orally once daily for 6 months
481983|NCT00537056|Procedure|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
481984|NCT00537056|Procedure|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
481985|NCT00537056|Drug|F-18 Fluoro-deoxi-glucose|15 mCi iv
481986|NCT00537056|Drug|Gadolinium-DTPA|0.1 mmol/kg iv
481987|NCT00537056|Drug|Sunitinib|50 mg/day po
481988|NCT00537043|Drug|SK&F-105517 (COREG CR FDC)|
481989|NCT00537030|Drug|Asparaginase|Given IM
481990|NCT00537030|Other|Laboratory Biomarker Analysis|Correlative studies
481991|NCT00537030|Other|Pharmacological Study|Correlative studies
481992|NCT00537017|Drug|Preladenant|5 mg BID capsules
481993|NCT00537017|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
481994|NCT00537017|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
481995|NCT00536991|Dietary Supplement|Calcitriol|Given PO
481996|NCT00536991|Drug|Ketoconazole|Given PO
481997|NCT00536991|Other|Laboratory Biomarker Analysis|Correlative studies
481998|NCT00536991|Other|Pharmacological Study|Correlative studies
481999|NCT00536991|Drug|Therapeutic Hydrocortisone|Given PO
482000|NCT00536978|Drug|ARA-C|100 mg/m^2 IV Daily Over 1 Hour for 4 Days
482001|NCT00536978|Drug|BCNU|300 mg/m^2 IV Over 1 Hour for 1 Day
482002|NCT00536978|Drug|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
482003|NCT00536978|Drug|Cyclophosphamide|1000 mg/m^2 IV Daily Over 1 Hour for 3 Days
482004|NCT00536978|Drug|Etoposide|100 mg/m^2 IV Daily Over 3 Hours for 4 Days
482005|NCT00536978|Drug|Fludarabine|30 mg/m^2 IV Daily Over 1 Hour for 3 Days
482006|NCT00536978|Drug|Melphalan|100 mg/m^2 IV Over 30 Minutes for 1 Day.
482007|NCT00536978|Drug|Rituximab|375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks.
482008|NCT00536978|Other|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
482009|NCT00536978|Radiation|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
482010|NCT00536978|Drug|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
482011|NCT00536978|Drug|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
482012|NCT00536978|Procedure|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
482013|NCT00536952|Drug|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
482014|NCT00536952|Drug|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
482015|NCT00536952|Radiation|Radiation Therapy|5 days per week for 4 weeks
482525|NCT00533377|Drug|CP-533,536|Active study drug
482017|NCT00536939|Drug|bevacizumab|10 mg/kg, IV, Day 1 and 15 every 28 days, until disease progression
482018|NCT00536939|Drug|paclitaxel|90 mg/m2, IV, Days 1 ,8, and 15 every 28 days until disease progression
482019|NCT00536939|Drug|placebo|oral, daily, until disease progression
482020|NCT00536926|Device|Home spirometry with data transfer via cell phone|home spirometry recording
482021|NCT00536926|Device|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
482022|NCT00536926|Device|Home spirometer w/o BT|Standard home spirometry
482023|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25ug + spacer|
482024|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25 ug|
482025|NCT00536900|Behavioral|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
482026|NCT00536900|Behavioral|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
482027|NCT00536887|Drug|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
482028|NCT00536874|Drug|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
482029|NCT00536874|Drug|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
482030|NCT00536874|Genetic|protein expression analysis|
482031|NCT00536874|Genetic|proteomic profiling|
482032|NCT00536874|Other|diagnostic laboratory biomarker analysis|
482033|NCT00536874|Procedure|adjuvant therapy|
482034|NCT00536874|Procedure|neoadjuvant therapy|
482035|NCT00536874|Procedure|therapeutic conventional surgery|
482036|NCT00536861|Drug|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity~Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
482037|NCT00536848|Dietary Supplement|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
482038|NCT00536848|Dietary Supplement|Placebo|
482039|NCT00536848|Drug|Metronidazole|
482040|NCT00536835|Drug|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
482041|NCT00536809|Drug|lapatinib|onced daily Days 1-21
482042|NCT00536809|Drug|oxaliplatin|Day one of each cycle
482043|NCT00536809|Drug|capecitabine|given BID days 1-14
482044|NCT00536783|Drug|Quetiapine|
482045|NCT00536770|Drug|placebo + gemcitabine + erlotinib|
482046|NCT00536770|Drug|Placebo + gemcitabine|
482047|NCT00536770|Drug|calcitriol + gemcitabine|
482048|NCT00536770|Drug|calcitriol + gemcitabine + erlotinib|
482049|NCT00536744|Device|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
482050|NCT00536744|Other|Sham|Non-energized (inactive - Sham) application + standard of care
482051|NCT00536731|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
482052|NCT00536731|Drug|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
482053|NCT00536731|Drug|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
482054|NCT00536718|Genetic|gene expression analysis|
482055|NCT00536718|Genetic|molecular diagnostic method|
482056|NCT00536718|Genetic|polymorphism analysis|
482057|NCT00536718|Genetic|protein expression analysis|
482058|NCT00536718|Other|medical chart review|
482059|NCT00536718|Other|questionnaire administration|
482060|NCT00536705|Drug|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
482061|NCT00536692|Drug|mecamylamine|topical ocular drops
482062|NCT00536679|Drug|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
482063|NCT00536679|Drug|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
482064|NCT00536679|Drug|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
482065|NCT00536666|Drug|Iron oligosaccharide|
482066|NCT00536653|Drug|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
482067|NCT00536653|Drug|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
482068|NCT00536653|Drug|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
482069|NCT00536640|Drug|Erlotinib|150 mg per os, given daily until tumor progression
482070|NCT00536640|Drug|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
482071|NCT00536640|Drug|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
482072|NCT00536640|Drug|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
482073|NCT00536627|Biological|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
482159|NCT00535925|Drug|current therapy|the patients have to be treated according the standard good medical practice by any center
482074|NCT00536614|Genetic|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
482075|NCT00536601|Drug|etoposide|Given IV
482076|NCT00536601|Drug|cyclophosphamide|Given IV
482077|NCT00536601|Drug|carmustine|Given IV
482078|NCT00536601|Drug|melphalan|Given IV
482079|NCT00536601|Drug|busulfan|Given IV
482080|NCT00536601|Drug|carboplatin|Given IV
482081|NCT00536601|Drug|thiotepa|Given IV
482082|NCT00536601|Radiation|total-body irradiation|Undergo TBI
482083|NCT00536601|Procedure|autologous hematopoietic stem cell transplantation|Undergo ASCT
482084|NCT00536601|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
482085|NCT00536588|Genetic|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10^9 to 3 x 10^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
482086|NCT00536575|Drug|Bortezomib|"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.~Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."
482087|NCT00536575|Drug|Sorafenib|"Dose Levels 1 and 2: 200 mg by mouth twice daily~Dose Level 3: 400 mg by mouth twice daily"
482088|NCT00536562|Behavioral|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition & psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
482089|NCT00536549|Device|Guardian RT|
482090|NCT00536549|Behavioral|Education about the self monitoring blood glucose|
482091|NCT00536536|Behavioral|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
482092|NCT00536510|Drug|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization"
482093|NCT00536510|Drug|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks~Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.~All patients will receive placebo for a 4 week run-in period before randomization."
482094|NCT00536497|Drug|GW842166X|
482095|NCT00536484|Drug|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
482096|NCT00536484|Drug|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
482097|NCT00536471|Drug|Duloxetine hydrochloride|
482098|NCT00536471|Drug|Placebo|
482099|NCT00536458|Procedure|radiotherapy|mini chep+ radiotherapy
482100|NCT00536458|Drug|MINI CHEP|chemotherapy minichep 6 courses
482101|NCT00536445|Device|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
482102|NCT00536419|Drug|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
482103|NCT00536419|Other|Placebo|Placebo, daily dose, 4 days, oral administration
482104|NCT00536406|Behavioral|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
482105|NCT00536406|Behavioral|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
482106|NCT00536393|Drug|Doxorubicin|
482107|NCT00536393|Drug|Doxorubicin pegylated|
482108|NCT00536380|Drug|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
482109|NCT00536380|Drug|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
482110|NCT00536380|Drug|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
482111|NCT00536367|Other|No intervention - observational study only|
482112|NCT00536354|Other|Postural Orientation|
482113|NCT00536341|Drug|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
482114|NCT00536341|Drug|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 & Day 2); 500 mg/m2 Day 1 of Cycles 2-6
482115|NCT00536341|Drug|Fludarabine|25 mg/m2 on Days 1, 2, and 3
482116|NCT00536302|Dietary Supplement|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
482117|NCT00536302|Dietary Supplement|Placebo|Matching placebo solution per day by mouth for 48 weeks.
482118|NCT00536289|Device|Blunt needle|Blunt tipped suture needle
482119|NCT00536276|Dietary Supplement|Vitamin D2|Daily enteral dose of 100IU/kg
482120|NCT00536276|Dietary Supplement|Vitamin D3|Daily enteral dose of 100IU/kg
482121|NCT00536263|Drug|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
482122|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
482123|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
482124|NCT00536237|Drug|Comparator: niacin / Duration of Treatment: 17 Weeks|
482125|NCT00536237|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
482126|NCT00536237|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
482160|NCT00535925|Drug|irbesartan|"Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
482161|NCT00535925|Drug|ramipril|"Therapy for hypertension:~- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
482526|NCT00533377|Drug|CP-533,536|Active study drug
495579|NCT00434382|Drug|Isoflurane|
482127|NCT00536224|Behavioral|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
482128|NCT00536224|Behavioral|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
482129|NCT00536211|Behavioral|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at ~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
482130|NCT00536211|Drug|Metformin|oral tablet, 1000 mg daily for 17 days
482131|NCT00536198|Drug|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
482132|NCT00536198|Drug|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
482133|NCT00536185|Dietary Supplement|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
482134|NCT00536185|Dietary Supplement|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
482135|NCT00536172|Drug|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
482136|NCT00536172|Drug|Placebo|Placebo distribution matches the active medication.
482137|NCT00536159|Other|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
482138|NCT00536159|Other|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
482139|NCT00536133|Drug|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
482140|NCT00536133|Other|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
482141|NCT00536120|Biological|BG00002 (natalizumab)|
482142|NCT00536120|Biological|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
482143|NCT00536120|Biological|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
482144|NCT00536107|Drug|Gefitinib|250 mg oral
482145|NCT00536107|Procedure|CT or MRI|performed at screening and every 6 weeks
482146|NCT00536107|Drug|Docetaxel|60mg/m2 intravenous infusion
482147|NCT00536094|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
482148|NCT00536094|Behavioral|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
482149|NCT00536081|Drug|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
482150|NCT00536068|Drug|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days~Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days~Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days~Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
482151|NCT00536042|Drug|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
482152|NCT00536016|Drug|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
482153|NCT00536003|Drug|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
482154|NCT00536003|Drug|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
482155|NCT00535977|Dietary Supplement|Broccoli|400g ITC-enriched broccoli per week for 12 months
482156|NCT00535977|Dietary Supplement|Peas|400g frozen garden peas per week for 12 months
482157|NCT00535951|Drug|LBH589|
482158|NCT00535938|Other|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
482162|NCT00535925|Drug|hydrochlorothiazide|"Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
482163|NCT00535925|Drug|furosemide|"Therapy for hypertension~- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
482164|NCT00535925|Drug|amlodipine|"Therapy for hypertension~- Step 3: amlodipine up to 10 mg/die"
482165|NCT00535925|Drug|atenolol|"Therapy for hypertension~- Step 4: atenolol up to 100 mg/die"
482166|NCT00535925|Drug|doxazosin|"Therapy for hypertension~- Step 5: doxazosin up to 4 mg/die"
482167|NCT00535925|Drug|clonidine|"Therapy for hypertension~- Step 6: clonidine"
482168|NCT00535925|Drug|insulin|"Therapy for Hyperglycaemia (to achieve HbA1c <7):~- insulin"
482169|NCT00535925|Drug|simvastatin|"Therapy for hypercholesterolemia:~- for reducing LDL cholesterol < 100 mg/dl: simvastatin up to 80 mg/die"
482170|NCT00535925|Drug|fibrate|"Therapy for hypertriglyceridemia~- for reducing triglycerides < 150 mg/dl and/or increasing HDL cholesterol > 40-50 mg/dl: a fibrate"
482171|NCT00535925|Drug|erythropoietin|"Treatment of anaemia:~- erythropoietin"
482172|NCT00535925|Drug|aspirin|"Antiplatelet therapy (in all patients without contraindications):~- aspirin up to 160 mg/die"
482173|NCT00535912|Procedure|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
482174|NCT00535886|Dietary Supplement|Man-made Trans FA|EA as 6% of total energy
482175|NCT00535886|Dietary Supplement|Natural Trans FA|VA as 6% of total energy
482176|NCT00535886|Dietary Supplement|Oleic Acid|OA as 6% of total energy
482177|NCT00535873|Drug|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
482178|NCT00535860|Drug|Teriparatide|Daily for 96 days
482179|NCT00535847|Drug|Telaprevir|Tablet
482180|NCT00535847|Drug|Ribavirin|Tablet
482181|NCT00535847|Drug|Pegylated interferon alfa 2a|Solution for Injection
482182|NCT00535834|Procedure|diagnostic procedure|
482183|NCT00535834|Procedure|molecular diagnostic method|
482184|NCT00535834|Procedure|protein expression analysis|
482185|NCT00535821|Device|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
482186|NCT00535821|Device|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
482187|NCT00535808|Drug|nitroprusside|Administration of nitroprusside
482188|NCT00535808|Drug|nitroglycerine|Administration of nitroglycerine
482189|NCT00535808|Drug|sevoflurane|Administration of Sevoflurane
482190|NCT00535795|Radiation|Radiation Therapy|Radiation Therapy
482191|NCT00535782|Drug|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
482192|NCT00535782|Drug|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
482193|NCT00535782|Drug|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
482194|NCT00535769|Device|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
482195|NCT00535769|Device|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
482196|NCT00535756|Drug|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
482197|NCT00535756|Drug|Placebo|Placebo
482198|NCT00535743|Drug|Sugammadex|Sugammadex administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®, dosed at 2, 4, 8, 12 or 16 mg/kg according to participant actual body weight.
482199|NCT00535743|Drug|Placebo|0.9% NaCl administered as a fast IV bolus dose (within 30 seconds) at 3 or 15 minutes following administration of Esmeron®,
482200|NCT00535743|Drug|Esmeron®|Esmeron® administered at 1 or 1.2 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
482201|NCT00535730|Biological|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
482202|NCT00535730|Biological|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
482203|NCT00535730|Biological|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
482204|NCT00535717|Procedure|uttarbasti (per urethral administration of medicated oil )|
482205|NCT00535704|Behavioral|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
482206|NCT00535704|Behavioral|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
482207|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
482208|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
482209|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
482210|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
482211|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
482212|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
482213|NCT00535652|Drug|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
482214|NCT00535639|Drug|Betula Verrucosa allergen extract|
482215|NCT00535626|Device|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
482216|NCT00535613|Drug|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
482217|NCT00535587|Behavioral|Exercise|
482218|NCT00535587|Drug|pyridostigmine|
482219|NCT00535587|Drug|Placibo|
482220|NCT00535587|Behavioral|Attention Control|
482221|NCT00535574|Drug|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
482222|NCT00535574|Drug|bexarotene|75 mg/day 6 weeks
482224|NCT00535561|Drug|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
482225|NCT00535548|Biological|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
482226|NCT00535535|Dietary Supplement|Fructose|Fructose, 0.5 g/kg
482227|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
482228|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
482229|NCT00535522|Drug|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
482230|NCT00535522|Drug|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
482231|NCT00535509|Radiation|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
482232|NCT00535509|Other|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
482233|NCT00535509|Drug|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
482234|NCT00535496|Drug|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
482235|NCT00535470|Drug|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
482236|NCT00535457|Other|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
482237|NCT00535444|Other|Parish nurse visit|One visit with the parish nurse in 2 weeks
482238|NCT00535431|Drug|AER 001|60 mg (in nebuliser), twice daily for 28 days
482239|NCT00535431|Drug|placebo|Sterile saline nebulised, twice daily for 28 days
482240|NCT00535418|Drug|Letrozole|
482241|NCT00535405|Drug|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
482242|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
482243|NCT00535405|Drug|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
482244|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
482245|NCT00535405|Drug|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
482246|NCT00535392|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.~Dosage for subjects not on levetiracetam at study entry was based on weight: if <50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
482247|NCT00535379|Drug|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
482248|NCT00535366|Drug|Tiotropium|Oral inhalation by HandiHaler® device
482249|NCT00535366|Drug|Salmeterol|Oral inhalation from Diskus®
482250|NCT00535366|Drug|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
482251|NCT00535366|Drug|Ciclesonide low|Oral inhalation from MDI
482252|NCT00535366|Drug|Ciclesonide high|Oral inhalation from MDI
482253|NCT00535366|Drug|Placebo|Oral inhalation from MDI
482254|NCT00535353|Drug|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
482255|NCT00535353|Drug|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
482256|NCT00535340|Drug|SR58611A|
482257|NCT00535314|Drug|RTA 402 Dose1|
482258|NCT00535314|Drug|RTA 402 Dose2|
482259|NCT00535301|Device|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
482260|NCT00535301|Procedure|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
482261|NCT00535288|Drug|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
482262|NCT00535288|Drug|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
482263|NCT00535275|Drug|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
482264|NCT00535275|Drug|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
482265|NCT00535262|Drug|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
482266|NCT00535236|Biological|V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
482267|NCT00535236|Biological|Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
482362|NCT00534482|Behavioral|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
482268|NCT00535223|Behavioral|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
482269|NCT00535223|Behavioral|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
482270|NCT00535210|Behavioral|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
482271|NCT00535210|Behavioral|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
482272|NCT00535197|Biological|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
482273|NCT00535158|Drug|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
482274|NCT00535145|Drug|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
482275|NCT00535132|Drug|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
482276|NCT00535132|Drug|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
482277|NCT00535119|Drug|Carboplatin|Given IV
482278|NCT00535119|Other|Laboratory Biomarker Analysis|Correlative studies
482279|NCT00535119|Drug|Paclitaxel|Given IV
482280|NCT00535119|Other|Pharmacological Study|Correlative studies
482281|NCT00535119|Drug|Veliparib|Given PO
482282|NCT00535106|Device|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
482283|NCT00535106|Device|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
482284|NCT00535106|Other|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
482285|NCT00535093|Device|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
482286|NCT00535080|Drug|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
482287|NCT00535067|Behavioral|Questionnaire|Questionnaires taking 60 minutes total to complete.
482288|NCT00535054|Drug|Tears Again|Liposome Eye Spray
482289|NCT00535041|Drug|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
482290|NCT00535028|Drug|AER 001|AER 001 25 mgs s.c. once daily for 28 days
482291|NCT00535028|Drug|placebo|sterile saline
482292|NCT00535015|Drug|Betamarc|2 tabs BID
482293|NCT00535002|Drug|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
482294|NCT00535002|Drug|Placebo|
482295|NCT00534989|Procedure|FDG PET|FDG PET
482296|NCT00534976|Drug|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily~Patients 6-14 years: 5 mg chewable tablet daily"
482297|NCT00534976|Drug|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily~Patients 6-14 years: 5 mg Pbo chewable tablet daily"
482298|NCT00534963|Procedure|cervical vs. uterine placement of balloon catheter|
482299|NCT00534950|Radiation|5 vs 6 weekly fraction of RT|Chemotherapy
482300|NCT00534937|Procedure|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
482301|NCT00534937|Procedure|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
482302|NCT00534924|Drug|Vit C|
482303|NCT00534924|Procedure|Postconditioning|
482304|NCT00534924|Other|no intervention|
482305|NCT00534911|Behavioral|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)"
482359|NCT00534521|Device|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
495580|NCT00434382|Drug|Desflurane|
482306|NCT00534911|Behavioral|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
482307|NCT00534898|Drug|Bexarotene|
482308|NCT00534898|Drug|Fenretinide|
482309|NCT00534898|Drug|Placebo|
482310|NCT00534885|Biological|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
482311|NCT00534885|Biological|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
482312|NCT00534885|Biological|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
482313|NCT00534885|Biological|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
482314|NCT00534872|Drug|SB-649868|10 mg
482315|NCT00534859|Device|High Risk PCI|High Risk Percutaneous Coronary Intervention
482316|NCT00534846|Drug|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
482317|NCT00534846|Drug|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
482318|NCT00534833|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
482319|NCT00534833|Biological|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
482320|NCT00534833|Biological|Oral Polio Vaccine|0.5 mL, Oral
482321|NCT00534820|Procedure|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
482322|NCT00534807|Drug|Vinflunine|
482323|NCT00534807|Drug|Rifampin|
482324|NCT00534794|Drug|Elestat|Elestat BID for 2 days
482325|NCT00534794|Drug|Pataday|Pataday QD for 2 days
482326|NCT00534781|Device|plasma microdebrider|Coblation of the Achilles
482327|NCT00534781|Procedure|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
482328|NCT00534768|Procedure|active debridement|debridement on 1st, 3-5th and 7th postoperative days
482329|NCT00534768|Procedure|control group|Postoperative debridement on 7th postoperative day
482330|NCT00534755|Other|Breast Cancer database|prospective breast cancer database
482331|NCT00534729|Drug|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
482332|NCT00534703|Genetic|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10^13 DRP (DNase resistant particles)
482333|NCT00534703|Drug|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
482334|NCT00534690|Procedure|One-Lung ventilation|Low Vt, High PEP
482335|NCT00534690|Procedure|One-Llung ventilation|High Vt, low PEP
482336|NCT00534677|Drug|Terlipressin|2 mg stat & then 1 mg q6h iv and Placebo of Octreotide
482337|NCT00534677|Drug|Octreotide|Octreotide 50mcg/hr infusion & a placebo of Terlipressin
482338|NCT00534664|Device|TheraBionic device|Daily outpatient treatment with theraBionic device
482339|NCT00534651|Drug|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
482340|NCT00534638|Biological|Cervarix|Intramuscular injection, 3 doses
482341|NCT00534638|Biological|Engerix-B|Intramuscular injection, 3 doses
482342|NCT00534625|Drug|zileuton|Single injection of zileuton 150 mg
482343|NCT00534625|Drug|placebo|Single injection of placebo
482344|NCT00534625|Drug|zileuton|Single injection of zileuton 300 mg
482345|NCT00534612|Procedure|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
482346|NCT00534599|Drug|Placebo|oral
482347|NCT00534599|Drug|quetiapine fumarate XR|oral
482348|NCT00534586|Drug|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
482349|NCT00534586|Drug|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
482350|NCT00534586|Drug|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
482351|NCT00534586|Drug|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
482352|NCT00534573|Drug|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
482353|NCT00534560|Drug|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
482354|NCT00534560|Drug|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
482355|NCT00534560|Drug|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
482356|NCT00534547|Procedure|Duodenal Exclusion|duodenal-jejunal bypass
482357|NCT00534534|Behavioral|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
482358|NCT00534521|Device|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
482360|NCT00534508|Drug|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
482363|NCT00534482|Behavioral|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
482364|NCT00534482|Behavioral|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
482365|NCT00534482|Behavioral|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
482366|NCT00534469|Biological|aldesleukin|
482367|NCT00534469|Biological|filgrastim|
482368|NCT00534469|Drug|busulfan|
482369|NCT00534469|Drug|cytarabine|
482370|NCT00534469|Drug|etoposide|
482371|NCT00534469|Drug|idarubicin|
482372|NCT00534469|Procedure|autologous hematopoietic stem cell transplantation|
482373|NCT00534469|Procedure|bone marrow transplantation|
482374|NCT00534469|Procedure|peripheral blood stem cell transplantation|
482375|NCT00534469|Radiation|total-body irradiation|
482376|NCT00534456|Drug|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
482377|NCT00534456|Drug|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
482378|NCT00534443|Procedure|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.~Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
482379|NCT00534430|Drug|busulfan|
482380|NCT00534430|Drug|cyclosporine|
482381|NCT00534430|Drug|etoposide|
482382|NCT00534430|Drug|mycophenolate mofetil|
482383|NCT00534430|Procedure|allogeneic bone marrow transplantation|
482384|NCT00534430|Procedure|allogeneic hematopoietic stem cell transplantation|
482385|NCT00534430|Procedure|peripheral blood stem cell transplantation|
482386|NCT00534430|Radiation|total-body irradiation|
482387|NCT00534417|Drug|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight < 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
482388|NCT00534417|Drug|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
482389|NCT00534404|Drug|Nicotine patches|Participants will wear nicotine patches.
482390|NCT00534404|Behavioral|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
482391|NCT00534404|Behavioral|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
482392|NCT00534391|Drug|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
482393|NCT00534391|Drug|Artificial tear|4 times daily
482394|NCT00534378|Drug|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
482395|NCT00534365|Device|tension-free vaginal tape|Retropubic mid-urethral sling
482396|NCT00534365|Device|TVT-SECUR device|Mid-urethral mini-sling
482397|NCT00534352|Drug|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
482398|NCT00534339|Device|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
482399|NCT00534326|Procedure|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
482400|NCT00534326|Procedure|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
482401|NCT00534313|Drug|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
482402|NCT00534313|Drug|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
482403|NCT00534300|Drug|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
482404|NCT00534300|Drug|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
482405|NCT00534287|Drug|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
482406|NCT00534287|Drug|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
482407|NCT00534274|Other|3'-deoxy-3'-[18F]fluorothymidine|
482408|NCT00534261|Drug|Interferon beta-1a|IM injection
482409|NCT00534248|Biological|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
482410|NCT00534248|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
495581|NCT00434382|Drug|Propofol|
482411|NCT00534235|Procedure|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
482412|NCT00534235|Device|Posterolateral Fusion and Implantation of Pedicle Screws|
482413|NCT00534235|Device|Implantation of coflex Interlaminar Technology|
482414|NCT00534209|Biological|Allogeneic B7.1/HLA-A1|Dose: At least 4x10^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
482415|NCT00534209|Other|Placebo|Given intradermally
482416|NCT00534196|Radiation|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
482417|NCT00534183|Drug|Olanzapine|Olanzapine in dose range of 10-20mg
482418|NCT00534183|Drug|Risperidone|Risperidone 1-6mg
482419|NCT00534183|Drug|Haloperidol|Haloperidol 10-20mg
482420|NCT00534170|Dietary Supplement|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
482421|NCT00534144|Drug|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
482422|NCT00534144|Drug|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
482423|NCT00534131|Procedure|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
482424|NCT00534131|Procedure|APPEAR Procedure|Perineal incision to reach the distal rectum
482425|NCT00534131|Procedure|Proctectomy|standard rectal excision which does not preserve the anal canal
482426|NCT00534118|Biological|donor lymphocytes|Given IV
482427|NCT00534105|Other|Total Cholesterol|
482428|NCT00534105|Other|Triglyceride|
482429|NCT00534105|Other|HDL|
482430|NCT00534105|Other|LDL|
482431|NCT00534092|Device|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
482432|NCT00534079|Drug|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
482433|NCT00534079|Drug|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
482434|NCT00534053|Other|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
482435|NCT00534027|Drug|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
482436|NCT00534027|Other|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
482437|NCT00534014|Dietary Supplement|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
482438|NCT00534001|Drug|bupropion hydrochloride|Given orally
482439|NCT00534001|Other|placebo|Given orally
482440|NCT00533988|Device|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
482441|NCT00533962|Drug|Anterior Juxtascleral Depot of Anecortave Acetate|
482442|NCT00533949|Biological|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
482443|NCT00533949|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
482444|NCT00533949|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.~Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
482445|NCT00533949|Radiation|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
482446|NCT00533949|Radiation|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
482447|NCT00533936|Biological|trastuzumab|
482448|NCT00533936|Drug|cyclophosphamide|
482449|NCT00533936|Drug|doxorubicin hydrochloride|
482450|NCT00533936|Drug|fluorouracil|
482451|NCT00533936|Drug|paclitaxel|
482452|NCT00533936|Procedure|adjuvant therapy|
482453|NCT00533936|Procedure|conventional surgery|
482454|NCT00533936|Procedure|neoadjuvant therapy|
482455|NCT00533923|Drug|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
482456|NCT00533910|Drug|Rifaximin|550mg BID rifaximin for 8 weeks
482457|NCT00533910|Drug|placebo|same as the experimental arm
482458|NCT00533897|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
482459|NCT00533897|Drug|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
482460|NCT00533884|Other|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
482461|NCT00533884|Other|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
482462|NCT00533884|Other|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
482463|NCT00533858|Drug|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
482464|NCT00533845|Drug|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
482465|NCT00533832|Device|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
482466|NCT00533819|Other|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
482523|NCT00533377|Procedure|Standard of Care|Standard surgical procedure
482467|NCT00533806|Behavioral|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
482468|NCT00533806|Behavioral|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
482469|NCT00533793|Procedure|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
482470|NCT00533780|Procedure|Healing Touch|
482471|NCT00533754|Procedure|drawing blood|
482472|NCT00533741|Drug|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
482473|NCT00533741|Drug|Placebo|Saline for injection.
482474|NCT00533741|Biological|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
482475|NCT00533728|Drug|Soluble beta-glucan (SBG)|
482476|NCT00533702|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
482477|NCT00533702|Drug|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
482478|NCT00533689|Procedure|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
482479|NCT00533676|Drug|MK0524A, /Duration of Treatment : 8 Weeks|
482480|NCT00533676|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
482481|NCT00533663|Procedure|Healing Touch|every other week (during their infusion)
482482|NCT00533663|Drug|Standard care|
482483|NCT00533663|Drug|guided relaxation|
482484|NCT00533650|Drug|MK0429|
482485|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
482486|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
482487|NCT00533637|Drug|Placebo|Citrate buffer with preservatives
482488|NCT00533624|Drug|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
482489|NCT00533624|Drug|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
482490|NCT00533611|Drug|MK0524A, /Duration of Treatment : 4 Weeks|
482491|NCT00533611|Drug|Comparator : niacin /Duration of Treatment : 1 Weeks|
482492|NCT00533598|Drug|MK0557|
482493|NCT00533585|Drug|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
482494|NCT00533585|Drug|Paclitaxel|200 mg/m^2 By Vein Over 3 Hours on Day 1.
482495|NCT00533585|Drug|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
482496|NCT00533585|Drug|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
482497|NCT00533559|Drug|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
482498|NCT00533559|Drug|Placebo|Placebo comparator
482499|NCT00533546|Drug|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
482500|NCT00533533|Drug|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.~Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
482501|NCT00533520|Drug|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
482502|NCT00533507|Biological|Synflorix|Intramuscular injection, 3 doses.
482503|NCT00533507|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
482504|NCT00533507|Biological|Rotarix|Oral, 2 doses.
482505|NCT00533494|Behavioral|physician feedback (A)|Feedback information to physicians
482506|NCT00533481|Drug|MK0557|
482507|NCT00533468|Drug|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
482508|NCT00533455|Drug|Gabapentin|
482509|NCT00533442|Drug|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
482510|NCT00533442|Drug|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
482511|NCT00533442|Drug|Tacrolimus|Part of standard maintenance.
482512|NCT00533442|Drug|Steroids|Part of standard maintenance
482513|NCT00533429|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until disease progression
482514|NCT00533429|Drug|pemetrexed|500 mg/m2, IV, day 8 of cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
482515|NCT00533429|Drug|carboplatin|AUC 6, IV day 8 cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
482516|NCT00533429|Drug|bevacizumab|15 mg/kg, IV, Day 8 of cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
482517|NCT00533429|Drug|Placebo|oral, daily
482518|NCT00533416|Drug|ON 01910 Na|
482519|NCT00533403|Drug|MK0686|
482520|NCT00533390|Drug|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
482521|NCT00533377|Drug|CP-533, 536|Active study drug
482522|NCT00533377|Drug|Placebo|Placebo vehicle
495582|NCT00434382|Drug|Fentanyl|
482527|NCT00533364|Drug|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
482528|NCT00533351|Drug|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
482529|NCT00533351|Drug|placebo|placebo 50 mg capsules three-times daily for 2 weeks
482530|NCT00533338|Behavioral|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
482531|NCT00533338|Behavioral|Questionnaire|Packet of questionnaires will be completed.
482532|NCT00533312|Drug|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
482533|NCT00533312|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
482534|NCT00533312|Drug|Comparator : niacin / Duraton of Treatment: 4 Weeks|
482535|NCT00533299|Drug|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
482536|NCT00533299|Drug|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
482537|NCT00533286|Drug|benzodiacepine|diazepam (2 x 5 mg/ die)
482538|NCT00533273|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
482539|NCT00533247|Drug|Celecoxib|
482540|NCT00533234|Device|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
482541|NCT00533221|Drug|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
482542|NCT00533221|Drug|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
482543|NCT00533208|Drug|MK0524|
482544|NCT00533195|Drug|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
482545|NCT00533195|Device|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients."
482546|NCT00533169|Drug|ZD6474|Part A = Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m^2 by mouth daily on days 2-28.
482547|NCT00533169|Drug|Retinoic Acid|Part B, C = 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
482548|NCT00533156|Device|Vascular access site closure (7F Ensure)|
482549|NCT00533143|Other|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
482550|NCT00533130|Procedure|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
482551|NCT00533130|Procedure|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
482552|NCT00533117|Drug|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
482553|NCT00533117|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
482554|NCT00533117|Behavioral|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
482555|NCT00533104|Procedure|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
482556|NCT00533104|Procedure|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.~Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
482557|NCT00533091|Biological|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
482558|NCT00533091|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
482559|NCT00533078|Dietary Supplement|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
482560|NCT00533065|Drug|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
482561|NCT00533052|Behavioral|Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
482562|NCT00533039|Drug|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
482563|NCT00533039|Drug|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
482564|NCT00533026|Drug|Duloxetine|
482565|NCT00533026|Drug|Warfarin|
482566|NCT00533013|Other|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
482567|NCT00533013|Other|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
482568|NCT00533000|Procedure|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
482569|NCT00532987|Behavioral|Questionnaire|Questionnaire form to be completed by patient
482570|NCT00532974|Biological|EP1090|Low dose
482571|NCT00532974|Biological|EP1090|High dose
482572|NCT00532961|Drug|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
482573|NCT00532961|Drug|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
482574|NCT00532948|Drug|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
482575|NCT00532935|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an ~32 wk treatment period
482576|NCT00532935|Drug|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an ~32-wk treatment period.
482577|NCT00532909|Drug|Vandetanib|100mg or 300mg By mouth every day continuous
482578|NCT00532909|Drug|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
482579|NCT00532909|Drug|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
482580|NCT00532909|Drug|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
482581|NCT00532883|Drug|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
482582|NCT00532883|Drug|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
482583|NCT00532883|Other|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
482584|NCT00532870|Other|laparoscopic|
482585|NCT00532857|Drug|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
482586|NCT00532844|Drug|6R-BH4 (sapropterin dihydrochloride)|5 mg/kg BID of 6R-BH4 tablets to be administered orally for 13.5 days
482587|NCT00532844|Drug|6R-BH4 (sapropterin dihydrochloride)|5 mg/kg BID of 6R-BH4 tablets, plus 500 mg BID of Vitamin C caplets to be administered orally for 13.5 days
482588|NCT00532818|Drug|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
482589|NCT00532818|Drug|Placebo|Cisplatin + Topotecan plus placebo
482590|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
482591|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
482592|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
482593|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
482594|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
482595|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
482596|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
482597|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
482598|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
482599|NCT00532792|Biological|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
482600|NCT00532779|Drug|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
482601|NCT00532779|Drug|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
482602|NCT00532779|Drug|Placebo|
482603|NCT00532779|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
482604|NCT00532766|Drug|Jusline|
482605|NCT00532753|Behavioral|Community Empowerment|
482606|NCT00532740|Radiation|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
482607|NCT00532727|Drug|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
482608|NCT00532727|Drug|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
482609|NCT00532714|Drug|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.~Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
482610|NCT00532701|Drug|Peg-IFN + WB RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 5-16"
482611|NCT00532701|Drug|Peg-IFN + LD RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-6~Rapid virologic response (RVR) at week 4 of therapy: achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
482612|NCT00532701|Drug|Peg-IFN + WB RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
482613|NCT00532701|Drug|Peg-IFN + WB RBV for 48 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4~Rapid virologic response (RVR) at week 4 of therapy: not achieved~Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
482614|NCT00532701|Drug|Peg-IFN + LD RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24~Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
482615|NCT00532688|Drug|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
482616|NCT00532675|Drug|LBH589|PAN 5 mg and PAN 20 mg capsules
482617|NCT00532675|Combination Product|Lenalidomide|Lenalidomide 5mg or 25 mg
482618|NCT00532662|Drug|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
482619|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
482620|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
482621|NCT00532623|Drug|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
482622|NCT00532623|Drug|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
482623|NCT00532610|Drug|GSK189075|
482624|NCT00532597|Procedure|On-line hemodiafiltration|
482625|NCT00532597|Procedure|Low flux hemodialysis|
482626|NCT00532584|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
482627|NCT00532571|Drug|CoQ10|
482628|NCT00532558|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
482629|NCT00532558|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
482630|NCT00532545|Drug|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
482631|NCT00532532|Drug|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
482632|NCT00532532|Drug|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
482633|NCT00532532|Drug|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
482634|NCT00532519|Drug|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
482635|NCT00532506|Drug|SK-0403|
482636|NCT00532493|Drug|prazosin|"Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually."
482637|NCT00532493|Other|placebo|"sugar pill"
482638|NCT00532480|Drug|Duloxetine|60 mg capsules
482639|NCT00532467|Drug|SRX251|
482640|NCT00532454|Drug|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
482641|NCT00532441|Drug|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
482642|NCT00532441|Drug|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
482643|NCT00532428|Drug|Raloxifene|60 mg QD
482644|NCT00532428|Drug|Raloxifene|120 mg QD
482645|NCT00532428|Drug|Placebo|Placebo
482646|NCT00532415|Drug|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
482647|NCT00532389|Drug|LBH589|
482648|NCT00532350|Drug|QAT370|
482649|NCT00532350|Drug|Placebo|
482650|NCT00532350|Drug|Tiotropium|
482651|NCT00532337|Drug|ONO-5334|Placebo - 24/mos.
482652|NCT00532337|Drug|ONO-5334|100mg QD /24 months
482653|NCT00532337|Drug|ONO-5334|50mg BID /24 mos.
482654|NCT00532337|Drug|ONO-5334|300mg QD /24 mos.
482655|NCT00532337|Drug|ONO-5334|Alendronate 70mg once weekly / 24 mos
482656|NCT00532324|Other|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
482657|NCT00532311|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
495583|NCT00434382|Drug|Sufentanil|
482658|NCT00532311|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
482659|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
482660|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
482661|NCT00532298|Biological|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
482662|NCT00532298|Biological|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
482663|NCT00532285|Drug|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
482664|NCT00532272|Drug|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
482665|NCT00532259|Drug|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
482666|NCT00532246|Drug|raloxifene|
482667|NCT00532246|Drug|Placebo|
482668|NCT00532233|Drug|QAX576|
482669|NCT00532220|Drug|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
482670|NCT00532220|Drug|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
482671|NCT00532207|Drug|teriparatide|subcutaneous 20 micrograms
482672|NCT00532194|Drug|cediranib|Once-daily oral tablet starting dose 20mg
482673|NCT00532181|Behavioral|Savings Behavior and Consumer's Approach to Risk|
482674|NCT00532168|Drug|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
482675|NCT00532168|Drug|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
482676|NCT00532168|Drug|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
482677|NCT00532155|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
482678|NCT00532155|Drug|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
482679|NCT00532155|Drug|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
482680|NCT00532155|Drug|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
482681|NCT00532142|Drug|Intravitreal Triamcinolone|
482682|NCT00532142|Procedure|Radial Optic Neurotomy|
482683|NCT00532142|Other|Placebo - Sham Intravitreal Injection|
482684|NCT00532129|Drug|Rituximab|375mg/m^2 IV on Day 1 of Cycle 1; 500mg/m^2 on Day 1 of Cycles 2-6.
482685|NCT00532129|Drug|Chlorambucil|10 mg/m^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
482686|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
482687|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
482688|NCT00532090|Drug|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
482689|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
482690|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
482691|NCT00532077|Drug|rhPTH(1-34)|
482692|NCT00532077|Drug|SB-751689 100 mg|
482693|NCT00532077|Drug|SB-751689 400 mg|
482694|NCT00532064|Procedure|Biospecimen Collection|Undergo collection of blood
482695|NCT00532064|Other|Questionnaire Administration|Ancillary studies
482696|NCT00532051|Device|OCT measurements|This study is about a new imaging method to study the front part of the eye. This imaging method is called Optical Coherence Tomography (OCT) which provides detailed cross-sectional (layered) views of structures in the eye. The OCT system scans a beam of light across the eye to take a picture. OCT provides a more detailed image than other imaging methods of the eye such as ultrasound, CT scan (computed tomography), and MRI (magnetic resonance imaging). In addition, OCT imaging does not touch the eye. OCT is routinely used in imaging structures in the back of the eye (retina) and cornea. This study uses high-speed FDA approved OCT systemsThe measurements from the OCT systems are used in selecting IOL power.
482697|NCT00532038|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
482698|NCT00532025|Drug|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
482699|NCT00532012|Drug|RhuDex®|
482700|NCT00531999|Drug|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
482701|NCT00531999|Drug|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
482702|NCT00531986|Drug|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
482703|NCT00531986|Drug|HAART|Patients will continued their current HAART
482704|NCT00531973|Drug|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
482705|NCT00531973|Drug|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
482706|NCT00531960|Drug|Erlotinib|150 mg, PO, daily
482707|NCT00531960|Drug|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
482708|NCT00531960|Drug|Standard platinum-based chemotherapy|At the discretion of the investigator
482709|NCT00531947|Drug|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
482710|NCT00531947|Drug|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
482711|NCT00531934|Drug|Doxycline|100mg po daily
482712|NCT00531934|Drug|erlotinib [Tarceva]|150mg po daily
482713|NCT00531908|Drug|furosemide|furosemide
482714|NCT00531895|Drug|duloxetine|duloxetine 60 mg/d
482715|NCT00531882|Drug|Pioglitazone|30 mg once a day
482716|NCT00531882|Drug|Simvastatin|40 mg once a day
482717|NCT00531882|Drug|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
482718|NCT00531869|Behavioral|biases towards products|
482719|NCT00531856|Drug|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
482720|NCT00531856|Drug|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
482721|NCT00531856|Drug|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
482722|NCT00531856|Drug|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
482723|NCT00531856|Drug|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
482724|NCT00531843|Drug|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
482725|NCT00531843|Device|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
482726|NCT00531817|Drug|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
482727|NCT00531817|Drug|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
482728|NCT00531817|Drug|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
482729|NCT00531804|Drug|gantenerumab|Administered iv at escalating doses (7 cohorts)
482730|NCT00531791|Drug|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
482731|NCT00531791|Drug|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
482732|NCT00531765|Other|sodium bicarbonate infusion|short infusion of sodium bicarbonate
482733|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
482734|NCT00531752|Drug|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
482735|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
482736|NCT00531739|Other|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
482737|NCT00531726|Device|DBS of Cg25|
482738|NCT00531713|Drug|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
482739|NCT00531700|Other|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
482740|NCT00531700|Other|Health messages|community level health messages unrelated to the study originating exposures
482741|NCT00531687|Drug|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
482742|NCT00531687|Drug|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
482743|NCT00531687|Drug|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)~Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
482744|NCT00531674|Dietary Supplement|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
482745|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
482746|NCT00531674|Dietary Supplement|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
482747|NCT00531674|Dietary Supplement|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
482748|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
482749|NCT00531674|Dietary Supplement|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
482750|NCT00531661|Device|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
482751|NCT00531635|Drug|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
482752|NCT00531622|Drug|saredutant (SR48968)|oral administration, capsules
482753|NCT00531622|Drug|escitalopram|oral administration, capsules
482754|NCT00531622|Drug|placebo|oral administration, capsules
482755|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
482756|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
482757|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
482758|NCT00531583|Drug|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
482759|NCT00531557|Drug|Darunavir ritonavir|
482760|NCT00531544|Drug|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
482761|NCT00531518|Drug|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
482762|NCT00531518|Behavioral|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
482763|NCT00531518|Behavioral|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
482764|NCT00531492|Behavioral|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
482765|NCT00531492|Other|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
482766|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
482767|NCT00531479|Drug|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
482768|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.~Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.~Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,~OR~Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.~Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
482769|NCT00531466|Drug|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
482770|NCT00531466|Drug|Placebo|One tablet orally three times a day for 28 days
482771|NCT00531453|Drug|bortezomib, dexamethasone, and thalidomide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime)."
482772|NCT00531453|Drug|bortezomib, dexamethasone, thalidomide, and cyclophosphamide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).~Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.~Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).~Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles."
482773|NCT00531440|Drug|Everolimus (RAD001)|
482774|NCT00531427|Drug|Buprenorphine|transdermal system 10 and 20 applied for 7-day wear
482775|NCT00531427|Drug|Placebo|transdermal system (placebo) applied for 7-day wear
482776|NCT00531401|Drug|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
482777|NCT00531375|Device|Silicone hydrogel contact lens|
482778|NCT00531362|Drug|Plain aspirin|Plain aspirin 75 mg or 150 mg
482779|NCT00531349|Procedure|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
482780|NCT00531349|Drug|Sevoflurane|General anesthesia
482781|NCT00531336|Drug|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
482782|NCT00531336|Drug|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
482783|NCT00531323|Drug|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
482828|NCT00530933|Procedure|Transcutaneous tibial nerve stimulation|30 minutes once weekly
495584|NCT00434382|Drug|Alfentanil|
482784|NCT00531323|Drug|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
482785|NCT00531310|Drug|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
482786|NCT00531297|Procedure|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
482787|NCT00531284|Drug|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
482788|NCT00531284|Drug|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
482789|NCT00531271|Drug|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
482790|NCT00531258|Device|rTMS|Bilateral rTMS
482791|NCT00531258|Device|Sham rTMS|sham rTMS
482792|NCT00531245|Drug|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
482793|NCT00531232|Drug|clofarabine|Oral daily x 5 every 28 days. 25 mg/day. Up to 8 cycles
482794|NCT00531219|Procedure|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
482795|NCT00531219|Procedure|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
482796|NCT00531206|Drug|Tipranavir|
482797|NCT00531206|Drug|Ritonavir|low dose
482798|NCT00531193|Drug|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
482799|NCT00531193|Other|[11C]SCH442416|11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
482800|NCT00531180|Procedure|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
482801|NCT00531180|Procedure|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
482802|NCT00531167|Drug|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
482803|NCT00531141|Other|examination only|OCT performed twice
482804|NCT00531128|Behavioral|High/Low Sitosterol|
482805|NCT00531115|Drug|cetuximab 5mg/ml|"Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).~The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment."
482806|NCT00531102|Other|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
482807|NCT00531102|Other|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
482808|NCT00531089|Drug|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
482809|NCT00531076|Biological|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.~In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
482810|NCT00531063|Drug|Everolimus (RAD001)|
482811|NCT00531050|Drug|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
482812|NCT00531050|Drug|Placebo|Single dose indacaterol matching placebo via Concept 1 device
482813|NCT00531050|Drug|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
482814|NCT00531024|Drug|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
482815|NCT00531024|Drug|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
482816|NCT00531011|Device|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
482817|NCT00531011|Device|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
482818|NCT00530998|Procedure|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
482819|NCT00530998|Procedure|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
482820|NCT00530985|Behavioral|Benefits Counseling|Help deciding whether to work
482821|NCT00530985|Behavioral|VA Orientation|Orientation to services available at VA
482822|NCT00530972|Drug|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg <75 kg, 1200 mg >75 kg)
482823|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
482824|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
482825|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
482826|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
482827|NCT00530933|Procedure|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
482829|NCT00530933|Procedure|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
482830|NCT00530920|Drug|tipranavir|
482831|NCT00530920|Drug|ritonavir|
482832|NCT00530907|Drug|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
482833|NCT00530907|Drug|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
482834|NCT00530894|Device|Edwards SAPIEN Transcatheter Heart Valve|
482835|NCT00530894|Device|Surgical Valve Replacement|
482836|NCT00530894|Other|medical management and/or balloon aortic valvuloplasty|
482837|NCT00530881|Drug|PHX1149|
482838|NCT00530868|Other|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
482839|NCT00530868|Drug|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
482840|NCT00530855|Drug|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
482841|NCT00530842|Drug|Tiotropium plus Salmeterol|
482842|NCT00530842|Drug|Fluticasone/Salmeterol|
482843|NCT00530829|Drug|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
482844|NCT00530816|Drug|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
482845|NCT00530803|Drug|EMLA Cream|60 minutes x1
482846|NCT00530803|Combination Product|Synera Patch|20 minutes x1
482847|NCT00530790|Drug|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
482848|NCT00530777|Drug|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
482849|NCT00530777|Drug|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
482850|NCT00530764|Drug|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
482851|NCT00530764|Drug|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
482852|NCT00530764|Drug|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
482853|NCT00530751|Other|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool [GREAT]) are explored.
482854|NCT00530738|Drug|Lipoplus|i.v. fat emulsion for parenteral nutrition
482855|NCT00530738|Drug|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
482856|NCT00530725|Procedure|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
482857|NCT00530725|Other|close clinical observation|close clinical observation in an operating room or intensive care unit without active intervention
482858|NCT00530712|Device|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
482859|NCT00530699|Drug|AZD1152|intravenous
482860|NCT00530686|Drug|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
482861|NCT00530660|Biological|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
482862|NCT00530634|Drug|cisplatin|
482863|NCT00530634|Drug|gemcitabine hydrochloride|
482864|NCT00530634|Genetic|gene expression analysis|
482865|NCT00530634|Genetic|reverse transcriptase-polymerase chain reaction|
482866|NCT00530634|Other|immunohistochemistry staining method|
482867|NCT00530634|Procedure|adjuvant therapy|
482868|NCT00530634|Procedure|conventional surgery|
482869|NCT00530634|Radiation|radiation therapy|
482870|NCT00530621|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
482871|NCT00530621|Drug|placebo|oral, daily
482872|NCT00530621|Drug|pemetrexed|500 mg/m2, IV, day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
482873|NCT00530595|Drug|candesartan or valsartan or losartan|
482874|NCT00530582|Drug|progesterone|300mg progesterone /placebo each for 21 days
482875|NCT00530569|Procedure|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
482876|NCT00530556|Drug|zolpidem|
482877|NCT00530543|Procedure|Robot-assisted gait training|
482878|NCT00530530|Drug|ASP8825|oral
482879|NCT00530530|Drug|Placebo|oral
482880|NCT00530517|Device|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
482881|NCT00530504|Device|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
482882|NCT00530491|Procedure|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
482883|NCT00530478|Drug|Donepezil|
482884|NCT00530452|Drug|CG100649|Dual-acting COX-2 inhibitor & carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
482885|NCT00530452|Drug|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
482886|NCT00530439|Other|Lifestyle intervention|Dietician counselling and physical training
482887|NCT00530439|Other|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
482888|NCT00530439|Behavioral|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.~Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
482889|NCT00530413|Drug|Phenobarbital|Phenobarbital will be given based on weight range
482890|NCT00530413|Other|Placebo|Placebo group
482891|NCT00530400|Drug|cefuroxime|preoperative intravenous 1.5g cefuroxime
482892|NCT00530400|Drug|placebo|preoperative intravenous placebo
482893|NCT00530387|Drug|19 organic sunscreen filters and 5 topical NSAIDs|
482894|NCT00530374|Dietary Supplement|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
482895|NCT00530374|Dietary Supplement|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
482896|NCT00530361|Drug|Nesiritide|
482897|NCT00530348|Biological|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
482898|NCT00530348|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
482899|NCT00530335|Drug|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
482900|NCT00530322|Procedure|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
482901|NCT00530309|Drug|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
482902|NCT00530309|Drug|Placebo|Subjects will also receive placebo.
482903|NCT00530296|Behavioral|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
482904|NCT00530283|Other|PET-CT|
482905|NCT00530270|Drug|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
482906|NCT00530270|Drug|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
482907|NCT00530257|Drug|Placebo|Placebo (sugar pill)
482908|NCT00530257|Drug|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
482909|NCT00530244|Dietary Supplement|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
482910|NCT00530244|Dietary Supplement|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
482911|NCT00530218|Drug|Ganciclovir|Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
482912|NCT00530205|Other|physiologic testing|
482913|NCT00530205|Other|questionnaire administration|
482914|NCT00530205|Procedure|management of therapy complications|
482915|NCT00530205|Radiation|radiation therapy|
482916|NCT00530192|Other|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
482917|NCT00530179|Procedure|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
482918|NCT00530179|Drug|R-CHOP|6 - 21 DAY Cycles of R-CHOP
482919|NCT00530166|Drug|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
482920|NCT00530166|Drug|sham comparator|3(100 mg) tablets once daily for 12 weeks
482921|NCT00530153|Behavioral|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
482922|NCT00530153|Dietary Supplement|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
482923|NCT00530140|Biological|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
482924|NCT00530127|Drug|placebo|Same dose and frequency as treatment
482925|NCT00530127|Drug|deferiprone|100 mg/mL
482926|NCT00530127|Drug|deferiprone|100 mg/mL
482927|NCT00530127|Drug|placebo|Same dosage and frequency as study drug
482928|NCT00530127|Drug|deferiprone|100 mg/mL
482929|NCT00530114|Drug|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
483026|NCT00529412|Other|Seprafilm|two sheets per body
482930|NCT00530114|Drug|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
482931|NCT00530101|Drug|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:~Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
482932|NCT00530088|Drug|porfimer sodium|IV
482933|NCT00530088|Drug|Photdynamic Therapy (PDT)|
482934|NCT00530075|Drug|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
482935|NCT00530062|Drug|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
482936|NCT00530062|Drug|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
482937|NCT00530049|Other|questionnaire administration|
482938|NCT00530049|Procedure|assessment of therapy complications|
482939|NCT00530049|Procedure|psychosocial assessment and care|
482940|NCT00530049|Procedure|quality-of-life assessment|
482941|NCT00530023|Device|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
482942|NCT00530010|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
482943|NCT00529997|Device|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
482944|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
482945|NCT00529984|Biological|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
482946|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
482947|NCT00529984|Biological|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
482948|NCT00529984|Biological|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
482949|NCT00529971|Behavioral|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
482950|NCT00529971|Other|Control|Treatment as usual, which could include medications or psychotherapy
482951|NCT00529958|Procedure|Patellar Tendon|Patellar Tendon autograft
482952|NCT00529958|Procedure|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
482953|NCT00529958|Procedure|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
482954|NCT00529945|Device|PFx Closure System|
482955|NCT00529932|Other|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
482956|NCT00529932|Other|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
482957|NCT00529919|Dietary Supplement|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
482958|NCT00529880|Drug|Fludarabine , cytarabine|
482959|NCT00529867|Drug|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
482960|NCT00529867|Drug|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
482961|NCT00529854|Other|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
482962|NCT00529841|Drug|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
482963|NCT00529828|Procedure|Consumption of CLA enriched food|
482964|NCT00529815|Device|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
482965|NCT00529815|Device|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
482966|NCT00529802|Drug|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
482967|NCT00529789|Drug|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is >40 kg, initial dose is 30 mg, then titrated up.
482968|NCT00529776|Procedure|Continuous lateral rotation therapy|
482969|NCT00529763|Drug|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
482970|NCT00529750|Drug|IRBESARTAN|Tablets
482971|NCT00529750|Drug|Atenolol|Tablets
482972|NCT00529737|Procedure|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
483201|NCT00528112|Drug|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
482973|NCT00529737|Procedure|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
482974|NCT00529724|Behavioral|Energy metabolism by chronic bilateral subthalamic stimulation|Patients will be studied before and after STN-DBS surgery
482975|NCT00529711|Drug|Hypertonic lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
482976|NCT00529711|Drug|Ringer's lactate|"Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
482977|NCT00529698|Biological|Biologically active recombinant Tat protein|
482978|NCT00529672|Procedure|crossectomy and short stripping|under spinal or complete anaesthesia
482979|NCT00529672|Procedure|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein>
482980|NCT00529672|Procedure|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
482981|NCT00529659|Drug|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
482982|NCT00529659|Drug|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
482983|NCT00529646|Drug|APD791|
482984|NCT00529633|Drug|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
482985|NCT00529633|Other|Sugar pill|Placebo by mouth at night for a total of 24 weeks
482986|NCT00529620|Drug|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
482987|NCT00529620|Drug|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
482988|NCT00529620|Drug|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
482989|NCT00529607|Drug|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
482990|NCT00529607|Procedure|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
482991|NCT00529607|Procedure|cardiac MRI|before discharge and after 6 months
482992|NCT00529607|Procedure|blood sampling|"routine lab work plus infarction and inflammation biomarkers~1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
482993|NCT00529594|Drug|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
482994|NCT00529594|Drug|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
482995|NCT00529581|Drug|C105|
482996|NCT00529568|Drug|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
482997|NCT00529568|Drug|placebo|double-blind matched placebo control daily oral administration
482998|NCT00529555|Drug|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
482999|NCT00529555|Procedure|Scaling and root planing|scaling and root planing
483000|NCT00529542|Drug|Lipitor|40mg caplets per day for six weeks
483001|NCT00529542|Drug|Placebo|1 placebo caplet per day for six weeks.
483002|NCT00529529|Drug|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
483003|NCT00529529|Drug|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
483004|NCT00529529|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
483005|NCT00529529|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
483006|NCT00529516|Biological|Fluarix|Single dose, Intramuscular injection
483007|NCT00529516|Biological|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
483008|NCT00529503|Drug|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
483009|NCT00529503|Drug|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
483010|NCT00529503|Drug|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
483011|NCT00529503|Drug|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
483012|NCT00529503|Drug|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
483013|NCT00529503|Drug|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
483014|NCT00529490|Drug|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
483015|NCT00529490|Drug|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
483016|NCT00529477|Other|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
483017|NCT00529477|Other|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
483018|NCT00529477|Other|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
483019|NCT00529464|Procedure|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
483020|NCT00529464|Procedure|Colposcopy|A standard colposcopy will be performed.
483021|NCT00529464|Procedure|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
483022|NCT00529451|Drug|Aliskiren|Aliskiren
483023|NCT00529451|Drug|Ramipril|comparator
483024|NCT00529438|Drug|Bardoxolone methyl|
483025|NCT00529425|Drug|Ropivacaine|
483027|NCT00529399|Drug|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
483028|NCT00529399|Drug|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
483029|NCT00529399|Drug|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
483030|NCT00529386|Drug|Botox|300 units
483031|NCT00529373|Drug|Odanacatib|50 mg tablet orally once weekly (OW)
483032|NCT00529373|Drug|Placebo for Odanacatib|50 mg tablet orally OW
483033|NCT00529373|Dietary Supplement|Vitamin D3|5600 IU orally OW
483034|NCT00529373|Dietary Supplement|Calcium carbonate|If needed. Total daily calcium intake (from both dietary and supplemental sources) will be approximately 1200 mg but not to exceed 1600 mg
483035|NCT00529360|Drug|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
483036|NCT00529360|Drug|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
483037|NCT00529347|Device|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
483038|NCT00529334|Radiation|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
483039|NCT00529321|Biological|MVA-HCV (Immunotherapy)|MVA-HCV
483040|NCT00529308|Device|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
483041|NCT00529308|Device|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
483042|NCT00529295|Drug|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
483043|NCT00529282|Drug|Ceftobiprole Medocaril|500 mg every 8 hours
483044|NCT00529282|Drug|Cefepime with or without vancomycin|120-minute infusion [250 mL]
483045|NCT00529269|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
483046|NCT00529256|Behavioral|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
483047|NCT00529243|Drug|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
483048|NCT00529230|Behavioral|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
483049|NCT00529230|Other|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
483050|NCT00529217|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
483051|NCT00529204|Drug|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
483052|NCT00529191|Drug|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
483053|NCT00529191|Other|Placebo|One out of three subjects will receive a placebo.
483054|NCT00529178|Drug|Pravastatin|
483055|NCT00529165|Procedure|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:~Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes~Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval~Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
483056|NCT00529152|Drug|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
483057|NCT00529139|Device|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
483058|NCT00529139|Device|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. <90 mg/dL (<15 mmol/L)
483059|NCT00529126|Drug|SKY0402|SKY0402
483060|NCT00529126|Drug|Bupivacaine HCl|Bupivacaine HCl
483061|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
483062|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
483063|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
483064|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
483065|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
483066|NCT00529113|Drug|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
483067|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
483068|NCT00529113|Drug|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
483069|NCT00529113|Drug|Placebo|Placebo capsules x 28 days
483202|NCT00528112|Drug|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
483070|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
483071|NCT00529100|Drug|Pemetrexed Phase 1|300 mg/m^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m^2 IV; then 500 mg/m^2 IV, repeated every 21 days (q 21 days) x 2 cycles
483072|NCT00529100|Drug|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m^2 IV, Days 1-3 and 22-24 then 75 mg/m^2 IV, q21 days x 2 cycles~Cohort 4 carried into Phase 2: 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles."
483073|NCT00529100|Procedure|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
483074|NCT00529100|Drug|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22.
483075|NCT00529100|Drug|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.
483076|NCT00529087|Drug|N-methylnaltrexone bromide (MOA-728)|Subcutaneous
483077|NCT00529087|Other|placebo|placebo
483078|NCT00529074|Device|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
483079|NCT00529048|Other|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
483080|NCT00529048|Other|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
483081|NCT00529048|Other|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
483082|NCT00529035|Drug|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
483083|NCT00529022|Drug|Azacitidine|75 mg/m^2 Subcutaneous Injection or by vein Daily for 5 Days.
483084|NCT00529022|Drug|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
483085|NCT00529022|Drug|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
483086|NCT00529009|Drug|UDCA|
483087|NCT00528996|Drug|BEA 2180 BR|
483088|NCT00528996|Drug|tiotropium|
483089|NCT00528983|Drug|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
483090|NCT00528983|Drug|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
483091|NCT00528983|Drug|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
483092|NCT00528970|Drug|MOA-728|MOA-728 will be administered per the dose and schedule specified in the arm.
483093|NCT00528970|Drug|Placebo|Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
483094|NCT00528957|Drug|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants > 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to > 37 kg may be switched from the oral powder to the tenofovir DF tablet.
483095|NCT00528957|Drug|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry (pediatric participants < 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
483096|NCT00528957|Drug|Stavudine|Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m^2 every 8 hours; pediatric participants > 12 years of age: 300 mg twice daily).
483097|NCT00528931|Biological|collagenase clostridium histolyticum|Single dose of AA4500 0.58 mg into the cord
483098|NCT00528918|Drug|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
483099|NCT00528905|Drug|AZD3480|oral capsule
483100|NCT00528892|Drug|Raltegravir|switching PI to raltegravir
483101|NCT00528892|Drug|boosted PI|continue on boosted-PI
483102|NCT00528879|Drug|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
483103|NCT00528879|Drug|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
483104|NCT00528879|Drug|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
483105|NCT00528866|Drug|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
483106|NCT00528866|Drug|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
483107|NCT00528866|Drug|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
483108|NCT00528866|Drug|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
483109|NCT00528866|Radiation|3-dimensional conformal radiation therapy|
483248|NCT00527696|Procedure|transvaginal obturator tape|
483110|NCT00528866|Radiation|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
483111|NCT00528840|Biological|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
483112|NCT00528827|Drug|Cardene® I.V.|"5 mcg/kg/min Cardene I.V.~2.5 mcg/kg/min Cardene I.V.~0.5 mcg/kg/min Cardene I.V."
483113|NCT00528814|Other|Active Hand Sanitizer|Active Hand Sanitizer
483114|NCT00528801|Behavioral|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
483115|NCT00528801|Procedure|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
483116|NCT00528788|Drug|doxercalciferol|
483117|NCT00528775|Drug|HPPH|4 mg/m2 IV
483118|NCT00528775|Procedure|endoscopic procedure|Treatment with 150 joules from laser
483119|NCT00528762|Behavioral|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
483120|NCT00528749|Other|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
483121|NCT00528723|Drug|salbutamol 100 mcg|To be used as needed for symptom relief
483122|NCT00528723|Drug|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
483123|NCT00528723|Drug|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
483124|NCT00528710|Dietary Supplement|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
483125|NCT00528697|Drug|ABT-089|Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
483126|NCT00528697|Drug|atomoxetine|Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
483127|NCT00528697|Drug|placebo|Subject will take a tablet once daily for 8 weeks
483128|NCT00528684|Biological|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
483129|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
483130|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
483131|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
483132|NCT00528658|Drug|Paracetamol|1g qid
483133|NCT00528658|Drug|Ibuprofen|400mg tid
483134|NCT00528658|Drug|Paracetamol Placebo|equivalent to 1g qid
483135|NCT00528658|Drug|Ibuprofen placebo|Equivalent to 400mg tid
483136|NCT00528645|Drug|saracatinib|Given orally
483137|NCT00528632|Other|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
483138|NCT00528619|Drug|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg*min/mL until progression or unacceptable toxicity.
483139|NCT00528606|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
483140|NCT00528606|Biological|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
483141|NCT00528593|Drug|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
483142|NCT00528580|Drug|Simvastatin|80 mg once daily PO/NG x 4 days
483143|NCT00528580|Drug|Identical-appearing placebo|once daily x 4 days
483144|NCT00528567|Drug|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
483145|NCT00528567|Drug|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
483146|NCT00528554|Procedure|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
483147|NCT00528554|Procedure|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
483148|NCT00528541|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
483149|NCT00528541|Biological|botulinum toxin type A|750 Units at Visit 1 (Day 1)
483150|NCT00528528|Drug|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
483151|NCT00528528|Drug|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
483152|NCT00528528|Drug|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
483153|NCT00528528|Drug|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
483154|NCT00528528|Drug|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
483155|NCT00528515|Drug|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
483156|NCT00528515|Drug|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
483157|NCT00528502|Drug|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
483158|NCT00528502|Drug|Saline|Saline is misted into the air that you breathe during the surgery.
483159|NCT00528489|Biological|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
483160|NCT00528489|Biological|IL-12|Cytokine injection
483161|NCT00528489|Biological|IL-15|Cytokine injection
483162|NCT00528463|Procedure|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
483163|NCT00528450|Drug|arsenic trioxide|
483164|NCT00528450|Drug|idarubicin|
483165|NCT00528450|Drug|tretinoin|
483166|NCT00528437|Drug|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
483167|NCT00528424|Biological|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
483168|NCT00528411|Drug|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
483169|NCT00528411|Drug|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
483170|NCT00528411|Drug|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
483171|NCT00528398|Drug|cytarabine|
483172|NCT00528398|Drug|idarubicin|
483173|NCT00528385|Drug|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
483174|NCT00528372|Drug|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
483175|NCT00528372|Drug|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
483176|NCT00528372|Drug|Metformin|
483177|NCT00528359|Drug|quetiapine or olanzapine or risperidone or aripiprazole|
483178|NCT00528346|Behavioral|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies—allowing them to view their brain activity.
483179|NCT00528346|Behavioral|placebo|Some participants will see simulated data that does not come from their own brains.
483180|NCT00528333|Drug|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
483181|NCT00528333|Drug|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
483182|NCT00528333|Drug|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
483183|NCT00528320|Device|Ovatio CRT|
483184|NCT00528307|Device|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
483185|NCT00528294|Radiation|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
483186|NCT00528281|Drug|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
483187|NCT00528281|Drug|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
483188|NCT00528268|Drug|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
483189|NCT00528255|Drug|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
483190|NCT00528242|Drug|SLx-2101|
483191|NCT00528242|Drug|Placebo|
483192|NCT00528229|Radiation|Computer Tomography|
483193|NCT00528216|Drug|Capsaicin Dermal Liquid|
483194|NCT00528190|Drug|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
483195|NCT00528177|Drug|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.~The patients will use the PCA until the next morning."
483196|NCT00528164|Behavioral|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
483197|NCT00528151|Drug|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
483198|NCT00528138|Other|Laboratory Test|CRP, white blood cell count, hepatic function tests
483199|NCT00528125|Procedure|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
483200|NCT00528125|Procedure|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
484575|NCT00517439|Drug|Pegasys|180 micrograms sc weekly for 24 weeks
483203|NCT00528099|Drug|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
483204|NCT00528073|Drug|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
483205|NCT00528060|Drug|Atazanavir|2pills/day
483206|NCT00528060|Drug|Ritonavir|1 pill/day
483207|NCT00528060|Drug|Tenofovir/emtricitabine|1 pill/day
483208|NCT00528047|Drug|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
483209|NCT00528034|Procedure|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
483210|NCT00528021|Drug|Placebo|Vehicle Only
483211|NCT00528021|Drug|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
483212|NCT00528008|Other|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
483213|NCT00528008|Other|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
483214|NCT00527995|Drug|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
483215|NCT00527982|Drug|Celecoxib|600 mg by mouth daily for a total of 12 months.
483216|NCT00527969|Drug|HT1001 extract of Panax quinquefolius L|
483217|NCT00527943|Drug|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
483218|NCT00527943|Drug|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
483219|NCT00527930|Drug|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week~Number of Cycles: until progression or unacceptable toxicity"
483220|NCT00527917|Device|placebo|bladder instillation
483221|NCT00527917|Device|Uracyst|20 ml sterile solution for weekly intravesical instillation
483222|NCT00527904|Drug|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
483223|NCT00527904|Drug|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
483224|NCT00527891|Procedure|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
483225|NCT00527878|Drug|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
483226|NCT00527878|Drug|Placebo|
483227|NCT00527865|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
483228|NCT00527865|Drug|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
483229|NCT00527852|Device|Flocked swab|
483230|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
483231|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
483232|NCT00527813|Procedure|prone position|prone position for at least 16 hours per day
483233|NCT00527800|Drug|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
483234|NCT00527800|Drug|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
483235|NCT00527800|Drug|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
483236|NCT00527787|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
483237|NCT00527787|Drug|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
483238|NCT00527761|Drug|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
483239|NCT00527761|Drug|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
483240|NCT00527761|Drug|Temodar|150 mg by mouth (PO) on Days 1 - 5.
483241|NCT00527748|Device|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
483242|NCT00527735|Drug|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
483243|NCT00527735|Drug|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
483244|NCT00527735|Drug|Paclitaxel|175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
483245|NCT00527735|Drug|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
483246|NCT00527722|Device|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
483247|NCT00527722|Other|No lung plug|Standard lung biopsy without placement of the plug.
483249|NCT00527683|Drug|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
483250|NCT00527683|Drug|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
483251|NCT00527683|Behavioral|Group therapy|Participants attend group sessions once a week
483252|NCT00527670|Procedure|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
483253|NCT00527670|Procedure|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
483254|NCT00527657|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
483255|NCT00527657|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
483256|NCT00527657|Drug|Thalidomide|200 mg/m^2 by mouth daily.
483257|NCT00527644|Device|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
483258|NCT00527631|Radiation|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
483259|NCT00527618|Drug|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
483260|NCT00527618|Drug|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
483261|NCT00527605|Drug|Dutasteride 0.5mg capsule|Dutasteride 0.5mg once daily orally
483262|NCT00527605|Drug|Dutasteride matched placebo|Dutasteride matched placebo once daily orally
483263|NCT00527592|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
483264|NCT00527592|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
483265|NCT00527579|Drug|[F-18]FBR|
483266|NCT00527566|Biological|Mepolizumab|IV mepolizumab, 750 mg
483267|NCT00527553|Dietary Supplement|not enriched egg|daily consumption of a regular egg, not enriched with either lutien nor zeaxanthin
483268|NCT00527553|Dietary Supplement|lutein|daily lutein enriched egg
483269|NCT00527553|Dietary Supplement|zeaxanthin|daily zeaxanthin enriched egg
483270|NCT00527553|Dietary Supplement|egg product from enriched eggs|daily egg product from lutein enriched eggs
483271|NCT00527540|Drug|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
483272|NCT00527527|Procedure|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
483273|NCT00527527|Other|placebo control|Placebo for comparison with flexion distraction treatment
483274|NCT00527514|Drug|Amlodipine|Tablets
483275|NCT00527514|Drug|Olmesartan medoxomil plus amlodipine|Tablets
483276|NCT00527501|Drug|Travoprost/brinzolamide|
483277|NCT00527488|Drug|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
483278|NCT00527488|Drug|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
483279|NCT00527488|Drug|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
483280|NCT00527488|Drug|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
483281|NCT00527475|Drug|ranibizumab|0.5 mg. given as an intraocular injection
483282|NCT00527475|Drug|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
483283|NCT00527462|Procedure|Bronchoscopy|bronchoscopy with segmental allergen challenge
483284|NCT00527462|Other|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
483285|NCT00527449|Drug|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
483286|NCT00527436|Dietary Supplement|fish oil|Fish oil pills will be taken daily for 12 weeks
483287|NCT00527436|Dietary Supplement|Placebo|Placebo (corn oil) will be taken daily for 12 weeks
483288|NCT00527423|Drug|VEGF Trap Eye|Intravitreal injection
483289|NCT00527410|Drug|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
483290|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
483291|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
483292|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
483293|NCT00527371|Device|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
483294|NCT00527371|Procedure|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
483334|NCT00527085|Drug|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
483335|NCT00527072|Biological|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
483336|NCT00527059|Drug|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
483337|NCT00527059|Drug|spironolactone, beta-blockers,ecc|
483338|NCT00527046|Drug|CP-424,391|
483295|NCT00527358|Behavioral|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;~youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;~school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;~Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
483296|NCT00527332|Drug|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
483297|NCT00527332|Drug|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
483298|NCT00527332|Drug|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
483299|NCT00527332|Drug|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
483300|NCT00527332|Drug|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
483301|NCT00527332|Drug|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
483302|NCT00527332|Drug|Morphine|5 mg is given IV (intravenously) before end of surgery
483303|NCT00527319|Drug|VT-122 low dose|VT-122 low dose, dose escalated
483304|NCT00527319|Drug|VT-122 high dose|VT-122 high dose, dose escalated
483305|NCT00527306|Dietary Supplement|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
483306|NCT00527293|Procedure|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
483307|NCT00527293|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
483308|NCT00527293|Radiation|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
483309|NCT00527280|Procedure|Feasibility ot face transplantation|Feasibility ot face transplantation
483310|NCT00527267|Drug|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
483311|NCT00527267|Drug|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
483312|NCT00527254|Device|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
483313|NCT00527241|Behavioral|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
483314|NCT00527228|Drug|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
483315|NCT00527228|Drug|placebo|
483316|NCT00527215|Drug|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
483317|NCT00527202|Drug|botulinum toxin A and saline|
483318|NCT00527189|Behavioral|Balance Exercises|Home based balance exercises based on Otago Exercise programme
483319|NCT00527150|Drug|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
483320|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
483321|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
483322|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
483323|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
483324|NCT00527137|Drug|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
483325|NCT00527137|Drug|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
483326|NCT00527124|Drug|cediranib maleate|Given orally
483327|NCT00527124|Drug|docetaxel|Given IV
483328|NCT00527124|Drug|prednisone|Given orally
483329|NCT00527124|Other|laboratory biomarker analysis|Correlative studies
483330|NCT00527111|Drug|Cetuximab|
483331|NCT00527111|Drug|5-fluorouracil|
483332|NCT00527111|Radiation|Pelvic irradiation|
483333|NCT00527085|Drug|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
483341|NCT00527020|Drug|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
483342|NCT00527020|Drug|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
483343|NCT00527020|Drug|Placebo|Placebo tablets will be given to the subjects.
483344|NCT00527007|Other|External cooling|External cooling
483345|NCT00526994|Other|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
483346|NCT00526994|Behavioral|universal education|receives referral information
483347|NCT00526981|Other|Prone position|Prone position during spontaneous breathing.
483348|NCT00526968|Drug|EVT 101|8 mg capsule, single oral dose
483349|NCT00526968|Drug|EVT 101|15 mg capsule, single oral dose
483350|NCT00526968|Drug|placebo|Placebo capsule, single oral dose
483351|NCT00526942|Behavioral|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
483352|NCT00526929|Drug|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
483353|NCT00526916|Drug|[C-11]PBR28|
483354|NCT00526903|Behavioral|Elimination Diet|Daily diet change for 8 days.
483355|NCT00526890|Dietary Supplement|selenomethionine|Oral Twice daily
483356|NCT00526890|Drug|carboplatin|Weekly IV
483357|NCT00526890|Drug|paclitaxel|Weekly IV
483358|NCT00526890|Other|laboratory biomarker analysis|Correlative Study
483359|NCT00526890|Radiation|radiation therapy|Undergoing radiation Therapy
483360|NCT00526877|Drug|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
483361|NCT00526851|Other|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
483362|NCT00526838|Drug|XL228|1-hour IV infusion
483363|NCT00526812|Drug|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
483364|NCT00526812|Drug|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
483365|NCT00526799|Drug|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD~Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
483366|NCT00526799|Drug|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
483367|NCT00526786|Device|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
483368|NCT00526773|Other|telephone management plus a motivational intervention|heart failure intervention
483369|NCT00526773|Other|telephone management with standard patient education|heart failure intervention
483370|NCT00526760|Drug|Dexmedetomidine|
483371|NCT00526734|Biological|filgrastim|
483372|NCT00526734|Biological|pegfilgrastim|
483373|NCT00526734|Drug|melphalan|
483374|NCT00526734|Procedure|autologous hematopoietic stem cell transplantation|
483375|NCT00526695|Drug|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
483376|NCT00526682|Dietary Supplement|Irvingia/cissus combo|
483377|NCT00526669|Drug|Lapatinib and Capecitabine|oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
483378|NCT00526656|Drug|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
483379|NCT00526643|Drug|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
483380|NCT00526643|Drug|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
483381|NCT00526630|Drug|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
483382|NCT00526630|Drug|Placebo|Participants will be given placebo instead of active MPD.
483383|NCT00526617|Drug|ABT-888|Oral capsules
483384|NCT00526617|Drug|Temozolomide|Oral capsules
483385|NCT00526604|Behavioral|work related rehabilitation|"The workplace intervention includes two steps:~Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.~Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
483386|NCT00526591|Drug|Everolimus|Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week
483387|NCT00526591|Procedure|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
483388|NCT00526578|Behavioral|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
483434|NCT00526318|Procedure|autologous hematopoietic stem cell transplantation|
483435|NCT00526318|Radiation|iobenguane I 131|
483436|NCT00526318|Radiation|radiation therapy|
483437|NCT00526305|Drug|Vincristine|1,5 mg/m2 i.v., days 1 and 8
483438|NCT00526305|Drug|Daunorubicin|60 mg/m2, i.v., days 1 and 8
483439|NCT00526305|Drug|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
483440|NCT00526305|Drug|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
483441|NCT00526305|Drug|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
483389|NCT00526565|Behavioral|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
483390|NCT00526565|Behavioral|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
483391|NCT00526539|Other|Total hip replacement, Spectron and Taperloc|
483392|NCT00526513|Drug|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
483393|NCT00526500|Behavioral|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
483394|NCT00526487|Device|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
483395|NCT00526487|Device|Endovascular Repair|Endovascular Repair
483396|NCT00526474|Drug|Vorapaxar|2.5-mg tablet daily for at least 1 year
483397|NCT00526474|Drug|Placebo|matching tablet daily for at least 1 year
483398|NCT00526461|Drug|HPPH|IV
483399|NCT00526448|Drug|ribavirin|2000 mg/day
483400|NCT00526448|Drug|ribavirin|1000-1200 mg/day
483401|NCT00526448|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
483402|NCT00526448|Drug|epoetin beta|epoetin beta 450 UI/week
483403|NCT00526435|Behavioral|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
483404|NCT00526435|Behavioral|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
483405|NCT00526422|Procedure|Dental Preventive|
483406|NCT00526409|Drug|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
483407|NCT00526409|Drug|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
483408|NCT00526409|Drug|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
483409|NCT00526409|Drug|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
483410|NCT00526409|Drug|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
483411|NCT00526409|Drug|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
483412|NCT00526409|Drug|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
483413|NCT00526396|Drug|cisplatin|80 mg/m2 on day 1 for 6 cycles
483414|NCT00526396|Drug|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
483415|NCT00526396|Drug|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
483416|NCT00526396|Drug|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
483417|NCT00526383|Drug|Tricyclic antidepressants|antidepressant version medical dispositive
483418|NCT00526357|Drug|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
483419|NCT00526331|Device|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
483420|NCT00526331|Device|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
483421|NCT00526318|Biological|filgrastim|
483422|NCT00526318|Drug|carboplatin|
483423|NCT00526318|Drug|cisplatin|
483424|NCT00526318|Drug|cyclophosphamide|
483425|NCT00526318|Drug|dacarbazine|
483426|NCT00526318|Drug|doxorubicin hydrochloride|
483427|NCT00526318|Drug|etoposide phosphate|
483428|NCT00526318|Drug|ifosfamide|
483429|NCT00526318|Drug|isotretinoin|
483430|NCT00526318|Drug|melphalan|
483431|NCT00526318|Drug|topotecan hydrochloride|
483432|NCT00526318|Drug|vincristine sulfate|
483442|NCT00526305|Drug|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
483443|NCT00526305|Drug|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
483444|NCT00526305|Drug|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
483445|NCT00526305|Drug|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
483446|NCT00526305|Drug|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
483447|NCT00526292|Biological|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
483448|NCT00526292|Drug|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
483449|NCT00526292|Drug|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
483450|NCT00526266|Behavioral|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
483451|NCT00526266|Behavioral|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
483452|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
483453|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
483454|NCT00526253|Procedure|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
483455|NCT00526227|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator will be implanted
483456|NCT00526214|Drug|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
483457|NCT00526201|Behavioral|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
483458|NCT00526201|Behavioral|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
483459|NCT00526188|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
483460|NCT00526175|Drug|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
483461|NCT00526175|Drug|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
483462|NCT00526175|Drug|Daunorubicin|30 mg/m2, i.v., days 8 and 15
483463|NCT00526175|Drug|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
483464|NCT00526175|Drug|Cyclophosphamide|1000 mg/m2, i.v., day 22.
483465|NCT00526175|Drug|Methotrexate|Age <1 year 1-2 years 2-3 years > 3 years MTX 5 mg 8 mg 10 mg 12 mg
483466|NCT00526175|Drug|Cytosine Arabinoside|Edad <1 year 1-2 years 2-3 years > 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
483467|NCT00526175|Drug|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
483468|NCT00526175|Drug|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
483469|NCT00526162|Device|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
483470|NCT00526149|Drug|BI 2536|
483471|NCT00526149|Other|high performance liquid chromatography|
483472|NCT00526149|Other|mass spectrometry|
483473|NCT00526149|Other|pharmacological study|
483474|NCT00526136|Drug|Placebo|
483475|NCT00526136|Drug|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
483476|NCT00526123|Device|Symmetric Tip Catheter|Dialysis catheter
483477|NCT00526123|Device|Conventional Split-tip Catheter|Dialysis Catheter
483478|NCT00526110|Drug|5-Fluorouracil|2.2 Gm/m^2 IV over 48 hours on Day 1.
483479|NCT00526110|Drug|Docetaxel|20 mg/m^2 IV over 60 minutes
483480|NCT00526110|Drug|Oxaliplatin|85 mg/m^2 IV over 120 minutes on Day 1.
483481|NCT00526097|Drug|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
483482|NCT00526097|Drug|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
483483|NCT00526071|Drug|migalastat HCl|
483484|NCT00526058|Device|Secura then Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
483485|NCT00526058|Device|Futura then Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
483486|NCT00526045|Drug|AUY922|
483487|NCT00526032|Procedure|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
483488|NCT00526006|Drug|esomeprazole|40 mg od for 8 wks
483489|NCT00525993|Drug|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
483490|NCT00525993|Drug|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
483491|NCT00525980|Behavioral|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.~Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
483492|NCT00525980|Behavioral|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
483493|NCT00525980|Other|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
483534|NCT00525733|Drug|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
483494|NCT00525980|Behavioral|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
483495|NCT00525967|Drug|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
483496|NCT00525954|Drug|A-002|
483497|NCT00525941|Drug|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
483498|NCT00525928|Drug|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
483499|NCT00525915|Drug|5-Fluorouracil|"Arm A = 250 mg/m^2 IV over 24 hours for 5 days weekly for 5 weeks.~Arm B = 2.2 mg/m^2 IV over 48 hours on days 1 and 15."
483500|NCT00525915|Drug|Oxaliplatin|"Arm A: 40 mg/m^2 IV daily over 2 hours for 5 weeks~Arm B: 100 mg/m^2 IV on Day 1 and 15"
483501|NCT00525915|Radiation|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
483502|NCT00525915|Procedure|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
483503|NCT00525902|Drug|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
483504|NCT00525889|Drug|IL-2|Administered by subcutaneous injection at a dose of 4.5x10^6 IU/day, three times weekly for 28 days starting on day 0.
483505|NCT00525889|Drug|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
483506|NCT00525876|Drug|Cyclophosphamide|"Matched Donors:~750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~Unrelated or Mismatched Donors:~1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
483507|NCT00525876|Drug|Fludarabine|"30 mg/m^2 given intravenously on Days -5 and -3 before transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
483508|NCT00525876|Drug|Rituximab|"Matched Donors:~375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.~Unrelated/Mismatched Donors:~375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)~For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m^2 given intravenously, then 1000 mg/m^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.~DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:~375 mg/m^2 then 1000 mg/m^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
483509|NCT00525876|Drug|Alemtuzumab|"Unrelated/Mismatched Donors:~15 mg per day given intravenously days 1 through 3 after transplantation.~(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
483510|NCT00525876|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells.
483511|NCT00525863|Drug|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to ~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
483512|NCT00525850|Other|high fat diet|high saturated fat no starch diet
483513|NCT00525850|Other|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
483514|NCT00525837|Drug|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
483515|NCT00525837|Drug|varenicline|up to 1 mg twice daily
483516|NCT00525824|Drug|Rosuvastatin (Crestor)|10mg and 20 mg
483517|NCT00525824|Drug|Ezetimibe|10 mg
483518|NCT00525824|Drug|Simvastatin|40mg and 80 mg
483519|NCT00525811|Other|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
483520|NCT00525811|Other|patient information|Information on acute low back pain, information on depression
483521|NCT00525798|Drug|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
483522|NCT00525798|Drug|SMC021 Placebo|SMC021 - Placebo, once daily
483523|NCT00525785|Drug|5-Fluorouracil|"2.2 Gm/m^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
483524|NCT00525785|Drug|Folinic Acid|200 mg/m^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
483525|NCT00525785|Drug|Oxaliplatin|"100 mg/m^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.~Chemoradiotherapy: 45 mg/m2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
483526|NCT00525785|Radiation|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
483527|NCT00525772|Drug|ciclesonide|low dose- 50ug and 200ug
483528|NCT00525772|Drug|ciclesonide|high dose- 100ug and 400ug
483529|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
483530|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
483531|NCT00525746|Behavioral|Interview|Interview lasting about 50 minutes.
483532|NCT00525733|Drug|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
483533|NCT00525733|Drug|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
483535|NCT00525733|Drug|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
483536|NCT00525733|Drug|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
483537|NCT00525720|Procedure|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
483538|NCT00525720|Behavioral|Questionnaire|Questionnaires taking 30 total minutes.
483539|NCT00525707|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
483540|NCT00525694|Other|Glucose tolerance test|10 ounces glucose tolerance test solution
483541|NCT00525694|Other|glucose tolerance test solution|75 grams glucose load
483542|NCT00525694|Other|Diet Coke|10 ounces of Diet Coke
483543|NCT00525694|Other|Coke Zero|10 ounces of Coke Zero
483544|NCT00525681|Drug|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
483545|NCT00525681|Drug|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
483546|NCT00525668|Drug|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
483547|NCT00525668|Drug|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
483548|NCT00525655|Behavioral|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
483549|NCT00525655|Behavioral|Questionnaire|Questionnaires taking 10-15 minutes to complete.
483550|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
483551|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
483552|NCT00525629|Dietary Supplement|Walnuts|48 Grams of Walnuts Daily
483553|NCT00525629|Dietary Supplement|Control|Control Diet with No Walnuts
483554|NCT00525616|Drug|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
483555|NCT00525603|Drug|Cyclophosphamide|200 mg/m^2/day 3-5 IV 5-30 minutes
483556|NCT00525603|Drug|Fludarabine|20 mg/m^2/day 3-5 IV 5-30 minutes
483557|NCT00525603|Drug|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
483558|NCT00525603|Drug|Rituximab|375 mg/m^2/day 2 IV 4-6 hours
483559|NCT00525590|Drug|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
483560|NCT00525577|Drug|Placebo|Placebo tablet, once daily
483561|NCT00525577|Drug|AGI-1067|75 mg AGI-1067 tablet, once daily
483562|NCT00525577|Drug|AGI-1067|150 mg AGI-1067 Tablet, once daily
483563|NCT00525564|Drug|Placebo|Placebo diskus inhalation powder
483564|NCT00525564|Drug|Salmeterol diskus inhalation powder|50 micrograms twice a day
483565|NCT00525551|Drug|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
483566|NCT00525551|Drug|Placebo (NaCl)|300 mL 0.9% NaCl
483567|NCT00525538|Radiation|conformal radiotherapy|
483568|NCT00525525|Drug|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
483569|NCT00525525|Drug|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
483570|NCT00525525|Drug|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
483571|NCT00525512|Drug|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
483572|NCT00525512|Drug|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
483573|NCT00525499|Drug|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
483574|NCT00525499|Drug|placebo|vehicle control applied topically twice daily for 12 weeks
483575|NCT00525486|Drug|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
483576|NCT00525473|Drug|Azathioprine|azathioprine usual dosage 100mg per day
483577|NCT00525460|Behavioral|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
483578|NCT00525447|Drug|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
483579|NCT00525447|Drug|lenalidomide|Up to 25 mg daily of a 21-day cycle.
483580|NCT00525447|Drug|dexamethasone|40 mg administered weekly.
483581|NCT00525434|Device|Seraffix LTB|wounds closure by using laser and albumin
483582|NCT00525421|Drug|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
483583|NCT00525421|Drug|Placebo|
483584|NCT00525408|Biological|Mycobacterium w.|Immunomodulator
483585|NCT00525408|Drug|Docetaxel|Chemotherapeutic agent
483586|NCT00525395|Genetic|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
483587|NCT00525395|Procedure|Continuous phototherapy|Group B: 6 months non-stop treatment.
483588|NCT00525382|Drug|levocetirizine dihydrochloride|
483589|NCT00525356|Device|Medtronic Talent Stent-Graft-System|
483932|NCT00522418|Drug|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
495585|NCT00434382|Drug|Remifentanil|
483590|NCT00525330|Drug|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
483591|NCT00525330|Drug|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
483592|NCT00525330|Drug|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
483593|NCT00525317|Drug|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
483594|NCT00525304|Behavioral|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
483595|NCT00525291|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
483596|NCT00525291|Device|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
483597|NCT00525278|Drug|Levocetirizine dihydrochloride|
483598|NCT00525265|Drug|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
483599|NCT00525265|Drug|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
483600|NCT00525252|Drug|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
483601|NCT00525252|Drug|placebo|Placebo will be orally administered for 12 consecutive weeks
483602|NCT00525239|Drug|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
483603|NCT00525213|Drug|Rob 803|two capsules per day during 12 weeks
483604|NCT00525213|Drug|Placebo|two capsules per day during 12 weeks
483605|NCT00525200|Drug|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"
483606|NCT00525200|Drug|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
483607|NCT00525174|Device|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
483608|NCT00525174|Device|Patching|2 hours daily patching of the sound eye
483609|NCT00525174|Procedure|Near activities|one hour near visual activities
483610|NCT00525161|Drug|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
483611|NCT00525148|Drug|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
483612|NCT00525135|Drug|Valproic Acid|"OUTLINE: This is a pilot study.~Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.~Quality of life is assessed at the end of every week through a study diary.~Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months."
483613|NCT00525109|Other|No Intervention|No intervention
483614|NCT00525096|Drug|placebo|2 tablets twice a day per os
483615|NCT00525096|Drug|Celecoxib|2*200 mg tablets twice a day per os
483616|NCT00525096|Drug|Exemestane|Exemestane 25 mg per day per os
483617|NCT00525057|Drug|Dalteparin|Given SC
483618|NCT00525044|Drug|Ambroxol|
483619|NCT00525044|Drug|Placebo|
483620|NCT00525031|Drug|Temozolomide (TMZ)|150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
483621|NCT00525031|Drug|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
483622|NCT00525018|Device|contact heat evoked potential stimulator|
483623|NCT00525005|Drug|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
483624|NCT00524966|Procedure|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
483625|NCT00524953|Device|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last ~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
483626|NCT00524940|Biological|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
483627|NCT00524927|Drug|Methoxyflurane|
483628|NCT00524927|Drug|Normal Saline|
483629|NCT00524914|Drug|apomorphine|Acute apomorphine subcutaneous 3 mg
483630|NCT00524914|Drug|placebo|placebo subcutaneous
483631|NCT00524901|Drug|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
483632|NCT00524901|Drug|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
483633|NCT00524888|Procedure|suturing laceration|suturing simple lacerations of the hand
483634|NCT00524888|Procedure|bioadhesive|using bioadhesive on simple lacerations of the hand
483635|NCT00524875|Drug|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
483636|NCT00524862|Drug|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
483637|NCT00524862|Device|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
483638|NCT00524849|Biological|Zoledronic acid|Zometa 1 mg weekly (intravenous)
483639|NCT00524849|Drug|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
483640|NCT00524836|Drug|levocetirizine dihydrochloride|
483641|NCT00524810|Drug|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
483642|NCT00524810|Drug|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
483643|NCT00524797|Dietary Supplement|Profonycia|
483644|NCT00524784|Biological|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
483645|NCT00524758|Device|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
483646|NCT00524758|Drug|MMC in Trabeculectomy|MMC in Trabeculectomy
483647|NCT00524745|Biological|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
483648|NCT00524732|Biological|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
483649|NCT00524719|Procedure|Open Reduction and Internal Fixation|Fixation with volar locked plate
483650|NCT00524719|Procedure|Non-Spanning External Fixation|Radio-radial external fixation
483651|NCT00524719|Procedure|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
483652|NCT00524706|Drug|S-1, oral Leucovorin, Oxaliplatin|
483653|NCT00524693|Drug|Montelukast|4mg sachets
483654|NCT00524693|Drug|Placebo granules|
483655|NCT00524680|Dietary Supplement|cholecalciferol|Given orally
483656|NCT00524667|Drug|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
483657|NCT00524654|Procedure|HVLA chiropractic manipulation|
483658|NCT00524615|Drug|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
483659|NCT00524602|Procedure|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
483660|NCT00524589|Dietary Supplement|calcitriol|IV
483661|NCT00524589|Drug|dexamethasone|Oral
483662|NCT00524589|Genetic|protein expression analysis|Correlative Study
483663|NCT00524589|Other|laboratory biomarker analysis|Correlative Study
483664|NCT00524576|Biological|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
483665|NCT00524550|Dietary Supplement|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
483666|NCT00524524|Drug|ARQ 501|Weekly IV Infusion; 450 mg/m2
483667|NCT00524511|Device|Surgical skin staples|Standard method to close abdominal surgical wounds
483668|NCT00524511|Device|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
483669|NCT00524498|Drug|OPC-18|OPC-18: 500IU * 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
483670|NCT00524498|Drug|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
483671|NCT00524485|Drug|aminolevulinic acid|
483672|NCT00524485|Procedure|laser therapy|
483673|NCT00524472|Other|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
483674|NCT00524472|Other|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
483675|NCT00524459|Drug|docetaxel|
483676|NCT00524459|Drug|pegylated liposomal doxorubicin hydrochloride|
483677|NCT00524459|Procedure|conventional surgery|
483678|NCT00524459|Procedure|neoadjuvant therapy|
483679|NCT00524446|Dietary Supplement|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
483680|NCT00524446|Dietary Supplement|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
483681|NCT00524446|Dietary Supplement|Maize-soy flour|Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
483682|NCT00524433|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
483683|NCT00524433|Drug|placebo|
483684|NCT00524420|Device|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
483685|NCT00524420|Device|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
483686|NCT00524407|Drug|Epoetin alfa|
483687|NCT00524381|Drug|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
483688|NCT00524381|Drug|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
483689|NCT00524368|Drug|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
483753|NCT00523965|Drug|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
483690|NCT00524368|Drug|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
483691|NCT00524342|Drug|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
483692|NCT00524316|Drug|doxorubicin hydrochloride|Transarterial chemoembolization
483693|NCT00524316|Drug|sunitinib malate|Given Orally
483694|NCT00524316|Other|laboratory biomarker analysis|Correlative Study
483695|NCT00524316|Procedure|hepatic artery embolization|Surgical procedure
483696|NCT00524316|Procedure|quality-of-life assessment|Correlative Study
483697|NCT00524303|Drug|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
483698|NCT00524303|Drug|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
483699|NCT00524303|Drug|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
483700|NCT00524303|Drug|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
483701|NCT00524277|Biological|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
483702|NCT00524277|Biological|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
483703|NCT00524277|Biological|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
483704|NCT00524277|Biological|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
483705|NCT00524264|Drug|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.~Placebo"
483706|NCT00524251|Drug|esomeprazole|
483707|NCT00524238|Drug|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
483708|NCT00524225|Drug|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
483709|NCT00524199|Drug|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
483710|NCT00524199|Other|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
483711|NCT00524186|Drug|fluorouracil|Given IV
483712|NCT00524186|Drug|irinotecan hydrochloride|Given IV
483713|NCT00524186|Drug|leucovorin calcium|Given IV
483714|NCT00524186|Drug|sunitinib malate|Taken Orally
483715|NCT00524186|Other|flow cytometry|Correlative Study
483716|NCT00524186|Other|pharmacological study|Correlative Study
483717|NCT00524173|Drug|Tenofovir & Emtricitabine|
483718|NCT00524173|Drug|Tenofovir|
483719|NCT00524160|Drug|Fentanyl transdermal patch|
483720|NCT00524147|Procedure|Pigtail drainage|
483721|NCT00524134|Drug|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
483722|NCT00524121|Drug|erlotinib hydrochloride|Oral
483723|NCT00524121|Other|immunohistochemistry staining method|Correlative Study
483724|NCT00524121|Radiation|radiation therapy|Radiation Treatment
483725|NCT00524095|Drug|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
483726|NCT00524095|Drug|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
483727|NCT00524069|Biological|bevacizumab|
483728|NCT00524069|Drug|capecitabine|
483729|NCT00524069|Drug|gemcitabine hydrochloride|
483730|NCT00524069|Other|flow cytometry|
483731|NCT00524069|Other|laboratory biomarker analysis|
483732|NCT00524069|Procedure|adjuvant therapy|
483733|NCT00524069|Procedure|computed tomography|
483734|NCT00524069|Procedure|neoadjuvant therapy|
483735|NCT00524056|Drug|Carisbamate|two 100 mg tablets twice per day
483736|NCT00524056|Drug|Placebo|two placebo tablets twice per day
483737|NCT00524043|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
483738|NCT00524043|Drug|Placebo|Once daily for 6 weeks
483739|NCT00524043|Drug|Paliperidone ER|6 mg tablet once daily for 6 weeks
483740|NCT00524030|Drug|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
483741|NCT00524030|Drug|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
483742|NCT00524017|Biological|cetuximab|given IV
483743|NCT00524017|Procedure|standard follow-up care|Patients receive regular follow-up care
483744|NCT00524004|Biological|Anti-CsbD Bovine IgG|Three times a day for seven days
483745|NCT00524004|Other|Placebo|Three times a day for seven days
483746|NCT00524004|Biological|Anti-CS17 Bovin IgG|Three times a day for seven days
483747|NCT00523991|Drug|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
483748|NCT00523991|Drug|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
483749|NCT00523978|Device|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
483750|NCT00523978|Drug|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
483751|NCT00523965|Drug|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
483752|NCT00523965|Drug|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or > 25 kg Miltefosine 50 mg once daily if patient weighs <25 mg
483846|NCT00523107|Drug|Placebo|500 ml normal saline t.i.w. per week
483754|NCT00523965|Drug|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
483755|NCT00523952|Drug|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
483756|NCT00523939|Drug|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
483757|NCT00523926|Drug|TMC207|
483758|NCT00523913|Drug|rosiglitazone|
483759|NCT00523900|Dietary Supplement|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
483760|NCT00523887|Drug|Fentanyl transdermal therapeutic system|
483761|NCT00523861|Dietary Supplement|Moderate alcohol consumption|
483762|NCT00523848|Drug|bortezomib|IV
483763|NCT00523848|Drug|pegylated liposomal doxorubicin hydrochloride|IV
483764|NCT00523848|Drug|thalidomide|Oral
483765|NCT00523822|Other|Spinal Manipulative Therapy|
483766|NCT00523809|Drug|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
483767|NCT00523809|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
483768|NCT00523809|Drug|Fludarabine|25 mg/m^2 IV Daily Over 30 Minutes for 5 Days
483769|NCT00523809|Drug|Melphalan|70 mg/m^2 IV Daily Over 30 Minutes for 2 Days
483770|NCT00523809|Drug|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
483771|NCT00523770|Procedure|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
483772|NCT00523757|Drug|Spironolactone|
483773|NCT00523757|Drug|Placebo|
483774|NCT00523744|Drug|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
483775|NCT00523744|Drug|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
483776|NCT00523744|Drug|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
483777|NCT00523744|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
483778|NCT00523731|Procedure|Angiogenic Cell Precursors (ACPs) or Vescell TM|
483779|NCT00523718|Drug|riluzole|50 mg PO bid, 12 weeks
483780|NCT00523718|Drug|placebo|placebo, 1 capsule PO bid, 12 weeks
483781|NCT00523705|Drug|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
483782|NCT00523705|Other|placebo|Placebo tablets matched to drug
483783|NCT00523692|Drug|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
483784|NCT00523692|Drug|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
483785|NCT00523666|Drug|Galantamine (Reminyl®)|8mg - 24mg
483786|NCT00523666|Drug|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.~Dose scheme: 8mg-24mg"
483787|NCT00523653|Other|blood test|looking at DNA
483788|NCT00523640|Drug|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
483789|NCT00523588|Procedure|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
483790|NCT00523575|Dietary Supplement|Cubitan|400 ml/d
483791|NCT00523562|Other|diet intervention|controlled hypercaloric high fructose, high fat, or high fat/high protein diet
483792|NCT00523549|Drug|valsartan|160 mg or 320 mg tablets once a day
483793|NCT00523549|Drug|amlodipine|5 mg or 10 mg tablets once a day
483794|NCT00523536|Behavioral|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
483795|NCT00523523|Behavioral|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
483796|NCT00523523|Behavioral|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
483797|NCT00523510|Procedure|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
483798|NCT00523497|Device|Non invasive mechanical ventilation|
483799|NCT00523471|Procedure|Blood test|
483800|NCT00523458|Drug|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
483801|NCT00523445|Drug|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
483802|NCT00523445|Drug|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
483803|NCT00523432|Drug|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
483804|NCT00523432|Drug|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
483805|NCT00523419|Drug|Pemetrexed|500 mg/m^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
483806|NCT00523406|Procedure|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
483807|NCT00523393|Drug|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
483808|NCT00523393|Drug|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
483809|NCT00523380|Drug|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
483810|NCT00523380|Drug|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
483811|NCT00523367|Procedure|24 hour pH testing|24 hour pH testing will be used to screen patients
483812|NCT00523354|Drug|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
483813|NCT00523341|Biological|Denosumab|Administered by subcutaneous injection once every 6 months.
483814|NCT00523328|Drug|BG9924|dosage administered as per Biogen-idec protocol
483815|NCT00523302|Device|Active TMS|Active TMS uses the active TMS coil to stimulate the cortical area of interest. Active TMS involves 80 trains x 15 sec = 4000 pulses per session, 5 x per week= 20,000 pulses per week, x 2 weeks = 40,000 pulses.
483816|NCT00523302|Device|Sham TMS|Sham TMS uses the same stimulation frequency as the Active TMS but uses the Sham TMS coil instead to prevent actual stimulation from occurring (chosen as a priori stimulation based on studies showing antidepressant and anti-nociceptive effects): 10 Hertz - Pulse train duration (on time) 5 seconds, Power (intensity) level 120% of stored motor threshold, Inter-train interval (off time) 10 seconds (15 second cycle time). Additionally, stimulation-train duration and inter-stimulus intervals were determined such that they are in compliance with current published rTMS safety guidelines.
483817|NCT00523289|Drug|Bupivacaine|Dosage: 150mg at once for anesthesia induction
483818|NCT00523289|Drug|Ropivacaine|Single dose of ropivacaine, 150mg
483819|NCT00523263|Device|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
483820|NCT00523263|Device|Human umbilical vein femoro-popliteal bypass|
483821|NCT00523250|Drug|AR-102 0.003% Ophthalmic Solution|
483822|NCT00523250|Drug|AR-102 0.005% Ophthalmic Solution|
483823|NCT00523250|Drug|AR-102 0.01% Ophthalmic Solution|
483824|NCT00523250|Drug|AR-102 0.03% Ophthalmic Solution|
483825|NCT00523250|Drug|AR-102 Vehicle Ophthalmic Solution|
483826|NCT00523237|Drug|Raltegravir|400 mg Twice daily for 24 weeks
483827|NCT00523224|Procedure|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
483828|NCT00523224|Biological|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
483829|NCT00523211|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
483830|NCT00523211|Drug|Placebo|One tablet of placebo once daily.
483831|NCT00523185|Drug|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
483832|NCT00523185|Drug|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
483833|NCT00523172|Procedure|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
483834|NCT00523172|Procedure|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
483835|NCT00523172|Procedure|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.~Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
483836|NCT00523159|Drug|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
483837|NCT00523159|Drug|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
483838|NCT00523146|Drug|Kanion Capsule|
483839|NCT00523133|Drug|naltrexone|50 mg naltrexone daily for 3 months
483840|NCT00523133|Drug|naltrexone|50 mg of naltrexone daily for 6 months
483841|NCT00523133|Behavioral|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
483842|NCT00523133|Behavioral|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
483843|NCT00523120|Drug|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
483844|NCT00523120|Drug|dexotc|aural drops
483845|NCT00523107|Drug|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
483847|NCT00523081|Behavioral|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
483848|NCT00523081|Behavioral|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
483849|NCT00523068|Drug|Tolterodine|
483850|NCT00523068|Procedure|tension free vaginal tape|
483851|NCT00523055|Drug|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
483852|NCT00523042|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
483853|NCT00523042|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
483854|NCT00523029|Behavioral|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
483855|NCT00523016|Procedure|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
483856|NCT00523016|Procedure|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
483857|NCT00523003|Dietary Supplement|high protein|2.2 g protein/kg of LBM per day
483858|NCT00523003|Dietary Supplement|standard protein|1.1 g protein/kg LBM/day standard protein diet
483859|NCT00522990|Drug|AT9283|Three weekly intravenous administration of AT9283
483860|NCT00522964|Behavioral|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
483861|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
483862|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
483863|NCT00522951|Drug|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
483864|NCT00522938|Drug|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
483865|NCT00522938|Drug|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
483866|NCT00522925|Drug|PS433540|200mg capsule, once daily for 28 days
483867|NCT00522925|Drug|placebo|placebo capsule, once daily for 28 days
483868|NCT00522925|Drug|PS433540|500mg capsule, once daily for 28 days
483869|NCT00522912|Procedure|Trichiasis surgery|Posterior lamella tarsal rotation
483870|NCT00522912|Procedure|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
483871|NCT00522899|Behavioral|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
483872|NCT00522899|Behavioral|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
483873|NCT00522899|Behavioral|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
483874|NCT00522899|Behavioral|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
483875|NCT00522886|Drug|Cetuximab|"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.~14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.~Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.~Vinorelbine:~Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."
483876|NCT00522873|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
483877|NCT00522873|Drug|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
483878|NCT00522860|Procedure|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
483879|NCT00522860|Procedure|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
483880|NCT00522834|Drug|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
483881|NCT00522834|Drug|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
483882|NCT00522821|Drug|intravenous immunoglobulins|"Adults: 600 mg/kg bodyweight every 3 weeks~Children: 800 mg/kg bodyweight every 3 week"
483883|NCT00522821|Drug|antibiotics|"Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.~Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
483884|NCT00522808|Drug|A-831|
483885|NCT00522795|Drug|PPX with cisplatin and radiation|weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
483886|NCT00522782|Drug|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
483887|NCT00522782|Device|Nitric Oxide Analyzer|Niox NO analyzer
483888|NCT00522769|Behavioral|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
483889|NCT00522756|Drug|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
483890|NCT00522756|Drug|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
483891|NCT00522743|Drug|growth hormone and gonadotropin-releasing hormone agonist|GH & GNRHa treatment
483892|NCT00522743|Drug|growth hormone|GH treatment
483893|NCT00522730|Other|Parenteral nutrition|Duration : 5 days
483894|NCT00522730|Other|Enteral nutrition|Duration : 5 days
483895|NCT00522717|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
483896|NCT00522717|Behavioral|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
483897|NCT00522704|Other|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
483898|NCT00522691|Procedure|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
483899|NCT00522678|Drug|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
483900|NCT00522678|Drug|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
483901|NCT00522665|Drug|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
483902|NCT00522665|Biological|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
483903|NCT00522665|Biological|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
483904|NCT00522652|Drug|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
483905|NCT00522639|Other|18F-deoxyglucose (FDG)|contrast medium
483906|NCT00522626|Device|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
483907|NCT00522613|Behavioral|Recovery Group Project|Recovery Group Workbook & Group Sessions
483908|NCT00522587|Drug|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
483909|NCT00522587|Drug|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
483910|NCT00522587|Drug|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
483911|NCT00522587|Drug|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
483912|NCT00522587|Drug|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
483913|NCT00522587|Drug|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
483914|NCT00522587|Drug|Fixed remifentanil dose 1|Dose 1 of remifentanil
483915|NCT00522587|Drug|Fixed remifentanil dose 2|Dose 2 of remifentanil
483916|NCT00522587|Drug|Fixed remifentanil dose 3|Dose 3 of remifentanil
483917|NCT00522587|Drug|Fixed remifentanil dose 4|Dose 4 of remifentanil
483918|NCT00522587|Drug|Fixed remifentanil dose 5|Dose 5 of remifentanil
483919|NCT00522587|Drug|Fixed remifentanil dose 6|Dose 6 of remifentanil
483920|NCT00522574|Drug|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
483921|NCT00522561|Other|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
483922|NCT00522548|Drug|Enteric coated mycophenolate sodium|Patients in this group will receive Myfortic (enteric-coated mycophenolate sodium) in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
483923|NCT00522548|Drug|Mycophenolate mofetil|Patients in this group will receive CellCept (mycophenolate mofetil) or its generic equivalent formulation manufactured by Sandoz, in combination with Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, Prograf (tacrolimus) or its generic equivalent, and corticosteroid immunosuppression.
483924|NCT00522535|Procedure|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
483925|NCT00522535|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
483926|NCT00522509|Drug|Floxuridine FUDR|
483927|NCT00522470|Drug|rosiglitazone|
483928|NCT00522457|Drug|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
483929|NCT00522444|Drug|Nebulized Magnesium Sulfate|
483930|NCT00522431|Drug|Testosterone|2% gel
483931|NCT00522418|Device|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
483933|NCT00522405|Procedure|TACE|"Under local anesthesia, the Femoral artery would be punctured~A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency~Superselective catheterization of the hepatic artery feeding the tumor would be done~By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.~Gelfoam particles would be injected following this for embolization"
483934|NCT00522392|Drug|bortezomib|Given IV
483935|NCT00522392|Drug|lenalidomide|Given PO
483936|NCT00522392|Drug|dexamethasone|Given PO
483937|NCT00522379|Drug|Rotigotine|2 mg/24 hr (one 10 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
483938|NCT00522379|Drug|Rotigotine|4 mg/24 hr (one 20 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
483939|NCT00522379|Other|Placebo|Placebo transdermal patch applied daily
483940|NCT00522379|Drug|Rotigotine|6 mg/24 hr (one 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
483941|NCT00522379|Drug|Rotigotine|8 mg/24 hr (two 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
483942|NCT00522353|Dietary Supplement|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
483943|NCT00522353|Dietary Supplement|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
483944|NCT00522340|Behavioral|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
483945|NCT00522327|Other|remote simultaneous medical interpreting|remote simultaneous medical interpretation
483946|NCT00522327|Other|usual and customary|usual and customary interpreting
483947|NCT00522327|Other|ENglish speaking|English speakers
483948|NCT00522314|Device|NIV and ACBT|
483949|NCT00522314|Other|Active Cycle of Breathing Techniques|
483950|NCT00522301|Drug|sorafenib tosylate|
483951|NCT00522301|Other|immunoenzyme technique|
483952|NCT00522301|Other|immunohistochemistry staining method|
483953|NCT00522301|Other|laboratory biomarker analysis|
483954|NCT00522301|Other|pharmacological study|
483955|NCT00522288|Device|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
483956|NCT00522288|Device|Spectacle|Spectacles for the treatment of myopia
483957|NCT00522275|Drug|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
483958|NCT00522262|Behavioral|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
483959|NCT00522249|Drug|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
483960|NCT00522249|Drug|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
483961|NCT00522249|Drug|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
483962|NCT00522236|Biological|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:~A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)~A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)~B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.~The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.~A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
483963|NCT00522223|Behavioral|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.~Participants who undergo a radical hysterectomy: Questionnaires 4 times."
483964|NCT00522210|Drug|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
483965|NCT00522210|Other|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
483966|NCT00522197|Dietary Supplement|multi-herbal agent ACAPHA|
483967|NCT00522197|Dietary Supplement|Sugar Pill|
483968|NCT00522184|Procedure|intra-articular injection of etanercept|
483969|NCT00522184|Procedure|intra-articular injection of steroid|
483970|NCT00522171|Device|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
483971|NCT00522158|Drug|simvastatin|
483972|NCT00522158|Drug|atorvastatin|
483973|NCT00522145|Drug|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
483974|NCT00522132|Drug|Artesunate|intravenous application
484021|NCT00521677|Procedure|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
484022|NCT00521677|Procedure|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
484167|NCT00520676|Drug|carboplatin|AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum
483975|NCT00522106|Behavioral|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
483976|NCT00522106|Other|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
483977|NCT00522093|Drug|TJ-100|TJ-100 2.5g three times per day for 6 weeks
483978|NCT00522067|Biological|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
483979|NCT00522054|Other|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
483980|NCT00522041|Drug|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
483981|NCT00522041|Drug|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
483982|NCT00522015|Drug|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
483983|NCT00521989|Drug|CRx-102 (2.7/90)|CRx-102 dose 1
483984|NCT00521989|Drug|Prednisolone|Prednisolone
483985|NCT00521989|Drug|Placebo|Placebo
483986|NCT00521989|Drug|CRx-102 (2.7/180)|CRx-102 dose 2
483987|NCT00521989|Drug|CRx-102 (2.7/360)|CRx-102 dose 3
483988|NCT00521963|Biological|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
483989|NCT00521950|Genetic|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT*2, *3A, *3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.~Patients are advised an initial treatment dose based on the enzyme activity:~Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);~Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;~Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
483990|NCT00521950|Drug|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:~AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
483991|NCT00521937|Other|Dermagen®|Weekly topical applications
483992|NCT00521924|Biological|infliximab|infliximab 3 mg/kg and basic treatment
483993|NCT00521924|Drug|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
483994|NCT00521911|Behavioral|Cognitive Behavioural Therapy|
483995|NCT00521898|Procedure|Descemet Membrane Endothelial Keratoplasty (DMEK)|
483996|NCT00521885|Drug|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
483997|NCT00521885|Drug|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
483998|NCT00521872|Procedure|STARR Operation|
483999|NCT00521859|Drug|Cloretazine|800 mg/m^2 by vein daily
484000|NCT00521859|Drug|Fludarabine|25 mg/m^2 by vein daily x 5 Days
484001|NCT00521846|Device|Biomet Explor Modular Radial Head Replacement|As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
484002|NCT00521833|Procedure|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
484003|NCT00521820|Drug|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
484004|NCT00521820|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
484005|NCT00521807|Procedure|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
484006|NCT00521781|Drug|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
484007|NCT00521781|Drug|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
484008|NCT00521781|Drug|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
484009|NCT00521768|Behavioral|Prolonged exposure|
484010|NCT00521755|Device|Seraffix LTB|laser soldering for soft tissue wounds
484011|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
484012|NCT00521742|Drug|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
484013|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
484014|NCT00521742|Drug|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
484015|NCT00521729|Procedure|Exposure to Cold Temperature|
484016|NCT00521716|Device|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
484017|NCT00521716|Device|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
484018|NCT00521703|Drug|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
484019|NCT00521703|Drug|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
484020|NCT00521690|Drug|insulin detemir|
484205|NCT00520390|Drug|EZN-2208|
484023|NCT00521664|Biological|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
484024|NCT00521664|Biological|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
484025|NCT00521638|Biological|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
484026|NCT00521612|Drug|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
484027|NCT00521612|Drug|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
484028|NCT00521599|Drug|Mometasone furoate dry powder inhaler|
484029|NCT00521599|Drug|Placebo|
484030|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
484031|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
484032|NCT00521573|Other|Dark chocolate|
484033|NCT00521560|Drug|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.~High dose therapy will be given as BEAM"
484034|NCT00521547|Procedure|Electroacupuncture|
484035|NCT00521534|Device|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
484036|NCT00521521|Drug|docetaxel and cisplatin|
484037|NCT00521521|Drug|docetaxel|
484038|NCT00521508|Procedure|gene transcription and cytometry|samply of 30 ml of blood
484039|NCT00521495|Device|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
484040|NCT00521495|Device|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
484041|NCT00521495|Device|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
484042|NCT00521482|Drug|Temozolomide|
484043|NCT00521482|Drug|Temozolomide plus Thalidomide|
484044|NCT00521469|Device|Pro Adjuster|
484045|NCT00521456|Drug|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day~Placebo"
484046|NCT00521443|Procedure|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
484047|NCT00521430|Biological|anti-thymocyte globulin|
484048|NCT00521430|Drug|busulfan|
484049|NCT00521430|Drug|cyclosporine|
484050|NCT00521430|Drug|fludarabine phosphate|
484051|NCT00521430|Drug|methotrexate|
484052|NCT00521430|Drug|methylprednisolone|
484053|NCT00521430|Procedure|allogeneic hematopoietic stem cell transplantation|
484054|NCT00521430|Procedure|peripheral blood stem cell transplantation|
484055|NCT00521417|Behavioral|short-term dynamic therapy|
484056|NCT00521417|Behavioral|long-term dynamic therapy|
484057|NCT00521404|Drug|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
484058|NCT00521404|Drug|gemcitabine|Gemcitabine - 1000mg/meter sq
484059|NCT00521391|Other|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
484060|NCT00521365|Drug|Quetiapine 600mg|"300 mg quetiapine fumarate tablets for oral use.~Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day."
484061|NCT00521352|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
484062|NCT00521352|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
484063|NCT00521339|Drug|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
484064|NCT00521300|Drug|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
484065|NCT00521300|Procedure|Direct surgery for acromegaly|Direct transsphenoidal surgery
484066|NCT00521287|Other|Immune profiling and DC vaccine|"For observational study (immune profiling): blood sampling 3-5 mL~For DC vaccine: one dose of DC vaccine(~10 million cells)/2 week for at least 6 month or until progression."
484067|NCT00521274|Biological|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
484165|NCT00520676|Drug|pemetrexed|500 mg/m^2, IV, q 21 days x 6 cycles maximum
496218|NCT00429949|Drug|Dasatinib|
484068|NCT00521274|Drug|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
484069|NCT00521261|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
484070|NCT00521248|Drug|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
484071|NCT00521248|Drug|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
484072|NCT00521222|Drug|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
484073|NCT00521222|Drug|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
484074|NCT00521209|Behavioral|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
484075|NCT00521209|Other|Stand procedures, no intervention|
484076|NCT00521196|Device|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
484077|NCT00521183|Drug|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
484078|NCT00521183|Drug|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
484079|NCT00521183|Radiation|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
484080|NCT00521170|Drug|Levocetirizine|
484081|NCT00521157|Drug|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
484082|NCT00521144|Drug|obatoclax mesylate|Given IV
484083|NCT00521144|Drug|topotecan hydrochloride|Given IV
484084|NCT00521144|Other|laboratory biomarker analysis|Correlative studies
484085|NCT00521131|Drug|Levocetirizine dihydrochloride|
484086|NCT00521118|Other|Laboratory Biomarker Analysis|Correlative studies
484087|NCT00521118|Procedure|Therapeutic Conventional Surgery|Undergo second curettage
484088|NCT00521105|Other|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
484089|NCT00521092|Drug|sunitinib malate|Given orally
484090|NCT00521092|Procedure|laboratory biomarker analysis|Correlative study
484091|NCT00521092|Procedure|pharmacological study|Correlative study
484092|NCT00521079|Device|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
484093|NCT00521079|Device|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
484094|NCT00521066|Device|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
484095|NCT00521053|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
484096|NCT00521040|Drug|Levocetirizine dihydrochloride|
484097|NCT00521027|Device|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
484098|NCT00521027|Procedure|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
484099|NCT00521014|Biological|filgrastim|
484100|NCT00521014|Biological|rituximab|
484101|NCT00521014|Biological|sargramostim|
484102|NCT00521014|Drug|carmustine|
484103|NCT00521014|Drug|cytarabine|
484104|NCT00521014|Drug|etoposide|
484105|NCT00521014|Drug|melphalan|
484106|NCT00521014|Procedure|autologous hematopoietic stem cell transplantation|
484107|NCT00521001|Drug|everolimus|
484108|NCT00521001|Drug|temozolomide|
484166|NCT00520676|Drug|docetaxel|75 mg/m^2, IV, q 21 days x 6 cycles maximum
484576|NCT00517439|Drug|Pegasys|90 micrograms sc weekly for 24 weeks
484109|NCT00520988|Behavioral|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
484110|NCT00520975|Biological|Bevacizumab|Given IV
484111|NCT00520975|Drug|Carboplatin|Given IV
484112|NCT00520975|Drug|Paclitaxel|Given IV
484113|NCT00520975|Other|Placebo|Given IV
484114|NCT00520975|Biological|Trastuzumab|Given IV
484115|NCT00520949|Drug|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
484116|NCT00520949|Drug|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
484117|NCT00520949|Drug|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
484118|NCT00520949|Drug|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
484119|NCT00520936|Drug|pemetrexed|1910 milligrams per meter squared (mg/m^2) (or 60 milligrams per kilogram [mg/kg] if patient <12 months old), intravenous (IV), for 21 days x 17 cycles
484120|NCT00520923|Drug|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
484121|NCT00520923|Drug|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
484122|NCT00520923|Drug|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
484123|NCT00520923|Drug|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
484124|NCT00520923|Drug|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
484125|NCT00520923|Drug|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
484126|NCT00520923|Drug|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
484127|NCT00520910|Drug|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
484128|NCT00520897|Drug|Raltegravir (MK0518)|400mg BID; 48 weeks
484129|NCT00520897|Drug|Placebo|400mg QD
484130|NCT00520897|Procedure|Leukopheresis|pack of cells as per protocol
484131|NCT00520897|Procedure|Sigmoid Biopsy|gut samples as per protocol
484132|NCT00520884|Drug|Ghrelin Infusion - Healthy|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
484133|NCT00520884|Drug|Ghrelin Infusion - Frail|At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
484134|NCT00520884|Other|Placebo Infusion -Healthy|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
484135|NCT00520884|Other|Placebo Infusion - Frail|At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
484136|NCT00520871|Drug|Blueberry juice|
484137|NCT00520858|Other|Resistance Exercise (RE)|
484138|NCT00520858|Other|Aerobic Exercise (AE)|
484139|NCT00520858|Other|Resistance and Aerobic Exercise (RAE)|
484140|NCT00520845|Drug|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
484141|NCT00520845|Drug|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
484142|NCT00520845|Drug|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
484143|NCT00520845|Other|laboratory biomarker analysis|Blood collection
484144|NCT00520832|Device|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
484145|NCT00520832|Device|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
484146|NCT00520819|Drug|Antioxidant-rich food items|
484147|NCT00520806|Drug|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
484148|NCT00520806|Drug|Placebo|Intravenous infusion for 48 h
484149|NCT00520780|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.~After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
484150|NCT00520780|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
484151|NCT00520767|Drug|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
484152|NCT00520767|Drug|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
484153|NCT00520767|Drug|melphalan|Melphalan 9 mg/m2/day days 1-4
484154|NCT00520767|Genetic|microarray analysis|≤28 days prior to enrollment
484155|NCT00520767|Other|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
484156|NCT00520767|Other|laboratory biomarker analysis|≤28 days prior to enrollment
484157|NCT00520767|Procedure|quality-of-life assessment|Start of each cycle
484158|NCT00520754|Drug|levocetirizine dihydrochloride|
484159|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
484160|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
484161|NCT00520728|Behavioral|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
484162|NCT00520702|Procedure|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
484163|NCT00520702|Procedure|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
484164|NCT00520689|Device|Silicone Hydrogel Contact Lens|use of lens over 2 days
496733|NCT00425841|Drug|oxaliplatin|
484168|NCT00520663|Drug|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
484169|NCT00520650|Drug|Aripiprazole|
484170|NCT00520637|Drug|EZN-2208|
484171|NCT00520624|Device|inspiratory muscle strength training|
484172|NCT00520624|Procedure|Surgery|
484173|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
484174|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
484175|NCT00520598|Biological|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
484176|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
484177|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
484178|NCT00520598|Biological|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
484179|NCT00520598|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
484180|NCT00520598|Biological|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
484181|NCT00520585|Drug|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
484182|NCT00520572|Drug|AZD9056|
484183|NCT00520572|Drug|Etanercept|
484184|NCT00520572|Drug|Placebo|
484185|NCT00520546|Other|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq [18F]Fluoroethylcholine chloride (FEC; Eckert & Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
484186|NCT00520546|Other|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
484187|NCT00520533|Biological|Chimeric monoclonal antibody cG250|"First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st & 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (¹²⁴I-cG250)~Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No ¹²⁴I-cG250 will be used in the 2nd cycle.~Up to 2 cycles available."
484188|NCT00520533|Drug|Sunitinib malate|"First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.~Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.~Up to 2 cycles available on-study."
484189|NCT00520507|Drug|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
484190|NCT00520507|Drug|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
484191|NCT00520494|Drug|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
484192|NCT00520481|Drug|IMC-A12 (Cixutumumab)|10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
484193|NCT00520468|Drug|Erythropoietin|40,000 units injected under the skin (SQ) weekly
484194|NCT00520468|Drug|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
484195|NCT00520468|Drug|G-CSF|300 mcg injected under the skin (SQ) two times per week
484196|NCT00520468|Drug|Prednisone|60 mg per day for 7 days, taper over 1 month
484197|NCT00520455|Drug|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
484198|NCT00520442|Drug|ibuprofen|
484199|NCT00520442|Drug|acetamin w codeine|
484200|NCT00520429|Behavioral|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
484201|NCT00520416|Procedure|Carbon dioxide angiogram|see description of procedure
484202|NCT00520403|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
484203|NCT00520403|Drug|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
484204|NCT00520403|Drug|Vinblastine|0.1mg/kg iv every 3 weeks
484206|NCT00520377|Drug|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
484207|NCT00520377|Device|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
484208|NCT00520364|Other|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
484209|NCT00520351|Drug|ClearCare|contact lens care system
484210|NCT00520351|Drug|Optifree Replenish|contact lens care system
484211|NCT00520338|Drug|celecoxib|"placebo~celecoxib 400 mg oral single dose"
484212|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
484213|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
484214|NCT00520299|Drug|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
484215|NCT00520286|Drug|Modafinil|200 mg or 400 mg /daily
484216|NCT00520286|Drug|Placebo|Placebo / daily
484217|NCT00520273|Device|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
484218|NCT00520260|Drug|bromfenac|0.09%, BID, 6 weeks
484219|NCT00520260|Drug|ketorolac|0.4%, BID, 6 weeks
484220|NCT00520247|Drug|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
484221|NCT00520234|Drug|Caspofungin|50 mg IV daily
484222|NCT00520234|Drug|Normal Saline|100 cc IV daily
484223|NCT00520208|Drug|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
484224|NCT00520195|Behavioral|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
484225|NCT00520182|Behavioral|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids [MUFA]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
484226|NCT00520182|Behavioral|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
484227|NCT00520182|Behavioral|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
484228|NCT00520169|Drug|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
484229|NCT00520156|Device|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
484230|NCT00520143|Biological|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
484231|NCT00520130|Biological|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
484232|NCT00520130|Drug|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
484233|NCT00520130|Drug|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
484234|NCT00520130|Drug|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
484235|NCT00520130|Drug|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
484236|NCT00520130|Drug|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
484347|NCT00519285|Drug|Prednisone or Prednisolone|"Marketed formulation~5 mg twice daily PO from day 1 continuously"
484237|NCT00520130|Drug|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
484238|NCT00520130|Biological|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
484239|NCT00520104|Drug|intranasal ketamine|drug interaction
484240|NCT00520091|Drug|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
484241|NCT00520091|Drug|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
484242|NCT00520091|Drug|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
484243|NCT00520091|Radiation|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
484244|NCT00520091|Procedure|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
484245|NCT00520065|Other|enteral nutritional formula|Meal glucose tolerance test
484246|NCT00520065|Other|Diabetes specific enteral product|Meal Glucose tolerance test
484247|NCT00520052|Drug|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
484248|NCT00520039|Procedure|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
484249|NCT00520026|Drug|lithium|
484250|NCT00520026|Drug|placebo|
484251|NCT00520013|Drug|bevacizumab|
484252|NCT00520013|Drug|erlotinib|
484253|NCT00520013|Drug|paclitaxel|
484254|NCT00520013|Drug|carboplatin|
484255|NCT00520000|Drug|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
484256|NCT00520000|Drug|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
484257|NCT00520000|Drug|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
484258|NCT00520000|Drug|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
484259|NCT00519987|Drug|intranasal ketamine|intranasal ketamine
484260|NCT00519974|Other|counseling intervention|
484261|NCT00519974|Other|study of socioeconomic and demographic variables|
484262|NCT00519974|Procedure|management of therapy complications|
484263|NCT00519974|Procedure|psychosocial assessment and care|
484264|NCT00519961|Device|Elecsys®proBNP|
484265|NCT00519948|Drug|new MPS, opti-free express no rub MPS|
484266|NCT00519935|Behavioral|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
484267|NCT00519922|Other|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion & agility, dynamic proprioception,functional strength & endurance.~Kinesthesia & Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability & confidence in ADL activities.~Soft pads will be used to progress some of the kinesthesia & balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
484268|NCT00519922|Other|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal & external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
484269|NCT00519909|Other|Dairy calcium|Diets with different content of calcium and fat
484270|NCT00519896|Drug|sunitinib malate|Given PO
484271|NCT00519883|Other|Exercise|
484272|NCT00519883|Other|Supportive Care|
484273|NCT00519870|Drug|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
484274|NCT00519870|Drug|losartan|II: losartan
484275|NCT00519870|Drug|Nifedipine, losartan|I: nifedipine II: losartan
484276|NCT00519857|Drug|Tibolone|1.25 mg p.o, once daily for 3 years
484277|NCT00519857|Drug|Placebo|Tablet p.o, once daily for 3 years
484278|NCT00519844|Drug|somatropin|
484279|NCT00519831|Biological|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
484280|NCT00519831|Drug|vinflunine|Vinflunine 320 mg/m² every 21 days
484281|NCT00519818|Drug|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
484282|NCT00519818|Drug|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
484283|NCT00519805|Drug|dalteparin|
484284|NCT00519805|Procedure|quality-of-life assessment|
484285|NCT00519792|Drug|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
484286|NCT00519779|Dietary Supplement|omega-3 supplementation|2.5 g/day omega-3
484287|NCT00519779|Dietary Supplement|Oral omega-3 fish oil placebo|to match experimental dosage
484288|NCT00519753|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
484289|NCT00519740|Other|inhalative specific bronchial provocation with grass-pollen|
484526|NCT00517829|Drug|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
484290|NCT00519727|Drug|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg~Placebo: 0.9% Sodium Chloride"
484291|NCT00519714|Dietary Supplement|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
484292|NCT00519714|Dietary Supplement|Placebo|Placebo
484293|NCT00519701|Drug|hydroxyurea|
484294|NCT00519688|Drug|Thalidomide|100 mg, BID
484295|NCT00519688|Drug|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
484296|NCT00519675|Drug|alitretinoin|
484297|NCT00519662|Drug|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15~Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
484298|NCT00519649|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
484299|NCT00519636|Drug|FPNS|fluticasone propionate nasal spray
484300|NCT00519636|Drug|FFNS|fluticasone furoate nasal spray
484301|NCT00519636|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
484302|NCT00519636|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
484303|NCT00519623|Other|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
484304|NCT00519610|Other|Chart Review|Patients' charts will be reviewed for relevant medical information.
484305|NCT00519597|Device|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
484306|NCT00519584|Drug|Ropivacaine|30 ml 0.5%
484307|NCT00519584|Drug|dex|8 mg (2 ml)
484308|NCT00519584|Drug|Bupivacaine|30 ml 0.5%
484309|NCT00519584|Drug|Saline|0.9% saline; systemic and local
484310|NCT00519571|Device|ImplantLock device|dental implant
484311|NCT00519558|Drug|somatropin|
484312|NCT00519545|Behavioral|Prayer|Data collection on physiological biomarkers
484313|NCT00519532|Drug|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
484314|NCT00519519|Drug|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
484315|NCT00519506|Other|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
484316|NCT00519493|Procedure|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
484317|NCT00519493|Device|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
484318|NCT00519480|Drug|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
484319|NCT00519480|Drug|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
484320|NCT00519480|Drug|Placebo|Placebo will be available as an oral tablets.
484321|NCT00519467|Drug|Chlorproguanil-dapsone-artesunate (CDA)|
484322|NCT00519454|Other|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
484323|NCT00519441|Other|pH study|All patients will have 48 hour pH study
484324|NCT00519428|Drug|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
484325|NCT00519428|Drug|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
484326|NCT00519428|Drug|escitalopram + bupropion|same dosing schedule as for monotherapy
484327|NCT00519415|Other|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
484328|NCT00519415|Other|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
484329|NCT00519402|Other|tonsillar examination and questionnaire completion|
484330|NCT00519389|Biological|H5N1 VLP Vaccine|Two doses - Day 0 & Day 28
484331|NCT00519389|Biological|Placebo|Two doses - Day 0 & Day 28
484332|NCT00519376|Drug|GW642444M|drug
484333|NCT00519376|Drug|GW642444H|drug
484334|NCT00519376|Drug|placebo|
484335|NCT00519363|Drug|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
484336|NCT00519350|Procedure|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
484337|NCT00519337|Drug|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
484338|NCT00519337|Drug|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
484339|NCT00519324|Drug|Everolimus|10 mg/day (2 tablets of 5 mg each)
484340|NCT00519311|Behavioral|Health Intervention Package|CHAP and Ask Diary
484341|NCT00519298|Drug|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
484342|NCT00519298|Other|placebo|placebo
484343|NCT00519298|Drug|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
484344|NCT00519285|Drug|Aflibercept|"25 mg/ml solution~6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
484345|NCT00519285|Drug|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept~1-hour IV on Day 1 of each 3-Week cycle"
484346|NCT00519285|Drug|Docetaxel|"Marketed formulation~75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
484527|NCT00517829|Drug|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
484348|NCT00519272|Behavioral|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
484349|NCT00519259|Drug|Lobeline|
484350|NCT00519246|Drug|Saline|Saline 5 ml administrated intravenously
484351|NCT00519246|Drug|Opioid|Butorphanol tartrate 1 mg i.v.
484352|NCT00519246|Drug|Opioid|Butorphanol Tartrate 2 mg i.v.
484353|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 50 mg i.v.
484354|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 100 mg i.v.
484355|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 10 mg i.v.
484356|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 20 mg i.v.
484357|NCT00519233|Drug|AGS-1C4D4|IV
484358|NCT00519220|Other|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
484359|NCT00519207|Drug|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
484360|NCT00519207|Drug|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
484361|NCT00519194|Device|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
484362|NCT00519194|Procedure|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
484363|NCT00519181|Drug|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
484364|NCT00519168|Procedure|Urine sample|Standard of care
484365|NCT00519168|Device|Electrode sleep recorder|Standard of care
484366|NCT00519168|Procedure|phlebotomy|Standard of care
484367|NCT00519155|Drug|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
484368|NCT00519155|Procedure|Open flap debridement|Open flap debridement alone
484369|NCT00519142|Drug|placebo for mitiglinide|three times a day with meals
484370|NCT00519142|Drug|mitiglinide|three times a day with meals
484371|NCT00519142|Drug|mitiglinide|two times a day with meals
484372|NCT00519129|Device|3D-imager|3D-imager vs fluoroscopy during coloscopy
484373|NCT00519116|Drug|Rapamune® (Sirolimus)|
484374|NCT00519116|Drug|Tacrolimus|
484375|NCT00519116|Drug|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
484376|NCT00519103|Other|exercise|
484377|NCT00519090|Drug|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
484378|NCT00519090|Drug|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
484379|NCT00519077|Drug|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
484380|NCT00519064|Biological|Adjuvanted influenza vaccine|
484381|NCT00519051|Other|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
484382|NCT00519038|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
484383|NCT00519038|Other|Usual Care|Usual care is the current practice actually performed in the hospital
484384|NCT00519012|Drug|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
484385|NCT00519012|Drug|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
484386|NCT00518986|Drug|armodafinil|200 mg/day
484387|NCT00518986|Drug|placebo|placebo
484388|NCT00518973|Drug|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
484431|NCT00518648|Other|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
484432|NCT00518648|Other|Usual care|Usual care
484389|NCT00518973|Drug|Placebo|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of placebo will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
484390|NCT00518960|Drug|ProAlgaZyme|
484391|NCT00518947|Drug|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
484392|NCT00518947|Drug|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
484393|NCT00518947|Drug|verapamil plus lithium|
484394|NCT00518934|Other|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
484395|NCT00518921|Drug|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
484396|NCT00518921|Drug|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
484397|NCT00518921|Drug|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
484398|NCT00518921|Drug|Placebo|Placebo, double dummy
484399|NCT00518908|Drug|Sevoflurane|3.2 Vol % for postconditioning
484400|NCT00518895|Drug|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
484401|NCT00518895|Drug|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
484402|NCT00518882|Drug|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
484403|NCT00518882|Drug|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
484404|NCT00518869|Drug|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
484405|NCT00518856|Other|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
484406|NCT00518856|Other|Standard of care|continued with current standard of care for birth attendants
484407|NCT00518843|Behavioral|FBT-BN|Mobilizing parents to curtail binge eating and purging
484408|NCT00518843|Behavioral|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
484409|NCT00518830|Other|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
484410|NCT00518830|Other|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
484411|NCT00518804|Behavioral|Functional Behavioural Skills Group and Parent Training|
484412|NCT00518791|Other|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
484413|NCT00518791|Other|Usual Care|No altered organisation of care
484414|NCT00518765|Drug|Aliskiren|
484415|NCT00518765|Drug|Aliskiren plus placebo|
484416|NCT00518765|Drug|Aliskiren|
484417|NCT00518765|Drug|Aliskiren plus placebo|
484418|NCT00518752|Procedure|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
484419|NCT00518752|Procedure|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
484420|NCT00518739|Drug|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 & beyond).
484421|NCT00518726|Biological|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
484422|NCT00518713|Drug|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
484423|NCT00518713|Drug|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
484424|NCT00518713|Drug|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
484425|NCT00518713|Drug|Placebo|tablets; orally; daily for 15-18 weeks
484426|NCT00518700|Other|new MPS|
484427|NCT00518700|Other|RepleniSH|
484428|NCT00518687|Biological|V710|0.5-mL single injection of V710 (60 µg)
484429|NCT00518687|Biological|Placebo|0.5-mL single injection of matching placebo
484430|NCT00518674|Procedure|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
484433|NCT00518635|Drug|Nutropin|Nutropin 0.1 mg/day self-administered once a day
496848|NCT00425178|Drug|FGF-1|
484434|NCT00518622|Drug|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
484435|NCT00518622|Drug|Comparator: Placebo|MK7009 Placebo
484436|NCT00518596|Dietary Supplement|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
484437|NCT00518583|Drug|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
484438|NCT00518570|Drug|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
484439|NCT00518557|Procedure|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
484440|NCT00518544|Drug|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
484441|NCT00518531|Drug|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
484442|NCT00518531|Drug|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
484443|NCT00518518|Drug|Staloral 300|Staloral 300
484444|NCT00518518|Drug|placebo|placebo
484445|NCT00518505|Other|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
484446|NCT00518492|Procedure|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
484447|NCT00518479|Drug|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
484448|NCT00518479|Drug|Valsartan 160mg OD; Moxonidine 400mcg OD|
484449|NCT00518466|Drug|topiramate|25 mg modified-release capsules
484450|NCT00518466|Drug|phentermine|7.5 mg immediate-release capsules
484451|NCT00518466|Drug|topiramate|100 and 25 mg immediate-release tablets
484452|NCT00518466|Drug|phentermine|37.5 and 7.5 mg immediate-release tablets
484453|NCT00518453|Biological|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
484454|NCT00518427|Drug|Insulin Glargine|"Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml.~Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
484455|NCT00518414|Other|Marketed infant formula with DHA and ARA|
484456|NCT00518414|Other|Milk-based infant formula with DHA and ARA|
484457|NCT00518414|Other|Milk-based formula with DHA, ARA, prebiotics|
484458|NCT00518401|Biological|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
484459|NCT00518388|Behavioral|Focus Group|Focus groups each lasting about 2 hours.
484460|NCT00518388|Behavioral|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
484461|NCT00518375|Drug|Rapamune® (Sirolimus)|
484462|NCT00518375|Drug|Neoral® (Cyclosporine)|
484463|NCT00518375|Drug|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
484464|NCT00518362|Drug|TW|TW,120 mg/d
484465|NCT00518349|Device|Passive bending function|Colonoscope with a passive bending function
484466|NCT00518349|Device|No passive bending function|Examination using standard colonoscope without passive bending function
484467|NCT00518336|Procedure|Blood sampling|Blood sampling at Visit 3, 5 and 7.
484468|NCT00518336|Procedure|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
484469|NCT00518336|Biological|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
484470|NCT00518323|Drug|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
484471|NCT00518323|Drug|Placebo|Once daily for 6 weeks
484472|NCT00518323|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
484473|NCT00518323|Drug|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
484474|NCT00518310|Drug|Placebo|
484475|NCT00518310|Drug|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
484476|NCT00518297|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
484477|NCT00518297|Drug|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
484478|NCT00518297|Drug|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
484479|NCT00518284|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m^2.
484480|NCT00518271|Drug|Rapamune® (Sirolimus)|
484481|NCT00518271|Drug|Tacrolimus|
484482|NCT00518271|Drug|Corticosteroids|Perioperative
484483|NCT00518245|Drug|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
484484|NCT00518232|Drug|OROS-methylphenidate|
484485|NCT00518219|Drug|TW|TW,120mg/d
484525|NCT00517829|Drug|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
484486|NCT00518206|Biological|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
484487|NCT00518206|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
484488|NCT00518193|Drug|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
484489|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
484490|NCT00518180|Biological|Tdap Vaccine|One dose of vaccine administered intramuscularly
484491|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
484492|NCT00518167|Behavioral|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at~weight reduction~dietary fibre 15 g /1000 kcal or more~energy proportion of dietary fat less than 30%~energy proportion of saturated fat less than 10%~moderate physical activity >30 minutes per day or 4 hours per week"
484493|NCT00518154|Drug|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
484494|NCT00518141|Drug|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
484495|NCT00518128|Procedure|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
484496|NCT00518128|Procedure|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
484497|NCT00518115|Drug|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
484498|NCT00518102|Drug|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
484499|NCT00518102|Other|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
484500|NCT00518089|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
484501|NCT00518089|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
484502|NCT00518050|Behavioral|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:~Screening, skin self-examination, sun protection, and other cancer preventive practices;~Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,~Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
484503|NCT00518050|Behavioral|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
484504|NCT00518037|Behavioral|surveys|anxiety surveys
484505|NCT00518024|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
484506|NCT00518011|Drug|Erlotinib|150 mg po daily
484507|NCT00518011|Drug|Gemcitabine|As prescribed
484508|NCT00517998|Drug|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
484509|NCT00517985|Drug|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
484510|NCT00517972|Drug|Omacor (omega-3-acid ethyl esters)|
484511|NCT00517959|Radiation|Stereotactic Conformal radiotherapy|SCRT
484512|NCT00517959|Radiation|Conventional radiotherapy|
484513|NCT00517946|Drug|pseudoephedrine hydrochloride|
484514|NCT00517946|Drug|cetirizine hydrochloride|
484515|NCT00517933|Drug|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day [TID] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
484516|NCT00517933|Other|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
484517|NCT00517920|Drug|ABT-869|0.25 mg/kg QD
484518|NCT00517907|Drug|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.~Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
484519|NCT00517894|Drug|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
484520|NCT00517881|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
484521|NCT00517868|Drug|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
484522|NCT00517868|Drug|Placebo|Liquid formulation without active URG101 drug components
484523|NCT00517855|Biological|PRTX-100 (Staphylococcal protein A)|
484524|NCT00517842|Drug|ViNeuro|
484528|NCT00517816|Drug|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
484529|NCT00517803|Dietary Supplement|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
484530|NCT00517803|Dietary Supplement|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
484531|NCT00517803|Dietary Supplement|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
484532|NCT00517803|Dietary Supplement|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
484533|NCT00517790|Drug|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
484534|NCT00517790|Drug|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
484535|NCT00517777|Device|continuous positive airway pressure ventilation|nighttime
484536|NCT00517777|Behavioral|dietary and life style recommendations|
484537|NCT00517777|Behavioral|dietary and life style recommendations|
484538|NCT00517764|Drug|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
484539|NCT00517751|Device|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
484540|NCT00517738|Other|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
484541|NCT00517738|Other|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
484542|NCT00517725|Drug|carvedilol|
484543|NCT00517725|Drug|bisoprolol|
484544|NCT00517725|Drug|Nebivolol|
484545|NCT00517712|Drug|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
484546|NCT00517699|Drug|rituximab [MabThera/Rituxan]|750mg/m2 iv
484547|NCT00517699|Drug|Methotrexate|8g/m2 iv
484548|NCT00517699|Drug|Cytarabine|2g/m2 iv
484549|NCT00517686|Other|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
484550|NCT00517673|Drug|GSK945237|
484551|NCT00517673|Drug|Sugar Pill|Placebo
484552|NCT00517647|Drug|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
484553|NCT00517634|Drug|FP|Fluticasone Propionate 100 mcg BD
484554|NCT00517634|Drug|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
484555|NCT00517634|Drug|Placebo|Matching Placebo
484556|NCT00517621|Drug|Paclitaxel|
484557|NCT00517621|Drug|EPO|
484558|NCT00517608|Device|Laparoscopic colectomy|
484559|NCT00517595|Drug|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m^2 and gemcitabine 1500 mg/m^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
484560|NCT00517582|Drug|HOE-140|Subcutaneous at time 0 and 6 hours
484561|NCT00517582|Other|Placebo|Subcutaneous at time 0 and 6 hours
484562|NCT00517569|Genetic|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
484563|NCT00517569|Drug|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
484564|NCT00517556|Drug|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
484565|NCT00517556|Drug|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
484566|NCT00517543|Drug|GW856553|
484567|NCT00517530|Drug|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
484568|NCT00517517|Biological|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
484569|NCT00517504|Drug|Methylphenidate|"1-week single blind placebo lead-in phase.~step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.~Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.~After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control."
484570|NCT00517491|Drug|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
484571|NCT00517478|Procedure|Blood Sample|
484572|NCT00517465|Drug|Placebo|po bid
484573|NCT00517465|Drug|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
484574|NCT00517439|Drug|Copegus|1000/1200mg po daily for 24 weeks
499118|NCT00408213|Drug|Placebo|po bid
484577|NCT00517439|Drug|RO4588161|1000mg po bid for 24 weeks
484578|NCT00517439|Drug|RO4588161|500mg po bid for 24 weeks
484579|NCT00517439|Drug|RO4588161|1500mg po bid for 24 weeks
484580|NCT00517426|Drug|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
484581|NCT00517413|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
484582|NCT00517400|Device|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
484583|NCT00517387|Drug|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
484584|NCT00517361|Drug|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
484585|NCT00517361|Drug|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
484586|NCT00517348|Biological|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
484587|NCT00517335|Procedure|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
484588|NCT00517322|Drug|ramipril|ramipril 2.5- 5 mg once daily
484589|NCT00517322|Drug|irbesartan|irbesartan 150-300 mg once daily
484590|NCT00517309|Biological|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
484591|NCT00517309|Biological|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
484592|NCT00517296|Procedure|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
484593|NCT00517296|Drug|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
484594|NCT00517296|Procedure|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
484595|NCT00517283|Drug|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
484596|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
484597|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
484598|NCT00517270|Drug|Rabeprazole 20mg twice daily|
484599|NCT00517257|Drug|Atorvastatin|80 mg orally once daily for 24 weeks
484600|NCT00517257|Drug|Placebo|Placebo tablet orally once daily for 24 weeks
484601|NCT00517218|Drug|Genasense® (, oblimersen sodium G3139)|
484602|NCT00517205|Procedure|Non-contrast helical computerized tomogram (NCHCT)|
484603|NCT00517192|Drug|Tipranavir|
484604|NCT00517192|Drug|Darunavir|
484605|NCT00517192|Drug|Ritonavir|
484606|NCT00517179|Drug|Vardenafil 10mg|
484607|NCT00517166|Device|CAT (Combat Arms Tourniquet)|device
484608|NCT00517153|Drug|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
484609|NCT00517140|Procedure|Repeat Caesaen section|
484610|NCT00517140|Procedure|vaginal delivery|
484611|NCT00517127|Drug|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
484612|NCT00517127|Drug|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
484613|NCT00517114|Drug|Rabeprazole 20mg twice daily|
484614|NCT00517088|Drug|IPAQ|
484615|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
484616|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
484677|NCT00516620|Behavioral|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
484724|NCT00516347|Procedure|study of high risk factors|
484725|NCT00516321|Drug|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
484617|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
484618|NCT00517075|Device|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
484619|NCT00517062|Drug|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
484620|NCT00517062|Drug|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
484621|NCT00517049|Drug|PRO95780|Intravenous repeating dose
484622|NCT00517049|Drug|rituximab|Intravenous repeating dose
484623|NCT00517036|Dietary Supplement|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
484624|NCT00517036|Dietary Supplement|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
484625|NCT00517036|Dietary Supplement|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
484626|NCT00517023|Device|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
484627|NCT00517023|Other|Other|Routine care and tests usually offered for syncope patients.
484628|NCT00517010|Drug|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
484629|NCT00516984|Procedure|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
484630|NCT00516984|Procedure|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
484631|NCT00516984|Procedure|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
484632|NCT00516971|Drug|Esomeprazole 20mg once daily|
484633|NCT00516958|Drug|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
484634|NCT00516958|Drug|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
484635|NCT00516958|Drug|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
484636|NCT00516945|Drug|Lamivudine|
484637|NCT00516919|Drug|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
484638|NCT00516919|Behavioral|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
484639|NCT00516906|Drug|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
484640|NCT00516906|Drug|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
484641|NCT00516893|Biological|BG00002-E (natalizumab high titer)|
484642|NCT00516880|Drug|rosiglitazone|
484643|NCT00516867|Radiation|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
484644|NCT00516867|Radiation|UV radiation|UVB 1.4 % and UVA 98.6
484645|NCT00516854|Drug|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
484646|NCT00516841|Drug|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
484647|NCT00516828|Drug|cytarabine|subcutaneously twice daily from Day 1 to 10
484648|NCT00516802|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
484649|NCT00516802|Drug|dacarbazine|intravenous injection over at least 20 minutes
484650|NCT00516750|Drug|cisplatin|
484651|NCT00516750|Drug|doxorubicin hydrochloride|
484652|NCT00516750|Drug|methotrexate|
484653|NCT00516750|Drug|vinblastine|
484654|NCT00516750|Genetic|gene expression profiling|
484655|NCT00516750|Procedure|neoadjuvant therapy|
484656|NCT00516737|Drug|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
484657|NCT00516737|Drug|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
484658|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
484659|NCT00516724|Drug|Carboplatin|intravenous injection
484660|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
484661|NCT00516724|Drug|Paclitaxel|Intravenous injection
484662|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
484663|NCT00516724|Drug|Paclitaxel + Carboplatin|Intravenous injection
484664|NCT00516711|Drug|Sevoflurane|
484665|NCT00516698|Genetic|polymorphism analysis|
484666|NCT00516698|Other|high performance liquid chromatography|
484667|NCT00516698|Other|laboratory biomarker analysis|
484668|NCT00516698|Procedure|radiomammography|
484669|NCT00516685|Biological|Recombinant Human rEGF-P64K/Montanide Vaccine|
484670|NCT00516672|Drug|pazopanib|Pazopanib oral tablet
484671|NCT00516672|Drug|Lapatinib|Lapatinib oral tablet
484672|NCT00516659|Biological|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
484673|NCT00516659|Biological|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
484674|NCT00516646|Drug|ALT-711|200 mg bid
484675|NCT00516646|Drug|Placebo|bid
484676|NCT00516633|Behavioral|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
484723|NCT00516347|Other|questionnaire administration|
484678|NCT00516620|Behavioral|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
484679|NCT00516620|Behavioral|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
484680|NCT00516620|Behavioral|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
484681|NCT00516620|Behavioral|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
484682|NCT00516620|Behavioral|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
484683|NCT00516620|Behavioral|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
484684|NCT00516620|Behavioral|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
484685|NCT00516607|Drug|enzastaurin hydrochloride|
484686|NCT00516607|Drug|temozolomide|
484687|NCT00516607|Other|pharmacological study|
484688|NCT00516594|Procedure|Diet with polyfructans and viscous fibers or soy protein|
484689|NCT00516542|Drug|letrozole|A daily dose of 2.5 mg will be used throughout the study.
484690|NCT00516542|Drug|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
484691|NCT00516542|Other|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
484692|NCT00516516|Dietary Supplement|L-Carnitine|L-Carnitine, 1g orally, twice daily
484693|NCT00516516|Dietary Supplement|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
484694|NCT00516503|Drug|baclofen/amitriptyline/ketamine gel|Applied topically
484695|NCT00516503|Other|placebo|Applied topically
484696|NCT00516490|Drug|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
484697|NCT00516490|Drug|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
484698|NCT00516477|Biological|voretigene neparvovec-rzyl|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
484699|NCT00516464|Drug|Lucentis (ranibizumab)|
484700|NCT00516451|Drug|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
484701|NCT00516438|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
484702|NCT00516438|Drug|Topotecan|intravenous infusion
484703|NCT00516425|Biological|pegfilgrastim|
484704|NCT00516425|Drug|cyclophosphamide|
484705|NCT00516425|Drug|doxorubicin hydrochloride|
484706|NCT00516425|Drug|epirubicin hydrochloride|
484707|NCT00516425|Genetic|proteomic profiling|
484708|NCT00516425|Other|diagnostic laboratory biomarker analysis|
484709|NCT00516425|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
484710|NCT00516425|Other|pharmacological study|
484711|NCT00516425|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
484712|NCT00516425|Procedure|adjuvant therapy|
484713|NCT00516412|Drug|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
484714|NCT00516412|Genetic|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
484715|NCT00516399|Drug|povidone-iodine 1.25% ophthalmic solution|
484716|NCT00516399|Drug|natamycin ophthalmic suspension, USP 5%|
484717|NCT00516386|Drug|RhIGF-1|35-40 mcg/k/dose twice daily SC
484718|NCT00516373|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
484719|NCT00516360|Device|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
484720|NCT00516347|Genetic|comparative genomic hybridization|
484721|NCT00516347|Genetic|genetic linkage analysis|
484722|NCT00516347|Other|laboratory biomarker analysis|
484726|NCT00516321|Drug|placebo|matched placebo taken once daily orally
484727|NCT00516308|Device|NightHawk|
484728|NCT00516295|Drug|topotecan hydrochloride|Given IV
484729|NCT00516295|Drug|vincristine sulfate|Given IV
484730|NCT00516295|Drug|cyclophosphamide|Given IV
484731|NCT00516295|Biological|bevacizumab|Given IV
484732|NCT00516282|Drug|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
484733|NCT00516282|Drug|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
484734|NCT00516269|Drug|Methylphenidate|18 mg by mouth daily for 2 weeks
484735|NCT00516269|Drug|Placebo|Capsule by mouth daily for 2 weeks
484736|NCT00516256|Behavioral|CHESS System|Internet-based computer program for 6 months.
484737|NCT00516256|Behavioral|Cancer Information Mentor|Phone calls to the patient for 6 months.
484738|NCT00516243|Other|placebo|Given PO
484739|NCT00516243|Other|quality-of-life assessment|Ancillary studies
484740|NCT00516243|Procedure|questionnaire administration|Ancillary studies
484741|NCT00516243|Procedure|laboratory biomarker analysis|Correlative studies
484742|NCT00516243|Drug|defined green tea catechin extract|Given PO
484743|NCT00516217|Biological|galiximab|
484744|NCT00516191|Drug|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV~The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
484745|NCT00516178|Drug|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
484746|NCT00516178|Drug|Saline|3 infusions, perioperative or post-PTCA
484747|NCT00516165|Drug|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
484748|NCT00516152|Drug|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis~7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV~3 Fludarabine 30 mg/m(2)IV~2 REST Tacrolimus 0.01 mg/kg CIVI~1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion~1 Methotrexate 5mg/m(2)IV~3 Methotrexate 5mg/m(2)IV~6 Methotrexate 5mg/m(2)IV~7 G-CSF 5mcg/kg SQ daily~11 Methotrexate 5mg/m(2)IV~90 Evaluate Response"
484749|NCT00516139|Drug|Lamotrigine|Open-label
484750|NCT00516113|Drug|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
484751|NCT00516100|Drug|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
484752|NCT00516087|Biological|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2~Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2~Group Three Day 0 1x10^8 cells/m2 Day 14 2x10^8 cells/m2"
484753|NCT00516074|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
484754|NCT00516074|Drug|placebo|subcutaneous injection, volume equivalent to active, twice a day
484755|NCT00516048|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
484756|NCT00516035|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
484757|NCT00516022|Drug|Mistletoe extract|The drug will be administered 3 times a week at home.
484758|NCT00516009|Drug|DEXAMETHASONE|
484759|NCT00516009|Other|PLACEBO|
484760|NCT00515983|Biological|DC/Apo-Nec|
484761|NCT00515970|Procedure|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
484762|NCT00515970|Procedure|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
484763|NCT00515970|Procedure|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
484816|NCT00515476|Behavioral|physical exercise|8 weeks of regular exercise training
484817|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
484764|NCT00515970|Procedure|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
484765|NCT00515957|Genetic|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).~--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.~Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level <100 ng/ml)~--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~2x 10^7 cells/m2~1x 10^8 cells/m2 3 x 10^8 cells/m2~1 x 10^9 cells/m2"
484766|NCT00515944|Drug|Botulinum neurotoxin type A, free of complexing proteins|
484767|NCT00515931|Radiation|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
484768|NCT00515918|Dietary Supplement|iron|
484769|NCT00515905|Drug|Sevoflurane/propofol|Sevoflurane/propofol
484770|NCT00515892|Drug|Immunotoxin therapy|
484771|NCT00515892|Drug|CAT-8015 Immunotoxin|
484772|NCT00515892|Procedure|Biological therapy|
484773|NCT00515892|Procedure|Antibody Therapy|
484774|NCT00515892|Procedure|Monoclonal Antibody Therapy|
484775|NCT00515879|Drug|D-cycloserine|50 mg
484776|NCT00515879|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
484777|NCT00515879|Drug|Placebo|Same dosage as active pill
484778|NCT00515866|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
484779|NCT00515866|Drug|Gemcitabine|intravenous injection
484780|NCT00515853|Behavioral|Biofeedback|Biofeedback sessions or biofeedback exercises
484781|NCT00515840|Other|Physiotherapist|Physiotherapist administered breathing retraining programme
484782|NCT00515827|Drug|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
484783|NCT00515827|Drug|Placebo|400 mg placebo tablet taken orally twice daily
484784|NCT00515814|Device|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation & mobility.
484785|NCT00515801|Drug|glibenclamide|glibenclamide 15 mg single dose
484786|NCT00515801|Drug|placebo|placebo capsules, single dose
484787|NCT00515788|Drug|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
484788|NCT00515788|Drug|Temozolomide|100 mg/m^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
484789|NCT00515762|Device|elasto-gel cap|scalp cooling cap
484790|NCT00515736|Drug|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
484791|NCT00515736|Drug|Placebo|vehicle
484792|NCT00515723|Drug|risperidone|randomized to 12 week trial of risperidone.
484793|NCT00515723|Drug|olanzapine|randomized to 12 week trial of olanzapine.
484794|NCT00515723|Drug|quetiapine|randomized to 12 week trial of quetiapine.
484795|NCT00515723|Drug|ziprasidone|randomized to 12 week trial of ziprasidone.
484796|NCT00515697|Biological|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
484797|NCT00515684|Drug|bevacizumab (Avastin)|
484798|NCT00515671|Behavioral|Illness Management and Recovery|a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
484799|NCT00515671|Behavioral|Problem Solving|Weekly problem-solving support group
484800|NCT00515658|Device|theta-burst rTMS|
484801|NCT00515645|Other|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
484802|NCT00515632|Drug|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
484803|NCT00515619|Drug|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
484804|NCT00515606|Drug|helium:oxygen|
484805|NCT00515593|Drug|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
484806|NCT00515580|Procedure|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
484807|NCT00515554|Drug|Rituximab|addition of Rituximab to BEACOPP escalated
484808|NCT00515554|Drug|BEACOPP escalated|chemotherapy with BEACOPP escalated
484809|NCT00515541|Drug|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
484810|NCT00515528|Drug|4-peptide melanoma vaccine|draft
484811|NCT00515528|Drug|4-peptide melanoma vaccine plus Ontak|draft
484812|NCT00515528|Drug|ontak|draft
484813|NCT00515502|Drug|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
484814|NCT00515502|Drug|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
484815|NCT00515489|Drug|Risperidone|as prescribed
484818|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
484819|NCT00515450|Biological|GB-0998 (Intravenous immunoglobulin)|
484820|NCT00515450|Procedure|Plasmapheresis|
484821|NCT00515437|Biological|Botulinum Toxin Type B (Myobloc)|
484822|NCT00515437|Biological|Matched placebo to Myobloc|
484823|NCT00515424|Drug|RKI983|
484824|NCT00515411|Drug|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
484825|NCT00515411|Drug|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17~* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
484826|NCT00515398|Other|Observation|Ex vivo administration of AT2220
484827|NCT00515385|Drug|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
484828|NCT00515385|Drug|MGAWN1|Single IV dose
484829|NCT00515385|Other|Placebo|Single IV dose
484830|NCT00515372|Other|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
484831|NCT00515372|Other|Usual Care|Lists of professional resources and referral recommendations will be provided.
484832|NCT00515359|Procedure|Intermittent Propofol Sedation|Intermittent versus continuous dosage
484833|NCT00515359|Procedure|Continuous Propofol Sedation|intermittent vs continuous dosage
484834|NCT00515346|Device|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
484835|NCT00515333|Drug|TRx0014|Hard capsule; 60 milligrams; t.i.d.
484836|NCT00515333|Drug|TRx0014|Hard capsule; 30 milligrams; t.i.d.
484837|NCT00515333|Drug|Placebo|Hard capsule; 0 milligrams; t.i.d.
484838|NCT00515333|Drug|TRx0014|Hard capsule, 100 milligrams, t.i.d.
484839|NCT00515320|Drug|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
484840|NCT00515320|Drug|Placebo|Oral dispersible tablet placebo
484841|NCT00515307|Procedure|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
484842|NCT00515294|Drug|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
484843|NCT00515294|Other|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
484844|NCT00515294|Drug|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
484845|NCT00515294|Other|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
484846|NCT00515281|Drug|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
484847|NCT00515281|Drug|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
484848|NCT00515268|Drug|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
484849|NCT00515268|Drug|Placebo|Subjects will receive placebo inhaler.
484850|NCT00515255|Drug|Minocycline|Capsules
484851|NCT00515242|Behavioral|massage|therapeutic massage
484852|NCT00515242|Behavioral|thermotherapy|heat therapy
484853|NCT00515242|Behavioral|relaxing environment|time in a relaxing environment
484854|NCT00515229|Drug|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.~Placebo: 25 mg corn starch"
484855|NCT00515216|Drug|5-fluorouracil|
484856|NCT00515216|Drug|Oxaliplatin|
484857|NCT00515216|Drug|Leucovorin|
484858|NCT00515203|Drug|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
484859|NCT00515203|Drug|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
484860|NCT00515190|Drug|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.~Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
484861|NCT00515177|Behavioral|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
484862|NCT00515177|Drug|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
484863|NCT00515164|Drug|Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel|20 mL Hydrogel
484864|NCT00515151|Drug|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
484865|NCT00515151|Drug|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
484905|NCT00514904|Biological|Mencevax|Single dose, subcutaneous injection
484866|NCT00515138|Drug|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
484867|NCT00515125|Behavioral|Dietary Advice|Dietary Advice sheet
484868|NCT00515125|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.~A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
484869|NCT00515112|Drug|AndroGel|Androgel 1%, 10g daily
484870|NCT00515112|Drug|placebo|placebo
484871|NCT00515099|Drug|Antithymocyte globulin|Daily 4-day escalating dose
484872|NCT00515099|Drug|Placebo|Daily 4-day saline solution
484873|NCT00515086|Drug|Everolimus|Tablets taken once a day with a full glass of water.
484874|NCT00515086|Procedure|Surgery|Salvage surgical resection
484875|NCT00515073|Drug|Paclitaxel|50 mg/m^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
484876|NCT00515073|Radiation|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
484877|NCT00515073|Drug|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
484878|NCT00515073|Drug|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
484879|NCT00515073|Drug|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
484880|NCT00515060|Other|Sensory Tests|Tests to find the threshold at which perceive stimuli.
484881|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
484882|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
484883|NCT00515034|Drug|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
484884|NCT00515034|Drug|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
484885|NCT00515021|Drug|Eplerenone (Morning)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
484886|NCT00515021|Drug|Eplerenone (Night-time)|Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
484887|NCT00515008|Behavioral|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
484888|NCT00515008|Behavioral|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
484889|NCT00514995|Drug|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
484890|NCT00514982|Drug|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
484891|NCT00514982|Drug|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
484892|NCT00514982|Drug|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
484893|NCT00514982|Drug|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
484894|NCT00514982|Drug|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
484895|NCT00514982|Drug|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
484896|NCT00514969|Drug|Imatinib (STI571)|
484897|NCT00514956|Behavioral|Emotional Freedom Techniques (EFT)|
484898|NCT00514943|Drug|BIBW 2992|experimental drug taken once daily orally
484899|NCT00514943|Drug|Cetuximab|active comparator administered weekly intravenously
484900|NCT00514930|Device|Hexablate|
484901|NCT00514917|Drug|Docetaxel|75 mg/m^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
484902|NCT00514917|Drug|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
484903|NCT00514917|Drug|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
484904|NCT00514904|Biological|Nimenrix|Single dose, intramuscular injection
484906|NCT00514891|Biological|Vitamin A|The effect of vitamin A given with different vaccines will be studied
484907|NCT00514865|Drug|ONO-2333Ms|5-10 mg QD for 8 weeks
484908|NCT00514865|Drug|ONO-2333Ms|0 mg QD for 8 weeks
484909|NCT00514865|Drug|ONO-2333Ms|1-2 mg QD for 8 weeks
484910|NCT00514852|Drug|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
484911|NCT00514852|Drug|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
484912|NCT00514839|Behavioral|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
484913|NCT00514826|Other|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
484914|NCT00514813|Drug|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
484915|NCT00514800|Behavioral|Intervention - a validated home BP monitor and support from the specialist nurse|
484916|NCT00514800|Behavioral|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
484917|NCT00514774|Drug|ursodiol|"ursodiol 300 mg twice daily for study days 0 through 28~ursodiol 600mg twice daily on study days 0 through 28"
484918|NCT00514774|Drug|placebo|placebo 600mg twice daily for study days 0 through 28
484919|NCT00514761|Drug|AZD6244|oral vial
484920|NCT00514761|Drug|Capecitabine|oral tablet
484921|NCT00514748|Procedure|DIEP|flap survival, operation time, flap complications, donor site morbidity.
484922|NCT00514748|Procedure|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
484923|NCT00514735|Procedure|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
484924|NCT00514735|Drug|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
484925|NCT00514722|Other|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
484926|NCT00514709|Biological|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
484927|NCT00514709|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, IM
484928|NCT00514709|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine.
484929|NCT00514696|Drug|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
484930|NCT00514683|Drug|low dose BIBF1120 once daily|low dose BIBF1120 once daily
484931|NCT00514683|Drug|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
484932|NCT00514683|Drug|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
484933|NCT00514683|Drug|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
484934|NCT00514683|Drug|placebo|placebo
484935|NCT00514670|Other|Alcohol-based hand sanitizer & quaternary ammonium wipes|
484936|NCT00514657|Drug|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
484937|NCT00514644|Other|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
484938|NCT00514644|Other|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
484939|NCT00514618|Drug|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
484940|NCT00514618|Dietary Supplement|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
484941|NCT00514605|Other|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
484942|NCT00514605|Device|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
484943|NCT00514592|Other|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
484944|NCT00514579|Procedure|Cord blood transplantation|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
484945|NCT00514566|Device|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
484946|NCT00514540|Drug|Docetaxel|75 mg/m^2 IV Over 60 Minutes On Day 1 Repeat Every 3 Weeks.
484947|NCT00514540|Drug|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 repeat every 3 weeks.
484948|NCT00514527|Drug|oritavancin|Oritavancin as a single, infrequent or daily dose.
484949|NCT00514514|Drug|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
484950|NCT00514514|Drug|Myfortic|"1 tablet containing 180 mg or 360 mg~Dosing schedule:~Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
484951|NCT00514514|Drug|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
484952|NCT00514514|Drug|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
484953|NCT00514501|Drug|Iodofiltic acid I 123|
484954|NCT00514488|Drug|STI571 (400 mg/day; or 800 mg/day)|
484955|NCT00514475|Drug|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
484956|NCT00514462|Device|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
484957|NCT00514449|Drug|Valacyclovir|1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
484958|NCT00514449|Drug|Placebo|2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
484959|NCT00514436|Behavioral|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
484960|NCT00514423|Other|Psychoeducation by professonals|
484961|NCT00514423|Other|Psychoeducation by peer-moderators|
484962|NCT00514423|Other|Video-education|
484963|NCT00514423|Other|Noneducational video group (control group)|
484964|NCT00514410|Drug|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
484965|NCT00514410|Drug|Placebo|Matching placebo taken once a day for three months
484966|NCT00514397|Drug|motexafin gadolinium|
484967|NCT00514397|Drug|temozolomide|
484968|NCT00514397|Procedure|adjuvant therapy|
484969|NCT00514397|Procedure|quality-of-life assessment|
484970|NCT00514397|Radiation|radiation therapy|
484971|NCT00514371|Drug|tanespimycin|High dose
484972|NCT00514371|Drug|Bortezomib|Mid dose, and low dose
484973|NCT00514345|Genetic|gene expression analysis|
484974|NCT00514345|Genetic|polymorphism analysis|
484975|NCT00514345|Procedure|management of therapy complications|
484976|NCT00514332|Procedure|stent|stent placement for colorectal cancer obstruction
484977|NCT00514306|Drug|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
484978|NCT00514293|Drug|bexarotene|
484979|NCT00514293|Drug|capecitabine|
484980|NCT00514293|Drug|carboplatin|
484981|NCT00514293|Drug|cisplatin|
484982|NCT00514293|Drug|docetaxel|
484983|NCT00514293|Drug|tretinoin|
484984|NCT00514267|Drug|YM 155|IV
484985|NCT00514267|Drug|Docetaxel|IV
484986|NCT00514267|Drug|Prednisone|Oral
484987|NCT00514254|Other|questionnaire administration|
484988|NCT00514254|Other|study of socioeconomic and demographic variables|
484989|NCT00514254|Procedure|evaluation of cancer risk factors|
484990|NCT00514241|Device|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
484991|NCT00514228|Drug|sunitinib malate|"Starting dose: 37.5 mg 3 x 12.5 mg capsule~Reduced dose: 25 mg 2 x 12.5 mg capsule"
484992|NCT00514215|Biological|sargramostim|250 μg, inhaled, two times a day, on days 4-10 and days 36-42
484993|NCT00514215|Other|flow cytometry|Days 1 & 32
484994|NCT00514215|Other|immunoenzyme technique|Days 1 & 32
484995|NCT00514215|Procedure|biopsy|CT guided biopsy on days 1 & 32
484996|NCT00514215|Procedure|cryosurgery|Days 1 and 32
484997|NCT00514202|Drug|Placebo|matched placebo
484998|NCT00514202|Drug|Dextroamphetamine SR|60 mg/day
484999|NCT00514189|Biological|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
485000|NCT00514163|Drug|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
485001|NCT00514163|Drug|gemcitabine|gemcitabine DIV on day one , 8th and 15th
485002|NCT00514150|Drug|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
485003|NCT00514150|Drug|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
485004|NCT00514137|Drug|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
485005|NCT00514111|Drug|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
485006|NCT00514085|Biological|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.~Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
485007|NCT00514085|Other|immunohistochemistry staining method|﻿Cycle 1 Day 1 and Cycle 1 Day 29
485008|NCT00514085|Other|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
485009|NCT00514085|Other|pharmacological study|Starting dose of 50μg/kg/day as an IV push
485010|NCT00514072|Biological|BCG vaccine|given intradermally
485011|NCT00514072|Biological|prostate cancer vaccine ONY-P1|given intradermally
485012|NCT00514072|Other|placebo|given intradermally
485013|NCT00514059|Drug|Boostrix polio|1 dose (0.5 ml) i.m.
485014|NCT00514046|Drug|Vandetanib|once daily continuously (28 day cycles)
485015|NCT00514033|Biological|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
485016|NCT00514020|Drug|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
485017|NCT00514020|Drug|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
485018|NCT00514020|Drug|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
485019|NCT00514020|Genetic|gene expression analysis|Blood collection
485020|NCT00514020|Genetic|polymorphism analysis|Blood collection
485021|NCT00514020|Genetic|protein expression analysis|Blood collection
485022|NCT00514020|Other|pharmacological study|Blood collection
485023|NCT00514007|Drug|OSI-906|OSI-906 administered orally
485374|NCT00511563|Drug|GW876008 and GSK561679|GW876008 and GSK561679
485024|NCT00513994|Drug|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
485025|NCT00513981|Drug|leucovorin calcium|
485026|NCT00513981|Drug|methotrexate|
485027|NCT00513981|Other|mass spectrometry|
485028|NCT00513981|Other|pharmacological study|
485029|NCT00513968|Genetic|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
485030|NCT00513968|Drug|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
485031|NCT00513955|Drug|bortezomib|
485032|NCT00513955|Drug|cyclophosphamide|
485033|NCT00513955|Drug|doxorubicin hydrochloride|
485034|NCT00513955|Drug|prednisolone|
485035|NCT00513955|Drug|vincristine sulfate|
485036|NCT00513955|Other|questionnaire administration|
485037|NCT00513955|Procedure|quality-of-life assessment|
485038|NCT00513942|Other|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
485039|NCT00513929|Dietary Supplement|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
485040|NCT00513916|Dietary Supplement|soy isoflavones|High or low dose of soy isoflavones in the diet.
485041|NCT00513903|Behavioral|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
485042|NCT00513903|Behavioral|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
485043|NCT00513890|Device|Infantflow [EME, Brighton, England]|
485044|NCT00513877|Drug|bortezomib|
485045|NCT00513877|Procedure|quality-of-life assessment|
485046|NCT00513864|Drug|Dextromethorphan|one time dose - 0.3mg/kg PO
485047|NCT00513864|Drug|Codeine|one time dose - 2mg/kg PO
485048|NCT00513864|Drug|Morphine|one time dose - 0.15mg/kg IV
485049|NCT00513851|Drug|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
485050|NCT00513851|Drug|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
485051|NCT00513825|Drug|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
485052|NCT00513799|Drug|Mupirocin ointment|Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.
485053|NCT00513799|Genetic|Chlorhexidine showers|Apply Clorhexidine wash to entire body once daily for 5 days.
485054|NCT00513799|Procedure|Bleach baths (dilute)|Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.
485055|NCT00513799|Behavioral|Intensive education on personal hygiene|Repeat hygiene methods for 5 days.
485056|NCT00513786|Drug|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
485057|NCT00513786|Drug|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
485058|NCT00513786|Drug|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
485059|NCT00513760|Dietary Supplement|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
485060|NCT00513760|Dietary Supplement|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
485061|NCT00513760|Dietary Supplement|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
485062|NCT00513747|Biological|rituximab|Given IV over 4 hours
485063|NCT00513747|Drug|fludarabine phosphate|Given IV over 30 minutes
485064|NCT00513734|Other|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
485065|NCT00513734|Other|Lacrilube ointment|lubricant put into eye (inferior formix)
485066|NCT00513708|Behavioral|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
485067|NCT00513708|Behavioral|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
485068|NCT00513695|Drug|sunitinib malate|Given PO
485069|NCT00513695|Drug|paclitaxel|Given IV
485070|NCT00513695|Drug|doxorubicin hydrochloride|Given IV
485071|NCT00513695|Drug|cyclophosphamide|Given PO
485072|NCT00513695|Biological|filgrastim|Given SC
485073|NCT00513695|Procedure|therapeutic conventional surgery|Undergo surgery
485074|NCT00513695|Other|laboratory biomarker analysis|Correlative studies
485075|NCT00513695|Other|flow cytometry|Correlative studies
485076|NCT00513682|Drug|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
485077|NCT00513669|Biological|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
486499|NCT00503581|Other|Pharmacological Study|Correlative studies
485078|NCT00513669|Biological|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
485079|NCT00513656|Drug|Oxycodone|
485080|NCT00513656|Drug|Oxycodone/Naloxone|
485081|NCT00513643|Drug|insulin aspart|6, 12, 24 U s.c.
485082|NCT00513643|Drug|human regular insulin|6, 12 and 24 IU sc
485083|NCT00513630|Drug|Glipizide|
485084|NCT00513630|Drug|Metformin|
485085|NCT00513617|Drug|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
485086|NCT00513617|Drug|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
485087|NCT00513604|Biological|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
485088|NCT00513604|Biological|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10^11 lymphocytes (minimum of 1 x 10^9), day 0
485089|NCT00513604|Drug|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
485090|NCT00513604|Drug|Fludarabine phosphate|Given intravenously 25 mg/m^2/day over 15-30 minutes, day -5 to -1
485091|NCT00513604|Radiation|Total body irradiation|600 cGy
485092|NCT00513578|Biological|PR1 leukemia peptide vaccine|
485093|NCT00513578|Biological|incomplete Freund's adjuvant|
485094|NCT00513578|Biological|sargramostim|
485095|NCT00513565|Drug|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
485096|NCT00513552|Drug|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
485097|NCT00513539|Drug|porfimer sodium|
485098|NCT00513539|Procedure|biliary stenting|
485099|NCT00513526|Biological|Gardasil|week 0, 8, 24, 128
485100|NCT00513513|Drug|TMC114 (darunavir) / ritonavir|
485101|NCT00513500|Drug|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
485102|NCT00513500|Drug|Coartem|Give Coartem without RDT and refer fast breathing
485103|NCT00513487|Drug|Dust mite extract, Fluticasone, Methacholine|Dust mite extract, Fluticasone, Methacholine
485104|NCT00513474|Drug|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
485105|NCT00513474|Drug|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
485106|NCT00513474|Drug|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
485107|NCT00513474|Drug|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
485108|NCT00513474|Drug|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
485109|NCT00513474|Drug|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
485110|NCT00513474|Drug|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
485111|NCT00513474|Drug|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
485112|NCT00513474|Procedure|allogeneic hematopoietic stem cell transplantation|
485113|NCT00513474|Procedure|peripheral blood stem cell transplantation|
485114|NCT00513474|Radiation|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
485115|NCT00513474|Drug|fludarabine|Fludarabine 40 mg/m^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
485116|NCT00513474|Drug|allopurinol|Allopurinol per institutional guidelines
485117|NCT00513461|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
485118|NCT00513461|Other|placebo|Given PO
485119|NCT00513461|Other|laboratory biomarker analysis|Correlative studies
485120|NCT00513461|Other|immunoenzyme technique|Correlative studies
485121|NCT00513461|Other|high performance liquid chromatography|Correlative studies
485122|NCT00513448|Other|Group wellness intervention|
485123|NCT00513448|Other|Individualized physical rehabilitation|
485124|NCT00513435|Drug|saracatinib|Given PO
485125|NCT00513435|Other|laboratory biomarker analysis|Correlative studies
485126|NCT00513422|Dietary Supplement|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;~Chondroitin: Two 400mg capsules once daily for two years."
485127|NCT00513422|Dietary Supplement|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;~Placebo Chondroitin: Two capsules once daily for two years."
485128|NCT00513422|Dietary Supplement|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;~Placebo glucosamine: Two capsules once daily for two years."
485129|NCT00513422|Dietary Supplement|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;~Two placebo chondroitin capsules once daily for two years."
485130|NCT00513409|Biological|Synflorix|Intramuscular injection, 1 or 2 doses
485131|NCT00513409|Biological|Infanrix Hexa|1 Intramuscular injection
485132|NCT00513409|Biological|Havrix|1 Intramuscular injection
485133|NCT00513396|Drug|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)~Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
486500|NCT00503581|Other|Quality-of-Life Assessment|Ancillary studies
485134|NCT00513396|Drug|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
485135|NCT00513383|Drug|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
485136|NCT00513383|Drug|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
485137|NCT00513383|Drug|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
485138|NCT00513383|Radiation|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
485139|NCT00513383|Drug|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
485140|NCT00513383|Drug|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
485141|NCT00513383|Drug|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
485142|NCT00513370|Biological|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
485143|NCT00513357|Drug|Melatonin|20 mg by mouth daily for 4 Weeks
485144|NCT00513357|Drug|Placebo|Capsule by mouth daily for 4 Weeks
485145|NCT00513344|Dietary Supplement|Dark Chocolate|1 portion
485146|NCT00513344|Dietary Supplement|Milk Chocolate|1 portion
485147|NCT00513344|Dietary Supplement|"Control (polyphenol-free) Chocolate"|one portion
485148|NCT00513331|Procedure|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
485149|NCT00513331|Procedure|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
485150|NCT00513331|Procedure|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
485151|NCT00513305|Drug|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
485152|NCT00513305|Drug|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m^2 subcutaneously (sc) twice a day (bid).
485153|NCT00513292|Drug|Cyclophosphamide|Given IV
485154|NCT00513292|Drug|Epirubicin Hydrochloride|Given IV
485155|NCT00513292|Other|Laboratory Biomarker Analysis|Correlative studies
485156|NCT00513292|Drug|Paclitaxel|Given IV
485157|NCT00513292|Procedure|Therapeutic Conventional Surgery|Undergo surgery
485158|NCT00513292|Biological|Trastuzumab|Given IV
485159|NCT00513279|Drug|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
485160|NCT00513279|Drug|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
485161|NCT00513266|Biological|bevacizumab|
485162|NCT00513266|Biological|cetuximab|
485163|NCT00513266|Drug|fluorouracil|
485164|NCT00513266|Drug|irinotecan hydrochloride|
485165|NCT00513266|Drug|leucovorin calcium|
485166|NCT00513266|Drug|oxaliplatin|
485167|NCT00513266|Other|laboratory biomarker analysis|
485168|NCT00513266|Procedure|adjuvant therapy|
485169|NCT00513266|Procedure|biopsy|
485170|NCT00513266|Procedure|conventional surgery|
485171|NCT00513266|Procedure|neoadjuvant therapy|
485172|NCT00513253|Drug|lapatinib|
485173|NCT00513240|Drug|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
485174|NCT00513240|Drug|Normal saline|"Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~."
485175|NCT00513214|Drug|XOMA 052|"Part 1, Single IV infusion at one of six dose levels (mg/kg).~Part 2, Single SC injection at one of three dose levels (mg/kg).~Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
485176|NCT00513214|Drug|Placebo|"Part 1, Single IV infusion at one of six dose levels (mg/kg).~Part 2, Single SC injection at one of three dose levels (mg/kg).~Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
485177|NCT00513201|Drug|lyspro|
485178|NCT00513201|Drug|regular insulin|
485179|NCT00513188|Biological|denileukin diftitox|
485180|NCT00513188|Drug|cyclophosphamide|
485181|NCT00513188|Drug|cytarabine|
485182|NCT00513188|Drug|doxorubicin hydrochloride|
485183|NCT00513188|Drug|leucovorin calcium|
485184|NCT00513188|Drug|methotrexate|
485185|NCT00513188|Drug|prednisone|
485186|NCT00513188|Drug|vincristine sulfate|
485187|NCT00513188|Genetic|protein expression analysis|
485188|NCT00513188|Other|flow cytometry|
485189|NCT00513188|Other|laboratory biomarker analysis|
485190|NCT00513162|Drug|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
485191|NCT00513162|Drug|Etoposide|25 - 50 mg/m^2 By Mouth Daily
485192|NCT00513149|Drug|Clopidogrel|Clopidogrel 600 mg loading
485193|NCT00513136|Behavioral|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
485526|NCT00510289|Drug|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
485194|NCT00513136|Behavioral|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
485195|NCT00513123|Procedure|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
485196|NCT00513110|Genetic|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
485197|NCT00513110|Drug|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
485198|NCT00513110|Drug|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
485199|NCT00513097|Behavioral|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
485200|NCT00513097|Behavioral|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
485201|NCT00513097|Behavioral|Survey|On-line evaluations and questionnaires
485202|NCT00513084|Behavioral|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
485203|NCT00513071|Drug|saracatinib|Given orally
485204|NCT00513071|Other|laboratory biomarker analysis|Correlative studies
485205|NCT00513058|Drug|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
485206|NCT00513058|Drug|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
485207|NCT00513045|Behavioral|IRT|Cognitive behavior intervention
485208|NCT00513045|Behavioral|Exposure|Exposure intervention
485209|NCT00513032|Drug|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
485210|NCT00513019|Drug|Lamictal (lamotrigine)|once daily from beginning to end of study. Dosage varies.
485211|NCT00513019|Drug|Placebo|daily
485212|NCT00512993|Drug|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
485213|NCT00512980|Drug|prednisone|
485214|NCT00512980|Drug|vinblastine|
485215|NCT00512980|Drug|doxorubicin|
485216|NCT00512980|Drug|gemcitabine|
485217|NCT00512928|Drug|acenocoumarol|max 5 mg per day during 10 weeks
485218|NCT00512928|Dietary Supplement|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
485219|NCT00512915|Device|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
485220|NCT00512902|Drug|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
485221|NCT00512902|Drug|Imatinib|Up to 600 mg QD PO for up to 1 year.
485222|NCT00512889|Biological|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
485223|NCT00512889|Genetic|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
485224|NCT00512889|Drug|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
485225|NCT00512889|Radiation|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
485226|NCT00512876|Drug|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
485227|NCT00512863|Drug|Humira (adalimumab)|
485228|NCT00512850|Dietary Supplement|Folic acid|Intervention group 1g folic acid per day
485229|NCT00512850|Other|Placebo|One placebo pill per day
485230|NCT00512837|Behavioral|Mobile phone technology|
485231|NCT00512824|Dietary Supplement|low calcium milk of 180 ml|twice daily for 24 weeks
485232|NCT00512824|Dietary Supplement|regular milk of 180 ml|twice daily for 24 weeks
485233|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
485234|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
485235|NCT00512811|Drug|furosemide|
485236|NCT00512798|Drug|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)~Level -1 0.7 mg/m2~Level 1 1.0 mg/m2~Level 2 1.0 mg/m2~Level 3 1.3 mg/m2~Level 4 1.5 mg/m2"
485237|NCT00512798|Drug|temozolomide|"Temozolomide (day 8)~Level - 1 50 mg/m2~Level 1 50 mg/m2~Level 2 75/mg/m2~Level 3 75 mg/m2~Level 4 75 mg/m2"
485238|NCT00512798|Other|immunoenzyme technique|Not noted
485239|NCT00512798|Drug|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
485240|NCT00512798|Drug|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
485241|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
485242|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
485243|NCT00512759|Drug|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
485244|NCT00512746|Other|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
502590|NCT00382629|Drug|BHT-3009 1.5 mg|
485245|NCT00512746|Other|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
485246|NCT00512746|Procedure|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
485247|NCT00512746|Procedure|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
485248|NCT00512707|Drug|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
485249|NCT00512707|Drug|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
485250|NCT00512707|Other|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
485251|NCT00512681|Drug|Irinotecan, Oxaliplatin, TS-1|"S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)~Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1~Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
485252|NCT00512668|Drug|leuprolide acetate|Given intramuscularly
485253|NCT00512668|Drug|goserelin acetate|Given subcutaneously
485254|NCT00512668|Drug|bicalutamide|Given PO
485255|NCT00512668|Drug|nilutamide|Given PO
485256|NCT00512668|Drug|flutamide|Given PO
485257|NCT00512668|Drug|temsirolimus|Given IV
485258|NCT00512668|Other|laboratory biomarker analysis|Optional correlative studies
485259|NCT00512655|Behavioral|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
485260|NCT00512629|Drug|Omegaven|Omegaven is a fish based intravenous fat emulsion
485261|NCT00512629|Drug|Intralipid|Intralipid is a plant based intravenous fat emulsion
485262|NCT00512616|Drug|Ceftriaxone|
485263|NCT00512590|Behavioral|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.~Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
485264|NCT00512577|Other|Red cell blood transfusion|
485265|NCT00512564|Other|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
485266|NCT00512551|Procedure|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
485267|NCT00512538|Device|Bi-layered cell therapy (Apligraf)|
485268|NCT00512525|Drug|Ghrelin and saline (as placebo)|Intravenous infusion
485269|NCT00512512|Procedure|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
485270|NCT00512499|Behavioral|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
485271|NCT00512499|Behavioral|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
485272|NCT00512499|Behavioral|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.~Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
485273|NCT00512486|Biological|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:~0.03 mg/kg intravenous injection~0.1 mg/kg intravenous injection~0.3 mg/kg intravenous injection~1.0 mg/kg intravenous injection~3.0 mg/kg intravenous injection~Following the -3.0 mg/kg dose level,~BIW-8405/MEDI-563 administered at one of two lower dose levels:~0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
485274|NCT00512473|Drug|Saline infusion|0.9 % NaCl
485275|NCT00512473|Drug|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
485276|NCT00512473|Drug|Pegvisomant|30 mg Somavert administered at t = - 36 hours
485277|NCT00512460|Drug|RTA 744|4.8 mg/m^2 by vein Over 2 Hours On Days 1-3.
485278|NCT00512434|Procedure|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
485279|NCT00512421|Procedure|computer-assisted surgery|
485280|NCT00512408|Drug|testosterone|
485281|NCT00512395|Drug|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
485282|NCT00512382|Device|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
485283|NCT00512356|Biological|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
485284|NCT00512317|Drug|ganaxolone|liquid suspension dosed tid
485285|NCT00512304|Procedure|association chemotherapy and radiochemotherapy|
485286|NCT00512291|Drug|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
485287|NCT00512278|Drug|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
485288|NCT00512278|Drug|Placebo|Placebo
485289|NCT00512265|Drug|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
485290|NCT00512265|Drug|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
485291|NCT00512252|Drug|AMD3100|
485292|NCT00512252|Drug|Mitoxantrone|
485293|NCT00512252|Drug|Etoposide|
485294|NCT00512252|Drug|Cytarabine|
485295|NCT00512226|Other|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2* MRI analysis.
485296|NCT00512213|Dietary Supplement|Immunonutrition for 5 days preoperative|Impact vs Meritene
485297|NCT00512213|Dietary Supplement|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
485298|NCT00512187|Other|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
485299|NCT00512174|Other|BladderScan BVI 3000|
485300|NCT00512148|Device|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
485301|NCT00512135|Drug|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
485302|NCT00512122|Other|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
485303|NCT00512122|Drug|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
485304|NCT00512096|Drug|Ifosfamide|1200 mg/m^2 By Vein Over 2 Hours on Days 1-3
485305|NCT00512096|Drug|Paclitaxel (Taxol)|175 mg/m^2 By Vein Over 3 Hours on Day 1
485306|NCT00512096|Drug|Cisplatin|25 mg/m^2 By Vein Over 2 Hours on Days 1-3
485307|NCT00512083|Drug|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
485308|NCT00512070|Drug|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
485309|NCT00512057|Drug|allopurinol|allopurinol 300mg twice a day
485310|NCT00512057|Drug|placebo|placebo
485311|NCT00512044|Procedure|Local anesthesia (pudendal block)|local anesthesia as indicated
485312|NCT00512044|Procedure|general anesthesia (spinal and general)|general according to guidelines
485313|NCT00512018|Device|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
485314|NCT00512018|Other|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
485315|NCT00512005|Device|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
485316|NCT00511992|Drug|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)~Consolidation Treatment:~Avastin 15mg/kg IV every 21 days x 12 cycles"
485317|NCT00511992|Drug|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
485318|NCT00511992|Drug|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
485319|NCT00511979|Drug|Technosphere Insulin|
485320|NCT00511979|Drug|Technosphere insulin|
485321|NCT00511979|Drug|Technosphere insulin|
485322|NCT00511979|Drug|Regular human insulin|
485323|NCT00511966|Other|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
485324|NCT00511966|Drug|Rabeprazole|As prescribed
485325|NCT00511953|Drug|Gabapentin Extended Release tablets|1800mg
485326|NCT00511953|Drug|Gabapentin|1800mg
485327|NCT00511940|Drug|acamprosate|999 mg/day - 2997 mg/day, oral
485328|NCT00511940|Other|placebo|oral, placebo
485329|NCT00511914|Biological|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
485330|NCT00511901|Drug|placebo|
485331|NCT00511901|Drug|epoetin alpha|
485332|NCT00511901|Drug|Niferex|
485333|NCT00511875|Drug|doxycycline monohydrate|50mg once daily for 24 months
485334|NCT00511875|Drug|placebo|placebo taken once daily for 24 months
485614|NCT00509626|Other|questionnaire administration|
485615|NCT00509626|Procedure|CAM exercise therapy|
485335|NCT00511862|Device|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
485336|NCT00511849|Drug|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
485337|NCT00511836|Drug|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
485338|NCT00511836|Drug|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
485339|NCT00511823|Drug|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
485340|NCT00511823|Drug|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
485341|NCT00511823|Drug|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
485342|NCT00511823|Drug|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
485343|NCT00511810|Drug|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
485344|NCT00511810|Drug|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
485345|NCT00511797|Drug|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
485346|NCT00511797|Drug|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
485347|NCT00511797|Drug|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
485348|NCT00511797|Drug|Placebo|Placebo
485349|NCT00511771|Drug|Tegaserod|Tegaserod maleate
485350|NCT00511758|Procedure|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
485351|NCT00511745|Drug|Rabeprazol|As prescribed
485352|NCT00511732|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
485353|NCT00511732|Drug|Technosphere Placebo|Technosphere Inhalation Powder
485354|NCT00511719|Drug|Technosphere Insulin|48U
485355|NCT00511719|Drug|Actrapid|24IU
485356|NCT00511706|Drug|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
485357|NCT00511706|Biological|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
485358|NCT00511706|Other|sham|Sham needle-less injection administered in the study eye at Day 1.
485359|NCT00511693|Behavioral|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
485360|NCT00511693|Behavioral|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
485361|NCT00511680|Behavioral|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
485362|NCT00511667|Drug|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
485363|NCT00511667|Drug|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
485364|NCT00511654|Drug|GW823296 tablet|GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
485365|NCT00511654|Drug|GW823296 matching placebo|Matching placebo tablets will be identical in appearance to the GW823296 tablets.
485366|NCT00511654|Drug|Midazolam|Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
485367|NCT00511641|Behavioral|Questionnaire|Questionnaires lasting up to 30 minutes.
485368|NCT00511628|Drug|Risperidone|As prescribed
485369|NCT00511615|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
485370|NCT00511602|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
485371|NCT00511602|Drug|Technosphere Placebo|Technosphere Inhalation Powder
485372|NCT00511589|Other|chagas disease diagnostic|
485373|NCT00511576|Drug|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.~In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.~There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
485375|NCT00511524|Drug|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
485376|NCT00511524|Drug|[carbonyl-^11C]GW842166|[carbonyl-^11C]GW842166 will b available as Intravenous solution.
485377|NCT00511498|Drug|Sildenafil|50 mg daily at bedtime
485378|NCT00511485|Drug|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
485379|NCT00511485|Drug|Etarfolatide|
485380|NCT00511472|Drug|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.~Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
485381|NCT00511472|Drug|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
485382|NCT00511472|Drug|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
485383|NCT00511459|Drug|AMG 386 Placebo|AMG 386 Placebo [blinded]
485384|NCT00511459|Drug|AMG 386|AMG 386 3mg/kg IV QW [blinded]
485385|NCT00511459|Drug|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
485386|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [Open-Label]
485387|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [blinded]
485388|NCT00511459|Drug|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
485389|NCT00511446|Drug|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops."
485390|NCT00511433|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28~for 6 consecutive 28-day menstrual cycles."
485391|NCT00511433|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
485392|NCT00511420|Dietary Supplement|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
485393|NCT00511420|Dietary Supplement|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
485394|NCT00511420|Dietary Supplement|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
485395|NCT00511420|Dietary Supplement|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
485396|NCT00511407|Device|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
485397|NCT00511394|Drug|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
485398|NCT00511394|Drug|Normal Saline|Infusion of 100 mL of Normal Saline
485399|NCT00511381|Genetic|No intervention|No intervention
485400|NCT00511368|Drug|matching placebo|
485401|NCT00511368|Drug|Bevirimat|
485402|NCT00511355|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
485403|NCT00511355|Drug|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
485404|NCT00511342|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
485405|NCT00511342|Drug|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
485406|NCT00511329|Drug|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
485407|NCT00511316|Drug|Montelukast/ Singulair|20 mg daily for six months
485408|NCT00511316|Drug|Placebo|Placebo 20 mg daily for 6 months
485409|NCT00511303|Drug|STI571|
485410|NCT00511290|Other|no generic names|
485411|NCT00511277|Drug|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
485412|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
485413|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
485414|NCT00511225|Dietary Supplement|cholecalciferol|10,000 IU weekly
485415|NCT00511225|Dietary Supplement|placebo|placebo capsule
485416|NCT00511212|Drug|intravenous immunoglobulin|
485417|NCT00511199|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg~NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
485418|NCT00511199|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
502591|NCT00382629|Drug|Placebo|
485419|NCT00511186|Drug|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
485420|NCT00511186|Drug|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
485421|NCT00511173|Genetic|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
485422|NCT00511160|Procedure|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
485423|NCT00511160|Procedure|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
485424|NCT00511147|Biological|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
485425|NCT00511134|Drug|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
485426|NCT00511134|Drug|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
485427|NCT00511121|Drug|STI571 and PEG INTRON|
485428|NCT00511108|Drug|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
485429|NCT00511108|Drug|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
485430|NCT00511108|Drug|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
485431|NCT00511108|Drug|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
485432|NCT00511095|Biological|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
485433|NCT00511082|Drug|OPB-31121|Patients will receive OPB-31121 administered orally, once daily for 4 weeks.
485434|NCT00511069|Drug|Bortezomib|
485435|NCT00511043|Drug|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
485436|NCT00511017|Drug|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
485437|NCT00511004|Drug|Albendazole|Comparing 400 mg to 800 mg dose
485438|NCT00511004|Drug|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
485439|NCT00510991|Device|nippv|
485440|NCT00510978|Biological|Bifidobacterium infantis 35624|1 sachet/day for one year
485441|NCT00510978|Biological|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
485442|NCT00510978|Biological|Placebo|1 sachet per day for 1 year
485443|NCT00510965|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
485444|NCT00510952|Drug|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
485445|NCT00510952|Drug|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
485446|NCT00510939|Drug|Tipifarnib plus Bortezomib|
485447|NCT00510926|Drug|Imatinib Mesilate (Glivec)|
485448|NCT00510913|Drug|tacrolimus|
485449|NCT00510887|Drug|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
485450|NCT00510887|Drug|Rituximab|Rituximab 375 mg/m2 IV on day 1
485451|NCT00510887|Drug|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
485452|NCT00510887|Drug|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
485453|NCT00510887|Drug|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
485454|NCT00510874|Biological|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
485455|NCT00510874|Biological|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
485456|NCT00510848|Procedure|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
485457|NCT00510848|Procedure|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
485458|NCT00510835|Procedure|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
485459|NCT00510835|Procedure|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
485460|NCT00510835|Procedure|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
485461|NCT00510822|Drug|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
485462|NCT00510822|Drug|Placebo|tablet
485463|NCT00510809|Drug|Policosanol|Policosanol 20 mg daily
485464|NCT00510809|Other|Placebo|Placebo daily
485465|NCT00510809|Drug|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
485466|NCT00510796|Behavioral|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
485467|NCT00510783|Drug|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
485468|NCT00510783|Drug|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
485616|NCT00509626|Procedure|management of therapy complications|
485469|NCT00510783|Drug|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
485470|NCT00510770|Device|CPAP application|
485471|NCT00510744|Drug|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
485472|NCT00510718|Drug|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
485473|NCT00510705|Other|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
485474|NCT00510705|Other|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
485475|NCT00510705|Other|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
485476|NCT00510692|Drug|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
485477|NCT00510692|Procedure|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
485478|NCT00510692|Procedure|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
485479|NCT00510692|Drug|Placebo|2 x 500mg placebo capsules twice daily for 6 months
485480|NCT00510679|Behavioral|Health worker supports (supervision, job aids, incentives)|
485481|NCT00510666|Drug|Saline|Saline infusion adjunct to morphine PCA pump
485482|NCT00510666|Drug|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
485483|NCT00510666|Drug|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
485484|NCT00510666|Drug|Saline|Preemptive saline as a control group to tramadol one
485485|NCT00510653|Drug|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
485486|NCT00510640|Drug|Sunitinib|Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
485487|NCT00510627|Device|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
485488|NCT00510627|Drug|Chemotherapy|Standard of care chemotherapy regimen
485489|NCT00510614|Drug|tinidazole|1 gram twice weekly for 12 weeks
485490|NCT00510614|Drug|Placebo|one pill twice weekly for 12 weeks
485491|NCT00510601|Device|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
485492|NCT00510588|Other|training|regular physical exercise training for 6 months
485493|NCT00510588|Other|training + metformin|regular physical exercise training in combination with metformin for 6 months
485494|NCT00510588|Other|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
485495|NCT00510575|Device|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
485496|NCT00510562|Procedure|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
485497|NCT00510562|Procedure|Sham/Placebo|A laying on of hands with no treatment being performed.
485498|NCT00510549|Procedure|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
485499|NCT00510536|Drug|Acetaminophen|dose to be determined by investigator
485500|NCT00510536|Drug|NSAID|dose to be determined by investigator
485501|NCT00510523|Device|Whole Body Vibration machine|
485502|NCT00510510|Drug|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
485503|NCT00510510|Drug|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
485504|NCT00510510|Drug|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
485505|NCT00510497|Biological|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
485506|NCT00510484|Drug|Pancrelipase Delayed Release|24000 unit Capsule
485507|NCT00510484|Drug|Placebo Comparator|Placebo
485508|NCT00510471|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
485509|NCT00510458|Device|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
485510|NCT00510445|Drug|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.~Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
485511|NCT00510419|Drug|"InvestigationalAuto-injector (sumatriptan succinate)"|
485512|NCT00510406|Drug|tamsulosin hydrochloride|Alphablocker
485513|NCT00510406|Drug|solifenacin succinate|antimuscarinic
485514|NCT00510406|Drug|Placebo|Placebo
485515|NCT00510393|Device|XIENCE V everolimus eluting coronary stent system|
485516|NCT00510393|Device|MULTILINK VISION coronary stent system|
485517|NCT00510367|Drug|5-Fluorouracil|500 mg/m^2 By Vein Daily x 2 Days
485518|NCT00510367|Drug|Cyclophosphamide|500 mg/m^2 By Vein On Day 1
485519|NCT00510367|Drug|Doxorubicin|50 mg/m^2 By Vein Over 72 Hours
485520|NCT00510354|Drug|Imatinib mesylate|
485521|NCT00510341|Behavioral|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
485522|NCT00510328|Device|Whole Body Vibration|
485523|NCT00510315|Other|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
485524|NCT00510302|Behavioral|Questionnaire|Questionnaire regarding melanoma risk-reduction.
485525|NCT00510302|Behavioral|Interview|Interview via telephone about topics related to melanoma risk-reduction.
485527|NCT00510276|Drug|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
485528|NCT00510276|Drug|Placebo|twice a day, by mouth for 12 weeks
485529|NCT00510263|Drug|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
485530|NCT00510263|Drug|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
485531|NCT00510263|Drug|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
485532|NCT00510263|Drug|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
485533|NCT00510250|Drug|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
485534|NCT00510250|Drug|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
485535|NCT00510250|Procedure|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
485536|NCT00510237|Behavioral|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
485537|NCT00510224|Drug|Sandostatin|Sandostatin 30mg intramuscular every 28 days
485538|NCT00510211|Drug|olanzapine|
485539|NCT00510198|Device|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
485540|NCT00510198|Device|Standard of Care alone (clinical assessment)|Clinical assessment utilizing standard of care, alone.
485541|NCT00510185|Other|systematic coronary intervention|Coronary angiography within 72 hrs
485542|NCT00510185|Other|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
485543|NCT00510172|Drug|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
485544|NCT00510172|Drug|Placebo|NaCL 0,9%
485545|NCT00510159|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
485546|NCT00510159|Drug|Praziquantel|
485547|NCT00510146|Drug|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
485548|NCT00510146|Drug|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
485549|NCT00510133|Biological|GRNVAC1|Autologous dendritic cell vaccine
485550|NCT00510120|Behavioral|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
485551|NCT00510120|Behavioral|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
485552|NCT00510120|Behavioral|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
485553|NCT00510107|Drug|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
485554|NCT00510107|Drug|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
485555|NCT00510094|Behavioral|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
485556|NCT00510094|Behavioral|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
485557|NCT00510081|Device|Calcium Hydroxylapatite injection|filler injection
485558|NCT00510068|Drug|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
485559|NCT00510068|Drug|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
485560|NCT00510055|Procedure|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
485561|NCT00510055|Procedure|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
485562|NCT00510029|Drug|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
485563|NCT00510016|Drug|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
485564|NCT00510003|Drug|Pimecrolimus|Pimecrolimus cream 1 %
485565|NCT00509990|Drug|Pimecrolimus|Pimecrolimus cream 1 %
485566|NCT00509977|Procedure|Light Treatment|Light treatment applied to half of the face at each study visit
485567|NCT00509977|Procedure|Laser Treatment|Laser treatment applied to half of the face at each study visit
485568|NCT00509964|Drug|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
485569|NCT00509964|Drug|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
485617|NCT00509626|Procedure|psychosocial assessment and care|
485618|NCT00509626|Procedure|quality-of-life assessment|
485619|NCT00509613|Drug|Sorafenib|
485620|NCT00509613|Drug|Sirolimus|
485570|NCT00509951|Behavioral|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
485571|NCT00509951|Behavioral|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
485572|NCT00509938|Drug|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
485573|NCT00509925|Drug|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
485574|NCT00509925|Drug|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
485575|NCT00509925|Drug|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
485576|NCT00509899|Drug|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
485577|NCT00509886|Drug|Drysol|20% aluminum chloride hexahydrate
485578|NCT00509886|Drug|Drioff|1% aluminum acetate
485579|NCT00509873|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
485580|NCT00509873|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
485581|NCT00509860|Drug|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
485582|NCT00509847|Drug|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
485583|NCT00509834|Drug|hLF1-11|"The study treatment consists of IV administration of:~(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
485584|NCT00509834|Drug|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
485585|NCT00509834|Drug|Placebo|Placebo
485586|NCT00509821|Drug|Enzastaurin 500 milligram (mg) Once Daily (QD)|1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression, given with and without radiotherapy treatment.
485587|NCT00509821|Drug|Enzastaurin 250 mg Twice Daily (BID)|1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression, given with and without radiotherapy treatment.
485588|NCT00509808|Device|Electrostimulation|"1st month GN wearing (activated or sham mode)~2nd month wearing (opposite mode)~3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes~6th - 8th month: activated GN wearing for 1, 5 or 10 minutes~9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
485589|NCT00509795|Biological|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
485590|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
485591|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
485592|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
485593|NCT00509782|Drug|ZIO-101|Starting Dose 78 mg/m^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
485594|NCT00509769|Drug|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
485595|NCT00509756|Drug|FXR-450|capsule, single oral doses from 10 mg to 450 mg
485596|NCT00509756|Drug|Placebo|capsule similar to active drug
485597|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
485598|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
485599|NCT00509730|Procedure|Urodynamics|
485600|NCT00509717|Other|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
485601|NCT00509717|Other|control|educational manual
485602|NCT00509691|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
485603|NCT00509691|Genetic|polymerase chain reaction|
485604|NCT00509691|Other|diagnostic laboratory biomarker analysis|
485605|NCT00509691|Other|flow cytometry|
485606|NCT00509691|Other|immunologic technique|
485607|NCT00509678|Drug|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
485608|NCT00509665|Drug|doxorubicin hydrochloride|given as 25mgm2 IV on days 1 and 8 of each 21-day cycle.
485609|NCT00509665|Drug|gemcitabine hydrochloride|given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
485610|NCT00509652|Procedure|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
485611|NCT00509652|Procedure|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
485612|NCT00509639|Drug|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
485613|NCT00509626|Behavioral|exercise intervention|
502663|NCT00382096|Drug|Metformin|
485621|NCT00509600|Drug|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
485622|NCT00509587|Drug|pazopanib hydrochloride|Given orally
485623|NCT00509587|Procedure|pharmacological study|Correlative studies
485624|NCT00509587|Procedure|laboratory biomarker analysis|Correlative studies
485625|NCT00509561|Biological|cetuximab|
485626|NCT00509561|Drug|capecitabine|
485627|NCT00509561|Drug|cisplatin|
485628|NCT00509561|Radiation|radiation therapy|
485629|NCT00509548|Drug|TG100801|Eye drop, twice a day, 30 days.
485630|NCT00509535|Drug|vitreoscilla filiformis cream|
485631|NCT00509496|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days.
485632|NCT00509496|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenous
485633|NCT00509496|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
485634|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes."
485635|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes."
485636|NCT00509483|Radiation|Radioactive iodine|Radioactive iodine preceded by rhTSH
485637|NCT00509470|Drug|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
485638|NCT00509470|Device|Amlodipine|
485639|NCT00509457|Biological|GV 1001 Telomerase peptide|
485640|NCT00509444|Behavioral|Educational materials|
485641|NCT00509444|Behavioral|educational materials, plus patient navigation|
485642|NCT00509431|Drug|Erlotinib + Sirolimus|In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
485643|NCT00509418|Dietary Supplement|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
485644|NCT00509418|Other|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
485645|NCT00509405|Drug|potassium citrate|6 times 10 mEq per day, oral for 24 months
485646|NCT00509392|Device|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
485647|NCT00509392|Device|Endovenous Laser|laser catheter
485648|NCT00509379|Drug|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
485649|NCT00509379|Drug|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
485650|NCT00509366|Drug|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
485651|NCT00509366|Drug|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
485652|NCT00509366|Drug|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
485653|NCT00509366|Drug|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
485654|NCT00509353|Drug|irinotecan hydrochloride|
485655|NCT00509353|Drug|vincristine sulfate|
485656|NCT00509353|Radiation|iobenguane I 131|
485657|NCT00509340|Behavioral|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
485658|NCT00509327|Drug|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
485659|NCT00509327|Drug|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
485660|NCT00509314|Behavioral|melanocyte self-assembly and functional analysis|
485661|NCT00509301|Drug|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
485662|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.~A minimum of approximately 5 X 10^8 cells will be given up to 3x10^11 anti-MART-1 F5 TCR engineered TIL or PBL."
485663|NCT00509288|Drug|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
485664|NCT00509288|Drug|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
485665|NCT00509288|Biological|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e^11 (with a minimum of 5x10e^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
485666|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
485667|NCT00509275|Drug|W0027|capsule
485668|NCT00509275|Drug|Placebo|Placebo
485669|NCT00509262|Drug|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
485670|NCT00509262|Drug|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
485671|NCT00509262|Drug|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
485672|NCT00509262|Drug|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
485673|NCT00509249|Biological|ziv-aflibercept|Given IV
485674|NCT00509249|Other|laboratory biomarker analysis|Correlative studies
485675|NCT00509249|Other|pharmacological study|Correlative studies
485676|NCT00509236|Drug|Sitagliptin|25 mg (one 25-mg tablet) once daily
485677|NCT00509236|Drug|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
485678|NCT00509223|Device|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
485679|NCT00509223|Behavioral|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
485680|NCT00509210|Drug|telaprevir (VX-950)|
485681|NCT00509197|Drug|Placebo (sham inhaler)|
485682|NCT00509197|Drug|Fluticasone|Fluticasone 250mcg bid for one month
485683|NCT00509184|Drug|Rituximab|375 mg/m^2, weekly (4 weeks), repeated after 4 weeks gap
485684|NCT00509171|Device|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
485685|NCT00509158|Biological|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
485686|NCT00509158|Biological|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
485687|NCT00509145|Drug|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
485688|NCT00509145|Other|Placebo|oral, once daily, capsule
485689|NCT00509132|Drug|trodusquemine|
485690|NCT00509106|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
485691|NCT00509106|Drug|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
485692|NCT00509106|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
485693|NCT00509093|Drug|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
485694|NCT00509093|Genetic|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
485695|NCT00509093|Genetic|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
485696|NCT00509093|Genetic|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
485697|NCT00509093|Other|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
485698|NCT00509093|Procedure|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
485699|NCT00509067|Drug|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
485700|NCT00509067|Drug|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
485701|NCT00509067|Drug|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
485702|NCT00509067|Drug|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
485703|NCT00509054|Procedure|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
485704|NCT00509041|Drug|dasatinib|50 mg PO bid
485705|NCT00509028|Drug|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
485706|NCT00509028|Drug|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
485707|NCT00509015|Drug|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S&25mg P/20 kg, 1 day, single dose
485708|NCT00509015|Drug|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
485709|NCT00509015|Drug|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
485710|NCT00509015|Drug|placebo tablets|3 days of lactose tablets (160mg) albochin
485711|NCT00509002|Drug|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
485712|NCT00508989|Drug|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
505705|NCT00357786|Drug|Replagal|
485713|NCT00508989|Drug|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
485714|NCT00508989|Drug|L-NMMA|
485715|NCT00508989|Drug|Acetylcholine|
485716|NCT00508976|Drug|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
485717|NCT00508976|Drug|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
485718|NCT00508976|Drug|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
485719|NCT00508976|Drug|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
485720|NCT00508963|Drug|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
485721|NCT00508950|Procedure|Large volume blood draw|Large volume blood draw
485722|NCT00508937|Other|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
485723|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
485724|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
485725|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
485726|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
485727|NCT00508924|Drug|Argatroban|
485728|NCT00508924|Drug|Argatroban|
485729|NCT00508924|Drug|Argatroban|
485730|NCT00508924|Drug|Heparin|
485731|NCT00508911|Drug|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
485732|NCT00508911|Drug|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
485733|NCT00508898|Drug|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
485734|NCT00508898|Drug|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
485735|NCT00508885|Drug|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
485736|NCT00508885|Drug|Placebo|Placebo
485737|NCT00508872|Drug|5-Fluorouracil|400 mg/m^2 IV over 15 minutes, followed by 2400 mg/m^2 IV Over 46 Hours
485738|NCT00508872|Drug|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
485739|NCT00508872|Drug|Leucovorin|400 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
485740|NCT00508872|Drug|Oxaliplatin|85 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
485741|NCT00508859|Drug|Sertraline|maintenance treatment with sertraline
485742|NCT00508859|Drug|placebo|placebo
485743|NCT00508846|Behavioral|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
485744|NCT00508833|Biological|287615 containing HBsAg with adjuvants|
485745|NCT00508820|Biological|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
485746|NCT00508807|Drug|RTA 402|5 mg by mouth (PO) daily for 21 days
485747|NCT00508794|Behavioral|Yoga Group|3 sessions of yoga each week for 6 weeks.
485748|NCT00508794|Behavioral|Stretching Control Group|3 sessions of stretching each week for 6 weeks
485749|NCT00508794|Behavioral|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
485750|NCT00508794|Other|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
485751|NCT00508781|Behavioral|Multiphoton laser image in cutaneous pathology|
485752|NCT00508768|Drug|Oral SCIO-469 capsule|
485753|NCT00508755|Device|Gait Robot|gait training with the use of a gait robot
485754|NCT00508755|Device|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
485755|NCT00508742|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
485756|NCT00508742|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
485757|NCT00508729|Drug|Qingyi granules|
485758|NCT00508716|Behavioral|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
485759|NCT00508703|Radiation|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
485760|NCT00508703|Procedure|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
485761|NCT00508690|Drug|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
485909|NCT00507585|Drug|Fluorouracil|300 mg/m^2 IV over 10 Minutes, then 600 mg/m^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
485762|NCT00508690|Drug|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
485763|NCT00508664|Radiation|Radiation|Radiation start in week 11
485764|NCT00508664|Drug|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
485765|NCT00508664|Drug|Docetaxel|75 mg/m2 i.v. day 1 3 times
485766|NCT00508664|Drug|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
485767|NCT00508664|Drug|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
485768|NCT00508651|Biological|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
485769|NCT00508651|Biological|Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
485770|NCT00508625|Drug|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
485771|NCT00508625|Drug|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
485772|NCT00508625|Drug|Carboplatin|Standard platinum based chemotherapy
485773|NCT00508625|Drug|Paclitaxel|Standard taxane chemotherapy
485774|NCT00508612|Behavioral|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
485775|NCT00508612|Behavioral|High school classes|The control group will attend regular high school classes.
485776|NCT00508599|Other|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
485777|NCT00508586|Drug|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
485778|NCT00508573|Behavioral|Questionnaire|Follow-up questionnaire done once a year for five years.
485779|NCT00508560|Behavioral|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
485780|NCT00508560|Behavioral|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
485781|NCT00508547|Biological|Ustekinumab|Ustekinumab will be administered as prescribed by physician.
485782|NCT00508547|Biological|Biological therapies other than infliximab, ustekinumab and guselkumab|Biological therapies will be administered as prescribed by physician.
485783|NCT00508547|Drug|Conventional systemic agents|Conventional systemic agents will be administered as prescribed by physician.
485784|NCT00508547|Biological|Infliximab|Infliximab will be administered as prescribed by physician.
485785|NCT00508547|Biological|Guselkumab|Guselkumab will be administered as prescribed by physician.
485786|NCT00508534|Drug|SB-751689|
485787|NCT00508521|Device|Functional Electrical Stimulation|commercially available surface electrical stimulator
485788|NCT00508521|Other|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
485789|NCT00508508|Behavioral|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
485790|NCT00508508|Behavioral|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
485791|NCT00508495|Drug|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
485792|NCT00508495|Drug|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
485793|NCT00508495|Drug|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
485794|NCT00508482|Other|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks."
485795|NCT00508482|Drug|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
485796|NCT00508482|Other|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
485797|NCT00508469|Drug|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
485798|NCT00508469|Drug|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
485799|NCT00508469|Drug|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
485800|NCT00508469|Device|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
485801|NCT00508456|Drug|Temodar (Temozolomide)|150 mg/m^2 orally once a day for 7 consecutive days (days 8 through 15).
485802|NCT00508456|Dietary Supplement|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
485803|NCT00508443|Radiation|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
485804|NCT00508430|Drug|ASP8825|oral
485805|NCT00508430|Drug|Placebo|oral
485806|NCT00508404|Drug|Panitumumab|Administered by intravenous infusion
485859|NCT00507988|Behavioral|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
485807|NCT00508404|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
485808|NCT00508391|Device|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
485809|NCT00508378|Behavioral|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
485810|NCT00508378|Behavioral|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
485811|NCT00508365|Drug|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
485812|NCT00508365|Drug|Placebo|Placebo capsules to match each dose level will be provided.
485813|NCT00508365|Drug|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
485814|NCT00508352|Procedure|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
485815|NCT00508339|Behavioral|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
485816|NCT00508326|Drug|Paclitaxel|Starting dose 150 mg/m^2 HAI once every 4 weeks
485817|NCT00508313|Procedure|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
485818|NCT00508300|Procedure|Epidural analgesia|Thoracic epidural analgesia until day 2
485819|NCT00508300|Procedure|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
485820|NCT00508287|Drug|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
485821|NCT00508287|Drug|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
485822|NCT00508287|Drug|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
485823|NCT00508274|Drug|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
485824|NCT00508261|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection
485825|NCT00508261|Biological|Infanrix™ hexa|Single dose intramuscular injection
485826|NCT00508261|Biological|Meningitec™|Single dose intramuscular injection
485827|NCT00508248|Dietary Supplement|omega 3 fatty acids|1g daily
485828|NCT00508248|Dietary Supplement|placebo|olive oil capsule
485829|NCT00508235|Behavioral|Questionnaire|Questionnaire about the patient's relationship with their best friend.
485830|NCT00508222|Drug|Kaletra Tablets|Kaletra 800/200 OD
485831|NCT00508209|Drug|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
485832|NCT00508196|Other|RVP-min|DDD pacing with long AV delay
485833|NCT00508196|Other|RVP-max|DDD pacing with short AV delay
485834|NCT00508183|Procedure|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
485835|NCT00508183|Procedure|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
485836|NCT00508170|Behavioral|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
485837|NCT00508157|Drug|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
485838|NCT00508157|Drug|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
485839|NCT00508144|Drug|Alimta|500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks
485840|NCT00508131|Other|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
485841|NCT00508118|Drug|Nicardipine|on bypass
485842|NCT00508118|Drug|0.9% saline|on bypass
485843|NCT00508105|Procedure|tenotomy|This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.
485844|NCT00508105|Procedure|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
485845|NCT00508092|Procedure|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight~OR~Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
485846|NCT00508066|Drug|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
485847|NCT00508066|Drug|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
485848|NCT00508053|Procedure|Small stitches|
485849|NCT00508053|Procedure|Mass closure|
485850|NCT00508040|Drug|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
485851|NCT00508040|Drug|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
485852|NCT00508027|Drug|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
485853|NCT00508014|Other|Usual Care|Usual Care with primary care provider during time period
485854|NCT00508014|Behavioral|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
485855|NCT00508001|Drug|Vandetanib|ZD6474 300mg
485856|NCT00508001|Drug|Vandetanib|ZD6474 100 mg
485857|NCT00508001|Drug|Best Supportive Care|Placebo + Best Supportive Care
485858|NCT00507988|Behavioral|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
487007|NCT00499473|Drug|sunitinib malate|Given orally
485860|NCT00507975|Drug|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
485861|NCT00507962|Drug|Cisplatin|100 mg/m^2 Intraarterial On Day 1 Every 4 Weeks
485862|NCT00507962|Drug|Liposomal Doxorubicin|Starting dose 20 mg/m^2 IV On Day 1 Every 4 Weeks
485863|NCT00507949|Drug|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
485864|NCT00507949|Drug|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
485865|NCT00507936|Drug|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
485866|NCT00507936|Drug|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
485867|NCT00507936|Drug|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
485868|NCT00507936|Drug|placebo|placebo capsule BID throughout the treatment period
485869|NCT00507936|Drug|Duloxetine|Duloxetine 60 mg QD throughout treatment period
485870|NCT00507923|Behavioral|Tibetan Yoga|4 sessions of yoga over 12 weeks.
485871|NCT00507923|Behavioral|Stretching Program|4 sessions of simple stretching exercises for 12 weeks. Each session lasting 90 minutes.
485872|NCT00507923|Other|No Intervention|Option of participating in the Tibetan yoga program after completion of the study.
485873|NCT00507923|Behavioral|Questionnaire|Questionnaires to be completed before and after the end of the yoga or stretching sessions (or similar time for the usual care group).
485874|NCT00507923|Behavioral|Booster Program|"3 booster sessions consisting of a review and practice of the entire program."
485875|NCT00507884|Procedure|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
485876|NCT00507858|Drug|Pemetrexed|Starting dose of 500 mg/m^2 IV Once Over 10 Minutes Every 3 Weeks
485877|NCT00507858|Drug|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
485878|NCT00507845|Drug|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
485879|NCT00507832|Drug|Pimecrolimus|twice daily topical
485880|NCT00507832|Drug|Hydrocortisone|twice daily topical
485881|NCT00507832|Drug|Pimecrolimus|topical application as a cream twice daily
485882|NCT00507819|Drug|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
485883|NCT00507819|Drug|Placebo|One placebo capsule will be taken by mouth three times-a-day.
485884|NCT00507806|Drug|perflutren lipid microsphere|
485885|NCT00507793|Drug|Sirolimus|
485886|NCT00507793|Drug|Cyclosporine|
485887|NCT00507780|Drug|GnRH antagonist|
485888|NCT00507767|Drug|dasatinib|Given PO or via PEG tube
485889|NCT00507767|Procedure|pharmacological study|Correlative studies
485890|NCT00507767|Procedure|laboratory biomarker analysis|Correlative studies
485891|NCT00507754|Other|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
485892|NCT00507741|Drug|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
485893|NCT00507741|Drug|Ertafolide|
485894|NCT00507728|Drug|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
485895|NCT00507728|Drug|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
485896|NCT00507728|Drug|Placebo|Placebo by mouth for 12 weeks.
485897|NCT00507728|Behavioral|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
485898|NCT00507715|Drug|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
485899|NCT00507715|Other|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
485900|NCT00507702|Procedure|phlebotomy|Standard of care
485901|NCT00507689|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
485902|NCT00507689|Drug|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
485903|NCT00507663|Drug|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
485904|NCT00507650|Dietary Supplement|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
485905|NCT00507650|Dietary Supplement|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
485906|NCT00507637|Drug|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
485907|NCT00507611|Procedure|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
485908|NCT00507598|Other|No intervention|Correlative study collecting serum and tissue samples
487008|NCT00499473|Other|pharmacological study|Correlative studies
485910|NCT00507585|Drug|Avastin|10 mg/m^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
485911|NCT00507585|Drug|Leucovorin|200 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
485912|NCT00507585|Drug|Oxaliplatin|60 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
485913|NCT00507572|Other|Data Collection|Information about the type of cancer, type of treatment, and details about pregnancy will be collected.
485914|NCT00507559|Device|Aptus Endovascular AAA Repair System|EVAR (endovascular aneurysm repair)
485915|NCT00507546|Drug|Ramelteon|8 mg nightly
485916|NCT00507546|Drug|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
485917|NCT00507533|Procedure|Continuous positive airway pressure|
485918|NCT00507520|Procedure|Full dose almonds|
485919|NCT00507520|Procedure|Half dose almonds+half dose muffin|
485920|NCT00507520|Procedure|Full dose whole wheat muffin|
485921|NCT00507507|Drug|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
485922|NCT00507507|Drug|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
485923|NCT00507507|Drug|Placebo|Placebo to match FTC taken once daily
485924|NCT00507494|Drug|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
485925|NCT00507468|Procedure|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
485926|NCT00507455|Drug|solifenacin succinate|Solifenacin succinate tablets
485927|NCT00507455|Drug|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
485928|NCT00507455|Drug|Placebo to solifenacin|
485929|NCT00507455|Drug|Placebo to tamsulosin|
485930|NCT00507442|Drug|VELCADE (bortezomib)|bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
485931|NCT00507442|Drug|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
485932|NCT00507442|Drug|cyclophosphamide|cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
485933|NCT00507442|Drug|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)~lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
485934|NCT00507429|Drug|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
485935|NCT00507429|Drug|paclitaxel|200mg/m squared on Day 1
485936|NCT00507429|Drug|carboplatin|6 AUC on Day 1 following paclitaxel
485937|NCT00507416|Drug|Bortezomib|Bortezomib bolus intravenous (IV) injection
485938|NCT00507416|Drug|Dexamethasone|Dexamethasone for oral administration
485939|NCT00507416|Drug|Melphalan|Melphalan for oral administration
485940|NCT00507416|Drug|Prednisone|Prednisone for oral administration
485941|NCT00507416|Drug|Thalidomide|Thalidomide for oral administration
485942|NCT00507403|Drug|infliximab|
485943|NCT00507390|Dietary Supplement|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
485944|NCT00507390|Dietary Supplement|olive oil|1 capsule day
485945|NCT00507364|Drug|Local injection of activated macrophages to anal fissure|
485946|NCT00507351|Behavioral|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
485947|NCT00507338|Procedure|PCI|early PCI for NSTEMI; primary PCI for STEMI
485948|NCT00507325|Procedure|Blood Sample|Blood samples will be collected.
485949|NCT00507325|Procedure|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
485950|NCT00507312|Device|HD medical device (ViScope)|Device
485951|NCT00507312|Device|CSIRO device|device
485952|NCT00507299|Behavioral|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
485953|NCT00507299|Behavioral|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
485954|NCT00507286|Drug|combination of various doses of sildenefil and alprostadil|
485955|NCT00507273|Other|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
485956|NCT00507260|Behavioral|Food Record|A record of the amount and kind of food and drink you intake will be completed.
485957|NCT00507260|Other|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
485958|NCT00507247|Drug|Daptomycin|6mg/kg/day IV for at least 10 days.
485959|NCT00507234|Drug|formoterol fumarate inhalation solution|
485960|NCT00507221|Drug|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):~400mg/day X 3 days"
485961|NCT00507221|Drug|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
485962|NCT00507221|Drug|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
485963|NCT00507208|Device|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
485964|NCT00507208|Other|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
485965|NCT00507195|Drug|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
485966|NCT00507182|Procedure|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
485967|NCT00507169|Drug|SVT-40776|
506124|NCT00354666|Drug|GSK159797|
485968|NCT00507156|Procedure|Standard primary PCI|Acute re-opening of the occluded coronary artery
485969|NCT00507156|Procedure|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
485970|NCT00507143|Drug|irinotecan|
485971|NCT00507130|Biological|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
485972|NCT00507130|Biological|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
485973|NCT00507130|Biological|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
485974|NCT00507130|Other|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
485975|NCT00507117|Drug|Lunesta|Lunesta 3mg prior to PSG
485976|NCT00507117|Drug|Placebo control|matching placebo
485977|NCT00507091|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
485978|NCT00507091|Drug|Irinotecan|intravenous infusion
485979|NCT00507091|Drug|5-Fluorouracil|intravenous infusion
485980|NCT00507091|Drug|Leucovorin|intravenous infusion
485981|NCT00507091|Drug|ZD6474 (vandetanib) 300mg|once daily oral tablet
485982|NCT00507078|Procedure|Surgical treatment for OSA|
485983|NCT00507065|Drug|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
485984|NCT00507065|Drug|Placebo|
485985|NCT00507052|Drug|N-acetylcysteine|
485986|NCT00507039|Procedure|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
485987|NCT00507026|Drug|IV Diclofenac|IV Diclofenac q6h
485988|NCT00507026|Drug|IV ketorolac|IV ketorolac q6h
485989|NCT00507026|Drug|Placebo|Placebo q6h
485990|NCT00507013|Device|QuickClose device|
485991|NCT00507000|Drug|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
485992|NCT00507000|Drug|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
485993|NCT00506987|Drug|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
485994|NCT00506987|Drug|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
485995|NCT00506974|Drug|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
485996|NCT00506961|Drug|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
485997|NCT00506961|Drug|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
485998|NCT00506948|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
485999|NCT00506948|Drug|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
486000|NCT00506948|Drug|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
486001|NCT00506948|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
486002|NCT00506935|Drug|GVG|5 grams GVG
486003|NCT00506935|Drug|placebo|placebo
486004|NCT00506922|Drug|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:~Group 2 - Pentostatin 0.5 mg/m^2~Group 3 - Pentostatin 1 mg/m^2~Group 4 - Pentostatin 1.5 mg/m^2~Group 5 - Pentostatin 2 mg/m^2"
486005|NCT00506922|Drug|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
486006|NCT00506922|Drug|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
486007|NCT00506909|Drug|Oxytocin|20 IU BID or 40 IU BID
486008|NCT00506909|Drug|Placebo|20 IU BID or 40 IU BID
486009|NCT00506896|Drug|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
486010|NCT00506883|Drug|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
486011|NCT00506883|Drug|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
486012|NCT00506883|Other|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
486013|NCT00506870|Device|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
486014|NCT00506870|Device|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
486015|NCT00506857|Drug|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
486016|NCT00506857|Drug|Fludarabine|30 mg/m^2 by vein daily x 4 days.
486017|NCT00506844|Drug|Cetuximab, Irinotecan, Capecitabine|
486199|NCT00505635|Drug|Intron-A|5 mu/m^2 Subcutaneously (Under the skin) Daily On Days 1-5
486018|NCT00506831|Drug|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
486019|NCT00506818|Other|Multifactorial vascular-risk-factor-intervention|
486020|NCT00506805|Drug|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
486021|NCT00506792|Drug|QAU145|
486022|NCT00506792|Drug|Placebo|
486023|NCT00506779|Drug|Imatinib Mesylate|"Phase I = 400 mg by mouth daily~Phase II (Arm 2) = 400 mg by mouth daily"
486024|NCT00506779|Drug|Paclitaxel|175 mg/m^2 by vein Over 3 Hours Every 21 Days
486025|NCT00506766|Behavioral|Bladder Health Class consisting of 6 weekly group sessions|1 time
486026|NCT00506766|Behavioral|Practice PFMT and BT|As needed for 4 years
486027|NCT00506766|Behavioral|Clinic examination for pelvic muscle function|1/year for 4 years
486028|NCT00506766|Behavioral|Record keeping in 3-day voiding diary|Every 6 months for 4 years
486029|NCT00506753|Behavioral|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
486030|NCT00506753|Behavioral|RT/SU|Relaxation Training followed by Treatment as Usual
486031|NCT00506740|Device|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
486032|NCT00506740|Device|monopolar electrosurgery generator and tip|
486033|NCT00506727|Drug|Mixed amphetamine salts (ADDERALL XR)|
486034|NCT00506727|Drug|Atomoxetine hydrochloride|
486035|NCT00506714|Device|single point cane|Adjustable single point cane with SureGrip handle
486036|NCT00506701|Drug|Tadalafil|40 mg tablet
486037|NCT00506688|Drug|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
486038|NCT00506688|Drug|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
486039|NCT00506675|Device|Patching|42 hours per week of patching
486040|NCT00506675|Drug|Atropine|daily atropine (1%)
486041|NCT00506675|Device|Patching|two hours of daily patching for 4 weeks, then no treatment
486042|NCT00506675|Drug|Atropine|once weekly atropine for 4 weeks, then no treatment
486043|NCT00506662|Drug|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
486044|NCT00506662|Drug|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
486045|NCT00506649|Other|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
486046|NCT00506636|Behavioral|Tissue engineering for hair follicle regeneration|
486047|NCT00506623|Drug|Capecitabine, Irinotecan|
486048|NCT00506610|Drug|T-62|
486049|NCT00506597|Drug|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
486050|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
486051|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
486052|NCT00506584|Dietary Supplement|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
486053|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
486054|NCT00506584|Dietary Supplement|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
486055|NCT00506571|Drug|S-1, irinotecan, oxaliplatin|
486056|NCT00506558|Procedure|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
486057|NCT00506558|Procedure|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
486058|NCT00506545|Drug|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
486059|NCT00506545|Drug|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
486060|NCT00506532|Drug|Surfactant (calfactant)|
486061|NCT00506519|Drug|antithrombin alfa (INN name)|
486062|NCT00506506|Drug|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
486063|NCT00506506|Drug|Placebo|
486064|NCT00506493|Device|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
486065|NCT00506493|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
486066|NCT00506480|Procedure|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
486067|NCT00506467|Procedure|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
486068|NCT00506454|Drug|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
486069|NCT00506454|Drug|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
486070|NCT00506441|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
486071|NCT00506441|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
486072|NCT00506428|Behavioral|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
486073|NCT00506415|Drug|Rivastigmine 5 cm^2|5 cm^2 transdermal patch
486074|NCT00506415|Drug|Rivastigmine 10 cm^2|10 cm^2 transdermal patch.
486075|NCT00506415|Drug|Rivastigmine 15 cm^2|15 cm^2 transdermal patch.
486076|NCT00506415|Drug|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm^2.
486077|NCT00506415|Drug|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm^2.
486078|NCT00506402|Drug|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
486079|NCT00506389|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name corn starch), magnesium stearate, and lactose monohydrate.
486080|NCT00506389|Drug|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
486081|NCT00506376|Behavioral|Interview|Interview that will take about 20 minutes to complete.
486082|NCT00506363|Procedure|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
486083|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
486084|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
486085|NCT00506337|Drug|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.~Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
486086|NCT00506311|Drug|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
486087|NCT00506298|Drug|bezafibrate + diflunisal|bezafibrate + diflunisal
486088|NCT00506298|Drug|bezafibrate + placebo|bezafibrate + placebo
486089|NCT00506285|Drug|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
486090|NCT00506285|Other|placebo patch|This patch is designed to appear identical to the actual intervention patch
486091|NCT00506272|Procedure|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
486092|NCT00506272|Procedure|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
486093|NCT00506259|Drug|dTR Melatonin (NIH CC PDS)|
486094|NCT00506259|Device|Phototherapy (Bright Light)|
486095|NCT00506259|Drug|Melatonin CR|
486096|NCT00506246|Drug|Propofol|"intravenous (total intravenous anaesthesia)~induction and maintenance"
486097|NCT00506233|Behavioral|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
486098|NCT00506207|Drug|S-1, Irinotecan, Oxaliplatin|
486099|NCT00506194|Drug|Insulin|
486100|NCT00506194|Drug|OAD|Gliclazide-MR, Metformin, Glimepiride
486101|NCT00506181|Drug|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
486102|NCT00506181|Drug|Placebo|
486103|NCT00506168|Drug|Irinotecan, Capecitabine|
486104|NCT00506155|Drug|Avastin|10 mg/kg by vein over 90 minutes
486105|NCT00506155|Drug|Cisplatin|70 mg/m^2 by vein over 4 hours
486106|NCT00506155|Drug|Doxorubicin|30 mg/m^2 by vein over 15 minutes
486107|NCT00506155|Drug|Methotrexate|30 mg/m^2 by vein over 30 minutes
486108|NCT00506155|Drug|Vinblastine Sulfate|3 mg/m^2 by vein over 30 minutes
486109|NCT00506142|Drug|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
486110|NCT00506129|Drug|Fludarabine|25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
486111|NCT00506129|Drug|Melphalan|70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
486112|NCT00506129|Procedure|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
486113|NCT00506129|Drug|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
486114|NCT00506116|Behavioral|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
486115|NCT00506116|Behavioral|PME practice and record keeping (in diaries)|
486116|NCT00506116|Behavioral|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
486117|NCT00506116|Procedure|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
486118|NCT00506090|Procedure|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
486119|NCT00506077|Drug|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
486120|NCT00506077|Drug|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
486121|NCT00506064|Drug|Melatonin|0.15 mg/kg by mouth (PO) Daily
486122|NCT00506064|Drug|Placebo|Two, three, or four starch tablet or capsules before bed
486123|NCT00506064|Behavioral|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
486124|NCT00506051|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
486125|NCT00506051|Drug|pemetrexed|intravenous infusion
486126|NCT00506051|Drug|ZD6474 (vandetanib) 300mg|
486127|NCT00506038|Procedure|fine needle technique|
486128|NCT00506025|Dietary Supplement|Cranberry Juice|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
486129|NCT00506025|Dietary Supplement|De-Activated Cranberry juice|De-Activated Cranberry juice in the am, then placebo (P) in the pm
486130|NCT00506012|Drug|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
486131|NCT00505999|Behavioral|Questionnaire|Questionnaire taking 30-40 minutes to complete.
486132|NCT00505986|Procedure|endometrial biopsy|
486133|NCT00505973|Drug|SCA-136|
486134|NCT00505960|Behavioral|Diabetes Care for Korean Americans|Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
486135|NCT00505947|Drug|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
486136|NCT00505947|Drug|placebo|placebo 5 mg/Kg body weight by intravenous infusion
486137|NCT00505934|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days~Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).~For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:~Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily).~Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
486138|NCT00505921|Drug|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
486139|NCT00505921|Drug|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
486140|NCT00505921|Drug|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
486141|NCT00505921|Drug|BCNU|300 mg/m2 IV over 1 hour on day -6
486142|NCT00505921|Drug|Stem Cell Transplant|Stem cell infusion on Day 0.
486143|NCT00505921|Drug|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
486144|NCT00505921|Drug|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
486145|NCT00505921|Drug|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
486146|NCT00505921|Drug|Melphalan|140 mg/m2 IV on day -1.
486147|NCT00505921|Drug|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
486148|NCT00505921|Drug|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
486149|NCT00505921|Drug|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
486150|NCT00505921|Radiation|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
486151|NCT00505895|Drug|Melphalan|Arm 1 = 140 mg/m^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m^2 intravenous over 20 Minutes on Day -1.
486152|NCT00505895|Drug|Fludarabine|30 mg/m^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
486153|NCT00505895|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
486154|NCT00505895|Drug|Rituximab|375 mg/m^2 intravenous on Day -5, +2 +9 and +16.
486155|NCT00505882|Drug|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
486156|NCT00505882|Drug|Glargine|
486157|NCT00505882|Drug|Lispro|
486158|NCT00505882|Drug|Aspart|
486200|NCT00505635|Drug|Thalidomide|400 mg By Mouth Daily
486201|NCT00505622|Drug|Perampanel|
486159|NCT00505869|Behavioral|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
486160|NCT00505869|Behavioral|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
486161|NCT00505869|Behavioral|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
486162|NCT00505843|Drug|MK0657|7mg MK0657 capsules
486163|NCT00505843|Drug|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
486164|NCT00505843|Drug|Comparator: levodopa|levodopa >/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
486165|NCT00505843|Drug|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
486166|NCT00505830|Other|questionnaires|"Primary outcome:~Autism Spectrum Quotient (AQ)~Secondary outcome measure:~Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
486167|NCT00505817|Drug|Cetrorelix and Leuprolide|
486168|NCT00505804|Drug|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
486169|NCT00505804|Drug|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
486170|NCT00505791|Drug|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
486171|NCT00505778|Drug|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
486172|NCT00505778|Drug|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
486173|NCT00505765|Drug|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
486174|NCT00505765|Drug|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
486175|NCT00505765|Drug|Placebo|Placebo- 3 sprays in each nostril, twice per day
486176|NCT00505765|Drug|Placebo|Placebo- one spray in each nostril, once per day
486177|NCT00505752|Drug|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
486178|NCT00505752|Drug|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
486179|NCT00505752|Drug|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
486180|NCT00505752|Drug|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
486181|NCT00505752|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to [>=] 18 millimeter [mm], two or more additional follicles with a diameter of >= 16 mm, and Estradiol [E2] levels will approximately 150 picogram per milliliter [pg/mL] per mature follicle).
486182|NCT00505739|Drug|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
486183|NCT00505726|Procedure|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
486184|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
486185|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486186|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486187|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486188|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486189|NCT00505700|Drug|velcade|
486190|NCT00505700|Drug|Idarubicin|
486191|NCT00505700|Drug|Cytarabine|
486192|NCT00505687|Drug|Rotigotine|"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."
486193|NCT00505661|Drug|Letrozole|2.5 mg PO Once Daily
486194|NCT00505648|Drug|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
486195|NCT00505635|Drug|Temozolomide|250 mg/m^2 By Mouth Every 4 Hours x 3 Doses On Day 1
486196|NCT00505635|Drug|Velban|1.5 mg/m^2 By Vein Over 15-30 Minutes On Days 1-4
486197|NCT00505635|Drug|Cisplatin|20 mg/m^2 By Vein Over 45-120 Minutes On Days 1-4
486198|NCT00505635|Drug|Interleukin-2|9 MIU/m^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
486202|NCT00505609|Behavioral|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
486203|NCT00505596|Behavioral|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
486204|NCT00505583|Drug|MOA-728|
486205|NCT00505570|Device|AMPLATZER® PFO Occluder Device|PFO device closure
486206|NCT00505557|Procedure|Transaxillary dual plane technique|
486207|NCT00505544|Behavioral|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
486208|NCT00505544|Device|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
486209|NCT00505531|Drug|Tramadol Extended Release Oral Capsule|Tramadol ER- up to either 200 mg or 300 mg based on randomization
486210|NCT00505531|Drug|Benadryl|Placebo group will take up to 25 mg of Benadryl
486211|NCT00505518|Drug|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
486212|NCT00505518|Behavioral|Collaborative psychiatric and primary medical care|Regular care visits from health workers
486213|NCT00505505|Drug|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
486214|NCT00505492|Drug|Carboplatin|AUC 5 by vein once every 28 Days
486215|NCT00505492|Drug|Cisplatin|40 mg/m^2 by vein (IV) Weekly Over 4 Hours
486216|NCT00505492|Drug|Paclitaxel|135 mg/m^2 by vein (IV) Once Every 28 Days
486217|NCT00505466|Behavioral|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
486218|NCT00505453|Biological|Fluviral®|
486219|NCT00505440|Behavioral|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
486220|NCT00505440|Behavioral|Usual care|Usual care with mailed screening results
486221|NCT00505427|Dietary Supplement|Alpha Lipoic Acid|
486222|NCT00505414|Drug|Tapentadol in the Titration Phase|
486223|NCT00505414|Drug|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.~Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
486224|NCT00505414|Drug|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
486225|NCT00505414|Drug|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
486226|NCT00505414|Drug|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
486227|NCT00505401|Biological|recombinant HIV-1 Tat protein|
486228|NCT00505375|Drug|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
486229|NCT00505375|Other|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
486230|NCT00505362|Procedure|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
486231|NCT00505349|Behavioral|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
486232|NCT00505336|Drug|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
486233|NCT00505336|Other|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
486234|NCT00505336|Drug|Atorvastatin|oral Atorvastatin 40mg
486235|NCT00505323|Device|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :~Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
486236|NCT00505310|Behavioral|Writing|20 minutes of writing on different topics at four different times.
486237|NCT00505310|Behavioral|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
486238|NCT00505284|Drug|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
486239|NCT00505284|Drug|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
486240|NCT00505284|Drug|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
486241|NCT00505284|Drug|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
486390|NCT00504205|Drug|multitargeted receptor tyrosine kinase inhibitor MP470|
506125|NCT00354653|Drug|LAMIVUDINE|
486242|NCT00505284|Drug|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
486243|NCT00505271|Genetic|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.~At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
486244|NCT00505258|Drug|ceftobiprole medocaril|
486245|NCT00505245|Other|Interview|Complete interview
486246|NCT00505245|Other|Quality-of-Life Assessment|Complete quality of life assessment
486247|NCT00505245|Other|Questionnaire Administration|Complete questionnaires
486248|NCT00505232|Drug|Y-90 Ibritumomab tiuxetan|"Study Design~The present study will be split into two cohorts:~Patients younger than 60 years who will receive 8 chemotherapy cycles~Patients older than 60 years who will receive 6 chemotherapy cycles~The induction schema summarises as follows :~Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).~Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) [0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets < 100,000/µl] will be administered 8 to 12 weeks after last chemotherapy."
486249|NCT00505219|Biological|Ixmyelocel-T|Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
486250|NCT00505219|Other|Standard of Care Only|Core decompression of the femoral head to remove necrotic tissue
486251|NCT00505167|Drug|Memantine|Patients randomized to receive either memantine or donepezil
486252|NCT00505167|Drug|Donepezil|Patients randomized to receive either memantine or donepezil
486253|NCT00505154|Drug|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
486254|NCT00505154|Drug|placebo|placebo
486255|NCT00505128|Procedure|Endoscopic sphincterotomy|procedure
486256|NCT00505102|Drug|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
486257|NCT00505089|Drug|ACZ885|
486258|NCT00505089|Drug|ACZ885|
486259|NCT00505089|Drug|ACZ885|
486260|NCT00505089|Drug|ACZ885|
486261|NCT00505076|Drug|MK-0777|MK-0777 GEM, 8 mg BID
486262|NCT00505076|Drug|MK-0777|MK-0777 GEM, 3 mg BID
486263|NCT00505076|Drug|placebo|2 tablets placebo BID
486264|NCT00505063|Biological|Immunization Schedule patients <7 years.|"Time 0 months: Prevnar 13 #1, Hib #1~Time 1 months: Pediarix #1~Time 2 months: Prevnar 13 #2, Hib #2~Time 3-4 months: Pediarix #2~Time 4-6 months: Draw post vaccine titers~Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
486265|NCT00505063|Biological|Immunization Schedule patients > or = to 7 years and <11 years of age|"Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1~Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2~Time 2-3 months: Prevnar 13 #2, Hib #2~Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
486266|NCT00505063|Biological|Immunization Schedule patients > or = to 11 years of age|"Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1~Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2~Time 2-3 months: Hib #2, Prevnar 13#2, Menactra~Time 3-6 months: IPV, Draw post vaccine titers~Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
486267|NCT00505050|Other|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.~After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
486268|NCT00505037|Drug|ASP1585|Oral
486269|NCT00505037|Drug|Placebo|Oral
486270|NCT00505037|Drug|Sevelamer hydrochloride|Oral
486271|NCT00505024|Behavioral|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
486272|NCT00505024|Other|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
486273|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486274|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486275|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486276|NCT00504998|Genetic|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
486277|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
486278|NCT00504985|Behavioral|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
506240|NCT00354068|Drug|imatinib mesylate|
486279|NCT00504972|Drug|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
486280|NCT00504959|Drug|ranibizumab|
486281|NCT00504946|Drug|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone+ 0.3mg lactose"
486282|NCT00504946|Drug|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
486283|NCT00504946|Drug|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:~0.3mg lactose"
486284|NCT00504946|Drug|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children > 14 years old received 10mg oral tablet once daily at bedtime
486285|NCT00504946|Drug|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
486286|NCT00504933|Drug|bilastine|20 mg (encapsulated) tablets QD/14days
486287|NCT00504933|Drug|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
486288|NCT00504933|Drug|Placebo|(encapsulated) Tablets QD/14 days
486289|NCT00504920|Behavioral|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
486290|NCT00504907|Drug|BTA9881|Single oral escalating doses
486291|NCT00504907|Drug|Placebo|
486292|NCT00504894|Drug|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
486293|NCT00504894|Drug|Propofol|A low dose of propofol 0.90 μgml−1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
486294|NCT00504881|Drug|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
486295|NCT00504881|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
486296|NCT00504855|Other|Casting using Gortex (waterproof) cast padding materials|
486297|NCT00504855|Other|Casting using cotton/cotton-poly cast padding materials|
486298|NCT00504842|Drug|MRX-801|
486299|NCT00504842|Drug|Placebo|
486300|NCT00504829|Drug|LCP-AtorFen|anti-dyslipidemia
486301|NCT00504829|Drug|atorvastatin|anti-dyslipidemia
486302|NCT00504829|Drug|fenofibrate|anti-dyslipidemia
486303|NCT00504816|Drug|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
486304|NCT00504816|Drug|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
486305|NCT00504803|Procedure|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
486306|NCT00504790|Drug|GSK923295|anti-mitotic compound
486307|NCT00504777|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
486308|NCT00504777|Drug|Methotrexate|10-25mg/week po or parenteral
486309|NCT00504764|Drug|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.~Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
486310|NCT00504764|Procedure|Autologous Transplantation|Autologous Transplantation
486311|NCT00504764|Procedure|Allogenic Transplantation|Allogenic Transplantation
486312|NCT00504764|Drug|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
486313|NCT00504751|Drug|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:~Dexamethasone 40 mg IV days 1-4~Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~Cisplatin 25 mg IV days 1-4~Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~VELCADE 1.5 mg/m2 on days 2 and 5"
486314|NCT00504751|Drug|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:~Dexamethasone 40 mg IV days 1-4~Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4~Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)~Cisplatin 25 mg IV days 1-4~Etoposide 100 mg/m2 CIVI over 24 hours days 1-4~Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)~VELCADE 1.5 mg/m2 on days 2 and 5"
486315|NCT00504725|Drug|Ketamine|Interventional
486316|NCT00504725|Drug|0.9% saline|placebo
486317|NCT00504712|Drug|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
486318|NCT00504712|Drug|saline|Saline injection every two weeks
486319|NCT00504699|Procedure|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
486320|NCT00504686|Other|manual therapy|manual therapy - thoracic spine thrust manipulation
486321|NCT00504686|Other|exercise|therapeutic exercise
486322|NCT00504673|Drug|insulin detemir|
486323|NCT00504673|Drug|insulin NPH|
486324|NCT00504673|Drug|insulin aspart|
486325|NCT00504660|Drug|Capecitabine|Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
486326|NCT00504660|Drug|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
486327|NCT00504660|Drug|Temozolomide|Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
486328|NCT00504660|Drug|Lomustine|Arms 2,3 = 100 mg/m^2 PO on Day 4.
486329|NCT00504660|Drug|6-Thioguanine|Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
486330|NCT00504647|Device|Biventricular Pacemaker|
486331|NCT00504634|Drug|Bortezomib|1 mg/m^2 IV On Days 1, 4, 8, and 11.
486332|NCT00504608|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
486391|NCT00504205|Other|laboratory biomarker analysis|
486392|NCT00504205|Other|pharmacological study|
506241|NCT00354068|Drug|temozolomide|
486333|NCT00504595|Drug|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
486334|NCT00504595|Drug|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
486335|NCT00504582|Drug|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
486336|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet once daily
486337|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet once daily
486338|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet two times a day
486339|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet two times a day
486340|NCT00504556|Drug|warfarin|warfarin tablets
486341|NCT00504543|Drug|AEB071|oral, twice daily
486342|NCT00504543|Drug|Certican|twice daily
486343|NCT00504543|Drug|Neoral|twice daily
486344|NCT00504530|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
486345|NCT00504517|Other|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
486346|NCT00504504|Drug|Rituximab|375 mg/m^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
486347|NCT00504504|Drug|Adriamycin|25 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
486348|NCT00504504|Drug|Bleomycin|10 U/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
486349|NCT00504504|Drug|Vinblastine|6 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
486350|NCT00504504|Drug|Dacarbazine (DTIC)|375 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
486351|NCT00504491|Drug|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
486352|NCT00504478|Dietary Supplement|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
486353|NCT00504478|Other|high complex carbohydrate diet|
486354|NCT00504465|Drug|dinoprostone|
486355|NCT00504452|Drug|KP-1461|Oral dosage, 1600 mg bid for 124 days
486356|NCT00504439|Drug|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
486357|NCT00504439|Drug|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
486358|NCT00504439|Drug|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
486359|NCT00504426|Drug|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
486360|NCT00504413|Drug|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
486361|NCT00504413|Drug|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
486362|NCT00504413|Drug|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
486363|NCT00504400|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
486364|NCT00504374|Behavioral|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
486365|NCT00504348|Drug|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
486366|NCT00504335|Drug|BIO 300 Capsules|
486367|NCT00504322|Genetic|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
486368|NCT00504322|Genetic|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
486369|NCT00504309|Drug|4/day of 4g P-OM3 capsules|4/day of 4g P-OM3 capsules for 8 weeks
486370|NCT00504309|Drug|4/day of 1g P-OM3 capsules|4/day of 1g P-OM3 capsules for 8 weeks
486371|NCT00504309|Drug|Corn Oil Placebo, 4 capsules/day for 8 weeks|4 capsules per day of corn oil placebo for 8 weeks
486372|NCT00504296|Drug|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
486373|NCT00504296|Other|immunoenzyme technique|
486374|NCT00504296|Other|immunohistochemistry staining method|
486375|NCT00504296|Other|immunologic technique|
486376|NCT00504296|Other|laboratory biomarker analysis|
486377|NCT00504296|Other|liquid chromatography|
486378|NCT00504296|Other|mass spectrometry|
486379|NCT00504296|Other|pharmacological study|
486380|NCT00504283|Drug|Toradol|
486381|NCT00504283|Drug|Morphine|
486382|NCT00504270|Drug|Placebo|po daily
486383|NCT00504270|Drug|RG3421 120mg|120mg po daily
486384|NCT00504270|Drug|RG3421 20mg|20mg po daily
486385|NCT00504257|Drug|Avastin|Day 1, every 21 day cycle
486386|NCT00504257|Drug|Docetaxel|Day 1, 8, every 21 day cycle
486387|NCT00504244|Drug|switch to Myfortic|Myfortic 2 dd 720 mg
486388|NCT00504244|Drug|continuation of azathioprine|Azathioprine 2 mg/kg
486389|NCT00504231|Biological|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
486393|NCT00504205|Procedure|positron emission tomography|
486394|NCT00504192|Drug|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
486395|NCT00504179|Procedure|Osteopathic Manipulative Treatment|
486396|NCT00504166|Drug|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
486397|NCT00504166|Other|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
486398|NCT00504153|Drug|dasatinib|
486399|NCT00504153|Other|laboratory biomarker analysis|Correlative studies
486400|NCT00504140|Drug|Etoposide|100 mg/m^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
486401|NCT00504140|Drug|Interferon Alpha|5x10^6 mu/m^2 Subcutaneously Daily for 5 Days
486402|NCT00504127|Drug|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
486403|NCT00504127|Drug|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
486404|NCT00504127|Drug|Naproxen 500 mg bid|Naproxen 500 mg bid
486405|NCT00504127|Drug|placebo|placebo
486406|NCT00504114|Procedure|ACL Reconstruction Surgery|
486407|NCT00504114|Procedure|Cartilage Resurfacing Surgery|
486408|NCT00504114|Procedure|Total Knee Replacement|
486409|NCT00504101|Drug|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
486410|NCT00504101|Drug|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
486411|NCT00504101|Drug|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
486412|NCT00504101|Biological|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
486413|NCT00504088|Procedure|Bypass|
486414|NCT00504088|Procedure|Silverhawk Plaque Excision|
486415|NCT00504075|Biological|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).~The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
486416|NCT00504062|Drug|budesonide|
486417|NCT00504062|Drug|fluticasone|
486418|NCT00504036|Device|inflatable intra-gastric balloon|inflatable intra-gastric balloon
486419|NCT00504023|Drug|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
486420|NCT00504023|Procedure|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
486421|NCT00504023|Procedure|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
486422|NCT00504010|Drug|Arnica Montana|Applied to lower extremity once a day for 3 days
486423|NCT00504010|Drug|placebo cream|placebo cream applied to leg daily for 3 days
486424|NCT00503997|Drug|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
486425|NCT00503997|Drug|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
486426|NCT00503984|Drug|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
486427|NCT00503984|Drug|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
486428|NCT00503984|Drug|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
486429|NCT00503984|Genetic|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.~Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
486430|NCT00503984|Drug|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
486431|NCT00503984|Drug|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
486432|NCT00503971|Drug|Vorinostat plus Erlotinib|"Phase I:~Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily~Phase II:~Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
486433|NCT00503958|Genetic|DNA methylation analysis|
486434|NCT00503958|Genetic|DNA stability analysis|
486435|NCT00503958|Genetic|gene expression analysis|
486436|NCT00503958|Other|epidemiologic study|
486437|NCT00503958|Other|study of socioeconomic and demographic variables|
486438|NCT00503958|Procedure|biopsy|
486439|NCT00503958|Procedure|evaluation of cancer risk factors|
486440|NCT00503958|Procedure|study of high risk factors|
486441|NCT00503945|Device|Nasal continuous positive airway pressure (nCPAP)|
486442|NCT00503932|Procedure|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
486443|NCT00503932|Drug|Capecitabine|825 mg/m^2 by mouth (PO) twice daily on days receive radiation.
486444|NCT00503919|Procedure|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
486445|NCT00503906|Drug|Avastin|
486448|NCT00503893|Behavioral|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
486449|NCT00503893|Other|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
486450|NCT00503880|Biological|filgrastim|subcutaneously one day prior to treatment
486451|NCT00503880|Drug|clofarabine|single IV dose over 1 hour daily for 5 days
486452|NCT00503880|Drug|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
486453|NCT00503880|Genetic|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
486454|NCT00503880|Procedure|biopsy|bone marrow biopsy
486455|NCT00503867|Device|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
486456|NCT00503854|Behavioral|Questionnaire|Ancillary studies
486457|NCT00503841|Drug|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
486458|NCT00503841|Other|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
486459|NCT00503841|Other|laboratory biomarker analysis|Correlative studies
486460|NCT00503841|Procedure|biopsy|14 days prior to surgery
486461|NCT00503841|Procedure|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
486462|NCT00503841|Procedure|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
486463|NCT00503828|Drug|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
486464|NCT00503828|Drug|naproxen|Naproxen 500 mg/day for 4 weeks
486465|NCT00503815|Drug|BLI-800|
486466|NCT00503815|Drug|Polyethylene glycol 3350 based bowel preparation|
486467|NCT00503802|Procedure|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
486468|NCT00503802|Procedure|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
486469|NCT00503789|Procedure|fecal bacteria analysis|ad lib feeding
486470|NCT00503776|Behavioral|exercise intervention|Patients undergo low weight resistance training.
486471|NCT00503776|Drug|amifostine trihydrate|Given subcutaneously
486472|NCT00503776|Procedure|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
486473|NCT00503763|Drug|Simvastatin|
486474|NCT00503750|Drug|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
486475|NCT00503750|Drug|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
486476|NCT00503750|Drug|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
486477|NCT00503737|Behavioral|National Colorectal Cancer Roundtable Toolbox|
486478|NCT00503724|Drug|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
486479|NCT00503711|Drug|Vandetanib|100 mg every other day, 100mg once daily
486480|NCT00503711|Drug|Vandetanib 300 mg|300mg once daily
486481|NCT00503698|Drug|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
486482|NCT00503698|Drug|placebo|Placebo injected s.c (under the skin)
486483|NCT00503685|Biological|IMC-A12|10 milligrams/kilogram (mg/kg) intravenous infusion every 2 weeks.
486484|NCT00503685|Biological|cetuximab|Participants will receive cetuximab 500 milligrams/square meter (mg/m²) intravenous over 2 hours every 2 weeks.
486485|NCT00503659|Procedure|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
486486|NCT00503659|Procedure|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
486487|NCT00503646|Other|communication intervention|
486488|NCT00503646|Other|counseling intervention|
486489|NCT00503646|Other|questionnaire administration|
486490|NCT00503646|Procedure|psychosocial assessment and care|
486491|NCT00503620|Drug|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
486492|NCT00503607|Drug|BLI-800|
486493|NCT00503607|Drug|Polyethylene glycol 3350 based bowel preparation|
486494|NCT00503594|Drug|Methotrexate and temozolomide|Methotrexate and temozolomide
486495|NCT00503594|Drug|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
486496|NCT00503581|Procedure|Biopsy|Undergo biopsy
486497|NCT00503581|Other|Laboratory Biomarker Analysis|Correlative studies
486498|NCT00503581|Drug|Megestrol Acetate|given orally
486501|NCT00503581|Procedure|Therapeutic Conventional Surgery|undergo hysterectomy
486502|NCT00503568|Biological|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10^7 cells twice weekly, maximum 36 vaccines/patient
486503|NCT00503542|Drug|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
486504|NCT00503542|Drug|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
486505|NCT00503542|Drug|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
486506|NCT00503542|Other|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
486507|NCT00503529|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
486508|NCT00503516|Drug|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
486509|NCT00503516|Drug|Placebo|1 sachet of 160 mg of placebo b.i.d.
486510|NCT00503503|Drug|Enbrel (etanercept)|
486511|NCT00503490|Drug|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
486512|NCT00503490|Drug|placebo|BID
486513|NCT00503477|Drug|AZD2171|oral tablet
486514|NCT00503451|Drug|LBH589|
486515|NCT00503438|Device|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
486516|NCT00503425|Drug|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
486517|NCT00503412|Drug|AZD2171|oral 14C
486518|NCT00503399|Drug|Teriparatide|20 µg/day sc for 18 months
486519|NCT00503399|Drug|Risedronate|35 mg/week po for 18 months
486520|NCT00503386|Drug|Palonosetron|
486521|NCT00503386|Drug|Granisetron|
486522|NCT00503360|Drug|SAD448|
486523|NCT00503347|Drug|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
486524|NCT00503334|Dietary Supplement|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
486525|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
486526|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
486527|NCT00503308|Procedure|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
486528|NCT00503295|Biological|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
486529|NCT00503269|Procedure|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
486530|NCT00503269|Procedure|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
486531|NCT00503256|Behavioral|Questionnaire|Questionnaires each taking 60 minutes to complete.
486532|NCT00503243|Drug|Delayed and extended release mesalazine|
486533|NCT00503230|Behavioral|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
486534|NCT00503230|Behavioral|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
486535|NCT00503217|Drug|Tryptorelin|
486536|NCT00503204|Drug|Cediranib|oral tablet
486537|NCT00503204|Drug|Lomustine|oral capsule
486538|NCT00503191|Behavioral|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
486539|NCT00503178|Procedure|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
486540|NCT00503165|Biological|Menitorix (MenC and Hib conjugate)|
486541|NCT00503152|Drug|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
486542|NCT00503152|Drug|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
486543|NCT00503152|Drug|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
486544|NCT00503139|Drug|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
486545|NCT00503126|Drug|bivalirudin|anticoagulation
486546|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
486547|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
486548|NCT00503113|Drug|Alendronate|70mg per oral (po) weekly
486599|NCT00502671|Drug|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
506356|NCT00353054|Drug|Caltrate® 600 + D|
486549|NCT00503100|Device|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
486550|NCT00503087|Procedure|Saline Injection|
486551|NCT00503087|Device|Pneumatic Skin Flattening (PSF)|
486552|NCT00503074|Behavioral|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
486553|NCT00503074|Behavioral|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
486554|NCT00503035|Drug|Celecoxib|400 mg by mouth twice daily x 6 months
486555|NCT00503035|Procedure|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
486556|NCT00503022|Drug|ACZ885|
486557|NCT00503009|Drug|fluticasone propionate/salmeterol|comparator
486558|NCT00503009|Drug|fluticasone propionate|Comparator
486559|NCT00503009|Drug|placebo|Placebo
486560|NCT00502996|Drug|Methotrexate|>=15 mg po/week
486561|NCT00502996|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
486562|NCT00502983|Behavioral|Interview|Interview lasting approximately 50 minutes.
486563|NCT00502970|Drug|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
486564|NCT00502970|Drug|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
486565|NCT00502957|Behavioral|Biofeedback|
486566|NCT00502944|Behavioral|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
486567|NCT00502944|Behavioral|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
486568|NCT00502918|Device|CLM - HA Continuous Monitoring System Heart Application|
486569|NCT00502905|Drug|Busulfan|130 mg/m^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
486570|NCT00502905|Drug|Fludarabine|40 mg/m^2 through a central venous catheter over one hour, once a day, for four days.
486571|NCT00502892|Drug|Topotecan|0.5 mg/m^2 IV Daily x 3 Days
486572|NCT00502892|Drug|Ifosfamide|1.8 grams/m^2 IV Over 1 Hour x 5 Days
486573|NCT00502892|Drug|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days [for patients > 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days]
486574|NCT00502879|Drug|Enbrel (etanercept)|
486575|NCT00502853|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
486576|NCT00502853|Drug|Methotrexate|10-25mg/week
486577|NCT00502840|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
486578|NCT00502827|Behavioral|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
486579|NCT00502827|Other|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
486580|NCT00502814|Procedure|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
486581|NCT00502814|Procedure|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
486582|NCT00502814|Procedure|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
486583|NCT00502814|Procedure|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
486584|NCT00502801|Drug|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
486585|NCT00502788|Drug|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:~Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
486586|NCT00502788|Drug|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight > 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
486587|NCT00502775|Drug|fluticasone furoate, fexofenadine|
486588|NCT00502762|Drug|topotecan|
486589|NCT00502749|Behavioral|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
486590|NCT00502749|Behavioral|Questionnaires|Questionnaires taking 15 minutes to complete.
486591|NCT00502736|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
486592|NCT00502723|Procedure|Radical retropubic prostatectomy|Radical retropubic prostatectomy
486593|NCT00502723|Procedure|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
486594|NCT00502710|Drug|Placebo|Placebo po daily.
486595|NCT00502710|Drug|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
486596|NCT00502697|Behavioral|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
486597|NCT00502697|Other|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
486598|NCT00502684|Drug|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
487011|NCT00499447|Procedure|radiofrequency ablation|
486600|NCT00502658|Behavioral|Dietary supplement containing vitamins, minerals, and herbs|
486601|NCT00502658|Behavioral|Shakes with nutrients and herbs|
486602|NCT00502658|Behavioral|Control dietary supplement|
486603|NCT00502658|Behavioral|Isocaloric, isonitrogenous control shakes without herbs|
486604|NCT00502658|Behavioral|Personal energy tracking tool|
486605|NCT00502645|Device|CS-1 DECISION SUPPORT SYSTEM|
486606|NCT00502632|Drug|Urokinase and Dornase alfa|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
486607|NCT00502632|Drug|Urokinase|"Intrapleural administration of:~Urokinase 40,000 in 40ml normal saline, twice daily for 4 days~25ml normal saline, twice daily for 4 days"
486608|NCT00502619|Procedure|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
486609|NCT00502619|Other|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
486610|NCT00502593|Biological|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
486611|NCT00502593|Biological|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
486612|NCT00502580|Behavioral|Interview|Interview taking about 10 minutes to complete.
486613|NCT00502567|Drug|AZD2171|oral tablet once daily
486614|NCT00502567|Drug|FOLFOX|intravenous infusion
486615|NCT00502567|Drug|Pemetrexed|intravenous infusion
486616|NCT00502567|Drug|Irinotecan (administered with & without Cetuximab)|intravenous injection
486617|NCT00502567|Drug|Docetaxel|intravenous infusion
486618|NCT00502554|Procedure|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
486619|NCT00502541|Drug|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
486620|NCT00502541|Procedure|Standard of Care|Repeat macular grid laser or observation
486621|NCT00502528|Drug|Placebo|Peri-interventional
486622|NCT00502528|Drug|BQ-123|Peri-interventional
486623|NCT00502515|Drug|SSR180575|Oral, once daily dosing
486624|NCT00502515|Drug|Placebo|Oral, once daily dosing
486625|NCT00502502|Behavioral|Questionnaire|Weekly questionnaires lasting about 30 minutes.
486626|NCT00502489|Procedure|Closed-loop sytem for5 weaning from mechanical ventilation|
486627|NCT00502476|Procedure|Bathing with Chlorhexidine Impregnated Washcloths|
486628|NCT00502463|Procedure|radio-immunotherapy|
486629|NCT00502437|Drug|GRANISETRON|
486630|NCT00502424|Device|Splint|
486631|NCT00502411|Drug|Doxorubicin|17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
486632|NCT00502411|Radiation|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
486633|NCT00502398|Procedure|Blood test|
486634|NCT00502385|Drug|AZD2171|
486635|NCT00502372|Dietary Supplement|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
486636|NCT00502372|Dietary Supplement|Juven|comparison of Juven with arginine only product in wound healing
486637|NCT00502359|Device|capillary blood glucose measurement|
486638|NCT00502346|Drug|PM10|
486639|NCT00502320|Drug|Ramelteon|one 8 mg tablet at bed for up to 4 months
486640|NCT00502320|Drug|Placebo|one tablet at bedtime for up to 4 months
486641|NCT00502307|Drug|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
486642|NCT00502307|Drug|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
486643|NCT00502294|Drug|Visilizumab (HuM291; Nuvion®)|
486644|NCT00502281|Drug|highly purified urinary FSH|
486645|NCT00502281|Behavioral|timed intercourses, intrauterine insemination|
486646|NCT00502268|Drug|Doxercalciferol administration|Doxercalciferol administration
486647|NCT00502268|Drug|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
486648|NCT00502255|Device|Health Buddy system|Patients are followed on distance by the Health Buddy system.
486649|NCT00502255|Device|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
486650|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
486651|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
486652|NCT00502229|Drug|Clomiphene citrate, metformin, highly purified urinary FSH|
486653|NCT00502216|Drug|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
486654|NCT00502216|Drug|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
486655|NCT00502203|Drug|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
486656|NCT00502203|Drug|Paclitaxel|175 mg/m^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
486657|NCT00502190|Device|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
486658|NCT00502177|Behavioral|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
486659|NCT00502164|Drug|AZD2171|
486660|NCT00502138|Drug|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
486661|NCT00502125|Procedure|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
486729|NCT00501631|Drug|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
487012|NCT00499447|Radiation|radiation therapy|
486662|NCT00502112|Drug|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
486663|NCT00502112|Drug|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
486664|NCT00502099|Drug|Pegylated interferon alpha 2a|Injections: 180 ug once per week
486665|NCT00502099|Drug|Ribavirin|Tablets, 1000-1200 daily
486666|NCT00502099|Drug|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
486667|NCT00502086|Dietary Supplement|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
486668|NCT00502086|Other|Placebo|Placebo three sachets daily during 96 weeks
486669|NCT00502073|Drug|cyclosporine|
486670|NCT00502060|Drug|AZD2171|
486671|NCT00502060|Drug|ZD1839|
486672|NCT00502047|Drug|Plantago ovata husk|
486673|NCT00502034|Drug|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
486674|NCT00502034|Drug|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
486675|NCT00502021|Dietary Supplement|Placebo|Manioc powder (placebo) 60 g/day
486676|NCT00502021|Dietary Supplement|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
486677|NCT00502021|Dietary Supplement|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
486678|NCT00502021|Dietary Supplement|Placebo|Safflower oil 30 ml/day
486679|NCT00502008|Drug|Coccinia Cordifolia (herbal extract)|
486680|NCT00501995|Drug|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
486681|NCT00501982|Drug|Poractant alfa (Curosurf®)|
486682|NCT00501969|Drug|Rotigotine|"Rotigotine trans-dermal patches once daily:~20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
486683|NCT00501956|Drug|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
486684|NCT00501943|Drug|Avonex (Interferon beta 1a)|
486685|NCT00501943|Drug|Riluzole|
486686|NCT00501943|Drug|Placebo|
486687|NCT00501930|Drug|GSK189075|
486688|NCT00501917|Drug|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
486689|NCT00501904|Drug|Metformin|
486690|NCT00501891|Drug|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
486691|NCT00501891|Drug|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
486692|NCT00501878|Drug|2.5% or 10% phenylephrine|
486693|NCT00501865|Drug|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
486694|NCT00501852|Drug|NVA237|single-dose dry-powder inhaler (SDDPI)
486695|NCT00501852|Drug|Placebo|single-dose dry-powder inhaler (SDDPI)
486696|NCT00501852|Drug|Tiotropium|Handihaler inhaler
486697|NCT00501839|Drug|clomiphene citrate|
486698|NCT00501826|Drug|Cyclophosphamide|Given IV
486699|NCT00501826|Drug|Cytarabine|Given IV
486700|NCT00501826|Drug|Dexamethasone|Given IV or PO
486701|NCT00501826|Drug|Doxorubicin Hydrochloride|Given IV
486702|NCT00501826|Drug|Mercaptopurine|Given PO
486703|NCT00501826|Drug|Methotrexate|Given IV and PO
486704|NCT00501826|Drug|Nelarabine|Given IV
486705|NCT00501826|Drug|Pegaspargase|Given IV
486706|NCT00501826|Drug|Prednisone|Given PO
486707|NCT00501826|Drug|Venetoclax|Given PO
486708|NCT00501826|Drug|Vincristine Sulfate|Given IV
486709|NCT00501813|Procedure|Hepatectomy|irregular Hepatectomy
486710|NCT00501813|Procedure|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
486711|NCT00501787|Drug|Metformin|
486712|NCT00501761|Behavioral|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
486713|NCT00501761|Behavioral|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
486714|NCT00501761|Behavioral|Suggested Exercise Program|Exercise program performed over 7 days.
486715|NCT00501748|Drug|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
486716|NCT00501735|Drug|Forodesine 200 mg|2 x 100mg tablets once daily
486717|NCT00501722|Drug|satavaptan (SR121463B)|
486718|NCT00501709|Drug|Belatacept and Raptiva|immunosuppressant agent to prevent rejection in transplant recipients
486719|NCT00501696|Drug|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
486720|NCT00501696|Drug|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
486721|NCT00501683|Drug|Radiolabelled GSK189075|
486722|NCT00501670|Procedure|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
486723|NCT00501670|Procedure|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
486724|NCT00501657|Drug|Sitagliptin|100mg mane for 2 days
486725|NCT00501657|Drug|Placebo|100mg mane for 2 days
486726|NCT00501644|Drug|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
486727|NCT00501644|Drug|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
486728|NCT00501644|Drug|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
506717|NCT00350233|Device|ExAblate 2000|
486730|NCT00501631|Drug|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
486731|NCT00501618|Drug|Fazaclo|single-arm
486732|NCT00501605|Drug|AZD2171|
486733|NCT00501592|Drug|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
486734|NCT00501592|Drug|Placebo|Placebo
486735|NCT00501579|Drug|Difluprednate|
486736|NCT00501579|Drug|Prednisolone Acetate|
486737|NCT00501566|Drug|satavaptan (SR121463B)|
486738|NCT00501540|Drug|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
486739|NCT00501527|Biological|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
486740|NCT00501527|Other|Placebo|Placebo 2 drops daily
486741|NCT00501514|Drug|Growth hormone|
486742|NCT00501501|Procedure|Cesarean section|
486743|NCT00501501|Procedure|Vaginal delivery|
486744|NCT00501488|Drug|rosiglitazone|
486745|NCT00501475|Drug|NAC Bicarbonate|
486746|NCT00501462|Drug|GSK189075|single 250 mg dose of drug
486747|NCT00501449|Behavioral|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
486748|NCT00501410|Drug|5-FU|2400 mg/m^2 by vein over 46 Hours On Days 1 & 2.
486749|NCT00501410|Drug|Cetuximab|Initial Dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8
486750|NCT00501410|Drug|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
486751|NCT00501410|Drug|Leucovorin|400 mg/m^2 by vein on day 1.
486752|NCT00501410|Drug|Oxaliplatin|85 mg/m^2 by vein on day 1.
486753|NCT00501397|Drug|ketoconazole|
486754|NCT00501397|Drug|GSK189075|
486755|NCT00501384|Drug|satavaptan (SR121463B)|
486756|NCT00501371|Drug|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
486757|NCT00501371|Drug|Placebo|soft-gel capsule, Qd, 12 weeks
486758|NCT00501345|Drug|Aspirin|325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
486759|NCT00501332|Biological|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
486760|NCT00501319|Behavioral|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
486761|NCT00501319|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
486762|NCT00501293|Drug|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
486763|NCT00501280|Behavioral|Interview|Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
486764|NCT00501267|Drug|solabegron and oxybutynin|
486765|NCT00501254|Drug|Slow release acetyl salicylic acid|
486766|NCT00501254|Behavioral|Antithrombotic effect|
486767|NCT00501241|Drug|ATI-7505|Tablet,placebo, BID
486768|NCT00501241|Drug|ATI-7505|ATI-7505 20 mg BID for 4 weeks
486769|NCT00501241|Drug|ATI-7505|tablet, 40 mg, BID, $ weeks
486770|NCT00501241|Drug|ATI-7505|80 mg ATI-7505, BID for 4 weeks
486771|NCT00501241|Drug|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
486772|NCT00501228|Drug|Filgrastim|5 mg/kg ID Once Daily x 1 Week
486773|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
486774|NCT00501215|Behavioral|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
486775|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
486776|NCT00501215|Behavioral|Polysomnography (PSG)|"2 overnight sleep tests~Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery~Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
486777|NCT00501202|Drug|placebo|twice daily for 4 weeks
486778|NCT00501202|Drug|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
486779|NCT00501189|Biological|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
486780|NCT00501176|Procedure|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
486781|NCT00501150|Drug|linezolid|
486782|NCT00501137|Biological|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
486783|NCT00501124|Drug|Clevudine|
486784|NCT00501124|Biological|Purified hepatitis B surface antigen|
486785|NCT00501111|Drug|AZD3480|3 oral doses
486786|NCT00501111|Drug|Donepezil|
486787|NCT00501098|Drug|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.~No stratification is planned."
486788|NCT00501085|Device|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
486789|NCT00501072|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
486790|NCT00501059|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
486791|NCT00501059|Drug|Placebo|Placebo, taken daily
486792|NCT00501046|Drug|Placebo|9g /day (3 times a day)
486793|NCT00501046|Drug|AST-120|9g /day (3 times a day)
486794|NCT00501033|Device|Mechanical induction of labor|
486795|NCT00501033|Device|Double Balloon|
486796|NCT00501033|Device|Foley Catheter|
486797|NCT00501020|Drug|Rosiglitazone|
486798|NCT00500981|Procedure|Volume challenge|
486799|NCT00500981|Procedure|Ultrasound evaluation of internal jugular vein|
486800|NCT00500968|Procedure|stent|ERCP guided stent insertion before transection of the gland
486801|NCT00500968|Procedure|Distal pancreatectomy|conventional distal pancreatectomy
486802|NCT00500955|Drug|Rosiglitazone|
486803|NCT00500942|Behavioral|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
486804|NCT00500929|Drug|CMI X-11S|
486805|NCT00500916|Device|ProSeal LMA|GEB vs digital vs introducer tool
486806|NCT00500903|Drug|Alisertib|Alisertib (MLN8237) will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
486807|NCT00500890|Drug|Carboplatin|350 mg/m^2 by vein, Over 2 Hours x 2 Days
486808|NCT00500890|Drug|Cyclophosphamide|1 g/m^2 by vein, Over 1 Hour x 2 Days
486809|NCT00500890|Drug|Etoposide|100 mg/m^2 by vein, Over 1 Hour x 5 Days
486810|NCT00500890|Drug|Vincristine|1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5
486811|NCT00500890|Radiation|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
486812|NCT00500877|Behavioral|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
486813|NCT00500864|Drug|Magnesium Sulfate 2 grams|
486814|NCT00500851|Device|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
486815|NCT00500851|Device|Endoscopy|Endoscopic placement of jejunal feeding tubes
486816|NCT00500838|Device|Transthoracic Impedance|Impedance measures will be automatically collected via the device
486817|NCT00500825|Procedure|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
486818|NCT00500812|Drug|Cethrin|
486819|NCT00500786|Biological|CYT006-AngQb|
486820|NCT00500760|Drug|Cisplatin|Administered intravenously (IV; in a vein)
486821|NCT00500760|Radiation|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
486822|NCT00500760|Drug|Panitumumab|Administered intravenously
486823|NCT00500747|Biological|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
486824|NCT00500747|Drug|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
486825|NCT00500734|Procedure|Blood Sample|One time blood draw of 2 teaspoons.
486826|NCT00500721|Drug|HCV-796|HCV-796 500mg BID x 14 days
486827|NCT00500721|Drug|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.~Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.~Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
486828|NCT00500695|Behavioral|Motivational Interviewing|Motivational Interviewing
486829|NCT00500695|Behavioral|Psychoeducation|Psychoeducation
486830|NCT00500682|Drug|Placebo|9g /day (3 times a day)
486831|NCT00500682|Drug|AST-120|9g /day (3 times a day)
486832|NCT00500669|Drug|Betadine|Topically
486833|NCT00500656|Drug|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
486834|NCT00500656|Drug|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
486835|NCT00500656|Drug|Oral Placebo|hard capsule matched to tranexamic acid
486836|NCT00500656|Drug|S.C. Placebo|solution for injection, matched to icatibant for injection
486837|NCT00500630|Device|Body fixed 3D sensors|
486838|NCT00500617|Diagnostic Test|Corus CAD (ASGES)|Age/Sex/Gene Expression Score - ASGES
486839|NCT00500604|Drug|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
486840|NCT00500604|Drug|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
486841|NCT00500604|Drug|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
486842|NCT00500591|Behavioral|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
486843|NCT00500578|Drug|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
486844|NCT00500578|Drug|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
486845|NCT00500565|Drug|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
486846|NCT00500565|Drug|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
486847|NCT00500552|Drug|Perhexiline/Placebo|
486848|NCT00500539|Drug|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
486849|NCT00500526|Other|Singing practice|
486850|NCT00500526|Other|Singing classes|
486851|NCT00500526|Other|Hand craft classes|
486852|NCT00500513|Procedure|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
486853|NCT00500513|Procedure|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
486854|NCT00500513|Radiation|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
486855|NCT00500500|Drug|EGb 761® (Tanakan®)|
487010|NCT00499460|Drug|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
486856|NCT00500487|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
486857|NCT00500487|Behavioral|HIV Prevention Skills|12-session group intervention including sexual health skills training.
486858|NCT00500487|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of health topics.
486859|NCT00500474|Procedure|endolymphatic sac drainage with steroids|
486860|NCT00500461|Drug|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
486861|NCT00500448|Device|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
486862|NCT00500435|Procedure|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
486863|NCT00500422|Drug|Doxil|Starting dose of 20 mg/m^2 IV over 2 hours on Day 1, 21 day cycle
486864|NCT00500422|Drug|Gemcitabine|500 mg/m^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
486865|NCT00500422|Drug|Velcade|Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
486866|NCT00500409|Drug|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
486867|NCT00500409|Drug|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
486868|NCT00500396|Procedure|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
486869|NCT00500370|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
486870|NCT00500370|Drug|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
486871|NCT00500357|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
486872|NCT00500344|Drug|Lucentis (ranibizumab)|intravitreal injection
486873|NCT00500331|Drug|GSK189075|Experimental Drug
486874|NCT00500331|Drug|pioglitazone|Active Control
486875|NCT00500331|Other|Placebo|Placebo Comparator
486876|NCT00500318|Drug|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
486877|NCT00500318|Drug|Placebo|Dose matched placebo, once daily oral inhalation.
486878|NCT00500305|Procedure|Withhold standard INDO dose if BNP < 100 pg/ml|
486879|NCT00500292|Drug|Vandetanib|once daily oral tablet two dose strengths
486880|NCT00500292|Drug|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
486881|NCT00500279|Drug|Celecoxib|
486882|NCT00500253|Device|exhaled nitric oxide measurement|exhaled nitric oxide measurement
486883|NCT00500253|Procedure|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
486884|NCT00500253|Procedure|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
486885|NCT00500240|Drug|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
486886|NCT00500240|Drug|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
486887|NCT00500214|Procedure|elective ilioinguinal nerve excision|
486888|NCT00500201|Drug|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
486889|NCT00500201|Drug|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
486890|NCT00500201|Drug|Placebo|Placebo tablets will be administered orally by subjects.
486891|NCT00500188|Drug|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
486892|NCT00500175|Device|TempTouchRM|
486893|NCT00500175|Device|Offloading|
486894|NCT00500162|Behavioral|Tri-Luma Maintenance regimen|
486895|NCT00500149|Drug|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
486896|NCT00500149|Drug|Placebo|Placebo
486897|NCT00500136|Procedure|mortality salience|
486898|NCT00500123|Procedure|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
486899|NCT00500110|Drug|Docetaxel|30 mg/m^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
486900|NCT00500110|Drug|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
486901|NCT00500110|Drug|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
486902|NCT00500110|Drug|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
486903|NCT00500097|Device|Digital retina image|
486904|NCT00500097|Device|direct ophthalmoscopy|
486905|NCT00500097|Procedure|comprehensive eye exam|
486906|NCT00500084|Drug|Liprotamase|Administered orally
486907|NCT00500071|Drug|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
486908|NCT00500058|Drug|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
486909|NCT00500058|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered by IV infusion.
486910|NCT00500045|Drug|nicotinic acid|niacin 1500 mg po qd
486911|NCT00500032|Procedure|blood draw|Blood draw from subjects previously vaccinated in 6108A1-500 trial
486912|NCT00500006|Drug|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
486913|NCT00500006|Drug|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
486914|NCT00499993|Drug|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
508813|NCT00330525|Drug|sibutramine|
486915|NCT00499967|Drug|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
486916|NCT00499967|Drug|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
486917|NCT00499967|Drug|Placebo|Placebo matching GS-9191 ointment
486918|NCT00499954|Procedure|Microdialysis|
486919|NCT00499954|Device|Guardian RT|
486920|NCT00499954|Device|Glucoday S|
486921|NCT00499928|Drug|SB-751689|
486922|NCT00499915|Behavioral|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
486923|NCT00499915|Behavioral|Asthma Education|Asthma education will be provided at NICU discharge.
486924|NCT00499902|Drug|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
486925|NCT00499889|Drug|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
486926|NCT00499889|Drug|Fludarabine (Fludara)|40 mg/m^2 by vein daily for 4 Days
486927|NCT00499889|Drug|Busulfan|130 mg/m^2 by vein daily for 2 Days
486928|NCT00499889|Drug|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
486929|NCT00499889|Drug|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
486930|NCT00499889|Drug|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
486931|NCT00499889|Procedure|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after >4 weeks of imatinib.
486932|NCT00499889|Procedure|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
486933|NCT00499876|Drug|mefloquine|250mg weekly PO for 6 months
486934|NCT00499876|Other|placebo|1 tablet weekly PO for 6 months
486935|NCT00499863|Drug|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
486936|NCT00499863|Drug|Placebo|Placebo patch
486937|NCT00499850|Drug|ZD6474 (vandetanib)|once daily oral dose
486938|NCT00499850|Drug|5-Fluorouracil|intravenous infusion
486939|NCT00499850|Drug|Leucovorin|intravenous infusion
486940|NCT00499850|Drug|Oxaliplatin|intravenous infusion
486941|NCT00499837|Drug|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
486942|NCT00500266|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
486943|NCT00499824|Behavioral|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
486944|NCT00499811|Drug|vorinostat|Given orally
486945|NCT00499811|Other|pharmacological study|Correlative studies
486946|NCT00499759|Behavioral|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
486947|NCT00499759|Behavioral|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
486948|NCT00499759|Behavioral|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
486949|NCT00499759|Behavioral|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
487005|NCT00499499|Drug|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
487009|NCT00499460|Dietary Supplement|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
486950|NCT00499759|Behavioral|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
486951|NCT00499759|Behavioral|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
486952|NCT00499746|Drug|tramadol|oral dose, once per day
486953|NCT00499746|Drug|placebo|oral dose, once per day
486954|NCT00499746|Drug|Hydromorphone|oral dose, once per day
486955|NCT00499746|Drug|Methylphenidate|oral dose, once per day
486956|NCT00499733|Drug|cyclophosphamide|500 mg/m^2 of cyclophosphamide is infused via intravenous route three days post cryoablation surgery.
486957|NCT00499733|Device|Cryoablation|Per treating physician's discretion, largest and most accessible lesion will be treated with cryoablation surgery on day 0 of the study.
486958|NCT00499720|Drug|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
486959|NCT00499707|Drug|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
486960|NCT00499694|Biological|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
486961|NCT00499694|Drug|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
486962|NCT00499681|Drug|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
486963|NCT00499681|Drug|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
486964|NCT00499681|Other|placebo|Given once daily for 2 weeks
486965|NCT00499668|Drug|aprepitant|125 mg orally for 7 days
486966|NCT00499668|Drug|ondansetron hydrochloride|24 mg orally for 7 days
486967|NCT00499655|Drug|erlotinib hydrochloride|Given orally
486968|NCT00499655|Drug|celecoxib|Given orally
486969|NCT00499655|Other|placebo|Given orally
486970|NCT00499655|Other|laboratory biomarker analysis|Correlative studies
486971|NCT00499655|Other|immunohistochemistry staining method|Correlative studies
486972|NCT00499655|Genetic|fluorescence in situ hybridization|Correlative studies
486973|NCT00499655|Genetic|mutation analysis|Correlative studies
486974|NCT00499655|Genetic|protein expression analysis|Correlative studies
486975|NCT00499655|Genetic|gene expression analysis|Correlative studies
486976|NCT00499642|Drug|Lecozotan SR|
486977|NCT00499642|Drug|Moxifloxacin|
486978|NCT00499629|Drug|FXR 450|capsule, single oral doses from 10 mg to 450 mg
486979|NCT00499629|Drug|placebo|capsule similar to active drug
486980|NCT00499616|Drug|carboplatin|Given IV
486981|NCT00499616|Drug|cyclophosphamide|Given IV
486982|NCT00499616|Drug|doxorubicin hydrochloride|Given IV
486983|NCT00499616|Drug|etoposide|Given orally
486984|NCT00499616|Drug|topotecan hydrochloride|Given IV
486985|NCT00499616|Drug|Isotretinoin|Given orally
486986|NCT00499616|Procedure|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
486987|NCT00499616|Drug|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy & continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
486988|NCT00499603|Drug|Paclitaxel|80 mg/m^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
486989|NCT00499603|Drug|5-Fluorouracil|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
486990|NCT00499603|Drug|Epirubicin|100 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
486991|NCT00499603|Drug|Cyclophosphamide|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
486992|NCT00499603|Drug|RAD001|30 mg by mouth weekly on Days 1, 8, & 15 for 12 cycles.
486993|NCT00499590|Drug|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
486994|NCT00499590|Drug|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
486995|NCT00499577|Biological|CMV pp65 peptide|Given intramuscularly
486996|NCT00499577|Biological|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
486997|NCT00499577|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
486998|NCT00499577|Biological|survivin Sur1M2 peptide vaccine|Given subcutaneously
486999|NCT00499551|Device|Iontophoresis second generation Eyegate II device|
487000|NCT00499538|Drug|SKI-606|
487001|NCT00499525|Drug|paclitaxel|given IV
487002|NCT00499525|Drug|sorafenib tosylate|given orallly
487003|NCT00499525|Other|placebo|given orally
487004|NCT00499512|Behavioral|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
487006|NCT00499486|Drug|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
487013|NCT00499421|Procedure|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
487014|NCT00499408|Dietary Supplement|Vitamin D|Patients will receive oral supplementation of 2,000 IU per day of vitamin D (cholecalciferol)
487015|NCT00499408|Dietary Supplement|soy|Patients will receive oral supplementation of soy (160 mg per day soy isoflavones).
487016|NCT00499395|Procedure|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
487017|NCT00499395|Procedure|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
487018|NCT00499382|Procedure|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
487019|NCT00499382|Procedure|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
487020|NCT00499369|Drug|irinotecan hydrochloride|Given IV
487021|NCT00499369|Drug|leucovorin calcium|Given IV
487022|NCT00499369|Drug|fluorouracil|Given IV
487023|NCT00499369|Biological|cetuximab|Given IV
487024|NCT00499369|Biological|bevacizumab|Given IV
487025|NCT00499356|Device|pressure reducing insole|
487026|NCT00499356|Device|GlideSoft®|
487027|NCT00499343|Drug|Etoposide|150 mg/m^2 given intravenously over 2 hours every 12 hours x 6 doses.
487028|NCT00499343|Drug|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
487029|NCT00499343|Drug|GM-CSF|250 mcg/m^2 injection given every evening till the completion of apheresis.
487030|NCT00499343|Drug|Isophosphamide|10 g/m^2 given intravenously continuous infusion over 72 hours.
487031|NCT00499343|Drug|Rituximab|Days +1 (375 mg/m^2) and +8 (1000 mg/m^2) given intravenously.
487032|NCT00499343|Procedure|Apheresis|Peripheral blood stem cell collection.
487033|NCT00499330|Procedure|lobectomy|
487034|NCT00499330|Procedure|segmentectomy or wedge resection|
487035|NCT00499291|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
487036|NCT00499291|Procedure|gene expression analysis|
487037|NCT00499291|Procedure|laboratory biomarker analysis|
487038|NCT00499291|Procedure|pharmacological study|
487039|NCT00499291|Procedure|polymerase chain reaction|
487040|NCT00499278|Behavioral|Rehabilitation after joint replacement surgery|
487041|NCT00499265|Drug|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
487042|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
487043|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
487044|NCT00499252|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
487045|NCT00499239|Drug|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.~GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
487046|NCT00499213|Procedure|Home Care Assisted Peritoneal Dialysis|
487047|NCT00499200|Drug|SRA-444|
487048|NCT00499187|Procedure|Blood Draws|A single whole blood sample was collected for genomic analysis.
487049|NCT00499174|Procedure|conventional surgery|Radical prostatectomy
487050|NCT00499174|Radiation|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
487051|NCT00499174|Radiation|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
487052|NCT00499174|Procedure|Biopsies|Periodic repeat biopsies
487053|NCT00499161|Behavioral|New model of nursing care|
487054|NCT00499148|Other|herbal extract; root of woody shrub grown in India/Sri-Lanka|
487055|NCT00499135|Other|Computed Tomography|Correlative studies
487056|NCT00499135|Other|Fluorothymidine F-18|Correlative studies
487057|NCT00499135|Other|Laboratory Biomarker Analysis|Correlative studies
487058|NCT00499135|Other|Pharmacological Study|Correlative studies
487059|NCT00499135|Other|Positron Emission Tomography|Correlative studies
487060|NCT00499135|Drug|Sunitinib Malate|Given PO
487061|NCT00499122|Drug|Cyclophosphamide|
487062|NCT00499122|Drug|Docetaxel|
487063|NCT00499122|Drug|Doxorubicin|
487064|NCT00499122|Drug|NOV 002|
487065|NCT00499109|Drug|Docetaxel|"GD Group: 40 mg/m^2 on days 1 and 8, every 21 days~DCb Group: 75 mg/m^2 on day 1~DV Group: 50 mg/m^2 on days 1 and 15, every 28 days"
487066|NCT00499109|Drug|Vinorelbine|DV Group: 35 mg/m^2 on days 1 and 15
487067|NCT00499109|Drug|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days~DCb Group: AUC 6 on day 1, every 21 days~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
487068|NCT00499109|Drug|Gemcitabine|"GCb Group: 1,250 mg/m^2 on days 1 and 8~GD Group: 1,250 mg/m^2 on days 1 and 8~Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
487150|NCT00498888|Procedure|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
487281|NCT00497679|Drug|AZD1152|7-day continuous intravenous infusion
508972|NCT00329251|Biological|Hepatitis B|
487069|NCT00499096|Behavioral|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
487070|NCT00499083|Biological|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
487071|NCT00499083|Drug|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
487072|NCT00499083|Drug|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
487073|NCT00499083|Drug|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
487074|NCT00499083|Drug|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
487075|NCT00499083|Drug|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
487076|NCT00499083|Genetic|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
487077|NCT00499083|Genetic|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
487078|NCT00499083|Genetic|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
487079|NCT00499083|Other|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
487080|NCT00499083|Other|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
487081|NCT00499083|Other|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.~CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).~COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
487082|NCT00499083|Procedure|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
487083|NCT00499083|Procedure|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
487084|NCT00499083|Procedure|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
487085|NCT00499083|Procedure|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
508973|NCT00329251|Biological|Influenza|
487086|NCT00499083|Radiation|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
487087|NCT00499070|Genetic|polymerase chain reaction|
487088|NCT00499070|Other|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
487089|NCT00499070|Other|immunologic technique|
487090|NCT00499070|Procedure|biopsy|
487091|NCT00499057|Radiation|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
487092|NCT00499044|Other|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
487093|NCT00499044|Other|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
487094|NCT00499031|Biological|Cetuximab|Given IV
487095|NCT00499018|Drug|Rituximab|375 mg/m2 day 1
487096|NCT00499018|Drug|Ciclofosfamide|1200 mg/m2 day 1
487097|NCT00499018|Drug|Doxorubicina|70 mg/m2 day 1
487098|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
487099|NCT00499018|Drug|Prednisone|100 mg day g 1-5
487100|NCT00499018|Drug|Pegfilgrastim|6 mg day +1
487101|NCT00499018|Drug|Mitoxantrone|8 mg/m2/days 1-3
487102|NCT00499018|Drug|ARA-C|2000 mg/m2/12h day 1 - 3
487103|NCT00499018|Drug|Lenograstim|5 μg/Kg/days +2
487104|NCT00499018|Drug|BCNU|300 mg/m2 day -7
487105|NCT00499018|Drug|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
487106|NCT00499018|Drug|VP-16|100 mg/m2/12h days -6,-5,-4,-3
487107|NCT00499018|Procedure|ASCT|PBSC Reinfusion
487108|NCT00499018|Drug|Ciclofosfamide|750 mg/m2 day 1
487109|NCT00499018|Drug|Doxorubicina|50 mg/m2 day 1
487110|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
487111|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
487112|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
487113|NCT00498992|Dietary Supplement|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
487114|NCT00498979|Biological|recombinant interferon alfa-2b|recombinant interferon alfa-2b
487115|NCT00498979|Drug|cisplatin|recombinant interferon alfa-2b
487116|NCT00498979|Drug|sodium stibogluconate|sodium stibogluconate
487117|NCT00498979|Drug|dacarbazine|dacarbazine
487118|NCT00498979|Drug|vinblastine|vinblastine
487119|NCT00498966|Drug|Perifosine|"Perifosine 100 mg PO Perifosine is supplied as a film-coated tablet containing 50 mg of active ingredient.~Treatment will be administered on an outpatient basis in 28-day cycles. The patient dose for daily administration will be 100 mg qhs daily with food."
487120|NCT00498953|Drug|carboplatin|
487121|NCT00498953|Drug|cisplatin|
487122|NCT00498953|Drug|docetaxel|
487123|NCT00498953|Drug|fluorouracil|
487124|NCT00498953|Drug|lapatinib ditosylate|
487125|NCT00498953|Genetic|cytogenetic analysis|
487126|NCT00498953|Genetic|fluorescence in situ hybridization|
487127|NCT00498953|Genetic|in situ hybridization|
487128|NCT00498953|Genetic|polymerase chain reaction|
487129|NCT00498953|Genetic|reverse transcriptase-polymerase chain reaction|
487130|NCT00498953|Other|immunohistochemistry staining method|
487131|NCT00498953|Other|laboratory biomarker analysis|
487132|NCT00498953|Procedure|conventional surgery|
487133|NCT00498953|Procedure|neoadjuvant therapy|
487134|NCT00498953|Radiation|fludeoxyglucose F 18|
487135|NCT00498953|Radiation|radiation therapy|
487136|NCT00498940|Device|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
487137|NCT00498940|Device|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
487138|NCT00498927|Drug|temozolomide|
487139|NCT00498927|Genetic|protein expression analysis|
487140|NCT00498927|Genetic|reverse transcriptase-polymerase chain reaction|
487141|NCT00498927|Other|diagnostic laboratory biomarker analysis|
487142|NCT00498927|Other|immunoenzyme technique|
487143|NCT00498914|Drug|YM155|Continuous IV infusion
487144|NCT00498901|Drug|goserelin|
487145|NCT00498901|Drug|letrozole|
487146|NCT00498901|Drug|leuprolide acetate|
487147|NCT00498901|Procedure|conventional surgery|
487148|NCT00498888|Procedure|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
487149|NCT00498888|Procedure|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
487151|NCT00498888|Procedure|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
487152|NCT00498875|Behavioral|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
487153|NCT00498875|Behavioral|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
487154|NCT00498849|Device|CPAP|
487155|NCT00498836|Drug|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
487156|NCT00498836|Drug|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
487157|NCT00498810|Procedure|complete repair|
487158|NCT00498810|Procedure|partial repair of the abdominal wall|
487159|NCT00498797|Drug|Zactima (vandetanib)|
487160|NCT00498797|Drug|Docetaxel|
487161|NCT00498797|Drug|Prednisolone|
487162|NCT00498784|Drug|Mirena|Mirena 52mg during 1 year
487163|NCT00498771|Behavioral|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
487164|NCT00498758|Device|APOS System - biomechanical wedge shoe|
487165|NCT00498745|Drug|neratinib|HKI-272
487166|NCT00498732|Device|CPAP|CPAP treatment for 4 weeks
487167|NCT00498719|Behavioral|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
487168|NCT00498719|Other|Control Group|Standard educational support.
487169|NCT00498706|Behavioral|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
487170|NCT00498706|Behavioral|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
487171|NCT00498680|Drug|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
487172|NCT00498680|Drug|Sildenafil|100mg
487173|NCT00498680|Drug|Vardenafil|20mg
487174|NCT00498680|Drug|Sildenafil & Vardenafil|50mg & 10 mg
487175|NCT00498654|Biological|Ty800 (Salmonella typhi) Oral Vaccine|
487176|NCT00498641|Procedure|computer program and patching|
487177|NCT00498628|Drug|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
487178|NCT00498628|Other|Placebo|Placebo
487179|NCT00498615|Drug|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
487180|NCT00498602|Biological|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
487181|NCT00498602|Biological|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
487182|NCT00498602|Other|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
487183|NCT00498602|Biological|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
487184|NCT00498589|Drug|methotrexate|25 mg per week IM or SC during 24 weeks
487185|NCT00498589|Drug|placebo|one intramuscular injection per week
487186|NCT00498563|Procedure|altitude exposure in hypobaric chamber|
487187|NCT00498550|Drug|Clozapine|Clozapine up to 550mg per day
487188|NCT00498550|Drug|Treatment as usual|Remain on pre-study antipsychotic treatment
487189|NCT00498537|Drug|spironolactone|
487190|NCT00498524|Device|ICD|Received an ICD
487191|NCT00498524|Device|ICD|Have not received an ICD
487192|NCT00498511|Procedure|upper gastrointestinal endoscopy, colonoscopy|
487193|NCT00498485|Drug|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
487224|NCT00498277|Procedure|Magnetic Resonance Imaging|One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
487225|NCT00498264|Behavioral|walking program, resistance muscular exercise|
508974|NCT00329251|Biological|Pneumococcal|
487194|NCT00498485|Drug|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
487195|NCT00498472|Procedure|Pre-discharge NT-ProBNP based treatment|"Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.~Discharge may be postponed and medical treatment may be changed when NT-ProBNP is >3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy."
487196|NCT00498459|Behavioral|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
487197|NCT00498433|Drug|Aliskiren|300 mg tablet once daily
487198|NCT00498433|Drug|Amlodipine|5 mg capsule once daily
487199|NCT00498433|Drug|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
487200|NCT00498433|Drug|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
487201|NCT00498407|Drug|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
487202|NCT00498394|Behavioral|Clinical diet trial|
487203|NCT00498381|Device|CPAP|
487204|NCT00498368|Drug|Intravenous Rituximab|"Rituximab Therapy [27 Patients]~Rituximab 1 gm IV on Treatment Day 1~Rituximab 1 gm IV on Treatment Day 15~Rituximab 1 gm IV on Treatment Day 168~Rituximab 1 gm IV on Treatment Day 182"
487205|NCT00498368|Drug|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of <130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
487206|NCT00498368|Dietary Supplement|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
487207|NCT00498355|Drug|Ranibizumab|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
487208|NCT00498342|Drug|N-acetylcysteine|
487209|NCT00498316|Procedure|Cord Blood Infusion|Cord blood transplantation performed on day 0.
487210|NCT00498316|Drug|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
487211|NCT00498316|Drug|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).~40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
487212|NCT00498316|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
487213|NCT00498316|Other|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.~1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
487214|NCT00498316|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
487215|NCT00498316|Drug|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
487216|NCT00498316|Radiation|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
487217|NCT00498316|Drug|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
487218|NCT00498316|Drug|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
487219|NCT00498316|Drug|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
487220|NCT00498316|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is > 2.5 x 109/L.
487221|NCT00498303|Biological|trivalent split influenza vaccine|
487222|NCT00498290|Procedure|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
487223|NCT00498290|Procedure|control|normal recovery protocol as usually
487226|NCT00498251|Drug|inhalation of salbutamol (5 mg)|
487227|NCT00498251|Drug|ipratropium|
487229|NCT00498225|Drug|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
487230|NCT00498225|Drug|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
487231|NCT00498225|Drug|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
487232|NCT00498212|Biological|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
487233|NCT00498212|Biological|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
487234|NCT00498199|Procedure|visual tests|
487235|NCT00498186|Drug|Rotigotine|"Rotigotine transdermal patches once daily:~2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
487236|NCT00498173|Drug|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
487237|NCT00498173|Drug|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
487238|NCT00498160|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
487239|NCT00498147|Other|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
487240|NCT00498134|Drug|Triple therapy for H. pylori infection|
487241|NCT00498134|Drug|Cox-2 inhibitor|
487242|NCT00498121|Device|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
487243|NCT00498108|Drug|Rotigotine|
487244|NCT00498095|Procedure|Renal biopsy|
487245|NCT00498069|Device|Harvest Smartprep2 BMAC System|injection of 40cc bmac
487246|NCT00498069|Device|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
487247|NCT00498069|Biological|placebo|injection of placebo into ischemic tissue of the lower extremity
487248|NCT00498056|Biological|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
487249|NCT00498056|Biological|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
487250|NCT00498056|Biological|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
487251|NCT00498056|Biological|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
487252|NCT00498043|Drug|R-CHOP14 induction regimen|R-CHOP14 induction regimen
487253|NCT00498043|Drug|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
487254|NCT00498004|Drug|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
487255|NCT00497991|Drug|AZD1152|
487256|NCT00497978|Dietary Supplement|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
487257|NCT00497978|Dietary Supplement|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
487258|NCT00497965|Procedure|Chiropractic Manipulation|
487259|NCT00497965|Behavioral|Balance Exercises|
487260|NCT00497952|Biological|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
487261|NCT00497939|Drug|Saw palmetto and sanmiaoshan capsule|
487262|NCT00497926|Biological|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
487263|NCT00497913|Drug|NaCl 0.9%|
487264|NCT00497913|Drug|Botulinum Toxin A|
487265|NCT00497900|Drug|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
487266|NCT00497874|Behavioral|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
487267|NCT00497861|Procedure|Activator Methods Chiropractic Technique|
487268|NCT00497848|Behavioral|motivational interviewing|"An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy"
487269|NCT00497848|Other|The System-Orientated Intervention|"Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on."
487270|NCT00497822|Procedure|Aerobic exercise training|
487271|NCT00497809|Drug|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
487272|NCT00497796|Drug|maribavir|100mg twice a day for 14 weeks.
487273|NCT00497796|Drug|ganciclovir|1000mg three times per day for 14 weeks.
487274|NCT00497783|Drug|Lactoserum|
487275|NCT00497770|Drug|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
487276|NCT00497757|Biological|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
487277|NCT00497744|Drug|Intraperitoneal Cefepime|
487278|NCT00497731|Drug|AZD1152|2-hour continuous intravenous infusion
487279|NCT00497718|Procedure|Chiropractic Manipulation|
487282|NCT00497666|Drug|Rosiglitasone (retrospective observation)|
487283|NCT00497653|Drug|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
487284|NCT00497653|Drug|Placebo|Placebo, twice daily for 6 weeks
487285|NCT00497640|Procedure|Artificial Neural Network|Use of a predicted optimal CPAP
487286|NCT00497614|Drug|adalimumab|
487287|NCT00497601|Drug|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 & 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 & 5 mg/kg on day 1 & 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 & 2.5 mg/kg on day 1 & 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
487288|NCT00497601|Drug|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
487289|NCT00497601|Drug|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
487290|NCT00497588|Procedure|surgery|
487291|NCT00497588|Radiation|radiotherapy|
487292|NCT00497562|Drug|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
487293|NCT00497562|Drug|amitriptyline, fluoxetine and tramadol alone (control group)|
487294|NCT00497549|Procedure|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
487295|NCT00497549|Procedure|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
487296|NCT00497536|Drug|Insulin Aspart (IAsp)|"IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus)."
487297|NCT00497536|Drug|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
487298|NCT00497536|Drug|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate"
487299|NCT00497523|Drug|Beclomethasone dipropionate|
487300|NCT00497523|Drug|Beclomethasone dipropionate/Salbutamol combination|
487301|NCT00497523|Drug|Salbutamol|
487302|NCT00497510|Procedure|Chiropractic manipulation|
487303|NCT00497497|Drug|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
487304|NCT00497497|Drug|cetuximab|Intravenous repeating dose
487305|NCT00497497|Drug|FOLFIRI regimen|Intravenous repeating dose
487306|NCT00497497|Drug|irinotecan|Intravenous repeating dose
487307|NCT00497497|Drug|PRO95780|Intravenous repeating dose
487308|NCT00497484|Drug|recombinant human somatotropin|
487309|NCT00497471|Drug|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
487310|NCT00497471|Drug|iron (2 mg/kg/daily)|
487311|NCT00497458|Drug|Testosterone|testosterone 40 or 80 mg once a day
487312|NCT00497445|Procedure|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
487313|NCT00497445|Procedure|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
487314|NCT00497419|Procedure|fast track|
487315|NCT00497406|Procedure|Salivary gland transfer|Retrograde flow method
487316|NCT00497406|Procedure|Helical Tomotherapy treatment|total of 30 fractions
487317|NCT00497393|Behavioral|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
487318|NCT00497380|Dietary Supplement|Arginine|Oral nutritional supplement
487319|NCT00497367|Device|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
487320|NCT00497354|Drug|Variation in volume of local anesthetic|
487321|NCT00497354|Procedure|Ultrasound-guided interscalene brachial plexus block|
487322|NCT00497341|Drug|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
487323|NCT00497341|Drug|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
487324|NCT00497328|Drug|N-acetylcysteine|
487325|NCT00497328|Drug|Sodium Bicarbonate|
487326|NCT00497315|Drug|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
487327|NCT00497315|Radiation|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
487328|NCT00497302|Behavioral|RBT|Contingency management and behavioral counseling including motivational interviewing
487329|NCT00497302|Behavioral|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
487330|NCT00497289|Drug|Lipofundin MCT/LCT 20 %|daily i.v. infusion for up to 5 days
487331|NCT00497289|Drug|Lipidem 20%|daily i.v. infusion for up to 5 days
487332|NCT00497276|Procedure|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
487333|NCT00497263|Device|Niti CAR|
487334|NCT00497250|Drug|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
487335|NCT00497250|Device|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
487336|NCT00497237|Drug|Beclomethasone plus formoterol fixed combination|100+6 pMDI
487337|NCT00497237|Drug|Fluticasone plus salmeterol fixed combination|diskus 250/50
487338|NCT00497224|Drug|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
487339|NCT00497211|Procedure|Intracoronary mononuclear cell infusion|
487340|NCT00497198|Drug|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
487341|NCT00497198|Drug|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
487342|NCT00497185|Behavioral|Mindfulness-Based Cognitive Therapy for Functional Disorders|"Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.~The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system."
487343|NCT00497172|Device|CYPHER Sirolimus-eluting stent|drug-eluting stent
487344|NCT00497172|Device|Bx SONIC bare metal stent|bare-metal stent
487345|NCT00497159|Other|Placebo|Placebo TID x 90 days
487346|NCT00497159|Drug|Dimebon|Dimebon 20 mg TID x 90 days
487347|NCT00497146|Drug|paricalcitol|2 µg capsule
487348|NCT00497146|Drug|placebo|placebo capsule
487349|NCT00497120|Drug|acetazolamide|
487350|NCT00497120|Drug|placebo|
487351|NCT00497120|Procedure|uvulopalatopharygoplasty|
487352|NCT00497107|Drug|UFT, Calcium Folinate, PSK|
487353|NCT00497107|Drug|UFT, Calcium Folinate|
487354|NCT00497094|Device|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
487355|NCT00497081|Drug|mirtazapine|mirtazapine 30 mg daily for 3 months
487356|NCT00497081|Drug|placebo|placebo 30 mg daily for 3 months
487357|NCT00497068|Behavioral|tobacco abstinent contingent|Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
487358|NCT00497068|Behavioral|non-contingent|Participants receive vouchers regardless of tobacco use status
487359|NCT00497068|Behavioral|control|this group receives no vouchers
487360|NCT00497055|Drug|Aripiprazole|
487361|NCT00497055|Drug|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
487362|NCT00497042|Device|Self Adjusting File|
487363|NCT00497029|Drug|fluoride varnish|
487364|NCT00497029|Behavioral|patient education|
487365|NCT00497016|Drug|atorvastatin 80 mg|
487366|NCT00497003|Drug|Treatment with either metoprolol or carvedilol|
487367|NCT00496990|Behavioral|Enhanced care|this group received counseling, contingency management and methadone or detoxification
487368|NCT00496990|Behavioral|control|this group receives the opportunity to participate in a support group
487369|NCT00496977|Procedure|annual CT screening|
487370|NCT00496964|Drug|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
487371|NCT00496964|Drug|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
487372|NCT00496951|Device|Vagal tone assessment|An EKG will be obtained using a Physio-control EKG monitor (R wave Electronics of Florida) in standard application, with three chest leads. The EKG data is inputted into a vagal tone monitor (Delta Biometrix, Bethesda MD) which computes vagal tone from the EKG signal. This data is then transferred to a disk which is analyzed off-line.
487373|NCT00496938|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
487374|NCT00496873|Drug|Cytoxan|600 mg/m^2 on Day 1 of 21-day cycle.
487375|NCT00496873|Drug|Nipent|4 mg/m^2 on Day 1 of 21 Day Cycle.
487376|NCT00496873|Drug|Rituxan|375 mg/m^2 on Day 1 of 21 Day Cycle.
487377|NCT00496860|Biological|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
487378|NCT00496847|Drug|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
487379|NCT00496847|Drug|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
487380|NCT00496834|Drug|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
487414|NCT00496600|Drug|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
487381|NCT00496834|Drug|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
487382|NCT00496834|Drug|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
487383|NCT00496834|Drug|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
487384|NCT00496821|Drug|ALN-RSV01|
487385|NCT00496808|Drug|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
487386|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
487387|NCT00496782|Drug|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
487388|NCT00496782|Procedure|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
487389|NCT00496769|Drug|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
487390|NCT00496769|Drug|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
487391|NCT00496756|Drug|Sorafenib|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
487392|NCT00496743|Device|Low-dose total skin electron beam therapy (4 Gy)|
487393|NCT00496730|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
487394|NCT00496730|Drug|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
487395|NCT00496717|Device|Helicoidal fast scann|Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
487396|NCT00496704|Drug|capecitabine|
487397|NCT00496704|Drug|gemcitabine hydrochloride|
487398|NCT00496704|Drug|oxaliplatin|
487399|NCT00496691|Behavioral|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
487400|NCT00496678|Behavioral|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
487401|NCT00496678|Behavioral|Standard of Care|Cancer patients receive standard of care for their cancer treatment
487402|NCT00496665|Drug|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
487403|NCT00496665|Drug|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
487404|NCT00496665|Drug|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
487405|NCT00496652|Radiation|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
487406|NCT00496652|Drug|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
487407|NCT00496639|Procedure|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
487408|NCT00496639|Procedure|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
487409|NCT00496626|Biological|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
487410|NCT00496626|Biological|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
487411|NCT00496613|Behavioral|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
487412|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
487413|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
487511|NCT00495820|Other|Placebo|Standard inactive pill.
487415|NCT00496600|Drug|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
487416|NCT00496587|Drug|Capecitabine|800 mg/m^2 By Mouth Twice Daily On Days 1-21.
487417|NCT00496587|Drug|Gemcitabine|900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15.
487418|NCT00496587|Drug|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
487419|NCT00496574|Biological|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
487420|NCT00496561|Biological|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
487421|NCT00496561|Other|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
487422|NCT00496548|Procedure|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
487423|NCT00496548|Procedure|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
487424|NCT00496535|Drug|TNFerade biologic|
487425|NCT00496522|Procedure|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
487426|NCT00496509|Drug|ZD6474 (Zactima) 100mg|
487427|NCT00496509|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
487428|NCT00496509|Procedure|Biomarker Draws|
487429|NCT00496509|Drug|ZD6474 (Zactima) 300mg|
487430|NCT00496483|Drug|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
487431|NCT00496483|Drug|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.~Other Names:~Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
487432|NCT00496470|Drug|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
487433|NCT00496470|Drug|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
487434|NCT00496457|Drug|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
487435|NCT00496457|Drug|Placebo comparator|4 Capsules of PBO per day before noon meal
487436|NCT00496444|Drug|Azacitidine|Starting Dose 20 mg/m^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
487437|NCT00496444|Drug|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
487438|NCT00496431|Drug|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
487439|NCT00496418|Device|Mesh in permanent colostomy|
487440|NCT00496405|Drug|bevacizumab|
487441|NCT00496392|Drug|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
487442|NCT00496379|Drug|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
487443|NCT00496366|Drug|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
487444|NCT00496366|Drug|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
487445|NCT00496353|Drug|MK2461|MK2461 treatment, bid, 28-day
487446|NCT00496340|Drug|Pentostatin|"Pre-conditioning therapy:~All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.~Participant will receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3."
487447|NCT00496340|Drug|Busulfan|"Pre-conditioning therapy:~Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.~Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
487448|NCT00496340|Drug|Rituximab|"Pre-conditioning therapy:~Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
487449|NCT00496340|Procedure|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
487450|NCT00496327|Biological|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) [Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
487451|NCT00496314|Device|e2TM Cervical Cell Collector|
487452|NCT00496301|Drug|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
487453|NCT00496288|Radiation|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
487454|NCT00496275|Drug|Zactima (ZD6474)|
487455|NCT00496275|Drug|Vinorelbine plus cisplatin|
487456|NCT00496275|Drug|Gemcitabine plus cisplatin|
487457|NCT00496262|Biological|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
487458|NCT00496236|Drug|TNFerade biologic|
487459|NCT00496223|Drug|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
487460|NCT00496223|Drug|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
487461|NCT00496197|Drug|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
487462|NCT00496197|Drug|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
487463|NCT00496197|Drug|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
487464|NCT00496184|Drug|Nifedipine cream topical application|
487465|NCT00496158|Drug|Clevudine|
487466|NCT00496158|Drug|Adefovir|
487467|NCT00496145|Behavioral|Spanish Diabetes Self-Management Program|small-group self management education program
487468|NCT00496132|Drug|PRO131921|Escalating doses by IV infusion
487469|NCT00496119|Radiation|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
487470|NCT00496119|Radiation|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
487471|NCT00496106|Behavioral|Telephone counseling|6 telephone counseling sessions
487472|NCT00496106|Behavioral|Telephone interview|telephone interview
487473|NCT00496093|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
487474|NCT00496080|Device|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
487475|NCT00496067|Device|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
487476|NCT00496054|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 & P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
487477|NCT00496041|Procedure|Registry|A Registry will be used.
487478|NCT00496028|Drug|AZD0530|oral tablet
487479|NCT00496028|Drug|Carboplatin|intravenous infusion
487480|NCT00496028|Drug|Paclitaxel|intravenous infusion
487481|NCT00496015|Biological|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
487482|NCT00496015|Biological|Infanrix hexa.|1 intramuscular injection.
487483|NCT00496015|Biological|Meningococcal vaccine GSK134612.|1 intramuscular injection.
487484|NCT00496015|Drug|Paracetamol.|Body weight of < 7 kg: none; Body weight of ≥ 7 kg to < 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
487485|NCT00496002|Drug|Clevudine|
487486|NCT00496002|Drug|Adefovir|
487487|NCT00495989|Procedure|saliva sampling + dental calculus collection|
487488|NCT00495976|Other|A commercially produced cordial drink|
487489|NCT00495963|Procedure|bronchoaleolar lavage|
487490|NCT00495963|Procedure|Bronchoscopy|
487491|NCT00495950|Behavioral|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
487492|NCT00495924|Procedure|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
487493|NCT00495898|Device|CYPHER sirolimus-eluting stent|drug-eluting stent
487494|NCT00495898|Device|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
487495|NCT00495885|Drug|volinanserin (M100907)|oral, one tablet taken around bedtime
487496|NCT00495885|Drug|Placebo|oral, one tablet taken around bedtime
487497|NCT00495872|Drug|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
487498|NCT00495872|Drug|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
487499|NCT00495872|Drug|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
487500|NCT00495872|Drug|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
487501|NCT00495872|Drug|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
487502|NCT00495872|Drug|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
487503|NCT00495872|Drug|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
487504|NCT00495859|Dietary Supplement|Immunonutrition|food for special medical purpose (FSMP)
487505|NCT00495859|Dietary Supplement|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
487506|NCT00495846|Drug|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
487507|NCT00495846|Other|Locoregional treatments|
487508|NCT00495833|Behavioral|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
487509|NCT00495833|Behavioral|Promotional gift|half of participants who go to a fire station will receive a gift card.
487510|NCT00495820|Drug|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
487512|NCT00495807|Behavioral|No Words|Without any words was given during pain management
487513|NCT00495807|Behavioral|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
487514|NCT00495807|Behavioral|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
487515|NCT00495807|Behavioral|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
487516|NCT00495794|Behavioral|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
487517|NCT00495781|Procedure|%-hypo (laboratory parameter, functional iron deficiency)|
487518|NCT00495781|Procedure|CHr (laboratory parameter, functional iron deficiency)|
487519|NCT00495781|Procedure|RET-HE (laboratory parameter, functional iron deficiency)|
487520|NCT00495768|Behavioral|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
487521|NCT00495755|Drug|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
487522|NCT00495729|Drug|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
487523|NCT00495729|Drug|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
487524|NCT00495729|Drug|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
487525|NCT00495716|Drug|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
487526|NCT00495716|Drug|acyclovir|400 mg acyclovir orally twice daily for 1 year
487527|NCT00495703|Behavioral|Exercise|6-months of regular aerobic exercise
487528|NCT00495703|Behavioral|Usual Care|6-months of behavioral strategies to aid memory/cognition
487529|NCT00495690|Drug|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
487530|NCT00495677|Drug|PF-00232798|Solution, 20 mg. once daily, 10 days
487531|NCT00495677|Drug|PF-00232798|Solution, 150 mg. once daily, 10 days
487532|NCT00495677|Drug|PF-00232798|Solution, 5 mg. once daily, 10 days
487533|NCT00495677|Drug|PF-00232798|Solution, 40 mg. once daily, 10 days
487534|NCT00495677|Drug|PF-00232798|Solution, 300 mg. once daily, 10 days
487535|NCT00495677|Drug|PF-00232798|Solution, 400 mg. once daily, 10 days
487536|NCT00495664|Device|Titan stent and Taxus-Liberte stent|
487537|NCT00495651|Drug|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
487538|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.~Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
487539|NCT00495651|Drug|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
487540|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria~Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
487541|NCT00495625|Drug|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
487542|NCT00495612|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
487543|NCT00495612|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
487544|NCT00495599|Procedure|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
487545|NCT00495586|Drug|Placebo|One pill to be taken every eight hours for 8 days
487546|NCT00495586|Drug|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
487547|NCT00495573|Drug|acyclovir|400 mg acyclovir, orally three times a day for 5 days
487548|NCT00495560|Drug|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
487549|NCT00495547|Drug|Azacitidine|Azacitidine
487550|NCT00495547|Drug|Beta Erythropoietin|Beta Erythropoietin
487551|NCT00495521|Drug|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
487552|NCT00495508|Drug|Quinine|
487553|NCT00495508|Drug|artemether / lumefantrine|
487554|NCT00495495|Device|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
487555|NCT00495495|Device|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
487556|NCT00495469|Drug|GSK189075|GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
487557|NCT00495469|Drug|Placebo|Available as Placebo matching tablet to GSK189075
487558|NCT00495443|Device|Peterio|
487559|NCT00495417|Biological|AFFITOPE AD01|s.c. injection
487560|NCT00495417|Biological|AFFITOPE AD01 adjuvanted|s.c. injection
487561|NCT00495404|Behavioral|Physician Treatment Guidelines|
487562|NCT00495391|Drug|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
487563|NCT00495391|Drug|Placebo|One oral placebo tablet twice daily for 52 weeks.
511215|NCT00310856|Biological|DTaP-Hib-IPV|
487564|NCT00495391|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
487565|NCT00495391|Drug|Ribavirin|1000 mg (if <75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
487566|NCT00495378|Drug|epoetin alfa|
487567|NCT00495365|Drug|Epoetin alfa|
487568|NCT00495352|Drug|Hihg-doseNRT, Low-dose NRT, bupropion|
487569|NCT00495339|Drug|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
487570|NCT00495326|Drug|Nevirapine based therapy|"Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg~Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
487571|NCT00495326|Drug|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
487572|NCT00495326|Drug|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.~Continuation phase: 4 months daily H(RMP).~Patients with meningitis will receive Streptomycin instead of E during intensive phase."
487573|NCT00495313|Drug|doxycycline|COL-101, QD plus metronidazole
487574|NCT00495313|Drug|doxycycline|40 mg with metronidazole QD
487575|NCT00495287|Drug|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.~Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
487576|NCT00495274|Drug|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
487577|NCT00495274|Drug|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
487578|NCT00495274|Drug|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
487579|NCT00495274|Drug|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
487580|NCT00495274|Drug|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
487581|NCT00495274|Drug|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
487582|NCT00495274|Drug|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
487583|NCT00495261|Behavioral|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
487584|NCT00495261|Behavioral|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
487585|NCT00495248|Behavioral|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
487586|NCT00495248|Behavioral|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
487587|NCT00495235|Behavioral|Questionnaire|Questionnaire taking about 20 minutes to complete.
487588|NCT00495222|Procedure|Tissue plication|Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
487589|NCT00495222|Device|Endoscopic Suturing System|Tissue plication of dilated GJ stoma
487590|NCT00495222|Device|Tissue Plication|Tissue plication for GJ stoma reduction
487591|NCT00495209|Other|Qigong|EQT daily for 5 consecutive days prior to surgery.
487592|NCT00495196|Procedure|Experimental lung function test|Administration of several CO2 gas mixtures
487593|NCT00495183|Drug|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
487594|NCT00495183|Drug|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
487595|NCT00495183|Drug|Placebo|Placebo
487596|NCT00495170|Drug|Carboplatin|2 area under curve (AUC) by vein Weekly
487597|NCT00495170|Radiation|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
487598|NCT00495170|Drug|Paclitaxel|50 mg/m^2 by vein Weekly
487599|NCT00495157|Behavioral|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
487600|NCT00495157|Behavioral|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
487601|NCT00495157|Behavioral|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
487602|NCT00495144|Drug|TH-302|
487603|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
487604|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
487605|NCT00495118|Drug|risperidone|
487606|NCT00495105|Behavioral|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
487607|NCT00495092|Drug|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
487608|NCT00495092|Drug|Biperiden|Biperiden 2-4 mg/d p.o.
487609|NCT00495092|Drug|Placebo|Placebo + Placebo
487695|NCT00494494|Drug|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
487610|NCT00495079|Drug|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
487611|NCT00495066|Drug|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
487612|NCT00495053|Drug|hMaxi-K|Two dose levels (5000 µg/90 mL intravesical instillation and 10000 µg/90 mL intravesical instillation)
487613|NCT00495053|Other|Placebo|Matching placebo (PBS-20% sucrose)
487614|NCT00495040|Radiation|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
487615|NCT00495027|Behavioral|Internet-delivered Stress Innoculation Training|
487616|NCT00495014|Drug|GSK376501|
487617|NCT00495014|Drug|Placebo|
487618|NCT00494988|Drug|insulin aspart|
487619|NCT00494988|Drug|insulin NPH|
487620|NCT00494975|Device|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
487621|NCT00494962|Drug|lecozotan SR|
487622|NCT00494949|Drug|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
487623|NCT00494949|Drug|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
487624|NCT00494910|Behavioral|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
487625|NCT00494910|Behavioral|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
487626|NCT00494897|Drug|Asparaginase|
487627|NCT00494897|Drug|Cyclophosphamide|
487628|NCT00494897|Drug|Cytarabine|
487629|NCT00494897|Drug|Daunorubicin|
487630|NCT00494897|Drug|Mercaptopurine|
487631|NCT00494897|Drug|Prednisone|
487632|NCT00494897|Drug|Vincristine|
487633|NCT00494897|Drug|Methotrexate|
487634|NCT00494897|Procedure|Intrathecally treatment|
487635|NCT00494884|Drug|vildagliptin|
487636|NCT00494871|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL [creatinine clearance] >= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
487637|NCT00494871|Drug|Warfarin|Participants orally administered a warfarin potassium tablet (INR [international normalized ratio] target was 1.6-2.6 for patients >70 years and 2.0-3.0 for patients <70 years)
487638|NCT00494871|Drug|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
487639|NCT00494871|Drug|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
487640|NCT00494858|Behavioral|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
487641|NCT00494858|Behavioral|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
487642|NCT00494845|Behavioral|Mindfulness|8-week mindfulness program will be compared to an education control group.
487643|NCT00494845|Behavioral|Control: Health Education Class|8-week education program
487644|NCT00494832|Drug|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
487645|NCT00494832|Drug|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg~Maintenance dose of 0.6 mcg/kg/hour"
487646|NCT00494806|Other|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
487647|NCT00494793|Procedure|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed"
487648|NCT00494780|Drug|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
487649|NCT00494780|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
487650|NCT00494780|Drug|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
487651|NCT00494780|Drug|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
487652|NCT00494780|Drug|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
487653|NCT00494767|Drug|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
487654|NCT00494767|Drug|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
487655|NCT00494767|Drug|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
487656|NCT00494767|Drug|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
487790|NCT00493662|Drug|0.15% sodium Hyaluronate|
487791|NCT00493662|Drug|sodium chloride|
487657|NCT00494741|Drug|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
487658|NCT00494741|Drug|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight > 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
487659|NCT00494728|Behavioral|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
487660|NCT00494728|Drug|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
487661|NCT00494728|Behavioral|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
487662|NCT00494715|Drug|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
487663|NCT00494715|Drug|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
487664|NCT00494715|Drug|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
487665|NCT00494702|Procedure|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
487666|NCT00494702|Procedure|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
487667|NCT00494676|Device|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
487668|NCT00494676|Device|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
487669|NCT00494663|Drug|DIO-902|150mg tablet once per day for 16 weeks
487670|NCT00494663|Drug|DIO-902|300mg tablet once per day for 16 weeks
487671|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
487672|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
487673|NCT00494663|Drug|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
487674|NCT00494663|Drug|DIO-902|300mg DIO-902 tablet daily for 16 weeks
487675|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet for 16 weeks
487676|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
487677|NCT00494650|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
487678|NCT00494650|Behavioral|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
487679|NCT00494637|Drug|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
487680|NCT00494624|Drug|prednisolone|
487681|NCT00494611|Drug|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
487682|NCT00494598|Drug|Sufentanil|200 mcg intra-arterial one time bolus
487683|NCT00494585|Drug|CEP-701|80 mg orally twice a day for 30 days
487684|NCT00494572|Drug|Montelukast|10 mg rapid dissolving granule in sterile water orally once
487685|NCT00494572|Other|sterile water|sterile water
487686|NCT00494559|Drug|Pioglitazone|Actos 15mg once a day before breakfast
487687|NCT00494559|Drug|Placebo|Placebo drug with the same appearance as actos
487688|NCT00494546|Procedure|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
487689|NCT00494533|Drug|Remodulin (treprostinil sodium)|
487690|NCT00494520|Procedure|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
487691|NCT00494520|Procedure|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
487692|NCT00494507|Drug|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
487693|NCT00494507|Drug|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
487694|NCT00494507|Drug|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
487792|NCT00493662|Drug|sodium phosphate monobasic|
487696|NCT00494494|Drug|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
487697|NCT00494481|Drug|Vandetanib (ZD6474)|once daily oral dose
487698|NCT00494481|Drug|Docetaxel|intravenous infusion
487699|NCT00494468|Drug|Zolpidem|
487700|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
487701|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
487702|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
487703|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
487704|NCT00494429|Drug|Morphine|Gestational Age< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
487705|NCT00494429|Drug|Morphine|Gestational Age>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
487706|NCT00494416|Other|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.~Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
487707|NCT00494377|Drug|duloxetine|
487708|NCT00494351|Procedure|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
487709|NCT00494338|Drug|Docetaxel|
487710|NCT00494312|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
487711|NCT00494312|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
487712|NCT00494299|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
487713|NCT00494299|Drug|Placebo|Placebo: matching placebo
487714|NCT00494286|Behavioral|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
487715|NCT00494286|Behavioral|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
487716|NCT00494273|Behavioral|Cognitive Behavioral and Standard Care with Healthy Living|
487717|NCT00494260|Behavioral|Social Learning and Cognitive Behavioral Therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
487718|NCT00494260|Behavioral|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
487719|NCT00494247|Device|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
487720|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|oral
487721|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|
487722|NCT00494221|Drug|AZD2171|oral tablet
487723|NCT00494221|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
487724|NCT00494221|Drug|Placebo Cediranib|oral tablet
487725|NCT00494208|Drug|Testosterone|Testosterone ester
487726|NCT00494195|Genetic|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.~In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
487727|NCT00494195|Genetic|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
487728|NCT00494182|Drug|Carboplatin|Given IV
487729|NCT00494182|Drug|Paclitaxel|Given IV
487730|NCT00494182|Drug|Sorafenib|Given PO
487731|NCT00494156|Drug|heparin|
487732|NCT00494156|Drug|aspirin and clopidogrel|
487733|NCT00494143|Device|CESR Prosthetic Foot|a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle
487734|NCT00494143|Device|typical prosthetic foot|patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team
487735|NCT00494143|Device|standardized prosthetic foot|a standard foot that has had weights applied to match the mass of the CESR foot
487736|NCT00494117|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
487877|NCT00493025|Radiation|radiation therapy|Radiotherapy
487737|NCT00494104|Dietary Supplement|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
487738|NCT00494091|Drug|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
487739|NCT00494091|Drug|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
487740|NCT00494078|Device|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
487741|NCT00494078|Drug|intensive insulin therapy|intensive insulin therapy according to an algorithm
487742|NCT00494065|Other|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
487743|NCT00494065|Other|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
487744|NCT00494052|Behavioral|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
487745|NCT00494052|Behavioral|Physician Education Session|A physician education session will be included in the program.
487746|NCT00494039|Procedure|Radioactive seed implant to prostate|
487747|NCT00494026|Drug|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
487748|NCT00494026|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
487749|NCT00494026|Procedure|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
487750|NCT00494013|Drug|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
487751|NCT00494013|Drug|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
487752|NCT00493987|Drug|Testosterone Enanthate|testosterone ester
487753|NCT00493987|Drug|Dutasteride|5 alpha-reductase inhibitor
487754|NCT00493974|Drug|Zileuton|Zyflo tablets, 600 mg, 4 times a day
487755|NCT00493974|Drug|Placebo|Placebo 4 x daily
487756|NCT00493961|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
487757|NCT00493948|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
487758|NCT00493922|Procedure|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
487759|NCT00493922|Procedure|Microscopy|Microscopy for diagnosis of malaria
487760|NCT00493922|Procedure|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
487761|NCT00493909|Procedure|intrathecal opioids and thoracic paravertebral analgesia|
487762|NCT00493909|Procedure|thoracic epidural analgesia|
487763|NCT00493896|Drug|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
487764|NCT00493896|Drug|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
487765|NCT00493883|Device|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
487766|NCT00493870|Drug|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
487767|NCT00493870|Drug|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
487768|NCT00493870|Drug|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
487769|NCT00493857|Drug|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
487770|NCT00493857|Drug|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
487771|NCT00493844|Other|Exercise testing|Exercise testing
487772|NCT00493844|Other|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
487773|NCT00493831|Drug|nicotine polacrilex, transdermal system or inhaler|
487774|NCT00493818|Drug|GSK690693|
487775|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
487776|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
487777|NCT00493792|Device|Stryker X3 crosslink|Radiographs, questionnaires and an exam will be obtained at key post-surgical follow up dates. 3months, 2years, 5 years, 7 years and 10 years.
487778|NCT00493779|Procedure|Blood Collection|4 weeks
487779|NCT00493766|Drug|LBH589|
487780|NCT00493753|Procedure|Acupuncture|
487781|NCT00493740|Procedure|chocolate cake|
487782|NCT00493727|Drug|N-acetylcysteine(Mucomyst)|
487783|NCT00493714|Behavioral|Questionnaire|Surveys lasting 30 minutes or more.
487784|NCT00493701|Behavioral|High Fat Diet|Daily eating
487785|NCT00493701|Behavioral|Low Fat Diet|Life style eating habits
487786|NCT00493688|Other|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
487787|NCT00493675|Procedure|endoscopic bile duct stenting|
487788|NCT00493662|Drug|Polyethylene Glycol 400 0.4%|
487789|NCT00493662|Drug|Propylene Glycol 0.3%|
487793|NCT00493649|Drug|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
487794|NCT00493649|Drug|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
487795|NCT00493649|Drug|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
487796|NCT00493636|Drug|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
487797|NCT00493636|Drug|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
487798|NCT00493636|Drug|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
487799|NCT00493636|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
487800|NCT00493623|Drug|Placebo|Placebo i.v. single dose
487801|NCT00493623|Drug|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
487802|NCT00493610|Drug|N-acetylcysteine(Mucomyst)|
487803|NCT00493584|Procedure|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
487804|NCT00493584|Procedure|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
487805|NCT00493571|Drug|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
487806|NCT00493558|Device|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
487807|NCT00493545|Biological|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
487808|NCT00493532|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
487809|NCT00493519|Procedure|chocolate cake|
487810|NCT00493506|Drug|ProAlgaZyme|
487811|NCT00493493|Procedure|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
487812|NCT00493480|Drug|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
487813|NCT00493480|Drug|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
487814|NCT00493467|Drug|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of ^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.~90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
487815|NCT00493467|Drug|Rituximab|250 mg/m^2 Intravenously Over 4-6 Hours On Days 1 and 8.
487816|NCT00493454|Drug|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
487817|NCT00493454|Drug|Rituximab|250 mg/m^2 IV Over 6 to 8 Hours
487818|NCT00493454|Drug|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
487819|NCT00493441|Drug|AVN944|150, 200, 250, 300, or 400 mg q12h
487820|NCT00493428|Drug|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
487821|NCT00493415|Drug|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
487822|NCT00493415|Drug|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
487823|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
487824|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
487825|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
487826|NCT00493389|Drug|Adrenocorticotrophic hormone|
487827|NCT00493376|Procedure|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
488330|NCT00489710|Procedure|flow cytometry|
487828|NCT00493376|Procedure|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
487829|NCT00493376|Procedure|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
487830|NCT00493376|Procedure|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
487831|NCT00493363|Drug|Artesunate|Artesunate 2 mg/kg/day for 7 days
487832|NCT00493363|Drug|Artesunate + Mefloquine|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
487833|NCT00493350|Procedure|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
487834|NCT00493337|Behavioral|advanced adherence counseling+reminder|
487835|NCT00493337|Device|Compliance Card|
487836|NCT00493324|Drug|alefacept|Intramuscular
487837|NCT00493324|Drug|polyvalent pneumococcal vaccine|Injection
487838|NCT00493311|Drug|IV Placebo|IV Placebo
487839|NCT00493311|Drug|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
487840|NCT00493311|Biological|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
487841|NCT00493298|Drug|natalizumab|According to the local prescribing information
487842|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
487843|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
487844|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.
487845|NCT00493272|Drug|Fibrinogen|Fibrinogen behandling
487846|NCT00493259|Behavioral|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
487847|NCT00493259|Behavioral|Depression Scale for Children (CES-DC)|questionnaire
487848|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
487849|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)~Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
487850|NCT00493233|Drug|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
487851|NCT00493233|Drug|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
487852|NCT00493220|Drug|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
487853|NCT00493220|Drug|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
487854|NCT00493220|Drug|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
487855|NCT00493194|Drug|sirolimus|
487856|NCT00493194|Drug|cyclosporine|
487857|NCT00493194|Drug|daclizumab|
487858|NCT00493181|Drug|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
487859|NCT00493155|Drug|RG1530|Administered po at escalating doses (10 cohorts)
487860|NCT00493142|Behavioral|Exercise|physical therapy home exercise
487861|NCT00493129|Drug|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
487862|NCT00493116|Drug|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
487863|NCT00493116|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
487864|NCT00493090|Behavioral|modification of an interactive seminar|
487865|NCT00493077|Drug|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
487866|NCT00493064|Drug|Nicotinic acid|topical eye drops
487867|NCT00493064|Drug|Prednisolone acetate|topical eye drops
487868|NCT00493051|Biological|GAM501|Ad5PDGF-B formulated in a collagen gel
487869|NCT00493051|Biological|Placebo|Collagen gel
487870|NCT00493051|Other|Standard of care|moist dressing changes daily
487871|NCT00493038|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
487872|NCT00493038|Drug|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
487873|NCT00493025|Drug|cisplatin|Cisplatin IV
487874|NCT00493025|Drug|gefitinib|Gefitinib IV
487875|NCT00493025|Drug|paclitaxel|Paclitaxel IV
487876|NCT00493025|Procedure|adjuvant therapy|Postoperative ZD1839
487878|NCT00493012|Dietary Supplement|vitamin D|6 drops of a vitamin D containing oil
487879|NCT00492999|Drug|dexamethasone|Given by hepatic arterial infusion
487880|NCT00492999|Drug|floxuridine|Given by hepatic arterial infusion
487881|NCT00492999|Drug|fluorouracil|Given IV
487882|NCT00492999|Drug|irinotecan hydrochloride|Given IV
487883|NCT00492999|Drug|leucovorin calcium|Given IV
487884|NCT00492999|Drug|oxaliplatin|Given IV
487885|NCT00492986|Drug|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
487886|NCT00492973|Drug|methylprednisolone acetate|Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
487887|NCT00492973|Drug|active comparator|bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
487888|NCT00492960|Drug|larazotide acetate|gelatin capsules
487889|NCT00492960|Drug|placebo|gelatin capsules
487890|NCT00492960|Dietary Supplement|900 mg gluten|gelatin capsules
487891|NCT00492947|Biological|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
487892|NCT00492934|Drug|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
487893|NCT00492921|Drug|Cyclophosphamide|
487894|NCT00492908|Device|Helistent Titan2 (Titanium coated stent)|Titan2
487895|NCT00492908|Device|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
487896|NCT00492895|Drug|Discontinuation of Azathioprin|Discontinuation of Azathioprin
487897|NCT00492882|Drug|usual administration of exogenous recombinant FSH|
487898|NCT00492869|Drug|AEB071|
487899|NCT00492856|Drug|mercaptopurine|Given orally
487900|NCT00492856|Drug|methotrexate|Given orally
487901|NCT00492856|Drug|tretinoin|Given orally
487902|NCT00492843|Drug|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
487903|NCT00492830|Drug|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
487904|NCT00492817|Procedure|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
487905|NCT00492804|Procedure|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
487906|NCT00492804|Procedure|Neurectomy|Neurectomy
487907|NCT00492791|Device|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
487908|NCT00492778|Radiation|3-Dimensional Conformal Radiation Therapy|Given to the pelvis
487909|NCT00492778|Drug|Cisplatin|Given IV
487910|NCT00492778|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
487911|NCT00492778|Radiation|Internal Radiation Therapy|Given intracavitarily or interstitially
487912|NCT00492765|Drug|Interferon-beta-1a|dosage and frequency as per label
487913|NCT00492765|Drug|Simvastatin|dosage and frequency as per Biogen Idec protocol
487914|NCT00492765|Drug|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
487915|NCT00492752|Drug|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
487916|NCT00492752|Drug|Placebo|Matching placebo (orally) twice daily
487917|NCT00492739|Biological|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
487918|NCT00492726|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
487919|NCT00492726|Drug|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
487920|NCT00492713|Other|dark chocolate|dark chocolate
487921|NCT00492713|Other|Milk chocolate 1|Milk chocolate 1
487922|NCT00492713|Other|Milk chocolate 2|Milk chocolate 2
487923|NCT00492700|Drug|rosiglitazone|
487924|NCT00492687|Drug|carboplatin|
487925|NCT00492687|Drug|tamoxifen citrate|
487926|NCT00492687|Drug|temozolomide|
487927|NCT00492687|Procedure|adjuvant therapy|
487928|NCT00492687|Radiation|radiation therapy|
487929|NCT00492674|Device|APOS biomechanical gait system|
487930|NCT00492674|Procedure|Physical Therapy|
487931|NCT00492661|Drug|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
487932|NCT00492648|Procedure|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
487933|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
487934|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
487935|NCT00492635|Drug|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
487936|NCT00492622|Drug|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
487937|NCT00492622|Drug|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
487938|NCT00492596|Device|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
487939|NCT00492596|Procedure|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
488006|NCT00492232|Drug|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
488007|NCT00492232|Drug|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
487940|NCT00492583|Drug|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
487941|NCT00492583|Drug|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
487942|NCT00492557|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
487943|NCT00492557|Biological|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
487944|NCT00492544|Biological|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
487945|NCT00492531|Drug|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
487946|NCT00492531|Drug|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
487947|NCT00492518|Drug|Acetylcysteine|
487948|NCT00492518|Drug|Theophylline|
487949|NCT00492518|Drug|Placebo|
487950|NCT00492505|Drug|cisplatin|
487951|NCT00492505|Drug|sorafenib tosylate|
487952|NCT00492505|Drug|tamoxifen citrate|
487953|NCT00492505|Procedure|adjuvant therapy|
487954|NCT00492492|Procedure|trans-styloid and intrafocal pinning on the one side|
487955|NCT00492492|Procedure|volar fixed-angle plating on the other side|
487956|NCT00492479|Drug|Kinerase Pro+Therapy Line day repair, serum, night repair|
487957|NCT00492479|Drug|Kinerase Pro+Therapy Line Ultra rich day repair|
487958|NCT00492479|Drug|LubriDerm|
487959|NCT00492466|Drug|Interferon-beta-1a|dosage and frequency as per label
487960|NCT00492466|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
487961|NCT00492453|Procedure|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
487962|NCT00492440|Biological|recombinant interleukin-7|
487963|NCT00492440|Genetic|gene expression analysis|
487964|NCT00492440|Genetic|polymerase chain reaction|
487965|NCT00492440|Genetic|protein expression analysis|
487966|NCT00492440|Other|flow cytometry|
487967|NCT00492440|Other|immunoenzyme technique|
487968|NCT00492440|Other|immunologic technique|
487969|NCT00492440|Other|laboratory biomarker analysis|
487970|NCT00492440|Other|pharmacological study|
487971|NCT00492427|Drug|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25~250μg(s.c.)/4week for 24~26weeks in total.
487972|NCT00492427|Drug|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k~12000IU(s.c.)/2week for 24~26weeks in total.
487973|NCT00492414|Drug|Paroxetine CR|
487974|NCT00492401|Drug|decitabine|Given IV
487975|NCT00492401|Other|laboratory biomarker analysis|Correlative studies
487976|NCT00492401|Other|pharmacological study|Correlative studies
487977|NCT00492401|Other|high performance liquid chromatography|Correlative studies
487978|NCT00492401|Genetic|microarray analysis|Correlative studies
487979|NCT00492401|Genetic|RNA analysis|Correlative studies
487980|NCT00492401|Other|mass spectrometry|Correlative studies
487981|NCT00492401|Genetic|DNA methylation analysis|Correlative studies
487982|NCT00492401|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
487983|NCT00492388|Drug|PMI-150 (intranasal ketamine)|intranasal dosing
487984|NCT00492388|Drug|placebo|placebo
487985|NCT00492362|Behavioral|ergometer exercise during hemodialysis|
487986|NCT00492362|Behavioral|pedometer activity outside of hemodialysis|
487987|NCT00492349|Drug|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
487988|NCT00492349|Drug|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
487989|NCT00492336|Drug|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
487990|NCT00492336|Drug|Placebo|Placebo 1 tablet each day
487991|NCT00492323|Drug|placebo|twice daily for 4 weeks
487992|NCT00492323|Drug|carisbamate|200 mg tablet twice daily for 4 weeks
487993|NCT00492310|Behavioral|yoga|vinyasa yoga
487994|NCT00492310|Behavioral|cognitive therapy|cognitive behavioral therapy once weekly
487995|NCT00492310|Behavioral|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
487996|NCT00492310|Behavioral|wellness|wellness program with smoking cessation
487997|NCT00492297|Drug|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
487998|NCT00492284|Drug|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
487999|NCT00492284|Drug|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
488000|NCT00492284|Drug|ranibizumab|0.5 mg intravitreal injection
488001|NCT00492284|Drug|dexamethasone|0.5 mg intravitreal injection
488002|NCT00492271|Drug|Friulimicin B|Intravenous, once daily, single dose
488003|NCT00492258|Drug|sorafenib tosylate|
488004|NCT00492258|Procedure|adjuvant therapy|
488005|NCT00492245|Procedure|PTK with mitomycin in Adenoviral Opacities|
488060|NCT00491855|Drug|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
488008|NCT00492219|Device|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
488009|NCT00492219|Device|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
488010|NCT00492206|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
488011|NCT00492167|Biological|beta-glucan|
488012|NCT00492167|Biological|monoclonal antibody 3F8|
488013|NCT00492167|Other|immunohistochemistry staining method|
488014|NCT00492167|Other|laboratory biomarker analysis|
488015|NCT00492141|Drug|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
488016|NCT00492141|Drug|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.~Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.~Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
488017|NCT00492128|Drug|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
488018|NCT00492115|Device|Continuous positive airway pressure (CPAP)|therapeutic Continuous positive airway pressure (tCPAP) nightly for 6 weeks
488019|NCT00492115|Device|Placebo CPAP|Ineffective Continuous positive airway pressure (pCPAP) for 3 weeks followed by therapeutic CPAP for 3 weeks
488020|NCT00492102|Drug|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing >1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
488021|NCT00492089|Drug|bevacizumab|Given IV
488022|NCT00492089|Drug|placebo|Given IV
488023|NCT00492089|Procedure|magnetic resonance imaging|
488024|NCT00492089|Procedure|quality-of-life assessment|
488025|NCT00492076|Biological|Pangramin Plus D. pteronyssinus 100%|"Active. Pangramin Plus D. pteronyssinus 100%~Placebo. Pangramin Plus placebo"
488026|NCT00492063|Biological|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
488027|NCT00492063|Biological|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
488028|NCT00492050|Drug|Bortezomib|1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22.
488029|NCT00492050|Drug|Rituximab|375 mg/m^2 IV on Day 8 and 22.
488030|NCT00492050|Drug|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
488031|NCT00492037|Drug|YM087 oral|
488032|NCT00492024|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
488033|NCT00492024|Drug|Placebo|Placebo - 380 mg Microcrystalline Cellulose
488034|NCT00492011|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
488035|NCT00492011|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
488036|NCT00492011|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
488037|NCT00492011|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
488038|NCT00491998|Drug|V1512|6 doses of IMP at 2-hourly intervals
488039|NCT00491998|Drug|V1512|3-hourly dosing
488040|NCT00491998|Drug|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
488041|NCT00491985|Biological|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
488042|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
488043|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
488044|NCT00491959|Procedure|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
488045|NCT00491946|Drug|Actinomycin-D|
488046|NCT00491946|Drug|Vincristine|
488047|NCT00491933|Procedure|Quantiferon-TB Gold assay|
488048|NCT00491933|Procedure|Tuberculin skin test|
488049|NCT00491920|Drug|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week~+ calcium 500 mg/cholecalciferol 400 IU x2/d"
488050|NCT00491920|Drug|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
488051|NCT00491907|Drug|folic acid 5mg/day|
488052|NCT00491894|Drug|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
488053|NCT00491881|Behavioral|no added salt diet|
488054|NCT00491868|Drug|R744|100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
488055|NCT00491868|Drug|R744|150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
488056|NCT00491868|Drug|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
488057|NCT00491868|Drug|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
488058|NCT00491868|Drug|R744 placebo|0 μg/4week for 24 weeks
488059|NCT00491868|Drug|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks
488061|NCT00491855|Drug|Oxaliplatin|Starting dose level 25 mg/m^2 given intraperitoneally on day 2.
488062|NCT00491855|Drug|Paclitaxel|Starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
488063|NCT00491829|Drug|50 mg qhs|flibanserin 50 mg
488064|NCT00491829|Drug|100 mg|flibanserin 100mg
488065|NCT00491829|Drug|placebo|placebo
488066|NCT00491816|Drug|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
488067|NCT00491803|Drug|Sildenafil|sildenafil 20 mg orally
488068|NCT00491803|Drug|Sildenafil|sildenafil 40 mg orally
488069|NCT00491790|Drug|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
488070|NCT00491790|Other|Sterile water|Sterile water
488071|NCT00491777|Device|Noninvasive Hemodynamic Patient Monitor|
488072|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
488073|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
488074|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
488075|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
488076|NCT00491764|Drug|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
488077|NCT00491764|Drug|Placebo|Placebo for 24 weeks.
488078|NCT00491751|Drug|atorvastatin|atorvastatin 40 or 80 mg/day
488079|NCT00491751|Drug|ascorbic acid|ascorbic acid 500 mg/day
488080|NCT00491751|Drug|Placebo|matching placebo
488081|NCT00491738|Drug|bevacizumab|Intravenous repeating dose
488082|NCT00491738|Drug|sunitinib|Oral repeating dose
488083|NCT00491738|Drug|placebo|Intravenous repeating dose
488084|NCT00491725|Drug|repaglinide|
488085|NCT00491725|Drug|metformin|
488086|NCT00491712|Procedure|Glaucoma drainage implant with/without triamcinolone|
488087|NCT00491699|Drug|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
488088|NCT00491686|Drug|AZD6765|intravenous infusion
488089|NCT00491673|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
488090|NCT00491673|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
488091|NCT00491660|Behavioral|supine positioning|
488092|NCT00491660|Behavioral|lateral positioning|
488093|NCT00491634|Drug|treosulfan|12 g/m2 x 3 days
488094|NCT00491634|Drug|Treosulfan|12 g/m2 x 3
488095|NCT00491621|Procedure|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
488096|NCT00491608|Biological|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
488097|NCT00491595|Drug|High Dose Soy isoflavones|
488098|NCT00491582|Drug|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
488099|NCT00491569|Drug|Sarcosine and D-serine|
488100|NCT00491556|Procedure|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
488101|NCT00491556|Procedure|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
488102|NCT00491543|Drug|ALT-2074|
488103|NCT00491530|Drug|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
488104|NCT00491530|Drug|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
488105|NCT00491530|Drug|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
488106|NCT00491530|Drug|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
488107|NCT00491517|Drug|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
488108|NCT00491517|Drug|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
488109|NCT00491504|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
488110|NCT00491504|Other|Placebo|Placebo: 2 sprays in each nostril
488111|NCT00491491|Drug|ibritumomab tiuxetan|0.4 mCi/kg
488112|NCT00491491|Procedure|BEAM chemotherapy and autologous stem-cell transplantation|
488113|NCT00491478|Drug|sertraline|
488114|NCT00491465|Behavioral|Intensive Physical activity|
488115|NCT00491465|Behavioral|Control- regular physical activity|
488116|NCT00491426|Drug|Ampicillin|Drug prescribed per routine medical care.
488117|NCT00491426|Drug|Metronidazole|Drug prescribed per routine medical care.
488118|NCT00491426|Drug|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
488119|NCT00491426|Drug|Acyclovir|Drug prescribed per routine medical care.
512447|NCT00301834|Drug|busulfan|
488120|NCT00491426|Drug|Amphotericin B|Drug prescribed per routine medical care.
488121|NCT00491426|Drug|Ambisome|Drug prescribed per routine medical care.
488122|NCT00491426|Drug|Anidulafungin|Drug prescribed per routine medical care.
488123|NCT00491426|Drug|Caspofungin|Drug prescribed per routine medical care.
488124|NCT00491413|Drug|epoetin|
488125|NCT00491400|Drug|Fenofibrate|140 mg/day for 8 weeks
488126|NCT00491400|Drug|Atorvastatin|20 mg/day for 8 weeks
488127|NCT00491387|Drug|Metoprolol Succinate|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
488128|NCT00491374|Drug|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
488129|NCT00491374|Drug|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
488130|NCT00491348|Drug|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
488131|NCT00491322|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units once a week for 12 weeks
488132|NCT00491322|Dietary Supplement|Ergocalciferol placebo|Ergocalciferol placebo once a week for 12 weeks
488133|NCT00491309|Behavioral|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
488134|NCT00491296|Device|SYNERGO|
488135|NCT00491296|Device|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
488136|NCT00491283|Device|Swab Specimen Collection (QuickVue)|
488137|NCT00491270|Device|VS Sense|An applicator to diagnose pH increase above 5.2
488138|NCT00491257|Biological|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
488139|NCT00491244|Drug|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
488140|NCT00491244|Drug|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
488141|NCT00491192|Drug|Diclofenac|
488142|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
488143|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
488144|NCT00491166|Drug|Bromfenac ophthalmic solution|
488145|NCT00491140|Genetic|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
488146|NCT00491127|Drug|gemcitabine|
488147|NCT00491127|Drug|cisplatin|
488148|NCT00491127|Drug|dexamethasone|
488149|NCT00491114|Drug|Gemcitabine|
488150|NCT00491101|Other|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
488151|NCT00491101|Other|spirometry|spirometry
488152|NCT00491088|Device|CPAP|CPAP for 12 weeks
488153|NCT00491075|Drug|Pemetrexed|500 mg/m^2 IV Over 10 Minutes on Day 1.
488154|NCT00491075|Drug|Gemcitabine|1500 mg/m^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
488155|NCT00491062|Procedure|Biopsies|
488156|NCT00491049|Drug|0.5% levofloxacin eye drops|
488157|NCT00491036|Device|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
488158|NCT00491010|Procedure|radiofrequency catheter ablation|
488159|NCT00490997|Drug|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).~Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
488160|NCT00490997|Drug|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).~Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
488161|NCT00490984|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
488162|NCT00490971|Drug|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
488163|NCT00490971|Drug|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
488164|NCT00490971|Drug|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
488165|NCT00490958|Drug|telmisartan|
488166|NCT00490945|Drug|VEC-162|
488167|NCT00490932|Drug|Hypo-osmolar ORS|
488168|NCT00490919|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
488169|NCT00490919|Drug|Placebo|transdermal system (placebo) worn for 7 days
488170|NCT00490906|Drug|Copaxone|20 mg, subcutaneous injections, taken daily
488171|NCT00490906|Drug|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
488172|NCT00490906|Drug|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
488173|NCT00490893|Drug|Detemir|
488174|NCT00490880|Drug|gemcitabine|
488175|NCT00490880|Drug|cisplatin|
488176|NCT00490880|Procedure|radical cystectomy|
488177|NCT00490880|Procedure|radiotherapy|
488178|NCT00490867|Drug|Alpha lipoic acid|
488179|NCT00490854|Drug|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
488180|NCT00490854|Drug|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
488181|NCT00490841|Device|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
488182|NCT00490828|Drug|Hydrocortisone|Hydrocortisone
488183|NCT00490815|Drug|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
488184|NCT00490815|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
488185|NCT00490802|Drug|Oxytocin|Intranasal Oxytocin
488186|NCT00490802|Drug|Placebo|Placebo Comparator
488187|NCT00490789|Drug|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
488188|NCT00490776|Drug|LBH589|
488189|NCT00490763|Behavioral|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
488190|NCT00490750|Procedure|Dor fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
488191|NCT00490750|Procedure|Toupet fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
488192|NCT00490737|Drug|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
488193|NCT00490724|Drug|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
488194|NCT00490724|Drug|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
488195|NCT00490724|Drug|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
488196|NCT00490711|Drug|gemcitabine|
488197|NCT00490711|Drug|carboplatin|
488198|NCT00490711|Drug|paclitaxel|
488199|NCT00490698|Drug|Zoledronate|4 mg IV Once Every 4 Weeks
488200|NCT00490698|Drug|Atorvastatin|20 mg PO Daily
488201|NCT00490685|Drug|Sorafenib (BAY-43-9006)|
488202|NCT00490672|Behavioral|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
488203|NCT00490672|Behavioral|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
488204|NCT00490659|Drug|gemcitabine|
488205|NCT00490659|Drug|cisplatin|
488206|NCT00490659|Procedure|radical surgery|
488207|NCT00490659|Procedure|chemoradiotherapy|
488208|NCT00490646|Drug|ixabepilone|"Ixabepilone 40 mg/m^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.~For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
488209|NCT00490646|Drug|docetaxel|Docetaxel 100 mg/m^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
488210|NCT00490646|Drug|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
488211|NCT00490633|Behavioral|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
488212|NCT00490633|Behavioral|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
488213|NCT00490620|Drug|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
488214|NCT00490620|Drug|Placebo|placebo BID for 6 months
488215|NCT00490594|Device|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
488216|NCT00490581|Other|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
488217|NCT00490568|Drug|Rosiglitazone XR|Experimental drug
488218|NCT00490555|Drug|Testosterone gel|Testosterone gel 10 g
488219|NCT00490555|Drug|Dutasteride|dutasteride 0.5 mg orally
488220|NCT00490555|Drug|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
488221|NCT00490555|Other|Placebo Testosterone gel|Place gel applied daily for 12 weeks
488222|NCT00490555|Other|Placebo dutasteride|placebo pill for 12 weeks
488223|NCT00490555|Other|Placebo DMPA|placebo DMPA injection Once
488224|NCT00490542|Drug|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
488225|NCT00490542|Drug|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
488327|NCT00489710|Drug|talabostat mesylate|
488328|NCT00489710|Procedure|diagnostic procedure|
488329|NCT00489710|Procedure|enzyme inhibitor therapy|
488226|NCT00490529|Biological|CpG-MCL vaccine|"The CpG-MCL vaccine is a suspension of the participant's mantle cell lymphoma (MCL), that have been cultured for 72 hours with 3 mcg/mL PF-3512676, then irradiated to 200 Gy. Aliquots are frozen prior to use.~At each of 3 vaccination time points, 1 x 10e8 CpG-MCL cells will be given as a subcutaneous injection in the patient's lateral thigh."
488227|NCT00490529|Procedure|Vaccine-primed T-cells|Vaccine primed T-cells are a leukapheresis harvest of peripheral blood mononuclear cells (PMPC). Each collection will be approximately 1 x 10e10 CD3+ T-cells.
488228|NCT00490529|Drug|PF-3512676|"PF-03512676 is an immunostimulatory single-stranded oligodeoxynucleotide containing unmethylated cytosine and guanine (CpG) motifs and synthesized with a nuclease-resistant phosphorothioate backbone~With each CpG-MCL vaccination, participants will receive a concurrent subcutaneous injection of PF-3512676 as an adjuvant."
488229|NCT00490529|Procedure|Autologous peripheral blood stem cell (PBSC) transplant|Regular medical care procedure
488230|NCT00490529|Drug|Rituximab|375 mg/m² by intravenous (IV) infusion
488231|NCT00490516|Drug|ACP-104|200 mg, tablet, BID, 6 weeks
488232|NCT00490516|Drug|ACP-104|100 mg, tablet, BID, 6 weeks
488233|NCT00490516|Drug|Placebo|placebo, tablet BID, 6 weeks
488234|NCT00490503|Procedure|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
488235|NCT00490503|Procedure|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
488236|NCT00490490|Drug|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
488237|NCT00490490|Procedure|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
488238|NCT00490490|Drug|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:~Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,~Lugol's solution 20 drops orally 3-times-a-day, OR~KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
488239|NCT00490477|Device|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
488240|NCT00490464|Drug|Nicardipine and Nipride|
488241|NCT00490451|Drug|LY573636-sodium|LY573636 dose is dependent on patient's height, weight, and gender to target a specific maximum concentration (Cmax). LY573636 is administered intravenously every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
488242|NCT00490425|Drug|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
488243|NCT00490412|Dietary Supplement|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
488244|NCT00490412|Other|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
488245|NCT00490399|Drug|gemcitabine|
488246|NCT00490399|Drug|cisplatin|
488247|NCT00490373|Drug|pemetrexed|
488248|NCT00490360|Drug|Gemcitabine / Cisplatin|
488249|NCT00490347|Device|VentrAssist Left Ventricular Assist Device|
488250|NCT00490321|Device|VentrAssistTM Left Ventricular Assist Device|
488251|NCT00490308|Drug|Treatment with estradiol valerate|
488252|NCT00490282|Radiation|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
488253|NCT00490282|Radiation|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
488254|NCT00490269|Drug|Placebo|
488255|NCT00490269|Drug|Dronabinol|
488256|NCT00490256|Procedure|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
488257|NCT00490243|Drug|budesonide and montelukast|
488258|NCT00490243|Drug|budesonide and formoterol|
488259|NCT00490243|Drug|montelukast|
488260|NCT00490243|Drug|budesonide|
488261|NCT00490243|Drug|placebo|
488262|NCT00490230|Drug|WR 279396|
488263|NCT00490204|Drug|Cetirizine|
488264|NCT00490191|Drug|Somatropin|
488265|NCT00490178|Drug|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
488266|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
488267|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
488268|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
488269|NCT00490139|Drug|Lapatinib|Small molecule inhibitor
488270|NCT00490139|Biological|Trastuzumab|Antibody
488271|NCT00490126|Other|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
488272|NCT00490113|Drug|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
488273|NCT00490100|Drug|Increlex|
488274|NCT00490087|Device|Levonorgestrel intrauterine device (IUD)|
488275|NCT00490074|Biological|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
488276|NCT00490074|Biological|NYVAC-C|NYVAC-C 1 ml IM
488277|NCT00490061|Drug|Lapatinib|1500 mg po daily orally
488278|NCT00490061|Procedure|Radiotherapy (radiation)|Standard of Care
488279|NCT00490061|Device|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
488280|NCT00490061|Device|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
488281|NCT00490048|Procedure|Induced sputum (inhalation of 3.5% saline)|
488282|NCT00490035|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
488283|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
488284|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
488285|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
488286|NCT00490022|Drug|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
488287|NCT00490022|Drug|Placebo gel|Placebo gel for one month
488288|NCT00490009|Drug|Bexxar|"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.~Bexxar will be administered to provide the following patient-specific radiotherapy:~Platelet count of 150,000/mm³ = 75 cGy~Platelet count ≥ 100,000/mm³ but < 150,000/mm³ = 65 cGy"
488289|NCT00490009|Drug|Acetaminophen|As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
488290|NCT00490009|Drug|Diphenhydramine|As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
488291|NCT00490009|Drug|Potassium Iodide (KI)|Administered to prevent thyroid blockage 130 mg orally 3 times a day,
488292|NCT00489996|Drug|gemcitabine|
488293|NCT00489996|Drug|cisplatin|
488294|NCT00489983|Drug|pemetrexed|
488295|NCT00489983|Drug|gemcitabine|
488296|NCT00489970|Procedure|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
488297|NCT00489970|Biological|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
488298|NCT00489970|Biological|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
488299|NCT00489944|Drug|cisplatin|
488300|NCT00489944|Drug|sunitinib malate|
488301|NCT00489944|Drug|tamoxifen citrate|
488302|NCT00489944|Procedure|adjuvant therapy|
488303|NCT00489931|Drug|VRC-AVIDNA036-00-VP|
488304|NCT00489918|Drug|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
488305|NCT00489918|Drug|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
488306|NCT00489905|Drug|Zolderonic acid (Zometa)|
488307|NCT00489892|Drug|Modafinil|
488308|NCT00489879|Device|Mobile Health Care System (DrUB)|
488309|NCT00489866|Drug|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
488310|NCT00489866|Drug|Placebo|Same as active drug.
488311|NCT00489853|Drug|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
488312|NCT00489853|Drug|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
488313|NCT00489853|Other|Placebo|Placebo, 1 inhalation twice daily
488314|NCT00489840|Drug|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
488315|NCT00489840|Drug|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
488316|NCT00489827|Drug|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
488317|NCT00489827|Other|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
488318|NCT00489814|Behavioral|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
488319|NCT00489801|Other|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
488320|NCT00489775|Drug|Duloxetine|
488321|NCT00489775|Drug|Paroxetine|
488322|NCT00489762|Procedure|Installation of an energy efficient heater|
488323|NCT00489749|Procedure|Protected early weightbearing/Achilles tendon surgery|
488324|NCT00489736|Drug|dronedarone (SR33589)|oral administration
488325|NCT00489736|Drug|amiodarone|oral administration
488326|NCT00489723|Drug|tamsulosin 0.4mg|
488331|NCT00489710|Procedure|laboratory biomarker analysis|
488332|NCT00489710|Procedure|non-specific immune-modulator therapy|
488333|NCT00489697|Device|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
488334|NCT00489658|Drug|Eflornithine plus Nifurtimox combination therapy|
488335|NCT00489645|Drug|placebo|placebo SC during euglycemia
488336|NCT00489645|Drug|pramlintide|pramlintide SC during eglycemia
488337|NCT00489645|Drug|placebo|placebo during hyperglycemia
488338|NCT00489645|Drug|pramlintide|pramlintide SC during hyperglycemia
488339|NCT00489632|Behavioral|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
488340|NCT00489606|Drug|SK3530|
488341|NCT00489593|Drug|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
488342|NCT00489580|Device|SaeboFlex Dynamic Hand Orthosis|
488343|NCT00489580|Procedure|Saebo F.T.M. Arm Training Program|
488344|NCT00489567|Procedure|Blood sample collection|
488345|NCT00489554|Biological|Synflorix|Intramuscular injection, 3 doses.
488346|NCT00489554|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
488347|NCT00489554|Biological|Rotarix|Oral, 2 doses.
488348|NCT00489541|Device|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
488349|NCT00489528|Drug|Somatropin; Recombinant human growth hormone (r hGH)|
488350|NCT00489502|Behavioral|Brief Counseling|
488351|NCT00489502|Device|REE Assessment|
488352|NCT00489489|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
488353|NCT00489489|Drug|Placebo (for Teriflunomide)|"Film-coated tablet~Oral administration"
488354|NCT00489489|Drug|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
488355|NCT00489476|Drug|Staccato Loxapine|
488356|NCT00489476|Drug|Staccato Placebo|Placebo aerosol inhalation (0mg)
488357|NCT00489463|Device|intra-uterine device (TCu 380A)|
488358|NCT00489450|Drug|SK3530|
488359|NCT00489437|Device|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
488360|NCT00489437|Procedure|Clinical Prediction Score-HIT Score Card|"clinical prediction rule~rapid immunoassay"
488361|NCT00489424|Drug|Placebo|
488362|NCT00489424|Drug|Acetaminophen|
488363|NCT00489424|Drug|Fluvastatin|
488364|NCT00489411|Drug|duloxetine hydrochloride|Given orally
488365|NCT00489411|Other|placebo|Given orally
488366|NCT00489398|Drug|epinastine HCL and olopatadine HCL|
488367|NCT00489385|Drug|Albinterferon|
488368|NCT00489385|Drug|Ribavirin|
488369|NCT00489385|Drug|Albuferon|
488370|NCT00489372|Drug|Se-methyl-seleno-L-cysteine|Given orally
488371|NCT00489372|Other|placebo|Given orally
488372|NCT00489372|Other|pharmacological study|Correlative studies
488373|NCT00489372|Other|laboratory biomarker analysis|Correlative studies
488374|NCT00489359|Drug|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
488375|NCT00489359|Drug|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
488376|NCT00489359|Drug|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m^2, administered IV, every 21 days x 6 cycles
488377|NCT00489359|Drug|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL*min, administered IV, every 21 days x 6 cycles
488378|NCT00489346|Drug|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
488379|NCT00489346|Drug|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
488380|NCT00489333|Drug|ProAlgaZyme|
488381|NCT00489320|Device|Cypher Stent|
488382|NCT00489307|Drug|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
488383|NCT00489307|Drug|Placebo|Placebo PO twice daily x 14 days
488384|NCT00489294|Drug|Syntropin|
488385|NCT00489281|Drug|Cyclophosphamide|Cyclophosphamide (Cy) 14.5 mg/kg/day intravenously (IV) on Days -6 and -5 and 50 mg/kg/day IV on Days +3 and +4.
488386|NCT00489281|Drug|Fludarabine|Fludarabine 30 mg/m^2/day IV on Days -6, -5, -4, -3, and -2.
488387|NCT00489281|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth (PO) three times a day from Day +5 to Day +35.
488388|NCT00489281|Drug|Sirolimus|The first dose of Sirolimus is 6 mg PO on Day +5. Further dosing is adjusted according to drug levels. Sirolimus is continued through Day +365.
488389|NCT00489281|Procedure|Allogeneic bone marrow transplant|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
488390|NCT00489281|Radiation|Total body irradiation - 200|200 centigray (cGy) in one fraction on Day -1.
488391|NCT00489281|Drug|Levetiracetam|Given at 500 mg PO twice daily from Day -6 to Day +365.
488392|NCT00489281|Biological|Anti-thymocyte globulin|Test dose of 0.5 mg/kg IV given on Day -9, then 2 mg/kg/day IV on Day -8 and -7.
488393|NCT00489281|Radiation|Total body irradiation - 400|400 centigray (cGy) in one fraction on Day -1.
488394|NCT00489268|Device|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit~******Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
488395|NCT00489255|Drug|Tigan®|Oral capsule, 300mg three times daily
488396|NCT00489255|Drug|Placebo|Oral capsule, three times daily
488397|NCT00489242|Procedure|Procedure / Percutaneous angioplasty|
488398|NCT00489229|Drug|Rosiglitazone|
488399|NCT00489229|Drug|Ramipril|
512448|NCT00301834|Drug|cyclosporine|
488400|NCT00489216|Biological|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg"
488401|NCT00489203|Drug|beclomethasone dipropionate|Given orally
488402|NCT00489203|Drug|placebo|Given orally
488403|NCT00489203|Drug|tacrolimus|Given after transplant
488404|NCT00489203|Drug|methotrexate|Given after transplant
488405|NCT00489203|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
488406|NCT00489190|Drug|Insulin Glulisine|
488407|NCT00489177|Device|A|QuickOpt intra-cardiac electrogram optimization
488408|NCT00489177|Device|B|Single optimization in initial month post-implant
488409|NCT00489164|Device|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
488410|NCT00489151|Drug|adefovir dipivoxil|
488411|NCT00489151|Drug|lamivudine|
488412|NCT00489138|Drug|Ertapenem|1g a day by drip of 30 min
488413|NCT00489125|Other|physiologic testing|physical testing of range of motion, grip strength etc.
488414|NCT00489112|Drug|Alfuzocine XL 10 mg once a day|
488415|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot A|
488416|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot B|
488417|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot C|
488418|NCT00489099|Biological|V232 Current Process Hepatitis B Vaccine|
488419|NCT00489086|Drug|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
488420|NCT00489073|Drug|duloxetine|
488421|NCT00489073|Drug|placebo|
488422|NCT00489060|Procedure|Cryoablation and External Beam Radiation|
488423|NCT00489034|Behavioral|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
488424|NCT00489034|Behavioral|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
488425|NCT00489034|Behavioral|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
488426|NCT00489021|Procedure|sub-acute hospitalization|
488427|NCT00489008|Procedure|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 & 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments~Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
488428|NCT00488995|Drug|CP-675,206|
488429|NCT00488982|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days
488430|NCT00488982|Drug|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
488431|NCT00488969|Drug|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
488432|NCT00488969|Drug|Placebo|
488433|NCT00488943|Device|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
488434|NCT00488930|Other|Observational|data collection ONLY
488435|NCT00488904|Dietary Supplement|supportan|2 sip feed pr. day
488436|NCT00488904|Dietary Supplement|supportan placebo|2 sip feed pr. day
488437|NCT00488891|Drug|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
488438|NCT00488891|Drug|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
488439|NCT00488878|Behavioral|Data Collection|Data collection from ovarian cancer patients seen at M.D. Anderson since January, 1950.
488440|NCT00488865|Device|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
488441|NCT00488839|Drug|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
488442|NCT00488839|Drug|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
488443|NCT00488839|Drug|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
488444|NCT00488839|Drug|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
488445|NCT00488839|Drug|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
488446|NCT00488839|Drug|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
488447|NCT00488839|Drug|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
488448|NCT00488839|Drug|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
488449|NCT00488839|Drug|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
488450|NCT00488826|Biological|7-valent pneumococcal conjugate vaccine|
488809|NCT00485979|Drug|trastuzumab|intravenous administration
488451|NCT00488826|Biological|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
488452|NCT00488813|Drug|Third generation cephalosporins|
488453|NCT00488800|Biological|pneumococcal conjugate vaccine|
488454|NCT00488787|Drug|intranasal ketamine|low dose
488455|NCT00488787|Drug|intranasal ketamine|medium dose
488456|NCT00488787|Drug|intranasal ketamine|high dose
488457|NCT00488787|Drug|placebo|placebo
488458|NCT00488774|Other|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
488459|NCT00488774|Drug|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
488460|NCT00488774|Drug|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
488461|NCT00488774|Drug|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
488462|NCT00488761|Drug|Tigecycline|
488463|NCT00488748|Device|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
488464|NCT00488748|Device|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
488465|NCT00488735|Behavioral|Cognitive-behavioral rehabilitation|
488466|NCT00488735|Behavioral|Traditional primary care|
488467|NCT00488722|Drug|Zoladex|
488468|NCT00488709|Drug|Topotecan|
488469|NCT00488709|Drug|Fludarabine|
488470|NCT00488709|Drug|Cytarabine|
488471|NCT00488696|Device|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
488472|NCT00488683|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
488473|NCT00488683|Biological|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
488474|NCT00488683|Biological|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
488475|NCT00488683|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
488476|NCT00488683|Biological|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
488477|NCT00488670|Drug|Escitalopram|See Detailed Description.
488478|NCT00488657|Device|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
488479|NCT00488644|Drug|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
488480|NCT00488644|Drug|Liothyronine|15 mcg PO Daily for 8 Weeks
488481|NCT00488631|Biological|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
488482|NCT00488631|Biological|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
488483|NCT00488631|Biological|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
488484|NCT00488631|Biological|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
488485|NCT00488618|Drug|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
488486|NCT00488618|Drug|Placebo|Dose-matched placebo oral administration, once per day.
488487|NCT00488605|Drug|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
488488|NCT00488605|Drug|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
488489|NCT00488592|Biological|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
488687|NCT00486850|Other|Extubation to Nasal IPPV|Comparison of extubation to NIPPV versus NCPAP
488490|NCT00488592|Biological|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
488491|NCT00488592|Drug|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
488492|NCT00488592|Biological|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
488493|NCT00488579|Drug|Two policies of iron prophylaxis|60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb>9g/dl only folic acid, Hb<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
488494|NCT00488566|Drug|GSK drug|GSK drug
488495|NCT00488566|Other|Placebo|Placebo
488496|NCT00488566|Other|Lamictal|Positive control
488497|NCT00488553|Behavioral|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
488498|NCT00488540|Drug|Paracetamol|Suppository
488499|NCT00488540|Drug|Placebos|Suppository
488500|NCT00488527|Drug|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (<6.0 mmol/L), and the active treatment is to be continued for three more months.
488501|NCT00488514|Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
488502|NCT00488488|Drug|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
488503|NCT00488475|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
488504|NCT00488462|Device|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
488505|NCT00488449|Drug|GSK256073A tablets|
488506|NCT00488436|Drug|Antithymocyte globulin|
488507|NCT00488436|Drug|Cyclosporine|
488508|NCT00488423|Procedure|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test & hyperglycemic clamp to assess insulin secretion & sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp & mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting & specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass & gastric banding.
488509|NCT00488410|Device|Doppler echocardiography|
488510|NCT00488397|Other|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
488511|NCT00488384|Drug|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
488512|NCT00488371|Biological|Pneumococcal Conjugated Vaccine (Prevnar®)|
488513|NCT00488345|Drug|Tygacil|
488514|NCT00488332|Procedure|Optical Coherence Tomography|Before radiation treatment and once a week thereafter.
488515|NCT00488332|Procedure|Fluorescence Spectroscopy|Before radiation treatment and once a week thereafter.
488516|NCT00488332|Behavioral|Pain Scale Questionnaire|Administered before the examination, OCT, and FS and immediately afterward.
488517|NCT00488319|Drug|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
488518|NCT00488306|Drug|tigecycline|
488519|NCT00488293|Procedure|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
488520|NCT00488280|Behavioral|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
488521|NCT00488267|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
488522|NCT00488267|Drug|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
488523|NCT00488267|Drug|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
488524|NCT00488241|Device|Zarzenda|Topically applied daily for 2 weeks
488525|NCT00488228|Behavioral|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
488810|NCT00485966|Drug|CX-3543|360 mg/m2 daily x 5 q 21 days
488526|NCT00488215|Drug|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
488527|NCT00488215|Other|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
488528|NCT00488189|Drug|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
488529|NCT00488176|Drug|montelukast|montelukast sodium
488530|NCT00488176|Drug|cetirizine|cetirizine
488531|NCT00488176|Drug|montelukast and cetirizine|montelukast and cetirizine
488532|NCT00488176|Drug|placebo|placebo
488533|NCT00488163|Drug|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
488534|NCT00488137|Drug|Prucalopride|2 mg o.d.
488535|NCT00488137|Other|Placebo|o.d.
488536|NCT00488137|Drug|Prucalopride|4 mg o.d.
488537|NCT00488124|Drug|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
488538|NCT00488111|Other|Ringer's Lactate|Ringer's Lactate was used 15min before operation
488539|NCT00488111|Other|6% Starch|6% Starch was used 15min before operation
488540|NCT00488098|Drug|GSK372475|
488541|NCT00488072|Drug|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
488542|NCT00488072|Drug|Placebo|One placebo tablet by mouth daily.
488543|NCT00488059|Drug|enfuvirtide [Fuzeon]|90 mg SC twice daily
488544|NCT00488059|Drug|Optimized background ARV|As prescribed
488545|NCT00488059|Drug|Integrase inhibitor|As prescribed
488546|NCT00488059|Drug|enfuvirtide [Fuzeon]|180 mg SC once daily
488547|NCT00488046|Biological|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
488548|NCT00488033|Procedure|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
488549|NCT00488020|Procedure|stem cells transplant|
488550|NCT00488007|Device|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
488551|NCT00487994|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
488552|NCT00487994|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
488553|NCT00487994|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
488554|NCT00487981|Device|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
488555|NCT00487968|Drug|eltrombopag|
488556|NCT00487955|Procedure|Resting Energy Expenditure examination|
488557|NCT00487942|Drug|armodafinil|50 mg/day armodafinil
488558|NCT00487942|Drug|armodafinil|100 mg/day armodafinil
488559|NCT00487942|Drug|armodafinil|200 mg/day armodafinil
488560|NCT00487942|Drug|placebo|placebo
488561|NCT00487929|Device|nasal CPAP|Nocturnal
488562|NCT00487929|Device|Sham CPAP|Nocturnal
488563|NCT00487916|Drug|AMA1-C1/ISA 720|
488564|NCT00487903|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
488565|NCT00487877|Device|SenseWear Pro3 Armband|
488566|NCT00487877|Device|i-button DS2191 H|
488567|NCT00487851|Procedure|surgery|hepaticojejunostomy and gastroenterostomy
488568|NCT00487851|Procedure|endoscopic strategy|Stent insertion
488569|NCT00487825|Drug|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
488570|NCT00487825|Drug|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
488571|NCT00487825|Drug|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
488572|NCT00487812|Procedure|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
488573|NCT00487799|Drug|Ularitide|
488574|NCT00487786|Drug|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
488575|NCT00487786|Drug|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 & 7 only, together with appropriate dose of OGX-427 until withdrawn from study
488576|NCT00487773|Drug|budesonide|budesonide
488577|NCT00487773|Drug|D3 vitamin|D3 vitamin
488578|NCT00487773|Drug|montelukast sodium|montelukast sodium
488579|NCT00487773|Drug|salbutamol|salbutamol
488580|NCT00487747|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
488581|NCT00487734|Radiation|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
488582|NCT00487734|Drug|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
488583|NCT00487721|Drug|Silibin-Phytosome|Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
488584|NCT00487708|Drug|canakinumab|
488688|NCT00486837|Drug|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
513166|NCT00295984|Drug|nicotine|
488585|NCT00487695|Device|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
488586|NCT00487695|Device|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
488587|NCT00487682|Drug|ASP2151|oral
488588|NCT00487682|Drug|Valacyclovir hydrochloride|oral
488589|NCT00487669|Drug|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
488590|NCT00487656|Drug|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
488591|NCT00487656|Drug|placebo|6 mg/ml ampule solution for injection at .01mg/kg
488592|NCT00487643|Procedure|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
488593|NCT00487630|Drug|recombinant alpha-galactosidase A|
488594|NCT00487617|Procedure|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
488595|NCT00487591|Drug|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
488596|NCT00487591|Drug|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
488597|NCT00487578|Drug|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
488598|NCT00487565|Device|Total knee arthroplasty|Total knee arthroplasty using a posterior stabilized implant
488599|NCT00487552|Device|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
488600|NCT00487539|Biological|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
488601|NCT00487539|Biological|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -> 50 mg arm group and at Week 2 for Golimumab 200 mg -> 100 mg arm group.
488602|NCT00487539|Biological|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -> 100 mg arm group and at Week 2 for Golimumab 400 mg -> 200 mg arm group.
488603|NCT00487539|Biological|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -> 200 mg arm group.
488604|NCT00487539|Biological|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -> 50 mg arm group.
488605|NCT00487526|Procedure|duodenal jejunal bypass|
488606|NCT00487513|Procedure|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
488607|NCT00487500|Device|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
488608|NCT00487474|Device|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
488609|NCT00487461|Drug|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
488610|NCT00487461|Drug|Placebo|Placebo tablet
488611|NCT00487461|Drug|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
488612|NCT00487448|Drug|Fludarabine|
488613|NCT00487448|Drug|Cytarabine|
488614|NCT00487448|Drug|G-CSF|
488615|NCT00487448|Drug|Idarubicin|
488616|NCT00487448|Procedure|Peripheral blood stem cell transplantation|
488617|NCT00487448|Procedure|Bone marrow transplantation|
488618|NCT00487435|Drug|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
488619|NCT00487422|Drug|prucalopride|2 mg o.d.
488620|NCT00487422|Drug|Prucalopride|4 mg o.d.
488621|NCT00487422|Other|Placebo|o.d.
488622|NCT00487409|Procedure|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
488623|NCT00487409|Procedure|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
488624|NCT00487396|Device|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
488625|NCT00487370|Procedure|Implantation of gold beads around a knee through needles|
488626|NCT00487370|Procedure|Sham implantation: Insertion of needles around a knee|
488627|NCT00487357|Behavioral|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
488628|NCT00487344|Procedure|Non-Personalized Meal Planning|
488629|NCT00487344|Procedure|Personalized Meal Planning and Dietetic Consultation|
488630|NCT00487331|Other|Acupuncture|Acupuncture sessions 1-3 times per week.
488631|NCT00487331|Behavioral|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
488632|NCT00487318|Drug|standard of care|peginterferon/RBV
488633|NCT00487318|Drug|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
488689|NCT00486824|Drug|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
513479|NCT00293462|Biological|sargramostim|
488634|NCT00487305|Biological|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
488635|NCT00487292|Behavioral|naps and pulses of bright light|
488636|NCT00487279|Device|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
488637|NCT00487279|Other|Control|No Intervention
488638|NCT00487266|Other|Acupuncture|Acupuncture of low back and legs.
488639|NCT00487253|Drug|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
488640|NCT00487253|Drug|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
488641|NCT00487240|Drug|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
488642|NCT00487240|Drug|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
488643|NCT00487227|Drug|caffeine|
488644|NCT00487227|Drug|Placebo|
488645|NCT00487201|Procedure|endoscopic balloon dilatation|
488646|NCT00487201|Procedure|plastic stent placement|
488647|NCT00487188|Drug|Enfuvirtide|90 mg subcutaneous injection twice a day
488648|NCT00487188|Drug|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
488649|NCT00487175|Drug|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
488650|NCT00487162|Procedure|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
488651|NCT00487162|Drug|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
488652|NCT00487136|Drug|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
488653|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
488654|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
488655|NCT00487123|Drug|Valsartan+/- Hydrochlorothiazide|
488656|NCT00487110|Drug|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
488657|NCT00487110|Drug|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
488658|NCT00487097|Dietary Supplement|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
488659|NCT00487084|Drug|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
488660|NCT00487084|Drug|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
488661|NCT00487084|Drug|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
488662|NCT00487071|Device|Anal fistula plug|
488663|NCT00487058|Drug|Gimatecan|
488664|NCT00487045|Device|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
488665|NCT00487032|Drug|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
488666|NCT00487032|Drug|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
488667|NCT00487032|Drug|Prazosin hydrochloride|Prazosin 1mg one dose only
488668|NCT00487032|Drug|Placebo to Prazosin|Placebo 1 tablet one dose only
488669|NCT00487006|Other|Serum Lab testing|Serum Lab testing
488670|NCT00486993|Behavioral|Dietary and nutritional modification|
488671|NCT00486993|Behavioral|Stop smoking|
488672|NCT00486993|Behavioral|Regular physical activities|
488673|NCT00486993|Behavioral|Weight reduction to normal ranges|
488674|NCT00486993|Behavioral|Regular intake of polyphenols, esp. from Ilex paraguayensis|
488675|NCT00486980|Drug|Peramivir 150mg|
488676|NCT00486980|Drug|Peramivir 300mg|
488677|NCT00486954|Drug|Lapatinib|6 pills at 250 mg each once daily
488678|NCT00486954|Drug|Paclitaxel|Infusion at 80 mg/m2 weekly
488679|NCT00486941|Behavioral|Exercise and diet - based on DPS and DPP|
488680|NCT00486915|Procedure|Left Atrial Appendage Ligation|
488681|NCT00486902|Drug|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
488682|NCT00486902|Drug|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
488683|NCT00486889|Biological|alglucosidase alfa|Intravenous (IV) infusion: 20mg/kg every 2 weeks
488684|NCT00486876|Drug|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
488685|NCT00486863|Drug|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
488686|NCT00486863|Other|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
488807|NCT00485979|Drug|larotaxel (XRP9881)|intravenous administration
488690|NCT00486824|Drug|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
488691|NCT00486811|Drug|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
488692|NCT00486811|Drug|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
488693|NCT00486811|Drug|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
488694|NCT00486798|Drug|Quetiapine|
488695|NCT00486798|Procedure|Rating Scales|
488696|NCT00486798|Procedure|Self Assessment Form|
488697|NCT00486798|Procedure|Blood and urine samples|
488698|NCT00486798|Procedure|Sleeping pattern|
488699|NCT00486785|Drug|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
488700|NCT00486772|Drug|Sevelamer (Renagel), calcium acetate (Phos-ex)|
488701|NCT00486759|Drug|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
488702|NCT00486759|Drug|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
488703|NCT00486759|Drug|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
488704|NCT00486759|Drug|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
488705|NCT00486746|Behavioral|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
488706|NCT00486746|Behavioral|General information on healthy lifestyle habits|A single session
488707|NCT00486733|Device|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
488708|NCT00486720|Drug|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
488709|NCT00486720|Drug|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
488710|NCT00486707|Behavioral|Questionnaire|A questionnaire will be completed.
488711|NCT00486694|Drug|Sulfadoxine-pyrimethamine + artesunate|
488712|NCT00486694|Drug|Chloroquine|
488713|NCT00486681|Device|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
488714|NCT00486668|Drug|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
488715|NCT00486668|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
488716|NCT00486668|Drug|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
488717|NCT00486668|Drug|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
488718|NCT00486668|Drug|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
488719|NCT00486655|Procedure|NOTES-Assisted Cholecystectomy|
488720|NCT00486642|Drug|Bicalutamide|Given PO
488721|NCT00486642|Other|Laboratory Biomarker Analysis|Correlative studies
488722|NCT00486642|Drug|Pazopanib Hydrochloride|Given PO
488723|NCT00486642|Other|Pharmacological Study|Correlative studies
488724|NCT00486629|Behavioral|Exercise and dietary education|Exercise and dietary education. Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
488725|NCT00486616|Device|electrical impedance tomography|
488726|NCT00486616|Procedure|double-lumen tube placement|
488727|NCT00486603|Drug|hydroxychloroquine|see arm description, the first 10 week cycle is call initiation cycle, Post the 10 week cycle of just HCQ, 4 week cycles are called Maintenance Cycles
488728|NCT00486603|Drug|temozolomide|TMZ daily 75mg/m2 for 6wks with RT+HCQ (TMZ is given only during Initiation cycle)
488729|NCT00486603|Other|pharmacological study|Seven samples in total will be collected baseline, initiation cycle -week3-4, week9-10, Maintenance Cycle 1 Week 4 (C1W4), Cycle2 Week4, Cycle3 Week4, Cycle6 Week4
488730|NCT00486603|Radiation|Radiation|Radiation during the first six weeks of treatment Monday-Friday
488731|NCT00486590|Procedure|Prolact-Plus Human Milk Fortifier|
488732|NCT00486577|Procedure|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
488733|NCT00486577|Procedure|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
488734|NCT00486564|Drug|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
488735|NCT00486551|Behavioral|Anger control training|
488736|NCT00486538|Drug|ABT-869|One oral dose daily.
488737|NCT00486525|Procedure|Yoga Therapy|Patients will undergo yoga therapy
488808|NCT00485979|Drug|docetaxel|intravenous administration
488738|NCT00486512|Drug|aspirin, 1,25-dihydroxycholecalciferol, calcium|Oral Calcitriol (1α 25-dihydroxy cholecalciferol) capsules, 0.5 µg (QD) Oral acetylsalicylic acid 37.5 mg and calcium carbonate 625 mg combination tablets (bid)
488739|NCT00486512|Drug|placebo|placebo to oral Calcitriol (1α 25-dihydroxy cholecalciferol) capsules, 0.5 µg (QD) placebo to oral acetylsalicylic acid 37.5 mg and calcium carbonate 625 mg combination tablets (bid)
488740|NCT00486499|Procedure|I-125 versus Pd-103 radioactive seed insertion|
488741|NCT00486486|Drug|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
488742|NCT00486486|Drug|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
488743|NCT00486473|Drug|Multihance|0.5 Molar at a single dose injection
488744|NCT00486473|Drug|Magnevist|0.5M at a single dose injection
488745|NCT00486460|Drug|Gemcitabine|
488746|NCT00486460|Drug|Curcumin|
488747|NCT00486460|Drug|Celebrex|
488748|NCT00486447|Device|64 Channel VCT|cardiac CT angiography exam
488749|NCT00486434|Drug|SMC021 Oral Calcitonin|0.8mg SMC021 (Oral Calcitoinin) twice daily
488750|NCT00486434|Drug|SMC021 Placebo|Placebo orally, twice daily
488751|NCT00486421|Biological|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
488752|NCT00486421|Drug|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
488753|NCT00486408|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5x10^10 Ad vg
488754|NCT00486395|Device|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
488755|NCT00486395|Device|Mechanical ventilation|Volume guarantee strategy
488756|NCT00486382|Biological|Leish-111f + MPL-SE Adjuvant|
488757|NCT00486369|Drug|Oral salmon calcitonin|
488758|NCT00486356|Drug|capecitabine|
488759|NCT00486356|Drug|carboplatin|
488760|NCT00486356|Drug|epirubicin hydrochloride|
488761|NCT00486356|Genetic|microarray analysis|
488762|NCT00486356|Genetic|polymorphism analysis|
488763|NCT00486356|Other|pharmacological study|
488764|NCT00486343|Drug|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
488765|NCT00486343|Drug|Placebo|Placebo tablets 2x600mg BID for 24 weeks
488766|NCT00486330|Drug|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
488767|NCT00486317|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
488768|NCT00486304|Other|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
488769|NCT00486304|Other|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
488770|NCT00486291|Drug|VI-0521|phentermine 15mg/topiramate 100mg
488771|NCT00486291|Drug|Placebo|matched placebo
488772|NCT00486278|Drug|eptacog alfa (activated)|90 mcg/kg, injected i.v.
488773|NCT00486278|Drug|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
488774|NCT00486278|Drug|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
488775|NCT00486278|Drug|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
488776|NCT00486278|Drug|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
488777|NCT00486278|Drug|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
488778|NCT00486265|Drug|AZD4877|intravenous infusion administered on days 1, 2 and 3
488779|NCT00486252|Other|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
488780|NCT00486239|Behavioral|neuropsychological evaluation|
488781|NCT00486226|Device|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
488782|NCT00486213|Dietary Supplement|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
488783|NCT00486213|Other|Placebo|
488784|NCT00486200|Drug|ASP2151|Oral administration.
488785|NCT00486200|Drug|valacyclovir|Oral administration of active comparator.
488786|NCT00486200|Drug|Placebo|Oral administration of placebo.
488787|NCT00486187|Drug|rosiglitazone|
488788|NCT00486187|Drug|metformin or sulfonylurea|
488789|NCT00486174|Drug|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
488790|NCT00486148|Other|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
488791|NCT00486135|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
488792|NCT00486135|Drug|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
488793|NCT00486122|Drug|Atomoxetine Hydrochloride|
488794|NCT00486122|Drug|Placebo|
488795|NCT00486109|Device|I-Port(TM) Injection Port|
488796|NCT00486083|Drug|Atomoxetine Hydrochloride|
488797|NCT00486083|Drug|Methylphenidate Hydrochloride|
488798|NCT00486044|Drug|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
488799|NCT00486044|Drug|Placebo|Matching tablet each night for 9 months
488800|NCT00486031|Drug|Balsalazide Disodium|
488801|NCT00486018|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
488802|NCT00486018|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
488803|NCT00486018|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
488804|NCT00486005|Drug|Olanzapine Hydrochloride|
488805|NCT00486005|Drug|Nizatidine|
488806|NCT00486005|Drug|Placebo|
488811|NCT00485953|Drug|risedronate|risedronate 35 mg per week
488812|NCT00485940|Drug|Prucalopride|2 mg o.d.
488813|NCT00485940|Other|Placebo|Placebo o.d.
488814|NCT00485940|Drug|Prucalopride|4 mg o.d.
488815|NCT00485927|Behavioral|stress|
488816|NCT00485914|Behavioral|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
488817|NCT00485914|Behavioral|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
488818|NCT00485901|Drug|Olanzapine Hydrochloride|
488819|NCT00485901|Drug|Haloperidol|
488820|NCT00485888|Drug|Cipralex|10-20mg; one per day
488821|NCT00485888|Drug|Placebo|Matched to Cipralex
488822|NCT00485875|Drug|Atomoxetine Hydrochloride|
488823|NCT00485862|Drug|Atomoxetine Hydrochloride|
488824|NCT00485862|Drug|Sertraline|
488825|NCT00485862|Drug|Placebo|
488826|NCT00485849|Drug|Atomoxetine Hydrochloride|
488827|NCT00485836|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
488828|NCT00485836|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
488829|NCT00485836|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
488830|NCT00485823|Drug|Olanzapine Hydrochloride|
488831|NCT00485823|Procedure|Weight Management Program|
488832|NCT00485810|Drug|Olanzapine Hydrochloride|
488833|NCT00485797|Drug|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
488834|NCT00485784|Other|Blood test|Blood test
488835|NCT00485771|Drug|Olanzapine|
488836|NCT00485771|Drug|Fluoxetine|
488837|NCT00485771|Drug|Lamotrigine|
488838|NCT00485758|Drug|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
488839|NCT00485758|Drug|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
488840|NCT00485732|Biological|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
488841|NCT00485732|Biological|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
488842|NCT00485719|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
488843|NCT00485706|Procedure|high calcium dialysate|
488844|NCT00485693|Drug|Bupivacaine HCl|150 mg Bupivacaine HCl
488845|NCT00485693|Drug|SKY0402|600 mg SKY0402 (study drug)
488846|NCT00485680|Drug|Olanzapine Hydrochloride|
488847|NCT00485680|Drug|Lithium Carbonate|
488848|NCT00485667|Drug|SKY0402|Subects received either 300mg or 450mg
488849|NCT00485667|Drug|Moxifloxacin 400mg|
488850|NCT00485667|Drug|Placebo injection|
488851|NCT00485667|Drug|Placebo tablet|
488852|NCT00485641|Device|SaeboFlex Dynamic Hand Orthosis|
488853|NCT00485641|Procedure|Saebo F.T.M. Arm Training Program|
488854|NCT00485628|Drug|Atomoxetine Hydrochloride|
488855|NCT00485615|Drug|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
488856|NCT00485602|Procedure|"orthodontic treatment with Rafenalign appliance"|
488857|NCT00485589|Drug|methotrexate|Oral repeating dose
488858|NCT00485589|Drug|ocrelizumab|Intravenous repeating dose
488859|NCT00485589|Drug|placebo|Intravenous repeating dose
488860|NCT00485576|Drug|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
488861|NCT00485563|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
488862|NCT00485563|Biological|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
488863|NCT00485563|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
488864|NCT00485563|Drug|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
488865|NCT00485563|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
488866|NCT00485550|Drug|Atomoxetine Hydrochloride|
488867|NCT00485550|Drug|Methylphenidate Hydrochloride|
488868|NCT00485550|Drug|Placebo|
488869|NCT00485537|Procedure|oocyte retrieval and ICSI procedure|
488870|NCT00485511|Drug|Hydroxyurea|
488871|NCT00485498|Drug|Olanzapine Hydrochloride|
488872|NCT00485498|Drug|Risperidone|
513537|NCT00293072|Drug|Rituximab|
488873|NCT00485485|Drug|Imatinib Mesylate|400 mg by mouth daily
488874|NCT00485485|Drug|Docetaxel|60 mg/m^2 by vein (IV) over 1 hour every 3 weeks
488875|NCT00485472|Drug|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
488876|NCT00485472|Other|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
488877|NCT00485459|Drug|Atomoxetine Hydrochloride|
488878|NCT00485459|Drug|Placebo|
488879|NCT00485446|Procedure|blood analysis|
488880|NCT00485433|Drug|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
488881|NCT00485433|Drug|SKY0402|SKY0402 given during hernia repair
488882|NCT00485420|Other|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
488883|NCT00485407|Drug|Atomoxetine Hydrochloride|
488884|NCT00485394|Drug|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
488885|NCT00485394|Drug|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
488886|NCT00485394|Drug|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
488887|NCT00485368|Drug|Coversyl (perindopril)|
488888|NCT00485355|Procedure|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
488889|NCT00485355|Procedure|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
488890|NCT00485342|Drug|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg).~Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
488891|NCT00485342|Drug|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.~The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
488892|NCT00485329|Other|Papain|15,000 USP U/ml
488893|NCT00485329|Other|Papain|30,000 USP U/ml
488894|NCT00485329|Other|Papain|60,000 USP U/ml
488895|NCT00485316|Procedure|Laparoscopic assisted resection of colorectal carcinoma|
488896|NCT00485303|Drug|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
488897|NCT00485303|Drug|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
488898|NCT00485290|Behavioral|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
488899|NCT00485277|Biological|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
488900|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
488901|NCT00485264|Drug|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
488902|NCT00485264|Drug|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
488903|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet.
488904|NCT00485251|Procedure|hand-assisted laparoscopic right hemicolectomy|using the lap disc that allows the insertion of single and into the abdomen for operation
488905|NCT00485251|Procedure|total laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
488906|NCT00485251|Procedure|hand-assisted right hemicolectomy|hand-assisted right hemicolectomy
488907|NCT00485251|Procedure|laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
488908|NCT00485238|Procedure|Argon laser Iridoplasty|
488909|NCT00485238|Drug|Intravenous acetazolamide|
488910|NCT00485225|Drug|EN3270|Transdermal Therapeutic System
488911|NCT00485212|Device|compression bandage|
488912|NCT00485199|Procedure|Pneumatic Retinopexy|
488913|NCT00485199|Procedure|Vitrectomy with Gas|
488914|NCT00485173|Device|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
488915|NCT00485160|Drug|Continuous indomethacin|
488916|NCT00485160|Drug|ibuprofen|
488917|NCT00485147|Procedure|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
488918|NCT00485134|Biological|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
488919|NCT00485134|Biological|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
488920|NCT00485134|Biological|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
488921|NCT00485134|Other|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
488922|NCT00485121|Drug|Ezetimibe|
488923|NCT00485108|Drug|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
488924|NCT00485108|Drug|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
489112|NCT00483652|Drug|Placebo|placebo (sugar pill)
488925|NCT00485108|Drug|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
488926|NCT00485095|Behavioral|Intake of plant sterols|
488927|NCT00485069|Drug|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
488928|NCT00485069|Drug|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
488929|NCT00485056|Drug|Pioglitazone|45mgs daily
488930|NCT00485043|Behavioral|Modified T'ai Chi: T'ai Chi for Arthritis|
488931|NCT00485030|Device|Cypher|sirolimus-eluting stent
488932|NCT00485030|Device|Xience-V|everolimus-eluting stent
488933|NCT00485017|Drug|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
488934|NCT00485017|Drug|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
488935|NCT00485004|Device|Cutting balloon|Cutting balloon
488936|NCT00485004|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
488937|NCT00484991|Drug|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
488938|NCT00484978|Procedure|Stereotactic Radiosurgery|
488939|NCT00484965|Procedure|Coronary stenting|
488940|NCT00484939|Drug|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
488941|NCT00484939|Drug|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
488942|NCT00484926|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
488943|NCT00484926|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
488944|NCT00484913|Procedure|abdominal hot compress|
488945|NCT00484900|Drug|Co-Arinate FDC|
488946|NCT00484900|Drug|Coartem|
488947|NCT00484874|Drug|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
488948|NCT00484848|Device|Vortex port and Celsite port|
488949|NCT00484835|Procedure|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
488950|NCT00484822|Drug|Bemiparina Sodica|3.500 UI/día.
488951|NCT00484822|Drug|Heparina Cálcica|10.000 UI/día.
488952|NCT00484809|Drug|Enbrel (Etanercept)|
488953|NCT00484796|Procedure|MED-SEP|intraoperative neurophysiological monitoring
488954|NCT00484796|Procedure|TRI-SEP|intraoperative neurophysiologic monitoring
488955|NCT00484796|Procedure|neuropsychological tests|neurological short- and longterm outcome
488956|NCT00484783|Procedure|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
488957|NCT00484783|Procedure|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
488958|NCT00484770|Device|Brain Natriuretic Peptide Levels -- Diagnostic testing|
488959|NCT00484770|Other|clinical assessment|
488960|NCT00484757|Drug|Orexine A|
488961|NCT00484744|Drug|Acetaminophen|
488962|NCT00484744|Drug|Avicel (placebo)|
488963|NCT00484744|Drug|Ibuprofen|
488964|NCT00484731|Procedure|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
488965|NCT00484731|Procedure|Infiltration with Bupivacaine|
488966|NCT00484718|Drug|celecoxib|oral, 100 mg bid
488967|NCT00484718|Drug|Oxycodone|oral, 20 mg bid
488968|NCT00484718|Drug|placebo|oral bid
488969|NCT00484705|Procedure|Electroacupuncture|
488970|NCT00484705|Procedure|Physical exercise|
488971|NCT00484705|Procedure|Untreated control|
488972|NCT00484692|Drug|sustained-release bupropion (Zyban(R))|
488973|NCT00484692|Behavioral|Psychodynamic Model Training (R) = PDM(R)|
488974|NCT00484679|Drug|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
488975|NCT00484653|Procedure|cervical smear|biological analysis
488976|NCT00484640|Drug|Coumadin|
488977|NCT00484627|Procedure|Use of creatine monohydrate (a dietary supplement)|
488978|NCT00484627|Behavioral|Progressive resistance exercise training|
488979|NCT00484614|Procedure|Positron Emission Mammography|Molecular Imaging Device
488980|NCT00484614|Procedure|Magnetic Resonance Imaging|Imaging Device
488981|NCT00484601|Drug|Ifosfamide|
488982|NCT00484601|Drug|Doxorubicin|
488983|NCT00484575|Drug|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
488984|NCT00484575|Drug|propofol|propofol given intravenously for sedation in control group
488985|NCT00484562|Device|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
488986|NCT00484562|Device|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
488987|NCT00484562|Device|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
488988|NCT00484562|Device|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
488989|NCT00484549|Procedure|Blood sample|Ischemic stroke hospitalized
488990|NCT00484536|Drug|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
488991|NCT00484536|Drug|placebo|capsules, once daily
488992|NCT00484536|Drug|CDP323|250 mg Capsules, 500 mg, once daily
488993|NCT00484523|Procedure|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
488994|NCT00484510|Drug|Ascorbic acid (Vitamin C)|Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
488995|NCT00484510|Drug|placebo|Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
488996|NCT00484497|Drug|cyclamax|
488997|NCT00484484|Drug|Ketamine|Ketamine
488998|NCT00484471|Drug|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
488999|NCT00484471|Drug|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
489000|NCT00484471|Drug|placebo|placebo to aripiprazole, 22 weeks
489001|NCT00484458|Device|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
489002|NCT00484458|Device|Total Disc Replacement|Total disc
489003|NCT00484432|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs
489004|NCT00484432|Drug|doxorubicin|Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
489005|NCT00484419|Drug|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
489006|NCT00484419|Drug|rosiglitazone maleate|rosiglitazone tablets 4mg
489007|NCT00484419|Drug|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
489008|NCT00484393|Drug|tetracaine 4% gel|tetracaine applied prior to 1 injection
489009|NCT00484393|Drug|Placebo|placebo applied prior to 1 injection
489010|NCT00484380|Procedure|Coronary scanner|multislice spiral computed tomography coronary angiography
489011|NCT00484367|Behavioral|Adolescent group therapy|Adolescent group therapy
489012|NCT00484367|Behavioral|Transitional family therapy|Transitional family therapy
489013|NCT00484354|Drug|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
489014|NCT00484354|Other|Normal saline|IV Normal saline with volume given determined by patient weight
489015|NCT00484354|Other|Bicarbonate|IV bicarbonate, dosed by weight
489016|NCT00484354|Other|Placebo|Normal saline, with volume given based on patient weight
489017|NCT00484341|Drug|low-dose NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
489018|NCT00484341|Drug|high-dose NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minutes intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
489019|NCT00484341|Drug|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
489020|NCT00484328|Drug|Ribavirin|different dosing regimes of Ribavirin
489021|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
489022|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
489023|NCT00484302|Behavioral|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
489024|NCT00484302|Behavioral|Non-manualized standard treatment|Treatment by case-manager
489025|NCT00484289|Drug|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants > 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
489026|NCT00484276|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
489027|NCT00484263|Drug|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
489028|NCT00484250|Drug|metronidazole,doxycycline|
489029|NCT00484237|Drug|etanercept|
489030|NCT00484211|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
489031|NCT00484198|Drug|pioglitazone|Tablets
489032|NCT00484198|Drug|placebo|Tablets
489033|NCT00484198|Drug|rivoglitazone HCl|Tablets
489034|NCT00484198|Drug|rivoglitazone HCl|Tablets
489035|NCT00484185|Drug|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
489036|NCT00484172|Procedure|blood draws|
489037|NCT00484159|Procedure|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
489038|NCT00484159|Drug|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
489039|NCT00484159|Drug|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
489040|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
489041|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
489042|NCT00484159|Procedure|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
489043|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
489044|NCT00484133|Drug|Dopamine|
489045|NCT00484133|Drug|dobutamine|
489046|NCT00484133|Drug|enoximone|
489047|NCT00484133|Drug|nitroglycerine|
489048|NCT00484133|Drug|noradrenaline|
489049|NCT00484120|Drug|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
489050|NCT00484120|Drug|Placebo cream|Placebo cream
489051|NCT00484107|Drug|Conjugated Estrogen Cream (Premarin®)|
489052|NCT00484094|Drug|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
489053|NCT00484081|Procedure|Microdissection Testicular Sperm Extraction|
489054|NCT00484081|Procedure|ICSI|
489055|NCT00484068|Drug|enalapril|
489056|NCT00484068|Procedure|chicken diet|
489057|NCT00484055|Drug|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
489058|NCT00484055|Procedure|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
489059|NCT00484029|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
489060|NCT00484029|Other|Air|Air (Medical Grade)
489061|NCT00484003|Drug|Pimecrolimus cream 1%|
489062|NCT00483990|Drug|PSD502|
489063|NCT00483977|Drug|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
489064|NCT00483977|Drug|Placebo|Placebo: oral for 2 weeks.
489065|NCT00483977|Drug|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
489066|NCT00483964|Drug|Bacopa monnieri|
489067|NCT00483964|Drug|Nardostachys jatamansi|
489068|NCT00483964|Drug|Olanzapine|
489069|NCT00483951|Device|Toshiba Aquilion ONE CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
489070|NCT00483951|Device|SWiemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
489071|NCT00483938|Drug|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
489072|NCT00483938|Drug|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
489073|NCT00483912|Device|Molecular adsorbent recirculating system|
489074|NCT00483899|Drug|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
489075|NCT00483899|Drug|Placebo|Placebo matching GW870086X will be administered by subjects
489076|NCT00483886|Drug|Prucalopride|2 mg o.d.
489077|NCT00483886|Other|Placebo|Placebo o.d.
489078|NCT00483886|Drug|Prucalopride|4 mg o.d.
489079|NCT00483860|Drug|Topotecan|once a day
489080|NCT00483834|Drug|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
489081|NCT00483834|Drug|Irinotecan|200mg/m^2, IV, day 1 each cycle
489082|NCT00483834|Drug|Capecitabine|1000mg/m^2 or 750mg/m^2 for patients over 65yrs old PO BID, day 1-14 each cycle
489083|NCT00483821|Other|medical chart review|medical chart review
489084|NCT00483808|Device|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
489085|NCT00483795|Drug|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
489086|NCT00483782|Biological|bevacizumab|
489087|NCT00483782|Drug|carboplatin|
489088|NCT00483782|Drug|paclitaxel|
489089|NCT00483782|Other|questionnaire administration|
489090|NCT00483782|Other|study of socioeconomic and demographic variables|
489091|NCT00483782|Procedure|quality-of-life assessment|
489092|NCT00483769|Drug|Glargine|
489093|NCT00483756|Drug|Cyclosporine|Standard of care
489094|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
489095|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
489096|NCT00483743|Drug|TPI 1020|250 mcg/caps 2 caps BID x 42 days
489097|NCT00483743|Drug|Budesonide|400mcg mcg capsules- 2 capsules BID
489098|NCT00483743|Drug|Placebo|2 caps BID x42 days
489099|NCT00483730|Drug|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
489100|NCT00483717|Drug|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
489101|NCT00483717|Drug|Placebo|Intranasal (IN) placebo
489102|NCT00483704|Drug|Telcagepant 140 mg|Telcagepant 140 mg tablets
489103|NCT00483704|Drug|Talcagepant 280 mg|Telcagepant 280 mg tablets
489104|NCT00483704|Drug|Placebo|Placebo tablets
489105|NCT00483691|Behavioral|Home Visit|Homw visits scheduled weekly for one year.
489106|NCT00483678|Other|counseling intervention|
489107|NCT00483678|Other|questionnaire administration|
489108|NCT00483678|Procedure|psychosocial assessment and care|
489109|NCT00483665|Procedure|Computed tomography angiography|Computed tomography angiography
489110|NCT00483665|Procedure|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
489111|NCT00483652|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
514496|NCT00285298|Drug|Pentoxifylline|
489113|NCT00483639|Other|Medical chart review|medical chart review
489114|NCT00483639|Other|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
489115|NCT00483639|Procedure|management of therapy complications|management of therapy complications
489116|NCT00483639|Procedure|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
489117|NCT00483639|Other|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
489118|NCT00483626|Drug|oral sildenafil|
489119|NCT00483613|Behavioral|Cognitive-behavioral therapy of Meichenbaum|
489120|NCT00483600|Drug|fondaparinux|injections of 2.5mg every other day for 4 weeks
489121|NCT00483587|Drug|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
489122|NCT00483574|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
489123|NCT00483574|Biological|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
489124|NCT00483574|Biological|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
489125|NCT00483574|Biological|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
489126|NCT00483561|Drug|Gefitinib plus etoposide|Gefitinib 250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial with Etoposide 50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
489127|NCT00483548|Drug|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
489128|NCT00483548|Drug|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
489129|NCT00483535|Drug|GW273225|GW273225 will be available as 25 milligram tablets.
489130|NCT00483535|Drug|COC|COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
489131|NCT00483522|Behavioral|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
489132|NCT00483509|Drug|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
489133|NCT00483509|Drug|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
489134|NCT00483496|Drug|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
489135|NCT00483496|Drug|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
489136|NCT00483496|Drug|bisoctrizole 10% alone (formula RV3131A-MV1237)|
489137|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
489138|NCT00483496|Drug|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
489139|NCT00483496|Drug|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
489140|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
489141|NCT00483496|Drug|V0096 CR vehicle (formula RV3131A-MV1197)|
489142|NCT00483483|Behavioral|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
489143|NCT00483483|Behavioral|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
489144|NCT00483470|Biological|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
489145|NCT00483470|Biological|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
489146|NCT00483457|Drug|enzyme inhibitor therapy|enzyme inhibitor therapy
489147|NCT00483457|Genetic|protein expression analysis|protein expression analysis
489148|NCT00483457|Other|immunohistochemistry staining method|immunohistochemistry staining method
489149|NCT00483457|Other|laboratory biomarker analysis|laboratory biomarker analysis
489150|NCT00483457|Procedure|biopsy|biopsy
489151|NCT00483444|Behavioral|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
489152|NCT00483431|Dietary Supplement|Placebo|
489153|NCT00483431|Dietary Supplement|MK7|
489154|NCT00483405|Biological|cetuximab|250 mg/m2, intravenously, once per week
489155|NCT00483405|Drug|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
489156|NCT00483405|Drug|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
489157|NCT00483392|Drug|metformin, rosiglitazone|
489158|NCT00483379|Biological|alglucosidase alfa|intravenous infusion
489159|NCT00483366|Drug|capecitabine|"Dose level Capecitabine~-1 400 mg/m2 bid~0 500 mg/m2 bid~500 mg/m2 bid~600 mg/m2 bid~600 mg/m2 bid~725 mg/m2 bid~725 mg/m2 bid~850 mg/m2 bid~850 mg/m2 bid"
489160|NCT00483366|Drug|gemcitabine hydrochloride|"Dose level Gemcitabine~-1 400 mg/m2 0 450 mg/m2~550 mg/m2~550 mg/m2~675 mg/m2~675 mg/m2~825 mg/m2~825 mg/m2~1000 mg/m2"
489161|NCT00483366|Drug|imatinib mesylate|"Dose level Imatinib~-1 400 mg/d 0 400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d~400 mg/d"
489162|NCT00483366|Genetic|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
489224|NCT00482872|Genetic|gene expression analysis|
489225|NCT00482872|Genetic|mutation analysis|
514497|NCT00285298|Drug|Placebo|
489163|NCT00483366|Genetic|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
489164|NCT00483366|Genetic|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
489165|NCT00483353|Procedure|Intra-nasal allergen challenge with Phleum pratense.|
489166|NCT00483353|Procedure|Collection of nasal effluent using filter paper.|
489167|NCT00483353|Procedure|Measurement of nasal congestion using acoustic rhinometry.|
489168|NCT00483327|Drug|Megestrol Acetate|
489169|NCT00483314|Drug|N-acetylcysteine|2 g p.o. BID x 60 days
489170|NCT00483301|Drug|Sorafenib (BAY 43-9006)|dosage
489171|NCT00483301|Drug|ABI-007(Abraxane)|dosage
489172|NCT00483288|Other|educational intervention|
489173|NCT00483288|Other|questionnaire administration|
489174|NCT00483288|Other|study of socioeconomic and demographic variables|
489175|NCT00483288|Other|survey administration|
489176|NCT00483275|Drug|Alfacalcidol|
489177|NCT00483275|Behavioral|Balance, gait and strength training|
489178|NCT00483275|Behavioral|Patient education|
489179|NCT00483262|Drug|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
489180|NCT00483262|Drug|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
489181|NCT00483249|Device|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
489182|NCT00483223|Drug|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
489183|NCT00483223|Drug|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
489184|NCT00483210|Drug|Fenofibrate|
489185|NCT00483197|Device|VentrAssistTM Left Ventricular Assist Device|
489186|NCT00483184|Biological|Veldona,|Very low dose oral natural human interferon alpha lozenges
489187|NCT00483171|Drug|CP-945,598|CP-945,598
489188|NCT00483171|Behavioral|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
489189|NCT00483171|Behavioral|Low Calorie Diet|Low calorie diet
489190|NCT00483158|Drug|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
489191|NCT00483145|Device|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
489192|NCT00483145|Device|Long-pulsed dye laser|
489193|NCT00483145|Device|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
489194|NCT00483132|Drug|interferon alpha 2a|
489195|NCT00483119|Drug|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
489196|NCT00483119|Drug|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
489197|NCT00483106|Drug|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
489198|NCT00483106|Drug|Placebo|taken orally twice a day for 7 consecutive days
489199|NCT00483093|Drug|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
489200|NCT00483093|Drug|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
489201|NCT00483080|Drug|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
489202|NCT00483067|Drug|2-CdA|12 mg/m^2/day by vein (IV) Continuous Infusion x 5 Days
489203|NCT00483067|Drug|Ara-C|1 gm/m^2/day IV Over 2 Hours x 5 Days
489204|NCT00483067|Drug|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
489205|NCT00483054|Drug|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
489206|NCT00483054|Drug|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
489207|NCT00483041|Other|PLACEBO|Placebo administered as a single intravenous infusion
489208|NCT00483041|Biological|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
489209|NCT00483028|Drug|donezepil (Aricept)|
489210|NCT00483015|Behavioral|smoking|
489211|NCT00483002|Drug|varenicline|As prescribed by physician in usual clinical practice.
489212|NCT00482989|Biological|MEDI 545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
489213|NCT00482989|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
489214|NCT00482976|Drug|Ruboxistaurin|
489215|NCT00482976|Drug|Placebo|
489216|NCT00482963|Drug|levonorgestrel, efavirenz|
489217|NCT00482950|Drug|PHX1149T|
489218|NCT00482937|Drug|CD-NP|
489219|NCT00482924|Other|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
489220|NCT00482911|Drug|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
489221|NCT00482911|Drug|lenalidomide|10 mg by mouth once daily on days 1-28.
489222|NCT00482911|Drug|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
489223|NCT00482898|Drug|MK0359|
489226|NCT00482872|Genetic|polymerase chain reaction|
489227|NCT00482872|Genetic|polymorphism analysis|
489228|NCT00482872|Other|flow cytometry|
489229|NCT00482872|Other|laboratory biomarker analysis|
489230|NCT00482846|Biological|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
489231|NCT00482846|Drug|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:~Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;~Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:~Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
489232|NCT00482846|Other|questionnaire administration|Day -5 to Day +28
489233|NCT00482846|Procedure|autologous peripheral blood stem cell transplantation|Day 0
489234|NCT00482846|Other|quality-of-life assessment|Day -5 to Day +28
489235|NCT00482833|Drug|arsenic trioxide|"Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.~Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28)."
489236|NCT00482833|Drug|idarubicin|"Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1."
489237|NCT00482833|Drug|mercaptopurine|Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
489238|NCT00482833|Drug|methotrexate|Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
489239|NCT00482833|Drug|all-trans retinoic acid|"Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed."
489240|NCT00482833|Drug|all-trans retinoic acid (ATRA)|"Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26)."
489241|NCT00482820|Behavioral|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
489242|NCT00482807|Drug|bicalutamide|
489243|NCT00482807|Drug|docetaxel|
489244|NCT00482807|Drug|goserelin|
489245|NCT00482807|Radiation|intensity-modulated radiation therapy|
489246|NCT00482781|Biological|Infanrix|
489247|NCT00482781|Biological|Pediatrix|
489248|NCT00482768|Behavioral|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
489249|NCT00482755|Drug|sunitinib malate|
489250|NCT00482755|Other|immunohistochemistry staining method|
489251|NCT00482755|Other|laboratory biomarker analysis|
489252|NCT00482755|Other|pharmacological study|
489253|NCT00482755|Procedure|needle biopsy|
489254|NCT00482755|Procedure|neoadjuvant therapy|
489255|NCT00482742|Device|CiTop(TM) Guidewire|
489256|NCT00482729|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
489257|NCT00482729|Drug|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
489258|NCT00482716|Biological|epoetin alfa|
489259|NCT00482716|Biological|epoetin beta|
489260|NCT00482716|Dietary Supplement|iron dextran complex|
489261|NCT00482716|Dietary Supplement|iron sucrose injection|
489262|NCT00482703|Drug|Dasatinib|tablets, Oral, 100 mg, once daily
489263|NCT00482703|Drug|dasatinib|tablets, Oral, 50 mg, twice daily
489264|NCT00482690|Drug|nicotine polacrilex|
489265|NCT00482690|Drug|nicotine transdermal system|
489266|NCT00482690|Drug|nicotine inhaler|
489267|NCT00482677|Drug|temozolomide|Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
489268|NCT00482677|Genetic|DNA methylation analysis|A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
489269|NCT00482677|Procedure|quality-of-life assessment|prior to randomization until end of study
489270|NCT00482677|Radiation|Radiation|Short course radiotherapy
489271|NCT00482664|Drug|CP-866,087|Tablets for oral administration
489272|NCT00482664|Drug|CP-866,087|Tablets for oral administration
489273|NCT00482664|Drug|CP-866,087|Tablets for oral administration
489274|NCT00482664|Drug|Placebo|Tablets for oral administration
489275|NCT00482651|Radiation|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
489276|NCT00482651|Procedure|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
489277|NCT00482651|Procedure|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
489278|NCT00482651|Procedure|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
489279|NCT00482638|Drug|MK0493|
489280|NCT00482625|Drug|erlotinib hydrochloride|Given PO
489281|NCT00482625|Procedure|conventional surgery|Undergo pancreatectomy
489282|NCT00482625|Other|immunohistochemistry staining method|Correlative studies
489283|NCT00482625|Genetic|protein expression analysis|Correlative studies
489284|NCT00482625|Procedure|biopsy|Correlative studies
489285|NCT00482625|Other|pharmacological study|Correlative studies
489286|NCT00482625|Other|laboratory biomarker analysis|Correlative studies
489287|NCT00482612|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
489288|NCT00482612|Drug|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
489289|NCT00482599|Drug|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
489290|NCT00482586|Other|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
489291|NCT00482586|Other|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
489292|NCT00482586|Procedure|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
489293|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution with epinephrine 1:100,000~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
489294|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution without vasoconstrictor~infusion of 1,8 mL (one cartridge)~Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
489295|NCT00482560|Drug|Sucrose solution 30%1 ml|
489296|NCT00482560|Behavioral|Breastfeeding|
489297|NCT00482547|Device|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
489298|NCT00482547|Device|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
489299|NCT00482521|Drug|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
489300|NCT00482508|Drug|Omalizumab|
489301|NCT00482495|Biological|bevacizumab|
489302|NCT00482495|Genetic|gene expression analysis|
489303|NCT00482495|Genetic|protein expression analysis|
489304|NCT00482495|Other|laboratory biomarker analysis|
489305|NCT00482482|Behavioral|psychoeducation|on weekly basis for 8 weeks
489306|NCT00482482|Behavioral|Yoga|on weekly basis for 8 weeks
489307|NCT00482456|Drug|Nitrous oxide|
489308|NCT00482443|Other|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
489309|NCT00482443|Other|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
489310|NCT00482430|Drug|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
489311|NCT00482430|Drug|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
489312|NCT00482417|Drug|MK0359|
489313|NCT00482404|Behavioral|Romantic kissing|
489314|NCT00482391|Biological|trastuzumab|
489315|NCT00482391|Drug|cyclophosphamide|
489316|NCT00482391|Drug|doxorubicin hydrochloride|
489317|NCT00482391|Drug|lapatinib ditosylate|
489318|NCT00482391|Drug|paclitaxel|
489319|NCT00482391|Other|laboratory biomarker analysis|
489320|NCT00482378|Drug|Pamidronate|90 mg by IV monthly.
489321|NCT00482378|Drug|Zoledronic acid|4 mg by IV monthly.
489322|NCT00482378|Radiation|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
489323|NCT00482365|Other|biologic sample preservation procedure|biologic sample preservation procedure
489324|NCT00482365|Other|medical chart review|review of patients' medical records at study entry and every 6 months
489325|NCT00482365|Other|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
489326|NCT00482352|Other|laboratory biomarker analysis|Correlative studies
489327|NCT00482313|Drug|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
489328|NCT00482313|Drug|Placebo|Sugar pill
489329|NCT00482300|Procedure|Systematic pelvic lymphadenectomy|
489330|NCT00482287|Drug|MTR105|Intravenous administration, dose escalating (4 arms), single dose
489331|NCT00482274|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
489332|NCT00482261|Drug|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
489333|NCT00482261|Drug|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
489334|NCT00482261|Drug|aspirin|100mg/day
489342|NCT00482222|Other|study of socioeconomic and demographic variables|
489343|NCT00482222|Procedure|adjuvant therapy|
489344|NCT00482222|Procedure|neoadjuvant therapy|
489345|NCT00482222|Procedure|quality-of-life assessment|
489346|NCT00482209|Drug|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
489347|NCT00482209|Drug|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
489348|NCT00482196|Drug|MK0493|
489349|NCT00482183|Drug|Pioglitazone|
489350|NCT00482170|Device|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
489351|NCT00482170|Device|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
489352|NCT00482157|Drug|Vitamin D (Calcitriol)|
489353|NCT00482144|Procedure|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
489354|NCT00482144|Procedure|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
489355|NCT00482105|Other|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
489356|NCT00482092|Drug|adult human mesenchymal stem cells|Intravenous infusion of suspension of adult human mesenchymal stem cells, total of 1200 million (high dose) or 600 million (low dose) cells infused in four visits over two weeks.
489357|NCT00482092|Drug|Placebo|Placebo
489358|NCT00482079|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
489359|NCT00482079|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
489360|NCT00482066|Drug|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg~1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
489361|NCT00482053|Procedure|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
489362|NCT00482053|Procedure|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
489363|NCT00482053|Procedure|Total lymphoid irradiation (TLI)|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
489364|NCT00482053|Drug|Rituximab|375 mg/m2 IV days 1 and 7 over 4 to 8 hours
489365|NCT00482053|Drug|Carmustine|"Based on body weight, unless its more than 15 kg greater than the idal body 15mg/kg (max dose 550 mg/m2) day -6 over 2 hours.~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
489366|NCT00482053|Drug|Etoposide|60 mg/kg over 4 hours day -4 and alternatively VP-16 2 Gm/m² may be used (for mobilization)
489367|NCT00482053|Drug|Filgrastim|10 µg/kg/day subcutaneous starting Day 9 until last day of apheresis. 5 ug/kg actual body weight per day will be started at Day +6 after allo-HCT until hematologic recovery
489368|NCT00482053|Drug|Anti-thymocyte globulin (ATG)|1.5 mg/kg/day for 5 days
489369|NCT00482053|Drug|Cyclosporine|5.0 mg/kg twice daily from day -3 until after day +56
489370|NCT00482053|Drug|Mycophenolate mofetil (MMF)|"250 mg (total) twice daily, oral~15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. On day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor."
489371|NCT00482053|Drug|Cyclophosphamide|100 mg/kg will be administered over 2 hours on day -2
489372|NCT00482053|Drug|Acetaminophen|Pre-medication for rituximab and PBPC infusion. Administered at 650 mg by mouth 1 hour prior to infusion
489373|NCT00482053|Drug|Diphenhydramine|Pre-medication for rituximab and PBPC infusion. Administered at 50 mg intravenous 1 hour prior to infusion
489374|NCT00482053|Drug|Hydrocortisone|Pre-medication for the PBPC infusion. Administered at 100 mg intravenous 1 hour prior to infusion
489375|NCT00482053|Drug|Methylprednisolone|Anti-reaction medication for the ATG infusion. Administered at 1 mg/kg, Day-11 to Day-7
489376|NCT00482040|Device|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
489377|NCT00482027|Biological|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
489378|NCT00482014|Drug|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles~Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles~Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
489379|NCT00482014|Drug|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
489380|NCT00482014|Drug|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter*minute (mg/mL*min), administered intravenously, Days 1, 8, 22, 29 and 43~Phase 2 - dosed at AUC 5 mg/mL*min, administered intravenously, every 21 days for 3 cycles"
489381|NCT00482014|Radiation|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51~Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
489382|NCT00482001|Drug|donepezil|
489383|NCT00482001|Drug|Placebo (cornstarch)|
489384|NCT00481988|Device|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
489385|NCT00481988|Device|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
489386|NCT00481988|Device|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
489387|NCT00481988|Device|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
489388|NCT00481975|Drug|rimonabant (SR141716)|
489389|NCT00481962|Drug|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
489390|NCT00481936|Drug|VB6-845|Intravenous infusion once weekly for 4 weeks
489391|NCT00481923|Drug|rimonabant (SR141716)|
489392|NCT00481897|Behavioral|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
489393|NCT00481884|Other|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
489394|NCT00481884|Other|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
489395|NCT00481871|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).~Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
489396|NCT00481871|Drug|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.~Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.~Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
489397|NCT00481871|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection~Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
489398|NCT00481871|Dietary Supplement|Folic Acid|"1 mg orally~Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
489399|NCT00481845|Drug|Vandetanib|300 mg daily
489400|NCT00481845|Drug|Anastrozole|1 mg daily
489401|NCT00481832|Drug|Cyclophosphamide|4 gm /m² IV over 2 hours on day 8
489402|NCT00481832|Drug|BCNU|"The dose of BCNU will be based on actual body weight unless the actual body weight is more than 15 kg greater than the ideal body weight in which case the adjusted ideal body weight will be used:~Males IBW = 50 kg + 2.3 kg/inch over 5 feet Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet Adjusted IBW = IBW + 50% (actual weight - IBW)"
489403|NCT00481832|Drug|Etoposide|60mg/kg, IV over 4 hours on day -4 pre-transplant and for preparative regimen. The dose of etoposide for mobilization is 2 gm/ m².
489404|NCT00481832|Drug|Filgrastim|10µg/kg sc qd starting day following cyclosphamide (or VP-16) until last day of apheresis
489405|NCT00481832|Drug|Antithymocyte globulin|1.5 mg/kg/d, IV from day -11 to -7
489406|NCT00481832|Drug|Cyclosporine|5mg/kgbid,variable, po or IV
489407|NCT00481832|Drug|Mycophenolate mofetil|15 mg/kg po on day 0, at 5-10 hours after mobilized PBPC infusion is complete. Thereafter, beginning on day +1 MMF is taken at 15 mg/kg po b.i.d. (30 mg/kg/day) if transplantation was using a matched related donor and 15 mg/kg po t.i.d if from a matched unrelated donor or a one antigen mismatched donor. Doses will be rounded up to the nearest 250 mg (capsules are 250 mg). MMF will be stopped on day +28 for matched related donors. For one antigen mismatched related or unrelated donors, the taper will begin on day +40. MMF will be tapered by 10% weekly till off, typically by day +96. If there is nausea and vomiting at any time preventing the oral administration of MMF, MMF should be administered intravenously at an equal dose. MMF dosing is based on actual body weight.
489408|NCT00481832|Drug|Rituximab|375 mg/m2 IV (calculated based on actual body weight) on day 1 and day 7. Administered per current standard of care..
489409|NCT00481832|Procedure|Autologous hematopoietic stem cell transplantation (auto-HSCT)|Auto-HCT involves an intravenous infusion of a participant's previously collected and frozen white blood cells collected after treatment with mobilizing agents
489410|NCT00481832|Procedure|Allogeneic hematopoietic stem cell transplantation (allo-HSCT)|Allo-HCT involves an intravenous infusion of a donor's white blood cells collected after treatment with mobilization with filgrastim (G-CSF)
489411|NCT00481832|Procedure|Total lymphoid irradiation|TLI is administered in 80cGy fractions on Days -11 to Day-7 relative to allo-HSCT
489412|NCT00481832|Drug|CD34+ Cells|2 x 10e6 CD34+ cells per kg actual body weight on Day 0
489413|NCT00481832|Drug|Solu-Medrol|1 mg/kg, Day-11 to Day-7
489414|NCT00481819|Drug|FK506MR|oral
489415|NCT00481819|Drug|Prograf|oral
489416|NCT00481819|Drug|Mycophenolate Mofetil|oral
489417|NCT00481819|Drug|Methylprednisolone|oral
489418|NCT00481819|Drug|Prednisolone|oral
489419|NCT00481780|Device|plain balloon angioplasty|
489420|NCT00481780|Device|cutting balloon angioplasty|
489421|NCT00481767|Biological|Cervarix|The vaccine was administered according to a 0, 1, and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
489422|NCT00481767|Drug|Placebo Al(OH)3|Placebo was administered according to a 0, 1 and 6-month schedule, intramuscularly into the deltoid region of the non-dominant arm.
489423|NCT00481741|Device|SafeSeal(TM) Hemostasis Patch|
489424|NCT00481728|Drug|Tolterodine|Single dose per patient as determined by protocol.
489425|NCT00481728|Procedure|Filling cystometry|This is a procedure.
489426|NCT00481728|Procedure|Intravesical neurostimulation|This is a procedure.
489427|NCT00481715|Behavioral|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
489428|NCT00481715|Behavioral|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
489429|NCT00481702|Drug|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
489430|NCT00481702|Drug|MK0826, /Duration of Treatment : 8 Weeks|
489431|NCT00481702|Drug|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
489432|NCT00481689|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
489433|NCT00481676|Drug|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
489434|NCT00481676|Drug|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
489435|NCT00481676|Drug|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
489436|NCT00481676|Drug|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
489437|NCT00481663|Drug|Sitagliptin|
489438|NCT00481663|Drug|Placebo to sitagliptin|
489439|NCT00481663|Drug|Metformin|
489440|NCT00481663|Drug|Rescue|Patients whose FPG >240 mg/dL from Week 16 or HbA1C >8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently >240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C >8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C >7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
489441|NCT00481650|Drug|Leios/Alesse|
489442|NCT00481624|Drug|Epoetin Alfa plus Iron|"One (1) injection of Procrit®, by needle, inserted just under the skin;~125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.~These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.~In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan."
489443|NCT00481598|Procedure|magnet resonance spectroscopy|magnet resonance spectroscopy
489444|NCT00481572|Drug|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
489445|NCT00481572|Drug|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
489446|NCT00481572|Drug|Norepinephrine|titrated norepinephrine over a period of 48 hrs
489447|NCT00481559|Drug|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
489448|NCT00481546|Genetic|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
489449|NCT00481533|Drug|Methyl-Ergonovine-Oxytocin|
489450|NCT00481533|Drug|Oxytocin|
489451|NCT00481520|Drug|SAM-531|
489452|NCT00481520|Other|placebo|
489453|NCT00481507|Other|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
489454|NCT00481507|Other|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
489455|NCT00481481|Drug|tacrolimus|immunosuppression
489456|NCT00481455|Drug|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
489457|NCT00481455|Drug|Temozolomide|Fixed dose
489458|NCT00481442|Drug|Phenylephrine|
489459|NCT00481429|Drug|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
489460|NCT00481416|Device|PillCam Eso|
489461|NCT00481403|Behavioral|Microarray analysis|Microarray analysis
489462|NCT00481403|Behavioral|Microarray|Microarray
489463|NCT00481390|Procedure|Cheek cells sample|Cheek cells sample
489464|NCT00481390|Procedure|Blood sample|Blood sample
489465|NCT00481377|Procedure|ablation|
489466|NCT00481364|Drug|atorvastatin|atorvastatin 40 mg/day
489467|NCT00481364|Drug|placebo|1 tb/day
489468|NCT00481351|Drug|Simvastatin 20mg plus ezetimibe 10mg|simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
489469|NCT00481351|Drug|ezetimibe|ezetimiba 10mg once a day
489470|NCT00481351|Drug|simvastatin 20mg|simvastatin 20mg once a day
489471|NCT00481351|Drug|Simvastatin 80mg|simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
489472|NCT00481338|Procedure|X-rays|X-rays (hip and knee) every 2 years
489473|NCT00481338|Biological|biological samples|biological sample (blood and urine) every 2 years
489528|NCT00480883|Drug|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
489474|NCT00481338|Other|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
489475|NCT00481325|Drug|pexacerfont|Tablets & Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
489476|NCT00481325|Drug|escitalopram|Tablets & Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
489477|NCT00481325|Drug|placebo|Tablets & Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
489478|NCT00481312|Drug|Dexmedetomidine|Continuous Infusion
489479|NCT00481312|Drug|Midazolam|Continuous Infusion
489480|NCT00481286|Behavioral|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
489481|NCT00481286|Behavioral|Standard of Care|Standard of care for diabetes patients
489482|NCT00481273|Drug|Azacitidine|Physician's discretion
489483|NCT00481260|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
489484|NCT00481247|Drug|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
489485|NCT00481247|Drug|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
489486|NCT00481234|Device|Heart Rate Variability analysis|
489487|NCT00481221|Procedure|Observation of results from laboratory tests|Laboratory data summary only
489488|NCT00481195|Drug|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day [2 tablets]) was allowed. The dosage could not be increased after it was decreased.
489489|NCT00481195|Drug|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
489490|NCT00481182|Drug|fosamprenavir + ritonavir + methadone|
489491|NCT00481169|Drug|Bazedoxifene Acetate (TSE-424)|
489492|NCT00481156|Behavioral|Cognitive Remediation|
489493|NCT00481156|Behavioral|Cognitive Behavioral Social Skills Training|
489494|NCT00481156|Other|Retest in Health Controls|Pre/Post test performance and neuroimaging only
489495|NCT00481143|Drug|ICL670/Deferasirox|
489496|NCT00481117|Drug|LY2405319|
489497|NCT00481117|Drug|Placebo|
489498|NCT00481104|Drug|Tesofensine|
489499|NCT00481091|Drug|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days or (14/21) or continuous dosing.~Phase 2a dosing at the recommended phase 2a dose and schedule"
489500|NCT00481078|Drug|vorinostat|Given PO
489501|NCT00481078|Drug|paclitaxel|Given IV
489502|NCT00481078|Drug|carboplatin|Given IV
489503|NCT00481078|Other|placebo|Given PO
489504|NCT00481078|Other|laboratory biomarker analysis|Correlative studies
489505|NCT00481065|Biological|MF59-eH5N1|
489506|NCT00481065|Biological|eTIV_a|
489507|NCT00481065|Biological|MF59-eH5N1 + eTIV_a|
489508|NCT00481052|Drug|Nilotinib|
489509|NCT00481039|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
489510|NCT00481026|Device|transcranial direct current stimulation (tDCS)|tDCS
489511|NCT00481026|Device|active tDCS|Active tDCS
489512|NCT00481013|Drug|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
489513|NCT00481013|Drug|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
489514|NCT00481000|Behavioral|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
489515|NCT00480987|Drug|Oxaliplatin|30 mg/m^2 IV days 1-4
489516|NCT00480987|Drug|Fludarabine|30 mg/m^2 IV days 2-6
489517|NCT00480987|Drug|Cytarabine|500 mg/m^2 by IV continuous infusion days 2-6
489518|NCT00480974|Other|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
489519|NCT00480961|Procedure|intramiocardiac autograft of autologous stem cells|
489520|NCT00480948|Behavioral|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing ~49% of C16:0 at sn-2 position), 24 wk
489521|NCT00480948|Dietary Supplement|Control|Standard vegetable oil based infant formula
489522|NCT00480935|Drug|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
489523|NCT00480922|Behavioral|Low glycemic load diet|Outpatient behavioral counseling
489524|NCT00480922|Behavioral|Low fat diet|Outpatient behavioral counseling
489525|NCT00480896|Drug|tacrolimus ointment|Topical application
489526|NCT00480896|Drug|Placebo ointment|Topical application
489527|NCT00480883|Drug|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
489658|NCT00479856|Drug|nab-Paclitaxel|Chemotherapy
489529|NCT00480883|Drug|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
489530|NCT00480870|Drug|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
489531|NCT00480870|Drug|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
489532|NCT00480857|Drug|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
489533|NCT00480844|Drug|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
489534|NCT00480844|Drug|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
489535|NCT00480831|Drug|bevacizumab|Intravenous repeating dose
489536|NCT00480831|Drug|carboplatin|Intravenous repeating dose
489537|NCT00480831|Drug|paclitaxel|Intravenous repeating dose
489538|NCT00480831|Drug|placebo|Intravenous repeating dose
489539|NCT00480831|Drug|PRO95780|Intravenous repeating dose
489540|NCT00480818|Drug|SAM-531|
489541|NCT00480805|Drug|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
489542|NCT00480805|Drug|Comparator : ramipril /Duration of Treatment : 8 Weeks|
489543|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
489544|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
489545|NCT00480792|Biological|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
489546|NCT00480779|Behavioral|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
489547|NCT00480779|Behavioral|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
489548|NCT00480766|Drug|MK0217/Duration of Treatment : 12 Months|
489549|NCT00480753|Drug|Nitroglycerin|
489550|NCT00480740|Drug|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
489551|NCT00480727|Procedure|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
489552|NCT00480727|Procedure|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
489553|NCT00480714|Biological|BCG (SSI Strain)|
489554|NCT00480701|Drug|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
489555|NCT00480688|Biological|BCG|
489556|NCT00480675|Procedure|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
489557|NCT00480675|Procedure|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
489558|NCT00480662|Drug|alendronate|Duration of Treatment : 6 Months
489559|NCT00480649|Drug|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
489560|NCT00480636|Drug|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
489561|NCT00480623|Drug|Satraplatin plus radiation therapy|
489562|NCT00480610|Drug|tacrolimus ointment|Topical application
489563|NCT00480610|Drug|Placebo ointment|Topical application
489564|NCT00480597|Drug|gemcitabine|
489565|NCT00480597|Drug|cisplatin|
489566|NCT00480597|Drug|vinorelbine|
489567|NCT00480597|Drug|capecitabine|
489568|NCT00480584|Drug|gemcitabine|Levels 1 through 4: 1000 mg/m^2
489569|NCT00480584|Drug|capecitabine|Level 1: 500 mg/m^2; Level 2: 825 mg/m^2; Level 3: 1000 mg/m^2; Level 4: 1250 mg/m^2
489570|NCT00480584|Drug|erlotinib|Levels 1 through 4: 100 mg
489571|NCT00480571|Drug|BL-1020|BL-1020 Low Dose
489572|NCT00480571|Drug|BL 1020 High Dose|BL 1020 High Dose
489573|NCT00480558|Biological|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10^7
489574|NCT00480532|Drug|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
489575|NCT00480532|Drug|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
489576|NCT00480532|Drug|Oracea|40-mg tablet daily for 84 days
489577|NCT00480532|Drug|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
489578|NCT00480532|Drug|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
489579|NCT00480532|Drug|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
489580|NCT00480532|Drug|placebo daily|Placebo daily for the first 84 days of the study
489581|NCT00480519|Procedure|Meatotomy|
489582|NCT00480493|Behavioral|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
489583|NCT00480480|Behavioral|Trauma and Grief Component Therapy for Adolescents (Group Version)|
489584|NCT00480467|Drug|SAM-315|
489585|NCT00480454|Biological|MVA 85A|intradermal vaccine
489586|NCT00480441|Drug|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
489587|NCT00480441|Behavioral|BRENDA therapy|weekly therapy sessions for 6 weeks
489588|NCT00480441|Drug|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
489589|NCT00480402|Drug|200 mg of Progesterone|Administration of 200 mg of Progesterone
489590|NCT00480402|Drug|400 mg Progesterone|Administration of 400 mg Progesterone
489591|NCT00480402|Drug|Placebo|Administration of a Placebo
489592|NCT00480389|Drug|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
489593|NCT00480376|Drug|ofloxacin|
489594|NCT00480376|Drug|gentamicin|
489595|NCT00480363|Procedure|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
489596|NCT00480350|Behavioral|rice based food supplement|
489597|NCT00480337|Procedure|In Vitro Maturation of immature oocytes|
489598|NCT00480324|Biological|Rotarix|Two-dose oral vaccination.
489599|NCT00480324|Biological|Placebo|Two-dose oral administration.
489600|NCT00480311|Other|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
489601|NCT00480298|Drug|Administration of oral methylprednisolone|
489602|NCT00480285|Procedure|Laparoscopic Nissen Fundoplication|
489603|NCT00480285|Procedure|Laparoscopic anterior partial fundoplication|
489604|NCT00480272|Drug|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
489605|NCT00480272|Drug|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
489606|NCT00480259|Behavioral|hyperproteic nutrition|
489607|NCT00480246|Drug|BL 1020|
489608|NCT00480246|Drug|Perphenazine|
489609|NCT00480220|Procedure|Global care and support program|
489610|NCT00480207|Dietary Supplement|folic acid|
489611|NCT00480207|Dietary Supplement|omega-3|
489612|NCT00480207|Dietary Supplement|vit B12|
489613|NCT00480207|Other|folic acid placebo|
489614|NCT00480207|Other|omega-3 placebo|
489615|NCT00480194|Drug|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
489616|NCT00480181|Drug|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
489617|NCT00480181|Other|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
489618|NCT00480155|Biological|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
489619|NCT00480155|Other|Placebo|
489620|NCT00480142|Drug|Oxycodone 10 mg|
489621|NCT00480129|Behavioral|Probiotic or placebo yogurt consumed daily|
489622|NCT00480129|Device|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
489623|NCT00480129|Procedure|Blood sample|
489624|NCT00480129|Procedure|Nasal lavage|
489625|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
489626|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
489627|NCT00480116|Biological|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
489628|NCT00480103|Device|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
489629|NCT00480090|Drug|Cytarabine|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
489630|NCT00480077|Device|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
489631|NCT00480064|Drug|Lomustine, intermediate dose cytarabine|
489632|NCT00480051|Device|Cardiac Resynchronization Pacing|
489633|NCT00480038|Other|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
489634|NCT00480025|Biological|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
489635|NCT00480025|Biological|Placebo Control|Intramuscular administration, 13 doses
489636|NCT00480012|Device|rTMS|repetitive transcranial meagnetic stimulation of the brain
489637|NCT00479999|Drug|VRC-HIVADV027-00-VP|
489638|NCT00479999|Drug|VRC-HIVADV038-00-VP|
489639|NCT00479986|Drug|pioglitazone|
489640|NCT00479986|Drug|placebo|
489641|NCT00479973|Dietary Supplement|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.~2 capsules after the two largest meals of the day"
489642|NCT00479973|Dietary Supplement|Placebo|Placebo. 2 capsules after the two largest meals of the day
489643|NCT00479960|Behavioral|commercially available omega-3 fatty acids supplementation|
489644|NCT00479947|Drug|Probiotics (Natural product)|
489645|NCT00479947|Drug|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
489646|NCT00479934|Drug|imatinib mesylate|6 month treatment with 400mg/day (per os)
489647|NCT00479921|Biological|Trivalent influenza subunit vaccine|
489648|NCT00479908|Drug|Sildenafil citrate|
489649|NCT00479908|Drug|Glyceryl trinitrate|
489650|NCT00479895|Drug|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
489651|NCT00479882|Drug|Comparator: simvastatin|
489652|NCT00479882|Drug|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
489653|NCT00479882|Drug|Placebo|
489654|NCT00479882|Drug|MK-0524B|
489655|NCT00479856|Drug|Lapatinib|Small molecule tyrosine kinase inhibitor
489656|NCT00479856|Drug|Capecitabine|Chemotherapy
489657|NCT00479856|Drug|Docetaxel|Chemotherapy
489659|NCT00479843|Behavioral|Nutritional programme|
489660|NCT00479830|Behavioral|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
489661|NCT00479830|Behavioral|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
489662|NCT00479830|Behavioral|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
489663|NCT00479817|Drug|AMG 386|10mg/kg
489664|NCT00479817|Drug|AMG 386|3 mg/kg
489665|NCT00479817|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
489666|NCT00479817|Drug|AMG 386 Placebo|AMG 386 Placebo
489667|NCT00479804|Device|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
489668|NCT00479804|Device|spirometry|spirometry for testing the ventilatory function
489669|NCT00479804|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
489670|NCT00479791|Behavioral|Test meals rich in different fatty acids|
489671|NCT00479778|Drug|Bazedoxifene/conjugated estrogens|
489672|NCT00479765|Drug|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
489673|NCT00479752|Drug|FOLFOX4 (Oxaliplatin), Cetuximab|"Arm A FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks~Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².~Arm B FOLFOX4:~Oxaliplatin 85 mg/m² d1~Leucovorin 200 mg/m² d1+d2, followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks~Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
489674|NCT00479739|Drug|Salmeterol/fluticasone propionate or formoterol/budesonide|
489675|NCT00479726|Drug|duloxetine hydrochloride|
489676|NCT00479713|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
489677|NCT00479713|Drug|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
489678|NCT00479713|Drug|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
489679|NCT00479713|Drug|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
489680|NCT00479700|Drug|SAM-531|
489681|NCT00479687|Device|SUPARTZ|Supartz injection into the glenohumeral joint space.
489682|NCT00479687|Device|Phosphate Buffered Saline|Saline injection into the glenohumeral joint space.
489683|NCT00479674|Drug|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
489684|NCT00479674|Drug|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
489685|NCT00479674|Drug|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
489686|NCT00479661|Drug|Dexmedetomidine|Continuous infusion
489687|NCT00479661|Drug|Propofol|Continuous infusion
489688|NCT00479648|Biological|CSL412|
489689|NCT00479648|Biological|Inactivated trivalent influenza vaccine|
489690|NCT00479635|Drug|TPI 287|160 mg/m2 every three weeks for six cycles
489691|NCT00479635|Drug|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
489692|NCT00479622|Drug|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
489693|NCT00479609|Drug|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
489694|NCT00479609|Drug|Placebo|Placebo gel
489695|NCT00479596|Drug|Botox|
489696|NCT00479583|Drug|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
489697|NCT00479583|Drug|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
489698|NCT00479570|Drug|PF-00446687|Single 200mg dose
489699|NCT00479570|Drug|Placebo|
489700|NCT00479557|Biological|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
489701|NCT00479557|Biological|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
489702|NCT00479557|Biological|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
489703|NCT00479557|Drug|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
489704|NCT00479531|Device|AirCast Sequential Compression Device|
489705|NCT00479505|Drug|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
489706|NCT00479505|Drug|Placebo|Placebo
489707|NCT00479492|Drug|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
489708|NCT00479492|Drug|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
489709|NCT00479492|Drug|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
489710|NCT00479492|Drug|placebo|placebo administered QD for 84 days
489711|NCT00479479|Drug|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
489712|NCT00479466|Drug|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
489713|NCT00479466|Drug|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
489714|NCT00479466|Drug|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
489715|NCT00479466|Drug|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
489717|NCT00479427|Drug|GW842166|100 mg once daily
489718|NCT00479427|Drug|Placebo|once daily
489719|NCT00479401|Drug|Pramipexol Extended Release|
489720|NCT00479401|Drug|Pramipexol Immediate Release|
489721|NCT00479401|Drug|Placebo|
489722|NCT00479388|Drug|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
489723|NCT00479388|Drug|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
489724|NCT00479388|Drug|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
489725|NCT00479375|Procedure|Adding Human Papillomavirus testing to organised cervical screening|
489726|NCT00479362|Drug|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
489727|NCT00479362|Drug|Aspirin|Aspirin is continued without interruption prior to device implantation
489728|NCT00479362|Device|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
489729|NCT00479362|Device|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
489730|NCT00479349|Drug|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
489731|NCT00479336|Drug|OPC-41061 7.5mg|7.5mg, 1 tablet a day
489732|NCT00479336|Drug|OPC-41061 placebo|placebo, 1 tablet a day
489733|NCT00479336|Drug|OPC-41061 15mg|15mg, 1 tablet a day
489734|NCT00479336|Drug|OPC-41601 30mg|30mg, 1 tablet a day
489735|NCT00479323|Biological|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
489736|NCT00479310|Drug|Summers 5% L.A.|
489737|NCT00479297|Drug|SAM-531|
489738|NCT00479284|Procedure|Average volume assured pressure support (AVAPS)|
489739|NCT00479271|Behavioral|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
489740|NCT00479271|Behavioral|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
489741|NCT00479258|Drug|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
489742|NCT00479258|Drug|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
489743|NCT00479245|Other|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
489744|NCT00479232|Drug|vorinostat|
489745|NCT00479232|Drug|decitabine|
489746|NCT00479219|Drug|GSI-953|
489747|NCT00479219|Other|Placebo|
489748|NCT00479206|Drug|Artesunate|
489749|NCT00479193|Drug|bacitracin/xeroform|single layer, change every 3 days
489750|NCT00479193|Drug|Polymem|single layer of Polymen, change every 3 days
489751|NCT00479180|Biological|Vascugel|One time implant on the day of surgery
489752|NCT00479180|Biological|Placebo Comparator|One time implant on the day of surgery
489753|NCT00479167|Drug|Bortezomib and Tositumomab I-131|
489754|NCT00479154|Drug|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
489755|NCT00479141|Behavioral|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
489756|NCT00479141|Behavioral|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
489757|NCT00479128|Drug|Bortezomib|Starting dose: 0.8 mg/m^2 IV Over 3-5 Seconds
489758|NCT00479128|Drug|Gemcitabine|Starting dose: 225 mg/m^2 IV Up to 90 Minutes
489759|NCT00479128|Drug|Doxorubicin|Starting dose: 12.5 mg/m^2 IV Over 15-30 minutes
489760|NCT00479115|Drug|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
489761|NCT00479115|Device|AmCell CliniMACs|CD34+ cell selection from peripheral collection
489762|NCT00479102|Drug|Ferripel-3 - iron polysaccharide complex for prevention|
489763|NCT00479089|Drug|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
489764|NCT00479089|Drug|ZD1839|250 mg by mouth daily, without break.
489765|NCT00479089|Drug|Dexamethasone|"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.~Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.~Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."
489766|NCT00479076|Drug|aflibercept (AVE0005)|intravenous infusion
489767|NCT00479076|Drug|S-1|oral administration
489768|NCT00479050|Procedure|chemoembolization ,Radiofrequency ablation|
489769|NCT00479037|Drug|Full Length Parathyroid Hormone, PTH(1-84)|Once daily subcutaneous injection in the abdomen by self administration
489770|NCT00479037|Drug|Strontium Ranelate|The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
489771|NCT00479024|Drug|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
489772|NCT00479011|Procedure|fluid management based on arterial pulse pressure variation|
489773|NCT00478998|Drug|Tamsulosin|
489774|NCT00478985|Behavioral|Imatinib ending|Interruption of the treatment by Imatinib
489775|NCT00478972|Drug|Rimonabant|Tablet, oral administration
489776|NCT00478972|Drug|placebo (for Rimonabant)|Tablet, oral administration
489777|NCT00478972|Other|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
489820|NCT00478556|Drug|Gastroview|Oral CT contrast
489778|NCT00478959|Drug|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
489779|NCT00478946|Drug|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
489780|NCT00478946|Drug|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
489781|NCT00478946|Drug|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
489782|NCT00478933|Device|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
489783|NCT00478933|Procedure|Blood sampling|Blood sampling
489784|NCT00478907|Drug|KETAMINE, PROPOFOL, THIOPENTAL|
489785|NCT00478881|Drug|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
489786|NCT00478881|Drug|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
489787|NCT00478855|Drug|Tazocin (Piperacillin/Tazobactem)|
489788|NCT00478842|Device|Deep brain stimulation|Deep brain stimulation
489789|NCT00478816|Biological|Fluad H5N1 Pandemic Influenza Vaccine|Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
489790|NCT00478803|Procedure|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
489791|NCT00478803|Device|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
489792|NCT00478790|Device|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
489793|NCT00478777|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
489794|NCT00478777|Drug|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
489795|NCT00478764|Drug|intraocular triamcinolone and gatifloxicin|
489796|NCT00478738|Drug|GSK961081|
489797|NCT00478725|Drug|GW786034, oral|oral, 800 mg
489798|NCT00478725|Drug|GW786034, IV|IV, 5 mg
489799|NCT00478725|Drug|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
489800|NCT00478712|Other|Identification of genetic causes of Hirschsprung Disease|Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
489801|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
489802|NCT00478699|Drug|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
489803|NCT00478699|Drug|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
489804|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
489805|NCT00478686|Procedure|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
489806|NCT00478673|Device|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
489807|NCT00478673|Device|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
489808|NCT00478660|Drug|adalimumab (Humira)|
489809|NCT00478647|Biological|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
489810|NCT00478634|Drug|RAD001, Cetuximab, Irinotecan|
489811|NCT00478621|Biological|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
489812|NCT00478621|Biological|Cervarix TM|Intramuscular administration
489813|NCT00478608|Drug|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
489814|NCT00478595|Drug|Rimonabant|Tablet, oral administration
489815|NCT00478595|Drug|Placebo (for Rimonabant)|Tablet, oral administration
489816|NCT00478595|Drug|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
489817|NCT00478582|Procedure|Estimation of Hb concentrations with the HemoHue card|
489818|NCT00478569|Drug|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
489819|NCT00478556|Drug|Omnipaque|Oral CT contrast
489822|NCT00478530|Procedure|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
489823|NCT00478517|Drug|Erythropoetin (rHuEPO, EPREX®)|
489824|NCT00478504|Drug|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
489825|NCT00478504|Drug|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
489826|NCT00478478|Procedure|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
489827|NCT00478465|Drug|valganciclovir|
489828|NCT00478452|Biological|DC-Ova|
489829|NCT00478452|Biological|DC Ova with Cyclophosphamide|
489830|NCT00478439|Dietary Supplement|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
489831|NCT00478439|Dietary Supplement|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
489832|NCT00478426|Drug|Sunitinib Malate|Given PO
489833|NCT00478387|Biological|The current season's trivalent killed influenza vaccine|
489834|NCT00478374|Drug|Sorafenib|Sorafenib 400mg bid
489835|NCT00478374|Procedure|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
489836|NCT00478361|Drug|Gemcitabine hydrochloride|Gemcitabine 900 mg/m^2 IV over 90 minutes repeat every 14 days.
489837|NCT00478361|Drug|Paclitaxel|135 mg/m^2 IV over 1 hour
489838|NCT00478361|Drug|Doxorubicin hydrochloride|Doxorubicin 40 mg/m^2 IV over 20 minutes
489839|NCT00478361|Drug|Pegfilgrastim|Subcutaneously injection on day 1.
489840|NCT00478348|Procedure|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
489841|NCT00478335|Drug|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
489842|NCT00478335|Drug|calcitonin|one nasal spray daily for 4 days
489843|NCT00478335|Drug|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
489844|NCT00478335|Drug|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
489845|NCT00478335|Drug|Placebo for sildenafil|one tablet daily for 4 days
489846|NCT00478335|Drug|placebo for calcitonin|one nasal spray daily
489847|NCT00478322|Drug|Placebo|Matching placebo of 100 mg BID
489848|NCT00478322|Drug|INCB013739|INCB013739 100 mg BID
489849|NCT00478309|Other|counseling intervention|
489850|NCT00478309|Other|educational intervention|
489851|NCT00478283|Other|survey administration|
489852|NCT00478270|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
489853|NCT00478257|Device|bright white light|Intervention: Bright white light administered for 30 minutes each morning
489854|NCT00478257|Device|comparator red light treatment|dim red light administered for 30 minutes every morning
489855|NCT00478244|Drug|busulfan|Day -9 through Day -6: 1.1 mg/kg if < 12 kg IV every 6 hours; 0.8 mg/kg if > 12 kg.
489856|NCT00478244|Drug|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
489857|NCT00478244|Drug|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
489858|NCT00478244|Procedure|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
489859|NCT00478231|Drug|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
489860|NCT00478218|Drug|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
489861|NCT00478218|Drug|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 & 22
489862|NCT00478218|Drug|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
489863|NCT00478205|Drug|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
489864|NCT00478205|Drug|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:~10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
489865|NCT00478192|Drug|Conivaptan|premix bag
489866|NCT00478192|Drug|Placebo|premix bag
489867|NCT00478179|Drug|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
489868|NCT00478140|Biological|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
489869|NCT00478140|Other|laboratory biomarker analysis|Correlative studies
489870|NCT00478114|Drug|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
489871|NCT00478101|Drug|oxycodone fentanyl|
489872|NCT00478088|Device|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
489873|NCT00478088|Device|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
489874|NCT00478075|Drug|bortezomib|
489875|NCT00478075|Other|immunologic technique|
489876|NCT00478075|Radiation|samarium Sm 153 lexidronam pentasodium|
489877|NCT00478062|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
489878|NCT00478062|Procedure|adjuvant therapy|
489879|NCT00478049|Drug|Gefitinib|250 mg oral tablet
489880|NCT00478049|Drug|Docetaxel|intravenous infusion
489881|NCT00478036|Drug|Acular LS|Details covered in arm description
489882|NCT00478036|Drug|Pred Forte|Details covered in arm description
489883|NCT00478036|Other|Refresh Tears|Placebo
489884|NCT00478023|Drug|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
489885|NCT00478023|Drug|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
489886|NCT00478023|Drug|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
489887|NCT00478023|Drug|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
489888|NCT00478023|Drug|Placebo|4 - 6 hourly; Total 72 hours
489889|NCT00478010|Other|counseling intervention|
489890|NCT00478010|Other|study of socioeconomic and demographic variables|
489891|NCT00478010|Procedure|psychosocial assessment and care|
489892|NCT00478010|Procedure|quality-of-life assessment|
489893|NCT00477997|Device|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
489894|NCT00477984|Drug|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
489895|NCT00477971|Biological|filgrastim|No administration information given
489896|NCT00477971|Drug|dexamethasone|Given orally
489897|NCT00477971|Drug|melphalan|Given IV or orally
489898|NCT00477971|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
489899|NCT00477958|Other|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
489900|NCT00477958|Procedure|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
489901|NCT00477958|Procedure|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
489902|NCT00477945|Drug|clofarabine|"Cohort N Clofarabine (mg/m2/day)~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
489903|NCT00477906|Biological|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
489904|NCT00477893|Drug|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
489905|NCT00477893|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
489906|NCT00477880|Biological|Cetuximab|
489907|NCT00477867|Procedure|quality-of-life assessment|
489908|NCT00477854|Drug|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
489909|NCT00477841|Procedure|Esophageal stent placement|
489910|NCT00477841|Procedure|dysphagia scores|
489911|NCT00477841|Procedure|complications of therapy|
489912|NCT00477841|Procedure|survival time of therapy|
489913|NCT00477828|Device|Continuous positive airway pressure|
489914|NCT00477815|Biological|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
489915|NCT00477815|Drug|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
489916|NCT00477815|Biological|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
489917|NCT00477815|Biological|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
489918|NCT00477815|Radiation|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
489919|NCT00477815|Biological|111In Zevalin|5.0 mCi by IV
489920|NCT00477802|Biological|Botulinum Toxin Type A|Injected once during the course of the study.
489921|NCT00477802|Biological|Placebo|Injected once during the course of the study.
489922|NCT00477789|Drug|allopurinol|
489923|NCT00477776|Drug|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
489924|NCT00477776|Drug|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
489925|NCT00477763|Drug|Restasis, Refresh Endura|"Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening~Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening"
489926|NCT00477750|Drug|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression~Phase II - 10 mg orally days 1-21 every 28 days until progression"
489927|NCT00477750|Drug|melphalan|"Phase I - dose escalating: 5mg/m^2 dose level -1, 5 mg/m^2 dose level 0, 8 mg/m^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression~Phase II - 5mg/m^2 orally days 1-4 every 28 days until progression"
489928|NCT00477750|Drug|prednisone|60mg/m^2, orally days 1-4 every 28 days until progression
489929|NCT00477737|Drug|Sevoflurane|
489930|NCT00477737|Drug|propofol|
489931|NCT00477724|Behavioral|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
489932|NCT00477724|Other|sedentary control group|control group with no specific training
489933|NCT00477711|Drug|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
489934|NCT00477685|Device|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
489935|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
489936|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
489937|NCT00477672|Drug|Placebo|tablet, once daily by mouth, 6 weeks
489938|NCT00477659|Drug|donepezil HCl (Aricept)|Oral donepezil 5mg/day for 4 weeks, followed by 10 mg/day for 8 weeks
489939|NCT00477646|Behavioral|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
489940|NCT00477633|Drug|Norethindrone/ethinyl estradiol|1 tablet per day
489941|NCT00477620|Behavioral|Wearing of reading glasses during prolonged near work|
489942|NCT00477607|Drug|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
489943|NCT00477607|Behavioral|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
489944|NCT00477607|Biological|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
489945|NCT00477607|Drug|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
489946|NCT00477594|Drug|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
489947|NCT00477581|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
489948|NCT00477581|Drug|sitagliptin|oral administration (100mg), once a day in the morning
489949|NCT00477555|Device|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
489950|NCT00477542|Drug|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~3-6 30~3-6 40~3-6 50~3-6 60~6-10 70"
489951|NCT00477529|Drug|ABI-008|nab-docetaxel
489952|NCT00477516|Procedure|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
489953|NCT00477503|Drug|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.~Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
489954|NCT00477503|Drug|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.~Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
489955|NCT00477490|Drug|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
489956|NCT00477490|Drug|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
489957|NCT00477477|Other|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
489958|NCT00477477|Other|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
489959|NCT00477464|Drug|Lapatinib|1250mg once daily
489960|NCT00477464|Drug|capecitabine|2000mg/m^2 twice daily (14 days out of 21 days)
489961|NCT00477451|Drug|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
489962|NCT00477451|Drug|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
489963|NCT00477451|Drug|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
489964|NCT00477451|Drug|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
489965|NCT00477412|Drug|Bortezomib|Given IV
489966|NCT00477412|Drug|Cyclophosphamide|Given IV
489967|NCT00477412|Drug|Cytarabine|Given IV
489968|NCT00477412|Drug|Dexamethasone|Given PO or IV
489969|NCT00477412|Drug|Doxorubicin|Given IV
489970|NCT00477412|Drug|Methotrexate|Given IV
489971|NCT00477412|Biological|Rituximab|Given IV
489972|NCT00477412|Drug|Vincristine|Given IV
489973|NCT00477399|Behavioral|The Evje Model|
489974|NCT00477386|Drug|decitabine|"Decitabine dose will be escalated as follows.~Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
489975|NCT00477373|Drug|depakine chrono|Depakine Chrono 500 mg
489976|NCT00477360|Device|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
489977|NCT00477347|Device|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
489978|NCT00477347|Device|Manual administration|intraoperative manual administration of propofol and remifentanil
489979|NCT00477334|Drug|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
489980|NCT00477334|Drug|Placebo|oral; two tablets twice a day; single day treatment
489981|NCT00477321|Drug|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
489982|NCT00477308|Procedure|salvage therapy|
489983|NCT00477295|Drug|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
489984|NCT00477295|Drug|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
489985|NCT00477282|Drug|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
489986|NCT00477282|Drug|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
489987|NCT00477269|Drug|Imatinib mesylate|
489988|NCT00477269|Drug|Placebo|
489989|NCT00477256|Behavioral|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
489990|NCT00477243|Behavioral|Questionnaire|8 questionnaires will take about 40 minutes to complete.
489991|NCT00477230|Device|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
489992|NCT00477230|Drug|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
489993|NCT00477217|Drug|Zoledronic acid|
489994|NCT00477204|Drug|Simvastatin|simvastatin 20 mg daily
489995|NCT00477204|Drug|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
489996|NCT00477191|Drug|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
489997|NCT00477165|Drug|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
489998|NCT00477165|Drug|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
489999|NCT00477152|Drug|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
490000|NCT00477126|Drug|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
490001|NCT00477100|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, and stool
490002|NCT00477100|Other|Interview|Participate in interview
490003|NCT00477100|Other|Medical Chart Review|Undergo collection of medical data
490004|NCT00477100|Other|Questionnaire Administration|Ancillary Studies
490005|NCT00477087|Drug|Mitoxantrone|Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.
490006|NCT00477087|Drug|GM-CSF|GM-CSF is a biologic response modifier, classified as a colony stimulating factor.
490007|NCT00477074|Procedure|bronchoalveolar lavage, blood analysis|
490008|NCT00477061|Drug|Morphine|
490009|NCT00477048|Drug|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
490010|NCT00477035|Drug|CIK cells|2x10e8 cells/kg
490011|NCT00477035|Drug|etoposide|60 mg/kg
490012|NCT00477035|Drug|bcnu|15 mg/kg
490013|NCT00477035|Drug|cyclophosphamide|100 mg/kg
490014|NCT00477035|Drug|gemcitabine|1250 mg/m2
490015|NCT00477035|Drug|vinorelbine|30 mg/m2
490016|NCT00477035|Drug|melphalan|200 mg/m2
490017|NCT00477022|Device|Vasotrain-447|
490018|NCT00477009|Device|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
490019|NCT00476996|Drug|Leflunomide|Oral repeating dose
490020|NCT00476996|Drug|Methotrexate|Oral or parenteral repeating dose
490021|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (200mg)
490022|NCT00476996|Drug|Ocrelizumab|Intravenous repeating dose (500mg)
490023|NCT00476996|Drug|Placebo|Intravenous repeating dose
490024|NCT00476983|Drug|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
490025|NCT00476970|Behavioral|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
490026|NCT00476957|Device|Stent|Stent implantation
490027|NCT00476957|Device|Stent|Stent implantation
490028|NCT00476944|Procedure|Percutaneous Coronary Intervention (PCI)|
490029|NCT00476931|Biological|SB-509|60 mg dose
490030|NCT00476931|Other|Placebo|Saline
490031|NCT00476918|Drug|Intravitreal injection (triamcinolone acetonide)|
490032|NCT00476905|Device|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
490033|NCT00476892|Procedure|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
490034|NCT00476879|Drug|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
490035|NCT00476866|Device|intermittent positive-pressure breathing (IPPB)|
490036|NCT00476853|Drug|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
490037|NCT00476827|Drug|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
490038|NCT00476827|Drug|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
490039|NCT00476827|Drug|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
490040|NCT00476827|Drug|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
490041|NCT00476827|Drug|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
490042|NCT00476827|Drug|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
490043|NCT00476801|Device|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
490044|NCT00476788|Device|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
490045|NCT00476775|Behavioral|after school ethnic dance program - ballet folklorica|
490046|NCT00476775|Behavioral|culturally-tailored, home-based screen time reduction|
490047|NCT00476775|Behavioral|culturally-tailored health and nutrition education|
490048|NCT00476736|Drug|Effect on small airways (N-Acetylcystein)|
490049|NCT00476710|Drug|Colesevelam HCl|
490050|NCT00476697|Device|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
490051|NCT00476684|Procedure|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
490052|NCT00476684|Procedure|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
490053|NCT00476671|Procedure|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
490054|NCT00476645|Drug|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
490055|NCT00476632|Behavioral|Questionnaire|50 Minute Interview
490056|NCT00476619|Drug|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
490057|NCT00476606|Drug|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
490058|NCT00476606|Drug|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
490059|NCT00476606|Drug|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
490060|NCT00476593|Drug|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
490061|NCT00476593|Drug|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.~Pharms). One drop four times daily in one eys for three days.~The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
490062|NCT00476580|Behavioral|Questionnaire|Questions to collect health information specific to Sri Lankans.
490063|NCT00476567|Other|standard|standard antenatal care
490064|NCT00476567|Behavioral|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
490065|NCT00476554|Drug|Sapacitabine|Sapacitabine
490066|NCT00476541|Drug|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
490067|NCT00476528|Behavioral|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
490068|NCT00476528|Behavioral|Reality Orientation|A quasiexperimental study
490069|NCT00476515|Drug|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
490070|NCT00476502|Genetic|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
490071|NCT00476476|Drug|Erlotinib|Orally every day for about 4-6 weeks
490072|NCT00476463|Drug|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
490073|NCT00476437|Drug|biphasic insulin aspart|
490074|NCT00476437|Drug|biphasic human insulin|
490075|NCT00476424|Drug|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
490076|NCT00476411|Biological|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
490077|NCT00476398|Procedure|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
490078|NCT00476385|Drug|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
490079|NCT00476359|Drug|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
490080|NCT00476346|Dietary Supplement|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
490081|NCT00476333|Device|APOS biomechanical gait system|
490082|NCT00476320|Procedure|Magnetic Resonance Imaging|
490083|NCT00476320|Procedure|Revascularization|
490084|NCT00476320|Procedure|Echocardiography with myocardial deformation imaging|
490085|NCT00476307|Biological|Fluarix™/Influsplit SSW® 2007/2008|
490086|NCT00476294|Other|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
490087|NCT00476281|Procedure|Urinary collect|
490088|NCT00476281|Procedure|Continuous Glucose Monitoring System (CGMS)|
490089|NCT00476268|Drug|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
490090|NCT00476268|Drug|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
490091|NCT00476268|Drug|Formoterol powder 12 µg/unit dose|2 inhalations bid
490092|NCT00476255|Behavioral|Enhanced Standard Care (ESC)|Reading material
490093|NCT00476255|Behavioral|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
490094|NCT00476242|Drug|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
490095|NCT00476242|Drug|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
490096|NCT00476229|Drug|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
490097|NCT00476229|Radiation|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
490098|NCT00476229|Procedure|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
490099|NCT00476229|Drug|Rituximab|375 mg/m^2 by vein on days -13, -6, 1, & 8. Only those patients whose tumors express CD20 will receive Rituximab.
490145|NCT00475956|Drug|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
514681|NCT00283673|Behavioral|Exercise|
490100|NCT00476216|Drug|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:~Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.~Patients in both cohorts 1 & 2 will receive standard chemotherapy alone during cycle 1.~Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.~Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
490101|NCT00476203|Behavioral|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
490102|NCT00476203|Other|Delayed yoga classes|Delayed yoga classes (after 6 months) offered [wait list control group]
490103|NCT00476190|Drug|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
490104|NCT00476190|Drug|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
490105|NCT00476190|Drug|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).~Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
490106|NCT00476190|Drug|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
490107|NCT00476190|Drug|Cyclophosphamide|Consolidation IB: Intravenously on day 1
490108|NCT00476190|Drug|Methylprednisone|Prophase: Intravenously on days 1-3
490109|NCT00476190|Drug|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
490110|NCT00476190|Drug|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
490111|NCT00476190|Drug|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
490112|NCT00476190|Drug|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.~Consolidation II: Intravenously every 3 weeks."
490113|NCT00476190|Drug|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
490114|NCT00476190|Drug|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
490115|NCT00476190|Procedure|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
490116|NCT00476190|Drug|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
490117|NCT00476177|Biological|Infusion of donor dendritic cells|Given in the outpatient setting
490118|NCT00476177|Biological|Infusion of donor lymphocytes|Given in outpatient setting
490119|NCT00476164|Drug|Rituximab|2 doses of 1g 14 days apart
490120|NCT00476164|Other|Control arm|Continue of optimised oral immunosuppression
490121|NCT00476151|Drug|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
490122|NCT00476151|Drug|placebo cream|inactive placebo cream applied two times daily
490123|NCT00476138|Drug|Epigallocatechin-gallate|
490124|NCT00476125|Behavioral|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
490125|NCT00476125|Behavioral|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
490126|NCT00476125|Behavioral|16 Hour Fast|Subjects will fast for 16 hours.
490127|NCT00476112|Drug|Vernakalant Injection 20 mg/mL|
490128|NCT00476099|Drug|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
490129|NCT00476099|Drug|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
490130|NCT00476099|Drug|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
490131|NCT00476086|Drug|Gemcitabine|
490132|NCT00476086|Drug|Oxaliplatin|
490133|NCT00476086|Radiation|Radiation|
490134|NCT00476073|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
490135|NCT00476060|Procedure|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
490136|NCT00476047|Combination Product|Tositumomab and Iodine I 131 Tositumomab|Give IV
490137|NCT00476034|Drug|lumiracoxib|
490138|NCT00476021|Device|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
490139|NCT00476008|Drug|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
490140|NCT00476008|Drug|Placebo|One tablet placebo morning and evening (BID) for 12 months
490141|NCT00475982|Behavioral|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
490142|NCT00475982|Other|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
490146|NCT00475956|Drug|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
490147|NCT00475930|Drug|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
490148|NCT00475930|Drug|Comfort Bath cloths (placebo cloths)|self applied three times weekly
490149|NCT00475917|Drug|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
490150|NCT00475917|Drug|Gemcitabine|once-weekly 30-minute IV infusion
490151|NCT00475904|Drug|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
490152|NCT00475904|Drug|Gabapentin Capsules|1800mg/day capsules for 4 weeks
490153|NCT00475904|Drug|placebo|placebo cream and caps
490154|NCT00475878|Drug|escitalopram|10mg escitalopram/day for 3 months
490155|NCT00475878|Drug|placebo|placebo capsule/day for 3 months
490156|NCT00475865|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
490157|NCT00475865|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
490158|NCT00475865|Drug|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
490159|NCT00475852|Drug|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
490160|NCT00475852|Drug|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
490161|NCT00475839|Device|Tension-free Vaginal Tape|
490162|NCT00475839|Device|Monarc sub-fascial hammock|
490163|NCT00475826|Drug|Statins and Ezetimibe|
490164|NCT00475813|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
490165|NCT00475800|Drug|Lumiracoxib|
490166|NCT00475787|Procedure|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
490167|NCT00475787|Procedure|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
490168|NCT00475774|Behavioral|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
490169|NCT00475748|Procedure|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
490170|NCT00475735|Drug|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
490171|NCT00475735|Drug|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
490172|NCT00475735|Drug|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
490173|NCT00475722|Behavioral|1 Healthy Eating|6 months telephone counseling
490174|NCT00475722|Behavioral|2 Mediterranean|6 months telephone counseling
490175|NCT00475709|Device|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
490176|NCT00475696|Drug|Duloxetine|
490177|NCT00475683|Other|Mouth wash|Mouth wash with chlorehexidin, three times a day
490178|NCT00475683|Dietary Supplement|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
490179|NCT00475670|Drug|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
490180|NCT00475670|Drug|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
490181|NCT00475657|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
490182|NCT00475657|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
490183|NCT00475644|Drug|Enzastaurin|Administered orally
490184|NCT00475618|Procedure|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
490185|NCT00475618|Procedure|professional cleaning|Daily use fluoride toothpaste 500 ppm.
490186|NCT00475618|Procedure|No fluoride toothpaste|Daily use no fluoride toothpaste.
490187|NCT00475592|Device|Esophageal Capsule Endoscopy|
490188|NCT00475592|Device|Upper Gastrointestinal Endoscopy|
490189|NCT00475579|Procedure|tube with subglottic drainage and polyurethane cuff|
490190|NCT00475566|Device|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
490191|NCT00475566|Device|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
490192|NCT00475553|Other|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
490193|NCT00475553|Other|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
490194|NCT00475540|Device|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
490195|NCT00475527|Drug|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
490196|NCT00475514|Drug|Frovatriptan 2.5mg QD|
490197|NCT00475514|Drug|Frovatriptan 2.5 mg BID|
490198|NCT00475514|Drug|placebo|
490199|NCT00475501|Drug|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
490200|NCT00475501|Drug|Finasteride|5 mg, oral, once/day, for 52 weeks
490201|NCT00475501|Other|Placebo|Placebo
490202|NCT00475488|Procedure|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
490203|NCT00475475|Behavioral|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
490204|NCT00475475|Behavioral|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
490205|NCT00475475|Behavioral|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
490206|NCT00475462|Drug|metoprolol|
490207|NCT00475462|Drug|conventional treatment|
490208|NCT00475449|Procedure|percutaneous coronary intervention|
490209|NCT00475449|Procedure|coronary artery bypass grafting|
490210|NCT00475436|Drug|GSK573719|
490211|NCT00475423|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
490212|NCT00475410|Drug|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.~Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
490213|NCT00475410|Drug|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
490214|NCT00475397|Drug|Duloxetine|
490215|NCT00475397|Drug|Placebo|
490216|NCT00475371|Drug|MKC253 Inhalation Powder|Inhalation powder
490217|NCT00475358|Drug|Duloxetine|
490218|NCT00475358|Drug|Placebo|
490219|NCT00475345|Behavioral|Bedtime snacks|
490220|NCT00475332|Drug|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm^3) total body radiation dose can be calculated."
490221|NCT00475332|Procedure|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
490222|NCT00475319|Drug|placebo|comparison of different dosages of drug
490223|NCT00475319|Drug|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
490224|NCT00475319|Drug|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
490225|NCT00475306|Drug|metoclopramide 10 mg|an anti-emetic medication
490226|NCT00475306|Drug|Diphenhydramine 25 mg|used for prophylaxis against akathisia
490227|NCT00475306|Drug|Placebo|placebo
490228|NCT00475306|Drug|Metoclopramide 20 mg|Metoclopramide 20 mg
490229|NCT00475293|Drug|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg~Irinotecan: 350 or 300 mg/m2. day 1~One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
490230|NCT00475280|Procedure|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
490231|NCT00475280|Procedure|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
490232|NCT00475267|Device|Trifecta aortic heart valve|Intended as a replacement for a diseased, damaged, or malfunctioning aortic heart valve.
490233|NCT00475241|Behavioral|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
490234|NCT00475241|Behavioral|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
490235|NCT00475228|Drug|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
490236|NCT00475215|Drug|Sugammadex|Sugammadex solution for injection.
490237|NCT00475215|Drug|Rocuronium|Rocuronium bromide solution for injection.
490238|NCT00475189|Drug|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
490239|NCT00475189|Drug|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
490240|NCT00475176|Drug|Peginterferon alfa-2a|
490241|NCT00475176|Drug|Ribavirin|
490242|NCT00475176|Drug|S-adenosyl methionine for Chronic Liver Disease|
490243|NCT00475163|Behavioral|Behavior modification|
490244|NCT00475150|Drug|cediranib maleate|Given orally
490245|NCT00475150|Other|laboratory biomarker analysis|Correlative studies
490246|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
490247|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
490248|NCT00475124|Device|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
490249|NCT00475124|Device|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
490250|NCT00475111|Behavioral|Cognitive Behavior Therapy for Pain (CBT-P)|
490251|NCT00475111|Behavioral|Mindfulness Meditation for Emotion Regulation (MM-ER)|
490252|NCT00475111|Behavioral|Rheumatoid arthritis education|
490253|NCT00475098|Drug|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
490254|NCT00475085|Drug|aprepitant|Given orally or IV
490255|NCT00475085|Drug|dexamethasone|Given orally or IV
490256|NCT00475085|Drug|granisetron hydrochloride|Given orally or IV
490257|NCT00475085|Drug|palonosetron hydrochloride|Given orally or IV
490258|NCT00475085|Drug|prochlorperazine|Given orally or IV
490259|NCT00475085|Drug|placebo|Given orally
490260|NCT00475072|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
490261|NCT00475072|Drug|ribavirin|1000/1200mg po daily for 48 weeks
490262|NCT00475059|Drug|cimetidine arrow|patients who received cimétidine
490263|NCT00475046|Behavioral|Motivational Interviewing|
490264|NCT00475033|Biological|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
490265|NCT00475033|Biological|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
490266|NCT00475020|Drug|Busulfan|Test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days
490267|NCT00475020|Drug|Fludarabine|40 mg/m^2 by vein daily over 1 hour x 4 days
490268|NCT00475020|Drug|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
490269|NCT00475007|Device|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
490270|NCT00474994|Drug|sunitinib malate|
490271|NCT00474981|Behavioral|IMNCI|Implementation of IMNCI in the intervention sites
490272|NCT00474968|Device|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector [SoftPAP(R)]
490273|NCT00474968|Device|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
490274|NCT00474955|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
490275|NCT00474929|Drug|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
490276|NCT00474929|Drug|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
490277|NCT00474916|Drug|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
490278|NCT00474916|Drug|Placebo|Normal Saline given as dose escalation for placebo
490279|NCT00474903|Drug|acetylsalicylic acid|Given orally
490280|NCT00474903|Drug|esomeprazole magnesium|Given orally
490281|NCT00474903|Other|placebo|Given orally
490282|NCT00474890|Drug|cetericine and pseudoephedrine|
490283|NCT00474877|Device|Static resting splints|
490284|NCT00474864|Drug|GW856553|
490285|NCT00474851|Drug|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
490286|NCT00474851|Drug|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
490287|NCT00474838|Drug|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
490288|NCT00474838|Drug|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
490289|NCT00474825|Drug|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
490290|NCT00474825|Drug|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
490291|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
490292|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
490293|NCT00474812|Drug|dasatinib|
490294|NCT00474812|Procedure|laboratory biomarker analysis|Correlative study
490295|NCT00474812|Procedure|physiologic testing|Correlative study
490296|NCT00474799|Drug|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
490297|NCT00474786|Drug|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
490298|NCT00474786|Drug|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
490299|NCT00474773|Drug|Celecoxib|
490300|NCT00474760|Drug|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
490301|NCT00474734|Device|Intravascular ultrasound of the liver|
490302|NCT00474721|Drug|ibuprofen|
490303|NCT00474721|Drug|acetaminophen with codeine|
490304|NCT00474708|Drug|Effexor|
490305|NCT00474708|Drug|SSRI|
490306|NCT00474695|Drug|Lucentis|0.05 mg intravitreal injection
490307|NCT00474682|Drug|Micronized dispersible ferric pyrophosphate|
490308|NCT00474669|Drug|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
490309|NCT00474656|Device|High-frequency oscillation|
490310|NCT00474656|Device|Conventional lung-open mechanical ventilation|
490311|NCT00474630|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
490312|NCT00474630|Drug|Placebo|
490313|NCT00474630|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
490314|NCT00474617|Drug|Sugammadex|
490315|NCT00474617|Drug|Rocurium|intravenous (IV) single bolus dose of 0.6 mg.kg-1
490316|NCT00474604|Procedure|diffusion-weighted magnetic resonance imaging|A scan will be performed.
490317|NCT00474604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
490318|NCT00474604|Procedure|magnetic resonance spectroscopic imaging|A scan will be performed.
490319|NCT00474591|Drug|Fondaparinux|
490320|NCT00474565|Procedure|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
490321|NCT00474552|Drug|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
490322|NCT00474539|Biological|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
490323|NCT00474539|Biological|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
490324|NCT00474526|Biological|Meningococcal ACWY Conjugate Vaccine|
490325|NCT00474526|Biological|DTaP-IPV-HBV|
490326|NCT00474526|Biological|Hib|
490327|NCT00474526|Biological|Rotavirus|
490328|NCT00474526|Biological|Pneumococcal 7-valent Conjugate Vaccine|
490329|NCT00474526|Biological|HAV|
490330|NCT00474526|Biological|MMR-V|
490331|NCT00474526|Biological|DTaP|
490332|NCT00474513|Drug|GSK239512|
490333|NCT00474500|Drug|Coca, Cola, Diet Coke|
490334|NCT00474487|Biological|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
490335|NCT00474487|Biological|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
490336|NCT00474487|Biological|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
490337|NCT00474487|Biological|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
490338|NCT00474474|Procedure|Virtual patient is NOT introduced|
490339|NCT00474461|Biological|Treatment group|Intracoronary injection of cardiac stem cells
490340|NCT00474435|Drug|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):~emtricitabine 200 mg~tenofovir DF 300 mg~efavirenz 600 mg"
490341|NCT00474422|Behavioral|Proactive assignment to attend a breastfeeding clinic|
490342|NCT00474409|Drug|Merislon|
490343|NCT00474396|Behavioral|Low fat dairy diet|
490344|NCT00474383|Drug|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
490345|NCT00474383|Drug|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
490346|NCT00474370|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
490347|NCT00474370|Drug|Placebo|One tablet of placebo once daily.
490348|NCT00474357|Behavioral|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
490349|NCT00474305|Behavioral|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
490350|NCT00474279|Drug|Orally active growth hormone secretagogue (MK-677)|
490351|NCT00474266|Biological|Meningococcal vaccine GSK134612 (Nimenrix)|Single dose intramuscular injection
490352|NCT00474266|Biological|Priorix-Tetra|2-dose subcutaneous injection
490353|NCT00474266|Biological|Meningitec|Single dose intramuscular injection
490354|NCT00474253|Drug|Sugammadex|Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex
490355|NCT00474253|Drug|Succinylcholine|Single bolus IV dose of 1.0 mg/kg succinylcholine
490356|NCT00474253|Drug|Rocuronium|Single bolus IV dose of 1.2 mg/kg rocuronium
490357|NCT00474240|Drug|Atorvastatin 20 mg|
490358|NCT00474240|Drug|AEGR-733 5 mg|
490359|NCT00474240|Drug|AEGR-733 10 mg|
490360|NCT00474240|Drug|Placebo|
490361|NCT00474240|Drug|AEGR-733 5 mg + atorvastatin 20 mg|
490362|NCT00474240|Drug|AEGR-733 10 mg + atorvastatin 20 mg|
490363|NCT00474227|Behavioral|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
490364|NCT00474214|Behavioral|Early hospital discharge facilitated by close nurse practitioner follow-up|
490365|NCT00474201|Drug|Lopinavir/Ritonavir|lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
490366|NCT00474201|Drug|Gemfibrozil|Control arm (no intervention used in this arm)
490367|NCT00474188|Drug|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
490368|NCT00474188|Drug|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
490369|NCT00474175|Drug|Placebo gel|single dose (less than 1g) of a matching placebo gel
490370|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
490486|NCT00473239|Drug|cholecalciferol.|100,000 IU of Vitamin D
490371|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
490372|NCT00474162|Drug|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
490373|NCT00474162|Drug|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
490374|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
490375|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
490376|NCT00474136|Drug|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
490377|NCT00474123|Drug|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
490378|NCT00474123|Drug|Ezetimibe 10 mg / Simvastatin 20 mg|"Ezetimibe 10 mg / Simvastatin 20 mg~Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks"
490379|NCT00474110|Drug|Ketamine & hydromorphone|See Detailed Description
490380|NCT00474084|Device|Intravascular Coronary Stent|
490381|NCT00474071|Drug|Remifentanil|See Detailed Description.
490382|NCT00474058|Drug|Rotigotine|"Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
490383|NCT00474058|Other|Placebo|Placebo transdermal patches
490384|NCT00474045|Drug|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
490385|NCT00474045|Drug|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
490386|NCT00474045|Drug|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
490387|NCT00474032|Drug|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
490388|NCT00474019|Drug|esomeprazole|IV qd for 4 days
490389|NCT00474006|Drug|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
490390|NCT00473980|Drug|Indomethacin, celecoxib, esomeprazole|
490391|NCT00473967|Biological|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
490392|NCT00473954|Genetic|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
490393|NCT00473941|Behavioral|Expressive writing|Quality of life measures through writing
490394|NCT00473928|Drug|POT-4|Single intravitreal injection.
490395|NCT00473915|Drug|fluticasone furoate|corticosteroid nasal spray
490396|NCT00473902|Behavioral|Training|
490397|NCT00473902|Drug|Creatine Monohydrate, Conjugated Linoleic Acid|
490398|NCT00473889|Drug|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
490399|NCT00473889|Drug|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
490400|NCT00473889|Drug|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
490401|NCT00473889|Drug|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
490402|NCT00473876|Drug|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
490403|NCT00473876|Drug|Matched Placebo (Capsules)|Similar dosing regime as active comparator
490404|NCT00473863|Procedure|Coronary Computed Tomographic Angiography|CCTA will be performed
490405|NCT00473837|Drug|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
490406|NCT00473837|Drug|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
490407|NCT00473824|Biological|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, [Civacir]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
490408|NCT00473811|Behavioral|Low GI|low-GI education
490409|NCT00473811|Behavioral|ADA diet|ADA dietary education
490410|NCT00473798|Behavioral|Questionnaire|Questionnaire
490411|NCT00473785|Behavioral|Group-based motivational interviewing|
490412|NCT00473785|Behavioral|Individual CVD-risk factor feedback|
490413|NCT00473785|Behavioral|Education for protective health behavior change|
490414|NCT00473772|Device|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
490415|NCT00473746|Drug|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
490416|NCT00473746|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
490417|NCT00473746|Drug|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
490418|NCT00473733|Procedure|GLP receptors expression|
490419|NCT00473733|Procedure|ESOPHAGOGASTRODUODENOSCOPY|
490420|NCT00473720|Drug|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
490421|NCT00473720|Drug|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
490483|NCT00473317|Behavioral|Sun Exposure|Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
490422|NCT00473707|Procedure|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
490423|NCT00473707|Procedure|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
490424|NCT00473707|Drug|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
490425|NCT00473707|Drug|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
490426|NCT00473694|Drug|sugammadex|Administered as an intravenous (IV) infusion
490427|NCT00473694|Drug|neostigmine|Administered as an IV infusion
490428|NCT00473694|Drug|vecuronium|Administered as an IV infusion
490429|NCT00473694|Drug|rocuronium|Administered as an IV infusion
490430|NCT00473694|Drug|glycopyrrolate|Administered as an IV infusion
490431|NCT00473681|Behavioral|Self-Help Intervention Program-High Blood Pressure|
490432|NCT00473668|Biological|Zilbrix-Hib|Intramuscular injection, 1 dose
490433|NCT00473668|Biological|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
490434|NCT00473655|Drug|rosuvastatin|10mg or 20mg
490435|NCT00473642|Drug|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
490436|NCT00473642|Drug|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
490437|NCT00473642|Drug|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
490438|NCT00473616|Drug|AZD7762|intravenous infusion
490439|NCT00473616|Drug|Irinotecan|intravenous injection
490440|NCT00473603|Drug|lipid/heparin infusion|to perform an i.v. lipid heparin infusion infusion for 4 h
490441|NCT00473590|Drug|Bevacizumab|15 mg/kg administered by intravenous infusion
490442|NCT00473590|Drug|Bortezomib|1.3 mg/m^2 administered by intravenous bolus injection
490443|NCT00473590|Drug|placebo|Intravenous repeating dose
490444|NCT00473577|Drug|CRA-24781|
490445|NCT00473564|Procedure|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
490446|NCT00473551|Drug|Rituximab|375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8.
490447|NCT00473551|Drug|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
490448|NCT00473551|Drug|Fludarabine|40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
490449|NCT00473551|Drug|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
490450|NCT00473551|Radiation|Radiation Treatment|2Gy Total body radiation day before transplantation
490451|NCT00473551|Procedure|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
490452|NCT00473551|Drug|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
490453|NCT00473551|Procedure|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
490454|NCT00473538|Behavioral|Structured exercise training|
490455|NCT00473538|Behavioral|Hypocaloric hyperproteic diet|
490456|NCT00473525|Drug|Placebo|Placebo QD
490457|NCT00473525|Drug|PF-00734200 10 mg QD|10 mg QD
490458|NCT00473525|Drug|PF-00734200 20 mg QD|20 mg QD
490459|NCT00473525|Drug|PF-00734200 5 mg QD|5 mg QD
490460|NCT00473525|Drug|PF-00734200 2 mg QD|2 mg QD
490461|NCT00473512|Drug|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
490462|NCT00473512|Drug|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
490463|NCT00473512|Drug|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
490464|NCT00473499|Device|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
490465|NCT00473486|Drug|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19~Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
490466|NCT00473486|Drug|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
490467|NCT00473473|Drug|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
490468|NCT00473473|Drug|Placebo homeopathic remedy|identical to treatment without active component
490469|NCT00473460|Drug|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
490470|NCT00473460|Drug|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
490471|NCT00473447|Behavioral|Modified Constraint-induced movement therapy|
490472|NCT00473434|Drug|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
490473|NCT00473421|Procedure|Barium Sulphate and Zirconium Oxide|
490474|NCT00473408|Device|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
490475|NCT00473408|Procedure|Blood sample|See protocol.
490476|NCT00473408|Procedure|Tumor sample|See protocol.
490477|NCT00473382|Drug|Ranibizumab|Sterile solution for intravitreal injection.
490478|NCT00473382|Drug|Sham injection|
490479|NCT00473356|Dietary Supplement|receive amino acid supplement|Receive amino acid supplement
490480|NCT00473343|Procedure|Photodynamic therapy with Metvix 160 mg/g cream|
490481|NCT00473330|Drug|Ranibizumab|Sterile solution for intravitreal injection.
490482|NCT00473330|Drug|Sham injection|
490484|NCT00473304|Device|Johnson&Johnson Acuevue daily disposable lenses|
490485|NCT00473265|Drug|PTH|
490488|NCT00473200|Dietary Supplement|S-adenosylmethionine|1200 mg daily
490489|NCT00473187|Drug|somatropin|
490490|NCT00473174|Drug|Ramipril|Dosing on awakening versus bedtime
490491|NCT00473174|Device|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
490492|NCT00473161|Device|surface EMG biofeedback|
490493|NCT00473148|Procedure|BNP-guided weaning|BNP-guided weaning
490494|NCT00473148|Procedure|Standard physician-directed weaning|Standard physician-directed weaning
490495|NCT00473135|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10^3 PFU
490496|NCT00473135|Biological|Placebo|Placebo for rDEN1delta30
490497|NCT00473122|Procedure|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
490498|NCT00473109|Procedure|Dialysis without systemic heparinization|Dialysis without systemic heparinization
490499|NCT00473096|Behavioral|Informed breast cancer surgical treatment|
490500|NCT00473083|Drug|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
490501|NCT00473083|Drug|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.~If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
490502|NCT00473083|Drug|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
490503|NCT00473083|Drug|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
490504|NCT00473070|Drug|Tobradex AF|
490505|NCT00473057|Other|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
490506|NCT00473044|Behavioral|Sisters in Motion|
490507|NCT00473031|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
490508|NCT00473031|Behavioral|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
490509|NCT00473031|Behavioral|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
490510|NCT00473018|Behavioral|standard versus enhanced risk reduction counseling|
490511|NCT00473005|Drug|Capecitabine|825 mg/m2 bid, Oral
490512|NCT00473005|Drug|RAD001|2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral
490513|NCT00472966|Drug|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
490514|NCT00472953|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
490515|NCT00472953|Drug|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
490516|NCT00472927|Drug|Premarin/MPA 0.45 mg/1.5 mg|
490517|NCT00472914|Device|portable surface electromyography|
490518|NCT00472901|Drug|Afamelanotide (CUV1647)|16mg implant
490519|NCT00472875|Drug|Glibenclamide|
490520|NCT00472862|Behavioral|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
490521|NCT00472849|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
490522|NCT00472849|Drug|Fludarabine|Fludarabine 30 mg/m^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
490523|NCT00472849|Drug|Cytarabine|Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
490524|NCT00472849|Drug|Rituximab|Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).
490525|NCT00472849|Drug|Pegfilgrastim|6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
490526|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
490527|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
490528|NCT00472823|Dietary Supplement|Vitamin D3|Orally for one year
490529|NCT00472823|Dietary Supplement|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
490530|NCT00472810|Device|ologen collagen matrix in glaucoma filtering surgery|If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
490531|NCT00472810|Drug|MMC in glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
490532|NCT00472797|Drug|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
490533|NCT00472797|Drug|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
490534|NCT00472771|Drug|INNO-206|
490535|NCT00472758|Biological|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
490536|NCT00472758|Other|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
490633|NCT00471783|Procedure|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
490537|NCT00472745|Behavioral|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
490538|NCT00472745|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 months
490539|NCT00472719|Biological|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
490540|NCT00472719|Biological|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
490541|NCT00472719|Biological|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
490542|NCT00472706|Procedure|excision|excision 3 mm margin
490543|NCT00472706|Procedure|Photodynamic therapy|Photodynamic therapy
490544|NCT00472693|Drug|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
490545|NCT00472680|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
490546|NCT00472680|Behavioral|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
490547|NCT00472680|Behavioral|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
490548|NCT00472667|Procedure|Procalcitonin guided strategy|Procalcitonin guided strategy
490549|NCT00472654|Behavioral|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
490550|NCT00472654|Dietary Supplement|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
490551|NCT00472654|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 weeks
490552|NCT00472641|Drug|Ziprasidone/Geodon|Ziprasidone/Geodon
490553|NCT00472628|Procedure|Blood samples collected|
490554|NCT00472576|Drug|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
490555|NCT00472576|Drug|Placebo|Daily double-blind administration of placebo
490556|NCT00472563|Drug|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
490557|NCT00472550|Drug|esomeprazole 20 mg|
490558|NCT00472537|Procedure|Retromuscular Mesh repair of midline incisional hernia|
490559|NCT00472537|Procedure|Laparoscopic repair of midline incisional hernia|
490560|NCT00472524|Procedure|Mydriasis/cycloplegia via different modes of administration|
490561|NCT00472485|Procedure|eye movement therapy|
490562|NCT00472472|Device|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
490563|NCT00472459|Procedure|Photodynamic therapy with Metvix 160 mg/g cream|
490564|NCT00472446|Drug|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
490565|NCT00472446|Drug|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.~Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
490566|NCT00472433|Drug|Alemtuzumab|
490567|NCT00472420|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
490568|NCT00472420|Drug|First line chemotherapy|As prescribed
490569|NCT00472381|Drug|Insulin|Insulin
490570|NCT00472368|Drug|LBH589|
490571|NCT00472355|Drug|apomorphine|
490572|NCT00472342|Behavioral|exercise prescription|
490573|NCT00472329|Procedure|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
490574|NCT00472329|Drug|fludarabine|
490575|NCT00472329|Procedure|TBI|
490576|NCT00472316|Behavioral|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
490577|NCT00472303|Drug|Tapentadol Extended Release|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
490578|NCT00472303|Drug|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
490579|NCT00472303|Drug|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
490580|NCT00472290|Drug|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.~Except for:~Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.~Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
490581|NCT00472264|Procedure|PET imaging|Medical imaging assessment
490582|NCT00472238|Behavioral|endurance training|control group.
490583|NCT00472238|Behavioral|exercise training|Treadmill exercise training to optimize physical endurance
490584|NCT00472225|Drug|Rituximab|"Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks~Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months"
490585|NCT00472212|Device|Spectacles|Hyperopic spectacle lenses
490586|NCT00472212|Device|Control|Plano (no power, control) spectacle lenses
490587|NCT00472199|Drug|Pramipexole|
490588|NCT00472199|Drug|Placebo|
490634|NCT00471744|Drug|Treatment with levetiracetam or sulthiame over a six-month period.|
490589|NCT00472186|Drug|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
490590|NCT00472186|Drug|Placebo|Placebo will also be administered based on weight.
490591|NCT00472173|Drug|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
490592|NCT00472173|Drug|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
490593|NCT00472160|Procedure|Non Invasive Ventilation|Non Invasive Ventilation
490594|NCT00472147|Procedure|shock efficacy|
490595|NCT00472134|Drug|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
490596|NCT00472134|Device|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
490597|NCT00472121|Device|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
490598|NCT00472108|Procedure|PDT with Metvix 160 mg/g cream|
490599|NCT00472108|Procedure|PDT with placebo cream|
490600|NCT00472095|Procedure|fotonovela|
490601|NCT00472082|Drug|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
490602|NCT00472069|Procedure|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
490603|NCT00472056|Drug|Carmustine|300 mg/m^2 IV for 1 Day
490604|NCT00472056|Drug|Etoposide|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
490605|NCT00472056|Drug|Cytarabine|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
490606|NCT00472056|Drug|Melphalan|140 mg/m^2 IV x 1 Day
490607|NCT00472056|Drug|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion.
490608|NCT00472043|Procedure|PDT with Metvix 160 mg/g cream and Placebo cream|
490609|NCT00472030|Drug|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
490610|NCT00472030|Drug|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
490611|NCT00472017|Drug|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
490612|NCT00472004|Drug|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
490613|NCT00472004|Drug|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
490614|NCT00471991|Drug|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
490615|NCT00471991|Drug|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
490616|NCT00471965|Drug|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks"
490617|NCT00471965|Drug|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
490618|NCT00471952|Drug|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
490619|NCT00471952|Drug|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
490620|NCT00471952|Drug|Placebo + Placebo|One migraine attack will be treated with double placebo
490621|NCT00471939|Drug|I-020502|1 mcg/mL TG-PDGF.AB
490622|NCT00471913|Device|Femoral Nailing with Different Entry Points|See Detailed Description.
490623|NCT00471900|Drug|dehydroepiandrosterone (DHEA)|
490624|NCT00471887|Biological|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
490625|NCT00471848|Drug|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
490626|NCT00471835|Procedure|computed tomography|
490627|NCT00471835|Procedure|positron emission tomography|
490628|NCT00471835|Radiation|stereotactic body radiation therapy|
490629|NCT00471809|Drug|Budesonide + Salmeterol + Azithromycin|
490630|NCT00471809|Drug|Budesonide + Salmeterol + Montelukast|
490631|NCT00471809|Drug|Budesonide + Salmeterol + Placebo|
490632|NCT00471796|Behavioral|Biofeedback|
490635|NCT00471718|Drug|ABT-751|"Phase I:~Cohort | Number of Patients |Dose (mg) ABT-751 (BID)~-1 | 3-6 |100 mg BID~1 | 3-6 |125 mg BID~2 | 3-6 |150 mg BID~3 | 3-6 |175 mg BID~4 | 3-6 |200 mg BID~Phase II:~Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle"
490636|NCT00471705|Drug|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
490637|NCT00471705|Device|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
490638|NCT00471705|Drug|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
490639|NCT00471692|Drug|Ropivicaine|
490640|NCT00471679|Drug|ethanol|
490641|NCT00471653|Drug|temozolomide|
490642|NCT00471653|Genetic|comparative genomic hybridization|
490643|NCT00471653|Genetic|polymorphism analysis|
490644|NCT00471653|Other|laboratory biomarker analysis|
490645|NCT00471653|Other|pharmacological study|
490646|NCT00471653|Radiation|radiation therapy|
490647|NCT00471640|Drug|dexamethasone|4 days 5 mg
490648|NCT00471627|Procedure|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
490649|NCT00471614|Drug|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
490650|NCT00471601|Behavioral|counseling intervention|
490651|NCT00471601|Behavioral|questionnaire administration|
490652|NCT00471601|Behavioral|psychosocial assessment and care|
490653|NCT00471601|Behavioral|quality-of-life assessment|
490654|NCT00471588|Drug|Pramipexole, Amisulpride|Study Drug
490655|NCT00471575|Procedure|ultra sound examination|
490656|NCT00471562|Biological|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
490657|NCT00471549|Drug|Statin (simvastatin)|
490658|NCT00471536|Drug|pazopanib hydrochloride|800 mg Given orally
490659|NCT00471523|Drug|Clomiphene citrate|
490660|NCT00471523|Drug|Metformin|
490661|NCT00471510|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
490662|NCT00471497|Drug|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
490663|NCT00471497|Drug|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
490664|NCT00471484|Biological|recombinant interferon alfa-2b|
490665|NCT00471484|Drug|doxorubicin hydrochloride|
490666|NCT00471484|Drug|fluorouracil|
490667|NCT00471484|Drug|oxaliplatin|
490668|NCT00471484|Other|diagnostic laboratory biomarker analysis|
490669|NCT00471484|Other|immunoenzyme technique|
490670|NCT00471484|Other|immunohistochemistry staining method|
490671|NCT00471484|Procedure|adjuvant therapy|
490672|NCT00471484|Procedure|biopsy|
490673|NCT00471484|Procedure|neoadjuvant therapy|
490674|NCT00471484|Procedure|therapeutic conventional surgery|
490675|NCT00471471|Biological|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
490676|NCT00471471|Biological|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
490677|NCT00471471|Biological|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
490678|NCT00471445|Drug|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
490679|NCT00471445|Other|placebo|Applied topically
490680|NCT00471432|Drug|custirsen sodium|
490681|NCT00471432|Drug|docetaxel|
490682|NCT00471432|Other|pharmacological study|
490683|NCT00471419|Drug|Rimexolone|
490684|NCT00471406|Procedure|Photodynamic Therapy with Verteporfin|
490685|NCT00471393|Drug|1.5% diclofenac in 45.5% DMSO (topical treatment)|
490686|NCT00471393|Drug|45.5% DMSO (topical placebo)|
490687|NCT00471380|Drug|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
490688|NCT00471380|Drug|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
490689|NCT00471367|Drug|AZD4877|intravenous infusion administered twice a week for 2 weeks
490690|NCT00471354|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
490691|NCT00471341|Drug|Celecoxib|
490692|NCT00471341|Drug|placebo|
490693|NCT00471328|Drug|Nilotinib|Nilotinib 400 mg twice daily (bid)
490694|NCT00471328|Other|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
490695|NCT00471315|Drug|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
490696|NCT00471289|Device|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
490698|NCT00471276|Drug|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
490699|NCT00471263|Drug|Casigold|
490700|NCT00471263|Drug|Casimax|
490701|NCT00471263|Drug|Placebo|
490702|NCT00471237|Drug|Ronacaleret|100mg, 200mg, 300mg, 400mg
490703|NCT00471237|Drug|Teriparatide|PTH (1-34)
490704|NCT00471237|Drug|Alendronate|Bisphosphonate
490705|NCT00471224|Other|Observational Trial|No intervention is being used in this study.
490706|NCT00471211|Drug|PBT2|
490707|NCT00471185|Drug|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
490708|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
490709|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (monthly)|
490710|NCT00471172|Behavioral|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
490711|NCT00471172|Behavioral|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
490712|NCT00471172|Behavioral|Self help|
490713|NCT00471159|Drug|docetaxel|
490714|NCT00471159|Drug|PF-3512676|
490715|NCT00471146|Drug|AG-013736|oral administration, starting dose 5 mg twice daily [BID] every day until unacceptable toxicity or tumor progression.
490716|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
490717|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
490718|NCT00471146|Drug|placebo|placebo
490719|NCT00471133|Biological|Xenogeneic Tyrosinase DNA Vaccine|
490720|NCT00471133|Device|TriGrid Delivery System for Intramuscular Electroporation|
490721|NCT00471120|Other|P2x7 assay|compare P2X7 assay to biopsy
490722|NCT00471107|Device|DC brain polarization|0.08 mA/cm2
490723|NCT00471094|Drug|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
490724|NCT00471094|Drug|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
490725|NCT00471094|Drug|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
490726|NCT00471094|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
490727|NCT00471081|Biological|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
490728|NCT00471068|Drug|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
490729|NCT00471068|Drug|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
490730|NCT00471068|Drug|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
490731|NCT00471055|Drug|"0.0125% Capsaicin gel CAPSIKA gel"|
490732|NCT00471055|Drug|Placebo|Placebo
490733|NCT00471042|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
490734|NCT00471029|Drug|esomeprazole|
490735|NCT00471016|Behavioral|Guided intervention|
490736|NCT00471003|Drug|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
490737|NCT00470990|Drug|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
490738|NCT00470977|Drug|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
490739|NCT00470964|Procedure|Titanium Sapphire laser trabeculoplasty|
490740|NCT00470951|Procedure|open rectal resection|open rectal resection
490741|NCT00470951|Procedure|laparoscopic rectal resection|laparoscopic assisted rectal resection
490742|NCT00470938|Device|SpineForce Reactive Neuromuscular Trainer|
490743|NCT00470925|Drug|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
490744|NCT00470912|Drug|sunscreen RV 2547C|
490745|NCT00470899|Procedure|drainage of placenta of fetal blood|
490746|NCT00470886|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
490747|NCT00470873|Drug|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
490748|NCT00470860|Behavioral|Participation in LOFTS online tutorial|
490749|NCT00470847|Drug|Lapatinib|Orally twice daily
490750|NCT00470847|Procedure|Whole Brain Radiation|15 treatments over a period of 3 weeks
490751|NCT00470847|Drug|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
490752|NCT00470834|Drug|dutasteride|0.5mg dutasteride (Investigation Product)
490753|NCT00470834|Drug|placebo|making placebo
490754|NCT00470834|Drug|bicalutamide|50 mg Casodex or generic equivalent
490755|NCT00470821|Drug|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
490756|NCT00470821|Drug|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
490757|NCT00470808|Drug|POMx|
490816|NCT00470353|Other|immunohistochemistry staining method|
490817|NCT00470353|Other|laboratory biomarker analysis|
490758|NCT00470795|Other|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
490759|NCT00470795|Procedure|placebo/sham acupuncture|acupuncture at sham points without skin penetration
490760|NCT00470769|Procedure|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
490761|NCT00470756|Other|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
490762|NCT00470743|Drug|Ibuprofen|
490763|NCT00470743|Drug|Indomethacin|
490764|NCT00470717|Procedure|Weekly telephone call|Details of feeding and health/sickness will be obtained
490765|NCT00470704|Drug|Lapatinib|Oral dose taken daily
490766|NCT00470704|Drug|Herceptin|Given intravenously once a week or once every 3 weeks
490767|NCT00470691|Procedure|plaster cast|complete circular plaster cast
490768|NCT00470691|Procedure|dorsal splint|dorsal plaster splint
490769|NCT00470678|Drug|ranibizumab|
490770|NCT00470665|Drug|Rapamune|
490771|NCT00470652|Device|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was >4/10. After a 10-day test period, the post-intervention data collection started.
490772|NCT00470639|Device|Transcranial Magnetic Stimulation|
490773|NCT00470626|Device|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
490774|NCT00470613|Genetic|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
490775|NCT00470600|Drug|Caldolor|800 milligrams intravenous
490776|NCT00470600|Other|Normal Saline|Placebo comparator
490777|NCT00470574|Biological|QS21|
490778|NCT00470574|Biological|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
490779|NCT00470574|Other|immunoenzyme technique|
490780|NCT00470574|Other|immunologic technique|
490781|NCT00470574|Other|laboratory biomarker analysis|
490782|NCT00470561|Drug|Aspirin|Two 325 mg doses of aspirin per day for 6 months
490783|NCT00470561|Drug|Placebo|Two placebo pills per day for 6 months
490784|NCT00470548|Drug|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
490785|NCT00470548|Drug|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
490786|NCT00470535|Drug|erlotinib hydrochloride|Oral
490787|NCT00470535|Other|immunohistochemistry staining method|Correlative Study
490788|NCT00470535|Other|laboratory biomarker analysis|Correlative Study
490789|NCT00470522|Drug|Methotrexate and folic acid|
490790|NCT00470509|Drug|Adalimumab|2 subcutaneous injections on day 0 and 7
490791|NCT00470509|Drug|Placebos|2 subcutaneous injections on day 0 and 7
490792|NCT00470496|Drug|HPPH|Given IV
490793|NCT00470496|Drug|photodynamic therapy|Undergo laser light exposure
490794|NCT00470496|Procedure|conventional surgery|Undergo surgery
490795|NCT00470483|Drug|Placebo treatment during 8 weeks|comparator
490796|NCT00470483|Drug|Paroxetine treatment during 8 weeks|treatment drug
490797|NCT00470470|Drug|imatinib mesylate|Given orally
490798|NCT00470470|Other|laboratory biomarker analysis|Correlative studies
490799|NCT00470457|Biological|Allergen specific immunotherapy|
490800|NCT00470444|Procedure|Transfusion with Red Blood Cells|Units of donated Red blood cells
490801|NCT00470444|Biological|1 unit of donated red blood cells|Units of red blood cells
490802|NCT00470444|Biological|1 unit of donated red blood cells|Units of donated red blood cells
490803|NCT00470418|Drug|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
490804|NCT00470418|Drug|Placebo|placebo comparator
490805|NCT00470405|Drug|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
490806|NCT00470405|Drug|pemetrexed disodium|a novel antifolate with multiple targets.
490807|NCT00470392|Drug|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
490808|NCT00470392|Drug|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
490809|NCT00470379|Drug|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
490810|NCT00470366|Biological|pegfilgrastim|
490811|NCT00470366|Drug|cisplatin|
490812|NCT00470366|Drug|ifosfamide|
490813|NCT00470366|Drug|paclitaxel|
490814|NCT00470353|Dietary Supplement|calcium carbonate|
490815|NCT00470353|Dietary Supplement|cholecalciferol|
490818|NCT00470353|Other|pharmacological study|
490819|NCT00470353|Procedure|biopsy|
490820|NCT00470340|Drug|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
490821|NCT00470314|Drug|L-Ornithine L-Aspartate|
490822|NCT00470301|Drug|tipifarnib|Given orally
490823|NCT00470301|Drug|paclitaxel|Given IV
490824|NCT00470301|Drug|doxorubicin|Given IV
490825|NCT00470301|Drug|cyclophosphamide|Given IV
490826|NCT00470288|Procedure|bladder flap during cesarean section|
490827|NCT00470275|Drug|cytarabine|Given IV
490828|NCT00470262|Drug|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
490829|NCT00470262|Drug|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
490830|NCT00470249|Drug|carboplatin|
490831|NCT00470249|Drug|gemcitabine hydrochloride|
490832|NCT00470236|Radiation|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
490833|NCT00470236|Radiation|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
490834|NCT00470236|Radiation|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
490835|NCT00470236|Radiation|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).~Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
490836|NCT00470223|Drug|cisplatin|
490837|NCT00470223|Drug|doxorubicin hydrochloride|
490838|NCT00470223|Drug|etoposide|
490839|NCT00470223|Drug|ifosfamide|
490840|NCT00470223|Drug|methotrexate|
490841|NCT00470223|Drug|zoledronic acid|
490842|NCT00470223|Procedure|conventional surgery|
490843|NCT00470210|Drug|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
490844|NCT00470210|Drug|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
490845|NCT00470210|Drug|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
490846|NCT00470197|Drug|alvocidib|Given IV
490847|NCT00470197|Drug|cytarabine|Given IV
490848|NCT00470197|Drug|mitoxantrone hydrochloride|Given IV
490849|NCT00470197|Other|pharmacological study|Correlative study
490850|NCT00470184|Drug|capecitabine|Oral
490851|NCT00470184|Drug|oxaliplatin|IV
490852|NCT00470184|Genetic|gene expression analysis|Correlative Study
490853|NCT00470184|Genetic|microarray analysis|Correlative Study
490854|NCT00470184|Genetic|reverse transcriptase-polymerase chain reaction|Correlative Study
490855|NCT00470184|Procedure|adjuvant therapy|Metastatic growth control
490856|NCT00470184|Procedure|biopsy|Examination of tissue type
490857|NCT00470184|Procedure|conventional surgery|Tissue removal
490858|NCT00470184|Procedure|neoadjuvant therapy|Tumor shrinkage
490859|NCT00470184|Procedure|quality-of-life assessment|Correlative Study
490860|NCT00470184|Radiation|radiation therapy|Undergoing radiation therapy
490861|NCT00470171|Drug|Ursodesoxycholic acid|
490862|NCT00470158|Dietary Supplement|iron and zinc combined|Children >= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
490863|NCT00470158|Dietary Supplement|iron and zinc on separate days|Children >= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
490864|NCT00470158|Dietary Supplement|iron|Children >= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
490865|NCT00470158|Dietary Supplement|Zinc|Children >= 12 months received an average of 5mg zinc/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
490866|NCT00470158|Dietary Supplement|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
490867|NCT00470145|Drug|SB-568859|
490868|NCT00470119|Behavioral|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
490869|NCT00470119|Behavioral|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
490870|NCT00470106|Behavioral|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
490871|NCT00470106|Behavioral|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
490872|NCT00470106|Behavioral|hybrid intervention|A combination of the two groups listed above.
490873|NCT00470106|Behavioral|skills training|Skills training in how to identify symptoms of illness and medication side effects.
490874|NCT00470093|Biological|recombinant interferon-α|
490875|NCT00470093|Biological|recombinant interleukin-6|
490876|NCT00470080|Procedure|venepuncture|venepuncture
490877|NCT00470067|Drug|carboplatin|IV
490878|NCT00470067|Drug|pegylated liposomal doxorubicin hydrochloride|IV
490879|NCT00470054|Drug|dasatinib|Given PO
490880|NCT00470041|Drug|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
490881|NCT00470028|Device|Transcranial Magnetic Stimulation|
490882|NCT00470015|Biological|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
490883|NCT00470015|Biological|IL-2|0.5x10^6/m^2
490884|NCT00470015|Biological|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
490885|NCT00470015|Biological|GM-CSF|300mcg
490886|NCT00470015|Biological|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
490887|NCT00470002|Drug|Somatropin|
490888|NCT00469989|Procedure|Infection with hookworm larvae|
490889|NCT00469976|Drug|bevacizumab|
490890|NCT00469976|Drug|carboplatin|
490891|NCT00469976|Drug|enzastaurin hydrochloride|
490892|NCT00469976|Drug|gemcitabine hydrochloride|
490893|NCT00469963|Procedure|quality-of-life assessment|quality-of-life assessment
490894|NCT00469963|Radiation|yttrium Y 90 resin microspheres|radiation therapy
490895|NCT00469950|Behavioral|exercise training|Exercise training in groups
490896|NCT00469937|Drug|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
490897|NCT00469937|Procedure|cognitive assessment|cognitive assessment
490898|NCT00469937|Procedure|quality-of-life assessment|quality-of-life assessment
490899|NCT00469937|Radiation|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
490900|NCT00469924|Procedure|Real Time Clinical Alerting|
490901|NCT00469911|Procedure|Magnetic Resonance Spectroscopy|Magnetic Resonance Spectroscopy is a noninvasive procedure that provides detailed body images on any plane.
490902|NCT00469911|Procedure|Ex vivo heart biopsy|Heart transplant patients will have their normal clinical routine heart biopsy
490903|NCT00469898|Drug|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:~Carboplatin (mg) = (AUC of 5) x (GFR + 25)~*up to 6 cycles at physician's discretion"
490904|NCT00469898|Drug|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days~Should be infused IV over 30- 90 minutes."
490905|NCT00469885|Drug|Nicotine replacement|For reduction
490906|NCT00469885|Behavioral|Motivational counseling|No drugs
490907|NCT00469872|Procedure|Context-focused compared to child-focused interventions|
490908|NCT00469859|Drug|cytarabine|given IV
490909|NCT00469859|Drug|idarubicin|Given IV
490910|NCT00469859|Drug|lestaurtinib|Given orally
490911|NCT00469846|Procedure|L-arginine supplementation in a medical food|
490912|NCT00469846|Procedure|Vitamin C and E supplementation in a medical food|
490913|NCT00469833|Drug|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
490914|NCT00469820|Biological|autologous tumor cell vaccine|
490915|NCT00469820|Biological|peripheral blood lymphocyte therapy|
490916|NCT00469794|Procedure|stress test|
490917|NCT00469781|Drug|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
490918|NCT00469781|Drug|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.~Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
490919|NCT00469768|Drug|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
490920|NCT00469768|Drug|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
490921|NCT00469768|Other|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
490922|NCT00469755|Drug|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
490923|NCT00469755|Drug|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
490924|NCT00469755|Drug|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
490925|NCT00469729|Drug|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
490926|NCT00469716|Drug|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
490927|NCT00469703|Drug|Thalidomide|
490928|NCT00469690|Drug|Acular, Xibrom|"Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)~Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)"
490929|NCT00469664|Drug|Guanfacine/Tenex|
490930|NCT00469651|Biological|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
490931|NCT00469651|Biological|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
490932|NCT00469651|Biological|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
490933|NCT00469651|Biological|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
490934|NCT00469651|Biological|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
491147|NCT00468000|Biological|Ixmyelocel-T|IM injection
490935|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
490936|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
490937|NCT00469625|Drug|paricalcitol (initial dose 1 mcg orally per day)|
490938|NCT00469612|Device|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).~The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
490939|NCT00469599|Drug|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
490940|NCT00469599|Drug|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
490941|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
490942|NCT00469586|Drug|metformin|Tablets, 2000 mg/day.
490943|NCT00469586|Drug|glimepiride|Tablets, 4 mg/day.
490944|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
490945|NCT00469573|Drug|1. Optive|Optive 15ml- (in the eye) Instill one drop twice daily in each eye
490946|NCT00469560|Drug|Deferasirox|
490947|NCT00469547|Other|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
490948|NCT00469547|Drug|Placebo|15% ethanol in emollient gel used as a topical male microbicide
490949|NCT00469547|Other|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
490950|NCT00469534|Procedure|IMRT|
490951|NCT00469521|Drug|Refresh Tears, 9582X|
490952|NCT00469508|Drug|Modafinil|400mg pills taken orally daily for 12 wks.
490953|NCT00469508|Drug|Placebo|400mg pills taken orally daily for 12 wks
490954|NCT00469495|Drug|Anti-helminthic|
490955|NCT00469495|Drug|meglumine antimony|
490956|NCT00469482|Other|Sedation,RASS Targeted plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
490957|NCT00469482|Other|Sedation, RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
490958|NCT00469469|Drug|Bevacizumab|
490959|NCT00469456|Drug|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
490960|NCT00469456|Drug|placebo|Placebo oral administration twice daily for 12 weeks
490961|NCT00469443|Drug|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
490962|NCT00469443|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
490963|NCT00469443|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
490964|NCT00469443|Drug|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
490965|NCT00469443|Drug|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
490966|NCT00469443|Drug|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
490967|NCT00469443|Drug|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
490968|NCT00469430|Drug|cefotaxim and metronidazol|iv administration for at least 24 h
490969|NCT00469417|Procedure|Cryotherapy or Photodynamic therapy with methyl aminolevulinate cream|
490970|NCT00469404|Drug|Buprenorphine|
490971|NCT00469391|Device|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
490972|NCT00469391|Procedure|Sham Procedure|Weight loss
490973|NCT00469378|Drug|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
490974|NCT00469365|Behavioral|pharmacist contact with the patient via telephone|
490975|NCT00469365|Behavioral|Pharmacist contact with the patient's physician via fax|
490976|NCT00469365|Behavioral|Usual care|
490977|NCT00469352|Drug|Ranibizumab|Ranibizumab as needed
490978|NCT00469326|Drug|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
490979|NCT00469300|Drug|Iontophoretic delivery of acyclovir|
490980|NCT00469274|Drug|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
490981|NCT00469274|Drug|Antibiotic PEP|TMP-SMX DS po BID for 14 days
490982|NCT00469261|Drug|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
490983|NCT00469261|Drug|Current medical therapy for AMI|Current medical therapy for AMI
490984|NCT00469248|Device|Intra-aortic balloon pump counterpulsation|
490985|NCT00469235|Drug|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.~10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
490986|NCT00469222|Procedure|hypofractionated external beam|
490987|NCT00469209|Drug|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
490988|NCT00469209|Drug|Velcade (Bortezomib)|"Arm 1 (Level 1):~1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).~Arm 2 (Level 2):~1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
515476|NCT00277823|Drug|Placebo|
490989|NCT00469209|Drug|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
490990|NCT00469209|Drug|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
490991|NCT00469196|Procedure|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
490992|NCT00469183|Drug|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
490993|NCT00469170|Device|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
490994|NCT00469157|Drug|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
490995|NCT00469144|Drug|Busulfan|"Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
490996|NCT00469144|Drug|Fludarabine|40 mg/m^2 IV Daily Over 1 Hour x 4 Days
490997|NCT00469131|Drug|tacrolimus + steroid|
490998|NCT00469131|Drug|tacrolimus + mycophenolate mofetil|
490999|NCT00469118|Device|DRX9000™|Nonsurgical spinal decompression
491000|NCT00469105|Behavioral|Literacy/Numeracy oriented educational intervention|Receives comprehensive literacy/num sensitive diabetes care
491001|NCT00469105|Behavioral|Control Group|Receives standard diabetes disease management
491002|NCT00469092|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
491003|NCT00469092|Drug|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
491004|NCT00469092|Drug|metformin|Tablets, 2550 mcg. Administered once daily.
491005|NCT00469092|Drug|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
491006|NCT00469079|Drug|Nicotine gum and lozenge|Nicotine replacement
491007|NCT00469079|Other|Taboka|smokeless tobacco product
491008|NCT00469079|Other|Camel Snus|smokeless tobacco product
491009|NCT00469053|Drug|Buprenorphine|
491010|NCT00469040|Drug|GW642444M for 14 days|M salt
491011|NCT00469027|Biological|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
491012|NCT00469014|Drug|Clofarabine|Arm 1 = 10 mg/m^2 intavenous (IV) Daily; Arm 2 = 20 mg/m^2 IV Daily; Arm 3 = 30 mg/m^2 IV Daily; Arm 4 = 40 mg/m^2 IV Daily
491013|NCT00469014|Drug|Busulfan|Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily; Arm 4: 40 mg/m^2 IV Daily
491014|NCT00469014|Drug|Fludarabine|Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily
491015|NCT00469001|Procedure|Treatment according NT Pro BNP level|
491016|NCT00468988|Drug|Travatan® Z|
491017|NCT00468988|Drug|Xalatan®|
491018|NCT00468975|Drug|PF-610,355|
491019|NCT00468975|Drug|Salmeterol|
491020|NCT00468962|Drug|FACOS (functional food)|
491021|NCT00468936|Drug|Myfortic|enteric coated Cellcept pills in applicable dose for patient
491022|NCT00468923|Drug|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
491023|NCT00468923|Drug|Rosuvastatin|Rosuvastatin 10 mg once daily
491024|NCT00468910|Drug|acetylsalicylic acid|Given orally
491025|NCT00468910|Drug|placebo|Given orally
491026|NCT00468910|Other|laboratory biomarker analysis|Correlative study
491027|NCT00468897|Drug|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
491028|NCT00468884|Drug|Increasing doses of GLP-1|
491029|NCT00468884|Drug|PYY3-36|
491030|NCT00468871|Drug|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
491031|NCT00468871|Drug|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
491032|NCT00468858|Other|Placebo|"Lyophilized, single dose vials and sterile water for~> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
491033|NCT00468858|Biological|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
491034|NCT00468858|Biological|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
491035|NCT00468845|Drug|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
491036|NCT00468845|Drug|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
491037|NCT00468845|Drug|matched placebo|matched placebo
491038|NCT00468819|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
491039|NCT00468806|Drug|GSK598809, using [11C]-(+)-PHNO|
491040|NCT00468793|Procedure|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
491041|NCT00468767|Drug|Vernakalant Injection 20 mg/mL|
491042|NCT00468754|Device|Insulin pumps|
491043|NCT00468741|Behavioral|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
491044|NCT00468741|Behavioral|CHESS|informational services of CHESS available to subject
491045|NCT00468741|Behavioral|CHESS|CHESS informational services and social support available to subject
491046|NCT00468728|Drug|PAR-101/OPT-80|capsules
491047|NCT00468728|Drug|Vancomycin|Capsules
491048|NCT00468715|Drug|bicalutamide|
491049|NCT00468715|Other|diagnostic laboratory biomarker analysis|
491050|NCT00468715|Other|immunohistochemistry staining method|
491051|NCT00468702|Device|CoaguChek S|
491052|NCT00468689|Drug|SB-751689 oral tablets (100 and 400 ng)|
491053|NCT00468689|Drug|Ketoconazole (NIZORAL) oral tablets (200 mg)|
491145|NCT00468013|Behavioral|Resilience Building Exercises|Weekly exercises for 6 weeks
491054|NCT00468676|Behavioral|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
491055|NCT00468676|Behavioral|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
491056|NCT00468650|Drug|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
491057|NCT00468624|Drug|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
491058|NCT00468624|Procedure|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
491059|NCT00468624|Procedure|blood sampling before and after pegvisomant/placebo|
491060|NCT00468624|Procedure|arginine stimulation test after each limb|
491061|NCT00468611|Drug|MBP8298|500mg MBP8298 IV every six months for a period of two years
491062|NCT00468585|Drug|Capecitabine|
491063|NCT00468585|Drug|Bevacizumab|
491064|NCT00468572|Behavioral|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
491065|NCT00468572|Behavioral|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
491066|NCT00468559|Drug|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
491067|NCT00468559|Drug|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
491068|NCT00468559|Drug|Double Blind Placebo|Double Blind Placebo
491069|NCT00468546|Drug|MabThera/Rituxan|1
491070|NCT00468546|Drug|Methotrexate|2
491071|NCT00468546|Other|Placebo|3
491072|NCT00468533|Drug|Aripiprazole|
491073|NCT00468520|Drug|low dose oxytocin|
491074|NCT00468507|Dietary Supplement|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
491075|NCT00468481|Drug|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
491076|NCT00468481|Drug|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
491077|NCT00468468|Behavioral|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
491078|NCT00468455|Procedure|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
491079|NCT00468442|Biological|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
491080|NCT00468442|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
491081|NCT00468442|Biological|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
491082|NCT00468442|Biological|Rituximab|Depletes transient B-cells
491083|NCT00468442|Drug|Sirolimus|Maintenance immunosuppressive therapy
491084|NCT00468429|Drug|Subconjunctival Bevacizumab|
491085|NCT00468416|Device|Compression Anastomosis Ring (CAR)|
491086|NCT00468403|Biological|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
491087|NCT00468403|Biological|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
491088|NCT00468403|Biological|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
491089|NCT00468403|Drug|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
491090|NCT00468403|Drug|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
491146|NCT00468013|Behavioral|Journaling|Weekly exercises for 6 weeks
491091|NCT00468403|Procedure|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant[s]) will occur intraportally.
491092|NCT00468364|Drug|insulin glargine|
491093|NCT00468364|Drug|NPH insulin|
491094|NCT00468351|Procedure|Intravitreal Injection of 1,5 mg of bevacizumab|
491095|NCT00468351|Procedure|Intravitreal injection of 4 mg of Triamcinolone acetonide|
491096|NCT00468338|Device|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
491097|NCT00468325|Procedure|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
491098|NCT00468325|Procedure|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
491099|NCT00468325|Procedure|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
491100|NCT00468312|Drug|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
491101|NCT00468312|Drug|Placebo|Two sprays in each nostril in the morning
491102|NCT00468299|Drug|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
491103|NCT00468299|Drug|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
491104|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
491105|NCT00468286|Drug|Degarelix|"Experimental~Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
491106|NCT00468273|Drug|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
491107|NCT00468260|Drug|Patupilone|
491108|NCT00468247|Device|Navigator|Navigator circulatory mgt system
491109|NCT00468247|Other|Conventional care|Conventional haemodynamic care
491110|NCT00468234|Drug|nicotine polacrilex|
491111|NCT00468234|Drug|nicotine transdermal system|
491112|NCT00468234|Drug|nicotine inhaler|
491113|NCT00468221|Drug|Ozone Exposure|Low dose ozone exposure in chamber
491114|NCT00468208|Drug|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:~500 mg of abatacept for body weight less than 60 kg~750 mg of abatacept for body weight between 60 and 100 kg~1000 mg of abatacept for body weight greater than 100 kg~Abatacept is administered in a 30-minute intravenous infusion."
491115|NCT00468182|Drug|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
491116|NCT00468169|Drug|Cetuximab|250mg/m2(day 1, weekly x 10);
491117|NCT00468169|Drug|5-FU|600 mg/m2/day; days 0-5 (120 h total) every other week x 5
491118|NCT00468169|Drug|Hydroxyurea|500 mg PO BID, days 0-5 every other week x 5
491119|NCT00468169|Radiation|Twice-daily radiation|150 cGy per fraction, days 1-5, every other week x 5 (total duration 10 weeks)
491120|NCT00468169|Drug|Cisplatin|100 mg/m2, week 1 and 4 on day 1 (or 2)
491121|NCT00468169|Radiation|Accelerated fraction radiotherapy with concomitant boost|72 Gy/42 F/6 W (3-D or IMRT based). Total duration 7 weeks.
491122|NCT00468156|Behavioral|written materials only|related to fruit/vegetable servings/day
491123|NCT00468156|Behavioral|written materials|related to fruit/vegetable servings/day
491124|NCT00468156|Behavioral|telephone support|related to fruit/vegetable servings/day
491125|NCT00468143|Drug|Adderall ® Immediate Release|Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
491126|NCT00468143|Drug|Adderall XR ®|Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
491127|NCT00468130|Drug|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole or placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
491128|NCT00468117|Procedure|Islet transplantation|
491129|NCT00468117|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
491130|NCT00468117|Biological|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
491131|NCT00468117|Biological|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
491132|NCT00468117|Biological|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
491133|NCT00468104|Drug|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
491134|NCT00468104|Drug|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
491135|NCT00468091|Drug|exendin(9-39)amide|
491136|NCT00468091|Drug|atropine|
491137|NCT00468078|Procedure|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
491138|NCT00468078|Drug|F-18 FPCIT|5mCi, intravenous injection
491139|NCT00468065|Device|VeinViewer|Veinveiwer is used to view veins subQ
491140|NCT00468065|Device|Veinviewer|near infrared light reveals veins subcutaneously
491141|NCT00468052|Drug|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
491142|NCT00468052|Drug|fentanyl|1 microgram/kilogram as a bolus
491143|NCT00468039|Drug|vildagliptin + metformin|
491144|NCT00468026|Device|ProstaPlant Stent|
516347|NCT00270933|Device|Registry|
491148|NCT00468000|Biological|Placebo|IM Injection
491149|NCT00467987|Drug|androgel|androgel 1%
491150|NCT00467987|Drug|placebo|placebo
491151|NCT00467974|Procedure|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
491152|NCT00467974|Procedure|TACE|Transarterial chemoembolisation (TACE)
491153|NCT00467961|Combination Product|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
491154|NCT00467948|Drug|cefazolin|
491155|NCT00467935|Drug|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
491156|NCT00467922|Drug|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
491157|NCT00467922|Drug|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
491158|NCT00467909|Behavioral|micronutrients|
491159|NCT00467896|Drug|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
491160|NCT00467896|Drug|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
491161|NCT00467883|Drug|Liposomal Amphotericin B|high dosage
491162|NCT00467870|Drug|Testosterone Undecanoate 750 mg|
491163|NCT00467870|Drug|Testosterone Undecanoate 1000 mg|
491164|NCT00467857|Procedure|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
491165|NCT00467857|Other|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
491166|NCT00467844|Drug|GTx-024|1 mg GTx 024
491167|NCT00467844|Drug|GTx-024|3 mg GTx-024
491168|NCT00467844|Drug|Placebo|Matching Placebo
491169|NCT00467831|Drug|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
491170|NCT00467831|Drug|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
491171|NCT00467831|Drug|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
491172|NCT00467831|Drug|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
491173|NCT00467831|Drug|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
491174|NCT00467818|Dietary Supplement|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
491175|NCT00467818|Other|Placebo|Smae dosage as that of omega 3 fatty acids
491176|NCT00467805|Procedure|Light therapy|
491177|NCT00467779|Drug|cobimetinib|Repeating oral dose
491178|NCT00467779|Drug|dextromethorphan|In Stage III only: single dose of dextromethorphan
491179|NCT00467779|Drug|midazolam|In Stage III only: single dose of midazolam
491180|NCT00467766|Behavioral|Psychosocial information, counseling, and support|
491181|NCT00467766|Drug|Donepezil (Aricept)|
491182|NCT00467753|Drug|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
491183|NCT00467753|Other|Placebo/sugar pill|Dosage similar to active drug
491184|NCT00467740|Drug|BI 1744 CL|
491185|NCT00467727|Other|Phase Contrast Mammography|Standard and magnification views
491186|NCT00467714|Procedure|rhinoplasty|COLUMELLA STRUT PLACEMENT
491187|NCT00467688|Device|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
491188|NCT00467675|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
491189|NCT00467662|Drug|Acyclovir 5%|
491190|NCT00467662|Drug|Docosanol 10%|
491191|NCT00467662|Device|Superlysine gel|
491192|NCT00467649|Drug|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
491193|NCT00467649|Drug|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
491194|NCT00467649|Drug|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
491195|NCT00467636|Procedure|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
491196|NCT00467636|Drug|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI < 30 = 0.1 unit/kg. BMI > 30 = 0.2 unit/kg)
491197|NCT00467610|Drug|Panhematin|
491198|NCT00467597|Drug|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
491199|NCT00467584|Drug|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
491317|NCT00466752|Procedure|therapeutic conventional surgery|Undergo prostatectomy
491200|NCT00467584|Drug|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
491201|NCT00467584|Drug|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
491202|NCT00467571|Drug|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
491203|NCT00467558|Drug|Naltrexone|daily
491204|NCT00467558|Drug|Sugar pill|daily
491205|NCT00467545|Drug|telbivudine|
491206|NCT00467519|Biological|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
491207|NCT00467519|Biological|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
491208|NCT00467506|Drug|bispecific antibody and di-DTPA-131I|
491209|NCT00467493|Drug|Anastrozole|
491210|NCT00467467|Drug|Alfuzosin Hydrochloride|
491211|NCT00467454|Drug|Naltrexone|daily
491212|NCT00467454|Drug|Placebo|daily
491213|NCT00467441|Drug|VSF-173|
491214|NCT00467428|Drug|NS2359|
491215|NCT00467428|Drug|Placebo|
491216|NCT00467415|Behavioral|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
491217|NCT00467415|Behavioral|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
491218|NCT00467402|Drug|agomelatine|
491219|NCT00467402|Drug|placebo|
491220|NCT00467389|Drug|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
491221|NCT00467389|Other|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
491222|NCT00467376|Drug|Insulin Glulisine|3 times a day before each meal
491223|NCT00467376|Drug|Lispro|3 times a day before each meal
491224|NCT00467376|Drug|Insulin Glargine|once daily
491225|NCT00467363|Drug|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
491226|NCT00467363|Dietary Supplement|Folic acid|400micrograms of folic acid.
491227|NCT00467350|Drug|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
491228|NCT00467350|Drug|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
491229|NCT00467337|Procedure|Medial-Wedge Insole intervention|
491230|NCT00467324|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
491231|NCT00467298|Behavioral|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
491232|NCT00467298|Behavioral|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
491233|NCT00467298|Behavioral|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
491234|NCT00467272|Drug|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria.
491235|NCT00467259|Drug|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
491236|NCT00467259|Drug|Placebo patch|placebo patch, changed twice a week for 52 weeks
491237|NCT00467246|Drug|Levemir|
491238|NCT00467233|Procedure|Laser Treatment|Laser treatment to half of the face at each study visit
491239|NCT00467233|Procedure|Acid Peel|Acid peel to half of the face at each study visit
491240|NCT00467220|Behavioral|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
491241|NCT00467207|Drug|Botulinum Toxin A|
491242|NCT00467207|Behavioral|Resistance training|
491243|NCT00467194|Drug|Rapamycin|
491244|NCT00467194|Drug|Bevacizumab|
491245|NCT00467181|Drug|Fenoldopam|
491246|NCT00467168|Behavioral|Diet|
491247|NCT00467142|Biological|bevacizumab|
491248|NCT00467142|Drug|fluorouracil|
491249|NCT00467142|Drug|irinotecan hydrochloride|
491250|NCT00467142|Drug|leucovorin calcium|
491251|NCT00467142|Genetic|polymorphism analysis|
491252|NCT00467129|Genetic|microarray analysis|
491253|NCT00467129|Genetic|mutation analysis|
491254|NCT00467129|Genetic|polymerase chain reaction|
491255|NCT00467129|Genetic|polymorphism analysis|
491256|NCT00467129|Other|laboratory biomarker analysis|
491257|NCT00467129|Other|questionnaire administration|
491258|NCT00467116|Biological|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
491259|NCT00467116|Drug|gemcitabine hydrochloride|"Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~300mg/m2 30 minutes~400mg/m2 40 minutes"
491260|NCT00467116|Radiation|radiation therapy|"50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions > 3 days."
491261|NCT00467077|Biological|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
491262|NCT00467077|Drug|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
517474|NCT00261820|Drug|tacrolimus|
491263|NCT00467064|Behavioral|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
491264|NCT00467064|Other|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
491265|NCT00467051|Drug|Carboplatin|Given IV
491266|NCT00467051|Biological|Filgrastim|Given IV or subcutaneously
491267|NCT00467051|Drug|Ifosfamide|Given IV
491268|NCT00467051|Other|Laboratory Biomarker Analysis|Optional correlative studies
491269|NCT00467051|Drug|Paclitaxel|Given IV
491270|NCT00467038|Behavioral|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
491271|NCT00467025|Drug|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
491272|NCT00467025|Drug|Sorafenib|400 mg PO BID
491273|NCT00467025|Drug|AMG 386 placebo IV|AMG 386 placebo IV
491274|NCT00467012|Drug|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
491275|NCT00467012|Drug|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
491276|NCT00466999|Drug|misoprostol|single dose of 400 mcg misoprostol administered sublingually
491277|NCT00466999|Procedure|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
491278|NCT00466986|Drug|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
491279|NCT00466973|Device|Dry bipolar radiofrequency (RF) clamp|Specified device used for ablation during standard surgical procedure
491280|NCT00466973|Device|Unipolar microwave antenna|Specified device used for ablation during standard surgical procedure
491281|NCT00466973|Device|Unipolar cryothermic probe|Specified device used for ablation during standard surgical procedure
491282|NCT00466973|Device|Irrigated unipolar RF antenna|Specified device used for ablation during standard surgical procedure
491283|NCT00466973|Device|Irrigated bipolar RF clamp|Specified device used for ablation during standard surgical procedure
491284|NCT00466973|Device|Hi-intensity focused ultrasound wand|Specified device used for ablation during standard surgical procedure
491285|NCT00466960|Biological|sargramostim|Given SC
491286|NCT00466960|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
491287|NCT00466960|Other|laboratory biomarker analysis|Correlative studies
491288|NCT00466960|Other|immunologic technique|Correlative studies
491289|NCT00466947|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
491290|NCT00466947|Biological|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
491291|NCT00466947|Biological|Engerix-B|Intramuscular injection, 3 doses
491292|NCT00466947|Biological|Infanrix hexa|Intramuscular injection,3 doses
491293|NCT00466947|Biological|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
491294|NCT00466921|Drug|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
491295|NCT00466908|Device|Pentacam and IOL Master|Pentacam and IOL Master
491296|NCT00466895|Drug|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
491297|NCT00466882|Device|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two years.
491298|NCT00466869|Drug|Betahistine|
491299|NCT00466856|Drug|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres~<10% Administer full dose of SIR-Spheres~10% to 15% Reduce dose of SIR-Spheres by 20%~16% to 20% Reduce dose of SIR-Spheres by 40%~>20% Do not give SIR-Spheres"
491300|NCT00466856|Radiation|yttrium Y 90 resin microspheres|radiation
491301|NCT00466843|Drug|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
491302|NCT00466843|Drug|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
491303|NCT00466830|Other|questionnaire administration|
491304|NCT00466830|Procedure|management of therapy complications|
491305|NCT00466830|Procedure|psychosocial assessment and care|
491306|NCT00466830|Procedure|quality-of-life assessment|
491307|NCT00466817|Other|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
491308|NCT00466817|Drug|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
491309|NCT00466804|Procedure|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
491310|NCT00466791|Drug|Methylphenidate Transdermal System|Placebo
491311|NCT00466765|Device|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
491312|NCT00466752|Drug|sorafenib tosylate|Given PO
491313|NCT00466752|Genetic|microarray analysis|Correlative studies
491314|NCT00466752|Other|immunohistochemistry staining method|Correlative studies
491315|NCT00466752|Genetic|gene expression analysis|Correlative studies
491316|NCT00466752|Procedure|needle biopsy|Correlative studies
519203|NCT00247442|Behavioral|Decision aid|
491318|NCT00466752|Other|laboratory biomarker analysis|Correlative studies
491319|NCT00466752|Genetic|western blotting|Correlative studies
491320|NCT00466752|Genetic|RNA analysis|Correlative studies
491321|NCT00466726|Biological|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
491322|NCT00466726|Biological|sargramostim|
491323|NCT00466713|Drug|Rosiglitazone therapy|
491324|NCT00466687|Biological|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
491325|NCT00466687|Drug|erlotinib hydrochloride|150mg PO qd
491326|NCT00466687|Genetic|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
491327|NCT00466687|Genetic|gene expression analysis|gene expression analysis
491328|NCT00466687|Other|immunologic technique|immunologic technique
491329|NCT00466687|Other|laboratory biomarker analysis|laboratory biomarker analysis
491330|NCT00466687|Procedure|biopsy|biopsy
491331|NCT00466674|Drug|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
491332|NCT00466661|Drug|Acamprosate|666 mg po TID
491333|NCT00466661|Drug|Placebo|2 tabs po TID
491334|NCT00466648|Procedure|Tissue adhesive|
491335|NCT00466635|Drug|GT267-004 (tolevamer potassium sodium)|
491336|NCT00466622|Drug|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
491337|NCT00466622|Drug|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
491338|NCT00466609|Drug|Clomipramine (fluoxetine plus clomipramine)|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
491339|NCT00466609|Drug|Quetiapine (fluoxetine plus quetiapine)|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
491340|NCT00466609|Drug|Placebo (fluoxetine plus placebo)|Placebo plus fluoxetine at maximum dosage of 80mg per day
491341|NCT00466596|Drug|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
491342|NCT00466583|Drug|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
491343|NCT00466570|Drug|gatifloxacin, moxifloxacin|
491344|NCT00466544|Device|Plasmaknife|
491345|NCT00466544|Device|Monopolar|
491346|NCT00466531|Biological|therapeutic autologous lymphocytes|
491347|NCT00466531|Drug|cyclophosphamide|
491348|NCT00466518|Drug|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
491349|NCT00466505|Biological|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
491350|NCT00466505|Drug|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
491351|NCT00466505|Genetic|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
491352|NCT00466505|Other|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
491353|NCT00466505|Other|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
491354|NCT00466505|Other|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
491355|NCT00466492|Procedure|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
491356|NCT00466479|Drug|brimonidine|
491357|NCT00466479|Procedure|laser trabeculoplasty|
491358|NCT00466466|Drug|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
491359|NCT00466453|Behavioral|knowledge-adaptive Web-based instruction|
491360|NCT00466440|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression, toxicity, or maximum 3 years
491361|NCT00466440|Drug|placebo|oral, daily
491362|NCT00466440|Drug|docetaxel|75 mg/m2, IV, q 21 days, six 21 day cycles, maximum 10 cycles
491363|NCT00466440|Drug|prednisone|5 mg, oral, BID, six 21 day cycles
491364|NCT00466414|Device|Polycaprolactone Scaffold|
491365|NCT00466401|Drug|Simvastatin|
491366|NCT00466401|Drug|Ezetimibe|
491367|NCT00466375|Genetic|Cheek cell samples or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
491368|NCT00466375|Genetic|Cheek cell sample or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
491369|NCT00466362|Behavioral|The Evje Model|
491370|NCT00466323|Behavioral|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
491371|NCT00466323|Behavioral|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
491372|NCT00466310|Drug|Aripiprazole|Aripiprazole for 4 weeks
491373|NCT00466310|Drug|Risperidone|Subjects will be randomized to risperidone for 4 weeks
491374|NCT00466310|Other|Healthy volunteers|Healthy volunteers
491375|NCT00466297|Behavioral|Face-to-face communication interactions|
491376|NCT00466284|Drug|Tarceva (erlotinib)|
491377|NCT00466258|Drug|R-CHOP|"Cyclophosphamide 750 mg/m2 i.v. day 1~Adriamycin 50 mg/m2 i.v. day 1~Vincristine 1,4 mg/m2 i.v. day 1~Prednisone 100 mg i.v or oral. days 1-5."
491378|NCT00466258|Drug|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
491379|NCT00466258|Drug|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
491380|NCT00466258|Drug|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
491381|NCT00466245|Drug|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
491382|NCT00466245|Drug|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
491383|NCT00466232|Drug|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
491384|NCT00466232|Drug|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
491385|NCT00466219|Drug|Ribavirin|
491386|NCT00466219|Drug|Pegylated interferon alpha2a|
491387|NCT00466206|Device|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
491388|NCT00466206|Device|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
491389|NCT00466206|Procedure|3MP (Magnetic Mini-Mover Procedure)|"Subject has EKG performed to measure baseline cardiac activity.~Magnimplant is implanted.~After one week, Magnatract is fitted.~Chest x-ray and 2nd EKG performed 30 days post-implantation.~Patient and parents complete QoL questionnaire 30d post-implantation.~Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~CT scan and third EKG performed after explanation.~Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
491390|NCT00466193|Drug|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
491391|NCT00466193|Drug|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
491392|NCT00466180|Behavioral|Nevirapine from twice-a-day to once-a-day|
491393|NCT00466167|Drug|Pramipexol Extended Release|
491394|NCT00466167|Drug|Pramipexol Immediate Release|
491395|NCT00466167|Drug|Placebo|
491396|NCT00466154|Drug|Aspirin|
491397|NCT00466141|Behavioral|Increased Exercise for weight loss maintenance|
491398|NCT00466141|Behavioral|Daily Self-weighing for weight loss maintenance|
491399|NCT00466141|Behavioral|Education for weight loss maintenance|
491400|NCT00466128|Drug|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
491401|NCT00466102|Drug|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
491402|NCT00466102|Drug|Placebo|2 tablets are taken once daily during study therapy
491403|NCT00466089|Drug|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
491404|NCT00466076|Drug|Copaxone (Glatiramer acetate)|
491405|NCT00466063|Drug|Deferasirox|
491406|NCT00466037|Biological|Influenza vaccine|
491407|NCT00466024|Behavioral|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
491408|NCT00466024|Behavioral|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
491409|NCT00465985|Drug|ACZ885|
491410|NCT00465985|Drug|Placebo|
491411|NCT00465972|Drug|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
491412|NCT00465972|Drug|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
491413|NCT00465972|Drug|Placebo|Placebo capsule nightly for duration of study
491414|NCT00465959|Drug|trospium chloride inhalation powder (TrIP)|
491415|NCT00465959|Drug|Placebo|
491416|NCT00465946|Behavioral|Salt Supplementation|
491417|NCT00465933|Drug|AIDA|
491418|NCT00465920|Behavioral|modified cognitive behavioural therapy (mCBT)|
491419|NCT00465907|Drug|Paclitaxel, Carboplatin and Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
491420|NCT00465894|Drug|Extended Release Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks
491421|NCT00465894|Drug|Intra Vaginal Estradiol Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks. At 12 Weeks, the subjects were offered the addition of the alternative therapy with follow-up at 24 and 52 weeks.
491422|NCT00465881|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
491423|NCT00465868|Procedure|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
491424|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
491425|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.~The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
491426|NCT00465816|Biological|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
491427|NCT00465816|Biological|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
491428|NCT00465803|Drug|Travoprost 0.004%/timolol 0.5% ophthalmic solution|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
491429|NCT00465803|Drug|Travoprost ophthalmic solution, 0.004%|One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
491430|NCT00465803|Drug|Timolol maleate ophthalmic solution, 0.5%|One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
491431|NCT00465777|Behavioral|Guideline adherence and financial incentive|
491432|NCT00465764|Other|Alternate protein infant formula|Feed as per HCP directions
491433|NCT00465764|Other|Standard infant formula|Feed as per HCP directions
491434|NCT00465751|Drug|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
491435|NCT00465751|Drug|placebo capsules|placebo capsules containing mannitol tid po
491436|NCT00465738|Drug|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
491437|NCT00465725|Drug|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
491438|NCT00465712|Procedure|transabdominal amnioinfusion|transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
491439|NCT00465699|Drug|Topical B12 0.07%|
491440|NCT00465686|Device|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
491441|NCT00465686|Device|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
491442|NCT00465673|Drug|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
491443|NCT00465660|Behavioral|Progressive resistance training|
491444|NCT00465647|Drug|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
491445|NCT00465621|Drug|Xalatan|
491446|NCT00465608|Drug|propranolol|propranolol by mouth (per os)
491447|NCT00465595|Drug|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
491448|NCT00465569|Drug|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
491449|NCT00465569|Other|Placebo|
491450|NCT00465556|Behavioral|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
491451|NCT00465556|Behavioral|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
491452|NCT00465543|Other|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
491453|NCT00465543|Other|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
491454|NCT00465530|Drug|Saline|Intranasal Saline
491455|NCT00465530|Drug|Gentamycin|Intranasal irrigation
491456|NCT00465517|Drug|Ganaxolone|Oral suspension 200-500 mg 3x/day
491457|NCT00465504|Procedure|iontophoresis|See Detailed Description.
491458|NCT00465491|Drug|picoplatin|IV picoplatin 150mg/m2 q3wk
491459|NCT00465491|Other|best supportive care|best supportive care
491460|NCT00465478|Procedure|Autologous bone marrow mononuclear cell transplantation|
491461|NCT00465465|Biological|MVA 85A|i.d. injection
491462|NCT00465452|Drug|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
491463|NCT00465439|Drug|Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine|10 ml subcutaneously
491464|NCT00465413|Device|Small volume spacer and/or Rinsing the mouth with water|
519364|NCT00245947|Drug|ERB-041|
491465|NCT00465387|Behavioral|Falls, Fractures & Osteoporosis Risk Assessment & Management|
491466|NCT00465374|Procedure|Change ventilatory parameters with stress index monitoring|
491467|NCT00465361|Procedure|performance feedback with an educational module|individual performance feedback with an educational module
491468|NCT00465322|Drug|fluvastatin|
491469|NCT00465309|Procedure|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat < 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH > 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
491470|NCT00465296|Drug|rosiglitazone|
491471|NCT00466388|Drug|Cevimeline|
491472|NCT00465283|Drug|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
491473|NCT00465270|Device|AMPLATZER PFO Occluder|patent foramen ovale closure device
491474|NCT00465270|Other|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
491475|NCT00465257|Drug|artesunate + amodiaquine|
491476|NCT00465244|Drug|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
491477|NCT00465244|Drug|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
491478|NCT00465231|Drug|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
491479|NCT00465231|Drug|preservative free saline|10mL saline solution
491480|NCT00465218|Procedure|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
491481|NCT00465205|Drug|Valacyclovir|500mg oral twice daily
491482|NCT00465205|Drug|Matching Placebo|500 mg oral twice daily
491483|NCT00465192|Drug|estradiol, 10 mcg|
491484|NCT00465192|Drug|estradiol, 25 mcg|
491485|NCT00465192|Drug|placebo|
491486|NCT00465179|Drug|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
491487|NCT00465166|Procedure|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
491488|NCT00465153|Dietary Supplement|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
491489|NCT00465153|Behavioral|Resistance exercise training|Resistance training
491490|NCT00465140|Drug|creatine supplementation|
491491|NCT00465140|Behavioral|aerobic exercise training|
491492|NCT00465114|Procedure|Hemodynamic Monitoring|
491493|NCT00465101|Device|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
491494|NCT00465088|Drug|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
491495|NCT00465088|Drug|atorvastatin|40 mg at bedtime
491496|NCT00465075|Drug|Bazedoxifene/conjugated estrogens combination|
491497|NCT00465049|Other|PRIMARY CLOSRE|SUTURE
491498|NCT00465049|Other|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
491499|NCT00465049|Other|SPONTANEOUS HALING|SECONDARY HEALING AFTER I&D
491500|NCT00465036|Dietary Supplement|Whole flaxseeds, flaxseed mucilage, glucomannan|
491501|NCT00465023|Procedure|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
491502|NCT00465010|Behavioral|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
491503|NCT00464984|Behavioral|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
491504|NCT00464971|Drug|estradiol, 25 mcg|
491505|NCT00464958|Drug|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
491506|NCT00464945|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
491507|NCT00464932|Drug|Vasoactive Intestinal Peptide (VIP)|
491508|NCT00464919|Drug|Sorafenib|
491509|NCT00464919|Drug|tegafur/uracil (UFUR®)|
491510|NCT00464893|Drug|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
491511|NCT00464893|Drug|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
491512|NCT00464880|Drug|Aliskiren|
491513|NCT00464867|Biological|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
491514|NCT00464854|Drug|Glargine and insulin aspart or lispro|
491515|NCT00464841|Procedure|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
491516|NCT00464841|Procedure|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
491517|NCT00464828|Procedure|Internal jugular vein cannulation|
491518|NCT00464828|Device|ultrasound|
491519|NCT00464815|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
491520|NCT00464815|Biological|Mencevax™ ACWY|One subcutaneous dose
491521|NCT00464802|Drug|MOA-728|
491522|NCT00464789|Drug|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
491523|NCT00464776|Drug|Aliskiren|
491524|NCT00464776|Drug|Aliskiren|
491525|NCT00464776|Drug|Aliskiren|
491526|NCT00464776|Drug|Aliskiren|
491527|NCT00464763|Drug|Dexmedetomidine|
491528|NCT00464763|Drug|Placebo|
491574|NCT00464438|Drug|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
519365|NCT00245934|Drug|Enbrel|
491529|NCT00464750|Device|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
491530|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
491531|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
491532|NCT00464737|Other|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
491533|NCT00464724|Procedure|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
491534|NCT00464711|Drug|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
491535|NCT00464698|Drug|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
491536|NCT00464685|Drug|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
491537|NCT00464685|Drug|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
491538|NCT00464685|Procedure|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
491539|NCT00464672|Biological|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
491540|NCT00464672|Biological|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
491541|NCT00464659|Device|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
491542|NCT00464659|Device|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
491543|NCT00464646|Drug|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
491544|NCT00464646|Drug|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
491545|NCT00464646|Drug|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
491546|NCT00464646|Drug|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV~Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
491547|NCT00464646|Drug|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses~Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
491548|NCT00464633|Drug|alvocidib|"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion~Then, every treatment week, depending upon the patient's objective response to initial therapy:~30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or~30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."
491549|NCT00464620|Drug|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
491550|NCT00464607|Drug|hMG-IBSA|
491551|NCT00464607|Procedure|Ovarian stimulation|
491552|NCT00464594|Behavioral|Standard lifestyle guidance|
491553|NCT00464594|Drug|Lifestyle guidance and monotherapy with acarbose|
491554|NCT00464594|Drug|Lifestyle guidance and monotherapy with metformin|
491555|NCT00464594|Drug|Lifestyle guidance and monotherapy with gliclazide|
491556|NCT00464568|Drug|GSK256066|
491557|NCT00464555|Procedure|Islet transplant|Transplantation of pancreatic islet cells
491558|NCT00464555|Drug|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
491559|NCT00464555|Drug|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
491560|NCT00464555|Drug|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
491561|NCT00464555|Drug|Sirolimus|Maintenance immunosuppressive therapy
491562|NCT00464555|Drug|Tacrolimus|Maintenance immunosuppressive therapy
491563|NCT00464542|Drug|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
491564|NCT00464529|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
491565|NCT00464516|Drug|placebo|once daily for 14 days orally
491566|NCT00464516|Drug|Estetrol|once daily for 14 days orally
491567|NCT00464503|Drug|Rosuvastatin-Crestor|
491568|NCT00464503|Drug|Pravastatin-Pravasine|
491569|NCT00464490|Drug|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
491570|NCT00464464|Behavioral|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
491571|NCT00464451|Drug|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
491572|NCT00464451|Drug|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
491573|NCT00464438|Drug|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
491575|NCT00464425|Procedure|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
491576|NCT00464425|Procedure|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
491577|NCT00464425|Other|No Acupuncture|Control
491578|NCT00464412|Behavioral|Education|
491579|NCT00464399|Drug|everolimus|
491580|NCT00464386|Device|Continuous Glucose Monitoring|measure glucose levels on burn patients
491581|NCT00464373|Drug|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
491582|NCT00464373|Drug|Placebo|4ml NaCl 0.9%
491583|NCT00464347|Drug|Avastin|
491584|NCT00464347|Procedure|Photodynamic Therapy (PDT)|
491585|NCT00464347|Drug|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
491586|NCT00464334|Biological|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
491587|NCT00464334|Biological|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
491588|NCT00464334|Biological|Placebo to V950|
491589|NCT00464321|Biological|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
491590|NCT00464321|Biological|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
491591|NCT00464321|Biological|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
491592|NCT00464321|Biological|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
491593|NCT00464308|Drug|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
491594|NCT00464308|Drug|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
491595|NCT00464308|Drug|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
491596|NCT00464295|Drug|Capecitabine in HCC|
491597|NCT00464269|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Film-coated tablet~Concentration: 2.5 mg, 10 mg and 25 mg~Route of Administration: Oral use"
491598|NCT00464269|Drug|Brivaracetam 2.5 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 2.5 mg~Route of Administration: Oral use"
491599|NCT00464269|Drug|Brivaracetam 10 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 10 mg~Route of Administration: Oral use"
491600|NCT00464269|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 25 mg~Route of Administration: Oral use"
491601|NCT00464256|Drug|rimonabant|
491602|NCT00464243|Drug|volinanserin|oral administration
491603|NCT00464243|Drug|placebo|oral administration
491604|NCT00464230|Procedure|Bipolar hemiarthroplasty (Charnley/Hastings)|
491605|NCT00464230|Procedure|Internal fixation with two parallel screws (Olmed)|
491606|NCT00464217|Drug|ARA-C|
491607|NCT00464217|Drug|Idarubicin|
491608|NCT00464217|Drug|Leucomax|
491609|NCT00464204|Drug|"6 % Hydroxyethylstarch 130/0.4 = Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
491610|NCT00464204|Drug|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
491611|NCT00464191|Drug|escitalopram|
491612|NCT00464178|Drug|Bortezomilb|Bortezomilb will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
491613|NCT00464165|Drug|rimonabant|
491614|NCT00464139|Procedure|Laparoscopy|Laparoscopy
491615|NCT00464126|Other|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
491616|NCT00464126|Other|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
491617|NCT00464113|Drug|XL228|1-hour IV infusion
491618|NCT00464087|Drug|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
491619|NCT00464061|Drug|Volinanserin|oral administration
491620|NCT00464061|Drug|Placebo|oral administration
491621|NCT00464048|Procedure|controlled physical exercise|
491622|NCT00464035|Behavioral|high calcium intake|
491623|NCT00464022|Device|Carbon dioxide|
491624|NCT00464009|Behavioral|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
491625|NCT00463983|Drug|octreotide|
491626|NCT00463970|Behavioral|Brief Intervention|Physical examination, education and follow up by a physiotherapist
491627|NCT00463970|Behavioral|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
491628|NCT00463970|Dietary Supplement|Seal oil|20 capsules per day for 3 months
491629|NCT00463970|Dietary Supplement|Soy oil|20 capsules per day for 3 months
491630|NCT00463957|Drug|sildenafil|
491631|NCT00463957|Drug|tadalafil|
491632|NCT00463957|Drug|placebo|
491633|NCT00463944|Behavioral|Effect of an electronic voting system|
491634|NCT00463918|Drug|varenicline|
491752|NCT00462982|Drug|sunitinib malate|
491635|NCT00463905|Procedure|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
491636|NCT00463892|Procedure|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
491637|NCT00463879|Drug|Galantamine|
491638|NCT00463866|Drug|Budesonide/formoterol|
491639|NCT00463853|Procedure|Autologous stem cell therapy|
491640|NCT00463853|Procedure|CABG|
491641|NCT00463853|Radiation|CMRI|
491642|NCT00463840|Drug|Oxaliplatin|
491643|NCT00463840|Drug|5FU|
491644|NCT00463840|Radiation|Radiation|
491645|NCT00463840|Procedure|Surgery|
491646|NCT00463840|Drug|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
491647|NCT00463827|Drug|Atorvastatin|
491648|NCT00463827|Drug|atorvastatin|atorvastatin 40mg
491649|NCT00463827|Drug|matched placebo|Matched placebo
491650|NCT00463814|Drug|AZD6244|oral capsule
491651|NCT00463801|Drug|Daptomycin|
491652|NCT00463788|Drug|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m^2) followed by weekly doses of 250 mg/m^2. All doses will be given by intravenous (IV) infusion.~Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
491653|NCT00463788|Drug|cisplatin|"Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.~Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.~Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
491654|NCT00463775|Drug|Topiramate|SSRI plus topiramate SSRI plus placebo
491655|NCT00463762|Drug|CP-75385-02 Cefoperazone/sulbactam|
491656|NCT00463749|Drug|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
491657|NCT00463749|Drug|Placebo|NaCl as placebo
491658|NCT00463736|Drug|Magnesium sulfate|
491659|NCT00463723|Drug|FK506 0.06% (eye drops)|
491660|NCT00463710|Drug|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
491661|NCT00463697|Drug|GW642444H (100mcg)|H salt
491662|NCT00463697|Drug|placebo|placebo
491663|NCT00463697|Drug|GW642444M (25, 100 & 400 mcg)|M salt
491664|NCT00463684|Biological|Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine|Manufactured by Chengdu Institute of Biological Products (CDIBP), Chengdu, China; batch 200611A078-1. Administered subcutaneously in the right brachium.
491665|NCT00463684|Biological|Live, attenuated measles vaccine|Manufactured by Serum Institute of India, Ltd, Pune, India; batch EU3244. Administered subcutaneously in the left brachium.
491666|NCT00463671|Drug|N-acetylcysteine|
491667|NCT00463658|Other|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
491668|NCT00463645|Procedure|microdialysis|
491669|NCT00463645|Procedure|microperfusion|
491670|NCT00463619|Drug|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
491671|NCT00463606|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
491672|NCT00463606|Drug|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
491673|NCT00463606|Drug|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
491674|NCT00463580|Drug|Infliximab|Participants will receive three infusions 5mg/kg of infliximab (at Baseline, Week 2 and Week 6)
491675|NCT00463580|Drug|Placebo|Participants will receive three infusions of a placebo (at Baseline, Week 2 and Week 6)
491676|NCT00463567|Drug|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
491677|NCT00463567|Drug|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
491678|NCT00463567|Drug|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
491679|NCT00463567|Drug|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
491680|NCT00463567|Drug|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
491681|NCT00463554|Device|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
491682|NCT00463541|Drug|solifenacin succinate|oral
491683|NCT00463515|Drug|carboplatin/gemcitabine|
491684|NCT00463515|Procedure|cisplatin/radiation therapy|
491685|NCT00463502|Drug|Metformin|
491686|NCT00463489|Behavioral|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
491687|NCT00463489|Behavioral|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
491688|NCT00463476|Biological|Japanese encephalitis live attenuated SA 14-14-2 vaccine|
491689|NCT00463463|Drug|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
519813|NCT00242463|Drug|Placebo|
491690|NCT00463450|Drug|Gynodian® Depot (BAY86-5032)|Injection monthly
491691|NCT00463450|Drug|BAY86-4980|orally
491692|NCT00463437|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
491693|NCT00463437|Biological|Prevenar|Intramuscular injection, 1 dose.
491694|NCT00463437|Biological|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
491695|NCT00463437|Biological|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
491696|NCT00463437|Biological|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
491697|NCT00463437|Biological|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
491698|NCT00463437|Biological|Meningitec|Intramuscular injection, 1 dose.
491699|NCT00463437|Biological|NeisVac-C|Intramuscular injection, 1 dose.
491700|NCT00463437|Biological|Menitorix|Intramuscular injection, 1 dose.
491701|NCT00463424|Device|NeuFlex metacarpophalangeal implant|
491702|NCT00463424|Device|Swanson metacarpophalangeal implant|
491703|NCT00463385|Drug|Pomalidomide|
491704|NCT00463385|Drug|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
491705|NCT00463385|Drug|Placebo to pomalidomide|Matching pomalidomide placebo tablets
491706|NCT00463385|Drug|Placebo to prednisone|Matching prednisone placebo tablets
491707|NCT00463372|Drug|PF-02545920|
491708|NCT00463359|Drug|Imiquimod cream|
491709|NCT00463359|Procedure|curettage and cautery|
491710|NCT00463346|Drug|Acamprosate|Acamprosate 1998 mg tid
491711|NCT00463346|Drug|Placebo|Placebo
491712|NCT00463320|Drug|Pazopanib eye drops and Allergen Refresh Plus eye drops|
491713|NCT00463294|Procedure|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
491714|NCT00463294|Procedure|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
491715|NCT00463268|Drug|alendronate|alendronate 70 mg every 2 weeks
491716|NCT00463268|Dietary Supplement|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
491717|NCT00463268|Drug|placebo|identical placebo every 2 weeks
491718|NCT00463255|Behavioral|diet|
491719|NCT00463242|Drug|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
491720|NCT00463242|Drug|paroxetine|
491721|NCT00463242|Drug|placebo|
491722|NCT00463229|Other|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
491723|NCT00463216|Behavioral|A multidisciplinary diagnostic evaluation|
491724|NCT00463203|Drug|Bevacizumab|10 mg/kg every 2 weeks
491725|NCT00463203|Drug|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
491726|NCT00463190|Drug|Biothree|
491727|NCT00463151|Drug|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
491728|NCT00463138|Behavioral|Crisis intervention|
491729|NCT00463125|Drug|Platelet Gel|
491730|NCT00463112|Drug|Sibutramine|
491731|NCT00463086|Drug|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
491732|NCT00463086|Drug|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
491733|NCT00463073|Drug|Cetuximab|
491734|NCT00463073|Drug|Bevacizumab|
491735|NCT00463073|Drug|Irinotecan|
491736|NCT00463060|Drug|sunitinib malate (Sutent)|Sutent administered PO QD from days 1 to 28 Two weeks after completion of any chemotherapy, maintenance Sutent in 6 week cycles (consisting of Sutent 50 mg PO QD weeks 1-4 followed by no treatment weeks 5-6) until progression or death If no chemotherapy is planned, maintenance Sutent (as described above) will start on day 43.
491737|NCT00463060|Procedure|radiotherapy|Radiation is to be delivered to each site over 10 fractions separated by at least 16 hours. Up to 5 sites may be treated
491738|NCT00463047|Drug|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
491739|NCT00463034|Genetic|microarray analysis|
491740|NCT00463034|Genetic|polymerase chain reaction|
491741|NCT00463034|Genetic|polymorphism analysis|
491742|NCT00463034|Other|high performance liquid chromatography|
491743|NCT00463034|Other|immunohistochemistry staining method|
491744|NCT00463034|Other|laboratory biomarker analysis|
491745|NCT00463034|Other|questionnaire administration|
491746|NCT00463021|Drug|Hectorol (doxercalciferol capsules)|
491747|NCT00463021|Drug|Zemplar (paricalcitol injection)|
491748|NCT00463008|Drug|methotrexate|
491749|NCT00463008|Other|pharmacological study|
491750|NCT00462995|Drug|Erlotinib|150mg once a day for 28 days
491751|NCT00462995|Drug|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
491753|NCT00462969|Procedure|Sonohysterography|Sonohysterography
491754|NCT00462956|Drug|Tykerb|lapatinib 1500mg daily
491755|NCT00462943|Drug|Omacetaxine mepesuccinate|"Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days.~Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days.~Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
491756|NCT00462917|Behavioral|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during an in-person disclosure session."
491757|NCT00462917|Behavioral|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
491758|NCT00462917|Behavioral|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.~Genetic counselors communicate results to participants during a telephone disclosure session."
491759|NCT00462917|Behavioral|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.~Genetic counselors communicate results to participants during an in-person disclosure session."
491760|NCT00462904|Drug|BPI|BPI will be give IV with an initial bolus given over 30 minutes and then a continuous infusion for the next 47.5 hours
491761|NCT00462891|Other|IT System|
491762|NCT00462878|Drug|Meropenem|antibiotic
491763|NCT00462878|Drug|Vancomycin|Antibiotic
491764|NCT00462878|Drug|Teicoplanin|Antibiotic
491765|NCT00462865|Drug|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
491766|NCT00462852|Drug|dalteparin|
491767|NCT00462852|Drug|gemcitabine hydrochloride|
491768|NCT00462852|Other|diagnostic laboratory biomarker analysis|
491769|NCT00462839|Procedure|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
491770|NCT00462826|Biological|ziv-aflibercept|
491771|NCT00462813|Drug|oral microencapsulated diindolylmethane|
491772|NCT00462813|Genetic|polymerase chain reaction|
491773|NCT00462813|Other|cervical Papanicolaou test|
491774|NCT00462813|Other|cytology specimen collection procedure|
491775|NCT00462813|Procedure|colposcopic biopsy|
491776|NCT00462787|Biological|filgrastim|
491777|NCT00462787|Drug|clofarabine|
491778|NCT00462787|Drug|dexamethasone|
491779|NCT00462787|Drug|thiotepa|
491780|NCT00462787|Drug|topotecan hydrochloride|
491781|NCT00462787|Drug|vinorelbine tartrate|
491782|NCT00462774|Procedure|Intramyocardial injection of autologous CD133+ marrow cells|
491783|NCT00462761|Drug|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
491784|NCT00462748|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
491785|NCT00462748|Drug|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
491786|NCT00462748|Drug|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
491787|NCT00462735|Drug|Cetuximab|250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
491788|NCT00462735|Drug|Hydroxyurea|500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
491789|NCT00462735|Drug|Fluorouracil|continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
491790|NCT00462735|Procedure|radiotherapy|"Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients."
491791|NCT00462722|Drug|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
491792|NCT00462722|Drug|Placebo|with each exercise session (up to 5 days per week) for 9 months
491793|NCT00462722|Behavioral|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
491794|NCT00462709|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
491795|NCT00462696|Drug|docetaxel|
491796|NCT00462696|Drug|epirubicin hydrochloride|
491797|NCT00462696|Procedure|conventional surgery|
491798|NCT00462696|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
491799|NCT00462696|Procedure|neoadjuvant therapy|
491800|NCT00462696|Procedure|radiomammography|
491801|NCT00462670|Drug|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
491802|NCT00462657|Genetic|polymerase chain reaction|
491803|NCT00462657|Other|bronchoalveolar lavage|
491804|NCT00462657|Other|immunoenzyme technique|
491805|NCT00462657|Other|laboratory biomarker analysis|
491806|NCT00462657|Procedure|bronchoscopy|
491807|NCT00462657|Procedure|management of therapy complications|
491808|NCT00462644|Drug|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
491809|NCT00462644|Drug|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
491810|NCT00462631|Device|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
491811|NCT00462631|Device|paclitaxel eluting stent|paclitaxel eluting stent
491812|NCT00462631|Device|bare metal stent|bare metal stent
491813|NCT00462618|Drug|Quetiapine|
491814|NCT00462618|Behavioral|Cogntive behavioral therapy|
491815|NCT00462605|Drug|entinostat|Given PO
491816|NCT00462605|Drug|sargramostim|Given SC
491817|NCT00462592|Drug|budesonide|inhaled budesonide turbuhaler 200ug taken 1 puff morning & 1 puff evening.
491818|NCT00462592|Drug|montelukast|montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
491819|NCT00462592|Other|placebo|placebo
491820|NCT00462566|Device|motor cortex stimulation|
491821|NCT00462553|Drug|sunitinib malate|Given orally
491822|NCT00462553|Drug|gemcitabine hydrochloride|Given IV
491823|NCT00462540|Drug|Formoterol Fumurate inhalation solution 20 mcg|
491824|NCT00462540|Drug|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
491825|NCT00462501|Biological|bevacizumab|
491826|NCT00462501|Drug|fluorouracil|
491827|NCT00462501|Drug|leucovorin calcium|
491828|NCT00462501|Drug|oxaliplatin|
491829|NCT00462501|Procedure|conventional surgery|
491830|NCT00462501|Radiation|radiation therapy|
491831|NCT00462488|Drug|Vicinium|Intravesical administration of Vicinium
491832|NCT00462475|Drug|Recombinant Growth Hormone, Genotropin (Pfizer)|
491833|NCT00462462|Drug|Ethanol 96% Gel|
491834|NCT00462462|Drug|Ethanol 98% Solution|
491835|NCT00462449|Device|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
491836|NCT00462436|Behavioral|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
491837|NCT00462423|Drug|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
491838|NCT00462423|Drug|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
491839|NCT00462410|Other|counseling intervention|
491840|NCT00462410|Procedure|psychosocial assessment and care|
491841|NCT00462397|Drug|carboplatin|
491842|NCT00462397|Drug|cisplatin|
491843|NCT00462397|Drug|paclitaxel|
491844|NCT00462397|Procedure|neoadjuvant therapy|
491845|NCT00462397|Radiation|brachytherapy|
491846|NCT00462397|Radiation|radiation therapy|
491847|NCT00462384|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
491848|NCT00462371|Device|Insulin pump (CSII)|
491849|NCT00462358|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
491850|NCT00462358|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
491851|NCT00462345|Drug|rituximab|1000 mg i.v. on Days 1 and 15
491852|NCT00462345|Drug|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
491853|NCT00462345|Drug|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
491854|NCT00462345|Dietary Supplement|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
491855|NCT00462332|Drug|Fludarabine|Induction therapy
491856|NCT00462332|Drug|Campath|Induction therapy
491857|NCT00462332|Procedure|Transplant|Post-induction therapy
491858|NCT00462332|Drug|Campath|Post-induction therapy
491859|NCT00462332|Drug|Fludarabine|Induction therapy
491860|NCT00462332|Drug|Campath|Induction therapy
491861|NCT00462332|Drug|Campath|Post-induction therapy
491862|NCT00462319|Behavioral|Education, weight reduction and physical exercise|
491863|NCT00462306|Procedure|Survey: Berlin questionnaire|Completion of questionnaire
491864|NCT00462280|Drug|lovastatin|Given PO
491865|NCT00462280|Other|placebo|Given PO
491866|NCT00462280|Procedure|biopsy|Correlative studies
491867|NCT00462280|Procedure|laboratory biomarker analysis|Correlative studies
491868|NCT00462267|Behavioral|Enriched lifestyle intervention|Multi-component lifestyle intervention
491869|NCT00462254|Drug|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
491870|NCT00462254|Drug|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
491871|NCT00462241|Procedure|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
491872|NCT00462241|Other|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
491873|NCT00462228|Drug|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
491874|NCT00462228|Drug|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
491875|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
491876|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
491877|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
491878|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
491879|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
491880|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
491881|NCT00462202|Drug|sulodexide|
491882|NCT00462189|Drug|Immunotoxin therapy|
491883|NCT00462189|Drug|CAT-8015 Immunotoxin|
491884|NCT00462189|Procedure|Biological therapy|
491885|NCT00462176|Procedure|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
491886|NCT00462176|Other|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
491887|NCT00462150|Behavioral|home-based emotional disclosure|
491888|NCT00462150|Behavioral|time management control condition|
491889|NCT00462137|Procedure|Sleep Studies|
491890|NCT00462124|Device|Absorbable perirectal spacer|biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
491891|NCT00462111|Drug|Indometacin|
491892|NCT00462098|Device|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
491893|NCT00462098|Device|non-treated control group|no change from routine care, no HBO
491894|NCT00462072|Drug|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
491895|NCT00462059|Behavioral|Treatment|
491896|NCT00462046|Drug|Berberine|
491897|NCT00462020|Drug|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
491898|NCT00462020|Drug|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
491899|NCT00462007|Drug|Stalevo|Oral 3-4 daily doses for 6 weeks
491900|NCT00461994|Behavioral|diet|
491901|NCT00461994|Behavioral|exercise|
491902|NCT00461994|Behavioral|diet and exercise|
491903|NCT00461981|Biological|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
491904|NCT00461981|Biological|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
491905|NCT00461968|Drug|Ezetimibe and Simvastatin|
491906|NCT00461955|Procedure|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
491907|NCT00461942|Drug|Green Tea Polyphenols (EGCG/ECG)|
491908|NCT00461929|Procedure|bone marrow aspiration|
491909|NCT00461916|Drug|Half-Dose Depot Triptorelin|
491910|NCT00461916|Drug|Reduced-Dose Daily Buserelin|
491911|NCT00461903|Drug|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
491912|NCT00461890|Drug|Injectable Naltrexone|
491913|NCT00461864|Procedure|ultrasound examination of the hip|
491914|NCT00461851|Drug|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
491915|NCT00461851|Drug|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
491916|NCT00461851|Drug|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
491917|NCT00461838|Procedure|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
491918|NCT00461838|Other|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
491919|NCT00461825|Drug|Cyclosporin A: C0: 75–125ng/ml-dose adapted in the 3 groups|
491920|NCT00461825|Drug|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
491921|NCT00461825|Drug|Group B: CsA + CellCept(500 mg x 2/day)|
491922|NCT00461825|Drug|Group C: CsAm|
491923|NCT00461812|Drug|Mometasone|
491924|NCT00461812|Drug|Advair|
491925|NCT00461799|Drug|orlistat|
491926|NCT00461786|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
491927|NCT00461773|Drug|Letrozole|Letrozole 2.5 mg po qd
491928|NCT00461773|Drug|Bevacizumab|bevacizumab 10 mg/kg IV
491929|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
491930|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
491931|NCT00461747|Drug|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.~VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
491932|NCT00461747|Drug|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.~Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
491933|NCT00461747|Drug|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.~Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.~Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
491934|NCT00461734|Other|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
491935|NCT00461708|Drug|Erlotinib|100 mg, PO, once per day
491936|NCT00461708|Drug|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
491937|NCT00461695|Biological|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
491938|NCT00461682|Drug|SB-705498|
491939|NCT00461669|Procedure|ultrasound examination of the hip|
491940|NCT00461656|Drug|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
491941|NCT00461643|Drug|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
491942|NCT00461630|Drug|ER niacin/laropiprant|
491943|NCT00461630|Drug|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
491944|NCT00461630|Drug|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
491945|NCT00461617|Drug|Mitiglinide|10mg tablet, 10mg TID
491946|NCT00461591|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
491947|NCT00461591|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
491948|NCT00461591|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
491949|NCT00461578|Drug|Chlorproguanil-dapsone + artesunate|
491950|NCT00461565|Drug|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
491951|NCT00461565|Drug|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
491952|NCT00461565|Drug|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
491953|NCT00461565|Drug|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
491954|NCT00461552|Drug|Leptin|weight based, sub-cutaneous injection, twice daily
491955|NCT00461552|Other|Placebo|weight based, sub-cutaneous injection, twice daily
491956|NCT00461539|Other|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
492041|NCT00460707|Drug|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
492094|NCT00460343|Other|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
491957|NCT00461539|Behavioral|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
491958|NCT00461526|Drug|crofelemer|125 mg crofelemer vs. placebo
491959|NCT00461513|Behavioral|Intervention|Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
491960|NCT00461500|Drug|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
491961|NCT00461500|Drug|Fluticasone propionate|FP 100
491962|NCT00461487|Behavioral|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
491963|NCT00461487|Behavioral|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
491964|NCT00461474|Behavioral|Shoulder strengthening exercises|
491965|NCT00461474|Behavioral|Movement Optimization|
491966|NCT00461461|Procedure|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:~Meeting with the ICU staff to discuss the epidemiology of patients on each theme.~Pocket card with guidelines on the theme and ICU protocol in each study ICU.~Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
491967|NCT00461448|Dietary Supplement|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
491968|NCT00461435|Procedure|hyperbaric oxygen therapy|
491969|NCT00461422|Drug|Ganirelix|sc injection of Ganirelix 0.25 mg per day
491970|NCT00461396|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
491971|NCT00461370|Drug|SRX251|
491972|NCT00461344|Drug|Docetaxel|
491973|NCT00461344|Drug|Doxorubicin|
491974|NCT00461331|Drug|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
491975|NCT00461331|Drug|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
491976|NCT00461318|Procedure|Individual placement and support (vocational rehabilitation)|
491977|NCT00461305|Drug|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
491978|NCT00461305|Drug|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
491979|NCT00461292|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
491980|NCT00461292|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
491981|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
491982|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
491983|NCT00461279|Behavioral|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
491984|NCT00461279|Behavioral|Interpersonal Psychotherapy|Established psychotherapy for depression
491985|NCT00461266|Drug|enfuvirtide [Fuzeon]|90mg sc bid
491986|NCT00461266|Drug|Antiretroviral therapy|As prescribed
491987|NCT00461253|Device|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
491988|NCT00461253|Device|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
491989|NCT00461214|Other|Participation in laparoscopic training curriculum|General Surgery Training Outcome
491990|NCT00461201|Procedure|Nurse practitioner care of patients|
491991|NCT00461162|Behavioral|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
492095|NCT00460317|Drug|AMG 706|125 mg QD orally every day
492096|NCT00460317|Drug|placebo|125 mg QD orally every day
491992|NCT00461162|Behavioral|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
491993|NCT00461162|Behavioral|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
491994|NCT00461149|Drug|Octreotide-LAR|
491995|NCT00461136|Drug|Aliskiren|
491996|NCT00461123|Drug|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
491997|NCT00461123|Drug|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
491998|NCT00461110|Drug|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
491999|NCT00461097|Drug|Egg oral immunotherapy|Egg white solid powder
492000|NCT00461097|Drug|Control Group|Placebo for egg white solid
492001|NCT00461084|Drug|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
492002|NCT00461084|Drug|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
492003|NCT00461071|Behavioral|Guided Self-help for Bulimia nervosa|bibliotherapy
492004|NCT00461058|Drug|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
492005|NCT00461058|Drug|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
492006|NCT00461045|Drug|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
492007|NCT00461032|Drug|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
492008|NCT00461032|Drug|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
492009|NCT00461019|Procedure|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
492010|NCT00461006|Drug|Actos|45mg po daily
492011|NCT00461006|Drug|aleglitazar|0.6mg po daily
492012|NCT00460993|Drug|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
492013|NCT00460980|Behavioral|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
492014|NCT00460967|Device|Rheopheresis|8 rheopheresis treatments over 10 wks.
492015|NCT00460967|Device|Rheopheresis|Sham treatment
492016|NCT00460954|Drug|Sinemet® controlled release (Carbidopa/levodopa)|
492017|NCT00460941|Drug|Placebo|sc weekly
492018|NCT00460941|Drug|Taspoglutide 20mg|sc weekly
492019|NCT00460941|Drug|Taspoglutide 20mg-30mg|sc weekly
492020|NCT00460941|Drug|Taspoglutide 20mg-40mg|sc weekly
492021|NCT00460928|Drug|intravenous immune globulin (IVIG)|
492022|NCT00460915|Drug|Lacidipine & Amlodipine|
492023|NCT00460902|Device|Transcranial Magnetic Stimulation (TMS)|
492024|NCT00460889|Procedure|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
492025|NCT00460876|Drug|Topotecan|
492026|NCT00460863|Procedure|using cool versus warm dialysate during hemodialysis|
492027|NCT00460850|Drug|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
492028|NCT00460837|Drug|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
492029|NCT00460811|Drug|Linaclotide Acetate|Oral, once daily
492030|NCT00460811|Drug|Matching placebo|Oral, once daily
492031|NCT00460798|Other|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
492032|NCT00460785|Drug|Opioid|
492033|NCT00460759|Drug|Moxifloxacin|
492034|NCT00460759|Drug|Rifapentine|
492035|NCT00460746|Drug|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
492036|NCT00460733|Drug|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
492037|NCT00460733|Drug|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
492038|NCT00460720|Other|Observational treatment compliance survey|Observational treatment compliance survey
492039|NCT00460707|Drug|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
492040|NCT00460707|Drug|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
519814|NCT00242450|Drug|Metoclopramide|
492042|NCT00460707|Drug|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
492043|NCT00460707|Drug|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
492044|NCT00460694|Biological|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
492045|NCT00460681|Drug|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
492046|NCT00460668|Behavioral|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
492047|NCT00460655|Drug|GSK1358820|botulinum toxin type A
492048|NCT00460655|Drug|Placebo|Placebo
492049|NCT00460642|Drug|GnRH Antagonist (Cetrotide)|
492050|NCT00460629|Procedure|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
492051|NCT00460616|Drug|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
492052|NCT00460603|Drug|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
492053|NCT00460603|Drug|AG-013726|AG-013726 5 mg bid every 2 weeks
492054|NCT00460603|Drug|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
492055|NCT00460590|Biological|MVA 85A|ID vaccine
492056|NCT00460577|Drug|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
492057|NCT00460577|Drug|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
492058|NCT00460564|Drug|GSK1358820|botulinum toxin type A
492059|NCT00460564|Drug|Placebo|Placebo
492060|NCT00460551|Biological|Zalutumumab|8 mg/kg
492061|NCT00460551|Drug|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
492062|NCT00460551|Radiation|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
492063|NCT00460538|Dietary Supplement|Lectranal|"Dosage form: capsule~1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
492064|NCT00460538|Dietary Supplement|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
492065|NCT00460525|Biological|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
492066|NCT00460525|Biological|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
492067|NCT00460512|Drug|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
492068|NCT00460499|Drug|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
492069|NCT00460499|Drug|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
492070|NCT00460499|Drug|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
492071|NCT00460486|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
492072|NCT00460473|Drug|Dexmedetomidine|
492073|NCT00460473|Drug|Placebo|
492074|NCT00460460|Drug|AZD4877|
492075|NCT00460447|Drug|Gemtuzumab Ozogamicin|
492076|NCT00460434|Device|TVT|Prophylactic TVT
492077|NCT00460434|Other|Sham|Sham TVT
492078|NCT00460421|Drug|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
492079|NCT00460421|Radiation|Total Body irradiation|
492080|NCT00460421|Drug|Chemotherapy|High dose etoposide, Cyclophosphamide
492081|NCT00460408|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
492082|NCT00460395|Procedure|Surgery|
492083|NCT00460395|Procedure|Stereotactic radiosurgery|
492084|NCT00460382|Drug|raltegravir potassium|400 mg twice a day
492085|NCT00460382|Drug|darunavir/ritonavir|2 pills of 300 mg twice a day
492086|NCT00460382|Drug|etravirine|2 pills of 100 mg twice a day
492087|NCT00460382|Drug|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
492088|NCT00460369|Drug|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake"
492089|NCT00460369|Drug|artemether-lumefantrine|"tablets 20/120 mg~1 tablet twice daily for 3 days below 15 kg of bodyweight~2 tablets twice daily for 3 days below 24 kg of bodyweight~3 tablets twice daily for 3 days below 35 kg of bodyweight"
492090|NCT00460369|Drug|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg"
492091|NCT00460356|Other|Laboratory Biomarker Analysis|Correlative studies
492092|NCT00460356|Procedure|Lymphadenectomy|Undergo lymphadenectomy
492093|NCT00460343|Other|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
492097|NCT00460317|Drug|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
492098|NCT00460317|Drug|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
492099|NCT00460304|Drug|pramlintide|
492100|NCT00460304|Procedure|continuous glucose monitoring|
492101|NCT00460291|Device|Implantation of the ProVena vein graft during bypass surgery|
492102|NCT00460278|Drug|XL418|
492103|NCT00460265|Drug|ARM 2|Subjects will receive Cisplatin plus 5FU
492104|NCT00460265|Drug|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
492105|NCT00460252|Procedure|insulin titration applying a computer algorithm|
492106|NCT00460239|Drug|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
492107|NCT00460239|Drug|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
492108|NCT00460239|Drug|Placebo|Intramuscular; double blind; once per week
492109|NCT00460226|Drug|lamotrigine|lamotrigine treatment for 12weeks
492110|NCT00460213|Drug|Valsartan 80mg daily|
492111|NCT00460213|Drug|Valsartan 160mg daily|
492112|NCT00460200|Genetic|polymorphism analysis|
492113|NCT00460200|Other|laboratory biomarker analysis|
492114|NCT00460200|Other|physiologic testing|
492115|NCT00460200|Other|questionnaire administration|
492116|NCT00460200|Procedure|conventional surgery|
492117|NCT00460200|Procedure|fatigue assessment and management|
492118|NCT00460200|Procedure|psychosocial assessment and care|
492119|NCT00460187|Device|Percutaneous intervention of the carotid artery|
492120|NCT00460174|Biological|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
492121|NCT00460174|Drug|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
492122|NCT00460174|Procedure|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
492123|NCT00460174|Radiation|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
492124|NCT00460161|Procedure|acupuncture|2 treatments/week for 4 weeks
492125|NCT00460161|Other|placebo/sham acupuncture|2 treatments/week for 4 weeks
492126|NCT00460148|Drug|Ropinirole|
492127|NCT00460135|Behavioral|resistance training|2 times a week resistance training
492128|NCT00460109|Biological|denileukin diftitox|
492129|NCT00460109|Biological|rituximab|
492130|NCT00460096|Drug|Kamada-API|
492131|NCT00460083|Drug|Elidel(R) (pimecrolimus 1%)|
492132|NCT00460083|Device|EpiCeram(R) -ceramide based barrier repair cream|
492133|NCT00460057|Drug|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
492134|NCT00460031|Drug|ketoconazole|400 tid
492135|NCT00460031|Drug|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
492136|NCT00460031|Drug|therapeutic hydrocortisone|20mg qam 10mg qhs
492137|NCT00460018|Behavioral|Diet, Exercise, and Breastfeeding Intervention|"Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant~Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant~Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant~Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)"
492138|NCT00459992|Drug|Betahistine Hydrochloride|
492139|NCT00459979|Drug|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
492140|NCT00459979|Procedure|conventional surgery|nephrectomy
492141|NCT00459966|Procedure|Preoperative rehabilitation|
492142|NCT00459953|Drug|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
492143|NCT00459940|Drug|Pioglitazone|
492144|NCT00459927|Device|Floseal tonsillectomy|
492145|NCT00459927|Device|Coblation tonsillectomy|
492146|NCT00459914|Device|cpap treatment during sleep|CPAP
492147|NCT00459901|Drug|Erlotinib and capecitabine|
492148|NCT00459888|Device|PolarCath Peripheral Dilatation System (Boston Scientific)|
492149|NCT00459875|Drug|sunitinib malate|
492150|NCT00459862|Other|laboratory biomarker analysis|Correlative study
492151|NCT00459862|Drug|pazopanib hydrochloride|Given orally
492152|NCT00459849|Procedure|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
492153|NCT00459836|Drug|PR-104|
492154|NCT00459836|Drug|docetaxel|
492155|NCT00459836|Drug|gemcitabine hydrochloride|
492156|NCT00459836|Other|laboratory biomarker analysis|
492157|NCT00459836|Other|pharmacological study|
492158|NCT00459823|Drug|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
492159|NCT00459810|Drug|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
492160|NCT00459810|Drug|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
492161|NCT00459797|Device|Conventional (reusable) Glidescope|
492162|NCT00459797|Device|Single-use Glidescope videolaryngoscope|
492163|NCT00459784|Procedure|Dementia Training Program|
492164|NCT00459771|Drug|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
492165|NCT00459771|Drug|Placebo|Placebo, 32 mg, oral QD
492170|NCT00459732|Dietary Supplement|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
492171|NCT00459732|Dietary Supplement|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
492172|NCT00459719|Drug|Tacrolimus modified-release|oral
492173|NCT00459719|Drug|Prograf|oral
492174|NCT00459706|Device|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
492175|NCT00459706|Device|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
492176|NCT00459693|Drug|[11C]PBR28|
492177|NCT00459680|Device|Laser acupoint treatment|Laser
492178|NCT00459680|Procedure|Acupuncture|Needle acupuncture on ST36 and LI11.
492179|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
492180|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
492181|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.~Phase B: All patients will receive 500µg s.c.every other day (open-label)."
492182|NCT00459654|Drug|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
492183|NCT00459654|Drug|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
492184|NCT00459641|Drug|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
492185|NCT00459641|Other|Standard of Care|Bone marrow aspirate or steroids
492186|NCT00459628|Radiation|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
492187|NCT00459628|Radiation|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
492188|NCT00459615|Drug|Artesunate for Injection|
492189|NCT00459589|Behavioral|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
492190|NCT00459589|Behavioral|usual nutritional care|usual nutritional care
492191|NCT00459563|Drug|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
492192|NCT00459563|Drug|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
492193|NCT00459563|Drug|Placebo|Placebo once a week for 3 weeks
492194|NCT00459550|Drug|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
492195|NCT00459550|Drug|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
492196|NCT00459537|Drug|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
492197|NCT00459537|Drug|amorolfine nail lacquer|5 % amorolfine nail lacquer
492198|NCT00459524|Behavioral|Questionnaire|Questionnaires taking about 30 minutes to complete.
492199|NCT00459524|Behavioral|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
492200|NCT00459511|Procedure|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
492201|NCT00459485|Dietary Supplement|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
492202|NCT00459485|Dietary Supplement|Placebo|Daily placebo for 3 weeks
492203|NCT00459472|Behavioral|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
492204|NCT00459459|Procedure|Fine needle aspiration of the thyroid|
492205|NCT00459446|Drug|MS-325 Injection (Gadofosveset Trisodium)|
492206|NCT00459433|Procedure|Biopsychosocial intervention|Psychosocial versus usual care
492207|NCT00459420|Drug|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
492208|NCT00459420|Drug|placebo|placebo
492209|NCT00459407|Dietary Supplement|defined green tea catechin extract|Given orally
492210|NCT00459407|Drug|placebo|Given orally
492211|NCT00459407|Other|immunohistochemistry staining method|Correlative studies
492212|NCT00459407|Other|immunoenzyme technique|Correlative studies
492213|NCT00459407|Other|laboratory biomarker analysis|Correlative studies
492214|NCT00459407|Procedure|biopsy|Undergo biopsy
492215|NCT00459407|Other|mass spectrometry|Correlative studies
492216|NCT00459407|Other|high performance liquid chromatography|Correlative studies
492217|NCT00459381|Drug|pazopanib hydrochloride|Given orally
492218|NCT00459381|Other|laboratory biomarker analysis|Correlative studies
492219|NCT00459368|Behavioral|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
492220|NCT00459368|Behavioral|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
492221|NCT00459355|Behavioral|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
492222|NCT00459342|Drug|dasatinib|Given orally
492223|NCT00459329|Behavioral|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).~PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.~Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.~After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
492224|NCT00459316|Biological|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
492225|NCT00459303|Device|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
492226|NCT00459303|Device|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
492227|NCT00459290|Drug|mifepristone|
492228|NCT00459277|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|
492229|NCT00459264|Drug|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
492230|NCT00459264|Drug|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
492231|NCT00459238|Other|counseling intervention|subjects will receive telephone based counseling
492232|NCT00459238|Other|educational intervention|subjects will received telephone based education
492233|NCT00459225|Drug|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
492234|NCT00459212|Drug|GTI-2040|Given IV
492235|NCT00459212|Procedure|pharmacological study|Correlative study
492236|NCT00459212|Procedure|laboratory biomarker analysis|Correlative study
492237|NCT00459186|Drug|RAD001|Daily for two weeks
492238|NCT00459186|Drug|Docetaxel|Infusion once per cycle
492239|NCT00459186|Drug|Prednisone|Prednisone 5 mg by mouth twice daily
492240|NCT00459173|Drug|rimonabant (SR141716)|
492241|NCT00459160|Procedure|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
492242|NCT00459134|Dietary Supplement|ArginMax|Given orally
492243|NCT00459134|Dietary Supplement|Placebo|Given orally
492244|NCT00459121|Drug|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
492245|NCT00459121|Drug|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
492246|NCT00459121|Drug|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
492247|NCT00459121|Procedure|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
492248|NCT00459108|Drug|dasatinib|Given orally
492249|NCT00459082|Drug|Dexmedetomine|
492250|NCT00459069|Biological|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
492251|NCT00459056|Drug|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
492252|NCT00459056|Drug|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
492253|NCT00459043|Drug|ZD6474|Taken orally once every morning
492254|NCT00459043|Drug|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
492255|NCT00459030|Other|educational intervention via internet|additional cancer screening information via password protected internet site
492256|NCT00459030|Other|educational intervention mailed|
492257|NCT00459030|Other|No additional educational intervention|
492258|NCT00459017|Device|Portable blood pressure wrist manometer|
492259|NCT00459004|Drug|rimonabant (SR141716)|
492260|NCT00458991|Drug|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
492261|NCT00458978|Drug|Cediranib Maleate|Given orally
492262|NCT00458978|Other|Laboratory Biomarker Analysis|Correlative studies
492263|NCT00458952|Drug|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
492264|NCT00458913|Drug|bortezomib|
492265|NCT00458913|Drug|cisplatin|
492266|NCT00458900|Drug|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
492267|NCT00458887|Procedure|management of therapy complications|Undergo hearing tests
492436|NCT00457639|Drug|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
492268|NCT00458874|Behavioral|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
492269|NCT00458861|Biological|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
492270|NCT00458861|Other|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
492271|NCT00458848|Drug|asparaginase|
492272|NCT00458848|Drug|daunorubicin hydrochloride|
492273|NCT00458848|Drug|etoposide|
492274|NCT00458848|Drug|idarubicin|
492275|NCT00458848|Drug|imatinib mesylate|
492276|NCT00458848|Drug|mercaptopurine|
492277|NCT00458848|Drug|methotrexate|
492278|NCT00458848|Drug|methylprednisolone|
492279|NCT00458848|Drug|mitoxantrone hydrochloride|
492280|NCT00458848|Drug|prednisone|
492281|NCT00458848|Drug|vincristine sulfate|
492282|NCT00458848|Procedure|allogeneic hematopoietic stem cell transplantation|
492283|NCT00458848|Procedure|autologous hematopoietic stem cell transplantation|
492284|NCT00458848|Procedure|peripheral blood stem cell transplantation|
492285|NCT00458848|Radiation|radiation therapy|
492286|NCT00458835|Drug|Ciclesonide|
492287|NCT00458822|Drug|bortezomib|Given IV
492288|NCT00458822|Drug|dexamethasone|Given orally
492289|NCT00458809|Drug|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
492290|NCT00458796|Drug|zoledronic acid|
492291|NCT00458796|Procedure|quality-of-life assessment|
492292|NCT00458783|Biological|Prolonged RBC storage|Transfusion with oldest available matching RBCs
492293|NCT00458783|Biological|Short RBC storage|Transfusion with youngest available matching RBCs
492294|NCT00458770|Procedure|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
492295|NCT00458744|Drug|talotrexin|
492296|NCT00458744|Procedure|chemotherapy|
492297|NCT00458731|Biological|bevacizumab|Given IV
492298|NCT00458731|Drug|cediranib maleate|Given orally
492299|NCT00458718|Drug|rimonabant (SR141716)|
492300|NCT00458705|Drug|bortezomib|
492301|NCT00458705|Drug|dexamethasone|
492302|NCT00458705|Drug|pegylated liposomal doxorubicin hydrochloride|
492303|NCT00458705|Drug|thalidomide|
492304|NCT00458679|Biological|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10^7) of IL-2 secreting B-cells together with (2 x 10^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
492305|NCT00458653|Biological|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.~Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
492306|NCT00458614|Drug|Lansoprazole|
492307|NCT00458601|Drug|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
492308|NCT00458601|Drug|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
492309|NCT00458588|Other|physiologic testing|
492310|NCT00458588|Other|questionnaire administration|
492311|NCT00458588|Procedure|breast imaging study|
492312|NCT00458588|Procedure|dual x-ray absorptometry|
492313|NCT00458588|Procedure|evaluation of cancer risk factors|
492314|NCT00458588|Procedure|magnetic resonance imaging|
492315|NCT00458575|Drug|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
492316|NCT00458549|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids Oral 8g once a day for 21 days prior to (biopsy) surgery
492317|NCT00458549|Procedure|biopsy|
492318|NCT00458536|Biological|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
492319|NCT00458536|Drug|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
492320|NCT00458523|Biological|alemtuzumab|
492321|NCT00458523|Genetic|fluorescence in situ hybridization|
492322|NCT00458523|Genetic|mutation analysis|
492323|NCT00458523|Other|flow cytometry|
492324|NCT00458510|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
492325|NCT00458497|Device|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
492326|NCT00458497|Device|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
492376|NCT00458094|Behavioral|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
519923|NCT00241280|Device|galyfilcon A|
492327|NCT00458484|Radiation|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy. The radiation treatment planning and evaluation details are appended.~Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each."
492328|NCT00458484|Procedure|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
492329|NCT00458484|Procedure|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
492330|NCT00458471|Device|Insertion of a urinary catheter coated with benign E. coli|
492331|NCT00458458|Drug|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
492332|NCT00458458|Drug|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
492333|NCT00458445|Drug|SPD465|
492334|NCT00458419|Drug|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
492335|NCT00458419|Drug|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
492336|NCT00458406|Device|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months"
492337|NCT00458406|Device|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months."
492338|NCT00458393|Drug|daily TDF/FTC|daily oral medication
492339|NCT00458393|Drug|Placebo|daily oral medication
492340|NCT00458380|Procedure|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
492341|NCT00458367|Drug|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
492342|NCT00458354|Device|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
492343|NCT00458354|Procedure|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
492344|NCT00458341|Drug|PTC124|
492345|NCT00458328|Drug|Z-338|
492346|NCT00458315|Drug|Cisplatin|
492347|NCT00458315|Drug|Paclitaxel|
492348|NCT00458315|Drug|Gemcitabine|
492349|NCT00458315|Drug|Avastin (Bevacizumab)|
492350|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
492351|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
492352|NCT00458289|Drug|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
492353|NCT00458276|Drug|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
492354|NCT00458276|Drug|placebo|Placebo (i.e., normal saline) for i.v. use.
492355|NCT00458263|Drug|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
492356|NCT00458250|Procedure|Haploidentical hematopoietic stem cell transplantation|
492357|NCT00458250|Drug|Busulfan|
492358|NCT00458250|Drug|Cyclophosphamide|
492359|NCT00458250|Drug|CAMPATH-1H|
492360|NCT00458250|Drug|Cyclosporin A|
492361|NCT00458250|Drug|Methotrexate|
492362|NCT00458237|Drug|Everolimus|Everolimus is being administered orally 7 days per week.
492363|NCT00458237|Drug|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
492364|NCT00458224|Behavioral|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
492365|NCT00458211|Drug|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
492366|NCT00458198|Behavioral|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
492367|NCT00458185|Drug|etanercept|
492368|NCT00458172|Behavioral|Assessment of beliefs and attitudes|
492369|NCT00458159|Drug|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, & 50mg, taken once daily, orally.
492370|NCT00458146|Drug|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
492371|NCT00458133|Behavioral|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching & relaxing groups.
492372|NCT00458120|Biological|rDEN1delta30|Live attenuated 10^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
492373|NCT00458120|Biological|rDEN2/4delta30(ME)|Live attenuated 10^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
492374|NCT00458120|Biological|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
492375|NCT00458107|Drug|SCA-136|
492377|NCT00458094|Behavioral|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
492378|NCT00458081|Drug|Rimonabant|20 mg once per day + slightly reduced calorie diet
492379|NCT00458081|Drug|Placebo|placebo once per day + slightly reduced calorie diet
492380|NCT00458068|Drug|Oral administration of ferrous sulphate|
492381|NCT00458055|Drug|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
492382|NCT00458042|Drug|treprostinil sodium|
492383|NCT00458029|Behavioral|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
492384|NCT00458016|Drug|MB07803|Daily oral administration
492385|NCT00458016|Drug|Placebo|Daily oral administration
492386|NCT00458003|Drug|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
492387|NCT00458003|Drug|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
492388|NCT00457990|Drug|Oral administration of ferrous sulphate|
492389|NCT00457977|Biological|Pneumovax (PPSV23)|Injection
492390|NCT00457977|Biological|Prevnar (PCV7)|Injection
492391|NCT00457964|Drug|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
492392|NCT00457951|Drug|Open-Label|ODSH administered open-label
492393|NCT00457951|Drug|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
492394|NCT00457951|Drug|ODSH|Randomized, Blinded, ODSH Arm
492395|NCT00457938|Other|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
492396|NCT00457938|Other|Diet|10 % versus 35 % fat in diet
492397|NCT00457925|Drug|GSK221149A|
492398|NCT00457899|Drug|Quetiapine IR (Immediate Release)|oral
492399|NCT00457873|Drug|0.9% saline in 5% dextrose (intravenous)|
492400|NCT00457873|Drug|0.45% saline in 5% dextrose (intravenous)|
492401|NCT00457860|Drug|Immunotoxin therapy|
492402|NCT00457860|Drug|CAT-8015 immunotoxin|
492403|NCT00457860|Procedure|Biological therapy|
492404|NCT00457834|Device|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
492405|NCT00457821|Drug|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
492406|NCT00457821|Drug|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
492407|NCT00457821|Drug|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
492408|NCT00457821|Drug|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
492409|NCT00457808|Drug|Rapamycin, sirolimus|
492410|NCT00457795|Drug|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
492411|NCT00457782|Drug|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
492412|NCT00457769|Drug|Donepezil and self-generated memory training|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
492413|NCT00457769|Drug|Donepezil and experimenter-administered memory training|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
492414|NCT00457756|Dietary Supplement|BiosLife Complete|
492415|NCT00457756|Dietary Supplement|Placebo|
492416|NCT00457743|Drug|Sunitinib malate (SU011248)|SU011248
492417|NCT00457730|Drug|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
492418|NCT00457730|Drug|Placebo|Subjects are randomized to either Duloxetine or Placebo
492419|NCT00457717|Drug|0.25 % atropine|
492420|NCT00457717|Drug|0.5 % atropine|
492421|NCT00457717|Procedure|0.25 % atropine+auricular acupoints|
492422|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
492423|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
492424|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
492425|NCT00457691|Drug|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
492426|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
492427|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
492428|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
492429|NCT00457691|Drug|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
492430|NCT00457678|Drug|Visudyne|
492431|NCT00457678|Drug|Lucentis|
492432|NCT00457678|Drug|Dexamethasone|
492433|NCT00457665|Drug|Nelfinavir|
492434|NCT00457665|Drug|Efavirenz|
492435|NCT00457652|Drug|Rosuvastatin|7 day treatment rosuvastatin 20mg
492813|NCT00454480|Drug|gemtuzumab ozogamicin|
492814|NCT00454480|Drug|melphalan|
492437|NCT00457626|Drug|Valsartan|All patients started with dose 1 mg/kg once daily for first 2 weeks, up-titration to 2mg/kg (then to 4mg/kg) depending on MSSBP.
492438|NCT00457613|Drug|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
492439|NCT00457600|Procedure|patient-driven health IT product|
492440|NCT00457574|Drug|GMX1777|
492441|NCT00457548|Behavioral|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
492442|NCT00457522|Behavioral|Nurse/community health worker telephone intervention|
492443|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
492444|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
492445|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
492446|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
492447|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
492448|NCT00457496|Behavioral|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
492449|NCT00457483|Drug|hydrochlorothiazide|12.5 mg once-a-day
492450|NCT00457483|Drug|valsartan, 80 mg once-a-day|80 mg once-a-day
492451|NCT00457470|Drug|AG-014699|
492452|NCT00457457|Drug|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
492453|NCT00457457|Drug|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (>80 fold) compared to sildenafil (~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
492454|NCT00457444|Drug|Pollen|
492455|NCT00457431|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
492456|NCT00457418|Drug|PEG-Intron|
492457|NCT00457405|Drug|dipyridamole|dipyridamole 200mg twice daily
492458|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
492459|NCT00457392|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
492460|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
492461|NCT00457392|Drug|placebo|Placebo daily by oral capsules in a continuous regimen
492462|NCT00457379|Behavioral|physical exercise|
492463|NCT00457366|Drug|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary up to a maximum dose of Quetiapine 600mg PO QD
492464|NCT00457366|Drug|Haloperidol|given in combination with Lorazepam 2 mg IM, Cogentin 2 mg IM; repeated at 2 hours as deemed clinically necessary
492465|NCT00457366|Drug|Lorazepam|given in combination with Haloperidol 5mg IM and cogentin 2mg IM; repeated at 2 hours as deemed clinically necessary.
492466|NCT00457366|Drug|Cogentin|given in combination with haloperidol 5mg IM, and Lorazepam 2mg IM; repeated at 2 hours as deemed clinically necessary.
492467|NCT00457353|Drug|Bacillus Clausii|For 5 days
492468|NCT00457353|Other|Oral rehydration therapy|For 5 days
492469|NCT00457340|Drug|Atorvastatin 80mg|
492470|NCT00457327|Procedure|protective ileostomy|
492471|NCT00457314|Behavioral|Exercise|Regular exercise training
492472|NCT00457301|Behavioral|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
492473|NCT00457288|Drug|TF 002|
492474|NCT00457275|Drug|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
492475|NCT00457262|Procedure|soy consumption|
492476|NCT00457249|Biological|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
492477|NCT00457249|Biological|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
492478|NCT00457223|Procedure|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
492479|NCT00457210|Procedure|Brain Radiotherapy/Stereotactic Radiosurgery|
492480|NCT00457197|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
492481|NCT00457197|Drug|Quetiapine|Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
492482|NCT00457184|Procedure|Blood tests|
492483|NCT00457171|Drug|GI-270384|
492484|NCT00457158|Device|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
492485|NCT00457145|Drug|Ranibizumab|
492486|NCT00457132|Device|APOS biomechanical gait system|
492487|NCT00457119|Drug|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
492488|NCT00457106|Drug|Paroxetine|
492489|NCT00457106|Drug|Risperidone|
492490|NCT00457093|Drug|glargine|
492491|NCT00457093|Drug|detemir|
492492|NCT00457080|Device|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
492493|NCT00457067|Drug|Ranibizumab|
492494|NCT00457054|Drug|Lithium|starting dose 600 mg increase as tolerated
492495|NCT00457015|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
492496|NCT00457015|Drug|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
492497|NCT00457002|Drug|Apixaban|"Apixaban: Twice daily, 30 days~Placebo: Once daily, 6-14 days"
492498|NCT00457002|Drug|Enoxaparin|"Enoxaparin: Once daily, 6-14 days~Placebo: Twice daily, 30 days"
492499|NCT00456989|Drug|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
492500|NCT00456989|Drug|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
492501|NCT00456976|Drug|Selegiline|
492502|NCT00456963|Behavioral|Diet|total fat < 5%, saturated fat < 10%, vegetables, fruit
492503|NCT00456963|Behavioral|Moderate exercise|30 min at least 5 times/week
492504|NCT00456963|Drug|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
492505|NCT00456963|Drug|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
492506|NCT00456963|Drug|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
492507|NCT00456937|Drug|Escitalopram|
492508|NCT00456924|Drug|VA2914|
492509|NCT00456911|Behavioral|Fat and carbohydrate controlled diet|
492510|NCT00456898|Drug|desvenlafaxine sustained release (DVS SR)|
492511|NCT00456898|Drug|Paroxetine|
492512|NCT00456898|Drug|Codeine|
492513|NCT00456885|Drug|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
492514|NCT00456885|Drug|Placebo|Twice daily injection of placebo
492515|NCT00456872|Drug|lidocaine|
492516|NCT00456859|Drug|Kremezin|
492517|NCT00456846|Drug|ABI-007|100 mg/m^2 ABI-007 weekly for 3 weeks followed by 1 week rest
492518|NCT00456833|Drug|RAD001|
492519|NCT00456833|Drug|erlotinib|
492520|NCT00456820|Drug|Wellbutrin XL|
492521|NCT00456807|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
492522|NCT00456807|Biological|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
492523|NCT00456794|Drug|Istradefylline (KW-6002)|
492524|NCT00456781|Device|Augmentation|Rotator Cuff Repair plus Graft Jacket
492525|NCT00456781|Procedure|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
492526|NCT00456755|Drug|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
492527|NCT00456755|Other|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
492528|NCT00456729|Drug|Metronidazole|
492529|NCT00456729|Procedure|Blood tests|
492530|NCT00456716|Drug|sorafenib|400mg po bid
492531|NCT00456703|Other|intraoperative fluid management|fluid restriction
492532|NCT00456703|Other|fluid restriction|restriction of fluids
492533|NCT00456690|Other|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
492534|NCT00456677|Drug|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
492535|NCT00456677|Drug|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
492536|NCT00456664|Genetic|IE gene|
492537|NCT00456651|Device|CPAP (Continuous Positive Airway Pressure)|
492538|NCT00456638|Drug|Depodur|Depodur vs. traditional management
492539|NCT00456625|Biological|Engerix™-B|Intramuscular injection, 1 dose
492540|NCT00456612|Procedure|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
492541|NCT00456599|Drug|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
492542|NCT00456599|Drug|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
492543|NCT00456599|Procedure|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
492544|NCT00456586|Drug|KW-6002 (istradefylline)|
492545|NCT00456573|Procedure|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
492546|NCT00456560|Drug|AV650|
492547|NCT00456560|Drug|Fluvoxamine|
492548|NCT00456560|Drug|Paroxetine|
492549|NCT00456547|Procedure|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
492550|NCT00456521|Drug|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
492551|NCT00456521|Drug|Placebo|
492552|NCT00456521|Behavioral|Intensive group lifestyle modification counseling|
492553|NCT00456508|Drug|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
492554|NCT00456495|Drug|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
492555|NCT00456482|Drug|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
492556|NCT00456482|Drug|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
492557|NCT00456443|Procedure|Historical records|
492558|NCT00456430|Drug|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
492559|NCT00456417|Drug|123-I MNI-187 Injection and Imaging Procedures|
492560|NCT00456404|Drug|peppermint water|
492561|NCT00456391|Procedure|Medical history|
492562|NCT00456391|Procedure|Brain CT scan|
492563|NCT00456378|Device|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
492564|NCT00456378|Procedure|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
492565|NCT00456365|Drug|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
492566|NCT00456365|Drug|Placebo|Placebo daily
492567|NCT00456352|Procedure|duodenal exclusion|
492815|NCT00454480|Drug|tipifarnib|
520445|NCT00236808|Drug|levofloxacin|
492568|NCT00456339|Drug|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
492569|NCT00456313|Drug|FLIXOTIDE and SERETIDE|comparator
492570|NCT00456300|Drug|Exenatide|In each intervention arm the participant receives a different dose (1.25 or 2.5 mcg) of exenatide.
492571|NCT00456300|Drug|Insulin|Each subject received a baseline study with insulin alone
492572|NCT00456287|Device|CPAP (Continuous Positive Airway Pressure)|
492573|NCT00456274|Procedure|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
492574|NCT00456261|Drug|Pemetrexed|pemetrexed 500 mg/m2
492575|NCT00456261|Drug|Gemcitabine|gemcitabine 1500 mg/m2
492576|NCT00456261|Drug|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
492577|NCT00456261|Drug|Carboplatin|carboplatin AUC=5
492578|NCT00456248|Drug|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
492579|NCT00456235|Drug|Mycophénolate Mofétil|
492580|NCT00456235|Drug|Ciclosporine A|
492581|NCT00456235|Drug|Tacrolimus|
492582|NCT00456222|Behavioral|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
492583|NCT00456183|Biological|MVA 85A|
492584|NCT00456170|Procedure|Performing Vaginal hysterectomy with Harmonic Scalpel|
492585|NCT00456157|Drug|Intra-articular Injection of OP-1 to affected knee|
492586|NCT00456144|Drug|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
492587|NCT00456131|Behavioral|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
492588|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
492589|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
492590|NCT00456105|Behavioral|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
492591|NCT00456092|Drug|Apremilast|Capsules for oral administration
492592|NCT00456092|Drug|Placebo|Capsules for oral administration
492593|NCT00456066|Device|Export Aspiration System|Patients scheduled for emergency angioplasty
492594|NCT00456053|Drug|FG2216|
492595|NCT00456027|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
492596|NCT00456014|Drug|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
492597|NCT00456014|Drug|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
492598|NCT00455975|Drug|Bevacizumab|Bevacizumab
492599|NCT00455962|Drug|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
492600|NCT00455962|Drug|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
492601|NCT00455936|Drug|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
492602|NCT00455936|Procedure|chemotherapy|gemcitabine(1250mg/m2 iv on D1 & 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
492603|NCT00455923|Drug|Seretide|Seretide
492604|NCT00455923|Drug|Flixotide|Flixotide
492605|NCT00455910|Drug|Thalidomide|
492606|NCT00455897|Drug|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
492607|NCT00455897|Drug|CHOP|Administered as part of standard care
492608|NCT00455897|Drug|Rituximab|Administered as part of standard treatment
492609|NCT00455871|Drug|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
492610|NCT00455871|Drug|Lucentis|Lucentis intravitreal injection
492611|NCT00455858|Drug|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
492612|NCT00455845|Device|Levonorgestrel IUD|levonorgestrel IUD
492613|NCT00455832|Procedure|peginterferon alpha and ribavirin|sperm collection
492614|NCT00455819|Procedure|home treatment|
492615|NCT00455806|Drug|esomeprazole|
492616|NCT00455806|Drug|moxifloxacin|
492617|NCT00455806|Drug|amoxicillin|
492618|NCT00455780|Behavioral|Weight Loss Phase|Weight loss using CBT and meal replacements
492619|NCT00455780|Behavioral|Continued CBT|Using CBT during weight loss maintenance
492620|NCT00455780|Behavioral|reduced energy density education|Additional nutritional learning
492621|NCT00455780|Behavioral|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
492622|NCT00455767|Drug|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
492623|NCT00455767|Drug|Placebo|Placebo
492624|NCT00455754|Drug|Esomeprazole|
492625|NCT00455741|Drug|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
492626|NCT00455741|Drug|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
492627|NCT00455715|Drug|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
492628|NCT00455702|Drug|d-cycloserine|50mg dose d-cycloserine v placebo
492816|NCT00454480|Genetic|DNA methylation analysis|
492817|NCT00454480|Genetic|cytogenetic analysis|
492629|NCT00455689|Drug|Leuprolide acetate|"Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection~Leuprolide is a widely used gonadotropin-releasing hormone agonist (GnRHa) that is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women."
492630|NCT00455676|Procedure|Chevron osteotomy versus Scarf osteotomy|
492631|NCT00455663|Behavioral|Cognitive Adaptation Training|Environmental supports for all independent living skills
492632|NCT00455663|Behavioral|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
492633|NCT00455663|Other|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
492634|NCT00455650|Drug|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
492635|NCT00455650|Drug|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
492636|NCT00455650|Drug|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
492637|NCT00455637|Biological|Botulinum toxin type A|
492638|NCT00455624|Drug|Androgen deprivation therapy|According to standard medical care
492639|NCT00455611|Device|CPAP (Continuous Positive Airway Pressure)|
492640|NCT00455598|Drug|ISIS 113715|doses of 100 and 200 mg per week
492641|NCT00455585|Drug|nevirapine, stavudine, lamivudine|
492642|NCT00455572|Biological|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
492643|NCT00455572|Drug|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
492644|NCT00455572|Drug|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
492645|NCT00455572|Procedure|Radiotherapy|Regimen will be based upon the site's own standard procedures
492646|NCT00455559|Drug|Perifosine|
492647|NCT00455559|Drug|Imatinib Mesylate|
492648|NCT00455546|Drug|A-002|
492649|NCT00455533|Drug|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
492650|NCT00455533|Drug|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
492651|NCT00455533|Drug|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
492652|NCT00455533|Drug|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
492653|NCT00455520|Drug|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
492654|NCT00455520|Drug|placebo|matching placebo twice daily for 12 weeks
492655|NCT00455507|Drug|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
492656|NCT00455507|Drug|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
492657|NCT00455507|Drug|Placebo|Two placebo tablets orally once daily for 12 weeks
492658|NCT00455494|Drug|AQ-13|
492659|NCT00455468|Procedure|Day-care treatment vs. hospital care|
492660|NCT00455455|Drug|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
492661|NCT00455455|Drug|ReNu Multiplus Multipurpose Solution|lens care system
492662|NCT00455442|Drug|Mifepristone|
492663|NCT00455429|Drug|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram [mg]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
492664|NCT00455429|Drug|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
492665|NCT00455429|Drug|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
492666|NCT00455429|Drug|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
492667|NCT00455429|Drug|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
492668|NCT00455416|Drug|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
492669|NCT00455416|Drug|Selenium (L-Selenomethionine),|100mcgx2 daily
492670|NCT00455416|Drug|Garlic extract (Allicin)|6 garlic pearls daily
492671|NCT00455416|Drug|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
492672|NCT00455416|Drug|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
492673|NCT00455416|Drug|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
492674|NCT00455403|Drug|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
492675|NCT00455403|Drug|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
492676|NCT00455390|Procedure|Post-immediate Psychotherapeutic Intervention|
492677|NCT00455364|Drug|Voriconazole|
492678|NCT00455351|Drug|Vorinostat|Increasing dosing, phase I
492679|NCT00455338|Behavioral|Meal Composition|
492680|NCT00455325|Drug|Placebo Comparator Limb 1|1 chloroquine placebo tablet for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
492681|NCT00455325|Drug|Chloroquine|80mg chloroquine or placebo tablet weekly for Weeks 1-3;euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
492682|NCT00455325|Drug|Chloroquine|80mg tablet daily for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
492683|NCT00455325|Drug|Chloroquine|250mg tablet daily for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
492684|NCT00455312|Drug|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
492685|NCT00455312|Drug|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
492686|NCT00455312|Drug|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
492687|NCT00455312|Procedure|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
492688|NCT00455312|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
492689|NCT00455312|Drug|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
492690|NCT00455312|Drug|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
492691|NCT00455299|Procedure|Laparoscopic ventral hernia repair|
492692|NCT00455286|Drug|Methotrexate|
492693|NCT00455286|Drug|Methylprednisolone|
492694|NCT00455286|Drug|Temozolomide|
492695|NCT00455260|Drug|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
492696|NCT00455260|Device|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).~The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
492697|NCT00455247|Drug|Glutamine|
492698|NCT00455234|Drug|Intramuscular Olanzepine 10 mg|
492699|NCT00455234|Drug|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
492700|NCT00455221|Biological|Bcr-abl multipeptide vaccine|The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
492701|NCT00455221|Genetic|Cytokine gene adjuvant|Cytokine gene adjuvant
492702|NCT00455208|Drug|Cura-100|
492703|NCT00455195|Biological|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
492704|NCT00455182|Procedure|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
492705|NCT00455182|Procedure|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
492706|NCT00455182|Procedure|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
492707|NCT00455169|Biological|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
492708|NCT00455156|Drug|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
492709|NCT00455143|Drug|Precedex (Dexmedetomidine)|Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
492710|NCT00455143|Drug|Placebo|Matching placebo given prior to surgery and continued for 24 hours postoperatively
492711|NCT00455130|Drug|Inhaled mannitol|
492712|NCT00455117|Drug|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
492713|NCT00455104|Other|No intervention|This is an observational, voluntary registry.
492714|NCT00455091|Drug|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/> 105 copies/mL and ALT > 2.0 x UNL
492715|NCT00455078|Procedure|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
492716|NCT00455078|Other|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
492717|NCT00455078|Procedure|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
492718|NCT00455078|Procedure|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
492719|NCT00455078|Procedure|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
492720|NCT00455065|Behavioral|Whole Grain Foods|
492721|NCT00455052|Drug|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
492722|NCT00455039|Drug|GW572016|Dose: 1500 mg daily
492723|NCT00455026|Drug|remifentanil|target effect site concentration during induction
520519|NCT00236054|Drug|Gabitril|
492724|NCT00455013|Drug|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
492725|NCT00455013|Drug|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
492726|NCT00455013|Drug|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
492727|NCT00455013|Drug|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
492728|NCT00455013|Drug|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
492729|NCT00455000|Biological|PF-04360365|Monoclonal antibody
492730|NCT00455000|Drug|Placebo|Placebo
492731|NCT00454987|Biological|Menitorix|Menitorix was only administered to subjects of the group NoBoost at 40 to 43 months of age.
492732|NCT00454987|Biological|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
492733|NCT00454974|Device|Wearable artificial kidney|
492734|NCT00454961|Drug|artemether-lumefantrine|
492735|NCT00454948|Behavioral|Home-based nutrition sessions and play group exercise|
492736|NCT00454948|Behavioral|Group-based nutrition sessions and mail-out activities|
492737|NCT00454922|Behavioral|standard of care|no intervention
492738|NCT00454922|Other|education|meet with trained glaucoma educator 6 times over life of study
492739|NCT00454909|Biological|Meningococcal vaccine 134612|Single dose intramuscular injection.
492740|NCT00454909|Biological|Menactra®|Single dose intramuscular injection.
492741|NCT00454896|Drug|VESIcare®|Oral
492742|NCT00454896|Drug|placebo|Oral
492743|NCT00454883|Drug|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
492744|NCT00454870|Drug|MEM 3454|
492745|NCT00454857|Other|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
492746|NCT00454857|Other|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
492747|NCT00454857|Other|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
492748|NCT00454831|Device|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
492749|NCT00454818|Genetic|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
492750|NCT00454818|Procedure|Placebo Infusion|Saline; epicardial coronary artery infusion
492751|NCT00454818|Genetic|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
492752|NCT00454805|Drug|AZD2171|Oral tablet
492753|NCT00454805|Drug|Fulvestrant|intramuscular injection
492754|NCT00454792|Other|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
492755|NCT00454792|Other|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
492756|NCT00454779|Drug|Cisplatin|chemotherapy arm
492757|NCT00454779|Drug|Panitumumab|experimental arm
492758|NCT00454779|Drug|Docetaxel|chemotherapy arm
492759|NCT00454779|Drug|Cisplatin|experimental arm
492760|NCT00454779|Drug|Docetaxel|experimental arm
492761|NCT00454766|Behavioral|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
492762|NCT00454753|Drug|Dasatinib|"tablet, Oral, 140mg/day, BID, until;~the time of reimbursement in Korea~the application for marketing authorization is withdrawn~the application for marketing authorization is denied"
492763|NCT00454740|Drug|solifenacin succinate|Oral
492764|NCT00454714|Drug|single dose Sildenafil|Application of a single dose Sildenafil
492765|NCT00454714|Drug|Single dose placebo|Application of a single dose placebo
492766|NCT00454701|Drug|Alefacept exposure|Observational
492767|NCT00454688|Drug|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
492768|NCT00454688|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
492769|NCT00454662|Drug|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
492770|NCT00454662|Drug|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
492818|NCT00454480|Genetic|gene expression analysis|
492819|NCT00454480|Genetic|mutation analysis|
492820|NCT00454480|Other|diagnostic laboratory biomarker analysis|
492821|NCT00454480|Other|immunologic technique|
492822|NCT00454480|Procedure|allogeneic hematopoietic stem cell transplantation|
493180|NCT00451646|Drug|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
492771|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel [200 milligram/square meter (mg/m^2)] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram*minute/milliliter (mg*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
492772|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
492773|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
492774|NCT00454649|Drug|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
492775|NCT00454649|Drug|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
492776|NCT00454649|Drug|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m^2) 60-minute infusion on Day 1 of each cycle.
492777|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
492778|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
492779|NCT00454649|Drug|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m^2) infusion on Day 1 of each cycle.
492780|NCT00454649|Drug|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m^2) 10-minute infusion followed by cisplatin (75 mg/m^2) infusion on Day 1 of each cycle.
492781|NCT00454636|Drug|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
492782|NCT00454636|Drug|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
492783|NCT00454636|Drug|Epirubicin|50 mg/m2/day, IV, every 3 weeks
492784|NCT00454636|Drug|Cisplatin|60 mg/m2/day, IV, every 3 weeks
492785|NCT00454636|Drug|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
492786|NCT00454636|Drug|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
492787|NCT00454636|Drug|Docetaxel|60 mg/m2/day, IV, every 3 weeks
492788|NCT00454636|Drug|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
492789|NCT00454623|Behavioral|drawing serum adiponectin level|
492790|NCT00454610|Behavioral|FLOW|
492791|NCT00454610|Behavioral|SelfHelp|
492792|NCT00454597|Procedure|omentectomy|surgery omentectomy
492793|NCT00454584|Drug|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
492794|NCT00454584|Drug|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
492795|NCT00454584|Drug|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
492796|NCT00454571|Drug|pazopanib hydrochloride|Given PO
492797|NCT00454571|Drug|leuprolide acetate|
492798|NCT00454571|Drug|goserelin acetate|
492799|NCT00454558|Drug|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
492800|NCT00454545|Drug|Atorvastatin|
492801|NCT00454532|Drug|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
492802|NCT00454519|Procedure|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
492803|NCT00454519|Procedure|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
492804|NCT00454493|Drug|Omacor (omega-3-acid ethyl esters)|
492805|NCT00454480|Biological|alemtuzumab|
492806|NCT00454480|Drug|arsenic trioxide|
492807|NCT00454480|Drug|azacitidine|
492808|NCT00454480|Drug|busulfan|
492809|NCT00454480|Drug|clofarabine|
492810|NCT00454480|Drug|cytarabine|
492811|NCT00454480|Drug|daunorubicin hydrochloride|
492812|NCT00454480|Drug|fludarabine phosphate|
492823|NCT00454480|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
492824|NCT00454467|Procedure|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
492825|NCT00454467|Procedure|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
492826|NCT00454467|Procedure|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
492827|NCT00454467|Procedure|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
492828|NCT00454467|Procedure|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
492829|NCT00454467|Procedure|Cost Data|Cost Data will be collected via hospital billing databases.
492830|NCT00454467|Procedure|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
492831|NCT00454441|Drug|MF101|
492832|NCT00454428|Procedure|pulsatile intra-aortic balloon pump|
492833|NCT00454402|Drug|Alfuzosin|
492834|NCT00454389|Device|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
492835|NCT00454389|Drug|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
492836|NCT00454376|Other|questionnaire administration|
492837|NCT00454376|Procedure|quality-of-life assessment|
492838|NCT00454363|Other|Laboratory Biomarker Analysis|Correlative studies
492839|NCT00454363|Drug|Pazopanib Hydrochloride|Given PO
492840|NCT00454363|Other|Pharmacological Study|Correlative studies
492841|NCT00454350|Drug|Hectorol (doxercalciferol injection)|
492842|NCT00454350|Drug|Zemplar (Paricalcitol injection)|
492843|NCT00454337|Drug|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
492844|NCT00454337|Drug|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
492845|NCT00454324|Drug|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
492846|NCT00454324|Drug|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)~Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
492847|NCT00454311|Procedure|Biopsy of Day 3 Embryo|
492848|NCT00454311|Procedure|· day embryo biopsy|
492849|NCT00454298|Drug|AGG-523 (Aggrecanase Inhibitor)|
492850|NCT00454285|Drug|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
492851|NCT00454272|Drug|Teicoplanin|
492852|NCT00454272|Drug|Vancomycin|
492853|NCT00454259|Drug|Fentanyl/Placebo injection|Ultra low dose intravenous injection
492854|NCT00454246|Drug|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
492855|NCT00454246|Drug|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
492856|NCT00454246|Drug|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
492857|NCT00454233|Drug|YM543|Oral
492858|NCT00454233|Drug|Metformin|Oral
492859|NCT00454233|Drug|Placebo|oral
492860|NCT00454220|Other|Placebo|33 patients to placebo + 131-I arm
492861|NCT00454220|Drug|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
492862|NCT00454220|Drug|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
492863|NCT00454207|Drug|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
492864|NCT00454194|Drug|pemetrexed disodium|given IV
492865|NCT00454194|Drug|sorafenib tosylate|given orally
492866|NCT00454181|Drug|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
492867|NCT00454181|Other|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
492868|NCT00454168|Biological|PR1 leukemia peptide vaccine|Given subcutaneously
492869|NCT00454168|Biological|sargramostim|Given subcutaneously
492870|NCT00454168|Other|placebo|Given subcutaneously
492871|NCT00454155|Drug|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
492872|NCT00454142|Drug|pazopanib hydrochloride|Given PO
492873|NCT00454142|Other|pharmacological study|Correlative studies
492874|NCT00454142|Procedure|computed tomography|Correlative studies
492875|NCT00454129|Procedure|cholangiography via double-balloon enteroscopy|
492876|NCT00454129|Procedure|MR cholangiography|
492877|NCT00454116|Drug|Vandetanib|once daily oral tablet two doses
492878|NCT00454116|Drug|FOLFIRI|Intravenous infusion
492879|NCT00454103|Drug|123I-Iodometomidate|
492880|NCT00454090|Drug|AZD8330|oral tablet
492881|NCT00454077|Procedure|radioiodine therapy after rhTSH|
492882|NCT00454064|Behavioral|cognitive-behavioral treatment|
492937|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
492938|NCT00453570|Biological|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
492939|NCT00453557|Drug|rhGH|
493181|NCT00451633|Drug|E2007|
520520|NCT00236041|Drug|ACTIQ®|
492883|NCT00454051|Drug|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
492884|NCT00454051|Drug|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
492885|NCT00454038|Device|HYPRO SORB F|resorbable, double layered, collagen membrane
492886|NCT00454012|Procedure|biophysical profile|
492887|NCT00453999|Drug|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
492888|NCT00453999|Drug|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
492889|NCT00453999|Drug|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
492890|NCT00453986|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
492891|NCT00453986|Biological|Mencevax™ACWY|One subcutaneous dose
492892|NCT00453986|Biological|Fluarix™|One intramuscular dose
492893|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
492894|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
492895|NCT00453960|Dietary Supplement|Genivis|54 mg/day daily for 6 months
492896|NCT00453960|Drug|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
492897|NCT00453960|Other|placebo|tablets daily for 6 months
492898|NCT00453947|Device|CPAP and Non Invasive Ventilation|
492899|NCT00453934|Device|h-Patch|
492900|NCT00453921|Drug|Methylphenidate|Dosage dependent on weight
492901|NCT00453921|Behavioral|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
492902|NCT00453921|Other|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
492903|NCT00453908|Drug|Alfuzosin|
492904|NCT00453895|Drug|Sunitinib|50mg Sunitinib
492905|NCT00453882|Device|flostat (TM) System|
492906|NCT00453869|Other|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
492907|NCT00453856|Drug|Sulfadoxine Pyrimethamine|
492908|NCT00453843|Device|rehabilitation robotics|sequence of intervention
492909|NCT00453843|Procedure|Movement therapy|sequence of intervention
492910|NCT00453830|Procedure|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
492911|NCT00453817|Drug|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
492912|NCT00453817|Procedure|Islet transplantation|intraportal percutaneous islet transplantation
492913|NCT00453817|Procedure|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
492914|NCT00453804|Drug|injectable naltrexone|
492915|NCT00453804|Drug|oral naltrexone|
492916|NCT00453791|Drug|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
492917|NCT00453791|Drug|Placebo|Placebo MDI will be given to the subjects.
492918|NCT00453778|Drug|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
492919|NCT00453765|Drug|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
492920|NCT00453765|Drug|placebo|placebo
492921|NCT00453726|Procedure|Non invasive mechanical ventilation|
492922|NCT00453700|Procedure|Trypanosoma cruzi serology|
492923|NCT00453687|Drug|GSK233705|investigational drug
492924|NCT00453661|Behavioral|Questionnaire|"Intervention Group:~Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.~Comparison Group:~Exit Questionnaire only."
492925|NCT00453661|Behavioral|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
492926|NCT00453648|Other|White-fleshed sweet potatoes|
492927|NCT00453648|Other|Orange-fleshed sweet potatoes (boiled)|
492928|NCT00453648|Other|Orange-fleshed sweet potatoes (fried)|
492929|NCT00453648|Other|WFSP and capsule of retinyl palmitate|
492930|NCT00453635|Drug|Docetaxel|Docetaxel at the dose of 75mg/m^2 IV on day 1 every 3 weeks for 6 consecutive cycles
492931|NCT00453635|Drug|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
492932|NCT00453635|Drug|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
492933|NCT00453635|Drug|Vinorelbine|Vinorelbine at the dose of 60mg/m^2 per os,weekly
492934|NCT00453622|Device|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
492935|NCT00453609|Drug|long-lasting injectable naltrexone|
492936|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
493475|NCT00449696|Device|Gel-200|Single intra-articular injection
492940|NCT00453544|Other|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
492941|NCT00453544|Other|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
492942|NCT00453531|Procedure|Limb Ischemia|
492943|NCT00453531|Drug|Acetylcholine|
492944|NCT00453518|Device|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
492945|NCT00453492|Drug|risedronate sodium|
492946|NCT00453479|Drug|GSK233705B|
492947|NCT00453466|Behavioral|EBW group intervention to empower battered women|
492948|NCT00453453|Drug|Nesiritide|Nesiritide given orally in the emergency department
492949|NCT00453440|Procedure|Cheek swab & blood test|Cheek swab & blood test
492950|NCT00453427|Drug|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
492951|NCT00453414|Drug|Iloprost Inhalation Solution (Ventavis)|
492952|NCT00453401|Drug|NB-001|
492953|NCT00453388|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
492954|NCT00453388|Drug|Cyclophosphamide|Given IV
492955|NCT00453388|Drug|Cyclosporine|Given IV or PO
492956|NCT00453388|Drug|Fludarabine Phosphate|Given IV
492957|NCT00453388|Other|Laboratory Biomarker Analysis|Correlative studies
492958|NCT00453388|Drug|Mycophenolate Mofetil|Given PO
492959|NCT00453388|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
492960|NCT00453388|Radiation|Total-Body Irradiation|Undergo TBI
492961|NCT00453375|Drug|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
492962|NCT00453375|Drug|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
492963|NCT00453362|Other|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
492964|NCT00453362|Other|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
492965|NCT00453362|Drug|erlotinib HCl|Tablets taken orally 150 mg/day.
492966|NCT00453349|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
492967|NCT00453349|Drug|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
492968|NCT00453336|Drug|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
492969|NCT00453336|Procedure|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
492970|NCT00453323|Drug|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
492971|NCT00453323|Drug|Capecitabine|capecitabine 900mg/m2 bid po on day 1~14, 1 weeks rest, until disease progression
492972|NCT00453310|Drug|sunitinib malate|
492973|NCT00453297|Drug|MF101|
492974|NCT00453271|Drug|NB-002|
492975|NCT00453271|Drug|Vehicle control|
492976|NCT00453258|Other|Eye Examination|Subjects receiving eye examination
492977|NCT00453232|Biological|bleomycin sulfate|
492978|NCT00453232|Biological|pegfilgrastim|
492979|NCT00453232|Drug|cisplatin|
492980|NCT00453232|Drug|etoposide|
492981|NCT00453219|Procedure|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
492982|NCT00453219|Procedure|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
492983|NCT00453219|Genetic|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
492984|NCT00453219|Procedure|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
492985|NCT00453219|Procedure|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
492986|NCT00453206|Procedure|allogeneic bone marrow transplantation|
492987|NCT00453206|Procedure|allogeneic hematopoietic stem cell transplantation|
492988|NCT00453206|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
492989|NCT00453206|Procedure|peripheral blood stem cell transplantation|
492990|NCT00453193|Drug|Pentostatin|4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
492991|NCT00453193|Drug|Alemtuzumab|30 mg IV three times weekly
492992|NCT00453180|Drug|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
492993|NCT00453180|Drug|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
493476|NCT00449696|Device|Placebo|Single intra-articular injection
492994|NCT00453167|Drug|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
492995|NCT00453167|Drug|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
492996|NCT00453154|Drug|Carboplatin|Given IV
492997|NCT00453154|Drug|Cisplatin|Given IV
492998|NCT00453154|Drug|Etoposide|Given IV
492999|NCT00453154|Other|Laboratory Biomarker Analysis|Correlative studies
493000|NCT00453154|Other|Placebo|Given PO
493001|NCT00453154|Drug|Sunitinib Malate|Given PO
493002|NCT00453141|Drug|dosing of Betamethasone|
493003|NCT00453115|Drug|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
493004|NCT00453115|Drug|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
493005|NCT00453102|Drug|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
493006|NCT00453102|Drug|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:~0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
493007|NCT00453089|Drug|VG101|
493008|NCT00453076|Device|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
493009|NCT00453063|Drug|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
493010|NCT00453063|Drug|Placebo|Two sprays in each nostril once daily in the morning
493011|NCT00453050|Drug|imiquimod|
493012|NCT00453050|Drug|indocyanine green solution|
493013|NCT00453050|Other|flow cytometry|
493014|NCT00453050|Other|immunologic technique|
493015|NCT00453050|Other|laboratory biomarker analysis|
493016|NCT00453037|Behavioral|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
493017|NCT00453037|Behavioral|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
493018|NCT00453024|Procedure|Pericardial graft & tissue glue|
493019|NCT00453024|Procedure|scleral flap & sutures|
493020|NCT00453011|Device|posterior chamber intraocular lens|
493021|NCT00453011|Device|anterior chamber intraocular lens|
493022|NCT00452998|Procedure|Q-switched fd Nd:yag in Laser Iridotomy|
493023|NCT00452985|Drug|Docetaxel|60-75 mg/m²
493024|NCT00452985|Drug|Carboplatin|AUC 5
493025|NCT00452972|Drug|Spinal Anesthesia|
493026|NCT00452920|Drug|docetaxel|
493027|NCT00452920|Radiation|cesium Cs 137|
493028|NCT00452920|Radiation|radiation therapy|
493029|NCT00452907|Drug|Artesunate|oad, per os, 3 days of treatment
493030|NCT00452907|Drug|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
493031|NCT00452907|Drug|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
493032|NCT00452894|Drug|varenicline tartrate|
493033|NCT00452881|Drug|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
493034|NCT00452881|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
493035|NCT00452881|Drug|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
493036|NCT00452868|Drug|Donepezil|Donepezil 5 milligrams a day for 6 weeks
493037|NCT00452855|Procedure|Sevoflurane-remifentanil anaesthesia|
493038|NCT00452829|Drug|Folic Acid and inositol|Folic Acid and inositol
493039|NCT00452829|Drug|Folic acid and placebo|Folic acid and placebo
493040|NCT00452816|Behavioral|Workplace Solutions Consulting approach|"Consulting process includes:~baseline measure of best practices~gap analysis and recommendations reporting~delivery of solution set toolkits for each practice chosen for implementation"
493041|NCT00452816|Behavioral|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
493042|NCT00452803|Drug|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
493043|NCT00452803|Drug|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
493044|NCT00452803|Radiation|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
493045|NCT00452790|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
493046|NCT00452790|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
493047|NCT00452777|Drug|BVT.115959|
493048|NCT00452777|Drug|Placebo|
493049|NCT00452764|Behavioral|Withdrawal of medication|
493050|NCT00452751|Procedure|laparoscopy-assisted distal gastrectomy|
493051|NCT00452751|Procedure|open distal gastrectomy|
493052|NCT00452738|Behavioral|Therapy dog|
493053|NCT00452738|Behavioral|Costumed character|
493054|NCT00452738|Behavioral|Parents-only|
493055|NCT00452725|Drug|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
493056|NCT00452712|Procedure|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
493057|NCT00452699|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
493058|NCT00452699|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
493059|NCT00452686|Biological|Boostrix|
493060|NCT00452686|Biological|Chinese DT vaccine|
493107|NCT00452374|Drug|Oxaliplatin|Starting dose of 17.5 mg/m^2 IV for 4 days (Days 1 through 4).
493061|NCT00452673|Drug|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
493062|NCT00452673|Drug|Capecitabine|Tablets, Oral, 660 - 1250 mg/m^2 twice a day (BID). Treatment may continue until disease progression.
493063|NCT00452660|Drug|Exjade|
493064|NCT00452634|Drug|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
493065|NCT00452634|Drug|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
493066|NCT00452634|Drug|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
493067|NCT00452621|Procedure|blood draw|
493068|NCT00452608|Drug|amido pill|one pill of amido/d by mouth for 10 days
493069|NCT00452608|Drug|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
493070|NCT00452595|Drug|DVS-233 SR (desvenlafaxine sustained release )|
493071|NCT00452582|Drug|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
493072|NCT00452582|Other|Usual care|Physical therapy, occupational therapy, speech therapy
493073|NCT00452569|Drug|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
493074|NCT00452569|Drug|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
493075|NCT00452556|Drug|Docetaxel|Weekly
493076|NCT00452556|Drug|Leuprolide Acetate (Eligard®)|2.5 years
493077|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
493078|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
493079|NCT00452543|Drug|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
493080|NCT00452543|Drug|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
493081|NCT00452543|Behavioral|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
493082|NCT00452543|Drug|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
493083|NCT00452530|Drug|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
493084|NCT00452530|Drug|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
493085|NCT00452530|Drug|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
493086|NCT00452530|Drug|Apixaban-matching placebo|Oral tablet administered twice daily
493087|NCT00452517|Procedure|Percutaneous Coronary Intervention|
493088|NCT00452504|Drug|SRA-444|
493089|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
493090|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
493091|NCT00452478|Drug|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
493092|NCT00452465|Behavioral|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
493093|NCT00452452|Biological|13-valent Pneumococcal Conjugate Vaccine|
493094|NCT00452439|Drug|Actonel (Risedronate)|35 mg (pill) by mouth weekly
493095|NCT00452439|Dietary Supplement|Calcium|500 mg by mouth twice a day for a total of 24 months.
493096|NCT00452439|Dietary Supplement|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
493097|NCT00452426|Device|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
493098|NCT00452426|Other|benzodiazepines and opioid sedation|per site's current standard of care
493099|NCT00452413|Drug|enzastaurin|Administered orally
493100|NCT00452413|Drug|erlotinib|Administered orally
493101|NCT00452400|Drug|BI 1744CL|
493102|NCT00452387|Drug|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Mitoxantrone 9mg/m2~Dose Level -1 Mitoxantrone 12mg/m2~Dose Level 1 Mitoxantrone 12mg/m2"
493103|NCT00452387|Drug|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Prednisone 5mg bid~Dose Level -1 Prednisone 5mg bid~Dose Level 1 Prednisone 5mg bid"
493104|NCT00452387|Drug|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.~Dose Level -2, Sorafenib 400 mg QD~Dose Level -1 Sorafenib 400 mg QD~Dose Level 1 Sorafenib 400 mg bid"
493105|NCT00452374|Drug|Cytarabine|1 g/m^2 given IV for two days (Days 2 and 3).
493106|NCT00452374|Drug|Fludarabine|30 mg/m^2 given IV for two days (Days 2 and 3).
493108|NCT00452374|Drug|Rituximab|375 mg/m^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
493109|NCT00452361|Drug|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
493110|NCT00452361|Drug|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:~MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day~AZA will not exceed 75 mg/day~Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:~continued for the entire 104-week period of randomized therapy~subsequently discontinued~restarted after discontinuation"
493111|NCT00452348|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
493112|NCT00452348|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
493113|NCT00452335|Drug|Lubiprostone|12 mcg capsule once daily (QD)
493114|NCT00452335|Drug|Lubiprostone|12 mcg capsule twice daily (BID)
493115|NCT00452335|Drug|Lubiprostone|24 mcg capsule twice daily (BID)
493116|NCT00452322|Drug|Testosterone Substitution by Testosterone Undecanoate i.m.|
493117|NCT00452296|Drug|tight insulin treatment in patients hospitalized with COPD exacerbation|treatment with basal plus bolus insulin
493118|NCT00452296|Procedure|tight glycemic control|treatment with basal and bolus insulin
493119|NCT00452270|Drug|Xylometazoline|
493120|NCT00452257|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
493121|NCT00452244|Drug|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
493122|NCT00452244|Drug|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
493123|NCT00452231|Drug|D-cycloserine|
493124|NCT00452231|Behavioral|Cognitive-Behavioral Therapy|
493125|NCT00452218|Drug|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
493126|NCT00452192|Drug|Telmisartan|telmisartan 80 mg daily over 2 weeks
493127|NCT00452179|Drug|APD125|
493128|NCT00452166|Drug|rosiglitazone|
493129|NCT00452153|Procedure|Characterization Legionnella|"Characterisation Legionnella by polymerase chain reaction (PCR)~Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
493130|NCT00452140|Biological|ertumaxomab|10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.
493131|NCT00452127|Drug|PRO131921|Escalating doses by IV infusion
493132|NCT00452114|Device|In-Exsufflator Cough Assist Device|
493133|NCT00452114|Device|Active Comparator: Flutter Valve Device|Active Comparator
493134|NCT00452101|Drug|Aquamin F|
493135|NCT00452088|Biological|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
493136|NCT00452088|Biological|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
493137|NCT00452088|Biological|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
493138|NCT00452075|Drug|erlotinib|150mg daily
493139|NCT00452062|Drug|Dexamethasone|
493140|NCT00452049|Procedure|parathyroidectomy|parathyroidectomy
493141|NCT00452023|Drug|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
493142|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
493143|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
493144|NCT00451997|Drug|Gleevec|600 mg (capsules) by mouth once daily
493145|NCT00451997|Drug|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
493146|NCT00451984|Biological|Twinrix|
493147|NCT00451984|Biological|interleukin-2|
493148|NCT00451971|Drug|LEFLUNOMIDE|
493149|NCT00451958|Drug|Degarelix 80 mg / Degarelix 80 mg|
493150|NCT00451958|Drug|Degarelix 160 mg / Degarelix 160 mg|
493151|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 80 mg|
493152|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 160 mg|
493153|NCT00451945|Procedure|biopsy|
493154|NCT00451945|Device|3d-ultrasound and fusion of UL and PET/CT|
493155|NCT00451932|Drug|FK778|
493156|NCT00451906|Drug|Platinum-based chemotherapy|As prescribed
493157|NCT00451906|Drug|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
493158|NCT00451893|Procedure|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
493159|NCT00451893|Procedure|Lichtenstein operation with a light-weight mesh|Johnson&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
493160|NCT00451880|Drug|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
493161|NCT00451880|Drug|famotidine|single dose, supplied as 20-mg or 40-mg tablets
493162|NCT00451867|Drug|Mycophenolate Mofetil|
493163|NCT00451867|Drug|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
493164|NCT00451867|Drug|Placebo|Placebo
493165|NCT00451854|Procedure|Random, no advanced notice drug and alcohol testing|
493166|NCT00451841|Device|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
493167|NCT00451828|Drug|Simvastatin|40mg/day
493168|NCT00451815|Drug|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
493169|NCT00451815|Drug|placebo|
493170|NCT00451776|Drug|etomidate|patients who received etomidate
493171|NCT00451776|Drug|propofol|patients who received propofol
493172|NCT00451763|Drug|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
493173|NCT00451750|Drug|Cortisol|20 mg for 3 times
493174|NCT00451737|Device|Isokinetic test|
493175|NCT00451724|Drug|Intranasal ketamine|
493176|NCT00451711|Drug|Liposomal amphotericin B|
493177|NCT00451698|Drug|acyanotic erythropoietin|Single dose IV push
493178|NCT00451698|Drug|acyanotic placebo|Single dose IV push
493179|NCT00451672|Drug|bromocriptine|
493182|NCT00451620|Drug|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
493183|NCT00451620|Drug|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
493184|NCT00451594|Drug|Dexamethasone|"Pulse high dose dexamethasone (Arm 1)~Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.~Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14~If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.~If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.~Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments."
493185|NCT00451594|Drug|Prednisolone|"Conventional dose prednisone (Arm 2)~Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months"
493186|NCT00451581|Procedure|Endoscopic papillary balloon dilation-5 minutes|
493187|NCT00451581|Procedure|Endoscopic papillary balloon dilation-1 minute|
493188|NCT00451568|Drug|Metformin|500 mg 2 tablets 2 times a day
493189|NCT00451568|Drug|Desorelle|1 tablet/day in 21 days
493190|NCT00451555|Drug|enzastaurin|1125 milligram (mg) loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
493191|NCT00451555|Drug|placebo|oral, daily
493192|NCT00451555|Drug|fulvestrant|500 mg, intramuscular (IM), day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, every 28 days, until disease progression
493193|NCT00451516|Drug|Herbal medicine (St. John's wort and Kava)|
493194|NCT00451503|Device|Middle Ear Implant|surgery
493195|NCT00451490|Drug|Agomelatine|
493196|NCT00451490|Drug|Fluoxentine|
493197|NCT00451451|Drug|BG00012|
493198|NCT00451451|Drug|Placebo|
493199|NCT00451451|Drug|Glatiramer Acetate|
493200|NCT00451425|Behavioral|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
493201|NCT00451412|Drug|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
493202|NCT00451412|Drug|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
493203|NCT00451399|Drug|metformin|
493204|NCT00451399|Behavioral|lifestyle intervention|
493205|NCT00451386|Drug|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
493206|NCT00451386|Drug|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
493207|NCT00451373|Device|CVVH and SLED|
493208|NCT00451373|Drug|Vancomycin|
493209|NCT00451373|Drug|Daptomycin|
493210|NCT00451373|Device|FX60, AV600 (dialyzer)|
493211|NCT00451360|Drug|diacerein|
493212|NCT00451347|Device|Quadriceps strength training|
493213|NCT00451347|Device|Taping|
493214|NCT00451347|Device|Home exercise|
493215|NCT00451321|Drug|Otelixizumab|Infusion
493216|NCT00451308|Procedure|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
493217|NCT00451308|Procedure|Induction of labor with foley balloon with 30cc|30cc of saline in foley
493218|NCT00451295|Drug|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
493219|NCT00451295|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
493220|NCT00451282|Behavioral|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
493221|NCT00451269|Device|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
493222|NCT00451256|Drug|AVI-5126|
493223|NCT00451230|Drug|cocaine|
493224|NCT00451230|Drug|hydrocortisone|
493225|NCT00451217|Drug|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered
493226|NCT00451217|Drug|Neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
493227|NCT00451204|Drug|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
493228|NCT00451204|Drug|Placebo|Placebo capsule, once a day, treatment duration is 2 years
493229|NCT00451204|Drug|Copaxone|Injection, once a day, all subjects
493230|NCT00451191|Drug|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
493231|NCT00451178|Drug|enzastaurin|1125 mg then 500 mg, oral, daily, six 21 day cycles or up to 3 years
493232|NCT00451178|Drug|rituximab|375 mg/m2, IV, day 1 every 21 days, six 21 day cycles
493233|NCT00451178|Drug|cyclophosphamide|750 mg/m2, IV, day 1 every 21 days, six 21 day cycles
493234|NCT00451178|Drug|doxorubicin|50 mg/m2, IV, day 1 every 21 days, six 21 day cycles
520521|NCT00236028|Drug|Infliximab|
493235|NCT00451178|Drug|vincristine|1.4 mg/m2, IV, day 1 every 21 days, six 21 day cycles
493236|NCT00451178|Drug|prednisone|100 mg, oral, days 1-5, six 21 day cycles
493237|NCT00451165|Procedure|laparoscopic colorectal surgery|laparoscopic colorectal surgery
493238|NCT00451152|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
493239|NCT00451152|Other|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
493240|NCT00451139|Drug|artemether/lumefantrine|
493241|NCT00451139|Drug|quinine|
493242|NCT00451139|Drug|atovaquone/proguanil|
493243|NCT00451113|Drug|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
493244|NCT00451100|Drug|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
493245|NCT00451100|Drug|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
493246|NCT00451087|Procedure|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
493247|NCT00451087|Procedure|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
493248|NCT00451074|Drug|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
493249|NCT00451061|Drug|Alfuzosin|
493250|NCT00451061|Drug|Tamsulosin|
493251|NCT00451048|Drug|sunitinib malate|Given orally
493252|NCT00451035|Drug|LBH589|
493253|NCT00451009|Device|Viacell's product Media Kits|
493254|NCT00450996|Drug|Topical Steroids|
493255|NCT00450983|Biological|muromonab-CD3|
493256|NCT00450983|Biological|natural killer cell therapy|
493257|NCT00450983|Drug|fludarabine phosphate|
493258|NCT00450983|Drug|methotrexate|
493259|NCT00450983|Drug|thiotepa|
493260|NCT00450983|Genetic|gene expression analysis|
493261|NCT00450983|Other|flow cytometry|
493262|NCT00450983|Other|immunologic technique|
493263|NCT00450983|Procedure|allogeneic hematopoietic stem cell transplantation|
493264|NCT00450983|Procedure|in vitro-treated peripheral blood stem cell transplantation|
493265|NCT00450983|Radiation|total-body irradiation|
493266|NCT00450970|Drug|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
493267|NCT00450957|Dietary Supplement|lycopene|Given orally
493268|NCT00450957|Other|pharmacological study|Correlative studies
493269|NCT00450944|Biological|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
493270|NCT00450931|Other|counseling intervention|
493271|NCT00450931|Other|educational intervention|
493272|NCT00450905|Device|PRIMA Device|
493273|NCT00450892|Drug|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
493274|NCT00450892|Drug|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
493275|NCT00450892|Drug|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule~+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
493276|NCT00450879|Drug|Pazopanib Hydrochloride|Given PO
493277|NCT00450879|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
493278|NCT00450879|Other|Pharmacological Study|Correlative studies
493279|NCT00450879|Other|Laboratory Biomarker Analysis|Correlative studies
493280|NCT00450866|Biological|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
493281|NCT00450853|Drug|granisetron|Granisetron SC followed by granisetron IV
493282|NCT00450840|Drug|Simvastatin|
493283|NCT00450827|Biological|bevacizumab|
493284|NCT00450827|Biological|filgrastim|
493285|NCT00450827|Procedure|autologous hematopoietic stem cell transplantation|
493286|NCT00450827|Radiation|iodine I 131 monoclonal antibody 3F8|
493287|NCT00450814|Drug|Cyclophosphamide|Given IV
493288|NCT00450814|Other|Laboratory Biomarker Analysis|Correlative studies
493289|NCT00450814|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
493290|NCT00450814|Other|Pharmacological Study|Correlative studies
493291|NCT00450801|Drug|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
493292|NCT00450801|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
493293|NCT00450801|Drug|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
493294|NCT00450801|Drug|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
493295|NCT00450801|Drug|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
493296|NCT00450801|Drug|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
493297|NCT00450801|Drug|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
493298|NCT00450801|Drug|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
493299|NCT00450801|Drug|Thalidomide|Maintenance therapy.
520522|NCT00236015|Drug|Gabitril|
493300|NCT00450801|Drug|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
493301|NCT00450801|Drug|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
493302|NCT00450801|Drug|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
493303|NCT00450801|Drug|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
493304|NCT00450801|Drug|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
493305|NCT00450775|Drug|Dermatix Q|Dermatix Q applied twice daily
493306|NCT00450762|Drug|gemcitabine|
493307|NCT00450762|Drug|carboplatin|
493308|NCT00450749|Other|placebo|Given PO
493309|NCT00450749|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
493310|NCT00450749|Other|laboratory biomarker analysis|Correlative studies
493311|NCT00450749|Drug|lycopene|Given PO
493312|NCT00450736|Drug|celecoxib|
493313|NCT00450736|Procedure|adjuvant therapy|
493314|NCT00450736|Radiation|radiation therapy|
493315|NCT00450723|Drug|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
493316|NCT00450723|Procedure|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
493317|NCT00450723|Procedure|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
493318|NCT00450723|Procedure|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
493319|NCT00450723|Procedure|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
493320|NCT00450723|Radiation|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
493321|NCT00450710|Procedure|ileal interposition with a sleeve gastrectomy|
493322|NCT00450684|Device|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
493323|NCT00450684|Device|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
493324|NCT00450671|Procedure|Collagen Plug Placement|
493325|NCT00450671|Procedure|Seton placement|
493326|NCT00450658|Drug|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
493327|NCT00450658|Drug|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
493328|NCT00450645|Drug|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
493329|NCT00450619|Radiation|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
493330|NCT00450619|Biological|Sargramostim|100 mcg/injection x 4 days given subcutaneously
493331|NCT00450619|Biological|Recombinant vaccinia-TRICOM vaccine|2 x 10^8 PFU given subcutaneously on day 1.
493332|NCT00450619|Biological|Recombinant fowlpox-TRICOM vaccine|1 x 10^9 PFU given subcutaneously on days 15 and 29
493333|NCT00450606|Procedure|Balneotherapy and hydrotherapy|
493334|NCT00450593|Genetic|gene expression analysis|
493335|NCT00450593|Genetic|microarray analysis|
493336|NCT00450593|Genetic|molecular genetic technique|
493337|NCT00450593|Genetic|mutation analysis|
493338|NCT00450593|Other|laboratory biomarker analysis|
493339|NCT00450593|Procedure|mutation carrier screening|
493340|NCT00450593|Procedure|study of high risk factors|
493341|NCT00450580|Drug|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
493342|NCT00450567|Procedure|computed tomography|
493343|NCT00450567|Procedure|positron emission tomography|
493344|NCT00450567|Radiation|fludeoxyglucose F 18|
493345|NCT00450541|Behavioral|Questionnaire|Four questionnaires taking 15-20 minutes total to complete.
493346|NCT00450541|Behavioral|Interview|Interview lasting about 30 minutes.
493347|NCT00450515|Drug|capecitabine|
493348|NCT00450515|Drug|vinflunine|
493349|NCT00450502|Drug|Batracylin|
493350|NCT00450476|Device|Hi-Lo Evac Endotracheal Tube|
493351|NCT00450463|Drug|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
493352|NCT00450463|Drug|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
493353|NCT00450463|Biological|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
493354|NCT00450463|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human prostatic specific antigen (PSA) and three co-stimulatory molecules.
493355|NCT00450450|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
493356|NCT00450450|Other|laboratory biomarker analysis|Correlative studies
493357|NCT00450450|Biological|filgrastim|Given IV
493358|NCT00450437|Biological|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
493410|NCT00450203|Procedure|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
493359|NCT00450437|Biological|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
493360|NCT00450424|Other|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
493361|NCT00450424|Other|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
493362|NCT00450411|Radiation|125-Iodine|Brachytherapy to the prostate via 125-iodine (I-125) seeds with a planned dose of 140 Gy
493363|NCT00450411|Radiation|103-palladium|Brachytherapy to the prostate via 103-palladium (Pd-103) seeds with a planned dose of 120 Gy
493364|NCT00450398|Drug|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
493365|NCT00450398|Drug|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
493366|NCT00450385|Drug|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
493367|NCT00450385|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
493368|NCT00450385|Drug|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
493369|NCT00450385|Drug|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
493370|NCT00450385|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
493371|NCT00450372|Biological|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
493372|NCT00450372|Other|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
493373|NCT00450359|Procedure|breast imaging study|
493374|NCT00450359|Procedure|comparison of screening methods|
493375|NCT00450359|Procedure|radiomammography|
493376|NCT00450333|Drug|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
493377|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
493378|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
493379|NCT00450333|Drug|Dynepo|subcutaneous, Q2W for 24 weeks
493380|NCT00450320|Drug|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
493381|NCT00450307|Biological|monoclonal antibody 3F8|
493382|NCT00450307|Biological|sargramostim|
493383|NCT00450281|Genetic|chromogenic in situ hybridization|
493384|NCT00450281|Genetic|gene expression analysis|
493385|NCT00450281|Genetic|mutation analysis|
493386|NCT00450281|Genetic|polymerase chain reaction|
493387|NCT00450281|Genetic|polymorphism analysis|
493388|NCT00450281|Other|fluorescent antibody technique|
493389|NCT00450281|Other|immunohistochemistry staining method|
493390|NCT00450281|Other|laboratory biomarker analysis|
493391|NCT00450281|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
493392|NCT00450281|Other|study of socioeconomic and demographic variables|
493393|NCT00450281|Procedure|study of high risk factors|
493394|NCT00450268|Procedure|blood draw, skin shave biopsy|
493395|NCT00450255|Biological|ziv-aflibercept|Given IV
493396|NCT00450255|Other|pharmacological study|Correlative studies
493397|NCT00450242|Drug|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
493398|NCT00450242|Drug|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
493399|NCT00450229|Drug|diindolylmethane|Given PO
493400|NCT00450229|Drug|placebo|Given PO
493401|NCT00450229|Procedure|therapeutic conventional surgery|Undergo surgical resection
493402|NCT00450229|Other|laboratory biomarker analysis|Correlative studies
493403|NCT00450229|Other|pharmacological study|Correlative studies
493404|NCT00450216|Drug|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
493405|NCT00450216|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
493406|NCT00450203|Biological|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
493407|NCT00450203|Drug|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
493408|NCT00450203|Drug|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
493409|NCT00450203|Drug|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
493411|NCT00450203|Procedure|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
493412|NCT00450203|Procedure|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
493413|NCT00450203|Drug|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
493414|NCT00450190|Device|Saizen® E-Device|Saizen® (recombinant human growth hormone [r-hGH]) injection 8 milligram (mg) per 137 milliliter (mL) will be administered using an electronic auto-injector (E-Device) subcutaneously (SC) in the evening as per local Summary of Product Characteristics (SmPC) for 60 days.
493415|NCT00450177|Drug|Ferrous Sulfate|Iron group
493416|NCT00450177|Drug|Placebo Oral Tablet|Placebo group
493417|NCT00450164|Procedure|esofagic varices ligation|
493418|NCT00450164|Drug|Nadolol|
493419|NCT00450164|Drug|Isosorbide mononitrate|
493420|NCT00450164|Drug|Prazosin|
493421|NCT00450138|Drug|ZD6474 (vandetanib)|once daily oral dose
493422|NCT00450138|Drug|Cisplatin|intravenous infusion
493423|NCT00450138|Radiation|Radiation|radiation of head and neck
493424|NCT00450125|Other|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
493425|NCT00450125|Other|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
493426|NCT00450112|Device|Gel-200|Single Intra-articular Injection
493427|NCT00450099|Drug|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
493428|NCT00450086|Drug|Budesonide|9 mg per day
493429|NCT00450086|Drug|Mesalazine|3 g per day
493430|NCT00450086|Drug|Placebo|0 g per day
493431|NCT00450073|Drug|ergocalciferol (vitamin D2)|50,000 IU weekly
493432|NCT00450073|Device|Sperti Del Sol Lamp|5 times a week for 12 weeks
493433|NCT00450073|Drug|Vitamin D3|50,000 IU weekly
493434|NCT00450060|Device|lumbar puncture with Quincke-design needles|
493435|NCT00450060|Device|lumbar puncture with Sprotte-design needles|
493436|NCT00450047|Device|Speed-feedback therapy system with a bicycle ergometer|
493437|NCT00450047|Device|Ergometer at conventional settings|
493438|NCT00450034|Procedure|drug - oriented multifaceted intervention|oriented multifaceted intervention
493439|NCT00450021|Drug|[(11)C] MePPEP|
493440|NCT00450008|Drug|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
493441|NCT00450008|Drug|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
493442|NCT00450008|Drug|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
493443|NCT00449995|Procedure|confocal laser microscopy|
493444|NCT00449982|Drug|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
493445|NCT00449969|Device|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
493446|NCT00449969|Device|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
493447|NCT00449956|Drug|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
493448|NCT00449956|Drug|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
493449|NCT00449956|Drug|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
493450|NCT00449943|Procedure|Computed Tomographic Angiography|CT scan
493451|NCT00449943|Procedure|Myocardial Perfusion Imaging Scan|SPECT
493452|NCT00449930|Drug|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
493453|NCT00449930|Drug|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
493454|NCT00449917|Drug|lutein|
493455|NCT00449917|Drug|DHA|
493456|NCT00449917|Drug|vitamins|
493457|NCT00449904|Drug|Liprotamase|Administered orally
493458|NCT00449878|Drug|Liprotamase|Administered orally
493459|NCT00449878|Drug|Placebo|Administered orally
493460|NCT00449865|Drug|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.~The study is comparing creatine 5 grams twice daily with placebo."
493461|NCT00449865|Other|placebo|an inactive substance
493462|NCT00449852|Behavioral|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
493463|NCT00449839|Drug|Insulin Aspart|"A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.~C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted."
493464|NCT00449826|Procedure|Computed Tomographic Angiography|CT scan
493465|NCT00449813|Drug|Pantoprazole|40 mg Pantoprazole
493466|NCT00449800|Drug|ceftriaxone|
493467|NCT00449787|Drug|Sumatriptan 100 mg|Sumatriptan 100mg tablet
493468|NCT00449787|Drug|Naproxen|Naproxen 500mg tablet
493469|NCT00449774|Drug|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
493470|NCT00449774|Drug|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
493471|NCT00449761|Drug|panobinostat|LBH589
493472|NCT00449748|Drug|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
493473|NCT00449722|Drug|mesalazine|
493474|NCT00449709|Drug|GSK221149|
493477|NCT00449683|Drug|terazosin|off-label use of terazosin to treat antidepressant-induced sweating
493478|NCT00449670|Biological|Influenza Vaccine GSK1562902A - 6 different formulations|3 doses for experimental groups & 4 doses for control groups, intramuscular injection
493479|NCT00449657|Drug|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
493480|NCT00449657|Procedure|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.~Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
493481|NCT00449657|Drug|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 & 9
493482|NCT00449657|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 & 9
493483|NCT00449644|Drug|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
493484|NCT00449644|Drug|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
493485|NCT00449644|Drug|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
493486|NCT00449618|Drug|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
493487|NCT00449618|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
493488|NCT00449618|Procedure|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
493489|NCT00449618|Drug|Placebo|Use of placebo on awakening versus bedtime
493490|NCT00449605|Drug|Rimonabant|Tablet, oral administration
493491|NCT00449605|Drug|Glimepiride|Tablet, oral administration
493492|NCT00449605|Drug|Metformin|Metformin continued at stable dose as background therapy
493493|NCT00449592|Drug|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
493494|NCT00449592|Drug|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
493495|NCT00449579|Device|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
493496|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
493497|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
493498|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
493499|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
493500|NCT00449540|Device|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
493501|NCT00449540|Device|Sham TMS Device|Simulated Sham treatment without TMS delivery
493502|NCT00449527|Drug|Budesonide/formoterol pMDI|
493503|NCT00449527|Drug|Budesonide HFA pMDI|
493504|NCT00449514|Drug|tamoxifen|
493505|NCT00449514|Drug|clomiphene citrate|
493506|NCT00449501|Drug|Budesonide/formoterol pMDI|
493507|NCT00449501|Drug|Budesonide HFA pMDI|
493508|NCT00449488|Drug|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
493509|NCT00449462|Procedure|consumption of CLA enriched food|
493510|NCT00449449|Drug|Pertubation with Lidocain Solution|
493511|NCT00449436|Drug|TRIZIVIR|TRIZIVIR
493512|NCT00449436|Drug|Non-nucleoside reverse transcriptase inhibitor|Non-nucleoside reverse transcriptase inhibitor
493513|NCT00449436|Drug|Boosted Protease Inhibitor|Boosted Protease Inhibitor
493514|NCT00449423|Drug|acipimox|
493515|NCT00449410|Drug|Atorvastatin|
493516|NCT00449410|Drug|ezetimibe|
493517|NCT00449397|Drug|Quetiapine Fumarate|
493518|NCT00449384|Behavioral|Diagnostic Screening|
493519|NCT00449358|Procedure|apply methyl-ALA cream|
493520|NCT00449345|Procedure|Blood test for Quantiferon-GOLD assay|
493521|NCT00449319|Procedure|Identification of appropriate therapies according to risks factors|
493522|NCT00449319|Drug|Daunorubicine|
493523|NCT00449319|Procedure|Transplant|
493524|NCT00449293|Behavioral|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
493525|NCT00449293|Behavioral|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
493526|NCT00449280|Drug|Sorafenib|400mg BID (200 mg twice daily)
493527|NCT00449280|Drug|Rapamycin|30mg once weekly
493528|NCT00449280|Drug|Rapamycin|3mg once daily
493529|NCT00449267|Device|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
493530|NCT00449254|Drug|oleoyl-estrone (MP-101)|
493531|NCT00449241|Device|Acupuncture|
493532|NCT00449228|Procedure|-preoperative education and total hip replacement|-preoperative education and total hip replacement
493533|NCT00449202|Drug|oleoyl-estrone (MP 101)|
493534|NCT00449176|Drug|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
493535|NCT00449176|Drug|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
493536|NCT00449176|Drug|placebo|matching placebo twice daily for 15 weeks
493537|NCT00449163|Biological|Bevacizumab|
493538|NCT00449163|Drug|Floxuridine|
493539|NCT00449163|Drug|Irinotecan|
493540|NCT00449163|Drug|Leucovorin|
493541|NCT00449150|Drug|Cetrorelix 78 mg + 78 mg|
493542|NCT00449150|Drug|Cetrorelix 78 mg + 52 mg|
493543|NCT00449150|Drug|Placebo|
493588|NCT00448838|Drug|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
493589|NCT00448838|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
522281|NCT00220090|Drug|dexloxiglumide|
493544|NCT00449137|Drug|Arsenic trioxide|ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
493545|NCT00449137|Drug|Fluorouracil|Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
493546|NCT00449137|Drug|Leucovorin calcium|On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
493547|NCT00449137|Other|Plasma levels of elemental arsenic|Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
493548|NCT00449137|Genetic|Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
493549|NCT00449137|Procedure|Tumor Biopsy (Fine-Needle Aspiration)|Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
493550|NCT00449124|Drug|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
493551|NCT00449124|Biological|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10^6 PFU, TG4040 10^7 PFU and TG4040 10^8 PFU.
493552|NCT00449111|Drug|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
493553|NCT00449098|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
493554|NCT00449098|Drug|Trabeculectomy with MMC|Trabeculectomy with MMC
493555|NCT00449085|Procedure|Electrophysiology|
493556|NCT00449085|Device|CARTO™ XP EP Navigation System V9|
493557|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
493558|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
493559|NCT00449072|Drug|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
493560|NCT00449072|Drug|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
493561|NCT00449059|Drug|acute infusion of nitroglycerine into the pulmonary artery|
493562|NCT00449046|Drug|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
493563|NCT00449033|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
493564|NCT00449033|Drug|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
493565|NCT00449033|Drug|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m^2 IV
493566|NCT00449033|Drug|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m^2 IV
493567|NCT00449020|Drug|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
493568|NCT00449020|Drug|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
493569|NCT00449020|Drug|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
493570|NCT00449020|Radiation|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
493571|NCT00449007|Drug|fluoxetine|6 months
493572|NCT00449007|Drug|bupropion|6 months
493573|NCT00448981|Behavioral|Hand hygiene and educational material|
493574|NCT00448981|Device|Mask, alcohol and hand sanitizer|
493575|NCT00448955|Drug|ARD-0403|ARD-0403
493576|NCT00448942|Behavioral|Daily bathing with Chlorhexidine based product|
493577|NCT00448929|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
493578|NCT00448916|Drug|Pregabalin|Orally-administered pregabalin
493579|NCT00448903|Drug|Bemiparin|Bemiparin sodium
493580|NCT00448903|Drug|Placebo|Sodium Chloride 0,9%
493581|NCT00448890|Drug|GSK729327|Tablets
493582|NCT00448890|Drug|Placebo|GSK729327 Matching placebo - Tablets
493583|NCT00448877|Device|fNIR light emitting and sensing device|
493584|NCT00448864|Drug|Ecallantide|
493585|NCT00448864|Drug|Placebo|
493586|NCT00448851|Biological|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
493587|NCT00448838|Biological|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
493758|NCT00447603|Drug|Placebo for Losartan|
493590|NCT00448825|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
493591|NCT00448825|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
493592|NCT00448799|Radiation|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of [123I] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
493593|NCT00448786|Drug|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
493594|NCT00448786|Drug|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
493595|NCT00448786|Drug|AMG 706|AMG 706 125 mg daily continuously (Arm A)
493596|NCT00448773|Behavioral|Online education|
493597|NCT00448760|Drug|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
493598|NCT00448760|Drug|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
493599|NCT00448760|Drug|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
493600|NCT00448760|Drug|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
493601|NCT00448760|Genetic|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
493602|NCT00448760|Genetic|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
493603|NCT00448760|Procedure|Conventional surgery|Surgical removal of tumor for correlative studies
493604|NCT00448747|Drug|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
493605|NCT00448747|Drug|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
493606|NCT00448734|Drug|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
493607|NCT00448734|Drug|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.~Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
493608|NCT00448721|Drug|Perifosine|Perifosine will be administered orally at 100mg PO daily with food.
493609|NCT00448708|Device|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm^2 paclitaxel
493610|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
493611|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
493612|NCT00448695|Procedure|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
493613|NCT00448682|Drug|Docetaxel|
493614|NCT00448682|Drug|Floxuridine|
493615|NCT00448682|Drug|Leucovorin|
493616|NCT00448682|Drug|Oxaliplatin|
493617|NCT00448669|Drug|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.
493618|NCT00448669|Drug|TDF-FTC placebo|Placebo comparator for TDF-FTC
493619|NCT00448656|Procedure|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
493620|NCT00448643|Radiation|Vaginal Brachytherapy|High-Dose Rate [HDR] or Low-Dose Rate [LDR], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
493621|NCT00448643|Drug|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
493622|NCT00448643|Radiation|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated [2-Levels]; 6 -8 hours after administration of Cisplatin chemotherapy
493623|NCT00448630|Other|No intervention|Non-interventional study
493624|NCT00448591|Drug|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
493625|NCT00448591|Drug|Taxane-based chemotherapy|As prescribed
493626|NCT00448578|Drug|Quetiapine Fumarate|
493627|NCT00448578|Drug|Lithium|
493628|NCT00448552|Drug|capecitabine|
493629|NCT00448552|Drug|oxaliplatin|
493630|NCT00448539|Drug|Rufinamide|Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
493631|NCT00448526|Behavioral|low protein diet|
493632|NCT00448513|Dietary Supplement|catechin extracts|comparison with placebo
493633|NCT00448474|Behavioral|Mailed Arthritis Self-Management Education|
493634|NCT00448461|Drug|heparin|comparison between heparin and bivalirudin
493635|NCT00448461|Drug|bivalirudin|comparison between heparin and bivalirudin
493636|NCT00448448|Device|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
493637|NCT00448448|Other|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
493638|NCT00448435|Drug|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
493639|NCT00448435|Drug|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
493640|NCT00448422|Drug|prulifloxacin|Tablet
493641|NCT00448409|Biological|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
493642|NCT00448409|Drug|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
493643|NCT00448396|Drug|Patupilone|
493644|NCT00448383|Biological|adalimumab|40mg every other week
493871|NCT00446615|Behavioral|audit and feedback|
493645|NCT00448357|Biological|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
493646|NCT00448357|Biological|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
493647|NCT00448357|Drug|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
493648|NCT00448357|Drug|fludarabine phosphate|30 mg/m^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
493649|NCT00448357|Drug|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
493650|NCT00448357|Procedure|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10^6 cells/kg and maximum of 8 x 10^6 cells/kg will be infused on day 0
493651|NCT00448357|Procedure|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
493652|NCT00448357|Drug|methotrexate|5 mg/m^2 on days +1, +3 and +6
493653|NCT00448344|Behavioral|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
493654|NCT00448344|Behavioral|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
493655|NCT00448318|Procedure|Music Therapy|
493656|NCT00448305|Drug|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
493657|NCT00448305|Drug|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
493658|NCT00448305|Drug|Paclitaxel|Paclitaxel 90 mg/m² weekly
493659|NCT00448292|Drug|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
493660|NCT00448292|Drug|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
493661|NCT00448279|Drug|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
493662|NCT00448279|Drug|Chemotherapy|Schedule and dose at the investigator's discretion
493663|NCT00448266|Drug|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
493664|NCT00448266|Drug|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
493665|NCT00448253|Biological|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.~And a Fourth Cohort at 840 units TNA with 2 additional product lots."
493666|NCT00448240|Drug|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
493667|NCT00448227|Drug|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
493668|NCT00448214|Drug|YM150|Oral
493669|NCT00448214|Drug|warfarin|Oral
493670|NCT00448201|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
493671|NCT00448201|Biological|sargramostim|GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) < 1000/microliter (uL) past day 20
493672|NCT00448201|Biological|therapeutic allogeneic lymphocytes|A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10^6 cells/kg and a maximum 8 x 10^6 cells/kg will be infused on day 0
493673|NCT00448201|Drug|busulfan|6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
493674|NCT00448201|Drug|fludarabine phosphate|fludarabine 30 mg/m^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
493675|NCT00448201|Drug|methotrexate|Methotrexate 5 mg/m^2 per day on days +1, +3 and +6
493676|NCT00448201|Drug|tacrolimus|Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
493677|NCT00448201|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
493678|NCT00448201|Procedure|peripheral blood stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
493679|NCT00448188|Procedure|central venous catheter application|
493680|NCT00448175|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
493681|NCT00448175|Drug|Tolterodine|
493682|NCT00448149|Drug|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
493683|NCT00448149|Drug|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
493684|NCT00448136|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
493685|NCT00448136|Drug|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
493686|NCT00448136|Drug|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
493687|NCT00448136|Drug|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
493688|NCT00448123|Drug|Tamsulosin|Study Drug
493689|NCT00448123|Drug|Placebo|Placebo
493690|NCT00448110|Drug|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
493691|NCT00448110|Drug|Intravenous Ketorolac|Intravenous Ketorolac
493692|NCT00448110|Drug|placebo|placebo
493693|NCT00448097|Drug|cetuximab|No verifiable data available, PI relocated
493694|NCT00448097|Drug|docetaxel|No verifiable data available, PI relocated
493695|NCT00448071|Drug|MTR107|
493696|NCT00448058|Drug|GSK372475|daily administration during the 10-week treatment phase
493697|NCT00448058|Drug|venlafaxine|daily administration during the 10-week treatment phase
493698|NCT00448058|Drug|placebo|daily administration during the 10-week treatment phase
493757|NCT00447603|Drug|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
493699|NCT00448045|Behavioral|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
493700|NCT00448045|Behavioral|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
493701|NCT00448032|Drug|PPM-204|
493702|NCT00448019|Drug|Fludarabine|25 mg/m^2 IV over 30 minutes daily for 3 days
493703|NCT00448019|Drug|Cyclophosphamide|250 mg/m^2 IV over 30 minutes daily for 3 days
493704|NCT00448019|Drug|Rituximab|375 mg/m^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m^2 IV 30-minute infusion.
493705|NCT00448019|Drug|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
493706|NCT00448006|Device|Allium Biliary Stent|device
493707|NCT00448006|Device|allium biliary stent|allium biliary stent
493708|NCT00447993|Drug|NT-501|High Dose
493709|NCT00447993|Drug|NT-501|Low Dose
493710|NCT00447980|Drug|NT-501|High Dose
493711|NCT00447980|Drug|NT-501|Low Dose
493712|NCT00447967|Drug|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
493713|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
493714|NCT00447967|Drug|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
493715|NCT00447967|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
493716|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
493717|NCT00447954|Drug|NT-501 implant|High Dose
493718|NCT00447954|Drug|NT-501 implant|Low Dose
493719|NCT00447954|Other|Sham Procedure|Sham Procedure
493720|NCT00447941|Drug|SCA-136|
493721|NCT00447928|Drug|OrthoDerm transdermal nitroglycerin patch|
493722|NCT00447915|Drug|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
493723|NCT00447915|Drug|RIS placebo|0 mg(p.o.)/day for 36 months
493724|NCT00447915|Drug|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
493725|NCT00447915|Drug|ibandronic acid placebo|0mg(i.v.)/month for 35 months
493726|NCT00447915|Drug|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
493727|NCT00447915|Dietary Supplement|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
493728|NCT00447902|Drug|tipranavir|
493729|NCT00447902|Drug|ritonavir|
493730|NCT00447889|Drug|gadoteric acid|
493731|NCT00447876|Biological|Botulinum toxin type A|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
493732|NCT00447876|Drug|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
493733|NCT00447863|Drug|Levonorgestrel/Ethinyl Estradiol|
493734|NCT00447850|Procedure|endometrial biopsy|
493735|NCT00447837|Drug|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
493736|NCT00447824|Procedure|Introduction of better conditions during blood sampling|
493737|NCT00447811|Drug|MOA-728|
493738|NCT00447798|Behavioral|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building & strengths based case management
493739|NCT00447772|Biological|Botulinum toxin type A|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
493740|NCT00447759|Drug|Celecoxib|200-400mg daily in divided doses
493741|NCT00447759|Drug|Diclofenac|prescribed medication taken orally
493742|NCT00447746|Procedure|D1 or D2 lymphadenectomy for gastric cancer patients|
493743|NCT00447733|Behavioral|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
493744|NCT00447733|Behavioral|Treatment as usual|Non-standardized psychiatric outpatient treatment
493745|NCT00447720|Behavioral|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
493746|NCT00447707|Behavioral|Positive Choice|
493747|NCT00447694|Drug|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
493748|NCT00447681|Drug|ILV-094|
493749|NCT00447668|Behavioral|Yoga|Yoga for back pain
493750|NCT00447668|Behavioral|Exercise|exercises for back pain
493751|NCT00447668|Behavioral|Self-care book recommendations|Self-care book for back pain
493752|NCT00447655|Behavioral|Self-management and peer support|
493753|NCT00447642|Drug|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
493754|NCT00447642|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
493755|NCT00447629|Drug|PPM-204|
493756|NCT00447603|Drug|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
493759|NCT00447603|Drug|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
493760|NCT00447590|Device|LAP-BAND System|Restriction of food intake
493761|NCT00447577|Drug|Loteprednol etabonate and tobramycin ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
493762|NCT00447577|Drug|Tobramycin and dexamethasone ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
493763|NCT00447564|Drug|Probuphine|4 implants
493764|NCT00447564|Drug|placebo|4 implants
493765|NCT00447551|Drug|Poly-L-Lactic Acid|Deep dermal injection
493766|NCT00447525|Biological|REVAXIS®|
493767|NCT00447525|Biological|DT-Polio®|
493768|NCT00447512|Drug|ghrelin|acylated ghrelin
493769|NCT00447499|Drug|Somatuline Autogel (lanreotide acetate)|Injections
493770|NCT00447499|Behavioral|Home administration|Questionnaire
493771|NCT00447486|Drug|GW842166|
493772|NCT00447473|Drug|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
493773|NCT00447473|Drug|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
493774|NCT00447473|Drug|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
493775|NCT00447460|Procedure|Mesenchymal stem cell (MSC)|
493776|NCT00447434|Drug|Natto extract (Nattokinase)|
493777|NCT00447421|Drug|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
493778|NCT00447421|Drug|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
493779|NCT00447421|Radiation|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
493780|NCT00447408|Behavioral|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
493781|NCT00447408|Behavioral|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
493782|NCT00447382|Drug|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
493783|NCT00447382|Drug|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
493784|NCT00447382|Drug|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
493785|NCT00447369|Drug|Pregabalin|
493786|NCT00447369|Drug|sodium valproate|
493787|NCT00447356|Drug|recombinant interferon alfa|
493788|NCT00447343|Procedure|Decompressive cervical spine surgery|"Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery~Healthy volunteers will ONLY undergo two scans 6 months apart."
493789|NCT00447343|Procedure|fMRI and MRS scan|A scan pre-op and 6 months post-op.
493790|NCT00447330|Drug|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.~Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.~Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
493791|NCT00447317|Behavioral|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
493792|NCT00447317|Behavioral|Attention control|Standard peritoneal dialysis dietary education
493793|NCT00447304|Drug|moxifloxacin|
493794|NCT00447304|Procedure|cholecystectomy|
493795|NCT00447291|Drug|Supplement: Omega-3 Fish Oil|
493796|NCT00447291|Behavioral|Multi-Disciplinary Nutrition & Exercise program|
493797|NCT00447278|Drug|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
493798|NCT00447278|Drug|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
493799|NCT00447265|Drug|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
493800|NCT00447265|Drug|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
493801|NCT00447265|Drug|Placebo|
493802|NCT00447239|Procedure|glucontrol (insulin therapy)|
493803|NCT00447226|Drug|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
493804|NCT00447213|Drug|Insulin glargine|Patient specific, injected, daily, 24 weeks
493805|NCT00447213|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
493806|NCT00447213|Drug|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
493807|NCT00447200|Procedure|Esophagus Doppler monitoring|
493808|NCT00447200|Procedure|Fluid optimization|
493872|NCT00446615|Behavioral|group learning session|
493873|NCT00446602|Drug|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
493809|NCT00447187|Drug|LX201|"LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
493810|NCT00447187|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
493811|NCT00447174|Behavioral|Dyadic treatment for parental bereavement|
493812|NCT00447161|Drug|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water
493813|NCT00447161|Drug|Placebo|Matched placebo
493814|NCT00447148|Procedure|3-dimensional coronary angiography|3-dimensional coronary angiography
493815|NCT00447122|Drug|gemcitabine and Lapatinib|
493816|NCT00447109|Device|Closed system suction|
493817|NCT00447096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
493818|NCT00447083|Device|UVB|UVB exposure by a tanning bed
493819|NCT00447083|Procedure|Non-UVB|Non-UVB exposure by a tanning bed
493820|NCT00447070|Drug|ATAZANAVIR|
493821|NCT00447057|Drug|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
493822|NCT00447057|Drug|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
493823|NCT00447057|Drug|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
493824|NCT00447057|Drug|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
493825|NCT00447044|Behavioral|Resistance Exercise|Subjects will lift weights with their legs.
493826|NCT00447044|Dietary Supplement|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
493827|NCT00447044|Dietary Supplement|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
493828|NCT00447031|Drug|intravitreal bevacizumab and triamcinolone acetonide|
493829|NCT00447018|Drug|20% mannitol|
493830|NCT00447018|Drug|7.45% hypertonic saline solution|
493831|NCT00447005|Drug|Axitinib (AG-013736)|AG-013736 5mg twice daily [BID]
493832|NCT00446992|Drug|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
493833|NCT00446979|Drug|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
493834|NCT00446979|Drug|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
493835|NCT00446966|Drug|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams orally daily after until primary endpoint or 14 days.
493836|NCT00446953|Drug|betamethasone|2x12 mg betamethazone c-section at 38 weeks
493837|NCT00446953|Other|placebo|c-section at 39 weeks
493838|NCT00446940|Drug|rosuvastatin|
493839|NCT00446940|Drug|atorvastatin|
493840|NCT00446914|Behavioral|Systems Change (High Blood Pressure Strategy)|
493841|NCT00446901|Dietary Supplement|Selenium|Selenized yeast, 300 ug/day
493842|NCT00446888|Behavioral|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
493843|NCT00446888|Dietary Supplement|Forticare|400 ml of commercially-available nutritional supplement.
493844|NCT00446888|Dietary Supplement|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
493845|NCT00446875|Other|Administration of oral Sucrose|Participants received oral sucrose 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
493846|NCT00446875|Other|Administration of oral Placebo|Participants received Placebo 2 minutes prior to the combind DTaP, IPV, and Hep B vaccine.
493847|NCT00446862|Drug|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
493848|NCT00446849|Drug|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
493849|NCT00446836|Drug|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
493850|NCT00446823|Device|XCell cellulose wound dressing|
493851|NCT00446823|Device|Impregnated gauze dressing|
493852|NCT00446810|Drug|Benfotiamine|
493853|NCT00446810|Drug|Placebo|
493854|NCT00446797|Drug|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
493855|NCT00446797|Drug|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
493856|NCT00446784|Drug|CE-224,535|
493857|NCT00446784|Drug|Methotrexate|
493858|NCT00446771|Drug|Mannitol|
493859|NCT00446758|Dietary Supplement|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.
493860|NCT00446732|Device|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
493861|NCT00446719|Drug|Rellidep|2000 mg P.O. daily for 8 weeks
493862|NCT00446693|Device|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
493863|NCT00446680|Drug|Mannitol|400mg BD for 6 months followed by a 6 month open label period
493864|NCT00446680|Drug|placebo|placebo BD for 6 months
493865|NCT00446667|Drug|mannitol|400mg BD for 2 days
493866|NCT00446654|Drug|CGC-11047|16.5 mg (3.3%) subconjunctival injection
493867|NCT00446641|Drug|Cilostazol|cilostazol 100mg twice a day for 4 weeks
493868|NCT00446641|Drug|placebo|placebo 1 tablet twice a day matching for cilostazol
493869|NCT00446628|Behavioral|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
493870|NCT00446615|Behavioral|computer decision support tool|
493874|NCT00446589|Drug|ibandronate|iv 1mg ibandronate monthly for one year
493875|NCT00446589|Drug|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
493876|NCT00446576|Drug|Epoetin Alfa|
493877|NCT00446563|Drug|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
493878|NCT00446563|Drug|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
493879|NCT00446563|Drug|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
493880|NCT00446563|Drug|Losartan|100 mg tablets taken orally once daily in the morning.
493881|NCT00446550|Drug|afegostat tartrate|
493882|NCT00446537|Procedure|Methylphenidate|
493883|NCT00446524|Drug|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
493884|NCT00446511|Drug|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
493885|NCT00446511|Drug|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
493886|NCT00446511|Drug|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
493887|NCT00446511|Drug|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
493888|NCT00446498|Device|CPAP and Non Invasive Ventilation|
493889|NCT00446485|Drug|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
493890|NCT00446485|Drug|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
493891|NCT00446485|Drug|placebo|placebo during 6 months
493892|NCT00446472|Drug|Regranex®|Regranex gel will be used for a total of 16 weeks
493893|NCT00446472|Drug|Hydrogel|Placebo hydrogel will be applied for 16 weeks
493894|NCT00446459|Drug|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
493895|NCT00446446|Drug|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
493896|NCT00446433|Drug|CC-5013|
493897|NCT00446420|Drug|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
493898|NCT00446407|Other|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
493899|NCT00446407|Other|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
493900|NCT00446394|Behavioral|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
493901|NCT00446394|Behavioral|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
493902|NCT00446381|Drug|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
493903|NCT00446381|Drug|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
493904|NCT00446368|Drug|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
493905|NCT00446342|Drug|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
493906|NCT00446329|Drug|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
493907|NCT00446316|Drug|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
493908|NCT00446316|Drug|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
493909|NCT00446303|Drug|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.~Extension of maintenance in responders after 24 courses until relapse or death."
493910|NCT00446290|Drug|Docetaxel, Capecitabine and Oxaliplatin|
493911|NCT00446277|Procedure|cataract surgery|
493912|NCT00446264|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
493913|NCT00446264|Drug|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
493914|NCT00446251|Drug|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
493915|NCT00446251|Drug|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
493916|NCT00446238|Behavioral|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
493917|NCT00446238|Behavioral|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
493918|NCT00446225|Drug|Erlotinib (Tarceva)|150 mg/day
493919|NCT00446225|Drug|Carboplatin // Gemcitabine // Docetaxel //Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2); Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8); Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)
493920|NCT00446212|Drug|Propofol|target controlled infusion of propofol
493921|NCT00446212|Drug|desflurane|Anaesthetic maintenance with desflurane
493922|NCT00446199|Drug|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
493923|NCT00446199|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
493924|NCT00446199|Drug|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
493925|NCT00446199|Drug|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
493926|NCT00446186|Drug|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
493927|NCT00446186|Drug|Comparator: placebo / Duration of Treatment: 2 Weeks|
493928|NCT00446173|Drug|Busulfan|130 mg/m^2 IV Daily Over 3 Hours x 4 Days
493929|NCT00446173|Drug|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
493930|NCT00446173|Drug|G-CSF|10 mcg/kg Subcutaneously Once Daily
493931|NCT00446173|Drug|GM-CSF|250 mcg/kg Subcutaneously Once Daily
493932|NCT00446147|Drug|Pyridoxine|100mg BID/daily, Per oral
493933|NCT00446147|Drug|Placebo|placebo 100mg BID/daily, Per oral
493934|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
493935|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
493936|NCT00446134|Drug|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
493937|NCT00446134|Drug|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
493938|NCT00446095|Drug|fostamatinib|200 mg PO BID
493939|NCT00446082|Drug|Pasireotide|
493940|NCT00446069|Drug|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
493941|NCT00446056|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
493942|NCT00446056|Drug|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
493943|NCT00446043|Drug|Adapalene/Benzoyl Peroxide|
493944|NCT00446030|Drug|Docetaxel|"75 mg/m^2 administered IV on Day 1 for Cycles 1-6~All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
493945|NCT00446030|Drug|Doxorubicin|50 mg/m^2 administered IV on Day 1 for Cycles 1-6
493946|NCT00446030|Drug|Carboplatin|6 mg/mL/min (target area under the curve [AUC] dose) administered IV on Day 1 for Cycles 1-6
493947|NCT00446030|Drug|Cyclophosphamide|500 mg/m^2 administered IV on Day 1 for Cycles 1-6
493948|NCT00446030|Drug|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
493949|NCT00446030|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
493950|NCT00446017|Drug|adrenaline|
493951|NCT00446017|Drug|milrinone|
493952|NCT00446004|Drug|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
493953|NCT00446004|Drug|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
493954|NCT00445978|Drug|6R-BH4 (sapropterin dihydrochloride)|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) of 6R-BH4 during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
493955|NCT00445965|Genetic|DNA analysis|
493956|NCT00445965|Other|immunologic technique|
493957|NCT00445965|Other|pharmacological study|
493958|NCT00445965|Radiation|iodine I 131 monoclonal antibody 3F8|
493959|NCT00445965|Radiation|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
493960|NCT00445952|Other|clinical observation|
493961|NCT00445952|Procedure|management of therapy complications|
493962|NCT00445939|Biological|adalimumab|160 mg at Week 0, 80 mg at Week 2
493963|NCT00445939|Biological|adalimumab|80 mg at Week 0, 40 mg at Week 2
493964|NCT00445939|Biological|placebo|Placebo at Week 0 and Week 2
493965|NCT00445926|Device|deep TMS H-coil|
494023|NCT00445679|Drug|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
494024|NCT00445679|Drug|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
494025|NCT00445614|Behavioral|Effects of trout on CVD risk markers and plasma proteome|
493966|NCT00445913|Biological|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
493967|NCT00445913|Biological|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
493968|NCT00445900|Drug|cyclophosphamide|
493969|NCT00445900|Drug|prednisone|
493970|NCT00445900|Drug|thalidomide|
493971|NCT00445900|Other|immunohistochemistry staining method|
493972|NCT00445900|Other|laboratory biomarker analysis|
493973|NCT00445900|Procedure|biopsy|
493974|NCT00445887|Other|Laboratory Biomarker Analysis|Correlative studies
493975|NCT00445887|Drug|Levonorgestrel|Given orally
493976|NCT00445887|Other|Placebo|Given orally
493977|NCT00445874|Drug|Ketotifen with a Contact Lens (no generic name)|
493978|NCT00445861|Biological|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
493979|NCT00445861|Biological|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
493980|NCT00445861|Biological|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
493981|NCT00445861|Procedure|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
493982|NCT00445848|Biological|bevacizumab|
493983|NCT00445848|Drug|erlotinib hydrochloride|
493984|NCT00445835|Other|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
493985|NCT00445835|Other|Conservative arm|Conservative medical approach
493986|NCT00445796|Drug|Artesunate|
493987|NCT00445796|Drug|Amodiaquine|
493988|NCT00445783|Genetic|gene expression analysis|
493989|NCT00445783|Genetic|mutation analysis|
493990|NCT00445783|Other|immunohistochemistry staining method|
493991|NCT00445783|Other|laboratory biomarker analysis|
493992|NCT00445783|Procedure|examination|
493993|NCT00445783|Procedure|mutation carrier screening|
493994|NCT00445783|Procedure|study of high risk factors|
493995|NCT00445770|Drug|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
493996|NCT00445770|Drug|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
493997|NCT00445770|Drug|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
493998|NCT00445757|Procedure|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
493999|NCT00445757|Radiation|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
494000|NCT00445744|Drug|cyclophosphamide|Given IV
494001|NCT00445744|Drug|busulfan|Given IV
494002|NCT00445744|Drug|tacrolimus|Given IV or PO
494003|NCT00445744|Drug|methotrexate|Given IV
494004|NCT00445744|Genetic|cytogenetic analysis|Correlative studies
494005|NCT00445744|Other|flow cytometry|Correlative studies
494006|NCT00445744|Other|pharmacological study|Correlative studies
494007|NCT00445744|Other|pharmacogenomic studies|Correlative studies
494008|NCT00445744|Procedure|peripheral blood stem cell transplantation|Undergo PBPC transplantation
494009|NCT00445744|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
494010|NCT00445731|Behavioral|exercise intervention|
494011|NCT00445731|Procedure|management of therapy complications|
494012|NCT00445731|Procedure|observation|
494013|NCT00445718|Procedure|computed tomography|
494014|NCT00445718|Procedure|3-Tesla magnetic resonance imaging|
494015|NCT00445718|Procedure|Abdominal Sonogram|Sonogram of the abdomen area
494016|NCT00445705|Drug|placebo|Part A: Placebo every 12 hours for 4 weeks
494017|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
494018|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
494019|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
494020|NCT00445692|Drug|Clarithromycin|Given Orally (PO)
494021|NCT00445692|Drug|Dexamethasone|Given PO
494022|NCT00445692|Drug|Lenalidomide|Given Orally (PO)
494026|NCT00445601|Drug|gemcitabine hydrochloride|Given intravesically
494027|NCT00445601|Other|placebo|Given intravesically
522282|NCT00220077|Procedure|Endoscopy|
494028|NCT00445588|Drug|erlotinib hydrochloride|150mg Given orally once daily
494029|NCT00445588|Drug|sorafenib tosylate|400mg Given orally twice daily
494030|NCT00445588|Other|pharmacological study|Correlative studies
494031|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
494032|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
494033|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
494034|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
494035|NCT00445562|Other|biologic sample preservation procedure|
494036|NCT00445562|Other|informational intervention|
494037|NCT00445549|Drug|Vandetanib|300 mg daily dose, 28 day cycle
494038|NCT00445523|Biological|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
494039|NCT00445523|Drug|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
494040|NCT00445510|Drug|GSK256066|
494041|NCT00445497|Drug|amoxicillin-clavulanate potassium|
494042|NCT00445497|Drug|ciprofloxacin|
494043|NCT00445497|Procedure|psychosocial assessment and care|
494044|NCT00445497|Procedure|quality-of-life assessment|
494045|NCT00445484|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
494046|NCT00445484|Drug|lenalidomide|Given orally
494047|NCT00445471|Behavioral|Mifne Approach to PDD|
494048|NCT00445471|Behavioral|Treatment as usual|
494049|NCT00445458|Drug|HKI-272|
494050|NCT00445458|Drug|Paclitaxel|
494051|NCT00445445|Other|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
494052|NCT00445445|Other|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
494053|NCT00445445|Procedure|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
494054|NCT00445445|Procedure|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
494055|NCT00445445|Procedure|study of high risk factors|"Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.~Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
494056|NCT00445432|Biological|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
494057|NCT00445432|Other|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
494058|NCT00445419|Biological|PEV2A PEV2B|
494059|NCT00445406|Drug|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
494060|NCT00445406|Drug|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
494061|NCT00445354|Drug|cinnamon|
494062|NCT00445341|Drug|Flavopiridol|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
494063|NCT00445328|Drug|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
494064|NCT00445328|Drug|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
494065|NCT00445315|Drug|PF-00868554|300 mg BID
494066|NCT00445315|Drug|PF-00868554|450 mg BID
494067|NCT00445315|Drug|PF-00868554|100 mg BID
494068|NCT00445315|Drug|PF-00868554|300 mg TID
494069|NCT00445315|Drug|Placebo|Placebo
494070|NCT00445302|Drug|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
494071|NCT00445289|Device|SmartCare/PS|
494072|NCT00445276|Drug|Diacerein|
494073|NCT00445263|Drug|TIROFIBAN|intravenous infusion
494074|NCT00445263|Procedure|CORONAROGRAPHY|standard procedure of coronarography
494075|NCT00445250|Drug|Calcipotriol|
494076|NCT00445237|Device|H1 and H2 deep TMS coils|
494077|NCT00445224|Other|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
494171|NCT00444509|Drug|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
494078|NCT00445224|Other|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
494079|NCT00445211|Drug|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
494080|NCT00445211|Other|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
494081|NCT00445198|Drug|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~- 40 patients with SCLC"
494082|NCT00445185|Biological|Henogen HB vaccine|Month 12, 24 and 36
494083|NCT00445185|Biological|Fendrix vaccine|Month 12, 24 and 36
494084|NCT00445172|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin twice a week.
494085|NCT00445159|Drug|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
494086|NCT00445146|Drug|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
494087|NCT00445146|Drug|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
494088|NCT00445146|Drug|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
494089|NCT00445133|Device|Magnetic Sleep Pad|
494090|NCT00445120|Drug|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
494091|NCT00445120|Drug|placebo (sugar)|Placebo will be administered to patients once daily for six months
494092|NCT00445107|Drug|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
494093|NCT00445094|Drug|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
494094|NCT00445094|Drug|Comparator: amikacin / Duration of Treatment: 3 Days|
494095|NCT00445094|Drug|Comparator: tazocin / Duration of Treatment: 3 Days|
494096|NCT00445094|Drug|Comparator: vancomycin / Duration of Treatment: 3 Days|
494097|NCT00445081|Drug|Prednisolone|
494098|NCT00445081|Drug|Ciclosporine A|
494099|NCT00445068|Drug|LBH589|
494100|NCT00445055|Drug|Droperidol|Intravenous injection
494101|NCT00445042|Drug|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
494102|NCT00445016|Procedure|peripheral regional anesthesia|evaluation and description of adverse effects
494103|NCT00445003|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
494104|NCT00445003|Drug|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
494105|NCT00445003|Behavioral|Sham injection|Sham injection at baseline and 4 weeks
494106|NCT00445003|Procedure|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
494107|NCT00444990|Device|Magnetic Flex Pad|
494108|NCT00444977|Behavioral|Case-management linkage intervention|dental care
494109|NCT00444964|Drug|Nutropin AQ|
494110|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
494111|NCT00444951|Biological|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
494112|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
494113|NCT00444938|Device|H1 -coil TMS device|
494114|NCT00444925|Drug|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
494115|NCT00444925|Drug|placebo|once daily (OD)for 12 weeks
494116|NCT00444925|Drug|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
494117|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
494118|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5*10^6 CD34+ cells/kg were collected.
494119|NCT00444912|Biological|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
494120|NCT00444899|Behavioral|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
494121|NCT00444899|Other|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
494122|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
494123|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
494124|NCT00444873|Drug|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
494125|NCT00444860|Biological|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
494126|NCT00444847|Device|Hyperbaric chamber|
494127|NCT00444834|Drug|Carvedilol|50 mg
494128|NCT00444821|Device|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
494129|NCT00444808|Drug|Intranasal calcitonin|
494130|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
494131|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
494132|NCT00444795|Drug|sunitinib malate|Sunitinib : dosing not pre-determined
494133|NCT00444782|Biological|GV1001|
494134|NCT00444769|Drug|GW842166|
494135|NCT00444756|Procedure|J-tip jet injection of 1% buffered lidocaine|
494136|NCT00444743|Drug|MM-093|60 mg, administered subcutaneously, weekly
494137|NCT00444743|Other|Placebo|Placebo
494138|NCT00444730|Procedure|Radical Prostatectomy|Surgical procedure for prostate cancer.
494139|NCT00444730|Procedure|InterStim Implantation|surgical placement of the interstim
494140|NCT00444730|Procedure|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
494141|NCT00444717|Drug|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
494142|NCT00444704|Drug|PRA-027|
494143|NCT00444691|Device|ultra-sonography|"o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).~The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline."
494144|NCT00444678|Drug|Cetuximab|500 mg/m2, IV every two weeks
494145|NCT00444678|Drug|Oxaliplatin|85 mg/m2, IV, q 2 weeks
494146|NCT00444678|Drug|Capecitabine|2500 mg, po bid x 7 days every two weeks
494147|NCT00444665|Drug|Travatan-Z|
494148|NCT00444652|Drug|Enoxaparin|injection of enoxaparin a few time
494149|NCT00444639|Drug|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
494150|NCT00444626|Device|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
494151|NCT00444626|Device|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
494152|NCT00444626|Drug|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
494153|NCT00444613|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
494154|NCT00444613|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
494155|NCT00444613|Drug|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
494156|NCT00444600|Drug|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
494157|NCT00444600|Drug|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
494158|NCT00444600|Drug|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
494159|NCT00444600|Drug|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
494160|NCT00444587|Drug|Second line chemotherapy|As prescribed
494161|NCT00444587|Drug|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
494162|NCT00444574|Drug|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
494163|NCT00444574|Drug|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
494164|NCT00444574|Drug|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
494165|NCT00444561|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC administration
494166|NCT00444548|Drug|[S,S]-Reboxetine|
494167|NCT00444535|Drug|lapatinib|1500 mg oral lapatinib (once daily)
494168|NCT00444535|Drug|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
494169|NCT00444522|Drug|Alprazolam thermal aerosol|
494170|NCT00444509|Drug|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
523597|NCT00208221|Drug|ramipril|
494172|NCT00444483|Behavioral|Structured diabetes teaching and treatment program|
494173|NCT00444470|Drug|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
494174|NCT00444470|Drug|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
494175|NCT00444457|Biological|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
494176|NCT00444457|Biological|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
494177|NCT00444431|Procedure|Pyeloplasty|
494178|NCT00444418|Drug|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
494179|NCT00444418|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
494180|NCT00444418|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
494181|NCT00444392|Behavioral|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
494182|NCT00444379|Drug|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
494183|NCT00444353|Device|DL6049 (injectable poly-L-lactic acid)|
494184|NCT00444340|Drug|Enbrel (Etanercept)|
494185|NCT00444314|Drug|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
494186|NCT00444314|Drug|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
494187|NCT00444275|Drug|esomeprazole (Nexium®)|"This randomized study was conducted on parallel groups and included two phases:~One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
494188|NCT00444275|Drug|Xolaam®|"This randomized study was conducted on parallel groups and included two phases:~One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision~One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
494189|NCT00444262|Procedure|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
494190|NCT00444262|Drug|VOLUVEN and others solute|VOLUVEN and others solute
494191|NCT00444249|Procedure|White Alcon IOL|Implantation of white Alcon IOL
494192|NCT00444249|Procedure|Yellow Alcon IOL|Implantation of yellow Alcon IOL
494193|NCT00444249|Procedure|White Hoya IOL|Implantation of white Hoya IOL
494194|NCT00444249|Procedure|Yellow Hoya IOL|Implantation of yellow Hoya IOL
494195|NCT00444236|Drug|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
494196|NCT00444236|Drug|Placebo|matching placebo for active drug
494197|NCT00444223|Procedure|fluorine F 18 FEQA + positron emission tomography|
494198|NCT00444210|Device|DL6049 (injectable poly-L-lactic acid)|
494199|NCT00444197|Behavioral|Mentoring and violence prevention curriculum with parental monitoring|
494200|NCT00444184|Drug|Travoprost/timolol fixed combination, travoprost|
494201|NCT00444171|Procedure|insulin infusion rate controled by computer algorithm|
494202|NCT00444171|Procedure|insulin infusion rate guided by in-house glucose management protocol|
494203|NCT00444158|Drug|MOA-728|
494204|NCT00444145|Drug|Prevacid|30 mg bid for 3 months
494205|NCT00444145|Procedure|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
494206|NCT00444132|Drug|clopidogrel|
494207|NCT00444106|Drug|Artesunate-mefloquine|
494208|NCT00444106|Drug|Atovaquone-proguanil|
494209|NCT00444106|Drug|Artemether-lumefantrine|
494210|NCT00444093|Drug|Opii normata treatment|"After beginning of diarrhea grade 1:~5 drops tincture of opium three times a day~After beginning of diarrhea grade 2:~Intensive therapy with 15 drops tincture of opium three times a day."
494211|NCT00444093|Drug|Loperamid Treatment|"All patients who receive as a result of randomisation loperamide~After beginning of diarrhea grade 1:~Initial 4mg and 2mg after any unformed stool. The maximum dose amounts to16mg per day.~After beginning of diarrhea grade 2:~Intensive therapy with 2mg loperamide every 2 h. The maximum dose amounts to 16mg per day."
494212|NCT00444080|Procedure|Trabeculectomy|"Standard trabeculectomy procedure~Creation of a fornix or limbal based conjunctival flap in upper quadrants~Creation of a limbal-based scleral flap extending into clear cornea~Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~Creation of fistula 1mm x 2mm in size~Iridectomy~Suturing the scleral flap~Repositioning of conjunctiva with sutures After procedure, antibiotics & steroids are administered topically; eye is covered with a pad - patient is discharged."
494213|NCT00444080|Device|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:~Creation of a fornix or limbal based conjunctival flap in upper quadrants~Creation of limbal-based scleral flap extending into clear cornea~Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)~Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus~Prior to implantation, a thorough mobility check should be performed~Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision~Withdrawal of introducer~Tucking plate under the scleral flap, and verification of its position~Suturing scleral flap After implantation procedure, antibiotics & steroids administered topically; eye is covered with a pad - patient is discharged."
494214|NCT00444067|Device|Spinal Sealant|Spinal Sealant System
524563|NCT00199069|Drug|Ifosfamide|
494215|NCT00444067|Other|Standard of Care|Standard of Care
494216|NCT00444054|Behavioral|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
494217|NCT00444041|Drug|Bevacizumab|neoadjuvant therapy prior to elective surgery
494218|NCT00444028|Drug|inhaled Loxapine 0.625 mg|Single 0.625 mg (lowest) dose of inhaled loxapine
494219|NCT00444028|Drug|inhaled Loxapine 1.25 mg|Single 1.25 mg (2nd) dose of inhaled loxapine
494220|NCT00444028|Drug|inhaled Loxapine 2.5 mg|Single 2.5 mg (3rd) dose of inhaled loxapine
494221|NCT00444028|Drug|inhaled Loxapine 5 mg|Single 5 mg (4th) dose of inhaled loxapine
494222|NCT00444028|Drug|inhaled Loxapine 10 mg|Single 10 mg (5th) dose of inhaled loxapine
494223|NCT00444028|Drug|inhaled Placebo (0 mg)|Single placebo dose of inhaled loxapine
494224|NCT00444015|Drug|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
494225|NCT00443976|Drug|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
494226|NCT00443963|Drug|Esomeprazole Magnesium|
494227|NCT00443950|Drug|Etanercept|
494228|NCT00443937|Drug|enteric-coated mycophenolate sodium|oral
494229|NCT00443937|Drug|everolimus|oral
494230|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
494231|NCT00443924|Drug|Placebo|One drop of placebo in each eye every 12 hours for three days
494232|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
494233|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
494234|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
494235|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
494236|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 48 weeks
494237|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
494238|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 24 weeks
494239|NCT00443872|Drug|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
494240|NCT00443846|Biological|RotaTeq®|Rotavirus vaccine, live, oral, pentavalent, 2 mL solution for oral administration.
494241|NCT00443846|Biological|NeisVac-C®|Meningiococcal Group C Polysaccharide Conjugate Vaccine Absorbed, 0.5 mL suspension for intramuscular injection.
494242|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
494243|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 48 weeks
494244|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
494245|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 24 weeks
494246|NCT00443807|Device|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
494247|NCT00443807|Device|EEGo vs BIS|comparison of two processed EEG monitors.
494248|NCT00443794|Drug|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
494249|NCT00443794|Drug|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
494250|NCT00443794|Drug|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
494251|NCT00443794|Drug|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
494252|NCT00443794|Drug|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
494253|NCT00443794|Drug|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
494254|NCT00443794|Drug|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
494255|NCT00443794|Drug|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
494256|NCT00443794|Drug|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
494257|NCT00443781|Procedure|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
494258|NCT00443781|Procedure|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
494259|NCT00443755|Drug|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
494260|NCT00443755|Drug|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
494261|NCT00443755|Drug|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
494262|NCT00443742|Procedure|Validation|
494263|NCT00443729|Drug|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
494264|NCT00443729|Drug|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
494265|NCT00443729|Drug|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
494266|NCT00443729|Drug|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
494267|NCT00443716|Drug|estrogen|
494268|NCT00443703|Drug|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
494269|NCT00443703|Drug|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
494270|NCT00443703|Drug|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
494271|NCT00443703|Drug|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
494272|NCT00443690|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
494273|NCT00443690|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
494274|NCT00443677|Drug|COPPEBVCAD vs BEACOPP vs ABVD|
494275|NCT00443664|Device|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
494276|NCT00443651|Drug|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
494277|NCT00443651|Drug|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
494278|NCT00443638|Behavioral|nurse home visitation|Nurse home visitation
494279|NCT00443625|Drug|SK3530|
494280|NCT00443612|Drug|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
494281|NCT00443612|Drug|Irbesartan|Administration of irbesartan 150 mg/day
494282|NCT00443599|Drug|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
494283|NCT00443599|Other|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
494284|NCT00443586|Behavioral|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
494285|NCT00443586|Behavioral|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
494286|NCT00443586|Behavioral|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
494287|NCT00443586|Behavioral|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
494288|NCT00443573|Drug|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
494289|NCT00443560|Other|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
494290|NCT00443547|Device|Vectra-T|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
494291|NCT00443534|Drug|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
494292|NCT00443521|Drug|Triamcinolone Acetonide 4 mg intravitreal injection|
494293|NCT00443521|Procedure|Panretinal photocoagulation|
494294|NCT00443508|Drug|adding Certican to therapy|
494295|NCT00443508|Drug|reducing Tacrolimus|
494296|NCT00443495|Drug|Chitin microparticles by nasal route|
494297|NCT00443482|Drug|formoterol|
494298|NCT00443469|Device|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
494299|NCT00443469|Device|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
494300|NCT00443456|Drug|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
494301|NCT00443430|Drug|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
494302|NCT00443430|Drug|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
494303|NCT00443417|Drug|SK-PC-B70M|dosage, frequency
494357|NCT00443040|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
524564|NCT00199069|Drug|Cytarabine|
494304|NCT00443404|Procedure|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
494305|NCT00443391|Drug|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
494306|NCT00443378|Behavioral|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
494307|NCT00443365|Procedure|Mitral valve repair|mitral valve annuloplasty
494308|NCT00443352|Drug|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
494309|NCT00443339|Drug|Darbepoetin|
494310|NCT00020475|Drug|gp100 antigen|
494311|NCT00020475|Drug|interleukin-2|
494312|NCT00020475|Drug|MART-1 antigen|
494313|NCT00020475|Drug|Montanide ISA-51|
494314|NCT00020371|Drug|BMS-247550|
494315|NCT00020371|Drug|filgrastim|
494316|NCT00020345|Drug|fluorouracil|
494317|NCT00020345|Drug|gemcitabine|
494318|NCT00020267|Drug|interleukin-2|
494319|NCT00020267|Drug|MAGE-12 peptide vaccine|
494320|NCT00020267|Drug|Montanide ISA-51|
494321|NCT00443326|Drug|AMG 714|Dosing Regimen is 6 Doses over 3 Months
494322|NCT00443287|Drug|ataciguat (HMR1766)|oral administration
494323|NCT00443287|Drug|placebo|oral administration
494324|NCT00443287|Drug|cilostazol|oral administration
494325|NCT00443274|Other|NBIR Placeholder|
494326|NCT00443274|Device|410 Arm|
494327|NCT00443274|Device|BIFs|
494328|NCT00443261|Drug|Azacitidine|SC azacitidine
494329|NCT00443261|Drug|Cisplatin|cisplatin 75 mg/m^2 day 8 every 28 days
494330|NCT00443248|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
494331|NCT00443235|Drug|Melphalan/Prednisone/Velcade|"One cycle:~Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
494332|NCT00443235|Drug|Thalidomide/Prednisone/Velcade|"One cycle:~Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)~Five cycles:~Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
494333|NCT00443222|Drug|Infliximab|
494334|NCT00443209|Drug|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
494335|NCT00443209|Drug|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
494336|NCT00443209|Drug|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
494337|NCT00443209|Drug|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
494338|NCT00443209|Drug|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
494339|NCT00443209|Drug|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
494340|NCT00443196|Procedure|MiCK Assay|Physician determined treatment
494341|NCT00443183|Behavioral|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
494342|NCT00443183|Behavioral|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
494343|NCT00443170|Drug|GSK626616, placebo, midazolam|
494344|NCT00443170|Drug|omeprazole, caffeine, flurbiprofen, rosiglitazone|
494345|NCT00443157|Biological|Meningococcal B Vaccine NZ|
494346|NCT00443144|Drug|recombinant human growth hormone|
494347|NCT00443131|Biological|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
494348|NCT00443118|Device|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
494349|NCT00443118|Device|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
494350|NCT00443118|Device|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
494351|NCT00443105|Drug|Tacrolimus 0.03% ointment (Protopic)|
494352|NCT00443092|Other|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
494353|NCT00443092|Other|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
494354|NCT00443079|Drug|IdB 1016 (Siliphos)|1 pill 3 times daily x 3 months
494355|NCT00443053|Drug|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
494356|NCT00443040|Drug|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
494358|NCT00443027|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
494359|NCT00443014|Device|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
494360|NCT00443001|Device|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
494361|NCT00442975|Biological|Fluarix|
494362|NCT00442962|Drug|Efavirenz|600-mg tablet taken orally daily
494363|NCT00442962|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
494364|NCT00442949|Procedure|Catheterization immediate PCI|Catheterization immediate PCI
494365|NCT00442949|Procedure|delayed PCI|delayed PCI
494366|NCT00442936|Drug|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
494367|NCT00442936|Drug|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
494368|NCT00442936|Drug|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
494369|NCT00442936|Drug|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
494370|NCT00442936|Drug|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
494371|NCT00442936|Drug|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
494372|NCT00442936|Drug|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
494373|NCT00442923|Drug|Coreg|
494374|NCT00442910|Drug|3% SPL7013 Gel (VivaGel)|3% vaginal gel
494375|NCT00442910|Drug|Placebo Gel|Placebo for SPL7013 gel
494376|NCT00442910|Drug|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
494377|NCT00442897|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
494378|NCT00442897|Drug|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
494379|NCT00442884|Behavioral|Trier Social Stress Test (TSST)|
494380|NCT00442871|Drug|eltrombopag|eltrombopag 50 mg oral
494381|NCT00020202|Drug|FR901228|
494382|NCT00020046|Drug|docetaxel|
494383|NCT00020046|Drug|thalidomide|
494384|NCT00019968|Drug|melphalan|
494385|NCT00019968|Drug|tumor necrosis factor|
494386|NCT00019890|Drug|dendritic cell-gp100-MART-1 antigen vaccine|
494387|NCT00019890|Drug|sargramostim|
494388|NCT00019760|Drug|floxuridine|
494389|NCT00019760|Drug|leucovorin calcium|
494390|NCT00019760|Drug|melphalan|
494391|NCT00019695|Drug|alendronate sodium|
494392|NCT00019695|Drug|ketoconazole|
494393|NCT00019630|Drug|doxorubicin HCl liposome|
494394|NCT00019448|Drug|gp100 antigen|
494395|NCT00019448|Drug|interleukin-2|
494396|NCT00019396|Drug|flt3 ligand|
494397|NCT00019396|Drug|gp100 antigen|
494398|NCT00019396|Drug|MART-1 antigen|
494399|NCT00019396|Drug|Montanide ISA-51|
494400|NCT00019396|Drug|tyrosinase peptide|
494401|NCT00019188|Drug|interleukin-12|
494402|NCT00019097|Drug|autologous tumor cell vaccine|
494403|NCT00019097|Drug|keyhole limpet hemocyanin|
494404|NCT00019097|Drug|melphalan|
494405|NCT00019097|Drug|sargramostim|
494406|NCT00003552|Drug|allogeneic lymphocytes|
494407|NCT00003552|Drug|anti-thymocyte globulin|
494408|NCT00003552|Drug|cyclophosphamide|
494409|NCT00003552|Drug|fludarabine|
494410|NCT00442845|Drug|Atorvastatin (Lipitor)|
494411|NCT00442832|Drug|TD-1792|TD-1792 2 mg/kg/day IV
494412|NCT00442832|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
494413|NCT00442819|Procedure|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
494414|NCT00442806|Drug|Injection of ADRC's|ADRC's are injected
494415|NCT00442806|Other|Injection of Placebo|Placebo is injected
494416|NCT00442793|Drug|Epoetin beta|As prescribed, 3 times weekly
494417|NCT00442793|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
494418|NCT00442780|Drug|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
494419|NCT00442780|Drug|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
494420|NCT00442767|Drug|Insulin|Insulin therapy was continued as per prescribed home regimen without pramlintide. Subjects self-administered a rapid-acting insulin analog (aspart or lispro) bolus based on their individual insulin: carbohydrate ratio, before meal.
494421|NCT00442767|Drug|Pramlintide + Insulin|30mcg of pramlintide was administered subcutaneously immediately prior to the meal and insulin was given 15 minutes after the meal. The dose of insulin was reduced by 20%.
494422|NCT00442754|Biological|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
494423|NCT00442741|Drug|Patupilone|
494424|NCT00442741|Drug|Patupilone + Omeprazole|
494425|NCT00442728|Device|ELECTRICAL STIMULATION|
494426|NCT00442715|Procedure|Exercise chalenge test|
494427|NCT00442702|Drug|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
494428|NCT00442702|Drug|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
494429|NCT00442689|Drug|flutamide|250 mg twice daily
494430|NCT00442689|Drug|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
494431|NCT00442689|Other|placebo|
494432|NCT00442676|Drug|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
494433|NCT00442676|Drug|Placebo|Gelatin capsules of lactose
494434|NCT00442663|Device|Transcervical Foley Catheter|
494435|NCT00442663|Device|Transcervical Foley Catheter with an EASI|
494436|NCT00442650|Drug|Efalizumab|
494437|NCT00442637|Drug|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
494438|NCT00442637|Other|observation|observation after induction treatment
494439|NCT00442611|Drug|Abatacept|
494440|NCT00442611|Drug|Placebo|
494441|NCT00442598|Drug|Glufosfamide|
494442|NCT00442585|Drug|S(+)-ibuprofen|
494443|NCT00442572|Drug|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
494444|NCT00442559|Drug|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
494445|NCT00442559|Drug|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
494446|NCT00442546|Drug|pregabalin|150 milligram (mg)/ day (double blind)
494447|NCT00442546|Drug|pregabalin|300 mg/day (double blind)
494448|NCT00442546|Drug|Placebo|Placebo
494449|NCT00442533|Drug|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
494450|NCT00442507|Drug|Erlotinib|
494451|NCT00442507|Drug|Avastin|
494452|NCT00442494|Drug|intravenous hydrocortisone|
494453|NCT00442481|Drug|Escitalopram|
494454|NCT00442481|Procedure|A baseline overnight polysomnography (oPSG)|
494455|NCT00442468|Other|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
494456|NCT00442455|Drug|Erlotinib chlorhydrate|150 mg/day for 7 weeks
494457|NCT00442455|Drug|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
494458|NCT00442455|Procedure|Radiation therapy|63 Gy, five days a week, for 7 weeks
494459|NCT00442442|Device|mosquito coils|mosquito coil / night mosquito coil & LLIN / night
494460|NCT00442442|Device|LLIN|Sleep under LLIN every night
494461|NCT00442416|Drug|Epoetin alfa|As prescribed, SC
494462|NCT00442416|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
494463|NCT00019578|Procedure|Sterotactic radiosurgery|
494464|NCT00019006|Drug|Detox-B adjuvant|
494465|NCT00019006|Drug|ras peptide cancer vaccine|
494466|NCT00442403|Drug|chloroquine|
494467|NCT00442403|Drug|dehydroepiandrosterone sulphate|
494468|NCT00442390|Drug|hydrocortisone substitution therapy versus withdrawal|
494469|NCT00442377|Procedure|exposure to malaria sporozoites|
494470|NCT00442364|Drug|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
494471|NCT00442364|Procedure|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
494472|NCT00442351|Drug|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
494473|NCT00442351|Other|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
494474|NCT00442338|Drug|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
494475|NCT00442338|Drug|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
494476|NCT00442338|Drug|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
494477|NCT00442325|Drug|Atorvastatin (Lipitor)|
494478|NCT00442312|Drug|Combigan Ophthalmic Solutiom|
494479|NCT00442299|Device|Fractionated Plasma Separation and Adsorption (FPSA)|
494480|NCT00442286|Device|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
494481|NCT00442273|Drug|Umbilical cord serum eyedrops|
494482|NCT00442273|Drug|Autologous serum eyedrops|
494483|NCT00442260|Drug|DOXIL|
494484|NCT00442260|Drug|Abraxane|
494485|NCT00442247|Device|Pelvicol|
494486|NCT00442234|Drug|Monteplase|
494487|NCT00442221|Drug|Sumatriptan and Naproxen sodium|
494488|NCT00442208|Drug|PN 200|
494489|NCT00442182|Drug|ITF2357|
494490|NCT00442169|Biological|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
494491|NCT00442169|Biological|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
494492|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
494493|NCT00442169|Biological|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
494494|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
494495|NCT00442169|Biological|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
494496|NCT00442156|Procedure|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
494497|NCT00442143|Procedure|Stem cell implantation|
494498|NCT00442130|Biological|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
494499|NCT00442130|Procedure|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
494500|NCT00442117|Drug|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
494501|NCT00442117|Drug|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
494502|NCT00442104|Drug|Ganaxolone|
494503|NCT00442091|Drug|dandelion juice|10 ml bid for 20-30 days
494504|NCT00442078|Device|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
494505|NCT00442065|Device|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
494506|NCT00442052|Drug|aspirin|
494507|NCT00442052|Drug|omeprazole|
494508|NCT00442039|Drug|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing < 20 kg
494509|NCT00442039|Drug|Lithium Carbonate|The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient‟s response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient‟s response and tolerability
494510|NCT00442039|Drug|Lithium Carbonate|The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient‟s response and tolerability.
494511|NCT00442039|Drug|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
494512|NCT00442026|Drug|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
494513|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
494514|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
494515|NCT00442013|Drug|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
494516|NCT00442013|Drug|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
494517|NCT00442000|Procedure|Prostatectomy|Patients undergoing prostatectomy.
494518|NCT00441987|Drug|GSI-953|
494519|NCT00441974|Drug|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
494520|NCT00441961|Drug|methotrexate|methotrexate
494521|NCT00441948|Device|Peterio|
494522|NCT00441935|Device|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
494523|NCT00441922|Drug|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
494524|NCT00441922|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
494525|NCT00441909|Drug|UC-781|0.1% UC-781 Vaginal Gel
494526|NCT00441909|Drug|UC-781 placebo|Vaginal Gel Placebo
494527|NCT00441896|Drug|Ganaxolone|
494528|NCT00441883|Drug|PF-03187207 and Latanoprost Vehicle|
494529|NCT00441883|Drug|Latanoprost 0.005% and PF-03187207 Vehicle|
494530|NCT00441870|Drug|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
494531|NCT00441870|Drug|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
494532|NCT00441857|Behavioral|plant stanol consumption|
494533|NCT00441844|Drug|Simvastatin|
494534|NCT00441818|Drug|TNX-650|
494535|NCT00441805|Device|Radio Frequency|
494536|NCT00441792|Drug|Etomidate|Etomidate at induction dose based on weight
494537|NCT00441792|Drug|midazolam|Midazolam at induction dose based on weight
494538|NCT00441766|Drug|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
494539|NCT00441766|Drug|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
494540|NCT00441766|Drug|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
494541|NCT00441766|Drug|placebo|Part A: placebo capsule every 12 hours for 4 weeks
494542|NCT00441740|Drug|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
494543|NCT00441740|Drug|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
494544|NCT00441740|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
494545|NCT00441740|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
494546|NCT00441727|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
494547|NCT00441727|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
494548|NCT00441727|Drug|Placebo|Placebo once daily
494549|NCT00441714|Procedure|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
494550|NCT00441701|Drug|Navarixin 1 mg|Navarixin 1 mg capsules
494551|NCT00441701|Drug|Navarixin 10 mg|Navarixin 10 mg capsules
494552|NCT00441701|Drug|Placebo to match navarixin|Placebo to navarixin capsules
494553|NCT00441701|Drug|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
494554|NCT00441688|Drug|GI265235|
494555|NCT00441675|Procedure|Symptom Score|Symptom Score
494556|NCT00441675|Procedure|Symptom Score and PD20|Symptom Score and PD20
494557|NCT00441662|Drug|Sub-Tenon triamcinolone 40mg|
494558|NCT00441649|Drug|Methylphenidate|
494559|NCT00441636|Device|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
494560|NCT00441623|Behavioral|observational|effect of protein-bound uremic retention solutes
494561|NCT00441610|Drug|Gimatecan|
494562|NCT00441597|Drug|atorvastatin|atorvastatine 80mg, during 3 days
494563|NCT00441584|Biological|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
494564|NCT00441584|Drug|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
494566|NCT00441558|Drug|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
494567|NCT00441545|Drug|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
494568|NCT00441545|Drug|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
494569|NCT00441532|Drug|Lidocaine|
494570|NCT00441519|Drug|aspirin|
494571|NCT00441519|Drug|omeprazole|
494572|NCT00441506|Drug|daily interruption of sedatives|
494573|NCT00441493|Drug|fluvastatin|
494574|NCT00441480|Dietary Supplement|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
494575|NCT00441480|Dietary Supplement|placebo|4 gr of corn oil
494576|NCT00441467|Drug|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
494577|NCT00441454|Device|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
494578|NCT00441454|Device|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
494579|NCT00441441|Drug|fluticasone propionate|fluticasone propionate 100mcg HFA
494580|NCT00441441|Drug|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
494581|NCT00441428|Drug|solifenacin|
494582|NCT00441415|Drug|Adapalene BPO|
494583|NCT00441376|Drug|ThermoDox|15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
494584|NCT00441363|Drug|Bromocriptine Mesylate|0.8 mg tablet
494585|NCT00441350|Drug|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
494586|NCT00441350|Drug|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
494587|NCT00441337|Biological|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
494588|NCT00441324|Procedure|recombinant human LH|
494589|NCT00441311|Behavioral|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
494590|NCT00441298|Drug|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
494591|NCT00441298|Drug|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
494592|NCT00441285|Drug|Praziquantel|- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
494593|NCT00441285|Drug|Albendazole|"Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.~Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days."
494594|NCT00441285|Drug|ABZ Placebo|- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
494595|NCT00441285|Drug|PZQ Placebo|- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
494596|NCT00441272|Drug|Pioglitazone|
494597|NCT00441259|Biological|ChimeriVax™-JE|One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged > 3 years and 0.5 ml to children and infants aged < 3 years administered subcutaneously
494598|NCT00441259|Biological|Japanese Encephalitis Inactivated Mouse Brain Vaccine|Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged > 3 years and 0.5 ml is given to children and infants aged < 3 years administered subcutaneously
494599|NCT00441246|Drug|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
494600|NCT00441233|Device|Silicone hydrogel contact lens|
494601|NCT00441207|Drug|Ascorbic Acid|Delivered via IV Infusion.
494602|NCT00441194|Device|Visual Field (Octopus 311 and the HFA 700 series)|
494603|NCT00441181|Drug|Travoprost|
494604|NCT00441168|Drug|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
494605|NCT00441168|Drug|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
494606|NCT00441168|Drug|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
494607|NCT00441168|Drug|vincristine|vincristine: 0.4mg IV push on days 1 to 4
494608|NCT00441155|Drug|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
494609|NCT00441142|Drug|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
494670|NCT00440700|Behavioral|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
494783|NCT00440063|Drug|epoetin beta [NeoRecormon]|
494940|NCT00439049|Drug|Naltrexone|50mg daily
524565|NCT00199069|Drug|Mitoxantrone|
494610|NCT00441142|Drug|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.~During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
494611|NCT00441142|Radiation|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
494612|NCT00441129|Device|Minimed paradigm Real Time Sytem|Minimed paradigm Real Time Sytem
494613|NCT00441129|Device|Minimed Paradigm 512/712 Insulin pump|Minimed Paradigm 512/712 Insulin pump
494614|NCT00441116|Drug|Dutasteride 0.5mg oral tablets|Dutasteride
494615|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
494616|NCT00441103|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
494617|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
494618|NCT00441090|Drug|Placebo|Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
494619|NCT00441090|Drug|Avatrombopag tablets|Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
494620|NCT00441077|Behavioral|Education|
494621|NCT00441064|Drug|Aliskiren|
494622|NCT00441051|Drug|Diclofenac sodium 1mg/g|
494623|NCT00441038|Behavioral|The Back Guide|Education on postural hygiene and handout of The Back Guide
494624|NCT00441038|Behavioral|The Back Book|Education on active management and Handout of The Back Book
494625|NCT00441038|Behavioral|Cardiovascular and general health|Education on cardiovascular and general health
494626|NCT00441025|Drug|Alemtuzumab|
494627|NCT00441012|Biological|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 & 12 months of age. Duration of treatment is 11 months.
494628|NCT00441012|Biological|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
494629|NCT00440999|Drug|Pyronaridine artesunate|
494630|NCT00440999|Drug|Chloroquine|
494631|NCT00440986|Procedure|Eritrocytoapheresis|
494632|NCT00440973|Drug|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
494633|NCT00440973|Drug|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T & B lymphocyte proliferation
494634|NCT00440960|Drug|propofol|
494635|NCT00440960|Drug|midazolam|
494636|NCT00440960|Drug|alfentanil|
494637|NCT00440960|Drug|lidocaine|
494638|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
494639|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
494640|NCT00440934|Device|Amplitude-modulated electromagnetic fields|
494641|NCT00440921|Drug|Single donor Allogenous Fibrin Sealant|
494642|NCT00440895|Drug|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
494643|NCT00440869|Dietary Supplement|N-acetylcysteine|600 mg po bid
494644|NCT00440869|Dietary Supplement|placebo|bid oral dosing
494645|NCT00440856|Behavioral|Presentation of excised intervertebral disc fragments|
494646|NCT00440843|Drug|Olanzapine (Zyprexa)|OLZ
494647|NCT00440843|Drug|Typicals|Stay on typicals regimen
494648|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
494649|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
494650|NCT00440830|Drug|placebo|placebo patch applied to smokers
494651|NCT00440830|Drug|placebo|placebo patch applied to nonsmokers
494652|NCT00440817|Other|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
494653|NCT00440804|Drug|ibuprofen l-lysine iv solution (NeoProfen (R) )|
494654|NCT00440791|Device|PillCam Colon capsule endoscopy|
494655|NCT00440778|Drug|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
494656|NCT00440765|Drug|bortezomib|dose as determined (observational study) by treating physician
494657|NCT00440739|Drug|etoricoxib|etoricoxib 120 mg
494658|NCT00440739|Drug|flavoxate|flavoxate 200 mg 3 times
494659|NCT00440739|Drug|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
494660|NCT00440739|Drug|placebo|placebo once and placebo 3 times
494661|NCT00440726|Drug|bortezomib (Velcade)|Intravenous at 1.3mg/m2 on days 1, 4, 8 and 11
494662|NCT00440726|Drug|dexamethasone|Intravenous or oral administration for 14 days.
494663|NCT00440726|Drug|PEG-asparaginase|Intramuscular injection
494664|NCT00440726|Drug|doxorubicin|Intravenous infusion
494665|NCT00440726|Drug|cytarabine|Intrathecal administration on day 1
494666|NCT00440726|Drug|methotrexate|Intrathecal administration
494667|NCT00440726|Drug|vincristine|Intravenous push on days 1, 8, 15, 22
494668|NCT00440713|Drug|Aripiprazole|
494669|NCT00440713|Behavioral|Interpersonal Therapy|
494781|NCT00440089|Behavioral|Hands-on-Healing|
494782|NCT00440076|Drug|Velcade|
524566|NCT00199069|Drug|Methotrexate|
494671|NCT00440700|Behavioral|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
494672|NCT00440700|Behavioral|Control 2: Standard of Care|Usual ICU nursing care.
494673|NCT00440687|Drug|Fluticasone 500mcg BD via accuhaler or identical placebo|
494674|NCT00440674|Device|CoStar Paclitaxel-eluting coronary stent system|
494675|NCT00440661|Drug|Diacerhein|
494676|NCT00440648|Drug|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
494677|NCT00440648|Drug|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
494678|NCT00440635|Drug|Bortezomib, tradename Velcade|
494679|NCT00440622|Drug|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
494680|NCT00440622|Drug|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
494681|NCT00440622|Drug|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
494682|NCT00440609|Drug|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
494683|NCT00440596|Behavioral|Mindfulness based stress reduction|8 weeks group MBSR
494684|NCT00440596|Behavioral|Progressive Muscle Relaxation|8 weeks PMR in group format
494685|NCT00440583|Drug|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
494686|NCT00440570|Device|Low levels of amplitude-modulated electromagnetic fields|
494687|NCT00440570|Device|Emitter of low levels of amplitude-modulated electromagnetic fields|
494688|NCT00440557|Drug|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
494689|NCT00440557|Drug|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
494690|NCT00440557|Drug|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
494691|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
494692|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
494693|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
494694|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
494695|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
494696|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
494697|NCT00440531|Biological|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
494698|NCT00440531|Biological|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
494699|NCT00440531|Biological|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
494700|NCT00440518|Drug|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
494701|NCT00440518|Other|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
494702|NCT00440518|Drug|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
494703|NCT00440505|Drug|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
494704|NCT00440505|Drug|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
494705|NCT00440505|Drug|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
494706|NCT00440492|Drug|PLA-695|
494707|NCT00440479|Drug|Bortezomib|dose as determined (observational study) by treating physician
494708|NCT00440466|Drug|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
494709|NCT00440466|Drug|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
494710|NCT00440466|Drug|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
494711|NCT00440453|Other|Nutritional therapy|Nutritional therapy by dietician
494712|NCT00440440|Drug|Testosterone gel|Testosterone gel to be applied daily, starting does 5g.
494713|NCT00440440|Drug|placebo|placebo gel apply daily
494714|NCT00440427|Drug|Desvenlafaxine Sustained Release (DVS SR)|
494715|NCT00440414|Drug|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
494716|NCT00440414|Drug|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
494717|NCT00440401|Drug|fibrinogen (human) + thrombin (human)|
494718|NCT00440401|Drug|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
494719|NCT00440388|Drug|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
494720|NCT00440388|Drug|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
494721|NCT00440375|Drug|Rosiglitazone|
494722|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at t=0 via IM route
494723|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
494724|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
494725|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
494726|NCT00440362|Biological|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
494727|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
494728|NCT00440362|Biological|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
494729|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
494730|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the IM route
494731|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the SC route
494732|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
494733|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
494734|NCT00440349|Drug|Tamoxifen|
494735|NCT00440349|Drug|Prednisone|
494736|NCT00440336|Drug|Cosopt|
494737|NCT00440336|Drug|Xalatan|
494738|NCT00440323|Drug|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
494739|NCT00440323|Drug|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
494740|NCT00440323|Drug|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
494741|NCT00440310|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
494742|NCT00440310|Procedure|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
494743|NCT00440310|Device|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
494744|NCT00440310|Drug|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
494745|NCT00440310|Drug|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
494746|NCT00440297|Biological|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
494747|NCT00440297|Biological|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
494748|NCT00440284|Drug|conventional vs. flexible, intensive insulin therapy|
494749|NCT00440271|Drug|tipranavir|
494750|NCT00440271|Drug|ritonavir|
494751|NCT00440271|Drug|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
494752|NCT00440258|Drug|Cabergoline|
494753|NCT00440258|Procedure|MR|
494754|NCT00440258|Procedure|Ultrasound|
494755|NCT00440258|Procedure|Blood Analysis|
494756|NCT00440245|Drug|salbutamol|200 micrograms salbutamol from MDI
494757|NCT00440232|Drug|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
494758|NCT00440232|Drug|Placebo|Inert tab identical in appearance to Frovatriptan
494759|NCT00440219|Drug|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
494760|NCT00440219|Drug|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
494761|NCT00440193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
494762|NCT00440193|Drug|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
494763|NCT00440180|Drug|Anastrozole|1 mg qd for 4 months
494764|NCT00440180|Drug|Placebo|Placebo Comparator
494765|NCT00440167|Drug|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
494766|NCT00440167|Drug|Capecitabine|"Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)"
494767|NCT00440167|Drug|Erlotinib|Erlotinib 150 mg/d oral, daily without break
494768|NCT00440154|Drug|AVE5530|
494769|NCT00440154|Drug|placebo|
494770|NCT00440154|Drug|ezetimibe|
494771|NCT00440141|Drug|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
494772|NCT00440141|Drug|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
494773|NCT00440128|Drug|Docetaxel|Docetaxel
494774|NCT00440128|Drug|Casopitant/Docetaxel|Casopitant/Docetaxel
494775|NCT00440115|Behavioral|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
494776|NCT00440115|Behavioral|Low intensity disease management|Health education mailings, one motivation interview/counseling
494777|NCT00440115|Behavioral|Comparison group|Health education mailings
494778|NCT00440115|Drug|Bupropion|Buproprion or Nicotine Replacement Therapy
494779|NCT00440102|Drug|Ketamine|Ketamine
494780|NCT00440102|Drug|Etomidate|Etomidate
494784|NCT00440050|Drug|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
494785|NCT00440050|Drug|Placebo|2 placebo capsules twice a day for 18 months
494786|NCT00440037|Biological|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
494787|NCT00440024|Drug|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
494788|NCT00440024|Drug|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
494789|NCT00440024|Drug|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
494790|NCT00440011|Drug|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
494791|NCT00440011|Drug|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
494792|NCT00439998|Procedure|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
494793|NCT00439985|Behavioral|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
494794|NCT00439972|Drug|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
494795|NCT00439972|Drug|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
494796|NCT00439972|Drug|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
494797|NCT00439959|Drug|GSK625433/placebo|
494798|NCT00439946|Drug|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
494799|NCT00439946|Device|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
494800|NCT00439933|Behavioral|low fat and polysaccharide rich diet|
494801|NCT00439933|Behavioral|specific physical training program for obese children|
494802|NCT00439920|Drug|High-dose anthracycline|
494803|NCT00439907|Procedure|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
494804|NCT00439907|Procedure|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
494805|NCT00439894|Procedure|Blood draw|blood draw at baseline, week 12 and week 24
494806|NCT00439881|Drug|SB-681323|
494807|NCT00439868|Drug|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
494808|NCT00439868|Drug|placebo|Matching placebo tablets to WELLBUTRIN XL.
494809|NCT00439855|Drug|Enoxaparin i.v.|
494810|NCT00439855|Drug|unfractionated heparin|
494811|NCT00439842|Behavioral|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
494812|NCT00439829|Drug|Gonal F|"450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).~Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).~Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
494813|NCT00439829|Drug|Luveris|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
494814|NCT00439829|Drug|Cetrotide|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:~leading follicle is > 13 mm in diameter~if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L~Dosing to continue until administration of hCG (see below)."
494815|NCT00439829|Drug|hCG|"- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:~o > 3 follicles are > 17 mm in diameter"
494816|NCT00439816|Behavioral|Group Visits|
494817|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
494818|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
494819|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
494820|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
494821|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
494822|NCT00439803|Biological|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
494823|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
494824|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
494825|NCT00439790|Procedure|Microneurography|Microneurography
494826|NCT00439777|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
494882|NCT00439413|Behavioral|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
494827|NCT00439777|Drug|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
494828|NCT00439764|Behavioral|General health talk|Routine clinical practice and talk on general health
494829|NCT00439764|Behavioral|Handout of The Back Book|Talk on health of the back and handout of The Back Book
494830|NCT00439764|Behavioral|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
494831|NCT00439751|Drug|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
494832|NCT00439738|Drug|HCTZ + Amlodipine|"12.5 mg HCTZ capsules~25 mg HCTZ capsules~5 mg amlodipine capsules~10 mg amlodipine capsules"
494833|NCT00439738|Drug|Valsartan/HCTZ|"160 mg film-coated valsartan tablets~320 mg film-coated valsartan tablets~12.5 mg HCTZ capsules~25 mg HCTZ capsules"
494834|NCT00439725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
494835|NCT00439725|Drug|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
494836|NCT00439712|Drug|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
494837|NCT00439712|Drug|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
494838|NCT00439699|Drug|Memantine|Mematine administration
494839|NCT00439686|Drug|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
494840|NCT00439673|Drug|5-Azacytidine|
494841|NCT00439673|Drug|Valproic Acid|
494842|NCT00439673|Drug|ATRA|
494843|NCT00439660|Biological|Oral Rotavirus Vaccine 116E Live Attenuated|
494844|NCT00439647|Drug|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
494845|NCT00439647|Drug|Placebo|Placebo intravenous (i.v.) once a year
494846|NCT00439634|Drug|AVE1625|oral administration
494847|NCT00439634|Drug|placebo|oral administration
494848|NCT00439621|Biological|RP 01|Active immunotherapy
494849|NCT00439608|Drug|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
494850|NCT00439595|Device|Hemocue 210 meter|Diagnostic device
494851|NCT00439595|Device|Copack HBCS|
494852|NCT00439582|Dietary Supplement|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
494853|NCT00439582|Dietary Supplement|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
494854|NCT00439569|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
494855|NCT00439556|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
494856|NCT00439556|Biological|Anti-Thymocyte Globulin|Given IV
494857|NCT00439556|Drug|Bortezomib|Given IV
494858|NCT00439556|Drug|Carmustine|Given IV
494859|NCT00439556|Drug|Cytarabine|Given IV
494860|NCT00439556|Drug|Etoposide|Given IV
494861|NCT00439556|Biological|Filgrastim|Given SC
494862|NCT00439556|Drug|Melphalan|Given IV
494863|NCT00439556|Drug|Methotrexate|Given IV
494864|NCT00439556|Biological|Rituximab|Given IV
494865|NCT00439556|Drug|Tacrolimus|Given IV and PO
494866|NCT00439543|Drug|Iloprost inhalation|
494867|NCT00439530|Drug|oseltamivir|
494868|NCT00439530|Drug|probenecid|
494869|NCT00439517|Drug|UFOX + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)~Oxaliplatin infusion (85mg/m^2) on days 1 and 15 (every 2 weeks)~Oral UFT® (250mg/m^2 tegafur + 560 mg/m^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21~Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
494870|NCT00439517|Drug|FOLFOX4 + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)~Oxaliplatin infusion (85 mg/m^2) on days 1 and 15 (every 2 weeks)~5-FU bolus + infusions (400 mg/m^2) on days 1, 2, 15 and 16~Folinic Acid infusions (200 mg/m^2) on days 1, 2, 15 and 16"
494871|NCT00439504|Drug|Lobeline|
494872|NCT00439491|Behavioral|Hypocaloric diet|
494873|NCT00439478|Drug|Radioiodine|
494874|NCT00439465|Biological|Ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
494875|NCT00439452|Other|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
494876|NCT00439452|Other|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
494877|NCT00439439|Radiation|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
494878|NCT00439426|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
494879|NCT00439426|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
494880|NCT00439413|Drug|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
494881|NCT00439413|Drug|Placebo|Matching placebo via transdermal system
494883|NCT00439400|Drug|doxycycline|
494884|NCT00439400|Drug|placebo|
494885|NCT00439374|Drug|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
494886|NCT00439374|Other|Placebo Oil|Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
494887|NCT00439361|Drug|Bortezomib|1.0 mg/m^2 by Vein Over 5 Seconds on Days 1 and 4
494888|NCT00439361|Drug|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
494889|NCT00439361|Drug|Etoposide|100 mg/m^2 By Vein Over 2 Hours On Days 1-3
494890|NCT00439361|Drug|Ifosfamide|5 Gm/m^2 By Vein Continuous Infusion Over 24 Hours On Day 1
494891|NCT00439361|Drug|Mesna|5 mg/m^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
494892|NCT00439348|Behavioral|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
494893|NCT00439348|Behavioral|Prescription|Patients receive a prescription for a specific over-the-counter medication.
494894|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
494895|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
494896|NCT00439335|Drug|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
494897|NCT00439335|Drug|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
494898|NCT00439309|Device|Gelfoam/Thrombin|Gelfoam/Thrombin
494899|NCT00439309|Device|VascuSeal|VascuSeal
494900|NCT00439296|Drug|ABT-751|Oral capsule to be given daily for 21 days.
494901|NCT00439296|Drug|dexamethasone|IV or Oral daily for 14 days
494902|NCT00439296|Drug|PEG-asparaginase|Intramuscular injection
494903|NCT00439296|Drug|doxorubicin|IV infusion
494904|NCT00439296|Drug|cytarabine|Intrathecal dose on day 1
494905|NCT00439296|Drug|methotrexate|Intrathecal dose
494906|NCT00439296|Drug|cyclophosphamide|Intravenous dose
494907|NCT00439296|Drug|6-thioguanine|Oral dose, course #2
494908|NCT00439283|Drug|infliximab|
494909|NCT00439283|Drug|methotrexate|
494910|NCT00439270|Drug|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
494911|NCT00439270|Drug|Docetaxel|Infusion, 60 or 75 mg/m^2, administered every 3 weeks.
494912|NCT00439244|Drug|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
494913|NCT00439244|Drug|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
494914|NCT00439244|Drug|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.~Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
494915|NCT00439231|Drug|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
494916|NCT00439218|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
494917|NCT00439205|Device|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
494918|NCT00439205|Device|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
494919|NCT00439192|Drug|ELB245|
494920|NCT00439192|Drug|Tolterodine|
494921|NCT00439179|Drug|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
494922|NCT00439179|Drug|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
494923|NCT00439179|Drug|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
494924|NCT00439179|Drug|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
494925|NCT00439166|Drug|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
494926|NCT00439166|Drug|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
494927|NCT00439166|Drug|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
494928|NCT00439166|Drug|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
494929|NCT00439153|Device|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
494930|NCT00439140|Biological|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
494931|NCT00439140|Drug|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
494932|NCT00439101|Drug|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
494933|NCT00439101|Other|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
494934|NCT00439075|Procedure|CPAP|
494935|NCT00439075|Drug|standard treatment|
494936|NCT00439062|Drug|Roxithromycin|
494937|NCT00439049|Drug|modafinil|400 mg daily
494938|NCT00439049|Drug|d-amphetamine|60mg daily
494939|NCT00439049|Drug|L-Dopa|800/200mg daily
494941|NCT00439036|Behavioral|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
494942|NCT00439036|Behavioral|Drug Counseling|
494943|NCT00439023|Procedure|dialysis with glucose in dialysis water|
494944|NCT00439010|Drug|[123I] AV 39|
494945|NCT00438984|Drug|cyclophosphamide|Given IV
494946|NCT00438984|Biological|therapeutic autologous lymphocytes|Given IV
494947|NCT00438984|Biological|aldesleukin|Given IV or SC
494948|NCT00438984|Other|immunohistochemistry staining method|Correlative studies
494949|NCT00438984|Procedure|biopsy|Optional correlative studies
494950|NCT00438984|Other|laboratory biomarker analysis|Correlative studies
494951|NCT00438984|Other|immunologic technique|Correlative studies
494952|NCT00438984|Genetic|polymerase chain reaction|Correlative studies
494953|NCT00438971|Drug|Duloxetine|Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
494954|NCT00438958|Biological|filgrastim|Given on day 0.
494955|NCT00438958|Procedure|allogeneic bone marrow transplantation|Given on day 0
494956|NCT00438958|Procedure|peripheral blood stem cell transplantation|Given on day 0
494957|NCT00438945|Drug|Eprosartan|
494958|NCT00438932|Drug|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
494959|NCT00438932|Dietary Supplement|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
494960|NCT00438932|Dietary Supplement|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
494961|NCT00438932|Drug|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
494962|NCT00438919|Device|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
494963|NCT00438906|Procedure|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
494964|NCT00438906|Drug|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
494965|NCT00438893|Dietary Supplement|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
494966|NCT00438880|Drug|Agatolimod Sodium|Given IV
494967|NCT00438880|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
494968|NCT00438880|Other|Laboratory Biomarker Analysis|Correlative study
494969|NCT00438880|Procedure|Radionuclide Imaging|Undergo imaging scans
494970|NCT00438880|Biological|Rituximab|Given IV
494971|NCT00438880|Procedure|Single Photon Emission Computed Tomography|Undergo imaging scans
494972|NCT00438880|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
494973|NCT00438867|Genetic|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
494974|NCT00438867|Genetic|Placebo|Control group
494975|NCT00438854|Drug|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
494976|NCT00438841|Drug|bortezomib|
494977|NCT00438841|Drug|cyclophosphamide|
494978|NCT00438841|Drug|dexamethasone|
494979|NCT00438841|Drug|thalidomide|
494980|NCT00438828|Drug|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
494981|NCT00438815|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
494982|NCT00438802|Drug|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
494983|NCT00438789|Drug|eculizumab|600mg IV every week and 900mg IV every 2 weeks
494984|NCT00438776|Drug|olanzapine|2.5mg to 15mg daily
494985|NCT00438776|Drug|sugar pill|matching placebo to olanzapine
494986|NCT00438750|Other|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
494987|NCT00438750|Other|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
494988|NCT00438737|Biological|bevacizumab|
494989|NCT00438737|Biological|cetuximab|
494990|NCT00438737|Drug|fluorouracil|
494991|NCT00438737|Drug|leucovorin calcium|
494992|NCT00438737|Drug|oxaliplatin|
494993|NCT00438737|Procedure|adjuvant therapy|
494994|NCT00438737|Procedure|conventional surgery|
494995|NCT00438737|Procedure|neoadjuvant therapy|
494996|NCT00438724|Behavioral|Information, counseling and support|
494997|NCT00438698|Other|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
494998|NCT00438698|Other|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
494999|NCT00438685|Behavioral|Outpatient MST/OPTION-A|
495000|NCT00438685|Behavioral|Usual Services|
495001|NCT00438672|Drug|Placebo Injection|Injection without steroid
495002|NCT00438672|Drug|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
495003|NCT00438659|Drug|mometasone furoate|Applied to treatment area
495004|NCT00438659|Other|placebo|Applied to treatment area
495005|NCT00438620|Behavioral|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
524567|NCT00199069|Drug|6-Mercaptopurine|
495006|NCT00438607|Drug|BIIB014|oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
495007|NCT00438607|Drug|Placebo|Matched placebo for MTD or MTD-1
495008|NCT00438594|Behavioral|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
495009|NCT00438581|Drug|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
495010|NCT00438568|Drug|Regular Insulin|administered intra-nasally twice a day for 16 weeks
495011|NCT00438568|Drug|Placebo|administered intra-nasally twice a day for 16 weeks
495012|NCT00438555|Behavioral|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
495013|NCT00438555|Behavioral|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
495014|NCT00438516|Behavioral|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
495015|NCT00438503|Procedure|Procedure|
495016|NCT00438490|Drug|Recombinant Human Prolactin|
495017|NCT00438477|Drug|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
495018|NCT00438477|Procedure|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
495019|NCT00438477|Radiation|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.~At the time of surgery, patients receive isosulfan blue by subareolar injection."
495020|NCT00438464|Drug|Finasteride|Given PO
495021|NCT00438464|Other|Placebo|Given PO
495022|NCT00438464|Procedure|Prostatectomy|Undergo prostatectomy
495023|NCT00438464|Other|Laboratory biomarker analysis|Correlative studies
495024|NCT00438451|Drug|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
495025|NCT00438451|Drug|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
495026|NCT00438451|Drug|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
495027|NCT00438438|Behavioral|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
495028|NCT00438425|Dietary Supplement|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
495029|NCT00438425|Dietary Supplement|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
495030|NCT00438425|Dietary Supplement|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
495031|NCT00438399|Drug|C. propionate - Corticosteroid 1|Twice daily application
495032|NCT00438399|Drug|C. propionate- Corticosteroid 2|Twice daily application
495033|NCT00438399|Drug|C. propionate -Corticosteroid 3|Twice daily application
495034|NCT00438399|Drug|Corticosteroid 1- C. propionate|Twice daily application
495035|NCT00438399|Drug|Corticosteroid 2 - C. propionate|Twice daily application
495036|NCT00438399|Drug|Corticosteroid 3 - C. propionate|Twice daily application
495037|NCT00438386|Drug|Aripiprazole|
495038|NCT00438360|Drug|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
495039|NCT00438360|Drug|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
495040|NCT00438347|Behavioral|Aerobic Exercise|One hour per day three times a week for one year
495041|NCT00438347|Behavioral|Stretching and toning|One hour per day three times a week for one year
495042|NCT00438334|Device|Programmable directional/omni-directional hearing aid|
495043|NCT00438321|Drug|Zoladex|
495044|NCT00438321|Drug|Testosterone gel|
495045|NCT00438321|Drug|Anastrozole Pill|
495046|NCT00438321|Other|Placebo|
495047|NCT00438295|Procedure|temperature control|
495048|NCT00438282|Behavioral|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
495049|NCT00438269|Drug|Site-specific empiric regimens included: Meropenem|
495050|NCT00438269|Drug|Piperacillin/tazobactam|
495051|NCT00438269|Drug|Ciprofloxacin and cefazolin +/- metronidazole|
495052|NCT00438256|Procedure|Proton Beam Radiation|Given over different schedules and duration
524568|NCT00199069|Drug|6-Thioguanine|
495053|NCT00438256|Drug|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
495054|NCT00438243|Drug|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
495055|NCT00438243|Drug|Refresh Plus|1 drop in the affected eye twice daily
495056|NCT00438230|Drug|Warfarin|
495057|NCT00438217|Drug|Triptorelin (GnRH agonists)|
495058|NCT00438217|Drug|Leuprolide (GnRH agonists)|
495059|NCT00438204|Biological|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
495060|NCT00438204|Drug|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
495061|NCT00438204|Drug|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
495062|NCT00438178|Drug|Obatoclax mesylate (GX15-070MS)|
495063|NCT00438165|Behavioral|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
495064|NCT00438152|Drug|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
495065|NCT00438152|Drug|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
495066|NCT00438139|Drug|Dronabinol|
495067|NCT00438126|Behavioral|A lifestyle educational program|
495068|NCT00438113|Drug|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
495069|NCT00438100|Drug|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
495070|NCT00438100|Drug|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
495071|NCT00438087|Drug|methylprednisolone|methylprednisolone administrated intra and post operatively
495072|NCT00438061|Behavioral|Weight loss by dietary restriction|
495073|NCT00438048|Procedure|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
495074|NCT00438048|Drug|Artificial Saliva|5ml 3 times daily
495075|NCT00438035|Procedure|ECG spectral|
495076|NCT00438009|Drug|Coxsackievirus A21|Two doses of drug, separated by 48 hours
495077|NCT00437996|Drug|Clonidine|
495078|NCT00437996|Drug|Levobupivacaine|
495079|NCT00437996|Drug|Sufentanil|
495080|NCT00437983|Dietary Supplement|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
495081|NCT00437983|Dietary Supplement|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
495082|NCT00437970|Drug|Pioglitazone|15mg of Pioglitazone taken orally twice a day
495083|NCT00437970|Drug|Metformin|500 mg of Metformin taken orally twice a day
495084|NCT00437957|Drug|Temozolomide|75 Mg/m2/day for all Cohorts
495085|NCT00437957|Drug|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
495086|NCT00437957|Procedure|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
495087|NCT00437918|Drug|nateglinide|
495088|NCT00437918|Drug|acarbose|
495089|NCT00437905|Procedure|angioplasty|
495090|NCT00437892|Drug|atorvastatin|tablets, 40 mg day, 3 months
495091|NCT00437892|Drug|atorvastatin|tablets, 40 mg once daily
495092|NCT00437892|Behavioral|diet|daily
495093|NCT00437892|Behavioral|diet|daily diet
495094|NCT00437853|Drug|Anastrozole|
495095|NCT00437840|Drug|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
495096|NCT00437840|Drug|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
495097|NCT00437827|Other|Star*D algorithm|Standard of care based upon the therapies selected in the Star*D study.
495098|NCT00437827|Other|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
495099|NCT00437814|Drug|Ketamine, effect on intracranial pressure|
495100|NCT00437762|Drug|Botulinum Toxin A Injection|Botulinum Toxin A Injection
495101|NCT00437762|Drug|Placebo injection|Placebo Injection
495102|NCT00437749|Drug|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
495103|NCT00437749|Other|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
495104|NCT00437736|Drug|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
495105|NCT00437723|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
495106|NCT00437710|Procedure|cell therapy, bone marrow derived stem cell|
495107|NCT00437697|Drug|dalteparin|
495108|NCT00437684|Drug|LPV/r|200/50 mg 2 cpr bid monotherapy
495109|NCT00437684|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
495110|NCT00437684|Drug|Ribavirin|Ribavirin 1-1.2 g/day
495111|NCT00437684|Drug|NUCS|Nucleoside Reverse Transcriptase Inhibitors
495112|NCT00437671|Drug|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
495113|NCT00437671|Biological|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
495114|NCT00437658|Drug|Elagolix|Provided as tablets for oral administration
495115|NCT00437658|Drug|Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)|Provided for subcutaneous injection in a prefilled syringe, 104 mg/0.65 mL per syringe.
495116|NCT00437658|Drug|Placebo to Elagolix|Matching placebo tablets for oral administration
495117|NCT00437658|Drug|Placebo to DMPA-SC|Matching placebo for subcutaneous injection in a pre-filled syringe
495118|NCT00437645|Drug|Valsartan 160 mg capsules|
495119|NCT00437645|Drug|Amlodipine 5 mg capsules|
495120|NCT00437645|Drug|placebo|capsules
495121|NCT00437632|Drug|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
495122|NCT00437632|Drug|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
495123|NCT00437632|Drug|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
495124|NCT00437619|Drug|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.
495125|NCT00437606|Drug|GK Activator (2)|100mg po
495126|NCT00437606|Drug|Ethanol|40g po
495127|NCT00437593|Procedure|ppVE, MP, ICG|surgery with ILM staining
495128|NCT00437593|Procedure|ppVE, MP, MB|Surgery with ERM staining
495129|NCT00437580|Drug|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
495130|NCT00437567|Dietary Supplement|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
495131|NCT00437567|Other|Placebo|Similar quantity of sterile water to be added to milk
495132|NCT00437554|Drug|Glimepiride|
495133|NCT00437541|Device|Insulation retrofitted into house|
495134|NCT00437502|Biological|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
495135|NCT00437502|Biological|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
495136|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
495137|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
495138|NCT00437476|Drug|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
495139|NCT00437476|Drug|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
495140|NCT00437476|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
495141|NCT00437476|Drug|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
495142|NCT00437463|Drug|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
495143|NCT00437450|Drug|Epoetin/Atra|
495144|NCT00437437|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
495145|NCT00437424|Drug|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
495146|NCT00437411|Behavioral|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
495147|NCT00437398|Biological|Islet Transplant|Purified pancreatic islets
495148|NCT00437385|Drug|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
495149|NCT00437385|Procedure|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
495150|NCT00437385|Behavioral|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
495151|NCT00437372|Drug|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
495152|NCT00437372|Radiation|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
495153|NCT00437359|Drug|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
495154|NCT00437359|Drug|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
495155|NCT00437346|Procedure|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
495156|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
495157|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
495158|NCT00437333|Drug|Metformin cloridrate|
495159|NCT00437320|Procedure|Metvix PDT|Metvix PDT
495160|NCT00437320|Procedure|placebo|placebo
495161|NCT00437307|Drug|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
495162|NCT00437294|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 21 day cycles until progressive disease
495163|NCT00437294|Drug|placebo|oral, daily, 21 day cycles until progressive disease
495164|NCT00437294|Drug|capecitabine|1250 mg/m2, BID, days 1-14 of each 21 day cycle until progressive disease
495165|NCT00437281|Drug|Placebo|Placebo
495166|NCT00437281|Drug|Pregabalin|Orally-administered pregabalin
495167|NCT00437268|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, 21 day cycles until progressive disease
495168|NCT00437268|Drug|irinotecan|300 mg/m2, IV, day 1 every 21 days until progressive disease
495226|NCT00436917|Procedure|Letrozole as adjuvant therapy|standard care
524569|NCT00199069|Drug|VM26|
495169|NCT00437268|Drug|cetuximab|400 mg/m2, IV, day 1, 250 mg/m2 day 8, day 15 cycle 1 then 250 mg/m2, IV, day 1, 8 and 15 of each cycle, IV, 21 day cycles until progressive disease
495170|NCT00437255|Drug|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
495171|NCT00437255|Drug|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
495172|NCT00437242|Drug|Odiparcil|
495173|NCT00437229|Drug|Casopitant (GW679769) Oral Tablets|Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.
495174|NCT00437229|Drug|dexamethasone|Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.
495175|NCT00437229|Drug|ondansetron|Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.
495176|NCT00437216|Drug|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
495177|NCT00437216|Drug|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
495178|NCT00437203|Drug|PF-00477736|"Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
495179|NCT00437203|Drug|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
495180|NCT00437190|Device|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
495181|NCT00437190|Device|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
495182|NCT00437177|Drug|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
495183|NCT00437177|Drug|[(123)I] iodobenzamide|[(123)I] iodobenzamide 185 MBq I.V., at discharge.
495184|NCT00437164|Drug|Insulin|
495185|NCT00437164|Drug|Oral GW677954 Capsules (15 mg)|
495186|NCT00437151|Other|More frequent than normal office visits|Mode of patient reminder
495187|NCT00437151|Other|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
495188|NCT00437151|Other|Parenteral involvement / intervention reminders|Mode of patient reminder
495189|NCT00437151|Other|No intervention or reminders|Mode of patient reminder
495190|NCT00437138|Behavioral|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
495191|NCT00437125|Drug|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
495192|NCT00437112|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
495193|NCT00437112|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
495194|NCT00437099|Drug|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
495195|NCT00437099|Drug|Placebo|Placebo
495196|NCT00437086|Drug|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
495197|NCT00437073|Drug|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
495198|NCT00437073|Drug|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
495199|NCT00437073|Drug|lapatinib|lapatinib administered 1250mg once daily orally
495200|NCT00437060|Procedure|Cognitive Assessment|Ancillary studies
495201|NCT00437060|Procedure|Diffusion Tensor Imaging|Correlative studies
495202|NCT00437060|Other|Laboratory Biomarker Analysis|Correlative studies
495203|NCT00437060|Other|Pharmacological Study|Correlative studies
495204|NCT00437060|Procedure|Psychosocial Assessment and Care|Ancillary studies
495205|NCT00437034|Biological|aflibercept|Given IV
495206|NCT00437021|Drug|Placebo (subcutaneous)|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia [Sterile Saline Placebo (SSP)].
495207|NCT00437021|Drug|Placebo (scarification)|Physiologic normal saline for injection.
495208|NCT00437021|Biological|Dryvax®|Dryvax® Vaccinia Vaccine (~10^5 [plaque forming units (pfu)/dose] given via scarification, titer 10^8 pfu per mL after reconstitution).
495209|NCT00437021|Biological|IMVAMUNE®|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
495210|NCT00437008|Drug|Benfotiamine 1050mg, 3 days|
495211|NCT00437008|Behavioral|high-AGE vs. low-AGE meal|
495212|NCT00436995|Drug|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
495213|NCT00436982|Device|Cemented Triathlon total knee system|Orthopaedic implant
495214|NCT00436982|Device|Duracon total knee system|Orthopaedic implant
495215|NCT00436969|Device|Orthovisc|Orthovisc injection
495216|NCT00436969|Drug|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
495217|NCT00436956|Procedure|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
495218|NCT00436956|Drug|AZD2171|20 mg oral daily for 28 days
495219|NCT00436956|Drug|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
495220|NCT00436943|Drug|nicotine replacement therapy and bupropion|3-6 months
495221|NCT00436943|Behavioral|smoking cessation counseling and referrals|Organizational counseling and referrals
495222|NCT00436930|Biological|autologous tumor cell vaccine|Given subcutaneously
495223|NCT00436930|Biological|sargramostim|Given subcutaneously
495224|NCT00436930|Biological|therapeutic autologous dendritic cells|Given subcutaneously
495225|NCT00436917|Drug|zoledronic acid|zoledronic acid
495227|NCT00436904|Drug|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
495228|NCT00436904|Drug|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
495229|NCT00436878|Behavioral|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
495230|NCT00436865|Behavioral|Weight loss|
495231|NCT00436852|Drug|ABT-751|Given orally
495232|NCT00436852|Procedure|quality-of-life assessment|Ancillary studies
495233|NCT00436839|Drug|Docetaxel|75mg/m² intravenously (day 1) every 21 days
495234|NCT00436839|Drug|Mitoxantrone|12mg/m² intravenously every 21 days
495235|NCT00436839|Drug|Prednisone|10mg orally given daily
495236|NCT00436826|Drug|Cladribine|Subjects will receive cladribine tablets orally as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the double blind (DB) period of 96 weeks. Subjects who will complete the DB period will to enter in open label (OL) extension period, if they meet the eligibility criteria they will be given total cladribine dose of 3.5 mg/kg over 48 weeks.
495237|NCT00436826|Drug|Placebo|Subjects will receive matching placebo tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total matching placebo dose of 3.5 mg/kg during the DB period of 96 weeks.
495238|NCT00436826|Drug|Interferon-beta (IFN-beta)|Subjects will receive IFN-beta therapy (Rebif® new formulation [RNF] 44 microgram [mcg] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
495239|NCT00436800|Drug|Gemcitabine|1000mg/m² over 10mg/m²/min
495240|NCT00436800|Drug|Oxaliplatin|100 mg/m² over 2 hours.
495241|NCT00436787|Drug|Fondaparinux Sodium|
495242|NCT00436774|Procedure|assessment of therapy complications|
495243|NCT00436774|Procedure|quality-of-life assessment|
495244|NCT00436761|Biological|anti-thymocyte globulin|
495245|NCT00436761|Biological|graft-versus-tumor induction therapy|
495246|NCT00436761|Biological|sargramostim|
495247|NCT00436761|Drug|busulfan|
495248|NCT00436761|Drug|cyclosporine|
495249|NCT00436761|Drug|melphalan|
495250|NCT00436761|Drug|methylprednisolone|
495251|NCT00436761|Other|flow cytometry|
495252|NCT00436761|Other|immunologic technique|
495253|NCT00436761|Other|laboratory biomarker analysis|
495254|NCT00436761|Procedure|allogeneic hematopoietic stem cell transplantation|
495255|NCT00436761|Procedure|umbilical cord blood transplantation|
495256|NCT00436748|Drug|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
495257|NCT00436748|Drug|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
495258|NCT00436722|Drug|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
495259|NCT00436709|Biological|bevacizumab|
495260|NCT00436709|Biological|pegfilgrastim|
495261|NCT00436709|Drug|cyclophosphamide|
495262|NCT00436709|Drug|doxorubicin hydrochloride|
495263|NCT00436709|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
495264|NCT00436709|Other|flow cytometry|
495265|NCT00436709|Other|immunoenzyme technique|
495266|NCT00436709|Other|immunologic technique|
495267|NCT00436709|Other|laboratory biomarker analysis|
495268|NCT00436709|Procedure|adjuvant therapy|
495269|NCT00436709|Procedure|immunoscintigraphy|
495270|NCT00436696|Other|Laboratory Biomarker Analysis|Correlative studies
495271|NCT00436683|Drug|Fermagate|Film coated tablet 500mg
495272|NCT00436683|Drug|Sevelamer HCl|tablet 800mg
495273|NCT00436670|Biological|AMG 317 75 mg|75 mg SC weekly injection
495274|NCT00436670|Biological|AMG 317 150 mg|150 mg SC once weekly injection
495275|NCT00436670|Biological|AMG 317 300 mg|300 mg weekly SC injection
495276|NCT00436670|Biological|Placebo|Placebo SC once weekly injection
495277|NCT00436657|Drug|CHPP of Cisplatin|Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
495278|NCT00436657|Procedure|Abdominal Surgery|Surgical removal of abdominal tumors.
495279|NCT00436644|Drug|Lapatinib|1250 mg orally days 1 -28.
495280|NCT00436644|Drug|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 & 15.
495281|NCT00436631|Behavioral|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
495282|NCT00436618|Drug|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
495283|NCT00436605|Drug|dasatinib|
495284|NCT00436592|Device|NeuroFlo™ Catheter|45 minute Treatment
495285|NCT00436579|Drug|sorafenib tosylate|Given orally
495286|NCT00436579|Other|pharmacological study|
495287|NCT00436579|Procedure|assessment of therapy complications|Ancillary studies
495288|NCT00436579|Other|laboratory biomarker analysis|Correlative studies
495289|NCT00436566|Biological|trastuzumab|
495290|NCT00436566|Drug|cyclophosphamide|
495291|NCT00436566|Drug|doxorubicin hydrochloride|
495292|NCT00436566|Drug|lapatinib ditosylate|
495293|NCT00436566|Drug|paclitaxel|
495294|NCT00436566|Genetic|gene expression analysis|
495295|NCT00436566|Genetic|reverse transcriptase-polymerase chain reaction|
495297|NCT00436566|Other|laboratory biomarker analysis|
495298|NCT00436566|Other|mass spectrometry|
495299|NCT00436566|Procedure|adjuvant therapy|
495300|NCT00436566|Procedure|quality-of-life assessment|
495301|NCT00436553|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 (Standard Fluence rate) or 25 J/cm^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
495302|NCT00436553|Drug|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
495303|NCT00436553|Drug|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
495304|NCT00436553|Drug|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
495305|NCT00436540|Drug|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
495306|NCT00436540|Drug|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
495307|NCT00436527|Drug|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
495308|NCT00436514|Behavioral|diet and absorption of ColoPEG|4l of PEG during 2 days
495309|NCT00436514|Procedure|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
495310|NCT00436514|Procedure|Standard colonoscopy|1l of PEG the morning just before colonoscopy
495311|NCT00436501|Drug|docetaxel|25 mg/m^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
495312|NCT00436501|Biological|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
495313|NCT00436501|Other|laboratory biomarker analysis|Correlative studies
495314|NCT00436501|Other|pharmacological study|Correlative studies
495315|NCT00436475|Drug|Vitamin D3 2,000 IU orally once daily|Vitamin D3 2,000 IU orally once daily
495316|NCT00436475|Drug|Calcium Carbonate 400 mg orally twice daily|Calcium Carbonate 400 mg orally twice daily
495317|NCT00436475|Drug|Vitamin D3-Placebo|Vitamin D3-Placebo
495318|NCT00436475|Drug|Calcium-Placebo|Calcium-Placebo
495319|NCT00436449|Drug|Avotermin|
495320|NCT00436436|Drug|O6-benzylguanine|
495321|NCT00436436|Drug|temozolomide|
495322|NCT00436423|Drug|gemcitabine, TS-1|
495323|NCT00436410|Biological|colloidal gold-bound tumor necrosis factor|
495324|NCT00436410|Other|electron microscopy|
495325|NCT00436410|Other|pharmacological study|
495326|NCT00436410|Procedure|conventional surgery|
495327|NCT00436397|Radiation|radiation therapy|
495328|NCT00436384|Procedure|Monitoring-blood samples drawn for CMV testing|
495329|NCT00436371|Drug|Amisulpride|Oral tablets
495330|NCT00436358|Other|Not applicable: none|Please refer to the detailed description section
495331|NCT00436345|Drug|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
495332|NCT00436345|Drug|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
495333|NCT00436332|Biological|bevacizumab|
495334|NCT00436332|Drug|erlotinib hydrochloride|
495335|NCT00436319|Procedure|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.~The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2<80 pg/ml and progesterone <1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.~The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
495336|NCT00436306|Behavioral|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
495337|NCT00436306|Behavioral|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
495338|NCT00436293|Drug|Docetaxel|75 mg/m²
495339|NCT00436293|Drug|Cisplatin|75 mg/m²
495340|NCT00436280|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
495341|NCT00436280|Drug|gemcitabine|1000 mg/m2, IV, once, every two weeks, four to eight 2 week cycles
495342|NCT00436280|Drug|rituximab|375 mg/m2, IV, once every 2 weeks, four to eight 2 week cycles
495343|NCT00436280|Drug|oxaliplatin|100 mg/m2, IV, once every two weeks, four to eight 2 week cycles
495344|NCT00436267|Drug|fluorouracil|
495345|NCT00436267|Radiation|selective external radiation therapy|
495346|NCT00436267|Radiation|tomotherapy|
495347|NCT00436267|Radiation|yttrium Y 90 glass microspheres|
495348|NCT00436267|Radiation|yttrium Y 90 resin microspheres|
495349|NCT00436254|Biological|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
495350|NCT00436254|Biological|sargramostim|Given intradermally
495351|NCT00436254|Other|flow cytometry|Correlative studies
495352|NCT00436254|Other|immunologic technique|Correlative studies
495353|NCT00436254|Other|immunoenzyme technique|Undergo ELIspot (correlative studies)
495354|NCT00436254|Genetic|protein expression analysis|Undergo ELISA (correlative studies)
495355|NCT00436254|Procedure|biopsy|Undergo punch biopsy (correlative studies)
495356|NCT00436241|Drug|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
495357|NCT00436241|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
495358|NCT00436215|Drug|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
495359|NCT00436215|Drug|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
495360|NCT00436202|Behavioral|Iron supplement|
495361|NCT00436189|Procedure|Blood Draw|
495362|NCT00436176|Behavioral|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
495363|NCT00436163|Drug|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
495364|NCT00436150|Behavioral|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
495365|NCT00436150|Behavioral|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
495366|NCT00436137|Behavioral|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
495367|NCT00436124|Drug|oseltamivir [Tamiflu]|
495368|NCT00436098|Behavioral|Motorpedagogic exercise|physical training
495369|NCT00436085|Behavioral|Cognitive behavioral stress management training|
495370|NCT00436072|Drug|ZD6474|Orally on a daily basis
495371|NCT00436072|Drug|Cetuximab|Infusion once weekly
495372|NCT00436072|Drug|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
495373|NCT00436059|Drug|bortezomib|
495374|NCT00436046|Biological|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
495375|NCT00436046|Biological|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
495376|NCT00436033|Drug|milnacipran|
495377|NCT00436033|Drug|Placebo|
495378|NCT00436020|Device|TMS|Transcranial Magnetic Stimulation
495379|NCT00436020|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
495380|NCT00436007|Biological|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
495381|NCT00436007|Biological|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
495382|NCT00436007|Biological|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
495383|NCT00436007|Biological|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
495384|NCT00436007|Biological|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
495385|NCT00435994|Drug|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
495386|NCT00435994|Other|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
495387|NCT00435981|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
495388|NCT00435968|Drug|CVT E002 (Cold-fX)|
495389|NCT00435955|Procedure|High dose chemotherapy with autologous transplantation|
495390|NCT00435955|Drug|Rituximab|
495391|NCT00435942|Device|Relay Thoracic Stent-Graft|implant
495392|NCT00435942|Procedure|Open Repair|Open surgery
495393|NCT00435929|Drug|Ritonavir|100mg po bid
495394|NCT00435929|Drug|saquinavir [Invirase]|1000mg po bid
495395|NCT00435916|Drug|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
495396|NCT00435903|Device|Palm Pilot|
495397|NCT00435890|Behavioral|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
495398|NCT00435864|Procedure|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
495399|NCT00435851|Drug|Thyrogen, thyroid hormone withdrawal, iode 131|
495400|NCT00435838|Drug|No Intervention -- Observational study|
495401|NCT00435825|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
495402|NCT00435812|Biological|HEPLISAV and/or Placebo|Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24
495403|NCT00435812|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4, and Week 24
495404|NCT00435799|Procedure|corneal cross-linking (CCL)|
495405|NCT00435799|Drug|Riboflavin/dextran eyedrops|
495406|NCT00435799|Device|UV-X system|
495407|NCT00435773|Procedure|Single Leeching|
495408|NCT00435773|Procedure|Repeated Leeching after 4 weeks|
495409|NCT00435773|Procedure|Placebo Leeching|
495410|NCT00435760|Drug|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
495411|NCT00435760|Drug|Placebo Tiotropium|1 puff once daily, 1 day treatment
495412|NCT00435760|Drug|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
495413|NCT00435760|Drug|Placebo LAS34273|1 puff, 1 dat treatment
495414|NCT00435747|Drug|PARECOXIB SODIUM|
495415|NCT00435734|Behavioral|obesity intervention|
495416|NCT00435721|Behavioral|Psychoeducation|
495417|NCT00435708|Behavioral|5 portions fruit and vegetables/day|Participants consume > = 5 portions fruit and veg per day
495418|NCT00435695|Drug|GSK163090|
495419|NCT00435682|Drug|Botox (Allergan Inc., US)|
495420|NCT00435669|Drug|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
495421|NCT00435669|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
495422|NCT00435643|Procedure|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
495423|NCT00435630|Other|LapSim training|complete curriculum training on LapSim surgical simulator
495424|NCT00435617|Device|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
495425|NCT00435604|Drug|Hylenex|
495426|NCT00435591|Drug|Conivaptan|ampoule or premix bag
495427|NCT00435591|Drug|placebo|ampoule or premix bag
495428|NCT00435578|Drug|Glufosfamide|
495429|NCT00435552|Procedure|Ease-It Spray|
495430|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
495431|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
495432|NCT00435539|Drug|Sham Comparator|Intravitreal sham injection
495433|NCT00435526|Biological|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
495434|NCT00435500|Drug|Fluoride varnish|
495435|NCT00435487|Drug|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
495436|NCT00435487|Drug|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg [units per kilogram] and initial infusion of 12 U/kg/h [units per kilogram per hour]).
495437|NCT00435474|Procedure|Wound treatment|wound treatment (silver product, alginate and foam dressing)
495438|NCT00435474|Procedure|wound treatment|wound treatment (honey product, alginate and foam dressing)
495439|NCT00435474|Other|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
495440|NCT00435474|Other|relaxation therapy|relaxation therapy
495441|NCT00435461|Drug|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
495442|NCT00435448|Drug|Lonidamine|
495443|NCT00435435|Drug|Disulfiram|
495444|NCT00435435|Drug|Acamprosate|
495445|NCT00435435|Drug|Naltexone|
495446|NCT00435422|Procedure|Stroke volume optimization|Stroke volume optimization
495447|NCT00435409|Drug|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day [1000 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
495448|NCT00435409|Drug|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day [1250 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
495449|NCT00435396|Biological|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
495450|NCT00435370|Drug|Tropisetron|10 mg/day
495451|NCT00435370|Drug|Placebo|placebo
495452|NCT00435370|Drug|Risperidone|6mg/day
495453|NCT00435357|Device|mobile-bearing TKA|
495454|NCT00435357|Device|fixed- bearing TKA|
495455|NCT00435344|Behavioral|Pediatric Practice-Based Smoking Intervention|
495456|NCT00435331|Drug|sapropterin dihydrochloride (6R-BH4)|2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
495457|NCT00435318|Procedure|Iontophoresis|
495458|NCT00435305|Drug|Meropenem|
495459|NCT00435305|Drug|Vancomycin|
495460|NCT00435305|Drug|Linezolid|
495461|NCT00435305|Drug|Piperacillin/Tazobactam|
495462|NCT00435305|Drug|Cefepim|
495463|NCT00435305|Drug|Ceftazidim|
495464|NCT00435292|Drug|Naproxen|nonsteroidal anti-inflammatory drug
495465|NCT00435292|Dietary Supplement|flavocoxid 250 mg|flavonoid mixture
495466|NCT00435292|Dietary Supplement|flavocoxid 500 mg|flavonoid mixture
495467|NCT00435279|Drug|Eszopiclone|Eszopiclone 3 mg
495468|NCT00435279|Drug|Placebo|Placebo
495469|NCT00435279|Drug|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
495470|NCT00435266|Procedure|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
495471|NCT00435253|Biological|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
495472|NCT00435240|Behavioral|Paleolithic diet|
495473|NCT00435227|Biological|MEDI-524|30 mg/kg of MEDI-524
495474|NCT00435227|Other|Placebo|30 mg/kg of Placebo
495475|NCT00435188|Behavioral|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
495476|NCT00435175|Drug|estradiol|
495477|NCT00435162|Drug|Valsartan 0.25 mg/kg|once daily
495478|NCT00435162|Drug|Valsartan 1.0 mg/kg|once daily
495479|NCT00435162|Drug|Valsartan 4.0 mg/kg|once daily
495480|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
495481|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
495482|NCT00435123|Dietary Supplement|Nutritional Supplement ProStat 64 twice a day|
495483|NCT00435123|Dietary Supplement|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
495484|NCT00435110|Procedure|standard ventilatory settings|
495485|NCT00435110|Procedure|PEEP and FiO2|
495486|NCT00435084|Drug|APO866|
495487|NCT00435071|Procedure|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
495488|NCT00435071|Procedure|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
495489|NCT00435058|Drug|timolol maleate 0,5%|
495490|NCT00435058|Drug|brimonidine tartrate 0,2%|
495491|NCT00435058|Drug|travoprost 0,004%|
495492|NCT00435045|Drug|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
495493|NCT00435045|Drug|atorvastatin|atorvastatin + placebo
495494|NCT00435032|Procedure|early appendectomy|Appendectomy within 24 hours of admission
495495|NCT00435032|Procedure|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
495496|NCT00435019|Drug|insulin detemir|s.c. injection, once or twice daily.
495497|NCT00435019|Drug|insulin NPH|s.c. injection, once or twice daily.
495498|NCT00435019|Drug|insulin aspart|s.c. injection, at main meals.
495499|NCT00434993|Drug|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:~The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.~The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
495500|NCT00434993|Procedure|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
495501|NCT00434993|Drug|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.~A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).~The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
495502|NCT00434980|Behavioral|Family-Directed Cognitive Adaptation Program|
495503|NCT00434967|Drug|Candesartan cilexetil|32 mg oral tablet
495504|NCT00434967|Drug|Hydrochlorothiazide|25 mg oral tablet
495505|NCT00434967|Drug|Candesartan/HCT 32/25 mg|
495506|NCT00434954|Drug|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
495507|NCT00434954|Drug|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
495508|NCT00434941|Drug|Capecitabine|
495509|NCT00434941|Radiation|Radiotherapy|
495510|NCT00434915|Drug|DHEA|
495511|NCT00434876|Drug|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
495512|NCT00434876|Drug|Placebo.|Inactive or inert pill which will be used as a comparator.
495513|NCT00434863|Drug|botulinum toxin type A|
495514|NCT00434850|Biological|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
495515|NCT00434850|Drug|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
495516|NCT00434850|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
495517|NCT00434850|Biological|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
495518|NCT00434850|Drug|Sirolimus|Maintenance immunosuppressive therapy
495519|NCT00434850|Drug|Tacrolimus|Maintenance immunosuppressive therapy
495520|NCT00434850|Biological|Etanercept|Blocks TNF-alpha which is toxic to islet cells
495521|NCT00434837|Procedure|Initial graft tension during ACL reconstruction surgery|"The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg (the High Tension treatment). When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg (the Low Tension treatment). Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown."
495522|NCT00434824|Drug|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
495523|NCT00434824|Drug|Placebo|treatment for 12 months with placebo in divided doses
495524|NCT00434811|Biological|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
495525|NCT00434811|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
495526|NCT00434811|Drug|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
495527|NCT00434811|Drug|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
495528|NCT00434811|Biological|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
495529|NCT00434811|Procedure|Islet Transplantation|Transplantation of pancreatic islet cell
495530|NCT00434811|Biological|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
495586|NCT00434382|Device|Midlatency auditory evoked potentials|
495587|NCT00434369|Drug|CoFactor (ANX-510)|
495588|NCT00434356|Drug|bevacizumab|Intravenous repeating dose
495531|NCT00434798|Biological|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10^6-10^9 CFU
495532|NCT00434785|Drug|AGG-523|
495533|NCT00434772|Drug|glucagon|
495534|NCT00434759|Behavioral|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
495535|NCT00434759|Behavioral|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
495536|NCT00434746|Drug|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
495537|NCT00434733|Biological|Pandemic influenza vaccine|
495538|NCT00434720|Device|GlideScope Specific Stylet|
495539|NCT00434694|Procedure|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
495540|NCT00434681|Drug|paracetamol 4.8% paediatric oral suspension|
495541|NCT00434668|Drug|cisplatin/docetaxel|
495542|NCT00434668|Drug|cisplatin/vinorelbine|
495543|NCT00434655|Procedure|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
495544|NCT00434642|Drug|Carboplatin|Carboplatin was provided as commercially available drug.
495545|NCT00434642|Drug|Gemcitabine|Gemcitabine was provided as commercially available drug.
495546|NCT00434642|Drug|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL [25 mg/mL]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
495547|NCT00434642|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
495548|NCT00434629|Drug|Bexxar|"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.~1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."
495549|NCT00434616|Procedure|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
495550|NCT00434616|Biological|saline injection|saline injections
495551|NCT00434603|Behavioral|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
495552|NCT00434590|Drug|Enteric coated mycophenolate sodium (Myfortic®)|
495553|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Low Dose|Single or two-dose intramuscular injection.
495554|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Medium Dose|Single or two-dose intramuscular injection.
495555|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A High Dose|Single or two-dose intramuscular injection.
495556|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A Modified|Single or two-dose intramuscular injection.
495557|NCT00434577|Biological|Placebo|Single intramuscular injection
495558|NCT00434564|Procedure|Stress nuclear scan|
495559|NCT00434538|Device|BST-DermOn|
495560|NCT00434525|Procedure|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
495561|NCT00434525|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
495562|NCT00434512|Biological|HIV vaccine 732461|
495563|NCT00434499|Drug|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
495564|NCT00434486|Drug|SKI-606|
495565|NCT00434473|Drug|A-001|A-001
495566|NCT00434473|Other|Placebo|Placebo
495567|NCT00434460|Behavioral|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
495568|NCT00434447|Drug|Zoledronic acid|
495569|NCT00434434|Drug|omalizumab|Aged Liquid; subcutaneous repeating dose
495570|NCT00434434|Drug|omalizumab|Lyophilized; subcutaneous repeating dose
495571|NCT00434434|Drug|placebo|Subcutaneous repeating dose
495572|NCT00434421|Drug|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters [mL], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose [0.42 mL, 1:10 wt/vol] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
495573|NCT00434421|Drug|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
495574|NCT00434408|Behavioral|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
495575|NCT00434408|Behavioral|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
495576|NCT00434408|Behavioral|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
495577|NCT00434395|Drug|MOA-728|
495578|NCT00434382|Drug|Sevoflurane|
495589|NCT00434356|Drug|sunitinib|Oral repeating dose
495590|NCT00434356|Drug|paclitaxel|Intravenous repeating dose
495591|NCT00434343|Procedure|Physical Therapy|
495592|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
495593|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
495594|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
495595|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
495596|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
495597|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
495598|NCT00434317|Drug|Zoledronic acid|
495599|NCT00434304|Drug|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
495600|NCT00434291|Drug|TG-873870(Nemonoxacin)|
495601|NCT00434278|Drug|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
495602|NCT00434278|Drug|placebo|2.5 mg inhalation dose twice daily for 14±2 days
495603|NCT00434265|Behavioral|Physical training|
495604|NCT00434252|Drug|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
495605|NCT00434252|Drug|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
495606|NCT00434252|Drug|paclitaxel|175 mg/m^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
495607|NCT00434252|Drug|placebo|Administered by IV infusion on the first day of each 3-week cycle
495608|NCT00434239|Drug|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
495609|NCT00434226|Drug|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
495610|NCT00434226|Drug|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
495611|NCT00434226|Drug|carboplatin|On the first day of each cycle for 4 cycles
495612|NCT00434226|Drug|paclitaxel|On the first day of each cycle for 4 cycles
495613|NCT00434213|Drug|Daytrana|Methylphenidate Transdermal System (MTS)
495614|NCT00434200|Procedure|long-term intensive exercise|
495615|NCT00434187|Drug|ERB-041|
495616|NCT00434174|Drug|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.~Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
495617|NCT00434174|Drug|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
495618|NCT00434161|Drug|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 & 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
495619|NCT00434161|Drug|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
495620|NCT00434161|Drug|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).~Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
495621|NCT00434148|Drug|Pasireotide|
495751|NCT00433394|Procedure|cancer prevention intervention|
495752|NCT00433394|Procedure|educational intervention|
495622|NCT00434135|Drug|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&8
495623|NCT00434122|Drug|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
495624|NCT00434122|Drug|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
495625|NCT00434109|Drug|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
495626|NCT00434109|Procedure|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
495627|NCT00434096|Drug|rimonabant (SR141716)|oral administration once daily
495628|NCT00434096|Drug|placebo|oral administration once daily
495629|NCT00434083|Drug|sumatriptan|
495630|NCT00434083|Drug|naproxen sodium|
495631|NCT00434057|Device|MelaFind(R)|Biopsy ratio comparison
495632|NCT00434044|Drug|Enbrel (etanercept)|
495633|NCT00434031|Drug|docetaxel|
495634|NCT00434031|Drug|cyclophosphamide|
495635|NCT00434031|Drug|trastuzumab|
495636|NCT00434031|Drug|liposomal doxorubicin|
495637|NCT00434018|Behavioral|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
495638|NCT00434018|Behavioral|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
495639|NCT00434005|Drug|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
495640|NCT00434005|Drug|Placebo|matched appearance to acetylcysteine and ascorbate intervention
495641|NCT00433979|Drug|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
495642|NCT00433966|Drug|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
495643|NCT00433966|Drug|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
495644|NCT00433966|Device|Bare metal stent|Uncoated bare metal stent
495645|NCT00433966|Device|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
495646|NCT00433953|Drug|Mycophenolate Mofetil (CellCept)|
495647|NCT00433953|Behavioral|Dietary Monitoring|
495648|NCT00433953|Behavioral|Drug Diary|
495649|NCT00433953|Procedure|Blood Sampling|
495650|NCT00433940|Drug|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
495651|NCT00433927|Drug|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
495652|NCT00433927|Drug|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
495653|NCT00433927|Drug|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
495654|NCT00433927|Drug|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
495655|NCT00433927|Drug|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
495656|NCT00433914|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
495657|NCT00433914|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
495658|NCT00433901|Behavioral|Targeted parental instruction for positive lifestyle change with follow-up calls.|
495659|NCT00433888|Drug|R744|100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
495660|NCT00433888|Drug|R744|150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
495661|NCT00433875|Drug|AMG 714|
495662|NCT00433849|Drug|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
495663|NCT00433849|Drug|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
495664|NCT00433836|Drug|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
495665|NCT00433836|Drug|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
495666|NCT00433823|Drug|Atorvastatin, Ezetimibe|
495667|NCT00433797|Dietary Supplement|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
495668|NCT00433784|Drug|Clopidogrel|
495669|NCT00433784|Procedure|Blood sampling - platelet aggregation|
495670|NCT00433784|Procedure|Blood sampling - genotyping|
495671|NCT00433771|Device|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
495672|NCT00433758|Device|GlucoTrack|GT
495673|NCT00433745|Drug|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
495674|NCT00433732|Drug|sumatriptan|
495675|NCT00433732|Drug|naproxen sodium|
495753|NCT00433381|Biological|Bevacizumab|Given IV
495754|NCT00433381|Drug|Irinotecan Hydrochloride|Given IV
495676|NCT00433719|Drug|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
495677|NCT00433706|Procedure|Control position by 3DOBI before the fraction|
495678|NCT00433706|Procedure|Standard imaging|
495679|NCT00433693|Drug|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25~300μg(i.v.)/4 week
495680|NCT00433680|Behavioral|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
495681|NCT00433667|Drug|RWJ-333369|
495682|NCT00433654|Device|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
495683|NCT00433654|Other|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
495684|NCT00433641|Drug|sibutramine|placebo
495685|NCT00433641|Drug|sibutramine|oral 15 mg sibutramine once per day
495686|NCT00433641|Drug|sibutramine|oral sibutramine 10 mg once per day
495687|NCT00433615|Drug|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
495688|NCT00433615|Drug|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
495689|NCT00433602|Other|clinical observation|
495690|NCT00433602|Procedure|management of therapy complications|
495691|NCT00433602|Procedure|ultrasound imaging|
495692|NCT00433589|Drug|anthracycline-based|
495693|NCT00433589|Drug|docetaxel and capecitabine|
495694|NCT00433576|Drug|resveratrol|Given orally
495695|NCT00433576|Other|pharmacological study|Correlative studies
495696|NCT00433576|Other|laboratory biomarker analysis|Correlative studies
495697|NCT00433563|Radiation|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
495698|NCT00433563|Radiation|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
495699|NCT00433550|Drug|capecitabine|given orally
495700|NCT00433550|Drug|irinotecan hydrochloride|given IV
495701|NCT00433550|Drug|oxaliplatin|given IV
495702|NCT00433537|Drug|bortezomib|Given IV
495703|NCT00433537|Biological|rituximab|Given IV
495704|NCT00433537|Drug|cyclophosphamide|Given IV
495705|NCT00433537|Drug|doxorubicin hydrochloride|Given IV
495706|NCT00433537|Drug|vincristine|Given IV
495707|NCT00433537|Drug|dexamethasone|Given IV
495708|NCT00433537|Biological|filgrastim|Given SC
495709|NCT00433537|Biological|pegfilgrastim|Given SC
495710|NCT00433537|Procedure|Autologous stem cell transplantation (ASCT)|
495711|NCT00433524|Procedure|computed tomography|
495712|NCT00433511|Biological|Bevacizumab|Given IV
495713|NCT00433511|Drug|Cyclophosphamide|Given IV
495714|NCT00433511|Drug|Doxorubicin Hydrochloride|Given IV
495715|NCT00433511|Drug|Paclitaxel|Given IV
495716|NCT00433511|Other|Placebo|Given IV
495717|NCT00433498|Drug|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
495718|NCT00433498|Drug|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
495719|NCT00433498|Drug|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
495720|NCT00433498|Drug|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
495721|NCT00433485|Drug|sirolimus|
495722|NCT00433485|Genetic|comparative genomic hybridization|
495723|NCT00433485|Genetic|gene expression analysis|
495724|NCT00433485|Genetic|microarray analysis|
495725|NCT00433485|Genetic|protein expression analysis|
495726|NCT00433485|Genetic|proteomic profiling|
495727|NCT00433485|Other|laboratory biomarker analysis|
495728|NCT00433485|Other|mass spectrometry|
495729|NCT00433485|Procedure|biopsy|
495730|NCT00433472|Device|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
495731|NCT00433459|Drug|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
495732|NCT00433459|Drug|dacarbazine|drug is used in first line treatment in combination (COPDAC)
495733|NCT00433459|Drug|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
495734|NCT00433459|Drug|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
495735|NCT00433459|Drug|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
495736|NCT00433459|Drug|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
495737|NCT00433459|Radiation|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
495738|NCT00433459|Radiation|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
495739|NCT00433446|Biological|CNTO 328|
495740|NCT00433433|Drug|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
495741|NCT00433433|Drug|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes>1.0x109/l
495742|NCT00433433|Radiation|IN-RT 30 Gy (+ boost 6 Gy residual)|
495743|NCT00433433|Procedure|FDG-PET scan|
495744|NCT00433420|Biological|pegfilgrastim|
495745|NCT00433420|Drug|cyclophosphamide|
495746|NCT00433420|Drug|epirubicin hydrochloride|
495747|NCT00433420|Drug|fluorouracil|
495748|NCT00433420|Drug|paclitaxel|
495749|NCT00433420|Procedure|adjuvant therapy|
495750|NCT00433407|Biological|trastuzumab|
495755|NCT00433381|Drug|Temozolomide|Given orally
495756|NCT00433368|Drug|L-Ornithine L-Aspartate|
495757|NCT00433342|Drug|Flucloxacillin|500 mg QD oral
495758|NCT00433329|Drug|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
495759|NCT00433329|Drug|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
495760|NCT00433316|Drug|ropivacaine|1% ropivacaine
495761|NCT00433316|Device|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
495762|NCT00433303|Behavioral|Correlation between early delivery and coital activity|
495763|NCT00433290|Drug|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
495764|NCT00433290|Drug|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
495765|NCT00433277|Drug|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
495766|NCT00433264|Procedure|peritoneal dialysis|individualised
495767|NCT00433238|Behavioral|Participants will be screened for depression and cognitive impairment, then receive screening results.|
495768|NCT00433225|Drug|Prednisolone Acetate|
495769|NCT00433225|Drug|Ketorolac 0.4%|
495770|NCT00433225|Drug|Gatifloxacin 0.3%|
495771|NCT00433212|Device|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
495772|NCT00433212|Device|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
495773|NCT00433199|Drug|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
495774|NCT00433199|Drug|Placebo|Placebo Control
495775|NCT00433186|Drug|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
495776|NCT00433173|Procedure|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
495777|NCT00433173|Drug|testosterone|transdermal 7.5 g/per day for 3 months
495778|NCT00433173|Drug|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
495779|NCT00433173|Drug|goserelin acetate implant|single depot injection 10.8 mg 3 months
495780|NCT00433173|Procedure|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
495781|NCT00433173|Procedure|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
495782|NCT00433173|Procedure|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
495783|NCT00433173|Procedure|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
495784|NCT00433173|Procedure|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
495785|NCT00433173|Procedure|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
495786|NCT00433160|Drug|Teriparatide|daily, subcutaneous
495787|NCT00433160|Drug|Placebo|daily, subcutaneous
495788|NCT00433147|Drug|Afegostat tartrate|
495789|NCT00433134|Behavioral|Adherence|
495790|NCT00433121|Drug|Risperidone|
495791|NCT00433121|Drug|Olanzapine|
495792|NCT00433121|Drug|Haloperidole|
495793|NCT00433121|Drug|Quetiapin|
495794|NCT00433121|Drug|Escitalopram|
495795|NCT00433121|Drug|Citalopram|
495796|NCT00433121|Drug|Sertralin|
495797|NCT00433108|Drug|Mitoquinone mesylate (MitoQ)|
495798|NCT00433095|Drug|Navelbine|
495799|NCT00433095|Drug|Herceptin|
495800|NCT00433095|Drug|Navelbine (oraly)|
495801|NCT00433082|Behavioral|Ramadan Fasting|
495802|NCT00433069|Drug|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
495803|NCT00433069|Drug|Interferon Alfa-2a|Standard of care for chronic hepatitis C
495804|NCT00433069|Drug|Ribavirin|Standard of care for chronic hepatitis C
495805|NCT00433056|Other|STI|CD4 guided treatment interruption
495806|NCT00433056|Drug|stable HAART|continuous therapy
495807|NCT00433043|Drug|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
495808|NCT00433043|Procedure|CRT (cardiac resynchronization therapy)|Both arms
495809|NCT00433017|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of the infusion.
495810|NCT00433017|Drug|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
495811|NCT00433017|Drug|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
495812|NCT00433004|Drug|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
495813|NCT00432991|Drug|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
495814|NCT00432991|Drug|Saline Placebo|0.5 mL, IM (in the muscle), one time
495815|NCT00432978|Drug|Bosentan administration|
495816|NCT00432965|Device|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
495817|NCT00432965|Device|VAC Therapy|VAC Therapy
495818|NCT00432952|Behavioral|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
495819|NCT00432926|Behavioral|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
495820|NCT00432926|Behavioral|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
495821|NCT00432926|Behavioral|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
495822|NCT00432913|Drug|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
495823|NCT00432913|Procedure|Endoscopy|At baseline, month 3 and month 6.
495824|NCT00432913|Procedure|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
495825|NCT00432913|Procedure|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
495826|NCT00432913|Procedure|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
495827|NCT00432913|Procedure|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
495828|NCT00432913|Procedure|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
495829|NCT00432913|Procedure|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
495830|NCT00432913|Procedure|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
495831|NCT00432900|Radiation|[(11)C]PBR28|PET Ligand
495832|NCT00432887|Drug|caffeine administration|
495833|NCT00432874|Procedure|wound hydration method|Anterior vs lateral wound hydration
495834|NCT00432861|Drug|PANCRECARB® (pancrelipase)|Capsules
495835|NCT00432861|Drug|Placebo|Capsules
495836|NCT00432835|Device|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
495837|NCT00432822|Drug|tetrahydrobiopterin (BH4)|
495838|NCT00432809|Procedure|Gastric bypass|Roux-en-Y gastric bypass
495839|NCT00432809|Procedure|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
495840|NCT00432796|Drug|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
495841|NCT00432796|Other|Placebo|"patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg"
495842|NCT00432770|Drug|ARC1779|
495843|NCT00432757|Drug|Ketotifen with a Contact Lens (generic name not yet established)|
495844|NCT00432744|Drug|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
495845|NCT00432744|Drug|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
495846|NCT00432731|Biological|VARIVAX®|
495847|NCT00432731|Biological|M-M-RTM II|
495848|NCT00432718|Procedure|Saline Instillation before Tracheal Suctioning|
495849|NCT00432705|Procedure|Checking stability of ankle|Flexing and walking
495850|NCT00432692|Procedure|Falls Prevention Program|
495851|NCT00432679|Drug|Rosiglitazone (BRL49653C)|study drug
495852|NCT00432666|Drug|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
495853|NCT00432666|Drug|Placebo|Placebo
495854|NCT00432653|Drug|rituximab|
495855|NCT00432640|Procedure|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
495856|NCT00432640|Procedure|Surgical staging|Surgical staging
495857|NCT00432627|Drug|Deferasirox|one dose of 20 mg/kg/day
495858|NCT00432614|Drug|SR58611A|oral administration
495859|NCT00432614|Drug|escitalopram|oral administration
495860|NCT00432614|Drug|placebo|oral administration
495861|NCT00432601|Behavioral|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
495862|NCT00432588|Drug|misoprostol|
495863|NCT00432588|Drug|dinoprostone|
495864|NCT00432575|Drug|surinabant (SR147778)|oral administration
495865|NCT00432575|Drug|placebo|oral administration
495960|NCT00431808|Biological|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
495866|NCT00432562|Drug|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
495867|NCT00432549|Drug|Almotriptan|
495868|NCT00432549|Drug|Topiramate|
495869|NCT00432536|Other|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
495870|NCT00432523|Biological|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
495871|NCT00432510|Drug|C1 esterase inhibitor [human] (C1INH-nf)|
495872|NCT00432484|Drug|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
495873|NCT00432471|Procedure|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
495874|NCT00432458|Drug|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
495875|NCT00432458|Drug|zoledronic acid|4 mg^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
495876|NCT00432445|Radiation|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
495877|NCT00432445|Procedure|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
495878|NCT00432432|Drug|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
495879|NCT00432419|Procedure|autologous peripheral blood cell transplantation|
495880|NCT00432406|Drug|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
495881|NCT00432406|Drug|Etanercept|Etanercept 25 mg twice weekly
495882|NCT00432393|Drug|levodopa-carbidopa|
495883|NCT00432380|Biological|Rotarix™|oral doses
495884|NCT00432380|Biological|Placebo|oral dose
495885|NCT00432367|Drug|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:~Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.~Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.~Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.~All enrolled women will be given one long lasting insecticide treated bed net each for use."
495886|NCT00432354|Drug|atorvastatin|
495887|NCT00432341|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
495888|NCT00432341|Biological|botulinum toxin type A|500 Units at Visit 1 (Day 1)
495889|NCT00432328|Drug|Avotermin|
495890|NCT00432315|Drug|Docetaxel + CDDP|"3 cycles chemotherapy : docetaxel + CDDP~Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)~3 cycles adjuvant chemotherapy docetaxel"
495891|NCT00432315|Drug|docetaxel + CDDP|"3 cycles chemotherapy: docetaxel + CDDP~Radiochemotherapy~3 cycles adjuvant chemotherapy docetaxel"
495892|NCT00432302|Drug|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg [14C]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
495893|NCT00432289|Procedure|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
495894|NCT00432276|Drug|Alogliptin|Alogliptin tablets.
495895|NCT00432276|Drug|Pioglitazone|Pioglitazone tablets.
495896|NCT00432276|Drug|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
495897|NCT00432276|Drug|Placebo|Matching placebo tablets.
495898|NCT00432263|Drug|Genotropin (PN-180,307) Somatropin|
495899|NCT00432250|Procedure|Cervical length ultrasound|
495900|NCT00432237|Drug|MK0974 50 mg|
495901|NCT00432237|Drug|MK0974 150 mg|
495902|NCT00432237|Drug|MK0974 300 mg|
495903|NCT00432237|Drug|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
495904|NCT00432224|Procedure|photodynamic therapy|
495905|NCT00432211|Drug|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.~Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
495906|NCT00432198|Drug|Zolpidem (Myslee®)|Oral
495907|NCT00432198|Drug|placebo|Oral
495908|NCT00432185|Drug|PEP005|0.25% PEP005 Gel
495909|NCT00432172|Drug|Epirubicin|
495910|NCT00432172|Drug|Cyclophosphamide|
495911|NCT00432172|Drug|Docetaxel|
495912|NCT00432172|Drug|Exemestane|
495913|NCT00432172|Drug|Goserelin|
495914|NCT00432172|Drug|Carboplatin|
495915|NCT00432159|Device|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
495916|NCT00432159|Device|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
495917|NCT00432146|Drug|lugol's solution|
495918|NCT00432133|Behavioral|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
495919|NCT00432133|Behavioral|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
495920|NCT00432120|Drug|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
495921|NCT00432107|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
495922|NCT00432094|Drug|carboplatin|Days -6, -5, -4: 500mg/m2^/day intravenously (IV) over 60 minutes
495923|NCT00432094|Drug|etoposide|600mg/m^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
495924|NCT00432094|Drug|ifosfamide|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
495925|NCT00432094|Drug|paclitaxel|225 mg/m^2 intravenous over 3 hours on Day -7.
495926|NCT00432094|Drug|thiotepa|150mg/m^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
495927|NCT00432094|Procedure|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (< 4 x 10^6 CD34+ cells/kg)
495928|NCT00432094|Drug|Mesna|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
495929|NCT00432094|Biological|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
495930|NCT00432081|Drug|indomethacin|
495931|NCT00432068|Drug|Octreotide pamoate|
495932|NCT00432055|Drug|Botulinum toxin type A (Botox)|
495933|NCT00432055|Drug|placebo (saline)|
495934|NCT00432042|Biological|ProQuad®|Participants received a 0.5 mL subcutaneous injection of ProQuad® containing the following live attenuated virus strains: measles virus Enders' Edmonston strain (≥3.00 log10 50% cell culture infectious dose [CCID]50), mumps virus Jeryl Lynn™ (Level B) strain (≥4.30 log10 CCID50), rubella virus Wistar RA 27/3 strain (≥3.00 log10 CCID50), and varicella virus Oka/Merck strain (≥3.99 log10 plaque-forming units [PFU]).
495935|NCT00432042|Biological|Infanrix® hexa|Participants received a 0.5 mL intramuscular injection of Infanrix® hexa containing the following: diphtheria toxoid (≥30 IU), tetanus toxoid (≥40 IU), 3-component acellular pertussis (pertussis taxoid, filamentous haemagglutinin, and pertactin) (25 ug), Hepatitis B surface antigen recombinant (S protein) (10 ug), inactivated poliovirus types 1-3 (type 1: 40 D-antigen units; type 2: 8 D-antigen units; type 3: 32 D-antigen units), and Haemophilus influenzae type B (Hib) polysaccharide conjugate to tetanus toxoid (20-40 ug).
495936|NCT00432029|Procedure|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
495937|NCT00432029|Device|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
495938|NCT00432016|Drug|zidovudine|
495939|NCT00432016|Drug|amdoxovir|
495940|NCT00432016|Procedure|pharmacokinetic sampling|
495941|NCT00431990|Drug|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
495942|NCT00431990|Drug|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
495943|NCT00431990|Drug|dexamethasone|20mg for 2 days with each dose of bortezomib
495944|NCT00431977|Procedure|coronary computed tomography angiography|
495945|NCT00431964|Drug|azithromycin 250 mg tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs~Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
495946|NCT00431964|Drug|placebo tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs~Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
495947|NCT00431951|Drug|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
495948|NCT00431951|Drug|Placebo|Capsules to match experimental drug
495949|NCT00431912|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
495950|NCT00431899|Behavioral|fish oil supplementation|
495951|NCT00431886|Procedure|64 multi-detector computed tomography|
495952|NCT00431873|Drug|MGCD0103|MGCD0103 Administered orally three times per week.
495953|NCT00431860|Procedure|Coronary computed tomographic angiography|
495954|NCT00431847|Procedure|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
495955|NCT00431847|Procedure|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
495956|NCT00431834|Device|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
495957|NCT00431834|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
495958|NCT00431821|Behavioral|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
495959|NCT00431821|Other|Stroke education|Stroke education program with matched attention phone calls
525597|NCT00191542|Drug|Placebo|
495961|NCT00431808|Biological|AMA1|50 micrograms of AMA1
495962|NCT00431795|Drug|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m^2 IV every 4 weeks for 6 consecutive cycles
495963|NCT00431795|Drug|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m^2 IV every 3 weeks for 6 consecutive cycles
495964|NCT00431782|Drug|ATI-5923|
495965|NCT00431769|Drug|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
495966|NCT00431743|Drug|Hydroxyethylstarch 130/0,4|
495967|NCT00431743|Drug|Lactated Ringer's solution|
495968|NCT00431730|Procedure|flicker light stimulation|
495969|NCT00431704|Drug|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
495970|NCT00431704|Drug|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
495971|NCT00431704|Drug|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
495972|NCT00431691|Drug|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks~vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
495973|NCT00431691|Drug|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
495974|NCT00431691|Drug|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
495975|NCT00431691|Drug|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
495976|NCT00431678|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
495977|NCT00431678|Drug|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
495978|NCT00431665|Drug|NG-monomethyl-L-Arginine (L-NMMA)|
495979|NCT00431665|Drug|triglycerides (Intralipid 20%)|
495980|NCT00431665|Drug|heparin|
495981|NCT00431665|Drug|somatostatin|
495982|NCT00431665|Drug|insulin|
495983|NCT00431665|Drug|glucose|
495984|NCT00431665|Drug|inulin|
495985|NCT00431665|Drug|paraamino hippurate (PAH)|
495986|NCT00431639|Behavioral|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
495987|NCT00431626|Drug|Dutasteride (Avodart)|
495988|NCT00431626|Drug|Placebo|Placebo before and after treatment of TURP
495989|NCT00431613|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
495990|NCT00431613|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
495991|NCT00431613|Drug|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
495992|NCT00431613|Radiation|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.~During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
495993|NCT00431613|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
495994|NCT00431600|Other|100% Oxygen|100% Oxygen- breathing over 30 minutes
495995|NCT00431574|Procedure|dosing|
495996|NCT00431561|Drug|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
495997|NCT00431561|Drug|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
495998|NCT00431561|Drug|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
495999|NCT00431561|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
496000|NCT00431561|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
496001|NCT00431548|Drug|100% O2|
496002|NCT00431522|Drug|Valproic acid, sodium salt|
496003|NCT00431509|Procedure|conventional vs. navigated total knee arthroplasty|
496004|NCT00431496|Drug|Cinacalcet|Cinacalcet tablets
496005|NCT00431483|Behavioral|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
496006|NCT00431470|Behavioral|Six classroom based character building education lessons|
496007|NCT00431457|Device|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
496008|NCT00431457|Procedure|amygddohyppocampertomy|Resective surgery
496009|NCT00431444|Drug|Raloxifene|
496010|NCT00431444|Drug|Zoledronic acid|
496011|NCT00431444|Drug|Placebo oral pills|
496012|NCT00431444|Drug|Placebo intravenous (i.v.) infusion|
496013|NCT00431431|Drug|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
496014|NCT00431431|Drug|raloxifen|2 years treatment with raloxifene (60 mg)
496015|NCT00431418|Drug|Sildenafil|Sildenafil oral solution
496016|NCT00431418|Drug|Placebo|Placebo solution
496017|NCT00431392|Drug|Phenylephrine|
496018|NCT00431392|Drug|NG-Monomethyl-L-Arginine|
496019|NCT00431392|Drug|Propanolol|
496020|NCT00431392|Drug|Atropine|
496021|NCT00431379|Drug|Tenecteplase|
496022|NCT00431353|Drug|Ganciclovir|5mg/kg iv bid for 21 days
496023|NCT00431353|Drug|valganciclovir [Valcyte]|900mg po bid for 21 days
496024|NCT00431340|Drug|PXD101|
496025|NCT00431327|Behavioral|Peer coach phone call|
496026|NCT00431288|Behavioral|diet high in fruits, vegetables, and dairy|
496027|NCT00431288|Behavioral|Routine nutrition care|
496028|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
496029|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
496030|NCT00431262|Drug|antabuse (disulfiram)|
496031|NCT00431249|Drug|Cilostazol|
496032|NCT00431236|Drug|Oral Casopitant (GW679769)|
496033|NCT00431236|Drug|IV Casopitant (GW679769)|
496034|NCT00431236|Drug|IV ondansetron hydrochloride|
496035|NCT00431236|Drug|Oral dexamethasone|
496036|NCT00431223|Behavioral|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
496037|NCT00431210|Biological|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
496038|NCT00431197|Drug|Ketoconazole, Dexamethesone, Androgel,GnRH|
496039|NCT00431184|Drug|Pentazocine|see arms description
496040|NCT00431184|Drug|Lorazepam|see arms description
496041|NCT00431171|Drug|Lithium carbonate|
496042|NCT00431158|Other|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers~ARDSnet Group: ARDSnet protocol"
496043|NCT00431145|Drug|Niacin|
496044|NCT00431145|Drug|Niacin+Statin|
496045|NCT00431132|Drug|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
496046|NCT00431119|Drug|Azathioprine or Mycophenolate mofetil|
496047|NCT00431106|Drug|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
496048|NCT00431106|Drug|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
496049|NCT00431106|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
496050|NCT00431093|Drug|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
496051|NCT00431093|Drug|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.~Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
496052|NCT00431080|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
496053|NCT00431080|Drug|Paclitaxel|Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
496054|NCT00431080|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
496055|NCT00431080|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
496056|NCT00431080|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
496057|NCT00431080|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
496058|NCT00431067|Drug|BIBW 2992|
496059|NCT00431054|Drug|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
496060|NCT00431054|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour every 4 weeks
496061|NCT00431041|Drug|solifenacin|Oral
496062|NCT00431041|Drug|oxybutynin immediate release|Oral
496063|NCT00431028|Device|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
496064|NCT00431015|Drug|IPI-504|IV Hsp90 inhibitor
496065|NCT00431002|Behavioral|Resistance training|See Detailed Description.
496066|NCT00430989|Other|Nitrous Oxide|General anaesthesia with the inclusion of Nitrous Oxide at 70%
496067|NCT00430989|Other|No Nitrous Oxide|General anaesthesia with no use of Nitrous Oxide
496068|NCT00430976|Behavioral|Minds in Motion|
496069|NCT00430963|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|
496070|NCT00430963|Drug|Placebo|
496071|NCT00430950|Drug|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
496072|NCT00430950|Drug|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
496073|NCT00430937|Drug|Daptomycin|4 mg/kg intravenous once daily
496074|NCT00430937|Drug|Vancomycin|1 g intravenous twice daily
496075|NCT00430937|Drug|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
496076|NCT00430924|Drug|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
496077|NCT00430911|Drug|Radiotherapy|
496078|NCT00430898|Drug|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
496079|NCT00430885|Drug|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
496080|NCT00430872|Behavioral|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
496081|NCT00430859|Drug|Alkaline Phosphatase|Intravenous over a period of 24 hours
496082|NCT00430859|Drug|Placebo|Saline over a period of 24h
496083|NCT00430846|Drug|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
496084|NCT00430833|Drug|candesartan|
496085|NCT00430820|Procedure|per intervention|per intervention
496086|NCT00430807|Drug|hydroxychloroquine/placebo|
496087|NCT00430794|Drug|Spironolactone|
496088|NCT00430781|Drug|pazopanib (GW786034)|
496089|NCT00430781|Drug|lapatinib (GW572016)|
496090|NCT00430768|Biological|rAAV1-CB-hAAT|
496134|NCT00430482|Behavioral|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
496135|NCT00430469|Drug|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
496136|NCT00430456|Procedure|Exercise|Treadmill Training
496137|NCT00430443|Drug|Liposomal Annamycin|3-day IV infusion
525598|NCT00191529|Drug|somatropin|
496091|NCT00430755|Device|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.~Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
496092|NCT00430755|Procedure|physician taken history|Convential history taking by physicians
496093|NCT00430755|Other|Computer-assisted history taking|
496094|NCT00430742|Drug|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
496095|NCT00430742|Drug|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
496096|NCT00430729|Drug|Roflumilast|
496097|NCT00430716|Drug|Sildenafil citrate|oral, 20 mg, tid
496098|NCT00430716|Drug|Sildenafil citrate|oral 1 mg, tid
496099|NCT00430716|Drug|Sildenafil citrate|oral 5 mg, tid
496100|NCT00430716|Drug|Sildenafil citrate|oral 20 mg, tid
496101|NCT00430703|Behavioral|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
496102|NCT00430690|Procedure|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
496103|NCT00430677|Drug|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
496104|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
496105|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
496106|NCT00430677|Drug|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
496107|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
496108|NCT00430664|Procedure|Pleurodesis with either talc or iodopovidone|
496109|NCT00430651|Drug|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
496110|NCT00430651|Drug|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
496111|NCT00430638|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
496112|NCT00430638|Drug|Placebo|Oral tablets administered for once daily for 12 weeks
496113|NCT00430625|Biological|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
496114|NCT00430586|Drug|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
496115|NCT00430586|Drug|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
496116|NCT00430573|Drug|D-cycloserine|Single dosage of D-cycloserine is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
496117|NCT00430573|Drug|Placebo|Single dosage of placebo is given prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
496118|NCT00430560|Behavioral|cognitive rehabilitation|computer training
496119|NCT00430560|Procedure|work therapy|opportunity to work in carefully supervised hospital job
496120|NCT00430560|Behavioral|work therapy|work therapy
496121|NCT00430547|Drug|Carbimazole, radio-active iodine (I131)|
496122|NCT00430534|Biological|EBV vaccine (268664)|
496123|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
496124|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
496125|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
496126|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
496127|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
496128|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
496129|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
496130|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
496131|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
496132|NCT00430495|Drug|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
496133|NCT00430482|Behavioral|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
496138|NCT00430430|Procedure|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
496139|NCT00430430|Procedure|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
496140|NCT00430404|Other|Collaborative care (Intervention)|Structured shared care with treatment protocol & support
496141|NCT00430391|Other|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
496142|NCT00430391|Other|Routine Control|Participants are assigned to the routine, standard consent.
496143|NCT00430378|Procedure|Acupuncture|Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.
496144|NCT00430378|Other|Standard Care|No Acupuncture.
496145|NCT00430365|Drug|lenalidomide|oral drug
496146|NCT00430365|Drug|placebo|oral placebo
496147|NCT00430352|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
496148|NCT00430326|Drug|Avotermin|
496149|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
496150|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
496151|NCT00430300|Drug|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
496152|NCT00430300|Drug|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
496153|NCT00430261|Drug|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
496154|NCT00430248|Drug|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
496155|NCT00430248|Drug|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
496156|NCT00430248|Drug|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.~Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
496157|NCT00430235|Drug|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
496158|NCT00430196|Drug|BOTOX®|
496159|NCT00430196|Drug|Zanaflex®|
496160|NCT00430183|Drug|docetaxel|75 mg/m^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
496161|NCT00430183|Drug|LHRH agonist|Given intramuscularly
496162|NCT00430183|Procedure|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
496163|NCT00430170|Drug|Dipyridamole|Dipyridamole 2x200mg 7day per os
496164|NCT00430170|Drug|caffeine|caffeine 4mg/kg iv
496165|NCT00430157|Drug|GSK256066|
496166|NCT00430144|Drug|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
496167|NCT00430131|Procedure|Cognitive Orientation to Occupational Performance|
496168|NCT00430131|Procedure|Contemporary Treatment Approach|
496169|NCT00430118|Drug|asparaginase|
496170|NCT00430118|Drug|cyclophosphamide|
496171|NCT00430118|Drug|cytarabine|
496172|NCT00430118|Drug|daunorubicin hydrochloride|
496173|NCT00430118|Drug|dexamethasone|
496174|NCT00430118|Drug|doxorubicin hydrochloride|
496175|NCT00430118|Drug|etoposide|
496176|NCT00430118|Drug|ifosfamide|
496177|NCT00430118|Drug|mercaptopurine|
496178|NCT00430118|Drug|methotrexate|
496179|NCT00430118|Drug|prednisone|
496180|NCT00430118|Drug|thioguanine|
496181|NCT00430118|Drug|vincristine sulfate|
496182|NCT00430118|Drug|vindesine|
496183|NCT00430118|Radiation|radiation therapy|
496184|NCT00430105|Drug|cyclophosphamide|
496185|NCT00430092|Drug|Difluprednate|
496186|NCT00430092|Drug|Difluprednate|
496187|NCT00430092|Drug|Placebo|
496188|NCT00430079|Drug|etanidazole|Given IV
496189|NCT00430079|Procedure|conventional surgery|Undergo surgery
496190|NCT00430079|Other|pharmacological study|Correlative studies
496191|NCT00430079|Other|laboratory biomarker analysis|Correlative studies
496192|NCT00430066|Drug|Imatinib Mesylate|400 mg/die for 6 months
496193|NCT00430053|Genetic|gene rearrangement analysis|
496194|NCT00430053|Genetic|polymerase chain reaction|
496195|NCT00430053|Genetic|proteomic profiling|
496196|NCT00430053|Other|flow cytometry|
496197|NCT00430053|Other|immunohistochemistry staining method|
496198|NCT00430053|Procedure|biopsy|
496199|NCT00430040|Drug|carvedilol|carvedilol
496200|NCT00430040|Drug|lisinopril|lisinopril
496201|NCT00430027|Drug|Capecitabine|Given 650 mg/m^2 BID on days of ration therapy, 825 mg/m^2 day 1-14, day 15-20 off x 4
496202|NCT00430027|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2, 130mg/m2 IV Q 21 days x 4
496203|NCT00430027|Drug|Cetuximab|Initial Cetuximab 400 mg/m^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
496204|NCT00430014|Drug|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
496205|NCT00430001|Drug|docetaxel|
496206|NCT00430001|Drug|vinorelbine|
496207|NCT00430001|Drug|trastuzumab|
496208|NCT00429988|Genetic|fluorescence in situ hybridization|
496209|NCT00429988|Genetic|polymerase chain reaction|
496210|NCT00429988|Genetic|proteomic profiling|
496211|NCT00429988|Other|cytology specimen collection procedure|
496212|NCT00429988|Other|immunohistochemistry staining method|
496213|NCT00429988|Procedure|breast duct lavage|
496214|NCT00429975|Drug|levofloxacin|
496215|NCT00429975|Drug|ceftriaxone|
496216|NCT00429962|Drug|intravitreal ranibizumab|intraocular injection
496217|NCT00429962|Drug|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
496219|NCT00429936|Drug|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
496220|NCT00429923|Drug|Difluprednate|
496221|NCT00429923|Drug|Difluprednate|
496222|NCT00429923|Drug|Placebo|
496223|NCT00429897|Drug|Bendroflumethiazide 2.5mg - 5mg|
496224|NCT00429897|Drug|Amiloride 20-40mg|
496225|NCT00429897|Drug|Spironolactone 50-100mg|
496226|NCT00429897|Drug|Frusemide 20-40mg|
496227|NCT00429897|Drug|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
496228|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
496229|NCT00429871|Drug|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
496230|NCT00429871|Drug|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
496231|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
496232|NCT00429858|Drug|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
496233|NCT00429858|Drug|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
496234|NCT00429858|Drug|Bevacizumab|
496235|NCT00429845|Behavioral|Nutritional|
496236|NCT00429832|Drug|Ondansetron|
496237|NCT00429832|Drug|promethazine|
496238|NCT00429806|Drug|DHEA|DHEA
496239|NCT00429806|Drug|Placebo|Placebo
496240|NCT00429793|Drug|temsirolimus|Given IV
496241|NCT00429780|Biological|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
496242|NCT00429754|Drug|Aprepitant|
496243|NCT00429728|Drug|GW876008|
496244|NCT00429715|Biological|Alum-ALM + BCG|Alum precipitated autoclaved L. major
496245|NCT00429715|Biological|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
496246|NCT00429715|Biological|Alum-ALM + BCG|Alum-ALM + BCG
496247|NCT00429702|Drug|Decadron®|Given IV
496248|NCT00429702|Drug|Benadryl®|Given IV
496249|NCT00429702|Drug|Ativan®|Given IV
496250|NCT00429702|Drug|ondansetron hydrochloride|Given IV
496251|NCT00429689|Procedure|Saliva sample|
496252|NCT00429676|Drug|Haloperidol|
496253|NCT00429663|Device|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
496254|NCT00429663|Device|locking periarticular plate|Standard of care device for femur fractures
496255|NCT00429650|Behavioral|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
496256|NCT00429650|Behavioral|diet|Use a prescribed diet to maintain weight loss
496257|NCT00429650|Behavioral|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
496258|NCT00429624|Procedure|Chiropractic manipulation|
496259|NCT00429624|Drug|acetaminophen|
496260|NCT00429611|Procedure|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
496261|NCT00429585|Device|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
496262|NCT00429585|Device|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
496263|NCT00429572|Drug|Fludarabine|30 mg/m^2 intravenously Daily for 5 Days
496264|NCT00429572|Drug|Melphalan|70 mg/m^2 intravenously Daily for 2 Days
496265|NCT00429572|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
496266|NCT00429559|Drug|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
496267|NCT00429559|Drug|Gemcitabine|"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression"
496268|NCT00429546|Behavioral|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
496269|NCT00429546|Other|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
496270|NCT00429533|Drug|Dapsone|
496271|NCT00429520|Drug|Hyaluronic acid filler/IMD1 basic|
496272|NCT00429507|Drug|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
496273|NCT00429507|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
496274|NCT00429507|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
496275|NCT00429494|Drug|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
496276|NCT00429494|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
496277|NCT00429494|Procedure|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
496278|NCT00429481|Biological|Rotarix|
496279|NCT00429468|Drug|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
496280|NCT00429455|Behavioral|Survey|3-Part Questionnaire
496281|NCT00429442|Drug|Simvastatin|80 mg once daily
496282|NCT00429442|Drug|placebo|calcium tablets once daily
496283|NCT00429429|Procedure|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
496284|NCT00429416|Drug|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
496285|NCT00429416|Drug|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
496286|NCT00429416|Drug|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
496287|NCT00429416|Drug|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
496288|NCT00429416|Drug|Tacrolimus|Tacrolimus given before and after HSCT infusion
496289|NCT00429416|Drug|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
496290|NCT00429416|Biological|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
496291|NCT00429416|Procedure|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
496292|NCT00429403|Drug|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
496293|NCT00429390|Behavioral|Ramadan Fasting|
496294|NCT00429377|Drug|tacrolimus|
496295|NCT00429364|Drug|Losartan Potassium|Losartan .3 - 1.4 mg/kg
496296|NCT00429364|Drug|Atenolol|Atenolol .5 - 4 mg/kg
496297|NCT00429338|Procedure|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
496298|NCT00429338|Procedure|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
496299|NCT00429312|Biological|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
496300|NCT00429299|Drug|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
496301|NCT00429299|Biological|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
496302|NCT00429299|Drug|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
496303|NCT00429299|Drug|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
496304|NCT00429299|Drug|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
496305|NCT00429299|Drug|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
496306|NCT00429286|Behavioral|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
496307|NCT00429273|Drug|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
496308|NCT00429273|Drug|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
496309|NCT00429260|Drug|Saredutant|
496310|NCT00429247|Drug|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
496311|NCT00429234|Drug|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
496312|NCT00429234|Drug|Gemcitabine|Starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
496313|NCT00429221|Behavioral|Tailored Medication Messages for Parents|
496314|NCT00429208|Drug|Nicotine|
496315|NCT00429195|Behavioral|Dietary Fatty Acid Modification|
496316|NCT00429182|Drug|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
496317|NCT00429182|Drug|Cyclophosphamide|1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
496318|NCT00429182|Drug|Thiotepa|120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
496319|NCT00429182|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0.
496320|NCT00429169|Drug|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
496321|NCT00429169|Drug|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
496322|NCT00429156|Device|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
496323|NCT00429156|Device|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
496324|NCT00429143|Radiation|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
496325|NCT00429143|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
496326|NCT00429143|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
496327|NCT00429143|Drug|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
496328|NCT00429143|Drug|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
496329|NCT00429143|Biological|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
496330|NCT00429117|Behavioral|Survey|Internet survey lasting 30 to 40 minutes.
496331|NCT00429104|Drug|Herceptin|4 mg/kg IV Over 90 Minutes
496332|NCT00429104|Drug|GM-CSF|250 mcg/m^2 Subcutaneously
496333|NCT00429091|Drug|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
496334|NCT00429091|Drug|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
496335|NCT00429091|Drug|placebo|Subjects will take BID for up to four weeks
496336|NCT00429078|Genetic|2nd Generation Designer T Cells|
496337|NCT00429065|Drug|Rituximab|
496338|NCT00429039|Drug|L-leucyl-L-leucine methyl ester (LLME)|
496339|NCT00429026|Drug|Fludarabine|25 mg/m^2 intravenous (IV) daily for 5 Days
496340|NCT00429026|Drug|Melphalan|70 mg/m^2 IV Daily for 2 Days
496341|NCT00429026|Drug|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
496342|NCT00429026|Procedure|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
496343|NCT00429013|Device|Tongue Display Unit|lingual electric stimulation
496344|NCT00429000|Device|thermospot|
525599|NCT00191516|Drug|Atomoxetine|
496345|NCT00428974|Drug|CF101|CF101 1 mg q12 hours for 12 weeks
496346|NCT00428974|Drug|CF101|CF101 2 mg q12 hours for 12 weeks
496347|NCT00428974|Drug|CF101|CF101 4 mg q12 hours for 12 weeks
496348|NCT00428974|Drug|Placebo|Placebo tablets q12 hours for 12 weeks
496349|NCT00428948|Drug|Tolvaptan|Tolvaptan was supplied as tablets.
496350|NCT00428948|Drug|Placebo|Placebo was supplied as tablets.
496351|NCT00428935|Biological|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
496352|NCT00428922|Drug|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
496353|NCT00428922|Drug|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
496354|NCT00428922|Drug|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
496355|NCT00428909|Drug|Imatinib/Acetaminophen|
496356|NCT00428896|Drug|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
496357|NCT00428883|Drug|N-acetylcysteine (NAC)|
496358|NCT00428870|Procedure|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
496359|NCT00428857|Procedure|non invasive ventilation|non invasive ventilation
496360|NCT00428844|Drug|daptomycin|6 mg/kg
496361|NCT00428844|Drug|daptomycin|8 mg/kg
496362|NCT00428844|Drug|vancomycin|1 gram
496363|NCT00428844|Drug|teicoplanin|6 mg/kg; used only at UK sites
496364|NCT00428844|Drug|nafcillin|1-2 gram
496365|NCT00428844|Drug|oxacillin|1-2 gram
496366|NCT00428844|Drug|flucloxacillin|1-2 mg
496367|NCT00428818|Drug|trimethoprim-sulfamethoxazole or doxycycline|
496368|NCT00428805|Behavioral|classroom curriculum|"classroom curriculum for 3 & 4 year old children includes activities to increase intake of fruits, vegetables, & whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.~Teachers are trained to carry out the classroom curriculum."
496369|NCT00428805|Behavioral|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
496370|NCT00428805|Behavioral|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
496371|NCT00428805|Behavioral|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
496372|NCT00428805|Behavioral|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
496373|NCT00428805|Behavioral|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
496374|NCT00428805|Behavioral|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
496375|NCT00428792|Drug|Methylphenidate 20 mg long-acting capsules|
496376|NCT00428779|Procedure|running during 24 hours without sleep|patients running during 24 hours without sleep
496377|NCT00428779|Other|no sleeping|patients without sleep during 24 hours
496378|NCT00428766|Drug|MORAb-003|
496379|NCT00428727|Drug|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
496380|NCT00428727|Drug|placebo patch|daily application during 90 days
496381|NCT00428714|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 28 day cycles until disease progression, unacceptable toxicity or 3 years
496382|NCT00428701|Drug|Esomeprazole Sodium|
496383|NCT00428662|Device|drug eluting nonpolymeric nanoporous stent|
496384|NCT00428649|Dietary Supplement|20 µg selenium|20 µg selenium as selenomethionine
496385|NCT00428649|Dietary Supplement|40 µg selenium|40 µg selenium as selenomethionine
496386|NCT00428649|Dietary Supplement|60 µg selenium|60 µg selenium as selenomethionine
496387|NCT00428649|Dietary Supplement|80 µg selenium|80 µg selenium as selenomethionine
496388|NCT00428649|Dietary Supplement|100 µg selenium|100 µg selenium as selenomethionine
496389|NCT00428649|Dietary Supplement|120 µg selenium|120 µg selenium as selenomethionine
496390|NCT00428649|Dietary Supplement|placebo|placebo
496391|NCT00428636|Procedure|ileostomy|
496392|NCT00428623|Procedure|wound dressing|
496393|NCT00428610|Drug|LY573636-sodium|LY573636 dose is dependent on participant's height, weight, and gender and is adjusted to target a specific maximum concentration (Cmax) based on participant laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for participant discontinuation are met.
496394|NCT00428597|Drug|sunitinib malate|"sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).~Dose may be decreased to 25 mg daily in case of adverse events.~It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.~Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
496395|NCT00428597|Drug|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
496396|NCT00428584|Drug|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
496397|NCT00428584|Drug|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
496398|NCT00428571|Procedure|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
496399|NCT00428571|Procedure|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
496400|NCT00428571|Procedure|Intensive Medical Management|lifestyle, diet, medication optimization
496401|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
496402|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
496403|NCT00428545|Drug|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
496404|NCT00428545|Drug|Bortezomib|Starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days
496405|NCT00428532|Drug|Licorice root extract or Pomegranate juice|
496406|NCT00428519|Drug|Placebo|Placebo for 14 days
496407|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
496408|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
496409|NCT00428506|Drug|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
496410|NCT00428506|Drug|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
496411|NCT00428480|Behavioral|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
496412|NCT00428480|Behavioral|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
496413|NCT00428467|Procedure|LV Apex Compression|
496414|NCT00428454|Device|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
496415|NCT00428441|Drug|Warfarin|tablets, based on INR levels, according to D-dimer levels
496416|NCT00428428|Drug|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
496417|NCT00428415|Drug|Tesofensine|
496418|NCT00428402|Behavioral|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
496419|NCT00428389|Drug|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
496420|NCT00428389|Drug|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
496421|NCT00428376|Device|Building Blocks|
496422|NCT00428363|Device|Cataract surgery with implantation of an intraocular lens|
496423|NCT00428350|Drug|Quetiapine Fumarate (Seroquel)|
496424|NCT00428337|Biological|EP-1233|DNA-HIV-recombinant vaccine
496425|NCT00428337|Biological|MVA-mBN32|HIV-recombinant viral vaccine
496426|NCT00428311|Drug|Metformin|
496427|NCT00428311|Drug|Ethynyl-estradiol plus cyproterone acetate|
496428|NCT00428298|Drug|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
496429|NCT00428298|Drug|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
496430|NCT00428285|Procedure|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
496431|NCT00428272|Drug|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
496432|NCT00428272|Drug|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
496433|NCT00428272|Drug|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
496434|NCT00428272|Drug|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
496435|NCT00428246|Drug|paricalcitol|1 mcg or 2 mcg for 4 weeks.
496436|NCT00428246|Drug|Placebo|Placebo
496437|NCT00428233|Procedure|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
496438|NCT00428220|Drug|sunitinib|sunitinib
496439|NCT00428207|Drug|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
496440|NCT00428207|Drug|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
496441|NCT00428194|Drug|cisplatin|40 mg/m^2 every 7 days during radiation
496442|NCT00428194|Drug|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m^2 by mouth once a day beginning day 1.
496443|NCT00428194|Procedure|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
496444|NCT00428181|Behavioral|Brief alcohol intervention|Brief alcohol intervention
496445|NCT00428181|Behavioral|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
496446|NCT00428168|Drug|Betahistine|Betahistine 24mg BID
496447|NCT00428155|Device|closure device placement|
496448|NCT00428142|Biological|rituximab|375mg/m2 day 1
496449|NCT00428142|Drug|bortezomib|1.3mg/m2 days 1 & 8
496450|NCT00428142|Drug|cyclophosphamide|750mg/m2 day 1
496451|NCT00428142|Drug|prednisone|40mg/m2 days 1-5
496452|NCT00428142|Drug|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
496453|NCT00428129|Drug|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
496454|NCT00428116|Drug|HAART|Combination first line antiretrovirals as previously described.
496455|NCT00428103|Procedure|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
496456|NCT00428090|Drug|Rosiglitazone|XR (extended release) oral tablets
496457|NCT00428077|Biological|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
496458|NCT00428077|Genetic|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
496459|NCT00428064|Drug|Sirolimus|
496460|NCT00428064|Drug|cyclosporine|
496461|NCT00428051|Other|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
496462|NCT00428025|Drug|diclofenac|100 mg diclofenac rectal suppository
496463|NCT00428025|Drug|placebo|similar shape and size suppository
496464|NCT00428012|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
496465|NCT00428012|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
496466|NCT00427999|Drug|imatinib mesylate|
496467|NCT00427999|Drug|Treosulfane|
496468|NCT00427999|Drug|etoricoxib|
496469|NCT00427999|Drug|pioglitazone|
496470|NCT00427999|Drug|dexamethasone|
496471|NCT00427986|Drug|Galactose, intravenous|
496472|NCT00427973|Drug|cediranib maleate|Given orally
496473|NCT00427973|Other|laboratory biomarker analysis|Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R&D Systems.
496474|NCT00427973|Procedure|computed tomography|computed tomography (CT) every 8 weeks to evaluate response and progression.
496475|NCT00427973|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
496476|NCT00427973|Other|pharmacological study|Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
496477|NCT00427960|Behavioral|Dietary advice|
496478|NCT00427960|Drug|rosuvastatin|rosuvastatin 5 mg
496479|NCT00427960|Drug|atorvastatin|atorvastatin 10 mg
496480|NCT00427947|Drug|ropivacaine/placebo|Continuous sciatic nerve bloc
496481|NCT00427934|Drug|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
496482|NCT00427934|Drug|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
496483|NCT00427921|Biological|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
496484|NCT00427908|Biological|GSK Biolgicals' meningococcal vaccine 134612 (Nimenrix)|One intramuscular dose.
496485|NCT00427908|Biological|Mencevax™ ACWY|One subcutaneous dose.
496486|NCT00427908|Biological|Meningitec™|One intramuscular dose.
496487|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
496488|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
496489|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
496490|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
496491|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
496492|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
496493|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
496494|NCT00427882|Drug|ALFUZOSIN|
496495|NCT00427856|Drug|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
496496|NCT00427856|Drug|Rituximab|Rituximab
496497|NCT00427843|Behavioral|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.~The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
496498|NCT00427830|Biological|MVA85A|
496499|NCT00427804|Drug|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
496500|NCT00427791|Drug|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
496501|NCT00427791|Radiation|Total Body Irradiation|3 Gy Daily for 4 Days
496502|NCT00427791|Drug|Rituximab|375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
496503|NCT00427778|Device|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.~Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
496504|NCT00427765|Drug|Busulfan|Test Dose = 32 mg/m^2 IV for 1 Day; 130 mg/m^2 IV for 4 Days
496505|NCT00427765|Drug|Melphalan|70 mg/m^2 IV for 2 Days
496506|NCT00427752|Procedure|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
496507|NCT00427739|Procedure|Cardiac CT|64 slice spiral computerized tomography
496508|NCT00427713|Drug|capecitabine|
496509|NCT00427713|Drug|oxaliplatin|
496510|NCT00427713|Procedure|adjuvant therapy|
496511|NCT00427713|Procedure|standard follow-up care|
496512|NCT00427700|Drug|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
496513|NCT00427700|Drug|raloxifene|100mg PO on days 5-9 of the menstrual cycle
496514|NCT00427687|Drug|AGG-523|
496515|NCT00427674|Drug|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
496516|NCT00427661|Other|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
496517|NCT00427648|Drug|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
496518|NCT00427648|Drug|placebo|normal saline
496519|NCT00427635|Drug|Esomeprazole|
496520|NCT00427622|Other|physiologic testing|
496521|NCT00427609|Drug|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
496522|NCT00427596|Drug|Solabegron|
496523|NCT00427583|Drug|imatinib mesylate|
496524|NCT00427570|Biological|BCG vaccine|
496525|NCT00427570|Biological|biological therapy|
496526|NCT00427570|Drug|fluorouracil|
496527|NCT00427570|Drug|semustine|
496528|NCT00427570|Drug|vincristine sulfate|
496529|NCT00427557|Drug|Fludarabine|30 mg/m^2 by vein for 4 Days (Day -10 through Day -7).
496530|NCT00427557|Drug|Melphalan|140 mg/m^2 by vein for 1 Day (Day -7).
496531|NCT00427557|Procedure|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
496532|NCT00427557|Drug|Rituximab|375 mg/m^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
496533|NCT00427557|Other|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
496534|NCT00427544|Drug|PRA-027|
496535|NCT00427531|Other|physiologic testing|
496536|NCT00427505|Drug|Deferasirox|
496537|NCT00427492|Drug|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
496538|NCT00427492|Drug|Placebo|
496539|NCT00427466|Drug|Pemetrexed|
496540|NCT00427453|Biological|MVA85A|
496541|NCT00427440|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
496542|NCT00427440|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
496543|NCT00427427|Drug|Trastuzumab|
496544|NCT00427414|Drug|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
496545|NCT00427401|Drug|PF-00915275|
496546|NCT00427388|Drug|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
496547|NCT00427388|Other|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
496548|NCT00427375|Procedure|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
496549|NCT00427375|Procedure|total mesorectal excision|standard surgery
496550|NCT00427362|Drug|Adalimumab|
496551|NCT00427349|Drug|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
496552|NCT00427349|Drug|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
496553|NCT00427336|Drug|Fludarabine|30 mg/m^2 by vein daily over 30 minutes
496554|NCT00427336|Drug|Cyclophosphamide|300 mg/m^2 by vein daily over 2 hours
496555|NCT00427336|Drug|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
496556|NCT00427323|Procedure|light exposure|
496557|NCT00427310|Drug|fluorouracil|
496558|NCT00427310|Other|Observation|
496559|NCT00427310|Drug|sodium heparin|
496560|NCT00427297|Drug|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
496561|NCT00427297|Drug|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
496562|NCT00427297|Drug|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
496563|NCT00427297|Drug|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of<8g/dl), AZT will be substituted for d4T.
496564|NCT00427297|Drug|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
496629|NCT00426777|Drug|risedronate|risedronate 35mg tablet, weekly for 12 months
496630|NCT00426777|Drug|risedronate|35mg weekly
496631|NCT00426777|Drug|Control|risedronate-matched placebo weekly
496632|NCT00426764|Drug|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
496565|NCT00427297|Drug|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
496566|NCT00427297|Drug|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
496567|NCT00427271|Drug|aspirin|
496568|NCT00427258|Drug|MOA-728|
496569|NCT00427245|Drug|cyclophosphamide|
496570|NCT00427245|Drug|goserelin acetate|
496571|NCT00427245|Procedure|adjuvant therapy|
496572|NCT00427245|Procedure|fertility assessment and management|
496573|NCT00427245|Procedure|neoadjuvant therapy|
496574|NCT00427232|Drug|BQ-123 and BQ-788|
496575|NCT00427219|Drug|Ozarelix/Placebo|Ozarelix 15 mg or placebo will be administered IM on Day 0 and Day 14
496576|NCT00427219|Drug|Placebo|Eligible patients entered a placebo run-in phase in which placebo was administered twice over a 2 week period (Day -28 and Day -14) and patients were assessed to establish baseline values approximately 14 days following the second placebo injection
496577|NCT00427206|Drug|acetaminophen (4g/day)|
496578|NCT00427206|Drug|placebo|
496579|NCT00427193|Behavioral|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
496580|NCT00427193|Behavioral|Control|Participants continue their current diet for 24 months
496581|NCT00427180|Device|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
496582|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
496583|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
496584|NCT00427167|Drug|AMA1-C1/Alhydrogel + CPG 7909|
496585|NCT00427154|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
496586|NCT00427154|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
496587|NCT00427154|Drug|metformin|Tablets, 2000 mg/day.
496588|NCT00427154|Drug|glimepiride|Tablets, 8 mg/day.
496589|NCT00427141|Drug|GSK580416|
496590|NCT00427128|Drug|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
496591|NCT00427128|Drug|placebo|Week 13-36.
496592|NCT00427115|Behavioral|Multimodal exercise and psychosocial program|
496593|NCT00427102|Drug|Oral MRX-1024|
496594|NCT00427102|Procedure|Standard Fractionation Radiation Therapy|
496595|NCT00427102|Drug|High-Dose Cisplatin Chemotherapy|
496596|NCT00427089|Drug|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
496597|NCT00427089|Drug|Sodium Phosphate solution (NaP)|45 ml solution; BID
496598|NCT00427076|Drug|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR<30.
496599|NCT00427076|Drug|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR <10 1gr Q 4-7 days.
496600|NCT00427050|Drug|PEP005|
496601|NCT00427037|Drug|Cholecalciferol|50,000 IU weekly by mouth
496602|NCT00427037|Drug|Placebo|identical placebo pill orally by mouth
496603|NCT00427011|Drug|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
496604|NCT00426998|Drug|Verteporfin|
496605|NCT00426998|Drug|Bevacizumab|
496606|NCT00426985|Drug|Ketoprofen Topical Patch 20%|
496607|NCT00426972|Drug|estradiol (Zesteem)|
496608|NCT00426959|Device|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
496609|NCT00426946|Drug|Reboxetine|
496610|NCT00426933|Drug|Daptomycin|
496611|NCT00426933|Drug|Vancomycin|
496612|NCT00426920|Drug|Insulin|
496613|NCT00426907|Procedure|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
496614|NCT00426894|Procedure|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
496615|NCT00426881|Behavioral|Exercise Training|Twice weekly resistance training for 52 weeks.
496616|NCT00426881|Behavioral|Exercise training|Once weekly resistance training for 52 weeks.
496617|NCT00426881|Behavioral|Exercise training|Twice weekly resistance training for 52 weeks.
496618|NCT00426868|Other|Direct injection of ADRCs into the Left Ventricle|Dose escalation
496619|NCT00426868|Other|Direct injection of placebo into the Left Ventricle|
496620|NCT00426855|Drug|Bendamustine|starting with 60 mg/m^ 2, IV, dose escalation, weekly d1,8,15 q5w
496621|NCT00426855|Drug|Bortezomib|weekly 1.5mg/m^2, IV, d1,8,15,22 q5w
496622|NCT00426842|Drug|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
496623|NCT00426829|Drug|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
496624|NCT00426829|Radiation|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
496625|NCT00426816|Drug|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
496626|NCT00426816|Drug|Placebo|Placebo to match SB-649868
496627|NCT00426803|Drug|activated recombinant human factor VII|
496628|NCT00426790|Procedure|Positive end-expiratory pressure|
496633|NCT00426751|Drug|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
496634|NCT00426751|Drug|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
496635|NCT00426725|Device|EasyLabour|According to the trial protocol
496636|NCT00426712|Biological|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
496637|NCT00426712|Biological|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
496638|NCT00426673|Drug|Brivaracetam (ucb34714)|
496639|NCT00426660|Drug|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
496640|NCT00426647|Drug|Buprenorphine|
496641|NCT00426647|Drug|Tramadol|
496642|NCT00426621|Drug|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
496643|NCT00426621|Drug|Placebo|4 grams per knee, 4 times per day, for 12 weeks
496644|NCT00426608|Drug|metyrapone|Metyrapone will be available as 250 mg dose capsule.
496645|NCT00426608|Drug|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
496646|NCT00426608|Drug|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
496647|NCT00426608|Drug|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
496648|NCT00426595|Drug|Administration of omeprazole suspension|
496649|NCT00426595|Drug|omeprazole administered as a multi-unit-pellet system|
496650|NCT00426582|Drug|Patupilone|
496651|NCT00426556|Drug|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
496652|NCT00426556|Drug|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel & Trastuzumab
496653|NCT00426556|Drug|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
496654|NCT00426543|Drug|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
496655|NCT00426543|Drug|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
496656|NCT00426530|Drug|everolimus (RAD001)|
496657|NCT00426517|Drug|Fludarabine|For patients with inflammatory disorders or immunodeficiencies with a predominant inflammatory component, we may use Fludarabine instead of TBI to increase the immunosuppression induced by the regimen as well as to try to decrease the target cells responsible for the inflammatory symptoms
496658|NCT00426517|Drug|Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine|Conditioning regimen in various combination based on patient underlining immune deficiency disorder
496659|NCT00426517|Drug|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
496660|NCT00426517|Drug|Granulocyte Colony Stimulating Factor (G-CSF)|For mobilization of sibling donors
496661|NCT00426517|Other|hematopoietic progenitor cells|Allogeneic Stem Cells (sibling donor, Unrelated Donor (MUD) or Cord Blood Unit (CBU)
496662|NCT00426504|Procedure|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
496663|NCT00426491|Drug|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
496664|NCT00426478|Drug|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
496665|NCT00426478|Drug|Amlodipine (5mg)|
496666|NCT00426452|Drug|Vatalinib|
496667|NCT00426439|Drug|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
496668|NCT00426439|Drug|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, < 34 kg: 4 tablets.
496669|NCT00426426|Behavioral|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
496670|NCT00426426|Behavioral|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
496671|NCT00426426|Behavioral|Waiting list|
496672|NCT00426413|Drug|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
496673|NCT00426400|Drug|The cessation of anti-aggregative treatment for 10 days|
496674|NCT00426374|Procedure|echocardiography and blood test|
496675|NCT00426361|Biological|Boostrix ® Polio|One dose of vaccine administered intramuscularly
496676|NCT00426361|Biological|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
496677|NCT00426348|Drug|Valsartan|Valsartan (80-160mg/day)
496678|NCT00426348|Drug|Probucol|Probucol (750mg/day)
496679|NCT00426348|Drug|Placebo|Placebo
496680|NCT00426322|Device|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
496681|NCT00426296|Drug|atazanavir (Reyataz)|
496682|NCT00426296|Drug|ritonavir (Norvir)|
496683|NCT00426283|Drug|Flovent|1760 mcg daily
496684|NCT00426283|Other|Placebo|1760 mcg daily
496685|NCT00426270|Drug|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
496686|NCT00426257|Procedure|Secondary debulking|Secondary debulking
496687|NCT00426257|Procedure|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
496688|NCT00426244|Other|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
496689|NCT00426244|Other|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.~The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
496690|NCT00426231|Behavioral|Navigation by a health worker|Help provided by health worker to navigate medication access programs
496691|NCT00426231|Behavioral|Information control|Information about medication access programs provided to the participant and their healthcare provider
496692|NCT00426218|Drug|ACZ885|
496693|NCT00426205|Biological|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
496694|NCT00426192|Drug|i.v. mannitol|
496695|NCT00426192|Procedure|hemofiltration|
496696|NCT00426179|Drug|Imatinib|
496697|NCT00426166|Device|Low Level Laser Therapy|Low Level Laser Therapy on Wound
496698|NCT00426153|Drug|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
496699|NCT00426153|Drug|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
496700|NCT00426140|Drug|Patupilone|
496701|NCT00426127|Drug|Docetaxel|
496702|NCT00426127|Drug|Liposomal Doxorubicin|
496703|NCT00426127|Drug|Enoxaparin|
496704|NCT00426114|Drug|Administration of an IV glucose-injection|
496705|NCT00426101|Drug|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8~If continuation:~Pulses every 2nd wk, 10 mg/m2 for 3 days"
496706|NCT00426101|Drug|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)~If continuation:~150 mg/m2 iv, every 2nd wk"
496707|NCT00426101|Drug|Cyclosporin|"WK 1-8:~- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.~If continuation:~- Aim for around 200 microgram/L. Monitor GFR."
496708|NCT00426101|Procedure|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: <1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, >3 yrs 12 mg. Prednisolone: <1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, >3 yrs 10 mg."
496709|NCT00426101|Procedure|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
496710|NCT00426075|Device|Elastic stockings|
496711|NCT00426049|Drug|Everolimus|
496712|NCT00426036|Drug|Licarbazepine|
496713|NCT00426023|Drug|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
496714|NCT00426023|Drug|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
496715|NCT00426010|Drug|caffeine/placebo|caffeine or placebo, either overt or covert
496716|NCT00425997|Drug|Valsartan/HCTZ|
496717|NCT00425997|Drug|amlodipine|
496718|NCT00425997|Drug|HCTZ|
496719|NCT00425984|Procedure|Adult male circumcision|
496720|NCT00425971|Drug|BMEC-1217B|
496721|NCT00425945|Drug|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.~Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
496722|NCT00425932|Biological|Rituximab|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
496723|NCT00425919|Drug|PPM-204|
496724|NCT00425906|Drug|nicotine|
496725|NCT00425906|Other|Placebo|
496726|NCT00425906|Procedure|Quality of life|
496727|NCT00425893|Behavioral|hand hygiene|alcohol-based hand wash
496728|NCT00425893|Other|health education|Proper nutrition, etc.
496729|NCT00425893|Device|face masks|face masks
496730|NCT00425867|Behavioral|PAR1 polymoprhisms and placental invasion|
496731|NCT00425854|Drug|BIBW 2992|high dose once daily
496732|NCT00425841|Drug|gemcitabine hydrochloride|
496734|NCT00425841|Procedure|adjuvant therapy|
496735|NCT00425841|Procedure|neoadjuvant therapy|
496736|NCT00425841|Radiation|hypofractionated radiation therapy|
496737|NCT00425841|Radiation|stereotactic radiosurgery|
496738|NCT00425815|Drug|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
496739|NCT00425815|Other|Placebo|Placebo comparison
496740|NCT00425802|Biological|anti-thymocyte globulin|
496741|NCT00425802|Biological|filgrastim|
496742|NCT00425802|Biological|graft-versus-tumor induction therapy|
496743|NCT00425802|Biological|rituximab|
496744|NCT00425802|Drug|cyclophosphamide|
496745|NCT00425802|Drug|cyclosporine|
496746|NCT00425802|Drug|fludarabine phosphate|
496747|NCT00425802|Drug|mycophenolate mofetil|
496748|NCT00425802|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
496749|NCT00425802|Radiation|total-body irradiation|
496750|NCT00425789|Procedure|Treatment with Hyperbaric oxygen|
496751|NCT00425776|Device|acupuncture|
496752|NCT00425776|Device|Sham acupuncture|
496753|NCT00425763|Drug|AQAS|AQAS dosed by body weight, on days 0, 1, 2
496754|NCT00425750|Drug|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
496755|NCT00425750|Drug|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
496756|NCT00425750|Other|laboratory biomarker analysis|Tissue and blood collection.
496757|NCT00425750|Other|pharmacological study|Blood collection.
496758|NCT00425737|Biological|Rotarix|
496759|NCT00425724|Drug|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
496760|NCT00425711|Drug|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
496761|NCT00425698|Drug|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
496762|NCT00425698|Drug|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
496763|NCT00425672|Biological|ONTAK|Given IV
496764|NCT00425672|Other|flow cytometry|Correlative studies
496765|NCT00425672|Other|immunohistochemistry staining method|Correlative studies
496766|NCT00425672|Other|enzyme-linked immunosorbent assay|Correlative studies
496767|NCT00425672|Other|laboratory biomarker analysis|Correlative studies
496768|NCT00425672|Genetic|protein expression analysis|Correlative studies
496769|NCT00425659|Device|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
496770|NCT00425659|Device|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
496771|NCT00425659|Device|CPAP|usual practice
496772|NCT00425646|Biological|bevacizumab|
496773|NCT00425646|Drug|imatinib mesylate|
496774|NCT00425633|Drug|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
496775|NCT00425620|Drug|SinuNase|Lavage
496776|NCT00425607|Drug|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
496777|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 1|
496778|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 2|
496779|NCT00425594|Drug|NuLYTELY|
496780|NCT00425568|Drug|AndroGel (Transdermal Testosterone Gel)|
496781|NCT00425555|Drug|Panobinostat|
496782|NCT00425542|Other|Outpatient care (vs traditional inpatient care)|Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
496783|NCT00425529|Device|Module AOX (attached to Sondalis ISO)|
496784|NCT00425516|Drug|Taxotere|
496785|NCT00425516|Drug|5-Fluorouracil|
496786|NCT00425516|Drug|Epirubicin|
496787|NCT00425516|Drug|Cyclophosphamide|
496788|NCT00425503|Drug|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
496789|NCT00425490|Drug|sitagliptin|
496790|NCT00425477|Biological|sargramostim|
496791|NCT00425477|Drug|bexarotene|
496792|NCT00425477|Genetic|cytogenetic analysis|
496793|NCT00425477|Genetic|fluorescence in situ hybridization|
496794|NCT00425477|Other|flow cytometry|
496795|NCT00425477|Other|laboratory biomarker analysis|
496796|NCT00425477|Procedure|biopsy|
496847|NCT00425191|Drug|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
496797|NCT00425464|Device|Standard Monofocal Intraocular Lens|"The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
496798|NCT00425464|Device|Synchrony® Dual Optic Intraocular Lens|"The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.~Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
496799|NCT00425451|Drug|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
496800|NCT00425438|Drug|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
496801|NCT00425438|Drug|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
496802|NCT00425438|Drug|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
496803|NCT00425438|Drug|Cyclophosphamide|0.75 g/m^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m^2 to maintain a minimum WBC count of ≥ 2500 per mm^3 from Weeks 5 through 24
496804|NCT00425425|Biological|cetuximab|
496805|NCT00425425|Drug|fluorouracil|
496806|NCT00425425|Drug|oxaliplatin|
496807|NCT00425425|Procedure|conventional surgery|
496808|NCT00425425|Procedure|neoadjuvant therapy|
496809|NCT00425425|Radiation|radiation therapy|
496810|NCT00425399|Procedure|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
496811|NCT00425386|Drug|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;~100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;~150 mg/day, continuous daily"
496812|NCT00425386|Drug|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
496813|NCT00425386|Procedure|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
496814|NCT00425373|Drug|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
496815|NCT00425373|Drug|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
496816|NCT00425373|Drug|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
496817|NCT00425373|Drug|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
496818|NCT00425373|Drug|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
496819|NCT00425373|Drug|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
496820|NCT00425373|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
496821|NCT00425373|Drug|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
496822|NCT00425373|Drug|Placebo|4 tablet and 2 capsule placebos taken once daily
496823|NCT00425360|Biological|sargramostim|
496824|NCT00425360|Biological|telomerase peptide vaccine GV1001|
496825|NCT00425360|Drug|capecitabine|
496826|NCT00425360|Drug|gemcitabine hydrochloride|
496827|NCT00425347|Drug|HuLuc63|Not applicable for HuLuc63.
496828|NCT00425334|Drug|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
496829|NCT00425334|Drug|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
496830|NCT00425321|Drug|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
496831|NCT00425321|Drug|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
496832|NCT00425321|Drug|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
496833|NCT00425321|Drug|Placebo|Placebo once daily for up to 12 weeks
496834|NCT00425308|Drug|Everolimus + Cyclosporine|
496835|NCT00425308|Drug|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
496836|NCT00425308|Drug|Steroids|
496837|NCT00425295|Behavioral|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
496838|NCT00425282|Drug|RWJ-333369|
496839|NCT00425269|Behavioral|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
496840|NCT00425256|Drug|Bremelanotide|
496841|NCT00425243|Drug|zolpidem-MR (SL800750)|
496842|NCT00425230|Drug|Duloxetine|
496843|NCT00425217|Drug|Rituximab|
496844|NCT00425204|Drug|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
496845|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
496846|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
496849|NCT00425165|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
496850|NCT00425152|Drug|fluorouracil|
496851|NCT00425152|Drug|leucovorin calcium|
496852|NCT00425152|Drug|levamisole hydrochloride|
496853|NCT00425139|Behavioral|Re-Mission|
496854|NCT00425126|Drug|Epoetin Alfa|
496855|NCT00425113|Drug|Metronidazole|
496856|NCT00425113|Procedure|Blood Draw|
496857|NCT00425113|Procedure|CT Scan|
496858|NCT00425113|Procedure|PET Scan|
496859|NCT00425100|Drug|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
496860|NCT00425074|Drug|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
496861|NCT00425074|Drug|ASA|normal release acetylsalicylic acid
496862|NCT00425074|Drug|SR-ASA|slow release acetylsalicylic acid 150 mg
496863|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
496864|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
496865|NCT00425061|Other|placebo|placebo
496866|NCT00425048|Procedure|wearing gloves|
496867|NCT00425035|Drug|Panitumumab (ABX-EGF)|
496868|NCT00425022|Procedure|thoracoscopy|
496869|NCT00425009|Drug|Berberine|
496870|NCT00425009|Drug|Metformin|
496871|NCT00424983|Drug|Zoledronic acid|
496872|NCT00424970|Drug|acetazolamide|
496873|NCT00424944|Biological|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
496874|NCT00424944|Biological|GMZ2 malaria vaccine|100 micrograms of GMZ2
496875|NCT00424944|Biological|Verorab vaccine|Anti-rabies vaccine
496876|NCT00424931|Drug|JNJ-17216498|50mg one time
496877|NCT00424931|Drug|JNJ-17216498|10mg one time
496878|NCT00424931|Drug|Modafinil|200 mg X 2
496879|NCT00424918|Behavioral|Physical Activity, reduced sedentary behavior|
496880|NCT00424905|Drug|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
496881|NCT00424892|Drug|Desvenlafaxine Sustained Release|
496882|NCT00424866|Drug|FGF-1|"Doses of FGF-1: 3 ug/kg; 10 ug/kg; 30 ug/kg~Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
496883|NCT00424866|Drug|Placebo|Vehicle: 0 µg/kg
496884|NCT00424853|Drug|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
496885|NCT00424853|Drug|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
496886|NCT00424840|Drug|Bortezomib 1.3 mg/m2|"Level I (every 21 day cycle, D8), 1.3 mg/m2:~Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2~Level II (every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2~Level III(every 21 day cycle):~Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2"
496887|NCT00424840|Drug|Bortezomib 1.6 mg/m2|Level II (every 21 day cycle, D8), 1.6 mg/m2
496888|NCT00424840|Drug|Bortezomib 1.8 mg/m2|Level III (every 21 day cycle, D8) 1.8 mg/m2
496889|NCT00424840|Drug|Carboplatin AUC 6|Carboplatin AUC6
496890|NCT00424840|Drug|Bevacizumab|Bevacizumab 15 mg/kg
496891|NCT00424840|Drug|Taxotere|Taxotere 70 + G-CSF
496892|NCT00424827|Drug|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
496893|NCT00424814|Drug|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
496894|NCT00424814|Drug|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
496895|NCT00424801|Drug|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
496896|NCT00424801|Drug|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
496897|NCT00424801|Drug|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
496898|NCT00424801|Drug|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
496899|NCT00424801|Drug|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
496900|NCT00424801|Drug|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
496901|NCT00424801|Drug|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
496902|NCT00424788|Procedure|Plasma exchange|
496903|NCT00424788|Drug|natalizumab treatment|
496904|NCT00424775|Drug|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
496905|NCT00424762|Drug|rosiglitazone|6 months of treatment of blinded study drug
496906|NCT00424762|Drug|placebo|blinded treatment with matching placebo
496907|NCT00424749|Drug|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m^2.
496908|NCT00424749|Drug|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
496909|NCT00424736|Procedure|whole body CT scan|
497263|NCT00422487|Drug|Placebo for MBX-2044|Placebo Intervention
496910|NCT00424723|Drug|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
496911|NCT00424710|Drug|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
496912|NCT00424697|Drug|placebo|
496913|NCT00424697|Drug|lorazepam|
496914|NCT00424697|Drug|GW876008|
496915|NCT00424684|Procedure|collection of blood sample|
496916|NCT00424671|Drug|Licarbazepine|
496917|NCT00424658|Procedure|SAHS diagnosis|
496918|NCT00424645|Drug|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
496919|NCT00424645|Drug|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
496920|NCT00424632|Drug|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
496921|NCT00424619|Drug|Vitamin D2|50 000 IU vitamin D2, one time bolus dose
496922|NCT00424619|Drug|Vitamin D2|100 000 IU vitamin D2, one time bolus dose
496923|NCT00424619|Drug|Placebo|Placebo, 1 time bolus dose
496924|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
496925|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
496926|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
496927|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
496928|NCT00424593|Drug|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
496929|NCT00424593|Drug|Placebo|every day (QD), by mouth (PO), 13 weeks
496930|NCT00424580|Drug|Montelukast (10mg) and Desloratadine (5mg)|
496931|NCT00424567|Procedure|Fracture surgery|
496932|NCT00424567|Drug|Cultured Bone Marrow Tissue|
496933|NCT00424554|Drug|temozolomide|"Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
496934|NCT00424541|Drug|SPP100 (aliskiren)|
496935|NCT00424528|Drug|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
496936|NCT00424528|Drug|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
496937|NCT00424528|Drug|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
496938|NCT00424528|Drug|Placebo|Placebo inhalation solution and placebo inhalation powder
496939|NCT00424515|Drug|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
496940|NCT00424502|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
496941|NCT00424502|Drug|Methotrexate|10-25mg po/week
496942|NCT00424489|Biological|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
496943|NCT00424489|Drug|Cyclophosphamide|
496944|NCT00424489|Drug|ATG (rabbit)|
496945|NCT00424489|Drug|Mesna|
496946|NCT00424489|Drug|Methylprednisolone|
496947|NCT00424489|Drug|G-CSF|
496948|NCT00424476|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
496949|NCT00424476|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
496950|NCT00424476|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
496951|NCT00424463|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
496952|NCT00424463|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
496953|NCT00424450|Procedure|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
496954|NCT00424450|Procedure|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
496955|NCT00424437|Drug|Inhaled human insulin|
496956|NCT00424424|Drug|MK0719|
496957|NCT00424411|Drug|Inhaled human insulin (EXUBERA™)|
496958|NCT00424398|Drug|Bepreve|sterile ophthalmic solution
496959|NCT00424398|Drug|Placebo|sterile ophthalmic solution
496960|NCT00424398|Drug|Bepotastine Besilate|sterile ophthalmic solution
496961|NCT00424385|Drug|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
496962|NCT00424372|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
496963|NCT00424346|Drug|Canakinumab|
496964|NCT00424346|Drug|Placebo|
496965|NCT00424333|Drug|Inhaled human insulin|
496966|NCT00424320|Drug|Sodium bicarbonate|
496967|NCT00424307|Device|HiResolution Bionic Ear System|
496968|NCT00424294|Drug|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
496969|NCT00424294|Drug|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
497034|NCT00423878|Drug|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
497467|NCT00420836|Drug|Tobramycin|
496970|NCT00424294|Drug|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
496971|NCT00424281|Drug|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
496972|NCT00424268|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
496973|NCT00424268|Drug|Placebo|once daily
496974|NCT00424255|Drug|Lapatinib|Dual ErbB1/2 inhibitor
496975|NCT00424255|Radiation|Chemoradiation|Radiation plus platinum based chemotherapy
496976|NCT00424255|Other|Placebo|Placebo
496977|NCT00424242|Drug|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
496978|NCT00424229|Drug|LENALIDOMIDE|
496979|NCT00424216|Procedure|DC Polarization|
496980|NCT00424203|Drug|AC regimen|
496981|NCT00424203|Drug|cyclophosphamide|
496982|NCT00424203|Drug|doxorubicin hydrochloride|
496983|NCT00424203|Procedure|adjuvant therapy|
496984|NCT00424203|Procedure|cognitive assessment|
496985|NCT00424203|Procedure|management of therapy complications|
496986|NCT00424203|Procedure|psychosocial assessment and care|
496987|NCT00424203|Procedure|quality-of-life assessment|
496988|NCT00424190|Drug|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
496989|NCT00424190|Drug|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
496990|NCT00424177|Drug|eltrombopag|experimental
496991|NCT00424164|Drug|lapatinib ditosylate|
496992|NCT00424164|Drug|tamoxifen citrate|
496993|NCT00424164|Other|pharmacological study|
496994|NCT00424151|Drug|Rituximab|
496995|NCT00424138|Radiation|FDG|
496996|NCT00424125|Behavioral|Enhanced Pharmacy Care|"Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers."
496997|NCT00424125|Behavioral|Control|Usual care.
496998|NCT00424099|Drug|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
496999|NCT00424099|Behavioral|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
497000|NCT00424099|Drug|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
497001|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
497002|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
497003|NCT00424060|Drug|sagopilone|
497004|NCT00424060|Genetic|fluorescence in situ hybridization|
497005|NCT00424060|Genetic|gene expression analysis|
497006|NCT00424060|Other|immunohistochemistry staining method|
497007|NCT00424060|Other|laboratory biomarker analysis|
497008|NCT00424060|Other|pharmacological study|
497009|NCT00424047|Drug|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
497010|NCT00424047|Drug|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
497011|NCT00424034|Drug|GSK1325760A|
497012|NCT00424021|Drug|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
497013|NCT00424008|Drug|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
497014|NCT00424008|Drug|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
497015|NCT00423995|Drug|Loratadine/montelukast combination|
497016|NCT00423982|Drug|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
497017|NCT00423982|Drug|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
497018|NCT00423969|Drug|Galantamine|
497019|NCT00423969|Drug|Escitalopram|
497020|NCT00423956|Procedure|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
497021|NCT00423943|Drug|modafinil|200 milligrams daily dose
497022|NCT00423943|Drug|Placebos|capsule containing placebo
497023|NCT00423930|Biological|bevacizumab|
497024|NCT00423930|Drug|cisplatin|
497025|NCT00423930|Procedure|conventional surgery|
497026|NCT00423930|Radiation|intensity-modulated radiation therapy|
497027|NCT00423917|Biological|bevacizumab|
497028|NCT00423917|Drug|fulvestrant|
497029|NCT00423904|Behavioral|Brief intervention|
497030|NCT00423891|Drug|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
497031|NCT00423878|Drug|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
497032|NCT00423878|Drug|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
497033|NCT00423878|Drug|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
497035|NCT00423865|Drug|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
497036|NCT00423865|Drug|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
497037|NCT00423865|Genetic|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
497038|NCT00423865|Other|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
497039|NCT00423865|Other|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
497040|NCT00423865|Other|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
497041|NCT00423865|Procedure|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
497042|NCT00423852|Biological|filgrastim|
497043|NCT00423852|Drug|carboplatin|
497044|NCT00423852|Drug|ifosfamide|
497045|NCT00423852|Drug|paclitaxel|
497046|NCT00423852|Procedure|autologous hematopoietic stem cell transplantation|
497047|NCT00423852|Procedure|peripheral blood stem cell transplantation|
497048|NCT00423839|Biological|MVA85A (Tuberculosis vaccine)|
497049|NCT00423826|Drug|Busulfan|3 mg/kg intravenously over 3 hours
497050|NCT00423826|Drug|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
497051|NCT00423826|Drug|Fludarabine phosphate|25 mg/M2/day IV
497052|NCT00423826|Drug|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
497053|NCT00423826|Drug|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
497054|NCT00423826|Procedure|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
497055|NCT00423826|Procedure|umbilical cord blood transplantation|10 days post drug intervention
497056|NCT00423826|Radiation|total-body irradiation|10 days post drug intervention
497057|NCT00423813|Drug|placebo|Oral Solution
497058|NCT00423813|Drug|Xyrem®|two doses
497059|NCT00423800|Drug|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks~200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
497060|NCT00423787|Biological|Ragweed MATA MPL|"4 injections of increasing dose strength:~300 SU/0.5 ml~700 SU/0.5 ml~2000 SU/0.5 ml~6000 SU/0.5 ml"
497061|NCT00423774|Behavioral|Problem-Solving Education|
497062|NCT00423761|Drug|midazolam|
497063|NCT00423761|Drug|GW876008|
497064|NCT00423748|Drug|ambrisentan|
497065|NCT00423735|Drug|Dasatinib|Given PO
497066|NCT00423735|Other|Pharmacological Study|Correlative studies
497067|NCT00423722|Drug|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
497068|NCT00423722|Drug|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
497069|NCT00423709|Procedure|Allogeneic Blood Stem Cell Transplantation|
497070|NCT00423709|Drug|Fludarabine|
497071|NCT00423709|Drug|Melphalan|
497072|NCT00423696|Biological|bevacizumab|
497073|NCT00423696|Drug|capecitabine|
497074|NCT00423696|Drug|fluorouracil|
497075|NCT00423696|Drug|irinotecan hydrochloride|
497076|NCT00423696|Drug|leucovorin calcium|
497077|NCT00423696|Procedure|quality-of-life assessment|
497078|NCT00423683|Drug|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
497079|NCT00423683|Device|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
497080|NCT00423670|Drug|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
497081|NCT00423670|Drug|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
497082|NCT00423670|Drug|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
497083|NCT00423670|Drug|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
497084|NCT00423657|Drug|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
497085|NCT00423657|Drug|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
497086|NCT00423657|Drug|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
497087|NCT00423644|Drug|Darinaparson|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
497147|NCT00423280|Drug|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
497088|NCT00423631|Behavioral|Standard care and web|A static web site containing cognitive and behavioral self management instructions.
497089|NCT00423631|Behavioral|Standard Care|Standard care delivered by the primary care provider.
497090|NCT00423618|Radiation|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
497091|NCT00423605|Drug|Xyrem®|flexible dosing
497092|NCT00423592|Drug|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
497093|NCT00423579|Drug|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
497094|NCT00423579|Drug|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
497095|NCT00423566|Biological|MVA85A (Tuberculosis vaccine)|
497096|NCT00423540|Drug|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
497097|NCT00423527|Drug|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
497098|NCT00423514|Biological|filgrastim|
497099|NCT00423514|Drug|clofarabine|
497100|NCT00423514|Drug|melphalan|
497101|NCT00423514|Drug|mycophenolate mofetil|
497102|NCT00423514|Drug|tacrolimus|
497103|NCT00423514|Drug|thiotepa|
497104|NCT00423514|Procedure|allogeneic bone marrow transplantation|
497105|NCT00423514|Procedure|allogeneic hematopoietic stem cell transplantation|
497106|NCT00423514|Procedure|peripheral blood stem cell transplantation|
497107|NCT00423501|Drug|Placebo|sc weekly
497108|NCT00423501|Drug|taspoglutide|20mg sc weekly
497109|NCT00423501|Drug|taspoglutide|10mg sc every 2 weeks
497110|NCT00423501|Drug|taspoglutide|5mg sc weekly
497111|NCT00423501|Drug|taspoglutide|10mg sc weekly
497112|NCT00423501|Drug|taspoglutide|20mg sc every 2 weeks
497113|NCT00423488|Drug|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
497114|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
497115|NCT00423488|Drug|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
497116|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
497117|NCT00423488|Drug|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
497118|NCT00423475|Drug|goserelin acetate|
497119|NCT00423475|Procedure|adjuvant therapy|
497120|NCT00423475|Radiation|radiation therapy|
497121|NCT00423462|Behavioral|Brief dynamic psychotherapy|
497122|NCT00423449|Drug|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
497123|NCT00423449|Drug|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
497124|NCT00423449|Drug|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
497125|NCT00423436|Behavioral|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
497126|NCT00423436|Behavioral|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
497127|NCT00423436|Behavioral|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
497128|NCT00423410|Drug|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
497129|NCT00423397|Biological|PEG-interferon alfa-2a|
497130|NCT00423397|Drug|gefitinib|
497131|NCT00423384|Drug|Placebo|Placebo
497132|NCT00423384|Drug|Ibandronate|I.v.
497133|NCT00423371|Device|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
497134|NCT00423371|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
497135|NCT00423358|Dietary Supplement|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
497136|NCT00423358|Dietary Supplement|placebo|matching placebo
497137|NCT00423332|Drug|Cediranib|45 mg oral tablet
497138|NCT00423332|Drug|Cediranib Placebo|oral tablet
497139|NCT00423319|Drug|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
497140|NCT00423319|Drug|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
497141|NCT00423319|Drug|Enoxaparin-matching placebo|Administered as injection
497142|NCT00423319|Drug|Apixaban-matching placebo|Administered as oral tablets
497143|NCT00423306|Drug|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
497144|NCT00423293|Drug|fluorouracil|1000 mg/m^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
497145|NCT00423293|Drug|mitomycin C|10 mg/m^2 intravenous therapy on day 1 and day 29 of radiation therapy.
497146|NCT00423293|Radiation|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.~T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.~T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.~For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes > 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
497468|NCT00420823|Drug|Taurine 4g|
497148|NCT00423267|Drug|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
497149|NCT00423267|Drug|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
497150|NCT00423254|Biological|PSMA/PRAME|Low dose
497151|NCT00423254|Biological|PSMA/PRAME|high dose
497152|NCT00423241|Device|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
497153|NCT00423241|Device|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
497154|NCT00423228|Drug|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
497155|NCT00423228|Drug|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
497156|NCT00423215|Drug|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.~Treatment duration: 4 months."
497157|NCT00423202|Drug|ambrisentan|
497158|NCT00423189|Drug|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
497159|NCT00423189|Drug|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
497160|NCT00423176|Drug|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
497161|NCT00423176|Drug|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
497162|NCT00423163|Drug|micafungin|
497163|NCT00423163|Drug|voriconazole|
497164|NCT00423150|Drug|Temozolomide|Temozolomide capsules 150 mg/m^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
497165|NCT00423137|Drug|BIBW 2948 BS|
497166|NCT00423137|Drug|Placebo|
497167|NCT00423124|Genetic|HSV-TK|Infusion of genetically modified lymphocytes (1x10^6-1x10^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
497168|NCT00423098|Drug|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
497169|NCT00423098|Drug|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
497170|NCT00423098|Drug|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
497171|NCT00423085|Drug|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:~2.5 cm^2 (4.5 mg), 5 cm^2 (9 mg), 7.5 cm^2 (13.5 mg), and 10 cm^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
497172|NCT00423085|Drug|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm^2, 5 cm^2, 7.5 cm^2 and 10 cm^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
497173|NCT00423059|Drug|bevacizumab|
497174|NCT00423046|Biological|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
497175|NCT00423046|Biological|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
497176|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
497177|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
497178|NCT00423020|Drug|Erythropoietin|
497179|NCT00423007|Drug|Bromfenac|
497180|NCT00423007|Drug|Placebo|
497181|NCT00422994|Drug|ropinirole dosing for up to 28 days|
497182|NCT00422981|Drug|AL-108|5 mg QD
497183|NCT00422981|Drug|AL-108|15 mg BID
497184|NCT00422981|Drug|Placebo|Placebo
497185|NCT00422968|Device|Percutaneous coronary intervention|Using silorimus eluting stent
497186|NCT00422968|Procedure|coronary artery bypass graft|coronary artery bypass graft
497187|NCT00422955|Drug|rosiglitazone|
497188|NCT00422942|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
497189|NCT00422942|Drug|Methotrexate|10-25mg po weekly
497190|NCT00422916|Behavioral|behavioral intervention|
497191|NCT00422903|Drug|lapatinib|1500 mg administered orally daily
497192|NCT00422903|Drug|letrozole|2.5 mg administered orally daily
497193|NCT00422903|Other|placebo|1500 mg administered orally daily
497194|NCT00422890|Drug|5-Azacytidin|in case of decreasing CD34 chimerism
497195|NCT00422877|Drug|Taxoprexin|DHA-paclitaxel
497196|NCT00422864|Drug|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
497197|NCT00422864|Drug|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
497198|NCT00422864|Drug|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
497262|NCT00422487|Drug|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
497199|NCT00422864|Procedure|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
497200|NCT00422838|Procedure|fine-needle aspiration biopsy|aspiration of intrahepatic cells
497201|NCT00422825|Drug|imatinib|
497202|NCT00422812|Drug|Inhaled Placebo|Inhaled Staccato Placebo
497203|NCT00422812|Drug|Inhaled PCZ 5 mg|Inhaled Staccato Prochlorperazine 5 mg
497204|NCT00422812|Drug|Inhaled PCZ 7.5 mg|Inhaled Staccato Prochlorperazine 7.5 mg
497205|NCT00422812|Drug|Inhaled PCZ 10 mg|Inhaled Staccato Prochlorperazine 10 mg
497206|NCT00422799|Drug|Bortezomib|Once weekly for 3 weeks
497207|NCT00422799|Drug|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
497208|NCT00422786|Drug|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
497209|NCT00422773|Drug|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
497210|NCT00422747|Drug|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
497211|NCT00422734|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
497212|NCT00422734|Drug|Placebo|placebo tablet taken by mouth once a day for 12 weeks
497213|NCT00422721|Procedure|realization of a family tree|
497214|NCT00422721|Procedure|refractometry|
497215|NCT00422721|Procedure|evaluation of the presence of a nystagmus|
497216|NCT00422721|Procedure|ocular behavior|
497217|NCT00422721|Procedure|test of baby vision|
497218|NCT00422721|Procedure|test of keenness|
497219|NCT00422721|Procedure|reading test|
497220|NCT00422721|Procedure|visual field|
497221|NCT00422721|Procedure|color vision|
497222|NCT00422721|Procedure|electroretinographical activity|
497223|NCT00422721|Procedure|biomicroscopical test|
497224|NCT00422721|Procedure|retinal imaging|
497225|NCT00422721|Procedure|retinal autofluorescence|
497226|NCT00422721|Procedure|genotyping|
497227|NCT00422708|Procedure|Local anesthesia|
497228|NCT00422682|Drug|bsi-201 + topotecan|21 day cycle
497229|NCT00422682|Drug|bsi-201 + temozolomide|28 day cycle
497230|NCT00422682|Drug|bsi-201 + gemcitabine|28 day cycle
497231|NCT00422682|Drug|bsi-201 + carboplatin/paclitaxel|21 day cycle
497232|NCT00422669|Device|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
497233|NCT00422669|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
497234|NCT00422656|Drug|Perifosine|
497235|NCT00422643|Drug|Sodium hyaluronate (hyaluronic acid)|
497236|NCT00422630|Behavioral|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
497237|NCT00422630|Behavioral|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
497238|NCT00422630|Behavioral|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
497239|NCT00422617|Drug|Alefacept (Amevive)|
497240|NCT00422604|Drug|salmeterol|
497241|NCT00422604|Drug|tiotropium|
497242|NCT00422604|Drug|GSK233705|
497243|NCT00422591|Drug|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
497244|NCT00422591|Drug|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
497245|NCT00422578|Drug|tadalafil|
497246|NCT00422565|Device|Endeavor, Medtronic|Zotarolimus-eluting stent
497247|NCT00422565|Device|Cypher, Cordis|Sirolimus-eluting stent
497248|NCT00422565|Device|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
497249|NCT00422552|Drug|Indacaterol (QAB149)|
497250|NCT00422539|Drug|70% trichloroacetic acid|
497251|NCT00422526|Drug|Micronised progesterone (Utrogestan)|
497252|NCT00422513|Drug|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
497253|NCT00422513|Drug|Epoetin alfa|As prescribed, iv, 3 times weekly
497254|NCT00422500|Behavioral|Questionnaire|Surveys about symptoms, mood, and quality of life.
497255|NCT00422500|Behavioral|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
497256|NCT00422500|Other|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
497257|NCT00422487|Drug|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
497258|NCT00422487|Drug|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
497259|NCT00422487|Drug|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
497260|NCT00422487|Drug|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
497261|NCT00422487|Drug|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
497264|NCT00422461|Drug|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
497265|NCT00422461|Drug|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
497266|NCT00422461|Drug|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
497267|NCT00422461|Drug|placebo|placebo, oral, tablets, once daily, for 28 days
497268|NCT00422448|Genetic|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
497269|NCT00422435|Device|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
497270|NCT00422422|Drug|Brivaracetam|"Oral solution~Evaluation period (3 weeks up-titration):~For subjects ≥8 years:~~0.4 mg/kg bid for Week 1~~0.8 mg/kg bid for Week 2~~1.6 mg/kg bid for Week 3~For subjects <8 years:~~0.5 mg/kg bid for Week 1~~1.0 mg/kg bid for Week 2~~2.0 mg/kg bid for Week 3~Down-titration period (up to 2 weeks):~For subjects ≥8 years:~~0.8 mg/kg bid for Week 4~~0.4 mg/kg bid for Week 5~For subjects <8 years:~~1.0 mg/kg bid for Week 4~~0.5 mg/kg bid for Week 5"
497271|NCT00422409|Procedure|Endoscopic stenting|
497272|NCT00422396|Drug|Fenofibrate (drug)|
497273|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
497274|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
497275|NCT00422383|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
497276|NCT00422370|Device|lipid based additives based on vegetable oil & lecithin|
497277|NCT00422357|Drug|Urtica Dioica (Tea bag)|
497278|NCT00422344|Drug|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
497279|NCT00422331|Drug|Lithium Carbonate Capsule|
497280|NCT00422318|Drug|Benzbromarone (drug)|
497281|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
497282|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
497283|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
497284|NCT00422292|Biological|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
497285|NCT00422279|Device|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
497286|NCT00422266|Drug|Omega 3 fatty acids and plant sterol enriched drink|
497287|NCT00422266|Dietary Supplement|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
497288|NCT00422253|Behavioral|dietary intervention|
497289|NCT00422240|Drug|Adapalene/Benzoyl Peroxide|
497290|NCT00422227|Drug|Etanercept , Methotrexate|"Etanercept: 25 mg twice weekly over 16 weeks, SC~Methotrexate: > 7.5 mg/week and no more than 25 mg/week, PO"
497291|NCT00422227|Drug|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO~Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO~Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day~Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
497292|NCT00422214|Drug|Quetiapine fumarate (Seroquel) SR|
497293|NCT00422201|Drug|Mifepristone|Singe dose
497294|NCT00422188|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
497295|NCT00422188|Drug|Placebo|Administered via intralipomal injection.
497296|NCT00422175|Drug|BAF 312|
497297|NCT00422162|Drug|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
497298|NCT00422162|Drug|Placebo|placebo capsule by mouth
497299|NCT00422149|Drug|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
497300|NCT00422149|Drug|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
497301|NCT00422149|Drug|Placebo treatment|Placebo treatment
497302|NCT00422123|Drug|Quetiapine fumarate (Seroquel) SR|
497303|NCT00422110|Drug|Seletracetam|
497304|NCT00422097|Drug|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
497305|NCT00422097|Drug|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
497306|NCT00422097|Drug|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
497307|NCT00422097|Drug|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
497308|NCT00422097|Drug|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
497309|NCT00422097|Drug|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
497310|NCT00422097|Drug|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
497311|NCT00422097|Drug|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
497312|NCT00422084|Drug|Pyronaridine artesunate|once a day for 3 days
497313|NCT00422084|Drug|Coartem® (artemether lumefantrine)|twice a day for 3 days
497314|NCT00422058|Drug|liraglutide|Injected s.c. (under the skin) once daily
497315|NCT00422058|Drug|orlistat|120 mg capsule. Administered thrice daily
497316|NCT00422058|Drug|placebo|Injected s.c. (under the skin) once daily
497317|NCT00422045|Device|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
497318|NCT00422032|Drug|Clofarabine|"Group A: 15 mg/m^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m^2 IV over 1 hour daily for 5 days"
497319|NCT00422019|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
497320|NCT00422019|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
497321|NCT00422006|Procedure|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
497322|NCT00422006|Procedure|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
497323|NCT00422006|Behavioral|diet|diet
497324|NCT00422006|Other|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
497325|NCT00421993|Drug|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
497326|NCT00421993|Drug|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
497327|NCT00421993|Drug|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
497328|NCT00421993|Drug|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
497329|NCT00421980|Drug|Etanercept|
497330|NCT00421967|Drug|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
497331|NCT00421967|Drug|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
497332|NCT00421954|Drug|Ziprasidone|subjects will use ziprasidone
497333|NCT00421941|Procedure|Tube feeding|
497334|NCT00421928|Drug|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
497335|NCT00421928|Drug|placebo|matching placebo twice a day (BID) during 15 weeks
497336|NCT00421928|Drug|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
497337|NCT00421915|Drug|Enbrel (etanercept)|
497338|NCT00421902|Procedure|Acupuncture|Patients will be have acupuncture (with electro stimulation)
497339|NCT00421889|Drug|belinostat|
497340|NCT00421889|Drug|Paclitaxel|
497341|NCT00421889|Drug|Carboplatin|
497342|NCT00421876|Behavioral|multifactorial continued educational - behavioural programme|
497343|NCT00421863|Drug|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497344|NCT00421863|Drug|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497345|NCT00421863|Drug|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497346|NCT00421863|Drug|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497347|NCT00421863|Drug|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497348|NCT00421863|Drug|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497349|NCT00421863|Drug|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497350|NCT00421863|Drug|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497351|NCT00421863|Drug|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
497352|NCT00421850|Behavioral|UNITED Planned Care|
497353|NCT00421824|Drug|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
497354|NCT00421824|Drug|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
497355|NCT00421811|Drug|ADH-1|4 gm IV Days 1 and 8
497356|NCT00421811|Drug|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
497357|NCT00421785|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
497358|NCT00421759|Device|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
497359|NCT00421746|Drug|Piboserod|
497360|NCT00421733|Drug|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
497469|NCT00420810|Drug|MK0928 / Duration of Treatment : 8 Weeks|
497361|NCT00421733|Drug|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
497362|NCT00421733|Drug|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
497363|NCT00421720|Drug|Sufentanil|
497364|NCT00421720|Drug|Remifentanil|
497365|NCT00421707|Drug|GW876008|
497366|NCT00421707|Other|Placebo|
497367|NCT00421694|Drug|Bicalutamide|
497368|NCT00421681|Behavioral|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
497369|NCT00421668|Drug|Zinc|zinc
497370|NCT00421668|Drug|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
497371|NCT00421668|Drug|Placebo|Placebo
497372|NCT00421655|Drug|Grazax|Tablets 75,000 SQT and matching placebo. One tablet daily.
497373|NCT00421642|Drug|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
497374|NCT00421629|Behavioral|After-sales service and supportive supervision (AfterSS)|
497375|NCT00421629|Behavioral|Prospective reimbursement (PR)|
497376|NCT00421629|Behavioral|Both (AfterSS and PR)|
497377|NCT00421616|Behavioral|High protein diet study|
497378|NCT00421603|Drug|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
497379|NCT00421603|Drug|Placebo|Placebo
497380|NCT00421590|Drug|SMC021|
497381|NCT00421564|Drug|DBT-Danggui Buxue Tang|
497382|NCT00421551|Drug|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
497383|NCT00421551|Drug|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
497384|NCT00421538|Drug|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
497385|NCT00421538|Drug|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
497386|NCT00421525|Biological|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
497387|NCT00421512|Drug|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
497388|NCT00421499|Drug|dark chocolate|
497389|NCT00421486|Procedure|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
497390|NCT00421473|Drug|Atovaquone / Proguanil|
497391|NCT00421460|Drug|Testosterone Undecanoate,1000mg|duration for 4 injections
497392|NCT00421447|Drug|Anastrozole|Group of women with breast cancer
497393|NCT00421434|Drug|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
497394|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
497395|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
497396|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
497397|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
497398|NCT00421421|Drug|Dutasteride|
497399|NCT00421408|Dietary Supplement|Whey protein supplement|40-g whey protein supplement daily for 18 months
497400|NCT00421408|Dietary Supplement|Placebo|Placebo supplement daily for 18 months
497401|NCT00421395|Biological|90Y-hLL2|weekly dosing for either 2 or 3 weeks
497402|NCT00421369|Drug|sertraline|
497403|NCT00421369|Drug|triiodothyronine (T3)|
497404|NCT00421369|Drug|reboxetine|
497405|NCT00421343|Drug|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
497406|NCT00421343|Drug|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
497407|NCT00421343|Behavioral|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
497408|NCT00421330|Procedure|Open Aneurysm Repair|
497409|NCT00421330|Procedure|Endovascular Aneurysm Repair|
497410|NCT00421317|Drug|Imatinib|800 mg/day until disease progression or toxicity
497411|NCT00421304|Biological|Motavizumab|Will receive a single dose of IV of Motavizumab (100mg/kg)
497412|NCT00421304|Other|Biological/Vaccine: Motavizumab|A single IV dose of placebo (30 mg/kg).
497413|NCT00421304|Other|Placebo|A single IV dose of placebo (30 or 100 mg/kg).
497414|NCT00421291|Behavioral|Education|
497415|NCT00421278|Drug|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
497416|NCT00421252|Drug|clopidogrel 600 mg|Clopidogrel load > 2hrs pre-angiography
497417|NCT00421252|Device|arterial access sheath|randomize to 5Fr vs 6Fr
497418|NCT00421226|Drug|ACZ885|
497419|NCT00421213|Drug|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
497420|NCT00421200|Drug|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
497421|NCT00421200|Drug|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
497422|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
497423|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
497424|NCT00421174|Drug|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
497425|NCT00421174|Drug|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.~Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
497426|NCT00421161|Drug|olive oil and omega 3 in a combined cream|
497427|NCT00421148|Drug|Sugammadex 0.5 mg/kg|IV infusion
497428|NCT00421148|Drug|Sugammadex 1 mg/kg|IV infusion
497429|NCT00421148|Drug|Sugammadex 2 mg/kg|IV infusion
497430|NCT00421148|Drug|Sugammadex 4 mg/kg|IV infusion
497431|NCT00421148|Drug|Placebo|IV infusion
497432|NCT00421148|Drug|Rocuronium bromide|IV infusion
497433|NCT00421135|Drug|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
497434|NCT00421122|Drug|budesonide/formoterol (Symbicort)|inhalation therapy
497435|NCT00421122|Drug|budesonide (Pulmicort)|inhalation
497436|NCT00421122|Drug|terbutaline sulfate (Bricasol)|inhalation therapy
497437|NCT00421109|Drug|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
497438|NCT00421109|Drug|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
497439|NCT00421109|Drug|Placebo|Encapsulated tablet. Once daily for 28 days
497440|NCT00421096|Drug|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
497441|NCT00421096|Procedure|Radiotherapy|"45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area"
497442|NCT00421096|Drug|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
497443|NCT00421083|Drug|tadalafil|
497444|NCT00421070|Procedure|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
497445|NCT00421057|Behavioral|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
497446|NCT00421057|Behavioral|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
497447|NCT00421044|Drug|Patupilone/EPO906|
497448|NCT00421031|Drug|DVS-233 SR|
497449|NCT00421018|Drug|Single corticosteroid inhalers and Singulair|Treatment steps according to preset algorithm
497450|NCT00421005|Drug|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
497451|NCT00420992|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
497452|NCT00420992|Drug|Placebo|capsules, bid
497453|NCT00420953|Drug|Cordarone|
497454|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
497455|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
497456|NCT00420927|Biological|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
497457|NCT00420927|Drug|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
497458|NCT00420927|Biological|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
497459|NCT00420914|Procedure|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
497460|NCT00420901|Drug|sildenafil|
497461|NCT00420888|Drug|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
497462|NCT00420888|Drug|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
497463|NCT00420875|Device|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
497464|NCT00420862|Procedure|Spiral Computed Tomography|
497465|NCT00420849|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
497466|NCT00420849|Drug|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
497470|NCT00420797|Drug|10% Phenylephrine hydrochloride gel|
497471|NCT00420784|Drug|Telaprevir|tablet
497472|NCT00420784|Drug|Ribavirin|tablet
497473|NCT00420784|Drug|Pegylated Interferon Alfa 2a|Solution for injection
497474|NCT00420784|Drug|Matching Placebo|Tablet
497475|NCT00420771|Drug|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
497476|NCT00420771|Drug|Placebo|placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
497477|NCT00420758|Dietary Supplement|Food supplement: fortified spread|Provision of fortified spread
497478|NCT00420758|Dietary Supplement|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
497479|NCT00420745|Biological|Rotarix™|Two-dose oral vaccination.
497480|NCT00420745|Biological|Placebo|Two-dose oral administration
497481|NCT00420732|Biological|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
497482|NCT00420719|Device|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
497483|NCT00420706|Drug|SCA-136|
497484|NCT00420693|Drug|sevoflurane|
497485|NCT00420680|Drug|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
497486|NCT00420680|Drug|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
497487|NCT00420680|Drug|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
497488|NCT00420667|Drug|Enoxaparin|
497489|NCT00420654|Drug|Growth Hormone|1.25 mg, 6 months
497490|NCT00420654|Drug|Placebo|Equivalent to 1.25 mg, 6 months
497491|NCT00420654|Other|Healthy controls|Healthy controls
497492|NCT00420641|Drug|GSK372475|GSK372475 1.0-1.5 mg/day
497493|NCT00420641|Drug|Paroxetine|Paroxetine 20-30 mg/day
497494|NCT00420641|Other|Placebo|Placebo to Match
497495|NCT00420628|Drug|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
497496|NCT00420628|Drug|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
497497|NCT00420615|Drug|Patupilone and Omeprazole|
497498|NCT00420615|Drug|Patupilone + Midalzolam|
497499|NCT00420602|Dietary Supplement|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
497500|NCT00420589|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
497501|NCT00420589|Drug|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
497502|NCT00420576|Drug|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
497503|NCT00420563|Drug|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
497504|NCT00420563|Drug|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
497505|NCT00420550|Behavioral|Relaxation Response using Guided Imagery|
497506|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 100 and 150
497507|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
497508|NCT00420537|Drug|Mycophenolate mofetil|mycophenolate with low doses
497509|NCT00420537|Drug|Everolimus|
497510|NCT00420524|Drug|Patupilone/EPO906|
497511|NCT00420511|Drug|Sitagliptin|sitagliptin 100 mg once a day
497512|NCT00420511|Drug|Placebo|placebo once a day
497513|NCT00420511|Drug|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
497514|NCT00420498|Drug|Atomoxetine (Strattera™)|
497515|NCT00420485|Drug|gimatecan|
497516|NCT00420472|Drug|mycophenolate mofetil [CellCept]|
497517|NCT00420459|Drug|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
497518|NCT00420446|Behavioral|Adjusted diet|
497519|NCT00420433|Procedure|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
497520|NCT00420433|Procedure|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
497521|NCT00420433|Procedure|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
497522|NCT00420420|Drug|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
497523|NCT00420420|Drug|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
497524|NCT00420407|Drug|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
497525|NCT00420407|Drug|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
497526|NCT00420394|Procedure|Chemotherapy|
497527|NCT00420394|Procedure|surgery|
497528|NCT00420394|Procedure|radiotherapy|
497529|NCT00420381|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
497530|NCT00420368|Dietary Supplement|No food supplement|
497531|NCT00420368|Dietary Supplement|Food supplement: fortified spread|
497532|NCT00420368|Dietary Supplement|Food supplement: maize-soy flour|
497533|NCT00420355|Drug|atazanavir|Atazanavir 300 mg daily on Days 6-12.
497534|NCT00420355|Drug|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
497535|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
497536|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
497537|NCT00420342|Drug|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
497538|NCT00420316|Biological|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
497539|NCT00420316|Biological|Placebo (primary vaccination study)|Two liquid oral doses of placebo
497540|NCT00420303|Drug|Etanercept|50 mg injection once weekly
497541|NCT00420303|Other|Placebo|placebo
497542|NCT00420290|Drug|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
497543|NCT00420290|Drug|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
497544|NCT00420277|Drug|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
497545|NCT00420277|Drug|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
497546|NCT00420264|Device|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
497547|NCT00420251|Drug|Genotropin|
497548|NCT00420238|Drug|Etanercept (Enbrel)|50 mg injection once weekly
497549|NCT00420238|Other|Placebo|placebo
497550|NCT00420225|Device|Low-weight prolypropylene mesh|
497551|NCT00420212|Drug|BG00012|
497552|NCT00420212|Drug|Placebo|
497553|NCT00420199|Drug|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
497554|NCT00420199|Drug|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
497555|NCT00420186|Drug|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
497556|NCT00420173|Procedure|Laboratory analysis|blood withdrawal
497557|NCT00420160|Behavioral|Smoking cessation treatment plus moderate intensity exercise|
497558|NCT00420160|Behavioral|Smoking cessation treatment plus health education|
497559|NCT00420147|Device|wedged inshoe orthosis|Treatment subjects were prescribed an inshoe wedged orthosis
497560|NCT00420147|Device|neutral inshoe orthosis|Control subjects were prescribed a neutral inshoe orthosis
497561|NCT00420134|Procedure|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
497562|NCT00420121|Procedure|laboratory analysis|blood withdrawal for laboratory analysis
497563|NCT00420095|Drug|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
497564|NCT00420095|Drug|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
497565|NCT00420082|Drug|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
497566|NCT00420082|Drug|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
497567|NCT00420082|Drug|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
497568|NCT00420082|Drug|Placebo|Encapsulated Placebo tablets Q.D.
497569|NCT00420069|Device|MRTX device|device for ventilation
497570|NCT00420056|Drug|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
497571|NCT00420043|Drug|imatinib|
497572|NCT00420030|Drug|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
497573|NCT00420017|Drug|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
497574|NCT00420017|Other|Control|No amiodarone
497575|NCT00420004|Drug|LY2216684|3-mg and 6-mg tablets
497576|NCT00420004|Drug|Placebo|
497577|NCT00420004|Drug|Escitalopram|10-mg capsules
497578|NCT00419991|Drug|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
497579|NCT00419978|Procedure|Colectomy|
497580|NCT00419952|Drug|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
497581|NCT00419952|Drug|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
497582|NCT00419926|Drug|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
497583|NCT00419926|Drug|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
497584|NCT00419926|Drug|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
497585|NCT00419913|Dietary Supplement|Dehydroepiandrosterone|DHEA 25 mg tid
497586|NCT00419900|Procedure|diagnosis of breast cancer by x-ray diffraction of hair|
497587|NCT00419887|Drug|Vildagliptin (LAF237)|
497588|NCT00419848|Drug|Doxycycline|Cap 100mg- 100mg/daily
497589|NCT00419848|Drug|Azithromycin|Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
497590|NCT00419835|Drug|enalapril|
497591|NCT00419835|Drug|losartan|
497592|NCT00419822|Procedure|Acupuncture|6 Acupuncture visits
497593|NCT00419822|Procedure|Sham Acupuncture|6 Acupuncture visits with sham procedure
497594|NCT00419822|Other|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
497595|NCT00419809|Drug|SB-681323 oral tablets|
497596|NCT00419796|Drug|Lumiracoxib|
497597|NCT00419783|Drug|bilastine|20 mg tablets.
497598|NCT00419783|Drug|Bilastine|100 mg (5 tablets of 20 mg)
497599|NCT00419783|Drug|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
497600|NCT00419783|Drug|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
497601|NCT00419783|Drug|Placebo|Placebo tablets
497602|NCT00419770|Drug|deferasirox|20 mg/kg enterally per day
497603|NCT00419770|Drug|Placebo|
497604|NCT00419770|Drug|Liposomal amphotericin B|
497605|NCT00419757|Drug|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
497606|NCT00419757|Drug|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
497607|NCT00419744|Drug|Budesonide/formoterol (SYMBICORT) pMDI|
497608|NCT00419744|Drug|Formoterol Turbuhaler|
497609|NCT00419731|Drug|Bupropion|"Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Placebo, 25 mg, q.d., for 7 weeks."
497610|NCT00419731|Drug|Bupropion + Naltrexone|"Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.~Naltrexone, 25 mg, q.d., for 7 weeks."
497611|NCT00419718|Drug|inhaled human insulin|
497612|NCT00419705|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
497613|NCT00419692|Drug|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
497614|NCT00419679|Procedure|x-ray diffraction of human hair|
497615|NCT00419666|Drug|Calcitriol|BID
497616|NCT00419653|Drug|Amisulpride|
497617|NCT00419653|Drug|Olanzapine|
497618|NCT00419653|Drug|Haloperidol|
497619|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
497620|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
497621|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
497622|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
497623|NCT00419601|Drug|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
497624|NCT00419601|Drug|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
497625|NCT00419562|Drug|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
497626|NCT00419549|Drug|Glyceryl - trinitrate|Transdermal Patch once only
497627|NCT00419549|Drug|Valdecoxib|Single parenteral administration
497628|NCT00419536|Drug|LBH589|
497629|NCT00419510|Behavioral|Culturally Tailored Genetic Counseling|
497630|NCT00419497|Behavioral|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
497631|NCT00419484|Drug|pioglitazone|
497632|NCT00419471|Drug|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
497633|NCT00419471|Drug|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
497634|NCT00419458|Procedure|inspiratory muscle strength training|
497635|NCT00419445|Drug|GTS21/Placebo|
497636|NCT00419432|Other|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
497637|NCT00419432|Other|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
497638|NCT00419419|Drug|Topical AmphiMatrix with nitroglycerin (MQX-503)|
497639|NCT00419406|Procedure|UVA1 phototherapy|
497640|NCT00419406|Procedure|NB-UVB phototherapy|
497641|NCT00419393|Drug|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
497642|NCT00419380|Drug|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment [dornase alfa (Pulmozyme®)]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
497643|NCT00419367|Drug|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
497644|NCT00419341|Biological|Human Normal Immunoglobulin for Subcutaneous Administration|
497645|NCT00419328|Drug|NGR-hTNF|iv q3W escalating dose up 1.6 mcg/sqm
497646|NCT00419315|Behavioral|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
497647|NCT00419315|Behavioral|Usual Care|Usual care included a referral to a specialty addiction treatment program.
497648|NCT00419302|Drug|Technosphere/Insulin|
497649|NCT00419289|Behavioral|follow-up rehabilitation of participants with COPD|
497650|NCT00419276|Procedure|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
497651|NCT00419263|Drug|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
497652|NCT00419263|Drug|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
497653|NCT00419263|Drug|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
497654|NCT00419250|Drug|lenalidomide|
497655|NCT00419250|Drug|lenalidomide|
497656|NCT00419250|Drug|lenalidomide|
497657|NCT00419250|Drug|lenalidomide|
497658|NCT00419250|Drug|lenalidomide|
497659|NCT00419237|Drug|GW685698X|GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
497660|NCT00419224|Biological|inactivated split-virus influenza vaccine|
497661|NCT00419211|Behavioral|Exercise|Tailored exercise program
497662|NCT00419198|Procedure|Postconditioning|Postconditioning during angioplasty
497663|NCT00419198|Procedure|standard angioplasty|standard angioplasty without postconditioning
497664|NCT00419185|Procedure|Delamination of the Internal limiting membrane|
497665|NCT00419172|Drug|Deferasirox|
497666|NCT00419172|Drug|Rifampicin|
497667|NCT00419159|Drug|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
497668|NCT00419146|Drug|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
497669|NCT00419146|Drug|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
497670|NCT00419146|Other|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
497671|NCT00419146|Other|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
497672|NCT00419133|Biological|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
497673|NCT00419133|Biological|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
497674|NCT00419120|Biological|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
497675|NCT00419094|Drug|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
497676|NCT00419094|Drug|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
497677|NCT00419081|Drug|Forodesine Hydrochloride Sterile Solution, 5 mg/mL|
497678|NCT00419081|Drug|Forodesine Hydrochloride Capsules (100 mg)|
497679|NCT00419068|Drug|Cholecalciferol|
497680|NCT00419068|Drug|Migliol Placebo Oil|
497681|NCT00419055|Procedure|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
497682|NCT00419042|Drug|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
497683|NCT00419042|Drug|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein—called intravenous infusion (IV). This will take about 30 minutes
497684|NCT00419029|Behavioral|telephone-administered motivational interviewing|telephone motivational interviewing
497685|NCT00419029|Behavioral|control|brief telephone check-in (no motivational interviewing)
497686|NCT00419003|Drug|Lamotrigine|anticonvulsant medication
497687|NCT00419003|Drug|Ketamine|subanesthetic dose of NMDAR antagonist
497688|NCT00419003|Drug|Riluzole|glutamate release inhibitor
497689|NCT00418990|Drug|Multivitamin/Mineral supplements|
497690|NCT00418977|Behavioral|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
497691|NCT00418977|Behavioral|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
497692|NCT00418964|Procedure|Single bundle hamstring|Single bundle hamstring
497693|NCT00418964|Procedure|Double bundle hamstring|Double bundle hamstring
497694|NCT00418964|Procedure|Bone patellar tendon bone|Bone patellar tendon bone
497695|NCT00418951|Drug|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
497696|NCT00418951|Drug|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
497697|NCT00418951|Drug|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
497698|NCT00418938|Drug|Panitumumab|6mg/kg IV
497699|NCT00418938|Drug|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
497700|NCT00418938|Drug|Leucovorin|400mg/m^2 IV (in the vein)
497701|NCT00418938|Drug|Irinotecan|180mg/m^2 IV (in the vein)
497702|NCT00418938|Drug|5-Fluorouracil|400mg/m^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m^2 thereafter if no significant side effects
497823|NCT00417898|Drug|Aspirin|
497703|NCT00418925|Drug|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
497704|NCT00418899|Behavioral|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
497705|NCT00418886|Drug|Vandetanib|oral once daily tablet
497706|NCT00418886|Drug|Pemetrexed|intravenous infusion
497707|NCT00418873|Drug|Zotepine|Oral
497708|NCT00418873|Drug|Risperidone|Oral
497709|NCT00418860|Drug|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
497710|NCT00418847|Drug|miglustat|Target dose of 320 mg/m^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA > 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
497711|NCT00418834|Drug|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
497712|NCT00418834|Drug|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
497713|NCT00418834|Drug|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
497714|NCT00418821|Biological|Aldurazyme (laronidase)|dose of 0.58mg/kg body weight intravenously (IV) every week
497715|NCT00418795|Drug|recombinant human porphobilinogen deaminase (Porphozym)|
497716|NCT00418782|Drug|naproxen|
497717|NCT00418782|Drug|CE-224535|
497718|NCT00418782|Drug|placebo|
497719|NCT00418769|Drug|Nilotinib|
497720|NCT00418756|Drug|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
497721|NCT00418730|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
497722|NCT00418717|Drug|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
497723|NCT00418704|Drug|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
497724|NCT00418704|Drug|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
497725|NCT00418691|Drug|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
497726|NCT00418691|Drug|Modafinil|200 mg PO Once Daily x 4 Weeks
497727|NCT00418691|Drug|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
497728|NCT00418678|Drug|Cesamet|2 mg BID on Days 2-5.
497729|NCT00418665|Biological|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
497730|NCT00418665|Drug|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
497731|NCT00418652|Device|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
497732|NCT00418652|Device|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
497733|NCT00418652|Device|TMS over the vertex|10Hz TMS for over vertex.
497734|NCT00418639|Drug|Nitazoxanide|
497735|NCT00418626|Drug|Nilotinib|
497736|NCT00418613|Drug|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
497737|NCT00418613|Drug|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
497738|NCT00418600|Drug|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
497739|NCT00418600|Drug|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
497740|NCT00418600|Drug|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
497741|NCT00418587|Drug|Cholecalciferol|800 IU oral daily
497742|NCT00418587|Drug|Cholecalciferol|2000 IU oral daily
497743|NCT00418587|Drug|Cholecalciferol|4000 IU oral daily
497744|NCT00418574|Biological|Abagovomab|2 mg/ml SC (subcutaneously)
497745|NCT00418574|Biological|Placebo|2 mg/ml SC (subcutaneously)
497746|NCT00418561|Drug|rhASA|intravenous infusion 25 U/kg,50 U/kg, 100U/kg or 200 U/kg every other week for 26 weeks
497747|NCT00418548|Drug|Etanercept|
497748|NCT00418535|Drug|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
497749|NCT00418522|Drug|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
497750|NCT00418522|Drug|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
497751|NCT00418509|Drug|Mometasone furoate|
497752|NCT00418509|Drug|Formoterol fumarate|
497753|NCT00418496|Drug|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
497754|NCT00418496|Drug|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
497755|NCT00418483|Biological|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
497756|NCT00418483|Biological|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
497757|NCT00418483|Biological|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
497758|NCT00418483|Biological|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
497759|NCT00418483|Biological|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
497760|NCT00418483|Biological|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
497761|NCT00418483|Biological|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
497762|NCT00418470|Procedure|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
497763|NCT00418470|Procedure|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
497764|NCT00418457|Drug|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
497765|NCT00418457|Drug|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
497766|NCT00418444|Behavioral|Group Therapy Intervention|
497767|NCT00418431|Drug|Intravitreal injection of Bevacizumab|
497768|NCT00418418|Procedure|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
497769|NCT00418418|Procedure|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
497770|NCT00418418|Biological|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
497771|NCT00418418|Biological|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
497772|NCT00418392|Procedure|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
497773|NCT00418392|Procedure|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
497774|NCT00418379|Drug|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
497775|NCT00418379|Drug|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
497776|NCT00418379|Drug|Placebo|Placebo tablet
497777|NCT00418366|Drug|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
497778|NCT00418353|Drug|Betamethasone(Celestone soluspan) and Dexamethasone|
497779|NCT00418340|Drug|probiotic (bacterial/dietary supplement)|
497780|NCT00418327|Drug|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
497781|NCT00418314|Device|Control|Empiric programming or one-time optimization using a non-IEGM method.
497782|NCT00418314|Device|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
497783|NCT00418301|Other|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
497784|NCT00418288|Drug|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
497785|NCT00418288|Drug|placebo|intravenous infusion of 1.2pmol/kg/min
497786|NCT00418275|Genetic|Recombinant Human Plasminogen Activator (HTUPA)|
497787|NCT00418262|Drug|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
497788|NCT00418249|Drug|AS101|
497789|NCT00418210|Radiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
497790|NCT00418197|Device|Total Facet Arthroplasty System® (TFAS®)|
497791|NCT00418184|Dietary Supplement|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
497792|NCT00418184|Other|Colored cellulose tainted with fishy odor|as arm 1
497793|NCT00418171|Drug|Ziprasidone|
497794|NCT00418171|Drug|Olanzapine|
497795|NCT00418158|Behavioral|use of Airlife (therapy)|
497796|NCT00418145|Drug|megadose oral methylprednisolone|1400 mg qd/5 days
497797|NCT00418145|Drug|IV methylprednisolone|1000 mg/qd/5 days
497798|NCT00418132|Drug|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
497799|NCT00418132|Drug|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
497800|NCT00418119|Drug|erythropoietin|
497801|NCT00418093|Drug|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
497802|NCT00418093|Drug|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
497803|NCT00418093|Drug|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
497804|NCT00418080|Drug|bicalutamide|
497805|NCT00418067|Device|Endeavor|Zotarolimus-eluting stent
497806|NCT00418067|Device|Cypher|Sirolimus-eluting stent
497807|NCT00418067|Device|Taxus Liberte|Paclitaxel-eluting stent
497808|NCT00418054|Drug|Nitazoxanide plus peginterferon alfa-2b|
497809|NCT00418054|Drug|Peginterferon alfa-2b|
497810|NCT00418028|Drug|Capecitabine|
497811|NCT00418015|Procedure|Blood Draw|Blood for OPRM1 analysis
497812|NCT00418002|Drug|AQW051|
497813|NCT00417989|Device|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
497814|NCT00417976|Drug|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
497815|NCT00417976|Drug|Bevacizumab|10 mg/kg every 2 weeks.
497816|NCT00417976|Drug|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
497817|NCT00417963|Device|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
497818|NCT00417950|Drug|Acarbose|
497819|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
497820|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
497821|NCT00417924|Behavioral|Patient education|
497822|NCT00417911|Drug|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
497824|NCT00417885|Drug|exemestane|25 mg, oral, daily dosing
497825|NCT00417885|Drug|sunitinib malate|37.5 mg, oral, continuous dosing, daily
497826|NCT00417872|Drug|Nitazoxanide|
497827|NCT00417872|Drug|Metronidazole|
497828|NCT00417859|Device|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
497829|NCT00417833|Drug|Intravitreal Bevacizumab|
497830|NCT00417820|Drug|BCT194|
497831|NCT00417807|Drug|Imatinib mesilate|
497832|NCT00417794|Drug|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
497833|NCT00417794|Drug|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
497834|NCT00417768|Drug|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
497835|NCT00417768|Other|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
497836|NCT00417742|Behavioral|Service delivery through a Headache Management Program|
497837|NCT00417729|Drug|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
497838|NCT00417716|Drug|Intravitreal Bevacizumab|
497839|NCT00417690|Drug|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
497840|NCT00417690|Drug|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
497841|NCT00417677|Drug|Combination of Temsirolimus and Sunitinib|
497842|NCT00417664|Drug|dexmedetomidine|
497843|NCT00417664|Drug|midazolam|
497844|NCT00417664|Drug|propofol|
497845|NCT00417638|Device|Endovascular cooling by the Celsius Control System|
497846|NCT00417638|Other|Standard of care|
497847|NCT00417612|Drug|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
497848|NCT00417612|Other|Placebo|Placebo sugar pill
497849|NCT00417599|Behavioral|Lifestyle Intervention|lifestyle intervention .
497850|NCT00417599|Other|control group|waiting list control group
497851|NCT00417586|Device|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
497852|NCT00417573|Drug|IV Gamunex 10%|
497853|NCT00417560|Biological|inactivated influenza A/H5N1 vaccine|
497854|NCT00417521|Behavioral|Family-Based Treatment|
497855|NCT00417508|Dietary Supplement|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
497856|NCT00417508|Dietary Supplement|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
497857|NCT00417495|Behavioral|Sentinel Lymph Node Technique|
497858|NCT00417482|Drug|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
497859|NCT00417469|Device|NADGL|
497860|NCT00417456|Other|Evisit|Asynchronous,remote care delivery via a secure web platform
497861|NCT00417456|Other|Office visit|Conventional office-based care
497862|NCT00417443|Drug|Clonidine|
497863|NCT00417430|Drug|ICI 182,780 (Faslodex)|
497864|NCT00417417|Drug|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
497865|NCT00417417|Drug|Placebo|Normal saline subcutaneously at each treatment visit.
497866|NCT00417404|Drug|Aquasol A|IM Aquasol A 10,000IU three times weekly
497867|NCT00417404|Drug|aquasol A|10,000 IU three times weeks, by intramuscular injection
497868|NCT00417404|Other|sham injection|sham injection
497869|NCT00417391|Drug|RR110 (Tamibarotene)|1 mg RR110
497870|NCT00417391|Drug|RR110 (Tamibarotene)|4 mg RR110
497871|NCT00417378|Device|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
497872|NCT00417378|Device|Intraaortic Balloon Pump|Counterpulsation
497873|NCT00417365|Device|WaterWorks Douching Device|
497874|NCT00417352|Device|Brace|
497875|NCT00417352|Device|Added mass|
497876|NCT00417339|Procedure|hemodialysis|individualised
497877|NCT00417326|Drug|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
497878|NCT00417326|Drug|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
497879|NCT00417313|Device|periosteal electro-acupuncture (osteopuncture).|
497880|NCT00417287|Drug|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
497881|NCT00417274|Drug|Quinacrine|100 mg daily
497882|NCT00417261|Drug|ATF936|
497883|NCT00417261|Drug|AXT914|
497884|NCT00417248|Drug|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
497885|NCT00417248|Drug|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
497886|NCT00417248|Procedure|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
497887|NCT00417248|Drug|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
498033|NCT00416598|Drug|Etoposide|Given IV
497888|NCT00417235|Device|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
497889|NCT00417235|Behavioral|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
497890|NCT00417222|Drug|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
497891|NCT00417209|Drug|Larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
497892|NCT00417209|Drug|5-Fluorouracil|administered as IV infusion from Day 1 to Day 4
497893|NCT00417209|Drug|Capecitabine|administered orally from Day 1 to Day 14 q3w
497894|NCT00417196|Drug|QAX576|
497895|NCT00417183|Drug|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
497896|NCT00417183|Drug|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
497897|NCT00417170|Drug|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
497898|NCT00417170|Drug|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
497899|NCT00417170|Drug|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
497900|NCT00417170|Drug|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
497901|NCT00417157|Drug|recombinant FSH (Puregon, Organon, The Netherlands)|
497902|NCT00417157|Drug|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
497903|NCT00417157|Drug|hCG (Pregnyl, Organon, The Netherlands)|
497904|NCT00417144|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
497905|NCT00417144|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
497906|NCT00417118|Drug|Saredutant|oral administration (capsules)
497907|NCT00417118|Drug|Escitalopram|oral administration (capsules)
497908|NCT00417118|Drug|Placebo|oral administration (capsules)
497909|NCT00417105|Procedure|hemodialysis|group 1: twice weekly, four hours
497910|NCT00417105|Procedure|hemodialysis|group 2: twice weekly, eight hours
497911|NCT00417105|Procedure|hemodialysis|group 3: every other day, eight hours
497912|NCT00417105|Procedure|hemodialysis|group 4: six days a week, eight hours
497913|NCT00417092|Procedure|Postoperative Pacing|
497914|NCT00417079|Drug|cabazitaxel (XRP6258) (RPR116258)|25 mg/m^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
497915|NCT00417079|Drug|mitoxantrone|12 mg/m^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
497916|NCT00417079|Drug|prednisone|10 mg daily administered by oral route
497917|NCT00417066|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
497918|NCT00417066|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
497919|NCT00417053|Biological|filgrastim|
497920|NCT00417053|Drug|busulfan|
497921|NCT00417053|Drug|carboplatin|
497922|NCT00417053|Drug|cyclophosphamide|
497923|NCT00417053|Drug|doxorubicin hydrochloride|
497924|NCT00417053|Drug|etoposide phosphate|
497925|NCT00417053|Drug|melphalan|
497926|NCT00417053|Drug|vincristine sulfate|
497927|NCT00417053|Procedure|autologous bone marrow transplantation|
497928|NCT00417053|Procedure|bone marrow ablation with stem cell support|
497929|NCT00417053|Procedure|conventional surgery|
497930|NCT00417053|Procedure|peripheral blood stem cell transplantation|
497931|NCT00417053|Radiation|radiation therapy|
497932|NCT00417040|Other|internet-based intervention|Use the STAR database system
497933|NCT00417040|Other|assessment of therapy complications|Use the STAR database system
497934|NCT00417040|Other|Questionnaire Administration|Ancillary studies
497935|NCT00417027|Procedure|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
497936|NCT00417014|Drug|chlorambucil|
497937|NCT00417014|Drug|prednisolone|
497938|NCT00417014|Drug|procarbazine hydrochloride|
497939|NCT00417014|Drug|vinblastine sulfate|
497940|NCT00417014|Radiation|radiation therapy|
497941|NCT00417001|Procedure|Aroma therapy|
497942|NCT00416988|Other|educational intervention|
497943|NCT00416975|Other|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
497944|NCT00416975|Other|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
498034|NCT00416598|Biological|Filgrastim|Given SC
498035|NCT00416598|Other|Laboratory Biomarker Analysis|Correlative studies
498036|NCT00416598|Other|Pharmacological Study|Correlative studies
498037|NCT00416585|Drug|isotretinoin (Roaccutane)|
498095|NCT00416221|Drug|Lexapro, an antidepressant medicine|
498096|NCT00416221|Behavioral|Physical Activity|
525600|NCT00191503|Drug|Pemetrexed|
497945|NCT00416975|Procedure|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
497946|NCT00416962|Drug|amantadine hydrochloride|
497947|NCT00416962|Drug|oseltamivir phosphate|
497948|NCT00416949|Device|Patient-specific dosimetry|Patient-specific 3D-RD dosimetry was applied to the data collected
497949|NCT00416923|Biological|rituximab|
497950|NCT00416910|Biological|Filgrastim|
497951|NCT00416910|Drug|Fludarabine|
497952|NCT00416910|Drug|Cyclophosphamide|
497953|NCT00416910|Drug|Mitoxantrone|
497954|NCT00416897|Drug|chemotherapy|
497955|NCT00416897|Drug|dexamethasone|
497956|NCT00416897|Procedure|plasmapheresis|
497957|NCT00416884|Drug|Campath|30 mg on day -8 over 5-6 hours
497958|NCT00416884|Drug|Fludarabine|Fludarabine 30 mg/m^2 on day -4 through day -2
497959|NCT00416884|Radiation|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
497960|NCT00416884|Other|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
497961|NCT00416871|Biological|aldesleukin|
497962|NCT00416871|Biological|recombinant interferon alfa|
497963|NCT00416858|Drug|cisplatin|
497964|NCT00416858|Drug|fluorouracil|
497965|NCT00416858|Procedure|adjuvant therapy|
497966|NCT00416858|Procedure|conventional surgery|
497967|NCT00416858|Procedure|neoadjuvant therapy|
497968|NCT00416858|Radiation|radiation therapy|
497969|NCT00416845|Drug|FTY720|
497970|NCT00416832|Drug|cyclophosphamide|
497971|NCT00416832|Drug|dacarbazine|
497972|NCT00416832|Drug|doxorubicin hydrochloride|
497973|NCT00416832|Drug|etoposide|
497974|NCT00416832|Drug|prednisone|
497975|NCT00416832|Drug|procarbazine hydrochloride|
497976|NCT00416832|Drug|vincristine sulfate|
497977|NCT00416832|Radiation|radiation therapy|
497978|NCT00416819|Biological|filgrastim|
497979|NCT00416819|Biological|rituximab|
497980|NCT00416819|Drug|cytarabine|
497981|NCT00416819|Drug|etoposide phosphate|
497982|NCT00416819|Drug|leucovorin calcium|
497983|NCT00416819|Drug|methotrexate|
497984|NCT00416819|Drug|temozolomide|
497985|NCT00416793|Drug|bortezomib|Given IV
497986|NCT00416793|Drug|carboplatin|Given IV
497987|NCT00416793|Other|laboratory biomarker analysis|Correlative studies
497988|NCT00416780|Other|counseling intervention|
497989|NCT00416780|Other|educational intervention|
497990|NCT00416780|Procedure|psychosocial assessment and care|
497991|NCT00416767|Drug|fluorouracil|
497992|NCT00416767|Drug|irinotecan hydrochloride|
497993|NCT00416767|Drug|leucovorin calcium|
497994|NCT00416754|Other|counseling intervention|subjects will receive genetic counseling
497995|NCT00416741|Behavioral|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting [plasma flucose
497996|NCT00416728|Drug|Aliskiren|
497997|NCT00416728|Drug|Valsartan|
497998|NCT00416715|Drug|letrozole|Given PO
497999|NCT00416715|Dietary Supplement|calcium carbonate|Given PO
498000|NCT00416715|Other|laboratory biomarker analysis|Optional correlative studies
498001|NCT00416715|Dietary Supplement|calcium citrate|Given PO
498002|NCT00416715|Dietary Supplement|calcium glucarate|Given PO
498003|NCT00416715|Drug|calcium gluconate|Given PO
498004|NCT00416715|Dietary Supplement|cholecalciferol|Given PO
498005|NCT00416715|Procedure|assessment of therapy complications|Ancillary studies
498006|NCT00416715|Procedure|musculoskeletal complications management/prevention|Correlative studies
498007|NCT00416702|Drug|QAB149|
498008|NCT00416689|Procedure|assessment of therapy complications|
498009|NCT00416689|Procedure|quality-of-life assessment|
498010|NCT00416676|Drug|carboplatin|
498011|NCT00416676|Drug|cisplatin|
498012|NCT00416676|Drug|cyclophosphamide|
498013|NCT00416676|Drug|etoposide|
498014|NCT00416676|Drug|vincristine sulfate|
498015|NCT00416676|Procedure|adjuvant therapy|
498016|NCT00416676|Procedure|conventional surgery|
498017|NCT00416676|Procedure|neoadjuvant therapy|
498018|NCT00416676|Radiation|radiation therapy|
498019|NCT00416663|Procedure|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
498020|NCT00416650|Drug|erlotinib hydrochloride|All patients will receive 150 mg orally daily
498021|NCT00416637|Biological|Bevacizumab (Avastin)|
498022|NCT00416624|Drug|darbepoetin alfa|
498023|NCT00416624|Drug|epoetin alfa|
498024|NCT00416624|Procedure|fatigue assessment and management|
498025|NCT00416624|Procedure|quality-of-life assessment|
498026|NCT00416611|Behavioral|Implementation of guidelines|
498027|NCT00416598|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
498028|NCT00416598|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
498029|NCT00416598|Drug|Busulfan|Given IV
498030|NCT00416598|Drug|Cytarabine|Given IV
498031|NCT00416598|Drug|Daunorubicin Hydrochloride|Given IV
498032|NCT00416598|Drug|Decitabine|Given IV
498038|NCT00416572|Behavioral|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
498039|NCT00416572|Behavioral|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
498040|NCT00416559|Other|clinical observation|
498041|NCT00416546|Drug|AEB071|
498042|NCT00416533|Drug|docetaxel|
498043|NCT00416533|Drug|doxorubicin hydrochloride|
498044|NCT00416533|Drug|prednisone|
498045|NCT00416520|Drug|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
498046|NCT00416520|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
498047|NCT00416520|Drug|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
498048|NCT00416507|Drug|fluorouracil|
498049|NCT00416507|Drug|gemcitabine hydrochloride|
498050|NCT00416507|Drug|liposomal cisplatin|
498051|NCT00416494|Biological|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
498052|NCT00416494|Drug|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
498053|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
498054|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
498055|NCT00416481|Behavioral|quality of life questionnaires|
498056|NCT00416468|Drug|Aliskiren|
498057|NCT00416468|Drug|Valsartan|
498058|NCT00416455|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
498059|NCT00416455|Procedure|positron emission tomography|Undergo FDG PET/CT
498060|NCT00416455|Procedure|computed tomography|Undergo FDG PET/CT
498061|NCT00416455|Drug|ferumoxtran-10|Undergo femoxtran-10 MRI
498062|NCT00416455|Procedure|magnetic resonance imaging|Undergo femoxtran-10 MRI
498063|NCT00416455|Procedure|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
498064|NCT00416455|Procedure|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
498065|NCT00416442|Drug|RSV604|
498066|NCT00416429|Biological|aldesleukin|
498067|NCT00416429|Biological|recombinant interferon alpha-2a|
498068|NCT00416429|Drug|medroxyprogesterone|
498069|NCT00416403|Drug|fluvastatin sodium|Given orally
498070|NCT00416403|Procedure|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
498071|NCT00416390|Dietary Supplement|lycopene|
498072|NCT00416390|Other|laboratory biomarker analysis|
498073|NCT00416390|Procedure|biopsy|
498074|NCT00416377|Biological|bleomycin sulfate|
498075|NCT00416377|Drug|chlorambucil|
498076|NCT00416377|Drug|dacarbazine|
498077|NCT00416377|Drug|doxorubicin hydrochloride|
498078|NCT00416377|Drug|prednisolone|
498079|NCT00416377|Drug|procarbazine hydrochloride|
498080|NCT00416377|Drug|vinblastine sulfate|
498081|NCT00416377|Drug|vincristine sulfate|
498082|NCT00416377|Radiation|radiation therapy|
498083|NCT00416351|Drug|clofarabine|
498084|NCT00416338|Device|film dressing by adhesive|
498085|NCT00416325|Dietary Supplement|lycopene|
498086|NCT00416325|Other|laboratory biomarker analysis|
498087|NCT00416312|Device|Patient-specific dosimetry|"Tumor absorbed dose calculation using patient-specific 3D-RD dosimetry software.~Patients receive dosimetric tositumomab IV over 60 minutes followed by iodine I 131 (^131I) tositumomab IV over 20 minutes on day 0. Patients undergo PET/CT scans and SPECT/CT scans on days 0; 2, 3 or 4; and 6 or 7. Patients who have acceptable biodistribution receive therapeutic tositumomab IV over 60 minutes followed by ^131I tositumomab IV over 20 minutes on approximately day 7."
498088|NCT00416312|Device|conventional dosimetry|"Doses calculated using conventional dosimetry software.~Patients receive dosimetric rituximab IV followed by indium In 111 (^111In) ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo positron emission tomography (PET)/CT scans and single-photon emission computed tomography (SPECT)/CT scans between 2-24, 48-72, and 90-120 hours after ^111In ibritumomab tiuxetan administration. Patients who have acceptable biodistribution receive therapeutic rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes between days 7-9."
498089|NCT00416273|Drug|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
498090|NCT00416273|Drug|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
498091|NCT00416260|Other|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
498092|NCT00416247|Behavioral|Hypnosis|Hypnosis
498093|NCT00416234|Procedure|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
498094|NCT00416234|Procedure|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
498097|NCT00416221|Behavioral|Mood Management Skills|
498098|NCT00416221|Behavioral|Personalized support from a Family Nurse Practitioner|
498099|NCT00416208|Drug|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
498100|NCT00416195|Drug|E2007|
498101|NCT00416195|Drug|Placebo|
498102|NCT00416182|Drug|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
498103|NCT00416182|Drug|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
498104|NCT00416169|Drug|galantamine hydrobromide|
498105|NCT00416156|Behavioral|Lifestyle modification|
498106|NCT00416143|Procedure|bed rest|
498107|NCT00416143|Drug|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
498108|NCT00416130|Drug|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
498109|NCT00416117|Procedure|Manual Physical Therapy and Exercise|
498110|NCT00416117|Procedure|Minimal Intervention|
498111|NCT00416078|Behavioral|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
498112|NCT00416078|Behavioral|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
498113|NCT00416065|Device|PET/CT imaging|
498114|NCT00416039|Drug|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
498115|NCT00416039|Drug|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
498116|NCT00416026|Behavioral|Educational/Counseling/Training|
498117|NCT00415987|Procedure|Hematopoietic Stem Cell Transplantation|
498118|NCT00415974|Behavioral|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
498119|NCT00415974|Behavioral|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
498120|NCT00415974|Behavioral|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
498121|NCT00415974|Behavioral|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
498122|NCT00415961|Device|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
498123|NCT00415948|Device|Biomarkers|
498124|NCT00415935|Drug|methotrexate|
498125|NCT00415922|Drug|ELC200 (carbidopa+levodopa+entacapone)|
498126|NCT00415909|Drug|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
498127|NCT00415909|Drug|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
498128|NCT00415896|Device|positive pressure ventilation|
498129|NCT00415883|Drug|Valsartan|
498130|NCT00415870|Behavioral|Printed Material|Printed Material
498131|NCT00415870|Behavioral|Weekly Weighing|Weekly Weighing
498132|NCT00415870|Behavioral|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
498133|NCT00415870|Device|Text Message|Text Message
498134|NCT00415870|Behavioral|Diet Goals via Cell Phone|Diet Goals via Cell Phone
498135|NCT00415870|Behavioral|Food Monitoring|Food Monitoring
498136|NCT00415857|Biological|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
498137|NCT00415857|Drug|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
498588|NCT00412152|Drug|Oxycodone nalaxone prolonged release tablets (OXN)|
498138|NCT00415857|Drug|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
498139|NCT00415857|Drug|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
498140|NCT00415844|Drug|ELC200 (carbidopa+levodopa+entacapone)|
498141|NCT00415831|Drug|ELC200 (carbidopa+levodopa+entacapone)|
498142|NCT00415818|Biological|MVA-MUC1-IL2|"MVA-MUC1-IL2:~Dose of 10exp8 plaque forming units (pfu).~Chemotherapy:~Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
498143|NCT00415818|Drug|1st line Chemotherapy|
498144|NCT00415805|Drug|Multihance|0.5 Molar, single injection at 0.2 mL/kg
498145|NCT00415805|Drug|vasovist|0.25 molar single injection 0.03 ml/kg
498146|NCT00415792|Drug|Arvekap, Pregnyl|
498147|NCT00415779|Drug|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
498148|NCT00415779|Drug|zoledronic acid|2 mg IV every 2 weeks
498149|NCT00415766|Drug|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
498150|NCT00415766|Drug|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
498151|NCT00415766|Drug|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
498152|NCT00415753|Behavioral|No antibiotics if se-procalcitonin is below stated limit|
498153|NCT00415740|Drug|ELC200 (carbidopa+levodopa+entacapone)|
498154|NCT00415727|Device|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
498155|NCT00415714|Device|Portable Biofeedback|
498156|NCT00415701|Drug|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
498157|NCT00415701|Drug|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
498158|NCT00415701|Drug|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
498159|NCT00415701|Drug|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
498160|NCT00415701|Other|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
498161|NCT00415688|Behavioral|Low carbohydrate, ketogenic diet|
498162|NCT00415688|Behavioral|Low glycemic index, reduced calorie diet|
498163|NCT00415675|Procedure|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
498164|NCT00415662|Device|Pulsed Signal Therapy (PST)|
498165|NCT00415649|Biological|VRC-HIVDNA016-00-VP|
498166|NCT00415649|Biological|VRC-HIVADV014-00-VP|
498167|NCT00415649|Biological|Vaccine placebo|Placebo comparator
498168|NCT00415636|Drug|IC83/LY2603618|40 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles. Dose finding study: dose is escalated after a minimum of 6 participants receive 40 mg/m^2.
498169|NCT00415636|Drug|IC83/LY2603618|70 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
498170|NCT00415636|Drug|IC83/LY2603618|105 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
498171|NCT00415636|Drug|IC83/LY2603618|150 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
498172|NCT00415636|Drug|IC83/LY2603618|195 mg/m^2 Day 1 and Day 9 of Cycle 1, Day 2 of subsequent cycles, unlimited 21-day cycles.
498173|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2, intravenous (IV), Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
498174|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m^2 IV, Day 8 of Cycle 1, Day 1 of subsequent cycles, unlimited 21-day cycles
498175|NCT00415623|Drug|Amlodipine|Amlodipine 5mg/ day
498176|NCT00415623|Drug|Amlodipine|Amlodipine 10mg/ day
498177|NCT00415610|Drug|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~Started at 5mg/h~Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour *Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
498178|NCT00415597|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
498179|NCT00415584|Drug|Cinacalcet HCl|
498180|NCT00415571|Drug|Fispemifene (once daily for 8 weeks)|
498181|NCT00415558|Device|Microwave Ablation System|
498182|NCT00415545|Behavioral|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
498183|NCT00415545|Behavioral|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
498184|NCT00415532|Drug|Medical Standard of Care for ITP|
498185|NCT00415532|Biological|Romiplostim|
498186|NCT00415519|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
498187|NCT00415519|Drug|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
498188|NCT00415506|Drug|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
498189|NCT00415493|Other|Cold-dry air provocation|15 minute exposure to cold-dry air by nasal mask
498190|NCT00415493|Other|Warm-moist air provocation|15 minute exposure to warm-moist air by nasal mask
498191|NCT00415467|Device|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
498192|NCT00415454|Genetic|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
498193|NCT00415441|Procedure|Physiotherapy program|
498194|NCT00415441|Procedure|Placebo physiotherapy treatment|
498195|NCT00415428|Behavioral|Patient adherence to national educational guidelines.|
498196|NCT00415402|Drug|Vitamin D3|
498197|NCT00415389|Behavioral|interactive educational program|2-session interactive stroke educational program
498198|NCT00415389|Behavioral|usual medical care|standard educational materials and usual care
498199|NCT00415376|Drug|levetiracetam|
498200|NCT00415376|Procedure|quality-of-life assessment|
498201|NCT00415363|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
498202|NCT00415363|Drug|placebo|oral, daily
498203|NCT00415350|Drug|Azithromycin|Azithromycin Tablet 250 mg daily
498204|NCT00415350|Other|Placebo|Placebo tablet 1 daily
498205|NCT00415337|Procedure|endobronchial ultrasound|EBUS
498206|NCT00415324|Drug|eribulin mesylate|Given IV
498207|NCT00415324|Drug|cisplatin|Given IV
498208|NCT00415324|Other|laboratory biomarker analysis|correlative study
498209|NCT00415324|Other|pharmacological study|correlative study
498210|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
498211|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
498212|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
498213|NCT00415298|Drug|DACH polymer platinate AP5346|
498214|NCT00415298|Drug|oxaliplatin|
498215|NCT00415298|Genetic|gene expression analysis|
498216|NCT00415298|Other|immunohistochemistry staining method|
498217|NCT00415298|Other|pharmacological study|
498218|NCT00415298|Procedure|biopsy|
498219|NCT00415285|Drug|Docetaxel|
498220|NCT00415285|Drug|Capecitabine|
498221|NCT00415285|Drug|Docetaxel/Capecitabine|
498222|NCT00415272|Behavioral|Pulmonary Rehabilitation|
498223|NCT00415259|Device|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
498224|NCT00415259|Device|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
498225|NCT00415246|Drug|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
498226|NCT00415233|Biological|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
498227|NCT00415233|Radiation|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
498228|NCT00415220|Procedure|Spinal Manipulation, Microdiscectomy|
498229|NCT00415194|Drug|pemetrexed|500 mg/m^2, IV, every 21 days, six 21 day cycles
498230|NCT00415194|Drug|cisplatin|75 mg/m^2, administered IV, every 21 days, six 21 day cycles
498231|NCT00415194|Drug|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
498232|NCT00415168|Drug|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
498233|NCT00415168|Drug|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
498234|NCT00415155|Drug|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)~Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
498235|NCT00415142|Drug|saredutant (SR48968)|oral administration (capsules)
498236|NCT00415142|Drug|placebo|oral administration (capsules)
498237|NCT00415142|Drug|escitalopram|oral administration (capsules)
498238|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
498239|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
498240|NCT00415116|Drug|carboplatin|
498241|NCT00415116|Drug|docetaxel|
498242|NCT00415116|Drug|lenalidomide|
498243|NCT00415103|Drug|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
498244|NCT00415103|Drug|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
498245|NCT00415103|Drug|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
498246|NCT00415090|Drug|Nevirapine|Switch one of ARV drugs to Nevirapine
498247|NCT00415077|Procedure|PRK|PRK
498248|NCT00415077|Procedure|MMC PRK|mitomycin C PRK
498249|NCT00415077|Procedure|LASEK|LASEK
498250|NCT00415064|Drug|Perifosine|Perifosine given in either 50 mg or 100 mg / day
498251|NCT00415064|Drug|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
498252|NCT00415064|Drug|Dexamethasone|Dexamethasone given in 20 mg / day
498253|NCT00415051|Biological|RVF MP-12|Administer 1 ml SQ
498254|NCT00415038|Drug|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
498255|NCT00415038|Drug|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
498256|NCT00415038|Drug|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
498257|NCT00415038|Drug|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
498258|NCT00415038|Drug|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
498259|NCT00415025|Procedure|adjuvant therapy|
498260|NCT00415025|Procedure|management of therapy complications|
498261|NCT00415025|Procedure|quality-of-life assessment|
498262|NCT00415025|Radiation|intensity-modulated radiation therapy|
498263|NCT00414999|Drug|TG100801|
498264|NCT00414986|Behavioral|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
498265|NCT00414986|Behavioral|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
498266|NCT00414986|Behavioral|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
498267|NCT00414973|Drug|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
498268|NCT00414973|Drug|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
498269|NCT00414960|Drug|enzastaurin|500 mg, daily, oral, 6 months
498270|NCT00414960|Drug|placebo|oral, daily
498271|NCT00414947|Drug|Vildagliptin (LAF237)|
498272|NCT00414921|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
498273|NCT00414921|Drug|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
498274|NCT00414921|Other|placebo|inactive substance
498275|NCT00414908|Drug|Pancrelipase delayed release capsule|24,000 unit capsule
498276|NCT00414908|Drug|Placebo Comparator|Placebo
498277|NCT00414869|Drug|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
498278|NCT00414869|Drug|Placebo|Inactive powder matching NCX-1000
498279|NCT00414856|Drug|AFQ056|
498280|NCT00414817|Behavioral|Automated Phone-Based Refill Reminders|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
498281|NCT00414804|Device|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
498282|NCT00414804|Procedure|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
498283|NCT00414778|Drug|LHT344|
498284|NCT00414765|Drug|Aldesleukin|
498285|NCT00414752|Drug|AFQ065|
498286|NCT00414739|Drug|Benzalkonium chloride|
498287|NCT00414726|Drug|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
498288|NCT00414726|Drug|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
498289|NCT00414713|Procedure|red blood cell transfusion|red blood cell transfusion
498290|NCT00414700|Drug|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.~The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
498291|NCT00414700|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
498292|NCT00414687|Drug|Ventavis (Iloprost, BAYQ6256)|
498293|NCT00414661|Drug|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
498294|NCT00414648|Drug|Sirolimus|A sirolimus dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
498295|NCT00414648|Drug|Placebo sirolimus|A placebo dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
498296|NCT00414635|Drug|Intermitent Dosing|"Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. ."
498297|NCT00414622|Drug|DMXB-A|
498298|NCT00414609|Drug|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
498299|NCT00414609|Drug|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
498300|NCT00414596|Device|DRX9000™|Device is designed to apply spinal decompressive forces.
498301|NCT00414583|Other|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
498302|NCT00414570|Drug|[18]F-FLT PET scan|Injection of [18]F-FLT radiopharmaceutical followed by PET imaging.
498303|NCT00414557|Procedure|Quadriceps strengthening|
498304|NCT00414544|Device|CosmetaLife|Dermal filler
498305|NCT00414544|Device|Restylane|Dermal filler
498306|NCT00414531|Drug|Atorvastatin|20 to 80 mg per day
498307|NCT00414518|Drug|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
498308|NCT00414518|Drug|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
498309|NCT00414505|Device|Intradermal Acupuncture Treatment|
498310|NCT00414479|Drug|praziquantl, iron, ACT|
498311|NCT00414466|Drug|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
498312|NCT00414453|Drug|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
498313|NCT00414453|Drug|Extended-release oxycodone|extended-release oxycodone titrating schedule
498314|NCT00414453|Drug|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
498315|NCT00414453|Drug|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
498316|NCT00414440|Drug|Placebo|placebo comparator
498317|NCT00414440|Drug|Everolimus|experimental
498318|NCT00414427|Procedure|Intraarticular steroids|
498319|NCT00414414|Drug|Prednisone|
498320|NCT00414414|Drug|placebo|placebo
498321|NCT00414401|Behavioral|Clinical Reminder|
498322|NCT00414388|Drug|Sorafenib|400mg twice daily
498323|NCT00414375|Procedure|Operation on Admission|Laparoscopic appendectomy on admission
498324|NCT00414375|Procedure|Drainage and Interval Appendectomy|drainage with interval appendectomy
498325|NCT00414349|Drug|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
498326|NCT00414349|Drug|oral intake|300 to 600 mg per day taken orally
498327|NCT00414349|Drug|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
498328|NCT00414336|Drug|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
498329|NCT00414323|Drug|Duloxetine|
498330|NCT00414323|Drug|Escitalopram|
498331|NCT00414323|Drug|Placebo|
498332|NCT00414310|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days.
498333|NCT00414310|Drug|Valproic Acid|50 mg/kg orally daily for 7 days
498334|NCT00414297|Device|ECP Therapy|application of ECP Therapy to CAD Patients
498335|NCT00414284|Drug|Increased dose of Kaletra|
498336|NCT00414271|Drug|Docetaxel|Docetaxel 60 mg/m2 IV on day 1
498337|NCT00414271|Drug|Capecitabine|Capecitabine 900 mg/m2 PO two times per day from day 1 to day 14 every 3 weeks for 2 cycles.
498338|NCT00414258|Procedure|breastfeeding|See detailed description.
498339|NCT00414245|Drug|metformin|
498340|NCT00414219|Behavioral|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
498341|NCT00414206|Drug|Mecamylamine|
498342|NCT00414206|Drug|Placebo|
498343|NCT00414180|Drug|Bupropion SR|
498344|NCT00414167|Drug|bupropion|300 mg per day for 8 weeks
498345|NCT00414167|Other|Placebo|Placebo
498346|NCT00414154|Behavioral|Group based multidisciplinary patient education programme|
498347|NCT00414141|Biological|Grass MATA MPL|4 subcutaneous injections
498348|NCT00414141|Biological|Placebo|4 subcutaneous injections
498349|NCT00414128|Drug|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
498350|NCT00414128|Drug|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
498351|NCT00414102|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
498352|NCT00414102|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
498353|NCT00414089|Drug|90Y-ibritumomab tiuxetan (Zevalin)|
498354|NCT00414076|Drug|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
498355|NCT00414050|Biological|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
498356|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
498357|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
498358|NCT00414037|Drug|Eszopiclone|
498359|NCT00414037|Drug|Placebo|Placebo-treatment
498360|NCT00414024|Drug|Tegaserod|
498361|NCT00414011|Drug|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
498362|NCT00414011|Drug|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
498363|NCT00413998|Procedure|CABG + Mitral valve annuloplasty|Patients will receive a mitral annuloplasty ring in addition to coronary artery bypass grafting.
498364|NCT00413998|Procedure|CABG|Patients will undergo coronary artery bypass grafting alone.
498365|NCT00413985|Drug|Nutrient-enriched human milk|
498366|NCT00413972|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
498367|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
498368|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
498369|NCT00413972|Drug|Placebo|Placebo once daily for a total of eight weeks
498370|NCT00413959|Drug|VELCADE®|1.6 mg/m^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
498371|NCT00413959|Drug|Rituximab|375 mg/m^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
498372|NCT00413959|Drug|Cyclophosphamide|400 mg/m^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
498373|NCT00413959|Drug|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
498374|NCT00413946|Drug|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
498375|NCT00413946|Drug|saline|three doses of 1.0 ml saline per body weight
498376|NCT00413933|Procedure|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
498377|NCT00413920|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
498378|NCT00413920|Drug|Prednisone|Oral tablets
498379|NCT00413894|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
498380|NCT00413881|Procedure|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
498381|NCT00413881|Procedure|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
498382|NCT00413868|Procedure|LASIK|
498383|NCT00413868|Procedure|PRK|
498384|NCT00413868|Behavioral|Small target contrast sensitivity and disability glare|
498385|NCT00413855|Procedure|laparoscopic appendectomy or not (surgery)|
498386|NCT00413829|Drug|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
498387|NCT00413803|Procedure|4-hour thrice weekly in center hemodialysis|conventional hemodialysis
498388|NCT00413803|Procedure|8-hour thrice weekly in center hemodialysis|long dialysis
498389|NCT00413790|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
498390|NCT00413790|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
498391|NCT00413790|Drug|Placebo|Placebo tablet once daily
498392|NCT00413777|Drug|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
498393|NCT00413764|Drug|tibolone|tibolone (2.5 mg) over 24 weeks
498394|NCT00413764|Drug|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
498395|NCT00413751|Drug|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
498396|NCT00413738|Device|Antiseptic-coated central venous catheters|
498397|NCT00413725|Biological|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
498398|NCT00413725|Other|Placebo|Placebo
498399|NCT00413712|Drug|Calcium Channel Blocker & Adenosine|
498400|NCT00413699|Drug|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
498401|NCT00413699|Drug|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
498402|NCT00413686|Drug|AZD7762|intravenous infusion
498403|NCT00413686|Drug|Gemcitabine|weekly intravenous infusion
498404|NCT00413673|Procedure|PRK|PRK
498405|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
498406|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
498407|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
498408|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
498409|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
498410|NCT00413660|Drug|CP-690,550|Oral tablets
498411|NCT00413660|Other|placebo|Placebo
498412|NCT00413647|Drug|CardioPET|
498413|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; patients will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the patient specific anagrelide dose will be administered from a controlled study specific supply.
498414|NCT00413608|Drug|Clopidogrel|Clopidogrel
498415|NCT00413595|Other|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
498416|NCT00413582|Drug|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
498417|NCT00413582|Drug|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are > 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of > 4/10 throughout the duration of PCA use.
498418|NCT00413569|Procedure|cervical spine surgery|
498419|NCT00413556|Biological|ALK Grass tablet|
498420|NCT00413543|Other|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
498421|NCT00413517|Procedure|Epi-Lasik|A vision correcting surgery
498422|NCT00413504|Drug|Fondaparinux|
498423|NCT00413491|Procedure|MR mammography|MR mammography
498424|NCT00413491|Procedure|MR|MR
498425|NCT00413478|Drug|5-Azacytidine|Starting dose level: 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
498426|NCT00413465|Drug|Escherichia Coli Endotoxin|
498427|NCT00413452|Drug|Etanercept|50 mg once weekly
498428|NCT00413439|Drug|Isavuconazole|Intravenous solution or oral capsules
498429|NCT00413426|Drug|Darifenacin (DAR328)|
498430|NCT00413413|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
498589|NCT00412126|Drug|Insulin|
498431|NCT00413413|Drug|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
498432|NCT00413413|Drug|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
498433|NCT00413400|Drug|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
498434|NCT00413400|Drug|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
498435|NCT00413387|Drug|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
498436|NCT00413387|Drug|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
498437|NCT00413374|Drug|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
498438|NCT00413361|Drug|versus hydroxychloroquine|versus hydroxychloroquine
498439|NCT00413348|Drug|Lactobacillus acidophilus NCFM|
498440|NCT00413335|Drug|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
498441|NCT00413335|Drug|Placebo|Subject receives placebo.
498442|NCT00413322|Drug|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
498443|NCT00413322|Drug|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
498444|NCT00413309|Procedure|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
498445|NCT00413296|Drug|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
498446|NCT00413296|Drug|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
498447|NCT00413296|Drug|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
498448|NCT00413283|Biological|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
498449|NCT00413283|Drug|Placebo|Placebo subcutaneous injection.
498450|NCT00413283|Drug|Gemcitabine|Intravenous infusion
498451|NCT00413283|Drug|Carboplatin|Intravenous infusion
498452|NCT00413283|Drug|Cisplatin|Intravenous infusion
498453|NCT00413270|Drug|nilotinib|
498454|NCT00413257|Drug|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
498455|NCT00413257|Drug|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
498456|NCT00413257|Drug|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
498457|NCT00413244|Drug|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
498458|NCT00413244|Drug|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.~Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
498459|NCT00413231|Device|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
498460|NCT00413218|Drug|Isavuconazole|Administered by intravenous infusion.
498461|NCT00413218|Drug|Caspofungin|Administered by intravenous infusion.
498462|NCT00413218|Drug|Voriconazole|Administered by intravenous infusion.
498463|NCT00413205|Drug|Placebo|po daily
498464|NCT00413205|Drug|RAR Gamma|5mg po daily
498465|NCT00413192|Drug|E7389|1.4 mg/m^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
498466|NCT00413179|Drug|Metformin|
498467|NCT00413179|Drug|Clomiphene citrate|
498468|NCT00413179|Drug|Placebo|
498469|NCT00413166|Drug|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
498470|NCT00413166|Drug|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
498471|NCT00413166|Drug|Idarubicin|"12 mg/m2 one dose only (may be given on day 1 to 5 of induction)~If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
498472|NCT00413166|Drug|Gemtuzumab Ozogamicin|Induction: 9 mg/m2 on day 1 of induction
498473|NCT00413153|Drug|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
498474|NCT00413153|Drug|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
498475|NCT00413127|Drug|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
498476|NCT00413127|Drug|NaCl 0,9%|Administration of placebo i.v.
498477|NCT00413114|Drug|Obatoclax mesylate (GX15-070MS)|
498478|NCT00413101|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/L
498479|NCT00413088|Drug|bemiparin|
498480|NCT00413075|Drug|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
498481|NCT00413062|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
498482|NCT00413062|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
525601|NCT00191503|Drug|Gemcitabine|
498483|NCT00413049|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
498484|NCT00413049|Drug|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
498485|NCT00413036|Drug|lenalidomide|once daily oral capsule
498486|NCT00413023|Drug|GW679769|
498487|NCT00413010|Drug|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
498488|NCT00413010|Drug|placebo|placebo + concurrent GAD treatment from the open-label study period
498489|NCT00412997|Drug|LBH589|
498490|NCT00412984|Drug|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
498491|NCT00412984|Drug|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
498492|NCT00412971|Drug|Hexvix|Single installation, TURB
498493|NCT00412971|Other|Standard white light cystoscopy|
498494|NCT00412958|Drug|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
498495|NCT00412958|Drug|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
498496|NCT00412958|Drug|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
498497|NCT00412958|Drug|Placebo|Intravitreal injection of placebo
498498|NCT00412932|Drug|Olmesartan medoxomil|Tablets
498499|NCT00412932|Drug|Olmesartan medoxomil/hydrochlorothiazide|Tablets
498500|NCT00412919|Drug|Azacitidine|
498501|NCT00412906|Drug|Escherichia Coli Endotoxin|
498502|NCT00412893|Drug|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
498503|NCT00412893|Drug|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
498504|NCT00412880|Drug|BI 2536|
498505|NCT00412867|Drug|Alteplase|0.6 mg/kg of Alteplase is intravenously administered
498506|NCT00412854|Biological|Infanrix™/Hib|
498507|NCT00412854|Biological|Infanrix|
498508|NCT00412854|Biological|Hiberix|
498509|NCT00412841|Drug|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
498510|NCT00412841|Procedure|MRI, Venipuncture|MRIs done baseline, four and nine months
498511|NCT00412841|Drug|Placebo|Tablets identical to atorvastatin 40mg
498512|NCT00412828|Drug|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
498513|NCT00412815|Behavioral|Exercise training|
498514|NCT00412802|Drug|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
498515|NCT00412802|Drug|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
498516|NCT00412789|Drug|Patupilone|
498517|NCT00412776|Drug|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
498518|NCT00412763|Drug|Silymarin (Silybum marianum)|
498519|NCT00412750|Drug|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
498520|NCT00412750|Drug|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
498521|NCT00412737|Drug|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
498522|NCT00412737|Drug|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
498523|NCT00412698|Drug|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.~White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
498524|NCT00412698|Drug|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
498525|NCT00412659|Procedure|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
498526|NCT00412659|Procedure|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
498527|NCT00412646|Drug|TMC125|
498528|NCT00412633|Behavioral|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
498529|NCT00412633|Behavioral|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
498530|NCT00412620|Drug|ABT-925|
498531|NCT00412620|Drug|Placebo|
498532|NCT00412607|Device|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
498533|NCT00412594|Drug|Cladribine|Given IV
498534|NCT00412594|Other|Laboratory Biomarker Analysis|Correlative studies
498535|NCT00412594|Biological|Rituximab|Given IV
498536|NCT00412581|Drug|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
498537|NCT00412581|Drug|Dacarbazine|600 mg/m^2 intravenously on Day 1 of every study cycle.
498538|NCT00412568|Procedure|Photorefractive Keratectomy (PRK)|vision correction with PRK
498539|NCT00412555|Drug|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
498540|NCT00412542|Drug|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
498541|NCT00412542|Drug|CPT-11|125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
498542|NCT00412542|Procedure|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
498543|NCT00412542|Procedure|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
498544|NCT00412529|Drug|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
498545|NCT00412529|Drug|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
498546|NCT00412516|Biological|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
498547|NCT00412503|Drug|Topotecan, Temozolomide|
498548|NCT00412490|Behavioral|Questionnaire|Written survey at 1 Month & 6 Months post surgery.
498549|NCT00412490|Behavioral|Interview|One-on-One meeting lasting about one hour, at 1 Month & 6 Months post surgery.
498550|NCT00412477|Biological|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
498551|NCT00412464|Drug|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
498552|NCT00412451|Drug|ocriplasmin|Intravitreal injection, single administration
498553|NCT00412451|Other|Sham injection|Sham intravitreal injection
498554|NCT00412425|Drug|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
498555|NCT00412412|Drug|CNF2024|Oral doses of CNF2024 as specified in the protocol.
498556|NCT00412412|Drug|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
498557|NCT00412373|Drug|Placebo|for 6 weeks
498558|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
498559|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
498560|NCT00412360|Biological|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
498561|NCT00412360|Biological|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
498562|NCT00412360|Radiation|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
498563|NCT00412360|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
498564|NCT00412360|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
498565|NCT00412360|Drug|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
498566|NCT00412360|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if > 50 kg or 15 mg/kg IV q 8 hours if < 50 kg beginning the morning of Day -3.
498567|NCT00412347|Drug|Insulin Drip Therapy|
498568|NCT00412334|Drug|Copegus|1200-1600mg/day po
498569|NCT00412334|Drug|Copegus|1000-1200mg/day po
498570|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
498571|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
498572|NCT00412321|Drug|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
498573|NCT00412308|Procedure|Tidal volume used in mechanical ventilation|
498574|NCT00412295|Device|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
498575|NCT00412256|Drug|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
498576|NCT00412243|Drug|Clofarabine|40 mg/m^2 Daily for 3 Days
498577|NCT00412243|Drug|Cyclophosphamide|Beginning dose 200 mg/m^2 every 12 hours for 3 days
498578|NCT00412217|Drug|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
498579|NCT00412217|Drug|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
498580|NCT00412217|Other|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
498581|NCT00412204|Drug|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
498582|NCT00412204|Other|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
498583|NCT00412191|Drug|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
498584|NCT00412178|Device|telecommunication based glucose monitoring system|
498585|NCT00412165|Behavioral|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
498586|NCT00412165|Behavioral|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
498587|NCT00412165|Behavioral|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
498590|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 5 mg
498591|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
498592|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 10 mg
498593|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
498594|NCT00412100|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
498595|NCT00412087|Drug|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
498596|NCT00412087|Drug|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
498597|NCT00412087|Drug|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
498598|NCT00412074|Drug|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
498599|NCT00412074|Drug|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
498600|NCT00412074|Drug|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
498601|NCT00412061|Drug|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
498602|NCT00412061|Drug|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
498603|NCT00412061|Drug|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
498604|NCT00412048|Procedure|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
498605|NCT00412035|Drug|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
498606|NCT00412035|Drug|saline injection|10 units per kilo to maximum of 400 units
498607|NCT00412022|Drug|tamoxifen|20 mg daily for 5 years
498608|NCT00412022|Drug|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
498609|NCT00412022|Drug|letrozole|2.5 mg daily for 5 years
498610|NCT00412022|Drug|zoledronic acid|4 mg every 6 months
498611|NCT00412009|Procedure|Comprehensive package of activities|
498612|NCT00411996|Drug|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
498613|NCT00411970|Device|20- and 23 gauge vitreoretinal surgery systems|
498614|NCT00411957|Drug|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
498615|NCT00411931|Drug|Multihance|0.5M administered as a single injection
498616|NCT00411905|Drug|Bortezomib|
498617|NCT00411892|Drug|pioglitazone|Tablets, 45 mg/day.
498618|NCT00411892|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
498619|NCT00411879|Drug|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin [20 IU IV maximum dose = 100 IU] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
498620|NCT00411879|Drug|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
498621|NCT00411866|Drug|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
498622|NCT00411866|Drug|Ketoconazole|Ketoconazole will be available as 200mg tablets.
498623|NCT00411853|Drug|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
498624|NCT00411840|Procedure|intraarterial and intramuscular injection of BMCs|
498625|NCT00411827|Procedure|PRK with conjunctival impression cytology before and after surgery|
498626|NCT00411827|Procedure|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
498627|NCT00411814|Drug|GSK679586|Active Drug
498628|NCT00411814|Drug|Placebo|Saline
498629|NCT00411801|Biological|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
498630|NCT00411801|Biological|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
498631|NCT00411788|Drug|Rapamycin|oral rapamycin 6 mg daily
498632|NCT00411788|Drug|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
498633|NCT00411762|Drug|Capecitabine|
498634|NCT00411762|Drug|PHY906|
498635|NCT00411749|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
498636|NCT00411749|Biological|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
498637|NCT00411736|Drug|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
498638|NCT00411736|Drug|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
498639|NCT00411723|Drug|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
498640|NCT00411723|Drug|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
498641|NCT00411697|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
498642|NCT00411684|Drug|CDB-2914|
498643|NCT00411671|Drug|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
498644|NCT00411658|Device|Investigational Device|
498645|NCT00411658|Device|Experimental|
498646|NCT00411658|Other|Cryopreserved|
498647|NCT00411645|Drug|maribavir|100 mg twice daily for up to 12 weeks
498648|NCT00411645|Other|placebo|twice daily for up to 12 weeks
498649|NCT00411632|Drug|Bexarotene|400 mg/m^2 by mouth daily x 28 Days
498650|NCT00411632|Drug|Erlotinib|150 mg by mouth daily x 28 Days
498651|NCT00411619|Drug|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
498652|NCT00411606|Procedure|Thermography|Subjects will have a picture of their face taken with a thermal camera
498653|NCT00411593|Drug|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
498654|NCT00411593|Drug|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.~Phase II: MTD from Phase I."
498655|NCT00411580|Biological|CAD106|
498656|NCT00411580|Drug|Placebo|
498657|NCT00411567|Drug|inhaled corticosteroid therapy|
498658|NCT00411554|Drug|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
498659|NCT00411554|Drug|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
498660|NCT00411541|Drug|vincristine|
498661|NCT00411541|Drug|dexamethasone|
498662|NCT00411528|Drug|Patupilone|
498663|NCT00411515|Drug|Mycophenolate Mofetil 2x 1g|
498664|NCT00411489|Procedure|endolumenal surgery|
498665|NCT00411463|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
498666|NCT00411463|Drug|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
498667|NCT00411450|Biological|Panitumumab|Administered by intravenous infusion
498668|NCT00411450|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
498669|NCT00411437|Drug|Tolterodine ER|
498670|NCT00411437|Drug|Oxybutynin ER|
498671|NCT00411424|Drug|ASK8007|IV
498672|NCT00411424|Drug|Placebo|IV
498673|NCT00411411|Drug|Januvia|200 mg t.i.d
498674|NCT00411411|Drug|Placebo|Placebo
498675|NCT00411398|Drug|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
498676|NCT00411385|Drug|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
498677|NCT00411385|Drug|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
498678|NCT00411385|Drug|Ribavirin|800mg/day for 24 weeks
498679|NCT00411372|Drug|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
498680|NCT00411359|Behavioral|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
498681|NCT00411346|Procedure|Nurse-led telemonitoring|
498682|NCT00411333|Drug|triamcinolone acetonide (Kenalog)|
498683|NCT00411320|Drug|oral steroid-dexamethasone|2 week steroid trial
498684|NCT00411307|Drug|OROS hydromorphone HCI|
498685|NCT00411281|Drug|cytarabine|Given subcutaneously
498686|NCT00411281|Procedure|observation|No intervention
498687|NCT00411268|Drug|OROS hydromorphone HCI SR (slow release)|
498688|NCT00411255|Procedure|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
498689|NCT00411242|Drug|agomelatine|
498690|NCT00411242|Drug|placebo|
498691|NCT00411229|Drug|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
498692|NCT00411229|Drug|Oxaliplatin|IV infusion, 130mg/m²
498693|NCT00411216|Other|Control exercises|saccadic eye movements against a plain background; no head movements
498694|NCT00411216|Other|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
498695|NCT00411203|Drug|Tamoxifen Citrate|
498696|NCT00411203|Drug|Placebo|
498697|NCT00411190|Drug|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
498698|NCT00411190|Drug|Acetaminophen|Acetaminophen will be administered orally
498699|NCT00411190|Drug|Ibuprofen|Ibuprofen will be administered orally
498700|NCT00411190|Drug|Atorvastatin|Atorvastatin will be administered orally
498701|NCT00411177|Procedure|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
498702|NCT00411177|Procedure|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
498703|NCT00411164|Drug|OROS hydromorphone HCI (slow release)|
498704|NCT00411151|Drug|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
498705|NCT00411138|Radiation|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
498706|NCT00411138|Drug|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
525602|NCT00191490|Drug|Gemcitabine|
498707|NCT00411138|Drug|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
498708|NCT00411138|Drug|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
498709|NCT00411125|Drug|Oral salmon calcitonin|
498710|NCT00411112|Procedure|blue and isotopic detection of sentinel lymph nodes|
498711|NCT00411099|Drug|agomelatine|
498712|NCT00411099|Drug|placebo|
498713|NCT00411086|Biological|Rituximab|375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22.
498714|NCT00411086|Biological|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
498715|NCT00411073|Drug|Darapladib|
498716|NCT00411047|Drug|gefitinib|oral drug taken daily around the same time
498717|NCT00411034|Drug|OROS Hydromorphone HCI|
498718|NCT00411021|Procedure|Pipelle (Endometrial Sampling)|
498719|NCT00410995|Drug|Naproxen|
498720|NCT00410982|Drug|Busulfan|Day -10 = 32 mg/m^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m^2 Intravenous
498721|NCT00410982|Drug|Gemcitabine|Day -8 = 75 mg/m^2 Intravenous bolus; Day -3 = 75 mg/m^2 Intravenous bolus.
498722|NCT00410982|Drug|Melphalan|Day -3 and Day -2 = 60 mg/m^2 Intravenous.
498723|NCT00410982|Other|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
498724|NCT00410982|Drug|Rituximab for Patients with B-Cell Malignancies|375 mg/m^2 Intravenous on Days 1 and 8.
498725|NCT00410982|Drug|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
498726|NCT00410969|Device|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
498727|NCT00410956|Biological|bevacizumab|
498728|NCT00410956|Drug|dexamethasone|
498729|NCT00410956|Drug|floxuridine|
498730|NCT00410956|Genetic|protein expression analysis|
498731|NCT00410956|Other|flow cytometry|
498732|NCT00410956|Other|immunoenzyme technique|
498733|NCT00410956|Other|immunohistochemistry staining method|
498734|NCT00410956|Other|immunologic technique|
498735|NCT00410956|Other|laboratory biomarker analysis|
498736|NCT00410956|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
498737|NCT00410943|Drug|OROS Hydromorphone HCI SR (slow release)|
498738|NCT00410930|Biological|Subcutaneous immunotherapy - Recombinant birch pollen|
498739|NCT00410904|Drug|cediranib maleate|
498740|NCT00410904|Drug|pemetrexed disodium|
498741|NCT00410891|Drug|gatifloxacin|
498742|NCT00410878|Drug|OROS Hydromorphone HCI (slow release)|
498743|NCT00410865|Genetic|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
498744|NCT00410852|Procedure|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
498745|NCT00410852|Procedure|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
498746|NCT00410852|Procedure|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
498747|NCT00410839|Procedure|ALA rich diet|
498748|NCT00410826|Drug|erlotinib hydrochloride|Given orally
498749|NCT00410826|Drug|cisplatin|Given IV
498750|NCT00410826|Radiation|3-dimensional conformal radiation therapy|35 fractions
498751|NCT00410826|Radiation|intensity-modulated radiation therapy|35 fractions
498752|NCT00410826|Procedure|quality-of-life assessment|Ancillary studies
498753|NCT00410813|Drug|dasatinib|given orally
498754|NCT00410787|Drug|OROS hydromorphone HCI (slow release)|
498755|NCT00410774|Biological|bevacizumab|
498756|NCT00410774|Drug|gemcitabine hydrochloride|
498757|NCT00410774|Procedure|adjuvant therapy|
498758|NCT00410761|Drug|ZD6474 (Vandetanib)|once daily oral tablet
498759|NCT00410748|Drug|OROS hydromorphone HCI CR|
498760|NCT00410735|Drug|Placebo|0 mg BID for 12 weeks
498761|NCT00410735|Drug|Pranlukast hydrate|225 mg BID for 12 weeks
498762|NCT00410722|Dietary Supplement|Whole wheat and bran muffin|
498763|NCT00410722|Dietary Supplement|Mixed tree nuts|
498764|NCT00410709|Drug|NatrOVA Creme Rinse (1%)|
498765|NCT00410696|Drug|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
498766|NCT00410696|Drug|Pegfilgrastim|6 mg/day sc at day +1
498767|NCT00410683|Other|clinical observation|
498768|NCT00410683|Procedure|adjuvant therapy|
498769|NCT00410683|Radiation|3-dimensional conformal radiation therapy|
498770|NCT00410657|Biological|alemtuzumab|
498771|NCT00410657|Drug|methylprednisolone|
498772|NCT00410657|Drug|prednisone|
498773|NCT00410657|Other|flow cytometry|
498774|NCT00410657|Other|immunologic technique|
498775|NCT00410657|Other|pharmacological study|
498776|NCT00410644|Drug|OROS Hydromorphone HCI|
498777|NCT00410631|Biological|filgrastim|
498778|NCT00410631|Drug|carboplatin|
498779|NCT00410631|Drug|cisplatin|
498780|NCT00410631|Drug|cyclophosphamide|
498781|NCT00410631|Drug|dacarbazine|
498782|NCT00410631|Drug|doxorubicin hydrochloride|
498783|NCT00410631|Drug|etoposide phosphate|
498784|NCT00410631|Drug|ifosfamide|
498785|NCT00410631|Drug|isotretinoin|
498786|NCT00410631|Drug|melphalan|
498787|NCT00410631|Drug|topotecan hydrochloride|
498788|NCT00410631|Drug|vincristine sulfate|
498789|NCT00410631|Drug|vindesine|
498790|NCT00410631|Procedure|autologous hematopoietic stem cell transplantation|
498791|NCT00410631|Procedure|conventional surgery|
498792|NCT00410631|Procedure|peripheral blood stem cell transplantation|
498793|NCT00410631|Radiation|iobenguane I 131|
498794|NCT00410631|Radiation|radiation therapy|
498795|NCT00410618|Procedure|cognitive assessment|
498796|NCT00410618|Procedure|magnetic resonance imaging|
498797|NCT00410618|Procedure|management of therapy complications|
498798|NCT00410605|Biological|bevacizumab|Given IV
498799|NCT00410605|Drug|lenalidomide|Given orally
498800|NCT00410605|Drug|dexamethasone|Given orally
498801|NCT00410592|Drug|Esomeprazole 40mg|
498802|NCT00410592|Drug|Pantoprazole 40mg|
498803|NCT00410592|Drug|Lansoprazole 30mg|
498804|NCT00410579|Other|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
498805|NCT00410566|Drug|rhASM|Single dose of 0.03mg/kg body weight IV
498806|NCT00410566|Drug|rhASM|Single dose of 0.1mg/kg body weight IV
498807|NCT00410566|Drug|rhASM|Single dose of 0.3mg/kg body weight IV
498808|NCT00410566|Drug|rhASM|Single dose of 0.6mg/kg body weight IV
498809|NCT00410566|Drug|rhASM|Single dose of 1.0mg/kg body weight IV
498810|NCT00410553|Drug|Eribulin Mesylate|Given IV
498811|NCT00410553|Drug|Gemcitabine Hydrochloride|Given IV
498812|NCT00410540|Drug|OROS hydromorphone HCL ; Morphine sulfate|
498813|NCT00410527|Drug|Merrem|
498814|NCT00410514|Drug|Mirabegron|oral
498815|NCT00410514|Drug|Placebo|oral
498816|NCT00410501|Drug|Indacaterol (QAB149)|
498817|NCT00410488|Drug|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
498818|NCT00410488|Drug|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
498819|NCT00410488|Drug|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
498820|NCT00410488|Drug|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
498821|NCT00410488|Drug|Zinecard|750 mg/m2 as an IV bolus.
498822|NCT00410488|Drug|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
498823|NCT00410488|Drug|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).~For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
498824|NCT00410488|Drug|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
498825|NCT00410462|Drug|brostallicin|
498826|NCT00410462|Drug|doxorubicin hydrochloride|
498827|NCT00410449|Drug|Alpha tocopherol|
498828|NCT00410436|Behavioral|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
498829|NCT00410423|Drug|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
498830|NCT00410423|Drug|Bortezomib 1.0mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
498831|NCT00410423|Drug|Bortezomib 1.3mg/m^2|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
498832|NCT00410410|Drug|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57 (ABA 30/~10 mg/kg Group).~Induction Period 3 months~Maintenance Period 12 months"
498833|NCT00410410|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
498834|NCT00410410|Drug|abatacept|"~10 mg/kg, once monthly~Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
498835|NCT00410397|Procedure|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
498836|NCT00410397|Procedure|Sham Manipulation|Neutral positional, gentle palpation
498837|NCT00410384|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
498838|NCT00410384|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
498839|NCT00410384|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
498840|NCT00410371|Drug|Lamotrigine|Lamotrigine
498841|NCT00410371|Drug|GI267119|25 mg ODT
498842|NCT00410358|Drug|Gimatecan|
498843|NCT00410345|Drug|Mifepristone|
498844|NCT00410332|Drug|Traumeel S|homeopathic remedy
498845|NCT00410332|Drug|Placebo|placebo drug, identical in size, form and taste as treatment remedy
498846|NCT00410319|Behavioral|Fear-reducing Information|
498847|NCT00410319|Behavioral|Symptom-based exercise|
498848|NCT00410306|Drug|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
498849|NCT00410293|Procedure|NT-proBNP testing|
498850|NCT00410280|Biological|IMA-638 is a biologic|
498851|NCT00410254|Drug|HCV-796|
498852|NCT00410254|Drug|midazolam|
498853|NCT00410228|Drug|AHT956|
498854|NCT00410215|Drug|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
499049|NCT00408655|Drug|temsirolimus|Given IV
498855|NCT00410215|Drug|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
498856|NCT00410215|Drug|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
498857|NCT00410202|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
498858|NCT00410202|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily
498859|NCT00410202|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
498860|NCT00410202|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
498861|NCT00410189|Drug|ZD6474|300 mg by mouth daily for 28 Days.
498862|NCT00410176|Behavioral|sanitation and personal hygiene|
498863|NCT00410163|Drug|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
498864|NCT00410163|Drug|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
498865|NCT00410163|Drug|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
498866|NCT00410163|Drug|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
498867|NCT00410150|Drug|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
498868|NCT00410150|Drug|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
498869|NCT00410124|Drug|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
498870|NCT00410124|Drug|Placebo|
498871|NCT00410098|Behavioral|Bikram Yoga|
498872|NCT00410085|Drug|L-NMMA (N-mono.methyl-L-arginine)|
498873|NCT00410072|Drug|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
498874|NCT00410072|Drug|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
498875|NCT00410059|Drug|Erlotinib|150 mg by mouth daily x 28 days
498876|NCT00410046|Drug|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
498877|NCT00410033|Drug|soluble human insulin|
498878|NCT00410033|Drug|isophane human insulin|
498879|NCT00410033|Drug|insulin aspart|
498880|NCT00410020|Behavioral|Alpha-linolenic enriched diet|
498881|NCT00410007|Behavioral|High Sodium Diet|250-350 mmol
498882|NCT00410007|Behavioral|Low Sodium Diet|25-35 mmol
498883|NCT00410007|Behavioral|Hypertonic saline infusion|7 ml/ kg of 3% saline were given over 30 minutes.
498884|NCT00409994|Drug|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
498885|NCT00409981|Device|paclitaxel coated balloon catheter (device with drug)|
498886|NCT00409968|Procedure|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
498887|NCT00409955|Procedure|Lamellar transplant with lyophilized corneas|
498888|NCT00409942|Drug|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
498889|NCT00409942|Drug|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
498890|NCT00409929|Drug|AEB071|
498891|NCT00409916|Device|BioZ Dx|
498892|NCT00409903|Drug|Eprosartan|
498893|NCT00409890|Drug|Hyoscine Butyl Bromide|
498894|NCT00409864|Procedure|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
498895|NCT00409851|Drug|valsartan+amlodipine|
498896|NCT00409838|Drug|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg <60 kg); (750 mg 60-100 kg); (1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
498897|NCT00409838|Drug|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
498898|NCT00409838|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
498899|NCT00409838|Drug|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
498900|NCT00409838|Drug|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
498901|NCT00409825|Drug|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
498902|NCT00409825|Procedure|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
498903|NCT00409799|Drug|I-0401 (a new bone graft substitute)|1 time application
498904|NCT00409786|Behavioral|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
498905|NCT00409773|Drug|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
498906|NCT00409773|Drug|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.~Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
498907|NCT00409773|Drug|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.~ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.~Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
498908|NCT00409760|Drug|valsartan+amlodipine combination, valsartan, amlodipine|
498909|NCT00409747|Drug|Minocycline|
499252|NCT00407056|Drug|Difluprednate Ophthalmic Emulsion|
498910|NCT00409734|Behavioral|Children with pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
498911|NCT00409734|Behavioral|Children without pyloric stenosis|Both cohorts' feeding habits will be observed and recorded for the purposes of comparison
498912|NCT00409721|Drug|Memantine|
498913|NCT00409708|Drug|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
498914|NCT00409708|Behavioral|Behavior Therapy|
498915|NCT00409695|Drug|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
498916|NCT00409695|Drug|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
498917|NCT00409682|Biological|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
498918|NCT00409682|Biological|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
498919|NCT00409682|Biological|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
498920|NCT00409669|Device|Barraquer tonometer|barraquer tonometer
498921|NCT00409656|Drug|Basiliximab|
498922|NCT00409643|Drug|valsartan+amlodipine combination|
498923|NCT00409643|Drug|valsartan|
498924|NCT00409643|Drug|amlodipine|
498925|NCT00409630|Drug|fluticasone|
498926|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Other Week dosing
498927|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
498928|NCT00409604|Device|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
498929|NCT00409591|Drug|Maternal and infant nevirapine|"In women, one NVP 200 mg tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately"
498930|NCT00409591|Drug|Maternal placebo and infant nevirapine|"In women, one placebo tablet at onset of labor;~In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded."
498931|NCT00409591|Drug|Maternal lopinavir+ritonavir|- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
498932|NCT00409591|Drug|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
498933|NCT00409578|Drug|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
498934|NCT00409578|Drug|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
498935|NCT00409578|Drug|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
498936|NCT00409578|Drug|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
498937|NCT00409565|Drug|Cetuximab|"Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY~Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
498938|NCT00409565|Drug|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
499115|NCT00408226|Drug|MKC-1|capsules, twice daily for 14 days in 21 day cycle
499253|NCT00407043|Drug|Lotemax|
498939|NCT00409552|Behavioral|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
498940|NCT00409552|Behavioral|VR with flat projection display|VR with flat projection display
498941|NCT00409552|Behavioral|non-interactive video with head display|non-interactive video with head display
498942|NCT00409552|Behavioral|non-interactive video with with flat projection display|non-interactive video with with flat projection display
498943|NCT00409539|Drug|Placebo|Placebo, 2 week duration.
498944|NCT00409539|Drug|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
498945|NCT00409539|Drug|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
498946|NCT00409526|Drug|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
498947|NCT00409500|Drug|AQW051|
498948|NCT00409487|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
498949|NCT00409487|Drug|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
498950|NCT00409461|Drug|ATG-Sirolimus-Tacrolimus|
498951|NCT00409448|Behavioral|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
498952|NCT00409448|Behavioral|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
498953|NCT00409435|Drug|pyridostigmine|one 180 mg capsule per day for 3 days
498954|NCT00409435|Drug|Placebo|one capsule per day for 3 days
498955|NCT00409422|Behavioral|weight management program|
498956|NCT00409409|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
498957|NCT00409409|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
498958|NCT00409396|Procedure|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
498959|NCT00409396|Procedure|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
498960|NCT00409383|Drug|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
498961|NCT00409383|Drug|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
498962|NCT00409383|Drug|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
498963|NCT00409370|Device|SOMA safe enclosure|
498964|NCT00409357|Drug|SL77.0499-10 (alfuzosin hydrochloride)|
498965|NCT00409344|Drug|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
498966|NCT00409344|Other|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
498967|NCT00409331|Drug|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
498968|NCT00409331|Procedure|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
498969|NCT00409318|Drug|Etanercept|50 mg SC q week
498970|NCT00409318|Drug|Placebo|SC q week
498971|NCT00409305|Drug|Betahistine|
498972|NCT00409305|Behavioral|Dietary counseling|
498973|NCT00409292|Drug|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
498974|NCT00409279|Behavioral|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
498975|NCT00409266|Device|Computer assisted navigation|
498976|NCT00409253|Drug|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
498977|NCT00409253|Drug|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD >105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
498978|NCT00409240|Other|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
498979|NCT00409227|Drug|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
498980|NCT00409227|Drug|placebo|placebo once a day for 3 months or stone free
498981|NCT00409214|Drug|LS11 (talaporfin sodium)|
498982|NCT00409214|Device|Light source (interstitial light emitting diodes)|
498983|NCT00409214|Procedure|Intraoperative placement of device in glioma|
498984|NCT00409201|Drug|reboxetine adjuvant therapy|
498985|NCT00409188|Biological|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
498986|NCT00409188|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
499116|NCT00408226|Drug|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
499117|NCT00408213|Drug|mycophenolate mofetil [CellCept]|1g po bid
498987|NCT00409188|Drug|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
498988|NCT00409175|Drug|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
498989|NCT00409175|Drug|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
498990|NCT00409162|Device|Eraser TM device, with washing fluid|
498991|NCT00409149|Behavioral|CALM Approache|
498992|NCT00409149|Behavioral|DASH approach|standard dietary DASH approach in hypertensive patients
498993|NCT00409136|Behavioral|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
498994|NCT00409097|Drug|Rosiglitazone|
498995|NCT00409084|Procedure|endoscopic variceal band ligation|endoscopic variceal band ligation
498996|NCT00409071|Drug|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
498997|NCT00409071|Drug|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
498998|NCT00409058|Behavioral|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
498999|NCT00409032|Drug|Strontium malonate|
499000|NCT00409019|Drug|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
499001|NCT00409019|Drug|Adefovir|
499002|NCT00409019|Drug|Tenofovir|
499003|NCT00409006|Drug|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
499004|NCT00409006|Drug|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
499005|NCT00409006|Drug|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
499006|NCT00408993|Drug|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
499007|NCT00408993|Drug|Placebo|Placebo every day (QD), by mouth (PO)
499008|NCT00408980|Behavioral|Fat and calorie controlled diet|
499009|NCT00408967|Drug|Tucotuzumab celmoleukin (EMD 273066)|
499010|NCT00408954|Drug|UK-369,003|100 mg MR tablet once daily for 2 weeks
499011|NCT00408954|Drug|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
499012|NCT00408941|Drug|Propofol|
499013|NCT00408941|Drug|Prilocaine|
499014|NCT00408928|Drug|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
499015|NCT00408915|Drug|Continuous Subcutaneous Lisuride Infusion|
499016|NCT00408902|Drug|tandutinib|Given orally, 500 mg bid daily
499017|NCT00408902|Other|laboratory biomarker analysis|Correlative studies
499018|NCT00408876|Drug|Duloxetine|
499019|NCT00408876|Drug|Placebo|
499020|NCT00408863|Drug|tibolone|tibolone 2.5 mg/day
499021|NCT00408863|Drug|placebo|
499022|NCT00408850|Drug|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
499023|NCT00408850|Drug|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
499024|NCT00408798|Drug|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
499025|NCT00408785|Drug|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
499026|NCT00408785|Drug|sodium chloride|sodium chloride 0.9 mg
499027|NCT00408772|Biological|bevacizumab|
499028|NCT00408772|Drug|capecitabine|
499029|NCT00408772|Drug|oxaliplatin|
499030|NCT00408772|Procedure|conventional surgery|
499031|NCT00408772|Procedure|neoadjuvant therapy|
499032|NCT00408772|Procedure|radiofrequency ablation|
499033|NCT00408759|Behavioral|hypnosis|
499034|NCT00408746|Behavioral|palatal development|Impressions of preterm and term palates.
499035|NCT00408733|Other|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
499036|NCT00408707|Procedure|local infiltration analgesia|
499037|NCT00408694|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
499038|NCT00408694|Biological|Bevacizumab|Given IV
499039|NCT00408694|Drug|Cisplatin|Given IV
499040|NCT00408694|Drug|Fluorouracil|Given IV
499041|NCT00408694|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
499042|NCT00408681|Drug|lithium carbonate|Given orally
499043|NCT00408681|Other|laboratory biomarker analysis|Correlative studies
499044|NCT00408668|Biological|PEV3A|
499045|NCT00408668|Biological|FP9 ME-TRAP|
499046|NCT00408668|Biological|MVA ME-TRAP|
499047|NCT00408655|Drug|paclitaxel|Given IV
499048|NCT00408655|Drug|carboplatin|Given IV
499050|NCT00408642|Behavioral|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
499051|NCT00408642|Behavioral|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
499052|NCT00408629|Biological|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
499053|NCT00408629|Biological|placebo|Matching Placebo for prefilled syringe, 40 mg,
499054|NCT00408616|Biological|Grazax-R|Grass tablet, 75.000 SQ per day for one year
499055|NCT00408616|Biological|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
499056|NCT00408603|Drug|Voreloxin Injection|All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
499057|NCT00408590|Biological|carcinoembryonic antigen-expressing measles virus|
499058|NCT00408590|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|
499059|NCT00408590|Genetic|reverse transcriptase-polymerase chain reaction|
499060|NCT00408590|Other|laboratory biomarker analysis|
499061|NCT00408577|Drug|L-arginine|
499062|NCT00408564|Biological|cetuximab|
499063|NCT00408564|Drug|capecitabine|
499064|NCT00408564|Drug|oxaliplatin|
499065|NCT00408564|Procedure|conventional surgery|
499066|NCT00408564|Radiation|radiation therapy|
499067|NCT00408564|Drug|Gemcitabine|
499068|NCT00408551|Drug|floxuridine|Given IV
499069|NCT00408551|Drug|fluorouracil|Given IV
499070|NCT00408551|Drug|irinotecan hydrochloride|Given IV
499071|NCT00408551|Drug|leucovorin calcium|Given IV
499072|NCT00408551|Drug|oxaliplatin|Given IV
499073|NCT00408538|Drug|UC-781 microbicide gel (0.1% and 0.25%)|
499074|NCT00408538|Drug|placebo|
499075|NCT00408525|Drug|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
499076|NCT00408512|Drug|thiazides|Up to 25 mg per day
499077|NCT00408512|Procedure|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
499078|NCT00408499|Drug|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
499079|NCT00408499|Drug|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
499080|NCT00408473|Drug|Flecainide|
499081|NCT00408460|Drug|imatinib mesylate|Given PO
499082|NCT00408460|Drug|paclitaxel|Given IV
499083|NCT00408447|Drug|Busulfan|Busulfan 4 mg/kg/d x 4d
499084|NCT00408447|Drug|Fludarabine|Fludarabine 30 mg/m2/d x 6d
499085|NCT00408447|Drug|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
499086|NCT00408447|Procedure|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
499087|NCT00408434|Drug|CS-7017|CS-7017 0.05mg and 1.0mg tablets
499088|NCT00408421|Drug|Duloxetine|
499089|NCT00408421|Drug|placebo|
499090|NCT00408408|Biological|bevacizumab|15 mg/kg IV
499091|NCT00408408|Drug|capecitabine|825 mg/m2 orally
499092|NCT00408408|Drug|cyclophosphamide|600 mg/m2 IV
499093|NCT00408408|Drug|docetaxel|100 mg/m2 IV
499094|NCT00408408|Drug|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
499095|NCT00408408|Drug|gemcitabine hydrochloride|1000 mg/m2 IV
499096|NCT00408395|Biological|Influenza vaccine|Seasonal Influenza Vaccine
499097|NCT00408382|Drug|atorvastatin, Lipitor|
499098|NCT00408369|Drug|DB289|
499099|NCT00408356|Drug|Zinc|
499100|NCT00408330|Drug|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
499101|NCT00408330|Drug|Inactive 15% gel base|placebo, topically applied daily for six weeks
499102|NCT00408317|Drug|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
499103|NCT00408317|Drug|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
499104|NCT00408304|Drug|omega-3 fatty acid|
499105|NCT00408291|Procedure|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
499106|NCT00408278|Drug|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
499107|NCT00408278|Drug|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
499108|NCT00408278|Drug|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
499109|NCT00408278|Drug|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
499110|NCT00408265|Behavioral|Contingency Management|
499111|NCT00408252|Other|biopsies|No intervention, only biopsy for translational project
499112|NCT00408252|Drug|SU011248|no intervention
499113|NCT00408239|Drug|YM150|Oral
499114|NCT00408239|Drug|enoxaparin|Sub cutaneous
499119|NCT00408200|Drug|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
499120|NCT00408200|Device|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
499121|NCT00408187|Drug|voclosporin|voclosporin 0.4 mg/kg po BID
499122|NCT00408187|Drug|Ciclosporin|ciclosporin 1.5 mg/kg po BID
499123|NCT00408187|Drug|Placebo|Placebo
499124|NCT00408174|Drug|Balsalazide disodium|
499125|NCT00408161|Behavioral|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
499126|NCT00408161|Behavioral|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
499127|NCT00408148|Drug|Placebo|Undistinguishable placebo tablets
499128|NCT00408148|Drug|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
499129|NCT00408135|Drug|telithromycin (HMR3647)|
499130|NCT00408122|Procedure|PET/CT scan and EUS|
499131|NCT00408109|Drug|VRC-AVIDNA036-00-VP|
499132|NCT00408096|Procedure|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
499133|NCT00408083|Drug|MultiHance|0.5 mmol/kg as a single dose administration
499134|NCT00408083|Drug|Magnevist|0.5 mmol/kg as a single dose administration
499135|NCT00408070|Drug|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
499136|NCT00408070|Drug|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
499137|NCT00408070|Drug|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
499138|NCT00408057|Other|no intervention|no intervenion
499139|NCT00408044|Procedure|cardiac surgery with sternotomy|
499140|NCT00408031|Drug|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
499141|NCT00408018|Drug|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
499142|NCT00408005|Drug|Asparaginase|Given IM or IV
499143|NCT00408005|Drug|Cyclophosphamide|Given IV
499144|NCT00408005|Drug|Cytarabine|Given IT, IV, or SC
499145|NCT00408005|Drug|Daunorubicin Hydrochloride|Given IV
499146|NCT00408005|Drug|Dexamethasone|Given IV or PO
499147|NCT00408005|Drug|Doxorubicin Hydrochloride|Given IV
499148|NCT00408005|Other|Laboratory Biomarker Analysis|Correlative studies
499149|NCT00408005|Drug|Leucovorin Calcium|Given PO
499150|NCT00408005|Drug|Mercaptopurine|Given PO
499151|NCT00408005|Drug|Methotrexate|Given IT or PO
499152|NCT00408005|Drug|Nelarabine|Given IV
499153|NCT00408005|Drug|Pegaspargase|Given IM or IV
499154|NCT00408005|Drug|Prednisone|Given IV or PO
499155|NCT00408005|Radiation|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
499156|NCT00408005|Drug|Thioguanine|Given PO
499157|NCT00408005|Drug|Vincristine Sulfate|Given IV
499158|NCT00407992|Device|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
499159|NCT00407992|Device|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
499160|NCT00407966|Drug|alvocidib|Given IV
499161|NCT00407966|Drug|cytarabine|Given IV
499162|NCT00407966|Drug|mitoxantrone hydrochloride|Given IV
499163|NCT00407940|Device|Lower extremity Atherectomy and Cryoplasty|
499164|NCT00407927|Drug|Epinastine Nasal Spray|
499165|NCT00407914|Device|Aquamid|Subcutaneous injection
499166|NCT00407914|Device|Restylane|Injection in dermis
499167|NCT00407888|Drug|doxorubicin hydrochloride|Given IV
499168|NCT00407888|Drug|cyclophosphamide|Given orally
499169|NCT00407888|Biological|filgrastim|Given SC
499170|NCT00407888|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
499171|NCT00407888|Biological|trastuzumab|Given IV
499172|NCT00407888|Other|laboratory biomarker analysis|Correlative studies
499173|NCT00407888|Procedure|quality-of-life assessment|Ancillary studies
499174|NCT00407875|Procedure|Intensity Modulated External Beam Radiation Therapy|
499175|NCT00407862|Drug|Telmisartan 80 mg|
499176|NCT00407862|Drug|Losartan 50 mg|
499177|NCT00407849|Drug|triamcinolone acetonide|Intravitreal injection
499178|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
499179|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
499180|NCT00407823|Procedure|Central venous oxygen saturation continuous monitoring|
499181|NCT00407797|Drug|Pregabalin|150 to 600 mg/day during 21 weeks
499182|NCT00407784|Drug|eplerenone|
499183|NCT00407771|Drug|Tirofiban|
499184|NCT00407758|Drug|enzastaurin hydrochloride|
499185|NCT00407745|Drug|placebo|Placebo
499186|NCT00407745|Drug|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
499187|NCT00407732|Behavioral|psychosocial intervention|motivational enhancing case management intervention
499188|NCT00407719|Drug|Bevacizumab|
499189|NCT00407706|Procedure|blood test|
499190|NCT00407693|Drug|[C-11]PRB28|
499191|NCT00407680|Drug|Intensive therapy Valsartan,Fluvastatin|
499192|NCT00407667|Device|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
499193|NCT00407654|Drug|aflibercept|Given intravenously
499194|NCT00407641|Drug|Tinzaparin administration|Patients will receive tinzaparin during the HD session
499195|NCT00407641|Drug|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
499196|NCT00407615|Device|Flex Pad/Static Magnet|
499197|NCT00407602|Device|Argus II Retinal Stimulation System|epiretinal implantation of device
499198|NCT00407589|Drug|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
499199|NCT00407576|Drug|[11C]MeS-IMPY|
499200|NCT00407563|Drug|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
499201|NCT00407563|Drug|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
499202|NCT00407550|Drug|gemcitabine HCL|1250 mg/m^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 & 8 of each cycle (21 days) x6 cycles.
499203|NCT00407550|Drug|pemetrexed disodium|500 mg/m^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
499204|NCT00407550|Drug|gemcitabine HCL|1500 mg/m^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
499205|NCT00407537|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
499206|NCT00407524|Drug|AKL 1|
499207|NCT00407511|Drug|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
499208|NCT00407498|Drug|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
499209|NCT00407485|Biological|ziv-aflibercept|Given IV
499210|NCT00407485|Other|pharmacological study|Correlative studies
499211|NCT00407472|Device|ATS-1 needle free device|
499212|NCT00407459|Drug|Bevacizumab, Pemetrexed, Carboplatin|"Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
499213|NCT00407446|Drug|sildenafil|
499214|NCT00407433|Drug|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
499215|NCT00407420|Device|Mandometer|A computerised device, Mandometer, providing real time feedback to participants during meals to slow down speed of eating and reduce total intake; standard lifestyle modification therapy.
499216|NCT00407420|Behavioral|Lifestyle|Typical dietary and activity advice as normally provided in clinic (control).
499217|NCT00407407|Drug|ABI-007|80mg/m^2 to 150mg/m^2 IV every 3 weeks
499218|NCT00407407|Drug|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
499219|NCT00407394|Drug|Amoxycillin|
499220|NCT00407381|Drug|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
499221|NCT00407381|Procedure|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
499222|NCT00407368|Procedure|Blood Sample|
499223|NCT00407355|Drug|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
499224|NCT00407355|Drug|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
499225|NCT00407342|Drug|Alefacept (drug)|alefaceptgiven iv
499226|NCT00407342|Procedure|Narrowband UVB phototherapy|
499227|NCT00407329|Procedure|transurethral resection of the prostate|resection of prostate
499228|NCT00407303|Drug|Obatoclax mesylate|30 mg, 45 mg
499229|NCT00407303|Drug|Bortezomib|1.0mg/m2, 1.3 mg/m2
499230|NCT00407290|Drug|neostigmine|
499231|NCT00407277|Drug|Nicotine patch|21 mg of nicotine via a dermal patch
499232|NCT00407277|Other|placebo|placebo via a dermal patch
499233|NCT00407277|Behavioral|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
499234|NCT00407264|Drug|Fluticasone propionate|
499235|NCT00407251|Drug|Patupilone|
499236|NCT00407238|Device|Multi-purpose solutions (polyquaternium-1 and PHMB)|
499237|NCT00407225|Drug|Difluprednate Ophthalmic Emulsion|
499238|NCT00407212|Drug|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
499239|NCT00407199|Drug|quetiapine|
499240|NCT00407186|Drug|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
499241|NCT00407186|Radiation|radiotherapy|45 Gy in 25 fracions (5 days/week)
499242|NCT00407186|Drug|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
499243|NCT00407173|Drug|HCV-796|HCV-796 1000mg single dose
499244|NCT00407147|Device|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
499245|NCT00407134|Procedure|Different abdominal volumes and different glucose-concentrations during peritoneal dialysis|
499246|NCT00407121|Drug|Bevacizumab|
499247|NCT00407121|Procedure|Intravitreal Injection of Bevacizumab|
499248|NCT00407108|Procedure|Vitrectomy|
499249|NCT00407095|Drug|Pardoprunox|12-42 mg/day
499250|NCT00407082|Drug|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
499251|NCT00407082|Drug|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
499254|NCT00407043|Drug|Restasis|
499255|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
499256|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
499257|NCT00407030|Drug|Placebo|Placebo
499258|NCT00407017|Drug|Gatifloxacin|
499259|NCT00407017|Drug|Ketorolac LS|
499260|NCT00407017|Drug|Pred Forte|
499261|NCT00407017|Drug|Moxifloxacin|
499262|NCT00407017|Drug|Nepafenac|
499263|NCT00407017|Drug|EconoPred Plus|
499264|NCT00407004|Device|MARS (Molecular Adsorbents Recirculating System)|
499265|NCT00407004|Device|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
499266|NCT00406991|Drug|aspirin|
499267|NCT00406991|Drug|clopidogrel|
499268|NCT00406978|Drug|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
499269|NCT00406978|Drug|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
499270|NCT00406978|Drug|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
499271|NCT00406978|Drug|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
499272|NCT00406965|Drug|HAE1 (PRO98498)|
499273|NCT00406952|Procedure|electronic diary|
499274|NCT00406952|Drug|Sertraline|
499275|NCT00406952|Drug|Placebo|
499276|NCT00406952|Procedure|voice acoustics|
499277|NCT00406939|Genetic|IL-12 gene|
499278|NCT00406926|Drug|Somatropin|
499279|NCT00406913|Drug|mupirocin ointment|
499280|NCT00406913|Other|SOC sterilization|
499281|NCT00406900|Procedure|Treatment of metastatic disease|
499282|NCT00406887|Drug|Difluprednate Ophthalmic Emulsion|
499283|NCT00406874|Drug|omega 3 fats|1,000 mg daily
499284|NCT00406874|Drug|folic acid|800 micrograms daily
499285|NCT00406861|Drug|montelukast in treatment of ENL reaction|
499286|NCT00406848|Drug|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
499287|NCT00406848|Drug|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
499288|NCT00406835|Procedure|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
499289|NCT00406822|Device|OculusGen Biodegradable Collagen Matrix Implant|
499290|NCT00406809|Drug|ABT-263|"Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose."
499291|NCT00406796|Drug|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
499292|NCT00406783|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
499293|NCT00406783|Drug|Placebo|Placebo tablet, once daily for 15 days
499294|NCT00406770|Device|Light therapy|
499295|NCT00406757|Drug|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.~Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
499296|NCT00406757|Drug|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
499297|NCT00406757|Drug|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.~Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
499298|NCT00406757|Drug|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
499299|NCT00406744|Drug|Intravitreal injection of Bevacizumab|
499300|NCT00406731|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
499301|NCT00406731|Drug|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
499302|NCT00406731|Drug|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
499303|NCT00406731|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
499304|NCT00406731|Device|Goldmann applanation tonometer|Intraocular pressure measurements
499305|NCT00406731|Device|HP-CMS patient monitor|blood pressure and pulse rate measurements
499306|NCT00406731|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
525603|NCT00191490|Drug|docetaxel|
499307|NCT00406718|Behavioral|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
499308|NCT00406718|Behavioral|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
499309|NCT00406718|Behavioral|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
499310|NCT00406705|Behavioral|Helium-Hyperoxia|
499311|NCT00406692|Drug|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
499312|NCT00406679|Drug|Paracetamol (acetaminophen) solution experimental|1 gm IV
499313|NCT00406679|Drug|paracetamol (acetaminophen) solution commercial|1 gm IV
499314|NCT00406679|Drug|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
499315|NCT00406653|Drug|abatacept|"Dextrose 5% in water, intravenous (IV).~Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;~3 mg/kg on days IP-1, IP-15,IP-29, IP-57;~~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,~or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57.~Induction Period 3 months~Maintenance Period 12 months"
499316|NCT00406653|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.~Induction Period 3 months~Maintenance Period 12 months"
499317|NCT00406653|Drug|abatacept|"~10 mg/kg, every 28 days.~Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
499318|NCT00406640|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
499319|NCT00406640|Drug|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
499320|NCT00406614|Behavioral|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
499321|NCT00406601|Drug|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
499322|NCT00406588|Drug|Levodopa (Pardoprunox)|12-42mg
499323|NCT00406588|Drug|Placebo Comparator|Placebo
499324|NCT00406575|Drug|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
499325|NCT00406575|Drug|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
499326|NCT00406562|Biological|Boostrix|
499327|NCT00406536|Dietary Supplement|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
499328|NCT00406536|Dietary Supplement|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is >99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
499329|NCT00406523|Device|JANUS Stent|
499330|NCT00406510|Drug|Optive, Systane|
499331|NCT00406497|Drug|Difluprednate Ophthalmic Emulsion|
499332|NCT00406484|Behavioral|Standard drug counseling|Individual drug counseling
499333|NCT00406484|Behavioral|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
499334|NCT00406471|Drug|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
499335|NCT00406458|Drug|SB-509|60 mg dose
499336|NCT00406458|Other|Normal Saline|
499337|NCT00406432|Drug|Paroxetine Controlled Release Tablet|Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
499338|NCT00406419|Drug|methotrexate|Oral repeating dose
499339|NCT00406419|Drug|ocrelizumab|Intravenous repeating dose (200mg)
499340|NCT00406419|Drug|ocrelizumab|Intravenous repeating dose (500mg)
499341|NCT00406419|Drug|placebo|Intravenous repeating dose
499342|NCT00406406|Drug|SKI-606|
499343|NCT00406393|Drug|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.~The target serum level for tacrolimus is 5-10 ng/mL."
499344|NCT00406393|Drug|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
499400|NCT00405938|Drug|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
499401|NCT00405925|Drug|Trizivir|
525604|NCT00191490|Drug|cisplatin|
499345|NCT00406393|Drug|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.~Children: Children aged < 12.0 years OR weighing < 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.~The target serum level for sirolimus is 3-12 ng/mL."
499346|NCT00406380|Drug|Bevacizumab|
499347|NCT00406380|Procedure|Intravitreal injection of Bevacizumab|
499348|NCT00406367|Drug|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"
499349|NCT00406367|Drug|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
499350|NCT00406354|Drug|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
499351|NCT00406354|Drug|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
499352|NCT00406341|Drug|Difluprednate Ophthalmic Emulsion|
499353|NCT00406315|Drug|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
499354|NCT00406302|Drug|Docetaxel|75mg/m², day 1,22
499355|NCT00406302|Drug|oxaliplatin|40mg/m², d1,2,22,23
499356|NCT00406302|Drug|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
499357|NCT00406302|Procedure|surgery|28 days after end of induction chemotherapy
499358|NCT00406289|Procedure|18F-FDG-PET radiotherapy|
499359|NCT00406276|Drug|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
499360|NCT00406276|Drug|Docetaxel|In combination with RAD001
499361|NCT00406263|Procedure|Scheimpflug crystalline lens photographs|scheimpflug photographs
499362|NCT00406250|Drug|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
499363|NCT00406250|Drug|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
499364|NCT00406237|Drug|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
499365|NCT00406224|Drug|breathing 100% oxygen|
499366|NCT00406211|Biological|MMRV|
499367|NCT00406211|Biological|MMR (Priorix®)|
499368|NCT00406211|Biological|Varicella (Varilrix®)|
499369|NCT00406198|Procedure|venovenous hemofiltration|
499370|NCT00406172|Drug|Bevacizumab|
499371|NCT00406159|Device|Hyperbaric Oxygen Therapy|
499372|NCT00406146|Drug|amodiaquine+artesunate/artemether-lumefantrine|
499373|NCT00406133|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
499374|NCT00406120|Procedure|Fine needle aspiration biopsy|
499375|NCT00406107|Drug|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
499376|NCT00406094|Drug|montelukast|10mg
499377|NCT00406094|Drug|placebo|placebo
499378|NCT00406068|Drug|Mycobacterial cell wall-DNA complex|8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
499379|NCT00406055|Device|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
499380|NCT00406042|Drug|prednisolone acetate 1%|
499381|NCT00406029|Drug|Preladenant|1 mg BID capsules
499382|NCT00406029|Drug|Preladenant|2 mg BID capsules
499383|NCT00406029|Drug|Preladenant|5 mg BID capsules
499384|NCT00406029|Drug|Preladenant|10 mg BID capsules
499385|NCT00406029|Drug|Placebo|BID capsules
499386|NCT00406029|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
499387|NCT00406029|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
499388|NCT00406016|Drug|ATI355|
499389|NCT00406003|Drug|Paroxetine controlled release tablet|Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
499390|NCT00405990|Behavioral|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
499391|NCT00405990|Behavioral|VCT|HIV VCT for PMTCT
499392|NCT00405977|Drug|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
499393|NCT00405977|Drug|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
499394|NCT00405964|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
499395|NCT00405964|Drug|Placebo tablet|Placebo tablet, once daily for 12 weeks
499396|NCT00405951|Drug|Obatoclax mesylate 250 ml|
499397|NCT00405951|Drug|Docetaxel|
499398|NCT00405938|Drug|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
499399|NCT00405938|Drug|Anastrozole|anastrozole (1 mg orally daily)
499402|NCT00405925|Drug|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
499403|NCT00405912|Drug|Placebo|Placebo (inactive drug) given 3 times per day
499404|NCT00405912|Drug|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
499405|NCT00405912|Drug|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
499406|NCT00405886|Drug|Neramexane|Oral tablets, duration: 16 weeks
499407|NCT00405886|Drug|Placebo|Oral tablets, duration: 16 weeks
499408|NCT00405873|Drug|AMT2003|
499409|NCT00405860|Drug|CellCept (mycophenolate mofetil)|
499410|NCT00405847|Drug|Dexmedetomidine|
499411|NCT00405834|Device|Envision® Patient Support System|
499412|NCT00405821|Drug|Acyclovir|400mg twice daily for 24 months
499413|NCT00405821|Drug|Placebo|Placebo tablet twice daily for 24 months
499414|NCT00405808|Drug|Rimonabant|Once daily in the morning
499415|NCT00405808|Drug|Placebo|Once daily in the morning
499416|NCT00405795|Device|Envision® Patient Support System|
499417|NCT00405782|Behavioral|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
499418|NCT00405769|Drug|red yeast rice|600 mg 3 caps bid
499419|NCT00405769|Drug|placebo|3 caps bid
499420|NCT00405756|Drug|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
499421|NCT00405756|Drug|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
499422|NCT00405756|Drug|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
499423|NCT00405756|Drug|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.~Double-blind maintenance: at the investigator's discretion"
499424|NCT00405756|Drug|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.~Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
499425|NCT00405756|Drug|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
499426|NCT00405756|Drug|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
499427|NCT00405743|Drug|CP-4055|CP-4055 Continuous IV infusion
499428|NCT00405743|Drug|CP-4055|CP4055 2 and 4 hour IV infusion
499429|NCT00405730|Drug|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
499430|NCT00405730|Drug|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
499431|NCT00405730|Other|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
499432|NCT00405717|Drug|atorvastatin,pravastatin|
499433|NCT00405704|Drug|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
499434|NCT00405704|Drug|Placebo|Cherry flavored liquid suspension matched to active comparator.
499435|NCT00405691|Device|"TOPS System - Total Posterior Arthroplasty Implant"|
499436|NCT00405678|Behavioral|Exercise Training|Subjects receiving chemo with exercise training
499437|NCT00405678|Behavioral|Chemo only|Subjects receiving chemo only
499438|NCT00405665|Drug|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
499439|NCT00405665|Drug|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
499440|NCT00405652|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
499441|NCT00405639|Drug|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
499442|NCT00405639|Drug|Placebo|Normal saline will be used for placebo.
499443|NCT00405626|Drug|Bellis Perenis ,Arnica montana|
499444|NCT00405613|Drug|Aspirin|
499445|NCT00405600|Procedure|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
499446|NCT00405587|Drug|PLX4032|Oral capsules administered BID
499447|NCT00405574|Drug|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
499448|NCT00405561|Drug|AMT2003|
499449|NCT00405548|Drug|BNP (nesiritide)|
499450|NCT00405548|Drug|Placebo|
499451|NCT00405535|Drug|glycine|
499452|NCT00405535|Other|placebo|
499560|NCT00404638|Behavioral|Paula Method of Circular Muscle Exercise|
499561|NCT00404625|Behavioral|Risk factors for infections due to ESBL+ Enterobacteriaceae|
499453|NCT00405522|Drug|Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
499454|NCT00405522|Drug|Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
499455|NCT00405496|Drug|Difluprednate Ophthalmic Emulsion|
499456|NCT00405483|Procedure|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
499457|NCT00405483|Procedure|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
499458|NCT00405470|Device|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
499459|NCT00405457|Drug|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
499460|NCT00405444|Drug|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
499461|NCT00405444|Drug|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
499462|NCT00405431|Drug|Restasis|1 drop in study eye twice a day X 6 months
499463|NCT00405431|Drug|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
499464|NCT00405418|Drug|Insulin glargine|Subcutaneous injection, once a day in the evening
499465|NCT00405418|Drug|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
499466|NCT00405405|Drug|Cisplatin|"Two cycles during neoadjuvant therapy~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
499467|NCT00405405|Drug|Docetaxel|"Two cycles during neoadjuvant therapy~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
499468|NCT00405405|Drug|Bevacizumab|"Two cycles during neoadjuvant therapy~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
499469|NCT00405405|Drug|Erlotinib|"Two cycles during neoadjuvant therapy (dose escalation)~Response assessment at approximately day 36~Concurrent biochemoradiotherapy"
499470|NCT00405405|Radiation|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
499471|NCT00405392|Drug|Ibandronate (SB743830HD)|
499472|NCT00405379|Device|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
499473|NCT00405366|Drug|sorafenib tosylate|Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
499474|NCT00405353|Drug|Androgel 10 grams of gel containing 100 mg of testosterone|testosterone gel
499475|NCT00405340|Drug|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
499476|NCT00405327|Biological|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
499477|NCT00405327|Other|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
499478|NCT00405314|Device|Continuous positive airway pressure ventilation mask|
499479|NCT00405301|Drug|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
499480|NCT00405288|Drug|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
499481|NCT00405275|Drug|Etanercept|etanercept, subcutaneous injection
499482|NCT00405275|Drug|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
499483|NCT00405275|Drug|Sulfasalazine|sulfasalazine, oral
499484|NCT00405275|Drug|Hydroxychloroquine|hydroxychloroquine, oral
499485|NCT00405275|Drug|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
499486|NCT00405275|Drug|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
499487|NCT00405262|Drug|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
499488|NCT00405262|Drug|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
499489|NCT00405262|Drug|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
499490|NCT00405249|Drug|elvucitabine|
499491|NCT00405236|Drug|tiotropium|
499492|NCT00405210|Drug|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
499493|NCT00405197|Behavioral|Isocaloric diet high in MUFA or Mediterranean diet|
499562|NCT00404625|Behavioral|Risk factors for inadequate initial antimicrobial therapy|
499494|NCT00405184|Drug|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
499495|NCT00405184|Drug|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
499496|NCT00405171|Drug|Nevirapine|
499497|NCT00405158|Procedure|Acupuncture treatment|
499498|NCT00405158|Procedure|Administration of oxytocin nasal spray|
499499|NCT00405158|Procedure|Improved breast milk removal|
499500|NCT00405158|Procedure|Warmth applied to breasts|
499501|NCT00405158|Procedure|Breast massage|
499502|NCT00405158|Drug|Anti-pyretic medication, paracetamol|
499503|NCT00405158|Drug|cefadroxil|
499504|NCT00405158|Drug|penicillin|
499505|NCT00405158|Drug|flucloxacillin|
499506|NCT00405119|Drug|AH23844 (lavoltidine)|
499507|NCT00405119|Drug|NEXIUM (esomeprazole)|
499508|NCT00405119|Drug|ZANTAC (ranitidine)|
499509|NCT00405080|Drug|GW679769 (Casopitant) oral tablets|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
499510|NCT00405080|Drug|Rifampin oral capsules|Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
499511|NCT00405067|Drug|BMS-201038 (AEGR-733)|
499512|NCT00405067|Drug|Ezetimibe|
499513|NCT00405054|Drug|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
499514|NCT00405041|Dietary Supplement|Dietary supplement GVG 2|2.670 g/day for 14 days
499515|NCT00405015|Drug|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
499516|NCT00405002|Procedure|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
499517|NCT00404963|Drug|placebo|
499518|NCT00404963|Drug|GSK376501|
499519|NCT00404937|Drug|Tobradex (Antibiotic steroid combination)|
499520|NCT00404924|Drug|ZD6474 (vandetanib)|once daily oral tablet
499521|NCT00404924|Other|Best Supportive Care|standard of care
499522|NCT00404911|Behavioral|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
499523|NCT00404911|Behavioral|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
499524|NCT00404885|Drug|Placebo|PO BID
499525|NCT00404885|Drug|LX211|0.2 mg/kg, twice a day (BID)
499526|NCT00404885|Drug|LX211|0.4 mg/kg, twice a day (BID)
499527|NCT00404885|Drug|LX211|0.6 mg/kg, twice a day (BID)
499528|NCT00404846|Procedure|Hyperbaric Oxygenation Therapy|
499529|NCT00404833|Drug|prednisolone and mycophenolate mofetil|
499530|NCT00404833|Drug|prednisolone and chlorambucil|
499531|NCT00404820|Drug|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
499532|NCT00404820|Drug|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
499533|NCT00404820|Drug|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
499534|NCT00404807|Device|CPAP(Continuous Positive Airway Pressure)|
499535|NCT00404794|Drug|prednisolone and mycophenolate mofetil|
499536|NCT00404794|Drug|prednisolone and tacrolimus|
499537|NCT00404781|Drug|cilostazol in addition to aspirin and clopidogrel|
499538|NCT00404768|Drug|GSK221149A|6mg/h and 12 mg/h
499539|NCT00404768|Drug|Placebo|Matched Placebo to Drug
499540|NCT00404755|Drug|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
499541|NCT00404755|Drug|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
499542|NCT00404755|Drug|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
499543|NCT00404742|Drug|Placebo|PO BID
499544|NCT00404742|Drug|LX211|0.2 mg/kg, twice a day (BID)
499545|NCT00404742|Drug|LX211|0.4 mg/kg, twice a day (BID)
499546|NCT00404742|Drug|LX211|0.6 mg/kg, twice a day (BID)
499547|NCT00404729|Drug|Cytidine-5’-diphosphocholine (Citicoline)|
499548|NCT00404716|Drug|Cilostazol|
499549|NCT00404703|Drug|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
499550|NCT00404703|Drug|Platinum-based chemotherapy|As prescribed
499551|NCT00404690|Procedure|Bedside Silo|silo placed at bedside on admission
499552|NCT00404690|Procedure|Operative attempt at closure|go the operating room to attempt closure
499553|NCT00404677|Other|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
499554|NCT00404664|Behavioral|influenza vaccine, reminders letters, raffle prize|
499555|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
499556|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
499557|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
499558|NCT00404651|Biological|DTaP-HBV-IPV vaccine|0.5 mL, IM
499559|NCT00404638|Drug|Desmopresin|
499563|NCT00404625|Behavioral|Overall and 30-day mortality in bad first antibiotic therapy|
499564|NCT00404612|Drug|Placebo|PO BID
499565|NCT00404612|Drug|LX211|0.2 mg/kg, twice a day (BID)
499566|NCT00404612|Drug|LX211|0.4 mg/kg, twice a day (BID)
499567|NCT00404612|Drug|LX211|0.6 mg/kg, twice a day (BID)
499568|NCT00404599|Drug|atrorvastatin 10mg|Atorvastatin 10 mg once a day
499569|NCT00404599|Drug|simvastatin 40mg|simvastatin 40mg once a day
499570|NCT00404586|Drug|GW784568X|GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
499571|NCT00404586|Drug|Fluticasone propionate|Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
499572|NCT00404586|Drug|Placebo|Matching Placebo to GW784568X as aqueous nasal spray.
499573|NCT00404573|Drug|RGH-188|
499574|NCT00404547|Drug|Ciclesonide|Asthma Care with Alvesco
499575|NCT00404547|Drug|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
499576|NCT00404534|Drug|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
499577|NCT00404521|Drug|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
499578|NCT00404508|Drug|Hydralazine and magnesium valproate|
499579|NCT00404495|Drug|Irinotecan|Irinotecan 10 mg/m^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
499580|NCT00404495|Drug|Temozolomide|Temozolomide 100-125 mg/m^2 daily on days 1-5 in repeated 3 week cycles
499581|NCT00404482|Drug|Cyclosporine A|
499582|NCT00404469|Procedure|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
499583|NCT00404469|Procedure|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
499584|NCT00404469|Procedure|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
499585|NCT00404456|Drug|Melatonin|Melatonin 3 mg once-daily
499586|NCT00404443|Device|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
499587|NCT00404417|Drug|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
499588|NCT00404417|Drug|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
499589|NCT00404417|Drug|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
499590|NCT00404417|Drug|Placebo / Placebo|Placebo at first injection / Placebo at second injection
499591|NCT00404404|Biological|bevacizumab|
499592|NCT00404404|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
499593|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|1 tablet every 12 hours
499594|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets every 12 hours
499595|NCT00404391|Drug|Placebo|2 tablets every 12 hours
499596|NCT00404378|Drug|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
499597|NCT00404378|Drug|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
499598|NCT00404378|Drug|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
499599|NCT00404365|Other|counseling intervention|
499600|NCT00404365|Other|screening questionnaire administration|
499601|NCT00404365|Other|study of socioeconomic and demographic variables|
499602|NCT00404365|Procedure|psychosocial assessment and care|
499603|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
499604|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
499605|NCT00404352|Drug|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
499606|NCT00404339|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
499607|NCT00404339|Biological|tetanus toxoid helper peptide|
499608|NCT00404339|Procedure|adjuvant therapy|
499609|NCT00404326|Drug|Hydralazine and magnesium valproate|
499610|NCT00404326|Procedure|Punch biopsy of the primary tumor|
499611|NCT00404313|Drug|MK0633|Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
499612|NCT00404313|Drug|Comparator: placebo|Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
499613|NCT00404300|Drug|Optivate|Plasma-derived Factor VIII
499614|NCT00404287|Drug|Fluvastatin|
499615|NCT00404274|Drug|Casopitant (GW679769) oral tablets|Casopitant will be available in the dose strength of 20,30 or 50 mg
499616|NCT00404274|Drug|Warfarin oral tablets|Warfarin will be available in the dose strength of 5 mg
499617|NCT00404261|Drug|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
499777|NCT00403065|Procedure|quality-of-life assessment|
499618|NCT00404248|Drug|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
499619|NCT00404248|Other|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
499620|NCT00404235|Drug|carboplatin|
499621|NCT00404235|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
499622|NCT00404222|Drug|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
499623|NCT00404222|Drug|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
499624|NCT00404222|Drug|Placebo|q 4 hours x 3
499625|NCT00404209|Procedure|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
499626|NCT00404196|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
499627|NCT00404183|Drug|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
499628|NCT00404183|Drug|Placebo|2 tablets BID
499629|NCT00404170|Drug|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
499630|NCT00404157|Drug|Rituximab|
499631|NCT00404144|Device|Drug Eluting Balloon|PCI of small vessels single arm study
499632|NCT00404131|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
499633|NCT00404105|Procedure|PRK|
499634|NCT00404105|Procedure|LASIK|
499635|NCT00404092|Drug|caspofungin|i.v.
499636|NCT00404079|Drug|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
499637|NCT00404079|Drug|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
499638|NCT00404066|Drug|Lapatinib|1250 mg, tablets, oral daily during treatment with docetaxel (3-week cycles x 4 cycles)
499639|NCT00404066|Drug|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
499640|NCT00404066|Drug|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
499641|NCT00404066|Drug|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
499642|NCT00404066|Drug|Pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
499643|NCT00404066|Drug|Filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
499644|NCT00404066|Drug|Dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
499645|NCT00404066|Drug|Trastuzumab|Loading dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeks for 1 year
499646|NCT00404053|Drug|Clopidogrel|
499647|NCT00404040|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
499648|NCT00404040|Drug|Lactulose|
499649|NCT00404014|Drug|AL-208|1 dose of 300 mg
499650|NCT00404014|Drug|Placebo|1 dose of placebo
499651|NCT00404001|Drug|MD-0727|
499652|NCT00403988|Drug|Oxaliplatin|
499653|NCT00403988|Drug|vinorelbine|
499654|NCT00403975|Drug|diquafosol tetrasodium ophthalmic solution, 2%|
499655|NCT00403962|Drug|vestipitant/paroxetine|
499656|NCT00403949|Drug|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
499657|NCT00403949|Drug|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
499658|NCT00403936|Procedure|OA decompression manipulation|
499659|NCT00403923|Dietary Supplement|Lactose in water|
499660|NCT00403910|Drug|Canrenone|
499661|NCT00403897|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
499662|NCT00403884|Procedure|Selective RPE laser treatment|interventional SRT laser treatment
499663|NCT00403858|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
499664|NCT00403858|Drug|Lactulose|
499665|NCT00403845|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
499666|NCT00403845|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
499667|NCT00403845|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
499668|NCT00403832|Device|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
499669|NCT00403819|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
499670|NCT00403806|Drug|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
499671|NCT00403806|Drug|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
499672|NCT00403806|Drug|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
499673|NCT00403806|Drug|Saline|Intravenous saline
499674|NCT00403793|Drug|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
499675|NCT00403793|Drug|Placebo|42 or 44 weeks with placebo implant and placebo injections
499676|NCT00403780|Drug|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.~Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
499677|NCT00403780|Drug|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
499678|NCT00403767|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
499778|NCT00403065|Radiation|radiation therapy|
499679|NCT00403767|Drug|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
499680|NCT00403767|Drug|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
499681|NCT00403767|Drug|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
499682|NCT00403754|Drug|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
499683|NCT00403754|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
499684|NCT00403754|Drug|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
499685|NCT00403741|Behavioral|motivational interviewing|
499686|NCT00403728|Drug|ciclosporine A|
499687|NCT00403715|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
499688|NCT00403702|Drug|Oxane HD [oil-RMN3-mixture]|
499689|NCT00403702|Drug|Densiron [(F6H8)|
499690|NCT00403689|Dietary Supplement|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
499691|NCT00403689|Dietary Supplement|placebo|1.5 g waxy maize starch daily
499692|NCT00403676|Other|Follow up bu a nurse|Follow up bu a nurse
499693|NCT00403676|Other|Follow up by a medical doctor|Follow up by a medical doctor
499694|NCT00403663|Drug|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
499695|NCT00403650|Drug|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
499696|NCT00403637|Drug|indacaterol maleate|
499697|NCT00403624|Drug|OXALIPLATIN|
499698|NCT00403611|Drug|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
499699|NCT00403611|Drug|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
499700|NCT00403585|Drug|adefovir dipivoxil 10mg|
499701|NCT00403559|Drug|Elidel|
499702|NCT00403546|Drug|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
499703|NCT00403546|Drug|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
499704|NCT00403546|Drug|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
499705|NCT00403533|Drug|20 mg of atorvastatin daily|
499706|NCT00403520|Drug|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
499707|NCT00403520|Drug|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
499708|NCT00403507|Behavioral|Participation in a monitored exercise program|No contact with control group during 20 weeks.
499709|NCT00403507|Behavioral|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
499710|NCT00403494|Drug|Placebo for 6R-BH4 (sapropterin dihydrochloride)|Placebo to be administered in the same manner as that of the investigational product for 24 weeks
499711|NCT00403494|Drug|6R-BH4 (sapropterin dihydrochloride)|800 mg/day 6R-BH4 tablets, divided into two doses, administered orally for 24 weeks
499712|NCT00403494|Drug|6R-BH4 (sapropterin dihydrochloride)|800 mg/day of 6R-BH4 tablets, divided into two doses, administered orally, plus 1000mg/day Vitamin C caplets, divided into two doses, administered orally for 24 weeks
499713|NCT00403494|Drug|Placebo for 6R-BH4 (sapropterin dihydrochloride)|Placebo to be administered in the same manner as that of the investigational product, plus 1000mg/day Vitamin C, divided into two doses, for 24 weeks
499714|NCT00403481|Drug|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
499715|NCT00403481|Drug|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
499716|NCT00403455|Drug|Paroxetine|SSRI
499717|NCT00403442|Device|Verteporfin Therapy/ Drug: Bevacizumab|
499718|NCT00403429|Drug|capecitabine|
499719|NCT00403416|Drug|AEB071|
499720|NCT00403416|Drug|Mycophenolic Acid|
499721|NCT00403403|Drug|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
499722|NCT00403403|Drug|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve [AUC]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
499723|NCT00403403|Drug|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
499724|NCT00403390|Drug|Brand Name Levothyroxine (Synthroid)|Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
499725|NCT00403390|Drug|Generic formulation of Levothyroxine|Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
499779|NCT00403052|Drug|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
499726|NCT00403377|Behavioral|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
499727|NCT00403364|Drug|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
499728|NCT00403338|Device|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
499729|NCT00403325|Drug|rhuFab V2 [ranibizumab] ( Lucentis )|
499730|NCT00403312|Behavioral|Smoking Cessation Behavioral Program|
499731|NCT00403312|Drug|Nicotine Patch|
499732|NCT00403312|Behavioral|Physical Activity|
499733|NCT00403299|Procedure|MDCT of the coronary arteries.|
499734|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
499735|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
499736|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
499737|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
499738|NCT00403286|Drug|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
499739|NCT00403286|Drug|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
499740|NCT00403286|Drug|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
499741|NCT00403286|Drug|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
499742|NCT00403273|Drug|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
499743|NCT00403273|Drug|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
499744|NCT00403260|Drug|Pyronaridine artesunate|once a day for 3 days
499745|NCT00403260|Drug|Mefloquine plus artesunate|once a day for 3 days
499746|NCT00403247|Dietary Supplement|Capsule with folate, Vitamin B12 & pyridoxine|
499747|NCT00403247|Other|placebo|placebo capsule
499748|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
499749|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
499750|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
499751|NCT00403234|Drug|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
499752|NCT00403221|Genetic|RTVP-1 Gene|"Cohort Level #1 1.0 x 1010vp Cohort Level #2 5.0x1010vp Cohort Level #3 1.0 x 1011vp Cohort Level #4 5.0x1011vp Cohort Level #5 1.0 x 1012vp Cohort Level #6 5.0x1012vp~One dose only followed by a radical prostatectomy 4 weeks later."
499753|NCT00403208|Procedure|Analgesia based sedation in ICU patients|
499754|NCT00403182|Drug|chemotherapy|
499755|NCT00403182|Drug|letrozole|
499756|NCT00403169|Drug|lenalidomide|drug
499757|NCT00403156|Drug|Imatinib Mesylate /Ranibizumab|
499758|NCT00403143|Procedure|cataract surgery|
499759|NCT00403130|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
499760|NCT00403130|Drug|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
499761|NCT00403130|Drug|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
499762|NCT00403117|Drug|Placebo + Inactive Marijuana (0% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
499763|NCT00403117|Drug|Placebo + Active Marijuana (3.27% THC)|One capsule containing placebo was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before administration of a marijuana cigarette containing 3.27% THC (ca. 800 mg) provided by the National Institute on Drug Abuse.
499764|NCT00403117|Drug|Naltrexone 12 Mg+ Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
499765|NCT00403117|Drug|Naltrexone 25 Mg + Active Marijuana (3.27% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before active marijuana administration.
499766|NCT00403117|Drug|Naltrexone 50 Mg+ Active Marijuana (3.27% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
499767|NCT00403117|Drug|Naltrexone 100 Mg+ Active Marijuana (3.27% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
499768|NCT00403117|Drug|Naltrexone 12 Mg + Inactive Marijuana (0% THC)|One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
499769|NCT00403117|Drug|Naltrexone 25 Mg + Inactive Marijuana (0% THC)|One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
499770|NCT00403117|Drug|Naltrexone 50 Mg + Inactive Marijuana (0% THC)|One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
499771|NCT00403117|Drug|Naltrexone 100 Mg + Inactive Marijuana (0% THC)|One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
499772|NCT00403104|Drug|ONO-2506PO|1200 mg QD / 18 months
499773|NCT00403104|Drug|ONO-2506PO|0 mg QD / 18 months
499774|NCT00403091|Behavioral|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
499775|NCT00403091|Behavioral|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
499776|NCT00403065|Drug|dexamethasone|
499780|NCT00403039|Drug|Ranibizumab (Lucentis )|
499781|NCT00403026|Drug|Bevacizumab ( Avastin)|
499782|NCT00403013|Procedure|Positioning and anesthesia|Positioning during axillary plexus block
499783|NCT00403000|Drug|dutasteride|Oral
499784|NCT00402987|Drug|celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
499785|NCT00402987|Drug|celecoxib followed by placebo|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
499786|NCT00402987|Drug|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
499787|NCT00402987|Drug|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
499788|NCT00402974|Drug|menaquinone 7|
499789|NCT00402961|Other|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
499790|NCT00402961|Other|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
499791|NCT00402948|Drug|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
499792|NCT00402948|Drug|ASM8|inhalation 0.25mg daily for 14 days
499793|NCT00402935|Other|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
499794|NCT00402935|Procedure|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
499795|NCT00402935|Procedure|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
499796|NCT00402935|Procedure|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
499797|NCT00402909|Drug|Nateglinide|
499798|NCT00402896|Drug|ZD6474|300 mg/day orally for 10 weeks.
499799|NCT00402883|Drug|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
499800|NCT00402883|Drug|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
499801|NCT00402883|Procedure|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
499802|NCT00402883|Other|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
499803|NCT00402883|Other|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
499804|NCT00402883|Drug|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
499805|NCT00402870|Device|ProSeal LMA|ProSeal LMA vs Tracheal Tube
499806|NCT00402870|Device|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
499807|NCT00402857|Behavioral|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
499808|NCT00402844|Device|Transvaginal mesh- PROLIFT®-system|
499809|NCT00402831|Biological|ProQuad®|Each dose (0.5 mL) contains live attenuated versions of measles virus Enders' Edmonston strain, mumps virus Jeryl Lynn™ (Level B) strain, rubella virus Wistar RA 27/3 strain, and varicella virus Oka/Merck strain.
499810|NCT00402805|Biological|Trivalent Inactivated Influenza Vaccine|
499811|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
499812|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
499813|NCT00402792|Drug|Placebo|2 tablets q 12 hours
499814|NCT00402779|Drug|Erlotinib|150 mg by mouth daily
499815|NCT00402779|Drug|Placebo|Tablet by mouth daily
499816|NCT00402766|Drug|Cisplatin|Starting Dose: 60 mg/m^2 by vein, Over 2 Hours
499817|NCT00402766|Drug|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
499818|NCT00402766|Drug|Pemetrexed|Starting Dose: 500 mg/m^2 by vein, Over 40 Minutes
499819|NCT00402766|Drug|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
499820|NCT00402753|Behavioral|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
499821|NCT00402740|Device|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
499822|NCT00402727|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
499823|NCT00402727|Drug|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
500101|NCT00400946|Drug|vincristine sulfate|
500102|NCT00400946|Radiation|radiation therapy|
499824|NCT00402714|Procedure|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
499825|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
499826|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
499827|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
499828|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
499829|NCT00402701|Behavioral|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
499830|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
499831|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
499832|NCT00402688|Drug|levofloxacin|500mg tablet once daily for 4 weeks.
499833|NCT00402675|Procedure|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
499834|NCT00402662|Drug|everolimus|
499835|NCT00402662|Drug|Imatinib|
499836|NCT00402649|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
499837|NCT00402636|Device|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
499838|NCT00402636|Device|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
499839|NCT00402623|Dietary Supplement|quercetin|1000 mg quercetin within 24 hours
499840|NCT00402623|Other|placebo|
499841|NCT00402610|Drug|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
499842|NCT00402597|Drug|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
499843|NCT00402597|Drug|Placebo|1 placebo tablet twice daily for 6 months.
499844|NCT00402597|Drug|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
499845|NCT00402584|Drug|sibutramine|
499846|NCT00402571|Drug|acetaminophen|
499847|NCT00402558|Drug|Thymoglobulin|1.5 mg/kg By Vein Daily x 3 Days
499848|NCT00402558|Drug|Busulfan|130 mg/m^2 By Vein Over 3 Hours x 4 Days
499849|NCT00402558|Drug|Fludarabine|40 mg/m^2 By Vein Over 30 Minutes x 4 Days
499850|NCT00402558|Procedure|Alloreactive NK Infusion|Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
499851|NCT00402558|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.
499852|NCT00402558|Drug|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
499853|NCT00402558|Drug|Methotrexate|5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
499854|NCT00402558|Drug|Interleukin-2|0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
499855|NCT00402545|Drug|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
499856|NCT00402545|Drug|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
499857|NCT00402545|Drug|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
499858|NCT00402545|Drug|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
499859|NCT00402532|Drug|Everolimus|Initial dosage 2 x 0.75 mg/d
499860|NCT00402532|Drug|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
499861|NCT00402519|Radiation|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
499862|NCT00402519|Radiation|External beam whole breast irradiation|Standard Whole breast irradiation
499863|NCT00402506|Drug|(MC-1) Pyridoxal 5'-phosphate|
499864|NCT00402493|Drug|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
499865|NCT00402493|Drug|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
499866|NCT00402493|Drug|Ibuprofen|ibuprofen 200mg
499867|NCT00402480|Drug|Hydroxyurea|
499868|NCT00402467|Drug|Rivaroxaban (BAY59-7939)|2.5mg bid
499869|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|5mg bid
499870|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|10 mg bid
499871|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|20mg bid
499872|NCT00402467|Drug|Enoxaparine|30mg bid
499873|NCT00402467|Drug|Enoxaparine|30mg bid
499874|NCT00402454|Drug|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
499875|NCT00402441|Drug|Risedronate (HMR4003)|
499876|NCT00402428|Drug|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
499877|NCT00402428|Drug|peginterferon alfa-2a|180 mcg once a week for 48 weeks
499878|NCT00402428|Drug|Ribavirin|"1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects~=,> 75kg)"
499879|NCT00402415|Drug|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
499880|NCT00402415|Drug|Rapamycin|"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
499881|NCT00402402|Procedure|Tuberculin skin test|
499882|NCT00402402|Procedure|Quantiferon-TB Gold assay|
499883|NCT00402389|Drug|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
500168|NCT00400374|Drug|Celecoxib|Celecoxib, 400 mg, daily for 6 months.
499884|NCT00402389|Behavioral|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
499885|NCT00402389|Drug|Placebo|Four capsules will be taken daily for 8 weeks.
499886|NCT00402376|Drug|Pravastatin, Carvedilol, Perindopril|
499887|NCT00402376|Device|Biventricular assist device (Thoratec paracorporeal assist device)|
499888|NCT00402363|Drug|omega-3-acid ethyl esters|
499889|NCT00402363|Drug|Placebo|
499890|NCT00402350|Drug|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
499891|NCT00402350|Drug|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
499892|NCT00402350|Drug|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
499893|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
499894|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
499895|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
499896|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
499897|NCT00402337|Drug|linaclotide acetate|oral, once daily.
499898|NCT00402337|Drug|Matching placebo|oral, once daily
499899|NCT00402324|Drug|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
499900|NCT00402324|Drug|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
499901|NCT00402324|Drug|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
499902|NCT00402311|Procedure|DOC-PG: integrated multidisciplinary assessment|
499903|NCT00402311|Procedure|Usual care: assessment by GP or one of the regional services|
499904|NCT00402298|Drug|3,4-methylenedioxymethemphetmaine (MDMA_|Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long psychotherapy session.
499905|NCT00402298|Drug|3,4-methylenedioxymethamphetamine|Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long psychotherapy sessions.
499906|NCT00402285|Dietary Supplement|lycopene supplement|
499907|NCT00402285|Dietary Supplement|fish oil supplement|
499908|NCT00402285|Other|Placebo|placebos for lycopene and fish oil.
499909|NCT00402272|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
499910|NCT00402259|Drug|Esomeprazole IV|
499911|NCT00402259|Drug|Omeprazole IV|
499912|NCT00402246|Other|Remote Management|"The Remote Management method of treating patients consists of 3 components:~CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)~Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line~CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.~The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
499913|NCT00402246|Other|In-Office Care|Routine in-office care
499914|NCT00402233|Drug|Pramipexole|
499915|NCT00402233|Drug|Placebo|
499916|NCT00402220|Drug|TMS|Active Transcranial Magnetic Stimulation
499917|NCT00402220|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
499918|NCT00402207|Drug|extrafine HFA-beclomethasone|
499919|NCT00402207|Drug|HFA-fluticasone|
499920|NCT00402194|Drug|Losartan|Tablet, 100mg, once per day for 3 months
499921|NCT00402181|Biological|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
499922|NCT00402181|Drug|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
499923|NCT00402168|Drug|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
499924|NCT00402168|Drug|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2* daily for one year
499925|NCT00402168|Drug|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2* daily for one year
499926|NCT00402155|Behavioral|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
499927|NCT00402142|Biological|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
499928|NCT00402142|Biological|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
499929|NCT00402142|Biological|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
499930|NCT00402142|Biological|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
499931|NCT00402142|Biological|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
499932|NCT00402129|Procedure|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
499933|NCT00402116|Drug|enzastaurin|Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles
499934|NCT00402116|Drug|temozolomide|75 mg/m2, oral, daily, 6 weeks 200 mg/m2, oral, daily, twelve 28 day cycles
499935|NCT00402116|Radiation|radiation|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
499936|NCT00402103|Drug|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
499937|NCT00402103|Drug|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
527545|NCT00173641|Procedure|blood drawing|
499938|NCT00402103|Drug|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
499939|NCT00402077|Drug|pramlintide acetate|subcutaneous injection, three times a day, 120mcg
499940|NCT00402077|Drug|sibutramine|oral tablet, once a day, 10mg
499941|NCT00402077|Drug|phentermine|oral tablet, once a day, 37.5mg
499942|NCT00402077|Drug|placebo|subcutaneous injection, three times a day
499943|NCT00402051|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
499944|NCT00402051|Drug|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
499945|NCT00402051|Drug|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
499946|NCT00402038|Drug|SC Methylnaltrexone|Dose 1
499947|NCT00402038|Drug|SC Placebo|
499948|NCT00402025|Biological|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
499949|NCT00402012|Drug|Pioglitazone|During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
499950|NCT00401986|Device|Bronchial thermopladsty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY
499951|NCT00401973|Drug|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
499952|NCT00401973|Drug|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
499953|NCT00401973|Drug|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
499954|NCT00401973|Drug|zonisamide|Zonisamide, 100-400mg, oral, daily.
499955|NCT00401973|Behavioral|Wellness education|weight management
499956|NCT00401960|Drug|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
499957|NCT00401947|Drug|ACH-0137171|
499958|NCT00401921|Drug|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
499959|NCT00401921|Drug|Placebo oral capsule|1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
499960|NCT00401895|Device|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
499961|NCT00401882|Drug|Epinephrine|Epinephrine (1 mg) IV additional doses
499962|NCT00401882|Drug|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
499963|NCT00401869|Drug|Epoetin alfa|
499964|NCT00401856|Drug|Eplerenone|50mg oral route
499965|NCT00401856|Drug|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
499966|NCT00401843|Biological|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
499967|NCT00401843|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
499968|NCT00401843|Drug|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
499969|NCT00401843|Drug|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
499970|NCT00401830|Drug|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
499971|NCT00401830|Other|Placebo|Matching placebo tablet administered twice daily
499972|NCT00401817|Drug|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
499973|NCT00401817|Drug|Rituximab|"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.~The dose to be administered is:~Rituximab: 375 mg/m2"
499974|NCT00401817|Drug|CHOP|Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
499975|NCT00401804|Drug|Dexamethasone, Bortezomib, Doxorubicin|
499976|NCT00401791|Behavioral|Exercise|"Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period~Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer."
499977|NCT00401778|Drug|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
500103|NCT00400933|Behavioral|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
499978|NCT00401765|Drug|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
499979|NCT00401765|Drug|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
499980|NCT00401752|Drug|Esomeprazole|
499981|NCT00401752|Drug|Ranitidine|
499982|NCT00401739|Drug|CSL360|Weekly IV Infusion. Dose escalation study.
499983|NCT00401726|Drug|Venlafaxine ER|
499984|NCT00401726|Behavioral|Dialogues Time to Talk Program|
499985|NCT00401713|Procedure|Transplantation of autologous RPE|RPE cell suspension
499986|NCT00401713|Procedure|Translocation of autologous RPE and Choroid|RPE patch
499987|NCT00401687|Drug|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
499988|NCT00401674|Drug|carboplatin|
499989|NCT00401674|Drug|paclitaxel|
499990|NCT00401661|Drug|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
499991|NCT00401648|Drug|Brivaracetam|
499992|NCT00401635|Drug|liposomal doxorubicin|
499993|NCT00401635|Drug|carboplatin|
499994|NCT00401622|Behavioral|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
499995|NCT00401622|Behavioral|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
499996|NCT00401609|Drug|gemcitabine|
499997|NCT00401609|Drug|vinorelbine|
499998|NCT00401609|Drug|cisplatin|
499999|NCT00401609|Drug|etoposide|
500000|NCT00401609|Drug|carboplatin|
500001|NCT00401596|Drug|Xolair (omalizumab)|
500002|NCT00401583|Drug|GW786034 (pazopanib)|Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
500003|NCT00401583|Drug|Probe drugs|probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).
500004|NCT00401570|Drug|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
500005|NCT00401570|Drug|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
500006|NCT00401544|Drug|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
500007|NCT00401544|Drug|IV iron dextran|Administered by intravenous (IV) injection.
500008|NCT00401531|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
500009|NCT00401531|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
500010|NCT00401518|Device|ACADIA® Facet Replacement System|Investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
500011|NCT00401518|Device|Instrumented posterolateral fusion|Control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
500012|NCT00401492|Drug|gemcitabine prolonged continuous infusion|
500013|NCT00401492|Drug|cisplatin|
500014|NCT00401492|Drug|vinorelbine|
500015|NCT00401479|Drug|Placebo|
500016|NCT00401479|Drug|Solabegron (GW427353)|
500017|NCT00401466|Device|Implantable Cardioverter Defibrillator|ICD with Biotronik Home Monitoring capability
500018|NCT00401453|Behavioral|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
500019|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
500020|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
500021|NCT00401427|Drug|trastuzumab|
500022|NCT00401427|Drug|vinorelbine|
500023|NCT00401414|Drug|Warfarin|2 mg tablets take as directed by study staff (based on INR)
500024|NCT00401401|Drug|zalutumumab|Eight weekly infusions
500025|NCT00401401|Drug|cisplatin|Infusions
500026|NCT00401401|Procedure|Radiotherapy|Daily in the treatment period
500027|NCT00401388|Drug|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
500028|NCT00401388|Other|Loperamide|All patients should be instructed to take loperamide at the earliest signs of diarrhea and/or abdominal cramping after beginning perifosine.
500029|NCT00401388|Other|Allopurinol|Patients with a known history of hyperuricemia and/or gout should receive prophylactic treatment with allopurinol 300 mg po daily.
500030|NCT00401388|Other|Antiemetics|Antiemetic prophylaxis will be administered at the treating investigator's discretion.
500031|NCT00401375|Drug|Methylnaltrexone|Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.
500032|NCT00401375|Drug|Placebo|Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.
500033|NCT00401362|Drug|SC Methylnaltrexone|Dose 1
500034|NCT00401362|Drug|SC Placebo|
500035|NCT00401362|Drug|SC Methylnaltrexone|Dose 2
500036|NCT00401336|Device|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
500037|NCT00401323|Drug|docetaxel (XRP6976)|
500038|NCT00401323|Drug|cisplatin|
500039|NCT00401323|Drug|5-fluorouracil (5-FU)|
500040|NCT00401310|Drug|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
500041|NCT00401310|Drug|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
500042|NCT00401284|Drug|EVT 201|
500043|NCT00401271|Drug|OPC-67683|
500044|NCT00401271|Drug|Rifafour e-275|
500104|NCT00400907|Other|clinical observation|
500105|NCT00400907|Procedure|management of therapy complications|
500045|NCT00401258|Drug|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
500046|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 100 mg
500047|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 50 mg
500048|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
500049|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg
500050|NCT00401245|Drug|Placebo|Tapering placebo
500051|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
500052|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
500053|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
500054|NCT00401232|Procedure|Blood Collection|Blood Collection
500055|NCT00401219|Drug|conjugated estrogens/progestin (MPA)|
500056|NCT00401206|Drug|dexmedetomidine|
500057|NCT00401193|Drug|Tranexamic acid tablets|3900 mg/Day
500058|NCT00401193|Drug|Tranexamic acid tablets|1950 mg/Day
500059|NCT00401193|Drug|Placebo tablets|
500060|NCT00401180|Drug|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
500061|NCT00401180|Drug|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
500062|NCT00401167|Drug|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
500063|NCT00401154|Other|Stationary Cycling|Use of a stationary bicycle for exercise
500064|NCT00401141|Procedure|Blood samples|
500065|NCT00401128|Drug|gemcitabine hydrochloride|
500066|NCT00401128|Drug|irinotecan hydrochloride|
500067|NCT00401115|Drug|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
500068|NCT00401115|Drug|MS-R001 (rapamycin)|Intraocular injection in various dosages
500069|NCT00401102|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
500070|NCT00401089|Drug|Panax Ginseng|The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
500071|NCT00401076|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
500072|NCT00401063|Device|Acupuncture|Acupuncture treatment twice a day for eight weeks
500073|NCT00401050|Procedure|chiropractic manipulative therapy|
500074|NCT00401050|Procedure|knee exercises|
500075|NCT00401050|Procedure|Graston Instrument Soft Tissue Mobilization (GISTM)|
500076|NCT00401024|Drug|imatinib mesylate|
500077|NCT00401024|Other|pharmacological study|
500078|NCT00401024|Procedure|conventional surgery|
500079|NCT00401011|Drug|Perifosine|"Phase I: Patients will receive daily perifosine (doses 50 mg/m2 or 100 mg/m2) at bedtime.~Phase II: All patients will receive daily perifosine at bedtime. Patients will be evaluated every 3 weeks."
500080|NCT00401011|Drug|Bortezomib|Phase I: Patients will receive 1 mg/m2 or 1.3 mg/m2 on days 1, 4, 8, and 11 every 3 weeks. Phase II: Patients will receive bortezomib on days 1,4,8 and 11 every 3 weeks.
500081|NCT00401011|Drug|Dexamethasone|Phase II: If the patient shows progressive disease after 3 weeks, dexamethasone 20 mg will be added to perifosine and bortezomib on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine at bedtime and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
500082|NCT00400998|Drug|Fluticasone Propionate|"Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:~- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate."
500083|NCT00400998|Other|Matched FPANS placebo|"Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:~Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL."
500084|NCT00400985|Device|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is non randomized trial. Study divided in 3 phases among which the first phase is blinded towards device diagnostic data.
500085|NCT00400972|Device|GlideScope videolaryngoscope|
500086|NCT00400959|Procedure|cd133+cell intracoronary administration|
500087|NCT00400946|Drug|asparaginase|
500088|NCT00400946|Drug|cyclophosphamide|
500089|NCT00400946|Drug|cytarabine|
500090|NCT00400946|Drug|dexamethasone|
500091|NCT00400946|Drug|dexrazoxane hydrochloride|
500092|NCT00400946|Drug|doxorubicin hydrochloride|
500093|NCT00400946|Drug|etoposide|Given IV
500094|NCT00400946|Drug|leucovorin calcium|
500095|NCT00400946|Drug|mercaptopurine|Given orally
500096|NCT00400946|Drug|methotrexate|
500097|NCT00400946|Drug|methylprednisolone|
500098|NCT00400946|Drug|pegaspargase|Given IV
500099|NCT00400946|Drug|prednisolone|
500100|NCT00400946|Drug|therapeutic hydrocortisone|
500106|NCT00400881|Other|automatic tube compensation|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
500107|NCT00400868|Behavioral|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
500108|NCT00400855|Drug|Fluticasone propionate|Study drug
500109|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
500110|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
500111|NCT00400842|Drug|Placebo|Placebo
500112|NCT00400829|Drug|eribulin mesylate|Given IV
500113|NCT00400816|Drug|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off]
500114|NCT00400803|Drug|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
500115|NCT00400790|Drug|propofol|Propofol used as the primary anaesthetic agent
500116|NCT00400790|Drug|desflurane|Desflurane used as the primary anaesthetic
500117|NCT00400777|Drug|Valsartan, hydrochlorothiazide and amlodipine|
500118|NCT00400764|Drug|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
500119|NCT00400764|Drug|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
500120|NCT00400751|Behavioral|FAMCON (Family Consultation)|
500121|NCT00400738|Drug|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
500122|NCT00400725|Drug|Clobex Shampoo 0.05%|twice weekly
500123|NCT00400725|Drug|clobex shampoo placebo|twice weekly
500124|NCT00400712|Behavioral|physical rehabilitation|two weeks intensive physical rehabilitation
500125|NCT00400699|Other|counseling intervention|
500126|NCT00400699|Other|study of socioeconomic and demographic variables|
500127|NCT00400699|Procedure|psychosocial assessment and care|
500128|NCT00400686|Biological|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
500129|NCT00400673|Behavioral|Two-step remission induction and risk-oriented consolidation|
500130|NCT00400660|Drug|GSK615915A|GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
500131|NCT00400660|Drug|Placebo|Subjects will also receive placebo inhaler.
500132|NCT00400647|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
500133|NCT00400647|Drug|Mycophenolate mofetil|
500134|NCT00400634|Drug|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10^11 vg
500135|NCT00400634|Procedure|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
500136|NCT00400621|Drug|acetaminophen|
500137|NCT00400608|Drug|ADVAIR HFA|
500138|NCT00400608|Drug|ADVAIR DISKUS|
500139|NCT00400595|Drug|Mupirocin ointment|topical ointment (already in widespread clinical use)
500140|NCT00400595|Drug|Polysporin Triple|
500141|NCT00400582|Drug|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
500142|NCT00400569|Drug|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
500143|NCT00400556|Drug|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
500144|NCT00400543|Device|Continuous positive airway pressure (CPAP)|
500145|NCT00400530|Drug|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
500146|NCT00400530|Drug|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
500147|NCT00400517|Biological|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
500148|NCT00400517|Drug|thalidomide|doses up to 400 mg/day
500149|NCT00400517|Procedure|conventional surgery|SOC care surgery
500150|NCT00400517|Procedure|neoadjuvant therapy|post radical prostatectomy
500151|NCT00400491|Drug|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
500152|NCT00400491|Drug|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
500153|NCT00400478|Drug|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
500154|NCT00400465|Procedure|Normal dressing|Normal dressing
500155|NCT00400465|Procedure|Pressure dressing|Pressure dressing
500156|NCT00400452|Behavioral|wheelchair skills training|
500157|NCT00400439|Drug|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
500158|NCT00400439|Drug|placebo|po daily for 24 weeks
500159|NCT00400426|Procedure|Radiotherapy|20 Gy in 4 fx
500160|NCT00400413|Procedure|fMRI|
500161|NCT00400400|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
500162|NCT00400400|Drug|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
500163|NCT00400400|Drug|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
500164|NCT00400400|Drug|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
500165|NCT00400387|Drug|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
500166|NCT00400387|Dietary Supplement|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
500167|NCT00400374|Drug|Erlotinib|Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
527546|NCT00173628|Procedure|blood drawing|
500169|NCT00400361|Drug|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
500170|NCT00400348|Drug|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
500171|NCT00400335|Drug|Nanomilled testosterone|
500172|NCT00400335|Drug|commercially available dutasteride|
500173|NCT00400335|Drug|Nanomilled dutasteride|
500174|NCT00400322|Drug|Valganciclovir (Valcyte)|
500175|NCT00400309|Biological|REPEVAX® after REVAXIS®|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
500176|NCT00400309|Biological|REPEVAX® after Placebo|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
500177|NCT00400296|Drug|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
500178|NCT00400283|Drug|NNC 55-0414|
500179|NCT00400270|Procedure|Breathing and relaxation exercises: the Papworth Method|
500180|NCT00400257|Behavioral|Early detection of heart failure|Early detection of heart failure
500181|NCT00400244|Procedure|Wheelchair skills traing program|
500182|NCT00400231|Drug|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
500183|NCT00400231|Drug|Study Drug: Metformin|2000mg/day
500184|NCT00400231|Drug|Study Drug: fenofibrate|145mg/day of fenofibrate
500185|NCT00400231|Drug|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
500186|NCT00400218|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
500187|NCT00400205|Drug|Docetaxel|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
500188|NCT00400205|Drug|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
500189|NCT00400205|Drug|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
500190|NCT00400179|Drug|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.~Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
500191|NCT00400179|Drug|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
500192|NCT00400166|Behavioral|Recovery Mentor|Provided Recovery Mentor services
500193|NCT00400153|Drug|Atrovent Respimat (20 mcg)|
500194|NCT00400153|Drug|COMBIVENT MDI (36/206 mcg)|
500195|NCT00400153|Drug|Combivent Respimat (20 mcg/100 mcg)|
500196|NCT00400153|Drug|Placebo via corresponding inhaler for blinding purposes|
500197|NCT00400140|Device|Hyperopic lens|+3 D glasses
500198|NCT00400127|Device|Silesian suspension belt|
500199|NCT00400114|Drug|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
500200|NCT00400114|Drug|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
500201|NCT00400114|Procedure|Radiation|Radiation 50 Gy (weeks 4-9)
500202|NCT00400114|Procedure|Surgery|Esophagectomy
500203|NCT00400114|Drug|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
500204|NCT00400101|Biological|Virosome-formulated synthetic peptides (malaria vaccine)|
500205|NCT00400088|Drug|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
500206|NCT00400088|Drug|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
500207|NCT00400075|Drug|azathioprine|
500208|NCT00400075|Drug|cyclophosphamide|
500209|NCT00400036|Behavioral|Cod protein NCEP-diet|
500210|NCT00400023|Drug|S-1|"During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.~During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
500211|NCT00400023|Drug|FT|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
500212|NCT00400010|Behavioral|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
500213|NCT00399997|Behavioral|Exercise on Prescription|
500214|NCT00399984|Behavioral|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
500215|NCT00399971|Procedure|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
500216|NCT00399971|Drug|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
500217|NCT00399945|Drug|Tobramycin|
500218|NCT00399919|Drug|Propionyl-L-Carnitine|2 grams per day for six months
500219|NCT00399919|Drug|PLC|2 grams/day for six months
500220|NCT00399906|Drug|BMS-582949|Tablets, Oral, Once daily, 12 weeks
500221|NCT00399906|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks
500222|NCT00399893|Drug|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
500223|NCT00399893|Drug|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
500224|NCT00399880|Behavioral|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
500225|NCT00399867|Drug|Simvastatin|
527553|NCT00173472|Drug|Chemotherapy|
500226|NCT00399854|Device|Dhermia® – Industra Mecânica Fina Ltda|
500227|NCT00399841|Device|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
500228|NCT00399828|Device|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
500229|NCT00399802|Drug|ZA|Single ZA 4 mg IV infusion at the start of treatment
500230|NCT00399802|Drug|Odanacatib|Once-daily odanacatib 5 mg tablet for 4 weeks
500231|NCT00399802|Drug|Odanacatib matching placebo|Once-daily odanacatib matching placebo for 4 weeks
500232|NCT00399802|Drug|ZA matching placebo|Single IV infusion of ZA matching placebo given at the start of treatment
500233|NCT00399789|Drug|Perifosine|Perifosine will be tested in 3 dose forms
500234|NCT00399776|Radiation|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
500235|NCT00399763|Drug|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
500236|NCT00399763|Drug|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
500237|NCT00399750|Drug|oxaliplatin|
500238|NCT00399750|Drug|fluoropyrimidine|
500239|NCT00399750|Drug|bevacizumab|
500240|NCT00399737|Drug|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
500241|NCT00399724|Drug|Insulin glargine|
500242|NCT00399711|Drug|repaglinide and metformin combination tablet|
500243|NCT00399711|Drug|rosiglitazone and metformin combination tablet|
500244|NCT00399698|Drug|Risperdal|
500245|NCT00399685|Drug|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
500246|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
500247|NCT00399685|Drug|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
500248|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
500249|NCT00399672|Drug|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
500250|NCT00399672|Drug|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
500251|NCT00399659|Drug|Tegaserod|
500252|NCT00399646|Device|Metricath Gemini System|
500253|NCT00399633|Drug|sumatriptan|
500254|NCT00399620|Procedure|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
500255|NCT00399607|Procedure|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
500256|NCT00399607|Procedure|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
500257|NCT00399607|Procedure|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
500258|NCT00399607|Procedure|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
500259|NCT00399607|Procedure|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
500260|NCT00399594|Procedure|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
500261|NCT00399594|Procedure|B|LV lead placement in standard (lateral / posterolateral) position.
500262|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
500263|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
500264|NCT00399568|Drug|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
500265|NCT00399568|Drug|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
500266|NCT00399542|Drug|Lubiprostone|
500267|NCT00399542|Drug|Placebo|
500268|NCT00399529|Biological|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
500269|NCT00399529|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu (Carter et al., 1992) that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms (Emens, 2005). The antibody decreases heterodimer formation with other members of the EGFR family, thereby indirectly inhibiting signaling through the ras/Raf/MAPK and PI3K/Akt pathways (Arteaga, 2003). It also inhibits tumor neovascularization (Izumi et al., 2002), and augments apoptosis both in vitro and in vivo (Lee et al., 2002; Chang et al., 2003). Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
500270|NCT00399529|Drug|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
500271|NCT00399516|Device|Precision|
500272|NCT00399503|Procedure|Spectral T Wave Alternans|
500273|NCT00399503|Procedure|Modified Moving Average T Wave Alternans|
500274|NCT00399503|Procedure|Baroreceptor Sensitivity|
500275|NCT00399503|Procedure|Heart Rate Variability|
500276|NCT00399503|Procedure|Heart Rate Turbulence|
500277|NCT00399503|Procedure|Deceleration Capacity|
500278|NCT00399503|Procedure|Signal Averaged ECG|
500279|NCT00399490|Drug|RN624 (PF-04383119)|50 mcg/kg
500280|NCT00399477|Drug|rasagiline mesylate|Azilect®
500281|NCT00399477|Drug|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
500282|NCT00399477|Drug|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
500283|NCT00399477|Drug|Rasagiline mesylate with Requip|Azilect®, Requip
500284|NCT00399464|Drug|alfuzosin|
500285|NCT00399451|Drug|Polidocanol Sclerotherapy|
500286|NCT00399438|Drug|Placebo|Tablets, Oral, once daily, 2 weeks
500287|NCT00399438|Drug|BMS-562086|Tablets, Oral, once daily, 2 weeks
500288|NCT00399425|Drug|bemiparin (low molecular weight heparin)|
500289|NCT00399412|Device|subcutaneous ICD|
500290|NCT00399399|Drug|azathioprine|
500291|NCT00399399|Drug|cyclophosphamide|
500292|NCT00399386|Procedure|EP|
500293|NCT00399386|Procedure|ICD|
500294|NCT00399386|Procedure|Ablation|
500295|NCT00399360|Drug|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
500296|NCT00399360|Drug|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
500297|NCT00399360|Behavioral|Lifestyle Modification|Lifestyle Modification
500298|NCT00399334|Drug|antipsychotic medications|as prescribed
500299|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
500300|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
500301|NCT00399308|Device|Control (compression bandaging)|Multi-layer compression bandaging
500302|NCT00399295|Drug|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
500303|NCT00399282|Drug|Omega-3 and Vitamin E supplementation|
500304|NCT00399269|Drug|Recombinant Human Erythropoietin alpha|
500305|NCT00399256|Drug|Acetylcysteine|
500306|NCT00399256|Drug|Zinc|
500307|NCT00399243|Drug|Sumatriptan 4mg Statdose injection|4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
500308|NCT00399230|Drug|Optive|
500309|NCT00399217|Device|Subcutaneous Implantable Defibrillator (S-ICD) system|
500310|NCT00399217|Device|ICD|
500311|NCT00399204|Drug|Pioglitazone vs Metformin|
500312|NCT00399191|Drug|stable isotope of iron, dysprosium|
500313|NCT00399178|Drug|Transdermal delivery system|
500314|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
500315|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
500316|NCT00399165|Drug|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
500317|NCT00399165|Other|placebo sesame oil|placebo sesame oil
500318|NCT00399165|Drug|Dutasteride|24.5 mg po once (Day 0)
500319|NCT00399152|Drug|Perifosine|Perifosine Oral Dose
500320|NCT00399152|Drug|Sunitinib Malate|Sunitinib oral dose
500321|NCT00399126|Drug|Perifosine|Perifosine oral dose
500322|NCT00399126|Drug|Paclitaxel|Paclitaxel IV
500323|NCT00399113|Drug|188Re-PTI-6D2|monoclonal antibody
500324|NCT00399100|Procedure|HBO - hyperbaric oxygen treatment|
500325|NCT00399087|Drug|Perifosine|Perifosine oral administration
500326|NCT00399087|Drug|Docetaxel|IV administration
500327|NCT00399087|Drug|Prednisone|Oral administration
500328|NCT00399074|Drug|sulfadoxine pyrimethamine|Monthly SP
500329|NCT00399061|Drug|Systane, Optive, Restasis|Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
500330|NCT00399048|Drug|OROS hydromorphone HCL ; OxyContin|
500331|NCT00399035|Drug|Cediranib|oral tablet
500332|NCT00399035|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
500333|NCT00399035|Drug|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m^2(day 1) followed by oral capecitabine 1,000 mg/ m^2twice daily (day 1 to day 15)
500334|NCT00399035|Drug|Cediranib Placebo|oral tablet
500335|NCT00399022|Drug|Duloxetine|
500336|NCT00399009|Device|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
500460|NCT00398138|Other|immunoenzyme technique|
500461|NCT00398125|Drug|GSK364735|
500337|NCT00398996|Drug|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
500338|NCT00398983|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days
500339|NCT00398970|Device|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
500340|NCT00398957|Drug|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
500341|NCT00398944|Device|Evaluation of the impact of a guideline based computerized decision support system.|
500342|NCT00398931|Drug|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
500343|NCT00398931|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
500344|NCT00398918|Drug|zonisamide|zonisamide (100 mg)one time
500345|NCT00398918|Drug|Placebo|Placebo Comparator
500346|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
500347|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
500348|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
500349|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
500350|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
500351|NCT00398905|Drug|Enoxaparin|40 mg once daily (40 mg total daily dose)
500352|NCT00398892|Drug|Lipoic acid|Lipoic acid capsules
500353|NCT00398879|Drug|Perifosine|Perifosine 50 mg/d qd
500354|NCT00398879|Drug|Capecitabine|Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks
500355|NCT00398879|Other|Perifosine Placebo|Placebo to Perifosine 50 mg/d qd
500356|NCT00398866|Drug|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
500357|NCT00398866|Drug|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
500358|NCT00398866|Drug|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
500359|NCT00398853|Dietary Supplement|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
500360|NCT00398853|Other|Placebo|Placebo
500361|NCT00398840|Drug|ARQ 171|
500362|NCT00398827|Drug|Dexmedetomidine|
500363|NCT00398827|Drug|Placebo|
500364|NCT00398814|Drug|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
500365|NCT00398814|Drug|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
500366|NCT00398788|Drug|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
500367|NCT00398775|Procedure|antibiotic discontinuation|
500368|NCT00398749|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length
500369|NCT00398736|Procedure|sonographic measurement of inferior caval vein diameter|
500370|NCT00398723|Device|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
500371|NCT00398710|Drug|Perifosine|150 mg daily (100 mg daily in case of dose reduction)
500372|NCT00398697|Drug|Perifosine|
500373|NCT00398697|Drug|Gemcitabine|
500374|NCT00398684|Drug|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
500375|NCT00398684|Drug|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
500376|NCT00398684|Drug|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
500377|NCT00398671|Device|Application of cool cap after primary successful CPR|
500378|NCT00398658|Drug|gentamycin and clindamycin|
500379|NCT00398645|Drug|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
500380|NCT00398632|Drug|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
500381|NCT00398619|Drug|INCB13739|
500382|NCT00398606|Drug|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
500383|NCT00398606|Drug|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
500384|NCT00398593|Behavioral|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
500385|NCT00398580|Drug|Nanomilled testosterone|
500386|NCT00398580|Drug|Nanomilled dutasteride|
500387|NCT00398580|Drug|commercially available dutasteride|
500388|NCT00398567|Drug|HKI-272|HKI-272 by mouth
500389|NCT00398567|Drug|trastuzumab|trastuzumab 4 mg/kg IV as a loading dose followed by trastuzumab 2 mg/kg weekly thereafter
500390|NCT00398554|Drug|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
500391|NCT00398554|Drug|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
500392|NCT00398554|Drug|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
500393|NCT00398554|Drug|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
500394|NCT00398554|Drug|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
500395|NCT00398554|Drug|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
500396|NCT00398554|Radiation|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
500397|NCT00398541|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
500398|NCT00398528|Drug|Glatiramer acetate, (Copaxone®)|
500399|NCT00398528|Drug|IFN-β-1a, (Avonex®)|
500400|NCT00398515|Drug|lenalidomide|Given orally
500401|NCT00398515|Drug|temsirolimus|Given IV
500402|NCT00398515|Other|pharmacological study|Correlative studies
500403|NCT00398515|Other|laboratory biomarker analysis|Correlative studies
500404|NCT00398502|Drug|MOA-728|
500405|NCT00398489|Biological|trastuzumab|
500406|NCT00398489|Drug|anastrozole|
500407|NCT00398489|Drug|cyclophosphamide|
500408|NCT00398489|Drug|docetaxel|
500409|NCT00398489|Drug|epirubicin hydrochloride|
500410|NCT00398489|Drug|goserelin acetate|
500411|NCT00398489|Drug|tamoxifen citrate|
500412|NCT00398489|Procedure|adjuvant therapy|
500413|NCT00398489|Procedure|conventional surgery|
500414|NCT00398489|Procedure|neoadjuvant therapy|
500415|NCT00398489|Radiation|radiation therapy|
500416|NCT00398476|Drug|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
500417|NCT00398476|Drug|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
500418|NCT00398463|Drug|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
500419|NCT00398463|Drug|Placebo|Saline infusion will be administered for 14-24 hours
500420|NCT00398450|Biological|recombinant interferon alfa-2b|
500421|NCT00398450|Drug|azacitidine|
500422|NCT00398437|Biological|trastuzumab|
500423|NCT00398437|Drug|chemotherapy|
500424|NCT00398437|Procedure|magnetic resonance imaging|
500425|NCT00398424|Drug|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.~On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.~Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
500426|NCT00398411|Drug|moxifloxacin|400 mg p.o. per day
500427|NCT00398411|Drug|placebo|one tablet per day p.o.
500428|NCT00398398|Drug|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
500429|NCT00398385|Drug|cisplatin|
500430|NCT00398385|Drug|gemcitabine hydrochloride|
500431|NCT00398385|Procedure|adjuvant therapy|
500432|NCT00398385|Procedure|conventional surgery|
500433|NCT00398385|Procedure|neoadjuvant therapy|
500434|NCT00398372|Drug|Rituximab|
500435|NCT00398372|Drug|Epratuzumab|
500436|NCT00398359|Behavioral|Motivational Interviewing (physicians)|Identifying and referring children with BMI >93%.
500437|NCT00398359|Behavioral|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
500438|NCT00398333|Dietary Supplement|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
500439|NCT00398320|Drug|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
500440|NCT00398320|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
500441|NCT00398320|Drug|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
500442|NCT00398307|Drug|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:~Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD~Pharmacokinetic Phase (Part 1):~On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.~Treatment will be followed by 1 week of recovery (Days 15 through 21).~Extension Phase (Part 2):~S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
500443|NCT00398294|Drug|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
500444|NCT00398281|Drug|dutasteride|Given orally
500445|NCT00398281|Other|placebo|Given orally
500446|NCT00398268|Procedure|Kirschner-wire fixation|
500447|NCT00398255|Behavioral|self-management program|
500448|NCT00398242|Device|above or below elbow cast for the last 3 weeks of treatment|
500449|NCT00398229|Drug|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
500450|NCT00398216|Drug|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
500451|NCT00398203|Device|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
500452|NCT00398190|Behavioral|Control|Standard anti-tobacco programming
500453|NCT00398190|Behavioral|Media Literacy|Anti-smoking media literacy curriculum intervention
500454|NCT00398151|Drug|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
500455|NCT00398138|Biological|WT-1 analog peptide vaccine|
500456|NCT00398138|Biological|incomplete Freund's adjuvant|
500457|NCT00398138|Biological|sargramostim|
500458|NCT00398138|Genetic|polymerase chain reaction|
500459|NCT00398138|Other|flow cytometry|
500462|NCT00398112|Drug|sunitinib malate|Given orally
500463|NCT00398112|Other|pharmacological study|Correlative studies
500464|NCT00398112|Other|laboratory biomarker analysis|Correlative studies
500465|NCT00398099|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
500466|NCT00398086|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
500467|NCT00398086|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
500468|NCT00398073|Biological|mouse gp100 plasmid DNA vaccine|
500469|NCT00398073|Device|The Dermal PowderMed® devices|
500470|NCT00398073|Other|intramuscularly (IM injection)|
500471|NCT00398060|Behavioral|Cognitive-behavioral life-style counseling|
500472|NCT00398047|Drug|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
500473|NCT00398034|Drug|Testosterone Gel|
500474|NCT00398008|Drug|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
500475|NCT00398008|Drug|Naltrexone|Opioid antagonist medication to treat opiate dependence
500476|NCT00398008|Behavioral|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
500477|NCT00397995|Procedure|above- or under elbow cast|
500478|NCT00397982|Biological|Bevacizumab|Given IV
500479|NCT00397982|Other|Laboratory Biomarker Analysis|Correlative studies
500480|NCT00397982|Drug|Temsirolimus|Given IV
500481|NCT00397982|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
500482|NCT00397969|Other|counseling intervention|
500483|NCT00397969|Procedure|screening colonoscopy|
500484|NCT00397956|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
500485|NCT00397943|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
500486|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
500487|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
500488|NCT00397943|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
500489|NCT00397930|Procedure|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
500490|NCT00397930|Procedure|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
500491|NCT00397917|Drug|Folic acid: 4 mg versus 0.4 mg per day|Folic acid
500492|NCT00397904|Biological|cetuximab|
500493|NCT00397904|Drug|cisplatin|
500494|NCT00397904|Drug|irinotecan hydrochloride|
500495|NCT00397904|Other|immunohistochemistry staining method|
500496|NCT00397904|Other|laboratory biomarker analysis|
500497|NCT00397904|Procedure|biopsy|
500498|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
500499|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
500500|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
500501|NCT00397878|Drug|saracatinib|Given orally
500502|NCT00397878|Other|laboratory biomarker analysis|Correlative studies
500503|NCT00397865|Behavioral|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
500504|NCT00397852|Procedure|Kirschner-wires or not|
500505|NCT00397839|Drug|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
500506|NCT00397839|Drug|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
500507|NCT00397826|Drug|MK0733|Duration of Treatment: 12 Weeks
500508|NCT00397813|Drug|Cyclosporine|Given PO
500509|NCT00397813|Drug|Fludarabine Phosphate|Given IV
500510|NCT00397813|Other|Laboratory Biomarker Analysis|Correlative studies
500511|NCT00397813|Drug|Mycophenolate Mofetil|Given PO
500512|NCT00397813|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
500513|NCT00397813|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
500514|NCT00397813|Radiation|Total-Body Irradiation|Undergo TBI
500515|NCT00397800|Biological|rituximab|
500516|NCT00397800|Drug|cyclophosphamide|
500517|NCT00397800|Drug|fludarabine phosphate|
500518|NCT00397800|Radiation|yttrium Y 90 ibritumomab tiuxetan|
500519|NCT00397787|Drug|sunitinib malate|Given PO
500520|NCT00397774|Behavioral|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
500521|NCT00397774|Other|best supportive care|
500522|NCT00397761|Drug|capecitabine|
500523|NCT00397761|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
500524|NCT00397761|Procedure|neoadjuvant therapy|
500525|NCT00397735|Procedure|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
500526|NCT00397735|Drug|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
500527|NCT00397722|Drug|GW876008|
500528|NCT00397722|Drug|paroxetine|
500529|NCT00397709|Drug|I ( isoniazid), II (isoniazid + rifampin )|
500530|NCT00397696|Drug|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of [123I] 5-IA followed by SPECT imaging as described below. A second [123I] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial [123I] 5IA imaging session.
500531|NCT00397683|Drug|MK0822|
500532|NCT00397670|Drug|Drug: BufferGel® with diaphragm|
500533|NCT00397657|Drug|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
500534|NCT00397657|Drug|ezetimibe|Ezetimibe 10mg once daily
500535|NCT00397644|Behavioral|Prompting (survey instrument/resources list) (behavior)|
500536|NCT00397631|Drug|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
500537|NCT00397631|Drug|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
500538|NCT00397605|Drug|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
500539|NCT00397592|Drug|Growth Hormone|
500540|NCT00397579|Drug|DT388IL3|Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
500541|NCT00397566|Drug|HIV Integrase Inhibitor (BMS-707035)|
500542|NCT00397553|Drug|Insulin glulisine|
500543|NCT00397540|Procedure|PEIT|Percutaneous Ethanol Injection Therapy
500544|NCT00397540|Procedure|RFTA|Radiofrequency Thermal Ablation
500545|NCT00397527|Drug|lactoserum|
500546|NCT00397514|Procedure|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
500547|NCT00397501|Biological|trastuzumab|"Trastuzamab, 6mg/kg, within 48 hrs before BBBD~Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles"
500548|NCT00397501|Drug|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
500549|NCT00397501|Drug|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
500550|NCT00397501|Drug|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
500551|NCT00397488|Drug|sunitinib malate|
500552|NCT00397475|Drug|Colecalciferol|
500553|NCT00397462|Device|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
500554|NCT00397449|Biological|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
500555|NCT00397436|Procedure|UV Irradiation|UV irradiation
500556|NCT00397423|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd*5 days,3 months interval for 4 times
500557|NCT00397423|Drug|NS|NS 1ml iH Qd*5 days, 3 months interval for 4 times
500558|NCT00397410|Device|Hip protectors|
500559|NCT00397384|Drug|cetuximab|Given IV
500560|NCT00397384|Drug|erlotinib hydrochloride|Given PO
500561|NCT00397384|Other|laboratory biomarker analysis|Correlative studies
500562|NCT00397358|Drug|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
500563|NCT00397345|Biological|Trovax|1ml IM injection 2-8 weeks apart.
500564|NCT00397332|Drug|Alefacept|IM Alefacept
500565|NCT00397319|Drug|Growth Hormone|
500566|NCT00397306|Device|Bioimpedance Analysis|
500567|NCT00397293|Drug|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
500568|NCT00397293|Drug|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
500569|NCT00397267|Drug|inhalation of corticosteroids|
500570|NCT00397254|Drug|rizatriptan|10mg ODT 27 tablets
500571|NCT00397254|Drug|rizatriptan|10mg ODT 9 tablets
500572|NCT00397241|Drug|Drug: dorzolamide/timolol|
500573|NCT00397241|Drug|Drug: latanoprost/timolol|
500574|NCT00397241|Drug|dorzolamide/timolol and latanoprost|
500575|NCT00397241|Drug|placebo (artificial tears)|
500576|NCT00397228|Drug|ALTROPANE®|ALTROPANE® SPECT imaging
500577|NCT00397215|Biological|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
500578|NCT00397215|Biological|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
500579|NCT00397202|Device|Diva Cup TM|See Detailed Description.
500580|NCT00397189|Drug|Circadin|Prolonged release melatonin 2 mg
500581|NCT00397189|Drug|placebo circadin|placebo circadin tablets
500582|NCT00397176|Drug|desvenlafaxine succinate sustained release (DVS SR)|
500583|NCT00397163|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
500584|NCT00397163|Procedure|Placebo|Deflated cuff on upper arm and thigh for 20 min
500585|NCT00397150|Behavioral|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
500586|NCT00397137|Procedure|Circular stapled anopexy|Patients receiving stapled anopexy to treat haemorrhoids
500587|NCT00397137|Procedure|Closed diathermy haemorrhoidectomy|Conventional haemorrhoidectomy as described by Ferguson method
500588|NCT00397124|Device|PET/CT imaging|
500589|NCT00397098|Drug|SR58611A|
500590|NCT00397072|Drug|ZK 219477|
500591|NCT00397059|Drug|Escitalopram|
500592|NCT00397046|Drug|neratinib|HKI-272
500593|NCT00397033|Drug|Paliperidone ER|6mg/day paliperidone er for 6 weeks
500594|NCT00397033|Drug|Paliperidone ER|12mg/day paliperidone er for 6 weeks
500595|NCT00397033|Drug|Placebo|Placebo for 6 weeks
500596|NCT00397020|Drug|divalproex ER|Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
500597|NCT00397020|Drug|quetiapine|Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.
500598|NCT00397007|Behavioral|Biofeedback-based cognitive-behavioural intervention|
500599|NCT00396994|Device|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
500600|NCT00396994|Device|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
500601|NCT00396981|Device|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
500602|NCT00396981|Device|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
500603|NCT00396968|Drug|AMD3100|
500604|NCT00396968|Procedure|Allogeneic Stem Cell Transplantation|
500605|NCT00396955|Drug|PLA-695|
500606|NCT00396929|Drug|local intracoronary dosis of Paclitaxel|
500607|NCT00396916|Device|PET/CT imaging|
500608|NCT00396903|Device|catheter|
500609|NCT00396877|Drug|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
500610|NCT00396877|Drug|placebo|"Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight"
500611|NCT00396864|Drug|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
500612|NCT00396851|Drug|Gurmar|
500613|NCT00396851|Drug|Metformin|
500614|NCT00396825|Behavioral|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
500615|NCT00396812|Drug|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.~Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
500616|NCT00396799|Drug|bazedoxifene/conjugated estrogens|
500617|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
500618|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
500619|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
500620|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
500621|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
500622|NCT00396786|Drug|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
500623|NCT00396760|Drug|aprotinin or tranexamic acid|
500624|NCT00396747|Drug|Infliximab, methylprednisolone, methotrexate|
500625|NCT00396747|Drug|Methotrexate|
500626|NCT00396747|Drug|Methotrexate + Methylprednisolone|
500627|NCT00396747|Drug|Methotrexate + Infliximab|
500628|NCT00396734|Drug|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
500629|NCT00396734|Drug|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
500630|NCT00396721|Drug|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
500631|NCT00396721|Drug|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
500632|NCT00396708|Device|myomo e100 neurorobotic elbow brace|
500633|NCT00396695|Procedure|Blood test|
500634|NCT00396682|Drug|Cyclophosphamide|150 - 250 - 350 mg
500635|NCT00396669|Drug|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
500636|NCT00396669|Drug|Bupropion|Brain imaging after treatment with Bupropion
500637|NCT00396656|Drug|Atenolol|100 mg tablets orally once a day (od) in the morning.
500638|NCT00396656|Drug|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
500639|NCT00396656|Drug|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
500719|NCT00396032|Drug|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
500720|NCT00396019|Drug|PEG-Intron|
500721|NCT00396006|Biological|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
500787|NCT00395408|Drug|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
500640|NCT00396643|Drug|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
500641|NCT00396630|Biological|Rotarix|Two-dose oral vaccination.
500642|NCT00396630|Biological|Placebo|Two-dose oral administration.
500643|NCT00396617|Device|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
500644|NCT00396617|Procedure|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
500645|NCT00396604|Drug|indacaterol maleate|
500646|NCT00396591|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
500647|NCT00396578|Drug|aerosolized vancomycin or gentamicin|
500648|NCT00396565|Drug|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
500649|NCT00396565|Drug|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
500650|NCT00396565|Drug|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
500651|NCT00396552|Device|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
500652|NCT00396552|Device|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
500653|NCT00396526|Drug|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
500654|NCT00396513|Drug|Simvastatin|
500655|NCT00396513|Drug|Simvastatin and Metformin|
500656|NCT00396513|Drug|Metformin|
500657|NCT00396500|Drug|Albendazole (400 mg) and/or Vitamin a|
500658|NCT00396487|Drug|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
500659|NCT00396474|Other|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
500660|NCT00396461|Drug|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
500661|NCT00396461|Drug|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
500662|NCT00396448|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
500663|NCT00396448|Drug|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
500664|NCT00396448|Drug|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
500665|NCT00396435|Drug|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
500666|NCT00396422|Drug|RWJ-445380|
500667|NCT00396409|Drug|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
500668|NCT00396409|Drug|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
500669|NCT00396409|Drug|Placebo|Placebo given during the 2006 core study
500670|NCT00396396|Drug|Acetylcysteine|
500671|NCT00396383|Drug|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4*10^6 CD34+ cells/kg body weight had been collected.
500672|NCT00396370|Biological|BCG strain Connaught|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10^5 CFU vaccine for intradermal administration.
500673|NCT00396370|Biological|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
500674|NCT00396370|Biological|BCG strain Danish|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
500675|NCT00396370|Other|Placebo|0.1 mL of sterile Sauton medium for intradermal administration.
500676|NCT00396370|Other|Placebo|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
500677|NCT00396357|Drug|Vildagliptin|
500678|NCT00396357|Drug|metformin|
500679|NCT00396344|Other|Çontrol|Intravenous saline
500680|NCT00396344|Drug|Hydrocortisone|Intravenous stress dose of hydrocortisone
500681|NCT00396344|Drug|Hydrocortisone|Intravenous pharmacologic hydrocortisone
500722|NCT00395993|Drug|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
500723|NCT00395993|Drug|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
500724|NCT00395980|Device|surgical table pressure mat|
500682|NCT00396331|Drug|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2*10^6 CD34+ cells/kg were collected.
500683|NCT00396318|Drug|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.~Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
500684|NCT00396305|Drug|Placebo|Sterile phosphate buffered saline solution.
500685|NCT00396305|Biological|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
500686|NCT00396292|Drug|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
500687|NCT00396292|Drug|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
500688|NCT00396279|Biological|Denosumab|Administered by subcutaneous injection
500689|NCT00396279|Dietary Supplement|Calcium/Vitamin D|
500690|NCT00396266|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
500691|NCT00396253|Drug|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
500692|NCT00396240|Drug|Rosuvastatin|
500693|NCT00396240|Procedure|Initiatives to improve compliance|
500694|NCT00396227|Drug|vildagliptin|vildagliptin as add-on to metformin
500695|NCT00396227|Drug|thiazolidinedione (TZD)|TZD add-on to metformin
500696|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
500697|NCT00396214|Drug|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
500698|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
500699|NCT00396201|Drug|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
500700|NCT00396175|Drug|MK0906, finasteride / Duration of Treatment : 48 Weeks|
500701|NCT00396175|Drug|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
500702|NCT00396162|Drug|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
500703|NCT00396162|Other|Placebo|Placebo pill
500704|NCT00396149|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
500705|NCT00396149|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
500706|NCT00396136|Device|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
500707|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
500708|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
500709|NCT00396084|Drug|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
500710|NCT00396084|Drug|Isoniazid|Isoniazid 300 mg/day x 7 days.
500711|NCT00396084|Drug|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
500712|NCT00396084|Drug|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
500713|NCT00396084|Drug|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
500714|NCT00396071|Drug|vildagliptin|vildagliptin 100 mg
500715|NCT00396071|Drug|Placebo|matching placebo
500716|NCT00396058|Drug|Methylphenidate|
500717|NCT00396045|Drug|Revlimid (CC-5013)|
500718|NCT00396032|Drug|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
500786|NCT00395408|Drug|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
501075|NCT00393263|Drug|pimecrolimus and clobetasol|
500725|NCT00395967|Drug|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
500726|NCT00395941|Drug|Pioglitazone|
500727|NCT00395941|Drug|Acitretin|Acitretin
500728|NCT00395915|Drug|aripiprazole|
500729|NCT00395902|Drug|Sensipar after Post Transplant|
500730|NCT00395889|Procedure|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
500731|NCT00395889|Procedure|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
500732|NCT00395876|Drug|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
500733|NCT00395876|Drug|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
500734|NCT00395863|Drug|Multihance|0.5 M at a single injection
500735|NCT00395863|Drug|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
500736|NCT00395850|Drug|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
500737|NCT00395837|Behavioral|Aerobic exercise|
500738|NCT00395824|Procedure|anticoagulation procedure|
500739|NCT00395811|Procedure|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
500740|NCT00395798|Device|Soft or stiff cervical collar(device), neck school(behavior)|
500741|NCT00395785|Device|Carotid Stent Implantation|
500742|NCT00395785|Device|Embolic Protection|
500743|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
500744|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
500745|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
500746|NCT00395772|Drug|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
500747|NCT00395759|Drug|Optiva artificial tear by Allergan|
500748|NCT00395746|Drug|sulfonylurea|SU agent
500749|NCT00395746|Drug|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
500750|NCT00395746|Drug|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
500751|NCT00395733|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
500752|NCT00395733|Drug|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
500753|NCT00395720|Biological|MVA85A (TB vaccine)|Intradermal vaccine
500754|NCT00395720|Biological|MVA 85A|Intradermal vaccine
500755|NCT00395707|Drug|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
500756|NCT00395707|Drug|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
500757|NCT00395707|Drug|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
500758|NCT00395707|Drug|Ranibizumab (Lucentis)|0.5mg/0.05 ml
500759|NCT00395694|Drug|lamictal|anti-epileptic drug
500760|NCT00395681|Drug|Diprivan|Propofol 200 mg versus 350 mg
500761|NCT00395668|Device|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
500762|NCT00395655|Drug|Hydralazine and magnesium valproate administration|
500763|NCT00395655|Procedure|Core-needle biopsy of the breast|
500764|NCT00395642|Device|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
500765|NCT00395629|Drug|Deferasirox (ICL670)|
500766|NCT00395616|Drug|Botox (drug)|
500767|NCT00395603|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
500768|NCT00395603|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
500769|NCT00395577|Drug|VX-702|
500770|NCT00395551|Drug|ranibizumab|0.5mg intravitreal injection
500771|NCT00395538|Drug|PTH 1-34|Given twice daily by subcutaneous
500772|NCT00395512|Drug|Alogliptin|Alogliptin tablets.
500773|NCT00395512|Drug|Pioglitazone|Pioglitazone tablets.
500774|NCT00395512|Drug|Placebo|Matching placebo tablets.
500775|NCT00395499|Drug|Risperidone|
500776|NCT00395486|Drug|Rosuvastatin|10mg
500777|NCT00395486|Drug|Atorvastatin|10mg
500778|NCT00395473|Drug|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
500779|NCT00395460|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
500780|NCT00395460|Drug|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
500781|NCT00395447|Procedure|Straight-forward Device Replacement|
500782|NCT00395447|Procedure|Device Replacement with Upgrade|
500783|NCT00395434|Drug|Combretastatin A4 Phosphate (CA4P)|
500784|NCT00395434|Drug|Bevacizumab (Avastin)|
500785|NCT00395421|Drug|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
500788|NCT00395395|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
500789|NCT00395382|Drug|Alendronate|70mg weekly orally
500790|NCT00395382|Drug|Placebo|weekly orally
500791|NCT00395369|Drug|intraoperative aprotinin administration|
500792|NCT00395356|Behavioral|calorie controlled diet|
500793|NCT00395343|Drug|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
500794|NCT00395343|Drug|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
500795|NCT00395317|Other|Placebo|placebo tablet
500796|NCT00395317|Drug|Firategrast 150 mg|150 mg tablet
500797|NCT00395317|Drug|Firategrast 300 mg|300 mg tablet
500798|NCT00395304|Drug|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
500799|NCT00395304|Drug|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
500800|NCT00395304|Drug|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
500801|NCT00395291|Drug|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
500802|NCT00395291|Drug|Placebo|Placebo
500803|NCT00395252|Drug|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:~Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)~Gemcitabine:~1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered~Mode of administration:~Intravenous infusion"
500804|NCT00395239|Drug|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
500805|NCT00395226|Drug|zinc sulfate|zinc sulfate 220 mg bis for 90 days
500806|NCT00395226|Drug|placebo|placebo bid for 90 days
500807|NCT00395213|Drug|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
500808|NCT00395200|Procedure|MSC Treatment|Intravenous administration of up to 2x10^6 autologous MSCs per kg
500809|NCT00395187|Procedure|Photodynamic Therapy|
500810|NCT00395174|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
500811|NCT00395161|Drug|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
500812|NCT00395161|Drug|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants < or equal to one year of age, and 20 mg/day elemental zinc for patients > 1 year of age)
500813|NCT00395161|Dietary Supplement|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
500814|NCT00395161|Drug|Selenium|one enteral dose daily of selenium (40 μg for infants < 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children > 13 years)
500815|NCT00395161|Other|saline|equivalent volume of intravenous saline
500816|NCT00395161|Other|sterile water|equivalent volume of sterile water
500817|NCT00395161|Other|selenium|equivalent volume of sterile water
500818|NCT00395161|Dietary Supplement|whey-protein|one enteral dose daily of whey-protein
500819|NCT00395148|Drug|rHDL|
500820|NCT00395135|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
500821|NCT00395135|Drug|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
500822|NCT00395122|Device|Retinal nerve fiber layer and macular thickness measurements|
500823|NCT00395109|Device|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
500824|NCT00395083|Behavioral|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
500825|NCT00395070|Biological|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
500826|NCT00395070|Drug|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
500827|NCT00395070|Drug|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
500828|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
500829|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
500830|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
500831|NCT00395057|Drug|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
500832|NCT00395044|Drug|Placebo|Placebo
500833|NCT00395044|Drug|Gabapentin|
500834|NCT00395031|Drug|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
500835|NCT00395018|Drug|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
500836|NCT00394992|Drug|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
500837|NCT00394992|Drug|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
500838|NCT00394966|Drug|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
500839|NCT00394966|Drug|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
500840|NCT00394966|Drug|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
501076|NCT00393263|Drug|clobetasol 0.05% cream|twice daily for three months
528491|NCT00163423|Drug|Ciclesonide|
500841|NCT00394966|Drug|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
500842|NCT00394966|Drug|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
500843|NCT00394953|Drug|Darbepoetin alfa|As prescribed, iv.
500844|NCT00394953|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
500845|NCT00394914|Drug|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
500846|NCT00394914|Drug|Placebo to Pleconaril|Placebo nasal suspension
500847|NCT00394901|Drug|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
500848|NCT00394901|Drug|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
500849|NCT00394901|Drug|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
500850|NCT00394901|Drug|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
500851|NCT00394888|Device|MRI|MRI of the spine.
500852|NCT00394888|Device|MRI of head and neck|MRI of head and C-spine
500853|NCT00394888|Other|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
500854|NCT00394888|Other|Cardiac examination|Complete cardiac examination
500855|NCT00394888|Device|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
500856|NCT00394875|Procedure|Treated and educated by nurses specialized in diabetes.|
500857|NCT00394862|Drug|multivitamin|
500858|NCT00394849|Procedure|suture one tonsillar fossa|one tonsillar fossa was sutured. One side was not sutured. Pain was compared side to side.
500859|NCT00394836|Drug|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
500860|NCT00394836|Drug|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
500861|NCT00394823|Behavioral|Set of supportive tools/measures vs. standard care|
500862|NCT00394810|Drug|Panzem® NCD|suspension, 100 mg/mL, four times daily continuous dosing
500863|NCT00394797|Procedure|mitral valve annuloplasty|
500864|NCT00394771|Drug|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
500865|NCT00394771|Drug|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
500866|NCT00394771|Drug|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
500867|NCT00394758|Procedure|CO2 laser surgery|
500868|NCT00394758|Procedure|ultrasonic surgical aspiration|
500869|NCT00394745|Drug|Valsartan|
500870|NCT00394732|Device|Total Disc Prosthesis|
500871|NCT00394732|Behavioral|Multidisciplinary rehabilitation program|
500872|NCT00394706|Device|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
500873|NCT00394706|Device|Sham ITD|Sham ITD
500874|NCT00394706|Other|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
500875|NCT00394706|Other|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
500876|NCT00394693|Genetic|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
500877|NCT00394667|Drug|Tesofensine|
500878|NCT00394654|Biological|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
500879|NCT00394654|Other|Placebo|Placebo administered as a single intravenous infusion
500880|NCT00394641|Behavioral|listening to music / stories via stereophonic headphones|
500881|NCT00394628|Drug|AQ4N|
500882|NCT00394628|Drug|Temozolomide|
500883|NCT00394628|Procedure|Radiotherapy|
500884|NCT00394615|Procedure|Metabolic Imaging|
500885|NCT00394602|Behavioral|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
500886|NCT00394602|Other|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
500887|NCT00394589|Drug|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
500888|NCT00394589|Drug|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
500889|NCT00394589|Drug|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
500890|NCT00394576|Behavioral|Internet-based nutrition module along with usual care|usual care plus Internet-based nutrition module
500891|NCT00394576|Behavioral|usual care|usual care
500892|NCT00394563|Drug|RN624 (PF-04383119)|10 mcg/kg
500893|NCT00394563|Drug|RN624 (PF-04383119)|25 mcg/kg
500894|NCT00394563|Drug|RN624 (PF-04383119)|50 mcg/kg
500895|NCT00394563|Drug|RN624 (PF-04383119)|100 mcg/kg
500896|NCT00394563|Drug|RN624 (PF-04383119)|200 mcg/kg
500897|NCT00394563|Drug|placebo|
500947|NCT00394251|Drug|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
501137|NCT00392886|Drug|vincristine sulfate|Given IV
501138|NCT00392886|Procedure|autologous bone marrow transplantation|Given on day 0
500898|NCT00394550|Procedure|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
500899|NCT00394550|Procedure|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
500900|NCT00394537|Drug|Labetalol 10mg iv|
500901|NCT00394524|Device|Glucommander|Glucommander is a Computer-guided Intravenous (IV) insulin infusion protocol used for glycemic control in inpatients. This algorithm directs the administration of IV insulin in response to Blood Glucose (BG) measurement at the patient's bedside. In this study, the Glucommander program was loaded into a PalmOne (Zire 31, Tungsten E2 by Palm Inc.) handheld personal digital assistant (PDA) device. During the infusion, the nurse entered BG levels into the system and the computer recommended the insulin infusion rate and a variable time to check the next glucose testing. An alarm prompted the scheduled glucose check. The insulin infusion followed the formula: Insulin/Hour = Multiplier × (BG− 60).
500902|NCT00394524|Other|Standard insulin infusion algorithm|Standard insulin infusion Algorithm is a standard paper form insulin infusion algorithm. The algorithm is divided into four columns based on empirically determined insulin sensitivity. The first column was for the most insulin-sensitive patients, and the fourth column was for the most insulin resistant patients. The majority of patients are started in the algorithm 1 column. Insulin resistant patients, such as those receiving glucocorticoids or receiving >80 units of insulin per day as outpatients, started in the algorithm 2 column. The insulin infusion rate was determined by the patient's BG level and was measured hourly until the patient was stable and within the target range. If BG targets were not achieved and the BG had not decreased by at least 60 mg/dL in the preceding hour, the patient was moved to the next column.
500903|NCT00394511|Procedure|low-LET photon therapy|
500904|NCT00394498|Drug|Granulocyte Colony Stimulating Factor|
500905|NCT00394485|Drug|Procaterol|
500906|NCT00394485|Drug|Tiotropium|
500907|NCT00394472|Drug|AZD3355|
500908|NCT00394459|Device|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
500909|NCT00394459|Device|Perifix Standard|Perifix Standard
500910|NCT00394459|Device|Perifix New|Perifix New
500911|NCT00394446|Drug|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
500912|NCT00394433|Drug|Bevacizumab|
500913|NCT00394433|Drug|Docetaxel|
500914|NCT00394433|Drug|Cisplatin|
500915|NCT00394433|Drug|Irinotecan|
500916|NCT00394420|Behavioral|Telephone Quitline|
500917|NCT00394407|Drug|sliding scale regular insulin|SSRI acqhs
500918|NCT00394407|Drug|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
500919|NCT00394394|Drug|Amiloride 2,5/d or Enalapril/d 10 mg|
500920|NCT00394381|Procedure|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
500921|NCT00394368|Drug|beclomethasone dipropionate plus formoterol fumarate combination|
500922|NCT00394368|Drug|fluticasone propionate plus salmeterol xinafoate combination|
500923|NCT00394355|Drug|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
500924|NCT00394355|Drug|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
500925|NCT00394355|Drug|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
500926|NCT00394355|Drug|montelukast|10 mg given once daily in the evening by mouth for 1 year.
500927|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
500928|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
500929|NCT00394329|Drug|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
500930|NCT00394316|Drug|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
500931|NCT00394303|Drug|Intraoperative continuous insulin infusion|Nomogram specified in appendix
500932|NCT00394303|Other|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels <200 mg.dl, reflecting current practice.
500933|NCT00394290|Device|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
500934|NCT00394277|Drug|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
500935|NCT00394277|Drug|Ribavirin|1200 mg po daily for 48 weeks
500936|NCT00394277|Drug|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
500937|NCT00394277|Drug|Ribavirin|1400-1600 mg po daily for 48 weeks
500938|NCT00394264|Procedure|Soft Tissue|
500939|NCT00394264|Procedure|Myofascial release|
500940|NCT00394264|Procedure|Counterstrain|
500941|NCT00394264|Procedure|Muscle energy|
500942|NCT00394264|Procedure|Sacro-iliac articulation|
500943|NCT00394264|Procedure|High-velocity, low amplitude|
500944|NCT00394251|Drug|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m^2 intravenous, plus Cytoxan 600 mg/m^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
500945|NCT00394251|Drug|ABI-007|260 mg/m^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
500946|NCT00394251|Drug|Taxol|175 mg/m^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
528492|NCT00163410|Drug|Ciclesonide|
500948|NCT00394251|Drug|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
500949|NCT00394238|Procedure|Ultrasonographic imaging|
500950|NCT00394225|Drug|Oxygen|
500951|NCT00394225|Drug|Helium|
500952|NCT00394212|Device|Transoral Suturing|suturing of anastomosis
500953|NCT00394212|Other|Sham Endoscopy|suturing not performed
500954|NCT00394199|Drug|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
500955|NCT00394199|Drug|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
500956|NCT00394199|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
500957|NCT00394186|Drug|GW427353|
500958|NCT00394186|Drug|Placebo|
500959|NCT00394173|Drug|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
500960|NCT00394173|Drug|Placebo|Matching placebo
500961|NCT00394160|Drug|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
500962|NCT00394147|Drug|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
500963|NCT00394147|Drug|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
500964|NCT00394134|Behavioral|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
500965|NCT00394121|Drug|Fluticasone propionate/formoterol fumarate|
500966|NCT00394108|Procedure|Determination of neuropsychological status|
500967|NCT00394095|Drug|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
500968|NCT00394095|Drug|Placebo|Matched placebo to Experimental arm
500969|NCT00394082|Drug|ABI-007|125 mg/m^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
500970|NCT00394082|Drug|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
500971|NCT00394069|Drug|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
500972|NCT00394056|Drug|Vestipitant|NK1 receptor antagonist
500973|NCT00394056|Drug|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
500974|NCT00394056|Other|Placebo|Placebo
500975|NCT00394043|Procedure|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
500976|NCT00394043|Procedure|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
500977|NCT00394030|Drug|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
500978|NCT00394017|Behavioral|Reminder letters|3 mailed reminder letters
500979|NCT00393991|Drug|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
500980|NCT00393991|Drug|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
500981|NCT00393991|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
500982|NCT00393991|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
500983|NCT00393978|Drug|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
500984|NCT00393978|Drug|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
500985|NCT00393965|Drug|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
500986|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
500987|NCT00393952|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
500988|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
500989|NCT00393952|Drug|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
500990|NCT00393952|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
500991|NCT00393939|Drug|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
500992|NCT00393939|Drug|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
500993|NCT00393926|Device|TheraDrive Assistive Device|
500994|NCT00393926|Procedure|Rote Therapy versus Fun Therapy|
500995|NCT00393913|Device|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
500996|NCT00393887|Device|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
500997|NCT00393887|Device|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
501068|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
528493|NCT00163397|Drug|Ciclesonide|
500998|NCT00393874|Behavioral|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
500999|NCT00393874|Drug|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
501000|NCT00393874|Drug|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
501001|NCT00393861|Drug|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
501002|NCT00393848|Drug|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
501003|NCT00393848|Drug|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
501004|NCT00393848|Drug|Placebo|Placebo for Ketoconazole
501005|NCT00393835|Drug|Azithromycin SR|
501006|NCT00393822|Drug|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
501007|NCT00393822|Drug|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
501008|NCT00393809|Drug|DTA-H19|
501009|NCT00393796|Drug|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
501010|NCT00393796|Other|Placebo|
501011|NCT00393783|Biological|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
501012|NCT00393770|Drug|L-acetylcarnitine|250-500 mg/kg/die.
501013|NCT00393744|Drug|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
501014|NCT00393744|Drug|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
501015|NCT00393731|Drug|Misoprostol|
501016|NCT00393731|Drug|oxytocin|
501017|NCT00393718|Drug|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
501018|NCT00393718|Drug|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
501019|NCT00393718|Drug|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
501020|NCT00393718|Drug|placebo|glibenclamide placebo. Given orally once or twice daily.
501021|NCT00393705|Drug|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
501022|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
501023|NCT00393705|Drug|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
501024|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
501025|NCT00393679|Drug|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
501026|NCT00393679|Drug|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
501027|NCT00393679|Drug|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
501028|NCT00393679|Drug|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
501029|NCT00393653|Procedure|N-of-1 prescription method|
501030|NCT00393640|Procedure|Early and regular breast milk expression|Breast pump given to be used on regular intervals
501069|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
501070|NCT00393315|Device|paclitaxel coated balloon catheter|
501071|NCT00393302|Procedure|HIV screening in pregnancy|
501072|NCT00393289|Behavioral|Calcium controlled diet|
501073|NCT00393276|Biological|Twinrix|Combined hepatitis A and hepatitis B immunization
501074|NCT00393276|Biological|Decavac|Diphtheria and tetanus toxoid vaccine
501031|NCT00393627|Behavioral|Sleep Education Program|The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
501032|NCT00393614|Drug|levetiracetam|20 mg pr. kg a day
501033|NCT00393575|Behavioral|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
501034|NCT00393562|Drug|modafinil|
501035|NCT00393562|Drug|methylphenidate|
501036|NCT00393549|Device|NeuroPath|
501037|NCT00393536|Behavioral|Educational outreach visiting|
501038|NCT00393523|Biological|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
501039|NCT00393523|Biological|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
501040|NCT00393510|Drug|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The formula consisted of 12 herbs, viz:~Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
501041|NCT00393510|Drug|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.~The placebo was made with starch and colouring materials."
501042|NCT00393497|Drug|bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
501043|NCT00393484|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
501044|NCT00393484|Drug|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
501045|NCT00393484|Drug|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)~Tablets, Oral, 100 mg, once daily (96-240 weeks)"
501046|NCT00393484|Drug|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
501047|NCT00393471|Drug|Etanercept|
501048|NCT00393458|Drug|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
501049|NCT00393458|Drug|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
501050|NCT00393458|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
501051|NCT00393458|Drug|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
501052|NCT00393445|Drug|GLP-1 control|intravenous infusion of GLP-1
501053|NCT00393445|Drug|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
501054|NCT00393445|Drug|saline control|intravenous infusion of saline
501055|NCT00393445|Drug|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
501056|NCT00393445|Drug|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
501057|NCT00393445|Drug|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
501058|NCT00393419|Behavioral|Comprehensive pharmacy care program|
501059|NCT00393393|Drug|intra-articular injection of Hylan G-F 20|
501060|NCT00393380|Drug|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC>2000/microL: PTH 100 mcg
501061|NCT00393367|Drug|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
501062|NCT00393367|Drug|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
501063|NCT00393367|Drug|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
501064|NCT00393367|Drug|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
501065|NCT00393354|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
501066|NCT00393354|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
501067|NCT00393341|Procedure|Blood Draw|Blood sample will be drawn from a vein in the arm.
528494|NCT00163384|Drug|Ciclesonide|
501077|NCT00393250|Other|Hypnosis|Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.
501078|NCT00393250|Other|Control|Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study
501079|NCT00393211|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
501080|NCT00393211|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
501081|NCT00393198|Drug|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
501082|NCT00393198|Drug|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
501083|NCT00393198|Drug|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
501084|NCT00393185|Biological|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
501085|NCT00393172|Behavioral|exercise|5 days per week exercise for 4 months
501086|NCT00393159|Device|Ear Popper|
501087|NCT00393146|Drug|GW856553|Study drug
501088|NCT00393120|Drug|INCB009471|100mg SR (sustained release) orally once daily
501089|NCT00393120|Drug|INCB009471|300mg SR (sustained release) orally once daily
501090|NCT00393120|Drug|Placebo comparator|Orally once daily
501091|NCT00393107|Drug|rituximab|
501092|NCT00393107|Drug|rituximab,fludarabine, cyclophosphamide|
501093|NCT00393094|Biological|Bevacizumab|10 mg/kg intravenous injection
501094|NCT00393094|Drug|Irinotecan hydrochloride|125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
501095|NCT00393068|Drug|Erlotinib|Erlotinib
501096|NCT00393068|Drug|Bevacizumab|Bevacizumab
501097|NCT00393068|Drug|Paclitaxel|Paclitaxel
501098|NCT00393068|Drug|Carboplatin|Carboplatin
501099|NCT00393068|Drug|5-FU|5-FU
501100|NCT00393068|Procedure|Radiation therapy|Radiation therapy
501101|NCT00393068|Procedure|Surgery|Surgery
501102|NCT00393055|Dietary Supplement|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
501103|NCT00393055|Dietary Supplement|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
501104|NCT00393042|Drug|Dexmethylphenidate|10, 20, 25-30 mg.
501105|NCT00393042|Drug|Mixed Amphetamine Salts, ER|10, 20, 25-30
501106|NCT00393042|Drug|placebo|randomized placebo week during each 4 week period
501107|NCT00393029|Biological|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
501108|NCT00393029|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
501109|NCT00393029|Biological|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count > 1.0 x 10^9/L x 3 days or > 5.0 x 10^9/L.
501110|NCT00393029|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
501111|NCT00393029|Drug|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
501112|NCT00393003|Device|Closed-loop anesthesia system|
501113|NCT00392990|Drug|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
501114|NCT00392990|Drug|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
501115|NCT00392977|Dietary Supplement|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
501116|NCT00392951|Drug|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
501117|NCT00392938|Drug|antiandrogen therapy|
501118|NCT00392938|Drug|docetaxel|
501119|NCT00392938|Diagnostic Test|C-11 acetate PET scan|
501120|NCT00392938|Diagnostic Test|F-18 FDG PET scan|
501121|NCT00392938|Diagnostic Test|Tc-99m bone scan|
501122|NCT00392938|Diagnostic Test|CT scan of the chest, abdomen and pelvis|
501123|NCT00392925|Drug|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
501124|NCT00392925|Drug|metreleptin|subcutaneous injection, twice a day, 5mg
501125|NCT00392925|Drug|placebo-pramlintide 600 uL|twice a day
501126|NCT00392925|Drug|placebo-metreleptin 1 mL|twice a day
501127|NCT00392925|Drug|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
501128|NCT00392912|Drug|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
501129|NCT00392899|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
501130|NCT00392886|Drug|carboplatin|Given IV
501131|NCT00392886|Drug|cisplatin|Given IV
501132|NCT00392886|Drug|cyclophosphamide|Given IV
501133|NCT00392886|Drug|etoposide|Given IV and orally
501134|NCT00392886|Drug|methotrexate|Given IV
501135|NCT00392886|Drug|temozolomide|Given orally
501136|NCT00392886|Drug|thiotepa|Given IV
501139|NCT00392886|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
501140|NCT00392886|Procedure|peripheral blood stem cell transplantation|Given on day 0
501141|NCT00392886|Radiation|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
501142|NCT00392873|Behavioral|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
501143|NCT00392860|Device|Natural-Fit|Ergonomic handrim for wheelchairs
501144|NCT00392860|Device|PalmRim|Ergonomic handrim for wheelchair
501145|NCT00392860|Device|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
501146|NCT00392847|Behavioral|Promoting Parental Skills and Enhancing Attachment|The first group will receive routine follow-up as currently provided by national community health and social services.
501147|NCT00392847|Behavioral|had home visits by community workers during pregnancy|had home visits by community workers during pregnancy to the child's second birthday.
501148|NCT00392834|Biological|filgrastim|given subcutaneously
501149|NCT00392834|Biological|pegfilgrastim|given subcutaneously
501150|NCT00392834|Biological|rituximab|given IV
501151|NCT00392834|Drug|cyclophosphamide|given IV
501152|NCT00392834|Drug|cytarabine|given intrathecally
501153|NCT00392834|Drug|doxorubicin hydrochloride|given IV
501154|NCT00392834|Drug|etoposide|given IV
501155|NCT00392834|Drug|ifosfamide|given IV
501156|NCT00392834|Drug|leucovorin calcium|given IV
501157|NCT00392834|Drug|liposomal cytarabine|given intrathecally
501158|NCT00392834|Drug|methotrexate|given intrathecally
501159|NCT00392834|Drug|therapeutic hydrocortisone|given intrathecally
501160|NCT00392834|Drug|vincristine sulfate|given IV
501161|NCT00392821|Drug|Sorafenib|Sorafenib
501162|NCT00392821|Drug|RAD001|RAD001
501163|NCT00392808|Biological|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
501164|NCT00392782|Biological|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
501165|NCT00392782|Drug|fludarabine phosphate|Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
501166|NCT00392782|Drug|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
501167|NCT00392782|Procedure|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
501168|NCT00392782|Radiation|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
501169|NCT00392769|Drug|Cetuximab|Initial Dose = 400 mg/m^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m^2 IV Over 60 Minutes.
501170|NCT00392756|Drug|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
501171|NCT00392743|Procedure|pet/spect scan|
501172|NCT00392730|Dietary Supplement|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
501173|NCT00392717|Drug|Atorvastatin|
501174|NCT00392717|Drug|Fish oils|
501175|NCT00392704|Drug|Bevacizumab|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
501176|NCT00392704|Drug|Erlotinib|"Induction Treatment:~Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.~Combined Modality Treatment:~Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
501177|NCT00392704|Drug|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22~Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
501178|NCT00392704|Drug|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
501179|NCT00392704|Radiation|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
501180|NCT00392691|Drug|ibritumomab tiuxetan|185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients > 80kg) for imaging.
501181|NCT00392691|Drug|rituximab|250 mg/m2
501182|NCT00392691|Drug|melphalan|"Dose level 1: 100 mg/m2~Dose level 2: 140 mg/m2~Dose level 3: 170 mg/m2~Dose level 4: 200 mg/m2"
501183|NCT00392691|Drug|vinorelbine tartrate / G-CSF|on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days
501258|NCT00392197|Drug|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
501184|NCT00392691|Procedure|autologous hematopoietic stem cell harvesting and transplantation|"Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.~Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils > 0.5x109/l for at least 2 consecutive days."
501185|NCT00392678|Drug|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
501186|NCT00392678|Drug|Placebo|Placebo to Salsalate
501187|NCT00392665|Drug|Bevacizumab|Given intravenously on day one of each 3 week cycle
501188|NCT00392665|Drug|erlotinib|Given orally once a day
501189|NCT00392665|Drug|Sulindac|Given orally twice a day
501190|NCT00392652|Drug|oral microencapsulated diindolylmethane|Given PO
501191|NCT00392639|Procedure|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
501192|NCT00392613|Procedure|Strict versus lenient rate control|
501193|NCT00392587|Drug|GW856553|
501194|NCT00392574|Drug|Prulifloxacin|Tablet
501195|NCT00392574|Drug|Placebo|Tablet
501196|NCT00392561|Dietary Supplement|Selenium|200 ug Selenium daily
501197|NCT00392561|Dietary Supplement|vitamin E|100 mg Vitamin E daily
501198|NCT00392535|Radiation|conventional radiotherapy 74 Gy delivered in 37 fractions|
501199|NCT00392535|Radiation|hypofractionated radiation therapy 60 Gy in 20 fractions|
501200|NCT00392535|Radiation|hypofractionated radiation therapy 57 Gy in 19 fractions|
501201|NCT00392522|Drug|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
501202|NCT00392509|Procedure|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
501203|NCT00392496|Drug|sunitinib malate|Given orally
501204|NCT00392470|Biological|cetuximab|
501205|NCT00392470|Drug|irinotecan hydrochloride|
501206|NCT00392470|Procedure|conventional surgery|
501207|NCT00392470|Procedure|neoadjuvant therapy|
501208|NCT00392470|Radiation|3-dimensional conformal radiation therapy|
501209|NCT00392470|Radiation|intensity-modulated radiation therapy|
501210|NCT00392457|Drug|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
501211|NCT00392457|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
501212|NCT00392444|Drug|sunitinib malate|Given orally
501213|NCT00392431|Drug|amiodarone|
501214|NCT00392418|Drug|Multiple micronutrient supplement (iron)|
501215|NCT00392405|Drug|3 amps of sodium bicarbonate mixed in one liter of D5W|
501216|NCT00392392|Drug|nab-paclitaxel|ABI-007
501217|NCT00392392|Drug|Bevacizumab|Bevacizumab
501218|NCT00392392|Drug|Trastuzumab|Trastuzumab
501219|NCT00392379|Drug|Nicotine Lozenges|Nicotine lozenges, 4 mg
501220|NCT00392379|Drug|Placebo lozenge|Placebo lozenge
501221|NCT00392366|Device|MR-guided Laser Interstitial Thermal Therapy System|
501222|NCT00392353|Drug|Azacitidine|Given SC
501223|NCT00392353|Other|Laboratory Biomarker Analysis|Correlative studies
501224|NCT00392353|Other|Pharmacological Study|Correlative studies
501225|NCT00392353|Drug|Vorinostat|Given PO
501226|NCT00392340|Biological|filgrastim|
501227|NCT00392340|Drug|doxorubicin hydrochloride|
501228|NCT00392340|Drug|topotecan hydrochloride|
501229|NCT00392340|Drug|vincristine sulfate|
501230|NCT00392327|Drug|Carboplatin|Given IV
501231|NCT00392327|Drug|Cisplatin|Given IV
501232|NCT00392327|Drug|Cyclophosphamide|Given IV
501233|NCT00392327|Biological|Filgrastim|Given IV or SC
501234|NCT00392327|Drug|Isotretinoin|Given PO
501235|NCT00392327|Other|Laboratory Biomarker Analysis|Correlative studies
501236|NCT00392327|Other|Quality-of-Life Assessment|Ancillary studies
501237|NCT00392327|Radiation|Radiation Therapy|Undergo radiation therapy
501238|NCT00392327|Drug|Vincristine Sulfate|Given IV
501239|NCT00392314|Other|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
501240|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
501241|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
501242|NCT00392288|Drug|Placebo|Placebo MDI over twelve weeks
501243|NCT00392275|Drug|Ofloxacin 0.3%|
501244|NCT00392275|Drug|Ciprofloxacin 0.3%|
501245|NCT00392275|Drug|Levofloxacin 0.5%|
501246|NCT00392275|Drug|Ofloxacin 400mg|
501247|NCT00392275|Drug|Ciprofloxacin 400mg|
501248|NCT00392275|Drug|Levofloxacin 250mg|
501249|NCT00392262|Drug|valsartan + amlodipine|
501250|NCT00392249|Behavioral|Supervised Treatment of Schizophrenia by a family member|
501251|NCT00392236|Device|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
501252|NCT00392236|Behavioral|Treatment as usual|Participants will receive treatment as usual.
501253|NCT00392223|Drug|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
501254|NCT00392223|Drug|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
501255|NCT00392223|Drug|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
501256|NCT00392223|Drug|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
501257|NCT00392210|Genetic|Voiding Trial|Post-void residual and uroflow study will be done twice
501259|NCT00392184|Procedure|Accelerated partial breast irradiation|
501260|NCT00392171|Drug|Temozolomide|Subjects will receive temozolomide 50 mg/m^2 for cycles of 28 days for 12 months or until progression
501261|NCT00392158|Device|Closed-loop anesthesia system|
501262|NCT00392145|Drug|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
501263|NCT00392145|Drug|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
501264|NCT00392119|Device|MR-guided Laser Interstitial Thermal Therapy System|
501265|NCT00392106|Drug|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
501266|NCT00392106|Drug|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
501267|NCT00392106|Drug|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
501268|NCT00392106|Drug|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
501269|NCT00392106|Device|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
501270|NCT00392106|Drug|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
501271|NCT00392093|Drug|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
501272|NCT00392080|Drug|CJ-023,423|75 mg BID
501273|NCT00392080|Drug|placebo|placebo
501274|NCT00392080|Drug|naproxen|naproxen
501275|NCT00392067|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
501276|NCT00392054|Procedure|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
501277|NCT00392054|Drug|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
501278|NCT00392041|Drug|Eszopiclone|3mg qpm for 12 weeks
501279|NCT00392041|Drug|placebo|1 pill qpm for 12 weeks
501280|NCT00392028|Drug|ertapenem|
501281|NCT00392015|Biological|NMRC-M3V-Ad-PfCA|Malaria Vaccine
501282|NCT00392015|Biological|NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA|Malaria Vaccines
501283|NCT00392002|Drug|Esomeprazole|
501284|NCT00391989|Drug|Dasatinib|
501285|NCT00391976|Drug|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
501286|NCT00391963|Device|Bispectral index, Entropy|
501287|NCT00391950|Drug|Zoledronic acid|
501288|NCT00391937|Device|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
501289|NCT00391924|Drug|Dehydroepiandrosterone|
501290|NCT00391911|Drug|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
501291|NCT00391911|Other|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
501292|NCT00391911|Other|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
501293|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
501294|NCT00391898|Drug|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
501295|NCT00391898|Drug|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
501296|NCT00391885|Device|Closed-loop anesthesia system|
501297|NCT00391872|Drug|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
501298|NCT00391872|Drug|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
501299|NCT00391859|Procedure|Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)|See Detailed Description.
501300|NCT00391846|Drug|Captopril|
501301|NCT00391846|Drug|Enalapril|
501302|NCT00391846|Drug|Lisinopril|
501303|NCT00391846|Drug|Ramipril|
501304|NCT00391846|Drug|Trandolapril|
501305|NCT00391846|Drug|Bisoprolol|
501306|NCT00391846|Drug|Carvedilol|
501307|NCT00391846|Drug|Metoprolol succinate|
501308|NCT00391846|Drug|Candesartan|
501309|NCT00391846|Drug|Valsartan|
501310|NCT00391846|Drug|Eplerenone|
501311|NCT00391846|Drug|Spironolactone|
501312|NCT00391846|Drug|Diuretics|
501313|NCT00391846|Drug|HF treatment according to Swedish guidelines|
501314|NCT00391846|Procedure|Blood samples|
501315|NCT00391846|Procedure|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
501316|NCT00391833|Drug|Panax Ginseng|
501317|NCT00391820|Drug|TD-5108|
501318|NCT00391807|Drug|Norethindrone acetate/ethinyl estradiol|one tablet per day
501319|NCT00391794|Behavioral|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
501320|NCT00391794|Behavioral|Educational Seminar|4 hour education session led by trained facilitators
501321|NCT00391781|Procedure|Temperature of contrast medium|
501363|NCT00391430|Drug|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
501483|NCT00390533|Drug|Saredutant|oral administration (capsules)
501322|NCT00391768|Drug|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
501323|NCT00391755|Drug|ramelteon|"ramelteon 8mg po qhs with sleep and headache diary~placebo 1 po qhs with sleep and headache diary"
501324|NCT00391742|Behavioral|Brief intervention|
501325|NCT00391729|Drug|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
501326|NCT00391729|Drug|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
501327|NCT00391716|Drug|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
501328|NCT00391716|Behavioral|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
501329|NCT00391716|Drug|placebo|lactose capsule compounded to mimic gabapentin capsules
501330|NCT00391716|Drug|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
501331|NCT00391703|Behavioral|Electrostimulation programme: using a cycloergometer|Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
501332|NCT00391703|Behavioral|Usual sport activity|Usual sport activity performed prior to an endurance retraining program using a cycloergometer
501333|NCT00391690|Drug|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
501334|NCT00391677|Behavioral|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
501335|NCT00391677|Behavioral|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
501336|NCT00391664|Behavioral|Psychosocial|
501337|NCT00391651|Drug|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
501338|NCT00391651|Drug|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
501339|NCT00391638|Drug|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
501340|NCT00391638|Biological|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
501341|NCT00391625|Drug|GA-GCB|15-60 U/kg every other week via intravenous infusion
501342|NCT00391612|Device|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
501343|NCT00391612|Device|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
501344|NCT00391599|Procedure|enema|
501345|NCT00391586|Drug|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.~Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
501346|NCT00391586|Drug|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
501347|NCT00391573|Procedure|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
501348|NCT00391573|Procedure|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
501349|NCT00391560|Drug|perifosine|Identical intervention in both arms.
501350|NCT00391547|Drug|Frio Oral Rinse|
501351|NCT00391534|Drug|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
501352|NCT00391534|Drug|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
501353|NCT00391521|Drug|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
501354|NCT00391521|Drug|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
501355|NCT00391521|Drug|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
501356|NCT00391495|Procedure|Blood drawing|
501357|NCT00391482|Behavioral|Peer Mentoring Intervention for HCV-Infected IDUs|
501358|NCT00391469|Other|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
501359|NCT00391469|Drug|Rapid infusion of cold normal saline|
501360|NCT00391456|Behavioral|Animal-assisted Therapy|
501361|NCT00391443|Drug|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight > 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight < 40 kg)
501362|NCT00391443|Drug|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
501481|NCT00390546|Drug|Digoxin|
501364|NCT00391430|Behavioral|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
501365|NCT00391417|Drug|estradiol gel|
501366|NCT00391404|Drug|Alendronate|Alendronate 70 mg weekly (oral)
501367|NCT00391404|Drug|Placebo|Placebo
501368|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
501369|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
501370|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
501371|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
501372|NCT00391365|Procedure|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
501373|NCT00391352|Drug|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
501374|NCT00391339|Drug|Bryophyllum p.|
501375|NCT00391313|Drug|Chloroquine|
501376|NCT00391300|Procedure|bioelectric field imaging|
501377|NCT00391300|Procedure|biopsy|
501378|NCT00391300|Procedure|histopathologic examination|
501379|NCT00391274|Drug|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
501380|NCT00391274|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
501381|NCT00391261|Drug|Metformin|open-label, flexible dosing
501382|NCT00391248|Drug|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
501383|NCT00391222|Drug|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
501384|NCT00391222|Drug|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
501385|NCT00391222|Drug|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
501386|NCT00391209|Drug|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
501387|NCT00391209|Drug|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
501388|NCT00391196|Drug|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
501389|NCT00391196|Drug|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
501390|NCT00391196|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
501391|NCT00391183|Procedure|Biliary stenting|ERCP and stenting
501392|NCT00391170|Drug|Topical Dexamethasone|dexamethasone 0.01%
501393|NCT00391170|Other|Placebo|Placebo
501394|NCT00391157|Drug|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
501395|NCT00391144|Procedure|intravitreal triamcinolone injection of avastin (1.25 mg)|
501396|NCT00391131|Drug|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
501397|NCT00391118|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, six 21 day cycles or up to 3 years
501398|NCT00391118|Drug|carboplatin|AUC 5, IV, q 21 days, six 21 day cycles
501399|NCT00391118|Drug|paclitaxel|175 mg/m2, IV, q 21 days, six 21 day cycles
501400|NCT00391118|Drug|placebo|oral, daily
501401|NCT00391105|Drug|Remifentanil|
501402|NCT00391092|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
501403|NCT00391092|Drug|Docetaxel|100mg/m2 iv every 3 weeks
501404|NCT00391092|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
501405|NCT00391079|Drug|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.~Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
501406|NCT00391079|Drug|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
501407|NCT00391066|Drug|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
501408|NCT00391066|Drug|FCR|Dose, schedule, and duration specified in protocol
501409|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
501410|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
501411|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
501412|NCT00391053|Biological|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
501413|NCT00391040|Behavioral|SGS education|
501414|NCT00391027|Drug|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
501415|NCT00391027|Drug|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
501416|NCT00391014|Drug|liposomal Amphotericine B|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.~If patient required ALO-TPH, the prophylaxis should be followed."
501417|NCT00391001|Drug|Taurine|double-blind, placebo-controlled, adjunctive medication
501418|NCT00390988|Procedure|blood sampling|
501419|NCT00390975|Drug|Tegaserod|
501420|NCT00390949|Behavioral|Peer education among commercial sex workers and clients|
501421|NCT00390949|Behavioral|Condom distribution and promotion|
501422|NCT00390949|Procedure|Syndromic treatment of sexually transmitted infections|
501423|NCT00390949|Procedure|Systemic counselling for STI patients|
501482|NCT00390546|Drug|Propranolol|
501424|NCT00390936|Drug|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
501425|NCT00390923|Drug|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
501426|NCT00390923|Drug|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
501427|NCT00390910|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
501428|NCT00390910|Biological|Infanrix hexa|Intramuscular injection, 3 doses
501429|NCT00390897|Drug|Glivec|
501430|NCT00390897|Drug|Interferon|
501431|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
501432|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
501433|NCT00390871|Drug|Fentanyl/Dexmedetomidine|
501434|NCT00390871|Drug|Fentanyl/Propofol|
501435|NCT00390871|Drug|Fentanyl|
501436|NCT00390858|Drug|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
501437|NCT00390845|Drug|SB681323|15 milligrams (mg)/day
501438|NCT00390845|Drug|Placebo|
501439|NCT00390832|Drug|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
501440|NCT00390832|Other|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
501441|NCT00390806|Drug|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
501442|NCT00390806|Radiation|Radiation|Whole brain radiation
501443|NCT00390793|Drug|Cyclophosphamide|Given IV
501444|NCT00390793|Drug|Cytarabine|Given IV or IT
501445|NCT00390793|Drug|Dasatinib|Given PO
501446|NCT00390793|Drug|Dexamethasone|Given IV or PO
501447|NCT00390793|Drug|Doxorubicin|Given IV
501448|NCT00390793|Drug|Methotrexate|Given IV or IT
501449|NCT00390793|Drug|Prednisone|Given PO
501450|NCT00390793|Drug|Vincristine|Given IV
501451|NCT00390780|Drug|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
501452|NCT00390780|Drug|Clotrimazole|10mg troches administered Five Times a Day for 14 days
501453|NCT00390767|Biological|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
501454|NCT00390754|Behavioral|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
501455|NCT00390741|Behavioral|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
501456|NCT00390728|Drug|Insulin Glargine|
501457|NCT00390715|Drug|chemotherapy|
501458|NCT00390702|Device|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
501459|NCT00390689|Drug|Pramipexole 0.125 mg tablet|
501460|NCT00390689|Drug|Pramipexole 0.5 mg tablet|
501461|NCT00390676|Drug|ADH -1 and carboplatin|
501462|NCT00390676|Drug|ADH -1 and docetaxel|
501463|NCT00390676|Drug|ADH -1 and capecitabine|
501464|NCT00390663|Procedure|Nasal Cautery|
501465|NCT00390650|Drug|Saredutant|
501466|NCT00390637|Behavioral|High or low Glycemic Index and high or low Protein Diet|
501467|NCT00390624|Drug|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
501468|NCT00390624|Drug|MANNITOL|
501469|NCT00390611|Drug|Sorafenib|
501470|NCT00390611|Drug|Paclitaxel|Paclitaxel
501471|NCT00390611|Drug|Carboplatin|Carboplatin
501472|NCT00390598|Drug|PEG (solution given 4 L)|
501473|NCT00390598|Drug|senna glycoside 36 mg and PEG (solution given 2 L)|
501474|NCT00390585|Drug|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
501475|NCT00390585|Drug|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
501476|NCT00390572|Behavioral|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
501477|NCT00390559|Drug|nicotine transdermal system|21 mg nicotine transdermal system
501478|NCT00390559|Drug|Nicotine transdermal system|Placebo nicotine patch
501479|NCT00390559|Other|Nicotine containing cigarette|Nicotine containing cigarette
501480|NCT00390559|Other|Placebo cigarette|Non nicotine containing cigarette
501484|NCT00390533|Drug|Placebo|oral administration (capsules)
501485|NCT00390520|Drug|Vildagliptin|
501486|NCT00390507|Procedure|Post-tetanic count frequency|
501487|NCT00390494|Procedure|Hysterectomy|
501488|NCT00390494|Procedure|Myomectomy|
501489|NCT00390494|Procedure|Uterine Fibroid Embolization|
501490|NCT00390481|Procedure|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
501491|NCT00390468|Drug|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
501492|NCT00390455|Drug|Fulvestrant|Given IM
501493|NCT00390455|Other|Laboratory Biomarker Analysis|Correlative studies
501494|NCT00390455|Drug|Lapatinib Ditosylate|Given PO
501495|NCT00390455|Other|Placebo|Given PO
501496|NCT00390442|Device|continuous positive airway pressure|
501497|NCT00390429|Drug|docetaxel|Given IV
501498|NCT00390429|Drug|erlotinib hydrochloride|Given orally
501499|NCT00390416|Drug|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
501500|NCT00390403|Drug|R-(-)-gossypol acetic acid|
501501|NCT00390403|Drug|temozolomide|
501502|NCT00390403|Genetic|gene expression analysis|
501503|NCT00390403|Genetic|mutation analysis|
501504|NCT00390403|Genetic|protein expression analysis|
501505|NCT00390403|Other|laboratory biomarker analysis|
501506|NCT00390403|Other|pharmacological study|
501507|NCT00390403|Procedure|adjuvant therapy|
501508|NCT00390403|Radiation|radiation therapy|
501509|NCT00390390|Drug|Lansoprazole|
501510|NCT00390377|Procedure|Cutting scalp hair|
501511|NCT00390364|Drug|everolimus|
501512|NCT00390364|Procedure|antiangiogenesis therapy|
501513|NCT00390364|Procedure|biopsy|
501514|NCT00390364|Procedure|diagnostic procedure|
501515|NCT00390364|Procedure|gene expression analysis|
501516|NCT00390364|Procedure|immunohistochemistry staining method|
501517|NCT00390364|Procedure|laboratory biomarker analysis|
501518|NCT00390364|Procedure|mutation analysis|
501519|NCT00390364|Procedure|protein tyrosine kinase inhibitor therapy|
501520|NCT00390364|Procedure|reverse transcriptase-polymerase chain reaction|
501521|NCT00390351|Device|optical coherence tomography|
501522|NCT00390338|Biological|polarized dendritic cells|
501523|NCT00390338|Biological|non-polarized dendritic cells|
501524|NCT00390325|Drug|Sorafenib|Given PO
501525|NCT00390325|Drug|Sorafenib Tosylate|Given PO
501526|NCT00390312|Drug|Intranasal Placebo|Intranasal placebo
501527|NCT00390312|Drug|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
501528|NCT00390312|Drug|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
501529|NCT00390312|Drug|Intravenous morphine|Intravenous morphine 7.5 mg
501530|NCT00390312|Drug|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
501531|NCT00390312|Drug|Oral placebo|Oral placebo
501532|NCT00390312|Drug|Intravenous placebo|Intravenous placebo
501533|NCT00390299|Biological|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
501534|NCT00390299|Other|Laboratory Biomarker Analysis|Correlative studies
501535|NCT00390299|Procedure|Therapeutic Conventional Surgery|Undergo en bloc resection
501536|NCT00390273|Drug|Metformin|
501537|NCT00390260|Drug|MK0966 / Duration of Treatment: 1 Days|
501538|NCT00390260|Drug|Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|
501539|NCT00390260|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 1 Days|
501540|NCT00390247|Drug|thalidomide|
501541|NCT00390234|Drug|ziv-aflibercept|Given IV
501542|NCT00390221|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
501543|NCT00390221|Drug|Placebo|Placebo SC injection
501544|NCT00390208|Drug|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
501545|NCT00390208|Drug|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
501546|NCT00390195|Drug|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
501547|NCT00390195|Drug|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
501548|NCT00390182|Drug|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.~Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.~**Radiation is the experimental part of the study."
501549|NCT00390169|Behavioral|Mindfulness Meditation-Based Stress Reduction|
501550|NCT00390169|Behavioral|Supportive-Expressive Group Therapy|
501551|NCT00390156|Biological|bevacizumab|5 mg/kg
501552|NCT00390156|Drug|cyclophosphamide|Current dose 50 mg
501553|NCT00390156|Drug|imatinib|Current dose 400 mg
501554|NCT00390143|Biological|Meningococcal vaccine 134612|One intramuscular dose during the primary study
501555|NCT00390143|Biological|Mencevax™ ACWY|One subcutaneous dose during the primary study
501556|NCT00390130|Drug|Pentacel (DPTaP+Hib)|
501557|NCT00390130|Drug|Prevnar (conjugated pneumococcal vaccine)|
501558|NCT00390117|Drug|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
501738|NCT00389038|Drug|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
501559|NCT00390117|Other|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
501560|NCT00390091|Drug|abetimus sodium (LJP 394)|
501561|NCT00390078|Biological|MVA-mBN32|3 immunizations: 1x 10E8_TCID50 MVA-mBN32
501562|NCT00390078|Biological|IMVAMUNE|3 immunizations: 1x 10E8_TCID50 IMVAMUNE
501563|NCT00390065|Drug|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
501564|NCT00390052|Drug|triapine|Given IV and orally
501565|NCT00390052|Other|pharmacological study|correlative study
501566|NCT00390052|Procedure|laboratory biomarker analysis|Correlative study
501567|NCT00390039|Drug|Intranasal Morphine|MNS075 7.5mg q1h PRN
501568|NCT00390039|Drug|Placebo|IN Placebo q1h PRN
501569|NCT00390039|Drug|IV morphine|IV morphine 7.5mg q3h PRN
501570|NCT00390039|Drug|Placebo|IV Placebo q3h PRN
501571|NCT00390039|Drug|Intranasal morphine|MNS075 15mg q3h PRN
501572|NCT00390039|Drug|Placebo|IN Placebo q3h PRN
501573|NCT00390026|Drug|Bevacizumab (Avastin)|
501574|NCT00390026|Drug|Verteporfin photodynamic therapy (PDT)|
501575|NCT00390013|Drug|Gabapentin|"300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
501576|NCT00390013|Drug|Placebo oral capsule|"Placebo capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~day 1 you will take 1 capsule for the day~day 2 you will take 1 capsule 2 times for that day~days 3-6 you will take 1 capsule 3 times for those days~days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~days 13-14 you will take 2 capsules 3 times each day~continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~at completion of study treatment you will titrate off study drug over a weeks time."
501577|NCT00390000|Drug|vatalanib|Given orally
501578|NCT00390000|Drug|pemetrexed disodium|Given IV
501579|NCT00390000|Other|pharmacological study|Correlative study
501580|NCT00390000|Procedure|ultrasound imaging|Correlative study
501581|NCT00389987|Drug|MK0826, /Duration of Treatment : 8 Weeks|
501582|NCT00389987|Drug|Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks|
501583|NCT00389974|Drug|sunitinib malate|Given PO
501584|NCT00389948|Drug|Lanzoprazole|
501585|NCT00389935|Drug|Thalidomide|Thalidomide 50 - 200 mg once at nightime
501586|NCT00389922|Drug|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
501587|NCT00389922|Drug|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
501588|NCT00389922|Genetic|comparative genomic hybridization|Molecular correlative study
501589|NCT00389922|Genetic|cytogenetic analysis|Molecular correlative study
501590|NCT00389922|Genetic|gene expression analysis|Molecular correlative study
501591|NCT00389922|Genetic|mutation analysis|Molecular correlative study
501592|NCT00389922|Genetic|polymerase chain reaction|Molecular correlative study
501593|NCT00389922|Genetic|polymorphism analysis|Molecular correlative study
501594|NCT00389922|Genetic|proteomic profiling|Molecular correlative study
501595|NCT00389922|Genetic|reverse transcriptase-polymerase chain reaction|Molecular correlative study
501596|NCT00389922|Other|immunohistochemistry staining method|Molecular correlative study
501597|NCT00389922|Other|laboratory biomarker analysis|Molecular correlative study
501598|NCT00389922|Drug|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
501599|NCT00389922|Drug|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
501600|NCT00389909|Drug|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender."
501601|NCT00389896|Drug|MK0733 / Duration of Treatment: 18 Weeks|
501602|NCT00389896|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
501603|NCT00389883|Drug|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
501604|NCT00389870|Biological|panitumumab|
501605|NCT00389870|Drug|cyclosporine|
501606|NCT00389870|Drug|irinotecan hydrochloride|
501607|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
501608|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
501609|NCT00389844|Behavioral|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
501610|NCT00389844|Behavioral|Plus component (motivation) of the Exercise Plus Program|Motivation only
501611|NCT00389844|Behavioral|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
501612|NCT00389831|Drug|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
501613|NCT00389831|Other|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
501739|NCT00389025|Drug|Olopatadine (generic name)|
501740|NCT00389012|Procedure|exercise therapy|
501614|NCT00389818|Biological|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
501615|NCT00389818|Biological|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
501616|NCT00389818|Biological|rituximab|375 mg/m2 IV Day 1 of each cycle
501617|NCT00389818|Biological|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
501618|NCT00389818|Drug|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
501619|NCT00389818|Drug|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
501620|NCT00389818|Drug|prednisone|100 mg PO Days 1-5 of each cycle
501621|NCT00389818|Drug|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
501622|NCT00389818|Other|immunohistochemistry staining method|tissue specimen collected at baseline
501623|NCT00389818|Other|laboratory biomarker analysis|tissue specimen collected at baseline
501624|NCT00389805|Drug|bortezomib|
501625|NCT00389805|Drug|pemetrexed disodium|
501626|NCT00389805|Genetic|gene expression analysis|
501627|NCT00389805|Genetic|mutation analysis|
501628|NCT00389805|Genetic|protein expression analysis|
501629|NCT00389805|Genetic|reverse transcriptase-polymerase chain reaction|
501630|NCT00389805|Other|flow cytometry|
501631|NCT00389805|Other|immunoenzyme technique|
501632|NCT00389805|Other|immunohistochemistry staining method|
501633|NCT00389792|Drug|ATI-2042|no intervention
501634|NCT00389792|Drug|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
501635|NCT00389779|Drug|Darusentan|Darusentan capsules administered orally once daily
501636|NCT00389779|Drug|Guanfacine|Guanfacine capsules administered orally once daily
501637|NCT00389779|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
501638|NCT00389766|Drug|iodine I 131 metaiodobenzylguanidine|
501639|NCT00389766|Drug|topotecan hydrochloride|
501640|NCT00389766|Procedure|chemotherapy|
501641|NCT00389766|Procedure|peripheral blood stem cell transplantation|
501642|NCT00389766|Procedure|radioisotope therapy|
501643|NCT00389766|Procedure|radionuclide imaging|
501644|NCT00389766|Procedure|radiosensitization|
501645|NCT00389766|Procedure|total-body irradiation|
501646|NCT00389753|Drug|Application of Aruba Aloë formula F-BC-096 or control|
501647|NCT00389740|Drug|MK0217, /Duration of Treatment : 12 Months|
501648|NCT00389740|Drug|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
501649|NCT00389727|Drug|Radiotherapy|Radiotherapy
501650|NCT00389714|Device|dental restoration|
501651|NCT00389701|Drug|bortezomib|
501652|NCT00389701|Drug|dexamethasone|
501653|NCT00389688|Drug|cisplatin|
501654|NCT00389688|Drug|pemetrexed disodium|
501655|NCT00389688|Procedure|adjuvant therapy|
501656|NCT00389688|Procedure|conventional surgery|
501657|NCT00389688|Procedure|neoadjuvant therapy|
501658|NCT00389675|Drug|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
501659|NCT00389675|Drug|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
501660|NCT00389662|Device|"Wearing the Nike Free shoe"|
501661|NCT00389649|Device|heart rate setting|
501662|NCT00389636|Device|TheraGauze|TheraGauze
501663|NCT00389636|Drug|Regranex|Regranex + TheraGauze
501664|NCT00389610|Biological|allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine|Given subcutaneously
501665|NCT00389597|Device|Cervical Artificial Disc|Cervical artificial disc mechanical device
501666|NCT00389584|Drug|irinotecan hydrochloride|
501667|NCT00389584|Procedure|cognitive assessment|
501668|NCT00389584|Procedure|management of therapy complications|
501669|NCT00389584|Radiation|radiation therapy|
501670|NCT00389558|Procedure|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
501671|NCT00389558|Procedure|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
501672|NCT00389545|Procedure|Intracoronary infusion of autologous bone-marrow derived stem cells|
501673|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
501674|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
501675|NCT00389519|Drug|ramipril|once a day oral ramipril capsules given for 4 weeks
501676|NCT00389519|Drug|placebo|once a day oral placebo capsule for 4 weeks
501677|NCT00389506|Biological|LMB-2 immunotoxin|
501678|NCT00389506|Drug|cyclophosphamide|
501679|NCT00389506|Drug|fludarabine phosphate|
501680|NCT00389506|Other|pharmacological study|
501681|NCT00389493|Drug|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
501682|NCT00389493|Behavioral|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
501683|NCT00389493|Drug|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
501684|NCT00389480|Drug|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
501736|NCT00389038|Behavioral|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
501737|NCT00389038|Behavioral|Headache Education|Behavioral Treatment 2 (headache education)
501685|NCT00389467|Device|Merci Retriever and Penumbra System|"The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2)."
501686|NCT00389441|Drug|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
501687|NCT00389428|Drug|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
501688|NCT00389415|Drug|Vildagliptin|
501689|NCT00389402|Drug|saquinavir/ritonavir|
501690|NCT00389402|Drug|atazanavir/ritonavir|
501691|NCT00389389|Drug|AZD4877|intravenous infusion
501692|NCT00389376|Drug|Placebo|Placebo
501693|NCT00389376|Drug|Silymarin|140 mg every 8 hours
501694|NCT00389376|Drug|Silymarin|280 mg single dose
501695|NCT00389376|Drug|Silymarin|280 mg single dose + every 8 hours
501696|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
501697|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
501698|NCT00389376|Drug|Silymarin|280 mg every 8 hours
501699|NCT00389376|Drug|Silymarin|700 mg single dose + every 8 hours
501700|NCT00389363|Drug|ALK HDM tablet|
501701|NCT00389350|Drug|Extract of Green and Black Tea|
501702|NCT00389324|Biological|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
501703|NCT00389311|Drug|Normosol-R|
501704|NCT00389311|Drug|Nonoxynol-9|
501705|NCT00389311|Procedure|Gastrointestinal instrumentation|
501706|NCT00389298|Drug|VCH-759 (BCH-27759)|
501707|NCT00389285|Drug|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
501708|NCT00389285|Drug|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
501709|NCT00389272|Drug|Ibuprofen, acetaminophen|
501710|NCT00389259|Drug|Placebo|IV placebo q4h
501711|NCT00389246|Behavioral|Consultation without genetic information|
501712|NCT00389246|Behavioral|Consultation with genetic information|
501713|NCT00389233|Drug|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|"1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid."
501714|NCT00389233|Drug|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|"1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour."
501715|NCT00389220|Device|Coronary stent placement|Coronary stent placement
501716|NCT00389207|Drug|nevirapine bid|nevirapine twice daily
501717|NCT00389207|Drug|nevirapine qd|nevirapine once daily
501718|NCT00389207|Drug|atazanavir|atazanavir once daily
501719|NCT00389194|Drug|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
501720|NCT00389181|Procedure|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
501721|NCT00389181|Other|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
501722|NCT00389168|Drug|Irbesartan|Titrated to 300 mg od, 48 weeks.
501723|NCT00389168|Drug|Atenolol|Titrated to 100 mg od, 48 weeks.
501724|NCT00389155|Drug|Vinflunine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
501725|NCT00389155|Drug|Gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
501726|NCT00389155|Other|Placebo|
501727|NCT00389129|Drug|acetylsalicylic acid|
501728|NCT00389116|Drug|gastrograffin|ingestion
501729|NCT00389116|Drug|water|oral water ingestion
501730|NCT00389103|Biological|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
501731|NCT00389090|Drug|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
501732|NCT00389077|Drug|Perifosine|Perifosine 50 mg tablets
501733|NCT00389064|Drug|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
501734|NCT00389064|Drug|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
501735|NCT00389051|Drug|bendamustine hydrochloride|
501741|NCT00389012|Procedure|walking rehabilitation|
501742|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
501743|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
501744|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
501745|NCT00388986|Drug|GK Activator (2)|100mg po bid
501746|NCT00388986|Drug|Glyburide|10-20mg po daily
501747|NCT00388973|Drug|Quetiapine|
501748|NCT00388960|Drug|Amrubicin|"Amrubicin 45mg/m<2> IV days 1, 2 3 of each 21-day cycle until disease progression.~Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression."
501749|NCT00388960|Drug|Cisplatin|"Amrubicin 40mg/m<2> IV days 1, 2, 3 plus Cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression.~Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression."
501750|NCT00388960|Drug|Etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
501751|NCT00388947|Device|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
501752|NCT00388934|Device|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
501753|NCT00388921|Drug|Vitamin A|
501754|NCT00388908|Behavioral|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
501755|NCT00388908|Other|Usual Care|
501756|NCT00388895|Drug|chemotherapy|
501757|NCT00388895|Drug|Glivec|
501758|NCT00388882|Drug|tiotropium|
501759|NCT00388882|Drug|ipratropium bromide / albuterol|
501760|NCT00388856|Drug|Vitamin C 1000mg and E 400IU|
501761|NCT00388830|Procedure|Ultrasound|
501762|NCT00388817|Behavioral|Pharmacist intervention|
501763|NCT00388804|Procedure|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
501764|NCT00388804|Drug|Bicalutamide|50 mg By Mouth (PO) Daily
501765|NCT00388804|Drug|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
501766|NCT00388804|Drug|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
501767|NCT00388804|Drug|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
501768|NCT00388804|Behavioral|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
501769|NCT00388791|Drug|Systane Free|
501770|NCT00388778|Drug|Doxycycline|
501771|NCT00388752|Procedure|Acupuncture|
501772|NCT00388739|Drug|Pulmicort|
501773|NCT00388739|Behavioral|TEDAS ED Educational Intervention|
501774|NCT00388726|Drug|E7389|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
501775|NCT00388726|Drug|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
501776|NCT00388713|Procedure|carotid intima-media thickening ultrasound|
501777|NCT00388700|Drug|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
501778|NCT00388700|Drug|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
501779|NCT00388687|Drug|18F Fluoroazomycin Arabinoside (FAZA)|
501780|NCT00388674|Drug|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
501781|NCT00388674|Drug|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
501782|NCT00388661|Drug|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
501783|NCT00388661|Drug|Placebo comparator|Placebo comparator
501784|NCT00388648|Drug|mixture of amino and keto acids|
501785|NCT00388635|Drug|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
501786|NCT00388635|Drug|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
501787|NCT00388635|Drug|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
501788|NCT00388622|Behavioral|Pharmacist intervention|
501789|NCT00388609|Drug|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
501790|NCT00388609|Drug|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
501791|NCT00388596|Drug|SB-751689|
501792|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
501793|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
501794|NCT00388570|Device|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
528495|NCT00163371|Drug|Ciclesonide|
501795|NCT00388557|Drug|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
501796|NCT00388544|Behavioral|Activity matched to interest|Recreational activities are tailored to subject's style of interest
501797|NCT00388544|Behavioral|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
501798|NCT00388544|Behavioral|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
501799|NCT00388531|Drug|Depocyte®|Depocyte® is a cytostatic drug
501800|NCT00388518|Drug|Actos|45mg po daily
501801|NCT00388518|Drug|Placebo|po daily
501802|NCT00388518|Drug|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
501803|NCT00388505|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
501804|NCT00388505|Drug|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
501805|NCT00388479|Drug|Alvimopan|
501806|NCT00388466|Device|GALILEO|
501807|NCT00388453|Device|Dx-pH Probe|24 hour ph monitoring
501808|NCT00388453|Procedure|Manometry|procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
501809|NCT00388440|Biological|MMR vaccine (Priorix)|
501810|NCT00388427|Drug|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
501811|NCT00388427|Drug|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m^2 on Day 1 of Cycle 1; IV 250 mg/m^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
501812|NCT00388414|Drug|duloxetine|30-60mg of duloxetine daily
501813|NCT00388414|Drug|Placebo|Placebo pill once daily
501814|NCT00388401|Drug|Alvimopan|
501815|NCT00388388|Drug|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
501816|NCT00388375|Procedure|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
501817|NCT00388362|Drug|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
501818|NCT00388362|Drug|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
501819|NCT00388349|Drug|Gemcitabine|
501820|NCT00388349|Drug|Vinorelbine|
501821|NCT00388349|Drug|Carmustine|
501822|NCT00388349|Drug|Etoposide|
501823|NCT00388349|Drug|Cyclophosphamide|
501824|NCT00388349|Procedure|Autologous HCT|
501825|NCT00388336|Drug|Epoetin Alfa|
501826|NCT00388323|Other|blood and biopsies|blood and biopsies
501827|NCT00388310|Procedure|Culture|Culture
501828|NCT00388297|Drug|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
501829|NCT00388297|Drug|Placebo for Levothyroxine|
501830|NCT00388284|Device|Arterial Sealing|
501831|NCT00388271|Drug|Alfuzosin (Xatral)|standard treatment plus alfuzosin
501832|NCT00388271|Drug|standard treatment|standard treatment
501833|NCT00388258|Drug|Alvimopan|
501834|NCT00388245|Procedure|Percutaneous Coronary Intervention|
501835|NCT00388245|Procedure|Coronary Artery Bypass Grafting|
501836|NCT00388219|Drug|Transtec (R) PRO (buprenorphine)|
501837|NCT00388193|Drug|RITUXIMAB|375 mg/m2/d day 1
501838|NCT00388180|Drug|GW501516|
501839|NCT00388180|Drug|GW590735|
501840|NCT00388167|Drug|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
501841|NCT00388154|Drug|Gemcitabine|900 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
501842|NCT00388154|Drug|Cisplatin|30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
501843|NCT00388141|Behavioral|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
501844|NCT00388128|Drug|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
501845|NCT00388115|Procedure|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
501846|NCT00388115|Procedure|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
501847|NCT00388115|Procedure|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
501848|NCT00388089|Drug|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
501849|NCT00388089|Drug|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
501850|NCT00388089|Other|flow cytometry|No description
501851|NCT00388089|Other|immunoenzyme technique|No description
501852|NCT00388089|Other|immunohistochemistry staining method|No description
501853|NCT00388089|Other|laboratory biomarker analysis|No description
501854|NCT00388076|Drug|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
501855|NCT00388076|Drug|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
501856|NCT00388076|Drug|paclitaxel|in combination with pazopanib
501857|NCT00388076|Drug|carboplatin|in combination with pazopanib
501858|NCT00388063|Drug|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
501859|NCT00388050|Behavioral|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
501860|NCT00388050|Behavioral|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
501861|NCT00388037|Drug|sunitinib malate|Given PO
501862|NCT00388037|Other|laboratory biomarker analysis|Correlative studies
501863|NCT00388011|Drug|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
501864|NCT00388011|Drug|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
501865|NCT00388011|Drug|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
501866|NCT00388011|Drug|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
501867|NCT00388011|Drug|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
501868|NCT00388011|Drug|Intranasal placebo|Intranasal placebo
501869|NCT00387998|Other|AHRQ staying healthy booklet|educational booklet about prevention
501870|NCT00387998|Other|Risk primer|Know your chances booklet
501871|NCT00387985|Drug|MOA-728|
501872|NCT00387972|Drug|denagliptin (GW823093)|
501873|NCT00387959|Biological|filgrastim|
501874|NCT00387959|Biological|rituximab|
501875|NCT00387959|Drug|cyclophosphamide|
501876|NCT00387959|Drug|cyclosporine|
501877|NCT00387959|Drug|fludarabine phosphate|
501878|NCT00387959|Drug|mycophenolate mofetil|
501879|NCT00387959|Procedure|allogeneic hematopoietic stem cell transplantation|
501880|NCT00387959|Procedure|umbilical cord blood transplantation|
501881|NCT00387959|Radiation|total-body irradiation|
501882|NCT00387946|Drug|SSR591813L (dianicline)|
501883|NCT00387933|Drug|hydroxyurea|
501884|NCT00387933|Drug|imatinib mesylate|
501885|NCT00387933|Drug|vatalanib|
501886|NCT00387920|Drug|sunitinib malate|Given orally
501887|NCT00387920|Other|pharmacological study|Correlative studies
501888|NCT00387920|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
501889|NCT00387920|Other|laboratory biomarker analysis|Correlative studies
501890|NCT00387907|Drug|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
501891|NCT00387907|Drug|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
501892|NCT00387894|Drug|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
501893|NCT00387881|Drug|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
501894|NCT00387881|Drug|Placebo|Placebo to match Treximet tablets
501895|NCT00387868|Drug|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29&36 Etoposide: 50 mg/m2 - administered on days 1-5 & 29-33
501896|NCT00387868|Procedure|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
501897|NCT00387868|Radiation|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
501898|NCT00387855|Behavioral|SOS program|screening and didactic programming to raise awareness of depression suicidality
501899|NCT00387842|Procedure|Laparoscopic surgery|
501900|NCT00387842|Procedure|Conventional surgery|
501901|NCT00387829|Device|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
501902|NCT00387803|Device|Cardiac Resynchronization Therapy with Defibrillation|
501903|NCT00387790|Drug|motexafin gadolinium|Given IV
501904|NCT00387790|Radiation|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
501905|NCT00387777|Drug|Patch with centrally acting analgesic|
501906|NCT00387777|Drug|Transtec(R) PRO (buprenorphine)|
501907|NCT00387764|Drug|pazopanib|800 mg daily dosing continously until progression
501908|NCT00387751|Biological|Bevacizumab|Given IV
501909|NCT00387751|Other|Laboratory Biomarker Analysis|Correlative studies
501910|NCT00387751|Other|Pharmacological Study|Correlative studies
501911|NCT00387751|Drug|Sorafenib Tosylate|Given orally
501912|NCT00387738|Biological|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
501913|NCT00387738|Biological|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
501914|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
501915|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
501916|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
501917|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
501918|NCT00387712|Other|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
502018|NCT00386971|Dietary Supplement|L-carnitine|3 grams daily in liquid form by mouth
501919|NCT00387712|Other|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
501920|NCT00387699|Biological|bevacizumab|
501921|NCT00387699|Drug|cisplatin|
501922|NCT00387699|Drug|etoposide|
501923|NCT00387699|Radiation|radiation therapy|
501924|NCT00387686|Drug|rhBMP-2/CPM|
501925|NCT00387686|Drug|rhBMP-2/CPM|
501926|NCT00387686|Drug|rhBMP-2/CPM|
501927|NCT00387686|Drug|rhBMP-2/CPM|
501928|NCT00387673|Behavioral|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
501929|NCT00387660|Drug|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
501930|NCT00387660|Drug|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
501931|NCT00387647|Drug|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
501932|NCT00387634|Biological|TBE vaccine for adults|Serology blood draw.
501933|NCT00387621|Drug|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
501934|NCT00387621|Drug|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
501935|NCT00387621|Drug|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
501936|NCT00387608|Drug|veliparib|
501937|NCT00387608|Other|pharmacological study|
501938|NCT00387608|Procedure|biopsy|
501939|NCT00387582|Drug|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
501940|NCT00387582|Procedure|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
501941|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
501942|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
501943|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
501944|NCT00387556|Drug|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
501945|NCT00387530|Drug|oral sodium phenylbutyrate|
501946|NCT00387530|Drug|valganciclovir|
501947|NCT00387530|Genetic|polymerase chain reaction|
501948|NCT00387530|Genetic|protein expression analysis|
501949|NCT00387530|Procedure|biopsy|
501950|NCT00387517|Drug|Aliskiren/HCTZ|
501951|NCT00387504|Drug|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
501952|NCT00387504|Other|pharmacological study|samples drawn per protocol
501953|NCT00387491|Drug|MOA-728|
501954|NCT00387478|Biological|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:~600 SU/0.5 ml~1600 SU/0.5 ml~4000 SU/0.5 ml~4000 SU/0.6 ml~4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
501955|NCT00387465|Drug|Azacitidine 30mg/m2|Azacitidine 30mg/m2 subcutaneously (SQ)
501956|NCT00387465|Drug|Entinostat|7mg by mouth (PO) on days 3 and 10 of each cycle
501957|NCT00387465|Drug|Azacitidine 40mg/m2|Azacitidine 40mg/m2 SQ
501958|NCT00387452|Behavioral|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
501959|NCT00387452|Behavioral|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
501960|NCT00387439|Behavioral|standard medical treatment + anoperineal physiotherapy.|
501961|NCT00387439|Behavioral|Standard medical treatment|
501962|NCT00387426|Drug|sunitinib malate|Given PO
501963|NCT00387413|Drug|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
501964|NCT00387413|Drug|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
501965|NCT00387413|Drug|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
501966|NCT00387413|Drug|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
501967|NCT00387400|Drug|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
501968|NCT00387400|Drug|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
501969|NCT00387400|Genetic|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
502019|NCT00386971|Other|placebo|1 oz sweet tasting liquid daily by mouth
502020|NCT00386958|Drug|Povidone-Iodine|
528496|NCT00163358|Drug|Ciclesonide|
501970|NCT00387400|Other|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
501971|NCT00387387|Drug|Pazopanib|Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
501972|NCT00387387|Drug|FOLFOX 6|FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter^2[mg/m^2]), and folinic acid (400 mg/m^2), IV 5-fluorouracil bolus (400 mg/m^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m^2) infusion over 48 hours on Day 1 of every 14-day cycle.
501973|NCT00387387|Drug|CapeOx|CapeOx treatment consists of IV oxaliplatin (130 mg/m^2) on Day 1 plus oral capecitabine (1000 mg/m^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m^2 twice daily.
501974|NCT00387374|Biological|bevacizumab|Given IV
501975|NCT00387374|Drug|paclitaxel|Given IV
501976|NCT00387374|Drug|carboplatin|Given IV
501977|NCT00387374|Radiation|radiation therapy|Undergo radiotherapy
501978|NCT00387361|Procedure|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
501979|NCT00387348|Drug|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
501980|NCT00387348|Drug|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
501981|NCT00387335|Drug|sunitinib malate|Given orally
501982|NCT00387322|Drug|erlotinib hydrochloride|Given orally
501983|NCT00387322|Drug|pemetrexed disodium|Given IV
501984|NCT00387309|Drug|Methylnaltrexone (MOA-728)|
501985|NCT00387296|Device|functional microarray|functional microarray application
501986|NCT00387283|Drug|AVI-4020 Injection|
501987|NCT00387270|Drug|Dimebon|Dimebon 10 or 20 mg TID x 7 days
501988|NCT00387257|Drug|Rilapladib (SB-659032)|
501989|NCT00387244|Device|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
501990|NCT00387231|Procedure|Percutaneous coronary angioplasty/intervention (PCI)|
501991|NCT00387231|Drug|Anti-ischemic drug therapy|
501992|NCT00387218|Behavioral|Exercise, Physical therapy|
501993|NCT00387205|Drug|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
501994|NCT00387192|Drug|Optivate|Plasma-derived Factor VIII
501995|NCT00387179|Drug|Melatonin|5mg, pill, once
501996|NCT00387179|Drug|Methylxanthine|2.9 mg/kg, pill, once
501997|NCT00387179|Procedure|Light Therapy|Bright light exposure
501998|NCT00387153|Drug|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
501999|NCT00387140|Drug|MK2295|
502000|NCT00387127|Drug|Lapatinib oral tablets|Lapatinib is administered orally once daily.
502001|NCT00387127|Drug|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
502002|NCT00387127|Drug|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
502003|NCT00387114|Drug|Vitamin C|
502004|NCT00387101|Device|Dermal - Living Skin Replacement (Dermal - LSR)|
502005|NCT00387088|Device|Respimat|
502006|NCT00387088|Drug|Tiotropium|
502007|NCT00387075|Procedure|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
502008|NCT00387075|Drug|[123I]β-CIT|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
502009|NCT00387062|Device|Computer-based Cognitive Training|
502010|NCT00387049|Behavioral|Anxiety Sensitivity Program for Smoking Cessation|
502011|NCT00387036|Drug|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
502012|NCT00387036|Drug|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
502013|NCT00387023|Drug|Rituximab|250 mg/m^2 IV over 4-6 hours for 2 weeks.
502014|NCT00387023|Drug|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
502015|NCT00387010|Drug|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.~Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.~Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
502016|NCT00386997|Drug|liposomal amphotericin B (AmBisome®)|
502017|NCT00386984|Drug|Somatostatin (octreotide)|
502355|NCT00384176|Drug|Cediranib|oral tablet once daily
502021|NCT00386945|Behavioral|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
502022|NCT00386919|Procedure|CyberKnife|
502023|NCT00386906|Procedure|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
502024|NCT00386893|Procedure|simultaneous EEG/fMRI|fMRI/EEG recordings
502025|NCT00386893|Device|fMRI|
502026|NCT00386880|Other|Sounds|
502027|NCT00386867|Drug|800 mcg misoprostol via oral or buccal administration|
502028|NCT00386854|Behavioral|physical training|
502029|NCT00386841|Drug|Escitalopram|Escitalopram 10 mg p.o. per day
502030|NCT00386841|Drug|Placebo|Placebo
502031|NCT00386828|Drug|Bevacizumab:|
502032|NCT00386815|Drug|pemetrexed|
502033|NCT00386815|Drug|cisplatin|
502034|NCT00386802|Drug|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
502035|NCT00386776|Other|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
502036|NCT00386763|Drug|Artemether-lumefantrine|
502037|NCT00386750|Drug|Artemether-lumefantrine|
502038|NCT00386724|Device|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
502039|NCT00386724|Device|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
502040|NCT00386711|Behavioral|training on identification of suicide risk and depression|
502041|NCT00386698|Biological|Fluarix|
502042|NCT00386698|Biological|adjuvanted influenza vaccine|
502043|NCT00386685|Drug|larotaxel (XRP9881)|intravenous administration
502044|NCT00386685|Drug|trastuzumab|intravenous administration
502045|NCT00386672|Dietary Supplement|Reduced energy (lite) OJ fortified with Calcium and Vitamin D|Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
502046|NCT00386672|Behavioral|Nutrition Counseling|Individual and group nutritional counseling by a registered dietician.
502047|NCT00386672|Dietary Supplement|Reduced energy (lite) OJ without Calcium and Vitamin D|Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
502048|NCT00386659|Drug|tenofovir + abacavir + lopinavir/ritonavir|
502049|NCT00386659|Drug|tenofovir + abacavir + efavirenz|
502050|NCT00386646|Drug|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
502051|NCT00386633|Biological|MVA-mBN32|3 immunizations; first study group: 10E7_TCID50
502052|NCT00386633|Biological|MVA-mBN32|3 immunizations; second study group: 10E8_TCID50
502053|NCT00386620|Behavioral|Questionnaire|45 minute survey about health, pain and relationships
502054|NCT00386620|Behavioral|Interview|Feedback on use of handheld computer electronic diaries (ED).
502055|NCT00386607|Drug|Aliskiren|Aliskiren 300 mg
502056|NCT00386607|Drug|Valsartan|Valsartan 320 mg
502057|NCT00386607|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
502058|NCT00386594|Drug|852A|
502059|NCT00386581|Drug|atomoxetine|
502060|NCT00386581|Drug|placebo|
502061|NCT00386555|Drug|docetaxel|
502062|NCT00386555|Drug|CP-868,596 + docetaxel|
502063|NCT00386555|Drug|AG-013736 + docetaxel|
502064|NCT00386555|Drug|CP-868,596 + AG-013736 + docetaxel|
502065|NCT00386542|Biological|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
502066|NCT00386542|Device|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
502067|NCT00386529|Drug|Aspirin enteric coated pellests 100mg|
502068|NCT00386516|Drug|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
502069|NCT00386516|Drug|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
502070|NCT00386503|Drug|Artesunate + Amodiaquine|
502071|NCT00386490|Drug|larazotide acetate|capsule for oral administration
502072|NCT00386477|Procedure|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
502073|NCT00386464|Device|noninvasive positive pressure ventilation|
502074|NCT00386451|Device|Catheter locking systems|
502075|NCT00386438|Procedure|Honan balloon application|
502076|NCT00386425|Drug|Drotrecogin alfa (activated)|intravenous
502077|NCT00386412|Drug|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
502078|NCT00386399|Drug|Mitomycin-C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
502079|NCT00386386|Other|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
502080|NCT00386373|Drug|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
502081|NCT00386360|Drug|Placebo comparator|oral weekly for one year
502082|NCT00386360|Drug|risedronate|35 mg risedronate, once a week for one year
502083|NCT00386347|Drug|GSK364735 oral solution and oral tablets|
502084|NCT00386334|Drug|Eszopiclone|2 mg tablet once per day in the evening
502085|NCT00386334|Drug|Placebo|Tablet one per day in the evening.
502086|NCT00386321|Drug|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
502087|NCT00386308|Drug|Tranexamic acid tablets|3900 mg/Day
502088|NCT00386308|Drug|Placebo tablets|
502431|NCT00383695|Drug|oxaliplatin|
502089|NCT00386282|Drug|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
502090|NCT00386269|Drug|Codeine Phosphate Analgesia|
502091|NCT00386256|Device|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
502092|NCT00386256|Other|Telephone counseling|
502093|NCT00386243|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
502094|NCT00386243|Behavioral|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
502095|NCT00386243|Drug|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg~Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin~Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
502096|NCT00386243|Drug|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
502097|NCT00386230|Drug|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
502098|NCT00386230|Drug|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
502099|NCT00386230|Drug|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
502100|NCT00386230|Drug|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
502101|NCT00386217|Behavioral|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
502102|NCT00386204|Device|Q-switched Ruby Laser|
502103|NCT00386191|Drug|clopidogrel (SR25990C)|oral administration
502104|NCT00386178|Drug|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
502105|NCT00386165|Drug|larazotide acetate|larazotide acetate 4 mg capsules
502106|NCT00386152|Drug|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
502107|NCT00386152|Drug|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
502108|NCT00386139|Drug|Aliskiren/HCTZ|
502109|NCT00386126|Drug|Iron Sucrose IV 200mg, once a week, for 5 weeks|
502110|NCT00386126|Drug|Ferrous sulfate 200mg PO TID, for 8 weeks|
502111|NCT00386113|Biological|Fluarix and adjuvanted influenza vaccine|
502112|NCT00386100|Drug|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
502113|NCT00386100|Drug|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
502114|NCT00386100|Drug|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
502115|NCT00386100|Drug|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
502116|NCT00386100|Drug|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
502117|NCT00386100|Drug|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
502118|NCT00386100|Drug|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
502119|NCT00386100|Drug|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
502120|NCT00386087|Drug|Enzastaurin Hydrochloride|
502121|NCT00386074|Drug|NaFeEDTA, Electrolytic Iron|
502122|NCT00386061|Drug|rimonabant (SR141716)|
502123|NCT00386048|Behavioral|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
502239|NCT00385138|Drug|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
502124|NCT00386035|Drug|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
502125|NCT00386035|Drug|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
502126|NCT00386022|Drug|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
502127|NCT00386022|Drug|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
502128|NCT00386022|Drug|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
502129|NCT00386009|Drug|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
502130|NCT00386009|Drug|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
502131|NCT00385996|Drug|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
502132|NCT00385983|Device|Harmonic Scalpel|
502133|NCT00385970|Drug|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
502134|NCT00385970|Drug|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
502135|NCT00385970|Drug|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
502136|NCT00385957|Drug|AZT+3TC+IDV+RTV|
502137|NCT00385957|Drug|AZT+3TC+EFV|
502138|NCT00385944|Drug|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
502139|NCT00385944|Drug|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
502140|NCT00385931|Drug|Valsartan and simvastatin|
502141|NCT00385918|Device|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
502142|NCT00385918|Other|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
502143|NCT00385905|Device|Excel Drug-eluting stent|
502144|NCT00385892|Device|Abdominal binder|
502145|NCT00385879|Behavioral|Case management|
502146|NCT00385866|Behavioral|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
502147|NCT00385866|Behavioral|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
502148|NCT00385853|Drug|PTK787/ZK 222584|Twice daily for each 28-day cycle
502149|NCT00385853|Drug|Temozolomide|Daily for each 28-day cycle
502150|NCT00385853|Procedure|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
502151|NCT00385840|Biological|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
502152|NCT00385840|Biological|FluarixTM|Single dose, intramuscular injection
502153|NCT00385827|Drug|Mitoxantrone|Mitoxantrone 12 mg/m^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2)
502154|NCT00385827|Drug|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
502155|NCT00385827|Drug|Prednisone|Prednisone 5 mg orally twice daily
502156|NCT00385801|Drug|Risperidone|
502157|NCT00385801|Drug|Placebo|
502158|NCT00385788|Drug|Gemcitabine|800 mg/m^2 IV over 30 minutes on Day -7 (1 day)
502159|NCT00385788|Drug|Fludarabine|33 mg/m^2 IV over 30 minutes Day -5 to Day -2 (4 days)
502160|NCT00385788|Drug|Melphalan|70 mg/m^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
502161|NCT00385788|Drug|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
502162|NCT00385788|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
502163|NCT00385788|Drug|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
502164|NCT00385788|Drug|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
502165|NCT00385788|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
502166|NCT00385775|Drug|AEG35156|weekly IV solution infused over 2 hrs
502167|NCT00385762|Drug|paroxetine|paroxetine 10-40mg daily x 5 weeks
502168|NCT00385749|Device|RV apical vs RV septal defibrillation threshold testing|
502169|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
502170|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
502171|NCT00385736|Biological|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
502172|NCT00385723|Dietary Supplement|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
502173|NCT00385723|Dietary Supplement|Placebo|matching placebo capsule daily for 4 months
502174|NCT00385710|Drug|valproic acid|Depakine
502175|NCT00385710|Drug|Placebo|Placebo
502176|NCT00385697|Drug|Teplizumab|IV dosing daily for 14 days times 2 courses
502177|NCT00385697|Other|Placebo|IV dosing daily for 14 days times 2 courses
502178|NCT00385684|Drug|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
502179|NCT00385684|Drug|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
502180|NCT00385684|Drug|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
502181|NCT00385671|Drug|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
502182|NCT00385671|Drug|pregabalin|Pregabalin (PGB) orally (PO)
502183|NCT00385671|Drug|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
502184|NCT00385658|Drug|Fluvastatin extended release, fenofibrate|
502185|NCT00385658|Drug|Fixed combination simvastatin/ezetimibe|
502186|NCT00385645|Drug|Combivir+Kaletra|
502187|NCT00385645|Drug|Combivir+Reyataz|
502188|NCT00385632|Drug|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
502189|NCT00385606|Drug|gemcitabine|
502190|NCT00385606|Drug|prolonged continuous infusion gemcitabine|
502191|NCT00385606|Drug|cisplatin|
502192|NCT00385606|Drug|rofecoxib|
502193|NCT00385593|Drug|Symbicort (budesonide/formoterol) Turbuhaler|
502194|NCT00385593|Drug|Conventional treatment|
502195|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
502196|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
502197|NCT00385567|Drug|PEHRG214|
502198|NCT00385554|Drug|UC-781 carbomer gel, 0.1% and 0.25%|
502199|NCT00385541|Drug|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
502200|NCT00385541|Drug|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
502201|NCT00385528|Behavioral|Multi-faceted psychiatric intervention|
502202|NCT00385515|Drug|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
502203|NCT00385515|Drug|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
502204|NCT00385502|Drug|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
502205|NCT00385489|Drug|LXR-623|
502206|NCT00385476|Behavioral|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
502207|NCT00385463|Drug|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
502208|NCT00385450|Drug|Nelfinavir/placebo|1250mg/twice each day/four days.
502209|NCT00385437|Behavioral|Driving Simulator Testing|
502210|NCT00385437|Drug|Mirtazapine Treatment|
502211|NCT00385411|Drug|valproate microgranules|20 to 30 mg/kg/day
502212|NCT00385398|Drug|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
502213|NCT00385398|Drug|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
502214|NCT00385398|Radiation|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
502215|NCT00385385|Drug|Rifalazil|
502216|NCT00385372|Procedure|elimination diet|
502217|NCT00385372|Procedure|provocation diet|
502218|NCT00385359|Procedure|aerosol drug deposition strategies|
502219|NCT00385359|Drug|Albuterol|
502220|NCT00385346|Behavioral|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
502221|NCT00385333|Procedure|Feasibility Study - Imaging System|
502222|NCT00385320|Biological|HRV vaccine|
502223|NCT00385307|Drug|amibegron (SR58611A)|
502224|NCT00385281|Biological|FluMist|
502225|NCT00385268|Drug|acamprosate|1998 mg/dau fpr 8 weeks
502226|NCT00385268|Drug|placebo|placebo pills
502227|NCT00385255|Biological|Fluarix®|GSK Biologicals' inactivated influenza split virus vaccine.
502228|NCT00385255|Biological|Boostrix®|GSK Biologicals' tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
502229|NCT00385242|Procedure|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
502230|NCT00385242|Other|PET imaging|PET viability imaging
502231|NCT00385229|Drug|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
502232|NCT00385216|Drug|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
502233|NCT00385216|Other|Placebo|Placebo nasal spray 0mg x 1 before surgery
502234|NCT00385203|Drug|AZD2171|45 mg oral tablet once daily dose
502235|NCT00385190|Drug|HCV-796|
502236|NCT00385177|Drug|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
502237|NCT00385164|Procedure|PET/CT scan for RT planning|
502238|NCT00385138|Drug|Cangrelor|cangrelor bolus (30 mcg/kg) & cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
502240|NCT00385138|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
502241|NCT00385138|Drug|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
502242|NCT00385138|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
502243|NCT00385125|Drug|Bendamustine|
502244|NCT00385125|Drug|Rituximab|
502245|NCT00385112|Procedure|Echocardiogram|2D echocardiogram with Doppler flow
502246|NCT00385099|Drug|GW876008|
502247|NCT00385086|Drug|TNF blocker|Treatment with TNF-alpha blocker
502248|NCT00385086|Drug|Placebo|Treatment with placebo
502249|NCT00385047|Biological|Group A FMP2.1/AS01B|
502250|NCT00385047|Biological|Group B FMP2.1/AS02A|
502251|NCT00385034|Device|Interactive computer based health-risk survey before doctor's visit|
502252|NCT00385021|Drug|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
502253|NCT00385008|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
502254|NCT00385008|Drug|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
502255|NCT00384995|Drug|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
502256|NCT00384995|Drug|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
502257|NCT00384982|Procedure|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
502258|NCT00384969|Drug|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
502259|NCT00384956|Drug|Azacitidine|
502260|NCT00384943|Behavioral|Moderate-intensity Exercise|
502261|NCT00384930|Drug|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
502262|NCT00384930|Drug|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
502263|NCT00384930|Drug|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
502264|NCT00384930|Drug|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
502265|NCT00384930|Drug|placebo|Placebo tablet taken by mouth one a day for twelve weeks
502266|NCT00384917|Drug|Ketoconazole|
502267|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
502268|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
502269|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
502270|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
502271|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
502272|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
502273|NCT00384891|Device|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
502274|NCT00384891|Drug|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
502275|NCT00384878|Drug|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
502276|NCT00384865|Drug|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
502277|NCT00384865|Drug|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
502278|NCT00384865|Drug|Placebo|Placebo, taken orally, once a day for 6 months
502279|NCT00384852|Drug|rhBMP-2/CPM|
502280|NCT00384839|Drug|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
502281|NCT00384826|Drug|erlotinib|Erlotinib 150 mg/day (until progression)
502282|NCT00384826|Drug|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
502283|NCT00384813|Behavioral|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
502284|NCT00384813|Behavioral|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
502285|NCT00384800|Drug|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
502286|NCT00384787|Biological|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
502287|NCT00384787|Biological|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
502288|NCT00384774|Drug|COL-144|
502289|NCT00384748|Behavioral|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
502290|NCT00384748|Behavioral|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
502291|NCT00384748|Behavioral|Usual care|Routine VA care.
502292|NCT00384722|Device|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
502293|NCT00384696|Drug|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke >10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
502294|NCT00384696|Behavioral|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
502295|NCT00384670|Biological|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
502296|NCT00384670|Biological|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
502297|NCT00384657|Drug|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.~Patient in Group II will receive conventional treatment for chronic heart failure."
502298|NCT00384644|Device|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
502299|NCT00384631|Other|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
502300|NCT00384631|Drug|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
502301|NCT00384618|Drug|pravastatin|
502302|NCT00384618|Drug|vitamin E|
502303|NCT00384605|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
502304|NCT00384605|Drug|placebo|Placebo capsule once daily. Treatment for 52 weeks.
502305|NCT00384592|Drug|Esomeprazole|
502306|NCT00384592|Procedure|Physical exam|
502307|NCT00384592|Procedure|Pregnancy test if applicable|
502308|NCT00384579|Drug|Botulinum toxin B|Botulinum Toxin B
502309|NCT00384579|Drug|Placebo|Placebo
502310|NCT00384566|Drug|Carvedilol|anit hypertensive medication
502311|NCT00384566|Drug|Metoprolol|Anti hypertensive medication
502312|NCT00384553|Drug|Rituximab|
502313|NCT00384553|Drug|DHAP|
502314|NCT00384553|Drug|TEC|
502315|NCT00384553|Drug|autologous stem cell transplantation|
502316|NCT00384540|Procedure|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
502317|NCT00384527|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
502318|NCT00384527|Drug|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
502319|NCT00384514|Device|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
502320|NCT00384501|Device|Intacs|
502321|NCT00384488|Behavioral|Interactive Voice Response System (IVR)|
502322|NCT00384475|Drug|Ciclesonide Nasal Spray|
502323|NCT00384449|Drug|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
502324|NCT00384436|Drug|escitalopram|
502325|NCT00384423|Drug|PRX-03140|
502326|NCT00384410|Drug|Nabilone|
502327|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
502328|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
502329|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
502330|NCT00384384|Drug|oral 18B Glycyrrhetinic acid versus placebo|
502331|NCT00384371|Drug|Botulinum Toxin A|Botulinum Toxin A
502332|NCT00384371|Drug|Placebo|Placebo
502333|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
502334|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
502335|NCT00384358|Other|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
502336|NCT00384345|Device|Bright Light Therapy|
502337|NCT00384345|Behavioral|Exercise|
502338|NCT00384332|Drug|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
502339|NCT00384332|Drug|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
502340|NCT00384319|Device|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
502341|NCT00384306|Drug|prednisolone|
502342|NCT00384293|Drug|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
502343|NCT00384293|Drug|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
502344|NCT00384280|Drug|Rifampin|
502345|NCT00384254|Behavioral|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
502346|NCT00384254|Behavioral|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
502347|NCT00384241|Behavioral|Induced Stress|Participation in an active coping task by playing a video game against another participant.
502348|NCT00384241|Procedure|Buccal Swab|One Buccal swab collected from each parent
502349|NCT00384228|Drug|Nilotinib|
502350|NCT00384215|Drug|insulin glargine [rDNA origin] injection|
502351|NCT00384202|Drug|Tacrolimus|Immunosuppression
502352|NCT00384189|Drug|Ciclesonide|inhaled Ciclesonide
502353|NCT00384189|Drug|Placebo|Ciclesonide placebo-matching inhaler
502354|NCT00384189|Drug|Salbutamol|Salbutamol inhalation powder
528497|NCT00163345|Drug|Ciclesonide|
502356|NCT00384176|Drug|Bevacizumab|intravenous infusion
502357|NCT00384176|Drug|5-fluorouracil ( in FOLFOX)|intravenous infusion
502358|NCT00384176|Drug|Leucovorin (in FOLFOX)|intravenous infusion
502359|NCT00384176|Drug|Oxaliplatin (in FOLFOX)|intravenous infusion
502360|NCT00384150|Drug|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
502361|NCT00384137|Drug|Tacrolimus|Immunosuppression
502362|NCT00384124|Drug|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
502363|NCT00384111|Drug|R-CVP + Zevalin Therapeutic Regimen|Standard R-CVP followed by Zevalin Theraeputic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
502364|NCT00384111|Drug|R-CVP|Standard R-CVP
502365|NCT00384098|Drug|CTA018 cream|
502366|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
502367|NCT00384085|Drug|Insulin Glargine|Subcutaneous injection once-a-day
502368|NCT00384085|Drug|Premixed Insulin|Subcutaneous injection twice-a-day.
502369|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
502370|NCT00384072|Drug|bazedoxifene BZA-20|
502371|NCT00384059|Biological|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
502372|NCT00384059|Biological|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
502373|NCT00384059|Biological|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
502374|NCT00384059|Biological|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
502375|NCT00384059|Biological|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
502376|NCT00384046|Drug|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
502377|NCT00384046|Drug|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
502378|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
502379|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
502380|NCT00384033|Drug|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
502381|NCT00384033|Drug|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
502382|NCT00384020|Drug|Paroxetine (Seroxat)|
502383|NCT00384020|Drug|Escitalopram (Lexapro)|
502384|NCT00384007|Procedure|Hydrodiscectomy with Spinejet|
502385|NCT00383994|Drug|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
502386|NCT00383994|Drug|Rituximab|375 mg/m^2 by vein followed by 1000 mg/m^2 weekly for 3 weeks for a total of 4 doses.
502387|NCT00383994|Biological|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
502388|NCT00383942|Drug|Misoprostol|Misoprostol,25 micrograms every 4 hours.
502389|NCT00383942|Device|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
502390|NCT00383929|Drug|Candesartan cilexetil|32mg oral
502391|NCT00383929|Drug|Hydrochlorothiazide|12.5 mg oral
502392|NCT00383929|Drug|Hydrochlorothiazide|25 mg oral
502393|NCT00383916|Drug|pantoprazole|
502394|NCT00383903|Biological|HRV vaccine|Two or three oral doses
502395|NCT00383890|Drug|Dexmedetomidine HCL Injection|
502396|NCT00383890|Drug|Placebo|
502397|NCT00383877|Drug|insulin detemir|
502398|NCT00383877|Drug|insulin NPH|
502399|NCT00383864|Drug|Pegylated interferon and ribavirin|
502400|NCT00383851|Drug|ATN-224|
502401|NCT00383851|Drug|Temozolomide|
502402|NCT00383838|Behavioral|brief, voluntary substance use intervention|
502403|NCT00383825|Procedure|Anterior segment indocyanine green angiography|
502404|NCT00383812|Drug|Intravitreal Bevacizumab|
502405|NCT00383799|Drug|iv Amiodarone|
502406|NCT00383799|Drug|iv Procainamide|
502407|NCT00383786|Drug|NK1 Antagoist (GR205171)|
502408|NCT00383786|Procedure|Psychophysiology (Trauma Script)|
502409|NCT00383786|Procedure|Psychophysiology (Verbal Threat)|
502410|NCT00383786|Procedure|Psychophysiology (Fear Conditioning)|
502411|NCT00383786|Procedure|Psychophysiology (Affective Modulation)|
502412|NCT00383786|Procedure|Psychophysiology (Heart rate variability)|
502413|NCT00383786|Procedure|Lumbar Puncture|
502414|NCT00383786|Procedure|24-hour plasma sampling|
502415|NCT00383786|Procedure|MRI|
502416|NCT00383773|Procedure|Retinal endo vascular surgery|
502417|NCT00383760|Drug|eribulin mesylate|Given IV
502418|NCT00383747|Drug|transdermal nicotine patch|14mg transdermal nicotine application
502419|NCT00383747|Drug|Transdermal Nicotine Patch|14mg transdermal nicotine application
502420|NCT00383734|Device|Newfill|1 to 7 injections of drug
502421|NCT00383734|Device|Eutrophill|1 to 7 injections of drug
502422|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
502423|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
502424|NCT00383721|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
502425|NCT00383721|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
502426|NCT00383721|Drug|Placebo|Placebo MDI twice a day for 26 weeks
502427|NCT00383708|Drug|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
502428|NCT00383708|Drug|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
502429|NCT00383695|Biological|cetuximab|
502430|NCT00383695|Drug|capecitabine|
502432|NCT00383695|Procedure|adjuvant therapy|
502433|NCT00383695|Procedure|conventional surgery|
502434|NCT00383695|Procedure|neoadjuvant therapy|
502435|NCT00383695|Radiation|radiation therapy|
502436|NCT00383682|Drug|morphine and mexiletine|
502437|NCT00383669|Dietary Supplement|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
502438|NCT00383669|Dietary Supplement|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
502439|NCT00383656|Drug|GnRH|75 ng/kg GnRH IV
502440|NCT00383656|Device|Pump|portable, infusion pump for GnRH
502441|NCT00383643|Drug|zolpidem tartrate|
502442|NCT00383643|Drug|sodium oxybate|
502443|NCT00383643|Drug|Matching Placebos|
502444|NCT00383630|Biological|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
502445|NCT00383630|Biological|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
502446|NCT00383630|Device|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
502447|NCT00383591|Biological|Hepatitis B adjuvanted vaccine|
502448|NCT00383591|Biological|Engerix-B|
502449|NCT00383578|Drug|Vildagliptin 100 mg qd|
502450|NCT00383578|Drug|Metformin 1500 mg daily|
502451|NCT00383565|Drug|romidepsin|Given IV
502452|NCT00383552|Drug|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
502453|NCT00383552|Drug|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
502454|NCT00383552|Drug|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
502455|NCT00383552|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
502456|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
502457|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
502458|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
502459|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Control Vaccine
502460|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
502461|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
502462|NCT00383513|Biological|Epratuzumab|360 mg/m^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
502463|NCT00383500|Device|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
502464|NCT00383500|Device|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
502465|NCT00383487|Drug|Calcitriol|0.5 micrograms/kilogram q weekly
502466|NCT00383487|Drug|Naproxen-n-butyl nitrate|400 mg BID, oral
502467|NCT00383474|Drug|Bortezomib|Given IV
502468|NCT00383474|Other|Laboratory Biomarker Analysis|Correlative studies
502469|NCT00383474|Drug|Tipifarnib|Given orally
502470|NCT00383461|Behavioral|smoking cessation intervention|
502471|NCT00383461|Other|counseling intervention|
502472|NCT00383448|Drug|Clofarabine|days -7 through -3: 40 mg/m^2 intravenously over 2 hours
502473|NCT00383448|Procedure|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
502474|NCT00383448|Drug|Melphalan|day -2: 140 mg/m^2 intravenously over 30 minutes
502475|NCT00383448|Biological|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
502476|NCT00383448|Drug|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
502477|NCT00383448|Drug|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR<25 mL/minute corrected)
502478|NCT00383448|Device|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).~CsA taper begins at day +100."
502479|NCT00383448|Drug|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
502480|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
502481|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
502482|NCT00383435|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
502483|NCT00383435|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
502484|NCT00383435|Drug|Placebo|Placebo MDI twice a day for 26 weeks
502485|NCT00383422|Drug|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
502486|NCT00383422|Drug|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
502487|NCT00383409|Drug|multivitamins|
502488|NCT00383409|Drug|placebo|
502489|NCT00383396|Drug|Topical Cyclosporine|
502490|NCT00383383|Biological|Hepatitis B adjuvanted vaccine|
502491|NCT00383383|Biological|Engerix-B|
502492|NCT00383370|Drug|VEGF Trap|VEGF Trap formulation 1, ITV-1
502493|NCT00383370|Biological|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
502494|NCT00383357|Drug|zolpidem|
502495|NCT00383344|Procedure|FDG PET/CT|
502496|NCT00383331|Drug|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
502497|NCT00383331|Drug|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
502498|NCT00383318|Procedure|Gene mutation sample|
502499|NCT00383305|Device|Cool-Cap|
502500|NCT00383292|Drug|tasisulam|Tasisulam dose is dependent on participant's height, weight, and gender and is adjusted to target a specific Cmax based on participant laboratory parameters. Tasisulam is administered intravenously every 28 days until disease progression or other criteria for participant discontinuation are met.
502501|NCT00383279|Other|counseling intervention|
502502|NCT00383279|Other|study of socioeconomic and demographic variables|
502503|NCT00383266|Drug|Pemetrexed|
502504|NCT00383266|Drug|Carboplatin|
502505|NCT00383253|Behavioral|caloric restriction - 10%|Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
502506|NCT00383253|Behavioral|caloric restriction - 25%|Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
502507|NCT00383253|Behavioral|caloric restriction - 50%|Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
502508|NCT00383253|Behavioral|caloric restriction - Control|Subjects maintained on their baseline caloric intake (caloric restriction = none)
502509|NCT00383240|Drug|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
502510|NCT00383240|Drug|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
502511|NCT00383240|Drug|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
502512|NCT00383240|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
502513|NCT00383227|Biological|Hepatitis B adjuvanted vaccine|
502514|NCT00383214|Drug|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
502515|NCT00383214|Other|Placebo|Intravenous
502516|NCT00383201|Device|OptiFree Multi-Purpose Disinfecting Solution|
502517|NCT00383188|Drug|placebo|Capsule, once daily (QD) for 12 weeks
502518|NCT00383188|Drug|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
502519|NCT00383188|Drug|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
502520|NCT00383188|Drug|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
502521|NCT00383188|Drug|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
502522|NCT00383175|Other|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
502523|NCT00383162|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
502524|NCT00383162|Drug|Placebo|Matching placebo tablet.
502525|NCT00383149|Drug|Ixabepilone|Intravenous Infusion (IV), 32 mg/m^2 every 21 days.
502526|NCT00383149|Drug|Cetuximab|Initial dose of 400 mg/m^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m^2 IV over 1 hour.
502527|NCT00383136|Drug|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
502528|NCT00383136|Drug|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
502529|NCT00383123|Biological|Fluarix™|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.~*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
502530|NCT00383123|Biological|Fluzone|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.~*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
502531|NCT00383097|Genetic|LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
502532|NCT00383097|Genetic|LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
502533|NCT00383084|Behavioral|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
502534|NCT00383084|Behavioral|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
502535|NCT00383071|Biological|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
502536|NCT00383071|Procedure|Apheresis|Once subjects achieved a high antibody titer (>1:160), they could begin apheresis to collect plasma.
502537|NCT00383058|Drug|the extract of green tea|
502538|NCT00383045|Drug|Buprenorphine/Subutex|
502539|NCT00383045|Drug|Naltrexone|
502540|NCT00383045|Procedure|Drug counseling|
502541|NCT00383032|Drug|mifepristone|
502542|NCT00383019|Drug|Xalacom (KP2035)|
502543|NCT00383019|Drug|Xalatan|
502544|NCT00383006|Behavioral|Skills for affect regulation (behavior)|
502545|NCT00382993|Drug|Placebo|Matching placebo tablet
502588|NCT00382642|Drug|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
502589|NCT00382629|Drug|BHT-3009 0.5 mg|
502546|NCT00382993|Drug|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
502547|NCT00382980|Biological|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
502548|NCT00382980|Biological|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
502549|NCT00382980|Drug|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
502550|NCT00382967|Procedure|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
502551|NCT00382954|Drug|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
502552|NCT00382954|Drug|Idarubicin|I.V., 8, or 10 or 12 mg/m^2 weekly (days 1, 8, 15, and 22) for 4 weeks
502553|NCT00382941|Device|Red and near infrared LED phototherapy device|
502554|NCT00382928|Device|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
502555|NCT00382915|Device|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
502556|NCT00382902|Device|OptiFree Multi-Purpose Disinfecting Solution|
502557|NCT00382889|Drug|beclomethasone/salbutamol combination|
502558|NCT00382889|Drug|beclomethasone|
502559|NCT00382889|Drug|salbutamol|
502560|NCT00382863|Device|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
502561|NCT00382863|Drug|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
502562|NCT00382850|Procedure|Nissen fundoplication|
502563|NCT00382837|Drug|Epratuzumab|
502564|NCT00382824|Dietary Supplement|Coenzyme Q10|active drug
502565|NCT00382824|Other|Placebo|Placebo
502566|NCT00382811|Drug|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
502567|NCT00382811|Drug|carboplatin|AUC=2 weekly in 28 day cycles
502568|NCT00382811|Drug|placebo|every 8 hours daily in 28 day cycles
502569|NCT00382798|Drug|RO5024048|
502570|NCT00382785|Behavioral|moderated support|one 12-week online support group led by a professional healthcare provider
502571|NCT00382785|Behavioral|peer-led|12-week online support in a peer-led format
502572|NCT00382772|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
502573|NCT00382759|Procedure|stem cell transplant|
502574|NCT00382746|Device|EarlySense monitoring device|
502575|NCT00382733|Drug|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
502576|NCT00382720|Drug|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):~Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1~Dose level 2 (optimal dose):~Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
502577|NCT00382720|Drug|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):~Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.~Dose level 2 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
502578|NCT00382720|Drug|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):~Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.~Dose level 2 (non-optimal dose):~Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
502579|NCT00382707|Device|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
502580|NCT00382694|Drug|Fludarabine|
502581|NCT00382681|Device|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
502582|NCT00382681|Device|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
502583|NCT00382668|Drug|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
502584|NCT00382668|Drug|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
502585|NCT00382668|Drug|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
502586|NCT00382655|Procedure|Education and referral|
502587|NCT00382642|Drug|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
502592|NCT00382616|Drug|Phosphatidylserine-Omega3|
502593|NCT00382603|Device|OptiFree Multi-Purpose Disinfecting Solution|
502594|NCT00382590|Drug|5-Azacytidine|75 mg/m^2 daily for 7 days (days 1-7) via subcutaneous injection.
502595|NCT00382590|Drug|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
502596|NCT00382590|Drug|Valproic Acid (VPA)|50 mg/m^2 orally daily days 1-7.
502597|NCT00382577|Drug|Itopride|
502598|NCT00382577|Drug|Placebo|
502599|NCT00382551|Behavioral|Moderate daily consumption of Red wine|
502600|NCT00382551|Behavioral|Moderate daily consumption of beer|
502601|NCT00382551|Behavioral|Moderate consumption of fruit juice rich in polyphenolics|
502602|NCT00382538|Drug|Addition of mifepristone 200 mg 24 hours before induction|
502603|NCT00382525|Device|Cardiac Rhythm Management device|
502604|NCT00382512|Drug|Raptiva (efalizumab)|
502605|NCT00382499|Drug|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
502606|NCT00382486|Procedure|Reduce the risk of allograft rejection|
502607|NCT00382473|Behavioral|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
502608|NCT00382460|Drug|PRAVASTATIN SODIUM|
502609|NCT00382447|Device|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
502610|NCT00382447|Device|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
502611|NCT00382434|Procedure|presence of an emergency pharmacist in the ED|
502612|NCT00382421|Drug|bisoprolol|
502613|NCT00382421|Drug|amlodipine|
502614|NCT00382421|Drug|molsidomine|
502615|NCT00382421|Drug|acetylsalicylic acid|
502616|NCT00382408|Biological|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
502617|NCT00382408|Other|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
502618|NCT00382395|Device|SOLX Gold Shunt GMS-plus|Single use implant
502619|NCT00382395|Device|Ahmed FP7 Glaucoma Valve|Single use implant
502620|NCT00382382|Other|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
502621|NCT00382356|Drug|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
502622|NCT00382343|Drug|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
502623|NCT00382330|Drug|Ciclopirox|
502624|NCT00382317|Drug|Iobitridol|
502625|NCT00382304|Drug|tolevamer potassium-sodium (GT267-004)|
502626|NCT00382291|Drug|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
502627|NCT00382291|Drug|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
502628|NCT00382291|Drug|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
502629|NCT00382278|Procedure|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
502630|NCT00382265|Drug|tamsulosin|tamsulosin 0.4mg po qd for 28 days
502631|NCT00382265|Other|Placebo|placebo po qd for 28 days
502632|NCT00382252|Procedure|computed tomography|
502633|NCT00382252|Procedure|positron emission tomography|
502634|NCT00382252|Procedure|radiofrequency ablation|
502635|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
502636|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
502637|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
502638|NCT00382239|Drug|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
502639|NCT00382226|Drug|Azopt|
502640|NCT00382213|Drug|Olmesartan medoxomil|
502641|NCT00382213|Drug|Placebo|
502642|NCT00382200|Drug|decitabine|
502643|NCT00382200|Drug|tretinoin|
502644|NCT00382200|Genetic|DNA methylation analysis|
502645|NCT00382200|Genetic|cytogenetic analysis|
502646|NCT00382200|Genetic|microarray analysis|
502647|NCT00382200|Other|flow cytometry|
502648|NCT00382200|Other|immunohistochemistry staining method|
502649|NCT00382187|Biological|MF59 adjuvanted H5N1 influenza vaccine|"MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~non-adjuvanted influenza vaccine containing 15 ug of H5N1"
502650|NCT00382174|Drug|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
502651|NCT00382174|Drug|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
502652|NCT00382161|Drug|Fluvastatin-sodium|
502653|NCT00382148|Drug|omalizumab|SC repeating dose
502654|NCT00382135|Drug|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
502655|NCT00382135|Drug|placebo|Placebo tablet taken by mouth once a day for 40 weeks
502656|NCT00382109|Drug|thiotepa|Given IV
502657|NCT00382109|Drug|cyclophosphamide|Given IV
502658|NCT00382109|Drug|tacrolimus|Given IV or orally
502659|NCT00382109|Drug|methotrexate|Given IV
502660|NCT00382109|Drug|sirolimus|Given orally
502661|NCT00382109|Radiation|total body irradiation|Part of the transplant preparatory regimen
502662|NCT00382096|Drug|Vildagliptin|
502664|NCT00382096|Drug|Vildagliptin + Metformin|
502665|NCT00382083|Drug|1000 mg acetaminophen|
502666|NCT00382083|Drug|800 mg ibuprofen|
502667|NCT00382083|Drug|1 oz 4% lidocaine gel|
502668|NCT00382070|Drug|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
502669|NCT00382070|Other|Placebo|Placebo tablet taken orally once daily for 5 years
502670|NCT00382057|Drug|Testosterone|
502671|NCT00382057|Drug|Anastrozole|
502672|NCT00382057|Drug|Goserelin|
502673|NCT00382044|Drug|Eprex; Neorecormon; Aranesp|
502674|NCT00382031|Drug|Zalutumumab|Individual dose titration weekly i.v doses
502675|NCT00382031|Other|Control|Best Supportive Care
502676|NCT00382018|Drug|chemotherapy|No administration details available
502677|NCT00381979|Other|Supportive Expressive Therapy|
502678|NCT00381966|Device|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
502679|NCT00381953|Drug|Peginterferon alfa-2a|
502680|NCT00381953|Drug|Interferon alfa-2a|
502681|NCT00381953|Drug|Ribavirin|
502682|NCT00381940|Drug|ifosfamide|Given IV
502683|NCT00381940|Drug|bortezomib|Given IV
502684|NCT00381940|Drug|vinorelbine tartrate|Given IV
502685|NCT00381940|Biological|filgrastim|Given IV or SC
502686|NCT00381927|Behavioral|Physician Counseling|
502687|NCT00381914|Drug|Vitamin D|400 IU vitamin D / day
502688|NCT00381914|Drug|Vitamin D|800 IU vitamin D / day
502689|NCT00381914|Drug|Vitamin D|1200 IU vitamin D / day
502690|NCT00381901|Biological|trastuzumab|
502691|NCT00381901|Genetic|polymorphism analysis|
502692|NCT00381901|Procedure|adjuvant therapy|
502693|NCT00381888|Drug|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
502694|NCT00381875|Biological|E1M184V peptide vaccine|
502695|NCT00381875|Biological|incomplete Freund's adjuvant|
502696|NCT00381875|Biological|sargramostim|
502697|NCT00381875|Other|immunoenzyme technique|
502698|NCT00381862|Drug|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
502699|NCT00381862|Drug|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
502700|NCT00381862|Drug|fluorouracil|as per institutional standard of care
502701|NCT00381862|Drug|irinotecan hydrochloride|as per institutional standard of care
502702|NCT00381862|Drug|leucovorin calcium|as per institutional standard of care
502703|NCT00381862|Drug|oxaliplatin|as per institutional standard of care
502704|NCT00381862|Drug|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
502705|NCT00381862|Procedure|quality-of-life assessment|baseline
502706|NCT00381849|Drug|Cystone|"Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
502707|NCT00381849|Drug|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
502708|NCT00381836|Drug|Darbepoetin Alfa|
502709|NCT00381823|Behavioral|Cognitive Behavioral Therapy|
502710|NCT00381810|Drug|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
502711|NCT00381810|Drug|Methylprednisolone|
502712|NCT00381810|Drug|Acetaminophen|
502713|NCT00381810|Drug|Diphenhydramine|
502714|NCT00381797|Biological|Bevacizumab|Given IV
502715|NCT00381797|Radiation|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
502716|NCT00381797|Drug|Irinotecan Hydrochloride|Given IV
502717|NCT00381784|Behavioral|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
502718|NCT00381784|Behavioral|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.~Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.~Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.~Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.~Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
502719|NCT00381771|Behavioral|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
502720|NCT00381758|Drug|Methylphenidate Extended Release Capsules|
502721|NCT00381732|Drug|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
502722|NCT00381732|Drug|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
502723|NCT00381719|Drug|AGN 203818|3 mg Capsule twice daily for 4 weeks
502724|NCT00381719|Drug|AGN 203818|20 mg Capsule twice daily for 4 weeks
502725|NCT00381719|Drug|AGN 203818|60 mg Capsule twice daily for 4 weeks
502726|NCT00381719|Drug|placebo capsule|Capsule twice daily for 4 weeks
502727|NCT00381706|Biological|cetuximab|given IV
502728|NCT00381706|Drug|ECF|epirubicin and 5-fluorouracil given IV
502729|NCT00381706|Drug|IC|cisplatin and irinotecan given IV
502730|NCT00381706|Drug|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
502731|NCT00381693|Drug|azacitidine|
502732|NCT00381680|Drug|vincristine sulfate|Given IV
502733|NCT00381680|Drug|prednisone|Given PO
502734|NCT00381680|Drug|doxorubicin hydrochloride|Given IV
502735|NCT00381680|Drug|pegaspargase|Given IM
502736|NCT00381680|Drug|cytarabine|Given IT or IV
502737|NCT00381680|Drug|methotrexate|Given IT or IV
502738|NCT00381680|Drug|dexamethasone|Given PO
502739|NCT00381680|Drug|etoposide|Given IV
502740|NCT00381680|Drug|cyclophosphamide|Given IV
502741|NCT00381680|Drug|leucovorin calcium|Given IV or PO
502742|NCT00381680|Biological|filgrastim|Given IV or SC
502743|NCT00381680|Drug|asparaginase|Given IM
502744|NCT00381680|Drug|mercaptopurine|Given PO
502745|NCT00381667|Drug|GW642444M|M salt
502746|NCT00381667|Drug|GW642444H|H salt
502747|NCT00381667|Other|placebo|placebo
502748|NCT00381654|Drug|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
502749|NCT00381641|Other|Laboratory Biomarker Analysis|Optional correlative studies
502750|NCT00381641|Other|Pharmacogenomic Study|Optional correlative studies
502751|NCT00381641|Drug|Sunitinib|Given PO
502752|NCT00381641|Drug|Sunitinib Malate|Given PO
502753|NCT00381628|Procedure|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
502754|NCT00381615|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
502755|NCT00381615|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
502756|NCT00381615|Biological|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
502757|NCT00381615|Biological|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
502758|NCT00381615|Biological|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
502759|NCT00381615|Biological|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
502760|NCT00381615|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
502761|NCT00381602|Drug|GHRP-1/AG 70 mg depot in ESRD|
502762|NCT00381602|Other|Placebo|
502763|NCT00381589|Drug|ipratropium bromide 0.03% spray|
502764|NCT00381576|Behavioral|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
502765|NCT00381563|Device|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
502766|NCT00381563|Device|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
502767|NCT00381550|Drug|fludarabine phosphate|Given IV
502768|NCT00381550|Drug|triapine|Given IV
502769|NCT00381550|Procedure|laboratory biomarker analysis|Correlative study
502770|NCT00381537|Drug|phenobarbitone|
502771|NCT00381537|Drug|carbamazepine|
502772|NCT00381524|Behavioral|Increase condom use|Voluntary increase in condom use
502773|NCT00381511|Drug|low molecular weight heparin|
502774|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
502775|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
502776|NCT00381485|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
502777|NCT00381472|Drug|Ropinirole|
502778|NCT00381446|Device|Marketed contact lens care products|
502779|NCT00381433|Drug|AVI-4065 Injection|
502780|NCT00381420|Device|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
502781|NCT00381420|Device|bare-metal stent|un-coated Bx VELOCITY Stent
502782|NCT00381407|Behavioral|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
502783|NCT00381407|Behavioral|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
502784|NCT00381394|Drug|sitamaquine|
503419|NCT00376480|Procedure|in vitro-treated peripheral blood stem cell transplantation|
502785|NCT00381381|Drug|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
502786|NCT00381368|Drug|Ibandronic acid|
502787|NCT00381355|Procedure|Written Action Plan for Acute Asthma|
502788|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
502789|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
502790|NCT00381342|Drug|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
502791|NCT00381329|Behavioral|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
502792|NCT00381329|Behavioral|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
502793|NCT00381316|Drug|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
502794|NCT00381316|Drug|Thallous Chloride T1-201|Myoview SPECT Imaging
502795|NCT00381303|Drug|darunavir|600mg bid for 48 wks
502796|NCT00381303|Drug|ritonavir|100mg bid for 48 wks
502797|NCT00381290|Behavioral|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
502798|NCT00381290|Behavioral|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
502799|NCT00381277|Drug|Gatorade|
502800|NCT00381277|Drug|Performance|
502801|NCT00381264|Drug|Cesamet™ (nabilone)|
502802|NCT00381251|Drug|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
502803|NCT00381238|Drug|rosiglitazone|Extended Release Tablets
502804|NCT00381225|Procedure|Ultra-sound guided radio-frequency ablation|
502805|NCT00381212|Biological|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
502806|NCT00381199|Drug|Amitriptyline Hydrochloride|
502807|NCT00381199|Drug|Nabilone|
502808|NCT00381186|Behavioral|diet- and exercise intervention|
502809|NCT00381173|Drug|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
502810|NCT00381160|Behavioral|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
502811|NCT00381147|Drug|Clarithromycin|
502812|NCT00381134|Drug|losartan 100 mg orally once daily|
502813|NCT00381134|Drug|spironolactone 25 mg orally once daily|
502814|NCT00381134|Drug|placebo once orally once daily|
502815|NCT00381108|Drug|Placebo Tablet|Two tablets, twice daily.
502816|NCT00381108|Drug|Pomegranate Tablet|Two tablets, twice daily.
502817|NCT00381095|Drug|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
502818|NCT00381095|Drug|Placebo|Placebo
502819|NCT00381082|Drug|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
502820|NCT00381082|Drug|Banlice Mousse Aerosol (Pfizer, Australia)|
502821|NCT00381082|Drug|3) KP24 Medicated Foam (Nelson Laboratories)|
502822|NCT00381069|Behavioral|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
502823|NCT00381056|Behavioral|Labor and Delivery Team Coordination Course|
502824|NCT00381043|Drug|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
502825|NCT00381030|Drug|carvedilol plus nurse management|
502826|NCT00381017|Drug|Peg interferon alpha-2b|
502827|NCT00381004|Drug|Cyclophosphamide|Course 1: 250 mg/m^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
502828|NCT00381004|Drug|Fludarabine|Course 1: 25 mg/m^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
502829|NCT00381004|Drug|Sargramostim|Course 1: 250 mcg/m^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m^2 SQ on Days -1 and Days 4 - 10
502830|NCT00381004|Drug|Rituximab|Course 1: 375 mg/m^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m^2 by vein over 2-6 Hours on Day 1
502831|NCT00380991|Drug|lactoserum|
502886|NCT00380419|Behavioral|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
502887|NCT00380406|Drug|Leuprolide acetate|
502888|NCT00380393|Biological|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
502889|NCT00380393|Biological|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
502890|NCT00380380|Drug|Vildagliptin|
502832|NCT00380978|Procedure|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
502833|NCT00380978|Procedure|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
502834|NCT00380965|Drug|Cesamet™ (nabilone)|
502835|NCT00380952|Device|Dune Device|
502836|NCT00380939|Drug|Atorvastatin|
502837|NCT00380939|Drug|Pravastatin|
502838|NCT00380926|Drug|polyunsatturated fatty acids (fish oil)|
502839|NCT00380913|Drug|Cesamet™ (nabilone)|
502840|NCT00380900|Drug|AGG-523|
502841|NCT00380887|Drug|Premarin|
502842|NCT00380874|Drug|Pregabalin|150- 600 mg/day (double blind in divided doses)
502843|NCT00380874|Drug|Placebo|Placebo
502844|NCT00380861|Device|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
502845|NCT00380861|Device|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
502846|NCT00380848|Procedure|Hemodiafiltration|
502847|NCT00380835|Drug|Amrubicin|
502848|NCT00380822|Drug|miglitol|
502849|NCT00380809|Procedure|Rotational Atherectomy + PES|
502850|NCT00380809|Procedure|Standard Treatment (PES without Rotational Atherectomy)|
502851|NCT00380796|Drug|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
502852|NCT00380783|Drug|AGN 203818|
502853|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
502854|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
502855|NCT00380757|Procedure|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
502856|NCT00380744|Drug|LY2189102|
502857|NCT00380744|Drug|placebo|
502858|NCT00380731|Behavioral|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
502859|NCT00380718|Drug|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets <50 x 10^9/L; absolute neutrophil count <1.0 x 10^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade >2; Skin Grade >2; Serum bilirubin >3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase >10 x ULN; Other non-hematologic toxicities Grade >2 (except nausea, vomiting)."
502860|NCT00380705|Drug|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
502861|NCT00380692|Drug|Atomoxetine|
502862|NCT00380692|Drug|Placebo|
502863|NCT00380679|Biological|Influenza vaccination|
502864|NCT00380679|Biological|Pneumococcal polysaccharide vaccination|
502865|NCT00380666|Procedure|PET/CT scan|
502866|NCT00380653|Drug|sapacitabine|
502867|NCT00380640|Drug|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
502868|NCT00380640|Drug|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
502869|NCT00380627|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
502870|NCT00380614|Drug|Lamivudine|
502871|NCT00380601|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
502872|NCT00380588|Drug|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
502873|NCT00380588|Drug|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
502874|NCT00380575|Drug|YM087|
502875|NCT00380562|Behavioral|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
502876|NCT00380549|Diagnostic Test|Blood ion levels|Blood ion levels or the levels of cobalt and chromium ions in the blood and urine will be analyzed.
502877|NCT00380536|Behavioral|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
502878|NCT00380523|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
502879|NCT00380497|Drug|PEG-Lyte®|
502880|NCT00380497|Drug|Pico-Salax®|
502881|NCT00380484|Drug|Budesonide|200µg daily
502882|NCT00380484|Drug|Montelukast|5 mg daily
502883|NCT00380471|Device|Bath PUVA|
502884|NCT00380458|Device|Coblation (radiofrequency-based device)|
502885|NCT00380445|Drug|Vildagliptin|
503056|NCT00379158|Drug|Micronutrient supplements|
503057|NCT00379145|Drug|trabectedin|
502891|NCT00380367|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
502892|NCT00380354|Drug|GSK256066|
502893|NCT00380341|Procedure|Instrument-applied spinal manipulative therapy|
502894|NCT00380328|Drug|neratinib|HKI-272
502895|NCT00380315|Drug|AG1321001(drug)|
502896|NCT00380302|Drug|AVE1625|
502897|NCT00380289|Drug|Thiazide and beta blocker|
502898|NCT00380276|Drug|MPC-7869|800 mg BID Oral dosing
502899|NCT00380263|Drug|PACAP38|10 pmol/kg/min given one time
502900|NCT00380250|Drug|Lubiprostone|
502901|NCT00380250|Drug|Placebo|
502902|NCT00380237|Biological|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
502903|NCT00380224|Drug|bifeprunox, olanzapine|
502904|NCT00380211|Biological|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
502905|NCT00380211|Biological|Fluarix|
502906|NCT00380198|Drug|Apadenoson|
502907|NCT00380172|Device|Rheopheresis blood filtration|
502908|NCT00380159|Drug|elvucitabine|elvucitabine 10 mg in combination with background ART
502909|NCT00380159|Drug|Lamivudine|
502910|NCT00380159|Drug|Emtricitabine|
502911|NCT00380146|Drug|sulfadoxine-pyrimethamine|
502912|NCT00380133|Drug|SB681323|5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
502913|NCT00380133|Drug|Prednisolone|5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
502914|NCT00380133|Drug|Placebo|Tablets matched to SB681323 or prednisolone
502915|NCT00380120|Drug|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
502916|NCT00380120|Drug|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
502917|NCT00380081|Drug|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
502918|NCT00380081|Drug|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
502919|NCT00380081|Drug|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
502920|NCT00380068|Drug|Ambrisentan|Oral tablets taken once daily.
502921|NCT00380055|Behavioral|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
502922|NCT00380055|Behavioral|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
502923|NCT00380042|Device|Cortical Stimulation|Cortical stimulation of prefrontal cortex
502924|NCT00380042|Device|Sham|Sham stimulation
502925|NCT00380029|Drug|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
502926|NCT00380029|Procedure|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
502927|NCT00380016|Procedure|Percutaneous Transluminal Angioplasty|
502928|NCT00380003|Drug|EVT 201|
502929|NCT00379990|Drug|GW274150|60 mg /day
502930|NCT00379990|Drug|Prednisolone|7.5 mg/day
502931|NCT00379990|Other|Placebo|Placebo
502932|NCT00379977|Biological|diphtheria, tetanus, pertussis & Hib vaccine|
502933|NCT00379964|Drug|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC>500/mm3), and for up to 72 hours later.
502934|NCT00379951|Drug|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
502935|NCT00379938|Biological|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
502936|NCT00379938|Drug|Placebo|Saline control
502937|NCT00379938|Biological|MF-59|Adjuvant
502938|NCT00379925|Behavioral|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
502939|NCT00379912|Drug|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
502940|NCT00379912|Drug|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
502941|NCT00379912|Drug|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
502942|NCT00379899|Drug|cinacalcet|Low dose vitamin D with cinacalcet
502943|NCT00379886|Drug|Propofol Thiopental|
502944|NCT00379873|Device|ProAdjuster|
502945|NCT00379860|Drug|LXR-623|
502946|NCT00379847|Drug|conivaptan|IV
502947|NCT00379834|Drug|Cosopt|Cosopt twice daily in both eyes
503420|NCT00376480|Radiation|total-body irradiation|
502948|NCT00379821|Drug|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
502949|NCT00379821|Drug|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
502950|NCT00379821|Drug|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
502951|NCT00379821|Drug|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
502952|NCT00379808|Drug|montelukast|10 mg tablet (masked by capsule) daily for 1 month
502953|NCT00379808|Drug|Placebo|1 lactose-containing capsule daily for 1 month
502954|NCT00379795|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
502955|NCT00379782|Other|Navigation|Navigation and escourt
502956|NCT00379769|Drug|Rosiglitazone|Rosiglitazone maximum 8 mg per day
502957|NCT00379769|Drug|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
502958|NCT00379769|Drug|Metformin|Metformin maximum permitted daily dose .
502959|NCT00379756|Drug|LEVITRA (vardenafil)|active comparator
502960|NCT00379756|Drug|placebo|placebo comparator
502961|NCT00379743|Behavioral|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
502962|NCT00379743|Behavioral|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
502963|NCT00379730|Drug|Prednisolone|
502964|NCT00379717|Drug|Cisplatinum|
502965|NCT00379717|Drug|Docetaxel|
502966|NCT00379717|Device|Tomotherapy|
502967|NCT00379691|Drug|phenylephrine|
502968|NCT00379665|Drug|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
502969|NCT00379652|Behavioral|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
502970|NCT00379652|Behavioral|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
502971|NCT00379652|Other|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
502972|NCT00379639|Drug|Romidepsin|7, 10 or 12 mg/m^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
502973|NCT00379639|Drug|Gemcitabine|800 or 1000 mg/m^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
502974|NCT00379626|Drug|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
502975|NCT00379613|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
502976|NCT00379613|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)~At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
502977|NCT00379600|Drug|rosiglitazone XR|
502978|NCT00379587|Drug|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
502979|NCT00379587|Drug|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
502980|NCT00379574|Drug|Bortezomib|"Bortezomib:~For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.~For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
502981|NCT00379574|Drug|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
502982|NCT00379574|Drug|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
502983|NCT00379574|Drug|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
502984|NCT00379574|Drug|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
502985|NCT00379574|Drug|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
502986|NCT00379561|Drug|PSA-Activated PSA-PAH1|
502987|NCT00379548|Behavioral|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
502988|NCT00379535|Drug|potassium iodide|per os
502989|NCT00379535|Drug|placebo|per os
502990|NCT00379522|Drug|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
502991|NCT00379522|Drug|Saline placebo|Placebo for arginine vasopressin
502992|NCT00379509|Drug|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
502993|NCT00379509|Genetic|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
502994|NCT00379509|Genetic|gene expression analysis|Genetic analysis of tumor tissue.
502995|NCT00379509|Genetic|microarray analysis|Genetic analysis of tumor tissue.
502996|NCT00379509|Other|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
502997|NCT00379509|Procedure|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
503135|NCT00378664|Procedure|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
503136|NCT00378651|Procedure|Neck Auscultation|
503137|NCT00378638|Drug|bevacizumab combined with dose dense chemotherapy|
502998|NCT00379509|Radiation|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
502999|NCT00379496|Procedure|Antidepressants|
503000|NCT00379496|Procedure|acupuncture|
503001|NCT00379483|Drug|Deferasirox|
503002|NCT00379470|Device|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
503003|NCT00379457|Biological|dactinomycin|
503004|NCT00379457|Drug|carboplatin|
503005|NCT00379457|Drug|cyclophosphamide|
503006|NCT00379457|Drug|doxorubicin hydrochloride|
503007|NCT00379457|Drug|etoposide|
503008|NCT00379457|Drug|ifosfamide|
503009|NCT00379457|Drug|topotecan hydrochloride|
503010|NCT00379457|Drug|vincristine sulfate|
503011|NCT00379457|Drug|vinorelbine tartrate|
503012|NCT00379457|Procedure|conventional surgery|
503013|NCT00379457|Radiation|radiation therapy|
503014|NCT00379444|Behavioral|Standard intervention (counseling + self-help written materials)|counseling
503015|NCT00379444|Behavioral|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
503016|NCT00379431|Drug|Administration of rituximab and methylprednisolone|"Rituximab:~Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."
503017|NCT00379418|Drug|Abciximab|
503018|NCT00379405|Drug|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
503019|NCT00379392|Behavioral|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
503020|NCT00379392|Procedure|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
503021|NCT00379379|Device|electroacupuncture|
503022|NCT00379366|Device|External ionizing radiations|14 Gy in one time
503023|NCT00379353|Drug|Thalidomide|100 mg capsules orally, once a day for 14 days.
503024|NCT00379353|Drug|Placebo|Two placebo capsules orally, once a day for 14 days.
503025|NCT00379340|Drug|doxorubicin hydrochloride|Given IV
503026|NCT00379340|Drug|liposomal vincristine sulfate|Given IV
503027|NCT00379340|Procedure|conventional surgery|
503028|NCT00379340|Radiation|3-dimensional conformal radiation therapy|
503029|NCT00379340|Biological|dactinomycin|Given IV
503030|NCT00379340|Drug|cyclophosphamide|Given IV
503031|NCT00379340|Drug|etoposide|Given IV
503032|NCT00379327|Procedure|Acupuncture|Acupuncture administered in last three weeks of pregnancy
503033|NCT00379327|Device|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
503034|NCT00379314|Procedure|TVT and TVT-O minimally invasive surgical procedures|
503035|NCT00379314|Procedure|Surgery for female stress urinary incontinence|
503036|NCT00379301|Procedure|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
503037|NCT00379288|Drug|mometasone furoate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
503038|NCT00379288|Drug|mometasone furoate combination MDI 400/10 mcg BID|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
503039|NCT00379288|Drug|Fluticasone/Salmeterol 250/50 mcg BID|F/SC 250/50 twice daily for 1 year
503040|NCT00379288|Drug|Fluticasone/Salmeterol 500/50 mcg BID|F/SC 500/50 twice daily for 1 year
503041|NCT00379262|Drug|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
503042|NCT00379262|Drug|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
503043|NCT00379262|Drug|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
503044|NCT00379249|Drug|Rosuvastatin|
503045|NCT00379236|Device|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
503046|NCT00379236|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
503047|NCT00379223|Procedure|vitrectomy with radial optic neurotomy|
503048|NCT00379210|Behavioral|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
503049|NCT00379210|Behavioral|Nutrition Education course|8-week course in nutrition
503050|NCT00379197|Drug|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
503051|NCT00379197|Procedure|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-[18F]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
503052|NCT00379171|Behavioral|Cow's milk with fish oil|
503053|NCT00379171|Behavioral|Cow's milk without fish oil|
503054|NCT00379171|Behavioral|Formula with fish oil|
503055|NCT00379171|Behavioral|Formula without fish oil|
503138|NCT00378625|Drug|Artesunate|
503058|NCT00379132|Drug|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.~Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
503059|NCT00379119|Other|diagnostic laboratory biomarker analysis|
503060|NCT00379119|Other|flow cytometry|
503061|NCT00379119|Other|physiologic testing|
503062|NCT00379119|Procedure|computed tomography|
503063|NCT00379106|Procedure|Arm exercises.|Basic active exercise program at home.
503064|NCT00379106|Procedure|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
503065|NCT00379093|Behavioral|Brief advice|"The intervention will have the following components:~A) At the time of the recruitment visit, all intervention group patients will receive:~A personalized risk report;~An educational booklet titled Healthy Drinking as You Age;~A drinking diary;~Brief advice to reduce their drinking by their physicians;~B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.~Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
503066|NCT00379080|Procedure|conventional surgery|Undergo surgery
503067|NCT00379080|Drug|tandutinib|Given orally
503068|NCT00379080|Other|pharmacological study|Correlative studies
503069|NCT00379080|Other|Tissue samples|Correlative studies
503070|NCT00379067|Drug|Tamsulosin OCAS|Adrenoceptor antagonist
503071|NCT00379067|Drug|Placebo|placebo
503072|NCT00379054|Behavioral|telephone based skills training intervention|
503073|NCT00379041|Biological|bleomycin sulfate|
503074|NCT00379041|Drug|doxorubicin hydrochloride|
503075|NCT00379041|Drug|mechlorethamine hydrochloride|
503076|NCT00379041|Drug|prednisone|
503077|NCT00379041|Drug|procarbazine hydrochloride|
503078|NCT00379041|Drug|vinblastine sulfate|
503079|NCT00379041|Drug|vincristine sulfate|
503080|NCT00379041|Radiation|radiation therapy|
503081|NCT00379028|Drug|Budesonide/Formoterol Turbuhaler|
503082|NCT00379028|Drug|Salmeterol/Fluticasone Diskus|
503083|NCT00379015|Biological|trastuzumab|
503084|NCT00379015|Drug|cyclophosphamide|
503085|NCT00379015|Drug|docetaxel|
503086|NCT00379015|Drug|epirubicin hydrochloride|
503087|NCT00379015|Procedure|conventional surgery|
503088|NCT00379015|Procedure|neoadjuvant therapy|
503089|NCT00378989|Behavioral|Consultation at the occupational health services|Consultation at the occupational health services
503090|NCT00378976|Drug|valacyclovir|500 mg twice-daily oral
503091|NCT00378976|Drug|matching placebo|twice daily as per experimental drug
503092|NCT00378963|Device|ProAdjuster|
503093|NCT00378950|Behavioral|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
503094|NCT00378950|Behavioral|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
503095|NCT00378937|Drug|acetaminophen|
503096|NCT00378937|Drug|codeine phosphate|
503097|NCT00378937|Drug|dextropropoxyphene hydrochloride|
503098|NCT00378937|Drug|morphine sulfate|
503099|NCT00378937|Drug|oxycodone hydrochloride|
503100|NCT00378937|Procedure|management of therapy complications|
503101|NCT00378937|Procedure|quality-of-life assessment|
503102|NCT00378911|Drug|sunitinib malate|Given orally
503103|NCT00378898|Device|BRAVO capsule|
503104|NCT00378898|Procedure|Fluoroscopy|"one time xray to determine evacuation of bravo"
503105|NCT00378898|Other|sham BRAVO capsule placement|
503106|NCT00378885|Behavioral|Cognitive-behavioral tailored intervention|
503107|NCT00378872|Drug|IV Tranexamic acid 10mg/kg pt body weight|
503108|NCT00378872|Drug|Quixil topical sealant|
503109|NCT00378859|Behavioral|Skim milk|
503110|NCT00378859|Behavioral|Lean meat|
503111|NCT00378846|Procedure|infrared thermography|
503112|NCT00378833|Drug|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
503113|NCT00378833|Drug|niacin|Duration of Treatment: 18 Weeks
503114|NCT00378820|Behavioral|Whey without milk minerals|
503115|NCT00378820|Behavioral|Whey with milk minerals|
503116|NCT00378820|Behavioral|Casein without milk minerals|
503117|NCT00378820|Behavioral|Casein with milk minerals|
503118|NCT00378781|Drug|Heparin|Heparin flush solution into CVC once daily.
503119|NCT00378781|Drug|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
503120|NCT00378768|Biological|anti-thymocyte globulin|
503121|NCT00378755|Drug|velcade|
503122|NCT00378729|Drug|Metformin and FSHr|treatment for infertility
503123|NCT00378729|Procedure|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
503124|NCT00378716|Drug|5-fluorouracil|
503125|NCT00378716|Drug|leucovorin calcium|
503126|NCT00378716|Drug|tegafur|
503127|NCT00378716|Drug|uracil|
503128|NCT00378703|Biological|Bevacizumab|Given IV
503129|NCT00378703|Other|Laboratory Biomarker Analysis|Correlative studies
503130|NCT00378703|Other|Pharmacological Study|Correlative studies
503131|NCT00378703|Drug|Sorafenib Tosylate|Given PO
503132|NCT00378703|Drug|Temsirolimus|Given IV
503133|NCT00378690|Drug|leuprorelin acetate|LHRH antagonist
503134|NCT00378677|Drug|Cyclosporine A dry powder inhalation (Drug)|
503421|NCT00376467|Drug|Imatinib|
503139|NCT00378612|Device|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
503140|NCT00378599|Drug|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
503141|NCT00378586|Procedure|Rectal biopsy|Rectal biopsy.
503142|NCT00378586|Procedure|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
503143|NCT00378586|Procedure|Measurement of rectal lactic acid|Equilibrium dialysis.
503144|NCT00378573|Drug|docetaxel|
503145|NCT00378573|Drug|gemcitabine|
503146|NCT00378573|Drug|bevacizumab|
503147|NCT00378560|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
503148|NCT00378560|Biological|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
503149|NCT00378547|Drug|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
503150|NCT00378547|Drug|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
503151|NCT00378547|Drug|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
503152|NCT00378534|Device|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selectioni and delayed T cell depletion add back
503153|NCT00378534|Drug|Fludarabine|Therapeutic
503154|NCT00378534|Drug|Cyclosporine|Therapeutic
503155|NCT00378534|Drug|Cyclophosphamide|Therapeutic
503156|NCT00378521|Drug|MQX-503|
503157|NCT00378508|Drug|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
503158|NCT00378508|Drug|Placebo Arm|
503159|NCT00378495|Drug|Miltefosine: initially 2.5 mg/kg/day for 28 days|
503160|NCT00378482|Drug|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
503161|NCT00378469|Behavioral|45 minute exercise on ergocycle|
503162|NCT00378456|Drug|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
503163|NCT00378456|Drug|Folinic acid|
503164|NCT00378456|Drug|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
503165|NCT00378456|Drug|Placebo|
503166|NCT00378443|Drug|prednisone + Inhibace/Cozaar|
503167|NCT00378443|Drug|Inhibace/Cozaar|
503168|NCT00378417|Biological|7-valent pneumococcal-CRM197 conjugate vaccine|
503169|NCT00378417|Biological|7-valent pneumococcal-OMPC conjugate vaccine|
503170|NCT00378404|Drug|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
503171|NCT00378404|Radiation|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
503172|NCT00378378|Drug|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
503173|NCT00378378|Drug|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
503174|NCT00378365|Procedure|Arsenic trioxide|Arsenic trioxide
503175|NCT00378365|Procedure|ATRA|ATRA
503176|NCT00378352|Drug|Epoetin alfa|Randomized
503177|NCT00378339|Device|gold berlocks|
503178|NCT00378326|Drug|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
503179|NCT00378313|Drug|gemcitabine, epirubicin, paclitaxel|
503180|NCT00378300|Drug|Oral Probiotics|
503181|NCT00378287|Drug|rabeprazole sodium|
503182|NCT00378274|Behavioral|Observation|
503183|NCT00378261|Procedure|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
503184|NCT00378248|Behavioral|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
503185|NCT00378248|Behavioral|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
503186|NCT00378235|Drug|IL13-PE38QQR|
503187|NCT00378222|Procedure|Autologous Stem Cell Transplantation|
503188|NCT00378209|Drug|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
503189|NCT00378209|Drug|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
503190|NCT00378209|Drug|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
503191|NCT00378196|Drug|Ranibizumab|0.3 mg/0.05 ml dose
503192|NCT00378196|Drug|Ranibizumab|0.5 mg/0.05 ml dose
503193|NCT00378183|Drug|risperidone|
503194|NCT00378170|Device|intubation of patients undergoing elective surgery|
503195|NCT00378157|Behavioral|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
503196|NCT00378144|Drug|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]
503197|NCT00378131|Drug|RC-1291|
503198|NCT00378131|Drug|placebo|
503199|NCT00378118|Other|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
503200|NCT00378118|Other|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
503201|NCT00378105|Drug|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
503202|NCT00378105|Drug|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
503422|NCT00376454|Drug|GW493838|
503203|NCT00378105|Drug|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
503204|NCT00378092|Drug|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
503205|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
503206|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
503207|NCT00378079|Other|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
503208|NCT00378079|Drug|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
503209|NCT00378079|Drug|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
503210|NCT00378066|Drug|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
503211|NCT00378027|Drug|Fondaparinux|Administer Fondaparinux Risk Stratify
503212|NCT00378014|Drug|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
503213|NCT00378014|Drug|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
503214|NCT00378014|Drug|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
503215|NCT00378001|Drug|FSH-IBSA|
503216|NCT00378001|Drug|GONAL-F|
503217|NCT00377988|Drug|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
503218|NCT00377988|Drug|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
503219|NCT00377975|Drug|Ephedrine|
503220|NCT00377975|Drug|Pioglitazone|
503221|NCT00377975|Drug|Caffeine|
503222|NCT00377962|Drug|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
503223|NCT00377962|Drug|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
503224|NCT00377962|Drug|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
503225|NCT00377962|Drug|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
503226|NCT00377936|Drug|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
503227|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
503228|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
503229|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
503230|NCT00377923|Drug|Progesterone|
503231|NCT00377910|Drug|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
503232|NCT00377897|Procedure|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
503233|NCT00377871|Device|biological heart valve prosthesis|Two heart valve designs
503234|NCT00377858|Drug|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
503235|NCT00377858|Drug|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
503236|NCT00377845|Procedure|Regular Tampax used in 3 hours|
503237|NCT00377832|Drug|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
503238|NCT00377819|Drug|alendronate|70 mg oral QW
503239|NCT00377819|Drug|Denosumab (AMG 162)|60 mg SC q 6 mos
503240|NCT00377806|Drug|Diclofenac gel|
503241|NCT00377793|Drug|Levitra (Vardenafil, BAY38-9456)|
503242|NCT00377793|Drug|Placebo|
503243|NCT00377780|Drug|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
503244|NCT00377767|Behavioral|To change structure and roles of primary care teams to optimize prevention of obesity|
503245|NCT00377741|Drug|valganciclovir [Valcyte]|900mg po
503246|NCT00377728|Drug|GSK256066|
503247|NCT00377715|Drug|Dimebon|
503248|NCT00377715|Drug|Placebo|
503249|NCT00377689|Behavioral|high intensity functional exercise|high intensity functional exercise
503250|NCT00377676|Drug|Cycloset|Usual diabetes therapy plus Cycloset
503251|NCT00377676|Drug|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
503252|NCT00377663|Behavioral|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
503253|NCT00377650|Device|Percutaneous thrombectomy|
503660|NCT00374387|Drug|low-dose combination pill|
503254|NCT00377637|Drug|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
503255|NCT00377637|Drug|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.~Dosing was started at 0.75 g/m^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m^2. The target dose was 1.0 g/m^2, but doses were titrated by 0.25 g/m^2 increments to maintain nadir leukocyte count between 2500-4000/mm^3."
503256|NCT00377637|Drug|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
503257|NCT00377637|Drug|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
503258|NCT00377637|Drug|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
503259|NCT00377637|Drug|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
503260|NCT00377624|Drug|sodium hyaluronate|
503261|NCT00377611|Biological|Fluarix™|
503262|NCT00377598|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
503263|NCT00377598|Drug|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
503264|NCT00377598|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
503265|NCT00377598|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
503266|NCT00377598|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
503267|NCT00377585|Biological|Fluarix|
503268|NCT00377585|Biological|adjuvanted influenza vaccine|
503269|NCT00377572|Biological|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
503270|NCT00377572|Biological|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
503271|NCT00377559|Drug|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
503272|NCT00377546|Drug|Nepafenac|
503273|NCT00377546|Drug|Ketorolac LS, Bromfenac|
503274|NCT00377533|Device|wheelchair rear anti-tip device|assistive device
503275|NCT00377520|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
503276|NCT00377507|Dietary Supplement|catechin extracts|catechin extracts solution
503277|NCT00377494|Biological|MVA-CSO Vaccine|
503278|NCT00377494|Biological|PfCSP DNA (VCL-2510) Vaccine|
503279|NCT00377481|Drug|darbepoetin alfa|30 micrograms sc weekly (2 doses)
503280|NCT00377481|Drug|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
503281|NCT00377468|Drug|Delta9-Tetrahydrocannabinol|
503282|NCT00377455|Drug|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
503283|NCT00377455|Drug|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
503284|NCT00377442|Drug|GK Activator (2)|100mg po
503285|NCT00377442|Drug|Simvastatin|80mg po
503286|NCT00377429|Drug|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
503287|NCT00377416|Genetic|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
503288|NCT00377403|Drug|Acetaminophen|"Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever"
503289|NCT00377403|Drug|Amoxicillin|"Intervention drug:~Dose: 500mg tid for 10 days"
503290|NCT00377403|Drug|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:~Dose: 10mls every 4 to 6 hours for cough"
503291|NCT00377403|Drug|Guaifenesin|"Symptomatic treatment:~Dose: 600mg every 12 hours to thin secretions"
503292|NCT00377403|Drug|Pseudoephedrine Sustained Action|"Symptomatic treatment:~Dose: 120mg every 12 hours for nasal congestion"
503293|NCT00377403|Drug|Saline spray (0.65%)|"Symptomatic treatment:~Dose: 2 squeezes per nostril as needed for nasal congestion"
503294|NCT00377390|Biological|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
503295|NCT00377377|Drug|EP1572 (ghrelin agonist) oral and duodenal application|
503296|NCT00377364|Drug|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
503297|NCT00377325|Drug|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
503298|NCT00377312|Drug|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
503299|NCT00377299|Drug|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
503300|NCT00377299|Drug|Placebo|Placebo matching active medication in all other physical aspects
503301|NCT00377286|Dietary Supplement|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
503302|NCT00377286|Other|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
503303|NCT00377273|Drug|fluorouracil cream 0.5%|
503304|NCT00377260|Drug|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
503305|NCT00377260|Drug|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
503661|NCT00374387|Drug|minipill|
503306|NCT00377247|Biological|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
503307|NCT00377234|Drug|Risedronate|35mg po weekly for 12 weeks
503308|NCT00377234|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
503309|NCT00377208|Behavioral|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
503310|NCT00377195|Radiation|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.~Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
503311|NCT00377182|Drug|Copegus|1000/1200mg po daily for 4 weeks
503312|NCT00377182|Drug|PEGASYS|180 micrograms sc weekly for 4 weeks
503313|NCT00377182|Drug|RO5024048 1500mg|1500mg po bid for 4 weeks
503314|NCT00377182|Drug|RO5024048 3000mg|3000mg po bid for 4 weeks
503315|NCT00377156|Radiation|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
503316|NCT00377156|Radiation|stereotactic radiosurgery|
503317|NCT00377143|Drug|Warfarin Dosing|
503318|NCT00377130|Other|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
503319|NCT00377117|Procedure|Management|
503320|NCT00377117|Procedure|Screening|
503321|NCT00377104|Drug|alvocidib|Given IV
503322|NCT00377104|Other|pharmacological study|Correlative studies
503323|NCT00377104|Other|laboratory biomarker analysis|Correlative studies
503324|NCT00377091|Drug|Fondaparinux|
503325|NCT00377078|Drug|recombinant human lactoferrin|
503326|NCT00377065|Drug|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
503327|NCT00377052|Drug|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
503328|NCT00377052|Drug|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
503329|NCT00377039|Drug|AD 337|
503330|NCT00377026|Behavioral|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
503331|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% gel pump|
503332|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% tube|
503333|NCT00376987|Dietary Supplement|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
503334|NCT00376974|Behavioral|American Academy of Ophthalmology Glaucoma Educational Tape|
503335|NCT00376961|Biological|rituximab|375 mg/m^2 on day 1 for cycles 1-6.
503336|NCT00376961|Drug|bortezomib|1.3 mg/m^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
503337|NCT00376961|Drug|cyclophosphamide|750 mg/m^2 on day 1 of cycles 1-6.
503338|NCT00376961|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 1 of cycles 1-6.
503339|NCT00376961|Drug|prednisone|100 mg on days 1-5 of cycles 1-6.
503340|NCT00376961|Drug|vincristine sulfate|1.4 mg/m^2 on day 1 of cycles 1-6.
503341|NCT00376948|Dietary Supplement|genistein|
503342|NCT00376948|Drug|erlotinib hydrochloride|
503343|NCT00376948|Drug|gemcitabine hydrochloride|
503344|NCT00376935|Drug|Palifermin|Keratinocyte growth factor administered via injection
503345|NCT00376935|Drug|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
503346|NCT00376922|Procedure|music therapy|music played for patient during bone marrow biopsy collection
503347|NCT00376909|Other|educational intervention|
503348|NCT00376909|Other|study of socioeconomic and demographic variables|
503349|NCT00376896|Drug|GW876008 200mcg|GW876008
503350|NCT00376896|Drug|GW876008 20mcg|GW876008 20mcg
503351|NCT00376896|Other|Placebo|placebo
503352|NCT00376883|Drug|pamidronate|
503353|NCT00376870|Drug|Pioglitazone|pioglitazone 30 mg/d
503354|NCT00376870|Drug|Placebo|Placebo 30 mg/d
503355|NCT00376857|Drug|Surgery with and without the aid of Indocyanine Green (ICG)|
503356|NCT00376844|Radiation|External Beam Radiation Therapy|
503357|NCT00376844|Radiation|Vaginal Brachytherapy|
503358|NCT00376831|Drug|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
503359|NCT00376831|Drug|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
503360|NCT00376818|Behavioral|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
503361|NCT00376818|Other|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
503362|NCT00376818|Other|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
503418|NCT00376480|Procedure|allogeneic hematopoietic stem cell transplantation|
503363|NCT00376818|Other|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
503364|NCT00376818|Behavioral|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
503365|NCT00376818|Procedure|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
503366|NCT00376805|Drug|Fludarabine|administered intravenously 25 mg/m^2 times 5 doses
503367|NCT00376805|Drug|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
503368|NCT00376805|Radiation|Total body irradiation|200 cGy (gray) on day -1
503369|NCT00376805|Other|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
503370|NCT00376805|Biological|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
503371|NCT00376792|Drug|docetaxel|
503372|NCT00376792|Other|active surveillance|
503373|NCT00376792|Procedure|adjuvant therapy|
503374|NCT00376779|Biological|Infanrix hexa Vaccine|
503375|NCT00376766|Drug|levetiracetam|
503376|NCT00376740|Drug|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
503377|NCT00376727|Biological|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
503378|NCT00376727|Genetic|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
503379|NCT00376727|Other|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
503380|NCT00376727|Other|laboratory biomarker analysis|Cetuximab Pharmacodynamics
503381|NCT00376714|Drug|GSK233705|
503382|NCT00376701|Drug|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
503383|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
503384|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
503385|NCT00376701|Drug|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
503386|NCT00376688|Other|Laboratory Biomarker Analysis|Correlative studies
503387|NCT00376688|Drug|Temsirolimus|Given IV
503388|NCT00376675|Drug|methylphenidate hydrochloride|Given orally
503389|NCT00376675|Other|placebo|Given orally
503390|NCT00376662|Drug|Hormone Replacement Therapy and Etidronate|
503391|NCT00376649|Behavioral|lifestyle changing workshop|
503392|NCT00376636|Drug|SPP635 (drug)|
503393|NCT00376623|Drug|BI 2536|
503394|NCT00376610|Device|ASR/Re-cap|
503395|NCT00376597|Other|quality of life assessment|Ancillary studies
503396|NCT00376597|Other|educational intervention|Receive lymphedema educational materials
503397|NCT00376597|Procedure|Physical therapy|Complete physical therapy-focused intervention
503398|NCT00376584|Drug|MK-0524A|
503399|NCT00376584|Drug|ER Niacin|
503400|NCT00376584|Drug|Placebo|
503401|NCT00376571|Procedure|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
503402|NCT00376558|Behavioral|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
503403|NCT00376519|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
503404|NCT00376519|Drug|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of >200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
503405|NCT00376519|Drug|fludarabine phosphate|Fludarabine 25 mg/m^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
503406|NCT00376519|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
503407|NCT00376519|Procedure|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10^6/kg, 0.3 x 10^6/kg, 1 x 10^6/kg and 3 x 10^6/kg weight (determined on the day prior to administration of the preparative therapy).
503408|NCT00376519|Procedure|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
503409|NCT00376519|Radiation|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
503410|NCT00376506|Device|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
503411|NCT00376506|Device|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
503412|NCT00376493|Drug|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
503413|NCT00376480|Biological|anti-thymocyte globulin|
503414|NCT00376480|Biological|peripheral blood lymphocyte therapy|
503415|NCT00376480|Drug|fludarabine phosphate|
503416|NCT00376480|Drug|methylprednisolone|
503417|NCT00376480|Drug|thiotepa|
503423|NCT00376441|Procedure|Vaginal Surgery|patients undergoing vaginal surgery
503424|NCT00376428|Drug|Gentamicin|
503425|NCT00376415|Drug|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
503426|NCT00376415|Drug|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
503427|NCT00376402|Biological|H5N1 Pandemic Influenza Vaccine|
503428|NCT00376376|Drug|levofloxacin at 250, 500, 750, and 1000 mg doses|
503429|NCT00376363|Device|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
503430|NCT00376363|Device|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
503431|NCT00376350|Procedure|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
503432|NCT00376350|Procedure|Light Massage|light pressure massage of the low back.
503433|NCT00376350|Procedure|Pulsed Ultrasound|5 minutes pulsed ultrasound
503434|NCT00376337|Drug|Micafungin|IV
503435|NCT00376337|Drug|Systemic antifungal therapy|IV
503436|NCT00376324|Drug|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
503437|NCT00376311|Drug|oral salmon calcitonin|
503438|NCT00376285|Drug|CP-742,033|
503439|NCT00376285|Drug|Fenofibrate|
503440|NCT00376272|Drug|Valsartan|
503441|NCT00376272|Drug|Placebo|
503442|NCT00376259|Drug|telbivudine|600mg/day oral tablet for 96 weeks
503443|NCT00376259|Drug|adefovir dipivoxil|10 mg of adefovir by mouth once daily
503444|NCT00376246|Drug|Ezetimibe|
503445|NCT00376220|Drug|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.
503446|NCT00376220|Other|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
503447|NCT00376207|Behavioral|Physical exercise|
503448|NCT00376194|Drug|DMSA|
503449|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
503450|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
503451|NCT00376181|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
503452|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
503453|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
503454|NCT00376155|Drug|sulfadoxine /pyrimethamine plus amodiaquine|
503455|NCT00376142|Behavioral|Psychological theory-based behaviour change interventions|
503456|NCT00376129|Drug|Alefacept|15 mg i.m. once weekly for 12 weeks
503457|NCT00376116|Device|Cardiac resynchronisation therapy|
503458|NCT00376116|Device|Implantable cardioverter-defibrillator|
503459|NCT00376103|Drug|temozolomide|75 mg/m2/day
503460|NCT00376103|Procedure|Brachytherapy|60 Gy to 1 cm
503461|NCT00376103|Procedure|External Beam Radiation Therapy|60 Gy
503462|NCT00376090|Biological|MVA-CMDR|10^7 PFU IM, 1.0 mL
503463|NCT00376090|Biological|Placebo|1.0 mL IM
503464|NCT00376090|Biological|MVA-CMDR|10^6 PFU ID, 0.1 mL
503465|NCT00376090|Biological|Placebo|0.1 mL ID
503466|NCT00376090|Biological|MVA-CMDR|10^8 PFU IM, 1.0 mL
503467|NCT00376090|Biological|MVA-CMDR|10^7 PFD ID, 0.1 mL
503468|NCT00376077|Drug|Methylprednisolone and IVIG|Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
503469|NCT00376077|Drug|Placebo and IVIG|Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
503470|NCT00376064|Drug|Octreotide acetate and cabergoline/Octrotide and Somavert|
503471|NCT00376051|Drug|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
503472|NCT00376038|Drug|GSK189075 oral tablets|
503473|NCT00376038|Drug|metformin tablets|
503474|NCT00376025|Dietary Supplement|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
503475|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
503476|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
503477|NCT00375999|Drug|Docetaxel and epirubicin|
503478|NCT00375986|Procedure|Manual placental removal at Cesarean delivery|
503479|NCT00375986|Procedure|Spontaneous placental removal at Cesarean delivery|
503480|NCT00375973|Drug|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
503481|NCT00375973|Drug|Placebo|Sugar pill dose comparable to duloxetine
503482|NCT00375960|Drug|V3381|
503483|NCT00375960|Drug|Placebo|
503484|NCT00375947|Other|Hand Exercise|
503485|NCT00375947|Other|sham hand cream|placebo intervention
503486|NCT00375934|Drug|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
503487|NCT00375934|Drug|Placebo|Oral placebo capsule, every 6 hours
503488|NCT00375895|Drug|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
503489|NCT00375882|Procedure|hypothermia|
503490|NCT00375882|Procedure|cochlear implantation with mild hypothermia|
503491|NCT00375869|Drug|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
503492|NCT00375869|Drug|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
503493|NCT00375856|Device|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
503494|NCT00375843|Drug|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
503495|NCT00375843|Drug|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
503496|NCT00375830|Procedure|Bone scan|Scan to diagnose a number of bone conditions including cancer or metastasis
503497|NCT00375830|Drug|99mTc-methyl diphosphonate|Radiolabel for bone scan procedures
503498|NCT00375830|Procedure|Positron Emission Tomography (PET) scan|Scan to detect gamma rays emitted by a positron-emitting radioligand such as 18F
503499|NCT00375830|Drug|18F-Fludeoxyglucose (18F-FDG)|Radiolabel for positron emission tomography scan procedures
503500|NCT00375830|Procedure|Computed Tomography (CT) scan|Scan to detect & analyze X-rays
503501|NCT00375830|Drug|18F-Sodium Fluoride (18F-NaF)|Radiolabel for CT and PET scans, & as a contrast agent for MRI scans.
503502|NCT00375830|Procedure|Whole Body Magnetic Resonance Imaging (WB-MRI) scan|Whole Body Magnetic Resonance Imaging (WB-MRI) scan: Scan that uses strong magnetic fields & radio waves to generate images of the organs in the body.
503503|NCT00375830|Drug|Gadopentetate dimeglumine|A gadolinium-based contrast agent for MRI
503504|NCT00375830|Drug|Gadofosveset|A gadolinium-based contrast agent for MRI
503505|NCT00375830|Drug|Gadobutrol|A gadolinium-based contrast agent for MRI
503506|NCT00375817|Procedure|Myoblasts injection with MyoCath catheter|
503507|NCT00375791|Drug|perifosine|100 - 150 mg daily
503508|NCT00375791|Drug|dexamethasone|20 mg twice weekly
503509|NCT00375778|Drug|memantine (drug)|
503510|NCT00375765|Drug|Dutasteride|
503511|NCT00375752|Drug|Letrozole|2.5 mg.tablet.
503512|NCT00375752|Drug|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
503513|NCT00375739|Drug|PEP005|
503514|NCT00375726|Biological|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
503515|NCT00375726|Biological|Placebo|Placebo for rDEN3/4delta30(ME)
503516|NCT00375713|Drug|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
503517|NCT00375713|Drug|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
503518|NCT00375713|Drug|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
503519|NCT00375713|Drug|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
503520|NCT00375713|Drug|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
503521|NCT00375700|Dietary Supplement|Nutritional Supplement|
503522|NCT00375687|Drug|Triptorelin|
503523|NCT00375674|Drug|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
503524|NCT00375674|Other|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
503525|NCT00375661|Drug|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
503526|NCT00375648|Drug|Zoledronic acid|
503527|NCT00375635|Procedure|mFPSA treatment|
503528|NCT00375622|Drug|Tamoxifen|
503529|NCT00375609|Drug|Betrixaban|Capsule
503530|NCT00375609|Drug|Enoxaparin|Administered subcutaneously
503531|NCT00375596|Drug|Ketotifen/vasoconstrictor|
503532|NCT00375583|Drug|DEC/Albendazole|
503533|NCT00375570|Drug|ME-609|Topical treatment 5 times daily for 5 days
503534|NCT00375557|Drug|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
503535|NCT00375557|Drug|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
503536|NCT00375544|Device|Low level light therapy|
503537|NCT00375531|Behavioral|Mindfulness Meditation (MfM)|
503538|NCT00375518|Drug|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
503539|NCT00375518|Drug|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
503540|NCT00375505|Drug|Zoledronic acid|
503541|NCT00375505|Drug|Placebo|Placebo
503542|NCT00375492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
503543|NCT00375492|Drug|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
503544|NCT00375466|Drug|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
503545|NCT00375466|Drug|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
503546|NCT00375453|Drug|SH U04722|
503547|NCT00375440|Drug|Tranexamic Acid|
503548|NCT00375427|Drug|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
503549|NCT00375414|Procedure|PEG-Gastropexy|
503550|NCT00375401|Drug|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
503551|NCT00375401|Drug|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
503552|NCT00375401|Drug|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
503553|NCT00375388|Drug|Metformin on top of intensive insulin therapy|
503554|NCT00375375|Drug|Lactulose|
503555|NCT00375362|Drug|Nitroderm patch|
503556|NCT00375349|Procedure|Ultrasound to demonstrate existence of fatty liver|
503557|NCT00375323|Drug|NovoSeven|
503558|NCT00375310|Drug|Gemcitabine, Sorafenib|"Gemcitabine is given IV~Sorafenib is given orally of varying doses:~Sorafenib 200 mg po qd ( during combination therapy)~Sorafenib 400 mg po qd ( during combination therapy)~Sorafenib 400 mg po bid ( during combination therapy)"
503559|NCT00375310|Procedure|Radiotherapy|1.8 Gy CTV daily for 5 weeks
503560|NCT00375297|Drug|sildenafil|
503561|NCT00375284|Drug|Pramipexole|
503562|NCT00375271|Procedure|perioperative hemodynamic optimization protocol|
503563|NCT00375258|Drug|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
503564|NCT00375258|Drug|Sodium Chloride 0.9%|Visual matched placebo
503565|NCT00375245|Drug|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
503566|NCT00375245|Other|Grapefruit Juice|Daily oral doses starting during the second week on study.
503567|NCT00375232|Drug|Administration of montelukast or placebo|
503568|NCT00375219|Drug|Omacetaxine mepesuccinate|"Induction:~1.25 mg/m^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.~Maintenance:~1.25 mg/m^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
503569|NCT00375206|Biological|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
503570|NCT00375193|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
503571|NCT00375167|Behavioral|Recovery Workbook Training (psychoeducational training)|The Recovery Workbook uses an educational process to increase awareness of recovery, increase knowledge and control of the illness, increase awareness of the importance and nature of stress, enhance personal meaning, build personal support, and develop goals and plans of action. The intervention period of 30 weekly sessions recommended by Spaniol and colleagues was shortened to 12 weekly sessions to accommodate for clinical and participant commitment. No workbook content was excluded, and all practice exercises were covered.
503572|NCT00375167|Behavioral|ACT as usual|Assertive Community Treatment services provided as per established and evidence-based fidelity standards.
503573|NCT00375154|Device|Noninvasive Positive-Pressure Ventilation (NPPV)|
503574|NCT00375141|Device|Pulsed dye laser, Intense pulsed light|
503575|NCT00375128|Biological|FP9-PP (FP9 polyprotein)|
503576|NCT00375128|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
503577|NCT00375115|Drug|Sambucol|
503578|NCT00375102|Procedure|Acupuncture|
503579|NCT00375102|Behavioral|Relaxation Response|
503580|NCT00375089|Other|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
503581|NCT00375089|Other|Group 2|Individuals with Early-onset Morbid Obesity.
503582|NCT00375076|Drug|enoxaparin|
503583|NCT00375063|Procedure|Percutaneous Coronary Intervention|
503584|NCT00375063|Procedure|Coronary Artery Bypass Grafting|
503585|NCT00375050|Drug|Riluzole|
503586|NCT00375050|Drug|Placebo|placebo
503587|NCT00375037|Behavioral|feedback|
503588|NCT00375037|Behavioral|Education|
503589|NCT00375037|Other|usual care|
503590|NCT00375024|Procedure|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
503591|NCT00375024|Procedure|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
503592|NCT00374998|Biological|FP9-PP (FP9 polyprotein)|
503593|NCT00374998|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
503594|NCT00374985|Drug|Docetaxel, Oxaliplatin|weekly doses
503595|NCT00374985|Procedure|Radiotherapy|regular fractions
503596|NCT00374959|Drug|ceftriaxone|
503597|NCT00374959|Device|Endotracheal tube for aspiration of subglottic secretions.|
503598|NCT00374946|Device|THA|
503599|NCT00374933|Drug|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
503600|NCT00374933|Drug|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
503662|NCT00374374|Behavioral|Administration of probiotic|
528498|NCT00163332|Drug|Ciclesonide|
503601|NCT00374933|Drug|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
503602|NCT00374920|Drug|MEM 1003|
503603|NCT00374907|Drug|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
503604|NCT00374907|Drug|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
503605|NCT00374907|Drug|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
503606|NCT00374907|Drug|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
503607|NCT00374894|Drug|2,3-dimercaptosuccinic acid|
503608|NCT00374881|Drug|Morphine|Morphine
503609|NCT00374881|Drug|Morphine|Morphine low dose
503610|NCT00374881|Drug|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
503611|NCT00374881|Drug|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
503612|NCT00374881|Drug|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
503613|NCT00374868|Drug|pemetrexed|"Phase 1: 300 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m^2, 400 mg/m^2, and 500 mg/m^2)~Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
503614|NCT00374868|Drug|cisplatin|"Phase 1: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles~Phase 2: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
503615|NCT00374855|Drug|PPAR alpha|
503616|NCT00374855|Drug|Hydrochlorothiazide|
503617|NCT00374855|Drug|Placebo|
503618|NCT00374842|Biological|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
503619|NCT00374842|Biological|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
503620|NCT00374829|Behavioral|An IT-based patient follow-up and reminder system|
503621|NCT00374803|Drug|Mycophenolic Acid (Myfortic)|"Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter~Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."
503622|NCT00374790|Drug|Ferrous sulfate|
503623|NCT00374777|Drug|zolpidem MR|oral
503624|NCT00374777|Drug|nitrazepam|oral
503625|NCT00374777|Drug|placebo|oral
503626|NCT00374764|Drug|Risperidone|
503627|NCT00374764|Behavioral|ABA|
503628|NCT00374751|Drug|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
503629|NCT00374738|Behavioral|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
503630|NCT00374725|Behavioral|Administration of probiotic (L. rhamnosus and L. acidophilus)|
503631|NCT00374699|Drug|Velcade|
503632|NCT00374686|Drug|Valganciclovir|
503633|NCT00374673|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
503634|NCT00374660|Drug|Irofulven + oxaliplatin|"Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. Starting dose 40 mg/m^2, dose escalation 50, 60, 70, and 80 mg/m^2 every 28 days if no dose-limiting toxicity.~Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered in a 30-minute infusion on Days 1 and 15 of a 28-day cycle. Starting dose 0.30 mg/kg, dose escalation to 0.40 mg/kg every 28 days if no dose-limiting toxicity."
503635|NCT00374647|Drug|mycophenolate mofetil|
503636|NCT00374647|Drug|sirolimus|
503637|NCT00374634|Drug|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
503638|NCT00374634|Drug|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
503639|NCT00374621|Drug|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
503640|NCT00374582|Device|Bodystat Quadscan 4000|device determining body composition and nutritional status
503641|NCT00374582|Device|bodystat quadscan 400|device determining body composition and nutritional status
503642|NCT00374569|Procedure|Gymnastic Routine|A combination of gymnastic movements are performed
503643|NCT00374556|Drug|Placebo|3mg placebo capsule, once daily at bedtime
503644|NCT00374556|Drug|Eszopiclone|3mg capsule, once daily at bedtime
503645|NCT00374543|Drug|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
503646|NCT00374543|Drug|Placebo|Placebo administered daily for 8 weeks
503647|NCT00374530|Drug|PGE2|
503648|NCT00374517|Drug|Pimonidazole hydrochloride|
503649|NCT00374478|Drug|Scopolamine|
503650|NCT00374465|Drug|Verapamil|
503651|NCT00374465|Drug|Carvedilol|
503652|NCT00374452|Other|ATHENA-CDS-HTN plus Guideline Link|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
503653|NCT00374452|Other|Guideline Link Only|Primary care providers were sent, once, a link (URL) to the VA/DoD and JNC7 hypertension guidelines.
503654|NCT00374439|Behavioral|Cognitive-behavioral|Cognitive-behavioral approach
503655|NCT00374439|Behavioral|Interpersonal Therapy|Interpersonal therapy approach
503656|NCT00374426|Drug|sertraline|
503657|NCT00374413|Device|Artificial disk|Implant
503658|NCT00374413|Device|Artificial disc|Implant
503659|NCT00374387|Drug|Nuvaring|
528499|NCT00163319|Drug|Ciclesonide|
503663|NCT00374348|Drug|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
503664|NCT00374335|Procedure|abdominal ultrasound|abdominal ultrasound to detect hepatic hemangiomas
503665|NCT00374335|Other|Dermatologic Examination|Complete dermatologic examination
503666|NCT00374322|Drug|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
503667|NCT00374322|Other|placebo|6 tablets daily for 12 months
503668|NCT00374309|Drug|VRC-EBOADV018-00-VP|
503669|NCT00374296|Drug|MGCD0103|MGCD0103 administered orally three-times per week
503670|NCT00374270|Behavioral|Lifestyle Counselling; Opinion Leader Influence Statements|
503671|NCT00374257|Procedure|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
503672|NCT00374244|Drug|Pimozide|half of the subjects are randomized to the active drug group
503673|NCT00374244|Drug|placebo|half of the subjects are randomized to placebo group
503674|NCT00374231|Drug|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
503675|NCT00374231|Drug|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
503676|NCT00374231|Drug|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
503677|NCT00374218|Drug|High Fructose Corn Syrup|
503678|NCT00374218|Drug|Sucromalt|
503679|NCT00374205|Drug|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
503680|NCT00374205|Drug|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
503681|NCT00374192|Drug|Eszopiclone|3 mg per day
503682|NCT00374192|Drug|Placebo|Placebo
503683|NCT00374179|Drug|CT-322|IV solution, weekly or bi-weekly
503684|NCT00374166|Drug|SSR149415|Oral administration (capsules of 50 and 100 mg)
503685|NCT00374166|Drug|Placebo|Oral administration (capsules)
503686|NCT00374166|Drug|Paroxetine|Oral administration (capsules)
503687|NCT00374153|Behavioral|Feedback|Online personal feedback report
503688|NCT00374153|Behavioral|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
503689|NCT00374153|Behavioral|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
503690|NCT00374140|Drug|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
503691|NCT00374127|Drug|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
503692|NCT00374127|Drug|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
503693|NCT00374114|Procedure|cervical conization|
503694|NCT00374114|Procedure|ultrasonic surgical aspiration of the cervix|
503695|NCT00374101|Drug|omeprazole|
503696|NCT00374101|Drug|pantoprazole|
503697|NCT00374088|Drug|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.~Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
503698|NCT00374088|Drug|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
503699|NCT00374075|Drug|Valproic Acid|
503700|NCT00374062|Behavioral|relaxation therapy 1|relaxation therapy 1
503701|NCT00374062|Behavioral|relaxation therapy 2|relaxation therapy 2
503702|NCT00374062|Behavioral|relaxation therapy 3|relaxation therapy 3
503703|NCT00374049|Drug|MUC_1|Pretreatment with Poly-ICLC alone week 1 &2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
503704|NCT00374036|Drug|ECC|capecitabine
503705|NCT00374036|Drug|FOLFIRI|Irinotecan
503706|NCT00374023|Drug|Zinc, or Vitamin A or both|
503707|NCT00374010|Behavioral|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:~Representational assessment (10 - 15 minutes);~Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);~Creating conditions for conceptual change (5 minutes);~Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and~Summary (3 - 5 minutes)"
503708|NCT00373997|Procedure|Esophageal and Laryngeal biopsies|one day procedure
503709|NCT00373997|Procedure|egd with biopsy|standard of care procedure with biopsy
503710|NCT00373971|Behavioral|Involving the patients in their own nutritional care|
503711|NCT00373958|Biological|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
503712|NCT00373958|Biological|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
503713|NCT00373945|Drug|Observational Study|
503835|NCT00373022|Behavioral|exercise intervention|
503836|NCT00373022|Other|flow cytometry|
503714|NCT00373932|Behavioral|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
503715|NCT00373932|Behavioral|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
503716|NCT00373919|Drug|intravenous (IV) administration of erythromycin|
503717|NCT00373906|Drug|Bortezomib (Velcade)|
503718|NCT00373893|Drug|Lidoderm Patch|
503719|NCT00373880|Drug|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
503720|NCT00373880|Drug|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
503721|NCT00373867|Behavioral|Standard physical therapy|Treatment-based classification physical therapy
503722|NCT00373867|Behavioral|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
503723|NCT00373867|Other|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
503724|NCT00373815|Drug|Everolimus|
503725|NCT00373802|Drug|Phenylephrine|
503726|NCT00373789|Drug|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
503727|NCT00373789|Drug|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
503728|NCT00373776|Drug|miltefosine 2.5 mg/kg/day for 28 days|
503729|NCT00373763|Procedure|Fetoscopic tracheal balloon occlusion|
503730|NCT00373750|Procedure|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
503731|NCT00373724|Procedure|radiofrequency denervation|
503732|NCT00373711|Drug|Iodine-124|2 mCi, oral
503733|NCT00373711|Drug|Iodine-123|2 mCi, oral
503734|NCT00373711|Drug|F-18 FDG|10-15 mCi, iv
503735|NCT00373698|Behavioral|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
503736|NCT00373685|Drug|Celecoxib|open-label
503737|NCT00373685|Drug|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
503738|NCT00373672|Drug|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
503739|NCT00373672|Drug|placebo|identical in appearance to active comparator
503740|NCT00373659|Drug|Ranibizumab (Lucentis)|
503741|NCT00373646|Drug|Thalidomide, Pharmion|200 mg p.o. daily
503742|NCT00373633|Procedure|Thoracic Epidural|Gold standard for post thoracotomy pain
503743|NCT00373633|Procedure|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
503744|NCT00373620|Drug|paclitaxel|
503745|NCT00373607|Drug|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
503746|NCT00373607|Drug|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
503747|NCT00373594|Drug|Rituximab|
503748|NCT00373594|Drug|Fludarabine|
503749|NCT00373581|Drug|Vigabatrin|
503750|NCT00373581|Drug|Cocaine|
503751|NCT00373568|Drug|miltefosine: 2.5 mg/kg/day for 42 days|
503752|NCT00373555|Procedure|Bronchoscopy|
503753|NCT00373542|Drug|ropinirole CR-RLS|
503754|NCT00373529|Drug|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.~Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days."
503755|NCT00373516|Drug|Vehicle (Placebo) applied BID|
503756|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied QD|
503757|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied BID|
503758|NCT00373503|Drug|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
503759|NCT00373503|Drug|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
503760|NCT00373503|Drug|Marijuana|marijuana intoxication, withdrawal and relapse assessed
503761|NCT00373490|Drug|Vorinostat|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
503762|NCT00373490|Drug|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
503763|NCT00373477|Procedure|Generalist Care Manager vs Usual Care|
503764|NCT00373464|Drug|etoricoxib|
503765|NCT00373451|Drug|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute [maximum of 10 µg/minute] infusion for 12 hours)
503766|NCT00373451|Drug|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
503767|NCT00373451|Drug|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
503768|NCT00373438|Procedure|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
503769|NCT00373425|Drug|Erlotinib|150 mg tablet
503770|NCT00373425|Drug|Placebo|Placebo tablet
503771|NCT00373412|Biological|VCL CT02 pDNA vaccine|
503772|NCT00373412|Biological|Towne CMV vaccine|
503837|NCT00373022|Other|laboratory biomarker analysis|
503773|NCT00373399|Drug|Inactive Marijuana (0% THC)|Placebo marijuana was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
503774|NCT00373399|Drug|Low THC marijuana (1.8 %THC)|Active marijuana (1.8 % THC) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
503775|NCT00373399|Drug|High THC marijuana (3.9% THC)|Active marijuana (3.9%) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma THC. All marijuana cigarettes were administered in a double-blind fashion.
503776|NCT00373386|Drug|growth hormone|Growth Hormone treatment
503777|NCT00373373|Drug|Sorafenib|2 x 400 mg/d
503778|NCT00373373|Drug|Placebo|Chemotherapy + Placebo
503779|NCT00373360|Drug|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
503780|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
503781|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
503782|NCT00373334|Drug|placebo|placebo
503783|NCT00373295|Drug|Baclofen|Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
503784|NCT00373295|Drug|Marijuana|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
503785|NCT00373295|Drug|Placebo|
503786|NCT00373282|Drug|Triamcinolone acetonide|
503787|NCT00373256|Drug|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
503788|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
503789|NCT00373256|Drug|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
503790|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
503791|NCT00373243|Drug|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
503792|NCT00373230|Behavioral|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
503793|NCT00373217|Biological|MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine|Given intradermally or subcutaneously
503794|NCT00373217|Biological|tetanus toxoid helper peptide|Given intradermally or subcutaneously
503795|NCT00373217|Drug|carboplatin|Given IV
503796|NCT00373217|Drug|paclitaxel|Given IV
503797|NCT00373217|Procedure|conventional surgery|Patients undergo primary optimal cytoreductive surgery
503798|NCT00373204|Drug|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:~MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
503799|NCT00373191|Drug|chemotherapy|N/A- not dictated by study
503800|NCT00373191|Drug|endocrine therapy|N/A- not dictated by study
503801|NCT00373191|Genetic|DNA methylation analysis|laboratory analysis
503802|NCT00373191|Genetic|protein analysis|laboratory analysis
503803|NCT00373191|Other|laboratory biomarker analysis|laboratory analysis
503804|NCT00373191|Other|questionnaire administration|questionnaire
503805|NCT00373191|Procedure|adjuvant therapy|N/A- not dictated by study
503806|NCT00373191|Procedure|conventional surgery|N/A- not dictated by study
503807|NCT00373191|Radiation|radiation therapy|N/A- not dictated by study
503808|NCT00373178|Drug|rosiglitazone|
503809|NCT00373178|Drug|metformin|
503810|NCT00373178|Drug|Anti-diabetic medications|
503811|NCT00373165|Drug|Ganciclovir|
503812|NCT00373152|Procedure|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
503813|NCT00373152|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
503814|NCT00373152|Procedure|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
503815|NCT00373152|Radiation|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
503816|NCT00373126|Drug|transdermal nicotine patch|
503817|NCT00373113|Drug|Capecitabine|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
503818|NCT00373113|Drug|Sunitinib malate|37.5 mg daily, continuous dosing
503819|NCT00373100|Drug|Zinc acetate|
503820|NCT00373100|Drug|Placebo|Placebo
503821|NCT00373087|Drug|entacapone|entacapone
503822|NCT00373087|Drug|l dopa versus placebo|l dopa versus placebo
503823|NCT00373074|Other|Epidural Blood Patch|Use 15 cc of blood
503824|NCT00373074|Other|Epidural Blood Patch|Inject 20 cc of blood into epidural space
503825|NCT00373074|Other|Epidural Blood Patch|Inject 30 cc of autologous blood
503826|NCT00373061|Drug|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
503827|NCT00373048|Drug|mefloquine|tablet, once weekly
503828|NCT00373048|Drug|placebo|tablet, once weekly
503829|NCT00373035|Genetic|proteomic profiling|
503830|NCT00373035|Other|immunological diagnostic method|
503831|NCT00373035|Other|laboratory biomarker analysis|
503832|NCT00373035|Other|mass spectrometry|
503833|NCT00373035|Procedure|biopsy|
503834|NCT00373035|Procedure|ultrasound imaging|
503838|NCT00373022|Procedure|management of therapy complications|
503839|NCT00373022|Procedure|psychosocial assessment and care|
503840|NCT00373022|Procedure|quality-of-life assessment|
503841|NCT00373009|Behavioral|Traditional Army training|As usual training for Soldiers
503842|NCT00373009|Behavioral|Core stabilization exercise only|Core stabilization exercise
503843|NCT00373009|Behavioral|Psychosocial education class only|Psychosocial education class
503844|NCT00373009|Behavioral|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
503845|NCT00372996|Drug|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
503846|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day.
503847|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
503848|NCT00372996|Drug|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
503849|NCT00372983|Drug|NOV-205|
503850|NCT00372970|Drug|Botulinum toxin A|200 U given by injection into the pylorus.
503851|NCT00372970|Drug|Placebo|saline injection into pylorus.
503852|NCT00372957|Drug|GW823093 15mg|White opaque capsule containing 15mg of GW823093 as free base
503853|NCT00372957|Drug|GW823093 placebo capsule|Matching placebo of GW823093 capsule or 15mg capsule
503854|NCT00372957|Drug|GW823093 30mg|White opaque capsule containing 15mg of GW823093 as free base
503855|NCT00372944|Drug|AZD6244|oral capsule
503856|NCT00372944|Drug|capecitabine|oral tablet
503857|NCT00372931|Drug|AL-37807|
503858|NCT00372918|Procedure|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
503859|NCT00372905|Drug|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
503860|NCT00372905|Drug|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
503861|NCT00372905|Drug|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
503862|NCT00372892|Drug|Rituximab|375mg/m2 per week for 4 consecutive weeks
503863|NCT00372892|Drug|Placebo|Saline IV placebo once per week for 4 consecutive weeks
503864|NCT00372879|Dietary Supplement|Vitamin E|Vitamin E 800IU bid
503865|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
503866|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
503867|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
503868|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
503869|NCT00372840|Other|educational intervention|
503870|NCT00372840|Procedure|psychosocial assessment and care|
503871|NCT00372840|Procedure|quality-of-life assessment|
503872|NCT00372827|Drug|Brinzolamide 1% added to Travoprost 0.004%|
503873|NCT00372814|Behavioral|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
503874|NCT00372814|Behavioral|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
503875|NCT00372801|Drug|Ibuprofen|
503876|NCT00372788|Drug|AZD6244|oral vial
503877|NCT00372788|Drug|Pemetrexed|oral
503878|NCT00372775|Drug|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
503879|NCT00372762|Drug|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
503880|NCT00372762|Drug|Bumetanide|Equivalent dose to pre-existing furosemide will be used
503881|NCT00372762|Drug|furosemide|20mg to 80mg orally once or twice daily
503882|NCT00372762|Drug|bumetanide|0.5mg to 2mg orally once or twice daily
503883|NCT00372749|Behavioral|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
503884|NCT00372736|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
503885|NCT00372736|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
503886|NCT00372736|Genetic|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs > 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs > 5 x ULN1
504712|NCT00365768|Other|Placebo|Administered orally twice daily for 21 days
503887|NCT00372736|Genetic|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
503888|NCT00372736|Other|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
503889|NCT00372736|Other|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
503890|NCT00372736|Other|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
503891|NCT00372736|Other|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
503892|NCT00372723|Drug|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
503893|NCT00372710|Drug|Zoledronic acid|
503894|NCT00372697|Drug|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
503895|NCT00372684|Genetic|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
503896|NCT00372684|Genetic|with uncomplicated malaria|with uncomplicated malaria
503897|NCT00372671|Behavioral|Survey|
503898|NCT00372671|Behavioral|Survey and videotape|
503899|NCT00372658|Drug|1% Lidocaine intracervical injection|
503900|NCT00372645|Dietary Supplement|Folic acid (supplement)|200 µg folate per day from supplemental folic acid
503901|NCT00372645|Dietary Supplement|Metafolin (supplement)|200 µg folate per day from supplemental Metafolin®
503902|NCT00372645|Drug|Placebo|Placebo
503903|NCT00372645|Other|Folate rich foods|200 µg folate per day from folate-rich foods
503904|NCT00372632|Drug|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
503905|NCT00372632|Drug|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
503906|NCT00372619|Drug|clofarabine|Given IV for 5 days
503907|NCT00372619|Drug|cytarabine|Given IV
503908|NCT00372619|Drug|methotrexate|Given intrathecally or IT age based dosage
503909|NCT00372619|Other|laboratory biomarker analysis|
503910|NCT00372606|Behavioral|Online MiDieta Diet and Weight Management Program for Hispanics|
503911|NCT00372593|Drug|asparaginase|Given intramuscularly
503912|NCT00372593|Drug|cytarabine|Given IV
503913|NCT00372593|Drug|daunorubicin hydrochloride|Given IV over 6 hours
503914|NCT00372593|Drug|etoposide|Given IV over 1-4 hours
503915|NCT00372593|Drug|gemtuzumab ozogamicin|Given IV over 2 hours
503916|NCT00372593|Drug|mitoxantrone hydrochloride|Given IV over 1 hour
503917|NCT00372580|Procedure|blood test|
503918|NCT00372567|Drug|sunitinib malate|37.5 mg daily
503919|NCT00372567|Drug|imatinib mesylate|800mg daily
503920|NCT00372541|Drug|ceftriaxone|
503921|NCT00372528|Drug|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
503922|NCT00372515|Drug|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
503923|NCT00372502|Procedure|Modified EGDT|Early goal directed therapy with lactate clearance
503924|NCT00372502|Procedure|Standard EGDT|Early goal directed therapy
503925|NCT00372489|Drug|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
503926|NCT00372476|Drug|Imatinib and Vinorelbine|
503927|NCT00372463|Behavioral|6-week Online Diabetes Self-Management Educational Program|
503928|NCT00372450|Procedure|management of therapy complications|
503929|NCT00372450|Procedure|quality-of-life assessment|
503930|NCT00372437|Drug|MGCD0103|MGCD0103 as an oral dose three times per week.
503931|NCT00372437|Drug|Gemcitabine|Gemcitabine 1000mg/m<2> intravenously days 1, 8, 15 of a 28 day cycle.
503932|NCT00372424|Drug|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
503933|NCT00372424|Drug|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
503934|NCT00372424|Drug|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
503935|NCT00372411|Device|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
503993|NCT00371865|Behavioral|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
503936|NCT00372411|Other|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
503937|NCT00372411|Other|Usual Care|The usual chronic stroke care as delivered at each participating medical center
503938|NCT00372385|Drug|Ribavirin|tablet
503939|NCT00372385|Drug|Pegylated Interferon Alfa 2a|Solution for injection
503940|NCT00372385|Drug|Placebo|tablet
503941|NCT00372385|Drug|Telaprevir|tablet
503942|NCT00372372|Drug|risedronate|
503943|NCT00372346|Procedure|Transplantation of autologous endothelial progenitor cells|
503944|NCT00372333|Drug|IDEA-033|
503945|NCT00372320|Genetic|Gene Transfer|
503946|NCT00372320|Drug|AdhAQP1|
503947|NCT00372307|Drug|Application of pimecrolimus|
503948|NCT00372294|Drug|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
503949|NCT00372294|Drug|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
503950|NCT00372281|Drug|Cliavist|Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
503951|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
503952|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
503953|NCT00372255|Biological|Influsplit SSW® 2005/2006|Study influenza vaccine was administered intramuscularly in the non-dominant arm
503954|NCT00372242|Behavioral|Prospective Longitudinal Interventional Stury|
503955|NCT00372229|Drug|Pre-emptive therapy|As prescribed
503956|NCT00372229|Drug|valganciclovir [Valcyte]|900mg po for 100 days
503957|NCT00372216|Drug|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
503958|NCT00372203|Procedure|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
503959|NCT00372190|Device|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
503960|NCT00372190|Procedure|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
503961|NCT00372177|Radiation|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
503962|NCT00372164|Procedure|American Society of Interventional Pain Physician Guidelines|
503963|NCT00372151|Dietary Supplement|L-Theanine|400 mg/day, caps.
503964|NCT00372151|Other|Placebo|caps.
503965|NCT00372138|Procedure|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
503966|NCT00372125|Drug|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
503967|NCT00372112|Drug|GW642444|GW642444H
503968|NCT00372112|Other|Placebo|Placebo administered twice daily
503969|NCT00372099|Drug|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
503970|NCT00372086|Drug|Rosiglitazone|
503971|NCT00372073|Drug|seliciclib|1200 mg bid x 3 days every 2 weeks
503972|NCT00372073|Drug|placebo|1200 mg bid x 3 days every 2 weeks
503973|NCT00372060|Drug|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
503974|NCT00372060|Drug|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
503975|NCT00372060|Drug|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
503976|NCT00372060|Drug|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
503977|NCT00372047|Device|multiphoton laser imaging|
503978|NCT00372034|Device|Temporary Collagen Inserts|
503979|NCT00372021|Procedure|optic nerve neurotomy|
503980|NCT00372008|Drug|Testosterone|
503981|NCT00371995|Drug|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.~Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
503982|NCT00371982|Drug|Fish oil (Maxepa)|
503983|NCT00371969|Behavioral|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
503984|NCT00371969|Behavioral|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
503985|NCT00371956|Drug|raloxifene|60mg/day
503986|NCT00371956|Drug|placebo|tab 1 daily
503987|NCT00371943|Procedure|band ligation|
503988|NCT00371930|Procedure|application of a dye suspension followed by a laser intervention|
503989|NCT00371904|Drug|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
503990|NCT00371904|Drug|Standard Care|Standard care
503991|NCT00371891|Procedure|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
503992|NCT00371878|Biological|7-valent pneumococcal conjugate vaccine (Prevnar)|
504713|NCT00365755|Drug|carboplatin|
503994|NCT00371865|Behavioral|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
503995|NCT00371852|Drug|lactoserum|
503996|NCT00371839|Procedure|Audiological Evaluation|Tests of hearing, cognition, and speech perception
503997|NCT00371826|Drug|Everolimus (RAD001)|
503998|NCT00371826|Drug|Cyclosporine (Calcineurin Inhibitor (CNI))|
503999|NCT00371826|Drug|Methylprednisone/prednisone|
504000|NCT00371826|Drug|Mycophenolate sodium (MPA)|
504001|NCT00371813|Drug|Varenicline tartrate|
504002|NCT00371813|Drug|Placebo|
504003|NCT00371800|Drug|cinnamon|
504004|NCT00371787|Device|Soft contact lens|Soft contact lens
504005|NCT00371761|Biological|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
504006|NCT00371761|Drug|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
504007|NCT00371748|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
504008|NCT00371748|Device|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
504009|NCT00371748|Device|Express2|Coronary Stent System
504010|NCT00371735|Drug|chlorproguanil-dapsone-artesunate|
504011|NCT00371735|Drug|chlorproguanil-dapsone|
504012|NCT00371722|Procedure|Appendectomy|
504013|NCT00371709|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
504014|NCT00371709|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
504015|NCT00371696|Drug|diclofenac|
504016|NCT00371696|Drug|paracetamol|
504017|NCT00371696|Device|heat retaining knee support|
504018|NCT00371696|Device|standard knee support|
504019|NCT00371683|Drug|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
504020|NCT00371683|Drug|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
504021|NCT00371670|Drug|balicatib (AAE581)|
504022|NCT00371644|Behavioral|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
504023|NCT00371644|Behavioral|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
504024|NCT00371631|Biological|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
504025|NCT00371618|Procedure|Fluoroscopy|
504026|NCT00371592|Drug|Acyclovir|800 mg tablet taken orally twice daily
504027|NCT00371592|Drug|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
504028|NCT00371579|Drug|rosuvastatin|
504029|NCT00371566|Drug|Lapatinib oral tablets|
504030|NCT00371566|Drug|Placebo|
504031|NCT00371553|Drug|SU011248 (Sunitinib)|
504032|NCT00371540|Other|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
504033|NCT00371527|Drug|ipratropium|
504034|NCT00371501|Drug|Rosuvastatin|10mg/day
504035|NCT00371501|Drug|placebo|one tablet/day
504036|NCT00371501|Drug|aspirin|80mg/day
504037|NCT00371501|Drug|placebo|placebo
504038|NCT00371488|Drug|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
504039|NCT00371475|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
504040|NCT00371475|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
504041|NCT00371462|Behavioral|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
504042|NCT00371462|Behavioral|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
504043|NCT00371436|Procedure|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
504044|NCT00371436|Procedure|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
504045|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
504046|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
504047|NCT00371410|Procedure|vitrectomy|
504048|NCT00371410|Drug|intravitreal triamcinolone acetonide|
504049|NCT00371410|Procedure|macular focal laser photocoagulation|
504105|NCT00370916|Behavioral|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
504106|NCT00370916|Behavioral|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
504714|NCT00365755|Drug|cisplatin|
504715|NCT00365755|Drug|cyclophosphamide|
504050|NCT00371397|Behavioral|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
504051|NCT00371397|Behavioral|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
504052|NCT00371384|Procedure|massage|UP to 10 massages over 10 weeks
504053|NCT00371371|Procedure|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
504054|NCT00371371|Procedure|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
504055|NCT00371371|Procedure|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
504056|NCT00371345|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average <6 months)
504057|NCT00371345|Drug|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average <6 months)
504058|NCT00371332|Drug|Minocycline HCL Microspheres|
504059|NCT00371319|Drug|tacrolimus|0.06-0.1 mg/kg/day
504060|NCT00371319|Drug|mycophenolate mofetil|2-3 gm/day
504061|NCT00371306|Drug|Insulin versus glucovance (glyburide/metformin)|
504062|NCT00371293|Behavioral|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
504063|NCT00371293|Device|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
504064|NCT00371280|Procedure|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
504065|NCT00371267|Behavioral|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
504066|NCT00371267|Other|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
504067|NCT00371254|Drug|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg <6 months)
504068|NCT00371254|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg <6 months)
504069|NCT00371228|Procedure|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
504070|NCT00371215|Biological|rThrombin|1000 U/mL applied topically
504071|NCT00371202|Procedure|keratoplasty|
504072|NCT00371189|Drug|Placebo|Normal saline.
504073|NCT00371189|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
504074|NCT00371176|Behavioral|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
504075|NCT00371176|Drug|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
504076|NCT00371176|Other|Placebo pill|
504077|NCT00371150|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
504078|NCT00371137|Drug|Xyrem®|two doses
504079|NCT00371137|Drug|Placebo|Oral Solution
504080|NCT00371124|Drug|Atropine Eye drops|
504081|NCT00371111|Drug|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
504082|NCT00371111|Drug|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
504083|NCT00371098|Biological|Influenza vaccination: Influvac (SolvayPharma)|
504084|NCT00371098|Biological|placebo influenza vaccine|
504085|NCT00371085|Behavioral|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
504086|NCT00371072|Procedure|trabeculectomy with mitomycin-C|
504087|NCT00371059|Drug|Memantine|Memantine 10mg BD
504088|NCT00371059|Drug|Placebo|Placebo 10 mgs BD
504089|NCT00371046|Procedure|Transvaginal ultrasound cervical length|
504090|NCT00371046|Procedure|Cervicovaginal fetal fibronectin|
504091|NCT00371033|Drug|Pregabalin|dosage
504092|NCT00371033|Drug|Placebo|dosage
504093|NCT00371020|Drug|low molecular weight heparin, 5-FU|
504094|NCT00371007|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
504095|NCT00371007|Drug|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
504096|NCT00370994|Procedure|Caudal epidural injection|Caudal epidural injection with catheterization
504097|NCT00370994|Procedure|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
504098|NCT00370981|Drug|pagoclone|
504099|NCT00370968|Drug|Zinc sulphate|
504100|NCT00370955|Procedure|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
504101|NCT00370942|Drug|GW823093C A|A=45 mg
504102|NCT00370942|Drug|GW823093C B|B=30 mg
504103|NCT00370942|Drug|GW823093C C|C=25 mg
504104|NCT00370929|Behavioral|Meditation|
504150|NCT00370539|Drug|verteporfin, bevacizumab, triamcinolone acetonide|
504716|NCT00365755|Drug|etoposide|
504107|NCT00370890|Drug|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
504108|NCT00370877|Drug|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
504109|NCT00370877|Procedure|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
504110|NCT00370864|Biological|H5N1 pandemic influenza vaccine|
504111|NCT00370851|Drug|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
504112|NCT00370838|Drug|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
504113|NCT00370838|Drug|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
504114|NCT00370825|Drug|Combination therapy with AmBisome and miltefosine|
504115|NCT00370812|Procedure|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
504116|NCT00370799|Drug|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
504117|NCT00370799|Drug|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
504118|NCT00370799|Drug|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
504119|NCT00370799|Drug|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
504120|NCT00370786|Drug|bevacizumab|
504121|NCT00370773|Device|Precision Spinal Cord Stimulation System|
504122|NCT00370760|Drug|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
504123|NCT00370760|Drug|placebo|
504124|NCT00370747|Drug|Ecabet|ophthalmic solution 2.83%
504125|NCT00370747|Drug|Ecabet|ophthalmic solution 3.70%
504126|NCT00370747|Drug|Placebo|
504127|NCT00370734|Drug|Botulinum toxin A injection|
504128|NCT00370721|Drug|bevacizumab|
504129|NCT00370708|Procedure|Oral Intake following admittance to the postpartum ward|
504130|NCT00370695|Device|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
504131|NCT00370682|Biological|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
504132|NCT00370682|Biological|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
504133|NCT00370682|Other|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
504134|NCT00370669|Drug|bevacizumab|
504135|NCT00370669|Drug|triamcinolone acetonide|
504136|NCT00370656|Drug|Pregabalin|capsule, 150mg bd, 300mg bd
504137|NCT00370656|Drug|Duloxetine|Capsule, 60mg on, 60mg bd
504138|NCT00370656|Drug|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
504139|NCT00370643|Drug|human regular insulin|
504140|NCT00370630|Drug|Avastin (Bevacizumab) and triamcinolone|
504141|NCT00370617|Drug|metformin|
504142|NCT00370604|Device|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
504143|NCT00370604|Device|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
504144|NCT00370591|Drug|Salmeterol/fluticasone propionate and fluticasone propionate|
504145|NCT00370578|Device|repeated thrombus aspiration during primary PCI|
504146|NCT00370565|Drug|Inhaled Human Insulin|
504147|NCT00370552|Drug|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
504148|NCT00370552|Drug|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
504149|NCT00370552|Drug|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
504151|NCT00370526|Procedure|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
504152|NCT00370513|Drug|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
504153|NCT00370500|Drug|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
504154|NCT00370474|Device|Bi-ventricular lead placement|
504155|NCT00370448|Behavioral|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
504156|NCT00370435|Drug|GW274150|
504157|NCT00370422|Drug|Triamcinolone, Bevacizumab|
504158|NCT00370409|Procedure|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
504159|NCT00370396|Biological|Synflorix|1 dose injected IM in the right thigh or deltoid.
504160|NCT00370396|Biological|Prevenar|1 dose injected IM in the right thigh or deltoid.
504161|NCT00370396|Biological|Infanrix hexa|1 dose injected IM in the right thigh or deltoid.
504162|NCT00370383|Drug|Erlotinib|erlotinib 150 mg/day once daily
504163|NCT00370383|Drug|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).~Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
504164|NCT00370370|Drug|bevacizumab|Injection of intravitreal bevacizumab
504165|NCT00370370|Drug|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
504166|NCT00370357|Drug|3% w/w SPL7013 Gel (VivaGel™)|
504167|NCT00370344|Procedure|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
504168|NCT00370344|Procedure|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
504169|NCT00370331|Drug|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
504170|NCT00370331|Drug|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
504171|NCT00370318|Biological|10 valent pneumococcal conjugate vaccine|
504172|NCT00370318|Biological|Infanrix Hexa|
504173|NCT00370318|Biological|Rotarix|
504174|NCT00370318|Drug|Paracetamol|
504175|NCT00370305|Drug|rosiglitazone|89 mg BID for 8 weeks, orally
504176|NCT00370292|Drug|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
504177|NCT00370292|Drug|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
504178|NCT00370279|Procedure|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
504179|NCT00370266|Drug|Triamcinolone|
504180|NCT00370253|Drug|Terlipressin|1mg/4 h per day
504181|NCT00370253|Drug|Noradrenalin|0,1 mcg/kg/min
504182|NCT00370240|Drug|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
504183|NCT00370240|Other|placebo|The PCB group received saline solution in equal volume.
504184|NCT00370227|Biological|10 valent pneumococcal conjugate (vaccine)|
504185|NCT00370201|Drug|colchicine|
504186|NCT00370188|Drug|Topiramate|
504187|NCT00370162|Drug|lactoserum|
504188|NCT00370149|Device|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
504189|NCT00370149|Device|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
504190|NCT00370136|Drug|ultrasound contrast|
504191|NCT00370110|Drug|Itopride 100 mg|100 mg three times daily
504192|NCT00370110|Other|Placebo|
504193|NCT00370110|Drug|Itopride 200 mg|200 mg three times daily
504194|NCT00370097|Drug|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
504195|NCT00370097|Drug|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
504196|NCT00370084|Drug|Itopride|oral, three times daily
504197|NCT00370084|Other|Placebo|oral, three times daily
504198|NCT00370071|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
504199|NCT00370058|Procedure|ECT treatment|
504200|NCT00370045|Drug|Bivalirudin with and without eptifibatide|
504201|NCT00370032|Drug|alosetron|
504202|NCT00370019|Drug|Estradiol/Medroxyprogesterone acetate|
504203|NCT00370006|Biological|Towne CMV vaccine|
504204|NCT00369993|Drug|fluticasone propionate/salmeterol|
504205|NCT00369967|Drug|NuvaRing|Initiation of NuvaRing for contraception
504206|NCT00369954|Drug|carboplatin|
504207|NCT00369954|Drug|gemcitabine hydrochloride|
504208|NCT00369941|Drug|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
504209|NCT00369941|Drug|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
504417|NCT00368342|Drug|Erythromycin, Azithromycin , Clarithromycin|
504210|NCT00369941|Drug|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
504211|NCT00369941|Drug|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
504212|NCT00369941|Drug|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
504213|NCT00369928|Drug|PG-760564|100 mg BID, of oral PG-760564
504214|NCT00369928|Drug|Placebo dose|placebo, BID, oral for 12 weeks
504215|NCT00369928|Drug|PG-760564|25 mg BID, of oral PG-760564
504216|NCT00369915|Drug|Scopolamine|
504217|NCT00369915|Drug|Scopolamine|
504218|NCT00369902|Procedure|acupuncture|
504219|NCT00369889|Drug|bevacizumab|iv every 21 days
504220|NCT00369889|Drug|Erlotinib|oral daily
504221|NCT00369863|Drug|Triamcinolone acetonide|
504222|NCT00369850|Other|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
504223|NCT00369850|Procedure|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
504224|NCT00369850|Procedure|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
504225|NCT00369837|Drug|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
504226|NCT00369824|Biological|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
504227|NCT00369824|Biological|Menactra TM|One dose of vaccine administered intramuscularly
504228|NCT00369824|Biological|Boostrix TM|One dose of vaccine administered intramuscularly
504229|NCT00369811|Drug|Oxycodone, fentanyl|
504230|NCT00369798|Procedure|PET scan|
504231|NCT00369798|Drug|Rolipram|
504232|NCT00369785|Drug|donepezil hydrochloride|Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
504233|NCT00369785|Drug|Placebo|Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
504234|NCT00369772|Drug|darbepoetin alfa|
504235|NCT00369759|Other|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
504236|NCT00369746|Drug|citalopram|tablets, 60 mg maximum, daily, 12 weeks
504237|NCT00369733|Drug|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
504238|NCT00369720|Procedure|Titration of oxygen in delivery room|
504239|NCT00369707|Drug|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
504240|NCT00369707|Drug|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
504241|NCT00369694|Drug|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
504242|NCT00369694|Drug|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
504243|NCT00369681|Drug|Bleomycin|
504244|NCT00369681|Biological|Rituximab|
504245|NCT00369681|Drug|Dacarbazine|
504246|NCT00369681|Drug|Doxorubicin|
504247|NCT00369681|Drug|Vinblastine|
504248|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
504249|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
504250|NCT00369668|Behavioral|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
504251|NCT00369655|Biological|ziv-aflibercept|
504252|NCT00369642|Behavioral|Cognitive-behavioral therapy|
504253|NCT00369629|Drug|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m^2.
504254|NCT00369629|Drug|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m^2.
504255|NCT00369616|Biological|CYT002-NicQb|
504256|NCT00369603|Drug|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
504257|NCT00369603|Drug|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
504258|NCT00369590|Biological|ziv-aflibercept|Given IV
504259|NCT00369590|Other|pharmacological study|correlative studies
504260|NCT00369590|Other|laboratory biomarker analysis|correlative studies
504261|NCT00369577|Drug|Inhaled Placebo|Inhaled Placebo, single dose
504262|NCT00369577|Drug|Inhaled Loxapine 5 mg|Inhaled Staccato Loxapine 5 mg, single dose
504263|NCT00369577|Drug|Inhaled Loxapine 10 mg|Inhaled Staccato Loxapine 10 mg, single dose
504264|NCT00369564|Drug|glutamic acid|Given orally 3 times daily
504265|NCT00369564|Other|placebo|Given orally 3 times daily
504266|NCT00369551|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
504267|NCT00369551|Drug|paclitaxel|Given IV
504268|NCT00369551|Biological|bevacizumab|Given IV
504269|NCT00369551|Drug|carboplatin|Given IV
504270|NCT00369551|Other|laboratory biomarker analysis|Correlative studies
504271|NCT00369538|Drug|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
504272|NCT00369538|Drug|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
504273|NCT00369512|Drug|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
504274|NCT00369499|Device|PFO Closure|
504275|NCT00369486|Procedure|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
504276|NCT00369486|Drug|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
504277|NCT00369486|Drug|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
504278|NCT00369486|Drug|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
504279|NCT00369486|Drug|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
504280|NCT00369473|Drug|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
504281|NCT00369473|Drug|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
504282|NCT00369460|Other|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
504283|NCT00369447|Procedure|External radiotherapy|Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
504284|NCT00369447|Biological|nimotuzumab|weekly dose until disease progression
504285|NCT00369434|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|
504286|NCT00369408|Drug|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
504287|NCT00369408|Drug|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
504288|NCT00369395|Drug|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
504289|NCT00369382|Drug|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
504290|NCT00369382|Drug|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
504291|NCT00369356|Drug|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
504292|NCT00369356|Device|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
504293|NCT00369356|Device|Bare metal coronary stent|Stenting with BMS only
504294|NCT00369343|Drug|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
504295|NCT00369343|Drug|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
504296|NCT00369330|Device|external electrical cardioversion|
504297|NCT00369317|Drug|asparaginase|Given IM
504298|NCT00369317|Drug|daunorubicin hydrochloride|Given IV
504299|NCT00369317|Drug|cytarabine|Given IV or IT
504300|NCT00369317|Drug|thioguanine|Given orally
504301|NCT00369317|Drug|etoposide|Given IV
504302|NCT00369317|Other|laboratory biomarker analysis|Correlative studies
504303|NCT00369304|Drug|pharmacokinetic (how the body absorbs and eliminates) interaction|
504304|NCT00369291|Biological|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
504305|NCT00369291|Biological|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
504306|NCT00369278|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
504307|NCT00369265|Drug|Lansoprazole|Lansoprazole 30mg twice daily
504308|NCT00369265|Dietary Supplement|Sugar pill|placebo twice daily
504309|NCT00369252|Drug|Nimotuzumab (TheraCIM h-R3)|
504310|NCT00369239|Drug|risperidone long acting injectable|
504311|NCT00369226|Drug|Bortezomib (Velcade)|Infusion for a total of 3 doses
504312|NCT00369226|Drug|Tacrolimus|Taken until Doctor determines it is not necessary any more
504313|NCT00369226|Drug|Methotrexate|Infusion for a total of 4 doses
504717|NCT00365755|Drug|melphalan|
504718|NCT00365755|Drug|vincristine sulfate|
504314|NCT00369226|Procedure|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
504315|NCT00369213|Device|Additional spermicidal lubricant to condoms|
504316|NCT00369200|Drug|AFP464|Given IV
504317|NCT00369200|Other|laboratory biomarker analysis|Correlative study
504318|NCT00369200|Other|pharmacological study|Correlative study
504319|NCT00369187|Drug|large protein molecule|
504320|NCT00369174|Drug|rosiglitazone maleate|Given orally
504321|NCT00369174|Other|laboratory biomarker analysis|Correlative studies
504322|NCT00369161|Drug|Everolimus (RAD001)|
504323|NCT00369161|Drug|Tacrolimus|
504324|NCT00369161|Drug|Basiliximab|
504325|NCT00369161|Drug|Corticosteroids|
504326|NCT00369148|Drug|nateglinide(drug) mitiglinide(drug)|
504327|NCT00369135|Procedure|combined intervention|
504328|NCT00369122|Biological|Bevacizumab|Given IV
504329|NCT00369122|Drug|Cisplatin|Given IV
504330|NCT00369122|Radiation|External Beam Radiation Therapy|Undergo EBRT
504331|NCT00369122|Radiation|Internal Radiation Therapy|Undergo brachytherapy
504332|NCT00369109|Other|biologic sample preservation procedure|
504333|NCT00369109|Other|immunohistochemistry staining method|
504334|NCT00369109|Other|laboratory biomarker analysis|
504335|NCT00369109|Procedure|biopsy|
504336|NCT00369096|Drug|bemiparin 3500 IU/day|
504337|NCT00369083|Procedure|Hospital at home treatment|
504338|NCT00369070|Biological|Bevacizumab|15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
504339|NCT00369070|Drug|AMG 706|subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
504340|NCT00369070|Drug|Paclitaxel|All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
504341|NCT00369070|Drug|Carboplatin|All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
504342|NCT00369044|Drug|prednisone|
504343|NCT00369031|Biological|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
504344|NCT00369031|Biological|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
504345|NCT00369031|Biological|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
504346|NCT00369018|Drug|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
504347|NCT00369005|Procedure|Red blood cell transfusion guidelines|
504348|NCT00368992|Biological|cetuximab|Given IV
504349|NCT00368992|Drug|paclitaxel|Given IV
504350|NCT00368992|Biological|bevacizumab|Given IV
504351|NCT00368979|Drug|Dutasteride|once daily
504352|NCT00368979|Drug|Placebo|once daily
504353|NCT00368966|Biological|13-valent Pneumococcal Conjugate Vaccine|
504354|NCT00368966|Biological|7-valent Pneumococcal Conjugate Vaccine|
504355|NCT00368953|Device|Yukon Choice stent system|coronary stent implantation
504356|NCT00368953|Device|Taxus Liberté stent system|coronary stent implantation
504357|NCT00368940|Behavioral|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
504358|NCT00368940|Behavioral|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
504359|NCT00368927|Drug|sulindac|Given orally
504360|NCT00368927|Other|placebo|Given orally
504361|NCT00368914|Drug|sirolimus|
504362|NCT00368914|Other|laboratory biomarker analysis|
504363|NCT00368914|Other|pharmacological study|
504364|NCT00368914|Procedure|biopsy|
504365|NCT00368901|Drug|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
504366|NCT00368888|Device|Urine collection bag for infants|
504367|NCT00368875|Drug|vorinostat|Given orally
504368|NCT00368875|Drug|paclitaxel|Given IV
504369|NCT00368875|Biological|bevacizumab|Given IV
504370|NCT00368862|Drug|Ebixa (memantine hydrochloride)|
504371|NCT00368862|Drug|Cipralex (escitalopram)|
504372|NCT00368849|Drug|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
504373|NCT00368849|Drug|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
504374|NCT00368836|Device|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
504375|NCT00368823|Device|Electronic point-of-care delivery system|
504376|NCT00368797|Drug|XRP0038 (NV1FGF)|
504418|NCT00368329|Drug|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg & 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
504419|NCT00368329|Drug|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
504420|NCT00368329|Drug|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
504421|NCT00368329|Drug|Carboplatin|AUC 2, based onCalvert formula IV infusion
504377|NCT00368771|Behavioral|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
504378|NCT00368771|Behavioral|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
504379|NCT00368771|Behavioral|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
504380|NCT00368758|Drug|Probiotic bacteria (Trevis R)|
504381|NCT00368745|Drug|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
504382|NCT00368745|Drug|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
504383|NCT00368719|Drug|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
504384|NCT00368706|Drug|solifenacin succinate|Oral
504385|NCT00368706|Drug|tolterodine|oral
504386|NCT00368693|Device|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
504387|NCT00368680|Device|Early Bubble CPAP|
504388|NCT00368654|Drug|Methotrexate|Initial dose 5 mg, then 15 mg per week
504389|NCT00368654|Drug|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
504390|NCT00368641|Drug|Extraneal|Periotneal Dialysis
504391|NCT00368628|Procedure|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
504392|NCT00368602|Drug|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
504393|NCT00368602|Other|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
504394|NCT00368589|Drug|atorvastatin|
504395|NCT00368576|Drug|SB 480848, tablets|
504396|NCT00368563|Drug|Helioblock SX|
504397|NCT00368550|Drug|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
504398|NCT00368550|Drug|Placebo|Placebo for 14-week treatment period
504399|NCT00368537|Drug|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
504400|NCT00368537|Drug|ampicillin-sulbactam|"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.~A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
504401|NCT00368524|Behavioral|contingency management and behavioral day treatment|
504402|NCT00368511|Procedure|Music Listening|Listen to music and posture measurements
504403|NCT00368498|Drug|teicoplanin|
504404|NCT00368485|Device|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
504405|NCT00368472|Drug|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
504406|NCT00368459|Drug|raloxifene|Raloxifene is a selective estrogen receptor modulator
504407|NCT00368459|Drug|Placebo|Identical appearing placebo
504408|NCT00368407|Device|308-nm excimer laser|
504409|NCT00368394|Drug|Insulin glulisine|
504410|NCT00368381|Drug|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
504411|NCT00368368|Drug|GK Activator (2)|100mg po
504412|NCT00368355|Drug|Ara-C|"day-8 through day-5~3 g/m2 q 12 hours"
504413|NCT00368355|Drug|Cyclophosphamide|"day-7 and day-6~45 mg/kg"
504414|NCT00368355|Biological|Campath-1H|"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"
504415|NCT00368355|Radiation|Total Body Irradiation|"day-4 through day-1~175 cGy x 2 at 24 cGy/min"
504416|NCT00368355|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
504422|NCT00368316|Biological|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
504423|NCT00368303|Drug|Paroxetine CR|
504424|NCT00368303|Drug|Paroxetine IR|
504425|NCT00368290|Drug|Modafinil|300mg a day for 8 weeks
504426|NCT00368290|Drug|placebo|placebo pills for 8 weeks
504427|NCT00368290|Behavioral|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
504428|NCT00368277|Drug|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
504429|NCT00368277|Drug|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
504430|NCT00368277|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
504431|NCT00368277|Drug|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
504432|NCT00368264|Drug|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
504433|NCT00368264|Drug|placebo|azathioprine (2 mg/kg) plus four placebo infusions
504434|NCT00368251|Other|Placebo|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg, 25 mg and 50 mg~Route of Administration: Oral use"
504435|NCT00368251|Drug|BRV 2.5 mg|"Pharmaceutical Form: Tablet~Concentration: 2.5 mg~Route of Administration: Oral use"
504436|NCT00368251|Drug|BRV 25 mg|"Pharmaceutical Form: Tablet~Concentration: 25 mg~Route of Administration: Oral use"
504437|NCT00368251|Drug|BRV 50 mg|"Pharmaceutical Form: Tablet~Concentration: 50 mg~Route of Administration: Oral use"
504438|NCT00368238|Drug|Recombinant human erythropoietin alfa (drug)|
504439|NCT00368238|Drug|Aspirin (drug)|
504440|NCT00368238|Drug|Clopidogrel (drug)|
504441|NCT00368212|Behavioral|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
504442|NCT00368212|Behavioral|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
504443|NCT00368186|Biological|Pneumo 23|
504444|NCT00368173|Drug|rhIGF-I/rhIGFBP-3|
504445|NCT00368160|Drug|Eszopiclone|eszopiclone 3 mg
504446|NCT00368160|Drug|Placebo|Placebo tablet
504447|NCT00368134|Drug|Vildagliptin|
504448|NCT00368121|Drug|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:~• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion~Dexamethasone dosing schedule:~• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.~Mode of administration: orally"
504449|NCT00368108|Drug|2 mg perampanel|2 mg perampanel
504450|NCT00368108|Drug|4 mg perampanel|4 mg perampanel
504451|NCT00368108|Drug|placebo comparator|placebo comparator
504452|NCT00368095|Behavioral|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
504453|NCT00368082|Biological|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Group One:~Day 0 2 x 10^7 cells/m2 Day 14 2 x 10^7 cells/m2~Group Two:~Day 0 6 x 10^7 cells/m2 Day 14 6 x 10^7 cells/m2~Group Three:~Day 0 1.5 x 10^8 cells/m2 Day 14 1.5 x 10^8 cells/m2"
504454|NCT00368069|Drug|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
504455|NCT00368069|Drug|Placebo|oral tablets, 2 tablets once daily
504456|NCT00368056|Drug|Eszopiclone|eszopiclone 3 mg
504457|NCT00368056|Drug|Placebo|Placebo tablet
504458|NCT00368030|Drug|Eszopiclone|Eszopiclone 3 mg QD
504459|NCT00368030|Other|Placebo|Placebo tablet
504460|NCT00368017|Drug|pioglitazone|30 mg once a day for 12 weeks
504461|NCT00368017|Drug|placebo|1 pill once a day for 12 weeks
504462|NCT00367991|Drug|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
504463|NCT00367991|Drug|Placebo|Normal saline to match active drug (rHuEpo)
504464|NCT00367978|Drug|Amlodipine/benazepril|
504465|NCT00367965|Drug|Eszopiclone|eszopiclone 3 mg
504466|NCT00367965|Drug|placebo|placebo tablet
504467|NCT00367952|Drug|apricitabine|800mg apricitabine twice daily orally for 96 weeks
504468|NCT00367939|Drug|valsartan + amlodipine|
504469|NCT00367926|Drug|American ginseng root / polysaccharides|
504470|NCT00367913|Drug|Addition of clarithromycin to rifampicin and ethambutol|
504471|NCT00367913|Drug|Addition of Ciprofloxacin to rifampicin and ethambutol|
504472|NCT00367913|Biological|Vaccination with M.vaccae|
504473|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
504474|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
504475|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
504476|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
504477|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
504478|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
504479|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
504480|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
504481|NCT00367874|Drug|Buprenorphine|
504482|NCT00367874|Drug|Valproate|
504483|NCT00367861|Drug|interruption of Glivec®|interruption of Glivec®
504484|NCT00367835|Drug|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
504485|NCT00367835|Drug|Placebo|Placebo
504486|NCT00367822|Drug|Lisuride|
504487|NCT00367822|Drug|Ropinirole|
504488|NCT00367822|Drug|Placebo|
504489|NCT00367809|Behavioral|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
504490|NCT00367809|Behavioral|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
504491|NCT00367809|Behavioral|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
504492|NCT00367783|Drug|CP-741,952|
504493|NCT00367770|Drug|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
504494|NCT00367757|Procedure|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
504495|NCT00367757|Procedure|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
504496|NCT00367757|Procedure|Combined approach for AF ablation|Combined trigger and substrate based approach
504497|NCT00367744|Drug|Rosiglitazone|Rosiglitazone 4mg BID
504498|NCT00367744|Drug|Placebo|Placebo for rosiglitazone
504499|NCT00367731|Drug|Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
504500|NCT00367718|Drug|Velcade|velcade 1.3 mg/m2 given at the day 1,4,8,and 11 every 21 days schedule.
504501|NCT00367705|Dietary Supplement|VSL#3®|1-2 sachets/day per os, 6 months
504502|NCT00367705|Dietary Supplement|Placebo|1-2 sachets/day per os, 6 months
504503|NCT00367692|Drug|PSI-697|
504504|NCT00367679|Drug|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
504505|NCT00367666|Device|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
504506|NCT00367653|Drug|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
504507|NCT00367653|Drug|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg [three 250 mg capsules]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
504508|NCT00367640|Drug|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
504509|NCT00367640|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
504510|NCT00367640|Drug|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
504511|NCT00367640|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
504512|NCT00367627|Drug|Albendazole|
504513|NCT00367614|Drug|pantoprazole|
504514|NCT00367601|Drug|Erlotinib|Erlotinib 150 mg qd days 1-21
504515|NCT00367601|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
504516|NCT00367588|Behavioral|Low bacterial diet|
504517|NCT00367575|Procedure|Internet personalized alcohol feedback (PAF)|
504518|NCT00367562|Drug|ENALAPRIL VALSARTAN METHYLPREDNISONE|
504519|NCT00367549|Dietary Supplement|Energy-containing soft drink|Commercial energy/sports drink
504520|NCT00367536|Drug|bazedoxifene/conjugated estrogens combination tablet|
504521|NCT00367497|Drug|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
504522|NCT00367484|Biological|Rebif® (clone 484-39)|s.c. administered Rebif®
504523|NCT00367471|Drug|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
504524|NCT00367471|Drug|carboplatin|An alkylating agent used in the treatment of ome cancers
504525|NCT00367471|Drug|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
504526|NCT00367471|Drug|paclitaxel|A mitotic inhibitor used in cancer treatment
504527|NCT00367458|Drug|Atorvastatin|80 mg atorvastatin oral daily
504528|NCT00367445|Drug|Inhaled Human Insulin (Exubera)|
504529|NCT00367445|Drug|Insulin Glargine (Lantus)|
504530|NCT00367432|Drug|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
504531|NCT00367419|Drug|Erythromycin|
504532|NCT00367406|Device|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
504533|NCT00367393|Drug|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
504534|NCT00367380|Other|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
504535|NCT00367380|Other|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
504536|NCT00367380|Other|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
504537|NCT00367367|Procedure|Hysteroscopy and Curettage|
504538|NCT00367341|Drug|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
504539|NCT00367341|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
504589|NCT00366899|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
504719|NCT00365755|Procedure|autologous bone marrow transplantation|
504540|NCT00367328|Device|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
504541|NCT00367315|Drug|Lumiracoxib|
504542|NCT00367302|Drug|buprenorphine|maintenance
504543|NCT00367302|Drug|methadone|maintenance
504544|NCT00367276|Drug|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
504545|NCT00367263|Drug|Alvesco (Ciclesonide) 160 ug/day|
504546|NCT00367250|Drug|Cetuximab|weekly i.v.
504547|NCT00367250|Drug|Trastuzumab|weekly i.v.
504548|NCT00367237|Drug|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
504549|NCT00367237|Drug|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
504550|NCT00367224|Procedure|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
504551|NCT00367224|Procedure|Skin biopsies|4 mm punch biopsies of the skin
504552|NCT00367211|Drug|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
504553|NCT00367211|Drug|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
504554|NCT00367198|Dietary Supplement|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
504555|NCT00367185|Drug|Thalidomide|
504556|NCT00367172|Behavioral|Directly Administered Antiretroviral Therapy|
504557|NCT00367159|Procedure|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
504558|NCT00367146|Drug|MMF|
504559|NCT00367133|Procedure|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
504560|NCT00367133|Drug|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
504561|NCT00367133|Drug|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
504562|NCT00367120|Drug|Azithromycin Extended Release|
504563|NCT00367120|Drug|Amoxicillin/Clavulanate|
504564|NCT00367094|Drug|Benazepril plus hydrochlorothiazide|
504565|NCT00367081|Drug|TMX-SMX (Bactrim(R))|
504566|NCT00367081|Drug|Pyrimethamine plus Sulfadiazine plus leucoverin|
504567|NCT00367068|Drug|baclofen, intrathecal|
504568|NCT00367068|Device|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
504569|NCT00367055|Drug|rosiglitazone-metformin|
504570|NCT00367055|Drug|Metformin|
504571|NCT00367055|Drug|metformin+ gliclazide|
504572|NCT00367042|Device|Scalpel for tissue scoring|During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
504573|NCT00367042|Device|Surgical marker for tissue marking|You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
504574|NCT00367029|Behavioral|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.~Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
504575|NCT00367016|Drug|Xolair (Omalizumab)|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
504576|NCT00367016|Drug|Placebo|Placebo
504577|NCT00367003|Device|Deep Brain Stimulator, implantable|Deep Brain Stimulator
504578|NCT00366990|Behavioral|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics with a focus on lowering sodium intake.
504579|NCT00366990|Behavioral|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics.
504580|NCT00366977|Behavioral|Multi-session telephone counseling|
504581|NCT00366977|Drug|NRT patches|
504582|NCT00366964|Device|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
504583|NCT00366964|Device|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
504584|NCT00366951|Procedure|Foley catheter only|
504585|NCT00366951|Procedure|Extraamniotic saline infusion|
504586|NCT00366938|Drug|Lumiracoxib|
504587|NCT00366925|Device|Adacolumn®|
504588|NCT00366912|Device|non-invasive ventilation|
504590|NCT00366899|Biological|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
504591|NCT00366873|Procedure|Calcium absorption|formula with or without prebiotics
504592|NCT00366860|Behavioral|Soy bread|
504593|NCT00366834|Drug|Casopitant (GW679769) oral tablets|
504594|NCT00366834|Drug|Casopitant (GW679769) intravenous|
504595|NCT00366834|Drug|Dexamethasone intravenous|
504596|NCT00366834|Drug|Ondansetron oral tablets|
504597|NCT00366834|Drug|placebo|casopitant placebo
504598|NCT00366808|Procedure|LASIK surgery|
504599|NCT00366795|Drug|Satavaptan|oral administration once daily
504600|NCT00366795|Drug|placebo|oral administration once daily
504601|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^6 TCID50
504602|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^5 TCID50
504603|NCT00366782|Biological|Placebo|Placebo for rB/HPIV3 vaccine
504604|NCT00366769|Device|Wavefront-guided LASIK using CustomVue platform|
504605|NCT00366743|Procedure|Conventional LASIK|
504606|NCT00366743|Procedure|Wavefront-guided LASIK|
504607|NCT00366730|Drug|Nitazoxanide|
504608|NCT00366704|Drug|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
504609|NCT00366704|Drug|risperidone|4mg, QD, 8 week treatment
504610|NCT00366691|Drug|Acular LS|
504611|NCT00366691|Drug|Lotemax|
504612|NCT00366678|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
504613|NCT00366678|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
504614|NCT00366678|Drug|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
504615|NCT00366665|Device|Legacy 20000|
504616|NCT00366665|Device|Infinit system|
504617|NCT00366652|Drug|desvenlafaxine SR|
504618|NCT00366652|Drug|desipramine|
504619|NCT00366652|Drug|duloxetine|
504620|NCT00366639|Other|Acute Decompensated Heart Failure|Treatment & outcomes during hospital admission for Acute DHF
504621|NCT00366626|Drug|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
504622|NCT00366626|Drug|Placebo|Placebo for 7 days matched to Naltrexone
504623|NCT00366613|Procedure|Cataract surgery with Perfect Capsule and Sodium Chloride|
504624|NCT00366600|Drug|neratinib|HKI-272
504625|NCT00366587|Device|Cataract surgery and IOL implantation|
504626|NCT00366574|Device|Amadeus Microkeratome|
504627|NCT00366574|Device|IntraLase|
504628|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
504629|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
504630|NCT00366535|Drug|Placebo|4 tabs b.i.d.
504631|NCT00366535|Drug|Neurotropin|4 tabs b.i.d.
504632|NCT00366522|Drug|LXR-623|
504633|NCT00366496|Device|Acrysof single piece (SA60AT)|
504634|NCT00366496|Device|Acrysof IQ (SN60WF)|
504635|NCT00366483|Drug|Lecozotan SR|
504636|NCT00366470|Drug|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
504637|NCT00366470|Other|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
504638|NCT00366457|Drug|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
504639|NCT00366457|Drug|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
504640|NCT00366457|Drug|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
504641|NCT00366444|Drug|diclofenac potassium (XP21L)|25 mg every 6 hours
504642|NCT00366444|Drug|Placebo|Placebo every 6 hours
504643|NCT00366431|Drug|MOA-728|
504644|NCT00366418|Drug|Rituximab|
504645|NCT00366392|Device|Optical Aids|
504646|NCT00366379|Drug|GK Activator (2)|25-200mg po bid for 20 weeks
504647|NCT00366366|Biological|Infanrix-Hexa|
504648|NCT00366353|Other|Sedation during SBT|
504649|NCT00366353|Other|No sedation|
504650|NCT00366340|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
504651|NCT00366340|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
504652|NCT00366327|Drug|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
504653|NCT00366301|Drug|Insulin glargine injection|Once daily for 14 weeks
504654|NCT00366301|Drug|metformin|Up to 4 pils per day (2g per day) maximum
504655|NCT00366301|Drug|Placebo pill|Up to 4 pills per day
504656|NCT00366288|Drug|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
504657|NCT00366275|Procedure|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 2 and cyclophosphamide 400 mg/m^2 on days 2-6. Courses were started if granulocytes >1.5 · 10^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM [carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m^2 on days +14 and +21 after autotransplant.
504658|NCT00366262|Drug|PLA-695|
504659|NCT00366262|Drug|Naproxen|
504660|NCT00366262|Drug|Placebo|
504661|NCT00366249|Drug|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
504662|NCT00366249|Drug|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
504663|NCT00366236|Drug|Nitazoxanide|
504664|NCT00366210|Behavioral|Constraint-Induced Movement (CI) Therapy|
504665|NCT00366210|Behavioral|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
504666|NCT00366171|Drug|Bifeprunox|
504667|NCT00366158|Device|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
504668|NCT00366158|Device|Ventricular Intrinsic Preference|Programming of pacemaker
504669|NCT00366145|Biological|Mesenchymal Stem Cells|2 million cells/kg twice a week for 4 weeks
504670|NCT00366145|Biological|placebo|2 infusions a week for 4 weeks
504671|NCT00366132|Device|Extracorporeal Shockwaves|
504672|NCT00366119|Drug|Ramipril|
504673|NCT00366106|Drug|bortezomib|Patients will be treated with bortezomib at 1.3mg/m^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
504674|NCT00366106|Drug|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
504675|NCT00366106|Drug|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m^2 on Day 4 every 28 days (cycle).
504676|NCT00366093|Drug|Eszopiclone|eszopiclone 3 mg
504677|NCT00366093|Drug|Placebo|placebo tablet
504678|NCT00366080|Drug|GSK189254|
504679|NCT00366067|Drug|Phenytoin|
504680|NCT00366041|Drug|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
504681|NCT00366041|Device|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
504682|NCT00366028|Behavioral|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
504683|NCT00366028|Behavioral|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
504684|NCT00366015|Procedure|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
504685|NCT00366015|Procedure|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
504686|NCT00366002|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
504687|NCT00365989|Device|ExAblate Enhanced Sonication|
504688|NCT00365976|Drug|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
504689|NCT00365976|Drug|Placebo|Placebo nightly over duration of double blind study phase
504690|NCT00365963|Device|Comprehensive Health Enhancement Support System|computer based support and education
504691|NCT00365950|Drug|Duration of anticoagulation|
504692|NCT00365950|Drug|Warfarin duration|
504693|NCT00365937|Biological|Immunological peptides and immunological adjuvants|
504694|NCT00365937|Biological|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
504695|NCT00365937|Biological|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
504696|NCT00365937|Biological|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.~The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
504697|NCT00365924|Drug|Forteo|Open label single arm study with Forteo as an intervention
504698|NCT00365911|Procedure|Taking blood sample|A blood sample will be taken.
504699|NCT00365898|Drug|Hydromorphone Hydrochloride Extended-Release|
504700|NCT00365885|Other|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
504701|NCT00365872|Biological|Dendritic Cell (DC) Injections|"DCs (10^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.~One additional DC injection was given before surgery to assess DC migration~Patients were assigned to one of three cohorts:~Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
504702|NCT00365872|Procedure|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
504703|NCT00365872|Procedure|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
504704|NCT00365859|Drug|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
504705|NCT00365846|Drug|Campath-1H|
504706|NCT00365820|Drug|Tegaserod|
504707|NCT00365807|Behavioral|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
504708|NCT00365807|Other|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
504709|NCT00365794|Drug|Topical testosterone gel 10 g/day|Testosterone gel therapy for 20 weeks
504710|NCT00365781|Drug|ISIS 113715|
504711|NCT00365768|Drug|Glutamine|Administered orally twice daily for 21 days
504720|NCT00365755|Procedure|conventional surgery|
504721|NCT00365742|Drug|simvastatin|
504722|NCT00365742|Drug|red yeast rice|
504723|NCT00365742|Drug|pharmaceutical grade fish oil|
504724|NCT00365742|Behavioral|therapeutic lifestyle changes|
504725|NCT00365729|Behavioral|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
504726|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
504727|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
504728|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
504729|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
504730|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
504731|NCT00365703|Procedure|Feeding tube insertion|"Orogastric feeding tube~Nasogastric feeding tube"
504732|NCT00365690|Behavioral|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
504733|NCT00365690|Behavioral|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
504734|NCT00365690|Behavioral|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
504735|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
504736|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
504737|NCT00365651|Procedure|Youth Soccer|
504738|NCT00365638|Drug|simvastatin|
504739|NCT00365612|Drug|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
504740|NCT00365599|Drug|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
504741|NCT00365599|Drug|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
504742|NCT00365586|Drug|Ketoprofen Topical Patch , 20%|
504743|NCT00365560|Drug|tiotropium|
504744|NCT00365560|Drug|placebo|
504745|NCT00365547|Biological|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
504746|NCT00365547|Drug|topotecan hydrochloride|Topotecan 4 mg/m^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
504747|NCT00365534|Procedure|MEI|
504748|NCT00365521|Procedure|Photodynamic Therapy|
504749|NCT00365508|Drug|nicotine lozenge|nicotine lozenge
504750|NCT00365508|Drug|nicotine patch|transdermal nicotine patch
504751|NCT00365495|Procedure|Physical training (aerobic training)|
504752|NCT00365469|Dietary Supplement|Probiotic|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
504753|NCT00365469|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
504754|NCT00365456|Drug|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
504755|NCT00365456|Drug|Risedronate|Orally once weekly as one 35 mg tablet.
504756|NCT00365443|Biological|V502|
504757|NCT00365430|Behavioral|safety program|Education, patient involvement, tailored implementation and a computerized registration system
504758|NCT00365417|Drug|Bevacizumab|15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
504759|NCT00365417|Drug|Doxorubicin|60 mg/m^2 IV every 21 days x 4 cycles
504760|NCT00365417|Drug|Cyclophosphamide|600 mg/m^2 IV every 21 days x 4 cycles
504761|NCT00365417|Drug|Capecitabine|Following clinical response assessment, 650 mg/m^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
504762|NCT00365417|Drug|Docetaxel|Following clinical response assessment, 75 mg/m^2 IV every 21 days x 4 cycles
504763|NCT00365404|Behavioral|Diet and exercise promotion|
504764|NCT00365391|Biological|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
504765|NCT00365391|Drug|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
504766|NCT00365378|Biological|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
504767|NCT00365378|Biological|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
504768|NCT00365365|Drug|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 60 mg/m^2 IV push or infusion followed by cyclophosphamide 600 mg/m^2 IV push or infusion~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
504769|NCT00365365|Drug|Docetaxel (T) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel 100 mg/m^2 IV~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy~Note: The starting dose of docetaxel was reduced to 75 mg/m^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
504770|NCT00365365|Drug|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~doxorubicin 50 mg/m^2 IV push or infusion followed by cyclophosphamide 500 mg/m^2 IV push or infusion followed by docetaxel 75 mg/m^2~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
504771|NCT00365365|Drug|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle~bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by~docetaxel in 75 mg/m^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by~trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)~Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
504772|NCT00365365|Drug|Bevacizumab and trastuzumab maintenance therapy|"bevacizumab 15 mg/kg was infused IV followed by~trastuzumab 6 mg/kg IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
504773|NCT00365365|Drug|Bevacizumab maintenance therapy|"- bevacizumab 15 mg/kg was infused IV~Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
504774|NCT00365352|Drug|XP13512 600MG|XP13512 600MG ONCE DAILY
504775|NCT00365352|Drug|XP13512 1200MG|XP13512 1200MG ONCE DAILY
504776|NCT00365352|Drug|PLACEBO|PLACEBO ONCE DAILY
504777|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
504778|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
504779|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
504780|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
504781|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
504782|NCT00365326|Procedure|catheter-based intracoronary injection|
504783|NCT00365313|Drug|celecoxib, esomeprazole|
504784|NCT00365300|Drug|pantoprazole|
504785|NCT00365300|Drug|Placebo|
504786|NCT00365287|Drug|anti-thymocyte globulin|
504787|NCT00365287|Drug|cyclophosphamide|
504788|NCT00365287|Drug|cyclosporine|
504789|NCT00365287|Drug|fludarabine phosphate|
504790|NCT00365287|Drug|mycophenolate mofetil|
504791|NCT00365287|Procedure|radiation therapy|
504792|NCT00365287|Procedure|umbilical cord blood transplantation|
504793|NCT00365274|Drug|Cyclophosphamide|Given IV 750 mg/m^2 day 1
504794|NCT00365274|Drug|Doxorubicin hydrochloride|Given 50 mg/m^2 IV day 1
504795|NCT00365274|Drug|vincristine sulfate|Given 1.4 mg/m^2 IV
504796|NCT00365274|Drug|prednisone|100 mg orally daily days 1 - 5
504797|NCT00365274|Drug|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
504798|NCT00365261|Drug|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
504799|NCT00365261|Drug|Placebo|placebo 2 to 3 mg po at bedtime
504800|NCT00365248|Drug|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
504801|NCT00365222|Drug|Temozolomide|temozolomide 75 mg/m2 /d
504802|NCT00365209|Other|laboratory biomarker analysis|Correlative studies
504803|NCT00365209|Other|pharmacological study|Correlative studies
504804|NCT00365209|Drug|curcumin|Given orally
504805|NCT00365196|Behavioral|CBT Hostility Reduction Program|
504806|NCT00365183|Drug|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
504807|NCT00365170|Drug|human insulin|
504808|NCT00365170|Drug|insulin aspart|
504809|NCT00365157|Drug|Eribulin Mesylate|Given IV
504810|NCT00365157|Other|Laboratory Biomarker Analysis|Correlative studies
504811|NCT00365157|Other|Pharmacological Study|Correlative studies
504812|NCT00365144|Biological|bevacizumab|
504813|NCT00365144|Drug|erlotinib hydrochloride|
504814|NCT00365144|Other|laboratory biomarker analysis|
504815|NCT00365131|Drug|Cerezyme (imiglucerase for injection)|
504816|NCT00365118|Device|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
504817|NCT00365105|Dietary Supplement|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
504818|NCT00365105|Dietary Supplement|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
504819|NCT00365105|Drug|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
504820|NCT00365105|Drug|Sm-153|Single dose intravenously 1 mCi/kg body weight.
504821|NCT00365105|Radiation|Sr-89|Single dose intravenously 4 mCi.
504822|NCT00365092|Procedure|Insertion of tympanostomy tubes|
504823|NCT00365053|Drug|belinostat|Given IV
504824|NCT00365053|Other|laboratory biomarker analysis|Correlative studies
504825|NCT00365040|Procedure|Prk with mitomycin vs Lasik|
504826|NCT00365027|Procedure|Delayed embryo transfer|
504827|NCT00365001|Drug|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
504828|NCT00365001|Drug|Methotrexate|10-25mg po/week
504829|NCT00365001|Drug|Simvastatin|40mg po on days 1, 15 and 43
504830|NCT00364988|Drug|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
504831|NCT00364988|Drug|losartan|losartan (100 mg daily)
504832|NCT00364975|Behavioral|gourmet cooking workshop|
504833|NCT00364936|Procedure|Palliative care service|
504834|NCT00364923|Drug|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
504835|NCT00364910|Behavioral|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
504836|NCT00364910|Behavioral|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
504837|NCT00364884|Drug|ketoaminoacid|
504838|NCT00364871|Drug|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
504839|NCT00364858|Drug|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
504840|NCT00364845|Drug|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
504841|NCT00364845|Drug|Placebo|Prefilled syringe placebo, to match active arm
504842|NCT00364832|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
504843|NCT00364819|Drug|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
504844|NCT00364806|Drug|Prochlorperazine|
504845|NCT00364806|Drug|Metoclopramide|
504846|NCT00364793|Drug|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily~Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)~Didanosine (ddI) 240 mg/m2 (max 400 mg)~Emtricitabine (FTC) 6 mg/kg (max 200 mg)~Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);~Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
504847|NCT00364780|Drug|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 & 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
504848|NCT00364767|Dietary Supplement|A|Alcohol consumption (32 g/day) for 4 weeks
504849|NCT00364767|Dietary Supplement|B|Water
504850|NCT00364754|Drug|Tesmilifene (YMB 1002)|
504851|NCT00364741|Drug|Oxygen|During and 2 hours after surgery
504852|NCT00364702|Drug|methylphenidate|
504853|NCT00364689|Drug|Rifaximin|
504854|NCT00364689|Drug|Lactulose|
504855|NCT00364689|Other|Placebo|
504856|NCT00364676|Drug|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
504857|NCT00364676|Drug|VLI|Patients are dosed on Day 1 of a 21-day cycle.
504858|NCT00364650|Drug|Probiotic Supplement|2 capsules twice daily
504859|NCT00364650|Other|Placebo|placebo
504860|NCT00364637|Drug|Sevoflurane (Volatile Anesthetic)|
504861|NCT00364637|Drug|Total intravenous anesthesia|
504862|NCT00364611|Drug|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on~On Day 1 of the 1st cycle over 120 minutes~On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose~On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses~On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
504863|NCT00364611|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
504864|NCT00364611|Drug|Trastuzumab|"A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.~For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
504865|NCT00364598|Drug|Anginera, a human tissue replacement therapy|
504866|NCT00364585|Device|GreenLight Model 120 Laser System|
504867|NCT00364572|Drug|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
504868|NCT00364572|Drug|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
504869|NCT00364559|Drug|Rosuvastatin|20 mg 10 days daily
504870|NCT00364546|Drug|CG 5503;tapentadol|
504871|NCT00364533|Drug|Tapentadol IR (CG5503)|Fixed Dose 50, 75, & 100 mg BID for 3 days
504872|NCT00364533|Drug|Placebo|Fixed Dose Matching placebo for 3 days
504873|NCT00364533|Drug|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
504874|NCT00364533|Drug|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
504875|NCT00364520|Other|Shanghai workers|
504876|NCT00364494|Procedure|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht>25% bleed or not
504877|NCT00364481|Drug|omeprazole|
504878|NCT00364481|Behavioral|Tongue exercises|
504879|NCT00364468|Drug|pegfilgrastim|
504880|NCT00364455|Drug|Epoetin alfa|
505000|NCT00363428|Other|educational intervention|life style
504881|NCT00364442|Drug|fluticasone propionate/salmeterol|investigational drug
504882|NCT00364429|Drug|[123]I-CNS 1261|Study Drug
504883|NCT00364429|Drug|Lorazepam|Study Drug
504884|NCT00364429|Drug|Risperidone|Study Drug
504885|NCT00364416|Other|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
504886|NCT00364403|Behavioral|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
504887|NCT00364403|Behavioral|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
504888|NCT00364390|Drug|Anginera, a human tissue replacement therapy|
504889|NCT00364377|Drug|Sitagliptin|100 mg once daily
504890|NCT00364377|Other|Placebo|once daily for duration of the study
504891|NCT00364364|Drug|Radiolabeled humanized PAM4 IgG|
504892|NCT00364351|Drug|Vandetanib|once daily oral tablet
504893|NCT00364351|Drug|Erlotinib|oral dose
504894|NCT00364338|Behavioral|gourment cooking workshop|
504895|NCT00364325|Other|Acute Decompensated Heart Failure|Standard of Care
504896|NCT00364312|Behavioral|diet and physical activity|
504897|NCT00364299|Device|Automatic control of tracheal tube cuff pressure|
504898|NCT00364286|Drug|Dasatinib (BMS-354825)|50mg Orally twice daily
504899|NCT00364273|Drug|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
504900|NCT00364273|Drug|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
504901|NCT00364273|Drug|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
504902|NCT00364260|Drug|epoetin alfa|
504903|NCT00364247|Drug|CG5503 IR;tapentadol|
504904|NCT00364234|Device|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
504905|NCT00364221|Drug|Rosiglitazone|
504906|NCT00364195|Drug|Tesmilifene (YMB1002)|
504907|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
504908|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
504909|NCT00364169|Procedure|Degree of constipation|
504910|NCT00364156|Drug|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
504911|NCT00364156|Drug|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
504912|NCT00364143|Drug|IHL-305 (irinotecan liposome injection)|
504913|NCT00364130|Device|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
504914|NCT00364130|Device|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
504915|NCT00364117|Behavioral|Timely Discharge (Remote Presence Technology)|
504916|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
504917|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
504918|NCT00364104|Drug|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
504919|NCT00364104|Drug|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
504920|NCT00364091|Drug|R89674 0.025% ophthalmic solution|
504921|NCT00364065|Device|Ferris PainWrap|
504922|NCT00364052|Drug|oral Valganciclovir vs oral Ganciclovir|
504923|NCT00364039|Drug|AV650|
504924|NCT00364026|Drug|darusentan|
504925|NCT00364013|Drug|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
504926|NCT00364013|Drug|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m^2 IV bolus followed by 600 mg/m^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
504927|NCT00364000|Drug|Calcium acetate|Calcium acetate in 240 chronic HD patients
504928|NCT00364000|Drug|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
504929|NCT00363987|Drug|Ketosteril®|1 tablet Ketosteril/5kgBW/d
504930|NCT00363987|Other|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
504931|NCT00363974|Drug|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
504932|NCT00363961|Behavioral|Resistance exercise|resistance exercise vs sham comparison
504933|NCT00363948|Drug|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
504934|NCT00363948|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
504935|NCT00363935|Drug|Dexmedetomidine|
504936|NCT00363922|Behavioral|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
504937|NCT00363922|Behavioral|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
504938|NCT00363922|Behavioral|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
504939|NCT00363909|Drug|citalopram hydrobromide|
504940|NCT00363909|Other|placebo|
505001|NCT00363428|Procedure|conventional surgery|life style
528500|NCT00163306|Drug|Pantoprazole|
504941|NCT00363896|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
504942|NCT00363896|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
504943|NCT00363883|Drug|vorinostat|Given orally
504944|NCT00363883|Other|laboratory biomarker analysis|Correlative studies
504945|NCT00363870|Biological|Fluarix vaccine|
504946|NCT00363857|Drug|Ropinirole|
504947|NCT00363844|Drug|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
504948|NCT00363831|Drug|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
504949|NCT00363805|Dietary Supplement|green tea|Given orally
504950|NCT00363805|Drug|Polyphenon E|Given orally
504951|NCT00363805|Other|placebo|Given orally
504952|NCT00363792|Drug|Glyceryl trinitrate, azetazolamide|
504953|NCT00363779|Drug|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
504954|NCT00363779|Genetic|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
504955|NCT00363779|Genetic|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
504956|NCT00363779|Other|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
504957|NCT00363766|Drug|LY573636-sodium|A loading dose to target 420 micrograms/milliliter (µg/mL) maximum concentration (Cmax) or 380 µg/mL Cmax followed by a lower chronic dose to maintain Cmax within these target ranges, intravenous, every 21 days until disease progression.
504958|NCT00363753|Drug|aspirin versus clopidogrel|
504959|NCT00363740|Drug|GW685698X Aqueous Nasal Spray|
504960|NCT00363727|Drug|ropinirole controlled-release (REQUIP CR) for RLS|
504961|NCT00363714|Drug|AGN211745|100microgram single intravitreal injection
504962|NCT00363714|Drug|AGN211745|200microgram single intravitreal injection
504963|NCT00363714|Drug|AGN211745|400microgram single intravitreal injection
504964|NCT00363714|Drug|AGN211745|800microgram single intravitreal injection
504965|NCT00363714|Drug|AGN211745|1200microgram single intravitreal injection
504966|NCT00363714|Drug|AGN211745|1600microgram single intravitreal injection
504967|NCT00363701|Drug|esomeprazole|
504968|NCT00363688|Drug|Penicillin test and challenge|
504969|NCT00363675|Behavioral|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
504970|NCT00363649|Biological|GM-K562 cell vaccine|Given by injection
504971|NCT00363649|Biological|Interferon alfa|Given by injection
504972|NCT00363649|Biological|Sargramostim|Given by injection
504973|NCT00363636|Drug|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
504974|NCT00363636|Drug|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
504975|NCT00363623|Device|Silicone hydrogel contact lens|
504976|NCT00363610|Drug|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
504977|NCT00363597|Device|in vitro and in vivo permeability testing|single oral dose, 2 mL/kg (maximum 100 mL) of Sugar Absorption Solution containing 5 gm lactulose, 2 gm mannitol and 40 gm sucrose dissolved in demineralized water.
504978|NCT00363584|Drug|capecitabine|
504979|NCT00363584|Other|clinical observation|
504980|NCT00363584|Procedure|adjuvant therapy|
504981|NCT00363571|Drug|GTN, Diamox|
504982|NCT00363545|Biological|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
504983|NCT00363545|Biological|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
504984|NCT00363532|Drug|infusion of calcitonin gene related peptide (CGRP)|
504985|NCT00363519|Drug|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
504986|NCT00363519|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
504987|NCT00363506|Behavioral|Serotona Plus and dietary behavior management|
504988|NCT00363480|Drug|Salmeterol/Fluticasone 50/250 mcg|Participant received salmeterol/fluticasone combination 50/250 mcg using DISKUS™ powder inhalers.
504989|NCT00363480|Drug|Salbutamol 100 mcg|This medication was provided in metered dose inhalers containing at least 200 puffs of 100 mcg salbutamol.
504990|NCT00363480|Device|DISKUS™ powder inhalers|Participant received salmeterol and fluticasone using DISKUS™ powder inhalers.
504991|NCT00363467|Drug|G-CSF|"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."
504992|NCT00363467|Drug|Leukapheresis|leukapheresis
504993|NCT00363467|Drug|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
504994|NCT00363467|Procedure|Stem cell reinfusion|autologous stem cell transplant
504995|NCT00363454|Drug|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m^2; Level 2: 25 mg/m^2; 35 mg/m^2; 45 mg/m^2.
504996|NCT00363441|Procedure|Intensity Modulated Radiotherapy|
504997|NCT00363428|Behavioral|exercise intervention|life style
504998|NCT00363428|Behavioral|smoking cessation intervention|Life style
504999|NCT00363428|Other|counseling intervention|life style
529386|NCT00154440|Drug|metronidazole|
505002|NCT00363428|Procedure|pulmonary complications management/prevention|life style
505003|NCT00363415|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
505004|NCT00363415|Drug|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
505005|NCT00363415|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
505006|NCT00363402|Procedure|PET-CT|
505007|NCT00363389|Drug|misoprostol and cervical ripening|
505008|NCT00363376|Drug|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
505009|NCT00363376|Drug|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
505010|NCT00363376|Drug|Zonisamide|zonisamide ranging from 100mg to 600mg daily
505011|NCT00363376|Drug|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
505012|NCT00363363|Behavioral|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
505013|NCT00363363|Behavioral|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
505014|NCT00363350|Drug|rituximab (anti-CD20)|2 infusions of 1000 mg
505015|NCT00363337|Drug|aripiprazole|open label treatment with aripiprazole
505016|NCT00363324|Procedure|intracoronary injection of bone marrow cells|
505017|NCT00363311|Drug|Dutasteride|Dutasteride 0.5mg
505018|NCT00363311|Drug|Matching placebo|Matching placebo
505019|NCT00363298|Drug|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
505020|NCT00363298|Drug|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
505021|NCT00363285|Biological|gonadotrophin releasing hormone|
505022|NCT00363285|Drug|cyproterone acetate|
505023|NCT00363285|Procedure|quality-of-life assessment|
505024|NCT00363272|Drug|ispinesib|Given IV
505025|NCT00363272|Other|laboratory biomarker analysis|Correlative studies
505026|NCT00363272|Other|pharmacological study|Correlative studies
505027|NCT00363259|Drug|Peginterferon alfa-2b|
505028|NCT00363259|Drug|Ribavirin|
505029|NCT00363233|Drug|flax lignans|
505030|NCT00363194|Drug|Pazopanib (GW786034)|Pazopanib (GW786034)
505031|NCT00363168|Drug|Ranibizumab|0.3 mg/0.05 ml dose
505032|NCT00363168|Drug|Ranibizumab|0.5 mg/0.05 ml dose
505033|NCT00363155|Drug|KRN7000|
505034|NCT00363142|Drug|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
505035|NCT00363142|Drug|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
505036|NCT00363129|Dietary Supplement|vitamin E|Given orally
505037|NCT00363129|Other|placebo|Given orally
505038|NCT00363116|Drug|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
505039|NCT00363090|Biological|alemtuzumab|
505040|NCT00363090|Drug|cyclophosphamide|
505041|NCT00363090|Drug|doxorubicin hydrochloride|
505042|NCT00363090|Drug|prednisone|
505043|NCT00363090|Drug|vincristine sulfate|
505044|NCT00363090|Other|flow cytometry|
505045|NCT00363090|Other|pharmacological study|
505046|NCT00363077|Biological|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
505047|NCT00363077|Biological|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
505048|NCT00363051|Drug|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
505049|NCT00363051|Drug|Octreotide Depot|
505050|NCT00363038|Drug|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
505051|NCT00363038|Drug|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
505052|NCT00363038|Drug|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
505053|NCT00363038|Drug|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
505054|NCT00363025|Procedure|Two post-remission strategies|
505055|NCT00363025|Drug|Idarubicin versus daunorubicin|
505056|NCT00363012|Biological|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
505057|NCT00363012|Other|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
505169|NCT00362180|Drug|Placebo|subcutaneous injections
505170|NCT00362141|Drug|levetiracetam (add-on)|
505058|NCT00363012|Other|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
505059|NCT00363012|Procedure|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
505060|NCT00363012|Other|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
505061|NCT00362986|Drug|sunscreen|
505062|NCT00362986|Other|placebo|
505063|NCT00362973|Other|laboratory biomarker analysis|
505064|NCT00362973|Procedure|needle biopsy|
505065|NCT00362973|Procedure|positron emission tomography|
505066|NCT00362973|Procedure|radionuclide imaging|
505067|NCT00362973|Radiation|fludeoxyglucose F 18|
505068|NCT00362960|Drug|Olmesartan medoxomil|
505069|NCT00362960|Drug|Losartan|
505070|NCT00362947|Drug|LMWH parnaparin subcutaneously|
505071|NCT00362934|Drug|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
505072|NCT00362934|Drug|Atorvastatin|Atorvastatin 10 mg and 20mg
505073|NCT00362921|Drug|Gliadel wafers in combination with O6-benzylguanine|
505074|NCT00362908|Behavioral|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
505075|NCT00362908|Behavioral|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
505076|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
505077|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
505078|NCT00362882|Drug|docetaxel|Given IV
505079|NCT00362882|Drug|bortezomib|Given IV
505080|NCT00362882|Other|laboratory biomarker analysis|correlative study
505081|NCT00362882|Other|immunoenzyme technique|correlative study
505082|NCT00362882|Other|immunohistochemistry staining method|correlative study
505083|NCT00362882|Other|pharmacological study|correlative study
505084|NCT00362869|Drug|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
505085|NCT00362869|Drug|Placebo|Sodium bicarbonate solution
505086|NCT00362869|Biological|Enteroaggregative E. coli (EAEC)|Dosages: 1X10^9, 5X10^9, 1X10^10, and 5X10^10 cfu; given in a sodium bicarbonate solution
505087|NCT00362856|Drug|larazotide acetate|capsule
505088|NCT00362856|Drug|Placebo|capsule
505089|NCT00362830|Drug|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
505090|NCT00362817|Drug|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
505091|NCT00362817|Drug|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
505092|NCT00362804|Drug|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
505093|NCT00362791|Behavioral|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
505094|NCT00362791|Behavioral|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
505095|NCT00362791|Behavioral|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
505096|NCT00362778|Drug|Insulin|intravenous continuous insulin infusion for 48 hours
505097|NCT00362765|Drug|Fenofibrate|160 mg
505098|NCT00362765|Drug|Metformin|2000 mg
505099|NCT00362765|Drug|Placebo|Placebo
505100|NCT00362752|Drug|Norfloxacin|400 mg po bid
505101|NCT00362752|Drug|Placebo|Placebo 400 mg po bid
505102|NCT00362726|Drug|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
505103|NCT00362726|Drug|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
505104|NCT00362726|Drug|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
505105|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
505106|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
505107|NCT00362713|Drug|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
505108|NCT00362700|Drug|Clevudine|
505109|NCT00362687|Drug|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
505110|NCT00362687|Drug|FTC alone|emtricitabine 200 mg
505111|NCT00362687|Procedure|No HAART|No HAART
505112|NCT00362661|Drug|Cortisol|Cortisol 10 mg/d for 3 months
505113|NCT00362648|Biological|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
505114|NCT00362648|Biological|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
505115|NCT00362635|Drug|Clevudine|
505116|NCT00362609|Drug|pantoprazole|
505117|NCT00362596|Drug|acyclovir|
505118|NCT00362583|Drug|Fentanyl|
505119|NCT00362570|Drug|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off] using a standardized dosing range.~Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
505120|NCT00362557|Device|MRI|Magnetic resonance imaging
505121|NCT00362544|Drug|Ambisome|
505122|NCT00362531|Drug|tacrolimus combined with prednisone|
505446|NCT00360061|Behavioral|Cognitive Behaviour Therapy|
505123|NCT00362518|Dietary Supplement|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
505124|NCT00362518|Dietary Supplement|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
505125|NCT00362518|Dietary Supplement|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
505126|NCT00362518|Dietary Supplement|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
505127|NCT00362505|Drug|Clevudine|
505128|NCT00362492|Procedure|Bilateral ultrasound examination 7+/- 2 after surgery|
505129|NCT00362479|Drug|DR-1021|1 tablet daily
505130|NCT00362466|Drug|Dasatinib|Tablets, Oral, Once daily, 5-7 years
505131|NCT00362466|Drug|Imatinib|Tablets, Oral, Once daily, 5-7 years
505132|NCT00362453|Behavioral|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
505133|NCT00362440|Drug|Leptin|
505134|NCT00362440|Drug|Pioglitazone or metformin|
505135|NCT00362440|Drug|Placebo|
505136|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
505137|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
505138|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
505139|NCT00362414|Drug|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation~30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
505140|NCT00362388|Procedure|Intramyocardial injection of autologous bone marrow cells|
505141|NCT00362375|Behavioral|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
505142|NCT00362375|Behavioral|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
505143|NCT00362349|Drug|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
505144|NCT00362336|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
505145|NCT00362336|Biological|CombAct-HIB®|0.5 mL, IM
505146|NCT00362336|Biological|Engerix B® Pediatric|0.5 mL, IM
505147|NCT00362323|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
505148|NCT00362323|Drug|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
505149|NCT00362310|Drug|indinavir|
505150|NCT00362297|Drug|acyclovir|800 mg orally three times daily for 7 weeks
505151|NCT00362297|Drug|valacyclovir|500 mg orally once daily for 7 weeks
505152|NCT00362284|Behavioral|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
505153|NCT00362271|Drug|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
505154|NCT00362258|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
505155|NCT00362245|Drug|Systemic and Intra-Thecal Amikacin Therapy|
505156|NCT00362232|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
505157|NCT00362232|Drug|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
505158|NCT00362232|Drug|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
505159|NCT00362232|Drug|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
505160|NCT00362219|Other|Placebo|Gel with no active ingredient.
505161|NCT00362219|Drug|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
505162|NCT00362219|Drug|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
505163|NCT00362219|Drug|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
505164|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
505165|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
505166|NCT00362206|Drug|Pravastatin|Pravastatin 40 mg
505167|NCT00362193|Behavioral|Telephonic diabetes care|
505168|NCT00362180|Drug|mipomersen|200 mg subcutaneous injections
505171|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
505172|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
505173|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
505174|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
505175|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
505176|NCT00362115|Drug|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
505177|NCT00362115|Drug|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
505178|NCT00362102|Drug|Cetuximab|
505179|NCT00362089|Dietary Supplement|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
505180|NCT00362063|Drug|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
505181|NCT00362050|Drug|Treatment with 3 dose groups of RBx11160 over 7 days|
505182|NCT00362037|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
505183|NCT00362024|Drug|MK0952|
505184|NCT00362024|Drug|Comparator: Placebo|
505185|NCT00362011|Behavioral|Salba diet|
505186|NCT00361998|Drug|NITROFURANTOIN MACROCRYSTALS|
505187|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally.
505188|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally
505189|NCT00361972|Drug|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
505190|NCT00361972|Drug|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
505191|NCT00361959|Drug|Tiotropium bromide 18mcg|
505192|NCT00361959|Drug|Fluticasone propionate/ salmeterol combination 50/500mcg|
505193|NCT00361933|Drug|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
505194|NCT00361920|Drug|prednisone|
505195|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
505196|NCT00361907|Procedure|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
505197|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
505198|NCT00361894|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
505199|NCT00361894|Drug|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
505200|NCT00361881|Drug|ME-609|Cream, dose 5 times daily during 5 days.
505201|NCT00361881|Drug|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
505202|NCT00361881|Drug|Vehicle|Dose 5 times daily for 5 days
505203|NCT00361868|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
505204|NCT00361868|Drug|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
505205|NCT00361855|Drug|NX-CP105|
505206|NCT00361842|Drug|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
505207|NCT00361803|Drug|topotecan|topotecan
505208|NCT00361790|Drug|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
505209|NCT00361751|Drug|fenofibrate|
505210|NCT00361738|Drug|AVE2268|
505211|NCT00361712|Procedure|Preemptive epidural analgesia|Parturients will receive early epidural analgesia before onset of painful contractions as oppose to standard of care in which parturients receive epidural analgesia with onset of painful contractions.
505212|NCT00361712|Drug|Standard of care|Epidural analgesia with parturients with cervical dilatation and painful labor (VAS >5)
505213|NCT00361699|Drug|Statin|
505214|NCT00361686|Drug|tramadol|
505215|NCT00361686|Drug|remifentanyl|
505216|NCT00361686|Device|patient contolled analgesia|
505217|NCT00361660|Behavioral|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
505218|NCT00361660|Behavioral|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
505219|NCT00361647|Procedure|Diagnostic screening for occult malignancy|
505220|NCT00361634|Drug|Etanercept|
505221|NCT00361621|Drug|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
505222|NCT00361621|Drug|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
505223|NCT00361621|Drug|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
505224|NCT00361621|Drug|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
505225|NCT00361621|Drug|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
505226|NCT00361621|Drug|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
505227|NCT00361621|Radiation|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
505228|NCT00361608|Device|EarlySense ES 16|
505229|NCT00361595|Drug|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
505230|NCT00361582|Drug|CG5503 IR; tapentadol|
505231|NCT00361569|Drug|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
505232|NCT00361569|Drug|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
505233|NCT00361569|Other|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
505234|NCT00361569|Other|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
505235|NCT00361556|Behavioral|The Back Book|A book on how to prevent back pain
505236|NCT00361556|Behavioral|The Back Guide|A guide for the prevention of back pain.
505237|NCT00361556|Behavioral|General health book|A book on general health
505238|NCT00361543|Drug|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
505239|NCT00361543|Other|Lactose Capsules|1 tablet daily for 12 weeks
505240|NCT00361530|Drug|Statin|
505241|NCT00361517|Behavioral|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
505242|NCT00361517|Other|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
505243|NCT00361517|Other|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
505244|NCT00361517|Drug|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
505245|NCT00361517|Other|blood test|Blood will be tested twice a week for the presence of Galactomannan.
505246|NCT00361517|Other|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
505247|NCT00361504|Drug|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
505248|NCT00361504|Drug|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
505249|NCT00361491|Drug|SSR149415|
505250|NCT00361478|Behavioral|Exercise and education|Weekly exercise and education program for 8 weeks
505251|NCT00361478|Behavioral|Education|Written educational material
505252|NCT00361465|Other|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:~discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.~try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.~For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
505253|NCT00361452|Drug|nebulized epinephrine and nebulized albuterol|
505254|NCT00361439|Drug|Mometasone|2 puffs in each nostril once daily of nasal spray
505255|NCT00361439|Drug|Placebo|2 puffs in each nostril once daily of nasal spray
505256|NCT00361426|Device|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
505257|NCT00361413|Drug|Alefacept (AMEVIVE®)|Alefacept
505258|NCT00361413|Drug|control group|these patients will receive the same treatment as group A, without alefacept
505259|NCT00361387|Drug|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
505260|NCT00361374|Dietary Supplement|eicosapentaenoic acid|1 gram/day
505261|NCT00361374|Dietary Supplement|docosahexaenoic acid|1 gram/day
505262|NCT00361374|Drug|Placebo|980 milligram/day
505263|NCT00361361|Device|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
505264|NCT00361348|Drug|Palifermin|
505265|NCT00361348|Drug|Heparin|
505266|NCT00361335|Drug|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
505267|NCT00361335|Drug|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
505268|NCT00361335|Drug|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
505269|NCT00361322|Drug|clindamycin phosphate|
505270|NCT00361322|Drug|salicylic acid|
505271|NCT00361309|Drug|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
505272|NCT00361296|Biological|K562/GM-CSF cell vaccine|
505273|NCT00361283|Drug|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
505274|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
505275|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
505276|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
505277|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
505278|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
505279|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
505447|NCT00360048|Drug|oxytocin|
529827|NCT00151060|Drug|Etoposide|
505280|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
505281|NCT00361270|Behavioral|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
505282|NCT00361257|Drug|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
505283|NCT00361257|Drug|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
505284|NCT00361244|Drug|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
505285|NCT00361244|Drug|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
505286|NCT00361244|Drug|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
505287|NCT00361231|Drug|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
505288|NCT00361231|Drug|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
505289|NCT00361231|Drug|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
505290|NCT00361218|Drug|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
505291|NCT00361205|Device|Electronic Monitoring cap|
505292|NCT00361192|Procedure|biopsy of temporal artery|
505293|NCT00361166|Drug|ACP-103|
505294|NCT00361153|Drug|Colesevelam hydrochloride|Welchol tablet 625mg
505295|NCT00361153|Drug|placebo|placebo
505296|NCT00361140|Drug|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.~Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.~Subsequent daily doses will be adjusted to achieve target AUCs."
505297|NCT00361140|Drug|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
505298|NCT00361127|Drug|isotonic saline infusion|
505299|NCT00361114|Drug|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
505300|NCT00361114|Drug|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
505301|NCT00361114|Drug|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
505302|NCT00361101|Drug|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
505303|NCT00361088|Drug|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
505304|NCT00361088|Drug|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.~Phase II: Maximum Tolerated Dose (MTD)"
505305|NCT00361075|Drug|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
505306|NCT00361062|Behavioral|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
505307|NCT00361049|Biological|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
505308|NCT00361049|Genetic|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
505309|NCT00361049|Other|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
505310|NCT00361049|Other|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
505311|NCT00361049|Other|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
505312|NCT00361049|Procedure|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
505313|NCT00361049|Procedure|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
505314|NCT00361036|Device|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
505315|NCT00361036|Device|Uterine fibroid embolization Embosphere®|Embosphere - control arm
505316|NCT00361023|Drug|losartan|
505317|NCT00361010|Drug|Levetiracetam|
505318|NCT00360997|Behavioral|Conventional UK physical therapy|
505319|NCT00360997|Procedure|Con UK PT + Mobilisation & tactile stimulation (MTS)|Con UK PT + Mobilisation & Tactile Stimulation (MTS) which is further randomised to 30, 60 or 120 mins/day
505320|NCT00360984|Drug|insulin glargine|
505321|NCT00360984|Device|continuous subcutaneous insulin infusion|
505322|NCT00360971|Biological|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
505323|NCT00360971|Drug|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
505324|NCT00360971|Other|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
505325|NCT00360971|Procedure|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
505326|NCT00360971|Radiation|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
505327|NCT00360958|Procedure|ultrafiltration|
505328|NCT00360945|Drug|cisplatin|
505329|NCT00360945|Drug|temozolomide|
505330|NCT00360945|Genetic|fluorescence in situ hybridization|
505331|NCT00360945|Genetic|loss of heterozygosity analysis|
505332|NCT00360945|Other|immunohistochemistry staining method|
505333|NCT00360945|Other|laboratory biomarker analysis|
505334|NCT00360945|Radiation|radiation therapy|
505335|NCT00360932|Device|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
505336|NCT00360919|Behavioral|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.~Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.~At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
505337|NCT00360906|Drug|Triomar™ (omega-3 fatty acids)|
505338|NCT00360867|Drug|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
505339|NCT00360854|Drug|erlotinib hydrochloride|
505340|NCT00360854|Genetic|mutation analysis|
505341|NCT00360854|Genetic|polymorphism analysis|
505342|NCT00360854|Other|laboratory biomarker analysis|
505343|NCT00360854|Other|pharmacological study|
505344|NCT00360854|Radiation|radiation therapy|
505345|NCT00360841|Procedure|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
505346|NCT00360841|Procedure|Sham auricular acupuncture|
505347|NCT00360828|Drug|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride [CPT-11; CAMPTOSAR] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
505348|NCT00360828|Drug|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
505349|NCT00360815|Behavioral|Insulin|
505350|NCT00360802|Behavioral|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
505351|NCT00360802|Behavioral|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
505352|NCT00360789|Behavioral|Conventional UK physical therapy|
505353|NCT00360789|Behavioral|Increased intensity of UK conventional physical therapy (PT)|
505354|NCT00360789|Behavioral|UK conventional PT plus functional strength training|
505355|NCT00360776|Drug|tipifarnib|Given orally
505356|NCT00360776|Other|laboratory biomarker analysis|Correlative studies
505357|NCT00360763|Drug|candesartan cilexetil|
505358|NCT00360750|Drug|carboplatin|
505359|NCT00360750|Drug|cytarabine|
505360|NCT00360750|Drug|etoposide|
505361|NCT00360750|Drug|vincristine sulfate|
505362|NCT00360750|Other|clinical observation|
505363|NCT00360750|Procedure|adjuvant therapy|
505364|NCT00360750|Radiation|radiation therapy|
505365|NCT00360737|Biological|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 Experimental with 8 Cohorts of 5 Subjects each evaluating 2 Dosage levels of 1 or 2 vials of NP-018 administered intravenously.
505366|NCT00360724|Drug|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
505367|NCT00360698|Drug|Insulin Glargine|One daily injection at bedtime
505368|NCT00360698|Drug|Glimepiride|At same dosage as during the run-in period
505369|NCT00360698|Drug|Insulin Glulisine|One bolus given before the main meal
505370|NCT00360698|Drug|Metformin|At same dosage as during the run-in period
505371|NCT00360685|Drug|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
505448|NCT00360035|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
505498|NCT00359606|Drug|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
505372|NCT00360685|Drug|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
505373|NCT00360672|Drug|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
505374|NCT00360659|Device|Continuous Positive Airway Pressure|
505375|NCT00360607|Drug|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
505376|NCT00360607|Drug|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
505377|NCT00360607|Drug|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
505378|NCT00360607|Drug|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
505379|NCT00360594|Drug|Acamprosate|3 pills (666 mg) for 1998mg/day
505380|NCT00360594|Drug|Placebo|3 pills (666mg) for 1998mg/day
505381|NCT00360581|Behavioral|Yoga|
505382|NCT00360581|Behavioral|Yoga and Cognitive Behavioral Therapy|
505383|NCT00360568|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
505384|NCT00360568|Device|CADD-Legacy® 1400 ambulatory infusion pump|
505385|NCT00360568|Device|PEG tube|percutaneous endoscopic gastrostomy tube
505386|NCT00360568|Device|J-tube|jejunal tube
505387|NCT00360555|Drug|flibanserin|flibanserin 25 mg b.i.d
505388|NCT00360555|Drug|flibanserin 50mg|flibanserin 50mg qhs/b.i.d.
505389|NCT00360555|Drug|flibanserin 100mg|flibanserin 50 mg b.i.d/100mg qhs
505390|NCT00360555|Drug|placebo|placebo comparator
505391|NCT00360529|Drug|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
505392|NCT00360516|Behavioral|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
505393|NCT00360490|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
505394|NCT00360490|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
505395|NCT00360477|Procedure|Floseal|Bioglue that seals the kidney
505396|NCT00360477|Procedure|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
505397|NCT00360477|Procedure|Fascial Stitch|Stitch that closes the kidney
505398|NCT00360464|Drug|Azithromycin SR|
505399|NCT00360451|Behavioral|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
505400|NCT00360451|Behavioral|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
505401|NCT00360438|Drug|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
505402|NCT00360425|Drug|ferumoxytol|
505403|NCT00360425|Drug|moxifloxacin|
505404|NCT00360425|Drug|placebo|
505405|NCT00360412|Drug|E2007|
505406|NCT00360399|Drug|Escitalopram|Escitalopram 10 to 20 mg per day for 12 weeks
505407|NCT00360399|Drug|Duloxetine|Duloxetine 30 to 60 mg per day for 12 weeks
505408|NCT00360399|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 16 one-hour sessions provided over 12 weeks.
505409|NCT00360386|Drug|Clopidogrel|
505410|NCT00360360|Drug|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
505411|NCT00360360|Drug|carboplatin|Carboplatin AUC 6.0 IV Day 1
505412|NCT00360360|Drug|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
505413|NCT00360360|Drug|erlotinib|Erlotinib 150 mg by mouth daily
505414|NCT00360347|Drug|C.E.R.A.|
505415|NCT00360334|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
505416|NCT00360334|Drug|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
505417|NCT00360308|Drug|Placebo|
505418|NCT00360308|Drug|E2007|
505419|NCT00360308|Drug|E2007|
505420|NCT00360295|Drug|Azithromycin SR|
505421|NCT00360282|Drug|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
505422|NCT00360282|Other|Placebo|In an unlabeled pill given once on one of two visits.
505423|NCT00360269|Drug|Atomoxetine|25 to 100 mg daily
505424|NCT00360269|Procedure|Motivational enhancement therapy|Three sessions
505425|NCT00360269|Drug|Placebo|25 to 100 mg daily
505426|NCT00360243|Drug|flibanserin|Experimental: flibanserin 25 mg b.i.d
505427|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg qhs
505428|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg b.i.d.
505429|NCT00360243|Drug|placebo|placebo
505430|NCT00360230|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
505431|NCT00360230|Biological|Rabipur|3-dose intramuscular injection.
505432|NCT00360217|Drug|docosahexanoic acid (DHA)|
505433|NCT00360204|Behavioral|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
505434|NCT00360191|Drug|Buspirone|
505435|NCT00360191|Procedure|Motivational enhancement therapy|
505436|NCT00360178|Drug|Valsartan plus Hydrochlorothiazide|
505437|NCT00360178|Drug|Candesartan plus Hydrochlorothiazide|
505438|NCT00360178|Drug|Amlodipine|
505439|NCT00360152|Procedure|Fine needle aspiration biopsy (FNAB)|
505440|NCT00360152|Procedure|Sentinel Lymph Node Biopsy|
505441|NCT00360139|Device|Sculptra Injection|
505442|NCT00360126|Drug|lamotrigine|
505443|NCT00360100|Drug|Zmax|
505444|NCT00360087|Drug|Bosentan|
505445|NCT00360074|Drug|Thyroxin, Triiodothyronine|
505449|NCT00360022|Other|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
505450|NCT00360009|Procedure|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
505451|NCT00360009|Procedure|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
505452|NCT00359996|Behavioral|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
505453|NCT00359996|Other|No additional educational sessions|
505454|NCT00359983|Biological|MenHibrix (Hib-MenCY-TT)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
505455|NCT00359983|Biological|Hib conjugate vaccine (ActHIB)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
505456|NCT00359970|Drug|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
505457|NCT00359970|Drug|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
505458|NCT00359970|Drug|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
505459|NCT00359970|Other|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
505460|NCT00359957|Behavioral|Pediatric Obesity Intervention (STANDARD)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
505461|NCT00359957|Behavioral|Pediatric Obesity Intervention + High Activity (ADDED)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
505462|NCT00359944|Drug|AC-3933|5mg twice daily
505463|NCT00359944|Drug|AC-3933|AC-3933, 20 mg twice daily
505464|NCT00359944|Other|Sugar Pill|Sugar Pill twice daily
505465|NCT00359918|Drug|fibrinolysis|Primary PCI
505466|NCT00359918|Procedure|Primary PCI|Primary PCI
505467|NCT00359905|Drug|Silodosin|8 mg daily for 12 weeks
505468|NCT00359905|Drug|Tamsulosin|0.4 mg daily for 12 weeks
505469|NCT00359905|Drug|Placebo|once daily for 12 weeks
505470|NCT00359892|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
505471|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
505472|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
505473|NCT00359866|Radiation|IMRT with tomotherapy|
505474|NCT00359853|Drug|Oral norfloxacin|
505475|NCT00359840|Drug|darbepoetin alfa|
505476|NCT00359814|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
505477|NCT00359814|Drug|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
505478|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
505479|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
505480|NCT00359788|Drug|tiotropium|
505481|NCT00359788|Drug|Combivent (Ipratropium/Albuterol)|
505482|NCT00359775|Behavioral|Coping Skills Training|6 session behavioral program
505483|NCT00359762|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
505484|NCT00359762|Drug|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
505485|NCT00359736|Drug|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
505486|NCT00359723|Drug|methylphenidate|
505487|NCT00359697|Drug|Hypertonic Saline, Mannitol|
505488|NCT00359671|Drug|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
505489|NCT00359671|Drug|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
505490|NCT00359658|Drug|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
505491|NCT00359658|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
505492|NCT00359658|Drug|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
505493|NCT00359645|Procedure|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
505494|NCT00359632|Drug|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
505495|NCT00359632|Drug|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
505496|NCT00359619|Biological|CervarixTM|Subjects were administered three doses of HPV vaccine
505497|NCT00359619|Biological|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
505499|NCT00359606|Other|Laboratory Biomarker Analysis|Correlative Studies
505500|NCT00359606|Other|Pharmacological Study|Correlative Studies
505501|NCT00359606|Drug|Tetrahydrouridine (THU)|Given PO and IV
505502|NCT00359593|Behavioral|Knowledge translation intervention package|
505503|NCT00359567|Drug|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
505504|NCT00359567|Drug|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
505505|NCT00359554|Biological|VAXIGRIPPE|
505506|NCT00359489|Device|cardiac echosonography|
505507|NCT00359476|Drug|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
505508|NCT00359463|Drug|eltrombopag|Subjects will be administered a single oral dose of 50 mg eltrombopag.
505509|NCT00359450|Drug|BMS-275183 (oral taxane)|
505510|NCT00359437|Drug|Satavaptan|oral administration once daily
505511|NCT00359437|Drug|placebo|oral administration once daily
505512|NCT00359424|Drug|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
505513|NCT00359424|Other|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
505514|NCT00359398|Procedure|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
505515|NCT00359385|Drug|Alendronate 70mg weekly|70mg weekly
505516|NCT00359359|Drug|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
505517|NCT00359359|Drug|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
505518|NCT00359333|Drug|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
505519|NCT00359320|Procedure|pancreaticojejunostomy|
505520|NCT00359294|Drug|Zalypsis (PM00104)|Intravenously over 1 hour daily for 5 days, every 3 weeks.
505521|NCT00359281|Drug|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
505522|NCT00359281|Drug|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
505523|NCT00359281|Drug|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
505524|NCT00359281|Drug|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
505525|NCT00359281|Drug|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
505526|NCT00359281|Drug|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
505527|NCT00359255|Behavioral|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
505528|NCT00359255|Behavioral|An inpatient homework based exercise program for the upper limb post stroke|"The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.~The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing."
505529|NCT00359242|Behavioral|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
505530|NCT00359242|Behavioral|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
505531|NCT00359229|Drug|Zolpidem|Administration of Zolpidem 5mg
505532|NCT00359216|Drug|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
505533|NCT00359216|Drug|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
505534|NCT00359203|Device|Dual chamber pacemeker|
505535|NCT00359190|Drug|lapatinib|GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
505536|NCT00359177|Drug|GW679769|GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
505537|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds [light dose of 25 J/cm2]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
505538|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
505539|NCT00359164|Drug|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.~Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
505540|NCT00359151|Drug|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
505700|NCT00357864|Drug|carbachol|
505541|NCT00359151|Drug|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
505542|NCT00359138|Drug|desloratadine|5 mg tablet once daily
505543|NCT00359138|Drug|levocetirizine|5 mg capsule once daily
505544|NCT00359138|Drug|Desloratadine placebo tablet|once daily
505545|NCT00359138|Drug|Levocetirizine placebo capsule|once daily
505546|NCT00359125|Drug|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
505547|NCT00359125|Other|Placebo|Placebo, 600 mg/day for 1 week.
505548|NCT00359112|Drug|metformin|
505549|NCT00359112|Drug|sulphonylurea|
505550|NCT00359112|Drug|Avandamet|
505551|NCT00359086|Drug|MGCD0103|MGCD0103 given orally three times per week
505552|NCT00359073|Drug|montelukast|10 mg everyday
505553|NCT00359073|Drug|placebo|like placebo
505554|NCT00359060|Behavioral|Physical activity|
505555|NCT00359047|Behavioral|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
505556|NCT00359047|Behavioral|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
505557|NCT00359021|Drug|TMC125|200 mg twice daily until commercially available
505558|NCT00358995|Behavioral|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
505559|NCT00358995|Behavioral|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
505560|NCT00358982|Drug|MGCD0103|MGCD0103 administered orally three times per wek
505561|NCT00358969|Drug|guanfacine (Tenex)|
505562|NCT00358956|Drug|ZD6474 (vandetanib)|100 mg once daily oral tablet
505563|NCT00358930|Drug|ARQ 501|
505564|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
505565|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
505566|NCT00358878|Drug|Satavaptan|oral administration once daily
505567|NCT00358878|Drug|placebo|oral administration once daily
505568|NCT00358852|Other|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
505569|NCT00358839|Drug|CGRP|
505570|NCT00358826|Drug|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
505571|NCT00358826|Drug|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
505572|NCT00358813|Drug|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
505573|NCT00358800|Device|REMStar Auto with C-Flex|
505574|NCT00358787|Procedure|Crossed K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
505575|NCT00358787|Procedure|Lateral K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
505576|NCT00358774|Procedure|homeopathic nasal spray|
505577|NCT00358748|Drug|Hydrocortisone|See detailed description above.
505578|NCT00358735|Device|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
505579|NCT00358735|Drug|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
505580|NCT00358722|Drug|Fermagate|Film coated tablet 500mg
505581|NCT00358709|Behavioral|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
505582|NCT00358696|Drug|tenofovir|See Detailed Description.
505583|NCT00358683|Drug|Certolizumab pegol|
505584|NCT00358670|Biological|infliximab|"Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
505701|NCT00357851|Drug|Aprotinin|
505702|NCT00357825|Drug|[S,S]-Reboxetine|
505585|NCT00358670|Biological|infliximab|"Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 [NCT00251641] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a >=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
505586|NCT00358657|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
505587|NCT00358657|Drug|Cyclophosphamide|Given IV
505588|NCT00358657|Drug|Fludarabine Phosphate|Given IV
505589|NCT00358657|Other|Laboratory Biomarker Analysis|Correlative studies
505590|NCT00358657|Drug|Mycophenolate Mofetil|Given PO
505591|NCT00358657|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
505592|NCT00358657|Drug|Sirolimus|Given PO
505593|NCT00358657|Drug|Tacrolimus|Given IV or PO
505594|NCT00358657|Radiation|Total-Body Irradiation|Undergo total-body irradiation
505595|NCT00358644|Drug|Decitabine|20 mg/m^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
505596|NCT00358631|Drug|SSR149415|
505597|NCT00358618|Drug|Propofol|See Detailed Description.
505598|NCT00358605|Device|The Klearway™ oral appliance|See Detailed Description.
505599|NCT00358592|Device|Mobius™ retractor|
505600|NCT00358592|Device|traditional metal retraction instruments|
505601|NCT00358579|Drug|Adrenaline|1 mg
505602|NCT00358579|Drug|Vasopressin|40 IU
505603|NCT00358566|Biological|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
505604|NCT00358566|Drug|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
505605|NCT00358553|Drug|Insulin|
505606|NCT00358540|Drug|eltrombopag|Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
505607|NCT00358527|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
505608|NCT00358527|Other|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
505609|NCT00358514|Device|Continuous Compartment Pressure Monitoring|See Detailed Description.
505610|NCT00358501|Drug|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
505611|NCT00358488|Drug|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
505612|NCT00358488|Drug|salbutamol|salbutamol
505613|NCT00358488|Drug|salmeterol 50mcg|salmeterol 50mcg
505614|NCT00358488|Drug|placebo|placebo
505615|NCT00358475|Drug|GW685698|
505616|NCT00358462|Drug|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
505617|NCT00358462|Drug|Doxycycline|one 100mg capsule administered twice daily for seven days
505618|NCT00358449|Drug|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
505619|NCT00358436|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
505620|NCT00358436|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
505621|NCT00358423|Drug|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
505622|NCT00358423|Drug|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
505623|NCT00358410|Drug|GW679769 oral tablets|2x GW679769 60mg tablets
505624|NCT00358410|Drug|Placebo|Placebo oral tablets to match experimental intervention
505625|NCT00358397|Drug|Clostridium novyi-NT spores|
505626|NCT00358384|Drug|Pazopanib|Pazopanib will be available in dosing strengths of 0.1, 0.5 and 1 percent.
505627|NCT00358384|Drug|Pazopanib vehicle|Pazopanib vehicle will be given to subjects.
505628|NCT00358384|Drug|Betamethasone valerate|Betamethasone valerate ointment with 0.1 percent concentration will be given to subjects.
505629|NCT00358384|Drug|Calcipotriol|Calcipotriol ointment with 0.005 percent concentration will be given to subjects.
505630|NCT00358371|Drug|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
505631|NCT00358371|Drug|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
505632|NCT00358358|Drug|Fluticasone Propionate/Salmeterol 500/50mcg combination|
505633|NCT00358358|Drug|Fluticasone Propionate 500mcg|
505634|NCT00358358|Drug|Salmeterol 50mcg|
505635|NCT00358332|Biological|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
505636|NCT00358332|Biological|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
505637|NCT00358319|Drug|Karenitecin|
505638|NCT00358319|Drug|Valproic Acid|
505639|NCT00358293|Drug|Tizanidine (sublingual or oral)|
505640|NCT00358280|Drug|Ropivacaine|
505641|NCT00358280|Drug|Bupivacaine|
505642|NCT00358267|Procedure|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
505703|NCT00357799|Device|VeinViewer|Using the VeinViewer, IV attempts will be made
505704|NCT00357786|Drug|Replagal agalsidase alfa|
505643|NCT00358267|Procedure|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
505644|NCT00358241|Procedure|Nerve block|
505645|NCT00358228|Drug|Rimonabant|
505646|NCT00358215|Drug|Darbepoetin alfa|Administered by subcutaneous injection
505647|NCT00358215|Drug|Placebo|Placebo subcutaneous injection
505648|NCT00358202|Drug|cefepime|cefepime hydrochloride 1gm IM q24h
505649|NCT00358202|Drug|ceftriaxone|ceftriaxone 1 gm IM q24h
505650|NCT00358189|Device|Deep Brain Stimulation|
505651|NCT00358176|Drug|Risedronate (HMR4003)|
505652|NCT00358163|Drug|PTK787/ZK 222584|Taken in tablet form daily
505653|NCT00358163|Drug|paclitaxel|Given as a 3-hour infusion once every 21 days
505654|NCT00358150|Drug|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067[active moiety of eliglustat in plasma] trough plasma concentration was greater than or equal to [>=]5 nanogram per milliliter [ng/mL] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than [<] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
505655|NCT00358137|Behavioral|Aerobic Conditioning Program|
505656|NCT00358137|Behavioral|Strength Training Program|
505657|NCT00358124|Drug|insulin glargine|
505658|NCT00358124|Drug|rosiglitazone|
505659|NCT00358124|Drug|metformin|
505660|NCT00358111|Device|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
505661|NCT00358085|Procedure|Endovascular Repair of Abdominal Aortic Aneurysm|
505662|NCT00358085|Procedure|Conventional open repair of Abdominal Aortic Aneurysm|
505663|NCT00358072|Behavioral|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
505664|NCT00358059|Behavioral|Behavioral Family Systems Therapy for Diabetes|
505665|NCT00358046|Drug|ILY101|
505666|NCT00358033|Behavioral|Counseling|
505667|NCT00358033|Behavioral|Interactive Education|
505668|NCT00358033|Behavioral|Group Support|
505669|NCT00358033|Procedure|Pharmacologic case management|Provided by clinical pharmacists
505670|NCT00358020|Drug|THALIDOMIDE|
505671|NCT00358020|Drug|BORTEZOMIB|
505672|NCT00358007|Device|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
505673|NCT00357994|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
505674|NCT00357994|Drug|Placebo gel|
505675|NCT00357994|Drug|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
505676|NCT00357994|Drug|Placebo (PBO) oral capsules|
505677|NCT00357994|Device|CADD-Legacy® 1400 ambulatory infusion pump|
505678|NCT00357994|Device|PEG tube|percutaneous endoscopic gastrostomy tube
505679|NCT00357994|Device|J-tube|jejunal tube
505680|NCT00357981|Drug|ORTHO EVRA, the contraceptive patch|
505681|NCT00357968|Drug|Prasugrel|Administered orally
505682|NCT00357968|Drug|Clopidogrel|Administered orally
505683|NCT00357968|Drug|Placebo for Prasugrel|Administered orally
505684|NCT00357968|Drug|Placebo for Clopidogrel|Administered orally
505685|NCT00357955|Behavioral|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
505686|NCT00357955|Behavioral|Interactive Education|interactive lectures with hands-on learning
505687|NCT00357955|Behavioral|Role modeling|learning from peers with similar disease and problems
505688|NCT00357955|Procedure|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
505689|NCT00357942|Drug|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
505690|NCT00357942|Drug|Placebo|Placebo mouthwash
505691|NCT00357942|Drug|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
505692|NCT00357942|Drug|Placebo|Placebo solution for injection every 3 hour for 24 hours
505693|NCT00357929|Procedure|Permissive hypercarbia|
505694|NCT00357916|Drug|PEP005 Topical Gel (0.01% concentration)|
505695|NCT00357903|Biological|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
505696|NCT00357890|Device|Pump therapy (CSII)|CSII initiated within 1 month of dx
505697|NCT00357890|Drug|Multiple daily injections (MDI) using insulin glargine + rapid acting analog|MDI as control
505698|NCT00357877|Drug|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
505699|NCT00357877|Other|Placebo|
505706|NCT00357773|Drug|Azithromycin (T1225)|
505707|NCT00357760|Biological|VEGF Trap|Given IV
505708|NCT00357747|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
505709|NCT00357747|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
505710|NCT00357734|Drug|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
505711|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
505712|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
505713|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
505714|NCT00357708|Drug|decitabine|Given IV
505715|NCT00357708|Drug|vorinostat|Given orally
505716|NCT00357708|Other|laboratory biomarker analysis|Correlative studies
505717|NCT00357708|Other|pharmacological study|Correlative studies
505718|NCT00357682|Drug|Esomeprazole|20mg per day
505719|NCT00357682|Drug|Esomeprazole|80mg per day
505720|NCT00357682|Drug|Aspirin|300mg per day
505721|NCT00357669|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 25 mg~Route of Administration: Oral use"
505722|NCT00357669|Drug|Brivaracetam 50 mg|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 50 mg~Route of Administration: Oral use"
505723|NCT00357669|Other|Placebo|"Active Substance: Placebo Pharmaceutical Form: Tablet~Concentration: 25 mg and 50 mg~Route of Administration: Oral use"
505724|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period <= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.~CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.~All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always >= 0.4 mL/h."
505725|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period <= 5 minutes (maximum infusion rate, 10 mL/min).
505726|NCT00357643|Drug|Calcium 500 mg/day and vitamin D 700 IU/day|
505727|NCT00357630|Drug|gemcitabine hydrochloride|
505728|NCT00357630|Procedure|quality-of-life assessment|
505729|NCT00357617|Drug|celecoxib|
505730|NCT00357617|Genetic|microarray analysis|
505731|NCT00357617|Genetic|protein expression analysis|
505732|NCT00357617|Other|immunoenzyme technique|
505733|NCT00357617|Other|immunohistochemistry staining method|
505734|NCT00357617|Other|laboratory biomarker analysis|
505735|NCT00357617|Procedure|biopsy|
505736|NCT00357617|Procedure|conventional surgery|
505737|NCT00357617|Procedure|neoadjuvant therapy|
505738|NCT00357604|Drug|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
505739|NCT00357604|Drug|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
505740|NCT00357591|Device|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
505741|NCT00357565|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
505742|NCT00357565|Drug|busulfan|Administered 1.1 mg/kg if <12 kg intravenous (IV) every 6 hours (0.8 mg/kg if >12 kg IV every 6 hours on Days -8 through -5.
505743|NCT00357565|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of >200 ng/mL. For children < 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
505744|NCT00357565|Drug|fludarabine phosphate|Administered 25 mg/m^2 intravenous (IV) over 60 minutes on Days -4 through -2.
505745|NCT00357565|Drug|melphalan|Administered 60 mg/m^2 intravenous (IV) over 30 minutes on Days -4 through -2.
505746|NCT00357565|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients <45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
505747|NCT00357565|Procedure|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
505748|NCT00357552|Drug|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
505749|NCT00357552|Drug|Lopinavir/Ritonavir|Twice daily
505750|NCT00357539|Drug|Azithromycin (T1225)|
505751|NCT00357526|Drug|OCPs|
505752|NCT00357526|Device|vaginal ring|
505753|NCT00357500|Drug|celecoxib|
505754|NCT00357500|Drug|cyclophosphamide|
505755|NCT00357500|Drug|etoposide|
505756|NCT00357500|Drug|fenofibrate|
505757|NCT00357500|Drug|thalidomide|
505758|NCT00357487|Device|peroperative scintillating probe|
505759|NCT00357487|Device|operative gamma camera|
505760|NCT00357474|Procedure|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
505826|NCT00357032|Drug|belinostat|Given IV
529828|NCT00151060|Drug|Paclitaxel|
505761|NCT00357474|Procedure|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
505762|NCT00357461|Biological|gp100:209-217(210M) peptide vaccine|
505763|NCT00357461|Biological|gp100:280-288(288V) peptide vaccine|
505764|NCT00357461|Biological|incomplete Freund's adjuvant|
505765|NCT00357461|Biological|ipilimumab|
505766|NCT00357448|Biological|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
505767|NCT00357448|Procedure|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
505768|NCT00357448|Other|laboratory biomarker analysis|Correlative studies
505769|NCT00357448|Other|enzyme-linked immunosorbent assay|Correlative studies
505770|NCT00357448|Other|flow cytometry|Correlative studies
505771|NCT00357422|Procedure|Operation|No drug needed
505772|NCT00357422|Procedure|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
505773|NCT00357396|Biological|graft versus host disease prophylaxis/therapy|
505774|NCT00357396|Drug|busulfan|
505775|NCT00357396|Drug|melphalan|
505776|NCT00357396|Drug|thiotepa|
505777|NCT00357396|Procedure|allogeneic bone marrow transplantation|
505778|NCT00357396|Procedure|allogeneic hematopoietic stem cell transplantation|
505779|NCT00357396|Procedure|peripheral blood stem cell transplantation|
505780|NCT00357383|Drug|Azithromycin (T1225)|
505781|NCT00357370|Drug|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
505782|NCT00357370|Drug|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
505783|NCT00357357|Drug|HF0220|comparison of different dosages of drug
505784|NCT00357331|Drug|potassium citrate|20 meq by mouth in capsule form twice daily
505785|NCT00357318|Drug|sunitinib malate|Given PO
505786|NCT00357318|Biological|bevacizumab|Given IV
505787|NCT00357318|Other|pharmacological study|Correlative studies
505788|NCT00357318|Other|laboratory biomarker analysis|Correlative studies
505789|NCT00357305|Drug|vorinostat|Given orally
505790|NCT00357305|Drug|cytarabine|Given IV
505791|NCT00357305|Drug|etoposide|Given IV
505792|NCT00357305|Other|pharmacological study|Correlative studies
505793|NCT00357305|Other|laboratory biomarker analysis|Correlative studies
505794|NCT00357292|Drug|Azithromycin (T1225)|
505795|NCT00357279|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
505796|NCT00357279|Drug|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
505797|NCT00357253|Drug|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
505798|NCT00357253|Radiation|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
505799|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
505800|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
505801|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
505802|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
505803|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
505804|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
505805|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
505806|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
505807|NCT00357214|Dietary Supplement|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
505808|NCT00357214|Dietary Supplement|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
505809|NCT00357214|Dietary Supplement|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
505810|NCT00357214|Dietary Supplement|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
505811|NCT00357201|Drug|Food supplement (T1675)|
505812|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
505813|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
505814|NCT00357162|Drug|belinostat|Given IV
505815|NCT00357149|Drug|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
505816|NCT00357149|Drug|Concomitant cisplatin, 5-FU and radiotherapy|
505817|NCT00357136|Behavioral|password usage|
505818|NCT00357123|Drug|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
505819|NCT00357110|Drug|Fulvestrant|intramuscular injection
505820|NCT00357110|Drug|Anastrozole|1 mg oral tablet
505821|NCT00357097|Drug|Ropinirole|
505822|NCT00357084|Drug|methotrexate|
505823|NCT00357084|Drug|methylprednisolone|
505824|NCT00357084|Drug|prednisone|
505825|NCT00357045|Drug|Paroxetine|
505827|NCT00357032|Other|laboratory biomarker analysis|Correlative studies
505828|NCT00357019|Drug|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
505829|NCT00357006|Drug|Estradiol|100 mcg adjunctive transdermal estradiol
505830|NCT00357006|Drug|Estradiol|200 mcg adjunctive transdermal estradiol
505831|NCT00357006|Other|placebo|adjunctive transdermal placebo
505832|NCT00356993|Drug|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
505833|NCT00356993|Behavioral|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
505834|NCT00356980|Biological|colloidal gold-bound tumor necrosis factor|
505835|NCT00356980|Other|pharmacological study|
505836|NCT00356967|Drug|dianicline|
505837|NCT00356954|Drug|N-acetylcystein|
505838|NCT00356954|Drug|ascorbic acid|
505839|NCT00356941|Drug|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
505840|NCT00356941|Drug|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
505841|NCT00356941|Procedure|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
505842|NCT00356928|Drug|Cyclophosphamide|50 mg/kg/day intravenously (IV) on Days -2 and -1.
505843|NCT00356928|Biological|Donor T cells|"CD8-depleted T cells given IV on Day 0. Dose levels are as follows (all doses in cells/kg):~Dose level 1: 1E5 CD4+ cells and less than 3.2E3 CD8+ cells Dose level 2: 1E6 CD4+ cells and less than 3.2E4 CD8+ cells Dose level 3: 1E7 CD4+ cells and less than 3.2E5 CD8+ cells Dose level 4: 5E7 CD4+ cells and less than 1.6E6 CD8+ cells"
505844|NCT00356915|Drug|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
505845|NCT00356915|Drug|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
505846|NCT00356915|Drug|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
505847|NCT00356902|Procedure|titration of oxygen during resuscitation|
505848|NCT00356889|Drug|erlotinib hydrochloride|Given orally, 150 mg, once daily.
505849|NCT00356889|Biological|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
505850|NCT00356863|Behavioral|Increasing awareness to cardiac rehabilitation programs|Increasing awareness to cardiac rehabilitation programs: Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
505851|NCT00356850|Drug|Azithromycin|
505852|NCT00356837|Procedure|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
505853|NCT00356824|Drug|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
505854|NCT00356824|Drug|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
505855|NCT00356811|Drug|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
505856|NCT00356811|Drug|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
505857|NCT00356798|Biological|an inactivated whole virion H5N1 vaccine, adjuvanted|
505858|NCT00356785|Behavioral|health education|
505859|NCT00356785|Behavioral|food supplementation|
505860|NCT00356785|Behavioral|food supplementation combined with physical activity program|
505861|NCT00356772|Drug|Azithromycin|
505862|NCT00356759|Drug|Dosing warfarin every 12 weeks, sham INRs 2 out of 3 times|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
505863|NCT00356733|Drug|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
505864|NCT00356720|Drug|Azithromycin|
505865|NCT00356681|Drug|AMG 706 placebo|Blinded placebo
505866|NCT00356681|Drug|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
505867|NCT00356681|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
505868|NCT00356681|Drug|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
505869|NCT00356668|Device|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
505870|NCT00356655|Behavioral|Psychoeducation|
505871|NCT00356642|Drug|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
505872|NCT00356642|Drug|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
505873|NCT00356616|Drug|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
505874|NCT00356616|Drug|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
505875|NCT00356603|Drug|Sumatriptan Succinate|Sumatriptan Succinate
505876|NCT00356590|Biological|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
505877|NCT00356564|Biological|hepatitis B vaccine|
505878|NCT00356551|Behavioral|Family Spirit curriculum|
529829|NCT00151047|Drug|Capecitabine|
505879|NCT00356525|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
505880|NCT00356525|Drug|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
505881|NCT00356525|Drug|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
505882|NCT00356525|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
505883|NCT00356486|Drug|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
505884|NCT00356486|Drug|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
505885|NCT00356473|Drug|Atorvastatin|
505886|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
505887|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
505888|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
505889|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
505890|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
505891|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
505892|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
505893|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
505894|NCT00356447|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
505895|NCT00356447|Drug|Placebo|Same administration.
505896|NCT00356434|Device|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
505897|NCT00356434|Device|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
505898|NCT00356421|Drug|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
505899|NCT00356421|Drug|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
505900|NCT00356408|Biological|Certolizumab pegol|"Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).~Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2."
505901|NCT00356395|Drug|ramipril, candesartan|
505902|NCT00356382|Drug|Lactobacillus (L.) casei|
505903|NCT00356369|Biological|meningococcal ACWY (vaccine)|One intramuscular dose.
505904|NCT00356369|Biological|Mencevax™ ACWY|One subcutaneous dose.
505905|NCT00356356|Drug|Etanercept|Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
505906|NCT00356343|Device|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
505907|NCT00356343|Other|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
505908|NCT00356317|Behavioral|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
505909|NCT00356317|Behavioral|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
505910|NCT00356304|Behavioral|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
505911|NCT00356304|Behavioral|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
505912|NCT00356291|Behavioral|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
529830|NCT00151047|Drug|Docetaxel|
505913|NCT00356291|Behavioral|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
505914|NCT00356278|Drug|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
505915|NCT00356278|Drug|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
505916|NCT00356278|Behavioral|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
505917|NCT00356278|Drug|Placebo|Placebo will be administered in the same manner as the active drugs.
505918|NCT00356265|Drug|Procedure: Regional phenylephrine arterial infusion|
505919|NCT00356252|Drug|mixed carotenoids|
505920|NCT00356226|Drug|clonidine|
505921|NCT00356213|Procedure|sleeve gastrectomy|laparoscopic sleeve gastrectomy
505922|NCT00356213|Procedure|Roux-Y-gastric bypass|laparoscopic gastric bypass
505923|NCT00356200|Drug|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
505924|NCT00356200|Drug|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
505925|NCT00356187|Drug|Propranolol|
505926|NCT00356161|Device|interventionally implanted hepatic arterial port catheter|
505927|NCT00356148|Drug|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
505928|NCT00356135|Drug|prasugrel 10 mg|10 mg tablet taken orally
505929|NCT00356135|Drug|clopidogrel|75 mg tablet taken orally
505930|NCT00356135|Drug|prasugrel placebo|oral, as blinding mechanism.
505931|NCT00356135|Drug|prasugrel 60 mg|60 mg (six 10-mg tablets) taken orally
505932|NCT00356135|Drug|clopidogrel placebo|oral, as blinding mechanism
505933|NCT00356122|Drug|Docetaxel|70 mg/m^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
505934|NCT00356122|Drug|Oxaliplatin|100 mg/m^2 administered IV on Day 1 for Cycles 1-6
505935|NCT00356122|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
505936|NCT00356109|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
505937|NCT00356109|Drug|Injectable insulin|patient specific dose, injected, before meals, 6 months
505938|NCT00356109|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
505939|NCT00356096|Drug|pramipexole|
505940|NCT00356083|Drug|Methadone|
505941|NCT00356070|Drug|Strattera|
505942|NCT00356057|Device|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
505943|NCT00356044|Procedure|Coronary angioplasty|
505944|NCT00356031|Drug|Bevacizumab|Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses
505945|NCT00356031|Radiation|Radiation Therapy|External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.
505946|NCT00356031|Procedure|Surgery|Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
505947|NCT00356018|Behavioral|Compliance|
505948|NCT00356005|Drug|azithromycin plus artesunate|
505949|NCT00356005|Drug|Artesunate|
505950|NCT00355979|Device|intragastric balloon|
505951|NCT00355966|Drug|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
505952|NCT00355966|Drug|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
505953|NCT00355953|Drug|Genistein|
505954|NCT00355940|Device|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.~In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
505955|NCT00355940|Device|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
505956|NCT00355927|Procedure|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
505957|NCT00355914|Procedure|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
505958|NCT00355901|Drug|Visilizumab (Nuvion®; HuM291)|
505959|NCT00355888|Drug|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
505960|NCT00355875|Procedure|titration of oxygen during resuscitation|
505961|NCT00355862|Drug|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
505962|NCT00355862|Drug|Sirolimus|Sirolimus based immunosuppression
505963|NCT00355849|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
505964|NCT00355849|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
505965|NCT00355836|Behavioral|Mental Imagery|
505966|NCT00355810|Dietary Supplement|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
505967|NCT00355810|Dietary Supplement|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
505968|NCT00355797|Device|Closed Loop Stimulation (CLS)|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
505969|NCT00355797|Device|Standard Rate Adaptive (R) Technology|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
505970|NCT00355797|Device|Non-rate adaptive (DDD) pacing|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
505971|NCT00355784|Other|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
505972|NCT00355784|Drug|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
505973|NCT00355771|Drug|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
505974|NCT00355771|Drug|Placebo|1 tablet OD in the morning for 8 weeks
505975|NCT00355745|Device|Ultrasound breast scanning|breast scanning
505976|NCT00355732|Procedure|Weaning from mechanical ventilation|
505977|NCT00355719|Drug|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
505978|NCT00355719|Drug|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
505979|NCT00355719|Drug|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h*)
505980|NCT00355706|Procedure|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
505981|NCT00355693|Device|Pump for propofol delivery|
505982|NCT00355680|Device|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
505983|NCT00355680|Device|Green Laser (Iridex)|Already available green laser
505984|NCT00355667|Drug|furosemide|Patients with chronic heart failure receive furosemide and other standard treatment/
505985|NCT00355667|Drug|azosemide|Patients with chronic heart failure receive azosemide and other standard treatment.
505986|NCT00355654|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
505987|NCT00355654|Biological|DT3aP-HBs-IPV|0.5 mL, IM
505988|NCT00355641|Drug|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
505989|NCT00355628|Drug|KW-2246 (fentanyl citrate)|KW-2246
505990|NCT00355615|Drug|Rosuvastatin|oral
505991|NCT00355615|Drug|Placebo|oral
505992|NCT00355602|Drug|Cefuroxime|
505993|NCT00355602|Drug|Ciprofloxacin|
505994|NCT00355602|Drug|Clarithromycin|
505995|NCT00355602|Drug|Cotrimoxazole|
505996|NCT00355602|Drug|Coamoxiclav|
505997|NCT00355602|Drug|metronidazole|
505998|NCT00355602|Drug|neomycin|
505999|NCT00355602|Drug|rifaximin|
506000|NCT00355602|Drug|Vancomycin|
506001|NCT00355602|Drug|Doxycycline|
506002|NCT00355589|Drug|Ramipril and hydrochlorothiazide|
506003|NCT00355576|Drug|Celecoxib|Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
506004|NCT00355576|Drug|Creatine|10 g BID for either study arm
506005|NCT00355576|Drug|Minocycline|Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
506006|NCT00355563|Device|PAS-Port Automated Proximal Anastomosis System|
506007|NCT00355550|Drug|Ketasyn|
506008|NCT00355537|Drug|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
506009|NCT00355537|Drug|0.9% saline|Saline injection intramuscular every 2 weeks
506010|NCT00355524|Drug|TMC114|TMC114 will be administered as oral tablets (75 milligram [mg] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
506011|NCT00355524|Drug|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
506012|NCT00355511|Behavioral|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
506013|NCT00355485|Device|microdermabrasion|"Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.~Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart."
506014|NCT00355472|Drug|KW-0761|IV administration at 4 escalating dose levels.
506015|NCT00355459|Drug|Tetracycline: Doxycycline analog|
506016|NCT00355446|Drug|Bimatoprost 0.03%|
506017|NCT00355433|Procedure|Urodymanics|
506018|NCT00355407|Drug|Darbepoetin alfa|
506019|NCT00355394|Drug|Metoclopramide|Intravenous bolus administration.
506020|NCT00355394|Other|Placebo|Standard care including intravenous fluid, but no metoclopramide.
506021|NCT00355381|Behavioral|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
506022|NCT00355368|Drug|Succinylcholine|1mg/kg iv
506023|NCT00355368|Drug|Rocuronium|0.6mg/kg iv
506024|NCT00355355|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
506025|NCT00355355|Device|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
506026|NCT00355355|Procedure|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
506027|NCT00355355|Procedure|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
506028|NCT00355342|Drug|Salmeterol 50 mcg BID|Salmeterol xinafoate 50 mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
506029|NCT00355342|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg BID|Fluticasone propionate/salmeterol xinafoate combination product 250/50mcg strength DISKUS inhaler (formulated with lactose), BID in the morning and evening.
506030|NCT00355342|Device|DISKUS inhaler|Each participant received study medication via the DISKUS, for one of two possible treatment groups. Each DISKUS contained 60 doses of study medication. Participants were instructed to administer medication BID (one inhalation in the morning and one inhalation in the evening) approximately 12 hours apart for 156-week treatment period.
506031|NCT00355329|Procedure|Tongue Acupuncture (Procedure)|
506032|NCT00355316|Other|Blood draw|
506033|NCT00355303|Drug|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
506034|NCT00355303|Drug|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
506035|NCT00355290|Behavioral|Changes on Oral Vitamin K Intake|
506036|NCT00355277|Drug|Amitriptyline|
506037|NCT00355264|Drug|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
506038|NCT00355251|Drug|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
506039|NCT00355238|Drug|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
506040|NCT00355225|Procedure|ITN distribution channel|
506041|NCT00355212|Procedure|percutaneous ablation of hepatocellular carcinoma|
506042|NCT00355199|Drug|Rituximab-HDS|Rituximab-HDS
506043|NCT00355199|Drug|Rituximab-CHOP|Rituximab-CHOP
506044|NCT00355186|Procedure|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
506045|NCT00355173|Device|Lubo cervical collar|
506046|NCT00355147|Behavioral|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
506047|NCT00355147|Behavioral|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
506048|NCT00355147|Other|Attention Control Group|Received Phone Calls from Staff to Control for Attention
506049|NCT00355134|Drug|Fingolimod|Fingolimod capsules for oral administration
506050|NCT00355134|Drug|Placebo|Matching placebo capsules for oral administration.
506051|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
506052|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
506053|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
506054|NCT00355108|Drug|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
506055|NCT00355095|Drug|Erythropoietin|intravenous daily 3.3 *10^4 Units, duration 3 days
506056|NCT00355082|Drug|lamotrigine, 300 mg/day|300 mg/day
506057|NCT00355082|Drug|lamotrigine, 250 mg/day|250 mg/day
506058|NCT00355069|Behavioral|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
506059|NCT00355056|Other|Sham Procedure|Sham Procedure
506060|NCT00355056|Device|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
506061|NCT00355043|Drug|Zinc sulphate 20 mg|
506062|NCT00355030|Drug|somatropin|0.05 mg/kg/day
506063|NCT00355030|Drug|leuprorelin|11.25 mg/3 months
506064|NCT00355017|Procedure|BNP-guided care in addition to multidisciplinary management|
506065|NCT00355004|Other|counseling intervention|
506066|NCT00355004|Procedure|fecal occult blood test|
506067|NCT00355004|Procedure|screening colonoscopy|
506068|NCT00354991|Drug|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
506069|NCT00354978|Drug|5-Fluorouracil|"400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.~2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection."
506070|NCT00354978|Drug|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.~5 mg/kg by vein on Day 1 of 14 day cycle."
506071|NCT00354978|Drug|Leucovorin|400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
506072|NCT00354978|Drug|Irinotecan|180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.
506123|NCT00354679|Radiation|radiation therapy|
506073|NCT00354965|Drug|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
506074|NCT00354952|Drug|Macrolides (azithromycin or clarithromycin)|
506075|NCT00354939|Drug|Insulin glargine|
506076|NCT00354926|Biological|AME-133v (LY2469298)|IV 4X weekly X 4
506077|NCT00354913|Drug|hydroxyurea|Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
506078|NCT00354913|Drug|imatinib mesylate|"Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.~Dose for Imatinib:~Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.~If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately."
506079|NCT00354900|Drug|Aprotinin|
506080|NCT00354887|Drug|Capecitabine|Oral capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m^2) on Days 1-14 in 21 Day Cycle.
506081|NCT00354887|Drug|Oxaliplatin|130 mg/m^2 by vein Day 1 over 2 hours in 21 Day Cycle
506082|NCT00354874|Drug|GW642444|drug
506083|NCT00354874|Drug|Placebo|placebo
506084|NCT00354874|Drug|salmeterol 50mcg|salmeterol
506085|NCT00354861|Biological|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
506086|NCT00354861|Biological|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
506087|NCT00354861|Biological|Engerix B|20 µg hepatitis B antigen absorbed on alum
506088|NCT00354835|Drug|Irinotecan Hydrochloride|Given IV
506089|NCT00354835|Biological|Dactinomycin|Given IV
506090|NCT00354835|Drug|Cyclophosphamide|Given IV
506091|NCT00354835|Drug|Vincristine Sulfate|Given IV
506092|NCT00354835|Radiation|Radiation Therapy|Undergo radiotherapy
506093|NCT00354835|Other|Laboratory Biomarker Analysis|Correlative studies
506094|NCT00354835|Other|Questionnaire Administration|Ancillary studies
506095|NCT00354822|Drug|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
506096|NCT00354809|Drug|GW679769|
506097|NCT00354770|Drug|Placebo|daily
506098|NCT00354770|Drug|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
506099|NCT00354757|Drug|rabeprazole|
506100|NCT00354744|Biological|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), < 1 year 0.025 mg/kg.~Day 1 of Weeks 35, 38, 41 and 44.~Given IV"
506101|NCT00354744|Drug|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, <3 years 40 mg/kg.~Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.~Given IV"
506102|NCT00354744|Drug|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².~Days 1 and 2 of weeks 7, 11, 15, 28 and 32.~Given IV"
506103|NCT00354744|Drug|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
506104|NCT00354744|Drug|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.~Days 1-5 of weeks 9, 13, 17, 26 and 30.~Given IV"
506105|NCT00354744|Drug|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.~Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.~Given IV"
506106|NCT00354744|Drug|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and < 3 years 0.05 mg/kg (max dose 2 mg), < 1 year 0.025 mg/kg.~Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.~Given IV"
506107|NCT00354744|Procedure|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
506108|NCT00354744|Radiation|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
506109|NCT00354744|Biological|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.~Given subcutaneously."
506110|NCT00354731|Drug|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
506111|NCT00354731|Drug|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
506112|NCT00354705|Behavioral|Questionnaire|Two questionnaires taking 30 minutes to complete.
506113|NCT00354692|Drug|Sodium Ferric Gluconate and Iron sucrose|
506114|NCT00354679|Biological|bevacizumab|
506115|NCT00354679|Drug|cisplatin|
506116|NCT00354679|Drug|irinotecan hydrochloride|
506117|NCT00354679|Genetic|proteomic profiling|
506118|NCT00354679|Other|diagnostic laboratory biomarker analysis|
506119|NCT00354679|Other|mass spectrometry|
506120|NCT00354679|Procedure|adjuvant therapy|
506121|NCT00354679|Procedure|neoadjuvant therapy|
506122|NCT00354679|Procedure|therapeutic conventional surgery|
506126|NCT00354640|Drug|anastrozole|1 milligram tablet PO QD for 14 days
506127|NCT00354640|Drug|simvastatin|40 milligram tablet PO QD for 14 days
506128|NCT00354640|Other|pharmacological study|laboratory analysis
506129|NCT00354640|Procedure|adjuvant therapy|laboratory analysis
506130|NCT00354627|Drug|TMC125|200 mg b.i.d. till commercially available.
506131|NCT00354614|Device|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
506132|NCT00354601|Drug|capecitabine|oral capecitabine twice daily on days 1-21
506133|NCT00354601|Drug|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
506134|NCT00354575|Drug|Chinese Herb: CCH1|1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
506135|NCT00354562|Drug|ABT-751|200mg ABT-751 daily for 14 days every 21 days
506136|NCT00354562|Drug|Placebo|Placebo daily for 14 days every 21 days
506137|NCT00354562|Drug|Docetaxel|Standard Docetaxel every 21 days
506138|NCT00354549|Drug|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
506139|NCT00354549|Drug|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
506140|NCT00354536|Drug|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
506141|NCT00354536|Biological|placebo injection|placebo injection
506142|NCT00354523|Drug|Capecitabine (Xeloda)|Starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle.
506143|NCT00354523|Drug|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle.
506144|NCT00354523|Drug|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
506145|NCT00354510|Drug|GW842470X cream|
506146|NCT00354497|Other|physiologic testing|
506147|NCT00354497|Other|study of socioeconomic and demographic variables|
506148|NCT00354497|Procedure|evaluation of cancer risk factors|
506149|NCT00354497|Procedure|mutation carrier screening|
506150|NCT00354497|Procedure|study of high risk factors|
506151|NCT00354484|Drug|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
506152|NCT00354484|Drug|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
506153|NCT00354471|Procedure|Uterine Artery Embolization|
506154|NCT00354458|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
506155|NCT00354458|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
506156|NCT00354445|Drug|pegaptanib sodium (Macugen)|
506157|NCT00354432|Dietary Supplement|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
506158|NCT00354432|Drug|Venlafaxine|Patients receive oral venlafaxine 75mg.
506159|NCT00354432|Dietary Supplement|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
506160|NCT00354432|Drug|Placebo Pill|Patients receive oral placebo pill.
506161|NCT00354419|Radiation|total-body irradiation|Undergo radiotherapy
506162|NCT00354419|Drug|cyclophosphamide|Given IV
506163|NCT00354419|Biological|anti-thymocyte globulin|Given IV
506164|NCT00354419|Drug|cyclosporine|Given IV
506165|NCT00354419|Procedure|umbilical cord blood transplantation|Undergo transplantation
506166|NCT00354419|Drug|mycophenolate mofetil|Given IV or orally
506167|NCT00354419|Procedure|bone marrow aspiration|Correlative study
506168|NCT00354419|Genetic|DNA analysis|Correlative study
506169|NCT00354419|Biological|filgrastim|Given IV or SC
506170|NCT00354406|Drug|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
506171|NCT00354393|Drug|cisplatin|
506172|NCT00354393|Drug|methotrexate|
506173|NCT00354393|Drug|vinorelbine ditartrate|
506174|NCT00354393|Procedure|adjuvant therapy|
506175|NCT00354393|Procedure|conventional surgery|
506176|NCT00354393|Procedure|neoadjuvant therapy|
506177|NCT00354393|Radiation|3-dimensional conformal radiation therapy|
506178|NCT00354393|Radiation|intensity-modulated radiation therapy|
506179|NCT00354380|Drug|Methylene blue|
506180|NCT00354380|Drug|Artesunate|
506181|NCT00354380|Drug|Amodiaquine|
506182|NCT00354367|Drug|Certolizumab pegol|
506183|NCT00354354|Drug|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
506184|NCT00354341|Drug|Epoetin beta|
506185|NCT00354315|Behavioral|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
506186|NCT00354302|Dietary Supplement|calcium carbonate|
506187|NCT00354302|Dietary Supplement|calcium citrate|
506188|NCT00354302|Dietary Supplement|cholecalciferol|
506189|NCT00354302|Drug|alendronate sodium|
506190|NCT00354302|Drug|calcium gluconate|
506191|NCT00354302|Drug|risedronate sodium|
506192|NCT00354302|Other|laboratory biomarker analysis|
506193|NCT00354302|Procedure|dual x-ray absorptometry|
506194|NCT00354276|Drug|cytarabine|
506195|NCT00354276|Drug|laromustine|
506237|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
506238|NCT00354081|Drug|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
529831|NCT00151034|Drug|Trastuzumab|
506196|NCT00354263|Biological|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
506197|NCT00354263|Biological|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
506198|NCT00354250|Drug|ispinesib|Given IV
506199|NCT00354237|Other|Conventional antidiabetic treatment|No intensive treatment
506200|NCT00354237|Other|Intensive insulin treatment|Intensive insulin treatment
506201|NCT00354224|Drug|capecitabine|
506202|NCT00354224|Drug|oxaliplatin|
506203|NCT00354211|Device|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
506204|NCT00354198|Drug|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
506205|NCT00354198|Drug|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
506206|NCT00354185|Drug|tanespimycin|Given IV
506207|NCT00354185|Drug|belinostat|Given IV
506208|NCT00354185|Other|laboratory biomarker analysis|Correlative studies
506209|NCT00354185|Other|pharmacological study|Correlative studies
506210|NCT00354172|Biological|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If < 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
506211|NCT00354172|Biological|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
506212|NCT00354172|Biological|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
506213|NCT00354172|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
506214|NCT00354172|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
506215|NCT00354172|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
506216|NCT00354172|Drug|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.~Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
506217|NCT00354172|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients~≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.~Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9 /L)."
506218|NCT00354172|Procedure|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
506219|NCT00354172|Radiation|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13)."
506220|NCT00354159|Device|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
506221|NCT00354146|Drug|tipifarnib (R115777)|
506222|NCT00354133|Device|Kinetra and Soletra (neurostimulator, Medtronic)|Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.
506223|NCT00354133|Drug|Best Medical Treatment|Patients in this arm get best medical treatment only
506224|NCT00354120|Drug|Alentuzumab|Alentuzumab
506225|NCT00354120|Drug|Globulina antilinfocitaria|Globulina antilinfocitaria
506226|NCT00354107|Biological|monoclonal antibody SGN-30|Given IV
506227|NCT00354107|Drug|therapeutic hydrocortisone|Given IT
506228|NCT00354107|Drug|ifosfamide|Given IV
506229|NCT00354107|Drug|carboplatin|Given IV
506230|NCT00354107|Drug|etoposide|Given IV
506231|NCT00354107|Drug|methotrexate|Given IT
506232|NCT00354107|Drug|cytarabine|Given IT
506233|NCT00354107|Other|pharmacological study|Correlative studies
506234|NCT00354107|Other|laboratory biomarker analysis|Correlative studies
506235|NCT00354094|Drug|[S,S]-Reboxetine|
506236|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
506239|NCT00354081|Drug|placebo|placebo, in a capsule, taken orally once a day
506242|NCT00354068|Other|pharmacological study|
506243|NCT00354042|Drug|GW597901X|
506244|NCT00354029|Drug|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
506245|NCT00354029|Drug|Placebo|isotonic saline
506246|NCT00354016|Biological|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
506247|NCT00354003|Behavioral|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
506248|NCT00353990|Drug|Insulin Aspart|
506249|NCT00353977|Biological|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.~Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.~Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
506250|NCT00353964|Drug|rEV131|
506251|NCT00353964|Drug|Prenisolone sodium phosphate 1.0%|
506252|NCT00353964|Drug|rEV131 vehicle|
506253|NCT00353938|Drug|3,4-methylenedioxymethamphetamine 125 mg|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2-2.5 hours later they receive 62.5 mg MDMA orally.
506254|NCT00353938|Drug|3,4-methyelendioxymethamphetamine 25 mg|Participants will receive a 25 mg MDMA and if investigator and participant agree, 2 to 2.5 hours later a dose of 12.5 mg MDMA.
506255|NCT00353938|Behavioral|Psychotherapy|Psychotherapy performed by a team of two co-therapists
506256|NCT00353912|Drug|valsartan + amlodipine|
506257|NCT00353886|Procedure|TONI-3|
506258|NCT00353886|Procedure|WRAT-3|
506259|NCT00353886|Procedure|Connor's Rating Scales PRS & TRS|
506260|NCT00353886|Procedure|Peabody Picture Vocabulary Test|
506261|NCT00353886|Procedure|Children's Memory Scale|
506262|NCT00353886|Procedure|WISC-3|
506263|NCT00353886|Procedure|Behavioral Assessment System for Children PRS & TRS|
506264|NCT00353873|Drug|Fluticasone propionate|200μg twice daily
506265|NCT00353873|Drug|Fluticasone propionate/salmeterol|50/100μg twice daily
506266|NCT00353860|Device|SOLEX 300i Stem Cell Selection|
506267|NCT00353847|Device|Acupuncture|
506268|NCT00353834|Drug|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
506269|NCT00353834|Drug|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
506270|NCT00353808|Drug|[S,S]-Reboxetine|
506271|NCT00353795|Procedure|MR Imaging of the Coronary Arteries|
506272|NCT00353769|Procedure|Hair Apposition Technique|
506273|NCT00353756|Drug|C326, IL-6 Inhibitory Avimer protein|
506274|NCT00353743|Drug|placebo|placebo
506275|NCT00353743|Drug|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
506276|NCT00353717|Drug|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
506277|NCT00353704|Drug|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
506278|NCT00353704|Drug|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
506279|NCT00353704|Drug|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
506280|NCT00353691|Drug|glimepiride|
506281|NCT00353691|Drug|metformin|
506282|NCT00353678|Drug|YM150|
506283|NCT00353665|Drug|Memantine (Ebixa)|10 mg bid
506284|NCT00353665|Drug|riluzole|riluzole 50 mg bid
506285|NCT00353665|Drug|Placebo|
506286|NCT00353652|Drug|Study#1: chlorthalidone (CTD), titrated dose|Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg
506287|NCT00353652|Drug|Study #1: spironolactone (SP), titrated dose|Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP < 130/80 mmHg.
506288|NCT00353652|Drug|Study# 2 chlorthalidone (CTD), fixed dose|Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
506289|NCT00353652|Drug|Study# 2 spironolactone (SP), fixed dose|Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
506290|NCT00353652|Drug|Study# 2 irbsesartan (IR), fixed dose|Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.
506291|NCT00353613|Behavioral|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
506292|NCT00353587|Drug|MBX-102|MBX-102 200 mg once daily for 16 weeks
506293|NCT00353587|Drug|MBX-102|MBX-102 400 mg once daily for 16 weeks
506294|NCT00353587|Drug|MBX-102|MBX-102 600 mg once daily for 16 weeks
506295|NCT00353587|Drug|Placebo|MBX-102 Placebo once daily for 16 weeks
506296|NCT00353587|Drug|Actos|Actos 30 mg once daily for 16 weeks
506297|NCT00353574|Drug|Darusentan|Darusentan capsules administered orally once daily
506298|NCT00353561|Drug|Boric|Gelatin capsules filled with 600 mg of boric acid
506299|NCT00353561|Drug|Fluconazole|150 mg oral fluconazole gives once in 14 days
506300|NCT00353535|Procedure|Total Lymphoid irradiation|
506301|NCT00353522|Drug|Placebo|po daily for 24 weeks
506302|NCT00353522|Drug|dalcetrapib|900mg po daily for 24 weeks
506303|NCT00353509|Device|Device Closure of a Septal Defect|
506304|NCT00353496|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
506305|NCT00353496|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
506306|NCT00353483|Procedure|Peripheral blood draw|
506307|NCT00353483|Procedure|Breast tissue collection|
506308|NCT00353483|Procedure|Bone marrow biopsy|
506309|NCT00353470|Behavioral|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
506310|NCT00353470|Behavioral|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
506311|NCT00353470|Behavioral|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
506312|NCT00353457|Drug|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
506313|NCT00353457|Radiation|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
506314|NCT00353431|Drug|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
506315|NCT00353418|Drug|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
506316|NCT00353418|Drug|Ribavirin|800 mg orally daily for 48 weeks
506317|NCT00353418|Drug|Ribavirin|1000 mg or 1200 mg (based on patient weight of < 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
506318|NCT00353405|Behavioral|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
506319|NCT00353405|Behavioral|Mass media|Mass media provides messages that support sexual health skills.
506320|NCT00353405|Behavioral|Control|Control group received no social skills training and no media mass media messages.
506321|NCT00353392|Device|Laser Therapy|
506322|NCT00353379|Drug|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
506323|NCT00353379|Drug|Placebo|Participants will take placebo for 6 weeks.
506324|NCT00353366|Biological|Rotarix|Two doses of the oral vaccine
506325|NCT00353366|Other|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
506326|NCT00353353|Procedure|consumption of fortified bread|
506327|NCT00353340|Drug|n acetylcysteine|
506328|NCT00353340|Drug|sodium bicarbonate|
506329|NCT00353340|Drug|sodium chloride|
506330|NCT00353327|Procedure|Plasma infusion|
506331|NCT00353301|Drug|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
506332|NCT00353301|Drug|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
506333|NCT00353288|Biological|MeMuRu-OKA (study vacc)|
506334|NCT00353288|Biological|MMR, Varicella vacc (control)|
506335|NCT00353275|Drug|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
506336|NCT00353275|Drug|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
506337|NCT00353262|Drug|Avastin|7.5mg/kg iv (cycle 3 only)
506338|NCT00353262|Drug|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
506339|NCT00353262|Drug|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
506340|NCT00353249|Behavioral|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
506341|NCT00353223|Behavioral|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
506342|NCT00353223|Behavioral|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
506343|NCT00353184|Drug|Montelukast 5-mg orally added to standard therapy|
506344|NCT00353158|Drug|Doxycycline|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
506345|NCT00353158|Drug|Voriconazole|After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
506346|NCT00353145|Drug|Gemcitabine (Gemox)|1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 repeated every 14 days (one cycle).
506347|NCT00353145|Drug|Oxaliplatin|100 mg/m^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
506348|NCT00353145|Behavioral|Questionnaire|Quality of Life Surveys
506349|NCT00353119|Drug|Placebo comparator|Patients received placebo subcutaneously twice weekly
506350|NCT00353119|Drug|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
506351|NCT00353106|Behavioral|Interview|30-minute interviews of participating patients and their caregiver(s).
506352|NCT00353106|Behavioral|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
506353|NCT00353093|Procedure|Ultrasonography of the deep vein system of the legs|
506354|NCT00353080|Drug|risedronate (HMR4003)|
506355|NCT00353067|Drug|veliflapon (DG-031)|
506357|NCT00353054|Behavioral|Weight loss intervention|
506358|NCT00353041|Drug|lidocaine topical|
506359|NCT00353028|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
506360|NCT00353028|Drug|Placebo|Placebo
506361|NCT00353015|Drug|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
506362|NCT00353015|Drug|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
506363|NCT00353002|Drug|Ametop (4% Amethocaine cream )|
506364|NCT00353002|Drug|Maxilene (4% Liposomal Lidocaine)|
506365|NCT00352989|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
506366|NCT00352976|Drug|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
506367|NCT00352976|Drug|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m^2 intravenous (IV)
506368|NCT00352976|Procedure|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
506369|NCT00352976|Procedure|Bone Marrow Transplantation|A target of 5 * 10^6/kg and a minimum of 4 * 10^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
506370|NCT00352976|Drug|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 * 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
506371|NCT00352976|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
506372|NCT00352963|Biological|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
506373|NCT00352950|Drug|AMG 954/Panitumumab|
506374|NCT00352911|Drug|VGX-410 (Mifepristone)|
506375|NCT00352911|Drug|Placebo for VGX-410 (Mifepristone)|
506376|NCT00352898|Biological|MeMuRu-OKA (study vac)|
506377|NCT00352898|Biological|MMR, Varicella vacc (control)|
506378|NCT00352885|Drug|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
506379|NCT00352885|Drug|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
506380|NCT00352885|Drug|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
506381|NCT00352859|Drug|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
506382|NCT00352859|Drug|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
506383|NCT00352846|Drug|Zoledronic Acid|4 mg/m^2 by vein over 30 Minutes at baseline and 6 months.
506384|NCT00352846|Drug|Vitamin D|400 mg by mouth daily
506385|NCT00352846|Drug|Calcium Carbonate|1200 mg by mouth daily
506386|NCT00352833|Drug|catumaxomab|
506387|NCT00352820|Behavioral|Interview|Recorded face-to-face session.
506388|NCT00352820|Behavioral|Questionnaire|Written survey lasting approximately 30 minutes.
506389|NCT00352807|Drug|Brimonidine Purite|
506390|NCT00352794|Drug|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
506391|NCT00352794|Drug|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
506392|NCT00352781|Drug|nicotine replacement therapy|nicotine transdermal patches as per product monograph
506393|NCT00352781|Behavioral|behavioural intervention|Smoking cessation counselling and relapse prevention
506394|NCT00352768|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
506395|NCT00352768|Drug|Placebo|Placebo
506396|NCT00352755|Procedure|Surgical debulking with peritonectomy|
506397|NCT00352755|Drug|Intraperitoneal 5FU|
506398|NCT00352755|Drug|FOLFOX|
506399|NCT00352742|Drug|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
506400|NCT00352729|Device|ACell dressing|dressing
506401|NCT00352716|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
506402|NCT00352703|Drug|Kepivance (Palifermin)|
506403|NCT00352690|Drug|Paclitaxel poliglumex|
506404|NCT00352690|Drug|Carboplatin|
506405|NCT00352690|Radiation|External beam radiation therapy|
506406|NCT00352677|Drug|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
506407|NCT00352664|Drug|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
506716|NCT00350246|Procedure|Laser Refractive Surgery|
506408|NCT00352664|Drug|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
506409|NCT00352651|Drug|Pregabalin|
506410|NCT00352638|Other|counseling intervention|
506411|NCT00352638|Other|educational intervention|
506412|NCT00352638|Other|study of socioeconomic and demographic variables|
506413|NCT00352625|Drug|Ketoprofen Topical Patch 20%|
506414|NCT00352612|Drug|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
506415|NCT00352612|Drug|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
506416|NCT00352599|Drug|Lovastatin|
506417|NCT00352599|Drug|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
506418|NCT00352599|Drug|placebo pill|
506419|NCT00352560|Drug|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
506420|NCT00352560|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
506421|NCT00352534|Procedure|therapeutic conventional surgery|Undergo surgery
506422|NCT00352534|Drug|vincristine sulfate|Given IV
506423|NCT00352534|Biological|dactinomycin|Given IV
506424|NCT00352534|Drug|doxorubicin hydrochloride|Given IV
506425|NCT00352534|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
506426|NCT00352521|Drug|bevacizumab|
506427|NCT00352521|Drug|irinotecan|
506428|NCT00352521|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
506429|NCT00352508|Behavioral|Dietary advice|
506430|NCT00352495|Drug|carboplatin|
506431|NCT00352495|Drug|vinblastine sulfate|
506432|NCT00352482|Drug|Sildenafil (50 mg)|
506433|NCT00352469|Drug|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
506434|NCT00352443|Drug|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
506435|NCT00352443|Drug|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
506436|NCT00352430|Drug|Nitric Oxide/INP Pulse Delivery|
506437|NCT00352430|Drug|Nitric Oxide/INO Pulse Delivery|
506438|NCT00352417|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
506439|NCT00352417|Drug|Placebo|oral dosing, 1 time daily for 12 weeks
506440|NCT00352404|Device|Endomicroscope|
506441|NCT00352391|Other|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
506442|NCT00352378|Drug|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:~Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
506443|NCT00352365|Drug|lenalidomide|Given orally
506444|NCT00352352|Procedure|Tongue Acupuncture (Procedure)|
506445|NCT00352339|Drug|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
506446|NCT00352339|Drug|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
506447|NCT00352339|Drug|Abilify|Start with abilify and keep it through the end of study
506448|NCT00352326|Device|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
506449|NCT00352313|Drug|ATN-161|Given IV
506450|NCT00352313|Drug|carboplatin|Given IV
506451|NCT00352300|Procedure|Adjuvant Therapy|
506452|NCT00352300|Drug|Carboplatin|Given IV
506453|NCT00352300|Drug|Paclitaxel|Given IV
506454|NCT00352300|Biological|Pegfilgrastim|Given IV
506455|NCT00352287|Drug|Recombinant human growth hormone; pioglitazone|
506456|NCT00352261|Drug|Esomeprazole|
506457|NCT00352261|Drug|Lansoprazole|
506458|NCT00352248|Procedure|Tongue Acupuncture (Procedure)|
506459|NCT00352235|Drug|KRN7000|
506460|NCT00352222|Device|stent implantation|
506461|NCT00352196|Drug|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
506462|NCT00352196|Other|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
506463|NCT00352183|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
506464|NCT00352183|Drug|Simvastatin|Simvastatin 40mg
506465|NCT00352170|Dietary Supplement|calcium supplementation|calcium carbonate 1500 mg/day
506466|NCT00352170|Dietary Supplement|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
506467|NCT00352170|Dietary Supplement|Placebo|calcium and vitamin D3 placebo
506468|NCT00352157|Behavioral|Revival Soy Dietary Supplement|
506469|NCT00352144|Drug|Eszopiclone|Eszopiclone 3 mg
506470|NCT00352144|Drug|Placebo|Placebo tablet
506471|NCT00352131|Drug|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
506472|NCT00352118|Biological|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
506473|NCT00352118|Biological|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
506474|NCT00352118|Drug|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
506475|NCT00352118|Drug|docetaxel|Intravenous over 1 hour on day 1.
506476|NCT00352118|Drug|fluorouracil|Intravenous continuously on days 1-4.
506477|NCT00352118|Procedure|conventional surgery|As appropriate, neck dissection.
506478|NCT00352118|Radiation|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
506479|NCT00352105|Drug|cisplatin|20mg/m2/d IV continuous infusion x4 days
506480|NCT00352105|Drug|fluorouracil|1000mg.m2/d IV continuous x 4 days
506481|NCT00352105|Drug|Iressa|250mg/PO qd x 2 years
506482|NCT00352105|Radiation|hyperfractionated radiation therapy|120cGy bid
506483|NCT00352092|Drug|calcineurin inhibitor|
506484|NCT00352092|Drug|sirolimus|
506485|NCT00352092|Drug|mycophenolate mofetil|
506486|NCT00352079|Biological|BCG vaccine|"Intravesical BCG:~Induction:~q weekly x 6 (cycle 1)~Maintenance:~q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
506487|NCT00352079|Drug|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
506488|NCT00352079|Procedure|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
506489|NCT00352066|Drug|apricitabine|
506490|NCT00352053|Drug|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
506491|NCT00352053|Drug|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
506492|NCT00352027|Drug|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
506493|NCT00352027|Drug|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
506494|NCT00352027|Drug|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
506495|NCT00352027|Drug|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
506496|NCT00352027|Drug|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
506497|NCT00352027|Drug|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
506498|NCT00352027|Drug|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
506499|NCT00352027|Drug|Prednisone|Given PO every other day of weeks 1-12.
506500|NCT00352027|Biological|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
506501|NCT00352027|Procedure|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
506502|NCT00352001|Drug|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
506503|NCT00352001|Drug|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
506504|NCT00351988|Behavioral|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
506505|NCT00351988|Behavioral|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
506506|NCT00351975|Drug|Belinostat|Given IV
506507|NCT00351975|Drug|Azacitidine|Given SC
506508|NCT00351975|Other|Laboratory Biomarker Analysis|Correlative studies
506509|NCT00351962|Procedure|Fractionated Stereotactic Radiotherapy|
506510|NCT00351949|Biological|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
506511|NCT00351936|Drug|Aripiprazole|
506512|NCT00351936|Drug|placebo|
506513|NCT00351923|Biological|MeMuRu-OKA (study vaccine)|
506514|NCT00351910|Drug|Quetiapine|
506515|NCT00351910|Drug|Amitriptyline|
506516|NCT00351910|Drug|Bupropion|
506517|NCT00351910|Drug|Citalopram|
506518|NCT00351910|Drug|Duloxetine|
506519|NCT00351910|Drug|Escitalopram|
506520|NCT00351910|Drug|Fluoxetine|
506521|NCT00351910|Drug|Paroxetine|
506522|NCT00351910|Drug|Sertraline|
506523|NCT00351910|Drug|Venlafaxine|
506524|NCT00351897|Device|pulsed dye (585nm) laser therapy|
506525|NCT00351884|Drug|Vildagliptin AM|
506526|NCT00351884|Drug|vildagliptin pm|
506527|NCT00351884|Drug|placebo|
506528|NCT00351871|Drug|PEG-Intron Plus REBETOL|
506529|NCT00351858|Drug|ertumaxomab|
506530|NCT00351845|Behavioral|Low carbohydrate diet (behavior)|
506531|NCT00351832|Drug|Vildagliptin|
506532|NCT00351819|Drug|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
506533|NCT00351819|Other|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
506534|NCT00351806|Drug|Erigeron breviscapus injection|
506535|NCT00351806|Drug|hua tuo zai zao wan (a herbal medicine pill)|
506536|NCT00351806|Drug|Compound stroke herbal medicine (8 herbal)|
506537|NCT00351793|Device|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
506538|NCT00351780|Device|FFR measurement, side branch angioplasty|
506539|NCT00351767|Drug|placebo|Topically applied
506540|NCT00351767|Drug|telbermin|Topically applied
506541|NCT00351754|Drug|Isovue|
506542|NCT00351741|Device|Ventilation - High Frequency Percussive Ventilation|Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator
506543|NCT00351741|Device|Ventilation - ARDSnet|Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
506544|NCT00351715|Drug|Sublingual Methadone|
506545|NCT00351702|Drug|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
506546|NCT00351689|Behavioral|dietary supplement|
506547|NCT00351676|Behavioral|Integration of a team based clinical pharmacist|
506548|NCT00351676|Drug|Optimizing therapeutic treatments|
506549|NCT00351676|Behavioral|Optimizing processes of care|
506550|NCT00351663|Drug|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:~Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)~Subcutaneous Enoxaparine 40mg x1/day"
506551|NCT00351637|Drug|Sublingual Methadone|
506552|NCT00351624|Behavioral|DHA|
506553|NCT00351624|Behavioral|placebo|
506554|NCT00351611|Drug|Lyrica (pregabalin)|150 mg twice a day, oral administration
506555|NCT00351611|Drug|placebo|Twice a day, oral administration
506556|NCT00351598|Radiation|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
506557|NCT00351585|Drug|Vildagliptin|
506558|NCT00351572|Procedure|Cell Search Assay|
506559|NCT00351559|Device|AlloMap molecular expression testing|
506560|NCT00351559|Procedure|Right ventricular endomyocardial biopsy|
506561|NCT00351546|Drug|Vildagliptin|
506562|NCT00351533|Drug|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
506563|NCT00351520|Drug|Miltefose|
506564|NCT00351507|Drug|Vildagliptin|
506565|NCT00351494|Procedure|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.~Abdominal route 2.4 ml sonovue per injection / bolus"
506566|NCT00351494|Procedure|embolization|Intervention is described in the case report form for each patient
506567|NCT00351468|Drug|eltrombopag olamine (SB-497115-GR)|Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
506568|NCT00351455|Behavioral|smoking cessation|
506569|NCT00351455|Behavioral|tighter diabetic control|
506570|NCT00351455|Behavioral|diet and exercise program|
506571|NCT00351429|Device|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
506572|NCT00351416|Drug|Letrozole|Letrozole 20 mg orally one time
506573|NCT00351416|Drug|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
506574|NCT00351403|Drug|Ribavirin|Rebetol 200 mg: applied as hard capsule
506575|NCT00351403|Drug|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
506576|NCT00351390|Other|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
506577|NCT00351390|Other|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP <1000 pg/mL
506578|NCT00351377|Drug|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
506579|NCT00351364|Drug|Montelukast Sodium|100 mg P.O. One time only
506580|NCT00351351|Device|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
506581|NCT00351351|Device|single probe ultrasonic|FDA-approved - single probe ultrasonic
506582|NCT00351325|Drug|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
506583|NCT00351312|Device|special socks|
506584|NCT00351299|Drug|Dexmedetomidine|dexmedetomidine infusion titrated to effect
506585|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
506586|NCT00351286|Drug|L-citrulline tablets, 1000 mg|
506587|NCT00351286|Drug|Placebo tablets matching L-citrulline tablets|
506588|NCT00351286|Drug|Background simvastatin at a stable dose of 40 mg qHS|
506589|NCT00351273|Drug|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
506590|NCT00351273|Drug|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
506591|NCT00351273|Drug|Placebo|Methylcellulose
506592|NCT00351260|Procedure|Coronary Angioplasty|
506593|NCT00351247|Procedure|Postconditioning|
506594|NCT00351234|Drug|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
506595|NCT00351221|Drug|rhIGF-1/rhIGFBP-3|
506596|NCT00351208|Device|Medtronic Manufactured Spinal Cord Stimulators|
506597|NCT00351195|Drug|Etoposide|
506598|NCT00351195|Drug|Oxaliplatin|
506599|NCT00351195|Drug|Capecitabine|
506600|NCT00351182|Drug|Telithromycin|
506601|NCT00351182|Drug|Doxycycline|
506602|NCT00351169|Drug|Quetiapine SR|
506603|NCT00351169|Drug|Escitalopram|
506604|NCT00351156|Procedure|Blood sample|
506605|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
506606|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
506607|NCT00351130|Drug|valsartan|
506608|NCT00351130|Drug|amlodipine|
506609|NCT00351117|Drug|St. John's Wort|SJW in capsule form 300 mg PO TID
506610|NCT00351117|Drug|Lactose|lactose in gelatin capsule that same as St. John's wort
506611|NCT00351104|Drug|Ketoprofen Topical Patch 20%|
506612|NCT00351091|Drug|RISEDRONATE|
506613|NCT00351078|Drug|PTC124|4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
506614|NCT00351065|Drug|SK3530|
506615|NCT00351052|Drug|Pimecrolimus|Pimecroliums cream 1 % bid.
506616|NCT00351052|Drug|Placebo|Vehicle control (placebo) bid.
506617|NCT00351039|Drug|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
506618|NCT00351039|Drug|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
506619|NCT00351039|Drug|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
506620|NCT00351026|Drug|Methadone|short-term methadone maintenance
506621|NCT00351013|Other|Malaria Tropica Nosode D200|5 pellets every four months
506622|NCT00351000|Drug|Ziprasidone|
506623|NCT00350987|Behavioral|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
506624|NCT00350961|Drug|Gemcitabine|
506625|NCT00350961|Drug|Oxaliplatin|
506626|NCT00350961|Drug|Capecitabine|
506627|NCT00350948|Drug|Telcyta|Day 1 of 28 day Cycle.
506628|NCT00350948|Drug|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
506629|NCT00350935|Procedure|fMRI|One 30 minute session
506630|NCT00350922|Behavioral|Psychoeducation|
506631|NCT00350909|Behavioral|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
506632|NCT00350896|Device|Thumb orthoses|
506633|NCT00350883|Behavioral|Cognitive Therapy|Goal-oriented talk therapy
506634|NCT00350883|Other|Treatment as Usual|Keep getting usual care
506635|NCT00350870|Drug|disulfiram|250mg per day of Disulfiram plus CBT
506636|NCT00350870|Drug|Placebo|Placebo plus CBT
506637|NCT00350870|Behavioral|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
506638|NCT00350870|Drug|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
506639|NCT00350857|Drug|Extended-Release Carbamazepine|
506640|NCT00350844|Drug|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
506641|NCT00350831|Drug|XL820|
506642|NCT00350818|Drug|Azacitidine|8 mg/m^2 Subcutaneously Once Daily for 5 Days
506643|NCT00350805|Procedure|EEG|One 20 minutes session
506644|NCT00350792|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles
506645|NCT00350792|Drug|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
506646|NCT00350779|Drug|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
506647|NCT00350779|Drug|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
506648|NCT00350779|Drug|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
506649|NCT00350779|Drug|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
506650|NCT00350779|Drug|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
506651|NCT00350766|Procedure|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
506652|NCT00350753|Drug|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
506653|NCT00350727|Drug|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
506654|NCT00350727|Drug|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
506655|NCT00350714|Other|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
506656|NCT00350701|Drug|androgel|androgel 5g
506657|NCT00350701|Drug|androgel 10g|androgel 10g
506658|NCT00350701|Drug|placebo|placebo
506659|NCT00350688|Radiation|Helical tomotherapy IMRT|Helical tomotherapy IMRT
506660|NCT00350662|Drug|Deferiprone (L1)|75 mg/kg body weight daily
506661|NCT00350662|Drug|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
506662|NCT00350649|Behavioral|Standard CBT|Manualized delivery of CBT by trained clinicians
506663|NCT00350649|Behavioral|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
506664|NCT00350649|Behavioral|CM/abstinence|Contingency Management
506665|NCT00350649|Behavioral|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
506666|NCT00350636|Drug|Oxybutynin topical gel|1 application daily to skin for 12 weeks
506667|NCT00350636|Other|Placebo topical gel|1 application daily to skin for 12 weeks
506668|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
506669|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
506670|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
506671|NCT00350610|Other|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
506672|NCT00350610|Behavioral|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
506673|NCT00350597|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
506674|NCT00350584|Behavioral|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
506675|NCT00350584|Behavioral|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
506676|NCT00350571|Behavioral|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
506677|NCT00350571|Behavioral|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
506678|NCT00350571|Behavioral|standard care follow up|routine counselor phone calls and letters
506679|NCT00350545|Drug|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
506680|NCT00350545|Drug|Prednisone|1 mg/kg; po per day with taper
506681|NCT00350545|Drug|Cyclosporine A|trough 200-300 or lower; po
506682|NCT00350545|Drug|tacrolimus|trough 5-10 or lower; po
506683|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
506684|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
506685|NCT00350519|Drug|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
506686|NCT00350519|Drug|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
506687|NCT00350506|Device|64 Channel VCT|
506688|NCT00350480|Drug|Provera|
506689|NCT00350480|Drug|Combination Birth Control pills|
506690|NCT00350467|Drug|ER OROS paliperidone and Olanzapine|
506691|NCT00350454|Device|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
506692|NCT00350454|Device|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
506693|NCT00350454|Device|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
506694|NCT00350441|Drug|Sildenafil Citrate|
506695|NCT00350428|Procedure|Laser Preipheral Iridotomy and phacoemulsification|
506696|NCT00350415|Drug|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks~OR~Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
506697|NCT00350402|Behavioral|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
506698|NCT00350389|Behavioral|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
506699|NCT00350363|Drug|Zymar|zymar qid
506700|NCT00350350|Device|oxygenated oil|oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
506701|NCT00350350|Device|medical device. Spray containing essentially oxygenated oil|"protective oral spray containing :~94.4% of oxygenated oil~Silicium dioxide~aspartame artificial flavoring"
506702|NCT00350337|Biological|Pre-transfection F17|Dengue tetravalent Vaccine F17 Pre transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
506703|NCT00350337|Biological|Post-transfection F17|Dengue tetravalent Vaccine F17 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
506704|NCT00350337|Biological|Post-transfection F19|Dengue tetravalent Vaccine F19 Post transfection: 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection. For the booster phase of the study, a booster dose was administered at five months to one year following the second dose.
506705|NCT00350337|Other|Placebo|Sterile solution of buffered water (0.9% NaCl), U.S. FDA accepted vaccine excipient, phenol red dye(phenolsulfonphthalein, used in vaccines as a pH indicator); 0.5 mL volume per dose, administered at 0 and 6 months via subcutaneous injection
506706|NCT00350311|Drug|nicotine transdermal patch/lozenge|
506707|NCT00350298|Biological|GS-CDA1|one dose IV
506708|NCT00350298|Biological|MDX-1388|one dose IV
506709|NCT00350298|Biological|normal saline|200ml IV once
506710|NCT00350285|Behavioral|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
506711|NCT00350285|Behavioral|Marijuana education|Information about health and behavioral effects of marijuana use.
506712|NCT00350272|Drug|elvucitabine|elvucitabine 10 mg orally daily
506713|NCT00350272|Drug|Lamivudine|lamivudine 300 mg orally daily
506714|NCT00350272|Drug|Tenofovir|tenofovir open-label 300 mg orally daily
506715|NCT00350272|Drug|Efavirenz|efavirenze open-label 600 mg orally daily
506718|NCT00350220|Other|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb >13.0 g/dl
506719|NCT00350220|Other|Low Hb transfusion group|RBCs will not be transfused unless the Hb < 9.0 g/dl
506720|NCT00350207|Drug|Tiotropium bromide|
506721|NCT00350207|Drug|Placebo|
506722|NCT00350207|Drug|Salmeterol xinafoate|
506723|NCT00350194|Dietary Supplement|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
506724|NCT00350181|Drug|Sirolimus|
506725|NCT00350181|Drug|Mycophenolate Mofetil|
506726|NCT00350168|Drug|valsartan + amlodipine|
506727|NCT00350155|Drug|Lumiracoxib|
506728|NCT00350142|Radiation|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
506729|NCT00350142|Drug|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
506730|NCT00350142|Other|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
506731|NCT00350142|Radiation|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
506732|NCT00350116|Drug|topical vitamin B12|
506733|NCT00350103|Drug|SPM 929|
506734|NCT00350090|Drug|Epoetin Alfa|
506735|NCT00350077|Drug|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
506736|NCT00350077|Drug|Vitamin C|IV vitamin C
506737|NCT00350064|Behavioral|Exercise Training|16 weeks of aerobic exercise training at two different intensities
506738|NCT00350051|Drug|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
506739|NCT00350038|Drug|Irbesartan|
506740|NCT00350038|Drug|Ciprofibrate|
506741|NCT00350025|Drug|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
506742|NCT00350025|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
506743|NCT00349986|Drug|Insuline glargine|
506744|NCT00349973|Drug|Dipyridamole|Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
506745|NCT00349973|Other|Olanzapine|Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
506746|NCT00349960|Drug|NeoRecormon SC once-weekly versus once-every-other-week|
506747|NCT00349947|Behavioral|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
506748|NCT00349934|Biological|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).~Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.~The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
506749|NCT00349921|Drug|clonidine|Clonidine—a drug commonly used to treat high blood pressure—has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
506750|NCT00349921|Drug|adenosine|Adenosine—a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms—has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
506751|NCT00349921|Drug|placebo|inactive substance
506752|NCT00349921|Drug|placebo|inactive substance
506753|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
506754|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
506755|NCT00349895|Device|Coronary stent implantation|Percutaneous Coronary Intervention
506756|NCT00349882|Device|soft contact lens|
506757|NCT00349882|Drug|Marketed multipurpose disinfection regimen|
506758|NCT00349869|Behavioral|yoga|8-week yoga program.
506759|NCT00349856|Device|Biofinity|Soft contact lens
506760|NCT00349843|Device|Soft contact lens|
506761|NCT00349843|Drug|Marketed soft lens multipurpose disinfection regimen|
506762|NCT00349830|Procedure|blood draw|
506763|NCT00349817|Behavioral|web-based learning, didactic lecture and role-play|
506764|NCT00349804|Other|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
506765|NCT00349791|Drug|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
506766|NCT00349791|Drug|Placebo patch|placebo patch replaced twice a week for two years
506767|NCT00349778|Drug|Cyclophosphamide|Cyclophosphamide as a white powder in 100 mg, 200 mg and 500 mg vials, to be dissolved in ~250 mL of saline or D5W and infused IV over 2 hours
506768|NCT00349778|Drug|Etoposide|100 mg etoposide as 5 mL solution in clear ampules for injection.
506769|NCT00349778|Drug|Melphalan|Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
506836|NCT00349232|Behavioral|lifestyle intervention (diet and physical activity)|
506837|NCT00349219|Drug|erlotinib|erlotinib 150 mg taken orally daily until disease progression
506770|NCT00349778|Drug|Carmustine|Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
506771|NCT00349778|Drug|Filgrastim|Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
506772|NCT00349765|Behavioral|higher fat, high polyunsaturated fat diet|
506773|NCT00349765|Behavioral|higher fat, high saturated and trans fat diet|
506774|NCT00349765|Behavioral|lower fat diet|
506775|NCT00349752|Biological|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
506776|NCT00349752|Other|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
506777|NCT00349739|Drug|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
506778|NCT00349726|Drug|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
506779|NCT00349726|Drug|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
506780|NCT00349726|Drug|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
506781|NCT00349726|Drug|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
506782|NCT00349713|Biological|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
506783|NCT00349713|Biological|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
506784|NCT00349700|Procedure|Compression: 2 weeks four layer bandages, then stockings|
506785|NCT00349700|Procedure|debridement|
506786|NCT00349700|Procedure|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
506787|NCT00349687|Behavioral|self-control practice|
506788|NCT00349674|Drug|Azathioprine: 2 mg/kg/day|
506789|NCT00349674|Drug|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
506790|NCT00349661|Drug|impact on VASP test|
506791|NCT00349648|Procedure|acromioplasty|
506792|NCT00349635|Drug|Metformin and Metformin + Fenofibrate|
506793|NCT00349622|Drug|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.~Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
506794|NCT00349622|Other|placebo|an inactive substance
506795|NCT00349596|Drug|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
506796|NCT00349583|Drug|Topical Cyclosporine, Tears|
506797|NCT00349570|Device|Xtract Aspiration Catheter|
506798|NCT00349557|Drug|bevacizumab, bicalutamide and goserelin|
506799|NCT00349557|Procedure|intensity modulated radiation therapy (IMRT)|
506800|NCT00349531|Drug|Pramipexole|
506801|NCT00349518|Drug|Dasatinib|
506802|NCT00349505|Procedure|hyper thermic chemo + surgery|
506803|NCT00349492|Drug|IP|irinotecan+cisplatin
506804|NCT00349479|Behavioral|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
506805|NCT00349466|Drug|CF101|Orally CF101 1mg
506806|NCT00349466|Drug|Placebo|Orally matching Placebo
506807|NCT00349453|Drug|Deferiprone (L1)|50-100 mg/kg body weight daily
506808|NCT00349453|Drug|Deferiprone (L1)|75 mg/kg body weight daily
506809|NCT00349453|Drug|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
506810|NCT00349440|Drug|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.~Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
506811|NCT00349427|Drug|Rosiglitazone 4 mg|
506812|NCT00349414|Procedure|Micropulse Transscleral Cyclophotocoagulation|
506813|NCT00349414|Procedure|Conventional Transscleral Cyclophotocoagulation|
506814|NCT00349401|Drug|ketorolac|
506815|NCT00349401|Drug|morphine|
506816|NCT00349388|Drug|Asacol|Asacol is given once a day versus twice or three times a day
506817|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
506818|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
506819|NCT00349375|Drug|Simvastatin|Simvastatin 40 mg
506820|NCT00349362|Drug|Testosterone|Sustanon- 200mg intramuscular testosterone
506821|NCT00349362|Drug|0.9% saline|Saline intramuscular injection every two weeks
506822|NCT00349349|Drug|ofatumumab|Intravenous infusion
506823|NCT00349336|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
506824|NCT00349336|Drug|XELOX|As prescribed
506825|NCT00349336|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
506826|NCT00349336|Drug|FOLFOX-4|As prescribed
506827|NCT00349323|Behavioral|Community directed treatment|
506828|NCT00349310|Drug|Pramipexole|
506829|NCT00349284|Drug|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
506830|NCT00349271|Procedure|Stem cell|Stem cell
506831|NCT00349271|Drug|Filgrastime (G-CSF)|Filgrastime (G-CSF)
506832|NCT00349271|Drug|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
506833|NCT00349258|Drug|Leuprolide acetate|
506834|NCT00349245|Drug|Remifentanil|
506835|NCT00349245|Drug|Dexmedetomidine|
506838|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
506839|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
506840|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
506841|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
506842|NCT00349219|Drug|erlotinib|erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
506843|NCT00349206|Drug|sorafenib tosylate|Given orally
506844|NCT00349206|Drug|temsirolimus|Given IV
506845|NCT00349193|Drug|laquinimod 0.3|laquinimod 0.3mg
506846|NCT00349193|Drug|laquinimod 0.6|laquinimod 0.6mg
506847|NCT00349193|Other|Placebo|Blinded Placebo
506848|NCT00349180|Drug|Enoxaparin sodium|
506849|NCT00349167|Drug|PR-104|
506850|NCT00349167|Other|laboratory biomarker analysis|
506851|NCT00349167|Other|pharmacological study|
506852|NCT00349141|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
506853|NCT00349128|Drug|fenofibrate and metformin combination (drug)|
506854|NCT00349115|Drug|Thalidomide|
506855|NCT00349102|Radiation|Free breathing|Free breathing during conformal radiation
506856|NCT00349102|Radiation|Breath holding|Breath holding during conformal radiation
506857|NCT00349089|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
506858|NCT00349089|Drug|Cisplatin|"Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22~Comparator:~Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
506859|NCT00349089|Drug|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
506860|NCT00349076|Drug|5-FU and oxaliplatin|"Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
506861|NCT00349076|Drug|5-FU|"Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
506862|NCT00349063|Device|soft contact lens|
506863|NCT00349063|Drug|Soft contact lens multipurpose disinfection regimen|
506864|NCT00349050|Device|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
506865|NCT00349050|Procedure|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
506866|NCT00349037|Biological|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
506867|NCT00349024|Drug|polyvinylpyrrolidone-sodium hyaluronate gel|
506868|NCT00349011|Procedure|Personalized risk assessment|
506869|NCT00349011|Procedure|genetic counseling intervention|
506870|NCT00348998|Biological|bevacizumab|
506871|NCT00348998|Drug|bicalutamide|
506872|NCT00348998|Drug|goserelin acetate|
506873|NCT00348998|Radiation|radiation therapy|
506874|NCT00348985|Drug|belinostat|
506875|NCT00348985|Drug|bortezomib|
506876|NCT00348985|Other|pharmacological study|
506877|NCT00348972|Drug|Lantus® (insulin glargine)|
506878|NCT00348959|Behavioral|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.~Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
506879|NCT00348946|Drug|androgen oxandrolone|Oxandrolone or placebo capsule, .06 >mg/kg/day, orally, for 2 years
506880|NCT00348946|Other|placebo|an inactive substance
506881|NCT00348933|Drug|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
506882|NCT00348933|Drug|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
506883|NCT00348933|Drug|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
506884|NCT00348933|Drug|Vitamin B12|1 mg by mouth per day for all weights and ages
506885|NCT00348920|Procedure|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
506886|NCT00348907|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
506887|NCT00348907|Drug|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
506888|NCT00348894|Drug|[S,S]-Reboxetine|[S,S]-reboxetine
506889|NCT00348894|Drug|Any|Any standard of care treatment for DPN
506890|NCT00348881|Biological|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
506891|NCT00348881|Biological|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
506892|NCT00348881|Biological|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
506893|NCT00348868|Behavioral|enhanced behavioral motivation counseling|
506894|NCT00348868|Behavioral|Motivational counseling|
506895|NCT00348868|Behavioral|Standard counseling|
506896|NCT00348855|Other|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
506897|NCT00348855|Behavioral|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
506898|NCT00348855|Behavioral|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
506899|NCT00348855|Behavioral|Stop Smoking|Minimal intervention
506900|NCT00348855|Behavioral|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
506901|NCT00348855|Other|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
506902|NCT00348842|Procedure|Newcastle Virus|
506903|NCT00348829|Procedure|mitral valve repair|surgical mitral valve repair
506904|NCT00348816|Drug|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
506905|NCT00348816|Drug|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
506906|NCT00348816|Procedure|Radical prostatectomy|Radical prostatectomy as part of standard care
506907|NCT00348816|Radiation|Radiation therapy|Doses for standard care radiation therapy: The initial target volume will be the lower pelvis followed by a boost to the prostate fossa and immediate periprostatic tissue. The initial dose will be 4500 cGy. With the final boost, the total dose will be 6840-6900 cGy. (4500/25 plus 2340/13 or 2400/12) with a total of 37 or 38 fractions.
506908|NCT00348790|Drug|vatalanib|
506909|NCT00348777|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
506910|NCT00348777|Drug|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
506911|NCT00348764|Drug|lauromacrogol|
506912|NCT00348751|Device|CholGate|
506913|NCT00348738|Drug|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of >14g/dl, <15g/dl is reached or until the end of the radiation therapy.
506914|NCT00348725|Drug|fenofibrate and metformin fixed combination (drug)|
506915|NCT00348712|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
506916|NCT00348712|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
506917|NCT00348712|Drug|metformin|Tablets, 2000 mg/day.
506918|NCT00348699|Drug|AFP464|Given IV
506919|NCT00348699|Other|pharmacological study|Correlative studies
506920|NCT00348699|Other|laboratory biomarker analysis|Correlative studies
506921|NCT00348686|Drug|Candesartan|16 mg once daily in oral tablet form
506922|NCT00348686|Drug|Candesartan|32 mg once daily in oral tablet form
506923|NCT00348686|Drug|Felodipine|5 mg once daily in oral tablet form
506924|NCT00348686|Drug|Felodipine|10 mg once daily in oral tablet form
506925|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
506926|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
506927|NCT00348647|Behavioral|physical training program to prevent injuries|
506928|NCT00348634|Drug|Tegaserod|
506929|NCT00348621|Procedure|Visual impairment intervention program|enhanced access to eye care services
506930|NCT00348608|Drug|iodixanol|
506931|NCT00348595|Drug|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
506932|NCT00348582|Drug|Ketorolac, Nepafenac|
506933|NCT00348569|Device|64 Channel VCT|
506934|NCT00348556|Drug|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
506935|NCT00348543|Procedure|laser treatment|
506936|NCT00348530|Drug|Verapamil|
506937|NCT00348517|Other|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
506938|NCT00348517|Other|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
506939|NCT00348504|Drug|levosimendan|
506940|NCT00348504|Drug|dobutamine|
506941|NCT00348491|Drug|Lumiracoxib|
506942|NCT00348478|Behavioral|water and health education program to improve hygiene|
506943|NCT00348465|Procedure|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
506944|NCT00348452|Drug|tramadol HCl ER; celecoxib|
506945|NCT00348439|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
506946|NCT00348439|Drug|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
506947|NCT00348426|Drug|Botulinum AntiToxin|
506948|NCT00348426|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
506949|NCT00348426|Procedure|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
506950|NCT00348413|Drug|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
506951|NCT00348400|Drug|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
506952|NCT00348387|Biological|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
506953|NCT00348387|Biological|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
506954|NCT00348374|Drug|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
506955|NCT00348374|Drug|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
506956|NCT00348361|Drug|Fluticasone Propionate|
506957|NCT00348348|Drug|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
506958|NCT00348348|Drug|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
506959|NCT00348335|Drug|Cyclosporine 0.05%|
506960|NCT00348335|Drug|Ocular lubricant|
506961|NCT00348322|Drug|Systane Free Lubricant Eye Drops|
506962|NCT00348309|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
506963|NCT00348309|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
506964|NCT00348309|Other|Placebo|Placebo
506965|NCT00348309|Other|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
506966|NCT00348296|Drug|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
506967|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
506968|NCT00348283|Biological|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
506969|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
506970|NCT00348270|Device|Tecnis Z9000 intraocular lens|
506971|NCT00348270|Device|MA60 intraocular lens|
506972|NCT00348257|Device|Hair removal by laser/IPL device|
506973|NCT00348244|Drug|Ketorolac, Prednisolone Acetate|
506974|NCT00348231|Drug|dual-action insulin analog|
506975|NCT00348218|Device|NeuroVision|
506976|NCT00348205|Device|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
506977|NCT00348192|Drug|SB-742457|
506978|NCT00348192|Drug|donepezil|
506979|NCT00348179|Procedure|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
506980|NCT00348166|Drug|cyclopentolate|
506981|NCT00348153|Drug|Adalimumab|
506982|NCT00348140|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
506983|NCT00348140|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
506984|NCT00348140|Other|Placebo|Placebo
506985|NCT00348127|Device|Neurovision|
506986|NCT00348114|Procedure|Transplantation of cultivated limbal epithelium|
506987|NCT00348101|Drug|Combined therapy with enoximone and esmolol|
506988|NCT00348075|Device|Neurovision|
506989|NCT00348062|Drug|Bimatoprost|
506990|NCT00348049|Procedure|Laser in Situ Keratomileusis (LASIK)|
506991|NCT00348049|Procedure|Photorefractive Keratectomy (PRK)|
506992|NCT00348036|Behavioral|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
506993|NCT00348036|Other|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
506994|NCT00348023|Drug|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
506995|NCT00348010|Drug|Tramadol HCl ER|
506996|NCT00347997|Device|217z Laser|LASIK correction of myopia and myopic astigmatism
506997|NCT00347984|Other|Systane Lubricant eye drops|
506998|NCT00347971|Drug|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
506999|NCT00347958|Biological|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
507000|NCT00347945|Procedure|Pencil Push-ups|
507001|NCT00347945|Procedure|Office-based Vision Therapy|
507002|NCT00347945|Procedure|Placebo Office-based Vision Therapy|
507003|NCT00347932|Drug|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
507004|NCT00347932|Drug|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
507005|NCT00347919|Drug|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
507006|NCT00347919|Drug|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
507007|NCT00347919|Drug|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
507008|NCT00347919|Drug|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
507009|NCT00347906|Procedure|laser treatment|
529832|NCT00151034|Drug|Paclitaxel|
507010|NCT00347893|Procedure|Selective laser trabeculoplasty|
507011|NCT00347867|Drug|Viagra administration in IUGR/PET pregnancies|
507012|NCT00347854|Other|Systane Free lubricant eye drops|
507013|NCT00347854|Other|Visine Tears Lubricant Eye Drops|
507014|NCT00347854|Other|Refresh Liquigel Lubricant Eye Drops|
507015|NCT00347854|Other|Refresh Plus Lubricant Eye Drops|
507016|NCT00347841|Drug|Bimatoprost 0.03%, Latanoprost|
507017|NCT00347828|Drug|Moxifloxacin ophthalmic solution 0.5%|
507018|NCT00347828|Drug|Gatifloxacin ophthalmic solution 0.3%|
507019|NCT00347815|Drug|Buprenorphine|
507020|NCT00347802|Drug|Bimatoprost 0.03%, Travoprost 0.004%|
507021|NCT00347789|Procedure|Glaucoma surgery- Bleb revision|
507022|NCT00347776|Drug|azithromycin|oral antibiotic
507023|NCT00347776|Drug|topical tetracycline|
507024|NCT00347763|Procedure|10% permethrin in water applied as low volume spray|
507025|NCT00347750|Drug|Lopinavir pharmacokinetic/pharmacodynamic analysis|
507026|NCT00347737|Drug|teriparatide|Teriparatide
507027|NCT00347724|Drug|Tramadol HCl ER|
507028|NCT00347711|Drug|Intravitreal injection|
507029|NCT00347698|Drug|intravitreal injection of bevacizumab|
507030|NCT00347698|Procedure|panretinal photocoagulation|
507031|NCT00347685|Drug|tramadol ER|
507032|NCT00347672|Biological|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
507033|NCT00347659|Drug|BLVR System|Treatment is administered in a single treatment session.
507034|NCT00347646|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
507035|NCT00347620|Device|spectacles|
507036|NCT00347620|Procedure|Cataract Surgery|
507037|NCT00347607|Behavioral|community surveillance and re-treatment|
507038|NCT00347594|Device|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
507039|NCT00347594|Device|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
507040|NCT00347581|Procedure|Base-in prism glasses for reading|
507041|NCT00347581|Procedure|Placebo reading glasses|
507042|NCT00347568|Device|TX-plore|PI has terminated at institution and there is no one available to report.
507043|NCT00347555|Biological|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
507044|NCT00347555|Drug|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
507045|NCT00347555|Biological|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
507046|NCT00347542|Drug|Vitamin D|
507047|NCT00347529|Biological|pPML7789 with and without pPJV2012 administered by PMED|
507048|NCT00347516|Procedure|IOL calculation formula|
507049|NCT00347503|Drug|ketorolac 0.4%, bromfenac 0.09%|
507050|NCT00347490|Drug|Enoxaparine|
507051|NCT00347477|Drug|HyperHAES vs. RA-solution/NaCl|
507052|NCT00347438|Drug|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
507053|NCT00347425|Drug|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
507054|NCT00347425|Drug|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
507055|NCT00347425|Drug|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
507056|NCT00347425|Drug|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
507057|NCT00347425|Drug|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
507058|NCT00347425|Drug|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
507059|NCT00347425|Drug|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
507060|NCT00347425|Drug|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
507061|NCT00347425|Drug|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
507062|NCT00347425|Drug|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
507063|NCT00347412|Drug|Paclitaxel and Carboplatin|"Paclitaxel and carboplatin: (All randomized patients)~All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.~The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel,as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing."
507131|NCT00346840|Drug|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
507132|NCT00346840|Drug|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
507133|NCT00346827|Drug|Apomorphine Nasal Powder|
507134|NCT00346814|Drug|intravitreal injection|
507206|NCT00346151|Drug|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
507064|NCT00347412|Drug|NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin|"NOV-002: (Group A only)~Two 60mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one~For each nominal 21-day paclitaxel and carboplatin cycle:~60mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin~followed by 60mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins.~Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first."
507065|NCT00347399|Drug|bevacizumab intravitreal injection|
507066|NCT00347399|Procedure|verteporfin photodynamic therapy|
507067|NCT00347386|Drug|Drug: Zinc (zinc sulphate)|Dissolvable tablet 10 mg. Once daily during the illness
507068|NCT00347386|Drug|Placebo|Placebo tablet, once daily
507069|NCT00347373|Drug|Tonalin Conjugated linoleic acid (dietary supplement)|
507070|NCT00347360|Drug|lisinopril|
507071|NCT00347360|Drug|carvedilol controlled release formulation|
507072|NCT00347334|Behavioral|infant home positioning|
507073|NCT00347321|Procedure|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
507074|NCT00347308|Behavioral|Eyebrow Position|Photography of brow positions
507075|NCT00347295|Drug|Brotizolam|
507076|NCT00347295|Drug|Estazolam|
507077|NCT00347269|Behavioral|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
507078|NCT00347269|Drug|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
507079|NCT00347269|Behavioral|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
507080|NCT00347256|Drug|cisplatin|
507081|NCT00347256|Procedure|targeted radiation therapy|
507082|NCT00347256|Procedure|tumor resection|
507083|NCT00347243|Procedure|phacoemulsification (cataract surgery)|
507084|NCT00347230|Device|Intacs intracorneal ring insertion for the treatment of keratoconus|
507085|NCT00347204|Drug|ketorolac (Acular LS)|
507086|NCT00347204|Drug|Nepafenac (Nevanac)|
507087|NCT00347178|Procedure|Laser Peripheral Iridotomy|
507088|NCT00347165|Drug|bevacizumab intravitreal injection|
507089|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
507090|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
507091|NCT00347139|Drug|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
507092|NCT00347139|Drug|Salmeterol 50mcg|Salmeterol 50mcg
507093|NCT00347113|Drug|Albendazole and praziquantel|
507094|NCT00347100|Drug|Insulin Glargine|Throughout study period
507095|NCT00347100|Drug|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
507096|NCT00347100|Drug|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
507097|NCT00347100|Drug|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
507098|NCT00347100|Drug|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
507099|NCT00347100|Drug|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
507100|NCT00347087|Drug|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
507101|NCT00347061|Drug|afuzosin|
507102|NCT00347048|Drug|tacrolimus|oral
507103|NCT00347048|Drug|Placebo|oral
507104|NCT00347035|Drug|brimonidine|
507105|NCT00347022|Drug|Xenetix|300 mg of iodine/ml
507106|NCT00347022|Drug|Visipaque|270 mg of iodine/ml
507107|NCT00347009|Drug|adefovir dipivoxil|10mg once daily
507108|NCT00346996|Drug|insulin levemir / aspart|for subcutaneous injection
507109|NCT00346996|Drug|human insulin /insulin isophane|for subcutaneous injection
507110|NCT00346983|Drug|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
507111|NCT00346983|Drug|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
507112|NCT00346970|Drug|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
507113|NCT00346970|Drug|Placebo|Placebo tablets
507114|NCT00346957|Drug|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
507115|NCT00346957|Drug|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
507116|NCT00346957|Drug|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
507117|NCT00346957|Other|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
507118|NCT00346944|Procedure|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
507119|NCT00346931|Procedure|Phacoemulsification, implantation of intraocular lens|
507120|NCT00346931|Procedure|Phacoemulsification, Implantation of IOL, trabeculotomy|
507121|NCT00346918|Drug|Sirolimus|Standard plus Sirolimus
507122|NCT00346918|Other|Standard|Standard
507123|NCT00346905|Drug|Enteryx|
507124|NCT00346892|Biological|Rotavirus (vaccine)|
507125|NCT00346879|Drug|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
507126|NCT00346866|Drug|anecortave acetate|
507127|NCT00346853|Drug|4-Methylpyrazole|15 mg/kg dose
507128|NCT00346853|Other|saline|
507129|NCT00346840|Drug|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
507130|NCT00346840|Drug|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
507371|NCT00344864|Device|LADARWave|
507135|NCT00346801|Drug|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
507136|NCT00346801|Drug|Cisplatin|25 mg/m^2 IV over 60 minutes on Day 1, Weeks 2-8
507137|NCT00346801|Drug|CPT-11|30 mg/m^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
507138|NCT00346801|Radiation|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
507139|NCT00346788|Procedure|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
507140|NCT00346775|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate
507141|NCT00346775|Drug|Flunisolide|Flunisolide
507142|NCT00346762|Behavioral|Education|HIV prevention education and risk reduction counselig
507143|NCT00346749|Drug|Salmeterol|
507144|NCT00346749|Drug|Fluticasone Propionate/Salmeterol Combination Product|
507145|NCT00346736|Procedure|Acupuncture (Procedure)|
507146|NCT00346723|Biological|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
507147|NCT00346697|Drug|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
507148|NCT00346697|Drug|Placebo|Corn-oil placebo
507149|NCT00346684|Drug|Rituximab|
507150|NCT00346671|Other|Rest|30 min supine rest
507151|NCT00346671|Other|Sham|30 min session with Sham practitioner
507152|NCT00346671|Other|Reiki|30 min session with Reiki practitioner
507153|NCT00346658|Drug|magnesium|
507154|NCT00346645|Drug|Bortezomid (VELCADE®)|
507155|NCT00346632|Drug|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
507156|NCT00346619|Drug|Nelfinavir|
507157|NCT00346606|Drug|Denosin® and Xyzal®|
507158|NCT00346593|Device|Silicone hydrogel contact lens|
507159|NCT00346580|Drug|Nelfinavir|
507160|NCT00346567|Drug|Zidovudine and Lamivudine (Combivir)|
507161|NCT00346567|Drug|Emtricitabine and Tenofovir (Truvada)|
507162|NCT00346528|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
507163|NCT00346528|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
507164|NCT00346515|Device|FiberNet Emboli Protection System|
507165|NCT00346502|Drug|20% betulinic acid ointment|
507166|NCT00346502|Drug|BA|20% Betulinic Acid Ointment
507167|NCT00346489|Drug|5-fluorouracil|
507168|NCT00346489|Drug|Mitomycin C|
507169|NCT00346463|Drug|Allopurinol|
507170|NCT00346450|Procedure|Cultivated conjunctival transplantation|
507171|NCT00346437|Genetic|Ad5FGF-4 vs. Placebo|Intracoronary infusion
507172|NCT00346424|Drug|Alfimeprase|
507173|NCT00346398|Biological|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
507174|NCT00346398|Biological|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
507175|NCT00346385|Drug|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
507176|NCT00346359|Biological|anti-thymocyte globulin|
507177|NCT00346359|Drug|busulfan|
507178|NCT00346359|Drug|fludarabine phosphate|
507179|NCT00346359|Drug|methotrexate|
507180|NCT00346359|Drug|tacrolimus|
507181|NCT00346359|Procedure|allogeneic hematopoietic stem cell transplantation|
507182|NCT00346359|Procedure|peripheral blood stem cell transplantation|
507183|NCT00346333|Drug|Lutein|12mg/d
507184|NCT00346333|Dietary Supplement|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
507185|NCT00346320|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
507186|NCT00346294|Other|Etanercept|Intervention type was to study the drug delivery method.
507187|NCT00346281|Device|32P BioSilicon|
507188|NCT00346268|Drug|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
507189|NCT00346268|Drug|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
507190|NCT00346255|Drug|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
507191|NCT00346242|Drug|Zoledronic Acid|
507192|NCT00346229|Biological|filgrastim|
507193|NCT00346229|Biological|pegfilgrastim|
507194|NCT00346229|Drug|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
507195|NCT00346229|Procedure|hyperthermia treatment|
507196|NCT00346216|Drug|celecoxib|100 to 200 mg twice daily, taken by mouth
507197|NCT00346216|Drug|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
507198|NCT00346216|Drug|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
507199|NCT00346190|Drug|Alendronate|
507200|NCT00346177|Biological|Autologous Stem Cells|Intramyocardial injections
507201|NCT00346164|Drug|doxorubicin hydrochloride|Given IV
507202|NCT00346164|Other|clinical observation|Patients undergo observation
507203|NCT00346164|Procedure|therapeutic conventional surgery|Patients undergo surgery
507204|NCT00346164|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
507205|NCT00346164|Drug|ifosfamide|Given IV
507418|NCT00344318|Biological|Tritanrix-HepB|3 Intramuscular injections
507207|NCT00346151|Drug|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
507208|NCT00346151|Drug|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
507209|NCT00346151|Drug|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
507210|NCT00346138|Procedure|Corneal transplantation|
507211|NCT00346125|Biological|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
507212|NCT00346125|Drug|doxorubicin hydrochloride|65 mg/m^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
507213|NCT00346125|Drug|ifosfamide|9 g/m^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m^2 by continuous IV infusion over 7 days beginning on day 1
507214|NCT00346125|Drug|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
507215|NCT00346125|Procedure|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
507216|NCT00346125|Radiation|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
507217|NCT00346112|Procedure|psycho-educational|
507218|NCT00346099|Drug|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
507219|NCT00346099|Drug|Panitumumab with capecitabine and radiation|
507220|NCT00346086|Drug|AIC (Amb a 1 Immunostimulatory Conjugate)|
507221|NCT00346073|Biological|Boostrix™|Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine
507222|NCT00346073|Biological|ADACEL®|Sanofi Pasteur
507223|NCT00346060|Device|Retinal transplantation instrument|
507224|NCT00346060|Device|Fetal tissue.|
507225|NCT00346047|Drug|Placebo|Corresponding placebo is applied for 12weeks
507226|NCT00346047|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
507227|NCT00346034|Drug|Pregabalin|150 to 600mg/day
507228|NCT00346021|Behavioral|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
507229|NCT00346008|Genetic|mutation analysis|
507230|NCT00346008|Other|high performance liquid chromatography|
507231|NCT00346008|Other|laboratory biomarker analysis|
507232|NCT00346008|Other|questionnaire administration|
507233|NCT00345982|Drug|Serdolect|16 mg, 12 weeks
507234|NCT00345982|Drug|placebo|placebo
507235|NCT00345969|Drug|Transdermal Testosterone gel (1%)|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
507236|NCT00345969|Behavioral|Supervised exercise training|Supervised exercise training performed on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and physical therapy-type exercises, followed by 4 months of progressive resistance training.
507237|NCT00345956|Biological|Human rotavirus liquid vaccine|
507238|NCT00345943|Other|MRI|Magnetic Resonance Imaging scans
507239|NCT00345943|Behavioral|Neuropsychological Testing|Neuropsychological tests
507240|NCT00345917|Device|Retinal transplantation instrument|
507241|NCT00345917|Device|Fetal tissue.|
507242|NCT00345904|Biological|Fluarix|
507243|NCT00345891|Behavioral|Coping-focused counseling telephone calls|
507244|NCT00345878|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
507245|NCT00345878|Biological|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
507246|NCT00345865|Drug|carmustine|Day -6, 300 mg/m^2 over 2 hour
507247|NCT00345865|Drug|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
507248|NCT00345865|Drug|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.~HL without radiation: 150 mg/m^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
507249|NCT00345865|Procedure|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
507250|NCT00345865|Radiation|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.~> 1000 cGy to whole lung, kidney, or abdominal bath.~> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.~> 3600 cGy to whole brain."
507251|NCT00345865|Biological|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.~Continue G-CSF until absolute neutrophil count (ANC) > 1500/μl x 3 consecutive days.~If ANC falls <1000/μL, restart G-CSF."
507252|NCT00345865|Drug|Cytarabine|100 mg/m^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
507253|NCT00345852|Procedure|Fetoscopic Selective Laser Photocoagulation|
507254|NCT00345839|Drug|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
507564|NCT00343356|Drug|Trement|
507255|NCT00345839|Drug|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
507256|NCT00345826|Drug|dasatinib|
507257|NCT00345813|Dietary Supplement|soy isoflavones|Given orally
507258|NCT00345813|Dietary Supplement|soy protein isolate|Given orally
507259|NCT00345813|Other|placebo|Given orally
507260|NCT00345800|Drug|Sodium Oxybate (Xyrem)|Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral
507261|NCT00345787|Drug|Placebo|Corresponding placebo is applied for 12weeks
507262|NCT00345787|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
507263|NCT00345774|Drug|PRX-08066|
507264|NCT00345761|Drug|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
507265|NCT00345761|Drug|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
507266|NCT00345761|Drug|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
507267|NCT00345748|Drug|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
507268|NCT00345748|Drug|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
507269|NCT00345735|Drug|Fentanyl|
507270|NCT00345722|Procedure|strawberry dietary intervention|
507271|NCT00345709|Behavioral|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
507272|NCT00345696|Drug|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
507273|NCT00345696|Drug|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
507274|NCT00345696|Drug|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
507275|NCT00345683|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
507276|NCT00345683|Biological|PedvaxHIB|Booster dose by intramuscular injection
507277|NCT00345683|Biological|Prevnar|Booster dose by intramuscular injection
507278|NCT00345683|Biological|M-M-R II|Single dose by subcutaneous injection
507279|NCT00345683|Biological|Varivax|Single dose by subcutaneous injection
507280|NCT00345670|Biological|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
507281|NCT00345670|Biological|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
507282|NCT00345670|Biological|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
507283|NCT00345657|Drug|Niacin Extended Release/Lovastatin|
507284|NCT00345644|Drug|risedronate|risedronate sodium 35 mg tablets (once a week dose)
507285|NCT00345644|Drug|risedronate placebo|placebo for risedronate tablets (once a week dose)
507286|NCT00345631|Other|Manual Compression|Manual compression
507287|NCT00345631|Device|Vascular Closure Device|Investigational vascular closure device
507288|NCT00345618|Drug|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
507289|NCT00345618|Drug|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration"
507290|NCT00345618|Drug|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe~Subcutaneous injection"
507291|NCT00345618|Drug|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
507292|NCT00345618|Drug|Placebo (for warfarin)|"Warfarin matching capsules~Oral administration"
507293|NCT00345618|Drug|Enoxaparin|"Prefilled syringes as locally registered~Subcutaneous injection"
507294|NCT00345605|Drug|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
507295|NCT00345605|Drug|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
507296|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
507297|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
507298|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
507299|NCT00345579|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
507300|NCT00345579|Biological|ActHIB|3-dose intramuscular injection
507301|NCT00345579|Biological|Pediarix/Infanrix Penta|3-dose intramuscular injection
507302|NCT00345566|Procedure|Nutrition composition|
507303|NCT00345540|Drug|NOV-002|60 mg / mL / day / 20-23 Days
507304|NCT00345540|Drug|Carboplatin|AUC 5 following IV bolus administration of NOV-002
507305|NCT00345527|Behavioral|Emotion and Behaviour Regulation Treatment (EBRT)|
507306|NCT00345527|Behavioral|Cognitive Behavioural Therapy|
507307|NCT00345514|Behavioral|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
507308|NCT00345514|Behavioral|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
507309|NCT00345501|Drug|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
507372|NCT00344851|Drug|metformin, exenatide or combined (metformin & exenatide )|
507310|NCT00345501|Drug|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
507311|NCT00345462|Biological|Trivalent virosomal influenza vaccine|
507312|NCT00345449|Behavioral|Decision Aid|
507313|NCT00345410|Drug|AVE1625 B|
507314|NCT00345397|Device|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
507315|NCT00345384|Drug|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
507316|NCT00345384|Other|Placebo (Normal Saline)|
507317|NCT00345371|Drug|Topiramate|
507318|NCT00345371|Drug|Placebo Oral Tablet|
507319|NCT00345358|Biological|Synflorix|1, 2, 3 or 4 Intramuscular injections, depending on age group
507320|NCT00345358|Biological|Infanrix IPV/Hib|4 intramuscular injections
507321|NCT00345345|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.
507322|NCT00345332|Drug|Botox|Injected
507323|NCT00345332|Drug|Placebo|Injected
507324|NCT00345319|Biological|rabies vaccine|Administration of PCECV according to ESSEN regimen
507325|NCT00345306|Drug|Comparison between two different progesterone administration|
507326|NCT00345293|Biological|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
507327|NCT00345280|Procedure|impression cytology, obtain the tear fluid|Vitamin A
507328|NCT00345267|Device|Integrated Care Pathway|
507329|NCT00345254|Procedure|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
507330|NCT00345241|Drug|Systane Ocular Drops (OTC)|
507331|NCT00345241|Drug|Placebo - Saline Drops|
507332|NCT00345215|Behavioral|High Sodium Diet|250-350 mmol
507333|NCT00345215|Behavioral|Low Sodium Diet|25-35 mmol
507334|NCT00345202|Drug|HMG-CoA reductase inhibition (atorvastatin)|
507335|NCT00345189|Drug|CNF2024|"CNF2024 capsules administered orally following 2 schedules:~starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
507336|NCT00345176|Dietary Supplement|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
507337|NCT00345176|Dietary Supplement|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
507338|NCT00345176|Drug|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
507339|NCT00345163|Drug|bevacizumab|Intravenous repeating dose
507340|NCT00345163|Drug|irinotecan|Intravenous repeating dose
507341|NCT00345150|Drug|Ng-monomethyl-L-arginine (drug)|
507342|NCT00345137|Drug|Ng-monomethyl-L-arginine (drug)|
507343|NCT00345124|Behavioral|high sodium diet|250-350 mmol
507344|NCT00345124|Behavioral|Low Sodium Diet|25-35 mmol
507345|NCT00345111|Procedure|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
507346|NCT00345098|Drug|SR58611A|
507347|NCT00345085|Device|Wavefront and Contrast Sensitivity|
507348|NCT00345072|Device|Web-based decision aid system|
507349|NCT00345059|Drug|docetaxel|
507350|NCT00345059|Drug|vinorelbine|
507351|NCT00345059|Drug|gemcitabine|
507352|NCT00345059|Drug|capecitabine|
507353|NCT00345046|Drug|Pred Forte|Four drops daily decreasing to once daily over four weeks.
507354|NCT00345046|Drug|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
507355|NCT00345046|Drug|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
507356|NCT00345033|Drug|Aripiprazole|15-mg dose once a day for 8 weeks
507357|NCT00345033|Drug|Placebo|1 tablet placebo dose once a day for 8 weeks
507358|NCT00345020|Procedure|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
507359|NCT00345007|Procedure|Scleral buckling|
507360|NCT00344994|Drug|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
507361|NCT00344981|Drug|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
507362|NCT00344981|Drug|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches >400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
507363|NCT00344968|Drug|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
507364|NCT00344968|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
507365|NCT00344968|Procedure|Standard of care laser photocoagulation|Laser photocoagulation
507366|NCT00344955|Drug|HMG-CoA reductase inhibition (atorvastatin)|
507367|NCT00344942|Drug|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
507368|NCT00344942|Drug|placebo|a double spray into each nostril once daily
507369|NCT00344916|Drug|Ng-monomethyl-L-arginine (drug)|
507370|NCT00344890|Procedure|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
507373|NCT00344838|Device|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
507374|NCT00344825|Drug|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.~QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
507375|NCT00344812|Drug|LAAM. buprenorphine and methadone|
507376|NCT00344786|Drug|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.~Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
507377|NCT00344773|Drug|Gefitinib|250mg tablet oral tablet once daily
507378|NCT00344760|Drug|Enfuvirtide|subcutaneously twice a day
507379|NCT00344760|Drug|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
507380|NCT00344747|Behavioral|dietary, behavioral, physical activity|
507381|NCT00344734|Drug|Ng-monomethyl-L-arginine (drug)|
507382|NCT00344721|Dietary Supplement|Omega-3 fatty acid supplement|Participants receive four oral doses of soft-gel capsules to be taken daily (QD) for 3 months.
507383|NCT00344721|Dietary Supplement|Placebo|Participants receive four oral doses of soft-gel capsules containing wheat germ oil to be taken daily for 3 months.
507384|NCT00344708|Procedure|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
507385|NCT00344695|Drug|bupropion SR|
507386|NCT00344682|Drug|memantine|memantine 5mg - 20mg PO daily
507387|NCT00344682|Drug|Placebo|5mg - 20mg PO daily over 8 weeks
507388|NCT00344669|Drug|Albendazole 400 mg, given 6 monthly|
507389|NCT00344643|Device|Silicone Hydrogel Soft Contact Lenses|
507390|NCT00344630|Device|TAXUS Stent and Cypher Stent|
507391|NCT00344617|Drug|Bevacizumab (tradename: Avastin)|
507392|NCT00344604|Behavioral|Role of psychosocial and quality of life parameters prior to and following LASIK.|
507393|NCT00344591|Behavioral|Structured Ecosystems Therapy (SET)|
507394|NCT00344591|Behavioral|Individually tailored intervention|
507395|NCT00344578|Device|Restor IOL|
507396|NCT00344565|Drug|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
507397|NCT00344565|Behavioral|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
507398|NCT00344552|Drug|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
507399|NCT00344539|Biological|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
507400|NCT00344539|Biological|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
507401|NCT00344526|Drug|Melphalan|
507402|NCT00344526|Drug|Dexamethasone|
507403|NCT00344526|Procedure|Autologous stem cell transplantation|
507404|NCT00344513|Drug|Beta-blockers including Carvedilol|
507405|NCT00344513|Drug|ACE inhibitors|
507406|NCT00344500|Behavioral|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient~Be given a 7% weight loss goal~Be assisted in obtaining a 500 calorie reduction per day~Exercise for at least 30 min/day, at least 5 days a week~Maintain weekly food and exercise diaries~Be quizzed on their knowledge of healthy eating habits and nutrition"
507407|NCT00344487|Drug|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
507408|NCT00344474|Behavioral|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
507409|NCT00344461|Drug|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
507410|NCT00344448|Drug|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
507411|NCT00344422|Drug|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
507412|NCT00344409|Drug|darbepoetin alfa|
507413|NCT00344383|Drug|Norgestimate/Ethinyl Estradiol tablet|
507414|NCT00344370|Drug|Pitavastatin|Pitavastatin 4 mg QD
507415|NCT00344370|Drug|Atorvastatin|Atorvastatin 40 mg
507416|NCT00344318|Biological|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
507417|NCT00344318|Biological|Prevenar|3 Intramuscular injections
507419|NCT00344318|Biological|Hiberix|Reconstituted with Tritanrix before injection
507420|NCT00344318|Biological|Polio Sabin.|3 oral doses.
507421|NCT00344318|Biological|Poliorix.|3 intramuscular injections
507422|NCT00344305|Biological|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains.
507423|NCT00344253|Drug|Interferon beta|
507424|NCT00344253|Drug|Methotrexate|
507425|NCT00344240|Behavioral|Functional circuit training with lifestyle behavior|
507426|NCT00344227|Drug|Lucentis (Ranibizumab)|
507427|NCT00344214|Behavioral|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
507428|NCT00344214|Behavioral|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
507429|NCT00344201|Device|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
507430|NCT00344175|Drug|pitavastatin|
507431|NCT00344175|Drug|simvastatin|
507432|NCT00344149|Drug|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
507433|NCT00344123|Drug|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
507434|NCT00344123|Drug|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).~On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
507435|NCT00344110|Drug|Aliskiren|
507436|NCT00344097|Procedure|Soy protein|
507437|NCT00344058|Drug|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
507438|NCT00344045|Drug|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
507439|NCT00344045|Drug|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
507440|NCT00344032|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
507441|NCT00344032|Biological|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
507442|NCT00344019|Drug|Placebo Oral Tablet|placebo pre-PCI for ACS
507443|NCT00344019|Drug|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
507444|NCT00344019|Other|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
507445|NCT00344006|Drug|chlorproguanil-dapsone-artesunate|
507446|NCT00344006|Drug|artemether-lumefantrine|
507447|NCT00343993|Device|noninvasive positive pressure ventilation|
507448|NCT00343980|Drug|rosiglitazone|Tablets, 4 mg once or twice a day.
507449|NCT00343980|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
507450|NCT00343980|Drug|glimepiride|Tablets, 4 mg/day.
507451|NCT00343954|Drug|L-citrulline tablets, 1000 mg|
507452|NCT00343941|Drug|Tucaresol tablets 25 mg|
507453|NCT00343928|Other|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
507454|NCT00343915|Biological|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, & 6)
507455|NCT00343915|Biological|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 & 6)
507456|NCT00343915|Biological|placebo|In the primary study: 1 deep intramuscular injection (month 1)
507457|NCT00343902|Drug|Crataegus Special Extract WS 1442|
507458|NCT00343889|Biological|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
507459|NCT00343889|Biological|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
507460|NCT00343889|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine
507461|NCT00343876|Drug|aspirin|
507462|NCT00343876|Drug|clopidogrel|
507463|NCT00343863|Drug|palonosetron hydrochloride|Given IV
507464|NCT00343863|Drug|cyclophosphamide|Given orally
507465|NCT00343863|Drug|dexamethasone|Given orally or IV
507466|NCT00343863|Drug|doxorubicin hydrochloride|Given IV
507467|NCT00343863|Procedure|quality-of-life assessment|Ancillary studies
507468|NCT00343863|Procedure|nausea and vomiting therapy|Given IV
507469|NCT00343863|Procedure|management of therapy complications|Given IV
507470|NCT00343863|Drug|ondansetron hydrochloride|Given IV
507471|NCT00343863|Other|survey administration|Ancillary studies
507472|NCT00343850|Drug|Asacol (mesalamine)|
507473|NCT00343824|Procedure|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
507474|NCT00343811|Drug|Modafinil|
507475|NCT00343798|Drug|cyclophosphamide|Given IV
507476|NCT00343798|Drug|fludarabine phosphate|Given IV
507477|NCT00343798|Drug|cyclosporine|Given IV
507478|NCT00343798|Drug|mycophenolate mofetil|Given IV or PO
507479|NCT00343798|Other|ex-vivo umbilical cord blood expansion|Undergo double-unit umbilical cord blood transplantation
507480|NCT00343798|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit umbilical cord blood transplantation
507481|NCT00343798|Procedure|biopsy|Optional correlative studies
507482|NCT00343798|Other|immunologic technique|Correlative studies
507483|NCT00343798|Other|diagnostic laboratory biomarker analysis|Correlative studies
507484|NCT00343785|Drug|cyclophosphamide|Given IV
507485|NCT00343785|Biological|anti-thymocyte globulin|Given IV
507486|NCT00343785|Drug|cyclosporine|Given IV or PO
507487|NCT00343785|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
507488|NCT00343785|Drug|methotrexate|Given IV
507489|NCT00343785|Genetic|DNA analysis|Correlative studies
507490|NCT00343785|Other|flow cytometry|Correlative studies
507491|NCT00343785|Genetic|polymorphism analysis|Correlative studies
507492|NCT00343785|Other|laboratory biomarker analysis|Correlative studies
507493|NCT00343759|Drug|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
507494|NCT00343733|Drug|OraVescent Fentanyl|
507495|NCT00343720|Drug|VELCADE|
507496|NCT00343720|Drug|Alimta|
507497|NCT00343707|Drug|vestipitant|
507498|NCT00343707|Drug|paroxetine|
507499|NCT00343681|Biological|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
507500|NCT00343668|Drug|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
507501|NCT00343655|Drug|Atorvastatin|
507502|NCT00343642|Dietary Supplement|Time and attention + fructo-oligosaccharide placebo|2 teaspoons of placebo powder daily
507503|NCT00343642|Dietary Supplement|dietary therapy + fructo-oligosaccharide placebo|Medical nutrition therapy and 2 teaspoons of placebo powder
507504|NCT00343642|Drug|Time and attention + active fructooligosaccharide supplementation|2 teaspoons of fructooligosaccharides daily
507505|NCT00343629|Drug|sulindac|
507506|NCT00343629|Other|pharmacological study|
507507|NCT00343616|Procedure|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
507508|NCT00343616|Procedure|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
507509|NCT00343616|Procedure|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
507510|NCT00343616|Procedure|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
507511|NCT00343590|Device|Whole Body Vibration machine|
507512|NCT00343564|Drug|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
507513|NCT00343564|Drug|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
507514|NCT00343551|Drug|Aliskiren|
507515|NCT00343525|Drug|bavituximab|
507516|NCT00343512|Drug|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
507517|NCT00343512|Genetic|protein expression analysis|protein expression analysis
507518|NCT00343512|Other|laboratory biomarker analysis|laboratory biomarker analysis
507519|NCT00343512|Procedure|biopsy|biopsy
507520|NCT00343512|Procedure|conventional surgery|conventional surgery
507521|NCT00343512|Procedure|neoadjuvant therapy|neoadjuvant therapy
507522|NCT00343499|Drug|valsartan|
507523|NCT00343486|Drug|Solabegron|
507524|NCT00343460|Drug|APF530|Given subcutanously
507525|NCT00343460|Drug|dexamethasone|Given IV and orally
507526|NCT00343460|Drug|Palonosetron Hydrochloride|Given IV
507527|NCT00343460|Other|placebo|Given subcutanously or IV
507528|NCT00343447|Biological|autologous tumor cell vaccine|
507529|NCT00343447|Biological|rituximab|
507530|NCT00343447|Drug|cyclophosphamide|
507531|NCT00343434|Behavioral|behavioral dietary intervention|
507532|NCT00343434|Behavioral|exercise intervention|
507533|NCT00343434|Dietary Supplement|soy isoflavones|
507534|NCT00343434|Dietary Supplement|soy protein isolate|
507535|NCT00343434|Other|counseling intervention|
507536|NCT00343434|Other|educational intervention|
507537|NCT00343434|Procedure|psychosocial assessment and care|
507538|NCT00343434|Procedure|quality-of-life assessment|
507539|NCT00343421|Biological|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
507540|NCT00343421|Biological|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
507541|NCT00343408|Drug|cediranib maleate|
507542|NCT00343408|Drug|cisplatin|
507543|NCT00343408|Drug|fluorouracil|
507544|NCT00343408|Drug|gemcitabine hydrochloride|
507545|NCT00343408|Drug|leucovorin calcium|
507546|NCT00343408|Drug|oxaliplatin|
507547|NCT00343395|Drug|AVANDAMET|2/500 mg
507548|NCT00343382|Drug|pilocarpine hydrochloride|Given orally
507549|NCT00343382|Other|placebo|Given orally
507550|NCT00343369|Drug|asparaginase|
507551|NCT00343369|Drug|cyclophosphamide|
507552|NCT00343369|Drug|cytarabine|
507553|NCT00343369|Drug|daunorubicin hydrochloride|
507554|NCT00343369|Drug|dexamethasone|
507555|NCT00343369|Drug|doxorubicin hydrochloride|
507556|NCT00343369|Drug|mercaptopurine|
507557|NCT00343369|Drug|methotrexate|
507558|NCT00343369|Drug|pegaspargase|
507559|NCT00343369|Drug|prednisolone|
507560|NCT00343369|Drug|teniposide|
507561|NCT00343369|Drug|thioguanine|
507562|NCT00343369|Drug|vincristine sulfate|
507563|NCT00343369|Radiation|radiation therapy|
507565|NCT00343343|Device|NovoFine® needle 6 mm|
507566|NCT00343343|Device|NovoFine® needle 4 mm|
507567|NCT00343317|Drug|Intrapartum Cefoxitin (2g) vs. placebo|
507568|NCT00343304|Device|Robot|
507569|NCT00343304|Device|Ergometer|
507570|NCT00343291|Biological|Cetuximab|Administered intravenously
507571|NCT00343291|Biological|Bevacizumab|Administered intravenously
507572|NCT00343291|Drug|Paclitaxel|Administered intravenously
507573|NCT00343291|Drug|Carboplatin|Administered intravenously
507574|NCT00343278|Drug|Valaciclovir Hydrochloride|
507575|NCT00343265|Drug|Vaginal progesterone gel|Vaginal gel once daily
507576|NCT00343265|Drug|Placebo gel|once daily
507577|NCT00343252|Drug|teriparatide|20 ug/day, subcutaneous, 18 months
507578|NCT00343252|Drug|risedronate|35 mg/once weekly, oral, 18 months
507579|NCT00343252|Drug|placebo|once weekly, oral, 18 months
507580|NCT00343252|Drug|placebo|daily, subcutaneous, 18 months
507581|NCT00343239|Drug|Docetaxel|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
507582|NCT00343239|Drug|Cisplatin|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 75 mg/m2"
507583|NCT00343239|Drug|Fluorouracil|"Formulation: infusion solution~Route of administration: IV infusion on the first day of each 21-day cycle~Dose regimen: 750 mg/m2/day for 5 days"
507584|NCT00343226|Drug|Basiliximab|
507585|NCT00343213|Procedure|colposcopy|
507586|NCT00343200|Drug|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
507587|NCT00343200|Drug|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
507588|NCT00343187|Drug|ACZONE (dapsone) Gel, 5%|
507589|NCT00343187|Drug|Vehicle Control|
507590|NCT00343174|Drug|Ancrod|
507591|NCT00343161|Drug|esomeprazole|
507592|NCT00343161|Drug|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
507593|NCT00343148|Drug|AVI-4126 Injection (RESTEN-NG®)|
507594|NCT00343135|Drug|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
507595|NCT00343122|Procedure|echocardiography for intrapulmonary vasodilatation|
507596|NCT00343109|Biological|HER-2/neu intracellular domain protein|Given ID
507597|NCT00343109|Procedure|leukapheresis|Optional correlative studies
507598|NCT00343109|Other|laboratory biomarker analysis|Correlative studies
507599|NCT00343109|Biological|sargramostim|Given ID
507600|NCT00343109|Other|immunologic technique|Correlative studies
507601|NCT00343109|Biological|synthetic tumor-associated peptide vaccine therapy|Given ID
507602|NCT00343096|Drug|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
507603|NCT00343083|Drug|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,~1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.~Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.~Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
507604|NCT00343083|Radiation|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
507605|NCT00343070|Drug|Oral administration of escitalopram during 8 weeks|
507606|NCT00343057|Other|Patients' questionnaire|
507607|NCT00343044|Drug|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
507608|NCT00343044|Drug|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
507609|NCT00343005|Biological|AMA1-C1|
507610|NCT00343005|Drug|AMA1-C1/alhydrogel Malaria Vaccine|
507611|NCT00342940|Biological|influenza surface antigen inactivated vaccine|
507612|NCT00342862|Drug|Amevive exposure|Observational
507613|NCT00342849|Drug|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
507614|NCT00342849|Drug|Placebo|
507615|NCT00342836|Procedure|Akt levels|
507616|NCT00342706|Procedure|Community based intervention|
507617|NCT00342628|Biological|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
507618|NCT00342628|Biological|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
507619|NCT00342628|Biological|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
507620|NCT00342563|Drug|mecamylamine|mecamylamine 10mg/day
507621|NCT00342563|Drug|Placebo|Placebo
507622|NCT00342381|Drug|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
507623|NCT00342381|Drug|Placebo|Single dose placebo treatment
507624|NCT00342368|Procedure|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
507625|NCT00342355|Drug|Zidovudine|600 mg once daily
507626|NCT00342355|Drug|Stavudine|40 mg once daily
507627|NCT00342355|Drug|Didanosine|<60 kg/125 mg twice daily or >60kg/200 mg twice daily
507628|NCT00342355|Drug|Lamivudine|300 mg once daily
507629|NCT00342355|Drug|Efavirenz|600 mg once daily
507630|NCT00342355|Drug|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
507631|NCT00342316|Procedure|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:~Busulphan (orally or IV), fludarabine~Fludarabine, carmustine, melfalan~Cyclophosphamide, fludarabine"
507632|NCT00342134|Procedure|Stem Cell Transplanataion|
507633|NCT00342108|Behavioral|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
507634|NCT00341640|Procedure|Blood testing|
507635|NCT00341614|Behavioral|3-month Exercise Training and Diet Education|
507636|NCT00341471|Procedure|Risk Behavior Prevention Intervention Program|
507637|NCT00341445|Behavioral|Effect of Cockroach Allergen|
507638|NCT00341432|Behavioral|Nicotine Replacement Therapy|
507639|NCT00341354|Behavioral|Prolonged Mechanical Ventilation|
507640|NCT00341328|Biological|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
507641|NCT00341250|Drug|AMA1-C1/Alhydrogel Malaria Vaccine|
507642|NCT00341224|Behavioral|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
507643|NCT00341055|Drug|Epoetin alfa|
507644|NCT00340938|Procedure|Blood testing|
507645|NCT00340834|Drug|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
507646|NCT00340834|Drug|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.~Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
507647|NCT00340834|Drug|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.~Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
507648|NCT00340704|Drug|tamsulosin hydrochloride|oral
507649|NCT00340691|Drug|Doxycycline|
507650|NCT00340678|Drug|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
507651|NCT00340678|Drug|Placebo|Treatment with placebo corresponding to each dose of losartan.
507652|NCT00340613|Drug|glargine insulin|
507653|NCT00340574|Drug|AMA1-C1/Alhydrogel + CpG 7909|
507654|NCT00340483|Behavioral|Smoking cessation|
507655|NCT00340470|Behavioral|Driver Education|
507656|NCT00340431|Drug|MSP1(42)-FVO & MSP1(42)-3D7|
507657|NCT00340379|Drug|Ziprasidone|Target dosage 120-160mg/day based on tolerance
507658|NCT00340379|Drug|Sertraline|Target dosage 150-200mg/day based on tolerance.
507659|NCT00340379|Drug|Haloperidol|Target dosage 6-8mg/day based on tolerance.
507660|NCT00340327|Drug|IMA-638|
507661|NCT00340314|Procedure|Circumferential Pulmonary Vein Ablation|
507662|NCT00340314|Drug|Antiarrhythmic Drug Therapy|
507663|NCT00340184|Drug|paclitaxel, carboplatin|
507664|NCT00340106|Behavioral|Counseling|
507665|NCT00340093|Behavioral|Managing Diabetes|
507666|NCT00340080|Drug|Abacavir|
507667|NCT00340054|Other|questionnaire administration|
507668|NCT00340054|Procedure|study of high risk factors|
507669|NCT00339872|Drug|IMA-638|
507670|NCT00339833|Drug|Salsalate|The intervention was salsalate (3g/day) for 7 days.
507671|NCT00339833|Drug|Placebo|Identical placebo for 7 days.
507672|NCT00339768|Drug|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
507673|NCT00339690|Other|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
507674|NCT00339625|Other|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
507675|NCT00339586|Drug|Erlotinib|
507676|NCT00339469|Dietary Supplement|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
507677|NCT00339456|Drug|HAART|
507678|NCT00339417|Drug|Albendazole|
507679|NCT00339417|Drug|Ivermectin|
507680|NCT00339365|Behavioral|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
507681|NCT00339365|Behavioral|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
507682|NCT00339196|Drug|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
529833|NCT00151034|Drug|Carboplatin|
507683|NCT00339183|Drug|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
507684|NCT00339183|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m^2, leucovorin 400 mg/m^2 racemate (or 200 mg/m^2 I-leucovorin), 5-FU bolus 400 mg/m^2, 5-FU infusion 2400 mg/m^2.
507685|NCT00339170|Behavioral|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
507686|NCT00339170|Behavioral|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
507687|NCT00339157|Drug|Anakinra|
507688|NCT00339157|Biological|Pneumo23|
507689|NCT00339144|Drug|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
507690|NCT00339144|Drug|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
507691|NCT00339144|Drug|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
507692|NCT00339131|Drug|Ultratrace iobenguane I 131|
507693|NCT00339118|Drug|doxorubicin, cytoxan|
507694|NCT00339092|Behavioral|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
507695|NCT00339092|Behavioral|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
507696|NCT00339079|Drug|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
507697|NCT00339079|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
507698|NCT00339079|Other|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
507699|NCT00339079|Drug|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
507700|NCT00339066|Drug|Sertraline|
507701|NCT00339053|Drug|Immunonutrition ( Impact)|
507702|NCT00339040|Biological|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
507703|NCT00339040|Other|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
507704|NCT00339014|Drug|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
507705|NCT00339014|Other|Placebo|Identical placebo
507706|NCT00339001|Drug|erythropoietin and early iron supplements|
507707|NCT00338988|Drug|Capecitabine|1500 mg/m^2 PO twice daily x 14 days.
507708|NCT00338988|Drug|Oxaliplatin|130 mg/m^2 IV over 2 hours on day 1 of cycle.
507709|NCT00338975|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
507710|NCT00338975|Behavioral|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
507711|NCT00338975|Behavioral|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
507712|NCT00338975|Behavioral|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
507713|NCT00338962|Drug|paroxetine|paroxetine (40mg/day)
507714|NCT00338962|Drug|desipramine|200 mg per day
507715|NCT00338962|Drug|Naltrexone|50 mg per day
507716|NCT00338962|Drug|Placebo|placebo
507717|NCT00338949|Drug|Ziprasidone|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
507718|NCT00338949|Drug|Standard atypical antipsychotic drug|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
507719|NCT00338936|Drug|Valsartan + Hydrochlorothiazide|
507720|NCT00338923|Drug|HO/03/03|
507721|NCT00338910|Drug|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
507722|NCT00338897|Drug|SR123781A|
507723|NCT00338884|Drug|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
507724|NCT00338871|Procedure|home exercise|
507725|NCT00338858|Other|walking and balance performance evaluation|
507726|NCT00338858|Procedure|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
507727|NCT00338845|Behavioral|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
507728|NCT00338845|Behavioral|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
507729|NCT00338832|Behavioral|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
507730|NCT00338832|Behavioral|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
507731|NCT00338806|Behavioral|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
507732|NCT00338806|Behavioral|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
507733|NCT00338793|Drug|prednisolone|
507734|NCT00338780|Drug|Lamivudine/ Placebo 100mg daily|
507735|NCT00338767|Behavioral|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
507736|NCT00338767|Drug|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
507737|NCT00338754|Drug|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
507738|NCT00338728|Drug|Imatinib Mesylate|Given PO
507739|NCT00338728|Drug|Letrozole|Given PO
507740|NCT00338715|Device|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
507741|NCT00338702|Procedure|Autologous Platelet Gel|
507742|NCT00338689|Dietary Supplement|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
507743|NCT00338663|Device|knee immobilization splint|
507744|NCT00338650|Drug|adalimumab|
507745|NCT00338637|Device|APOS shoe kit|
507746|NCT00338624|Drug|oxybutynin chloride extended release|
507747|NCT00338611|Behavioral|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
507748|NCT00338611|Behavioral|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
507749|NCT00338611|Behavioral|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
507809|NCT00338104|Drug|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
507750|NCT00338611|Behavioral|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
507751|NCT00338598|Drug|Glycine|Glycine, 0.8 gr per kg given in two daily doses
507752|NCT00338598|Drug|placebo|
507753|NCT00338585|Drug|alfimeprase|
507754|NCT00338572|Behavioral|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
507755|NCT00338572|Behavioral|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
507756|NCT00338546|Drug|Cocaine hydrochloride|
507757|NCT00338546|Drug|Dexmedetomidine|
507758|NCT00338546|Procedure|Microneurography|
507759|NCT00338546|Procedure|Laser doppler velocimetry|
507760|NCT00338533|Device|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
507761|NCT00338507|Drug|Erdosteine|
507762|NCT00338494|Drug|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
507763|NCT00338481|Drug|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
507764|NCT00338481|Drug|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
507765|NCT00338468|Drug|epoetin alfa|
507766|NCT00338455|Drug|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
507767|NCT00338455|Drug|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
507768|NCT00338442|Drug|VariZIG™|Biological / Vaccine
507769|NCT00338429|Behavioral|FHP Sleep Program|Cognitive-Behavioral Intervention
507770|NCT00338416|Drug|Epoetin alfa|
507771|NCT00338403|Procedure|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
507772|NCT00338390|Drug|Abacavir|Change tenofovir to abacavir
507773|NCT00338390|Drug|Didanosine|Increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
507774|NCT00338390|Drug|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
507775|NCT00338377|Biological|Dendritic Cell Immunization|1x10^7 to 2.5x10^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
507776|NCT00338377|Drug|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
507777|NCT00338377|Drug|Fludarabine|25 mg/m^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
507778|NCT00338377|Biological|T-Cells|On Days 0, up to 1.5 x 10^11 T-cells by vein infusion over 30-60 minutes.
507779|NCT00338377|Biological|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
507780|NCT00338377|Drug|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
507781|NCT00338377|Biological|Intrathecal T-Cells|5.0x10^9 T-cells administered on Day 1, and 10x10^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
507782|NCT00338377|Biological|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
507783|NCT00338364|Behavioral|PAT|Coping and Distraction Intervention
507784|NCT00338351|Biological|Pneumococcal (vaccine)|
507785|NCT00338338|Drug|Lacidipine 4 or 6 mg (oral)|
507786|NCT00338338|Drug|Amlodipine 5 or 10 mg(oral)|
507787|NCT00338325|Behavioral|Reading program|Reading of children's story/picture books preoperatively
507788|NCT00338312|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
507789|NCT00338312|Drug|Placebo patch|placebo patch changed twice a week for one year
507790|NCT00338299|Drug|Epoetin alfa|
507791|NCT00338286|Other|Standard supportive care (packed RBC transfusion)|Per doctor prescription
507792|NCT00338286|Drug|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
507793|NCT00338273|Drug|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
507794|NCT00338273|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
507795|NCT00338260|Drug|MK0954, /Duration of Treatment : 5 Years|
507796|NCT00338260|Drug|Comparator : atenolol /Duration of Treatment : 5 Years|
507797|NCT00338247|Drug|lapatinib + capecitabine|Experimental
507798|NCT00338221|Drug|alanyl-glutamine|
507799|NCT00338221|Drug|glycine|
507800|NCT00338208|Behavioral|Training in the Use of Low Vision Devices|
507801|NCT00338195|Behavioral|Individualized caffeine cessation instructions|Intervention is described in the protocol
507802|NCT00338182|Drug|AZD1152 part A|48-hour continuous intravenous infusion
507803|NCT00338182|Drug|AZD1152 part B|2-hour intravenous infusion
507804|NCT00338143|Drug|efalizumab|
507805|NCT00338130|Drug|AZD6244|Oral liquid or Capsule
507806|NCT00338130|Drug|Temozolomide|oral
507807|NCT00338117|Drug|Galantamine hydrobromide|
507808|NCT00338104|Drug|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
529834|NCT00151034|Drug|Gemcitabine|
507810|NCT00338104|Drug|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
507811|NCT00338091|Drug|Benazepril|
507812|NCT00338091|Drug|Losartan|
507813|NCT00338078|Device|nocturnal oxygen treatment from oxygen concentrators|
507814|NCT00338065|Behavioral|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
507815|NCT00338065|Behavioral|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
507816|NCT00338052|Drug|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
507817|NCT00338039|Drug|Cetuximab|500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
507818|NCT00338039|Drug|Gemcitabine|"Induction Therapy: 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.~Chemotherapy Maintenance: 1 gm/m^2/week over 100 minutes weekly for 3 weeks then 1 week off."
507819|NCT00338039|Drug|Oxaliplatin|Induction Chemotherapy: 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
507820|NCT00338039|Drug|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
507821|NCT00338039|Radiation|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
507822|NCT00338026|Drug|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
507823|NCT00338000|Drug|Epoetin alfa|
507824|NCT00337987|Drug|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
507825|NCT00337987|Drug|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
507826|NCT00337974|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
507827|NCT00337974|Other|Educational DVDs|
507828|NCT00337961|Procedure|Optic Nerve Sheath Fenestration|
507829|NCT00337948|Drug|Epoetin alfa|
507830|NCT00337935|Drug|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
507831|NCT00337935|Other|Standard of care|
507832|NCT00337922|Drug|Lamivudine / Abacavir Sulfate|
507833|NCT00337909|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
507834|NCT00337909|Other|Educational DVDs|
507835|NCT00337883|Drug|Erlotinib HCl (OSI-774)|
507836|NCT00337870|Behavioral|PAT|Cognitive-Behavioral/Relaxation Intervention
507837|NCT00337831|Procedure|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
507838|NCT00337818|Biological|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
507839|NCT00337805|Other|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
507840|NCT00337792|Drug|oxycodone + lorazepam versus fentanyl + midazolam|
507841|NCT00337779|Drug|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
507842|NCT00337779|Drug|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
507843|NCT00337766|Drug|Desmopressin (DDAVP)|
507844|NCT00337766|Drug|Placebo|
507845|NCT00337753|Behavioral|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
507846|NCT00337753|Behavioral|Wait-list|subjects assigned to wait-list condition for six-weeks
507847|NCT00337740|Procedure|endoscopic variceal banding|
507848|NCT00337740|Drug|propranolol|
507849|NCT00337727|Drug|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
507850|NCT00337727|Drug|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
507851|NCT00337727|Drug|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
507852|NCT00337727|Drug|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
507853|NCT00337727|Drug|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
507854|NCT00337727|Drug|Comparator; Placebo (unspecified)|Aprepitant 80 mg & 125 mg Pbo capsules.
507855|NCT00337714|Procedure|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
507856|NCT00337714|Procedure|CVC cannulation|placement of conventional trilumen CVCs
507857|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
507858|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
507859|NCT00337688|Device|isometric joystick|isometric joystick
507860|NCT00337675|Drug|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
507861|NCT00337675|Drug|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
507862|NCT00337675|Drug|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
507863|NCT00337662|Drug|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
507864|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, for 10 weeks.
507865|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, 10 weeks
507866|NCT00337649|Drug|Epothilone D|<100mg/m2 iv on days 1, 8 and 15 every 4 weeks
507867|NCT00337649|Drug|Herceptin|4mg/kg iv loading dose followed by 2mg/kg iv weekly
507868|NCT00337636|Procedure|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
529923|NCT00150215|Drug|PF-00184562|
507869|NCT00337636|Drug|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
507870|NCT00337623|Drug|Prednisolone|
507871|NCT00337610|Drug|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
507872|NCT00337610|Drug|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
507873|NCT00337597|Other|Glucose 5%|
507874|NCT00337597|Other|NaCl 0.9%|
507875|NCT00337584|Procedure|Pre-surgical screening|
507876|NCT00337571|Drug|Aripiprazole|Tablets, Oral, once daily, 8 weeks
507877|NCT00337571|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
507878|NCT00337558|Drug|Solifenacin succinate|tablet
507879|NCT00337558|Behavioral|Simplified bladder training|Instructions
507880|NCT00337545|Drug|RAD001|
507881|NCT00337532|Drug|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
507882|NCT00337532|Drug|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
507883|NCT00337519|Procedure|allogeneic stem cell transplantation|see detailed description
507884|NCT00337519|Drug|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
507885|NCT00337506|Drug|Dexamethasone|
507886|NCT00337506|Drug|velcade|
507887|NCT00337493|Drug|mycophenolate mofetil [CellCept]|Concentration-controlled
507888|NCT00337493|Drug|mycophenolate mofetil [CellCept]|1g po bid
507889|NCT00337493|Drug|Cyclosporine or tacrolimus|Reduced
507890|NCT00337493|Drug|Cyclosporine or tacrolimus|Standard, as prescribed
507891|NCT00337480|Behavioral|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
507892|NCT00337467|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
507893|NCT00337454|Drug|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
507894|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
507895|NCT00337454|Drug|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
507896|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
507897|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
507898|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
507899|NCT00337441|Drug|Epoetin Alfa (drug)|
507900|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
507901|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
507902|NCT00337428|Biological|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
507903|NCT00337428|Biological|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
507904|NCT00337415|Drug|MK0354|
507905|NCT00337389|Drug|5- Fluorouracil (5-FU)|
507906|NCT00337389|Drug|bevacizumab (Avastin)|
507907|NCT00337389|Drug|Leucovorin|
507908|NCT00337389|Drug|CoFactor (ANX-510)|
507909|NCT00337376|Drug|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
507910|NCT00337376|Drug|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
507911|NCT00337350|Drug|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
507912|NCT00337350|Drug|placebo|matched placebo for rosiglitazone 4mg/day
507913|NCT00337337|Behavioral|Multiple grain|
507914|NCT00337337|Behavioral|Ordinary Asian- rice|
507915|NCT00337324|Device|Frequency-modulated electromagnetic neural stimulation|
507916|NCT00337298|Drug|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
507917|NCT00337298|Drug|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
507918|NCT00337285|Drug|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
507919|NCT00337272|Drug|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
507920|NCT00337272|Drug|Ramelteon|8 mgs daily for days 1-28 of treatment period
507921|NCT00337259|Drug|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
507922|NCT00337246|Biological|rituximab|
507923|NCT00337246|Drug|cyclophosphamide|
507924|NCT00337246|Drug|fludarabine phosphate|
507925|NCT00337246|Drug|mitoxantrone hydrochloride|
507926|NCT00337233|Procedure|yoga therapy|10 week yoga class
508036|NCT00336297|Procedure|Face to face screening|
507927|NCT00337207|Biological|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
507928|NCT00337194|Biological|monoclonal antibody SGN-30|Given IV
507929|NCT00337194|Other|placebo|Given IV
507930|NCT00337194|Drug|vinorelbine tartrate|Given IV
507931|NCT00337194|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
507932|NCT00337194|Drug|gemcitabine hydrochloride|Given IV
507933|NCT00337194|Other|laboratory biomarker analysis|Correlative studies
507934|NCT00337194|Other|pharmacological study|Correlative studies
507935|NCT00337168|Drug|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
507936|NCT00337168|Drug|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
507937|NCT00337155|Drug|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
507938|NCT00337129|Drug|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
507939|NCT00337116|Drug|iso sorbide dinitrate iv bolus or s/l|
507940|NCT00337103|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
507941|NCT00337103|Drug|Capecitabine|Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
507942|NCT00337090|Drug|YM178|
507943|NCT00337077|Drug|eribulin mesylate|Given IV
507944|NCT00337064|Procedure|Radiation Therapy|
507945|NCT00337051|Drug|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
507946|NCT00337051|Drug|Propofol|General anesthesia with propofol TCI
507947|NCT00337038|Drug|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
507948|NCT00336986|Drug|recombinant interleukin-21|
507949|NCT00336973|Drug|efalizumab|Subcutaneous repeating dose
507950|NCT00336960|Drug|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
507951|NCT00336960|Drug|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
507952|NCT00336960|Procedure|conventional surgery|4-10 weeks after completion of chemoradiotherapy
507953|NCT00336960|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
507954|NCT00336960|Procedure|tumor biopsy|at baseline and then at the time of surgical resection
507955|NCT00336960|Other|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
507956|NCT00336947|Drug|tegafur-gimeracil-oteracil potassium|
507957|NCT00336947|Drug|tegafur-uracil|
507958|NCT00336947|Procedure|adjuvant therapy|
507959|NCT00336934|Dietary Supplement|pomegranate juice|Given orally daily.
507960|NCT00336934|Other|placebo|Given orally daily.
507961|NCT00336921|Drug|Alfuzosin|Once daily
507962|NCT00336921|Drug|Placebo|Once daily
507963|NCT00336908|Drug|a combination of MCT, LCT , and Fish Oil|
507964|NCT00336895|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
507965|NCT00336882|Drug|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
507966|NCT00336882|Drug|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
507967|NCT00336856|Drug|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
507968|NCT00336856|Drug|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
507969|NCT00336843|Drug|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days −21 and −14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day −14) Busulfan (IV, 0.8 mg/kg every 6 h from day −7 to day −5) Cyclophosphamide (IV, 50 mg/kg on days −3 and −2) Etoposide (IV, 200 mg/m2 every 12 h on days −5 and −4) Autologous stem cells infusion on day 0
507970|NCT00336830|Behavioral|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
507971|NCT00336830|Behavioral|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
507972|NCT00336817|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
507973|NCT00336817|Drug|CellCept|CellCept 500mg or 1000mg BID for 90 days
507974|NCT00336791|Drug|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m^2 IV on day 1 of 21 day cycle.~FAC Chemotherapy: 500 mg/m^2 IV on day 1 and day 4 of 21 day cycle."
507975|NCT00336791|Drug|Cyclophosphamide|"FAC and FEC Chemotherapy:~500 mg/m^2 IV on day 1 of 21 day cycle."
507976|NCT00336791|Drug|Doxorubicin|FAC Chemotherapy: 50 mg/m^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
507977|NCT00336791|Drug|Paclitaxel|80 mg/m^2 by vein (IVPB) over 1 hour every week for 12 weeks
507978|NCT00336791|Drug|Epirubicin|FEC: 100 mg/m^2 IV on day 1 of 21 day cycle.
508037|NCT00336297|Procedure|Written screening on forms|
529924|NCT00150215|Drug|Olanzapine|
507979|NCT00336778|Drug|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
507980|NCT00336765|Drug|XL647|Tablets supplied in 50-mg strength administered orally daily
507981|NCT00336752|Procedure|non operative treatment|non operative treatment -casting for 6 weeks
507982|NCT00336752|Procedure|operative treatment of ankle fractures|operative treatment of ankle fractures
507983|NCT00336739|Drug|cinacalcet|
507984|NCT00336713|Drug|Saredutant (SR48968C)|oral administration (capsules)
507985|NCT00336713|Drug|Placebo|oral administration (capsules)
507986|NCT00336700|Drug|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
507987|NCT00336700|Drug|Erlotinib|150 mg/d Daily, oral 12 months
507988|NCT00336674|Biological|Intranasal insulin|440IU Insulin
507989|NCT00336674|Other|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
507990|NCT00336661|Device|PerioWave|
507991|NCT00336648|Drug|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
507992|NCT00336648|Drug|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
507993|NCT00336648|Procedure|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
507994|NCT00336635|Biological|cell-culture derived smallpox vaccine|
507995|NCT00336622|Device|Splint fabricated by an OT versus an off-the-shelf splint|"Experimental:~Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises~Control:~Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises"
507996|NCT00336596|Procedure|transcranial ultrasound in patients treated with iv t-PA|
507997|NCT00336583|Drug|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
507998|NCT00336557|Procedure|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
507999|NCT00336544|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
508000|NCT00336544|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
508001|NCT00336531|Drug|itraconazole|2.5 mg/kg twice daily for the first two days --> once daily
508002|NCT00336518|Drug|peginterferon alfa-2a|
508003|NCT00336518|Drug|ribavirin|
508004|NCT00336505|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
508005|NCT00336505|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
508006|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
508007|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
508008|NCT00336492|Biological|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
508009|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
508010|NCT00336479|Drug|Telaprevir|tablet
508011|NCT00336479|Drug|Ribavirin|tablet
508012|NCT00336479|Drug|Pegylated Interferon Alfa 2a|Solution for injection
508013|NCT00336479|Other|Placebo|matching placebo tablet
508014|NCT00336466|Drug|Human recombinant erythropoietin|
508015|NCT00336453|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
508016|NCT00336453|Biological|Influenza Vaccination|0.25mL dose for intramuscular injection
508017|NCT00336414|Drug|cyclophosphamide-prednisone-azathioprine|
508018|NCT00336401|Drug|Sevoflurane or Propofol|
508019|NCT00336388|Device|Paracheck Device|
508020|NCT00336375|Drug|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
508021|NCT00336362|Drug|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).~G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
508022|NCT00336349|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
508023|NCT00336336|Drug|n-3 PUFA|1 g die per os
508024|NCT00336336|Drug|Rosuvastatin|10 mg die per os
508025|NCT00336336|Drug|Placebo|1 gram c. per os
508026|NCT00336336|Drug|Placebo|10 mg c. per os
508027|NCT00336323|Procedure|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
508028|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
508029|NCT00336323|Drug|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
508030|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
508031|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
508032|NCT00336310|Drug|Repaglinide|
508033|NCT00336297|Procedure|Woman Abuse Screening Tool|
508034|NCT00336297|Procedure|Partner Violence Screen|
508035|NCT00336297|Procedure|Computerized screening|
508442|NCT00333567|Drug|Lumiracoxib|
508038|NCT00336284|Other|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
508039|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
508040|NCT00336245|Device|Copper T Intrauterine Contraceptive Device|
508041|NCT00336245|Drug|Hormonal Contraception|
508042|NCT00336232|Drug|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
508043|NCT00336219|Drug|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
508044|NCT00336206|Drug|Alemtuzumab|
508045|NCT00336193|Behavioral|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
508046|NCT00336180|Behavioral|HealthWise South Africa curriculum|18 classroom lessons
508047|NCT00336167|Drug|bezafibrate (drug)|
508048|NCT00336154|Drug|tetracyclin|
508049|NCT00336141|Drug|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
508050|NCT00336128|Behavioral|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
508051|NCT00336128|Behavioral|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
508052|NCT00336115|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
508053|NCT00336102|Other|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
508054|NCT00336102|Procedure|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
508055|NCT00336102|Procedure|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
508056|NCT00336089|Behavioral|exercise intervention|
508057|NCT00336089|Other|educational intervention|
508058|NCT00336089|Procedure|complementary or alternative medicine procedure|
508059|NCT00336089|Procedure|fatigue assessment and management|
508060|NCT00336089|Procedure|management of therapy complications|
508061|NCT00336089|Procedure|pain therapy|
508062|NCT00336089|Procedure|quality-of-life assessment|
508063|NCT00336076|Other|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
508064|NCT00336063|Drug|Azacitidine|Given SC
508065|NCT00336063|Other|Laboratory Biomarker Analysis|Correlative studies
508066|NCT00336063|Other|Pharmacological Study|Correlative studies
508067|NCT00336063|Drug|Vorinostat|Given PO
508068|NCT00336024|Drug|etoposide|Given IV
508069|NCT00336024|Drug|cyclophosphamide|Given IV
508070|NCT00336024|Drug|cisplatin|Given IV
508071|NCT00336024|Biological|filgrastim|Given IV or SC
508072|NCT00336024|Drug|carboplatin|Given IV
508073|NCT00336024|Drug|thiotepa|Given IV
508074|NCT00336024|Drug|methotrexate|Given IV
508075|NCT00336024|Drug|leucovorin calcium|Given IV or orally
508076|NCT00336024|Drug|vincristine sulfate|Given IV
508077|NCT00336024|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSC transplantation
508078|NCT00336024|Other|laboratory biomarker analysis|Correlative studies
508079|NCT00336024|Procedure|quality-of-life assessment|Ancillary studies
508080|NCT00336011|Device|Magnetic resonance imaging|
508081|NCT00335998|Drug|triapine|Given IV
508082|NCT00335998|Other|laboratory biomarker analysis|Correlative studies
508083|NCT00335998|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
508084|NCT00335998|Radiation|brachytherapy|Undergo intracavitary or interstitial brachytherapy
508085|NCT00335998|Drug|cisplatin|Given IV
508086|NCT00335998|Other|pharmacological study|Correlative studies
508087|NCT00335985|Drug|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
508088|NCT00335985|Drug|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
508089|NCT00335972|Drug|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
508090|NCT00335972|Drug|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
508091|NCT00335959|Drug|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
508092|NCT00335959|Drug|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
508093|NCT00335959|Procedure|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
508094|NCT00335959|Radiation|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
508095|NCT00335946|Device|HANS non-needle acupuncture|
508096|NCT00335946|Procedure|Stimulation of two acupuncture points bi-lateral|
508097|NCT00335933|Drug|Gabapentin extended-release tablets|
508098|NCT00335920|Drug|Dexamethasone-dihydrogenphosphate (4mg/ml)|
508099|NCT00335907|Procedure|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
508100|NCT00335894|Drug|hMG-IBSA|
508101|NCT00335881|Biological|hepatitis B vaccine|
508102|NCT00335868|Drug|danusertib|
508103|NCT00335868|Other|laboratory biomarker analysis|
508104|NCT00335868|Other|pharmacological study|
508105|NCT00335855|Device|Auto-injector for IM/SC vaccine administration|
508106|NCT00335829|Biological|bevacizumab|
508107|NCT00335829|Drug|chemotherapy|
508108|NCT00335829|Drug|embolization therapy|
508109|NCT00335829|Procedure|hepatic artery infusion|
508110|NCT00335816|Drug|fluorouracil|Given IV
508111|NCT00335816|Drug|leucovorin calcium|Given IV
508112|NCT00335816|Drug|oxaliplatin|Given IV
508113|NCT00335816|Procedure|conventional surgery|Patients undergo surgery
508114|NCT00335816|Radiation|radiation therapy|Patients undergo radiotherapy
508115|NCT00335816|Other|laboratory biomarker analysis|Correlative studies
508116|NCT00335816|Genetic|DNA analysis|Correlative studies
508117|NCT00335816|Genetic|polymerase chain reaction|Correlative studies
508118|NCT00335816|Other|immunohistochemistry staining method|Correlative studies
508119|NCT00335790|Procedure|Hyperbaric Therapy|
508120|NCT00335777|Drug|Migranal nasal spray|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
508121|NCT00335777|Drug|Migranal nasal spray|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
508122|NCT00335764|Drug|sorafenib tosylate|given orally
508123|NCT00335764|Drug|erlotinib hydrochloride|given orally
508124|NCT00335764|Drug|tipifarnib|given orally
508125|NCT00335764|Drug|temsirolimus|IV administration
508126|NCT00335751|Procedure|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
508127|NCT00335738|Drug|liposomal vincristine sulfate|Given IV
508128|NCT00335738|Drug|carboplatin|Given IV
508129|NCT00335738|Drug|etoposide|Given IV
508130|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
508131|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
508132|NCT00335712|Drug|ONO-5129|
508133|NCT00335699|Drug|Rosuvastatin|
508134|NCT00335686|Drug|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
508135|NCT00335686|Drug|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
508136|NCT00335673|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
508137|NCT00335660|Drug|AV608|
508138|NCT00335647|Drug|fluphenazine hydrochloride|
508139|NCT00335621|Drug|Inhaled Tiotropium|
508140|NCT00335595|Drug|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
508141|NCT00335595|Drug|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks"
508142|NCT00335582|Drug|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
508143|NCT00335569|Drug|hCG-IBSA|
508144|NCT00335556|Drug|Doxorubicin Hydrochloride|Given IV
508145|NCT00335556|Drug|Irinotecan Hydrochloride|Given IV
508146|NCT00335556|Procedure|Conventional Surgery|Patients undergo resection
508147|NCT00335556|Drug|Cyclophosphamide|Given IV
508148|NCT00335556|Drug|Etoposide|Given IV
508149|NCT00335556|Drug|Carboplatin|Given IV
508150|NCT00335556|Biological|Dactinomycin|Given IV
508151|NCT00335556|Drug|Vincristine Sulfate|Given IV
508152|NCT00335556|Radiation|Radiation Therapy|Undergo radiotherapy
508153|NCT00335556|Other|Laboratory Biomarker Analysis|Correlative studies
508154|NCT00335543|Drug|cisplatin|
508155|NCT00335543|Drug|gemcitabine hydrochloride|
508156|NCT00335543|Procedure|adjuvant therapy|
508157|NCT00335543|Procedure|conventional surgery|
508158|NCT00335543|Procedure|neoadjuvant therapy|
508159|NCT00335543|Radiation|radiation therapy|
508160|NCT00335517|Drug|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
508161|NCT00335504|Drug|oligofructose-enriched inulin|Given orally
508162|NCT00335504|Drug|sulindac|Given orally
508163|NCT00335504|Drug|placebo|Given orally
508164|NCT00335504|Drug|atorvastatin calcium|Given orally
508165|NCT00335504|Other|laboratory biomarker analysis|Correlative studies
508166|NCT00335491|Behavioral|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
508167|NCT00335491|Procedure|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
508168|NCT00335491|Procedure|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
508169|NCT00335491|Procedure|physical therapy|12 weeks of 3x/week training on the eccentron
529925|NCT00150202|Drug|pegaptanib sodium|
508170|NCT00335478|Drug|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.
508171|NCT00335465|Drug|Insulin glargine|once a daily, sc injection, 100IU/ml
508172|NCT00335452|Drug|Clopidogrel|oral administration
508173|NCT00335452|Drug|acetylsalicyclic acid (ASA)|oral administration
508174|NCT00335439|Drug|ketorolac tromethamine 0.5% (Acular®)|
508175|NCT00335426|Procedure|Spinal manipulative therapy|
508176|NCT00335413|Drug|Spironolactone|
508177|NCT00335400|Drug|Anesthetic Dilating Gel|
508178|NCT00335374|Drug|Pardoprunox|12 -42 mg
508179|NCT00335361|Device|Intra Vas Device (IVD)|
508180|NCT00335348|Drug|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
508181|NCT00335348|Drug|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
508182|NCT00335335|Drug|iodixanol|
508183|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
508184|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
508185|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
508186|NCT00335309|Procedure|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
508187|NCT00335309|Drug|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
508188|NCT00335296|Device|PFx catheter|
508189|NCT00335283|Drug|Lansoprazole Tablet|40 mg bid x 16 weeks
508190|NCT00335283|Procedure|PH and impedence testing|24 hour ph monitoring
508191|NCT00335283|Procedure|manometry|done prior to pH probe to measure length of esophagus
508192|NCT00335283|Drug|lansoprazole|40mg bid
508193|NCT00335283|Drug|placebo|one tablet bid
508194|NCT00335270|Drug|fos-amprenavir calcium, ritonavir|
508195|NCT00335270|Drug|abacavir/lamivudine as Epzicom|
508196|NCT00335244|Drug|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
508197|NCT00335244|Drug|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
508198|NCT00335231|Drug|gatifloxacin ophthalmic (ZYMAR)|
508199|NCT00335218|Drug|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
508200|NCT00335218|Drug|Placebo|1 tablet daily
508201|NCT00335205|Drug|ropinirole|
508202|NCT00335192|Drug|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
508203|NCT00335192|Drug|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
508204|NCT00335192|Drug|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
508205|NCT00335179|Drug|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
508206|NCT00335179|Drug|Vehicle cream|Vehicle cream in 250 mg
508207|NCT00335166|Drug|Pardaprunox|12-42 mg
508208|NCT00335166|Drug|pramipexole|1.5-4.5 mg
508209|NCT00335166|Drug|Placebo Comparator|Placebo
508210|NCT00335153|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
508211|NCT00335153|Device|CADD-Legacy® 1400 ambulatory infusion pump|
508212|NCT00335153|Device|PEG tube|percutaneous endoscopic gastrostomy tube
508213|NCT00335153|Device|J-tube|jejunal tube
508214|NCT00335140|Biological|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
508215|NCT00335140|Drug|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
508216|NCT00335140|Drug|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
508217|NCT00335140|Drug|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
508218|NCT00335140|Drug|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9~For patients with meningeal involvement additionally:~12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
508219|NCT00335140|Drug|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
508220|NCT00335140|Drug|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
508221|NCT00335114|Drug|cyclosporine ophthalmic emulsion|
508222|NCT00335101|Drug|Iodixanol, Ioversol, Iopromide|
508223|NCT00335088|Drug|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
508224|NCT00335075|Drug|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
508225|NCT00335075|Drug|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
508226|NCT00335049|Device|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
508227|NCT00335049|Device|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
508228|NCT00335036|Device|ICD lead implant|Randomization of ICD lead type at implant
508229|NCT00335036|Device|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
508230|NCT00335023|Other|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
508231|NCT00335010|Drug|Nitroglycerin|
508232|NCT00334997|Procedure|endoscopic surgery|
508233|NCT00334997|Procedure|laser surgery|
508234|NCT00334997|Radiation|radiation therapy|
508235|NCT00334984|Drug|glutamine|
508236|NCT00334984|Procedure|chemoprotection|
508237|NCT00334984|Procedure|management of therapy complications|
508238|NCT00334984|Procedure|therapeutic nutritional supplementation|
508239|NCT00334971|Procedure|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
508240|NCT00334958|Drug|Placebo|BID for 12-day Titration Phase and 12-week Maintenance Phase.
508241|NCT00334958|Drug|Rufinamide|400 mg twice daily (BID) orally uptitrated every 3 days in 400 mg BID increments up to 1600 mg BID (total daily dose of 3200 mg/day) over 12-day Titration Phase; followed by 1600 mg BID over 12-week Maintenance Phase.
508242|NCT00334932|Drug|bortezomib|
508243|NCT00334932|Drug|melphalan|
508244|NCT00334932|Drug|pegylated liposomal doxorubicin hydrochloride|
508245|NCT00334919|Behavioral|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
508246|NCT00334906|Drug|memantine HCl|
508247|NCT00334893|Drug|eribulin mesylate|Given IV
508248|NCT00334880|Drug|NRP104|
508249|NCT00334867|Drug|cyclophosphamide|Given IV
508250|NCT00334867|Drug|dexrazoxane hydrochloride|Given IV
508251|NCT00334867|Drug|doxorubicin hydrochloride|Given IV
508252|NCT00334867|Drug|etoposide|Given IV
508253|NCT00334867|Drug|ifosfamide|Given IV
508254|NCT00334867|Drug|topotecan hydrochloride|Given IV
508255|NCT00334867|Drug|vincristine sulfate|Given IV
508256|NCT00334867|Procedure|conventional surgery|Patients undergo surgery in week 18
508257|NCT00334867|Procedure|radiation therapy|Patients undergo radiation therapy in week 19
508258|NCT00334854|Drug|doxorubicin hydrochloride|
508259|NCT00334854|Drug|ifosfamide|
508260|NCT00334854|Procedure|adjuvant therapy|
508261|NCT00334854|Procedure|conventional surgery|
508262|NCT00334854|Procedure|neoadjuvant therapy|
508263|NCT00334854|Radiation|radiation therapy|
508264|NCT00334828|Drug|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
508265|NCT00334828|Drug|Placebo|Matching placebo; intravenous infusion.
508266|NCT00334815|Biological|Bevacizumab|Given IV
508267|NCT00334815|Drug|Cisplatin|Given IV
508268|NCT00334815|Drug|Docetaxel|Given IV
508269|NCT00334815|Drug|Etoposide|Given IV
508270|NCT00334815|Biological|Filgrastim|Given SC
508271|NCT00334815|Biological|Pegfilgrastim|Given SC
508272|NCT00334815|Radiation|Radiation Therapy|Undergo thoracic radiotherapy
508273|NCT00334802|Drug|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)~Phase 2: dose determined by phase 1"
508274|NCT00334802|Drug|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles~Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
508275|NCT00334789|Drug|Belinostat|Given IV
508276|NCT00334789|Drug|Isotretinoin|Given orally
508277|NCT00334789|Other|Pharmacological Study|Correlative studies
508278|NCT00334776|Biological|MART-1 antigen|
508279|NCT00334776|Biological|gp100:209-217(210M) peptide vaccine|
508280|NCT00334776|Biological|therapeutic autologous dendritic cells|
508281|NCT00334776|Biological|tyrosinase peptide|
508282|NCT00334763|Biological|bevacizumab|
508283|NCT00334763|Drug|carboplatin|
508284|NCT00334763|Drug|chemoprotection|
508285|NCT00334763|Drug|paclitaxel|
508286|NCT00334763|Radiation|radiation therapy|
508287|NCT00334750|Other|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
508288|NCT00334737|Drug|Darbepoetin Alfa Injection|darbepoetin alfa injection 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
508289|NCT00334737|Drug|erythropoietin alfa injection|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
508290|NCT00334737|Drug|sham injection|sham injection other names: not applicable
508291|NCT00334724|Procedure|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
508292|NCT00334724|Procedure|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
508293|NCT00334711|Drug|Sulfonylurea|
508294|NCT00334698|Drug|Cetirizine|
508295|NCT00334698|Drug|Pseudoephedrine|
508296|NCT00334698|Drug|Cetirizine with Pseudoephedrine|
508297|NCT00334685|Drug|[S,S]-Reboxetine|
508298|NCT00334672|Biological|anti-thymocyte globulin|
508299|NCT00334672|Drug|busulfan|
508300|NCT00334672|Drug|cyclophosphamide|
508301|NCT00334672|Drug|cyclosporine|
508302|NCT00334672|Drug|dexamethasone|
508303|NCT00334672|Drug|etoposide|
508304|NCT00334672|Drug|methotrexate|
508305|NCT00334672|Drug|mycophenolate mofetil|
508306|NCT00334672|Drug|therapeutic hydrocortisone|
508307|NCT00334672|Other|laboratory biomarker analysis|
508308|NCT00334672|Procedure|allogeneic hematopoietic stem cell transplantation|
508309|NCT00334672|Procedure|biopsy|
508310|NCT00334659|Drug|apricitabine|
508311|NCT00334646|Drug|Oral GW679769|150mg oral, once daily on days 1-3
529926|NCT00150189|Behavioral|Sucrose|
508312|NCT00334646|Drug|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
508313|NCT00334633|Drug|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
508314|NCT00334620|Procedure|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
508315|NCT00334607|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
508316|NCT00334594|Drug|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
508317|NCT00334594|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
508318|NCT00334594|Procedure|Therapeutic conventional surgery|Extrapleural pneumonectomy
508319|NCT00334594|Radiation|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
508320|NCT00334581|Drug|Irbesartan|Administration throughout the study period
508321|NCT00334581|Drug|Irbesartan|Administration throughout the study period
508322|NCT00334568|Drug|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
508323|NCT00334568|Drug|Placebo|Placebo
508324|NCT00334555|Other|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
508325|NCT00334555|Other|partner delivered meds|patient given meds to give to her partner
508326|NCT00334555|Other|field intervention|health worker finds partners
508327|NCT00334542|Drug|simvastatin|24-28 weeks of simvastatin
508328|NCT00334529|Drug|Oseltamivir|
508329|NCT00334503|Drug|Miglitol|
508330|NCT00334490|Drug|Sildenafil|12.5 mg Sildenafil once with optional second dose
508331|NCT00334490|Drug|Sildenafil|12.5 mg orally once with optional second dose
508332|NCT00334490|Drug|Placebo|Oral Placebo in 5 mls distilled water
508333|NCT00334477|Drug|tadalafil|
508334|NCT00334464|Drug|Standard of care or genotyping dosing of warfarin dosing|
508335|NCT00334438|Biological|rituximab|250mg/m2, IV, Days 1 and 8
508336|NCT00334438|Drug|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
508337|NCT00334438|Radiation|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
508338|NCT00334438|Radiation|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
508339|NCT00334425|Drug|MENOPUR; GONAL-F|
508340|NCT00334412|Drug|Ambisome|
508341|NCT00334412|Drug|caspofungin|
508342|NCT00334399|Drug|Miglitol|
508343|NCT00334386|Drug|Torasemide Prolonged Release (loop diuretic)|
508344|NCT00334386|Drug|Torasemide Immediate Release (loop diuretic)|
508345|NCT00334373|Procedure|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
508346|NCT00334360|Drug|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
508347|NCT00334360|Drug|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
508348|NCT00334360|Drug|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
508349|NCT00334360|Drug|Control|No drugs given during controlled hypothermia
508350|NCT00334347|Drug|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
508351|NCT00334347|Drug|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
508352|NCT00334334|Biological|Pneumococcal (vaccine)|
508353|NCT00334321|Radiation|IMRT|
508354|NCT00334321|Radiation|Intracavitary vaginal brachytherapy|
508355|NCT00334321|Drug|Paclitaxel|
508356|NCT00334321|Drug|Carboplatin|
508357|NCT00334308|Procedure|Barley protein bread or control (casein) bread|
508358|NCT00334295|Drug|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
508359|NCT00334282|Drug|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
508360|NCT00334282|Drug|placebo|matching placebo (800 mg tablet) once daily
508361|NCT00334269|Behavioral|Health messaging at weekly home visits by health counsellor|
508362|NCT00334269|Behavioral|Weekly home delivery of bottled spring water|
508363|NCT00334269|Behavioral|Weekly afterschool physical activity program for 5-18y.o.|
508364|NCT00334269|Behavioral|Cooking classes and grocery store tours with dietician|
508365|NCT00334269|Behavioral|Pedometers to track/increase weekly physical activity|
508366|NCT00334256|Drug|Tenofovir (TDF)|
508367|NCT00334256|Drug|Emtricitabine (FTC)|
508368|NCT00334243|Drug|Microflare protocol for IVF|
508369|NCT00334243|Drug|Antagonist protocol for IVF|
508370|NCT00334243|Drug|Demi-halt protocol for IVF|
508371|NCT00334217|Behavioral|Cognitive Remediation|PSS Cogrehab
508372|NCT00334204|Device|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
508373|NCT00334191|Drug|Sodium Bicarbonate|
508374|NCT00334191|Drug|Placebo|
508375|NCT00334178|Drug|Laxymig ER (drug)|
508376|NCT00334165|Procedure|Auricular acupuncture (procedure)|
508377|NCT00334152|Drug|casopitant|
508378|NCT00334139|Drug|Zoledronic Acid|every 4 weeks for 4 months
508379|NCT00334126|Drug|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
508380|NCT00334113|Behavioral|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
508381|NCT00334100|Behavioral|Exercise|Treadmill exercise
508382|NCT00334087|Behavioral|feeding habits|
508383|NCT00334074|Drug|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
508384|NCT00334061|Device|Penumbra System|
508385|NCT00334048|Drug|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
508386|NCT00334035|Drug|Quetiapine|
508387|NCT00334022|Drug|enfuvirtide|1ml BID
508388|NCT00333996|Drug|Dexamethasone|
508389|NCT00333983|Device|Robotic Upper Extremity Neurorehabilitation|Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
508390|NCT00333983|Other|Traditional Upper Extremity Exercise Group|Upper extremity stretching, skateboard reaching activities, and arm ergometer
508391|NCT00333970|Behavioral|cognitive remediation|individual cognitive training
508392|NCT00333944|Drug|Pralidoxime(drug)|
508393|NCT00333931|Drug|Phenytoin|
508394|NCT00333931|Behavioral|Cognitive Behavioral Therapy|
508395|NCT00333918|Drug|bromfenac ophthalmic solution|
508396|NCT00333918|Drug|placebo comparator|
508397|NCT00333905|Procedure|Ischemic exercise training|
508398|NCT00333892|Procedure|leukapheresis|pack of cells as per protocol
508399|NCT00333879|Device|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
508400|NCT00333866|Drug|pregabalin|600mg/day
508401|NCT00333866|Drug|pregabalin|450mg/day
508402|NCT00333866|Drug|pregabalin|300mg/day
508403|NCT00333866|Drug|placebo|placebo
508404|NCT00333853|Device|OneTouch(r) UltraSmart(r)|
508405|NCT00333840|Drug|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
508406|NCT00333840|Drug|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day.
508407|NCT00333840|Drug|cytarabine (ARA-C)|cytarabine 20 mg/m^2/day (max 40 mg) SC for 10 days every month.
508408|NCT00333827|Drug|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
508409|NCT00333827|Procedure|cell|stem cell
508410|NCT00333814|Drug|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
508411|NCT00333814|Drug|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
508412|NCT00333814|Drug|Sham injection|Sham injection at Day 0
508413|NCT00333801|Behavioral|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
508414|NCT00333801|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
508415|NCT00333788|Biological|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
508416|NCT00333775|Drug|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
508417|NCT00333775|Drug|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
508418|NCT00333775|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
508419|NCT00333762|Device|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
508420|NCT00333762|Device|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
508421|NCT00333749|Biological|Drinking or rinsing the mouth 2-3 times for 1 day|
508422|NCT00333749|Biological|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
508423|NCT00333736|Device|Biojector|All patients received biojector to use with BID enfuvirtide doses
508424|NCT00333723|Drug|Rosiglitazone|
508425|NCT00333710|Behavioral|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
508426|NCT00333710|Behavioral|Telehealth Intervention|Individual telephone contact with educational and goal setting components
508427|NCT00333697|Other|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
508428|NCT00333684|Device|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
508429|NCT00333671|Drug|Glycerol|
508430|NCT00333658|Behavioral|Goal setting and work feedback group|Goal setting and feedback using WBI
508431|NCT00333645|Drug|Caspofungin|
508432|NCT00333632|Drug|Dexmedetomidine|
508433|NCT00333632|Drug|Propofol|
508434|NCT00333632|Drug|Midazolam|
508435|NCT00333632|Drug|Fentanyl|
508436|NCT00333632|Drug|Isoflurane|
508437|NCT00333619|Behavioral|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
508438|NCT00333619|Behavioral|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
508439|NCT00333606|Behavioral|Acupuncture|Body acupuncture of 1 specific point per trial session
508440|NCT00333593|Device|Large pore dialyser|
508441|NCT00333593|Device|Standard dialyser|
508443|NCT00333554|Dietary Supplement|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
508444|NCT00333554|Dietary Supplement|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
508445|NCT00333541|Behavioral|Using internet/E-mail for follow-up|follow-up via email link to survey
508446|NCT00333528|Drug|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
508447|NCT00333528|Drug|Placebo: Normal saline|Intramuscular administration
508448|NCT00333515|Drug|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
508449|NCT00333515|Drug|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
508450|NCT00333502|Drug|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
508451|NCT00333489|Drug|valsartan|
508452|NCT00333476|Drug|MSI-1256F (Squalamine Lactate)|
508453|NCT00333463|Behavioral|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
508454|NCT00333450|Biological|Pneumococcal vaccine|
508455|NCT00333437|Drug|Mycophenolate mofetil|
508456|NCT00333424|Biological|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
508457|NCT00333411|Drug|BIRT 2584 XX|
508458|NCT00333411|Drug|Placebo|
508459|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
508460|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
508461|NCT00333398|Biological|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
508462|NCT00333385|Drug|ceftazidime|
508463|NCT00333372|Drug|Z-338|
508464|NCT00333359|Drug|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
508465|NCT00333346|Drug|Administration of tramadol intravenously|
508466|NCT00333333|Procedure|Cord blood|Cord blood will be obtained at the time of delivery.
508467|NCT00333320|Procedure|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
508468|NCT00333320|Procedure|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
508469|NCT00333307|Drug|recombinant human relaxin|
508470|NCT00333294|Drug|Gefitinib|
508471|NCT00333294|Procedure|Radiation therapy|
508472|NCT00333294|Drug|Cisplatin|
508473|NCT00333294|Drug|Vinorelbine|
508474|NCT00333281|Drug|tadalafil|
508475|NCT00333268|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
508476|NCT00333268|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
508477|NCT00333255|Drug|Nepafenac Ophthalmic Suspension, 0.1%|
508478|NCT00333242|Drug|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
508479|NCT00333229|Drug|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
508480|NCT00333229|Drug|Placebo|Matching Placebo
508481|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
508482|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
508483|NCT00333216|Other|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
508484|NCT00333203|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
508485|NCT00333203|Other|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
508486|NCT00333190|Device|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
508487|NCT00333177|Behavioral|Cognitive remediation|Cognitive remediation training includes computerized cognitive training plus learning skills group.
508488|NCT00333177|Behavioral|Health behavior training|Health behavior training includes group skills training in nutrition, exercise, and relaxation.
508489|NCT00333177|Drug|Risperidone, administered orally|Oral risperidone at dosage judged optimal by treating psychiatrist
508490|NCT00333177|Drug|Risperidone, administered via injection|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
508491|NCT00333177|Behavioral|Individual Placement and Support|Supported education/employment
508492|NCT00333164|Drug|Asprin, Cilostazol|
508493|NCT00333151|Drug|liraglutide|
508494|NCT00333151|Drug|rosiglitazone|
508495|NCT00333151|Drug|metformin|
508496|NCT00333138|Drug|FTY720|FTY720 capsule was taken orally once a day
508497|NCT00333138|Drug|Placebo|Placebo 1.25 mg capsule was given once daily
508498|NCT00333125|Drug|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
508499|NCT00333125|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
508500|NCT00333125|Other|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
508501|NCT00333112|Drug|solifenacin succinate|Oral
508502|NCT00333112|Drug|tamsulosin|oral
508503|NCT00333112|Drug|placebo|oral
508504|NCT00333099|Dietary Supplement|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
508505|NCT00333099|Other|impact|"1500 calories every day :~-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
508506|NCT00333086|Drug|Letrozole|
508507|NCT00333073|Device|Bulkamid|initial injection with option for second (if required)
508508|NCT00333060|Drug|OT-551 ophthalmic solution|
508509|NCT00333047|Drug|Letrozole|
508510|NCT00333034|Drug|Etanercept|
508511|NCT00333021|Drug|Fondaparinux sodium|
508512|NCT00333021|Drug|GSK576428|
508513|NCT00333008|Drug|Doxil|
508514|NCT00333008|Drug|Cyclophosphamide|
508515|NCT00333008|Drug|Vincristine|
508516|NCT00333008|Drug|Prednisone|
508517|NCT00333008|Drug|Rituximab|
508518|NCT00333008|Drug|Pegfilgrastim|
508519|NCT00332995|Drug|dapivirine (TMC120) vaginal ring|
508520|NCT00332982|Behavioral|Focused knowledge translation strategies|
508521|NCT00332969|Drug|Octreotide|
508522|NCT00332956|Biological|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
508523|NCT00332956|Biological|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
508524|NCT00332956|Biological|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
508525|NCT00332956|Biological|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
508526|NCT00332943|Procedure|MR colonography with fecal tagging|
508527|NCT00332930|Biological|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
508528|NCT00332930|Biological|HIV gag-pol antigens and interferon-gamma (IFN-y)|
508529|NCT00332917|Drug|Pardoprunox|12-42 mg
508530|NCT00332904|Drug|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
508531|NCT00332904|Drug|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
508532|NCT00332891|Drug|SR58611A|
508533|NCT00332878|Behavioral|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
508534|NCT00332878|Behavioral|stepping Stones short|3 hour intervention on HIV and safer sex
508535|NCT00332865|Behavioral|Swallowing Exercises|Daily exercises
508536|NCT00332852|Drug|Letrozole|2.5 mg/day - oraly
508537|NCT00332839|Drug|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
508538|NCT00332839|Drug|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
508539|NCT00332839|Drug|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
508540|NCT00332839|Drug|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
508541|NCT00332839|Drug|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
508542|NCT00332826|Drug|Technosphere Insulin|
508543|NCT00332813|Behavioral|HIV Risk Behavior Intervention|
508544|NCT00332800|Drug|Nutritional Supplementation|
508545|NCT00332787|Drug|Fluoxetine|
508546|NCT00332774|Drug|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
508547|NCT00332774|Drug|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
508548|NCT00332774|Other|Nepafenac ophthalmic suspension vehicle|
508549|NCT00332761|Drug|Caduet|
508550|NCT00332748|Drug|Oral Taxane|
508551|NCT00332735|Drug|spinal administration of articaine|
508552|NCT00332735|Drug|spinal administration of bupivacaine|
508553|NCT00332722|Procedure|Cervical facet joint nerve blocks|
508554|NCT00332709|Drug|Letrozole|2.5 mg/day for 3 years
508555|NCT00332709|Drug|Zoledronic acid|4 mg every 6 months
508556|NCT00332696|Drug|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
508557|NCT00332696|Drug|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
508558|NCT00332696|Drug|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
508559|NCT00332696|Drug|Placebo|Physiologic saline solution
508560|NCT00332683|Procedure|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
508561|NCT00332683|Procedure|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
508562|NCT00332670|Procedure|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
508563|NCT00332670|Procedure|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
508564|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
508565|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
508566|NCT00332657|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
508567|NCT00332644|Drug|nicotine patch|used according to FDA package label
508568|NCT00332644|Drug|nicotine lozenge|used according to FDA-approved package directions
508569|NCT00332644|Drug|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
531530|NCT00136487|Drug|Celecoxib|
508570|NCT00332644|Drug|bupropion|dosage according to FDA-approved instructions
508571|NCT00332644|Drug|bupropion + lozenge|dosage according to FDA approved standard instructions
508572|NCT00332644|Drug|placebo|dosage same as active drug conditions
508573|NCT00332631|Drug|N-acetylcysteine|
508574|NCT00332631|Drug|Placebo|
508575|NCT00332618|Device|OXYGENATED GLYCEROL TRIESTERS|
508576|NCT00332605|Drug|Naltrexone plus N-Acetyl Cysteine|daily
508577|NCT00332605|Drug|Placebo|daily
508578|NCT00332579|Drug|Naltrexone|daily
508579|NCT00332579|Drug|Placebo|daily
508580|NCT00332566|Biological|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
508581|NCT00332566|Biological|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
508582|NCT00332553|Drug|Raloxifene|
508583|NCT00332553|Drug|medroxyprogesterone acetate|
508584|NCT00332553|Drug|estrogen|
508585|NCT00332553|Drug|17 beta estradiol|
508586|NCT00332540|Drug|bimatoprost/timolol fixed combination|
508587|NCT00332514|Behavioral|telephone call by a pharmacist|
508588|NCT00332488|Drug|Technosphere Insulin|Inhalation, 15U/30U, prandial
508589|NCT00332488|Drug|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
508590|NCT00332488|Drug|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
508591|NCT00332462|Drug|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
508592|NCT00332462|Drug|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
508593|NCT00332436|Drug|brimonidine/timolol fixed combination|
508594|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
508595|NCT00332397|Device|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
508596|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
508597|NCT00332384|Drug|brimonidine/timolol fixed combination|
508598|NCT00332371|Device|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.~It consists of:~a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)~a hemofilter (polyethersulfone 1,4 m2)~a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)~The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
508599|NCT00332345|Drug|brimonidine/timolol fixed combination|
508600|NCT00332332|Biological|etanercept|etanercept subcutaneous injection
508601|NCT00332319|Drug|GW679769|
508602|NCT00332306|Drug|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients <60kg, 400mg patients > 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
508603|NCT00332306|Drug|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients < 60kg, 400 mg OD patients > 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
508604|NCT00332293|Drug|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
508605|NCT00332293|Drug|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
508606|NCT00332280|Drug|AMT2003|
508607|NCT00332267|Procedure|Endotoxin infusion, Normobaric hypoxia|
508608|NCT00332254|Drug|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
508609|NCT00332241|Drug|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
508610|NCT00332241|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
508611|NCT00332228|Drug|depot naltrexone|long-acting depot parenteral formulation of naltrexone
508612|NCT00332228|Behavioral|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
508613|NCT00332228|Drug|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
508614|NCT00332215|Drug|Inhaled Sodium Pyruvate|
508615|NCT00332202|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
508616|NCT00332202|Drug|placebo|oral, daily
508617|NCT00332189|Drug|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
508618|NCT00332176|Drug|Celgosivir|400mg qd + standard of care for 12 weeks
508619|NCT00332176|Drug|Celgosivir|600mg qd + standard of care for 12 weeks
508620|NCT00332176|Drug|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
508621|NCT00332163|Biological|Panitumumab|Administered by intravenous infusion
508622|NCT00332163|Drug|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
508623|NCT00332163|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
508624|NCT00332163|Drug|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
508690|NCT00331552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
508691|NCT00331552|Drug|cyclophosphamide|Given orally
508692|NCT00331552|Biological|trastuzumab|Given IV
508693|NCT00331539|Device|Cochlear Implant|
508694|NCT00331526|Biological|aldesleukin|
508625|NCT00332163|Drug|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
508626|NCT00332137|Drug|Tolterodine|
508627|NCT00332124|Drug|Choline|900 mg every day until birth of infant
508628|NCT00332124|Dietary Supplement|Placebo|Corn oil every day in place of choline
508629|NCT00332098|Behavioral|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
508630|NCT00332098|Behavioral|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
508631|NCT00332085|Drug|Chromium Picolinate|
508632|NCT00332072|Drug|bimatoprost/timolol fixed combination|
508633|NCT00332059|Drug|bimatoprost/timolol fixed combination|
508634|NCT00332046|Drug|GW679769|
508635|NCT00332033|Drug|Pirfenidone|
508636|NCT00332020|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
508637|NCT00332020|Drug|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
508638|NCT00332007|Drug|Tonabersat|two tablets once daily
508639|NCT00332007|Drug|Placebo|two tablets once daily
508640|NCT00331994|Drug|Bacillus clausii|3 bacillus clausii vials/day for one month
508641|NCT00331994|Drug|Metronidazole|3 Metronidazole tablets/day for one week
508642|NCT00331981|Drug|Amisulpride|
508643|NCT00331955|Drug|doxorubicin hydrochloride|Given IV
508644|NCT00331955|Drug|vorinostat|Given orally
508645|NCT00331955|Other|pharmacological study|Correlative studies
508646|NCT00331955|Other|laboratory biomarker analysis|Correlative studies
508647|NCT00331929|Device|Minato A 500 AS spirometer|Spirometry at rest
508648|NCT00331916|Drug|quinolone|
508649|NCT00331890|Drug|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
508650|NCT00331890|Drug|Placebo|As active drug
508651|NCT00331877|Procedure|family conference with bereavement information leaflet|
508652|NCT00331864|Drug|Ranibizumab|
508653|NCT00331851|Drug|liraglutide|
508654|NCT00331851|Drug|insulin glargine|
508655|NCT00331851|Drug|metformin|
508656|NCT00331851|Drug|glimepiride|
508657|NCT00331838|Drug|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials~Subcutaneous injection"
508658|NCT00331838|Drug|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
508659|NCT00331838|Drug|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe~Subcutaneous injection"
508660|NCT00331838|Drug|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component~Subcutaneous injection"
508661|NCT00331825|Drug|Risperidone and Olanzapine|
508662|NCT00331812|Procedure|Mitochondrial functions and oxidative stress|
508663|NCT00331799|Drug|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
508664|NCT00331786|Drug|nitric oxide-releasing acetylsalicylic acid derivative|
508665|NCT00331786|Other|laboratory biomarker analysis|
508666|NCT00331786|Procedure|biopsy|
508667|NCT00331773|Radiation|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
508668|NCT00331773|Radiation|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
508669|NCT00331760|Drug|cisplatin|
508670|NCT00331760|Radiation|intensity-modulated radiation therapy|
508671|NCT00331747|Drug|Glatiramer acetate|
508672|NCT00331721|Drug|Enecadin|Dose escalating
508673|NCT00331721|Drug|Placebo|Placebo comparator
508674|NCT00331708|Drug|Artesunate plus sulfadoxine-pyrimethamine|
508675|NCT00331695|Drug|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
508676|NCT00331682|Drug|alvocidib|Given IV
508677|NCT00331682|Drug|docetaxel|Given IV
508678|NCT00331669|Procedure|deep brain stimulation|high frequency stimulation
508679|NCT00331656|Device|Non-invasive positive pressure mask ventilators|
508680|NCT00331656|Device|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
508681|NCT00331643|Drug|ixabepilone|Given IV
508682|NCT00331630|Drug|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
508683|NCT00331630|Drug|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
508684|NCT00331604|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
508685|NCT00331604|Drug|insulin detemir|Injection s.c., 50% of daily dose.
508686|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
508687|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
508688|NCT00331578|Device|Excel drug-eluting coronary artery stent|
508689|NCT00331565|Procedure|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
508695|NCT00331526|Biological|therapeutic autologous lymphocytes|
508696|NCT00331526|Procedure|adjuvant therapy|
508697|NCT00331526|Procedure|conventional surgery|
508698|NCT00331513|Drug|vorinostat|Given orally
508699|NCT00331513|Drug|idarubicin|Given IV
508700|NCT00331513|Other|laboratory biomarker analysis|Correlative studies
508701|NCT00331513|Other|pharmacological study|Correlative studies
508702|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
508703|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
508704|NCT00331487|Drug|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
508705|NCT00331487|Drug|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
508706|NCT00331474|Biological|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
508707|NCT00331435|Procedure|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
508708|NCT00331422|Drug|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
508709|NCT00331422|Drug|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
508710|NCT00331422|Procedure|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
508711|NCT00331409|Drug|Everolimus|2.5 mg by mouth daily
508712|NCT00331409|Drug|imatinib mesylate|600 mg by mouth daily
508713|NCT00331370|Behavioral|GP training and Health Education|
508714|NCT00331344|Drug|mitoxantrone hydrochloride|Given IV
508715|NCT00331344|Drug|ixabepilone|Given IV
508716|NCT00331344|Drug|prednisone|Given orally
508717|NCT00331305|Behavioral|Supervised Exercise|
508718|NCT00331305|Behavioral|Home-Based Exercise|
508719|NCT00331305|Drug|Sertraline (Zoloft)|
508720|NCT00331305|Drug|Placebo Pill|
508721|NCT00331279|Drug|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
508722|NCT00331279|Drug|Placebo|Placebo pills in likeness of the cinnamon extract
508723|NCT00331253|Procedure|Indocyanine Green-Mediated Photothrombosis|
508724|NCT00331240|Drug|travoprost/timolol fixed combination|
508725|NCT00331240|Drug|placebo (artificial tears)|
508726|NCT00331227|Drug|Isotonix OPC-3 (flavonoid supplement)|
508727|NCT00331214|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
508728|NCT00331214|Drug|placebo patch|placebo patch replaced every 3-4 days for 6 months
508729|NCT00331201|Drug|SAFEstart|
508730|NCT00331188|Drug|Sanvar® (vapreotide)|
508731|NCT00331175|Drug|Peptide YY3-36|
508732|NCT00331162|Drug|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
508733|NCT00331162|Drug|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr < 3-4 mg/dL.~Give first dose over 6 hours, subsequent doses over 4 hours.~Premedication to be given with the first 3 doses:~Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.~Hold infusion if temperature > 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
508734|NCT00331149|Drug|Ropinirole prolonged release|
508735|NCT00331149|Drug|ropinirole immediate release|
508736|NCT00331136|Drug|Pyronaridine-Artesunate|once a day for 3 days
508737|NCT00331123|Drug|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
508738|NCT00331123|Drug|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
508739|NCT00331110|Device|Laterally-Wedged Insole with Ankle Strapping|
508740|NCT00331110|Device|Laterally-Weged Insole|
508741|NCT00331097|Drug|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
508742|NCT00331097|Drug|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
508743|NCT00331097|Drug|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
508744|NCT00331097|Drug|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
508745|NCT00331084|Drug|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
508746|NCT00331084|Drug|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
508747|NCT00331071|Drug|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
508748|NCT00331071|Drug|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
508749|NCT00331058|Procedure|Bronchoscopsy|Healthy and Asthmatic Volunteers
508750|NCT00331058|Procedure|Prednisolone|Asthmatic Volunteers
508751|NCT00331045|Drug|alvimopan|0.25 mg/day
508752|NCT00331045|Drug|Placebo|
508753|NCT00331045|Drug|Alvimopan 0.5 mg/day|
508754|NCT00331045|Drug|Alvimopan 1 mg/day|
508755|NCT00331032|Drug|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
508756|NCT00331032|Drug|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
508757|NCT00331006|Drug|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
508758|NCT00330993|Drug|mifepristone, misoprostol|
508759|NCT00330980|Drug|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
508760|NCT00330980|Drug|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
508761|NCT00330980|Drug|Placebo|Participants will receive placebo for 6 months.
508762|NCT00330967|Drug|20% Intralipid|lipid infusion
508763|NCT00330941|Drug|lidocaine|
508764|NCT00330928|Device|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
508765|NCT00330928|Device|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
508766|NCT00330915|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
508767|NCT00330902|Drug|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
508768|NCT00330902|Drug|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
508769|NCT00330876|Drug|Pitavastatin|
508770|NCT00330863|Drug|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
508771|NCT00330863|Drug|Risperidone|Target dose is 4 mg/day.
508772|NCT00330863|Drug|Olanzapine|Target dose is 15 mg/day.
508773|NCT00330863|Drug|Quetiapine|Target dose is 600 mg/day.
508774|NCT00330863|Drug|Ziprasidone|Target dose is 120 mg/day.
508775|NCT00330863|Drug|Aripiprazole|Target dose is 20 mg/day.
508776|NCT00330863|Drug|Paliperidone|Target dose is 6 mg/day.
508777|NCT00330850|Drug|PRO-513|
508778|NCT00330824|Drug|antibiotic/steroid combination|1gtt, 4x/d, 15 days
508779|NCT00330824|Drug|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
508780|NCT00330798|Drug|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
508781|NCT00330798|Other|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
508782|NCT00330785|Drug|Amlodipine/Atorvastatin|
508783|NCT00330772|Drug|Aspirin|
508784|NCT00330772|Drug|Clopidogrel|
508785|NCT00330759|Biological|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
508786|NCT00330759|Drug|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
508787|NCT00330746|Drug|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
508788|NCT00330746|Drug|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
508789|NCT00330746|Drug|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
508790|NCT00330746|Drug|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
508791|NCT00330733|Drug|Salsalate|Salsalate therapy
508792|NCT00330733|Drug|Placebo|Matching placebo
508793|NCT00330720|Device|Emergency Response System (Device)|
508794|NCT00330707|Drug|Bacillus Calmette Guerin and interferon alpha|
508795|NCT00330694|Other|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
508796|NCT00330694|Other|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
508797|NCT00330681|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
508798|NCT00330681|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
508799|NCT00330668|Drug|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
508800|NCT00330655|Drug|memantine|
508801|NCT00330629|Behavioral|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
508802|NCT00330629|Behavioral|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
508803|NCT00330616|Drug|323U66 SR|
508804|NCT00330603|Procedure|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
508805|NCT00330577|Drug|timolol maleate 0.5%|
508806|NCT00330577|Drug|latanoprost/timolol fixed combination|
508807|NCT00330577|Drug|placebo (artificial tears)|
508808|NCT00330564|Drug|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
508809|NCT00330551|Behavioral|Group Skills Training and Psychoeducation|Group skills training sessions will be weekly throughout the study. The sessions will include group therapy meetings focused on everyday living skills, family education about schizophrenia, assessments of medication response, and individual meetings with a case manager for counseling and evaluations of schizophrenia symptoms.
508810|NCT00330551|Behavioral|Individual Case Management|An individual therapist will provide therapy focused on everyday life skills and aid in interfacing with community agencies, work, and/or school settings.
508811|NCT00330551|Drug|Oral Risperidone|Daily oral risperidone dosage will determined by treating psychiatrist.
508812|NCT00330551|Drug|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone once every 2 weeks. Dosage will be adjusted if needed.
508814|NCT00330499|Drug|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
508815|NCT00330499|Radiation|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
508816|NCT00330486|Drug|Acamprosate|
508817|NCT00330473|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
508818|NCT00330473|Drug|Insulin|patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
508819|NCT00330460|Drug|Alendronate|ALN; 70 mg; oral; once weekly
508820|NCT00330460|Drug|Denosumab|60 mg; SC; every 6 months
508821|NCT00330434|Drug|Bupropion|
508822|NCT00330434|Drug|Chlorzoxazone|
508823|NCT00330434|Drug|Ethanol|
508824|NCT00330421|Drug|sorafenib tosylate|Given PO
508825|NCT00330421|Procedure|therapeutic conventional surgery|Undergo surgery
508826|NCT00330421|Other|laboratory biomarker analysis|Correlative studies
508827|NCT00330421|Other|pharmacological study|Correlative studies
508828|NCT00330421|Procedure|computed tomography|Correlative studies
508829|NCT00330421|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
508830|NCT00330408|Behavioral|GP training|
508831|NCT00330395|Drug|caspofungin acetate|Duration of Treatment 28 Days
508832|NCT00330382|Drug|Bowman-Birk inhibitor concentrate|Given orally
508833|NCT00330382|Other|placebo|Given orally
508834|NCT00330382|Other|laboratory biomarker analysis|Correlative studies
508835|NCT00330369|Drug|Darusentan|Darusentan administered orally once daily
508836|NCT00330369|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
508837|NCT00330356|Behavioral|Low Salt Diet versus High salt diet|
508838|NCT00330343|Drug|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
508839|NCT00330330|Drug|ISIS 113715|
508840|NCT00330317|Drug|letrozole|2.5mg letrozole once-daily
508841|NCT00330304|Drug|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
508842|NCT00330304|Drug|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
508843|NCT00330304|Drug|isoniazid|Isoniazid, 10mg/kg daily for study period
508844|NCT00330304|Other|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
508845|NCT00330291|Drug|Xyrem|
508846|NCT00330278|Drug|Cefazolin|
508847|NCT00330265|Device|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
508848|NCT00330265|Other|Conventional Wound Therapy|Normal Saline Dressings
508849|NCT00330252|Drug|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
508850|NCT00330252|Drug|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
508851|NCT00330239|Drug|Paroxetine CR|
508852|NCT00330213|Behavioral|red wine and cognac consumption|
508853|NCT00330200|Drug|ISIS 113715|
508854|NCT00330187|Drug|Bupropion SR|Bupropion SR, with goal dose 300 mg/day, for 6 weeks of active treatment
508855|NCT00330187|Behavioral|Contingency Management|Contingency Management provided at twice-weekly visits during the 6-week active treatment. Escalating schedule, with resets, reinforcing smoking abstinence.
508856|NCT00330187|Other|Placebo|Placebo, matched in appearance to Bupropion SR, for 6 weeks of treatment
508857|NCT00330174|Drug|Acamprosate|2 333mg tablets three times daily
508858|NCT00330161|Drug|vorinostat|Given orally
508859|NCT00330161|Other|laboratory biomarker analysis|Correlative studies
508860|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d|
508861|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d|
508862|NCT00330148|Drug|nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d|
508863|NCT00330135|Drug|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
508864|NCT00330135|Drug|placebo injection|placebo injection - 1 injection
508865|NCT00330122|Procedure|fore locked plate|
508866|NCT00330122|Procedure|external radiocarpal fixer|
508867|NCT00330109|Procedure|MRS Imaging|Performed on a 3.0 Tesla Philips Intera MRI Unit (Best, Netherlands). Scout views and T2 transverse images are obtained to locate the tumor in conjunction with any previous diagnostic images.
508868|NCT00330109|Procedure|PET Scanning|Using an Allegro scanner, the patient will be scanned for approximately 20-30 minutes. All emission scan data is processed by a multi-step procedure.
508869|NCT00330109|Procedure|Diffusion Tensor Imaging|Subjects will be scanned with a 3T Philips Intera MRI scanner for approximately 26 minutes for anatomical and DTI imaging. Total DTI acquisition time will be 6:06 minutes with 40 contiguous axial slices for full brain coverage.
508870|NCT00330096|Drug|Hesperidin|
508871|NCT00330096|Other|Placebo|
508872|NCT00330083|Biological|ALK Ragweed Tablet|
508873|NCT00330070|Drug|IPL512,602 20 mg once daily|
508874|NCT00330070|Drug|IPL512,602 Matching Placebo once daily|
508875|NCT00330044|Drug|Premetrexed (Alimta)|
508876|NCT00330044|Drug|Carboplatin|
508877|NCT00330018|Drug|Valganciclovir|Valganciclovir
508878|NCT00330018|Drug|Acyclovir|Acyclovir
508879|NCT00330005|Behavioral|Group Psychotherapy|
508880|NCT00329992|Behavioral|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
508881|NCT00329979|Behavioral|vascular access site|Randomized vascular access site
508882|NCT00329966|Biological|Surface Antigen, Inactivated, Influenza (form.2006-07)|
508883|NCT00329940|Drug|Letrozole|
508884|NCT00329927|Biological|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
508885|NCT00329914|Drug|Progesterone|Vaginal pessaries, 200 mg/day
508886|NCT00329914|Drug|Placebo|Placebo pessaries containing peanut oil
508887|NCT00329901|Biological|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
508888|NCT00329901|Biological|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
508889|NCT00329901|Biological|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
508890|NCT00329888|Procedure|Endoscopic papillary balloon dilatation|
508891|NCT00329888|Procedure|Endoscopic sphincterotomy|
508892|NCT00329862|Procedure|Laparoscopic Truncal Vagotomy|
508893|NCT00329849|Biological|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
508894|NCT00329849|Biological|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
508895|NCT00329836|Other|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
508896|NCT00329823|Drug|Etanercept sc 50mg per week for 12 weeks|
508897|NCT00329810|Drug|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
508898|NCT00329797|Dietary Supplement|Calcium|A single dose of 500 mg of elemental calcium orally each day for 3 years.
508899|NCT00329797|Dietary Supplement|Zoledronic acid|Patients receive IV over 15 minutes once every 6 months for 3 years. The goal dose of zoledronic acid is 4 mg, but the selection of dose is determined based on calculated creatinine clearance at baseline.
508900|NCT00329797|Radiation|radiation therapy|Patients must receive external beam irradiation, brachytherapy (HDR or LDR), or a combination of external beam irradiation and brachytherapy at the discretion of the treating physician. Dose/duration also will be at the discretion of the treating physician; however, dose will not exceed 45 Gy to 100% of the proximal femur, and no proximal femur will receive ≥ 60 Gy.
508901|NCT00329797|Drug|LHRH|LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
508902|NCT00329797|Dietary Supplement|Vitamin D|400 IU (10μg), orally each day for 3 years.
508903|NCT00329784|Biological|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
508904|NCT00329771|Other|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
508905|NCT00329758|Drug|rosuvastatin|20 mg oral, during 10 days
508906|NCT00329758|Drug|Placebo|
508907|NCT00329745|Biological|Rotarix™|Oral administration, 2 doses
508908|NCT00329745|Biological|Placebo|Oral administration, 2 doses
508909|NCT00329732|Drug|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
508910|NCT00329732|Drug|Saline placebo|matching volume of saline (placebo)
508911|NCT00329719|Procedure|Conventional Surgery|Undergo surgery
508912|NCT00329719|Other|Laboratory Biomarker Analysis|Correlative studies
508913|NCT00329719|Drug|Sorafenib Tosylate|Given PO
508914|NCT00329719|Drug|Temsirolimus|Given IV
508915|NCT00329706|Procedure|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
508916|NCT00329693|Drug|Norprolac|Placebo
508917|NCT00329693|Drug|Norprolac|Quinagolide
508918|NCT00329693|Drug|Norprolac|Quinagolide
508919|NCT00329693|Drug|Norprolac|Quinagolide
508920|NCT00329680|Dietary Supplement|Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins|An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
508921|NCT00329680|Dietary Supplement|Standard ICU enteral diet, isocaloric to the study diet|Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
508922|NCT00329667|Device|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
508923|NCT00329654|Procedure|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
508924|NCT00329641|Drug|carboplatin|Given IV
508925|NCT00329641|Drug|paclitaxel|Given IV
508926|NCT00329641|Drug|sorafenib tosylate|Given orally
508927|NCT00329628|Drug|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
508928|NCT00329628|Drug|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
508929|NCT00329615|Drug|Insulatard, flexpen|
508930|NCT00329602|Drug|Placebo|Matching Placebo
508931|NCT00329602|Drug|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
508932|NCT00329589|Drug|Velcade (bortezomib)|
508933|NCT00329576|Biological|Hepatitis B vaccine|
508934|NCT00329563|Drug|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
508975|NCT00329251|Biological|Tetanus-diphteria|
508976|NCT00329251|Biological|Varicella|
508935|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
508936|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
508937|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
508938|NCT00329537|Drug|Sargramostim (Leukine)|Self-subcutaneous injection
508939|NCT00329537|Drug|Placebo|Self-subcutaneous injection
508940|NCT00329524|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
508941|NCT00329511|Drug|methyldopa vs. clonidine|Comparison of compliance
508942|NCT00329511|Drug|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
508943|NCT00329498|Drug|L-Ascorbic Acid|
508944|NCT00329485|Drug|CORvalen (D-Ribose)|
508945|NCT00329472|Drug|gemcitabine, cisplatin|
508946|NCT00329459|Drug|sumatriptan succinate/naproxen sodium|
508947|NCT00329459|Drug|placebo|placebo to match
508948|NCT00329446|Drug|Quetiapine Fumarate|
508949|NCT00329446|Drug|Escitalopram oxylate|
508950|NCT00329433|Drug|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
508951|NCT00329433|Drug|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
508952|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
508953|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
508954|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
508955|NCT00329407|Drug|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
508956|NCT00329394|Drug|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
508957|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
508958|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
508959|NCT00329368|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
508960|NCT00329368|Biological|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
508961|NCT00329368|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
508962|NCT00329368|Drug|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
508963|NCT00329368|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
508964|NCT00329355|Drug|sumatriptan succinate/naproxen sodium|
508965|NCT00329342|Behavioral|Occupational ergonomic training|Adequate postural habits in activities of daily living
508966|NCT00329329|Drug|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
508967|NCT00329316|Drug|Crinone Gel 8%|
508968|NCT00329303|Drug|Certolizumab Pegol (Cimzia®)|"Pharmaceutical Form: Solution for injection in pre-filled syringe~Route of Administration: Subcutaneous use~Dose and Administration details :~2 x 1 mL Certolizumab Pegol at Week 0, followed by~1 x 1 mL Certolizumab Pegol plus 1 x 1 mL Placebo (for blinding reasons) in the Certolizumab Pegol 200 mg arm at Weeks 2, 4, 6, 8 and 10~2 x 1 mL Certolizumab Pegol in the Certolizumab Pegol 400 mg arm at Weeks 2, 4, 6, 8 and 10"
508969|NCT00329277|Procedure|perimetry|
508970|NCT00329264|Drug|Quetiapine fumarate|
508971|NCT00329251|Biological|Hepatitis A|
508977|NCT00329251|Biological|Measles-Mumps-Rubella|
508978|NCT00329238|Drug|Dabigatran|Dabigatran 150 mg BID (twice daily)
508979|NCT00329238|Drug|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
508980|NCT00329225|Drug|rosiglitazone|
508981|NCT00329212|Drug|San Huang Xie Jin Tang|
508982|NCT00329199|Behavioral|Attachment-Based Family Therapy|
508983|NCT00329186|Drug|desvenlafaxine SR|
508984|NCT00329186|Drug|venlafaxine ER|
508985|NCT00329173|Drug|Rosuvastatin|
508986|NCT00329173|Drug|Atorvastatin|
508987|NCT00329160|Drug|Rosuvastatin|2.5-20 mg
508988|NCT00329160|Drug|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
508989|NCT00329147|Drug|desvenlafaxine SR|
508990|NCT00329147|Drug|desipramine|
508991|NCT00329147|Drug|paroxetine|
508992|NCT00329134|Drug|Administration of quinine sulphate taste-masked pellets|
508993|NCT00329121|Drug|PEP005|
508994|NCT00329108|Drug|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
508995|NCT00329108|Drug|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
508996|NCT00329095|Drug|travoprost, latanoprost, or bimatoprost|
508997|NCT00329095|Drug|Additional ocular hypotensive medication|
508998|NCT00329082|Drug|LY2062430|"100mg QW IV for 12 weeks~100mg Q4W IV for 12 weeks~400mg QW IV for 12 weeks~400mg Q4W IV for 12 weeks"
508999|NCT00329082|Drug|Placebo|5: Placebo QW IV for 12 weeks
509000|NCT00329069|Drug|atorvastatin (drug)|
509001|NCT00329056|Drug|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
509002|NCT00329043|Drug|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
509003|NCT00329043|Drug|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
509004|NCT00329043|Procedure|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
509005|NCT00329030|Drug|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
509006|NCT00329030|Drug|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
509007|NCT00329017|Procedure|Fine needle aspiration|Fine needle aspiration
509008|NCT00329004|Drug|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
509009|NCT00328991|Device|duct tape occlusion therapy|
509010|NCT00328978|Drug|Quetiapine|
509011|NCT00328965|Drug|Lacidipine|Lacidipine 2, 4, 6mg
509012|NCT00328939|Drug|ARIXTRA infusion|
509013|NCT00328939|Drug|Enoxaparine infusion|
509014|NCT00328926|Drug|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol [E2] levels). Total duration will be of 3 treatment cycles.
509015|NCT00328926|Drug|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
509016|NCT00328926|Drug|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
509017|NCT00328926|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
509018|NCT00328926|Drug|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
509019|NCT00328913|Drug|5-hydroxytryptophan (food supplement)|
509020|NCT00328900|Drug|Administration of 0,7 mg of atropine|
509021|NCT00328900|Device|Measurement of skin conductance with Pain detector|
509022|NCT00328887|Genetic|CD40 Gene Transfer|gene transfer, intratumoral administration
509023|NCT00328874|Drug|Coenzyme Q10|
509024|NCT00328861|Drug|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
509025|NCT00328861|Biological|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
509026|NCT00328861|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
509027|NCT00328861|Drug|Fludarabine|Fludarabine 25 mg/m^2 day intravenous on days -6 through -2.
509028|NCT00328848|Behavioral|Behavioral|Group Treatment(patient education, self management support, caregiver support)
509029|NCT00328848|Behavioral|behavioral|patient education, self management support, caregiver support
509030|NCT00328835|Procedure|Brief Elevation of IOP|
509031|NCT00328822|Drug|Quetiapine|
509032|NCT00328822|Drug|placebo|
532263|NCT00131040|Drug|Aprotinin|
509033|NCT00328809|Drug|spironolactone|spironolactone administered to ESRD patients at low dose
509034|NCT00328796|Procedure|acupuncture in 6 specific points|
509035|NCT00328796|Drug|lidocaine 10mg/ml|
509036|NCT00328783|Device|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
509037|NCT00328783|Radiation|Radiation Therapy|
509038|NCT00328770|Drug|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
509039|NCT00328757|Behavioral|Regular diet as the first postoperative meal|
509040|NCT00328744|Behavioral|Standard|18-month standard behavioral weight loss intervention
509041|NCT00328744|Behavioral|Limited Variety|Two chosen snack foods
509042|NCT00328731|Procedure|Procedure|
509043|NCT00328718|Drug|montelukast (5mg QD)|
509044|NCT00328718|Drug|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
509045|NCT00328705|Device|Implantable Cardioverter Defibrillator|
509046|NCT00328692|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
509047|NCT00328692|Drug|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
509048|NCT00328679|Device|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
509049|NCT00328666|Behavioral|Iyengar yoga|
509050|NCT00328666|Behavioral|Enhanced nutritional care classes|
509051|NCT00328653|Drug|cyclosporine|
509052|NCT00328640|Drug|Optimal treatment|
509053|NCT00328627|Drug|Alogliptin|Alogliptin tablets.
509054|NCT00328627|Drug|Alogliptin placebo|Alogliptin placebo-matching tablets.
509055|NCT00328627|Drug|Pioglitazone|Pioglitazone tablets.
509056|NCT00328627|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
509057|NCT00328614|Drug|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
509058|NCT00328614|Drug|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
509059|NCT00328614|Drug|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
509060|NCT00328614|Device|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
509061|NCT00328601|Drug|Thioctic Acid|
509062|NCT00328588|Drug|YM155|IV
509063|NCT00328575|Radiation|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.~For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
509064|NCT00328562|Drug|ZD1839 (Iressa)|
509065|NCT00328562|Radiation|Thoracic Radiotherapy|
509066|NCT00328549|Drug|Pegylated Interferon and Ribavirin|
509067|NCT00328536|Drug|Omacor|
509068|NCT00328523|Drug|MK-0653, ezetimibe|
509069|NCT00328523|Drug|Duration of Treatment: 3 months|
509070|NCT00328510|Device|GTC frame|
509071|NCT00328510|Device|Thermoplastic facemask|
509072|NCT00328510|Radiation|Stereotactic radiation therapy|
509073|NCT00328497|Drug|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
509074|NCT00328484|Behavioral|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
509075|NCT00328484|Behavioral|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
509076|NCT00328471|Behavioral|care management|
509077|NCT00328458|Drug|EPO906 (epothilone B)|
509078|NCT00328445|Behavioral|Positive Action|See publications
509079|NCT00328432|Drug|celecoxib 400 mg bid|
509080|NCT00328419|Device|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
509081|NCT00328419|Device|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
509082|NCT00328393|Drug|Pioglitazone|45 mg 8 weeks
509083|NCT00328393|Drug|Placebo|Placebo
509084|NCT00328380|Drug|Rifaximin|
509085|NCT00328367|Drug|aripiprazole|aripiprazole augmentation of clozapine
509086|NCT00328367|Drug|placebo|placebo
509087|NCT00328302|Drug|Candesartan|
509088|NCT00328302|Drug|Placebo|
509089|NCT00328289|Device|transcutaneous muscle stimulation, treadmill|
509090|NCT00328276|Drug|Sarcosine|
509091|NCT00328263|Dietary Supplement|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
509092|NCT00328263|Dietary Supplement|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
509093|NCT00328250|Behavioral|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
509094|NCT00328237|Procedure|Cord Blood Transplant|
509095|NCT00328211|Dietary Supplement|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
509096|NCT00328211|Dietary Supplement|Sphingomyelin|1000mg/day for 19 days
509097|NCT00328211|Drug|Pluronic F-68|"Pluronic F-68 is a detergent and potent inhibitor of cholesterol absorption. Dose = 0.5%-1.0% by weight of the diet."
509098|NCT00328211|Other|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
509099|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
509100|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
509101|NCT00328172|Drug|Placebo|Placebo matching BI 1356
509102|NCT00328172|Drug|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
509103|NCT00328172|Drug|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
509104|NCT00328172|Drug|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
509105|NCT00328172|Drug|Metformin|Metformin
509106|NCT00328159|Drug|Oil special 107 and MYGLIOL 810|
509107|NCT00328146|Other|Observation of sternal reentry|Observation of sternal reentry
509108|NCT00328120|Drug|Fulvestrant|500 mg intramuscular injection
509109|NCT00328107|Biological|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
509110|NCT00328094|Drug|continuous intravenous insulin infusion|Tight glucose control versus standard of care
509111|NCT00328055|Behavioral|AD-Easy (Advance Directive-Easy)|
509112|NCT00328055|Behavioral|AD-Standard (Advance Directive-Standard)|
509113|NCT00328042|Behavioral|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
509114|NCT00328042|Behavioral|Information Only|This is an individual self-paced at home study program.
509115|NCT00328029|Drug|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
509116|NCT00328029|Procedure|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
509117|NCT00328029|Procedure|pharmacokinetics, done during the treatment|"12 blood collections :~after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.~3 hours after 2nd taken of Busulfan~3 hours after 3rd taken of Busulfan~3 hours after 4th taken of Busulfan~3 hours after 5th taken of Busulfan~3 hours after 6th taken of Busulfan."
509118|NCT00328016|Behavioral|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
509119|NCT00328016|Device|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
509120|NCT00327990|Drug|Ibandronate|
509121|NCT00327990|Drug|Alendronate|
509122|NCT00327938|Device|Measuring of skin conductance|
509123|NCT00327938|Procedure|Tetanic stimuli|
509124|NCT00327925|Procedure|Find Cancer Associated Antibodies|
509125|NCT00327912|Procedure|Laparoscopic Biliopancreatic diversion with Duodenal switch|
509126|NCT00327912|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
509127|NCT00327873|Other|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
509128|NCT00327873|Other|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
509129|NCT00327847|Drug|Oral Vitamin D Supplementation|
509130|NCT00327834|Drug|atomoxetine|
509131|NCT00327821|Behavioral|calorie controlled diet|
509132|NCT00327808|Drug|TPI-1020|600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
509133|NCT00327808|Drug|budesonide|400 mcg BID x 14 days then 800 mcg/day x 7 more days
509134|NCT00327769|Drug|Fulvestrant|250 mg intramuscular injection
509135|NCT00327769|Drug|Anastrozole|1 mg tablet
509136|NCT00327756|Drug|Coenzyme Q10|
509137|NCT00327743|Drug|larotaxel|IV infusion on Day 1 of a 21-day cycle
509138|NCT00327743|Drug|capecitabine|oral, twice daily, Day 1-Day 14 of a 21-day cycle
509139|NCT00327730|Drug|Eperisone|
509140|NCT00327717|Drug|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
509141|NCT00327717|Drug|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
509142|NCT00327704|Drug|albumin|albumin 20% 100 ml/8 hours for 3 days
509143|NCT00327704|Drug|saline|saline 100 ml/8hours for 3 days
509144|NCT00327691|Drug|Atorvastatin|
509145|NCT00327678|Drug|Rituximab|
509146|NCT00327678|Drug|Imatinib Mesylate|
509147|NCT00327665|Biological|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
509148|NCT00327665|Biological|Pneumo 23™|Single-dose intramuscular injection.
509149|NCT00327665|Biological|Placebo|1 intramuscular injection.
509150|NCT00327665|Biological|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
509151|NCT00327652|Drug|CRS-100|Live-attenuated Listeria monocytogenes
509152|NCT00327626|Drug|ISIS 113715|
509153|NCT00327600|Drug|imexon|
509154|NCT00327600|Drug|DTIC|
509155|NCT00327587|Drug|Valsartan + amlodipine|
509156|NCT00327587|Drug|Valsartan + HCTZ|
509157|NCT00327587|Drug|Amlodipine + HCTZ|
509158|NCT00327587|Drug|Valsartan + amlodipine + HCTZ|
509159|NCT00327574|Behavioral|Home heath education +/_ GP training|
509160|NCT00327561|Procedure|Intensive periodontal therapy|
509161|NCT00327561|Procedure|Community based periodontal therapy|
509162|NCT00327548|Behavioral|guided imagery|
509163|NCT00327535|Drug|Darbepoetin alfa|According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
509164|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|6.3 micrograms/kg every 3 weeks
509165|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|9 micrograms/kg every 3 weeks
509166|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|12 micrograms/kg every 3 weeks
509167|NCT00327522|Biological|pneumococcal vaccine|
509168|NCT00327496|Biological|DC vaccine|
509169|NCT00327483|Behavioral|Internet based education software|
509170|NCT00327470|Drug|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
509171|NCT00327457|Behavioral|Help with physician office and patient management|
509172|NCT00327457|Behavioral|Tailored physician recommendation letter|
509173|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
509174|NCT00327444|Drug|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
509175|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
509176|NCT00327431|Genetic|Cheek swab samples for DNA|
509177|NCT00327418|Drug|Atorvastatin|
509178|NCT00327392|Drug|AQUAVAN® (fospropofol disodium) Injection|
509179|NCT00327379|Drug|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
509180|NCT00327379|Drug|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
509181|NCT00327366|Procedure|Light therapy|
509182|NCT00327353|Drug|formoterol (TURBOHALER)|
509183|NCT00327353|Drug|Salmeterol (DISKUS)|
509184|NCT00327340|Drug|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment."
509185|NCT00327340|Drug|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment."
509186|NCT00327327|Drug|imexon|30-60 minutes IV, days 1,8,15 every 28 days
509187|NCT00327327|Drug|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
509188|NCT00327314|Procedure|Transplantation|
509189|NCT00327314|Procedure|Hematopoietic cell transplantation|
509190|NCT00327288|Drug|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
509191|NCT00327288|Drug|docetaxel|IV once every 21 days for duration of study
509192|NCT00327275|Behavioral|strength training|
509193|NCT00327262|Drug|Imatinib|
509194|NCT00327249|Drug|imexon|
509195|NCT00327223|Drug|imexon|
509196|NCT00327210|Behavioral|Blood Glucose Awareness Training|
509197|NCT00327197|Drug|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
509198|NCT00327197|Procedure|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
509199|NCT00327184|Biological|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
509200|NCT00327184|Biological|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
509201|NCT00327184|Biological|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
509202|NCT00327184|Biological|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
532264|NCT00131027|Drug|Cyclophosphamide|
509203|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
509204|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
509205|NCT00327158|Procedure|Transesophageal transducer|One time use of reamer during surgery
509206|NCT00327158|Procedure|echocardiography|takes photos of right atrium during the reaming processes
509207|NCT00327145|Drug|valsartan|
509208|NCT00327145|Drug|hydrochlorothiazide|
509209|NCT00327145|Drug|amlodipine|
509210|NCT00327132|Drug|Omeprazole, Amoxicillin, Clarithromycin|
509211|NCT00327119|Drug|ABX-EGF (panitumumab)|
509212|NCT00327106|Drug|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
509213|NCT00327106|Drug|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
509214|NCT00327093|Drug|cetuximab|indication : second intention treatment
509215|NCT00327093|Drug|bevacizumab|Indication: first intention treatment
509216|NCT00327080|Procedure|MRI|
509217|NCT00327080|Drug|L-NMMA|
509218|NCT00327080|Drug|Acetylcholine|
509219|NCT00327054|Drug|Nigella sativa seed|
509220|NCT00327028|Drug|Diphenine|
509221|NCT00327015|Drug|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
509222|NCT00327015|Drug|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
509223|NCT00327015|Drug|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
509224|NCT00327015|Drug|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
509225|NCT00327015|Drug|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
509226|NCT00327002|Drug|LY518674|
509227|NCT00326989|Procedure|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
509228|NCT00326976|Drug|FX06|400 mg as intravenous injection in two divided boluses
509229|NCT00326976|Procedure|Percutaneous coronary intervention|
509230|NCT00326963|Drug|Background ARVs|As prescribed
509231|NCT00326963|Drug|PI|As prescribed
509232|NCT00326963|Drug|enfuvirtide [Fuzeon]|90mg sc bid
509233|NCT00326950|Drug|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
509234|NCT00326924|Biological|Transfusion|PRBC blood transfusions.
509235|NCT00326911|Biological|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
509236|NCT00326911|Biological|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
509237|NCT00326911|Drug|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
509238|NCT00326911|Biological|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
509239|NCT00326898|Other|Laboratory Biomarker Analysis|Correlative studies
509240|NCT00326898|Other|Placebo|Given PO
509241|NCT00326898|Other|Quality-of-Life Assessment|Ancillary studies
509242|NCT00326898|Drug|Sorafenib Tosylate|Given PO
509243|NCT00326898|Drug|Sunitinib Malate|Given PO
509244|NCT00326885|Drug|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
509245|NCT00326872|Drug|Cediranib Maleate|
509246|NCT00326859|Drug|remifentanil|
509247|NCT00326833|Drug|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
509248|NCT00326820|Drug|ibandronate sodium|
509249|NCT00326820|Drug|zoledronic acid|
509250|NCT00326820|Drug|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
509251|NCT00326807|Drug|Naltrexone|
509252|NCT00326794|Procedure|mobilisation (rehabilitation)|
509253|NCT00326781|Drug|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
509254|NCT00326781|Drug|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
509255|NCT00326768|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
509256|NCT00326768|Drug|Telmisartan 40 mg|
509257|NCT00326768|Drug|Telmisartan 80 mg/HCTZ 12.5 mg|
509258|NCT00326742|Behavioral|Trier Social Stress Test|
509259|NCT00326716|Drug|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
509260|NCT00326703|Procedure|Hypobaric hypoxia|
509261|NCT00326690|Device|Blue Egg Device|
509262|NCT00326677|Behavioral|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
509263|NCT00326677|Behavioral|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
509264|NCT00326664|Drug|Cediranib Maleate|Given orally
509381|NCT00325559|Procedure|Normoinsulinemic eu- or hyperglycemic clamp|
509382|NCT00325546|Drug|Rimonabant (SR141716)|
509265|NCT00326638|Radiation|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks~Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23~Boost IMRT to Prostate 3,200 cGy/16"
509266|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"3DCRT 7800 cGY/39 Fractions/ STD Technique* once daily Monday to Friday for 8 weeks~Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23~Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
509267|NCT00326625|Drug|40 mg glatiramer acetate|parenteral drug
509268|NCT00326625|Drug|Placebo|
509269|NCT00326612|Drug|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
509270|NCT00326612|Drug|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
509271|NCT00326599|Drug|carboplatin|Given IV
509272|NCT00326599|Drug|cediranib maleate|Given orally
509273|NCT00326599|Drug|gemcitabine hydrochloride|Given IV
509274|NCT00326586|Drug|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
509275|NCT00326573|Behavioral|Motivational Interviewing|
509276|NCT00326560|Procedure|Pterygium excision and conjunctival autograft|
509277|NCT00326508|Drug|Daclizumab|
509278|NCT00326495|Drug|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
509279|NCT00326495|Drug|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
509280|NCT00326469|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
509281|NCT00326456|Drug|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
509282|NCT00326456|Drug|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
509283|NCT00326456|Drug|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
509284|NCT00326443|Biological|CVD 909|5 X 10^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
509285|NCT00326443|Drug|Placebo|Buffer placebo administered on Day 0.
509286|NCT00326443|Biological|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
509287|NCT00326430|Behavioral|Cognitive Therapy, Interpersonal Therapy|
509288|NCT00326417|Drug|Fludarabine|Doses of 30 mg/m^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
509289|NCT00326417|Drug|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
509290|NCT00326417|Drug|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
509291|NCT00326417|Drug|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
509292|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
509293|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
509294|NCT00326391|Drug|methylphenidate hydrochloride extended-release tablets|
509295|NCT00326378|Drug|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
509296|NCT00326378|Drug|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
509297|NCT00326365|Drug|Kali bichromicum 10-60 (C30)|
509298|NCT00326352|Drug|Sedation with propofol and remifentanil|
509299|NCT00326339|Drug|R788|R788 50 mg, 100 mg, or 150 mg PO bid
509300|NCT00326339|Drug|Placebo|Placebo PO bid
509301|NCT00326326|Drug|CP-778,875|
509302|NCT00326300|Drug|methylphenidate hydrochloride extended-release tablets|
509303|NCT00326287|Drug|Ceftobiprole medocaril|
509304|NCT00326287|Drug|Ceftriaxone with or without Linezolid|
509305|NCT00326274|Drug|Helioblock® SX Cream|
509306|NCT00326261|Procedure|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
509307|NCT00326261|Procedure|Ultrasound|
509308|NCT00326248|Drug|GW679769 (casopitant)|
509309|NCT00326235|Drug|Buspirone|
509310|NCT00326222|Behavioral|Lifestyle counseling|Self-management group education
509311|NCT00326209|Drug|Encapsulated Mesalamine Granules (eMG)|eMG capsules will be administered per dose and schedule specified in the arm.
509312|NCT00326196|Device|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
509313|NCT00326196|Procedure|Coronary artery bypass graft (CABG)|coronary bypass
509314|NCT00326183|Biological|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
509315|NCT00326183|Biological|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
509316|NCT00326170|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
509317|NCT00326170|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
509318|NCT00326170|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
509383|NCT00325546|Drug|Placebo|
532265|NCT00131027|Drug|Daunorubicin|
509319|NCT00326157|Drug|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
509320|NCT00326144|Drug|Quetiapine fumarate|
509321|NCT00326131|Drug|Oral Taxane|
509322|NCT00326118|Biological|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
509323|NCT00326118|Biological|Priorix™|One subcutaneous dose at 12-18 months of age
509324|NCT00326118|Biological|Hiberix™|One intramuscular dose at 12-18 months of age.
509325|NCT00326118|Biological|Meningitec™|One intramuscular dose at 12-18 months of age
509326|NCT00326105|Drug|Quetiapine fumarate|
509327|NCT00326092|Drug|Brinzolamide/Timolol|
509328|NCT00326079|Device|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
509329|NCT00326066|Device|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
509330|NCT00326066|Procedure|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
509331|NCT00326053|Drug|Budesonide/formoterol|
509332|NCT00326040|Device|Glaucoma Surgery|
509333|NCT00326027|Drug|Pantoprazole|Efficacy of Pantoprazole
509334|NCT00326014|Device|iStent|Glaucoma Surgery
509335|NCT00326001|Device|Gold tip catheter|Radiofrquency ablation using gold tip catheter
509336|NCT00326001|Device|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
509337|NCT00325962|Drug|6R-BH4 (sapropterin dihydrochloride)|
509338|NCT00325949|Drug|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
509339|NCT00325949|Drug|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
509340|NCT00325949|Drug|placebo|2 tablets BID
509341|NCT00325936|Drug|Cilnidipine|10~20mg, qd, po for 3 months or 12 months.
509342|NCT00325923|Behavioral|Decision aid|
509343|NCT00325910|Drug|Metformin|
509344|NCT00325897|Drug|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
509345|NCT00325897|Drug|Placebo|Placebo taken on a daily basis
509346|NCT00325871|Procedure|concurrent chemoradiation|
509347|NCT00325858|Drug|Tramadol HCl ER|
509348|NCT00325845|Procedure|Synvisc viscosupplementation|
509349|NCT00325832|Device|BpTRU|
509350|NCT00325832|Device|Conventional mercury sphygmomanometry|
509351|NCT00325819|Drug|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
509352|NCT00325819|Other|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
509353|NCT00325806|Drug|Ramipril|
509354|NCT00325793|Drug|Nicardipine|
509355|NCT00325780|Drug|Pitavastatin|Pitavastatin 4 mg once daily
509356|NCT00325767|Drug|nebulized albuterol (2.5 mg/3ml/dose)|
509357|NCT00325767|Drug|nebulized levalbuterol (1.25 mg/3ml/dose)|
509358|NCT00325767|Drug|nebulized placebo (3ml/dose)|
509359|NCT00325754|Device|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
509360|NCT00325754|Device|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
509361|NCT00325741|Procedure|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
509362|NCT00325728|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
509363|NCT00325728|Drug|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
509364|NCT00325715|Drug|AGN 201904|
509365|NCT00325715|Drug|esomeprazole|
509366|NCT00325702|Behavioral|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
509367|NCT00325689|Drug|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
509368|NCT00325689|Drug|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
509369|NCT00325676|Drug|Pantoprazole|
509370|NCT00325663|Procedure|Acupuncture|
509371|NCT00325650|Drug|Rimonabant|Tablet, oral administration
509372|NCT00325650|Drug|Placebo (for Rimonabant)|Tablet, oral administration
509373|NCT00325637|Drug|cilnidipine|Cilnidipine 10~20mg, qd, po for 4 weeks.
509374|NCT00325624|Device|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
509375|NCT00325611|Behavioral|Multidisciplinary palliative care team met with patient|
509376|NCT00325598|Radiation|Partial Breast Irradiation (PBI)|
509377|NCT00325585|Behavioral|Couples HIV counseling and testing|
509378|NCT00325585|Behavioral|Women's relationship-focused HIV counseling and testing|
509379|NCT00325572|Drug|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
509380|NCT00325572|Other|oral Placebo|Each child will be provided separate Placebo suspensions C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
532266|NCT00131027|Drug|Vincristine|
509384|NCT00325533|Behavioral|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
509385|NCT00325533|Other|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
509386|NCT00325507|Biological|TroVax®|
509387|NCT00325494|Drug|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m^2 up to 400 mg/m^2.
509388|NCT00325481|Drug|FluMist|
509389|NCT00325468|Drug|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
509390|NCT00325455|Drug|MK0859|
509391|NCT00325442|Drug|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
509392|NCT00325442|Drug|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
509393|NCT00325429|Drug|Vildagliptin|
509394|NCT00325416|Drug|melphalan|(Days -4,-3,-2) 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2)
509395|NCT00325416|Drug|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m^2; Level 2 - 30 mg/m^2; Level 4 - 54 mg/m^2; Level 5 - 72 mg/m^2; Level 6 - 96 mg/m^2; Level 7 - 127.8 mg/m^2; Level 8 - 170.1 mg/m^2~Phase II: Treatment at maximum tolerated dose (MTD)"
509396|NCT00325416|Procedure|Autologous Stem Cell Rescue|Day 0
509397|NCT00325403|Drug|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
509398|NCT00325403|Other|Placebo|Placebo oral tablet twice daily
509399|NCT00325390|Drug|clopidogrel (SR25990C)|
509400|NCT00325377|Procedure|MME Procedure|
509401|NCT00325364|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
509402|NCT00325364|Drug|Injectable insulin|patient specific dose, injectable, before meals, 24 months
509403|NCT00325351|Drug|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
509404|NCT00325338|Biological|Ragweed MATAMPL|
509405|NCT00325325|Drug|everolimus and tacrolimus|
509406|NCT00325312|Drug|carbon dioxide, subcutaneous application|
509407|NCT00325299|Drug|Magnesium|
509408|NCT00325286|Drug|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
509409|NCT00325273|Dietary Supplement|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
509410|NCT00325260|Biological|Influvac; subunit influenza vaccine|
509411|NCT00325247|Drug|ZINC|
509412|NCT00325234|Drug|Pemetrexed|600 mg/m^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
509413|NCT00325234|Drug|Carboplatin|AUC 5 mg*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
509414|NCT00325234|Drug|Gemcitabine|1200 mg/m^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
509415|NCT00325234|Drug|Vinorelbine|30 mg/m^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
509416|NCT00325221|Device|HM on|Home Monitoring activated after implantation
509417|NCT00325221|Device|HM Off|Home Monitoring activated 9 months after implantation
509418|NCT00325208|Device|partial-vacuum milk bottle|
509419|NCT00325208|Device|anti-vacuum milk bottle|
509420|NCT00325195|Other|placebo|placebo by intravenous infusion every 2 weeks
509421|NCT00325195|Biological|pegloticase|8 mg pegloticase by intravenous infusion
509422|NCT00325182|Drug|Levetiracetam|
509423|NCT00325182|Other|Historical controls|
509424|NCT00325169|Drug|Tiotropium + SERETIDE 50/500|
509425|NCT00325156|Biological|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
509426|NCT00325143|Biological|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
509427|NCT00325143|Biological|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
509428|NCT00325130|Biological|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
509429|NCT00325130|Biological|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
509430|NCT00325130|Biological|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
509431|NCT00325130|Biological|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
509432|NCT00325130|Biological|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
509433|NCT00325117|Drug|Vildagliptin|
509434|NCT00325104|Procedure|Parathyroid hormone testing|
509435|NCT00325104|Procedure|Serum calcium testing|
509436|NCT00325078|Drug|Infliximab|
509437|NCT00325039|Procedure|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
509513|NCT00324623|Biological|adoptive immunotherapy|
509438|NCT00325039|Procedure|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
509439|NCT00325026|Drug|Misoprostol|
509440|NCT00325026|Device|Foley bulb|
509441|NCT00325013|Drug|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
509442|NCT00325000|Behavioral|Interpersonal Psychotherapy|
509443|NCT00325000|Drug|sertraline or amitriptyline|
509444|NCT00324987|Biological|Bevacizumab|Given IV
509445|NCT00324987|Drug|Imatinib Mesylate|Given PO
509446|NCT00324987|Other|Laboratory Biomarker Analysis|Correlative studies
509447|NCT00324987|Other|Pharmacological Study|Correlative studies
509448|NCT00324974|Drug|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
509449|NCT00324974|Drug|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
509450|NCT00324961|Drug|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
509451|NCT00324948|Drug|Topical alprostadil (PGE-1)|
509452|NCT00324922|Drug|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
509453|NCT00324922|Drug|vancomycin|1g iv bid
509454|NCT00324909|Drug|Hyperbaric Oxygen Therapy|
509455|NCT00324896|Drug|eszopiclone|eszopiclone
509456|NCT00324896|Other|placebo|matching placebo administered at night
509457|NCT00324870|Drug|vorinostat|Given orally
509458|NCT00324870|Drug|bevacizumab|Given IV
509459|NCT00324857|Behavioral|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
509460|NCT00324857|Behavioral|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
509461|NCT00324857|Behavioral|MI plus Decision aid|Patient viewed the video and then underwent MI.
509462|NCT00324857|Other|Attention control|patients received a booklet.
509463|NCT00324831|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
509464|NCT00324831|Drug|cyclophosphamide|
509465|NCT00324831|Drug|doxorubicin hydrochloride|
509466|NCT00324831|Drug|prednisone|
509467|NCT00324831|Drug|rituximab|
509468|NCT00324831|Drug|sargramostim|
509469|NCT00324831|Drug|vincristine|
509470|NCT00324831|Procedure|Intervention/procedure|
509471|NCT00324831|Procedure|antibody therapy|
509472|NCT00324831|Procedure|biological therapy|
509473|NCT00324831|Procedure|chemotherapy|
509474|NCT00324831|Procedure|colony-stimulating factor therapy|
509475|NCT00324831|Procedure|cytokine therapy|
509476|NCT00324831|Procedure|monoclonal antibody therapy|
509477|NCT00324831|Procedure|non-specific immune-modulator therapy|
509478|NCT00324831|Procedure|therapeutic procedure|
509479|NCT00324831|Procedure|tumor cell derivative vaccine|
509480|NCT00324831|Procedure|vaccine therapy|
509481|NCT00324818|Drug|metronidazole and azithromycin|
509482|NCT00324805|Biological|Bevacizumab|Given IV
509483|NCT00324805|Drug|Cisplatin|Given IV
509484|NCT00324805|Drug|Docetaxel|Given IV
509485|NCT00324805|Drug|Gemcitabine Hydrochloride|Given IV
509486|NCT00324805|Other|Laboratory Biomarker Analysis|Correlative studies
509487|NCT00324805|Drug|Pemetrexed Disodium|Given IV
509488|NCT00324805|Other|Questionnaire Administration|Ancillary studies
509489|NCT00324805|Drug|Vinorelbine Tartrate|Given IV
509490|NCT00324792|Drug|intensive insulin therapy|
509491|NCT00324779|Biological|rituximab|
509492|NCT00324766|Drug|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
509493|NCT00324766|Drug|placebo,|24 h, infusion
509494|NCT00324753|Behavioral|Communication|Communication sheet
509495|NCT00324753|Behavioral|Standard of care|Standard of care brochures
509496|NCT00324740|Drug|vorinostat|Given orally
509497|NCT00324740|Drug|isotretinoin|Given orally
509498|NCT00324727|Drug|melphalan|Given throug isolated hepatic artery infusion
509499|NCT00324727|Drug|regional chemotherapy|Patients receive the best alternative therapy
509500|NCT00324727|Drug|systemic chemotherapy|Patients receive the best alternative therapy
509501|NCT00324727|Procedure|hepatic artery embolization|Patients receive the best alternative therapy
509502|NCT00324714|Drug|risedronate sodium|
509503|NCT00324714|Other|diagnostic laboratory biomarker analysis|
509504|NCT00324701|Behavioral|Telepsychology|therapy done at patients house
509505|NCT00324701|Behavioral|Face-to-face therapy|therapy delivered at the VAMC
509506|NCT00324688|Drug|Viread|
509507|NCT00324675|Drug|Rosiglitazone|4 mg tablets, bid, 12 months
509508|NCT00324675|Drug|Placebo|2 tablets per day
509509|NCT00324662|Device|Implantable cardioverter-defibrillator|
509510|NCT00324649|Drug|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
509511|NCT00324649|Drug|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
509512|NCT00324623|Biological|Melan-A VLP vaccine, IMP321 adjuvant|
509514|NCT00324623|Biological|therapeutic autologous lymphocytes|
509515|NCT00324623|Drug|cyclophosphamide|
509516|NCT00324623|Drug|fludarabine phosphate|
509517|NCT00324610|Drug|capecitabine|
509518|NCT00324597|Drug|gemcitabine hydrochloride|
509519|NCT00324597|Drug|motesanib diphosphate|
509520|NCT00324597|Other|pharmacological study|
509521|NCT00324584|Device|Telemonitoring of glucose values using GlucoNet device|
509522|NCT00324571|Drug|Sevelamer hydrochloride|
509523|NCT00324571|Drug|Calcium-based phosphate binder|
509524|NCT00324558|Drug|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
509525|NCT00324545|Behavioral|Medium-intensity Minimally-directive Counseling|
509526|NCT00324532|Drug|ProBactrix|
509527|NCT00324519|Device|Foley bulb|
509528|NCT00324519|Drug|misoprostol|
509529|NCT00324506|Drug|Mycophenolate Mofetil (CellCept)|
509530|NCT00324480|Drug|alvocidib|Given IV
509531|NCT00324480|Drug|vorinostat|Given orally
509532|NCT00324480|Other|pharmacological study|Correlative studies
509533|NCT00324467|Drug|Cyclophosphamide|"Dose: 750 mg/m^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
509534|NCT00324467|Drug|Doxorubicin|"Dose: 50 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
509535|NCT00324467|Drug|Vincristine|"Dose: 1.4 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
509536|NCT00324467|Drug|Prednisone|"Dose: 45 mg/m^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)~* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
509537|NCT00324467|Drug|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
509538|NCT00324467|Drug|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
509539|NCT00324467|Drug|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
509540|NCT00324467|Drug|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
509541|NCT00324467|Drug|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
509542|NCT00324467|Drug|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
509543|NCT00324467|Drug|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
509544|NCT00324467|Drug|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)~*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.~Estimate Creatinine Clearance (CrCl)"
509545|NCT00324467|Drug|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
509546|NCT00324467|Drug|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
509547|NCT00324467|Drug|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
509548|NCT00324467|Drug|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
509549|NCT00324467|Drug|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
509550|NCT00324467|Drug|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
509551|NCT00324467|Other|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
509552|NCT00324454|Biological|Levetiracetam|Levetiracetam 1500 mg BID
509553|NCT00324441|Device|Iratherm® 1000|
509554|NCT00324428|Procedure|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
509555|NCT00324415|Biological|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
509556|NCT00324415|Drug|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
509557|NCT00324415|Drug|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
509558|NCT00324415|Radiation|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy [5 weeks if given on schedule and without interruption], maximum 54.0 Gy [6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
509559|NCT00324389|Drug|Interferon alpha|
509560|NCT00324376|Drug|Sevelamer hydrochloride|
509561|NCT00324363|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
509562|NCT00324363|Drug|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
509563|NCT00324350|Drug|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
509616|NCT00323817|Drug|Z-338|
509716|NCT00323128|Procedure|Measuring serum creatinine|Measuring serum creatinine.
509564|NCT00324324|Drug|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
509565|NCT00324324|Drug|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
509566|NCT00324311|Drug|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
509567|NCT00324298|Biological|bleomycin sulfate|
509568|NCT00324298|Drug|cisplatin|
509569|NCT00324298|Drug|etoposide|
509570|NCT00324298|Procedure|management of therapy complications|
509571|NCT00324285|Drug|Amylase resistant starch added ORS|
509572|NCT00324272|Drug|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
509573|NCT00324259|Drug|Estradiol|
509574|NCT00324233|Device|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
509575|NCT00324233|Device|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
509576|NCT00324220|Drug|MGCD0103|MGCD0103 Oral administration 3 times per week.
509577|NCT00324194|Drug|MGCD0103|MGCD0103 oral dose given 2 times per week.
509578|NCT00324168|Drug|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
509579|NCT00324168|Drug|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
509580|NCT00324168|Drug|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
509581|NCT00324155|Drug|Ipilimumab|"Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent~In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression"
509582|NCT00324155|Drug|Placebo|Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
509583|NCT00324155|Drug|Dacarbazine|Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
509584|NCT00324142|Drug|Oral tinidazole|
509585|NCT00324129|Drug|MGCD0103|MGCD0103 given orally three times per week.
509586|NCT00324116|Drug|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
509587|NCT00324103|Drug|Structured Treatment Interruptions|
509588|NCT00324090|Behavioral|High and low glycemic index|
509589|NCT00324077|Drug|Dasatinib in combination with imatinib|
509590|NCT00324064|Procedure|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
509591|NCT00324051|Drug|olanzapine therapy|
509592|NCT00324038|Drug|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
509593|NCT00324038|Drug|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
509594|NCT00324025|Drug|Mycograb|
509595|NCT00324025|Drug|placebo|
509596|NCT00324012|Drug|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
509597|NCT00323999|Procedure|Hysteroscopic resection of fibroids, polyps and endometrium.|
509598|NCT00323986|Drug|azithromycin (drug)|
509599|NCT00323973|Drug|Bisoprolol|10 mg qd
509600|NCT00323960|Drug|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
509601|NCT00323960|Drug|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
509602|NCT00323960|Drug|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
509603|NCT00323947|Drug|Extended Release Methylphenidate (OROS-Methylphenidate)|"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."
509604|NCT00323934|Drug|MGCD0103|Oral dosage 2 times weekly.
509605|NCT00323921|Device|dermatological infrared laser|
509606|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
509607|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
509608|NCT00323895|Device|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
509609|NCT00323882|Drug|MDX-010|selected dose administered IV every 3 weeks
509610|NCT00323869|Drug|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
509611|NCT00323869|Drug|Gemcitabine|Nucleoside analog
509612|NCT00323869|Drug|Carboplatin|Alkylating agent
509613|NCT00323856|Drug|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
509614|NCT00323843|Drug|Isoproterenol|
509615|NCT00323830|Drug|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
509617|NCT00323804|Biological|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
509618|NCT00323804|Drug|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
509619|NCT00323804|Drug|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
509620|NCT00323791|Drug|gemcitabine hydrochloride|
509621|NCT00323791|Drug|imatinib mesylate|
509622|NCT00323791|Genetic|gene expression analysis|
509623|NCT00323791|Genetic|protein expression analysis|
509624|NCT00323791|Other|immunohistochemistry staining method|
509625|NCT00323791|Other|laboratory biomarker analysis|
509626|NCT00323778|Drug|Hyalgan|
509627|NCT00323752|Procedure|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
509628|NCT00323739|Drug|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
509629|NCT00323739|Drug|RAD001|RAD001 10 mg by mouth daily
509630|NCT00323713|Behavioral|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
509631|NCT00323713|Behavioral|Low protein diet|0.6 g of protein per kilo of body weight per day
509632|NCT00323687|Drug|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
509633|NCT00323674|Device|Polysoft Mesh|Polysoft Mesh is used.
509634|NCT00323674|Device|Light Weight Mesh|Light Weight Mesh is used.
509635|NCT00323661|Device|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
509636|NCT00323661|Device|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
509637|NCT00323648|Drug|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
509638|NCT00323635|Drug|tolterodine|tablet, 4 mg, daily, 1 month
509639|NCT00323622|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
509640|NCT00323622|Biological|Engerix™-B|IM injection in the deltoid muscle
509641|NCT00323622|Biological|Hiberix®|IM injection in the deltoid muscle
509642|NCT00323622|Biological|Prevnar™|IM injection in the deltoid muscle
509643|NCT00323622|Drug|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
509644|NCT00323622|Drug|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
509645|NCT00323609|Procedure|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
509646|NCT00323609|Procedure|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
509647|NCT00323596|Behavioral|physical activity program of strength and balance retraining|
509648|NCT00323583|Drug|paclitaxel|
509649|NCT00323583|Drug|oxaliplatin|
509650|NCT00323583|Drug|leucovorin|
509651|NCT00323583|Drug|5-fluorouracil|
509652|NCT00323583|Drug|glutathione|
509653|NCT00323583|Drug|calcium and magnesium|
509654|NCT00323583|Procedure|Chemotherapy|
509655|NCT00323583|Procedure|Chemoprotection|
509656|NCT00323583|Procedure|Complementary and alternative therapy|
509657|NCT00323570|Drug|activated recombinant human factor VII|
509658|NCT00323557|Drug|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
509659|NCT00323557|Biological|Pneumococcal Vaccine|Subcutaneously on Day 0
509660|NCT00323544|Drug|zidovudine and lamivudine (Combivir®)|
509661|NCT00323544|Drug|emtricitabine and tenofovir DF|
509662|NCT00323531|Procedure|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
509663|NCT00323531|Procedure|VATS decortication|thoracoscopic decortication
509664|NCT00323518|Drug|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
509665|NCT00323518|Drug|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
509666|NCT00323505|Drug|Pegylated Interferon|
509667|NCT00323505|Drug|Interferon-alpha2a|
509668|NCT00323492|Drug|Truvada|Truvada + NNRTI or PI.
509669|NCT00323492|Drug|Current HAART regimen|Maintain baseline regimen
509670|NCT00323479|Drug|Anastrozole|1mg/Day oral
509671|NCT00323466|Procedure|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
509672|NCT00323453|Device|Open appendectomy using Alexis Wound Retractor followed by standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
509673|NCT00323453|Procedure|Open appendectomy with standardized wound closure|The control arm subjects will undergo open appendectomy and standardized wound closure. The experimental arm will undergo open appendectomy utilizing the Alexis® retractor, followed by standardized wound closure.
509674|NCT00323427|Behavioral|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
509675|NCT00323427|Device|hearing aid services|Standard VA audiological hearing aid dispensing services
509676|NCT00323414|Drug|Polyunsaturated fatty acid (Opti-EPA)|Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)[360 mg EPA and 240 DHA in each capsule] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
509677|NCT00323414|Drug|Placebo|Placebo gelcaps containing corn oil identical to the PUFA gelcaps 6 capsules-3 capsules by mouth 2x per day x 48 weeks
509678|NCT00323401|Other|Antenatal classes|3 sessions of 3 hours each
509679|NCT00323401|Other|Antenatal classes|antenatal programme
509680|NCT00323401|Other|Educational programme|3 times, 3 hours intervention programme
509681|NCT00323401|Other|Educational programme|no programme are offered
509682|NCT00323375|Drug|AQ-13 and Chloroquine|
509683|NCT00323362|Drug|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
509684|NCT00323362|Drug|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
509685|NCT00323349|Procedure|Oral Glucose Tolerance Testing|
509686|NCT00323349|Behavioral|Education tailored to learning style preferences|
509687|NCT00323323|Drug|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
509688|NCT00323323|Drug|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
509689|NCT00323323|Procedure|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
509690|NCT00323310|Drug|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
509691|NCT00323297|Drug|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
509692|NCT00323297|Other|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
509693|NCT00323297|Drug|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
509694|NCT00323297|Drug|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
509695|NCT00323284|Device|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
509696|NCT00323284|Procedure|Cataract surgery only|Cataract surgery only
509697|NCT00323271|Behavioral|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
509698|NCT00323271|Other|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
509699|NCT00323258|Behavioral|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
509700|NCT00323258|Device|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
509701|NCT00323258|Device|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
509702|NCT00323258|Behavioral|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
509703|NCT00323258|Behavioral|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
509704|NCT00323258|Behavioral|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
509705|NCT00323258|Behavioral|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
509706|NCT00323258|Other|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
509707|NCT00323245|Behavioral|Physiotherapy for urinary incontinence|See Detailed Description.
509708|NCT00323232|Device|2 Versus 4 Hole DHS|See Detailed Description.
509709|NCT00323219|Drug|Cefazolin and Moxifloxacin|See Detailed Description.
509710|NCT00323206|Biological|IL-12p DNA|Plasmid IL-12 will be administered as an intratympanic (IT) injection.
509711|NCT00323206|Procedure|Intratumoral Electroporation|The electroporation apparatus with the electrical contacts will be placed around the tumor site and activated.
509712|NCT00323193|Behavioral|MOVE!|group based psychoeducation, motivation and support
509713|NCT00323154|Drug|Nalbuphine|
509714|NCT00323141|Device|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
509715|NCT00323128|Procedure|Calculation of inuline clearance|Calculation of inuline clearance.
509717|NCT00323115|Biological|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
509718|NCT00323115|Drug|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
509719|NCT00323115|Procedure|Radiotherapy|RT is standard of care (SOC) post surgery
509720|NCT00323115|Biological|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
509721|NCT00323102|Drug|Multihance|
509722|NCT00323089|Procedure|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
509723|NCT00323076|Drug|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.~Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
509724|NCT00323063|Drug|gemcitabine hydrochloride|Given IV
509725|NCT00323063|Drug|imatinib mesylate|Given orally
509726|NCT00323050|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
509727|NCT00323037|Drug|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
509728|NCT00323037|Drug|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
509729|NCT00323024|Drug|NX1011|
509730|NCT00323011|Drug|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
509731|NCT00322985|Drug|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
509732|NCT00322972|Drug|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
509733|NCT00322946|Biological|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
509734|NCT00322946|Biological|Placebo|Placebo for rDEN4delta30-4995
509735|NCT00322933|Procedure|renal replacement therapy (intermittent or continuous)|
509736|NCT00322920|Drug|Topotecan|
509737|NCT00322920|Drug|Cisplatin|
509738|NCT00322907|Drug|Cotrifazid vs mefloquine or quinine+SP|
509739|NCT00322881|Drug|Paclitaxel|
509740|NCT00322881|Drug|Carboplatin|
509741|NCT00322868|Drug|pioglitazone|All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
509742|NCT00322842|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
509743|NCT00322803|Drug|ELB139|
509744|NCT00322777|Behavioral|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
509745|NCT00322764|Drug|Uridine|
509746|NCT00322751|Drug|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
509747|NCT00322699|Procedure|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
509748|NCT00322699|Drug|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
509749|NCT00322686|Drug|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
509750|NCT00322686|Drug|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
509751|NCT00322673|Drug|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
509752|NCT00322660|Drug|Adrenaline|
509753|NCT00322621|Drug|Duloxetine|
509754|NCT00322608|Drug|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
509755|NCT00322595|Drug|Quetiapine fumarate|
509756|NCT00322595|Drug|Paroxetine|
509757|NCT00322569|Device|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
509799|NCT00322296|Drug|Bexarotene 1% gel|
509758|NCT00322569|Device|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
509759|NCT00322569|Device|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
509760|NCT00322556|Drug|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
509761|NCT00322543|Device|Corio™ Pimecrolimus-eluting stent|
509762|NCT00322530|Procedure|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
509763|NCT00322517|Drug|SU014813|100 mg capsule/day for 6 cycle of 21 days
509764|NCT00322504|Procedure|Accupuncture|
509765|NCT00322491|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
509766|NCT00322478|Behavioral|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
509767|NCT00322478|Behavioral|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
509768|NCT00322478|Behavioral|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
509769|NCT00322465|Drug|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
509770|NCT00322465|Other|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
509771|NCT00322465|Drug|Doxycycline|100 mg orally, twice daily for 7 days.
509772|NCT00322465|Drug|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
509773|NCT00322452|Drug|Gefitinib|oral tablet
509774|NCT00322452|Drug|Carboplatin|IV
509775|NCT00322452|Drug|Paclitaxel|IV
509776|NCT00322439|Drug|Etanercept|Observational study - no drug administered
509777|NCT00322426|Device|Sensory Cueing Device|
509778|NCT00322413|Drug|Epoetin|
509779|NCT00322400|Drug|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
509780|NCT00322400|Drug|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
509781|NCT00322400|Drug|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.~Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
509782|NCT00322387|Drug|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
509783|NCT00322374|Drug|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
509784|NCT00322374|Drug|Epirubicin|Infusion, intravenous (IV): 75 mg/m^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
509785|NCT00322361|Biological|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
509786|NCT00322361|Biological|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
509787|NCT00322348|Drug|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
509788|NCT00322348|Drug|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
509789|NCT00322335|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
509790|NCT00322335|Biological|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
509791|NCT00322335|Biological|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
509792|NCT00322335|Biological|Engerix-B|Intramuscular injection into the thigh as a birth dose
509793|NCT00322335|Biological|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
509794|NCT00322335|Biological|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
509795|NCT00322335|Biological|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
509796|NCT00322322|Drug|L-Carnitine|L-Carnitine
509797|NCT00322309|Other|Placebo|Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
509798|NCT00322309|Drug|Mirtazapine|Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
509800|NCT00322283|Drug|Oglemilast|Oglemilast, 15mg once per day, oral administration
509801|NCT00322283|Drug|Placebo|Dose-marched placebo, once per day, oral administration
509802|NCT00322270|Drug|Alfimeprase|single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
509803|NCT00322257|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
509804|NCT00322257|Drug|insulin detemir|Injection s.c., 50% of daily dose
509805|NCT00322257|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
509806|NCT00322244|Procedure|Massage Therapy|
509807|NCT00322231|Biological|zoster vaccine live (ZOSTAVAX™)|1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
509808|NCT00322231|Biological|Comparator: Placebo|1 dose 0.65 mL/dose subcutaneous injection of placebo.
509809|NCT00322218|Drug|Zevalin Therapeutic Regimen|Zevalin Therapeutic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
509810|NCT00322218|Other|Observation|Observation
509811|NCT00322205|Drug|zyban|
509812|NCT00322192|Behavioral|Conventional UK Physical therapy|
509813|NCT00322192|Behavioral|Increased intensity of UK conventional physical therapy|
509814|NCT00322192|Behavioral|UK conventional physical therapy plus functional strength training|
509815|NCT00322166|Other|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
509816|NCT00322166|Other|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
509817|NCT00322166|Other|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
509818|NCT00322153|Drug|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
509819|NCT00322153|Drug|Placebo|Matching placebo oral administration once daily.
509820|NCT00322140|Drug|CDDO|
509821|NCT00322127|Drug|AMD3100|a 2 mL clear glass vial containing 1.7 mL of a sterile isotonic solution.
509822|NCT00322114|Dietary Supplement|lycopene|Given orally
509823|NCT00322114|Other|placebo|Given orally
509824|NCT00322101|Radiation|total-body irradiation|Radiation
509825|NCT00322101|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
509826|NCT00322101|Drug|cyclophosphamide|Given IV
509827|NCT00322101|Drug|mycophenolate mofetil|Given orally
509828|NCT00322101|Drug|busulfan|Given IV or orally
509829|NCT00322101|Drug|cyclosporine|Given IV or orally
509830|NCT00322101|Drug|fludarabine phosphate|Given IV
509831|NCT00322101|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
509832|NCT00322101|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
509833|NCT00322101|Other|laboratory biomarker analysis|Correlative studies
509834|NCT00322101|Genetic|cytogenetic analysis|Correlative studies
509835|NCT00322101|Other|flow cytometry|Correlative studies
509836|NCT00322101|Genetic|fluorescence in situ hybridization|Correlative studies
509837|NCT00322101|Other|pharmacological study|Correlative studies
509838|NCT00322101|Genetic|polymorphism analysis|Correlative studies
509839|NCT00322101|Drug|tacrolimus|Given IV or orally
509840|NCT00322101|Drug|methotrexate|Given IV
509841|NCT00322075|Drug|insulin glargine|
509842|NCT00322062|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
509843|NCT00322062|Drug|Sodium Phosphate Solution|1 x 45ml solution, BID
509844|NCT00322049|Biological|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.~Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.~All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.~A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
509845|NCT00322049|Biological|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
509846|NCT00322036|Drug|MPC-7869|Oral 800 mg BID
509847|NCT00322036|Drug|MPC-7869|Oral BID dosing
509848|NCT00322023|Drug|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
509849|NCT00322010|Procedure|early PT OT|"Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).~Sessions began with active assisted and active range of motion exercises in the supine position.~If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.~Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.~The session progresses to transfer training, and finally pre-gait exercises and ambulation.~Progression of activities is dependent on patient tolerance and stability.~Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
509850|NCT00321997|Drug|Pegaptanib sodium|
509851|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
509852|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
509853|NCT00321984|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
509854|NCT00321971|Behavioral|PST-MCI/AD Caregiving|The PST-based intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
509855|NCT00321971|Behavioral|NT-MCI/AD Caregiving|The nutritional education program will be based on the new USSDA dietary recommendations. Participants received 2 phases of treatment; the first phase involved 6 sessions conducted in the caregiver's home approximately 2 weeks apart, each lasting approximately 1.5 hours. The second phase included three telephone contacts (approximately 2 weeks apart) to reinforce principles taught during the first phase, each lasting approximately 45 minutes.
509856|NCT00321958|Device|CSA System (CryoSpray AblationTM System)|10 second spray times
509857|NCT00321958|Device|CryoSpray Ablation|10 second spray times
509858|NCT00321945|Procedure|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
509859|NCT00321932|Dietary Supplement|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
509860|NCT00321932|Dietary Supplement|cholecalciferol|Given orally
509861|NCT00321932|Drug|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
509862|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
509863|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to <10.5 g/dL had occurred.
509864|NCT00321906|Drug|azathioprine|azathioprine 2mg/kg
509865|NCT00321906|Drug|sirolimus|sirolimus 2-4mg daily
509866|NCT00321893|Drug|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
509867|NCT00321893|Other|Placebo|Inhaled placebo twice daily for one year.
509868|NCT00321880|Procedure|therapeutic touch|administration of healing touch in 30 minute sessions
509869|NCT00321867|Procedure|Graft augmented posterior repair|Posterior repair with graft
509870|NCT00321867|Procedure|Control|Native tissue repair
509871|NCT00321854|Drug|pramipexole|
509872|NCT00321828|Biological|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
509873|NCT00321828|Drug|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
509874|NCT00321828|Drug|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
509875|NCT00321828|Drug|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
509876|NCT00321815|Drug|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.~Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
509877|NCT00321815|Drug|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
509878|NCT00321802|Drug|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
509879|NCT00321802|Drug|Placebo|Placebo
509880|NCT00321789|Behavioral|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
509881|NCT00321763|Biological|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
509882|NCT00321763|Biological|Fluarix TM|Single dose, Intramuscular injection
509883|NCT00321750|Drug|1% pimecrolimus cream|
509884|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
509885|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
509886|NCT00321737|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
509887|NCT00321724|Drug|cediranib maleate|Given orally
509888|NCT00321724|Other|laboratory biomarker analysis|Correlative studies
509889|NCT00321711|Drug|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
509890|NCT00321711|Biological|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
509891|NCT00321711|Drug|Azacitidine|hypomethylating agent
509892|NCT00321711|Drug|Decitabine|hypomethylating agent
509893|NCT00321698|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
510006|NCT00320658|Biological|CPG 7909|Adjuvant
509894|NCT00321698|Drug|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation~Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
509895|NCT00321685|Biological|Bevacizumab|Given IV
509896|NCT00321685|Drug|Capecitabine|Given PO
509897|NCT00321685|Drug|Fluorouracil|Given IV
509898|NCT00321685|Drug|Leucovorin Calcium|Given IV
509899|NCT00321685|Drug|Oxaliplatin|Given IV
509900|NCT00321685|Radiation|Radiation Therapy|Undergo radiotherapy
509901|NCT00321685|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
509902|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
509903|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
509904|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
509905|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
509906|NCT00321659|Behavioral|Aerobic|3x/week of walking and cycling
509907|NCT00321659|Behavioral|Strength training|3x/week of resistance training activities
509908|NCT00321659|Behavioral|Combination|3x/week of aerobic and strength training activities
509909|NCT00321659|Behavioral|FSHC|Biweekly group education group meetings
509910|NCT00321646|Drug|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
509911|NCT00321646|Drug|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
509912|NCT00321633|Drug|carboplatin|
509913|NCT00321633|Drug|docetaxel|
509914|NCT00321620|Drug|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
509915|NCT00321620|Biological|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
509916|NCT00321594|Drug|belinostat|Given IV
509917|NCT00321581|Drug|Cediranib, AZD2171, RECENTIN|
509918|NCT00321555|Drug|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
509919|NCT00321542|Other|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
509920|NCT00321529|Device|motion analysis by durometer|
509921|NCT00321516|Drug|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
509922|NCT00321490|Drug|Quetiapine fumarate|
509923|NCT00321490|Drug|Duloxetine|
509924|NCT00321477|Drug|GW679769 oral tablets|
509925|NCT00321464|Biological|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
509926|NCT00321464|Drug|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
509927|NCT00321451|Behavioral|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
509928|NCT00321451|Behavioral|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
509929|NCT00321451|Other|Usual care|3 outpatient visits with study physician
509930|NCT00321425|Procedure|brachial plexus block|
509931|NCT00321425|Procedure|ultrasound guidance|
509932|NCT00321425|Procedure|electrical nerve stimulation|
509933|NCT00321412|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
509934|NCT00321373|Biological|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
509935|NCT00321373|Biological|FluarixTM|Single dose, Intramuscular injection
509936|NCT00321360|Drug|Propofol|
509937|NCT00321360|Device|Patient maintained sedation|
509938|NCT00321347|Drug|Lidocaine|
509939|NCT00321334|Procedure|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
509940|NCT00321321|Drug|Sulfonylurea|
509941|NCT00321308|Drug|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
509942|NCT00321308|Drug|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
509943|NCT00321295|Device|Atrial synchronous bi-ventricular pacing|
509944|NCT00321282|Procedure|Atrial Fibrillation|
509945|NCT00321269|Behavioral|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
509946|NCT00321269|Behavioral|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
509947|NCT00321256|Procedure|human pancreatic islet transplantation|
509948|NCT00321243|Behavioral|Visual clues|
509949|NCT00321230|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
509950|NCT00321204|Procedure|TZD reducing the incidence of atrial arrhythmias|
509951|NCT00321191|Drug|No nitrous oxide|
509952|NCT00321191|Drug|Administration of N2O|
509953|NCT00321178|Drug|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
509954|NCT00321165|Drug|taurolidine|
510007|NCT00320632|Drug|Desipramine|
510232|NCT00318591|Device|Conveen Uncoated|Uncoated urinary intermittent catheter
509955|NCT00321152|Other|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
509956|NCT00321126|Drug|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
509957|NCT00321113|Drug|tacrolimus|immunosuppression
509958|NCT00321113|Drug|mycophenolate mofetil|oral
509959|NCT00321113|Drug|steroids|oral
509960|NCT00321100|Drug|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
509961|NCT00321100|Drug|Cetuximab|Cetuximab 250mg/m2 IV weekly each 21 day cycle
509962|NCT00321100|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
509963|NCT00321100|Drug|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
509964|NCT00321087|Drug|T2000|Dose escalation from 600 to 1000 mg
509965|NCT00321087|Drug|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
509966|NCT00321087|Drug|T2000|Placebo followed by dose escalation from 600 to 1000
509967|NCT00321074|Drug|TACROLIMUS|Immunosuppression
509968|NCT00321061|Drug|VRC-HIVDNA016-00, VRC-HIVADV014-00|
509969|NCT00321048|Device|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
509970|NCT00321035|Device|OculusGen Biodegradable Collagen Matrix Implant|
509971|NCT00321022|Behavioral|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
509972|NCT00321009|Drug|Enoxaparin|
509973|NCT00320983|Drug|Topotecan|Topotecan
509974|NCT00320983|Drug|Cisplatin|Cisplatin
509975|NCT00320970|Drug|Candesartan|
509976|NCT00320957|Device|OculusGen Biodegradable Collagen Matrix Implant|
509977|NCT00320931|Device|PET/CT|
509978|NCT00320905|Behavioral|Observational|No intervention
509979|NCT00320892|Drug|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
509980|NCT00320879|Drug|irbesartan|
509981|NCT00320866|Device|syringe driver|
509982|NCT00320853|Drug|Vitamin D|
509983|NCT00320827|Drug|CS-1008 (humanized anti-DR5 antibody)|
509984|NCT00320814|Drug|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
509985|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
509986|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
509987|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
509988|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
509989|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
509990|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
509991|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
509992|NCT00320775|Drug|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.~Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.~Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.~After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
509993|NCT00320762|Device|OculusGen Biodegradable Collagen Matrix Implant|
509994|NCT00320749|Drug|Capecitabine|Will be give on days 8-21
509995|NCT00320749|Drug|Docetaxel|Will be given on days 1 and 8,
509996|NCT00320749|Drug|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
509997|NCT00320736|Drug|galantamine|
509998|NCT00320723|Drug|bupropion, transdermal nicotine patch|
509999|NCT00320710|Drug|Zoledronic acid|4mg IV
510000|NCT00320710|Drug|Placebo|Placebo to zoledronic acid
510001|NCT00320697|Drug|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
510002|NCT00320697|Drug|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
510003|NCT00320671|Drug|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
510004|NCT00320671|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
510005|NCT00320658|Biological|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
532267|NCT00131027|Drug|Prednisolone|
510008|NCT00320619|Drug|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
510009|NCT00320619|Drug|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
510010|NCT00320606|Drug|Immunosuppression Withdrawal|Gradual withdrawal of immunosuppressive medication. With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
510011|NCT00320593|Device|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
510012|NCT00320593|Device|Single Vision Lenses (SVLs)|Single vision lenses
510013|NCT00320580|Drug|norelgestromin/ethinyl estradiol|
510014|NCT00320567|Drug|norgestimate/ethinyl estradiol|
510015|NCT00320554|Behavioral|Durometer analysis|
510016|NCT00320541|Drug|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
510017|NCT00320541|Drug|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
510018|NCT00320541|Drug|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
510019|NCT00320528|Drug|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
510020|NCT00320515|Drug|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression~Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
510021|NCT00320515|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
510022|NCT00320502|Drug|BXT-51072|
510023|NCT00320489|Drug|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
510024|NCT00320489|Drug|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
510025|NCT00320476|Drug|Velcade|
510026|NCT00320463|Biological|DTPa-HBV-IPV/Hib vaccine|
510027|NCT00320450|Drug|SB-681323|
510028|NCT00320424|Drug|Fondaparinux|
510029|NCT00320411|Drug|lapatinib|Lapatinib 1500mg QD
510030|NCT00320398|Drug|Fondaparinux|
510031|NCT00320385|Drug|Lapatinib|oral lapatinib once daily
510032|NCT00320385|Biological|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
510033|NCT00320359|Drug|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
510034|NCT00320359|Drug|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
510035|NCT00320346|Biological|Pandemic Influenza Vaccine|
510036|NCT00320333|Procedure|pulmonary rehabilitation programme|
510037|NCT00320320|Drug|Irinotecan|
510038|NCT00320307|Drug|abacavir|
510039|NCT00320294|Drug|irinotecan|
510040|NCT00320294|Drug|cisplatin|
510041|NCT00320281|Drug|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
510042|NCT00320281|Other|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
510043|NCT00320268|Drug|Quetiapine fumarate|
510044|NCT00320255|Drug|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
510045|NCT00320255|Drug|Placebo|Oral tablets administered once daily
510046|NCT00320242|Device|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
510047|NCT00320229|Drug|abciximab|
510048|NCT00320216|Drug|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
510049|NCT00320216|Drug|Placebo|Patients in the placebo group will receive placebo medication.
510050|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Single injection, anterior juxtascleral depot (AJD)
510051|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single injection, anterior juxtascleral depot (AJD)
510052|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single injection, anterior juxtascleral depot (AJD)
510053|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
510054|NCT00320190|Drug|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
510055|NCT00320190|Drug|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
510056|NCT00320138|Procedure|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
510057|NCT00320125|Dietary Supplement|Orange juice plus calcium|> 1,200mg Ca (four glasses of orange juice plus calcium)per day
510058|NCT00320125|Dietary Supplement|Dairy products|> 1,200mg Ca (by consuming milk, yogurt, and cheese)
510170|NCT00319098|Biological|Fluarix|One intramuscular injection
510171|NCT00319098|Biological|Placebo|One intramuscular injection
510059|NCT00320112|Behavioral|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
510060|NCT00320112|Behavioral|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
510061|NCT00320112|Behavioral|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
510062|NCT00320099|Drug|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
510063|NCT00320099|Drug|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
510064|NCT00320099|Drug|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
510065|NCT00320099|Drug|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
510066|NCT00320073|Drug|erlotinib hydrochloride|75 mg to 150mg
510067|NCT00320073|Drug|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
510068|NCT00320073|Drug|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
510069|NCT00320060|Drug|Pyridorin (pyridoxamine dihydrochloride)|
510070|NCT00320047|Drug|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
510071|NCT00320034|Drug|R-albuterol, S-albuterol|
510072|NCT00320021|Drug|Pyridorin (pyridoxamine dihydrochloride)|
510073|NCT00320008|Behavioral|Diet|
510074|NCT00320008|Behavioral|Exercise|
510075|NCT00320008|Behavioral|Stop smoking|
510076|NCT00320008|Drug|Glucose lowering therapy|
510077|NCT00320008|Drug|Blood pressure lowering therapy|
510078|NCT00320008|Drug|Lipid lowering therapy|
510079|NCT00319995|Drug|loratadine; montelukast|
510080|NCT00319982|Drug|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
510081|NCT00319982|Drug|Placebo|Placebo comparator (double-blind allocation of study medication)
510082|NCT00319969|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
510083|NCT00319969|Drug|Topotecan|Topotecan 1.5mg/m<2> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
510084|NCT00319956|Drug|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
510085|NCT00319956|Drug|Placebo|vehicle dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
510086|NCT00319943|Procedure|Computer-based training for Mild Cognitive Impairment (MCI)|
510087|NCT00319930|Drug|CNF1010 (17-AAG)|
510088|NCT00319917|Drug|tacrolimus|oral
510089|NCT00319917|Drug|placebo|oral
510090|NCT00319891|Procedure|Computer-based Cognitive Training|
510091|NCT00319878|Drug|Sirolimus|"Oral loading dose followed by a once daily dose:~Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg~Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg~Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg~Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
510092|NCT00319878|Drug|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
510093|NCT00319865|Drug|Velcade|
510094|NCT00319865|Drug|Thalidomide|
510095|NCT00319865|Drug|Adriamycin|
510096|NCT00319865|Drug|Dexamethasone|
510097|NCT00319852|Biological|DTaP-IPV combined vaccine|0.5 mL, IM
510098|NCT00319852|Biological|DTaP vaccine|0.5 mL, IM
510099|NCT00319839|Drug|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
510100|NCT00319839|Drug|Cetuximab|Cetuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly: 250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
510101|NCT00319826|Other|No intervention|This is an observational study with no intervention
510102|NCT00319813|Behavioral|Education|
510103|NCT00319800|Drug|Gefitinib|
510104|NCT00319800|Drug|Irinotecan|
510105|NCT00319787|Drug|Iressa|
510106|NCT00319774|Device|Hemocontrol Biofeedback System|
510107|NCT00319761|Drug|Calcitriol|
510108|NCT00319748|Drug|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
510109|NCT00319735|Procedure|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
510110|NCT00319735|Procedure|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
510111|NCT00319735|Procedure|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
510112|NCT00319709|Drug|SR58611A|
510113|NCT00319696|Drug|Bosentan 62.5 mg|Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
510114|NCT00319696|Drug|Bosentan 125 mg|Bosentan 125-mg oral tablets administered b.i.d. (target dose)
510115|NCT00319683|Drug|ADH300004|
510116|NCT00319670|Drug|MiraLax|
510117|NCT00319657|Biological|Hematopoietic cell transplantation|Transplantation of hematopoietic stem cells from the living donor.
532268|NCT00131027|Drug|L-asparaginase|
510118|NCT00319657|Radiation|Total lymphoid irradiation|Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
510119|NCT00319644|Device|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
510120|NCT00319618|Drug|Gefitinib|
510121|NCT00319618|Drug|Docetaxel|
510122|NCT00319605|Drug|Levetiracetam|
510123|NCT00319592|Biological|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
510124|NCT00319592|Biological|JE-VAX® vaccine|1.0 mL, subcutaneously
510125|NCT00319566|Drug|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
510126|NCT00319553|Biological|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
510127|NCT00319553|Biological|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
510128|NCT00319540|Behavioral|Control with depression course (CWD)|
510129|NCT00319514|Drug|Docetaxel|
510130|NCT00319501|Drug|Placebo|Intramuscular autoinjector; administered at onset of an episode
510131|NCT00319501|Drug|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
510132|NCT00319488|Drug|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
510133|NCT00319488|Drug|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
510134|NCT00319488|Drug|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
510135|NCT00319475|Procedure|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
510136|NCT00319462|Device|hemoclip|
510137|NCT00319449|Drug|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
510138|NCT00319449|Drug|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
510139|NCT00319449|Drug|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
510140|NCT00319436|Behavioral|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
510141|NCT00319436|Behavioral|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
510142|NCT00319423|Procedure|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
510143|NCT00319410|Procedure|vaginoscopic hysteroscopy|
510144|NCT00319397|Behavioral|Exercise-Training Program|
510145|NCT00319384|Device|Ultrafiltration therapy|
510146|NCT00319358|Dietary Supplement|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
510147|NCT00319358|Dietary Supplement|Placebo|placebo
510148|NCT00319345|Drug|Mannitol, Sodium-Lactate|
510149|NCT00319332|Drug|Ibritumomab Tiuxetan|
510150|NCT00319332|Drug|Iodine I 131 Tositumomab|
510151|NCT00319319|Drug|Mecamylamine hydrochloride (Inversine)|
510152|NCT00319306|Drug|Budesonide/formoterol|
510153|NCT00319306|Device|Symbicort® Turbohaler®|
510154|NCT00319293|Drug|Metformin|
510155|NCT00319280|Procedure|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
510156|NCT00319267|Drug|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
510157|NCT00319254|Drug|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
510158|NCT00319241|Behavioral|Parenting Intervention|
510159|NCT00319228|Drug|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.~Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
510160|NCT00319215|Drug|Ramelteon 8 mg|
510161|NCT00319215|Drug|Zopiclone 7.5 mg|
510162|NCT00319202|Drug|Candesartan|32 mg/d for 6 months
510163|NCT00319202|Drug|Placebo|Placebo administration for 6 months
510164|NCT00319189|Drug|Nateglinide|
510165|NCT00319163|Drug|levonorgestrel/ethinyl estradiol|
510166|NCT00319150|Drug|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
510167|NCT00319137|Drug|GW274150|
510168|NCT00319111|Drug|bosentan|"Oral bosentan~Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients~Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight < 40 kg)"
510169|NCT00319098|Biological|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
510172|NCT00319085|Procedure|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
510173|NCT00319072|Behavioral|TalkToYourDoc(sm) hormone therapy module|
510174|NCT00319059|Drug|systemic administration of 99mTc-HYNIC-Annexin A5|
510175|NCT00319059|Behavioral|10 minutes of ischemic handgripping|
510176|NCT00319046|Drug|Miglustat|Oral capsules containing miglustat 100 mg, administered three times daily (t.i.d.)
510177|NCT00319033|Drug|bosentan|
510178|NCT00319020|Drug|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
510179|NCT00319007|Drug|Sulindac (drug)|
510180|NCT00319007|Drug|VSL#3 (probiotic)|
510181|NCT00319007|Drug|Inulin (probiotic)|
510182|NCT00318994|Drug|Meropenem|
510183|NCT00318981|Drug|Concerta|
510184|NCT00318968|Drug|Esomeprazole|
510185|NCT00318955|Drug|Dexmedetomidine|
510186|NCT00318955|Drug|Propofol|
510187|NCT00318942|Drug|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
510188|NCT00318942|Drug|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
510189|NCT00318942|Drug|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
510190|NCT00318942|Drug|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
510191|NCT00318929|Drug|Divalproex Sodium Extended-Release Tablets|Once a day dosing
510192|NCT00318903|Drug|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
510193|NCT00318903|Drug|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
510194|NCT00318903|Procedure|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
510195|NCT00318903|Procedure|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
510196|NCT00318890|Drug|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
510197|NCT00318890|Drug|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
510198|NCT00318890|Procedure|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
510199|NCT00318890|Drug|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
510200|NCT00318877|Behavioral|After school team sports program|
510201|NCT00318877|Behavioral|After school health education program|
510202|NCT00318864|Behavioral|Cognitive behavioral therapy|
510203|NCT00318851|Device|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
510204|NCT00318838|Drug|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
510205|NCT00318838|Drug|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
510206|NCT00318825|Drug|Nitrous oxide|
510207|NCT00318812|Drug|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
510208|NCT00318812|Drug|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
510209|NCT00318799|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
510210|NCT00318799|Drug|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
510211|NCT00318786|Drug|biphasic insulin aspart|
510212|NCT00318773|Drug|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
510213|NCT00318760|Drug|Clonidine|0.1 or 0.2 mg oral, one dose
510214|NCT00318760|Drug|Placebo|oral capsule 1 dose
510215|NCT00318747|Drug|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
510216|NCT00318721|Device|Long Lasting Impregnated Nets (LLIN)|Distribution of LLIN in selected clusters
510217|NCT00318708|Drug|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
510218|NCT00318708|Drug|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
510219|NCT00318708|Drug|placebo clarithromycin|placebo clarithromycin twice daily
510220|NCT00318695|Dietary Supplement|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
510221|NCT00318695|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
510222|NCT00318682|Device|FIBROSCAN|diagnostic examination of the hepato fibrosis
510223|NCT00318669|Drug|Paroxetine hydrochloride hydrate|
510224|NCT00318656|Drug|rosiglitazone-metformin fixed dose combination|
510225|NCT00318656|Drug|metformin + glimepiride|
510226|NCT00318643|Drug|Mitomycin C|intravesical administration
510227|NCT00318643|Drug|Chemophase|intravesical administration
510228|NCT00318630|Drug|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
510229|NCT00318630|Drug|Placebo|Subjects will also receive placebo oral tablet.
510230|NCT00318617|Drug|GW510516X|
510231|NCT00318591|Device|SpeediCath|hydrophilic coated urinary intermittent catheter
532269|NCT00131027|Drug|Cytarabine|
510233|NCT00318565|Device|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
510234|NCT00318552|Drug|Meropenem|
510235|NCT00318539|Drug|Quetiapine|
510236|NCT00318513|Drug|Bevacizumab|
510237|NCT00318500|Drug|ERB-041|
510238|NCT00318487|Procedure|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
510239|NCT00318474|Drug|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
510240|NCT00318474|Drug|MMF Placebo|Placebo only, oral administration
510241|NCT00318474|Drug|ACEi|Administer same as pre-treatment regimen.
510242|NCT00318474|Drug|FOS|Administer same as pre-treatment regimen
510243|NCT00318461|Drug|liraglutide|0.6 mg for s.c. (under the skin) injection.
510244|NCT00318461|Drug|metformin|1.5-2.0 g tablets
510245|NCT00318461|Drug|glimepiride|4 mg tablets
510246|NCT00318461|Drug|placebo|Glimepiride placebo 1 mg and 2 mg tablets
510247|NCT00318461|Drug|placebo|Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
510248|NCT00318461|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
510249|NCT00318461|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
510250|NCT00318448|Drug|Zolpidem (SL800750)|
510251|NCT00318435|Device|Stent or stent-graft deployment|
510252|NCT00318422|Drug|liraglutide|
510253|NCT00318422|Drug|rosiglitazone|
510254|NCT00318422|Drug|glimepiride|
510255|NCT00318409|Drug|Bupropion|
510256|NCT00318409|Drug|Placebo|
510257|NCT00318396|Procedure|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
510258|NCT00318396|Procedure|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
510259|NCT00318383|Biological|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
510260|NCT00318383|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
510261|NCT00318370|Drug|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
510262|NCT00318370|Drug|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
510263|NCT00318357|Device|Continuation of CRT|Implantation of CRT device and medical treatment according normal hospital routine.
510264|NCT00318357|Device|Upgrade to CRT|Recommended implantation of a Medtronic CRT InSync® family devices. Implantation of CRT device and medical treatment according normal hospital routine.
510265|NCT00318344|Drug|Atuna Racemosa|
510266|NCT00318331|Drug|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
510267|NCT00318318|Drug|Premarin|
510268|NCT00318292|Drug|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
510269|NCT00318292|Drug|Placebo|20 ml normal saline injection.
510270|NCT00318279|Device|Surgical simulator to practice vascular anastomosis|
510271|NCT00318266|Device|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
510272|NCT00318253|Procedure|cranberry juice|
510273|NCT00318240|Device|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
510274|NCT00318227|Procedure|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
510275|NCT00318214|Drug|MRE0094|Gel, 500 mcg/g once each day
510276|NCT00318214|Drug|Vehicle gel|Gel administered once per day
510277|NCT00318201|Drug|Erythromycin|
510278|NCT00318201|Drug|Diltiazem|
510279|NCT00318188|Procedure|standardized reeducation and readaptation program|
510280|NCT00318175|Drug|Bosentan (Tracleer)|
510281|NCT00318162|Drug|low dose naltrexone|
510282|NCT00318149|Biological|Fluarix|1 dose administered intramuscularly in the deltoid region of the non-dominant arm
510283|NCT00318149|Biological|Fluarix-AS25|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
510284|NCT00318149|Biological|Fluarix-AS50|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
510285|NCT00318149|Biological|Fluarix-AS01B|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
510286|NCT00318149|Biological|Fluarix-AS01E|1 dose administered intramuscularly into the deltoid region of the non-dominant arm
510287|NCT00318136|Drug|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
510288|NCT00318136|Drug|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
510289|NCT00318136|Drug|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
510290|NCT00318123|Drug|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
510291|NCT00318110|Procedure|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:~Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
510292|NCT00318084|Drug|Esomeprazole|
510293|NCT00318084|Procedure|Ambulatory 24-hour esophageal pH-monitoring|
510294|NCT00318071|Device|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography."
510295|NCT00318058|Biological|influenza vaccine Fluarix, Adjuvanted Fluarix|
510296|NCT00318045|Device|Eyeglass lenses|
510297|NCT00318032|Drug|multi-factorial intervention|
510298|NCT00318019|Dietary Supplement|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
510299|NCT00318019|Other|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
510300|NCT00318006|Procedure|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
510301|NCT00318006|Procedure|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
510302|NCT00317993|Drug|ezetimibe|
510303|NCT00317993|Drug|simvastatin|
510304|NCT00317993|Drug|ezetimibe plus simvastatin|
510305|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
510306|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
510307|NCT00317967|Drug|Atorvastatin|80 mg pills daily
510308|NCT00317967|Drug|Placebo|80 mg pills daily
510309|NCT00317954|Drug|Spironolactone|
510310|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject
510311|NCT00317941|Drug|Rebif|44ug administered with Rebiject II
510312|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject light
510313|NCT00317928|Drug|Metformin|
510314|NCT00317915|Drug|Irbesartan treatment|
510315|NCT00317902|Drug|Epoetin alfa|
510316|NCT00317889|Procedure|Bone preparation technique: compaction|
510317|NCT00317889|Procedure|Bone preparation technique: broaching|
510318|NCT00317876|Drug|cyclophosphamide|
510319|NCT00317876|Drug|cyclosporine|
510320|NCT00317876|Drug|methotrexate|
510321|NCT00317876|Procedure|allogeneic bone marrow transplantation|
510322|NCT00317876|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
510323|NCT00317850|Drug|Gabapentin (Neurontin)|
510324|NCT00317837|Procedure|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
510325|NCT00317837|Procedure|bipolar hemiarthroplasty|bipolar hemiarthroplasty
510326|NCT00317811|Dietary Supplement|ascorbic acid|
510327|NCT00317811|Drug|bortezomib|
510328|NCT00317811|Drug|melphalan|
510329|NCT00317798|Biological|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
510330|NCT00317798|Drug|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
510331|NCT00317785|Drug|cyclophosphamide|
510332|NCT00317785|Drug|cyclosporine|
510333|NCT00317785|Drug|methotrexate|
510334|NCT00317785|Drug|mycophenolate mofetil|
510335|NCT00317785|Drug|sirolimus|
510336|NCT00317785|Drug|tacrolimus|
510337|NCT00317785|Other|pharmacological study|
510338|NCT00317785|Procedure|allogeneic bone marrow transplantation|
510339|NCT00317785|Procedure|allogeneic hematopoietic stem cell transplantation|
510340|NCT00317785|Procedure|peripheral blood stem cell transplantation|
510341|NCT00317785|Radiation|total-body irradiation|
510342|NCT00317772|Drug|Topotecan|"Phase I Starting Dose: 2 mg/m^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.~Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
510343|NCT00317772|Drug|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.~Phase II: 250 mg by mouth daily for 28 Days."
510344|NCT00317759|Biological|therapeutic autologous lymphocytes|
510345|NCT00317759|Drug|fludarabine phosphate|
510346|NCT00317746|Drug|Citalopram|
510347|NCT00317746|Drug|Placebos|
510348|NCT00317733|Drug|Ketoprofen in Transfersome|
510349|NCT00317720|Drug|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.~If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
510350|NCT00317720|Drug|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
510351|NCT00317707|Drug|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
510352|NCT00317707|Drug|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
510353|NCT00317694|Drug|Fermagate|Film coated tablet 500mg
510354|NCT00317694|Drug|Placebo|Oral administration, film coated tablet, 0mg
510355|NCT00317681|Drug|Tacrolimus ointment|
510356|NCT00317655|Drug|Glucosamine sulphate|
510357|NCT00317655|Drug|Ginger|
510358|NCT00317655|Drug|Ginger-Avocado-Soya|
510359|NCT00317655|Drug|Ginger-ibuprofen|
510360|NCT00317642|Drug|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m^2 / day up to 3 cycles
510361|NCT00317642|Drug|placebo|placebo (sodium Chloride) 1-hour IV infusion
510362|NCT00317642|Drug|cytarabine|cytarabine IV infusion 1g/m^2/day for up to 3 cycles
510363|NCT00317629|Drug|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
510364|NCT00317629|Drug|meglumine antimoniate|20mg/kg daily during 20 days
510365|NCT00317603|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
510366|NCT00317590|Device|Rapid Diagnostic Test for Malaria (Paracheck®)|
510367|NCT00317577|Drug|brimonidine, timolol|
510368|NCT00317551|Device|Aberration controlled contact lens|
510369|NCT00317551|Behavioral|Vision training|
510370|NCT00317538|Drug|infliximab, etanercept|
510371|NCT00317525|Device|Spectacle Lenses|
510372|NCT00317512|Procedure|Percutaneous Coronary Revascularization|
510373|NCT00317512|Drug|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
510374|NCT00317512|Drug|Voluven|
510375|NCT00317499|Other|Placebo|Placebo
510376|NCT00317499|Drug|Etanercept|Etanercept
510377|NCT00317486|Drug|bosentan|
510378|NCT00317473|Biological|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
510379|NCT00317473|Biological|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
510380|NCT00317460|Other|Physician Management|Standard physician care
510381|NCT00317460|Behavioral|Counseling|Physician Management and Counseling
510382|NCT00317447|Drug|Oral Prednisone|
510383|NCT00317434|Drug|lapatinib|
510384|NCT00317421|Drug|Sildenafil citrate|
510385|NCT00317408|Biological|anti-thymocyte globulin|
510386|NCT00317408|Drug|busulfan|
510387|NCT00317408|Drug|carboplatin|
510388|NCT00317408|Drug|carmustine|
510389|NCT00317408|Drug|cyclosporine|
510390|NCT00317408|Drug|cytarabine|
510391|NCT00317408|Drug|dexamethasone|
510392|NCT00317408|Drug|etoposide phosphate|
510393|NCT00317408|Drug|idarubicin|
510394|NCT00317408|Drug|ifosfamide|
510395|NCT00317408|Drug|leucovorin calcium|
510396|NCT00317408|Drug|lomustine|
510397|NCT00317408|Drug|melphalan|
510398|NCT00317408|Drug|methotrexate|
510399|NCT00317408|Drug|mitoxantrone hydrochloride|
510400|NCT00317408|Drug|prednisolone|
510401|NCT00317408|Drug|thiotepa|
510402|NCT00317408|Drug|vinblastine sulfate|
510403|NCT00317408|Drug|vindesine|
510404|NCT00317408|Procedure|allogeneic hematopoietic stem cell transplantation|
510405|NCT00317408|Procedure|autologous hematopoietic stem cell transplantation|
510406|NCT00317408|Procedure|peripheral blood stem cell transplantation|
510407|NCT00317408|Radiation|total-body irradiation|
510408|NCT00317395|Drug|Otamixaban (XRP0673)|intravenous administration
510409|NCT00317395|Drug|unfractionated heparin|intravenous administration
510410|NCT00317395|Drug|eptifibatide|intravenous administration
510411|NCT00317382|Device|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
510412|NCT00317369|Drug|OPC-6535(Tetomilast)|
510413|NCT00317356|Drug|OPC-6535(Tetomilast)|
510414|NCT00317343|Drug|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
510415|NCT00317330|Drug|Isoniazid|
510416|NCT00317330|Drug|Pyrazinamide|
510417|NCT00317330|Drug|Rifampin|
510418|NCT00317317|Procedure|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
510419|NCT00317304|Behavioral|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
510420|NCT00317291|Procedure|Acupuncture/Moxibustion|Acupuncture/Moxibustion: 16 scheduled sessions
510421|NCT00317291|Other|Sham acupuncture/Placebo moxibustion|Sham acupuncture/Placebo moxibustion: 16 scheduled sessions
510422|NCT00317278|Other|massage therapy|massage therapy to stable preterm infants
510423|NCT00317278|Other|Sham|Sham (placebo) provided to the control group
510424|NCT00317265|Procedure|Coronary bypass surgery|
510425|NCT00317252|Drug|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
510426|NCT00317239|Drug|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
510427|NCT00317239|Drug|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
510428|NCT00317226|Drug|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
510429|NCT00317213|Drug|LIBERTAL- a phospholipid mixture|
510430|NCT00317200|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
510431|NCT00317200|Drug|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
510432|NCT00317187|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
510433|NCT00317187|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
510434|NCT00317174|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
510435|NCT00317161|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
510436|NCT00317148|Drug|Placebos|Placebo capsule
510437|NCT00317148|Drug|DHEA capsule|One capsule of DHEA
510438|NCT00317135|Biological|Tritanrix-HepB/Meningitec conjugate vaccine|The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
510439|NCT00317135|Biological|Tritanrix/Hiberix vaccine|The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
510440|NCT00317122|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
510441|NCT00317109|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
510442|NCT00317109|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
510443|NCT00317109|Biological|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
510444|NCT00317096|Procedure|FCM|Active comparator: Chemotherapy
510445|NCT00317096|Procedure|R-FCM|experimental: Chemotherapy with additional rituximab
510446|NCT00317096|Drug|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
510447|NCT00317096|Other|observation only|no Intervention after completion of FCM or R-FCM
510448|NCT00317083|Procedure|Cough reflex test|
510449|NCT00317070|Drug|dimethyl sulfoxide|intravesical installation 50 ml
510450|NCT00317070|Drug|IC Cocktail|"Heparin 10,000 units~Gentamicin 80 mg~Hydrocortisone sodium succinate (Solucortef) 100 mg~Lidocaine hydrochloride 1% 10 ml~Sodium Bicarbonate 8.4% 5 ml"
510451|NCT00317057|Procedure|Patient education and disease management|
510452|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg twice daily
510453|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg once daily
510454|NCT00317044|Drug|Placebo|Placebo twice daily
510455|NCT00317031|Drug|Acamprosate or Naltrexone|mg&d 90 days
510456|NCT00317018|Behavioral|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
510457|NCT00317005|Drug|folate treatment|
510458|NCT00316992|Drug|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
510459|NCT00316979|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
510460|NCT00316966|Behavioral|Multidisciplinary dietary intervention|
510461|NCT00316953|Drug|dasatinib|Given orally
510462|NCT00316953|Other|pharmacological study|Correlative studies
510463|NCT00316953|Other|laboratory biomarker analysis|Correlative studies
510464|NCT00316940|Drug|bortezomib|
510465|NCT00316940|Radiation|samarium Sm 153 lexidronam pentasodium|
510466|NCT00316927|Drug|acetylsalicylic acid|
510467|NCT00316927|Drug|dexamethasone|
510468|NCT00316927|Drug|diethylstilbestrol|
510469|NCT00316914|Drug|calcium gluconate|Given IV
510470|NCT00316914|Drug|magnesium sulfate|Given IV
510471|NCT00316914|Other|placebo|Given IV
510472|NCT00316901|Procedure|computed tomography|
510473|NCT00316901|Procedure|positron emission tomography|
510474|NCT00316901|Radiation|fludeoxyglucose F 18|
510475|NCT00316888|Biological|cetuximab|Given IV
510476|NCT00316888|Drug|cisplatin|Given IV
510477|NCT00316888|Drug|fluorouracil|Given IV
510478|NCT00316888|Radiation|radiotherapy|Given once daily 5 days a week for 5 weeks
510479|NCT00316875|Drug|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
510480|NCT00316875|Drug|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
510481|NCT00316862|Drug|cisplatin|Given IV
510482|NCT00316862|Drug|irinotecan hydrochloride|Given IV
510483|NCT00316862|Procedure|therapeutic conventional surgery|Undergo Surgery
510484|NCT00316862|Radiation|radiation therapy|Undergo radiation
510485|NCT00316849|Other|pharmacological study|
510486|NCT00316849|Procedure|adjuvant therapy|
510487|NCT00316849|Radiation|3-dimensional conformal radiation therapy|
510488|NCT00316849|Radiation|intensity-modulated radiation therapy|
510489|NCT00316849|Drug|temsirolimus|Given IV
510490|NCT00316849|Drug|temozolomide|Given orally
510491|NCT00316836|Procedure|mammography|
510492|NCT00316823|Genetic|gene expression analysis|
510493|NCT00316823|Genetic|polymerase chain reaction|
510494|NCT00316823|Genetic|reverse transcriptase-polymerase chain reaction|
510495|NCT00316823|Other|diagnostic laboratory biomarker analysis|
510496|NCT00316823|Other|immunohistochemistry staining method|
510497|NCT00316823|Procedure|needle biopsy|
510498|NCT00316810|Drug|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
510657|NCT00315458|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
510499|NCT00316810|Drug|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
510500|NCT00316797|Drug|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
510501|NCT00316784|Drug|IDEA-033 (and rescue medication)|
510502|NCT00316771|Drug|P38 Inhibitor (4) 150mg|150mg po qd
510503|NCT00316771|Drug|P38 Inhibitor (4) 25mg|25mg po bid
510504|NCT00316771|Drug|P38 Inhibitor (4) 300mg|300mg po qd
510505|NCT00316771|Drug|P38 Inhibitor (4) 50mg|50mg po qd
510506|NCT00316771|Drug|P38 Inhibitor (4) 75mg|75mg po bid
510507|NCT00316771|Drug|Placebo|po bid
510508|NCT00316758|Drug|GK Activator (2)|Escalating doses bid
510509|NCT00316758|Drug|Metformin|As prescribed, in patients who were in study BM18249
510510|NCT00316745|Drug|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
510511|NCT00316745|Drug|TS-1|S-1 Day1~14, everyday P.O.(Day 15~28 rest)
510512|NCT00316745|Drug|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
510513|NCT00316745|Drug|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
510514|NCT00316745|Drug|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1~3 (48 hours) of each 28 day cycle.
510515|NCT00316732|Procedure|IPSS Questionnaire|
510516|NCT00316732|Procedure|EQ-5D Questionnaire|
510517|NCT00316719|Drug|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
510518|NCT00316719|Drug|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
510519|NCT00316706|Biological|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
510520|NCT00316706|Biological|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
510521|NCT00316693|Biological|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
510522|NCT00316693|Biological|Aimmugen™|Intramuscular injection, 3 doses
510523|NCT00316680|Biological|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
510524|NCT00316654|Biological|Meningococcal C conjugate vaccine|
510525|NCT00316641|Drug|Lipid-lowing Tea|
510526|NCT00316628|Biological|influenza vaccine|
510527|NCT00316615|Biological|influenza vaccine|
510528|NCT00316602|Biological|IMVAMUNE|Subjects receiving two subcutaneous vaccinations
510529|NCT00316589|Biological|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
510530|NCT00316576|Procedure|Blood sampling for PCR|
510531|NCT00316563|Drug|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
510532|NCT00316563|Other|Placebo|
510533|NCT00316550|Drug|AV608|
510534|NCT00316537|Drug|ATG002 (study drug)|
510535|NCT00316524|Biological|MVA-BN® (IMVAMUNE)|1x 10E8_TCID50
510536|NCT00316524|Biological|Placebo|Tris-Buffer
510537|NCT00316511|Drug|Aroplatin|
510538|NCT00316498|Drug|OGT918|
510539|NCT00316472|Drug|Niacinamide|
510540|NCT00316459|Drug|ERB-041|
510541|NCT00316433|Drug|Irinotecan (CPT-11)|
510542|NCT00316433|Drug|Oxaliplatin (Eloxatin)|
510543|NCT00316420|Drug|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
510544|NCT00316420|Drug|Gemcitabine|750 mg/m2 IV Days 1 & 8 q 21 days
510545|NCT00316407|Drug|lapatinib (GW572016)|1000 mg po qd
510546|NCT00316407|Drug|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
510547|NCT00316407|Drug|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
510548|NCT00316394|Device|Preventive Care Checklist Form|
510549|NCT00316381|Procedure|Autologous bone marrow-derived stem cells|
510550|NCT00316368|Device|Ethicon TPW32 60 cm (pacing wires x 2)|
510551|NCT00316355|Behavioral|Traditional CBT|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
510552|NCT00316355|Behavioral|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
510553|NCT00316342|Device|Back supports|
510554|NCT00316329|Drug|Artesunate + Amodiaquine|
510555|NCT00316316|Behavioral|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
510556|NCT00316316|Behavioral|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
510557|NCT00316303|Drug|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
510558|NCT00316303|Behavioral|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
510559|NCT00316290|Behavioral|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
510843|NCT00313911|Biological|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
510560|NCT00316290|Behavioral|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
510561|NCT00316277|Behavioral|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
510562|NCT00316277|Behavioral|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
510563|NCT00316264|Biological|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
510564|NCT00316264|Biological|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
510565|NCT00316264|Biological|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
510566|NCT00316251|Device|Vibration Plate Therapy|
510567|NCT00316238|Drug|olanzapine-RAIM|
510568|NCT00316238|Drug|placebo|
510569|NCT00316225|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2) IV every 21 days for 6 cycles
510570|NCT00316212|Drug|INS50589 Intravenous Infusion|
510571|NCT00316199|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
510572|NCT00316199|Drug|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
510573|NCT00316186|Drug|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
510574|NCT00316186|Drug|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
510575|NCT00316173|Drug|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
510576|NCT00316173|Drug|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
510577|NCT00316160|Drug|Bupropion Hydrochloride Extended-release|
510578|NCT00316160|Drug|Extended-release Venlafaxine|
510579|NCT00316147|Biological|DTPa-HBV-IPV/Hib vaccine|
510580|NCT00316134|Procedure|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
510581|NCT00316121|Device|HEALOS and Leopard Cage|Placement in interbody space
510582|NCT00316121|Device|Leopard Cage and Autograft|Placement in the interbody space
510583|NCT00316108|Device|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
510584|NCT00316095|Drug|telmisartan|
510585|NCT00316095|Drug|simvastatin|
510586|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
510587|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
510588|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
510589|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
510590|NCT00316082|Drug|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
510591|NCT00316082|Drug|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
510592|NCT00316043|Behavioral|Written information for parents|
510593|NCT00316043|Behavioral|Distance learning package for General Practitioners|
510594|NCT00316043|Behavioral|Distance learning package for practice assistants|
510595|NCT00316030|Drug|Bexarotene|
510596|NCT00316017|Drug|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
510597|NCT00316017|Drug|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
510598|NCT00316017|Drug|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
510599|NCT00316004|Drug|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
510600|NCT00316004|Drug|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
510601|NCT00316004|Drug|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
510602|NCT00315991|Behavioral|Blood Glucose Awareness Training for Parents|
510603|NCT00315978|Device|Heart-to-Heart Decision Aid|
510604|NCT00315965|Drug|Nitric oxide, Carbon monoxide, Helium|
510605|NCT00315952|Drug|Exubera|
510658|NCT00315458|Drug|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
510659|NCT00315445|Drug|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
510660|NCT00315445|Drug|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
510606|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring & Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
510607|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring & Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
510608|NCT00315926|Drug|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
510609|NCT00315926|Drug|Placebo|a mixture of ethanol and physiological saline
510610|NCT00315913|Drug|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
510611|NCT00315913|Other|IV Placebo|IV Saline Solution
510612|NCT00315900|Drug|Depakote ER|depakote ER
510613|NCT00315900|Drug|Seroquel|seroquel
510614|NCT00315887|Drug|Buprenorphine transdermal delivery system|
510615|NCT00315874|Drug|Buprenorphine transdermal delivery system|
510616|NCT00315861|Drug|pemetrexed|
510617|NCT00315861|Drug|topotecan|
510618|NCT00315848|Drug|Buprenorphine transdermal delivery system|
510619|NCT00315835|Drug|Buprenorphine transdermal delivery system|
510620|NCT00315822|Other|80% oxygen|Supplemental oxygen will be administered during surgery
510621|NCT00315822|Other|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
510622|NCT00315796|Device|Biophilic Nature Scene and Sound|
510623|NCT00315770|Procedure|weight loss diets for young adults|
510624|NCT00315757|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
510625|NCT00315757|Biological|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
510626|NCT00315757|Drug|Bortezomib|1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
510627|NCT00315744|Drug|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
510628|NCT00315744|Drug|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
510629|NCT00315744|Drug|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
510630|NCT00315731|Biological|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
510631|NCT00315718|Drug|Extract from Hintonia latiflora bark|
510632|NCT00315705|Drug|clofarabine|Clofarabine 20‑40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
510633|NCT00315705|Drug|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
510634|NCT00315705|Drug|Cyclophosphamide|Cyclophosphamide 340‑440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
510635|NCT00315692|Device|Biomarker Assay (CA125 and HE4)|
510636|NCT00315679|Drug|Pentoxifylline (also known as oxpentifylline)|
510637|NCT00315666|Drug|memantine|
510638|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
510639|NCT00315640|Drug|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
510640|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
510641|NCT00315640|Other|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
510642|NCT00315627|Drug|Islet transplantation|Islet transplantation
510643|NCT00315614|Biological|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
510644|NCT00315601|Drug|Telithromycin|800 mg once a day for 5 days
510645|NCT00315601|Drug|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
510646|NCT00315601|Procedure|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
510647|NCT00315601|Drug|Telithromycin|Telithromycin 800 mg once a day
510648|NCT00315588|Drug|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
510649|NCT00315575|Procedure|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
510650|NCT00315562|Procedure|carotid endarterectomy|
510651|NCT00315549|Drug|Telithromycin|
510652|NCT00315549|Drug|Penicillin|
510653|NCT00315536|Drug|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
510654|NCT00315523|Drug|Levocetirizine|
510655|NCT00315510|Drug|Rosuvastatin|
510656|NCT00315484|Drug|Epoetin alfa and Darbepoetin alfa|
510661|NCT00315445|Drug|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
510662|NCT00315445|Drug|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
510663|NCT00315432|Drug|Pegylated Interferon and Ribavirin|
510664|NCT00315367|Drug|Donepezil HCI (drug)|
510665|NCT00315354|Other|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
510666|NCT00315354|Other|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
510667|NCT00315354|Other|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
510668|NCT00315341|Drug|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
510669|NCT00315341|Drug|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
510670|NCT00315328|Drug|Atropine|Atropine 1% each weekend day in the sound eye
510671|NCT00315328|Device|Patching|Patching 2 hours per day
510672|NCT00315328|Procedure|Near activities|near visual activities for at least one hour per day
510673|NCT00315315|Procedure|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
510674|NCT00315315|Procedure|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
510675|NCT00315315|Procedure|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
510676|NCT00315302|Drug|Atropine|Atropine 1% once each weekend day
510677|NCT00315302|Device|Plano Lens|Plano lens for the sound eye
510678|NCT00315289|Procedure|Nasolacrimal balloon catheter duct dilation|
510679|NCT00315289|Procedure|Nasolacrimal intubation|
510680|NCT00315289|Procedure|Simple Nasolacrimal duct probing|
510681|NCT00315276|Drug|Modafinil|
510682|NCT00315250|Drug|[123I]β-CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
510683|NCT00315237|Drug|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
510684|NCT00315224|Behavioral|heart-rate controlled 12 week exercise program|
510685|NCT00315211|Drug|Intravenous Topotecan|Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
510686|NCT00315211|Drug|Intravenous Docetaxel|Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 & 8 of a 21 day cycle
510687|NCT00315198|Device|Eye Patch|2 hours daily patching
510688|NCT00315198|Procedure|Near activities|near visual activities while patching
510689|NCT00315198|Procedure|Distance activities|distance visual activities while patching
510690|NCT00315185|Drug|Cetuximab|
510691|NCT00315172|Procedure|Non-Exercise Activity Thermogenesis (NEAT)|
510692|NCT00315159|Procedure|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
510693|NCT00315146|Drug|Pioglitazone|
510694|NCT00315146|Behavioral|Resistance exercise training to maximize muscle power|
510695|NCT00315146|Behavioral|Hypocaloric diet|
510696|NCT00315146|Drug|Placebo|
510697|NCT00315133|Procedure|Immunosuppression and autologous stem cell transplantation|Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
510698|NCT00315120|Procedure|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
510699|NCT00315120|Procedure|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
510700|NCT00315120|Procedure|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
510701|NCT00315120|Procedure|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
510702|NCT00315107|Drug|Alesse|
510703|NCT00315094|Behavioral|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
510704|NCT00315081|Drug|Bromocriptin|
510705|NCT00315055|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
510706|NCT00315055|Biological|DTaP-IPV//PRP~T combined|0.5 mL, IM
510707|NCT00315055|Biological|Hepatitis B vaccine|0.5 mL, IM
510708|NCT00315042|Drug|Telithromycin (HMR3647)|
510709|NCT00315042|Drug|Penicillin|
510710|NCT00315029|Behavioral|evidence based decision aid|evidence based decision aid
510711|NCT00315029|Behavioral|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
510712|NCT00315016|Drug|eplerenone|active comparator
510713|NCT00315016|Drug|fosinopril|doubling of fosinopril dose
510714|NCT00315016|Drug|placebo|placebo (double dummy)
510715|NCT00315003|Drug|Telithromycin|
510716|NCT00315003|Drug|Azithromycin|
510717|NCT00314990|Drug|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
510718|NCT00314977|Drug|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
510719|NCT00314977|Drug|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
510720|NCT00314977|Drug|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
510721|NCT00314964|Drug|PD-0299685|
510722|NCT00314951|Drug|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
510723|NCT00314951|Drug|Vancomycin|125 mg capsules q6hr (4 times a day)
510724|NCT00314951|Drug|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
510725|NCT00314938|Drug|PHA-794428|
510726|NCT00314925|Drug|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10^7 vp/kg), IV (in the vein) over 1 hour in a single administration
510727|NCT00314912|Drug|Tramiprosate (3APS)|
510728|NCT00314886|Drug|Diet|
510729|NCT00314873|Drug|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
510730|NCT00314860|Drug|ropinirole Extended Release (XR)|
510731|NCT00314847|Device|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
510732|NCT00314834|Drug|Intradialytic parenteral nutrition|
510733|NCT00314821|Drug|ropinirole|
510734|NCT00314808|Drug|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
510735|NCT00314795|Drug|Peginesatide|Peginesatide injection
510736|NCT00314782|Drug|ZD4054 (Zibotentan)|oral tablet
510737|NCT00314782|Drug|Docetaxel|intravenous infusion
510738|NCT00314782|Drug|Placebo|
510739|NCT00314756|Drug|imiquimod|
510740|NCT00314743|Drug|Ondansetron|
510741|NCT00314743|Drug|Dexamethasone|
510742|NCT00314743|Drug|Aprepitant|
510743|NCT00314730|Device|handheld Personal Digital Assistant (PDA)|
510744|NCT00314717|Behavioral|Control diet|
510745|NCT00314717|Behavioral|Low GI diet|
510746|NCT00314704|Drug|dopamine versus norepinephrine|
510747|NCT00314691|Genetic|Blood samples|
510748|NCT00314678|Drug|Topotecan|
510749|NCT00314678|Drug|Cisplatin|
510750|NCT00314678|Drug|Paclitaxel|
510751|NCT00314665|Drug|Thalidomide|
510752|NCT00314652|Drug|Buprenorphine transdermal delivery system|
510753|NCT00314639|Drug|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
510754|NCT00314626|Drug|efavirenz|Efavirenz
510755|NCT00314626|Drug|Abacavir+lamivudine|Abacavir+lamivudine
510756|NCT00314613|Drug|Antipsychotic/Risperidone Consta|
510757|NCT00314600|Device|above and below elbow cast|
510758|NCT00314587|Procedure|1 or 2 elastic stable intramedullary nails|
510759|NCT00314574|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
510760|NCT00314574|Drug|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
510761|NCT00314574|Drug|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
510762|NCT00314574|Drug|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
510763|NCT00314561|Drug|Pioglitazone, Rosiglitazone|
510764|NCT00314548|Drug|PGE1 (prostacyclin)|alprostadil nebulization
510765|NCT00314548|Drug|normal saline|nebulize for 30 mins
510766|NCT00314509|Drug|Ciclesonide/Formoterol Combination|
510767|NCT00314483|Drug|Mesenchymal Stem Cell Infusion|
510768|NCT00314457|Drug|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
510769|NCT00314431|Procedure|Care coordination by telephone contacts with a nurse|
510770|NCT00314418|Procedure|Colonoscopy in the prone position|
510771|NCT00314405|Drug|Methylene blue (1%)|
510772|NCT00314405|Drug|Rhenium sulfure|
510773|NCT00314405|Procedure|Surgical procedure|
510774|NCT00314405|Procedure|Anatomo-pathologic procedure|
510775|NCT00314392|Behavioral|Information (behavior)|
510776|NCT00314379|Drug|Vitamin E 400IU/day|
510777|NCT00314366|Biological|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
510778|NCT00314366|Other|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
510779|NCT00314353|Drug|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles*~*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
510780|NCT00314353|Drug|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
510839|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
510840|NCT00313937|Drug|Insulin glargine|
510841|NCT00313924|Drug|DETRUSITOL|
532270|NCT00131027|Drug|Etoposide|
510781|NCT00314353|Drug|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles*#~*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.~#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
510782|NCT00314353|Drug|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
510783|NCT00314340|Behavioral|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
510784|NCT00314340|Drug|ER Morphine|
510785|NCT00314340|Drug|hydrocodone plus acetaminophen|
510786|NCT00314340|Drug|placebo|
510787|NCT00314327|Drug|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
510788|NCT00314314|Drug|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
510789|NCT00314314|Drug|Diluent|Intranasal spray; 8 weeks
510790|NCT00314301|Device|loaded sit-to-stand training|
510791|NCT00314288|Drug|Sarizotan HCl|
510792|NCT00314275|Device|Coronary Artery Stenting|Drug eluting stent
510793|NCT00314275|Device|Endeavor|Drug eluting stent
510794|NCT00314262|Drug|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.~Celecoxib given 400 mg orally BID continuously for 6 months."
510795|NCT00314249|Drug|Placebo|Placebo, oral administration, twice daily for 12 weeks
510796|NCT00314249|Drug|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID [twice a day])
510797|NCT00314236|Device|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
510798|NCT00314236|Procedure|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
510799|NCT00314210|Drug|Quetiapine SR|
510800|NCT00314197|Behavioral|Telephone Linked Care - Behavior Change Counseling System|
510801|NCT00314197|Behavioral|Telephone-linked behavioral counseling|
510802|NCT00314184|Drug|quetiapine fumarate|
510803|NCT00314171|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
510804|NCT00314171|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
510805|NCT00314158|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
510806|NCT00314158|Drug|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
510807|NCT00314158|Drug|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
510808|NCT00314145|Biological|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
510809|NCT00314145|Biological|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
510810|NCT00314132|Biological|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
510811|NCT00314132|Biological|0.9% Saline|0.5 mL, Subcutaneous
510812|NCT00314106|Biological|Melanoma Reactive TIL|
510813|NCT00314106|Drug|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
510814|NCT00314106|Biological|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
510815|NCT00314106|Drug|Fludarabine|25 mg/m^2/day intravenous x 5 days
510816|NCT00314106|Radiation|1200 total body irradiation (TBI)|1200 cGY total body radiation
510817|NCT00314093|Drug|RFT5pdgA|
510818|NCT00314080|Drug|Botulinum AntiToxin|
510819|NCT00314080|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
510820|NCT00314080|Procedure|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
510821|NCT00314067|Procedure|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
510822|NCT00314067|Procedure|Physician training|
510823|NCT00314067|Procedure|Practice team training|
510824|NCT00314054|Drug|HCV-796|HCV-796 1000mg single dose
510825|NCT00314041|Biological|Meningococcal C|
510826|NCT00314041|Biological|DTP/Hib|
510827|NCT00314028|Behavioral|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
510828|NCT00314028|Other|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
510829|NCT00314015|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
510830|NCT00314015|Procedure|Questionnaires|Questionnaires will be used
510831|NCT00314002|Device|Mechanical Thrombectomy|
510832|NCT00313989|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants
510833|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
510834|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
510835|NCT00313963|Drug|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
510836|NCT00313963|Drug|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
510837|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
510838|NCT00313950|Biological|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
510842|NCT00313911|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
510844|NCT00313898|Drug|sildenafil (viagra)|
510845|NCT00313885|Drug|eplivanserin (SR46349)|oral administration
510846|NCT00313885|Drug|placebo|oral administration
510847|NCT00313872|Drug|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre & Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre & post hydration (if Mg <WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
510848|NCT00313872|Drug|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
510849|NCT00313859|Drug|simvastatin|
510850|NCT00313846|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
510851|NCT00313846|Drug|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
510852|NCT00313833|Drug|Buprenorphine transdermal delivery system|
510853|NCT00313820|Drug|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
510854|NCT00313820|Drug|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
510855|NCT00313807|Drug|Amino Acid|7% amino acid infusion
510856|NCT00313807|Drug|Placebo|0.9% Saline Infusion
510857|NCT00313794|Drug|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
510858|NCT00313781|Drug|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
510859|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
510860|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
510861|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
510862|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
510863|NCT00313768|Drug|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
510864|NCT00313768|Drug|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
510865|NCT00313755|Procedure|Narrow Band Imaging|
510866|NCT00313742|Drug|insulin detemir|
510867|NCT00313742|Drug|insulin glargine|
510868|NCT00313742|Drug|insulin NPH|
510869|NCT00313729|Drug|temozolomide|Chemotherapy
510870|NCT00313716|Drug|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
510871|NCT00313716|Other|placebo|an inactive substance
510872|NCT00313690|Drug|Bortezomib, Docetaxel and Cisplatin|
510873|NCT00313625|Drug|busulfan|
510874|NCT00313625|Drug|melphalan|
510875|NCT00313625|Drug|methotrexate|
510876|NCT00313625|Drug|tacrolimus|
510877|NCT00313625|Procedure|allogeneic hematopoietic stem cell transplantation|
510878|NCT00313625|Procedure|peripheral blood stem cell transplantation|
510879|NCT00313612|Drug|oxaliplatin|Given IV
510880|NCT00313612|Drug|topotecan|Given IV
510881|NCT00313599|Drug|lapatinib|
510882|NCT00313599|Drug|paclitaxel|
510883|NCT00313586|Drug|Azacitidine|Given SC
510884|NCT00313586|Drug|Entinostat|Given PO
510885|NCT00313586|Other|Laboratory Biomarker Analysis|Correlative studies
510886|NCT00313573|Procedure|management of therapy complications|
510887|NCT00313573|Procedure|pain therapy|
510888|NCT00313573|Procedure|psychosocial assessment and care|
510889|NCT00313573|Procedure|quality-of-life assessment|
510890|NCT00313560|Drug|erlotinib hydrochloride|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
510891|NCT00313547|Drug|Quinapril 40 mg|
510892|NCT00313547|Drug|Quinapril 10 mg and amlodipine 5 mg|
510893|NCT00313534|Drug|masoprocol|
510894|NCT00313521|Drug|thiotepa|
510895|NCT00313521|Procedure|adjuvant therapy|
510896|NCT00313521|Radiation|radiation therapy|
510897|NCT00313508|Biological|Autologous Dendritic Cells (DC)|Given intranodally
510898|NCT00313508|Drug|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
510899|NCT00313508|Biological|Autologous Lymphocyte Infusion (ALI)|Infusion
510900|NCT00313482|Drug|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
510901|NCT00313482|Drug|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
510902|NCT00313482|Drug|Prednisone|5 mg orally BID on Day 1 continuously
510903|NCT00313456|Drug|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
510904|NCT00313443|Procedure|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
510905|NCT00313417|Dietary Supplement|Creatine monohydrate|Up to 10 grams
510906|NCT00313417|Other|Placebo|Placebo will be given in the same way and appearance as the active treatment
510907|NCT00313404|Biological|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
510908|NCT00313391|Drug|Risperdal Consta|
510909|NCT00313378|Drug|Hypothetica|
510910|NCT00313365|Procedure|Surgical Lavage (Arthrotomy)|
510911|NCT00313365|Procedure|Arthrocentesis (Serial needle aspiration)|
510912|NCT00313339|Drug|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
510913|NCT00313326|Procedure|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
510914|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term [ST], 12 months long-term [LT])
510915|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
510916|NCT00313313|Drug|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
510917|NCT00313313|Drug|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
510918|NCT00313313|Drug|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
510919|NCT00313313|Drug|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
510920|NCT00313300|Drug|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
510921|NCT00313300|Drug|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
510922|NCT00313300|Drug|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
510923|NCT00313300|Drug|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
510924|NCT00313287|Drug|clevudine|
510925|NCT00313274|Drug|Clevudine|
510926|NCT00313261|Drug|Clevudine|
510927|NCT00313248|Drug|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
510928|NCT00313248|Drug|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
510929|NCT00313235|Biological|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).~Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.~CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
510930|NCT00313222|Drug|bosentan|
510931|NCT00313209|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
510932|NCT00313209|Drug|Placebo|once daily
510933|NCT00313196|Drug|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
510934|NCT00313183|Drug|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
510935|NCT00313170|Drug|Fulvestrant|intramuscular injection 250 mg & 500 mg
510936|NCT00313157|Drug|Metoprolol|
510937|NCT00313157|Drug|Diltiazem|
510938|NCT00313157|Drug|Verapamil|
510939|NCT00313157|Drug|Carvedilol|
510940|NCT00313144|Drug|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
510941|NCT00313131|Drug|tinidazole+fluconazole vs metronidazole+clotrimazole|
510942|NCT00313105|Drug|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
510943|NCT00313105|Behavioral|smoking cessation counseling|individual visits
510944|NCT00313092|Device|nCPAP treatment|treatment with positive air pressure during night
510945|NCT00313079|Drug|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
510946|NCT00313079|Drug|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
510947|NCT00313053|Drug|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
510948|NCT00313053|Drug|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
510949|NCT00313040|Behavioral|Brief Consultation with Health Counselor, workbook|
510950|NCT00313040|Behavioral|Usual Care wait list|
510951|NCT00313027|Radiation|PET scan|
510952|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
510953|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
510954|NCT00313014|Drug|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
510955|NCT00313001|Drug|biphasic insulin aspart|
510956|NCT00313001|Drug|exenatide|
510957|NCT00312988|Drug|Hycamtin|
510958|NCT00312988|Drug|Gemcitabine|
510959|NCT00312975|Drug|CP-675,206|Given intravenously every 3 months
510960|NCT00312975|Drug|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
511012|NCT00312481|Drug|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
511013|NCT00312455|Drug|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
510961|NCT00312962|Behavioral|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
510962|NCT00312962|Behavioral|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
510963|NCT00312949|Behavioral|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
510964|NCT00312949|Behavioral|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
510965|NCT00312936|Behavioral|Mindfulness-based Stress Reduction (MBSR)|8 week program
510966|NCT00312923|Drug|Policosanol|20 mg of policosanol in capsular form daily
510967|NCT00312923|Dietary Supplement|Placebo|Two capsules of 10 mg of microcrystalline cellulose daily
510968|NCT00312910|Drug|Probiotics-Bio-plus|
510969|NCT00312897|Drug|Omega-3 Fatty Acids|10 wk treatment period
510970|NCT00312897|Drug|corn oil|placebo comparator
510971|NCT00312884|Device|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
510972|NCT00312871|Drug|Epoetin alfa|
510973|NCT00312858|Biological|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
510974|NCT00312858|Biological|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
510975|NCT00312858|Biological|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
510976|NCT00312845|Drug|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
510977|NCT00312845|Drug|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
510978|NCT00312832|Drug|switching; dose reduction|
510979|NCT00312819|Drug|chemotherapy +/- disulfiram|
510980|NCT00312806|Drug|Pantoprazole|Pantoprazole 40 mg o.d.
510981|NCT00312793|Device|stimulation of the quadriceps muscle with Myospare|
510982|NCT00312780|Drug|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
510983|NCT00312767|Drug|Fabrazyme (agalsidase beta)|
510984|NCT00312754|Drug|Atazanavir|
510985|NCT00312741|Procedure|empirical versus microbiological guided treatment|
510986|NCT00312728|Drug|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
510987|NCT00312728|Drug|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
510988|NCT00312728|Drug|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.~All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
510989|NCT00312702|Biological|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
510990|NCT00312676|Procedure|Rapid versus slow conversion|
510991|NCT00312663|Biological|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
510992|NCT00312650|Drug|liposomal doxorubicin and gemcitabine|
510993|NCT00312637|Procedure|Magnetic Resonance Spectroscopy|
510994|NCT00312624|Procedure|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
510995|NCT00312611|Device|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
510996|NCT00312598|Drug|Aripiprazole|
510997|NCT00312585|Procedure|Acupuncture|
510998|NCT00312585|Procedure|Sham comparator|
510999|NCT00312572|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
511000|NCT00312559|Behavioral|Yoga Training|
511001|NCT00312546|Drug|Enfuvirtide|90 mg subcutaneously twice daily
511002|NCT00312546|Drug|Valproic acid|500 to 750 mg, taken orally twice daily
511003|NCT00312533|Drug|Hylan F- 20|
511004|NCT00312520|Drug|prednisolone|
511005|NCT00312520|Drug|methylprednisolone|
511006|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by lavage)|
511007|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by bolus)|
511008|NCT00312494|Drug|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
511009|NCT00312494|Drug|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
511010|NCT00312494|Drug|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
511011|NCT00312481|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
511014|NCT00312455|Drug|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
511015|NCT00312455|Drug|Placebo|5 capsules/day
511016|NCT00312442|Drug|Treatment with WST09 Vascular Photodynamic therapy|
511017|NCT00312429|Procedure|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
511018|NCT00312416|Drug|Clonidin|
511019|NCT00312416|Drug|Brimonidine|
511020|NCT00312403|Procedure|Blood Sample|A single venous blood sample will be taken (10 ml).
511021|NCT00312390|Procedure|Flicker|
511022|NCT00312390|Procedure|Retinal Vessel Diameter|
511023|NCT00312390|Procedure|Retinal Blood Flow|
511024|NCT00312377|Drug|Docetaxel|infusion
511025|NCT00312377|Drug|Vandetanib|oral
511026|NCT00312364|Drug|MRE0094|
511027|NCT00312351|Drug|Pegaptanib sodium|
511028|NCT00312338|Drug|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
511029|NCT00312325|Drug|Prednisolone|
511030|NCT00312312|Biological|Specific immunotherapy|
511031|NCT00312299|Device|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
511032|NCT00312299|Device|Round edge PMMA IOL|Round edge PMMA IOL
511033|NCT00312299|Device|Acrysof IOL|Acrysof IOL
511034|NCT00312299|Device|square Edge PMMA IOL|Square edge PMMA intra ocular lens
511035|NCT00312299|Device|Square Edge PMMA IOL|Square Edge PMMA IOL lens
511036|NCT00312286|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
511037|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
511038|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
511039|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
511040|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
511041|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
511042|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
511043|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
511044|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
511045|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
511046|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
511047|NCT00312273|Drug|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
511048|NCT00312260|Drug|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
511049|NCT00312260|Drug|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
511050|NCT00312234|Behavioral|Aerobic exercise|
511051|NCT00312234|Behavioral|Qigong exercise|
511052|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
511053|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
511054|NCT00312221|Drug|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
511055|NCT00312208|Drug|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
511056|NCT00312208|Drug|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
511057|NCT00312195|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
511058|NCT00312195|Drug|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
511059|NCT00312182|Drug|Nelfinavir|
511060|NCT00312156|Drug|insulin detemir|
511061|NCT00312156|Drug|insulin NPH|
511062|NCT00312156|Drug|insulin aspart|
511063|NCT00312143|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
511064|NCT00312130|Drug|Vildagliptin|
511065|NCT00312117|Drug|Sodium bicarbonate|
511066|NCT00312104|Drug|insulin detemir|
511067|NCT00312104|Drug|insulin glargine|
511068|NCT00312104|Drug|insulin aspart|
511069|NCT00312091|Drug|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
511070|NCT00312091|Drug|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
511071|NCT00312091|Drug|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
511072|NCT00312091|Drug|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
511073|NCT00312078|Dietary Supplement|Yogurt Supplementation|
511074|NCT00312065|Device|Application of reflective heat shield to thermistor probe|
511075|NCT00312052|Drug|E5555|50 mg or 100 mg E5555 tablets
511076|NCT00312052|Drug|Placebo|50 mg and/or 100 mg placebo tablets
511077|NCT00312039|Drug|elvucitabine|Elvucitabine 10 mg QD for 14days
511078|NCT00312039|Drug|Lamivudine|Lamivudine 300 mg QD for 14 days
511079|NCT00312026|Drug|efalizumab|
511080|NCT00312013|Drug|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
511081|NCT00312000|Drug|capecitabine-irinotecan|"st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
511082|NCT00312000|Drug|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
511083|NCT00311987|Drug|3,5-Diiodothyropropionic acid (DITPA) therapy|
511084|NCT00311974|Drug|Dihydralazine|
511085|NCT00311961|Drug|Intravenous prednisolone|
511086|NCT00311961|Drug|Oral prednisolone|
511087|NCT00311948|Behavioral|Telephone counseling + interactive website = more abstinence|
511088|NCT00311948|Behavioral|Behavioral: interactive website|
511089|NCT00311935|Procedure|method of hernia repair|
511090|NCT00311922|Behavioral|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
511091|NCT00311922|Behavioral|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
511092|NCT00311909|Device|Thalamic deep brain stimulation|
511093|NCT00311896|Drug|Bemiparin|
511094|NCT00311896|Drug|Placebo|
511095|NCT00311883|Drug|hydroxychloroquine|
511096|NCT00311870|Drug|nisoldipine|
511097|NCT00311870|Drug|lisinopril|
511098|NCT00311857|Drug|Cetuximab|
511099|NCT00311857|Drug|Temozolomide|
511100|NCT00311857|Procedure|Radiation therapy|
511101|NCT00311844|Drug|desloratadine|
511102|NCT00311831|Behavioral|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
511103|NCT00311831|Behavioral|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
511104|NCT00311818|Drug|Insulin glargine|
511105|NCT00311805|Biological|Autologous Stem Cells (CD34+)|Intramuscular Injections
511106|NCT00311792|Behavioral|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
511107|NCT00311792|Behavioral|Traditional clinical education|
511108|NCT00311779|Drug|Spinosad Creme Rinse|
511109|NCT00311766|Drug|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
511110|NCT00311766|Drug|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
511111|NCT00311753|Drug|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
511112|NCT00311753|Drug|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
511113|NCT00311740|Drug|Valsartan|
511114|NCT00311740|Drug|Hydrochlorothiazide|
511115|NCT00311727|Biological|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
511116|NCT00311714|Drug|CS-8958 formulated as dry powder|
511117|NCT00311714|Other|Placebo|
511118|NCT00311688|Drug|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
511119|NCT00311675|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
511120|NCT00311662|Drug|Tonabersat|Tablet 40mg daily for 12 weeks
511121|NCT00311662|Drug|Placebo|Tablet once daily for 12 weeks
511122|NCT00311649|Biological|Inactivated Influenza A Vaccine A/H5N1|
511123|NCT00311636|Drug|cyclophosphamide|
511124|NCT00311636|Drug|docetaxel|
511125|NCT00311636|Drug|doxorubicin hydrochloride|
511126|NCT00311636|Drug|epirubicin hydrochloride|
511127|NCT00311636|Drug|fluorouracil|
511128|NCT00311636|Drug|methotrexate|
511129|NCT00311636|Drug|paclitaxel|
511130|NCT00311636|Drug|triptorelin|
511131|NCT00311636|Procedure|adjuvant therapy|
511132|NCT00311623|Drug|Rapamycin 3mg|Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
511133|NCT00311623|Drug|Rapamycin 6mg|Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
511134|NCT00311623|Procedure|Radical prostatectomy|Radical prostatectomy performed on Day 15
511135|NCT00311610|Drug|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
511136|NCT00311597|Procedure|Radiosurgery|single fractionated radiation therapy
511137|NCT00311584|Drug|irinotecan hydrochloride|Given IV
511138|NCT00311584|Drug|temozolomide|Given IV
511139|NCT00311571|Drug|Ethidronate|
511140|NCT00311571|Behavioral|Physical training|
511141|NCT00311558|Biological|recombinant interferon alfa-2b|SSG x 5 week
511142|NCT00311558|Drug|sodium stibogluconate|SSG & IFN
511143|NCT00311558|Drug|SSG & interferon|1 arm study with SSG & interferon
511144|NCT00311545|Biological|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
511145|NCT00311519|Drug|Hylenex|
511146|NCT00311493|Biological|Tick-Borne Encephalitis vaccine|
511147|NCT00311480|Biological|Influenza vaccine surface antigen adjuvanted with MF59|
511148|NCT00311467|Drug|Capecitabine, Interferon, Interleukin|"Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.~Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.~Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.~Group B~Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.~Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
511149|NCT00311454|Drug|T.R.U.E.Test|
511150|NCT00311441|Biological|Tick-Borne Encephalitis vaccine|
511151|NCT00311428|Biological|Influenza|
511272|NCT00310466|Biological|Placebo|once daily intake of sublingual drops
511152|NCT00311415|Biological|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.~Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
511153|NCT00311402|Drug|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
511154|NCT00311402|Other|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
511155|NCT00311389|Drug|Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
511156|NCT00311389|Drug|Latanoprost 0.005%/Timolol 0.005% ophthalmic solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
511157|NCT00311376|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
511158|NCT00311376|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
511159|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
511160|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
511161|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
511162|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
511163|NCT00311363|Drug|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
511164|NCT00311350|Drug|MOA-728|
511165|NCT00311337|Drug|bortezomib|
511166|NCT00311324|Behavioral|Special Intervention|
511167|NCT00311324|Behavioral|Delayed Intervention|
511168|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
511169|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
511170|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
511171|NCT00311311|Drug|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.~On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
511172|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
511173|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
511174|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
511213|NCT00310856|Biological|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
511273|NCT00310453|Biological|ALK Grass tablet|
511805|NCT00306514|Biological|CYT004-MelQbG10|
511175|NCT00311298|Dietary Supplement|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
511176|NCT00311298|Dietary Supplement|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
511177|NCT00311285|Device|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
511178|NCT00311272|Biological|MelCancerVac|
511179|NCT00311259|Drug|Melatonin (drug)|
511180|NCT00311259|Drug|Laktose|
511181|NCT00311246|Drug|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcuetaneous injection for a total of 45 weeks.
511182|NCT00311220|Drug|tuberculin for skin test|
511183|NCT00311194|Behavioral|6 months readmission rate to hospital|
511184|NCT00311181|Device|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
511185|NCT00311168|Procedure|VIP On vs VIP Off|
511186|NCT00311155|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
511187|NCT00311129|Drug|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
511188|NCT00311129|Drug|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
511189|NCT00311116|Drug|Vitamin E|
511190|NCT00311103|Procedure|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
511191|NCT00311090|Drug|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection"
511192|NCT00311090|Drug|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg~Subcutaneous injection"
511193|NCT00311090|Drug|Avidin|"100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes"
511194|NCT00311090|Drug|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution~Intravenous infusion for 30 minutes"
511195|NCT00311077|Drug|Insulin Glulisine|
511196|NCT00311064|Behavioral|physical activity|
511197|NCT00311051|Drug|ramatroban|
511198|NCT00311051|Drug|montelukast|
511199|NCT00311038|Drug|ONO-1101|
511200|NCT00311025|Procedure|intensive endurance, strength and balance exercises|
511201|NCT00311012|Drug|Aliskiren|
511202|NCT00310999|Device|Shikani Optical Stylet|
511203|NCT00310986|Behavioral|Breathing Meditation|
511204|NCT00310973|Behavioral|Social Network Intervention|
511205|NCT00310934|Drug|methadone|
511206|NCT00310934|Drug|buprenorphine / methadone sequence|
511207|NCT00310934|Behavioral|Relapse prevention|
511208|NCT00310934|Behavioral|Contingency management|
511209|NCT00310921|Drug|Misoprostol|
511210|NCT00310908|Drug|Tramadol Hcl|Active Comparator
511211|NCT00310895|Drug|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
511212|NCT00310869|Behavioral|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
511214|NCT00310856|Biological|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
511216|NCT00310856|Biological|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
511217|NCT00310856|Biological|MMR|
511218|NCT00310856|Biological|Varicella|
511219|NCT00310843|Drug|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
511220|NCT00310830|Drug|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
511221|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
511222|NCT00310817|Biological|MenACWY polysaccharide vaccine|
511223|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
511224|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
511225|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
511226|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
511227|NCT00310804|Biological|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
511228|NCT00310791|Drug|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
511229|NCT00310791|Other|Placebo (Sugar Pill)|Placebo (sugar pill)
511230|NCT00310791|Drug|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
511231|NCT00310778|Drug|high sodium diet|high sodium diet
511232|NCT00310778|Drug|low sodium diet|low sodium diet
511233|NCT00310778|Drug|ramipril 10 mg|ramipril 10 mg
511234|NCT00310778|Drug|valsartan 160 mg|valsartan 160 mg
511235|NCT00310778|Drug|candesartan 8 mg|candesartan 8 mg
511236|NCT00310778|Drug|atenolol 50 mg|atenolol 50 mg
511237|NCT00310765|Drug|Pregabalin|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days
511238|NCT00310765|Drug|Pregabalin|75 mg po BID
511239|NCT00310752|Device|DermaStream(tm) application and Streaming of Saline|
511240|NCT00310726|Other|abrupt weaning at 4 months|abrupt weaning at 4 months
511241|NCT00310726|Other|Continued exclusive breastfeeding|Continued exclusive breastfeeding
511242|NCT00310713|Biological|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
511243|NCT00310700|Biological|Meningococcal C conjugate vaccine|
511244|NCT00310687|Procedure|BLOOD DRAW|
511245|NCT00310674|Biological|Meningococcal C Conjugate Vaccine|
511246|NCT00310661|Drug|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
511247|NCT00310661|Other|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
511248|NCT00310648|Biological|Influenza vaccine|
511249|NCT00310635|Biological|Meningococcal C conjugate vaccine|
511250|NCT00310622|Device|HyperQ Signal recording|
511251|NCT00310609|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
511252|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
511253|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
511254|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
511255|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
511256|NCT00310596|Drug|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
511257|NCT00310596|Drug|Placebo|0,9% saline at 0,6mL/kg at bolus rate
511258|NCT00310583|Drug|Pregabalin|
511259|NCT00310570|Device|Circumferential thermoplastic thimble splint|
511260|NCT00310570|Device|"dorsal aluminium foam Mexican Hat splint"|
511261|NCT00310570|Device|stack splint (control)|
511262|NCT00310557|Drug|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
511263|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
511264|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
511265|NCT00310531|Drug|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
511266|NCT00310531|Drug|Raloxifene|Raloxifene tbl. (60 mg/day)
511267|NCT00310518|Drug|ARQ 501|
511268|NCT00310505|Drug|Amphotericin B deoxycholate given as daily administration|
511269|NCT00310492|Biological|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
511270|NCT00310479|Device|Magnetic Resonance Spectroscopy (3Tesla)|
511271|NCT00310466|Biological|Sublingual immunotherapy|once daily intake of sublingual drops
511274|NCT00310440|Device|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
511275|NCT00310440|Other|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
511276|NCT00310427|Drug|LY686017|50 mg administered orally on a daily basis
511277|NCT00310427|Drug|Placebo|Administered on a daily basis
511278|NCT00310401|Drug|Albuterol|5 mg nebulized q4h
511279|NCT00310401|Drug|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
511280|NCT00310388|Drug|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
511281|NCT00310375|Drug|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
511282|NCT00310362|Behavioral|Use of IVR system to improve adherene to GI appointments and prep procedures|Interactive voice response system calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
511283|NCT00310349|Biological|23 valent pneumococcal polysaccharide vaccine|
511284|NCT00310336|Drug|S-adenosyl-L-methionine|
511285|NCT00310336|Drug|betaine|
511286|NCT00310336|Drug|pegylated interferon alpha2b|
511287|NCT00310336|Drug|ribavirin|
511288|NCT00310323|Drug|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
511289|NCT00310323|Drug|Caffeine|Administered as 4 ounces of Coca-Cola
511290|NCT00310310|Behavioral|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
511291|NCT00310310|Behavioral|Usual care|Usual sleep apnea and cpap care
511292|NCT00310297|Drug|Insulin Glulisine|
511293|NCT00310284|Behavioral|Computerized delivery of cognitive-behavioral treatment of insomnia|
511294|NCT00310284|Behavioral|Self-help manual to improve insomnia symptoms|
511295|NCT00310271|Biological|pPJV7630 with pPJV2012 administered by PMED|
511296|NCT00310258|Behavioral|Drug use prevention intervention|
511297|NCT00310245|Procedure|STI (structured Treatment Interruption)|
511298|NCT00310232|Drug|Epoetin Alfa|
511299|NCT00310219|Procedure|computed tomography|
511300|NCT00310219|Procedure|positron emission tomography|
511301|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
511302|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
511303|NCT00310180|Drug|Anastrozole|Given PO
511304|NCT00310180|Drug|Exemestane|Given PO
511305|NCT00310180|Other|Laboratory Biomarker Analysis|Correlative studies
511306|NCT00310180|Drug|Letrozole|Given PO
511307|NCT00310180|Other|Quality-of-Life Assessment|Ancillary studies
511308|NCT00310180|Radiation|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
511309|NCT00310180|Drug|Tamoxifen Citrate|Given PO
511310|NCT00310167|Radiation|radiation therapy|
511311|NCT00310154|Drug|docetaxel|
511312|NCT00310154|Drug|gefitinib|
511313|NCT00310154|Other|laboratory biomarker analysis|
511314|NCT00310154|Radiation|radiation therapy|
511315|NCT00310141|Behavioral|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
511316|NCT00310141|Other|Counseling intervention|In-person counseling (5 sessions)
511317|NCT00310141|Drug|Nicotine patch|6-week supply of the nicotine patch
511318|NCT00310128|Drug|cisplatin|
511319|NCT00310128|Drug|cytarabine|
511320|NCT00310128|Drug|etoposide|
511321|NCT00310128|Drug|methylprednisolone|
511322|NCT00310128|Drug|rituximab|
511323|NCT00310128|Drug|yttrium Y 90 ibritumomab tiuxetan|
511324|NCT00310128|Procedure|antibody therapy|
511325|NCT00310128|Procedure|biological therapy|
511326|NCT00310128|Procedure|chemotherapy|
511327|NCT00310128|Procedure|monoclonal antibody therapy|
511328|NCT00310128|Procedure|radiation therapy|
511329|NCT00310128|Procedure|radioimmunotherapy|
511330|NCT00310128|Procedure|radioisotope therapy|
511331|NCT00310115|Behavioral|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
511332|NCT00310115|Behavioral|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
511333|NCT00310115|Behavioral|Counseling Intervention|2 in-person counseling sessions
511334|NCT00310089|Biological|filgrastim|
511335|NCT00310089|Biological|pegfilgrastim|
511336|NCT00310089|Drug|cediranib maleate|
511337|NCT00310089|Drug|cyclophosphamide|
511338|NCT00310089|Drug|docetaxel|
511339|NCT00310089|Drug|doxorubicin hydrochloride|
511340|NCT00310089|Other|laboratory biomarker analysis|
511341|NCT00310089|Procedure|conventional surgery|
511342|NCT00310089|Procedure|neoadjuvant therapy|
511343|NCT00310076|Drug|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
511344|NCT00310076|Procedure|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
511345|NCT00310063|Procedure|acupressure therapy|Acupressure wristband
511346|NCT00310063|Procedure|sham intervention|Sham wristband
511417|NCT00309660|Drug|Rosiglitazone|
511347|NCT00310050|Drug|pemetrexed disodium|500 milligrams per meter squared day will be given during weeks 1, 3 and 5 of the radiation (3 total doses of Pemetrexed during the radiation therapy).
511348|NCT00310050|Device|Radiotherapy|During the chemoradiation, the radiotherapy will be administered in 1.8 Gy/fractions after completion of the Pemetrexed infusion, and continue daily (Monday through Friday) for 5 1/2 weeks for a total delivered dose of 50.4 Gy (Total of 28 radiation treatments).
511349|NCT00310037|Drug|bortezomib|Given IV
511350|NCT00310024|Drug|bortezomib|Given IV
511351|NCT00310024|Drug|vorinostat|Given orally
511352|NCT00310024|Other|laboratory biomarker analysis|Correlative studies
511353|NCT00310024|Other|pharmacological study|Correlative studies
511354|NCT00310011|Drug|cisplatin|
511355|NCT00310011|Drug|gemcitabine hydrochloride|
511356|NCT00310011|Drug|paclitaxel|
511357|NCT00310011|Procedure|conventional surgery|
511358|NCT00309998|Biological|bevacizumab|
511359|NCT00309998|Drug|vinorelbine tartrate|
511360|NCT00309985|Drug|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
511361|NCT00309985|Drug|docetaxel|Given IV
511362|NCT00309972|Drug|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
511363|NCT00309972|Drug|Experimental arm (CON):|concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
511364|NCT00309959|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
511365|NCT00309959|Other|Laboratory Biomarker Analysis|Correlative studies
511366|NCT00309946|Drug|cediranib maleate|Given orally
511367|NCT00309933|Procedure|cognitive assessment|
511368|NCT00309933|Procedure|psychosocial assessment and care|
511369|NCT00309933|Procedure|quality-of-life assessment|
511370|NCT00309920|Biological|darbepoetin alfa|
511371|NCT00309920|Drug|cyclophosphamide|
511372|NCT00309920|Drug|docetaxel|
511373|NCT00309920|Drug|doxorubicin hydrochloride|
511374|NCT00309920|Drug|epirubicin hydrochloride|
511375|NCT00309920|Drug|fluorouracil|
511376|NCT00309907|Biological|etanercept|Given IV and subcutaneously
511377|NCT00309907|Drug|methylprednisolone|Given IV and orally
511378|NCT00309894|Biological|sargramostim|
511379|NCT00309894|Drug|ketoconazole|
511380|NCT00309894|Drug|therapeutic hydrocortisone|
511381|NCT00309881|Biological|rituximab|
511382|NCT00309881|Drug|cyclophosphamide|
511383|NCT00309881|Drug|doxorubicin hydrochloride|
511384|NCT00309881|Drug|prednisone|
511385|NCT00309881|Drug|vincristine sulfate|
511386|NCT00309868|Drug|neseritide|
511387|NCT00309855|Drug|Placebo|im and orally
511388|NCT00309855|Drug|Testosterone|injections
511389|NCT00309855|Drug|Anastrazole|orally x 21 days
511390|NCT00309855|Drug|Dutasteride|orally x 21 days
511391|NCT00309842|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days.
511392|NCT00309842|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW > 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
511393|NCT00309842|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of > 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
511394|NCT00309842|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
511395|NCT00309842|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).~Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
511396|NCT00309842|Procedure|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
511397|NCT00309842|Radiation|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
511398|NCT00309816|Drug|sildenafil|
511399|NCT00309803|Device|FiberNet Embolic Protection Device|
511400|NCT00309790|Drug|sildenafil|
511401|NCT00309777|Drug|Pitavastatin|Pitavastatin once daily
511402|NCT00309777|Drug|Simvastatin|Simvastatin once daily
511403|NCT00309764|Behavioral|Telemedicine|
511404|NCT00309751|Drug|Pitavastatin|Pitavastatin 4 mg QD
511405|NCT00309751|Drug|Atorvastatin|Atorvastatin 20 mg
511406|NCT00309738|Drug|pitavastatin|
511407|NCT00309738|Drug|simvastatin|
511408|NCT00309725|Drug|galantamine|
511409|NCT00309712|Drug|fenofibrate 160 mg and placebo|
511410|NCT00309712|Drug|simvastatin 20 mg and placebo|
511411|NCT00309712|Drug|fenofibrate 160 mg and simvastatin 20 mg|
511412|NCT00309699|Drug|Placebo|Daily for 3 weeks
511413|NCT00309699|Drug|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
511414|NCT00309699|Drug|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
511415|NCT00309686|Drug|Paliperidone ER|
511416|NCT00309673|Drug|lidocaine / Prilocaine|
511418|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
511419|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
511420|NCT00309634|Biological|4 adjuvanted pandemic influenza candidate vaccines|
511421|NCT00309634|Biological|4 non-adjuvanted pandemic influenza candidate vaccines|
511422|NCT00309621|Drug|alitretinoin|
511423|NCT00309608|Drug|Linagliptin|Linagliptin medium dose tablet once daily
511424|NCT00309608|Drug|Linagliptin|Linagliptin high dose tablet once daily
511425|NCT00309608|Drug|Linagliptin|Linagliptin low dose tablet once daily
511426|NCT00309608|Drug|Placebo|Placebo tablets once daily
511427|NCT00309608|Drug|Glimepiride|Glimepiride tablets once daily
511428|NCT00309595|Device|stent|Cordis SMART™ Nitinol Stent System
511429|NCT00309595|Device|balloon|balloon angioplasty
511430|NCT00309569|Drug|Cyclophosphamide|
511431|NCT00309569|Drug|Methotrexate|
511432|NCT00309569|Drug|Fluorouracil|
511433|NCT00309569|Drug|Epirubicine|
511434|NCT00309556|Drug|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
511435|NCT00309556|Drug|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
511436|NCT00309556|Drug|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
511437|NCT00309556|Drug|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
511438|NCT00309543|Drug|Fluorouracil|
511439|NCT00309543|Drug|Leucovorin|
511440|NCT00309530|Drug|5-fluorouracil, levamisol, interferon|
511441|NCT00309517|Drug|Fluourouracil|
511442|NCT00309517|Drug|Leucovorin|
511443|NCT00309517|Drug|MAb 17-1A|
511444|NCT00309491|Drug|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
511445|NCT00309491|Drug|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~1st therapy week:125mg/-/125mg Aminoglutethimide daily~2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
511446|NCT00309478|Drug|cyclophosphamide|
511447|NCT00309478|Drug|Methotrexate|
511448|NCT00309478|Drug|Fluorouracil|
511449|NCT00309478|Drug|Goserelin|
511450|NCT00309478|Drug|Tamoxifen|
511451|NCT00309465|Drug|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
511452|NCT00309465|Other|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
511453|NCT00309465|Drug|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
511454|NCT00309452|Behavioral|Cognitive Behavioral Group Therapy|once per week
511455|NCT00309452|Behavioral|Cognitive remediation|as needed
511456|NCT00309452|Drug|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
511457|NCT00309452|Behavioral|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
511458|NCT00309452|Behavioral|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
511459|NCT00309452|Other|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
511460|NCT00309439|Procedure|ALA-rich diet|
511461|NCT00309413|Drug|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
511462|NCT00309413|Drug|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
511463|NCT00309387|Dietary Supplement|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
511464|NCT00309387|Other|Placebo|placebo tablets manufactured to mimic Centrum tablets.
511465|NCT00309374|Drug|LPS 2ng/kg intravenous bolus|
511466|NCT00309374|Drug|Simvastatin 80mg; administered daily p.o. over 5 days|
511467|NCT00309374|Drug|Rosuvastatin 40mg; administered daily p.o. over 5 days|
511468|NCT00309361|Drug|Phentolamine Mesylate (NV-101)|
511469|NCT00309348|Other|Weekly measurement of graft flow|
511470|NCT00309335|Drug|Phentolamine Mesylate (NV-101)|
511471|NCT00309322|Drug|Phentolamine Mesylate (NV-101)|
511472|NCT00309309|Drug|Rosiglitazone|
511473|NCT00309296|Behavioral|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
511474|NCT00309283|Drug|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
511475|NCT00309283|Other|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
511476|NCT00309270|Drug|Campath-1H|
511477|NCT00309257|Drug|ACE I, ATA II and Statins|
511575|NCT00308373|Drug|Metformin vs Thiazolidinedione (Pioglitazone)|
511576|NCT00308360|Drug|Risperidone, divalproex|
511577|NCT00308347|Drug|MK0954, losartan / Duration of Treatment: mean 3.4 years|
511578|NCT00308347|Drug|Placebo / Duration of Treatment: mean 3.4 years|
511478|NCT00309257|Drug|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
511479|NCT00309244|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
511480|NCT00309244|Drug|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
511481|NCT00309231|Procedure|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
511482|NCT00309218|Drug|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
511483|NCT00309205|Drug|dapivirine (TMC120) vaginal gel|
511484|NCT00309192|Drug|Triamcinolone Acetonide 4 mg intravitreal injection|
511485|NCT00309192|Procedure|ETDRS grid laser technique|
511486|NCT00309179|Drug|E7820 plus cetuximab|Escalating doses from 40 mg/m^2 irinotecan plus E7820 in combination with cetuximab.
511487|NCT00309166|Biological|Cervarix vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule.
511488|NCT00309166|Biological|Engerix-B vaccine|All subjects received an intramuscular injection into the deltoid of the non-dominant arm according to a 0, 1 and 6-month schedule
511489|NCT00309140|Drug|enzastaurin|500 mg, oral, daily, six 42 day cycles
511490|NCT00309127|Behavioral|Multidisciplinary team care|
511491|NCT00309114|Procedure|bacterial interference|
511492|NCT00309101|Drug|tacrolimus|Oral
511493|NCT00309088|Drug|tacrolimus|oral
511494|NCT00309088|Drug|placebo|oral
511495|NCT00309075|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
511496|NCT00309062|Biological|Recombinant birch pollen|
511497|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
511498|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
511499|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
511500|NCT00309036|Biological|Recombinant grass pollen|
511501|NCT00309023|Drug|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
511502|NCT00308997|Device|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
511503|NCT00308997|Device|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
511504|NCT00308971|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
511505|NCT00308971|Drug|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
511506|NCT00308971|Drug|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
511507|NCT00308971|Drug|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
511508|NCT00308958|Device|High frequency chest wall oscillator|
511509|NCT00308945|Drug|travoprost 0.004% (drug)|local drop application
511510|NCT00308945|Drug|latanoprost 0.005% (drug)|local drop application
511511|NCT00308932|Drug|HFA FP MDI|
511512|NCT00308919|Drug|WST09|Treatment with WST09 Vascular Photodynamic therapy
511513|NCT00308906|Drug|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
511514|NCT00308893|Genetic|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
511515|NCT00308880|Drug|Transamin|
511516|NCT00308867|Procedure|Photodynamic Therapy|
511517|NCT00308867|Procedure|Cryosurgery|
511518|NCT00308854|Procedure|Photodynamic Therapy|
511519|NCT00308841|Drug|Lidocaine (drug)|
511520|NCT00308815|Device|Automatic CPR machine|
511521|NCT00308802|Procedure|Kidney transplantation|Participants in this study will have had a kidney transplant
511522|NCT00308789|Procedure|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
511523|NCT00308789|Procedure|CPAP|Continuous positive airway pressure
511524|NCT00308776|Procedure|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
511525|NCT00308776|Procedure|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
511579|NCT00308334|Drug|Domperidone|10 mg po TID X 14 days
511580|NCT00308334|Drug|Placebo- Sugar pill|placebo po TID x 14 days
511698|NCT00307463|Procedure|antihypertensive drugs administration|continue antihypertensive medications
532271|NCT00131027|Drug|Dexamethasone|
511526|NCT00308763|Drug|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.~If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
511527|NCT00308763|Drug|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
511528|NCT00308750|Drug|enzastaurin|1125-1200 mg loading dose then 500 mg, oral, daily, until disease progression
511529|NCT00308750|Drug|pemetrexed|500 mg/m2, IV, q 21 days, six 21 day cycles or progressive disease
511530|NCT00308750|Drug|docetaxel|75 mg/m2, IV, q 21 days, six 21 day cycles or progressive disease
511531|NCT00308750|Drug|carboplatin|AUC 6, IV, q 21 days, six 21 day cycles or progressive disease
511532|NCT00308737|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
511533|NCT00308737|Drug|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
511534|NCT00308724|Behavioral|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
511535|NCT00308724|Behavioral|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
511536|NCT00308711|Drug|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
511537|NCT00308711|Drug|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
511538|NCT00308711|Drug|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
511539|NCT00308685|Drug|Albuterol 90mcg|
511540|NCT00308685|Drug|Placebo|Placebo
511541|NCT00308659|Procedure|FOB protected distal microbiological samplings|
511542|NCT00308620|Drug|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
511543|NCT00308620|Drug|Placebo|Placebo once daily for 8 weeks
511544|NCT00308607|Drug|Bevacizumab (Avastin)|
511545|NCT00308607|Drug|dacarbazine|
511546|NCT00308607|Drug|interferon-alfa-2a (Roferon-A)|
511547|NCT00308594|Drug|Dexamethasone|
511548|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
511549|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
511550|NCT00308581|Other|Placebo|placebo administered 4-weekly in Active 1
511551|NCT00308568|Behavioral|Mailed educational brochure|
511552|NCT00308555|Drug|Cannabis|
511553|NCT00308542|Drug|dexamethasone|
511554|NCT00308529|Drug|irinotecan|
511555|NCT00308529|Drug|carboplatin|
511556|NCT00308529|Drug|bevacizumab|
511557|NCT00308529|Procedure|Radiation Therapy|
511558|NCT00308516|Drug|5-Fluorouracil|"Combined Modality Treatment:~fluorouracil 225mg/m2 IV continuous infusion days 1-42~Systemic Treatment:~5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
511559|NCT00308516|Drug|Bevacizumab|"Combined Modality Treatment:~bevacizumab 5mg/kg IV infusion days 1, 15, and 29~Systemic Treatment:~bevacizumab 5 mg/kg days 1 and 15"
511560|NCT00308516|Procedure|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
511561|NCT00308516|Drug|Oxaliplatin|"Systemic Treatment:~oxaliplatin 85 mg/m2 days 1 and 15"
511562|NCT00308516|Drug|Leucovorin|"Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15"
511563|NCT00308503|Drug|eplivanserin (SR46349)|oral administration
511564|NCT00308503|Drug|placebo|oral administration
511565|NCT00308490|Drug|iron sucrose|
511566|NCT00308477|Drug|dexamethasone|
511567|NCT00308464|Drug|PHA-794428|
511568|NCT00308451|Drug|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
511569|NCT00308438|Drug|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
511570|NCT00308425|Drug|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
511571|NCT00308412|Biological|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
511572|NCT00308412|Biological|Placebo|Placebo for rHPIV3cp45 vaccine
511573|NCT00308399|Drug|Itopride|
511574|NCT00308386|Behavioral|Nurse Case Management intervention|Intervention is meeting with nurse case managers
533531|NCT00121355|Device|autocover needle|
511581|NCT00308321|Drug|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
511582|NCT00308321|Drug|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
511583|NCT00308308|Drug|Technosphere Insulin|Inhalation, 15U/30U
511584|NCT00308308|Drug|Active comparator|sc injectable insulin
511585|NCT00308295|Drug|Fish oil capsules|
511586|NCT00308295|Drug|matched placebo capsules|
511587|NCT00308282|Drug|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
511588|NCT00308282|Drug|Placebo|IV (in vein) in weeks 0, 3 and 6. Treatment duration: 6 weeks.
511589|NCT00308269|Drug|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
511590|NCT00308269|Drug|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
511591|NCT00308256|Behavioral|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
511592|NCT00308243|Drug|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
511593|NCT00308230|Procedure|Six minute walk test|
511594|NCT00308230|Behavioral|Minnesota Living with Heart Failure Questionnaire|
511595|NCT00308204|Drug|Raptiva (efalizumab)|
511596|NCT00308191|Drug|Formoterol Fumarate|
511597|NCT00308191|Drug|Tiotropium Bromide|
511598|NCT00308178|Drug|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
511599|NCT00308165|Procedure|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
511600|NCT00308165|Drug|Topotecan|chemotherapeutic drug for the treatment of brain tumors
511601|NCT00308152|Drug|Infusion of 1 litre of normal saline before colonoscopy|Prehydration with normal saline
511602|NCT00308139|Drug|exenatide, long acting release|
511603|NCT00308139|Drug|exenatide|
511604|NCT00308126|Drug|Hydroxyethyl Starch 130/0.4 (Voluven)|
511605|NCT00308113|Drug|Prednisone|Prednisone 0/75 mg/kg/day.
511606|NCT00308113|Dietary Supplement|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
511607|NCT00308100|Drug|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
511608|NCT00308100|Drug|5% Albumin|5% albumin, administered intra- and perioperatively
511609|NCT00308087|Drug|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
511610|NCT00308087|Drug|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
511611|NCT00308074|Drug|Aripiprazole|open-label, flexible-dosing
511612|NCT00308061|Biological|FMP1/AS02A|FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
511613|NCT00308061|Biological|Imovax Rabies Vaccine|Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, <150g of neomycin sulfate, and >2.5 IU of rabies antigen.
511614|NCT00308048|Drug|Pegylated Interferon alfa 2b and ribavirin|
511615|NCT00308022|Device|High Frequency Percussive Ventilation|
511616|NCT00308009|Procedure|Vaginal Repair for prolapse, TVT procedure|"TVT at the time of Vaginal Repair~TVT 3 months after Vaginal Repair"
511617|NCT00308009|Procedure|TVT and Prolapse surgery|"TVT at the time of Prolapse surgery~TVT 3 months after Prolapse Surgery"
511618|NCT00307996|Drug|Coenzyme Q10 (drug)|
511619|NCT00307970|Drug|HFA FP MDI|
511620|NCT00307970|Device|conventional chamber/mask; anti-static chamber/mask|
511621|NCT00307957|Device|Pillar Palatal Implants|
511622|NCT00307944|Drug|Pantoprazole|
511623|NCT00307931|Biological|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.~Treatment duration: 12 weeks."
511624|NCT00307918|Device|acupuncture|
511625|NCT00307905|Drug|Traumeel S|homeopathic remedy
511626|NCT00307905|Drug|Placebo remedy|identical size, shape and taste of treatment medication
511627|NCT00307892|Drug|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
511628|NCT00307892|Drug|Placebo|placebo remedy
511629|NCT00307879|Drug|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
511630|NCT00307879|Procedure|collection of mobilized peripheral blood stem cells|
511631|NCT00307879|Procedure|Intracoronary infusion of mobilized cells|
511632|NCT00307866|Procedure|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
511633|NCT00307853|Drug|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
511634|NCT00307853|Other|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
511695|NCT00307489|Drug|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
511696|NCT00307476|Device|Rusch Nasopharyngeal Airway|
511697|NCT00307463|Procedure|strict volume control policy|strict volume control by UF and dietary salt restriction
511635|NCT00307853|Other|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
511636|NCT00307840|Drug|paricalcitol|
511637|NCT00307827|Drug|Visilizumab|Visilizumab administered intravenously once per day for two days
511638|NCT00307814|Drug|Epoetin Alfa|
511639|NCT00307801|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
511640|NCT00307801|Drug|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
511641|NCT00307788|Procedure|acupuncture|acupuncture
511642|NCT00307775|Drug|oestradiol|
511643|NCT00307762|Behavioral|intensified gait trainer|Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
511644|NCT00307749|Drug|Placebo|once daily for 24 weeks
511645|NCT00307749|Drug|MCC-257|20mg, once daily for 24 weeks
511646|NCT00307749|Drug|MCC-257|40mg, once daily for 24 weeks
511647|NCT00307749|Drug|MCC-257|80mg, once daily for 24 weeks
511648|NCT00307736|Drug|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
511649|NCT00307736|Drug|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
511650|NCT00307736|Drug|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
511651|NCT00307736|Procedure|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
511652|NCT00307723|Drug|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
511653|NCT00307723|Drug|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
511654|NCT00307723|Drug|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
511655|NCT00307723|Drug|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
511656|NCT00307723|Procedure|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
511657|NCT00307710|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
511658|NCT00307697|Procedure|receipt of copy of psychiatic assessment letter|
511659|NCT00307684|Drug|double blind placebo|matching placebo tablets once daily for 4 weeks
511660|NCT00307684|Drug|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
511661|NCT00307684|Drug|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
511662|NCT00307671|Drug|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
511663|NCT00307671|Drug|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
511664|NCT00307671|Drug|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
511665|NCT00307658|Drug|Intravenous immunoglobulins (human immunoglobulins G)|
511666|NCT00307645|Drug|Cyclophosphamide|
511667|NCT00307645|Drug|Mycophenolate mofetil|
511668|NCT00307645|Drug|Azathioprine|
511669|NCT00307645|Drug|Prednisone (and methylprednisolone)|
511670|NCT00307632|Drug|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
511671|NCT00307619|Drug|topiramate|
511672|NCT00307606|Drug|Solu-medrol 125 mg|
511673|NCT00307593|Drug|Infliximab|Infliximab
511674|NCT00307593|Drug|Rituximab|Rituximab
511675|NCT00307580|Drug|Cathflo Activase (Alteplase)|
511676|NCT00307567|Biological|Pneumococcal (vaccine)|
511677|NCT00307554|Biological|Pneumococcal (vaccine)|
511678|NCT00307541|Biological|Pneumococcal (vaccine)|
511679|NCT00307528|Biological|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
511680|NCT00307528|Biological|Pneumovax 23™|Single dose intramuscular injection.
511681|NCT00307515|Drug|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
511682|NCT00307515|Device|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
511683|NCT00307502|Drug|Nevirapine|tablets 200 mg, 400 mg/day
511684|NCT00307502|Drug|Efavirenz|tablets 600 mg, 600 mg/day
511685|NCT00307502|Drug|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
511686|NCT00307502|Drug|Nelfinavir|tablets 250 mg, 2500 mg/day
511687|NCT00307502|Drug|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day~Ritonavir: tablets 100 mg, 200 mg/day"
511688|NCT00307502|Drug|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
511689|NCT00307502|Drug|Atazanavir|capsules 200 mg, 400 mg/day
511690|NCT00307502|Drug|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
511691|NCT00307502|Drug|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
511692|NCT00307502|Drug|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day~Ritonavir: capsules 100 mg, 400 mg/day"
511693|NCT00307502|Drug|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day~Ritonavir: capsules 100 mg, 200 mg/day"
511694|NCT00307489|Drug|tenofovir DF|300 mg tablet, once daily (QD)
533604|NCT00120861|Drug|valopicitabine|
511699|NCT00307450|Drug|Levetiracetam|up to 200 mg per day in two dosages per day.
511700|NCT00307437|Drug|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
511701|NCT00307437|Drug|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
511702|NCT00307437|Drug|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
511703|NCT00307424|Device|AutoCPAP|
511704|NCT00307424|Device|FixCPAP|
511705|NCT00307411|Drug|Growth hormone|
511706|NCT00307398|Drug|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
511707|NCT00307398|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
511708|NCT00307333|Device|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
511709|NCT00307320|Behavioral|Relaxation Training|Relaxation techniques training
511710|NCT00307307|Drug|Niacin/simvastatin compared to simvastatin alone at 2 doses|
511711|NCT00307294|Drug|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
511712|NCT00307294|Drug|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
511713|NCT00307255|Drug|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
511714|NCT00307255|Drug|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
511715|NCT00307242|Drug|Adefovir Dipivoxil|
511716|NCT00307229|Biological|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
511717|NCT00307216|Behavioral|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
511718|NCT00307216|Behavioral|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
511719|NCT00307203|Drug|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
511720|NCT00307203|Behavioral|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
511721|NCT00307203|Drug|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
511722|NCT00307177|Biological|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
511723|NCT00307177|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
511724|NCT00307164|Drug|NucleomaxX|36 g sachet taken orally three times daily
511725|NCT00307164|Drug|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
511726|NCT00307151|Drug|Lamivudine|4 mg/kg twice daily
511727|NCT00307151|Drug|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
511728|NCT00307151|Drug|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m^2/dose to max 200 mg twice daily
511729|NCT00307151|Drug|Zidovudine|180 mg/m^2 twice daily
511730|NCT00307138|Drug|hetastarch|
511731|NCT00307125|Drug|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma~Standard immunosuppression is site-specific."
511732|NCT00307125|Drug|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific."
511733|NCT00307099|Drug|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
511734|NCT00307099|Drug|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
511735|NCT00307086|Drug|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
534217|NCT00116701|Drug|Aranesp®|
511736|NCT00307086|Drug|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
511737|NCT00307086|Procedure|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
511738|NCT00307073|Device|Implantable Pulse Generator|
511739|NCT00307060|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
511740|NCT00307060|Drug|losartan / Duration of Treatment: 6 weeks|
511741|NCT00307047|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
511742|NCT00307047|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
511743|NCT00307034|Biological|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
511744|NCT00307034|Biological|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
511745|NCT00307034|Biological|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
511746|NCT00307021|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
511747|NCT00307008|Biological|Pneumovax 23™|Single dose intramuscular injection
511748|NCT00306995|Biological|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
511749|NCT00306995|Biological|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
511750|NCT00306995|Biological|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
511751|NCT00306995|Biological|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
511752|NCT00306995|Biological|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
511753|NCT00306995|Biological|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
511754|NCT00306995|Biological|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
511755|NCT00306982|Biological|Fluarix|
511756|NCT00306969|Drug|bexarotene|
511757|NCT00306969|Device|photopheresis|
511758|NCT00306956|Behavioral|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
511759|NCT00306943|Biological|Influsplit SSW®|
511760|NCT00306930|Device|Acetabular cup|Acetabular cup replacement
511761|NCT00306917|Device|non-coated femoral hip stem|total hip replacement
511762|NCT00306917|Device|coated femoral hip stem|total hip replacement
511763|NCT00306904|Drug|bevasiranib|
511764|NCT00306891|Drug|Cediranib|45 mg oral dose
511765|NCT00306891|Drug|Cediranib 30 - 90 mg|oral tablet dose escalation
511766|NCT00306878|Drug|Abatacept|
511767|NCT00306852|Procedure|Baerveldt implant|Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
511768|NCT00306852|Procedure|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant
511769|NCT00306839|Procedure|standardized Lichtenstein technique|
511770|NCT00306826|Drug|pioglitazone|
511771|NCT00306826|Drug|simvastatin|
511772|NCT00306826|Drug|pioglitazone + simvastatin|
511773|NCT00306813|Drug|Revlimid|
511774|NCT00306800|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
511775|NCT00306787|Drug|Famciclovir|Famciclovir 500 mg tablet
511776|NCT00306787|Drug|Valacyclovir|Valacyclovir 500 mg capsule
511777|NCT00306787|Drug|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
511778|NCT00306787|Drug|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
511779|NCT00306774|Dietary Supplement|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
511780|NCT00306774|Dietary Supplement|Placebo|Placebo capsule per day for 2 years
511781|NCT00306761|Device|Dynamic Wheelchair Seating System|
511782|NCT00306748|Drug|MD-1100 Acetate|
511783|NCT00306735|Drug|Palonosetron|
511784|NCT00306722|Drug|AQUAVAN® (fospropofol disodium) Injection|
511785|NCT00306709|Behavioral|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
511786|NCT00306696|Drug|Rosiglitazone|
511787|NCT00306696|Drug|spironolactone|
511788|NCT00306696|Drug|hydrochlorothiazide|
511789|NCT00306696|Drug|frusemide|
511790|NCT00306683|Drug|DIAZOXIDE|
511791|NCT00306670|Drug|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
511792|NCT00306670|Drug|prednisone|<30 mg/day
511793|NCT00306657|Procedure|Optic nerve sheath fenestration|
511794|NCT00306644|Drug|Rosiglitazone|study drug
511795|NCT00306631|Drug|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
511796|NCT00306618|Drug|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
511797|NCT00306605|Behavioral|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
511798|NCT00306592|Biological|BG00002 (natalizumab)|
511799|NCT00306566|Biological|CYT004-MelQbG10|
511800|NCT00306553|Biological|CYT004-MelQbG10|
511801|NCT00306540|Drug|Quetiapine Fumarate|oral flexible dose
511802|NCT00306540|Drug|quetiapine fumarate placebo|oral 0 mg
511803|NCT00306527|Biological|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
511804|NCT00306527|Biological|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
534336|NCT00115687|Drug|placebo|
511806|NCT00306501|Procedure|Swallowing Training|Swallowing Training with press of button
511807|NCT00306488|Drug|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
511808|NCT00306475|Drug|divalproex sodium ER|divalproex sodium ER1000 mg
511809|NCT00306475|Drug|placebo|placebo identical in appearance to active comparator
511810|NCT00306462|Drug|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is < 6/hour.
511811|NCT00306462|Drug|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is < 6/hour.
511812|NCT00306449|Behavioral|Small group seminar-based educational intervention|
511813|NCT00306436|Procedure|comprehensive management|
511814|NCT00306423|Procedure|Other: Exercise|exercise 3 times per week for 12 weeks
511815|NCT00306410|Drug|colecalciferol|
511816|NCT00306397|Drug|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
511817|NCT00306384|Drug|Alogliptin|Alogliptin tablets.
511818|NCT00306371|Device|1450nm diode laser|
511819|NCT00306358|Drug|Vitamin B12 (Cyanocobalamin)|
511820|NCT00306345|Behavioral|Outreach|
511821|NCT00306332|Procedure|T-cell and B-cell depletion|
511822|NCT00306319|Drug|moxifloxacin|
511823|NCT00306306|Device|Reprieve Endovascular Temperature Therapy System|
511824|NCT00306293|Drug|valacyclovir|valacyclovir
511825|NCT00306280|Device|Phototherapy|
511826|NCT00306267|Drug|epoetin alfa|
511827|NCT00306254|Drug|PD 0348292|
511828|NCT00306254|Drug|Enoxaparin|
511829|NCT00306241|Biological|HPV-16/18 L1 VLP AS04|
511830|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
511831|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
511832|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
511833|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
511834|NCT00306215|Drug|CCX282-B|CCX282-B or placebo capsules
511835|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. Once daily (QD), as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
511836|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
511837|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose level 2 of 80 mg/m^2, Escalated/Dose level 3 of 100 mg/m^2, and Escalated/Dose level 4 of 120 mg/m^2. QD, as long as clinical benefit was maintained.~Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
511838|NCT00306189|Drug|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
511839|NCT00306189|Drug|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
511840|NCT00306189|Drug|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
511841|NCT00306189|Drug|Placebo|Placebo SC every 6 months
511842|NCT00306176|Drug|Rosiglitazone|
511843|NCT00306163|Drug|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
511844|NCT00306163|Drug|Fluticasone|inhaled Fluticasone 100 µg, twice daily
511845|NCT00306150|Drug|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
511846|NCT00306150|Drug|Placebo|Placebo is used according to the description of Arm 1
512043|NCT00304551|Drug|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
511847|NCT00306137|Drug|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.~Subjects will be stratified into one of the 4 following strata:~Stratum 1: complete primary pneumonectomy~Stratum II: decortication or completion pneumonectomy~Stratum III: esophagectomy by transhiatal approach~Stratum IV: esophagectomy by transthoracic approach"
511848|NCT00306137|Drug|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
511849|NCT00306124|Drug|Levodopa|
511850|NCT00306111|Drug|pegfilgrastim|Single dose (6mg) one day after chemotherapy
511851|NCT00306098|Drug|islets|Islet transplantation
511852|NCT00306085|Genetic|Autologous bone marrow cells|
511853|NCT00306072|Drug|nutritional herbal extract from Salacia oblonga|
511854|NCT00306059|Procedure|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
511855|NCT00306046|Drug|Bisphosphonate treatment|
511856|NCT00306033|Drug|Intravenous ImmuneGlobulin|
511857|NCT00306020|Drug|topical morphine|
511858|NCT00305968|Behavioral|patient education|Patient education group
511859|NCT00305955|Device|Spectacles|optimal spectacle correction
511860|NCT00305942|Drug|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
511861|NCT00305942|Drug|carboplatin|Carboplatin AUC=5 IV day 1 only .
511862|NCT00305929|Drug|Treatment with Tookad VTP|
511863|NCT00305929|Drug|Treatment with Tookad VTP|Tookad 2 mg/kg
511864|NCT00305929|Drug|Treatment with Tookad VTP|2 mg/kg
511865|NCT00305916|Procedure|Multislice spiral computed tomography coronary angiography|
511866|NCT00305916|Procedure|conventional coronary angiography|
511867|NCT00305903|Drug|Rivastigmine, memantine|
511868|NCT00305890|Behavioral|Lifestyle Behavioral Weight Management Program|The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
511869|NCT00305890|Behavioral|Pain-Coping Skills Training|The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
511870|NCT00305890|Other|Standard Care|Standard care will include routine medical care.
511871|NCT00305877|Biological|cetuximab|Given IV
511872|NCT00305877|Drug|gemcitabine hydrochloride|Given IV
511873|NCT00305877|Drug|capecitabine|Given orally
511874|NCT00305877|Radiation|radiation therapy|Undergo radiation therapy
511875|NCT00305877|Biological|bevacizumab|Given IV
511876|NCT00305877|Other|laboratory biomarker analysis|Correlative studies
511877|NCT00305864|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
511878|NCT00305864|Drug|Motexafin Gadolinium|Given IV
511879|NCT00305864|Drug|Temozolomide|Given orally
511880|NCT00305851|Procedure|music therapy (books on tape)|
511881|NCT00305851|Procedure|psychosocial assessment and care|
511882|NCT00305851|Procedure|quality-of-life assessment|
511883|NCT00305851|Behavioral|Music Video|Song writing, recording the song with a digital accompaniment track, completing a video layout worksheet (determining the contents of the video), taking photos or making drawings for the video, and viewing clip art and pictures on a computer.
511884|NCT00305838|Drug|tamoxifen citrate|
511885|NCT00305838|Other|diagnostic laboratory biomarker analysis|
511886|NCT00305825|Biological|bevacizumab|
511887|NCT00305825|Drug|letrozole|
511888|NCT00305812|Drug|dexamethasone|
511889|NCT00305812|Drug|lenalidomide|
511890|NCT00305812|Drug|melphalan|
511891|NCT00305799|Procedure|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
511892|NCT00305786|Drug|gemcitabine hydrochloride|
511893|NCT00305786|Drug|oxaliplatin|
511894|NCT00305773|Drug|vorinostat|Given orally once daily
511895|NCT00305773|Drug|vorinostat|Given orally three times daily
511896|NCT00305760|Drug|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
511897|NCT00305760|Biological|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
511898|NCT00305760|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
511899|NCT00305747|Drug|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
511900|NCT00305734|Drug|bortezomib|Given IV
511901|NCT00305734|Drug|gemcitabine hydrochloride|Given IV
511902|NCT00305734|Other|laboratory biomarker analysis|Correlative studies
511903|NCT00305708|Biological|anti-thymocyte globulin|
511904|NCT00305708|Drug|busulfan|
511905|NCT00305708|Drug|fludarabine phosphate|
511906|NCT00305708|Procedure|allogeneic bone marrow transplantation|
511907|NCT00305708|Procedure|peripheral blood stem cell transplantation|
511908|NCT00305708|Procedure|umbilical cord blood transplantation|
511909|NCT00305708|Radiation|radiation therapy|
511910|NCT00305695|Other|Laboratory Biomarker Analysis|Correlative studies
511911|NCT00305695|Drug|Zoledronic Acid|Given IV
534338|NCT00115661|Drug|Rosiglitazone|
511912|NCT00305682|Biological|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
511913|NCT00305682|Drug|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
511914|NCT00305682|Drug|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
511915|NCT00305682|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
511916|NCT00305682|Procedure|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
511917|NCT00305682|Radiation|total body irradiation|Administered Day -1, 200 cGy
511918|NCT00305682|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
511919|NCT00305669|Biological|sargramostim|
511920|NCT00305669|Other|immunohistochemistry staining method|
511921|NCT00305669|Other|immunological diagnostic method|
511922|NCT00305669|Other|laboratory biomarker analysis|
511923|NCT00305669|Procedure|conventional surgery|
511924|NCT00305669|Procedure|neoadjuvant therapy|
511925|NCT00305656|Drug|cediranib maleate|Given orally
511926|NCT00305643|Drug|Capecitabine|Initial dose of 750-1500 mg/m^2 orally twice a day for each 21 day cycle.
511927|NCT00305643|Drug|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
511928|NCT00305643|Procedure|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
511929|NCT00305643|Drug|Placebo|Oral placebo twice daily on days 1-21
511930|NCT00305630|Drug|Periocular injection of triamcinolone acetonide 40mg|
511931|NCT00305617|Other|antitumor drug screening assay|
511932|NCT00305604|Drug|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
511933|NCT00305604|Drug|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
511934|NCT00305591|Drug|l-ornithine l-aspartate|
511935|NCT00305578|Drug|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
511936|NCT00305578|Drug|Placebo|No active medication, only placebo
511937|NCT00305565|Device|VNS Therapy|Received output current of 0.25 milliamps (mA)
511938|NCT00305565|Device|VNS Therapy|Received output current of 0.5-1.0 mA
511939|NCT00305565|Device|VNS Therapy|Received output current of 1.0-1.5 mA
511940|NCT00305552|Drug|THALIDOMIDE|THALIDOMIDE
511941|NCT00305539|Drug|adalimumab|40 mg sc / for 3 months
511942|NCT00305539|Drug|placebo|placebo
511943|NCT00305526|Device|Contak Renewal (CRT-D)|
511944|NCT00305513|Procedure|The phasic alerting treatment|
511945|NCT00305500|Drug|escitalopram|
511946|NCT00305487|Drug|Ciclesonide nasal spray|
511947|NCT00305474|Drug|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
511948|NCT00305461|Drug|Ciclesonide|Effect of Ciclesonide on Quality of Life
511949|NCT00305448|Drug|Fulvestrant|250 intramuscular injection
511950|NCT00305448|Drug|Fulvestrant|500 mg intramuscular injection
511951|NCT00305435|Drug|Romiplostim (AMG-531)|Romiplostim (AMG-531)
511952|NCT00305422|Drug|Quetiapine fumarate|
511953|NCT00305422|Drug|Risperidone|
511954|NCT00305409|Drug|Synbiotic (Synergy I / B.longum)|
511955|NCT00305396|Drug|Sirolimus|
511956|NCT00305383|Drug|Viramidine|
511957|NCT00305383|Drug|Peginterferon alfa-2b|
511958|NCT00305370|Drug|Aripiprazole|
511959|NCT00305344|Procedure|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
511960|NCT00305344|Biological|Cord blood|Develop Cord blood vaccine
511961|NCT00305331|Drug|Domperidone (drug)|
511962|NCT00305292|Drug|Modafinil-Alcohol Interactions|
511963|NCT00305279|Other|Dietary|Dietary
511964|NCT00305279|Other|Dietary|Dietary
511965|NCT00305279|Other|Dietary|Dietary
511966|NCT00305266|Drug|intravenous gammaglobulin|individual dose
511967|NCT00305253|Device|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
511968|NCT00305240|Procedure|T Wave Alternans Test|
511969|NCT00305227|Drug|Lactin-V|
511970|NCT00305227|Drug|Placebo|
511971|NCT00305214|Procedure|T Wave Alternans Test|
511972|NCT00305201|Drug|pravastatin|
511973|NCT00305188|Drug|Xaliproden (SR57746A)|oral administration
511974|NCT00305188|Drug|Placebo|oral administration
511975|NCT00305188|Drug|Oxaliplatin|IV administration
511976|NCT00305188|Drug|5-Fluorouracil|IV administration
511977|NCT00305188|Drug|Leucovorin|IV administration
511978|NCT00305162|Drug|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) & infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
512044|NCT00304538|Drug|very low dose (VLD) glucagon|
512119|NCT00303914|Procedure|psychosocial assessment and care|
512120|NCT00303901|Procedure|cryosurgery|
511979|NCT00305162|Drug|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
511980|NCT00305162|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
511981|NCT00305162|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
511982|NCT00305162|Drug|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
511983|NCT00305149|Procedure|interim therapy scintigraphy study gallium scan or PET/CT|
511984|NCT00305149|Procedure|"interim gallium or PET/CT"|
511985|NCT00305110|Drug|2 mg IV hydromorphone|
511986|NCT00305097|Dietary Supplement|Decaffeinated coffee|5 cups per day for 8 weeks
511987|NCT00305097|Dietary Supplement|Caffeinated coffee|5 cups per day for 8 weeks
511988|NCT00305097|Dietary Supplement|No coffee|
511989|NCT00305084|Drug|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
511990|NCT00305084|Drug|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
511991|NCT00305071|Drug|compound cranberry extract tablet|
511992|NCT00305058|Drug|Morphine|0.05 mg/kg Intravenous
511993|NCT00305058|Drug|Hydromorphone|0.0075 mg/kg intravenous
511994|NCT00305045|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
511995|NCT00305032|Procedure|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
511996|NCT00305019|Drug|clevudine|
511997|NCT00305006|Procedure|Constraint-Induced Movement Therapy|90 hours
511998|NCT00305006|Procedure|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
511999|NCT00304993|Drug|fenofibrate|
512000|NCT00304993|Drug|niacin|
512001|NCT00304993|Drug|rosiglitazone|
512002|NCT00304980|Drug|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
512003|NCT00304954|Drug|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
512004|NCT00304954|Drug|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
512005|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
512006|NCT00304954|Drug|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
512007|NCT00304915|Behavioral|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
512008|NCT00304863|Drug|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
512009|NCT00304850|Behavioral|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
512010|NCT00304850|Drug|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
512011|NCT00304837|Genetic|pVGI.1 (VEGF-2)|
512012|NCT00304811|Drug|Vancomycin|
512013|NCT00304811|Drug|Vancomycin plus Gentamicin|
512014|NCT00304811|Drug|Vancomycin plus Rifampin|
512015|NCT00304811|Drug|Vancomycin plus Gentamicin plus Rifampin|
512016|NCT00304798|Behavioral|Hospital admission|
512017|NCT00304785|Drug|latanoprost 0.005%|
512018|NCT00304785|Drug|Fotil|
512019|NCT00304785|Drug|placebo|
512020|NCT00304772|Drug|Fluconazole|400mg/day
512021|NCT00304772|Drug|Micafungin|150mg/day
512022|NCT00304759|Procedure|7800 cGy/39 fractions in 8 weeks|see above
512023|NCT00304759|Procedure|6000 cGy/20 fractions in 4 weeks|see above
512024|NCT00304746|Drug|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
512025|NCT00304746|Drug|Placebo|Placebo
512026|NCT00304733|Device|cast vs. shoe|
512027|NCT00304720|Drug|Tacrolimus and MMF|
512028|NCT00304707|Drug|Bupropion|300 mg QD
512029|NCT00304707|Drug|placebo|placebo
512030|NCT00304681|Drug|OROS*-Methylphenidate|
512031|NCT00304668|Drug|dapivirine (TMC120) vaginal gel|
512032|NCT00304655|Drug|Aripiprazole|
512033|NCT00304642|Drug|dapivirine (TMC120) vaginal gel|
512034|NCT00304629|Drug|galantamine|
512035|NCT00304616|Drug|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
512036|NCT00304603|Other|No intervention|No treatment was given to the patients as this is an observational study.
512037|NCT00304590|Drug|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
512038|NCT00304577|Procedure|Bilateral recession|
512039|NCT00304577|Procedure|Unilateral recession and resection|
512040|NCT00304564|Behavioral|Music Listening|subjects listen to music
512041|NCT00304551|Drug|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
512042|NCT00304551|Drug|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
512045|NCT00304525|Drug|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
512046|NCT00304512|Drug|migalastat HCl|
512047|NCT00304499|Drug|Oxybutynin|
512048|NCT00304473|Drug|Quetiapine fumarate|
512049|NCT00304460|Biological|aldesleukin|
512050|NCT00304447|Drug|Mylotarg|
512051|NCT00304434|Drug|Oseltamivir|
512052|NCT00304434|Drug|Probenecid|
512053|NCT00304421|Drug|rabeprazole|
512054|NCT00304421|Drug|pantoprazole|
512055|NCT00304382|Biological|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
512056|NCT00304382|Biological|Pneumovax|0.5 ml IM one time
512057|NCT00304369|Drug|Metronidazole|
512058|NCT00304356|Drug|Nitazoxanide|500 mg bid
512059|NCT00304317|Drug|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
512060|NCT00304317|Other|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
512061|NCT00304304|Behavioral|Asthma education|Research assistant worked with CCC staff on asthma prevention
512062|NCT00304291|Drug|Mitoxantrone|
512063|NCT00304278|Drug|Erlotinib (Tarceva)|150 mg daily X 7 weeks
512064|NCT00304278|Drug|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
512065|NCT00304278|Radiation|Radiation Therapy (RAD)|5 days per week X 7 weeks
512066|NCT00304265|Biological|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
512067|NCT00304252|Drug|Interferon beta-1a|
512068|NCT00304239|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
512069|NCT00304226|Drug|valsartan|
512070|NCT00304226|Drug|amlodipine|
512071|NCT00304213|Drug|Testosterone|
512072|NCT00304200|Drug|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
512073|NCT00304187|Drug|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
512074|NCT00304187|Drug|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
512075|NCT00304174|Behavioral|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
512076|NCT00304161|Drug|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
512077|NCT00304161|Drug|Placebo|40 to 80 mg orally once daily for 8 weeks
512078|NCT00304135|Drug|cisplatin|
512079|NCT00304135|Drug|gemcitabine hydrochloride|
512080|NCT00304135|Drug|oxaliplatin|
512081|NCT00304096|Biological|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
512082|NCT00304083|Biological|filgrastim|Given subcutaneously
512083|NCT00304083|Drug|doxorubicin hydrochloride|Given IV
512084|NCT00304083|Drug|etoposide|Given IV
512085|NCT00304083|Drug|ifosfamide|Given IV
512086|NCT00304083|Procedure|conventional surgery|Patients undergo surgery
512087|NCT00304083|Radiation|radiation therapy|Patients undergo radiotherapy
512088|NCT00304070|Drug|doxorubicin hydrochloride|Given IV
512089|NCT00304070|Procedure|conventional surgery|Patients undergo surgery
512090|NCT00304070|Drug|cisplatin|Given IV
512091|NCT00304070|Drug|mitotane|Given orally
512092|NCT00304070|Drug|etoposide|Given IV
512093|NCT00304070|Biological|filgrastim|Given subcutaneously
512094|NCT00304031|Drug|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
512095|NCT00304031|Radiation|Concurrent radiation therapy|60 Gy in 2 Gy fractions
512096|NCT00304031|Drug|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
512097|NCT00304031|Drug|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
512098|NCT00304018|Biological|anti-thymocyte globulin|
512099|NCT00304018|Biological|sargramostim|
512100|NCT00304018|Drug|busulfan|
512101|NCT00304018|Drug|etoposide|
512102|NCT00304018|Drug|fludarabine phosphate|
512103|NCT00304018|Drug|prednisone|
512104|NCT00304018|Drug|tacrolimus|
512105|NCT00304018|Procedure|allogeneic hematopoietic stem cell transplantation|
512106|NCT00304018|Procedure|umbilical cord blood transplantation|
512107|NCT00304005|Drug|laromustine|
512108|NCT00303992|Biological|trastuzumab|
512109|NCT00303992|Drug|irinotecan hydrochloride|
512110|NCT00303966|Drug|sorafenib tosylate|Given orally
512111|NCT00303953|Drug|belinostat|Given IV
512112|NCT00303940|Drug|carboplatin|
512113|NCT00303940|Drug|talabostat mesylate|
512114|NCT00303940|Drug|temozolomide|
512115|NCT00303940|Other|pharmacological study|
512116|NCT00303927|Drug|capecitabine|
512117|NCT00303914|Procedure|assessment of therapy complications|
512118|NCT00303914|Procedure|cognitive assessment|
512121|NCT00303901|Procedure|positron emission tomography|
512122|NCT00303888|Drug|docetaxel|Given IV
512123|NCT00303888|Drug|idronoxil|Given orally
512124|NCT00303888|Other|placebo|Given orally
512125|NCT00303875|Behavioral|behavioral dietary and exercise intervention|
512126|NCT00303862|Drug|cediranib maleate|Given orally
512127|NCT00303862|Other|laboratory biomarker analysis|Correlative studies
512128|NCT00303849|Drug|Carboplatin|Given IA
512129|NCT00303849|Drug|Etoposide Phosphate|Given IV
512130|NCT00303849|Other|Laboratory Biomarker Analysis|Correlative studies
512131|NCT00303849|Drug|Mannitol|Given IA
512132|NCT00303849|Drug|Melphalan|Given IA
512133|NCT00303849|Other|Quality-of-Life Assessment|Ancillary studies
512134|NCT00303849|Drug|Sodium Thiosulfate|Given IV
512135|NCT00303836|Drug|cyclophosphamide|Given IV
512136|NCT00303836|Drug|fludarabine phosphate|Given IV
512137|NCT00303836|Biological|therapeutic autologous lymphocytes|Given IV
512138|NCT00303836|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
512139|NCT00303836|Biological|gp100 antigen|Given SC
512140|NCT00303836|Biological|MART-1 antigen|Given SC
512141|NCT00303836|Biological|incomplete Freund's adjuvant|Given SC
512142|NCT00303836|Biological|filgrastim|Given SC
512143|NCT00303836|Biological|aldesleukin|Given IV
512144|NCT00303823|Drug|placebo|Given orally
512145|NCT00303823|Dietary Supplement|defined green tea catechin extract|Given orally
512146|NCT00303823|Other|laboratory biomarker analysis|Correlative studies
512147|NCT00303810|Drug|carboplatin|
512148|NCT00303810|Drug|cisplatin|
512149|NCT00303810|Drug|cyclophosphamide|
512150|NCT00303810|Drug|etoposide phosphate|
512151|NCT00303810|Drug|high-dose chemotherapy|
512152|NCT00303810|Drug|lomustine|
512153|NCT00303810|Drug|methotrexate|
512154|NCT00303810|Drug|thiotepa|
512155|NCT00303810|Drug|vincristine sulfate|
512156|NCT00303810|Radiation|radiation therapy|
512157|NCT00303797|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
512158|NCT00303797|Drug|sorafenib tosylate|
512159|NCT00303784|Drug|Goserelin|3.6mg implant, in pre-filled syringe
512160|NCT00303784|Drug|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
512161|NCT00303771|Drug|fluorouracil|
512162|NCT00303771|Drug|irinotecan hydrochloride|
512163|NCT00303771|Drug|leucovorin calcium|
512164|NCT00303758|Drug|cisplatin|
512165|NCT00303758|Drug|fluorouracil|
512166|NCT00303758|Drug|gemcitabine hydrochloride|
512167|NCT00303758|Drug|leucovorin calcium|
512168|NCT00303745|Drug|capecitabine|
512169|NCT00303745|Drug|irinotecan hydrochloride|
512170|NCT00303732|Drug|RAD001 (everolimus)|
512171|NCT00303732|Drug|PTK787 (vatalanib)|
512172|NCT00303719|Biological|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.~Those that should/will receive ATG in the preparative regimen:~Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should~Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will~Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should~Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
512173|NCT00303719|Drug|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
512174|NCT00303719|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of >200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
512175|NCT00303719|Drug|fludarabine|Fludarabine 30 mg/m^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m^2 for 5 days.
512176|NCT00303719|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if < 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) > 0.5 x 109 /L).
512177|NCT00303719|Procedure|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
512178|NCT00303719|Radiation|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
512179|NCT00303719|Drug|filgrastim|Patients with white blood cell (WBC) counts < 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) > 2500 for 2 consecutive days.
512180|NCT00303706|Procedure|Endoscopic Radial Artery Harvest|
512181|NCT00303667|Biological|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
512182|NCT00303667|Biological|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10^7 cells/kg.
512183|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
512184|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 40 mg/m^2 on Days -18 through -14
512185|NCT00303667|Procedure|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
512186|NCT00303667|Radiation|total body irradiation|Administered on Day -13, 200 cGy two times.
512187|NCT00303667|Biological|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
512188|NCT00303667|Drug|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
512189|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
512190|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 35 mg/m^2 on Days -18 through -14
512191|NCT00303654|Procedure|biopsy|
512192|NCT00303654|Procedure|therapeutic conventional surgery|
512193|NCT00303641|Device|Medtronic Resting Heart Bypass System|
512194|NCT00303628|Drug|oxaliplatin|Given IV
512195|NCT00303628|Drug|fluorouracil|Given IV
512196|NCT00303628|Drug|leucovorin calcium|Given IV
512197|NCT00303628|Drug|bevacizumab|Given IV
512198|NCT00303615|Drug|Fluoxymesterone 10 mg|
512199|NCT00303615|Drug|Anastrozole 1 mg|
512200|NCT00303602|Drug|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
512201|NCT00303602|Drug|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
512202|NCT00303589|Drug|Standard care|As prescribed
512203|NCT00303589|Drug|beta-lactam|750mg iv q8h
512204|NCT00303589|Drug|beta-lactam|1500mg iv q8h
512205|NCT00303576|Drug|dapivirine (TMC120) vaginal gel|
512206|NCT00303563|Drug|P38 Inhibitor (4)|50mg po qd
512207|NCT00303563|Drug|P38 Inhibitor (4)|150mg po qd
512208|NCT00303563|Drug|P38 Inhibitor (4)|300mg po qd
512209|NCT00303563|Drug|Placebo|po qd
512210|NCT00303550|Drug|Intravenous iclaprim|
512211|NCT00303550|Drug|Intravenous linezolid|
512212|NCT00303537|Drug|metformin|
512213|NCT00303524|Drug|Goserelin acetate|Injection 3.6 mg monthly
512214|NCT00303524|Drug|Goserelin acetate|injection 10.8 mg every 3 months
512215|NCT00303498|Drug|Sitaxsentan sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
512216|NCT00303498|Drug|Placebo|placebo identical to the study drug in description, dose and duration
512217|NCT00303485|Drug|Placebo|po monthly for 6 months
512218|NCT00303485|Drug|Vitamin D and calcium supplementation|As prescribed
512219|NCT00303485|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
512220|NCT00303472|Drug|Romiplostim|
512221|NCT00303459|Drug|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
512222|NCT00303459|Drug|placebo|Matching bosentan placebo/b.i.d.
512223|NCT00303446|Drug|Dutasteride|Dutasteride 0.5 mg/day
512224|NCT00303446|Drug|Placebo|Matched placebo
512225|NCT00303433|Drug|Namenda|
512226|NCT00303420|Drug|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
512227|NCT00303420|Drug|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
512228|NCT00303407|Drug|nadroparin|
512229|NCT00303394|Drug|IL-1Ra|
512230|NCT00303381|Drug|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
512231|NCT00303381|Drug|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
512232|NCT00303381|Drug|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
512233|NCT00303342|Behavioral|mind body treatment|regulation of attention, respiration and posture
512234|NCT00303342|Behavioral|desensitization|mentation on insomnia behaviors and cognitive activity
512235|NCT00303329|Drug|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
512236|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
512237|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
512238|NCT00303303|Biological|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
512239|NCT00303303|Biological|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
512240|NCT00303303|Biological|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
512241|NCT00303290|Drug|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
512242|NCT00303290|Drug|Ara-C (cytosine arabinoside)|10 mg under the skin daily
512243|NCT00303277|Drug|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
512244|NCT00303277|Drug|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
512245|NCT00303264|Drug|dexloxiglumide|
512246|NCT00303264|Drug|Nexium (esomeprazole)|
512247|NCT00303251|Drug|TKI258|
512248|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + resveravine|
512249|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
512250|NCT00303238|Drug|Rose hips extract + resveravine + Aframomum melegueta extract|
512251|NCT00303225|Drug|Vaccine: SIGA-246|
512252|NCT00303212|Other|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
512253|NCT00303199|Drug|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
512254|NCT00303173|Behavioral|Guided Imagery|
512255|NCT00303160|Drug|vitamin C & E supplements|
512256|NCT00303147|Behavioral|Expressive Writing|
512257|NCT00303134|Drug|Islet Cell Transplantation|Islet Cell Transplantation for patients with type 1 diabetes mellitus
512258|NCT00303108|Drug|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
512259|NCT00303108|Drug|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
512260|NCT00303108|Drug|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
512261|NCT00303082|Drug|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
512262|NCT00303069|Biological|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
512263|NCT00303069|Biological|Comparator: Placebo|Single dose of saline placebo intramuscularly
512264|NCT00303056|Drug|HOE140 Icatibant|
512265|NCT00303043|Procedure|Mixed venous saturation monitoring|Mixed venous saturation monitoring
512266|NCT00303030|Procedure|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
512267|NCT00303030|Procedure|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
512268|NCT00303017|Dietary Supplement|flavocoxid|flavonoid mixture
512269|NCT00303017|Drug|Naproxen|non-steroidal anti-inflammatory drug
512270|NCT00303004|Drug|Bosentan and Sildenafil|
512271|NCT00302978|Behavioral|Behavior therapy|
512272|NCT00302965|Drug|Frozen Plasma|
512273|NCT00302952|Drug|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
512274|NCT00302952|Drug|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
512275|NCT00302926|Procedure|energy restriction and maintenance|
512276|NCT00302913|Drug|Adjustment of clopidogrel dose|
512277|NCT00302900|Behavioral|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
512278|NCT00302900|Behavioral|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
512279|NCT00302900|Behavioral|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
512280|NCT00302887|Device|combined ultrasound therapy|
512281|NCT00302887|Procedure|connective tissue manipulation|
512282|NCT00302874|Behavioral|Implementation of a protocol for treatment of hyperglycemia|
512283|NCT00302861|Biological|MyVax|
512284|NCT00302848|Drug|Drospirenone|
512285|NCT00302848|Drug|Levonorgestrel|
512286|NCT00302848|Drug|Other progestin containing oral contraceptive|
512287|NCT00302835|Drug|non-phenacetin containing analgesics|
512288|NCT00302822|Drug|enfuvirtide|from week 0 to 24
512289|NCT00302822|Drug|emtricitabine/tenofovir|1 pill/day
512290|NCT00302822|Drug|lopinavir or efavirenz|investigator choice
512291|NCT00302809|Dietary Supplement|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
512292|NCT00302796|Drug|Bioclavid|500 + 125 mg times 3 or 6
512293|NCT00302796|Drug|Placebo|
512294|NCT00302783|Behavioral|Multi-Source Feedback: including self-assessment & coaching|
512295|NCT00302770|Drug|quetiapine|
512296|NCT00302757|Drug|Radioimmunotherapy|
512297|NCT00302757|Procedure|allogeneic hematopoietic cell transplantation|
512298|NCT00302744|Drug|Psilocybin (drug)|One placebo session (niacin) and one active drug session (.2 mg/kg). Treatment sessions are six hours.
512299|NCT00302731|Drug|Estradiol , estriol , progesterone|
512300|NCT00302731|Drug|estradiol, progesterone|
512301|NCT00302731|Drug|estriol, progesterone|
512302|NCT00302731|Drug|equine estrogens m-progesteroneacetate|
512303|NCT00302718|Behavioral|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
512304|NCT00302718|Behavioral|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
512305|NCT00302718|Behavioral|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
512306|NCT00302705|Drug|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
512307|NCT00302705|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
512308|NCT00302705|Procedure|Missing one dose|Patients skip the dose the second day of monitoring
512309|NCT00302692|Drug|Esmolol|
512310|NCT00302692|Drug|Metoprolol|
512311|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
512312|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
512313|NCT00302653|Drug|Rasburicase|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
512314|NCT00302640|Drug|Alinia (nitazoxanide)|
512315|NCT00302627|Drug|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
512316|NCT00302627|Drug|vitamin D|baseline, 6,12 months
512317|NCT00302627|Drug|Calcium Carbonate|baseline, 6,12 months
512318|NCT00302601|Procedure|Scintigraphic interpretation|Not relevant
512319|NCT00302575|Behavioral|Collaborative Behavioral Management|
512320|NCT00302575|Procedure|Integrated parole and outpatient addiction treatment|
512321|NCT00302549|Drug|FK506|FK506,0.1mg/kg/d
512322|NCT00302536|Drug|Tacrolimus|Tacrolimus
512323|NCT00302523|Drug|Tacrolimus|FK506,0.1mg/kg/d
512324|NCT00302510|Procedure|immunoadsorption|immunoadsorption
512325|NCT00302497|Drug|basiliximab|
512326|NCT00302484|Drug|Zoledronate|
512327|NCT00302471|Drug|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.~Disease."
512328|NCT00302471|Drug|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
512329|NCT00302471|Drug|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
512330|NCT00302471|Drug|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
512331|NCT00302458|Drug|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
512332|NCT00302458|Drug|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
512333|NCT00302458|Drug|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
512334|NCT00302445|Drug|Efalizumab|
512335|NCT00302445|Device|Narrow Band Phototherapy|
512336|NCT00302432|Behavioral|Behavior therapy, cigarette holders, Flowers Menthol|
512337|NCT00302419|Drug|intracoronary infusion,|streptokinase, 250,000 units
512338|NCT00302419|Procedure|primary percutaneous coronary angioplasty|
512339|NCT00302406|Drug|methylphenidate hydrochloride|
512340|NCT00302406|Drug|OROS methylphenidate hydrochloride (CONCERTA)|
512341|NCT00302393|Drug|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
512342|NCT00302393|Drug|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
512343|NCT00302380|Radiation|PET imaging using C-11 altropane as the ligand.|A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
512344|NCT00302367|Drug|OROS methylphenidate hydrochloride|
512345|NCT00302367|Drug|immediate release methylphenidate hydrochloride|
512346|NCT00302354|Drug|OROS methylphenidate HCl|
512347|NCT00302354|Drug|SODAS methylphenidate HCl|
512348|NCT00302341|Drug|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
512349|NCT00302341|Drug|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
512350|NCT00302328|Procedure|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
512351|NCT00302315|Device|transcutaneous electrical nerve stimulation|
512352|NCT00302302|Drug|L-arabinose|
512353|NCT00302289|Drug|tyrosine, green tea, caffeine|
512354|NCT00302276|Drug|Metobes-compound|
512355|NCT00302263|Drug|Metobes-compound|
512356|NCT00302250|Drug|ALT-711 (alagebrium chloride)|
512357|NCT00302237|Device|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
512358|NCT00302224|Drug|2S, 4R Ketoconazole (DIO-902)|
512359|NCT00302211|Drug|Inhaled Iloprost (5 μg)|iloprost inhalation solution (Ventavis) (5 μg)
512360|NCT00302211|Drug|Inhaled Placebo|inhaled placebo
512361|NCT00302211|Drug|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
512362|NCT00302211|Drug|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
512363|NCT00302198|Behavioral|ALS Registry|
512364|NCT00302185|Procedure|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
512365|NCT00302185|Behavioral|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
512437|NCT00301860|Biological|filgrastim|
512438|NCT00301860|Biological|therapeutic allogeneic lymphocytes|
512439|NCT00301860|Drug|cyclosporine|
512440|NCT00301860|Drug|fludarabine phosphate|
512441|NCT00301860|Drug|melphalan|
512442|NCT00301860|Drug|methotrexate|
512443|NCT00301860|Procedure|allogeneic hematopoietic stem cell transplantation|
512444|NCT00301860|Procedure|peripheral blood stem cell transplantation|
512445|NCT00301847|Drug|sorafenib tosylate|
512446|NCT00301834|Biological|alemtuzumab|
512366|NCT00302172|Drug|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).~Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.~All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
512367|NCT00302159|Procedure|adjuvant therapy|
512368|NCT00302159|Drug|Temozolomide|Orally 75mg/m^2 first day of radiation until completion. Restart 4 weeks post radiation.
512369|NCT00302159|Drug|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
512370|NCT00302159|Radiation|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
512371|NCT00302133|Drug|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
512372|NCT00302133|Other|Placebo|Placebo arm
512373|NCT00302120|Procedure|Contrast-enhanced MR mammography|
512374|NCT00302107|Drug|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
512375|NCT00302107|Drug|Placebo|Look-a-like placebo tablets under double-blind conditions
512376|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
512377|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
512378|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
512379|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
512380|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
512381|NCT00302068|Behavioral|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
512382|NCT00302068|Drug|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
512383|NCT00302068|Drug|Placebo Pill.|Placebo pill, daily, for 16 weeks.
512384|NCT00302055|Behavioral|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
512385|NCT00302055|Behavioral|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
512386|NCT00302042|Behavioral|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
512387|NCT00302042|Behavioral|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
512388|NCT00302016|Drug|AMN107|
512389|NCT00302003|Radiation|radiation therapy|Undergo radiation therapy
512390|NCT00302003|Drug|doxorubicin hydrochloride|Given IV
512391|NCT00302003|Drug|vincristine sulfate|Given IV
512392|NCT00302003|Drug|prednisone|Given orally
512393|NCT00302003|Drug|cyclophosphamide|Given IV
512394|NCT00302003|Drug|ifosfamide|Given IV
512395|NCT00302003|Drug|vinorelbine tartrate|Given IV
512396|NCT00302003|Drug|dexamethasone|Given IV
512397|NCT00302003|Drug|etoposide phosphate|Given IV
512398|NCT00302003|Drug|cisplatin|Given IV
512399|NCT00302003|Drug|cytarabine|Given IV
512400|NCT00302003|Biological|filgrastim|Given IV or subcutaneously
512401|NCT00301990|Biological|aldesleukin|
512402|NCT00301990|Biological|bevacizumab|
512403|NCT00301964|Biological|bevacizumab|Given IV
512404|NCT00301964|Other|laboratory biomarker analysis|Correlative studies
512405|NCT00301951|Biological|anti-thymocyte globulin|
512406|NCT00301951|Biological|sargramostim|
512407|NCT00301951|Drug|busulfan|
512408|NCT00301951|Drug|fludarabine phosphate|
512409|NCT00301951|Drug|mycophenolate mofetil|
512410|NCT00301951|Drug|tacrolimus|
512411|NCT00301951|Procedure|umbilical cord blood transplantation|
512412|NCT00301938|Drug|7-hydroxystaurosporine|Given IV
512413|NCT00301938|Drug|perifosine|Given orally
512414|NCT00301938|Other|pharmacological study|Correlative studies
512415|NCT00301925|Biological|pegfilgrastim|
512416|NCT00301925|Drug|capecitabine|
512417|NCT00301925|Drug|cyclophosphamide|
512418|NCT00301925|Drug|epirubicin hydrochloride|
512419|NCT00301925|Drug|fluorouracil|
512420|NCT00301925|Drug|methotrexate|
512421|NCT00301925|Procedure|adjuvant therapy|
512422|NCT00301912|Biological|filgrastim|
512423|NCT00301912|Drug|busulfan|
512424|NCT00301912|Drug|fludarabine phosphate|
512425|NCT00301912|Drug|methotrexate|
512426|NCT00301912|Drug|tacrolimus|
512427|NCT00301912|Procedure|allogeneic bone marrow transplantation|
512428|NCT00301912|Procedure|allogeneic hematopoietic stem cell transplantation|
512429|NCT00301912|Procedure|peripheral blood stem cell transplantation|
512430|NCT00301899|Biological|pertuzumab|
512431|NCT00301899|Biological|trastuzumab|
512432|NCT00301886|Drug|ibandronate|
512433|NCT00301886|Drug|zoledronate|
512434|NCT00301886|Procedure|quality-of-life assessment|
512435|NCT00301873|Drug|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
512436|NCT00301860|Biological|anti-thymocyte globulin|
512449|NCT00301834|Drug|fludarabine phosphate|
512450|NCT00301834|Drug|methotrexate|
512451|NCT00301834|Drug|methylprednisolone|
512452|NCT00301834|Procedure|allogeneic bone marrow transplantation|
512453|NCT00301834|Procedure|allogeneic hematopoietic stem cell transplantation|
512454|NCT00301834|Procedure|peripheral blood stem cell transplantation|
512455|NCT00301834|Procedure|umbilical cord blood transplantation|
512456|NCT00301821|Biological|epratuzumab|
512457|NCT00301821|Biological|rituximab|
512458|NCT00301821|Drug|cyclophosphamide|
512459|NCT00301821|Drug|doxorubicin hydrochloride|
512460|NCT00301821|Drug|prednisone|
512461|NCT00301821|Drug|vincristine sulfate|
512462|NCT00301808|Drug|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
512463|NCT00301808|Drug|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
512464|NCT00301808|Drug|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
512465|NCT00301808|Radiation|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
512466|NCT00301795|Biological|oblimersen sodium|Given IV
512467|NCT00301795|Biological|rituximab|Given IV
512468|NCT00301795|Other|laboratory biomarker analysis|Correlative studies
512469|NCT00301782|Biological|bleomycin sulfate|
512470|NCT00301782|Drug|carboplatin|
512471|NCT00301782|Drug|cisplatin|
512472|NCT00301782|Drug|etoposide phosphate|
512473|NCT00301782|Drug|vincristine sulfate|
512474|NCT00301769|Drug|SJG-136|Given IV
512475|NCT00301756|Drug|Belinostat|Given IV
512476|NCT00301756|Other|Laboratory Biomarker Analysis|Correlative studies
512477|NCT00301730|Biological|aldesleukin|
512478|NCT00301730|Biological|therapeutic tumor infiltrating lymphocytes|
512479|NCT00301730|Biological|trastuzumab|
512480|NCT00301730|Drug|paclitaxel|
512481|NCT00301730|Procedure|conventional surgery|
512482|NCT00301691|Behavioral|behavioral dietary intervention|
512483|NCT00301691|Other|educational intervention|
512484|NCT00301691|Other|preventative dietary intervention|
512485|NCT00301678|Behavioral|behavioral dietary intervention|
512486|NCT00301678|Other|educational intervention|
512487|NCT00301678|Other|preventative dietary intervention|
512488|NCT00301665|Biological|Botulinum toxin type A|
512489|NCT00301652|Drug|mycophenolate mofetil|MMF,1.0g/d
512490|NCT00301639|Drug|OROS methylphenidate hydrochloride|
512491|NCT00301639|Drug|methylphenidate hydrochloride|
512492|NCT00301626|Behavioral|smoking reduction intervention (including NRT)|
512493|NCT00301613|Drug|Mycophenolate mofetil|MMF,1.0g/d
512494|NCT00301600|Drug|Mycophenolate mofetil|MMF,1.0g/d
512495|NCT00301587|Drug|Norgestimate-ethinyl estradiol, with or without folic acid|
512496|NCT00301574|Drug|galantamine|
512497|NCT00301561|Procedure|Simplified follow-up approach of ARV treatment|"Simplify treatment follow-up :~some clinical consultations will be performed by nurses under the physicians' responsibility ;~the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;~the biologic assessment for tolerability will be limited"
512498|NCT00301561|Procedure|Standard follow-up approach of ARV treatment|"Standard treatment follow-up :~all clinical consultations will be performed by physicians ;~the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;~the biologic assessment for tolerability will be available as needed"
512499|NCT00301548|Drug|perioperative chemotherapy|
512500|NCT00301535|Drug|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
512501|NCT00301522|Device|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
512502|NCT00301522|Device|Express2|Coronary Stent System
512503|NCT00301509|Drug|peginterferon and ribavirin|
512504|NCT00301496|Device|Coban 2 Layer Compression System|
512505|NCT00301483|Drug|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
512506|NCT00301483|Other|Standard of Care|Standard Therapy
512507|NCT00301470|Device|MR urography|undergoing both renal scintigraphy and MR within a month
512508|NCT00301457|Drug|Anastrozole|1 mg once daily oral dose
512509|NCT00301444|Device|mirror-box treatment|
512510|NCT00301444|Behavioral|Mental visualization|
512511|NCT00301431|Drug|DVS-233|
512512|NCT00301418|Drug|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
512513|NCT00301405|Drug|Thalidomide|Open label drug
512514|NCT00301392|Other|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
512515|NCT00301392|Drug|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
512831|NCT00298584|Procedure|Urethral Catheterization|
512516|NCT00301379|Other|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
512517|NCT00301366|Drug|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
512518|NCT00301353|Drug|Isoflavones-enriched foods|
512519|NCT00301340|Drug|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
512520|NCT00301327|Drug|Summers 5% L.A.|
512521|NCT00301314|Procedure|Autologous stem cell transplant|
512522|NCT00301301|Drug|Gemcitabine|
512523|NCT00301301|Drug|Cisplatinum|
512524|NCT00301301|Drug|Rituximab|
512525|NCT00301288|Procedure|Autologous stem cell transplant|
512526|NCT00301262|Drug|Viagra (Sildenafil citrate)|
512527|NCT00301236|Drug|Dexmethylphenidate HCl extended-release capsules|
512528|NCT00301223|Drug|Pregabalin|
512529|NCT00301210|Drug|Tramadol|oral doses four times per day
512530|NCT00301197|Behavioral|Behavioral Skills Maintenance|
512531|NCT00301197|Behavioral|Social Facilitation Maintenance|
512532|NCT00301184|Biological|pGA2/JS7 DNA|DNA Vaccine
512533|NCT00301184|Biological|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
512534|NCT00301171|Drug|Inhaled Fluticasone|
512535|NCT00301158|Behavioral|exercise intervention|
512536|NCT00301158|Other|counseling intervention|
512537|NCT00301158|Other|educational intervention|
512538|NCT00301158|Procedure|complementary or alternative medicine procedure|
512539|NCT00301145|Behavioral|smoking cessation intervention|
512540|NCT00301145|Drug|varenicline|
512541|NCT00301145|Other|counseling intervention|
512542|NCT00301145|Other|internet-based intervention|
512543|NCT00301106|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
512544|NCT00301093|Biological|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
512545|NCT00301093|Drug|imatinib mesylate|Participants will continue on current dose
512546|NCT00301080|Drug|D-cycloserine|
512547|NCT00301080|Other|Placebo|
512548|NCT00301067|Dietary Supplement|Calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
512549|NCT00301067|Drug|Temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
512550|NCT00301054|Drug|Ferrous sulphate|
512551|NCT00301054|Drug|Sulphadoxine-Pyrimethamine|
512552|NCT00301041|Other|laboratory biomarker analysis|
512553|NCT00301041|Procedure|adjuvant therapy|
512554|NCT00301041|Radiation|radiation therapy|
512555|NCT00301028|Biological|Cetuximab|Beginning weekly dose 400 mg/m^2 IV over 1-2 hours, and 250 mg/m^2 weeks 2-6.
512556|NCT00301028|Drug|Carboplatin|AUC 2 weekly for 6 courses.
512557|NCT00301028|Drug|Paclitaxel|135 mg/m^2 weekly for 6 courses.
512558|NCT00301028|Procedure|Conventional Surgery|Following induction in second part of study.
512559|NCT00301028|Radiation|Radiation Therapy|Following induction in second part of study.
512560|NCT00301015|Device|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
512561|NCT00301002|Drug|Alefacept|
512562|NCT00300989|Device|Inion OTPS Biodegradable Fixation System|
512563|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c < 6.2%, BP < 120/75 mmHg, HDL-C 40 mg/dL , LDL-C < 80 mg/dL, TG < 120 mg/dL.~Follow-up study (Not provided)"
512564|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)"
512565|NCT00300963|Drug|Talnetant|
512566|NCT00300950|Biological|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
512567|NCT00300950|Drug|Gemcitabine|Chemotherapy
512568|NCT00300937|Dietary Supplement|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
512569|NCT00300924|Drug|Rizatriptan co-administered with Acetaminophen|
512570|NCT00300911|Drug|Rosiglitazone(drug), cardiac adverse effects|
512571|NCT00300898|Procedure|Nucleoplasty|
512572|NCT00300898|Procedure|Percutaneous decompression|
512573|NCT00300898|Procedure|Intervertebral electrothermal disc decompression (IDET)|
512574|NCT00300898|Behavioral|Conservative treatment|
512575|NCT00300885|Drug|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
512576|NCT00300885|Drug|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
512577|NCT00300872|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
512702|NCT00299676|Drug|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
512703|NCT00299650|Drug|cisatracurium|
512704|NCT00299650|Drug|Placebo|physiological serum infusion
512578|NCT00300872|Device|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
512579|NCT00300859|Behavioral|brief motivational intervention|
512580|NCT00300846|Drug|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
512581|NCT00300846|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
512582|NCT00300833|Drug|Tirofiban|pci
512583|NCT00300807|Drug|XTL 6865|
512584|NCT00300794|Drug|Ketamine|
512585|NCT00300781|Drug|neratinib|
512586|NCT00300768|Drug|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
512587|NCT00300768|Drug|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
512588|NCT00300768|Drug|4 mg moxidectin|Single dose, tablets encapsulated for blinding
512589|NCT00300768|Drug|8 mg moxidectin|single dose, tablets encapsulated for blinding
512590|NCT00300755|Drug|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
512591|NCT00300742|Drug|Topiramate|Topiramate up to 300 mg per day.
512592|NCT00300729|Drug|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
512593|NCT00300729|Drug|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
512594|NCT00300716|Drug|Memantine|
512595|NCT00300690|Device|6 mm Uni-graft® (B-Braun)|
512596|NCT00300690|Device|6 mm Gore-Tex® (WL Gore)|
512597|NCT00300677|Drug|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
512598|NCT00300664|Drug|Human Growth hormone|
512599|NCT00300651|Behavioral|Cognitive Behavioral Therapy|
512600|NCT00300638|Procedure|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
512601|NCT00300638|Behavioral|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
512602|NCT00300625|Procedure|Application of the San Francisco Syncope Rule|
512603|NCT00300612|Biological|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
512604|NCT00300599|Device|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
512605|NCT00300599|Other|Placebo|Placebo
512606|NCT00300586|Drug|observation|observation, second line chemotherapy if progression
512607|NCT00300586|Drug|gemcitabine|1250 mg/m² D1, D8 q21 days
512608|NCT00300586|Drug|erlotinib|150 mg daily
512609|NCT00300573|Drug|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
512610|NCT00300560|Drug|Colistin|
512611|NCT00300547|Procedure|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
512612|NCT00300534|Device|Abbott Laboratories Determine test for syphilis|
512613|NCT00300534|Device|Investigational syphilis immunochromatographic strip test|
512614|NCT00300521|Genetic|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
512615|NCT00300508|Drug|Anastrozole|
512616|NCT00300495|Drug|Amiodarone|Perioperative orally administered
512617|NCT00300495|Other|Control arm, standard care|Control
512618|NCT00300482|Drug|ABT-335|135 mg, daily, 12 weeks
512619|NCT00300482|Drug|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
512620|NCT00300482|Drug|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
512621|NCT00300469|Drug|ABT-335|135 mg, daily, 12 weeks
512622|NCT00300469|Drug|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
512623|NCT00300469|Drug|Placebo|daily, 12 weeks, see Arm Description for placebo information
512624|NCT00300456|Drug|ABT-335|135 mg, daily, 12 weeks
512625|NCT00300456|Drug|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
512626|NCT00300456|Drug|Placebo|Daily, 12 weeks, see Arm Description for placebo information
512627|NCT00300443|Drug|bimatoprost|
512628|NCT00300430|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
512629|NCT00300430|Drug|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
512630|NCT00300430|Drug|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
512631|NCT00300417|Drug|VRC-WNVDNA020-00-VP|
512632|NCT00300404|Drug|daraprim|
512633|NCT00300404|Drug|pyrimethamine|
512634|NCT00300404|Drug|folinic acid|
512705|NCT00299650|Drug|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
512706|NCT00299611|Drug|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
512707|NCT00299611|Drug|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
512708|NCT00299611|Drug|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
512635|NCT00300391|Drug|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
512636|NCT00300391|Other|Saline placebo|control arem
512637|NCT00300378|Drug|desvenlafaxine 50 mg|
512638|NCT00300378|Drug|desvenlafaxine 100 mg|
512639|NCT00300365|Drug|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
512640|NCT00300365|Other|Placebo|Pioglitazone placebo
512641|NCT00300365|Drug|Niacin ER|Niacin ER 2.0 g/day
512642|NCT00300365|Drug|Aspirin|asprin 325 mg/day
512643|NCT00300352|Drug|Folic Acid|
512644|NCT00300339|Drug|SL650472, Clopidogrel|
512645|NCT00300326|Procedure|Computer assist|same implant using a computer-assisted surgical technique.
512646|NCT00300313|Drug|Escitalopram|10 to 20 mg / day
512647|NCT00300313|Drug|Placebo|1-2 capsules
512648|NCT00300300|Procedure|Computer-assisted surgery|no description
512649|NCT00300287|Drug|Vildagliptin|
512650|NCT00300274|Drug|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
512651|NCT00300274|Drug|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
512652|NCT00300274|Drug|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
512653|NCT00300274|Drug|corticosteroids|Corticosteroids standard dose.
512654|NCT00300261|Behavioral|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
512655|NCT00300222|Drug|NGX-4010|
512656|NCT00300196|Biological|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
512657|NCT00300196|Drug|Placebo|0.6 mL/kg/hr
512658|NCT00300157|Device|Percutaneous coronary intervention with Taxus stent|
512659|NCT00300131|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
512660|NCT00300118|Drug|budesonide|9 mg
512661|NCT00300118|Drug|mesalazine|4.5 g
512662|NCT00300105|Drug|Tesaglitazar|
512663|NCT00300092|Drug|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
512664|NCT00300079|Drug|brinzolamide 1.0%|
512665|NCT00300053|Device|stem cell injection|
512666|NCT00300040|Drug|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
512667|NCT00300040|Drug|6% Hydroxyethylstarch|250ml for intravenous infusion
512668|NCT00300027|Drug|BMS-582664|
512669|NCT00300014|Procedure|Intravitreal triamcinolone injection|
512670|NCT00300014|Procedure|Air-fluid exchange|
512671|NCT00299988|Drug|Intravenous Immunoglobulin|
512672|NCT00299975|Drug|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
512673|NCT00299975|Drug|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
512674|NCT00299975|Drug|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
512675|NCT00299962|Biological|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
512676|NCT00299962|Biological|SCH 721015|Comparison of different doses and frequency of investigational agent
512677|NCT00299936|Drug|Ribavirin, PEG-Intron|
512678|NCT00299923|Drug|Peginterferon alfa-2a, Ribavirin, Amantadine|
512679|NCT00299910|Drug|Montelukast|
512680|NCT00299897|Drug|SP01A|
512681|NCT00299884|Drug|Lipitor 20 mg|A/A for 6 weeks
512682|NCT00299884|Drug|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
512683|NCT00299871|Drug|LIXISENATIDE (AVE0010)|
512684|NCT00299858|Drug|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.~Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
512685|NCT00299845|Drug|Lansoprazole|
512686|NCT00299832|Drug|Aliskiren|
512687|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
512688|NCT00299819|Biological|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
512689|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
512690|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
512691|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
512692|NCT00299806|Drug|Aliskiren|
512693|NCT00299780|Drug|Stem cell mobilization|
512694|NCT00299767|Procedure|sequential cord blood transplantation|Infused on Day 0
512695|NCT00299754|Drug|Misoprostol|
512696|NCT00299741|Drug|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
512697|NCT00299728|Biological|NY-ESO-1 protein with CpG 7909 and Montanide|
512698|NCT00299715|Drug|Paliperidone extended-release|
512699|NCT00299702|Drug|Abilify|10-30 mg once daily for 104 weeks
512700|NCT00299702|Drug|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
512701|NCT00299689|Drug|Denileukin diftitox|12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
534587|NCT00113724|Drug|TPI 287 Injection|
512709|NCT00299598|Device|alkylated polyethylenimine nanoparticles antibacterial evaluation|
512710|NCT00299585|Procedure|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
512711|NCT00299572|Drug|alendronate (Fosamax)|
512712|NCT00299559|Drug|smart textiles containing menthol, camphor, cineol|application to skin
512713|NCT00299546|Drug|Placebo|SC injections
512714|NCT00299546|Biological|Golimumab 50 mg|SC injections
512715|NCT00299546|Biological|Golimumab 100 mg|SC injections
512716|NCT00299533|Drug|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
512717|NCT00299520|Drug|intravenous iclaprim or intravenous linezolid|
512718|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
512719|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
512720|NCT00299507|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
512721|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
512722|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
512723|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
512724|NCT00299494|Drug|Rituximab|rituximab 375 mg/m^2 via IV infusion on Day 1
512725|NCT00299468|Behavioral|Patient Activation Measure Intervention Package|
512726|NCT00299455|Drug|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
512727|NCT00299455|Drug|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
512728|NCT00299442|Behavioral|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
512729|NCT00299429|Procedure|Stenting and minimally invasive bypass surgery|
512730|NCT00299429|Procedure|PCI with DES|PCI with DES
512731|NCT00299416|Drug|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
512732|NCT00299416|Procedure|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
512733|NCT00299403|Procedure|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2"
512734|NCT00299403|Procedure|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
512735|NCT00299390|Drug|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
512736|NCT00299377|Drug|Abciximab i.v.|
512737|NCT00299377|Drug|Abciximab i.c.|
512738|NCT00299364|Drug|Black Cohosh (iCR) or tibolone|
512739|NCT00299351|Drug|Depsipeptide|
512740|NCT00299338|Drug|SP01A|
512741|NCT00299325|Drug|Rimonabant|Tablet, oral administration
512742|NCT00299325|Drug|Placebo (for Rimonabant)|Tablet, oral administration
512743|NCT00299325|Other|Mild hypocaloric diet|Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
512744|NCT00299286|Drug|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
512745|NCT00299286|Drug|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).~Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
512746|NCT00299273|Behavioral|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
512747|NCT00299260|Biological|CMV gB vaccine|20 micrograms
512748|NCT00299260|Drug|Placebo|normal saline
512749|NCT00299247|Drug|sulfadoxine/pyrimethamine|
512750|NCT00299234|Drug|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
512751|NCT00299221|Drug|Tacrolimus|tacrolimus
512752|NCT00299221|Drug|combination therapy|MMF
512753|NCT00299208|Drug|Artesunate|
512754|NCT00299208|Drug|Azithromycin|
512755|NCT00299208|Drug|Quinine|
512756|NCT00299195|Drug|sulindac|Sulindac 150 mg po bid x 24 weeks
512757|NCT00299195|Drug|Placebo|Placebo bid x 24 weeks
512758|NCT00299182|Drug|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
512759|NCT00299182|Drug|Rituximab|375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.
512760|NCT00299182|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, & 5.
512761|NCT00299182|Drug|Vincristine|1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,& 5.
512762|NCT00299182|Drug|Doxorubicin|50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,& 5.
512763|NCT00299182|Drug|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,& 5.
512764|NCT00299182|Drug|Methotrexate|200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 & 6.
512830|NCT00298584|Procedure|Percutaneous Suprapubic Aspiration|
512765|NCT00299182|Drug|Cytarabine|3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,& 6.
512766|NCT00299182|Drug|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
512767|NCT00299169|Behavioral|N of 1 Trials|N of 1 Trials of statin therapy
512768|NCT00299156|Drug|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
512769|NCT00299130|Drug|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
512770|NCT00299130|Drug|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
512771|NCT00299130|Drug|Methylprednisolone|Intravenous infusion
512772|NCT00299130|Drug|Placebo|Placebo to rituximab intravenous infusion
512773|NCT00299130|Drug|Rituximab|Intravenous infusion
512774|NCT00299117|Behavioral|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
512775|NCT00299104|Drug|folate|Intravenous repeating dose
512776|NCT00299104|Drug|methotrexate|Oral or parenteral repeating dose
512777|NCT00299104|Drug|methylprednisolone|Intravenous repeating dose
512778|NCT00299104|Drug|placebo|Intravenous repeating dose
512779|NCT00299104|Drug|rituximab|Intravenous repeating dose
512780|NCT00299091|Drug|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
512781|NCT00299065|Drug|Zileuton injection|
512782|NCT00299052|Device|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
512783|NCT00299052|Biological|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
512784|NCT00299039|Drug|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
512785|NCT00299039|Drug|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
512786|NCT00299026|Device|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
512787|NCT00299013|Drug|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
512788|NCT00299013|Drug|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
512789|NCT00299000|Drug|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
512790|NCT00298987|Drug|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
512791|NCT00298974|Drug|hydrocodone / acetaminophen extended release|2 tablets twice daily
512792|NCT00298974|Drug|Placebo|2 tablets twice daily
512793|NCT00298961|Device|Videoconference equipment FALCON/IP|
512794|NCT00298935|Procedure|Osteopathic manipulative treatment (OMT)|
512795|NCT00298922|Drug|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
512796|NCT00298922|Drug|Placebo|tablet orally thrice weekly for 24 weeks
512797|NCT00298909|Behavioral|physical exercise|physical exercise
512798|NCT00298909|Drug|niaspan (extended-release niacin)|niaspan (extended-release niacin)
512799|NCT00298909|Drug|niacin|niacin extended-release
512800|NCT00298909|Other|control|control
512801|NCT00298896|Drug|SNS-595|
512802|NCT00298883|Drug|Myfortic|Myfortic 360mg PO BID for six weeks
512803|NCT00298870|Drug|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
512804|NCT00298870|Drug|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
512805|NCT00298857|Drug|Valproic acid|
512806|NCT00298831|Drug|Sugammadex|At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 was administered.
512807|NCT00298831|Drug|Rocuronium|Each participant received an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block was required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium was/were administered.
512808|NCT00298792|Behavioral|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
512809|NCT00298792|Behavioral|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
512810|NCT00298779|Drug|omeprazole and bortezomib|
512811|NCT00298766|Drug|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
512812|NCT00298753|Procedure|fluid restriction for 14 days (15ml fluid per kg weight)|
512813|NCT00298740|Device|Aventis U-400 Insulin|
512814|NCT00298727|Behavioral|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
512815|NCT00298727|Behavioral|ePBL|Online Problem-Based Course
512816|NCT00298714|Drug|Losartan|
512817|NCT00298701|Biological|ALK Grass tablet|
512818|NCT00298688|Drug|Gefitinib|
512819|NCT00298675|Drug|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
512820|NCT00298675|Drug|irinotecan|Irinotecan administered weekly, IV.
512821|NCT00298662|Drug|Interferon beta-1b and Tacrolimus|
512822|NCT00298649|Behavioral|Lay Health Advisor|
512823|NCT00298636|Drug|adenosine|
512824|NCT00298623|Drug|XP13512 (GSK1838262)|
512825|NCT00298623|Other|placebo|
512826|NCT00298610|Drug|Artesunate|Intravenous Artesunate (2.4 mg/kg) once a day for three days
512827|NCT00298610|Drug|Malarone|(proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
512828|NCT00298597|Drug|granulocyte - colony stimulating factor (G-CSF)|
512829|NCT00298597|Drug|erythropoetin (EPO)|
512832|NCT00298571|Drug|.5% bupivacaine with epinephrine|
512833|NCT00298558|Behavioral|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
512834|NCT00298545|Drug|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
512835|NCT00298545|Drug|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
512836|NCT00298532|Procedure|Advanced Life Support|
512837|NCT00298506|Drug|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
512838|NCT00298493|Procedure|Sedation management strategy|
512839|NCT00298467|Drug|MDX-060|
512840|NCT00298454|Drug|Furosemide|
512841|NCT00298441|Drug|chondroitin sulfate-iron colloid|
512842|NCT00298428|Procedure|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
512843|NCT00298415|Drug|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
512844|NCT00298415|Drug|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
512845|NCT00298363|Drug|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
512846|NCT00298363|Drug|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
512847|NCT00298363|Drug|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
512848|NCT00298363|Drug|TDF placebo|Placebo to match TDF QD
512849|NCT00298363|Drug|FTC/TDF placebo|Placebo to match FTC/TDF QD
512850|NCT00298363|Drug|ETV placebo|Placebo to match ETV QD
512851|NCT00298350|Drug|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
512852|NCT00298337|Drug|Mixture of probiotic bacteria and prebiotic oligosaccharide|
512853|NCT00298324|Drug|Myfortic|1440mg twice daily
512854|NCT00298324|Drug|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
512855|NCT00298311|Behavioral|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
512856|NCT00298298|Biological|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
512857|NCT00298285|Drug|enoxaparin|
512858|NCT00298272|Biological|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
512859|NCT00298272|Drug|Placebo|Participants will receive placebo on Day 1 and Day 15
512860|NCT00298272|Drug|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
512861|NCT00298272|Drug|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
512862|NCT00298272|Drug|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
512863|NCT00298272|Drug|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
512864|NCT00298272|Dietary Supplement|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
512865|NCT00298259|Procedure|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
512866|NCT00298233|Drug|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
512867|NCT00298220|Behavioral|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
512868|NCT00298220|Behavioral|Dissemination guideline and patient information letters|
512869|NCT00298220|Behavioral|Tailored educational training|for GP(T)s
512870|NCT00298220|Behavioral|Tailored outreach based facilitator support|in the practices of the GPTs
512871|NCT00298220|Behavioral|Facilitation of co-operation with local addiction services|
512872|NCT00298220|Behavioral|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
512873|NCT00298220|Behavioral|Reminder-card for GP's desk|
512874|NCT00298220|Behavioral|Personal feedback to patients|Patients receive advise based on their premeasurement answers
512875|NCT00298207|Behavioral|Walking (behavior)|
512876|NCT00298194|Drug|Z-338|
512877|NCT00298181|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
512878|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
512879|NCT00298168|Drug|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
512880|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
512881|NCT00298155|Drug|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
512882|NCT00298155|Drug|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
512883|NCT00298155|Drug|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
513105|NCT00296309|Drug|Tacrolimus|Immunosuppression
512884|NCT00298142|Procedure|Usual Care provided by a medical doctor (GP or Neurologist)|
512885|NCT00298142|Procedure|Usual care plus Physio-/ Manual Therapy|
512886|NCT00298129|Device|Ambulatory blood pressure monitoring|
512887|NCT00298090|Device|StO2 monitoring|placement of the StO2 device/ external noninvasive
512888|NCT00298064|Genetic|Tissue Repository|
512889|NCT00298051|Procedure|Delayed umbilical cord clamping|
512890|NCT00298038|Drug|Rifaximin|Oral
512891|NCT00298038|Drug|Placebo|Oral
512892|NCT00298025|Drug|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is >=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
512893|NCT00298025|Drug|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is >=14 mm until r-hCG day.
512894|NCT00298025|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
512895|NCT00298025|Drug|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
512896|NCT00298025|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
512897|NCT00298012|Drug|Methotrexate|
512898|NCT00297986|Device|Helmet|Evaluation of different interfaces for NPPV
512899|NCT00297973|Procedure|Blood pressure measurements|
512900|NCT00297973|Procedure|Blood samples|
512901|NCT00297960|Drug|ziprasidone or olanzapine|
512902|NCT00297960|Procedure|hyperinsulinaemic euglycaemic clamp|
512903|NCT00297960|Procedure|microdialysis (skeletal muscle)|
512904|NCT00297947|Drug|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
512905|NCT00297947|Drug|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
512906|NCT00297934|Device|Pro-adjuster mechanical spinal manipulative device|
512907|NCT00297921|Drug|tandutinib|
512908|NCT00297895|Procedure|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
512909|NCT00297895|Procedure|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
512910|NCT00297882|Drug|Artemether-Lumefantrine , Amodiaquine-Artesunate|"Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).~Amodiaquine-ArtemetherD0(0H),D1(24H),D2(48H)- Artesunate 4mg/kg and Amodiaquine at 10mg/kg"
512911|NCT00297869|Procedure|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
512912|NCT00297856|Biological|Boostrix®|Single dose
512913|NCT00297856|Biological|Td (Tetanus diphtheria) vaccine|Single dose
512914|NCT00297843|Procedure|allergen challenge (grass pollen), nasal lavage|
512915|NCT00297830|Drug|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
512916|NCT00297830|Drug|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
512917|NCT00297830|Other|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
512918|NCT00297830|Other|Placebo Alendronate|Placebo alendronate 70 mg once weekly
512919|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
512920|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
512921|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
512922|NCT00297804|Device|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
512923|NCT00297804|Device|Control stent|control stent
512924|NCT00297791|Procedure|surgery|randomized to open or laparoscopic technique
512925|NCT00297778|Drug|Pramipexole|Dopamine agonist
512926|NCT00297778|Other|Placebo|
512927|NCT00297765|Drug|Tacrolimus, Prograf®|
512928|NCT00297752|Drug|ceriumnitrate silversulfadiazine (flammacerium)|
512929|NCT00297752|Drug|silversulfadiazine (flammazine)|
512930|NCT00297739|Drug|Risperidone|
512931|NCT00297726|Behavioral|Self-Management Program|
512932|NCT00297713|Drug|ALTU-238|
512933|NCT00297700|Behavioral|Active referral|
512934|NCT00297687|Biological|MnB rLP2086|
512935|NCT00297674|Drug|Intravenous Clarithromycin|
512936|NCT00297661|Device|Sirolimus-eluting stent|
512937|NCT00297661|Device|Paclitaxel-eluting stent|
512938|NCT00297648|Biological|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
512939|NCT00297635|Device|GlucoDYNAMIX™ intervention system|
512940|NCT00297635|Device|GlucoMON™ telemetry device|
513106|NCT00296296|Drug|Cyclosporin|Dose adjustment to pre-established targets
512941|NCT00297596|Drug|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
512942|NCT00297596|Drug|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.~For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
512943|NCT00297583|Drug|Insulin Glulisine|
512944|NCT00297570|Drug|Pegylated Interferon and Imatinib|
512945|NCT00297544|Drug|Viagra|
512946|NCT00297531|Device|PerioWave|
512947|NCT00297531|Procedure|Scaling and Root Planing|
512948|NCT00297518|Device|PerioWave|
512949|NCT00297518|Procedure|Scaling and Root Planing|
512950|NCT00297505|Drug|citalopram|
512951|NCT00297492|Behavioral|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
512952|NCT00297492|Behavioral|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
512953|NCT00297492|Behavioral|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
512954|NCT00297492|Drug|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
512955|NCT00297492|Drug|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.~4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.~Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
512956|NCT00297479|Behavioral|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
512957|NCT00297479|Drug|Nicotine|6 weeks of nicotine patch therapy
512958|NCT00297479|Behavioral|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
512959|NCT00297479|Behavioral|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
512960|NCT00297466|Drug|transdermal nicotine patches|
512961|NCT00297466|Behavioral|Motivational interview|
512962|NCT00297453|Behavioral|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
512963|NCT00297453|Behavioral|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
512964|NCT00297453|Behavioral|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
512965|NCT00297440|Behavioral|Cognitive-behavioral treatment|
512966|NCT00297440|Behavioral|Exercise|
512967|NCT00297427|Procedure|Acupuncture|Acupuncture twice weekly for 6 weeks.
512968|NCT00297427|Other|Sham acupuncture|Twice a week for 6 weeks
512969|NCT00297414|Other|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
512970|NCT00297401|Drug|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
512971|NCT00297401|Drug|placebo|QD, PO, up to 8 weeks
512972|NCT00297388|Drug|Risperidone, long-acting injectable|
512973|NCT00297375|Drug|tramadol HCl/acetaminophen|
512974|NCT00297362|Drug|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
512975|NCT00297349|Drug|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
512976|NCT00297336|Drug|Topiramate|80 patients with diagnosed with migraine
512977|NCT00297323|Drug|Topiramate|75 patients over the age of 2 years old with epilepsy.
512978|NCT00297310|Drug|tacrolimus|
512979|NCT00297297|Other|No intervention. Applying gene profiling on needle aspirates|
512980|NCT00297284|Drug|Modafinil|
512981|NCT00297271|Other|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
512982|NCT00297258|Drug|pazopanib|oral tablet
512983|NCT00297245|Drug|cognitive function|
512984|NCT00297232|Drug|Natalizumab|
512985|NCT00297219|Drug|Low dialysate calcium|1.25 mmol/L dialysate calcium
512986|NCT00297219|Drug|high dialysate calcium|1.75 mmol/L dialysate calcium
512987|NCT00297206|Drug|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
512988|NCT00297193|Procedure|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
512989|NCT00297180|Drug|GW869682|
512990|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
512991|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
512992|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
512993|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
512994|NCT00297154|Behavioral|Lifestyle Modification (diet, exercise, and behavior)|
512995|NCT00297141|Drug|Capecitabine|chemotherapy oral use
512996|NCT00297141|Drug|Oxaliplatin|chemotherapy intravenous use
512997|NCT00297128|Drug|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
512998|NCT00297128|Drug|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
512999|NCT00297115|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
513000|NCT00297115|Drug|Placebo|once daily
513001|NCT00297102|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
513002|NCT00297102|Drug|Placebo|once daily
513003|NCT00297089|Drug|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
513004|NCT00297089|Drug|pemetrexed|Standard pemetrexed every 21 days
513005|NCT00297089|Drug|placebo|Placebo daily for 14 days every 21 days
513006|NCT00297076|Drug|GW873140|
513007|NCT00297063|Drug|Rosiglitazone|
513008|NCT00297050|Drug|Peramivir|
513009|NCT00297037|Drug|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
513010|NCT00297024|Procedure|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
513011|NCT00297011|Drug|valacyclovir+clobetasol gel|
513012|NCT00296985|Device|Fresenius Cellsaver|
513013|NCT00296972|Drug|peg interferon plus ribavirin|
513014|NCT00296959|Drug|topiramate (drug)|
513015|NCT00296946|Drug|ipratropium bromide (drug)|
513016|NCT00296933|Drug|Escitalopram|
513017|NCT00296933|Drug|Bupropion XL|
513018|NCT00296920|Device|Deep Brain Stimulation|
513019|NCT00296907|Behavioral|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
513020|NCT00296894|Drug|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
513021|NCT00296894|Drug|Placebo|Placebo
513022|NCT00296881|Device|PERIOWAVE|
513023|NCT00296868|Drug|ascorbic acid (vitamin C) versus placebo|
513024|NCT00296855|Drug|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
513025|NCT00296842|Behavioral|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
513026|NCT00296829|Biological|Inactivated, split-virion influenza vaccine|
513027|NCT00296816|Drug|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
513028|NCT00296816|Drug|Docetaxel (Taxotere®)|75 mg/m^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
513029|NCT00296816|Drug|Oxaliplatin (Eloxatin®)|85 mg/m^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
513030|NCT00296803|Drug|clopidogrel|
513031|NCT00296790|Drug|zolpidem tartrate|
513032|NCT00296777|Drug|Escitalopram|8 weeks: up to 40 mg/day
513033|NCT00296777|Drug|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
513034|NCT00296777|Drug|Imipramine|"8 weeks: up to 300mg/day~*if patient does not have contraindication."
513035|NCT00296751|Procedure|ECG recording|
513036|NCT00296751|Procedure|Epidural catheter insertion|
513037|NCT00296751|Drug|Intravenous meperidine injection|
513038|NCT00296751|Drug|Epidural Bupivacaine and fentanyl injection|
513039|NCT00296738|Device|SPECT/CT|GE INFINIA HAWKEYE
513040|NCT00296725|Drug|Fluoxetine|Phase 1: Fluoxetine: wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day *All increases only if tolerated.
513041|NCT00296725|Drug|Imipramine|Phase 2: Imipramine wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. *All increases only if tolerated.
513042|NCT00296712|Drug|escitalopram + bupropion|same dosing as for monotherapy arms
513043|NCT00296699|Drug|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.~* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
513165|NCT00295997|Procedure|peripheral blood stem cell transplantation|
513044|NCT00296686|Drug|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
513045|NCT00296686|Drug|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
513046|NCT00296686|Drug|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
513047|NCT00296673|Device|Rehabilitation device|
513048|NCT00296647|Drug|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
513049|NCT00296647|Drug|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
513050|NCT00296647|Drug|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
513051|NCT00296647|Drug|bupropion|dosage according to prescription directions: 12 weeks
513052|NCT00296647|Drug|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
513053|NCT00296647|Drug|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
513054|NCT00296634|Drug|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
513055|NCT00296634|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
513056|NCT00296621|Drug|L-Glutamine|L-Glutamine
513057|NCT00296621|Drug|placebo|placebo
513058|NCT00296608|Drug|fluorouracil|
513059|NCT00296608|Drug|leucovorin calcium|
513060|NCT00296608|Procedure|conventional surgery|
513061|NCT00296608|Radiation|radiation therapy|
513062|NCT00296595|Behavioral|Nutrition|
513063|NCT00296582|Behavioral|Gastric Motor Function Measurement|
513064|NCT00296569|Drug|MK0686|
513065|NCT00296556|Drug|Rivenprost (drug)|
513066|NCT00296530|Drug|fluticasone propionate/salmeterol|
513067|NCT00296530|Drug|fluticasone propionate|
513068|NCT00296530|Drug|montelukast|
513069|NCT00296517|Drug|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
513070|NCT00296517|Drug|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
513071|NCT00296504|Drug|fosamprenavir (GW433908)|
513072|NCT00296504|Drug|ritonavir|
513073|NCT00296491|Drug|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
513074|NCT00296491|Drug|montelukast (MON)|montelukast capsule
513075|NCT00296491|Drug|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
513076|NCT00296491|Drug|placebo nasal|vehicle placebo nasal spray
513077|NCT00296491|Drug|ADVAIR DISKUS|ADVAIR DISKUS
513078|NCT00296491|Drug|placebo capsule|placebo capsule
513079|NCT00296491|Drug|placebo DISKUS|placebo DISKUS
513080|NCT00296478|Drug|Endometrin|Endometrin 100mg BID x 10weeks
513081|NCT00296478|Drug|Endometrin|Endometrin 100mg TID x 10weeks
513082|NCT00296478|Drug|Crinone|Crinone QD x 10weeks
513083|NCT00296465|Drug|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
513084|NCT00296465|Drug|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
513085|NCT00296465|Drug|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
513086|NCT00296465|Drug|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
513087|NCT00296452|Behavioral|behavior|
513088|NCT00296439|Behavioral|Behavior|
513089|NCT00296426|Procedure|New technology - PAML|
513090|NCT00296400|Drug|Rosuvastatin|
513091|NCT00296400|Drug|Atorvastatin|
513092|NCT00296387|Drug|Rosuvastatin|
513093|NCT00296387|Drug|Atorvastatin|
513094|NCT00296374|Drug|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
513095|NCT00296374|Drug|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
513096|NCT00296374|Drug|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
513097|NCT00296361|Drug|Tacrolimus|immunosuppression
513098|NCT00296348|Drug|tacrolimus|immunosuppression
513099|NCT00296348|Drug|mycophenolate mofetil|oral
513100|NCT00296348|Drug|daclizumab|oral
513101|NCT00296348|Drug|steroids|oral
513102|NCT00296335|Drug|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
513103|NCT00296335|Drug|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
513104|NCT00296322|Drug|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)~iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
513107|NCT00296296|Drug|Tacrolimus|Dose adjustment to pre-established targets
513108|NCT00296296|Behavioral|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
513109|NCT00296283|Behavioral|integrative behavior couples therapy|
513110|NCT00296270|Behavioral|Memory for truth|
513111|NCT00296257|Drug|SMP-114|
513112|NCT00296244|Drug|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
513113|NCT00296244|Drug|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
513114|NCT00296244|Drug|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
513115|NCT00296244|Drug|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
513116|NCT00296231|Other|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
513117|NCT00296218|Drug|Irbesartan|
513118|NCT00296205|Drug|Cyclophosphamide|
513119|NCT00296192|Drug|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
513120|NCT00296192|Other|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
513121|NCT00296179|Drug|zolpidem tartrate|
513122|NCT00296166|Procedure|Catheter ablation|
513123|NCT00296166|Procedure|Thoracoscopic epicardial ablation|
513124|NCT00296153|Drug|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
513125|NCT00296140|Behavioral|self management of PSD symptoms|
513126|NCT00296140|Procedure|screening and treatment of PSD|
513127|NCT00296127|Drug|Celecoxib|
513128|NCT00296114|Procedure|Serum and DNA Samples|To collect serum and DNA samples from subjects
513129|NCT00296101|Behavioral|Physical Activity|
513130|NCT00296062|Biological|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
513131|NCT00296062|Drug|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
513132|NCT00296062|Drug|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
513133|NCT00296062|Drug|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Phase II: oxaliplatin (during even-numbered courses) as in phase I"
513134|NCT00296049|Drug|daptomycin|
513135|NCT00296049|Drug|vancomycin|
513136|NCT00296036|Dietary Supplement|pyridoxine hydrochloride|Given orally
513137|NCT00296036|Drug|urea/lactic acid-based topical cream|Applied topically
513138|NCT00296036|Other|placebo|Given orally or applied topically
513139|NCT00296023|Biological|anti-thymocyte globulin|
513140|NCT00296023|Biological|filgrastim|
513141|NCT00296023|Biological|therapeutic allogeneic lymphocytes|
513142|NCT00296023|Drug|busulfan|
513143|NCT00296023|Drug|fludarabine phosphate|
513144|NCT00296023|Drug|methotrexate|
513145|NCT00296023|Drug|tacrolimus|
513146|NCT00296023|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
513147|NCT00296023|Procedure|peripheral blood stem cell transplantation|
513148|NCT00296010|Drug|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
513149|NCT00296010|Drug|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
513150|NCT00296010|Drug|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
513151|NCT00296010|Procedure|adjuvant therapy|
513152|NCT00296010|Radiation|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
513153|NCT00295997|Biological|anti-thymocyte globulin|
513154|NCT00295997|Biological|filgrastim|
513155|NCT00295997|Biological|graft-versus-tumor induction therapy|
513156|NCT00295997|Biological|therapeutic allogeneic lymphocytes|
513157|NCT00295997|Drug|busulfan|
513158|NCT00295997|Drug|cyclophosphamide|
513159|NCT00295997|Drug|fludarabine phosphate|
513160|NCT00295997|Drug|methotrexate|
513161|NCT00295997|Drug|mycophenolate mofetil|
513162|NCT00295997|Drug|tacrolimus|
513163|NCT00295997|Procedure|allogeneic bone marrow transplantation|
513164|NCT00295997|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
513167|NCT00295971|Biological|anti-thymocyte globulin|
513168|NCT00295971|Biological|therapeutic allogeneic lymphocytes|
513169|NCT00295971|Drug|fludarabine phosphate|
513170|NCT00295971|Drug|thiotepa|
513171|NCT00295971|Procedure|allogeneic bone marrow transplantation|
513172|NCT00295971|Procedure|allogeneic hematopoietic stem cell transplantation|
513173|NCT00295971|Procedure|in vitro-treated peripheral blood stem cell transplantation|
513174|NCT00295971|Radiation|total-body irradiation|
513175|NCT00295958|Biological|LMB-2 immunotoxin|
513176|NCT00295958|Biological|MART-1 antigen|
513177|NCT00295958|Biological|gp100 antigen|
513178|NCT00295958|Biological|incomplete Freund's adjuvant|
513179|NCT00295945|Drug|fentanyl citrate|
513180|NCT00295945|Drug|hydromorphone hydrochloride|
513181|NCT00295945|Drug|ropivacaine hydrochloride|
513182|NCT00295932|Biological|rituximab|Given IV
513183|NCT00295932|Drug|bortezomib|Given IV
513184|NCT00295932|Drug|cyclophosphamide|Given IV
513185|NCT00295932|Drug|prednisone|Given orally
513186|NCT00295919|Drug|fenretinide lipid matrix|
513187|NCT00295919|Drug|ketoconazole|
513188|NCT00295919|Other|laboratory biomarker analysis|
513189|NCT00295919|Other|pharmacological study|
513190|NCT00295906|Other|educational intervention|
513191|NCT00295906|Other|internet-based intervention|
513192|NCT00295893|Biological|trastuzumab|Given IV
513193|NCT00295893|Drug|carboplatin|Given IV
513194|NCT00295893|Drug|cyclophosphamide|Given IV
513195|NCT00295893|Drug|docetaxel|Given IV
513196|NCT00295893|Drug|doxorubicin hydrochloride|Given IV
513197|NCT00295893|Drug|paclitaxel|Given IV
513198|NCT00295880|Procedure|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
513199|NCT00295867|Drug|zoledronic acid|
513200|NCT00295854|Drug|MN-001 BID|Eligible patients received 500 mg MN-001 bid
513201|NCT00295854|Drug|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
513202|NCT00295854|Drug|Placebo|Eligible patients received placebo
513203|NCT00295841|Drug|clofarabine|
513204|NCT00295841|Drug|cytarabine|
513205|NCT00295828|Other|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
513206|NCT00295828|Procedure|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
513207|NCT00295815|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
513208|NCT00295815|Drug|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
513209|NCT00295802|Device|Integrated Imaging High Intensity Focused Ultrasound|
513210|NCT00295802|Device|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
513211|NCT00295789|Drug|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
513212|NCT00295789|Drug|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
513213|NCT00295776|Drug|Lamictal in the treatment of Post-Herpetic Neuralgia|
513214|NCT00295763|Drug|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.~For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
513215|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
513216|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
513217|NCT00295750|Drug|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
513218|NCT00295737|Procedure|bronchoscopy, allergen/endotoxin instillation|
513219|NCT00295724|Drug|Bicifadine|
513220|NCT00295711|Drug|Bicifadine|
513221|NCT00295698|Drug|Diethylcarbamazine|
513222|NCT00295685|Drug|Antacids|
513223|NCT00295672|Drug|Vinorelbine|
513224|NCT00295646|Drug|tamoxifen|20 mg/d
513225|NCT00295646|Drug|anastrozole|1 mg/d
513226|NCT00295646|Drug|zoledronic acid|4 mg q6m
513227|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
513228|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
513229|NCT00295633|Drug|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
513230|NCT00295633|Drug|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
513231|NCT00295633|Drug|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
513232|NCT00295633|Drug|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
513233|NCT00295620|Drug|Anastrozole|1mg tablet daily
513234|NCT00295607|Drug|Tacrolimus|immunosuppression
513235|NCT00295607|Drug|steroids, monoclonal anti-IL2R antibody|immunosuppression
513236|NCT00295594|Drug|tacrolimus|Immunosuppression
513237|NCT00295581|Drug|PpPfs25/ISA51 & ScPvs25/ISA51|
513238|NCT00295555|Drug|Effects of doxazosin on morning surge in diabetic patients|
513239|NCT00295542|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
513240|NCT00295542|Procedure|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
513241|NCT00295542|Drug|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
513242|NCT00295542|Drug|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
513243|NCT00295542|Drug|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
513244|NCT00295542|Drug|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
513245|NCT00295542|Procedure|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
513246|NCT00295529|Behavioral|Multifaceted educational intervention|Educational materials available at end of study
513247|NCT00295516|Procedure|Fetal Middle Cerebral Artery Doppler measurement|
513248|NCT00295503|Drug|bevacizumab|15 mg/kg IV every 3 weeks
513249|NCT00295503|Drug|cisplatin|75 mg/m2 IV every 3 weeks
513250|NCT00295503|Drug|pemetrexed|500 mg/m2 every 3 weeks
513251|NCT00295490|Drug|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
513252|NCT00295490|Drug|Placebo|Placebo has same dosing freq as for active intervention and for same time period
513253|NCT00295477|Genetic|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
513254|NCT00295464|Drug|Betamethasone sodium phos (drug)|
513255|NCT00295438|Device|Robot-Based Tele-Echography (TER)|Robot-Based Tele-Echography, ultrasound performed by the radiologist
513256|NCT00295438|Device|ultrasound method FAST|FAST,ultrasound performed by the emergency doctor
513257|NCT00295425|Drug|Cyclosporine A versus mycophenolate mofetil for psoriasis|
513258|NCT00295412|Drug|quetiapine (drug)|
513259|NCT00295399|Device|The Jerusalem Telerehabilitation System|
513260|NCT00295386|Behavioral|Cognitive behavior therapy (CBT)|
513261|NCT00295386|Drug|Zopiclone|
513262|NCT00295373|Drug|Rosuvastatin|
513263|NCT00295373|Behavioral|Exercise Training|
513264|NCT00295360|Behavioral|no intervention, pathophysiological study|
513265|NCT00295347|Drug|Spironolactone|
513266|NCT00295347|Drug|fludrocortisone|
513267|NCT00295347|Drug|escitalopram|
513268|NCT00295334|Drug|alcohol|
513269|NCT00295308|Drug|Clonidine|clonidine up to 0.3 mg/day oral
513270|NCT00295308|Drug|Placebo|oral capsules daily
513271|NCT00295295|Device|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
513272|NCT00295295|Other|Standing|Standing 10 min/day
513273|NCT00295282|Drug|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
513274|NCT00295269|Drug|Mythylprednisolone|
513275|NCT00295256|Behavioral|nurse case manager|
513276|NCT00295243|Drug|Topotecan|
513277|NCT00295230|Procedure|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
513278|NCT00295217|Device|ExAblate 2000|
513279|NCT00295191|Procedure|high-flux membrane|high-flux dialyser
513280|NCT00295191|Procedure|low-flux membrane|low-flux dialyser
513281|NCT00295191|Procedure|conventional dialysate|conventional dialysate
513282|NCT00295191|Procedure|ultrapure dialysate|ultrapure dialysate
513283|NCT00295178|Drug|Daptomycin|
513284|NCT00295178|Drug|Vancomycin|
513285|NCT00295165|Drug|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
513286|NCT00295165|Drug|Placebo|Placebo subcutaneously once daily
513287|NCT00295152|Behavioral|community occupational therapy in dementia|
513288|NCT00295139|Behavioral|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
513289|NCT00295139|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
513290|NCT00295139|Behavioral|Critical Time Intervention (CTI)|Case management component
513291|NCT00295126|Procedure|cellular therapy : Autologous platelet concentrate (APC)|
513292|NCT00295113|Procedure|EFR|
513293|NCT00295100|Drug|Tamoxifen|
513294|NCT00295074|Procedure|neuropsychologic testing|
513295|NCT00295061|Drug|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
513296|NCT00295061|Drug|alpha-1 proteinase inhibitor (human)|Prolastin
513297|NCT00295048|Behavioral|Computer Assisted Cognitive Remediation (CACR)|
513298|NCT00295035|Drug|CELECOXIB|
513299|NCT00295035|Drug|CURCUMIN|
513300|NCT00295022|Drug|Placebo|"Pharmaceutical form: Over-encapsulated tablet~Route of administration: Oral use"
513301|NCT00295022|Drug|Montelukast|"Pharmaceutical form: Over-encapsulated tablet~Concentration: 10 mg~Route of administration: Oral use"
513302|NCT00295022|Drug|Levocetirizine|"Pharmaceutical form: Over-encapsulated tablet~Concentration: 5 mg~Route of administration: Oral use"
513303|NCT00295009|Device|ProDisc|Total disc replacement with ProDisc
513304|NCT00295009|Procedure|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
513305|NCT00294996|Drug|Myocet|
513306|NCT00294944|Drug|Idazoxan|
513307|NCT00294931|Drug|irinotecan|
513308|NCT00294931|Drug|carboplatin|
513309|NCT00294931|Drug|bevacizumab|
513364|NCT00294437|Drug|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
513310|NCT00294918|Drug|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
513311|NCT00294905|Behavioral|Implementation of a combined smoking cessation strategy|
513312|NCT00294892|Drug|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
513313|NCT00294892|Drug|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
513314|NCT00294879|Procedure|pressure support ventilation at 0, 5, and 10% IRT|
513315|NCT00294866|Drug|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
513316|NCT00294853|Procedure|MDCT calcium score|
513317|NCT00294840|Device|PET-CT|
513318|NCT00294827|Procedure|Liver transplantation and colo-rectal cancer|Liver transplantation
513319|NCT00294814|Device|Proximal anastomosis using Heartstring anastomotic device|
513320|NCT00294801|Drug|flex-a-new (food supplement)|
513321|NCT00294788|Biological|Fluvax|
513322|NCT00294788|Drug|PCC® (Lactobacillus fermentum VRI 003)|
513323|NCT00294775|Drug|Candesartan|
513324|NCT00294762|Drug|Tarceva|oral tablet
513325|NCT00294762|Drug|carboplatin|IV
513326|NCT00294762|Drug|paclitaxel|IV
513327|NCT00294749|Drug|Ciprofloxacine|
513328|NCT00294736|Drug|Tarceva|Dose Escalation: 150-350+ mg/day
513329|NCT00294723|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
513330|NCT00294723|Drug|glimepiride|8 mg capsule
513331|NCT00294723|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
513332|NCT00294723|Drug|placebo|Glimepiride placebo, 8mg capsule
513333|NCT00294723|Drug|placebo|Liraglutide placebo, 200 mcl
513334|NCT00294723|Drug|placebo|Liraglutide placebo, 300 mcl
513335|NCT00294710|Drug|Aliskiren|
513336|NCT00294684|Drug|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.~Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
513337|NCT00294684|Drug|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:~Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
513338|NCT00294671|Drug|diflunisal|given twice daily for 24 months
513339|NCT00294671|Other|placebo|an inactive substance given twice daily for 24 months
513340|NCT00294658|Procedure|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
513341|NCT00294658|Drug|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
513342|NCT00294645|Other|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
513343|NCT00294645|Other|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
513344|NCT00294632|Drug|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
513345|NCT00294632|Drug|Rituximab|375 mg/m^2 By Vein Weekly for 4 Weeks
513346|NCT00294619|Drug|growth hormone|subcutaneous injection, once-weekly
513347|NCT00294606|Drug|Comparison of Effects of Phenylephrine and Norepinephrine|
513348|NCT00294593|Drug|folinic acid|
513349|NCT00294580|Drug|Maloprim|
513350|NCT00294567|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
513351|NCT00294554|Drug|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
513352|NCT00294554|Drug|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
513353|NCT00294541|Drug|ICA-17043|
513354|NCT00294528|Device|Nexgen LPS-flex and AGC|
513355|NCT00294515|Drug|Valganciclovir|900 mg orally daily for up to 100 days
513356|NCT00294515|Drug|Valganciclovir|900 mg orally daily for up to 200 days
513357|NCT00294502|Drug|Gentamycin/citrate, Minocycline/EDTA|
513358|NCT00294476|Drug|IVIG|
513359|NCT00294476|Procedure|Biological Therapy|
513360|NCT00294463|Drug|Tibolone|
513361|NCT00294463|Drug|Estradiol|
513362|NCT00294463|Drug|Estradiol + Medroxy Progesterone Acetate|
513363|NCT00294450|Device|Fistula Pouching System|3 different sizes of fistula pounching system
513365|NCT00294424|Procedure|Short waiting time|
513366|NCT00294424|Procedure|Non-fixed waiting time|
513367|NCT00294411|Procedure|elective cesarean section|
513368|NCT00294398|Other|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:~1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
513369|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
513370|NCT00294385|Drug|Docetaxel|
513371|NCT00294385|Drug|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
513372|NCT00294385|Drug|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
513373|NCT00294372|Drug|BILR 355 BS|
513374|NCT00294372|Drug|Placebo|
513375|NCT00294359|Drug|Mitomycin C; Capecitabine; Bevacizumab|
513376|NCT00294346|Drug|AV608|
513377|NCT00294320|Drug|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
513378|NCT00294320|Other|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
513379|NCT00294307|Behavioral|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners [low intensity];
513380|NCT00294307|Behavioral|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home [medium intensity];.
513381|NCT00294307|Behavioral|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers [high intensity].
513382|NCT00294294|Biological|Prevenar|
513383|NCT00294294|Biological|Infanrix hexa|
513384|NCT00294281|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
513385|NCT00294268|Behavioral|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
513386|NCT00294255|Drug|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
513387|NCT00294242|Procedure|membrane sweeping|
513388|NCT00294229|Procedure|manipulative therapy|
513389|NCT00294216|Drug|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
513390|NCT00294203|Drug|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
513391|NCT00294203|Other|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
513392|NCT00294190|Drug|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
513393|NCT00294177|Device|atomic force microscopy|
513394|NCT00294177|Device|dual polarisation interferometry|
513395|NCT00294164|Drug|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
513396|NCT00294164|Drug|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
513397|NCT00294151|Procedure|Vertebroplasty|
513398|NCT00294125|Drug|Flavocoxid|Daily flavocoxid for 12 weeks
513399|NCT00294125|Drug|Placebo|Daily placebo for 12 weeks
513400|NCT00294112|Drug|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
513401|NCT00294112|Drug|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
513402|NCT00294099|Biological|Aluminum hydroxide|Aluminum hydroxide adjuvant.
513403|NCT00294099|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
513404|NCT00294086|Drug|valsartan 160 mg|
513405|NCT00294086|Drug|valsartan 160 mg BID|
513406|NCT00294073|Procedure|Fascia Iliaca Block|
513407|NCT00294073|Procedure|Femoral Block (with stimulating catheter)|
513408|NCT00294073|Procedure|Femoral Block (without stimulating catheter)|
513478|NCT00293475|Drug|Sodium Thiosulfate|Given IV
513409|NCT00294047|Biological|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
513410|NCT00294047|Biological|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
513411|NCT00294034|Device|Pacemaker|
513412|NCT00294008|Drug|Risperdal Consta|flexible dosage for 24 months
513413|NCT00293995|Procedure|Laparaoscopic repair, with closure of contralateral patent processus vaginalis|
513414|NCT00293995|Procedure|open repair|
513415|NCT00293982|Behavioral|Physician knowledge of parental expectations for the visit|
513416|NCT00293969|Drug|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
513417|NCT00293943|Procedure|Pulmonary vein ablation|
513418|NCT00293930|Drug|Tacrolimus|
513419|NCT00293917|Drug|Tacrolimus Cream|
513420|NCT00293904|Biological|CYT005-AllQbG10|
513421|NCT00293891|Drug|Tacrolimus Cream|
513422|NCT00293878|Drug|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
513423|NCT00293865|Procedure|sentinel node|detection of the sentinel node in breast cancer
513424|NCT00293865|Procedure|GAS|
513425|NCT00293852|Procedure|Outpatient clinic follow-up|
513426|NCT00293839|Drug|oxybutynin chloride|
513427|NCT00293826|Drug|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
513428|NCT00293826|Drug|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
513429|NCT00293826|Drug|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
513430|NCT00293826|Drug|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
513431|NCT00293813|Drug|Alendronate|Alendronate 70 mg PO QW
513432|NCT00293813|Drug|Denosumab|denosumab 60 mg SC q 6 mos
513433|NCT00293813|Drug|Placebo|Placebo for alendronate and placebo for denosumab
513434|NCT00293800|Drug|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
513435|NCT00293800|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
513436|NCT00293800|Drug|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
513437|NCT00293800|Other|Timolol Vehicle|Placebo
513438|NCT00293787|Drug|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
513439|NCT00293787|Other|Timolol Vehicle|Placebo
513440|NCT00293787|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
513441|NCT00293787|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
513442|NCT00293761|Drug|Travoprost, Investigational|One drop in study eye once daily for 13 days
513443|NCT00293761|Drug|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
513444|NCT00293735|Drug|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.~20mg labetalol PO every 6 hours"
513445|NCT00293735|Drug|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
513446|NCT00293722|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
513447|NCT00293709|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
513448|NCT00293696|Drug|bicalutamide (Casodex), goserelin (Zoladex)|
513449|NCT00293683|Device|Insorb absorbable skin staple|
513450|NCT00293670|Drug|Goserelin (Zoladex)|
513451|NCT00293657|Drug|Lornoxicam 8 mg|
513452|NCT00293657|Drug|Lornoxicam 16 mg|
513453|NCT00293657|Drug|Placebo|
513454|NCT00293644|Drug|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
513455|NCT00293631|Drug|Lornoxicam 8 mg|
513456|NCT00293631|Drug|Lornoxicam 16 mg|
513457|NCT00293631|Drug|Ketorolac 30 mg|
513458|NCT00293631|Drug|Placebo|
513459|NCT00293618|Device|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
513460|NCT00293618|Other|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
513461|NCT00293618|Other|Feedback|Feedback about the physician's personal performance on prevention of PONV
513462|NCT00293605|Procedure|Total Hip Replacement|Implantation of one of 3 stem designs
513463|NCT00293592|Drug|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
513464|NCT00293579|Drug|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
513465|NCT00293553|Procedure|Electronic Barostat|
513466|NCT00293540|Procedure|oophorectomy|Excision of an ovary
513467|NCT00293540|Drug|Tamoxifen|20 mg orally every day
513468|NCT00293527|Drug|Interferon Alpha-2b|
513469|NCT00293514|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|
513470|NCT00293501|Drug|tinzaparin sodium|
513471|NCT00293488|Drug|polyamine analogue PG11047|
513472|NCT00293475|Drug|Carboplatin|Given IA
513473|NCT00293475|Other|Laboratory Biomarker Analysis|Correlative studies
513474|NCT00293475|Drug|Mannitol|Given IA
513475|NCT00293475|Drug|Methotrexate|Given IA
513476|NCT00293475|Other|Quality-of-Life Assessment|Ancillary studies
513477|NCT00293475|Biological|Rituximab|Given IV
513480|NCT00293462|Other|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
513481|NCT00293436|Drug|celecoxib|
513482|NCT00293436|Drug|erlotinib hydrochloride|
513483|NCT00293436|Procedure|adjuvant therapy|
513484|NCT00293423|Biological|HSPPC-96|25 mcg ID
513485|NCT00293423|Procedure|conventional surgery|craniotomy
513486|NCT00293410|Drug|clofarabine|
513487|NCT00293410|Drug|cyclophosphamide|
513488|NCT00293397|Device|Drug-eluting beads loaded with doxorubicin hydrochloride|Doxorubicin eluting beads
513489|NCT00293384|Drug|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
513490|NCT00293384|Drug|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
513491|NCT00293384|Drug|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
513492|NCT00293384|Drug|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
513493|NCT00293371|Drug|docetaxel|
513494|NCT00293371|Drug|prednisone|
513495|NCT00293371|Drug|vatalanib|
513496|NCT00293358|Drug|carboplatin|
513497|NCT00293358|Drug|cisplatin|
513498|NCT00293358|Drug|etoposide phosphate|
513499|NCT00293358|Drug|ifosfamide|
513500|NCT00293358|Procedure|adjuvant therapy|
513501|NCT00293358|Procedure|conventional surgery|
513502|NCT00293358|Procedure|neoadjuvant therapy|
513503|NCT00293358|Radiation|radiation therapy|
513504|NCT00293345|Drug|gemcitabine hydrochloride|
513505|NCT00293345|Drug|triapine|
513506|NCT00293332|Biological|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
513507|NCT00293332|Drug|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
513508|NCT00293332|Drug|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
513509|NCT00293332|Procedure|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
513510|NCT00293319|Biological|filgrastim|
513511|NCT00293319|Radiation|iobenguane I 131|
513512|NCT00293293|Other|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
513513|NCT00293293|Other|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
513514|NCT00293293|Other|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
513515|NCT00293293|Drug|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
513516|NCT00293280|Drug|lomustine|
513517|NCT00293267|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
513518|NCT00293267|Drug|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
513519|NCT00293254|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
513520|NCT00293254|Drug|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
513521|NCT00293241|Device|Managed Ventricular Pacing programmed ON/OFF|Device programming
513522|NCT00293228|Drug|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
513523|NCT00293228|Drug|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
513524|NCT00293215|Drug|111-Indium-CMD-193|
513525|NCT00293215|Drug|CMD-193|
513526|NCT00293202|Drug|Etanercept|Hemodialysis patients having a serum albumin of less than or equal to 3.8 g/dl and a CRP greater than or equal to 0.8 mg/dL will receive either etanercept at a dose of 25 mg by subcutaneous injection twice a week or a placebo for a period of 48 weeks. The outcome is an increase in serum albumin and pre-albumin in the treated group.
513527|NCT00293202|Drug|Saline|Saline will be injected subcutaneously twice a week
513528|NCT00293176|Drug|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
513529|NCT00293176|Drug|Placebo|Subjects will receive matching placebo tablets.
513530|NCT00293163|Device|Hylaform, Hylaform Plus (hylan B gel)|
513531|NCT00293150|Drug|Eplerenone|
513532|NCT00293124|Drug|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
513533|NCT00293111|Drug|SDX-101 (R-Etodolac)|
513534|NCT00293098|Drug|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
513535|NCT00293085|Drug|Docetaxel|
513536|NCT00293085|Drug|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.~Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.~Premedication:~Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.~All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.~Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
513538|NCT00293059|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
513539|NCT00293059|Drug|Placebo|Matching placebo to be taken orally daily.
513540|NCT00293046|Biological|ALK Grass tablet - use of compliance device|
513541|NCT00293033|Drug|BEMA™|BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.
513542|NCT00293033|Drug|Placebo|
513543|NCT00293020|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
513544|NCT00292994|Behavioral|Exercise|
513545|NCT00292994|Behavioral|Weight Loss|
513546|NCT00292981|Drug|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
513547|NCT00292968|Behavioral|Computer based care|
513548|NCT00292968|Behavioral|Telephone counseling|
513549|NCT00292968|Behavioral|Group visits|
513550|NCT00292968|Behavioral|Usual care|
513551|NCT00292955|Drug|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
513552|NCT00292942|Drug|Intravenous Artesunate|Three doses of Intravenous Artesunate drug at 2, 4, or 8 mg/kg in diluent Phosphate Buffer (0.3 M, pH 8.1)
513553|NCT00292942|Drug|Placebo|Mannitol (200 mg/vial) diluted in Phosphate Buffer and given IV in equivalent volume by subject's weight.
513554|NCT00292929|Drug|Intravenous artesunate|
513555|NCT00292916|Behavioral|whole body vibration|
513556|NCT00292916|Behavioral|resistance exercise|
513557|NCT00292916|Behavioral|"wellness"|
513558|NCT00292903|Behavioral|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
513559|NCT00292903|Behavioral|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
513560|NCT00292890|Device|insulin needle|
513561|NCT00292877|Drug|SB-240563 (Mepolizumab)|
513562|NCT00292864|Drug|SNS-032 Injection|
513563|NCT00292838|Drug|fluticasone 25, 50, 100, 200 mcg|
513564|NCT00292825|Device|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
513565|NCT00292825|Device|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
513566|NCT00292812|Drug|Nutritional supplementation (nucleotides)|
513567|NCT00292799|Drug|Orlistat Vs Metformin|
513568|NCT00292786|Behavioral|Walking Practice with Functional Electrical Stimulation|
513569|NCT00292786|Behavioral|Walking Practice|
513570|NCT00292773|Procedure|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
513571|NCT00292760|Drug|Alemtuzumab|
513572|NCT00292760|Drug|Methyprednisolone|
513573|NCT00292747|Drug|Drotaverine|
513574|NCT00292747|Drug|Drotaverine Placebo|
513575|NCT00292747|Drug|Ibuprofen|
513576|NCT00292747|Drug|Ibuprofen Placebo|
513577|NCT00292734|Drug|Zolpidem|
513578|NCT00292721|Drug|Celecoxib|celecoxib: loading and maintenance for 6 months
513579|NCT00292708|Drug|Cefmetazole (drug)|
513580|NCT00292695|Other|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
513581|NCT00292656|Procedure|NAET|
513582|NCT00292591|Drug|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
513583|NCT00292591|Drug|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
513584|NCT00292578|Procedure|NAET Testing Modalities|
513585|NCT00292552|Other|Novel endpoint determination|Novel endpoint determination
513586|NCT00292539|Device|Any pacemaker with right ventricular pacing option|
513587|NCT00292526|Drug|Enalapril|enalapril orally administered
513588|NCT00292513|Device|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
513589|NCT00292500|Device|Automated distal anastomotic device|CABG
513590|NCT00292487|Drug|Iopamidol 370 mgI/mL|
513591|NCT00292474|Device|percutaneous coronary intervention|
513592|NCT00292461|Drug|Zonisamide|Tablet once or twice daily orally for 16 weeks
513593|NCT00292461|Drug|Lamotrigine|Tablet once daily orally for 16 weeks
513594|NCT00292448|Drug|Ba 679 BR Respimat|
513595|NCT00292448|Drug|Tiotropium (Spiriva) inhalation capsule 18 ug|
513596|NCT00292435|Drug|Read vine leaf extract (AS 195)|
513597|NCT00292422|Drug|BG9924|
513598|NCT00292409|Drug|Aripiprazole|
513599|NCT00292396|Drug|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
513600|NCT00292396|Drug|placebo|12 doses
513601|NCT00292383|Procedure|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
513602|NCT00292370|Drug|Open Label (OL) Paroxetine|Open-label Paroxetine
513603|NCT00292370|Drug|Placebo|Double-blind placebo taken with OL paroxetine
513604|NCT00292370|Drug|Quetiapine|Double-blind quetiapine taken with OL paroxetine
513605|NCT00292357|Procedure|Application of autologous bone marrow|
513606|NCT00292344|Drug|Rifaximin and loperamide|
513607|NCT00292331|Procedure|cyanoacrylate injection to treat gastric variceal hemorrhage|
513608|NCT00292318|Behavioral|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
513609|NCT00292318|Behavioral|control group|Medical counseling and ano-sphinctal exercises.
513610|NCT00292305|Procedure|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
513611|NCT00292292|Device|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
513612|NCT00292292|Device|Charite Artificial Disc|Insertion of the Charite
513613|NCT00292279|Drug|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
513614|NCT00292279|Drug|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
513615|NCT00292266|Drug|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
513616|NCT00292266|Drug|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
513617|NCT00292253|Device|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
513618|NCT00292253|Device|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
513619|NCT00292240|Behavioral|Brief motivational substance use intervention|
513620|NCT00292227|Drug|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
513621|NCT00292227|Other|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
513622|NCT00292227|Drug|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
513623|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
513624|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
513625|NCT00292214|Drug|Paracetamol (acetaminophen)|
513626|NCT00292201|Drug|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
513627|NCT00292188|Drug|pregabalin|pregabalin
513628|NCT00292188|Drug|Placebo|placebo
513629|NCT00292175|Procedure|Narrow Band Imaging|
513630|NCT00292175|Procedure|colonoscopy|
513631|NCT00292162|Procedure|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
513632|NCT00292162|Drug|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
513633|NCT00292162|Drug|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
513634|NCT00292162|Drug|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
513635|NCT00292123|Drug|Methadone|
513636|NCT00292123|Behavioral|Contingency Management|
513637|NCT00292110|Drug|Methadone|100 mg/day orally
513638|NCT00292110|Behavioral|Contingency Management|Incentives given for cocaine abstinence
513639|NCT00292110|Drug|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
513640|NCT00292110|Behavioral|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
513641|NCT00292097|Procedure|Early tracheostomy|early conversion - less than or equal to 72 hours
513642|NCT00292097|Procedure|Late tracheostomy|Late conversion (10-14 days)
513643|NCT00292084|Drug|Celgosivir|
513644|NCT00292071|Drug|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
513645|NCT00292058|Device|Videoconference equipment (telepsychiatry)|
513646|NCT00292045|Biological|NY-ESO-1 protein/CpG|
513647|NCT00292019|Procedure|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
513648|NCT00292006|Device|Computerized tomography|
513649|NCT00291980|Biological|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
513650|NCT00291980|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
513651|NCT00291967|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
513652|NCT00291954|Biological|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
513653|NCT00291954|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
513654|NCT00291941|Biological|Henogen HBV vaccine|20µg, Month 0, 2 and 6
513655|NCT00291941|Biological|FENDRIX|20 µg,Months 0, 1, 2 and 6
513656|NCT00291928|Drug|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
513657|NCT00291928|Drug|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
513658|NCT00291915|Drug|Adalimumab|
513659|NCT00291915|Drug|Methotrexate|
513660|NCT00291902|Drug|SB-681323|
513661|NCT00291889|Biological|Mtb72F/AS02.|
513662|NCT00291876|Biological|Havrix™|2 doses at 12 months interval
513663|NCT00291863|Drug|Simvastatin|
513664|NCT00291850|Drug|Paclitaxel, Cisplatin, Pegfilgrastim|
513665|NCT00291837|Drug|CT-2106|
513666|NCT00291824|Behavioral|Cardiovascular risk factors and willingness to change|
513667|NCT00291811|Drug|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
513668|NCT00291798|Procedure|rate of remission|
513669|NCT00291785|Drug|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 & 29 of each 42-day cycle
513670|NCT00291785|Drug|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
513671|NCT00291785|Drug|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
513672|NCT00291772|Drug|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
513673|NCT00291759|Drug|Tamoxifen|
513674|NCT00291759|Drug|Anastrozole|
513675|NCT00291746|Drug|Esomeprazole|
513676|NCT00291746|Procedure|Bravo technique|
513677|NCT00291733|Drug|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
513678|NCT00291733|Drug|Placebo|Placebo tabl
513679|NCT00291720|Drug|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
513680|NCT00291720|Drug|Placebo|matching placebo
513681|NCT00291707|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
513682|NCT00291707|Drug|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if >6000 cGy to be delivered)
513683|NCT00291707|Procedure|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
513684|NCT00291694|Drug|celecoxib|Celecoxib 400 mg BID
513685|NCT00291694|Other|placebo|placebo
513686|NCT00291668|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol~Pharmaceutical Form: Solution for injection in pre-filled syringe~Concentration: 200 mg/mL~Route of Administration: Subcutaneous use"
513687|NCT00291668|Other|Placebo|"Active Substance: isotonic sodium chloride solution~Pharmaceutical Form: Solution for injection~Concentration: 1 mL~Route of Administration: Subcutaneous use"
513688|NCT00291655|Drug|Levetiracetam|500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
513689|NCT00291642|Drug|Placebo drops|"Pharmaceutical form: Drops for oral administration~Route of administration: Oral use"
513690|NCT00291642|Drug|Placebo tablets matching to levocetirizine|"Pharmaceutical form: Tablets for oral administration~Route of administration: Oral use"
513691|NCT00291642|Drug|Placebo tablets matching to cetirizine|"Pharmaceutical form: Tablets for oral administration~Route of administration: Oral use"
513692|NCT00291642|Drug|Levocetirizine drops|"Pharmaceutical form: Drops for oral administration~Concentration: 5 mg/ml~Route of administration: Oral use"
513693|NCT00291642|Drug|Levocetirizine tablets|"Pharmaceutical form: Tablets for oral administration~Concentration: 5 mg~Route of administration: Oral use"
513694|NCT00291642|Drug|Cetirizine drops|"Pharmaceutical form: Drops for oral administration~Concentration: 10 mg/ml~Route of administration: Oral use"
513695|NCT00291642|Drug|Cetirizine tablets|"Pharmaceutical form: Tablets for oral administration~Concentration: 10 mg~Route of administration: Oral use"
513696|NCT00291629|Drug|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
513697|NCT00291629|Procedure|collection of mobilized peripheral blood stem cells|
513698|NCT00291629|Procedure|Intracoronary infusion of mobilized cells|
513699|NCT00291616|Drug|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
513700|NCT00291616|Drug|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
513701|NCT00291603|Device|FX-class of dialyser|
513702|NCT00291590|Behavioral|DHEP|
513703|NCT00291577|Drug|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
513704|NCT00291577|Drug|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
513705|NCT00291564|Device|Cardiac Resynchronization Therapy Device|
513706|NCT00291551|Device|Placement of the PVSS Implant|Implant is placed on epicardial surface of the heart surrounding both the right and left ventricles, to provide mechanical support to the ventricular walls.
513707|NCT00291538|Drug|bortezomib|
513708|NCT00291525|Device|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered warfarin
513709|NCT00291525|Device|On-X Valve with Standard warfarin Therapy|Valve replacement with standard dosage warfarin
513710|NCT00291512|Behavioral|Theory-based counseling program|
513711|NCT00291499|Drug|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
513712|NCT00291499|Other|Placebo|800 mg placebo/day for 6 months
513779|NCT00290823|Drug|Dexamethasone|6mg or 8mg taken daily
536361|NCT00100594|Drug|Efavirenz|
513713|NCT00291486|Drug|Capecitabine|Capecitabine will be administered at doses between 1000 and 1250 mg/m2/day depending on assigned dose level for 14 days per 21 day cycle. Daily doses may be rounded to the nearest 150mg.
513714|NCT00291486|Drug|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients will receive a scout dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 will comprise a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I therapy dose will be determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
513715|NCT00291473|Drug|CHP-HER2, CHP-NY-ESO-1|
513716|NCT00291460|Device|inspiratory muscle training|
513717|NCT00291447|Drug|ch806|
513718|NCT00291447|Drug|111-Indium-ch806|
513719|NCT00291408|Procedure|Skin Prick Test|
513720|NCT00291408|Procedure|Impulse Oscillometry|
513721|NCT00291408|Procedure|Exhaled Nitric Oxide|
513722|NCT00291408|Procedure|Spirometry|
513723|NCT00291408|Procedure|Reversibility|
513724|NCT00291408|Procedure|Exhaled Breath Condensate|
513725|NCT00291408|Procedure|Sputum Induction|
513726|NCT00291395|Drug|PGI2|
513727|NCT00291382|Drug|Salmeterol/fluticasone propionate combination|
513728|NCT00291369|Drug|Interleukin-2|
513729|NCT00291369|Drug|Interferon alfa|
513730|NCT00291369|Drug|medroxyprogesterone acetate|
513731|NCT00291356|Drug|GSK189075 oral tablets|
513732|NCT00291356|Drug|GW869682 oral tablets|
513733|NCT00291343|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
513734|NCT00291343|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
513735|NCT00291343|Biological|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
513736|NCT00291330|Drug|dabigatran etexilate 150 mg|twice daily
513737|NCT00291330|Drug|warfarin (INR 2-3)|prn to maintain INR (2-3)
513738|NCT00291317|Device|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD). Children were scheduled to attend three cycling sessions per week on non-consecutive days for up to 30 minutes per session over a 9 month period. The intervention was provided at Children's Specialized Hospital in Mountainside, and families were required to provide their own transportation. During the study, the participants continued to participate in their standard, primary rehabilitation program.
513739|NCT00291304|Procedure|MRI|pre-surgery
513740|NCT00291239|Behavioral|partial sleep deprivation|
513741|NCT00291226|Drug|Glycine|Glycine 0.4 g/kg bid
513742|NCT00291226|Drug|Placebo|Placebo
513743|NCT00291213|Drug|levetiracetam|
513744|NCT00291213|Drug|placebo|
513745|NCT00291187|Drug|20 mg VEC-162|20 mg VEC-162
513746|NCT00291187|Drug|50 mg VEC-162|50 mg VEC-162
513747|NCT00291187|Drug|100 mg VEC-162|100 mg VEC-162
513748|NCT00291187|Drug|Placebo|Placebo
513749|NCT00291161|Behavioral|Partners in Dementia Care|"Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:~Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient."
513750|NCT00291148|Drug|paroxetine|
513751|NCT00291148|Drug|pregabalin|
513752|NCT00291135|Drug|letrozole|Letrozole 2.5 mg daily
513753|NCT00291122|Drug|celecoxib 400 mg BID|
513754|NCT00291109|Drug|letrozole 2.5 mg|
513755|NCT00291070|Drug|L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.
513756|NCT00291057|Drug|MALG|30 minute application
513757|NCT00291044|Other|testing for HSV 1 and 2 IgG type specific antibosy|
513758|NCT00291031|Behavioral|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.~IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
513759|NCT00291018|Device|Total Disc Replacement|Total Disc Replacement using ProDisc-C
513760|NCT00291018|Device|ACDF|Anterior Cervical Discectomy and Fusion
513761|NCT00291005|Drug|ARD6562, Docetaxel|
513762|NCT00290992|Drug|rasburicase (SR29142)|
513763|NCT00290979|Drug|insulin glulisine|
513764|NCT00290966|Drug|XRP6976|
513765|NCT00290953|Drug|SR48692|
513766|NCT00290940|Drug|CS-917|
513767|NCT00290940|Drug|metformin hydrochloride|
513768|NCT00290940|Drug|pioglitazone|
513769|NCT00290927|Drug|insulin glulisine|
513770|NCT00290914|Drug|Vilazodone|
513771|NCT00290901|Drug|Tramadol Hydrochloride 50mg|
513772|NCT00290901|Drug|Celebrex 200mg|
513773|NCT00290888|Procedure|Acromioplasty|
513774|NCT00290875|Behavioral|Use of Xrays for diagnosis|
513775|NCT00290862|Device|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
513776|NCT00290849|Drug|Bivalirudin|
513777|NCT00290836|Drug|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
513778|NCT00290823|Drug|Albendazole|400 mg tablet taken orally twice daily
513780|NCT00290823|Drug|Omeprazole|20 mg tablet taken orally daily
513781|NCT00290810|Biological|bevacizumab|Given IV
513782|NCT00290771|Drug|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
513783|NCT00290771|Drug|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
513784|NCT00290758|Drug|placebo|Given orally
513785|NCT00290758|Drug|genistein|Given orally
513786|NCT00290758|Other|laboratory biomarker analysis|Correlative studies
513787|NCT00290745|Drug|letrozole|
513788|NCT00290745|Drug|tamoxifen citrate|
513789|NCT00290745|Procedure|conventional surgery|
513790|NCT00290745|Procedure|neoadjuvant therapy|
513791|NCT00290732|Drug|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
513792|NCT00290732|Drug|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
513793|NCT00290719|Drug|cisplatin|
513794|NCT00290719|Drug|gefitinib|
513795|NCT00290719|Drug|irinotecan hydrochloride|
513796|NCT00290719|Procedure|conventional surgery|
513797|NCT00290719|Procedure|neoadjuvant therapy|
513798|NCT00290719|Radiation|radiation therapy|
513799|NCT00290706|Drug|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
513800|NCT00290706|Drug|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
513801|NCT00290693|Drug|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
513802|NCT00290693|Drug|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
513803|NCT00290680|Drug|bortezomib|
513804|NCT00290680|Drug|celecoxib|
513805|NCT00290667|Biological|pegfilgrastim|
513806|NCT00290667|Biological|rituximab|
513807|NCT00290667|Drug|cyclophosphamide|
513808|NCT00290667|Drug|doxorubicin hydrochloride|
513809|NCT00290667|Drug|prednisone|
513810|NCT00290667|Drug|vincristine sulfate|
513811|NCT00290667|Other|pharmacological study|
513812|NCT00290667|Radiation|radiation therapy|
513813|NCT00290654|Drug|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
513814|NCT00290654|Procedure|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
513815|NCT00290654|Radiation|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
513816|NCT00290641|Biological|filgrastim|
513817|NCT00290641|Biological|graft-versus-tumor induction therapy|
513818|NCT00290641|Drug|cyclophosphamide|
513819|NCT00290641|Drug|cyclosporine|
513820|NCT00290641|Drug|fludarabine phosphate|
513821|NCT00290641|Drug|mycophenolate mofetil|
513822|NCT00290641|Procedure|umbilical cord blood transplantation|
513823|NCT00290641|Radiation|radiation therapy|
513824|NCT00290628|Drug|anti-thymocyte globulin|
513825|NCT00290628|Drug|busulfan|
513826|NCT00290628|Drug|cyclophosphamide|
513827|NCT00290628|Drug|cyclosporine|
513828|NCT00290628|Drug|filgrastim|
513829|NCT00290628|Drug|melphalan|
513830|NCT00290628|Drug|methylprednisolone|
513831|NCT00290628|Drug|mycophenolate mofetil|
513832|NCT00290628|Procedure|radiation therapy|
513833|NCT00290628|Procedure|umbilical cord blood transplantation|
513834|NCT00290615|Biological|bevacizumab|
513835|NCT00290615|Biological|cetuximab|
513836|NCT00290615|Drug|capecitabine|
513837|NCT00290615|Drug|oxaliplatin|
513838|NCT00290602|Drug|Methylprednisolone sodium succinate|
513839|NCT00290589|Drug|Intramuscular methylprednisolone acetate|Intramuscular methylprednisolone acetate 160mg
513840|NCT00290589|Drug|Placebo|Normal saline intramuscular injection
513841|NCT00290576|Dietary Supplement|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
513842|NCT00290563|Drug|MK0594|
513843|NCT00290550|Drug|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
513844|NCT00290537|Drug|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
513845|NCT00290537|Drug|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
513846|NCT00290537|Drug|Paclitaxel|200 mg/m^2 IV Over 3 Hours On Day 1
513847|NCT00290524|Behavioral|Oral alimentation started 12 hours after colorectal surgery|
513848|NCT00290511|Drug|Fludarabine|25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4.
513849|NCT00290511|Drug|Mitoxantrone|10 mg/m^2 IV over 5-30 minutes on Day 2.
513850|NCT00290511|Drug|Rituximab|375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
513851|NCT00290511|Drug|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
513852|NCT00290511|Drug|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
513853|NCT00290498|Drug|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
513854|NCT00290498|Drug|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.~Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
513855|NCT00290498|Drug|Doxorubicin|Arm A: Doxorubicin 50 mg/m^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
513856|NCT00290498|Drug|Vincristine|"Arm A: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
513857|NCT00290498|Drug|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
513858|NCT00290498|Drug|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
513859|NCT00290498|Drug|Cytarabine|Arm B: Cytarabine 3 g/m^2 by vein over 2 hours every 12 hours X 4 doses on days 3 & 4, cycle 2 and alternating cycles.
513860|NCT00290498|Drug|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
513861|NCT00290485|Drug|Imatinib mesylate|
513862|NCT00290472|Drug|temsirolimus|
513863|NCT00290433|Drug|Cyclophosphamide|Cycle 1: 300 mg/m^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
513864|NCT00290433|Drug|Mesna|Cycle 1: 600 mg/m^2 by vein Continuous Infusion Over Days 1, 2, and 3.
513865|NCT00290433|Drug|Vincristine|Cycle 1: 1.4 mg/m^2 by vein On Day 4 and 11.
513866|NCT00290433|Drug|Methotrexate|Cycle 1 and 2: 200 mg/m^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m^2 IV Over 22 Hours on Day 1.
513867|NCT00290433|Drug|Ara-C|Cycle 1 and 2: 3 Gm/m^2 Over 2 Hours Twice Daily On Days 2 and 3.
513868|NCT00290433|Drug|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
513869|NCT00290433|Drug|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
513870|NCT00290433|Drug|Doxil|Cycle 1: 25 mg/m^2 by vein Over 1 Hour on Day 2.
513871|NCT00290420|Drug|Chloroquine profilaxis|"Prevention:~Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
513872|NCT00290407|Drug|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
513873|NCT00290407|Dietary Supplement|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
513874|NCT00290394|Drug|rosiglitazone(drug), blood pressure lowering effect|
513875|NCT00290381|Drug|Study drug administration|
513876|NCT00290381|Procedure|Skin prick test|
513877|NCT00290381|Procedure|12-lead ECG|
513878|NCT00290381|Procedure|Laboratory safety samples|
513879|NCT00290381|Procedure|Alcohol breath test|
513880|NCT00290381|Procedure|Smokerlyzer test|
513881|NCT00290381|Procedure|Urine drug test|
513882|NCT00290381|Procedure|Blood test for drug concentrations|
513883|NCT00290381|Procedure|Nasal allergen challenge|
513884|NCT00290381|Procedure|Nasal filter paper placement|
513885|NCT00290381|Procedure|Total nasal symptoms scores|
513886|NCT00290368|Procedure|Skin Prick Test|
513887|NCT00290368|Procedure|Nasal allergen challenge|
513888|NCT00290368|Procedure|Nasal filter paper placement|
513889|NCT00290368|Procedure|Nasal lavage|
513890|NCT00290368|Procedure|Nasal scrape|
513891|NCT00290368|Procedure|Nasal symptoms score|
513892|NCT00290355|Biological|GSK 249553 vaccine|Intramuscular injection, 13 doses
513893|NCT00290355|Biological|Placebo|Intramuscular administration, 13 doses
513894|NCT00290342|Biological|DTPa-IPV|3 intramuscular injections
513895|NCT00290342|Biological|DTPa|3 intramuscular injections
513896|NCT00290342|Biological|IMOVAX Polio®|3 intramuscular injections
513897|NCT00290329|Biological|Mencevax ACWY|1 subcutaneous injection.
513898|NCT00290316|Procedure|Endoscopy ultrasound|
513899|NCT00290303|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
513900|NCT00290290|Drug|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
513901|NCT00290290|Drug|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
513902|NCT00290277|Biological|HPV-16/18 L1/AS04|
513903|NCT00290264|Drug|Budesonide/formoterol|
513904|NCT00290251|Drug|ulipristal acetate|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
513905|NCT00290251|Drug|ulipristal acetate|10 mg given daily for three menstrual cycles or 90 - 102 days
513906|NCT00290251|Drug|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
513907|NCT00290238|Device|Vertis Percutaneous Neuromodulation Therapy (PNT)|"Ten PNT sessions in eleven weeks~On average, one PNT session per week~Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage~Forty-five minutes of electrical stimulation for each session~Electrical stimulation parameters:~Continuous 50 Hz current~Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform~Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
513908|NCT00290238|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|"Ten TENS sessions in eleven weeks~On average, one TENS session per week~Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage~Forty-five minutes of electrical stimulation for each session~Electrical stimulation parameters:~Current at 2 Hz—low frequency~Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec~Intensity titrated according to subject's sensory threshold~To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
513909|NCT00290225|Behavioral|Breath Water Sound Course and Traumatic Incident Reduction|
513910|NCT00290212|Drug|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
513911|NCT00290212|Drug|Placebo capsules|
513912|NCT00290199|Device|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
513913|NCT00290186|Device|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
513914|NCT00290186|Device|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
513915|NCT00290173|Drug|efficacy of oral ritodrine in maintaining uterine quiescence|
513916|NCT00290160|Behavioral|Protein supplementation|
513917|NCT00290147|Biological|D1ME100 (dengue-1 premembrane/envelope DNA vaccine)|IM injection delivered by Biojector
513918|NCT00290134|Drug|Fispemifene once daily for 4 weeks|
513919|NCT00290121|Drug|Olanzapine|
513920|NCT00290108|Drug|Propofol|
513921|NCT00290082|Drug|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
513922|NCT00290082|Biological|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
513923|NCT00290082|Other|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
513924|NCT00290082|Drug|Loxapine|Loxapine 1 mL / 10 kg
513925|NCT00290082|Drug|Midazolam|Midazolam 1 mL / 10 Kg
513926|NCT00290069|Drug|Tacrolimus|
513927|NCT00290069|Drug|Rapamycin|
513928|NCT00290056|Drug|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
513929|NCT00290043|Drug|Insulin glulisine|
513930|NCT00290030|Drug|Alfuzosin|
513931|NCT00290017|Drug|talabostat|
513932|NCT00290017|Drug|pemetrexed|
513933|NCT00290004|Drug|motexafin gadolinium|
513934|NCT00289991|Drug|Itraconazole|Prophylaxis
513935|NCT00289991|Drug|Vfend - voriconazole|Prophylaxis
513936|NCT00289978|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
513937|NCT00289978|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
513938|NCT00289978|Drug|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
513939|NCT00289965|Behavioral|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
513940|NCT00289965|Behavioral|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
513941|NCT00289965|Behavioral|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
513942|NCT00289952|Drug|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
513943|NCT00289952|Drug|HAART|As per standard of care.
513944|NCT00289939|Behavioral|Motivational interviewing to reduce risk for HIV and DV|
513945|NCT00289926|Drug|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
513946|NCT00289926|Drug|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
513947|NCT00289913|Biological|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).~Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
513948|NCT00289913|Biological|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis~Vaccine Adsorbed, GlaxoSmithKline).~One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
513949|NCT00289913|Biological|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine [Meningococcal Protein Conjugate]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
513950|NCT00289900|Drug|MK-0524A|
513951|NCT00289900|Drug|Atorvastatin|
513952|NCT00289900|Drug|Simvastatin|
513953|NCT00289887|Drug|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
513954|NCT00289887|Drug|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
513955|NCT00289874|Drug|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
513956|NCT00289874|Drug|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
513957|NCT00289861|Drug|Risperidone|
513958|NCT00289861|Drug|placebo|
513959|NCT00289848|Drug|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
513960|NCT00289848|Drug|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
513961|NCT00289835|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
513962|NCT00289822|Drug|intracoronary infusion of progenitor cells|
513963|NCT00289809|Drug|combination of TLC D-99 and Ifosfamide|"TLC D-99: 40 mg/m2 Day 1 every 3 weeks;~Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
513964|NCT00289796|Biological|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
514182|NCT00288002|Procedure|neoadjuvant therapy|
514183|NCT00287989|Drug|Carboplatin|
513965|NCT00289783|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
513966|NCT00289783|Biological|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
513967|NCT00289783|Biological|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
513968|NCT00289783|Biological|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
513969|NCT00289783|Biological|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
513970|NCT00289783|Biological|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
513971|NCT00289783|Biological|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
513972|NCT00289770|Biological|Twinrix™|Intramuscular injection, 3 doses
513973|NCT00289757|Biological|Havrix™|2 doses at 6 months interval
513974|NCT00289744|Biological|TWINRIX™ ADULT|2 doses IM injection in primary study
513975|NCT00289744|Biological|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
513976|NCT00289731|Biological|TWINRIX™|Intramuscular injection, 3 doses
513977|NCT00289731|Biological|Engerix™-B|Intramuscular injection, 3 doses
513978|NCT00289731|Biological|HAVRIX™|Intramuscular injection, 2 doses
513979|NCT00289731|Biological|HB VAX PRO™|Intramuscular injection, 3 doses
513980|NCT00289731|Biological|Vaqta™|Intramuscular injection, 2 doses
513981|NCT00289718|Biological|Twinrix™ adult|Intramuscular administration
513982|NCT00289705|Procedure|Surgery|Laparoscopic Roux-en-Y gastric bypass
513983|NCT00289679|Device|Hip prosthesis revision|
513984|NCT00289653|Drug|Nicoderm|
513985|NCT00289640|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
513986|NCT00289640|Drug|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
513987|NCT00289640|Drug|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
513988|NCT00289627|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
513989|NCT00289614|Drug|Iopamidol 370 mgI/dL|
513990|NCT00289601|Drug|eptifibatide|
513991|NCT00289588|Drug|Mupirocin (drug)|
513992|NCT00289575|Device|MBCP|
513993|NCT00289562|Drug|forodesine hydrochloride (BCX-1777)|
513994|NCT00289549|Drug|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
513995|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
513996|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
513997|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
513998|NCT00289510|Biological|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
513999|NCT00289510|Biological|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
514000|NCT00289497|Device|TempTouch®|
514001|NCT00289484|Drug|Omega-3 Polyunsaturated Fatty Acids|
514002|NCT00289471|Other|No intervention delivered.|No intervention delivered.
514003|NCT00289458|Behavioral|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
514004|NCT00289458|Behavioral|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
514005|NCT00289458|Behavioral|Control|no exercise
514006|NCT00289445|Drug|Mitomycin C|
514007|NCT00289445|Drug|5-FU|
514008|NCT00289445|Drug|Folinic acid|
514009|NCT00289432|Behavioral|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
514010|NCT00289432|Other|Support group|Standard Hospital follow-up support group
514011|NCT00289419|Drug|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
514012|NCT00289419|Drug|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
514013|NCT00289406|Drug|S-amlodipine gentisate|
514014|NCT00289406|Drug|Amlodipine besylate|
514015|NCT00289393|Behavioral|Perceived outcome by both patient and physician|
514016|NCT00289367|Drug|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
514017|NCT00289367|Drug|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
514018|NCT00289354|Drug|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
514019|NCT00289341|Biological|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
514020|NCT00289341|Biological|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
514021|NCT00289315|Behavioral|Primary (Environmental) Weight Gain Prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
514022|NCT00289315|Behavioral|Secondary (Behavioral) Weight Gain Prevention|School-based environmental program to promote healthy eating and physical activity in the overweight students.
514023|NCT00289315|Behavioral|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
514024|NCT00289302|Device|Cardiac resynchronization therapy device|
514184|NCT00287989|Drug|erlotinib hydrochloride|150mg
514185|NCT00287989|Drug|Paclitaxel|200mg/m2
514025|NCT00289289|Device|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
514026|NCT00289276|Device|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
514027|NCT00289263|Drug|Paclitaxel|
514028|NCT00289250|Drug|Sulfadoxine-pyrimethamine|
514029|NCT00289250|Drug|Sulfadoxine-pyrimethamine plus artesunate|
514030|NCT00289237|Behavioral|Lifestyle intervention|
514031|NCT00289224|Biological|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
514032|NCT00289224|Biological|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
514033|NCT00289211|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
514034|NCT00289211|Drug|Placebo (saline)|
514035|NCT00289198|Drug|FF|fluticasone furoate 110 μg nasal spray
514036|NCT00289198|Drug|Placebo|placebo nasal spray
514037|NCT00289185|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
514038|NCT00289185|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
514039|NCT00289185|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
514040|NCT00289172|Biological|Live attenuated human rotavirus vaccine|
514041|NCT00289133|Device|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
514042|NCT00289133|Device|total knee arthroplasty|cross-linked polyethylene tibial insert
514043|NCT00289120|Drug|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
514044|NCT00289120|Drug|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
514045|NCT00289107|Device|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
514046|NCT00289107|Device|Total knee replacement|Fixed Cruciate Substituting Knee System
514047|NCT00289094|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
514048|NCT00289094|Device|Total knee replacement|Fixed Cruciate Retaining Knee System
514049|NCT00289081|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
514050|NCT00289081|Device|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
514051|NCT00289068|Procedure|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
514052|NCT00289068|Procedure|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
514053|NCT00289068|Procedure|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
514054|NCT00289055|Device|stent|Cordis SMART™ Nitinol Stent
514055|NCT00289055|Device|angioplasty|balloon angioplasty
514056|NCT00289042|Drug|Enoxaparin|
514057|NCT00289029|Drug|Iopamidol 370 mgI/mL|
514058|NCT00289016|Drug|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
514059|NCT00289003|Drug|Soluble beta-1,3/1,6-glucan|
514060|NCT00288977|Procedure|Islet Infusion|
514061|NCT00288964|Device|Hattler Respiratory Assist Catheter|
514062|NCT00288951|Drug|Travoprost 0.004% with and without BAK|
514063|NCT00288925|Drug|Z-360|
514064|NCT00288912|Behavioral|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
514065|NCT00288912|Behavioral|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
514066|NCT00288899|Other|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
514067|NCT00288899|Other|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
514068|NCT00288886|Behavioral|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
514069|NCT00288886|Behavioral|Control arm|Routine residential treatment and orientation to continuing care.
514070|NCT00288873|Drug|Ergocalciferol|
514071|NCT00288873|Drug|Cholecalciferol|
514072|NCT00288860|Behavioral|Telephone monitoring|Three months of biweekly telephone monitoring and support
514073|NCT00288860|Other|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
514074|NCT00288834|Behavioral|dysphagia rehabilitation|
514075|NCT00288808|Device|Hemosense (PT/InR point of care device)|
514076|NCT00288795|Other|Massage Therapy|Therapeutic Touch
514077|NCT00288795|Other|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
514078|NCT00288782|Drug|Mirtazapine|
514079|NCT00288769|Drug|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
514080|NCT00288756|Procedure|lv injection of contrast|
514081|NCT00288743|Drug|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
514082|NCT00288730|Drug|nesiritide|
514083|NCT00288717|Drug|Candesartan|
514084|NCT00288717|Drug|Telmisartan|
514186|NCT00287989|Drug|erlotinib hydrochloride|1500mg
514085|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
514086|NCT00288704|Drug|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
514087|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
514088|NCT00288691|Drug|Asoprisnil (BAY86-5294)|5mg/day
514089|NCT00288691|Drug|Asoprisnil (BAY86-5294)|10mg/day
514090|NCT00288691|Drug|Asoprisnil (BAY86-5294)|25mg/day
514091|NCT00288691|Drug|Placebo|Placebo
514092|NCT00288678|Procedure|Health Education|
514093|NCT00288665|Device|Export catheter (Medtronic)|
514094|NCT00288652|Drug|[S,S]-Reboxetine|
514095|NCT00288639|Drug|Pregabalin|"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).~Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."
514096|NCT00288626|Drug|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
514097|NCT00288626|Drug|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
514098|NCT00288626|Procedure|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
514099|NCT00288600|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin
514100|NCT00288600|Drug|Normal saline solution|Normal saline solution 10 ml/Kg
514101|NCT00288587|Drug|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
514102|NCT00288587|Device|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
514103|NCT00288574|Drug|Fluoxetine|
514104|NCT00288574|Drug|Placebo|
514105|NCT00288561|Drug|ranibizumab|
514106|NCT00288548|Drug|Metoprolol|
514107|NCT00288535|Procedure|PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique|
514108|NCT00288522|Drug|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
514109|NCT00288509|Biological|Botulinum toxin type A|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety & efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
514110|NCT00288496|Drug|polyethylene glycol bowel lavage solution|
514111|NCT00288483|Drug|Policosanol|
514112|NCT00288470|Device|Hylaform, Hylaform Plus (hylan B gel)|
514113|NCT00288457|Device|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
514114|NCT00288444|Drug|Lonafarnib|
514115|NCT00288444|Drug|Docetaxel|
514116|NCT00288431|Drug|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
514117|NCT00288431|Drug|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
514118|NCT00288418|Device|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
514119|NCT00288405|Device|Cordis Self Expanding Stent|
514120|NCT00288392|Drug|Soluble beta-1,3/1,6-glucan|
514121|NCT00288379|Drug|formoterol|
514122|NCT00288379|Drug|budesonide/formoterol|
514123|NCT00288366|Drug|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
514124|NCT00288366|Drug|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
514125|NCT00288353|Drug|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
514126|NCT00288353|Drug|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
514127|NCT00288340|Device|functional magnetic resonance imaging|
514128|NCT00288327|Behavioral|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
514129|NCT00288327|Behavioral|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
514130|NCT00288314|Procedure|Magnetic Resonance Imaging, Functional|Structural and functional MRI
514131|NCT00288301|Behavioral|Weight loss intervention|weight loss intervention
514132|NCT00288288|Procedure|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
514133|NCT00288288|Procedure|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
514134|NCT00288262|Drug|melatonin 0.5 mg|
514135|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
514136|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
514137|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
514138|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
514139|NCT00288236|Drug|Rimonabant (SR141716)|
514140|NCT00288236|Drug|Placebo|
514141|NCT00288223|Drug|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
514142|NCT00288210|Procedure|Primary angioplasty in acute myocardial infarction|
514143|NCT00288197|Drug|voriconazole|
514144|NCT00288184|Drug|Allopurinol|Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
514145|NCT00288184|Drug|Placebo|
514146|NCT00288171|Drug|Placebo|placebo capsule twice daily for one month
514147|NCT00288171|Drug|Allopurinol|Allopurinol 200mg twice daily for one month
514148|NCT00288158|Drug|Allopurinol|
514149|NCT00288158|Drug|Probenecid|
514150|NCT00288158|Drug|Placebo|
514151|NCT00288145|Behavioral|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
514152|NCT00288132|Behavioral|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted.
514153|NCT00288132|Behavioral|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
514154|NCT00288119|Device|Balloon Capsule Device|The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize & protect the site-specific sample collection.
514155|NCT00288119|Procedure|Endoscopy|An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.
514156|NCT00288106|Other|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
514157|NCT00288093|Radiation|3-Dimensional Conformal Radiation Therapy|
514158|NCT00288093|Drug|Triapine|
514159|NCT00288080|Drug|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
514160|NCT00288080|Drug|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
514161|NCT00288080|Drug|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
514162|NCT00288080|Drug|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
514163|NCT00288080|Radiation|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
514164|NCT00288080|Drug|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
514165|NCT00288067|Drug|fenretinide|Given PO
514166|NCT00288067|Drug|rituximab|Given IV
514167|NCT00288054|Biological|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.~250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
514168|NCT00288054|Drug|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.~20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
514169|NCT00288054|Radiation|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.~RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
514170|NCT00288041|Drug|carboplatin|Given IV
514171|NCT00288041|Drug|paclitaxel|Given IV
514172|NCT00288041|Drug|bortezomib|Given IV
514173|NCT00288028|Drug|bortezomib|Dose of Bortezomib* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
514174|NCT00288015|Biological|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
514175|NCT00288002|Biological|trastuzumab|
514176|NCT00288002|Drug|capecitabine|
514177|NCT00288002|Drug|cyclophosphamide|
514178|NCT00288002|Drug|docetaxel|
514179|NCT00288002|Drug|epirubicin hydrochloride|
514180|NCT00288002|Procedure|adjuvant therapy|
514181|NCT00288002|Procedure|conventional surgery|
514187|NCT00287976|Drug|irinotecan hydrochloride|
514188|NCT00287963|Drug|topotecan hydrochloride|
514189|NCT00287963|Drug|vinorelbine tartrate|
514190|NCT00287950|Drug|carboplatin|
514191|NCT00287950|Drug|cisplatin|
514192|NCT00287950|Drug|cyclophosphamide|
514193|NCT00287950|Drug|etoposide|
514194|NCT00287950|Drug|vincristine sulfate|
514195|NCT00287950|Procedure|adjuvant therapy|
514196|NCT00287950|Procedure|conventional surgery|
514197|NCT00287950|Procedure|neoadjuvant therapy|
514198|NCT00287950|Radiation|radiation therapy|
514199|NCT00287937|Drug|vorinostat|Given orally
514200|NCT00287937|Drug|paclitaxel|Given IV
514201|NCT00287937|Drug|carboplatin|Given IV
514202|NCT00287937|Other|laboratory biomarker analysis|Correlative studies
514203|NCT00287937|Other|pharmacological study|Correlative studies
514204|NCT00287924|Drug|methotrexate|
514205|NCT00287924|Procedure|adjuvant therapy|
514206|NCT00287911|Drug|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
514207|NCT00287911|Drug|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
514208|NCT00287911|Radiation|brachytherapy|Some patients may also undergo brachytherapy
514209|NCT00287911|Radiation|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
514210|NCT00287898|Behavioral|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
514211|NCT00287898|Behavioral|Usual Care|subjects will receive standard in-person genetic counseling
514212|NCT00287885|Drug|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m^2/day up to dose level 6 of 6.4 mg/m^2/day
514213|NCT00287872|Drug|bortezomib|
514214|NCT00287872|Drug|thalidomide|
514215|NCT00287859|Drug|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
514216|NCT00287846|Drug|imatinib mesylate|
514217|NCT00287833|Other|placebo|Given orally
514218|NCT00287833|Drug|Bowman-Birk inhibitor concentrate|Given orally
514219|NCT00287820|Drug|Olanzapine|olanzapine 5-40 mg/day
514220|NCT00287820|Drug|olanzapine|olanzapine 5-40 ,mg/day
514221|NCT00287820|Drug|risperidone|risperidone 1-12 mg/day
514222|NCT00287807|Behavioral|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
514223|NCT00287794|Drug|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
514224|NCT00287781|Drug|Lidocaine|
514225|NCT00287768|Drug|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
514226|NCT00287768|Drug|S-1|S-1 po days 1-28 every 6 weeks
514227|NCT00287755|Drug|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
514228|NCT00287742|Drug|risperidone|
514229|NCT00287729|Drug|Pirfenidone|2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
514230|NCT00287729|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
514231|NCT00287716|Drug|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
514232|NCT00287716|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
514233|NCT00287703|Device|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
514234|NCT00287703|Device|Pulsating Electro-Magnetic Fields sham|sham PEMF
514235|NCT00287690|Drug|Genistein|Drink taken once daily
514236|NCT00287690|Drug|Placebo|Drink taken once daily
514237|NCT00287677|Biological|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
514238|NCT00287677|Biological|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
514239|NCT00287677|Drug|HAART|HAART all over the trial
514240|NCT00287664|Drug|terlipressin|
514241|NCT00287651|Procedure|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
514242|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
514243|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
514244|NCT00287638|Device|CPAP|Continuous positive pressure device with a time clock
514245|NCT00287638|Device|placebo|no CPAP
514246|NCT00287625|Procedure|Pulmonary rehabilitation|Pulmonary rehabilitation
514247|NCT00287612|Procedure|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
514248|NCT00287612|Procedure|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
514249|NCT00287586|Drug|Testosterone Gel (Androgel)|7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
514250|NCT00287586|Drug|Placebo|Placebo-matching testosterone gel daily for 3 years
514251|NCT00287573|Device|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
514252|NCT00287573|Procedure|Brachytherapy (beta source)|Brachytherapy (beta source)
514253|NCT00287560|Drug|propofol (drug)|
514254|NCT00287547|Drug|CTLA4Ig / Abatacept|
514255|NCT00287534|Drug|Anastrozole|oral
514256|NCT00287534|Drug|Tamoxifen|oral
514257|NCT00287521|Drug|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
537167|NCT00094497|Drug|Mitotane|
514258|NCT00287521|Drug|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
514259|NCT00287521|Other|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
514260|NCT00287521|Drug|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
514261|NCT00287508|Device|Carotid artery stenting with filter (interventional)|
514262|NCT00287495|Drug|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
514263|NCT00287482|Drug|Essiac|
514264|NCT00287469|Biological|Hepatitis E vaccine, recombinant (Sar 56 kDa)|20mcg or rhE Sar 56 kDa/dose of 0.5 mL, aluminium hydroxide (0.5 mg/dose) and phenoxyethanol (2.5 mg/dose)
514265|NCT00287469|Other|Placebo|PBS buffer placebo containing alum
514266|NCT00287456|Device|Insulin Pump|
514267|NCT00287456|Drug|Insulin|0
514268|NCT00287456|Procedure|Oral Glucose Tolerance Test|0
514269|NCT00287456|Procedure|Whole body Protein Turnover|0
514270|NCT00287443|Procedure|Oral Glucose tolerance test|
514271|NCT00287443|Procedure|Whole body protein turnover|
514272|NCT00287443|Procedure|IV glucose tolerance test|
514273|NCT00287443|Procedure|Indirect Calorimetry|
514274|NCT00287443|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
514275|NCT00287443|Procedure|Growth Hormone Stimulation Test|
514276|NCT00287430|Drug|Growth Hormone|
514277|NCT00287430|Procedure|Whole body Protein Turnover Study|
514278|NCT00287430|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
514279|NCT00287417|Device|echography|
514280|NCT00287417|Other|blood sample|
514281|NCT00287391|Drug|Rabeprazole|
514282|NCT00287378|Drug|omalizumab|omalizumab as per weight and IgE
514283|NCT00287365|Drug|ozone|2 hour exposure to 0.4 ppm ozone
514284|NCT00287352|Drug|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
514285|NCT00287352|Drug|Olanzapine and placebo|Olanzapine continuing as clinically indicated
514286|NCT00287339|Drug|Esomeprazole|40mg capsule BID for 12 weeks
514287|NCT00287339|Drug|Placebo|placebo capsule BID for 12 weeks
514288|NCT00287326|Drug|Bupivacaine, Clonidine, Morphine|
514289|NCT00287313|Drug|Vitamin K|
514290|NCT00287300|Drug|Sulfadoxine-Pyrimethamine|
514291|NCT00287300|Drug|Azithromycin|
514292|NCT00287300|Drug|Artesunate|
514293|NCT00287287|Drug|Lenalidomide|Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
514294|NCT00287274|Device|computerized physician order entry|
514295|NCT00287261|Drug|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
514296|NCT00287248|Drug|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of [123I]IMPY, followed by SPECT imaging
514297|NCT00287235|Device|MARS|
514298|NCT00287235|Drug|Standard Medical Therapy|
514299|NCT00287222|Drug|Bevacizumab|15 mg/KG I.V. every 21 days
514300|NCT00287222|Drug|Erlotinib|150 mg orally every day
514301|NCT00287209|Drug|Amiodarone|
514302|NCT00287196|Radiation|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
514303|NCT00287183|Drug|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
514304|NCT00287183|Other|Placebo|Placebo
514305|NCT00287170|Drug|Delayed Release 6MP or Calcitriol vs. Purinethol|
514306|NCT00287157|Drug|Sublingual Tizanidine HCl|
514307|NCT00287131|Procedure|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
514308|NCT00287118|Drug|Efalizumab|Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
514309|NCT00287105|Drug|Standard chemotherapy + Imatinib|Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
514310|NCT00287092|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
514311|NCT00287092|Biological|Infanrix® -IPV+Hib|0.5 mL, IM
514312|NCT00287079|Drug|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
514313|NCT00287079|Other|No Treatment|No treatment for 96 weeks
514314|NCT00287066|Drug|Inhaled Human Insulin|
514315|NCT00287066|Drug|Regular Human Insulin|
514316|NCT00287053|Drug|divalproex sodium|Divalproex sodium vs. placebo
514317|NCT00287040|Behavioral|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
514318|NCT00287027|Drug|Risperdal Long Acting Injectable Antipsychotic Medication|
514319|NCT00287001|Device|Cold air cooling|
514320|NCT00286988|Drug|Topiramate|
514321|NCT00286975|Behavioral|Leadership development program educational intervention|
514322|NCT00286962|Device|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
514323|NCT00286962|Device|continuous subcutaneous insulin infusion (CSII) or MDI|
514324|NCT00286949|Drug|Atomoxetine|Open Label uncontrolled active Drug intervention
514325|NCT00286936|Drug|Zolpidem|
514326|NCT00286923|Drug|Topiramate|
514327|NCT00286897|Drug|E2007|
514328|NCT00286884|Procedure|Monitoring of heart rate variability|
514329|NCT00286871|Drug|Neoral|
514330|NCT00286871|Drug|Tacrolimus|
514331|NCT00286858|Device|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
514332|NCT00286845|Drug|Standard Chemotherapy|physician determined
514333|NCT00286832|Procedure|PET scan|One extra PET scan after 1 cycle of treatment.
514384|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
514334|NCT00286819|Drug|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
514335|NCT00286806|Drug|AT-101|
514336|NCT00286793|Drug|AT-101|Oral
514337|NCT00286780|Drug|AT-101|80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
514338|NCT00286754|Behavioral|SMI|Stage-matched intervention
514339|NCT00286754|Behavioral|HEI|Health Education Intervention
514340|NCT00286754|Behavioral|UC|Usual Care
514341|NCT00286754|Behavioral|SMI|Stage-matched intervention
514342|NCT00286754|Behavioral|HEI|Health Education Intervention
514343|NCT00286754|Behavioral|UC|Usual Care
514344|NCT00286741|Other|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
514345|NCT00286728|Behavioral|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
514346|NCT00286702|Device|hand splint|
514347|NCT00286689|Drug|Growth Hormone|
514348|NCT00286689|Procedure|Whole body Protein turnover|
514349|NCT00286689|Procedure|DEXA scan|
514350|NCT00286676|Drug|Nutropin|
514351|NCT00286676|Procedure|Oral Glucose Tolerance Test|
514352|NCT00286676|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
514353|NCT00286676|Procedure|Computed Tomography (CT) Scan|
514354|NCT00286650|Procedure|3rd molar teeth extraction|
514355|NCT00286624|Biological|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
514356|NCT00286624|Drug|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
514357|NCT00286624|Drug|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
514358|NCT00286624|Drug|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
514359|NCT00286611|Procedure|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
514360|NCT00286598|Behavioral|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
514361|NCT00286585|Drug|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
514362|NCT00286585|Drug|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
514363|NCT00286559|Drug|SonoVue|
514364|NCT00286559|Drug|Optison|
514365|NCT00286533|Procedure|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
514366|NCT00286533|Procedure|Questionnaires|Questionnaires are used.
514367|NCT00286520|Procedure|Transanal irrigation with Peristeen Anal Irrigation|
514368|NCT00286507|Procedure|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
514369|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
514370|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
514371|NCT00286494|Drug|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
514372|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
514373|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
514374|NCT00286481|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
514375|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
514376|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
514377|NCT00286468|Drug|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
514378|NCT00286455|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
514379|NCT00286455|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
514380|NCT00286455|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
514381|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
514382|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
514383|NCT00286442|Drug|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
514385|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
514386|NCT00286429|Drug|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
514387|NCT00286416|Drug|omalizumab (Xolair)|
514388|NCT00286403|Drug|Fenoldopam Mesylate and/or MESNA|
514389|NCT00286390|Procedure|Acupuncture|
514390|NCT00286377|Drug|prosaptide|
514391|NCT00286364|Drug|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
514392|NCT00286351|Drug|Combined treatment with Arimidex and Zoladex before IVF|
514393|NCT00286325|Drug|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
514394|NCT00286312|Drug|Atorvastatin|
514395|NCT00286299|Other|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
514396|NCT00286299|Other|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
514397|NCT00286299|Other|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
514398|NCT00286286|Device|Intraperitoneal Aerosolization System, IntraMyst|
514399|NCT00286273|Drug|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
514400|NCT00286273|Drug|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
514401|NCT00286260|Drug|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
514402|NCT00286247|Genetic|INGN 201|
514403|NCT00286234|Drug|omega-3 acid ethyl esters|4 q qd
514404|NCT00286234|Drug|extended release niacin|2 g qpm
514405|NCT00286234|Drug|placebo|omacor placebo plus niaspan placebo
514406|NCT00286234|Drug|omega-3 acid ethyl esters|4 g qd
514407|NCT00286234|Drug|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
514408|NCT00286221|Drug|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
514409|NCT00286221|Drug|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
514410|NCT00286208|Drug|Mifepristone, misoprostol|
514411|NCT00286195|Device|Multi-Link Frontier Coronary Stent System|Bare metal stent
514412|NCT00286182|Drug|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
514413|NCT00286182|Drug|Placebo|Placebo
514414|NCT00286169|Drug|Amrubicin Hydrochloride|
514415|NCT00286156|Drug|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
514416|NCT00286143|Drug|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
514417|NCT00286130|Drug|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
514418|NCT00286130|Drug|FOLFOX 6|"FOLFOX 6:~Oxaliplatin 100 mg/m² d1 concurrent with~Leucovorin 400 mg/m², followed by~Bolus 5FU 400 mg/m² , followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
514419|NCT00286130|Drug|FOLFIRI|"FOLFIRI:~Irinotecan 180 mg/m² day 1 concurrent with~Leucovorin 400 mg/m² followed by~Bolus 5FU 400 mg/m², followed by~Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
514420|NCT00286117|Drug|Anastrozole|oral
514421|NCT00286117|Drug|Tamoxifen|oral
514422|NCT00286104|Device|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
514423|NCT00286104|Device|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
514424|NCT00286091|Biological|Denosumab|Administered by subcutaneous injection
514425|NCT00286091|Biological|Placebo|Same volume subcutaneous injection
514426|NCT00286078|Device|Precision|Implantable neurostimulator
514427|NCT00286065|Drug|AeroLEF|
514428|NCT00286052|Drug|Low Dose Naloxone|
514429|NCT00286039|Procedure|Blood sampling|Blood sampling is used.
514430|NCT00286026|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
514431|NCT00286013|Drug|Association of gemcitabine, oxaliplatin and radiotherapy|
514432|NCT00286000|Drug|Administration of high dose simplified folfiri|
514433|NCT00285987|Procedure|Reconstruction of the cruciate ligament|
514434|NCT00285974|Device|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
514435|NCT00285961|Device|Cork splint materials (instead of plaster splint)|
514436|NCT00285948|Device|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
514437|NCT00285935|Drug|Treatment with SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.~Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)"
514438|NCT00285909|Behavioral|Alcohol: 25 gday (white wine)|
514439|NCT00285896|Drug|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
514440|NCT00285896|Drug|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
514441|NCT00285883|Drug|Invirase|
514442|NCT00285883|Drug|Norvir|
514443|NCT00285857|Drug|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.~Lovastatin is approved by FDA as a cholesterol-lowering agent."
514444|NCT00285844|Behavioral|weight loss|
514445|NCT00285844|Drug|thiazolidinedione|
514446|NCT00285818|Drug|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
514447|NCT00285818|Drug|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
514448|NCT00285805|Drug|Rosiglitazone versus placebo|
514449|NCT00285805|Drug|response (sodium excretion) to amiloride infusion|
514450|NCT00285805|Drug|response (sodium excretion) to furosemide infusion|
514451|NCT00285792|Behavioral|Physical Activity|
514452|NCT00285779|Drug|Etanercept|etanercept 50 mg twice weekly for 12 weeks
514453|NCT00285779|Drug|Placebo|
514454|NCT00285766|Drug|Selegiline Transdermal System|
514455|NCT00285753|Behavioral|support groups|cognitive behavioral intervention with psychoeducation
514456|NCT00285740|Behavioral|Cognitive Behavioral Therapy (CBT) in a Group Format|
514457|NCT00285727|Drug|Ropinirole CR|
514458|NCT00285714|Procedure|3D stereophotogrammetric imaging|
514459|NCT00285714|Procedure|3D CT-imaging with cone-beam CT|
514460|NCT00285714|Procedure|Case report form|
514461|NCT00285701|Drug|hexaminolevulinate|
514462|NCT00285688|Procedure|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
514463|NCT00285675|Drug|DN-101 (calcitriol) - Drug|
514464|NCT00285662|Drug|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
514465|NCT00285649|Other|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
514466|NCT00285649|Other|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
514467|NCT00285649|Other|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
514468|NCT00285623|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
514469|NCT00285597|Drug|Ursodeoxycholic Acid|
514470|NCT00285584|Drug|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
514471|NCT00285584|Drug|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
514472|NCT00285571|Behavioral|Controlled Feeding Intervention|
514473|NCT00285558|Behavioral|CBT with peer-enhanced activities|
514474|NCT00285558|Behavioral|CBT with supervised aerobic exercise|
514475|NCT00285519|Drug|Doxazosin (drug)|
514476|NCT00285493|Drug|Antibiotics|
514477|NCT00285467|Drug|doxercalciferol|form of vitamin D that is already in active form.
514478|NCT00285467|Drug|Cholecalciferol|from of vitamin D that requires cells in the body to make active
514479|NCT00285454|Procedure|Retrograde coronary venous delivery of cells.|
514480|NCT00285428|Drug|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
514481|NCT00285415|Drug|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
514482|NCT00285402|Drug|AST-726 Low dose|
514483|NCT00285402|Drug|AST-726 High dose|
514484|NCT00285402|Drug|AST-726 Placebo|
514485|NCT00285389|Drug|Adriblastin|
514486|NCT00285389|Drug|dexamethasone|
514487|NCT00285389|Drug|Chlorambucil|
514488|NCT00285389|Drug|rituximab|
514489|NCT00285389|Drug|cyclophosphamide|
514490|NCT00285389|Drug|alkeran|
514491|NCT00285389|Procedure|Total body irradiation (8Gy/4fr)|
514492|NCT00285389|Drug|vincristine|0,4 mg/day day 1 to day 4
514493|NCT00285376|Drug|vilazodone|titration to 40mg tablets qd for 8 weeks
514494|NCT00285350|Drug|mycophenolate mofetil|
514495|NCT00285337|Procedure|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
514498|NCT00285285|Device|Point of Care Device; i-Stat Analyzer|
514499|NCT00285259|Biological|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
514500|NCT00285259|Other|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
514501|NCT00285233|Biological|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
514502|NCT00285220|Procedure|Laparoscopic Truncal Vagotomy|
514503|NCT00285207|Drug|placebo|5 days of 28 day cycle for 2 cycles
514504|NCT00285207|Drug|A007|5 days of 28 day cycle
514505|NCT00285194|Drug|Allogeneic Islets of Langerhans|
514506|NCT00285194|Drug|hOKT3γ1 (Ala-Ala)|
514507|NCT00285181|Drug|Simvastatin|
514508|NCT00285168|Behavioral|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
514509|NCT00285155|Drug|Bupropion|
514510|NCT00285142|Drug|rosiglitazone|
514511|NCT00285129|Device|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
514512|NCT00285116|Procedure|Clinical examination and radiological evaluation|
514513|NCT00285103|Drug|SPC2996|
514514|NCT00285090|Dietary Supplement|Calcium, Vitamin D|
514515|NCT00285090|Dietary Supplement|Calcium,Vitamin D|
514516|NCT00285090|Dietary Supplement|Calcium, VitaminD|
514517|NCT00285090|Other|Sugar Pill|
514518|NCT00285077|Drug|SR57667B|
514519|NCT00285064|Procedure|CT|
514520|NCT00285051|Drug|inhaled delta-8-THC|
514521|NCT00285025|Drug|SR57667B|
514522|NCT00285012|Drug|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
514523|NCT00285012|Drug|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
514524|NCT00284999|Drug|Soothe|
514525|NCT00284999|Drug|Refresh Tears|
514526|NCT00284986|Drug|Prochymal (TM)|
514527|NCT00284973|Biological|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
514528|NCT00284947|Drug|basiliximab|40 mg once every 28 days intravenously for 24 weeks
514529|NCT00284947|Drug|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
514530|NCT00284947|Drug|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
514531|NCT00284934|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
514532|NCT00284934|Drug|Tacrolimus|
514533|NCT00284934|Drug|Corticosteroids|At a dose of at least 5 mg/day.
514534|NCT00284921|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
514535|NCT00284908|Drug|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
514536|NCT00284869|Drug|LPS|
514537|NCT00284856|Drug|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
514538|NCT00284856|Drug|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
514539|NCT00284856|Drug|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
514540|NCT00284856|Drug|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
514541|NCT00284830|Device|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
514542|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
514543|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
514544|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
514545|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
514546|NCT00284817|Drug|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
514547|NCT00284804|Drug|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
514548|NCT00284791|Drug|Lamotrigine (drug)|
514549|NCT00284791|Drug|Fluoxetine (drug)|
514550|NCT00284791|Drug|sertraline (drug)|
514551|NCT00284778|Drug|Alimta®|
514552|NCT00284778|Drug|Taxotere®|
514553|NCT00284765|Procedure|flector|
514554|NCT00284752|Drug|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
514555|NCT00284739|Drug|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
514556|NCT00284739|Other|saline|saline injection twice daily for three days
514557|NCT00284726|Device|Celsior Cold Storage Solution|
514558|NCT00284713|Procedure|intracoronary infusion of BMC|catheter delivery of stem cells
514559|NCT00284700|Drug|Iron|
514560|NCT00284687|Drug|Artesunate|PO Artesunate
514561|NCT00284674|Device|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
514562|NCT00284661|Procedure|FAST FIX|Fast fix repair of a meniscal tear
514563|NCT00284661|Procedure|Meniscal suturing|standard suturing of meniscal tear
514564|NCT00284648|Procedure|Surgical repair Achilles tendon rupture|
514565|NCT00284648|Procedure|Non-surgical repair Achilles tendon rupture|
514566|NCT00284635|Procedure|Fast track vs conventional|
514567|NCT00284622|Procedure|Arthroscopy|HTO with pre-scope
537168|NCT00094484|Drug|Cinacalcet HCl|
514568|NCT00284609|Behavioral|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.~24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.~3 x 3 hours cooking sessions in group classes supervised by a dietitian.~Intervention period: 6 month"
514569|NCT00284609|Behavioral|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.~4 x 1 hour with a diabetes nurse,~3 x 0.5 hour with a dietitian and~1 hour with a chiropodist.~Intervention period: 6 month"
514570|NCT00284596|Procedure|High tibial osteotomy|HTO
514571|NCT00284583|Drug|Injection of Steroid into Foot|
514572|NCT00284583|Drug|Injection of Alcohol into Foot|
514573|NCT00284583|Drug|Injection of Lidocaine into Foot|
514574|NCT00284557|Behavioral|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
514575|NCT00284531|Drug|Daclizumab|
514576|NCT00284518|Biological|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
514577|NCT00284518|Drug|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
514578|NCT00284505|Drug|thalidomide|
514579|NCT00284492|Procedure|Traditional chinese medicine type acupuncture|10 acupuncture sessions
514580|NCT00284492|Behavioral|Self Care|Lifestyle advice on diet, physical activity
514581|NCT00284479|Behavioral|Walking 45 mins 2x p.w.|
514582|NCT00284466|Procedure|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
514583|NCT00284453|Procedure|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving >2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
514584|NCT00284427|Drug|vitamin C|IV Vitamin C given 2-3 times a week
514585|NCT00284414|Procedure|Ultrasonography or MRI|
514586|NCT00284401|Procedure|Evaluation of the placement of the Delta prosthesis|
514587|NCT00284388|Procedure|Simultaneous controlled power measurement|
514588|NCT00284388|Procedure|Surface EMG measurement|
514589|NCT00284375|Procedure|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
514590|NCT00284362|Procedure|Arthroscopic or open surgery for hallux rigidus|
514591|NCT00284349|Device|Use of a rehabilitation brace instead of a plaster|
514592|NCT00284336|Drug|Caelyx|
514593|NCT00284336|Drug|endoxan|
514594|NCT00284323|Drug|Adenosine|
514595|NCT00284310|Procedure|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
514596|NCT00284297|Procedure|History taken and clinical examination|History is taken and clinical examination is followed
514597|NCT00284284|Device|Use of a rehabilitation brace|
514598|NCT00284271|Drug|Cyclophosphamide|
514599|NCT00284271|Drug|Adramycin|
514600|NCT00284271|Drug|Procarbacine|
514601|NCT00284271|Drug|Prednisone|
514602|NCT00284271|Drug|Vincristine|
514603|NCT00284271|Drug|Bleomycin|
514604|NCT00284271|Drug|Erythropoietin beta|
514605|NCT00284258|Drug|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
514606|NCT00284258|Drug|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
514607|NCT00284232|Behavioral|Use and interpretation of blood glucose results|
514608|NCT00284232|Drug|Insulin dosing based on SMBG chart and education|
514609|NCT00284219|Device|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
514610|NCT00284219|Device|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
514611|NCT00284206|Drug|long-acting injectable risperidone|
514612|NCT00284193|Drug|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
514613|NCT00284193|Drug|FEIBA- Activated Prothrombin Complexes|
514614|NCT00284180|Drug|Vinflunine|Novel second generation vinca alkaloid
514615|NCT00284180|Drug|Trastuzumab|Anti-HER2 monoclonal antibody
514616|NCT00284167|Behavioral|tailored web-based weight management intervention|
514617|NCT00284154|Drug|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
514618|NCT00284141|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
514619|NCT00284128|Drug|AVE7688|oral administration (capsules)
514620|NCT00284128|Drug|Losartan-potassium|oral administration (capsules)
514621|NCT00284115|Device|Gait trainer|Mechanical gait repetitive training
514622|NCT00284115|Device|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
514623|NCT00284102|Procedure|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
514682|NCT00283660|Dietary Supplement|10 mg zinc oxide|10 mg zinc oxide
514624|NCT00284089|Drug|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
514625|NCT00284076|Drug|L-arginine|
514626|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
514627|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
514628|NCT00284063|Procedure|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
514629|NCT00284050|Drug|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
514630|NCT00284050|Drug|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
514631|NCT00284050|Drug|Sham injection|Non-treatment control for sham intravitreal injection.
514632|NCT00284037|Device|continuous positive airway pressure therapy|
514633|NCT00284024|Drug|domperidone|
514634|NCT00284011|Dietary Supplement|SAMe|800 mg dose daily for 4 weeks.
514635|NCT00284011|Other|Placebo|2 placebo pills daily for 4 weeks.
514636|NCT00283998|Procedure|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
514637|NCT00283985|Drug|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
514638|NCT00283985|Drug|Methotrexate|3 gr/m2 at J1
514639|NCT00283985|Drug|Dexamethasone|40 mg/ per os at J1, J2 and J4.
514640|NCT00283985|Drug|Erwinase|"In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
514641|NCT00283972|Device|LAP-BAND System|
514642|NCT00283959|Drug|migalastat HCl|
514643|NCT00283946|Drug|Zolpidem MR|Oral
514644|NCT00283946|Drug|Zolpidem|Oral
514645|NCT00283933|Drug|migalastat HCl|
514646|NCT00283920|Drug|[(11)C] PBR28|
514647|NCT00283855|Behavioral|Online Self-Management|Online Self-Management
514648|NCT00283842|Drug|DVS SR|
514649|NCT00283842|Drug|Placebo|
514650|NCT00283829|Drug|docetaxel|chemotherapy
514651|NCT00283829|Drug|IL2|immunotherapy
514652|NCT00283816|Drug|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
514653|NCT00283816|Drug|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets~1 tab daily for duration of study"
514654|NCT00283816|Behavioral|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise & behavior modification skills on a regular weekly basis over the 24 week study
514655|NCT00283816|Behavioral|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
514656|NCT00283816|Procedure|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.~Performed twice during study, at baseline and conclusion"
514657|NCT00283816|Procedure|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
514658|NCT00283816|Procedure|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.~Performed twice during study, at baseline and conclusion"
514659|NCT00283816|Procedure|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
514660|NCT00283816|Drug|placebo|placebo capsules, two capsules BID
514661|NCT00283803|Drug|Exisulind|Oral antineoplastic agent that induces apoptosis in cancerous cells.
514662|NCT00283803|Drug|luteinizing hormone-releasing hormone (LHRH) agonist|Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
514663|NCT00283803|Drug|Antiandrogen|Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.
514664|NCT00283790|Drug|zolpidem tartrate|
514665|NCT00283777|Drug|Chromium Picolinate|
514666|NCT00283764|Drug|Xalatan|
514667|NCT00283751|Drug|insulin detemir|
514668|NCT00283751|Drug|insulin glargine|
514669|NCT00283738|Device|BioSTAR Septal Repair Implant System|PFO Closure
514670|NCT00283738|Procedure|Sham Procedure|Catheterization
514671|NCT00283725|Other|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor [AChEI] nor memantine).
514672|NCT00283712|Drug|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg
514673|NCT00283712|Other|Placebo Comparator|Placebo administered in place of infliximab for control group
514674|NCT00283699|Drug|albendazole|Active drug or placebo dosed bid p o for 8days
514675|NCT00283699|Other|placebo|an inactive substance
514676|NCT00283686|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
514677|NCT00283686|Drug|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
514678|NCT00283686|Drug|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
514679|NCT00283686|Other|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
514680|NCT00283686|Other|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
514683|NCT00283660|Other|Placebo|Placebo pill taken five days a week for six months.
514684|NCT00283634|Drug|erlotinib and bortezomib|
514685|NCT00283621|Drug|Aranesp (darbepoetin alfa)|
514686|NCT00283621|Drug|Neulasta (pegfilgrastim)|
514687|NCT00283621|Drug|Adriamycin|
514688|NCT00283621|Drug|Ifosfamide|
514689|NCT00283608|Genetic|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
514690|NCT00283608|Other|high performance liquid chromatography|analysis of plasma concentrations of drugs
514691|NCT00283608|Other|measurements by DXA|determine bone mineral density (BMD)
514692|NCT00283608|Other|questionnaire administration|determine attitude changes
514693|NCT00283595|Drug|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
514694|NCT00283595|Drug|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
514695|NCT00283582|Drug|rhTPO|
514696|NCT00283569|Other|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
514697|NCT00283556|Drug|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.~Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
514698|NCT00283543|Drug|Gliadel Wafer|
514699|NCT00283543|Drug|Temozolomide|
514700|NCT00283543|Procedure|Limited field radiation|
514701|NCT00283530|Procedure|Tumor biopsy|
514702|NCT00283517|Drug|antipsychotics|as prescribed
514703|NCT00283504|Drug|ANTI-IGE THERAPY (XOLAIR)|Xolair dosing is based on body weight and baseline serum total IgE concentration(0.016 x kg body weight x IgE levels), with a maximum dose per 4 weeks of 750mg.Depending on their weight and IgE levels, patients get their Xolair shots every 2 or every 4 weeks.
514704|NCT00283491|Behavioral|Active Lactobacillus plantarum 299v|10^11 cfu/meal in 2 meals on 2 consecutive days
514705|NCT00283491|Dietary Supplement|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
514706|NCT00283478|Drug|Iscar Quercus|
514707|NCT00283478|Drug|Gemcitabine|
514708|NCT00283465|Drug|Epoetin alfa|
514709|NCT00283452|Behavioral|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
514710|NCT00283439|Biological|AMG 531|"Planned Cohorts:~100 mcg,~300 mcg,~700 mcg,~1000 mcg;~Optional Cohorts:~cohort expansion,~schedule change,~new dose"
514711|NCT00283426|Drug|Soluble beta-1,3/1,6-glucan|
514712|NCT00283413|Device|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
514713|NCT00283413|Device|Bare metal stent|Any commercially available bare metal stent for coronary indication
514714|NCT00283400|Drug|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
514715|NCT00283387|Drug|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
514716|NCT00283387|Drug|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
514717|NCT00283374|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
514718|NCT00283361|Drug|ZP120|
514719|NCT00283361|Procedure|I.v. catherization|
514720|NCT00283361|Procedure|6-minutes walk performance|
514721|NCT00283361|Behavioral|Dyspnea severity assessment|
514722|NCT00283361|Procedure|Blood sampling for laboratory tests|
514723|NCT00283361|Procedure|ECG|
514724|NCT00283361|Procedure|Physical examination|
514725|NCT00283335|Drug|gemfibrozil|
514726|NCT00283335|Other|Placebo|Matching placebo tablets taken once per day
514727|NCT00283322|Other|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
514728|NCT00283309|Drug|Memantine|
514729|NCT00283309|Drug|Riluzole|
514730|NCT00283296|Device|Endeavor|Collapsible, forward folding manual wheelchair
514731|NCT00283283|Biological|Fluzone® (Aventis Pasteur inactivated influenza vaccine)|A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
514732|NCT00283270|Behavioral|Brief counselling|
514733|NCT00283270|Behavioral|Behavior|
514734|NCT00283257|Behavioral|Patients and caregivers are taught problem solving skills|
514735|NCT00283244|Drug|erlotinib hydrochloride|given orally
514736|NCT00283244|Drug|gemcitabine hydrochloride|given IV
514737|NCT00283231|Behavioral|Paced Respiration|
514738|NCT00283218|Drug|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
514739|NCT00283205|Behavioral|Yoga|
514740|NCT00283192|Drug|Sertraline|
514741|NCT00283179|Drug|Aripiprazole|
514742|NCT00283179|Drug|Risperidone|
514743|NCT00283166|Behavioral|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
514744|NCT00283153|Behavioral|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
514745|NCT00283153|Other|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
514746|NCT00283127|Procedure|Home sampling (urine test) for uro-genital C.trachomatis.|
514747|NCT00283114|Drug|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
514748|NCT00283101|Drug|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
514749|NCT00283088|Procedure|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.~Subjects are stratified by time to six groups."
514750|NCT00283088|Drug|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
514751|NCT00283075|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kg
514752|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
514753|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
514754|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.~Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
514755|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
514756|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
514757|NCT00283049|Drug|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
514758|NCT00283049|Drug|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
514759|NCT00283036|Drug|Irbesartan|
514760|NCT00283023|Procedure|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
514761|NCT00283010|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
514762|NCT00283010|Other|Educational DVDs|
514763|NCT00282997|Drug|pregabalin|
514764|NCT00282984|Drug|placebo|1 mg placebo twice daily by mouth for 12 weeks
514765|NCT00282984|Drug|Varenicline|1 mg twice daily by mouth for 12 weeks
514766|NCT00282971|Drug|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
514767|NCT00282971|Other|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
514768|NCT00282958|Drug|Botulinum Toxin type a (Botox)|
514769|NCT00282945|Drug|Rosiglitazone|
514770|NCT00282945|Drug|Metformin|
514771|NCT00282932|Drug|Detrol LA|
514772|NCT00282919|Drug|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
514773|NCT00282906|Device|hybrid PET-CT imaging system|15 mCi of FDG
514774|NCT00282893|Procedure|transluminal ballooning|
514775|NCT00282893|Other|currently existing therapies for the treatment of vasospasm|
514776|NCT00282867|Drug|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
514777|NCT00282867|Other|standard care|usual care
514778|NCT00282841|Other|ultrasound|single intravenous administration of maximum 1.5 milliliter ultrasound contrast agent (Definity), followed by maximum 15 minutes transcranial insonation using diagnostic ultrasound.
514779|NCT00282828|Drug|Sertraline|
514780|NCT00282828|Drug|Venlafaxine|
514781|NCT00282828|Drug|Placebo|
514782|NCT00282828|Drug|Clonazepam|
514783|NCT00282815|Device|continuous positive airway pressure or CPAP|RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
514784|NCT00282815|Device|sham CPAP|sham CPAP
514785|NCT00282789|Device|bilevel positive airway pressure|
514786|NCT00282789|Device|bilevel positive airway pressure (Device)|
514787|NCT00282776|Behavioral|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
514788|NCT00282776|Behavioral|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
514789|NCT00282763|Drug|MK0686|
514790|NCT00282750|Device|Bar coded sponge and scanner|
514791|NCT00282724|Drug|Liarozole|
514792|NCT00282698|Drug|Insulin infusion with a goal|
514793|NCT00282685|Procedure|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
514794|NCT00282672|Device|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
515471|NCT00277862|Drug|Pegylated IFN- alpha 2b|
514795|NCT00282672|Device|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
514796|NCT00282659|Drug|magnesium L-lactate|
514797|NCT00282646|Procedure|intraarterial stem cell therapy|catheter delivery of stem cells
514798|NCT00282646|Other|Stem cells|intraarterial application of bone marrow mononuclear cells versus placebo
514799|NCT00282633|Device|Dermabond|
514800|NCT00282620|Drug|Magnesium L-lactate|
514801|NCT00282607|Drug|DA-8159|
514802|NCT00282594|Drug|Novolin R (human recombinant Insulin)|
514803|NCT00282581|Biological|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
514804|NCT00282568|Drug|Tacrolimus Modified Release (MR)|Oral
514805|NCT00282568|Drug|tacrolimus|Oral
514806|NCT00282555|Drug|S-Tenatoprazole-Na (STU-Na)|
514807|NCT00282542|Procedure|Hepatocyte Infusion|
514808|NCT00282529|Device|High Risk Lymphedema Education and Device Intervention|
514809|NCT00282516|Procedure|In-home telemonitoring of pediatric patients with persistent asthma|
514810|NCT00282503|Drug|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:~Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),~Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be > 4 days between the ECP treatments within a week.)~Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:~Daily Dose (mg/kg)~1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
514811|NCT00282503|Procedure|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
514812|NCT00282490|Device|Nerve stimulator|
514813|NCT00282464|Drug|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
514814|NCT00282464|Drug|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
514815|NCT00282451|Drug|biphasic insulin aspart|
514816|NCT00282451|Drug|insulin aspart|
514817|NCT00282438|Biological|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
514818|NCT00282438|Biological|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
514819|NCT00282425|Biological|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
514820|NCT00282412|Biological|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
514821|NCT00282412|Drug|Fludarabine|inhibits DNA synthesis or repair
514822|NCT00282412|Drug|Cyclophosphamide|Causes prevention of cell division by forming adducts with DNA
514823|NCT00282412|Drug|Campath 1H|humanized monoclonal antibody against CD52 antigen
514824|NCT00282412|Drug|GCSF|Hematopoietic growth factor
514825|NCT00282412|Drug|Cyclosporins|immune suppressive drug
514826|NCT00282412|Drug|Mycophenolate Mofetil|immune suppressive drug
514827|NCT00282399|Drug|Subcutaneous Decitabine|
514828|NCT00282386|Drug|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
514829|NCT00282386|Drug|Placebo/ Duration of Treatment: 156 weeks|
514830|NCT00282373|Device|mild hypothermia|
514831|NCT00282360|Drug|Trimetazidine|
514832|NCT00282347|Drug|Rituximab|Rituximab was provided as a sterile solution for injection.
514833|NCT00282347|Drug|Placebo|Placebo was provided as a sterile solution for injection.
514834|NCT00282347|Drug|Mycophenolate mofetil|
514835|NCT00282347|Drug|Methylprednisolone|
514836|NCT00282347|Drug|Diphenhydramine|
514837|NCT00282347|Drug|Acetaminophen|
514838|NCT00282347|Drug|Prednisone|
514839|NCT00282334|Device|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
514840|NCT00282321|Behavioral|High Protein diet|
514841|NCT00282321|Behavioral|High carbohydrate diet|
514842|NCT00282308|Drug|Rituximab|Rituximab was supplied in single-use vials.
514843|NCT00282308|Drug|Methotrexate|
514844|NCT00282308|Drug|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
514845|NCT00282308|Biological|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
514846|NCT00282308|Biological|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
514847|NCT00282308|Biological|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
514848|NCT00282308|Biological|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
514849|NCT00282295|Biological|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
514850|NCT00282295|Biological|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
514851|NCT00282282|Drug|tacrolimus|Given orally just prior to and following stem cell transplant
514852|NCT00282282|Drug|sirolimus|Given orally just prior to and following stem cell transplant
514853|NCT00282282|Drug|fludarabine|Given once daily over 30 minutes for 4 days
514854|NCT00282282|Drug|busulfex|Given intravenously over 3 hours for 4 days
514855|NCT00282269|Procedure|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
514856|NCT00282256|Drug|tacrolimus modified release (MR)|Oral
514857|NCT00282256|Drug|tacrolimus|Oral
514858|NCT00282243|Drug|tacrolimus modified release (MR)|Oral
514859|NCT00282243|Drug|tacrolimus|Oral
514860|NCT00282230|Drug|FK778|
514861|NCT00282217|Drug|Sirolimus|
514862|NCT00282204|Behavioral|antenatal hypnosis + audio compact disc on hypnosis|
514863|NCT00282204|Behavioral|Audio compact disc on hypnosis|
514864|NCT00282178|Drug|Hydrochlorothiazide|25-50 mg once daily
514865|NCT00282178|Drug|Placebo|Once daily
514866|NCT00282178|Drug|Candesartan|16-32 mg once daily 12 weeks
514867|NCT00282165|Drug|naratriptan|four weeks double blind experimental treatment using oral naratriptan
514868|NCT00282165|Drug|placebo|four weeks double blind placebo treatment
514869|NCT00282152|Device|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
514870|NCT00282152|Drug|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
514871|NCT00282139|Drug|Aripiprazole|
514872|NCT00282126|Dietary Supplement|Potassium citrate|kcitrate
514873|NCT00282113|Dietary Supplement|ProBioPlus|ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
514874|NCT00282113|Dietary Supplement|Culturelle|Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
514875|NCT00282113|Other|Placebo|A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
514876|NCT00282100|Drug|Gefetinib (Iressa)|
514877|NCT00282087|Drug|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
514878|NCT00282074|Procedure|laparoscopic bilateral hernia repair|
514879|NCT00282061|Drug|Melatonin|
514880|NCT00282048|Drug|AG-013736 (axitinib)|AG-013736 5 mg twice daily [bid] continuous dosing in 28 day cycles.
514881|NCT00282035|Radiation|APBI utilizing 3D-CRT radiation|Accelerated partial breast irradiation utilizing 3D-CRT
514882|NCT00282035|Radiation|Whole breast irradiation|Whole breast irradiation
514883|NCT00282022|Drug|laromustine|
514884|NCT00282009|Behavioral|Basic Internet|Basic Internet control intervention
514885|NCT00282009|Behavioral|Enhanced Internet|enhanced Internet cessation intervention
514886|NCT00282009|Behavioral|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
514887|NCT00281996|Drug|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
514888|NCT00281996|Drug|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
514889|NCT00281983|Biological|alemtuzumab|
514890|NCT00281983|Biological|anti-thymocyte globulin|
514891|NCT00281983|Biological|filgrastim|
514892|NCT00281983|Biological|rituximab|
514893|NCT00281983|Biological|therapeutic allogeneic lymphocytes|
514894|NCT00281983|Drug|busulfan|
514895|NCT00281983|Drug|cyclophosphamide|
514896|NCT00281983|Drug|cyclosporine|
514897|NCT00281983|Drug|fludarabine phosphate|
514898|NCT00281983|Drug|methotrexate|
514899|NCT00281983|Drug|mycophenolate mofetil|
514900|NCT00281983|Procedure|peripheral blood stem cell transplantation|
514901|NCT00281983|Radiation|radiation therapy|
514902|NCT00281970|Drug|cisplatin|
514903|NCT00281970|Drug|docetaxel|
514904|NCT00281970|Procedure|adjuvant therapy|
514905|NCT00281957|Drug|sorafenib tosylate|Given orally
514906|NCT00281957|Drug|tipifarnib|Given orally
514907|NCT00281957|Drug|temsirolimus|Given IV
514908|NCT00281944|Drug|oxaliplatin|Given IV
514909|NCT00281944|Drug|fluorouracil|Given IV
514910|NCT00281944|Drug|leucovorin calcium|Given IV
514911|NCT00281944|Other|pharmacological study|Correlative studies
514912|NCT00281944|Procedure|positron emission tomography|Undergo PET scan
514913|NCT00281944|Procedure|computed tomography|Undergo PET/CT scan
514914|NCT00281931|Biological|rituximab|
514915|NCT00281931|Drug|cyclophosphamide|
514916|NCT00281931|Drug|fludarabine phosphate|
514917|NCT00281918|Drug|Rituximab|Intravenous repeating dose
514918|NCT00281918|Drug|Cyclophosphamide|Intravenous repeating dose
514919|NCT00281918|Drug|Fludarabine Phosphate|Intravenous repeating dose
514920|NCT00281905|Drug|carboplatin|
514921|NCT00281905|Drug|cisplatin|
514922|NCT00281905|Drug|cyclophosphamide|
514923|NCT00281905|Drug|methotrexate|
514924|NCT00281905|Drug|vincristine sulfate|
514925|NCT00281905|Radiation|radiation therapy|
514926|NCT00281892|Biological|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
515032|NCT00281411|Procedure|Computed Tomography Angiography|Computed Tomography Angiography
515033|NCT00281411|Procedure|Magnetic Resonance Angiography|Magnetic Resonance Angiography
515034|NCT00281398|Behavioral|Questionnaire|
515035|NCT00281385|Behavioral|traditional vs. lifestyle exercise|
515472|NCT00277862|Drug|Ribavirin|
514927|NCT00281892|Drug|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.~Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
514928|NCT00281879|Biological|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
514929|NCT00281879|Biological|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.~Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
514930|NCT00281879|Drug|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
514931|NCT00281879|Drug|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
514932|NCT00281879|Drug|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
514933|NCT00281879|Drug|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
514934|NCT00281879|Drug|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
514935|NCT00281879|Drug|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.~Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
514936|NCT00281879|Drug|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.~Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
514937|NCT00281879|Drug|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
514938|NCT00281879|Drug|methotrexate|Administered on days +1, +3, and +7.
514939|NCT00281879|Drug|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
514940|NCT00281879|Drug|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
514941|NCT00281879|Drug|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
514942|NCT00281879|Procedure|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
514943|NCT00281879|Procedure|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
514944|NCT00281879|Radiation|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
514945|NCT00281866|Drug|erlotinib hydrochloride|
514946|NCT00281853|Procedure|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
514947|NCT00281840|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
514948|NCT00281840|Drug|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
514949|NCT00281840|Procedure|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
514950|NCT00281840|Radiation|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
514951|NCT00281827|Drug|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
514952|NCT00281827|Drug|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
514953|NCT00281827|Drug|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
514954|NCT00281827|Procedure|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
514955|NCT00281814|Procedure|psychosocial assessment and care|psychosocial assessment and care
514956|NCT00281801|Procedure|psychosocial assessment and care|psychosocial assessment and care
514957|NCT00281801|Procedure|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
514958|NCT00281788|Drug|capecitabine|
514959|NCT00281788|Drug|carboplatin|
514960|NCT00281788|Drug|paclitaxel|
514961|NCT00281788|Radiation|radiation therapy|
514962|NCT00281762|Drug|NSAID|
514963|NCT00281749|Procedure|TELEPHONE CALL|
514964|NCT00281736|Drug|HPPH|Given IV
514965|NCT00281723|Drug|Pro-Pe adhesive tablet|
514966|NCT00281710|Drug|Methylprednisolone|
514967|NCT00281697|Drug|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
514968|NCT00281697|Drug|Placebo|
515036|NCT00281359|Device|With heat|heat pad followed by dynamic splinting
515037|NCT00281359|Device|No heat|No heat added to tissue prior to dynamic splinting
515038|NCT00281346|Procedure|Doppler echocardiography|Echocardiography
515473|NCT00277836|Drug|MST-997|
514969|NCT00281697|Drug|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.~Taxane - Paclitaxel (Taxol) 90 mg/m^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m^2 IV every 3 weeks.~Gemcitabine (Gemzar) 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle.~Vinorelbine (Navelbine) 30 mg/m^2 IV every week of each 3-week cycle.~Capecitabine (Xeloda) 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week cycle."
514970|NCT00281684|Drug|SB705498 400 mg|SB705498 400 mg
514971|NCT00281684|Drug|SB705498 1000 mg|SB705498 1000 mg
514972|NCT00281684|Drug|Placebo|Placebo
514973|NCT00281684|Drug|Co-Codamol|Co-Codamol
514974|NCT00281671|Drug|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
514975|NCT00281658|Drug|lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
514976|NCT00281658|Drug|paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
514977|NCT00281645|Drug|Bicifadine|
514978|NCT00281645|Drug|Standard of Care (pharmacological analgesic treatment)|
514979|NCT00281632|Drug|GW786034|800 mg GW786034 administered orally on a daily basis.
514980|NCT00281619|Drug|CellCept (mycophenolate mofetil)|
514981|NCT00281619|Behavioral|Dietary Monitoring|
514982|NCT00281619|Behavioral|Drug Diary|
514983|NCT00281619|Procedure|Blood Sampling|
514984|NCT00281606|Drug|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
514985|NCT00281593|Drug|Telmisartan|
514986|NCT00281593|Drug|Ramipril|
514987|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
514988|NCT00281580|Drug|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
514989|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
514990|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
514991|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
514992|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
514993|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
514994|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
514995|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
514996|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
514997|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
514998|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
514999|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
515000|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
515001|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
515002|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
515003|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
515004|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
515005|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
515006|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
515007|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
515008|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
515009|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
515010|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
515011|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
515012|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
515013|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
515014|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
515015|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
515016|NCT00281567|Drug|Tiotropium|
515017|NCT00281567|Device|Respimat SMI|
515018|NCT00281567|Device|HandiHaler|
515019|NCT00281554|Drug|RSD1235|IV
515020|NCT00281541|Drug|YM155|
515021|NCT00281528|Drug|ABI-007 (Abraxane)|30 minute infusions
515022|NCT00281528|Drug|bevacizumab|infusions
515023|NCT00281515|Drug|Lonafarnib|100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
515024|NCT00281502|Drug|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
515025|NCT00281489|Device|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
515026|NCT00281489|Behavioral|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
515027|NCT00281476|Drug|Simvastatine|
515028|NCT00281463|Device|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
515029|NCT00281450|Behavioral|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
515030|NCT00281437|Behavioral|choice of exercise program|
515031|NCT00281424|Device|pedometer|gave pedometer and info
515039|NCT00281333|Behavioral|"Karate exercises and strengthening exercises"|
515040|NCT00281320|Drug|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
515041|NCT00281307|Drug|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
515042|NCT00281294|Drug|Fontolizumab|
515043|NCT00281281|Drug|vancomycin|
515044|NCT00281268|Procedure|pulmonary artery catheter|
515045|NCT00281268|Procedure|central venous catheter|
515046|NCT00281268|Procedure|fluid management|
515047|NCT00281255|Drug|Allopurinol|
515048|NCT00281255|Drug|Dobutamine|
515049|NCT00281242|Other|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
515050|NCT00281203|Procedure|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
515051|NCT00281203|Procedure|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
515052|NCT00281190|Procedure|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
515053|NCT00281190|Procedure|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
515054|NCT00281177|Behavioral|Asthma Disparity Reduction Strategy|
515055|NCT00281125|Drug|PTK787 and Pemetrexed with or without Cisplatin|
515056|NCT00281099|Device|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
515057|NCT00281073|Device|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
515058|NCT00281073|Device|Intracardiac Echo|Intracardiac Echo Viewmate
515059|NCT00281073|Device|ICE|ICE or TEE
515060|NCT00281060|Procedure|primary stenting|
515061|NCT00281047|Drug|FP-10|
515062|NCT00281021|Drug|Erlotinib plus Digoxin|Each subject will receive erlotinib and digoxin daily until progression.
515063|NCT00281008|Drug|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
515064|NCT00281008|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
515065|NCT00281008|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
515066|NCT00281008|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
515067|NCT00280995|Drug|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
515068|NCT00280995|Drug|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
515069|NCT00280995|Drug|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
515070|NCT00280995|Drug|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
515071|NCT00280982|Biological|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
515072|NCT00280969|Drug|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
515073|NCT00280969|Drug|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
515074|NCT00280956|Drug|natalizumab|
515075|NCT00280943|Behavioral|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
515076|NCT00280930|Drug|Letrozole|
515077|NCT00280917|Drug|CF101|
515078|NCT00280904|Device|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
515079|NCT00280878|Drug|gemcitabine|
515080|NCT00280878|Drug|vinorelbine|
515081|NCT00280878|Drug|ifosfamide|
515082|NCT00280878|Drug|rituximab|
515083|NCT00280865|Drug|Tesaglitazar|
515084|NCT00280865|Drug|Pioglitazone|
515085|NCT00280865|Behavioral|Dietary and Lifestyle Modification Counseling|
515086|NCT00280826|Drug|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
515087|NCT00280813|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|
515088|NCT00280800|Device|constant CPAP devices|different CPAP mode
515089|NCT00280800|Device|automatic CPAP devices|different CPAP mode
515090|NCT00280787|Drug|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
515091|NCT00280787|Drug|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
515092|NCT00280787|Drug|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
515093|NCT00280787|Drug|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
515094|NCT00280787|Radiation|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
515095|NCT00280774|Drug|Memantine|
515096|NCT00280761|Drug|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
515142|NCT00280397|Drug|E7080|E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
515097|NCT00280761|Drug|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
515098|NCT00280761|Procedure|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
515099|NCT00280761|Radiation|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
515100|NCT00280748|Drug|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
515101|NCT00280748|Radiation|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
515102|NCT00280735|Drug|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
515103|NCT00280735|Drug|docetaxel|75 mg/m² intravenously, once, every 3 weeks
515104|NCT00280722|Behavioral|patient information leaflet|
515105|NCT00280709|Device|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
515106|NCT00280696|Drug|Levetiracetam 250 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 250 mg~Route of Administration: Oral Use"
515107|NCT00280696|Drug|Levetiracetam 500 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Film-coated tablet~Concentration: 500 mg~Route of Administration: Oral Use"
515108|NCT00280696|Other|Placebo|"Active Substance: Placebo~Pharmaceutical Form: Film-coated tablet~Concentration: 250 mg and 500 mg~Route of Administration: Oral Use"
515109|NCT00280683|Drug|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
515110|NCT00280683|Drug|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
515111|NCT00280670|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
515112|NCT00280657|Drug|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
515113|NCT00280657|Drug|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
515114|NCT00280657|Drug|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
515115|NCT00280644|Drug|Leflunomide|
515116|NCT00280631|Drug|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
515117|NCT00280618|Drug|Oxaliplatin|
515118|NCT00280605|Drug|Alfuzosin|
515119|NCT00280592|Drug|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
515120|NCT00280592|Drug|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
515121|NCT00280566|Drug|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
515122|NCT00280566|Drug|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
515123|NCT00280553|Drug|bupivicaine|PCA and bupivicaine infusion for up to five days
515124|NCT00280553|Other|Saline infusion|PCA and pump with saline infusion for up to five days
515125|NCT00280540|Drug|Valsartan/Hydrochlorothiazide|
515126|NCT00280514|Drug|cefpirome and moxifloxacin administration|
515127|NCT00280501|Drug|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
515128|NCT00280501|Drug|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
515129|NCT00280501|Drug|Placebo|Placebo
515130|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
515131|NCT00280488|Behavioral|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
515132|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
515133|NCT00280475|Device|Whole brain radiation therapy arm|Whole brain radiation therapy arm
515134|NCT00280475|Device|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
515135|NCT00280462|Drug|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
515136|NCT00280462|Drug|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
515137|NCT00280462|Drug|Placebo|Placebo
515138|NCT00280449|Behavioral|strengths-based case managed proactive service model|
515139|NCT00280436|Drug|GW679769|
515140|NCT00280423|Drug|GW679769|
515141|NCT00280410|Drug|E7337|
515143|NCT00280384|Drug|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
515144|NCT00280384|Drug|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
515145|NCT00280371|Drug|Formoterol Fumarate|
515146|NCT00280358|Drug|Fluticasone Propionate|
515147|NCT00280358|Drug|Formoterol Fumarate|
515148|NCT00280345|Procedure|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
515149|NCT00280345|Procedure|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
515150|NCT00280345|Procedure|Cataract surgery|Removal of the cataract from the eye
515151|NCT00280332|Procedure|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
515152|NCT00280319|Behavioral|interpersonal psychotherapy for groups|psychotherapy
515153|NCT00280319|Behavioral|creative play therapy|consisted of play activities
515154|NCT00280306|Other|No interventions|No intervention
515155|NCT00280293|Drug|Lamotrigine|Lamotrigine
515156|NCT00280293|Drug|Placebo|Placebo
515157|NCT00280280|Drug|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
515158|NCT00280267|Drug|Testosterone gel|
515159|NCT00280254|Procedure|Hemodynamically Oriented Echocardiography-based Strategy|
515160|NCT00280241|Drug|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
515161|NCT00280241|Drug|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
515162|NCT00280241|Drug|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
515163|NCT00280228|Behavioral|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
515164|NCT00280228|Behavioral|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
515165|NCT00280215|Drug|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
515166|NCT00280215|Drug|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
515167|NCT00280215|Drug|Placebo|Patients will receive placebo for 24 months
515168|NCT00280202|Procedure|Biopsy of the major carinal area|Biopsy performed intraoperatively
515169|NCT00280202|Procedure|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
515170|NCT00280202|Procedure|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
515171|NCT00280202|Procedure|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
515172|NCT00280202|Procedure|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
515173|NCT00280202|Procedure|Analysis of lymph nodes|Tissues banked for future analysis
515174|NCT00280189|Procedure|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
515175|NCT00280189|Behavioral|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
515176|NCT00280189|Behavioral|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
515177|NCT00280176|Drug|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
515178|NCT00280176|Drug|fluorouracil|225mg/m2 given weekly, up to 6 weeks
515179|NCT00280176|Radiation|radiation therapy|180 cGy, every 5 days, up to six weeks
515180|NCT00280150|Biological|bevacizumab|Given IV
515181|NCT00280150|Drug|carboplatin|Given IV
515182|NCT00280150|Drug|erlotinib hydrochloride|Given orally
515183|NCT00280150|Drug|paclitaxel|Given IV
515184|NCT00280150|Radiation|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
515185|NCT00280111|Biological|116E AGMK|Single dose of 116E 10^5 FFu
515186|NCT00280111|Drug|I321|Single dose of I321 10^5 FFu
515187|NCT00280111|Drug|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
515474|NCT00277823|Drug|DVS-SR 50 mg|
515188|NCT00280098|Drug|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
515189|NCT00280085|Procedure|MR imaging|
515190|NCT00280085|Procedure|Glucose clamp|
515191|NCT00280085|Drug|Arginine|
515192|NCT00280072|Device|Renal Assist Device|
515193|NCT00280059|Drug|Pregabalin|dose 150-600 mg/day given BID
515194|NCT00280059|Drug|Lamotrigine|dose 100-500 mg/day given BID
515195|NCT00280046|Drug|biphasic insulin aspart|
515196|NCT00280033|Biological|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
515197|NCT00280033|Biological|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
515198|NCT00280033|Biological|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
515199|NCT00280033|Drug|Placebo|Saline placebo.
515200|NCT00280020|Behavioral|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
515201|NCT00280020|Behavioral|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
515202|NCT00280020|Behavioral|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
515203|NCT00280007|Drug|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
515204|NCT00279994|Procedure|Exercise therapy|
515205|NCT00279994|Device|Accelerometer (PAM; Personal Activity Monitor)|
515206|NCT00279994|Procedure|Oral Exercise Therapy advise|
515207|NCT00279981|Device|Diagnostic|
515208|NCT00279968|Device|ICD|
515209|NCT00279955|Device|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
515210|NCT00279942|Dietary Supplement|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
515211|NCT00279942|Other|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
515212|NCT00279929|Procedure|DHEA Replacement|
515213|NCT00279916|Drug|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
515214|NCT00279916|Drug|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.~Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
515215|NCT00279903|Drug|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
515216|NCT00279903|Drug|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
515217|NCT00279890|Drug|Topical SR-01|
515218|NCT00279877|Procedure|Kyphoplasty|kyphoplasty
515219|NCT00279838|Procedure|Computer Assisted Navigation Knee Replacement|
515220|NCT00279825|Drug|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
515221|NCT00279825|Drug|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
515222|NCT00279825|Drug|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
515223|NCT00279825|Drug|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
515224|NCT00279825|Drug|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
515225|NCT00279825|Drug|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
515226|NCT00279825|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
515227|NCT00279825|Drug|CD-LD CR Placebo|Placebo to match CD-LD CR
515228|NCT00279812|Dietary Supplement|50ug selenium enriched yeast|Selenomethionine supplement (50ug/d Se) for 12 weeks
515229|NCT00279812|Dietary Supplement|100ug selenium enriched yeast|Selenomethionine supplement (100ug/d Se) for 12 weeks
515230|NCT00279812|Dietary Supplement|200ug selenium enriched yeast|Selenomethionine supplement (200ug/d Se) for 12 weeks
515231|NCT00279812|Dietary Supplement|Control onion|3 meals per week containing un-enriched onion (4ug/d) for 12 weeks
515232|NCT00279812|Dietary Supplement|Enriched onion|3 meals per week containing un-enriched onion (50ug/d) for 12 weeks
515233|NCT00279812|Other|Placebo|Placebo supplement for 12 weeks
515234|NCT00279799|Behavioral|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
515235|NCT00279799|Behavioral|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
515236|NCT00279786|Procedure|Blood draw|blood drawn
515237|NCT00279773|Drug|TKI258|
515238|NCT00279760|Drug|Belatacept|
515239|NCT00279760|Drug|Abatacept|
515240|NCT00279747|Drug|meloxicam 0.25 mg/kg|
515241|NCT00279747|Drug|meloxicam 0.125 mg/kg|
515242|NCT00279747|Drug|naproxen 10 mg/kg|
515243|NCT00279734|Drug|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
515244|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
515245|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
515246|NCT00279734|Drug|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
515247|NCT00279721|Procedure|IMRT|
515248|NCT00279708|Drug|Atorvastatin|Placebo vs. Atorvastatin
515249|NCT00279708|Other|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
515250|NCT00279695|Procedure|high frequency ultrasound examination|high frequency ultrasound examination of the eye
515251|NCT00279682|Behavioral|treatment guidelines and depression care management|
515252|NCT00279669|Procedure|Ultrasound examination|contact ultrasound examination
515253|NCT00279656|Behavioral|Pharmaceutical care|
515254|NCT00279643|Procedure|Laser Hair Removal|
515255|NCT00279630|Procedure|Orthoses and Exercise|orthrose and exercise - daily
515256|NCT00279617|Drug|levetiracetam|open label levetricetam
515257|NCT00279604|Behavioral|'Problem Profile Intervention' vs. WHO-Brief Intervention|
515258|NCT00279591|Device|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
515259|NCT00279591|Device|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
515260|NCT00279578|Drug|ReFacto (Recombinant factor VIII) and Tranexamic acid|
515261|NCT00279565|Drug|buprenorphine|
515262|NCT00279565|Drug|methadone|
515263|NCT00279565|Drug|pegylated interferon alfa-2b plus ribavirin|
515264|NCT00279552|Drug|Recombinant human intrinsic factor|
515265|NCT00279539|Genetic|Vascular Endothelial Growth Factor (VEGF1)|
515266|NCT00279513|Drug|Traumeel S|
515267|NCT00279500|Device|Argus 16 Retinal Stimulation System|The chronic retinal stimulation system is an implantable electronic device designed to provide electrical stimulation of the retina in order to elicit visual percepts in blind subjects.
515268|NCT00279487|Drug|Gabapentin|
515269|NCT00279487|Drug|Placebos|
515270|NCT00279474|Behavioral|cognitive-behavior groups|
515271|NCT00279461|Drug|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
515272|NCT00279461|Drug|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
515273|NCT00279448|Drug|exemestane|On tablet of 25 mg per day during 5 years
515274|NCT00279448|Drug|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
515275|NCT00279435|Drug|visilizumab|
515276|NCT00279422|Drug|visilizumab|
515277|NCT00279422|Drug|visilizumab|
515278|NCT00279409|Drug|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
515279|NCT00279383|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
515280|NCT00279357|Procedure|Narrow Band Imaging|
515281|NCT00279344|Drug|Fentanyl (Matrifen)|
515282|NCT00279305|Drug|Anti-CD20 (rituximab)|
515283|NCT00279305|Drug|Placebo Comparator|Placebo intravenous infusion
515284|NCT00279292|Procedure|Celiac Plexus Neurolysis|
515285|NCT00279279|Device|Implanted Device|
515286|NCT00279266|Drug|Thiamine|
515287|NCT00279253|Drug|clonidine (drug) intravenously|
515288|NCT00279240|Drug|Metformin|
515289|NCT00279214|Drug|drotrecogin alfa (activated)|
515290|NCT00279201|Drug|Insulin glargine|Subcutaneous injection daily
515291|NCT00279201|Drug|Lispro Low Mix|Subcutaneous injection twice daily.
515292|NCT00279201|Drug|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
515293|NCT00279201|Drug|Lispro|Lispro subcutaneous injection 3 times daily.
515294|NCT00279188|Procedure|Guiding therapy by bronchial hyperrsponsiveness|
515295|NCT00279175|Biological|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
515296|NCT00279175|Biological|Placebo medium supplemented with autologous serum|
515297|NCT00279162|Drug|Calcipotriene/betamethasone gel and ointment|
515298|NCT00279149|Procedure|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
515299|NCT00279123|Drug|pantoprazole infusion|
515300|NCT00279123|Drug|pantoprazole bolus|
515301|NCT00279123|Drug|no treatment|
515302|NCT00279110|Behavioral|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
515303|NCT00279097|Device|High Frequency Chest Wall Oscillation|
515304|NCT00279084|Drug|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
515305|NCT00279084|Drug|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
515306|NCT00279071|Device|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
515307|NCT00279058|Procedure|Immunotherapy treatment for melanoma|
515308|NCT00279045|Drug|Rosiglitazone|
515309|NCT00279045|Drug|glyburide|
515310|NCT00279045|Drug|metformin|
515311|NCT00279032|Drug|GW406381|
515312|NCT00279019|Drug|GSK233705|GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
515313|NCT00279019|Drug|Tiotropium|Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
515314|NCT00279019|Drug|Placebo|Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
515315|NCT00279006|Procedure|Percutaneous coronary intervention|
515316|NCT00278993|Drug|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
515317|NCT00278980|Drug|C-peptide|
515318|NCT00278967|Drug|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
515319|NCT00278967|Drug|HalfLytely - Reformulation|
515475|NCT00277823|Drug|DVS-SR 100 mg|
515320|NCT00278954|Biological|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
515321|NCT00278941|Drug|Quetiapine Fumarate Sustained Release|
515322|NCT00278928|Drug|Liposyn III 20% (lipid infusion)|
515323|NCT00278928|Drug|Intralipid 20% (lipid infusion)|
515324|NCT00278915|Drug|Fulvestrant|intramuscular injection
515325|NCT00278902|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
515326|NCT00278889|Drug|AZD2171|oral tablet
515327|NCT00278889|Drug|5-fluorouracil|intravenous infusion
515328|NCT00278889|Drug|Leucovorin|intravenous infusion
515329|NCT00278889|Drug|Oxaliplatin|intravenous infusion
515330|NCT00278889|Drug|Bevacizumab|intravenous infusion
515331|NCT00278876|Drug|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
515332|NCT00278863|Drug|S-1|
515333|NCT00278863|Drug|Capecitabine|
515334|NCT00278850|Behavioral|Educational|three 1 hour long educational seminars
515335|NCT00278837|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
515336|NCT00278824|Drug|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
515337|NCT00278824|Drug|Placebo Patch|Placebo patch applied every 3 days for 15 days
515338|NCT00278811|Procedure|mobile crisis team|
515339|NCT00278785|Behavioral|Brief Motivational Interview|10-20 minute brief motivational interview
515340|NCT00278772|Drug|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
515341|NCT00278772|Other|Placebo|oral dose, placebo
515342|NCT00278759|Procedure|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
515343|NCT00278746|Drug|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
515344|NCT00278746|Drug|ORS only|Promoted routine management of diarrhea in underfive with ORS
515345|NCT00278733|Behavioral|Brief intervention (physician advice)|
515346|NCT00278707|Drug|GTA: Glyceryltriacetate|
515347|NCT00278694|Drug|Oxaliplatin|
515348|NCT00278694|Drug|Chemoradiation|
515349|NCT00278694|Drug|5-FU|
515350|NCT00278694|Radiation|Preoperative chemoradiation|
515351|NCT00278694|Procedure|Pelvic surgery|
515352|NCT00278694|Drug|Neoadjuvant oxaliplatin|
515353|NCT00278681|Drug|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.~Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
515354|NCT00278655|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
515355|NCT00278642|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
515356|NCT00278629|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
515357|NCT00278616|Biological|Stem Cell Transplantation|Autologous Stem Cell Transplantation
515358|NCT00278603|Biological|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
515359|NCT00278590|Biological|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
515360|NCT00278577|Biological|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
515361|NCT00278564|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
515362|NCT00278564|Drug|Cyclophosphamide|
515363|NCT00278564|Drug|Mesna|
515364|NCT00278564|Drug|ATG(rabbit)|
515365|NCT00278564|Drug|Methylprednisolone|
515366|NCT00278564|Drug|G-CSF|
515367|NCT00278564|Drug|Rituxan|
515368|NCT00278551|Biological|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
515369|NCT00278538|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
515370|NCT00278525|Drug|standard of care|standard of care medication will be given
515371|NCT00278525|Procedure|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
515372|NCT00278512|Biological|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
515373|NCT00278512|Biological|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
515374|NCT00278512|Drug|Cyclophosphamide|Causes prevention of the cell division
515375|NCT00278512|Drug|ATG (rabbit)|A rabbit polyclonal antibody to lymphocyte
515376|NCT00278512|Drug|G-CSF|Hematopoietic growth factor
515377|NCT00278512|Drug|Campath-1h|Humanized monoclonal antibody against CD52 antigen
515378|NCT00278512|Drug|Fludarabine|inhibits DNA synthesis or repair
515379|NCT00278512|Drug|Tacrolimus|immune suppressive drug
515380|NCT00278512|Drug|Mesna|Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
515381|NCT00278499|Behavioral|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
515382|NCT00278499|Behavioral|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
515383|NCT00278486|Biological|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
515384|NCT00278473|Behavioral|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
515470|NCT00277875|Drug|ALT-711 (alagebrium chloride)|
515385|NCT00278473|Behavioral|Supportive Therapy|Social Support Problem-Solving Group Treatment
515386|NCT00278460|Drug|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
515387|NCT00278460|Drug|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
515388|NCT00278447|Behavioral|Chronic Disease Management for substance abuse|Referral to primary medical care & longitudinal, multidisciplinary care for persons with substance dependence.
515389|NCT00278447|Behavioral|Standard care|Referral to primary medical care for persons with substance dependence.
515390|NCT00278434|Drug|Zoledronate|
515391|NCT00278434|Other|Placebo (Saline)|
515392|NCT00278421|Biological|rituximab|
515393|NCT00278421|Drug|cyclophosphamide|
515394|NCT00278421|Drug|doxorubicin hydrochloride|
515395|NCT00278421|Drug|prednisone|
515396|NCT00278421|Drug|vincristine sulfate|
515397|NCT00278408|Biological|filgrastim|
515398|NCT00278408|Biological|rituximab|
515399|NCT00278408|Drug|cyclophosphamide|
515400|NCT00278408|Drug|doxorubicin hydrochloride|
515401|NCT00278408|Drug|prednisone|
515402|NCT00278408|Drug|vincristine sulfate|
515403|NCT00278408|Radiation|radiation therapy|
515404|NCT00278395|Drug|Vorinostat|Given orally
515405|NCT00278382|Drug|sorafenib tosylate|Given orally
515406|NCT00278382|Other|laboratory biomarker analysis|Correlative studies
515407|NCT00278369|Biological|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
515408|NCT00278369|Biological|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
515409|NCT00278343|Drug|cediranib maleate|30mg given PO, daily
515410|NCT00278343|Other|laboratory biomarker analysis|Correlative studies
515411|NCT00278330|Drug|alvocidib|Given by infusion
515412|NCT00278330|Drug|vorinostat|Given orally
515413|NCT00278304|Radiation|brachytherapy|
515414|NCT00278304|Radiation|radiation therapy|
515415|NCT00278278|Drug|cisplatin|Given IV
515416|NCT00278278|Drug|etoposide|Given IV
515417|NCT00278278|Drug|ifosfamide|Given IV
515418|NCT00278278|Drug|lomustine|Given IV
515419|NCT00278278|Drug|methotrexate|Given IV
515420|NCT00278278|Drug|prednisone|Given IV
515421|NCT00278278|Drug|vincristine sulfate|Given IV
515422|NCT00278265|Drug|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
515423|NCT00278252|Drug|etoposide|
515424|NCT00278252|Procedure|conventional surgery|
515425|NCT00278239|Procedure|cognitive assessment|
515426|NCT00278239|Procedure|psychosocial assessment and care|
515427|NCT00278239|Procedure|quality-of-life assessment|
515428|NCT00278226|Behavioral|smoking cessation intervention|
515429|NCT00278226|Other|educational intervention|
515430|NCT00278213|Biological|alemtuzumab|
515431|NCT00278213|Drug|cyclophosphamide|
515432|NCT00278213|Drug|fludarabine phosphate|
515433|NCT00278213|Drug|mitoxantrone hydrochloride|
515434|NCT00278200|Biological|Inactivated EBV-infected vaccine|
515435|NCT00278187|Biological|volociximab|
515436|NCT00278187|Drug|erlotinib hydrochloride|
515437|NCT00278174|Biological|recombinant interferon alpha-1b|
515438|NCT00278161|Biological|Pegfilgrastim|6 mg SQ 24-48 hours after last dose of cyclophosphamide.
515439|NCT00278161|Biological|Rituximab|375 mg/m^2/day on Days 1, 4, 8, 11, 45, and 52.
515440|NCT00278161|Drug|Cyclophosphamide|50 mg/kg/day on Days 15, 16, 17, and 18.
515441|NCT00278148|Drug|carboplatin|AUC2 weekly x 3 weeks
515442|NCT00278148|Drug|Tarceva|Daily
515443|NCT00278148|Drug|paclitaxel|50mg/m2/weekly x 3 weeks
515444|NCT00278148|Procedure|conventional surgery|conventional surgery
515445|NCT00278148|Radiation|radiation therapy|150 cGy bid
515446|NCT00278135|Dietary Supplement|DHA (nutritional supplement) or placebo|oral 900mg/day
515447|NCT00278122|Biological|sargramostim|
515448|NCT00278122|Drug|paclitaxel|
515449|NCT00278109|Drug|cyclophosphamide|chemotherapy
515450|NCT00278109|Drug|Doxorubicin|doxorubicin
515451|NCT00278109|Radiation|radiation|radiation
515452|NCT00278096|Behavioral|occupational therapy|
515453|NCT00278083|Drug|Study drug administration|
515454|NCT00278083|Procedure|Tuberculin intradermal skin test|
515455|NCT00278083|Procedure|Lung function test for FEV1|
515456|NCT00278083|Procedure|Asthma symptom scores diary|
515457|NCT00278083|Procedure|Quality of life diary|
515458|NCT00278083|Procedure|Breath nitric oxide|
515459|NCT00278083|Procedure|Breath condensate|
515460|NCT00278083|Procedure|Sputum induction|
515461|NCT00278083|Procedure|Blood sampling|
515462|NCT00278083|Procedure|Urinalysis|
515463|NCT00278070|Drug|vinorelbine oral formulation|Patients will take three times a week [Monday, Wednesday and Friday] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
515464|NCT00278057|Drug|dialysisis with and without glucose in the dialysis|
515465|NCT00278044|Procedure|blood sampling and medical records|
515466|NCT00278018|Procedure|Immunotherapy treatment for solid tumors|
515467|NCT00277914|Drug|Flibanserin|flibanserin flexible dosing
515468|NCT00277888|Procedure|Femoral route for hemodialysis|
515469|NCT00277888|Procedure|Jugular route for hemodialysis|
515477|NCT00277810|Drug|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extesnion to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
515478|NCT00277797|Device|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
515479|NCT00277797|Device|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
515480|NCT00277784|Procedure|Ultrasound examination|one ultrasound examination
515481|NCT00277771|Behavioral|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
515482|NCT00277771|Behavioral|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
515483|NCT00277771|Behavioral|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
515484|NCT00277758|Biological|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
515485|NCT00277758|Drug|Ribavirin|Ribavirin @ 800 mg daily (< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
515486|NCT00277758|Biological|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
515487|NCT00277758|Biological|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
515488|NCT00277758|Drug|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight <65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight >85 kg.
515489|NCT00277745|Device|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
515490|NCT00277732|Procedure|Pharmaceutical care at baseline and follow-up visits over 6 months|
515491|NCT00277706|Procedure|Periodontal surgery|
515492|NCT00277706|Drug|FORTEO|parathyroid hormone; self-administration for 6 weeks
515493|NCT00277706|Drug|Placebo|placebo; self administration for 6 weeks
515494|NCT00277706|Dietary Supplement|Vitamin D and Calcium|PO, QD, for six weeks
515495|NCT00277693|Drug|Spironolactone (drug)|
515496|NCT00277680|Procedure|Laparoscopic bilateral occlusion of uterine artery|
515497|NCT00277680|Procedure|Radiological embolization (UFE)|
515498|NCT00277667|Drug|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
515499|NCT00277654|Drug|Risperidone|risperidone 0.5mg up to 4mg daily vs. placebo
515500|NCT00277641|Drug|Lamotrigine|25 mg or 100 mg
515501|NCT00277641|Drug|placebo|identical tablets to study drug
515502|NCT00277602|Drug|Riluzole|
515503|NCT00277589|Drug|Levothyroxin-Na|1 tablet 30 minutes before breakfast
515504|NCT00277589|Drug|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
515505|NCT00277589|Drug|Iodide|1 tablet 30 minutes before breakfast
515506|NCT00277589|Drug|Placebo|1 tablet 30 minutes before breakfast
515507|NCT00277576|Biological|ppdpSC18 administered by PMED|
515508|NCT00277563|Device|reduction of pain scores by magnetic energy|
515509|NCT00277550|Drug|Tegaserod and Placebo|
515510|NCT00277537|Drug|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
515511|NCT00277537|Drug|placebo|BD for 12 weeks
515512|NCT00277511|Drug|Levofloxacin|
515513|NCT00277498|Drug|Xalacom|
515514|NCT00277498|Drug|Xalatan|
515515|NCT00277498|Drug|Timolol|
515516|NCT00277472|Drug|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
515517|NCT00277472|Drug|HCTZ|25 mg taken once daily orally
515518|NCT00277446|Drug|Soy isoflavones|
515519|NCT00277433|Other|Buccal Swab|collection of buccal swab
515520|NCT00277420|Behavioral|Comprehensive weight management|
515521|NCT00277407|Procedure|NAET with acupressure and/or chiropractic procedures|
515522|NCT00277394|Drug|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
515523|NCT00277394|Drug|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
515524|NCT00277381|Behavioral|Automated feedback regarding drug adherence|
515525|NCT00277368|Other|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
515526|NCT00277355|Drug|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (~ 8 hours apart)
515527|NCT00277355|Drug|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
515528|NCT00277342|Procedure|measurement of lipid-induced hepatic insulin resistance|
515529|NCT00277329|Drug|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
515530|NCT00277316|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
515575|NCT00276848|Drug|Fludarabine|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
515698|NCT00276159|Drug|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
515531|NCT00277303|Drug|XL999|XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.
515532|NCT00277290|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
515533|NCT00277277|Behavioral|Healthium|
515534|NCT00277264|Drug|Tiotropium (Spiriva®)|
515535|NCT00277251|Drug|Alendronate|
515536|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
515537|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
515538|NCT00277238|Drug|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
515539|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
515540|NCT00277225|Drug|Abatacept|
515541|NCT00277212|Drug|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~Aripiprazole 10-30 mg/day"
515542|NCT00277212|Drug|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks~Lamotrigine 100-200 mg/day~placebo 0 mg/day"
515543|NCT00277199|Drug|Abatacept|
515544|NCT00277186|Other|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
515545|NCT00277173|Behavioral|Adoption of Crew Resource Management approach|
515546|NCT00277160|Drug|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
515547|NCT00277147|Drug|BB IND 6989|
515548|NCT00277108|Drug|Escitalopram (Lexapro)|
515549|NCT00277095|Device|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
515550|NCT00277082|Drug|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
515551|NCT00277069|Drug|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
515552|NCT00277069|Device|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
515553|NCT00277069|Drug|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
515554|NCT00277043|Drug|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
515555|NCT00277043|Drug|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
515556|NCT00277030|Drug|Surfactant|
515557|NCT00277030|Device|Nasal CPAP|
515558|NCT00277017|Drug|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.~Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.~Treatment will be followed by 2 weeks of rest then repeated."
515559|NCT00276991|Drug|"Kallunk oxide (Immunotherapy) "|"The study was assigned only one Arm >450 cu/mm^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg Kallunk oxide molecules with 199.900 mg, and 499.800 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is Piper Longum."
515560|NCT00276978|Drug|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
515561|NCT00276965|Drug|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
515562|NCT00276965|Drug|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
515563|NCT00276952|Drug|Gonyautoxin|
515564|NCT00276939|Behavioral|Low-fat, low-Glycemic Index, vegan diet|
515565|NCT00276926|Drug|STI571|
515566|NCT00276913|Drug|STA-5312|
515567|NCT00276900|Drug|Sertraline|
515568|NCT00276887|Behavioral|Cognitive Behavior Therapy|
515569|NCT00276887|Behavioral|Psychiatric Consultation Letter|
515570|NCT00276874|Drug|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
515571|NCT00276874|Drug|Placebos|Placebo; 0 mg; oral; daily
515572|NCT00276861|Drug|gemcitabine hydrochloride|
515573|NCT00276861|Drug|oxaliplatin|
515574|NCT00276848|Drug|Fludarabine plus Cyclophosphamide|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
515638|NCT00276640|Radiation|radiation therapy|"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks~spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"
515576|NCT00276835|Biological|High-dose interleukin-2|Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
515577|NCT00276835|Dietary Supplement|genistein|Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
515578|NCT00276822|Other|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
515579|NCT00276809|Biological|alemtuzumab|
515580|NCT00276809|Biological|filgrastim|
515581|NCT00276809|Drug|carmustine|
515582|NCT00276809|Drug|cyclophosphamide|
515583|NCT00276809|Drug|cytarabine|
515584|NCT00276809|Drug|dexamethasone|
515585|NCT00276809|Drug|etoposide|
515586|NCT00276809|Drug|fludarabine phosphate|
515587|NCT00276809|Drug|melphalan|
515588|NCT00276809|Procedure|autologous bone marrow transplantation|
515589|NCT00276809|Procedure|peripheral blood stem cell transplantation|
515590|NCT00276809|Radiation|radiation therapy|
515591|NCT00276796|Drug|cisplatin|
515592|NCT00276796|Drug|paclitaxel|
515593|NCT00276796|Drug|topotecan hydrochloride|
515594|NCT00276783|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
515595|NCT00276770|Other|fluorine F 18 fluorothymidine|
515596|NCT00276770|Procedure|positron emission tomography|
515597|NCT00276757|Drug|leucovorin calcium|
515598|NCT00276757|Drug|methotrexate|
515599|NCT00276757|Drug|prednisolone|
515600|NCT00276757|Drug|vinblastine sulfate|
515601|NCT00276744|Biological|cetuximab|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515602|NCT00276744|Drug|capecitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515603|NCT00276744|Drug|docetaxel|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515604|NCT00276744|Drug|Erlotinib|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515605|NCT00276744|Drug|Gemcitabine|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515606|NCT00276744|Drug|Irinotecan|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515607|NCT00276744|Drug|mitomycin C|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515608|NCT00276744|Drug|rapamycin|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515609|NCT00276744|Procedure|conventional surgery|Tumors will be implanted in nude mice and treated with a set of 8 commercially available anticancer drugs. Drugs will be ranked based in their activity from most to least active. Biological studies will be conducted in tumor tissues to better understand the response to tested drugs.
515610|NCT00276731|Drug|carboplatin|
515611|NCT00276731|Drug|cisplatin|
515612|NCT00276731|Drug|cyclophosphamide|
515613|NCT00276731|Drug|etoposide|
515614|NCT00276731|Drug|vincristine sulfate|
515615|NCT00276731|Procedure|conventional surgery|
515616|NCT00276731|Procedure|neoadjuvant therapy|
515617|NCT00276731|Radiation|radiation therapy|
515618|NCT00276718|Biological|bleomycin sulfate|
515619|NCT00276718|Drug|carboplatin|
515620|NCT00276718|Drug|etoposide|
515621|NCT00276718|Procedure|conventional surgery|
515622|NCT00276705|Drug|cisplatin|
515623|NCT00276705|Drug|cyclophosphamide|
515624|NCT00276705|Drug|doxorubicin hydrochloride|
515625|NCT00276705|Drug|thalidomide|
515626|NCT00276705|Procedure|adjuvant therapy|
515627|NCT00276705|Procedure|conventional surgery|
515628|NCT00276705|Procedure|neoadjuvant therapy|
515629|NCT00276692|Drug|irinotecan hydrochloride|
515630|NCT00276679|Drug|temozolomide|
515631|NCT00276666|Drug|cisplatin|
515632|NCT00276666|Drug|lomustine|
515633|NCT00276666|Drug|vincristine sulfate|
515634|NCT00276666|Procedure|adjuvant therapy|
515635|NCT00276666|Radiation|radiation therapy|
515636|NCT00276640|Drug|vincristine, carboplatin|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"
515637|NCT00276640|Drug|vincristine, carboplatin, etoposide|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21~carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21~etoposide: 100 mg/m² i.v., week 1,4,7,10"
515639|NCT00276627|Behavioral|communication lecture|lecture on communication skills with oncology patients
515699|NCT00276146|Drug|oral dipyridamole, oral magnesium, or a combination of both|
515640|NCT00276627|Behavioral|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
515641|NCT00276614|Drug|bortezomib|
515642|NCT00276601|Drug|arsenic trioxide|
515643|NCT00276601|Drug|cytarabine|
515644|NCT00276601|Drug|daunorubicin hydrochloride|
515645|NCT00276601|Drug|mercaptopurine|
515646|NCT00276601|Drug|methotrexate|
515647|NCT00276601|Drug|tretinoin|
515648|NCT00276588|Drug|carboplatin|
515649|NCT00276588|Drug|gemcitabine hydrochloride|
515650|NCT00276588|Drug|paclitaxel|
515651|NCT00276575|Biological|bevacizumab|
515652|NCT00276575|Drug|erlotinib hydrochloride|
515653|NCT00276575|Drug|everolimus|
515654|NCT00276549|Drug|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
515655|NCT00276549|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
515656|NCT00276536|Biological|recombinant interferon alpha-1b|interferon
515657|NCT00276536|Drug|IFN|IFN daily
515658|NCT00276523|Biological|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
515659|NCT00276523|Procedure|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
515660|NCT00276523|Procedure|Neoadjuvant therapy|
515661|NCT00276510|Drug|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
515662|NCT00276510|Other|Placebo|1 tablet twice a day, oral route, during 5 years.
515663|NCT00276497|Drug|Pioglitazone|
515664|NCT00276484|Drug|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
515665|NCT00276484|Drug|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
515666|NCT00276484|Drug|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
515667|NCT00276471|Device|Implantable pulse generator and electrodes|
515668|NCT00276458|Drug|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
515669|NCT00276458|Drug|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
515670|NCT00276458|Drug|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
515671|NCT00276458|Drug|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
515672|NCT00276445|Drug|beta-1,3-glucan|
515673|NCT00276432|Device|iSTAT point of care analyzer|
515674|NCT00276419|Drug|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
515675|NCT00276419|Drug|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
515676|NCT00276406|Drug|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
515677|NCT00276406|Drug|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
515678|NCT00276393|Drug|Basal insulin|
515679|NCT00276380|Drug|EGb761|EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
515680|NCT00276380|Drug|Placebo|Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
515681|NCT00276380|Drug|Acetylsalicylic acid|Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
515682|NCT00276354|Drug|PEG 4000 (Forlax ®)|
515683|NCT00276341|Drug|EGb 761® (Tanakan®)|
515684|NCT00276328|Drug|Diosmectite (Smecta®)|
515685|NCT00276315|Biological|Botulinum toxin type A|
515686|NCT00276302|Drug|IPI-504|"IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.~For both Schedule A and B doses will be administered ≥ 72 hours apart."
515687|NCT00276289|Drug|Spironolactone|
515688|NCT00276276|Drug|topotecan|
515689|NCT00276263|Drug|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
515690|NCT00276250|Drug|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
515691|NCT00276250|Drug|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
515692|NCT00276250|Drug|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
515693|NCT00276224|Drug|ferrous sulphate (drug)|
515694|NCT00276198|Dietary Supplement|Sprinkles|Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
515695|NCT00276198|Dietary Supplement|Ferripel-3, Vitamins A&D drops|Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
515696|NCT00276185|Drug|Time delay treatment of botulinum toxin|
515697|NCT00276172|Drug|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
515700|NCT00276133|Drug|Effects of atorvastatin versus probucol on small dense LDL|
515701|NCT00276107|Biological|Prevenar|
515702|NCT00276094|Drug|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
515703|NCT00276094|Drug|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
515704|NCT00276094|Drug|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
515705|NCT00276094|Drug|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
515706|NCT00276081|Drug|Gabapentin, Estrogen and placebo administration|
515707|NCT00276068|Drug|topical lidocaine + oral desipramine, and/or placebo|
515708|NCT00276055|Drug|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
515709|NCT00276042|Drug|Faropenem Medoxomil|
515710|NCT00276029|Drug|Etanercept|
515711|NCT00276016|Drug|phenylephrine|immediate-release 12 mg capsules for oral administration
515712|NCT00276016|Drug|pseudoephedrine|60 mg immediate-release tablets for oral administration
515713|NCT00276016|Drug|placebo|placebo capsules
515714|NCT00276003|Drug|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
515715|NCT00275990|Device|rheolytic thrombectomy with direct stenting|
515716|NCT00275990|Device|direct stenting|
515717|NCT00275977|Procedure|Coronary catherization and stem cell infusion|
515718|NCT00275964|Drug|TMN-1|
515719|NCT00275951|Drug|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
515720|NCT00275938|Drug|interferon alpha 2b plus ribavirin|
515721|NCT00275938|Drug|interferon alpha 2b plus placebo|
515722|NCT00275925|Drug|Oxcarbazepine|
515723|NCT00275912|Drug|Oxcarbazepine|
515724|NCT00275834|Drug|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
515725|NCT00275821|Drug|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
515726|NCT00275821|Drug|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
515727|NCT00275821|Drug|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
515728|NCT00275795|Procedure|NAET Procedures|
515729|NCT00275769|Device|Pacemaker|
515730|NCT00275756|Drug|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp & Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
515731|NCT00275756|Drug|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp & Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
515732|NCT00275756|Drug|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
515733|NCT00275756|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
515734|NCT00275756|Device|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
515735|NCT00275756|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
515736|NCT00275743|Procedure|MRI|
515737|NCT00275730|Drug|indometacine (drug) effect on ocular blood flow|
515738|NCT00275704|Drug|Flaxseed|
515739|NCT00275678|Procedure|Blood stem cell versus bone marrow transplant|"Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.~Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.~Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.~Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
515740|NCT00275665|Drug|Valganciclovir|
515741|NCT00275652|Drug|LdT (Telbivudine) and lamivudine|
515742|NCT00275639|Drug|Cozaar|
515743|NCT00275613|Drug|Rituximab|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
515744|NCT00275600|Drug|Vitamin E, Evening Oil of Primrose, and Placebo|
515745|NCT00275574|Procedure|acupuncture|acupuncture
515746|NCT00275561|Drug|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
515747|NCT00275561|Drug|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
515748|NCT00275548|Drug|Pegasys|135-180 micrograms administered sc once weekly
515749|NCT00275548|Drug|Copegus|400-1200 mg/day for 48 weeks
515750|NCT00275535|Drug|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
515751|NCT00275535|Drug|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
515752|NCT00275535|Drug|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
515753|NCT00275535|Drug|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
515754|NCT00275535|Drug|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
515755|NCT00275522|Drug|Sirolimus|
515756|NCT00275509|Drug|Thymoglobulin|
515757|NCT00275509|Drug|Daclizumab|
515758|NCT00275509|Other|Plasmapheresis|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
515759|NCT00275509|Drug|Mycophenolate mofetil|2 gm/day. Standard of care
515760|NCT00275509|Drug|Tacrolimus|To achieve serum level of 8-10 ng/ml.
515761|NCT00275509|Drug|Dexamethasone|100 mg intra-operatively, and 25 mg every 6h post-operatively for six doses
515762|NCT00275509|Drug|Prednisone|Taper over three months to 5 mg daily
515763|NCT00275509|Drug|Cytogam|Following each plasmapheresis session, 100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered
515764|NCT00275496|Procedure|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
515765|NCT00275496|Procedure|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
515766|NCT00275496|Procedure|Wide Excision|Subject has wide excision only for primary melanoma.
515767|NCT00275483|Device|Vital-band (R)|
515768|NCT00275457|Drug|pramipexole|
515769|NCT00275444|Drug|Tipranavir|
515770|NCT00275431|Drug|AT-101|Oral
515771|NCT00275418|Drug|beta carotene from Dunaliella algae|
515772|NCT00275405|Drug|Garlic Oil Macerate|
515773|NCT00275392|Behavioral|Vestibular rehabilitation|vestibular adaptation and substitution exercises
515774|NCT00275392|Behavioral|Placebo|placebo vestibular exercises
515775|NCT00275379|Drug|ERB-041|
515776|NCT00275366|Device|Robotic Therapy|
515777|NCT00275353|Behavioral|Individualized Symptom Education|
515778|NCT00275340|Other|Peer Support|
515779|NCT00275314|Drug|Valganciclovir|
515780|NCT00275301|Drug|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
515781|NCT00275275|Drug|Requip PR|Requip 24-Hour once a day for one month
515782|NCT00275275|Drug|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
515783|NCT00275262|Drug|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
515784|NCT00275262|Drug|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
515785|NCT00275249|Drug|levorphanol|
515786|NCT00275236|Drug|Rotigotine|
515787|NCT00275210|Drug|Oxaliplatin (SR96669)|
515788|NCT00275197|Drug|Sertraline and Elzasonan Combination|
515789|NCT00275197|Drug|Sertraline|
515790|NCT00275197|Drug|Placebo|
515791|NCT00275184|Drug|Senna|
515792|NCT00275184|Drug|Citramag powder|
515793|NCT00275184|Drug|Metoclopramide|
515794|NCT00275171|Drug|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
515795|NCT00275171|Drug|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
515796|NCT00275171|Other|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
515797|NCT00275158|Drug|L-Arginine Supplementation|
515798|NCT00275145|Behavioral|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
515799|NCT00275145|Behavioral|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
515800|NCT00275145|Behavioral|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
515801|NCT00275145|Behavioral|Continued Sedentary lifestyle|No changes
515802|NCT00275132|Drug|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
515803|NCT00275132|Drug|Matched placebo|Matched placebo PO daily
515804|NCT00275119|Drug|fluorouracil|
515805|NCT00275119|Drug|gemcitabine hydrochloride|
515806|NCT00275119|Drug|oxaliplatin|
515807|NCT00275119|Radiation|radiation therapy|
515808|NCT00275106|Drug|asparaginase|
515809|NCT00275106|Drug|cyclophosphamide|
515810|NCT00275106|Drug|cytarabine|
515811|NCT00275106|Drug|daunorubicin hydrochloride|
515812|NCT00275106|Drug|dexamethasone|
515813|NCT00275106|Drug|doxorubicin hydrochloride|
515814|NCT00275106|Drug|leucovorin calcium|
515815|NCT00275106|Drug|mercaptopurine|
515816|NCT00275106|Drug|methotrexate|
515817|NCT00275106|Drug|prednisolone|
515818|NCT00275106|Drug|thioguanine|
515819|NCT00275106|Drug|vincristine sulfate|
515820|NCT00275106|Procedure|radiation therapy|
515821|NCT00275093|Drug|temsirolimus|Given IV
515822|NCT00275093|Other|laboratory biomarker analysis|Correlative studies
537368|NCT00002524|Drug|Zidovudine (AZT)|
515823|NCT00275093|Other|pharmacological study|Correlative studies
515824|NCT00275080|Drug|vorinostat|Given orally
515825|NCT00275080|Drug|decitabine|Given IV
515826|NCT00275067|Drug|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
515827|NCT00275067|Drug|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
515828|NCT00275067|Radiation|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
515829|NCT00275054|Drug|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
515830|NCT00275054|Drug|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
515831|NCT00275054|Biological|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d~cycles 2-6: 500 mg/m² i.v., d1, q28d"
515832|NCT00275041|Biological|cetuximab|
515833|NCT00275041|Drug|irinotecan hydrochloride|
515834|NCT00275028|Drug|cediranib maleate|Given orally
515835|NCT00275015|Biological|filgrastim|
515836|NCT00275015|Drug|carmustine|
515837|NCT00275015|Drug|cyclophosphamide|
515838|NCT00275015|Drug|cytarabine|
515839|NCT00275015|Drug|dexamethasone|
515840|NCT00275015|Drug|etoposide|
515841|NCT00275015|Drug|fludarabine phosphate|
515842|NCT00275015|Drug|melphalan|
515843|NCT00275015|Procedure|bone marrow ablation with stem cell support|
515844|NCT00275015|Procedure|peripheral blood stem cell transplantation|
515845|NCT00275015|Radiation|radiation therapy|
515846|NCT00275002|Drug|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
515847|NCT00275002|Drug|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
515848|NCT00274989|Drug|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
515849|NCT00274989|Biological|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6~2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
515850|NCT00274976|Biological|alemtuzumab|
515851|NCT00274963|Drug|bendamustine hydrochloride|
515852|NCT00274963|Drug|mitoxantrone hydrochloride|
515853|NCT00274950|Biological|bleomycin sulfate|
515854|NCT00274950|Drug|carboplatin|
515855|NCT00274950|Drug|cisplatin|
515856|NCT00274950|Drug|etoposide|
515857|NCT00274950|Drug|ifosfamide|
515858|NCT00274950|Drug|vinblastine sulfate|
515859|NCT00274950|Procedure|adjuvant therapy|
515860|NCT00274950|Procedure|conventional surgery|
515861|NCT00274937|Drug|amifostine trihydrate|Given subcutaneously
515862|NCT00274937|Drug|fluorouracil|Given IV
515863|NCT00274937|Drug|cisplatin|Given IV
515864|NCT00274937|Other|laboratory biomarker analysis|Correlative studies
515865|NCT00274937|Radiation|radiation therapy|Undergo radiotherapy
515866|NCT00274924|Biological|filgrastim|Given subcutaneously or intravenous bolus.
515867|NCT00274924|Biological|rituximab|Given IV
515868|NCT00274924|Drug|carboplatin|Given IV
515869|NCT00274924|Drug|cyclophosphamide|Given IV
515870|NCT00274924|Drug|doxorubicin hydrochloride|Given IV
515871|NCT00274924|Drug|etoposide|Given IV
515872|NCT00274924|Drug|ifosfamide|Given IV
515873|NCT00274924|Drug|prednisone|Taken orally
515874|NCT00274924|Drug|vincristine|Given IV
515875|NCT00274911|Drug|cisplatin|
515876|NCT00274911|Drug|lomustine|
515877|NCT00274911|Drug|vincristine sulfate|
515878|NCT00274911|Procedure|adjuvant therapy|
515879|NCT00274911|Radiation|radiation therapy|
515880|NCT00274898|Drug|celecoxib|
515881|NCT00274898|Drug|docetaxel|
515882|NCT00274898|Procedure|adjuvant therapy|
515883|NCT00274898|Radiation|radiation therapy|
515884|NCT00274885|Drug|oxaliplatin|
515885|NCT00274885|Procedure|management of therapy complications|
515886|NCT00274872|Drug|fluorouracil|
515887|NCT00274872|Drug|leucovorin calcium|
515888|NCT00274872|Drug|oxaliplatin|
515889|NCT00274859|Drug|gemcitabine hydrochloride|
515890|NCT00274859|Drug|oxaliplatin|
515891|NCT00274846|Biological|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
515892|NCT00274846|Biological|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10^9
515893|NCT00274846|Drug|cyclophosphamide|Days -5 and -4: 60 mg/kg
515894|NCT00274846|Drug|fludarabine phosphate|Days -5 through -2: 25 mg/m^2
515895|NCT00274846|Procedure|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
515896|NCT00274833|Drug|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
537822|NCT00003172|Drug|docetaxel|
515897|NCT00274833|Drug|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
515898|NCT00274833|Radiation|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
515899|NCT00274820|Dietary Supplement|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
515900|NCT00274820|Drug|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
515901|NCT00274820|Drug|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
515902|NCT00274820|Drug|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience < grade 1 thalidomide-attributed toxicity using CTC criteria.
515903|NCT00274807|Biological|filgrastim|
515904|NCT00274807|Drug|cytarabine|
515905|NCT00274807|Drug|etoposide|
515906|NCT00274807|Drug|mitoxantrone hydrochloride|
515907|NCT00274794|Biological|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
515908|NCT00274794|Biological|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
515909|NCT00274781|Drug|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
515910|NCT00274781|Drug|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
515911|NCT00274768|Drug|capecitabine|
515912|NCT00274755|Drug|chemotherapy|
515913|NCT00274755|Procedure|conventional surgery|
515914|NCT00274755|Procedure|magnetic resonance imaging|
515915|NCT00274755|Procedure|magnetic resonance spectroscopic imaging|
515916|NCT00274755|Radiation|radiation therapy|
515917|NCT00274742|Biological|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m^2/24hours by continuous intravenous infusion
515918|NCT00274729|Behavioral|Mono Unsaturated Fatty Acids in Obesity|
515919|NCT00274716|Drug|MK0736|
515920|NCT00274716|Drug|MK0916|
515921|NCT00274716|Drug|Placebo|
515922|NCT00274703|Drug|mepolizumab|
515923|NCT00274690|Drug|GW679769|
515924|NCT00274677|Drug|Placebo|Experimental treatment arm
515925|NCT00274677|Drug|lamotrigine|Experimental treatment
515926|NCT00274664|Device|6 hours occlusion by patching|
515927|NCT00274664|Device|12 hours occlusion by patching|
515928|NCT00274651|Drug|belinostat|
515929|NCT00274638|Drug|Telmisartan & Hydrochlorothiazide|
515930|NCT00274638|Drug|Losartan & Hydrochlorothiazide|
515931|NCT00274638|Procedure|ABPM|
515932|NCT00274625|Device|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
515933|NCT00274625|Procedure|Control|Incision is closed without the placement of a graft material (standard of care control)
515934|NCT00274612|Drug|Telmisartan|
515935|NCT00274612|Drug|Ramipril|
515936|NCT00274599|Drug|Telmisartan|
515937|NCT00274599|Drug|Ramipril|
515938|NCT00274586|Drug|Aggrenox® modified release capsules|
515939|NCT00274586|Drug|Aggrenox® modified release capsules matching placebo|
515940|NCT00274573|Drug|Tiotropium bromide|
515941|NCT00274560|Drug|Tiotropium|
515942|NCT00274560|Drug|Salmeterol|
515943|NCT00274547|Drug|Tiotropium|
515944|NCT00274534|Drug|Tiotropium|
515945|NCT00274534|Drug|Salmeterol|
515946|NCT00274521|Drug|Tiotropium|
515947|NCT00274508|Drug|tiotropium bromide|
515948|NCT00274495|Drug|Rosiglitazone and Pegasys/Ribavirin|
515949|NCT00274469|Drug|fulvestrant|500 mg intramuscular injection
515950|NCT00274469|Drug|anastrozole|1 mg oral tablet
515951|NCT00274456|Drug|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
515952|NCT00274456|Drug|Docetaxel|Docetaxel dosed q3w at 100 mg/m^2
515953|NCT00274443|Drug|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
515954|NCT00274430|Drug|dexamethasone 8 mg bid|
515955|NCT00274430|Drug|tadalafil 10mg bid|
515956|NCT00274417|Drug|dutasteride|
515957|NCT00274404|Drug|valacyclovir|
515958|NCT00274391|Drug|7% NaCl|
515959|NCT00274391|Drug|Amiloride HCl|
515960|NCT00274378|Device|ALLOMATRIX injectable putty in distal radius fractures|
515961|NCT00274365|Procedure|videoconference|
515962|NCT00274352|Drug|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
515963|NCT00274339|Drug|Prevacid 30mg BID|
515964|NCT00274339|Behavioral|Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.|
515965|NCT00274326|Drug|SR121463B|
515966|NCT00274313|Drug|552-02|
515967|NCT00274300|Biological|pPJV7630 administered by PMED|
515968|NCT00274287|Drug|GM CSF|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
515969|NCT00274274|Drug|insulin detemir|
515970|NCT00274274|Drug|insulin aspart|
515971|NCT00274261|Drug|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
515972|NCT00274261|Drug|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
515973|NCT00274248|Drug|MLN518|
515974|NCT00274235|Drug|sulfadoxine-pyrimethamine / mefloquine|
515975|NCT00274209|Procedure|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
515976|NCT00274196|Procedure|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
515977|NCT00274196|Procedure|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
515978|NCT00274170|Drug|Octreotide|
515979|NCT00274157|Behavioral|Behavior|
515980|NCT00274157|Behavioral|diet control, smoking cessation, exercize|
515981|NCT00274144|Drug|telmisartan 40 mg|
515982|NCT00274144|Drug|placebo 40 mg|
515983|NCT00274131|Drug|Pramipexole 0.125 mg tablets|
515984|NCT00274131|Drug|Pramipexole 0.5 mg tablets|
515985|NCT00274118|Drug|telmisartan|
515986|NCT00274118|Drug|enalapril|
515987|NCT00274105|Drug|telmisartan|
515988|NCT00274105|Drug|Placebo|
515989|NCT00274092|Drug|tiotropium inhalation capsules (18 mcg once daily)|
515990|NCT00274092|Drug|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
515991|NCT00274079|Drug|SPIRIVA|
515992|NCT00274066|Drug|Tiotropium + placebo|
515993|NCT00274066|Drug|Tiotropium + ipratropium|
515994|NCT00274066|Drug|Tiotropium + fenoterol|
515995|NCT00274053|Drug|tiotropium|
515996|NCT00274040|Drug|Tiotropium|
515997|NCT00274040|Drug|Ipratropium|
515998|NCT00274027|Drug|tiotropium bromide|
515999|NCT00274014|Drug|Tiotropium|
516000|NCT00274001|Drug|Nevirapine|
516001|NCT00273988|Drug|nevirapine|
516002|NCT00273975|Drug|Nevirapine|
516003|NCT00273975|Drug|Lamivudine|
516004|NCT00273975|Drug|Zidovudine|
516005|NCT00273962|Drug|ipratropium plus salbutamol UDV|
516006|NCT00273962|Drug|salbutamol UDV|
516007|NCT00273949|Drug|lactulose|
516008|NCT00273936|Drug|AVN-944 capsules for oral administration|
516009|NCT00273910|Drug|gp100:209-217 (210M)|
516010|NCT00273910|Drug|Montanide ISA-51|
516011|NCT00273910|Drug|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
516012|NCT00273897|Device|Phoresor II|
516013|NCT00273884|Drug|Amonafide L-Malate|
516014|NCT00273884|Drug|Cytarabine|
516015|NCT00273871|Drug|Cyclosporin or tacrolimus|
516016|NCT00273858|Other|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
516017|NCT00273845|Behavioral|Motivational interviewing|One session
516018|NCT00273845|Behavioral|Strengths-Based Case Management|5 sessions
516019|NCT00273832|Procedure|coronary artery computed tomography angiogram|
516020|NCT00273832|Procedure|single photon emission computed tomography|
516021|NCT00273819|Procedure|CT angiography|
516022|NCT00273806|Behavioral|Intervention for 4 behavioral risks by medical assistants.|
516023|NCT00273793|Behavioral|Contingency Management|incentives are available for reduced smoking on each study visit which occur each weekday.
516024|NCT00273780|Behavioral|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
516025|NCT00273780|Device|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
516026|NCT00273767|Drug|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
516027|NCT00273767|Drug|placebo|60ml of NaCl IV slow
516028|NCT00273754|Drug|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
516029|NCT00273754|Drug|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
516030|NCT00273741|Drug|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
516031|NCT00273741|Drug|placebo comparator|placebo capsules
516032|NCT00273728|Drug|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
516033|NCT00273715|Procedure|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
516034|NCT00273715|Procedure|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
516035|NCT00273702|Drug|N-Acetyl Cysteine|
516036|NCT00273689|Drug|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
516037|NCT00273689|Drug|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
516038|NCT00273676|Procedure|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
516039|NCT00273663|Device|TCES|
516112|NCT00273013|Drug|Placebo|Matching placebo for Singulair and GW274150 will be available.
516113|NCT00273000|Drug|GLP-2|
516114|NCT00272987|Drug|lapatinib|(GW572016) 1000 mg QD
516115|NCT00272987|Drug|paclitaxel|80 mg/m2 IV weekly for three weeks
516040|NCT00273650|Drug|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
516041|NCT00273650|Other|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
516042|NCT00273624|Drug|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
516043|NCT00273624|Drug|Placebo|placebo
516044|NCT00273611|Behavioral|Pharmacist Education about Vitamin D|
516045|NCT00273598|Procedure|Moss Miami Spine Instrumentation System|
516046|NCT00273598|Procedure|Universal Spine Instrumentation System|
516047|NCT00273585|Device|Personally-tailored educational software program|
516048|NCT00273572|Other|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
516049|NCT00273572|Other|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
516050|NCT00273559|Drug|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
516051|NCT00273546|Drug|XRP6976 (Docetaxel/Taxotere)|
516052|NCT00273533|Drug|Ramipril|
516053|NCT00273520|Drug|Telithromycin|
516054|NCT00273507|Drug|Carboplatin and Paclitaxel|
516055|NCT00273494|Procedure|Surgery|
516056|NCT00273481|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
516057|NCT00273481|Drug|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
516058|NCT00273481|Drug|timolol maleate 0.5%|
516059|NCT00273481|Drug|placebo|
516060|NCT00273468|Drug|Granisetron|
516061|NCT00273455|Drug|bimatoprost 0.03%|
516062|NCT00273455|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
516063|NCT00273455|Drug|placebo|
516064|NCT00273442|Drug|timolol maleate|
516065|NCT00273442|Drug|dorzolamide/timolol maleate fixed combination|
516066|NCT00273429|Drug|timolol maleate 0.5%|
516067|NCT00273429|Drug|dorzolamide/timolol maleate fixed combination|
516068|NCT00273429|Drug|latanoprost 0.005%|
516069|NCT00273429|Drug|placebo|
516070|NCT00273416|Drug|PF-00592379|
516071|NCT00273416|Drug|Sildenafil 100mg|
516072|NCT00273403|Behavioral|Maintenance in Care Services|
516073|NCT00273403|Behavioral|Access to Care Services|
516074|NCT00273390|Drug|Remicade (infliximab)|
516075|NCT00273377|Other|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
516076|NCT00273377|Other|Supplemental oxygen (80% vs. 30%)|
516077|NCT00273377|Drug|Dexamethasone|4 mg
516078|NCT00273377|Drug|Placebo|placebo
516079|NCT00273364|Procedure|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
516080|NCT00273364|Drug|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
516081|NCT00273351|Drug|[123I]B-CIT|Subjects will receive up to 6 mCi of [123I] B-CIT injected intravenously
516082|NCT00273338|Drug|calcitriol|
516083|NCT00273338|Drug|docetaxel|
516084|NCT00273312|Drug|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
516085|NCT00273299|Drug|valsartan plus hydrochlorothiazide|
516086|NCT00273286|Behavioral|family diabetes management intervention|a clinic-integrated, low intensity, multi-component behavioral intervention
516087|NCT00273273|Procedure|blood draw|
516088|NCT00273260|Behavioral|individualised bone density feedback and education|
516089|NCT00273247|Drug|Interferon alpha-2b|
516090|NCT00273234|Procedure|Autologous Platelet Gel (APG)|
516091|NCT00273221|Procedure|Glaucoma Implant Surgery|
516092|NCT00273221|Procedure|trabeculectomy|
516093|NCT00273221|Procedure|phacoemulsification|
516094|NCT00273208|Behavioral|10 week behavioral intervention program|
516095|NCT00273195|Device|Implantable Cardioverter Defibrillator|
516096|NCT00273182|Device|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
516097|NCT00273182|Device|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
516098|NCT00273156|Behavioral|Telephone quitline|
516099|NCT00273130|Procedure|transnasal endoscopy|
516100|NCT00273130|Procedure|transoral thin endoscopy|
516101|NCT00273117|Procedure|transnasal gastroscopy|
516102|NCT00273104|Procedure|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
516103|NCT00273104|Behavioral|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
516104|NCT00273091|Device|ICD with CRT therapy|permanently CRT pacing
516105|NCT00273065|Drug|Neosaxitoxin|
516106|NCT00273052|Drug|Carvedilol Phosphate modified release formulation|
516107|NCT00273052|Drug|metoprolol succinate|
516108|NCT00273039|Drug|paroxetine|
516109|NCT00273026|Drug|salmeterol xinafoate/fluticasone propionate|
516110|NCT00273013|Drug|GW274150|GW274150 will be available as 30 mg white oval tablets.
516111|NCT00273013|Drug|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
516346|NCT00270946|Device|Bilayered Cellular Matrix (OrCel)|
516116|NCT00272987|Drug|trastuzumab|4 mg/kg loading dose and 2 mg/kg weekly IV
516117|NCT00272974|Behavioral|Clinic-based counseling|
516118|NCT00272961|Drug|Placebo|placebo tablet once daily for 12 weeks
516119|NCT00272961|Drug|TBC3711|10 mg tablets once daily for 10 weeks
516120|NCT00272961|Drug|TBC3711|50 mg tablet once daily for 10 weeks
516121|NCT00272961|Drug|TBC3711|100 mg tablet once daily for 10 weeks
516122|NCT00272961|Drug|TBC3711|200 mg tablet once daily for 10 weeks
516123|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d
516124|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
516125|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
516126|NCT00272935|Drug|Cenestin 0.3 mg Tablets|1 tablet daily
516127|NCT00272935|Other|Placebo|1 tablet daily
516128|NCT00272922|Device|hernia repair|
516129|NCT00272909|Drug|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
516130|NCT00272909|Drug|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
516131|NCT00272909|Drug|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
516132|NCT00272896|Drug|Vasoactive intestinal peptide|
516133|NCT00272870|Drug|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
516134|NCT00272870|Genetic|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
516135|NCT00272870|Device|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
516136|NCT00272857|Genetic|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
516137|NCT00272844|Drug|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
516138|NCT00272831|Drug|Cilostazol|Cilostazol 100 mg twice daily
516139|NCT00272831|Drug|Placebo|1 tablet twice daily
516140|NCT00272805|Drug|carvedilol|
516141|NCT00272792|Drug|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
516142|NCT00272792|Drug|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
516143|NCT00272779|Drug|ATV|300mg Oral capsules for 96 weeks
516144|NCT00272779|Drug|RTV|100mg Oral Capsules for 96 weeks
516145|NCT00272779|Drug|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
516146|NCT00272779|Drug|LPV|400 mg (3 133mg capsules) BID for 96 weeks
516147|NCT00272766|Drug|pegaptanib sodium|
516148|NCT00272753|Drug|budesonide/formoterol Turbuhaler|
516149|NCT00272753|Drug|formoterol Turbuhaler|
516150|NCT00272753|Drug|salbutamol|
516151|NCT00272740|Drug|Fulvestrant|
516152|NCT00272727|Behavioral|Dialog tool for caregivers|
516153|NCT00272714|Drug|Afimoxifene (0.057%) in hydroalcoholic gel|
516154|NCT00272701|Drug|Esomeprazole|
516155|NCT00272701|Drug|Other PPI marketed in Sweden|
516156|NCT00272688|Drug|Levodopa (drug), intraduodenal administration|
516157|NCT00272675|Drug|Chlorhexidine gluconate (drug) vs placebo|
516158|NCT00272662|Drug|peginesatide|
516159|NCT00272649|Biological|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
516160|NCT00272636|Procedure|Radiofrequency catheter ablation|
516161|NCT00272636|Drug|Amiodarone and cardioversion|
516162|NCT00272623|Procedure|Seldinger technique or venous cut-down for port placement|
516163|NCT00272610|Drug|0.4% Retinol Cream|
516164|NCT00272597|Drug|Risperidone|See Detailed Description.
516165|NCT00272584|Drug|Risperidone|
516166|NCT00272571|Procedure|External counter pulsation therapy|
516167|NCT00272558|Drug|Carboplatin and Vinorelbine|
516168|NCT00272545|Behavioral|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
516169|NCT00272545|Behavioral|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
516170|NCT00272532|Drug|Thiocolchicoside|
516171|NCT00272519|Behavioral|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
516172|NCT00272506|Drug|inhaled corticosteroid|
516173|NCT00272506|Drug|long-acting beta2-agonist|
516174|NCT00272493|Biological|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
516175|NCT00272493|Biological|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
516176|NCT00272480|Drug|Zidovudine/lamivudine|
516177|NCT00272480|Drug|Placebos|
516227|NCT00271960|Behavioral|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
516178|NCT00272467|Drug|Rebamipide|"Brand name: Mucosta® Tab.~Generic name: Rebamipide.~Chemical name:~(±)-2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid.~Formulation: Tablet (White, film-coated tablet).~Strength: One tablet contains rebamipide 100mg.~Storage condition: 15℃~25℃.~Manufacturer: Korea Otsuka Pharmaceuticals"
516179|NCT00272467|Drug|Omeprazole|"Brand name: Losec® Cap.~Generic name: Omeprazole.~Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃~25℃. 7) Manufacturer: AstraZenaca Korea."
516180|NCT00272454|Drug|Cilostazol|
516181|NCT00272454|Drug|Aspirin|
516182|NCT00272441|Drug|inhaled corticosteroids|
516183|NCT00272428|Behavioral|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
516184|NCT00272415|Drug|INO-1001|Intravenous repeating dose
516185|NCT00272415|Drug|temozolomide|Oral repeating dose
516186|NCT00272402|Behavioral|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
516187|NCT00272402|Behavioral|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
516188|NCT00272350|Drug|Steroids|
516189|NCT00272350|Drug|ZD6474|
516190|NCT00272337|Drug|Aspirin|Dosage
516191|NCT00272324|Drug|Aspirin|
516192|NCT00272324|Drug|Folate|
516193|NCT00272311|Drug|Aspirin|Dosage
516194|NCT00272285|Drug|Ramosetron|IV, concomitant administration with dexamethasone
516195|NCT00272285|Drug|Granisetron|IV, concomitant administration with dexamethasone
516196|NCT00272272|Behavioral|Music Therapy|Listening to Music while standing
516197|NCT00272259|Procedure|Participants will interact with up to two small robots and a visual display|
516198|NCT00272246|Procedure|deep brain stimulation of the internal globus pallidus|
516199|NCT00272220|Behavioral|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
516200|NCT00272207|Drug|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
516201|NCT00272194|Device|Ambu Laryngeal Mask|
516202|NCT00272194|Device|Aintree Exchange Catheter|
516203|NCT00272194|Device|Laryngeal Mask Airway|
516204|NCT00272181|Drug|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
516205|NCT00272168|Behavioral|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
516206|NCT00272168|Other|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
516207|NCT00272155|Behavioral|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
516208|NCT00272155|Behavioral|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
516209|NCT00272142|Drug|Zinc|
516210|NCT00272142|Drug|Placebo|
516211|NCT00272116|Drug|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
516212|NCT00272116|Drug|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
516213|NCT00272103|Drug|Itopride (drug)|
516214|NCT00272090|Drug|Insulin glargine|
516215|NCT00272077|Drug|Insuline glargine|
516216|NCT00272064|Drug|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal < 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
516217|NCT00272064|Drug|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) <= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
516218|NCT00272064|Drug|Metformin|1000 mg b.i.d, since the qualification phase, oral
516219|NCT00272051|Drug|SR57746A|
516220|NCT00272038|Drug|Tarceva|150mg QD
516221|NCT00272025|Drug|Escitalopram|10mg to 20mg tablet daily for 6 weeks
516222|NCT00272025|Drug|placebo|
516223|NCT00272012|Drug|Insulin glulisine|
516224|NCT00271999|Behavioral|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
516225|NCT00271973|Drug|Oxycodone|
516226|NCT00271960|Behavioral|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
516228|NCT00271960|Behavioral|Usual care|Participants will receive usual prenatal care.
516229|NCT00271947|Biological|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
516230|NCT00271934|Biological|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
516231|NCT00271921|Behavioral|Calorie controlled diet|
516232|NCT00271908|Behavioral|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
516233|NCT00271869|Procedure|Extracorporeal photoimmunotherapy|
516234|NCT00271856|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
516235|NCT00271856|Behavioral|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
516236|NCT00271817|Drug|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
516237|NCT00271817|Drug|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be ~24 weeks.
516238|NCT00271817|Drug|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
516239|NCT00271817|Drug|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~24 weeks.
516240|NCT00271817|Drug|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~24 weeks.
516241|NCT00271817|Drug|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be ~40 additional weeks for a total of 64 weeks
516242|NCT00271817|Drug|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
516243|NCT00271817|Drug|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
516244|NCT00271804|Drug|bortezomib|
516245|NCT00271791|Drug|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
516246|NCT00271791|Drug|Prednisone|PO, Placebo, 17 days
516247|NCT00271778|Procedure|mastoidotympanoplasty and tympanoplasty|
516248|NCT00271765|Drug|INO-1001|
516249|NCT00271752|Procedure|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
516250|NCT00271739|Device|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
516251|NCT00271739|Other|usual care|usual diabetes care, as provided by primary care providers
516252|NCT00271726|Procedure|Osteosynthesis with palmar locking plate|
516253|NCT00271726|Procedure|Osteosynthesis with external fixator|
516254|NCT00271726|Procedure|Osteosynthesis with Kirschner wires|
516255|NCT00271713|Drug|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
516256|NCT00271713|Drug|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
516257|NCT00271700|Behavioral|Order Set, Education, Feedback|
516258|NCT00271687|Behavioral|Exercise training|
516259|NCT00271674|Device|Q-switched YAG laser|
516260|NCT00271635|Drug|Placebo|Placebo 4 capsules b.i.d. during 1 year
516261|NCT00271635|Drug|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
516262|NCT00271609|Drug|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
516263|NCT00271596|Drug|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
516264|NCT00271596|Drug|Placebo|a daily matching placebo administered over 16 weeks
516265|NCT00271583|Drug|CDB-2914|
516266|NCT00271583|Drug|levonorgestrel|
516267|NCT00271570|Drug|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
516268|NCT00271570|Biological|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
516269|NCT00271557|Drug|nesiritide|
516270|NCT00271544|Device|Pacing Lead|implant and follow-up of study device
516271|NCT00271518|Drug|growth hormone (somatropin)|dosing regimen is weight based.
516272|NCT00271505|Drug|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
516273|NCT00271505|Drug|Carboplatin|AUC 6 IV every 3 weeks
516274|NCT00271505|Drug|Docetaxel|75 mg/m2 IV every 3 weeks
516275|NCT00271492|Drug|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
516276|NCT00271492|Drug|Atrasentan|1 10mg capsule per day for the 6 month study period.
516277|NCT00271492|Drug|atrasentan|One 10 mg capsule per day for 6 month study period
516278|NCT00271479|Biological|A, C, Y, W135 meningococcal polysaccharide vaccine|
516279|NCT00271466|Drug|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
516280|NCT00271453|Drug|Durogesic® (fentanyl transdermal drug delivery system)|
516281|NCT00271440|Procedure|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
516282|NCT00271427|Drug|L-Selenomethionine|
516283|NCT00271414|Drug|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
516284|NCT00271401|Other|Angioplasty|
516285|NCT00271401|Other|Intracoronary Stent|
516286|NCT00271401|Drug|Abxicimab|
516287|NCT00271401|Drug|Heparin|
516288|NCT00271401|Drug|Placebo|
516289|NCT00271388|Device|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
516290|NCT00271375|Behavioral|Caring For You, Caring For Me|5-week Education and Support Program for Caregivers of older adults.
516291|NCT00271375|Behavioral|Caring for you, caring for me + social worker|5-week Education and Support Program for Caregivers of older adults.+ augmentation with social worker
516292|NCT00271375|Behavioral|Control|Control group usual care
516293|NCT00271362|Behavioral|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
516294|NCT00271362|Procedure|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
516295|NCT00271349|Drug|Budesonide|
516296|NCT00271336|Drug|Pentoxifylline|
516297|NCT00271323|Drug|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
516298|NCT00271323|Radiation|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
516299|NCT00271310|Drug|hypertonic saline|
516300|NCT00271297|Behavioral|Pelvic floor muscle training|
516301|NCT00271284|Drug|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
516302|NCT00271284|Drug|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
516303|NCT00271271|Drug|oxaliplatine / gemcitabine / Vinorelbine|
516304|NCT00271258|Drug|SODIUM DIVALPROATE|
516305|NCT00271245|Dietary Supplement|200 µg selenium as selenate|200 µg selenium as selenate
516306|NCT00271245|Dietary Supplement|400 µg selenium as selenate|400 µg selenium as selenate
516307|NCT00271245|Dietary Supplement|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
516308|NCT00271245|Dietary Supplement|Placebo|Placebo
516309|NCT00271232|Device|Cardiac resynchronization therapy|
516310|NCT00271219|Drug|Methadone|daily oral dosing 20-140 mg
516311|NCT00271219|Drug|Buprenorphine|sl daily 2-32 mg
516312|NCT00271206|Drug|Progesterone|compared to placebo
516313|NCT00271206|Drug|sugar pill|Compared to progesterone
516314|NCT00271193|Behavioral|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
516315|NCT00271180|Device|Device|
516316|NCT00271167|Drug|INO-1001|
516317|NCT00271154|Device|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
516318|NCT00271115|Behavioral|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
516319|NCT00271102|Procedure|anterior vaginal repair (colporrhaphy)|vaginal repair
516320|NCT00271102|Procedure|abdominal paravaginal defect repair|abdominal repair
516321|NCT00271089|Procedure|PBSC Collection|
516322|NCT00271089|Procedure|Bone Marrow Harvest|
516323|NCT00271089|Device|CliniMacs Cell Selection System|
516324|NCT00271076|Procedure|IVUS|
516325|NCT00271076|Device|CAS|
516326|NCT00271076|Procedure|CEA|
516327|NCT00271063|Drug|Liposomal Annamycin|3-day IV infusion
516328|NCT00271050|Other|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
516329|NCT00271037|Procedure|Colpocleisis prolapse repair surgery|
516330|NCT00271037|Procedure|sling or other to treat or prevent stress incontinence|
516331|NCT00271024|Drug|Naltrexone (drug)|50 mg q.d. for 13 weeks
516332|NCT00271024|Drug|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
516333|NCT00271011|Drug|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
516334|NCT00271011|Drug|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
516335|NCT00271011|Drug|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2.
516336|NCT00270998|Behavioral|Behavioral Therapy|Pelvic muscle training and exercises
516337|NCT00270998|Device|Intravaginal Pessary|Intravaginal pessary
516338|NCT00270998|Device|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
516339|NCT00270985|Behavioral|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
516340|NCT00270985|Behavioral|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
516341|NCT00270972|Device|Bilayered Cellular Matrix (OrCel)|
516342|NCT00270959|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
516343|NCT00270959|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
516344|NCT00270959|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
516345|NCT00270959|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
516348|NCT00270920|Behavioral|Lactation counseling|
516349|NCT00270907|Drug|CT-2103|135 mg/m^2 IV on Day 1.
516350|NCT00270907|Drug|Gemcitabine|1000 mg/m^2 IV on Day 1 and 8.
516351|NCT00270894|Drug|epirubicin|epirubicin (100 mg/m^2) every 2 weeks for 4 cycles
516352|NCT00270894|Drug|cyclophosphamide|cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles
516353|NCT00270894|Drug|docetaxel|docetaxel (75 mg/m^2) every 2 weeks for 4 cycles
516354|NCT00270894|Drug|trastuzumab|trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments
516355|NCT00270881|Procedure|Cord blood transplantation|unrelated cord blood transplantation
516356|NCT00270881|Radiation|TBI|Total body irradiation (TBI) 12Gy
516357|NCT00270881|Drug|cyclophosphamide|cyclophosphamide 120mg/kg
516358|NCT00270881|Drug|cytarabine|cytarabine 3g/m2x4
516359|NCT00270868|Procedure|Double guide wire technique|
516360|NCT00270868|Procedure|Standard bile duct cannulation|
516361|NCT00270855|Procedure|Arm Crank Ergometry|Use of an upper body cycle to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
516362|NCT00270855|Procedure|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise. 10-minute warm up, 40 minutes @ 70%HRMax (50RPM), 10 minute cool down 5x/week x 16 weeks
516363|NCT00270842|Behavioral|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
516364|NCT00270842|Behavioral|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
516365|NCT00270842|Behavioral|Education Control group|This control group participated in 10 weeks of general health education classes.
516366|NCT00270829|Drug|nesiritide|Drug given intrarenally or placebo
516367|NCT00270816|Drug|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
516368|NCT00270816|Drug|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
516369|NCT00270803|Drug|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
516370|NCT00270790|Drug|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
516371|NCT00270790|Drug|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
516372|NCT00270790|Drug|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
516373|NCT00270790|Device|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
516374|NCT00270777|Drug|adrenaline, promethazine, hydrocortisone|
516375|NCT00270751|Procedure|1 apical pleurectomy|
516376|NCT00270751|Procedure|2 pleural abrasion + minocycline pleurodesis|
516377|NCT00270738|Procedure|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
516378|NCT00270738|Procedure|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
516379|NCT00270738|Procedure|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
516380|NCT00270699|Biological|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
516381|NCT00270699|Biological|Placebo|Placebo for rDEN4delta30-200,201
516382|NCT00270673|Procedure|Early lactate-directed therapy|
516383|NCT00270660|Behavioral|biopsy, audiometry, ET function test, ear swab culture, DNE|
516384|NCT00270647|Dietary Supplement|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
516385|NCT00270647|Dietary Supplement|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
516386|NCT00270647|Dietary Supplement|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
516387|NCT00270647|Dietary Supplement|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
516388|NCT00270634|Drug|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
516389|NCT00270634|Drug|tacrolimus|tacrolimus 0.05 mg/kg po BID
516390|NCT00270621|Behavioral|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
516391|NCT00270608|Procedure|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
516392|NCT00270608|Procedure|MRI of the spine and the right knee|a single time 45 minutes procedure
516393|NCT00270608|Procedure|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
516394|NCT00270582|Drug|Taxotere, Cisplatin, Gemcitabine|
516395|NCT00270569|Drug|PhyxolTM, Cisplatin|
516396|NCT00270556|Drug|tenofovir disoproxil fumarate|
516397|NCT00270556|Drug|Abacavir|
516398|NCT00270543|Drug|Taxotere, Fluorouracil, Leucovorin|
516399|NCT00270530|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
516400|NCT00270517|Drug|EDP-420 / Duration of Treatment – 3 days|
516401|NCT00270517|Drug|Telithromycin / Duration of Treatment – 7 days|
516402|NCT00270504|Device|Memokath stenting|Urethral Stenting
516403|NCT00270491|Drug|Paclitaxel|
516404|NCT00270491|Drug|Capecitabine|
516405|NCT00270478|Drug|Erythropoietin and Hydroxyurea|
516406|NCT00270465|Drug|VRC-HIVDNA016-00-VP|
516407|NCT00270465|Drug|VRC-HIVADV014-00-VP|
516408|NCT00270452|Drug|WT1 and PR1 Peptide Vaccine|
516409|NCT00270439|Procedure|removal of omentum|patients with type 2 diabetes had their omentum removed
516410|NCT00270426|Drug|Benazepril|
516411|NCT00270413|Drug|SU11248|sutent 50 mg daily 4w on 2w off
516412|NCT00270400|Drug|nesiritide|
516413|NCT00270387|Drug|Natrecor (nesiritide)|
516414|NCT00270374|Drug|nesiritide|
516415|NCT00270361|Drug|nesiritide|
516416|NCT00270361|Drug|usual long term cardiac medications|
516417|NCT00270361|Drug|nesiritide|
516418|NCT00270348|Drug|ciclesonide|
516419|NCT00270335|Drug|Propofol|
516420|NCT00270322|Drug|Marcaine 0.166% + Fentanyl 3.33 mcg/ml|
516421|NCT00270322|Drug|Morphine sulphate|
516422|NCT00270309|Behavioral|Self-management|
516423|NCT00270296|Drug|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
516424|NCT00270296|Drug|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
516425|NCT00270296|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
516426|NCT00270296|Drug|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
516427|NCT00270283|Drug|epoetin alfa|
516428|NCT00270270|Drug|epoetin alfa|
516429|NCT00270257|Drug|Buprenorphine/Naloxone|Oral tablet
516430|NCT00270244|Behavioral|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions—one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
516431|NCT00270244|Behavioral|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
516432|NCT00270231|Drug|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.~Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
516433|NCT00270231|Drug|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
516434|NCT00270218|Biological|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
516435|NCT00270218|Biological|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
516436|NCT00270218|Biological|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
516437|NCT00270218|Biological|PBS|phosphate buffered saline
516438|NCT00270205|Biological|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
516439|NCT00270205|Biological|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
516440|NCT00270205|Biological|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
516441|NCT00270192|Behavioral|individual lactation counseling and educational material|
516442|NCT00270192|Behavioral|educational material alone|
516443|NCT00270192|Behavioral|routine antenatal care without educational intervention|
516444|NCT00270179|Drug|epoetin alfa|
516445|NCT00270166|Drug|epoetin alfa|
516446|NCT00270153|Drug|enalapril|5mg enalapril daily for 6 months
516447|NCT00270153|Drug|Placebo|5mg enalapril-matching placebo daily for 6 months
516448|NCT00270140|Drug|epoetin alfa|
516449|NCT00270127|Drug|Epoetin alfa|
516450|NCT00270114|Drug|epoetin alfa|
516451|NCT00270101|Drug|epoetin alfa|
516452|NCT00270088|Drug|epoetin alfa|
516453|NCT00270075|Drug|epoetin alfa|
516454|NCT00270062|Drug|epoetin alfa|
516455|NCT00270049|Drug|epoetin alfa|
516456|NCT00270036|Drug|epoetin alfa|
516457|NCT00270023|Drug|epoetin alfa|
516458|NCT00270010|Drug|epoetin alfa|
516459|NCT00269997|Drug|epoetin alfa|
516460|NCT00269984|Drug|Epoetin alfa|
516461|NCT00269971|Drug|epoetin alfa|
516462|NCT00269958|Drug|epoetin alfa|
516463|NCT00269945|Drug|epoetin alfa|
516464|NCT00269932|Drug|levofloxacin|
516465|NCT00269919|Drug|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
516466|NCT00269906|Drug|Abciximab|
516467|NCT00269906|Drug|Placebo|
516468|NCT00269893|Drug|Abciximab|0.25 mg/kg of body weight of abciximab either bolus or infusion.
516469|NCT00269893|Drug|Placebo|Matching Placebo soulution either bolus or infusion.
516470|NCT00269880|Drug|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
516471|NCT00269880|Drug|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
516472|NCT00269880|Drug|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
516473|NCT00269867|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
516474|NCT00269867|Drug|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
516475|NCT00269867|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
516476|NCT00269854|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
516477|NCT00269854|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
516478|NCT00269854|Drug|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
538010|NCT00002471|Drug|etoposide|
516479|NCT00269854|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
516480|NCT00269841|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
516481|NCT00269841|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
516482|NCT00269841|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
516483|NCT00269828|Drug|paclitaxel|
516484|NCT00269828|Drug|paclitaxel poliglumex|
516485|NCT00269815|Drug|methylphenidate HCl|
516486|NCT00269802|Drug|OROS methylphenidate HCl|
516487|NCT00269802|Drug|Ritalin|
516488|NCT00269802|Drug|Placebo|
516489|NCT00269789|Drug|Ritalin|
516490|NCT00269789|Drug|OROS Methylphenidate HCl|
516491|NCT00269789|Drug|Placebo|
516492|NCT00269776|Drug|Placebo|Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
516493|NCT00269776|Drug|OROS (methylphenidate HCl)|Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
516494|NCT00269776|Drug|Ritalin (methylphenidate)|Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
516495|NCT00269763|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
516496|NCT00269750|Drug|OROS® oxybutynin or Ditropan®|
516497|NCT00269737|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
516498|NCT00269724|Drug|OROS® oxybutynin|
516499|NCT00269685|Drug|vasopressin|
516500|NCT00269672|Biological|13-valent Pneumococcal Conjugate Vaccine|
516501|NCT00269646|Behavioral|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
516502|NCT00269633|Device|Blue Light Box 467 nm|467 nm Blue LED Light
516503|NCT00269633|Device|Red Light Box 657 nm|657 nm Red LED Light
516504|NCT00269620|Drug|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
516505|NCT00269620|Drug|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
516506|NCT00269607|Drug|Implantation of naltrexone implants|
516507|NCT00269594|Drug|Lamictal (lamotrigine)|
516508|NCT00269581|Other|Educational CD-rom|Educational CD-Rom
516509|NCT00269581|Other|Headstrong CD-rom|Headstrong CD-rom
516510|NCT00269568|Drug|mifepristone and misoprostol|
516511|NCT00269555|Drug|Genistein Combined Polysaccharide (GCP)|
516512|NCT00269542|Drug|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
516513|NCT00269542|Drug|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
516514|NCT00269529|Procedure|femoral nerve block|
516515|NCT00269529|Procedure|knee infiltration and injection via catheter|
516516|NCT00269516|Drug|pardoprunox|fixed dose 6 mg
516517|NCT00269516|Drug|Pardoprunox|fixed dose 12 mg
516518|NCT00269516|Drug|Pardoprunox|12-42mg
516519|NCT00269516|Drug|Placebo|Placebo
516520|NCT00269503|Procedure|Prone Distraction|
516521|NCT00269503|Procedure|Side-Posture Manipulation|
516522|NCT00269503|Procedure|Side-Posture Manipulation & Prone Distraction|
516523|NCT00269503|Procedure|Usual Care (Control Group)|
516524|NCT00269490|Behavioral|Yoga Nidra|
516525|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
516526|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
516527|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
516528|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
516529|NCT00269438|Drug|5 ASA, enemas, suppositories, corticosteroids|
516530|NCT00269425|Behavioral|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
516531|NCT00269425|Behavioral|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
516532|NCT00269412|Drug|Rifaximin|
516533|NCT00269399|Drug|Rifaximin (Xifaxan)|
516534|NCT00269399|Drug|Vancomycin|
516535|NCT00269386|Drug|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
516536|NCT00269386|Drug|Placebo|
516537|NCT00269373|Procedure|PET-CT|no drugs included
516538|NCT00269360|Procedure|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
516539|NCT00269360|Procedure|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
516626|NCT00268697|Drug|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
516540|NCT00269360|Behavioral|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
516541|NCT00269347|Procedure|Chiropractic Spinal Manipulation|
516542|NCT00269347|Procedure|Exercise|
516543|NCT00269347|Behavioral|Self-care|
516544|NCT00269334|Drug|Using Citalopram(drug) or Paroxetine(drug)|
516545|NCT00269321|Procedure|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
516546|NCT00269321|Procedure|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.~Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
516547|NCT00269321|Behavioral|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
516548|NCT00269308|Procedure|Chiropractic Manual treatment + home exercise ( procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
516549|NCT00269308|Procedure|Supervised rehabilitative exercise + home exercise|"The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.~Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
516550|NCT00269308|Behavioral|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
516551|NCT00269295|Biological|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10^7 cfu, 5 X 10^8 cfu, and 5 X 10^9 cfu.
516552|NCT00269295|Drug|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
516553|NCT00269282|Behavioral|Self-Management Training|Asthma education and self-monitoring strategies
516554|NCT00269282|Behavioral|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
516555|NCT00269269|Drug|antihypertensive drug|
516556|NCT00269269|Behavioral|placebo|
516557|NCT00269243|Drug|Quinapril|
516558|NCT00269230|Device|Pacing Lead|Left ventricular pacing lead
516559|NCT00269217|Drug|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
516560|NCT00269217|Drug|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
516561|NCT00269217|Drug|Comparator: simvastatin|Duration of Treatment 12 Weeks
516562|NCT00269204|Drug|niacin (+) laropiprant|Duration of Treatment - 24 weeks
516563|NCT00269204|Drug|ER-niacin|Duration of Treatment - 24 weeks
516564|NCT00269191|Drug|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
516565|NCT00269191|Drug|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
516566|NCT00269178|Behavioral|Peer Health Education Programme|
516567|NCT00269165|Procedure|Balloon Aortic Valvuloplasty|
516568|NCT00269165|Procedure|External Beam Radiation|
516569|NCT00269152|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 4 cycles
516570|NCT00269152|Drug|cisplatin|75 mg/m^2, intravenous (IV), every 21 days x 4 cycles
516571|NCT00269152|Drug|carboplatin|area under the curve (AUC) 5 milligrams per milliliter*minute (mg/ml*min), intravenous (IV), every 21 days x 4 cycles
516572|NCT00269139|Behavioral|Crisis resolution|
516573|NCT00269126|Drug|fluticasone propionate/salmeterol combination DISKUS|
516574|NCT00269126|Drug|salmeterol xinafoate|
516575|NCT00269113|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
516576|NCT00269113|Drug|Standard chemotherapy|As prescribed
516577|NCT00269087|Drug|fluticasone propionate/salmeterol combination DISKUS|
516578|NCT00269074|Drug|IDEA-070|
516579|NCT00269061|Drug|pioglitazone|
516580|NCT00269048|Drug|SB-480848|SB-480848
516581|NCT00269048|Drug|placebo|placebo
516582|NCT00269035|Drug|SB773812|SB-773812 tablets will be available with dose strength of 60 mg
516583|NCT00269035|Drug|Risperidone|Risperidone tablets will be available with dose strength of 3 and 6 mg
516584|NCT00269022|Drug|SB-705498|
516585|NCT00269009|Behavioral|CHERL|
516586|NCT00268996|Drug|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
516587|NCT00268996|Drug|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
516588|NCT00268983|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes~Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
516589|NCT00268983|Biological|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
516590|NCT00268970|Drug|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
516591|NCT00268957|Drug|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
516592|NCT00268957|Drug|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
516593|NCT00268944|Biological|Myozyme|20 mg/kg qow
516594|NCT00268931|Behavioral|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
516595|NCT00268931|Behavioral|Social Training|This group underwent special social interactions with their parents two times each day.
516596|NCT00268918|Drug|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
516597|NCT00268918|Drug|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
516598|NCT00268905|Drug|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
516599|NCT00268905|Drug|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).~If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
516600|NCT00268905|Drug|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
516601|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
516602|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
516603|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).~Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
516604|NCT00268879|Drug|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
516605|NCT00268866|Behavioral|Education|
516606|NCT00268853|Drug|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
516607|NCT00268853|Drug|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
516608|NCT00268840|Drug|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
516609|NCT00268840|Drug|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
516610|NCT00268827|Drug|Kaletra soft-gel capsules switched to Kaletra tablets|
516611|NCT00268827|Device|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
516612|NCT00268814|Drug|Diacetylmorphine|Diacetylmorphine (i.v.), daily
516613|NCT00268814|Behavioral|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
516614|NCT00268814|Drug|Methadone|Methadone (p.o.), daily
516615|NCT00268814|Behavioral|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
516616|NCT00268788|Drug|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
516617|NCT00268788|Drug|Intravenous immunoglobulin|Individual dose and frequency
516618|NCT00268775|Behavioral|training and follow-up of pharmacists|
516619|NCT00268775|Behavioral|patient-directed discontinuation letter|
516620|NCT00268762|Drug|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
516621|NCT00268749|Drug|glycine|0.8 g/kg/day
516622|NCT00268723|Drug|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
516623|NCT00268723|Drug|Placebo|Placebo MDI QID
516624|NCT00268710|Drug|docetaxel|
516625|NCT00268697|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
538011|NCT00002471|Drug|leucovorin calcium|
516627|NCT00268697|Drug|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
516628|NCT00268684|Drug|Erlotinib, Temozolomide|
516629|NCT00268671|Drug|Docetaxel|
516630|NCT00268658|Device|SmartStep(tm) biofeedback device|
516631|NCT00268645|Drug|Insulin Glargine|
516632|NCT00268632|Drug|risedronate|
516633|NCT00268619|Drug|Ramipril|
516634|NCT00268606|Behavioral|cognitive-behavioral therapy|
516635|NCT00268593|Drug|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
516636|NCT00268593|Drug|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
516637|NCT00268593|Drug|prednisone|5 mg twice a day orally
516638|NCT00268580|Behavioral|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
516639|NCT00268567|Drug|leflunomide combined with prednisone|
516640|NCT00268554|Drug|dipyridamole|
516641|NCT00268554|Drug|caffeine|
516642|NCT00268541|Behavioral|Physical activity|
516643|NCT00268528|Behavioral|Compliance Monitoring|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
516644|NCT00268528|Other|Laboratory Biomarker Analysis|Correlative studies
516645|NCT00268528|Drug|Mercaptopurine|Given PO
516646|NCT00268528|Drug|Methotrexate|Given PO
516647|NCT00268528|Other|Questionnaire Administration|Ancillary studies
516648|NCT00268528|Other|Study of Socioeconomic and Demographic Variables|Receive an electronic pill monitoring system comprising an empty MEMS medication bottle with TrackCap
516649|NCT00268515|Drug|cyclosporine|
516650|NCT00268515|Drug|tacrolimus|
516651|NCT00268515|Drug|prednisone|
516652|NCT00268515|Drug|azathioprine|
516653|NCT00268502|Other|study of socioeconomic and demographic variables|
516654|NCT00268502|Procedure|fatigue assessment and management|
516655|NCT00268502|Procedure|management of therapy complications|
516656|NCT00268502|Procedure|psychosocial assessment and care|
516657|NCT00268502|Procedure|quality-of-life assessment|
516658|NCT00268489|Biological|bevacizumab|
516659|NCT00268489|Drug|pemetrexed disodium|
516660|NCT00268476|Drug|Celecoxib|
516661|NCT00268476|Drug|Docetaxel|
516662|NCT00268476|Drug|Prednisolone|
516663|NCT00268476|Drug|ADT|
516664|NCT00268476|Drug|Zoledronic Acid|
516665|NCT00268476|Drug|Abiraterone|
516666|NCT00268476|Radiation|Radiotherapy to the prostate|
516667|NCT00268476|Drug|Enzalutamide|
516668|NCT00268476|Drug|Metformin|
516669|NCT00268476|Drug|Transdermal Oestradiol|
516670|NCT00268463|Drug|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1~Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
516671|NCT00268463|Drug|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
516672|NCT00268463|Drug|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1~Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
516673|NCT00268450|Biological|bevacizumab|"Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles~After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles"
516674|NCT00268450|Drug|cisplatin|Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
516675|NCT00268450|Drug|gemcitabine hydrochloride|Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
516676|NCT00268450|Drug|paclitaxel|After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
516677|NCT00268450|Procedure|cysectomy|
516678|NCT00268437|Drug|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
516679|NCT00268437|Drug|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
516680|NCT00268437|Procedure|conventional surgery|
516681|NCT00268437|Procedure|neoadjuvant therapy|
516682|NCT00268437|Radiation|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
516683|NCT00268411|Drug|gemcitabine hydrochloride|
516684|NCT00268411|Drug|oxaliplatin|
516685|NCT00268398|Drug|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1&2) continuous 5FU 600mg/m² (day 1 to 2)
516686|NCT00268398|Drug|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)~FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
516687|NCT00268385|Other|Laboratory Biomarker Analysis|Correlative studies
516688|NCT00268385|Other|Pharmacological Study|Correlative studies
516689|NCT00268385|Drug|Temozolomide|Given orally
516690|NCT00268385|Drug|Vorinostat|Given orally
516691|NCT00268372|Drug|cisplatin|
516692|NCT00268372|Drug|docetaxel|
516693|NCT00268372|Drug|5-fluorouracil|
516694|NCT00268372|Procedure|surgery|
516695|NCT00268372|Radiation|radiation therapy|
516696|NCT00268359|Biological|bevacizumab|
516697|NCT00268359|Drug|irinotecan hydrochloride|
516698|NCT00268346|Drug|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
516699|NCT00268333|Drug|fluorouracil|
516700|NCT00268333|Drug|leucovorin calcium|
516701|NCT00268333|Drug|oxaliplatin|
516702|NCT00268333|Procedure|neoadjuvant therapy|
538012|NCT00002471|Drug|methotrexate|
516703|NCT00268320|Device|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
516704|NCT00268307|Drug|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
516705|NCT00268294|Device|Cardiac Resynchronization Therapy|
516706|NCT00268281|Device|Left Ventricular Capture Management Software|
516707|NCT00268255|Drug|gefitinib|
516708|NCT00268255|Procedure|adjuvant therapy|
516709|NCT00268255|Procedure|enzyme inhibitor therapy|
516710|NCT00268255|Procedure|neoadjuvant therapy|
516711|NCT00268255|Procedure|protein tyrosine kinase inhibitor therapy|
516712|NCT00268255|Procedure|radiation therapy|
516713|NCT00268255|Procedure|radiosensitization|
516714|NCT00268242|Drug|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
516715|NCT00268242|Drug|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
516716|NCT00268229|Drug|cytarabine|300 mg/m2/day
516717|NCT00268229|Drug|daunorubicin hydrochloride|45 mg/m2/day
516718|NCT00268229|Drug|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
516719|NCT00268216|Drug|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
516720|NCT00268203|Biological|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
516721|NCT00268177|Drug|Salmeterol/fluticasone propionate 50/500mcg Diskus|
516722|NCT00268164|Drug|lactobacilus acidophilus & bifidobacterium animalis/lactis|
516723|NCT00268151|Drug|Oxaliplatin|
516724|NCT00268151|Drug|Capecitabine|
516725|NCT00268138|Drug|elmex gel|elmex gel once a week
516726|NCT00268125|Device|Acupression's bracelet|
516727|NCT00268125|Behavioral|Hygiene and dietetic advices|
516728|NCT00267969|Drug|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
516729|NCT00267969|Drug|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
516730|NCT00267956|Drug|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
516731|NCT00267956|Drug|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
516732|NCT00267943|Drug|telmisartan 80 mg + hydrochlorothiazide 25 mg|
516733|NCT00267930|Drug|Vernakalant (oral)|
516734|NCT00267930|Drug|Placebo comparator|
516735|NCT00267917|Device|Berodual Respimat|
516736|NCT00267917|Device|Berodual HFA-MDI|
516737|NCT00267865|Drug|Methotrexate|6000 mg/m2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patient s urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
516738|NCT00267865|Drug|Rituximab|375 mg/m2 IV day 1 of each cycle prior to administration of high-dose methotrexate
516739|NCT00267865|Drug|Leucovorin|Leucovorin calcium doses will be administered orally or by short IV infusion over 15 minutes
516740|NCT00267852|Other|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
516741|NCT00267839|Behavioral|physical exercise, wellness|
516742|NCT00267826|Drug|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
516743|NCT00267813|Drug|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
516744|NCT00267787|Other|genetic analysis|standard of care
516745|NCT00267774|Device|Fractional flow reserve|
516746|NCT00267774|Procedure|Angio-guided PCI|
516747|NCT00267748|Drug|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
516748|NCT00267748|Drug|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
516749|NCT00267735|Behavioral|Use of Computerized Decision Aid on Childbirth|
516750|NCT00267722|Drug|Visilizumab|
516751|NCT00267709|Drug|Visilizumab|
516752|NCT00267696|Drug|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
516753|NCT00267696|Drug|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
516754|NCT00267696|Drug|Carboplatin|
516755|NCT00267683|Drug|insulin aspart|
516756|NCT00267683|Drug|glibenclamide|
516757|NCT00267670|Drug|Pentoxifylline|400mg PO TID
516758|NCT00267670|Drug|Placebo|1 pill PO TID
516759|NCT00267657|Drug|Reserpine|
516760|NCT00267618|Behavioral|FHP Pain|Evidence-based psychological and behavioural Intervention
516761|NCT00267605|Behavioral|FHPADHD|Evidence-based psychological and behavioural distance intervention
516762|NCT00267605|Behavioral|ADHD Standard Care|
516763|NCT00267592|Drug|Talampanel|Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
516764|NCT00267592|Radiation|Radiation Therapy (RT) 5 days a week +|
516765|NCT00267592|Drug|temozolomide(TMZ) 75mg|temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
516766|NCT00267592|Drug|adjuvant TMZ 200mg|adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
516767|NCT00267579|Behavioral|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
516768|NCT00267566|Behavioral|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
516769|NCT00267553|Drug|Atamestane|
516770|NCT00267553|Drug|toremifene|
516771|NCT00267553|Drug|letrozole|
516772|NCT00267540|Behavioral|cholecalciferol (D3) (vitamin)|
516773|NCT00267527|Drug|CJC 1295|
516774|NCT00267514|Drug|sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)|sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
516775|NCT00267514|Drug|sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)|sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
516776|NCT00267488|Drug|topotecan|
516777|NCT00267449|Device|SoftScan Optical Breast Imaging System|
516778|NCT00267436|Behavioral|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
516779|NCT00267410|Behavioral|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
516780|NCT00267384|Drug|Oral N-Acetylcysteine|
516781|NCT00267371|Device|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
516782|NCT00267371|Drug|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
516783|NCT00267358|Drug|RC-1291 HCl|
516784|NCT00267358|Drug|Placebo|
516785|NCT00267332|Drug|Modafinil|
516786|NCT00267319|Drug|Glatiramer acetate|
516787|NCT00267306|Drug|Visilizumab|
516788|NCT00267293|Drug|Acetaminophen|Given for fever control 15mg/kg
516789|NCT00267293|Drug|Ibuprofen|Given for fever control 10 mg/kg
516790|NCT00267280|Drug|torcetrapib/atorvastatin|
516791|NCT00267280|Drug|simvastatin|
516792|NCT00267267|Drug|torcetrapib/atorvastatin|
516793|NCT00267267|Drug|ezetimibe/simvastatin|
516794|NCT00267254|Drug|torcetrapib/atorvastatin|
516795|NCT00267254|Drug|simvastatin|
516796|NCT00267241|Other|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
516797|NCT00267215|Drug|Lumiracoxib|
516798|NCT00267202|Drug|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
516799|NCT00267202|Drug|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
516800|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
516801|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
516802|NCT00267189|Drug|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
516803|NCT00267189|Drug|Calcineurin inhibitors (CNI)|
516804|NCT00267189|Drug|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
516805|NCT00267189|Drug|Steroids|
516806|NCT00267176|Drug|lumiracoxib|
516807|NCT00267163|Drug|donepezil|
516808|NCT00267163|Drug|Placebo|
516809|NCT00267150|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
516810|NCT00267137|Device|Pacing Algorithms|
516811|NCT00267111|Drug|Eucerin plus|1g, single application
516812|NCT00267111|Drug|Amethocaine gel 4%|1 g, single application
516813|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
516814|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
516815|NCT00267085|Biological|Synthetic Tumor-Specific Breakpoint Peptide Vaccine|CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
516816|NCT00267059|Drug|Lenalidomide|10 mg/day, orally once a day for 28 days
516817|NCT00267046|Drug|Palifermin|180 mcg/kg 3 days prior to chemotherapy
516818|NCT00267046|Drug|Placebo|Single dose 3 days prior to chemotherapy
516819|NCT00267046|Drug|Adriamycin (Doxorubicin)|30 mg/m^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m^2).
516820|NCT00267046|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m^2); for patients receiving the AI Regimen.
516821|NCT00267046|Drug|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
516822|NCT00267046|Drug|Cisplatin|120 mg/m^2 on day 0, for patients receiving the AP Regimen.
516823|NCT00267033|Procedure|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
516824|NCT00267020|Drug|enzastaurin|1200 mg loading dose then 500 mg, oral, daily, six 28 day cycles
516825|NCT00267020|Drug|gemcitabine|1000 mg/m2, IV, days 1, 8 and 15 per cycle, six 28 day cycles
516826|NCT00267007|Drug|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
516827|NCT00267007|Drug|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
516828|NCT00266981|Device|APOS - exercise component|
516829|NCT00266929|Procedure|surgical|surgical treatment of odontoid fractures
516830|NCT00266929|Procedure|conservative treatment|conservative stabilization of fractures
516831|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
516832|NCT00266864|Drug|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
516833|NCT00266851|Drug|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
516834|NCT00266851|Drug|Placebo|Matching placebo
516835|NCT00266838|Drug|Maxidex; Lacrystat|6 times daily, for 20 weeks.
516836|NCT00266825|Drug|DHA|600 mg DHA
516837|NCT00266825|Other|Placebo capsule|Placebo capsule
516838|NCT00266812|Drug|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
516839|NCT00266812|Procedure|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
516840|NCT00266799|Drug|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
516841|NCT00266799|Drug|Capecitabine|capecitabine (1250 mg/m^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
516842|NCT00266786|Drug|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
516843|NCT00266786|Drug|Intranasal Placebo|Intranasal Placebo
516844|NCT00266773|Behavioral|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
516845|NCT00266747|Drug|SR58611A|
516846|NCT00266734|Device|RPS Adeno Detector|
516847|NCT00266721|Drug|Pancrelipase (Creon) 2 tablets with each meal|
516848|NCT00266708|Drug|Risedronate|risedronate 35 mg weekly
516849|NCT00266708|Drug|Placebo|Risedronate Placebo 35 mg weekly
516850|NCT00266695|Drug|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
516851|NCT00266682|Device|Pacing Lead|
516852|NCT00266669|Drug|Topical organogel with nitroglycerin|
516853|NCT00266656|Drug|Humatrope|According to investigator's clinical practice and guided by the approved package insert
516854|NCT00266643|Drug|duloxetine hydrochloride|
516855|NCT00266630|Drug|olanzapine|oral, daily
516856|NCT00266630|Drug|lithium|Dose adjusted according to local package insert
516857|NCT00266630|Drug|valproate|Dose adjusted according to local package insert
516858|NCT00266630|Drug|carbamazepine|Dose adjusted according to local package insert
516859|NCT00266617|Drug|epoetin alfa|
516860|NCT00266604|Drug|Topiramate|
516861|NCT00266591|Drug|topiramate|
516862|NCT00266578|Drug|Fluticasone Propionate|Flovent vs. placebo daily for 3 months
516863|NCT00266565|Drug|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
516864|NCT00266552|Drug|risperidone|
516865|NCT00266539|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
516866|NCT00266526|Biological|Recombinant birch pollen|
516867|NCT00266487|Drug|Folic acid|
516868|NCT00266487|Drug|Vitamin B12|
516869|NCT00266487|Drug|Vitamin B6|
516870|NCT00266474|Other|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
516871|NCT00266461|Drug|Daikenchuto Extract Granules (TU-100)|
516872|NCT00266448|Drug|Chlorhexidine solution 4%|
516873|NCT00266409|Drug|Niravam|
516874|NCT00266409|Drug|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
516875|NCT00266396|Behavioral|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
516876|NCT00266396|Behavioral|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
516877|NCT00266357|Drug|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
516878|NCT00266357|Drug|Placebo / Duration of Treatment: 2 days for screening period|
516879|NCT00266344|Drug|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
516880|NCT00266344|Drug|Placebo / Duration of Treatment 3 Weeks|
516881|NCT00266331|Drug|Reduced glutathione|
516882|NCT00266318|Drug|Interferon Alfacon-1 and Ribavirin|
516883|NCT00266305|Behavioral|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
516884|NCT00266292|Behavioral|Fish oil (Bio-Marine, Pharma Nord)|
516885|NCT00266292|Behavioral|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
516886|NCT00266279|Drug|Oxaliplatin, Capecitabine|"Agent, DOSE AND SCHEDULE (28-days cycle):~Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21"
516887|NCT00266253|Drug|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
516888|NCT00266253|Drug|Metformin|As prescribed, for 12 weeks
516889|NCT00266240|Drug|GK Activator (2)|Escalating doses po bid
516890|NCT00266240|Drug|Placebo|po bid
516891|NCT00266227|Drug|placebo|Intravenous repeating dose
516892|NCT00266227|Drug|rituximab|Intravenous repeating dose
516893|NCT00266227|Drug|methotrexate|Oral or parenteral repeating dose
516894|NCT00266227|Drug|folate|Intravenous repeating dose
516895|NCT00266214|Drug|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
516896|NCT00266162|Drug|Bosentan administration|
516897|NCT00266149|Drug|Oral contraception|
516898|NCT00266149|Drug|Lamotrigine|
516899|NCT00266136|Drug|Cytarabine|see protocol
516900|NCT00266136|Drug|Thioguanine|see protocol
516901|NCT00266136|Drug|Daunorubicin|see protocol
516902|NCT00266136|Drug|Cyclophosphamide|see protocol
516903|NCT00266136|Drug|G-CSF|see protocol
516904|NCT00266136|Procedure|Autologous stem cell transplantation|for details see protocol
516905|NCT00266136|Procedure|Allogeneic stem cell transplantation|for details see protocol
516906|NCT00266123|Drug|Sirolimus|
516907|NCT00266110|Biological|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
516908|NCT00266110|Biological|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
516909|NCT00266110|Biological|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
516910|NCT00266110|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
516911|NCT00266097|Drug|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
516912|NCT00266097|Drug|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
516913|NCT00266097|Drug|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
516914|NCT00266097|Radiation|radiation therapy|5040 cGy, every week, up to 6 weeks
516915|NCT00266097|Drug|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
516916|NCT00266097|Drug|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
516917|NCT00266071|Behavioral|Cutaneous response|
516918|NCT00266058|Drug|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
516919|NCT00266032|Drug|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
516920|NCT00266032|Drug|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
516984|NCT00265642|Drug|placebo|one tablet per day during 2 years
516985|NCT00265629|Device|RF catheter ablation|RF ablation using mesh device
516921|NCT00266032|Drug|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
516922|NCT00266019|Behavioral|Weight Management (diet, exercise, and behavior modification)|
516923|NCT00266006|Drug|eptacog alfa (activated)|
516924|NCT00265993|Drug|enoxaparin|"All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.~Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months."
516925|NCT00265980|Drug|Subcutaneous Placebo|Twice daily injections of saline in the same volume as will be used for leptin injections.
516926|NCT00265980|Drug|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8 a.m. circulating leptin concentrations measured in the same subjects prior to weight loss.
516927|NCT00265967|Drug|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
516928|NCT00265954|Behavioral|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
516929|NCT00265941|Drug|cetuximab|Cetuximab 400 mg/m^2 IV loading dose 5-7 days before start of radiation therapy, then 250 mg/m^2 IV weekly for 7 weeks
516930|NCT00265941|Drug|cisplatin|Cisplatin 100 mg/m^2 IV on days 1 and 22
516931|NCT00265941|Radiation|Accelerated Fractionation by Concomitant Boost|3DCRT 54 Gy in 30 1.8 Gy fractions over 6 weeks with boost 18 Gy in 12 1.5 Gy fractions for last 12 days, for a total of 72 Gy in 42 fractions over 6 weeks
516932|NCT00265941|Radiation|Intensity-modulated radiation therapy|70 Gy in 35 2.0 Gy fractions over 6 weeks with 6 fractions per week (on Saturday or as second daily fraction) in 5 of the 6 weeks.
516933|NCT00265928|Drug|bortezomib|
516934|NCT00265928|Drug|rituximab|
516935|NCT00265928|Procedure|antibody therapy|
516936|NCT00265928|Procedure|biological therapy|
516937|NCT00265928|Procedure|enzyme inhibitor therapy|
516938|NCT00265928|Procedure|monoclonal antibody therapy|
516939|NCT00265915|Biological|rituximab|
516940|NCT00265915|Biological|sargramostim|
516941|NCT00265902|Procedure|diagnostic imaging|
516942|NCT00265889|Biological|filgrastim|480 mcg beginning day +5
516943|NCT00265889|Drug|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
516944|NCT00265889|Drug|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
516945|NCT00265889|Drug|etoposide|60 mg/kg, IV
516946|NCT00265889|Drug|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
516947|NCT00265889|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
516948|NCT00265889|Radiation|radiation therapy|radiation therapy
516949|NCT00265876|Drug|AZD0530|Taken daily every 4 weeks
516950|NCT00265876|Drug|gemcitabine hydrochloride|1000mg/m2 IV weekly
516951|NCT00265863|Drug|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
516952|NCT00265850|Biological|bevacizumab|Given IV
516953|NCT00265850|Biological|cetuximab|Given IV
516954|NCT00265850|Drug|FOLFOX or|Patients receive oxaliplatin 85 mg/m^2 IV infused over two hours followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus, then 2400 mg/m^2 continuous IV infusion over 46-48 hours
516955|NCT00265850|Drug|FOLFIRI|Patients receive irinotecan 180 mg/m^2 IV infused over 90 minutes followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus following leucovorin then 2400 mg/m^2 continuous IV infusion over 46-48 hours.
516956|NCT00265837|Biological|graft versus host disease prophylaxis/therapy|
516957|NCT00265837|Procedure|allogeneic bone marrow transplantation|
516958|NCT00265837|Procedure|in vitro-treated bone marrow transplantation|
516959|NCT00265824|Drug|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
516960|NCT00265824|Drug|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
516961|NCT00265811|Drug|Folfox + Cetuximab|
516962|NCT00265811|Drug|Folfox|
516963|NCT00265798|Drug|Sorafenib Tosylate|
516964|NCT00265785|Drug|pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
516965|NCT00265772|Drug|MODULEN IBD (R) (specific Enteral Nutrition)|
516966|NCT00265772|Drug|prednisolon|
516967|NCT00265759|Drug|anastrozole|Given PO
516968|NCT00265759|Drug|exemestane|Given PO
516969|NCT00265759|Drug|letrozole|Given PO
516970|NCT00265759|Procedure|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
516971|NCT00265746|Drug|Metformin|
516972|NCT00265746|Behavioral|Lifestyle intervention - diet, physical activity|
516973|NCT00265733|Drug|capecitabine|
516974|NCT00265733|Drug|paclitaxel poliglumex|
516975|NCT00265720|Other|Control|Written materials only
516976|NCT00265720|Other|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
516977|NCT00265720|Behavioral|one on one education|one on one education with a health educator
516978|NCT00265720|Behavioral|Group education|Education in a small group
516979|NCT00265707|Device|Blood pressure measurement|
516980|NCT00265694|Drug|vinorelbine, gemcitabine and carboplatin|
516981|NCT00265681|Behavioral|Phone counseling and written materials|
516982|NCT00265655|Drug|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
516983|NCT00265642|Drug|Irbesartan|one tablet of 150 mg/d during 2 years
516986|NCT00265616|Drug|propofol|liquid, mg/kg.h, titrated after EEG
516987|NCT00265616|Drug|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
516988|NCT00265603|Procedure|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
516989|NCT00265564|Behavioral|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
516990|NCT00265564|Behavioral|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
516991|NCT00265551|Drug|SCA-136 (200 mg)|
516992|NCT00265551|Drug|SCA-136 (400 mg)|
516993|NCT00265551|Drug|olanzapine (15 mg)|
516994|NCT00265551|Drug|placebo|
516995|NCT00265538|Behavioral|Patient education to engage provider in hypertension treatment discussion|Patients will receive a customized/tailored letter including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s)
516996|NCT00265538|Behavioral|Financial incentive and health educator phone call|Patients may receive 20$ for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the 20$ discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt.
516997|NCT00265525|Behavioral|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
516998|NCT00265512|Behavioral|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
516999|NCT00265512|Behavioral|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
517000|NCT00265499|Procedure|Skeletonization of the internal thoracic artery|
517001|NCT00265486|Drug|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
517002|NCT00265473|Biological|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
517003|NCT00265460|Drug|Oliwer Twist smokeless tobacco (tobacco)|
517004|NCT00265447|Behavioral|Strength training|3 months of strength training
517005|NCT00265447|Behavioral|Aerobic conditioning|3 months of aerobic conditioning
517006|NCT00265447|Behavioral|Delayed exercise|delayed exercise control group
517007|NCT00265434|Drug|Pulmozyme|
517008|NCT00265421|Procedure|Suture technique for perineal repair after delivery|
517009|NCT00265408|Drug|aspirin|
517010|NCT00265408|Drug|warfarin|
517011|NCT00265395|Drug|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
517012|NCT00265395|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
517013|NCT00265382|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
517014|NCT00265369|Drug|Spores of Bacillus Clausii Probiotic Strain|
517015|NCT00265356|Procedure|PET diagnostic imaging|PET diagnostic imaging
517016|NCT00265343|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
517017|NCT00265343|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
517018|NCT00265330|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
517019|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
517020|NCT00265317|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
517021|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
517022|NCT00265317|Drug|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
517023|NCT00265304|Drug|Ketoprofen|
517024|NCT00265291|Drug|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
517025|NCT00265278|Drug|Modafinil|
517026|NCT00265265|Drug|Atomoxetine|
517027|NCT00265252|Drug|Alendronate|
517028|NCT00265239|Drug|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
517182|NCT00264030|Device|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
517029|NCT00265226|Biological|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
517030|NCT00265200|Drug|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
517031|NCT00265148|Drug|Rosiglitazone|Extended Release Tablets
517032|NCT00265148|Other|Placebo|Placebo dummy to match
517033|NCT00265135|Drug|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
517034|NCT00265122|Drug|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
517035|NCT00265122|Drug|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
517036|NCT00265122|Drug|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
517037|NCT00265122|Drug|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
517038|NCT00265109|Drug|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
517039|NCT00265096|Biological|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
517040|NCT00265096|Biological|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
517041|NCT00265096|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
517042|NCT00265083|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
517043|NCT00265083|Biological|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
517044|NCT00265083|Biological|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
517045|NCT00265070|Drug|Gefitinib|250 mg tablet oral daily dose
517046|NCT00265057|Drug|ADH -1 (Exherin™)|
517047|NCT00265044|Behavioral|Provider Education|
517048|NCT00265044|Behavioral|Hypertension Alert|
517049|NCT00265044|Behavioral|Patient Education|
517050|NCT00265031|Drug|Cyclophosphamide|
517051|NCT00265031|Drug|Adriamycin|
517052|NCT00265031|Drug|Etoposide|
517053|NCT00265031|Drug|Procarbazine|
517054|NCT00265031|Drug|Prednisone|
517055|NCT00265031|Drug|Vincristine|
517056|NCT00265031|Drug|Bleomycin|
517057|NCT00265031|Procedure|radiation therapy|
517058|NCT00265018|Drug|Adriamycin|
517059|NCT00265018|Drug|Bleomycin|
517060|NCT00265018|Drug|Vinblastine|
517061|NCT00265018|Drug|DTIC|
517062|NCT00265018|Radiation|30 Gy IF-RT|
517063|NCT00265018|Radiation|20 Gy IF-RT|
517064|NCT00265005|Drug|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
517065|NCT00264979|Procedure|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
517066|NCT00264979|Procedure|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
517067|NCT00264966|Drug|ASM8|
517068|NCT00264953|Drug|Adriamycin|
517069|NCT00264953|Drug|Bleomycin|
517070|NCT00264953|Drug|Vinblastine|
517071|NCT00264953|Drug|DTIC|
517072|NCT00264953|Drug|Etoposide|
517073|NCT00264953|Drug|Procarbazine|
517074|NCT00264953|Drug|Prednisone|
517075|NCT00264953|Drug|Vincristine|
517076|NCT00264953|Radiation|radiation therapy|20 or 30Gy IF-RT
517077|NCT00264927|Drug|SR121463B|
517078|NCT00264914|Drug|SR121463B|
517079|NCT00264901|Drug|insulin detemir|
517080|NCT00264888|Drug|PTC124|
517081|NCT00264875|Drug|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
517082|NCT00264862|Procedure|DynaCT|
517083|NCT00264849|Drug|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
517084|NCT00264849|Other|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
517183|NCT00264030|Other|PTCA|PTCA
517184|NCT00264004|Drug|AZD2171|30 mg & 45 mg oral tablet
517185|NCT00263991|Device|EEC-techniques|
517186|NCT00263978|Drug|Defibrotide|
517187|NCT00263965|Drug|Tesaglitazar|
517188|NCT00263965|Drug|Metformin|
517189|NCT00263965|Behavioral|Dietary and lifestyle modification counseling|
517085|NCT00264823|Behavioral|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
517086|NCT00264810|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
517087|NCT00264810|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
517088|NCT00264797|Drug|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
517089|NCT00264797|Drug|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
517090|NCT00264758|Device|Conventional hemodialysis|Three times per week in-center hemodialysis
517091|NCT00264758|Device|Frequent hemodialysis|Six times per week in-center hemodialysis
517092|NCT00264745|Behavioral|TASK intervention|The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
517093|NCT00264745|Behavioral|Attention Control|Minimal intervention beyond initial hospital visit.
517094|NCT00264732|Drug|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
517095|NCT00264732|Drug|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
517096|NCT00264732|Other|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
517097|NCT00264719|Drug|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
517098|NCT00264719|Drug|placebo|placebo 10 mg
517099|NCT00264706|Drug|Nona-L-arginine|
517100|NCT00264680|Drug|lamotrigine|
517101|NCT00264680|Drug|valproic acid|
517102|NCT00264667|Drug|GW677954|
517103|NCT00264654|Drug|BRL29060A|
517104|NCT00264654|Drug|paroxetine hydrochloride hydrate|
517105|NCT00264641|Drug|Human insulin|Hyperinsulinaemic induced hypoglycaemia
517106|NCT00264628|Drug|GW679769|
517107|NCT00264615|Drug|lamotrigine extended-release|
517108|NCT00264602|Drug|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
517109|NCT00264589|Behavioral|8 weeks individualized training program|no drugs added
517110|NCT00264576|Biological|Influenza Virus Vaccine|
517111|NCT00264563|Behavioral|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
517112|NCT00264563|Behavioral|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
517113|NCT00264550|Drug|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
517114|NCT00264550|Drug|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
517115|NCT00264550|Drug|Methotrexate|Participants will receive methotrexate capsules weekly.
517116|NCT00264550|Drug|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
517117|NCT00264550|Drug|Placebo capsules|Participants will receive placebo capsules weekly
517118|NCT00264537|Drug|Placebo injections|SC injections
517119|NCT00264537|Drug|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
517120|NCT00264537|Drug|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
517121|NCT00264537|Biological|Golimumab 50 mg injections|SC injections
517122|NCT00264537|Biological|Golimumab 100 mg injections|SC injections
517123|NCT00264524|Procedure|venipuncture to withdraw patient's blood|
517190|NCT00263952|Biological|bee venom|
517239|NCT00263432|Procedure|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
517475|NCT00261820|Drug|mycophenolate mofetil|
517124|NCT00264511|Procedure|Hyperbaric Oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
517125|NCT00264498|Drug|Gefitinib|oral tablet
517126|NCT00264498|Drug|Gemcitabine|intravenous injection
517127|NCT00264498|Drug|Carboplatin|intravenous injection
517128|NCT00264485|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
517129|NCT00264472|Drug|ADH300004|5 mg
517130|NCT00264459|Biological|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.~The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
517131|NCT00264459|Other|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
517132|NCT00264446|Drug|ADH300004|
517133|NCT00264433|Drug|ADH -1 (Exherin™)|
517134|NCT00264420|Drug|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
517135|NCT00264407|Drug|Hormone Replacement Therapy - HRT|
517136|NCT00264394|Behavioral|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
517137|NCT00264394|Behavioral|Guidelines|provision of guidelines for CHD risk factor management only
517138|NCT00264381|Drug|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
517139|NCT00264368|Drug|intravenous (IV) ganciclovir|
517140|NCT00264355|Drug|cyclosporine A|
517141|NCT00264329|Other|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
517142|NCT00264316|Procedure|bone marrow-derived stem cell transfer|
517143|NCT00264303|Drug|Levocetirizine|5mg oral capsules, once daily, 4 week duration
517144|NCT00264303|Drug|Desloratadine|5mg oral capsules, once daily, 4 week duration
517145|NCT00264290|Drug|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
517146|NCT00264290|Drug|Placebo|Placebo designed to resemble Valganciclovir
517147|NCT00264277|Drug|Vitamin K antagonist (Coumarin anticoagulants)|
517148|NCT00264264|Procedure|Closure Device|
517149|NCT00264264|Procedure|Direct Compression|
517150|NCT00264251|Behavioral|Weight loss through diet and exercise|
517151|NCT00264251|Drug|Rosiglitazone insulin sensitizing agent|
517152|NCT00264238|Drug|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
517153|NCT00264225|Drug|Lamaline® , 3 different doses, Dafalgan codeine|
517154|NCT00264212|Drug|irbesartan and irbesartan-hydrochlorothiazide|
517155|NCT00264199|Drug|GLP-1|iv. by weight (1.0 pmol/kg/min )
517156|NCT00264199|Drug|placebo|same rate of infusion as GLP-1
517157|NCT00264186|Drug|LPS 2 ng/kg intravenous (IV) bolus|
517158|NCT00264186|Drug|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
517159|NCT00264186|Drug|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
517160|NCT00264186|Drug|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
517161|NCT00264186|Drug|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
517162|NCT00264173|Drug|Valproate sodium|
517163|NCT00264160|Drug|AMN107|
517164|NCT00264147|Drug|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
517165|NCT00264147|Drug|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
517166|NCT00264147|Drug|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
517167|NCT00264147|Drug|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
517168|NCT00264147|Drug|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
517169|NCT00264147|Drug|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
517170|NCT00264147|Drug|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
517171|NCT00264134|Drug|Docetaxel|
517172|NCT00264134|Drug|Irinotecan|
517173|NCT00264134|Drug|Carboplatin|
517174|NCT00264108|Drug|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
517175|NCT00264108|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length.
517176|NCT00264095|Procedure|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
517177|NCT00264082|Drug|Zometa(drug)|
517178|NCT00264069|Drug|antipsychotic|as prescribed
517179|NCT00264069|Drug|antidepressants|as prescribed
517180|NCT00264056|Device|hyperthermia|
517181|NCT00264043|Device|emboli capturing guidewire device combined with stent|AngioGuard™ device and Bx Velocity™ stent
517476|NCT00261820|Drug|methylprednisolone|
517477|NCT00261820|Drug|prednisolone|
517191|NCT00263939|Behavioral|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
517192|NCT00263926|Biological|wasp venom|
517193|NCT00263900|Device|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
517194|NCT00263887|Drug|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
517195|NCT00263887|Drug|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
517196|NCT00263874|Drug|UK-500,001|
517197|NCT00263861|Procedure|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
517198|NCT00263835|Behavioral|Empowerment|
517199|NCT00263822|Drug|erlotinib hydrochloride|
517200|NCT00263809|Device|Pathogen Reduction Technology|
517201|NCT00263796|Drug|Oxytocin|10 international units = 1 cc, IV over 4 hours
517202|NCT00263796|Drug|Placebo|Normal Saline, IV over 4 hours
517203|NCT00263783|Drug|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. [As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.]
517204|NCT00263770|Device|soft palate implant|
517205|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
517206|NCT00263757|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
517207|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
517208|NCT00263744|Biological|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
517209|NCT00263744|Other|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
517210|NCT00263731|Other|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
517211|NCT00263718|Drug|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
517212|NCT00263705|Drug|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
517213|NCT00263705|Drug|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
517214|NCT00263692|Biological|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
517215|NCT00263679|Biological|Prophylaxis: Diphtheria, tetanus and pertussis|
517216|NCT00263666|Biological|Rotarix|Oral vaccination
517217|NCT00263666|Biological|Placebo|Oral administration
517218|NCT00263666|Biological|TritanrixTM-HB+Hib|Concomitant routine vaccination, IM administration
517219|NCT00263666|Biological|SabinPolioTM vaccine|Oral administration, concomitant routine vaccination
517220|NCT00263653|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
517221|NCT00263640|Biological|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
517222|NCT00263640|Drug|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
517223|NCT00263627|Biological|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
517224|NCT00263627|Other|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
517225|NCT00263601|Biological|Allergovit 6-grasses|Subcutaneous injections
517226|NCT00263601|Other|Placebo|Subcutaneous injections
517227|NCT00263588|Drug|lapatinib|tyrosine kinase inhibitor
517228|NCT00263575|Drug|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
517229|NCT00263562|Drug|Methylprednisolone plus prednisone taper|
517230|NCT00263549|Biological|House dust mite Novo Helisen Depot|
517231|NCT00263536|Procedure|Interpersonal Psychotherapy|
517232|NCT00263523|Drug|[11C] (-)-RWAY|
517233|NCT00263497|Device|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
517234|NCT00263484|Drug|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
517235|NCT00263484|Drug|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
517236|NCT00263484|Drug|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
517237|NCT00263471|Drug|7-methylxanthine|
517238|NCT00263458|Other|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
517478|NCT00261820|Drug|sirolimus|
517479|NCT00261807|Drug|Daptomycin 6mg/kg/day|
517240|NCT00263419|Behavioral|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
517241|NCT00263406|Drug|Administration of an ACE-inhibitor or not|
517242|NCT00263393|Drug|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
517243|NCT00263393|Behavioral|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
517244|NCT00263367|Other|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
517245|NCT00263354|Drug|Oxaliplatin|
517246|NCT00263341|Combination Product|NES/EE CVR|This is a Phase 3, multicenter, open-label study of a 21/7-day regimen of the 150/15 NES/EE CVR, in healthy women followed on an outpatient basis up to one year (13 cycles) of treatment over one year. Because of the stop treatment date of December 31, 2008 for all participants, women enrolling or re-enrolling in 2008 may not complete a full 13 cycles of treatment. Subjects may also participate in a 6 month follow-up period after the 300B study. The ring is designed to last for 12 months.
517247|NCT00263328|Drug|Tacrolimus|Standard of care
517248|NCT00263328|Drug|CP-690,550|CP-690,550 5 mg BID
517249|NCT00263328|Drug|CP-690,550|CP-690,550 10 mg BID
517250|NCT00263315|Drug|nebulised liposomal amphotericin B|
517251|NCT00263302|Drug|dexamethasone|
517252|NCT00263289|Procedure|preprocedural fasting|
517253|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
517254|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
517255|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
517256|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
517257|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
517258|NCT00263276|Drug|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
517259|NCT00263276|Drug|metformin|Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.
517260|NCT00263263|Device|sirolimus-eluting stent|
517261|NCT00263263|Device|bare metal stent|
517262|NCT00263250|Procedure|watchful waiting or tension-free hernia repair|
517263|NCT00263237|Drug|STA-5326|
517264|NCT00263211|Drug|Plavix|
517265|NCT00263211|Drug|Aspirin|
517266|NCT00263198|Drug|PTK787/ZK222584|
517267|NCT00263198|Drug|Letrozole|
517268|NCT00263185|Dietary Supplement|Vitamin D|
517269|NCT00263185|Dietary Supplement|Calcium carbonate|
517270|NCT00263185|Drug|Vitamin D|
517271|NCT00263185|Other|Placebo|
517272|NCT00263172|Behavioral|behavior modification for weight loss|
517273|NCT00263159|Procedure|Pharmaceutical care for asthma patients|
517274|NCT00263146|Procedure|recruitment maneuver|
517275|NCT00263133|Drug|Sertraline|
517276|NCT00263120|Behavioral|Pain Questionnaire|
517277|NCT00263107|Procedure|telerounding versus bedside rounding|
517278|NCT00263094|Drug|Rofecoxib|
517279|NCT00263081|Drug|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:~Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.~Cohort 2: Weight is more than 50 kg:~Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
517280|NCT00263081|Drug|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
517281|NCT00263068|Drug|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:~1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
517282|NCT00263055|Drug|oxaliplatin|
517283|NCT00263042|Drug|Rimonabant|Tablet, oral administration
517284|NCT00263042|Drug|Placebo (for Rimonabant)|Tablet, oral administration
517285|NCT00263029|Drug|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
517286|NCT00263029|Drug|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
517287|NCT00263029|Radiation|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
517288|NCT00263016|Drug|Docetaxel|
517289|NCT00263003|Drug|Irbesartan/hydrochlorothiazide|
517290|NCT00263003|Drug|Irbesartan|
517291|NCT00262990|Drug|EPO906 (Patupilone)|
517292|NCT00262990|Drug|doxorubicin|
517293|NCT00262977|Behavioral|Electronic prompt plus patient-directed intervention|
517294|NCT00262977|Behavioral|Electronic prompt to clinician to prescribe aspirin|
517295|NCT00262964|Drug|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
517296|NCT00262964|Drug|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
517297|NCT00262964|Drug|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
517298|NCT00262951|Biological|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
517299|NCT00262951|Drug|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
517300|NCT00262951|Drug|fluorouracil|administered at a dose of 175 mg/m^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
517301|NCT00262951|Radiation|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
517541|NCT00261261|Drug|Midazolam|
517542|NCT00261261|Procedure|Parental presence|
517302|NCT00262951|Procedure|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
517303|NCT00262938|Behavioral|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
517304|NCT00262938|Other|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
517305|NCT00262938|Other|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
517306|NCT00262938|Other|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
517307|NCT00262938|Procedure|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
517308|NCT00262925|Biological|alemtuzumab|Given subcutaneously
517309|NCT00262925|Drug|asparaginase|Given IM
517310|NCT00262925|Drug|methotrexate|Given IV or orally
517311|NCT00262925|Drug|dexamethasone|Given orally
517312|NCT00262925|Drug|leucovorin calcium|Given IV
517313|NCT00262925|Drug|mercaptopurine|Given orally
517314|NCT00262925|Drug|vincristine|Given IV
517315|NCT00262899|Behavioral|counseling intervention|
517316|NCT00262899|Other|educational intervention|
517317|NCT00262899|Procedure|psychosocial assessment and care|
517318|NCT00262886|Biological|anti-thymocyte globulin|
517319|NCT00262886|Biological|graft-versus-tumor induction therapy|
517320|NCT00262886|Biological|therapeutic allogeneic lymphocytes|
517321|NCT00262886|Drug|cyclophosphamide|
517322|NCT00262886|Drug|fludarabine phosphate|
517323|NCT00262886|Drug|mycophenolate mofetil|
517324|NCT00262886|Drug|tacrolimus|
517325|NCT00262886|Procedure|allogeneic bone marrow transplantation|
517326|NCT00262886|Procedure|peripheral blood stem cell transplantation|
517327|NCT00262873|Drug|bortezomib|
517328|NCT00262860|Drug|bortezomib|
517329|NCT00262860|Drug|gemcitabine hydrochloride|
517330|NCT00262847|Biological|Bevacizumab|Given IV
517331|NCT00262847|Drug|Carboplatin|Given IV
517332|NCT00262847|Other|Laboratory Biomarker Analysis|Correlative studies
517333|NCT00262847|Drug|Paclitaxel|Given IV
517334|NCT00262847|Other|Placebo|Given IV
517335|NCT00262847|Other|Quality-of-Life Assessment|Ancillary studies
517336|NCT00262834|Drug|vorinostat|Given orally, conventional surgery to follow.
517337|NCT00262834|Other|conventional surgery|Undergo conventional surgery
517338|NCT00262821|Drug|cisplatin|Given IV
517339|NCT00262821|Drug|tirapazamine|Given IV
517340|NCT00262808|Biological|sargramostim|
517341|NCT00262808|Drug|fluorouracil|
517342|NCT00262808|Drug|leucovorin calcium|
517343|NCT00262808|Drug|oxaliplatin|
517344|NCT00262808|Procedure|adjuvant therapy|
517345|NCT00262808|Procedure|conventional surgery|
517346|NCT00262808|Procedure|neoadjuvant therapy|
517347|NCT00262795|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
517348|NCT00262795|Drug|Chlorambucil|Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
517349|NCT00262782|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
517350|NCT00262769|Drug|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
517351|NCT00262769|Drug|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
517352|NCT00262743|Biological|Polyphenon E|"Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day~Phase II: 2000 mg orally twice a day"
517353|NCT00262730|Drug|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
517354|NCT00262730|Drug|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
517355|NCT00262730|Radiation|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
517356|NCT00262717|Device|HIV drug resistance tests based upon genotype testing|
517357|NCT00262704|Behavioral|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
517358|NCT00262704|Behavioral|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
517359|NCT00262678|Drug|EN3267|
517360|NCT00262665|Drug|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
517361|NCT00262665|Drug|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
517362|NCT00262652|Drug|sodium pyruvate|
517363|NCT00262639|Drug|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
517364|NCT00262639|Drug|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
517365|NCT00262626|Drug|Intraocular pressure reduction|
517366|NCT00262626|Procedure|Argon laser trabeculoplasty|
517367|NCT00262626|Procedure|Trabeculectomy|
517368|NCT00262613|Drug|sodium pyruvate in 0.9% sodium chloride solution|
517369|NCT00262600|Drug|warfarin|once a day
517370|NCT00262600|Drug|Dabigatran dose 1|twice daily
517371|NCT00262600|Drug|Dabigatran dose 2|twice a day
517372|NCT00262587|Drug|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
517373|NCT00262587|Drug|Placebo|Inhaled sugar powder in a placebo inhaler
517374|NCT00262574|Drug|Nesiritide,|PCI
517375|NCT00262561|Drug|Aspirin|The effect of Aspirin on platelet function was assessed.
517376|NCT00262548|Drug|Rosuvastatin; improvement of lipid profile|
517377|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
517378|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
517379|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
517380|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
517381|NCT00262509|Device|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
517382|NCT00262496|Drug|Botox|
517383|NCT00262483|Drug|VX-950|
517384|NCT00262483|Drug|ribavirin|
517385|NCT00262483|Drug|peginterferon alfa-2a|
517386|NCT00262470|Drug|Acetazolamide|250 mg PO x 1
517387|NCT00262470|Drug|Atomoxetine|10-40 mg PO x 1 dose
517388|NCT00262470|Other|NO Drug|No intervention - just monitoring
517389|NCT00262470|Drug|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
517390|NCT00262470|Drug|Entacapone|Entacapone 200-400 mg PO x 1 dose
517391|NCT00262470|Drug|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
517392|NCT00262470|Drug|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
517393|NCT00262470|Drug|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
517394|NCT00262470|Drug|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
517395|NCT00262470|Drug|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
517396|NCT00262470|Dietary Supplement|Melatonin|melatonin 3 mg PO x 1 dose
517397|NCT00262470|Drug|Midodrine|midodrine 2.5-10 mg PO x 1 dose
517398|NCT00262470|Drug|Modafinil|modafinil 100-200 mg PO x 1 dose
517399|NCT00262470|Drug|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
517400|NCT00262470|Radiation|Placebo|lactose tablet x 1 pill
517401|NCT00262470|Drug|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
517402|NCT00262470|Drug|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
517403|NCT00262470|Drug|Sertraline|sertraline 25-50 mg PO x 1 dose
517404|NCT00262470|Procedure|IV Saline|1 liter IV over 2 hours
517405|NCT00262470|Other|Drinking Water|16 fluid ounces
517406|NCT00262470|Device|Breathing Device|Breathing through a dead space tube
517407|NCT00262470|Drug|memantine|memantine 5-20 mg PO x 1 dose
517408|NCT00262470|Device|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
517409|NCT00262457|Device|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
517410|NCT00262444|Procedure|Different turning frequencies|
517411|NCT00262431|Procedure|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
517412|NCT00262418|Drug|Administration of ivermectin or permethrin|
517413|NCT00262405|Drug|zileuton|
517414|NCT00262405|Drug|azathioprine/prednisone|
517415|NCT00262392|Drug|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
517416|NCT00262379|Drug|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
517417|NCT00262366|Device|Comparison of automatic CPAP versus fixed CPAP|
517418|NCT00262353|Device|Dialysis with different artificial devices|
517419|NCT00262340|Other|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
517420|NCT00262327|Drug|Antangiogenesis|
517421|NCT00262327|Genetic|endostatin gene|
517422|NCT00262301|Drug|recombinant human C1 inhibitor|IV
517423|NCT00262301|Drug|Placebo|IV
517424|NCT00262288|Drug|i.v. recombinant human C1 inhibitor|
517425|NCT00262275|Drug|Aspirin, Clopidogrel|
517471|NCT00261846|Drug|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.~Part 2, 500 mg oral, continuous, daily dosing."
517472|NCT00261833|Biological|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
538013|NCT00002471|Drug|methylprednisolone|
517426|NCT00262262|Drug|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
517427|NCT00262249|Drug|somatropin|
517428|NCT00262236|Drug|Aliskiren|
517429|NCT00262223|Behavioral|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
517430|NCT00262223|Drug|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
517431|NCT00262223|Drug|Pill placebo|
517432|NCT00262210|Drug|Cyclophosphamide Epirubicin Etoposide Prednisolone|
517433|NCT00262197|Behavioral|Customized Physician Intervention|
517434|NCT00262197|Behavioral|Customized Patient Intervention|
517435|NCT00262184|Drug|Soy Isoflavone|
517436|NCT00262145|Drug|tea extracts|
517437|NCT00262132|Drug|Mycophenolate|
517438|NCT00262119|Device|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
517439|NCT00262106|Drug|PRO 2000/5|Gel
517440|NCT00262106|Drug|Placebo|Placebo
517441|NCT00262080|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
517442|NCT00262080|Drug|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
517443|NCT00262067|Drug|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
517444|NCT00262067|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
517445|NCT00262067|Drug|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.~Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle~Docetaxel 75-100 mg/m^2 IV~Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV~Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle~5-fluorouracil 500 mg/m^2 IV + epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV~5-fluorouracil 500 mg/m^2 IV + doxorubicin 50 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV~Doxorubicin 50-60 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV~Epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV~Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle"
517446|NCT00262054|Drug|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
517447|NCT00262054|Drug|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
517448|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
517449|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
517450|NCT00262041|Biological|MenACWY polysaccharide vaccine|
517451|NCT00262028|Biological|MenACWY-CRM Vaccine|
517452|NCT00262028|Biological|MenACWY-PS Vaccine|
517453|NCT00262015|Biological|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
517454|NCT00262002|Biological|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
517455|NCT00262002|Biological|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
517456|NCT00262002|Biological|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
517457|NCT00262002|Biological|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
517458|NCT00262002|Biological|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
517459|NCT00262002|Biological|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
517460|NCT00262002|Biological|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
517461|NCT00262002|Biological|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
517462|NCT00261976|Drug|Infliximab (Remicade)|This is an non-interventional study. Participants took the study product as part of their medical routine.
517463|NCT00261963|Device|ultraviolet light|
517464|NCT00261950|Drug|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
517465|NCT00261937|Drug|Inhaled Furosemide vs Placebo (Normal Saline)|
517466|NCT00261924|Device|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
517467|NCT00261911|Drug|sibutramine|
517468|NCT00261898|Procedure|Increase sleep|
517469|NCT00261872|Drug|Methylphenidate|
517470|NCT00261859|Behavioral|BNI|behavioral- brief intervention
517473|NCT00261833|Other|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
517480|NCT00261794|Behavioral|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
517481|NCT00261794|Behavioral|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
517482|NCT00261781|Behavioral|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
517483|NCT00261768|Behavioral|Digital noise reduction|
517484|NCT00261755|Procedure|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
517485|NCT00261755|Other|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
517486|NCT00261755|Other|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
517487|NCT00261742|Drug|Penicillin versus cefuroxim per os|
517488|NCT00261729|Drug|Paroxetine|paroxetine 20 mg
517489|NCT00261729|Drug|Prazosin|Prazosin
517490|NCT00261729|Drug|placebo|placebo capsules
517491|NCT00261716|Behavioral|IPS|Individual Placement and Support Evidence based supported employment
517492|NCT00261716|Behavioral|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
517493|NCT00261716|Behavioral|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
517494|NCT00261703|Drug|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
517495|NCT00261703|Drug|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
517496|NCT00261703|Other|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
517497|NCT00261690|Behavioral|Virtual Reality Distraction|Using virtual reality distraction during a procedure
517498|NCT00261677|Drug|epoetin alfa|
517499|NCT00261664|Device|telehomecare|
517500|NCT00261625|Drug|alendronate|
517501|NCT00261612|Drug|bortezomib|
517502|NCT00261612|Drug|rituximab|
517503|NCT00261612|Drug|dexamethasone|
517504|NCT00261612|Procedure|treatment protocol|
517505|NCT00261599|Drug|AQUAVAN® (fospropofol disodium) Injection|
517506|NCT00261599|Drug|Midazolam HCI|
517507|NCT00261586|Drug|aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib|
517508|NCT00261573|Drug|galantamine hydrobromide|
517509|NCT00261560|Drug|acetaminophen|
517510|NCT00261547|Drug|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
517511|NCT00261521|Drug|epoetin alfa|
517512|NCT00261508|Drug|risperidone|
517513|NCT00261495|Drug|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
517514|NCT00261495|Drug|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
517515|NCT00261482|Drug|norelgestromin + ethinyl estradiol|
517516|NCT00261469|Drug|topiramate|
517517|NCT00261456|Behavioral|PSA test|Patients tested for their level of Prostate Specific Antigen.
517518|NCT00261456|Procedure|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
517519|NCT00261443|Drug|Lithium or Valproate with placebo (PBO)|"Tablets, Oral, once daily~lithium 250-2100 mg/day~valproate 250-2500mg/day~Placebo once daily"
517520|NCT00261443|Drug|Lithium or Valproate with Aripiprazole|"Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)~lithium 250-2100 mg/day~valproate 250-2500mg/day~aripiprazole 15-30 mg/day"
517521|NCT00261430|Behavioral|GAIN Acceptance Approach|
517522|NCT00261417|Drug|Tesaglitazar|
517523|NCT00261404|Drug|TNFerade™|
517524|NCT00261391|Drug|Marimastat|
517525|NCT00261378|Device|Transarterialchemoembolisation (TACE)|
517526|NCT00261378|Device|DC Bead with Doxorubicin|
517527|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
517528|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
517529|NCT00261352|Drug|Tesaglitazar|
517530|NCT00261352|Drug|Metformin|
517531|NCT00261352|Drug|Fenofibrate|
517532|NCT00261339|Drug|Pantoprazole|
517533|NCT00261326|Drug|simvastatin|80 mg once daily
517534|NCT00261326|Drug|placebo|calcium tablets once daily
517535|NCT00261313|Drug|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
517536|NCT00261313|Drug|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
517537|NCT00261300|Drug|Pantoprazole|Long term Pantoprozole trial
517538|NCT00261287|Drug|Ciclesonide|
517539|NCT00261274|Procedure|Enzyme converted ECO red blood cells|
517540|NCT00261261|Behavioral|ADVANCE|
517543|NCT00261248|Biological|Immunization with inactivated bacteria|
517544|NCT00261235|Behavioral|Supported Employment|
517545|NCT00261235|Behavioral|Using Strengths in Employment System (USES)|
517546|NCT00261222|Drug|Amodiaquine|
517547|NCT00261209|Drug|Collagenase|Collagenase injection into adhesion restricting tendon gliding
517548|NCT00261209|Drug|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
517549|NCT00261196|Drug|Collagenase|Anterior shoulder capsule injection
517550|NCT00261183|Drug|Melatonin|
517551|NCT00261170|Drug|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
517552|NCT00261170|Other|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
517553|NCT00261157|Device|InTouch Telerounding Robot|
517554|NCT00261144|Drug|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
517555|NCT00261144|Biological|Biological|Collagenase injection
517556|NCT00261131|Drug|Botulinum Toxin A|
517557|NCT00261118|Drug|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
517558|NCT00261105|Drug|telithromycin|
517559|NCT00261092|Drug|Oxaliplatin|
517560|NCT00261079|Drug|Fexofenadine|
517561|NCT00261053|Drug|i.v. recombinant human C1 inhibitor|
517562|NCT00261040|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
517563|NCT00261040|Procedure|Standard|standard approach hip surgery
517564|NCT00261027|Drug|Exemestane|
517565|NCT00261001|Biological|Transcutaneous mode of administration|
517566|NCT00261001|Biological|Intramuscular mode of administration|
517567|NCT00260988|Drug|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
517568|NCT00260988|Drug|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
517569|NCT00260962|Drug|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
517570|NCT00260962|Behavioral|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
517571|NCT00260949|Procedure|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
517572|NCT00260923|Drug|aliskiren|
517573|NCT00260884|Behavioral|conventional gastrectomy or radical lymph node dissection|
517574|NCT00260858|Drug|Test Meal: Reference food (glucose or white bread)|
517575|NCT00260858|Drug|Test Meal: Pirate's Booty|
517576|NCT00260858|Drug|Test Meal: Ceaprove wafer|
517577|NCT00260858|Drug|Test Meal: Stretch Island Strawberry Fruit Leather|
517578|NCT00260832|Drug|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one intervention.)
517579|NCT00260832|Drug|Dacogen (decitabine) only|20mg/m^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
517580|NCT00260819|Drug|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
517581|NCT00260819|Drug|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
517582|NCT00260793|Drug|Ropinirole Hydrochloride|
517583|NCT00260780|Behavioral|The MISTERS Intervention for Post Jail Release Men|
517584|NCT00260767|Drug|HEC placebo gel|
517585|NCT00260754|Behavioral|Community-Popular Opinion Leader Model|
517586|NCT00260754|Behavioral|Diffusion of Innovations|
517587|NCT00260741|Drug|Smoked Cannabis|
517588|NCT00260728|Device|vascular access graft implantation|vascular access graft implantation
517589|NCT00260715|Behavioral|Community-Popular Opinion Leader Model|
517590|NCT00260715|Behavioral|Diffusion of Innovations|
517591|NCT00260702|Drug|Omalizumab (Xolair)|
517592|NCT00260689|Biological|Anti-thymocyte globulin (rabbit)|
517593|NCT00260689|Biological|Anti-thymocyte globulin (horse)|
517594|NCT00260689|Drug|Cyclosporine|
517595|NCT00260689|Drug|Alemtuzumab|
517596|NCT00260676|Procedure|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
517597|NCT00260663|Procedure|Group hearing aid fittings|
517598|NCT00260663|Procedure|Group hearing aid follow-up|
517599|NCT00260650|Behavioral|Heart PACT Program|patient activation intervention
517600|NCT00260637|Procedure|Acupuncture|
517601|NCT00260624|Drug|Escitalopram (Lexapro)|
517602|NCT00260611|Drug|Oxaliplatin|
517603|NCT00260611|Drug|Taxotere|
517604|NCT00260598|Procedure|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
517605|NCT00260585|Procedure|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
517606|NCT00260585|Procedure|Blood specimen for non-DNA and DNA parts|Blood specimen is collected prior to surgery or at the time of scheduled routine surgical procedure(s), and at the time of routine follow-up visits
517607|NCT00260585|Procedure|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
517608|NCT00260585|Procedure|Biopsies from routine clinical surveillance endoscopies|Tissue from the biopsies is collected intraoperatively.
517609|NCT00260572|Behavioral|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
517668|NCT00260052|Drug|Erythropoietin administration|
517610|NCT00260572|Behavioral|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
517611|NCT00260572|Behavioral|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
517612|NCT00260572|Behavioral|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
517613|NCT00260559|Procedure|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
517614|NCT00260546|Procedure|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
517615|NCT00260533|Drug|atomoxetine|Flexible dose, up to 50 mg per day
517616|NCT00260533|Drug|placebo|placebo (matching to atomoxetine)
517617|NCT00260520|Drug|Dalteparin|
517618|NCT00260494|Other|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
517619|NCT00260494|Other|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
517620|NCT00260481|Drug|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
517621|NCT00260481|Drug|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
517622|NCT00260468|Other|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
517623|NCT00260442|Behavioral|Resistance Training|12 weeks, 3 times a week whole body resistance training
517624|NCT00260442|Behavioral|Sedentary|Absence of physical activity
517625|NCT00260429|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
517626|NCT00260416|Procedure|Primary angioplasty with stent and abciximab|
517627|NCT00260403|Procedure|Photodynamic therapy versus Transpupillary thermotherapy|
517628|NCT00260390|Drug|Testoviron|
517629|NCT00260377|Procedure|Coronary artery bypass surgery|
517630|NCT00260364|Drug|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
517631|NCT00260364|Drug|Capecitabine orally days 1 -21|
517632|NCT00260364|Drug|Erlotinib 100 mg orally days 1-28|
517633|NCT00260364|Drug|Bevacizumab 5 mg/kg intravenously every 2 weeks|
517634|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
517635|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
517636|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
517637|NCT00260338|Biological|stem cell|mesenchymal stromal cell
517638|NCT00260325|Drug|valdecoxib|
517639|NCT00260312|Biological|Inactivated Polio Vaccine given at an accelerated schedule|
517640|NCT00260286|Behavioral|Energy availability|
517641|NCT00260273|Behavioral|Cognitive Behaviour Therapy|therapy
517642|NCT00260260|Drug|Oxycodone|
517643|NCT00260247|Drug|carbamazepine oxcarbazepine|
517644|NCT00260234|Biological|Allogeneic Cultured Islet Cells (human); Encapsulated|
517645|NCT00260221|Behavioral|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
517646|NCT00260208|Drug|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
517647|NCT00260208|Drug|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
517648|NCT00260195|Behavioral|School-based cognitive behavioral support group|
517649|NCT00260169|Behavioral|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
517650|NCT00260169|Behavioral|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
517651|NCT00260156|Drug|vildagliptin|
517652|NCT00260156|Drug|placebo|
517653|NCT00260143|Drug|Testosterone enanthate|
517654|NCT00260143|Drug|Placebo|
517655|NCT00260130|Other|food in fluid form|dietary intake of fluid forms of vegetables
517656|NCT00260130|Other|food in solid form|dietary intake of solid forms of vegetables
517657|NCT00260117|Behavioral|Exercise|Referal to a website
517658|NCT00260091|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
517659|NCT00260091|Procedure|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
517660|NCT00260078|Drug|Atazanavir|200 mg to 400 mg orally daily
517661|NCT00260078|Drug|Darunavir|300 mg or 600 mg orally twice daily
517662|NCT00260078|Drug|Efavirenz|Dosage dependent on participant
517663|NCT00260078|Drug|Nevirapine|Dosage dependent on participant
517664|NCT00260078|Drug|Ritonavir|50 mg or 100 mg orally twice daily
517665|NCT00260078|Drug|Tenofovir disoproxil fumarate|300 mg orally daily
517666|NCT00260078|Procedure|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
517667|NCT00260065|Drug|Decitabine|20mg/m^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
517669|NCT00260039|Biological|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
517670|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
517671|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
517672|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
517673|NCT00260026|Drug|Docetaxel|
517674|NCT00260026|Drug|Jin Fu Kang|
517675|NCT00260013|Procedure|program of care delivery|
517676|NCT00260000|Drug|5,6,7,8-tetrahydrobiopterin|
517677|NCT00259987|Drug|Lapatinib (GW572016) oral tablets|
517678|NCT00259974|Drug|Rituximab|Rituximab
517679|NCT00259961|Procedure|open fundoplication|
517680|NCT00259961|Procedure|laparoscopic fundopliaction|
517681|NCT00259948|Procedure|Aerobic exercise training|
517682|NCT00259935|Drug|topotecan|topotecan
517683|NCT00259922|Drug|Placebo|Placebo
517684|NCT00259922|Drug|Alvimopan|0.5 mg QD
517685|NCT00259922|Drug|Alviompan|0.5 mg BID
517686|NCT00259909|Other|GSK questionnaire|GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
517687|NCT00259909|Other|St. George's Respiratory Questionnaire|The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
517688|NCT00259909|Other|Acute Short Form 12 version 2|The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
517689|NCT00259909|Other|Global Efficacy questionnaire|Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
517690|NCT00259896|Drug|exenatide|
517691|NCT00259883|Drug|paroxetine|1 or 2 tablets once a day
517692|NCT00259870|Drug|SB-773812|
517693|NCT00259870|Drug|Olanzapine|
517694|NCT00259857|Drug|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
517695|NCT00259844|Biological|TroVax|
517696|NCT00259831|Drug|CVT-E002 (Cold-FX); a natural health product|
517697|NCT00259818|Drug|EM-1421|
517698|NCT00259805|Drug|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
517699|NCT00259792|Drug|Budesonide/formoterol Turbuhaler|
517700|NCT00259779|Drug|budesonide/formoterol|
517701|NCT00259779|Drug|Prednisolone|
517702|NCT00259766|Drug|Budesonide|
517703|NCT00259766|Drug|Formoterol|
517704|NCT00259766|Drug|Terbutaline|
517705|NCT00259753|Drug|Bevasiranib|
517706|NCT00259740|Drug|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
517707|NCT00259714|Drug|dialysate sodium individualization|"Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
517708|NCT00259714|Drug|standard dialysate sodium|The prescribed dialysate sodium is 140 mEq/L
517709|NCT00259701|Device|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
517710|NCT00259688|Device|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
517711|NCT00259675|Drug|carboplatin/gemcitabine, carboplatin/taxol|
517712|NCT00259662|Drug|atorvastatin|
517713|NCT00259649|Drug|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
517714|NCT00259636|Drug|zonisamide|zonisamide 100 mg -300 mg daily vs placebo
517715|NCT00259623|Device|Radiofrequency ablation|
517716|NCT00259610|Drug|methotrexate|varies
517717|NCT00259610|Drug|sulfasalazine|varies
517718|NCT00259610|Drug|hydroxychloroquine|varies
517719|NCT00259610|Drug|etanercept|varies
517720|NCT00259597|Procedure|breast ductal lavage|breast ductal lavage and nipple aspiration done once
517721|NCT00259584|Behavioral|Management and Outcome of SVCO|
517722|NCT00259571|Drug|retarded release phosphatidylcholine|2g daily, given orally QTD
517723|NCT00259558|Drug|retarded release phosphatidylcholine|
517724|NCT00259545|Drug|Retarded Release Phosphatidylcholine (rPC)|
517725|NCT00259532|Procedure|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
517726|NCT00259519|Procedure|Induction of delivery|Induction of delivery
517727|NCT00259506|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|
517728|NCT00259493|Procedure|Off-Pump Coronary Artery Bypass Graft Surgery|
517729|NCT00259480|Behavioral|Home Based Intervention|occupational therapy
517730|NCT00259467|Behavioral|Home-Based Behavorial Intervention|
517731|NCT00259454|Behavioral|In-home intervention|occupational therapy techniques to reduce caregiver stress
517732|NCT00259441|Drug|Simvastatin|
517733|NCT00259428|Drug|Dronedarone (SR33589)|oral administration
517734|NCT00259428|Drug|placebo|oral administration
517735|NCT00259415|Behavioral|Caregiver support via telephone|
517736|NCT00259402|Drug|Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)|OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
517737|NCT00259389|Behavioral|Directly observed therapy (DOT)|
517738|NCT00259376|Drug|Dronedarone (SR33589)|oral administration
517739|NCT00259376|Drug|placebo|oral administration
517740|NCT00259363|Drug|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
517741|NCT00259350|Drug|Skin disinfection|
517742|NCT00259337|Biological|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
517743|NCT00259324|Behavioral|Diet and Activity|Diet and Activity
517744|NCT00259311|Drug|LY2422347|
517745|NCT00259311|Drug|placebo|
517746|NCT00259298|Drug|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
517747|NCT00259285|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
517748|NCT00259285|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 3 cycles
517749|NCT00259272|Drug|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
517750|NCT00259259|Behavioral|SALATRIM|
517751|NCT00259246|Drug|Peptide YY infusion|
517752|NCT00259233|Drug|peripheral Peptide YY administration|
517753|NCT00259220|Drug|erythomycin|erythomycin
517754|NCT00259220|Procedure|gastric lavage alone|gastric lavage alone
517755|NCT00259220|Procedure|erythromycine and gastric lavage|erythromycine and gastric lavage
517756|NCT00259207|Procedure|Pulmonary valve insertion|Pulmonary valve insertion
517757|NCT00259207|Procedure|medical surgery hybride|medical surgery hybride
517758|NCT00259194|Behavioral|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
517759|NCT00259194|Behavioral|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
517760|NCT00259181|Procedure|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
517761|NCT00259168|Drug|Nateglinide|
517762|NCT00259155|Drug|Rifaximin|
517763|NCT00259142|Drug|Chloroquine, sulphadoxine-pyrimethamine|
517764|NCT00259129|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
517765|NCT00259116|Drug|Relaxin|
517766|NCT00259103|Drug|Serelaxin|
517767|NCT00259103|Drug|Placebo|
517768|NCT00259090|Drug|Fulvestrant|500 mg intramuscular injection
517769|NCT00259090|Drug|Anastrazole|oral tablet
517770|NCT00259077|Drug|Omeprazole|
517771|NCT00259064|Drug|Gefitinib|
517772|NCT00259064|Other|Placebo|
517773|NCT00259051|Drug|Omeprazole|
517774|NCT00259038|Drug|Carperitide|
517775|NCT00259038|Drug|Placebo|
517776|NCT00259025|Drug|lipid emulsion with a high content of n-3 fatty acids|
517777|NCT00259012|Drug|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
517778|NCT00258999|Device|Skin Cholesterol Testing|
517779|NCT00258986|Procedure|Living donornephrectomy|
517780|NCT00258973|Procedure|Carotid Ultrasound performed in office practice|
517781|NCT00258960|Drug|Liposomal Doxorubicin|
517782|NCT00258960|Drug|Cyclophosphamide|
517783|NCT00258960|Drug|Trastuzumab|
517784|NCT00258947|Biological|Smallpox vaccine, LISTER strain, from chick embryo cells|
517785|NCT00258934|Biological|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
517786|NCT00258934|Biological|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
517787|NCT00258908|Biological|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
517788|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
517789|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
517790|NCT00258882|Biological|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
517791|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
517792|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
517793|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
517794|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
517795|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
517796|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, IM
517797|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
517798|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
517799|NCT00258817|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
517800|NCT00258817|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
517801|NCT00258804|Drug|Insulin glargine|
517802|NCT00258791|Drug|Ibuprofen|
517803|NCT00258778|Drug|Human Glucocerebrosidase (prGCD)|
517804|NCT00258765|Drug|Zoledronic Acid|
517805|NCT00258765|Drug|Docetaxel|
517806|NCT00258752|Behavioral|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
517807|NCT00258752|Other|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
517808|NCT00258752|Other|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
518060|NCT00256776|Drug|Thalidomide|
517809|NCT00258739|Drug|Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine|Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
517810|NCT00258739|Other|Docetaxel + gemcitabine + carboplatin + radiotherapy|Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
517811|NCT00258726|Biological|MMR-II|
517812|NCT00258726|Biological|Pro-Quad|
517813|NCT00258726|Biological|Varivax|
517814|NCT00258713|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
517815|NCT00258700|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
517816|NCT00258687|Biological|GVAX|4 vaccines every two weeks
517817|NCT00258674|Other|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
517818|NCT00258674|Other|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
517819|NCT00258674|Other|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
517820|NCT00258661|Procedure|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
517821|NCT00258661|Procedure|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
517822|NCT00258635|Biological|RagweedMATAMPL|
517823|NCT00258622|Drug|NS1209|
517824|NCT00258622|Drug|Lidocaine|
517825|NCT00258609|Drug|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
517826|NCT00258596|Device|sirolimus-eluting stent|
517827|NCT00258557|Drug|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
517828|NCT00258557|Drug|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
517829|NCT00258531|Device|Olympus ScopeGuide®, 3-dimentional magnetic imager|
517830|NCT00258518|Procedure|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
517831|NCT00258505|Procedure|Procedure: intracranial monitoring up to 9 days after injury|
517832|NCT00258492|Behavioral|Aerobic exercise|
517833|NCT00258479|Drug|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
517834|NCT00258479|Drug|Modafinil|See Modafinil Intervention Description above.
517835|NCT00258466|Radiation|radiation therapy|
517836|NCT00258453|Other|metabolic assessment|
517837|NCT00258453|Other|physiologic testing|
517838|NCT00258453|Procedure|biopsy|
517839|NCT00258453|Procedure|computed tomography|
517840|NCT00258453|Procedure|conventional surgery|
517841|NCT00258453|Procedure|magnetic resonance imaging|
517842|NCT00258453|Procedure|management of therapy complications|
517843|NCT00258453|Procedure|psychosocial assessment and care|
517844|NCT00258453|Procedure|quality-of-life assessment|
517845|NCT00258453|Radiation|radiation therapy|
517846|NCT00258440|Drug|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
517847|NCT00258440|Drug|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
517848|NCT00258427|Biological|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
517849|NCT00258427|Biological|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10^9/L)
517850|NCT00258427|Drug|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if <4 years old)
517851|NCT00258427|Drug|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
517852|NCT00258427|Drug|fludarabine phosphate|35 mg/m^2 intravenously (IV) on Days -5 through -2.
517853|NCT00258427|Drug|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
517854|NCT00258427|Biological|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
517855|NCT00258401|Dietary Supplement|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
517856|NCT00258401|Procedure|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
517857|NCT00258401|Procedure|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
517858|NCT00258388|Drug|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)~Subsequent cycles:~weekly on days 1, 8, 15 (3 week cycles)"
517859|NCT00258388|Drug|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
517860|NCT00258388|Drug|prednisone|5mg PO BID
517861|NCT00258375|Drug|custirsen sodium|
517862|NCT00258375|Drug|docetaxel|
517863|NCT00258362|Drug|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
517864|NCT00258362|Drug|docetaxel|75 mg/m^2 on Day 1 of each course
517865|NCT00258362|Radiation|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
517866|NCT00258349|Drug|vorinostat|Given orally
517867|NCT00258349|Drug|trastuzumab|Given IV
517868|NCT00258336|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
517869|NCT00258336|Biological|rituximab|
517870|NCT00258336|Biological|sargramostim|
517871|NCT00258323|Drug|cisplatin|20mg/m2d/IV continuous infusion x days
517872|NCT00258323|Drug|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
517873|NCT00258323|Drug|Iressa|250mg po qd days 1-28 then x 2 years
517874|NCT00258323|Procedure|conventional surgery|conventional surgery
517875|NCT00258323|Radiation|radiation therapy|150 cGy bid
517876|NCT00258310|Drug|capecitabine|Capecitabine 1000mg/day for one year
517877|NCT00258310|Procedure|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
517878|NCT00258297|Drug|gefitinib|
517879|NCT00258297|Procedure|conventional surgery|
517880|NCT00258297|Procedure|enzyme inhibitor therapy|
517881|NCT00258297|Procedure|neoadjuvant therapy|
517882|NCT00258297|Procedure|protein tyrosine kinase inhibitor therapy|
517883|NCT00258297|Procedure|surgery|
517884|NCT00258284|Drug|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
517885|NCT00258284|Drug|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
517886|NCT00258271|Biological|filgrastim|
517887|NCT00258271|Drug|cladribine|
517888|NCT00258271|Drug|cytarabine|
517889|NCT00258271|Drug|imatinib mesylate|
517890|NCT00258258|Drug|paricalcitol|
517891|NCT00258258|Drug|zoledronic acid|
517892|NCT00258245|Dietary Supplement|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11
517893|NCT00258245|Drug|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
517894|NCT00258245|Drug|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
517895|NCT00258245|Drug|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
517896|NCT00258245|Drug|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
517897|NCT00258245|Drug|Aspirin|Aspirin - 325 mg by mouth (PO) every day
517898|NCT00258232|Drug|capecitabine|
517899|NCT00258232|Drug|celecoxib|
517900|NCT00258232|Drug|irinotecan hydrochloride|
517901|NCT00258206|Biological|rituximab|
517902|NCT00258206|Drug|cyclophosphamide|
517903|NCT00258193|Drug|MD-1100 Acetate|
517904|NCT00258180|Biological|filgrastim|Administered IV or subcutaneously once daily beginning on day 10 and continuing for 3 days or until blood counts recover
517905|NCT00258180|Drug|cyclophosphamide|Administered IV over 1 hour on days 1-4
517906|NCT00258167|Behavioral|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
517907|NCT00258154|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
517908|NCT00258154|Biological|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
517909|NCT00258154|Biological|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
517910|NCT00258141|Drug|Rupatadine|
517911|NCT00258141|Drug|Placebo|
517912|NCT00258128|Drug|Salsalate|Active
517913|NCT00258128|Drug|Placebo|Placebo for salslate, used only in the third trial
517914|NCT00258115|Drug|salsalate|
517915|NCT00258102|Drug|Levofloxacin|
517916|NCT00258089|Drug|Levofloxacin|
517917|NCT00258076|Drug|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
517918|NCT00258063|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
517919|NCT00258050|Drug|Midazolam|Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
517920|NCT00258050|Drug|Lapatinib|Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
517921|NCT00258037|Behavioral|Pelvic Floor Muscle training|
517922|NCT00258024|Drug|IPT-sulphadoxinepyrimethamine|
517923|NCT00258011|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
517924|NCT00257998|Procedure|Mobilization|manualtherapy techniques
517925|NCT00257985|Drug|GTN|
517926|NCT00257972|Drug|aripiprazole|
517927|NCT00257959|Drug|amiodarone beta blocker sotalol|
517928|NCT00257946|Procedure|Repair of CDH w/SIS Gold|
517929|NCT00257946|Procedure|Repair of CDH w/Alloderm|
518061|NCT00256776|Drug|Dexamethasone|
517930|NCT00257933|Drug|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
517931|NCT00257933|Drug|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
517932|NCT00257920|Drug|Zemplar® injection|6 mcg QOD
517933|NCT00257920|Drug|Hectorol® injection|3.6 mcg QOD
517934|NCT00257894|Drug|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
517935|NCT00257894|Drug|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
517936|NCT00257881|Drug|CMD-193|
517937|NCT00257868|Drug|Rivastigmine prevention of delirium|
517938|NCT00257855|Drug|Lamotrigine|
517939|NCT00257842|Procedure|Standard treatment, sham feedback and biofeedback therapy|
517940|NCT00257829|Drug|Methazolamide|
517941|NCT00257829|Drug|Cisplatin|
517942|NCT00257816|Drug|Topotecan|"(First stage of accrual, 6 patients)-2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)~If none or 1 of the 6 patients in the first Stage of accrual finish the prescribed therapy in over 8 weeks, then the second Stage of accrual (an additional 6 patients) will increase the Topotecan dose to 3 mg/m2 on days 1, 8, 15, 22, 29 and once during parametrical boost (6 cycles). If 2 or 3 of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, the dose of the Topotecan will remain the same in the second Phase of accrual. If 4 or more of the patients in the first stage of accrual finish the prescribed therapy in over 8 weeks, there will be no second phase of accrual."
517943|NCT00257816|Drug|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
517944|NCT00257803|Drug|Oxytocin|See detailed description
517945|NCT00257803|Drug|Saline solution|See detailed description
517946|NCT00257790|Drug|Tobramycin once a day|
517947|NCT00257777|Procedure|Myocardial protection techniques|
517948|NCT00257764|Behavioral|behavioral swallowing exercises/ strategies|
517949|NCT00257751|Procedure|Aprotinine|
517950|NCT00257738|Biological|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
517951|NCT00257738|Biological|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
517952|NCT00257725|Drug|Ritalin LA™|
517953|NCT00257712|Drug|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
517954|NCT00257699|Drug|Metronidazole placebo|
517955|NCT00257699|Drug|ciprofloxacin placebo|
517956|NCT00257699|Drug|ciprofloxacin|500 mg bid po
517957|NCT00257699|Drug|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
517958|NCT00257686|Drug|Pitavastatin|
517959|NCT00257686|Drug|Pravastatin|
517960|NCT00257673|Drug|MEM 1003|30 mg twice a day
517961|NCT00257673|Drug|MEM 1003|90 mg MEM 1003 twice a day
517962|NCT00257673|Drug|Placebo for MEM 1003|Placebo twice a day
517963|NCT00257660|Biological|Botulinum toxin type A|500 units
517964|NCT00257660|Drug|Placebo|500 units
517965|NCT00257647|Other|SV40 vectors carrying siRNA|in vitro only use of gene therapy
517966|NCT00257634|Drug|dexamethasone to injury site|
517967|NCT00257621|Drug|GW640385|
517968|NCT00257621|Drug|Ritonavir|
517969|NCT00257608|Drug|bevacizumab|Intravenous repeating dose
517970|NCT00257608|Drug|placebo|Oral repeating dose
517971|NCT00257608|Drug|erlotinib HCl|Oral repeating dose
517972|NCT00257595|Drug|Cetirizine Dry Syrup|
517973|NCT00257582|Drug|Cetirizine Dry Syrup|
517974|NCT00257569|Drug|Cetirizine Dry Syrup|
517975|NCT00257556|Drug|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
517976|NCT00257556|Drug|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
517977|NCT00257543|Procedure|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
517978|NCT00257530|Drug|Imiquimod|
517979|NCT00257491|Drug|Telmisartan|
517980|NCT00257491|Drug|Telmisartan/HCTZ|
517981|NCT00257478|Drug|YM155|
517982|NCT00257465|Biological|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
517983|NCT00257465|Biological|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
517984|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|2.5 million cells
517985|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0.5 million cells
517986|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0 cells
517987|NCT00257452|Drug|tiotropium 18 mcg or 54 mcg qd|
517988|NCT00257452|Drug|placebo matching tiotropium qd|
517989|NCT00257452|Drug|moxifloxacin 200 mg|
517990|NCT00257426|Drug|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
517991|NCT00257413|Procedure|Transplantation of autologous endothelial progenitor cells|
517992|NCT00257400|Behavioral|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
517993|NCT00257400|Behavioral|Individual Psychotherapy|Individual Psychotherapy
517994|NCT00257387|Drug|Cyclosporine|
517995|NCT00257374|Drug|Gatorade, Pedialyte and New Solution|
517996|NCT00257361|Drug|D-Cycloserine|
517997|NCT00257348|Drug|Capecitabine|
517998|NCT00257348|Drug|Docetaxel|
517999|NCT00257335|Procedure|IMRT|
518000|NCT00257322|Drug|GM-CSF|250ug/m^2 SQ QD with a cap of 500mcg SQ QD
518001|NCT00257309|Drug|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
518002|NCT00257309|Procedure|Primary angioplasty|
518197|NCT00255710|Radiation|radiation therapy|
518003|NCT00257296|Other|Screening and Intervention|Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient
518004|NCT00257296|Other|Usual Care|Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
518005|NCT00257283|Drug|Omega-3-acid ethyl esters 90|
518006|NCT00257270|Drug|gabapentin|
518007|NCT00257257|Drug|Rimonabant (SR141716)|
518008|NCT00257218|Behavioral|Life style modification|
518009|NCT00257205|Drug|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
518010|NCT00257205|Drug|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
518011|NCT00257205|Drug|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
518012|NCT00257192|Drug|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
518013|NCT00257192|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
518014|NCT00257166|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
518015|NCT00257166|Drug|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
518016|NCT00257153|Device|Coronary thrombus aspiration catheter|
518017|NCT00257140|Drug|levofloxacin|
518018|NCT00257127|Biological|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
518019|NCT00257127|Biological|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
518020|NCT00257127|Biological|Hepatitis B vaccine|0.5 mL administered intramuscularly
518021|NCT00257127|Biological|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
518022|NCT00257114|Drug|bortezomib|
518023|NCT00257101|Behavioral|self-medication monitoring|
518024|NCT00257088|Behavioral|whole day first grade program|
518025|NCT00257075|Drug|Risperidone, oral tablets|
518026|NCT00257062|Drug|Levofloxacin|
518027|NCT00257049|Drug|levofloxacin|
518028|NCT00257036|Drug|levofloxacin|
518029|NCT00257023|Drug|paliperidone|
518030|NCT00257010|Drug|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
518031|NCT00256997|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
518032|NCT00256997|Drug|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
518033|NCT00256984|Procedure|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
518034|NCT00256971|Procedure|meniscectomy|
518035|NCT00256958|Procedure|total knee replacement|
518036|NCT00256945|Procedure|dental restorative material surface preparation|
518037|NCT00256932|Drug|alvimopan|0.5 mg
518038|NCT00256932|Drug|Placebo|
518039|NCT00256919|Drug|GW856553|
518040|NCT00256893|Drug|ropinirole|
518041|NCT00256880|Drug|GW786034|
518042|NCT00256867|Drug|GSK523338|
518043|NCT00256854|Drug|Ropinirole IR 1 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 1.0mg of active drug substance.
518044|NCT00256854|Drug|Ropinirole IR 2 mg|Ropinirole IR (SKF-101468) will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2.0mg of active drug substance.
518045|NCT00256854|Drug|Ropinirole IR 1 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 1 mg.
518046|NCT00256854|Drug|Ropinirole IR 2 mg Placebo|Ropinirole IR (SKF-101468) placebo will be supplied in the form of a 7mm round bi-convex white film coated tablet, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
518047|NCT00256854|Drug|Ropinirole CR 2 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 2mg of the active drug substance.
518048|NCT00256854|Drug|Ropinirole CR 3 mg|Ropinirole CR Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing ropinirole hydrochloride equivalent to 3mg of the active drug substance.
518049|NCT00256854|Drug|Ropinirole CR 2 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 2 mg.
518050|NCT00256854|Drug|Ropinirole CR 3 mg Placebo|Ropinirole CR placebo Tablets are presented as 7 mm round, bi-convex, white film coated tablets, de-bossed with 'GS' on both faces, containing matching placebo tablets of 3 mg.
518051|NCT00256841|Drug|Chemotherapy|
518052|NCT00256841|Procedure|Radiation Therapy|
518053|NCT00256828|Drug|didanosine + lamivudine + efavirenz|
518054|NCT00256815|Drug|chemotherapy|
518055|NCT00256815|Procedure|Radiation|
518056|NCT00256802|Device|MR-angiography, GTN|
518057|NCT00256789|Procedure|Radiation|
518058|NCT00256789|Drug|Chemotherapy|
518059|NCT00256776|Drug|Velcade (Bortezomib)|
518062|NCT00256750|Drug|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
518063|NCT00256750|Drug|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
518064|NCT00256750|Drug|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
518065|NCT00256737|Drug|Omeprazole|
518066|NCT00256724|Device|Impedance Threshold Device|Active impedance threshold device
518067|NCT00256724|Device|sham ITD|sham impedance threshold device
518068|NCT00256711|Drug|Gefitinib|
518069|NCT00256711|Drug|Vinorelbine|
518070|NCT00256698|Drug|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
518071|NCT00256698|Drug|Anastrozole|1 mg oral tablet
518072|NCT00256685|Drug|DVS-233 SR|
518073|NCT00256672|Device|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
518074|NCT00256659|Behavioral|Early assessment and referral to ancillary care services vs. standard care|
518075|NCT00256646|Drug|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
518076|NCT00256620|Procedure|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
518077|NCT00256594|Device|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
518078|NCT00256581|Procedure|Additional rest and stress image sets on new camera|
518079|NCT00256568|Behavioral|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
518080|NCT00256555|Drug|Nutropin AQ|
518081|NCT00256542|Drug|Alkalinized Lidocaine-Heparin|
518082|NCT00256529|Procedure|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
518083|NCT00256516|Other|Eco-Atkins diet (high vegetable protein and vegetable fat)|
518084|NCT00256516|Other|NCEP diet|
518085|NCT00256503|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
518086|NCT00256490|Procedure|PET/CT 20 days after the first cycle of chemotherapy|
518087|NCT00256477|Behavioral|Sudarshan KRIYA Breathing Technique|
518088|NCT00256464|Behavioral|Multi-component Yoga Intervention|
518089|NCT00256451|Drug|Naltrexone|50 mg/day for two days prior to the alcohol challenge session
518090|NCT00256451|Drug|placebo|placebo pills
518091|NCT00256451|Other|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice.
518092|NCT00256451|Other|Sham alcohol|non-alcoholic placebo alcohol
518093|NCT00256438|Device|Transcranial Direct Current Stimulation|
518094|NCT00256425|Behavioral|Cognitive rehabilitation|
518095|NCT00256412|Drug|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
518096|NCT00256412|Drug|Placebo|4 capsules of placebo each day
518097|NCT00256399|Drug|Alfuzosin 10 mg|
518098|NCT00256386|Device|Electronic Medical Record (EMR) to clinician's in-basket|
518099|NCT00256386|Device|Automated Voice Message (AVM) reminder to patient's phone|
518100|NCT00256386|Procedure|Pharmacy Team phone call-letter followup|
518101|NCT00256373|Procedure|Mod. functional restoration-Individ. dynamic back-muscle|
518102|NCT00256360|Drug|dose dense with neulasta|
518103|NCT00256347|Drug|intramuscular injections of morphine|
518104|NCT00256334|Drug|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
518105|NCT00256321|Drug|Oxaliplatin|Oxaliplatin 70mg/m2 IV on Days 1 and 8
518106|NCT00256321|Drug|Capecitabine|Capecitabine 1000mg/m2 PO BID from Days 1 through 14.
518107|NCT00256321|Drug|Celecoxib|Celecoxib 400mg PO BID from Days 1 through 21.
518108|NCT00256308|Drug|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
518109|NCT00256308|Procedure|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
518110|NCT00256295|Drug|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
518111|NCT00256295|Drug|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
518112|NCT00256282|Drug|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
518113|NCT00256282|Drug|Docetaxel|40mg/m2 IV over 1 hour every 14 days
518114|NCT00256282|Drug|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
518115|NCT00256269|Drug|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
518116|NCT00256269|Drug|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
518117|NCT00256256|Drug|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
518118|NCT00256243|Drug|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
518119|NCT00256243|Drug|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
518120|NCT00256243|Drug|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
518121|NCT00256243|Drug|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
518122|NCT00256243|Drug|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
518123|NCT00256243|Drug|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
518319|NCT00254735|Drug|quetiapine fumarate|
518124|NCT00256230|Drug|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
518125|NCT00256217|Drug|Anastrozole|1 mg. oral every day for 2 - 4 weeks
518126|NCT00256204|Drug|Rasagiline Mesylate|tablet, 1mg once daily
518127|NCT00256204|Drug|Rasagiline Mesylate|tablet, 2mg once daily
518128|NCT00256204|Other|Placebo|Placebo
518129|NCT00256191|Drug|TPI 287 Injection|
518130|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
518131|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
518132|NCT00256178|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
518133|NCT00256165|Device|Tissue valve|Aortic valve replacement
518134|NCT00256152|Device|AF Suppression Pacing Algorithm|
518135|NCT00256139|Drug|Raptiva|
518136|NCT00256126|Drug|Saizen|Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
518137|NCT00256126|Drug|Saizen|Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
518138|NCT00256113|Drug|Saredutant succinate (SR48968C)|
518139|NCT00256100|Drug|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
518140|NCT00256087|Drug|Probiotic Lactobacillus|
518141|NCT00256087|Other|Lactose Powder|
518142|NCT00256074|Procedure|Enteral feeding formula|
518143|NCT00256048|Procedure|Nasojejunal feeding|
518144|NCT00256035|Procedure|Measuring IL-4 levels|
518145|NCT00256022|Drug|Lactobacillus Probiotic|
518146|NCT00256022|Other|Lactose Powder|
518147|NCT00256009|Drug|Cytotec|
518148|NCT00255996|Drug|linezolid|
518149|NCT00255983|Drug|Faropenem medoxomil|600 mg BID for 5 days
518150|NCT00255983|Drug|placebo|placebo tablets BID for 5 days
518151|NCT00255970|Other|DFDBA|Demineralized Freeze Dried Allograft bone
518152|NCT00255970|Device|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
518153|NCT00255957|Drug|HES administration|
518154|NCT00255957|Drug|Hydroxy Ethyl Starch administration to stroke patients|
518155|NCT00255944|Behavioral|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
518156|NCT00255944|Behavioral|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
518157|NCT00255931|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
518158|NCT00255931|Behavioral|Attention Placebo|Untrained relaxation
518159|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
518160|NCT00255918|Drug|Placebo|Placebo dosed to match active medication
518161|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
518162|NCT00255905|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|
518163|NCT00255905|Behavioral|Clinician monitoring|
518164|NCT00255879|Drug|Quetiapine|
518165|NCT00255879|Drug|Risperidone|
518166|NCT00255879|Drug|Olanzapine|
518167|NCT00255866|Behavioral|Skills training for the care of dementia patients|
518168|NCT00255840|Behavioral|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
518169|NCT00255840|Behavioral|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
518170|NCT00255840|Drug|Efavirenz|600 mg tablet taken orally daily
518171|NCT00255840|Drug|Lamivudine|150 mg tablet taken orally daily
518172|NCT00255840|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
518173|NCT00255840|Drug|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
518174|NCT00255840|Drug|Stavudine|Tablet taken orally daily. Dosage depends on weight.
518175|NCT00255827|Biological|HyperAcute-Pancreatic Cancer Vaccine|
518176|NCT00255814|Radiation|radiation therapy|
518177|NCT00255801|Drug|Targretin® (bexarotene)|
518178|NCT00255801|Drug|pegylated liposomal doxorubicin hydrochloride|
518179|NCT00255788|Drug|everolimus|
518180|NCT00255775|Dietary Supplement|broccoli sprout extract|
518181|NCT00255775|Procedure|complementary or alternative medicine procedure|
518182|NCT00255762|Drug|carboplatin|Given IV
518183|NCT00255762|Drug|paclitaxel|Given IV
518184|NCT00255762|Biological|bevacizumab|Given IV
518185|NCT00255762|Other|laboratory biomarker analysis|Correlative studies
518186|NCT00255749|Biological|epoetin alfa|
518187|NCT00255723|Drug|carboplatin|Given IV
518188|NCT00255723|Drug|etoposide|Given IV
518189|NCT00255723|Drug|ifosfamide|Given IV
518190|NCT00255710|Biological|filgrastim|
518191|NCT00255710|Drug|cyclophosphamide|
518192|NCT00255710|Drug|fludarabine phosphate|
518193|NCT00255710|Drug|mycophenolate mofetil|
518194|NCT00255710|Drug|tacrolimus|
518195|NCT00255710|Procedure|allogeneic bone marrow transplantation|
518196|NCT00255710|Procedure|peripheral blood stem cell transplantation|
518320|NCT00254735|Drug|SSRI/Clomipramine|
518198|NCT00255697|Procedure|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
518199|NCT00255697|Procedure|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
518200|NCT00255684|Biological|graft-versus-tumor induction therapy|
518201|NCT00255684|Drug|cyclophosphamide|
518202|NCT00255684|Drug|cyclosporine|
518203|NCT00255684|Drug|fludarabine phosphate|
518204|NCT00255684|Drug|mycophenolate mofetil|
518205|NCT00255684|Procedure|umbilical cord blood transplantation|
518206|NCT00255684|Radiation|radiation therapy|
518207|NCT00255671|Other|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
518208|NCT00255658|Drug|sorafenib tosylate|Given orally
518209|NCT00255658|Drug|temsirolimus|Given IV
518210|NCT00255658|Other|laboratory biomarker analysis|Correlative studies
518211|NCT00255619|Device|Baxter’s UltraBag® and FMC Andy·Disc®|
518212|NCT00255606|Drug|docetaxel|Given in 3- or 4- week courses
518213|NCT00255606|Drug|prednisone|Given in 3- or 4- week courses
518214|NCT00255593|Drug|rituximab|
518215|NCT00255580|Drug|Smoked cannabis|
518216|NCT00255567|Drug|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
518217|NCT00255567|Drug|Paromomycin sulphate|Paromomycin sulphate
518218|NCT00255567|Drug|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
518219|NCT00255554|Behavioral|Dialectical Behavioral Therapy|
518220|NCT00255554|Drug|Escitalopram|
518221|NCT00255541|Drug|Tesaglitazar|
518222|NCT00255541|Drug|Glibenclamide|
518223|NCT00255528|Drug|metoprolol succinate|
518224|NCT00255515|Drug|Quetiapine fumarate|oral
518225|NCT00255515|Drug|conventional treatment for schizophrenia|various standard therapies
518226|NCT00255502|Drug|metoprolol succinate|
518227|NCT00255489|Drug|Gefitinib|
518228|NCT00255489|Procedure|palliative thoracic radiotherapy|
518229|NCT00255476|Drug|gefitinib|
518230|NCT00255476|Drug|cisplatin|
518231|NCT00255476|Drug|5-flourouracil|
518232|NCT00255463|Drug|Anastrazole|
518233|NCT00255463|Drug|Gefitinib|
518234|NCT00255450|Drug|ferumoxytol or placebo|
518235|NCT00255437|Drug|ferumoxytol or oral iron|
518236|NCT00255424|Drug|ferumoxytol or oral iron|
518237|NCT00255385|Drug|Micronutrient (Zinc and Iron) fortification|
518238|NCT00255385|Drug|Pre and Probiotic fortification|
518239|NCT00255372|Drug|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
518240|NCT00255372|Drug|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
518241|NCT00255359|Drug|XTL-2125|
518242|NCT00255346|Drug|Dasatinib (BMS-354825)|70 mg orally twice daily
518243|NCT00255333|Drug|INNO-105|
518244|NCT00255320|Drug|VIP|
518245|NCT00255307|Drug|CVT-E002 ginseng extract|
518246|NCT00255294|Drug|Cellulose sulfate vaginal gel|
518247|NCT00255281|Drug|AZD7009, no generic name available|
518248|NCT00255268|Drug|Goserelin|
518249|NCT00255268|Drug|Bicalutamide|
518250|NCT00255255|Drug|Budesonide/Formoterol|
518251|NCT00255242|Drug|Simvastatin treatment for 28 days|40 mg / day
518252|NCT00255229|Drug|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
518253|NCT00255229|Other|Placebo|Glutamine placebo
518254|NCT00255216|Drug|Policosanol supplement (oral capsule) vs. placebo|
518255|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
518256|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
518257|NCT00255177|Drug|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
518258|NCT00255177|Drug|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
518259|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
518260|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
518261|NCT00255164|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
518262|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
518263|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
518264|NCT00255151|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
518265|NCT00255138|Drug|Atomoxetine|
518317|NCT00254748|Drug|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
518318|NCT00254748|Drug|Placebo|placebo
518266|NCT00255125|Drug|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
518267|NCT00255125|Drug|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
518268|NCT00255112|Behavioral|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
518269|NCT00255099|Drug|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
518270|NCT00255099|Drug|Placebo|2 tablets b.i.d. / 96 weeks
518271|NCT00255086|Drug|Memantine|10mg Memantine
518272|NCT00255086|Drug|Placebo pill|10mg placebo pill
518273|NCT00255073|Drug|baclofen|
518274|NCT00255047|Biological|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
518275|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
518276|NCT00255047|Biological|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
518277|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
518278|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
518279|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
518280|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
518281|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
518282|NCT00255021|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
518283|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
518284|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
518285|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
518286|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
518287|NCT00254995|Biological|None administered in this study|N/A in this study
518288|NCT00254982|Biological|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
518289|NCT00254969|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
518290|NCT00254956|Drug|ciclesonide (XRP1526)|
518291|NCT00254930|Drug|risperidone|
518292|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
518293|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
518294|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
518295|NCT00254904|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
518296|NCT00254904|Drug|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
518297|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
518298|NCT00254904|Drug|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
518299|NCT00254891|Drug|PF-3512676 + Paclitaxel + Carboplatin|"PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.~Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
518300|NCT00254891|Drug|Paclitaxel + Carboplatin|"Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.~Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
518301|NCT00254878|Drug|Methylphenidate hydrochloride|
518302|NCT00254865|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
518303|NCT00254852|Procedure|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
518304|NCT00254852|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
518305|NCT00254852|Procedure|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
518306|NCT00254852|Procedure|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
518307|NCT00254852|Procedure|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
518308|NCT00254826|Biological|YF-VAX® plus saline|YF-VAX® plus saine
518309|NCT00254826|Biological|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
518310|NCT00254813|Drug|Quetiapine|
518311|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
518312|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
518313|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
518314|NCT00254787|Drug|IR (Immediate-Release) quetiapine fumarate (drug)|
518315|NCT00254774|Drug|quetiapine fumarate or valproate|
518316|NCT00254761|Drug|Cannabis|
518321|NCT00254722|Drug|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10^6 mononuclear cells/kg body weight, administered within 36 hours of injury
518322|NCT00254709|Drug|Sirolimus|
518323|NCT00254696|Drug|Extended-Spectrum-Lactamases (ESBLs)|
518324|NCT00254683|Device|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
518325|NCT00254670|Drug|Naltrexone|
518326|NCT00254657|Drug|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
518327|NCT00254657|Drug|Placebo|
518328|NCT00254644|Procedure|Morphological and functional MRI|one time
518329|NCT00254631|Drug|Oxycodone hydrochloride|
518330|NCT00254618|Drug|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
518331|NCT00254618|Drug|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
518332|NCT00254618|Drug|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
518333|NCT00254592|Drug|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
518334|NCT00254592|Drug|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
518335|NCT00254592|Drug|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
518336|NCT00254592|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
518337|NCT00254592|Drug|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
518338|NCT00254592|Drug|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
518339|NCT00254592|Drug|Bevacizumab|10mg/kg q 2 wks
518340|NCT00254579|Drug|CP-675,206|15 mg/kg Q12W dosing regimen
518341|NCT00254566|Other|Moxifloxacin Placebo|1 capsule once daily for 5 days
518342|NCT00254566|Drug|Moxifloxacin|1 X 400mg capsule once daily for 5 days
518343|NCT00254566|Other|Azithromycin SR Placebo|single dose, oral.
518344|NCT00254566|Drug|Azithromycin SR|single dose 2.0 g oral
518345|NCT00254553|Drug|Testim 1% (testosterone gel)|Testim_ 100 mg: two tubes of 50 mg of Testim_per day
518346|NCT00254553|Drug|Placebo|two tubes of placebo per day
518347|NCT00254540|Drug|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
518348|NCT00254514|Drug|somatropin|
518349|NCT00254501|Behavioral|Pharmacist Counseling|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
518350|NCT00254501|Behavioral|Educational materials|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
518351|NCT00254488|Drug|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
518352|NCT00254488|Drug|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
518353|NCT00254475|Drug|simvastatin|
518354|NCT00254475|Drug|valsartan|
518355|NCT00254462|Drug|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
518356|NCT00254462|Drug|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
518357|NCT00254462|Behavioral|Parent Training|All children will receive parent training for the duration of the study.
518358|NCT00254449|Drug|NGX-4010|
518359|NCT00254436|Drug|Procrit (epoetin alfa)|Weekly dose
518360|NCT00254423|Drug|Dasatinib|Given PO
518361|NCT00254423|Other|Laboratory Biomarker Analysis|Correlative studies
518362|NCT00254423|Other|Pharmacological Study|Correlative studies
518363|NCT00254423|Other|Quality-of-Life Assessment|Ancillary studies
518364|NCT00254423|Other|Questionnaire Administration|Ancillary studies
518365|NCT00254410|Drug|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
518366|NCT00254410|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
518367|NCT00254410|Drug|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
518368|NCT00254410|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
518369|NCT00254410|Drug|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
518370|NCT00254397|Drug|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
518371|NCT00254397|Biological|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
518372|NCT00254397|Biological|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
518373|NCT00254384|Drug|Cisplatin|Given IV
518374|NCT00254384|Drug|Docetaxel|Given IV
518375|NCT00254384|Drug|Erlotinib|Given PO
518376|NCT00254384|Drug|Erlotinib Hydrochloride|Given PO
518377|NCT00254384|Other|Laboratory Biomarker Analysis|Correlative studies
518378|NCT00254371|Procedure|Androgen Replacement|
518379|NCT00254345|Procedure|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
518380|NCT00254319|Drug|Avastin, Alimta|
518381|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
518501|NCT00253526|Procedure|chemotherapy|
518382|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
518383|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
518384|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
518385|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
518386|NCT00254293|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
518387|NCT00254280|Procedure|Intense Pulsed Light + paring versus paring alone|
518388|NCT00254267|Drug|AMG 706|AMG 706 125mg, oral, once a day
518389|NCT00254254|Drug|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
518390|NCT00254254|Drug|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
518391|NCT00254254|Drug|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
518392|NCT00254241|Drug|Seroquel and Risperidone|
518393|NCT00254228|Device|Electrotactile sensory substitution|
518394|NCT00254215|Behavioral|high protein & low glycemic index diets|
518395|NCT00254202|Drug|iloperidone|
518396|NCT00254202|Drug|active comparator|
518397|NCT00254202|Drug|placebo|
518398|NCT00254189|Drug|Levonorgestrel|
518399|NCT00254189|Drug|Ethinyl Estradiol|
518400|NCT00254176|Dietary Supplement|Parenteral cysteine-HCl supplementation|cysteine-HCl supplementation 121 mg per kg per day
518401|NCT00254176|Dietary Supplement|Placebo - added premasol|Premasol 121 mg per kg per day
518402|NCT00254163|Drug|Fludarabine|
518403|NCT00254163|Drug|Cyclophosphamide|
518404|NCT00254163|Drug|Rituximab|
518405|NCT00254163|Drug|Pentostatin|
518406|NCT00254150|Procedure|Increase oxygen extraction rate|
518407|NCT00254137|Drug|capecitabine|
518408|NCT00254137|Drug|irinotecan|
518409|NCT00254137|Drug|oxaliplatin|
518410|NCT00254137|Drug|cetuximab|
518411|NCT00254124|Device|The Diet Plate (R) TM portion control plate and bowl|
518412|NCT00254111|Device|Ultra Probe Laser System|
518413|NCT00254085|Drug|Insulin Aspart|
518414|NCT00254072|Procedure|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
518415|NCT00254059|Procedure|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
518416|NCT00254046|Drug|TMC125|2 X100 mg tablets b.i.d.96 weeks
518417|NCT00254046|Drug|Placebo|2 tablets b.i.d.96 weeks
518418|NCT00254033|Drug|Dextroamphetamine|
518419|NCT00254033|Drug|Methylphenidate|
518420|NCT00254020|Drug|Citalopram|Patients who are found to have major depression will be referred to a psychologist
518421|NCT00254007|Drug|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
518422|NCT00253994|Procedure|Acupuncture|
518423|NCT00253981|Device|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
518424|NCT00253968|Drug|Eplivanserin|oral administration
518425|NCT00253968|Drug|placebo|oral administration
518426|NCT00253955|Drug|Levofloxacin|
518427|NCT00253955|Drug|Piperacillin/Tazobactam|
518428|NCT00253942|Procedure|Injecting bee venom as a treatment for OA|
518429|NCT00253929|Drug|Intra-arterial infusion of adenosine|
518430|NCT00253929|Drug|intra-arterial infusion of caffeine|
518431|NCT00253929|Drug|intra-arterial infusion of acetylcholine|
518432|NCT00253929|Drug|intra-arterial infusion of sodium nitroprusside|
518433|NCT00253929|Procedure|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
518434|NCT00253916|Behavioral|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
518435|NCT00253916|Behavioral|Resistance Exercise Program|Resistance Exercise Program
518436|NCT00253903|Drug|eplivanserin (SR46349)|oral administration
518437|NCT00253903|Drug|placebo|oral administration
518438|NCT00253890|Drug|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
518439|NCT00253890|Drug|Placebo|1-3 at bedtime
518440|NCT00253877|Other|Complication rate|All patients in the active comparator group received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology. The complication rate and clinical efficacy will be recorded and compared to the Total Hip Replacement historical control group.
518502|NCT00253526|Procedure|conventional surgery|
518503|NCT00253526|Procedure|growth factor antagonist therapy|
518504|NCT00253526|Procedure|monoclonal antibody therapy|
518505|NCT00253526|Procedure|surgery|
518506|NCT00253513|Drug|fludarabine|30 mg/m2, IV for 5 days
518507|NCT00253513|Drug|treosulfan|12 or 14 g/m2, IV for 5 days
518508|NCT00253513|Procedure|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
518441|NCT00253851|Drug|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
518442|NCT00253838|Procedure|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
518443|NCT00253838|Procedure|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
518444|NCT00253825|Device|mCIMT combined with or without eye patching|
518445|NCT00253812|Procedure|flexible sigmoidoscopy|
518446|NCT00253799|Device|Hylan GF-20|
518447|NCT00253786|Other|Intensive multifactorial therapy|Blood glucose control: HbA1c < 6.2% Blood pressure control: SBP < 125 mmHg, DBP: < 75 mmHg Lipid profile: T-cho < 180 mg/dl, LDL-cho < 100 mg/dl, HDL-cho >40 mg/dl Dietary intervention: TDEI < 30 kcal/kg/day, sodium < 5 g/day, protein < 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
518448|NCT00253786|Other|Standard therapy|Blood glucose control: HbA1c < 6.9% Blood pressure control: SBP < 130 mmHg, DBP: < 80 mmHg Lipid profile: T-cho < 200 mg/dl, LDL-cho < 120 mg/dl, HDL-cho >40 mg/dl, Dietary intervention: TDEI < 25-30 kcal/kg/day, sodium < 6 g/day, protein < 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
518449|NCT00253773|Drug|acetominophen, sulfer amino acids; cysteine and methionine|
518450|NCT00253760|Drug|dietary amino acids; cysteine and methionine|
518451|NCT00253747|Drug|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
518452|NCT00253747|Drug|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
518453|NCT00253734|Biological|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
518454|NCT00253734|Biological|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
518455|NCT00253721|Drug|Melphalan|"All levels: Every 4 weeks for up to one year~Dose Escalation Plan:~Level 1: 4mg/m2/day x 2 days~Level 2: 6mg/m2/day x 2 days~Level 3: 8mg/m2/day x 2 days~Level 4: 10mg/m2/day x 2 days~Level 5: 12mg/m2/day x 2 days"
518456|NCT00253708|Procedure|management of therapy complications|
518457|NCT00253708|Procedure|massage therapy|
518458|NCT00253708|Procedure|pain therapy|
518459|NCT00253708|Procedure|psychosocial assessment and care|
518460|NCT00253708|Procedure|quality-of-life assessment|
518461|NCT00253695|Device|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
518462|NCT00253669|Other|laboratory biomarker analysis|
518463|NCT00253669|Other|physiologic testing|
518464|NCT00253669|Procedure|management of therapy complications|
518465|NCT00253643|Dietary Supplement|green tea catechin extract|Given orally 2 times/day
518466|NCT00253643|Dietary Supplement|fish oil|Given orally 3 times/day
518467|NCT00253643|Other|placebo|Given olive oil placebo orally 3 times/day
518468|NCT00253643|Other|placebo|Given green tea placebo orally 2 times/day
518469|NCT00253630|Other|Laboratory Biomarker Analysis|Correlative studies
518470|NCT00253630|Drug|Vorinostat|Given PO
518471|NCT00253617|Drug|porfimer sodium|
518472|NCT00253617|Procedure|adjuvant therapy|
518473|NCT00253617|Procedure|laser therapy|
518474|NCT00253617|Procedure|photodynamic therapy|
518475|NCT00253617|Procedure|phototherapy|
518476|NCT00253591|Drug|cisplatin|
518477|NCT00253591|Drug|vinorelbine tartrate|
518478|NCT00253591|Radiation|radiation therapy|
518479|NCT00253578|Drug|sorafenib tosylate|Given PO
518480|NCT00253578|Other|laboratory biomarker analysis|Correlative studies
518481|NCT00253565|Drug|capecitabine|
518482|NCT00253565|Drug|imatinib mesylate|
518483|NCT00253552|Biological|filgrastim|
518484|NCT00253552|Drug|busulfan|
518485|NCT00253552|Drug|cyclophosphamide|
518486|NCT00253552|Drug|cyclosporine|
518487|NCT00253552|Drug|etoposide|
518488|NCT00253552|Drug|methotrexate|
518489|NCT00253552|Procedure|allogeneic bone marrow transplantation|
518490|NCT00253552|Radiation|radiation therapy|
518491|NCT00253539|Drug|arzoxifene hydrochloride|Given orally
518492|NCT00253539|Drug|tamoxifen citrate|Given orally
518493|NCT00253539|Other|placebo|Given orally
518494|NCT00253526|Drug|bevacizumab|
518495|NCT00253526|Drug|gemcitabine hydrochloride|
518496|NCT00253526|Procedure|adjuvant therapy|
518497|NCT00253526|Procedure|anti-cytokine therapy|
518498|NCT00253526|Procedure|antiangiogenesis therapy|
518499|NCT00253526|Procedure|antibody therapy|
518500|NCT00253526|Procedure|biological therapy|
518509|NCT00253500|Biological|pegfilgrastim|6 mg in a syringe
518510|NCT00253500|Drug|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
518511|NCT00253500|Procedure|conventional surgery|to remove small piece of cancer
518512|NCT00253487|Drug|O6-benzylguanine|
518513|NCT00253487|Drug|busulfan|
518514|NCT00253487|Drug|temozolomide|
518515|NCT00253487|Procedure|adjuvant therapy|
518516|NCT00253487|Procedure|autologous bone marrow transplantation|
518517|NCT00253487|Procedure|conventional surgery|
518518|NCT00253487|Procedure|peripheral blood stem cell transplantation|
518519|NCT00253487|Radiation|radiation therapy|
518520|NCT00253474|Biological|PEG-interferon alfa-2a|
518521|NCT00253461|Procedure|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
518522|NCT00253461|Procedure|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.~Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
518523|NCT00253461|Radiation|11C topotecan|Phase I and II: IV over 10 minutes
518524|NCT00253461|Radiation|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
518525|NCT00253448|Radiation|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
518526|NCT00253448|Radiation|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
518527|NCT00253435|Biological|Filgrastim|Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0. The first dose should begin four hours after the stem cell infusion is completed. Filgrastim will continue daily until the ANC >=1500/uL for three consecutive days.
518528|NCT00253435|Drug|Carboplatin|"The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y."
518529|NCT00253435|Drug|Etoposide|The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR >= 100 ml/min/1.72 m^2, a dose of 300 mg/m^2/day (10 mg/kg/day if child is < 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m^2, the etoposide will be administered at a dose of 160 mg/m^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of < 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
518530|NCT00253435|Drug|Melphalan|For patients in either the normal GFR strata (>=100 ml/min/1.73 m^2), or reduced GFR strata (60-99 ml/min/1.73m^2), melphalan shall be administered at a dose of 60 mg/m^2/day (2 mg/kg/day if child is < 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration < 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m^2.
518531|NCT00253435|Procedure|Peripheral blood stem cell infusion|Stem cells or marrow will be infused on day 0 of study therapy. Where the DMSO concentration in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over two days to meet this standard. For purged PBSC: A minimum of 2.0 x 10^6 viable CD34+ cells/kg must be available. For unpurged PBSC, a minimum of 2.0 x 10^6 viable CD34+ cells/kg must be available. Having a back-up of 2.0 x 10^6 viable CD34+ cells/kg purged or unpurged PBSC is recommended but not required. For purged bone marrow, a minimum of 1.5 x10^8 mononuclear cells/kg must be available.
518532|NCT00253435|Radiation|131I-MIBG|Therapeutic 131I MIBG will be synthesized by Draximage Canada.with specific activity between 15 and 25mCi/ml. Radiopurity will be initially determined by Draximage, prior to shipment to participating centers. Free radioiodide content must then be rechecked at the treating center prior to infusion using HPLC or Sep-Pac methodology.
518533|NCT00253435|Radiation|Radiation therapy|Local irradiation is to be given to previously non-irradiated primary and metastatic sites of disease. Local irradiation should not start till the patient is medically stable, has an ANC > 1000/uL, platelets > 30,000 / uL, and is > 42 days post transplant. Recommended radiation guidelines consist of 2160 cGy total, given over 12 days using a single 180 cGy fraction/day. Any delay in local radiation that would extend treatment beyond day +84 should be discussed with the study chair. Local radiation will be administered at a participating NANT member site.
518534|NCT00253422|Drug|anastrozole|
518535|NCT00253422|Drug|exemestane|
518536|NCT00253422|Drug|fulvestrant|
518537|NCT00253409|Drug|chemotherapy|
518538|NCT00253409|Procedure|adjuvant therapy|
518539|NCT00253409|Procedure|conventional surgery|
518540|NCT00253409|Procedure|neoadjuvant therapy|
518541|NCT00253409|Radiation|radiation therapy|
518542|NCT00253396|Drug|Unfractionated heparin|
518543|NCT00253396|Drug|Enoxaparin|
518544|NCT00253383|Other|counseling intervention|
518545|NCT00253383|Other|educational intervention|
518546|NCT00253383|Procedure|psychosocial assessment and care|
518547|NCT00253383|Procedure|quality-of-life assessment|
518548|NCT00253370|Drug|BAY 43-9006|Given orally
518549|NCT00253370|Drug|docetaxel|Given IV
518550|NCT00253370|Drug|cisplatin|Given IV
518551|NCT00253344|Drug|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
518552|NCT00253344|Drug|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
518553|NCT00253331|Drug|topical organogel with nitroglycerin|
518554|NCT00253318|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
518555|NCT00253318|Drug|RAD001|30 mg orally on Days 1 and 8.
518556|NCT00253318|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
518557|NCT00253305|Drug|Organogel of naftifine, 2%|
518558|NCT00253305|Drug|Organogel of terbinafine, 2%|
518559|NCT00253305|Drug|Organogel of naftifine, 6%|
518560|NCT00253305|Drug|Organogel of terbinafine, 6%|
518561|NCT00253279|Procedure|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
518562|NCT00253266|Drug|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
518563|NCT00253266|Drug|Quetiapine|Quetiapine up to 200 mg/d for four weeks
518564|NCT00253240|Procedure|Screening|
518565|NCT00253240|Procedure|Management|
518566|NCT00253227|Drug|galantamine hydrobromide|
518567|NCT00253214|Drug|galantamine hydrobromide|
518568|NCT00253201|Drug|galantamine hydrobromide|
518569|NCT00253188|Drug|galantamine hydrobromide|
518570|NCT00253175|Drug|topiramate|
518571|NCT00253162|Drug|risperidone|
518572|NCT00253149|Drug|risperidone|
518573|NCT00253136|Drug|risperidone|
518574|NCT00253123|Drug|risperidone|
518575|NCT00253110|Drug|risperidone|
518576|NCT00253110|Drug|haloperidol|
518577|NCT00253097|Behavioral|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
518578|NCT00253084|Drug|IPX054 200 mg|IPX054 containing 50 mg carbidopa and 200 mg levodopa
518579|NCT00253084|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
518580|NCT00253084|Drug|IPX054 Placebo|Placebo to match IPX054 200 mg
518581|NCT00253084|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
518582|NCT00253071|Behavioral|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.~Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
518583|NCT00253058|Drug|Cetirizine Dry Syrup|
518584|NCT00253045|Behavioral|Motivational groups|Motivational interviewing in group format
518585|NCT00253032|Device|PRIMA|
518586|NCT00253006|Procedure|Tissue examination for protein- and mRNA-expression of NO|
518587|NCT00252993|Drug|DDP225|
518588|NCT00252980|Behavioral|Psychotherapy|
518589|NCT00252967|Drug|Atorvastatin|80 mg of Atorvastatin
518590|NCT00252967|Drug|Placebo|
518591|NCT00252954|Drug|Levetiracetam|Tablets 2000-3000 mg per day
518592|NCT00252941|Device|Memokath 028SW Urethral Stent|
518593|NCT00252928|Other|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
518594|NCT00252928|Other|Placebo|Placebo
518595|NCT00252915|Biological|GM-CSF (verum)|sagramostim
518596|NCT00252902|Behavioral|Behavior change counseling|
518597|NCT00252889|Drug|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
518598|NCT00252876|Drug|tesaglitazar|
518599|NCT00252863|Drug|Symbicort, used twice daily (b.i.d) and as needed (prn)|
518600|NCT00252863|Drug|Budesonide Turbuhaler 200 µg|
518601|NCT00252863|Drug|Fluticasone Discus 250 µg|
518602|NCT00252863|Drug|Formoterol Turbuhaler 4.5 µg|
518603|NCT00252863|Drug|Terbutaline Turbuhaler 0.5 mg|
518604|NCT00252863|Drug|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
518605|NCT00252863|Drug|Salmeterol Discus 50 µg|
518606|NCT00252863|Drug|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
518607|NCT00252863|Drug|Fluticasone/Salmeterol Discus 250/50 µg|
518608|NCT00252863|Drug|Fluticasone/Salmeterol Discus 500/50 µg|
518609|NCT00252863|Drug|Theophylline 200 mg|
518610|NCT00252863|Drug|Theophylline 300 mg|
518611|NCT00252863|Drug|Singulair 10 mg|
518612|NCT00252850|Genetic|CERE-120: AAV2-NTN|
518613|NCT00252837|Drug|Tesaglitazar|
518614|NCT00252837|Behavioral|Dietary and Lifestyle counseling|
518615|NCT00252824|Drug|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
518616|NCT00252811|Drug|Gefitinib|
518617|NCT00252798|Drug|Gefitinib|
518618|NCT00252798|Drug|Carboplatin|
518619|NCT00252798|Drug|Paclitaxel|
518620|NCT00252798|Procedure|Radiation|
518621|NCT00252785|Drug|Budesonide/Formoterol|
518622|NCT00252785|Drug|Budesonide|
518623|NCT00252785|Drug|Theophylline|
518624|NCT00252772|Drug|Tesaglitazar|
518625|NCT00252772|Behavioral|Dietary and Lifestyle counseling|
518626|NCT00252746|Drug|ZD6474 (vandetanib) 100mg|once daily oral dose
518627|NCT00252746|Drug|ZD6474 (vandetanib) 200mg|once daily oral dose
518628|NCT00252746|Drug|ZD6474 (vandetanib) 300mg|once daily oral dose
518629|NCT00252733|Drug|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
518630|NCT00252720|Drug|candesartan|32 mg oral tablet
518631|NCT00252707|Drug|Gefitinib or Docetaxel|
518632|NCT00252694|Drug|candesartan|32 mg oral tablet
518633|NCT00252681|Procedure|laparotomy|
518634|NCT00252681|Procedure|primary peritoneal drainage|
518635|NCT00252668|Drug|Etanercept|
518636|NCT00252668|Drug|Methotrexate|
518637|NCT00252655|Drug|Rapamune and Prograf|
518638|NCT00252642|Drug|Peginterferon Alpha-2a|
518639|NCT00252629|Other|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
518640|NCT00252616|Behavioral|trophic enteral feeds|10cc/hr
518641|NCT00252603|Drug|Galantamine|
518642|NCT00252590|Behavioral|Health Motivational Feedback|Personalized feedback on health status
518643|NCT00252590|Behavioral|Health Education|Generalized health education related to alcohol use
518644|NCT00252590|Behavioral|Control - treatment as usual|Control group with no additional intervention
518645|NCT00252577|Drug|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
518646|NCT00252564|Drug|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
518647|NCT00252564|Drug|Oxaliplatin|85 mg/m2 on Days 1 and 15
518648|NCT00252564|Drug|Leucovorin|400 mg/m2 on Days 1 and 15
518649|NCT00252564|Drug|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
518650|NCT00252564|Drug|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
518651|NCT00252551|Procedure|Osteosynthesis|
518652|NCT00252551|Procedure|Simple surgery|Surgery without device
518653|NCT00252512|Behavioral|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value.
518654|NCT00252512|Other|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
518655|NCT00252499|Drug|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
518656|NCT00252499|Drug|fenofibrate|PPAR-alpha agonist, reduces triglycerides
518657|NCT00252499|Drug|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
518658|NCT00252499|Drug|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
518659|NCT00252486|Drug|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
518660|NCT00252473|Device|MedTec S-frame Immobilization Masks|
518661|NCT00252460|Device|Computed Tomography Scan and Magnetic Resonance Imaging|
518662|NCT00252447|Procedure|Pre-Operative Conformal Radiotherapy|
518663|NCT00252434|Behavioral|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
518664|NCT00252421|Drug|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
518665|NCT00252421|Drug|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
518666|NCT00252408|Drug|Hormone replacement therapy|
518667|NCT00252395|Device|PDA-based Electronic Prescribing Software|
518668|NCT00252382|Drug|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
518669|NCT00252369|Drug|Infliximab|
518670|NCT00252369|Procedure|Instillation of fibrin glue|
518671|NCT00252356|Drug|SR58611A|
518672|NCT00252343|Drug|SR58611A|
518673|NCT00252330|Drug|SR58611A|
518674|NCT00252317|Drug|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
518675|NCT00252317|Drug|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
518676|NCT00252304|Drug|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
518677|NCT00252304|Drug|Placebo|Placebo
518678|NCT00252291|Drug|Aridol|
518679|NCT00252291|Drug|Methacholine|
518680|NCT00252291|Procedure|Exercise challenge|
518681|NCT00252278|Drug|atomoxetine|
518682|NCT00252252|Device|VPAP non-invasive ventilator|
518683|NCT00252252|Device|AutoVPAP non-invasive ventilator|
518684|NCT00252239|Drug|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
518685|NCT00252239|Drug|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
518686|NCT00252226|Drug|Quetiapine|
518687|NCT00252213|Drug|Human BNP|
518688|NCT00252200|Drug|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
518689|NCT00252187|Drug|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
518690|NCT00252187|Other|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
518691|NCT00252174|Drug|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
518692|NCT00252174|Drug|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
518693|NCT00252174|Behavioral|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
518752|NCT00251641|Drug|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
518694|NCT00252174|Drug|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
518695|NCT00252161|Procedure|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
518696|NCT00252161|Drug|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
518697|NCT00252148|Biological|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
518698|NCT00252122|Drug|Ketamine|Ketamine. 0.2 mg/kg, intravenously
518699|NCT00252109|Behavioral|Popular Opinion Leader|Popular opinion leaders of social networks are identified and attend 4 sessions to prepare them to have casual conversations with persons in the social networks that are meant to shift social norms to embrace safer behaviors (e.g., increased condom use, fewer sexual partners)
518700|NCT00252096|Device|Nucleic acid amplification test|
518701|NCT00252083|Behavioral|Popular Opinion Leader|
518702|NCT00252070|Behavioral|Functional Exercise for People with Arthritis (FEPA)|
518703|NCT00252057|Behavioral|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
518704|NCT00252044|Drug|Pergolide|
518705|NCT00252031|Behavioral|Dialectical Behavioral Therapy|
518706|NCT00252018|Behavioral|Daily intake of broccoli sprouts|
518707|NCT00252005|Drug|Apixaban|
518708|NCT00251992|Drug|Esomeprazole|
518709|NCT00251979|Drug|Esomeprazole|
518710|NCT00251966|Drug|Esomeprazole|
518711|NCT00251953|Drug|Tesaglitazar|
518712|NCT00251953|Drug|Metformin|
518713|NCT00251940|Drug|Tesaglitazar 0.5 or 1 mg|
518714|NCT00251940|Drug|Glibenclamide 2.5, 5, 10 or 15 mg|
518715|NCT00251927|Drug|esomeprazole|40 mg oral tablet administered daily
518716|NCT00251927|Procedure|Laparoscopic fundoplication (surgery)|Surgery
518717|NCT00251914|Drug|Esomeprazole|
518718|NCT00251901|Drug|Esomeprazole|
518719|NCT00251888|Drug|campto (irinotecan)|
518720|NCT00251888|Drug|cisplatin (cisplatyl)|
518721|NCT00251875|Device|online health information journal|
518722|NCT00251862|Behavioral|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
518723|NCT00251862|Behavioral|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
518724|NCT00251862|Behavioral|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
518725|NCT00251849|Drug|Rifalazil|
518726|NCT00251836|Procedure|Laparoscopic hand-assisted donor nephrectomy|
518727|NCT00251823|Drug|Eptifibatide facilitated PCI|
518728|NCT00251810|Device|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
518729|NCT00251797|Drug|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
518730|NCT00251797|Drug|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
518731|NCT00251784|Drug|Sildenafil|
518732|NCT00251771|Procedure|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
518733|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
518734|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
518735|NCT00251758|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
518736|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
518737|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
518738|NCT00251745|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
518739|NCT00251732|Drug|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
518740|NCT00251732|Drug|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
518741|NCT00251732|Drug|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
518742|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
518743|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
518744|NCT00251719|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
518745|NCT00251706|Drug|amiodarone|
518746|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
518747|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
518748|NCT00251693|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
518749|NCT00251680|Drug|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
518750|NCT00251680|Drug|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
518751|NCT00251654|Procedure|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
518799|NCT00251303|Drug|Placebo|Capsules matched active drug in appearance.
518753|NCT00251641|Drug|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a <25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
518754|NCT00251628|Other|Standard Care|standard care
518755|NCT00251628|Other|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
518756|NCT00251628|Other|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
518757|NCT00251628|Other|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
518758|NCT00251602|Drug|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
518759|NCT00251602|Drug|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
518760|NCT00251602|Drug|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
518761|NCT00251589|Drug|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
518762|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
518763|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
518764|NCT00251589|Drug|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
518765|NCT00251589|Drug|erlotinib|erlotinib 150 mg once a day.
518766|NCT00251576|Drug|A-Phase: tirofiban; Z-Phase simvastatin|
518767|NCT00251576|Drug|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
518768|NCT00251576|Drug|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
518769|NCT00251576|Drug|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
518770|NCT00251576|Drug|Duration of Treatment: Z-Phase, 2 years.|
518771|NCT00251550|Drug|Pemetrexed|
518772|NCT00251550|Drug|Cisplatin|
518773|NCT00251537|Drug|LTB4|
518774|NCT00251524|Drug|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
518775|NCT00251511|Drug|Arsenic Trioxide|
518776|NCT00251498|Drug|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
518777|NCT00251485|Drug|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
518778|NCT00251472|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
518779|NCT00251459|Drug|rhuFab V2 (ranibizumab)|
518780|NCT00251446|Drug|Vinflunine|320 mg/m2 as a 20-minute IV infusion
518781|NCT00251433|Drug|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
518782|NCT00251433|Drug|Docetaxel, trastuzumab|For Phase II, subjects will be pre-stratified for Eastern Cooperative Oncology Group (ECOG) performance (0 vs. 1; see Appendix 4 ) and site of disease (visceral vs. non-visceral). Subjects will then be randomised in a 2:1 ratio to receive either the triplet regimen or the docetaxel and trastuzumab combination.
518783|NCT00251420|Procedure|writing about disease|writing about physical or emotional consequences of pulmonary disease
518784|NCT00251407|Drug|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
518785|NCT00251407|Drug|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
518786|NCT00251407|Drug|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
518787|NCT00251394|Drug|Rituxan|Given intravenously once weekly for four weeks.
518788|NCT00251394|Drug|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
518789|NCT00251381|Drug|Cetuximab|
518790|NCT00251368|Drug|9-Aminocamptothecin (9-AC)|
518791|NCT00251355|Drug|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
518792|NCT00251355|Drug|5-Fluorouracil|5-FU via continuous IV infusion.
518793|NCT00251355|Procedure|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
518794|NCT00251342|Procedure|Edinburgh Postnatal Depression Scale|
518795|NCT00251329|Drug|neoadjuvant chemotherapy|
518796|NCT00251316|Drug|Lithium Carbonate|30 mCi of 131I
518797|NCT00251316|Drug|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
518798|NCT00251303|Drug|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
518800|NCT00251290|Procedure|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
518801|NCT00251277|Drug|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
518802|NCT00251264|Procedure|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
518803|NCT00251264|Procedure|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
518804|NCT00251251|Device|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
518805|NCT00251251|Device|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
518806|NCT00251238|Drug|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
518807|NCT00251225|Drug|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m^2 administered IV
518808|NCT00251225|Drug|Docetaxel|60 mg/m^2 administered IV on day 0
518809|NCT00251212|Behavioral|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
518810|NCT00251199|Drug|VX-950|
518811|NCT00251199|Drug|peginterferon|
518812|NCT00251186|Drug|Capecitabine and Cetuximab|
518813|NCT00251173|Behavioral|Strengths Based Case Management (SBCM)|
518814|NCT00251173|Behavioral|Motivational Enhancement Therapy (MET)|
518815|NCT00251173|Behavioral|Brief Informational Feedback (BIF) session|
518816|NCT00251160|Procedure|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
518817|NCT00251160|Procedure|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
518818|NCT00251147|Procedure|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
518819|NCT00251147|Procedure|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
518820|NCT00251134|Drug|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
518821|NCT00251134|Drug|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
518822|NCT00251121|Other|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
518823|NCT00251121|Other|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
518824|NCT00251108|Procedure|Cardiorespiratory fitness training|
518825|NCT00251095|Drug|Taxol|
518826|NCT00251095|Drug|TOCOSOL Paclitaxel|100 mg/m2/week
518827|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
518828|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
518829|NCT00251082|Drug|Placebo|Placebo
518830|NCT00251069|Drug|Glucosamine sulphate|
518831|NCT00251056|Drug|mannitol|120mg BD
518832|NCT00251056|Drug|mannitol|40 mg BD
518833|NCT00251056|Drug|mannitol|240mg BD
518834|NCT00251056|Drug|mannitol|400mg BD
518835|NCT00251043|Behavioral|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
518836|NCT00251043|Behavioral|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
518837|NCT00251030|Drug|Nelfinavir and Omeprazole|
518838|NCT00251017|Procedure|Vancomycin|Two hour creatinine clearance before and after vancomycin
518839|NCT00251017|Procedure|DNA are extracted from the whole blood of subjects|
518840|NCT00251004|Drug|Everolimus|oral, bis in diem/twice a day (bid)
518841|NCT00251004|Drug|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
518842|NCT00251004|Drug|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
518843|NCT00251004|Drug|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
518844|NCT00251004|Drug|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
518845|NCT00250991|Drug|activase|
518846|NCT00250991|Drug|integrilin|
518847|NCT00250978|Drug|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
518848|NCT00250965|Drug|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
518849|NCT00250952|Drug|Botox Cosmetic™|
518850|NCT00250939|Biological|Myozyme|20 mg/kg qow
518851|NCT00250926|Drug|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
518852|NCT00250926|Drug|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
518853|NCT00250926|Drug|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
518854|NCT00250913|Behavioral|Telephone-based physical activity counseling program|
518855|NCT00250900|Behavioral|Prescription Fill Status|
518856|NCT00250887|Drug|Gefitnib|
518857|NCT00250874|Drug|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
518858|NCT00250861|Drug|Rituximab|
518859|NCT00250861|Drug|Aldesleukin|
518860|NCT00250835|Other|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
518861|NCT00250822|Drug|Gemcitabine and Oxaliplatin|"Dose:~Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 & 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 & 16"
518862|NCT00250809|Procedure|Placement of a central venous catheter|Placement of a central venous catheter
518863|NCT00250796|Drug|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
518864|NCT00250796|Drug|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
518865|NCT00250744|Drug|Aprepitant vs. Gabapentin|Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
518866|NCT00250744|Drug|Aprepitant vs. Gabapentin|Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
518867|NCT00250731|Behavioral|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
518868|NCT00250731|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
518869|NCT00250718|Drug|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
518870|NCT00250718|Drug|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
518871|NCT00250718|Drug|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
518872|NCT00250718|Drug|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
518873|NCT00250718|Drug|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
518926|NCT00250185|Drug|Sodium Nitrate|
518927|NCT00250185|Drug|Acetylcholine|
518928|NCT00250172|Drug|[C-11](R)-rolipram|
518929|NCT00250146|Behavioral|Gluten (behaviour)|
518930|NCT00250133|Procedure|Blood draws|
518931|NCT00250120|Drug|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
538079|NCT00003406|Drug|carboplatin|
518874|NCT00250705|Drug|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: < 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
518875|NCT00250692|Drug|Nitrous Oxide|
518876|NCT00250679|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
518877|NCT00250679|Drug|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
518878|NCT00250679|Drug|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
518879|NCT00250679|Drug|Placebo|Placebo nebule or placebo aerolizer
518880|NCT00250666|Procedure|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
518881|NCT00250653|Drug|Saredutant succinate (SR48968C)|
518882|NCT00250640|Drug|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
518883|NCT00250627|Drug|Saredutant succinate (SR48968C)|
518884|NCT00250614|Drug|Saredutant succinate (SR48968C)|
518885|NCT00250601|Drug|Saredutant succinate (SR48968C)|
518886|NCT00250588|Behavioral|Problem solving skills training|See description in Results
518887|NCT00250588|Behavioral|Asthma care coordination|See description in Results
518888|NCT00250588|Other|Usual Care|Usual clinical care
518889|NCT00250575|Drug|Clozapine|
518890|NCT00250562|Drug|valsartan plus hydrochlorothiazide|
518891|NCT00250549|Behavioral|Post test video|We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
518892|NCT00250536|Drug|nandrolone decanoate|
518893|NCT00250536|Behavioral|resistance exercise training|
518894|NCT00250510|Behavioral|Simulated insurance reimbursement|Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
518895|NCT00250497|Behavioral|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
518896|NCT00250484|Device|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
518897|NCT00250484|Device|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
518898|NCT00250471|Procedure|Percutaneous Coronary Intervention (PCI)|
518899|NCT00250458|Drug|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
518900|NCT00250458|Drug|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
518901|NCT00250445|Drug|MK0663, etoricoxib|
518902|NCT00250445|Drug|Comparator: Diclofenac sodium|
518903|NCT00250432|Drug|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. Duration of Treatment - 14-90 days.
518904|NCT00250419|Biological|V930|
518905|NCT00250406|Device|Ureteral Stent|triclosan-eluting ureteral stent
518906|NCT00250406|Device|Ureteral Stent|Percuflex Plus Stent as the control
518907|NCT00250393|Drug|Istradefylline (KW-6002)|
518908|NCT00250367|Drug|risperidone|
518909|NCT00250354|Drug|Risperidone oral solution|
518910|NCT00250341|Drug|QVAR|480 mcg
518911|NCT00250341|Drug|Advair|250/50 mcg
518912|NCT00250341|Drug|Servent Diskus|50 mcg
518913|NCT00250328|Device|LapCAC Laparoscopic Compression Anastomosis Clip|
518914|NCT00250315|Drug|Dobutamine|
518915|NCT00250302|Procedure|autologous mesenchymal stem cells implantation|
518916|NCT00250289|Device|a mucosal sticker with herbal formula|
518917|NCT00250276|Biological|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
518918|NCT00250263|Drug|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily"
518919|NCT00250263|Drug|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily"
518920|NCT00250250|Drug|ZOMACTON|
518921|NCT00250237|Drug|Haloperidol|Haloperidol 1mg twice daily during 72hours
518922|NCT00250237|Drug|placebo|Placebo 1mg twice daily during 72hours
518923|NCT00250224|Device|Radiotherapy stent|
518924|NCT00250211|Procedure|Functional MRI imaging and tomotherapy|
518925|NCT00250198|Drug|STA-5326|
518932|NCT00250094|Drug|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.~Course 1B: On day 28, if ANC is >1,500 and platelets > 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
518933|NCT00250081|Procedure|Upper Extremity Tendon transfer|
518934|NCT00250081|Procedure|Botulinum Toxin injections in Upper Extremity|
518935|NCT00250081|Procedure|Regularly ongoing therapy|
518936|NCT00250068|Drug|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
518937|NCT00250055|Procedure|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
518938|NCT00250042|Drug|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, & were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) & then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
518939|NCT00250029|Drug|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion & the administration of any other drug.~Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 & the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
518940|NCT00250003|Behavioral|Preventive home visits|
518941|NCT00249990|Drug|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
518942|NCT00249977|Drug|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).~Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
518943|NCT00249964|Drug|Combination Treatment - Cohort 1|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6."
518944|NCT00249964|Drug|Combination Treatment - Cohort 2|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6."
518945|NCT00249964|Drug|Combination Treatment - Cohort 3|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6."
518946|NCT00249964|Drug|Combination Treatment - Cohort 4|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6."
518947|NCT00249951|Drug|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
518948|NCT00249938|Drug|Minute Maid Heart Wise orange juice|
518949|NCT00249938|Drug|Welchol|
518950|NCT00249925|Behavioral|Home-Based Intervention|
518951|NCT00249925|Behavioral|Multi-component home-based intervention|
518952|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
518953|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
518954|NCT00249912|Drug|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
518955|NCT00249899|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
518956|NCT00249899|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
518957|NCT00249886|Drug|Citalopram|
518958|NCT00249873|Drug|clopidogrel (SR25990C)|oral administration (tablets)
518959|NCT00249873|Drug|placebo|oral administration (tablets)
518960|NCT00249860|Drug|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
518961|NCT00249860|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
518962|NCT00249860|Drug|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
518963|NCT00249847|Drug|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
518964|NCT00249847|Drug|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
518965|NCT00249834|Drug|Gonal-f|GONAL-f (follitropin alfa) will be administered subcutaneously based on ART treatment guidelines, which determined the optimal dose of r-hFSH based on subject baseline characteristics/predictors of ovarian response throughout stimulation cycle.
518966|NCT00249834|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|When at least 1 follicle greater than or equal to (>=) 18 millimeter (mm) and 2 follicles >=16 mm in diameter develop, 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) will be administered.
518967|NCT00249821|Drug|Saizen®|Saizen® [somatropin (recombinant deoxyribonucleic acid [rDNA] origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
518968|NCT00249821|Drug|Saizen®|Saizen® [somatropin (rDNA origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
518969|NCT00249808|Drug|Efalizumab - anti-CD11a recombinant human monoclonal antibody|Participants will receive efalizumab 1.0 milligram per kilogram (mg/kg) (with an initial conditioning dose of 0.7 mg/kg) once weekly by subcutaneous injection for 12 weeks (first treatment [FT]). Depending on the response at Week 12, participants could receive additional 8 to 12 weekly injections of efalizumab 1.0 mg/kg.
518970|NCT00249795|Drug|Irbesartan|oral administration (tablets) once daily
518971|NCT00249795|Drug|placebo|oral administration (tablets) once daily
518972|NCT00249782|Drug|Vehicle control, 2x/day|
518973|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 2x/day|
518974|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day|
518975|NCT00249782|Drug|MetroGel® (metronidazole gel), 1.0% 1x/day|
518976|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
518977|NCT00249769|Biological|Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine|
518978|NCT00249756|Behavioral|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments — increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
518979|NCT00249756|Behavioral|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
518980|NCT00249743|Device|FallSaver (formerly called NOCwatch)|
518981|NCT00249730|Drug|Sildenafil|
518982|NCT00249717|Behavioral|Contingency management|Receive rewards (prizes) abstinence and attendance
518983|NCT00249704|Drug|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
518984|NCT00249704|Procedure|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
518985|NCT00249704|Procedure|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
518986|NCT00249704|Drug|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
518987|NCT00249691|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
518988|NCT00249691|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
518989|NCT00249678|Behavioral|Behavior Therapy|
518990|NCT00249652|Behavioral|TAP|12-session motivational interviewing-based telephone intervention.
518991|NCT00249652|Other|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
518992|NCT00249639|Behavioral|Contingency management|Rewards valued $1-$100
518993|NCT00249626|Behavioral|Contingency management|Rewards (prizes) for abstinence
518994|NCT00249613|Behavioral|Women-Only|Gender-responsive treatment for women only
518995|NCT00249600|Behavioral|Contingency management|
518996|NCT00249587|Drug|Methadone|dosed to effect, every six hours
518997|NCT00249574|Drug|Buprenorphine/naloxone|Human subjects HIV, HCV
518998|NCT00249574|Drug|pegInterferon|intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
518999|NCT00249561|Behavioral|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
519000|NCT00249561|Behavioral|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg & Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
519001|NCT00249548|Behavioral|Contingency management|
519002|NCT00249535|Behavioral|Contingency management|Rewards (prizes) for abstinence
519003|NCT00249522|Behavioral|Contingency management|
519004|NCT00249509|Drug|Nefazodone|
519005|NCT00249509|Drug|Bupropion|
519006|NCT00249496|Behavioral|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
519007|NCT00249496|Behavioral|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
519008|NCT00249483|Drug|Venlafaxine|Venlafaxiine 300mg/day
519009|NCT00249483|Drug|Placebo|Placebo
519010|NCT00249470|Behavioral|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
519011|NCT00249470|Behavioral|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
519012|NCT00249457|Behavioral|Contingency management|Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
519013|NCT00249444|Drug|Mirtazapine|Mirtazapine
519014|NCT00249444|Drug|Placebo|placebo
519015|NCT00249431|Drug|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
519016|NCT00249431|Behavioral|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
519017|NCT00249418|Behavioral|Contingency management|Rewards (prizes) for abstinence
519018|NCT00249405|Drug|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
519019|NCT00249405|Behavioral|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
519020|NCT00249379|Drug|Acamprosate|Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
519021|NCT00249366|Drug|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
519022|NCT00249366|Drug|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
519023|NCT00249353|Drug|methylphenidate hydrochloride|
519024|NCT00249340|Behavioral|Weight Watchers|
519025|NCT00249340|Behavioral|brief behavioral weight loss treatment|
519026|NCT00249340|Behavioral|brief behavioral + Weight Watchers combined treatment|
519027|NCT00249327|Behavioral|education|
519028|NCT00249301|Drug|MLN8054|MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
519029|NCT00249288|Drug|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
519030|NCT00249288|Drug|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
519031|NCT00249275|Device|spectacles|
519032|NCT00249262|Drug|Taxoprexin|
519033|NCT00249249|Drug|Pitavastatin|
519034|NCT00249249|Drug|Atorvastatin|
519035|NCT00249236|Drug|Risperidone, oral tablets|
519036|NCT00249223|Drug|Risperidone Long acting injectable|
519037|NCT00249210|Drug|levofloxacin|
519038|NCT00249197|Drug|levofloxacin|
519039|NCT00249171|Drug|risperidone|
519040|NCT00249158|Drug|Risperidone|
519041|NCT00249145|Drug|risperidone|
519042|NCT00249132|Drug|risperidone|
519043|NCT00249119|Drug|risperidone|
519044|NCT00249106|Biological|ADVAX|
519045|NCT00249093|Drug|oxygen|
519046|NCT00249054|Device|ASR hip prosthesis|Implantation of resurfacing prosthesis
519047|NCT00249054|Device|ReCap hip prosthesis|Implantation of resurfacing prosthesis
519048|NCT00249041|Drug|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
519049|NCT00249041|Drug|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
519050|NCT00249015|Behavioral|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
519051|NCT00249002|Drug|ABI-007|
519052|NCT00248989|Drug|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
519053|NCT00248989|Drug|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
519054|NCT00248976|Behavioral|Net-present value of individual health behaviors in years|
519055|NCT00248963|Drug|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
519056|NCT00248950|Behavioral|Positive affect induction and /or self affirmation induction|
519057|NCT00248937|Behavioral|Positive affect and self-affect induction|
519058|NCT00248924|Behavioral|Social Services|
519059|NCT00248911|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
519060|NCT00248898|Procedure|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
519366|NCT00245921|Drug|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
519061|NCT00248885|Procedure|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
519062|NCT00248872|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
519063|NCT00248846|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
519064|NCT00248833|Biological|25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
519065|NCT00248833|Biological|50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine|The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
519066|NCT00248820|Procedure|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
519067|NCT00248807|Drug|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
519068|NCT00248807|Other|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
519069|NCT00248794|Behavioral|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
519070|NCT00248794|Behavioral|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
519071|NCT00248794|Behavioral|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
519072|NCT00248781|Device|Telecommunications system|
519073|NCT00248781|Device|attention control|health education
519074|NCT00248768|Device|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
519075|NCT00248755|Procedure|mucociliary clearance scan|
519076|NCT00248742|Behavioral|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
519077|NCT00248729|Drug|Etomidate (20mg) or Midazolam (7mg)|
519078|NCT00248716|Drug|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
519079|NCT00248703|Drug|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
519080|NCT00248690|Device|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
519081|NCT00248677|Behavioral|Behavioral Family-Based Intervention|Behavioral family intervention
519082|NCT00248677|Behavioral|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
519083|NCT00248651|Drug|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
519084|NCT00248651|Drug|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
519085|NCT00248651|Drug|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
519086|NCT00248638|Drug|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
519087|NCT00248638|Drug|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
519088|NCT00248625|Drug|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
519089|NCT00248625|Drug|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
519137|NCT00248287|Drug|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
519090|NCT00248612|Drug|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
519091|NCT00248612|Behavioral|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
519092|NCT00248612|Other|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
519093|NCT00248612|Other|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
519094|NCT00248586|Behavioral|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
519095|NCT00248586|Behavioral|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
519096|NCT00248560|Drug|docetaxel|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
519097|NCT00248560|Drug|Gemcitabine|Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
519098|NCT00248547|Drug|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
519099|NCT00248547|Drug|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
519100|NCT00248547|Drug|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
519101|NCT00248547|Drug|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
519102|NCT00248534|Biological|rituximab|given IV days 1,8, 15 and 22
519103|NCT00248534|Drug|methylprednisolone|2hr IV every 28 days post consolidation cycles of Temozolomide (TMZ) (6 cycles TMZ = Consolidation cycles)
519104|NCT00248534|Drug|temozolomide|Induction Days 1-7 and 15-21 (150mg/m2 PO) Consolidation days 1-5 every 28 days X 6 cycles
519105|NCT00248521|Drug|alvespimycin hydrochloride|
519106|NCT00248495|Drug|cisplatin|Given IV
519107|NCT00248495|Drug|pemetrexed disodium|Given IV
519108|NCT00248495|Procedure|adjuvant therapy|Metastasis prevention/control
519109|NCT00248495|Procedure|conventional surgery|Undergoing tissue removal
519110|NCT00248495|Procedure|neoadjuvant therapy|Tumor Reduction
519111|NCT00248482|Drug|Cisplatin|Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
519112|NCT00248482|Drug|Gleevec™|Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
519113|NCT00248482|Drug|irinotecan|Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
519114|NCT00248469|Behavioral|In-school Sexual Health Education|
519115|NCT00248469|Behavioral|Youth-friendly health services|
519116|NCT00248469|Behavioral|Youth condom promotion & distribution|
519117|NCT00248469|Behavioral|Community activities related to adolescent sexual health|
519118|NCT00248456|Drug|Calcipotriol plus betamethasone dipropionate ointment|
519119|NCT00248443|Procedure|Fiberoptic bronchoscopy and bronchoalveolar lavage|
519120|NCT00248430|Biological|aldesleukin|
519121|NCT00248430|Biological|therapeutic allogeneic lymphocytes|
519122|NCT00248430|Drug|melphalan|
519123|NCT00248430|Procedure|bone marrow ablation with stem cell support|
519124|NCT00248430|Procedure|peripheral blood stem cell transplantation|
519125|NCT00248404|Drug|NB1011|
519126|NCT00248391|Behavioral|upright feeding|
519127|NCT00248378|Drug|Smoked Cannabis|
519128|NCT00248365|Biological|Theralux extracorporeal photochemotherapy|
519129|NCT00248352|Behavioral|Consultation with Endocrinologist|
519130|NCT00248352|Behavioral|Counseling from Dietician|
519131|NCT00248352|Behavioral|Counseling from Diabetes Educator|
519132|NCT00248339|Drug|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
519133|NCT00248339|Drug|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD~PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
519134|NCT00248339|Drug|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.~PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
519135|NCT00248313|Drug|Rapamune®|
519136|NCT00248300|Other|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
519202|NCT00247455|Drug|High fibre cereal (All Bran/Bran Flakes)|
519138|NCT00248287|Drug|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
519139|NCT00248261|Drug|ziprasidone, sertraline|
519140|NCT00248248|Drug|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
519141|NCT00248235|Behavioral|Exercise|
519142|NCT00248222|Behavioral|Supervised aerobic training|
519143|NCT00248209|Drug|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
519144|NCT00248196|Device|Reprieve Endovascular Temperature Therapy System|
519145|NCT00248183|Drug|PRX-00023|
519146|NCT00248170|Drug|Letrozole|2.5 mg tablets
519147|NCT00248170|Drug|Anastrozole|1 mg tablets
519148|NCT00248157|Drug|Octreotide acetate in microspheres|
519149|NCT00248144|Drug|Famciclovir|
519150|NCT00248131|Drug|Octreotide acetate in microspheres|
519151|NCT00248118|Drug|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
519152|NCT00248105|Behavioral|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
519153|NCT00248092|Drug|NRP104|
519154|NCT00248079|Device|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
519155|NCT00248066|Drug|RESTEN-MP|
519156|NCT00248053|Drug|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
519157|NCT00248040|Drug|Reparixin continuous infusion|Reparixin continuous infusion
519158|NCT00248040|Drug|reparixin intermittent infusion|reparixin intermittent infusion
519159|NCT00248040|Other|placebo infusion|placebo infusion
519160|NCT00248014|Device|Mandibular Advancement Via A Functional Appliance|Functional appliance
519161|NCT00247988|Drug|Weekly Taxotere with weekly carboplatin|
519162|NCT00247975|Drug|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
519163|NCT00247962|Drug|etanercept|50 mg
519164|NCT00247962|Drug|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
519165|NCT00247936|Procedure|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
519166|NCT00247923|Procedure|Hysteroscopic resection of endometrial polyps. (TCRP)|
519167|NCT00247910|Drug|Hydrochlorothiazide|Not recorded in detailed description.
519168|NCT00247897|Drug|Skin antisepsis|See Detailed Description
519169|NCT00247832|Behavioral|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
519170|NCT00247832|Behavioral|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
519171|NCT00247819|Procedure|Blood draw|
519172|NCT00247793|Drug|Oral Impact (preoperative enteral nutritional supplement)|
519173|NCT00247780|Procedure|Pulmonary vein isolation and cavotricuspid ishtmusblock|
519174|NCT00247754|Behavioral|Cognitive Behaviour Treatment|
519175|NCT00247741|Drug|spinal administration of articaine|
519176|NCT00247741|Drug|spinal administration of lidocaine|
519177|NCT00247728|Drug|PI-88|
519178|NCT00247715|Drug|algeldrate/magnesium oxide|
519179|NCT00247715|Drug|ranitidine|
519180|NCT00247715|Drug|pantoprazole|
519181|NCT00247702|Drug|warfarin|
519182|NCT00247676|Drug|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
519183|NCT00247663|Drug|Letrozole|
519184|NCT00247650|Drug|Zoledronic Acid; Letrozole|
519185|NCT00247624|Drug|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
519186|NCT00247624|Drug|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
519187|NCT00247624|Drug|Placebo|Placebo every night for 8 weeks
519188|NCT00247611|Behavioral|LifeWindows Intervention Sessions|At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
519189|NCT00247611|Other|Control|At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
519190|NCT00247585|Drug|Ethanol (Bourbon or Vodka)|
519191|NCT00247572|Drug|NRP104|
519192|NCT00247559|Biological|Botulinum toxin type A|
519193|NCT00247546|Behavioral|Multifactorial prevention|
519194|NCT00247533|Procedure|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
519195|NCT00247520|Drug|topical nasal rEV131|
519196|NCT00247507|Drug|acetylcysteine|
519197|NCT00247494|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
519198|NCT00247481|Drug|Gefitinib|
519199|NCT00247481|Drug|Docetaxel|
519200|NCT00247468|Procedure|Strict Glucose Control|
519201|NCT00247455|Drug|Low fibre breakfast cereal (puffed rice/cornflakes)|
519204|NCT00247416|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
519205|NCT00247416|Drug|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
519206|NCT00247416|Drug|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
519207|NCT00247403|Drug|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
519208|NCT00247390|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
519209|NCT00247390|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
519210|NCT00247377|Procedure|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
519211|NCT00247377|Procedure|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
519212|NCT00247364|Drug|Levetiracetam (Keppra)|
519213|NCT00247351|Procedure|Cryoablation|
519214|NCT00247338|Drug|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
519215|NCT00247325|Drug|Iodixanol(Drug)|
519216|NCT00247312|Radiation|Pd-103|
519217|NCT00247299|Device|IPL Quantum Product manufactured by Luminis Ltd.|
519218|NCT00247286|Behavioral|weighted vaginal cones|
519219|NCT00247286|Behavioral|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
519220|NCT00247273|Drug|risedronate|tablet, 5 mg risedronate, once a day for 2 years
519221|NCT00247273|Drug|risedronate|oral, 150 mg risedronate, once a month for 2 years
519222|NCT00247260|Device|32P BioSilicon|
519223|NCT00247247|Drug|Comtess®|
519224|NCT00247234|Behavioral|Schema Therapy|group based schema therapy
519225|NCT00247234|Behavioral|standard care|standard psychiatric out-patient care
519226|NCT00247221|Behavioral|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
519227|NCT00247221|Behavioral|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
519228|NCT00247208|Device|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
519229|NCT00247208|Device|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
519230|NCT00247195|Behavioral|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
519231|NCT00247182|Behavioral|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
519232|NCT00247182|Behavioral|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
519233|NCT00247182|Behavioral|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
519234|NCT00247169|Drug|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
519235|NCT00247156|Procedure|Acupressure treatments and NAET treatments|
519236|NCT00247143|Drug|Kaletra (drug)|
519237|NCT00247130|Drug|Omeprazole|
519238|NCT00247130|Drug|Ranitidine|
519239|NCT00247117|Drug|Metformin|
519240|NCT00247104|Drug|Cranberries - Vaccinium macrocarpon|
519241|NCT00247091|Biological|standard-titer measles vaccine|
519242|NCT00247078|Biological|widow spider antivenom|3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
519243|NCT00247078|Biological|Placebo|
519244|NCT00247052|Drug|diclofenac|diclofenac 50 mg bid versus placebo bid
519245|NCT00247052|Drug|diclofenac|diclofenac 100 mg per day for 14 days
519246|NCT00247052|Drug|matching placebo|
519247|NCT00247039|Dietary Supplement|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
519248|NCT00247039|Other|Placebo capsules|placebo capsules
519249|NCT00247026|Drug|curcumin; coenzyme q10|
519250|NCT00247013|Behavioral|Breast Cancer Screening Compliance|
519251|NCT00247000|Device|Routine Care in a HF clinic vs Home Telehealth Care for HF|
519252|NCT00246987|Drug|Muraglitazar|
519253|NCT00246974|Drug|Gemcitabine|intravenous
519254|NCT00246974|Drug|Cisplatin|intravenous
519255|NCT00246974|Drug|Gefitinib|oral
519256|NCT00246948|Procedure|Active conservative treatment of sciatica|
519257|NCT00246935|Drug|Roflumilast|
519258|NCT00246922|Drug|Roflumilast|
519259|NCT00246909|Drug|Pantoprazole|
519260|NCT00246896|Behavioral|care management|
519261|NCT00246883|Procedure|Exercise|
519262|NCT00246818|Procedure|Tai Chi Chuan|
519263|NCT00246805|Device|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
519264|NCT00246792|Behavioral|Group treatment|
519265|NCT00246779|Procedure|Modified ultrafiltration|
519266|NCT00246753|Drug|lapatinib ditosylate|1500 mg, daily until disease progression
519267|NCT00246740|Drug|Periostat|In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
519367|NCT00245908|Drug|azithromycin|
519268|NCT00246740|Drug|Placebo Oral Tablet|In addition to standard care, patients received oral administration of placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
519269|NCT00246727|Drug|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
519270|NCT00246714|Drug|repeated injections of endotoxin during 5 days|
519271|NCT00246701|Drug|Simvastatin|Simvastatin
519272|NCT00246701|Drug|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
519273|NCT00246688|Drug|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
519274|NCT00246675|Drug|Frusemide|
519275|NCT00246662|Drug|Vosaroxin|All patients receive vosaroxin Injection
519276|NCT00246636|Drug|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
519277|NCT00246636|Drug|Antara (fenofibrate)|Antara (fenofibrate) + placebo
519278|NCT00246623|Drug|Exubera (inhaled insulin)|
519279|NCT00246623|Procedure|8-point glucose diary (to assess pre- and post prandial glucoses)|
519280|NCT00246623|Procedure|Meal Tolerance Test|
519281|NCT00246623|Procedure|24-hour continuous glucose monitoring (at select sites)|
519282|NCT00246623|Procedure|Pulmonary Function Testing|
519283|NCT00246623|Procedure|Hypoglycemic Event Monitoring|
519284|NCT00246623|Procedure|Laboratory Assessments|
519285|NCT00246623|Behavioral|Nutritional Counseling and Diabetes Education|
519286|NCT00246610|Drug|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg [dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
519287|NCT00246597|Drug|epoetin alfa|
519288|NCT00246584|Drug|SPP100|
519289|NCT00246571|Drug|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
519290|NCT00246571|Drug|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~Docetaxel - 75-100 mg/m2 every 3 weeks~Paclitaxel - 175-200 mg/m2 every 3 weeks~Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
519291|NCT00246545|Behavioral|exercise|
519292|NCT00246532|Drug|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
519293|NCT00246532|Drug|Placebo|Patients will receive placebo tablets.
519294|NCT00246519|Drug|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
519295|NCT00246519|Drug|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
519296|NCT00246506|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
519297|NCT00246506|Procedure|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
519298|NCT00246467|Biological|Alhydrogel|
519299|NCT00246467|Biological|rF1 and rV protein antigens|
519300|NCT00246441|Drug|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
519301|NCT00246441|Drug|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
519302|NCT00246428|Behavioral|Motivational Interviewing|Experimental manipulations will be evaluated 6, 9, and 12 months
519303|NCT00246415|Drug|Memantine|
519304|NCT00246402|Drug|Acipimox|
519305|NCT00246389|Drug|cyclobenzaprine hydrochloride|
519306|NCT00246376|Behavioral|Diet|ATP-III diet
519307|NCT00246376|Behavioral|Exercise|Supervised exercise in study gym
519308|NCT00246376|Drug|Niacin|Niaspan, titrated up to 2 grams per day
519309|NCT00246376|Drug|Fenofibrate|Tricor, 120 mg per day
519310|NCT00246376|Other|Placebos|Placebos for Niaspan and Tricor
519311|NCT00246363|Drug|Silymarin|Silymarin (milk thistle)
519312|NCT00246363|Drug|Placebo|Placebo
519313|NCT00246350|Procedure|massage|8 light massage treatments and hot pack
519314|NCT00246350|Procedure|massage|16 light massage treatments and hot packs
519315|NCT00246350|Procedure|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
519316|NCT00246350|Procedure|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
519368|NCT00245895|Drug|Aranesp|Aranesp
519317|NCT00246337|Drug|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
519318|NCT00246337|Drug|MK0974|MK0974 25 mg; one orally-administered dose
519319|NCT00246337|Drug|MK0974|MK0974 50 mg; one orally-administered dose
519320|NCT00246337|Drug|MK0974|MK0974 100 mg; one orally-administered dose
519321|NCT00246337|Drug|MK0974|MK0974 200 mg; one orally-administered dose
519322|NCT00246337|Drug|MK0974|MK0974 300 mg; one orally-administered dose
519323|NCT00246337|Drug|MK0974|MK0974 400 mg; one orally-administered dose
519324|NCT00246337|Drug|MK0974|MK0974 600 mg; one orally-administered dose
519325|NCT00246337|Drug|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
519326|NCT00246324|Drug|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
519327|NCT00246298|Drug|epoetin alfa|
519328|NCT00246285|Drug|risperidone|
519329|NCT00246272|Drug|risperidone|
519330|NCT00246259|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
519331|NCT00246259|Drug|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
519332|NCT00246246|Drug|risperidone|
519333|NCT00246233|Drug|methylphenidate|
519334|NCT00246220|Drug|methylphenidate hydrochloride|
519335|NCT00246207|Drug|CONCERTA (OROS methylphenidate hydrochloride)|
519336|NCT00246194|Drug|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
519337|NCT00246181|Procedure|radiation therapy|Patients will receive 3 fractions
519338|NCT00246168|Drug|tramadol hydrochloride + acetaminophen|
519339|NCT00246155|Biological|Botulinum toxin type A|
519340|NCT00246142|Biological|Botulinum toxin type A|
519341|NCT00246129|Drug|Alemtuzumab|Monoclonal antibody induction therapy
519342|NCT00246129|Drug|Daclizumab|Monoclonal antibody induction therapy
519343|NCT00246116|Procedure|Functional Imaging of Treatment Effects|PET & VQ Scans
519344|NCT00246103|Drug|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
519345|NCT00246103|Drug|Epirubicin|Beginning Dose, Level 1: 75 mg/m^2.
519346|NCT00246103|Drug|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m^2.
519347|NCT00246103|Drug|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m^2.
519348|NCT00246090|Drug|E7389|E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
519349|NCT00246064|Drug|infliximab|
519350|NCT00246051|Behavioral|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
519351|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.~Positive on the Berlin Questionnaire~Clinic visit, exam with a physician, given a home diagnostic device (HDD)~High risk on HDD, seen by physician, given a CPAP machine~Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed~Contacted by a sleep health clinic at 3, 6, 12 months~After 12 months subject will be referred to their primary care physician"
519352|NCT00246051|Other|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
519353|NCT00246038|Device|Boston Scientific ENOVUS AAA Endograft|
519354|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
519355|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
519356|NCT00246025|Drug|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
519357|NCT00246025|Drug|placebo|matching placebo capsule, once a day, oral administration
519358|NCT00246012|Drug|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
519359|NCT00246012|Drug|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
519360|NCT00246012|Drug|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
519361|NCT00245986|Procedure|Blood draw|
519362|NCT00245973|Drug|Bifeprunox|
519363|NCT00245960|Drug|etanercept|Group A: Period 1: 50mg BIW. Period 2: 50 mg QW. Group B: Period 1 and 2: 50mg QW.
519369|NCT00245882|Behavioral|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
519370|NCT00245882|Behavioral|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
519371|NCT00245869|Procedure|Contrast-enhanced Ultrasound|
519372|NCT00245856|Drug|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
519373|NCT00245856|Drug|Warfarin|Titrated to INR 2-3 through study month 3
519374|NCT00245843|Behavioral|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
519375|NCT00245830|Procedure|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
519376|NCT00245817|Behavioral|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
519377|NCT00245791|Drug|Levofloxacin|
519378|NCT00245765|Drug|Certolizumab Pegol|"Pharmaceutical Form: solution for injection in pre-filled syringe~Route of Administration: subcutaneous use"
519379|NCT00245765|Other|Placebo|Matching Placebo to Certolizumab Pegol
519380|NCT00245752|Device|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
519381|NCT00245739|Drug|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
519382|NCT00245726|Device|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
519383|NCT00245726|Device|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
519384|NCT00245726|Device|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
519385|NCT00245713|Drug|levetiracetam|
519386|NCT00245687|Device|Tiger Tube|
519387|NCT00245674|Drug|amisulpride|
519388|NCT00245661|Drug|Temazepam|
519389|NCT00245648|Drug|fibrinolytic therapy or combination reduced fibrinolytic therapy|
519390|NCT00245635|Drug|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
519391|NCT00245635|Drug|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
519392|NCT00245622|Biological|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
519393|NCT00245622|Biological|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
519394|NCT00245609|Drug|Pregabalin|
519395|NCT00245609|Drug|Alprazolam|
519396|NCT00245609|Drug|Placebo|
519397|NCT00245596|Drug|sildenafil|
519398|NCT00245583|Drug|Topiramate|minimum does of 50mg/day
519399|NCT00245583|Drug|Placebo|matching tablet
519400|NCT00245570|Drug|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
519401|NCT00245570|Drug|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
519402|NCT00245570|Drug|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
519403|NCT00245570|Drug|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
519404|NCT00245557|Drug|Sertraline|"Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.~Duration of treatment was 12 weeks."
519405|NCT00245544|Drug|MK0759|
519406|NCT00245518|Drug|Isoflavone|
519407|NCT00245518|Drug|Placebos|
519408|NCT00245505|Drug|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
519409|NCT00245492|Procedure|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
519410|NCT00245479|Drug|Primary nocturnal enuresis|Desmopressin
519411|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
519412|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
519413|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
519414|NCT00245453|Drug|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
519415|NCT00245453|Drug|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
519416|NCT00245453|Drug|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
519417|NCT00245440|Drug|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
519418|NCT00245440|Drug|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
519419|NCT00245427|Drug|all macrolide antibiotics|Varies based on antibiotic
519420|NCT00245427|Drug|all beta-lactam antibiotics|Varies based on antibiotic
519421|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 48 weeks
519422|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 24 weeks
519423|NCT00245401|Device|CYPHERTM Sirolimus-Eluting Coronary Stent|
519424|NCT00245388|Drug|Muraglitazar|
519425|NCT00245375|Drug|Tylenol #3|
519426|NCT00245375|Drug|Combination Tylenol and Ibuprofen|
519427|NCT00245362|Biological|CG 8020 and CG 2505|
519428|NCT00245349|Procedure|F-18 Fluorothymidine|
519429|NCT00245336|Biological|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
519430|NCT00245336|Drug|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
519431|NCT00245323|Behavioral|Smoking status as a routine vital sign|
519432|NCT00245310|Procedure|Indocyangreen (ICG) clearance|
519433|NCT00245297|Drug|Kogenate FS, reconstituted in a suspension of liposomes|
519532|NCT00244855|Other|laboratory biomarker analysis|Correlative studies
519434|NCT00245271|Drug|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
519435|NCT00245271|Drug|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
519436|NCT00245258|Drug|Sildenafil Citrate|
519437|NCT00245245|Drug|recombinant porcine coagulation factor VIII (OBI-1)|
519438|NCT00245232|Behavioral|Cognitive Therapy|
519439|NCT00245232|Behavioral|Cognitive Processing Therapy|
519440|NCT00245232|Behavioral|Written Exposure|
519441|NCT00245219|Behavioral|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
519442|NCT00245219|Behavioral|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
519443|NCT00245206|Drug|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
519444|NCT00245206|Drug|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
519445|NCT00245206|Drug|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
519446|NCT00245193|Behavioral|Motivationally-Enhanced Interpersonal Psychotherapy|
519447|NCT00245180|Behavioral|Diet|
519448|NCT00245180|Behavioral|Exercise|
519449|NCT00245167|Procedure|Tracheal Aspirate Fluid|
519450|NCT00245154|Drug|carboplatin|Given IV
519451|NCT00245154|Drug|cediranib maleate|Given orally
519452|NCT00245154|Drug|paclitaxel|Given IV
519453|NCT00245154|Other|placebo|Given orally
519454|NCT00245141|Biological|dactinomycin|
519455|NCT00245141|Drug|cyclophosphamide|
519456|NCT00245141|Drug|vincristine sulfate|
519457|NCT00245141|Radiation|radiation therapy|
519458|NCT00245128|Drug|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
519459|NCT00245115|Biological|filgrastim|
519460|NCT00245115|Drug|busulfan|
519461|NCT00245115|Drug|cyclophosphamide|
519462|NCT00245115|Procedure|in vitro-treated bone marrow transplantation|
519463|NCT00245115|Procedure|in vitro-treated peripheral blood stem cell transplantation|
519464|NCT00245102|Drug|sorafenib tosylate|Given orally
519465|NCT00245089|Biological|dactinomycin|
519466|NCT00245089|Drug|cyclophosphamide|
519467|NCT00245089|Drug|vincristine sulfate|
519468|NCT00245076|Behavioral|smoking cessation intervention|
519469|NCT00245076|Other|internet-based intervention|
519470|NCT00245063|Drug|cediranib maleate|Given PO
519471|NCT00245063|Other|laboratory biomarker analysis|Correlative studies
519472|NCT00245063|Other|pharmacogenomic studies|Optional correlative studies
519473|NCT00245050|Dietary Supplement|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
519474|NCT00245050|Drug|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
519475|NCT00245050|Drug|doxorubicin HCL liposome|IV, 40mg/m2
519476|NCT00245037|Biological|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
519477|NCT00245037|Drug|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.~IV busulfan is available and diluted and administered per package insert guidelines."
519478|NCT00245037|Drug|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).~- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
519479|NCT00245037|Drug|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.~Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.~Monitoring: Fludarabine level is not monitored.~Dose Adjustments: There are no provisions for fludarabine dose adjustments."
519480|NCT00245037|Drug|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.~Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).~Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
519533|NCT00244842|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
519534|NCT00244842|Drug|Placebo|Placebo
519535|NCT00244829|Drug|imatinib mesylate|
519536|NCT00244829|Procedure|adjuvant therapy|
519537|NCT00244816|Drug|Taxoprexin|
538080|NCT00003406|Drug|docetaxel|
519481|NCT00245037|Procedure|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:~In autologous transplants, patients receive their own stem cells.~In syngeneic transplants, patients receive stem cells from their identical twin.~In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
519482|NCT00245037|Radiation|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.~Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.~Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
519483|NCT00245037|Drug|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).~It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.~Toxicities: At the dosage used, the most common side effect will be medullary bone pain.~Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
519484|NCT00245037|Drug|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
519485|NCT00245037|Drug|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
519486|NCT00245024|Drug|sulindac|
519487|NCT00245024|Other|laboratory biomarker analysis|
519488|NCT00245011|Biological|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
519489|NCT00245011|Drug|ifosfamide|Ifosfamide administered IV.
519490|NCT00245011|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
519491|NCT00245011|Radiation|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
519492|NCT00245011|Radiation|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
519493|NCT00244998|Drug|fulvestrant|IM
519494|NCT00244985|Biological|rituximab|IV
519495|NCT00244985|Drug|pegylated liposomal doxorubicin hydrochloride|IV
519496|NCT00244972|Other|Laboratory Biomarker Analysis|Correlative studies
519497|NCT00244972|Drug|Sorafenib Tosylate|Given PO
519498|NCT00244972|Drug|Tipifarnib|Given PO
519499|NCT00244959|Drug|anastrozole|1 mg orally daily for 12 months
519500|NCT00244959|Procedure|adjuvant therapy|treatment received after breast cancer surgery
519501|NCT00244946|Biological|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
519502|NCT00244946|Drug|carmustine|
519503|NCT00244946|Drug|cytarabine|
519504|NCT00244946|Drug|etoposide|
519505|NCT00244946|Drug|melphalan|
519506|NCT00244946|Procedure|peripheral blood stem cell transplantation (PBSCT)|
519507|NCT00244933|Dietary Supplement|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
519508|NCT00244933|Drug|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days
519509|NCT00244933|Procedure|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
519510|NCT00244920|Drug|bicalutamide|
519511|NCT00244920|Drug|leuprolide acetate|
519512|NCT00244920|Drug|squalamine lactate|
519513|NCT00244920|Procedure|adjuvant therapy|
519514|NCT00244920|Procedure|antiandrogen therapy|
519515|NCT00244920|Procedure|antiangiogenesis therapy|
519516|NCT00244920|Procedure|conventional surgery|
519517|NCT00244920|Procedure|neoadjuvant therapy|
519518|NCT00244920|Procedure|releasing hormone agonist therapy|
519519|NCT00244907|Dietary Supplement|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
519520|NCT00244894|Procedure|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
519521|NCT00244894|Procedure|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
519522|NCT00244894|Procedure|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
519523|NCT00244894|Procedure|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
519524|NCT00244894|Procedure|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
519525|NCT00244881|Drug|cediranib maleate|Given orally
519526|NCT00244881|Other|laboratory biomarker analysis|Correlative studies
519527|NCT00244868|Other|counseling intervention|
519528|NCT00244868|Other|educational intervention|
519529|NCT00244855|Other|pharmacological study|Correlative studies
519530|NCT00244855|Biological|rituximab|Given IV
519531|NCT00244855|Drug|dexamethasone|Given IV
538081|NCT00003406|Drug|ifosfamide|
519538|NCT00244790|Behavioral|Diet|crossover low vs high protein diet before and after weight loss
519539|NCT00244777|Drug|Hypo-osmolar ORS|
519540|NCT00244764|Drug|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
519541|NCT00244764|Drug|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
519542|NCT00244751|Drug|GI262570 0.5 mg|GI262570 0.5 mg
519543|NCT00244751|Drug|GI262570 1.0 mg|GI262570 1.0 mg
519544|NCT00244751|Drug|Placebo|Placebo
519545|NCT00244738|Dietary Supplement|Castor oil|Patients who received castor oil for labor induction
519546|NCT00244738|Dietary Supplement|Sunflower oil|Patients who received sunflower oil as a placebo
519547|NCT00244725|Drug|Odiparcil|
519548|NCT00244725|Drug|Warfarin|
519549|NCT00244725|Drug|Coumadin|
519550|NCT00244712|Drug|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
519551|NCT00244712|Drug|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
519552|NCT00244699|Behavioral|MI Alone or Plus Mindfulness-Based Skills Training|
519553|NCT00244686|Drug|Mepolizumab|open label investigational product
519554|NCT00244673|Biological|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
519555|NCT00244660|Procedure|Frequent blood pressure measurements|
519556|NCT00244660|Behavioral|Education|
519557|NCT00244647|Drug|RESTEN-MP|
519558|NCT00244634|Drug|candsartan cilexetil|
519559|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
519560|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
519561|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
519562|NCT00244608|Drug|Budesonide/Formoterol Turbuhaler|
519563|NCT00244608|Drug|Budesonide Turbuhaler (Pulmicort)|
519564|NCT00244608|Drug|Terbutaline Turbuhaler|
519565|NCT00244595|Drug|candsartan cilexetil|
519566|NCT00244569|Drug|13C-Methacetin|
519567|NCT00244569|Device|Breath ID Machine|
519568|NCT00244556|Drug|Methotrexate plus ENBREL or ENBREL alone|
519569|NCT00244543|Drug|R89674 (generic name not yet established)|
519570|NCT00244530|Drug|Nifedipine|
519571|NCT00244517|Drug|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
519572|NCT00244517|Drug|Sevoflurane, Isoflurane, Desflurane|1 MAC
519573|NCT00244504|Drug|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
519574|NCT00244491|Behavioral|Care Transitions Intervention|
519575|NCT00244478|Dietary Supplement|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
519576|NCT00244478|Dietary Supplement|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
519577|NCT00244452|Drug|Cetrorelix|
519578|NCT00244439|Drug|MALG|30 minute application
519579|NCT00244439|Drug|Ovide (malathion) lotion 0.05%|8-12 hour application
519580|NCT00244439|Drug|Permethrin 1%|10 minute application
519581|NCT00244426|Drug|indobufen|Indobufen capsules 100 and 200mg
519582|NCT00244426|Drug|aspirin|Acetylsalicylic acid capsules 300mg
519583|NCT00244387|Drug|SPM 962|
519584|NCT00244374|Biological|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects>18 years of age will receive the Twinrix vaccine and subjects<18 years of age will receive the Engerix-B vaccine. Cohort subjects>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
519585|NCT00244374|Behavioral|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
519586|NCT00244374|Behavioral|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
519587|NCT00244374|Behavioral|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
519588|NCT00244361|Drug|rituximab|
519589|NCT00244348|Drug|Oxaliplatin (via HAI)|
519590|NCT00244348|Drug|5 Fluorouracil (systemic)|
519591|NCT00244322|Drug|LY450139 dihydrate|
519592|NCT00244322|Drug|placebo|
519593|NCT00244309|Drug|tamsulosin and/or dutasteride|
519594|NCT00244296|Drug|Duloxetine hydrochloride|
519595|NCT00244296|Drug|placebo|
519596|NCT00244283|Drug|Sevoflurane|
519597|NCT00244283|Procedure|High thoracic epidural analgesia|
519598|NCT00244270|Device|totally implantable vascular access device|totally implantable vascular access device
519599|NCT00244257|Biological|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
519600|NCT00244257|Biological|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
519601|NCT00244257|Biological|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
519602|NCT00244257|Biological|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
519603|NCT00244257|Biological|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
519604|NCT00244244|Drug|arimoclomol|
519605|NCT00244231|Drug|Nidadd|
519606|NCT00244218|Drug|tetrahydrobiopterin (BH4)|Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
519607|NCT00244205|Procedure|Identifying genes methylated in urine|
519608|NCT00244192|Drug|infliximab (Remicade)|
519609|NCT00244179|Drug|interferon-gamma|
519610|NCT00244179|Drug|infliximab|
519611|NCT00244179|Drug|dmard|
519612|NCT00244166|Drug|prednisolone|
519613|NCT00244153|Drug|intraarticular morphine|
519614|NCT00244153|Drug|intraarticular dexamethasone|
519615|NCT00244140|Drug|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
519616|NCT00244140|Drug|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
519617|NCT00244127|Drug|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
519618|NCT00244114|Drug|blood draw|Single blood sample collected to perform histamine release assay.
519619|NCT00244114|Procedure|Blood draw|Single blood sample collected to perform histamine release assay.
519620|NCT00244101|Drug|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
519621|NCT00244101|Device|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
519622|NCT00244101|Drug|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
519623|NCT00244075|Dietary Supplement|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
519624|NCT00244075|Drug|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
519625|NCT00244075|Behavioral|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
519626|NCT00244062|Behavioral|counseling|
519627|NCT00244049|Behavioral|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
519628|NCT00244049|Other|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
519629|NCT00244023|Drug|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
519630|NCT00244023|Drug|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
519631|NCT00244023|Other|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
519632|NCT00244010|Device|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
519633|NCT00243997|Behavioral|Becoming Parents Program|Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
519634|NCT00243984|Drug|topiramate|
519635|NCT00243971|Drug|SPM 962|
519636|NCT00243945|Drug|Rotigotine|
519637|NCT00243932|Drug|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
519638|NCT00243932|Drug|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
519639|NCT00243919|Behavioral|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
519640|NCT00243919|Behavioral|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
519641|NCT00243919|Behavioral|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
519808|NCT00242502|Drug|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
519642|NCT00243906|Drug|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
519643|NCT00243906|Procedure|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS >/= 10) treated within 3 hours of symptoms onset.
519644|NCT00243893|Drug|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
519645|NCT00243893|Drug|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
519646|NCT00243880|Drug|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
519647|NCT00243867|Drug|Taxoprexin|6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
519648|NCT00243854|Drug|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
519649|NCT00243841|Radiation|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
519650|NCT00243828|Device|Total Face Mask|
519651|NCT00243815|Drug|ibuprofen|
519652|NCT00243789|Drug|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.~Based on weight at screening, <30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
519653|NCT00243763|Drug|TKI258|
519654|NCT00243750|Drug|Methotrexate|
519655|NCT00243737|Drug|Artesunate-Mefloquine|
519656|NCT00243724|Drug|Esomeprazole|
519657|NCT00243711|Drug|Carboxymethylcellulose sodium and Glycerin|
519658|NCT00243698|Drug|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
519659|NCT00243685|Other|Laboratory Assay|Chemotherapy
519660|NCT00243685|Other|Mick Assay|Chemotherapy doctor determined from results
519661|NCT00243672|Drug|Atorvastatin|
519662|NCT00243672|Drug|Gemfibrozil|
519663|NCT00243659|Biological|ReFacto AF|
519664|NCT00243646|Radiation|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
519665|NCT00243646|Drug|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
519666|NCT00243646|Drug|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
519667|NCT00243633|Procedure|Real-time contrast-enhanced ultrasound sonography|
519668|NCT00243620|Device|Vacuum therapy (device)|
519669|NCT00243607|Other|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
519670|NCT00243594|Biological|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
519671|NCT00243581|Behavioral|Dean Ornish Heart Disease Reversing Program|
519672|NCT00243568|Drug|Vicriviroc|
519673|NCT00243555|Procedure|allergy skin testing|
519674|NCT00243555|Procedure|venepuncture|
519675|NCT00243542|Drug|ACZONE Gel, 5%|
519676|NCT00243542|Drug|Vehicle|
519677|NCT00243529|Biological|autologous dendritic cell vaccine|
519678|NCT00243516|Device|PREtest Consult|
519679|NCT00243503|Drug|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
519680|NCT00243490|Procedure|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
519681|NCT00243477|Drug|Escitalopram|Escitalopram 10mg or placebo once a day
519682|NCT00243464|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
519683|NCT00243451|Other|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
519684|NCT00243438|Device|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
519685|NCT00243425|Procedure|Standard Quality Improvement|
519686|NCT00243425|Procedure|Patient-centered Intervention|
519687|NCT00243412|Drug|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
519688|NCT00243412|Drug|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
519689|NCT00243412|Drug|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
519690|NCT00243412|Drug|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
519691|NCT00243412|Drug|Rituximab|500 mg or 1000 mg IV*2.
519692|NCT00243399|Drug|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
519693|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
519809|NCT00242489|Drug|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
519694|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
519695|NCT00243373|Device|Barcode technology/eMAR|
519696|NCT00243360|Behavioral|diagnostic and treatment clinical algorithms|
519697|NCT00243347|Drug|AZD2171|oral tablet
519698|NCT00243334|Other|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
519699|NCT00243321|Procedure|high dose-rate brachytherapy|High dose-rate brachytherapy
519700|NCT00243321|Procedure|intensity-modulated radiation therapy|intensity-modulated radiation therapy
519701|NCT00243308|Drug|Serine proteinase-1 (Serp-1)|
519702|NCT00243295|Drug|rhBMP-2/CPM|
519703|NCT00243282|Behavioral|Relaxation Response (instruction, pocket practice card prov)|
519704|NCT00243282|Behavioral|Mindfulness training using model developed from UMass|
519705|NCT00243269|Behavioral|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.~This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
519706|NCT00243256|Drug|Cholecalciferol|
519707|NCT00243243|Drug|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
519708|NCT00243243|Drug|Placebo|intravenous infusion of placebo (sterile water)
519709|NCT00243230|Drug|Vicriviroc maleate 20 mg|Two tablets of vicriviroc maleate 10 mg and one tablet of placebo once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc.
519710|NCT00243230|Drug|Vicriviroc maleate 30 mg|Three tablets of vicriviroc maleate 10 mg once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc.
519711|NCT00243230|Drug|Placebo|Three tablets of placebo once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc
519712|NCT00243217|Drug|SPM 936|
519713|NCT00243204|Drug|talabostat mesylate|
519714|NCT00243204|Drug|docetaxel|
519715|NCT00243191|Drug|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
519716|NCT00243178|Drug|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
519717|NCT00243165|Behavioral|Lifemel honey intake every day|
519718|NCT00243152|Drug|Lamotrigine|: 25mg and 50mg tablets
519719|NCT00243152|Drug|Placebo (for Lamotrigine)|Sugar pill manufactured to mimic Lamotrigine tablets
519720|NCT00243139|Device|Mandibular advancement device (activator)|
519721|NCT00243126|Behavioral|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
519722|NCT00243113|Drug|docetaxel|
519723|NCT00243113|Radiation|radiation therapy|
519724|NCT00243100|Drug|vorinostat|Given orally
519725|NCT00243100|Drug|gemcitabine hydrochloride|Given IV
519726|NCT00243087|Drug|BI 2536|
519727|NCT00243074|Drug|cediranib maleate|Given orally
519728|NCT00243074|Other|laboratory biomarker analysis|Correlative studies
519729|NCT00243061|Drug|cediranib maleate|Given orally
519730|NCT00243048|Dietary Supplement|soy protein isolate|
519731|NCT00243048|Radiation|radiation therapy|
519732|NCT00243035|Drug|bortezomib|Given IV
519733|NCT00243035|Drug|tipifarnib|Given orally
519734|NCT00243035|Other|laboratory biomarker analysis|Correlative studies
519735|NCT00243022|Drug|Boswellia serrata extract|given orally
519736|NCT00243022|Dietary Supplement|cyanocobalamin|given orally
519737|NCT00243009|Drug|cyclosporine|
519738|NCT00243009|Drug|fludarabine phosphate|
519739|NCT00243009|Drug|mycophenolate mofetil|
519740|NCT00243009|Procedure|allogeneic bone marrow transplantation|
519741|NCT00243009|Procedure|peripheral blood stem cell transplantation|
519742|NCT00243009|Radiation|radiation therapy|
519743|NCT00242996|Biological|filgrastim|
519744|NCT00242996|Biological|rituximab|
519745|NCT00242996|Biological|sargramostim|
519746|NCT00242996|Drug|carmustine|
519747|NCT00242996|Drug|cyclophosphamide|
519748|NCT00242996|Drug|etoposide|
519749|NCT00242996|Procedure|adjuvant therapy|
519750|NCT00242996|Procedure|bone marrow ablation with stem cell support|
519751|NCT00242996|Procedure|peripheral blood stem cell transplantation|
519752|NCT00242983|Procedure|quality-of-life assessment|
519753|NCT00242970|Device|3-Dimensional Color Scanning|Color imaging of the face and neck.
519754|NCT00242957|Behavioral|Intervention with Microfinance for AIDS and Gender Equity|
519755|NCT00242944|Drug|Pitavastatin|Pitavastatin 4mg per day
519756|NCT00242944|Drug|Atorvastatin|Atorvastatin 20mg per day
519810|NCT00242489|Drug|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
519811|NCT00242476|Drug|MK0822A|
519757|NCT00242931|Other|Nonmyeloablative stem cell conditioning regimen|"Conditioning:~Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0~Hematopoeitic Stem Cell Transplantation:~Infusion of peripheral blood stem cells, day 0~Immunosuppression:~For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop~For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
519758|NCT00242918|Drug|docetaxel|
519759|NCT00242918|Drug|ZD1839|
519760|NCT00242905|Behavioral|Study of memory using MRI|Study of memory using MRI
519761|NCT00242892|Procedure|Intra coronary measures of pressure|Intra coronary measures of pressure
519762|NCT00242879|Drug|Physician determined comparator PI + ritonavir|
519763|NCT00242879|Drug|GW640385 + ritonavir|
519764|NCT00242866|Drug|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
519765|NCT00242866|Other|Placebo|Placebo to Match GW274150
519766|NCT00242853|Procedure|Power doppler ultrasonography|
519767|NCT00242853|Procedure|High frequency ultrasonography|
519768|NCT00242853|Procedure|Exhaled nitric oxide assessment|
519769|NCT00242840|Drug|No intervention; Observational study|
519770|NCT00242827|Drug|Oral CEP-701|
519771|NCT00242814|Drug|Micardis|
519772|NCT00242814|Drug|Amlodipine|
519773|NCT00242814|Procedure|Abdominal biopsy|
519774|NCT00242801|Drug|Gefitinib|
519775|NCT00242788|Drug|Gefitinib and capecitabine|
519776|NCT00242775|Drug|Budesonide/formoterol Turbuhaler|
519777|NCT00242775|Drug|Salmeterol/fluticasone Diskus|
519778|NCT00242762|Drug|ZD1839 (IRESSA™)|
519779|NCT00242762|Drug|Docetaxel|
519780|NCT00242762|Drug|Cisplatin|
519781|NCT00242749|Drug|Gefitinib, Cisplatin and Radiotherapy|
519782|NCT00242736|Drug|Esomeprazole|
519783|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
519784|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
519785|NCT00242710|Drug|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
519786|NCT00242710|Other|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
519787|NCT00242697|Procedure|spinal analgesia and anesthesia for coronary artery surgery|
519788|NCT00242671|Procedure|Isocapnic Hyperponea|
519789|NCT00242658|Behavioral|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
519790|NCT00242645|Behavioral|Health Information|
519791|NCT00242645|Behavioral|Preventive Services|
519792|NCT00242645|Behavioral|Computer tailored information|
519793|NCT00242632|Drug|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
519794|NCT00242619|Drug|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
519795|NCT00242606|Drug|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
519796|NCT00242606|Drug|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
519797|NCT00242593|Drug|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
519798|NCT00242580|Drug|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
519799|NCT00242580|Drug|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
519800|NCT00242580|Drug|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
519801|NCT00242567|Drug|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
519802|NCT00242567|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
519803|NCT00242554|Drug|Zoledronic acid|
519804|NCT00242541|Drug|Octreotide acetate|
519805|NCT00242528|Drug|Zoledronic acid|
519806|NCT00242515|Procedure|CD8+ T-cell depleted donor lymphocyte infusion|
519807|NCT00242502|Drug|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
519812|NCT00242463|Drug|Nandrolone (anabolic steroid)|
519815|NCT00242437|Device|Hemostatic matrix|
519816|NCT00242437|Device|bovine thrombin|
519817|NCT00242424|Biological|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
519818|NCT00242411|Drug|Budesonide/Formoterol Turbuhaler|
519819|NCT00242411|Drug|Conventional Best Asthma Therapy|
519820|NCT00242398|Device|AN69 ST|
519821|NCT00242385|Biological|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
519822|NCT00242385|Biological|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
519823|NCT00242372|Drug|Tesaglitazar 0.5|
519824|NCT00242372|Drug|Insulin at least 30 units/day|
519825|NCT00242359|Drug|omalizumab|
519826|NCT00242346|Drug|candesartan cilexetil|
519827|NCT00242333|Drug|AD 237|
519828|NCT00242320|Drug|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
519829|NCT00242320|Drug|Placebo|
519830|NCT00242307|Drug|Roflumilast|
519831|NCT00242294|Drug|Roflumilast|
519832|NCT00242281|Drug|APC-111 MP Tablet, 775 mg|
519833|NCT00242268|Drug|Simvastatin|
519834|NCT00242229|Drug|DVS-233 SR|
519835|NCT00242216|Drug|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
519836|NCT00242216|Drug|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
519837|NCT00242203|Drug|Zometa|
519838|NCT00242203|Drug|Epirubicin|
519839|NCT00242203|Drug|Docetaxel|
519840|NCT00242203|Drug|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
519841|NCT00242203|Radiation|External beam radiation|
519842|NCT00242203|Procedure|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
519843|NCT00242190|Drug|oxaliplatin|
519844|NCT00242190|Drug|gemcitabine|
519845|NCT00242190|Procedure|radiation therapy|
519846|NCT00242177|Drug|ACTOS (Pioglitazone)|
519847|NCT00242164|Drug|Dialysate Magnesium (Concentration)|
519848|NCT00242138|Behavioral|Erectile Dysfunction|
519849|NCT00242112|Procedure|MRI Prostate|
519850|NCT00242099|Procedure|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
519851|NCT00242086|Procedure|CT, PET and MRI|
519852|NCT00242073|Procedure|MRI Prostate|
519853|NCT00242060|Procedure|MRI|
519854|NCT00242047|Biological|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
519855|NCT00242034|Procedure|CT and MRI with contrast|
519856|NCT00242021|Behavioral|Fatty acid composition of a margarine (spread)|
519857|NCT00242008|Drug|Rotigotine|
519858|NCT00241995|Drug|Anticonvulsants|
519859|NCT00241982|Drug|long-circulating liposomal prednisolone|
519860|NCT00241969|Behavioral|Behavioral and Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills. The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
519861|NCT00241969|Behavioral|Education and Attention Control|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.The treatment is delivered through 8 weekly sessions followed by 4 monthly sessions, each lasting around 60 minutes.
519862|NCT00241943|Procedure|Hepatitis C educational video|
519863|NCT00241930|Behavioral|Integrating drug treatment into HIV services|
519864|NCT00241917|Behavioral|Hepatitis C educational video|
519865|NCT00241917|Other|Video|Prevention education video about hepatitis C
519866|NCT00241904|Behavioral|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
519867|NCT00241904|Drug|Antiplatelet Agents|Aspirin 81 mg q day
519868|NCT00241904|Drug|Beta Blocker|Oral medication
519869|NCT00241904|Drug|ACE Inhibitors|Oral medications, received 1-2 times per day
519870|NCT00241891|Behavioral|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
519871|NCT00241891|Behavioral|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
519872|NCT00241891|Behavioral|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
519924|NCT00241267|Device|Dedicated ultrasonographic probe during bronchoscopy|
519925|NCT00241254|Drug|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
519926|NCT00241254|Drug|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
519927|NCT00241241|Drug|pegylated interferon-alfa 2a|
519928|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
519929|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
519930|NCT00241215|Drug|Botulinum toxin serotype A|
519873|NCT00241878|Behavioral|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
519874|NCT00241878|Behavioral|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
519875|NCT00241852|Behavioral|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
519876|NCT00241852|Behavioral|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
519877|NCT00241839|Drug|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
519878|NCT00241839|Drug|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
519879|NCT00241839|Drug|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
519880|NCT00241839|Drug|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
519881|NCT00241826|Procedure|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
519882|NCT00241826|Procedure|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
519883|NCT00241813|Behavioral|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
519884|NCT00241813|Behavioral|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
519885|NCT00241813|Behavioral|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
519886|NCT00241722|Drug|Alvimopan|
519887|NCT00241722|Drug|Placebo|
519888|NCT00241670|Drug|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
519889|NCT00241657|Biological|BCG|
519890|NCT00241644|Biological|Rotarix™|Two or Three doses, oral administration
519891|NCT00241644|Biological|Placebo|One or three doses, oral administration.
519892|NCT00241631|Drug|fluticasone|500 mg b.d.
519893|NCT00241631|Drug|placebo|
519894|NCT00241618|Drug|Pegylated interferon alpha 2|
519895|NCT00241618|Drug|Ribavirin|
519896|NCT00241605|Drug|rosiglitazone/metformin|
519897|NCT00241592|Drug|Cannabis|
519898|NCT00241579|Drug|Smoked Cannabis|
519899|NCT00241566|Device|implantation of stimulator|
519900|NCT00241553|Drug|Esomeprazole|
519901|NCT00241540|Drug|Esomeprazole|
519902|NCT00241527|Drug|Esomeprazole|
519903|NCT00241514|Drug|Esomeprazole|
519904|NCT00241501|Drug|Esomeprazole (Nexium)|
519905|NCT00241488|Drug|Rosuvastatin|
519906|NCT00241475|Drug|Gefitinib|
519907|NCT00241449|Drug|Fulvestrant|intramuscular injection 250 mg
519908|NCT00241449|Drug|Tamoxifen|20 mg oral tablet
519909|NCT00241436|Drug|Anastrozole (ARIMIDEX™)|
519910|NCT00241423|Drug|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
519911|NCT00241423|Drug|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
519912|NCT00241410|Biological|OralvacB2MPL|Comparison of different dosages of drug
519913|NCT00241384|Procedure|External beam radiation|
519914|NCT00241384|Procedure|Pd-103|
519915|NCT00241371|Drug|Clofarabine|
519916|NCT00241358|Drug|AMD3100|
519917|NCT00241358|Procedure|Stem Cell Transplant|
519918|NCT00241345|Drug|Valganciclovir|
519919|NCT00241345|Drug|Ganciclovir|
519920|NCT00241332|Drug|fentanyl|
519921|NCT00241319|Drug|R89674 (generic name not yet established)|
519922|NCT00241280|Device|etafilcon A|
519931|NCT00241202|Behavioral|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
519932|NCT00241189|Drug|rapamycin|
519933|NCT00241189|Drug|methotrexate|
519934|NCT00241176|Drug|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS & CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
519935|NCT00241163|Procedure|Fibrinogen (human) + thrombin (human) (TachoSil)|
519936|NCT00241150|Drug|VALSARTAN|
519937|NCT00241137|Drug|valsartan|
519938|NCT00241124|Drug|valsartan|
519939|NCT00241124|Drug|lisinopril|
519940|NCT00241111|Drug|zoledronic acid|
519941|NCT00241098|Drug|valsartan|
519942|NCT00241085|Drug|valsartan|
519943|NCT00241072|Drug|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
519944|NCT00241059|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
519945|NCT00241046|Drug|Letrozole|
519946|NCT00241020|Drug|Octreotide|
519947|NCT00241007|Drug|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
519948|NCT00240994|Drug|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
519949|NCT00240994|Drug|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
519950|NCT00240994|Drug|Mycophenolate mofetil|Per recommendation
519951|NCT00240994|Drug|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
519952|NCT00240981|Drug|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
519953|NCT00240981|Drug|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
519954|NCT00240968|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
519955|NCT00240955|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
519956|NCT00240942|Drug|Letrozole|
519957|NCT00240929|Drug|MEDI-493|Active Comparator
519958|NCT00240916|Biological|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
519959|NCT00240916|Biological|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
519960|NCT00240903|Biological|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
519961|NCT00240877|Biological|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
519962|NCT00240877|Other|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
519963|NCT00240864|Drug|placebo|
519964|NCT00240864|Drug|acetaminophen|
519965|NCT00240864|Drug|ibuprofen|
519966|NCT00240851|Drug|acetaminophen extended release|
519967|NCT00240838|Drug|acetaminophen extended release caplets|
519968|NCT00240825|Drug|Ibuprofen|
519969|NCT00240825|Drug|Placebo|
519970|NCT00240825|Drug|Acetaminophen|
519971|NCT00240812|Drug|ibuprofen; pseudoephedrine HCl|
519972|NCT00240799|Drug|acetaminophen extended release|
519973|NCT00240799|Drug|placebo|
519974|NCT00240786|Drug|acetaminophen extended release|
519975|NCT00240773|Drug|acetaminophen|4 grams daily for six months
519976|NCT00240773|Drug|naproxen|750 mg daily for 12 months
519977|NCT00240773|Drug|acetaminophen|4 grams daily for 12 months
519978|NCT00240773|Drug|naproxen|750 mg daily for six months
519979|NCT00240760|Drug|Memantine Hydrochloride|
519980|NCT00240747|Drug|Synercid|
519981|NCT00240734|Drug|Epoetin alfa|
519982|NCT00240721|Drug|topiramate|
519983|NCT00240708|Drug|risperidone|
519984|NCT00240695|Drug|galantamine hydrobromide|
519985|NCT00240682|Drug|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
519986|NCT00240669|Device|Resorbable device PLLA/PGA|
519987|NCT00240669|Device|Titanium device|
519988|NCT00240656|Drug|spironolactone captopril carvedilol|
519989|NCT00240643|Drug|SB424323|
519990|NCT00240630|Drug|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
519991|NCT00240630|Drug|placebo|placebo to match
519992|NCT00240617|Drug|sumatriptan succinate/naproxen sodium|comparator
519993|NCT00240617|Drug|placebo|placebo to match
519994|NCT00240604|Drug|Rosiglitazone|4 mg rosiglitazone per day
519995|NCT00240565|Drug|Tositumomab 450 mg|Unlabeled TST
520122|NCT00239447|Device|HandiHaler|
519996|NCT00240565|Drug|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
519997|NCT00240552|Drug|fosamprenavir|
519998|NCT00240552|Drug|Telzir®|
519999|NCT00240539|Procedure|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
520000|NCT00240526|Biological|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
520001|NCT00240526|Biological|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
520002|NCT00240513|Drug|Minocycline|100 mg capsules OD for 3 months
520003|NCT00240513|Drug|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
520004|NCT00240500|Biological|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
520005|NCT00240487|Drug|Nitric Oxide|Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
520006|NCT00240487|Other|No Intervention|Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
520007|NCT00240474|Drug|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
520008|NCT00240474|Drug|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
520009|NCT00240461|Dietary Supplement|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
520010|NCT00240461|Dietary Supplement|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
520011|NCT00240461|Other|Placebo|crystalline substance 200 mg twice daily for 6 months
520012|NCT00240448|Drug|telmisartan 80 mg/hydrochlorothiazide 25 mg|
520013|NCT00240448|Drug|valsartan 160 mg/hydrochlorothiazide 25 mg|
520014|NCT00240448|Drug|placebo|
520015|NCT00240435|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
520016|NCT00240435|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
520017|NCT00240422|Drug|Telmisartan|
520018|NCT00240422|Drug|Ramipril|
520019|NCT00240409|Drug|Pramipexole|
520020|NCT00240409|Drug|Bromocriptine|
520021|NCT00240396|Drug|Narcotics alone|
520022|NCT00240396|Drug|Narcotics and NSAIDS|
520023|NCT00240383|Drug|Muraglitazar|
520024|NCT00240370|Drug|Muraglitazar|
520025|NCT00240357|Procedure|Lifestyle Regulation|
520026|NCT00240331|Drug|10mg Rosuvastatin|
520027|NCT00240331|Drug|Placebo|
520028|NCT00240318|Drug|Rosuvastatin calcium|
520029|NCT00240305|Drug|Rosuvastatin|
520030|NCT00240292|Drug|Rosuvastatin|
520031|NCT00240279|Drug|Rosuvastatin|
520032|NCT00240279|Procedure|aortic pulse wave velocity measurements|
520033|NCT00240266|Drug|Rosuvastatin|
520034|NCT00240253|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC injection
520035|NCT00240227|Drug|Prazosin|FDA approved medication for hypertension
520036|NCT00240227|Drug|placebo|
520037|NCT00240214|Drug|sirolimus|Tablet, dosage is determined by trough level
520038|NCT00240188|Procedure|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
520039|NCT00240188|Procedure|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
520040|NCT00240175|Other|No Intervention|No Intervention
520041|NCT00240162|Drug|PTK787/ZK 222584|
520042|NCT00240149|Drug|Regular Insulin via Insulin-Glucose Algorithm|
520043|NCT00240123|Drug|Benadryl versus Placebo|
520044|NCT00240110|Drug|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
520045|NCT00240110|Drug|Placebo|Control arm
520046|NCT00240110|Drug|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
520047|NCT00240097|Drug|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
520048|NCT00240097|Drug|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
520049|NCT00240084|Drug|nesiritide (Natrecor(TM))|administration of IV nesiritide
520050|NCT00240071|Drug|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
520051|NCT00240071|Drug|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
520052|NCT00240058|Drug|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
520053|NCT00240045|Drug|Midodrine, albumin, octreotide LAR|
520054|NCT00240045|Drug|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
520055|NCT00240032|Drug|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
520056|NCT00240032|Drug|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
520057|NCT00240019|Drug|Addition of furosemide 20 mg oral bid to baseline regimen|
520058|NCT00240006|Procedure|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
520059|NCT00239993|Drug|glatiramer acetate|
520060|NCT00239993|Procedure|Warm compress prior to injection of glatiramer acetate|
520123|NCT00239447|Device|Respimat SMI|
520061|NCT00239980|Drug|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
520062|NCT00239967|Drug|Rimonabant (SR141716)|
520063|NCT00239967|Drug|Placebo|
520064|NCT00239954|Drug|Escitalopram|
520065|NCT00239928|Drug|pegaptanib sodium|1 drop per dosed eye per protocol.
520066|NCT00239915|Drug|Pagoclone|
520067|NCT00239902|Drug|FTY720|
520068|NCT00239889|Drug|Salmon calcitonin|
520069|NCT00239876|Drug|FTY720|
520070|NCT00239863|Drug|FTY720|
520071|NCT00239850|Behavioral|lifestyle changes|
520072|NCT00239837|Behavioral|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
520073|NCT00239824|Behavioral|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.~Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
520074|NCT00239824|Behavioral|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
520075|NCT00239811|Drug|FTY720|
520076|NCT00239798|Drug|FTY720|
520077|NCT00239785|Drug|FTY720|
520078|NCT00239772|Behavioral|Cognitive Processing Therapy|
520079|NCT00239772|Behavioral|Prolonged Exposure Therapy|
520080|NCT00239746|Drug|Ibuprofen|200mg taken orally daily for 6-12 weeks
520081|NCT00239746|Drug|Placebo|200mg matched placebo taken orally daily for 6-12 weeks
520082|NCT00239733|Drug|Anti-D|30-minute infusion administered in an outpatient setting
520083|NCT00239720|Drug|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
520084|NCT00239720|Drug|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
520085|NCT00239707|Drug|GIP|One-time 20 ng/kg/min infusion over 3 hours
520086|NCT00239707|Drug|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
520087|NCT00239707|Drug|Normal Saline|one-time infusion over 3 hours
520088|NCT00239694|Biological|Pneumococcal Vaccine|One time preventative vaccine
520089|NCT00239694|Biological|Meningococcal Vaccine|One time preventative vaccine
520090|NCT00239681|Drug|Rosuvastatin|Oral
520091|NCT00239681|Other|Placebo|Oral
520092|NCT00239655|Drug|MK0812|
520093|NCT00239642|Drug|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
520094|NCT00239642|Drug|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
520095|NCT00239642|Drug|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
520096|NCT00239629|Drug|Teriparatide|
520097|NCT00239629|Drug|Strontium ranelate|
520098|NCT00239629|Procedure|Transiliac bone biopsy|
520099|NCT00239616|Drug|iron sucrose injection USP|
520100|NCT00239603|Device|OV-Watch|
520101|NCT00239590|Drug|Testosterone undecanoate|Licensed for androgen deficiency
520102|NCT00239577|Biological|Live attenuated tetravalent dengue vaccine|Live attenuated tetravalent dengue vaccine
520103|NCT00239577|Biological|Placebo|Placebo
520104|NCT00239564|Drug|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
520105|NCT00239564|Drug|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
520106|NCT00239564|Drug|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
520107|NCT00239564|Drug|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
520108|NCT00239564|Drug|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
520109|NCT00239551|Drug|Prevacid|Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 & EGD with biopsy at 8 weeks
520110|NCT00239538|Drug|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
520111|NCT00239538|Drug|valsartan combined with hydrochlorothiazide (160/12.5mg)|
520112|NCT00239525|Device|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
520113|NCT00239525|Drug|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
520114|NCT00239512|Drug|Indomethacin and Ibuprofen|
520115|NCT00239499|Drug|Tiotropium|
520116|NCT00239499|Drug|Salmeterol plus Fluticasone|
520117|NCT00239486|Drug|Pramipexole|
520118|NCT00239473|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
520119|NCT00239473|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
520120|NCT00239460|Drug|Tiotropium|
520121|NCT00239447|Drug|Tiotropium|
520124|NCT00239434|Drug|tiotropium inhalation powder capsule|
520125|NCT00239434|Drug|ipratropium bromide Metered Dose Inhaler|
520126|NCT00239421|Drug|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
520127|NCT00239421|Drug|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
520128|NCT00239408|Device|Pulmonary function Testing|
520129|NCT00239408|Drug|tiotropium bromide|
520130|NCT00239395|Drug|Meloxicam ampoule|
520131|NCT00239395|Drug|Meloxicam tablet|
520132|NCT00239382|Drug|Meloxicam ampoule|
520133|NCT00239382|Drug|Meloxicam tablet|
520134|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
520135|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
520136|NCT00239356|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
520137|NCT00239343|Drug|gefitinib|
520138|NCT00239330|Drug|Rosuvastatin|
520139|NCT00239330|Drug|Atorvastatin|
520140|NCT00239317|Drug|Tamusulosin|
520141|NCT00239304|Drug|Gefitinib|
520142|NCT00239304|Drug|Cisplatin|
520143|NCT00239304|Procedure|Radiotherapy|
520144|NCT00239291|Drug|Gefitinib, radiotherapy|
520145|NCT00239278|Drug|budesonide/formoterol, 2x 200/6 microgram. 4 times daily|
520146|NCT00239278|Drug|prednisolone, 30 mg once daily and placebo|
520147|NCT00239265|Drug|Tamuslosin|
520148|NCT00239252|Drug|Interferon alfacon-1|
520149|NCT00239239|Drug|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
520150|NCT00239226|Procedure|IAS pacing - study group|site of implant and permanent pacing
520151|NCT00239226|Procedure|IAS pacing control group|site of implant and permanent pacing
520152|NCT00239226|Procedure|Pacing RAA study group|site of implant and permanent pacing
520153|NCT00239226|Procedure|Pacing RAA control group|site of implant and permanent pacing
520154|NCT00239213|Drug|catechin extracts (health food)|
520155|NCT00239200|Drug|Lapatinib|
520156|NCT00239187|Drug|E1 and G1|
520157|NCT00239174|Drug|SR147778|
520158|NCT00239161|Drug|Levofloxacin|
520159|NCT00239148|Drug|E1 and G1|
520160|NCT00239135|Drug|PEP005|
520161|NCT00239122|Behavioral|Recovery Therapy (Cognitive Behaviour Therapy for psychosis)|
520162|NCT00239109|Drug|Ziprasidone|
520163|NCT00239109|Drug|Olanzapine|
520164|NCT00239109|Procedure|Scales|
520165|NCT00239109|Procedure|measures of the body (Weight...)|
520166|NCT00239109|Procedure|Serum analysis|
520167|NCT00239096|Drug|losartan (drug)|
520168|NCT00239083|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520169|NCT00239070|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520170|NCT00239057|Drug|Enteric-Coated Mycophenolate Sodium|
520171|NCT00239044|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
520172|NCT00239031|Drug|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
520173|NCT00239018|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520174|NCT00239005|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520175|NCT00239005|Drug|Mycophenolate Mofetil (MMF)|
520176|NCT00238992|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
520177|NCT00238979|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520178|NCT00238966|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520179|NCT00238953|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520180|NCT00238940|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
520181|NCT00238927|Drug|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
520182|NCT00238914|Drug|Naltrexone|50mg of oral naltrexone daily
520183|NCT00238914|Behavioral|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
520184|NCT00238914|Behavioral|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
520185|NCT00238901|Drug|Basiliximab|
520186|NCT00238888|Procedure|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
520187|NCT00238888|Procedure|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
520188|NCT00238875|Procedure|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
520189|NCT00238862|Procedure|Amniotic membrane transplantation|
520190|NCT00238862|Drug|Autologous serum/BSS 20%|
520191|NCT00238849|Drug|Oxaliplatin|
520192|NCT00238836|Behavioral|Self-management of chronic illness|
520193|NCT00238797|Drug|Gefitinib|
520194|NCT00238784|Drug|Budesonide/formoterol Turbuhaler|
520195|NCT00238758|Drug|Omega-3 Polyunsaturated Fatty Acids|
520196|NCT00238745|Drug|Bazedoxifene|
520197|NCT00238745|Drug|Placebo|
520198|NCT00238732|Drug|Bazedoxifene/Conjugated Estrogen|
520199|NCT00238719|Drug|Venlafaxine ER|
520200|NCT00238706|Device|Radiofrequency ablation|
520201|NCT00238680|Behavioral|Bladder rehabilitation|
520202|NCT00238680|Behavioral|Bladder rehabilitation with programmable timer|
520203|NCT00238667|Drug|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
520204|NCT00238667|Drug|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
520205|NCT00238641|Drug|Botulinum Toxin type B|
520206|NCT00238628|Drug|Bexarotene|
520207|NCT00238628|Drug|Iressa|
520208|NCT00238615|Drug|Docetaxel|20 mg/m2, 75 mg/m2 infusion
520209|NCT00238615|Drug|Carboplatin|AUC of 2 and 6 infusion
520210|NCT00238615|Procedure|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
520211|NCT00238615|Procedure|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
520212|NCT00238602|Procedure|Stereotactic radiosurgery|
520213|NCT00238563|Drug|Triamcinolone injection, sub-tenon|
520214|NCT00238550|Drug|Cannabis based medicine extract (CBME)|
520215|NCT00238537|Drug|Alteplase t-PA|
520216|NCT00238524|Drug|SPM 927|
520217|NCT00238511|Drug|SPM 927|
520218|NCT00238498|Drug|vildagliptin|
520219|NCT00238485|Drug|Licarbazepine|
520220|NCT00238472|Drug|nateglinide|
520221|NCT00238459|Drug|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
520222|NCT00238459|Drug|multiple licensed drugs not randomized|
520223|NCT00238459|Drug|multiple licensed antiretroviral drugs; not randomized|
520224|NCT00238459|Other|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
520225|NCT00238446|Drug|EC-MPS|
520226|NCT00238433|Biological|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC> 1500 for 2 consecutive days.
520227|NCT00238433|Drug|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
520228|NCT00238433|Drug|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
520229|NCT00238433|Drug|thiotepa|250 mg/m2/day/iv on days -3 and -2
520230|NCT00238433|Procedure|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
520231|NCT00238433|Procedure|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
520232|NCT00238420|Drug|Paclitaxel|Given IV
520233|NCT00238420|Radiation|Radiation Therapy|Undergo radiation therapy
520234|NCT00238420|Biological|Trastuzumab|Given IV
520235|NCT00238407|Drug|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
520236|NCT00238407|Radiation|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
520237|NCT00238394|Drug|cediranib maleate|Given orally
520238|NCT00238394|Other|laboratory biomarker analysis|Correlative studies
520239|NCT00238381|Procedure|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
520240|NCT00238381|Procedure|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
520241|NCT00238381|Procedure|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
520242|NCT00238368|Biological|filgrastim|
520243|NCT00238368|Biological|rituximab|
520244|NCT00238368|Drug|busulfan|
520245|NCT00238368|Drug|cisplatin|
520246|NCT00238368|Drug|cyclophosphamide|
520247|NCT00238368|Drug|cytarabine|
520248|NCT00238368|Drug|doxorubicin hydrochloride|
520249|NCT00238368|Drug|etoposide|
520250|NCT00238368|Drug|methylprednisolone|
520251|NCT00238368|Drug|prednisone|
520252|NCT00238368|Drug|vincristine sulfate|
520253|NCT00238368|Procedure|autologous bone marrow transplantation|
520254|NCT00238368|Procedure|peripheral blood stem cell transplantation|
520255|NCT00238368|Procedure|positron emission tomography|
520256|NCT00238368|Radiation|fludeoxyglucose F 18|
520257|NCT00238368|Radiation|radiation therapy|
520258|NCT00238355|Drug|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
520259|NCT00238355|Drug|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
520260|NCT00238342|Genetic|proteomic profiling|
520261|NCT00238342|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
520262|NCT00238342|Procedure|biopsy|
520263|NCT00238329|Biological|PEG-interferon alfa-2b|
520264|NCT00238329|Drug|thalidomide|
520265|NCT00238316|Drug|letrozole|2.5 mg PO daily for 1 year
520266|NCT00238316|Other|Placebo|2.5 mg PO daily for one 1 year
520267|NCT00238303|Drug|vorinostat|Given orally
520268|NCT00238303|Procedure|conventional surgery|Patients undergo surgery to remove tumor
520269|NCT00238290|Drug|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
520270|NCT00238277|Drug|temozolomide|
520271|NCT00238277|Procedure|adjuvant therapy|
520272|NCT00238277|Procedure|chemotherapy|
520273|NCT00238277|Procedure|radiation therapy|
520274|NCT00238264|Radiation|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
520275|NCT00238251|Drug|gefitinib|Once daily during days 1-28
520276|NCT00238251|Drug|temozolomide|Once daily on days 1-21
520277|NCT00238251|Radiation|radiation therapy|Whole brain radiotherapy
520278|NCT00238238|Biological|rituximab|Given IV
520279|NCT00238238|Drug|lenalidomide|Given orally
520280|NCT00238225|Dietary Supplement|calcitriol|
520281|NCT00238225|Drug|dexamethasone|
520282|NCT00238225|Drug|ketoconazole|
520283|NCT00238212|Drug|sorafenib tosylate|Given orally
520284|NCT00238212|Other|laboratory biomarker analysis|Correlative studies
520285|NCT00238199|Dietary Supplement|calcitriol|
520286|NCT00238199|Drug|docetaxel|
520287|NCT00238173|Biological|filgrastim|
520288|NCT00238173|Drug|acetylcysteine|administered i.v. over 30 to 60 minutes
520289|NCT00238173|Drug|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
520290|NCT00238173|Drug|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
520291|NCT00238173|Drug|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
520292|NCT00238173|Drug|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
520293|NCT00238173|Drug|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
520294|NCT00238160|Drug|cisplatin|
520295|NCT00238160|Drug|fluorouracil|
520296|NCT00238160|Procedure|adjuvant therapy|
520297|NCT00238160|Procedure|chemotherapy|
520298|NCT00238160|Procedure|conventional surgery|
520299|NCT00238160|Procedure|hepatic arterial infusion|
520300|NCT00238160|Procedure|surgery|
520301|NCT00238147|Drug|capecitabine|
520302|NCT00238147|Drug|carboplatin|
520303|NCT00238147|Drug|docetaxel|
520304|NCT00238147|Procedure|conventional surgery|
520305|NCT00238147|Procedure|neoadjuvant therapy|
520306|NCT00238147|Radiation|radiation therapy|
520307|NCT00238121|Drug|sorafenib tosylate|Given orally
520308|NCT00238108|Drug|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
520309|NCT00238108|Drug|Placebo|Placebo
520310|NCT00238082|Drug|HFA-134A Beclomethasone DIpropionate (QVAR)|
520311|NCT00238069|Device|CPAP machine as a result of sleep study|
520312|NCT00238056|Drug|domperidone Drug|
520313|NCT00238043|Drug|Biogeneric Epoetin|
520314|NCT00238030|Drug|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
520315|NCT00238030|Drug|iv thryoxine|thyroxine 2 mcg/kg iv
520316|NCT00238017|Drug|amodiaquine-artesunate versus amodiaquine|
520317|NCT00238004|Drug|Nicotinic acid|
520318|NCT00237991|Biological|Hepatitis A|
520319|NCT00237978|Drug|Adapalen|
520320|NCT00237978|Radiation|VIS and wIRA|
520321|NCT00237965|Behavioral|Mole Mapping Diagram|
520322|NCT00237952|Drug|EDTA chelating agents|
520323|NCT00237939|Drug|Aripiprazole|
520324|NCT00237926|Behavioral|Exercise|aerobic or resistance training
520325|NCT00237913|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
520326|NCT00237913|Drug|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
520327|NCT00237900|Drug|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
520328|NCT00237887|Drug|adalimumab|
520329|NCT00237874|Drug|Aripiprazole|
520330|NCT00237861|Drug|risperidone|
520331|NCT00237861|Drug|olanzapine|
520332|NCT00237861|Drug|quetiapine|
520333|NCT00237848|Drug|D-serine|
520334|NCT00237848|Behavioral|Cognitive retraining|
520335|NCT00237822|Behavioral|Adherence Feedback (AF)|
520336|NCT00237822|Behavioral|AF + Contingency Management (AF + CM)|
520337|NCT00237822|Behavioral|AF + Motivational Enhancement Therapy (AF + MET)|
520338|NCT00237809|Drug|D-serine|D-serine (30 mg/kg)
520339|NCT00237809|Behavioral|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
520340|NCT00237809|Drug|Placebo|Placebo D-serine Drug
520341|NCT00237809|Behavioral|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
520342|NCT00237796|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
520343|NCT00237796|Behavioral|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
520344|NCT00237783|Drug|dialysate sodium (140 mmol/L)|
520345|NCT00237783|Drug|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
520346|NCT00237770|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
520347|NCT00237770|Procedure|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
520391|NCT00237445|Drug|azithromycin|
520392|NCT00237419|Drug|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
520393|NCT00237406|Procedure|interactive voice response|
520394|NCT00237393|Drug|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
520348|NCT00237757|Behavioral|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
520349|NCT00237757|Behavioral|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
520350|NCT00237744|Device|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
520351|NCT00237744|Device|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
520352|NCT00237744|Other|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
520353|NCT00237731|Drug|morphine|morphine 0.05
520354|NCT00237731|Drug|morphine|morphine 0.10
520355|NCT00237718|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
520356|NCT00237718|Drug|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
520357|NCT00237718|Drug|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
520358|NCT00237718|Drug|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
520359|NCT00237705|Drug|metoclopramide|
520360|NCT00237692|Behavioral|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
520361|NCT00237692|Behavioral|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
520362|NCT00237692|Behavioral|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral & medication management
520363|NCT00237679|Behavioral|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
520364|NCT00237679|Behavioral|Unstimulated|No current is generated.
520365|NCT00237666|Drug|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
520366|NCT00237653|Drug|Valganciclovir|
520367|NCT00237640|Drug|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
520368|NCT00237627|Drug|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
520369|NCT00237627|Drug|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
520370|NCT00237627|Drug|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
520371|NCT00237614|Drug|intravenous and oral N-acetylcysteine|
520372|NCT00237601|Other|obstetric care|
520373|NCT00237588|Drug|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
520374|NCT00237575|Drug|gemcitabine|
520375|NCT00237575|Drug|cisplatin|
520376|NCT00237575|Drug|sargramostim|
520377|NCT00237575|Drug|filgrastim|
520378|NCT00237562|Procedure|Large loop electrosurgical excision|
520379|NCT00237549|Procedure|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.~The training included meetings, practice visiting, written feed back reports and reminders on controls."
520380|NCT00237536|Drug|Lonidamine|
520381|NCT00237523|Drug|IoGen (molecular iodine)|
520382|NCT00237510|Drug|terazosin|
520383|NCT00237497|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
520384|NCT00237497|Drug|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
520385|NCT00237497|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
520386|NCT00237484|Drug|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|"Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:~powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
520387|NCT00237484|Drug|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|"Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks~200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
520388|NCT00237471|Drug|Insulin (tight blood glucose control)|
520389|NCT00237458|Drug|Lacosamide|"Dosage: Lacosamide up to 400 mg/day;~Dosage form: Film-coated tablets;~Dosage Frequency and Duration: Two times per day; 9.5 years"
520390|NCT00237445|Drug|telithromycin|
520395|NCT00237393|Drug|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
520396|NCT00237380|Drug|PTC124|
520397|NCT00237367|Drug|rabeprazole and pantoprazole|
520398|NCT00237354|Drug|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
520399|NCT00237341|Drug|fentanyl|
520400|NCT00237328|Drug|Heparin|Heparin will be used as the intra-operative anticoagulant
520401|NCT00237302|Drug|topiramate|
520402|NCT00237289|Drug|topiramate|
520403|NCT00237276|Procedure|colonoscopy|
520404|NCT00237263|Drug|Entacapone|
520405|NCT00237250|Drug|vildagliptin|
520406|NCT00237237|Drug|vildagliptin|
520407|NCT00237224|Drug|Letrozole|
520408|NCT00237211|Drug|Letrozole|
520409|NCT00237198|Drug|Letrozole|
520410|NCT00237185|Drug|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
520411|NCT00237172|Drug|Imatinib Mesylate|once daily
520412|NCT00237159|Drug|Zoledronic acid|
520413|NCT00237146|Drug|Zoledronic acid|
520414|NCT00237133|Drug|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
520415|NCT00237120|Drug|Imatinib|
520416|NCT00237107|Procedure|Curretage|
520417|NCT00237094|Behavioral|Nurse Practitioner led multidisciplinary team approach|
520418|NCT00237068|Drug|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
520419|NCT00237042|Behavioral|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
520420|NCT00237042|Behavioral|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
520421|NCT00237042|Drug|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
520422|NCT00237016|Drug|doxycycline treatment|
520423|NCT00237003|Behavioral|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
520424|NCT00236990|Drug|pentosan polysulfate sodium|
520425|NCT00236977|Drug|Venofer|iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
520426|NCT00236977|Drug|Ferrous Sulfate|oral iron tablets; 325 mg three times a day orally for 56 days
520427|NCT00236964|Drug|Iron Sucrose + Erythropoietin|
520428|NCT00236964|Drug|Ferrous Sulfate + Erythropoietin|
520429|NCT00236951|Drug|iron sucrose injection USP|
520430|NCT00236951|Drug|stable erythropoietin therapy|
520431|NCT00236938|Drug|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
520432|NCT00236938|Drug|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
520433|NCT00236925|Drug|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
520434|NCT00236925|Drug|Placebo|Placebo
520435|NCT00236912|Drug|levofloxacin; metronidazole|
520436|NCT00236899|Drug|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).~Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
520437|NCT00236899|Drug|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
520438|NCT00236899|Drug|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.~Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
520439|NCT00236886|Drug|topiramate|
520440|NCT00236873|Drug|topiramate|
520441|NCT00236860|Drug|topiramate|
520442|NCT00236847|Drug|topiramate|
520443|NCT00236834|Drug|levofloxacin; imipenem/cilastitin|
520444|NCT00236821|Drug|levofloxacin|
520446|NCT00236795|Drug|norelgestromin + ethinyl estradiol; triphasil.|
520447|NCT00236782|Drug|norelgestromin + ethinyl estradiol; mercilon|
520448|NCT00236769|Drug|norelgestromin + ethinyl estradiol|
520449|NCT00236756|Drug|topiramate|
520450|NCT00236743|Drug|topiramate|
520451|NCT00236730|Drug|topiramate|
520452|NCT00236717|Drug|Topiramate; Carbamazepine; Valproate|
520453|NCT00236704|Drug|topiramate|
520454|NCT00236691|Drug|topiramate|
520455|NCT00236678|Drug|Epoetin alfa|
520456|NCT00236665|Drug|topiramate|
520457|NCT00236652|Drug|levofloxacin|
520458|NCT00236639|Drug|topiramate|
520459|NCT00236626|Drug|topiramate|
520460|NCT00236613|Drug|topiramate|
520461|NCT00236600|Drug|topiramate|
520462|NCT00236587|Drug|risperidone|
520463|NCT00236574|Drug|Galantamine hydrobromide|
520464|NCT00236561|Drug|topiramate, propranolol|
520465|NCT00236548|Drug|risperidone|
520466|NCT00236535|Drug|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
520467|NCT00236522|Drug|levofloxacin|
520468|NCT00236509|Drug|topiramate|
520469|NCT00236496|Drug|topiramate|
520470|NCT00236483|Drug|tramadol hydrochloride + acetaminophen|
520471|NCT00236470|Drug|risperidone|
520472|NCT00236457|Drug|risperidone|
520473|NCT00236444|Drug|risperidone|
520474|NCT00236431|Drug|Galantamine hydrobromide|
520475|NCT00236418|Drug|topiramate|
520476|NCT00236405|Drug|epoetin alfa|
520477|NCT00236392|Drug|rabeprazole|
520478|NCT00236379|Drug|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
520479|NCT00236379|Drug|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
520480|NCT00236366|Drug|fentanyl|
520481|NCT00236353|Drug|risperidone|
520482|NCT00236340|Device|syringe aspiration|
520483|NCT00236340|Device|Wall suction|
520484|NCT00236327|Drug|fentanyl|
520485|NCT00236301|Drug|CLIMASTON (drug)|CLIMASTON(drug)
520486|NCT00236301|Drug|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
520487|NCT00236301|Drug|placebo|placebo
520488|NCT00236288|Drug|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
520489|NCT00236275|Drug|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
520490|NCT00236262|Device|ventilatory strategies with pressure|
520491|NCT00236249|Drug|Lidocaine|
520492|NCT00236236|Device|Cardiac Resynchronization Therapy|
520493|NCT00236223|Drug|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
520494|NCT00236223|Drug|Placebo|Matching placebo
520495|NCT00236210|Behavioral|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
520496|NCT00236210|Behavioral|VIP program|Risk assessment, lifestyle counselling, exercise program
520497|NCT00236197|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
520498|NCT00236197|Drug|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
520499|NCT00236184|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
520500|NCT00236184|Other|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
520501|NCT00236171|Drug|Protopic, Advantan|
520502|NCT00236171|Procedure|Blood and Urine Test|
520503|NCT00236171|Procedure|coherence tomography|
520504|NCT00236158|Device|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
520505|NCT00236145|Drug|ACTIQ (Oral transmucosal fentanyl citrate)|
520506|NCT00236119|Drug|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
520507|NCT00236119|Drug|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
520508|NCT00236119|Drug|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
520509|NCT00236119|Drug|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
520510|NCT00236106|Drug|tacrolimus ointment 0.1%|
520511|NCT00236106|Drug|mometasone furoate 0.1%|
520512|NCT00236093|Drug|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
520513|NCT00236080|Drug|PROVIGIL 200 mg|PROVIGIL 200 mg/day
520514|NCT00236080|Drug|Armodafinil 250 mg|Armodafinil 250 mg/day
520515|NCT00236080|Drug|Armodafinil 200 mg|Armodafinil 200 mg/day
520516|NCT00236080|Drug|Armodafinil 150 mg|Armodafinil 150 mg/day
520517|NCT00236080|Drug|Placebo|Matching placebo tablets
520518|NCT00236067|Drug|Gabitril|
520523|NCT00236002|Drug|Alendronate|Alendronate 70mgm once a week for one year
520524|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
520525|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
520526|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
520527|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
520528|NCT00235976|Drug|Gantacurium Chloride for Injection (AV430A)|
520529|NCT00235963|Drug|Simvastatin|
520530|NCT00235950|Drug|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
520531|NCT00235937|Drug|Anastrozole and goserelin|
520532|NCT00235924|Drug|soy isoflavone|
520533|NCT00235911|Drug|budesonide/formoterol Turbuhaler|
520534|NCT00235898|Drug|CoFactor|
520535|NCT00235898|Drug|5-FU|
520536|NCT00235898|Drug|Leucovorin|
520537|NCT00235885|Drug|adalimumab|
520538|NCT00235872|Biological|adalimumab|40 mg eow, sc
520539|NCT00235859|Drug|adalimumab|
520540|NCT00235859|Drug|methotrexate|
520541|NCT00235846|Procedure|vein harvest|Conventional open vein harvest or endoscopic vein harvest
520542|NCT00235833|Biological|adalimumab|40 mg every other week (eow), subcutaneous (sc)
520543|NCT00235820|Drug|adalimumab|40 mg every other week following an 80 mg dose
520544|NCT00235820|Drug|MTX|MTX 7.5 to 25 mg once weekly
520545|NCT00235820|Drug|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
520546|NCT00235807|Procedure|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
520547|NCT00235807|Procedure|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
520548|NCT00235807|Procedure|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
520549|NCT00235794|Drug|temsirolimus|
520550|NCT00235781|Drug|Thymoglobulin|
520551|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
520552|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
520553|NCT00235755|Drug|Placebo|Oral tablet.
520554|NCT00235729|Drug|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
520555|NCT00235729|Drug|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
520556|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
520557|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
520558|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
520559|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
520560|NCT00235716|Drug|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
520561|NCT00235703|Device|Antimicrobial Prescribing Decision Support|
520562|NCT00235690|Procedure|Blood draws|PK samples obtained around a clinical dosing of colistin
520563|NCT00235690|Other|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
520564|NCT00235677|Procedure|Endoscopic gastroplication|
520565|NCT00235664|Procedure|Collection of stool and endotracheal aspirate samples|collection of samples
520566|NCT00235651|Drug|Amphotericin B|
520567|NCT00235625|Drug|Curcuminoids C3 Complex®|
520568|NCT00235599|Procedure|IGFBP-3 Stimulation Test|
520569|NCT00235586|Procedure|10 vit. D deficient subjects take vit. D for 3 months.|
520570|NCT00235573|Dietary Supplement|Vitamin B12|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
520571|NCT00235560|Drug|rapamycin|sirolimus
520706|NCT00234273|Procedure|Rehabilitation programme in Adapted Physical Activity (APA)|
538715|NCT00003661|Drug|melphalan|
520572|NCT00235547|Behavioral|timing of initiation of transdermal patch after an abortion|the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
520573|NCT00235534|Behavioral|Immediate initiation of OCPs|
520574|NCT00235534|Behavioral|Delayed initiation of OCPs|
520575|NCT00235521|Drug|aerosolized iloprost|
520576|NCT00235508|Drug|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
520577|NCT00235495|Biological|Albumin|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
520578|NCT00235495|Drug|Saline|equivalent volume of isotonic saline control
520579|NCT00235482|Drug|Coxsackievirus A21|
520580|NCT00235469|Drug|SPM 927|
520581|NCT00235456|Procedure|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
520582|NCT00235456|Procedure|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
520583|NCT00235443|Drug|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
520584|NCT00235417|Procedure|Bone marrow transplantation|
520585|NCT00235404|Other|Multicomponent treatment|Specialized care in preparing recharge to home
520586|NCT00235404|Other|usual care|Usual recharge directly from hospital to home
520587|NCT00235391|Drug|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
520588|NCT00235365|Behavioral|meta-cognitive therapy|Meta-cognitive therapy
520589|NCT00235365|Other|waiting list|waiting list control
520590|NCT00235352|Drug|CX516 (Ampakine)|
520591|NCT00235339|Behavioral|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
520592|NCT00235339|Behavioral|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
520593|NCT00235313|Procedure|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
520594|NCT00235313|Drug|nicotine patch|normal following with a nicotine patch
520595|NCT00235300|Biological|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
520596|NCT00235300|Drug|Simulect (basliximab)|20 mg per day on 2 days
520597|NCT00235287|Drug|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
520598|NCT00235287|Drug|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
520599|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
520600|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
520601|NCT00235274|Drug|Subcutaneous Secretin|
520602|NCT00235261|Drug|Pregabalin|
520603|NCT00235261|Drug|Dexamethasone|
520604|NCT00235248|Drug|Warfarin|Warfarin
520605|NCT00235248|Drug|Clopidogrel-aspirin|Clopidogrel-aspirin
520606|NCT00235235|Procedure|Biopsy|core biopsy
520607|NCT00235235|Procedure|Serum Collection|serum collection
520608|NCT00235235|Procedure|Urine Collection|urine collection
520609|NCT00235235|Drug|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
520610|NCT00235235|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
520611|NCT00235235|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
520612|NCT00235235|Drug|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
520613|NCT00235235|Drug|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
520614|NCT00235222|Drug|stavudine|
520615|NCT00235209|Device|Collagen ORC Antimicrobial Matrix (CAM)|
520616|NCT00235196|Device|Collagen ORC Antimicrobial Matrix (CAM)|
520617|NCT00235183|Other|plasma|transfusion of more than 15 mL/Kg of plasma
520618|NCT00235170|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
520619|NCT00235157|Device|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
520620|NCT00235144|Device|sirolimus-coated Bx Velocity stent|drug-eluting stent
520621|NCT00235144|Device|uncoated Bx Velocity stent|bare-metal stent
520622|NCT00235131|Device|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
520623|NCT00235131|Device|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
520624|NCT00235118|Device|Cordis AAA Bilateral Device|
520625|NCT00235105|Drug|Adalimumab 40 mg sc every other week|
520626|NCT00235092|Device|Cypher Sirolimus-Eluting Stent|
520627|NCT00235092|Device|Taxus Paclitaxel-Eluting Stent|
520628|NCT00235079|Drug|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
520629|NCT00235079|Drug|Placebo|Placebo comparator
520630|NCT00235066|Device|PCI|PCI with Cypher Sirolimus-Eluting Stent
520631|NCT00235053|Drug|fluticasone/salmeterol DISKUS 250/50|
520632|NCT00235040|Behavioral|Smart Form|Computer Decision Support System
520707|NCT00234273|Behavioral|Therapeutic education primarily focused on dietary|
538716|NCT00003661|Drug|methylprednisolone|
520633|NCT00235027|Other|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
520634|NCT00235014|Drug|trandolapril|2 mg QD
520635|NCT00235014|Drug|trandolapril/verapamil|180/2 mg QD
520636|NCT00235014|Drug|placebo|1 tablet QD
520637|NCT00235014|Drug|verapamil|SR 240 mg QD
520638|NCT00235001|Drug|trandolapril/verapamil|180/2 mg QD
520639|NCT00234988|Drug|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
520640|NCT00234975|Drug|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
520641|NCT00234962|Drug|Lopinavir/Ritonavir|
520642|NCT00234949|Drug|cefdinir|
520643|NCT00234949|Drug|cephalexin|
520644|NCT00234936|Drug|Adalimumab|
520645|NCT00234936|Drug|Methotrexate|
520646|NCT00234923|Drug|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
520647|NCT00234923|Drug|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
520648|NCT00234910|Drug|Tenofovir DF|TDF 300mg QD for 72 wks
520649|NCT00234910|Drug|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
520650|NCT00234897|Drug|adalimumab|
520651|NCT00234884|Biological|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
520652|NCT00234871|Drug|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
520653|NCT00234871|Drug|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
520654|NCT00234858|Drug|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
520655|NCT00234858|Drug|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
520656|NCT00234845|Drug|adalimumab|
520657|NCT00234845|Drug|methotrexate|
520658|NCT00234832|Drug|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
520659|NCT00234832|Drug|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
520660|NCT00234832|Drug|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
520661|NCT00234819|Drug|Bazedoxifene/Conjugated Estrogen|
520662|NCT00234806|Other|Health-e-Access|telemedicine intervention
520663|NCT00234793|Behavioral|Problem-Solving Skills Training|
520664|NCT00234780|Procedure|pediatric nursing used in home to avoid hospitalization|
520665|NCT00234767|Device|Pulmonary Artery Catheter|
520666|NCT00234767|Behavioral|Protocolized Fluid Management|
520667|NCT00234754|Procedure|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
520668|NCT00234741|Drug|STA-5326 mesylate|
520669|NCT00234728|Device|Occlusive dressing|
520670|NCT00234702|Drug|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
520671|NCT00234702|Drug|Placebo|Placebo
520672|NCT00234689|Drug|Naltrexone|
520673|NCT00234676|Drug|Premarin ®|Premarin ® 0.625 mg per day orally
520674|NCT00234663|Drug|PTC124|
520675|NCT00234650|Procedure|Colonoscopy|
520676|NCT00234637|Drug|Rivastigmine, memantine|
520677|NCT00234611|Procedure|Echocardiogram guided left ventricular lead placement|
520678|NCT00234598|Procedure|Toothbrushing only|Toothbrushing three times per 24 hours without chlorhexidine
520679|NCT00234598|Procedure|Chlorhexidine only|Chlorhexidine oral rinse twice per 24 hours without toothbrushing
520680|NCT00234598|Procedure|Toothbrushing and Chlorhexidine|Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
520681|NCT00234585|Device|Renal Artery Stent with Protective Device/Drug|
520682|NCT00234572|Drug|Lanreotide (Autogel formulation)|
520683|NCT00234559|Device|VAC® Therapy System|
520684|NCT00234546|Biological|Botulinum toxin type A|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
520685|NCT00234546|Drug|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
520686|NCT00234533|Drug|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
520687|NCT00234507|Biological|Botulinum toxin type A|
520688|NCT00234494|Drug|Cisplatin|Cisplatin 70 mg/m2, day 1
520689|NCT00234494|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
520690|NCT00234494|Drug|Bevacizumab|Bevacizumab 15mg/kg, day 1
520691|NCT00234481|Drug|XL844|
520692|NCT00234468|Drug|Iressa (Gefitinib)|
520693|NCT00234455|Device|drug eluting-stent|PCI
520694|NCT00234455|Device|drug-eluting stent|PCI
520695|NCT00234442|Drug|Iressa (Gefitinib)|
520696|NCT00234429|Drug|Gefitinib, raltitrexed|
520697|NCT00234416|Drug|Gefitinib|
520698|NCT00234416|Drug|Gemcitabine|
520699|NCT00234403|Drug|gefitinib and fulvestrant|
520700|NCT00234390|Drug|Pulmicort (budesonide) pMDI|
520701|NCT00234377|Drug|Seroquel SR|
520702|NCT00234312|Drug|escitalopram and sertraline|
520703|NCT00234299|Drug|Aspirin|325mg, one tablet orally, six months
520704|NCT00234299|Drug|Placebo|325mg, one tablet orally every day, 6 months
520705|NCT00234286|Behavioral|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
521664|NCT00225797|Drug|Oxymorphone Extended Release|
520708|NCT00234247|Other|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
520709|NCT00234234|Drug|Adalimumab|
520710|NCT00234221|Behavioral|Strengths Based Case Management|
520711|NCT00234221|Behavioral|Motivational Enhancement Therapy|
520712|NCT00234221|Behavioral|Brief Informational Feedback|
520713|NCT00234208|Procedure|Medical thoracoscopy|
520714|NCT00234208|Procedure|Simple chest tube drainage|
520715|NCT00234195|Drug|bupropion extended release (Wellbutrin XL)|
520716|NCT00234182|Drug|Interferon alpha-2b|
520717|NCT00234169|Drug|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.~Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
520718|NCT00234156|Procedure|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
520719|NCT00234143|Behavioral|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
520720|NCT00234143|Drug|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
520721|NCT00234130|Procedure|nocturnal vs conventional dialysis|
520722|NCT00234117|Drug|Rabeprazole|
520723|NCT00234104|Drug|OPC-41061(Tolvaptan)|
520724|NCT00234091|Drug|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
520725|NCT00234091|Drug|Efavirenz|200 to 600 mg taken orally once daily
520726|NCT00234091|Drug|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
520727|NCT00234091|Drug|Lopinavir/Ritonavir|230 mg/57.5 mg/m^2 body surface area taken orally twice daily with food
520728|NCT00234091|Drug|Nelfinavir|45-55 mg/kg taken orally twice daily with food
520729|NCT00234091|Drug|Nevirapine|120 mg/m^2 once daily for first 14 days, tehn 200 mg/m^2 (up to 400 mg/day) twice daily
520730|NCT00234091|Drug|Zidovudine|180-240 mg/m^2 every 12 hours (up to 300 mg/dose)
520731|NCT00234078|Drug|0.5% OPC-12759|
520732|NCT00234078|Drug|1% OPC-12759|
520733|NCT00234078|Drug|2% OPC-12759|
520734|NCT00234078|Drug|placebo|
520735|NCT00234065|Drug|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
520736|NCT00234065|Drug|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
520737|NCT00234052|Biological|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
520738|NCT00234052|Drug|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
520739|NCT00234052|Drug|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
520740|NCT00234039|Drug|gemcitabine hydrochloride|
520741|NCT00234026|Drug|gemcitabine hydrochloride|
520742|NCT00234000|Drug|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
520743|NCT00234000|Drug|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
520744|NCT00233987|Drug|carmustine|150 mg/m^2 IV over 2 hours 4, 5, and 6 days before transplant.
520745|NCT00233987|Drug|cyclophosphamide|100 mg/kg IV 2 days before transplant.
520746|NCT00233987|Drug|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
520747|NCT00233987|Drug|melphalan|150 mg/m^2 IV 1 day before transplant.
520748|NCT00233987|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
520749|NCT00233987|Radiation|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
520750|NCT00233974|Procedure|PET (positron emission tomography)|Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
520751|NCT00233961|Biological|filgrastim|
520752|NCT00233948|Drug|nelfinavir mesylate|Given orally
520753|NCT00233948|Procedure|biopsy|Correlative studies
520754|NCT00233948|Other|laboratory biomarker analysis|Correlative studies
520755|NCT00233948|Other|pharmacological study|Correlative studies
520756|NCT00233948|Genetic|gene expression analysis|Correlative studies
520757|NCT00233948|Genetic|western blotting|Correlative studies
520758|NCT00233948|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
520759|NCT00233948|Other|immunoenzyme technique|Correlative studies
520760|NCT00233935|Other|placebo|Given PO
520761|NCT00233935|Drug|defined green tea catechin extract|Given PO
520762|NCT00233922|Device|Osteosheet(r)|
520763|NCT00233909|Drug|Zosuquidar|
520764|NCT00233909|Drug|gemtuzumab ozogamicin|
520765|NCT00233896|Drug|Oral beclomethasone dipropionate (drug)|
520766|NCT00233883|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
520767|NCT00233883|Drug|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
520768|NCT00233870|Drug|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
520769|NCT00233857|Procedure|Auricular acupuncture|
520770|NCT00233844|Procedure|"Venipuncture with cough-trick"|
520771|NCT00233831|Device|Generator of electromagnetic millimeter waves|
520772|NCT00233818|Device|Sirolimus-coated Bx VELOCITY Stent|
520773|NCT00233805|Device|Sirolimus coated Bx Velocity™|drug-eluting stent
520774|NCT00233805|Device|Bare metal Bx Velocity™|bare-metal stent
520775|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - fast release|
520776|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - slow release|
520777|NCT00233779|Device|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
520778|NCT00233766|Device|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
520779|NCT00233753|Device|Cordis Neurovascular Self-Expanding Stent|
520780|NCT00233740|Device|OPTEASE Vena Cava Filter|
520781|NCT00233727|Procedure|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
520782|NCT00233727|Procedure|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
520783|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
520784|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
520785|NCT00233688|Device|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
520786|NCT00233688|Procedure|Open surgical repair|Open surgical repair
520787|NCT00233675|Drug|GABITRIL (tiagabine hydrochloride; CEP-6671)|
520788|NCT00233662|Drug|Alefacept|
520789|NCT00233636|Drug|Iressa (Gefitinib)|
520790|NCT00233636|Procedure|Radiotherapy|
520791|NCT00233623|Drug|Iressa (Gefitinib)|
520792|NCT00233623|Drug|Irinotecan|
520793|NCT00233623|Drug|5Fluorouracil|
520794|NCT00233623|Drug|Leucovorin|
520795|NCT00233610|Drug|Bicalutamide|
520796|NCT00233610|Drug|Tamoxifen|
520797|NCT00233597|Drug|ferumoxytol or oral iron|
520798|NCT00233584|Procedure|Pulmicort (budesonide) pMDI|
520799|NCT00233571|Biological|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
520800|NCT00233558|Drug|adalimumab (up to 9 months exposure)|
520801|NCT00233558|Drug|methotrexate|
520802|NCT00233545|Drug|miltefosine|
520803|NCT00233545|Drug|antimony|
520804|NCT00233532|Drug|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
520805|NCT00233519|Drug|SomatoKine/IPLEX|"Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.~Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection."
520806|NCT00233506|Drug|CpG 7909|
520807|NCT00233480|Drug|atorvastatin|atorvastatin 10mg PO QD
520808|NCT00233480|Drug|placebo|matched placebo Qd x 3 months
520809|NCT00233454|Drug|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
520810|NCT00233441|Drug|CELIVARONE (SSR149744C)|
520811|NCT00233428|Procedure|Blood Draw|
520812|NCT00233415|Device|Stereotactic Radiosurgery (Cyberknife)|
520813|NCT00233402|Drug|Hexvix|Single Instillation, Transurethral Resection of the Bladder
520814|NCT00233402|Procedure|Standard white light cystoscopy|
520815|NCT00233389|Drug|Rebamipide|
520816|NCT00233376|Procedure|Access to an antibiotic decision support system|
520817|NCT00233376|Behavioral|Distribution of local antibiotic guidelines|
520818|NCT00233363|Drug|Rebamipide|
520819|NCT00233350|Device|use of navigated 3D ultrasound during surgery|
520820|NCT00233337|Drug|Co-artemether|
520821|NCT00233324|Drug|Surfactant|Intubation and administration of surfactant by 1 hour of age.
520822|NCT00233324|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
520823|NCT00233324|Drug|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
520824|NCT00233324|Drug|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
520825|NCT00233259|Behavioral|Mediterranean Diet|Mediterranean dietary program
520826|NCT00233259|Behavioral|Physical Activity|Physical activity program
520827|NCT00233259|Behavioral|Stress Management|Stress management program
520828|NCT00233259|Behavioral|Social Support|Social support
520829|NCT00233259|Behavioral|Smoking Cessation|Smoking cessation program
520830|NCT00233259|Other|Control group|Usual Diabetes Care Control group
520831|NCT00233246|Procedure|FFP Infusion|
520832|NCT00233233|Behavioral|Standardized Asthma Education Program|
520893|NCT00232687|Drug|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
520894|NCT00232674|Drug|Pulmicort (budesonide) Turbuhaler|
520895|NCT00232661|Drug|ARIMIDEX (anastrazole)|
520896|NCT00232661|Drug|NOLVADEX (tamoxifen)|
520897|NCT00232648|Drug|Pulmicort (budesonide) Respules|
520898|NCT00232635|Drug|A-60444|
520899|NCT00232622|Drug|Streptokinase|Accelerated infusion of streptokinase
520900|NCT00232622|Drug|Streptokinase|Standard dose streptokinase
520901|NCT00232609|Device|GameCycle Exercise System|
520833|NCT00233220|Behavioral|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
520834|NCT00233220|Behavioral|Usual Care|Patients will receive usual care.
520835|NCT00233207|Drug|IC14|
520836|NCT00233194|Procedure|Observational follow-up study of adenotonsillectomy|Studies of sleep, behavior, cognition, and daytime sleepiness
520837|NCT00233181|Behavioral|Home-based adherence monitoring|
520838|NCT00233168|Behavioral|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
520839|NCT00233168|Behavioral|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
520840|NCT00233155|Drug|Capsaicin Dermal Patch|
520841|NCT00233142|Behavioral|Expressive writing|Writing as therapeutic intervention
520842|NCT00233142|Behavioral|Neutral writing|Non-expressive writing
520843|NCT00233129|Behavioral|Top Down|Six months
520844|NCT00233129|Other|cognitive rehabilitation day treatment program|six months
520845|NCT00233103|Drug|Sertraline|Sertraline arm
520846|NCT00233103|Drug|Placebo|Placebo
520847|NCT00233090|Drug|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
520848|NCT00233090|Drug|Placebo|daily dose of placebo for four weeks.
520849|NCT00233077|Behavioral|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer & its treatment, experience with & access to health care system, trust, depression, social support & self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
520850|NCT00233077|Behavioral|Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
520851|NCT00233064|Biological|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
520852|NCT00233064|Biological|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
520853|NCT00233051|Drug|Salmeterol or Salmeterol/Fluticasone|
520854|NCT00233038|Procedure|Ethanol injection into a cyst|
520855|NCT00233025|Drug|Duloxetine|
520856|NCT00233025|Drug|Placebo|
520857|NCT00233012|Drug|Topiramate|
520858|NCT00232999|Drug|Nebulized IVX-0142|
520859|NCT00232973|Drug|ICXP007|
520860|NCT00232960|Procedure|Radiotherapy 50 Gy|
520861|NCT00232947|Biological|Influenza virus vaccine (Fluviral)|
520862|NCT00232947|Biological|Influenza virus vaccine (Fluzone)|
520863|NCT00232934|Drug|Thalidomide|
520864|NCT00232921|Drug|caudal volume 1|
520865|NCT00232921|Biological|caudal volume 2|
520866|NCT00232921|Drug|caudal volume 3|
520867|NCT00232908|Drug|ARV regimen|As prescribed
520868|NCT00232908|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
520869|NCT00232895|Drug|lipuro propofol|
520870|NCT00232895|Drug|standard formulation propofol|
520871|NCT00232882|Drug|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
520872|NCT00232882|Drug|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
520873|NCT00232882|Drug|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
520874|NCT00232869|Device|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
520875|NCT00232869|Device|bare-metal stent|SMART™ bare-metal stent
520876|NCT00232856|Device|drug-eluting stent|PCI
520877|NCT00232843|Device|stent|Cordis SMART™ nitinol self-expanding stent.
520878|NCT00232843|Device|angioplasty|balloon angioplasty
520879|NCT00232830|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
520880|NCT00232830|Device|bare-metal stent|any bare-metal stent brand
520881|NCT00232817|Drug|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
520882|NCT00232804|Device|Bx Cypher stent|
520883|NCT00232791|Device|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
520884|NCT00232791|Device|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
520885|NCT00232778|Device|GAMMA-Iridium-192 catheter|
520886|NCT00232765|Device|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
520887|NCT00232765|Device|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
520888|NCT00232752|Device|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
520889|NCT00232739|Device|CYPHER Sirolimus-eluting Coronary Stent|2.25 Cypher Sirolimus-eluting Coronary Stent
520890|NCT00232726|Drug|CP-4055 (ELACYT)|
520891|NCT00232700|Drug|Escitalopram|
520892|NCT00232687|Drug|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
520902|NCT00232596|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
520903|NCT00232596|Drug|Placebo|Oral tablet.
520904|NCT00232583|Drug|Metformin|Metformin 1000mg/BID
520905|NCT00232583|Drug|Insulin|Insulin Novolg 70/30 per protocol titration
520906|NCT00232583|Drug|Metfomin|Metformin 1000mg/BID
520907|NCT00232583|Drug|Pioglitazone|Pioglitazone 45mg
520908|NCT00232583|Drug|glyburide|Glyburide per protocol titration
520909|NCT00232570|Drug|quetiapine|
520910|NCT00232557|Device|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
520911|NCT00232557|Device|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
520912|NCT00232544|Device|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
520913|NCT00232544|Other|TLC-Control|A TLC system for providing general health education
520914|NCT00232531|Drug|Niaspan|
520915|NCT00232518|Procedure|Infection with hookworm larvae|
520916|NCT00232505|Biological|cetuximab|Given IV
520917|NCT00232505|Drug|carboplatin|Given IV
520918|NCT00232492|Drug|Placebo males|Intravenous saline bolus (Placebo-control) males
520919|NCT00232492|Drug|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
520920|NCT00232492|Drug|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
520921|NCT00232492|Drug|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
520922|NCT00232492|Drug|Placebo females|Intravenous saline bolus (Placebo-control) females
520923|NCT00232492|Drug|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
520924|NCT00232492|Drug|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
520925|NCT00232492|Drug|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
520926|NCT00232479|Drug|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
520927|NCT00232466|Procedure|Vertebroplasty|"Procedure:~The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
520928|NCT00232453|Procedure|Combined Radiation and Chemotherapy|
520929|NCT00232440|Device|BodyFIX|
520930|NCT00232427|Procedure|Hemodynamic monitoring system PiCCO|
520931|NCT00232414|Drug|Quetiapine|
520932|NCT00232388|Procedure|Blood draw|
520933|NCT00232375|Drug|Insulin|
520934|NCT00232362|Drug|Pioglitazone (Actos)|
520935|NCT00232362|Drug|Anti-diabetic agent other than pioglitazone or rosiglitazone|
520936|NCT00232349|Drug|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
520937|NCT00232336|Drug|quetiapine|
520938|NCT00232323|Behavioral|simulation training|
520939|NCT00232310|Drug|CELIVARONE (SSR149744C)|
520940|NCT00232297|Drug|SSR149744C|
520941|NCT00232284|Drug|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
520942|NCT00232284|Behavioral|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
520943|NCT00232271|Drug|Clexane|
520944|NCT00232258|Drug|Nolpitantium besylate|
520945|NCT00232245|Drug|Fish oil|
520946|NCT00232232|Drug|Fish oil|
520947|NCT00232219|Drug|Fish oil|
520948|NCT00232206|Drug|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
520949|NCT00232180|Drug|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
520950|NCT00232167|Drug|Indiplon|
520951|NCT00232167|Drug|Sertraline|
520952|NCT00232154|Drug|Zithromax&#153; (azithromycin) 500mg tablets|
520953|NCT00232154|Procedure|Endoscopic Sinus Surgery|
520954|NCT00232154|Procedure|Blood sampling for hematology|
520955|NCT00232154|Procedure|Blood sampling for plasma chemistry profile|
520956|NCT00232154|Procedure|Serum pregnancy test (for women of child-bearing potential)|
520957|NCT00232141|Drug|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
520958|NCT00232141|Drug|Placebo|Placebo
520959|NCT00232128|Procedure|Radiofrequency Ablation of pulmonary neoplasms|
520960|NCT00232115|Drug|Pimecrolimus|Pimecrolimus cream 1 %
520961|NCT00232115|Drug|Placebo|Vehicle cream (placebo)
520962|NCT00232102|Drug|Tegaserod|
520963|NCT00232089|Drug|Tegaserod|
520964|NCT00232076|Drug|ciclosporin|
520965|NCT00232063|Drug|ciclosporin|
520966|NCT00232050|Drug|Omalizumab|
520967|NCT00232037|Drug|Tegaserod|
520968|NCT00232024|Drug|Tegaserod|
520969|NCT00232011|Drug|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
520970|NCT00231998|Drug|Pimecrolimus|Pimecrolimus cream 1 %
520971|NCT00231985|Behavioral|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
520972|NCT00231985|Behavioral|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
521026|NCT00231569|Drug|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
521027|NCT00231569|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
520973|NCT00231972|Behavioral|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
520974|NCT00231972|Behavioral|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
520975|NCT00231959|Drug|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
520976|NCT00231959|Drug|Placebo|sugar pill
520977|NCT00231946|Drug|VP4896|
520978|NCT00231933|Behavioral|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
520979|NCT00231933|Behavioral|Community integration (CI)|CI includes recovery group sessions and community integration activities.
520980|NCT00231933|Behavioral|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
520981|NCT00231920|Biological|Fluzone|
520982|NCT00231907|Biological|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
520983|NCT00231907|Biological|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
520984|NCT00231894|Drug|Pioglitazone|pioglitazone 30-45 mg/day
520985|NCT00231894|Behavioral|Life style diet group|life style diet education group 1x/week
520986|NCT00231894|Other|Placebo|placebo comparator capsules
520987|NCT00231868|Drug|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
520988|NCT00231868|Procedure|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
520989|NCT00231868|Drug|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
520990|NCT00231855|Drug|Topotecan and Taxotere|
520991|NCT00231842|Drug|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg/IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
520992|NCT00231842|Device|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IV bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L / day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333 mg /IV bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L /day x 5 days. Repeat q21 days x 3 cycles.
520993|NCT00231842|Drug|Cisplatin|dosage is 20 mg/m2/day for 5 days, ever 3 weeks.
520994|NCT00231829|Drug|Celecoxib|
520995|NCT00231816|Biological|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
520996|NCT00231816|Biological|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
520997|NCT00231816|Biological|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
520998|NCT00231803|Procedure|Combined CKD and CVD Prevention|
520999|NCT00231803|Procedure|Cardiovascular Disease prevention|
521000|NCT00231803|Procedure|Treatment of Chronic Kidney Disease complications|
521001|NCT00231790|Drug|MK-0634 50 mg|one capsule orally, once daily in morning
521002|NCT00231790|Drug|MK-0634 125 mg|one or three capsules orally, once daily in morning
521003|NCT00231790|Drug|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
521004|NCT00231777|Drug|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
521005|NCT00231777|Drug|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
521006|NCT00231764|Drug|daclizumab|
521007|NCT00231738|Drug|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
521008|NCT00231725|Drug|insulin lispro injection [rDNA origin] Low Mix|
521009|NCT00231699|Procedure|Plastic wrap (study group) and cotton (control group) wrap.|
521010|NCT00231686|Behavioral|Supervised aerobic training|
521011|NCT00231686|Behavioral|Supervised strength training|
521012|NCT00231686|Behavioral|Unsupervised training|
521013|NCT00231673|Drug|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
521014|NCT00231660|Drug|topiramate|
521015|NCT00231647|Drug|topiramate|
521016|NCT00231634|Drug|topiramate|
521017|NCT00231621|Drug|topiramate|
521018|NCT00231608|Drug|topiramate|
521019|NCT00231595|Drug|topiramate|
521020|NCT00231582|Drug|epirubicin|epirubicin
521021|NCT00231582|Procedure|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
521022|NCT00231582|Drug|paclitaxel|paclitaxel
521023|NCT00231582|Drug|etoposide|etoposide
521024|NCT00231582|Drug|ifosfamide|ifosfamide
521025|NCT00231582|Drug|carboplatin|carboplatin
521028|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
521029|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
521030|NCT00231569|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
521031|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
521032|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
521033|NCT00231556|Drug|topiramate|
521034|NCT00231543|Procedure|Laparoscopic fundoplication|
521035|NCT00231543|Procedure|open Nissen fundoplication|
521036|NCT00231530|Drug|topiramate|
521037|NCT00231517|Drug|topical opiod|
521038|NCT00231517|Drug|morphine sulphate in intrasite gel|
521039|NCT00231504|Procedure|Blood samples|Blood samples
521040|NCT00231491|Drug|Botulinum Toxin A (Botox )|
521041|NCT00231478|Drug|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
521042|NCT00231478|Drug|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
521043|NCT00231465|Drug|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
521044|NCT00231465|Drug|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
521045|NCT00231452|Drug|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
521046|NCT00231439|Drug|IvIg|
521047|NCT00231426|Device|ICD|
521048|NCT00231413|Biological|Novel HPV vaccine|
521049|NCT00231387|Drug|rosiglitazone|
521050|NCT00231374|Procedure|Myelogram|
521051|NCT00231348|Drug|Nefazodone|
521052|NCT00231335|Drug|escitalopram|
521053|NCT00231322|Drug|praziquantel|
521054|NCT00231309|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
521055|NCT00231296|Device|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
521056|NCT00231296|Drug|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
521057|NCT00231283|Device|CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
521058|NCT00231270|Device|Cordis Nitinol Stent|
521059|NCT00231270|Device|PRECISE tapered stent|
521060|NCT00231270|Device|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
521061|NCT00231257|Device|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
521062|NCT00231257|Procedure|Brachytherapy|Brachytherapy
521063|NCT00231244|Device|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
521064|NCT00231231|Device|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
521065|NCT00231231|Device|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
521066|NCT00231218|Drug|dietary supplement--echinacea, propolis, and vitamin c|
521067|NCT00231205|Procedure|Revascularization|
521068|NCT00231192|Drug|Repaglinide and Insulin|
521069|NCT00231179|Behavioral|Home visiting professional support model|Home visits and telephone calls keyed to well child visits.
521070|NCT00231179|Other|Control|The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
521071|NCT00231166|Drug|HCD122|
521072|NCT00231153|Drug|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
521073|NCT00231153|Drug|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
521074|NCT00231140|Drug|Thalidomide (drug)|
521075|NCT00231114|Device|Alair System|Treatment of airways with the Alair System
521076|NCT00231114|Device|Alair System|Sham treatment of airways with the Alair System
521077|NCT00231101|Drug|Quetiapine|
521078|NCT00231075|Drug|Paraplatin|
521079|NCT00231075|Drug|Paclitaxel|
521080|NCT00231062|Device|Sinuplasty|
521081|NCT00231049|Drug|AG-707|
521082|NCT00231023|Drug|Peribulbar Triamcinolone Acetonide|
521083|NCT00230997|Drug|Galantamine|
521084|NCT00230984|Behavioral|education|
521085|NCT00230984|Drug|Oral dietary supplements (563 kcal/d), RESPIFOR|
521086|NCT00230984|Behavioral|exercises on an ergometric bicycle 3 to 5 times a week|
521087|NCT00230984|Drug|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
521088|NCT00230971|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
521089|NCT00230971|Drug|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
521090|NCT00230958|Drug|Viramidine|
521091|NCT00230958|Drug|Ribavirin|
521092|NCT00230958|Drug|pegylated interferon alfa-2b|
521166|NCT00230152|Device|Imaging|
521167|NCT00230139|Device|SPECT/CT|
521223|NCT00229658|Drug|pramlintide acetate|Subcutaneous injection prior to each major meal
521224|NCT00229645|Drug|Quetiapine Fumarate (Seroquel®)|
521093|NCT00230945|Behavioral|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
521094|NCT00230919|Behavioral|Diet counseling|
521095|NCT00230906|Procedure|Haemodialysis with either low or high flux membranes|
521096|NCT00230880|Behavioral|follow-up phone counseling|9 calls over 12 months
521097|NCT00230867|Device|iontophoretic acyclovir|
521098|NCT00230854|Drug|EMZ702|
521099|NCT00230841|Device|nebulized humidity|
521100|NCT00230828|Drug|bifeprunox|
521101|NCT00230815|Device|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
521102|NCT00230815|Device|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
521103|NCT00230802|Drug|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
521104|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
521105|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
521106|NCT00230789|Drug|Tolterodine ER 4 mg QD|
521107|NCT00230789|Behavioral|OAB Patient Behavioral Training Material|
521108|NCT00230776|Drug|pregabalin|
521109|NCT00230776|Drug|placebo|
521110|NCT00230763|Procedure|GSS questionnaire|D0, D30 and D84
521111|NCT00230763|Procedure|IOP|D0, D30 and D84
521112|NCT00230763|Drug|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
521113|NCT00230763|Procedure|Visual acuity|D0 and D84
521114|NCT00230750|Biological|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
521115|NCT00230750|Drug|Placebo|Saline placebo.
521116|NCT00230737|Drug|Melatonin 0.4 mg|
521117|NCT00230737|Drug|Melatonin 4.0 mg|
521118|NCT00230737|Drug|Placebo|
521119|NCT00230724|Behavioral|Exercise Counseling|
521120|NCT00230711|Behavioral|Physical activity counseling|
521121|NCT00230698|Drug|topiramate|
521122|NCT00230659|Other|Blood sample to be taken.|Blood sample to be taken.
521123|NCT00230646|Behavioral|Exercise counseling|
521124|NCT00230607|Drug|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
521125|NCT00230594|Drug|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
521126|NCT00230594|Drug|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
521127|NCT00230581|Drug|DDP225|
521128|NCT00230568|Drug|Aricept|
521129|NCT00230555|Behavioral|professional support model|
521130|NCT00230542|Drug|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
521131|NCT00230542|Drug|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
521132|NCT00230529|Drug|infliximab|
521133|NCT00230516|Drug|Nexium|
521134|NCT00230516|Drug|Prevacid|
521135|NCT00230503|Drug|pradefovir mesylate|
521136|NCT00230503|Drug|adefovir dipivoxyl|
521137|NCT00230490|Drug|pradefovir mesylate|
521138|NCT00230490|Drug|adefovir dipivoxyl|
521139|NCT00230477|Drug|Hepsera|
521140|NCT00230477|Drug|Hepsera and lamivudine|
521141|NCT00230464|Drug|LAF 237|
521142|NCT00230451|Procedure|Radiation|
521143|NCT00230451|Drug|Paclitaxel|
521144|NCT00230451|Drug|Cisplatin|
521145|NCT00230451|Drug|5-Fluorouracil|
521146|NCT00230438|Procedure|External Beam Radiotherapy|
521147|NCT00230399|Drug|Celecoxib|
521148|NCT00230399|Drug|Capecitabine|
521149|NCT00230399|Drug|Irinotecan|
521150|NCT00230386|Device|MRI|
521151|NCT00230373|Drug|imiquimod 5% cream (Aldara)|
521152|NCT00230347|Procedure|Stereotactic radiosurgery|
521153|NCT00230334|Drug|Gleevec|
521154|NCT00230321|Drug|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
521155|NCT00230295|Procedure|IMR LAG|
521156|NCT00230282|Drug|Alemtuzumab|3 to 30 mg, IV
521157|NCT00230282|Drug|Fludarabine|[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid
521158|NCT00230282|Drug|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
521159|NCT00230269|Procedure|PET-CT|
521160|NCT00230230|Drug|SCH 486757|
521161|NCT00230217|Drug|Rasburicase (SR29142)|
521162|NCT00230204|Procedure|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
521163|NCT00230191|Drug|RK-0202|
521164|NCT00230178|Drug|Rasburicase (SR29142)|30-min IV infusion
521165|NCT00230178|Drug|Allopurinol|Oral administration
521168|NCT00230126|Drug|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
521169|NCT00230113|Dietary Supplement|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
521170|NCT00230113|Dietary Supplement|safflower oil|4 gm per day safflower oil
521171|NCT00230100|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
521172|NCT00230100|Behavioral|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
521173|NCT00230087|Procedure|blood donation|phlebotomy until iron depleted
521174|NCT00230074|Drug|TCH346|
521175|NCT00230061|Biological|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
521176|NCT00230048|Behavioral|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
521177|NCT00230035|Procedure|Leukapheresis|
521178|NCT00230035|Procedure|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
521179|NCT00230035|Procedure|Autologous CD34+HPC transplantation (HSCT)|
521180|NCT00230035|Procedure|Plasmapheresis|
521181|NCT00230035|Drug|Rabbit anti-thymocyte globulin|
521182|NCT00230035|Drug|Methylprednisolone|
521183|NCT00230035|Drug|Growth colony stimulating factor (G-CSF)|
521184|NCT00230035|Drug|Corticosteroids|
521185|NCT00230035|Drug|Mycophenolate mofetil|
521186|NCT00230035|Drug|Azathioprine|
521187|NCT00230035|Drug|Intravenous immunoglobulin|
521188|NCT00230035|Drug|Methotrexate|
521189|NCT00230035|Drug|Rituximab|
521190|NCT00230035|Drug|Leflunomide|
521191|NCT00230022|Behavioral|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
521192|NCT00230009|Behavioral|Brief motivational intervention|
521193|NCT00229996|Drug|Oral Contraceptive|
521194|NCT00229996|Drug|Depot-Leuprolide/Norethindrone|
521195|NCT00229983|Behavioral|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
521196|NCT00229970|Drug|montelukast sodium|7 mg or 14 mg single injection
521197|NCT00229970|Drug|Comparator: Placebo|Placebo single injection
521198|NCT00229957|Behavioral|Occupational therapy|
521199|NCT00229957|Behavioral|Physiotherapy|
521200|NCT00229957|Behavioral|Self-management|
521201|NCT00229944|Drug|Azithromycin|
521202|NCT00229931|Drug|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
521203|NCT00229931|Procedure|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
521204|NCT00229918|Drug|triamcinolone acetonide|
521205|NCT00229840|Procedure|Functional MRI, Diffusion Tensor Imaging|
521206|NCT00229801|Radiation|MRI|
521207|NCT00229775|Drug|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
521208|NCT00229762|Behavioral|phone call from nurses - informational only|
521209|NCT00229749|Drug|AVI-4065 Injection|
521210|NCT00229736|Genetic|AAV-hAADC-2|9 x 10^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
521211|NCT00229736|Genetic|AAV-hAADC-2|3 x 10^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
521212|NCT00229723|Drug|gefitinib (Iressa)|250 mg oral tablet
521213|NCT00229723|Drug|cisplatin|intravenous infusion
521214|NCT00229723|Radiation|radiotherapy|radiation therapy
521215|NCT00229723|Drug|Gefitinib (Iressa)|500 mg oral tablet
521216|NCT00229710|Drug|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
521217|NCT00229697|Drug|Gefitinib|
521218|NCT00229697|Drug|Tamoxifen|
521219|NCT00229684|Drug|Tesaglitazar|2 mg once daily in oral form
521220|NCT00229684|Drug|pioglitazone|45 mg once daily in oral form
521221|NCT00229671|Other|Survey 1|During the initial survey, we reviewed dispensed medications by having parents of patients with prescriptions under 21 read the medication label. We then asked questions about potential side effects, method of medication administration, communication regarding the medication with the pharmacist and the health care provider, and demographic information. Research assistants underwent several weeks of training to ensure a standardized approach to surveys.
521222|NCT00229671|Other|Survey 2|If the parent completed the initial survey, we attempted a second survey 2 months after the index visit to capture persistent symptoms. Surveys were translated and back translated into Spanish and Cambodian and conducted by fluent bilingual interviewers. Surveys were pretested and revised based on 2 focus groups of parents representing a broad array of socioeconomic backgrounds.
521338|NCT00228358|Biological|denileukin diftitox|Given IV
521225|NCT00229632|Drug|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
521226|NCT00229619|Drug|Rituximab|Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
521227|NCT00229593|Drug|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
521228|NCT00229593|Drug|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
521229|NCT00229580|Behavioral|3 session brief intervention with health behavior feedback|
521230|NCT00229580|Other|treatment as usual|
521231|NCT00229567|Drug|Lidocaine infusion plus ketamine injection|
521232|NCT00229541|Procedure|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
521233|NCT00229528|Drug|Paxil-CR|
521234|NCT00229515|Other|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
521235|NCT00229515|Other|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
521236|NCT00229515|Other|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
521237|NCT00229515|Other|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
521238|NCT00229476|Drug|sertraline (Zoloft)|
521239|NCT00229450|Drug|estrogen|
521240|NCT00229437|Drug|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
521241|NCT00229437|Drug|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
521242|NCT00229437|Drug|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
521243|NCT00229437|Drug|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
521244|NCT00229424|Drug|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
521245|NCT00229424|Drug|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
521246|NCT00229424|Other|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
521247|NCT00229411|Behavioral|simulation training|
521248|NCT00229385|Drug|Ziprasidone|40-80 mg BID
521249|NCT00229372|Behavioral|Prolonged Exposure (PE) therapy|
521250|NCT00229333|Drug|Escitalopram|
521251|NCT00229320|Behavioral|Group therapy|
521252|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|20 minutes exposure
521253|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|40 minutes exposure
521254|NCT00229281|Behavioral|Group therapy|
521255|NCT00229255|Other|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
521256|NCT00229255|Other|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
521257|NCT00229242|Drug|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
521258|NCT00229229|Other|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
521259|NCT00229229|Other|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
521260|NCT00229229|Other|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
521261|NCT00229229|Other|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
521262|NCT00229216|Drug|Tinidazole|
521263|NCT00229203|Drug|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
521264|NCT00229190|Procedure|Nasal lavage|
521265|NCT00229190|Procedure|Allergy skin testing|
521266|NCT00229190|Procedure|Peak nasal inspiratory flow|
521267|NCT00229190|Procedure|Acoustic rhinometry|
521268|NCT00229190|Procedure|Nasal examination|
521269|NCT00229190|Procedure|Quality of Life Questionnaire|
521270|NCT00229190|Procedure|Physical examination|
521271|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
521272|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
521273|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
521274|NCT00229164|Device|Transcutaneous Electric Nerve Stimulation (TENS)|
521275|NCT00229151|Behavioral|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
521276|NCT00229151|Other|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
521277|NCT00229138|Drug|EC-MPS, Tacrolimus|
521278|NCT00229125|Drug|Gabapentin|
521279|NCT00229125|Drug|Lorazepam|
521280|NCT00229112|Drug|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
521281|NCT00229112|Drug|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
521282|NCT00229099|Drug|GerEPO|
521283|NCT00229086|Device|Gatekeeper Reflux Repari System (Device)|
521284|NCT00229073|Drug|dapoxetine|
521285|NCT00229060|Drug|doripenem|
521286|NCT00229021|Drug|doripenum|
521287|NCT00229008|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
521479|NCT00227370|Other|Placebo|
521288|NCT00229008|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
521289|NCT00228995|Drug|epoetin alfa|
521290|NCT00228982|Drug|Ceftobiprole medocaril|
521291|NCT00228982|Drug|Vancomycin|
521292|NCT00228969|Drug|RWJ-333369|
521293|NCT00228956|Drug|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
521294|NCT00228943|Dietary Supplement|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
521295|NCT00228943|Dietary Supplement|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
521296|NCT00228930|Drug|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
521297|NCT00228917|Biological|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine
521298|NCT00228917|Biological|Trianrix-Hepb|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine
521299|NCT00228917|Biological|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
521300|NCT00228917|Biological|Hib-MenAC-TT|Haemophilus influenzae type b, Meningococcal Serogroups A and C -Tetanus toxoid conjugate vaccine
521301|NCT00228904|Procedure|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
521302|NCT00228904|Procedure|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
521303|NCT00228891|Procedure|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
521304|NCT00228891|Procedure|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
521305|NCT00228878|Procedure|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
521306|NCT00228865|Procedure|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
521307|NCT00228865|Procedure|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
521308|NCT00228852|Drug|Busulfan, Fludarabine and ATG|
521309|NCT00228839|Drug|Infliximab|
521310|NCT00228813|Drug|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.~Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.~Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.~Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.~Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
521311|NCT00228696|Other|none, screening only|Screening protocol with no intervention
521312|NCT00228683|Procedure|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
521313|NCT00228657|Drug|4% Albumin / 0.9% Sodium Chloride|
521314|NCT00228605|Drug|OraVescent Fentanyl|
521315|NCT00228592|Drug|HepeX-B|
521316|NCT00228592|Drug|Hepatitis B Immune Globulin (HBIg)|
521317|NCT00228566|Drug|Armodafinil|
521318|NCT00228553|Drug|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
521319|NCT00228540|Drug|Modafinil|
521320|NCT00228527|Drug|Esomeprazole (Nexium)|
521321|NCT00228514|Drug|Rosuvastatin|
521322|NCT00228514|Procedure|Positron emission tomography|
521323|NCT00228488|Drug|Gefitinib|
521324|NCT00228475|Drug|Pulmicort (budesonide) Turbuhaler|
521325|NCT00228462|Drug|Seroquel (quetiapine)|
521326|NCT00228449|Drug|peginesatide|
521327|NCT00228436|Drug|peginesatide|
521328|NCT00228423|Drug|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
521329|NCT00228423|Drug|water pill daily|Daily dose of water pill (placebo)
521330|NCT00228410|Drug|Tigecycline|
521331|NCT00228410|Drug|vancomycin with aztreonam|
521332|NCT00228397|Drug|CCI-779|
521333|NCT00228384|Device|GORE VIABAHN Endoprosthesis|Implantation
521334|NCT00228384|Device|Bare Nitinol Stent|Implantation
521335|NCT00228371|Device|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
521336|NCT00228358|Drug|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
521337|NCT00228358|Drug|cyclophosphamide|Given IV
521339|NCT00228358|Other|flow cytometry|Intracellular cytokine staining (correlative study)
521340|NCT00228358|Other|immunoenzyme technique|ELIspot assay (correlative study)
521341|NCT00228345|Procedure|Optical coherence tomography,Fluorescein angiography|
521342|NCT00228332|Drug|Administration of zinkgluconaat or placebo|
521343|NCT00228319|Dietary Supplement|Oral Ascorbic Acid|4 grams per day for 12 months
521344|NCT00228319|Drug|Paclitaxel|Six cycles
521345|NCT00228319|Drug|Carboplatin|Six cycles
521346|NCT00228319|Drug|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
521347|NCT00228319|Dietary Supplement|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
521348|NCT00228319|Dietary Supplement|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
521349|NCT00228306|Behavioral|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
521350|NCT00228293|Device|investigational monitor/defibrillator with CPR feedback|
521351|NCT00228280|Procedure|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
521352|NCT00228267|Drug|Propofol|
521353|NCT00228254|Drug|Zinc (12.5 mg/day)|
521354|NCT00228254|Drug|vitamin A 10,000 IU per week|
521355|NCT00228241|Device|AAI vs. DDD vs. BIV pacing in different patients groups|
521356|NCT00228228|Biological|T cell vaccination|
521357|NCT00228215|Behavioral|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
521358|NCT00228189|Biological|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
521359|NCT00228176|Drug|Rimonabant|Tablet, oral administration
521360|NCT00228176|Drug|Placebo (for Rimonabant)|Tablet, oral administration
521361|NCT00228163|Drug|teriflunomide (HMR1726)|tablet, oral administration once daily.
521362|NCT00228150|Drug|SR57667B|
521363|NCT00228098|Behavioral|Smoking cessation|
521364|NCT00228072|Procedure|Suction-curettage|
521365|NCT00228059|Drug|Licarbazepine|
521366|NCT00228046|Drug|Divalproex Sodium|
521367|NCT00228046|Drug|Methylphenidate|
521368|NCT00228046|Drug|Dextroamphetamine|
521369|NCT00228046|Drug|Mixed Amphetamine Salts|
521370|NCT00228046|Behavioral|Family Counseling|
521371|NCT00228046|Behavioral|Behavior Management Training with Parents|
521372|NCT00228033|Drug|Elemental calcium (as carbonate)|
521373|NCT00228020|Drug|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
521374|NCT00228020|Drug|MMF, cyclosporine, steroids|
521375|NCT00228007|Drug|Antidepressant Medication|
521376|NCT00227994|Drug|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
521377|NCT00227994|Drug|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
521378|NCT00227981|Behavioral|Interpersonal Psychotherapy|
521379|NCT00227981|Drug|Fluoxetine|
521380|NCT00227968|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
521381|NCT00227968|Behavioral|Clinical Status and Symptom Response Therapy (CSSRT)|
521382|NCT00227955|Drug|Imipramine|
521383|NCT00227955|Behavioral|Interpersonal Psychotherapy|
521384|NCT00227942|Drug|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
521385|NCT00227942|Drug|Zolpidem|10 mg/day, po qhs
521386|NCT00227942|Drug|placebo|placebo
521387|NCT00227929|Procedure|Care Management|
521388|NCT00227916|Behavioral|Behavior Therapy|
521389|NCT00227903|Behavioral|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
521390|NCT00227903|Behavioral|Brief Advice|Advice and education
521391|NCT00227890|Behavioral|MI/CBT|
521392|NCT00227890|Behavioral|RT/TU|
521393|NCT00227877|Behavioral|cSBA - New England, USA|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
521394|NCT00227877|Behavioral|cSBA - Prague, CZR|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
521395|NCT00227864|Behavioral|Behavior Therapy|
521396|NCT00227864|Other|Treatment as Usual|
521397|NCT00227838|Behavioral|Behavior Therapy|
521398|NCT00227825|Behavioral|Motivational interviewing|
521399|NCT00227812|Drug|Bupropion|
521400|NCT00227786|Behavioral|smoking cessation intervention|
521401|NCT00227786|Other|counseling intervention|
521402|NCT00227773|Drug|octreotide acetate|
521403|NCT00227773|Drug|vatalanib|
521404|NCT00227773|Procedure|anti-cytokine therapy|
521405|NCT00227773|Procedure|antiangiogenesis therapy|
521406|NCT00227773|Procedure|biological therapy|
521407|NCT00227773|Procedure|endocrine therapy|
521408|NCT00227773|Procedure|enzyme inhibitor therapy|
521409|NCT00227773|Procedure|growth factor antagonist therapy|
521410|NCT00227773|Procedure|hormone therapy|
521411|NCT00227773|Procedure|protein tyrosine kinase inhibitor therapy|
521412|NCT00227773|Procedure|somatostatin analogue therapy|
521413|NCT00227760|Drug|Cediranib Maleate|Given PO
521414|NCT00227760|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
521415|NCT00227760|Other|Laboratory Biomarker Analysis|Correlative studies
521416|NCT00227760|Other|Pharmacological Study|Correlative studies
521417|NCT00227747|Drug|capecitabine|
521418|NCT00227747|Drug|oxaliplatin|
521419|NCT00227747|Procedure|conventional surgery|
521420|NCT00227747|Procedure|neoadjuvant therapy|
521421|NCT00227747|Radiation|radiation therapy|
521422|NCT00227734|Drug|capecitabine and oxaliplatin + cetuximab|cetuximab
521423|NCT00227734|Drug|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
521424|NCT00227721|Drug|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
521425|NCT00227721|Drug|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
521426|NCT00227708|Drug|docetaxel|
521427|NCT00227708|Procedure|quality-of-life assessment|
521428|NCT00227695|Biological|rituximab|comparing two maintenance schedules of Rituximab
521429|NCT00227682|Dietary Supplement|ascorbic acid|
521430|NCT00227682|Drug|arsenic trioxide|
521431|NCT00227682|Drug|dexamethasone|
521432|NCT00227682|Drug|thalidomide|
521433|NCT00227669|Drug|docetaxel|
521434|NCT00227669|Drug|gemcitabine hydrochloride|
521435|NCT00227656|Biological|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
521436|NCT00227656|Drug|Capecitabine|1000 mg/m^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
521437|NCT00227630|Drug|cisplatin|
521438|NCT00227630|Drug|pemetrexed disodium|
521439|NCT00227630|Procedure|adjuvant therapy|
521440|NCT00227630|Procedure|conventional surgery|
521441|NCT00227630|Procedure|neoadjuvant therapy|
521442|NCT00227630|Radiation|radiation therapy|
521443|NCT00227617|Biological|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
521444|NCT00227617|Drug|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
521445|NCT00227617|Drug|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
521446|NCT00227617|Drug|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
521447|NCT00227591|Drug|lenalidomide|Given orally (PO)
521448|NCT00227591|Drug|prednisone|Given PO
521449|NCT00227591|Other|laboratory biomarker analysis|Correlative studies
521450|NCT00227565|Drug|carboplatin|
521451|NCT00227565|Drug|pemetrexed disodium|
521452|NCT00227565|Radiation|radiation|
521453|NCT00227539|Drug|cisplatin|
521454|NCT00227539|Drug|pemetrexed disodium|
521455|NCT00227539|Procedure|adjuvant therapy|
521456|NCT00227539|Procedure|therapeutic conventional surgery|
521457|NCT00227539|Radiation|fludeoxyglucose F 18|
521458|NCT00227526|Behavioral|Prehabilitation|
521459|NCT00227513|Drug|bortezomib|Given IV
521460|NCT00227513|Drug|vorinostat|Given orally
521461|NCT00227500|Drug|Pravastatin|
521462|NCT00227487|Other|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
521463|NCT00227487|Other|Administration of carbohydrate solution during clinically indicated endoscopy|"A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.~Clinically indicated pinch biopsies will then be obtained.~The endoscopy procedures will take at least 1 - 1 ½ hours.~Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.~Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
521464|NCT00227487|Other|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
521465|NCT00227474|Drug|recombinant modified vaccinia Ankara-5T4 vaccine|
521466|NCT00227474|Procedure|adjuvant therapy|
521467|NCT00227474|Procedure|recombinant viral vaccine therapy|
521468|NCT00227461|Drug|Wait first, then levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
521469|NCT00227461|Drug|Levetiracetam first, then wait|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
521470|NCT00227448|Drug|intravenous saline|
521471|NCT00227448|Drug|intravenous phenylephrine|
521472|NCT00227448|Drug|intravenous levophed|
521473|NCT00227448|Drug|oral midodrine|
521474|NCT00227435|Drug|val-mCyd|
521475|NCT00227422|Biological|Mencevax ACWY|
521476|NCT00227409|Drug|calcium disodium EDTA (edetate calcium disodium)|
521477|NCT00227383|Device|Electroacupuncture (device)|
521478|NCT00227370|Drug|valganciclovir|valgan 900mg QD x 9 months post lung transplant
521480|NCT00227357|Drug|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
521481|NCT00227357|Drug|Off-site - methadone or no agonist|
521482|NCT00227344|Device|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
521483|NCT00227344|Drug|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
521484|NCT00227331|Drug|Oral amoxicillin|
521485|NCT00227318|Drug|ATACAND|
521486|NCT00227305|Drug|quetiapine fumarate|Oral dosing, flexible dosing
521487|NCT00227292|Drug|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
521488|NCT00227292|Drug|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
521489|NCT00227279|Biological|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
521490|NCT00227266|Drug|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
521491|NCT00227266|Drug|Placebo|
521492|NCT00227253|Procedure|Determination of growth hormone status|Growth hormone stimulating testing using Arginine and Clonidine, Corticotrophin releasing hormone stimulation test
521493|NCT00227253|Procedure|Measurement of growth, thyroid and sex hormone levels|Gonadotrophin releasing hormone stimulation test Thyroid testing - T4, TSH, T3 uptake, and anti-thyroidal antibodies baseline sample - no medication administered
521494|NCT00227253|Procedure|Behavior and neuropsychometric evaluations|evaluation by neuropsychologist, standardized testing geared to study participant's age, abilities and past medical history
521495|NCT00227253|Procedure|Audiological and ear, nose and throat examination|neurotological exam, behavioral audiometry, immittance audiometry, assessment of the function of the inner ear using otoacoustic emissions, Auditory brain responses
521496|NCT00227253|Procedure|Magnetic resonance imaging of the brain|MRI of the brain - standard clinical procedure
521497|NCT00227253|Procedure|Dysmorphology evaluation|Genetic evaluation with picture and measurements, physical exam
521498|NCT00227253|Procedure|Neurology examination|physical examination including observation of balance, coordination and reflexes.
521499|NCT00227253|Procedure|Dental evaluation|Visual detal inspection with panorex X-ray of the entire mouth
521500|NCT00227253|Procedure|Speech pathology evaluation|Standardized speech & language tests and naturalistic assessment procedures.
521501|NCT00227253|Procedure|Psychiatric evaluation|Psychiatric interview about history of psychiatric and medical illnesses, family psychiatric and medical history, demographic info also obtained
521502|NCT00227253|Procedure|Orthopedic evaluation|Physical exam by orthopedic surgeon and a dysplasia series of radiographs including AP and lateral radiographics of the feet, APs of the knees, pelvis, thoracic lumbar spine and chest, laterals of thoracic lumbar and cervical spine, lateral of the skull, AP and lateral of the forearm, bone age evaluation with radiograph of left hand
521503|NCT00227253|Procedure|Ophthalmologic evaluation|exam will determine visual acuity using one of the following: Snellen chart, Allen acuity, target acuity, optokinetic nystagmus (OKN), or Teller acuity depending on study participants ability level. Motility/alignment will also be determined using cover/uncover test. Pupils examined using slit lamp. Dilated fundus exam and cycloplegic refraction which will require dilating drops in both eyes. Cyclogen 1% and NeuSynephrine 2.5% are using. In children less than 6 months old, less potent mydriatrics and cycloplegics are used Cyclogel 0.5% or Tropicamide 1%. Intraocular pressure will be measured in adults and cooperative teens using applanation tonometry. A topical anesthetic will be used to perform this measurement.
521504|NCT00227253|Procedure|Gastrointestinal evaluation|physical exam and medical history by board certified gastroenterologist.
521505|NCT00227201|Behavioral|Self-affirmation intervention|
521506|NCT00227188|Drug|Pneumococcal 7-valent conjugate vaccine Prevnar|
521507|NCT00227175|Behavioral|Semi-structured, open ended interview|
521508|NCT00227162|Behavioral|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
521509|NCT00227162|Behavioral|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
521510|NCT00227162|Behavioral|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
521511|NCT00227136|Drug|5-Hydroxy-Tryptamine|
521512|NCT00227123|Drug|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
521513|NCT00227110|Drug|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
521514|NCT00227110|Drug|Placebo|Placebo is given to match pioglitazone.
521515|NCT00227097|Behavioral|Education Notebook for anticoagulant treatment|
521516|NCT00227084|Drug|Arista AH hemostasis powder|
521517|NCT00227071|Behavioral|exercise|
521518|NCT00227058|Drug|Orotic acid and Glutathione-(Nutritional Supplements)|
521519|NCT00227032|Drug|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs"
521520|NCT00227019|Drug|Bevacizumab|15 mg/kg, IV over 10 minutes every 3 weeks
521521|NCT00227019|Drug|Pemetrexed|500 mg/m²; IV over 10 minutes every 3 weeks
521522|NCT00227019|Drug|Vitamin B12|1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
521523|NCT00227019|Drug|Folate|350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
521524|NCT00227019|Drug|Dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
521525|NCT00227006|Behavioral|Behavioral lifestyle/weight-loss intervention|
521526|NCT00226993|Drug|CPG 7909|
521527|NCT00226980|Drug|Thalidomide|
521528|NCT00226980|Drug|Capecitabine|
521529|NCT00226967|Drug|Sandostatin|Calculated per patient
521530|NCT00226954|Drug|zoledronic acid|
521657|NCT00225888|Behavioral|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
521658|NCT00225875|Drug|Mabthéra|
521531|NCT00226941|Drug|Cetuximab|Cetuximab is a chimeric anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, administered via a intravenous (IV) infusion at 400 mg/m² (initial loading dose) or 250 mg/m² (weekly dose). Dosage is based on m² of body surface area (BSA)
521532|NCT00226941|Drug|Oxaliplatin|Oxaliplatin is a cancer medication used to treat colorectal cancer, and is administered on Days 2 and 23.
521533|NCT00226941|Drug|Capecitabine|Capecitabine is a cancer medication, and is administered based on m² of body surface area (BSA) delivered in equivalent morning and evening doses
521534|NCT00226941|Radiation|Radiotherapy|"Radiotherapy is administered on weekdays in 180 centigray fractions (doses), for 28 total fractions delivering a total dose of 5040 centigray (cGy)"
521535|NCT00226941|Drug|Diphenhydramine hydrochloride (HCl)|Diphenhydramine HCl 50 mg (or equivalent) is administered as a per-medication for cetuximab
521536|NCT00226928|Behavioral|Supportive-Expressive Group Therapy plus education|
521537|NCT00226928|Behavioral|Education|
521538|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
521539|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
521540|NCT00226902|Procedure|Changing hemoglobin concentration|
521541|NCT00226889|Drug|bosentan|
521542|NCT00226863|Behavioral|meditation plus education|
521543|NCT00226863|Behavioral|group psychotherapy with hypnosis plus education|
521544|NCT00226863|Behavioral|education|
521545|NCT00226850|Behavioral|hypnosis|
521546|NCT00226837|Drug|Nitrous oxide|nitrous oxide by inhalation during induction
521547|NCT00226824|Drug|galantamine|
521548|NCT00226811|Drug|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
521549|NCT00226798|Drug|Capecitabine (Xeloda)|
521550|NCT00226785|Drug|Dexmedetomidine|
521551|NCT00226772|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
521552|NCT00226772|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
521553|NCT00226759|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
521554|NCT00226759|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
521555|NCT00226746|Drug|Paclitaxel and gemcitabine|"Radiation Therapy: 63.80 Gy (1.1 Gy twice a day X 58 fractions) Paclitaxel: 60 mg/m2 / week by 1- hour IV infusion on days 1, 8, 15, 22, 29, and 36.~Gemcitabine: 75 mg/m2 / week on days 1, 8, 15, 22, 29, and 36."
521556|NCT00226733|Behavioral|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
521557|NCT00226733|Behavioral|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
521558|NCT00226720|Procedure|Outpatient detoxification program|Outpatient detoxification program
521559|NCT00226707|Drug|Pimecrolimus Cream 1%|
521560|NCT00226694|Drug|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
521561|NCT00226694|Other|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
521562|NCT00226681|Behavioral|Nursing Telephone Support Protocol|
521563|NCT00226681|Behavioral|Usual Care|
521564|NCT00226668|Drug|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
521565|NCT00226668|Drug|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
521566|NCT00226655|Drug|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
521567|NCT00226642|Drug|Sertralin|
521568|NCT00226642|Behavioral|Cognitive-behavioral therapy|
521569|NCT00226642|Drug|Placebo|
521570|NCT00226642|Behavioral|Non-specific supporting group therapy|
521571|NCT00226629|Procedure|Endovascular vs Open Repair|
521572|NCT00226616|Drug|Zinc|
521573|NCT00226603|Behavioral|Specific training programme (behavior)|
521574|NCT00226590|Drug|Gemcitabine|Induction Chemotherapy.
521575|NCT00226590|Drug|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
521576|NCT00226590|Drug|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
521577|NCT00226590|Procedure|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
521578|NCT00226577|Drug|Gemcitabine|Gemcitabine (GemzarR) 1500 mg/m2
521579|NCT00226577|Drug|Pemetrexed|Pemetrexed (AlimtaR) 500 mg/m2
521580|NCT00226577|Procedure|Surgery|When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
521581|NCT00226564|Drug|Alfentanil|
521582|NCT00226551|Drug|Isoproterenol|
521583|NCT00226538|Drug|Phenytoin|
521584|NCT00226538|Drug|Rifampicin|
521585|NCT00226538|Drug|Diclophenac|
521586|NCT00226538|Drug|Fluconazole|
521587|NCT00226525|Procedure|skin sensitivity test|
521588|NCT00226512|Drug|Campath-1H /ATG|
521589|NCT00226499|Biological|Priorix-tetra™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group
521590|NCT00226499|Biological|Priorix™|2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group
521591|NCT00226499|Biological|Varilrix™|1 dose administered subcutaneously at Day 42 to subjects in OKAH Group
521659|NCT00225862|Drug|ropinirole|
521660|NCT00225849|Drug|Aspirin|
521661|NCT00225836|Device|OVA (TENS apparatus)|
521662|NCT00225823|Drug|GW685698X|
521592|NCT00226486|Other|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
521593|NCT00226486|Other|Usual care|No intervention, but ususal care after an accidental fall.
521594|NCT00226473|Drug|Cisplatin, Vindesine, Dacarbazine (drugs)|
521595|NCT00226460|Drug|Fetal porcine cells, Neurocell-PD|
521596|NCT00226447|Drug|Pegylated Interferon|
521597|NCT00226447|Drug|Lamivudine|
521598|NCT00226434|Procedure|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
521599|NCT00226434|Procedure|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
521600|NCT00226421|Drug|Oxymorphone Extended Release|
521601|NCT00226408|Drug|Interferon-alpha-2b|
521602|NCT00226395|Drug|Oxymorphone immediate release|
521603|NCT00226382|Drug|Pegylated Interferon-alfa-2a|Pegasys once weekly
521604|NCT00226369|Drug|CY-1503|
521605|NCT00226356|Drug|Supplements of L-methionine, betaine and folate|
521606|NCT00226343|Drug|Depakote-ER|
521607|NCT00226330|Drug|Tesaglitazar|(0.5 or 1 mg)
521608|NCT00226330|Drug|Pioglitazone|(15, 30 or 45 mg)
521609|NCT00226317|Drug|Aripiprazole|
521610|NCT00226291|Other|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
521611|NCT00226278|Drug|ORG 34517|
521612|NCT00226252|Procedure|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
521613|NCT00226252|Procedure|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
521614|NCT00226239|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV over 1 hour, day 1
521615|NCT00226239|Drug|Cisplatin|Cisplatin 75 mg/m^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
521616|NCT00226239|Drug|Cetuximab|Cetuximab dose will be 250 mg/m^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
521617|NCT00226239|Procedure|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies>6 MV may be utilized when appropriate to boost target localized centrally.
521618|NCT00226226|Procedure|Peripherally Inserted Central Catheter Placement|
521619|NCT00226213|Procedure|Peripherally Inserted Central Catheter Placement|
521620|NCT00226200|Drug|Omalizumab|
521621|NCT00226187|Procedure|Supplement of fatty acid (DHA and AA)|
521622|NCT00226174|Drug|Curcuminoids|
521623|NCT00226161|Procedure|Inguinal herniorrhaphy|
521624|NCT00226148|Procedure|Use of a membrane to cover bonedefects around implant|
521625|NCT00226148|Device|Use of bonechips to fill up defects around implant|
521626|NCT00226148|Procedure|Use of membrane and bonechips to manage defects|
521627|NCT00226135|Drug|lithium or lamotrigine|
521628|NCT00226122|Drug|Indomethacin|Indomethacin capsules 50 mg
521629|NCT00226109|Drug|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
521630|NCT00226096|Drug|Labetalol Hydrochloride|
521631|NCT00226096|Drug|Metoprolol tartrate|
521632|NCT00226096|Drug|Hydralazine Hydrochloride|
521633|NCT00226096|Drug|Glycerol Trinitrate|
521634|NCT00226096|Drug|Phentolamine mesylate|
521635|NCT00226096|Drug|Nicardipine|
521636|NCT00226096|Drug|Urapidil|
521637|NCT00226096|Drug|Esmolol|
521638|NCT00226096|Drug|Clonidine|
521639|NCT00226096|Drug|Enalaprilat|
521640|NCT00226096|Drug|Nitroprusside|
521641|NCT00226070|Procedure|interview and advising|
521642|NCT00226070|Behavioral|3 follow up interviews and personal advising|
521643|NCT00226070|Procedure|interview SF-36 self rated health|
521644|NCT00226057|Drug|Raptiva|
521645|NCT00226044|Drug|Omeprazole rectally 1mg/kg|A single dose of 1 mg/kg rectally administered omeprazole.
521646|NCT00226031|Procedure|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
521647|NCT00226018|Device|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
521648|NCT00226018|Device|Placebo|placebo
521649|NCT00226005|Drug|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
521650|NCT00225992|Drug|Arsenic Trioxide|
521651|NCT00225979|Drug|Octreotide LAR|
521652|NCT00225966|Device|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
521653|NCT00225927|Procedure|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
521654|NCT00225914|Drug|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
521655|NCT00225914|Drug|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
521656|NCT00225901|Drug|Recombinant human hepatocyte growth factor|
521663|NCT00225810|Drug|Crohn's Disease|
538866|NCT00002688|Drug|etoposide|
521665|NCT00225784|Drug|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
521666|NCT00225784|Procedure|Radiotherapy|Daily radiotherapy for 28 days
521667|NCT00225758|Drug|Lapatinib|1500 mg po daily for 26 weeks or longer
521668|NCT00225745|Procedure|Blood draw|One blood draw prior to first treatment
521669|NCT00225732|Other|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
521670|NCT00225732|Drug|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.~Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
521671|NCT00225719|Drug|rHDL|
521672|NCT00225706|Drug|Caldolor|
521673|NCT00225693|Device|drug eluting coronary stent|
521674|NCT00225680|Device|drug eluting coronary stent|
521675|NCT00225667|Drug|Irbesartan|
521676|NCT00225654|Device|coronary stent|
521677|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
521678|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
521679|NCT00225628|Behavioral|Computerized Reminders Medications Monitoring|
521680|NCT00225628|Behavioral|Computerized Test Results Management Application|
521681|NCT00225628|Behavioral|Computerized Reminders Hypertension Management|
521682|NCT00225628|Behavioral|Computerized Reminders Osteoporosis Screening and Mgt|
521683|NCT00225615|Drug|sapropterin dihydrochloride|
521684|NCT00225602|Behavioral|Assertive Community Treatment|
521685|NCT00225602|Behavioral|Treatment in Community Mental Health Center|
521686|NCT00225589|Drug|Rosuvastatin calcium|
521687|NCT00225576|Other|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
521688|NCT00225563|Device|Electronic Health Record|e-prescribing methods
521689|NCT00225550|Drug|ADH -1 (Exherin™)|
521690|NCT00225537|Drug|4-Methylumbelliferone (Heparvit®)|
521691|NCT00225524|Drug|Effexor XR|
521692|NCT00225511|Drug|Effexor XR|
521693|NCT00225511|Drug|Milnacipran|
521694|NCT00225498|Drug|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
521695|NCT00225485|Drug|Effexor XR|
521696|NCT00225472|Device|Modified Viaspan|
521697|NCT00225446|Device|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
521698|NCT00225433|Drug|follitropin beta|Follitropin beta
521699|NCT00225433|Drug|ganirelix acetate|Ganirelix acetate
521700|NCT00225420|Drug|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
521701|NCT00225420|Drug|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
521702|NCT00225420|Radiation|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
521703|NCT00225407|Drug|Smoking of cannabis cigarettes (different strength)|
521704|NCT00225381|Device|connection of measuring device to anesthesia circuit|same as name
521705|NCT00225381|Procedure|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
521706|NCT00225381|Procedure|changing operating room bed position (head down and up position)|same
521707|NCT00225381|Procedure|adding PEEP during anesthesia|same
521708|NCT00225381|Procedure|placement of esophageal Doppler for cardiac output measurements|same
521709|NCT00225381|Device|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
521710|NCT00225381|Device|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
521711|NCT00225381|Device|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
521712|NCT00225381|Device|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
521713|NCT00225368|Device|Insecticide treated bednets|
521714|NCT00225355|Drug|Rosiglitazone|
521715|NCT00225342|Drug|Rosiglitazone|
521716|NCT00225342|Drug|Gliclazide (Comparison drug)|
521717|NCT00225329|Procedure|Labour assessment and support|
521718|NCT00225316|Procedure|Acupuncture|See Detailed Description.
521719|NCT00225303|Drug|TMC125|
521720|NCT00225290|Drug|Thalidomide(Thado)|
521721|NCT00225277|Drug|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
521722|NCT00225277|Drug|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
521723|NCT00225264|Drug|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
521724|NCT00225264|Drug|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
521725|NCT00225251|Drug|bupropion XL|Antidepressant medication
521726|NCT00225251|Other|Placebo|Placebo
521727|NCT00225238|Drug|esomeprazole (PPI)|
521728|NCT00225225|Drug|Rosiglitazone|
521729|NCT00225225|Behavioral|dietary recommendation for weight maintenance|
521730|NCT00225212|Drug|Rituximab 375 mg/m2|
521731|NCT00225199|Drug|Visanne (BAY86-5258, SH T00660AA)|orally once daily
521732|NCT00225199|Drug|Placebo|orally once daily
521733|NCT00225186|Drug|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
521734|NCT00225173|Drug|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
521735|NCT00225173|Drug|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
521736|NCT00225173|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
521737|NCT00225173|Drug|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
521738|NCT00225173|Drug|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
521739|NCT00225173|Drug|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
521740|NCT00225173|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
521741|NCT00225173|Drug|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
521742|NCT00225173|Drug|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
521743|NCT00225160|Drug|acetyl L-carnitine|
521744|NCT00225147|Drug|Recombinant Human C1 Inhibitor|IV
521745|NCT00225147|Drug|placebo|saline solution
521746|NCT00225121|Drug|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
521747|NCT00225108|Drug|Tinzaparin|
521748|NCT00225095|Drug|Mesenchymal Stem Cells|
521749|NCT00225095|Drug|Hyaluronan|
521750|NCT00225082|Drug|Nucleoside analogue switch|stavudine switched to tenofovir
521751|NCT00225069|Procedure|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
521752|NCT00225056|Drug|docetaxel and capecitabine|
521753|NCT00225043|Drug|Epinephrine/phenylephrine|
521754|NCT00225030|Drug|antihypertensive drugs according to current guidelines|
521755|NCT00225017|Drug|Atazanavir|atazanavir 400 mg once daily
521756|NCT00225017|Drug|current antiretroviral regimen|Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus > 2 NRTIs
521757|NCT00225004|Procedure|DEXA scan|orto
521758|NCT00224991|Procedure|Intensive systematic information (osteoporosis school)|
521759|NCT00224978|Drug|Chloroquine|
521760|NCT00224965|Behavioral|Behavior Therapy|
521761|NCT00224952|Other|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
521762|NCT00224939|Drug|Potassium Chloride|
521763|NCT00224926|Procedure|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
521764|NCT00224913|Procedure|Neuromuscular electrical stimulation|
521765|NCT00224913|Procedure|Voluntary exercise|
521766|NCT00224887|Behavioral|In home nutrition counseling|
521767|NCT00224874|Drug|Etanercept|Etanercept [25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks].
521768|NCT00224874|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) [20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks].
521769|NCT00224874|Drug|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) [9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19].
521770|NCT00224874|Drug|Pentostatin|Pentostatin [1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
521771|NCT00224861|Behavioral|Self-Management|
521772|NCT00224861|Behavioral|Adherence|
521773|NCT00224848|Behavioral|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
521774|NCT00224835|Behavioral|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
521775|NCT00224835|Behavioral|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
521776|NCT00224822|Drug|Aripiprazole|
521777|NCT00224809|Drug|Angiotensin-Converting Enzyme Inhibitors|
521778|NCT00224809|Procedure|Coronary Artery Bypass Graft|
521779|NCT00224809|Drug|Angiotensin Receptor Blockers|
521780|NCT00224809|Drug|Spironolactone|
521781|NCT00224809|Drug|Aspirin|
521782|NCT00224809|Drug|Clopidogrel|
521783|NCT00224809|Procedure|Surgical Ventricular Restoration|
521784|NCT00224796|Device|V.A.C. ® System|
521785|NCT00224783|Biological|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
521786|NCT00224783|Biological|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
521787|NCT00224770|Drug|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
521788|NCT00224770|Procedure|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
521789|NCT00224757|Procedure|Transoesophageal echocardiography|TEE
521790|NCT00224744|Device|ultracision|Surgery by Ultracision
521791|NCT00224744|Device|classical lymphadenectomy|classical lymphadenectomy
521792|NCT00224718|Procedure|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
521793|NCT00224718|Procedure|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
521794|NCT00224705|Device|Molecular Adsorbent Recirculating System (MARS®)|
521795|NCT00224692|Drug|Low dose ketamine|
521796|NCT00224679|Drug|Aspirin|
521797|NCT00224666|Device|Cortex stimulation|
521798|NCT00224653|Procedure|Mechanical Ventilation|
521799|NCT00224640|Drug|Iron chelating intervention|Iron chelating intervention
521800|NCT00224627|Procedure|Capsule GIVEN IMAGING LTD|
521801|NCT00224614|Procedure|Allogenic transplantation|
521802|NCT00224601|Procedure|Colonoscopy with chromoscopy|
521803|NCT00224588|Drug|Ketamine (or placebo : isotonic saline solution)|
521804|NCT00224575|Other|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
521805|NCT00224575|Other|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
521806|NCT00224562|Drug|TNF-alpha antagonists|
521807|NCT00224549|Drug|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
521808|NCT00224536|Procedure|Intracoronary bone marrow cell transfer|
521809|NCT00224523|Drug|GW685698X|
521810|NCT00224523|Drug|mometasone furoate|
521811|NCT00224510|Drug|lamotrigine|
521812|NCT00224497|Drug|SB-742457|
521813|NCT00224484|Biological|GSK208141|3 intramuscular doses
521814|NCT00224484|Biological|Havrix (investigational formulation)|3 intramuscular doses
521815|NCT00224484|Biological|Placebo|3 intramuscular doses
521816|NCT00224471|Biological|GSK208141 vaccine|3 IM doses
521817|NCT00224458|Drug|Truvada|
521818|NCT00224458|Drug|efavirenz|
521819|NCT00224445|Drug|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
521820|NCT00224445|Drug|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
521821|NCT00224445|Drug|Ritonavir|Ritonavir 100 mg capsule administered orally QD
521822|NCT00224432|Drug|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
521823|NCT00224419|Behavioral|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
521824|NCT00224419|Behavioral|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
521825|NCT00224419|Drug|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
521826|NCT00224406|Drug|repertaxin|
521827|NCT00224393|Drug|Enbrel|
521828|NCT00224380|Behavioral|Using Medications Effectively|
521829|NCT00224367|Behavioral|time to first ambulation|
521830|NCT00224354|Biological|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
521831|NCT00224354|Biological|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
521832|NCT00224354|Biological|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
521833|NCT00224354|Drug|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
521834|NCT00224354|Biological|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
521835|NCT00280839|Drug|Topiramate|
521836|NCT00280839|Drug|Placebo|
521837|NCT00224341|Device|Pacemaker Vitatron Selection 9000|
521838|NCT00224341|Device|Pacemaker Vitatron T70|
521839|NCT00224328|Device|ODISsey Tissue Oximeter|
521840|NCT00224315|Drug|ziprasidone|
521841|NCT00224315|Drug|risperidone|
521842|NCT00224302|Drug|Duloxetine|
521843|NCT00224289|Drug|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
521844|NCT00224263|Drug|Lingzhi (Ganoderma)|
521845|NCT00224250|Procedure|One- versus two-layer hysterotomy closure|
521846|NCT00224211|Behavioral|Music|
521897|NCT00223743|Drug|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
521898|NCT00223730|Drug|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
521899|NCT00223730|Drug|Placebo|
521900|NCT00223717|Drug|Clonidine|0.1-0.2mg po. Single dose.
521847|NCT00224198|Procedure|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
521848|NCT00224185|Procedure|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
521849|NCT00224185|Procedure|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
521850|NCT00224185|Procedure|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
521851|NCT00224159|Behavioral|Drug and Dietary behavior|
521852|NCT00224146|Drug|oxybutynin transdermal delivery system (Oxytrol(r))|
521853|NCT00224133|Drug|Silodosin|8 mg daily
521854|NCT00224120|Drug|Silodosin|8 mg daily for 12 weeks
521855|NCT00224120|Other|Placebo|One capsule daily for 12 weeks
521856|NCT00224107|Drug|Silodosin|8 mg daily for 12 weeks
521857|NCT00224107|Other|Placebo|1 capsule daily for 12 weeks
521858|NCT00224094|Drug|Premarin® (oral) vs. Alora® (transdermal)|
521859|NCT00224081|Drug|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
521860|NCT00224068|Drug|Sodium ferric gluconate, ferrous sulfate, standard of care|
521861|NCT00224055|Drug|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
521862|NCT00224055|Drug|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
521863|NCT00224042|Drug|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
521864|NCT00224042|Drug|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
521865|NCT00224029|Drug|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
521866|NCT00224016|Drug|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
521867|NCT00224016|Drug|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
521868|NCT00224003|Drug|Sodium Ferric Gluconate Complex in Sucrose.|
521869|NCT00223990|Biological|FMP1/AS02A|
521870|NCT00223977|Drug|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
521871|NCT00223977|Drug|Sodium Ferric Gluconate Complex|250 mg weekly x 4
521872|NCT00223977|Drug|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
521873|NCT00223964|Drug|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
521874|NCT00223951|Drug|R89674 (generic name not yet established)|
521875|NCT00223938|Drug|Oral Iron|Oral Iron
521876|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 1
521877|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 2
521878|NCT00223925|Drug|Maribavir|
521879|NCT00223925|Drug|Placebo|
521880|NCT00223912|Device|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
521881|NCT00223899|Genetic|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
521882|NCT00223873|Procedure|Penile Vibratory Stimulation|
521883|NCT00223860|Drug|Human chorionic gonadotropin (hCG)|
521884|NCT00223860|Drug|Luteinizing hormone releasing hormone (LHRH)|
521885|NCT00223847|Behavioral|Constraint Induced Language Therapy|
521886|NCT00223834|Behavioral|single session of Motivational Interviewing|
521887|NCT00223821|Drug|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
521888|NCT00223821|Behavioral|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
521889|NCT00223808|Other|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
521890|NCT00223808|Other|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
521891|NCT00223808|Other|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
521892|NCT00223795|Device|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
521893|NCT00223782|Behavioral|Gait Training with Feedback|
521894|NCT00223782|Behavioral|Gait Training with no feedback|
521895|NCT00223769|Drug|Oxandrolone|
521896|NCT00223756|Other|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
521959|NCT00223600|Behavioral|Nutritional and life style counseling|
521901|NCT00223717|Drug|Nitroglycerin transdermal|0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
521902|NCT00223717|Drug|Dipyridamole/ Aspirin (Aggrenox)|dipyridamole 200 mg and aspirin 25 mg po. Single dose.
521903|NCT00223717|Drug|Desmopressin (DDAVP)|0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
521904|NCT00223717|Drug|Sildenafil|25- 100 mg po. Single dose.
521905|NCT00223717|Drug|Nifedipine|10-30 mg po. Single dose.
521906|NCT00223717|Drug|Hydralazine|10-50 mg po. Single dose
521907|NCT00223717|Drug|Hydrochlorothiazide|12.5-100 mg po. Single dose.
521908|NCT00223717|Drug|Placebo|Po or patch. Single dose.
521909|NCT00223717|Drug|Bosentan|62.5 -125 mg po. Single dose.
521910|NCT00223717|Drug|Diltiazem|30-60 mg po. Single dose.
521911|NCT00223717|Drug|Eplerenone|50-100 mg po. Single dose.
521912|NCT00223717|Drug|guanfacine|1-3 mg po. Single dose.
521913|NCT00223717|Dietary Supplement|L-arginine|6-17 g po. Single dose
521914|NCT00223717|Drug|captopril|25-50 mg PO. Single dose.
521915|NCT00223717|Drug|carbidopa|25-200 mg PO. Single dose.
521916|NCT00223717|Drug|losartan|25-200 mg PO. Single dose.
521917|NCT00223717|Drug|metoprolol tartrate|25-100 mg PO. Single dose.
521918|NCT00223717|Drug|nebivolol hydrochloride|2.5-40 mg PO. Single dose.
521919|NCT00223717|Drug|prazosin hydrochloride|0.5-1 mg PO. Single dose.
521920|NCT00223717|Drug|tamsulosin hydrochloride|0.4-0.8 mg PO. Single dose.
521921|NCT00223717|Other|Head-up tilt.|Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
521922|NCT00223717|Drug|aliskiren|aliskiren (Tekturna) 150-300mg po single dose
521923|NCT00223717|Other|Local heat stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
521924|NCT00223704|Drug|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
521925|NCT00223704|Drug|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
521926|NCT00223704|Drug|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
521927|NCT00223691|Drug|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
521928|NCT00223691|Drug|Acarbose|25-100 mg, PO. Single dose.
521929|NCT00223691|Drug|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
521930|NCT00223691|Drug|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
521931|NCT00223691|Drug|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
521932|NCT00223691|Drug|placebo|PO.Single dose.
521933|NCT00223691|Drug|Modafinil|50-400 mg PO. Single dose
521934|NCT00223691|Drug|Octreotide|5-50 µg, S.C. Single dose.
521935|NCT00223691|Other|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
521936|NCT00223691|Drug|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
521937|NCT00223691|Drug|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
521938|NCT00223691|Drug|Tranylcypromine|5 - 40 mg PO. Single dose
521939|NCT00223691|Drug|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
521940|NCT00223691|Drug|Celecoxib|50-200 mg PO. Single dose
521941|NCT00223691|Drug|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
521942|NCT00223691|Drug|Methylphenidate|5 or 10 mg PO. Single dose.
521943|NCT00223691|Drug|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
521944|NCT00223691|Drug|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
521945|NCT00223691|Drug|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
521946|NCT00223691|Dietary Supplement|Bovril|6-10 g, PO. Single dose.
521947|NCT00223691|Drug|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
521948|NCT00223691|Drug|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
521949|NCT00223691|Drug|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
521950|NCT00223691|Device|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
521951|NCT00223691|Device|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
521952|NCT00223678|Drug|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
521953|NCT00223665|Drug|Flutamide|Flutamide dosed at 250mg orally three times a day for 14 days prior to the initiation of Leuprolide Acetate.
521954|NCT00223665|Drug|Leuprolide Acetate|Leuprolide Acetate dosed at 7.5mg intramuscular (IM) injections once per month for a total of 9 months.
521955|NCT00223652|Behavioral|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
521956|NCT00223639|Drug|Topiramate|200mg twice a day
521957|NCT00223626|Drug|Topiramate|the maximum topiramate test dose is 200 mg/d.
521958|NCT00223613|Drug|daily intranasal administration of insulin|
539363|NCT00087256|Drug|Celecoxib|
521960|NCT00223587|Other|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
521961|NCT00223574|Drug|Control - high carbohydrate, high glycemic index foods|
521962|NCT00223574|Drug|high carbohydrate, low glycemic index foods|
521963|NCT00223574|Drug|low carbohydrate, high monounsaturate fat foods|
521964|NCT00223561|Drug|methylphenidate|
521965|NCT00223548|Drug|sodium 2-mercaptoethane sulfonate|
521966|NCT00223535|Behavioral|Cognitive Remediation|
521967|NCT00223535|Behavioral|Social Skills Training|
521968|NCT00223522|Device|MEMS caps|
521969|NCT00223509|Drug|Lamotrigine|
521970|NCT00223496|Drug|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
521971|NCT00223483|Genetic|Isolation of genomic DNA|One time blood draw
521972|NCT00223457|Behavioral|Factors that influence compliance|
521973|NCT00223431|Device|all-ceramic fixed partial denture|
521974|NCT00223418|Drug|aripiprazole|
521975|NCT00223405|Device|crown placement|
521976|NCT00223379|Procedure|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
521977|NCT00223353|Other|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
521978|NCT00223340|Behavioral|Patient Activation and Diabetes Registry|
521979|NCT00223314|Behavioral|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
521980|NCT00223301|Drug|Mycophenolate Mofetil (cellcept)|
521981|NCT00223288|Drug|Lexapro|
521982|NCT00223275|Drug|Naltrexone|
521983|NCT00223262|Drug|Lamotrigine (Drug)|
521984|NCT00223249|Drug|Quetiapine|
521985|NCT00223236|Drug|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
521986|NCT00223236|Drug|Placebo|Placebo matching active medication in all other aspects.
521987|NCT00223223|Drug|Levetiracetam, Keppra|
521988|NCT00223210|Drug|Quetiapine|Active Quetiapine
521989|NCT00223210|Drug|PLacebo|Placebo
521990|NCT00223197|Drug|Pregnenolone|
521991|NCT00223171|Drug|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
521992|NCT00223158|Drug|Liothyronine|
521993|NCT00223145|Radiation|Radiotherapy 70 Gy|Radiotherapy to the prostate
521994|NCT00223145|Radiation|Radiotherapy 76 Gy|Radiotherapy to the prostate
521995|NCT00223145|Drug|Androgen blockade|Duration : 6 months
521996|NCT00223132|Device|Absorbable sutures|
521997|NCT00223119|Device|Absorbable Sutures|
521998|NCT00223106|Device|Vaginal Sling|
521999|NCT00223093|Drug|TAIZ|
522000|NCT00223080|Biological|ALVAC-HIV vCP1521 + AIDSVAX|Combined dose of 600 μg (300 μg of each antigen), co-formulated and administered in alumi-um hydroxide gel at a dose of 600 μg/mL
522001|NCT00223080|Other|ALVAC Placebo + AIDSVAX Placebo|ALVAC carrier, supplied as a lyophilized product, without virus and Aluminum hydroxide adjuvant, 1.2 mL per vial, given as a 1 mL injection
522002|NCT00223067|Drug|TAIZ|
522003|NCT00223054|Drug|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
522004|NCT00223054|Drug|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
522005|NCT00223054|Drug|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
522006|NCT00223054|Drug|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
522007|NCT00223041|Drug|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
522008|NCT00223028|Drug|sirolimus, mycophenolat mofetil, fluvastatin|
522009|NCT00223015|Drug|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
522010|NCT00223002|Drug|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
522011|NCT00222989|Drug|PPI|
522012|NCT00222976|Drug|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
522013|NCT00222937|Behavioral|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
522014|NCT00222937|Behavioral|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
522015|NCT00222924|Behavioral|weight loss/ exercise|
522016|NCT00222911|Device|dorsiflexion night splint|
522017|NCT00222911|Device|medial arch support|
522018|NCT00222898|Procedure|DNA analysis of pancreatic cyst fluid / buccal swab|
522019|NCT00222872|Drug|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
522020|NCT00222872|Drug|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
522021|NCT00222846|Behavioral|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
522022|NCT00222846|Behavioral|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
522023|NCT00222833|Drug|Aripiprazole|
522024|NCT00222820|Drug|escitalopram|
522025|NCT00222820|Behavioral|Interpersonal Psychotherapy|
522026|NCT00222794|Drug|Atomoxetine (Strattera)|
522027|NCT00222755|Behavioral|Disease Management|Self-management, care management, guidelines
522028|NCT00222742|Procedure|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
522029|NCT00222729|Drug|Pemetrexed|500 mg/m2 day 1 q 21 days
522030|NCT00222729|Drug|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
522031|NCT00222716|Behavioral|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
522032|NCT00222703|Behavioral|Smoking relapse prevention|
522033|NCT00222677|Drug|aspirin|100 mg daily
522034|NCT00222664|Biological|Hep-V Vax|
522035|NCT00222651|Drug|tenecteplase|
522036|NCT00222638|Drug|Influenza vaccination|
522037|NCT00222625|Drug|rFVIIa + (vit K in AO patients)|
522038|NCT00222625|Drug|FFP or aPCC+ vit K in AO treated patients|
522039|NCT00222612|Other|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
522040|NCT00222612|Drug|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
522041|NCT00222612|Drug|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
522042|NCT00222573|Drug|clopidogrel and metoprolol|
522043|NCT00222560|Behavioral|Intensive physical activity counselling by an integrated physical activity counsellor|
522044|NCT00222547|Drug|Vitamin A|
522045|NCT00222547|Drug|Albendazole|
522046|NCT00222534|Drug|Acetazolamide|
522047|NCT00222534|Drug|Placebo|
522048|NCT00222521|Drug|Glargine insulin|
522049|NCT00222495|Drug|quetiapine|
522050|NCT00222495|Drug|olanzapine|
522051|NCT00222495|Drug|risperidone|
522052|NCT00222482|Drug|Depakote ER|
522053|NCT00222469|Drug|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
522054|NCT00222469|Drug|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
522055|NCT00222469|Drug|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
522056|NCT00222456|Behavioral|Sensitizing parents|
522057|NCT00222443|Drug|Irinotecan|
522058|NCT00222430|Procedure|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
522059|NCT00222430|Procedure|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
522060|NCT00222417|Procedure|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
522061|NCT00222417|Procedure|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
522062|NCT00222365|Drug|Arnica montana, 5 CH|
522063|NCT00222365|Drug|Bryonia alba, 5 CH|
522064|NCT00222365|Drug|Hypericum perforatum, 5 CH|
522065|NCT00222365|Drug|Ruta graveolens, 3 DH|
522066|NCT00222352|Diagnostic Test|Point of Care cTnL testing|"The study design will be a phase IV prospective, randomized (1:1), parallel-group trial utilizing concurrent controls. The experimental group of interest will be patients receiving the POC cTnI test, and the control group will be patients receiving the central laboratory cTnI test.~The treating physician will be blinded to the randomization and will receive only the POC results from half the study patients and only the laboratory results for the remaining half."
522067|NCT00222339|Behavioral|task-specific training|
522068|NCT00222326|Behavioral|Pelvic floor muscle training and lifestyle modification|
522069|NCT00222300|Behavioral|Strength training program|
522070|NCT00222287|Behavioral|Feldenkrais Movement class|
522071|NCT00222274|Behavioral|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
522072|NCT00222274|Behavioral|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
522073|NCT00222261|Drug|aspirin|Aspirin 160 mg once daily for two years
522074|NCT00222261|Drug|clopidogrel|clopidogrel 75 mg once daily for two years
522075|NCT00222248|Behavioral|Pelvic floor muscle training and bladder training|
522076|NCT00222235|Drug|d-cycloserine|
522077|NCT00222235|Drug|glycine|
522078|NCT00222235|Drug|placebo|
522079|NCT00222222|Procedure|vein puncture|comparison of different inflammatory markers in the blood of septic patients
522080|NCT00222209|Behavioral|Experimental heat pain model|
522081|NCT00222196|Procedure|lifestyle, PTA|
522082|NCT00222183|Drug|Elidel (pimecrolimus)|
522083|NCT00222170|Drug|Rabeprazole|
522084|NCT00222144|Drug|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
522085|NCT00222131|Drug|Esomeprazole|Esomeprazole 40 mg QD
522086|NCT00222131|Other|Placebo|Placebo
522087|NCT00222118|Behavioral|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
522088|NCT00222118|Other|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
539364|NCT00087256|Other|placebo|
522089|NCT00222118|Other|usual care|no intervention
522090|NCT00222105|Drug|Doxil|Doxil 40 mg/m2 IV day 1
522091|NCT00222105|Drug|Thalidomide|50-100 mg day 1-28
522092|NCT00222105|Drug|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
522093|NCT00222079|Drug|Esomeprazole (Nexium)|
522094|NCT00222066|Procedure|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
522095|NCT00222053|Drug|Thalidomide|Per os thalidomide
522096|NCT00222053|Drug|Biphosphonates|Biphosphonates
522097|NCT00222040|Radiation|Ultrasound|2-MHz, low intensity transcranial ultrasound
522098|NCT00222040|Drug|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
522099|NCT00222027|Procedure|Collection of treatment-stratefying prognostic factors|
522100|NCT00222014|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
522101|NCT00222014|Procedure|Paracenthese|Paracenthese
522102|NCT00221988|Drug|Levetiracetam (Keppra)|
522103|NCT00221975|Drug|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
522104|NCT00221975|Drug|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
522105|NCT00221975|Drug|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (<2 months versus ≥2 months).
522106|NCT00221962|Drug|Aripiprazole|Open label
522107|NCT00221949|Device|Ultrasound|
522108|NCT00221936|Behavioral|Self-administration or nurse administered medication|
522109|NCT00221910|Procedure|Ultrasound|
522110|NCT00221884|Procedure|Ultrasound|
522111|NCT00221871|Drug|Different dosages of Ketamine|
522112|NCT00221858|Procedure|Ultrasound guided blocks|
522113|NCT00221845|Drug|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
522114|NCT00221845|Drug|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
522115|NCT00221845|Drug|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
522116|NCT00221819|Device|heated humidifier (device)|
522117|NCT00221819|Device|Heat and moisture exchanger (device)|
522118|NCT00221806|Device|endothelialised prosthesis|
522119|NCT00221793|Procedure|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
522120|NCT00221780|Device|left ventricular pacing|
522121|NCT00221767|Device|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
522122|NCT00221754|Drug|Pravastatin (drug)|
522123|NCT00221741|Drug|Fresh Frozen Plasma (blood product)|
522124|NCT00221728|Device|Radiofrequency|
522125|NCT00221728|Procedure|conservative surgery|
522126|NCT00221715|Device|femoropopliteal artery bypass|Bypass by autologous saphenous vein
522127|NCT00221715|Device|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
522128|NCT00221702|Drug|PegIntron|100 mcg SC/week for 36 months
522129|NCT00221702|Drug|intron A|3mui TIWW SC for 18 months
522130|NCT00221689|Drug|baclofen (drug)|
522131|NCT00221676|Biological|Alfarix|
522132|NCT00221663|Device|surgery techniques (sternotomy for aortic valve replacement)|
522133|NCT00221650|Drug|Peginterferon alfa2a|
522134|NCT00221650|Drug|Ribavirin|
522135|NCT00221637|Drug|Sodium Valproate|
522136|NCT00221624|Drug|Peginterferon alfa-2a|
522137|NCT00221624|Drug|ribavirin|
522138|NCT00221624|Drug|amantadine|
522139|NCT00221611|Drug|Administration of intrathecal baclofen|
522140|NCT00221598|Procedure|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
522141|NCT00221585|Behavioral|Psychosocial treatment/Psychodynamic treatment|
522142|NCT00221572|Procedure|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
522143|NCT00221559|Procedure|Blood sampling for determination of serum Zn|
522144|NCT00221546|Drug|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
522145|NCT00221520|Drug|midazolam with 2 different levels of sedation scores|
522146|NCT00221507|Behavioral|Reminder-Recall-Outreach|
522147|NCT00221507|Behavioral|Case Management|
522148|NCT00221507|Behavioral|Patient Navigator|
522149|NCT00221494|Drug|citalopram + tiodothyronine, or + pindolol, or + placebo|
522150|NCT00221481|Drug|divalproex or olanzapine|
522151|NCT00221468|Drug|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
522152|NCT00221455|Behavioral|Patient diabetic self-management using the diabetic patient portal tools|
522153|NCT00221455|Behavioral|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
522154|NCT00221442|Drug|Zonegran|zonegran (zonisamide)
522155|NCT00221442|Drug|sugar pill|fake pill
522156|NCT00221429|Drug|lithium sodium divalproex|
522157|NCT00221416|Drug|Aripiprazole|5-20 mg/day
522158|NCT00221403|Drug|Risperidone Valproate|liquid, BID dosing.
522159|NCT00221390|Drug|Ropinirole (+ physical therapy)|
522160|NCT00221390|Drug|(vs.) Placebo + physical therapy|
522161|NCT00221377|Device|Intubation using tracheal tubes with or without cuff|
522162|NCT00221364|Drug|Mass treatment with oral azithromycin to an entire village|
522163|NCT00221351|Procedure|CRP point of care testing|
522164|NCT00221338|Drug|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
522165|NCT00221325|Drug|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.~First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.~If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.~Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
522166|NCT00221312|Drug|Fosamax|
522167|NCT00221299|Drug|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
522168|NCT00221299|Drug|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
522169|NCT00221286|Drug|pegylated interferon alfa-2a|
522170|NCT00221286|Drug|tenofovir DF / emtricitabine combination therapy|
522171|NCT00221286|Drug|pegIFN / TDF / FTC combination therapy|
522172|NCT00221273|Procedure|ACL surgery|
522173|NCT00221260|Procedure|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
522174|NCT00221247|Procedure|Acupuncture|acupuncture
522175|NCT00221234|Behavioral|Print materials, pedometers/logbooks|
522176|NCT00221234|Behavioral|Print materials, pedometers/logbooks, telephone counselling|
522177|NCT00221221|Device|Pedometer|
522178|NCT00221221|Device|Exercise guidebook|
522179|NCT00221208|Behavioral|Resistance Training|
522180|NCT00221195|Drug|activated prothrombin complex concentrate (FEIBA)|"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months~FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"
522181|NCT00221182|Genetic|Autologous peripheral blood CD34 positive cell therapy|
522182|NCT00221169|Procedure|Surgical resection|pet ct prior to surgery
522183|NCT00221156|Drug|Acarbose|
522184|NCT00221143|Genetic|Autologous peripheral blood CD34 positive cell therapy|
522185|NCT00221130|Procedure|surgical operation of cell transplantation|
522186|NCT00221117|Device|Neuroprosthesis-FES Therapy|The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
522187|NCT00221117|Other|Conventional Ocupational Therapy (COT)|Conventional occupational therapy pertaining to hand function represents control activities against which the FES therapy was assessed. The conventional occupational therapy included: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training.
522188|NCT00221104|Drug|Pravastatin|
522189|NCT00221091|Procedure|ventriculo-peritoneal shunt|
522190|NCT00221078|Device|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
522191|NCT00221065|Device|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
522192|NCT00221052|Drug|Diclofenac|
522193|NCT00221039|Drug|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
522194|NCT00221026|Drug|Methoxsalen +ECP|ECP + Uvadex given at weeks 1-12 weeks.
522195|NCT00221026|Procedure|Extracorporeal Photopheresis|ECP given at weeks 1 through 12.
522196|NCT00221013|Procedure|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
522197|NCT00221000|Drug|Methoxsalen|
522198|NCT00221000|Procedure|Extracorporeal Photopheresis|
522199|NCT00220987|Other|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
522200|NCT00220987|Other|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
522201|NCT00220974|Behavioral|Internet-based tailored advice on cardiovascular risk|
522202|NCT00220961|Drug|Pioglitazone|Pioglitazone tablets - 45 mg/day
522203|NCT00220961|Drug|Placebo|Placebo tablets similar to pioglitazone tablets - 1 tablet/day
522204|NCT00220948|Procedure|CERSR Myoelectric monitoring during standardized tasks|
522205|NCT00220935|Device|Orthotrac Pneumatic Vest|
522206|NCT00220922|Procedure|Alcohol Wipes vs. No Alcohol Wipes|
522207|NCT00220909|Drug|Lansoprazole|
522208|NCT00220896|Drug|Donepezil|
522209|NCT00220870|Behavioral|Decision aid|
522210|NCT00220857|Drug|Rabeprazole|
522211|NCT00220844|Drug|Desipramine|
522212|NCT00220844|Drug|Amitriptyline|
522213|NCT00220831|Drug|Natural source Vitamin E 400IU/day|
522214|NCT00220818|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
522215|NCT00220818|Drug|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
522280|NCT00220103|Procedure|Surgical resection|
522216|NCT00220805|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
522217|NCT00220805|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
522218|NCT00220792|Behavioral|Brief supportive-expressive group therapy|
522219|NCT00220779|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
522220|NCT00220779|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|
522221|NCT00220766|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
522222|NCT00220766|Drug|Dextrose, 5% in Water|
522223|NCT00220753|Device|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
522224|NCT00220740|Drug|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
522225|NCT00220740|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
522226|NCT00220727|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
522227|NCT00220714|Drug|atypical antipsychotics:oral vs. long-acting route|
522228|NCT00220714|Behavioral|Family Psychoeducation|
522229|NCT00220701|Drug|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
522230|NCT00220688|Device|Acupressure Wristbands|
522231|NCT00220675|Drug|Erythropoietin infusion|
522232|NCT00220662|Behavioral|Readiness and Motivation Therapy|
522233|NCT00220649|Drug|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
522234|NCT00220636|Drug|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
522235|NCT00220623|Drug|antidepressant medications, flexible drug choice|
522236|NCT00220623|Behavioral|CBT, Psychodynamic or Supportive Psychotherapy|
522237|NCT00220610|Device|Transcranial magnetic stimulation|
522238|NCT00220597|Behavioral|Trauma-focused group therapy|
522239|NCT00220584|Drug|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
522240|NCT00220571|Device|Coronary Angioplasty (PTCA)|
522241|NCT00220558|Device|Coronary placement of bare metal stent vs. drug eluting stent|
522242|NCT00220545|Procedure|Laparoscopic ovarian diathermy|
522243|NCT00220532|Drug|Folic acid with riboflavin|
522244|NCT00220519|Drug|Lactobacillus GG|
522245|NCT00220506|Drug|Provigil|
522246|NCT00220493|Drug|Ritalin|
522247|NCT00220480|Drug|escitalopram|10 to 30 mg / day
522248|NCT00220467|Behavioral|Aerobic exercise|
522249|NCT00220454|Drug|Climara|
522250|NCT00220454|Drug|Hydrocortone|
522251|NCT00220441|Behavioral|Aerobic exercise|
522252|NCT00220428|Biological|T-Cell Vaccination|
522253|NCT00220415|Drug|SPM 927|
522254|NCT00220402|Drug|SPM 907|
522255|NCT00220389|Drug|SPM 907|
522256|NCT00220376|Drug|SPM 907|
522257|NCT00220363|Drug|SPM 907|
522258|NCT00220350|Drug|leuprolide acetate|
522259|NCT00220337|Drug|lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
522260|NCT00220324|Drug|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
522261|NCT00220311|Drug|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
522262|NCT00220298|Drug|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
522263|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
522264|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
522265|NCT00220272|Drug|SR57667B|
522266|NCT00220259|Drug|Fluticasone or placebo|
522267|NCT00220233|Drug|olmesartan medoxomil|
522268|NCT00220233|Drug|amlodipine|
522269|NCT00220233|Drug|hydrochlorothiazide|
522270|NCT00220220|Drug|olmesartan medoxomil|
522271|NCT00220220|Drug|amlodipine|
522272|NCT00220207|Behavioral|Internet co-management module|
522273|NCT00220194|Drug|leuprolide acetate|
522274|NCT00220168|Drug|Irinotecan, Capecitabine|
522275|NCT00220155|Drug|Gemcitabine|
522276|NCT00220129|Drug|Epirubicin, Cisplatin, Capecitabine|
522277|NCT00220129|Procedure|Surgical Resection|
522278|NCT00220116|Drug|Capecitabine, Oxaliplatin|
522279|NCT00220103|Drug|epirubicin, capecitabine, cisplatin|
522283|NCT00220064|Drug|Irinotecan, 5-Fluorouracil, Leucovorin|
522284|NCT00220051|Drug|Oxaliplatin, Capecitabine|
522285|NCT00220051|Procedure|Pre operative radiotherapy|
522286|NCT00220051|Procedure|Surgical Resection|
522287|NCT00220038|Behavioral|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
522288|NCT00220025|Device|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
522289|NCT00220012|Procedure|Folate depletion and supplementation|
522290|NCT00219986|Drug|Potent HAART during acute or early HIV-1 infection|
522291|NCT00219973|Drug|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
522292|NCT00219960|Drug|North American Ginseng (Panax Quinquefolius)|
522293|NCT00219947|Other|blood draw|"T cell subset enumeration~Serologic reactivity with HIV antigens~Viral load assays by bDNA, PCR, or RT-PCR~Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~HIV-1 Resistance Testing"
522294|NCT00219934|Drug|Antiretroviral therapy|HAART therapy
522295|NCT00219921|Drug|Intrathecal morphine at surgery, 0.1mg and placebo|
522296|NCT00219921|Drug|Patient Controlled Analgesia with iv morphine and placebo|
522297|NCT00219921|Drug|intrathecal morphine AND patient controlled analgesia with iv morphine|
522298|NCT00219908|Drug|Mitoxantrone|
522299|NCT00219895|Drug|Ibuprofen|
522300|NCT00219882|Drug|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
522301|NCT00219869|Drug|Galantamine|
522302|NCT00219856|Drug|Propofol|"Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml~Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml"
522303|NCT00219856|Drug|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
522304|NCT00219856|Drug|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
522305|NCT00219843|Drug|PV-10 (rose bengal disodium, 10%)|
522306|NCT00219830|Behavioral|home-based walking program|Home-based walking program; included use of pedometer and daily walk diary
522307|NCT00219817|Drug|RC-1291 HCl|
522308|NCT00219804|Drug|tetrabenazine or placebo|
522309|NCT00219791|Drug|glucarpidase (50 Units/kg)|
522310|NCT00219778|Drug|mifepristone|
522311|NCT00219765|Drug|Imatinib mesylate 600 mg|
522312|NCT00219765|Drug|Cytarabine|
522313|NCT00219765|Drug|Daunorubicine|
522314|NCT00219752|Drug|Imatinib mesylate 400 mg|
522315|NCT00219739|Drug|Imatinib mesylate 400 mg|
522316|NCT00219739|Drug|Imatinib mesylate 600 mg|
522317|NCT00219739|Drug|Imatinib 400 mg + Peg-Interferon|
522318|NCT00219739|Drug|Imatinib mesylate 400 mg + Cytarabine|
522319|NCT00219726|Drug|Imatinib mesylate|
522320|NCT00219713|Drug|nitrous oxide and oxygen|
522321|NCT00219700|Drug|Ibuprofen-PC|
522322|NCT00219687|Other|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
522323|NCT00219687|Other|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
522324|NCT00219674|Behavioral|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
522325|NCT00219674|Behavioral|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
522326|NCT00219674|Behavioral|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
522327|NCT00219674|Behavioral|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
522328|NCT00219661|Procedure|drainage of subglottic secretions (HiLo Evac tube)|
522329|NCT00219648|Drug|PEP03|
522330|NCT00219635|Drug|UK-390,957|
522331|NCT00219622|Drug|tofimilast|
522332|NCT00219609|Drug|UK-390,957|
522333|NCT00219596|Drug|Xalacom|
522334|NCT00219596|Drug|unfixed Latanoprost and Timolol|
522335|NCT00219583|Drug|UK-390,957|
522336|NCT00219570|Drug|clindamycin|
522337|NCT00219570|Drug|nadifloxacin|
522338|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
522339|NCT00219557|Drug|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
522340|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
522341|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
522342|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
522343|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
522344|NCT00219544|Drug|Placebo|Placebo
522345|NCT00219531|Behavioral|perception of rectal balloon distention|functional Magnetic Resonance Imaging (fMRI) study with measurement of brain MRI response to rectal balloon distention.
522346|NCT00219518|Procedure|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
522347|NCT00219505|Procedure|acupuncture|
522348|NCT00219479|Drug|Phenytoin (Dilantin) levels during change in enteral feeding|
522349|NCT00219466|Other|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
522350|NCT00219466|Other|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
522351|NCT00219453|Device|Jet Injector with Protector Cap (HSI-500)|
522352|NCT00219440|Other|Actos plus standard diet|Actos plus standard diet
522353|NCT00219440|Other|Actos plus structured diet|Actos plus structured diet
522354|NCT00219440|Other|Metformin plus standard diet|Metformin plus standard diet
522355|NCT00219414|Device|Adacolumn Apheresis System|
522356|NCT00219401|Biological|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
522357|NCT00219388|Drug|Levosimendan|
522358|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
522359|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
522360|NCT00219362|Biological|one injection of vCP1452 at W0, W4, W8 and W20|
522361|NCT00219362|Biological|one injection of vCP1452 at W4, W8 and W20|
522362|NCT00219362|Biological|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
522363|NCT00219349|Behavioral|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
522364|NCT00219349|Drug|escitalopram|10-20 mg per day for 12 weeks
522365|NCT00219336|Behavioral|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
522366|NCT00219336|Behavioral|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
522367|NCT00219323|Drug|Omalizumab|
522368|NCT00219310|Drug|Famciclovir|
522369|NCT00219297|Drug|Patupilone|
522370|NCT00219284|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
522371|NCT00219271|Drug|Zoledronic acid|
522372|NCT00219258|Drug|Zoledronic acid|
522373|NCT00219245|Drug|Rivastigmine|
522374|NCT00219232|Drug|Rivastigmine Transdermal Patch|
522375|NCT00219219|Drug|Zoledronic acid|
522376|NCT00219193|Drug|aliskiren|
522377|NCT00219180|Drug|aliskiren|
522378|NCT00219167|Drug|aliskiren|
522379|NCT00219154|Drug|aliskiren|
522380|NCT00219141|Drug|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
522381|NCT00219141|Drug|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
522382|NCT00219141|Drug|Aliskiren placebo|Aliskiren 150 mg placebo tablet
522383|NCT00219141|Drug|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
522384|NCT00219128|Drug|aliskiren|
522385|NCT00219115|Drug|aliskiren|
522386|NCT00219102|Drug|aliskiren|
522387|NCT00219089|Drug|aliskiren|
522388|NCT00219076|Drug|aliskiren|
522389|NCT00219063|Drug|aliskiren|
522390|NCT00219050|Drug|aliskiren|
522391|NCT00219037|Drug|aliskiren|
522392|NCT00219024|Drug|aliskiren|
522393|NCT00219011|Drug|aliskiren|
522394|NCT00218998|Behavioral|exercise training|
522395|NCT00218985|Behavioral|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
522396|NCT00218972|Behavioral|Aerobic interval training|
522397|NCT00218972|Behavioral|moderate intensity training|
522398|NCT00218972|Behavioral|Recommendation of regular exercise|
522399|NCT00218959|Behavioral|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos & Monelli).
522400|NCT00218959|Behavioral|treatment as usual|
522401|NCT00218946|Drug|Sucrose|30 % sucrose
522402|NCT00218946|Device|Pacifier|
522403|NCT00218946|Other|sterile water|
522404|NCT00218933|Behavioral|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
522405|NCT00218933|Behavioral|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
522406|NCT00218920|Behavioral|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
522407|NCT00218920|Behavioral|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
522408|NCT00218920|Behavioral|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax [maximal HR (heart rate)], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
522409|NCT00218907|Procedure|Educational video|
522410|NCT00218894|Procedure|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
522411|NCT00218881|Procedure|HIV educational video|
522412|NCT00218868|Procedure|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
522413|NCT00218855|Drug|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
522579|NCT00217594|Drug|Alemtuzumab (Campath)|
522414|NCT00218855|Drug|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
522415|NCT00218842|Behavioral|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
522416|NCT00218816|Behavioral|Nebulizer Education Intervention|Asthma Education
522417|NCT00218816|Behavioral|Standard Asthma Education Groups|Asthma Education
522418|NCT00218803|Behavioral|Nurse asthma education intervention|Asthma Education
522419|NCT00218803|Behavioral|Control Group|Asthma Education
522420|NCT00218790|Procedure|Cool Dialysate|Decreased temperature of the dialysis bath
522421|NCT00218777|Behavioral|Comprehensive Behavioral Intervention for Tics|
522422|NCT00218751|Behavioral|Home Visiting|
522423|NCT00218725|Behavioral|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
522424|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
522425|NCT00218712|Behavioral|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
522426|NCT00218712|Behavioral|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
522427|NCT00218699|Behavioral|Cognitive-Behavioral Intervention|
522428|NCT00218686|Behavioral|psychoeducational|psychoeducational
522429|NCT00218686|Behavioral|control|VTC
522430|NCT00218673|Behavioral|Peer mentor intervention|groups sessions, 8
522431|NCT00218660|Drug|Naltrexone|150mg/day Naltrexone
522432|NCT00218660|Behavioral|BRENDA|Psychosocial Treatment
522433|NCT00218660|Behavioral|CBT|Cognitive Behavioral Therapy
522434|NCT00218660|Drug|Placebo|
522435|NCT00218634|Behavioral|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
522436|NCT00218634|Behavioral|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
522437|NCT00218621|Procedure|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
522438|NCT00218608|Drug|Disulfiram|Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
522439|NCT00218595|Behavioral|DBT|Dialectical behavior therapy plus opiate replacement medication.
522440|NCT00218595|Behavioral|I/GDC|Individual and group drug counseling plus opiate replacement medication.
522441|NCT00218582|Behavioral|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
522442|NCT00218582|Behavioral|Standard psychiatric day treatment|Individual counseling, groups, medication
522443|NCT00218569|Drug|Naltrexone|Naltrexone
522444|NCT00218569|Drug|Placebo|Placebo
522445|NCT00218556|Behavioral|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
522446|NCT00218543|Drug|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
522447|NCT00218530|Drug|Lofexidine|
522448|NCT00218517|Drug|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
522449|NCT00218517|Drug|Placebo|Matching placebo capsules using blue 00 capsules
522450|NCT00218504|Drug|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
522451|NCT00218491|Drug|N-Acetylcysteine|1200mg N-Acetylcysteine
522452|NCT00218491|Drug|N-Acetylcysteine|2400mg N-Acetylcysteine
522453|NCT00218491|Drug|Matching Placebo|Matching Placebo
522454|NCT00218478|Behavioral|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
522455|NCT00218465|Drug|GW468816|Pharmacotherapies for Relapse Prevention
522456|NCT00218465|Drug|Placebo Comparator: Placebo|
522457|NCT00218452|Behavioral|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
522458|NCT00218439|Drug|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
522459|NCT00218439|Drug|Placebo|
522460|NCT00218426|Drug|naltrexone implant|naltrexone implant is 1000 mg naltrexone
522461|NCT00218426|Drug|oral naltrexone|oral naltrexone 50 mg/day
522462|NCT00218426|Drug|oral placebo naltrexone|oral placebo naltrexone resembles active medication
522463|NCT00218426|Drug|placebo implant|placebo implant resembles active medication
522464|NCT00218413|Biological|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
522465|NCT00218413|Biological|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
522466|NCT00218413|Biological|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
522467|NCT00218413|Biological|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
522468|NCT00218413|Biological|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
522469|NCT00218387|Drug|Modafinil|200mg Modafinil
522470|NCT00218387|Drug|Modafinil|400mg Modafinil
522471|NCT00218387|Drug|Matching Placebo|Matching Placebo
522472|NCT00218374|Drug|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
522473|NCT00218361|Drug|Hydromorphone|
522474|NCT00218348|Drug|Dextro-Amphetamine Sulfate|
522475|NCT00218335|Behavioral|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
522476|NCT00218335|Behavioral|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
522477|NCT00218322|Drug|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
522478|NCT00218322|Drug|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
522479|NCT00218309|Drug|Hydromorphone|
522480|NCT00218296|Drug|Usual Care Group|Nicotine replacement therapy
522481|NCT00218296|Other|Reduction Group|Subject selects preferred method for reduction.
522482|NCT00218283|Drug|Nicotine Lozenge|Oral Nicotine replacement product
522483|NCT00218283|Behavioral|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
522484|NCT00218270|Drug|Tobacco free snuff|Tobacco free snuff
522485|NCT00218257|Drug|Progesterone|200mg progesterone BID
522486|NCT00218257|Other|placebo|
522487|NCT00218244|Other|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
522488|NCT00218244|Other|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
522489|NCT00218231|Drug|300 mg/day bupropion-sr|300 mg/day for 1 week
522490|NCT00218231|Drug|0 mg/day bupropion-sr|0 mg/day bupropion-sr
522491|NCT00218218|Drug|Transdermal Nicotine Patch|42 mg transdermal nicotine
522492|NCT00218218|Drug|21 mg transdermal nicotine|
522493|NCT00218218|Drug|placebo patch|
522494|NCT00218205|Drug|Epirubicin|
522495|NCT00218205|Drug|Estramustine Phosphate|
522496|NCT00218205|Drug|Celecoxib|
522497|NCT00218192|Behavioral|Behavior Therapy|
522498|NCT00218179|Other|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
522499|NCT00218166|Drug|GABA Agonists|GABA drugs administered acutely by mouth
522500|NCT00218153|Drug|Naltrexone|
522501|NCT00218140|Drug|nicotine transdermal system|
522502|NCT00218127|Drug|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
522503|NCT00218127|Drug|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
522504|NCT00218127|Drug|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
522505|NCT00218114|Drug|Divalproex Sodium|Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
522506|NCT00218114|Drug|Placebo|Participants will be on matching placebo.
522507|NCT00218101|Drug|Buprenorphine|
522508|NCT00218075|Drug|Levodopa|
522509|NCT00218075|Drug|Carbidopa|
522510|NCT00218075|Behavioral|Clinical Management|
522511|NCT00218075|Behavioral|Relapse Prevention Therapy|
522512|NCT00218075|Behavioral|Contingency Management|
522513|NCT00218062|Drug|D-Amphetamine 30mg|
522514|NCT00218062|Drug|D-Amphetamine 60mg|
522515|NCT00218062|Drug|Modafinil 200mg|
522516|NCT00218062|Drug|Modafinil 400mg|
522517|NCT00218062|Behavioral|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
522518|NCT00218062|Drug|Placebo|
522519|NCT00218049|Drug|GBR 12909|50mg GBR 12909 over 12 days
522520|NCT00218049|Drug|GBR 12909|GBR 12909 75 mg over 12 day period
522521|NCT00218049|Drug|GBR 12909|GBR 12909 100 mg over 12 day period
522522|NCT00218036|Drug|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
522523|NCT00218036|Drug|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
522524|NCT00218036|Drug|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
522525|NCT00218036|Drug|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
522526|NCT00218036|Drug|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
522527|NCT00218023|Drug|Modafinil|The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.
522772|NCT00216060|Drug|Placebo|Daily oral placebo combined with androgen deprivation
539581|NCT00086294|Drug|ACP-103|
522528|NCT00218023|Drug|Levodopa/Carbidopa|Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase I.
522529|NCT00218023|Drug|Naltrexone HCl|Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.
522530|NCT00218023|Drug|Placebo|Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
522531|NCT00218023|Behavioral|Motivational Interviewing (MI)|The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
522532|NCT00218023|Behavioral|Contingency management (CM)|Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
522533|NCT00218023|Behavioral|Cognitive-Behavioral Therapy (CBT)|Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
522534|NCT00217984|Other|Usual Care|Referral to smoking cessation clinic
522535|NCT00217984|Behavioral|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
522536|NCT00217971|Drug|Dronabinol|Dronabinol
522537|NCT00217971|Drug|Placebo|placebo
522538|NCT00217958|Behavioral|SHS reduction intervention based on social cognitive learning theory|
522539|NCT00217945|Behavioral|Shared-Decision Making|
522540|NCT00217932|Drug|Divalproex Sodium (Depakote)|
522541|NCT00217919|Behavioral|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.~We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
522542|NCT00217906|Behavioral|A+ Asthma early intervention program|
522543|NCT00217893|Behavioral|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
522544|NCT00217893|Behavioral|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
522545|NCT00217893|Behavioral|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
522546|NCT00217893|Behavioral|Usual education program|Participants will receive the usual education about ETS.
522547|NCT00217880|Procedure|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
522548|NCT00217867|Behavioral|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
522549|NCT00217854|Procedure|Bronchoscopic|Bronchoscopic procedure
522550|NCT00217841|Drug|Aurograb|
522551|NCT00217828|Drug|citalopram|
522552|NCT00217815|Drug|Mycograb, Docetaxel|
522553|NCT00217802|Behavioral|six-session telephone counseling program|
522554|NCT00217789|Procedure|Bronchoalveolar Lavage and Venipuncture|
522555|NCT00217776|Behavioral|Open Airways Educational Intervention|
522556|NCT00217776|Behavioral|Peer Asthma Action Educational Intervention|
522557|NCT00217763|Drug|3APS|
522558|NCT00217737|Biological|Bevacizumab|Given IV
522559|NCT00217737|Drug|Fluorouracil|Given IV
522560|NCT00217737|Other|Laboratory Biomarker Analysis|Correlative studies
522561|NCT00217737|Drug|Leucovorin Calcium|Given IV
522562|NCT00217737|Drug|Oxaliplatin|Given IV
522563|NCT00217724|Dietary Supplement|glutamine|Given orally
522564|NCT00217724|Other|placebo|Given orally
522565|NCT00217711|Drug|Capecitabine|capecitabine
522566|NCT00217711|Drug|irinotecan hydrochloride|irinotecan hydrochloride
522567|NCT00217711|Drug|oxaliplatin|oxaliplatin
522568|NCT00217698|Drug|cisplatin|
522569|NCT00217698|Drug|gefitinib|
522570|NCT00217698|Drug|gemcitabine hydrochloride|
522571|NCT00217672|Biological|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
522572|NCT00217672|Drug|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
522573|NCT00217659|Drug|anastrozole|
522574|NCT00217659|Drug|goserelin acetate|
522575|NCT00217646|Drug|Sorafenib Tosylate|Given orally
522576|NCT00217633|Procedure|Conventional Surgery|
522577|NCT00217620|Drug|sorafenib|800 mg per day, daily until progression
522578|NCT00217607|Drug|paclitaxel|
522580|NCT00217581|Biological|Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
522581|NCT00217581|Drug|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
522582|NCT00217581|Drug|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
522583|NCT00217568|Biological|pegfilgrastim|
522584|NCT00217568|Drug|carboplatin|
522585|NCT00217568|Drug|docetaxel|
522586|NCT00217555|Drug|gemcitabine hydrochloride|
522587|NCT00217555|Drug|topotecan hydrochloride|
522588|NCT00217542|Biological|recombinant interferon alfa-2b|Given SC
522589|NCT00217542|Drug|amifostine/azacitidine|Given SC
522590|NCT00217529|Biological|pegfilgrastim|
522591|NCT00217529|Drug|carboplatin|
522592|NCT00217529|Drug|docetaxel|
522593|NCT00217529|Drug|erlotinib hydrochloride|
522594|NCT00217516|Drug|selenium|Given orally
522595|NCT00217516|Other|placebo|Given orally
522596|NCT00217503|Biological|bevacizumab|
522597|NCT00217503|Biological|filgrastim|
522598|NCT00217503|Biological|pegfilgrastim|
522599|NCT00217503|Drug|bortezomib|
522600|NCT00217503|Drug|cyclophosphamide|
522601|NCT00217503|Drug|doxorubicin hydrochloride|
522602|NCT00217503|Drug|etoposide|
522603|NCT00217503|Drug|ganciclovir|
522604|NCT00217503|Drug|valganciclovir|
522605|NCT00217503|Drug|zidovudine|
522606|NCT00217490|Behavioral|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
522607|NCT00217490|Behavioral|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
522608|NCT00217490|Behavioral|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
522609|NCT00217490|Other|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
522610|NCT00217477|Drug|gemcitabine hydrochloride|Given IV
522611|NCT00217477|Drug|paricalcitol|Given IV
522612|NCT00217464|Drug|fulvestrant|intramuscularly
522613|NCT00217451|Drug|Fosmidomycin-clindamycin|
522614|NCT00217438|Drug|melphalan|Given IV
522615|NCT00217438|Drug|amifostine trihydrate|Given IV
522616|NCT00217438|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
522617|NCT00217438|Genetic|fluorescence in situ hybridization|Correlative study
522618|NCT00217438|Procedure|bone marrow ablation with stem cell support|Undergo transplant
522619|NCT00217425|Biological|bevacizumab|"A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.~Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus."
522620|NCT00217425|Drug|cyclophosphamide|IV infusion per institutional guidelines.
522621|NCT00217425|Drug|doxorubicin|Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
522622|NCT00217425|Drug|prednisone|Prednisone is taken orally.
522623|NCT00217425|Drug|vincristine|IV push using extravasation precautions.
522624|NCT00217412|Drug|vorinostat|Given orally
522625|NCT00217412|Drug|isotretinoin|Given orally
522626|NCT00217399|Drug|sorafenib tosylate|Given orally
522627|NCT00217399|Drug|anastrozole|Given orally
522628|NCT00217386|Biological|anti-thymocyte globulin|
522629|NCT00217386|Biological|etanercept|
522630|NCT00217373|Biological|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
522631|NCT00217373|Biological|Recombinant Interferon Alfa-2b|Given SC
522632|NCT00217373|Biological|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
522633|NCT00217373|Biological|Sargramostim|Given SC
522634|NCT00217360|Behavioral|a customised multifactorial falls prevention program|
522635|NCT00217347|Device|Esophageal Capsule Endoscopy|
522636|NCT00217334|Behavioral|Volunteer-led pharmacy sessions with feedback to physicians|
522637|NCT00217308|Drug|Lactobacilli GR-1 and RC-14|Probiotic Lactobacilli will be compared to placebo
522638|NCT00217295|Drug|Avonex and Topamax|
522639|NCT00217282|Drug|oxaliplatin, gemcitabine, bevacizumab|"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.~Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:~Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
522640|NCT00217269|Device|Coronary Artery Stenting|Endeavor Drug eluting stent
522641|NCT00217269|Device|Coronary Artery Stenting|Taxus Drug Eluting Stent
522642|NCT00217256|Device|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
522643|NCT00217256|Device|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
522773|NCT00216047|Drug|PTK787|PTK787 daily
539582|NCT00086255|Drug|Tiagabine|
522644|NCT00217243|Other|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
522645|NCT00217230|Biological|CAIV-T|
522646|NCT00217217|Device|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
522647|NCT00217204|Drug|Pancrelipase microtablets|
522648|NCT00217191|Drug|Ibuprofen|
522649|NCT00217178|Drug|Vitamins: Folic acid, B6, B12|
522650|NCT00217165|Drug|taurine|taurine 2mg BID po
522651|NCT00217152|Drug|CellCept|
522652|NCT00217139|Drug|Celgosivir|
522653|NCT00217113|Behavioral|Geriatric home visit and Action Plan|
522654|NCT00217100|Dietary Supplement|Multivitamin|1 tablet a day
522655|NCT00217100|Dietary Supplement|Placebo|1 tablet a day
522656|NCT00217087|Procedure|Endoscopic Mucosal Resection|Endoscopic mucosal resection at time of endoscopy if indicated.
522657|NCT00217087|Procedure|Photodynamic Therapy|Porfimer sodium 2mg/kg
522658|NCT00217074|Other|acupuncture|
522659|NCT00217061|Device|Decision Aid Statin Choice|
522660|NCT00217048|Drug|Yohimbine, oral|
522661|NCT00217035|Dietary Supplement|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
522662|NCT00217022|Other|Placebo|Placebo, 3 tablets daily
522663|NCT00217022|Drug|Budesonide|9 mg daily (three tablets)
522664|NCT00217009|Procedure|Narrowband Ultraviolet B (TL-01UVB) Therapy|
522665|NCT00217009|Procedure|Topical Psoralen plus ultraviolet A (PUVA)|
522666|NCT00216970|Dietary Supplement|Alteration in nutritional support|The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
522667|NCT00216957|Procedure|Coronary bypass surgery without cardiopulmonary bypass|
522668|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
522669|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
522670|NCT00216931|Drug|iloprost|
522671|NCT00216918|Drug|Atomoxetine Hydrochloride|
522672|NCT00216892|Drug|Calcipotriol, (calcipotriol + betamethasone)|
522673|NCT00216879|Drug|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
522674|NCT00216866|Drug|Dalteparin|
522675|NCT00216866|Drug|Warfarin|
522676|NCT00216840|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
522677|NCT00216827|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
522678|NCT00216788|Drug|Esomeprazole (Nexium) 40 mg/day|
522679|NCT00216775|Drug|interferon-alfa-2b and ribavirin|
522680|NCT00216762|Drug|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
522681|NCT00216736|Drug|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
522682|NCT00216736|Drug|placebo|Single dose oral placebo at ED discharge
522683|NCT00216723|Drug|Aripiprazole|"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.~(Administer 10 to 30 mg/day according to the patient's condition)"
522684|NCT00216710|Behavioral|Home Visiting|
522685|NCT00216697|Drug|bortezomib|
522686|NCT00216684|Drug|fentanyl|
522687|NCT00216671|Drug|early initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
522688|NCT00216671|Drug|routine initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
522689|NCT00216658|Drug|fentanyl|
522690|NCT00216645|Drug|doxorubicin hydrochloride|
522691|NCT00216632|Drug|risperidone|
522692|NCT00216619|Drug|Topiramate|topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
522693|NCT00216619|Drug|Topiramate - Placebo|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
522694|NCT00216606|Drug|topiramate|
522695|NCT00216593|Drug|galantamine hydrobromide|
522696|NCT00216580|Drug|Risperidone, long-acting injectable|
522697|NCT00216567|Drug|topamax|
522698|NCT00216554|Drug|risperidone|
522699|NCT00216541|Drug|epoetin alfa|
522700|NCT00216528|Drug|risperidone|
522701|NCT00216515|Drug|galantamine hydrobromide|
522702|NCT00216502|Drug|galantamine hydrobromide|
522703|NCT00216489|Drug|rabeprazole sodium|
522704|NCT00216476|Drug|Aripiprazole|10-30 mg oral once daily for 104 weeks
522705|NCT00216476|Drug|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
522774|NCT00216047|Drug|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle*
539915|NCT00002785|Drug|etoposide|
522706|NCT00216476|Drug|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
522707|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
522708|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
522709|NCT00216463|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
522710|NCT00216463|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
522711|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
522712|NCT00216450|Drug|rabeprazole sodium|
522713|NCT00216437|Drug|Capecitabine (Xeloda)|
522714|NCT00216424|Drug|Capecitabine (Xeloda)|
522715|NCT00216411|Biological|Botulinum toxin type A|
522716|NCT00216411|Drug|Placebo|
522717|NCT00216398|Drug|Lanreotide (Autogel formulation)|
522718|NCT00216385|Drug|Gatifloxacin combined regimen|
522719|NCT00216372|Drug|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
522720|NCT00216372|Other|Placebo|A single intra-muscular injection on day 0.
522721|NCT00216359|Drug|Fuzeon (Enfuvirtide)|
522722|NCT00216359|Procedure|Laboratory diagnostic (CD4-cells)|
522723|NCT00216359|Procedure|Laboratory diagnostics (HIV-1 viral load)|
522724|NCT00216359|Drug|antiretroviral co-medication beside Fuzeon|
522725|NCT00216346|Drug|Paromomycin sulfate|
522726|NCT00216346|Drug|Amphotericin B|
522727|NCT00216333|Drug|combined fixed dose combination|
522728|NCT00216320|Device|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
522729|NCT00216320|Device|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
522730|NCT00216320|Device|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
522731|NCT00216294|Drug|RG1068 (Synthetic Human Secretin)|
522732|NCT00216281|Drug|Clozapine augmented with atomoxetine up to 40 mg or placebo|
522733|NCT00216268|Drug|Ribavirin|
522734|NCT00216255|Drug|Pagoclone|
522735|NCT00216255|Drug|Placebo|
522736|NCT00216242|Biological|Influenza virus vaccine (Fluviral)|
522737|NCT00216242|Biological|Saline placebo|
522738|NCT00216229|Biological|Combined vaccine against hepatitis A and B (Twinrix)|
522739|NCT00216216|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
522740|NCT00216203|Drug|Pemetrexed|Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
522741|NCT00216203|Drug|Cetuximab|"Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle"
522742|NCT00216190|Drug|Dexmedetomidine HCL Injection|
522743|NCT00216190|Drug|Midazolam Injection|
522744|NCT00216177|Drug|Infliximab|Remicade
522745|NCT00216177|Drug|Adalimumab|Humira
522746|NCT00216164|Drug|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
522747|NCT00216164|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
522748|NCT00216151|Drug|Zoledronic Acid|Zoledronic Acid 4mg, every three months
522749|NCT00216138|Drug|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
522750|NCT00216138|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
522751|NCT00216138|Drug|Premedication|Dexamethasone and antiemetic premedication
522752|NCT00216125|Drug|Cisplatin|Cisplatin 50 mg/m2 day 1, 8, 29, 36
522753|NCT00216125|Drug|Etoposide|Etoposide 50 mg/m2, days 1-5, 29-33
522754|NCT00216125|Radiation|Radiation|Radiation 5940 cGy (180 cGy/day)
522755|NCT00216125|Drug|Docetaxel|docetaxel 75mg/m2 q3wk x 3 cycles
522756|NCT00216112|Drug|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
522757|NCT00216112|Drug|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
522758|NCT00216099|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
522759|NCT00216099|Dietary Supplement|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
522760|NCT00216099|Dietary Supplement|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
522761|NCT00216086|Drug|Capecitabine|"Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles~*For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
522762|NCT00216086|Drug|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
522763|NCT00216086|Procedure|EUS|biopsy per EUS
522764|NCT00216086|Drug|Neoadjuvant Chemotherapy|"Irinotecan 200 mg/m2 IV, day 1~Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
522765|NCT00216086|Procedure|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
522766|NCT00216086|Procedure|Surgery|Surgery within 8 weeks following chemoradiotherapy
522767|NCT00216086|Procedure|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
522768|NCT00216073|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
522769|NCT00216073|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
522770|NCT00216073|Drug|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
522771|NCT00216060|Drug|Risedronate|Daily oral risedronate combined with androgen deprivation
522863|NCT00215397|Drug|Formoterol Fumarate|
522775|NCT00216034|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
522776|NCT00216034|Drug|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
522777|NCT00216021|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
522778|NCT00216021|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
522779|NCT00216008|Drug|docetaxel|
522780|NCT00216008|Drug|cisplatin|
522781|NCT00216008|Procedure|radiation|
522782|NCT00216008|Procedure|surgery|
522783|NCT00215995|Drug|Cisplatin|As outlined in Detailed Description
522784|NCT00215995|Drug|Irinotecan|As outlined in Detailed Description
522785|NCT00215995|Drug|ZD 1839|As outlined in Detailed Description
522786|NCT00215982|Drug|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
522787|NCT00215982|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
522788|NCT00215982|Drug|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
522789|NCT00215956|Drug|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
522790|NCT00215956|Procedure|radiation|Preoperative radiation
522791|NCT00215956|Procedure|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
522792|NCT00215943|Drug|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
522793|NCT00215943|Drug|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
522794|NCT00215943|Drug|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
522795|NCT00215943|Drug|vincristine|As outlined in VAD Treatment Arm
522796|NCT00215943|Drug|adriamycin|As outlined in VAD Treatment arm
522797|NCT00215930|Drug|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
522798|NCT00215930|Drug|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
522799|NCT00215930|Drug|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.~RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
522800|NCT00215930|Drug|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.~RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
522801|NCT00215917|Drug|D-serine 2100 mg daily|
522802|NCT00215904|Drug|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (~2g/day). Second arm : adjuvant treatment with placebo (~2g/day).
522803|NCT00215891|Drug|PEG-Interferon a-2b + Ribavirin|
522804|NCT00215878|Drug|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine ~2g /day), in the second arm adjuvant treatment with placebo (~2g /day)
522805|NCT00215865|Drug|PEGIntron plus ribavirin|
522806|NCT00215852|Drug|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
522807|NCT00215839|Drug|Peginterferon a-2a plus Ribavirin|
522808|NCT00215826|Drug|Alferon LDO|
522809|NCT00215813|Drug|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
522810|NCT00215800|Drug|Ampligen|
522811|NCT00215787|Drug|lansoprazole|Lansoprazole 30 mg BID for 1 year
522812|NCT00215774|Drug|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
522813|NCT00215748|Drug|Dexamethasone|
522814|NCT00215735|Device|debridement, dressing, and APC|ebridement, dressing, and APC
522815|NCT00215722|Drug|Cetuximab|
522816|NCT00215709|Drug|docetaxel|
522817|NCT00215696|Genetic|BioBypass®|
522818|NCT00215683|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
522819|NCT00215670|Drug|pegaptanib sodium (Macugen)|
522820|NCT00215657|Drug|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
539916|NCT00002785|Drug|leucovorin calcium|
522821|NCT00215657|Drug|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
522822|NCT00215657|Drug|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
522823|NCT00215657|Drug|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
522824|NCT00215657|Drug|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
522825|NCT00215657|Drug|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
522826|NCT00215657|Drug|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
522827|NCT00215657|Drug|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
522828|NCT00215644|Drug|Matuzumab|Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn.
522829|NCT00215644|Drug|Epirubicin|Participants will receive epirubicin 50 milligrams per square meter (mg/m^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles.
522830|NCT00215644|Drug|Cisplatin|Participants will receive cisplatin 60 mg/m^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles.
522831|NCT00215644|Drug|Capecitabine|Participants will receive capecitabine 1250 mg/m^2 daily in a 21-day cycles up to a maximum of 8 cycles.
522832|NCT00215631|Drug|tadalafil|
522833|NCT00215618|Device|Uterine Balloon Therapy|UBT with post procedure curettage
522834|NCT00215618|Device|Uterine Balloon Therapy|UBT without post procedure curettage
522835|NCT00215605|Drug|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
522836|NCT00215592|Drug|Zonegran|
522837|NCT00215579|Drug|Depot Risperidone Microsphere (Consta)|
522838|NCT00215566|Drug|DDP733|
522839|NCT00215553|Drug|A.1 Lucinactant|3 30 mL aliquots at concentrations of 5, 5, and 10 mg/mL
522840|NCT00215553|Other|B.3 SoC|Standard ARDS management and ICU care
522841|NCT00215553|Drug|A.2 Lucinactant|3 30 mL aliquots at a concentration of 10 mg/mL each
522842|NCT00215553|Drug|A.3 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
522843|NCT00215553|Drug|A.4 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
522844|NCT00215553|Drug|B.1 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL
522845|NCT00215553|Drug|B.2 Lucinactant|2 50 mL aliquots at concentrations of 10 and 20 mg/mL, with bolus re-treatment allowed
522846|NCT00215540|Drug|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
522847|NCT00215540|Drug|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
522848|NCT00215540|Drug|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
522849|NCT00215527|Drug|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
522850|NCT00215514|Drug|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
522851|NCT00215514|Drug|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
522852|NCT00215514|Drug|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
522853|NCT00215514|Procedure|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
522854|NCT00215501|Drug|Capecitabine|Orally twice a day for 14 days (dosage will vary)
522855|NCT00215501|Drug|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
522856|NCT00215501|Drug|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
522857|NCT00215501|Drug|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
522858|NCT00215462|Drug|Vinorelbine|
522859|NCT00215449|Drug|Formoterol Fumarate|
522860|NCT00215436|Drug|Formoterol Fumarate|
522861|NCT00215423|Drug|Formoterol Fumarate|
522862|NCT00215410|Drug|Formoterol Fumarate|
522864|NCT00215384|Drug|Formoterol Fumarate|
522865|NCT00215371|Drug|Formoterol Fumarate|
522866|NCT00215358|Drug|Formoterol Fumarate|
522867|NCT00215345|Drug|Taxotere|
522868|NCT00215345|Drug|Celecoxib|
522869|NCT00215332|Device|CHARITE|Lumbar Total Disc Replacement
522870|NCT00215319|Device|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
522871|NCT00215306|Device|CHARITÉ Artificial Disc|
522872|NCT00215306|Device|Anterior Interbody Fusion with BAK Cage|
522873|NCT00215293|Device|Cervical I/F Cage|
522874|NCT00215293|Device|Autograft or allograft with a plate, or autograft alone.|
522875|NCT00215280|Drug|ivermectin and albendazole|
522876|NCT00215267|Drug|praziquantel|
522877|NCT00215254|Drug|quetiapine|
522878|NCT00215241|Drug|sertraline and risperidone|
522879|NCT00215228|Drug|duloxetine vs. escitalopram|
522880|NCT00215215|Device|Vagus Nerve Stimulation Therapy|
522881|NCT00215202|Drug|Iressa (ZD1839)|
522882|NCT00215189|Behavioral|In SHAPE (Pilot Health Promotion Intervention)|
522883|NCT00215176|Drug|modafinil|
522884|NCT00215163|Drug|Cognitive-behavioral therapy and paroxetine-CR|
522885|NCT00215150|Drug|Ziprasidone|Sertraline augmentation with ziprasidone
522886|NCT00215150|Drug|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
522887|NCT00215137|Drug|escitalopram|Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
522888|NCT00215137|Drug|Placebo ( sugar pill)|Placebo Comparator in double.blind phase.
522889|NCT00215124|Drug|Filgrastim|
522890|NCT00215111|Behavioral|Low carbohydrate, reduced glycemic load, and a control diet|
522891|NCT00215046|Drug|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
522892|NCT00215046|Drug|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
522893|NCT00215007|Drug|Levofloxacin|
522894|NCT00214994|Drug|Gabitril|
522895|NCT00214981|Drug|Modafinil|
522896|NCT00214968|Drug|Modafinil|maximum dosage 400 mg/day (4 tablets)
522897|NCT00214955|Drug|ORAVESCENT Fentanyl Citrate|
522898|NCT00214942|Drug|ORAVESCENT Fentanyl Citrate|
522899|NCT00214929|Behavioral|treatment at home|
522900|NCT00214916|Drug|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
522901|NCT00214916|Drug|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
522902|NCT00214890|Drug|Tenofovir|300 mg once daily
522903|NCT00214890|Drug|Abacavir|600 mg once daily
522904|NCT00214877|Drug|Methylene Blue|
522905|NCT00214864|Drug|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8
522906|NCT00214851|Drug|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
522907|NCT00214838|Drug|Atiprimod|
522908|NCT00214825|Drug|eplerenone|50 mg daily for 6 weeks with placebo
522909|NCT00214825|Drug|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
522910|NCT00214812|Drug|HEC placebo gel|
522911|NCT00214786|Biological|Islet cell transplantation|Allogenic islet transplantation
522912|NCT00214760|Device|PGET|resolbable liner
522913|NCT00214760|Device|PMMA|cement liner
522914|NCT00214747|Drug|Vehicle gel formulations|
522915|NCT00214734|Drug|rAHF-PFM|
522916|NCT00214721|Drug|Experimental Peritoneal Dialysis Solution|
522917|NCT00214708|Procedure|Screening for Tuberculosis|
522918|NCT00214695|Drug|Experimental Peritoneal Dialysis Solution|
522919|NCT00214682|Drug|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
522920|NCT00214682|Behavioral|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
522961|NCT00214344|Behavioral|family preparation for withdrawing life support|
522962|NCT00214331|Drug|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
522963|NCT00214331|Drug|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
522964|NCT00214331|Drug|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
522965|NCT00214318|Drug|Terbutaline plus Metoprolol or carvedilol|
523017|NCT00213564|Drug|response to infliximab associated with methotrexate|
523018|NCT00213551|Drug|Glutamine|
523019|NCT00213551|Drug|Glucose|
523020|NCT00213551|Drug|glutamine-antioxidants containing solution|
522921|NCT00214682|Behavioral|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
522922|NCT00214682|Drug|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
522923|NCT00214682|Behavioral|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
522924|NCT00214682|Behavioral|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
522925|NCT00214669|Behavioral|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
522926|NCT00214669|Behavioral|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
522927|NCT00214669|Behavioral|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
522928|NCT00214656|Drug|Recombinant Activated Factor VII|
522929|NCT00214643|Drug|Fosmidomycin|30 mg/kg
522930|NCT00214643|Drug|clindamycin|10 mg/kg
522931|NCT00214630|Drug|rosuvastatin calcium|
522932|NCT00214630|Drug|atorvastatin|
522933|NCT00214617|Drug|Rosuvastatin at 5 mg/day and 40 mg/day|
522934|NCT00214604|Drug|Rosuvastatin|10mg
522935|NCT00214604|Drug|rosuvastatin|20mg
522936|NCT00214604|Drug|pravastatin|40mg
522937|NCT00214591|Drug|GALIDA|
522938|NCT00214578|Drug|Seroquel (quetiapine)|
522939|NCT00214565|Drug|Galida|
522940|NCT00214552|Drug|rabeprazole|
522941|NCT00214539|Procedure|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
522942|NCT00214539|Drug|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
522943|NCT00214526|Procedure|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
522944|NCT00214526|Drug|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
522945|NCT00214513|Behavioral|Home-based exercise training|
522946|NCT00214500|Drug|migalastat HCl|
522947|NCT00214487|Device|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
522948|NCT00214487|Device|Placebo Control|Single vision soft contact lenses
522949|NCT00214474|Behavioral|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
522950|NCT00214474|Behavioral|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
522951|NCT00214461|Biological|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
522952|NCT00214461|Biological|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
522953|NCT00214461|Biological|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
522954|NCT00214461|Biological|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
522955|NCT00214435|Drug|once daily minimum 3-drug regimen of anti-retroviral medications|
522956|NCT00214422|Radiation|Radiation|Radiation will be given in dose escalations from 5040 Gray (cGy) to a maximum of 5900 cGy to lymph nodes.
522957|NCT00214383|Behavioral|CHESS Internet telehealth|CHESS Internet telehealth
522958|NCT00214370|Drug|Propofol-Fentanyl|
522959|NCT00214370|Drug|Propofol alone|
522960|NCT00214357|Behavioral|Mindfulness-based stress reduction|
522966|NCT00214305|Behavioral|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
522967|NCT00214305|Behavioral|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
522968|NCT00214292|Procedure|fluorescence spectroscopy and diffuse spectroscopy|
522969|NCT00214279|Drug|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
522970|NCT00214266|Drug|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
522971|NCT00214253|Drug|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
522972|NCT00214240|Drug|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
522973|NCT00214214|Drug|Campath 1H® (Alemtuzumab)|
522974|NCT00214201|Drug|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
522975|NCT00214162|Behavioral|Comprehensive Health Enhancement Support System|Full CHESS
522976|NCT00214162|Behavioral|computer with internet|computer with internet use x 1 year
522977|NCT00214149|Radiation|brachytherapy|breast brachytherapy to 34 Gy
522978|NCT00214136|Radiation|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
522979|NCT00214123|Radiation|radiation therapy (radiotherapy)|Bin assignment based on tumor volume
522980|NCT00214110|Drug|Tamoxifen|
522981|NCT00214097|Radiation|Radiotherapy|Daily radiation to prescribed dose
522982|NCT00214084|Drug|Allopurinol|
522983|NCT00214071|Biological|Influenza vaccine|
522984|NCT00214058|Drug|Carboplatin|
522985|NCT00214058|Drug|Docetaxel|
522986|NCT00214045|Device|Flexible Cystoscopy|
522987|NCT00214045|Device|Rigid Cystoscopy|
522988|NCT00214032|Drug|Pycnogenol|pycnogenol 300 mg daily
522989|NCT00214032|Drug|Placebo|placebo 3 capsules daily
522990|NCT00214019|Drug|salmeterol|salmeterol diskus 50 mcg twice per day
522991|NCT00214019|Drug|Fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
522992|NCT00214019|Drug|Placebo|placebo diskus
522993|NCT00213993|Drug|antiperspirant|antiperspirant topically once daily to one foot
522994|NCT00213980|Drug|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
522995|NCT00213967|Device|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
522996|NCT00213954|Procedure|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
522997|NCT00213941|Device|Echocardiography|
522998|NCT00213928|Drug|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
522999|NCT00213915|Drug|12 g of L-arginine glutamate during 6 weeks twice a day|
523000|NCT00213889|Other|None: molecular genetics diagnosis procedure only|None: molecular genetics diagnosis procedure only
523001|NCT00213863|Device|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
523002|NCT00213850|Procedure|EFR|
523003|NCT00213837|Device|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
523004|NCT00213811|Behavioral|clinical, biological, and radiological|
523005|NCT00213798|Procedure|Biopsy samples|
523006|NCT00213759|Drug|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
523007|NCT00213759|Drug|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
523008|NCT00213694|Drug|docetaxel and celecoxib|
523009|NCT00213681|Device|Boussignac CPAP - bilevel ventilation support|
523010|NCT00213668|Dietary Supplement|glutamine (dipeptiven)|
523011|NCT00213655|Biological|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
523012|NCT00213629|Other|transcriptome analysis|transcriptome analysis from muscle biopsy
523013|NCT00213629|Other|T cell repertoire analysis|blood T cell repertoire analysis
523014|NCT00213616|Procedure|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
523015|NCT00213590|Drug|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
523016|NCT00213577|Drug|type A botulinum toxin|
539917|NCT00002785|Drug|mercaptopurine|
523021|NCT00213538|Drug|Response to anakinra associated with methotrexate|
523022|NCT00213525|Other|Questionnary for environmental factors research|Questionnary for environmental factors research
523023|NCT00213512|Drug|Mabthera|
523024|NCT00213499|Procedure|non invasive ventilation|
523025|NCT00213486|Drug|irinotecan|
523026|NCT00213434|Device|Herbst oral appliance|
523027|NCT00213421|Drug|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight < 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight > 45kg or for multibullous form with weight < 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth > 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
523028|NCT00213408|Procedure|Radiofrequency catheter ablation of typical atrial flutter|
523029|NCT00213395|Device|Interface for noninvasive ventilation|
523030|NCT00213330|Procedure|rectal distension|
523031|NCT00213317|Procedure|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
523032|NCT00213304|Biological|varicella vaccine (VARIVAX)|
523033|NCT00213291|Drug|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
523034|NCT00213278|Drug|vinblastine sulphate injection|Vinblastine dose: 6 mg/m^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
523035|NCT00213265|Biological|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
523036|NCT00213265|Biological|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)~Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:~7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)~12-23 months of age: 2 doses (at least 2 months apart)~≥24 months through 9 years of age: 1 dose"
523037|NCT00213252|Drug|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
523038|NCT00213252|Drug|Prednisolone|Six daily doses of oral prednisolone
523039|NCT00213239|Drug|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
523040|NCT00213239|Drug|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
523041|NCT00213226|Drug|dexamethasone|
523042|NCT00213213|Drug|Sucrose|
523043|NCT00213200|Drug|morphine, amethocaine|
523044|NCT00213187|Behavioral|Aerobic and Qi gong Exercise|
523045|NCT00213174|Behavioral|school playgrounds|
523046|NCT00213161|Drug|iron supplement, iron drops|
523047|NCT00213148|Drug|Anastrozole 1 mg|Subjects will be administered orally with 1 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
523048|NCT00213148|Drug|Anastrozole 5 mg|Subjects will be administered orally with 5 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
523049|NCT00213148|Drug|Anastrozole 10 mg|Subjects will be administered orally with 10 mg of anastrozole once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
523050|NCT00213148|Drug|Clomiphene Citrate 50 mg|Subjects will be administered orally with 50 mg of clomiphene citrate once daily for 5 days in Cycle 1, 2 and 3 (each cycle = approximately 1 month).
523051|NCT00213148|Drug|Clomiphene Citrate 100 mg|Subjects will be administered orally with 100 mg of clomiphene citrate once daily for 5 days in Cycle 2 and 3 (each cycle = approximately 1 month).
523052|NCT00213135|Drug|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
523053|NCT00213135|Drug|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
523054|NCT00213135|Other|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
523055|NCT00213122|Drug|miglitol|
523056|NCT00213109|Drug|Miglitol|
523057|NCT00213096|Drug|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
523058|NCT00213083|Drug|Carraguard (PC-515)|
523059|NCT00213070|Drug|Miglitol|
523060|NCT00213057|Drug|Carraguard (PC-515)|
523061|NCT00213044|Drug|Carraguard (PC-515)|
523062|NCT00213031|Drug|Carraguard (PC-515)|
523063|NCT00213018|Drug|Carraguard (PC-515)|
523064|NCT00213005|Drug|Carraguard (PC-515)|
523065|NCT00212992|Procedure|fixed versus escalating biphasic defibrillation|
523066|NCT00212979|Other|non intervention study|
523067|NCT00212953|Procedure|Advanced Life Support|
523068|NCT00212940|Behavioral|Supportive Therapy for Adherence to ART (behavior)|
523069|NCT00212914|Behavioral|Reminder letter|
523070|NCT00212901|Drug|High dose ACE-I vs ARB|
523071|NCT00212888|Biological|Remune and ALVAC|"Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
523072|NCT00212875|Drug|epoetin alfa|
523073|NCT00212862|Other|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
523074|NCT00212836|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
523075|NCT00212836|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
523076|NCT00212823|Drug|almotriptan malate|
523077|NCT00212810|Drug|Topiramate|
523078|NCT00212797|Drug|Org 34517|low dose Org 34517
523079|NCT00212797|Drug|Org 34517|high dose Org 34517
523080|NCT00212797|Drug|Placebo|placebo
523081|NCT00212784|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
523082|NCT00212784|Drug|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
523083|NCT00212771|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
523084|NCT00212771|Drug|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
523085|NCT00212758|Drug|Nutropin AQ|Nutropin AQ
523086|NCT00212745|Behavioral|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
523087|NCT00212732|Drug|ONO-8025 (KRP-197)|
523088|NCT00212719|Drug|ONO-5920|
523089|NCT00212706|Drug|ONO-8025 (KRP-197)|
523090|NCT00212693|Drug|ONO-2506PO|
523091|NCT00212680|Drug|ONO-1101|
523092|NCT00212667|Drug|ONO-5920|
523093|NCT00212654|Drug|ONO-1101|
523094|NCT00212641|Drug|ONO-5129|
523095|NCT00212628|Drug|Minodronic acid hydrate|
523096|NCT00212615|Drug|Oxaliplatin (Eloxatin)|
523097|NCT00212615|Drug|Capecitabine (Xeloda)|
523098|NCT00212602|Drug|ONO-7436|
523099|NCT00212589|Drug|Capecitabine|
523100|NCT00212589|Drug|Fluorouracil + folinic acid|
523101|NCT00212576|Behavioral|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
523102|NCT00212576|Behavioral|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
523103|NCT00212550|Procedure|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
523104|NCT00212498|Procedure|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
523105|NCT00212485|Procedure|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
523106|NCT00212485|Procedure|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
523107|NCT00212472|Drug|Factor VIII concentrates|To be determined at the discretion of the investigator.
523108|NCT00212472|Other|Low-dose treatment|50 FVIII u/kg three times a week.
523109|NCT00212472|Other|High-dose treatment|200 FVIII u/kg per day.
523110|NCT00212459|Behavioral|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
523111|NCT00212459|Behavioral|Control|No more contacts are made with control patients after the initial counseling session.
523112|NCT00212446|Device|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
523113|NCT00212433|Drug|Tagitol V, Lo So, Readi-Cat 2|
523114|NCT00212420|Procedure|parenteral nutrition; enteral nutrition|
523115|NCT00212407|Biological|Umbilical Cord Blood Transplantation|
523116|NCT00212381|Drug|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
523117|NCT00212381|Dietary Supplement|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
523118|NCT00212368|Drug|Zinc acetate|
523119|NCT00212355|Drug|NPC-02|zinc acetate
523120|NCT00212342|Drug|Norethisterone,Ethinylestradiol|
523121|NCT00212342|Drug|Sugar pill|
523122|NCT00212329|Procedure|T Cell Proliferation and Autoreactivity Assays|
523123|NCT00212329|Procedure|Cellular Immunoblot Assays|
523124|NCT00212329|Procedure|Tetramer Studies|
523125|NCT00212329|Procedure|Cytokine ELISPOT|
523126|NCT00212316|Drug|sodium phenylbutyrate|
523127|NCT00212303|Behavioral|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
523128|NCT00212290|Drug|pioglitazone|
523129|NCT00212290|Drug|nateglinide|
523130|NCT00212290|Drug|placebo|
523131|NCT00212277|Drug|Norethindrone,Ethinyl Estradiol|
523132|NCT00212264|Behavioral|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
523133|NCT00212264|Device|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
523134|NCT00212264|Behavioral|Biofeedback|Pelvic Floor Muscle training via biofeedback
523135|NCT00212264|Other|No Treatment|No treatment
523136|NCT00212251|Behavioral|moderate exercise and healthy, low-fat diet|
523137|NCT00212238|Behavioral|internet behavioral weight loss program|
523138|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenate
523139|NCT00212212|Dietary Supplement|selenium|400 µg selenium as selenate
523140|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenomethionine
523141|NCT00212212|Dietary Supplement|placebo|placebo tablet
523142|NCT00212199|Drug|orlistat|
523143|NCT00212199|Behavioral|Brief cognitive behavioral counseling|
523144|NCT00212186|Drug|Selenium Supplements (essential nutrient)|
523145|NCT00212173|Drug|Sibutramine|
523146|NCT00212173|Dietary Supplement|Slim Fast|
523147|NCT00212160|Procedure|omentectomy|RYGB with omentectomy
523148|NCT00212147|Drug|general anesthesia|anesthesia regimen with nitrous oxide or without nitrous oxide
523149|NCT00212134|Device|Contact lens correction of aphakia|optical correction of infant surgical aphakia with Contact lens
523150|NCT00212134|Device|Intraocular lens implantation|optical correction of surgical aphakia with intraocular lens
523151|NCT00212121|Radiation|high dose boost|high dose boost
523152|NCT00212121|Procedure|boost|low dose versus high dose
523153|NCT00212108|Drug|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
523154|NCT00212095|Drug|docetaxel and ketoconazole|"Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.~Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration."
523155|NCT00212082|Drug|doxorubicin, docetaxel|
523156|NCT00212069|Drug|gemcitabine, carboplatin|
523157|NCT00212056|Drug|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
523158|NCT00212056|Drug|Control|placebo
523159|NCT00212043|Drug|carboplatin and gemcitabine|
523160|NCT00212030|Drug|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
523161|NCT00212030|Drug|placebo|Control
523162|NCT00212017|Drug|voglibose|
523163|NCT00212017|Behavioral|diet and exercise therapy|
523164|NCT00212004|Drug|pioglitazone|
523165|NCT00212004|Other|control|
523166|NCT00211991|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
523167|NCT00211978|Drug|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
523168|NCT00211978|Drug|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
523169|NCT00211965|Biological|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
523170|NCT00211965|Biological|placebo|single dose IM
523171|NCT00211952|Drug|celecoxib|
523172|NCT00211939|Drug|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
523173|NCT00211939|Drug|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
523174|NCT00211939|Drug|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
523175|NCT00211926|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
523176|NCT00211926|Biological|placebo|single dose of placebo
523177|NCT00211913|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
523178|NCT00211913|Biological|placebo|single IM dose
523179|NCT00211900|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
523180|NCT00211887|Drug|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
539918|NCT00002785|Drug|mesna|
523181|NCT00211887|Drug|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
523182|NCT00211887|Other|placebo|an inactive substance
523183|NCT00211874|Behavioral|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
523184|NCT00211848|Drug|Polyenylphosphatidylcholine (PPC)|
523185|NCT00211848|Drug|Pegylated Interferon|
523186|NCT00211848|Drug|Ribavirin|
523187|NCT00211835|Behavioral|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
523188|NCT00211835|Behavioral|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
523189|NCT00211822|Procedure|fMRI|fMRI
523190|NCT00211809|Behavioral|Cognitive Behavioral Therapy|standard psychiatric evaluation
523191|NCT00211809|Drug|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
523192|NCT00211796|Drug|Divalproex Sodium ER|
523193|NCT00211783|Procedure|fMRI|there is no intervention
523194|NCT00211770|Behavioral|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
523195|NCT00211757|Drug|Divalproex sodium|Study drug.
523196|NCT00211757|Drug|Placebo|Placebo comparator.
523197|NCT00211744|Drug|topiramate|
523198|NCT00211731|Behavioral|Chronic Disease Self Management Course|
523199|NCT00211718|Drug|intra-articular botulinum toxin type a|
523200|NCT00211705|Behavioral|Diet|
523201|NCT00211705|Drug|Diet+pravastatin|
523202|NCT00211692|Drug|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
523203|NCT00211692|Drug|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
523204|NCT00211679|Drug|Botulinum Toxin Type A|
523205|NCT00211666|Behavioral|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
523206|NCT00211653|Drug|N-Acetylcysteine|
523207|NCT00211627|Device|KEEPASLEEP enhanced breathing device|
523208|NCT00211614|Drug|Lansoprazole|
523209|NCT00211601|Behavioral|Disease Management Assessment|
523210|NCT00211588|Drug|galantamine|
523211|NCT00211575|Behavioral|Disease Management Assessment|
523212|NCT00211562|Drug|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
523213|NCT00211549|Drug|IDEA-033|
523214|NCT00211536|Drug|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
523215|NCT00211536|Device|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
523216|NCT00211536|Drug|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
523217|NCT00211523|Drug|MBI 226 Acne Solutions|
523218|NCT00211510|Device|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
523219|NCT00211510|Device|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
523220|NCT00211497|Drug|MBI 226 Acne Solutions|
523221|NCT00211484|Drug|Anecortave Acetate|
523222|NCT00211471|Drug|anecortave acetate|
523223|NCT00211458|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
523224|NCT00211445|Procedure|Photodynamic Therapy with Verteporfin|
523225|NCT00211445|Drug|verteporfin|
523226|NCT00211432|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
523227|NCT00211419|Drug|Anecortave Acetate 15 mg|
523228|NCT00211419|Drug|Triamcinolone Acetate 4 mg|
523229|NCT00211419|Procedure|Photodynamic Therapy with Verteporfin|
523230|NCT00211419|Procedure|Thermal Laser|
523231|NCT00211406|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
523232|NCT00211393|Drug|ketoconazole|600mg. /day for 6 weeks
523233|NCT00211380|Drug|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
523234|NCT00211367|Drug|Anecortave Acetate|
523235|NCT00211354|Drug|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
523236|NCT00211341|Dietary Supplement|Vitamin A|Weekly single oral dose 7000 micrograms
523237|NCT00211328|Drug|anecortave acetate|
523238|NCT00211315|Drug|anecortave acetate|
523239|NCT00211302|Drug|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
523240|NCT00211289|Behavioral|Education by community pharmacist|
523241|NCT00211276|Drug|ONTAK (denileukin diftitox)|
523242|NCT00211263|Behavioral|Enhanced Clinical Intervention|
523243|NCT00211263|Drug|mood stabilizer|
523244|NCT00211250|Drug|Valproic Acid and Depakote ER|
523311|NCT00210457|Drug|Lanreotide (Autogel formulation)|
523245|NCT00211237|Device|Balloon Kyphoplasty|Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
523246|NCT00211237|Other|Non Surgical Management|Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
523247|NCT00211224|Drug|Riluzole|
523248|NCT00211211|Device|Balloon Kyphoplasty|
523249|NCT00211198|Drug|ONTAK (denileukin difitox, DAB389IL-2)|
523250|NCT00211185|Drug|ONTAK (denileukin diftitox, DAB389 IL-2)|Ontak + CHOP every 3 weeks.
523251|NCT00211172|Behavioral|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
523252|NCT00211159|Drug|EPAX 1050TG|
523253|NCT00211146|Drug|epoetin alfa|
523254|NCT00211133|Drug|epoetin alfa|
523255|NCT00211120|Drug|Epoetin Alfa|
523256|NCT00211107|Drug|Dapoxetine|
523257|NCT00211094|Drug|Dapoxetine|
523258|NCT00211081|Drug|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
523259|NCT00211068|Drug|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
523260|NCT00211042|Other|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
523261|NCT00211016|Drug|doripenem|
523262|NCT00211003|Drug|doripenem|
523263|NCT00210990|Drug|doripenem|
523264|NCT00210977|Drug|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
523265|NCT00210964|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
523266|NCT00210964|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
523267|NCT00210951|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
523268|NCT00210938|Drug|Doripenem|
523269|NCT00210925|Drug|topiramate|
523270|NCT00210912|Drug|topiramate|
523271|NCT00210899|Drug|ceftobiprole medocaril|
523272|NCT00210899|Drug|Vancomycin plus Ceftazidime|
523273|NCT00210886|Drug|levofloxacin|
523274|NCT00210873|Drug|topiramate|
523275|NCT00210860|Drug|topiramate|
523276|NCT00210847|Drug|tramadol, acetaminophen|
523277|NCT00210834|Drug|epoetin alfa|
523278|NCT00210821|Drug|topiramate|
523279|NCT00210808|Drug|topiramate|
523280|NCT00210795|Drug|epoetin alfa|
523281|NCT00210782|Drug|topiramate, phenytoin|
523282|NCT00210769|Drug|paliperidone ER Oros|
523283|NCT00210756|Drug|epoetin alfa|
523284|NCT00210743|Drug|epoetin alfa|
523285|NCT00210730|Drug|epoetin alfa|
523286|NCT00210717|Drug|paliperidone palmitate|
523287|NCT00210704|Drug|Dapoxetine|
523288|NCT00210691|Drug|Risperidone|
523289|NCT00210678|Behavioral|No intervention|No treatment is given to the patients as this is an observational study.
523290|NCT00210665|Drug|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
523291|NCT00210652|Drug|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
523292|NCT00210639|Drug|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
523293|NCT00210626|Drug|PROCRIT|40,000 IU/mL/week for max of 12 weeks
523294|NCT00210626|Drug|Placebo|40,000 IU/mL/week for max of 12 weeks
523295|NCT00210613|Drug|Dapoxetine|
523296|NCT00210600|Drug|PROCRIT (Epoetin alfa)|
523297|NCT00210587|Drug|epoetin alfa|
523298|NCT00210574|Drug|topiramate|
523299|NCT00210561|Drug|tramadol hydrochloride , acetaminophen|
523300|NCT00210548|Drug|paliperidone palmitate|
523301|NCT00210535|Drug|Topiramate; Placebo|
523302|NCT00210522|Drug|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
523303|NCT00210509|Drug|almotriptan malate|
523304|NCT00210496|Drug|topiramate; almotriptan malate|
523305|NCT00210483|Drug|almotriptan malate|
523306|NCT00210470|Biological|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day), 1 initial injection of cyclophosphamide, and 3 weeks of indomethacin (tablets or injection) and zinc supplementation (multivitamin tablet)
523307|NCT00210470|Drug|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
523308|NCT00210470|Drug|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
523309|NCT00210470|Drug|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
523310|NCT00210470|Drug|Omeprazole|21 days of 20 mg. orally
523312|NCT00210444|Biological|Botulinum toxin type A|
523313|NCT00210418|Dietary Supplement|Fortified food rations|The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ <-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
523314|NCT00210418|Behavioral|Education and communication to improve feeding practices|The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
523315|NCT00210405|Dietary Supplement|"Sprinkles containing mulitple micronutrients"|
523316|NCT00210405|Behavioral|Education/communication on use of micronutrient sprinkles|
523317|NCT00210405|Dietary Supplement|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
523318|NCT00210392|Drug|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
523319|NCT00210379|Drug|rituximab|
523320|NCT00210379|Drug|CHOP|
523321|NCT00210379|Drug|intrathecal methotrexate|
523322|NCT00210379|Procedure|radiotherapy|
523323|NCT00210366|Drug|Idarubicin|
523324|NCT00210353|Drug|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
523325|NCT00210353|Drug|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
523326|NCT00210353|Drug|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
523327|NCT00210340|Drug|intrathecal rituximab|
523328|NCT00210327|Drug|Bortezomib (drug)|
523329|NCT00210314|Drug|high dose methotrexate|
523330|NCT00210314|Drug|high dose cytarabine|
523331|NCT00210314|Radiation|radiotherapy|
523332|NCT00210301|Drug|Provigil (modafinil)|
523333|NCT00210288|Biological|SC599|
523334|NCT00210275|Behavioral|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
523335|NCT00210262|Behavioral|Feedback and Education|
523336|NCT00210236|Procedure|Conventional surgery|
523337|NCT00210223|Procedure|Radiofrequency|
523338|NCT00210210|Drug|Ketamine|
523339|NCT00210197|Procedure|Blood collection (pre and postoperative): plasma coagulation parameters|
523340|NCT00210184|Drug|Irinotecan associated to fluorouracil and leucovorin|
523341|NCT00210171|Procedure|Toxicity : Time to progression, 1 and 2 years survival|
523342|NCT00210158|Procedure|Nitrous oxyde|
523343|NCT00210145|Behavioral|Aesthetic care|
523344|NCT00210132|Drug|Ropivacaine|
523345|NCT00210119|Drug|Imatinib mesylate and zoledronic acid|
523346|NCT00210106|Device|Ablathermy|
523347|NCT00210093|Drug|denufosol tetrasodium (INS37217)|
523348|NCT00210080|Drug|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
523349|NCT00210067|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
523350|NCT00210054|Drug|denufosol tetrasodium (INS37217)|
523351|NCT00210041|Drug|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
523352|NCT00210041|Drug|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
523353|NCT00210028|Drug|Tamoxifen|
523354|NCT00210028|Drug|Zarnestra|
523355|NCT00210015|Drug|INS37217 Nasal Spray|
523356|NCT00210002|Drug|Darbepoetin alfa (Aranesp®)|
523357|NCT00210002|Drug|Ferric saccharose(Venofer®)|
523358|NCT00209989|Drug|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
523359|NCT00209989|Procedure|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
523360|NCT00209963|Drug|Gaboxadol|
523361|NCT00209950|Drug|Gaboxadol|
523362|NCT00209937|Drug|Gaboxadol|
523363|NCT00209924|Drug|Gaboxadol|
523364|NCT00209911|Procedure|cardioversion|
523365|NCT00209898|Procedure|Fast initiation procedure|
523366|NCT00209885|Drug|Gabapentin|
523367|NCT00209885|Drug|S-ketamine|
523368|NCT00209885|Drug|Lidocaine|
523369|NCT00209885|Drug|Droperidol|
523370|NCT00209872|Drug|Gabapentin|
523371|NCT00209872|Drug|Lidocaine|
523372|NCT00209872|Drug|S-ketamine|
523373|NCT00209872|Procedure|Epidural analgesia|
523374|NCT00209859|Drug|Methotrexate|
523375|NCT00209859|Drug|Intraarticular betamethasone|
523376|NCT00209859|Drug|Cyclosporine/placebo-cyclosporine|
523377|NCT00209846|Drug|Gaboxadol|
523378|NCT00209833|Drug|Cytarabine|
523379|NCT00209833|Drug|Idarubicin|
523380|NCT00209833|Drug|Etoposide|
523381|NCT00209833|Drug|Fludarabine|
523382|NCT00209833|Drug|G-CSF|
523383|NCT00209833|Drug|Daunorubicine|
523384|NCT00209820|Behavioral|Supervised Nordic Walking|
523385|NCT00209820|Behavioral|Unsupervised Nordic Walking|
523386|NCT00209820|Behavioral|Advice to stay active|
523387|NCT00209807|Drug|escitalopram|escitalopram 10 mg/d for 6 weeks
523388|NCT00209807|Drug|Reboxetine|Reboxetine 8 mg/d for 6 weeks
523472|NCT00209222|Procedure|high-dose chemotherapy: Cyclophosphamide|chemotherapy
523389|NCT00209807|Other|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
523390|NCT00209794|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
523391|NCT00209781|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
523392|NCT00209781|Device|ITNs|
523393|NCT00209768|Device|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
523394|NCT00209755|Procedure|therapeutic drug monitoring of ribavirin and dose adaptation|
523395|NCT00209742|Drug|UFT|P.O. everyday
523396|NCT00209742|Drug|USEL/Leucovorin|P.O. everyday
523397|NCT00209742|Drug|Krestin|P.O. everyday
523398|NCT00209729|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
523399|NCT00209729|Drug|TS-1|Day 1-14, P.O. everyday
523400|NCT00209716|Drug|Taxotere|30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
523401|NCT00209716|Drug|5-Fluorouracil|800 mg/m2, CIV (CIV.in the vein) on day 1~5 of each 28 day cycle.
523402|NCT00209716|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle.
523403|NCT00209703|Drug|Oxaliplatin|
523404|NCT00209703|Drug|l-Leucovorin|
523405|NCT00209703|Drug|5-Fluorouracil|
523406|NCT00209690|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
523407|NCT00209690|Drug|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
523408|NCT00209690|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
523409|NCT00209677|Drug|Gemcitabine|
523410|NCT00209677|Drug|S-1|
523411|NCT00209664|Drug|irinotecan|
523412|NCT00209664|Drug|S-1|
523413|NCT00209651|Drug|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
523414|NCT00209651|Drug|TS-1|80 mg/m2, PO (oral) on day 1~14 of each 28 day cycle.
523415|NCT00209638|Drug|irinotecan|
523416|NCT00209638|Drug|S-1|
523417|NCT00209625|Drug|irinotecan|
523418|NCT00209625|Drug|leucovorin|
523419|NCT00209625|Drug|fluorouracil|
523420|NCT00209612|Drug|Taxol|Day1,15 X mg/m2, IV (in the vein)
523421|NCT00209612|Drug|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
523422|NCT00209599|Drug|fospropofol disodium|
523423|NCT00209586|Drug|fospropofol disodium|
523424|NCT00209573|Drug|fospropofol disodium|
523425|NCT00209560|Drug|fospropofol disodium|
523426|NCT00209547|Drug|fospropofol disodium|
523427|NCT00209534|Drug|fospropofol disodium|
523428|NCT00209521|Drug|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
523429|NCT00209521|Drug|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
523430|NCT00209508|Drug|GPI 1485|
523431|NCT00209495|Drug|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
523432|NCT00209482|Drug|glucophage XR|
523433|NCT00209469|Drug|alendronate sodium|
523434|NCT00209456|Drug|DatSCAN|
523435|NCT00209443|Drug|Gadodiamide Injection|
523436|NCT00209430|Drug|Iodixanol 320 mgI/mL|
523437|NCT00209417|Drug|Iodixanol 320-Arm 1|
523438|NCT00209417|Drug|Iopamidol 300-Arm 2|
523439|NCT00209404|Drug|Iodixanol 320 mg I/Ml|
523440|NCT00209391|Drug|Gadodiamide Injection|
523441|NCT00209378|Other|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
523442|NCT00209378|Other|HfCitPre|regional anticoagulation with citrate containing replacement solution
523443|NCT00209365|Procedure|exposure to grass pollen/starch granules|
523444|NCT00209352|Drug|Acyclovir|
523445|NCT00209339|Device|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
523446|NCT00209326|Drug|FE200440|
523447|NCT00209313|Drug|Acyclovir|Acyclovir 800 mg twice daily or placebo
523448|NCT00209300|Drug|Pentasa|
523449|NCT00209287|Behavioral|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
523450|NCT00209274|Device|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
523451|NCT00209274|Procedure|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
523452|NCT00209261|Drug|MINIRIN Oral Lyophilisate|
523453|NCT00209261|Drug|Minirin tablet|
523454|NCT00209235|Behavioral|Neurocognitive and psychosocial testing|Neurocognitive and psychosocial testing
523455|NCT00209222|Drug|Rituximab|antibody
523456|NCT00209222|Drug|Cyclophosphamide|chemotherapy
523457|NCT00209222|Drug|Doxorubicin|chemotherapy
523458|NCT00209222|Drug|Vincristine|chemotherapy
523459|NCT00209222|Drug|Prednisone|corticosteroide
523460|NCT00209222|Drug|Cisplatinum|chemotherapy
523461|NCT00209222|Drug|Ara-C|chemotherapy
523462|NCT00209222|Drug|Dexamethasone|corticosteroide
523463|NCT00209222|Drug|BCNU|chemotherapy
523464|NCT00209222|Drug|Melphalan|chemotherapy
523465|NCT00209222|Drug|Etoposide|chemotherapy
523466|NCT00209222|Drug|G-CSF|growth factor
523467|NCT00209222|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
523468|NCT00209222|Procedure|chemotherapy: R-DHAP|immuno-chemotherapy
523469|NCT00209222|Procedure|chemotherapy: Dexa-BEAM|chemotherapy
523470|NCT00209222|Procedure|stem cell harvest|procedure
523471|NCT00209222|Procedure|total body irradiation|radiation
523473|NCT00209222|Procedure|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
523474|NCT00209209|Drug|Rituximab|antibody
523475|NCT00209209|Drug|Cyclophosphamide|chemotherapy
523476|NCT00209209|Drug|Doxorubicin|chemotherapy
523477|NCT00209209|Drug|Vincristine|chemotherapy
523478|NCT00209209|Drug|Prednisone|coricosteroide
523479|NCT00209209|Drug|Fludarabine|chemotherapy
523480|NCT00209209|Drug|Interferon-alpha|cytokine
523481|NCT00209209|Drug|pegylated formula Interferon-alpha 2b|cytokine
523482|NCT00209209|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
523483|NCT00209209|Procedure|chemotherapy: R-FC|immuno-chemotherapy
523484|NCT00209209|Procedure|Interferon maintenance|cytokine
523485|NCT00209209|Procedure|Rituximab maintenance|antibody
523486|NCT00209170|Behavioral|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
523487|NCT00209170|Drug|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
523488|NCT00209170|Drug|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
523489|NCT00209144|Drug|Intensive insulin therapy|
523490|NCT00209131|Drug|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
523491|NCT00209131|Drug|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
523492|NCT00209118|Drug|paroxetine|
523493|NCT00209105|Drug|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
523494|NCT00209105|Behavioral|Psychosocial stress induction|Laboratory stress induction, no drug administration
523495|NCT00209105|Procedure|Brain imaging of sad mood , self-reference, reward|Brain imaging
523496|NCT00209105|Behavioral|Acoustic startle|No drugs involved
523497|NCT00209092|Drug|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.~Concurrent Therapy: Docetaxel will be given at 50 mg/m^2 IV Day 1."
523498|NCT00209092|Drug|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
523499|NCT00209079|Drug|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
523500|NCT00209053|Procedure|Coronary Artery Bypass|
523501|NCT00209040|Behavioral|Acoustic Startle Testing|See protocol description for methodological details
523502|NCT00209027|Other|fMRI|fMRI scanning during behavioral reward task
523503|NCT00209027|Drug|Aripiprazole|30 mg by mouth once daily
523504|NCT00209014|Drug|Thalidomide|
523505|NCT00209001|Procedure|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
523506|NCT00209001|Procedure|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
523507|NCT00208988|Procedure|Educational handout about prostate cancer screening|
523508|NCT00208988|Procedure|Simple cue for patient to talk to doctor|
523509|NCT00208975|Drug|Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF|"Initial patients (n=9) received fludarabine (25 mg/m^2 intravenously) and mitoxantrone (10 mg/m^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m^2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m^2 intravenously) and cyclophosphamide (250 mg/m^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
523510|NCT00208962|Procedure|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
523511|NCT00208949|Drug|G-CSF|G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
523512|NCT00208949|Drug|GM-CSF|GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
523513|NCT00208936|Drug|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
523514|NCT00208923|Drug|Busulfan, Cyclophosphamide and Fludarabine|"Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.~Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.~Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
523515|NCT00208910|Behavioral|Odorant Cue|
523516|NCT00208897|Drug|Fluoxetine|
523517|NCT00208871|Procedure|Stereoscopic Digital Mammography|screening digital 3D mammogram
523518|NCT00208858|Drug|Topiramate|
523519|NCT00208832|Procedure|Graphic medication schedule (Pill card)|
523520|NCT00208832|Procedure|Refill reminder postcard|
523521|NCT00208819|Drug|risperidone|
523522|NCT00208819|Drug|quetiapine|
523523|NCT00208819|Drug|olanzapine|
523524|NCT00208819|Drug|divalproex|
523525|NCT00208806|Other|congestive heart failure patients|observational echo data on congestive heart failure patients
523526|NCT00208793|Dietary Supplement|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
523527|NCT00208793|Drug|Placebo|Placebo
523528|NCT00208793|Dietary Supplement|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
523529|NCT00208793|Dietary Supplement|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
523530|NCT00208780|Drug|Tetrahydrobiopterin|
523531|NCT00208780|Drug|Tetrahydrobiopterin|
523532|NCT00208767|Drug|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
523533|NCT00208767|Drug|Placebo|A matched placebo pill will be given orally daily.
523534|NCT00208741|Drug|Gabitril|
523535|NCT00208728|Device|PC/SMART cardiopulmonary bypass circuit|
523536|NCT00208728|Device|PMEA modified cardiopulmonary bypass circuit|
523537|NCT00208728|Device|Standard of care uncoated cardiopulmonary bypass circuit|
523538|NCT00208715|Drug|Provigil|
523539|NCT00208702|Drug|Triiodothyronine|
523540|NCT00208702|Other|Placebo|
523541|NCT00208702|Drug|Sertraline|
523542|NCT00208637|Behavioral|moderate carbohydrate, high protein diet (MCHP)|
523543|NCT00208637|Behavioral|high carbohydrate-high fibre (HCHF) diet|
523544|NCT00208611|Dietary Supplement|Vitamin B12 Supplementation|1000 micrograms daily
523545|NCT00208585|Drug|sertraline|
523546|NCT00208572|Drug|Citalopram|
523547|NCT00208559|Drug|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
523548|NCT00208546|Drug|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
523549|NCT00208546|Drug|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
523550|NCT00208533|Drug|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
523551|NCT00208520|Drug|Carbamazepine|
523552|NCT00208520|Drug|Lamotrigine|
523553|NCT00208520|Drug|Levetiracetam|
523554|NCT00208507|Device|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
523555|NCT00208507|Device|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
523556|NCT00208494|Device|Total Hip Replacement|Total hip replacement
523557|NCT00208494|Device|Total hip replacement|Total hip replacement
523558|NCT00208468|Device|European Hip|A cementless femoral component for use in total hip replacement
523559|NCT00208468|Device|Zweymüller|A cementless femoral component for use in total hip replacement
523560|NCT00208468|Device|CLS Spotorno|A cementless femoral component for use in total hip replacement
523561|NCT00208455|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
523562|NCT00208442|Device|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
523563|NCT00208442|Device|Enduron|Standard polyethylene liner in a modular acetabular component
523564|NCT00208429|Device|Pinnacle Acetabular System|
523565|NCT00208416|Procedure|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
523566|NCT00208416|Procedure|Conventional surgical technique|A conventional surgical technique used in total hip replacement
523567|NCT00208403|Device|Acryloc™ GHV|A high viscosity bone cement for use in total hip replacement
523568|NCT00208403|Device|Palacos R|A high viscosity bone cement for use in total hip replacement
523569|NCT00208390|Device|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
523570|NCT00208377|Device|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
523571|NCT00208364|Device|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
523572|NCT00208351|Device|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
523573|NCT00208351|Device|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
523574|NCT00208351|Device|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
523575|NCT00208351|Device|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
523576|NCT00208338|Device|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
523577|NCT00208338|Procedure|Rotator cuff repair|Standard surgical repair of torn rotator cuff
523578|NCT00208325|Device|P.F.C Sigma Fixed Bearing total knee system|Orthopaedic implant for total knee replacement
523579|NCT00208325|Device|P.F.C Sigma RP Mobile Bearing knee system|Orthopaedic implant for total knee replacement
523580|NCT00208312|Drug|Regadenoson|0.4 mg, bolus intravenous injection
523581|NCT00208312|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
523582|NCT00208299|Drug|Regadenoson|0.4 mg, bolus intravenous injection
523583|NCT00208299|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
523584|NCT00208286|Device|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
523585|NCT00208286|Device|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
523586|NCT00208273|Drug|Letrozole - Concomitant|
523587|NCT00208273|Drug|Letrozole - Sequential|
523588|NCT00208260|Drug|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
523589|NCT00208260|Drug|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
523590|NCT00208260|Drug|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
523591|NCT00208260|Drug|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
523592|NCT00208260|Drug|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
523593|NCT00208247|Behavioral|Cognitive behavioral psychotherapy|
523594|NCT00208234|Drug|Omalizumab|0.016 mg/kg IgE
523595|NCT00208234|Drug|Placebo for Omalizumab|Placebo
523596|NCT00208234|Drug|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
523598|NCT00208221|Drug|ramipril-telmisartan|
523599|NCT00208208|Drug|Ziprasidone|
523600|NCT00208195|Drug|Divalproex ER|
523601|NCT00208182|Drug|Risperidone|
523602|NCT00208169|Drug|Aripiprazole|
523603|NCT00208156|Drug|Mifepristone|
523604|NCT00208143|Drug|Quetiapine|
523605|NCT00208143|Drug|Risperidone|
523606|NCT00208130|Drug|Topiramate|
523607|NCT00208117|Drug|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
523608|NCT00208117|Drug|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
523609|NCT00208104|Behavioral|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
523610|NCT00208091|Drug|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
523611|NCT00208078|Device|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
523612|NCT00208065|Drug|almotriptan or pseudoephedrine|
523613|NCT00208039|Drug|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
523614|NCT00208026|Drug|Pimecrolimus 1% Cream|Open label single arm
523615|NCT00208000|Drug|Marine active|
523616|NCT00207974|Drug|Marine active|
523617|NCT00207948|Drug|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
523618|NCT00207935|Behavioral|Swallow instruction|
523619|NCT00207844|Drug|Selenium as sodium selenite|
523620|NCT00207831|Drug|Tegafur and Uracil|
523621|NCT00207818|Device|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
523622|NCT00207805|Procedure|autologous PBSC transplant|optimal timining of a second autologous transplant
523623|NCT00207792|Drug|filgrastim|
523624|NCT00207779|Device|heparin impregnated central venous catheters|
523625|NCT00207766|Drug|infliximab or placebo|
523626|NCT00207753|Drug|albendazole vs. combined albendazole/ivermectin treatment|
523627|NCT00207740|Drug|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
523628|NCT00207740|Drug|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
523629|NCT00207727|Drug|CNTO 1275|
523630|NCT00207714|Drug|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
523631|NCT00207714|Drug|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
523632|NCT00207714|Drug|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
523633|NCT00207714|Drug|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
523634|NCT00207701|Drug|infliximab|
523635|NCT00207688|Drug|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
523636|NCT00207688|Drug|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
523637|NCT00207688|Drug|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
523638|NCT00207675|Drug|infliximab|
523639|NCT00207662|Drug|infliximab or placebo|
523640|NCT00207649|Behavioral|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
523641|NCT00207636|Behavioral|Computer-based prostate cancer screening decision aid|
523642|NCT00207623|Behavioral|Arthritis Basics for Change Education program|
523643|NCT00207610|Behavioral|Daily iron supplements of 65 mg a day for 3 months|
523644|NCT00207610|Behavioral|Universal anemia screening and treatment|
523645|NCT00207610|Behavioral|Selective anemia screening and treatment|
523646|NCT00207584|Drug|Doxycycline treatment|
523647|NCT00207571|Behavioral|Computer|
523648|NCT00207558|Drug|folic acid|
523649|NCT00207532|Drug|folic acid|
523650|NCT00207519|Behavioral|weekly behavioral modification group|
523651|NCT00207519|Behavioral|liquid meal replacements|
523652|NCT00207506|Behavioral|HoMBReS: A lay health advisor approach to STD prevention|
523653|NCT00207493|Behavioral|Kit enhancement to referral|
523654|NCT00207493|Procedure|patient referral versus contract referral|
523655|NCT00207480|Behavioral|Brief, motivational interviewing intervention|
523656|NCT00207467|Behavioral|Patient-delivered partner treatment|
539919|NCT00002785|Drug|methotrexate|
523657|NCT00207467|Behavioral|Booklet-enhanced partner referral|
523658|NCT00207454|Behavioral|Social Cognitive Counseling|
523659|NCT00207441|Behavioral|Arthritis Self management program|
523660|NCT00207441|Behavioral|Chronic Disease Self Management Program|
523661|NCT00207428|Drug|Carbamazepine|
523662|NCT00207415|Behavioral|ASHC and CDSMP|
523663|NCT00207402|Drug|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
523664|NCT00207376|Device|Solysafe Septal Occluder|
523665|NCT00207363|Drug|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
523666|NCT00207363|Drug|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
523667|NCT00207350|Device|Interstitial Laser Therapy|Device
523668|NCT00207337|Device|Exhale Drug-Eluting Stent|
523669|NCT00207324|Device|Silver Leaf Dressing|
523670|NCT00207311|Drug|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
523671|NCT00207311|Behavioral|Xenicare Program|Xenicare program for 36 weeks.
523672|NCT00207298|Procedure|Positron Emission Tomography|Each patient will receive an 18F-FDG PET/CT scan
523673|NCT00207285|Behavioral|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
523674|NCT00207285|Procedure|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
523675|NCT00207272|Behavioral|1170-1870 kcal/day liquid diet|
523676|NCT00207272|Procedure|Gastric bypass surgery|
523677|NCT00207272|Procedure|Biopsy.visceral adipose tissue|
523678|NCT00207272|Procedure|Biopsy.omental adipose tissue|
523679|NCT00207272|Procedure|Biopsy. subcutaneous abdominal adipose tissue|
523680|NCT00207272|Procedure|Blood sample|
523681|NCT00207259|Behavioral|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.~Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
523682|NCT00207233|Behavioral|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
523683|NCT00207233|Behavioral|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.~The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
523684|NCT00207233|Procedure|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.~This will be performed at baseline, 6 weeks, and 12 weeks."
523685|NCT00207220|Procedure|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
523686|NCT00207220|Procedure|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
523687|NCT00207207|Procedure|Alternate site blood glucose testing|
523688|NCT00207194|Behavioral|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
523689|NCT00207194|Behavioral|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
523690|NCT00207168|Behavioral|Compliance|
523691|NCT00207155|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
523753|NCT00206622|Drug|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
523692|NCT00207142|Drug|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
523693|NCT00207142|Drug|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
523694|NCT00207129|Drug|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
523695|NCT00207129|Drug|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
523696|NCT00207116|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
523697|NCT00207103|Drug|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
523698|NCT00207103|Drug|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
523699|NCT00207103|Drug|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
523700|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
523701|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
523702|NCT00207103|Drug|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
523703|NCT00207090|Drug|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
523704|NCT00207090|Drug|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
523705|NCT00207077|Drug|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
523706|NCT00207064|Drug|quetiapine|flexible doses according to the clinical condition
523707|NCT00207051|Drug|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
523708|NCT00207025|Drug|BMS-275183|
523709|NCT00207012|Drug|BMS-599626|
523710|NCT00206999|Drug|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
523711|NCT00206986|Drug|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
523712|NCT00206986|Drug|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
523713|NCT00206973|Procedure|mannitol test|
523714|NCT00206960|Drug|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
523715|NCT00206960|Drug|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
523716|NCT00206947|Drug|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
523717|NCT00206947|Drug|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
523718|NCT00206934|Drug|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
523719|NCT00206934|Drug|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
523720|NCT00206921|Device|Pulsed dye laser|
523721|NCT00206921|Device|Intense pulsed light|
523722|NCT00206895|Procedure|Photodynamic therapy|
523723|NCT00206882|Drug|corticosteroids|
523724|NCT00206869|Behavioral|exercise|
523725|NCT00206869|Behavioral|heat|
523726|NCT00206869|Procedure|red light illumination|
523727|NCT00206856|Device|Triage® B-Type Natriuretic Peptide (BNP) Test|
523728|NCT00206843|Device|Triage BNP Test|
523729|NCT00206830|Device|Triage Profiler S.O.B. Panel|
523730|NCT00206817|Device|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
523731|NCT00206791|Device|MBCP-Gel (tm)|
523732|NCT00206778|Drug|Lamotrigine|
523733|NCT00206778|Drug|Sodium Valproate|
523734|NCT00206765|Drug|Risperidone|
523735|NCT00206765|Drug|Paroxetine|
523736|NCT00206752|Radiation|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
523737|NCT00206752|Radiation|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
523738|NCT00206739|Drug|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
523739|NCT00206726|Drug|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
523740|NCT00206713|Drug|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
523741|NCT00206713|Drug|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
523742|NCT00206700|Drug|Sargramostim (Leukine)|Open Label, 8 week cycle
523743|NCT00206687|Biological|Spheramine (BAY86-5280)|Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
523744|NCT00206687|Procedure|Placebo|Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
523745|NCT00206674|Drug|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
523746|NCT00206674|Drug|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
523747|NCT00206661|Drug|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
523748|NCT00206661|Drug|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
523749|NCT00206648|Drug|Betaferon/Betaseron|Betaseron 250 µg SC every other day
523750|NCT00206648|Drug|Betaferon/Betaseron|Avonex 30 µg IM once per week
523751|NCT00206635|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
523752|NCT00206622|Drug|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
539920|NCT00002785|Drug|methylprednisolone|
523754|NCT00206622|Drug|Placebo transdermal|Placebo
523755|NCT00206609|Procedure|Oxygen and air administration|
523756|NCT00206596|Drug|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
523757|NCT00206596|Drug|Placebo|Once daily via subcutaneous injection for up 22 weeks
523758|NCT00206583|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
523759|NCT00206570|Drug|Estradiol|
523760|NCT00206557|Drug|Raloxifene|
523761|NCT00206557|Drug|Estradiol/dyhydroprogestrone|
523762|NCT00206544|Drug|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
523763|NCT00206544|Drug|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
523764|NCT00206544|Other|placebo|adjunctive placebo daily in oral capsule
523765|NCT00206518|Drug|Taxotere/Docetaxel|Taxotere
523766|NCT00206518|Drug|Adriamycin/Cytoxan|Adriamycin/Cytoxan
523767|NCT00206518|Drug|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
523768|NCT00206505|Drug|Taxotere|
523769|NCT00206492|Drug|Iressa|Iressa
523770|NCT00206492|Drug|Tamoxifen|Tamoxifen
523771|NCT00206466|Drug|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
523772|NCT00206466|Drug|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
523773|NCT00206453|Drug|Taxotere|Chemotherapy IV
523774|NCT00206440|Drug|esomeprazole|nexium
523775|NCT00206440|Other|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
523776|NCT00206427|Drug|GW572016|Lapatinib, 500 mg
523777|NCT00206427|Drug|lapatinib|Lapatinib 500 mg PO
523778|NCT00206414|Drug|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
523779|NCT00206414|Drug|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
523780|NCT00206401|Drug|Lantus and short acting analogs Vs NPH and short acting analogs|
523781|NCT00206388|Drug|Zolendric acid|IV, 2mg/m2/dose on day 0
523782|NCT00206388|Drug|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
523783|NCT00206375|Drug|Growth hormone|Growth hormone + Synthroid + Lupron
523784|NCT00206375|Drug|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
523785|NCT00206336|Drug|Topiramate (drug)|Topiramate 25 mg to 200 mg
523786|NCT00206323|Drug|Topiramate (drug)|Topiramate 25 mg titrated to 200 mg
523787|NCT00206323|Drug|placebo/sugar pill|placebo
523788|NCT00206310|Drug|CRESTOR|
523789|NCT00206297|Drug|Pramlintide|
523790|NCT00206284|Drug|AZD0865|
523791|NCT00206271|Behavioral|neck collar; advice to act-as-usual; active mobilisation|
523792|NCT00206258|Drug|Pramlintide and glucagon|
523793|NCT00206245|Drug|AZD0865|
523794|NCT00206232|Drug|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
523795|NCT00206219|Drug|Gefitinib|
523796|NCT00206219|Drug|methotrexate|
523797|NCT00206206|Procedure|Hyperglycemia Protocol Procedure|
523798|NCT00206193|Drug|mifepristone|
523799|NCT00206193|Drug|misoprostol|
523800|NCT00206193|Drug|sulprostone|
523801|NCT00206180|Drug|esomeprazole magnesium (oral medication)|
523802|NCT00206167|Drug|Budesonide/formoterol pMDI|
523803|NCT00206167|Drug|Formoterol Turbuhaler|
523804|NCT00206154|Drug|Budesonide/formoterol pMDI|
523805|NCT00206154|Drug|Budesonide pMDI|
523806|NCT00206154|Drug|Formoterol Turbuhaler|
523807|NCT00206141|Drug|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
523808|NCT00206128|Drug|Seroquel SR|
523809|NCT00206115|Drug|Seroquel Sustained Release (SR)|
523810|NCT00206115|Drug|Seroquel Immediate Release (IR)|
523811|NCT00206115|Drug|Placebo|
523812|NCT00206102|Drug|quetiapine fumarate|flexible dose oral
523813|NCT00206102|Drug|risperidone|flexible dose oral
523814|NCT00206089|Drug|EXANTA|
523815|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
523816|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil monotherapy
523817|NCT00206063|Drug|EXANTA|
523818|NCT00206050|Drug|Esomeprazole|
523819|NCT00206050|Drug|pantoprazole|
523820|NCT00206037|Device|COLLOSS E|
523821|NCT00206037|Device|TomoFix Plate|
523822|NCT00206024|Drug|Esomeprazole magnesium (Nexium)|
523823|NCT00206011|Procedure|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
523824|NCT00205998|Device|Locking Compression Plate 2,4mm|
523825|NCT00205998|Device|Locking Compression Plate 3,5mm|
523826|NCT00205985|Device|Scaphoid screw|Conservative treatment versus application of scaphoid screw
523827|NCT00205972|Device|Humerus Nail or LC Plate|
523828|NCT00205959|Device|Locking proximal humerus plate|
523829|NCT00205959|Device|Proximal Humerus Internal Locking System|
523830|NCT00205959|Device|Proximal Humerus Nail|
523831|NCT00205946|Drug|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
523832|NCT00205946|Drug|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
523833|NCT00205920|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
523834|NCT00205907|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
523835|NCT00205894|Device|bion microstimulator|
523836|NCT00205881|Device|HiRes 90K Bionic Ear System|Cochlear implant system
523837|NCT00205868|Device|Precision Spinal Cord Stimulation System|Stimulation on throughout study
523838|NCT00205855|Device|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
523839|NCT00205842|Drug|alvimopan|
523840|NCT00205829|Device|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
523841|NCT00205816|Drug|Tigecycline|
523842|NCT00205803|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
523843|NCT00205803|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
523844|NCT00205790|Device|Vascular graft|
523845|NCT00205777|Drug|Bazedoxifene Acetate|BZA 20mg, daily, oral
523846|NCT00205777|Other|Placebo|Placebo, daily, oral
523847|NCT00205764|Drug|Melphalan|
523848|NCT00205751|Drug|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
523849|NCT00205738|Drug|Risperidone, Olanzapine|
523850|NCT00205725|Drug|Ziprasidone, Olanzapine|
523851|NCT00205712|Drug|Ketamine|Ketamine without dexmedetomidine
523852|NCT00205712|Drug|Dexmedetomidine|Ketamine plus dexmedetomidine
523853|NCT00205699|Drug|risperidone|randomized to begin 12 week trial of risperidone
523854|NCT00205699|Drug|olanzapine|randomized to begin 12 week trial of olanzapine
523855|NCT00205699|Drug|aripiprazole|randomized to 12 week trial of aripiprazole
523856|NCT00205686|Drug|DHEA|
523857|NCT00205686|Behavioral|exercise|
523858|NCT00205660|Other|Stayers|Participants remain on their current antipsychotic.
523859|NCT00205660|Other|Switchers|Subjects are randomized to switch to aripiprazole from their current antipsychotic.
523860|NCT00205647|Drug|Oral N-acetycystein (NAC)|
523861|NCT00205634|Drug|Biaxin ( clarithromycin)|
523862|NCT00205621|Device|Positron Emission Tomography|
523863|NCT00205608|Device|Positron Emission Tomography|camera is new
523864|NCT00205595|Device|Positron Emission Tomography|
523865|NCT00205582|Device|Positron Emission Tomography|
523866|NCT00205569|Behavioral|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
523867|NCT00205556|Procedure|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
523868|NCT00205556|Procedure|low flux hemodialysis|standard treatment
523869|NCT00205543|Procedure|uvulopalatopharyngoplasty with or without sutures|standard UPPP
523870|NCT00205530|Behavioral|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
523871|NCT00205517|Procedure|Daily interruption of sedation versus sedation algorithm|
523872|NCT00205504|Drug|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
523873|NCT00205491|Drug|Venlafaxine|
523874|NCT00205478|Drug|VX-702|
523875|NCT00205465|Drug|VX-765|
523876|NCT00205426|Drug|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
523877|NCT00205400|Procedure|medical care delivery model|
523878|NCT00205387|Procedure|cardiac elastography and echocardiography|standard echocardiogram
523879|NCT00205374|Drug|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
523880|NCT00205374|Drug|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
523881|NCT00205335|Device|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
523882|NCT00205335|Device|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
523883|NCT00205322|Drug|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
523884|NCT00205296|Behavioral|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
523885|NCT00205283|Drug|Nelfinavir|
523886|NCT00205270|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
523887|NCT00205244|Behavioral|Healing images, relaxation and distraction materials|
523888|NCT00205231|Drug|etanercept|
523889|NCT00205205|Behavioral|peer mentoring|
523890|NCT00205192|Procedure|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
523891|NCT00205179|Drug|Novasoy|100mg/day soy isoflavones
523892|NCT00205179|Drug|Placebo|100mg/day matching placebo
523893|NCT00205166|Procedure|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
523894|NCT00205166|Drug|Caffeine|Caffeine 400 mg po
523895|NCT00205166|Drug|Caffeine|Caffeine 200 mg po
523896|NCT00205153|Behavioral|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
523897|NCT00205127|Procedure|Cardiac PET imaging- rest and pharmacological stress|
523898|NCT00205114|Behavioral|Individualized multifactorial intervention for community-living high-risk older adults|
523899|NCT00205114|Behavioral|Health professional education program about fall prevention|
523900|NCT00205062|Procedure|PET-CT|
523901|NCT00205049|Drug|pentoxifylline|daily dosing
523902|NCT00205023|Procedure|Sonohysterography|SHG during surgery for endometrial cancer.
523903|NCT00205010|Procedure|Lymphoscintigraphy|
523904|NCT00204997|Procedure|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
523905|NCT00204984|Drug|oral hydralazine and intravenous nesiritide|vasodilators
523906|NCT00204971|Dietary Supplement|Enteral glutamine powder|nutritional supplement
523907|NCT00204971|Other|placebo|placebo control
523908|NCT00204958|Drug|nutritional supplement|
523909|NCT00204958|Drug|glutamine popsicle|
523910|NCT00204945|Drug|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
523911|NCT00204932|Drug|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
523912|NCT00204919|Drug|Vitamin D|once-monthly vitamin D oral capsules (50,000 units)
523913|NCT00204919|Drug|placebo|once-monthly placebo capsules
523914|NCT00204906|Dietary Supplement|vitamin D supplementation|
523915|NCT00204893|Drug|calcium formate|Calcium formate - Each uncoated white tablet will contain 650 mg of calcium formate, (equivalent to 200 mg elemental calcium). Nephro-Tech, LLC, will formulate and provide the calcium formate tablets for the study.
523916|NCT00204867|Other|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
523917|NCT00204854|Behavioral|telephone counseling|
523918|NCT00204802|Behavioral|Patient-Centered Advance Care Planning|
523919|NCT00204789|Drug|Difluoromethylornithine|
523920|NCT00204776|Drug|Capecitabine and Oxaliplatin|
523921|NCT00204763|Device|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
523922|NCT00204763|Device|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
523923|NCT00204750|Procedure|Bougie Dilation|Bougie dilation will be performed as standard
523924|NCT00204750|Procedure|Needle-knife incision|Needle-knife incision will be performed
523925|NCT00204737|Drug|prednisone|20mg x 2 weeks
523926|NCT00204737|Drug|placebo|placebo
523927|NCT00204711|Other|SNAP II EEG System|A portable EEG monitor (SNAP II EEG System, Everest -St. Louis) is unique in that it monitors both low frequency EEG signals (1-40 Hz), which are typically used, and high frequency EEG signals (80-420 Hz), which are not usually used, and calculates a derived EEG parameter (the SNAP Index). The SNAP Index ranges from 100 (completely awake) to 0 (no brain activity) and has been shown in a few studies to correlate with increasing sedation and loss of consciousness in human volunteers and patients receiving general anesthesia during surgery.
523928|NCT00204698|Drug|Aciphex|20 mg of aciphex taken twice daily
523929|NCT00204685|Drug|dornase alfa|
523930|NCT00204672|Drug|Achipex|
523931|NCT00204659|Drug|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
523932|NCT00204646|Drug|Adriamycin|
523933|NCT00204646|Drug|Ifosfamide|
523934|NCT00204646|Drug|Etoposide|
523935|NCT00204646|Drug|Carboplatin|
523936|NCT00204633|Drug|Darbepoetin alfa|
523937|NCT00204620|Drug|Bendamustin|
523938|NCT00204607|Biological|mRNA|
523939|NCT00204607|Drug|GM-CSF s.c.|
523940|NCT00204594|Drug|rM28|
523941|NCT00204594|Drug|autologous PBMCs|
523942|NCT00204581|Drug|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
523943|NCT00204568|Drug|Adriamycin|60 mg/m2, d1, W d22
523944|NCT00204568|Drug|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
523945|NCT00204555|Drug|Imiquimod|
523946|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
523947|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
523948|NCT00204529|Drug|pegylated interferon-alpha-2a|
523949|NCT00204529|Drug|interferon-alpha-2a|
523950|NCT00204516|Biological|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
523951|NCT00204516|Drug|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
523952|NCT00204503|Drug|Depakote ER|
523953|NCT00204490|Dietary Supplement|isoflavones|soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
523954|NCT00204490|Dietary Supplement|carbohydrate|carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
523955|NCT00204477|Dietary Supplement|soy milk|Each drink contained soy protein, fat, and carbohydrates calcium and phosphorous to give a total energy of 177.8 kcal. Subjects took two drinks per day.
523956|NCT00204477|Dietary Supplement|cow's milk|Each drink contained casein, fat, carbohydrates, calcium and phosphorous to give a total energy of 178.6 kcal. Subjects took two drinks per day.
523957|NCT00204464|Procedure|Exercise|
523958|NCT00204451|Drug|0.75 levonorgestrel|
523959|NCT00204451|Drug|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
523960|NCT00204438|Drug|0.15mg desogestrel /0.03mg ethinyl estradiol|
524061|NCT00203515|Device|Standard Latex Foley Catheter|
539921|NCT00002785|Drug|pegaspargase|
523961|NCT00204425|Dietary Supplement|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
523962|NCT00204412|Dietary Supplement|Flax lignan|543 mg SDG per day
523963|NCT00204412|Behavioral|Exercise (walking)|walking 45 minutes per day 5 days per week
523964|NCT00204399|Behavioral|Telephone counseling support|
523965|NCT00204386|Drug|Topiramate|
523966|NCT00204373|Drug|Lansoprazole (Prevacid)|Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
523967|NCT00204347|Drug|risperidone|
523968|NCT00204334|Drug|darbopoeitin|
523969|NCT00204321|Drug|sirolimus (drug), mmf (drug)|
523970|NCT00204308|Drug|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
523971|NCT00204295|Drug|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
523972|NCT00204282|Behavioral|Educational presentation, group discussion, questionnaires|
523973|NCT00204269|Drug|Testosterone Gel Wolff|
523974|NCT00204256|Drug|Iron sucrose|
523975|NCT00204243|Drug|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
523976|NCT00204243|Drug|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
523977|NCT00204230|Drug|mycophenolate mofetil (drug)|
523978|NCT00204217|Device|endotracheal intubation|
523979|NCT00204191|Drug|tacrolimus|
523980|NCT00204178|Behavioral|Oxidative stress in kidney transplant recipients|
523981|NCT00204165|Procedure|MRI of the small bowel|
523982|NCT00204152|Behavioral|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
523983|NCT00204139|Procedure|Routine midtrimester pregnany ultrasound scan|
523984|NCT00204126|Device|Treadmill with partial body weight support|
523985|NCT00204126|Device|Surface Functional Electrical Stimulation|
523986|NCT00204113|Device|Multi-purpose rehabilitation frame|
523987|NCT00204113|Device|Surface Functional Electrical Stimulation|
523988|NCT00204100|Device|Surface Functional Electrical Stimulation|
523989|NCT00204087|Behavioral|Cognitive behavioral therapy (CBT)|
523990|NCT00204087|Behavioral|Supportive Counselling (SC)|
523991|NCT00204074|Drug|17-beta-estradiol (drug)|
523992|NCT00204061|Behavioral|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
523993|NCT00204061|Drug|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
523994|NCT00204048|Behavioral|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
523995|NCT00204035|Behavioral|Evaluation (behavior)|TEACH is a precollege enrichment program for highschool students to encourage and promote these students towards careers in clinical research. To accomplish this, instruments designed to evaluate the knowledge, attitudes, and behaviors are administered during their participation in the TEACH program.
523996|NCT00204022|Drug|Mycophenolate mofetil|Mycophenolate mofetil
523997|NCT00204022|Drug|Azathioprine|Azathioprine
523998|NCT00204009|Behavioral|Disease Surveillance, Family Studies, Questionnaire Followup|
523999|NCT00203996|Device|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
524000|NCT00203996|Drug|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
524001|NCT00203996|Drug|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
524002|NCT00203996|Procedure|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
524003|NCT00203996|Procedure|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
524004|NCT00203970|Behavioral|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
524005|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
524006|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
524007|NCT00203944|Behavioral|Behavioral, Development|
524008|NCT00203931|Drug|Cetuximab|
524009|NCT00203931|Drug|Pemetrexed|
539922|NCT00002785|Drug|prednisone|
524010|NCT00203918|Behavioral|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
524011|NCT00203918|Behavioral|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
524012|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
524013|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
524014|NCT00203892|Biological|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
524015|NCT00203892|Biological|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
524016|NCT00203892|Biological|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
524017|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
524018|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
524019|NCT00203866|Drug|G250 peptide|
524020|NCT00203866|Drug|IL-2|
524021|NCT00203853|Device|pillbox, wristwatch|
524022|NCT00203814|Drug|Sulfadoxine-pyrimethamine|
524023|NCT00203814|Drug|Artesunate plus sulfadoxine-pyrimethamine|
524024|NCT00203801|Drug|Sulfadoxine-pyrimethamine|
524025|NCT00203801|Drug|Artesunate plus sulfadoxine-pyrimethamine|
524026|NCT00203801|Drug|Artemether-lumefantrine|
524027|NCT00203788|Behavioral|Individual Placement and Support|Supported education/employment
524028|NCT00203788|Behavioral|Workplace Fundamentals Module|Group skills training on job/school topics
524029|NCT00203788|Behavioral|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
524030|NCT00203788|Drug|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
524031|NCT00203788|Behavioral|Skills training group|Group social skills training that did not focus primarily on work situations
524032|NCT00203775|Drug|risperidone|
524033|NCT00203762|Behavioral|Public sector antiretroviral treatment programmes|
524034|NCT00203749|Behavioral|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.~EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.~POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
524035|NCT00203749|Behavioral|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
524036|NCT00203736|Drug|Sulfadoxine-pyrimethamine|
524037|NCT00203736|Drug|Artesunate plus sulfadoxine-pyrimethamine|
524038|NCT00203723|Drug|Risperidone|
524039|NCT00203710|Device|Concentric Retriever Device|
524040|NCT00203697|Drug|minocycline|
524041|NCT00203684|Drug|Flunisolide-HFA|
524042|NCT00203658|Drug|Tinzaparin sodium|
524043|NCT00203645|Behavioral|Self-help treatment|"Workbook Becoming a Winner,"
524044|NCT00203632|Drug|rosiglitazone/placebo|
524045|NCT00203619|Device|Wireless capsule endoscopy|wire less capsule endoscopy
524046|NCT00203619|Other|standard care|standard diagnostic evaluation as decided by treating physician
524047|NCT00203606|Drug|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
524048|NCT00203593|Behavioral|Exercise|
524049|NCT00203593|Device|Blood volume|
524050|NCT00203593|Procedure|VO2max test|
524051|NCT00203593|Procedure|Lower body negative pressure|
524052|NCT00203593|Behavioral|Heart Rate|
524053|NCT00203593|Procedure|Blood Pressure|
524054|NCT00203593|Behavioral|Total Peripheral Resistance|
524055|NCT00203580|Drug|Tinzaparin sodium|
524056|NCT00203567|Drug|carbamazepine ER|Active study drug, no comparator
524057|NCT00203554|Genetic|Poly methylmetacrylate, PMMA|
524058|NCT00203541|Device|TELFA™ A.M.D. Island dressing|
524059|NCT00203528|Drug|divalproex sodium ER|
524060|NCT00203528|Drug|risperidone|
540077|NCT00084838|Drug|etoposide|
524062|NCT00203515|Device|Silver Coated Latex Foley Catheter|
524063|NCT00203502|Drug|Bevacizumab|IV 15mg/kg 21 days
524064|NCT00203502|Drug|Cyclophosphamide|500mg per meter squared, IV every 21 days
524065|NCT00203502|Drug|Docetaxel|60 mg per meter squared, IV every 21 days
524066|NCT00203489|Device|KERLIX A.M.D. Gauze|
524067|NCT00203476|Drug|Niacin|
524068|NCT00203476|Drug|Colestipol|
524069|NCT00203476|Drug|Ezetimibe|
524070|NCT00203463|Drug|topiramate|
524071|NCT00203450|Drug|Zonegran|zonisamide
524072|NCT00203450|Drug|Placebo|Placebo pill
524073|NCT00203424|Drug|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
524074|NCT00203411|Drug|Capecitabine (Xeloda)|1000mg/m^2 administered orally twice daily for two weeks followed by one week rest period
524075|NCT00203411|Drug|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
524076|NCT00203385|Drug|Divalproex|Depakote up to 2000mg/d
524077|NCT00203372|Drug|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
524078|NCT00203372|Drug|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
524079|NCT00203372|Drug|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
524080|NCT00203372|Drug|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
524081|NCT00203359|Drug|etanercept given by perispinal administration|
524082|NCT00203346|Procedure|Greater Occipital Nerve Block|
524083|NCT00203333|Device|Medtronic REVEAL|
524084|NCT00203320|Drug|etanercept given by perispinal administration|
524085|NCT00203307|Drug|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
524086|NCT00203307|Drug|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
524087|NCT00203294|Drug|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
524088|NCT00203294|Drug|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
524089|NCT00203281|Drug|tacrolimus|
524090|NCT00203281|Drug|mycophenolate mofetil|
524091|NCT00203281|Drug|daclizumab|
524092|NCT00203281|Drug|intravenous immune globulin|
524093|NCT00203281|Procedure|plasmapheresis|
524094|NCT00203268|Drug|dihydroergotamine mesylate|1.0 mg. intramuscularly
524095|NCT00203255|Drug|Soy Isoflavones|
524096|NCT00203242|Drug|Depacon IV and Depakote ER|
524097|NCT00203229|Drug|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
524098|NCT00203229|Drug|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
524099|NCT00203216|Drug|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
524100|NCT00203216|Procedure|Transcranial Magnetic Stimulation|
524101|NCT00203203|Device|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
524102|NCT00203203|Other|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
524103|NCT00203190|Drug|Topiramate|
524104|NCT00203177|Drug|rasagiline mesylate|0.5 rasagiline mesylate
524105|NCT00203177|Drug|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
524106|NCT00203164|Drug|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
524107|NCT00203151|Drug|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
524108|NCT00203138|Drug|rasagiline mesylate|
524109|NCT00203125|Drug|rasagiline mesylate|0.5 or 1 mg oral, once-daily
524110|NCT00203125|Other|tyramine|50 mg once daily
524111|NCT00203112|Drug|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
524112|NCT00203112|Drug|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
524113|NCT00203099|Drug|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
524114|NCT00203073|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
524115|NCT00203073|Drug|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
524116|NCT00203060|Drug|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
524117|NCT00203060|Drug|placebo|tablet, once daily, 58 weeks
524118|NCT00203047|Drug|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
524119|NCT00203047|Drug|Placebo|Placebo for prednisone given daily
524120|NCT00203047|Drug|Prednisone|Prednisone 1250 mg taken daily
524121|NCT00203034|Drug|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
524122|NCT00203034|Drug|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
524123|NCT00203034|Other|Placebo|oral placebo once daily
524124|NCT00203021|Drug|Glatiramer acetate|Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
524125|NCT00202995|Drug|Glatiramer Acetate|20 mg s.c. daily
524126|NCT00202995|Drug|Betaseron|250 mg every other day
524127|NCT00202995|Drug|Rebif|44 ug 3 times a week
524128|NCT00202982|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
524129|NCT00202982|Drug|glatiramer acetate 40 mg|glatiramer acetate 40 mg
524130|NCT00202969|Drug|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
524131|NCT00202969|Drug|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
524132|NCT00202969|Drug|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
524133|NCT00202956|Drug|Bugusan|
524134|NCT00202943|Procedure|TCRFVR and LAUP|
524135|NCT00202930|Drug|anti-CD20 (Rituximab)|
524136|NCT00202917|Drug|Fludarabine|
524137|NCT00202917|Drug|Thiotepa|
524138|NCT00202917|Drug|Melphalan|
524139|NCT00202917|Drug|OKT-3|
524140|NCT00202917|Procedure|CD3/CD19 depletion on CliniMACS|
524141|NCT00202904|Drug|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
524142|NCT00202904|Drug|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
524143|NCT00202891|Drug|sisomicin|
524144|NCT00202878|Drug|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
524145|NCT00202878|Drug|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
524146|NCT00202878|Drug|Placebo for simvastatin 40 mg|one or two tablets orally daily
524147|NCT00202878|Drug|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
524148|NCT00202865|Biological|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
524149|NCT00202865|Biological|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
524150|NCT00202852|Other|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
524151|NCT00202852|Drug|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
524152|NCT00202852|Biological|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
524153|NCT00202852|Drug|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
524154|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
524155|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
524156|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
524157|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
524158|NCT00202826|Procedure|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
524159|NCT00202813|Device|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
524160|NCT00202800|Drug|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
524161|NCT00202787|Drug|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);~FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
524162|NCT00202787|Drug|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
524163|NCT00202774|Drug|(capecitabine, oxaliplatin, 5-fluorouracil)|
524164|NCT00202761|Behavioral|PIH|Intensified training
524165|NCT00202748|Behavioral|Increase in activity to control weight|
524166|NCT00202748|Behavioral|Increase in activity to control weight.|
524167|NCT00202735|Procedure|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
524378|NCT00200694|Drug|ramipril 10 mg + valsartan 160 mg/day,|
524168|NCT00202735|Procedure|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
524169|NCT00202722|Drug|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
524170|NCT00202709|Behavioral|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
524171|NCT00202696|Drug|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
524172|NCT00202696|Other|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
524173|NCT00202657|Procedure|echocardiography|
524174|NCT00202644|Drug|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
524175|NCT00202644|Drug|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
524176|NCT00202631|Device|Surface Functional Electrical Stimulation|
524177|NCT00202618|Drug|Valsartan|
524178|NCT00202618|Drug|Amlodipine|
524179|NCT00202605|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
524180|NCT00202592|Drug|Perindopril|
524181|NCT00202579|Drug|Ivabradine|
524182|NCT00202566|Drug|Ivabradine|
524183|NCT00202553|Drug|Perindopril|
524184|NCT00202540|Drug|S18986|
524185|NCT00202527|Device|Nasal continuos positive airway pressure|
524186|NCT00202514|Drug|divalproex sodium extended release|
524187|NCT00202501|Device|Nasal CPAP (Continuous Positive Airway Pressure)|
524188|NCT00202488|Drug|H. pylori treatment|
524189|NCT00202475|Procedure|eythrocytapheresis|machinal collection of erythrocytes
524190|NCT00202475|Procedure|whole blood collection|collection of whole blood
524191|NCT00202462|Drug|Testosterone gel|Testosterone gel 7.5 gm qd
524192|NCT00202449|Drug|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
524193|NCT00202449|Drug|paroxetine|20 mg taken at 10a for duration of the study
524194|NCT00202449|Drug|Placebo|Placebo
524195|NCT00202436|Procedure|Phlebotomy|Removal of 500 ml whole blood
524196|NCT00202436|Procedure|Erythrocytapheresis|machinal removal of erythrocytes
524197|NCT00202423|Drug|Sativex|
524198|NCT00202410|Biological|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
524199|NCT00202410|Other|placebo|subcutaneous administration of physiologic solution
524200|NCT00202397|Drug|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
524201|NCT00202397|Other|placebo|capsule-shaped tablet bid for 8 weeks
524202|NCT00202371|Procedure|Red Blood Cell transfusion|
524203|NCT00202358|Drug|atenolol|
524204|NCT00202358|Drug|placebo|
524205|NCT00202345|Drug|Iron sucrose|
524206|NCT00202332|Procedure|Coronary artery bypass|
524207|NCT00202319|Procedure|Sedation management protocol|
524208|NCT00202306|Drug|lithium carbonate|
524209|NCT00202293|Drug|Olanzapine|
524210|NCT00202293|Drug|Lithium|
524211|NCT00202293|Drug|Chlorpromazine|
524212|NCT00202280|Drug|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
524213|NCT00202267|Device|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
524214|NCT00202267|Device|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
524215|NCT00202254|Behavioral|Physiotherapy|
524216|NCT00202254|Behavioral|Occupational therapy|
524217|NCT00202254|Behavioral|Speech pathology|
524218|NCT00202241|Procedure|testosterone injection|
524219|NCT00202228|Drug|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
524220|NCT00202215|Behavioral|Chrysalis Day Program|
524221|NCT00202202|Procedure|consultation format|
524222|NCT00202189|Drug|Budesonide|Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
524223|NCT00202176|Drug|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
524224|NCT00202163|Drug|DHEA|
524225|NCT00202163|Drug|Testosterone|
524226|NCT00202150|Behavioral|Application of a management action plan|
524227|NCT00202137|Behavioral|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
524228|NCT00202137|Behavioral|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
524229|NCT00202124|Drug|Tryptophan|
524230|NCT00202111|Procedure|Laparoscopic-assisted colectomy|
524231|NCT00202111|Procedure|Conventional open colectomy|
524232|NCT00202098|Procedure|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
524233|NCT00202059|Drug|Zoledronic acid|
524234|NCT00202059|Behavioral|Physical activity intervention|
524281|NCT00201721|Drug|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
524235|NCT00202033|Behavioral|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
524236|NCT00202020|Drug|Cilostazol 200mg/day Oral|
524237|NCT00202020|Drug|Aspirin 100mg/day Oral|
524238|NCT00202007|Drug|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
524239|NCT00202007|Drug|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
524240|NCT00201994|Drug|Tolvaptan|
524241|NCT00201981|Drug|Rebamipide|"OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
524242|NCT00201968|Device|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
524243|NCT00201968|Device|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
524244|NCT00201968|Other|Conventional Exercise|An aerobic and resistance training program.
524245|NCT00201955|Drug|Rebamipide|
524246|NCT00201942|Procedure|PET scan|
524247|NCT00201929|Procedure|Standard Decision Board|
524248|NCT00201929|Procedure|Computer Decision Board|
524249|NCT00201929|Procedure|Paper Decision Board|
524250|NCT00201916|Procedure|5250 cGy/20 fractions over 28 days|see above
524251|NCT00201916|Procedure|6600 cGy/33 fractions over 45 days|see above
524252|NCT00201890|Procedure|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
524253|NCT00201877|Drug|Velcade|"Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 & 14.~Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23."
524254|NCT00201877|Drug|Rituximab|"Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.~Maintenance: 375 mg/m2 day 1 weekly x 4 weeks."
524255|NCT00201864|Drug|Exemestane|25 mg orally per day
524256|NCT00201864|Drug|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
524257|NCT00201851|Drug|Tamoxifen|20 mg po daily x 5 years
524258|NCT00201851|Procedure|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
524259|NCT00201838|Drug|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
524260|NCT00201838|Drug|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
524261|NCT00201825|Drug|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
524262|NCT00201825|Drug|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
524263|NCT00201812|Drug|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
524264|NCT00201812|Drug|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
524265|NCT00201812|Drug|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
524266|NCT00201799|Drug|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
524267|NCT00201786|Drug|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
524268|NCT00201773|Drug|Exemestane|25 mg orally once per day for 16 weeks.
524269|NCT00201773|Drug|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
524270|NCT00201773|Other|Correlative studies|
524271|NCT00201760|Drug|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
524272|NCT00201760|Drug|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
524273|NCT00201760|Drug|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
524274|NCT00201747|Drug|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
524275|NCT00201747|Drug|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
524276|NCT00201734|Drug|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
524277|NCT00201734|Drug|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
524278|NCT00201734|Drug|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
524279|NCT00201721|Drug|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
524280|NCT00201721|Drug|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
524372|NCT00200759|Drug|Cranberry juice and capsules|
524282|NCT00201708|Drug|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
524283|NCT00201708|Drug|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
524284|NCT00201708|Drug|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
524285|NCT00201695|Drug|Doxil®|40 mg/m2 IV day 1
524286|NCT00201695|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
524287|NCT00201695|Drug|Dexamethasone|40 mg PO days 1-4
524288|NCT00201695|Drug|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
524289|NCT00201682|Drug|Etanercept|25 mg SQ twice weekly weeks 1-5
524290|NCT00201682|Drug|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
524291|NCT00201669|Drug|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
524292|NCT00201656|Procedure|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
524293|NCT00201656|Procedure|Removal of Cerclage|Immediate removal of Cerclage following randomization
524294|NCT00201656|Procedure|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
524295|NCT00201643|Drug|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
524296|NCT00201643|Drug|Placebo|Course of Placebo (NS)
524297|NCT00201630|Drug|Uroxatrol (drug)|
524298|NCT00201617|Device|Bone-anchored hearing aid|
524299|NCT00201591|Behavioral|Exercise training for 10 weeks|
524300|NCT00201552|Drug|Statin|
524301|NCT00201539|Drug|single dose Morphine|
524302|NCT00201539|Drug|double dose Morphine|
524303|NCT00201539|Drug|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
524304|NCT00201513|Behavioral|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
524305|NCT00201513|Behavioral|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
524306|NCT00201513|Behavioral|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
524307|NCT00201461|Device|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
524308|NCT00201461|Drug|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
524309|NCT00201448|Biological|Hepatitis A Vaccine|Single dose give IM
524310|NCT00201448|Biological|Towne CMV Vaccine|Single dose given subcutaneously
524311|NCT00201435|Drug|Paclitaxel weekly in combination with capecitabine|
524312|NCT00201435|Drug|Docetaxel every 3 week in combination with capecitabine|
524313|NCT00201422|Other|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
524314|NCT00201409|Drug|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
524315|NCT00201409|Drug|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
524316|NCT00201396|Radiation|CCRT|Radiation with weekly Cisplatin
524317|NCT00201396|Drug|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
524318|NCT00201383|Drug|cisplatin|
524319|NCT00201357|Drug|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
524320|NCT00201344|Drug|Cisplatin,5-FU,Leucovorin|
524321|NCT00201331|Drug|leucovorin+5-FU|
524322|NCT00201318|Drug|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
524323|NCT00201305|Drug|Gemcitabine+5FU+Leucovorin|
524324|NCT00201279|Drug|13-cis Retino Acid|
524325|NCT00201266|Procedure|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
524326|NCT00201253|Other|Bronchoalveolar lavages and venipunctures only|
524327|NCT00201240|Biological|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ >5 x 10*6/kg and CD3+ < 1 x 10*5/kg
524328|NCT00201227|Other|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
524329|NCT00201214|Drug|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
524330|NCT00201201|Other|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
524331|NCT00201201|Other|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
524332|NCT00201188|Behavioral|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
524333|NCT00201162|Dietary Supplement|Soy|Dietary supplement of isolated soy protein containing isoflavones
524334|NCT00201162|Dietary Supplement|Placebo|dietary supplement casein placebo
524373|NCT00200746|Drug|Arginine|Amino Acid Arginine
524374|NCT00200720|Behavioral|Atkins diet (low carbohydrate diet)|
524375|NCT00200720|Behavioral|DASH diet (high carbohydrate diet)|
524376|NCT00200707|Procedure|Intracoronary injection of autologous bone marrow mononuclear cells|
524377|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day,|
524335|NCT00201149|Behavioral|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
524336|NCT00201136|Behavioral|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
524337|NCT00201136|Behavioral|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
524338|NCT00201123|Drug|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
524339|NCT00201123|Drug|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
524340|NCT00201123|Other|Placebo|
524341|NCT00201110|Behavioral|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
524342|NCT00201110|Behavioral|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
524343|NCT00201084|Behavioral|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
524344|NCT00201058|Behavioral|Tailored Web-based Asthma Management|Web-based asthma management
524345|NCT00201058|Behavioral|Generic web-based asthma education|4 computer sessions over a period of 180 days
524346|NCT00201045|Other|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
524347|NCT00201019|Behavioral|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
524348|NCT00201006|Behavioral|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
524349|NCT00201006|Behavioral|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
524350|NCT00201006|Other|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
524351|NCT00200993|Behavioral|physical activity|
524352|NCT00200967|Drug|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
524353|NCT00200967|Drug|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
524354|NCT00200954|Dietary Supplement|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
524355|NCT00200954|Dietary Supplement|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
524356|NCT00200941|Drug|Topiramate|
524357|NCT00200928|Biological|BCG|
524358|NCT00200902|Drug|Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
524359|NCT00200902|Other|Placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
524360|NCT00200902|Behavioral|Interpersonal Clinical Interaction (ICI)|Interaction with and assessment by clinical research personnel on a fixed schedule, with the pharmacotherapeutic alliance assessed both by research personnel and subjects.
524361|NCT00200889|Device|active auricular tVNS|non-painful active auricular tVNS will be delivered to the left ear
524362|NCT00200889|Device|inactive auricular tVNS|non-painful inactive auricular tVNS will be delivered to the left ear
524363|NCT00200876|Procedure|Hypertonic saline|To elicit pain
524364|NCT00200876|Procedure|Isotonic saline|Non-painful control
524365|NCT00200863|Device|Monochromatic visible light exposure|Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
524366|NCT00200850|Biological|House Dust Mite SLIT|low dose SLIT 143 Allergen Units(AU)/ml daily
524367|NCT00200850|Biological|High dose SLIT|House Dust Mite SLIT- 10,000 Allergen units(AU)/ml daily
524368|NCT00200850|Biological|Placebo SLIT|Placebo SLIT daily
524369|NCT00200824|Drug|Soy Isoflavone Nutritional Supplements|
524370|NCT00200785|Dietary Supplement|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
524371|NCT00200785|Dietary Supplement|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
524379|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
524380|NCT00200681|Drug|Velcade|
524381|NCT00200668|Drug|FDG = fluorodeoxyglucose|
524382|NCT00200655|Drug|Pravastatin|
524383|NCT00200655|Drug|Placebo|
524384|NCT00200642|Device|Stretta® System|
524385|NCT00200629|Procedure|Adenosine SPECT myocardial perfusion imaging|
524386|NCT00200629|Procedure|Combined adenosine / exercise SPECT myocardial perfusion imaging|
524387|NCT00200616|Procedure|Antimicrobial prophylaxis|
524388|NCT00200603|Device|calcium phosphate macroporous bioceramics|
524389|NCT00200590|Drug|acetaminophen and nalbuphine|
524390|NCT00200590|Drug|acetaminophen and morphine|
524391|NCT00200590|Drug|acetaminophen and reduced dosage of prostaglandin|
524392|NCT00200577|Drug|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
524393|NCT00200564|Drug|ketamine|
524394|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
524395|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
524396|NCT00200538|Drug|memantine|
524397|NCT00200525|Drug|apomorphine HCl injection|
524398|NCT00200512|Drug|apomorphine HCl injection|
524399|NCT00200499|Drug|Nebivolol|
524400|NCT00200473|Drug|Nebivolol|
524401|NCT00200460|Drug|Nebivolol|
524402|NCT00200447|Drug|carbidopa/l-dopa|
524403|NCT00200447|Drug|carbidopa/l-dopa/entacapone|
524404|NCT00200447|Drug|Stalevo|
524405|NCT00200447|Procedure|[123I]-IBZM imaging|
524406|NCT00200434|Drug|Nebivolol|
524407|NCT00200421|Drug|Nebivolol and Atenolol|
524408|NCT00200395|Drug|Erlotinib (drug)|
524409|NCT00200382|Drug|PS-341 (Velcade-drug)|
524410|NCT00200369|Device|MEMS cap|
524411|NCT00200356|Drug|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
524412|NCT00200356|Drug|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
524413|NCT00200343|Drug|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
524414|NCT00200343|Drug|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
524415|NCT00200343|Drug|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
524416|NCT00200330|Behavioral|Behavioral weight loss treatment|
524417|NCT00200330|Behavioral|Behavioral and home environment weight loss treatment|
524418|NCT00200317|Behavioral|Internet and print-based interventions|
524419|NCT00200304|Behavioral|Internet weight loss with SlimFast and human counseling|
524420|NCT00200304|Behavioral|Internet weight loss with SlimFast and computer counseling|
524421|NCT00200304|Behavioral|Internet weight loss program with SlimFast|
524422|NCT00200291|Behavioral|hypocaloric, low-fat diet|hypocaloric, low-fat diet
524423|NCT00200278|Behavioral|PROJECT STRIDE|
524424|NCT00200265|Behavioral|diet|diet
524425|NCT00200252|Drug|oxytocin|
524426|NCT00200239|Behavioral|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
524427|NCT00200226|Drug|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
524428|NCT00200226|Drug|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
524429|NCT00200213|Behavioral|portion or unportioned food|
524430|NCT00200200|Drug|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
524431|NCT00200200|Drug|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
524432|NCT00200187|Procedure|low venous pressure general anesthesia|
524433|NCT00200187|Procedure|combined spinal-epidural anesthesia|
524434|NCT00200174|Drug|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
524435|NCT00200174|Drug|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
524436|NCT00200161|Drug|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
524437|NCT00200161|Drug|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
524466|NCT00199823|Genetic|Intracoronary aotologous stem cell transplantation|
524558|NCT00199082|Procedure|Irradiation (in specific conditions)|
524559|NCT00199069|Drug|Asparaginase|
524560|NCT00199069|Drug|Vincristine|
524561|NCT00199069|Drug|Daunorubicin, Adriamycin|
524562|NCT00199069|Drug|Cyclophosphamide|
524438|NCT00200148|Procedure|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
524439|NCT00200148|Procedure|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
524440|NCT00200122|Device|Spinal Cord Stimulation|
524441|NCT00200109|Device|Occipital Nerve Stimulation|Each group had a different plan
524442|NCT00200096|Procedure|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.~On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
524443|NCT00200096|Procedure|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.~Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
524444|NCT00200083|Device|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
524445|NCT00200070|Device|Spinal Cord Stimulation|
524446|NCT00200057|Device|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
524447|NCT00200044|Device|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score >15.
524448|NCT00200031|Device|Interstim therapy|
524449|NCT00200018|Device|Enterra Therapy System (H9900014)|
524450|NCT00200005|Device|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
524451|NCT00199992|Procedure|application of autologous platelet gel|
524452|NCT00199979|Drug|Nevirapine|
524453|NCT00199966|Drug|Divalproex sodium extended release|
524454|NCT00199953|Drug|Rabeprazole 20 mg twice a day for 90-day period treatment|
524455|NCT00199940|Drug|Ziprasidone|
524456|NCT00199927|Drug|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
524457|NCT00199927|Drug|standard therapy|standard therapy
524458|NCT00199914|Device|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
524459|NCT00199901|Biological|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.~Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
524460|NCT00199901|Biological|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® alone.~Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
524461|NCT00199888|Drug|124-Iodine-cG250 (124I-cG250)|
524462|NCT00199875|Drug|Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)|Patients received a single infusion of ^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
524463|NCT00199862|Drug|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
524464|NCT00199849|Biological|NY-ESO-1 plasmid DNA Cancer Vaccine|
524465|NCT00199836|Biological|NY-ESO-1b peptide plus CpG 7909 and Montanide ISA-51|
524467|NCT00199797|Drug|huA33 antibody plus chemotherapy|"huA33 will be administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2. Every second week, Oxaliplatin, 5-FU and Leucovorin are administered additionally. Oxaliplatin and Leucovorin will be given as an infusion over 2 hours. Afterwards patients will receive an bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.~The doses of Oxaliplatin will be 85mg/m2, Leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus infusion and 600mg/m2 as an continuous infusion. A complete treatment cycle consists of 12 weekly treatment days."
524468|NCT00199784|Drug|Phenylephrine|
524469|NCT00199771|Drug|7.5% NaCl in 6% dextran 70 solution|
524470|NCT00199758|Drug|cisplatin|
524471|NCT00199758|Drug|Gemcitabine|
524472|NCT00199758|Drug|Taxol|
524473|NCT00199745|Drug|atorvastatin|
524474|NCT00199719|Drug|Ribavirine|
524475|NCT00199706|Drug|7.2% NaCl in 6% hydroxyethyl starch solution|
524476|NCT00199680|Procedure|PET|
524477|NCT00199667|Drug|Mycophenolate Mofetil|
524478|NCT00199654|Procedure|PET|
524479|NCT00199641|Device|enteral nutrition|
524480|NCT00199615|Procedure|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
524481|NCT00199602|Drug|warfarine - low molecular heparin|
524482|NCT00199589|Drug|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
524483|NCT00199576|Drug|Methylprednisolone|
524484|NCT00199563|Drug|Viagra|Sildenafil 100mg daily for 12 weeks
524485|NCT00199550|Procedure|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
524486|NCT00199550|Procedure|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
524487|NCT00199524|Device|Navigator Ureteral Access Sheath|ureteral access sheath
524488|NCT00199511|Drug|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
524489|NCT00199498|Device|Apical RV lead placement|RV lead implanted ( according to randomization )at the apex
524490|NCT00199498|Device|Septal RV lead placement|RV lead is implanted (according to randomization), on septum
524491|NCT00199485|Drug|Angelica Sinensis|Angelica Sinensis / placebo
524492|NCT00199472|Procedure|Dynamic Contrast Enhanced CT & Diuretic Renogram|
524493|NCT00199446|Drug|Istradefylline (KW-6002)|
524494|NCT00199433|Drug|Istradefylline (KW-6002)|
524495|NCT00199420|Drug|Istradefylline (KW-6002)|
524496|NCT00199407|Drug|Istradefylline (KW-6002)|
524497|NCT00199394|Drug|Istradefylline (KW-6002)|
524498|NCT00199381|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
524499|NCT00199368|Drug|Istradefylline ( KW-6002)|
524500|NCT00199355|Drug|Istradefylline (KW-6002)|
524501|NCT00199342|Drug|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
524502|NCT00199329|Drug|ondansetron adding in PCA|
524503|NCT00199316|Drug|spinal morphine|
524504|NCT00199303|Drug|pre-operatively followed by 30 mg three times per day after surgery|
524505|NCT00199290|Drug|Trafermin (genetical recombination)|
524506|NCT00199277|Drug|i.v. iron sucrose|
524507|NCT00199277|Drug|Oral iron|
524508|NCT00199264|Drug|Albaconazole oral solution|
524509|NCT00199251|Drug|RUPATADINE|
524510|NCT00199238|Drug|RUPATADINE (ANTI-HISTAMINE)|
524511|NCT00199225|Drug|Rupatadine|
524512|NCT00199225|Drug|moxifloxacin|
524513|NCT00199225|Procedure|Continous electrocardiographic register|
524514|NCT00199225|Procedure|Pharmacokinetic profile|
524515|NCT00199212|Drug|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
524516|NCT00199186|Drug|imatinib|
524517|NCT00199186|Drug|vincristine|
524518|NCT00199186|Drug|cyclophosphamide|
524519|NCT00199186|Drug|cytosine arabinoside|
524520|NCT00199186|Drug|dexamethasone|
524521|NCT00199186|Drug|idarubicin|
524522|NCT00199186|Drug|methotrexate (intrathecal)|
524523|NCT00199186|Drug|AraC (intrathecal)|
524524|NCT00199186|Drug|dexamethasone (intrathecal)|
524525|NCT00199173|Device|SIR Spheres intra-arterial hepatic|
524526|NCT00199160|Drug|BAY 43-9006|
524527|NCT00199147|Drug|Cytarabine|
524528|NCT00199147|Drug|Etoposide|
524529|NCT00199147|Drug|Idarubicin|
524530|NCT00199147|Drug|G-CSF|
524531|NCT00199147|Drug|Fludarabine|
524532|NCT00199147|Procedure|Stem cell apheresis|
524533|NCT00199147|Procedure|Stem cell transplantation|
524534|NCT00199134|Drug|Letrozole|Size of the tumor is followed
524535|NCT00199121|Drug|Zidovudine (drug)|
524536|NCT00199108|Drug|Depocyt|
524537|NCT00199108|Drug|Dexamethasone|
524538|NCT00199095|Drug|Adriamycin|
524539|NCT00199095|Drug|Cyclophosphamide|
524540|NCT00199095|Drug|Cytarabine|
524541|NCT00199095|Drug|Dexamethasone|
524542|NCT00199095|Drug|Idarubicin|
524543|NCT00199095|Drug|Ifosfamide|
524544|NCT00199095|Drug|Methotrexate|
524545|NCT00199095|Drug|Mercaptopurine|
524546|NCT00199095|Drug|VM26|
524547|NCT00199095|Drug|Vincristine|
524548|NCT00199082|Drug|Adriamycin|
524549|NCT00199082|Drug|Cyclophosphamide|
524550|NCT00199082|Drug|Cytarabine|
524551|NCT00199082|Drug|Dexamethasone/Prednisolone|
524552|NCT00199082|Drug|VP16|
524553|NCT00199082|Drug|Ifosfamide|
524554|NCT00199082|Drug|Methotrexate|
524555|NCT00199082|Drug|G-CSF|
524556|NCT00199082|Drug|Rituximab|
524557|NCT00199082|Drug|Vincristine/Vindesine|
524570|NCT00199069|Drug|Dexamethasone / Prednisolone|
524571|NCT00199069|Procedure|CNS Irradiation|
524572|NCT00199069|Procedure|Mediastinal Irradiation|
524573|NCT00199069|Procedure|Stem Cell Transplantation|
524574|NCT00199056|Drug|Dexamethasone / Prednisolone|
524575|NCT00199056|Drug|Cyclophosphamide|
524576|NCT00199056|Drug|Methotrexate|
524577|NCT00199056|Drug|Vincristine / Vindesine|
524578|NCT00199056|Drug|Daunorubicin|
524579|NCT00199056|Drug|Asparaginase|
524580|NCT00199056|Drug|G-CSF|
524581|NCT00199056|Drug|Cytarabine|
524582|NCT00199056|Drug|6-Mercaptopurine|
524583|NCT00199056|Drug|VP16|
524584|NCT00199056|Drug|Adriamycin|
524585|NCT00199056|Drug|Thioguanine|
524586|NCT00199056|Drug|VM26|
524587|NCT00199056|Drug|Idarubicin|
524588|NCT00199056|Drug|Fludarabine|
524589|NCT00199056|Drug|Ifosfamide|
524590|NCT00199056|Procedure|CNS irradiation|
524591|NCT00199056|Procedure|Mediastinal irradiation (if residual tumor)|
524592|NCT00199056|Procedure|stem cell transplantation|
524593|NCT00199043|Drug|Allopurinol|
524594|NCT00199043|Drug|Rasburicase|
524595|NCT00199030|Drug|Alemtuzumab (MabCampath)|
524596|NCT00199030|Drug|Cladribine|
524597|NCT00199017|Drug|Dexamethasone/Prednisolone|
524598|NCT00199017|Drug|Cyclophosphamide|
524599|NCT00199017|Drug|Vincristine|
524600|NCT00199017|Drug|Daunorubicin|
524601|NCT00199017|Drug|Asparaginase|
524602|NCT00199017|Drug|G-CSF|
524603|NCT00199017|Drug|Mercaptopurine|
524604|NCT00199017|Drug|Cytarabine|
524605|NCT00199017|Drug|Methotrexate|
524606|NCT00199017|Drug|VP16|
524607|NCT00199017|Drug|Vindesine|
524608|NCT00199017|Drug|Adriamycin|
524609|NCT00199017|Drug|Thioguanine|
524610|NCT00199017|Drug|HDARAC|
524611|NCT00199017|Procedure|CNS irradiation|
524612|NCT00199017|Procedure|Mediastinal irradiation|
524613|NCT00199017|Drug|Cladribine|
524614|NCT00199004|Drug|Cyclophosphamide|
524615|NCT00199004|Drug|Dexamethasone / Prednisolone|
524616|NCT00199004|Drug|Vincristine|
524617|NCT00199004|Drug|Daunorubicin|
524618|NCT00199004|Drug|Asparaginase|
524619|NCT00199004|Drug|Methotrexate|
524620|NCT00199004|Drug|Cytarabine|
524621|NCT00199004|Drug|Mercaptopurine|
524622|NCT00199004|Drug|G-CSF|
524623|NCT00199004|Drug|Vindesine|
524624|NCT00199004|Drug|VP16|
524625|NCT00199004|Drug|Adriamycin|
524626|NCT00199004|Drug|Thioguanine|
524627|NCT00199004|Drug|VM26|
524628|NCT00199004|Drug|Rituximab|
524629|NCT00199004|Procedure|CNS irradiation|
524630|NCT00199004|Procedure|Mediastinal irradiation (if residual TU)|
524631|NCT00199004|Procedure|Stem cell transplantation|
524632|NCT00198991|Drug|Cyclophosphamide|
524633|NCT00198991|Drug|Dexamethasone|
524634|NCT00198991|Drug|Vincristine|
524635|NCT00198991|Drug|daunorubicin|
524636|NCT00198991|Drug|Asparaginase|
524637|NCT00198991|Drug|Methotrexate|
524638|NCT00198991|Drug|Cytarabine|
524639|NCT00198991|Drug|Mercaptopurine|
524640|NCT00198991|Drug|G-CSF|
524641|NCT00198991|Drug|Vindesine|
524642|NCT00198991|Drug|VP16|
524643|NCT00198991|Drug|Prednisolone|
524644|NCT00198991|Drug|Adriamycin|
524645|NCT00198991|Drug|Thioguanine|
524646|NCT00198991|Drug|VM26|
524647|NCT00198991|Procedure|CNS irradiation|
524648|NCT00198991|Procedure|Mediastinal Irradiation|
524649|NCT00198991|Procedure|Stem cell transplantation|
524650|NCT00198991|Drug|Idarubicin|
524651|NCT00198991|Drug|Fludarabine|
524652|NCT00198991|Drug|Cladribine|
524653|NCT00198978|Drug|Cyclophosphamide|
524654|NCT00198978|Drug|Dexamethasone / Prednisolone|
524655|NCT00198978|Drug|Cytarabine|
524656|NCT00198978|Drug|Idarubicin|
524657|NCT00198978|Drug|Granulocyte-Colony-Stimulating Factor|
524658|NCT00198978|Drug|Mercaptopurine|
524659|NCT00198978|Drug|Methotrexate|
524660|NCT00198978|Drug|Rituximab|
524661|NCT00198978|Drug|HDARAC|
524662|NCT00198978|Drug|Vincristine|
524663|NCT00198978|Drug|Depocyte|
524664|NCT00198978|Drug|Asparaginase|
524665|NCT00198965|Behavioral|dietary education|
524666|NCT00198965|Behavioral|dietary education and provided full fat snack foods|
524667|NCT00198965|Behavioral|dietary education and provided fat free snack foods|
524668|NCT00198952|Drug|DietPro|
524669|NCT00198952|Drug|Placebo|
524670|NCT00198939|Behavioral|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
524671|NCT00198939|Other|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
524672|NCT00198926|Behavioral|covert v overt nutrition labeling|
524673|NCT00198926|Behavioral|varying meal nutrition manipulation|
524674|NCT00198913|Behavioral|lower fat food supplied and education|
524675|NCT00198913|Behavioral|gift cards for grocery foods and written education|
524676|NCT00198900|Behavioral|survey of information|
524677|NCT00198887|Procedure|Operations research|
524678|NCT00198874|Behavioral|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
524679|NCT00198874|Other|Education|Drug education curriculum was delivered to participants assigned to this condition.
524680|NCT00198861|Other|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
524681|NCT00198848|Drug|Iron-folic acid supplement|
524682|NCT00198835|Behavioral|Maternal nutrition and infant feeding advice|
524683|NCT00198822|Dietary Supplement|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
524684|NCT00198809|Drug|Biolean + Diet education|
524685|NCT00198809|Drug|Biolean Free + Diet education|
524686|NCT00198809|Drug|Placebo + Diet education|
524687|NCT00198796|Biological|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
524688|NCT00198770|Dietary Supplement|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
524689|NCT00198757|Behavioral|Medifast Plus for Diabetics Meal Replacement Supplements|
524690|NCT00198757|Behavioral|Standard ADA recommended diet for type 2 diabetics|
524691|NCT00198744|Behavioral|Medifast FIT! for Kids|
524692|NCT00198744|Behavioral|standard recommendations for dietary intake in children|
524693|NCT00198744|Behavioral|both diet plans with and without a parent dieting|
524694|NCT00198731|Behavioral|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
524695|NCT00198718|Drug|Vitamin A (retinyl palmitate)|
524696|NCT00198705|Behavioral|Improved management of severe neonatal infections|
524697|NCT00198692|Behavioral|self-management|
524698|NCT00198679|Drug|Chlorhexidine|
524699|NCT00198666|Drug|Zinc|Elemental Zinc
524700|NCT00198653|Behavioral|Newborn Thermal Care Practice|
524701|NCT00198640|Procedure|Antibiotic use|
524702|NCT00198627|Drug|Co-Trimoxazole; TMP-SMZ|
524703|NCT00198614|Drug|Carvedilol versus Metoprolol|
524704|NCT00198601|Drug|Gentamicin in Uniject Pre-filled syringe|
524705|NCT00198588|Drug|argatroban|beginning dose: 0.7microgram/kg/H
524706|NCT00198562|Drug|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
524707|NCT00198549|Drug|Vitrase (ovine hyaluronidase) Lyophilized|
524708|NCT00198536|Drug|Ecabet 2.83%|
524709|NCT00198536|Drug|Ecabet 3.70%|
524710|NCT00198536|Drug|Vehicle|
524711|NCT00198523|Drug|Prednisolone and Tobramycin|
524712|NCT00198523|Drug|Prednisolone|
524713|NCT00198510|Drug|Vitrase|7.5 IU of Vitrase
524714|NCT00198510|Drug|Vitrase|55 IU of Vitrase
524715|NCT00198510|Drug|Vitrase|75 IU of Vitrase
524716|NCT00198497|Drug|Placebo|
524717|NCT00198497|Drug|Vitrase|Hyaluronidase 55 IU in saline solution
524718|NCT00198497|Drug|Vitrase|Hyaluronidase 75 IU in saline solution
524719|NCT00198484|Drug|Vitrase|
524720|NCT00198471|Drug|Vitrase|
524721|NCT00198458|Drug|Vitrase|
524722|NCT00198445|Drug|Bromfenac|One drop in study eye every 12 hours for 14 days
524723|NCT00198445|Drug|Placebo|One drop in study eye every 12 hours for 14 days
524724|NCT00198432|Drug|Paclitaxel, vinorelbine, cisplatin|
524725|NCT00198419|Drug|Vitrase|
524726|NCT00198406|Procedure|diagnostic and therapeutic management|
524727|NCT00198393|Drug|Gefitinib|250 mg/day, until progression
524728|NCT00198393|Drug|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
524729|NCT00198393|Drug|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
524730|NCT00198380|Drug|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
524731|NCT00198367|Drug|Cisplatin-Gemzar|
524732|NCT00198367|Drug|Cisplatin-Navelbine-Radiotherapy|
524733|NCT00198367|Drug|Carboplatin-Taxol-Radiotherapy|
524734|NCT00198354|Drug|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
524735|NCT00198354|Drug|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
524736|NCT00198341|Procedure|Radiological Arm|Clinical Visit + X-Ray Chest
524737|NCT00198341|Procedure|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
524738|NCT00198328|Combination Product|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
524739|NCT00198328|Procedure|Surgical Excision|Patients have their tumor surgically removed.
524740|NCT00198315|Combination Product|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
524741|NCT00198315|Procedure|Tumor surgical excision|Patients have their tumor surgically removed.
524742|NCT00198302|Drug|Aurexis®|
524743|NCT00198289|Drug|Aurexis® (tefibazumab)|
524744|NCT00198276|Combination Product|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
540078|NCT00084838|Drug|leucovorin calcium|
524745|NCT00198263|Combination Product|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
524746|NCT00198250|Drug|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
524747|NCT00198237|Drug|docetaxel & capecitabine|
524748|NCT00198224|Procedure|phlebotomy|
524749|NCT00198198|Drug|Aripiprazole|
524750|NCT00198185|Procedure|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
524751|NCT00198172|Drug|Cisplatin plus Epirubicin|
524752|NCT00198159|Drug|ZD1839 Iressa|
524753|NCT00198146|Drug|Zenapax|
524754|NCT00198133|Drug|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
524755|NCT00198120|Drug|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
524756|NCT00198120|Drug|Placebo|Placebo: same dosing schedule and capsule strength
524757|NCT00198107|Drug|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
524758|NCT00198107|Drug|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
524759|NCT00198107|Drug|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
524760|NCT00198094|Drug|Sertraline and Alprazolam XR|
524761|NCT00198081|Drug|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
524762|NCT00198081|Drug|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
524763|NCT00198055|Drug|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
524764|NCT00198042|Procedure|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
524765|NCT00198029|Device|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
524766|NCT00198016|Device|Coil|
524767|NCT00198003|Behavioral|Educational program to address patients' expectations|
524768|NCT00197977|Behavioral|Educational program to address patients' expectations|
524769|NCT00197964|Behavioral|Enhance asthma knowledge, self-efficacy, social support|
524770|NCT00197951|Drug|Treatment of psychiatric symptoms associated to alcoholism|
524771|NCT00197938|Procedure|Measurement of rectal lactic acid.|
524772|NCT00197925|Biological|Onco-peptide loaded autologous dendritic cells|
524773|NCT00197912|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
524774|NCT00197899|Drug|E. Coli endotoxin|
524775|NCT00197886|Drug|Changing dose of norepinephrine and blood pressure|
524776|NCT00197873|Dietary Supplement|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
524777|NCT00197873|Other|Placebo administration.|Placebo is administered during chemotherapy.
524778|NCT00197860|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
524779|NCT00197834|Drug|Depakote|
524780|NCT00197821|Biological|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
524781|NCT00197808|Biological|menjugate|men C conjugate vaccine
524782|NCT00197808|Biological|Men C conjugate vaccine|men C conjugate vaccine
524783|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
524784|NCT00197808|Biological|Men C Conjugate|men C conjugate vaccine
524785|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
524786|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
524787|NCT00197795|Biological|"Meningococcal outer membrane vesicle vaccine MenBVac"|
524788|NCT00197782|Biological|Hib conjugate vaccine|
524789|NCT00197769|Biological|9 valent pneumococcal con jugate vaccine|
524790|NCT00197756|Dietary Supplement|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
524791|NCT00197756|Dietary Supplement|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
524792|NCT00197756|Dietary Supplement|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
524793|NCT00197756|Other|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
524794|NCT00197743|Dietary Supplement|Vitamin A + Beta Carotene|one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
524795|NCT00197743|Dietary Supplement|Multivitamins|one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
524796|NCT00197743|Other|Placebo|Placebo pill
524797|NCT00197730|Drug|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
524798|NCT00197730|Drug|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
524799|NCT00197704|Dietary Supplement|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
524800|NCT00197704|Other|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
524801|NCT00197691|Procedure|blood draws, etc.|
524802|NCT00197678|Dietary Supplement|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
524803|NCT00197678|Dietary Supplement|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
524804|NCT00197639|Drug|Ritonavir-boosted indinavir|
524805|NCT00197613|Drug|(A) zidovudine, lamivudine and nevirapine|
524806|NCT00197613|Drug|(B) zidovudine, lamivudine and efavirenz|
524807|NCT00197613|Drug|(C) zidovudine, didanosine, and nevirapine|
524808|NCT00197613|Drug|(D) zidovudine, didanosine, and efavirenz|
524809|NCT00197613|Drug|(E) stavudine, lamivudine, and nevirapine|
524810|NCT00197613|Drug|(F) stavudine, lamivudine and efavirenz|
524811|NCT00197613|Procedure|Adherence Strategy Standard of Care (SOC)|
524812|NCT00197613|Procedure|Adherence Strategy Community-Based DOT|
524813|NCT00197587|Drug|Nevirapine|All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
524814|NCT00197587|Drug|No intervention|All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
524815|NCT00197561|Dietary Supplement|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
524816|NCT00197561|Dietary Supplement|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
524817|NCT00197548|Dietary Supplement|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
524818|NCT00197548|Dietary Supplement|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
524819|NCT00197522|Biological|CD34+ derived DCs|
524820|NCT00197509|Behavioral|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
524821|NCT00197496|Procedure|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
524822|NCT00197483|Drug|Pergolide (drug)|
524823|NCT00197470|Procedure|IL-1, TNF-alpha, Il-10|
524824|NCT00197457|Procedure|serum pepsinogen|
524825|NCT00197457|Procedure|urea breath test|
524826|NCT00197444|Drug|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
524827|NCT00197444|Radiation|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
524828|NCT00197431|Drug|S-1|
524829|NCT00197418|Drug|rabeprazole, amoxicillin, clarithromycin, metronidazole|
524830|NCT00197392|Device|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
524831|NCT00197392|Device|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
524832|NCT00197379|Drug|roxithromycin|
524833|NCT00197353|Drug|Epidural bupivacaine (dose/concentration/volume ranging)|
524834|NCT00197340|Drug|Epidural ropivacaine|
524835|NCT00197327|Drug|Epidural bupivacaine (0.25% versus 0.0625%)|
524836|NCT00197314|Behavioral|circular muscle exercises versus pelvic floor exercises|
524837|NCT00197301|Biological|Vaccination|
524838|NCT00197288|Biological|Influenza|
524839|NCT00197275|Biological|Hib-MenAC mixed with Tritanrix™-HepB|
524840|NCT00197262|Drug|GW685698X Aqueous Nasal Spray|
524841|NCT00197249|Biological|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
524842|NCT00197236|Biological|Havrix™|2 intramuscular injections, 6 months apart
524843|NCT00197236|Biological|Infanrix™|1 intramuscular injection
524844|NCT00197236|Biological|ActHIB™|1 intramuscular injection
524845|NCT00197223|Biological|Influenza vaccine|
524846|NCT00197210|Biological|Rotavirus|
524847|NCT00197197|Drug|GW873140|
524848|NCT00197184|Biological|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
524849|NCT00197184|Biological|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
524850|NCT00197171|Biological|Combined Hepatitis A and B vaccine|
524851|NCT00197158|Biological|Hepatitis B vaccine|
524852|NCT00197145|Drug|GW873140|400 mg twice daily
524853|NCT00197132|Drug|Avandia|
524854|NCT00197119|Biological|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
540079|NCT00084838|Drug|methotrexate|
524855|NCT00197119|Biological|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
524856|NCT00197106|Drug|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
524857|NCT00197106|Drug|fluticasone propionate 2 x 100 mcg|comparator
524858|NCT00197093|Drug|SB773812|
524859|NCT00197080|Drug|Ropinirole Extended Release (XR)|
524860|NCT00197067|Biological|RTS,S/AS02D and RTS,S/AS02A|
524861|NCT00197054|Biological|RTS,S/AS02A and RTS,S/AS01B|
524862|NCT00197041|Biological|RTS,S/AS02A|
524863|NCT00197028|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
524864|NCT00197028|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
524865|NCT00197028|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
524866|NCT00197015|Biological|Havrix®|2 doses administered intramuscularly
524867|NCT00197015|Biological|M-M-R®II|1 dose administered subcutaneously
524868|NCT00197015|Biological|VARIVAX®|1 dose administered subcutaneously
524869|NCT00197002|Biological|GSK Biologicals 2-dose inactivated hepatitis A vaccine (Havrix)|Two doses, administered intramuscularly in the right anterolateral thigh.
524870|NCT00197002|Biological|Prevnar™|One dose, administered intramuscularly in the left anterolateral thigh.
524871|NCT00196989|Drug|Pioglitazone|
524872|NCT00196989|Drug|GW677954|
524873|NCT00196976|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
524874|NCT00196976|Biological|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
524875|NCT00196976|Biological|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
524876|NCT00196976|Biological|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
524877|NCT00196976|Biological|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
524878|NCT00196963|Biological|Meningococcal (vaccine)|
524879|NCT00196950|Biological|Meningococcal (vaccine)|
524880|NCT00196937|Biological|Cervarix™|Three doses of vaccine administered intramuscularly according to a 0, 1, 6 months
524881|NCT00196924|Biological|HPV-16/18 L1/AS04|
524882|NCT00196911|Procedure|Implantation of stimulation electrodes in the STN|
524883|NCT00196885|Drug|N-acetylcysteine|
524884|NCT00196872|Drug|Epirubicine|Epirbubicne is given
524885|NCT00196872|Drug|Cyclophosphamide|Cyclophosphamide is given
524886|NCT00196872|Drug|Taxol|Taxol is given
524887|NCT00196872|Drug|Xeloda|Xeloda is given
524888|NCT00196872|Drug|Ibandronat|Ibandronat is given
524889|NCT00196859|Drug|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
524890|NCT00196859|Drug|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
524891|NCT00196846|Drug|Goserelin|
524892|NCT00196820|Drug|Capecitabine|
524893|NCT00196807|Behavioral|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
524894|NCT00196794|Drug|Tolevamer potassium-sodium (GT267-004)|
524895|NCT00196781|Behavioral|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
524896|NCT00196781|Behavioral|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
524897|NCT00196768|Drug|Arsenic trioxide|
524898|NCT00196768|Drug|Trisenox|
524899|NCT00196755|Drug|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
524900|NCT00196755|Drug|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
524901|NCT00196729|Drug|Thyrogen + Radioiodine (131I)|
524902|NCT00196716|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
524903|NCT00196703|Drug|memantine|
524904|NCT00196703|Procedure|constraint-induced language therapy|
524905|NCT00196690|Drug|Donepezil|
524906|NCT00196677|Drug|Vitamins, minerals and medical herbs|
524907|NCT00196664|Drug|Paroxetine|
524908|NCT00196651|Drug|IL-2|
524909|NCT00196651|Biological|LIPO-6T|
524910|NCT00196651|Biological|ALVAC VIH 1433|
524911|NCT00196638|Drug|Antiretroviral combination (drugs)|
524912|NCT00196638|Drug|Pegylated Interferon alpha (drug)|
524913|NCT00196625|Drug|Amprenavir (drug)|
524914|NCT00196625|Drug|ABT-378/r (drug)|
524915|NCT00196625|Drug|Ritonavir (drug)|
524916|NCT00196612|Drug|emtricitabine, FTC (drug)|
524917|NCT00196612|Drug|didanosine, ddI (drug)|
524918|NCT00196612|Drug|efavirenz (drug)|
524919|NCT00196599|Drug|emtricitabine, FTC (drug)|
524920|NCT00196599|Drug|didanosine, ddI (drug)|
524921|NCT00196599|Drug|efavirenz (drug)|
524922|NCT00196586|Drug|Interleukin 2|
524923|NCT00196586|Drug|pegylated interferon alpha 2a|
524924|NCT00196586|Drug|ribavirin|
524925|NCT00196573|Procedure|Shoulder bursectomy alone|
524926|NCT00196560|Device|Immobilization in External Rotation|
524927|NCT00196547|Drug|Montelukast (drug)|
524928|NCT00196534|Drug|Human Thrombin|
524929|NCT00196534|Drug|Bovine Thrombin|
524930|NCT00196521|Device|Tension-free vaginal tape obturator system|
524931|NCT00196508|Device|High Viscosity DERMABOND|
524932|NCT00196495|Device|Polypropylene Mesh|
524933|NCT00196482|Drug|changing of fortifier|
524934|NCT00196469|Drug|heparin|
524935|NCT00196456|Procedure|photosensitisation|
524936|NCT00196443|Device|urea contained compressing stockings|
524937|NCT00196443|Device|compressing stockings|
524938|NCT00196430|Device|silver-contained textiles|
524939|NCT00196430|Drug|corticosteroid|
524940|NCT00196417|Drug|Standard heparin (UFH) versus certoparin (LMWH)|
524941|NCT00196404|Drug|DR-3001a|4mg daily vaginally
524942|NCT00196404|Drug|DR-3001b|6 mg vaginally daily
524943|NCT00196404|Other|Placebo|Administered vaginally to match experimental arms
524944|NCT00196391|Drug|DR-2021a|1 capsule daily for 10 days
524945|NCT00196391|Drug|DR-2021b|1 capsule daily for 10 days
524946|NCT00196391|Drug|DR-2021c|1 capsule daily for 10 days
524947|NCT00196391|Drug|DR-2021d|1 capsule daily for 10 days
524948|NCT00196391|Drug|DR-2021e|1 capsule daily for 10 days
524949|NCT00196391|Other|Placebo|1 matching placebo capsule for 10 days
524950|NCT00196378|Drug|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
524951|NCT00196378|Other|Placebo|1 tablet daily
524952|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
524953|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
524954|NCT00196352|Drug|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
524955|NCT00196339|Drug|Cyproterone acetate 5|Cyproterone acetate 5 mg
524956|NCT00196339|Drug|Placebo|Matching placebo
524957|NCT00196339|Drug|Cyproterone acetate 15|Cyproterone acetate 15 mg
524958|NCT00196339|Drug|Cyproterone acetate 25|Cyproterone acetate 25 mg
524959|NCT00196326|Drug|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
524960|NCT00196313|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
524961|NCT00196313|Drug|Placebo tablet|1 tablet daily by mouth
524962|NCT00196222|Procedure|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
524963|NCT00196222|Procedure|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
524964|NCT00196209|Procedure|catheter ablation|catheter ablation to treat persistent atrial fibrillation
524965|NCT00196209|Procedure|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
524966|NCT00196196|Device|Codman VPV System|Valve Positioning Verification (VPV) System
524967|NCT00196183|Procedure|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
524968|NCT00196183|Procedure|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
524969|NCT00196170|Procedure|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
524970|NCT00196170|Procedure|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
524971|NCT00196170|Procedure|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
524972|NCT00196170|Procedure|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
524973|NCT00196157|Procedure|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
524974|NCT00196157|Procedure|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
524975|NCT00196144|Device|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
524976|NCT00196144|Device|Nominal PVAB|nominal pacemaker settings
524977|NCT00196131|Drug|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
524978|NCT00196118|Device|Günther Tulip Vena Cava Filter|
524979|NCT00196105|Device|6 mm Nitinol Zilver Stent|
524980|NCT00196105|Device|10 mm Nitinol Zilver Stent|
524981|NCT00196105|Device|10 mm Stainless Steel Wallstent|
524982|NCT00196092|Device|Roll-in|Proctored entry.
524983|NCT00196092|Device|Surgical|Surgery
524984|NCT00196092|Device|Standard Risk|Standard Endovascular repair
524985|NCT00196092|Device|High Risk|High Risk Endovascular repair.
524986|NCT00196092|Device|Compassionate Use|Endovascular repair for compassionate use patients.
524987|NCT00196092|Device|Treatment for females|Endovascular repair in female patients
524988|NCT00196092|Device|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
524989|NCT00196092|Device|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
524990|NCT00196079|Device|Coronary stent|
524991|NCT00196066|Device|Peripheral Vessel Stenting|
524992|NCT00196053|Device|Archimedes Constant Flow Implantable Pump|
524993|NCT00196040|Device|PFX Closure System|
524994|NCT00196027|Device|PFX Closure System|
524995|NCT00195988|Drug|tacrolimus, steroids, mycophenolate mofetil|
524996|NCT00195949|Procedure|Laparoscopic pyloromyotomy|
524997|NCT00195936|Drug|Cinacalcet|
524998|NCT00195923|Drug|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
524999|NCT00195910|Drug|Morphine|0.1 mg/kg IV morphine
525000|NCT00195910|Drug|Hydromorphone|0.015 mg/kg IV hydromorphone
525104|NCT00195000|Drug|Mylotarg|6 mg/m2 on day 1
525226|NCT00194051|Procedure|gastric bypass surgery|
525001|NCT00195884|Behavioral|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.~Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.~Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.~Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.~Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
525002|NCT00195871|Drug|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
525003|NCT00195871|Procedure|hematopoietic stem cell allograft|conventional procedures
525004|NCT00195858|Behavioral|aerobic and resistance exercise|aerobic and resistance exercise
525005|NCT00195845|Drug|Galantamine|
525006|NCT00195845|Drug|Placebos|
525007|NCT00195819|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
525008|NCT00195819|Biological|placebo|Placebo every other week (eow)
525009|NCT00195806|Drug|divalproex sodium|
525010|NCT00195793|Drug|fenofibrate|
525011|NCT00195793|Drug|ezetimibe|
525012|NCT00195793|Drug|atorvastatin|
525013|NCT00195780|Drug|Divalproex Sodium (Depakote ER)|
525014|NCT00195767|Drug|divalproex sodium|
525015|NCT00195754|Drug|divalproex sodium|
525016|NCT00195741|Drug|divalproex sodium|
525017|NCT00195728|Drug|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
525018|NCT00195715|Biological|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
525019|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
525020|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
525021|NCT00195702|Drug|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
525022|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
525023|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
525024|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
525025|NCT00195689|Biological|Human anti-TNF monoclonal antibody/adalimumab|
525026|NCT00195676|Drug|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
525027|NCT00195663|Biological|Adalimumab|
525028|NCT00195663|Drug|Methotrexate|
525029|NCT00195663|Biological|Adalimumab placebo|
525030|NCT00195663|Drug|Methotrexate placebo|
525031|NCT00195650|Biological|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
525032|NCT00195637|Drug|Immune Globulin|
525033|NCT00195624|Biological|Alemtuzumab (Campath )|Campath administered at a dose of 10/mg/day for 10 days
525034|NCT00195624|Drug|Cyclosporine|Subjects who relapse after initial response to alemtuzumab therapy will have cyclosporine added to the regimen after the 6 month visit. Dosing will be based on ideal body weight and will be adjusted to maintain a target level of 200 - 400 ng /ml.
525035|NCT00195611|Drug|Prevenar|
525036|NCT00195598|Drug|VENLAFAXINE|
525037|NCT00195598|Drug|Paroxetine|
525038|NCT00195585|Drug|Isovorin|
525039|NCT00195585|Drug|UFT|
525040|NCT00195572|Drug|Isovorin|
525041|NCT00195572|Drug|TS-1|
525042|NCT00195559|Drug|Levonorgestrel/Ethinyl Estradiol|
525043|NCT00195546|Drug|DVS-233|
525044|NCT00195533|Drug|piperacillin-tazobactam|
525045|NCT00195533|Drug|glycopeptide|
525046|NCT00195520|Drug|Totelle®|
525047|NCT00195507|Drug|Etanercept|
525048|NCT00195494|Drug|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
525049|NCT00195494|Drug|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2~Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2~Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
525050|NCT00195494|Drug|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2~Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
525051|NCT00195481|Drug|Rapamune|
525052|NCT00195468|Drug|CYCLOSPORINE|
525053|NCT00195455|Drug|Trimegestone|
525054|NCT00195455|Drug|17b Estradiol|
525105|NCT00195000|Drug|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
525106|NCT00194987|Drug|IVIG (Intravenous Immunoglobulin)|one gram per kg of IVIG per infusion given either once or twice
525055|NCT00195442|Drug|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
525056|NCT00195429|Drug|Tacrolimus|
525057|NCT00195429|Drug|Sirolimus|
525058|NCT00195429|Drug|prednisone|
525059|NCT00195416|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
525060|NCT00195403|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
525061|NCT00195390|Biological|Prevenar|Prevenar 0.5ml/ Vial and PFS
525062|NCT00195377|Drug|Etanercept|
525063|NCT00195364|Drug|Etanercept|
525064|NCT00195351|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
525065|NCT00195351|Drug|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
525066|NCT00195338|Drug|etanercept|
525067|NCT00195325|Drug|TTI-237|
525068|NCT00195312|Biological|HIV-1 gag DNA (formulated with bupivacaine)|
525069|NCT00195312|Biological|IL-15 DNA (formulated with bupivacaine)|
525070|NCT00195312|Biological|IL-12 DNA (formulated with bupivacaine)|
525071|NCT00195312|Biological|Sodium chloride injection USP (0.9%)|
525072|NCT00195299|Drug|Temsirolimus|
525073|NCT00195286|Drug|piperacillin/tazobactam|
525074|NCT00195273|Drug|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
525075|NCT00195273|Drug|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
525076|NCT00195273|Drug|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
525077|NCT00195273|Drug|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
525078|NCT00195273|Drug|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
525079|NCT00195260|Drug|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
525080|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
525081|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
525082|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
525083|NCT00195247|Drug|TTI-237|
525084|NCT00195234|Biological|HIV CTL MEP 1000 micrograms, 19 months per subject|
525085|NCT00195208|Drug|Pantoprazole for approximately 9 weeks|
525086|NCT00195195|Drug|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
525087|NCT00195182|Behavioral|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
525088|NCT00195156|Drug|ATRA-IV|
525089|NCT00195156|Drug|Depakote|
525090|NCT00195143|Genetic|Surgical infusion of AAV-GAD into the subthalamic nucleus|
525091|NCT00195130|Behavioral|There are no interventions in this study|
525092|NCT00195117|Behavioral|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
525093|NCT00195104|Drug|Arsenic Trioxide (Tricenox)|
525094|NCT00195104|Drug|Cytarabine|
525095|NCT00195091|Drug|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.~Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.~When target Cp window is reached, then the maintenance phase begins.~Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg~Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
525096|NCT00195078|Drug|ZD1839 (IRESSA)|
525097|NCT00195078|Drug|Cisplatin|
525098|NCT00195078|Procedure|Radiation Therapy|
525099|NCT00195065|Behavioral|Semi-structured, open-ended interviews|
525100|NCT00195039|Drug|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
525101|NCT00195026|Device|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
525102|NCT00195013|Drug|glutamine|10 grams three times a day (orally) for four days and then stop
525103|NCT00195013|Drug|Placebo|10 grams three times a day (orally) for four days and then stop
525107|NCT00194987|Drug|prednisone|in arm with IVIG 1 gm/kg/wk will also receive prednisone 0.5 mg/kg/day
525108|NCT00194974|Drug|methyldopa|
525109|NCT00194974|Drug|labetalol|
525110|NCT00194974|Drug|nifedipine|
525111|NCT00194974|Drug|clonidine|
525112|NCT00194961|Drug|Recombinant Human Growth Hormone|
525113|NCT00194948|Drug|escitalopram|
525114|NCT00194948|Behavioral|interpersonal psychotherapy|
525115|NCT00194935|Drug|Topotecan|
525116|NCT00194922|Dietary Supplement|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
525117|NCT00194909|Drug|sildenafil (Viagra)|
525118|NCT00194896|Drug|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
525119|NCT00194896|Drug|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
525120|NCT00194883|Drug|Recombinant Human Growth Hormone|
525121|NCT00194870|Procedure|EEG|computer-assisted analysis of the digitally-recorded EEG signals
525122|NCT00194857|Drug|erythropoietin, GCSF|
525123|NCT00194844|Behavioral|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
525124|NCT00194844|Behavioral|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
525125|NCT00194844|Behavioral|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
525126|NCT00194818|Drug|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
525127|NCT00194805|Behavioral|Telehealth for Diabetes Self Management|
525128|NCT00194805|Other|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
525129|NCT00194792|Drug|exemestane|Given PO
525130|NCT00194792|Drug|triptorelin pamoate|Given IM
525131|NCT00194792|Drug|capecitabine|Given PO
525132|NCT00194792|Drug|methotrexate|Given IV
525133|NCT00194792|Drug|vinorelbine tartrate|Given IV
525134|NCT00194792|Drug|paclitaxel|Given IV
525135|NCT00194792|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
525136|NCT00194792|Radiation|radiation therapy|Undergo radiation therapy
525137|NCT00194792|Other|laboratory biomarker analysis|Correlative studies
525138|NCT00194779|Drug|doxorubicin hydrochloride|Given IV
525139|NCT00194779|Drug|cyclophosphamide|Given PO
525140|NCT00194779|Drug|paclitaxel|Given IV
525141|NCT00194779|Biological|filgrastim|Given SC
525142|NCT00194779|Drug|capecitabine|Given PO
525143|NCT00194779|Drug|methotrexate|Given IV
525144|NCT00194779|Drug|vinorelbine tartrate|Given IV
525145|NCT00194779|Procedure|needle biopsy|Correlative studies
525146|NCT00194779|Procedure|therapeutic conventional surgery|Undergo definitive breast surgery
525147|NCT00194779|Other|immunohistochemistry staining method|Correlative studies
525148|NCT00194779|Biological|trastuzumab|Given IV
525149|NCT00194779|Drug|tamoxifen citrate|Given PO
525150|NCT00194779|Drug|letrozole|Given PO
525151|NCT00194779|Other|laboratory biomarker analysis|Correlative studies
525152|NCT00194766|Drug|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
525153|NCT00194753|Drug|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
525154|NCT00194753|Drug|Doxorubicin|24 mg/m2 IV weekly x 12
525155|NCT00194753|Drug|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
525156|NCT00194753|Drug|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
525157|NCT00194740|Drug|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
525158|NCT00194740|Drug|Vinorelbine|27.5 mg/m2, IV, days 8 & 15 of each 21 day cycle
525159|NCT00194740|Drug|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
525160|NCT00194727|Drug|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
525161|NCT00194727|Drug|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
525162|NCT00194714|Biological|HER-2/neu Peptide Vaccine|Given ID
525163|NCT00194714|Other|Laboratory Biomarker Analysis|Correlative studies
525164|NCT00194701|Behavioral|Walking exercise|
525165|NCT00194688|Drug|H. pylori treatment|
525166|NCT00194675|Drug|Dutasteride|Dutasteride 0.5 mg orally daily
525167|NCT00194675|Drug|Testosterone gel|Testosterone gel 7.5 g daily topical
525168|NCT00194675|Drug|Placebo dutasteride|placebo dutasteride orally daily
525169|NCT00194649|Drug|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
525170|NCT00194636|Procedure|nerve block|
525171|NCT00194623|Drug|Botulinum Toxin A (Botox)|
525172|NCT00194610|Drug|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
525173|NCT00194610|Other|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
525174|NCT00194597|Drug|Viagra (sildenafil citrate)|
525175|NCT00194584|Behavioral|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
525176|NCT00194571|Behavioral|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
525177|NCT00194558|Behavioral|Internet co-management module|
525178|NCT00194545|Behavioral|Medication diaries|Caregivers expected to complete medication diaries daily
525179|NCT00194532|Drug|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
525180|NCT00194532|Drug|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
525181|NCT00194519|Drug|Generic acyclovir|400 mg twice-daily oral
525182|NCT00194519|Drug|Placebo|twice-daily oral
525183|NCT00194506|Behavioral|Internet co-management module|
525184|NCT00194493|Behavioral|ESRA-C|Graphical summary of patient symptoms and quality of life
525185|NCT00194480|Drug|Pegylated Interferon|Weekly injections of pegIntereferon
525186|NCT00194467|Drug|valganciclovir|900 mg once a day for 8 weeks
525187|NCT00194467|Drug|placebo|matching placebo, once a day for 8 weeks
525188|NCT00194454|Behavioral|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
525189|NCT00194454|Other|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
525190|NCT00194441|Other|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
525191|NCT00194428|Behavioral|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
525192|NCT00194428|Behavioral|Low fat caloric diet|Low fat caloric diet
525193|NCT00194415|Behavioral|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
525194|NCT00194415|Procedure|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
525195|NCT00194402|Drug|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
525196|NCT00194376|Procedure|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
525197|NCT00194363|Behavioral|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
525198|NCT00194350|Procedure|Test for Factor V Leiden gene mutation|
525199|NCT00194337|Procedure|breast imaging study|
525200|NCT00194337|Procedure|comparison of screening methods|
525201|NCT00194337|Procedure|magnetic resonance imaging|
525202|NCT00194337|Procedure|positron emission tomography|
525203|NCT00194337|Procedure|radiomammography|
525204|NCT00194337|Procedure|ultrasound imaging|
525205|NCT00194337|Radiation|fludeoxyglucose F 18|
525206|NCT00194324|Drug|Miconazole nitrate|
525207|NCT00194324|Procedure|Magnetic resonance imaging|
525208|NCT00194324|Behavioral|Moderate levels of exercise|
525209|NCT00194298|Procedure|FDG-PET Imaging|
525210|NCT00194285|Procedure|FDG-PET Imaging|
525211|NCT00194272|Drug|Methotrexate|Two dose methotrexate
525212|NCT00194194|Behavioral|moderate|moderate behavioral management with RD
525213|NCT00194194|Device|Resting Metablic Rate measurements|intensive behavior management
525214|NCT00194181|Drug|TPA Infusion|
525215|NCT00194129|Drug|Lithium|Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
525216|NCT00194129|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
525217|NCT00194129|Drug|Placebo|Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
525218|NCT00194116|Drug|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
525219|NCT00194116|Drug|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
525220|NCT00194103|Behavioral|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
525221|NCT00194103|Behavioral|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
525222|NCT00194090|Drug|celecoxib|
525223|NCT00194077|Drug|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
525224|NCT00194077|Drug|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
525225|NCT00194064|Drug|Olanzapine|
540080|NCT00084838|Drug|temozolomide|
525227|NCT00194038|Drug|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
525228|NCT00194025|Drug|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
525229|NCT00194012|Drug|Aripiprazole|Addressed in arm description.
525230|NCT00194012|Drug|Placebo|Addressed in arm description.
525231|NCT00193999|Device|Placement of nasogastric tube|
525232|NCT00193986|Device|Arbitrary Waveform Defibrillator|
525233|NCT00193973|Drug|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
525234|NCT00193973|Radiation|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
525235|NCT00193960|Procedure|1) Intraocular pressure 2) visual acuity|
525236|NCT00193921|Drug|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
525237|NCT00193921|Radiation|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
525238|NCT00193921|Drug|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
525239|NCT00193921|Drug|Cisplatin|20mg/m2, IV, weekly
525240|NCT00193921|Radiation|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
525241|NCT00193908|Drug|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
525242|NCT00193908|Drug|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
525243|NCT00193908|Radiation|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
525244|NCT00193895|Drug|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
525245|NCT00193895|Radiation|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
525246|NCT00193882|Drug|Cisplatin|80mg/m2 IV day 1
525247|NCT00193882|Radiation|Radiotherapy|35 Gy in 15 fractions
525248|NCT00193882|Drug|5-Fluorouracil|800mg/m2/day IV days 1 - 4
525249|NCT00193869|Drug|Dexamethasone|
525250|NCT00193856|Drug|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
525251|NCT00193856|Drug|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
525252|NCT00193856|Radiation|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
525253|NCT00193843|Procedure|Post-operative chemoradiotherapy / accelerated radiotherapy|
525254|NCT00193830|Procedure|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
525255|NCT00193817|Procedure|Two field vs Three field lymphadenectomy|
525256|NCT00193804|Radiation|IMRT|IMRT in cervical cancers
525257|NCT00193791|Other|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
525258|NCT00193778|Procedure|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
525259|NCT00193778|Other|No Loco-regional treatment|This group will not receive any loco-regional treatment
525260|NCT00193765|Procedure|Elective neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers at the time of primary surgery
525261|NCT00193765|Procedure|Therapeutic Neck Dissection|There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
525262|NCT00193752|Other|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
525263|NCT00193739|Drug|NACT|3 cycles of neoadjuvant chemotherapy
525264|NCT00193739|Procedure|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
525265|NCT00193739|Drug|Inj.Cisplatin|Concurrent chemo radiotherapy
525266|NCT00193739|Radiation|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
525267|NCT00193726|Drug|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
525268|NCT00193726|Drug|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
525269|NCT00193713|Drug|bifeprunox|
525270|NCT00193700|Drug|Testosterone Gel (1%)|
525271|NCT00193687|Drug|bifeprunox|
525272|NCT00193674|Drug|Dydrogesterone|20 mg/day, oral
525273|NCT00193674|Drug|Placebo|Placebo
525274|NCT00193661|Drug|Testosterone Gel (1%)|
525275|NCT00193648|Drug|Rosiglitazone (Avandia)|oral drug administration
525276|NCT00193648|Drug|Adalimumab (Humira)|Injection of drug biweekly
525277|NCT00193635|Drug|mycophenolate mofetil|oral drug administration
525278|NCT00193622|Drug|Bevacizumab|
525279|NCT00193622|Drug|Erlotinib|
525280|NCT00193609|Drug|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
525281|NCT00193609|Drug|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
525282|NCT00193596|Drug|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
525283|NCT00193596|Drug|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
525284|NCT00193596|Drug|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
525285|NCT00193596|Drug|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
525286|NCT00193596|Drug|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
525287|NCT00193583|Drug|Topotecan|
525288|NCT00193583|Drug|Carboplatin|
525289|NCT00193570|Drug|Topotecan|
525290|NCT00193570|Drug|Docetaxel|
525291|NCT00193557|Drug|Bortezomib|
525292|NCT00193544|Drug|Arsenic Trioxide|
525293|NCT00193544|Drug|Thalidomide|
525294|NCT00193531|Drug|Paclitaxel|
525295|NCT00193531|Drug|Carboplatin|
525296|NCT00193531|Drug|Etoposide|
525297|NCT00193518|Drug|Arsenic Trioxide|
525298|NCT00193505|Drug|Ifosfamide|
525299|NCT00193505|Drug|Carboplatin|
525300|NCT00193505|Drug|Etoposide|
525301|NCT00193505|Drug|Rituximab|
525302|NCT00193505|Drug|90Y Zevalin|
525303|NCT00193492|Drug|Bevacizumab|
525304|NCT00193492|Drug|Rituximab|
525305|NCT00193479|Drug|Cyclophosphamide|Cyclophosphamide
525306|NCT00193479|Drug|Mitoxantrone|Mitoxantrone
525307|NCT00193479|Drug|Vincristine|Vincristine
525308|NCT00193479|Drug|Prednisone|Prednisone
525309|NCT00193479|Drug|Rituximab|Rituximab
525310|NCT00193466|Drug|Rituximab|
525311|NCT00193466|Drug|Fludarabine|
525312|NCT00193466|Drug|CAMPTH-1H|
525313|NCT00193453|Drug|Gemcitabine|1000mg/m2 30min IV, Day 1 & 8
525314|NCT00193453|Drug|Docetaxel|30mg/m2, 30min IV, day 1 & 8
525315|NCT00193453|Drug|Cetuximab|100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 & 15, all subsequent cycles 250mg/m2 IV day 1, 8, & 15
525316|NCT00193440|Drug|Rituximab|
525317|NCT00193440|Drug|CHOP|
525318|NCT00193440|Drug|CVP|
525319|NCT00193440|Drug|Ibritumomab Tiuxetan|
525320|NCT00193427|Drug|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
525321|NCT00193427|Drug|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
525322|NCT00193427|Drug|Carboplatin|AUC = 1.5 weekly x 7
525323|NCT00193427|Radiation|Radiation|To 63 Gy
525324|NCT00193414|Drug|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
525325|NCT00193414|Drug|Gemcitabine|1500mg/m2, 30min IV
525326|NCT00193401|Drug|Topotecan|
525327|NCT00193388|Drug|Topotecan|
525328|NCT00193375|Drug|Irinotecan|50mg/m2 days 1 & 8 each 21-day cycle 1 & 2, 28-day cycle 3 & 4
525329|NCT00193375|Drug|Carboplatin|AUC 5
525330|NCT00193375|Drug|Bevacizumab|10mg/kg IV every 2 weeks for 10 doses starting week 16
525331|NCT00193375|Radiation|Radiation|
525332|NCT00193362|Drug|Paclitaxel|
525333|NCT00193362|Drug|Carboplatin|
525334|NCT00193362|Drug|Gemcitabine|
525335|NCT00193362|Drug|Vinorelbine|
525336|NCT00193349|Drug|Imatinib|
525337|NCT00193349|Drug|Irinotecan|
525338|NCT00193349|Drug|Carboplatin|
525339|NCT00193336|Drug|ZD1839|
525340|NCT00193323|Drug|Docetaxel|
525341|NCT00193323|Drug|Gemcitabine|
525342|NCT00193310|Drug|Paclitaxel|
525343|NCT00193310|Drug|Carboplatin|
525344|NCT00193297|Drug|Topotecan|
525345|NCT00193297|Drug|Paclitaxel|
525346|NCT00193297|Drug|Carboplatin|
525347|NCT00193284|Drug|Gefitinib|
525348|NCT00193284|Drug|Docetaxel|
525349|NCT00193284|Drug|Carboplatin|
525350|NCT00193284|Drug|Fluorouracil|
525351|NCT00193271|Drug|Docetaxel|
525352|NCT00193271|Drug|Estramustine|
525353|NCT00193258|Drug|Bevacizumab|10mg/kg IV infusion every 2 weeks
525354|NCT00193258|Drug|Erlotinib|150 mg po daily
525355|NCT00193258|Drug|Imatinib|400-600mg daily
525356|NCT00193245|Drug|Topotecan|
525357|NCT00193245|Drug|Docetaxel|
525358|NCT00193232|Drug|Docetaxel|
525359|NCT00193232|Drug|Bortezomib|
525360|NCT00193219|Drug|Bevacizumab|5 mg/kg IV
525361|NCT00193219|Drug|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
525362|NCT00193219|Drug|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
525363|NCT00193219|Drug|Leucovorin|350 mg IV
525364|NCT00193219|Drug|Oxaliplatin|85 mg/m2 IV
525365|NCT00193206|Drug|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
525366|NCT00193206|Drug|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
525367|NCT00193206|Drug|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
525368|NCT00193193|Drug|Paclitaxel|
525369|NCT00193193|Drug|Estramustine|
525370|NCT00193193|Drug|Carboplatin|
525371|NCT00193180|Drug|Imatinib|Imatinib
525372|NCT00193180|Drug|Docetaxel|Docetaxel
525373|NCT00193167|Drug|Topotecan|
525374|NCT00193154|Drug|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
525375|NCT00193154|Drug|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
525376|NCT00193141|Drug|Paclitaxel|
525377|NCT00193141|Drug|Carboplatin|
525378|NCT00193141|Drug|5-Fluorouracil|
525379|NCT00193128|Drug|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
525380|NCT00193128|Drug|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
525381|NCT00193128|Drug|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
525468|NCT00192478|Biological|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
525382|NCT00193128|Radiation|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
525383|NCT00193115|Drug|Docetaxel|
525384|NCT00193115|Drug|Doxorubicin|
525385|NCT00193115|Drug|Cyclophosphamide|
525386|NCT00193102|Drug|Thalidomide|Thalidomide
525387|NCT00193102|Drug|Capecitabine|Capecitabine
525388|NCT00193089|Drug|Docetaxel|Docetaxel
525389|NCT00193089|Drug|Vinorelbine|Vinorelbine
525390|NCT00193089|Drug|Trastuzumab|Trastuzumab
525391|NCT00193076|Drug|Gemcitabine|Gemcitabine
525392|NCT00193076|Drug|Carboplatin|Carboplatin
525393|NCT00193076|Drug|Trastuzumab|Trastuzumab
525394|NCT00193063|Drug|Trastuzumab|Trastuzumab
525395|NCT00193063|Drug|Gemcitabine|Gemcitabine
525396|NCT00193050|Drug|Gemcitabine|Gemcitabine
525397|NCT00193050|Drug|Epirubicin|Epirubicin
525398|NCT00193050|Drug|Docetaxel|Docetaxel
525399|NCT00193037|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin
525400|NCT00193037|Drug|Docetaxel|Docetaxel
525401|NCT00193024|Drug|Docetaxel|
525402|NCT00193024|Drug|Epirubicin|
525403|NCT00193011|Drug|Docetaxel|Docetaxel
525404|NCT00193011|Drug|Cyclophosphamide|Cyclophosphamide
525405|NCT00193011|Drug|Methotrexate|Methotrexate
525406|NCT00193011|Drug|5-Fluorouracil|5-Fluorouracil
525407|NCT00192985|Device|Nitrofuranzone coated bladder catheter|
525408|NCT00192972|Procedure|Catheter ablation (pulmonary vein isolation)|
525409|NCT00192959|Drug|Xenon vs propofol|
525410|NCT00192946|Procedure|Temporary cardiac resynchronization therapy|
525411|NCT00192933|Procedure|NovoSeven treatment according to guideline|
525412|NCT00192920|Behavioral|Transfusion practice|
525413|NCT00192881|Device|Bx Sonic & Cypher stent from Cordis|
525414|NCT00192868|Procedure|Distal protection and drug eluting stent|
525415|NCT00192855|Drug|Entacapone|Entacapone 600mg BID
525416|NCT00192842|Drug|curcumin (+ gemcitabine)|
525417|NCT00192829|Procedure|Blood sample withdrawal|
525418|NCT00192816|Behavioral|reaction to pain|
525419|NCT00192803|Drug|candesartan|
525420|NCT00192777|Drug|Xeloda|
525421|NCT00192777|Procedure|External Beam Radiotherapy|
525422|NCT00192764|Drug|high-dose cyclophosphamide|
525423|NCT00192751|Behavioral|Psychoeducational group sessions|
525424|NCT00192725|Other|rapid tryptophan depletion|Amino-acid mixture without tryptophan
525425|NCT00192712|Drug|irinotecan, gemcitabine|
525426|NCT00192699|Device|Bimetric femoral stem|Cemented Bi-Metric femoral stem
525427|NCT00192686|Procedure|culture a.m. Kamme-Lindberg|
525428|NCT00192673|Drug|PEG-asparaginase|
525429|NCT00192660|Drug|Lamivudine|
525430|NCT00192660|Drug|Stavudine|
525431|NCT00192660|Drug|Didanosine|
525432|NCT00192660|Drug|Zidovudine|
525433|NCT00192660|Drug|Tenofovir|
525434|NCT00192660|Drug|Abacavir|
525435|NCT00192660|Drug|Efavirenz (EFV)|
525436|NCT00192660|Drug|Nevirapine|
525437|NCT00192660|Drug|Indinavir|
525438|NCT00192660|Drug|Saquinavir|
525439|NCT00192660|Drug|Amprenavir|
525440|NCT00192660|Drug|Ritonavir|
525441|NCT00192660|Drug|Nelfinavir|
525442|NCT00192660|Drug|Tipranavir|
525443|NCT00192660|Drug|enfuvirtide (T20)|
525444|NCT00192647|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
525445|NCT00192647|Drug|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
525446|NCT00192634|Drug|Emtricitabine 200mg - Tenofovir 300mg|1 tablet once daily for 96 weeks
525447|NCT00192634|Drug|Abacavir 600mg - Lamivudine 300mg|1 tablet once daily for 96 weeks
525448|NCT00192621|Drug|Combivir (zidovudine [AZT] / lamivudine [3TC])|
525449|NCT00192621|Drug|Kaletra (lopinavir [LPVr])|
525450|NCT00192608|Drug|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
525451|NCT00192608|Drug|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
525452|NCT00192595|Drug|Tenofovir|
525453|NCT00192595|Drug|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
525454|NCT00192582|Behavioral|Motivational Interview with care plan and education|
525455|NCT00192569|Drug|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
525456|NCT00192569|Drug|Ribavirin (HIV conifected patients only)|"genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg)~Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
525457|NCT00192556|Behavioral|food|
525458|NCT00192543|Behavioral|diet of fish and fruit|fish and fruit in specified quantities
525459|NCT00192543|Behavioral|fruit and fish|no drugs
525460|NCT00192543|Behavioral|diet only|Fish and fruit
525461|NCT00192543|Behavioral|regular diet|no change in regular diet
525462|NCT00192517|Drug|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
525463|NCT00192517|Other|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
525464|NCT00192504|Biological|MEDI-524|
525465|NCT00192491|Biological|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
525466|NCT00192491|Biological|FluMist|Nasal sprayer of FluMist
525467|NCT00192491|Other|Placebo|Nasal Sprayer of Placebo
525469|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
525470|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
525471|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
525472|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
525473|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
525474|NCT00192452|Drug|MEDI-507|
525475|NCT00192439|Behavioral|High Risk Respiratory Disease|
525476|NCT00192426|Biological|CAIV-T|
525477|NCT00192413|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
525478|NCT00192413|Biological|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
525479|NCT00192400|Biological|CAIV-T|
525480|NCT00192387|Biological|CAIV-T, Liquid|
525481|NCT00192374|Biological|CAIV-T, Liquid|
525482|NCT00192361|Biological|CAIV-T|
525483|NCT00192348|Biological|CAIV-T|
525484|NCT00192335|Biological|CAIV-T|
525485|NCT00192335|Biological|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
525486|NCT00192335|Biological|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
525487|NCT00192322|Biological|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
525488|NCT00192322|Biological|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T <10^5
525489|NCT00192322|Biological|Placebo|a single intranasal 0.2 mL dose of placebo
525490|NCT00192322|Biological|TIV|commercially available TIV injected intramuscularly
525491|NCT00192309|Biological|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
525492|NCT00192309|Biological|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
525493|NCT00192309|Biological|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
525494|NCT00192296|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
525495|NCT00192296|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
525496|NCT00192296|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
525497|NCT00192296|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
525498|NCT00192283|Biological|CAIV-T|The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
525499|NCT00192283|Other|Placebo|A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
525500|NCT00192270|Biological|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of ~3 x 10^7 TCID50 per dose.
525501|NCT00192257|Biological|CAIV-T and TIV|
525502|NCT00192244|Biological|CAIV-T, Liquid|
525503|NCT00192231|Biological|CAIV-T|
525504|NCT00192218|Biological|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
525505|NCT00192205|Biological|CAIV-T or TIV|
525506|NCT00192192|Biological|CAIV-T|
525507|NCT00192179|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
525508|NCT00192179|Biological|Placebo|The placebo consisted of physiologic normal saline.
525509|NCT00192166|Biological|CAIV-T|
525510|NCT00192153|Biological|CAIV-T or TIV|
525511|NCT00192140|Biological|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
525512|NCT00192127|Biological|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
525513|NCT00192127|Other|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
525514|NCT00192114|Drug|Enzastaurin HCl|1200 mg loading dose then 500 mg, oral, daily, up to six 28 day cycles
525515|NCT00192101|Drug|gemcitabine|
525516|NCT00192101|Drug|cisplatin|
525517|NCT00192088|Drug|pemetrexed|
525518|NCT00192088|Drug|oxaliplatin|
525519|NCT00192075|Drug|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
525520|NCT00192075|Drug|avastin|5 milligrams per kilogram (mg/kg)
525596|NCT00191542|Drug|Atomoxetine|
525521|NCT00192075|Drug|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).~Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).~5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
525522|NCT00192075|Drug|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
525523|NCT00192062|Drug|gemcitabine|
525524|NCT00192062|Drug|vinorelbine|
525525|NCT00192049|Drug|Gemcitabine|
525526|NCT00192049|Drug|mitomycin C|
525527|NCT00192036|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
525528|NCT00192036|Drug|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
525529|NCT00192036|Radiation|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
525530|NCT00192023|Drug|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
525531|NCT00192023|Drug|placebo|
525532|NCT00192023|Drug|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
525533|NCT00192023|Drug|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
525534|NCT00191997|Drug|Olanzapine|
525535|NCT00191984|Drug|pemetrexed|400 mg/m^2, intravenous (IV), every 14 days x 12 cycles
525536|NCT00191984|Drug|irinotecan|180 mg/m^2, intravenous (IV), every 14 days x 12 cycles
525537|NCT00191971|Drug|Gemcitabine|
525538|NCT00191945|Drug|Atomoxetine Hydrochloride|
525539|NCT00191945|Drug|placebo|
525540|NCT00191932|Drug|Duloxetine|
525541|NCT00191919|Drug|Duloxetine Hydrochloride|
525542|NCT00191919|Drug|Placebo|
525543|NCT00191906|Drug|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
525544|NCT00191906|Drug|placebo|Placebo, every day (QD), by mouth (PO)
525545|NCT00191893|Drug|teriparatide|
525546|NCT00191880|Drug|atomoxetine|
525547|NCT00191867|Drug|Teriparatide|
525548|NCT00191854|Drug|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
525549|NCT00191854|Drug|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
525550|NCT00191854|Drug|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
525551|NCT00191854|Drug|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
525552|NCT00191841|Drug|gemcitabine|
525553|NCT00191841|Drug|Cisplatin|
525554|NCT00191828|Drug|olanzapine|
525555|NCT00191815|Drug|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
525556|NCT00191815|Drug|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
525557|NCT00191802|Drug|teriparatide|
525558|NCT00191789|Drug|gemcitabine|1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
525559|NCT00191789|Drug|doxorubicin|60 mg/m^2, IV, every 21 days x 4 cycles (1-4)
525560|NCT00191789|Drug|cisplatin|70 mg/m^2, IV, every 21 days x 4 cycles (5-8)
525561|NCT00191789|Procedure|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
525562|NCT00191763|Drug|Gemcitabine|
525563|NCT00191763|Drug|cisplatin|
525564|NCT00191750|Drug|Pemetrexed|
525565|NCT00191737|Drug|Atomoxetine|
525566|NCT00191724|Drug|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
525567|NCT00191724|Drug|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
525568|NCT00191724|Drug|Placebo|intravenous (IV), one infusion, over 12 hours
525569|NCT00191724|Drug|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
525570|NCT00191724|Drug|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
525571|NCT00191724|Drug|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
525572|NCT00191711|Drug|Gemcitabine|
525573|NCT00191698|Drug|atomoxetine hydrochloride|
525574|NCT00191698|Drug|placebo|
525575|NCT00191685|Drug|duloxetine|
525576|NCT00191672|Drug|Gemcitabine|
525577|NCT00191672|Drug|Paclitaxel|
525578|NCT00191672|Drug|Docetaxel|
525579|NCT00191659|Drug|Atomoxetine Hydrochloride|
525580|NCT00191646|Drug|Gemcitabine|"1000 mg/m^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles~If anything other than complete response in Paclitaxel arm patients, 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
525581|NCT00191646|Drug|Paclitaxel|"175 mg/m^2, IV, Day 1, q 21 days x 6 cycles~If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m^2, IV, 3 hours q 28 days x 12 cycles (1 year)~If no complete response, then Gemcitabine arm patients may receive 175 mg/m^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
525582|NCT00191646|Drug|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles~Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
525583|NCT00191633|Drug|Atomoxetine|
525584|NCT00191620|Drug|Gemcitabine|
525585|NCT00191620|Drug|cisplatin|
525586|NCT00191607|Drug|Gemcitabine|
525587|NCT00191607|Drug|liposomal doxorubicin|
525588|NCT00191594|Drug|Duloxetine Hydrochloride|
525589|NCT00191581|Drug|Humalog Mix 50|
525590|NCT00191581|Drug|Human Insulin Mix 50:50|
525591|NCT00191568|Drug|Gemcitabine|
525592|NCT00191568|Drug|Oxaliplatin|
525593|NCT00191568|Procedure|Radiotherapy|
525594|NCT00191555|Drug|olanzapine|
525595|NCT00191555|Drug|haloperidol|
525605|NCT00191477|Drug|Gemcitabine|2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
525606|NCT00191477|Drug|Placebo|intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
525607|NCT00191464|Drug|premeal insulin lispro mixtures|
525608|NCT00191464|Drug|insulin glargine|
525609|NCT00191464|Drug|metformin|
525610|NCT00191451|Drug|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
525611|NCT00191451|Drug|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
525612|NCT00191451|Drug|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).~Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
525613|NCT00191438|Drug|gemcitabine|
525614|NCT00191438|Drug|capecitabine|
525615|NCT00191438|Drug|docetaxel|
525616|NCT00191425|Drug|Teriparatide|
525617|NCT00191425|Drug|Raloxifene|
525618|NCT00191412|Drug|Pemetrexed|
525619|NCT00191399|Drug|Olanzapine|
525620|NCT00191399|Drug|Fluoxetine|
525621|NCT00191386|Drug|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
525622|NCT00191373|Drug|Gemcitabine|
525623|NCT00191373|Drug|Trastuzumab|
525624|NCT00191360|Drug|Somatropin|
525625|NCT00191347|Drug|pemetrexed|
525626|NCT00191347|Drug|gemcitabine|
525627|NCT00191334|Drug|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
525628|NCT00191334|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
525629|NCT00191321|Drug|Teriparatide|
525630|NCT00191308|Drug|pemetrexed|500 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
525631|NCT00191308|Drug|cisplatin|75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
525632|NCT00191308|Procedure|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
525633|NCT00191295|Drug|Atomoxetine|
525634|NCT00191295|Drug|Placebo|
525635|NCT00191282|Drug|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
525636|NCT00191282|Drug|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values >8.0%
525637|NCT00191282|Drug|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
525638|NCT00191282|Drug|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
525639|NCT00191282|Drug|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values >8.0%.
525640|NCT00191269|Drug|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
525641|NCT00191269|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
525642|NCT00191256|Drug|Gemcitabine|
525643|NCT00191256|Drug|Carboplatin|
525644|NCT00191256|Drug|Paclitaxel|
525645|NCT00191243|Drug|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression~B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
525646|NCT00191243|Drug|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine~B: 80 mg/m2, IV, q 21 days until treatment failure"
525647|NCT00191230|Drug|gemcitabine|
525648|NCT00191230|Drug|carboplatin|
525649|NCT00191230|Drug|cisplatin|
525650|NCT00191204|Drug|Duloxetine|
525651|NCT00191191|Drug|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
525652|NCT00191191|Drug|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
525653|NCT00191178|Drug|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
525654|NCT00191178|Drug|insulin glargine|
525655|NCT00191165|Drug|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
525656|NCT00191165|Drug|Somatropin|In-label dosage
525657|NCT00191152|Drug|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
525658|NCT00191152|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
525659|NCT00191152|Drug|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
525660|NCT00191139|Drug|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
525661|NCT00191139|Drug|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
525662|NCT00191139|Drug|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
525663|NCT00191139|Drug|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
525664|NCT00191139|Radiation|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
525899|NCT00189020|Biological|PCV7|PCV7 at age 2 and 4 months
525665|NCT00191126|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
525666|NCT00191126|Drug|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
525667|NCT00191126|Procedure|surgery|surgery
525668|NCT00191113|Drug|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
525669|NCT00191113|Drug|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
525670|NCT00191113|Drug|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
525671|NCT00191100|Drug|Gemcitabine|
525672|NCT00191100|Drug|Cisplatin|
525673|NCT00191100|Radiation|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
525674|NCT00191100|Radiation|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
525675|NCT00191087|Drug|Duloxetine|
525676|NCT00191074|Drug|somatropin, rDNA origin, for injection|
525677|NCT00191061|Drug|duloxetine hydrochloride|
525678|NCT00191048|Drug|Atomoxetine|
525679|NCT00191035|Drug|Atomoxetine|
525680|NCT00191022|Drug|LY686017|
525681|NCT00191022|Drug|paroxetine|
525682|NCT00191022|Drug|placebo|
525683|NCT00191009|Drug|atomoxetine hydrochloride|
525684|NCT00191009|Drug|placebo|
525685|NCT00190996|Drug|Duloxetine Hydrochloride|
525686|NCT00190996|Drug|placebo|
525687|NCT00190983|Drug|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
525688|NCT00190970|Drug|Ruboxistaurin|
525689|NCT00190957|Drug|Atomoxetine|
525690|NCT00190957|Drug|placebo|
525691|NCT00190944|Drug|Teriparatide|
525692|NCT00190944|Drug|placebo|
525693|NCT00190931|Drug|Atomoxetine Hydrochloride|
525694|NCT00190931|Drug|placebo|
525695|NCT00190918|Drug|Pemetrexed|
525696|NCT00190905|Drug|duloxetine HCl|
525697|NCT00190892|Drug|olanzapine|
525698|NCT00190892|Drug|carbamazepine|
525699|NCT00190879|Drug|Atomoxetine hydrochloride|
525700|NCT00190879|Drug|placebo|
525701|NCT00190866|Drug|Duloxetine|
525702|NCT00190866|Drug|placebo|
525703|NCT00190853|Drug|Duloxetine|
525704|NCT00190840|Drug|pemetrexed|
525705|NCT00190827|Drug|duloxetine|
525706|NCT00190827|Drug|placebo|
525707|NCT00190814|Drug|duloxetine|
525708|NCT00190814|Drug|placebo|
525709|NCT00190801|Drug|pemetrexed|
525710|NCT00190801|Drug|cisplatin|
525711|NCT00190788|Drug|Drotrecogin Alfa (Activated)|
525712|NCT00190788|Drug|placebo|
525713|NCT00190775|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
525714|NCT00190775|Drug|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
525715|NCT00190762|Drug|Pemetrexed|
525716|NCT00190749|Drug|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
525717|NCT00190749|Drug|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
525718|NCT00190736|Drug|Atomoxetine Hydrochloride|
525719|NCT00190736|Drug|placebo|
525720|NCT00190723|Drug|Enzastaurin|
525721|NCT00190710|Drug|Gemcitabine|
525722|NCT00190710|Drug|Carboplatin|
525723|NCT00190697|Drug|arzoxifene|
525724|NCT00190684|Drug|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
525725|NCT00190671|Drug|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
525726|NCT00190671|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
525727|NCT00190671|Drug|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
525728|NCT00190658|Drug|Somatropin (rDNA origin) for injection|
525729|NCT00190645|Drug|Duloxetine|
525730|NCT00190632|Drug|Duloxetine|
525731|NCT00190619|Drug|Duloxetine|
525732|NCT00190619|Drug|Placebo|
525733|NCT00190606|Drug|Duloxetine|
525734|NCT00190606|Procedure|Pelvic Floor Muscle Training (PFMT)|
525735|NCT00190606|Procedure|Imitation PFMT|
525736|NCT00190606|Drug|placebo|
525737|NCT00190593|Drug|raloxifene|
525738|NCT00190593|Drug|placebo|
525739|NCT00190580|Drug|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
525740|NCT00190580|Drug|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
525741|NCT00190567|Drug|duloxetine|
525742|NCT00190567|Drug|Placebo|
525743|NCT00190554|Drug|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
525744|NCT00190554|Drug|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
525745|NCT00190541|Procedure|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
525746|NCT00190541|Procedure|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
525747|NCT00190528|Drug|neoadjuvant chemotherapy + radical hysterectomy|
525748|NCT00190528|Procedure|radical hysterectomy|
525749|NCT00190515|Drug|5FU+l-leucovorin|5FU+l-leucovorin
525750|NCT00190515|Drug|UFT+Leucovorin|UFT+Leucovorin
525751|NCT00190502|Drug|Polyclonal anti-T-cell antibodies|
525752|NCT00190489|Drug|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
525753|NCT00190489|Drug|Docetaxel 60mg/m2 every 21 days for 6 cycles|
540453|NCT00003399|Drug|cisplatin|
525754|NCT00190489|Drug|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
525755|NCT00190476|Drug|Weekly docetaxel alone|
525756|NCT00190476|Drug|Weekly docetaxel + cisplatin combination|
525757|NCT00190463|Drug|Amphotericin B|
525758|NCT00190450|Biological|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
525759|NCT00190437|Drug|Amoxicillin-clavulanic|Amoxicillin-clavulanic
525760|NCT00190424|Drug|CpG-ODN|
525761|NCT00190411|Drug|celiprolol|celiprolol
525762|NCT00190411|Drug|Control|Untreated controls excluding betablockers
525763|NCT00190398|Device|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
525764|NCT00190385|Procedure|Ultrasonographic screening|Ultrasonographic screening
525765|NCT00190372|Behavioral|Controlled diet|Controlled diet
525766|NCT00190372|Behavioral|Self-hypnotic relaxation|Self-hypnotic relaxation
525767|NCT00190346|Device|Humidification devices: HH vs HME|
525768|NCT00190333|Drug|escitalopram|escitalopram
525769|NCT00190320|Procedure|Induction of labor vs waiting|
525770|NCT00190307|Drug|aspirin 75 mg/day|aspirin 75 mg/day
525771|NCT00190294|Drug|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
525772|NCT00190268|Drug|3,4-diaminopyridine|3,4-diaminopyridine
525773|NCT00190255|Procedure|CY2PC9 genotyping|CY2PC9 genotyping
525774|NCT00190242|Drug|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
525775|NCT00190242|Drug|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
525776|NCT00190229|Drug|Cyclophosphamide|Cyclophosphamide
525777|NCT00190216|Device|Magnetic stimulator|
525778|NCT00190203|Procedure|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
525779|NCT00190203|Procedure|hemicraniectomy|hemicraniectomy
525780|NCT00190190|Procedure|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
525781|NCT00190190|Procedure|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
525782|NCT00190164|Procedure|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
525783|NCT00190164|Procedure|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
525784|NCT00190151|Drug|ciprofloxacin|
525785|NCT00190138|Device|Bi-ventricular pacing|
525786|NCT00190112|Procedure|ventral cardiac denervation|
525787|NCT00190099|Device|Dexamethasone-Eluting Stent|
525788|NCT00190060|Drug|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
525789|NCT00190060|Drug|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
525790|NCT00190047|Drug|DP-b99|
525791|NCT00190034|Drug|N-Acetylcysteine 600mg/tab|
525792|NCT00190021|Drug|donepezil|
525793|NCT00190008|Drug|piracetam|
525794|NCT00189995|Drug|clozapine|
525795|NCT00189995|Drug|haloperidol|
525796|NCT00189982|Drug|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
525797|NCT00189969|Biological|Elstree-BN|
525798|NCT00189956|Biological|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
525799|NCT00189943|Biological|MVA-BN|
525800|NCT00189930|Biological|MVA-nef|3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm
525801|NCT00189930|Biological|IMVAMUNE|3 immunizations: 1E8_TCID50 IMVAMUNE
525802|NCT00189917|Biological|IMVAMUNE (MVA-BN)|1x10E08 TCID50, subcutaneous vaccination
525803|NCT00189904|Biological|IMVAMUNE (MVA-BN)|
525804|NCT00189878|Drug|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
525805|NCT00189878|Drug|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
525806|NCT00189852|Device|Chronic heart failure monitoring system|
525807|NCT00189852|Device|Lifestyle monitoring system|
525808|NCT00189839|Drug|tacrolimus|Immunosuppression
525809|NCT00189826|Drug|tacrolimus|immunosuppression
525810|NCT00189813|Drug|YM060|
525811|NCT00189800|Drug|Solifenacin succinate|
525812|NCT00189787|Drug|tacrolimus|
525813|NCT00189774|Drug|nateglinide|
525814|NCT00189761|Drug|Tacrolimus|
525815|NCT00189748|Drug|Tacrolimus|
525816|NCT00189735|Drug|FK778|
525817|NCT00189722|Drug|Tacrolimus|
525818|NCT00189709|Drug|Micafungin|IV
525819|NCT00189709|Drug|fluconazole|IV
525820|NCT00189696|Drug|YM060|
525821|NCT00189683|Procedure|Monitoring|
525822|NCT00189683|Procedure|Xeloda|
525823|NCT00189670|Procedure|6 TEC q 3 weeks|
525824|NCT00189670|Procedure|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
525825|NCT00189670|Procedure|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
525826|NCT00189657|Procedure|5FU/LV Mayo Clinic or LV5FU2|
525827|NCT00189657|Procedure|LV5FU2 + irinotecan|
525828|NCT00189644|Procedure|6 FEC 100|
525829|NCT00189644|Procedure|4 FEC 100 followed by 4 Taxol|
525830|NCT00189631|Procedure|UFT/LV|
525831|NCT00189631|Procedure|Observation|
525832|NCT00189618|Drug|Aspirin|100mg p.o. OD
525833|NCT00189618|Drug|Clopidogrel|75mg p.o. OD
525834|NCT00189605|Device|Perc-DLR/Perc-DLG|Device technique will be used per IFU
525835|NCT00189605|Drug|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
525836|NCT00189592|Device|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
525837|NCT00189592|Procedure|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
525838|NCT00189579|Drug|Herceptin|
525839|NCT00189566|Drug|Paclitaxel|
525840|NCT00189566|Drug|Topotecan|
525841|NCT00189566|Drug|Carboplatin|
525842|NCT00189553|Drug|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
525843|NCT00189553|Drug|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
525844|NCT00189553|Drug|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
525845|NCT00189540|Genetic|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
525846|NCT00189540|Genetic|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
525847|NCT00189527|Procedure|respiratory settings|
525848|NCT00189514|Drug|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
525849|NCT00189514|Drug|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
525850|NCT00189501|Drug|Sensipar®|
525851|NCT00189488|Drug|Palifermin|Administered as an intravenous (IV) bolus.
525852|NCT00189488|Drug|Placebo|Administered as an intravenous (IV) bolus.
525853|NCT00189488|Other|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:~Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)~TBI/VP-16~Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)~Busulfan (Bu)/Cy~Bu/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])~Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])"
525854|NCT00189488|Procedure|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
525855|NCT00189488|Drug|Methotrexate|
525856|NCT00189475|Drug|Montelukast|
525857|NCT00189462|Drug|Montelukast|
525858|NCT00189436|Drug|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
525859|NCT00189436|Drug|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
525860|NCT00189423|Device|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.~The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
525861|NCT00189423|Procedure|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
525862|NCT00189410|Drug|Pegylated Liposomal Doxorubicin and Carboplatin|
525863|NCT00189397|Drug|azathioprine and corticosteroids for Parthenium dermatitis|
525864|NCT00189384|Drug|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
525865|NCT00189371|Drug|paclitaxel, carboplatin, epoetin alpha|
525866|NCT00189358|Drug|ZD1839|
525867|NCT00189358|Drug|tamoxifen|
525868|NCT00189345|Biological|anti-EpCAM x anti-CD3 (removab)|
525869|NCT00189332|Drug|852A|
525870|NCT00189319|Drug|Flecainide controlled release|
525871|NCT00189306|Drug|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
525872|NCT00189293|Drug|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
525873|NCT00189293|Other|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)~1 or 2 sachet(s)"
525874|NCT00189280|Drug|Imiquimod|cream 5%, 5 days out of seven, for 6 weeks
525875|NCT00189267|Drug|Imiquimod 5 % Cream|
525876|NCT00189254|Drug|Imiquimod|No defined treatments were given during this study.
525877|NCT00189241|Drug|imiquimod|
525878|NCT00189228|Drug|Xolair|Patients are administered Xolair
525879|NCT00189215|Device|cardiac stabilizer instead of cardiopulmonary bypass|
525880|NCT00189202|Drug|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
525881|NCT00189189|Behavioral|parent management training|
525882|NCT00189176|Drug|Tetrathiomolybdate|
525883|NCT00189163|Drug|Pioglitazone|30 mg, taken orally, once per day, for 48 weeks
525884|NCT00189163|Drug|Placebo Oral Tablet|Sugar Pill, taken orally, once per day, for 48 weeks
525885|NCT00189150|Drug|Mycophenolate mofetil|
525886|NCT00189150|Drug|Valganciclovir|
525887|NCT00189137|Drug|ifosfamide and doxorubicin vs gemcitabine and docetaxel|"Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.~Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.~All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection."
525888|NCT00189124|Drug|Dehydroepiandrosterone (DHEA)|
525889|NCT00189111|Procedure|Cardiac Imaging + Treatment|
525890|NCT00189098|Drug|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
525891|NCT00189098|Drug|Placebo|
525892|NCT00189085|Drug|simvastatin and ezetimibe|
525893|NCT00189072|Drug|gabapentin|
525894|NCT00189059|Drug|amitriptyline|
525895|NCT00189046|Behavioral|driving and laboratory tests|
525896|NCT00189033|Drug|psyllium fibre (dietary supplement)|
525897|NCT00189033|Drug|wheat bran (dietary supplement)|
525898|NCT00189033|Drug|rice wheat (placebo)|
525900|NCT00189020|Biological|PCV7|PCV7 at age 2, 4 and 11 months
525901|NCT00189007|Drug|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
525902|NCT00189007|Drug|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
525903|NCT00188994|Drug|Insulin Cardioplegia|
525904|NCT00188968|Procedure|Nasal Continuous Positive Airway Pressure|
525905|NCT00188968|Procedure|Synchronized Nasal Positive Pressure Ventilation|
525906|NCT00188955|Drug|sirolimus|
525907|NCT00188942|Drug|Fluoxetine+Olanzapine|
525908|NCT00188942|Drug|Olanzapine|
525909|NCT00188942|Procedure|Functional Magnetic Resonance Imaging|
525910|NCT00188929|Procedure|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
525911|NCT00188903|Procedure|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
525912|NCT00188877|Procedure|intensity modulated radiation therapy|
525913|NCT00188877|Drug|cisplatinium and fluorouracil - standard treatment|
525914|NCT00188864|Drug|dexamethasone|
525915|NCT00188851|Drug|therapeutic management strategy|
525916|NCT00188838|Behavioral|Psychoeduction|
525917|NCT00188838|Behavioral|Cognitive-Behavioral Therapy|
525918|NCT00188825|Other|placebo|
525919|NCT00188825|Drug|basiliximab|
525920|NCT00188812|Drug|donepezil hcl|
525921|NCT00188799|Procedure|daily Xray volume imaging for planning radiotherapy|
525922|NCT00188786|Procedure|daily Cone Beam CT for imaging guidance for radiotherapy|
525923|NCT00188773|Drug|N-acetylcysteine, intralipid, heparin|One visit subject will receive N-acetylcysteine plus intralipid and heparin, another visit n-acetylcyksteine plus saline, another visit intralipid and heparin and another visit saline alone
525924|NCT00188747|Procedure|Thromboelastograph, Point of Care|
525925|NCT00188708|Procedure|hypoxia measurement|transrectal oxygen measurement
525926|NCT00188695|Procedure|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
525927|NCT00188669|Drug|pentoxifylline|
525928|NCT00188669|Drug|alpha-Tocopherol|
525929|NCT00188656|Procedure|CT thorax|
525930|NCT00188643|Drug|Venlafaxine and Lamotrigine|
525931|NCT00188630|Drug|N-acetylcysteine|
525932|NCT00188630|Other|5% dextrose solution|
525933|NCT00188617|Drug|GEFITINIB|250 mg once a day for 28 days before surgery
525934|NCT00188604|Drug|sodium selenite|
525935|NCT00188578|Procedure|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
525936|NCT00188565|Drug|Celecoxib|
525937|NCT00188552|Drug|pentoxifylline|
525938|NCT00188552|Drug|α-Tocopherol|
525939|NCT00188539|Procedure|Pre-treatment tumour oxygen measurements (under anesthesia)|
525940|NCT00188526|Device|lung biopsy|
525941|NCT00188513|Procedure|conformal intensity modulated radiotherapy (IMRT)|
525942|NCT00188500|Behavioral|atkins diet|
525943|NCT00188500|Behavioral|ability to follow low carbohydrate diet|
525944|NCT00188487|Device|magnetic resonance imaging (MRI) of the thorax|
525945|NCT00188474|Behavioral|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
525946|NCT00188461|Device|CT Thorax|
525947|NCT00188448|Device|MRI|
525948|NCT00188435|Procedure|Minimum Dose CT|
525949|NCT00188422|Procedure|low dose CT|
525950|NCT00188409|Procedure|CT scan|
525951|NCT00188396|Drug|Citalopram|
525952|NCT00188383|Drug|Amantadine|
525953|NCT00188370|Procedure|high frequency ultrasound imaging|
525954|NCT00188357|Behavioral|Education|
525955|NCT00188344|Procedure|pneumatic dilatation|"The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.~The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours."
525956|NCT00188344|Procedure|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
525957|NCT00188331|Behavioral|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
525958|NCT00188318|Procedure|hyperfractionated accelerated radiotherapy|
525959|NCT00188305|Behavioral|General health counselling and risk information|General health counselling and risk information
525960|NCT00188279|Procedure|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
525961|NCT00188266|Drug|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
525962|NCT00188240|Drug|Pegasys; Copegus.|
525963|NCT00188227|Drug|Midazolam (sedative)|
525964|NCT00188227|Drug|Piritramid (analgetic)|
525965|NCT00188227|Behavioral|Cognitive exercises|
525966|NCT00188214|Procedure|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
525967|NCT00188188|Drug|quinipril|
525968|NCT00188175|Radiation|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
525969|NCT00188162|Device|CT|
525970|NCT00188149|Drug|Combined chemotherapy (ABVD, BACOPP-D)|
525971|NCT00188149|Procedure|Radiation therapy|
525972|NCT00188136|Drug|Melphalan, ATG, Fludarabine|allo Tx during aplasia
525973|NCT00188110|Procedure|Water-Enema Computed Tomography|
525974|NCT00188097|Behavioral|Diagnosis of variceal bleeding and dits control in cirrhosis|
525975|NCT00188084|Procedure|DNA Index|
525976|NCT00188084|Procedure|S-Phase%|
525977|NCT00188084|Procedure|CD45 expression|
525978|NCT00188084|Procedure|P16 metabolic way|
525979|NCT00188071|Drug|paracetamol|
525980|NCT00188071|Drug|ketoprofen|
525981|NCT00188071|Drug|ketoprofen + paracetamol|
525982|NCT00188058|Device|Setting of positive end-expiratory pressure|
525983|NCT00188045|Drug|Propranolol - Spironolactone|
525984|NCT00188032|Procedure|Computer-Assisted diagnostic Decision Support|
525985|NCT00188032|Procedure|written diagnostic guidelines|
525986|NCT00188032|Procedure|electronic therapeutic reminders|
525987|NCT00188019|Procedure|diagnosis methods|
525988|NCT00188006|Device|heparin-coated cardiopulmonary bypass|
525989|NCT00187993|Drug|Growth hormone|
525990|NCT00187967|Device|pumps used for cardiopulmonary bypass|
525991|NCT00187941|Drug|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
525992|NCT00187928|Drug|Topiramate|
525993|NCT00187915|Drug|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
525994|NCT00187915|Drug|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
525995|NCT00187889|Drug|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
525996|NCT00187889|Drug|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
525997|NCT00187876|Procedure|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
525998|NCT00187876|Procedure|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
525999|NCT00187863|Behavioral|pain perception|pain perception
526000|NCT00187850|Procedure|PP|Partial pulpotomy
526001|NCT00187850|Procedure|DPC|Direct pulp capping
526002|NCT00187837|Procedure|SW|Stepwise removal of carious tissue in 2 stages
526003|NCT00187837|Procedure|DCE|one complete excavation
526004|NCT00187811|Procedure|Delta amino leavulinic acid photodynamic therapy|
526005|NCT00187798|Drug|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
526006|NCT00187785|Behavioral|Spanish speaker level|
526007|NCT00187772|Behavioral|Child-Parent Psychotherapy (CPP)|
526008|NCT00187759|Drug|cephalexin|
526009|NCT00187746|Drug|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
526010|NCT00187733|Other|Fasting blood and urine collection|Not applicable no drugs dispensed
526011|NCT00187720|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
526012|NCT00187707|Drug|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
526013|NCT00187681|Drug|Metformin|2 doses of Metformin Day 1 1000mg, Day 2 850 mg
526014|NCT00187655|Drug|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
526015|NCT00187629|Behavioral|dietary phosphorus|varying amts dietary phosphorus
526016|NCT00187603|Behavioral|tobacco cessation program|
526017|NCT00187590|Behavioral|Case manager phone call after an ER visit|
526018|NCT00187577|Drug|Latanoprost (Xalatan)|
526019|NCT00187577|Drug|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
526020|NCT00187577|Drug|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
526021|NCT00187564|Drug|controlled-release oral alpha-lipoic acid|
526022|NCT00187551|Other|Interruption of enfuvirtide|treatment interruption
526023|NCT00187551|Other|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
526024|NCT00187538|Behavioral|Dietary|dietary
526025|NCT00187525|Drug|Memantine|
526026|NCT00187499|Drug|Inhaled fluticasone 500 ug BID for 8 weeks|
526027|NCT00187486|Drug|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
526028|NCT00187486|Drug|Temodar|Temodar 200 mg/m^2/day x 5 days every 28 days
526029|NCT00187486|Procedure|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
526030|NCT00187473|Procedure|liver biopsy|Liver biopsy every 5 years
526031|NCT00187460|Behavioral|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
526032|NCT00187447|Drug|indomethacin (two different dosing regimens)|
526033|NCT00187434|Device|Infant Flow System|
526034|NCT00187434|Device|Bubble CPAP|
526035|NCT00187421|Procedure|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.~transit time flowmetry performed on all grafts after all grafts completed."
526036|NCT00187408|Drug|Low Molecular Weight Heparin (dalteparin)|
540454|NCT00003399|Drug|cyclophosphamide|
526037|NCT00187395|Procedure|Randomized to either a 'less tight' group or a 'tight' group|
526038|NCT00187382|Drug|Multiple vs. single courses of antenatalcorticosteroids|
526039|NCT00187369|Procedure|Method of Delivery|CS or VB
526040|NCT00187356|Procedure|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
526041|NCT00187343|Device|Breast IMRT|
526042|NCT00187330|Drug|Intravenous N-acetylcysteine|
526043|NCT00187317|Behavioral|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
526044|NCT00187317|Other|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
526045|NCT00187304|Device|Aortic valve replacement|
526046|NCT00187291|Device|T-Wave Alternans test|
526047|NCT00187278|Device|Biventricular Pacing|Biventricular Pacemaker implant
526048|NCT00187278|Device|RV Pacing|Standard Pacemaker implant
526049|NCT00187265|Device|Cardiac Resynchronization Therapy|
526050|NCT00187252|Device|Atrial Overdrive Pacing|Pacemaker/ ICD implant
526051|NCT00187239|Device|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
526052|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
526053|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
526054|NCT00187213|Device|Cardiac Resynchronization Therapy|
526055|NCT00187200|Device|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
526056|NCT00187200|Device|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
526057|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
526058|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
526059|NCT00187174|Drug|Everolimus|The drug is given orally in 28 day courses.
526060|NCT00187161|Drug|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
526061|NCT00187148|Biological|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
526062|NCT00187135|Drug|Fentanyl|"Fentanyl - 1 mcg/kg in 3 ml normal saline~Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
526063|NCT00187135|Drug|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
526064|NCT00187135|Drug|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
526065|NCT00187135|Drug|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
526066|NCT00187122|Drug|Vincristine|See Detailed Description section for description of treatment plan.
526067|NCT00187122|Procedure|Radiation Therapy|See Detailed Description section for description of treatment plan.
526068|NCT00187122|Drug|Daunomycin|See Detailed Description section for description of treatment plan.
526069|NCT00187122|Drug|L-Asparaginase|See Detailed Description section for description of treatment plan.
526070|NCT00187122|Drug|Cytarabine|See Detailed Description section for description of treatment plan.
526071|NCT00187122|Drug|Methotrexate|See Detailed Description section for description of treatment plan.
526072|NCT00187122|Drug|Mercaptopurine|See Detailed Description section for description of treatment plan.
526073|NCT00187122|Drug|Etoposide|See Detailed Description section for description of treatment plan.
526074|NCT00187122|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
526075|NCT00187122|Drug|Prednisone|See Detailed Description section for description of treatment plan.
526076|NCT00187122|Drug|Dexamethasone|See Detailed Description section for description of treatment plan.
526077|NCT00187109|Drug|Recombinant Human Thrombopoietin|
526078|NCT00187096|Drug|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
526079|NCT00187096|Procedure|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
526080|NCT00187096|Device|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
526081|NCT00187083|Drug|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
526082|NCT00187083|Drug|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
526083|NCT00187083|Drug|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
526084|NCT00187083|Drug|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
526085|NCT00187083|Drug|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
526086|NCT00187083|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
526087|NCT00187070|Drug|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
526088|NCT00187070|Procedure|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
540455|NCT00003399|Drug|dexamethasone|
526089|NCT00187070|Radiation|Radiation Therapy|See Detailed Description section for details of treatment interventions.
526090|NCT00187057|Drug|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
526091|NCT00187057|Drug|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
526092|NCT00187057|Drug|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
526093|NCT00187057|Drug|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
526094|NCT00187057|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
526095|NCT00187044|Biological|PolyEnv1 vaccine|administered subcutaneously as 10*7 pfu in 0.8 mL
526096|NCT00187031|Drug|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
526097|NCT00187018|Biological|Bone marrow transplant|
526098|NCT00187005|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
526099|NCT00187005|Drug|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
526100|NCT00186992|Radiation|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
526101|NCT00186979|Drug|Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.|See Detailed Description section for details of treatment interventions.
526102|NCT00186966|Drug|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
526103|NCT00186966|Drug|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
526104|NCT00186966|Procedure|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
526105|NCT00186966|Radiation|Total body irradiation|See Detailed Description section for details of treatment interventions.
526106|NCT00186953|Drug|Optison|"Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m^2 and escalated at 0.15 ml/m^2 increments, to 0.275 ml/m^2 and 0.425ml/m^2 and 0.500ml/m^2. We will now continue to escalate the dose of Optison at 0.300ml/m^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
526107|NCT00186940|Drug|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
526108|NCT00186927|Biological|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10^5 to 5 x 10^7 EID(50) units.
526109|NCT00186914|Biological|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.~As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.~Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10^6 MSC/kg and the second dose of cells will be 5x10^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
526110|NCT00186901|Drug|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
526111|NCT00186901|Other|Placebo|Placebo
526112|NCT00186888|Procedure|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.~For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
526113|NCT00186888|Drug|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
526114|NCT00186888|Procedure|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
526115|NCT00186888|Radiation|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
526116|NCT00186888|Drug|Vincristine and Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml*hr, daily for 5 consecutive days, infused over 30 minutes.
526117|NCT00186888|Drug|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.~Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
526215|NCT00186056|Drug|Placebo Oral Tablet|Inactive placebo tab
526216|NCT00186043|Drug|Quetiapine/Seroquel|Quetiapine/Seroquel
526118|NCT00186888|Drug|vincristine, cyclophosphamide, and doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: < 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin < 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
526119|NCT00186888|Drug|Vincristine, Carboplatin and Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
526120|NCT00186888|Procedure|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
526121|NCT00186888|Other|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is > 2,000/mL in one occasion after the expected nadir.
526122|NCT00186875|Drug|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
526123|NCT00186875|Drug|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
526124|NCT00186875|Drug|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
526125|NCT00186875|Drug|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
526126|NCT00186875|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
526127|NCT00186875|Procedure|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
526128|NCT00186875|Procedure|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
526129|NCT00186862|Drug|Interleukin-2|"A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.~At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received."
526130|NCT00186849|Drug|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
526131|NCT00186849|Procedure|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
526132|NCT00186836|Biological|Engerix-B and Twinrix|
526133|NCT00186823|Device|Miltenyi Biotec CliniMACS|A stem cell selection device.
526134|NCT00186823|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
526135|NCT00186823|Drug|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
526136|NCT00186810|Drug|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
526137|NCT00186810|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
526138|NCT00186797|Procedure|Allogeneic stem cell transplant|
526139|NCT00186797|Drug|Fludarabine, Cyclophosphamide|
526140|NCT00186784|Procedure|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
526141|NCT00186771|Device|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
526142|NCT00186771|Device|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
526143|NCT00186758|Device|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.~Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
526144|NCT00186745|Drug|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
526145|NCT00186732|Procedure|Subcuticular Suture|
526146|NCT00186732|Procedure|Surgical Staples|
526147|NCT00186706|Drug|Selenium|
526148|NCT00186680|Procedure|high dose chemo then auto hematopoietic cell transplant|
526149|NCT00186667|Procedure|high dose chemotherapy and autologous hematopoietic cell transplant|
526150|NCT00186654|Procedure|Acupuncture|
526151|NCT00186654|Procedure|Perinatal massage|
526152|NCT00186641|Procedure|high dose chemo and auto hematopoietic cell transplant|
526153|NCT00186628|Procedure|Total lymphoid irradiation|Total lymphoid irradiation (TLI) administered at 80cGy for 10 days
526154|NCT00186628|Drug|Rituximab|Rituximab 375 mg/m2 administered as an intravenous (IV) infusion once weekly for 4 doses.
526155|NCT00186628|Drug|Anti-thymoglobulin, rabbit (ATG, rabbit ATG)|Rabbit anti-thymoglobulin (ATG) administered from Day -11 through Day -7 (5 doses) at 1.5 mg/kg/day, for a total dose of 7.5 mg/kg.
526217|NCT00186043|Drug|Placebo|Placebo
526218|NCT00186030|Behavioral|HIV Skills-based Prevention|
526266|NCT00185614|Procedure|Autologous hematopoietic cell transplant (Auto-HCT)|The target cell dose is 2.6 x 10e6 CD34+ cells/kg
526156|NCT00186628|Drug|Cyclosporine|Cyclosporine (CSP) administered orally at 6.25 mg/kg twice-a-day (BID) from Day -3 until through Day +56 post-peripheral blood progenitor cell (PBPC) infusion. Dose may be adjusted to maintain a therapeutic level of cyclosporine, or in response to renal insufficiency. If at Day +56, chimerism assessment demonstrates > 40% donor cells in the CD3+ lineage, and the patient is without evidence of GvHD, then cyclosporine taper will begin (6% reduction per week).
526157|NCT00186628|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) will be administered at 15 mg/kg po Day 0, at 5 to 10 hours after mobilized PBPC infusion is complete
526158|NCT00186628|Drug|Filgrastim|Filgrastim provided as needed for neutrophil support
526159|NCT00186628|Drug|Granisetron|Granisetron administered as an anti-nausea agent (anti-emetic) at 1 mg orally 30 to 60 minutes before TLI
526160|NCT00186628|Drug|Solumedrol|Solumedrol, an anti-inflammatory glucocorticoid containing methylprednisolone sodium succinate, administered at 1 mg/kg as a premedication for anti-thymoglobulin (ATG)
526161|NCT00186628|Drug|Acetaminophen|Acetaminophen administered orally at 650 mg 1 hour prior to infusion of PBPC
526162|NCT00186628|Drug|Diphenhydramine|Diphenhydramine administered by intravenous infusion at 50 mg 1 hour prior to infusion of PBPC
526163|NCT00186628|Drug|Hydrocortisone|Hydrocortisone administered by intravenous infusion at 100 mg 1 hour prior to infusion of PBPC
526164|NCT00186602|Behavioral|Peer counseling|
526165|NCT00186589|Drug|90Y Ibritumomab tiuxetan|
526166|NCT00186576|Procedure|nonmyeloablative allogeneic hematopoietic cell transplant|
526167|NCT00186563|Procedure|Micro-plasmapheresis|
526168|NCT00186550|Behavioral|Supportive Expressive Group Psychotherapy|
526169|NCT00186550|Behavioral|Education|
526170|NCT00186537|Drug|Rosiglitazone|
526171|NCT00186537|Drug|Fenofibrate|
526172|NCT00186537|Behavioral|Weight Loss|
526173|NCT00186524|Behavioral|Breast Cancer Support Group|
526174|NCT00186511|Behavioral|workbook/journal on coping with breast cancer|
526175|NCT00186511|Behavioral|supportive expressive group therapy using videoconferencing|
526176|NCT00186498|Drug|memantine|Patients received a memantine containing capsule starting the day before ECT begins and while receiving ECT
526177|NCT00186498|Drug|Placebo Oral Capsule|Patients received a placebo capsule starting the day before ECT begins and while receiving ECT
526178|NCT00186485|Device|MagStim|The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
526179|NCT00186472|Behavioral|Brief Cognitive Behavioral Treatment|
526180|NCT00186459|Behavioral|Hypocaloric diet of varying macronutrient composition|
526181|NCT00186446|Drug|bupropion and smoking cessation behavioral intervention|
526182|NCT00186420|Drug|Taxotere|
526183|NCT00186407|Procedure|high dose chemo then auto hematopoietic cell transplant|
526184|NCT00186394|Procedure|ablative allogeneic hematopoietic cell transplantation|
526185|NCT00186381|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
526186|NCT00186355|Procedure|high dose chemo then auto hematopoietic cell transplant|
526187|NCT00186342|Procedure|ablative allogeneic hematopoietic cell transplantation|
526188|NCT00186329|Drug|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
526189|NCT00186316|Biological|Idiotype-pulsed allogeneic dendritic cells|
526190|NCT00186303|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
526191|NCT00186303|Procedure|ablative allogeneic hematopoietic cell transplant|
526192|NCT00186290|Procedure|ablative allogeneic hematopoietic cell transplantation|
526193|NCT00186277|Drug|Oxaliplatin|Calculated per patient
526194|NCT00186277|Drug|Taxotere|Calculated per patient
526195|NCT00186264|Drug|venlafaxine XR|
526196|NCT00186264|Drug|hydrocortisone|
526197|NCT00186251|Procedure|high dose chemo then auto hematopoietic cell transplant|
526198|NCT00186238|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
526199|NCT00186225|Procedure|ablative allogeneic hematopoietic cell transplantation|
526200|NCT00186212|Behavioral|workbook/journal on coping with breast cancer|
526201|NCT00186212|Behavioral|standard educational materials on breast cancer|
526202|NCT00186186|Drug|Depakote ER|Depakote ER
526203|NCT00186173|Behavioral|After school sports program|After school team sports intervention designed specifically for overweight and obese children
526204|NCT00186173|Behavioral|After school health education|After school health and nutrition education program
526205|NCT00186147|Procedure|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
526206|NCT00186134|Behavioral|physical activity|
526207|NCT00186121|Drug|Anastrozole (Arimidex)|Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
526208|NCT00186121|Drug|Goserelin (Zoladex)|Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
526209|NCT00186108|Drug|Oral Triamcinalone|
526210|NCT00186095|Procedure|autologous followed by nonmyeloablative allogeneic transplant|
526211|NCT00186082|Drug|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.~Normal Saline, 100 ml intravenously for placebo arm."
526212|NCT00186069|Drug|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
526213|NCT00186069|Other|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
526214|NCT00186056|Drug|Mifepristone|Glucocorticoid antagonist
526219|NCT00186017|Drug|Olanzapine/Zyprexa|Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
526220|NCT00186004|Device|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
526221|NCT00185991|Drug|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).~Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
526222|NCT00185978|Behavioral|diet, physical activity, reduced sedentary behavior|
526223|NCT00185965|Drug|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
526224|NCT00185952|Drug|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
526225|NCT00185939|Drug|Augmentin|
526226|NCT00185900|Drug|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
526227|NCT00185900|Drug|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
526228|NCT00185887|Drug|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
526229|NCT00185874|Biological|Intratumoral Dendritic Cell Immunotherapy|
526230|NCT00185874|Biological|autologous dendritic cells|
526231|NCT00185861|Drug|Arsenic Trioxide|
526232|NCT00185861|Procedure|Stereotactic radiosurgery|
526233|NCT00185848|Radiation|[18F]FHBG|< 7mCi and 2 ug, iv
526234|NCT00185835|Drug|ZD-1839|
526235|NCT00185835|Drug|Cisplatin|
526236|NCT00185796|Procedure|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
526237|NCT00185796|Procedure|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
526238|NCT00185783|Drug|Hydrocortisone Administration (Standard of Care Therapy)|
526239|NCT00185770|Behavioral|Reducing television and other screen time (SMART curriculum)|
526240|NCT00185757|Drug|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
526241|NCT00185744|Radiation|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
526242|NCT00185744|Procedure|Lumpectomy|
526243|NCT00185744|Radiation|Whole Breast Radiotherapy|six and a half week treatment
526244|NCT00185744|Radiation|Intracavitary Brachytherapy|5 day treatment
526245|NCT00185744|Radiation|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
526246|NCT00185744|Radiation|Stereotactic APBI|4 day treatment
526247|NCT00185731|Drug|Atorvastatin|80 mg orally once daily
526248|NCT00185705|Drug|Telmisartan|
526249|NCT00185692|Procedure|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
526250|NCT00185692|Drug|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
526251|NCT00185692|Drug|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
526252|NCT00185692|Drug|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
526253|NCT00185692|Drug|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
526254|NCT00185692|Drug|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
526255|NCT00185692|Drug|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
526256|NCT00185692|Drug|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
526257|NCT00185692|Drug|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
526258|NCT00185679|Device|CliniMACS System|"The CliniMACS System is a cell selection device consisting of the following components:~Computer-controlled instrument;~Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)~Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)~Wash buffer"
526259|NCT00185666|Procedure|Stereotactic radiosurgery|
526260|NCT00185653|Procedure|Autologous followed by non-myeloablative allogeneic transplantation|
526261|NCT00185640|Drug|Cyclosporine|starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
526262|NCT00185640|Drug|Anti-Thymocyte Globulin|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
526263|NCT00185640|Drug|mycophenolate mofetil|Begins on day 0 after HCT at a dose of 15 mg/kg. Patients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
526264|NCT00185640|Drug|Granulocyte-Colony Stimulating Factor|Received on day 0
526265|NCT00185640|Radiation|Total Lymphoid Irradiation|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
540456|NCT00003399|Drug|etoposide|
526267|NCT00185614|Procedure|Allogeneic hematopoietic cell transplant (Allo-HCT)|The target cell dose is 5 x 10e6 CD34 cells/kg
526268|NCT00185614|Drug|Cyclophosphamide|Cyclophosphamide administered intravenously (IV) at 4 mg /m² mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion
526269|NCT00185614|Drug|Filgrastim|"Filgrastim 10 µg/kg/day to mobilize peripheral blood progenitor cells (PBPC) for autologous re-infusion (Auto-HCT)~Filgrastim 5 µg/kg/day starting 6 days after melphalan (Day 4 after Auto-HCT)~Filgrastim 16 µg/kg/day to mobilize donor peripheral blood progenitor cells (PBPC) for allogeneic transplant (Allo-HCT)"
526270|NCT00185614|Drug|Melphalan|Melphalan 200 mg/m2 (high-dose) intravenously as conditioning for Auto-HCT
526271|NCT00185614|Radiation|Total body irradiation (TBI)|200 centigray (cGy) total body irradiation delivered on Day 0
526272|NCT00185614|Procedure|Cyclosporine (CSP)|Cyclosporine administered twice-daily by mouth at a dose of 6.25 mg/kg from Day -3 through Day 56
526273|NCT00185614|Drug|Mycophenolate Mofetil (MMF)|Mycophenolate mofetil will begin at 15 mg/kg twice-daily by mouth from Day 0 to Day 27
526274|NCT00185601|Behavioral|Internet Diabetes Self-Management Program|
526275|NCT00185588|Drug|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
526276|NCT00185588|Drug|Gemcitabine|850 mg/m2
526277|NCT00185575|Drug|duloxetine|
526278|NCT00185562|Drug|Adalimumab|
526279|NCT00185549|Behavioral|CF. DOC|
526280|NCT00185536|Behavioral|Packaging and identification of source|
526281|NCT00185523|Procedure|Allogeneic hematopoietic cell transplantation|
526282|NCT00185510|Drug|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
526283|NCT00185510|Drug|Placebo|2 days a week Vehicle (Advabase)
526284|NCT00185484|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
526285|NCT00185458|Drug|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
526286|NCT00185445|Drug|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
526287|NCT00185419|Drug|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
526288|NCT00185419|Drug|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
526289|NCT00185393|Biological|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
526290|NCT00185393|Other|no treatment|no treatment
526291|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
526292|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
526293|NCT00185380|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
526294|NCT00185367|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
526295|NCT00185367|Drug|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
526296|NCT00185354|Drug|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
526297|NCT00185354|Drug|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
526298|NCT00185341|Drug|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
526299|NCT00185341|Drug|Placebo|Placebo
526300|NCT00185328|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
526301|NCT00185315|Drug|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
526302|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
526303|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
526304|NCT00185289|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
526305|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
526306|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
526307|NCT00185263|Genetic|AdF5FGF-4 vs. Placebo|Intracoronary infusion
526308|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
526309|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
526310|NCT00185250|Drug|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
526311|NCT00185250|Drug|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
526312|NCT00185237|Drug|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
526313|NCT00185237|Drug|Placebo|Placebo patch
526314|NCT00185224|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
526315|NCT00185224|Drug|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
526316|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
526317|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
526318|NCT00185198|Drug|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
526319|NCT00185198|Drug|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
526320|NCT00185185|Drug|Olmesartan medoxomil|
526321|NCT00185185|Drug|Atenolol|
526322|NCT00185185|Drug|Hydrochlorothiazide|tablets
526323|NCT00185185|Drug|olmesartan medoxomil|tablets
526324|NCT00185185|Drug|atenolol|tablets
526325|NCT00185172|Other|placebo|Placebo oral tablets for 2 weeks
526326|NCT00185172|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
526327|NCT00185172|Drug|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
526328|NCT00185159|Drug|Olmesartan medoxomil|tablets
526329|NCT00185159|Drug|Placebo Tablets|Tablets
526330|NCT00185146|Drug|Pactimibe|
526331|NCT00185133|Drug|Olmesartan medoxomil|
526332|NCT00185133|Drug|Amlodipine|
526333|NCT00185120|Drug|Olmesartan medoxomil|
526334|NCT00185120|Drug|Hydroclorothiazide|
526335|NCT00185120|Drug|Benazepril|
526336|NCT00185120|Drug|Amlodipine|
526337|NCT00185107|Drug|Colesevelam Hydrochloride|
526338|NCT00185107|Drug|Ezetimibe|
526339|NCT00185107|Drug|Simvastatin|
526340|NCT00185094|Drug|Olmesartan medoxomil|
526341|NCT00185094|Drug|Losartan potassium|
526342|NCT00185094|Drug|Atenolol|
526343|NCT00185081|Drug|Indium labeled IMP-205xm734|
526344|NCT00185068|Drug|Olmesartan medoxomil|
526345|NCT00185068|Drug|Olmesartan medoxomil/hydrochlorothiazide|
526346|NCT00185068|Drug|Hydrochlorothiazide|
526347|NCT00185055|Drug|Olmesartan medoxomil|
526348|NCT00185055|Drug|Irbesartan|
526349|NCT00185055|Drug|Valsartan|
526350|NCT00185042|Drug|Pactimibe, CS-505|
526351|NCT00185029|Procedure|Ferumoxtran-10 enhanced MRI (MRL)|
526352|NCT00185016|Behavioral|a training to improve recognition of partner abuse.|
526353|NCT00185003|Drug|endotoxin|
526354|NCT00185003|Drug|Potassium channel blockers: TEA, Quinin, Tolbutamide|
526355|NCT00185003|Drug|L-NMMA|
526356|NCT00184990|Drug|Aminoguanidine|
526357|NCT00184990|Drug|endotoxin|
526358|NCT00184977|Drug|N-acetylcysteine|
526359|NCT00184977|Drug|fluticasone propionate|
526360|NCT00184964|Procedure|CT-scan, PET-scan|
526361|NCT00184951|Drug|Rosuvastatin|
526362|NCT00184938|Drug|morphine|
526363|NCT00184938|Drug|naloxone|
526364|NCT00184938|Drug|Technetium-TC99m-labeled Annexin A5|
526365|NCT00184938|Procedure|forearm ischemic exercise|
526366|NCT00184938|Procedure|ten minute forearm ischemia|
526367|NCT00184925|Procedure|Tracheostomy|trachesotomy with subglottic drainage
526368|NCT00184925|Device|cannula with subglottic drainage|
526369|NCT00184912|Drug|caffeine|
526370|NCT00184912|Drug|Technetium-TC99m-labeled Annexin A5|
526371|NCT00184912|Procedure|ten minutes forearm ischemia|
526372|NCT00184912|Procedure|ischemic forearm exercise|
526373|NCT00184899|Drug|Intravenous infusion of Intralipid/heparin|
526374|NCT00184899|Drug|Intravenous infusion of Glycerol/heparin|
526375|NCT00184886|Drug|Methotrexate 15 mg/week for 12 weeks|
526376|NCT00184873|Behavioral|Health Counseling|
526377|NCT00184860|Procedure|PET-scan, MRI-scan|
526378|NCT00184847|Drug|acetylcholine|
526379|NCT00184847|Procedure|twenty minutes of forearm ischemia|
526380|NCT00184847|Procedure|three 5-minute periods of forearm ischemia|
526381|NCT00184847|Drug|adenosine|
526382|NCT00184847|Drug|caffeine|
526383|NCT00184834|Behavioral|quality of life|
526384|NCT00184821|Procedure|Ischemic preconditioning|
526385|NCT00184821|Procedure|Forearm ischemic exercise|
526386|NCT00184821|Procedure|Annexin A5 scintigraphy|
526387|NCT00184821|Drug|Diazoxide|
526388|NCT00184821|Drug|glibenclamide|
526389|NCT00184821|Drug|adenosine|
526390|NCT00184795|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
526391|NCT00184795|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
526392|NCT00184795|Drug|placebo|Placebo tablets for 24 weeks
526393|NCT00184782|Procedure|FDG-PET|
526394|NCT00184769|Drug|somatropin|
526395|NCT00184756|Drug|somatropin|
526396|NCT00184743|Drug|somatropin|
526397|NCT00184730|Drug|somatropin|
526398|NCT00184717|Drug|somatropin|0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
526399|NCT00184717|Drug|somatropin|0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
526400|NCT00184691|Drug|somatropin|
526401|NCT00184678|Drug|somatropin|
526402|NCT00184665|Drug|insulin detemir|
526403|NCT00184665|Drug|insulin NPH|
526404|NCT00184665|Drug|insulin aspart|
526405|NCT00184652|Drug|somatropin|
526406|NCT00184639|Drug|insulin detemir|
526407|NCT00184626|Drug|biphasic insulin aspart|
526408|NCT00184626|Drug|insulin glargine|
526409|NCT00184626|Drug|metformin|
526410|NCT00184613|Device|pump|
526411|NCT00184613|Drug|insulin glargine|
526412|NCT00184613|Drug|insulin aspart|
526413|NCT00184600|Drug|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
526414|NCT00184600|Drug|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
526415|NCT00184600|Drug|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
526416|NCT00184587|Drug|candesartan cilexetil|
526417|NCT00184587|Drug|placebo|
526418|NCT00184574|Drug|biphasic insulin aspart|
526419|NCT00184574|Drug|metformin|
526420|NCT00184561|Drug|biphasic insulin aspart|
526421|NCT00184548|Drug|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.~Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
526422|NCT00184548|Drug|placebo|placebo
526423|NCT00184522|Drug|Aflurax|
526424|NCT00184522|Drug|esomeprazole|
526425|NCT00184509|Behavioral|integrated psychosocial treatment (behavior)|
526426|NCT00184496|Drug|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
526427|NCT00184483|Procedure|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
526428|NCT00184483|Procedure|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
526429|NCT00184457|Behavioral|Strength training intervention|
526430|NCT00184444|Behavioral|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
526431|NCT00184444|Behavioral|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
526432|NCT00184431|Behavioral|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
526433|NCT00184392|Procedure|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
526434|NCT00184379|Behavioral|Psychoeducation|Structured disorder-related educational program for relatives
526435|NCT00184366|Drug|efalizumab|efalizumab
526436|NCT00184340|Device|eTherapy|secured e-mail system between patient and therapist
526437|NCT00184327|Behavioral|Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment
526438|NCT00184327|Behavioral|Diagnostic assessment - child and adolescent psychiatry|
526439|NCT00184301|Behavioral|inpatient treatment|inpatient treatment during 1 year
526440|NCT00184301|Behavioral|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
526441|NCT00184262|Behavioral|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
526442|NCT00184262|Behavioral|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
526443|NCT00184249|Procedure|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
526444|NCT00184236|Behavioral|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
526445|NCT00184236|Behavioral|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
526446|NCT00184223|Behavioral|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
526447|NCT00184223|Other|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
526448|NCT00184197|Drug|Botulinum toxin|
526449|NCT00184197|Drug|Placebos|
526450|NCT00184171|Drug|Budesonide|Budesonide 9 mg
526451|NCT00184171|Drug|Bismuth|Bismuth mixture
526452|NCT00184171|Drug|Fiber|Fiber for control
526453|NCT00184158|Procedure|decompression|Conservative, simple decompression and nerve transfer
526454|NCT00184145|Other|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
526455|NCT00184145|Other|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
526456|NCT00184132|Procedure|Psychiatric intensive care unit in Norwegian home style|
526457|NCT00184132|Procedure|Psychiatric intensive care unit sparsely furnished and not decorated|
526458|NCT00184119|Procedure|Psychiatric Intensive Care Unit|
526459|NCT00184119|Procedure|Care in whole acute unit|psychiatric acute care as usual
540457|NCT00003399|Drug|melphalan|
526460|NCT00184106|Drug|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
526461|NCT00184093|Drug|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
526462|NCT00184080|Drug|Elsamitrusin|
526463|NCT00184067|Biological|Montanide ISA 51|
526464|NCT00184054|Drug|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
526465|NCT00184054|Drug|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
526466|NCT00184041|Drug|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
526467|NCT00184028|Drug|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
526468|NCT00184028|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
526469|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
526470|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
526471|NCT00184002|Drug|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~1 cycle = 21 days.~Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
526472|NCT00183989|Drug|Fludarabine, Mitoxantrone and Rituximab|
526473|NCT00183976|Drug|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
526474|NCT00183963|Drug|Tamoxifen|20mg
526475|NCT00183963|Drug|Fulvestrant|250mg
526476|NCT00183963|Drug|Fulvestrant|500 mg IM
526477|NCT00183950|Drug|Noscapine|
526478|NCT00183937|Drug|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
526479|NCT00183937|Drug|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
526480|NCT00183924|Drug|Estramustine|
526481|NCT00183924|Drug|Docetaxel|
526482|NCT00183924|Drug|Carboplatin|
526483|NCT00183911|Drug|floxuridine, 5-Fluorouracil, leucovorin|
526484|NCT00183911|Procedure|External Beam Radiotherapy|
526485|NCT00183911|Procedure|Surgery|
526486|NCT00183898|Drug|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
526487|NCT00183885|Drug|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
526488|NCT00183872|Drug|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
526489|NCT00183859|Drug|irinotecan|Intraperitoneal Irinotecan given every three weeks
526490|NCT00183846|Drug|irinotecan|
526491|NCT00183846|Procedure|radiation therapy|
526492|NCT00183833|Drug|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
526493|NCT00183820|Drug|paclitaxel, gemcitabine, and oxaliplatin|"Paclitaxel 170 mg/m2 IV d 1 14 days~Gemcitabine 800 mg/m2 IV d 1 14 days~Oxaliplatin 100 mg/m2 IV d 1 14 days"
526494|NCT00183807|Drug|irinotecan, cisplatin, celecoxib|
526495|NCT00183794|Drug|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
526496|NCT00183781|Behavioral|FITT: Family Intervention - Telephone Tracking|
526497|NCT00183768|Behavioral|Cognitive Behavioral Therapy|
526498|NCT00183768|Behavioral|Psychopharmacology|
526499|NCT00183742|Drug|liposomal doxorubicin and docetaxel|
526500|NCT00183729|Drug|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
526501|NCT00183729|Other|Placebo|Placebo distribution is planned to mimic the active drug.
526502|NCT00183716|Behavioral|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
526503|NCT00183716|Behavioral|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
526504|NCT00183690|Procedure|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
526505|NCT00183690|Procedure|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
526506|NCT00183677|Drug|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
526507|NCT00183651|Behavioral|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
526508|NCT00183651|Behavioral|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
526509|NCT00183651|Behavioral|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
526547|NCT00183430|Drug|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
526548|NCT00183430|Behavioral|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
526549|NCT00183417|Behavioral|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
540458|NCT00003399|Drug|paclitaxel|
526510|NCT00183638|Behavioral|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
526511|NCT00183638|Behavioral|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
526512|NCT00183625|Behavioral|Individual Placement and Support (Supported Employment)|
526513|NCT00183625|Behavioral|Social Skills Training|
526514|NCT00183625|Drug|Olanzapine|
526515|NCT00183625|Drug|Risperidone|
526516|NCT00183612|Drug|Olanzapine|
526517|NCT00183599|Behavioral|5 Minutes of Simple Advice|
526518|NCT00183599|Behavioral|Motivational Enhancement Therapy (MET)|
526519|NCT00183599|Behavioral|Cognitive Behavioral Therapy (CBT)|
526520|NCT00183586|Behavioral|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
526521|NCT00183586|Behavioral|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
526522|NCT00183573|Behavioral|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
526523|NCT00183573|Behavioral|Brief Informational Intervention|15 minute informational DVD on safer sex
526524|NCT00183573|Behavioral|Intensive Informational Intervention|4-hour, information-only intensive group workshop
526525|NCT00183573|Behavioral|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
526526|NCT00183560|Behavioral|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
526527|NCT00183560|Drug|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
526528|NCT00183560|Drug|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
526529|NCT00183547|Behavioral|"Living in Harmony depression prevention program"|Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support
526530|NCT00183547|Behavioral|Depression-prevention education and support|Weekly therapy sessions offering general depression-prevention education and support
526531|NCT00183521|Behavioral|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
526532|NCT00183521|Behavioral|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
526533|NCT00183521|Behavioral|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
526534|NCT00183508|Behavioral|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
526535|NCT00183508|Behavioral|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
526536|NCT00183482|Behavioral|Family Group Cognitive Behavioral|Groups of families receive training in parenting and children learn about coping in ten weekly sessions and then three monthly sessions
526537|NCT00183482|Behavioral|Written Information|Families are mailed written materials that describe depression and stress in families with a depressed parent.
526538|NCT00183469|Drug|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
526539|NCT00183469|Drug|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
526540|NCT00183469|Drug|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
526541|NCT00183456|Behavioral|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
526542|NCT00183456|Behavioral|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
526543|NCT00183443|Drug|Divalproex-extended release (DVP-ER)|Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
526544|NCT00183443|Drug|Lithium|Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
526545|NCT00183443|Drug|Quetiapine|Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
526546|NCT00183430|Drug|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
540706|NCT00003405|Drug|idarubicin|
526550|NCT00183417|Behavioral|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
526551|NCT00183417|Behavioral|Bibliotherapy|Participants will be given a book on how to increase their mood.
526552|NCT00183404|Drug|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
526553|NCT00183391|Drug|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
526554|NCT00183391|Drug|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
526555|NCT00183378|Behavioral|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
526556|NCT00183378|Behavioral|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
526557|NCT00183378|Behavioral|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
526558|NCT00183378|Behavioral|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
526559|NCT00183365|Behavioral|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
526560|NCT00183365|Behavioral|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
526561|NCT00183339|Drug|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
526562|NCT00183339|Drug|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
526563|NCT00183326|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
526564|NCT00183326|Behavioral|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
526565|NCT00183313|Behavioral|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
526566|NCT00183313|Behavioral|Usual care|Usual care includes standard mental health services.
526567|NCT00183300|Behavioral|Prolonged Exposure Therapy|
526568|NCT00183274|Drug|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
526569|NCT00183274|Drug|Placebo|six month intervention with placebo drug
526570|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
526571|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
526572|NCT00183248|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
526573|NCT00183248|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
526574|NCT00183248|Drug|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
526575|NCT00183248|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
526576|NCT00183248|Procedure|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
526577|NCT00183248|Procedure|Kidney transplant|Occurs at study entry
526578|NCT00183235|Drug|aripiprazole (up to 15 mg/day) for 8 days|
526579|NCT00183222|Drug|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
526580|NCT00183209|Behavioral|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
526581|NCT00183196|Drug|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
526582|NCT00183196|Drug|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
526583|NCT00183196|Other|Inactive Placebo|Placebo
526584|NCT00183183|Behavioral|Screening and Brief Intervention|
526585|NCT00183170|Drug|Beer (alcohol)|
526631|NCT00182741|Dietary Supplement|calcitriol|
526632|NCT00182741|Drug|mitoxantrone hydrochloride|
526633|NCT00182741|Drug|prednisone|
526634|NCT00182728|Procedure|surgery|conventional
526635|NCT00182728|Procedure|therapy|neoadjuvant
526586|NCT00183157|Behavioral|Brief Motivational Intervention|One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
526587|NCT00183157|Behavioral|Assessment and list of resources|One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
526588|NCT00183157|Behavioral|Referral to Community Resources|All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
526589|NCT00183144|Behavioral|Contingency management|
526590|NCT00183131|Behavioral|Brief Personalized Feedback|
526591|NCT00183118|Behavioral|Adapted Enhanced-RESPECT (HIV prevention intervention)|
526592|NCT00183105|Behavioral|Brief Intervention (adaptation of motivational interviewing)|
526593|NCT00183092|Drug|Quinacrine|100mg by mouth three times a day
526594|NCT00183092|Drug|Placebo|100mg by mouth three times a day
526595|NCT00183079|Behavioral|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
526596|NCT00183053|Device|BedEx Patient Occupancy Monitoring System|
526597|NCT00183040|Drug|Topical testosterone|
526598|NCT00183040|Drug|Recombinant human growth hormone|
526599|NCT00183027|Behavioral|Dietary composition and energy intake|
526600|NCT00183014|Behavioral|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
526601|NCT00183014|Behavioral|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
526602|NCT00183001|Drug|Vitamin K|
526603|NCT00182975|Drug|DHEA replacement|
526604|NCT00182962|Behavioral|Geriatric Resources for Assessment & Care of Elders (GRACE)|
526605|NCT00182936|Behavioral|Delirium Abatement Program|
526606|NCT00182897|Behavioral|Skills Building for Caregiver Health and Care-recipient|
526607|NCT00182884|Drug|Donepezil|
526608|NCT00182871|Drug|testosterone|
526609|NCT00182845|Drug|Donepezil|
526610|NCT00182832|Behavioral|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
526611|NCT00182832|Behavioral|Standard Care|Standard care for hospitalized older patients with cognitive impairment
526612|NCT00182819|Drug|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
526613|NCT00182819|Radiation|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
526614|NCT00182806|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
526615|NCT00182806|Drug|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
526616|NCT00182793|Biological|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
526617|NCT00182793|Drug|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
526618|NCT00182793|Drug|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
526619|NCT00182793|Drug|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
526620|NCT00182793|Drug|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
526621|NCT00182793|Procedure|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
526622|NCT00182793|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
526623|NCT00182793|Procedure|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
526624|NCT00182793|Radiation|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
526625|NCT00182780|Dietary Supplement|American ginseng|
526626|NCT00182780|Other|Placebo|
526627|NCT00182767|Drug|ixabepilone|Given IV
526628|NCT00182767|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
526629|NCT00182754|Drug|octreotide acetate|Given subcutaneously
526630|NCT00182754|Other|placebo|Given subcutaneously
526636|NCT00182728|Radiation|radiation therapy|intraoperative radiation therapy
526637|NCT00182715|Biological|cetuximab|
526638|NCT00182715|Drug|capecitabine|
526639|NCT00182715|Drug|fluorouracil|
526640|NCT00182715|Drug|leucovorin calcium|
526641|NCT00182715|Drug|oxaliplatin|
526642|NCT00182702|Drug|ixabepilone|Given IV
526643|NCT00182702|Other|laboratory biomarker analysis|Correlative studies
526644|NCT00182689|Drug|sorafenib tosylate|Given orally
526645|NCT00182663|Drug|clarithromycin|Given PO
526646|NCT00182663|Drug|thalidomide|Given PO
526647|NCT00182663|Drug|dexamethasone|Given PO
526648|NCT00182650|Biological|aldesleukin|
526649|NCT00182650|Biological|rituximab|
526650|NCT00182650|Biological|therapeutic autologous lymphocytes|
526651|NCT00182650|Drug|fludarabine phosphate|
526652|NCT00182637|Drug|bortezomib|
526653|NCT00182611|Drug|cisplatin|
526654|NCT00182611|Drug|tegafur-gimeracil-oteracil potassium|
526655|NCT00182611|Procedure|adjuvant therapy|
526656|NCT00182611|Procedure|conventional surgery|
526657|NCT00182611|Procedure|neoadjuvant therapy|
526658|NCT00182598|Procedure|computer-based psychoeducational intervention|
526659|NCT00182598|Procedure|community-based substance abuse counseling|
526660|NCT00182585|Procedure|computer-based HIV, STD & Hepatitis Education|
526661|NCT00182585|Procedure|educator-delivered HIV, STD and Hepatitis education|
526662|NCT00182572|Drug|buprenorphine|
526663|NCT00182572|Drug|naltrexone|
526664|NCT00182572|Procedure|behavior therapy|
526665|NCT00182572|Procedure|voucher-based contingency management|
526666|NCT00182559|Drug|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
526667|NCT00182559|Drug|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
526668|NCT00182546|Procedure|Two diagnostic management strategies|
526669|NCT00182533|Drug|Sertraline|25 - 200 mg/day x 16 weeks
526670|NCT00182533|Drug|Placebo|25 - 200 mg/day x 16 weeks
526671|NCT00182520|Drug|Topiramate|25 mg - 400 mg/day x 12 weeks
526672|NCT00182520|Drug|placebo|25 - 400 mg/day x 12 weeks
526673|NCT00182507|Drug|Olanzapine|
526674|NCT00182494|Behavioral|Modified diabetes prevention protocol & Metformin|
526675|NCT00182481|Procedure|Induced sputum cell counts|
526676|NCT00182481|Drug|inhaled corticosteroids and other asthma drugs|
526677|NCT00182468|Other|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
526678|NCT00182455|Drug|Topiramate|25 - 400 mg/day x 12 weeks
526679|NCT00182455|Drug|Placebo|25 - 400 mg/day x 12 weeks
526680|NCT00182442|Drug|Olanzapine & Quetiapine|
526681|NCT00182429|Drug|Metronidazole and Rifampin|
526682|NCT00182416|Device|pacemaker|
526683|NCT00182403|Drug|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
526684|NCT00182390|Procedure|Red blood cell transfusion|
526685|NCT00182377|Drug|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
526686|NCT00182364|Drug|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
526687|NCT00182351|Procedure|D-dimer|
526688|NCT00182351|Procedure|Serial Compression Ultrasound|
526689|NCT00182325|Behavioral|personalized web prenatal information|
526690|NCT00182325|Behavioral|general web prenatal information|
526691|NCT00182312|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.~Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.~Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
526692|NCT00182299|Procedure|porcine small intestine submucosa (SIS)|
526693|NCT00182286|Behavioral|Assessment of continuity of care from the patient perspective|
526694|NCT00182286|Behavioral|Relationship between continuity of care, patient outcomes, and costs|
526695|NCT00182273|Procedure|Canalith repositioning maneuver (CRM)|
526696|NCT00182260|Drug|Proton Pump Inhibitors|
526697|NCT00182260|Procedure|Laparoscopic Nissen Fundoplication|
526698|NCT00182247|Procedure|venogram|
526699|NCT00182234|Behavioral|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
526700|NCT00182221|Procedure|MDA D-Dimer Testing|
526701|NCT00182208|Device|Veno-device (Venowave)|
526702|NCT00182195|Procedure|Control Ventilation Strategy|
526703|NCT00182182|Behavioral|Primary care based disease management strategy|
526704|NCT00182169|Drug|Human recombinant growth hormone|
526705|NCT00182143|Drug|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
526706|NCT00182143|Drug|Unfractionated Heparin|5000 IU BID
526707|NCT00182130|Procedure|Quality Initiative in Rectal Cancer (QIRC) strategy|
526708|NCT00182104|Drug|Warfarin vs ASA|
526709|NCT00182091|Drug|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
526710|NCT00182091|Drug|Saline|To maintain study-subject blinding, doses were sham adjusted.
526711|NCT00182078|Drug|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
526712|NCT00182078|Drug|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
526713|NCT00182052|Drug|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
526714|NCT00182052|Other|Placebo|Given orally twice daily.
526715|NCT00182039|Drug|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
526716|NCT00182039|Drug|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
526717|NCT00182026|Behavioral|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
526718|NCT00182013|Drug|Risperidone|Open treatment with Risperidone
526719|NCT00182013|Drug|Olanzapine|Open treatment with Olanzapine
526720|NCT00182013|Drug|Quetiapine|Open treatment with Quetiapine
526721|NCT00182000|Drug|seromycin|100mg tablet administered 1 hour prior to each therapy session
526722|NCT00182000|Behavioral|Behavior Therapy|10 weekly hour-long behavior therapy sessions
526723|NCT00181987|Drug|methylphenidate HCl (Concerta)|
526724|NCT00181974|Drug|Tisseel Fibrin Sealant|
526725|NCT00181961|Drug|Maca Root|
526726|NCT00181948|Drug|atomoxetine (Strattera)|
526727|NCT00181935|Drug|risperidone (Risperdal)|
526728|NCT00181935|Drug|olanzapine (Zyprexa)|
526729|NCT00181922|Drug|ziprasidone (Geodon)|
526730|NCT00181909|Behavioral|Smoking cessation counseling delivered by telephone|
526731|NCT00181896|Drug|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
526732|NCT00181883|Drug|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
526733|NCT00181870|Drug|carbamazepine ER (Equetro)|
526734|NCT00181844|Drug|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children <12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
526735|NCT00181831|Device|Proton Magnetic Resonance Spectroscopy|
526736|NCT00181818|Drug|bupropion SR (sustained-release)|
526737|NCT00181779|Drug|aripiprazole (Abilify)|
526738|NCT00181766|Drug|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
526739|NCT00181753|Drug|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for > 3 days before we conduct stable isotope tracer measurements.
526740|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant infusion
526741|NCT00181753|Dietary Supplement|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
526742|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
526743|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
526744|NCT00181740|Drug|atomoxetine (Strattera)|
526745|NCT00181727|Drug|divalproex sodium extended release|
526746|NCT00181714|Drug|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
526747|NCT00181701|Drug|Paclitaxel|
526748|NCT00181701|Drug|Carboplatin|
526749|NCT00181688|Drug|Iressa (ZD1839)|
526750|NCT00181688|Drug|Arimidex (Anastrozole)|
526751|NCT00181675|Drug|galantamine HBr|
526752|NCT00181662|Drug|Curcumin|
526753|NCT00181649|Drug|Recombinant human prolactin|
526754|NCT00181636|Drug|Galantamine-CR|
526755|NCT00181623|Drug|Recombinant Human Prolactin|
526756|NCT00181610|Drug|Recombinant Human Prolactin|60 mcg/kg every 12 hours
526757|NCT00181610|Biological|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
526758|NCT00181610|Biological|Normal Saline|twice per day
526759|NCT00181597|Drug|Trilostane|Taken orally once a day for three days then twice daily thereafter.
526760|NCT00181597|Drug|Hydrocortisone|Taken orally with trilostane.
526845|NCT00180531|Device|Renewal TR2|
526761|NCT00181584|Drug|Zoledronic acid|Given intravenously once.
526762|NCT00181584|Other|Placebo|Given intravenously once.
526763|NCT00181571|Drug|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
526764|NCT00181571|Drug|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
526765|NCT00181558|Drug|Atrasentan|
526766|NCT00181558|Drug|Zoledronic Acid (Zometa)|
526767|NCT00181545|Procedure|escalation of dose (radiotherapy treatment)|
526768|NCT00181532|Drug|Celecoxib|
526769|NCT00181506|Procedure|dose escalation (radiotherapy treatment schedule)|
526770|NCT00181363|Device|Mamma board|
526771|NCT00181350|Device|Relocatable fixation system|
526772|NCT00181311|Procedure|hysterectomy|
526773|NCT00181298|Drug|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
526774|NCT00181298|Drug|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
526775|NCT00181285|Device|High Frequency Chest Wall Oscillator|High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
526776|NCT00181272|Drug|azithromycin|
526777|NCT00181246|Drug|Transdermal Fentanyl|
526778|NCT00181220|Drug|valproic acid|
526779|NCT00181207|Device|pneumatic vest|
526780|NCT00181207|Other|placebo pneumatic vest|
526781|NCT00181194|Device|Asthma Control and Communication Instrument|
526782|NCT00181181|Drug|atorvastatin|Atorvastatin 80 mg daily for 3 months
526783|NCT00181181|Other|placebo|placebo daily
526784|NCT00181168|Drug|Euthyroid Group|Euthyroid Group: Received rhTSH to prepare for radioiodine therapy.
526785|NCT00181155|Drug|Allopurinol|intravenous infusion of allopurinol (300mg)
526786|NCT00181155|Drug|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
526787|NCT00181142|Drug|Zenapax|
526788|NCT00181129|Behavioral|home based self paced walking program|
526789|NCT00181116|Drug|Levetiracetam|
526790|NCT00181090|Behavioral|Modified Atkins diet|
526791|NCT00181077|Drug|2% buffered hypertonic saline administration|
526792|NCT00181064|Behavioral|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
526793|NCT00181051|Device|Alaris AEP monitor|
526794|NCT00181038|Device|Peri-Neuronal Catheter|
526795|NCT00181025|Drug|Tasonermine (TNFa)|
526796|NCT00181025|Drug|Melphalan|
526797|NCT00181012|Drug|Lidocaine|
526798|NCT00180999|Drug|Erythropoiétine|
526799|NCT00180986|Procedure|Platelet concentrates|
526800|NCT00180973|Drug|Hydroxyurea|
526801|NCT00180960|Drug|Oxaliplatin and irinotecan|
526802|NCT00180947|Drug|Vinorelbine, cyclofosfamide|
526803|NCT00180934|Procedure|Reirradiation with concomitant chemotherapy|
526804|NCT00180921|Drug|Imatinib|
526805|NCT00180908|Drug|Etoposide, Ifosfamide, Methotrexate|
526806|NCT00180908|Drug|Doxorubicin, Methotrexate|
526807|NCT00180895|Drug|Rituximab|
526808|NCT00180882|Drug|rituximab|
526809|NCT00180869|Procedure|transfusion of allogeneic red blood cell concentrate|
526810|NCT00180869|Procedure|transfusion of leuko-reduced red blood cell concentrate|
526811|NCT00180856|Procedure|Radiofrequency ablation|
526812|NCT00180843|Drug|salbutamol + ipratropium bromide nebules|
526813|NCT00180843|Drug|nebulized saline|
526814|NCT00180830|Drug|Glivec|
526815|NCT00180830|Drug|Gleevec|
526816|NCT00180791|Drug|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
526817|NCT00180778|Drug|Low dose steroids|
526818|NCT00180765|Procedure|Up to 100ml blood will be taken by venupuncture.|
526819|NCT00180739|Procedure|Magnetic Resonance Guided Focused Ultrasound|
526820|NCT00180726|Procedure|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
526821|NCT00180713|Drug|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
526822|NCT00180713|Drug|Placebo|Placebo tablet once daily.
526823|NCT00180700|Behavioral|Hypnosis|
526824|NCT00180687|Drug|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
526825|NCT00180687|Drug|Normal Saline|Nebulised Normal Saline
526826|NCT00180687|Drug|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
526827|NCT00180687|Other|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
526828|NCT00180674|Drug|Warfarin|
526829|NCT00180635|Drug|Aminoguanidine|500mg
526830|NCT00180635|Drug|Placebos|2ml
526831|NCT00180622|Procedure|Spirometry|
526832|NCT00180622|Procedure|Exhaled Nitric Oxide and Carbon Monoxide|
526833|NCT00180622|Procedure|Exhaled Breath Condensate|
526834|NCT00180622|Procedure|Induced Sputum|
526835|NCT00180622|Procedure|CT Scan|
526836|NCT00180622|Procedure|Blood test|
526837|NCT00180622|Procedure|St Georges Questionnaire|
526838|NCT00180622|Procedure|Bodypletysmography|
526839|NCT00180609|Device|Automatic threshold test in Insignia Pacemakers from Guidant|
526840|NCT00180596|Device|Contak heart failure devices|
526841|NCT00180583|Device|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
526842|NCT00180570|Device|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
526843|NCT00180557|Device|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
526844|NCT00180544|Device|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
526846|NCT00180518|Device|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).~The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.~The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
526847|NCT00180505|Device|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
526848|NCT00180492|Device|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
526849|NCT00180479|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
526850|NCT00180479|Device|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
526851|NCT00180453|Device|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
526852|NCT00180453|Device|Coronary artery stent placement|Coronary artery stent placement
526853|NCT00180440|Device|ICD|all models of Guidant/Bsc ICD's
526854|NCT00180427|Device|ICD|
526855|NCT00180414|Device|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
526856|NCT00180401|Behavioral|CRT-P and CRT-D devices|
526857|NCT00180388|Procedure|endoscopic vein harvesting|
526858|NCT00180388|Procedure|open vein harvesting|
526859|NCT00180375|Device|Prizm, Vitality, Renewal|Follow-up during 2 years
526860|NCT00180362|Device|procedure|
526861|NCT00180349|Device|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
526862|NCT00180336|Device|CRT-D|
526863|NCT00180323|Device|Renewal|Renewal is a CRT-D device for cardiac resynchronization therapy
526864|NCT00180310|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
526865|NCT00180310|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
526866|NCT00180297|Device|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
526867|NCT00180284|Device|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
526868|NCT00180271|Device|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
526869|NCT00180271|Device|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
526870|NCT00180258|Device|Cardiac Resynchronization Therapy with & without defibrillator|
526871|NCT00180206|Device|Birmingham Hip Resurfacing|
526872|NCT00180167|Drug|randomization between two established Chemotherapies|
526873|NCT00180141|Drug|Elidel-Creme|
526874|NCT00180128|Drug|all-trans retinoid acid|
526875|NCT00180128|Drug|idarubicin|
526876|NCT00180128|Drug|mitoxantrone|
526877|NCT00180128|Drug|daunorubicin|
526878|NCT00180128|Drug|cytarabine|
526879|NCT00180115|Drug|Cytarabine Dosage|
526880|NCT00180102|Drug|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
526881|NCT00180102|Procedure|early allogeneic PBSCT within induction therapy|
526882|NCT00180102|Procedure|autologous PBSCT|
526883|NCT00180089|Drug|Budesonide|
526884|NCT00180076|Drug|Budesonide|
526885|NCT00180063|Drug|L-NMMA(drug)|
526886|NCT00180050|Drug|Budesonide|
526887|NCT00180037|Drug|Coenzyme Q10 Nanodispersion (Nanoquinone)|
526888|NCT00180037|Drug|Placebo|
526889|NCT00180024|Drug|irbesartan (drug)|
526890|NCT00180011|Drug|Omalizumab|injectable medication
526891|NCT00179998|Drug|Recombinant Human DNase (Pulmozyme)|2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
526892|NCT00179998|Drug|Placebos|2.5 ml sterile solution (8.77 mg/ml sodium chloride, 0.15 mg/ml calcium chloride, pH 7.0 +/- 2.0) delivered daily by nebulization for 6 months, either preceding or following 6 months of Pulmozyme depending on randomization of the subject
526893|NCT00179972|Device|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
526894|NCT00179959|Drug|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
526895|NCT00179959|Drug|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
526896|NCT00179959|Drug|Water|Water baths twice weekly for three months
526897|NCT00179959|Drug|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
526898|NCT00179946|Procedure|HLA typing|
526899|NCT00179933|Behavioral|Newborn Individualized Assessment Program|
526900|NCT00179920|Drug|Carboplatin|
526901|NCT00179920|Drug|VP-16|
526902|NCT00179920|Procedure|Local Surgery|
526903|NCT00179920|Procedure|Cryotherapy|
526904|NCT00179920|Procedure|Laser hyperthermia|
526954|NCT00179465|Drug|Placebo|Placebo
526955|NCT00179452|Behavioral|Yoga|
526905|NCT00179907|Procedure|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors < 20 mm, 21-25 mm and 26-40 mm respectively
526906|NCT00179894|Behavioral|Physician training|Physicians are trained in guidelines for medication management.
526907|NCT00179881|Drug|Carboplatin|
526908|NCT00179881|Drug|Thalomid|
526909|NCT00179881|Procedure|External Beam Radiation Therapy|
526910|NCT00179868|Behavioral|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:~Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.~Acute GVHD > grade II defined according to the Seattle criteria~VOD- defined according to the modified Seattle criteria"
526911|NCT00179855|Procedure|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.~ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
526912|NCT00179842|Procedure|Stem Cell Transplant|
526913|NCT00179829|Procedure|WT 1 Testing|
526914|NCT00179816|Drug|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
526915|NCT00179803|Procedure|Stem Cell Transplant|"Group A: recurrent medulloblastoma, recurrent germ cell tumor~Cytoxan treatment~Stem cell autologous harvest~Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET~Carboplatin and Etoposide treatment~Autologous stem cell harvest~The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to >1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."
526916|NCT00179790|Procedure|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
526917|NCT00179777|Dietary Supplement|hydrolysed infant formula|hydrolysed infant formula
526918|NCT00179777|Dietary Supplement|nonhydrolysed infant formula|nonhydrolysed infant formula
526919|NCT00179764|Procedure|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
526920|NCT00179764|Procedure|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
526921|NCT00179764|Radiation|Central Nervous System (CNS) prophylaxis radiation|"Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.~Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant."
526922|NCT00179751|Drug|CC-5013|
526923|NCT00179751|Drug|gemcitabine|
526924|NCT00179738|Drug|CC5013|
526925|NCT00179725|Drug|CC-5013|
526926|NCT00179725|Drug|liposomal doxorubicin|
526927|NCT00179712|Drug|CC-5013|
526928|NCT00179712|Drug|topotecan|
526929|NCT00179699|Drug|CC-5013|
526930|NCT00179699|Drug|pemetrexed|
526931|NCT00179686|Drug|CC-5013|
526932|NCT00179673|Drug|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
526933|NCT00179660|Drug|Lenalidomide|Capsules for oral administration.
526934|NCT00179647|Drug|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
526935|NCT00179647|Drug|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
526936|NCT00179634|Behavioral|Visualization relaxation|
526937|NCT00179634|Behavioral|Visual Milieu Enhancement (Fine art photograph)|
526938|NCT00179621|Drug|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
526939|NCT00179621|Drug|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
526940|NCT00179621|Drug|Placebo|Placebo, matching to active study drug arms
526941|NCT00179608|Drug|CC-5013|
526942|NCT00179595|Behavioral|relaxation response- meditation|
526943|NCT00179582|Drug|VSL#3|
526944|NCT00179569|Behavioral|Relaxation response|8 weeks of relaxation response training
526945|NCT00179556|Drug|Isoflavone supplement|
526946|NCT00179543|Behavioral|Relaxation response|
526947|NCT00179530|Behavioral|Relaxation Response|Relaxation training
526948|NCT00179517|Drug|Anastrozole 1mg|
526949|NCT00179517|Drug|Placebo Oral Tablet|
526950|NCT00179504|Behavioral|Relaxation Response|Relaxation training
526951|NCT00179491|Behavioral|Intercessory Prayer|14 days of intercessory prayer from 3 sites
526952|NCT00179478|Drug|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
526953|NCT00179465|Drug|Tiagabine|Up to 36 mg daily
526956|NCT00179439|Procedure|nasal potential difference testing|
526957|NCT00179413|Drug|PEG -Intron|
526958|NCT00179413|Drug|Colchicine|0.6mg twice a day
526959|NCT00179400|Drug|Pioglitazone/EPA|
526960|NCT00179400|Drug|Placebo|
526961|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Psycho-educational group
526962|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Spiritual-Existential Group
526963|NCT00179374|Behavioral|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
526964|NCT00179374|Behavioral|Print educational intervention|diabetes educational materials by mail
526965|NCT00179348|Procedure|Quality-of-Life Assessment|Ancillary studies
526966|NCT00179348|Procedure|Yoga|Undergo a yoga-based rehabilitation program
526967|NCT00179335|Procedure|Blood drawing to determine drug levels|
526968|NCT00179309|Drug|Docetaxel|35 mg/m^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
526969|NCT00179309|Biological|PANVAC-V|2 x 10^8 PFU
526970|NCT00179309|Biological|PANVAC-F|1 x 10^9 PFU
526971|NCT00179309|Biological|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
526972|NCT00179283|Drug|sertraline|
526973|NCT00179283|Drug|venlafaxine XR|
526974|NCT00179257|Drug|sertraline (Zoloft)|
526975|NCT00179244|Drug|Rispridone (drug) and Bupropion ER (drug)|
526976|NCT00179231|Drug|olanzapine vs. clozapine|
526977|NCT00179218|Drug|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
526978|NCT00179218|Behavioral|exercise|leg press exercise; every other day, 3 days per week, for 6 months
526979|NCT00179205|Drug|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
526980|NCT00179205|Drug|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
526981|NCT00179192|Procedure|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
526982|NCT00179192|Procedure|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
526983|NCT00179179|Drug|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
526984|NCT00179179|Behavioral|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
526985|NCT00179166|Drug|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
526986|NCT00179153|Dietary Supplement|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
526987|NCT00179140|Drug|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
526988|NCT00179140|Behavioral|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
526989|NCT00179127|Drug|glargine|0.3u/kg of glargine, subcutaneously, once
526990|NCT00179127|Drug|saline|0.3u/kg of saline, subcutaneously, once
526991|NCT00179114|Drug|Botulinum Toxin Type A|
526992|NCT00179114|Drug|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
526993|NCT00179101|Procedure|Deep Brain Stimulation|
526994|NCT00179088|Behavioral|Patient may be able to put weight on the operated leg|
526995|NCT00179062|Drug|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
526996|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
526997|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
526998|NCT00179023|Drug|Pseudoephedrine|30mg tablet,VO. Single dose.
526999|NCT00179010|Drug|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
527000|NCT00179010|Drug|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
527001|NCT00178971|Drug|adjunctive treatment with buspirone|buspirone 15-30 mg qd
527002|NCT00178971|Drug|placebo|placebo
527003|NCT00178958|Device|Holter Monitor|
527004|NCT00178945|Drug|Botulinum Toxin Type A|
527005|NCT00178932|Procedure|genetic analysis|genetic assay of blood sample drawn with patient's consent
527006|NCT00178932|Procedure|genetic assay|genetic assay of blood sample drawn with patient's consent
527007|NCT00178919|Drug|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
527547|NCT00173615|Procedure|Extracorporeal membrane oxygenation|
527548|NCT00173550|Procedure|Hysterectomy and Bilateral salpingo-oophorectomy|
527008|NCT00178919|Drug|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
527009|NCT00178854|Drug|Risperidone|
527010|NCT00178841|Drug|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
527011|NCT00178828|Drug|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
527012|NCT00178828|Drug|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
527013|NCT00178802|Other|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days~Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour~Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily~Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
527014|NCT00178776|Behavioral|Transtheoretical Model Group Therapy|
527015|NCT00178776|Behavioral|Education & Advice|
527016|NCT00178763|Device|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
527017|NCT00178763|Other|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
527018|NCT00178763|Other|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
527019|NCT00178750|Device|18G Tuohy epidural needle|
527020|NCT00178750|Device|CompuFlo® computerized syringe pump|
527021|NCT00178737|Behavioral|Electronic reminder message|
527022|NCT00178724|Other|No Treatment Given|Intervention is not given.
527023|NCT00178711|Device|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
527024|NCT00178698|Other|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
527025|NCT00178698|Drug|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
527026|NCT00178698|Other|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
527027|NCT00178685|Behavioral|Self-determination Intervention for Tobacco Dependence|autonomy supported behavioral intervention for tobacco dependent individuals
527028|NCT00178672|Device|Angioguard XP distal protection device|Standard of care stenting of carotid arteries protocol is used.
527029|NCT00178672|Procedure|Heart Catheterization -Angioplasty|Standard of care carotid stenting. A catheter is inserted in the femoral vein into the carotid artery where a balloon is inflated and shortly thereafter a stent is placed in the target lesion area.
527030|NCT00178672|Device|stenting|stenting of carotid arteries
527031|NCT00178659|Other|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
527032|NCT00178646|Drug|Botox|Botox 75-150 units, single treatment only
527033|NCT00178633|Procedure|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
527034|NCT00178620|Drug|Retavase 10 U IV Bolus|Retavase IV Bolus, 10 U, one dose at time of myocardial infarction
527035|NCT00178620|Procedure|Angioplasty/Heart Catheterization|"Candidates will receive all the approved standard therapy for heart attacks patients and will go directly for emergent heart catheterization.~Following local anesthesia, a small flexible tube (catheter) will be inserted in an artery of your leg and advanced to the arteries of your heart. By injecting x-ray contrast through the catheter, any blockage in the artery can be seen. If your heart attack artery is still blocked by blood clot or cholesterol deposits, it will be opened up by angioplasty (balloon surgery procedure to open the blocked artery) and stenting (placement of a slotted metal tube in the artery to prevent it from closing on itself)."
527036|NCT00178620|Device|Drug eluting stent placed in heart attack related artery|Stents will be placed (if needed) during the end of the angioplasty/heart catheterization.
527037|NCT00178581|Drug|Glutamine|
527038|NCT00178568|Behavioral|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
527039|NCT00178555|Device|DCI Video Intubation System-Macintosh Laryngoscope|
527040|NCT00178555|Device|Macintosh Laryngoscope|
527041|NCT00178529|Behavioral|Psychoeducation, Counseling and Skill Training|
527042|NCT00178516|Other|behavior, procedure|
527043|NCT00178503|Drug|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
527231|NCT00176800|Procedure|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
527044|NCT00178503|Drug|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
527045|NCT00178503|Other|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
527046|NCT00178490|Drug|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
527047|NCT00178477|Procedure|MRI with breath-holding|Breath holding for diminished tumor motion.
527048|NCT00178464|Drug|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
527049|NCT00178451|Drug|Abciximab|
527050|NCT00178438|Device|Capsule Endoscopy|
527051|NCT00178425|Procedure|Serial blood sampling as described in protocol|
527052|NCT00178425|Procedure|Estimation of Creatinine Clearance at regular intervals|
527053|NCT00178412|Behavioral|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)~Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
527054|NCT00178412|Behavioral|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.~Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
527055|NCT00178399|Procedure|Stereotactic Body Radiation Therapy|
527056|NCT00178373|Drug|Modafinil|
527057|NCT00178373|Drug|sugar pill|
527058|NCT00178360|Behavioral|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.~Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:~Group singing~Group drumming~Music assisted relaxation~Group song writing~Lyric analysis~Improvisation~Music with art"
527059|NCT00178347|Radiation|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
527060|NCT00178321|Device|earplugs|
527061|NCT00178295|Radiation|Radiation Therapy|standard of care for the cancer being treated
527062|NCT00178282|Procedure|Pelvic Floor Muscle exercises|
527063|NCT00178269|Drug|docetaxel|
527064|NCT00178269|Procedure|Radiation Therapy|
527065|NCT00178256|Drug|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
527066|NCT00178256|Procedure|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
527067|NCT00178243|Procedure|3D Conformal Radiation Therapy and Radiosurgery|
527068|NCT00178217|Behavioral|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
527069|NCT00178191|Other|Bladder diary|3-day bladder diary
527070|NCT00178191|Other|Questionnaires|Incontinence Quality of Life questionnaires
527071|NCT00178191|Procedure|Urodynamics|Urodynamics
527072|NCT00178191|Other|Pad weight|Pad weight
527073|NCT00178178|Device|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
527074|NCT00178178|Drug|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
527075|NCT00178178|Drug|Placebo|Drug: Placebo
527076|NCT00178165|Procedure|Skill Training Condition – problem solving training|
527077|NCT00178165|Procedure|REACH for TLC (Telephone Linked Computer) system|
527078|NCT00178139|Behavioral|Music Therapy|Music Therapy
527079|NCT00178126|Device|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
527080|NCT00178126|Device|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
527081|NCT00178113|Drug|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
527082|NCT00178113|Drug|- Certagen (multivitamins with minerals)|
527083|NCT00178100|Behavioral|Interpersonal Psychotherapy|
527084|NCT00178100|Drug|paroxetine|
527085|NCT00178074|Behavioral|total sleep deprivation|
527086|NCT00178074|Procedure|PET imaging|
527087|NCT00178061|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
527088|NCT00178048|Drug|paroxetine|
527089|NCT00178035|Drug|paroxetine|
527090|NCT00178035|Behavioral|One night of Total Sleep Deprivation|
527091|NCT00178022|Behavioral|Case management and problem solving therapy|
527232|NCT00176800|Procedure|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
527092|NCT00178009|Behavioral|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
527093|NCT00177996|Drug|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
527094|NCT00177983|Behavioral|(relapse rate)|
527095|NCT00177970|Drug|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
527096|NCT00177970|Drug|Placebo|Placebo to be given IV to patients with C-Diff
527097|NCT00177892|Procedure|sleep disruption|experimentally-induced Sleep Fragmentation
527098|NCT00177892|Procedure|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
527099|NCT00177879|Behavioral|website comparison|
527100|NCT00177866|Drug|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
527101|NCT00177866|Drug|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
527102|NCT00177853|Drug|celecoxib|Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
527103|NCT00177853|Drug|irinotecan|Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
527104|NCT00177853|Procedure|concurrent radiotherapy|50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
527105|NCT00177840|Procedure|acupuncture|
527106|NCT00177775|Drug|MucoMilk product|
527107|NCT00177762|Behavioral|behavior weight loss|
527108|NCT00177749|Drug|Posaconazole|
527109|NCT00177710|Drug|Amphotericin B|
527110|NCT00177697|Behavioral|behavioral weight loss program|
527111|NCT00177684|Drug|Amphotericin B|
527112|NCT00177671|Drug|Escitalopram|Escitalopram, 10mg to 20mg daily.
527113|NCT00177671|Drug|Donepezil|Donepezil, 5mg to 10mg daily.
527114|NCT00177671|Drug|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
527115|NCT00177671|Drug|Placebo|
527116|NCT00177671|Drug|Duloxetine|
527117|NCT00177645|Procedure|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
527118|NCT00177632|Behavioral|behavioral weight loss|
527119|NCT00177619|Drug|Alendronate|
527120|NCT00177606|Behavioral|withdrawal of life sustaining treatments|
527121|NCT00177593|Behavioral|behavioral weight loss|
527122|NCT00177580|Drug|Pravastatin|
527123|NCT00177567|Drug|lithium carbonate|
527124|NCT00177567|Drug|Depakote-ER|
527125|NCT00177567|Drug|risperidone|
527126|NCT00177567|Drug|olanzapine|
527127|NCT00177567|Drug|paroxetine|
527128|NCT00177567|Drug|bupropion|
527129|NCT00177567|Drug|lamotrigine|
527130|NCT00177567|Drug|venlafaxine|
527131|NCT00177567|Drug|tranylcypromine|
527132|NCT00177567|Drug|mirtazapine|
527133|NCT00177554|Drug|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
527134|NCT00177541|Behavioral|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
527135|NCT00177528|Drug|venlafaxine-XR|
527136|NCT00177515|Behavioral|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
527137|NCT00177502|Behavioral|behavioral exercise intervention|
527138|NCT00177489|Behavioral|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
527139|NCT00177489|Other|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
527140|NCT00177476|Behavioral|behavioral weight loss|
527141|NCT00177463|Drug|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
527142|NCT00177437|Behavioral|home testing kit|
527143|NCT00177424|Drug|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
527144|NCT00177424|Drug|Placebo|matching placebo tablets
527145|NCT00177411|Drug|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
527146|NCT00177398|Drug|Glargine insulin vs regular insulin|
527147|NCT00177385|Behavioral|Modest sleep deprivation with sleep hygiene education|
527148|NCT00177372|Drug|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
527149|NCT00177359|Behavioral|gait intervention|
527150|NCT00177346|Device|CAS with cerebral protection|
527151|NCT00177346|Device|CAS without cerebral protection|
527152|NCT00177333|Drug|Doxycycline|
527153|NCT00177307|Drug|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
527233|NCT00176787|Drug|Capecitabine|
527234|NCT00176787|Procedure|Radiation|
527235|NCT00176787|Procedure|Surgery|
527549|NCT00173537|Procedure|for BMPR II study|
527550|NCT00173537|Genetic|BMPRII|
527154|NCT00177307|Drug|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
527155|NCT00177307|Drug|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
527156|NCT00177294|Drug|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
527157|NCT00177294|Behavioral|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
527158|NCT00177294|Behavioral|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
527159|NCT00177281|Drug|S CKD602|
527160|NCT00177268|Other|Blood draw, skin biopsy or urine collection|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
527161|NCT00177255|Drug|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
527162|NCT00177255|Drug|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22."
527163|NCT00177242|Drug|Gefitinib|
527164|NCT00177229|Behavioral|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
527165|NCT00177216|Drug|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
527166|NCT00177216|Drug|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
527167|NCT00177216|Drug|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
527168|NCT00177203|Behavioral|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.~In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
527169|NCT00177177|Drug|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
527170|NCT00177164|Drug|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks~Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
527171|NCT00177138|Drug|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
527172|NCT00177138|Drug|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV >monthly for 1 year (only if ALC>200 mm, up to a total of 10 doses in year)
527173|NCT00177125|Device|ErectAid|
527174|NCT00177112|Procedure|clean patient preparation for cystoscopy|
527175|NCT00177112|Procedure|sterile patient preparation for cystoscopy|
527176|NCT00177099|Drug|FK506, GP11046, GP11511|
527177|NCT00177086|Other|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
527178|NCT00177060|Drug|hydromorphone|
527179|NCT00177047|Procedure|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
527180|NCT00177047|Drug|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
527181|NCT00177047|Drug|Melphalan|Administered intravenously 200 mg/m^2
527182|NCT00177047|Biological|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
527183|NCT00177034|Drug|Narrow Band UVB Treatment|
527184|NCT00177021|Drug|Aldara Cream 5%|
527185|NCT00177008|Drug|Aripiprazole|
527186|NCT00176995|Drug|15% Eflornithine Hdyrochloride|
527187|NCT00176982|Drug|Hydroxychloroquine|
527188|NCT00176969|Drug|Capsaicin|
527189|NCT00176956|Procedure|Skin Biopsy|Skin biopsy.
527190|NCT00176943|Drug|Aldara Cream 5%|
527191|NCT00176930|Procedure|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
527192|NCT00176930|Drug|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
527193|NCT00176930|Radiation|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
527194|NCT00176930|Drug|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
527380|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
540707|NCT00003405|Drug|idoxuridine|
527195|NCT00176917|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
527196|NCT00176917|Drug|Busulfan, Cyclophosphamide, ATG|"Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
527197|NCT00176904|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
527198|NCT00176904|Drug|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients < or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
527199|NCT00176891|Procedure|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
527200|NCT00176891|Drug|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
527201|NCT00176878|Procedure|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.
527202|NCT00176878|Drug|Fludarabine monophosphate|fludarabine 175 mg/m^2 (total) on Days -6 through -3.
527203|NCT00176878|Procedure|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
527204|NCT00176878|Drug|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
527205|NCT00176878|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
527206|NCT00176865|Procedure|Stem Cell Transplant|IV on Day 0
527207|NCT00176865|Drug|Fludarabine|30mg/m^2 IV Day -7 through Day -3
527208|NCT00176865|Drug|Melphalan|140 mg/m^2 IV Day -1
527209|NCT00176865|Drug|Anti-thymocyte globulin (ATG)|30 mg/kg IV Day -5 through Day -1
527210|NCT00176865|Drug|Campath 1H|0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
527211|NCT00176865|Drug|Cyclosporin A|2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children <40 kg) maintaining a level of >200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
527212|NCT00176865|Drug|Mycophenolate mofetil|15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
527213|NCT00176865|Drug|Intravenous immunoglobulin (IVIG)|500 mg/kg IV weekly beginning on Day +7 until Day +100
527214|NCT00176852|Drug|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
527215|NCT00176852|Drug|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC >2500 x 2 days.
527216|NCT00176852|Drug|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
527217|NCT00176852|Radiation|Total Body Irradiation|300 cGY Day -1
527218|NCT00176852|Procedure|Stem cell infusion|Given Day 0
527219|NCT00176839|Procedure|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
527220|NCT00176839|Drug|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
527221|NCT00176839|Drug|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
527222|NCT00176839|Drug|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
527223|NCT00176839|Drug|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
527224|NCT00176839|Drug|ATG|ATG will be administered to umbilical cord blood recipients.
527225|NCT00176826|Procedure|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
527226|NCT00176826|Drug|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
527227|NCT00176813|Drug|Gemcitabine|
527228|NCT00176813|Drug|Cisplatin|
527229|NCT00176813|Drug|Celecoxib|
527230|NCT00176800|Drug|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
527551|NCT00173524|Behavioral|PharmacoEconomic Assessment|Collecting PE data.
527236|NCT00176774|Drug|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
527237|NCT00176774|Drug|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
527238|NCT00176774|Drug|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
527239|NCT00176774|Drug|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
527240|NCT00176761|Drug|Interleukin-2 (IL-2)|
527241|NCT00176748|Drug|AG 6013736|5 mg po bid
527242|NCT00176735|Drug|Capecitabine|
527243|NCT00176722|Other|table tilt|One group randomized to table tilt. One group will be flat.
527244|NCT00176696|Device|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
527245|NCT00176683|Procedure|Capnography|device which measures carbon dioxide at intubation
527246|NCT00176670|Drug|midazolam or GameBoy or parental presence|
527247|NCT00176657|Drug|HEMOBAG Assessment|
527248|NCT00176644|Drug|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.~The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
527249|NCT00176631|Dietary Supplement|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
527250|NCT00176631|Drug|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
527251|NCT00176618|Drug|sulindac|Sulindac 150 mg po BID
527252|NCT00176618|Drug|curcumin|Curcumin 250 mg po BID
527253|NCT00176605|Drug|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
527254|NCT00176605|Drug|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
527255|NCT00176592|Drug|Betaseron|Betaseron 250 micrograms injected SQ every other day
527256|NCT00176592|Drug|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
527257|NCT00176579|Procedure|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
527258|NCT00176566|Drug|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
527259|NCT00176553|Drug|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
527260|NCT00176540|Drug|dextromethorphan hydrobromide|
527261|NCT00176527|Biological|recombinant interferon alfa-2b|
527262|NCT00176527|Drug|docetaxel|
527263|NCT00176527|Drug|estramustine phosphate sodium|
527264|NCT00176527|Drug|isotretinoin|
527265|NCT00176527|Genetic|polyacrylamide gel electrophoresis|
527266|NCT00176527|Genetic|protein expression analysis|
527267|NCT00176527|Other|immunohistochemistry staining method|
527268|NCT00176514|Drug|Administration of the antineoplastic|
527269|NCT00176501|Biological|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
527270|NCT00176488|Drug|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
527271|NCT00176488|Drug|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
527272|NCT00176475|Biological|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
527273|NCT00176475|Biological|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
527274|NCT00176462|Drug|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527275|NCT00176462|Drug|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527276|NCT00176462|Drug|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527381|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
527552|NCT00173511|Device|24 hr Holter monitor|
527277|NCT00176462|Drug|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527278|NCT00176462|Drug|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527279|NCT00176462|Drug|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527280|NCT00176462|Drug|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527281|NCT00176462|Drug|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527282|NCT00176462|Drug|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527283|NCT00176462|Drug|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
527284|NCT00176462|Drug|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
527285|NCT00176462|Drug|Leucovorin|
527286|NCT00176449|Drug|Bupropion SR|150mg twice a day (starting with 150mg once a day for three days)
527287|NCT00176449|Drug|Placebo Oral Tablet|Comparable placebo
527288|NCT00176436|Behavioral|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
527289|NCT00176436|Behavioral|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
527290|NCT00176423|Drug|galantamine|
527291|NCT00176410|Drug|fluvastatin|40mg fluvastatin daily
527292|NCT00176397|Procedure|Percutaneous coronary intervention (left main)|
527293|NCT00176384|Behavioral|Aerobic endurance exercise training (ergometer)|
527294|NCT00176371|Behavioral|physical exercise|
527295|NCT00176358|Device|PTCA and Stent Implantation|
527296|NCT00176358|Behavioral|Exercise Training|
527297|NCT00176345|Behavioral|Exercise Training|
527298|NCT00176332|Drug|rosuvastatin|
527299|NCT00176319|Behavioral|Aerobic endurance exercise training (ergometer)|
527300|NCT00176306|Drug|Levofloxacin 750 mg IV|PK in obesity
527301|NCT00176293|Drug|dexamethasone|oral dexamethasone, 12mg BID on days 1, 2, 3, 4, & 5 of each 28-day cycle
527302|NCT00176293|Drug|doxorubicin|Doxorubicin 50mg/m^2 I.V. on day 5
527303|NCT00176280|Drug|Leukine|
527304|NCT00176280|Drug|Dexamethasone|
527305|NCT00176267|Radiation|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 & 36 of chemotherapy
527306|NCT00176267|Drug|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
527307|NCT00176267|Drug|Carboplatin|AUC of 6 on Days 1 & 22
527308|NCT00176254|Radiation|Radiotherapy|80 centigray (cGy) on Day 1 & 2 and 22 & 23 of chemotherapy
527309|NCT00176254|Drug|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
527310|NCT00176254|Drug|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
527311|NCT00176241|Drug|gemcitabine|2000-3000mg/m2 IV on days 1 & 15
527312|NCT00176241|Drug|paclitaxel|150 mg/m2 IV on days 1 & 15
527313|NCT00176241|Radiation|radiation|50-80 cGy on days 1,2,15,16
527314|NCT00176228|Drug|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.~The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
527315|NCT00176215|Procedure|survival failure of more than 20 %|
527316|NCT00176202|Drug|Divalproex Sodium|Divalproex sodium is a mood stabilizer
527317|NCT00176202|Drug|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
527318|NCT00176189|Device|All ceramic FPDs|
527319|NCT00176176|Device|EEG|
527320|NCT00176163|Behavioral|Operant behavioral treatment; Drug: THC|
527321|NCT00176137|Procedure|preoperative radiochemotherapy|
527322|NCT00176124|Procedure|leukocyte depletion of whole blood|
527323|NCT00176124|Other|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
527324|NCT00176111|Procedure|peripheral nerve stimulation (procedure)|
527325|NCT00176098|Procedure|Hypnoanalgesia; Hypnotic shielding|
527326|NCT00176059|Drug|intravenous immunoglobulins (IVIG)|
527327|NCT00176059|Procedure|kidney transplantation|
527328|NCT00176046|Drug|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
527329|NCT00176046|Drug|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
527330|NCT00176020|Drug|nicotinic acid|
527331|NCT00176007|Procedure|Hypoxia|
527332|NCT00175981|Drug|sildenafil, fluvoxamine|
527333|NCT00175968|Procedure|bed rest, hypocaloric nutrition|
527334|NCT00175955|Drug|Levetiracetam|
527335|NCT00175929|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
527541|NCT00173706|Drug|L-Carnitine Injection|
527542|NCT00173693|Behavioral|exercise for strength, balance, health education|
527336|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
527337|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
527338|NCT00175916|Drug|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
527339|NCT00175903|Drug|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
527340|NCT00175903|Drug|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
527341|NCT00175903|Drug|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
527342|NCT00175890|Drug|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
527343|NCT00175890|Other|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
527344|NCT00175877|Biological|Certolizumab Pegol|"Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
527345|NCT00175864|Drug|Seletracetam (ucb 44212)|
527346|NCT00175851|Drug|Seletracetam (ucb 44212)|
527347|NCT00175838|Drug|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
527348|NCT00175838|Drug|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
527349|NCT00175825|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
527350|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
527351|NCT00175812|Drug|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
527352|NCT00175812|Drug|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
527353|NCT00175812|Drug|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
527354|NCT00175760|Procedure|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
527355|NCT00175747|Drug|Inhaled Budesonide 800 µg twice daily|
527356|NCT00175734|Procedure|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
527357|NCT00175734|Procedure|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
527358|NCT00175721|Procedure|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
527359|NCT00175695|Drug|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
527360|NCT00175682|Drug|Prazosin HCL|See Detailed Description
527361|NCT00175669|Drug|Botox injections|Data not known.
527362|NCT00175656|Procedure|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
527363|NCT00175643|Drug|imiquimod|
527364|NCT00175630|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
527365|NCT00175617|Drug|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
527366|NCT00175617|Drug|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
527367|NCT00175604|Drug|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
527368|NCT00175591|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
527369|NCT00175565|Drug|inhaled fluticasone 500 mcg b.i.d.|
527370|NCT00175552|Behavioral|Psychotherapy Training|
527371|NCT00175539|Behavioral|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
527372|NCT00175526|Behavioral|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
527373|NCT00175513|Drug|Valacyclovir (Valtrex)|
527374|NCT00175500|Device|Large Diameter Femoral Head|
527375|NCT00175487|Procedure|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
527376|NCT00175474|Procedure|knee surgery|
527377|NCT00175461|Procedure|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
527378|NCT00175448|Procedure|physiotherapy|See Detailed Description.
527379|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
527382|NCT00175422|Behavioral|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
527383|NCT00175409|Procedure|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
527384|NCT00175409|Procedure|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
527385|NCT00175396|Procedure|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
527386|NCT00175396|Procedure|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
527387|NCT00175383|Drug|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
527388|NCT00175370|Drug|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
527389|NCT00175357|Drug|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
527390|NCT00175357|Drug|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
527391|NCT00175344|Procedure|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
527392|NCT00175318|Behavioral|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
527393|NCT00175305|Drug|Sandostatin LAR|
527394|NCT00175292|Drug|Probiotic - VSL#3|
527395|NCT00175279|Behavioral|Opinion leader generated and endorsed evidence summaries|
527396|NCT00175266|Drug|alemtuzumab|
527397|NCT00175266|Procedure|islet transplant|
527398|NCT00175266|Drug|infliximab|
527399|NCT00175253|Drug|alemtuzumab|
527400|NCT00175253|Procedure|islet transplant|
527401|NCT00175240|Behavioral|Evidence summaries endorsed by local opinion leaders|
527402|NCT00175227|Drug|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
527403|NCT00175227|Drug|intravenous saline hydration|500 mls half-normal saline
527404|NCT00175214|Behavioral|Multifaceted intervention (patient education, physician guidelines, reminders)|
527405|NCT00175201|Procedure|Proactive care and rehabilitation|
527406|NCT00175188|Device|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
527407|NCT00175175|Behavioral|"Allied health professional-run osteoporosis service (case-management)"|
527408|NCT00175162|Device|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
527409|NCT00175149|Drug|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
527410|NCT00175136|Device|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
527411|NCT00175123|Drug|Botulinum A toxin|Intravesical injection. 12 IE/kg b.w.
527412|NCT00175110|Behavioral|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
527413|NCT00175097|Other|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
527414|NCT00175097|Other|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
527415|NCT00175097|Other|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
527416|NCT00175097|Other|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
527417|NCT00175084|Behavioral|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
527418|NCT00175071|Behavioral|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
527419|NCT00175058|Device|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
527420|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
527421|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
527422|NCT00175032|Drug|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
527423|NCT00175032|Drug|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
527424|NCT00175019|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
527425|NCT00175019|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
527426|NCT00175019|Drug|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
527427|NCT00175006|Other|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
527428|NCT00174993|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
527429|NCT00174993|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
527430|NCT00174980|Drug|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
527431|NCT00174967|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
527432|NCT00174967|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
527433|NCT00174967|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
527434|NCT00174967|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
527435|NCT00174954|Procedure|MRI|Subjects underwent MRI to evaluate tophi.
527436|NCT00174941|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
527437|NCT00174941|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
527438|NCT00174941|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
527439|NCT00174928|Drug|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
527440|NCT00174928|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
527441|NCT00174915|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
527442|NCT00174915|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
527443|NCT00174915|Drug|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
527444|NCT00174915|Drug|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
527445|NCT00174915|Drug|Placebo|Placebo, orally, once daily for up to 28 weeks.
527446|NCT00174902|Drug|inderal (drug), acetylsalicylic acid (drug)|
527447|NCT00174889|Drug|Pregnenolone|
527448|NCT00174876|Drug|Drug Abilify|
527449|NCT00174863|Drug|SR31747A|
527450|NCT00174850|Drug|Gaitril|
527451|NCT00174837|Drug|Tirapazamine|in combination with cisplatin and concomitant radiation
527452|NCT00174837|Drug|Cisplatin|with concomitant radiation
527453|NCT00174824|Drug|Insulin glargine|
527454|NCT00174811|Drug|telithromycin (HMR3647)|
527455|NCT00174798|Drug|SSR240600C|once daily
527456|NCT00174798|Drug|Placebo|oral
527457|NCT00174798|Drug|Tolterodine|once daily
527458|NCT00174785|Drug|dronedarone (SR33589)|oral administration (tablets)
527459|NCT00174785|Drug|placebo|oral administration (tablets)
527460|NCT00174772|Drug|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
527461|NCT00174772|Drug|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
527462|NCT00174759|Drug|Clopidogrel|
527463|NCT00174746|Drug|AVE2635A|
527464|NCT00174733|Drug|Ciclesonide (XRP1526)|
527465|NCT00174720|Drug|Ciclesonide (XRP1526)|
527466|NCT00174707|Drug|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
527467|NCT00174707|Drug|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
527468|NCT00174707|Drug|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
527469|NCT00174694|Drug|Telithromycin|
527470|NCT00174681|Drug|Insulin Glargine|
527471|NCT00174668|Drug|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
527472|NCT00174668|Drug|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
527473|NCT00174668|Drug|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
527543|NCT00173667|Drug|Nifedipine 30 mg GITS|
527544|NCT00173654|Procedure|blood drawing|
527474|NCT00174655|Drug|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
527475|NCT00174655|Drug|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
527476|NCT00174655|Drug|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
527477|NCT00174655|Drug|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
527478|NCT00174642|Drug|Insulin Glargine|One daily injection in the evening. 100 U/ml
527479|NCT00174642|Drug|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
527480|NCT00174642|Drug|Metformin|At same dosages as the previous treatment
527481|NCT00174642|Drug|insulin secretagogue|sulfonylurea or glinide
527482|NCT00174629|Drug|Docetaxel/DDP|
527483|NCT00174629|Drug|docetaxel/gemcitabine|
527484|NCT00174616|Drug|Oxaliplatin, capecitabine, radiotherapy|"Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses~Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks~Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
527485|NCT00174603|Drug|quetiapine|
527486|NCT00174590|Drug|risperidone|
527487|NCT00174577|Drug|Risperidone|
527488|NCT00174564|Drug|oxaliplatin|
527489|NCT00174551|Drug|prazosin|
527490|NCT00174538|Drug|Codeine (30 mg)|
527491|NCT00174525|Drug|AAB-001|
527492|NCT00174512|Drug|GTN|
527493|NCT00174512|Drug|Moxifloxacin|
527494|NCT00174499|Drug|2 mg nicotine gum|2 mg nicotine gum
527495|NCT00174499|Drug|4 mg nicotine gum|4 mg nicotine gum
527496|NCT00174486|Drug|UK0369,003|
527497|NCT00174486|Drug|Cialis (Tadalafil)|
527498|NCT00174473|Drug|Voriconazole|
527499|NCT00174460|Drug|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
527500|NCT00174460|Other|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
527501|NCT00174447|Drug|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
527502|NCT00174434|Drug|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
527503|NCT00174434|Drug|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
527504|NCT00174421|Drug|Treatment with Genotropin in different dosages|
527505|NCT00174408|Drug|Genotropin|
527506|NCT00174395|Drug|eletriptan|
527507|NCT00174382|Drug|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
527508|NCT00174369|Drug|PD-0325901|15 mg BID
527509|NCT00174356|Drug|CI 1033|
527510|NCT00174356|Drug|PACLITAXEL|
527511|NCT00174356|Drug|CARBOPLATIN|
527512|NCT00174343|Drug|exemestane (Aromasin®)|
527513|NCT00174330|Drug|atorvastatin|
527514|NCT00174330|Drug|amlodipine|
527515|NCT00174317|Drug|Celecoxib|
527516|NCT00174317|Drug|Diclofenac|
527517|NCT00174304|Drug|Amlodipine/atorvastatin single pill|
527518|NCT00174291|Drug|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
527519|NCT00174278|Drug|Somatropin|
527520|NCT00174265|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
527521|NCT00174265|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
527522|NCT00174252|Drug|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
527523|NCT00174239|Drug|cabergoline|
527524|NCT00174239|Drug|controlled-release levodopa / carbidopa|
527525|NCT00174226|Drug|Atomoxetine|
527526|NCT00174226|Drug|Buspirone|
527527|NCT00174200|Drug|Risperidone 2 mg|
527528|NCT00174187|Drug|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
527529|NCT00174174|Drug|Modafinil|
527530|NCT00174161|Behavioral|self-care, health behavior|
527531|NCT00173992|Behavioral|Balance and Exercise|
527532|NCT00173953|Procedure|immune response|
527533|NCT00173901|Drug|ceftazidime|
527534|NCT00173888|Drug|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
527535|NCT00173888|Drug|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
527536|NCT00173875|Drug|Iressa|
527537|NCT00173862|Drug|Gemcitabine, Ifosfamide|
527538|NCT00173758|Procedure|co-culture of embryos and endometrial cells|
527539|NCT00173745|Drug|botulinum toxin A injection|
527540|NCT00173719|Device|Standard cane|
527554|NCT00173407|Procedure|immunohistochemical, methylation, gene transfection|
527555|NCT00173251|Procedure|obtain surgical specimen for analysis|
527556|NCT00173108|Behavioral|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
527557|NCT00173082|Procedure|Glucose tolerance test|
527558|NCT00173017|Device|wearing N95 masks|
527559|NCT00172939|Procedure|foreskin from healthy adults|
527560|NCT00172809|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
527561|NCT00172809|Drug|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
527562|NCT00172653|Procedure|functional tasks|
527563|NCT00172601|Procedure|mobilization|
527564|NCT00172536|Behavioral|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
527565|NCT00172536|Other|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
527566|NCT00172510|Procedure|blood drawing|
527567|NCT00172484|Procedure|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
527568|NCT00172484|Procedure|nursing program|To establish a systemic stroke prevention, education protocol
527569|NCT00172484|Procedure|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
527570|NCT00172445|Procedure|blood sampling, neck lymph node biopsy|
527571|NCT00172419|Drug|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
527572|NCT00172380|Drug|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
527573|NCT00172367|Drug|Lycopene|
527574|NCT00172354|Drug|Hydrocortisone|
527575|NCT00172341|Drug|Staloral TM|
527576|NCT00172328|Biological|Hepatitis B vaccine|
527577|NCT00172302|Drug|vitamin C, intravenous injection|
527578|NCT00172263|Procedure|blood sampling|
527579|NCT00172211|Drug|Physioneal|
527580|NCT00172198|Drug|Omegaven 10%|
527581|NCT00172185|Drug|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
527582|NCT00172185|Drug|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
527583|NCT00172172|Drug|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
527584|NCT00172172|Drug|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
527585|NCT00172172|Drug|placebo|Placebo injected subcutaneously and 700 mg calcium orally
527586|NCT00172159|Procedure|Hepatic resection|
527587|NCT00172133|Drug|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
527588|NCT00172120|Drug|ALX1-11|
527589|NCT00172107|Drug|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
527590|NCT00172107|Drug|placebo|placebo powder for subcutaneous injection
527591|NCT00172107|Drug|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
527592|NCT00172107|Drug|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
527593|NCT00172094|Drug|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
527594|NCT00172094|Drug|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
527595|NCT00172094|Drug|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
527596|NCT00172081|Drug|placebo|Daily subcutaneous injection with placebo
527597|NCT00172081|Drug|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
527598|NCT00172068|Drug|Zoledronic acid + Calcium/Vitamin D|
527599|NCT00172055|Drug|Zoledronic acid|
527600|NCT00172042|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
527601|NCT00172029|Drug|Zoledronic acid|
527602|NCT00172016|Drug|Zoledronic acid|
527603|NCT00172003|Drug|Zoledronic acid|
527604|NCT00171990|Drug|Famciclovir|
527605|NCT00171977|Drug|Imatinib Mesylate|
527606|NCT00171964|Drug|Zoledronic acid in combination with therapy|
527607|NCT00171951|Drug|Pasireotide|
527608|NCT00171938|Drug|imatinib mesylate|
527609|NCT00171925|Drug|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance > 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg*hr/l).
527610|NCT00171925|Dietary Supplement|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
527611|NCT00171912|Drug|imatinib mesylate|
527612|NCT00171899|Drug|imatinib mesylate|
527613|NCT00171886|Drug|Octreotide|
527614|NCT00171873|Drug|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
527615|NCT00171873|Drug|Placebo|Sodium chloride intramuscularly every 28 days
527616|NCT00171860|Drug|imatinib mesylate|
527617|NCT00171847|Drug|Letrozole|
527618|NCT00171847|Drug|Trastuzumab plus Letrozole|
527619|NCT00171847|Drug|Letrozole|
527620|NCT00171834|Drug|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
527621|NCT00171821|Drug|Deferasirox|
527622|NCT00171808|Drug|Letrozole|
527623|NCT00171795|Drug|Rivastigmine|
527624|NCT00171782|Drug|VALSARTAN+HYDROCHLOROTHIAZIDE|
527625|NCT00171769|Drug|Certoparin|
527626|NCT00171756|Drug|valsartan/atenolol|
527627|NCT00171743|Drug|Cyclosporine microemulsion|
527628|NCT00171730|Drug|Pasireotide|
527629|NCT00171717|Drug|Cyclosporine - cyclosporine microemulsion|
527630|NCT00171704|Drug|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
527631|NCT00171704|Drug|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
527632|NCT00171691|Drug|Diclofenac Topical Sodium Gel 1%|
527633|NCT00171678|Drug|Diclofenac Topical Sodium Gel 1%|
527634|NCT00171665|Drug|Diclofenac topical sodium gel 1%|
527635|NCT00171652|Drug|Diclofenac sodium gel 1%|
527636|NCT00171639|Drug|zoledronic acid|
527637|NCT00171626|Drug|Diclofenac Topical Sodium Gel 1%|
527638|NCT00171613|Drug|Octreotide|
527639|NCT00171600|Drug|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
527640|NCT00171587|Drug|PTK787/ZK 222584 (vatalanib)|
527641|NCT00171574|Drug|Valsartan|
527642|NCT00171574|Drug|Valsartan plus HCTZ|
527643|NCT00171574|Drug|Lisinopril|
527644|NCT00171561|Drug|valsartan/hydrochlorothiazide|
527645|NCT00171535|Drug|valsartan/amlodipine|
527646|NCT00171522|Drug|Tegaserod and Polyethylene Glycol 3350|
527647|NCT00171509|Drug|Cyclosporine microemulsion|
527648|NCT00171496|Drug|Cyclosporine microemulsion|
527649|NCT00171496|Drug|Tacrolimus|
527650|NCT00171483|Drug|Tegaserod|
527651|NCT00171470|Drug|Tegaserod|
527652|NCT00171457|Drug|Tegaserod|
527653|NCT00171444|Behavioral|Medical education|
527654|NCT00171431|Drug|Tegaserod|
527655|NCT00171418|Drug|Tegaserod|
527656|NCT00171405|Drug|aliskiren|
527657|NCT00171392|Drug|Enteric-coated mycophenolate sodium|
527658|NCT00171379|Drug|Enteric-Coated Mycophenolate Sodium|
527659|NCT00171366|Drug|amlodipine/benazepril|
527660|NCT00171353|Drug|valsartan|
527661|NCT00171340|Drug|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
527662|NCT00171340|Drug|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
527663|NCT00171327|Drug|valsartan, fluvastatin|
527664|NCT00171314|Drug|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
527665|NCT00171314|Drug|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
527666|NCT00171301|Drug|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
527667|NCT00171288|Drug|fluvastatin, ezetimibe|
527668|NCT00171275|Drug|Fluvastatin|
527669|NCT00171262|Drug|Fluvastatin|
527670|NCT00171249|Drug|imatinib mesylate|
527671|NCT00171236|Drug|Fluvastatin|
527672|NCT00171223|Drug|imatinib mesylate|
527673|NCT00171210|Drug|Deferasirox|Tablets taken orally once a day.
527674|NCT00171184|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
527675|NCT00171184|Drug|Placebo|Placebo tablet once daily with sham titration
527676|NCT00171171|Drug|deferasirox|
527677|NCT00171158|Drug|imatinib mesylate|
527678|NCT00171145|Drug|Darifenacin|Darifenacin 15 mg tablets once daily
527679|NCT00171145|Drug|Placebo|Placebo tablets once daily
527680|NCT00171132|Drug|valsartan|
527681|NCT00171132|Drug|atenolol|
527682|NCT00171132|Drug|hydrochlorothiazide|
527683|NCT00171119|Drug|valsartan|
527684|NCT00171106|Drug|valsartan|
527685|NCT00171093|Drug|valsartan + simvastatin|
527686|NCT00171080|Drug|valsartan|
527687|NCT00171080|Drug|irbesartan|
527688|NCT00171067|Drug|valsartan|
527689|NCT00171067|Drug|lisinopril|
527690|NCT00171054|Drug|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
527691|NCT00171054|Drug|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
527692|NCT00171054|Drug|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
527693|NCT00171041|Drug|valsartan|
527694|NCT00171028|Drug|valsartan|
527695|NCT00171015|Drug|valsartan plus hydrochlorothiazide|
527696|NCT00171002|Drug|valsartan/amlodipine|
527697|NCT00170989|Drug|valsartan plus hydrochlorothiazide|
527698|NCT00170976|Drug|valsartan + amlodipine|
527699|NCT00170963|Drug|valsartan/amlodipine|
527700|NCT00170950|Drug|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
527701|NCT00170950|Drug|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
540708|NCT00003405|Drug|isotretinoin|
527702|NCT00170950|Drug|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
527703|NCT00170950|Drug|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
527704|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
527705|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
527706|NCT00170937|Drug|valsartan plus hydrochlorothiazide|
527707|NCT00170924|Drug|Valsartan|
527708|NCT00170911|Drug|AAE581|
527709|NCT00170898|Drug|Lumiracoxib|
527710|NCT00170885|Drug|Everolimus|
527711|NCT00170872|Drug|Lumiracoxib|
527712|NCT00170859|Drug|Everolimus|
527713|NCT00170846|Drug|Everolimus (RAD001)|
527714|NCT00170846|Drug|Calcineurin Inhibitors (CNI)|
527715|NCT00170846|Drug|Mycophenolate acid (MPA)/Azathioprine (AZA)|
527716|NCT00170846|Drug|Steroids|
527717|NCT00170833|Drug|Everolimus|
527718|NCT00170820|Drug|Everolimus|
527719|NCT00170794|Drug|Everolimus (RAD001)|
527720|NCT00170781|Drug|Lumiracoxib|
527721|NCT00170768|Drug|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
527722|NCT00170768|Drug|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
527723|NCT00170768|Drug|Placebo|Placebo once daily tablet (sham titration)
527724|NCT00170755|Drug|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
527725|NCT00170742|Drug|Octreotide, 30 mg i.m. LAR formulation|
527726|NCT00170729|Drug|Prednisolone acetate|
527727|NCT00170716|Device|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
527728|NCT00170716|Other|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
527729|NCT00170703|Device|Cortical Electrical Stimulation|
527730|NCT00170690|Drug|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
527731|NCT00170690|Drug|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
527732|NCT00170677|Drug|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
527733|NCT00170677|Drug|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
527734|NCT00170664|Drug|Paclitaxel|
527735|NCT00170664|Drug|Carboplatin|
527736|NCT00170625|Drug|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
527737|NCT00170612|Biological|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
527738|NCT00170612|Biological|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
527739|NCT00170586|Device|Underglove coating (skin barrier)|
527740|NCT00170573|Drug|Caelyx|Caelyx 40 mg/ m2biweekly
527741|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
527742|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
527743|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
527744|NCT00170534|Behavioral|Behavior|
527745|NCT00170508|Biological|Fluzone®|
527746|NCT00170469|Biological|AVA|
527747|NCT00170469|Biological|rPA vaccine containing alhydrogel|
527748|NCT00170456|Biological|rPA vaccine containing alhydrogel|
527749|NCT00170443|Biological|rHAO Trivalent Influenza Vaccine|
527750|NCT00170430|Drug|Fluconazole|
527751|NCT00170430|Drug|Metronizadole|
527752|NCT00170417|Behavioral|Cognitive Behaviour Therapy|
527753|NCT00170404|Drug|Folic Acid|
527754|NCT00170404|Drug|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
527755|NCT00170404|Drug|Selenium|
527756|NCT00170404|Drug|Vitamin A|
527757|NCT00170391|Behavioral|Quarter of an Hour rule|
527758|NCT00170378|Drug|Enoxaparin|
527759|NCT00170365|Behavioral|Restorative Yoga|
527760|NCT00170352|Procedure|Hyperbaric Oxygen Treatment (HBOT)|
527761|NCT00170352|Procedure|Enhanced Oxygen Treatment (Enhanced FiO2)|
527762|NCT00170326|Procedure|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
527763|NCT00170326|Procedure|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
527764|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
527765|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
527766|NCT00170300|Device|Implantable Cardiac Resynchronisation (pacing) device|
527767|NCT00170287|Procedure|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
527768|NCT00170287|Device|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
527769|NCT00170274|Device|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
527770|NCT00170274|Device|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
527771|NCT00170261|Device|Use of an Implantable Loop Recorder|
527772|NCT00170248|Device|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
527773|NCT00170235|Other|Prehabilitation|Exercise class pre-surgery
527774|NCT00170235|Other|Usual care|Exercise booklet, physiotherapy if needed
527775|NCT00170222|Drug|doxycycline|
527776|NCT00170209|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
527777|NCT00170209|Drug|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
527778|NCT00170196|Drug|prednisone|
527779|NCT00170183|Drug|Nesiritide|
527780|NCT00170157|Drug|Bicalutamide|Given orally
527781|NCT00170157|Drug|Flutamide|Given orally
527782|NCT00170157|Drug|Goserelin Acetate|Given SC
527783|NCT00170157|Drug|Ipilimumab|Given IV
527784|NCT00170157|Drug|Leuprolide Acetate|Given IM
527785|NCT00170157|Other|Pharmacological Study|Correlative study
527786|NCT00170144|Drug|Branchamin 4%|
527787|NCT00170118|Behavioral|motivational interviewing|
527788|NCT00170079|Behavioral|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:~Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;~Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and~Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
527789|NCT00170053|Drug|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
527790|NCT00170027|Device|Magnetocardiograph|
527791|NCT00170014|Device|Magnetocardiograph|
527792|NCT00170001|Drug|Nexium|40 mg bid dosing
527793|NCT00170001|Drug|Sugar Pill|40 mg BID
527794|NCT00169988|Drug|risperidone|
527795|NCT00169988|Drug|sertraline-primary|
527796|NCT00169975|Device|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
527797|NCT00169962|Drug|rhDNAse (pulmozyme)|
527798|NCT00169949|Drug|aripiprazole|
527799|NCT00169936|Device|Magnetocardiograph|
527800|NCT00169923|Drug|rosiglitazone|
527801|NCT00169910|Drug|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
527802|NCT00169897|Behavioral|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
527803|NCT00169884|Behavioral|cognitive-behavioural therapy|
527804|NCT00169858|Biological|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
527805|NCT00169845|Dietary Supplement|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
527806|NCT00169845|Dietary Supplement|Placebo|Provided by Roche Vitamins Inc
527807|NCT00169832|Drug|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
527808|NCT00169819|Drug|Abciximab|
527809|NCT00169806|Other|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
527810|NCT00169793|Other|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
527811|NCT00169793|Other|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
527812|NCT00169780|Radiation|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
528018|NCT00168025|Drug|Immunoglobulins Intravenous (Human)|
527813|NCT00169767|Other|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
527814|NCT00169754|Other|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
527815|NCT00169741|Other|Renogram|Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
527816|NCT00169728|Biological|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
527817|NCT00169728|Biological|heptavalent pneumococcal conjugate vaccine, Prevenar|
527818|NCT00169715|Procedure|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
527819|NCT00169702|Behavioral|weight management program|12 sessions, psychoeducation
527820|NCT00169702|Behavioral|weight management program|2 weekly, 12 sessions, psychoeducational weight management
527821|NCT00169689|Procedure|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
527822|NCT00169689|Other|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
527823|NCT00169676|Other|observation|registry and database for surgery outcomes
527824|NCT00169650|Other|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
527825|NCT00169637|Drug|rhGH|
527826|NCT00169624|Drug|Metformin|
527827|NCT00169624|Drug|Gliclazide|
527828|NCT00169611|Drug|methylphenidate|
527829|NCT00169598|Procedure|positron emission tomography|
527830|NCT00169585|Drug|Levofloxacin oral tablets|
527831|NCT00169572|Drug|Aprepitant|
527832|NCT00169572|Drug|Ondansetron|
527833|NCT00169572|Drug|GW679769|
527834|NCT00169572|Drug|Dexamethasone|
527835|NCT00169559|Drug|GW590735|1µg to 20µg daily doses of GW590735
527836|NCT00169559|Drug|fenofibrate|Marketed Drug
527837|NCT00169546|Drug|Salmeterol/fluticasone propionate|
527838|NCT00169546|Drug|Fluticasone propionate|
527839|NCT00169533|Drug|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
527840|NCT00169520|Drug|docetaxel|
527841|NCT00169520|Drug|SB-715992|
527842|NCT00169507|Biological|Pneumococcal (vaccine)|
527843|NCT00169494|Biological|HPV-16/18 L1/AS04|
527844|NCT00169481|Biological|Pneumococcal (vaccine)|
527845|NCT00169468|Drug|Rituximab -CHOP plus Velcade|
527846|NCT00169455|Biological|Live attenuated human rotavirus vaccine|
527847|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
527848|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
527849|NCT00169442|Biological|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
527850|NCT00169442|Biological|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
527851|NCT00169442|Biological|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
527852|NCT00169416|Drug|valaciclovir HCl granules|
527853|NCT00169403|Procedure|Deep brain stimulation|
527854|NCT00169377|Procedure|deep brain stimulation|Stimulator on followed by off
527855|NCT00169377|Procedure|No stimulation|Stimulator off followed by on
527856|NCT00169364|Device|positron emission tomography|
527857|NCT00169338|Procedure|Deep brain stimulation|internal pallidal deep brain stimulation
527858|NCT00169325|Procedure|Magnetic resonance imaging|
527859|NCT00169312|Behavioral|behavioral dietary intervention|
527860|NCT00169312|Dietary Supplement|dietary intervention|
527861|NCT00169312|Other|educational intervention|
527862|NCT00169312|Other|internet-based intervention|
527863|NCT00169312|Other|preventative dietary intervention|
527864|NCT00169312|Procedure|evaluation of cancer risk factors|
527865|NCT00169299|Drug|Black cohosh|
527866|NCT00169299|Drug|Multibotanical preparation|
527867|NCT00169299|Drug|Multibotanical preparation + dietary soy counseling|
527868|NCT00169299|Drug|Conjugated equine estrogen +/- medroxyprogesterone acetate|
527869|NCT00169286|Procedure|Telephone care management|
527870|NCT00169286|Procedure|peer-led chronic disease self-management workshop|
527871|NCT00169286|Procedure|professionally-led cognitive behavioral psychotherapy group|
527872|NCT00169273|Behavioral|Structured behavioral weight loss group|Structured group weight loss program
527873|NCT00169273|Behavioral|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
527874|NCT00169260|Behavioral|motivational counseling|behavioral motivational counselling
527875|NCT00169260|Behavioral|placebo|
527876|NCT00169247|Drug|cetuximab|
527877|NCT00169247|Drug|Cisplatin|
527878|NCT00169247|Procedure|Radiotherapy 70 Gy, 35 fractions|
527879|NCT00169234|Biological|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
527880|NCT00169234|Biological|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
528019|NCT00168012|Drug|Immunoglobulins Intravenous (Human)|
527881|NCT00169221|Drug|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
527882|NCT00169221|Radiation|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
527883|NCT00169208|Drug|rituximab|375 mg/m² IV, D1 each cycle during 4 cycles
527884|NCT00169208|Drug|fludarabine|40 mg/m²/day IV , D1 each cycle during 4 cycles
527885|NCT00169208|Drug|mitoxantrone|10 mg/m² IV, D2-3-4 each cycle during 4 cycles
527886|NCT00169195|Drug|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
527887|NCT00169182|Drug|DOCETAXEL|75 mg/m 2 on day 1
527888|NCT00169182|Drug|Cisplatin|75 mg/m 2 on day 1
527889|NCT00169182|Drug|5-Fluoro-3-Pyridinecarboxylic Acid|750 mg/m 2 by 24-hour continuous infusion for 5 days
527890|NCT00169169|Drug|ACVBP|
527891|NCT00169169|Drug|ACE|
527892|NCT00169169|Drug|rituximab|
527893|NCT00169169|Procedure|Autologous stem cell transplant|
527894|NCT00169156|Drug|Rituximab|375 mg/m2 D1
527895|NCT00169156|Drug|Prednisone|40 mg/m2 D1 to D5
527896|NCT00169156|Drug|Doxorubicine|50 mg/m2 D1
527897|NCT00169156|Drug|Cyclophosphamide|750 mg/m2 D1
527898|NCT00169156|Drug|Vincristine|1,4 mg/m2 D1
527899|NCT00169143|Drug|Rituximab + ACVBP regimen plus Pegfilgrastim|
527900|NCT00169143|Procedure|Autologous stem cell transplant|
527901|NCT00169130|Drug|doxorubicin|
527902|NCT00169130|Drug|cyclophosphamide|
527903|NCT00169130|Procedure|Autologous stem cell transplantation|
527904|NCT00169117|Behavioral|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
527905|NCT00169104|Drug|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
527906|NCT00169104|Drug|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
527907|NCT00169104|Drug|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
527908|NCT00169104|Drug|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
527909|NCT00169104|Drug|saline placebo|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
527910|NCT00169091|Drug|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
527911|NCT00169091|Drug|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
527912|NCT00169078|Drug|Chloroquine|
527913|NCT00169065|Drug|Clozapine|
527914|NCT00169065|Drug|Olanzapine|
527915|NCT00169052|Behavioral|Health Care Management and Supported Rehabilitation|
527916|NCT00169039|Drug|Clozapine|
527917|NCT00169039|Drug|Chlorpromazine|
527918|NCT00169026|Drug|Clozapine versus typical (conventional) and atypical antipsychotic medications|
527919|NCT00169013|Drug|Gabapentin|
527920|NCT00169000|Drug|Capecitabine|"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID"
527921|NCT00169000|Drug|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
527922|NCT00168987|Drug|oral nutritional supplement rich in eicosapentanoic acid|
527923|NCT00168961|Dietary Supplement|High Protein Energy, Fresenius-Kabi (nutritional intervention)|
527924|NCT00168948|Drug|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
527925|NCT00168935|Drug|Fresubin protein energy Drink (CAVE! nutritional intervention)|
527926|NCT00168922|Drug|Bendamustin/Ribomustin|
527927|NCT00168909|Drug|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
527928|NCT00168909|Drug|placebo|placebo once daily, oral, for 3 years
527929|NCT00168896|Drug|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
527930|NCT00168883|Drug|Carboplatin|
527931|NCT00168883|Drug|Paclitaxel|
527932|NCT00168883|Drug|Vinorelbine|
527933|NCT00168870|Drug|Gemcitabine|
527934|NCT00168870|Drug|Treosulfan|
527935|NCT00168857|Drug|telmisartan|
527936|NCT00168857|Drug|losartan|
527937|NCT00168844|Drug|Tiotropium Inhalation Solution|
527938|NCT00168844|Other|Placebo|
527939|NCT00168831|Drug|Tiotropium Inhalation Solution|
527940|NCT00168831|Other|Placebo|
527941|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
527942|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
527943|NCT00168818|Drug|enoxaparin|40 mg once daily
527944|NCT00168805|Drug|enoxaparin|40 mg once daily
527945|NCT00168805|Drug|dabigatran etexilate|150 mg once daily
527946|NCT00168805|Drug|dabigatran etexilate|220 mg once daily
527947|NCT00168792|Drug|Tenecteplase|
527948|NCT00168792|Procedure|PCI|
527949|NCT00168779|Drug|telmisartan 80 mg / hydrochlorothiazide 25 mg|
527950|NCT00168779|Drug|valsartan 160 mg / hydrochlorothiazide 25 mg|
527951|NCT00168779|Drug|placebo|
527952|NCT00168766|Drug|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
527953|NCT00168753|Drug|Alefacept|IM
527954|NCT00168740|Drug|rituximab|
527955|NCT00168727|Drug|ibritumomab tiuxetan (Zevalin®)|
527956|NCT00168714|Drug|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
527957|NCT00168701|Drug|BG00012|
527958|NCT00168688|Dietary Supplement|multi micronutrient supplement|
528020|NCT00167999|Drug|piperacillin-tazobactam|
528021|NCT00167986|Drug|vancomycin-resistant enterococci and ESBL|
528022|NCT00167960|Drug|Piperacillin/tazobactam and other β-lactam/β-lactamase|
527959|NCT00168688|Dietary Supplement|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
527960|NCT00168688|Dietary Supplement|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
527961|NCT00168662|Biological|Measles and inactivated polio vaccine|
527962|NCT00168649|Drug|Vitamin A|
527963|NCT00168636|Drug|Vitamin A|
527964|NCT00168623|Drug|Vitamin A|
527965|NCT00168610|Drug|Vitamin A|
527966|NCT00168597|Drug|Vitamin A|
527967|NCT00168584|Drug|Vitamin A|
527968|NCT00168571|Biological|Measles vaccine|
527969|NCT00168558|Biological|Measles vaccine|"The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
527970|NCT00168545|Biological|Measles vaccine|
527971|NCT00168532|Drug|Sulfamethoxazole-Trimethoprim|
527972|NCT00168519|Drug|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion~Pentalong - two tablets orally (total 160mg)~Imdur - two tablets orally (total 120mg)"
527973|NCT00168506|Drug|SSRI|
527974|NCT00168506|Drug|CBT|
527975|NCT00168506|Drug|CBT/SSRI|
527976|NCT00168493|Drug|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
527977|NCT00168480|Biological|Botulinum Toxin Type A|100 U, repeated treatments at > 4 month intervals up to Month 32, over a 36-month study period
527978|NCT00168467|Drug|Ramipril|
527979|NCT00168454|Biological|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
527980|NCT00168454|Drug|Placebo|Placebo (normal saline) injected into detrusor on Day 1
527981|NCT00168441|Drug|Botulinum Toxin Type A|
527982|NCT00168428|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
527983|NCT00168428|Other|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
527984|NCT00168415|Biological|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
527985|NCT00168402|Drug|Botulinum Toxin Type A|
527986|NCT00168389|Drug|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
527987|NCT00168389|Other|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
527988|NCT00168376|Device|Transcranial Magnetic Stimulation|
527989|NCT00168363|Drug|brimonidine|
527990|NCT00168350|Drug|memantine|
527991|NCT00168337|Drug|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
527992|NCT00168337|Other|Sham|Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
527993|NCT00168324|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
527994|NCT00168324|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
527995|NCT00168324|Other|Sham Injection|Sham injection on Day 0.
527996|NCT00168311|Device|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
527997|NCT00168311|Device|sham TMS|
527998|NCT00168298|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
527999|NCT00168298|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
528000|NCT00168298|Other|Sham Injection|Sham injection on Day 0.
528001|NCT00168285|Behavioral|Pulmonary Rehabilitation|
528002|NCT00168272|Device|Transcranial Magnetic Stimulation|
528003|NCT00168181|Procedure|Submandibular gland Transfer|
528004|NCT00168181|Drug|Salagen|
528005|NCT00168168|Drug|G-CSF/Filgrastim|
528006|NCT00168155|Drug|perioperative chemotherapy|
528007|NCT00168129|Procedure|Helical tomotherapy|
528008|NCT00168116|Procedure|radiation treatment and surgery|
528009|NCT00168116|Procedure|radiation alone|
528010|NCT00168103|Biological|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
528011|NCT00168103|Biological|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
528012|NCT00168090|Drug|Blood coagulation Factor VIII and vWF, human|
528013|NCT00168077|Drug|Prothrombin Complex Concentrate|
528014|NCT00168064|Drug|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
528015|NCT00168051|Drug|ReFacto|
528016|NCT00168051|Drug|Advante|
528017|NCT00168038|Biological|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
528023|NCT00167947|Drug|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
528024|NCT00167947|Drug|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
528025|NCT00167947|Drug|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
528026|NCT00167934|Drug|Valproate|Depakote ER 500 mg to 3000 mg taken every night
528027|NCT00167934|Drug|Placebo|Placebo given at same frequency as Valproate
528028|NCT00167921|Drug|Premarin® Vaginal Cream|
528029|NCT00167921|Drug|Premarin® oral tablets|
528030|NCT00167908|Drug|Ethyol (drug)|
528031|NCT00167895|Procedure|Adding platelet concentrate to the wound|
528032|NCT00167882|Drug|5-aminosalicylate (Pentasa, Ferring)|
528033|NCT00167869|Behavioral|dairy peptides|
528034|NCT00167856|Drug|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
528035|NCT00167843|Drug|sulfadoxine-pyrimethamine|
528036|NCT00167830|Behavioral|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
528037|NCT00167830|Behavioral|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
528038|NCT00167830|Behavioral|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
528039|NCT00167817|Drug|Aripiprazole|
528040|NCT00167804|Behavioral|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
528041|NCT00167791|Drug|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
528042|NCT00167778|Device|Transverse plane rotation adaptor pylon|Potential future practice
528043|NCT00167778|Device|Rigid pylon|Current clinical practice
528044|NCT00167765|Drug|Abciximab|
528045|NCT00167739|Drug|Quinine plus sulfadoxine-pyrimethamine|
528046|NCT00167713|Drug|Ibuprofen|
528047|NCT00167700|Behavioral|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
528048|NCT00167700|Behavioral|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
528049|NCT00167700|Dietary Supplement|Placebo capsules|Placebo capsules
528050|NCT00167700|Dietary Supplement|Probiotics|
528051|NCT00167700|Dietary Supplement|Prebiotics|
528052|NCT00167687|Drug|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
528053|NCT00167674|Drug|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight > 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
528054|NCT00167674|Drug|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
528055|NCT00167661|Drug|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
528056|NCT00167648|Drug|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
528057|NCT00167648|Drug|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
528058|NCT00167635|Behavioral|cognitive-behavioral|Cognitive-behavioral over 9 weeks
528059|NCT00167622|Procedure|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
528060|NCT00167622|Procedure|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
528061|NCT00167609|Drug|dehydroepiandrosterone 100 and 400 mg|
528062|NCT00167596|Device|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
528063|NCT00167596|Device|conventional|resuscitation will be based according to Surviving Sepsis Campaign
528064|NCT00167583|Drug|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
528065|NCT00167583|Drug|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
528066|NCT00167570|Device|Prosthetic socket fabricated using selective laser sintering|
528067|NCT00167557|Drug|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
528068|NCT00167557|Drug|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
528069|NCT00167557|Procedure|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
528070|NCT00167544|Drug|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
528071|NCT00167544|Drug|Placebo|Saline
528072|NCT00167531|Behavioral|treadmill walking with partial weight support|
528073|NCT00167531|Behavioral|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
528074|NCT00167518|Drug|Triamcinolone acetate|
528211|NCT00165893|Procedure|Physical Therapy|
528212|NCT00165880|Drug|E7070|
528075|NCT00167505|Behavioral|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
528076|NCT00167505|Behavioral|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
528077|NCT00167492|Drug|Myfortic|720 mg by mouth every 12 hours
528078|NCT00167479|Drug|risperidone (Risperdal)|
528079|NCT00167466|Device|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
528080|NCT00167466|Device|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
528081|NCT00167453|Procedure|Exercise, Education|
528082|NCT00167414|Procedure|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
528083|NCT00167414|Radiation|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
528084|NCT00167401|Drug|docetaxel|
528085|NCT00167401|Drug|cisplatin|
528086|NCT00167401|Procedure|radiation treatment|
528087|NCT00167388|Other|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
528088|NCT00167375|Drug|eszopiclone 3 mg qHS|
528089|NCT00167375|Behavioral|General cognitive/behavioral interventions for insomnia|
528090|NCT00167362|Behavioral|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
528091|NCT00167362|Behavioral|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
528092|NCT00167323|Behavioral|Adherence therapy|
528093|NCT00167310|Drug|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
528094|NCT00167310|Drug|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
528095|NCT00167297|Drug|Atomoxetine|
528096|NCT00167284|Behavioral|physician and patient education; physician practice redesign|
528097|NCT00167271|Behavioral|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
528098|NCT00167258|Behavioral|Voucher Reinforcement|
528099|NCT00167258|Behavioral|Extra Counseling Services|
528100|NCT00167258|Behavioral|Voucher Reinforcement + Extra Counseling Services|
528101|NCT00167245|Drug|Topiramate|300mg/day for 13 weeks
528102|NCT00167245|Drug|placebo|placebo pills
528103|NCT00167232|Drug|Naltrexone|
528104|NCT00167219|Biological|Stem Cell Transplant|Transplantation on Day 0.
528105|NCT00167219|Drug|Preparative Regimen|"Busulfan~Cyclophosphamide~Mesna~Melphalan~Anti-thymocyte Globulin (ATG)"
528106|NCT00167206|Procedure|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
528107|NCT00167206|Procedure|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
528108|NCT00167206|Procedure|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
528109|NCT00167206|Drug|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
528110|NCT00167180|Procedure|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10^8 CD3+T-cells/kg
528111|NCT00167180|Drug|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
528112|NCT00167167|Procedure|Donor Lymphocyte Infusion|"Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer."
528113|NCT00167154|Drug|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
528114|NCT00167141|Drug|injection of hormonal male contraceptive|testosterone injections 4 times
528115|NCT00167128|Device|hearing aid, Phonak EduLink-FM System|
528116|NCT00167115|Drug|Alcohol|
528213|NCT00165867|Drug|E7070|
528214|NCT00165854|Drug|E7070|
528117|NCT00167102|Drug|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
528118|NCT00167089|Behavioral|Treadmill Training|Partian body weight support treadmill training, 30 min/day * 3 days /week
528119|NCT00167011|Procedure|CT|
528120|NCT00166946|Procedure|foreskin from healthy adults for organotypic culture|
528121|NCT00166907|Behavioral|Balance and Exercise|
528122|NCT00166881|Drug|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
528123|NCT00166868|Drug|Lactobacillus casei rhamnosus (Lcr35)|
528124|NCT00166868|Drug|Neomycin|
528125|NCT00166855|Procedure|dynamic MRI and bone marrow sampling|
528126|NCT00166842|Drug|sirolimus, cyclosporine, tacrolimus|
528127|NCT00166829|Drug|sirolimus, tacrolimus, mycophenolate mofetil|
528128|NCT00166816|Drug|sirolimus, cyclosporine, tacrolimus|
528129|NCT00166803|Drug|Rosiglitazone|Rosiglitazone , 4 mg daily
528130|NCT00166790|Drug|chemotherapy agents|
528131|NCT00166790|Procedure|suction curettage|
528132|NCT00166777|Procedure|exercise training|
528133|NCT00166725|Drug|Octreotide LAR|
528134|NCT00166712|Drug|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
528135|NCT00166712|Drug|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
528136|NCT00166712|Drug|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
528137|NCT00166712|Drug|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
528138|NCT00166699|Procedure|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
528139|NCT00166686|Drug|Clonidine|
528140|NCT00166673|Device|FreeStyle Navigator Continuous Glucose Monitoring System|
528141|NCT00166660|Behavioral|NIDCAP (Newborn Individualized Developmental Care)|The NIDCAP model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account the infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists formally observed each infant's behavior weekly throughout the hospitalization, starting with the phase of the infant's initial stabilization, and then every seven days throughout hospital discharge and to 2wCA.
528142|NCT00166647|Procedure|Blood Sampling|
528143|NCT00166634|Procedure|Ambulatory Blood Pressure Monitoring (ABPM)|
528144|NCT00166621|Drug|Buspirone|
528145|NCT00166608|Procedure|Blood sampling|
528146|NCT00166595|Drug|Risperidone|
528147|NCT00166582|Device|electronic medication monitoring system|
528148|NCT00166582|Behavioral|parent-adolescent communication and problem-solving skills|
528149|NCT00166556|Drug|Campath-1H and Tacrolimus|
528150|NCT00166543|Drug|TAS-108|
528151|NCT00166530|Drug|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
528152|NCT00166530|Drug|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
528153|NCT00166530|Drug|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
528154|NCT00166517|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
528155|NCT00166517|Biological|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
528156|NCT00166504|Drug|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
528157|NCT00166504|Drug|atorvastatin|atorvastatin 10 mg
528158|NCT00166491|Drug|Insulin|
528159|NCT00166478|Drug|Exisulind Therapy|
528160|NCT00166465|Drug|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
528161|NCT00166452|Drug|Lenalidamide|
528162|NCT00166439|Drug|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only~dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles~oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles~cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles~pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
528163|NCT00166426|Drug|Exisulind|
528164|NCT00166413|Drug|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
528165|NCT00166400|Drug|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
528166|NCT00166387|Procedure|Blood draw|A single blood draw.
528167|NCT00166374|Procedure|balloon kyphoplasty|
528168|NCT00166361|Device|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
528169|NCT00166361|Device|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
528170|NCT00166348|Behavioral|Cognitive Group Therapy|
528171|NCT00166322|Procedure|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
528172|NCT00166309|Drug|FEIBA and NovoSeven|
528173|NCT00166296|Drug|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
528174|NCT00166296|Drug|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
528175|NCT00166283|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
528176|NCT00166283|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
528177|NCT00166270|Device|ExAblate 2000|
528178|NCT00166257|Device|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
528179|NCT00166257|Drug|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
528180|NCT00166244|Drug|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
528181|NCT00166218|Device|near-infrared spectroscopy|
528182|NCT00166205|Device|Swedish Adjustable Gastric Band|Long term implantable device.
528183|NCT00166192|Procedure|Jessner's solution chemical peel|
528184|NCT00166192|Procedure|Trichloroacetic acid chemical peel|
528185|NCT00166166|Drug|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
528186|NCT00166166|Drug|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
528187|NCT00166166|Drug|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
528188|NCT00166166|Drug|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
528189|NCT00166166|Drug|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
528190|NCT00166166|Drug|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
528191|NCT00166166|Drug|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
528192|NCT00166153|Drug|Mycophenolate Mofetil|
528193|NCT00166127|Drug|Levosimendan|
528194|NCT00166114|Drug|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
528195|NCT00166114|Drug|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
528196|NCT00166088|Dietary Supplement|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
528197|NCT00166088|Dietary Supplement|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
528198|NCT00166075|Procedure|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
528199|NCT00166062|Procedure|Screening patients for IPV|
528200|NCT00166049|Behavioral|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
528201|NCT00166049|Behavioral|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
528202|NCT00166049|Behavioral|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
528203|NCT00166036|Drug|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
528204|NCT00166036|Drug|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
528205|NCT00166010|Drug|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
528206|NCT00165971|Procedure|BIS monitoring|
528207|NCT00165958|Procedure|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
528208|NCT00165958|Procedure|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
528209|NCT00165919|Other|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
528210|NCT00165893|Device|Accu-Spina Device/IDD therapy|
541122|NCT00082589|Drug|Eplerenone|
528215|NCT00165841|Drug|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
528216|NCT00165828|Drug|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
528217|NCT00165815|Drug|ARICEPT|
528218|NCT00165802|Drug|E7974|Maximum Tolerated Dose defined as 0.45 mg/m^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
528219|NCT00165789|Drug|E2007|
528220|NCT00165776|Drug|BOTULINUM TOXIN TYPE B|
528221|NCT00165763|Drug|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
528222|NCT00165750|Drug|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
528223|NCT00165737|Drug|Donepezil Hydrochloride|
528224|NCT00165724|Drug|Donepezil Hydrochloride|
528225|NCT00165711|Drug|Mecobalamin|
528226|NCT00165698|Drug|menatetranone|15 mg three times a day orally for 12 months
528227|NCT00165698|Drug|alfacalcidol|0.25 μg twice a day orally for 12 months
528228|NCT00165685|Drug|Sibutramine Hydrochloride Monohydrate|
528229|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
528230|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
528231|NCT00165659|Drug|DONEPEZIL HYDROCHLORIDE|
528232|NCT00165646|Drug|E3810|E3810 5mg: once daily orally for 4 weeks
528233|NCT00165646|Drug|E3810|E3810 10mg: once daily orally for 4 weeks
528234|NCT00165646|Drug|Placebo|Placebo: once daily orally for 4 weeks
528235|NCT00165633|Drug|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
528236|NCT00165633|Drug|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
528237|NCT00165633|Drug|Placebo|Placebo capsule, orally, three times a day, after meals.
528238|NCT00165620|Drug|Iomeprole|
528239|NCT00165607|Drug|MENATETRANONE|
528240|NCT00165594|Drug|E7070|
528241|NCT00165581|Device|High Dose Intracavitary Brachytherapy|
528242|NCT00165568|Drug|Bevacizumab|
528243|NCT00165555|Drug|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
528244|NCT00165555|Drug|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
528245|NCT00165542|Other|A PROTEIN level|
528246|NCT00165516|Drug|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
528247|NCT00165516|Drug|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
528248|NCT00165503|Drug|Cisplatin|
528249|NCT00165503|Drug|Sodium Thiosulfate|
528250|NCT00165503|Drug|ALIMTA|
528251|NCT00165490|Drug|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
528252|NCT00165490|Drug|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
528253|NCT00165490|Drug|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
528254|NCT00165490|Device|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
528255|NCT00165490|Procedure|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
528256|NCT00165477|Drug|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
528257|NCT00165477|Radiation|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
528258|NCT00165464|Drug|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
528259|NCT00165464|Drug|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
528260|NCT00165464|Drug|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
528261|NCT00165451|Drug|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
528262|NCT00165451|Drug|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
528263|NCT00165451|Drug|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
528264|NCT00165451|Drug|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
528265|NCT00165438|Procedure|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
528266|NCT00165438|Procedure|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
528267|NCT00165425|Procedure|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
528268|NCT00165412|Procedure|breast MRI|Repeated once a year for three years
528269|NCT00165412|Procedure|Mammogram|Repeated once a year for three years
528270|NCT00165399|Drug|Docetaxel|Given intravenously on day 2 of four three-week cycles
528271|NCT00165399|Drug|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
528272|NCT00165399|Drug|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
528273|NCT00165399|Drug|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
528274|NCT00165386|Procedure|Magnetic Resonance Imaging|
528275|NCT00165386|Procedure|Bone Marrow Biopsy|
528399|NCT00164411|Biological|23-valent polysaccharide vaccine|
528276|NCT00165373|Drug|rhEndostatin|Given by continuous infustion for 28 days (one of two dosing groups) for a total of 2 cycles. Treatment can be extended if tolerated well.
528277|NCT00165360|Drug|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
528278|NCT00165347|Drug|PTK787/ZK222584|
528279|NCT00165334|Drug|Cetuximab|
528280|NCT00165334|Drug|Vinorelbine (Navelbine)|
528281|NCT00165308|Drug|Tamoxifen|Given orally, daily for one year.
528282|NCT00165295|Drug|Sildenafil citrate (Viagra)|
528283|NCT00165282|Behavioral|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
528284|NCT00165282|Behavioral|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
528285|NCT00165269|Procedure|Mantle irradiation|Limited to above the diaphragm
528286|NCT00165256|Other|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
528287|NCT00165243|Procedure|Tangential radiation|Radiation given over 6 1/2 weeks
528288|NCT00165230|Drug|Thalidomide|
528289|NCT00165230|Drug|Temodar|
528290|NCT00165217|Drug|Capecitabine|
528291|NCT00165217|Drug|Thalidomide|
528292|NCT00165204|Drug|Tibolone|
528293|NCT00165191|Drug|Doxorubicin|
528294|NCT00165191|Drug|Cisplatin|
528295|NCT00165191|Drug|5-fluorouracil|
528296|NCT00165178|Drug|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
528297|NCT00165178|Drug|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
528298|NCT00165178|Drug|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
528299|NCT00165178|Drug|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
528300|NCT00165178|Drug|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
528301|NCT00165178|Drug|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
528302|NCT00165178|Drug|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
528303|NCT00165178|Drug|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
528304|NCT00165178|Drug|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
528305|NCT00165178|Drug|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
528306|NCT00165152|Procedure|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
528307|NCT00165152|Procedure|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
528308|NCT00165139|Drug|Vincristine|Described under detailed description
528309|NCT00165139|Drug|Cyclophosphamide|Described under detailed description
528310|NCT00165139|Drug|Adriamycin|Described under detailed description
528311|NCT00165139|Drug|Etoposide (VP-16)|Described under detailed description
528312|NCT00165139|Drug|Cisplatin|Described under detailed description
528313|NCT00165139|Drug|Carboplatin|Described under detailed description
528314|NCT00165139|Drug|Melphalan|Described under detailed description
528315|NCT00165139|Drug|Ifosfamide|Described under detailed description
528316|NCT00165139|Drug|G-CSF (granulocyte-colony stimulating factor)|Described under detailed description
528317|NCT00165139|Drug|Mesna|Described under detailed description
528318|NCT00165126|Procedure|Radiation therapy|Given as standard therapy
528319|NCT00165100|Procedure|Dynamic Area Telethermometry (DAT)|
528320|NCT00165087|Drug|asparaginase (E. Coli)|
528321|NCT00165087|Drug|asparaginase (Erwina)|
528322|NCT00165087|Drug|dexrazoxane|
528323|NCT00165087|Drug|doxorubicin|
528324|NCT00165087|Procedure|cranial radiation (once daily fractionation)|
528325|NCT00165087|Procedure|cranial radiation (twice-daily fractionation)|
528326|NCT00165087|Procedure|Intrathecal chemotherapy without radiation|
528327|NCT00165074|Drug|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
528328|NCT00165061|Procedure|Esophagectomy|
528329|NCT00165061|Procedure|Chemoradiation|
528330|NCT00165048|Drug|Vioxx (Rofecoxib)|
528331|NCT00165035|Device|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
528332|NCT00165035|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
528333|NCT00165009|Device|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
528334|NCT00164996|Procedure|Local pharyngeal anaesthesia|
528335|NCT00164996|Device|Ultrathin endoscope|
528336|NCT00164970|Dietary Supplement|Vitamin B12|
528337|NCT00164970|Dietary Supplement|folate|
528338|NCT00164957|Device|continuous pump feeding|
528339|NCT00164957|Other|intermittent bolus feeding|
528340|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
528490|NCT00163436|Drug|Ciclesonide|
528341|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
528342|NCT00164931|Drug|Intravenous omeprazole infusion|
528343|NCT00164931|Procedure|Scheduled second endoscopy|
528344|NCT00164918|Device|nasogastric tube|
528345|NCT00164905|Device|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
528346|NCT00164892|Drug|Oral Vioxx (Rofecoxib)|
528347|NCT00164879|Procedure|Endoscopic stenting followed by elective laparoscopic resection|
528348|NCT00164866|Drug|Omeprazole|
528349|NCT00164853|Procedure|endoscopic balloon dilatation|Refer to description under arms
528350|NCT00164853|Procedure|Standard sphincterotomy|Refer to under arms
528351|NCT00164840|Drug|Esomeprazole|
528352|NCT00164827|Device|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
528353|NCT00164801|Drug|Baclofen, Diltiazem|
528354|NCT00164788|Drug|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
528355|NCT00164788|Drug|Oral esomeprazole|40mg every 12 hours for 24 hours
528356|NCT00164775|Drug|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
528357|NCT00164775|Drug|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
528358|NCT00164749|Drug|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
528359|NCT00164749|Drug|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
528360|NCT00164749|Drug|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
528361|NCT00164736|Drug|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
528362|NCT00164736|Drug|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.~To 28 weeks while breastfeeding."
528363|NCT00164736|Dietary Supplement|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
528364|NCT00164723|Procedure|Capsule endoscopy|Capsule endoscopy and colonoscopy
528365|NCT00164710|Drug|sulfadoxine-pyrimethamine|
528366|NCT00164710|Drug|amodiaquine plus sulfadoxine-pyrimethamine|
528367|NCT00164710|Drug|amodiaquine plus artesunate|
528368|NCT00164710|Drug|chlorproguanil-dapsone plus artesunate|
528369|NCT00164710|Drug|lumefantrine-artemether|
528370|NCT00164697|Behavioral|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
528371|NCT00164684|Behavioral|Father Friendly Initiative|
528372|NCT00164671|Behavioral|POWER|
528373|NCT00164658|Behavioral|Familial risk assessment and personalized prevention messages|
528374|NCT00164645|Behavioral|Problem Solving intervention|
528375|NCT00164632|Behavioral|counselling, exercise, referrals (behavior)|
528376|NCT00164619|Behavioral|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). [see Brief Summary above]
528377|NCT00164619|Biological|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
528378|NCT00164606|Behavioral|Positive Parenting Program (Triple-P)|
528379|NCT00164593|Behavioral|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
528380|NCT00164580|Behavioral|Community-Level Intervention|
528381|NCT00164567|Behavioral|Onsite IPV specialist|
528382|NCT00164567|Behavioral|Empowerment focused intervention|
528383|NCT00164554|Behavioral|Parent-child Interaction Therapy (PCIT)|
528384|NCT00164541|Behavioral|Arts Based Program|
528385|NCT00164541|Behavioral|Curriculum|
528386|NCT00164528|Behavioral|Positive Behavior Support|
528387|NCT00164515|Behavioral|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
528388|NCT00164502|Behavioral|Community-based eight session group self-management program|
528389|NCT00164489|Behavioral|Weight control and physical activity promotion|
528390|NCT00164476|Behavioral|Preventive Services Prevention Kit|
528391|NCT00164476|Behavioral|peer mentors (control group)|
528392|NCT00164463|Drug|Moxifloxacin|400 mg po qd 5/7 days per week
528393|NCT00164463|Drug|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
528394|NCT00164450|Drug|Rifapentine + isoniazid once weekly for 3 months|
528395|NCT00164437|Behavioral|educational CD-ROM|
528396|NCT00164424|Drug|Acyclovir|
528397|NCT00164411|Biological|Tetanus-diphtheria toxoids (Td)|
528398|NCT00164411|Biological|7-valent pneumococcal conjugate vaccine|
528400|NCT00164398|Behavioral|HIP: HIV Intervention for Providers|
528401|NCT00164385|Behavioral|Adolescent Impact|
528402|NCT00164372|Behavioral|Peer Education Intervention|
528403|NCT00164359|Drug|Amodiaquine plus artesunate|
528404|NCT00164359|Drug|chlorproguanil-dapsone plus artesunate|
528405|NCT00164346|Behavioral|neurocognitive habilitation|
528406|NCT00164333|Behavioral|TAP: Treatment Advocacy Program|
528407|NCT00164320|Behavioral|TEAM|
528408|NCT00164307|Behavioral|Parent assisted social skills training|
528409|NCT00164294|Behavioral|Brief intervention|
528410|NCT00164281|Drug|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
528411|NCT00164268|Behavioral|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
528412|NCT00164255|Drug|sulfadoxine/pyrimethamine|
528413|NCT00164255|Drug|sulfadoxine/pyrimethamine plus artesunate|
528414|NCT00164242|Drug|Galantamine|
528415|NCT00164229|Behavioral|math|
528416|NCT00164229|Behavioral|behavior regulation|
528417|NCT00164216|Drug|mefloquine plus artesunate|
528418|NCT00164203|Behavioral|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
528419|NCT00164203|Behavioral|School-based CBT|12 sessions, weekly
528420|NCT00164203|Behavioral|activity control condition|weekly games & activities x 12 weeks
528421|NCT00164190|Procedure|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
528422|NCT00164177|Drug|HalfLytely|
528423|NCT00164164|Drug|HalfLytely|
528424|NCT00164164|Drug|NuLytely|
528425|NCT00164151|Drug|HalfLytely|
528426|NCT00164151|Drug|Visicol|
528427|NCT00164138|Procedure|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
528428|NCT00164125|Drug|polyethyleneglycol3350|
528429|NCT00164112|Drug|Cooperstown 5+1 alone|
528430|NCT00164112|Drug|Azithromycin plus Cooperstown 5+1|
528431|NCT00164112|Drug|Telithromycin plus Cooperstown 5+1|
528432|NCT00164112|Drug|Levofloxacin plus Cooperstown 5+1|
528433|NCT00164099|Drug|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
528434|NCT00164086|Drug|atorvastatin|
528435|NCT00164073|Procedure|Liver biopsy|
528436|NCT00164047|Drug|Nitrous Oxide|
528437|NCT00164034|Device|Real time computer prompted trauma algorithms|
528438|NCT00164021|Procedure|Physiotherapy, exercise, percutaneous gastrostomy feeds|
528439|NCT00164021|Drug|Anti-reflux pharmacotherapy|
528440|NCT00164008|Drug|zoledronic acid vs pamidronate|
528441|NCT00163995|Drug|urotensin II|
528442|NCT00163982|Drug|Norfloxacin|
528443|NCT00163969|Drug|ketamine|
528444|NCT00163943|Behavioral|Dietary weight loss +/- aerobic exercise|
528445|NCT00163917|Device|Virtual reality relaxation|
528446|NCT00163904|Behavioral|High mono-unsaturated fat/low carbohydrate diet|
528447|NCT00163904|Behavioral|High carbohydrate/low fat diet|
528448|NCT00163891|Behavioral|Chest physiotherapy|
528449|NCT00163878|Procedure|Sensory Stimulation|
528450|NCT00163878|Device|Sesnory Modality Assessment and Rehabilitation Technique|
528451|NCT00163852|Drug|Normal saline IV, salt tablets|
528452|NCT00163839|Behavioral|Dietary Therapy|
528453|NCT00163813|Procedure|Early jejunal feeding (using frictional NJ tube)|
528454|NCT00163813|Procedure|Standard feeding (using nasogastric [NG] tube)|
528455|NCT00163787|Behavioral|outcome measures and self report|
528456|NCT00163774|Device|Brain oxygenation and microdialysis catheters|
528457|NCT00163761|Drug|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
528458|NCT00163761|Drug|gemcitabine, vinorelbine, filgastrim|Drug
528459|NCT00163748|Drug|gemcitabine, vinorelbine|
528460|NCT00163735|Drug|Administration of wine fined with potential food allergens|
528461|NCT00163722|Other|Culture and histology|
528462|NCT00163722|Other|Aspergillus galactomannan and PCR|
528463|NCT00163709|Procedure|BNP test|
528464|NCT00163683|Behavioral|Dietary Therapy|
528465|NCT00163657|Drug|Daclizumub|anti-rejection drug
528466|NCT00163657|Drug|Tacrolimus|anti rejection drug
528467|NCT00163657|Drug|Cyclosporine|anti rejection drug
528468|NCT00163657|Drug|MMF|anti rejection drug
528469|NCT00163644|Procedure|aereobic plus resisted exercise|
528470|NCT00163644|Procedure|aerobic plus active exercise|
528471|NCT00163644|Other|No formal exercise plus phone calls|
528472|NCT00163618|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
528473|NCT00163605|Device|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
528474|NCT00163592|Drug|Tissucol®|
528475|NCT00163592|Procedure|Control: Conventional treatment, i.e. compression with swabs|
528476|NCT00163579|Drug|Bryophyllum|
528477|NCT00163579|Other|Placebo|
528478|NCT00163566|Drug|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
528479|NCT00163553|Drug|Pethidine|
528480|NCT00163553|Drug|Placebo|
528481|NCT00163540|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
528482|NCT00163527|Drug|Roflumilast|
528483|NCT00163514|Drug|Ciclesonide|
528484|NCT00163501|Drug|Ciclesonide|
528485|NCT00163488|Drug|Ciclesonide|
528486|NCT00163475|Drug|Roflumilast|
528487|NCT00163462|Drug|Ciclesonide|
528488|NCT00163449|Drug|Ciclesonide|Efficacy and Safety of Ciclesonide
528489|NCT00163449|Drug|Placebo|Placebo
528501|NCT00163293|Drug|Ciclesonide|Ciclesonide metered-dose inhaler
528502|NCT00163293|Drug|Placebo|Ciclesonide placebo-matching metered-dose inhaler
528503|NCT00163280|Drug|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
528504|NCT00163267|Drug|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
528505|NCT00163254|Drug|abciximab|
528506|NCT00163254|Device|stent and drug eluting stent|
528507|NCT00163241|Drug|celecoxib|
528508|NCT00163215|Drug|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
528509|NCT00163202|Procedure|Blood samples|
528510|NCT00163202|Drug|Atorvastatin|
528511|NCT00163189|Drug|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
528512|NCT00163163|Procedure|Echographic measurements|
528513|NCT00163163|Procedure|Blood samples|
528514|NCT00163150|Drug|Atorvastatin|
528515|NCT00163137|Drug|lasofoxifene|lasofoxifene 0.25mg
528516|NCT00163137|Drug|raloxifene|raloxifene 60 mg/day
528517|NCT00163137|Drug|Placebo|0 mg/day
528518|NCT00163124|Procedure|spinal manipulation & patient education/nutrition|
528519|NCT00163111|Drug|VFENDÂ® I.V., Oral|
528520|NCT00163111|Drug|Conventional amphotericin B|
528521|NCT00163111|Drug|Diflucan IV, oral|
528522|NCT00163098|Drug|UK-369,003|
528523|NCT00163085|Drug|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
528524|NCT00163072|Drug|transdermal Megace|oral vs transdermal levels
528525|NCT00163059|Drug|NMDA Antagonist, CP-101,606 (traxoprodil)|
528526|NCT00163046|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
528527|NCT00163046|Drug|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
528528|NCT00163033|Drug|estetrol|
528529|NCT00163020|Drug|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
528530|NCT00163020|Drug|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
528531|NCT00163007|Procedure|Nutritional support|
528532|NCT00162994|Procedure|adenoidectomy and tymapanostomy|
528533|NCT00162981|Drug|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
528534|NCT00162981|Drug|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
528535|NCT00162968|Drug|escitalopram|
528536|NCT00162955|Drug|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
528537|NCT00162942|Device|Adacolumn|"Ten apheresis sessions:~One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9)."
528538|NCT00162942|Device|Sham|Sham, ten apheresis sessions within 9 weeks
528539|NCT00162929|Biological|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
528540|NCT00162916|Drug|citalopram|20mg or 40mg, once daily, for 40 weeks
528541|NCT00162916|Drug|Placebo|Cornstarch
528542|NCT00162890|Behavioral|Therapeutic exercise|
528543|NCT00162877|Drug|Rabeprazole vs. Esomeprazole|
528544|NCT00162864|Drug|montelukast sodium|
528545|NCT00162851|Drug|alemtuzumab|
528546|NCT00162812|Drug|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
528547|NCT00162799|Drug|Triflusal (DCI)|
528548|NCT00162786|Drug|Rupatadine|
528549|NCT00162786|Drug|Hydroxyzine|
528550|NCT00162786|Drug|Placebo|
528551|NCT00162773|Drug|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
528552|NCT00162773|Other|Placebo|150-375 milligrams depending on body weight and serum IgE.
528553|NCT00162760|Drug|Thalidomide|
528554|NCT00162747|Drug|Aquaphor|
528555|NCT00162747|Drug|Sunflower Seed Oil|
528556|NCT00162734|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
528557|NCT00162721|Drug|doxorubicin, ifosfamide, cisplatin|
528558|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
528559|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
528560|NCT00162708|Drug|CDDP, 5 Fu|
528561|NCT00162695|Drug|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
528562|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
528563|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
528564|NCT00162669|Drug|bevacizumab|
528565|NCT00162656|Drug|half cyclophosphamide|
528566|NCT00162656|Drug|without COPADM3|
528567|NCT00162656|Drug|mini CYVE, without 3 maintenance courses|
528568|NCT00162656|Drug|LMB B|
528569|NCT00162656|Drug|LMB C|
528570|NCT00162643|Drug|zidovudine+lamivudine+lopinavir/ritonavir|
528571|NCT00162643|Drug|zidovudine + lamivudine + efavirenz|
528572|NCT00162630|Procedure|Fascia Iliaca Compartment Blockade|
528573|NCT00162617|Drug|Red blood cell transfusion|
528574|NCT00162604|Drug|Cefuroxime|
528575|NCT00162591|Drug|remifentanyl|
528576|NCT00162565|Drug|beta-blocker treatment|beta-blocker treatment
528577|NCT00162552|Drug|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
528578|NCT00162552|Drug|PLACEBO|Patients with severe cirrhosis treated with a placebo
528579|NCT00162539|Other|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
528580|NCT00162526|Drug|Tocopherol|
528581|NCT00162513|Biological|Allogeneic tumor cell vaccine|
528582|NCT00162500|Biological|Peptide Vaccine (MUC-1)|
528583|NCT00162487|Drug|Albuterol (1,200 μg) through metered-dose inhaler|
528584|NCT00162474|Drug|Warfarin|
528585|NCT00162474|Drug|Phenytoin|
528586|NCT00162461|Drug|Phenytoin single dose (300 mg)|
528587|NCT00162448|Drug|BMS-394136|Oral Solution, Oral, 100 mg, Single dose, 1 day.
528588|NCT00162448|Drug|Placebo|Oral Solution, Oral, 0 mg, Single dose, 1 day.
528589|NCT00162435|Drug|Warfarin|
528590|NCT00162422|Drug|albuterol|
528591|NCT00162409|Drug|Folic acid|
528592|NCT00162396|Drug|Albuterol|
528593|NCT00162383|Drug|Debrisoquine|
528594|NCT00162383|Drug|Mephenytoin|
528595|NCT00162383|Drug|Dapsone|
528596|NCT00162383|Drug|Caffeine|
528597|NCT00162370|Drug|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
528598|NCT00162357|Drug|Technetium Tc99m Sestamibi|
528599|NCT00162344|Drug|Technetium Tc99m Sestamibi|
528600|NCT00162331|Drug|Technetium Tc99m Sestamibi|
528601|NCT00162318|Drug|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
528602|NCT00162305|Drug|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
528603|NCT00162305|Drug|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
528604|NCT00162305|Drug|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
528605|NCT00162305|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
528606|NCT00162292|Drug|BMS-582949 and Methotrexate|
528607|NCT00162279|Drug|Abatacept|
528608|NCT00162266|Drug|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
528609|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
528610|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
528611|NCT00162266|Drug|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
528612|NCT00162253|Drug|BMS 587101|
528613|NCT00162240|Drug|Muraglitazar|
528614|NCT00162227|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
528615|NCT00162214|Drug|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
528616|NCT00162201|Drug|Abatacept|Parenteral, IV, 500 mg if < 60 kg; 750 mg if > 60 & < 100 kg; 1000 mg if > 100 kg, Monthly, 4 months.
528617|NCT00162188|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
528618|NCT00162175|Drug|Muraglitazar|
528619|NCT00162149|Drug|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
528620|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
528621|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
528622|NCT00162149|Drug|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
528623|NCT00162136|Drug|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 & 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
528624|NCT00162123|Drug|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
528625|NCT00162110|Drug|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
528626|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
528627|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
528628|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
528629|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
528630|NCT00162084|Drug|apadenoson|
528631|NCT00162071|Drug|apadenoson|
528632|NCT00162058|Drug|Peflutren Lipid Microsphere Injectable Suspension|
528633|NCT00162045|Drug|Technetium Tc99m Sestamibi|Rest and/or stress SPECT imaging study
528634|NCT00162032|Drug|Sestamibi|Sestamibi
528635|NCT00162019|Drug|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
528636|NCT00162006|Drug|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
528637|NCT00161993|Drug|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
528638|NCT00161993|Drug|Gammagard S/D (Solvent/Detergent)|
528639|NCT00161980|Drug|Fibrin Sealant VH S/D|
528640|NCT00161980|Procedure|Surgical intervention alone without Fibrin Sealant VH S/D application|
528701|NCT00161382|Behavioral|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
528641|NCT00161967|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
528642|NCT00161954|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
528643|NCT00161928|Biological|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
528644|NCT00161915|Drug|Fibrin Sealant|
528645|NCT00161902|Drug|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
528646|NCT00161889|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
528647|NCT00161876|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
528648|NCT00161863|Biological|FSME-IMMUN NEW 0.25 ml|
528649|NCT00161850|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
528650|NCT00161837|Biological|Vero Cell-derived Influenza Vaccine|
528651|NCT00161837|Biological|Egg-derived Influenza Vaccine|
528652|NCT00161824|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
528653|NCT00161811|Biological|Vero Cell-derived Influenza Vaccine|
528654|NCT00161811|Biological|Egg cell-derived Influenza Vaccine|
528655|NCT00161798|Biological|Tick-borne encephalitis vaccine|
528656|NCT00161785|Biological|FSME-IMMUN 0.5ml|
528657|NCT00161772|Biological|Tick-borne Encephalitis Vaccine|
528658|NCT00161759|Drug|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
528659|NCT00161746|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
528660|NCT00161733|Drug|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
528661|NCT00161733|Drug|TISSEEL VH fibrin sealant|
528662|NCT00161720|Drug|Protein C Concentrate (Human) Vapor Heated|
528663|NCT00161707|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
528664|NCT00161694|Dietary Supplement|sucrose solution|
528665|NCT00161681|Drug|Levonorgestrel/Ethinyl Estradiol|
528666|NCT00161668|Drug|Mylotarg|
528667|NCT00161655|Drug|Etanercept|
528668|NCT00161655|Drug|Methotrexate|
528669|NCT00161642|Drug|CMD-193|
528670|NCT00161629|Drug|rhBMP-2/CPM|
528671|NCT00161616|Drug|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
528672|NCT00161603|Behavioral|Semi-structured, open-ended interviews|
528673|NCT00161590|Drug|CHOP and alemtuzumab|
528674|NCT00161577|Drug|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
528675|NCT00161577|Other|Placebo|Placebo Comparator
528676|NCT00161564|Drug|Rituximab|
528677|NCT00161551|Device|Vitatron T70 DR|
528678|NCT00161538|Device|Pacing leads to be implanted according randomization.|
528679|NCT00161538|Device|Selection 9000 prevent AF an Diagnose AF|
528680|NCT00161525|Procedure|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
528681|NCT00161486|Drug|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
528682|NCT00161486|Drug|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
528683|NCT00161486|Drug|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
528684|NCT00161486|Drug|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
528685|NCT00161473|Drug|prazosin|"Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks."
528686|NCT00161473|Drug|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
528687|NCT00161460|Behavioral|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
528688|NCT00161447|Drug|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
528689|NCT00161447|Drug|Testosterone Gel|Testosterone Gel (10 g daily
528690|NCT00161447|Drug|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 & month 3
528691|NCT00161434|Drug|valacyclovir|1 gram daily for 8 weeks
528692|NCT00161434|Drug|placebo|matching placebo for 8 weeks
528693|NCT00161421|Drug|Oral Testosterone|200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
528694|NCT00161421|Drug|Leuprolide (Lupron)|7.5 mg injection into muscle (once) (Day -14)
528695|NCT00161421|Drug|Dutasteride|24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
528696|NCT00161408|Behavioral|cognitive behavioural therapy|
528697|NCT00161408|Behavioral|psychoeducation|
528698|NCT00161395|Behavioral|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
528699|NCT00161395|Behavioral|Preconception advice|Preconception advice for diet and frequency of intercourse.
528700|NCT00161382|Behavioral|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
528702|NCT00161356|Drug|Ambisome|5mg/kg IV - one time dose during liver transplant
528703|NCT00161356|Procedure|Liver Biopsy|post drug delivery (60 min. after completion of Ambisome infusion)
528704|NCT00161343|Behavioral|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
528705|NCT00161330|Drug|oral amoxicilline/clavulanic acid|
528706|NCT00161330|Drug|iv ceftriaxone|
528707|NCT00161317|Behavioral|Living with Hope Program|
528708|NCT00161304|Drug|Testosterone Enanthate|
528709|NCT00161291|Drug|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
528710|NCT00161278|Drug|Carboplatin|
528711|NCT00161278|Drug|Paclitaxel|
528712|NCT00161278|Procedure|Gene expression profiling (analysis) of tumor samples|
528713|NCT00161265|Procedure|tissue procurement|tissue procurement
528714|NCT00161239|Drug|Doxil, Methotrexate, L-Asparaginase, Prednisone|
528715|NCT00161226|Device|Levonorgestrel intrauterine system|
528716|NCT00161213|Drug|gemcitabine hydrochloride|
528717|NCT00161213|Drug|imatinib mesylate|
528718|NCT00161200|Drug|Ranitidine & Pantoprazole|
528719|NCT00161187|Biological|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
528720|NCT00161148|Drug|Probiotics|
528721|NCT00161122|Biological|trivalent inactivated influenza vaccine|
528722|NCT00161122|Biological|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
528723|NCT00161096|Drug|pantoprazole 20 mg (drug)|
528724|NCT00161083|Drug|ursodeoxycholic acid|
528725|NCT00161070|Drug|anticoagulation|
528726|NCT00161070|Drug|aspirin and dipyridamole|
528727|NCT00161070|Drug|aspirin alone|
528728|NCT00161044|Drug|Galantamine|
528729|NCT00161031|Drug|Atomoxetine|
528730|NCT00161018|Drug|Quetiapine, Risperidone, Fluphenazine|
528731|NCT00161005|Procedure|PCI|Immediate transport to invasive center after thrombolysis
528732|NCT00160992|Biological|Melan-A analog peptide|
528733|NCT00160979|Procedure|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
528734|NCT00160966|Drug|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
528735|NCT00160966|Drug|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
528736|NCT00160966|Drug|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
528737|NCT00160953|Procedure|Endorectal Coil Magnetic Resonance Images|
528738|NCT00160927|Device|local heating|
528739|NCT00160927|Device|iontophoresis|
528740|NCT00160927|Drug|actylcholine|
528741|NCT00160927|Drug|sodium nitroprusside|
528742|NCT00160914|Behavioral|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
528743|NCT00160901|Drug|two complex naturopathic add-on therapies, leaflet 5-a-day|
528744|NCT00160888|Drug|sodium nitroprusside, bradykinin, acetylcholine|
528745|NCT00160875|Drug|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
528746|NCT00160875|Drug|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
528747|NCT00160862|Drug|SLV317|
528748|NCT00160849|Drug|Lopinavir/r|
528749|NCT00160836|Device|"Tissue sampling (G.I.U.M. catheter)"|
528750|NCT00160823|Procedure|Self-administered leaflet|
528751|NCT00160797|Device|MIS™ Minimally Invasive Solutions™ TKA System|
528752|NCT00160784|Procedure|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
528753|NCT00160784|Procedure|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
528754|NCT00160784|Other|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
528755|NCT00160771|Behavioral|Joint Motion Analysis|Joint motion will be recorded for analysis.
528756|NCT00160758|Procedure|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
528757|NCT00160745|Drug|Rosuvastatin|
528758|NCT00160732|Drug|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
528759|NCT00160732|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
528760|NCT00160719|Procedure|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
528761|NCT00160706|Biological|Certolizumab Pegol (CDP870)|"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study."
528762|NCT00160693|Biological|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
528763|NCT00160680|Drug|Levocetirizine|"Pharmaceutical form: Tablet~Concentration: 5 mg~Route of administration: Oral use"
528764|NCT00160667|Drug|Placebo|Daily oral dose of two equal intakes.
528765|NCT00160667|Drug|Brivaracetam|Daily oral dose of two equal intakes.
528766|NCT00160654|Drug|Levetiracetam|
528767|NCT00160641|Biological|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.~Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.~Duration: Until end of study."
528768|NCT00160628|Drug|Levetiracetam|
528842|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
528769|NCT00160615|Drug|Levetiracetam|"Pharmaceutical form: Film-coating tablets~Concentration: 250 mg/ 500 mg~Route of administration: oral use"
528770|NCT00160602|Drug|Certolizumab Pegol|
528771|NCT00160589|Drug|Levocetirizine|
528772|NCT00160576|Drug|Levetiracetam|
528773|NCT00160563|Drug|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
528774|NCT00160563|Other|Placebo|Oral drops, bid for 18 months
528775|NCT00160550|Drug|Levetiracetam|
528776|NCT00160537|Drug|Levocetirizine|
528777|NCT00160524|Biological|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
528778|NCT00160511|Drug|Levetiracetam|
528779|NCT00160498|Drug|Lercanidipine|
528780|NCT00160485|Drug|Glyburide|dosage required to obtain adequate glucose control
528781|NCT00160485|Drug|Insulin|variable dosage to obtain glucose control
528782|NCT00160472|Procedure|removal of ovarian vessels|
528783|NCT00160459|Drug|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
528784|NCT00160459|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
528785|NCT00160459|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
528786|NCT00160459|Drug|Placebo|Tablet, oral Daily for 12 weeks
528787|NCT00160446|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
528788|NCT00160446|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
528789|NCT00160446|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
528790|NCT00160446|Drug|Placebo|Tablet, oral Daily for 12 weeks
528791|NCT00160433|Drug|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
528792|NCT00160433|Drug|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
528793|NCT00160433|Drug|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
528794|NCT00160433|Drug|Placebo|Tablet, oral Daily for 12 weeks
528795|NCT00160420|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 months
528796|NCT00160407|Drug|Orlistat (Xenical)|
528797|NCT00160407|Behavioral|1400 kcal diet (30% fat)|
528798|NCT00160394|Drug|Duac® Gel / Differin® Gel|
528799|NCT00160381|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
528800|NCT00160381|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
528801|NCT00160381|Drug|Placebo|Tablet, oral Daily for 12 months
528802|NCT00160368|Behavioral|Potassium supplementation|
528803|NCT00160355|Procedure|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
528804|NCT00160355|Device|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
528805|NCT00160355|Drug|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
528806|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
528807|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
528808|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
528809|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
528810|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
528811|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
528812|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
528813|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
528814|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
528815|NCT00160329|Drug|Atazanavir|300 mg with ritonavir boosting or 400 mg without
528816|NCT00160316|Drug|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
528817|NCT00160303|Drug|Prolotherapy|
528818|NCT00160303|Drug|Local Corticosteroid Therapy|
528819|NCT00160290|Drug|Lactulose|15 mL / 12 hours
528820|NCT00160290|Drug|Plantago ovata|3,5 g / 12 hours
528821|NCT00160277|Drug|Moxonidine|
528822|NCT00160264|Drug|Lactulose, Vitamin D, Calcium|
528823|NCT00160251|Drug|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
528824|NCT00160251|Biological|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
528825|NCT00160251|Drug|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight [weight-based dosing {WBD}])
528826|NCT00160238|Drug|Betahistine 24 mg bid (Betaserc)|
528827|NCT00160225|Drug|Daglutril|
528828|NCT00160212|Drug|Daglutril|
528829|NCT00160199|Drug|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
528830|NCT00160199|Drug|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
528831|NCT00160186|Drug|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
528832|NCT00160186|Drug|Placebo|Placebo
528833|NCT00160173|Drug|Estradiol|
528834|NCT00160160|Drug|eprosartan/HCTZ|
528835|NCT00160147|Drug|bifeprunox|One week titration with dose adjustments
528836|NCT00160147|Drug|Placebo|Placebo
528837|NCT00160134|Drug|SLV320|
528838|NCT00160121|Drug|Lanthanum carbonate|
528839|NCT00160108|Behavioral|dietary intervention|
528840|NCT00160082|Drug|Xepol|
528841|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
528843|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
528844|NCT00160056|Procedure|Hypoglycemia|
528845|NCT00160043|Drug|SH T00268C|1250 mg experimental drug od
528846|NCT00160043|Drug|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
528847|NCT00160030|Drug|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
528848|NCT00160030|Drug|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
528849|NCT00160017|Behavioral|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
528850|NCT00160004|Behavioral|Intensive Controlled Exercise|
528851|NCT00159991|Procedure|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
528852|NCT00159991|Procedure|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
528853|NCT00159978|Procedure|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
528854|NCT00159965|Drug|sertraline|flexible dose sertraline
528855|NCT00159965|Drug|placebo|flexible dose placebo
528856|NCT00159952|Procedure|intensive insulin therapy|"control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.~treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL"
528857|NCT00159939|Procedure|prone positioning|prone positioning
528858|NCT00159926|Procedure|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
528859|NCT00159926|Procedure|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
528860|NCT00159913|Drug|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
528861|NCT00159913|Drug|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
528862|NCT00159913|Drug|Placebo|oral; 3 times a day(TID)
528863|NCT00159913|Drug|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
528864|NCT00159900|Drug|Sildenafil Citrate|
528865|NCT00159887|Drug|Sildenafil citrate|
528866|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight >20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight >45 kg: 80 mg 3 times a day (tid)
528867|NCT00159874|Drug|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight >20 kg
528868|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight >20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight >45 kg: 40 mg 3 times a day (tid)
528869|NCT00159861|Drug|Sildenafil citrate|
528870|NCT00159848|Behavioral|Treatment Optimization Program (educational material)|
528871|NCT00159835|Drug|atorvastatin|
528872|NCT00159835|Drug|simvastatin|
528873|NCT00159822|Drug|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
528874|NCT00159809|Drug|Viagra (Sildenafil citrate)|
528875|NCT00159796|Drug|Asenapine|Asenapine, 3 weeks
528876|NCT00159796|Drug|Olanzapine|Olanzapine, 3 weeks
528877|NCT00159796|Drug|Placebo|placebo, 3 weeks
528878|NCT00159783|Drug|asenapine|Asenapine, 40 weeks
528879|NCT00159783|Drug|Olanzapine|Olanzapine, 40 weeks
528880|NCT00159770|Drug|ziprasidone versus olanzapine , risperidone or quetiapine|
528881|NCT00159770|Behavioral|Panss , CGI-C, UKU-SERS-Pa|
528882|NCT00159770|Procedure|Blood tests|
528883|NCT00159757|Drug|ziprazidone|
528884|NCT00159744|Drug|Asenapine|Asenapine, 3 weeks
528885|NCT00159744|Drug|Olanzapine|Olanzapine, 3 weeks
528886|NCT00159744|Drug|Placebo|placebo, 3 weeks
528887|NCT00159731|Drug|Pregabalin|
528888|NCT00159718|Drug|amlodipine|
528889|NCT00159718|Drug|atorvastatin|
528890|NCT00159705|Drug|pregabalin|
528891|NCT00159692|Drug|Amlodipine|
528892|NCT00159679|Drug|Pregabalin|
528893|NCT00159666|Drug|pregabalin|
528894|NCT00159653|Drug|Xalacom|
528895|NCT00159653|Drug|Xalatan|
528896|NCT00159653|Drug|Timolol|
528897|NCT00159640|Drug|PD-217,014|
528898|NCT00159627|Drug|KW-3902IV|
528899|NCT00159614|Drug|KW-3902IV|
528900|NCT00159588|Drug|Betablockers or other preventive drugs|Several preventive drugs based on each individual
528901|NCT00159575|Drug|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
528902|NCT00159562|Behavioral|individual education|individual sessions of psycho-education
528903|NCT00159562|Behavioral|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
528904|NCT00159549|Behavioral|education and training program|
528905|NCT00159536|Drug|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
528906|NCT00159536|Drug|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
528907|NCT00159523|Dietary Supplement|Probiotic|
528908|NCT00159523|Biological|placebo|
529291|NCT00156104|Drug|Asenapine|10 mg BID
528909|NCT00159510|Drug|Methylene blue|Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
528910|NCT00159510|Drug|Nitric oxide|An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
528911|NCT00159510|Drug|Methylene blue & nitric oxide|See the dosage in the previous arms
528912|NCT00159497|Device|porous coated Trilogy®|THA
528913|NCT00159497|Device|Trilogy Calcicoat®|THA
528914|NCT00159484|Drug|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
528915|NCT00159471|Drug|capecitabine, gemcitabine, docetaxel|
528916|NCT00159458|Drug|Gemcitabine and oxaliplatin|
528917|NCT00159445|Drug|gemcitabine, capecitabine|
528918|NCT00159432|Drug|Oxaliplatin|
528919|NCT00159432|Drug|Bevacizumab|
528920|NCT00159432|Drug|Capecitabine|
528921|NCT00159419|Drug|Alendronate|
528922|NCT00159419|Drug|Pamidronate|
528923|NCT00159406|Other|Registry and Database|Data Collection
528924|NCT00159393|Other|registry and database|data collection
528925|NCT00159380|Drug|Aminoguanidine|500mg
528926|NCT00159380|Drug|Placebos|2ml
528927|NCT00159367|Device|Repetitive magnetic stimulation to the quadriceps|
528928|NCT00159354|Drug|predisolone|
528929|NCT00159341|Procedure|Nasal lavage|Nasal lavage was carried out at specified timepoints
528930|NCT00159341|Procedure|Nasal filter paper|Nasal filter paper was placed at specified timepoints
528931|NCT00159341|Procedure|Blood sampling|Blood sampling was performed as a routine safety check
528932|NCT00159328|Procedure|Magnetic Resonance Guided Focused Ultrasound|
528933|NCT00159315|Procedure|Inhalation Challenge with ATP|
528934|NCT00159315|Procedure|Inhalation Challenge with AMP|
528935|NCT00159302|Procedure|Induced Sputum|
528936|NCT00159302|Procedure|Exhaled Nitric Oxide|
528937|NCT00159302|Procedure|Nasal Nitric Oxide|
528938|NCT00159302|Procedure|Blood Tests|
528939|NCT00159302|Procedure|24hr Urine Samples|
528940|NCT00159302|Procedure|Exhaled Breath Condensate|
528941|NCT00159302|Procedure|Spirometry|
528942|NCT00159289|Procedure|Inhalation of LPS|
528943|NCT00159289|Procedure|Placebo|
528944|NCT00159276|Procedure|Induced Sputum|
528945|NCT00159263|Drug|Placebos|Dry powder inhaler
528946|NCT00159263|Drug|Formoterol Inhalant Powder|12ug
528947|NCT00159263|Drug|Budesonide Powder|Inhaler
528948|NCT00159263|Drug|Budesonide and Formoterol Product|Combination Inhaler, Symbicort
528949|NCT00159250|Drug|AVI-4658 (PMO)|morpholino antisense oligonucleotide
528950|NCT00159237|Procedure|blood test|
528951|NCT00159224|Drug|Lopinavir/ritonavir simplification strategy|Simplification
528952|NCT00159211|Drug|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
528953|NCT00159211|Drug|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
528954|NCT00159172|Device|Motor cortex stimulation|
528955|NCT00159159|Drug|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
528956|NCT00159159|Drug|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
528957|NCT00159146|Drug|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
528958|NCT00159133|Drug|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
528959|NCT00159120|Other|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
528960|NCT00159107|Drug|Acamprosate|Acamprosate
528961|NCT00159107|Behavioral|Integrative behavior therapy|Integrative behavior therapy
528962|NCT00159107|Drug|Placebo|Placebo
528963|NCT00159094|Drug|Doxil and Vinorelbine|
528964|NCT00159081|Drug|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
528965|NCT00159055|Biological|CMV vaccine|
528966|NCT00159016|Drug|Glivec|
528967|NCT00158990|Drug|triiodothyronine|
528968|NCT00158990|Drug|sertraline|
528969|NCT00158977|Device|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
528970|NCT00158964|Device|EASYTRAK 4 STEERABLE LV lead|
528971|NCT00158951|Device|CONTAK RENEWAL 2/4/4HE CRT-D|
528972|NCT00158951|Device|EASYTRAK 2 Lead|
528973|NCT00158938|Device|EASYTRAK 3 left ventricular pacing lead|
528974|NCT00158925|Device|EASYTRAK EPI lead|EASYTRAK EPI lead
528975|NCT00158912|Device|Implantable Cardioverter Defibrillator|
528976|NCT00158899|Drug|GW501516 oral tablets|
528977|NCT00158886|Drug|Topotecan|Topotecan will be provided as capsules for oral administration and will be administered at least 3 hours before radiation therapy.
528978|NCT00158886|Radiation|Radiation therapy|For radiation therapy, subjects will receive 180 centigray (cGy) per fraction to a total dose of 4500 cGy to the pelvis using a 3 or 4 field technique and high energy photons (>=6 megavolt [mv]).
528979|NCT00158873|Drug|midazolam|
528980|NCT00158873|Drug|lorazepam|
528981|NCT00158873|Drug|fentanyl|
528982|NCT00158873|Drug|morphine|
528983|NCT00158873|Drug|remifentanil|
528984|NCT00158873|Drug|propofol|
528985|NCT00158860|Drug|Valaciclovir|1g once daily
528986|NCT00158860|Drug|Placebo|placebo
528987|NCT00158847|Drug|fluticasone 500 mcg|
528988|NCT00158847|Drug|fluticasone 500 mcg + salmeterol 50 mcg|
528989|NCT00158834|Drug|Salmeterol/Fluticasone propionate combination product|
528990|NCT00158834|Drug|Fluticasone propionate|
528991|NCT00158821|Drug|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
528992|NCT00158821|Drug|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
528993|NCT00158821|Drug|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
528994|NCT00158821|Drug|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
528995|NCT00158808|Biological|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
528996|NCT00158795|Biological|Haemophilus Influenza type b vaccine|
528997|NCT00158782|Drug|GW786034|GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.
528998|NCT00158782|Drug|lapatinib|Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.
528999|NCT00158769|Drug|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
529000|NCT00158756|Biological|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
529001|NCT00158756|Biological|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
529002|NCT00158756|Biological|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
529003|NCT00158756|Biological|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
529004|NCT00158756|Biological|Engerix™-B|GSK Biologicals' hepatitis B vaccine
529005|NCT00158756|Drug|Placebo|Placebo for the Rotarix™ vaccine
529006|NCT00158743|Drug|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
529007|NCT00158743|Other|sodium chloride|
529008|NCT00158730|Drug|AmBisome|
529009|NCT00158717|Drug|Hepsera|
529010|NCT00158704|Drug|Hepsera|
529011|NCT00158691|Drug|Ethyol|
529012|NCT00158678|Procedure|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
529013|NCT00158678|Procedure|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
529014|NCT00158678|Drug|concomitant cisplatin|100 mg/m2 D1, D22, D43
529015|NCT00158665|Biological|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
529016|NCT00158652|Procedure|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
529017|NCT00158652|Procedure|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
529018|NCT00158652|Procedure|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
529019|NCT00158652|Drug|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
529020|NCT00158639|Behavioral|Home BP;secure messaging;pharmaceutical care;|
529021|NCT00158626|Behavioral|pelvic floor muscle training|
529022|NCT00158613|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
529023|NCT00158600|Biological|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
529024|NCT00158600|Drug|Placebo|Placebo Comparator; qow for 78 weeks.
529025|NCT00158587|Drug|primaquine|
529026|NCT00158574|Drug|sulphadoxine-pyrimethamine|
529027|NCT00158574|Drug|mefloquine|
529028|NCT00158574|Drug|Chlorproguanil-dapsone|
529029|NCT00158574|Drug|Placebo|Placebo
529030|NCT00158574|Drug|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
529031|NCT00158574|Drug|IPTi mefloquine|IPTi doses 1 & 2 at ages 2 & 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
529032|NCT00158574|Drug|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
529033|NCT00158561|Drug|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
529034|NCT00158548|Drug|SP, chloroquine, amodiaquine, primaquine, artesunate|
529035|NCT00158535|Procedure|liver transplantation|
529036|NCT00158522|Drug|pegylated interferon alpha2a|
529037|NCT00158509|Drug|Valacyclovir|
529038|NCT00158496|Drug|pegylated interferon alpha2a|
529039|NCT00158496|Drug|ribavirin|
529040|NCT00158483|Drug|Acyclovir (ACV)|
529041|NCT00158470|Drug|efavirenz|
529042|NCT00158470|Drug|didanosine|
529043|NCT00158470|Drug|lamivudine|
529044|NCT00158457|Drug|Tenofovir (TDF)|
529045|NCT00158457|Drug|Emtricitabine (FTC)|
529046|NCT00158457|Drug|Efavirenz (EFV)|
529047|NCT00158431|Procedure|Arthroscopy plus Medical Management|Arthroscopic Surgery
529048|NCT00158431|Other|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
529049|NCT00158418|Procedure|Cemented Humeral Stem|
529050|NCT00158418|Procedure|Uncemented Humeral Stem|
529051|NCT00158405|Procedure|Structured Treatment Interruption|
529052|NCT00158405|Drug|Zidovudine (ZDV)|
529053|NCT00158405|Drug|Lamivudine (3TC)|
529054|NCT00158405|Drug|Efavirenz (EFV)|
529055|NCT00158405|Drug|Ritonavir (NRV)|
529056|NCT00158405|Drug|Indinavir (IDV)|
529057|NCT00158379|Drug|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
529058|NCT00158366|Behavioral|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
529059|NCT00158366|Behavioral|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
529292|NCT00156104|Drug|Haloperidol|4 mg BID
529293|NCT00156104|Other|Placebo arm|
529294|NCT00156091|Drug|Olanzapine|5- 20 mg QD
529295|NCT00156091|Drug|Asenapine|5 or 10 mg BID
529060|NCT00158366|Behavioral|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
529061|NCT00158353|Behavioral|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
529062|NCT00158353|Behavioral|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
529063|NCT00158340|Behavioral|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
529064|NCT00158340|Behavioral|Usual clinical care|Control group participants receive treatment as usual.
529065|NCT00158327|Behavioral|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
529066|NCT00158327|Behavioral|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
529067|NCT00158314|Behavioral|Referral to Gamblers Anonymous|
529068|NCT00158314|Behavioral|Cognitive behavioral therapy|
529069|NCT00158314|Behavioral|Cognitive behavioral self-help manual|
529070|NCT00158301|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
529071|NCT00158301|Drug|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
529072|NCT00158288|Behavioral|LAAM|
529073|NCT00158275|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
529074|NCT00158275|Drug|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
529075|NCT00158275|Behavioral|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
529076|NCT00158262|Drug|Propranolol|Propranolol short-acting or long-acting capsule
529077|NCT00158262|Drug|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
529078|NCT00158249|Drug|citicoline|2 gm/day, 8 weeks treatment
529079|NCT00158249|Drug|placebo|matched for physical appearance
529080|NCT00158236|Drug|Buprenorphine|
529081|NCT00158236|Drug|Buprenorphine and Naloxone|
529082|NCT00158236|Drug|Hydromorphone|
529083|NCT00158223|Drug|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
529084|NCT00158223|Drug|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
529085|NCT00158210|Drug|Rivastigmine|
529086|NCT00158197|Behavioral|contingency management voucher|participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
529087|NCT00158184|Drug|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
529088|NCT00158184|Drug|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
529089|NCT00158184|Drug|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
529090|NCT00158171|Drug|Nicotine Replacement Therapies|Nicotine gum 2 & 4 mg dependent on baseline smoking rate
529091|NCT00158171|Drug|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
529092|NCT00158171|Dietary Supplement|Folic Acid|400 mg
529093|NCT00158158|Drug|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
529094|NCT00158158|Other|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
529095|NCT00158132|Drug|Propranolol|Propranolol 100mg/day in 3 divided doses
529096|NCT00158132|Drug|Amantadine|Amantadine 100mg three times daily
529097|NCT00158132|Drug|Placebo|Placebo pills
529098|NCT00158119|Behavioral|InVEST (Increased Velocity Exercise Specific to Task)|
529099|NCT00158106|Procedure|Speech and Language therapy for dysarthria and/or aphasia|
529100|NCT00158093|Drug|Nebivolol|
529101|NCT00158093|Drug|Atenolol|
529102|NCT00158093|Drug|Moxifloxacin|
529103|NCT00158080|Procedure|hemofiltration|
529104|NCT00158067|Device|external Responsive Neurostimulator (eRNS) System|
529105|NCT00158054|Behavioral|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
529106|NCT00158054|Behavioral|Referred depression care|Physician notified of depression symptoms, usual care followed.
529107|NCT00158041|Drug|Amifostine administered subcutaneously|
529296|NCT00156091|Other|Placebo|
529297|NCT00156078|Drug|pregabalin|
529298|NCT00156065|Drug|Haloperidol|2-8 mg BID
529108|NCT00158028|Drug|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
529109|NCT00158028|Drug|Placebo|placebo match in identical tablets
529110|NCT00158002|Drug|Topiramate|
529111|NCT00157989|Procedure|Controlled tidal volume resuscitation|
529112|NCT00157976|Drug|Photrex (rostaporfin)|
529113|NCT00157963|Drug|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
529114|NCT00157950|Biological|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
529115|NCT00157950|Biological|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
529116|NCT00157937|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
529117|NCT00157937|Drug|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
529118|NCT00157924|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
529119|NCT00157924|Drug|atorvastatin|atorvastatin 10mg
529120|NCT00157911|Drug|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
529121|NCT00157911|Drug|Comparator: simvastatin / Duration of Treatment: 12 weeks|
529122|NCT00157898|Drug|MK0826; ertapenem sodium|
529123|NCT00157898|Drug|Comparator: ceftriaxone + metronidazole|
529124|NCT00157885|Drug|Amodiaquine plus artesunate; Artekin|
529125|NCT00157872|Drug|MK0966; rofecoxib|
529126|NCT00157872|Drug|Comparator: naproxen tablet 500 mg|
529127|NCT00157859|Drug|Chloroquine and sulphadoxine-pyrimethamine|
529128|NCT00157846|Device|CRT-P or CRT-D Device|Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)
529129|NCT00157833|Drug|Artekin / Coartemther|
529130|NCT00157820|Device|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
529131|NCT00157820|Device|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF & GemIII AT as DC ICDs (DC true and SC sim arms)
529132|NCT00157807|Procedure|bipolar radiofrequency ablation of persistent and permanent AF|
529133|NCT00157794|Device|Search AV+ algorithm|
529134|NCT00157781|Device|Medtronic AT500|
529135|NCT00157768|Device|Implantable cardioverter defibrillator|
529136|NCT00157755|Device|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
529137|NCT00157742|Procedure|Spinal Cord Stimulation (SCS)|
529138|NCT00157742|Procedure|Percutaneous Myocardial Laser Revascularisation (PMR)|
529139|NCT00157729|Drug|pyridoxal-5'-phosphate with and without ACE inhibitor|
529140|NCT00157716|Drug|(MC-1) Pyridoxal-5’-phosphate|
529141|NCT00157703|Drug|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
529142|NCT00157690|Drug|Alendronate|70 mg 1x weekly for 12 months
529143|NCT00157690|Drug|Placebo|70 mg 1 x weekly for 12 months
529144|NCT00157677|Procedure|D-dimer testing|Uniform D-dimer use
529145|NCT00157677|Procedure|D-dimer testing|Selective D-Dimer use
529146|NCT00157651|Drug|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
529147|NCT00157651|Drug|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
529148|NCT00157638|Behavioral|integration of pharmacist into primary care|
529149|NCT00157638|Drug|optimizing therapeutic treatments|
529150|NCT00157638|Behavioral|optimizing processes of care|
529151|NCT00157625|Behavioral|Automatic stop order|
529152|NCT00157612|Procedure|a clinical pathway nursing home acquired pneumonia|treatment in nursing homes according to a clinical pathway, which included use of oral anti-microbials, portable chest radiographs, oxygen saturation monitoring, rehydrations and close monitoring by research nurse
529153|NCT00157599|Procedure|various diagnostic measures for DVT (e.g., CUS)|
529154|NCT00157586|Drug|Delapril, Delapril-Manidipine Fixed combination|
529155|NCT00157573|Drug|GM-CSF, sargramostim|GM-CSF subcutaneous injection
529156|NCT00157560|Drug|Chemotherapy, multiple agents|
529157|NCT00157547|Drug|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
529158|NCT00157534|Drug|Celgosivir|
529159|NCT00157521|Drug|L-arginine|
529160|NCT00157508|Drug|nitroaspirin|
529161|NCT00157482|Drug|Ezetimibe|
529162|NCT00157482|Drug|Simvastatin|
529163|NCT00157378|Drug|Risperidone, Haloperidol|
529164|NCT00157339|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
529165|NCT00157339|Drug|injected insulin|patient specific dose, injected, before meals, 12 months.
529166|NCT00157326|Drug|tadalafil|
529167|NCT00157313|Behavioral|Integrated treatment, family involvement|
529168|NCT00157313|Behavioral|Social skills training|
529169|NCT00157300|Drug|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
529170|NCT00157287|Procedure|Evidence based weaning protocol|
529171|NCT00157274|Drug|alemtuzumab|
529172|NCT00157261|Drug|tenecteplase|
529173|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
529174|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
529175|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
529176|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
529177|NCT00157235|Drug|Tiotropium bromide|
529213|NCT00156910|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
529299|NCT00156065|Drug|Asenapine|5 or 10 mg BID
529300|NCT00156065|Drug|Asenapine|5 or 10 mg BID
529301|NCT00156052|Radiation|Conventional whole breast radiation schedule|
529178|NCT00157209|Biological|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
529179|NCT00157209|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
529180|NCT00157209|Other|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
529181|NCT00157196|Biological|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
529182|NCT00157196|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
529183|NCT00157196|Other|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
529184|NCT00157183|Device|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
529185|NCT00157170|Behavioral|supervised exercise|
529186|NCT00157157|Biological|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).~The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.~For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.~Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.~rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
529187|NCT00157131|Biological|Fibrin Sealant, ARTISS 4IU/ml VH SD|FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
529188|NCT00157131|Other|Staples|Administration by mechanical/multiple point fixation.
529189|NCT00157118|Drug|Protein C Concentrate (Human) Vapor Heated|
529190|NCT00157105|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
529191|NCT00157092|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
529192|NCT00157079|Biological|Immune Globulin Intravenous (Human), 10%|
529193|NCT00157066|Drug|Ergocalciferol|
529194|NCT00157053|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
529195|NCT00157040|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
529196|NCT00157027|Procedure|Extracorporeal photochemotherapy with UVADEX|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.~The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
529197|NCT00157014|Drug|Tacrolimus|Oral
529198|NCT00157014|Drug|Cyclosporine|Oral
529199|NCT00157014|Drug|Mycophenolate mofetil|Intravenous and Oral
529200|NCT00157014|Drug|Methylprednisolone|Intravenous
529201|NCT00157014|Drug|Prednisone|Oral
529202|NCT00157001|Procedure|Photopheresis Post Angioplasty|
529203|NCT00156988|Drug|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
529204|NCT00156975|Drug|Capecitabine|
529205|NCT00156975|Drug|Oxaliplatin|
529206|NCT00156962|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
529207|NCT00156962|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
529208|NCT00156949|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
529209|NCT00156936|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
529210|NCT00156936|Drug|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
529211|NCT00156923|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
529212|NCT00156923|Drug|Medisorb naltrexone 190 mg|Administered via IM injection once every 4 weeks for up to 3.5 years.
529287|NCT00156117|Drug|asenapine|5 mg BID or 10mg BID
529288|NCT00156117|Drug|Placebo|Placebo
529289|NCT00156117|Drug|olanzapine|olanzapine 15 mg QD
529214|NCT00156910|Other|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
529215|NCT00156897|Drug|ATL-962|
529216|NCT00156897|Drug|Orlistat|
529217|NCT00156884|Drug|strontium-89|
529218|NCT00156884|Drug|cisplatin|
529219|NCT00156871|Behavioral|exercise|
529220|NCT00156858|Drug|intravenous busulfan|
529221|NCT00156845|Procedure|AI-700 contrast-enhanced echocardiography|
529222|NCT00156819|Drug|fluticasone|fluticasone (100 microgram twice daily) treatment
529223|NCT00156819|Drug|montelukast|Montelukast (5 or 10 mg each night).
529224|NCT00156819|Drug|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
529225|NCT00156806|Procedure|Aloe barbadensis topical application in a moisturizing cream vehicle.|
529226|NCT00156793|Procedure|AI-700 contrast-enhanced echocardiography|
529227|NCT00156780|Drug|AI-700|
529228|NCT00156741|Device|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
529229|NCT00156741|Procedure|Required pacemaker setting|
529230|NCT00156728|Device|Vitatron biventricular pacemaker|
529231|NCT00156715|Drug|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
529232|NCT00156702|Behavioral|Feedback and Motivational Interviewing|
529233|NCT00156702|Behavioral|Smoking Prevention Video|
529234|NCT00156689|Drug|levetiracetam|
529235|NCT00156676|Device|Body-weight supported treadmill|
529236|NCT00156676|Device|Lokomat|
529237|NCT00156676|Device|Body-weight supported treadmill|
529238|NCT00156676|Device|Lokomat|
529239|NCT00156663|Behavioral|Caring for Women Veterans|
529240|NCT00156650|Drug|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
529241|NCT00156650|Drug|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
529242|NCT00156650|Drug|Depo-Medroxyprogesterone|300 mg IM every 3 months
529243|NCT00156637|Behavioral|Team-Based Quality Improvement Intervention|Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
529244|NCT00156637|Behavioral|Opinion Leader Intervention|Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
529245|NCT00156637|Behavioral|Team Based Quality Improvement|Intervention to increase appropriate use of clozapine through a team based quality intervention.
529246|NCT00156624|Drug|Balloon Angioplasty with or without drug administration|
529247|NCT00156611|Procedure|Balloon Angioplasty|
529248|NCT00156611|Drug|ReoPro|
529249|NCT00156572|Procedure|Sodium supplementation|
529250|NCT00156572|Procedure|Fluid restriction|
529251|NCT00156546|Drug|antibiotic to reduce the recurrence of infection|
529252|NCT00156533|Drug|Zolpidem|10 mg of Zolpidem
529253|NCT00156533|Drug|Sugar Pill|
529254|NCT00156520|Drug|aprotonin; epsilon aminocaproic acid|
529255|NCT00156507|Behavioral|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
529256|NCT00156468|Behavioral|Provider Prompt|
529257|NCT00156416|Behavioral|Mindfulness Meditation|8 weeks of meditation training
529258|NCT00156403|Drug|amlodipine (drug)|
529259|NCT00156390|Device|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
529260|NCT00156390|Other|LV lead placement as per standard of care (without echo guidance)|
529261|NCT00156377|Drug|Mupirocin|
529262|NCT00156351|Behavioral|Physical activity promotion|
529263|NCT00156338|Procedure|fluid management|volume and sodium restriction
529264|NCT00156338|Procedure|fluid management|volume restriction
529265|NCT00156338|Procedure|fluid management|liberal fluid management
529266|NCT00156325|Drug|Escitalopram (Lexapro)|
529267|NCT00156312|Drug|Docetaxel|
529268|NCT00156312|Drug|Capecitabine|
529269|NCT00156299|Drug|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
529270|NCT00156299|Drug|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
529271|NCT00156286|Drug|Gleevec|
529272|NCT00156260|Procedure|Ductal lavage|
529273|NCT00156247|Drug|acitretin|Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
529274|NCT00156234|Behavioral|One-knee extension ergometer|
529275|NCT00156208|Drug|Asoprisnil|10mg Tablet, oral Daily for 18 months
529276|NCT00156208|Drug|Asoprisnil|25 mg Tablet, oral Daily for 18 months
529277|NCT00156195|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 months
529278|NCT00156195|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
529279|NCT00156182|Drug|Asoprisnil|10mg Tablet, oral Daily for 6 months
529280|NCT00156169|Drug|Dunaliella|
529281|NCT00156156|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
529282|NCT00156156|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
529283|NCT00156143|Procedure|Blood sample|
529284|NCT00156143|Procedure|Radiography|
529285|NCT00156130|Radiation|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
529286|NCT00156130|Radiation|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
529290|NCT00156104|Drug|Asenapine|5 mg BID
529302|NCT00156052|Radiation|Hypofractionated whole breast radiation schedule|
529303|NCT00156039|Behavioral|Follow-up Strategy for Breast Cancer|
529304|NCT00156026|Procedure|loop electrosurgical excision procedure (LEEP)|1. loop electrosurgical excision procedure
529305|NCT00156013|Drug|CLOFARABINE|4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles
529306|NCT00156000|Device|Fetal Fibronectin|fFN test done during pregnancy
529307|NCT00156000|Device|Salivary Estriol|Salivary Estriol done during pregnancy
529308|NCT00155987|Procedure|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
529309|NCT00155974|Biological|Community-based vaccine outreach intervention|
529310|NCT00155935|Procedure|venous puncture|
529311|NCT00155883|Drug|Taxteral|
529312|NCT00155883|Drug|5-Fluorouracil|
529313|NCT00155883|Drug|Leucovorin|
529314|NCT00155870|Behavioral|questionnaires|
529315|NCT00155766|Biological|HPV16 E7 peptide-pulsed autologous DCs|
529316|NCT00155714|Drug|type-5 phosphodiesterase Inhibitor (Sildenafil)|
529317|NCT00155675|Drug|GUSUIBU|
529318|NCT00155662|Behavioral|work-hardening program|
529319|NCT00155610|Device|intravesical current perception test|
529320|NCT00155597|Behavioral|home physical therapy|
529321|NCT00155558|Drug|5-Fluorouracil, Leucovorin|
529322|NCT00155545|Behavioral|Motion analysis of patients|
529323|NCT00155532|Procedure|3 mm-punch biopsies of the skin|
529324|NCT00155493|Procedure|obtain surgical specimen for analysis|
529325|NCT00155480|Procedure|computed tomography|
529326|NCT00155467|Procedure|CT|
529327|NCT00155454|Procedure|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
529328|NCT00155441|Behavioral|cognitive-behavioral therapy|
529329|NCT00155428|Procedure|rapid prototyping|
529330|NCT00155428|Procedure|computed tomography|
529331|NCT00155415|Behavioral|Different timing of taking polyethylene glycol(PEG)|
529332|NCT00155402|Drug|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
529333|NCT00155389|Drug|Helicobacter pylori eradication|"For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013."
529334|NCT00155376|Drug|morphine and glucagon|
529335|NCT00155363|Device|conventional artificial kidney (AK) vs. high flux AK|
529336|NCT00155350|Drug|pioglitazone|
529337|NCT00155337|Procedure|photodynamic therapy|
529338|NCT00155324|Device|Extracorporeal Shock Wave Therapy (Device)|
529339|NCT00155311|Procedure|orthodontic treatment|
529340|NCT00155285|Procedure|computed tomography|
529341|NCT00155272|Drug|Thalidomide|
529342|NCT00155259|Drug|Docetaxel , Cisplatin , Capecitabine|
529343|NCT00155246|Drug|pentoxifylline (drug)|
529344|NCT00155233|Drug|Nalbuphine and morphine|
529345|NCT00155220|Device|Low Stretch Bandage and Kinesio Tape|
529346|NCT00155064|Drug|captopril, Losartan (drug)|
529347|NCT00154986|Procedure|immunohistochemical staining, transfection, invasion assay|
529348|NCT00154895|Drug|intrapleural minocycline instillation|
529349|NCT00154882|Drug|Paclitaxel (Phyxol) , Cisplatin|
529350|NCT00154869|Drug|Peginterferon Alfa-2a plus Ribavirin|
529351|NCT00154856|Behavioral|Detect the variation of limb lengthening|
529352|NCT00154843|Drug|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
529353|NCT00154830|Behavioral|cerebral palsy|
529354|NCT00154830|Behavioral|crouch gait|
529355|NCT00154817|Procedure|radiotherapy|
529356|NCT00154804|Drug|Paclitaxel, Cisplatin,Surgery, CCRT|
529357|NCT00154791|Drug|oxaliplatin|
529358|NCT00154791|Drug|gemcitabine|
529359|NCT00154791|Drug|5-FU/LV|
529360|NCT00154778|Drug|Taxol, UFT,Leucovorin|
529361|NCT00154765|Device|sling suspension exercises|
529362|NCT00154752|Procedure|CCRT, Pelvic lymphadenoectomy.|
529363|NCT00154739|Drug|Gemcitabine|
529364|NCT00154739|Drug|Cisplatin|
529365|NCT00154739|Drug|Epirubicin|
529366|NCT00154726|Drug|Paclitaxel-HDFL|
529367|NCT00154713|Biological|CEA pulsed dendritic cells|
529368|NCT00154700|Drug|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
529369|NCT00154687|Drug|Paclitaxel, Cisplatin, 5-Fluorouracil|
529370|NCT00154674|Device|ICY catheter, Thermoguard device|
529371|NCT00154661|Drug|pentoxifylline|
529372|NCT00154648|Procedure|CE-MRA|
529373|NCT00154635|Drug|DCB-AD1|
529374|NCT00154622|Behavioral|work hardening program|
529375|NCT00154609|Drug|Gu-Sui-Bu (Davallia Divaricata)|
529376|NCT00154570|Device|EGG, 24 hour esophageal pH monitor|
529377|NCT00154557|Behavioral|elite judo athletes program|
529378|NCT00154518|Procedure|Orthodontic treatment|
529379|NCT00154505|Device|Lateral trunk support of wheelchair seating|
529380|NCT00154492|Drug|activated recombinant human factor VII|
529381|NCT00154466|Behavioral|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
529382|NCT00154453|Procedure|obtain surgical specimen for analysis|
529383|NCT00154440|Drug|proton pump inhibitor|
529384|NCT00154440|Drug|clarithromycin|
529385|NCT00154440|Drug|amoxicillin|
529387|NCT00154440|Procedure|radiation therapy|
529388|NCT00154427|Drug|activated recombinant human factor VII|
529389|NCT00154414|Drug|liraglutide|
529390|NCT00154401|Drug|liraglutide|
529391|NCT00154388|Drug|Imatinib mesylate|
529392|NCT00154375|Drug|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
529393|NCT00154375|Drug|Hydroxyurea|
529394|NCT00154362|Drug|Oxcarbazepine|
529395|NCT00154349|Drug|Imatinib Mesylate|
529396|NCT00154336|Drug|Imatinib|
529397|NCT00154336|Drug|Methotrexate|
529398|NCT00154336|Drug|Imatinib Placebo|
529399|NCT00154323|Drug|Oxcarbazepine|
529400|NCT00154310|Drug|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
529401|NCT00154310|Drug|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
529402|NCT00154310|Drug|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
529403|NCT00154310|Drug|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
529404|NCT00154297|Drug|Everolimus (RAD001)|
529405|NCT00154284|Drug|Everolimus (Certican)|
529406|NCT00154284|Drug|Cyclosporine (Neoral)|
529407|NCT00154284|Drug|Steroid|Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
529408|NCT00154284|Drug|Basiliximab (Simulect)|
529409|NCT00154271|Drug|Valsartan, Valsartan HCT|
529410|NCT00154258|Drug|Clozapine|
529411|NCT00154245|Drug|Enteric-Coated Mycophenolate sodium (EC-MPS)|
529412|NCT00154232|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
529413|NCT00154219|Drug|Lumiracoxib (drug)|
529414|NCT00154206|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
529415|NCT00154193|Drug|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
529416|NCT00154180|Drug|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
529417|NCT00154180|Drug|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
529418|NCT00154180|Drug|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
529419|NCT00154180|Drug|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
529420|NCT00154180|Drug|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
529421|NCT00154167|Drug|NV-101 (phentolamine mesylate solution)|
529422|NCT00154154|Behavioral|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
529423|NCT00154154|Behavioral|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
529424|NCT00154141|Drug|Fibrin sealant (FS2)|
529425|NCT00154128|Device|occlusal appliance|
529426|NCT00154115|Drug|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
529427|NCT00154115|Drug|placebo|Placebo
529428|NCT00154102|Drug|Cetuximab|Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Number of Cycles: until progression or unacceptable toxicity develops
529429|NCT00154102|Drug|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops
529430|NCT00154089|Drug|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
529431|NCT00154076|Drug|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
529432|NCT00154076|Drug|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
529433|NCT00154063|Drug|E2007|
529434|NCT00154063|Other|Placebo|
529435|NCT00154050|Drug|candesartan (drug) or quinapril (drug)|
529436|NCT00154037|Drug|Pioglitazone (drug) and/or candesartan (drug)|
529437|NCT00154024|Drug|atorvastatin|
529438|NCT00154024|Drug|irbesartan|
529439|NCT00154011|Drug|rosiglitazone (drug)|
529440|NCT00153998|Drug|Cetuximab|
529441|NCT00153998|Procedure|Liver resection|
529442|NCT00153998|Drug|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
529443|NCT00153998|Drug|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:~Cetuximab 250 mg/m² (1.0 h i.v.) weekly~Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
529444|NCT00153985|Drug|Busulfex|Given once daily for 4 days
529445|NCT00153985|Drug|Fludarabine|Given intravenously once daily for 4 days
529446|NCT00153985|Drug|Alemtuzumab|One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.
529447|NCT00153985|Procedure|Stem Cell Transfusion|Performed three days after the end of chemotherapy
529448|NCT00153972|Drug|Cabergoline|
529449|NCT00153972|Drug|Levodopa|
529450|NCT00153959|Behavioral|acute psychiatric day care|
529451|NCT00153946|Drug|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
529452|NCT00153933|Drug|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
529453|NCT00153933|Drug|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
529454|NCT00153920|Drug|bortezomib|
529455|NCT00153907|Drug|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
529456|NCT00153907|Drug|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
529457|NCT00153894|Behavioral|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
529458|NCT00153894|Behavioral|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
529459|NCT00153881|Drug|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:~Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.~Concomitant chemotherapy and radiation:~Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
529460|NCT00153868|Drug|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
529461|NCT00153842|Drug|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).~Level 1: 300 mg"
529462|NCT00153842|Drug|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the intitial day of chemotherapy (Day 1).~Level 2: 400 mg"
529463|NCT00153829|Behavioral|Multifaceted outreach facilitation for chronic illness care|
529464|NCT00153816|Drug|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
529465|NCT00153816|Drug|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
529466|NCT00153816|Drug|placebo|placebo; two tablets per day
529467|NCT00153803|Drug|Erlotinib (tarceva)|Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 3 years of therapy.
529468|NCT00153803|Drug|Placebo|Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 3 years of therapy.
529469|NCT00153790|Drug|PhosphoLean|
529470|NCT00153777|Drug|Cellulose Sulfate gel (6%)|
529471|NCT00153764|Drug|Cooper Complete One-A-Day Vitamin Supplement|
529472|NCT00153751|Drug|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
529473|NCT00153751|Drug|Holopon|holopon
529474|NCT00153751|Other|placebo|placebo
529475|NCT00153738|Drug|phytosterol|
529476|NCT00153725|Drug|Aspirin and Pantoloc|
529477|NCT00153699|Drug|Topiramate|
529478|NCT00153686|Procedure|capsule endoscopy|capsule endoscopy of small intestine
529479|NCT00153686|Procedure|Mesenteric Angiogram|Mesenteric Angiogram
529480|NCT00153673|Drug|celecoxib|Celecoxib 200mg bd
529481|NCT00153673|Drug|Dologesics|Dologesics 2 tablets bd
529482|NCT00153660|Drug|Celecoxib(drug)|Celecoxib 100 mg bd
529483|NCT00153660|Drug|Naproxen(drug)|Naproxen 500 mg bd
529484|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
529485|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
529486|NCT00153634|Drug|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
529487|NCT00153634|Drug|PO azithromycin|250 mg once daily
529488|NCT00153634|Drug|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
529489|NCT00153634|Drug|PO ciprofloxacin|500 mg every 12 hours if weight <50 kg 750 mg every 12 hours if weight ≥50 kg
529490|NCT00153634|Drug|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
529491|NCT00153634|Drug|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
529492|NCT00153634|Drug|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
529493|NCT00153634|Drug|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
529494|NCT00153608|Biological|WT1 126-134 peptide|
529495|NCT00153595|Drug|EWO1|
529496|NCT00153582|Biological|WT1 126-134 peptide|
529497|NCT00153569|Biological|Tyrosinase, MAGE-3, GnTV|
529498|NCT00153556|Biological|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
529499|NCT00153543|Biological|Pneumococcal polysaccharide vaccine|
529500|NCT00153543|Biological|Pneumococcal conjugate vaccine|
529501|NCT00153530|Drug|methotrexate|"chemotherapy with radiotherapy~chemotherapy without radiotherapy"
529502|NCT00153530|Radiation|radiotherapy|whole-brain irradiation
529503|NCT00153517|Drug|oral versus vaginal metronidazole|
529504|NCT00153504|Behavioral|Housing and Health Study housing rental assistance|
529505|NCT00153504|Behavioral|Standard local practice housing assistance|
529506|NCT00153491|Drug|artemether-lumefantrine|
529507|NCT00153478|Behavioral|Brief Motivational Counseling|
529508|NCT00153465|Behavioral|Motivational intervention, parent training|
529509|NCT00153452|Behavioral|perpetration of intimate partner violence|
529510|NCT00153439|Behavioral|Motivational enhancements, parent training|
529511|NCT00153426|Behavioral|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
529512|NCT00153413|Behavioral|Women's health|
529513|NCT00153400|Behavioral|Women's health|
529514|NCT00153387|Behavioral|Women's health|
529515|NCT00153374|Behavioral|Women's health|
529516|NCT00153361|Behavioral|Discussion Group|
529517|NCT00153361|Behavioral|Video Discussion Group|
529518|NCT00153348|Behavioral|Women's health|
529519|NCT00153335|Behavioral|patient-provider interaction|
529520|NCT00153322|Behavioral|Nurtition and Physical Activity Education|
529521|NCT00153309|Behavioral|People with Arthritis Can Exercise|
529522|NCT00153296|Drug|Carbamazepine|
529523|NCT00153283|Drug|Gabapentin|
529524|NCT00153270|Drug|Sodium Valproate|
529525|NCT00153257|Device|Ugytex|Anterior repair reinforced by a specially designed mesh: UgytexTM
529526|NCT00153244|Drug|Lamotrigine|
529527|NCT00153231|Device|IVS|Infracoccygeal sacropexy
529528|NCT00153231|Procedure|Sacrospinofixation|
529529|NCT00153205|Behavioral|computerized physician order entry|
529530|NCT00153192|Drug|Marinol (dronabinol)|
529531|NCT00153179|Drug|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
529532|NCT00153179|Drug|placebo|matching placebo
529533|NCT00153166|Drug|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
529534|NCT00153166|Drug|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
529535|NCT00153166|Drug|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
529536|NCT00153166|Drug|placebo/placebo|placebo orally three times daily
529537|NCT00153153|Drug|polyethyleneglycol3350|
529538|NCT00153140|Drug|polyethyleneglycol3350|
529539|NCT00153127|Drug|polyethyleneglycol3350|
529540|NCT00153114|Drug|polyethyleneglycol3350|
529541|NCT00153101|Drug|Telmisartan|
529542|NCT00153101|Drug|Combination of Telmisartan and Ramipril|
529543|NCT00153101|Drug|Ramipril|
529544|NCT00153088|Drug|Telmisartan capsule 40 mg|
529545|NCT00153088|Drug|Placebo|
529546|NCT00153088|Drug|Telmisartan capsule 80 mg|
529547|NCT00153075|Device|Berodual Respimat|
529548|NCT00153075|Device|Berodual HFA-MDI|
529549|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
529550|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
529551|NCT00153062|Drug|Clopidogrel placebo|placebo
529552|NCT00153062|Drug|Clopidogrel placebo|placebo
529553|NCT00153062|Drug|Micardis|80 mg micardis
529554|NCT00153062|Drug|Micardis|80 mg micardis
529555|NCT00153062|Drug|Aggrenox placebo|placebo
529556|NCT00153062|Drug|Aggrenox placebo|placebo
529557|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
529558|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
529559|NCT00153062|Drug|Micardis placebo|placebo
529560|NCT00153062|Drug|Micardis placebo|placebo
529561|NCT00153049|Drug|Telmisartan|
529562|NCT00153049|Drug|Hydrochlorothiazide|
529563|NCT00153049|Drug|Telmisartan + Hydrochlorothiazide|
529564|NCT00153036|Drug|rt-PA 0.9 mg/kg verum or placebo Intravenous|
529565|NCT00153023|Drug|Telmisartan|
529566|NCT00153023|Drug|Valsartan|
529567|NCT00153010|Drug|NS 2330 (Tesofensine)|
529568|NCT00152997|Drug|Pramipexole 0.125 mg tablets|
529569|NCT00152997|Drug|Pramipexole 0.125 mg tablets Placebo|
529570|NCT00152984|Drug|Tiotropium inhalation capsules|
529571|NCT00152984|Drug|Placebo inhalation capsules|
529572|NCT00152971|Drug|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
529573|NCT00152971|Drug|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
529574|NCT00152971|Drug|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
529575|NCT00152971|Drug|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
529576|NCT00152971|Drug|Enoxaparin|30 mg subcutaneously twice daily
529577|NCT00152958|Drug|Pramipexole|
529578|NCT00152945|Drug|Intravenous Intralipid|intravenous infusion
529579|NCT00152945|Drug|Intravenous leucine, glycerol|intravenous infusion
529580|NCT00152932|Drug|Dorzolamide 2% drops|
529581|NCT00152932|Device|HRF and CLBF|
529582|NCT00152919|Drug|Meloxicam|
529583|NCT00152906|Procedure|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
529584|NCT00152893|Drug|chromium nicotinate|
529585|NCT00152893|Drug|Placebo|
529586|NCT00152867|Drug|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
529587|NCT00152854|Drug|Acetaminophen|acetaminophen 1g po qid
529588|NCT00152854|Drug|acetaminophen|acetaminophen 1g po qid for 7 days
529589|NCT00152854|Drug|placebo, sugar pill|
529590|NCT00152841|Drug|Iron supplement 300-600 mg/day|
529591|NCT00152841|Drug|Vitamin E 800IU|
529592|NCT00152828|Drug|Celecoxib|
529593|NCT00152815|Drug|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
529658|NCT00152308|Device|2% rapamycin-eluting YUKONdes PEARL-stent|
529659|NCT00152308|Device|1% rapamycin-eluting YUKONdes PEARL-stent|
541124|NCT00082576|Drug|Mefloquine|
529594|NCT00152815|Behavioral|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
529595|NCT00152802|Biological|The polysaccharide vaccine Pneumovax (Merck-Frosst)|
529596|NCT00152802|Biological|The conjugate vaccine used will be Prevnar (Wyeth vaccines)|
529597|NCT00152789|Procedure|Oxygen measurement - Eppendorf machine|
529598|NCT00152776|Drug|ovaria comp 10 globuli 3 times per day 24 weeks|order of intervention and placebo varies between Groups I-III
529599|NCT00152763|Behavioral|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
529600|NCT00152763|Other|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
529601|NCT00152750|Drug|APO-clonidine|
529602|NCT00152737|Procedure|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
529603|NCT00152737|Procedure|Ankle and arm pressure values|one test before and one test after surgery
529604|NCT00152724|Device|pressure strain system, iontophoresis|
529605|NCT00152724|Drug|scopolamin|
529606|NCT00152724|Drug|emla|
529607|NCT00152724|Drug|capsaicin|
529608|NCT00152724|Drug|aspirin|
529609|NCT00152724|Drug|clopidogrel|
529610|NCT00152724|Drug|celecoxib|
529611|NCT00152724|Drug|indomethacin|
529612|NCT00152724|Drug|acetylcholine|
529613|NCT00152724|Drug|sodium nitroprusside|
529614|NCT00152724|Drug|brethyllium|
529615|NCT00152724|Device|general and local heating|
529616|NCT00152711|Device|nCPAP|
529617|NCT00152698|Drug|Irbesartan|
529618|NCT00152685|Drug|human serum albumin|
529619|NCT00152672|Device|nCPAP vs oral appliance|
529620|NCT00152659|Procedure|Tissue sample (procedure/screening)|Tissue sampling
529621|NCT00152646|Drug|placebo, aspirine, clopidogrel|
529622|NCT00152633|Drug|Losartan|
529623|NCT00152633|Drug|Metoprolol|
529624|NCT00152633|Drug|Losartan|Treatment with Losartan
529625|NCT00152620|Drug|Dexamethasone|
529626|NCT00152620|Drug|Methylprednisolone|
529627|NCT00152607|Procedure|donor right hepatic lobectomy|
529628|NCT00152594|Drug|voriconazole|
529629|NCT00152581|Drug|Pegylated interferon-alfa2a (Pegasys); ribavirin|
529630|NCT00152568|Behavioral|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
529631|NCT00152555|Behavioral|Physical Therapy or Relaxation Therapy|
529632|NCT00152542|Drug|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
529633|NCT00152542|Drug|Placebo|No iNO given for days 1-7
529634|NCT00152529|Behavioral|Screening (Behavior)|
529635|NCT00152516|Drug|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
529636|NCT00152503|Drug|Seletracetam (ucb 44212)|
529637|NCT00152490|Drug|Certolizumab Pegol (CDP870)|
529638|NCT00152477|Drug|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.~Each cycle to be repeated every three weeks for a maximum of six cycles."
529639|NCT00152477|Drug|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
529640|NCT00152477|Drug|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
529641|NCT00152477|Drug|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
529642|NCT00152464|Drug|Placebo|Pharmaceutical form: Oral drops Route of administration: Oral use
529643|NCT00152464|Drug|Levocetirizine|Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use
529644|NCT00152451|Drug|Seletracetam (ucb 44212)|
529645|NCT00152438|Drug|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
529646|NCT00152438|Other|Placebo|3 identical placebo pills daily, no active ingredient.
529647|NCT00152425|Drug|Certolizumab Pegol (CDP870)|
529648|NCT00152412|Drug|Levocetirizine oral solution|
529649|NCT00152399|Drug|Somatostatin UCB (drug)|
529650|NCT00152386|Drug|Certolizumab pegol (CDP870)|
529651|NCT00152373|Drug|Levetiracetam|
529652|NCT00152360|Drug|Orlistat|See Detailed Description.
529653|NCT00152347|Drug|Botox|See Detailed Description
529654|NCT00152334|Drug|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
529655|NCT00152321|Behavioral|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
529656|NCT00152321|Behavioral|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
529657|NCT00152321|Other|Usual Care|
529660|NCT00152308|Device|YUKONdes PEARL-stent coated with placebo (ethanol)|
529661|NCT00152295|Drug|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
529662|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
529663|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
529664|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
529665|NCT00152282|Drug|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
529666|NCT00152269|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
529667|NCT00152269|Drug|Asoprisnil|25mg Tablet, oral Daily for 12 months
529668|NCT00152269|Drug|Placebo|Placebo, Tablet, oral Daily for 12 months
529669|NCT00152256|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
529670|NCT00152256|Drug|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
529671|NCT00152256|Drug|Placebo|Placebo Tablet, oral Daily for 6 months
529672|NCT00152243|Drug|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
529673|NCT00152243|Procedure|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
529674|NCT00152230|Drug|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
529675|NCT00152230|Procedure|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
529676|NCT00152217|Drug|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
529677|NCT00152217|Procedure|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
529678|NCT00152204|Drug|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
529679|NCT00152204|Drug|IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
529680|NCT00152191|Drug|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
529681|NCT00152191|Drug|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
529682|NCT00152178|Drug|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
529683|NCT00152178|Drug|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
529684|NCT00152165|Procedure|Radiostereometric Analysis beads inserted during surgery|
529685|NCT00152152|Procedure|Radiostereometric Analysis beads inserted during surgery|
529686|NCT00152139|Procedure|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
529687|NCT00152139|Drug|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
529688|NCT00152126|Procedure|Stem Cell Transplantation|Autologous stem cell transplantation
529689|NCT00152126|Drug|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
529690|NCT00152113|Procedure|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
529691|NCT00152113|Device|CliniMACS|
529692|NCT00152113|Drug|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
529693|NCT00152100|Procedure|Stem cell transplant|
529694|NCT00152100|Drug|Filgrastim, Alemtuzumab|
529695|NCT00152100|Device|Miltenyi CliniMACS|
529696|NCT00152087|Device|Brachytherapy|
529697|NCT00152074|Behavioral|Reduce salt intake|
529698|NCT00152061|Drug|3TC and FTC|
529699|NCT00152048|Drug|Eflornithine hydrochloride|
529700|NCT00152035|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
529701|NCT00152022|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
529702|NCT00152009|Drug|SPD503 (Guanfacine hydrochloride) (2 mg)|
529703|NCT00152009|Drug|SPD503 (3 mg)|
529704|NCT00152009|Drug|SPD503 (4 mg)|
529705|NCT00152009|Drug|Placebo|
529706|NCT00151996|Drug|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
529707|NCT00151996|Drug|Amphetamine + SPD503|
529708|NCT00151983|Drug|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
529709|NCT00151970|Drug|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
529710|NCT00151970|Drug|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
529711|NCT00151970|Drug|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
529712|NCT00151957|Drug|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
529713|NCT00151944|Drug|SPD476 (mesalazine)|
529714|NCT00151931|Drug|Lanthanum carbonate|
529715|NCT00151918|Drug|Lanthanum carbonate|
529716|NCT00151905|Drug|3 % hypertonic saline|
529717|NCT00151892|Drug|SPD476|2.4 g/day Once Daily (QD)
529718|NCT00151892|Drug|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
529719|NCT00151879|Drug|SPM 927|
529720|NCT00151866|Procedure|platelet transfusion|
529721|NCT00151853|Drug|PPSB-SD|
529722|NCT00151840|Drug|IVIG-L|
529723|NCT00151827|Drug|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
529724|NCT00151827|Drug|Losartan|Medications are taken once daily before breakfast with water.
529725|NCT00151827|Drug|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
529726|NCT00151814|Drug|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
529727|NCT00151801|Drug|estroprogestins|
529728|NCT00151801|Drug|interferon-beta 1a|
529729|NCT00151788|Drug|Pactimibe sulfate|
529730|NCT00151775|Drug|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.~Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
529731|NCT00151775|Drug|placebo|Cohorts A, B, C: placebo, once daily
529732|NCT00151775|Drug|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.~Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
529733|NCT00151762|Drug|Colesevelam hydrochloride|
529734|NCT00151749|Drug|Colesevelam hydrochloride|
529735|NCT00151736|Drug|Chlorambucil|Chlorambucil 2mg tablets
529736|NCT00151736|Drug|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
529737|NCT00151723|Procedure|treatment with 131I|
529738|NCT00151710|Drug|Pioglitazone|
529739|NCT00151697|Drug|Novomix 30|
529740|NCT00151697|Drug|Novorapid and Amaryl|
529741|NCT00151697|Drug|Lantus|
529742|NCT00151684|Drug|Diazoxide|
529743|NCT00151671|Drug|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
529744|NCT00151671|Drug|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
529745|NCT00151658|Device|Coronary Drug Eluting Stents for PCI|
529746|NCT00151645|Drug|activated lymphocytes|
529747|NCT00151632|Drug|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
529748|NCT00151632|Drug|Tacrolimus|"In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.~In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12."
529749|NCT00151619|Drug|Amlodipine|
529750|NCT00151606|Procedure|Reinforced isolation + Muciprocine|
529751|NCT00151593|Other|Celsior®|Graft preservation solution
529752|NCT00151580|Drug|Ribavirin|18 months of oral ribavirin maintenance treatment
529753|NCT00151580|Drug|Placebo|18 months oral placebo treatment
529754|NCT00151567|Drug|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
529755|NCT00151567|Drug|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
529756|NCT00151554|Behavioral|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
529757|NCT00151541|Drug|Dapsone Topical Gel + adapalene gel 0.1%|
529758|NCT00151541|Drug|Dapsone Topical Gel + benzoyl peroxide gel 4%|
529759|NCT00151541|Drug|Dapsone Topical Gel + vehicle control|
529760|NCT00151528|Drug|Pregabalin|
529761|NCT00151515|Drug|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
529762|NCT00151502|Drug|Atorvastatin|
529763|NCT00151489|Drug|pregabalin|
529764|NCT00151489|Drug|placebo|
529765|NCT00151476|Drug|Celecoxib|800 mg total daily dosing
529766|NCT00151476|Other|Routine Medical Care|
529767|NCT00151463|Drug|sildenafil citrate|
529768|NCT00151450|Drug|Pregabalin|
529769|NCT00151450|Drug|Venlafaxine XR|
529770|NCT00151437|Drug|Pegvisomant treatment|
529771|NCT00151437|Procedure|Medical History, demographics|
529772|NCT00151437|Procedure|Sign and symptoms: questionnaire|
529773|NCT00151437|Procedure|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
529774|NCT00151437|Procedure|MRI|
529775|NCT00151424|Drug|asenapine|Asenapine 5-10mgBID
529776|NCT00151424|Drug|Placebo|Matched against asenapine and olanzapine
529777|NCT00151424|Drug|Olanzapine|10-20 mg QD
529778|NCT00151411|Drug|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
529779|NCT00151411|Drug|Placebo|Placebo
529780|NCT00151411|Behavioral|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
529781|NCT00151398|Drug|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.~Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
529826|NCT00151060|Drug|Estramustine|
529782|NCT00151398|Drug|Donepezil|10 mg donepezil QD dosed up to 40 weeks
529783|NCT00151385|Procedure|single blood draw|
529784|NCT00151372|Behavioral|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
529785|NCT00151372|Behavioral|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
529786|NCT00151359|Device|SoleSensor|
529787|NCT00151346|Drug|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
529788|NCT00151346|Drug|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
529789|NCT00151333|Drug|SRA-333|
529790|NCT00151320|Drug|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
529791|NCT00151307|Device|INVOS cerebral oximeter|
529792|NCT00151294|Drug|escitalopram oxalate antidepressant|
529793|NCT00151281|Drug|PEPC|"Induction phase (month 1-3)~• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC < 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.~Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• PEPC QOD or fractionated weekly basis"
529794|NCT00151281|Drug|Thalidomide|"Induction phase (month 1-3)~• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.~Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Daily low dose thalidomide (50-100mg/d)"
529795|NCT00151281|Drug|Rituximab|"Induction phase (month 1-3)~• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.~Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.~Post-Month 12 Maintenance phase (post-month 12 until disease progression)~• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months"
529796|NCT00151255|Drug|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
529797|NCT00151255|Drug|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
529798|NCT00151255|Drug|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
529799|NCT00151255|Drug|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
529800|NCT00151255|Drug|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
529801|NCT00151242|Drug|Cytarabine|100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
529802|NCT00151242|Drug|Idarubicin|12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
529803|NCT00151242|Drug|Etoposide|100mg/m² i.v. day 1-3 (induction therapy)
529804|NCT00151242|Drug|All-trans retinoic acid|45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)
529805|NCT00151242|Drug|Pegfilgrastim|6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
529806|NCT00151229|Other|target blood pressure|
529807|NCT00151216|Biological|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
529808|NCT00151203|Drug|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.~Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.~Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
529809|NCT00151190|Behavioral|Education for diabetes self-management|
529810|NCT00151177|Device|non-invasive continuous positive airway pressure ventilation|
529811|NCT00151177|Device|CPAP-treatment|night time CPAP-mask ventilation
529812|NCT00151164|Procedure|donor bone marrow cell injection into thymus gland|
529813|NCT00151151|Behavioral|Computer-Assisted Motivational Intervention|
529814|NCT00151151|Behavioral|Didactic Educational Counseling|
529815|NCT00151138|Drug|Atenolol (drug), Lisinopril (drug)|
529816|NCT00151125|Drug|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
529817|NCT00151125|Drug|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
529818|NCT00151125|Drug|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
529819|NCT00151112|Procedure|Positioning and plexus anesthesia|positioning during plexus anesthesia
529820|NCT00151099|Drug|high caloric drink with protein|
529821|NCT00151086|Drug|Estramustine|
529822|NCT00151086|Drug|Vinorelbine|
529823|NCT00151073|Drug|Zoledronic acid|
529824|NCT00151073|Drug|Estramustine|
529825|NCT00151073|Drug|Docetaxel|
529835|NCT00151021|Behavioral|Tailored web-based walking program|
529836|NCT00151008|Drug|Bexarotene/NBUVB vs placebo NBUVB|
529837|NCT00150995|Drug|Tetrathiomolybdate|
529838|NCT00150982|Drug|Mechanism of action of alefacept|
529839|NCT00150969|Dietary Supplement|vitamin K1 (phylloquinone)|
529840|NCT00150969|Dietary Supplement|placebo|1 pill daily
529841|NCT00150956|Procedure|Daily home hemodialysis|
529842|NCT00150943|Device|Renal artery stent|
529843|NCT00150930|Device|narrowband UVB phototherapy at home|
529844|NCT00150917|Behavioral|Supportive-Expressive Group Therapy|
529845|NCT00150904|Procedure|venous blood puncture|
529846|NCT00150891|Procedure|Kidney transplantation|
529847|NCT00150891|Drug|cyclosporine A|
529848|NCT00150891|Drug|tacrolimus|
529849|NCT00150891|Drug|azathioprine|
529850|NCT00150891|Drug|mycophenolate mofetil|
529851|NCT00150878|Other|Conditioning therapy|Preparation before allogeneic transplantation
529852|NCT00150865|Drug|ropivacaine|
529853|NCT00150852|Drug|Vancomycin|
529854|NCT00150839|Drug|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
529855|NCT00150839|Drug|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
529856|NCT00150826|Drug|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
529857|NCT00150826|Drug|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
529858|NCT00150813|Drug|Levetiracetam|Pharmaceutical form: oral tablets Route of administration: Oral use
529859|NCT00150800|Drug|Brivaracetam|"Active Substance: Brivaracetam~Pharmaceutical Form: Tablet~Concentration: 10 mg and 25 mg~Route of Administration: Oral"
529860|NCT00150787|Drug|LEVETIRACETAM|
529861|NCT00150774|Drug|Levetiracetam|
529862|NCT00150761|Drug|Levocetirizine (drug)|
529863|NCT00150748|Drug|Levetiracetam 166 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Tablet~Concentration: 166 mg~Route of Administration: Oral use"
529864|NCT00150748|Drug|Levetiracetam 250 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Tablet~Concentration: 250 mg~Route of Administration: Oral use"
529865|NCT00150748|Drug|Levetiracetam 500 mg|"Active Substance: Levetiracetam~Pharmaceutical Form: Tablet~Concentration: 500 mg~Route of Administration: Oral use"
529866|NCT00150735|Drug|LEVETIRACETAM|
529867|NCT00150722|Drug|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
529868|NCT00150709|Drug|Levetiracetam (Keppra)|
529869|NCT00150696|Drug|Risedronate|
529870|NCT00150683|Device|vibration and passive standing versus passive standing alone|
529871|NCT00150670|Drug|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
529872|NCT00150670|Drug|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
529873|NCT00150657|Drug|bevacizumab|
529874|NCT00150657|Drug|carboplatin|
529875|NCT00150657|Drug|gemcitabine|
529876|NCT00150644|Drug|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
529877|NCT00150644|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
529878|NCT00150644|Drug|Placebo|Placebo Tablet, oral Daily for 12 weeks
529879|NCT00150631|Drug|Candesartan|placebo controlled double blind
529880|NCT00150618|Drug|SPD503 (1 mg)|
529881|NCT00150618|Drug|SPD503 (2 mg)|
529882|NCT00150618|Drug|SPD503 (3 mg)|
529883|NCT00150618|Drug|SPD503 (4 mg)|
529884|NCT00150618|Drug|Placebo|
529885|NCT00150605|Drug|Extended-release carbamazepine|
529886|NCT00150592|Drug|SPD503 (Guanfacine HCl)|
529887|NCT00150592|Drug|Placebo|
529888|NCT00150579|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
529889|NCT00150566|Drug|Lanthanum carbonate|
529890|NCT00150553|Drug|Extended-release carbamazepine|
529891|NCT00150540|Drug|Lanthanum carbonate|
529892|NCT00150527|Drug|Citalopram|40 mg, pill, single dose
529893|NCT00150527|Drug|Escitalopram|20 mg, pill, single dose
529894|NCT00150527|Drug|Dexamethasone|1 mg, pill, single dose
529895|NCT00150527|Behavioral|Cold Pressor Test|single test
529896|NCT00150514|Drug|Oralgen|
529897|NCT00150514|Procedure|Nasal biopsy|
529898|NCT00150514|Procedure|Nasal washing|
529899|NCT00150514|Procedure|Peak nasal inspiratory flow|
529900|NCT00150488|Device|Uracyst|2% weekly for 6 weeks, monthly for 4 months
529901|NCT00150475|Procedure|Powered Air purifying respirator|
529902|NCT00150462|Drug|Carfilzomib|Administered as an IV bolus dose
529903|NCT00150462|Drug|Dexamethasone|Administered orally prior to carfilzomib
529904|NCT00150449|Drug|Pregabalin|
529905|NCT00150436|Drug|Pregabalin|
529906|NCT00150423|Drug|Pregabalin|
529907|NCT00150410|Drug|Inhaled insulin|
529908|NCT00150397|Drug|Tofimilast|
529909|NCT00150384|Drug|Amlodipine/Atorvastatin|
529910|NCT00150371|Drug|atorvastatin|
529911|NCT00150358|Drug|Sildenafil Citrate|
529912|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, early treatment
529913|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, deferred treatment
529914|NCT00150332|Drug|linezolid|
529915|NCT00150319|Drug|Vfend®; I.V.|
529916|NCT00150306|Drug|Zoloft (Sertraline)|
529917|NCT00150293|Drug|Pregabalin|
529918|NCT00150280|Drug|celecoxib and ibuprofen SR|
529919|NCT00150267|Drug|Xalacom|
529920|NCT00150254|Drug|CP-526,555 (varenicline)|
529921|NCT00150241|Drug|CP-526,555 (varenicline)|
529922|NCT00150228|Drug|CP-526,555 (varenicline)|
529927|NCT00150176|Drug|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
529928|NCT00150176|Drug|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
529929|NCT00150176|Drug|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
529930|NCT00150150|Procedure|Interstitial laser photocoagulation|
529931|NCT00150137|Drug|Methimazole|
529932|NCT00150124|Drug|MTZ+LT4|
529933|NCT00150124|Drug|Methimazole|
529934|NCT00150111|Drug|Methimazole|
529935|NCT00150111|Drug|Rituximab|
529936|NCT00150111|Biological|Immunization with various vaccines|
529937|NCT00150098|Behavioral|Enhanced HIV risk reduction and HIV vaccine education|
529938|NCT00150085|Drug|cyclosporine micro-emulsion|
529939|NCT00150072|Drug|imatinib|
529940|NCT00150059|Drug|Pimecrolimus Cream 1%|
529941|NCT00150046|Drug|Everolimus|
529942|NCT00150020|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
529943|NCT00150007|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
529944|NCT00149994|Drug|Cyclosporine A|
529945|NCT00149994|Drug|Tacrolimus|
529946|NCT00149994|Drug|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
529947|NCT00149994|Drug|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
529948|NCT00149994|Drug|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
529949|NCT00149981|Drug|everolimus (RAD)|Everolimus
529950|NCT00149968|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
529951|NCT00149942|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
529952|NCT00149929|Drug|Mycophenolate sodium (enteric coated)|
529953|NCT00149916|Drug|Mycophenolate sodium (enteric coated)|
529954|NCT00149903|Drug|Mycophenolate sodium (enteric coated)|
529955|NCT00149890|Drug|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight <35 kg) or 20 mg (body weight ≥35 kg) strength.
529956|NCT00149890|Drug|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
529957|NCT00149890|Drug|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
529958|NCT00149877|Drug|Tegaserod|
529959|NCT00149864|Drug|Mycophenolate sodium (enteric coated)|
529960|NCT00149851|Drug|Tegaserod|
529961|NCT00149838|Procedure|Prefrontal rTMS|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
529962|NCT00149838|Drug|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
529963|NCT00149838|Procedure|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
529964|NCT00149825|Drug|Escitalopram|5 to 20 mg for 12 weeks
529965|NCT00149825|Behavioral|CBTI|Cognitive Behavioral Treatment for Insomnia
529966|NCT00149825|Behavioral|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
529967|NCT00149812|Behavioral|Family Functioning Intervention|
529968|NCT00149799|Drug|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
529969|NCT00149799|Drug|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
529970|NCT00149786|Behavioral|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
529971|NCT00149786|Behavioral|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
529972|NCT00149773|Behavioral|Cognitive Therapy|
529973|NCT00149760|Behavioral|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
529974|NCT00149760|Behavioral|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
529975|NCT00149747|Behavioral|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
529976|NCT00149747|Behavioral|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
529977|NCT00149734|Drug|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
529978|NCT00149734|Drug|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
529979|NCT00149721|Procedure|Ventriculo-peritonal shunting|
529980|NCT00149708|Drug|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
529981|NCT00149695|Behavioral|Weekly home delivery of milk products|
529982|NCT00149682|Behavioral|6-month educational program|
529983|NCT00149682|Behavioral|6-month standard care program|
529984|NCT00149669|Behavioral|employment-based reinforcement|Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
529985|NCT00149656|Dietary Supplement|Multivitamins|dietary supplement of multivitamins
529986|NCT00149656|Dietary Supplement|Selenium|dietary supplement of selenium only
529987|NCT00149656|Other|Placebo|placebo pill
529988|NCT00149643|Drug|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
529989|NCT00149643|Other|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
529990|NCT00149630|Drug|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
529991|NCT00149630|Drug|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
529992|NCT00149630|Behavioral|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
529993|NCT00149630|Other|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
529994|NCT00149617|Drug|Buspirone|
529995|NCT00149604|Drug|conjugated estrogens|
529996|NCT00149604|Drug|Raloxifene|
529997|NCT00149604|Behavioral|exercise plus mild caloric restriction for weight loss|
529998|NCT00149591|Procedure|coronary balloon-angioplasty with stenting|
529999|NCT00149578|Drug|Gemcitabine Oxaliplatin 5FU and Leucovorin|
530000|NCT00149565|Drug|IFN-α2b|
530001|NCT00149552|Dietary Supplement|zinc|supplementation with zinc gluconate
530002|NCT00149539|Drug|Buprenorphine/naloxone|
530003|NCT00149526|Behavioral|Shared Decision-Making|
530004|NCT00149513|Behavioral|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
530005|NCT00149513|Behavioral|Usual care|Participants will receive usual care.
530006|NCT00149500|Behavioral|Coaching|Patients received monthly calls to assist in behavioral change relative to asthma care
530007|NCT00149487|Behavioral|Tailored Problem Solving Intervention|
530008|NCT00149487|Behavioral|Family Education Intervention|
530009|NCT00149474|Behavioral|Peak Flow Monitoring|
530010|NCT00149461|Behavioral|Written Asthma Action Plan|
530011|NCT00149448|Behavioral|TB Contact Priority Model|
530012|NCT00149422|Device|NT-proBNP measurements|
530013|NCT00149409|Dietary Supplement|Omacor|
530014|NCT00149396|Drug|NV1020|NV1020 dose levels: 3x10^6, 1x10^7, 3x10^7, and 1x10^8 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
530015|NCT00149383|Drug|Rosiglitazone|
530016|NCT00149383|Drug|Placebo|
530017|NCT00149370|Procedure|Breast reduction surgery|
530018|NCT00149357|Other|Thrombophilia Testing|TP testing in Group 1 and 3 only
530019|NCT00149344|Radiation|Vertical scar versus inferior pedicle reduction mammoplasty|Vertical Scar Reduction Mammoplasty Inferior Pedicle Reduction Mammoplasty
530020|NCT00149331|Behavioral|Structured education program|
530021|NCT00149318|Other|Biochemical analyses.|Biochemical analyses.
530022|NCT00149305|Other|Genetic analyses|
530023|NCT00149305|Other|Genetic analyses|
530024|NCT00149292|Drug|LY2140023|
530025|NCT00149292|Drug|olanzapine|
530026|NCT00149292|Drug|placebo|
530027|NCT00149279|Procedure|Surgery: D2 dissection|
530028|NCT00149279|Procedure|Surgery: D2+paraaortic dissection|
530029|NCT00149266|Procedure|Surgery: abdominal and transhiatal approach|
530030|NCT00149266|Procedure|Surgery: left thoraco-abdominal approach|
530031|NCT00149253|Drug|a single-dose of Etoricoxib before induction of anesthesia|
530032|NCT00149240|Biological|Botulinum toxin type A|
530033|NCT00149227|Drug|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
530034|NCT00149227|Drug|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
530035|NCT00149214|Drug|pemetrexed|500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
530036|NCT00149214|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
530037|NCT00149214|Drug|doxorubicin|60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
530038|NCT00149214|Drug|docetaxel|100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)
530039|NCT00149201|Drug|5-FU continuous infusion|
530040|NCT00149201|Drug|MTX + 5-FU sequential therapy|
530041|NCT00149188|Drug|Lanreotide (Autogel formulation)|
530042|NCT00149175|Other|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
530043|NCT00149162|Drug|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)~1 cycle of treatment each month during 12 months"
530044|NCT00149149|Drug|Zinc carnosine|
530045|NCT00149136|Drug|imatinib|
530046|NCT00149123|Drug|hydrocortisone 200 mg/day|
530047|NCT00149110|Procedure|Sleep deprivation|3 days with a normal night between
530048|NCT00149110|Procedure|Light therapy|Daily light therapy for 29 weeks
530049|NCT00149110|Procedure|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
530050|NCT00149110|Behavioral|Exercise|Moderate intensity daily exercise for 30 minutes at least
530051|NCT00149110|Drug|duloxetine|60 mg daily
530052|NCT00149110|Drug|duloxetine|60 mg daily
530053|NCT00149084|Drug|Lansoprazole, clarithromycin, amoxicillin|
530054|NCT00149071|Device|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
530055|NCT00149071|Device|TMS|Transcraniel Magnetic Stimulation active and sham
530056|NCT00149071|Device|rTMS|active Transcranial Magnetic Stimulation
530057|NCT00149071|Device|rTMS|daily for three weeks
530058|NCT00149058|Drug|Erythropoietin|
530059|NCT00149032|Procedure|DLI sensitized against antigens expressed by the host.|
530060|NCT00149019|Drug|Cell therapy with bispecific antibodies|
530061|NCT00149006|Procedure|Cell therapy|
530062|NCT00148993|Biological|Tumor Cell Vaccine|
530063|NCT00148980|Device|DBM for creation of bone marrow microenvironment|
530064|NCT00148967|Device|Implantable Cardioverter Defibrillator|
530065|NCT00148954|Device|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
530066|NCT00148954|Device|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
530067|NCT00148941|Biological|Diphtheria, tetanus, pertussis, poliovirus type 1, 2 & 3|
530068|NCT00148928|Biological|P501-AS15 vaccine|
530069|NCT00148915|Drug|ibandronate|
530070|NCT00148915|Drug|Placebo|matching placebo
530071|NCT00148902|Drug|lapatinib|lapatinib
530072|NCT00148902|Drug|docetaxel|docetaxel
530073|NCT00148889|Device|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
530074|NCT00148876|Drug|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
530075|NCT00148876|Drug|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
530076|NCT00148863|Drug|Peg-interferon alpha 2a (drug)|
530077|NCT00148863|Drug|Ribavirin (drug)|
530078|NCT00148863|Drug|Interferon gamma (drug)|
530079|NCT00148850|Drug|Pioglitazone|
530080|NCT00148837|Drug|Peg-interferon alpha 2b (drug)|
530081|NCT00148837|Drug|Ribavirin (drug)|
530082|NCT00148837|Drug|Prazosin (drug)|
530083|NCT00148824|Biological|7-valent pneumococcal conjugate vaccine (vaccine)|
530084|NCT00148824|Biological|23-valent pneumococcal conjugate vaccine (vaccine)|
530085|NCT00148798|Drug|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
530086|NCT00148798|Drug|cisplatin + vinorelbine|cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
530087|NCT00148785|Drug|Indinavir/Ritonavir/Fosamprenavir|
530088|NCT00148772|Drug|Erlotinib (Tarceva)|
530089|NCT00148759|Drug|LPV/r|LPV/r 800/200 mg once daily
530090|NCT00148746|Drug|Pimecrolimus|
530091|NCT00148746|Drug|Tacrolimus|
530092|NCT00148746|Drug|Prednisolone|
530093|NCT00148746|Drug|Ciclosporin A|
530094|NCT00148746|Drug|Dermatop|
530095|NCT00148733|Drug|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
530096|NCT00148720|Drug|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
530097|NCT00148707|Drug|CT-2103 (Xyotax)|
530098|NCT00148694|Drug|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
530099|NCT00148681|Drug|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
530100|NCT00148681|Drug|Navelbine|Intravenously every week for 12 weeks
530101|NCT00148681|Drug|Doxorubicin|Every 3 weeks for 12 weeks
530102|NCT00148681|Drug|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
530103|NCT00148681|Drug|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
530104|NCT00148668|Drug|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
530105|NCT00148668|Drug|Navelbine|Weekly injections given starting week 3 and ending week 14
530106|NCT00148668|Drug|Taxotere|Given every three weeks starting week 3 and ending on week 14
530107|NCT00148668|Drug|Carboplatin|Given every three weeks starting week 3 and ending on week 14
530108|NCT00148655|Device|Decision Board|Decision board that explains the risks and benefits of treatment options
530109|NCT00148642|Device|silver salts coated endotracheal tube|intubation with silver coated tube
530110|NCT00148642|Device|uncoated endotracheal tube|intubation
530111|NCT00148629|Drug|multivitamin, mebendazole|
530112|NCT00148616|Drug|Memantine|Daily dosage of 20 mg Memantine add-on to Risperidone vs. Placebo add-on to Risperidone
530113|NCT00148616|Drug|Placebos|Daily dosage of 20 mg Placebo add-on to Risperidone vs. Memantine add-on to Risperidone
530114|NCT00148603|Drug|montelukast|
530115|NCT00148590|Drug|Memantine|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
530116|NCT00148590|Drug|Placebo|Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
530117|NCT00148577|Device|Transcutaneous Electrical Nerve Stimulation|
530118|NCT00148564|Drug|olanzapine|treatment with either Olanzapine or Ziprasidone
530119|NCT00148564|Drug|Ziprasidone|treatment with either Olanzapine or Ziprasidone
530120|NCT00148551|Drug|Triamcinolone Acetonide|
530121|NCT00148538|Behavioral|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
530122|NCT00148525|Behavioral|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
530123|NCT00148525|Behavioral|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
530124|NCT00148512|Drug|1. Tesofensine (NS 2330)|
530125|NCT00148499|Drug|Ambroxol hydrochloride (Mucoangin?)|
530126|NCT00148499|Drug|benzocaine|
530127|NCT00148486|Drug|NS 2330|
530128|NCT00148473|Drug|Misoprostol|
530129|NCT00148460|Drug|TNK-tPA|
530130|NCT00148460|Drug|rt-PA|
530131|NCT00148447|Drug|escitalopram|
530132|NCT00148434|Behavioral|Patient-held guideline for hypertension|
530133|NCT00148421|Drug|Darbepoetin alfa and Epoetin alfa|
530134|NCT00148408|Drug|Montelukast|
530135|NCT00148408|Behavioral|Education|
530136|NCT00148395|Drug|Gemcitabine|
530137|NCT00148395|Drug|Navelbine|
530138|NCT00148395|Drug|Carboplatin|
530139|NCT00148395|Drug|Cisplatin|
530140|NCT00148395|Drug|Mitomycin|
530141|NCT00148395|Drug|Ifosfamide|
530142|NCT00148382|Drug|ATL-962|
530143|NCT00148369|Drug|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
530144|NCT00148356|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
530145|NCT00148356|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
530146|NCT00148343|Device|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation & use for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
530147|NCT00148343|Other|Conventional Standard of Care|Conventional standard of care (which may include implementation & use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
530148|NCT00148343|Procedure|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
530149|NCT00148330|Drug|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia]) was injected into the vitreous under sterile conditions in a minor procedures area.
530150|NCT00148317|Drug|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
530151|NCT00148317|Drug|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
530152|NCT00148317|Drug|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
530153|NCT00148317|Drug|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
530154|NCT00148317|Drug|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
530155|NCT00148291|Drug|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
530156|NCT00148278|Drug|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
530157|NCT00148278|Drug|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
530158|NCT00148265|Drug|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
530159|NCT00148252|Drug|Mycophenolate mofetil withdrawal|
530160|NCT00148252|Drug|Cyclosporione A withdrawal|
530161|NCT00148239|Behavioral|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
530162|NCT00148239|Behavioral|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
530163|NCT00148239|Behavioral|Control|Participants given written educational materials at beginning of study; no treatment beyond this
530164|NCT00148226|Behavioral|Decision Aid|
530165|NCT00148174|Behavioral|Intensive telephone followup|Telephone calling
530166|NCT00148148|Drug|caspofungin|
530167|NCT00148148|Drug|liposomal amphotericin B|
530168|NCT00148135|Drug|Carboplatin|
530169|NCT00148135|Drug|Gemcitabine|
530170|NCT00148135|Drug|Capecitabine|
530171|NCT00148122|Drug|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
530229|NCT00147745|Drug|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
530230|NCT00147732|Radiation|Accelerated radiotherapy|68 Gy over 5.5 weeks
530231|NCT00147732|Radiation|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
530172|NCT00148122|Drug|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
530173|NCT00148109|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
530174|NCT00148109|Drug|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
530175|NCT00148096|Device|Mechanical Heat Recovery Ventilation|De-humidification without loss of heat
530176|NCT00148083|Drug|Risperdal Consta (drug)|
530177|NCT00148083|Behavioral|Social Skills Training|
530178|NCT00148070|Drug|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
530179|NCT00148070|Procedure|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
530180|NCT00148057|Behavioral|Low-fat diet|
530181|NCT00148044|Procedure|Blood sampling for determination of uremic toxins|
530182|NCT00148031|Drug|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
530183|NCT00148031|Behavioral|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
530184|NCT00148031|Behavioral|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
530185|NCT00148031|Behavioral|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
530186|NCT00148018|Drug|Bortezomib|
530187|NCT00148018|Drug|Dexamethasone|
530188|NCT00148005|Procedure|Questionnaire and micturition and drinking diaries|
530189|NCT00148005|Procedure|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
530190|NCT00148005|Behavioral|Adaptation of the drinking scheme|
530191|NCT00148005|Drug|Anticholinergic therapy|
530192|NCT00148005|Behavioral|Micturition clock|
530193|NCT00147992|Procedure|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
530194|NCT00147979|Device|Bridging by PTFE with bounded heparin|Bridging by PTFE with bounded heparin
530195|NCT00147979|Device|Bridging by PTFE without bounded heparin|Bridging by PTFE without bounded heparin
530196|NCT00147966|Drug|rituximab|treatment with rituximab
530197|NCT00147953|Drug|Rituximab|
530198|NCT00147953|Procedure|Total nodal irradiation|
530199|NCT00147940|Procedure|Acoustic rhinometry (procedure)|
530200|NCT00147927|Behavioral|Sequential emails and web support|
530201|NCT00147914|Drug|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
530202|NCT00147914|Drug|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
530203|NCT00147901|Drug|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
530204|NCT00147888|Procedure|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
530205|NCT00147875|Drug|Prednisone|
530206|NCT00147875|Drug|Vinblastine|
530207|NCT00147875|Drug|Doxorubicin (Adriamycin)|
530208|NCT00147875|Drug|Gemcitabine|
530209|NCT00147862|Drug|Tranexamic Acid|
530210|NCT00147849|Behavioral|mailing of printed educational materials|
530211|NCT00147849|Behavioral|a combination of interactive educational meetings, educational outreach visits, and reminders|
530212|NCT00147849|Behavioral|identification of local opinion leaders and establishment of local consensus processes|
530213|NCT00147836|Drug|Human Insulin (Novolin-R, Novo Nordisk)|
530214|NCT00147836|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
530215|NCT00147836|Other|Pre-meal|
530216|NCT00147836|Drug|Novolin-R|
530217|NCT00147836|Drug|Human Insulin NPH (Novolin-N, Novo Nordisk)|
530218|NCT00147836|Drug|Gliclazide (Diamicron, Servier)|
530219|NCT00147836|Drug|Diamicron and Glucophage|
530220|NCT00147823|Device|Vitoss Alone|Synthetic bone graft material
530221|NCT00147823|Device|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
530222|NCT00147810|Procedure|Telephone outreach to enhance asthma care|
530223|NCT00147784|Drug|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
530224|NCT00147784|Drug|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
530225|NCT00147771|Drug|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
530226|NCT00147758|Drug|Colesevelam hydrochloride|
530227|NCT00147745|Drug|Colesevelam|Colesevelam 3.8g for 12 weeks
530228|NCT00147745|Drug|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
541300|NCT00005612|Drug|paclitaxel|
530232|NCT00147719|Drug|Colesevelam hydrochloride|
530233|NCT00147706|Procedure|Tailored Healthmedia programs on EHR Patient Portal|
530234|NCT00147693|Behavioral|Diagnosis of caregivers' problems|
530235|NCT00147693|Behavioral|Professional service: treatment of problems by counseling or practical support|
530236|NCT00147680|Drug|Paclitaxel, Carboplatin|
530237|NCT00147667|Drug|Erythromycin|
530238|NCT00147654|Drug|Tolterodine ER 4 mg QD|
530239|NCT00147654|Drug|Tamsulosin 0.4 mg QD|
530240|NCT00147628|Drug|sildenafil citrate|
530241|NCT00147628|Drug|placebo for sildenafil citrate|
530242|NCT00147615|Drug|Eplerenone|
530243|NCT00147602|Drug|atorvastatin|
530244|NCT00147589|Drug|Eplerenone|
530245|NCT00147576|Drug|CP-866,087|
530246|NCT00147563|Drug|Eplerenone|
530247|NCT00147550|Drug|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
530248|NCT00147537|Drug|CP-751,871|"Phase 2 Arm A:~CP‑751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
530249|NCT00147537|Drug|paclitaxel|"Phase 2 Arm A:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles~Phase 2 Arm B:~Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
530250|NCT00147537|Drug|carboplatin|"Phase 2 Arm A:~Carboplatin AUC 6, IV over 15‑60 minutes up to 6 cycles~Phase 2 Arm B:~Carboplatin AUC 6, IV over 15‑60 minutes up to 6 cycles"
530251|NCT00147537|Drug|CP-751,871|Phase 1b Dose Escalation/Expansion: CP‑751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP‑751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
530252|NCT00147537|Drug|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
530253|NCT00147537|Drug|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
530254|NCT00147537|Drug|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
530255|NCT00147524|Drug|quinapril|
530256|NCT00147524|Procedure|Laser Doppler imaging|
530257|NCT00147511|Drug|linezolid|
530258|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
530259|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
530260|NCT00147498|Drug|CP-690,550|30 mg BID for 6 weeks
530261|NCT00147498|Other|Placebo|Placebo tablets
530262|NCT00147485|Drug|AG-024322|
530263|NCT00147472|Other|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
530264|NCT00147459|Biological|HBV vaccine booster|
530265|NCT00147446|Behavioral|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
530266|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
530267|NCT00147420|Drug|Zhi Byed 11|
530268|NCT00147394|Drug|Risperidone|
530269|NCT00147381|Drug|Alemtuzumab|"Day 0: Campath-1H 20 mg IV infusion over 3-6 hours~Day 1: Campath-1H 20 mg IV infusion over 3-6 hours"
530270|NCT00147381|Drug|Tacrolimus|"Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.~till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).~Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
530271|NCT00147381|Drug|Alemtuzumab|"Day 0: Campath-1H 30 mg IV infusion over 3-6 hours~Day 1: Campath-1H 30 mg IV infusion over 3-6 hours"
530272|NCT00147368|Drug|intravenous (IV) arginine|
530273|NCT00147355|Drug|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
530274|NCT00147355|Drug|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
530275|NCT00147355|Drug|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
530276|NCT00147355|Drug|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
530277|NCT00147329|Drug|MM-093|
530278|NCT00147316|Drug|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
530279|NCT00147303|Drug|MCI-9042|
530280|NCT00147290|Device|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
530281|NCT00147277|Device|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
530282|NCT00147264|Drug|Telmisartan (Micardis®) vs. Placebo|
530283|NCT00147264|Behavioral|Low-Glycemic Index Diet vs. Control Diet|
530284|NCT00147251|Drug|FDA approved drugs to treat blood pressure and cholesterol|
530285|NCT00147238|Drug|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
530611|NCT00144443|Behavioral|Asthma Trigger Education|
530286|NCT00147238|Procedure|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
530287|NCT00147225|Drug|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).~1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
530288|NCT00147225|Drug|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
530289|NCT00147225|Drug|Adriamycin|75-90 mg/m^2 IV
530290|NCT00147225|Drug|Ifosfamide|10 gm/m^2 IV; OR, High dose ifosfamide = 14 gm/m^2.
530291|NCT00147212|Drug|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
530292|NCT00147199|Drug|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
530293|NCT00147199|Drug|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
530294|NCT00147186|Device|Hylan G-F 20|
530295|NCT00147160|Drug|Temozolomide, Cisplatinum|
530296|NCT00147147|Procedure|Gastrectomy with D2 or greater lymph node dissection|
530297|NCT00147147|Drug|Gastrectomy+ chemotherapy|
530298|NCT00147134|Procedure|open colectomy|Procedure/Surgery: open colectomy
530299|NCT00147134|Procedure|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
530300|NCT00147121|Drug|Rituximab + Standard CHOP|Rituximab + Standard CHOP
530301|NCT00147121|Drug|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
530302|NCT00147108|Device|ExAblate 2000|
530303|NCT00147056|Device|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
530304|NCT00147043|Procedure|Leukapheresis|
530305|NCT00147043|Procedure|Infusion of stem cells via image guided scan|
530306|NCT00147030|Procedure|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
530307|NCT00147004|Drug|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
530308|NCT00147004|Drug|Placebo|
530309|NCT00146978|Procedure|intra-arterial treatment|
530310|NCT00146952|Device|Vibrotactile feedback|
530311|NCT00146926|Drug|kétamine 20mg|
530312|NCT00146926|Drug|ephedrine 3mg|
530313|NCT00146926|Drug|lidocaine 40mg|
530314|NCT00146913|Drug|Imatinib mesylate 600mg/day|
530315|NCT00146913|Drug|Peg-Interféron at 90 microg/week|
530316|NCT00146900|Procedure|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
530317|NCT00146900|Procedure|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
530318|NCT00146900|Drug|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
530319|NCT00146900|Other|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
530320|NCT00146887|Procedure|coronary catheterization|
530321|NCT00146874|Device|cardiac resynchronization therapy|
530322|NCT00146861|Device|sensor programming|
530323|NCT00146848|Device|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
530324|NCT00146835|Biological|Pediarix|1 or more injections
530325|NCT00146835|Biological|Licensed DTPa containing vaccine|1 or more injections
530326|NCT00146835|Biological|Prevnar®: (Wyeth)|Concomitant vaccination
530327|NCT00146822|Device|ENDOTAK RELIANCE G lead|
530328|NCT00146809|Drug|Minocyline|
530329|NCT00146796|Device|Rapid diagnostic test for malaria|
530330|NCT00146783|Drug|Sulphadoxine-pyrimethamine|
530331|NCT00146783|Drug|Sulphadoxine-pyrimethamine, amodiaquine|
530332|NCT00146770|Biological|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
530333|NCT00146770|Biological|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
530334|NCT00146770|Biological|placebo|Placebo for 26 weeks
530335|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
530336|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
530337|NCT00146744|Biological|Mtb72F/AS02A|
530338|NCT00146731|Drug|SP|
530339|NCT00146731|Drug|SP + amodiaquine|
530340|NCT00146731|Drug|AQ + artesunate|
530341|NCT00146731|Drug|chlorproguanil-dapsone|
530342|NCT00146718|Drug|Amodiaquine and Sulphadoxine/Pyrimethamine|
530343|NCT00146705|Procedure|blood samples are taken once|
530344|NCT00146692|Behavioral|Free medical treatment|
530345|NCT00146679|Behavioral|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
530346|NCT00146679|Behavioral|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
530347|NCT00146679|Behavioral|Usual Care|Usual Care provided by providers
530348|NCT00146666|Device|Intermittent compression|
530419|NCT00146107|Other|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
530349|NCT00146640|Drug|MR Prednisone|Participants will receive tablets containing MR prednisone (to achieve the appropriate dose of 3-10 milligrams [mg] prednisone per day) at bed time.
530350|NCT00146640|Drug|IR Prednisone|Participants will receive tablets containing IR prednisone (to achieve the appropriate dose of 3-10 mg prednisone per day) in the morning.
530351|NCT00146640|Drug|Placebo - MR Prednisone|Participants will receive placebo matching to MR prednisone tablet at bed time.
530352|NCT00146640|Drug|Placebo - IR Prednisone|Participants will receive placebo matching to IR prednisone tablet in the morning.
530353|NCT00146627|Drug|Eflornithine|
530354|NCT00146627|Drug|Nifurtimox|
530355|NCT00146614|Drug|Sirolimus|
530356|NCT00146614|Drug|Tacrolimus|
530357|NCT00146614|Drug|Methotrexate|
530358|NCT00146614|Procedure|Stem Cell Transplantation|
530359|NCT00146601|Drug|Fulvestrant|
530360|NCT00146588|Drug|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
530361|NCT00146588|Drug|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
530362|NCT00146588|Drug|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
530363|NCT00146575|Device|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
530364|NCT00146575|Device|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
530365|NCT00146562|Drug|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
530366|NCT00146562|Drug|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
530367|NCT00146562|Drug|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
530368|NCT00146562|Drug|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
530369|NCT00146562|Drug|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
530370|NCT00146549|Drug|Trastuzumab|
530371|NCT00146549|Drug|Vinorelbine|
530372|NCT00146549|Drug|Paclitaxel|
530373|NCT00146549|Drug|Docetaxel|
530374|NCT00146523|Drug|Mifepristone|
530375|NCT00146523|Drug|placebo|
530376|NCT00146510|Behavioral|HealtheLifestyle Program|
530377|NCT00146510|Behavioral|step counters with monthly feedback on logs|
530378|NCT00146497|Drug|Budesonide-Surfactant|
530379|NCT00146484|Drug|Twice Daily versus Three Times Daily Insulin Injections|
530380|NCT00146471|Drug|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
530381|NCT00146471|Drug|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
530382|NCT00146458|Procedure|18F-fluorodeoxyglucose positron emission tomography|
530383|NCT00146445|Behavioral|Peer Mentoring Intervention|
530384|NCT00146432|Procedure|Immunoadsorption of LPS, IL-6 and C5a|
530385|NCT00146419|Behavioral|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
530386|NCT00146406|Behavioral|Project Connect|
530387|NCT00146393|Behavioral|People with Arthritis Can Exercise program|
530388|NCT00146380|Drug|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum~ARVs continued for those that meet WHO treatment criteria"
530389|NCT00146380|Behavioral|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
530390|NCT00146367|Behavioral|Active Living Every Day|
530391|NCT00146354|Behavioral|Hospitalists Results Manager|
530392|NCT00146341|Drug|Telmisartan/HCTZ|
530393|NCT00146341|Drug|Telmisartan|
530394|NCT00146328|Drug|Tipranavir|
530395|NCT00146315|Behavioral|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
530396|NCT00146315|Behavioral|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
530397|NCT00146302|Biological|Bacille Calmette Guerin (BCG)|
530398|NCT00146289|Drug|MICARDIS® (telmisartan)|
530399|NCT00146276|Drug|gemcitabine|
530400|NCT00146263|Behavioral|computerized cognitive training|
530401|NCT00146250|Drug|Nitrous oxide|Substitution of Nitrous oxide for Nitrogen as balance gas in inspired gas mixture
530402|NCT00146237|Drug|phenytoin|
530403|NCT00146224|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
530404|NCT00146224|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
530405|NCT00146211|Drug|Ethyl-EPA (Miraxion™)|
530406|NCT00146198|Drug|ALGRX 4975|
530407|NCT00146185|Drug|ALGRX 3268|
530408|NCT00146172|Drug|neratinib|HKI-272
530409|NCT00146159|Drug|Mitoxantrone|dosage
530410|NCT00146146|Drug|testosterone undecanoate alone|1000 mg/12 weeks
530411|NCT00146146|Drug|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
530412|NCT00146146|Drug|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
530413|NCT00146133|Behavioral|diet, exercise|
530414|NCT00146120|Drug|Idarubicin|
530415|NCT00146120|Drug|Cytosin-Arabinosid|
530416|NCT00146120|Drug|Etoposide|
530417|NCT00146120|Drug|All-trans Retinoid acid|
530418|NCT00146107|Behavioral|Diet|10 percent weight loss through diet and behavioral modification
541955|NCT00004010|Drug|prednisone|
530420|NCT00146107|Other|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
530421|NCT00146094|Procedure|BMD Measurement|
530422|NCT00146081|Behavioral|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
530423|NCT00146068|Drug|Avonex/Zocor|
530424|NCT00146055|Procedure|Reduced intensity conditioning with allogeneic transplant|
530425|NCT00146042|Drug|Docetaxel|
530426|NCT00146042|Drug|Trastuzumab|
530427|NCT00146042|Procedure|Erythromycin Breath Test (ERMBT)|
530428|NCT00146016|Drug|Amantadine|
530429|NCT00146003|Drug|Efalizumab treatment|
530430|NCT00145990|Drug|methacholine|
530431|NCT00145990|Device|KoKo Digidoser|
530432|NCT00145990|Device|Rosethal Dosimeter|
530433|NCT00145977|Drug|Alendronate|alendronate 70 mg once weekly
530434|NCT00145977|Dietary Supplement|Calcium Citrate|600 mg of calcium citrate
530435|NCT00145977|Dietary Supplement|Vitamin D|500 mg of Vitamin D consumed with the evening meal.
530436|NCT00145951|Behavioral|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
530437|NCT00145938|Drug|sildenafil|
530438|NCT00145925|Drug|Perindopril-indapamide|
530439|NCT00145925|Drug|Gliclazide MR-based glucose lowering|
530440|NCT00145912|Behavioral|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
530441|NCT00145912|Behavioral|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
530442|NCT00145886|Drug|rhPTH|Subjects will be treated with rhPTH for 12 months.
530443|NCT00145873|Drug|nesiritide, continuous infusion|
530444|NCT00145847|Drug|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
530445|NCT00145834|Behavioral|community based trial|
530446|NCT00145808|Device|Given® Diagnostic System|
530447|NCT00145795|Drug|Kaletra + Current Dual NRTI Backbone|
530448|NCT00145795|Drug|Current Regimen|
530449|NCT00145782|Behavioral|Life style|
530450|NCT00145769|Drug|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
530451|NCT00145769|Drug|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
530452|NCT00145769|Radiation|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
530453|NCT00145769|Radiation|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
530454|NCT00145769|Drug|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
530455|NCT00145769|Procedure|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
530456|NCT00145756|Drug|low sodium high potassium salt substitute|
530457|NCT00145743|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
530458|NCT00145730|Drug|Ibuprofen|
530459|NCT00145717|Drug|Plant sterol enriched milk tea|
530460|NCT00145704|Drug|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
530461|NCT00145704|Dietary Supplement|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
530462|NCT00145704|Dietary Supplement|Calcium|calcium supplement given to patients with growth hormone deficiency
530463|NCT00145691|Drug|Oxcarbazepine|
530464|NCT00145678|Behavioral|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
530465|NCT00145678|Behavioral|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
530466|NCT00145665|Procedure|FLT-PET scan|PET scan using FLT
530467|NCT00145652|Drug|Neo-Recormon and Venofer|
530468|NCT00145639|Drug|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
530469|NCT00145639|Procedure|Limb Sparing|See Detailed Description for treatment plan.
530470|NCT00145626|Drug|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
530471|NCT00145626|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
530472|NCT00145626|Procedure|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
530473|NCT00145613|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
530474|NCT00145613|Device|Miltenyi Biotec CliniMACS|stem cell selection device
530475|NCT00145613|Drug|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
530476|NCT00145600|Drug|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
530610|NCT00144443|Behavioral|Basic home repair|
530477|NCT00145600|Drug|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
530478|NCT00145600|Drug|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
530479|NCT00145600|Drug|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
530480|NCT00145587|Procedure|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
530481|NCT00145587|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
530482|NCT00145587|Drug|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease~Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
530483|NCT00145574|Drug|colesevelam HCl|Tablets
530484|NCT00145574|Drug|placebo|Matching Tablets
530485|NCT00145561|Drug|Saquinavir and Ritonavir|
530486|NCT00145548|Device|Intra Bronchial Valve|
530487|NCT00145535|Device|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, ~50 spots over 180°
530488|NCT00145535|Device|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, ~50 spots over 180°
530489|NCT00145522|Drug|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
530490|NCT00145522|Drug|Tibolone|2,5 mg/day for 12 cycles of 28 days
530491|NCT00145509|Drug|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
530492|NCT00145509|Drug|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
530493|NCT00145496|Drug|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
530494|NCT00145496|Drug|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
530495|NCT00145483|Drug|Sildenafil|
530496|NCT00145470|Drug|Asenapine|Asenapine fast dissolving SL tablets 5 and 10 mg; starting dose 5 mg BID on Day 1; 5-10 mg BID after Day 1.
530497|NCT00145470|Drug|Placebo|Placebo fast dissolving SL tablets, BID
530498|NCT00145457|Procedure|Blood sample|
530499|NCT00145457|Procedure|Radiography|
530500|NCT00145444|Drug|olanzapine|
530501|NCT00145444|Drug|ziprasidone|
530502|NCT00145431|Drug|torcetrapib/atorvastatin|
530503|NCT00145431|Drug|atorvastatin|
530504|NCT00145431|Drug|fenofibrate|
530505|NCT00145418|Drug|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
530506|NCT00145405|Drug|Lanreotide Autogel and Octreotide LAR|
530507|NCT00145379|Drug|Tablet Metformin 500 mg|
530508|NCT00145379|Drug|Placebo|
530509|NCT00145366|Drug|Recombinant human thyrotropin (Thyrogen)|
530510|NCT00145353|Drug|Insulin NovoRapid versus Actrapid|
530511|NCT00145340|Drug|pioglitazone|30 Mg/day
530512|NCT00145327|Drug|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
530513|NCT00145327|Drug|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
530514|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
530515|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
530516|NCT00145314|Drug|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.~Cetuximab weekly."
530517|NCT00145301|Drug|Lumiracoxib|
530518|NCT00145275|Drug|zoledronic acid|
530519|NCT00145262|Procedure|Autologous Bone Marrow Mononuclear Cell Implantation|
530520|NCT00145249|Drug|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
530521|NCT00145249|Drug|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
530522|NCT00145236|Drug|Nebivolol|
530523|NCT00145210|Drug|Nebivolol and Atenolol|
530524|NCT00145197|Behavioral|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
530525|NCT00145184|Dietary Supplement|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
530526|NCT00145184|Drug|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
530527|NCT00145171|Drug|apomorphine HCl injection|
530528|NCT00145158|Biological|8 HLA-A2 restricted peptides and Montanide ISA-51|
530529|NCT00145145|Biological|MAGE-3.A1 peptide and CpG 7909|
530530|NCT00145132|Procedure|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
530531|NCT00145106|Drug|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
530532|NCT00145093|Drug|Baker’s yeast (Bio Chromium)|
530533|NCT00145080|Behavioral|Disease Management Assessment|
530534|NCT00145067|Behavioral|Disease Management Assessment|
530535|NCT00145054|Behavioral|MoodHelper Internet program for Depression Self-Help|
530536|NCT00145041|Drug|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
530537|NCT00145028|Drug|Carboplatin|
530538|NCT00145015|Behavioral|Increased dietary intake of salmon or cod|
530539|NCT00145002|Drug|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
530540|NCT00145002|Drug|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
530541|NCT00144989|Drug|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
530542|NCT00144989|Drug|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
530543|NCT00144976|Drug|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
530544|NCT00144963|Drug|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
530545|NCT00144963|Drug|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
530546|NCT00144950|Drug|insertion of a chest drain with urokinase instillation|
530547|NCT00144950|Procedure|primary video-assisted thorascopic surgery|
530548|NCT00144937|Drug|Stepwise therapy for dyslipidemia, hypertension and diabetes|
530549|NCT00144937|Behavioral|Dietary recommendations|
530550|NCT00144937|Behavioral|Increase in physical activity|
530551|NCT00144937|Behavioral|Smoking cessation|
530552|NCT00144924|Procedure|pyloromyotomy|laparoscopic pyloromytomy
530553|NCT00144911|Drug|Salmeterol|
530554|NCT00144911|Drug|Fluticasone Propionate/Salmeterol Combination Product|
530555|NCT00144898|Procedure|Sentinel Node Resection|Sentinel Node Resection
530556|NCT00144898|Procedure|Conventional Axillary Dissection|Conventional Axillary Dissection
530557|NCT00144885|Behavioral|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
530558|NCT00144872|Drug|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
530559|NCT00144859|Drug|SB681323|
530560|NCT00144846|Drug|albuterol sulfate inhalation aerosol|
530561|NCT00144833|Drug|fosamprenavir/ritonavir (700mg/100mg BID)|
530562|NCT00144833|Drug|fosamprenavir/ritonavir (1400mg/100mg BID)|
530563|NCT00144833|Drug|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
530564|NCT00144820|Drug|Injection of Hyaluronan or Saline|
530565|NCT00144807|Drug|rituximab|
530566|NCT00144807|Drug|doxorubicin|
530567|NCT00144807|Drug|cyclophosphamide|
530568|NCT00144807|Procedure|autologous stem cell transplantation|
530569|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
530570|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
530571|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
530572|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
530573|NCT00144768|Drug|laronidase|dose of 0.58mg/kg body weight IV every week
530574|NCT00144755|Drug|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
530575|NCT00144729|Procedure|Bone marrow transplant|
530576|NCT00144716|Device|Insect Repellent plus Insecticide Treated Net|
530577|NCT00144703|Drug|Sirolimus|
530578|NCT00144703|Drug|Tacrolimus|
530579|NCT00144690|Drug|E2007 (perampanel)|
530580|NCT00144690|Drug|Placebo|
530581|NCT00144677|Drug|sirolimus|
530582|NCT00144677|Drug|tacrolimus|
530583|NCT00144664|Drug|MRA(Tocilizumab)|
530584|NCT00144651|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
530585|NCT00144625|Drug|MRA(Tocilizumab)|8mg/kg/4weeks
530586|NCT00144612|Drug|MRA(Tocilizumab)|8mg/kg/2weeks
530587|NCT00144599|Drug|MRA(Tocilizumab)|
530588|NCT00144599|Drug|placebo|
530589|NCT00144586|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
530590|NCT00144573|Drug|MRA(Tocilizumab)|
530591|NCT00144560|Drug|MRA(Tocilizumab)|
530592|NCT00144547|Drug|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
530593|NCT00144534|Drug|MRA (Tocilizumab)|8mg/kg/4 weeks
530594|NCT00144521|Drug|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
530595|NCT00144521|Drug|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
530596|NCT00144521|Drug|MTX|8mg/week(p.o.) for 24 weeks
530597|NCT00144521|Drug|MTX placebo|0mg/week(p.o.) for 24 weeks
530598|NCT00144508|Drug|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
530599|NCT00144508|Other|current treatment|continue current treatment
530600|NCT00144495|Drug|recombinant human erythropoietin|3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
530601|NCT00144495|Drug|recombinant human erythropoietin|36000IU(s.c.)/week for 12 weeks
530602|NCT00144482|Drug|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
530603|NCT00144482|Drug|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
530604|NCT00144469|Drug|peginterferon alfa-2a|
530605|NCT00144469|Drug|rivavirin|
530606|NCT00144456|Drug|ED-71|0.75μg/day(p.o.)for 144 weeks
530607|NCT00144456|Drug|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
530608|NCT00144456|Drug|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
530609|NCT00144456|Drug|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
530612|NCT00144430|Drug|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
530613|NCT00144417|Drug|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
530614|NCT00144417|Drug|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
530615|NCT00144391|Drug|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
530616|NCT00144378|Drug|Irinotecan|
530617|NCT00144365|Drug|Antiretroviral therapy|
530618|NCT00144352|Drug|sulfadoxine-pyrimethamine|
530619|NCT00144339|Drug|tiotropium|
530620|NCT00144339|Drug|placebo|
530621|NCT00144326|Drug|Tiotropium Bromide|
530622|NCT00144326|Drug|Placebo|
530623|NCT00144313|Biological|hepatitis B vaccine|
530624|NCT00144300|Drug|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
530625|NCT00144300|Drug|Requip|Standard marketed product dispensed according to manufacturer's guidelines
530626|NCT00144287|Drug|Tipranavir/Ritonavir|
530627|NCT00144274|Drug|Ambroxol Lozenge|
530628|NCT00144261|Drug|nevirapine|
530629|NCT00144248|Drug|nevirapine|
530630|NCT00144235|Drug|Pharmaton PHL 00749|
530631|NCT00144235|Drug|Placebo|
530632|NCT00144222|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
530633|NCT00144222|Drug|Telmisartan 40 mg|
530634|NCT00144209|Drug|pramipexole|
530635|NCT00144209|Drug|levodopa in combination with benserazide|
530636|NCT00144196|Drug|tiotropium (Spiriva)|
530637|NCT00144183|Drug|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
530638|NCT00144183|Drug|Zidovudine (ZCV)|
530639|NCT00144183|Drug|3TC|
530640|NCT00144170|Drug|Tipranavir (with low dose ritonavir)|
530641|NCT00144170|Drug|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
530642|NCT00144157|Drug|Nevirapine|
530643|NCT00144157|Drug|Zidovudine|
530644|NCT00144157|Drug|3TC|
530645|NCT00144144|Drug|Angiotensin II receptor antagonists, Calcium channel blocker|
530646|NCT00144131|Drug|Aranesp®|
530647|NCT00144118|Drug|sevoflurane or isoflurane|
530648|NCT00144105|Drug|TPV500mg/RTV200mgBID|
530649|NCT00144105|Drug|TPV500mg/RTV100mgBID|
530650|NCT00144105|Drug|LPV400mg/RTV100mgBID|
530651|NCT00144092|Procedure|stem cell source|
530652|NCT00144079|Procedure|external beam radiotherapy|
530653|NCT00144066|Drug|platinum-based chemotherapy alone (up to six cycles)|
530654|NCT00144066|Drug|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
530655|NCT00144053|Drug|Cisplatin+Vindesine+MMC/ concurrent radiation|
530656|NCT00144053|Drug|Irinotecan+Carboplatin/concurrent radiation|
530657|NCT00144053|Drug|Paclitaxel+Carboplatin/concurrent radiation|
530658|NCT00144040|Behavioral|Physician & patient education on appropriate antibiotic use|
530659|NCT00144040|Procedure|Rapid C-reactive protein testing to guide antibiotic treatment|
530660|NCT00144027|Behavioral|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
530661|NCT00144014|Drug|V10153|Single acute intravenous bolus dose up to 10 mg/kg
530662|NCT00143988|Behavioral|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
530663|NCT00143988|Behavioral|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
530664|NCT00143975|Drug|Cytarabine|3 g/m2 bid. i.v day 1-3
530665|NCT00143975|Drug|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
530666|NCT00143975|Drug|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
530667|NCT00143975|Drug|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
530668|NCT00143962|Behavioral|Low Carbohydrate Diet|
530669|NCT00143949|Drug|enalapril|
530670|NCT00143949|Drug|losartan|
530671|NCT00143936|Behavioral|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
530672|NCT00143936|Behavioral|Low Calorie Diet|Maintain a low calorie diet
530673|NCT00143923|Behavioral|Nutrition, Exercise, Stress Management Counseling|Individualized advice
530674|NCT00143923|Other|usual care|usual care
530675|NCT00143910|Other|observation|
530676|NCT00143884|Procedure|Reduced intensity conditioning|
530677|NCT00143884|Procedure|Prophylactic donor leukocyte infusions|
530678|NCT00143871|Drug|Rituximab|
530679|NCT00143858|Device|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
530680|NCT00143845|Procedure|Reduced intensity conditioning|Busulfan and Fludarabine regimen
530681|NCT00143845|Procedure|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
530682|NCT00143845|Procedure|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
530683|NCT00143819|Drug|Neuroskin Forte|Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
530684|NCT00143819|Drug|Placebo Application|Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
530685|NCT00143806|Drug|Transitioning patients from cyclosporine to alefacept|
530686|NCT00143780|Biological|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
530687|NCT00143780|Biological|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
530688|NCT00143754|Procedure|Hydration|
530689|NCT00143741|Drug|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
530690|NCT00143728|Drug|Lamivudine|See Detailed Description.
530691|NCT00143715|Drug|Phytonadione (Vitamin K1)|1.25 mg given orally
530692|NCT00143702|Drug|d4T|See Detailed Description.
530693|NCT00143702|Drug|Abacavir|See Detailed Description.
530694|NCT00143702|Drug|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
530695|NCT00143689|Drug|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
530696|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
530697|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
530698|NCT00143676|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
530699|NCT00143663|Drug|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
530700|NCT00143663|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
530701|NCT00143650|Behavioral|House dust|
530702|NCT00143637|Other|Office dust|airborne office dust spiked with glucan
530703|NCT00143637|Other|clean air|Clean air
530704|NCT00143624|Drug|Rosiglitazone maleate|See Detailed Description.
530705|NCT00143624|Drug|Placebo|See detailed description.
530706|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
530707|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
530708|NCT00143611|Drug|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
530709|NCT00143598|Device|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
530710|NCT00143598|Device|Knee-length, placebo stocking|Worn daily for two years
530711|NCT00143585|Procedure|intramyocardial delivery of either VEGF165 or placebo|
530712|NCT00143572|Drug|Magnesium Pidolate, Hydroxyurea|Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
530713|NCT00143559|Drug|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
530714|NCT00143559|Procedure|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
530715|NCT00143559|Device|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
530716|NCT00143546|Drug|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
530717|NCT00143533|Drug|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
530718|NCT00143520|Drug|Rivoglitazone|
530719|NCT00143520|Drug|Pioglitazone|
530720|NCT00143520|Drug|Placebo|
530721|NCT00143507|Drug|Ivabradine|
530722|NCT00143507|Drug|Placebo|
530723|NCT00143494|Procedure|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
530724|NCT00143481|Drug|Tolterodine ER 4mg QD|
530725|NCT00143468|Behavioral|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
530726|NCT00143455|Drug|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
530727|NCT00143455|Drug|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
530728|NCT00143442|Drug|[S,S]-Reboxetine|
530729|NCT00143429|Drug|Xalatan|
530730|NCT00143416|Drug|Pegvisomant|
530731|NCT00143403|Drug|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
530732|NCT00143403|Drug|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
530733|NCT00143390|Drug|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
530734|NCT00143390|Drug|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
530735|NCT00143377|Drug|tolterodine SR, overactive bladder|
530736|NCT00143364|Drug|varenicline (CP-526,555)|
530737|NCT00143351|Drug|Ziprasidone|
530738|NCT00143338|Drug|Inhaled insulin|
530739|NCT00143325|Drug|varenicline (CP-526,555)|
530740|NCT00143312|Drug|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
530741|NCT00143299|Drug|varenicline (CP-526,555)|
530742|NCT00143286|Drug|varenicline (CP-526,555)|
530743|NCT00143273|Drug|lasofoxifene|0.05 mg tablets
530744|NCT00143273|Drug|Placebo|0 mg
530745|NCT00143273|Drug|Lasofoxifene|0.25 mg tablets
530746|NCT00143273|Drug|Lasofoxifene|0.5 mg tablets
530747|NCT00143260|Drug|Viagra (Sildenafil Citrate) 100 mg|
530748|NCT00143247|Drug|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
530749|NCT00143234|Drug|Amlodipine/atorvastatin single pill|
530750|NCT00143221|Drug|Viagra|
530751|NCT00143221|Drug|Placebo|
530752|NCT00143208|Drug|Xalacom|
530753|NCT00143195|Drug|Amlodipine|
530754|NCT00143195|Drug|iso- 5 - mononitrate|
530755|NCT00143195|Procedure|Blood tests|
530756|NCT00143195|Procedure|Exercise Stress Test|
530757|NCT00143182|Drug|Asenapine|Asenapine , 9 weeks
530758|NCT00143182|Drug|Olanzapine|Olanzapine, 9 weeks
530759|NCT00143169|Drug|Parecoxib and placebo|
530760|NCT00143156|Drug|pregabalin|
530761|NCT00143143|Drug|Pregabalin|
530762|NCT00143130|Drug|Pregabalin|Pregabalin
530763|NCT00143117|Drug|UK-390,957|
530764|NCT00143104|Drug|Inhaled insulin|
530765|NCT00143091|Drug|CP-316,311|
530766|NCT00143091|Drug|Placebo|
530767|NCT00143091|Drug|Sertraline|
530768|NCT00143065|Drug|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
530769|NCT00143065|Drug|Rituximab|"Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician."
530770|NCT00143065|Drug|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2,6,10,14,18,and 22).
530771|NCT00143039|Procedure|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
530772|NCT00143026|Drug|carbidopa, levodopa, entacapone|
530773|NCT00143000|Drug|Peginterferon alfa-2a 40KD and Ribavirin|
530774|NCT00142987|Drug|Tegaserod|
530775|NCT00142974|Drug|Tegaserod|
530776|NCT00142961|Drug|Atomoxetine|atomoxetine
530777|NCT00142961|Other|placebo|
530778|NCT00142948|Drug|Naltrexone|naltrexone
530779|NCT00142948|Drug|Placebo|placebo
530780|NCT00142935|Behavioral|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
530781|NCT00142935|Behavioral|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
530782|NCT00142935|Behavioral|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
530783|NCT00142922|Behavioral|Breaking Down Barriers|completed
530784|NCT00142909|Drug|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
530785|NCT00142909|Drug|Placebo|Lofexidine Placebo
530786|NCT00142896|Drug|Tramadol|
530787|NCT00142896|Drug|Naloxone|
530788|NCT00142896|Drug|Morphine|
530789|NCT00142883|Drug|Pregabalin|pregabalin compared to placebo
530790|NCT00142883|Drug|placebo|sugar pill compared to pregabalin
530791|NCT00142870|Drug|Bupropion|150 mg, twice a day
530792|NCT00142844|Drug|Naltrexone|
530793|NCT00142844|Drug|Disulfiram|
530794|NCT00142844|Drug|Placebo|
530795|NCT00142831|Drug|Pharmacotherapies for Smoking Cessation|Bupropion-SR or Identical Placebo
530796|NCT00142818|Drug|Naltrexone|150 mg daily for males; 100 mg daily for females
530797|NCT00142818|Drug|Modafinil|400 mg daily
530798|NCT00142818|Drug|Placebo|400 mg and/or 100-150 mg placebo pills
530799|NCT00142805|Drug|Ketasyn™ (AC-1202)|
530800|NCT00142792|Device|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
530801|NCT00142779|Drug|Fluoxetine|
530802|NCT00142766|Behavioral|Nurse Implemented Goal-Directed Comfort Algorithm|See description
530803|NCT00142753|Biological|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
530804|NCT00142753|Biological|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
530805|NCT00142753|Biological|Recombivax|Dosage at entry and week 24; non-responders ((<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
530806|NCT00142753|Biological|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
530807|NCT00142727|Drug|Methadone|
530808|NCT00142727|Drug|Full opioid agonist|
530809|NCT00142727|Drug|Partial opioid agonist|
530810|NCT00142727|Drug|Opioid antagonist|
530811|NCT00142714|Procedure|Sympathetic manipulation on sexual arousal in women|
530812|NCT00142701|Behavioral|diet|
530813|NCT00142701|Behavioral|physical activity|
530814|NCT00142701|Behavioral|stress management|
530815|NCT00142701|Behavioral|smoking cessation|
530816|NCT00142688|Behavioral|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
530817|NCT00142688|Behavioral|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
530818|NCT00142675|Behavioral|Physical Activity|
530819|NCT00142662|Behavioral|diet|
530820|NCT00142662|Behavioral|financial incentives|
530821|NCT00142649|Behavioral|diet|
530822|NCT00142649|Behavioral|physical activity|
530823|NCT00142623|Behavioral|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
530824|NCT00142610|Dietary Supplement|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
530825|NCT00142597|Device|Acupuncture|"Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.~Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
530826|NCT00142597|Other|Sham treatment|"Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.~All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
530827|NCT00142584|Drug|Nebivolol|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
530828|NCT00142584|Drug|Metoprolol|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
530829|NCT00142571|Drug|Gemcitabine|
530830|NCT00142571|Drug|Docetaxel|
530831|NCT00142558|Drug|MK0663; etoricoxib / Duration of Treatment: 5 Days|
530832|NCT00142558|Drug|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
530833|NCT00142545|Drug|apomorphine HCl injection|
530834|NCT00142532|Procedure|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.~Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.~Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
530835|NCT00142532|Procedure|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.~Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
530836|NCT00142519|Drug|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
530837|NCT00142519|Drug|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
530880|NCT00142168|Drug|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
530881|NCT00142168|Drug|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
530882|NCT00142155|Drug|Rituximab|
530883|NCT00142155|Drug|monoclonal antibodies|
530884|NCT00142129|Drug|Bortezomib (Velcade)|
530885|NCT00142116|Drug|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
530886|NCT00142116|Drug|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
530838|NCT00142506|Drug|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.~Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
530839|NCT00142506|Drug|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.~In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.~Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
530840|NCT00142493|Drug|Propofol|1.2ug/ml
530841|NCT00142493|Drug|Thiopental Sodium|2.0ug/ml
530842|NCT00142493|Drug|Dexmedetomidine Hydrochloride|0.5ng/ml
530843|NCT00142493|Drug|Midazolam Hydrochloride|60ng/ml
530844|NCT00142493|Drug|placebo|intralipid, saline, saline with multi-Vit solution
530845|NCT00142480|Drug|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
530846|NCT00142480|Drug|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
530847|NCT00142480|Drug|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
530848|NCT00142480|Procedure|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
530849|NCT00142467|Drug|Gemcitabine|
530850|NCT00142467|Drug|Oxaliplatin|
530851|NCT00142467|Drug|Bevacizumab|
530852|NCT00142454|Biological|NY-ESO-1 protein|
530853|NCT00142454|Drug|Imiquimod|
530854|NCT00142441|Device|Pulsed dye laser|
530855|NCT00142428|Drug|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
530856|NCT00142415|Drug|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
530857|NCT00142415|Drug|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m^2 in the initial cohort.
530858|NCT00142402|Drug|Modafinil|
530859|NCT00142389|Biological|pneumococcal polysaccharide and protein conjugate vaccines|
530860|NCT00142350|Drug|continuous infusion of 5-fluorouracil|
530861|NCT00142350|Drug|combination of irinotecan and cisplatin|
530862|NCT00142350|Drug|oral administration of S-1|
530863|NCT00142337|Drug|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
530864|NCT00142337|Drug|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight >60 kg) once daily, starting at the onset of labor and for one month postpartum
530865|NCT00142324|Drug|Donepezil|
530866|NCT00142298|Drug|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
530867|NCT00142285|Drug|Zinc sulphate (20 mg)|
530868|NCT00142272|Drug|Ciprofloxacin|
530869|NCT00142259|Device|Deep brain stimulation of the internal globus pallidus|
530870|NCT00142246|Drug|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
530871|NCT00142246|Other|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
530872|NCT00142233|Dietary Supplement|ANTOX (vers.)1.2|"300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)"
530873|NCT00142233|Drug|Magnesium|"15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)"
530874|NCT00142233|Other|Placebo ANTOX (vers)1.2|Placebo ANTOX (vers)1.2
530875|NCT00142233|Other|Placebo Magnesiocard (2.5 mmol)|Placebo Magnesiocard (2.5 mmol)
530876|NCT00142220|Drug|Defined percentage of omega-3-fatty acids|
530877|NCT00142207|Drug|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
530878|NCT00142207|Device|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
530879|NCT00142181|Drug|Campath-1H|Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
530887|NCT00142103|Drug|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
530888|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
530889|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
530890|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
530891|NCT00142103|Drug|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
530892|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
530893|NCT00142090|Drug|3% Hypertonic saline|
530894|NCT00142090|Drug|Placebo|Normal saline
530895|NCT00142077|Device|Electronic health record and messaging system|
530896|NCT00142064|Behavioral|observed levels of pain|
530897|NCT00142051|Drug|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
530898|NCT00142051|Drug|oxygen|oxygen fi02 21% (room air)
530899|NCT00142038|Drug|Docetaxel|
530900|NCT00142038|Drug|Capecitabine|
530901|NCT00142025|Drug|Oxcarbazepine|
530902|NCT00142012|Behavioral|Nutrition Intervention|
530903|NCT00141999|Biological|hepatitis B vaccine|
530904|NCT00141986|Dietary Supplement|vitamin D3|2000 IU per day
530905|NCT00141986|Dietary Supplement|vitamin D3|400 IU per os once daily
530906|NCT00141960|Drug|Famotidine|
530907|NCT00141947|Drug|bexarotene (Targretin)|
530908|NCT00141934|Drug|AD 452|
530909|NCT00141921|Drug|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
530910|NCT00141908|Drug|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
530911|NCT00141908|Drug|Castor oil|weekly IM injections
530912|NCT00141895|Drug|Misoprostol|2 tablets 200 micrograms Vaginal route
530913|NCT00141895|Drug|Misoprostol|2 tablets of 200 micrograms Sublingual route
530914|NCT00141882|Drug|memantine|
530915|NCT00141856|Behavioral|Telephone care|
530916|NCT00141843|Genetic|ReFacto AF|
530917|NCT00141843|Genetic|B-Domain deleted Recombinant Factor VIII|
530918|NCT00141843|Genetic|BDDrFVIII|
530919|NCT00141830|Drug|Methotrexate plus ERB-041 for 12 weeks|
530920|NCT00141830|Drug|Placebo for 12 weeks|
530921|NCT00141817|Drug|pantoprazole for approximately 9 weeks.|
530922|NCT00141804|Drug|Sirolimus|
530923|NCT00141791|Drug|Etanercept|
530924|NCT00141778|Drug|Placebo|Matching placebo taken once a day
530925|NCT00141778|Drug|Ramipril|Taken orally, once a day
530926|NCT00141778|Drug|Spironolactone|Taken orally, once a day
530927|NCT00141765|Procedure|Myeloablative Chemotherapy|High dose chemotherapy (carboplatin and thiotepa) transplant rescue
530928|NCT00141765|Procedure|Stem Cell Rescue|autologous stem cell transplantation
530929|NCT00141752|Device|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
530930|NCT00141739|Drug|Etanercept|"Etanercept 0.4 mg/kg per dose [maximum dose 25 mg] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.~Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant."
530931|NCT00141726|Drug|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
530932|NCT00141713|Drug|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
530933|NCT00141700|Drug|Rituximab|
530934|NCT00141687|Procedure|Early ECV between 34 0/7 and 35 6/7 weeks|Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation
530935|NCT00141687|Procedure|Delayed ECV at or after 37 0/7 weeks|Delayed external cephalic version at or after 37 0/7 weeks of gestation
530936|NCT00141674|Procedure|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
530937|NCT00141661|Drug|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
530938|NCT00141661|Drug|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
530939|NCT00141661|Drug|Placebo Comparator|Matching placebo.
530940|NCT00141648|Drug|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
530941|NCT00141648|Radiation|Radiotherapy|Total 45 Gy in 25 fractions
530942|NCT00141635|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|
530943|NCT00141622|Drug|Slow sodium|
530944|NCT00141609|Drug|Slow Sodium|
530945|NCT00141596|Drug|Cardura XL 4 mg bd|
530946|NCT00141596|Drug|Amiloride 5 mg bd|
530947|NCT00141596|Drug|Furosemide 40 mg bd|
530948|NCT00141583|Drug|Enalapril 20 mg bd|
530949|NCT00141583|Drug|Candesartan 8 mg bd|
530950|NCT00141570|Drug|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
530951|NCT00141557|Drug|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
530952|NCT00141557|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
530953|NCT00141544|Drug|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
530954|NCT00141544|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
542062|NCT00012311|Drug|methotrexate|
530955|NCT00141531|Drug|Apaziquone|"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.~In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."
530956|NCT00141518|Drug|Levodopa-carbidopa intestinal gel (LCIG)|
530957|NCT00141518|Device|CADD-Legacy® 1400 ambulatory infusion pump|
530958|NCT00141518|Device|percutaneous endoscopic gastrostomy tube (PEG tube)|
530959|NCT00141518|Device|jejunal extension tube (J-tube)|
530960|NCT00141505|Drug|Bifeprunox|
530961|NCT00141492|Drug|Androgel (testosterone gel)|
530962|NCT00141479|Drug|Bifeprunox|
530963|NCT00141466|Behavioral|Education for professionals|
530964|NCT00141466|Behavioral|Distribution of educational materials|
530965|NCT00141466|Behavioral|Feedback for professionals|
530966|NCT00141466|Behavioral|Reminders for professionals|
530967|NCT00141453|Drug|olmesartan medoxomil|Tablets 10, 20, or 40 mg
530968|NCT00141453|Drug|Placebo Tablets|Matching placebo tablets
530969|NCT00141440|Procedure|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
530970|NCT00141427|Drug|Pregabalin|
530971|NCT00141414|Drug|Pregabalin|
530972|NCT00141401|Drug|Pregabalin|
530973|NCT00141388|Drug|Pregabalin|
530974|NCT00141375|Drug|Pregabalin|
530975|NCT00141362|Drug|Pregabalin|
530976|NCT00141349|Drug|UK-369,003|
530977|NCT00141336|Drug|Pregabalin|
530978|NCT00141323|Drug|lasofoxifene|0.5 mg once per day, orally
530979|NCT00141323|Other|placebo|placebo
530980|NCT00141323|Drug|lasofoxifene|0.25 mg once per day, orally
530981|NCT00141310|Drug|Sildenafil citrate|
530982|NCT00141297|Drug|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
530983|NCT00141284|Drug|nelfinavir 1,250 mg twice daily|
530984|NCT00141284|Drug|Zidovudine 300 mg twice daily|
530985|NCT00141284|Drug|Lamivudine 150 mg twice daily|
530986|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
530987|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
530988|NCT00141271|Drug|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
530989|NCT00141258|Drug|pregabalin|
530990|NCT00141245|Drug|Pregabalin|
530991|NCT00141232|Drug|Atorvastatin and Omega-3 fatty acids|
530992|NCT00141219|Drug|pregabalin|150-600mg/day, BID
530993|NCT00141219|Drug|Placebo|Placebo
530994|NCT00141206|Drug|varenicline (CP-526,555)|
530995|NCT00141193|Drug|Celecoxib|
530996|NCT00141180|Drug|CP-481,715|
530997|NCT00141167|Drug|varenicline|
530998|NCT00141154|Drug|Celecoxib|
530999|NCT00141154|Drug|Placebo|
531000|NCT00141154|Drug|Loxoprofen|
531001|NCT00141141|Drug|Atorvastatin|
531002|NCT00141141|Drug|Simvastatin|
531003|NCT00141128|Drug|SS-RBX|
531004|NCT00141115|Drug|levetiracetam|Levetiracetam 1500 mg BID
531005|NCT00141102|Drug|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
531006|NCT00141102|Drug|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
531007|NCT00141089|Drug|Tegaserod|
531008|NCT00141076|Behavioral|low vs high glycemic index diet|
531009|NCT00141063|Drug|Focalin XR|
531010|NCT00141050|Drug|Focalin XR|
531011|NCT00141037|Drug|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)~Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
531012|NCT00141037|Drug|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
531013|NCT00141037|Drug|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40 kg and 1.5 mg/kg/day in subjects weighing >40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
531014|NCT00141037|Drug|Tacrolimus|Taken orally from immediately preoperatively to those>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects <age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) &5-7 ng/mL >= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 & 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
531015|NCT00141037|Drug|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
531016|NCT00141037|Drug|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
531017|NCT00141037|Drug|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
531018|NCT00141024|Biological|EP HIV-1043|"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.~The vaccine is provided in single-use 1.1-mL vials."
531019|NCT00141024|Biological|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
531020|NCT00141011|Drug|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
531021|NCT00141011|Drug|Placebo|0.6 mL/kg/hr
531022|NCT00140998|Drug|17 beta estradiol|
531023|NCT00140985|Drug|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
531024|NCT00140985|Drug|Comparator: amlodipine / Duration of Treatment: 20 weeks|
531025|NCT00140972|Drug|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
531026|NCT00140972|Drug|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
531027|NCT00140959|Drug|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
531028|NCT00140959|Drug|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
531029|NCT00140946|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
531030|NCT00140946|Drug|Comparator: placebo / Duration of Treatment: 16 weeks|
531031|NCT00140933|Drug|MK0966; rofecoxib|
531032|NCT00140933|Drug|Comparator: diclofenac, placebo|
531033|NCT00140920|Drug|MK0966; rofecoxib|
531034|NCT00140920|Drug|Comparator: diclofenac 2x 75 mg|
531035|NCT00140907|Drug|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
531036|NCT00140907|Drug|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
531037|NCT00140894|Drug|MK0966; rofecoxib / Duration of Treatment: 24 weeks|
531038|NCT00140894|Drug|Comparator: placebo / Duration of Treatment: 24 weeks|
531039|NCT00140881|Drug|MK0476; montelukast sodium|
531040|NCT00140881|Drug|Comparator: placebo|
531041|NCT00140868|Device|Luminal stents|
531042|NCT00140868|Procedure|Minimally Invasive Surgical Bowel Diversion|
531043|NCT00140855|Drug|Anti-CTLA4 (monoclonal antibody MDX-010)|
531044|NCT00140816|Behavioral|Increased intake of dairy products|
531045|NCT00140803|Drug|Visudyne|
531046|NCT00140803|Drug|Kenalog|
531047|NCT00140790|Drug|valsartan|valsartan 40 or 160 (80) mg per day
531048|NCT00140764|Drug|Metronidazole gel versus placebo gel|
531049|NCT00140751|Drug|Lopinavir/ritonavir (drug)|
531050|NCT00140738|Biological|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
531051|NCT00140725|Drug|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
531052|NCT00140725|Drug|Lamivudine|
531053|NCT00140712|Drug|Ropinirole Immediate Release|Ropinirole Immediate Release
531054|NCT00140699|Behavioral|Balance|
531055|NCT00140686|Biological|Rotavirus (vaccine)|
531056|NCT00140673|Biological|Rotavirus|
531057|NCT00140660|Drug|rituximab|375 mg/m2 on D1
531058|NCT00140647|Drug|Ramipril|
531059|NCT00140647|Drug|Rosiglitazone|
531060|NCT00140634|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
531061|NCT00140621|Drug|Agalsidase beta|
531062|NCT00140608|Device|Seprapack Sinus Dressing|
531063|NCT00140595|Drug|rituximab|
531064|NCT00140595|Drug|doxorubicin|
531065|NCT00140595|Drug|cyclophosphamide|
531066|NCT00140582|Drug|Rituximab|rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
531067|NCT00140569|Procedure|CHVP + interferon|
531068|NCT00140569|Drug|fludarabine|
531069|NCT00140569|Procedure|CHOP + TBI and autotransplant|
531070|NCT00140556|Radiation|Chemoradiotherapy|External beam radiation daily (M-F)
531071|NCT00140556|Drug|Cisplatin|Cisplatin week 1 and 5 of radiation
531072|NCT00140556|Drug|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
531073|NCT00140556|Drug|Erlotinib|Erlotinib daily during radiation
531074|NCT00140543|Drug|sirolimus versus mycophenolate mofetil|
531075|NCT00140530|Device|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
531076|NCT00140530|Device|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
531077|NCT00140517|Drug|sulphadoxine-pyrimethamine|
531078|NCT00140517|Drug|chloroquine|
531079|NCT00140504|Other|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
531080|NCT00140491|Device|Vision Restoration Therapy (NOVAVISION)|
531081|NCT00140478|Drug|Mifepristone|200mg orally once daily
531082|NCT00140465|Drug|Clopidogrel|after PCI
531083|NCT00140465|Drug|Clopidogrel|after PCI
531084|NCT00140452|Drug|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
531085|NCT00140439|Behavioral|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:~Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.~Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.~Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
531086|NCT00140426|Drug|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
531087|NCT00140426|Drug|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
531088|NCT00140413|Drug|Nutropin AQ|Daily injection. Dosage dependent on weight.
531089|NCT00140400|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
531090|NCT00140387|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
531091|NCT00140374|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
531092|NCT00140361|Drug|Sulfadoxine-pyrimethamine|
531093|NCT00140361|Drug|sulfadoxine-pyrimethamine plus artesunate|
531094|NCT00140361|Drug|lumefantrine plus artemether|
531095|NCT00140361|Behavioral|Sleeping under insecticide-treated bednet|
531096|NCT00140348|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
531097|NCT00140335|Behavioral|handwashing|
531098|NCT00140322|Behavioral|Exercise, fall risk reduction|
531099|NCT00140309|Drug|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
531100|NCT00140296|Behavioral|Contraceptive counseling|
531101|NCT00140283|Procedure|Educational interactive intervention|
531102|NCT00140270|Behavioral|PEP program|
531103|NCT00140257|Drug|Escitalopram|
531104|NCT00140244|Drug|r-metHuLeptin|
531105|NCT00140244|Drug|Placebo|
531106|NCT00140231|Drug|r-metHuLeptin|recombinant human leptin
531107|NCT00140231|Other|placebo|placebo (no active drug)
531108|NCT00140218|Drug|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
531109|NCT00140205|Drug|r-metHuLeptin|r-metreleptin was given in 3 different dose in fed and fasting states
531110|NCT00140192|Drug|creatine|
531111|NCT00140179|Drug|valnoctamide|
531112|NCT00140166|Drug|niacinamide|
531113|NCT00140166|Drug|pyridoxine|
531114|NCT00140166|Drug|ascorbate|
531115|NCT00140153|Drug|testosterone gel (Androgel)|
531116|NCT00140140|Drug|ABI-007|Weekly intravenous infusions over 30 minutes.
531117|NCT00140140|Drug|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
531118|NCT00140140|Drug|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor."
531119|NCT00140140|Biological|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was >20,000/mm^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor."
531120|NCT00140114|Drug|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
531121|NCT00140101|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
531122|NCT00140101|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
531123|NCT00140088|Drug|ALGRX 3268|
531124|NCT00140075|Drug|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2~Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
531125|NCT00140075|Drug|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle~Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
531126|NCT00140062|Drug|latanoprost 0.005% (Xalatan)|
531127|NCT00140049|Drug|Xalacom|
531128|NCT00140049|Drug|Cosopt|
531129|NCT00140036|Procedure|Blood draw|
531130|NCT00140023|Drug|Azithromycin microspheres 2.0 single dose|
531131|NCT00140010|Drug|erythropoietin beta|30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
531132|NCT00139997|Device|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
531133|NCT00139997|Device|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
531134|NCT00139984|Device|24 hour blood pressure measurement|
531135|NCT00139971|Drug|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
531136|NCT00139971|Drug|UFT 250mg/m2, daily for 1 year|
531137|NCT00139945|Drug|Human acylated ghrelin|5 pmol/kg body weight per min
531138|NCT00139932|Drug|formoterol fumarate|
531139|NCT00139919|Drug|Bifeprunox|
531140|NCT00139906|Drug|Bifeprunox|
531141|NCT00139893|Drug|Reglan ODT|
531142|NCT00139880|Drug|Parcopa|
531143|NCT00139867|Drug|PARCOPA|
531144|NCT00139854|Drug|Alprazolam orally disintegrating tablets|
531145|NCT00139841|Drug|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
531146|NCT00139828|Drug|human coagulation Factor IX|
531147|NCT00139815|Drug|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
531148|NCT00139815|Drug|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
531149|NCT00139802|Device|Coronary Stent Implantation|
531150|NCT00139789|Drug|Kemstro|
531151|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed."
531152|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
531153|NCT00139763|Procedure|Educational Materials|
531154|NCT00139750|Drug|CP-526,555 (varenicline)|
531155|NCT00139737|Drug|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
531156|NCT00139724|Drug|tolterodine extended release capsule|
531157|NCT00139711|Drug|Irinotecan|
531158|NCT00139711|Drug|Docetaxel|
531159|NCT00139698|Drug|olmesartan alone or in combination with hydrochlorothiazide|
531160|NCT00139685|Drug|Depo-Provera Contraceptive Injection - DP150CI|
531161|NCT00139672|Drug|PD-217,014|
531162|NCT00139659|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
531163|NCT00139659|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
531164|NCT00139646|Drug|Parecoxib|
531165|NCT00139646|Drug|Diclofenac|
531166|NCT00139633|Drug|carboplatin, 5FU, Taxol and radiation|
531167|NCT00139620|Drug|Tarceva, erlotinib, OSI-774|
531168|NCT00139607|Drug|Paracoxib|
531169|NCT00139594|Drug|licarbazepine|
531170|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
531171|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
531172|NCT00139568|Drug|Tegaserod|
531173|NCT00139555|Drug|amlodipine/benazepril|
531174|NCT00139542|Other|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
531175|NCT00139542|Other|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
531176|NCT00139529|Behavioral|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
531177|NCT00139529|Behavioral|Educational Intervention|Educational intervention will be completed during pregnancy.
531178|NCT00139516|Behavioral|self-help|
531179|NCT00139516|Drug|nicotine replacement therapy|
531180|NCT00139516|Behavioral|smoking cessation|
531181|NCT00139490|Behavioral|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
531182|NCT00139490|Behavioral|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
531183|NCT00139490|Behavioral|Control Group|Usual Care
531184|NCT00139477|Drug|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
531185|NCT00139477|Behavioral|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
531186|NCT00139477|Behavioral|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
531187|NCT00139451|Drug|Pediasure|With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.
531188|NCT00139451|Drug|GH|Growth Hormone will be 0.3mg/kg/week, given SC once daily.
531189|NCT00139438|Behavioral|Disease Management Assessment|
531190|NCT00139425|Behavioral|Disease Management Assessment|
531191|NCT00139399|Procedure|Coronary artery bypass graft (CABG) surgery|Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
531192|NCT00139386|Drug|Candesartan|Candesartan Cilexetil (4-12 mg per day)
531193|NCT00139373|Drug|donepezil|
531194|NCT00139360|Drug|Bevacizumab|Anti angiogenesis treatment
531195|NCT00139347|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
531196|NCT00139334|Biological|Rotavirus|
531197|NCT00139321|Device|Force platform and electromyography|
531198|NCT00139308|Device|high frequency stimulation|
531199|NCT00139295|Device|Hylastan|
531200|NCT00139282|Drug|Squalamine Lactate|
531201|NCT00139269|Drug|Docetaxel|
531202|NCT00139269|Drug|Cisplatin|
531203|NCT00139269|Drug|5-Fluorouracil|
531204|NCT00139256|Drug|Betamethasone|Betamethasone injection
531205|NCT00139243|Drug|Taxotere|
531206|NCT00139243|Drug|Cisplatin|
531207|NCT00139243|Drug|5-Fluorouracil|
531208|NCT00139243|Drug|Leucovorin|
531209|NCT00139230|Drug|Taxotere|
531210|NCT00139230|Drug|Cisplatin|
531211|NCT00139230|Drug|5-Fluorouracil|
531212|NCT00139230|Drug|Leucovorin|
531213|NCT00139230|Drug|G-CSF|
531214|NCT00139230|Drug|Ciprofloxacin|
531215|NCT00139217|Drug|iNO|
531216|NCT00139217|Procedure|Non-invasive nitric oxide|
531217|NCT00139204|Procedure|C11 Methionine PET scan|
531218|NCT00139191|Procedure|C-11 acetate PET scan|
531219|NCT00139178|Drug|Different HAART regimens|
531220|NCT00139165|Drug|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
531221|NCT00139165|Procedure|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
531222|NCT00139152|Drug|Placebo|Saline, Sub-Cuteanous (SQ)
531223|NCT00139152|Drug|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
531224|NCT00139139|Biological|Hepatitis A vaccine|
531225|NCT00139126|Behavioral|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
531226|NCT00139113|Biological|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
531227|NCT00139100|Drug|antimicrobial agent in soap|
531228|NCT00139087|Behavioral|Telephone Outreach for Therapy|
531229|NCT00139074|Drug|Quetiapine fumarate|oral variable dose
531230|NCT00139074|Drug|sodium valproate|oral
531231|NCT00139061|Drug|Torcetrapib/Atorvastatin|
531232|NCT00139061|Drug|Fenofibrate|
531233|NCT00139048|Behavioral|Decision Aid|
531234|NCT00139035|Drug|cyclosporine A|
531235|NCT00139022|Device|Continuous Positive Airway Pressure|
531236|NCT00139009|Drug|Cyclosporine A|
531237|NCT00138996|Device|automated direct feedback on CPR from defibrillator|
531238|NCT00138983|Drug|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
531239|NCT00138970|Drug|Zenapax®, CellCept® and prednisolone|
531240|NCT00138970|Drug|Sandimmun Neoral®, CellCept® and prednisolone|
531241|NCT00138957|Procedure|Laparoscopic parastomal hernia repair with mesh|
531242|NCT00138944|Drug|placebo|od
531243|NCT00138944|Drug|eplerenone|50mg od
531244|NCT00138931|Procedure|Blood draw (genetic testing)|Blood draw (genetic testing)
531245|NCT00138918|Biological|OGX-011|See Detailed Description, Treatment Plan
531246|NCT00138905|Device|UMTS mobile basestation radiation|
531247|NCT00138892|Procedure|Waiting time (access time to Total joint replacement)|See Detailed Description.
531248|NCT00138866|Drug|Risedronate|
531249|NCT00138853|Device|Tibial component|Tibial component inserted at the time of surgery
531250|NCT00138840|Drug|STA-5326 mesylate|
531251|NCT00138827|Drug|Biotene (mouth care)|
531252|NCT00138814|Procedure|Radiotherapy (boost versus no boost)|
531253|NCT00138801|Drug|Ceftriaxone|
531254|NCT00138801|Drug|Doxycycline|
531255|NCT00138788|Procedure|Radiotherapy, dose fractionation|
531256|NCT00138775|Drug|D-serine|
531257|NCT00138762|Drug|torcetrapib/atorvastatin|
531258|NCT00138762|Drug|atorvastatin|
531259|NCT00138762|Drug|placebo|
531260|NCT00138749|Drug|SS-RBX|
531261|NCT00138736|Drug|Mannan Binding Lectin (MBL)|
531262|NCT00138736|Drug|Mannan Binding Lectin|"MBL dose at a twice weekly dose interval (3 or 4 days):~0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval"
531263|NCT00138723|Drug|SPM 907|
531264|NCT00138710|Drug|Letrozole (Femara)|
531265|NCT00138697|Drug|IVIG-L|
531266|NCT00138684|Procedure|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
531267|NCT00138671|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
531268|NCT00138671|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
531334|NCT00137995|Drug|Rituximab|375 mg/m² D-2/D1
531335|NCT00137995|Drug|Etoposide|100 mg/m² D1-D2-D3
531336|NCT00137995|Drug|Carboplatine|max 800mg D2
531337|NCT00137995|Drug|Ifosfamide + Mesna|5 g/m² from D2 to D13
531338|NCT00137995|Drug|Cisplatine|100 mg/m² from D1 to D13
531269|NCT00138658|Drug|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
531270|NCT00138645|Behavioral|MicroDiet|MicroDiet
531271|NCT00138645|Behavioral|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
531272|NCT00138632|Drug|PTK787|Visudyne® + PTK787, 500 mg/day
531273|NCT00138632|Drug|PTK787|Visudyne® + PTK787 1000 mg/day
531274|NCT00138632|Drug|Placebo|Visudyne® + Placebo
531275|NCT00138619|Drug|vildagliptin|
531276|NCT00138606|Drug|vildagliptin|
531277|NCT00138593|Drug|vildagliptin|
531278|NCT00138580|Drug|vildagliptin|
531279|NCT00138567|Drug|vildagliptin|
531280|NCT00138554|Drug|vildagliptin|
531281|NCT00138554|Drug|pioglitazone|pioglitazone 45 mg qd
531282|NCT00138541|Drug|vildagliptin|
531283|NCT00138528|Drug|Fluvastatin|
531284|NCT00138515|Drug|vildagliptin|
531285|NCT00138476|Drug|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
531286|NCT00138476|Biological|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses [reverse transcription polymerase chain reaction (RT-PCR) Units] 4800, 48, 4.8, 0.48.
531287|NCT00138424|Drug|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
531288|NCT00138424|Drug|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
531289|NCT00138411|Drug|Ciprofloxacin 500 mg|
531290|NCT00138411|Drug|ETI-204 (Anthim)|
531291|NCT00138398|Biological|Commercial TriValent Split Influenza Virus|
531292|NCT00138385|Biological|FluMist|
531293|NCT00138385|Biological|Fluzone|
531294|NCT00138359|Drug|Niclosamide|
531295|NCT00138294|Biological|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
531296|NCT00138281|Biological|FluMist|
531297|NCT00138281|Biological|Fluzone|
531298|NCT00138242|Drug|carboplatin|
531299|NCT00138242|Drug|docetaxel|
531300|NCT00138242|Procedure|adjuvant therapy|
531301|NCT00138229|Biological|aldesleukin|
531302|NCT00138229|Biological|filgrastim|
531303|NCT00138229|Biological|therapeutic autologous lymphocytes|
531304|NCT00138229|Drug|cyclophosphamide|
531305|NCT00138229|Drug|fludarabine phosphate|
531306|NCT00138216|Drug|irinotecan hydrochloride|
531307|NCT00138216|Drug|temozolomide|
531308|NCT00138216|Drug|vincristine sulfate|
531309|NCT00138203|Drug|vorinostat|Given PO
531310|NCT00138203|Other|laboratory biomarker analysis|Correlative studies
531311|NCT00138177|Drug|oxaliplatin|Given IV
531312|NCT00138177|Drug|leucovorin calcium|Given IV
531313|NCT00138177|Drug|vorinostat|Given orally
531314|NCT00138177|Drug|fluorouracil|Given IV
531315|NCT00138164|Biological|denileukin diftitox|
531316|NCT00138151|Biological|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
531317|NCT00138151|Drug|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
531318|NCT00138151|Drug|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
531319|NCT00138138|Drug|Ritalin|
531320|NCT00138125|Drug|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
531321|NCT00138125|Biological|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
531322|NCT00138112|Drug|Empirical Vancomycin|
531323|NCT00138112|Drug|Prophylactic Vancomycin|
531324|NCT00138099|Drug|Fragmin (dalteparin sodium)|
531325|NCT00138086|Drug|Zevalin plus BEAM|
531326|NCT00138073|Device|Web-based waveform interpretation guide|Use of an educational website.
531327|NCT00138060|Drug|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
531328|NCT00138060|Drug|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
531329|NCT00138047|Drug|zinc supplementation|
531330|NCT00138034|Procedure|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
531331|NCT00138021|Device|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk & Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
531332|NCT00138008|Drug|endocrine therapy|Drug: endocrine therapy
531333|NCT00138008|Procedure|radiotherapy|Procedure/Surgery: radiotherapy
531339|NCT00137995|Drug|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
531340|NCT00137995|Drug|Dexamethasone|40 mg From D1 to D4
531341|NCT00137995|Procedure|Autologous Stem Cell Transplantation|
531342|NCT00137995|Drug|BCNU|300mg/m² on D-6
531343|NCT00137995|Drug|Etoposide|200 mg/m² from D-6 to D-3
531344|NCT00137995|Drug|Cytarabine|100 mg/m² from D-6 to D-3
531345|NCT00137995|Drug|Melphalan|140 mg/m² on D-2
531346|NCT00137982|Procedure|Treatment of ectopic pregnancy|
531347|NCT00137969|Drug|Rituximab|Rituximab will be supplied as a sterile liquid for IV administration.
531348|NCT00137969|Drug|Placebo|Placebo will be supplied as a sterile liquid for IV administration.
531349|NCT00137969|Drug|Prednisone|
531350|NCT00137969|Drug|Acetaminophen|
531351|NCT00137969|Drug|Diphenhydramine|
531352|NCT00137956|Device|Emphasys Endobronchial Valve (EBV) Device and Procedure|
531353|NCT00137943|Behavioral|Full Parent communication intervention|
531354|NCT00137943|Behavioral|Brief Parent Communication Intervention|
531355|NCT00137943|Behavioral|Control Parent Intervention|
531356|NCT00137930|Biological|Live attenuated rotavirus vaccine|
531357|NCT00137917|Biological|Meningococcal serogroup B vaccine|
531358|NCT00137891|Drug|Modified Release rhTSH|
531359|NCT00137878|Drug|TNFerade™|
531360|NCT00137865|Genetic|EGEN-001 (phIL-12-005/PPC)|
531361|NCT00137852|Drug|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
531362|NCT00137852|Drug|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
531363|NCT00137852|Drug|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
531364|NCT00137852|Procedure|Radiation Therapy|5 days a week for 5-6 weeks
531365|NCT00137852|Procedure|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
531366|NCT00137839|Drug|Erlotinib|
531367|NCT00137826|Drug|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
531368|NCT00137826|Drug|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
531369|NCT00137813|Drug|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
531370|NCT00137813|Drug|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
531371|NCT00137800|Drug|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
531372|NCT00137787|Drug|ciprofloxacin|
531373|NCT00137787|Drug|cefepime|
531374|NCT00137774|Drug|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
531375|NCT00137774|Drug|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
531376|NCT00137761|Drug|ZD 1839|Taken orally once daily
531377|NCT00137761|Drug|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
531378|NCT00137748|Drug|CMV-Ig|Drug: CMV-Ig
531379|NCT00137735|Drug|Gabapentin|300mg tds
531380|NCT00137735|Other|placebo|tds
531381|NCT00137722|Behavioral|Education of providers and their staff|
531382|NCT00137722|Behavioral|Case management|
531383|NCT00137722|Behavioral|Payment for desired behaviors|
531384|NCT00137709|Drug|Sodium valproate|Week 1 & 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
531385|NCT00137709|Drug|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
531386|NCT00137696|Biological|Vaccination with inactivated polio vaccine|
531387|NCT00137696|Procedure|Collection of serum|
531388|NCT00137683|Behavioral|one-on-one education, group education, small media|
531389|NCT00137670|Device|Video-based HIV/STD prevention intervention|
531390|NCT00137657|Drug|Cotrimoxazole (trimethoprim sulfamethoxazole)|
531391|NCT00137644|Behavioral|Preventing AIDS Through Live Movement and Sound (PALMS)|
531392|NCT00137631|Behavioral|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
531393|NCT00137618|Behavioral|Educational Intervention to Increase Informed Decision Making for Prostate Cancer Screening|
531394|NCT00137605|Biological|Pneumovax|
531395|NCT00137605|Biological|Prevnar|
531396|NCT00137592|Behavioral|small media, group education (multicomponent)|
531397|NCT00137579|Procedure|Influenza vaccine intramuscular administration route|
531398|NCT00137566|Drug|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
531399|NCT00137566|Other|Placebo|
531400|NCT00137553|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
531401|NCT00137540|Device|RF ablation|
531402|NCT00137540|Drug|anti-arrhythmic drug therapy|
531403|NCT00137527|Device|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
531404|NCT00137514|Drug|chloroquine|
531405|NCT00137514|Drug|amodiaquine|
531406|NCT00137501|Drug|Nifedipine|"Arm A:~Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.~Arm B:~Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks."
531474|NCT00136929|Procedure|Percutaneous coronary intervention (PCI)|
542063|NCT00012311|Drug|thiotepa|
531407|NCT00137488|Device|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
531408|NCT00137475|Procedure|Intensity-Modulated Radiation Therapy|
531409|NCT00137462|Drug|torcetrapib/atorvastatin|
531410|NCT00137462|Drug|atorvastatin|
531411|NCT00137449|Drug|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
531412|NCT00137436|Drug|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
531413|NCT00137436|Drug|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
531414|NCT00137436|Drug|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
531415|NCT00137423|Drug|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
531416|NCT00137410|Drug|Celebrex|
531417|NCT00137397|Drug|Tolterodine ER|
531418|NCT00137397|Drug|Placebo|
531419|NCT00137371|Drug|PVC (daily for 21 days, 7 days off)|
531420|NCT00137371|Drug|PVC (twice weekly)|
531421|NCT00137358|Procedure|Radiation Therapy|
531422|NCT00137358|Drug|Cisplatin|
531423|NCT00137358|Drug|Amifostine|
531424|NCT00137345|Drug|sirolimus|
531425|NCT00137332|Drug|GAP-486 (ZP-123)|
531426|NCT00137332|Drug|0.9% Sodium Chloride, USP|
531427|NCT00137319|Device|Impedance threshold device|
531428|NCT00137306|Procedure|Facilitate evidence-based treatment for depression|
531429|NCT00137293|Drug|GAP-486 (ZP-123)|
531430|NCT00137293|Drug|0.9% Sodium Chloride, USP|
531431|NCT00137280|Behavioral|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
531432|NCT00137267|Behavioral|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
531433|NCT00137267|Behavioral|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
531434|NCT00137254|Drug|Insulin|IV insulin
531435|NCT00137254|Drug|Stable Isotopes|IV administration of stable isotopes
531436|NCT00137254|Drug|Indocyanine Green|IV administration of ICG
531437|NCT00137228|Procedure|figure-of-eight hand measurements|
531438|NCT00137228|Procedure|water volumetry hand measurements|
531439|NCT00137215|Device|Silverlon|dressing for donor site mamagement
531440|NCT00137202|Drug|Ondansetron (Zofran)|
531441|NCT00137202|Drug|Diphenhydramine (Benadryl)|
531442|NCT00137189|Procedure|Resource-oriented music therapy|
531443|NCT00137189|Procedure|Standard care|
531444|NCT00137176|Drug|Rebif|Rebif 44mcg TIW
531445|NCT00137163|Device|Dermafill Dressing|
531446|NCT00137150|Procedure|Placement of implants|
531447|NCT00137137|Procedure|Placement of the mini-screw|
531448|NCT00137124|Drug|L-Arginine|oral administration of L-arginine for 4 weeks
531449|NCT00137111|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
531450|NCT00137111|Drug|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
531451|NCT00137111|Drug|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
531452|NCT00137111|Drug|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
531453|NCT00137111|Procedure|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
531454|NCT00137111|Procedure|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
531455|NCT00137098|Drug|Caffeine|
531456|NCT00137085|Drug|ketamine|
531457|NCT00137072|Drug|Viagra (Sildenafil Citrate) 100 mg|
531458|NCT00137059|Drug|acetaminophen sustained-release|
531459|NCT00137046|Drug|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
531460|NCT00137046|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
531461|NCT00137033|Drug|Celecoxib|
531462|NCT00137033|Drug|Naproxen|
531463|NCT00137033|Drug|ASA|
531464|NCT00137020|Drug|ziprasidone|
531465|NCT00137007|Drug|Azithromycin|
531466|NCT00137007|Drug|Ampicillin/sulbactam|
531467|NCT00136994|Drug|Ziprasidone|
531468|NCT00136981|Drug|torcetrapib/atorvastatin|
531469|NCT00136981|Drug|atorvastatin|
531470|NCT00136968|Drug|Voriconazole|
531471|NCT00136955|Drug|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
531472|NCT00136942|Drug|Atorvastatin|
531473|NCT00136929|Drug|Thrombolytic therapy|
531475|NCT00136916|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
531476|NCT00136916|Drug|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
531477|NCT00136903|Drug|Prochymal - 2 million cells|2 million cells/kg actual body weight, intravenously on study Days 1 and 4
531478|NCT00136903|Drug|Prochymal - 8 million cells|8 million cells/kg actual body weight intravenously on study Days 1 and 4
531479|NCT00136890|Procedure|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
531480|NCT00136877|Procedure|(adeno)tonsillectomy|
531481|NCT00136864|Procedure|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
531482|NCT00136851|Drug|amlodipine besylate/benazepril hydrochloride|
531483|NCT00136838|Behavioral|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
531484|NCT00136825|Drug|N-Acetylcysteine|
531485|NCT00136825|Drug|Placebo|
531486|NCT00136812|Behavioral|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
531487|NCT00136799|Drug|Fluvastatin|
531488|NCT00136786|Drug|Memantine|
531489|NCT00136773|Drug|amlodipine/benazepril|
531490|NCT00136760|Drug|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
531491|NCT00136760|Drug|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
531492|NCT00136760|Drug|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
531493|NCT00136760|Drug|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
531494|NCT00136747|Drug|Memantine|Two capsules of Memantine twice daily for 12 days.
531495|NCT00136747|Drug|bupropion|
531496|NCT00136747|Drug|placebo|
531497|NCT00136734|Drug|Methylphenidate|
531498|NCT00136734|Other|placebo|placebo
531499|NCT00136708|Procedure|Neonatal Resuscitation|
531500|NCT00136695|Drug|anastrozole|1 mg QD
531501|NCT00136682|Drug|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
531502|NCT00136682|Drug|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
531503|NCT00136669|Procedure|Acupuncture|
531504|NCT00136656|Drug|antibiotic|cephalosporine by oral route : cefixime
531505|NCT00136656|Drug|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
531506|NCT00136643|Drug|Invisible Condom®|
531507|NCT00136617|Drug|chlordiazepoxide|
531508|NCT00136604|Biological|Tritanrix-HepB|GlaxoSmithKline (GSK) Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis-hepatitis B vaccine
531509|NCT00136604|Biological|Mencevax™ ACWY|GSK Biologicals' Meningococcal serogroups A, C, W135 and Y polysaccharide vaccine
531510|NCT00136604|Biological|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
531511|NCT00136604|Biological|Meningitec™|Wyeth's MenC CRM197 conjugated vaccine, Meningitec
531512|NCT00136604|Biological|Hib-MenAC-TT|GSK Biologicals' combined Haemophilus influenzae type b-Neisseria meningitidis serogroup A and C-tetanus toxoid conjugate vaccine
531513|NCT00136591|Drug|Bortezomib|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
531514|NCT00136591|Drug|Bortezomib|Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
531515|NCT00136578|Drug|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
531516|NCT00136578|Drug|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
531517|NCT00136565|Drug|Velcade|1.5 mg/m², D1, D5, 4 cycles
531518|NCT00136565|Drug|Doxorubicin|75 mg/m², D1, 4 cycles
531519|NCT00136565|Drug|Prednisone|60 mg/m², D1-D5, 4 cycles
531520|NCT00136565|Drug|Cyclophosphamide|1200 mg/m², D1, 4 cycles
531521|NCT00136565|Drug|Vindesine|2 mg/m², D1, D5, 4 cycles
531522|NCT00136565|Drug|Bleomycin|10 mg, D1, D5, 4 cycles
531523|NCT00136552|Drug|rituximab|
531524|NCT00136539|Drug|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
531525|NCT00136539|Drug|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
531526|NCT00136539|Drug|Adriamycin|Given every three weeks for 12 weeks after surgery.
531527|NCT00136539|Drug|Cytoxan|Given every three weeks for 12 weeks after surgery.
531528|NCT00136526|Drug|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
531529|NCT00136513|Drug|SB-743921|
531531|NCT00136474|Drug|Amifostine|Given 30-60 minutes prior to daily radiation therapy
531532|NCT00136474|Radiation|Radiation Therapy|Daily radiation therapy
531533|NCT00136461|Drug|All-trans retinoic acid|
531534|NCT00136461|Drug|Bryostatin 1|
531535|NCT00136448|Drug|cytosine arabinoside (ara-C)|
531536|NCT00136448|Drug|daunomycin|
531537|NCT00136448|Drug|interleukin-2|
531538|NCT00136435|Drug|prednisone|Induction Phase: Given orally on days 1-28
531539|NCT00136435|Drug|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
531540|NCT00136435|Drug|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.~CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
531541|NCT00136435|Drug|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
531542|NCT00136435|Drug|asparaginase|Induction: Given into the muscle on day 5
531543|NCT00136435|Drug|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
531544|NCT00136435|Radiation|cranial radiation|Given in 10 daily treatments during CNS therapy phase
531545|NCT00136435|Drug|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
531546|NCT00136435|Drug|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
531547|NCT00136435|Drug|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
531548|NCT00136435|Drug|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
531549|NCT00136435|Drug|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
531550|NCT00136422|Biological|autologous tumor cells|
531551|NCT00136409|Drug|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
531552|NCT00136396|Drug|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
531553|NCT00136383|Drug|paroxetine versus duloxetine|
531554|NCT00136370|Drug|Chlorhexidine|
531555|NCT00136370|Procedure|Birth canal wipe|
531556|NCT00136370|Procedure|sterile water external genital wipe|
531557|NCT00136357|Behavioral|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
531558|NCT00136344|Drug|Cefuroxime|
531559|NCT00136344|Drug|Levofloxacin|
531560|NCT00136331|Biological|Pandemic influenza vaccine|
531561|NCT00136318|Drug|Escitalopram|
531562|NCT00136318|Drug|Placebo|
531563|NCT00136318|Drug|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
531564|NCT00136318|Drug|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
531565|NCT00136305|Behavioral|Pictorial asthma action plan|
531566|NCT00136305|Behavioral|Written asthma action plan|
531567|NCT00136292|Drug|daptomycin|
531568|NCT00136279|Behavioral|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
531569|NCT00136266|Drug|Ferrous sulphate drops with vitamins A, D, and C|
531570|NCT00136266|Drug|Ferrous fumarate sprinkles with vitamins and minerals|
531571|NCT00136253|Behavioral|Help dietitians and patients address specific nutritional barriers|
531572|NCT00136240|Behavioral|Computer Assisted Education for Behavior Change|
531573|NCT00136227|Behavioral|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
531574|NCT00136214|Diagnostic Test|MR brain and neuropsychiatric tests|
531575|NCT00136201|Drug|tigecycline|
531576|NCT00136188|Drug|Folic Acid|oral administration of folic acid 5mg /d for 4 weeks
531577|NCT00136175|Drug|Paclitaxel|
531578|NCT00136175|Drug|Carboplatin|
531579|NCT00136175|Drug|Gemcitabine|
531580|NCT00136149|Procedure|Immediate implants|Immediate implants are used.
531581|NCT00136136|Procedure|Registration of the bispectral index and spectral edge frequency|Registration of the bispectral index and spectral edge frequency
531582|NCT00136123|Procedure|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
531583|NCT00136110|Drug|Sodium Valproate|
531584|NCT00136097|Device|Placement of a silver impregnated central venous catheter|
531585|NCT00136084|Drug|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
531586|NCT00136084|Drug|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
531587|NCT00136071|Device|Transobturator tape-ARIS|
531588|NCT00136071|Device|TVT-O|
531589|NCT00136058|Procedure|bone densitometry (DEXA)|
531590|NCT00136058|Drug|alendronate or risedronate|
531591|NCT00136045|Drug|Rotigotine|
531592|NCT00136032|Drug|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
531593|NCT00136032|Drug|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
531594|NCT00136019|Drug|SPM 927|
531595|NCT00136006|Behavioral|Study to determine the burden of disease|
531596|NCT00135993|Drug|Rotigotine|
531597|NCT00135980|Behavioral|professional audit and feedback|
531598|NCT00135980|Behavioral|integrated care programmes|
531599|NCT00135967|Drug|mycophenolate mofetil orally 1000 mg twice a day (BID)|
531600|NCT00135967|Drug|prednisone 0,5 mg/kg orally on alternate days|
531601|NCT00135967|Drug|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
531602|NCT00135954|Drug|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
531603|NCT00135941|Drug|insulin glargine|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
531604|NCT00135941|Drug|insulin glulisine|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
531605|NCT00135928|Drug|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
531606|NCT00135902|Drug|17 alpha-Hydroxyprogesterone Caproate and Omega-3 supplement|Participants receive a weekly progesterone injection (17 alpha hydroxyprogesterone caproate) up to 37 weeks gestation and take daily Omega-3 supplements.
531607|NCT00135902|Drug|17 alpha-hydroxy progesterone caproate and Placebo supplement|Participants receive a weekly progesterone injection (17P) up to 37 weeks gestation and take daily placebo supplements
531608|NCT00135889|Drug|Femoral perineural infusion|
531609|NCT00135876|Drug|dalteparin|
531610|NCT00135863|Drug|tinzaparin|
531611|NCT00135850|Genetic|VEGF-A165 plasmid|
531612|NCT00135837|Drug|Verteporfin for injection|
531613|NCT00135824|Drug|Povidone K25 eye drops (povidone)|
531614|NCT00135811|Drug|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
531615|NCT00135811|Drug|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.~Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
531616|NCT00135798|Drug|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:~Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was <0.5 ug/kg, PEGIFN was permanently discontinued."
531617|NCT00135785|Drug|Bupropion|
531618|NCT00135785|Drug|Placebo|
531619|NCT00135759|Drug|Naltrexone|low dose naltrexone in addition to daily methadone taper
531620|NCT00135759|Drug|Placebo comparator|1 capsule/day for 6 days
531621|NCT00135759|Drug|naltrexone|0.125 mg capsule/day for 6 days
531622|NCT00135759|Drug|naltrexone|0.250 mg capsule/day for 6 days
531623|NCT00135746|Drug|nicotine transdermal system|
531624|NCT00135733|Drug|Amevive (Alefacept)|
531625|NCT00135733|Drug|Placebo|
531626|NCT00135720|Drug|Enbrel (Etanercept)|
531627|NCT00135707|Drug|Dietary Supplement/Vitamins|Vitamin C (1000 mg) and Vitamin E (400 IU) per capsule, two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
531628|NCT00135707|Drug|Placebo for Vitamin C and Vitamin E|Placebo two capsules daily between randomization (at 9 - 16 weeks gestation) up to delivery.
531629|NCT00135694|Drug|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
531630|NCT00135694|Procedure|liver transplant|Occurs at study entry
531631|NCT00135694|Drug|corticosteroids|3-month course of corticosteroids
531632|NCT00135694|Other|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
531633|NCT00135681|Drug|nedocromil budesonide|
531634|NCT00135668|Drug|nitroprusside|nitroprusside IV infusion 0.3-3 mcg/kg/ min
531635|NCT00135655|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
531636|NCT00135642|Biological|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
531637|NCT00135642|Procedure|Venepuncture: 20 ml blood sample taken on 2 separate visits|
531638|NCT00135629|Biological|Sublingual Alutard SQ grass pollen tablets (Phleum pratense)|
531639|NCT00135629|Procedure|Venepuncture: 100ml blood sample taken on 12 separate visits|
531640|NCT00135616|Device|surgical placement of a suburethral sling tvt or tvt-o|
531641|NCT00135603|Drug|amoxicillin/clavulanate potassium|1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
531642|NCT00135603|Procedure|appendectomy|ablation of the appendix by laparotomy or laparoscopy
531643|NCT00135590|Dietary Supplement|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
531644|NCT00135590|Dietary Supplement|Spread diet|Dietary protein was spread over the four meals.
531645|NCT00135577|Drug|alvimopan|
531646|NCT00135577|Drug|placebo|
531647|NCT00135564|Biological|MenC-TT|
531648|NCT00135564|Biological|Hib-MenC-TT|
531649|NCT00135551|Drug|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
531650|NCT00135551|Drug|β-blockers|benidipine+β-blockers, titlation scheme
531651|NCT00135551|Drug|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
531652|NCT00135538|Device|Noninvasive positive pressure ventilation|
531653|NCT00135525|Drug|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.~Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
531654|NCT00135525|Drug|Placebo|Placebo
531655|NCT00135512|Drug|bupropion hydrochloride|Study drug
531656|NCT00135499|Drug|Rituximab|375 mg/m², D1, 4 cycles
531657|NCT00135499|Drug|Doxorubicin|75 mg/m², D1, 4 cycles
531658|NCT00135499|Drug|Cyclophosphamide|1200 mg/m², D1, 4 cycles
531659|NCT00135499|Drug|Vindesine|2 mg/m², D1, D5, 4 cycles
531660|NCT00135499|Drug|Bleomycin|10 mg, D1, D5, 4 cycles
531661|NCT00135499|Drug|Prednisone|60 mg, D1-D5, 4 cycles
531662|NCT00135499|Drug|Prednisone|40 mg, D1-D5, 4 cycles
531663|NCT00135499|Drug|Doxorubicin|50 mg/m², D1, 4 cycles
531664|NCT00135499|Drug|Cyclophosphamide|750 mg/m², D1, 4 cycles
531665|NCT00135499|Drug|Vincristine|1.4 mg/m², D1, 4 cycles
531666|NCT00135486|Biological|MenC-TT|
531667|NCT00135486|Biological|Hib-MenC-TT|
531668|NCT00135473|Drug|10% Hemohes® (10% Hydroxyethyl starch)|
531669|NCT00135473|Drug|Sterofundin® (Ringer lactate solution)|
531670|NCT00135473|Drug|Actrapid® (Insulin)|
531671|NCT00135460|Drug|nucleoside analogue sparing HAART regimen|
531672|NCT00135434|Drug|Atazanavir/Ritonavir/Lopinavir/ritonavir|
531673|NCT00135421|Drug|Pexacerfont|Tablets & Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
531674|NCT00135421|Drug|Escitalopram|Tablets & Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
531675|NCT00135421|Drug|Placebo|Tablets & Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
531676|NCT00135408|Drug|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
531677|NCT00135408|Drug|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
531678|NCT00135395|Drug|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
531679|NCT00135395|Drug|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
531680|NCT00135382|Drug|Videx EC|
531681|NCT00135382|Drug|Epivir|
531682|NCT00135382|Drug|Sustiva|
531683|NCT00135369|Drug|stavudine extended-release, lamivudine, efavirenz|
531684|NCT00135356|Drug|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
531685|NCT00135356|Drug|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor [PI] combination + 2 NRTIs
531686|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
531687|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
531688|NCT00135330|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
531689|NCT00135330|Drug|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
531690|NCT00135317|Drug|darbepoetin alfa|
531691|NCT00135304|Drug|Sensipar®|Cinacalcet hydrochloride
531692|NCT00135304|Drug|Vitamin D|Vitamin D administered IV
531693|NCT00135291|Procedure|Leukoreduced blood transfusion|
531694|NCT00135278|Procedure|CSF Drainage|See Detailed Description
531695|NCT00135278|Procedure|No CSF Drainage|See Detailed Description
531696|NCT00135265|Behavioral|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
531697|NCT00135252|Procedure|nasal cannula oxygen delivery|
531698|NCT00135252|Procedure|supplemental oxygen delivery by hood|
531699|NCT00135239|Procedure|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
531700|NCT00135239|Procedure|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
531701|NCT00135226|Drug|Aspirin|
531702|NCT00135226|Drug|Omega-3 Ethyl Esters|
531703|NCT00135226|Drug|Placebo Aspirin|
531704|NCT00135226|Drug|Placebo Omega-3 Ethyl Esters|
531705|NCT00135213|Behavioral|training in smoking cessation|
531706|NCT00135200|Drug|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
531707|NCT00135187|Drug|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days~1, 4, 8, and 11) followed by a 1-week break."
531708|NCT00135187|Drug|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
531709|NCT00135187|Drug|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
531710|NCT00135161|Procedure|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
531711|NCT00135148|Procedure|Filling out a questionnaire on libido and possible partner relationship|
531712|NCT00135148|Procedure|Sex steroid analysis|
531713|NCT00135135|Drug|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
531714|NCT00135135|Procedure|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
531715|NCT00135122|Drug|prednisolone|Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
531716|NCT00135109|Drug|SPM 927|
531717|NCT00135096|Drug|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
531718|NCT00135096|Drug|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
531719|NCT00135083|Drug|insulin glulisine|"Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.~Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
531720|NCT00135070|Drug|Detemir|
531721|NCT00135057|Drug|insulin glulisine|
531722|NCT00135057|Drug|insulin glargine|
531723|NCT00135044|Procedure|intravenous taurine in nutritional supplement|
531724|NCT00135031|Drug|Bifidobacterium infantis 35624|
531725|NCT00135018|Drug|celecoxib and chemotherapy|
531726|NCT00135005|Drug|AMN107, STI571|
531727|NCT00134992|Drug|Prednisolone acetate|
531728|NCT00134979|Drug|Formoterol|
531729|NCT00134966|Drug|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
531730|NCT00134953|Drug|Rivastigmine|
531731|NCT00134914|Drug|Buprenorphine|single doses given by sublingual and parenteral routes
531732|NCT00134901|Drug|Memantine|Memantine
531733|NCT00134901|Drug|placebo|placebo
531734|NCT00134888|Drug|Buprenorphine/naloxone|
531735|NCT00134875|Drug|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
531736|NCT00134836|Behavioral|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
531737|NCT00134823|Other|weight based dosing decision support|weight based dosing decision support
531738|NCT00134810|Biological|Botulinum toxin type A|
531739|NCT00134784|Drug|[123I]B-CIT SPECT imaging|To assess [123I]B-CIT SPECT imaging
531740|NCT00134771|Drug|Nutrient enriched infant formula|
531741|NCT00134758|Drug|Ursodeoxycholic acid|"During 2 years :~between 40 and 50 kg : 500 mg/day~between 51 and 75 kg : 750 mg/day~between 76 and 100 kg : 1000 mg/day"
531742|NCT00134758|Drug|Placebo|"During 2 years :~between 40 and 50 kg : 2 tabs/day~between 51 and 75 kg : 3 tabs/day~between 76 and 100 kg : 4 tabs/day"
531743|NCT00134745|Drug|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
531744|NCT00134732|Biological|Live attenuated human rotavirus vaccine|
531745|NCT00134719|Biological|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
531746|NCT00134719|Biological|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
531747|NCT00134719|Biological|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
531748|NCT00134719|Biological|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
531749|NCT00134719|Biological|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
531750|NCT00134719|Biological|M-M-R®II|One subcutaneous dose at 12-15 months of age
531751|NCT00134719|Biological|Varivax®|One subcutaneous dose at 12 to 15 months of age
531752|NCT00134719|Biological|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
531753|NCT00134706|Drug|Docetaxel|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
531826|NCT00134108|Behavioral|Cognitive Behaviour Therapy|
531754|NCT00134706|Drug|Carboplatin|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
531755|NCT00134693|Drug|Prednisolone|
531756|NCT00134693|Drug|SB-681323|
531757|NCT00134680|Drug|Letrozole|Letrozole tablets 2.5 mg by mouth daily
531758|NCT00134680|Drug|Trastuzumab|Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
531759|NCT00134667|Drug|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
531760|NCT00134667|Drug|Macugen (pegaptanib sodium)|
531761|NCT00134654|Drug|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
531762|NCT00134641|Drug|gemcitabine|
531763|NCT00134641|Drug|vinorelbine|
531764|NCT00134628|Procedure|Hyperbaric Oxygen Therapy|HBO at 2.0 ATA
531765|NCT00134628|Procedure|Sham treatment|Normal air under pressure (1.1 ATA)
531766|NCT00134615|Behavioral|RQP patient health education module|
531767|NCT00134602|Behavioral|Needs assessment followed by tailored intervention|
531768|NCT00134589|Behavioral|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
531769|NCT00134576|Behavioral|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
531770|NCT00134563|Drug|Teriflunomide|"Film-coated tablet~Oral administration"
531771|NCT00134563|Drug|Placebo (for teriflunomide)|"Film-coated tablet~Oral administration"
531772|NCT00134550|Drug|Atorvastatin (10 mg or 80 mg)|
531773|NCT00134537|Device|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
531774|NCT00134537|Device|Conservative Care|Medication, exercise and spinal injections
531775|NCT00134524|Procedure|MME procedure|
531776|NCT00134511|Drug|Torcetrapib/atorvastatin|
531777|NCT00134498|Drug|torcetrapib/atorvastatin|
531778|NCT00134498|Drug|atorvastatin|
531779|NCT00134485|Drug|torcetrapib/atorvastatin|
531780|NCT00134485|Drug|atorvastatin|
531781|NCT00134472|Procedure|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
531782|NCT00134459|Drug|Bifeprunox|
531783|NCT00134459|Drug|Placebo|
531784|NCT00134446|Device|transcranial magnetic stimulation|
531785|NCT00134433|Genetic|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
531786|NCT00134433|Drug|oral L-arginine supplementation (at a dose of 6 g/day)|
531787|NCT00134420|Drug|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
531788|NCT00134420|Procedure|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
531789|NCT00134420|Procedure|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
531790|NCT00134420|Procedure|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
531791|NCT00134407|Procedure|Normal diet|
531792|NCT00134407|Procedure|Nutrition via jejunal needle-catheter|
531793|NCT00134394|Drug|Etanercept plus tacrolimus|
531794|NCT00134381|Drug|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
531795|NCT00134381|Drug|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
531796|NCT00134368|Drug|Etanercept|
531797|NCT00134355|Drug|PTK787|
531798|NCT00134342|Other|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
531799|NCT00134329|Procedure|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
531800|NCT00134316|Behavioral|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
531801|NCT00134303|Drug|Metformin|Metformin is used.
531802|NCT00134290|Drug|metformin|
531803|NCT00134290|Behavioral|"standard diet advice"|
531804|NCT00134290|Behavioral|"personal diet advice"|
531805|NCT00134277|Procedure|Infragenual dilatation|Infragenual dilatation
531806|NCT00134277|Procedure|Infragenual dilatation with stenting|Infragenual dilatation with stenting
531807|NCT00134277|Procedure|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
531808|NCT00134277|Procedure|Laser therapy|Laser therapy
531809|NCT00134264|Drug|torcetrapib/atorvastatin|
531810|NCT00134264|Drug|atorvastatin|
531811|NCT00134251|Drug|SLV308|
531812|NCT00134238|Drug|torcetrapib/atorvastatin|
531813|NCT00134238|Drug|atorvastatin|
531814|NCT00134225|Device|Muscle Pattern Recognition (MPR)|
531815|NCT00134212|Drug|Dopexamine and norepinephrine|
531816|NCT00134212|Drug|Epinephrine|
531817|NCT00134199|Drug|CP-945,598|
531818|NCT00134199|Drug|sibutramine|
531819|NCT00134186|Drug|motexafin gadolinium|
531820|NCT00134173|Drug|torcetrapib/atorvastatin|
531821|NCT00134173|Drug|atorvastatin|
531822|NCT00134160|Drug|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
531823|NCT00134160|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
531824|NCT00134147|Drug|Inhaled Insulin|
531825|NCT00134134|Drug|efalizumab|
531827|NCT00134095|Drug|irinotecan hydrochloride|
531828|NCT00134095|Drug|tegafur-gimeracil-oteracil potassium|
531829|NCT00134095|Procedure|adjuvant therapy|
531830|NCT00134095|Procedure|conventional surgery|
531831|NCT00134095|Procedure|neoadjuvant therapy|
531832|NCT00134082|Biological|KGEL vaccine|Vaccine was administered at weeks 0, 4, 8, 12, 16, and 24 at a dose of 1 x 10^8 cells per dose. The first dose was given on Day +1.
531833|NCT00134082|Biological|Filgrastim|5 mcg/kg/day starting on Day +6 until ANC is >= 1000/mcL.
531834|NCT00134082|Biological|Rituximab|375 mg/m^2/day on Days -10, -7, and at weeks 4, 5, 6, and 7.
531835|NCT00134082|Drug|Cyclophosphamide|50 mg/kg/day on Day -3, -2, -1, and 0.
531836|NCT00134069|Drug|sorafenib tosylate|Given orally
531837|NCT00134069|Drug|cetuximab|Given IV
531838|NCT00134069|Drug|irinotecan hydrochloride|Given IV
531839|NCT00134056|Drug|atrasentan hydrochloride|Given orally
531840|NCT00134056|Drug|docetaxel|Docetaxel given IV and prednisone given orally
531841|NCT00134056|Drug|prednisone|Docetaxel given IV and prednisone given orally
531842|NCT00134056|Other|placebo|Given orally
531843|NCT00134043|Drug|vorinostat|Given orally
531844|NCT00134030|Drug|Cisplatin|Given IV
531845|NCT00134030|Drug|Doxorubicin Hydrochloride|Given IV
531846|NCT00134030|Drug|Etoposide|Given IV
531847|NCT00134030|Drug|Ifosfamide|Given IV
531848|NCT00134030|Drug|Methotrexate|Given IV
531849|NCT00134030|Biological|Peginterferon Alfa-2b|Given subcutaneously
531850|NCT00134030|Other|Quality-of-Life Assessment|Ancillary studies
531851|NCT00134030|Other|Questionnaire Administration|Ancillary studies
531852|NCT00134030|Procedure|Therapeutic Conventional Surgery|Undergo amputation or limb salvage surgery
531853|NCT00134017|Drug|Busulfan|Days -7 to -4: 4 mg/kg PO daily OR 3.2 mg/kg IV daily OR 160 mg/m^2 daily (for pediatric recipients)
531854|NCT00134017|Drug|Cyclophosphamide|Days -3, -2, +3, +4: 50 mg/kg IV daily
531855|NCT00134004|Drug|cyclophosphamide|
531856|NCT00134004|Drug|fludarabine phosphate|
531857|NCT00134004|Drug|mycophenolate mofetil|
531858|NCT00134004|Drug|tacrolimus|
531859|NCT00134004|Procedure|allogeneic bone marrow transplantation|
531860|NCT00134004|Radiation|radiation therapy|
531861|NCT00133991|Biological|Filgrastim|5 mcg/kg/day starting on Day 3 after each R-CVP cycle and on Day 6 after HiCy.
531862|NCT00133991|Biological|Rituximab|375 mg/m^2 on Day 1 and Day 8 of each R-CVP cycle. 375 mg/m^2 on Day -4 of HiCy and weekly for four weeks after HiCy.
531863|NCT00133991|Drug|Cyclophosphamide|1500 mg/m^2 on Day 1 of each R-CVP cycle. 50 mg/kg/day on Days -3, -2, -1, and 0 of HiCy.
531864|NCT00133991|Drug|Cytarabine|100 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
531865|NCT00133991|Drug|Methotrexate|3 g/m^2 on Day 8 of each cycle of R-CVP.
531866|NCT00133991|Drug|Prednisone|100 mg on Days 1-5 of each cycle of R-CVP.
531867|NCT00133991|Drug|Hydrocortisone|50 mg intrathecal on Days 1, 4, and 11 of each cycle of R-CVP.
531868|NCT00133991|Drug|Vincristine|1.4 mg/m^2 on Day 1 of each cycle of R-CVP.
531869|NCT00133991|Drug|Leucovorin|25 mg four times daily after methotrexate administration. Dosing continues until adequate methotrexate levels are reached.
531870|NCT00133978|Other|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
531871|NCT00133978|Other|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
531872|NCT00133978|Other|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
531873|NCT00133978|Other|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
531874|NCT00133965|Behavioral|Dignity Psychotherapy|At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
531875|NCT00133965|Behavioral|Supportive Psychotherapy|you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
531876|NCT00133965|Behavioral|Standard Palliative Care|"If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes."
531877|NCT00133952|Drug|Ruboxistaurin|Administered orally
531878|NCT00133952|Drug|Placebo|Administered orally
531879|NCT00133939|Procedure|Mechanical ventilation|
531880|NCT00133926|Procedure|Treatment of periodontal disease|
531997|NCT00133172|Drug|Prednisone|IV
531881|NCT00133913|Procedure|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
531882|NCT00133900|Procedure|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
531883|NCT00133887|Drug|rapamycin|3 to 5 mg/day
531884|NCT00133887|Drug|ciclosporine|Blood residual level < or = to 125 ng/ml
531885|NCT00133887|Drug|tacrolimus|Blood residual level < or = to 8 ng/ml
531886|NCT00133874|Drug|SB-275833 ointment, 1%|
531887|NCT00133861|Drug|Botulinum toxin|
531888|NCT00133848|Drug|SB-275833 ointment, 1%|
531889|NCT00133835|Procedure|Extracorporeal shock wave lithotripsy|
531890|NCT00133835|Procedure|Endoscopic drainage of the main pancreatic duct|
531891|NCT00133822|Drug|Sertraline and Risperidone|
531892|NCT00133809|Drug|Transplantation of Human Islets|Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
531893|NCT00133796|Drug|Herceptin|IV
531894|NCT00133783|Behavioral|intermedin|
531895|NCT00133770|Drug|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
531896|NCT00133757|Drug|Bupropion SR|
531897|NCT00133744|Dietary Supplement|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
531898|NCT00133744|Dietary Supplement|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
531899|NCT00133744|Dietary Supplement|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
531900|NCT00133731|Drug|Otamixaban (XRP0673)|
531901|NCT00133731|Drug|Unfractionated Heparin|
531902|NCT00133731|Procedure|Percutaneous Coronary Intervention|
531903|NCT00133718|Drug|Combined lifestyle intervention and optimisation of pharmacological treatment|"6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)~standard care"
531904|NCT00133705|Drug|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
531905|NCT00133705|Drug|Inert Capsule|sugar pill
531906|NCT00133692|Drug|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
531907|NCT00133692|Drug|Atenolol/HCTZ/Trandolapril|
531908|NCT00133679|Drug|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
531909|NCT00133679|Drug|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
531910|NCT00133666|Behavioral|Asthma Communication Education|
531911|NCT00133666|Behavioral|Standard Asthma Education|
531912|NCT00133653|Behavioral|Observational|
531913|NCT00133640|Drug|cholecalciferol|
531914|NCT00133640|Behavioral|Physiotherapy|
531915|NCT00133627|Drug|Ketotifen|
531916|NCT00133614|Procedure|Prone Positioning|
531917|NCT00133601|Behavioral|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
531918|NCT00133588|Biological|Trivalent split Inf|
531919|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 intramuscularly (IM).
531920|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 subcutaneously (SC).
531921|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
531922|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
531923|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^6 or 10^7 TCID50 intradermally (ID).
531924|NCT00133575|Biological|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
531925|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
531926|NCT00133562|Drug|Alanyl-glutamine|
531927|NCT00133562|Drug|Glycine|
531928|NCT00133549|Drug|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
531929|NCT00133549|Biological|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
531930|NCT00133549|Biological|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
531931|NCT00133536|Biological|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
531932|NCT00133536|Drug|Placebo|Normal saline administered intramuscularly.
531933|NCT00133523|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
531934|NCT00133523|Other|Placebo|Physiological saline administered as an intramuscular injection.
531935|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
531936|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
531937|NCT00133523|Other|Placebo|Normal allantoic fluid administered annually as an internasal spray.
531938|NCT00133510|Biological|Trivalent Subviron Influenza vaccine (Fluzone)|
531939|NCT00133497|Biological|MF-59|Microfluoridized adjuvant 59 (MF59).
531940|NCT00133497|Drug|Placebo|0.5 mL of saline placebo.
531941|NCT00133497|Biological|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
531942|NCT00133484|Biological|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
531943|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Bacillus anthrax|
531944|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Escherichia coli|
531945|NCT00133471|Biological|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
531946|NCT00133471|Drug|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
531947|NCT00133458|Drug|Albendazole|
531948|NCT00133445|Biological|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
531949|NCT00133445|Biological|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
531950|NCT00133445|Drug|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
531951|NCT00133432|Drug|Zinc|
531952|NCT00133419|Drug|Vitamin + Zinc + micronutrient mixture|
531953|NCT00133419|Drug|Vitamin A|
531954|NCT00133419|Drug|Vitamin A + Zinc|
531955|NCT00133406|Drug|Glutamine|0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
531956|NCT00133406|Drug|Vitamin A|100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
531957|NCT00133406|Drug|glycine|0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
531958|NCT00133406|Drug|zinc|40 mg twice weekly for 12 months
531959|NCT00133393|Drug|Pentoxifylline|
531960|NCT00133380|Drug|PPAR alpha|
531961|NCT00133380|Drug|atorvastatin|
531962|NCT00133380|Drug|placebo|
531963|NCT00133367|Drug|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
531964|NCT00133367|Drug|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
531965|NCT00133367|Drug|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
531966|NCT00133367|Drug|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
531967|NCT00133367|Drug|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
531968|NCT00133367|Drug|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
531969|NCT00133367|Drug|Melphalan|Given intravenously on day 2 before transplant.
531970|NCT00133354|Drug|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
531971|NCT00133354|Drug|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
531972|NCT00133354|Drug|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of ~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
531973|NCT00133341|Drug|Goldnatriomthiosulphate, MDBGN, parthenolide|
531974|NCT00133328|Drug|valsartan|
531975|NCT00133315|Drug|Infliximab|
531976|NCT00133315|Drug|Etanercept|
531977|NCT00133315|Drug|Adalimumab|
531978|NCT00133302|Drug|Standard CHOP|
531979|NCT00133302|Drug|Bi-CHOP (dose intensified CHOP)|
531980|NCT00133289|Device|Pacemaker with Automatic Capture|
531981|NCT00133276|Drug|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
531982|NCT00133276|Other|Placebo|
531983|NCT00133263|Behavioral|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
531984|NCT00133263|Behavioral|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
531985|NCT00133250|Drug|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
531986|NCT00133250|Other|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
531987|NCT00133237|Device|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
531988|NCT00133237|Device|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
531989|NCT00133224|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
531990|NCT00133224|Drug|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
531991|NCT00133211|Procedure|Radiofrequency ablation|Pulmonary vein isolation
531992|NCT00133198|Drug|Pramipexole|
531993|NCT00133185|Drug|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
531994|NCT00133185|Drug|losartan 50 mg/hydrochlorothiazide 12.5 mg|
531995|NCT00133172|Drug|Tacrolimus|IV
531996|NCT00133172|Drug|mycophenolate mofetil|IV
531998|NCT00133159|Biological|Grass MATAMPL|
531999|NCT00133146|Biological|Grass MATAMPL|
532000|NCT00133133|Drug|ALGRX 4975|
532001|NCT00133107|Drug|efalizumab|
532002|NCT00133094|Drug|Simvastin|
532003|NCT00133094|Procedure|Computer-based decision support technology|
532004|NCT00133081|Drug|All registered antiepileptic drugs|
532005|NCT00133068|Behavioral|Computer|Computer intervention only
532006|NCT00133068|Behavioral|Reduction in financial barrier|Copay only
532007|NCT00133068|Behavioral|Computer intervention & reduction of financial barrier|computer intervention & copay
532008|NCT00133068|Behavioral|Control|No intervention
532009|NCT00133055|Behavioral|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
532010|NCT00133055|Behavioral|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
532011|NCT00133042|Drug|omalizumab|
532012|NCT00133029|Drug|Timing of prophylactic antibiotic administration|
532013|NCT00133016|Procedure|Amniotomy|
532014|NCT00133003|Drug|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute [maximum, 10 microg/min] infusion for 12 hours, plus heparin, 70 U/kg of body weight
532015|NCT00133003|Drug|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
532016|NCT00132990|Device|Deep brain stimulation|
532017|NCT00132977|Device|Cardiac Resynchronization Therapy|
532018|NCT00132964|Device|Below knee walking cast|Not required
532019|NCT00132964|Device|Removable ankle brace|not required
532020|NCT00132951|Drug|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
532021|NCT00132951|Drug|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
532022|NCT00132938|Drug|telithromycin|
532023|NCT00132925|Drug|Triamcinolone|
532024|NCT00132912|Drug|SCH 530348|
532025|NCT00132899|Drug|Methotrexate|Methotrexate and infliximab combination
532026|NCT00132899|Drug|Placebo|Placebo and infliximab combination therapy.
532027|NCT00132886|Drug|tolvaptan|
532028|NCT00132873|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
532029|NCT00132860|Drug|azithromycin|
532030|NCT00132847|Biological|German Cockroach Allergen extract|
532031|NCT00132834|Device|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
532032|NCT00132821|Drug|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
532033|NCT00132821|Drug|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
532034|NCT00132821|Drug|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
532035|NCT00132821|Drug|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
532036|NCT00132808|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous
532037|NCT00132808|Drug|Placebo|Physiologic 0.9% normal saline
532038|NCT00132795|Behavioral|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
532039|NCT00132795|Behavioral|control group|standard care (no added treatment)
532040|NCT00132769|Drug|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
532041|NCT00132769|Drug|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
532042|NCT00132756|Drug|Doxil and Estramustine|
532043|NCT00132743|Device|Stent|Stent
532044|NCT00132743|Behavioral|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
532045|NCT00132743|Drug|Cilostazol|Cilostazol, 100 mg twice a day
532046|NCT00132730|Drug|MK-0873 2.5 mg|
532047|NCT00132730|Drug|MK-0873 1.25 mg|
532048|NCT00132730|Drug|MK-0873 0.75 mg|
532049|NCT00132730|Drug|Placebo to MK-0873|
532050|NCT00132730|Drug|Usual Care|
532051|NCT00132717|Drug|MK0653A (ezetimibe [+] simvastatin)|
532052|NCT00132717|Drug|Comparator: atorvastatin|
532053|NCT00132717|Drug|Comparator: fluvastatin|
532054|NCT00132717|Drug|Comparator: lovastatin|
532055|NCT00132717|Drug|Comparator: pravastatin|
532056|NCT00132717|Drug|Comparator: rosuvastatin|
532057|NCT00132717|Drug|Comparator: simvastatin|
532058|NCT00132704|Radiation|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
532059|NCT00132704|Radiation|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
532118|NCT00132145|Behavioral|Web-based Vascular Tracker for Patient and Physician|
532119|NCT00132145|Behavioral|Automated Telephone Reminder System|
532120|NCT00132132|Behavioral|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
532060|NCT00132691|Drug|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
532061|NCT00132691|Drug|oral corticosteroid with immunosuppressive agents as needed|Prednisone
532062|NCT00132678|Drug|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
532063|NCT00132678|Drug|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
532064|NCT00132665|Procedure|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
532065|NCT00132665|Drug|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
532066|NCT00132652|Drug|Lamivudine|
532067|NCT00132652|Drug|Telbivudine|
532068|NCT00132639|Drug|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
532069|NCT00132639|Drug|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
532070|NCT00132626|Drug|[123I]ß-CIT and SPECT imaging|
532071|NCT00132613|Procedure|Observation alone after pericardial drainage|
532072|NCT00132613|Drug|Pericardial instillation of bleomycin after drainage|
532073|NCT00132600|Drug|bacitracin (allergen)|
532074|NCT00132587|Device|cement Palacos R40 and LV40|
532075|NCT00132574|Behavioral|Minimization of milk and dairy products in the diet|
532076|NCT00132561|Drug|Sulfadoxine/pyrimethamine and artesunate|
532077|NCT00132548|Drug|Pyrimethamine/sulfadoxine|
532078|NCT00132548|Drug|Amodiaquine|
532079|NCT00132548|Drug|Artesunate|
532080|NCT00132535|Drug|sulfadoxine-pyrimethamine intermittent preventive treatment|
532081|NCT00132535|Drug|chloroquine|
532082|NCT00132522|Drug|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.~Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
532083|NCT00132509|Drug|DFIL|Alteplase : 0.8mg/kg over 90 minutes
532084|NCT00132509|Drug|NINDS|Alteplase : 0.9mg/kg over 60 minutes
532085|NCT00132496|Drug|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
532086|NCT00132483|Behavioral|Instruction in physical training program|Instruction in physical training program.
532087|NCT00132470|Drug|AX200 (G-CSF)|
532088|NCT00132457|Procedure|Self-collected vaginal swab for chlamydia testing|
532089|NCT00132444|Drug|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
532090|NCT00132431|Drug|Sensipar|
532091|NCT00132418|Drug|Enbrel|Enbrel
532092|NCT00132418|Drug|Placebo|Placebo
532093|NCT00132405|Drug|ALGRX 3268|
532094|NCT00132392|Drug|ALGRX 4975|
532095|NCT00132379|Drug|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
532096|NCT00132379|Drug|docetaxel|75mg/m^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
532097|NCT00132340|Device|Electrodes|
532098|NCT00132314|Drug|IM risperidone|long-acting injectable risperidone
532099|NCT00132314|Drug|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
532100|NCT00132301|Drug|Docetaxel|Chemotherapy agent
532101|NCT00132301|Drug|Prednisone|steroid in combination with chemotherapy agent
532102|NCT00132288|Behavioral|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
532103|NCT00132288|Behavioral|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
532104|NCT00132275|Drug|Amoxicillin potassium clavulanate|
532105|NCT00132262|Behavioral|Brief intervention based on motivational interviewing|The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
532106|NCT00132262|Behavioral|Standard Care including referral for treatment|Standard hospital care provided the patient with information and referral for treatment as necessary.
532107|NCT00132236|Drug|nicotine sublingual tablets|
532108|NCT00132236|Behavioral|low and high behavior support|
532109|NCT00132223|Drug|Contrast agent|
532110|NCT00132210|Drug|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
532111|NCT00132197|Behavioral|Cognitive Behavioral Therapy|1. Specialised treatment includes cognitive groups therapy in 9 modules of 3,5 hours within 3½ months, in all 31,5 hours, consultancy over the phone to the patients' GPs and tuition in groups headed by an experienced social worker. Detailed treatment manuals are worked out separately for each module. Experienced psychotherapists (clinical psychologists and psychiatrists), who also function as consultants, will do the treatment. The Ph.D.-student functions as co-therapist.
532112|NCT00132197|Procedure|Recommendation of care (letter to general practitioner [GP])|After the diagnostic assessment the patient does not receive any treatment offers at the research clinic, but the patient and the GP will be informed about the diagnosis, and the GP will receive advice on further treatment possibilities.
532113|NCT00132184|Drug|Vitamin D|
532114|NCT00132171|Drug|Sequential therapy|
532115|NCT00132158|Drug|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
532116|NCT00132145|Behavioral|Vascular Management Program|
532117|NCT00132145|Behavioral|Clinical Care Coordinators|
532121|NCT00132119|Drug|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
532122|NCT00132119|Other|Placebo|Placebo tablet
532123|NCT00132106|Drug|phentolamine|
532124|NCT00132093|Drug|Eplerenone|
532125|NCT00132080|Drug|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
532126|NCT00132067|Drug|vorinostat|Given orally
532127|NCT00132054|Drug|amrubicin hydrochloride|
532128|NCT00132054|Drug|irinotecan hydrochloride|
532129|NCT00132041|Procedure|radiofrequency ablation|
532130|NCT00132028|Drug|vorinostat|Given orally
532131|NCT00132028|Other|laboratory biomarker analysis|Correlative studies
532132|NCT00132015|Drug|tanespimycin|
532133|NCT00132002|Drug|vorinostat|Given PO
532134|NCT00132002|Other|laboratory biomarker analysis|Correlative studies
532135|NCT00131989|Drug|sorafenib tosylate|Given orally
532136|NCT00131989|Other|pharmacological study|Correlative studies
532137|NCT00131989|Other|laboratory biomarker analysis|Correlative studies
532138|NCT00131963|Drug|cyclophosphamide|Given IV
532139|NCT00131963|Drug|doxorubicin|Given IV
532140|NCT00131963|Drug|paclitaxel|Given IV
532141|NCT00131950|Other|physiologic testing|
532142|NCT00131950|Other|study of socioeconomic and demographic variables|
532143|NCT00131950|Procedure|breast imaging study|
532144|NCT00131950|Procedure|study of high risk factors|
532145|NCT00131937|Drug|sorafenib tosylate|Given orally
532146|NCT00131924|Biological|esterified estrogens|
532147|NCT00131911|Drug|sorafenib tosylate|400 mg given orally
532148|NCT00131898|Procedure|Surgical Resection|
532149|NCT00131898|Procedure|Intensity Modulated Radiation Therapy (IMRT)|
532150|NCT00131885|Dietary Supplement|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
532151|NCT00131885|Dietary Supplement|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
532152|NCT00131885|Drug|Levonorgestrel|Levonorgestrel in a single oral dose
532153|NCT00131872|Device|Expedial Vascular Access Graft|
532154|NCT00131859|Procedure|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
532155|NCT00131846|Drug|Thiazide diuretics|Any dosage, frequency, and duration
532156|NCT00131846|Drug|No diuretics|Any antihypertensive regimen other than diuretics
532157|NCT00131833|Biological|Typhoid Vi vaccine|
532158|NCT00131833|Biological|Meningococcal A (control)|
532159|NCT00131820|Biological|Typhoid Vi vaccine|
532160|NCT00131820|Biological|Hepatitis A (control)|
532161|NCT00131807|Procedure|Blood Pressure Measurement|
532162|NCT00131807|Procedure|Questionnaire|
532163|NCT00131794|Biological|BCG|
532164|NCT00131781|Behavioral|Cognitive Therapy|
532165|NCT00131781|Behavioral|Supportive Therapy|
532166|NCT00131768|Device|Synvisc (hylan G-F 20)|
532167|NCT00131755|Drug|diazoxide|
532168|NCT00131742|Drug|telbivudine|
532169|NCT00131742|Drug|lamivudine|
532170|NCT00131729|Behavioral|Educational programme|
532171|NCT00131716|Drug|sulfadoxine-pyrimethamine|
532172|NCT00131703|Drug|Amodiaquine|
532173|NCT00131703|Drug|Sulphadoxine-pyrimethamine|
532174|NCT00131703|Drug|Chloroquine|
532175|NCT00131690|Drug|Nescafé Gold Blend (exposed)|
532176|NCT00131690|Drug|Nescafé Decaffeinated (controls)|
532177|NCT00131677|Drug|tenofovir disoproxil fumarate|study product taken daily
532178|NCT00131677|Drug|placebo|study product taken daily
532179|NCT00131664|Drug|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
532180|NCT00131664|Drug|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
532181|NCT00131664|Drug|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
532182|NCT00131651|Drug|ATN-161|
532183|NCT00131638|Drug|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
532184|NCT00131638|Drug|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
532185|NCT00131625|Behavioral|Health education according to WHO recommendations|
532186|NCT00131612|Drug|FEC 100|5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
532187|NCT00131599|Drug|5FU/LV|5FU/LV
532188|NCT00131573|Device|bion|battery powered bion microstimulator
532189|NCT00131560|Genetic|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
532190|NCT00131547|Behavioral|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
532191|NCT00131534|Behavioral|Individual therapy|Stage-based individual therapy for trauma survivors
532192|NCT00131534|Behavioral|Group therapy|Stage-based group therapy for trauma survivors
532193|NCT00131521|Drug|mucomyst|
532194|NCT00131521|Drug|sodium chloride (saline)|
532195|NCT00131508|Drug|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
532196|NCT00131508|Drug|Placebo|Placebo
532197|NCT00131495|Drug|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
532198|NCT00131495|Drug|Placebo patch|placebo patch changed twice a week for one year
532262|NCT00131053|Drug|Mercaptopurine|
532199|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
532200|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
532201|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
532202|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
532203|NCT00131482|Drug|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
532204|NCT00131469|Drug|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
532205|NCT00131469|Drug|Placebos|
532206|NCT00131456|Drug|Venlafaxine|375mg/day
532207|NCT00131456|Drug|Placebo|Placebo
532208|NCT00131443|Drug|Topiramate|
532209|NCT00131430|Drug|taranabant|
532210|NCT00131417|Drug|ready-to-use therapeutic food|
532211|NCT00131404|Drug|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
532212|NCT00131404|Drug|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
532213|NCT00131391|Drug|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
532214|NCT00131391|Drug|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
532215|NCT00131378|Drug|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
532216|NCT00131378|Drug|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
532217|NCT00131365|Device|ExAblate 2000|
532218|NCT00131352|Device|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
532219|NCT00131352|Other|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
532220|NCT00131339|Behavioral|Cognitive behavioral therapy|
532221|NCT00131339|Drug|D-cycloserine|
532222|NCT00131326|Device|Synvisc (hylan G-F 20)|
532223|NCT00131313|Drug|Nipent, Cytoxan, Rituxan|
532224|NCT00131300|Device|Synvisc (hylan G-F 20)|
532225|NCT00131287|Drug|Extract of Agaricus blazei Murill|
532226|NCT00131274|Drug|Imatinib Mesylate (Gleevec)|
532227|NCT00131261|Drug|PXD101|
532228|NCT00131261|Drug|Dexamethasone|
532229|NCT00131248|Drug|Metaclopramide|
532230|NCT00131248|Drug|Ranitidine|
532231|NCT00131248|Drug|placebo|
532232|NCT00131235|Drug|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.~2 placebo tablets for azithromycin taken at the same time points."
532233|NCT00131235|Drug|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
532234|NCT00131235|Drug|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.~2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
532235|NCT00131222|Procedure|Food supplement: fortified spread|
532236|NCT00131222|Procedure|Food supplement: maize and soy flour|
532237|NCT00131209|Dietary Supplement|fortified spread (RUTF)|
532238|NCT00131209|Dietary Supplement|maize and soy flour|
532239|NCT00131183|Drug|Nebido|
532240|NCT00131170|Procedure|paravertebral block|
532241|NCT00131157|Procedure|expert support for interpretation of spirometry|
532242|NCT00131144|Drug|Octreotide Acetate in Microspheres 20 mg|
532243|NCT00131144|Drug|Octreotide Acetate in Microspheres|
532244|NCT00131144|Drug|Placebo|
532245|NCT00131131|Behavioral|Exercise|
532246|NCT00131118|Drug|Zoledronic Acid|
532247|NCT00131105|Behavioral|The Stanford Active Choices program|
532248|NCT00131092|Behavioral|The Stanford Active Choices program|
532249|NCT00131092|Behavioral|The TLC system|
532250|NCT00131079|Behavioral|Experimental Programme for Physical Activity Promotion|"General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.~Educational materials summarizing benefits, risks and motivation.~Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log."
532251|NCT00131079|Behavioral|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
532252|NCT00131066|Other|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
532253|NCT00131053|Drug|Methotrexate|
532254|NCT00131053|Drug|Prednisolone|
532255|NCT00131053|Drug|Dexamethasone|
532256|NCT00131053|Drug|Vincristine|
532257|NCT00131053|Drug|Pirarubicin|
532258|NCT00131053|Drug|Cyclophosphamide|
532259|NCT00131053|Drug|L-asparaginase|
532260|NCT00131053|Drug|Cytarabine|
532261|NCT00131053|Drug|Hydrocortisone|
532272|NCT00131027|Drug|Methotrexate|3 g/sqm (high dose)
532273|NCT00131027|Drug|Mercaptopurine|
532274|NCT00131027|Drug|Doxorubicin|
532275|NCT00131027|Drug|Methotrexate|0.5 g/sqm (intermediate dose)
532276|NCT00131001|Procedure|contrast-enhanced magnetic resonance angiography|
532277|NCT00130988|Behavioral|DEPENAS cognitive and behavioural techniques|
532278|NCT00130975|Drug|Candesartan|
532279|NCT00130962|Drug|ALGRX 4975|
532280|NCT00130949|Drug|ALGRX 4975|
532281|NCT00130936|Drug|Epirubicin|
532282|NCT00130936|Drug|Carboplatin|
532283|NCT00130936|Drug|Capecitabine|
532284|NCT00130923|Drug|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
532285|NCT00130923|Drug|oral risperidone|0.50-6.00 mg oral risperidone daily
532286|NCT00130910|Drug|Albendazole|Albendazole 400mg x 3 first dose observed
532287|NCT00130910|Drug|Placebo|Albendazole Placebo 400mg x 3 first dose observed
532288|NCT00130897|Drug|Sutent|Sutent, 25, 37.5. or 50 mg daily
532289|NCT00130884|Drug|levosimendan|
532290|NCT00130871|Drug|levosimendan|
532291|NCT00130858|Drug|Topotecan|
532292|NCT00130858|Drug|Carboplatin|
532293|NCT00130845|Drug|Octreotide Acetate in Microspheres|
532294|NCT00130845|Drug|Placebo|
532295|NCT00130832|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
532296|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
532297|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
532298|NCT00130819|Behavioral|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
532299|NCT00130819|Behavioral|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
532300|NCT00130806|Drug|MK0478 (muraglitazar)|
532301|NCT00130806|Drug|Comparator: placebo|
532302|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
532303|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
532304|NCT00130780|Drug|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
532305|NCT00130780|Drug|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
532306|NCT00130767|Drug|finasteride|
532307|NCT00130754|Drug|Thymoglobuline|IV 7.5 mg/kg
532308|NCT00130741|Drug|CHT - herbal therapy|
532309|NCT00130728|Drug|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
532310|NCT00130728|Drug|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
532311|NCT00130728|Drug|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
532312|NCT00130715|Device|Seprafilm Bioresorbable Membrane|
532313|NCT00130702|Drug|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
532314|NCT00130689|Drug|Cetuximab|
532315|NCT00130676|Drug|Mifepristone|daily for 7 days
532316|NCT00130676|Drug|matching placebo|daily for 7 days
532317|NCT00130663|Device|PDA blood pressure screening program and chart reminder|
532318|NCT00130650|Device|Pain Ease|
532319|NCT00130637|Drug|Daclizumab|
532320|NCT00130624|Procedure|Multidisciplinary intervention: primary or secondary care|
532321|NCT00130611|Other|BNP measurement|
532322|NCT00130611|Other|Clinical examination|
532385|NCT00130156|Drug|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
532386|NCT00130143|Drug|Ethyol (Amifostine)|
532387|NCT00130117|Drug|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
532389|NCT00130117|Other|Placebo|placebo (no active medication)
532323|NCT00130598|Drug|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.~7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).~short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
532324|NCT00130585|Behavioral|Controlled diet|
532325|NCT00130585|Behavioral|folic acid supplement|
532326|NCT00130585|Behavioral|13C11-labelled folic acid supplement|
532327|NCT00130572|Drug|Pimecrolimus|
532328|NCT00130559|Procedure|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
532329|NCT00130546|Device|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
532330|NCT00130546|Device|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
532331|NCT00130533|Drug|Capecitabine|
532332|NCT00130520|Drug|bevacizumab|10mg/kg every two weeks IV-bevacizumab
532333|NCT00130520|Drug|erlotinib|150mg daily by mouth-erlotinib
532334|NCT00130507|Drug|Vinorelbine|
532335|NCT00130507|Drug|Capecitabine|
532336|NCT00130507|Drug|Trastuzumab|
532337|NCT00130494|Drug|Zoledronic acid|
532338|NCT00130481|Drug|Atorvastatin 20 mg daily for 3 months|
532339|NCT00130468|Drug|Hyalgan (sodium hyaluronate)|
532340|NCT00130455|Drug|escitalopram|
532341|NCT00130442|Drug|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
532342|NCT00130442|Drug|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
532343|NCT00130429|Drug|PYM50028|
532344|NCT00130416|Behavioral|E-mail coaching to improve patient communication with doctor|
532345|NCT00130403|Drug|risedronate sodium|
532346|NCT00130390|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
532347|NCT00130390|Other|Placebo|One placebo tablet twice daily for 28 days
532348|NCT00130377|Biological|cell therapy|autologous or allogeneic cells
532349|NCT00130364|Drug|Pimecrolimus|Pimecrolimus 1 % cream
532350|NCT00130364|Drug|Placebo|Pimecrolimus vehicle cream (placebo)
532351|NCT00130351|Device|formoterol|
532352|NCT00130338|Drug|Rivastigmine|
532353|NCT00130325|Drug|Isoniazid|Isoniazid 900mg, tablets, twice a week for 6 months
532354|NCT00130325|Drug|Isoniazid|INH 900mg twice weekly for 6 months
532355|NCT00130325|Drug|Placebo of Isoniazid tablets 300mg|Isoniazid BP 0mg twice weekly for 6 months
532356|NCT00130312|Drug|Sulodexide|
532357|NCT00130299|Behavioral|low glycemic load diet|
532358|NCT00130299|Behavioral|low fat diet|
532359|NCT00130286|Drug|Rosiglitazone|4 mg tablet twice a day x 12 weeks (double-blind phase)
532360|NCT00130286|Drug|Recombinant human growth hormone + rosiglitazone|Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
532361|NCT00130273|Behavioral|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
532362|NCT00130273|Behavioral|Standard care|Participants will receive standard of care for 12 months.
532363|NCT00130260|Biological|Staph aureus types 5 and 8 conjugate vaccine|each IM dose contains 200 mc total conjugate
532364|NCT00130260|Biological|placebo|placebo to match StaphVAX
532365|NCT00130247|Drug|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
532366|NCT00130247|Drug|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
532367|NCT00130247|Drug|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
532368|NCT00130247|Drug|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
532369|NCT00130234|Drug|Xolair® (Omalizumab)|
532370|NCT00130221|Drug|2% chlorhexidine gluconate impregnated cloth|
532371|NCT00130208|Drug|Sulodexide|100 mg sulodexide gelcaps
532372|NCT00130208|Drug|Placebo|0 mg gelcap
532373|NCT00130195|Drug|imatinib|
532374|NCT00130195|Drug|cyclophosphamide|
532375|NCT00130195|Drug|daunorubicin|
532376|NCT00130195|Drug|vincristine|
532377|NCT00130195|Drug|prednisolone|
532378|NCT00130195|Drug|methotrexate|
532379|NCT00130195|Drug|cytarabine|
532380|NCT00130195|Drug|dexamethasone|
532381|NCT00130182|Drug|denufosol tetrasodium (INS37217)|
532382|NCT00130169|Drug|E7974|Maximum Tolerated Dose defined as 0.35 mg/m^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
532383|NCT00130156|Drug|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
532384|NCT00130156|Drug|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
532388|NCT00130117|Drug|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
542233|NCT00080886|Biological|rituximab|
532390|NCT00130104|Procedure|Transthecal Metacarpal Block|
532391|NCT00130091|Drug|clonidine|2 mcg clonidine added to local anesthetic
532392|NCT00130078|Drug|1.0% C31G SAVVY vaginal gel|
532393|NCT00130065|Drug|Sulfadoxine-pyrimethamine/folic acid|
532394|NCT00130065|Drug|Sulfadoxine-pyrimethamine/placebo|
532395|NCT00130039|Drug|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
532396|NCT00130039|Drug|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
532397|NCT00130026|Drug|Caffeine|500 mg IV
532398|NCT00130013|Drug|Oral Amoxicillin|
532399|NCT00130000|Drug|Eculizumab|
532400|NCT00129987|Behavioral|Self management education|
532401|NCT00129974|Drug|pemetrexed and gemcitabine|
532402|NCT00129961|Drug|sirolimus|
532403|NCT00129961|Drug|cyclosporine or tacrolimus|
532404|NCT00129948|Drug|Troxatyl™ (troxacitabine)|
532405|NCT00129935|Drug|Docetaxel|
532406|NCT00129935|Drug|Capecitabine|
532407|NCT00129935|Drug|Epirubicin|
532408|NCT00129935|Drug|Cyclophosphamide|
532409|NCT00129922|Drug|paclitaxel|
532410|NCT00129922|Drug|Fluorouracil|
532411|NCT00129922|Drug|Epirubicin|
532412|NCT00129922|Drug|Cyclophosphamide|
532413|NCT00129909|Drug|fixed dose combination therapy|
532414|NCT00129896|Drug|Myocet|Myocet®: 60-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
532415|NCT00129896|Drug|Taxotere|Taxotere® 70-75 mg/m² ASC (vía IV) día 1 / c3s for 6 cycles
532416|NCT00129896|Drug|Herceptin|Herceptin® (4) 2 mg/kg (vía IV) Semanal for 6 cycles
532417|NCT00129883|Behavioral|Professional education|
532418|NCT00129883|Behavioral|Implementation of a Critical Care Pathway|
532419|NCT00129883|Behavioral|Professional audit and feedback|
532420|NCT00129883|Behavioral|Process analysis and redesign|
532421|NCT00129870|Drug|oxaliplatin|
532422|NCT00129857|Drug|Dexanabinol|
532423|NCT00129844|Drug|Motexafin Gadolinium|
532424|NCT00129831|Drug|QAB149|
532425|NCT00129818|Drug|Famciclovir|
532426|NCT00129805|Drug|MCI-9042|
532427|NCT00129805|Drug|Aspirin|
532428|NCT00129792|Drug|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
532429|NCT00129792|Behavioral|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
532430|NCT00129779|Behavioral|Intermediate care package|
532431|NCT00129766|Biological|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
532432|NCT00129766|Biological|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
532433|NCT00129753|Drug|Alemtuzumab (Campath-1H)|Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
532434|NCT00129740|Drug|Nilotinib|400 mg orally twice daily
532435|NCT00129727|Drug|Paclitaxel|Given intravenously
532436|NCT00129727|Drug|Carboplatin|Given intravenously
532437|NCT00129727|Drug|Bevacizumab|Given intravenously
532438|NCT00129714|Other|cervical collar|
532439|NCT00129714|Other|physiotherapy|
532440|NCT00129701|Procedure|Telephone consultation|
532441|NCT00129688|Drug|cloxacillin and amikacin (once or twice daily dosage)|
532442|NCT00129675|Drug|[123I]ß CIT|"Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
532443|NCT00129662|Behavioral|Pictorial action plan|
532444|NCT00129649|Behavioral|Telephone reminder call|
532445|NCT00129636|Procedure|Additional specific letter written to patient|
532446|NCT00129623|Drug|Placebo|po monthly for 1 year
532447|NCT00129623|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
532448|NCT00129610|Behavioral|Virtual Reality Therapy|
532449|NCT00129610|Behavioral|Cognitive Behavior Therapy|
532450|NCT00129597|Drug|ketalar|
532451|NCT00129584|Procedure|Emphasys Endobronchial Valve and procedure|
532452|NCT00129571|Drug|XL820|
532453|NCT00129558|Drug|PT-523 for Injection|
532454|NCT00129545|Device|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
532455|NCT00129545|Drug|Warfarin|Subjects receive warfarin
532456|NCT00129532|Drug|1.0% C31G SAVVY vaginal gel|
532457|NCT00129519|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
532458|NCT00129506|Drug|methotrexate + misoprostol|
532459|NCT00129506|Drug|misoprostol|
532460|NCT00129493|Behavioral|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
532461|NCT00129480|Behavioral|Assistance with Pain treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
532489|NCT00129285|Drug|Low Dose Modafinil|modafinil 200 mg/day
532462|NCT00129467|Drug|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.~If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.~Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is > 10 at day 18, the dose may be increased to 15 mg bid."
532463|NCT00129467|Drug|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.~If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
532464|NCT00129467|Drug|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.~A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
532465|NCT00129454|Behavioral|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
532466|NCT00129454|Behavioral|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
532467|NCT00129441|Drug|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
532468|NCT00129441|Drug|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
532469|NCT00129428|Procedure|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
532470|NCT00129415|Procedure|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
532471|NCT00129415|Procedure|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
532472|NCT00129402|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
532473|NCT00129402|Drug|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
532474|NCT00129389|Drug|Fluorouracil|Arm A: FAC Arm B: FAC-wP
532475|NCT00129389|Drug|Doxorubicin|Arm A: FAC Arm B: FAC-wP
532476|NCT00129389|Drug|Cyclophosphamide|Arm A: FAC Arm B: FAC-wP
532477|NCT00129389|Drug|Paclitaxel|Arm B: FAC-wP
532478|NCT00129376|Drug|Doxorubicin|
532479|NCT00129376|Drug|Cyclophosphamide|
532480|NCT00129376|Drug|Docetaxel|
532481|NCT00129363|Drug|Carvedilol|
532482|NCT00129350|Procedure|Pulmonary rehabilitation programme|
532483|NCT00129337|Drug|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
532484|NCT00129324|Procedure|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
532485|NCT00129324|Procedure|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
532486|NCT00129311|Drug|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
532487|NCT00129311|Drug|Placebo|
532488|NCT00129298|Drug|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
532490|NCT00129285|Drug|High Dose Modafinil|modafinil 400 mg/day
532491|NCT00129285|Drug|Placebo|placebo 400 mg/day
532492|NCT00129272|Drug|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
532493|NCT00129272|Other|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
532494|NCT00129259|Biological|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
532495|NCT00129259|Other|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
532496|NCT00129259|Dietary Supplement|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
532497|NCT00129246|Drug|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
532498|NCT00129246|Drug|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
532499|NCT00129233|Drug|Valsartan|valsartan 80 to 160 mg daily
532500|NCT00129233|Drug|Amlodipine|Amlodipine 5 to 10 mg daily.
532501|NCT00129220|Drug|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
532502|NCT00129220|Drug|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
532503|NCT00129220|Drug|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
532504|NCT00129207|Drug|bortezomib|
532505|NCT00129194|Drug|KP-1461|
532506|NCT00129181|Drug|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
532507|NCT00129181|Drug|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
532508|NCT00129181|Procedure|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
532509|NCT00129168|Drug|Zosuquidar|
532510|NCT00129168|Drug|Daunorubicin|
532511|NCT00129168|Drug|Cytarabine|
532512|NCT00129155|Drug|treosulfan|
532513|NCT00129142|Drug|Toremifene Citrate|
532514|NCT00129129|Biological|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
532515|NCT00129129|Biological|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
532516|NCT00129129|Biological|Pediarix|Primary phase: 3 IM doses
532517|NCT00129129|Biological|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
532518|NCT00129129|Biological|Menomune|Primary phase: 1 SC dose
532519|NCT00129116|Biological|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
532520|NCT00129116|Biological|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
532521|NCT00129116|Biological|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
532522|NCT00129116|Biological|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
532523|NCT00129116|Biological|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
532524|NCT00129090|Drug|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
532525|NCT00129077|Procedure|plastic wrap over eye & lubrication applied q6 hrs|
532526|NCT00129064|Behavioral|Electronic referral system|
532527|NCT00129051|Procedure|Tomotherapy|
532528|NCT00129038|Drug|modified-release dipyridamole/aspirin|
532529|NCT00129038|Drug|aspirin|
532530|NCT00129025|Procedure|Hypofractionated radiotherapy|
532531|NCT00129012|Procedure|Tomotherapy|
532532|NCT00128999|Procedure|Intensity-Modulated Radiation Therapy|
532533|NCT00128986|Procedure|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
532534|NCT00128947|Drug|Mycophenolic Acid|
532535|NCT00128947|Drug|Mycophenolate 7-O-Phenolic Glucuronide|
532536|NCT00128934|Drug|levonorgestrel/ethinyl estradiol|
532537|NCT00128921|Drug|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
532538|NCT00128908|Drug|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
532539|NCT00128908|Drug|Rapidly Cycled HAART|
532603|NCT00128440|Drug|tiotropium|
532540|NCT00128895|Drug|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
532541|NCT00128882|Drug|Anti-D|Subcutaneous injection
532542|NCT00128869|Procedure|spine mobilizations|
532543|NCT00128869|Procedure|spine manipulations|
532544|NCT00128856|Drug|Gemcitabine|
532545|NCT00128856|Drug|Adriamycine|
532546|NCT00128856|Drug|Paclitaxel|
532547|NCT00128843|Drug|Exemestane|25mg/day until progression disease
532548|NCT00128843|Drug|Anastrozole|1mg/day until progression disease
532549|NCT00128830|Drug|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
532550|NCT00128830|Drug|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
532551|NCT00128830|Drug|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
532552|NCT00128830|Drug|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
532553|NCT00128817|Radiation|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
532554|NCT00128817|Procedure|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
532555|NCT00128804|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
532556|NCT00128791|Drug|Nitroprusside|
532557|NCT00128778|Drug|Pegylated liposomal doxorubicin|
532558|NCT00128765|Behavioral|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
532559|NCT00128765|Behavioral|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
532560|NCT00128765|Behavioral|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
532561|NCT00128752|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
532562|NCT00128739|Drug|Budesonide|
532563|NCT00128713|Procedure|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10^11 platelets per m^2 BSA
532564|NCT00128713|Procedure|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10^11 platelets per m^2 BSA
532565|NCT00128713|Procedure|Higher Dose Prophylactic Platelet Transfusions|4.4 * 10^11 platelets per m^2 BSA
532566|NCT00128700|Drug|temozolomide|
532567|NCT00128700|Drug|vatalanib|
532568|NCT00128700|Procedure|adjuvant therapy|
532569|NCT00128700|Radiation|radiation therapy|
532570|NCT00128687|Behavioral|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
532571|NCT00128661|Biological|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
532572|NCT00128661|Biological|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
532573|NCT00128635|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
532574|NCT00128622|Biological|denileukin diftitox|
532575|NCT00128622|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
532576|NCT00128622|Biological|therapeutic autologous dendritic cells|
532577|NCT00128596|Drug|arsenic trioxide|
532578|NCT00128583|Biological|polyvalent melanoma vaccine|
532579|NCT00128570|Behavioral|behavioral dietary intervention|
532580|NCT00128570|Other|educational intervention|
532581|NCT00128570|Other|internet-based intervention|
532582|NCT00128570|Other|preventative dietary intervention|
532583|NCT00128570|Procedure|evaluation of cancer risk factors|
532584|NCT00128557|Drug|vitamin A supplementation (50,000 IU)|
532585|NCT00128544|Drug|telbivudine|
532586|NCT00128544|Drug|valtorcitabine|
532587|NCT00128531|Drug|leuprolide acetate|
532588|NCT00128518|Drug|Indapamide (T2)|1.5 mg/day during 4 weeks
532589|NCT00128518|Drug|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
532590|NCT00128518|Drug|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
532591|NCT00128518|Drug|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
532592|NCT00128505|Drug|Mifepristone|
532593|NCT00128492|Drug|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
532594|NCT00128479|Drug|mifepristone|mifepristone 300 mg daily for 7 dats
532595|NCT00128479|Drug|mifepristone matched placebo|daily for 7 days
532596|NCT00128479|Drug|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
532597|NCT00128479|Drug|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
532598|NCT00128466|Drug|gentamicin|
532599|NCT00128466|Drug|streptomycin|
532600|NCT00128453|Drug|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients>70Kg) or 0.5mg once daily
532601|NCT00128453|Drug|Placebo|placebo
532602|NCT00128440|Drug|BEA 2180 BR|
532604|NCT00128427|Drug|Colchicine (for 1 month)|
532605|NCT00128414|Drug|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
532606|NCT00128414|Drug|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
532607|NCT00128401|Drug|D-Cycloserine|
532608|NCT00128401|Drug|Placebo|
532609|NCT00128388|Other|PFPP|Psychoanalytic Psychotherapy for panic disorder
532610|NCT00128388|Other|ART|Applied Relaxation Training
532611|NCT00128375|Behavioral|Financial incentives|
532612|NCT00128362|Procedure|Radio-guided sentinel node biopsy|
532613|NCT00128362|Procedure|Axillary sampling|
532614|NCT00128336|Behavioral|Lifestyle: diet and exercise intervention|
532615|NCT00128323|Drug|Gentian violet 1% solution|
532616|NCT00128323|Drug|Gentian violet 0.00165% solution|
532617|NCT00128323|Drug|Nystatin solution|
532618|NCT00128310|Drug|Vinorelbine|
532619|NCT00128310|Drug|Gemcitabine|
532620|NCT00128297|Drug|Pamidronate|
532621|NCT00128271|Drug|Bavituximab|
532622|NCT00128258|Procedure|Injection of bone marrow cells in the heart|Biological implant into the heart
532623|NCT00128258|Biological|Biological bone marrow cell therapy|Biological implant into the heart
532624|NCT00128245|Drug|Pimecrolimus|
532625|NCT00128232|Drug|Octreotide LAR|
532626|NCT00128219|Biological|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
532627|NCT00128219|Biological|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
532628|NCT00128206|Drug|Isoniazid|Isoniazid 900 mg twice weekly
532629|NCT00128206|Drug|Rifampin|Rifampin 600mg once per day
532630|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
532631|NCT00128193|Other|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
532632|NCT00128193|Other|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
532633|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
532634|NCT00128193|Other|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
532635|NCT00128180|Drug|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
532636|NCT00128180|Drug|Placebo|Placebo
532637|NCT00128167|Drug|Liquid CAIV-T|
532638|NCT00128154|Drug|Chromium picolinate|
532639|NCT00128141|Behavioral|Tactile stimulus|four times a day
532640|NCT00128128|Drug|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
532641|NCT00128115|Drug|MK0677|
532642|NCT00128102|Drug|vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
532643|NCT00128102|Drug|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
532644|NCT00128089|Behavioral|Dietary treatment|
532645|NCT00128076|Procedure|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
532646|NCT00128076|Procedure|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
532647|NCT00128063|Drug|succinylated human serum albumin|
532648|NCT00128050|Drug|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
532649|NCT00128050|Drug|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
532650|NCT00128050|Other|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
532651|NCT00128037|Drug|mitomycin C, vindesine, cisplatin and radiotherapy|
532652|NCT00128024|Drug|lipid-lowering treatment|
532653|NCT00128011|Biological|killed oral cholera vaccine|
532654|NCT00127998|Drug|chloroquine|
532655|NCT00127998|Drug|sulfadoxine-pyrimethamine|
532656|NCT00127998|Drug|amodiaquine|
532657|NCT00127998|Drug|amodiaquine+artesunate|
532658|NCT00127998|Drug|amodiaquine+sulfadoxine-pyrimethamine|
532659|NCT00127998|Drug|sulfadoxine-pyrimethamine+artesunate|
532660|NCT00127998|Drug|artemether-lumefantrine|
532661|NCT00127998|Drug|mefloquine|
532662|NCT00127985|Drug|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
532663|NCT00127972|Drug|stavudine|
532664|NCT00127972|Drug|lamivudine|
532665|NCT00127972|Drug|nevirapine|
532666|NCT00127972|Drug|efavirenz|
532667|NCT00127972|Drug|trizivir|
532668|NCT00127959|Drug|tenofovir|
532669|NCT00127959|Drug|emtricitabine|
532670|NCT00127959|Drug|zidovudine|
532671|NCT00127959|Drug|efavirenz|
532783|NCT00127101|Drug|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
532672|NCT00127946|Procedure|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
532673|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
532674|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
532675|NCT00127933|Drug|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
532676|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
532677|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
532678|NCT00127920|Drug|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
532679|NCT00127907|Drug|epinephrine (1 mg/1 mL)|
532680|NCT00127907|Drug|arginine-vasopressin (40 UI/2 mL)|
532681|NCT00127881|Drug|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
532682|NCT00127868|Drug|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
532683|NCT00127855|Biological|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
532684|NCT00127855|Biological|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
532685|NCT00127855|Biological|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
532686|NCT00127855|Biological|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
532687|NCT00127855|Biological|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
532688|NCT00127855|Biological|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
532689|NCT00127855|Biological|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
532690|NCT00127842|Drug|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
532691|NCT00127829|Drug|Gefitinib|Oral tablet
532692|NCT00127816|Procedure|Permanent prostate implant|
532693|NCT00127803|Biological|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
532694|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
532695|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
532696|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
532697|NCT00127790|Behavioral|CBT for Insomnia (CBT-I)|
532698|NCT00127790|Behavioral|CBT for Pain (CBT-P)|
532699|NCT00127777|Drug|Amantadine sulphate (in addition to standard treatment)|
532700|NCT00127764|Drug|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
532701|NCT00127751|Behavioral|Enhance health lifestyle changes and medication compliance|
532702|NCT00127738|Procedure|Angiographic renal revascularization|
532703|NCT00127725|Device|Pulsed electromagnetic field stimulation|
532704|NCT00127712|Drug|Amiodarone|
532705|NCT00127699|Procedure|Alcohol swab of umbilical cord|
532706|NCT00127686|Drug|Dextromethorphan|
532707|NCT00127686|Drug|Buckwheat Honey|
532708|NCT00127673|Drug|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
532709|NCT00127673|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
532710|NCT00127660|Behavioral|Menu: calories=yes, value pricing=no|
532711|NCT00127660|Behavioral|Menu: calories=yes, value pricing = yes|
532712|NCT00127660|Behavioral|Menu: calories=no, value pricing = no|
532713|NCT00127647|Drug|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
532714|NCT00127647|Drug|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
532715|NCT00127634|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
532716|NCT00127634|Drug|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
532717|NCT00127634|Drug|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
532718|NCT00127621|Procedure|early tracheotomy|
532719|NCT00127621|Procedure|prolonged endotracheal intubation|
532720|NCT00127608|Procedure|Collection of clinical samples|"The following samples were obtained from each subject:~Vesicle fluid (VF) and vesicle swabs (VS) from four vesicles (for a total of eight samples)~Papule swabs (PS) from four papules~Crusts from two lesions~One throat swab (TS) Up to 15 samples were to be obtained for each subject, when possible. VFs, VSs, PSs, and crusts were either stored dry or in liquid medium. TS samples were stored in liquid medium.~After extraction of DNA, samples were tested for the presence of varicella virus using a Quantitative Polymerase Chain Reaction (Q-PCR) technique."
532721|NCT00127595|Drug|gemcitabine, oxaliplatin|
532722|NCT00127582|Procedure|Electrophysiological study|
532723|NCT00127582|Device|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
532724|NCT00127569|Drug|Rituximab|
532725|NCT00127556|Procedure|Label applied to blood bag|
532726|NCT00127543|Behavioral|Medication Education for Children|
532727|NCT00127530|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
532728|NCT00127530|Drug|Placebo|sugar pill, twice a day (b.i.d.)
532729|NCT00127517|Drug|peptide-nucleic acid solution AVR118|
532730|NCT00127504|Drug|Rifampin|
532731|NCT00127504|Drug|Azithromycin|
532784|NCT00127101|Drug|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
532785|NCT00127088|Drug|docetaxel|
542234|NCT00080886|Drug|carmustine|
532732|NCT00127491|Procedure|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
532733|NCT00127491|Other|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
532734|NCT00127491|Other|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
532735|NCT00127478|Drug|Atrasentan|
532736|NCT00127465|Procedure|Issue of information booklet|
532737|NCT00127452|Dietary Supplement|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
532738|NCT00127439|Procedure|Manually Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
532739|NCT00127439|Other|Robotic Assisted Locomotor Training|The total program is 45 sessions, 5x/week with total locomotor training (LT) duration of 30 stepping minutes/day. 1) BWS is initiated at 40% and gradually decreasing to 0%, 2) treadmill speed is set at normal walking speeds and increased as tolerated, and 3) manual assistance given when the subject is unable to independently step or control upright posture, and decreased as participant progresses. Trainers assist via verbal cues and manual assistance to achieve good stepping. The goal for endurance is 20 mins of continuous, independent, coordinated stepping on the treadmill at 0% BWS. Participants are encouraged to assist and/or independently maintain an upright posture, weight shift onto the loaded limb, flex or extend their legs, and to swing their arms in coordination with the legs.
532740|NCT00127413|Behavioral|Cognitive Behavioral Therapy - Pain|Pain treatment
532741|NCT00127413|Behavioral|Cognitive Behavioral Therapy-Integrated|Integrated treatment
532742|NCT00127413|Behavioral|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
532743|NCT00127413|Behavioral|Treat as Usual|Treatment as usual
532744|NCT00127400|Behavioral|anger management therapy|
532745|NCT00127387|Drug|Enbrel|
532746|NCT00127374|Behavioral|Dietary and physical activity modifications|
532747|NCT00127361|Behavioral|doula training|
532748|NCT00127348|Device|CPAP (Continuous Positive Airway Pressure)|
532749|NCT00127335|Drug|cellulose placebo vs. atorvastatin|drug
532750|NCT00127309|Drug|Glutathione|
532751|NCT00127296|Device|FlexPen®|
532752|NCT00127296|Device|vial and syringe|
532753|NCT00127283|Drug|eptacog alfa (activated)|
532754|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
532755|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
532756|NCT00127270|Behavioral|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
532757|NCT00127257|Behavioral|Biofeedback|
532758|NCT00127257|Drug|Diazepam|
532759|NCT00127257|Behavioral|Pelvic floor retraining|
532760|NCT00127244|Procedure|Periodontal Treatment|
532761|NCT00127231|Behavioral|Brief alcohol intervention based on Project Treat|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
532762|NCT00127231|Behavioral|Standard care|Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.
532763|NCT00127218|Drug|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
532764|NCT00127218|Drug|niacin|long-acting niacin daily for 18 months
532765|NCT00127218|Drug|Placebo|matching placebo pill daily for 18 months
532766|NCT00127205|Drug|clodronate disodium|Given orally
532767|NCT00127205|Drug|ibandronate sodium|Given orally
532768|NCT00127205|Drug|zoledronic acid|Given IV
532769|NCT00127192|Drug|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
532770|NCT00127192|Drug|Comparator: placebo (unspecified)|placebo QD 12-weeks
532771|NCT00127179|Drug|MK0906, finasteride / Duration of Treatment: 48 weeks|
532772|NCT00127179|Drug|Comparator: placebo / Duration of Treatment: 48 weeks|
532773|NCT00127166|Drug|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
532774|NCT00127166|Drug|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
532775|NCT00127166|Drug|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
532776|NCT00127166|Drug|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
532777|NCT00127166|Drug|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
532778|NCT00127153|Biological|V110, pneumococcal vaccine polyvalent|
532779|NCT00127140|Drug|vorinostat|
532780|NCT00127127|Drug|vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|vorinostat; level 1: 100 mg BID 14-day, level 2: 200 mg BID 14-day, level 3: 400 mg QD 14 day, level 5: 500 mg QD 14-day
532781|NCT00127114|Drug|Amantadine|
532782|NCT00127114|Drug|Placebo|
532786|NCT00127088|Procedure|laparoscopic radical prostatectomy|
532787|NCT00127075|Drug|nomegestrol acetate|10 mg/day
532788|NCT00127075|Drug|estradiol|75 mcg, once a week
532789|NCT00127075|Drug|placebo|matching placebo treatments
532790|NCT00127062|Other|Oxford street|2 h walk around Oxford street
532791|NCT00127062|Other|Hyde park|2 h walk around Hyde park
532792|NCT00127049|Drug|gemcitabine, ifosfamide, cisplatin, G-CSF|
532793|NCT00127036|Drug|XELOX|XELOX: Oxaliplatin 130 mg/m^2 intravenously (IV); Capecitabine 825 mg/m^2 by mouth (po)
532794|NCT00127036|Drug|XELIRI|XELIRI: Irinotecan 240 mg/m^2 IV; Capecitabine 825 mg/m^2 by mouth (po)
532795|NCT00127036|Drug|Bevacizumab|7.5 mg/kg intravenously (IV)
532796|NCT00127023|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
532797|NCT00127010|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
532798|NCT00126997|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
532799|NCT00126984|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
532800|NCT00126984|Biological|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
532801|NCT00126984|Biological|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
532802|NCT00126984|Biological|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
532803|NCT00126971|Drug|chlorproguanil-dapsone|
532804|NCT00126958|Procedure|urinary analysis|
532805|NCT00126945|Biological|Meningococcal Vaccine|
532806|NCT00126932|Device|SonoPrep|
532807|NCT00126919|Device|SonoPrep|
532808|NCT00126906|Drug|Monthly sulfadoxine/pyrimethamine|
532809|NCT00126906|Drug|2-dose sulfadoxine/pyrimethamine|
532810|NCT00126893|Drug|CC-401|
532811|NCT00126880|Drug|AVX754|apricitabine, 600mg BID or 800mg BID
532812|NCT00126880|Drug|3TC|3TC, 150mg BID
532813|NCT00126854|Procedure|Magnetic Resonance Spectroscopy Imaging|
532814|NCT00126841|Procedure|CT and MR fusion|
532815|NCT00126828|Procedure|External beam radiotherapy|
532816|NCT00126802|Procedure|Tomotherapy|Standard 45 Gy in 25 fractions in 5 weeks
532817|NCT00126789|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
532818|NCT00126776|Behavioral|case management|case/self management for COPD vs usual care
532819|NCT00126776|Behavioral|usual care|usual care for COPD
532820|NCT00126763|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
532821|NCT00126750|Behavioral|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
532822|NCT00126737|Other|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
532823|NCT00126737|Other|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
532824|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^11 DRP/mL
532825|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
532826|NCT00126724|Genetic|tgAAC94 placebo|placebo
532827|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^12 DRP/mL tgAAC94
532828|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
532829|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^13 DRP/mL tgAAC94
532830|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
532831|NCT00126698|Drug|trimethoprim-sulfamethoxazole|
532832|NCT00126698|Drug|ciprofloxacin|
532833|NCT00126685|Biological|autologous tumor cell vaccine|
532834|NCT00126685|Biological|therapeutic autologous dendritic cells|
532835|NCT00126672|Drug|sirolimus|
532836|NCT00126659|Procedure|therapeutic conventional surgery|Undergo cytoreductive nephrectomy
532837|NCT00126659|Drug|sorafenib tosylate|Given orally
532838|NCT00126659|Other|laboratory biomarker analysis|Correlative studies
532839|NCT00126646|Drug|BL22 immunotoxin|
532840|NCT00126646|Procedure|antibody-drug conjugate therapy|
532841|NCT00126646|Procedure|immunotoxin therapy|
532842|NCT00126633|Biological|bevacizumab|
532843|NCT00126633|Drug|cisplatin|
532844|NCT00126633|Drug|gemcitabine hydrochloride|
532845|NCT00126620|Drug|erlotinib hydrochloride|
532846|NCT00126620|Drug|sorafenib tosylate|
532847|NCT00126607|Biological|trastuzumab|Given IV
532848|NCT00126607|Other|laboratory biomarker analysis|Correlative studies
532849|NCT00126594|Drug|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
532850|NCT00126594|Biological|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10^6 international units twice daily
532851|NCT00126594|Other|Laboratory Biomarker Analysis|Correlative studies
532852|NCT00126581|Drug|Carboplatin|Given IV
532853|NCT00126581|Drug|Erlotinib|Given PO
532854|NCT00126581|Drug|Erlotinib Hydrochloride|Given PO
532855|NCT00126581|Drug|Paclitaxel|Given IV
532856|NCT00126568|Drug|sorafenib tosylate|Given orally
532857|NCT00126555|Drug|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
532858|NCT00126555|Radiation|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
532859|NCT00126555|Procedure|Conventional surgery|Undergo surgery
532860|NCT00126555|Other|laboratory biomarker analysis|Correlative studies
532861|NCT00126542|Biological|bevacizumab|Given IV
532862|NCT00126542|Drug|erlotinib hydrochloride|Given orally
532863|NCT00126542|Other|laboratory biomarker analysis|Correlative studies
532864|NCT00126516|Drug|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
532865|NCT00126516|Drug|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
532866|NCT00126503|Biological|Bevacizumab|Given IV
532867|NCT00126503|Drug|Sorafenib Tosylate|Given PO
532868|NCT00126503|Other|Pharmacological Study|Correlative studies
532869|NCT00126503|Other|Laboratory Biomarker Analysis|Correlative studies
532870|NCT00126490|Biological|Aldesleukin|Given subcutaneously
532871|NCT00126490|Biological|Bevacizumab|Given IV
532872|NCT00126490|Other|Laboratory Biomarker Analysis|Correlative studies
532873|NCT00126477|Procedure|cognitive assessment|
532874|NCT00126477|Procedure|management of therapy complications|
532875|NCT00126477|Procedure|psychosocial assessment and care|
532876|NCT00126477|Procedure|quality-of-life assessment|
532877|NCT00126464|Drug|fulvestrant|
532878|NCT00126464|Drug|tamoxifen citrate|
532879|NCT00126464|Procedure|conventional surgery|
532880|NCT00126464|Procedure|neoadjuvant therapy|
532881|NCT00126451|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
532882|NCT00126451|Drug|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
532883|NCT00126438|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
532884|NCT00126425|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single dose
532885|NCT00126412|Drug|123I-mIBG (meta-iodobenzylguanidine)|
532886|NCT00126399|Drug|doxycycline|
532887|NCT00126386|Drug|Zoledronic acid (Zometa)|
532888|NCT00126373|Drug|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
532889|NCT00126360|Drug|Timing of Anastrozole in respect to radiotherapy|
532890|NCT00126347|Procedure|supplementation with betaine, serine, and folic acid|
532891|NCT00126334|Procedure|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
532892|NCT00126321|Drug|cladribine|2-chlorodeoxyadenosine, 2-CdA
532893|NCT00126308|Device|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
532894|NCT00126308|Device|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
532895|NCT00126295|Device|'What you need to know about stroke' education package|
532896|NCT00126282|Behavioral|behavior therapy|
532897|NCT00126282|Drug|D-Cycloserine|
532898|NCT00126269|Drug|cisplatin|
532899|NCT00126269|Drug|gemcitabine|
532900|NCT00126256|Drug|5-fluorouracil|
532901|NCT00126256|Drug|leucovorin|
532902|NCT00126256|Drug|irinotecan|
532903|NCT00126256|Drug|oxaliplatin|
532904|NCT00126243|Drug|rituximab|
532905|NCT00126243|Drug|CHOP|
532906|NCT00126230|Drug|docetaxel and samarium|
532907|NCT00126217|Biological|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
532908|NCT00126204|Drug|Doxycycline|
532909|NCT00126191|Drug|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
532910|NCT00126191|Drug|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
532911|NCT00126191|Drug|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
532912|NCT00126191|Drug|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
532913|NCT00126191|Drug|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
532914|NCT00126191|Drug|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
532915|NCT00126191|Drug|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
532916|NCT00126191|Drug|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
532917|NCT00126191|Drug|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
532918|NCT00126191|Drug|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
532919|NCT00126178|Biological|HSPPC-96|
532920|NCT00126165|Procedure|radiotherapy|
532921|NCT00126152|Behavioral|Exercise, education and medical management|
532922|NCT00126139|Drug|Abciximab|
542235|NCT00080886|Drug|cytarabine|
532923|NCT00126126|Other|EBAR Program|Evidence Based Amputee Rehabilitation Program
532924|NCT00126113|Behavioral|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
532925|NCT00126113|Behavioral|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
532926|NCT00126100|Drug|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
532927|NCT00126100|Other|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
532928|NCT00126087|Drug|dopamine|
532929|NCT00126074|Drug|Tedisamil sesquifumarate|
532930|NCT00126061|Drug|Tedisamil sesquifumarate|
532931|NCT00126048|Drug|Atorvastatin|40mg tablet
532932|NCT00126048|Drug|Placebo|Placebo tablet
532933|NCT00126035|Device|Migraid|
532934|NCT00126022|Drug|Tedisamil sesquifumarate|
532935|NCT00126009|Drug|Amisulpride|
532936|NCT00125996|Drug|Venofer (intravenous iron sucrose)|
532937|NCT00125983|Drug|Lopinavir/ritonavir|
532938|NCT00125983|Drug|Ortho Novum 1/35|
532939|NCT00125983|Drug|Ortho Evra|
532940|NCT00125970|Biological|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
532941|NCT00125970|Biological|VRC-HIVADV014-00-VP|1 x 10^10 PU administered in deltoid
532942|NCT00125970|Biological|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
532943|NCT00125970|Biological|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
532944|NCT00125957|Drug|Wellbutrin|
532945|NCT00125957|Drug|Placebo|
532946|NCT00125944|Biological|FluMist|
532947|NCT00125931|Drug|Talwin Nx|Talwin NX 50mg po twice
532948|NCT00125918|Drug|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
532949|NCT00125918|Drug|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
532950|NCT00125918|Drug|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
532951|NCT00125918|Drug|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
532952|NCT00125918|Drug|placebo|placebo tablet taken by mouth once a day for 16 weeks
532953|NCT00125905|Behavioral|Advice|
532954|NCT00125905|Behavioral|Motivational Interviewing|
532955|NCT00125905|Drug|Nicotine Gum and Patch|
532956|NCT00125905|Drug|Bupropion|
532957|NCT00125892|Drug|duloxetine|
532958|NCT00125879|Biological|Myozyme|20 mg/kg qow or 40 mg/kg qow
532959|NCT00125866|Behavioral|Flavonoid rich or flavonoid depleted chocolate drink|
532960|NCT00125853|Drug|Nebivolol|Nebivolol 25mg daily
532961|NCT00125853|Drug|Atenolol|Atenolol 25mg daily
532962|NCT00125840|Drug|clofarabine (IV formulation)|
532963|NCT00125827|Drug|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
532964|NCT00125814|Drug|Interferon alfa-2b|
532965|NCT00125814|Procedure|Structured treatment interruptions|
532966|NCT00125801|Drug|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
532967|NCT00125788|Drug|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
532968|NCT00125788|Drug|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
532969|NCT00125775|Biological|Engerix-B|Engerix-B at 0, 1, 6 months
532970|NCT00125762|Device|FibroScan|
532971|NCT00125749|Biological|Dendritic cell vaccination|Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells
532972|NCT00125736|Drug|E0671|One 50 mg capsule is orally administered three times daily (150 mg/day)
532973|NCT00125736|Drug|rabeprazole sodium|One 10mg tablet is administered orally each day
532974|NCT00125736|Drug|E0671 placebo|One 50 mg capsule is orally administered three times daily (150 mg/day)
532975|NCT00125723|Other|PI Discretion|PI Discretion
532976|NCT00125697|Procedure|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
532977|NCT00125684|Drug|morphine|
532978|NCT00125671|Drug|Warfarin|
532979|NCT00125658|Other|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
532980|NCT00125658|Other|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
532981|NCT00125645|Drug|Irbesartan Oral Tablet|
532982|NCT00125632|Procedure|Eccentric Viewing Training for Reading|
533034|NCT00125190|Drug|rhIGF-1 (mecasermin) for a period of 86 weeks|once a day rhIGF-1 injections
533035|NCT00125177|Behavioral|Knack therapy|
532983|NCT00125619|Behavioral|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
532984|NCT00125606|Procedure|conditioning for allogeneic HSCT|
532985|NCT00125593|Drug|Simvastatin 20 mg|Once daily
532986|NCT00125593|Drug|Ezetimibe 10mg|Once daily
532987|NCT00125593|Drug|Placebo|Once daily
532988|NCT00125580|Behavioral|Infant sleep instruction|
532989|NCT00125567|Drug|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
532990|NCT00125567|Drug|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
532991|NCT00125554|Drug|Metyrapone|
532992|NCT00125541|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
532993|NCT00125528|Drug|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
532994|NCT00125528|Drug|placebo|placebo bid
532995|NCT00125515|Drug|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
532996|NCT00125515|Drug|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
532997|NCT00125502|Biological|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
532998|NCT00125502|Drug|MF59 adjuvant|Oil-in-water emulsion
532999|NCT00125502|Drug|Placebo|Normal saline solution
533000|NCT00125489|Drug|chloroquine sulfate|
533001|NCT00125489|Drug|sulfadoxine/pyrimethamine|
533002|NCT00125476|Behavioral|Exercise|
533003|NCT00125463|Drug|Candesartan cilexetil|
533004|NCT00125450|Procedure|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
533005|NCT00125450|Procedure|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
533006|NCT00125437|Drug|spironolactone|
533007|NCT00125424|Drug|AQUAVAN® (fospropofol disodium) Injection|
533008|NCT00125424|Drug|Midazolam HCl|
533009|NCT00125411|Drug|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.~Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
533010|NCT00125398|Drug|AQUAVAN (fospropofol disodium; GPI 15715 )|
533011|NCT00125385|Biological|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
533012|NCT00125385|Biological|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
533013|NCT00125385|Biological|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
533014|NCT00125385|Biological|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
533015|NCT00125385|Biological|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
533016|NCT00125372|Drug|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
533017|NCT00125359|Drug|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
533018|NCT00125346|Drug|Tobramycin Inhalation Powder|
533019|NCT00125333|Drug|NF-kappaB Decoy|
533020|NCT00125320|Drug|RSD1235|
533021|NCT00125307|Drug|tacrolimus|
533022|NCT00125294|Drug|Methadone|
533023|NCT00125281|Drug|S-adenosyl-methionine (SAMe) capsules|
533024|NCT00125268|Device|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
533025|NCT00125268|Device|Sham Device|The sham device is non-active but otherwise identical to the study device.
533026|NCT00125255|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
533027|NCT00125255|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
533028|NCT00125242|Behavioral|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
533029|NCT00125229|Drug|Mannitol|
533030|NCT00125229|Drug|Hypertonic Saline|
533031|NCT00125216|Behavioral|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
533032|NCT00125203|Drug|Botulinum toxin type B (Myobloc)|
533033|NCT00125203|Procedure|Injection of salivary glands|
533036|NCT00125164|Drug|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
533037|NCT00125151|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|
533038|NCT00125138|Drug|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
533039|NCT00125138|Drug|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
533040|NCT00125138|Drug|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
533041|NCT00125138|Drug|Placebo|Syrup formulation
533042|NCT00125125|Drug|Fluvastatin|
533043|NCT00125112|Behavioral|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
533044|NCT00125099|Biological|VRC-HIVDNA009-00-VP|
533045|NCT00125086|Device|autologous platelet gel|
533046|NCT00125073|Behavioral|Postoperative nutritional counseling|
533047|NCT00125060|Drug|Simvastatin (20mg versus 80mg/day)|
533048|NCT00125047|Biological|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
533049|NCT00125047|Biological|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
533050|NCT00125034|Biological|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
533051|NCT00125034|Drug|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).~Until progression or unacceptable toxicity develops"
533052|NCT00125021|Drug|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
533053|NCT00125021|Drug|OSI-774|Given once daily
533054|NCT00125008|Biological|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
533055|NCT00125008|Biological|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
533056|NCT00124995|Drug|terbutaline|
533057|NCT00124982|Drug|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
533058|NCT00124982|Drug|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
533059|NCT00124982|Drug|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
533060|NCT00124969|Drug|Amlodipine|10mg
533061|NCT00124969|Drug|Placebo|10mg
533062|NCT00124956|Drug|Doxorubicin|
533063|NCT00124943|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
533064|NCT00124930|Drug|Olanzapine|
533065|NCT00124930|Drug|Haldol|
533066|NCT00124917|Radiation|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 centigray (cGy) in 180 cGy daily fractions.[1]
533067|NCT00124904|Behavioral|Biofeedback|
533068|NCT00124904|Behavioral|Kegel exercises|
533069|NCT00124891|Drug|Double-blind investigational anti-arrhythmic|
533070|NCT00124891|Drug|GAP-486|
533071|NCT00124878|Procedure|Male circumcision|Sleeve circumcision
533072|NCT00124865|Biological|rFla-MBP|
533073|NCT00124852|Behavioral|n-3 Fatty Acid Supplementation|
533074|NCT00124839|Drug|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
533075|NCT00124826|Drug|Insulin|
533076|NCT00124813|Drug|thalidomide|
533077|NCT00124813|Drug|idarubicin|oral idarubicin
533078|NCT00124800|Behavioral|Tinnitus retraining therapy|Sound therapy and counseling
533079|NCT00124800|Device|Sound therapy|sound therapy and counselling
533080|NCT00124787|Drug|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
533081|NCT00124787|Drug|Placebo|Placebo PO q 6 hours x 4 doses
533082|NCT00124774|Procedure|Nucleoplasty|
533083|NCT00124761|Procedure|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
533084|NCT00124761|Radiation|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
533085|NCT00124748|Drug|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
533086|NCT00124735|Drug|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
533087|NCT00124735|Drug|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
533088|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
533089|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
533090|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
533091|NCT00124709|Drug|Pimecrolimus|Pimecrolimus cream 1 %
533092|NCT00124709|Drug|Corticosteroid|conventional corticosteroid-based treatment
533093|NCT00124696|Drug|Cocaethylene|
533094|NCT00124683|Drug|Bupropion|
533095|NCT00124683|Drug|nicotine transdermal patch|
542236|NCT00080886|Drug|etoposide|
533096|NCT00124657|Drug|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
533097|NCT00124644|Drug|cytarabine|
533098|NCT00124644|Drug|daunorubicin hydrochloride|
533099|NCT00124644|Drug|etoposide|
533100|NCT00124644|Drug|tipifarnib|
533101|NCT00124644|Procedure|chemotherapy|
533102|NCT00124644|Procedure|enzyme inhibitor therapy|
533103|NCT00124644|Procedure|high-dose chemotherapy|
533104|NCT00124618|Biological|cetuximab|
533105|NCT00124618|Radiation|radiation therapy|
533106|NCT00124605|Drug|pamidronate disodium|Given IV
533107|NCT00124605|Drug|arsenic trioxide|Given IV
533108|NCT00124605|Other|laboratory biomarker analysis|Correlative studies
533109|NCT00124605|Other|pharmacological study|Correlative studies
533110|NCT00124579|Drug|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
533111|NCT00124579|Drug|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
533112|NCT00124579|Drug|thalidomide|100 mg/d PO days 1-21 every 21 days
533113|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
533114|NCT00124566|Drug|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
533115|NCT00124566|Drug|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m^2 per day, once every 3 weeks.
533116|NCT00124566|Drug|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m^2 twice daily for 15 days every 28 days.
533117|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
533118|NCT00124553|Behavioral|Intensive dietary advice|
533119|NCT00124540|Drug|misoprostol|
533120|NCT00124540|Drug|placebo|placebo resembling misoprosotl
533121|NCT00124527|Drug|Irofulven + capecitabine|
533122|NCT00124514|Drug|Triptorelin pamoate|IM injection given monthly
533123|NCT00124501|Behavioral|Biofeedback-assisted relaxation training|10 sessions BART
533124|NCT00124488|Device|Tomotherapy Treatment Planning|
533125|NCT00124475|Drug|alitretinoin|
533126|NCT00124462|Device|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
533127|NCT00124462|Device|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
533128|NCT00124449|Drug|Abatacept|"solution, intravenous injection, monthly, 169 days~weight based:~<60 kg = 500 mg~60 to 100 kg = 750 mg~>100 kg = 1 g"
533129|NCT00124449|Drug|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
533130|NCT00124436|Drug|alitretinoin|
533131|NCT00124423|Procedure|Megavoltage CT scan|
533132|NCT00124397|Drug|Atorvastatin|
533133|NCT00124384|Behavioral|CBT-I|
533134|NCT00124384|Drug|modafinil|
533135|NCT00124371|Behavioral|a nurse led home-based education and support programme|
533136|NCT00124358|Drug|Buprenorphine|
533137|NCT00124358|Behavioral|Integrated HIV care and office-based opioid dependence treatment|
533138|NCT00124345|Device|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
533139|NCT00124332|Drug|Rimonabant (SR141716)|
533140|NCT00124332|Drug|Placebo|
533141|NCT00124306|Drug|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
533142|NCT00124306|Other|Placebo|Placebo will be dosed exactly as active arm.
533143|NCT00124293|Drug|activated recombinant human factor VII|
533144|NCT00124280|Drug|RAD001|
533145|NCT00124267|Drug|Intrarectal quinine|
533146|NCT00124254|Procedure|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
533147|NCT00124254|Other|Usual care|Non-surgical usual care
533148|NCT00124241|Drug|telbivudine|
533149|NCT00124241|Drug|lamivudine|
533150|NCT00124228|Drug|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
533151|NCT00124215|Biological|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
533152|NCT00124202|Behavioral|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
533153|NCT00124189|Drug|GRN163L|Weekly intravenous infusion
533154|NCT00124176|Drug|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
533155|NCT00124176|Drug|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
533156|NCT00124163|Procedure|Imaging procedure of CT colonography|
533157|NCT00124150|Drug|Intravenous magnesium sulfate infusion|80mg per day
533158|NCT00124137|Device|Aquadex system|
533159|NCT00124137|Drug|IV diuretic|
533228|NCT00123591|Drug|activated recombinant human factor VII|
533229|NCT00123578|Drug|Lorazepam|Lorazepam
533230|NCT00123578|Drug|Pentobarbital|Pentobarbital
533231|NCT00123565|Drug|Hexadecasaccharide (SR123781A)|
533232|NCT00123552|Drug|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
542237|NCT00080886|Drug|melphalan|
533160|NCT00124124|Drug|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
533161|NCT00124124|Drug|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
533162|NCT00124111|Drug|pegfilgrastim|
533163|NCT00124111|Drug|cyclophosphamide|
533164|NCT00124111|Drug|methotrexate|
533165|NCT00124111|Drug|5-fluorouracil|
533166|NCT00124098|Drug|Aranesp® (darbepoetin alfa)|
533167|NCT00124085|Behavioral|Disease Management|
533168|NCT00124085|Behavioral|Disease Management + Educational Home Visits|
533169|NCT00124072|Drug|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
533170|NCT00124072|Dietary Supplement|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
533171|NCT00124072|Drug|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
533172|NCT00124072|Drug|Placebo|Placebo vitamin B12/folic acid tablet once daily
533173|NCT00124059|Drug|Seroquel|400mg/day quetiapine
533174|NCT00124059|Drug|Placebo|400mg/day placebo
533175|NCT00124046|Procedure|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
533176|NCT00124046|Procedure|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
533177|NCT00124033|Procedure|Transcystic Stenting (Facilitated ERCP)|
533178|NCT00124020|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
533179|NCT00124020|Drug|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
533180|NCT00124007|Biological|VRC-HIVADV014-00-VP|
533181|NCT00124007|Biological|VRC-HIVDNA016-00-VP|
533182|NCT00123994|Behavioral|Tai Chi classes|
533183|NCT00123994|Behavioral|Hydrotherapy classes|
533184|NCT00123981|Procedure|Off-Pump Coronary Artery Bypass Grafting|
533185|NCT00123968|Biological|VRC-HIVDNA016-00-VP|1x10^11 per unit vaccine administered intramuscularly via Bioinjector
533186|NCT00123968|Biological|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
533187|NCT00123968|Biological|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
533188|NCT00123968|Biological|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
533189|NCT00123955|Drug|Spironolactone|25mg tablet daily for 9 months
533190|NCT00123955|Drug|Placebo|Placebo tablet daily for 9 months
533191|NCT00123942|Drug|MEDI-507|
533192|NCT00123929|Drug|docetaxel|100 mg/m2 every 3 weeks times 4
533193|NCT00123929|Drug|doxorubicin|75 mg/m2 every 3 weeks times 4
533194|NCT00123916|Drug|Benznidazole|Daily po Benznidazole or placebo (weight based) during 60 days,
533195|NCT00123916|Drug|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
533196|NCT00123903|Drug|metoprolol xl|
533197|NCT00123903|Drug|carvedilol MR|
533198|NCT00123903|Drug|lisinopril|
533199|NCT00123890|Drug|GW873140|
533200|NCT00123877|Drug|GPX-100 (13-deoxydoxorubicin)|
533201|NCT00123864|Procedure|Intensity-modulated radiation therapy|
533202|NCT00123851|Drug|Tarceva (OSI-774)|
533203|NCT00123851|Drug|Capecitabine|
533204|NCT00123851|Drug|Oxaliplatin|
533205|NCT00123838|Device|Calypso® 4D Localization System|Localization of prostate irradiation.
533206|NCT00123825|Drug|Gemcitabine|
533207|NCT00123825|Drug|Cisplatin|
533208|NCT00123799|Procedure|Positron Emission Tomography Imaging|
533209|NCT00123786|Procedure|Positron Emission Tomography|Positron Emission Tomography
533210|NCT00123773|Procedure|Positron Emission Tomography|
533211|NCT00123760|Procedure|Positron Emission Tomography (PET) scan|
533212|NCT00123747|Procedure|Positron Emission Tomography (PET) scan Imaging|
533213|NCT00123734|Drug|ThromboView|
533214|NCT00123682|Procedure|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
533215|NCT00123682|Procedure|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
533216|NCT00123682|Procedure|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
533217|NCT00123682|Procedure|Self-help|Project staff send out self-help materials for smoking cessation
533218|NCT00123669|Drug|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
533219|NCT00123656|Drug|esomeprazole|esomeprazole dosed qam for 8 weeks
533220|NCT00123656|Drug|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
533221|NCT00123643|Drug|rosiglitazone|
533222|NCT00123643|Drug|glyburide|
533223|NCT00123630|Drug|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
533224|NCT00123630|Drug|Placebo|Placebo given IV once every 2-4 weeks based on weight
533225|NCT00123617|Procedure|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
533226|NCT00123604|Drug|Carvedilol|25 mg twice daily for five months.
533227|NCT00123604|Drug|Metoprolol|200 mg twice daily for five months.
533233|NCT00123552|Drug|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
533234|NCT00123552|Drug|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to < 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; >35 kg:4 tabs per dose
533235|NCT00123539|Drug|Estrogen Replacement Therapy|
533236|NCT00123539|Procedure|Surgery|
533237|NCT00123526|Behavioral|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
533238|NCT00123526|Behavioral|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
533239|NCT00123513|Behavioral|Diet|Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
533240|NCT00123513|Behavioral|Exercise|Increase routing physical activity, walking routes, stairs intervention, etc.
533241|NCT00123513|Behavioral|Environment|Cafeteria and vending machine changes and identification of opportunities of physical activity.
533242|NCT00123500|Behavioral|Diet|Diet
533243|NCT00123500|Behavioral|Physical Activity|Physical Activity
533244|NCT00123500|Behavioral|Environment|Environment
533245|NCT00123500|Other|Control Group|Control Group
533246|NCT00123487|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
533247|NCT00123487|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
533248|NCT00123474|Drug|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
533249|NCT00123474|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
533250|NCT00123474|Drug|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
533251|NCT00123474|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
533252|NCT00123461|Drug|Hectorol (doxercalciferol capsules), 0.5mcg|
533253|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
533254|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
533255|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
533256|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
533257|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
533258|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
533259|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
533260|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
533261|NCT00123435|Device|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
533262|NCT00123422|Behavioral|Breathing retraining|exercise training with computerized training program
533263|NCT00123422|Behavioral|Heliox|exercise training with a helium oxygen combination
533264|NCT00123422|Behavioral|Exercise|exercise training
533265|NCT00123409|Behavioral|Telephone disease management|Telephone based care management
533266|NCT00123409|Behavioral|Usual Care|Usual care
533267|NCT00123396|Behavioral|BioCASES and BioTESTS|
533268|NCT00123383|Drug|Modafinil|
533269|NCT00123370|Drug|Modafinil|
533270|NCT00123344|Device|AT501 pacemaker|
533271|NCT00123331|Drug|Cyclosporine discontinuation|
533272|NCT00123331|Drug|Rapamycin medication|
533273|NCT00123318|Drug|epirubicin|50mg/m2 IV day 1
533274|NCT00123318|Drug|cisplatin|60mg/m2 IV day 1
533275|NCT00123318|Drug|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
533276|NCT00123318|Radiation|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
533277|NCT00123305|Drug|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
533278|NCT00123305|Drug|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
533279|NCT00123292|Drug|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
533280|NCT00123292|Drug|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
533281|NCT00123292|Drug|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
533282|NCT00123279|Drug|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
533283|NCT00123266|Drug|Microplasmin|2 mg/kg, IA over 75 mins
533284|NCT00123253|Drug|TH9507|
533285|NCT00123240|Behavioral|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
533286|NCT00123240|Behavioral|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
533287|NCT00123227|Drug|Rosiglitazone|
533288|NCT00123214|Drug|Controlled Dietary Intervention|
533289|NCT00123201|Drug|Dronabinol MDI|
533290|NCT00123188|Procedure|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
533291|NCT00123175|Device|Intrauterine Device|Mirena and Provera
533292|NCT00123162|Drug|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
533293|NCT00123162|Drug|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
533294|NCT00123149|Drug|Epoetin alfa|
533295|NCT00123136|Device|foot energizer|
533296|NCT00123123|Drug|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
533297|NCT00123123|Drug|placebo|
533298|NCT00123110|Drug|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
533299|NCT00123110|Drug|leuprolide injection|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
533300|NCT00123110|Drug|placebo pill|matching pill twice a day for 12 weeks
533301|NCT00123110|Drug|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
533302|NCT00123097|Combination Product|Chlorinated polyethylene elastomer|Chlorinated polyethylene
533303|NCT00123084|Behavioral|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
533304|NCT00123084|Behavioral|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
533305|NCT00123058|Behavioral|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
533306|NCT00123058|Device|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
533307|NCT00123045|Behavioral|health education|
533308|NCT00123032|Behavioral|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
533309|NCT00123032|Procedure|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
533310|NCT00123019|Behavioral|Exercise and diet|Advice and measurement only
533311|NCT00123019|Behavioral|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
533312|NCT00123019|Behavioral|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
533313|NCT00123019|Behavioral|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
533314|NCT00123006|Behavioral|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
533315|NCT00123006|Behavioral|Control Diet|4 week feeding intervention
533316|NCT00122993|Behavioral|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
533317|NCT00122993|Behavioral|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
533318|NCT00122993|Behavioral|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
533319|NCT00122980|Procedure|Red Cell Transfusions|Red Blood Cell Transfusions
533320|NCT00122980|Procedure|Iron Chelation|Iron Chelation Therapy
533321|NCT00122980|Drug|Hydroxyurea|Hydroxyurea
533322|NCT00122980|Procedure|Phlebotomy|Phlebotomy
533323|NCT00122954|Drug|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
533324|NCT00122954|Drug|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
533325|NCT00122941|Dietary Supplement|multiple micronutrients|
533326|NCT00122928|Behavioral|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
533327|NCT00122928|Behavioral|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
542326|NCT00003103|Drug|docetaxel|
533328|NCT00122928|Behavioral|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
533329|NCT00122915|Device|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
533330|NCT00122889|Drug|Garlic powder with high allicin content|
533331|NCT00122889|Drug|Garlic powder with low allicin content|
533332|NCT00122889|Drug|Garlic oil|
533333|NCT00122889|Drug|Aged garlic|
533334|NCT00122876|Procedure|Photodynamic therapy|
533335|NCT00122876|Drug|Talaporfin Sodium|
533336|NCT00122863|Drug|Duloxetine Hydrochloride|
533337|NCT00122863|Drug|placebo|
533338|NCT00122850|Drug|Duloxetine|
533339|NCT00122850|Drug|venlafaxine|
533340|NCT00122850|Drug|placebo|
533341|NCT00122837|Drug|Duloxetine|
533342|NCT00122837|Drug|venlafaxine|
533343|NCT00122837|Drug|placebo|
533344|NCT00122824|Drug|duloxetine hydrochloride|
533345|NCT00122824|Drug|placebo|
533346|NCT00122811|Drug|Indapamide SR 1.5mg; Perindopril 2-4mg|
533347|NCT00122798|Procedure|Stroke treatment|
533348|NCT00122785|Drug|dexamethasone|
533349|NCT00122772|Radiation|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy"
533350|NCT00122772|Radiation|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy"
533351|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly"
533352|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly"
533353|NCT00122759|Drug|ketamine|
533354|NCT00122746|Radiation|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
533355|NCT00122746|Radiation|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
533356|NCT00122733|Drug|loxapine|
533357|NCT00122720|Drug|Darbepoetin Alfa|
533358|NCT00122707|Device|catheters|
533359|NCT00122694|Drug|carbon monoxide|
533360|NCT00122681|Biological|Cervarix™|Intramuscular injection, 3 doses
533361|NCT00122681|Biological|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
533362|NCT00122668|Drug|non-nucleoside reverse transcriptase inhibitors|
533363|NCT00122668|Drug|nucleoside reverse transcriptase inhibitors|
533364|NCT00122668|Drug|protease inhibitor|
533365|NCT00122655|Drug|non-nucleoside reverse transcriptase inhibitors|
533366|NCT00122655|Drug|nucleoside reverse transcriptase inhibitors|
533367|NCT00122655|Drug|protease inhibitors|
533368|NCT00122642|Procedure|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
533369|NCT00122642|Drug|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
533370|NCT00122629|Drug|peg-interferon alfa-2b|
533371|NCT00122629|Drug|ribavirin|
533372|NCT00122629|Drug|amantadine|
533373|NCT00122616|Biological|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
533374|NCT00122616|Drug|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
533375|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
533376|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
533377|NCT00122603|Drug|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
533378|NCT00122603|Drug|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
533379|NCT00122590|Drug|nelfinavir|
533380|NCT00122590|Drug|lopinavir/r|
533381|NCT00122590|Drug|indinavir|
533382|NCT00122590|Drug|ritonavir|
533383|NCT00122577|Drug|Tenofovir|
533384|NCT00122577|Drug|Atazanavir|
533385|NCT00122577|Drug|Ritonavir|
533386|NCT00122564|Biological|HIV-1 gp 160|
533387|NCT00122564|Biological|DC-Chol|
533388|NCT00122551|Procedure|Intermittent antiretroviral therapy|
533389|NCT00122538|Drug|Efavirenz (EFV)|
533390|NCT00122538|Drug|Lamivudine (3TC)|
533391|NCT00122538|Drug|Didanosine (ddI)|
533392|NCT00122525|Procedure|Male Circumcision|
533393|NCT00122512|Drug|Tenofovir Disoproxil Fumarate|
533394|NCT00122499|Drug|tadalafil|
533395|NCT00122486|Drug|Tenofovir Disoproxil Fumarate|
533396|NCT00122473|Drug|Imatinib (Glivec)|
533397|NCT00122460|Drug|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
533464|NCT00121836|Drug|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
533465|NCT00121823|Biological|FP9 ME-TRAP|
533466|NCT00121823|Biological|MVA ME-TRAP|
542327|NCT00003012|Drug|CMF regimen|
533398|NCT00122460|Drug|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
533399|NCT00122447|Drug|Aspirin|325 mg PO QD
533400|NCT00122447|Drug|Alpha lipoic acid|600 mg PO BID
533401|NCT00122447|Drug|Olmesartan|40 mg PO QD
533402|NCT00122447|Drug|Placebo|"Identical placebo for each active comparator:~placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"
533403|NCT00122434|Drug|BEA 2180 BR|
533404|NCT00122434|Drug|tiotropium|
533405|NCT00122421|Behavioral|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
533406|NCT00122421|Other|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
533407|NCT00122408|Dietary Supplement|Ergyphilus|5 pills a day of Ergyphilus or placebo
533408|NCT00122395|Behavioral|Screening via pen and paper|
533409|NCT00122395|Behavioral|Screening via audiotape|
533410|NCT00122382|Drug|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
533411|NCT00122382|Drug|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
533412|NCT00122382|Drug|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
533413|NCT00122369|Behavioral|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
533414|NCT00122369|Behavioral|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
533415|NCT00122356|Drug|Alendronate sodium|70mg tablets, once weekly
533416|NCT00122343|Drug|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
533417|NCT00122330|Drug|eculizumab|
533418|NCT00122317|Drug|eculizumab|
533419|NCT00122304|Drug|eculizumab|
533420|NCT00122291|Drug|Capecitabine|
533421|NCT00122291|Procedure|Pelvic radiation|
533422|NCT00122278|Drug|Dexamethasone|Dexamethasone 10mg IV
533423|NCT00122278|Other|Placebo|Placebo Dexamethasone 10mg IV
533424|NCT00122226|Drug|Lopinavir/ritonavir + zidovudine + lamivudine|
533425|NCT00122226|Drug|Lopinavir/ritonavir + nevirapine|
533426|NCT00122213|Behavioral|Behavior change on physical activity and diet|
533427|NCT00122187|Device|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
533428|NCT00122174|Behavioral|Stress Busting Program for family caregivers|
533429|NCT00122161|Behavioral|ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers|
533430|NCT00122161|Behavioral|Profiling performance|
533431|NCT00122148|Behavioral|Feedback on provision of care|
533432|NCT00122135|Other|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
533433|NCT00122122|Behavioral|Enhanced Pharmacy Care|
533434|NCT00122109|Behavioral|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
533435|NCT00122096|Drug|valdecoxib|
533436|NCT00122083|Device|Health education information|
533437|NCT00122070|Drug|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
533438|NCT00122057|Drug|antibiotic treatment|
533439|NCT00122044|Drug|trihexyphenidyl|
533440|NCT00122031|Device|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
533441|NCT00122018|Drug|N-acetylcysteine|
533442|NCT00122018|Drug|fenoldopam|
533443|NCT00122005|Biological|GM-CSF gene transduced allogeneic vaccine GVAX|
533444|NCT00121992|Drug|Docetaxel|
533445|NCT00121992|Drug|5-fluorouracil|
533446|NCT00121992|Drug|Doxorubicin|
533447|NCT00121992|Drug|Cyclophosphamide|
533448|NCT00121979|Drug|Racivir, a non-nucleoside reverse transcriptase inhibitor|
533449|NCT00121966|Drug|Insulin Aspart|
533450|NCT00121966|Drug|Insulin NPH|
533451|NCT00121966|Drug|Metformin|
533452|NCT00121966|Drug|Rosiglitazone|
533453|NCT00121953|Drug|Rosiglitazone|
533454|NCT00121940|Behavioral|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
533455|NCT00121927|Behavioral|Atkins diet (15 grams/day carbohydrates)|
533456|NCT00121914|Procedure|percutaneous ethanol instillation (PEI)|
533457|NCT00121901|Drug|glyceryl nitrate|
533458|NCT00121888|Behavioral|Prolonged Exposure Therapy|
533459|NCT00121888|Drug|Paroxetine-CR|
533460|NCT00121875|Drug|somatropin (rDNA)|"Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period"
533461|NCT00121862|Biological|Leish-111f + MPL-SE vaccine|
533462|NCT00121849|Biological|Leish-111f + MPL-SE vaccine|
533463|NCT00121836|Drug|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
533467|NCT00121810|Drug|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
533468|NCT00121810|Drug|Corticosteroids|As prescribed
533469|NCT00121810|Drug|Calcineurin inhibitors|As prescribed
533470|NCT00121810|Drug|Sirolimus|As prescribed
533471|NCT00121797|Procedure|urine culture|
533472|NCT00121797|Drug|antibiotics according to culture|
533473|NCT00121784|Drug|mycophenolate mofetil [CellCept]|1
533474|NCT00121771|Biological|FP9 CS|
533475|NCT00121771|Biological|MVA CS|
533476|NCT00121758|Biological|LIPO-5|
533477|NCT00121745|Genetic|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
533478|NCT00121745|Genetic|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
533479|NCT00121745|Genetic|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
533480|NCT00121745|Genetic|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose~IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
533481|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.15 mg/m^2 administered on Days 1, 8, 15 of 28-day cycle.
533482|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.37 mg/m^2 administered on Days 1 and 8 of 21-day cycle.
533483|NCT00121719|Drug|Lenvatinib|Lenvatinib tablets taken orally, once daily.
533484|NCT00121706|Behavioral|Condition A (see detailed summary)|
533485|NCT00121706|Behavioral|Condition B (see detailed summary)|
533486|NCT00121706|Behavioral|Condition C (see detailed summary)|
533487|NCT00121693|Behavioral|Music therapy (listening to specific music)|Listening to Music
533488|NCT00121680|Drug|E7080|Oral.
533489|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
533490|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
533491|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
533492|NCT00121667|Drug|Placebo + Metformin|Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
533493|NCT00121667|Drug|Pioglitazone|Tablets, Oral, 15 - 45 mg (as needed for rescue)
533494|NCT00121654|Device|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
533495|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term [ST], 42 months long term [LT])
533496|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
533497|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
533498|NCT00121641|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
533499|NCT00121641|Drug|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
533500|NCT00121641|Drug|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
533501|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
533502|NCT00121641|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
533503|NCT00121628|Drug|AMG 706|
533504|NCT00121615|Drug|etanercept|
533505|NCT00121602|Drug|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
533506|NCT00121589|Drug|Lutein|
533507|NCT00121563|Drug|Thalidomide, Ibuprofen or Diazepam|
533508|NCT00121550|Drug|clarithromycin|
533509|NCT00121537|Device|Wound Care -Wound Vacuum Assisted Closure (VAC)|
533510|NCT00121537|Procedure|Wound Care - Wet to Dry Dressing Changes|
533511|NCT00121524|Drug|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
533512|NCT00121524|Device|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
533513|NCT00121524|Drug|Atropine|Atropine 3 mg iv in initial systole
533514|NCT00121524|Drug|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
533515|NCT00121511|Drug|Efudex (5-fluorouracil)|
533516|NCT00121498|Drug|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
533517|NCT00121485|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
533518|NCT00121472|Device|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
533519|NCT00121459|Device|Ortho All-Flex diaphragm and Replens lubricant gel|
533520|NCT00121446|Drug|tenecteplase|
533521|NCT00121446|Drug|enoxaparin|
533522|NCT00121446|Drug|clopidogrel|
533523|NCT00121446|Procedure|percutaneous coronary intervention|
533524|NCT00121433|Drug|leptin|
533525|NCT00121420|Drug|Motexafin gadolinium|
533526|NCT00121407|Drug|Visudyne for injection|
533527|NCT00121394|Procedure|Chlorhexidine vaginal and infant wash|
533528|NCT00121381|Drug|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
533529|NCT00121381|Drug|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
533530|NCT00121355|Device|safety glide|
533532|NCT00121329|Drug|Intrauterine lidocaine infusion 4%|
533533|NCT00121316|Drug|Pimecrolimus|Pimecrolimus Cream 1 %
533534|NCT00121316|Drug|Placebo|Vehicle cream (placebo cream)
533535|NCT00121303|Drug|cytarabine|
533536|NCT00121303|Drug|daunorubicin hydrochloride|
533537|NCT00121303|Drug|gemtuzumab ozogamicin|
533538|NCT00121290|Drug|SJG-136|Given IV
533539|NCT00121290|Other|laboratory biomarker analysis|Correlative studies
533540|NCT00121290|Other|pharmacological study|Correlative studies
533541|NCT00121277|Drug|capecitabine|
533542|NCT00121277|Drug|vorinostat|
533543|NCT00121264|Drug|sorafenib tosylate|Given orally
533544|NCT00121264|Drug|tanespimycin|Given IV
533545|NCT00121264|Other|laboratory biomarker analysis|Correlative studies
533546|NCT00121264|Other|pharmacological study|Correlative studies
533547|NCT00121264|Procedure|magnetic resonance imaging|Correlative studies
533548|NCT00121251|Drug|Capecitabine|Given PO
533549|NCT00121251|Drug|Gemcitabine Hydrochloride|Given IV
533550|NCT00121251|Drug|Sorafenib Tosylate|Given PO
533551|NCT00121238|Drug|cilengitide|Given IV
533552|NCT00121225|Drug|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
533553|NCT00121212|Procedure|carbon-11 acetate PET scan|
533554|NCT00121199|Biological|rituximab|Given IV
533555|NCT00121199|Biological|bevacizumab|Given IV
533556|NCT00121199|Drug|cyclophosphamide|Given IV
533557|NCT00121199|Drug|doxorubicin hydrochloride|Given IV
533558|NCT00121199|Drug|vincristine sulfate|Given IV
533559|NCT00121199|Drug|prednisone|Given PO
533560|NCT00121199|Other|laboratory biomarker analysis|Correlative studies
533561|NCT00121186|Drug|fludarabine phosphate|30 mg/m^2 on days -6 to -2 (2-6 days before transplant).
533562|NCT00121186|Drug|melphalan|70 mg/m^2 on days -3 and -2 (2-3 days before transplant).
533563|NCT00121186|Drug|methotrexate|5 mg/m^2 on days 1, 3, and 7 post-transplant.
533564|NCT00121186|Drug|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
533565|NCT00121186|Procedure|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
533566|NCT00121186|Procedure|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
533567|NCT00121173|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|recombinant DNA vaccine
533568|NCT00121160|Behavioral|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
533569|NCT00121147|Drug|Travatan|
533570|NCT00121147|Drug|Azopt|
533571|NCT00121147|Drug|Alphagan P|
533572|NCT00121134|Drug|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
533573|NCT00121134|Drug|Cyclophosphamide|Once a day for 6 months
533574|NCT00121134|Drug|Methotrexate|Twice daily for the first two days of every week for 6 months
533575|NCT00121134|Drug|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)~Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
533576|NCT00121121|Biological|Lipopeptides LIPO-4|
533577|NCT00121108|Biological|MEDI-524|15 mg/kg motavizumab administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season
533578|NCT00121108|Other|Placebo|15 mg/kg placebo administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season.
533579|NCT00121095|Drug|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
533580|NCT00121069|Drug|Escitalopram|
533581|NCT00121056|Drug|Enbrel®|
533582|NCT00121056|Drug|Kineret®|
533583|NCT00121043|Device|SimpleJectTM|
533584|NCT00121043|Drug|Kineret® (Anakinra)|
533585|NCT00121030|Drug|darbepoetin alfa|
533586|NCT00121030|Drug|recombinant human erythropoietin (rHuEPO)|
533587|NCT00121017|Drug|Kaletra (lopinavir/ritonavir)|
533588|NCT00121017|Drug|Sustiva (efavirenz)|
533589|NCT00121017|Drug|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
533590|NCT00121004|Behavioral|Advance Directive Selection|
533591|NCT00120991|Procedure|Coronary artery bypass grafting|
533592|NCT00120978|Drug|Advair|
533593|NCT00120978|Drug|Flovent|
533594|NCT00120965|Device|AutoPulse|Standard device settings
533595|NCT00120965|Other|Manual CPR|Manual CPR
533596|NCT00120952|Device|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
533597|NCT00120939|Drug|Motexafin Gadolinium|
533598|NCT00120926|Drug|Parenteral Nutrition|
533599|NCT00120913|Drug|Birth control pills|
533600|NCT00120900|Drug|GW406381|
533601|NCT00120887|Drug|Atorvastatin|
533602|NCT00120874|Behavioral|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
533603|NCT00120874|Drug|Memantine|Patients receive 10 milligrams of memantine twice daily.
533605|NCT00120861|Drug|pegylated interferon|
533606|NCT00120861|Drug|ribavirin|
533607|NCT00120848|Biological|HPV 16/18 VLP AS04|
533608|NCT00120835|Drug|valopicitabine|
533609|NCT00120835|Drug|pegylated interferon|
533610|NCT00120822|Drug|Folic acid|
533611|NCT00120809|Drug|Sulfadoxine-pyrimethamine|
533612|NCT00120796|Drug|Lamivudine|
533613|NCT00120796|Biological|Recombinant hepatitis B surface antigen|
533614|NCT00120783|Drug|Indinavir|
533615|NCT00120783|Drug|Lamivudine|
533616|NCT00120783|Drug|Ritonavir|
533617|NCT00120770|Drug|Cellulose Sulfate Vaginal Gel (Microbicide)|
533618|NCT00120757|Drug|Alendronate|
533619|NCT00120744|Drug|Ondansetron Oral Disintegrating Tablet|
533620|NCT00120731|Drug|Potassium Citrate|
533621|NCT00120731|Drug|Acetazolamide|
533622|NCT00120731|Behavioral|Diet low in oxalate and purines|
533623|NCT00120718|Drug|fasudil|
533624|NCT00120705|Drug|darbepoetin alfa|
533625|NCT00120692|Drug|Darbepoetin Alfa|
533626|NCT00120692|Drug|Recombinant Human Erythropoietin|
533627|NCT00120679|Drug|darbepoetin alfa|
533628|NCT00120679|Drug|recombinant human erythropoietin (rHuEPO)|
533629|NCT00120653|Drug|Metoclopramide|
533630|NCT00120640|Drug|17 hydroxyprogesterone caproate intramuscular injections|
533631|NCT00120627|Behavioral|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
533632|NCT00120627|Other|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
533633|NCT00120614|Behavioral|Premature infant behavior and development information|
533634|NCT00120614|Behavioral|Parental activities to support premature infant information|
533635|NCT00120601|Drug|Naltrexone|
533636|NCT00120601|Drug|Acamprosate|
533637|NCT00120588|Drug|magnesium|
533638|NCT00120575|Procedure|hemofiltration|
533639|NCT00120562|Procedure|Gastric Bypass Surgery|
533640|NCT00120549|Procedure|Assisted embryo hatching|
533641|NCT00120536|Drug|vildagliptin|
533642|NCT00120523|Drug|Pimecrolimus|Pimecrolimus cream 1 %
533643|NCT00120523|Drug|Topical corticosteroids|TCS
533644|NCT00120510|Drug|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
533645|NCT00120510|Drug|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
533646|NCT00120497|Drug|somatropin (rDNA)|"Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml~Dosage regimen: 0.48 mg/kg/week~Route/rate of administration: subcutaneous injection, daily dose"
533647|NCT00120484|Drug|Vitamin B12|
533648|NCT00120471|Drug|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
533649|NCT00120471|Drug|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
533650|NCT00120471|Drug|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
533651|NCT00120458|Dietary Supplement|Black cohosh|"32 to 128 mg (black cohosh)~1 to 4 capsules daily (placebo)"
533652|NCT00120445|Procedure|air|0.3 ml of filtered air
533653|NCT00120445|Procedure|expansile gas|0.3 ml of perfluoropropane gas
533654|NCT00120432|Drug|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
533655|NCT00120419|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
533656|NCT00120406|Device|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
533657|NCT00120406|Procedure|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
533658|NCT00120393|Drug|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
533659|NCT00120393|Drug|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
533660|NCT00120380|Drug|Aerosolized iloprost|
533661|NCT00120380|Drug|Placebo|
533662|NCT00120367|Drug|Enfuvirtide|
533663|NCT00120367|Drug|Tenofovir-Emtricitabine|
533664|NCT00120354|Procedure|Blood Testing|
533665|NCT00120354|Procedure|Percutaneous Liver Biopsy|
533666|NCT00120354|Procedure|Lamivudine Therapy|
533667|NCT00120341|Device|Anodyne Therapy System|
533668|NCT00120328|Drug|SPP301|
533669|NCT00120315|Drug|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
533670|NCT00120315|Procedure|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
533671|NCT00120302|Drug|Pimecrolimus|Pimecrolimus cream 1 %
533672|NCT00120302|Drug|Placebo|Matching vehicle cream
533673|NCT00120289|Drug|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
533674|NCT00120289|Drug|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
533675|NCT00120276|Device|Less invasive mitral valve repair|
533676|NCT00120263|Procedure|Plasma Exchange|
533737|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
533738|NCT00119678|Drug|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
533677|NCT00120250|Drug|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
533678|NCT00120237|Drug|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
533679|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiation Therapy 6 fractions per week
533680|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiotherapy 5 fractions per week
533681|NCT00120198|Drug|CDOP plus rituximab|
533682|NCT00120185|Drug|Interleukin-2|
533683|NCT00120172|Drug|oxaliplatin, capecitabine, bevacizumab|
533684|NCT00120133|Drug|Atorvastatin|
533685|NCT00120120|Drug|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
533686|NCT00120107|Drug|Black Tea|
533687|NCT00120081|Biological|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
533688|NCT00120081|Biological|Saline placebo|Inactive saline placebo control
533689|NCT00120068|Behavioral|Nursing inservices|
533690|NCT00120068|Procedure|Academic detailing to MDs; concurrent review and feedback|
533691|NCT00120055|Drug|Atorvastatin (Lipitor)|
533692|NCT00120042|Drug|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
533693|NCT00120042|Drug|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
533694|NCT00120029|Behavioral|weight loss counseling|
533695|NCT00120016|Behavioral|dietary counseling|telephone counseling
533696|NCT00120003|Drug|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
533697|NCT00120003|Drug|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
533698|NCT00119990|Drug|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
533699|NCT00119990|Drug|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
533700|NCT00119977|Procedure|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
533701|NCT00119964|Behavioral|internet based weight management tools|
533702|NCT00119951|Behavioral|Participation on the ACOR Listserv|
533703|NCT00119938|Behavioral|Access to online patient portal|
533704|NCT00119925|Behavioral|patient education|patient leaflets about national guideline contents
533705|NCT00119925|Behavioral|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
533706|NCT00119925|Behavioral|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
533707|NCT00119925|Other|information tools|tools and checklists to improve information provision
533708|NCT00119912|Procedure|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
533709|NCT00119912|Procedure|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
533710|NCT00119899|Procedure|FDG-PET scan|
533711|NCT00119886|Drug|Botulinum toxin|
533712|NCT00119873|Biological|VRC-HIVADV014-00-VP|
533713|NCT00119847|Procedure|PCI|
533714|NCT00119847|Drug|Optimal Medical Therapy|Guideline-directed drug therapies after MI
533715|NCT00119834|Device|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
533716|NCT00119821|Behavioral|Weight Reducing Diet|Behavioral intervention
533717|NCT00119821|Behavioral|Exercise|Moderate exercise implemented plus behavioral intervention.
533718|NCT00119821|Behavioral|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.~NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
533719|NCT00119795|Behavioral|Exercise|Increase Physical Activity to 150 min/wk
533720|NCT00119795|Behavioral|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
533721|NCT00119795|Behavioral|Health Education Control|Lectures on information relevant to successful aging
533722|NCT00119782|Behavioral|Diet|A dietary intervention that will promote lower calorie intake
533723|NCT00119782|Behavioral|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
533724|NCT00119782|Behavioral|Environment|Increase worksite access to both healthy foods and physical activity
533725|NCT00119769|Drug|Placebo|Placebo, 0.7 mg/day injected subcutaneously
533726|NCT00119769|Drug|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
533727|NCT00119756|Drug|paliperidone palmitate|
533728|NCT00119743|Biological|undecavalent pneumococcal-protein D conjugate vaccine|
533729|NCT00119730|Drug|Fludarabine|Given on days 1-3 of each 28-day cycle
533730|NCT00119730|Drug|Mitoxantrone|Given on day 1 of each 28-day cycle
533731|NCT00119730|Drug|Rituximab|Given on day 1 of each 28-day cycle
533732|NCT00119730|Drug|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
533733|NCT00119717|Device|NeuroFlo™ catheter|45 minute treatment
533734|NCT00119717|Other|Control|ASA Guidelines
533735|NCT00119704|Drug|Botulinum toxin A injection or normal saline|
533736|NCT00119691|Drug|Nesiritide|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
533739|NCT00119678|Drug|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
533740|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
533741|NCT00119665|Drug|MF101|
533742|NCT00119652|Drug|quetiapine fumarate (Seroquel)|
533743|NCT00119652|Drug|paroxetine|
533744|NCT00119652|Behavioral|mood stabilizing activity|
533745|NCT00119639|Drug|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
533746|NCT00119626|Drug|NXY-059|
533747|NCT00119613|Drug|placebo|placebo
533748|NCT00119613|Drug|darbepoetin alfa|darbepoetin alfa
533749|NCT00119600|Drug|AMG 114|
533750|NCT00119587|Drug|darbepoetin alfa|
533751|NCT00119574|Procedure|Collaborative Chronic Illness Model|
533752|NCT00119561|Behavioral|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
533753|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
533754|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
533755|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
533756|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
533757|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
533758|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
533759|NCT00119535|Behavioral|Implementation of Proactive Diabetes Eye Care Program|
533760|NCT00119509|Procedure|HPV DNA testing|
533761|NCT00119509|Procedure|Conventional management (repeat Pap smear at 6 months)|
533762|NCT00119509|Procedure|Decision aid with choice of management|
533763|NCT00119496|Drug|rosiglitazone|oral tablet, 4mg bd for 4 weeks
533764|NCT00119496|Drug|theophylline|Oral theophylline, 200mg bd
533765|NCT00119496|Drug|beclomethasone|inhaled beclomethasone, 200mcg bd
533766|NCT00119496|Drug|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
533767|NCT00119483|Drug|Nebido (Testosterone Undecanoate)|
533768|NCT00119470|Procedure|EUS-FNA|
533769|NCT00119470|Procedure|Conventional Surgical Technique|
533770|NCT00119457|Drug|TTP889|
533771|NCT00119444|Procedure|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
533772|NCT00119431|Drug|C1 inhibitor concentrate|
533773|NCT00119418|Drug|TU 025 Keishi Bukuryo Gan|
533774|NCT00119392|Biological|rituximab|Given IV
533775|NCT00119392|Drug|cyclosporine|Given orally
533776|NCT00119392|Drug|fludarabine phosphate|Given IV
533777|NCT00119392|Drug|mycophenolate mofetil|Given orally
533778|NCT00119392|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
533779|NCT00119392|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
533780|NCT00119392|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
533781|NCT00119392|Radiation|total-body irradiation|Undergo TBI
533782|NCT00119379|Drug|NucleomaxX|NucleomaxX 36 grams TID every other day
533783|NCT00119379|Drug|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
533784|NCT00119366|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
533785|NCT00119366|Drug|fludarabine phosphate|Given IV
533786|NCT00119366|Radiation|total-body irradiation|Undergo TBI
533787|NCT00119366|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
533788|NCT00119366|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
533789|NCT00119366|Drug|cyclosporine|Given IV or PO
533790|NCT00119366|Drug|mycophenolate mofetil|Given PO
533791|NCT00119366|Other|laboratory biomarker analysis|Correlative studies
533792|NCT00119340|Drug|cyclosporine|
533793|NCT00119340|Drug|fludarabine phosphate|
533794|NCT00119340|Drug|mycophenolate mofetil|
533795|NCT00119340|Procedure|peripheral blood stem cell transplantation|
533796|NCT00119340|Radiation|radiation therapy|
533797|NCT00119314|Drug|capecitabine|
533798|NCT00119314|Drug|docetaxel|
533799|NCT00119314|Drug|gemcitabine hydrochloride|
533800|NCT00119314|Procedure|positron emission tomography|
533801|NCT00119301|Drug|leucovorin calcium|
533802|NCT00119301|Drug|methotrexate|
533803|NCT00119301|Drug|trimetrexate glucuronate|
533804|NCT00119262|Drug|doxorubicin hydrochloride|Given IV
533805|NCT00119262|Drug|cyclophosphamide|Given IV
533806|NCT00119262|Biological|bevacizumab|Given IV
533807|NCT00119262|Drug|paclitaxel|Given IV
533808|NCT00119262|Biological|filgrastim|Given SC
533809|NCT00119262|Biological|pegfilgrastim|Given SC
533810|NCT00119262|Radiation|radiation therapy|Undergo radiation therapy
533811|NCT00119262|Drug|tamoxifen citrate|Given orally
533812|NCT00119262|Drug|aromatase inhibition therapy|Receive aromatase inhibition therapy
533813|NCT00119249|Drug|sorafenib tosylate|Given orally
533814|NCT00119249|Other|laboratory biomarker analysis|Correlative studies
533815|NCT00119236|Drug|tanespimycin|
533816|NCT00119236|Drug|irinotecan hydrochloride|
533817|NCT00119210|Drug|Bupropion SR|
533818|NCT00119210|Other|placebo|
533876|NCT00118872|Other|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
533877|NCT00118859|Behavioral|Integrative care for low back pain|
542328|NCT00003012|Drug|cyclophosphamide|
533819|NCT00119197|Biological|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:~Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells~Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells~Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells~Inactivated V.Cholerae O139 - 50.109 cells~each 1.5 mL dose given orally, two doses given 14 days apart"
533820|NCT00119197|Biological|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.~Each 1.5 mL dose given orally, two doses given 14 days apart"
533821|NCT00119184|Procedure|External cephalic version|7.5 mg bupivacaine intrathecally
533822|NCT00119184|Drug|spinal anesthesia|spinal anesthesia
533823|NCT00119171|Drug|Ispinesib|
533824|NCT00119171|Drug|Capecitabine|
533825|NCT00119158|Drug|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
533826|NCT00119158|Drug|pimecrolimus|apply daily with fluticasone cream for flares
533827|NCT00119145|Drug|artesunate-amodiaquine|
533828|NCT00119145|Drug|coartem|
533829|NCT00119145|Drug|artesunate-lapdap|
533830|NCT00119132|Drug|artesunate-amodiaquine|
533831|NCT00119132|Drug|sulphadoxine-pyrimethamine|
533832|NCT00119119|Drug|pentoxyphilline|
533833|NCT00119119|Drug|tocopherol|
533834|NCT00119106|Device|Tenofovir|
533835|NCT00119093|Procedure|Laboratory and clinical monitoring regimens|
533836|NCT00119080|Biological|meningococcal conjugate vaccine (Menactra)|
533837|NCT00119067|Biological|BioThrax or Anthrax Vaccine Adsorbed|
533838|NCT00119054|Behavioral|In Home Health Messaging Device|
533839|NCT00119041|Behavioral|The Diabetes Treatment Satisfaction Questionnaire|A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
533840|NCT00119041|Behavioral|Diabetes Empowerment Scale|A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
533841|NCT00119041|Behavioral|CBOC's undergo half-day joint-clinics via teleconference|A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
533842|NCT00119028|Procedure|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
533843|NCT00119015|Drug|Placebo|
533844|NCT00119015|Drug|Montelukast|
533845|NCT00119015|Drug|Fluticasone propionate|
533846|NCT00119002|Drug|dexamethasone|1mg/kg dexamethasone
533847|NCT00119002|Drug|Placebo|1mg/kg placebo
533848|NCT00118989|Dietary Supplement|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
533849|NCT00118976|Drug|Lisinopril|
533850|NCT00118963|Drug|Metformin|Tablets of 500 mg; 1000 mg two times daily.
533851|NCT00118963|Drug|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
533852|NCT00118963|Drug|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
533853|NCT00118963|Drug|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
533854|NCT00118963|Drug|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
533855|NCT00118950|Drug|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
533856|NCT00118950|Drug|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
533857|NCT00118950|Drug|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
533858|NCT00118950|Drug|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
533859|NCT00118950|Other|Diet-only.|Diet-only treatment. Duration: One month.
533860|NCT00118937|Drug|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
533861|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
533862|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
533863|NCT00118924|Biological|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
533864|NCT00118924|Biological|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
533865|NCT00118911|Behavioral|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
533866|NCT00118911|Other|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
533867|NCT00118898|Drug|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
533868|NCT00118898|Drug|Atazanavir|300 mg tablet taken orally daily
533869|NCT00118898|Drug|Efavirenz|600 mg tablet taken orally daily
533870|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
533871|NCT00118898|Drug|Ritonavir|100 mg tablet taken orally daily
533872|NCT00118898|Drug|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
533873|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
533874|NCT00118885|Behavioral|Tai Chi Chih|
533875|NCT00118872|Drug|LGG yogurt|Lactobacillus GG containing yogurt
533878|NCT00118859|Behavioral|Conventional treatment for low back pain|
533879|NCT00118846|Dietary Supplement|25 g soy protein supplement|25 g soy protein admisitered in equally divided dosage twice daily
533880|NCT00118846|Other|Matching placebo|Milk protein administered twice daily
533881|NCT00118833|Drug|Hypericum perforatum (St. John's wort)|
533882|NCT00118820|Drug|IV Preoperative antibiotic or placebo|
533883|NCT00118807|Drug|Amodiaquine plus artesunate (AQ/AS)|
533884|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
533885|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
533886|NCT00118794|Drug|Chlorproguanil-dapsone (Lapdap)|
533887|NCT00118794|Drug|Lumefantrine-artemether (Coartemether )|
533888|NCT00118781|Drug|iseganan hydrochloride|
533889|NCT00118768|Drug|valopicitabine|
533890|NCT00118768|Drug|Pegylated Interferon Alfa|
533891|NCT00118755|Drug|capecitabine|850 mg/m^2 po bid on Days 1-14 of each 3-week cycle
533892|NCT00118755|Drug|Oxaliplatin|130 mg/m^2 IV on Day 1 of each 3-week cycle
533893|NCT00118755|Drug|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
533894|NCT00118755|Drug|capecitabine|1500 mg/m^2 po bid on Days 1-7 of each 2-week cycle
533895|NCT00118755|Drug|Oxaliplatin|85 mg/m^2 IV on Day 1 of each 2-week cycle
533896|NCT00118755|Drug|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
533897|NCT00118742|Drug|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
533898|NCT00118742|Drug|Tacrolimus|As prescribed, for 12 months
533899|NCT00118742|Drug|Cyclosporine|As prescribed, for 12 months
533900|NCT00118742|Drug|Sirolimus|2-4 mg orally once daily for 9-11 months
533901|NCT00118729|Drug|GW685698X Aqueous Nasal Spray|
533902|NCT00118716|Drug|Fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol
533903|NCT00118716|Drug|Fluticasone Propionate|Fluticasone Propionate
533904|NCT00118703|Drug|GW685698X|
533905|NCT00118690|Drug|Fluticasone propionate/salmeterol|
533906|NCT00118677|Procedure|Treatment interruption|
533907|NCT00118638|Drug|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
533908|NCT00118638|Drug|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
533909|NCT00118625|Biological|Tree MATA MPL|
533910|NCT00118612|Biological|Tree MATA MPL|
533911|NCT00118573|Procedure|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
533912|NCT00118573|Procedure|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
533913|NCT00118560|Behavioral|Physical exercise|treadmill walking
533914|NCT00118560|Behavioral|Physical walking|calf muscle exercise
533915|NCT00118547|Behavioral|In home monitoring with feedback|Behavioral counseling
533916|NCT00118534|Behavioral|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
533917|NCT00118534|Behavioral|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
533918|NCT00118521|Procedure|Foot Orthotics|
533919|NCT00118521|Procedure|Physiotherapy|
533920|NCT00118508|Drug|risedronate (including placebo)|risedronate 35mg weekly
533921|NCT00118495|Drug|Non-prescription Zestra(TM): patented formulation|
533922|NCT00118482|Drug|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
533923|NCT00118469|Behavioral|Psychoeducation|
533924|NCT00118469|Behavioral|Cognitive behavior therapy|
533925|NCT00118456|Drug|AEE788|
533926|NCT00118443|Behavioral|Question, Persuade, Refer (QPR) training|
533927|NCT00118430|Behavioral|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
533928|NCT00118430|Drug|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
533929|NCT00118430|Drug|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
533930|NCT00118417|Drug|Clonazepam|Participants will receive clonazepam.
533931|NCT00118417|Drug|Sertraline|Participants will receive sertraline.
533932|NCT00118417|Behavioral|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
533933|NCT00118404|Behavioral|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
533934|NCT00118404|Drug|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
533935|NCT00118404|Other|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
533936|NCT00118404|Behavioral|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
533937|NCT00118391|Behavioral|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
533938|NCT00118391|Behavioral|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
533939|NCT00118378|Drug|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
533940|NCT00118378|Drug|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
533941|NCT00118365|Other|placebo|Given orally
533942|NCT00118365|Drug|eflornithine|Given orally
533943|NCT00118365|Drug|sulindac|Given orally
533944|NCT00118365|Other|laboratory biomarker analysis|Correlative studies
533945|NCT00118352|Biological|alemtuzumab|Given IV
533946|NCT00118352|Radiation|total-body irradiation|Undergo low-dose TBI
533947|NCT00118352|Drug|fludarabine phosphate|Given IV
533948|NCT00118352|Drug|cyclosporine|Given PO or IV
533949|NCT00118352|Drug|mycophenolate mofetil|Given PO
533950|NCT00118352|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
533951|NCT00118352|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
533952|NCT00118352|Biological|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
533953|NCT00118352|Other|laboratory biomarker analysis|Correlative studies
533954|NCT00118339|Drug|chemoprotection|
533955|NCT00118339|Procedure|complementary or alternative medicine procedure|
533956|NCT00118339|Procedure|management of therapy complications|
533957|NCT00118326|Biological|filgrastim|
533958|NCT00118326|Procedure|allogeneic bone marrow transplantation|
533959|NCT00118313|Biological|incomplete Freund's adjuvant|
533960|NCT00118313|Biological|multi-epitope melanoma peptide vaccine|
533961|NCT00118313|Biological|sargramostim|
533962|NCT00118313|Biological|tetanus toxoid helper peptide|
533963|NCT00118313|Drug|dimethyl sulfoxide|
533964|NCT00118313|Drug|imiquimod|
533965|NCT00118313|Procedure|adjuvant therapy|
533966|NCT00118300|Drug|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
533967|NCT00118300|Radiation|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly in weeks 4-8.
533968|NCT00118300|Radiation|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
533969|NCT00118287|Drug|azacitidine|Given SC or IV
533970|NCT00118287|Biological|etanercept|Given SC
533971|NCT00118274|Biological|incomplete Freund's adjuvant|Given intradermally and subcutaneously
533972|NCT00118274|Biological|melanoma helper peptide vaccine|Given intradermally and subcutaneously
533973|NCT00118274|Biological|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
533974|NCT00118274|Biological|tetanus toxoid helper peptide|Given intradermally and subcutaneously
533975|NCT00118274|Drug|cyclophosphamide|Given IV
533976|NCT00118261|Biological|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
533977|NCT00118261|Drug|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
533978|NCT00118261|Drug|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
533979|NCT00118261|Drug|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
533980|NCT00118261|Drug|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
533981|NCT00118248|Drug|tanespimycin|Given IV
533982|NCT00118235|Drug|cisplatin|Given IV
533983|NCT00118235|Drug|irinotecan hydrochloride|Given IV
533984|NCT00118235|Biological|bevacizumab|Given IV
533985|NCT00118235|Other|laboratory biomarker analysis|Correlative studies
533986|NCT00118222|Drug|porfimer sodium|All patients receive porfimer sodium IV.
533987|NCT00118222|Procedure|adjuvant therapy|All patients receive porfimer sodium IV.
533988|NCT00118222|Procedure|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
533989|NCT00118209|Biological|rituximab|IV
533990|NCT00118209|Drug|cyclophosphamide|IV
533991|NCT00118209|Drug|doxorubicin|IV or CIVI
533992|NCT00118209|Drug|vincristine|IV or CIVI
533993|NCT00118209|Drug|prednisone|oral
533994|NCT00118209|Drug|etoposide|CIVI
533995|NCT00118209|Drug|filgrastim|IV
533996|NCT00118209|Drug|pegfilgrastim|IV
533997|NCT00118196|Drug|arsenic trioxide|
533998|NCT00118196|Drug|azacitidine|
533999|NCT00118183|Drug|docetaxel|Given IV
534000|NCT00118183|Biological|cetuximab|Given IV
534001|NCT00118183|Drug|bortezomib|Given IV
534002|NCT00118170|Drug|sorafenib tosylate|Given orally
534003|NCT00118170|Other|pharmacological study|Correlative studies
534004|NCT00118157|Other|Laboratory Biomarker Analysis|Correlative studies
534005|NCT00118157|Drug|Lapatinib Ditosylate|Given PO
534006|NCT00118157|Drug|Tamoxifen Citrate|Given PO
534007|NCT00118144|Drug|bortezomib|Given IV
534008|NCT00118131|Drug|cisplatin|
534009|NCT00118131|Drug|docetaxel|
534010|NCT00118105|Biological|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
534011|NCT00118105|Drug|capecitabine|Pre & Post Operative: 1,700 mg/m^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
534012|NCT00118105|Drug|oxaliplatin|130 mg/m^2, IV, Day 1 of cycles 1,2,3,4
534013|NCT00118105|Procedure|conventional surgery|Resection
534014|NCT00118092|Drug|tanespimycin|Given IV
534015|NCT00118092|Other|laboratory biomarker analysis|Correlative studies
534016|NCT00118066|Dietary Supplement|calcitriol|Given orally
534017|NCT00118066|Procedure|observation|No initial intervention
534018|NCT00118053|Biological|herceptin|
534019|NCT00118053|Drug|carboplatin|
534020|NCT00118053|Drug|docetaxel|
534021|NCT00118053|Procedure|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
534022|NCT00118053|Procedure|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
534023|NCT00118040|Drug|genistein|Given orally
534024|NCT00118040|Other|laboratory biomarker analysis|Correlative studies
534025|NCT00118040|Other|placebo|Given orally
534026|NCT00118040|Procedure|therapeutic conventional surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
534027|NCT00118040|Other|pharmacological study|Correlative studies
534028|NCT00118027|Drug|sulphadoxine-pyrimethamine intermittent preventive treatment|
534029|NCT00118014|Drug|Sertraline|
534030|NCT00118014|Behavioral|Habit Reversal Training|
534031|NCT00118001|Behavioral|Worry exposure|
534032|NCT00118001|Behavioral|Applied relaxation|
534033|NCT00117988|Drug|tanespimycin|
534034|NCT00117975|Biological|galiximab|given IV
534035|NCT00117975|Biological|rituximab|Given IV
534036|NCT00117962|Biological|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
534037|NCT00117962|Drug|carboplatin|AUC = 5 q 21 days for 4 cycles
534038|NCT00117962|Drug|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
534039|NCT00117962|Radiation|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
534040|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
534041|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
534042|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
534043|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
534044|NCT00117936|Combination Product|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose|Up to ten intramyocardial injections of low dose FGF 1-141, via a NOGA Injection Catheter, single cath lab session
534045|NCT00117936|Combination Product|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose|Up to ten intramyocardial injections of high dose group (FGF-1-141), via a NOGA Injection Catheter, single cath lab session
534046|NCT00117936|Combination Product|Placebo|Up to ten intramyocardial injections of placebo via a NOGA Injection Catheter, single cath lab session
534047|NCT00117923|Drug|Resiquimod|
534048|NCT00117910|Drug|pegfilgrastim|
534049|NCT00117897|Drug|pegfilgrastim|
534050|NCT00117897|Drug|Filgrastim|
534051|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534052|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534053|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534054|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534055|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534056|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534057|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534058|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534059|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534060|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534061|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
534062|NCT00117871|Drug|Resiquimod|
534063|NCT00117858|Procedure|Anodal DC polarization of left prefrontal cortex|
534064|NCT00117845|Biological|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
534065|NCT00117832|Drug|Azelastine nasal spray|
534066|NCT00117819|Drug|[123I]ß CIT and SPECT imaging|To assess [123I]ß CIT and SPECT imaging
534067|NCT00117806|Behavioral|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
534068|NCT00117806|Behavioral|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
534069|NCT00117793|Device|Total Surface Bearing Suction Socket|Current clinical practice
534070|NCT00117793|Device|Vacuum assisted socket system|Novel socket system
534071|NCT00117780|Drug|insulin detemir|
534072|NCT00117780|Drug|insulin aspart|
534073|NCT00117767|Drug|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
534074|NCT00117767|Drug|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
534075|NCT00117754|Drug|Terbinafine hydrochloride|
534076|NCT00117741|Behavioral|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
534077|NCT00117741|Behavioral|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
534078|NCT00117728|Drug|nevirapine|
534079|NCT00117715|Procedure|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
534080|NCT00117702|Drug|Tacrolimus|day 0-100, then taper
534081|NCT00117702|Drug|Everolimus|day 0-56
534082|NCT00117689|Biological|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
534083|NCT00117689|Drug|Corticosteroid|For a minimum of 3 months
534084|NCT00117689|Drug|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
534085|NCT00117689|Drug|Mycophenolate Mofetil|for at least 1 month posttransplant
534086|NCT00117676|Drug|TDF|300 mg tablet administered orally once daily
534087|NCT00117676|Drug|ADV|10 mg tablet administered orally once daily
534088|NCT00117676|Drug|TDF placebo|Tablet administered orally once daily
534089|NCT00117676|Drug|ADV placebo|Tablet administered orally once daily
534090|NCT00117676|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
534091|NCT00117663|Drug|Cessation of Hormone Replacement Therapy|
534092|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
534093|NCT00117650|Biological|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
534094|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
534095|NCT00117650|Other|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
534096|NCT00117637|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
534097|NCT00117637|Drug|Interferon|Interferon
534098|NCT00117624|Drug|darbepoetin alfa|
534099|NCT00117611|Drug|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
534100|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
534101|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
534102|NCT00117598|Drug|Investigator's choice|"Any of the following single agent treatments:~Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.~Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days~Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days~Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days~Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,~Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days~Prednisone 40 (20-60) mg/m2 PO daily or every other day~Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
534103|NCT00117585|Other|Treatment Phase 1|"Patient Education~Physical Therapy Exercises~Increased Salt Intake~Elevation of head of bed with 2-4 inch wedge~Medication Review by MD, Pharma"
534104|NCT00117585|Drug|Treatment Phase 2|"Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~Fludrocortisone~Salt tablet"
534105|NCT00117585|Other|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
534106|NCT00117572|Drug|docetaxel|75 mg/m2 on day 1 (induction phase); 25 mg/m2 on day 1 (chemoradiotherapy phase)
534107|NCT00117572|Drug|cisplatin|75 mg/m2 on day 1
534108|NCT00117572|Drug|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
534109|NCT00117572|Drug|fluorouracil|750 mg/m2/day on days 1-5 (induction phase); 600 mg/m2/day, day 0-4 (chemoradiotherapy phase)
534110|NCT00117572|Procedure|chemotherapy|See protocol for details
534111|NCT00117572|Procedure|radiotherapy|See protocol for details
534112|NCT00117559|Behavioral|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
534113|NCT00117546|Drug|alpha methyldopa|500 mg twice a day
534114|NCT00117533|Drug|pegylated IFN alfa-2b plus ribavirin|
534115|NCT00117520|Drug|Caffeine|
534116|NCT00117507|Drug|deferasirox|deferasirox 20 mg/kg/day taken over one year.Deferasirox should be taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets should be dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
534117|NCT00117494|Drug|Pravastatin|
534118|NCT00117494|Drug|Rosuvastatin|
534119|NCT00117481|Drug|DR-2001a|DR-2001a administered vaginally each month
534120|NCT00117481|Drug|DR-2001b|DR-2001b administered vaginally each month
534121|NCT00117481|Other|Placebo|Placebo administered vaginally each month
534122|NCT00117468|Drug|DR-2011|Administered vaginally from Day 14 to Day 31
534123|NCT00117468|Drug|Progesterone 8% Vaginal Gel|Administered vaginally from Cycle Day 14 to Day 31
534124|NCT00117455|Drug|pegfilgrastim|
534125|NCT00117455|Drug|filgrastim|
534126|NCT00117442|Drug|carboplatin|Chemotherapy
534127|NCT00117442|Drug|paclitaxel|chemotherapy
534128|NCT00117442|Drug|pegfilgrastim|Growth factor for mobilization
534129|NCT00117429|Biological|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
534130|NCT00117416|Procedure|controlling the MAP|
534131|NCT00117403|Drug|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
534132|NCT00117403|Drug|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
534133|NCT00117403|Drug|Placebo capsules|one placebo capsule three times per day with meals
534134|NCT00117403|Drug|Placebo wafers|two placebo wafers three times per day with meals
534135|NCT00117390|Procedure|Measurement of inulin clearance|
534136|NCT00117377|Drug|Pimecrolimus|Pimecrolimus cream 1 % bid
534137|NCT00117377|Drug|Placebo|Placebo application bid
534138|NCT00117364|Drug|SACCHACHITIN patch|
534139|NCT00117351|Drug|VELCADE|
534140|NCT00117338|Drug|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
534141|NCT00117338|Drug|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
534142|NCT00117325|Drug|GW685698X|Aqueous Nasal Spray 100mcg
534143|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
534144|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
534145|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
534146|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
534147|NCT00117299|Drug|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
534148|NCT00117286|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
534149|NCT00117273|Drug|Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]|1 tablet daily
534150|NCT00117273|Drug|Seasonique (LNG/EE and EE)|1 tablet daily
534151|NCT00117273|Drug|Portia (LNG/EE)|1 tablet daily x 28 days
534152|NCT00117260|Drug|Seasonale (levonorgestrel and ethinyl estradiol)|
534153|NCT00117247|Drug|darbepoetin alfa|
534154|NCT00117234|Drug|darbepoetin alfa|
534155|NCT00117208|Drug|mannitol|400mg BD for 12 weeks
534156|NCT00117208|Drug|mannitol + pulmozyme|combination
534157|NCT00117208|Drug|Dornase alpha|2.5mg daily for 2 weeks
534158|NCT00117195|Device|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
534159|NCT00117182|Drug|Dry powder mannitol|
534160|NCT00117182|Drug|Budesonide 400mcg administered via turbuhaler|
534161|NCT00117182|Drug|Ipratropium bromide 80mcg|
534162|NCT00117182|Drug|Salbutamol 400mcg|
534163|NCT00117169|Procedure|multi-detector helical computed tomography|
534164|NCT00117156|Drug|Fludarabine|
534165|NCT00117156|Drug|Rituximab|
534166|NCT00117143|Drug|AMG 531|
534167|NCT00117130|Drug|Aranesp®|
534168|NCT00117117|Drug|Aranesp|
534169|NCT00117104|Drug|Aranesp®|
534170|NCT00117091|Drug|Anakinra (Kineret®)|
534171|NCT00117078|Drug|Aranesp®|
534172|NCT00117065|Drug|Aranesp®|
534173|NCT00117052|Drug|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
534174|NCT00117039|Drug|Aranesp®|
534175|NCT00117026|Drug|Placebo|Placebo for benfotiamine
534176|NCT00117026|Drug|Benfotiamine|300mg/day
534177|NCT00117013|Drug|Fluorine-19-Fluoroded Xyglucose|
534178|NCT00117013|Drug|Topotecan|
534179|NCT00117000|Drug|testosterone undecanoate|
534180|NCT00116987|Device|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
534181|NCT00116987|Device|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
534182|NCT00116974|Procedure|Scaling and root planing|Scaling and root planing
534183|NCT00116961|Drug|Velcade|
534184|NCT00116961|Drug|Doxil|
534185|NCT00116961|Drug|Dexamethasone|
534186|NCT00116948|Device|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
534187|NCT00116935|Drug|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
534188|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
534189|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
534190|NCT00116922|Drug|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|[Rosiglitazone 2mg/ Metformin 500mg] twice daily
534191|NCT00116909|Drug|OSI 7904L|
534192|NCT00116896|Drug|OSI-7904L|
534193|NCT00116896|Drug|Cisplatin|
534194|NCT00116883|Drug|GW685698X aqueous nasal spray|
534195|NCT00116870|Drug|lovastatin|
534196|NCT00116857|Drug|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
534197|NCT00116857|Drug|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
534198|NCT00116844|Drug|Valaciclovir|Valtrex 1g once daily
534199|NCT00116844|Drug|Placebo|placebo
534200|NCT00116831|Drug|Glipizide|oral anti-diabetic medication
534201|NCT00116831|Drug|rosiglitazone maleate|oral antidiabetic medication
534202|NCT00116818|Drug|GW685698X aqueous nasal spray|
534203|NCT00116805|Drug|TDF|300 mg tablet administered orally once daily
534204|NCT00116805|Drug|ADV|10 mg tablet administered orally once daily
534205|NCT00116805|Drug|TDF placebo|Tablet administered orally once daily
534206|NCT00116805|Drug|ADV placebo|Tablet administered orally once daily
534207|NCT00116805|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
534208|NCT00116792|Procedure|Percutaneous Coronary Intervention (PCI)|
534209|NCT00116779|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
534210|NCT00116766|Device|anti-mosquito plant use|
534211|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
534212|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
534213|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
534214|NCT00116740|Drug|APD356|
534215|NCT00116727|Drug|ENBREL®|50 mg/wk SC
534216|NCT00116714|Drug|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
534218|NCT00116688|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
534219|NCT00116675|Drug|Resiquimod|
534220|NCT00116662|Drug|Resiquimod|
534221|NCT00116649|Drug|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
534222|NCT00116636|Drug|Kaletra|
534223|NCT00116623|Drug|Indomethacin|
534224|NCT00116623|Drug|Magnesium sulfate|
534225|NCT00116610|Drug|picoplatin|
534226|NCT00116597|Genetic|Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|
534227|NCT00116597|Biological|Intranodal booster immunizations with synthetic melanoma associated epitopes|
534228|NCT00116584|Drug|heliox|continuous heliox therapy
534229|NCT00116571|Drug|Lemuteporfin for injection|
534230|NCT00116571|Device|Transurethral drug delivery system|
534231|NCT00116571|Device|Transurethral light delivery system|
534232|NCT00116558|Device|Early NIPPV|Early intervention with non-invasive positive pressure ventilation (NIPPV) at 80% forced vital capacity (FVC).
534233|NCT00116558|Device|Standard NIPPV|Standard of care non-invasive positive pressure ventilation (NIPPV) at 50% forced vital capacity (FVC).
534234|NCT00116545|Drug|troglitazone|
534235|NCT00116532|Drug|Escitalopram|
534236|NCT00116519|Drug|PPAR alpha|
534237|NCT00116519|Drug|placebo|
534238|NCT00116506|Drug|erlotinib|
534239|NCT00116506|Drug|FOLFOX|
534240|NCT00116506|Drug|bevacizumab|
534241|NCT00116493|Dietary Supplement|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children~1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
534242|NCT00116493|Drug|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
534243|NCT00116493|Dietary Supplement|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
534244|NCT00116493|Drug|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
534245|NCT00116480|Drug|Misoprostol|600 mcg of sublingual misoprostol
534246|NCT00116467|Biological|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
534247|NCT00116454|Drug|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
534248|NCT00116441|Biological|Therapeutic Cellular Vaccine, GM-CSF Producing|
534249|NCT00116428|Device|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
534250|NCT00116428|Drug|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
534251|NCT00116415|Drug|efavirenz; didanosine EC; lamivudine|
534252|NCT00116402|Drug|fluticasone and salmeterol|"will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID~will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID."
534253|NCT00116389|Drug|talabostat mesylate tablets|
534254|NCT00116389|Drug|gemcitabine|
534255|NCT00116376|Drug|AEE788|
534256|NCT00116363|Genetic|investigational drug INGN 241|
534257|NCT00116350|Drug|Misoprostol|800 mcg sublingual misoprostol
534258|NCT00116350|Drug|Oxytocin|40 IU Oxytocin IV
534259|NCT00116337|Procedure|Spinal Cord Stimulation|Participants will have small electrodes (metal discs) placed — by a routine surgical procedure — over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
534260|NCT00116337|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
534261|NCT00116324|Drug|Montelukast|
534262|NCT00116311|Behavioral|allergen inhalation|
534263|NCT00116311|Behavioral|withdrawal of medication|
534264|NCT00116311|Procedure|sputum induction|
534265|NCT00116298|Drug|stavudine, efavirenz, lamivudine|
534266|NCT00116285|Biological|Ragweed MATA MPL|
534267|NCT00116272|Drug|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
534268|NCT00116259|Drug|Aripiprazole|
534269|NCT00116246|Procedure|McRobert's manoeuvre|
534270|NCT00116233|Device|REPEL-CV|
534271|NCT00116220|Drug|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
534272|NCT00116220|Radiation|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
534273|NCT00116207|Drug|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
534274|NCT00116194|Behavioral|Physical Activity|
534275|NCT00116181|Drug|Etanercept|"All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.~Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24."
534337|NCT00115687|Drug|2 mg nicotine polacrilex|
534276|NCT00116168|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
534277|NCT00116168|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
534278|NCT00116168|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
534279|NCT00116168|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
534280|NCT00116155|Biological|CV787 (CG7870)|
534281|NCT00116142|Drug|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
534282|NCT00116142|Drug|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
534283|NCT00116142|Drug|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
534284|NCT00116129|Drug|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
534285|NCT00116116|Drug|efavirenz, stavudine extended release, lamivudine|
534286|NCT00116103|Drug|Tacrolimus Inhalation Aerosol|
534287|NCT00116064|Drug|intranasal lorazepam|
534288|NCT00116064|Drug|intramuscular paraldehyde|
534289|NCT00116051|Device|Acetabular implant, Monoblock cup|
534290|NCT00116038|Device|Femoral implant (Versys Fiber Metal Taper®)|
534291|NCT00116025|Drug|Human acylated ghrelin|
534292|NCT00116012|Drug|rNAPc2|
534293|NCT00115999|Drug|alfimeprase|
534294|NCT00115986|Biological|Influenza A/H5N1 Vaccine|
534295|NCT00115973|Device|pump|
534296|NCT00115973|Drug|insulin aspart|
534297|NCT00115960|Biological|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
534298|NCT00115960|Biological|IL-15 DNA adjuvant|Cytokine injection
534299|NCT00115960|Biological|IL-12 DNA adjuvant|Cytokine injection
534300|NCT00115947|Drug|Terlipressin|
534301|NCT00115934|Procedure|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
534302|NCT00115934|Procedure|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
534303|NCT00115921|Behavioral|Provision of antimalarial treatment at home|
534304|NCT00115908|Drug|Albuferon|
534305|NCT00115908|Drug|Ribavirin|
534306|NCT00115908|Drug|PEG-IFNalfa2a|
534307|NCT00115895|Drug|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
534308|NCT00115882|Behavioral|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
534309|NCT00115869|Behavioral|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
534310|NCT00115856|Procedure|Intravascular MRI|Arterial imaging of atherosclerosis
534311|NCT00115843|Device|Mobile Cardiac Outpatient Telemetry|
534312|NCT00115830|Drug|Atorvastatin|
534313|NCT00115830|Drug|Rosuvastatin|
534314|NCT00115817|Drug|Atorvastatin|
534315|NCT00115804|Drug|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
534316|NCT00115791|Drug|RSD1235|IV
534317|NCT00115791|Drug|placebo|IV
534318|NCT00115778|Drug|IVIG|10% Caprylate/Chromatography Purified Intravenous Immunoglobulin 400 mg/kg IV every 4 weeks
534319|NCT00115778|Other|Placebo|0.1% Albumin in an equal volume to the investigational product
534320|NCT00115765|Drug|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
534321|NCT00115765|Drug|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
534322|NCT00115765|Drug|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
534323|NCT00115765|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
534324|NCT00115752|Drug|Valdecoxib|
534325|NCT00115752|Drug|COX Inhibitor|
534326|NCT00115739|Drug|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
534327|NCT00115726|Drug|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
534328|NCT00115726|Drug|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
534329|NCT00115713|Behavioral|Aerobic Exercise Training|
534330|NCT00115713|Behavioral|Resistance Exercise Training|
534331|NCT00115700|Drug|Cyclophosphamide|1000 mg/m2 I.V. on day 1
534332|NCT00115700|Radiation|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
534333|NCT00115700|Drug|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
534334|NCT00115700|Drug|Prednisolone|50 mg/m2 orally daily for days 1 - 5
534335|NCT00115700|Drug|Rituximab|375 mg/m2 IV Infusion day 1
534339|NCT00115648|Drug|Nevirapine|Oral NVP daily dosage
534340|NCT00115648|Drug|AZT|Oral AZT daily
534341|NCT00115648|Drug|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
534342|NCT00115648|Drug|NVP|Oral NVP daily to age 14 weeks
534343|NCT00115648|Drug|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
534344|NCT00115635|Drug|docetaxel|
534345|NCT00115635|Drug|gemcitabine|
534346|NCT00115622|Drug|fluticasone furoate|
534347|NCT00115609|Drug|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
534348|NCT00115609|Drug|tenofovir DF|300mg once a day
534349|NCT00115609|Drug|emtricitabine|one pill of 200mg once a day
534350|NCT00115596|Other|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
534351|NCT00115583|Drug|Drug Infusion (BQ-123)|
534352|NCT00115570|Drug|Insulin glulisine|Subcutaneous injection
534353|NCT00115570|Drug|insulin lispro|Subcutaneous injection
534354|NCT00115570|Drug|insulin glargine|Subcutaneous injection once daily
534355|NCT00115570|Drug|NPH insulin|subcutaneous injection twice daily
534356|NCT00115557|Other|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
534357|NCT00115557|Other|Practice intervention 2|Performance feedback only.
534358|NCT00115544|Drug|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
534359|NCT00115531|Biological|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
534360|NCT00115531|Biological|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
534361|NCT00115518|Drug|cetuximab|After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
534362|NCT00115505|Other|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
534363|NCT00115505|Other|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
534364|NCT00115492|Drug|Fluticasone Propionate/Salmeterol Combination Product|
534365|NCT00115492|Drug|Salmeterol|
534366|NCT00115479|Drug|intensive insulin therapy to maintain normoglycemia|
534367|NCT00115466|Procedure|Non-surgical autologous implant of ASCs|
534368|NCT00115453|Radiation|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
534369|NCT00115440|Radiation|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
534370|NCT00115427|Drug|Liatermin (r-metHuGDNF)|
534371|NCT00115414|Drug|pegfilgrastim|
534372|NCT00115414|Drug|docetaxel|
534373|NCT00115414|Drug|doxorubicin|
534374|NCT00115414|Drug|cyclophosphamide|
534375|NCT00019500|Drug|raloxifene|
534376|NCT00019500|Procedure|evaluation of cancer risk factors|
534377|NCT00115388|Procedure|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
534378|NCT00115375|Drug|Clopidogrel (SR25990)|
534379|NCT00115362|Drug|venlafaxine|
534380|NCT00115349|Drug|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
534381|NCT00115349|Drug|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
534382|NCT00115336|Drug|Intravenous Ketorolac|Intravenous ketorolac
534383|NCT00115336|Drug|Ibuprofen|Ibuprofen, taken orally
534384|NCT00115323|Behavioral|Problem Solving|Problem solving intervention
534385|NCT00115323|Behavioral|Attention Control|Attention control intervention
534386|NCT00115310|Drug|NGX-4010|
534387|NCT00115297|Drug|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
534388|NCT00115297|Drug|Placebo|Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
534389|NCT00115284|Behavioral|ABIM asthma practice improvement module|
534390|NCT00115271|Drug|Nutritional supplements|
534391|NCT00115258|Other|parenteral nutrition titrated to measured REE|
534392|NCT00115245|Drug|Telbivudine (LdT)|
534393|NCT00115245|Drug|Adefovir Dipivoxil|
534394|NCT00115219|Drug|Etanercept|
534395|NCT00115206|Drug|Neulasta® (pegfilgrastim)|
534396|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
534397|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
534398|NCT00115180|Other|No intervention|No intervention
534399|NCT00115167|Drug|Placebo|Q4W
534400|NCT00115167|Drug|Darbepoetin alfa|Q4W
534401|NCT00115154|Drug|Aldara (imiquimod) cream, 5%|
534402|NCT00115141|Drug|Resiquimod|
534403|NCT00115128|Drug|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
534404|NCT00115115|Drug|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
534405|NCT00115102|Drug|fentanyl|
534406|NCT00115102|Drug|S-ketamine|
534407|NCT00115089|Drug|R926112|
534408|NCT00115089|Drug|Beclomethasone dipropionate|
542747|NCT00005848|Drug|tipifarnib|
534409|NCT00115076|Drug|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
534410|NCT00115063|Behavioral|group sessions|group sessions lead by a trained primary care clinic employee
534411|NCT00115063|Drug|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
534412|NCT00115063|Behavioral|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
534413|NCT00115063|Other|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
534414|NCT00115063|Other|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
534415|NCT00115050|Drug|TMC114|
534416|NCT00115037|Drug|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
534417|NCT00115037|Drug|placebo|placebo comparer for 16 weeks in phase 2.
534418|NCT00115037|Behavioral|Medication Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
534419|NCT00115037|Behavioral|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
534420|NCT00115037|Behavioral|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
534421|NCT00115024|Drug|Micronized 17B-estradiol|
534422|NCT00115011|Drug|Escitalopram|
534423|NCT00114985|Device|Prostate Immobilization Device|Device placed during radiation treatment
534424|NCT00114972|Device|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
534425|NCT00114972|Procedure|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
534426|NCT00114959|Drug|Homoharringtonine|"Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.~Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule."
534427|NCT00114959|Drug|Imatinib Mesylate|Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
534428|NCT00114946|Drug|Avastin|
534429|NCT00114933|Drug|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
534430|NCT00114920|Drug|Resiquimod|
534431|NCT00114907|Behavioral|Consumption of black tea|
534432|NCT00114894|Other|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
534433|NCT00114894|Other|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
534434|NCT00114868|Drug|Vitamin A|
534435|NCT00114855|Drug|HYPOCOL®|
534436|NCT00114842|Procedure|MR colonography|
534437|NCT00114829|Procedure|MR colonography with dynamic contrast uptake|
534438|NCT00114816|Drug|capecitabine|
534439|NCT00114816|Drug|docetaxel|
534440|NCT00114803|Drug|Calcitonin nasal spray (salmon)|
534441|NCT00114790|Radiation|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
534442|NCT00114777|Drug|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
534443|NCT00114777|Drug|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
534444|NCT00114777|Drug|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
534445|NCT00114764|Drug|filgrastim|Filgrastim given daily after induction chemotherapy
534446|NCT00114764|Drug|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
534447|NCT00114738|Drug|Rituximab (R)|Rituximab is given with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and bortezomib every 3 weeks for 6 cycles.
534448|NCT00114738|Biological|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
534449|NCT00114738|Drug|Bortezomib (B)|Bortezomib is given alone for one cycle.
534450|NCT00114738|Drug|Bortezomib|Bortezomib is given with EPOCH and rituximab every 6 weeks for 12 cycles.
534451|NCT00114738|Drug|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
534452|NCT00114725|Procedure|Laser-assisted intracytoplasmic sperm injection|
534453|NCT00114699|Drug|CCR5mAb004|
534454|NCT00114686|Drug|Quetiapine fumarate|
534455|NCT00114686|Drug|lithium|
534456|NCT00114686|Drug|divalproex|
534457|NCT00114660|Drug|Cocoa butter application|
534458|NCT00114634|Dietary Supplement|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
534459|NCT00114634|Dietary Supplement|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
534460|NCT00114621|Drug|Anthrax Vaccine|
534461|NCT00114621|Procedure|Blood Chemistry|
534462|NCT00114621|Procedure|Hematology|
534463|NCT00114621|Procedure|Urinalysis|
534588|NCT00113711|Behavioral|smoking cessation|
534589|NCT00113711|Behavioral|reducing diet|
534590|NCT00113698|Drug|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
534464|NCT00114608|Device|The Focus™ Neuromuscular Stimulation System|"Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles."
534465|NCT00114595|Drug|eicosapentaenoic acid|
534466|NCT00114582|Procedure|family style dinner|
534467|NCT00114569|Drug|lorazepam|
534468|NCT00114556|Drug|zoledronic acid|
534469|NCT00114543|Procedure|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
534470|NCT00114543|Procedure|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
534471|NCT00114543|Procedure|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
534472|NCT00114543|Procedure|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
534473|NCT00114530|Biological|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
534474|NCT00114530|Drug|cyclophosphamide|An initial intravenous dose of 500 mg/m^2 was followed by 11 infusions of 750 mg/m^2 with mesna given for bladder protection.
534475|NCT00114517|Drug|Oral 17B-estradiol|Oral 17B-estradiol 1 mg daily
534476|NCT00114517|Drug|Placebo|Matched placebo oral 17B-estradiol
534477|NCT00114504|Drug|simvastatin|simvastatin 5-10 mg/day
534478|NCT00114491|Drug|Rosuvastatin|
534479|NCT00114478|Drug|Epinephrine|
534480|NCT00114478|Drug|albuterol (salbutamol)|
534481|NCT00114465|Drug|VSL#3|VSL#3 1 sachet twice a day
534482|NCT00114465|Other|Placebo|Placebo 1 sachel twice a day
534483|NCT00114452|Drug|Provacel|
534484|NCT00114439|Drug|Lithium carbonate|
534485|NCT00114426|Device|non-invasive mechanical ventilation|
534486|NCT00114413|Drug|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
534487|NCT00114413|Procedure|eNO measurement|measured by Aerocrine® NIOX device
534488|NCT00114400|Drug|folic acid|
534489|NCT00114400|Drug|vitamin B12|
534490|NCT00114400|Drug|vitamin B6|
534491|NCT00114387|Drug|DL-alpha-tocopherol|
534492|NCT00114374|Drug|Escitalopram|
534493|NCT00114361|Drug|Ribavirin|1200 mg a day, 48 weeks
534494|NCT00114361|Drug|Peginterferon alpha 2a|180 µg per week, 48 weeks
534495|NCT00114348|Procedure|R-Blocks|
534496|NCT00114348|Procedure|Protocol II-Ida|
534497|NCT00114322|Device|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
534498|NCT00114309|Drug|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
534499|NCT00114309|Drug|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
534500|NCT00114296|Dietary Supplement|omega-3 fatty acid|
534501|NCT00114283|Drug|lapatinib ditosylate|Given PO
534502|NCT00114283|Other|laboratory biomarker analysis|Correlative studies
534503|NCT00114270|Drug|letrozole|
534504|NCT00114270|Drug|zoledronic acid|
534505|NCT00114257|Drug|decitabine|
534506|NCT00114257|Drug|romidepsin|
534507|NCT00114244|Drug|sorafenib tosylate|Given PO
534508|NCT00114244|Drug|gemcitabine hydrochloride|Given IV
534509|NCT00114244|Other|laboratory biomarker analysis|Correlative studies
534510|NCT00114231|Drug|capecitabine|
534511|NCT00114231|Drug|oxaliplatin|Given IV
534512|NCT00114231|Procedure|neoadjuvant therapy|Undergo surgery
534513|NCT00114231|Radiation|radiation therapy|Undergo radiotherapy
534514|NCT00114218|Drug|Gemcitabine Hydrochloride|Given IV
534515|NCT00114218|Drug|Docetaxel|Given IV
534516|NCT00114205|Drug|docetaxel|
534517|NCT00114205|Procedure|therapeutic thoracoscopy|
534518|NCT00114192|Drug|docetaxel|
534519|NCT00114192|Drug|thalidomide|
534520|NCT00114179|Drug|capecitabine|Given orally
534521|NCT00114179|Radiation|radiation therapy|Undergo radiotherapy
534522|NCT00114179|Biological|bevacizumab|Given IV
534523|NCT00114179|Procedure|therapeutic conventional surgery|Undergo surgery
534524|NCT00114179|Drug|gemcitabine hydrochloride|Given IV
534525|NCT00114166|Drug|topotecan hydrochloride|
534526|NCT00114153|Drug|capecitabine|
534527|NCT00114153|Drug|carboplatin|
534528|NCT00114153|Procedure|conventional surgery|
534529|NCT00114153|Radiation|radiation therapy|
534582|NCT00113763|Other|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
534530|NCT00114140|Drug|Temozolomide|"Concurrent chemoradiotherapy temozolomide given 75 mg/m^2 daily during radiotherapy for 6 weeks.~Post-Radiation Temozolomide given 150 mg/m2 daily on days 1-5 every 28 days with cycle one beginning 28 days post-radiotherapy. In the absence of grade 3 or 4 adverse events, a single dose escalation to 200 mg/m2/day could be attempted for cycle 2 and, if tolerated, that dose should continue for all subsequent cycles. Cycles were repeated every 28 days (+/- 2 days) for a total of 12 cycles."
534531|NCT00114140|Radiation|Radiation therapy|One treatment of 1.8 Gy given daily, 5 days per week (over 6 weeks) for a total dose of 54.0 Gy.
534532|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day
534533|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
534534|NCT00114127|Drug|Placebo|60mg placebo 1x per day
534535|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10* gms topically each day
534536|NCT00114114|Drug|Goserelin acetate|3.6 gms sc every 4 weeks
534537|NCT00114101|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
534538|NCT00114101|Other|Laboratory Biomarker Analysis|Correlative studies
534539|NCT00114101|Drug|Lenalidomide|Given PO
534540|NCT00114101|Drug|Melphalan|Given IV
534541|NCT00114101|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
534542|NCT00114101|Other|Placebo|Given PO
534543|NCT00114088|Procedure|hysterectomy|
534544|NCT00114088|Procedure|endometrial ablation|
534545|NCT00114075|Procedure|Surgery with gait analysis report|Orthopaedic surgery with access to gait analysis report
534546|NCT00114075|Procedure|Surgery without gait analysis report|Orthopaedic surgery without access to gait analysis report
534547|NCT00114062|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
534548|NCT00114049|Drug|GW406381|
534549|NCT00114036|Behavioral|Quality improvement strategies|
534550|NCT00114023|Drug|Imiquimod 5% cream|
534551|NCT00114010|Drug|AMA1/Alhydrogel|
534552|NCT00113997|Drug|REG1|
534553|NCT00113984|Biological|PROSTVAC-V/TRICOM|
534554|NCT00113984|Biological|PROSTVAC-F/TRICOM|
534555|NCT00113984|Drug|MDX-010|
534556|NCT00113984|Drug|Sargramostim|
534557|NCT00113971|Drug|epratuzumab|
534558|NCT00113958|Drug|Cinacalcet|
534559|NCT00113945|Drug|Cinacalcet|
534560|NCT00113932|Procedure|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, & every 2 weeks until HB >12 gm/dl***; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount <30,000/μl
534561|NCT00113919|Drug|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin* 10 mg/m, Continuous infusion 1-4 Adriamycin** 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
534562|NCT00113906|Drug|melatonin|
534563|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
534564|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
534565|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
534566|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
534567|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
534568|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
534569|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
534570|NCT00113854|Drug|Mannitol|
534571|NCT00113841|Drug|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
534572|NCT00113841|Drug|Bioperine|5 mg (Tablets) orally twice daily
534573|NCT00113828|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.~Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant."
534574|NCT00113828|Procedure|T-cell depleted peripheral blood stem cell transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.~T-cell depleted peripheral blood stem cell transplant ."
534575|NCT00113815|Drug|topiramate|15 mg/kg/day
534576|NCT00113815|Drug|topiramate|5 mg/kg/day
534577|NCT00113815|Drug|topiramate|25 mg/kg/day
534578|NCT00113815|Drug|placebo|placebo
534579|NCT00113802|Drug|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
534580|NCT00113789|Other|PI Discretion|PI Discretion
534581|NCT00113776|Drug|ABX-EGF|
534583|NCT00113763|Drug|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
534584|NCT00113750|Biological|TreeMATA MPL|
534585|NCT00113737|Drug|fluoxetine|
534586|NCT00113737|Behavioral|cognitive behavioral therapy|
534591|NCT00113698|Other|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
534592|NCT00113685|Drug|Hypertonic Saline-Dextran Solution|
534593|NCT00113685|Drug|Lactated Ringer's Solution|
534594|NCT00113672|Behavioral|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
534595|NCT00113672|Behavioral|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
534596|NCT00113672|Behavioral|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
534597|NCT00113672|Behavioral|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
534598|NCT00113659|Dietary Supplement|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
534599|NCT00113659|Dietary Supplement|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
534600|NCT00113646|Drug|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
534601|NCT00113646|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
534602|NCT00113633|Behavioral|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
534603|NCT00113620|Drug|Neurodex|
534604|NCT00113607|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
534605|NCT00113607|Drug|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
534606|NCT00113607|Drug|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
534607|NCT00113594|Drug|Olanzapine|
534608|NCT00113581|Drug|EMD 72000 (matuzumab) + ECX|
534609|NCT00113568|Drug|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
534610|NCT00113555|Device|ACT (Adjustable Continence Therapy)|surgically implanted device
534611|NCT00113542|Drug|Tetrathiomolybdate (TM)|
534612|NCT00113529|Drug|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
534613|NCT00113516|Drug|carboplatin|AUC of 6 mg*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
534614|NCT00113516|Drug|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
534615|NCT00113516|Drug|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
534616|NCT00113503|Drug|Azathioprine weight-based dose|
534617|NCT00113503|Drug|Azathioprine individualised dose|
534618|NCT00113490|Biological|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
534619|NCT00113490|Biological|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
534620|NCT00113477|Drug|Q10|
534621|NCT00113477|Drug|Selen|
534622|NCT00113438|Drug|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
534623|NCT00113425|Device|V-Beam laser, Candela Corp., 595 nm wavelength|Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
534624|NCT00113412|Drug|SP01A|
534625|NCT00113399|Biological|filgrastim|
534626|NCT00113399|Drug|cisplatin|
534627|NCT00113399|Drug|docetaxel|
534628|NCT00113399|Drug|fluorouracil|
534629|NCT00113399|Drug|paclitaxel|
534630|NCT00113399|Radiation|radiation therapy|
534631|NCT00113386|Biological|filgrastim|Consolidation chemotherapy
534632|NCT00113386|Biological|pegfilgrastim|Consolidation chemotherapy
534633|NCT00113386|Drug|cisplatin|
534634|NCT00113386|Drug|docetaxel|
534635|NCT00113386|Procedure|adjuvant therapy|
534636|NCT00113386|Procedure|conventional surgery|
534637|NCT00113386|Procedure|neoadjuvant therapy|
534638|NCT00113386|Radiation|radiation therapy|
534639|NCT00113373|Drug|lapatinib ditosylate|Given orally
534640|NCT00113373|Other|laboratory biomarker analysis|Correlative studies
534641|NCT00113360|Drug|RAD001|Starting dose of 5 or 10 mg by mouth daily.
534642|NCT00113360|Drug|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
534643|NCT00113347|Drug|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
534644|NCT00113347|Drug|Docetaxel|15 mg/m^2 or 20 mg/m^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
534722|NCT00112827|Genetic|fluorescence in situ hybridization|Correlative studies
534645|NCT00113347|Radiation|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
534646|NCT00113334|Drug|ABT-510|100 mg subcutaneously twice daily
534647|NCT00113321|Drug|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
534648|NCT00113308|Drug|GW406381|
534649|NCT00113295|Drug|Continued Paroxetine CR|
534650|NCT00113295|Drug|Quetiapine|
534651|NCT00113295|Drug|Placebo|
534652|NCT00113282|Drug|Interleukin-2 (IL-2)|
534653|NCT00113269|Drug|basiliximab|IV
534654|NCT00113269|Drug|rabbit anti-thymocyte globulin|IV
534655|NCT00113269|Drug|tacrolimus|oral
534656|NCT00113269|Drug|alemtuzumab|Intravenous (IV)
534657|NCT00113269|Drug|mycophenolate mofetil|oral
534658|NCT00113269|Drug|steroids|IV and/or oral
534659|NCT00113256|Drug|Rubitecan|
534660|NCT00113243|Drug|adult stem cells|
534661|NCT00113230|Drug|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
534662|NCT00113230|Drug|Capecitabine|900 mg/m^2 by mouth twice a day during days of radiation for all five weeks of therapy.
534663|NCT00113230|Radiation|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
534664|NCT00113217|Drug|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
534665|NCT00113204|Drug|IPI-504|
534666|NCT00113191|Drug|Veronate|
534667|NCT00113178|Device|Catheter-based cardiac cryoablation|
534668|NCT00113165|Drug|LAMICTAL extended-release|
534669|NCT00113139|Behavioral|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
534670|NCT00113139|Other|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
534671|NCT00113126|Drug|Treatment interruption|
534672|NCT00113113|Drug|Rubitecan|
534673|NCT00113100|Drug|Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)|
534674|NCT00113087|Drug|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
534675|NCT00113087|Drug|Placebo|Participants will receive placebo
534676|NCT00113074|Drug|Nicotine Replacement Therapy|Nicotine replacement therapy program
534677|NCT00113074|Behavioral|Diet|Diet program
534678|NCT00113061|Procedure|Exercise|
534679|NCT00113048|Drug|CAMPATH (alemtuzumab)|
534680|NCT00113022|Drug|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
534681|NCT00113022|Drug|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
534682|NCT00113009|Drug|VLTS-934|
534683|NCT00112996|Drug|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
534684|NCT00112996|Other|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
534685|NCT00112983|Biological|eculizumab|
534686|NCT00112957|Biological|rV-NY-ESO-1 vaccine|Patients received a single intradermal injection of rV-NY-ESO-1 (3.1 × 10^7 PFU) on Day 1.
534687|NCT00112957|Biological|rF-NY-ESO-1 vaccine|Patients received subcutaneous injections of rF-NY-ESO-1 (7.41 × 10^7 PFU) on Days 29, 57, 85, 113, 141, and 169.
534688|NCT00112931|Biological|rituximab|
534689|NCT00112931|Other|No treatment|
534690|NCT00112918|Biological|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
534691|NCT00112918|Drug|Capecitabine|Film-coated tablets
534692|NCT00112918|Drug|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
534693|NCT00112918|Drug|Leucovorin calcium|Administered as a 200 mg/m^2 infusion over 2 hours.
534694|NCT00112918|Drug|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
534695|NCT00112905|Drug|sorafenib tosylate|Given PO
534696|NCT00112905|Other|laboratory biomarker analysis|Optional correlative studies
534697|NCT00112892|Dietary Supplement|selenium|
534698|NCT00112892|Drug|irinotecan hydrochloride|
534699|NCT00112879|Drug|arsenic trioxide|
534700|NCT00112879|Drug|ascorbic acid|
534701|NCT00112879|Drug|dexamethasone|
534702|NCT00112879|Drug|thalidomide|
534703|NCT00112879|Procedure|anti-cytokine therapy|
534704|NCT00112879|Procedure|antiangiogenesis therapy|
534705|NCT00112879|Procedure|biological therapy|
534706|NCT00112879|Procedure|chemotherapy|
534707|NCT00112879|Procedure|drug resistance inhibition|
534708|NCT00112879|Procedure|growth factor antagonist therapy|
534709|NCT00112879|Procedure|non-specific immune-modulator therapy|
534710|NCT00112866|Drug|cilengitide|Given IV
534711|NCT00112866|Procedure|therapeutic conventional surgery|Undergo tumor resection
534712|NCT00112866|Other|pharmacological study|Correlative studies
534713|NCT00112866|Other|laboratory biomarker analysis|Correlative studies
534714|NCT00112853|Drug|tipifarnib|Given orally
534715|NCT00112853|Drug|etoposide|Given orally
534716|NCT00112840|Drug|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
534717|NCT00112840|Drug|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
534718|NCT00112827|Radiation|total marrow irradiation|Undergo irradiation
534719|NCT00112827|Drug|melphalan|Given IV
534720|NCT00112827|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
534721|NCT00112827|Biological|filgrastim|Given IV
534723|NCT00112827|Genetic|cytogenetic analysis|Correlative studies
534724|NCT00112827|Drug|cyclophosphamide|Given IV
534725|NCT00112827|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo transplantation
534726|NCT00112827|Drug|lenalidomide|Given orally
534727|NCT00112775|Drug|dasatinib|
534728|NCT00112775|Drug|imatinib mesylate|
534729|NCT00112749|Biological|infliximab|A single infusion of 1mg/kg will be administered.
534730|NCT00112749|Other|Clinical Assessment|Medical, psychiatric, and immune evaluation.
534731|NCT00112749|Other|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
534732|NCT00112749|Other|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
534733|NCT00112736|Drug|erlotinib|Given orally
534734|NCT00112736|Drug|temsirolimus|Given IV
534735|NCT00112736|Procedure|therapeutic conventional surgery|Undergo surgical resection
534736|NCT00112736|Other|laboratory biomarker analysis|Correlative studies
534737|NCT00112736|Other|pharmacological study|Correlative studies
534738|NCT00112723|Drug|alvocidib|Given IV
534739|NCT00112710|Drug|carboplatin|
534740|NCT00112710|Drug|cisplatin|
534741|NCT00112710|Drug|gemcitabine hydrochloride|
534742|NCT00112697|Drug|cisplatin|
534743|NCT00112697|Drug|docetaxel|
534744|NCT00112697|Drug|fluorouracil|
534745|NCT00112697|Radiation|radiation therapy|
534746|NCT00112684|Drug|alvocidib|Given IV
534747|NCT00112684|Other|pharmacological study|Correlative studies
534748|NCT00112684|Other|laboratory biomarker analysis|Correlative studies
534749|NCT00112671|Drug|sorafenib tosylate|Given orally 400mg orally twice daily
534750|NCT00112671|Other|laboratory biomarker analysis|Correlative studies
534751|NCT00112658|Drug|fluorouracil|
534752|NCT00112658|Drug|gemcitabine hydrochloride|
534753|NCT00112658|Drug|irinotecan hydrochloride|
534754|NCT00112658|Drug|leucovorin calcium|
534755|NCT00112658|Drug|oxaliplatin|
534756|NCT00112645|Biological|anti-thymocyte globulin|
534757|NCT00112645|Drug|busulfan|
534758|NCT00112645|Drug|cyclosporine|
534759|NCT00112645|Drug|melphalan|
534760|NCT00112645|Drug|methotrexate|
534761|NCT00112645|Drug|methylprednisolone|
534762|NCT00112645|Procedure|allogeneic bone marrow transplantation|
534763|NCT00112645|Procedure|peripheral blood stem cell transplantation|
534764|NCT00112645|Procedure|umbilical cord blood transplantation|
534765|NCT00112632|Drug|imatinib mesylate|
534766|NCT00112632|Procedure|conventional surgery|
534767|NCT00112632|Procedure|neoadjuvant therapy|
534768|NCT00112619|Drug|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
534769|NCT00112593|Drug|fludarabine phosphate|Given IV
534770|NCT00112593|Radiation|total-body irradiation|Undergo TBI
534771|NCT00112593|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
534772|NCT00112593|Drug|cyclosporine|Given IV or PO
534773|NCT00112593|Drug|mycophenolate mofetil|Given IV or PO
534774|NCT00112593|Other|laboratory biomarker analysis|Correlative studies
534775|NCT00112580|Biological|ipilimumab|
534776|NCT00112567|Drug|fludarabine phosphate|
534777|NCT00112567|Drug|thiotepa|
534778|NCT00112567|Procedure|peripheral blood stem cell transplantation|
534779|NCT00112567|Radiation|radiation therapy|
534780|NCT00112554|Drug|cytarabine|Given IV
534781|NCT00112554|Drug|laromustine|Given IV
534782|NCT00112554|Other|placebo|Given IV
534783|NCT00112528|Biological|bevacizumab|
534784|NCT00112528|Drug|gemcitabine hydrochloride|
534785|NCT00112528|Drug|oxaliplatin|
534786|NCT00112515|Drug|modafinil|
534787|NCT00112515|Procedure|cognitive assessment|
534788|NCT00112515|Procedure|psychosocial assessment and care|
534789|NCT00112515|Procedure|quality-of-life assessment|
534790|NCT00112502|Drug|Celecoxib|400 mg orally twice a day continuous dosing
534791|NCT00112502|Drug|Isotretinoin|40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.
534792|NCT00112502|Drug|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
534793|NCT00112502|Drug|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
534794|NCT00112489|Drug|carboplatin|
534795|NCT00112489|Drug|paclitaxel|
534796|NCT00112476|Drug|bryostatin 1|Given IV
534797|NCT00112476|Drug|temsirolimus|Given IV
534798|NCT00112463|Drug|romidepsin|DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
534799|NCT00112437|Drug|Odanacatib|Odanacatib 3 mg, once weekly for 24 months
534800|NCT00112437|Drug|Odanacatib|Odanacatib 10 mg, once weekly for 24 months
534801|NCT00112437|Drug|Odanacatib|Odanacatib 25 mg, once weekly for 24 months
534802|NCT00112437|Drug|Odanacatib|Odanacatib 50 mg, once weekly for 24 months
534803|NCT00112437|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
534804|NCT00112437|Dietary Supplement|Calcium Carbonate|Participants who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
534805|NCT00112437|Drug|Placebo|Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
534806|NCT00112424|Procedure|Diagnostic cardiac MRI|Routine cardiac MRI done under general anesthesia as pre-operative evaluation.
534807|NCT00112424|Procedure|Cardiac catheterization|Routine cardiac catheterization prior to Glenn operation.
534808|NCT00112411|Drug|Bronchodilator|
534809|NCT00112398|Procedure|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
534810|NCT00112385|Drug|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
534811|NCT00112385|Drug|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
534812|NCT00112372|Drug|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
534813|NCT00112359|Drug|AZLI 75 mg three times a day (TID)|
534814|NCT00112359|Drug|Placebo three times a day (TID)|
534815|NCT00112346|Drug|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
534816|NCT00112346|Drug|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
534817|NCT00112333|Procedure|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
534818|NCT00112320|Procedure|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
534819|NCT00112320|Procedure|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
534820|NCT00112307|Procedure|Brachytherapy|
534821|NCT00112294|Drug|Paclitaxel (Taxane)|IV, 225 mg/m^2
534822|NCT00112294|Drug|Docetaxel (Taxane)|IV, 75 mg/m^2
534823|NCT00112294|Drug|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
534824|NCT00112294|Drug|Cetuximab|Intravenous, 400 mg/m^2, initial dose followed by 250 mg/m^2, weekly starting on Week 2
534825|NCT00112281|Drug|Tilarginine Acetate Injection intravenous infusion|
534826|NCT00112268|Behavioral|QuitLink (office support system for quit line referral)|
534827|NCT00112255|Behavioral|Practice nurse-led partner notification|
534828|NCT00112255|Behavioral|Referral to specialist genitourinary clinic|
534829|NCT00112242|Biological|Montanide + Melan-A analogue peptide|1 ml Montanide+ 500 mcg Melan-A analog peptide
534830|NCT00112242|Biological|Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|1 ml Montanide + 500 mcg Melan-A analog peptide + 500 mcg NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
534831|NCT00112242|Biological|Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 500 mcg Melan-A analog peptide, 500 mcg + NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
534832|NCT00112242|Biological|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide
534833|NCT00112242|Biological|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide + low dose IL-2
534834|NCT00112229|Biological|group 1|Melan-A analog peptide + CpG + Montanide
534835|NCT00112229|Biological|group 2|Melan-A natural peptide + CpG + Montanide
534836|NCT00112229|Biological|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
534837|NCT00112229|Biological|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
534838|NCT00112216|Biological|Melan-A analog peptide|
534839|NCT00112216|Biological|FluMa peptide|
534840|NCT00112216|Biological|Mage-A10 peptide|
534841|NCT00112216|Biological|SB AS-2 adjuvant|
534842|NCT00112216|Biological|Montanide adjuvant|
534843|NCT00112203|Drug|Itopride|
534844|NCT00112190|Drug|Itopride Hydrochloride|100 mg tid
534845|NCT00112190|Drug|itopride|100 mg three times daily
534846|NCT00112177|Drug|Itopride Hydrochloride|
534847|NCT00112164|Drug|Xigris|
534848|NCT00112151|Drug|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
534849|NCT00112151|Behavioral|Resistance Training|Weight training 45-60 minutes 3 times per week
534850|NCT00112151|Drug|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
534851|NCT00112151|Drug|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
534852|NCT00112138|Drug|gabapentin|
534853|NCT00112125|Device|OPTIMIZER System|
534854|NCT00112112|Biological|FluMist|"The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.~brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
543317|NCT00004216|Drug|cefixime|
534855|NCT00112112|Biological|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
534856|NCT00112099|Procedure|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
534857|NCT00112099|Procedure|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
534858|NCT00112086|Drug|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
534859|NCT00112073|Drug|bapineuzumab|IV, Q13w
534860|NCT00112073|Other|placebo|IV Q13w
534861|NCT00112060|Drug|PT-523 for Injection|
534862|NCT00112047|Drug|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
534863|NCT00112047|Drug|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
534864|NCT00112047|Drug|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
534865|NCT00112047|Drug|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
534866|NCT00112047|Drug|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
534867|NCT00112047|Drug|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
534868|NCT00112034|Drug|Methotrexate|
534869|NCT00112034|Drug|IV methylprednisolone|
534870|NCT00112021|Drug|pramlintide acetate|
534871|NCT00112008|Drug|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
534872|NCT00111995|Drug|Aranesp®|
534873|NCT00111982|Biological|Liatermin|Liatermin
534874|NCT00111969|Device|Celacade™ system|
534875|NCT00111956|Drug|Etanercept|
534876|NCT00111956|Drug|Placebo|
534877|NCT00111943|Drug|1% tenofovir gel|
534878|NCT00111930|Drug|DHEA|
534879|NCT00111917|Drug|Infliximab|anti-TNF
534880|NCT00111917|Other|Placebo|Placebo infusion
534881|NCT00111904|Drug|paclitaxel-loaded polymeric micelle|
534882|NCT00111891|Drug|niacin (+) laropiprant|
534883|NCT00111891|Drug|Comparator: placebo (unspecified)|
534884|NCT00111878|Drug|MEDI-534|
534885|NCT00111865|Behavioral|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
534886|NCT00111852|Drug|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
534887|NCT00111852|Drug|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
534888|NCT00111852|Drug|Placebo|Dose-Match Placebo, intravenous administration.
534889|NCT00111839|Drug|Pemetrexed|Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.
534890|NCT00111839|Drug|Matuzumab|Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
534891|NCT00111826|Device|Celacade™ system|
534892|NCT00111813|Drug|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
534893|NCT00111813|Drug|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
534894|NCT00111800|Drug|Placebo|Placebo capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
534895|NCT00111800|Drug|DEN 2.5 mg|DEN 2.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
534896|NCT00111800|Drug|DEN 7.5 mg|DEN 7.5 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
534897|NCT00111800|Drug|DEN 15 mg|DEN 15 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
534898|NCT00111800|Drug|DEN 30 mg|DEN 30 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
534899|NCT00111800|Drug|DEN 45 mg|DEN 45 mg capsules which were white, opaque capsules with no identifying markings, containing white to off-white beads.
534900|NCT00111787|Drug|Lapatinib|Daily-monotherapy [1500 milligrams (mg)] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
534901|NCT00111787|Drug|Paclitaxel|Weekly (80mg/m^2) combination therapy (with daily Lapatinib) for 12 weeks
534902|NCT00111774|Drug|ABX-EGF|
534903|NCT00111761|Drug|Irinotecan|Part 1: 125 mg/m^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m^2 IV infusion every other week until disease progression or unable to tolerate.
534904|NCT00111761|Biological|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
534905|NCT00111761|Drug|5-Fluorouracil|Part 1: IV bolus 500 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m^2 and infusional 2400-3000 mg/m^2 over 46 hours once every other week until disease progression or unable to tolerate.
534906|NCT00111761|Drug|Leucovorin|Part 1: IV bolus 20 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m^2 every other week until disease progression or unable to tolerate.
534907|NCT00111748|Drug|Velcade, Thalidomide, Dexamethasone|"Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14~This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit."
534908|NCT00111735|Drug|Thyroxine|
543318|NCT00004216|Drug|ceftriaxone sodium|
534909|NCT00111722|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
534910|NCT00111722|Drug|Comparator: placebo / Duration of Treatment - 1 day|
534911|NCT00111709|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
534912|NCT00111709|Drug|Comparator: placebo / Duration of Treatment - 1 day|
534913|NCT00111696|Biological|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
534914|NCT00111683|Drug|MK0457|
534915|NCT00111670|Drug|DPP-IV Inhibitor|Escalating doses po bid or qd
534916|NCT00111670|Drug|Placebo|po bid or qd
534917|NCT00111657|Biological|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
534918|NCT00111644|Drug|Ceftriaxone|1000mg iv daily
534919|NCT00111644|Drug|beta-lactam|750mg iv q 23h for 3-14 days
534920|NCT00111644|Drug|beta-lactam|1500mg iv q 12h for 3-14 days
534921|NCT00111631|Drug|DPP-IV Inhibitor|Escalating doses po bid
534922|NCT00111631|Drug|Metformin|As prescribed
534923|NCT00111631|Drug|Placebo|po bid
534924|NCT00111618|Drug|AS1404 (DMXAA)|
534925|NCT00111605|Biological|HIV-1 gag DNA|A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
534926|NCT00111605|Biological|HIV-1 gag DNA plus IL-12 DNA adjuvant|Injection IL-12 DNA adjuvant intramuscularly into the deltoid
534927|NCT00111605|Biological|CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)|A 1 mL intramuscular injection in the deltoid
534928|NCT00111605|Biological|Sodium chloride injection (0.9%)|"All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.~Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273."
534929|NCT00111592|Procedure|current usual care|current usual care
534930|NCT00111592|Procedure|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
534931|NCT00111579|Biological|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
534932|NCT00111579|Other|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
534933|NCT00111566|Drug|eptifibatide|
534934|NCT00111553|Biological|Leish-111f + MPL-SE vaccine|
534935|NCT00111540|Drug|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
534936|NCT00111527|Other|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
534937|NCT00111527|Other|normal RV pacing|PM or ICD implant according to patient indication
534938|NCT00111514|Biological|Leish-111f + MPL-SE vaccine|
534939|NCT00111501|Behavioral|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
534940|NCT00111501|Behavioral|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
534941|NCT00111488|Device|Flex 4 and Generator|
534942|NCT00111475|Drug|AMG 531|
534943|NCT00111462|Drug|Darbepoetin alfa|
534944|NCT00111449|Drug|Etanercept|
534945|NCT00111436|Drug|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
534946|NCT00111423|Drug|Pegsunercept (PEG sTNF-RI)|
534947|NCT00111410|Drug|Anakinra (r-metHuIL-1ra)|
534948|NCT00111397|Procedure|Cytokine therapy|
534949|NCT00111397|Drug|Interferon Gamma, GM-CSF|
534950|NCT00111371|Drug|Levodopa|
534951|NCT00111358|Behavioral|Lifestyle Modification|
534952|NCT00111358|Other|No lifestyle modification|
534953|NCT00111345|Drug|Anthracyclines|3x12 mg/qm
534954|NCT00111345|Drug|liposomal daunorubicin|3x80 mg/qm
534955|NCT00111345|Drug|2-CDA|2x6 mg/qm
534956|NCT00111345|Drug|AI|AI
534957|NCT00111332|Behavioral|Progressive resistance and aerobic training|
534958|NCT00111319|Drug|bortezomib|
534959|NCT00111306|Drug|epratuzumab|
534960|NCT00111280|Drug|TMC125|
534961|NCT00111267|Behavioral|vitamin B12 supplementation|
534962|NCT00111267|Behavioral|vitamin B12 + folic acid combined supplementation|
534963|NCT00111254|Procedure|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
534964|NCT00111241|Drug|aromatase inhibitors (letrozole, anastrozole)|Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study
534965|NCT00111228|Device|Guardian RT|
534966|NCT00111228|Device|SMBG only|SMBG only
534967|NCT00111215|Drug|Tranexamic Acid|
534968|NCT00111215|Drug|Desmopressin Acetate|
534969|NCT00111189|Drug|Placebo|Placebo every 4 wk up to 24 mo
534970|NCT00111189|Drug|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
534971|NCT00111176|Device|Endovascular repair|Endovascular repair.
534972|NCT00111176|Procedure|Surgical|Surgical endovascular repair
534973|NCT00111163|Drug|sulfadoxine-pyrimethamine with artesunate|
534974|NCT00111163|Drug|amodiaquine with artesunate|
534975|NCT00111163|Drug|chlorproguanil-dapsone|
534976|NCT00111150|Drug|Tenofovir Disoproxil Fumarate 300 mg daily|
534977|NCT00111137|Drug|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
534978|NCT00111137|Drug|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
534979|NCT00111124|Drug|Enbrel®|
534980|NCT00111111|Drug|Etanercept|
535275|NCT00109031|Drug|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
534981|NCT00111098|Drug|Darbepoetin Alfa|QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
534982|NCT00111085|Drug|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
534983|NCT00111085|Drug|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
534984|NCT00111085|Drug|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
534985|NCT00111085|Drug|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
534986|NCT00111046|Drug|Ibuprofen|
534987|NCT00111046|Drug|Tramadol|
534988|NCT00111020|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
534989|NCT00111007|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
534990|NCT00111007|Drug|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
534991|NCT00111007|Drug|Placebo|Placebo, 2 tablets bid Study Days 2-19
534992|NCT00110994|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
534993|NCT00110994|Drug|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
534994|NCT00110994|Drug|Dacarbazine|Dacarbazine, 1000 mg/m^2 intravenous on Study Day 1
534995|NCT00110981|Device|NB-UVB|Three times a week (TIW) for 12 weeks
534996|NCT00110981|Drug|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
534997|NCT00110981|Drug|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
534998|NCT00110968|Drug|Itopride hydrochloride|
534999|NCT00110955|Drug|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
535000|NCT00110955|Drug|Placebo|Q3W dosing of placebo
535001|NCT00110942|Drug|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
535002|NCT00110942|Other|Placebo|SC placebo injection Q4W for 3 doses
535003|NCT00110929|Drug|AMG 073|
535004|NCT00110916|Drug|Intra-articular metHuIL-1ra (anakinra)|anakinra
535005|NCT00110916|Drug|placebo|placebo
535006|NCT00110903|Drug|Etanercept Liquid|
535007|NCT00110890|Drug|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
535008|NCT00110890|Other|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
535009|NCT00111072|Drug|dexamethasone 0.01% solution|
535010|NCT00110877|Drug|LPV/rtv|One 400mg LPV tablet twice daily with 100mg RTV
535011|NCT00110877|Drug|TMC114/rtv|Two 300mg TMC114 tablets twice daily with 100mg RTV
535012|NCT00110864|Drug|PN2034|
535013|NCT00110864|Drug|Insulin|
535014|NCT00110851|Drug|rosiglitazone|
535015|NCT00110851|Drug|metformin|
535016|NCT00110851|Drug|PN2034|
535017|NCT00110838|Procedure|Supplementation with fish oil versus placebo|
535018|NCT00110825|Behavioral|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
535019|NCT00110812|Drug|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
535020|NCT00110799|Drug|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
535021|NCT00110799|Other|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
535022|NCT00110786|Biological|Ragweed MATAMPL|
535023|NCT00110773|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
535024|NCT00110773|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
535025|NCT00110760|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
535026|NCT00110760|Drug|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
535027|NCT00110747|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
535028|NCT00110747|Drug|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
535029|NCT00110734|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
535030|NCT00110721|Drug|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
535031|NCT00110708|Drug|Oralgam (human immunoglobulin)|
535141|NCT00110006|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
535032|NCT00110695|Drug|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. [or if given with trastuzumab 75 mg/m2 IV over 15 min.]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
535033|NCT00110682|Drug|Imiquimod used as an adjunct to cryotherapy|
535034|NCT00110669|Drug|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
535035|NCT00110656|Other|Observations|This is a non-interventional study- only observational.
535036|NCT00110643|Device|CoolTouch II laser|
535037|NCT00110630|Behavioral|10-week smoking cessation group therapy combined with NicoDerm CQ|
535038|NCT00110617|Drug|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
535039|NCT00110617|Drug|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
535040|NCT00110604|Behavioral|folic acid (0.8 mg)|
535041|NCT00110591|Drug|PRO 140|Monoclonal antibody to CCR5
535042|NCT00110578|Procedure|Adoptive transfer of HIV-specific CD8+ T cells|
535043|NCT00110578|Drug|Aldesleukin|
535044|NCT00110565|Device|Pulsed magnetic field pad|
535045|NCT00110552|Drug|Salvia officinalis (sage)|oral dosage
535046|NCT00110539|Behavioral|Complementary and alternative medicine education|
535047|NCT00110526|Genetic|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
535048|NCT00110513|Biological|Recombinant human antithrombin (rhAT)|Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is > 80% and < 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at > 80% and < 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
535049|NCT00110500|Genetic|hVEGF-A|
535050|NCT00110487|Drug|ERB-041|
535051|NCT00110474|Drug|Glucosamine sulfate|
535052|NCT00110474|Drug|Acetaminophen|
535053|NCT00110461|Drug|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
535054|NCT00110461|Drug|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
535055|NCT00110461|Drug|placebo|Placebo tablet
535056|NCT00110448|Drug|Aspirin|Aspirin 81 mg or 100 mg per day
535057|NCT00110448|Drug|No aspirin|No aspirin use
535058|NCT00110435|Drug|MK0653A, ezetimibe (+) simvastatin|
535059|NCT00110435|Drug|Duration of Treatment: 4 wk placebo run in then 6 wk active|
535060|NCT00110435|Drug|Comparator: atorvastatin|
535061|NCT00110422|Drug|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
535062|NCT00110422|Drug|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
535063|NCT00110409|Behavioral|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
535064|NCT00110409|Behavioral|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
535065|NCT00110396|Biological|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
535066|NCT00110383|Behavioral|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
535067|NCT00110370|Drug|Lispro Mixture Therapy|
535068|NCT00110370|Drug|Glargine Basal-Bolus Therapy|
535069|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
535070|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
535071|NCT00110344|Drug|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
535142|NCT00110006|Drug|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
543319|NCT00004216|Drug|ciprofloxacin|
535072|NCT00110344|Drug|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
535073|NCT00110318|Procedure|Manual therapy and therapeutic exercise|
535074|NCT00110318|Procedure|Corticosteroid injections|
535075|NCT00110305|Drug|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
535076|NCT00110305|Drug|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
535077|NCT00110305|Drug|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
535078|NCT00110305|Drug|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
535079|NCT00110305|Drug|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
535080|NCT00110292|Behavioral|Age-specific parenting newsletters and developmental toys|
535081|NCT00110292|Behavioral|Parent-completed Ages & Stages Questionnaires|
535082|NCT00110292|Behavioral|Clinic-based distribution of children's books|
535083|NCT00110279|Biological|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
535084|NCT00110266|Drug|Deferasirox|20 mg/kg/day over one year in patients with MDS
535085|NCT00110253|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
535086|NCT00110240|Drug|vildagliptin|
535087|NCT00110227|Behavioral|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
535088|NCT00110227|Behavioral|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
535089|NCT00110214|Drug|docetaxel|Given IV
535090|NCT00110214|Other|placebo|Given IV
535091|NCT00110214|Drug|prednisone|Given orally
535092|NCT00110214|Biological|bevacizumab|Given IV
535093|NCT00110214|Other|laboratory biomarker analysis|Correlative studies
535094|NCT00110201|Drug|Nesiritide|
535095|NCT00110188|Drug|ridaforolimus|
535096|NCT00110162|Drug|antiandrogen therapy|
535097|NCT00110162|Drug|releasing hormone agonist therapy|
535098|NCT00110162|Procedure|orchiectomy|
535099|NCT00110149|Biological|rituximab|
535100|NCT00110149|Radiation|yttrium Y 90 ibritumomab tiuxetan|
535101|NCT00110136|Drug|St. John's Wort|St. John's Wort 300mg tablet three times per day
535102|NCT00110123|Drug|fotemustine|
535103|NCT00110123|Drug|isolated perfusion|
535104|NCT00110110|Biological|filgrastim|Given after chemo cycle for 7 days or until neutrophil counts return to normal.
535105|NCT00110110|Drug|Carboplatin|Given at 28 mg/kg/dose.
535106|NCT00110110|Drug|Cyclosporine|Given at 33 mg/kg/dose
535107|NCT00110110|Drug|Etoposide|Given at 12 mg/kg/dose
535108|NCT00110110|Drug|vincristine sulfate|Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
535109|NCT00110110|Procedure|cryosurgery|Local application of extreme cold to destroy residual tumor.
535110|NCT00110110|Procedure|laser therapy|Local and precise application of laser beams to destroy residual tumor.
535111|NCT00110084|Drug|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
535112|NCT00110084|Drug|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
535113|NCT00110071|Drug|fludarabine phosphate|Given IV
535114|NCT00110071|Procedure|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
535115|NCT00110071|Radiation|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
535116|NCT00110071|Other|laboratory biomarker analysis|Correlative studies
535117|NCT00110071|Other|flow cytometry|Correlative studies
535118|NCT00110071|Genetic|polymerase chain reaction|Correlative studies
535119|NCT00110058|Biological|recombinant interferon alfa|
535120|NCT00110058|Biological|therapeutic allogeneic lymphocytes|
535121|NCT00110058|Drug|cyclosporine|
535122|NCT00110058|Drug|fludarabine phosphate|
535123|NCT00110058|Drug|imatinib mesylate|
535124|NCT00110058|Drug|mycophenolate mofetil|
535125|NCT00110058|Procedure|peripheral blood stem cell transplantation|
535126|NCT00110058|Radiation|radiation therapy|
535127|NCT00110045|Drug|caspofungin acetate|
535128|NCT00110032|Drug|EF5|Given IV
535129|NCT00110032|Procedure|conventional surgery|Undergo surgery
535130|NCT00110032|Procedure|positron emission tomography|Undergo PET
535131|NCT00110032|Radiation|fluorine F 18 EF5|Given IV
535132|NCT00110032|Other|pharmacological study|Correlative studies
535133|NCT00110019|Drug|Carboplatin|Given IV
535134|NCT00110019|Other|Laboratory Biomarker Analysis|Correlative studies
535135|NCT00110019|Drug|Paclitaxel|Given IV
535136|NCT00110019|Other|Pharmacological Study|Correlative studies
535137|NCT00110019|Other|Placebo|Given PO
535138|NCT00110019|Drug|Sorafenib Tosylate|Given PO
535139|NCT00110006|Biological|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
535140|NCT00110006|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
535276|NCT00109031|Drug|Placebo|Administered as one daily intravenous bolus.
535143|NCT00110006|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
535144|NCT00110006|Procedure|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat ^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
535145|NCT00110006|Radiation|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (^18FDG) IV.
535146|NCT00109993|Biological|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
535147|NCT00109993|Drug|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
535148|NCT00109993|Drug|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
535149|NCT00109967|Biological|rituximab|375 mg/m^2 Given IV
535150|NCT00109967|Drug|temsirolimus|25 mg given IV
535151|NCT00109954|Drug|cisplatin|
535152|NCT00109954|Radiation|brachytherapy|
535153|NCT00109954|Radiation|yttrium Y 90 glass microspheres|
535154|NCT00109941|Biological|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
535155|NCT00109941|Biological|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
535156|NCT00109928|Drug|cisplatin|
535157|NCT00109928|Drug|etoposide|
535158|NCT00109928|Drug|gemcitabine|
535159|NCT00109928|Drug|methylprednisolone|
535160|NCT00109889|Procedure|magnetic resonance imaging|magnetic resonance imaging (MRI)
535161|NCT00109889|Procedure|positron emission tomography|positron emission tomography (PET)
535162|NCT00109876|Procedure|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
535163|NCT00109863|Biological|hu14.18-IL2 fusion protein|
535164|NCT00109850|Biological|cetuximab|400mg/m^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m^2 maintenance dose, IV over 60 min, Days 8 & 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
535165|NCT00109850|Drug|cisplatin|30mg/m^2, bolus intravenous (IV), on Days 1 & 8 of each cycle.
535166|NCT00109850|Drug|irinotecan hydrochloride|65mg/m^2, intravenous (IV) over 30 min, on Days 1 & 8 of each cycle.
535167|NCT00109850|Radiation|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
535168|NCT00109837|Biological|filgrastim|As needed per physician discretion
535169|NCT00109837|Drug|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
535170|NCT00109837|Drug|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
535171|NCT00109837|Drug|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
535172|NCT00109837|Drug|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
535173|NCT00109837|Drug|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
535174|NCT00109837|Drug|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC < 3,000
535175|NCT00109837|Drug|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
535176|NCT00109837|Drug|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
535177|NCT00109837|Drug|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
535178|NCT00109837|Drug|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
535179|NCT00109837|Drug|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
535180|NCT00109837|Drug|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
535181|NCT00109837|Drug|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
535182|NCT00109837|Radiation|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
535183|NCT00109837|Drug|allopurinol|300 mg/d PO Days 1-7
535184|NCT00109837|Drug|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
535185|NCT00109824|Drug|decitabine|Given IV
535186|NCT00109824|Drug|valproic acid|Given PO
535187|NCT00109824|Other|pharmacological study|Correlative studies
535188|NCT00109824|Other|laboratory biomarker analysis|Correlative studies
535189|NCT00109811|Biological|PSA:154-163(155L) peptide vaccine|Given subcutaneously
535190|NCT00109811|Biological|incomplete Freund's adjuvant|Given subcutaneously
535191|NCT00109811|Other|laboratory biomarker analysis|Correlative studies
535192|NCT00109798|Drug|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
535193|NCT00109798|Drug|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
535194|NCT00109785|Procedure|positron emission tomography|
535195|NCT00109785|Radiation|fludeoxyglucose F 18|
535196|NCT00109785|Radiation|iodine I 124 iododeoxyuridine|
535197|NCT00109772|Drug|lenalidomide|Two 5 mg capsules taken one time per day
535198|NCT00109772|Drug|Placebo|Two placebo capsules taken one time per day
535199|NCT00109759|Biological|RagweedMATAMPL|
535200|NCT00109746|Dietary Supplement|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
535201|NCT00109733|Biological|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
535403|NCT00108017|Drug|Duration of Treatment: Part 1) 6 wk timolol maleate run in|
535202|NCT00109733|Biological|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
535203|NCT00109720|Behavioral|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
535204|NCT00109720|Behavioral|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
535205|NCT00109707|Drug|Nilotinib|
535206|NCT00109681|Drug|Iloprost Inhalation Solution (Ventavis)|
535207|NCT00109668|Drug|beclomethasone dipropionate (QVAR)|
535208|NCT00109655|Biological|Oncolytic adenovirus (serotype 5) - CG0070|Intravesical administration of CG0070 (in suspension) directly into the bladder
535209|NCT00109629|Drug|VRC-HIVDNA016-00-VP|
535210|NCT00109629|Drug|VRC-HIVADV014-00|
535211|NCT00109616|Behavioral|Newborn skin cleansing with 0.25% chlorhexidine solution|
535212|NCT00109616|Behavioral|Cleansing of umbilical cord with soap and water solution|
535213|NCT00109616|Behavioral|Cleansing of umbilical cord with 4% chlorhexidine|
535214|NCT00109603|Drug|Tenofovir disoproxil fumarate|
535215|NCT00109590|Drug|Didanosine, enteric-coated|once daily
535216|NCT00109590|Drug|Lopinavir/ritonavir|twice daily
535217|NCT00109590|Drug|Nevirapine|single-dose at the onset of labor
535218|NCT00109590|Drug|Zidovudine|twice daily
535219|NCT00109577|Drug|MCN36 (nutritional supplement)|nutritional supplement
535220|NCT00109577|Drug|Placebo|nutritional supplement
535221|NCT00109564|Drug|ispronicline (nicotinic acetylcholine receptor agonist)|
535222|NCT00109551|Drug|zinc sulphate dietary supplement|
535223|NCT00109551|Drug|iron sulphate-folic acid dietary supplement|
535224|NCT00109538|Drug|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
535225|NCT00109538|Other|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
535226|NCT00109512|Drug|NBI-56418 (GnRH antagonist)|
535227|NCT00109512|Drug|placebo|
535228|NCT00109499|Drug|AdGVPEDF.11D|
535229|NCT00109486|Drug|GW685698X|
535230|NCT00109473|Drug|growth hormone|Nutropin AQ 0.075mg/kg/day subcutaneously daily
535231|NCT00109473|Drug|cortecosteroid|As prescribed by the referring gastroenterologist
535232|NCT00109460|Behavioral|Tobacco Use Disorder|
535233|NCT00109421|Behavioral|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
535234|NCT00109408|Drug|Methotrexate|7.5-20mg po weekly
535235|NCT00109408|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
535236|NCT00109395|Drug|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
535237|NCT00109395|Drug|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
535238|NCT00109395|Drug|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
535239|NCT00109382|Drug|Aspirin|
535240|NCT00109382|Drug|Clopidogrel|
535241|NCT00109382|Drug|Simvastatin|
535242|NCT00109369|Other|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
535243|NCT00109356|Drug|AQ4N (Chemotherapy)|
535244|NCT00109343|Biological|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
535245|NCT00109343|Biological|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
535246|NCT00109330|Biological|Combined diphtheria, tetanus, acellular pertussis vaccine|
535247|NCT00109317|Drug|Raptiva (efalizumab)|
535248|NCT00109304|Biological|VEE 3526|
535249|NCT00109291|Drug|Placebo|
535250|NCT00109291|Drug|peginesatide|
535251|NCT00109278|Biological|V205C, measles, mumps, and rubella virus vaccine live|
535252|NCT00109278|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
535253|NCT00109265|Drug|Erlotinib HCl (OSI-774)|
535254|NCT00109252|Drug|Raptiva (efalizumab)|
535255|NCT00109239|Drug|rhuMAb VEGF (Bevacizumab)|
535256|NCT00109226|Drug|Avastin (Bevacizumab)|
535257|NCT00109213|Procedure|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
535258|NCT00109213|Procedure|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
535259|NCT00109200|Drug|Xolair (omalizumab)|
535260|NCT00109187|Drug|Xolair (omalizumab)|
535261|NCT00109161|Drug|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
535262|NCT00109148|Drug|MK0364|
535263|NCT00109135|Drug|taranabant|
535264|NCT00109122|Biological|zoster vaccine live (Oka/Merck)|
535265|NCT00109122|Biological|Comparator: placebo (unspecified)|
535266|NCT00109109|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
535267|NCT00109096|Drug|Pemetrexed|
535268|NCT00109083|Drug|RWJ-333369|
535269|NCT00109070|Drug|Avastin (bevacizumab)|
535270|NCT00109057|Drug|Avastin (bevacizumab)|
535271|NCT00109044|Drug|Escitalopram|
535272|NCT00109031|Drug|palifermin|Administered as one daily intravenous bolus.
535273|NCT00109031|Radiation|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
535274|NCT00109031|Drug|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
535468|NCT00107523|Drug|pravastatin|
535277|NCT00109005|Drug|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
535278|NCT00108992|Drug|Diclofenac, topical|
535279|NCT00108979|Drug|Escitalopram|
535280|NCT00108953|Drug|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
535281|NCT00108953|Drug|Doxorubicin/Placebo|Chemotherapy plus Placebo
535282|NCT00108927|Behavioral|TRANSLATE|
535283|NCT00108914|Drug|GW685698X|
535284|NCT00108901|Behavioral|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of >150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
535285|NCT00108875|Biological|Survivin peptide vaccine|
535286|NCT00108862|Other|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
535287|NCT00108862|Other|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
535288|NCT00108849|Drug|estradiol, 10 mcg|
535289|NCT00108836|Drug|XBD173|
535290|NCT00108823|Drug|Roflumilast|
535291|NCT00108810|Drug|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
535292|NCT00108810|Drug|Placebo transdermal patch|12 hours application for 28 days
535293|NCT00108797|Drug|eptacog alfa (activated)|
535294|NCT00108797|Drug|Feiba VH|
535295|NCT00108784|Behavioral|Reduced-energy-density diet|
535296|NCT00108771|Drug|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
535297|NCT00108771|Drug|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
535298|NCT00108758|Drug|activated recombinant human factor VII|
535299|NCT00108745|Other|Clinical Observation|Undergo observation
535300|NCT00108745|Other|Laboratory Biomarker Analysis|Correlative studies
535301|NCT00108745|Drug|Paclitaxel|Given IV
535302|NCT00108745|Drug|Paclitaxel Poliglumex|Given IV
535303|NCT00108745|Procedure|Quality-of-Life Assessment|Ancillary studies
535304|NCT00108732|Drug|Bicalutamide|Given orally
535305|NCT00108732|Drug|Goserelin Acetate|Given SC
535306|NCT00108732|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
535307|NCT00108732|Biological|Recombinant Vaccinia-TRICOM Vaccine|Given SC
535308|NCT00108732|Biological|Sargramostim|Given SC
535309|NCT00108706|Drug|Candesartan|
535310|NCT00108667|Drug|IV Levodopa|
535311|NCT00108667|Drug|Talampanel|
535312|NCT00108654|Drug|VRC-HIVADV014-00-VP|
535313|NCT00108628|Behavioral|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
535314|NCT00108628|Behavioral|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
535315|NCT00108615|Drug|Metformin|
535316|NCT00108615|Drug|Pioglitazone|
535317|NCT00108615|Drug|Metformin|
535318|NCT00108615|Drug|Pioglitazone|
535319|NCT00108615|Radiation|CT scans|To measure changes in adipose tissue volumes
535320|NCT00108615|Procedure|Oral glucose tolerance test|To detect a change in glucose tolerance
535321|NCT00108602|Drug|acetazolamide|
535322|NCT00108589|Drug|S-adenosylmethionine|
535323|NCT00108576|Drug|Divalproex|anticonvulsant; mood stabilizer
535324|NCT00108576|Other|placebo|Look-a-like placebo
535325|NCT00108563|Drug|Citalopram or Placebo|
535326|NCT00108550|Drug|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
535327|NCT00108550|Drug|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
535328|NCT00108537|Drug|bupropion and transdermal patch|
535329|NCT00108537|Drug|transdermal patch and nicotine inhaler|
535330|NCT00108524|Behavioral|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
535331|NCT00108524|Drug|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
535332|NCT00108524|Behavioral|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
535333|NCT00108511|Drug|Gemfibrozil|
535334|NCT00108498|Drug|mirtazapine|
535335|NCT00108485|Drug|Extended release niacin|Extended release niacin 1500-2000mg once daily
535336|NCT00108485|Other|Placebo|Placebo tablets
535337|NCT00108459|Behavioral|Low Carbohydrate Diet|
535338|NCT00108446|Drug|dextromethorphan|
535339|NCT00108446|Drug|naloxone|
535340|NCT00108446|Drug|fentanyl|
535341|NCT00108446|Drug|lidocaine|
535342|NCT00108433|Drug|Cefazolin IV|
535343|NCT00108433|Drug|Linezolid IV|
535344|NCT00108433|Drug|Vancomycin (IV)|
535345|NCT00108420|Drug|Prazosin|
535346|NCT00108407|Behavioral|Integrated Cognitive Behavioral Therapy|
535347|NCT00108407|Behavioral|Twelve Step Facilitation Therapy|
535348|NCT00108394|Drug|pamidronate|
535349|NCT00108381|Behavioral|tailored cognitive behavior therapy|tailored psychological treatment
535350|NCT00108381|Behavioral|standard care|standard psychological treatment
535351|NCT00108368|Drug|Risperidone|
535352|NCT00108368|Drug|Olanzapine|
535353|NCT00108355|Drug|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
535354|NCT00108355|Drug|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
535355|NCT00108355|Drug|Midodrine|Midodrine oral tablet at 10 mg three times a day.
535356|NCT00108355|Drug|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
535357|NCT00108355|Drug|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
535358|NCT00108355|Drug|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
535359|NCT00108355|Procedure|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
535360|NCT00108342|Drug|Nicotine gum - 2 mg and 4 mg|
535361|NCT00108342|Drug|Nicotine lozenges - 2 mg and 4 mg|
535362|NCT00108342|Drug|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
535363|NCT00108342|Other|Computer learning|
535364|NCT00108329|Behavioral|Weight Loss|
535365|NCT00108316|Drug|Fluoxetine (Liquid Prozac)|
535366|NCT00108303|Other|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
535367|NCT00108290|Drug|Chemotherapy|
535368|NCT00108277|Behavioral|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
535369|NCT00108277|Behavioral|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
535370|NCT00108264|Biological|Tumor RNA transfected dendritic cells|
535371|NCT00108251|Drug|Eplerenone|aldosterone receptor blocker
535372|NCT00108251|Drug|Placebo|matching placebo
535373|NCT00108238|Drug|Estradiol followed by progesterone|
535374|NCT00108238|Drug|Raloxifene|
535375|NCT00108225|Other|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
535376|NCT00108225|Other|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
535377|NCT00108212|Behavioral|Diet|
535378|NCT00108199|Behavioral|Problem-Solving Training|
535379|NCT00108199|Behavioral|Work-Related Social Skills Training|
535380|NCT00108186|Drug|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
535381|NCT00108173|Drug|Zyban|
535382|NCT00108160|Drug|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
535383|NCT00108160|Drug|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
535384|NCT00108147|Procedure|Circuit Training|
535385|NCT00108147|Procedure|Cardiac Rehabilitation|
535386|NCT00108147|Procedure|Flexibility and toning|
535387|NCT00108134|Drug|PEP005|
535388|NCT00108121|Drug|PEP005|
535389|NCT00108108|Drug|HCD122|
535390|NCT00108095|Drug|intravenous ondansetron|
535391|NCT00108082|Drug|carvedilol MR|Study drug
535392|NCT00108082|Drug|atenolol|Comparator
535393|NCT00108082|Drug|lisinopril|Comparator
535394|NCT00108069|Drug|Tamoxifen citrate|oral dose 120 mg twice a day, every day
535395|NCT00108069|Drug|Bortezomib|intravenous (IV) injection 1.3 mg/m^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
535396|NCT00108056|Drug|Enzastaurin (LY317615) monohydronchloride|
535397|NCT00108043|Procedure|FES-evoked functional upright gait|
535398|NCT00108030|Procedure|Partial Body-weight supported Treadmill Training|
535399|NCT00108030|Procedure|PBWST + Power training|
535400|NCT00108030|Procedure|"Usual physiotherapy care"|
535401|NCT00108017|Drug|MK0507A, dorzolamide hydrochloride (+) timolol maleate|
535402|NCT00108017|Drug|Comparator: timolol maleate|
535724|NCT00105300|Drug|Adalimumab|
535404|NCT00108017|Drug|Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds|
535405|NCT00108004|Drug|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
535406|NCT00107991|Drug|etanercept|etanercept 50 mg/week subcutaneous injection
535407|NCT00107978|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
535408|NCT00107978|Drug|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
535409|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,2 application)
535410|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,2 application)
535411|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,2 application)
535412|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,2 application)
535413|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,8 application)
535414|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,8 application)
535415|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,8 application)
535416|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,8 application)
535417|NCT00107952|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
535418|NCT00107952|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
535419|NCT00107939|Drug|Licarbazepine|
535420|NCT00107926|Drug|Licarbazepine|
535421|NCT00107926|Drug|Placebo|
535422|NCT00107913|Drug|Doxil|
535423|NCT00107900|Drug|DU-176b|
535424|NCT00107887|Drug|INH preventive therapy|Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
535425|NCT00107887|Drug|TST (tuberculin skin test)|Clinics will be trained in the use of TST for assessing exposure to TB
535426|NCT00107874|Drug|misoprostol|
535427|NCT00107861|Drug|Ad.hIFN-β (BG00001, IDEC-201)|
535428|NCT00107848|Drug|Modafinil|
535429|NCT00107835|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
535430|NCT00107822|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
535431|NCT00107809|Drug|Modafinil|
535432|NCT00107796|Drug|Modafinil|
535433|NCT00107783|Drug|Nitisinone (NTBC)|Treatment
535434|NCT00107770|Drug|sodium phenylbutyrate|histone deacteylase inhibitor
535435|NCT00107757|Drug|GW685698X|
535436|NCT00107744|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
535437|NCT00107744|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
535438|NCT00107744|Dietary Supplement|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks.
535439|NCT00107731|Drug|quetiapine fumarate|
535440|NCT00107731|Drug|lithium|
535441|NCT00107731|Drug|divalproex|
535442|NCT00107718|Drug|SB-485232|
535443|NCT00107705|Biological|Tree MATA MPL|
535444|NCT00107692|Behavioral|Physical activity and diet|
535445|NCT00107666|Drug|CTI-01 (ethyl pyruvate)|
535446|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
535447|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
535448|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
535449|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
535450|NCT00107640|Behavioral|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
535451|NCT00107627|Other|Caprosyn subcuticular sutures.|Caprosyn subcuticular sutures.
535452|NCT00107627|Other|Monocryl subcuticular sutures.|Monocryl subcuticular sutures.
535453|NCT00107627|Other|Skin staples;|Skin staples;
535454|NCT00107614|Drug|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with < 50% response to induction) OR MEL-DT PACE (Patients with > 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
535455|NCT00107601|Drug|Insulin|
535456|NCT00107588|Behavioral|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
535457|NCT00107588|Behavioral|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
535458|NCT00107588|Behavioral|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
535459|NCT00107575|Behavioral|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
535460|NCT00107575|Other|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
535461|NCT00107562|Behavioral|Adolescent Safer Sex Social Network Intervention|
535462|NCT00107549|Biological|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
535463|NCT00107549|Biological|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
535464|NCT00107536|Drug|lapatinib ditosylate|
535465|NCT00107536|Other|laboratory biomarker analysis|Correlative studies
535466|NCT00107523|Drug|cytarabine|
535467|NCT00107523|Drug|idarubicin|
535469|NCT00107510|Biological|pegfilgrastim|
535470|NCT00107510|Drug|carboplatin|
535471|NCT00107510|Drug|docetaxel|
535472|NCT00107510|Procedure|conventional surgery|
535473|NCT00107497|Radiation|Radiation therapy|
535474|NCT00107484|Drug|ferumoxtran-10|
535475|NCT00107484|Procedure|magnetic resonance imaging|
535476|NCT00107484|Procedure|sentinel lymph node biopsy|
535477|NCT00107471|Biological|filgrastim|Given PO
535478|NCT00107471|Drug|topotecan hydrochloride|Given IV
535479|NCT00107471|Radiation|radiation therapy|
535480|NCT00107458|Drug|valproic acid|
535481|NCT00107445|Drug|EF5|Given IV
535482|NCT00107432|Drug|sorafenib tosylate|Given orally
535483|NCT00107432|Other|laboratory biomarker analysis|Correlative studies
535484|NCT00107419|Drug|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
535485|NCT00107393|Biological|trastuzumab|
535486|NCT00107393|Drug|capecitabine|
535487|NCT00107380|Biological|rituximab|
535488|NCT00107380|Drug|cyclophosphamide|
535489|NCT00107380|Drug|doxorubicin hydrochloride|
535490|NCT00107380|Drug|prednisone|
535491|NCT00107380|Drug|vincristine sulfate|
535492|NCT00107380|Radiation|tositumomab and iodine I 131 tositumomab|
535493|NCT00107367|Procedure|conventional surgery|
535494|NCT00107367|Radiation|intraoperative radiation therapy|
535495|NCT00107354|Biological|aldesleukin|
535496|NCT00107354|Biological|therapeutic allogeneic lymphocytes|
535497|NCT00107354|Biological|therapeutic autologous lymphocytes|
535498|NCT00107354|Drug|cytarabine|
535499|NCT00107354|Drug|etoposide|
535500|NCT00107354|Drug|mitoxantrone hydrochloride|
535501|NCT00107354|Procedure|allogeneic bone marrow transplantation|
535502|NCT00107354|Procedure|peripheral blood stem cell transplantation|
535503|NCT00107341|Drug|bortezomib|
535504|NCT00107341|Drug|carboplatin|
535505|NCT00107341|Drug|paclitaxel|
535506|NCT00107315|Biological|bevacizumab|
535507|NCT00107315|Drug|capecitabine|
535508|NCT00107289|Radiation|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) IV over 30 minutes to 4 hours on day 0. Patients undergo radiation dosimetry following the first dose of ^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.~After completion of study treatment, patients are followed at 4-6 weeks after ^131I-MIBG administration and then every 3 months for up to 1 year."
535509|NCT00107276|Drug|capecitabine|
535510|NCT00107276|Drug|cyclophosphamide|
535511|NCT00107263|Drug|letrozole|
535512|NCT00107263|Drug|zoledronic acid|
535513|NCT00107250|Drug|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
535514|NCT00107250|Drug|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
535515|NCT00107250|Drug|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
535516|NCT00107250|Drug|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
535517|NCT00107237|Drug|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
535518|NCT00107237|Drug|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
535519|NCT00107211|Biological|therapeutic autologous dendritic cells|
535520|NCT00107211|Procedure|conventional surgery|
535521|NCT00107211|Procedure|neoadjuvant therapy|
535522|NCT00107198|Drug|doxorubicin hydrochloride|Given IV
535523|NCT00107198|Procedure|conventional surgery|Undergo surgery
535524|NCT00107198|Drug|cyclophosphamide|Given IV
535525|NCT00107198|Drug|prednisone|Given IV or PO
535526|NCT00107198|Drug|vincristine sulfate|Given IV
535527|NCT00107198|Radiation|radiation therapy|Undergo IFRT
535528|NCT00107185|Biological|therapeutic autologous dendritic cells|
535529|NCT00107172|Procedure|surgery|
535530|NCT00107172|Radiation|brachytherapy|
535531|NCT00107159|Biological|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
535532|NCT00107120|Drug|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
535533|NCT00107120|Drug|Placebo|Placebo once daily for up to 8 weeks
535534|NCT00107107|Drug|pramlintide acetate|Syringe vial and Pen-cartridge
535535|NCT00107094|Drug|Abraxane|
535536|NCT00107081|Drug|ciprofloxacin and amoxicillin|
535537|NCT00107081|Procedure|Outpatient management|
535538|NCT00107081|Drug|i.v. antibiotics|
535539|NCT00107081|Procedure|inpatient management|
535540|NCT00107068|Procedure|[A] Aerobic isokinetic cycling exercise|
535541|NCT00107068|Procedure|[B] Progressive Resistance Training|
535542|NCT00107068|Procedure|[A] + [B]|
535543|NCT00107055|Drug|REN-1654|
535544|NCT00107042|Biological|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
535545|NCT00107042|Biological|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
535546|NCT00107016|Drug|RAD001, Letrozole 2.5mg|
535547|NCT00107016|Drug|Letrozole 2.5mg|
535548|NCT00107003|Drug|lapatinib ditosylate|
535549|NCT00107003|Procedure|Adjuvant therapy|
535550|NCT00107003|Procedure|Conventional surgery|
535551|NCT00107003|Procedure|Neoadjuvant therapy|
535552|NCT00106964|Biological|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
535878|NCT00104273|Drug|Rasagiline|
535553|NCT00106964|Biological|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
535554|NCT00106964|Biological|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:~A single dose of 1 mL will be administered in the deltoid muscle."
535555|NCT00106938|Device|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
535556|NCT00106938|Procedure|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
535557|NCT00106899|Procedure|Magnetic Resonance Imaging (MRI)|MRI scans
535558|NCT00106899|Procedure|Positron Emission Tomography (PET)|PET scans
535559|NCT00106899|Procedure|Lumbar Puncture (LP)|collection of cerebrospinal fluid
535560|NCT00106886|Drug|Folic acid, vitamin B6 and B12 or placebo|
535561|NCT00106860|Drug|a benzodiazepine drug|
535562|NCT00106847|Drug|Infliximab|
535563|NCT00106834|Drug|Infliximab|
535564|NCT00106821|Drug|Tiotropium Bromide Inhalation Powder|
535565|NCT00106808|Drug|Muraglitazar|
535566|NCT00106808|Drug|Pioglitazone|
535567|NCT00106782|Procedure|Transcranial Electrical Polarization (TEP)|
535568|NCT00106769|Drug|VRC-WNVDNA017-00-VP|
535569|NCT00106717|Procedure|Narrative medicine|
535570|NCT00106704|Drug|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
535571|NCT00106704|Drug|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
535572|NCT00106704|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
535573|NCT00106691|Drug|Toremifene 20 mg|20 mg once a day
535574|NCT00106691|Drug|Placebo|placebo tablet identically appearing to the toremifene 20 mg tablet, administered daily for 360 days.
535575|NCT00106639|Drug|CP-690,550|15 mg twice daily
535576|NCT00106639|Drug|CP-690,550|30 mg twice daily
535577|NCT00106639|Drug|tacrolimus|dose adjusted according to level
535578|NCT00106626|Drug|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
535579|NCT00106613|Drug|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
535580|NCT00106600|Drug|Pixantrone IV infusion|
535581|NCT00106587|Device|paclitaxel coated balloon catheter (device with drug)|
535582|NCT00106574|Drug|Placebo|iv every 4 weeks
535583|NCT00106574|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
535584|NCT00106561|Drug|Spironolactone|
535585|NCT00106561|Drug|Irbesartan|
535586|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
535587|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
535588|NCT00106548|Drug|Placebo|iv / month
535589|NCT00106548|Drug|Methotrexate|10-25mg/week
535590|NCT00106535|Drug|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
535591|NCT00106535|Drug|Placebo|IV/month
535592|NCT00106535|Drug|Methotrexate|10-25 mg/week
535593|NCT00106522|Drug|Methotrexate|10-25mg weekly
535594|NCT00106522|Drug|Placebo|iv every 4 weeks
535595|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
535596|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
535597|NCT00106509|Drug|tolevamer potassium-sodium (GT267-004)|
535598|NCT00106496|Drug|Protopic|topical
535599|NCT00106496|Drug|Corticosteroid|topical
535600|NCT00106496|Drug|placebo|topical
535601|NCT00106431|Drug|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
535602|NCT00106418|Drug|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
535603|NCT00106405|Drug|Memantine HCl|
535604|NCT00106392|Drug|Tacrolimus|oral
535605|NCT00106392|Drug|Placebo|oral
535606|NCT00106379|Drug|Truvada (tenofovir DF + emtricitabine)|
535607|NCT00106379|Drug|Emtriva (emtricitabine)|
535608|NCT00106379|Drug|Viread (tenofovir DF)|
535609|NCT00106366|Drug|insulin detemir|
535610|NCT00106366|Drug|insulin glargine|
535611|NCT00106366|Drug|insulin aspart|
535612|NCT00106353|Drug|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
535613|NCT00106340|Drug|vildagliptin|
535614|NCT00106340|Drug|glimepiride|
535615|NCT00106340|Drug|Metformin|
535616|NCT00106340|Drug|Vildagliptin matching placebo|
535617|NCT00106340|Drug|Glimepiride matching placebo|
535618|NCT00106327|Behavioral|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
535619|NCT00106327|Behavioral|Diet|11 nutrition education sessions
535620|NCT00106314|Drug|Dehydroepiandrosterone [DHEA]|
535621|NCT00106301|Drug|FK228 (romidepsin)|Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
535622|NCT00106288|Drug|Micafungin|IV
535623|NCT00106288|Drug|Liposomal Amphotericin B|IV
535624|NCT00106275|Behavioral|Mindfulness Based Stress Reduction|
535625|NCT00106262|Drug|Velcade (bortezomib)|
535626|NCT00106262|Drug|Irinotecan|
535627|NCT00106249|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
535628|NCT00106249|Device|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
535629|NCT00106236|Behavioral|exercise|
535630|NCT00106223|Behavioral|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
535631|NCT00106210|Behavioral|Early intervention blending several tx approaches, w/ focus|Early intervention blending several different treatment approaches, with a focus on certain skills
535632|NCT00106210|Behavioral|Early intervention blending several treatment approaches|Early intervention blending several different treatment approaches
535633|NCT00106197|Drug|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
535634|NCT00106184|Drug|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
535635|NCT00106184|Drug|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
535636|NCT00106171|Drug|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
535637|NCT00106158|Biological|protein vaccination|
535638|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
535639|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
535640|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
535641|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
535642|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
535643|NCT00106132|Drug|Triamcinolone Acetonide|
535644|NCT00106119|Drug|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
535645|NCT00106106|Procedure|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
535646|NCT00106106|Drug|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
535647|NCT00106080|Behavioral|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
535648|NCT00106067|Behavioral|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.~The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
535649|NCT00106054|Drug|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
535650|NCT00106041|Behavioral|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
535651|NCT00106028|Drug|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
535652|NCT00106028|Drug|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
535653|NCT00106002|Drug|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
535654|NCT00105989|Drug|Duloxetine|
535655|NCT00105989|Drug|placebo|
535656|NCT00105976|Drug|MM-093|
535657|NCT00105963|Behavioral|Education about infant crying|
535658|NCT00105950|Drug|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
535659|NCT00105937|Drug|OraVescent fentanyl citrate|
535660|NCT00105911|Behavioral|Cognitive Behavioral Therapy|
535661|NCT00105898|Procedure|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
535662|NCT00105898|Procedure|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
535663|NCT00105898|Procedure|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
535664|NCT00105885|Procedure|telephone care|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
535665|NCT00105872|Behavioral|Cognitive-Behavioral Therapy|
535666|NCT00105859|Behavioral|Education and Counseling|
535667|NCT00105846|Procedure|Home care telemedicine|
535668|NCT00105833|Behavioral|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
535669|NCT00105820|Procedure|System level depression care quality improvement|
535670|NCT00105807|Behavioral|participation in low intensity exercise|
535671|NCT00105807|Behavioral|participation in art and music activities|
535672|NCT00105794|Procedure|Psychiatric Advance Directives intervention|
535673|NCT00105781|Behavioral|Exercise counseling|
535674|NCT00105768|Behavioral|Advisor-Teller Money Management-Substance Abuse Counselling|
535675|NCT00105755|Device|personal dermal thermometer (DT)|
535676|NCT00105755|Device|Device|
535677|NCT00105742|Procedure|Diagnosis|
535678|NCT00105729|Behavioral|Intensive referral to 12-step self-help groups|
535679|NCT00105716|Behavioral|Telephone behavioral education|
535680|NCT00105716|Behavioral|Computer behavioral education|
535681|NCT00105703|Behavioral|Case management using advanced nurse practitioners|
535682|NCT00105690|Behavioral|Telemedicine intervention|
535683|NCT00105664|Procedure|Collaborative care model|
535684|NCT00105664|Procedure|Group interventions|
535685|NCT00105664|Procedure|Facilitated consultation|
535686|NCT00105651|Behavioral|Combined nursing invention|
535687|NCT00105638|Behavioral|educational program, by telephone|
535688|NCT00105612|Device|Memory and Organizational Aid|
535689|NCT00105612|Behavioral|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
535690|NCT00105599|Behavioral|End of life care coordination|
535691|NCT00105599|Procedure|FairCare System|
535692|NCT00105586|Drug|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
535693|NCT00105573|Behavioral|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
535694|NCT00105573|Behavioral|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
535695|NCT00105573|Behavioral|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
535696|NCT00105560|Radiation|radiation therapy|Radiation therapy with proton beam to standard doses
535697|NCT00105547|Drug|MPC-7869|oral 800 mg BID
535698|NCT00105547|Drug|MPC-7869|Oral BID dosing
535699|NCT00105534|Drug|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected~eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
535700|NCT00105534|Other|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
535701|NCT00105521|Drug|Sarizotan|Sarizotan will be administered twice daily.
535702|NCT00105521|Drug|Placebo|Placebo matching to sarizotan will be administered twice daily.
535703|NCT00105508|Drug|Sarizotan|Subjects will receive sarizotan 1 milligram orally twice daily for 24 weeks.
535704|NCT00105508|Drug|Placebo|Subjects will receive placebo matched to sarizotan orally twice daily for 24 weeks.
535705|NCT00105495|Drug|Ferriprox (deferiprone)|
535706|NCT00105495|Drug|Desferal (deferoxamine)|
535707|NCT00105482|Drug|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
535708|NCT00105482|Drug|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
535709|NCT00105482|Behavioral|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
535710|NCT00105469|Drug|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
535711|NCT00105469|Drug|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
535712|NCT00105443|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
535713|NCT00105443|Drug|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
535714|NCT00105430|Procedure|Deep Brain Stimulation|
535715|NCT00105417|Drug|IL-7|
535716|NCT00105404|Drug|Triamcinolone Acetonide|
535717|NCT00105378|Behavioral|Dutch EASYcare Study Geriatric Intermediate Care Programme|
535718|NCT00105365|Device|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
535719|NCT00105365|Other|walking shoes|walking shoes
535720|NCT00105352|Procedure|Mixed Meal Tolerance Test|
535721|NCT00105352|Procedure|Glucagon Stimulation Test|
535722|NCT00105326|Drug|paliperidone ER|
535723|NCT00105313|Drug|MEDI-507|
535725|NCT00105287|Drug|OraVescent fentanyl (OVF)|
535726|NCT00105248|Behavioral|patient-centered communication training|
535727|NCT00105235|Drug|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
535728|NCT00105235|Drug|Cyclosporine|Oral immunosuppressant
535729|NCT00105235|Drug|Mycophenolate mofetil|Oral immunosuppressant
535730|NCT00105235|Drug|Tacrolimus|Oral immunosuppressant
535731|NCT00105235|Procedure|Liver transplant|Occurs at study entry
535732|NCT00105235|Procedure|Immunosuppression withdrawal|Beginning no earlier than Year 1
535733|NCT00105222|Drug|Sodium Nitrite|
535734|NCT00105209|Drug|Aspirin|
535735|NCT00105209|Drug|clopidogrel|
535736|NCT00105196|Drug|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
535737|NCT00105196|Drug|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
535738|NCT00105183|Biological|Placebo|placebo infusion, single
535739|NCT00105183|Biological|EZ-2053|single IV infusion, 9 mg/kg
535740|NCT00105183|Biological|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
535741|NCT00105170|Drug|hCBE-11|
535742|NCT00105157|Drug|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
535743|NCT00105157|Drug|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
535744|NCT00105157|Drug|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
535745|NCT00105157|Drug|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
535746|NCT00105144|Drug|Micafungin|IV
535747|NCT00105144|Drug|Caspofungin|IV
535748|NCT00105118|Device|Magstim Super Rapid Magnetic Stimulator|
535749|NCT00105105|Drug|Mifepristone|
535750|NCT00105092|Drug|Enzastaurin HCL|
535751|NCT00105079|Drug|saquinavir [Invirase]|1000 milligram (mg) Oral (po) twice daily (bid)
535752|NCT00105079|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg po bid
535753|NCT00105079|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
535754|NCT00105079|Drug|Ritonavir|100 mg po bid
535755|NCT00105066|Drug|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
535756|NCT00105066|Drug|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
535757|NCT00105053|Biological|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
535758|NCT00105040|Drug|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
535759|NCT00105040|Other|Placebo (PB)|Oral tablets and oral solution
535760|NCT00105027|Other|Standard Care|CRVO: observation; BRVO: standard care
535761|NCT00105027|Drug|intravitreal triamcinolone injection|1 mg dose
535762|NCT00105027|Drug|intravitreal triamcinolone injection|4 mg
535763|NCT00105001|Drug|Fludarabine Phosphate|Given IV
535764|NCT00105001|Radiation|Total-Body Irradiation|Undergo total-body irradiation
535765|NCT00105001|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
535766|NCT00105001|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
535767|NCT00105001|Drug|Tacrolimus|Given IV or PO
535768|NCT00105001|Drug|Mycophenolate Mofetil|Given PO
535769|NCT00105001|Drug|Sirolimus|Given PO
535770|NCT00104988|Drug|temozolomide|75 mg/m^2/day PO daily for 6 weeks followed by a 2-week break
535771|NCT00104988|Drug|thalidomide|200 mg/day PO daily
535772|NCT00104975|Biological|alemtuzumab|
535773|NCT00104975|Biological|therapeutic allogeneic lymphocytes|
535774|NCT00104975|Drug|fludarabine phosphate|
535775|NCT00104975|Drug|melphalan|
535776|NCT00104975|Drug|tacrolimus|
535777|NCT00104975|Drug|thiotepa|
535778|NCT00104975|Procedure|peripheral blood stem cell transplantation|
535779|NCT00104962|Drug|lenalidomide|Given orally
535780|NCT00104949|Biological|trastuzumab|
535781|NCT00104936|Procedure|adjuvant therapy|
535782|NCT00104936|Radiation|radiation therapy|
535783|NCT00104936|Radiation|stereotactic radiosurgery|
535784|NCT00104923|Drug|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
535785|NCT00104910|Radiation|Internal Radiation Therapy|
535786|NCT00104910|Radiation|3-Dimensional Conformal Radiation Therapy|
535787|NCT00104910|Biological|Cetuximab|Given IV
535788|NCT00104910|Drug|Cisplatin|Given IV
535789|NCT00104897|Drug|tanespimycin|
535790|NCT00104884|Drug|Depsipeptide|Given IV
535791|NCT00104871|Drug|Bortezomib|Administered IV at the dose of 1.3 mg/m^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
535792|NCT00104858|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
535793|NCT00104858|Drug|Cyclosporine|Given PO
535794|NCT00104858|Drug|Fludarabine Phosphate|Given IV
535795|NCT00104858|Other|Laboratory Biomarker Analysis|Correlative studies
535796|NCT00104858|Drug|Mycophenolate Mofetil|Given PO
535797|NCT00104858|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
535798|NCT00104858|Other|Pharmacological Study|Correlative studies
535799|NCT00104858|Biological|Rituximab|Given IV
535800|NCT00104858|Radiation|Total-Body Irradiation|Undergo TBI
535801|NCT00104845|Biological|human gp100 plasmid DNA vaccine|
535802|NCT00104845|Biological|mouse gp100 plasmid DNA vaccine|
535803|NCT00104819|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
535804|NCT00104819|Biological|sargramostim|
535805|NCT00104806|Dietary Supplement|cholecalciferol|100 milligrams orally once a day for 28 days
535806|NCT00104806|Drug|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
535807|NCT00104793|Drug|carboplatin|
535808|NCT00104793|Drug|irinotecan hydrochloride|
535809|NCT00104780|Biological|EP-2101|
535810|NCT00104780|Biological|incomplete Freund's adjuvant|
535811|NCT00104767|Drug|celecoxib|
535812|NCT00104754|Drug|liposomal SN-38|
535813|NCT00104741|Drug|flutamide|
535814|NCT00104741|Drug|triptorelin|
535815|NCT00104741|Procedure|neoadjuvant therapy|
535816|NCT00104741|Radiation|radiation therapy|
535817|NCT00104728|Drug|ZD1839|
535818|NCT00104715|Drug|antiandrogen therapy|
535819|NCT00104715|Drug|docetaxel|
535820|NCT00104715|Drug|goserelin acetate|
535821|NCT00104715|Procedure|orchiectomy|
535822|NCT00104702|Procedure|adjuvant therapy|
535823|NCT00104702|Procedure|conventional surgery|
535824|NCT00104702|Radiation|radiation therapy|
535825|NCT00104689|Drug|capecitabine|
535826|NCT00104689|Drug|oxaliplatin|
535827|NCT00104676|Biological|bleomycin sulfate|At least one course administered
535828|NCT00104676|Drug|cisplatin|At least one course administered
535829|NCT00104676|Drug|etoposide|At least one course administered
535830|NCT00104676|Drug|ifosfamide|Given in a dose-dense sequential fashion
535831|NCT00104676|Drug|oxaliplatin|Given in a dose-dense sequential fashion
535832|NCT00104676|Drug|paclitaxel|Given in a dose-dense sequential fashion
535833|NCT00104663|Drug|Quinacrine|
535834|NCT00104650|Genetic|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
535835|NCT00104650|Drug|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
535836|NCT00104650|Genetic|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
535837|NCT00104637|Drug|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
535838|NCT00104637|Drug|Placebo|25 mg po tid
535839|NCT00104624|Drug|docetaxel|
535840|NCT00104624|Procedure|quality-of-life assessment|
535841|NCT00104611|Device|Repetitive Transcranial Magnetic Stimulation|
535842|NCT00104598|Drug|Bupropion|
535843|NCT00104598|Behavioral|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
535844|NCT00104572|Drug|Androgel (Testosterone Gel)|1 mg tablet for 12 months
535845|NCT00104572|Drug|Anastrozole (Aromatase Inhibitor)|
535846|NCT00104572|Drug|Placebo tablet|Daily for 12 months
535847|NCT00104572|Drug|Placebo gel|Daily for 12 months
535848|NCT00104572|Dietary Supplement|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
535849|NCT00104559|Behavioral|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
535850|NCT00104559|Behavioral|Standard paper consent form|Standard paper consent form
535851|NCT00104546|Procedure|Acupuncture point injection of vitamin K|
535852|NCT00104533|Device|Magnets|
535853|NCT00104520|Drug|AZLI 75 mg two times a day (BID)/three times a day (TID)|
535854|NCT00104520|Drug|Placebo two times a day (BID)/three times a day (TID)|
535855|NCT00104507|Drug|APD356|
535856|NCT00104494|Drug|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
535857|NCT00104481|Behavioral|cognitive behavior therapy|
535858|NCT00104468|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
535859|NCT00104455|Drug|activated recombinant human factor VII|
535860|NCT00104442|Drug|Rivastigmine|
535861|NCT00104429|Drug|GW873140|
535862|NCT00104429|Drug|Combivir|
535863|NCT00104416|Drug|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
535864|NCT00104416|Drug|Placebo|Placebo control
535865|NCT00104403|Drug|GW679769|
535866|NCT00104403|Drug|Dexamethasone|
535867|NCT00104403|Drug|Ondansetron Hydrochloride|
535868|NCT00104390|Biological|Grass MATA MPL|
535869|NCT00104377|Biological|Grass MATA MPL|
535870|NCT00104364|Drug|MK0731|
535871|NCT00104338|Drug|FK778|
535872|NCT00104299|Drug|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m^2 infusions once weekly for 4 week
535873|NCT00104299|Drug|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
535874|NCT00104299|Drug|Azathioprine|2 mg/kg/day orally for months 4-6
535875|NCT00104299|Drug|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
535876|NCT00104299|Drug|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
535877|NCT00104286|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
535879|NCT00104260|Drug|sapropterin dihydrochloride|
535880|NCT00104247|Drug|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
535881|NCT00104234|Drug|N-acetylgalactosamine 4-sulfatase|
535882|NCT00104234|Drug|Placebo/rhASB|
535883|NCT00104182|Drug|insulin detemir|
535884|NCT00104182|Drug|insulin NPH|
535885|NCT00104169|Drug|Epoetin Alfa|
535886|NCT00104156|Procedure|External Qigong therapy|
535887|NCT00104143|Drug|A4I Antagonist|
535888|NCT00104130|Drug|KOS-862|
535889|NCT00104117|Drug|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
535890|NCT00104104|Drug|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
535891|NCT00104091|Drug|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
535892|NCT00104078|Drug|MYO-029|
535893|NCT00104065|Drug|CG53135-05, velafermin|
535894|NCT00104052|Biological|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
535895|NCT00104052|Drug|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
535896|NCT00104013|Drug|xaliproden (SR57746A)|
535897|NCT00103974|Biological|BHT-3009-01|
535898|NCT00103961|Behavioral|Questionnaire|A behavioral questionnaire will occur at Week 8
535899|NCT00103948|Drug|Aricept|
535900|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
535901|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
535902|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
535903|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
535904|NCT00103922|Drug|cilomilast|
535905|NCT00103870|Procedure|Electrodermal stimulation|
535906|NCT00103870|Procedure|Music listening task|
535907|NCT00103857|Drug|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
535908|NCT00103857|Drug|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
535909|NCT00103857|Drug|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
535910|NCT00103857|Drug|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
535911|NCT00103857|Drug|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
535912|NCT00103857|Drug|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
535913|NCT00103844|Drug|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
535914|NCT00103844|Drug|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
535915|NCT00103831|Drug|Oral Taxane|
535916|NCT00103818|Drug|gaboxadol|Duration of Treatment: 3 months
535917|NCT00103818|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
535918|NCT00103805|Drug|levodopa|
535919|NCT00103792|Drug|mycophenolate mofetil|2000 mg mycophenolate per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
535920|NCT00103792|Drug|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
535921|NCT00103779|Drug|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
535922|NCT00103766|Drug|Alteplase|
535923|NCT00103753|Drug|deferiprone|
535924|NCT00103740|Drug|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
535925|NCT00103740|Drug|placebo to zoledronic acid|5 mL of sterile water for infusion
535926|NCT00103740|Drug|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
535927|NCT00103740|Drug|Placebo to risedronate|oral capsules
535928|NCT00103740|Drug|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
535929|NCT00103727|Drug|Talnetant|talnetant
535930|NCT00103727|Other|placebo|Placebo Comparator
535931|NCT00103727|Other|risperidone|Active Comparator
535932|NCT00103714|Drug|denufosol tetrasodium (INS37217)|
535933|NCT00103701|Drug|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
535934|NCT00103675|Procedure|Acupuncture|
535935|NCT00103662|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
535936|NCT00103662|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
535937|NCT00103649|Drug|xaliproden (SR57746A)|
535938|NCT00103636|Procedure|Extending peripheral intravenous (IV) cannula dwell times|
535939|NCT00103623|Drug|Plenaxis|
535940|NCT00103610|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
535941|NCT00103610|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
535942|NCT00103597|Drug|Fludrocortisone|
535943|NCT00103597|Drug|Domperidone|
535944|NCT00103597|Behavioral|Conservative Measures for Orthostatic Hypotension|
535945|NCT00103584|Biological|LC16m8 Smallpox Vaccine|
535946|NCT00103571|Drug|Olanzapine|
535947|NCT00103571|Drug|Aripiprazole|
535948|NCT00103558|Drug|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
535949|NCT00103545|Biological|ACA 125|
535950|NCT00103532|Behavioral|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
535951|NCT00103532|Behavioral|Standard care|Participants will receive standard care plus referrals at three months post-baseline
535952|NCT00103519|Drug|DITPA (3,5-diiodothyropropionic acid)|
535953|NCT00103519|Drug|Placebo|Placebo
535954|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
535955|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
535956|NCT00103506|Drug|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
535957|NCT00103493|Behavioral|Motivational interviewing|
535958|NCT00103493|Behavioral|Targeted DVD-based educational program|
535959|NCT00103467|Biological|rPA102 Vaccine|
535960|NCT00103454|Drug|GW685698X|
535961|NCT00103428|Biological|CG7870|
535962|NCT00103415|Behavioral|Endurance training|
535963|NCT00103415|Behavioral|Weight-lifting training|
535964|NCT00103402|Drug|Alfuzosin|
535965|NCT00103389|Drug|PI-88|PI-88+docetaxel
535966|NCT00103389|Drug|docetaxel|docetaxel only
536357|NCT00100633|Drug|CpG7909 oligodeoxynucleotides (ODN)|
535967|NCT00103376|Drug|Velcade|"Part A: 1.3 mg/m2 administered on days 1, 4, 8 and 11 followed by 10 days rest. A second cycle will be given at the same schedule. Cycle 3 will include 3 weekly injections.~Part B: 1.3mg/m2 administered weekly for 3 weeks followed by 1 week break"
535968|NCT00103376|Drug|LH-RH Agonist|given as a 3 month depo-injection
535969|NCT00103376|Drug|Androgen Receptor Antagonists|given orally daily for 3 months
535970|NCT00103363|Other|cytology specimen collection procedure|
535971|NCT00103363|Other|physiologic testing|
535972|NCT00103363|Procedure|annual screening|
535973|NCT00103363|Procedure|study of high risk factors|
535974|NCT00103350|Drug|TG100-115|
535975|NCT00103337|Drug|cilengitide|Given IV
535976|NCT00103337|Other|laboratory biomarker analysis|Correlative studies
535977|NCT00103324|Drug|lapatinib ditosylate|Given orally
535978|NCT00103324|Other|laboratory biomarker analysis|Correlative studies
535979|NCT00103311|Drug|ispinesib|Given IV
535980|NCT00103311|Other|laboratory biomarker analysis|Correlative studies
535981|NCT00103298|Drug|FOLFOX regimen|
535982|NCT00103298|Drug|fluorouracil|
535983|NCT00103298|Drug|isolated perfusion|
535984|NCT00103298|Drug|leucovorin calcium|
535985|NCT00103298|Drug|melphalan|
535986|NCT00103298|Drug|oxaliplatin|
535987|NCT00103285|Drug|doxorubicin hydrochloride|Given IV or IT
535988|NCT00103285|Radiation|3-dimensional conformal radiation therapy|Some patients undergo cranial radiotherapy
535989|NCT00103285|Drug|cytarabine|Given IV or SC
535990|NCT00103285|Drug|dexamethasone|Given IV or PO
535991|NCT00103285|Drug|pegaspargase|Given IM
535992|NCT00103285|Drug|methotrexate|Given IM or IT
535993|NCT00103285|Drug|leucovorin calcium|Given PO
535994|NCT00103285|Drug|mercaptopurine|Given PO
535995|NCT00103285|Drug|cyclophosphamide|Given IV
535996|NCT00103285|Drug|thioguanine|Given PO
535997|NCT00103285|Drug|vincristine sulfate|Given IV
535998|NCT00103272|Drug|tanespimycin|Given IV
535999|NCT00103272|Drug|bortezomib|Given IV
536000|NCT00103259|Drug|bortezomib|Given IV
536001|NCT00103259|Drug|irinotecan hydrochloride|Given IV
536002|NCT00103259|Other|laboratory biomarker analysis|Optional correlative studies
536003|NCT00103246|Drug|silicon phthalocyanine 4|Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
536004|NCT00103233|Biological|trastuzumab|
536005|NCT00103233|Drug|vinorelbine tartrate|
536006|NCT00103220|Drug|SJG-136|Given IV
536007|NCT00103207|Biological|cetuximab|
536008|NCT00103194|Drug|lapatinib ditosylate|Given PO
536009|NCT00103194|Other|laboratory biomarker analysis|Correlative studies
536010|NCT00103181|Radiation|3-dimensional conformal accelerated partial breast irradiation|
536011|NCT00103181|Radiation|brachytherapy|
536012|NCT00103181|Radiation|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
536013|NCT00103181|Radiation|MammoSite or other single-entry intracavitary device|
536014|NCT00103168|Drug|imatinib mesylate|400 mg/day for 2 years
536015|NCT00103155|Procedure|conventional surgery|
536016|NCT00103155|Procedure|radiofrequency ablation|
536017|NCT00103142|Biological|falimarev|Given subcutaneously and intradermally
536018|NCT00103142|Biological|inalimarev|Given subcutaneously and intradermally
536019|NCT00103142|Biological|sargramostim|Given subcutaneously
536020|NCT00103142|Biological|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
536021|NCT00103116|Biological|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.~Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
536022|NCT00103103|Drug|bortezomib|
536023|NCT00103103|Drug|fluorouracil|
536024|NCT00103103|Drug|leucovorin calcium|
536025|NCT00103051|Drug|cisplatin|
536026|NCT00103051|Drug|gefitinib|
536027|NCT00103051|Drug|gemcitabine hydrochloride|
536028|NCT00103051|Procedure|conventional surgery|
536029|NCT00103051|Procedure|neoadjuvant therapy|
536030|NCT00103038|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
536031|NCT00103038|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
536032|NCT00103038|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
536033|NCT00103038|Drug|Ferumoxytol|Given IV
536034|NCT00103038|Drug|Gadolinium|Given IV
536035|NCT00103038|Procedure|MRI-Based Angiogram|Undergo MRA
536036|NCT00103025|Drug|Sodium Nitrite|
536037|NCT00103025|Drug|Sodium Nitrite Injection|
536038|NCT00103012|Drug|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
536039|NCT00103012|Drug|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
536040|NCT00103012|Drug|Panax ginseng|Panax ginseng 500 mg twice daily
536041|NCT00102986|Drug|Lopinavir/ritonavir|
536042|NCT00102973|Drug|TLK286 in Combination with Carboplatin|Experimental Arm
536043|NCT00102973|Drug|Doxorubicin HCl Liposome Injection|Active Comparator
536044|NCT00102960|Drug|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
536045|NCT00102960|Drug|Didanosine|Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
543470|NCT00006122|Drug|etoposide|
536046|NCT00102960|Drug|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
536047|NCT00102960|Drug|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
536048|NCT00102960|Drug|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
536049|NCT00102960|Drug|Nevirapine|Second Line Regimen: 150 - 200 mg/m^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
536050|NCT00102960|Drug|Zidovudine|First Line Regimen: 240 mg/m^2 taken orally twice daily
536051|NCT00102947|Drug|daptomycin (up to 14 days)|
536052|NCT00102934|Drug|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
536053|NCT00102921|Drug|CCX282-B|
536054|NCT00102908|Drug|Zoledronate|Zoledronate infusion
536055|NCT00102908|Drug|Zoledronate placebo|Zoledronate placebo infusion
536056|NCT00102895|Drug|CP-724,714|
536057|NCT00102882|Drug|fluticasone propionate/salmeterol|
536058|NCT00102882|Drug|salmeterol xinafoate|
536059|NCT00102869|Drug|levodopa|100mg levodopa per day over 10 days/ treatment phase
536060|NCT00102856|Drug|Pramipexole|
536061|NCT00102856|Drug|Rivastigmine|
536062|NCT00102843|Procedure|supplementation with folic acid and betaine|
536063|NCT00102830|Drug|AMG 386|
536064|NCT00102817|Drug|somatropin|
536065|NCT00102804|Drug|Pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV) administration, every (q) 21 days, until disease progression
536066|NCT00102804|Drug|Placebo|IV administration, q 21 days
536067|NCT00102804|Other|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
536068|NCT00102791|Drug|ICA-17043|
536069|NCT00102778|Drug|GW873140|
536070|NCT00102778|Drug|Kaletra (lopinavir/ritonavir)|
536071|NCT00102765|Drug|fluticasone propionate/salmeterol powder|
536072|NCT00102765|Drug|fluticasone propionate powder|
536073|NCT00102752|Drug|Glufosfamide|
536074|NCT00102752|Drug|Gemcitabine|
536075|NCT00102739|Drug|SB497115|
536076|NCT00102726|Drug|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
536077|NCT00102726|Other|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
536078|NCT00102713|Drug|Divalproex Sodium (Depakote Sprinkle Capsules)|
536079|NCT00102700|Drug|ARQ 501 in combination with gemcitabine|
536080|NCT00102687|Drug|azacitidine|"Azacitidine is administered subcutaneously~Total of 18 cycles on treatment or early discontinuation."
536081|NCT00102674|Drug|cangrelor|
536082|NCT00102661|Drug|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
536083|NCT00102648|Drug|Lonafarnib|Given PO
536084|NCT00102648|Drug|Temozolomide|Given PO
536085|NCT00102635|Drug|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
536086|NCT00102635|Drug|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
536087|NCT00102622|Biological|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
536088|NCT00102622|Drug|Paclitaxel|80 mg/m^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
536089|NCT00102609|Drug|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
536090|NCT00102609|Drug|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
536091|NCT00102609|Drug|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
536092|NCT00102596|Drug|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
536093|NCT00102583|Drug|Subconjunctival Cyclosporine Implant|
536094|NCT00102557|Drug|Hydroxychloroquine|
536095|NCT00102544|Device|EM Tracking|Utilizing electromagnetic tracking technology as a fusion and navigation tool for minimally invasive interventional procedures.
536096|NCT00102531|Drug|Cisplatin liposomal|
536097|NCT00102518|Drug|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
536098|NCT00102505|Drug|Motexafin Gadolinium Injection|
536099|NCT00102492|Drug|GW679769|
536100|NCT00102479|Drug|Aripiprazole|
536101|NCT00102466|Drug|vildagliptin|
536102|NCT00102466|Drug|Gliclazide|
536103|NCT00102466|Drug|Metformin|
536104|NCT00102453|Drug|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
536105|NCT00102440|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
536106|NCT00102440|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
536107|NCT00102440|Drug|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
536108|NCT00102427|Behavioral|Telephone-based collaborative care management|
536109|NCT00102414|Drug|Gemcitabine|
544794|NCT00072709|Drug|TCH346|
536110|NCT00102401|Behavioral|Internet-based Dyspnea Self-Management Program|
536111|NCT00102401|Behavioral|Face-to-face Dyspnea Self-Management Program|
536112|NCT00102388|Drug|vildagliptin|
536113|NCT00102388|Drug|Gliclazide|
536114|NCT00102375|Drug|Topotecan|
536115|NCT00102362|Behavioral|Behavior Therapy|
536116|NCT00102349|Behavioral|Behavior Therapy|
536117|NCT00102336|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
536118|NCT00102336|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
536119|NCT00102323|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
536120|NCT00102323|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
536121|NCT00102310|Drug|YM443|
536122|NCT00102297|Drug|FG-3019|
536123|NCT00102284|Drug|levodopa|
536124|NCT00102284|Drug|rivastigmine|
536125|NCT00102284|Drug|pergolid|
536126|NCT00102284|Drug|modafinil|
536127|NCT00102271|Drug|Oxypurinol|
536128|NCT00102271|Drug|Sodium Nitrite|
536129|NCT00102258|Drug|Growth Hormone Therapy|
536130|NCT00102232|Procedure|supplementation with phosphatidylcholine|
536131|NCT00102219|Drug|Pemetrexed|
536132|NCT00102219|Drug|Doxorubicin|
536133|NCT00102206|Drug|Abacavir sulfate|
536134|NCT00102206|Drug|Emtricitabine|
536135|NCT00102206|Drug|Lamivudine|
536136|NCT00102206|Drug|Lopinavir/ritonavir|
536137|NCT00102206|Drug|Saquinavir|
536138|NCT00102206|Drug|Tenofovir disoproxil fumarate|
536139|NCT00102206|Drug|Zidovudine|
536140|NCT00102193|Device|Adacolumn Apheresis System|
536141|NCT00102167|Drug|gaboxadol|Duration of Treatment -1 day
536142|NCT00102154|Drug|MK0928, gaboxadol / Duration of Treatment: 10 months|
536143|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
536144|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
536145|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
536146|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
536147|NCT00102141|Drug|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
536148|NCT00102128|Drug|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
536149|NCT00102115|Drug|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
536150|NCT00102102|Drug|[18F]SPA-RQ|
536151|NCT00102089|Biological|VRC-HIVADV014-00-VP booster|
536152|NCT00102089|Drug|VRC-HIVADV014-00-VP|
536153|NCT00102063|Drug|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
536154|NCT00102063|Drug|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
536155|NCT00102063|Drug|Placebo tablet|Placebo tablet po qd x 42 days
536156|NCT00102050|Drug|NM-702 (phosphodiesterase inhibitor)|
536157|NCT00102037|Drug|eptacog alfa (activated)|
536158|NCT00102024|Drug|Unconjugated IDEC-159|
536159|NCT00102024|Drug|111In-IDEC-159|
536160|NCT00102024|Drug|90Y-IDEC-159|
536161|NCT00102011|Procedure|annual screening|Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
536162|NCT00102011|Procedure|fecal occult blood test|Participants undergo a baseline fecal occult blood test (FOBT)
536163|NCT00102011|Procedure|screening colonoscopy|Patients undergo baseline screening colonoscopy
536164|NCT00102011|Procedure|standard follow-up care|Standard care
536165|NCT00101998|Drug|alvimopan|
536166|NCT00101998|Drug|placebo|
536167|NCT00101985|Drug|talnetant|
536168|NCT00101972|Biological|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
536169|NCT00101959|Drug|Rebif|
536170|NCT00101946|Drug|683699|
536171|NCT00101933|Device|Medtronic DBS Therapy for epilepsy|Stimulation On
536172|NCT00101933|Device|Medtronic DBS Therapy for epilepsy|Stimulation Off
536173|NCT00101920|Drug|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
536174|NCT00101907|Drug|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
536175|NCT00101907|Biological|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
536176|NCT00101907|Drug|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m^2.
536177|NCT00101907|Drug|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m^2.
536216|NCT00101569|Drug|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
536217|NCT00101569|Drug|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
536218|NCT00101543|Device|Electrical Stimulation with Intramuscular Electrodes|
536219|NCT00101543|Procedure|Body Weight Supported Treadmill Training|
536358|NCT00100633|Biological|Hepatitis B virus vaccine|
536178|NCT00101894|Drug|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:~Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
536179|NCT00101894|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
536180|NCT00101894|Biological|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
536181|NCT00101894|Drug|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
536182|NCT00101881|Device|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
536183|NCT00101868|Device|Discharge communication software|Computerized physician order entry software used by discharging physician
536184|NCT00101868|Other|Usual care discharge process|Handwritten
536185|NCT00101855|Procedure|An evidence based tailored web site|
536186|NCT00101842|Drug|Pemetrexed|
536187|NCT00101842|Drug|Gemcitabine|
536188|NCT00101842|Drug|Platinol|
536189|NCT00101829|Drug|Rituximab|1000 mg intravenous infusion
536190|NCT00101816|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
536191|NCT00101803|Drug|vildagliptin|
536192|NCT00101790|Drug|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
536193|NCT00101764|Drug|Triamcinolone Acetonide|
536194|NCT00101751|Drug|biphasic insulin aspart|
536195|NCT00101751|Behavioral|dietary regimen|
536196|NCT00101738|Drug|Myfortic|
536197|NCT00101725|Drug|crofelemer|
536198|NCT00101712|Drug|vildagliptin|
536199|NCT00101712|Drug|Vildagliptin Placebo|
536200|NCT00101686|Drug|Modified Bolus 5-FU/LV with Irinotecan|Day 1 & 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID [two times a day] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
536201|NCT00101686|Drug|FOLFIRI + bevacizumab|"Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks~Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.~I m m e d i a t e l y f o l l o w e d b y :~5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID [two times a day] oral Every 2 weeks"
536202|NCT00101686|Drug|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV *over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID [two times a day] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID [two times a day] continues daily without interruption Every 3 weeks
536203|NCT00101686|Drug|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID [two times a day](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
536204|NCT00101686|Drug|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID [two times a day] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
536205|NCT00101673|Drug|vildagliptin|
536206|NCT00101660|Drug|Dasatinib|Tablets; oral; 70 mg BID, depending on response
536207|NCT00101647|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
536208|NCT00101634|Drug|Paliperidone palmitate|
536209|NCT00101621|Drug|M40403|
536210|NCT00101608|Drug|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
536211|NCT00101595|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
536212|NCT00101582|Drug|Placebo|
536213|NCT00101582|Drug|palifermin|
536214|NCT00101582|Drug|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m^2 on Days 1, 22, and 43.
536215|NCT00101582|Radiation|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
536359|NCT00100620|Drug|Zoledronic Acid|
536220|NCT00101491|Behavioral|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
536221|NCT00101452|Drug|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
536222|NCT00101452|Drug|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
536223|NCT00101452|Drug|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
536224|NCT00101439|Drug|ezetimibe|
536225|NCT00101439|Drug|Comparator: placebo|
536226|NCT00101426|Drug|ranirestat, (AS-3201)|
536227|NCT00101413|Drug|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles [Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
536228|NCT00101400|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
536229|NCT00101387|Other|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
536230|NCT00101387|Other|Lumbar PENS|As above
536231|NCT00101387|Other|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
536232|NCT00101387|Other|Control PENS + exercise|as above
536233|NCT00101374|Drug|Leflunomide|
536234|NCT00101361|Drug|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
536235|NCT00101361|Drug|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
536236|NCT00101348|Drug|erlotinib hydrochloride|Given orally
536237|NCT00101348|Biological|cetuximab|Given IV
536238|NCT00101348|Biological|bevacizumab|Given IV
536239|NCT00101348|Other|laboratory biomarker analysis|Correlative studies
536240|NCT00101335|Drug|celecoxib|
536241|NCT00101309|Biological|aldesleukin|
536242|NCT00101309|Biological|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
536243|NCT00101309|Biological|therapeutic autologous lymphocytes|
536244|NCT00101296|Drug|tipifarnib|Given orally
536245|NCT00101296|Other|pharmacological study|Correlative studies
536246|NCT00101296|Other|laboratory biomarker analysis|Correlative studies
536247|NCT00101283|Drug|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
536248|NCT00101283|Drug|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
536249|NCT00101283|Drug|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
536250|NCT00101270|Drug|irinotecan hydrochloride|Given IV
536251|NCT00101270|Drug|oxaliplatin|Given IV
536252|NCT00101257|Biological|therapeutic autologous lymphocytes|
536253|NCT00101244|Drug|ispinesib|Given IV
536254|NCT00101244|Other|laboratory biomarker analysis|Correlative studies
536255|NCT00101244|Other|pharmacological study|Correlative studies
536256|NCT00101231|Drug|alvocidib|Given IV
536257|NCT00101205|Drug|oxaliplatin|Given IV
536258|NCT00101205|Drug|etoposide|Given IV
536259|NCT00101192|Biological|cetuximab|
536260|NCT00101192|Drug|cisplatin|
536261|NCT00101179|Drug|Azacitidine|Given SC
536262|NCT00101179|Drug|Entinostat|Given orally
536263|NCT00101166|Biological|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
536264|NCT00101153|Drug|cytarabine|
536265|NCT00101153|Drug|daunorubicin hydrochloride|
536266|NCT00101153|Drug|tipifarnib|
536267|NCT00101140|Drug|anti-thymocyte globulin|
536268|NCT00101140|Drug|fludarabine phosphate|
536269|NCT00101140|Drug|thiotepa|
536270|NCT00101140|Procedure|biological therapy|
536271|NCT00101140|Procedure|bone marrow ablation with stem cell support|
536272|NCT00101140|Procedure|chemotherapy|
536273|NCT00101140|Procedure|non-specific immune-modulator therapy|
536274|NCT00101140|Procedure|peripheral blood stem cell transplantation|
536275|NCT00101140|Procedure|radiation therapy|
536276|NCT00101127|Biological|filgrastim|
536277|NCT00101127|Biological|pegfilgrastim|
536278|NCT00101127|Drug|docetaxel|
536279|NCT00101127|Drug|gemcitabine hydrochloride|
536280|NCT00101114|Drug|sorafenib tosylate|Given PO
536281|NCT00101114|Biological|recombinant interferon alfa-2b|Given SC
536282|NCT00101114|Other|laboratory biomarker analysis|Optional correlative studies
536283|NCT00101101|Drug|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
536284|NCT00101101|Drug|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
536285|NCT00101101|Drug|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
536286|NCT00101101|Drug|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
536356|NCT00100646|Biological|Rabies de novo antigen|Vaccine injected intramuscularly
536287|NCT00101101|Drug|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
536288|NCT00101101|Biological|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
536289|NCT00101101|Drug|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
536290|NCT00101088|Drug|imatinib mesylate|Given orally
536291|NCT00101088|Drug|temsirolimus|Given IV
536292|NCT00101088|Other|laboratory biomarker analysis|Correlative studies
536293|NCT00101075|Drug|Capecitabine|
536294|NCT00101075|Drug|Oxaliplatin|
536295|NCT00101062|Drug|celecoxib|
536296|NCT00101062|Drug|letrozole|
536297|NCT00101036|Drug|lapatinib ditosylate|Given PO
536298|NCT00101036|Other|laboratory biomarker analysis|Correlative studies
536299|NCT00101010|Biological|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
536300|NCT00101010|Biological|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
536301|NCT00101010|Biological|Rituximab|375 mg/m^2 intravenous piggy back (IVPB) on day 1, administered 1st
536302|NCT00101010|Drug|Cyclophosphamide|750 mg/m^2 IVPB on day 1
536303|NCT00101010|Drug|Pegylated liposomal doxorubicin hydrochloride|40 mg/m^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
536304|NCT00101010|Drug|Prednisone|40 mg/m^2 oral days 1 - 5.
536305|NCT00101010|Drug|Vincristine Sulfate|2 mg IV, day 1
536306|NCT00100997|Drug|tanespimycin|
536307|NCT00100984|Drug|FUZEON [enfuvirtide]|
536308|NCT00100971|Drug|autologous tumor cell vaccine|
536309|NCT00100971|Drug|therapeutic autologous dendritic cells|
536310|NCT00100971|Procedure|tumor cell-derivative vaccine therapy|
536311|NCT00100958|Drug|indole-3-carbinol|
536312|NCT00100945|Drug|gefitinib|
536313|NCT00100932|Drug|E7389 28 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
536314|NCT00100932|Drug|E7389 21 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1 and 8 of a 21 day cycle.
536315|NCT00100906|Drug|IL-2|Immunotherapy with interleukin-2
536316|NCT00100906|Drug|ATRA|
536317|NCT00100893|Dietary Supplement|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
536318|NCT00100880|Drug|lenalidomide|Given PO
536319|NCT00100880|Procedure|perfusion-weighted magnetic resonance imaging|Correlative studies
536320|NCT00100880|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
536321|NCT00100880|Other|laboratory biomarker analysis|Correlative studies
536322|NCT00100854|Drug|erlotinib hydrochloride|Given orally
536323|NCT00100854|Drug|fulvestrant|Given intramuscularly
536324|NCT00100841|Biological|cetuximab|Given IV
536325|NCT00100841|Biological|bevacizumab|Given IV
536326|NCT00100841|Drug|oxaliplatin|Given IV
536327|NCT00100841|Drug|leucovorin calcium|Given IV
536328|NCT00100841|Drug|fluorouracil|Given IV
536329|NCT00100828|Drug|irinotecan hydrochloride|
536330|NCT00100815|Biological|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
536331|NCT00100815|Drug|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
536332|NCT00100815|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
536333|NCT00100802|Drug|lomustine|Capsule
536334|NCT00100802|Drug|temozolomide|Capsule
536335|NCT00100802|Procedure|adjuvant therapy|
536336|NCT00100802|Radiation|radiation therapy|
536337|NCT00100789|Drug|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
536338|NCT00100789|Drug|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
536339|NCT00100776|Drug|Olanzapine|
536340|NCT00100750|Drug|Gemcitabine Hydrochloride|Given IV
536341|NCT00100750|Drug|Tipifarnib|Given PO
536342|NCT00100750|Other|Laboratory Biomarker Analysis|Correlative studies
536343|NCT00100737|Drug|interleukin-2|
536344|NCT00100737|Drug|rituximab|
536345|NCT00100724|Biological|rPA102|
536346|NCT00100711|Drug|Motexafin Gadolinium|
536347|NCT00100698|Drug|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
536348|NCT00100698|Drug|placebo|placebo subcutaneously once a day, 18 months
536349|NCT00100685|Drug|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
536350|NCT00100672|Drug|LErafAON-ETU|
536351|NCT00100659|Drug|Pegylated Interferon/ribavirin|
536352|NCT00100646|Behavioral|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
536353|NCT00100646|Drug|Lamivudine|300 mg tablet taken orally daily
536354|NCT00100646|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
536355|NCT00100646|Drug|Stavudine|Dosage dependent on weight
536360|NCT00100607|Drug|AAE581|
536362|NCT00100594|Drug|Lamivudine/zidovudine|
536363|NCT00100581|Drug|Efavirenz|
536364|NCT00100581|Drug|Lamivudine|
536365|NCT00100581|Drug|Lopinavir/ritonavir|
536366|NCT00100581|Drug|Pegylated interferon alfa-2a|
536367|NCT00100581|Drug|Ribavirin|
536368|NCT00100581|Drug|Tenofovir disoproxil fumarate|
536369|NCT00100568|Drug|Efavirenz|600 mg tablet taken orally daily
536370|NCT00100568|Drug|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
536371|NCT00100555|Drug|zoledronic acid|
536372|NCT00100542|Behavioral|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
536373|NCT00100477|Drug|Topotecan|
536374|NCT00100477|Drug|Mitozantrone|
536375|NCT00100477|Drug|Etoposide|
536376|NCT00100464|Drug|Paroxetine|
536377|NCT00100464|Drug|5HTP|
536378|NCT00100451|Procedure|exercise|
536379|NCT00100425|Procedure|Viceral Perception Testing|
536380|NCT00100412|Drug|Graded dobutamine infusions|
536381|NCT00100412|Drug|Graded phenylephrine injections|
536382|NCT00100412|Behavioral|Psychosocial challenge involving socioevaluative public speaking|
536383|NCT00100399|Biological|Fluarix|
536384|NCT00100386|Procedure|Intensive Control Strategy|
536385|NCT00100386|Behavioral|Standard Control Strategy|
536386|NCT00100373|Drug|RSV challenge material|
536387|NCT00100347|Drug|PPI-2458|
536388|NCT00100334|Drug|PPI-1019 (APAN)|
536389|NCT00100308|Drug|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
536390|NCT00100308|Drug|saline|Saline placebo
536391|NCT00100295|Drug|Hypericum perforatum|300 mg capsule taken three times a day
536392|NCT00100295|Other|Placebo|300 mg given three times a day, containing rice protein powder
536393|NCT00100282|Drug|PPI-1019 (APAN)|
536394|NCT00100269|Drug|Menevit anti-oxidant|
536395|NCT00100256|Drug|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
536396|NCT00100243|Drug|Plenaxis|
536397|NCT00100230|Drug|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
536398|NCT00100191|Procedure|uterine artery embolization|
536399|NCT00100191|Procedure|hysterectomy|
536400|NCT00100178|Drug|Mycophenolate mofeteil (MMF)|
536401|NCT00100178|Drug|Daclizumab (DZB)|
536402|NCT00100178|Drug|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
536403|NCT00100178|Drug|Placebo control for Daclizumab (DZB)|saline intravenous infusions
536404|NCT00100165|Drug|3-2,4 dimethoxybenzylidene 75 or 150 mg bid|3-2,4 dimethoxybenzylidene 75 or 150 mg bid
536405|NCT00100165|Drug|Placebo|Placebo
536406|NCT00100152|Drug|MK0752, (Notch Inhibitor)|
536407|NCT00100139|Drug|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
536408|NCT00100139|Drug|Paclitaxel for injection (Taxol)|
536409|NCT00100126|Drug|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
536410|NCT00100113|Drug|GBR 12909|
536411|NCT00100100|Drug|Modafinil|
536412|NCT00100087|Device|Ocular Brachytherapy|
536413|NCT00100074|Drug|Lobeline|
536414|NCT00100061|Drug|Cranberry juice|liquid juice taken daily
536415|NCT00100061|Dietary Supplement|Cranberry Juice|Taken orally
536416|NCT00100061|Dietary Supplement|Placebo cranberry juice|Placebo comparitor
536417|NCT00100048|Drug|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
536418|NCT00100048|Drug|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
536419|NCT00100048|Drug|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
536420|NCT00100048|Drug|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
536421|NCT00100048|Drug|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
536422|NCT00100048|Drug|Placebo monotherapy|Placebo to MK0518 twice daily
536423|NCT00100035|Procedure|Polarity therapy|
536424|NCT00100009|Drug|TAC-PF|
536425|NCT00100009|Drug|Triamcinolone Acetonide|
536426|NCT00099996|Drug|SCH-58235|
536427|NCT00099996|Drug|Ezetimibe|
536428|NCT00099983|Drug|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
536429|NCT00099983|Drug|Placebo|Placebo
536430|NCT00099970|Drug|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
536431|NCT00099957|Drug|vildagliptin|
536432|NCT00099944|Drug|vildagliptin|
536433|NCT00099944|Drug|Glimepiride|Glimepiride 4 mg qd
536434|NCT00099944|Drug|LAF237 placebo|
536435|NCT00099931|Drug|vildagliptin|
536436|NCT00099918|Drug|vildagliptin|
536437|NCT00099905|Drug|vildagliptin|
536438|NCT00099892|Drug|vildagliptin|
536439|NCT00099879|Drug|BMS-275183|
536440|NCT00099866|Drug|vildagliptin|
536441|NCT00099866|Drug|Metformin Comparator|
536442|NCT00099853|Drug|Vildagliptin|Vildagliptin 50 mg tablets
536443|NCT00099853|Drug|pioglitazone|pioglitazone 45 mg qd
536444|NCT00099853|Drug|Placebo|Vildagliptin matching placebo
536445|NCT00099840|Procedure|Procalcitonin guided antibiotic therapy|
536446|NCT00099827|Behavioral|Education|Individuals will receive information about depression
536447|NCT00099814|Procedure|Two different loop designs which deliver distinctive forces|
536448|NCT00099801|Drug|FTY720|
536449|NCT00099788|Drug|Ranolazine|IV to oral transition.
544795|NCT00072683|Drug|tolvaptan|
536450|NCT00099788|Drug|Placebo|IV to oral transition.
536451|NCT00099775|Drug|Caspofungin|
536452|NCT00099749|Drug|FTY 720|
536453|NCT00099736|Drug|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
536454|NCT00099736|Drug|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
536455|NCT00099736|Drug|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
536456|NCT00099723|Drug|VSL#3|
536457|NCT00099710|Dietary Supplement|Curcumin C3 Complex|
536458|NCT00099697|Drug|DHEA|
536459|NCT00099684|Drug|Ezetimibe|
536460|NCT00099671|Drug|Recombinant human interleukin-7|
536461|NCT00099658|Biological|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
536462|NCT00099645|Drug|Mifepristone|
536463|NCT00099632|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
536464|NCT00099632|Drug|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
536465|NCT00099632|Drug|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
536466|NCT00099632|Drug|single dose Nevirapine|one 200 mg tablet taken orally
536467|NCT00099619|Drug|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
536468|NCT00099619|Drug|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
536469|NCT00099606|Drug|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
536470|NCT00099593|Biological|Autologous Dendritic Cell Vaccine|
536471|NCT00099580|Drug|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
536472|NCT00099580|Drug|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
536473|NCT00099554|Drug|Etanercept|
536474|NCT00099541|Drug|zoledronic acid|
536475|NCT00099528|Drug|REN-1654|
536476|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
536477|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
536478|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
536479|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
536480|NCT00099502|Drug|Copaxone|20 mg administered s.c. once daily.
536481|NCT00099489|Drug|Interferon Beta-1a|
536482|NCT00099476|Behavioral|Effects of dark chocolate|
536483|NCT00099463|Procedure|Blood Test|
536484|NCT00099463|Procedure|Urine Test|
536485|NCT00099463|Procedure|Physical Exam|
536486|NCT00099463|Drug|Vaccine|
536487|NCT00099463|Drug|VRC-SRSDNA015-00-VP|
536488|NCT00099450|Drug|INS50589 Intravenous Infusion|
536489|NCT00099437|Drug|Fulvestrant|intramuscular injection
536490|NCT00099424|Behavioral|High-intensity exercise training|
536491|NCT00099385|Behavioral|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg & Kusche) curriculum.
536492|NCT00099359|Drug|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) > 2000 grams 8 mg PO BID if BW < 2000 grams
536493|NCT00099359|Drug|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus~NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :~12 mg PO per dose if BW > 2000 grams, 8 mg PO per dose if BW < 2000 grams"
536494|NCT00099359|Drug|Epivir (3TC)|"Stand of care (Zidovudine) plus~3TC, given for 2 weeks: 6 mg po bid if BW > 2000 grams 4 mg po bid if BW < 2000 grams AND~NFV, given for 2 weeks:~200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 - 3000 grams 100 mg PO BID if BW < 2000 grams"
536495|NCT00099359|Drug|Nelfinavir (NFV)|200 mg BID if birth weight (BW) > 3000 grams for 2 weeks;150 mg BID if BW > 2000-3000 grams for 2 weeks; 100 mg BID BW </= 2000 grams for 2 weeks
536496|NCT00099346|Drug|MK0457, VX-680 (Aurora Kinase Inhibitor)|
536497|NCT00099333|Drug|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
536498|NCT00099333|Drug|Insulin|Insulin will be taken according to the subject's current regimen
536499|NCT00099320|Drug|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units [5 μg] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units [10 μg] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
536500|NCT00099320|Drug|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
536501|NCT00099294|Drug|Glufosfamide|
536502|NCT00099281|Drug|YMB 1002|
536503|NCT00099268|Drug|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
536504|NCT00099268|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
536505|NCT00099255|Drug|SGN-30|
536506|NCT00099242|Drug|rivastigmine transdermal patch|
536507|NCT00099229|Drug|Licarbazepine|
536508|NCT00099216|Drug|Rivastigmine|
536509|NCT00099203|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
536510|NCT00099203|Drug|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
536511|NCT00099190|Drug|ARQ 501|
536512|NCT00099177|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
536513|NCT00099177|Drug|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
536514|NCT00099164|Drug|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
536515|NCT00099151|Behavioral|Caloric Restriction (CR)|
536516|NCT00099151|Behavioral|Exercise|
536517|NCT00099138|Behavioral|Caloric Restriction (CR)|
536518|NCT00099138|Behavioral|Exercise|
536519|NCT00099125|Drug|irinotecan hydrochloride|
536520|NCT00099125|Drug|temozolomide|
536521|NCT00099125|Procedure|adjuvant therapy|
536522|NCT00099125|Radiation|radiation therapy|
536523|NCT00099112|Genetic|microarray analysis|
536524|NCT00099112|Procedure|biopsy|
536525|NCT00099112|Procedure|evaluation of cancer risk factors|
536526|NCT00099099|Behavioral|Caloric Restriction (CR)|
536527|NCT00099086|Drug|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
536528|NCT00099086|Drug|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
536529|NCT00099086|Drug|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
536530|NCT00099086|Radiation|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
536531|NCT00099060|Drug|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):~Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).~Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.~For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):~• Phase II: 750 mg GW572016 po b.i.d.~For all patients:~• Dose reductions as required based on adverse events."
536532|NCT00099047|Drug|celecoxib|Given PO
536533|NCT00099047|Drug|placebo|Given PO
536534|NCT00099047|Other|laboratory biomarker analysis|Correlative studies
536535|NCT00099021|Drug|pioglitazone hydrochloride|Given PO
536536|NCT00099008|Dietary Supplement|Genistein|oral Genistein twice daily on days 1-84
536537|NCT00099008|Dietary Supplement|Placebo|oral Placebo twice daily on days 1-84
536538|NCT00098995|Drug|cisplatin|
536539|NCT00098995|Drug|tirapazamine|
536540|NCT00098995|Radiation|brachytherapy|
536541|NCT00098995|Radiation|radiation therapy|
536542|NCT00098982|Drug|bortezomib|
536543|NCT00098982|Drug|fluorouracil|
536544|NCT00098982|Drug|leucovorin calcium|
536545|NCT00098982|Drug|oxaliplatin|
536546|NCT00098969|Drug|resveratrol|
536547|NCT00098956|Drug|topotecan hydrochloride|Given IV
536548|NCT00098956|Drug|7-hydroxystaurosporine|Given IV
536549|NCT00098943|Biological|CNGRC peptide-TNF alpha conjugate|
536550|NCT00098917|Drug|autologous tumor cell vaccine|
536551|NCT00098917|Drug|therapeutic autologous dendritic cells|
536552|NCT00098917|Procedure|adjuvant therapy|
536553|NCT00098917|Procedure|biological therapy|
536554|NCT00098917|Procedure|conventional surgery|
536555|NCT00098917|Procedure|surgery|
536556|NCT00098917|Procedure|tumor cell derivative vaccine|
536557|NCT00098917|Procedure|vaccine therapy|
536558|NCT00098891|Drug|entinostat|Given orally
536559|NCT00098891|Drug|isotretinoin|Given orally
536560|NCT00098878|Drug|carboplatin|
536561|NCT00098865|Drug|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
536562|NCT00098865|Drug|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
536563|NCT00098852|Drug|rosiglitazone maleate|
536564|NCT00098839|Drug|L-asparaginase|Given IM
536565|NCT00098839|Drug|doxorubicin hydrochloride|Given IV
536566|NCT00098839|Drug|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
536567|NCT00098839|Drug|vincristine sulfate|Given IV
536568|NCT00098839|Biological|epratuzumab|Given IV
536569|NCT00098839|Drug|cytarabine|Given IT
536570|NCT00098839|Drug|prednisone|Given orally
536571|NCT00098839|Drug|pegaspargase|Given IM
536572|NCT00098839|Drug|dexrazoxane hydrochloride|Given IV
536573|NCT00098839|Drug|methotrexate|Given IT
536574|NCT00098839|Drug|etoposide|Given IV
536575|NCT00098839|Drug|cyclophosphamide|Given IV
536576|NCT00098839|Drug|leucovorin calcium|Given IV
536577|NCT00098839|Biological|filgrastim|Given SC
536578|NCT00098826|Drug|ispinesib|Given IV
536579|NCT00098826|Other|laboratory biomarker analysis|Correlative studies
536580|NCT00098826|Other|pharmacological study|Correlative studies
536581|NCT00098813|Drug|romidepsin|Given IV
536582|NCT00098813|Other|laboratory biomarker analysis|Correlative studies
536583|NCT00098813|Procedure|positron emission tomography|Correlative studies
536584|NCT00098800|Drug|fenretinide|
536585|NCT00098787|Biological|bevacizumab|Given IV
536586|NCT00098787|Drug|fluorouracil|Given IV
546302|NCT00065104|Drug|DHEA|
536587|NCT00098787|Drug|irinotecan hydrochloride|Given IV
536588|NCT00098787|Drug|leucovorin calcium|Given IV
536589|NCT00098787|Drug|Oxaliplatin|Given IV
536590|NCT00098774|Biological|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC > or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
536591|NCT00098774|Biological|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, & 24 of Cycle 1 nad Days 3 & 10 of Cycle 2
536592|NCT00098774|Drug|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
536593|NCT00098774|Drug|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
536594|NCT00098774|Drug|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX < or = 0.05uM Cycles 1-5.
536595|NCT00098774|Drug|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 & 15 Cycles 1, 2, & 3; Day 15 Cycle 4 and Day 1 Cycle 5.
536596|NCT00098774|Drug|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
536597|NCT00098761|Drug|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
536598|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
536599|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
536600|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
536601|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
536602|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
536603|NCT00098735|Drug|FTY720|
536604|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
536605|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
536606|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
536607|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
536608|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
536609|NCT00098709|Device|Fetal pulse oximeter|
536610|NCT00098683|Drug|amifostine trihydrate|
536611|NCT00098670|Biological|alemtuzumab|Given SC
536612|NCT00098670|Biological|rituximab|Given IV
536613|NCT00098670|Drug|fludarabine phosphate|Given IV
536614|NCT00098631|Drug|lapatinib ditosylate|Given orally
536615|NCT00098631|Other|laboratory biomarker analysis|Correlative studies
536616|NCT00098618|Drug|sorafenib tosylate|Given orally
536617|NCT00098618|Biological|recombinant interferon alfa|Given orally
536618|NCT00098618|Other|laboratory biomarker analysis|Correlative studies
536619|NCT00098605|Drug|lapatinib ditosylate|Given orally
536620|NCT00098605|Other|laboratory biomarker analysis|Correlative studies
536621|NCT00098605|Procedure|quality-of-life assessment|Ancillary studies
536622|NCT00098605|Other|questionnaire administration|Ancillary studies
536623|NCT00098579|Drug|alvocidib|Given IV
536624|NCT00098579|Drug|doxorubicin hydrochloride|Given IV
536625|NCT00098553|Drug|everolimus|
536626|NCT00098540|Drug|sorafenib tosylate|Given orally
536627|NCT00098540|Other|laboratory biomarker analysis|Correlative studies
536628|NCT00098527|Drug|romidepsin|Given IV
536629|NCT00098527|Other|laboratory biomarker analysis|Correlative studies
536630|NCT00098514|Drug|talotrexin ammonium|
536631|NCT00098501|Drug|pelitinib|
536632|NCT00098501|Drug|temsirolimus|Given PO
536633|NCT00098488|Drug|tanespimycin|Given IV
536634|NCT00098488|Biological|rituximab|Given IV
536635|NCT00098475|Drug|Dexamethasone|Given PO
536636|NCT00098475|Other|Laboratory Biomarker Analysis|Optional correlative studies
536637|NCT00098475|Drug|Lenalidomide|Given PO
536638|NCT00098475|Drug|Thalidomide|Given PO
536639|NCT00098462|Drug|gefitinib|
536640|NCT00098462|Drug|sirolimus|
536641|NCT00098436|Drug|laromustine|
536642|NCT00098436|Drug|temozolomide|
536643|NCT00098423|Drug|tanespimycin|Given IV
536644|NCT00098423|Drug|cytarabine|Given IV
536645|NCT00098397|Drug|romidepsin|Given IV
536646|NCT00098397|Other|laboratory biomarker analysis|Optional correlative studies
536647|NCT00098384|Drug|rifaximin|
536648|NCT00098371|Drug|alvocidib|
536649|NCT00098358|Drug|Zileuton|
536650|NCT00098345|Drug|ZD6474 (vandetanib)|oral once daily tablet
536651|NCT00098332|Drug|forodesine hydrochloride|
536652|NCT00098319|Drug|Folic acid (0.4mg vs. 4.0mg)|
536653|NCT00098306|Drug|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
536654|NCT00098306|Drug|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
536655|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
536656|NCT00098306|Drug|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
536771|NCT00097227|Biological|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
536904|NCT00096187|Drug|pemetrexed disodium|
546429|NCT00064259|Drug|cisplatin|Given IV
536657|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
536658|NCT00098293|Drug|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
536659|NCT00098293|Drug|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
536660|NCT00098293|Drug|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
536661|NCT00098280|Drug|Eculizumab|
536662|NCT00098254|Drug|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
536663|NCT00098241|Drug|Certican|
536664|NCT00098228|Drug|QAB149|
536665|NCT00098215|Behavioral|Pediatric residency training on tobacco|
536666|NCT00098202|Drug|Low phytic acid maize|
536667|NCT00098202|Drug|Zinc|
536668|NCT00098163|Biological|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
536669|NCT00098163|Biological|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
536670|NCT00098137|Drug|Olmesartan|
536671|NCT00098124|Drug|milnacipran hydrochloride|
536672|NCT00098111|Drug|azathioprine|
536673|NCT00098098|Biological|rBV A/B|
536674|NCT00098085|Biological|HSPPC-96|
536675|NCT00098072|Procedure|Heart Catheterization|Heart Catheterization and collection of samples
536676|NCT00098059|Drug|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
536677|NCT00098046|Drug|famciclovir|
536678|NCT00098033|Drug|clofarabine|
536679|NCT00098020|Drug|Isotretinoin|
536680|NCT00098007|Drug|Everolimus (Certican)|
536681|NCT00097981|Drug|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
536682|NCT00097981|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
536683|NCT00097981|Drug|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
536684|NCT00097968|Drug|everolimus|
536685|NCT00097955|Drug|aliskiren|
536686|NCT00097942|Drug|memantine HCl|
536687|NCT00097929|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
536688|NCT00097916|Drug|memantine HCl|
536689|NCT00097903|Drug|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
536690|NCT00097890|Drug|Replagal (Agalsidase Alfa)|
536691|NCT00097890|Drug|Replagal|
536692|NCT00097877|Drug|biphasic insulin aspart|
536693|NCT00097877|Drug|insulin glargine|
536694|NCT00097851|Drug|docetaxel|
536695|NCT00097851|Drug|PI-88|
536696|NCT00097838|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
536697|NCT00097838|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
536698|NCT00097825|Drug|Zoledronic Acid|
536699|NCT00097812|Drug|zoledronic acid|
536700|NCT00097799|Drug|Tipranavir|500 mg twice daily
536701|NCT00097799|Drug|Ritonavir|200 mg twice daily
536702|NCT00097786|Drug|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
536703|NCT00097786|Drug|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
536704|NCT00097786|Drug|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
536772|NCT00097227|Drug|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
536705|NCT00097786|Drug|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
536706|NCT00097773|Drug|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
536707|NCT00097773|Drug|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
536708|NCT00097773|Drug|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
536709|NCT00097760|Drug|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
536710|NCT00097760|Drug|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
536711|NCT00097760|Drug|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
536712|NCT00097747|Drug|Placebo|
536713|NCT00097747|Drug|peginesatide|
536714|NCT00097734|Drug|ertapenem|
536715|NCT00097721|Drug|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
536716|NCT00097708|Drug|experimental anti-anxiety drug|
536717|NCT00097695|Drug|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
536718|NCT00097695|Drug|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
536719|NCT00097669|Other|folic acid|2 mg
536720|NCT00097669|Dietary Supplement|Vitamin B6|25mg
536721|NCT00097669|Dietary Supplement|Vitamin B12|500ug
536722|NCT00097656|Other|multi-center, randomized, controled periodontal therapy|periodontal therapy
536723|NCT00097643|Behavioral|exercise|
536724|NCT00097643|Behavioral|health promotion|
536725|NCT00097630|Procedure|SAT: Spontaneous Awakening Trial|
536726|NCT00097630|Procedure|SBT: Spontaneous Breathing Trial|
536727|NCT00097604|Dietary Supplement|Valerian root extract|Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
536728|NCT00097591|Drug|Prasugrel|Administered orally
536729|NCT00097591|Drug|Clopidogrel|Administered orally
536730|NCT00097539|Biological|Somatrem|
536731|NCT00097539|Biological|Somatropin|
536732|NCT00097500|Drug|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
536733|NCT00097500|Drug|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
536734|NCT00097500|Drug|Metformin|Patients usual dosage
536735|NCT00097474|Drug|Hydrocortisone|Hydrocortisone will be given alone or in combination with Melatonin to see if symptoms of jet lag are alleviated
536736|NCT00097474|Drug|Melatonin|Melatonin will be given alone or in combination with Hydrocortisone to see if symptoms of jet lag are alleviated
536737|NCT00097474|Drug|Placebo|Placebo
536738|NCT00097448|Drug|prednisone|Oral, 19 days
536739|NCT00097448|Drug|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
536740|NCT00097435|Drug|Albuferon|
536741|NCT00097435|Drug|Ribavirin|
536742|NCT00097422|Drug|OPT-80|
536743|NCT00097409|Drug|Ispinesib|
536744|NCT00097396|Biological|rF1V vaccine|
536745|NCT00097383|Drug|ALIMTA plus Epirubicin|
536746|NCT00097370|Drug|mepolizumab|Study Drug
536747|NCT00097357|Drug|Apixaban|Tablets, Oral, 12 +/- 2 days
536748|NCT00097357|Drug|Enoxaparin|Injection, SQ, Q12H, 12 +/- 2 days
536749|NCT00097357|Drug|Warfarin|Tablets, Oral, QD, 12 +/- 2 days
536750|NCT00097357|Drug|Enoxaparin Placebo|Injection, SQ, BID, 12 +/- 2 days
536751|NCT00097357|Drug|Apixaban Placebo|Tablets, Oral, BID, 12 +/- 2 days
536752|NCT00097344|Drug|Atamestane|
536753|NCT00097344|Drug|Toremifene|
536754|NCT00097344|Drug|Letrozole|
536755|NCT00097344|Drug|Aromatase inhibition|
536756|NCT00097344|Drug|Estrogen receptor blocker|
536757|NCT00097344|Procedure|Hormone therapy|
536758|NCT00097344|Procedure|Endocrine therapy|
536759|NCT00097344|Procedure|Antiestrogen therapy|
536760|NCT00097331|Drug|SB683699|
536761|NCT00097318|Drug|Interferon beta-1a|
536762|NCT00097305|Behavioral|Body-Oriented Therapy|
536763|NCT00097305|Behavioral|Standardized Massage Therapy|
536764|NCT00097279|Drug|biphasic insulin aspart|
536765|NCT00097279|Drug|pioglitazone|
536766|NCT00097279|Drug|metformin|
536767|NCT00097266|Drug|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
536768|NCT00097266|Drug|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
536769|NCT00097266|Drug|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
536770|NCT00097253|Behavioral|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
536773|NCT00097227|Drug|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
536774|NCT00097214|Drug|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
536775|NCT00097214|Biological|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
536776|NCT00097188|Drug|rituximab|
536777|NCT00097162|Procedure|Anodal stimulation|
536778|NCT00097149|Procedure|Systematic pediatric care|
536779|NCT00097123|Drug|Misoprostol|
536780|NCT00097110|Drug|Vitamin C and E|
536781|NCT00097097|Procedure|Neonatal Resuscitation|
536782|NCT00097084|Drug|insulin detemir|
536783|NCT00097084|Drug|insulin glargine|
536784|NCT00097084|Drug|insulin aspart|
536785|NCT00097071|Drug|insulin lispro|
536786|NCT00097071|Drug|insulin aspart|
536787|NCT00097045|Drug|omega interferon|
536788|NCT00097045|Drug|Ribavirin|
536789|NCT00097032|Drug|risperidone; quetiapine|
536790|NCT00097019|Drug|bevacizumab|
536791|NCT00096993|Drug|Placebo|Placebo was provided as a single-use formulation for infusion.
536792|NCT00096993|Drug|Gemcitabine|Gemcitabine was provided as a solution for infusion.
536793|NCT00096993|Drug|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
536794|NCT00096980|Drug|Raptiva (efalizumab)|
536795|NCT00096967|Drug|Avastin (bevacizumab)|
536796|NCT00096954|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of > 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
536797|NCT00096954|Drug|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
536798|NCT00096941|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
536799|NCT00096915|Drug|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
536800|NCT00096902|Procedure|Tilt table test|
536801|NCT00096863|Drug|Ziprasidone|
536802|NCT00096863|Drug|Haloperidol|
536803|NCT00096863|Other|Placebo|
536804|NCT00096850|Drug|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
536805|NCT00096850|Drug|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
536806|NCT00096850|Drug|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
536807|NCT00096837|Drug|Motexafin Gadolinium Injection|
536808|NCT00096824|Behavioral|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
536809|NCT00096811|Drug|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
536810|NCT00096798|Drug|Ethyl-eicosapentanoic acid (ethyl-EPA)|
536811|NCT00096785|Drug|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
536812|NCT00096785|Drug|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
536813|NCT00096759|Behavioral|Tai Chi Chih|
536814|NCT00096759|Behavioral|Relaxation training|
536815|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
536816|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
536817|NCT00096720|Drug|levodopa|
536818|NCT00096720|Drug|Mirapex (pramipexole)|
536819|NCT00096720|Procedure|[123I]ß-CIT and SPECT imaging|
536820|NCT00096707|Drug|2-deoxy-D-glucose (2DG)|
536821|NCT00096694|Device|Levonorgestrel-releasing intrauterine device (IUD)|
536822|NCT00096668|Drug|TOCOSOL(R) Paclitaxel|
536823|NCT00096655|Drug|Infliximab|
536824|NCT00096642|Behavioral|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
536825|NCT00096629|Biological|human prostate-specific membrane antigen plasmid DNA vaccine|
536826|NCT00096629|Biological|mouse prostate-specific membrane antigen plasmid DNA vaccine|
536827|NCT00096616|Drug|Combivent® CFC MDI|
536828|NCT00096616|Drug|Albuterol HFA MDI|
536829|NCT00096603|Drug|Raptiva (efalizumab)|
536830|NCT00096590|Other|coagulation study|
536831|NCT00096590|Other|immunoenzyme technique|
536832|NCT00096590|Other|laboratory biomarker analysis|
536833|NCT00096590|Other|physiologic testing|
536834|NCT00096590|Procedure|study of high risk factors|
536835|NCT00096551|Drug|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
536836|NCT00096551|Drug|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
536837|NCT00096551|Drug|Recombinant Fowlpox-GM-CSF|
536838|NCT00096538|Drug|valganciclovir|
536839|NCT00096525|Drug|lenalidomide|
536840|NCT00096512|Drug|sorafenib tosylate|Given orally
536841|NCT00096512|Other|laboratory biomarker analysis|Correlative studies
536842|NCT00096499|Drug|ispinesib|Given IV
536843|NCT00096499|Other|pharmacological study|Correlative studies
536844|NCT00096499|Other|laboratory biomarker analysis|Correlative studies
536845|NCT00096486|Drug|everolimus|
536846|NCT00096486|Drug|gefitinib|
536847|NCT00096473|Drug|Donepezil hydrochloride|
536848|NCT00096460|Drug|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
536902|NCT00096200|Drug|Paclitaxel|Given IV
536903|NCT00096200|Drug|Sorafenib Tosylate|Given orally
536849|NCT00096460|Drug|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
536850|NCT00096460|Radiation|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.~Radiation - administered at a rate of < 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.~Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC > 500/mm3 x 3 days."
536851|NCT00096460|Drug|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
536852|NCT00096460|Procedure|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
536853|NCT00096460|Procedure|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
536854|NCT00096460|Drug|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:~Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
536855|NCT00096460|Drug|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
536856|NCT00096447|Drug|lapatinib ditosylate|
536857|NCT00096434|Drug|sorafenib tosylate|Given orally
536858|NCT00096434|Other|laboratory biomarker analysis|Correlative studies
536859|NCT00096421|Behavioral|Tight control of blood glucose levels|
536860|NCT00096421|Behavioral|Conventional control of glucose levels|
536861|NCT00096408|Procedure|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
536862|NCT00096408|Procedure|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
536863|NCT00096395|Drug|gemcitabine hydrochloride|Given IV
536864|NCT00096395|Drug|sorafenib tosylate|Given orally
536865|NCT00096395|Other|laboratory biomarker analysis|Correlative studies
536866|NCT00096382|Biological|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
536867|NCT00096382|Biological|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count >1x10^9/1.
536868|NCT00096382|Biological|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
536869|NCT00096382|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
536870|NCT00096382|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggyback daily over 15-20 minutes for 5 days
536871|NCT00096382|Radiation|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
536872|NCT00096369|Drug|tamoxifen citrate|
536873|NCT00096356|Dietary Supplement|CoQ10 & Vitamin E|
536874|NCT00096356|Dietary Supplement|Placebo & Vitamin E|
536875|NCT00096343|Drug|carboplatin|
536876|NCT00096343|Drug|paclitaxel|
536877|NCT00096330|Dietary Supplement|dietary intervention|oral folic acid supplementation once daily on days 57-84
536878|NCT00096330|Dietary Supplement|folic acid|oral folic acid supplementation once daily on days 1-56.
536879|NCT00096317|Drug|ixabepilone|
536880|NCT00096317|Drug|ketoconazole|
536881|NCT00096304|Drug|docetaxel|
536882|NCT00096304|Drug|epirubicin hydrochloride|
536883|NCT00096291|Other|Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"
536884|NCT00096291|Other|Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:~Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
536885|NCT00096278|Biological|Bevacizumab|Given IV
536886|NCT00096278|Drug|Fluorouracil|Given IV
536887|NCT00096278|Drug|Leucovorin Calcium|Given IV
536888|NCT00096278|Drug|Oxaliplatin|Given IV
536889|NCT00096265|Radiation|3-Dimensional Conformal Radiation Therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
536890|NCT00096265|Drug|Erlotinib Hydrochloride|Given orally
536891|NCT00096265|Radiation|Stereotactic Radiosurgery|Patients undergo surgery after radiation therapy
536892|NCT00096265|Drug|Temozolomide|Given orally
536893|NCT00096239|Drug|CP-547,632|
536894|NCT00096226|Drug|Induction Carboplatin|
536895|NCT00096226|Drug|Induction Paclitaxel|
536896|NCT00096226|Procedure|Resection|
536897|NCT00096226|Drug|Consolidation Carboplatin|
536898|NCT00096226|Radiation|Radiation Therapy|
536899|NCT00096226|Drug|Consolidation Paclitaxel|
536900|NCT00096213|Procedure|conventional surgery|surgery
536901|NCT00096200|Drug|Carboplatin|Given IV
537164|NCT00094497|Drug|Doxorubicin|
536905|NCT00096174|Biological|cetuximab C225|400 mg/m^2 IV over 120 minutes on Day 1, 250 mg/m^2 IV over 60 minutes on Day 8, then weekly
536906|NCT00096174|Drug|cisplatin|75 mg/m^2 IV over 30-60 minutes starting day 15 every 3 weeks * 3 (Days 1, 22, and 43 of radiation therapy (RT))
536907|NCT00096174|Radiation|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d * 7 weeks (35 fractions)
536908|NCT00096161|Drug|Cyclosporine|Given PO
536909|NCT00096161|Drug|Mycophenolate Mofetil|Given PO
536910|NCT00096161|Drug|Pentostatin|Given IV
536911|NCT00096161|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
536912|NCT00096148|Drug|idarubicin|Given IV
536913|NCT00096148|Drug|cytarabine|Given IV
536914|NCT00096148|Biological|bevacizumab|Given IV
536915|NCT00096148|Other|laboratory biomarker analysis|Correlative studies
536916|NCT00096135|Biological|filgrastim|given subcutaneously (SC)
536917|NCT00096135|Drug|cyclophosphamide|IV over 15-30 minutes
536918|NCT00096135|Drug|cytarabine|IV over 3 hours twice daily
536919|NCT00096135|Drug|daunorubicin hydrochloride|IV over 15 minutes
536920|NCT00096135|Drug|dexamethasone|oral twice daily
536921|NCT00096135|Drug|etoposide|IV over 1 hour
536922|NCT00096135|Drug|leucovorin calcium|rescue IV over 24 hours
536923|NCT00096135|Drug|mercaptopurine|oral
536924|NCT00096135|Drug|methotrexate|intramuscularly (IM)
536925|NCT00096135|Drug|pegaspargase|intramuscularly (IM)
536926|NCT00096135|Drug|therapeutic hydrocortisone|
536927|NCT00096135|Drug|vincristine sulfate|given IV
536928|NCT00096135|Radiation|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
536929|NCT00096122|Drug|cytarabine|Given IV
536930|NCT00096122|Drug|idarubicin|Given IV
536931|NCT00096122|Drug|tipifarnib|Given orally
536932|NCT00096109|Drug|tanespimycin|Given IV
536933|NCT00096109|Other|laboratory biomarker analysis|Correlative studies
536934|NCT00096096|Drug|mycophenolate mofetil|
536935|NCT00096096|Drug|tacrolimus|
536936|NCT00096083|Drug|isolated perfusion|
536937|NCT00096083|Drug|melphalan|
536938|NCT00096070|Radiation|radiation therapy|Undergo radiation therapy
536939|NCT00096070|Drug|oxaliplatin|Given IV
536940|NCT00096070|Drug|fluorouracil|Given IV
536941|NCT00096070|Drug|gemcitabine hydrochloride|Given IV
536942|NCT00096057|Biological|monoclonal antibody HuHMFG1|
536943|NCT00096044|Biological|rituximab|IV
536944|NCT00096044|Drug|lenalidomide|Oral
536945|NCT00096031|Biological|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
536946|NCT00096018|Drug|fludarabine phosphate|Given IV
536947|NCT00096018|Drug|thalidomide|Orally
536948|NCT00096005|Drug|tanespimycin|Given IV
536949|NCT00096005|Drug|bortezomib|Given IV
536950|NCT00096005|Other|laboratory biomarker analysis|Correlative studies
536951|NCT00095992|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
536952|NCT00095979|Drug|ixabepilone|Given IV
536953|NCT00095966|Drug|sorafenib tosylate|Given orally
536954|NCT00095966|Drug|gemcitabine hydrochloride|Given IV
536955|NCT00095953|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
536956|NCT00095940|Drug|lapatinib ditosylate|Given orally
536957|NCT00095940|Procedure|therapeutic conventional surgery|Undergo surgery
536958|NCT00095940|Other|laboratory biomarker analysis|Correlative studies
536959|NCT00095940|Other|pharmacological study|Correlative studies
536960|NCT00095940|Procedure|positron emission tomography|Correlative studies
536961|NCT00095940|Procedure|magnetic resonance imaging|Correlative studies
536962|NCT00095927|Drug|Amifostine|Given subcutaneously
536963|NCT00095927|Drug|Carboplatin|Given IV
536964|NCT00095927|Drug|Paclitaxel|Given IV
536965|NCT00095927|Radiation|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
536966|NCT00095914|Drug|paclitaxel|
536967|NCT00095914|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
536968|NCT00095901|Drug|Capecitabine|
536969|NCT00095888|Drug|triapine|Given IV
536970|NCT00095888|Drug|gemcitabine hydrochloride|Given IV
536971|NCT00095888|Other|laboratory biomarker analysis|Correlative studies
536972|NCT00095888|Other|pharmacological study|Correlative studies
536973|NCT00095875|Drug|carboplatin|Given IV
536974|NCT00095875|Drug|cisplatin|Given IV
536975|NCT00095875|Drug|docetaxel|Given IV
536976|NCT00095875|Drug|fluorouracil|Given IV
536977|NCT00095862|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|
536978|NCT00095862|Biological|recombinant interferon alfa|
536979|NCT00095862|Drug|cyclophosphamide|
536980|NCT00095836|Drug|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
536981|NCT00095823|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
536982|NCT00095823|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
536983|NCT00095810|Drug|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
536984|NCT00095797|Drug|R(+)XK469|Given IV
536985|NCT00095797|Other|pharmacological study|Correlative studies
537165|NCT00094497|Drug|Cisplatin|
536986|NCT00095797|Other|laboratory biomarker analysis|Optional correlative studies
536987|NCT00095784|Drug|Decitabine|Given SC
536988|NCT00095784|Other|Laboratory Biomarker Analysis|Correlative studies
536989|NCT00095771|Drug|arsenic trioxide|
536990|NCT00095771|Radiation|radiation therapy|
536991|NCT00095758|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
536992|NCT00095758|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
536993|NCT00095745|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
536994|NCT00095732|Drug|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
536995|NCT00095732|Drug|Placebo|Administered orally in either Size 2 or Size 5 capsules
536996|NCT00095719|Drug|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
536997|NCT00095719|Drug|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
536998|NCT00095706|Drug|Bevacizumab (drug), Herceptin (drug)|
536999|NCT00095693|Drug|sorafenib tosylate|Given PO
537000|NCT00095693|Other|laboratory biomarker analysis|Correlative studies
537001|NCT00095693|Other|pharmacological study|Correlative studies
537002|NCT00095693|Radiation|fludeoxyglucose F 18|Correlative studies
537003|NCT00095693|Procedure|positron emission tomography|Correlative studies
537004|NCT00095693|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
537005|NCT00095680|Drug|SCIO-469|two 30-mg capsules three times daily
537006|NCT00095680|Drug|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
537007|NCT00095667|Drug|lapatinib ditosylate|Given orally
537008|NCT00095667|Other|laboratory biomarker analysis|Correlative studies
537009|NCT00095654|Drug|Ramipril|
537010|NCT00095654|Drug|Rosiglitazone|
537011|NCT00095641|Drug|capecitabine|
537012|NCT00095641|Procedure|adjuvant therapy|
537013|NCT00095641|Procedure|chemotherapy|
537014|NCT00095628|Drug|ispinesib|Given IV
537015|NCT00095628|Other|laboratory biomarker analysis|Correlative studies
537016|NCT00095628|Other|pharmacological study|Correlative studies
537017|NCT00095589|Genetic|loss of heterozygosity analysis|
537018|NCT00095589|Genetic|microarray analysis|
537019|NCT00095589|Genetic|microsatellite instability analysis|
537020|NCT00095589|Other|cytology specimen collection procedure|
537021|NCT00095589|Other|laboratory biomarker analysis|
537022|NCT00095589|Procedure|computed tomography|
537023|NCT00095589|Procedure|cystoscopy|
537024|NCT00095576|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 adenovirus genomes [ad-vg]/dose).~This dose is equivalent to 3x10^10 vp/dose used in study V520-016."
537025|NCT00095576|Drug|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
537026|NCT00095563|Drug|lapatinib ditosylate|Given orally
537027|NCT00095563|Other|laboratory biomarker analysis|Correlative studies
537028|NCT00095550|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
537029|NCT00095550|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
537030|NCT00095550|Drug|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
537031|NCT00095537|Drug|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
537032|NCT00095524|Drug|Aripiprazole|
537033|NCT00095511|Drug|aripiprazole|
537034|NCT00095498|Drug|placebo|placebo subcutaneous injection
537035|NCT00095498|Drug|denosumab|For subcutaneous injection
537036|NCT00095472|Drug|L-NMMA|
537037|NCT00095472|Drug|Sodium Nitrite|
537038|NCT00095459|Drug|Bevacizumab|
537039|NCT00095459|Drug|BAY 43-9006|
537040|NCT00095446|Drug|insulin aspart|
537041|NCT00095433|Drug|rhuFab V2 (ranibizumab)|
537042|NCT00095420|Behavioral|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
537043|NCT00095420|Behavioral|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
537044|NCT00095420|Behavioral|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
537045|NCT00095420|Behavioral|Usual training|Participants will receive the usual training offered in their local school districts.
537046|NCT00095394|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
537047|NCT00095394|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
537048|NCT00095381|Drug|forodesine hydrochloride (BCX-1777)|
537049|NCT00095368|Drug|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
537050|NCT00095355|Drug|Lithium|
537051|NCT00095355|Drug|Divalproex|
537052|NCT00095342|Drug|TMI-005|
537053|NCT00095329|Biological|sirolimus|
537054|NCT00095316|Drug|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
537055|NCT00095316|Other|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
537056|NCT00095303|Behavioral|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
537057|NCT00095303|Behavioral|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
537058|NCT00095290|Drug|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
537059|NCT00095290|Drug|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
537060|NCT00095277|Drug|Darbepoetin Alfa|
537061|NCT00095264|Drug|Darbepoetin Alfa|
537062|NCT00095251|Drug|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
537063|NCT00095251|Drug|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
537064|NCT00095238|Drug|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
537065|NCT00095238|Drug|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
537066|NCT00095225|Drug|Avastin (bevacizumab)|
537067|NCT00095225|Drug|Tarceva (erlotinib HCl)|
537068|NCT00095212|Drug|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
537069|NCT00095212|Drug|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
537070|NCT00095199|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
537071|NCT00095199|Biological|Cetuximab|Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
537072|NCT00095199|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
537073|NCT00095186|Drug|Recombinant Human Lactoferrin|
537074|NCT00095173|Drug|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
537075|NCT00095173|Drug|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
537076|NCT00095173|Drug|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing < 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing > 100 kg, monthly
537077|NCT00095160|Drug|852A|
537078|NCT00095147|Drug|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
537079|NCT00095147|Drug|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
537080|NCT00095147|Drug|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
537081|NCT00095147|Drug|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
537082|NCT00095147|Drug|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
537083|NCT00095134|Drug|risperidone|
537084|NCT00095121|Drug|Placebo (PLB)|Matching placebo
537085|NCT00095121|Drug|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
537086|NCT00095121|Drug|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration >= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained >= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
537087|NCT00095108|Drug|Recombinant Human Interleukin-21|
537088|NCT00095095|Device|Lumbar Interbody Fusion|
537089|NCT00095082|Drug|insulin detemir|
537090|NCT00095082|Drug|insulin glargine|
537091|NCT00095082|Drug|insulin aspart|
537092|NCT00095069|Drug|MK0928, gaboxadol / Duration of Treatment - 1 year|
537093|NCT00095069|Drug|Comparator: placebo / Duration of Treatment -1 year|
537094|NCT00095056|Drug|sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
537095|NCT00095056|Drug|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
537096|NCT00095056|Drug|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
537166|NCT00094497|Drug|Streptozotocin|
537097|NCT00095056|Drug|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
537098|NCT00095043|Drug|MK0928, gaboxadol|
537099|NCT00095043|Drug|Comparator: placebo|
537100|NCT00095030|Drug|muraglitazar|
537101|NCT00095017|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
537102|NCT00095004|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
537103|NCT00095004|Drug|Comparator: placebo / Duration of Treatment: 1 day|
537104|NCT00094991|Drug|Muraglitazar|
537105|NCT00094978|Drug|Depsipeptide|
537106|NCT00094978|Drug|Flavopiridol (alvocidib)|
537107|NCT00094965|Drug|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
537108|NCT00094926|Drug|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
537109|NCT00094926|Drug|placebo|matching placebo IM injections every 2wks for 52wks
537110|NCT00094900|Drug|IL-1 Trap|
537111|NCT00094887|Drug|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
537112|NCT00094887|Drug|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
537113|NCT00094874|Procedure|Acupuncture|
537114|NCT00094861|Drug|Palifermin|
537115|NCT00094861|Drug|Placebo|
537116|NCT00094861|Radiation|Radiotherapy|
537117|NCT00094861|Drug|Paclitaxel|
537118|NCT00094861|Drug|Carboplatin|
537119|NCT00094848|Drug|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
537120|NCT00094835|Biological|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
537121|NCT00094835|Drug|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
537122|NCT00094835|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 administered by IV infusion over 3 hours.
537123|NCT00094835|Drug|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
537124|NCT00094822|Other|PI Discretion|PI Discretion
537125|NCT00094809|Drug|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
537126|NCT00094809|Drug|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
537127|NCT00094796|Procedure|Exercise cardiopulmonary metabolic testing|
537128|NCT00094796|Procedure|Skeletal muscle biopsy|
537129|NCT00094796|Procedure|Brachial artery reactivity testing|
537130|NCT00094783|Procedure|MRI|
537131|NCT00094770|Drug|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
537132|NCT00094770|Drug|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
537133|NCT00094757|Drug|Comparator: sitagliptin 100 mg|sitagliptin 100 mg oral tablet once daily for 54 weeks
537134|NCT00094757|Drug|Comparator: sitagliptin 200 mg|sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
537135|NCT00094757|Drug|Comparator: placebo|placebo oral tablet once daily during Phase A (Weeks 0-18)
537136|NCT00094757|Drug|Comparator: pioglitazone|pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
537137|NCT00094744|Device|Eye patch|adhesive eye patch used to cover the sound eye
537138|NCT00094731|Procedure|Memory Training|
537139|NCT00094718|Biological|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
537140|NCT00094718|Biological|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
537141|NCT00094705|Biological|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
537142|NCT00094705|Biological|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
537143|NCT00094692|Device|Eye patch|
537144|NCT00094692|Device|spectacles|
537145|NCT00094692|Drug|atropine|
537146|NCT00094679|Device|Eye patch|adhesive patch to cover the sound eye
537147|NCT00094666|Drug|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
537148|NCT00094666|Drug|Comparator: placebo / Duration of Treatment - 6 weeks|
537149|NCT00094653|Drug|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous [iv] infusion over 90 minutes), every 3 weeks for 4 doses
537150|NCT00094653|Biological|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
537151|NCT00094640|Drug|Intramuscular Olanzapine Depot|
537152|NCT00094627|Drug|gaboxadol|Duration of Treatment - 6 weeks
537153|NCT00094627|Drug|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
537154|NCT00094614|Drug|Atropine|
537155|NCT00094575|Procedure|Endovascular Repair|Endovascular Repair
537156|NCT00094575|Procedure|Standard Open Repair|Standard Open Repair
537157|NCT00094562|Drug|Fish oil supplement|
537158|NCT00094549|Drug|olanzapine|
537159|NCT00094549|Drug|divalproex sodium|
537160|NCT00094549|Drug|placebo|
537161|NCT00094536|Device|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
537162|NCT00094523|Drug|Fosamprenavir|Fosamprenavir
537163|NCT00094497|Drug|Etoposide|
537169|NCT00094458|Biological|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
537170|NCT00094458|Other|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
537171|NCT00094458|Drug|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
537172|NCT00094445|Drug|Curcumin|8 gm per day
537173|NCT00094432|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
537174|NCT00094432|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
537175|NCT00094406|Procedure|Bronchoscopy|
537176|NCT00094406|Procedure|Bronchoalveolar lavage|
537177|NCT00094406|Drug|Endotoxin|
537178|NCT00094406|Drug|Carbon Monoxide|
537179|NCT00094380|Drug|CTLA4-IgG4m (RG2077)|
537180|NCT00094380|Drug|Cyclophosphamide|
537181|NCT00094367|Drug|Abacavir/Lamivudine|
537182|NCT00094341|Drug|Etanercept|
537183|NCT00094328|Drug|Bicalutamide|oral
537184|NCT00094328|Drug|Anastrozole|oral
537185|NCT00094315|Drug|Cocaine (IV)|
537186|NCT00094302|Drug|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
537187|NCT00094302|Drug|Placebo|Placebo of spironolactone
537188|NCT00094289|Drug|Disulfiram|
537189|NCT00094276|Behavioral|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
537190|NCT00094276|Behavioral|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
537191|NCT00094250|Behavioral|Resistance and Aerobic Training|
537192|NCT00094172|Drug|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
537193|NCT00094172|Drug|Placebo|tablet form
537194|NCT00094159|Drug|SNS-595|
537195|NCT00094146|Drug|Sandostatin LAR Depot|
537196|NCT00094133|Procedure|hot flashes attenuation|
537197|NCT00094133|Procedure|hypnotherapy|
537198|NCT00094120|Drug|MSI-1256F (Squalamine Lactate)|
537199|NCT00094107|Drug|Axitinib [AG-013736]|VEGFR [vascular endothelial growth factor Receptor] and PDGFR [Platelet-Derived Growth Factor Receptor] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
537200|NCT00094094|Drug|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
537201|NCT00094081|Drug|tirapazamine (SR259075)|
537202|NCT00094081|Drug|cisplatin|
537203|NCT00094081|Procedure|Radiation Therapy|
537204|NCT00091468|Drug|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
537205|NCT00091468|Drug|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
537206|NCT00081627|Drug|CoFactor and 5FU|
537207|NCT00094055|Drug|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
537208|NCT00094042|Drug|Iron Supplement, 120mg|
537209|NCT00094029|Drug|Sutent|Sutent, 25, 37.5, or 50 mg daily
537210|NCT00094016|Drug|beclomethasone dipropionate|
537211|NCT00094003|Drug|NS-9 [Poly I: Poly C]|
537212|NCT00093990|Drug|Tipifarnib;Zarnestra; R115777|
537213|NCT00093977|Drug|darbepoetin alfa SF|"Frequency of dosing depends on frequency at randomization:~rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL"
537214|NCT00093964|Drug|Cilengitide 500 mg|Subjects will receive 1-hour intravenous infusion of 500 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
537215|NCT00093964|Drug|Cilengitide 2000 mg|Subjects will receive 1-hour intravenous infusion of 2000 mg cilengitide twice weekly on Day 1 and 4 of each week during every 4-week cycle, for a total of 8 infusions per cycle. Cycles were repeated without pause until progressive disease (PD), unacceptable adverse events (AEs), or withdrawal of consent.
537216|NCT00093951|Drug|SGS742|
537217|NCT00093938|Drug|Cranberry juice|
537218|NCT00093925|Drug|clevidipine|
537219|NCT00093925|Drug|nicardipine|
537220|NCT00093912|Drug|clevidipine|
537221|NCT00093912|Drug|sodium nitroprusside|
537222|NCT00093899|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
537223|NCT00093886|Drug|clevidipine|
537224|NCT00093886|Drug|nitroglycerin|
537225|NCT00093873|Drug|Anti-angiogenesis|Anti-angiogenesis
537226|NCT00093873|Drug|AMG 706|Anti-angiogenesis
537227|NCT00093847|Drug|S-adenosyl methione (SAMe)|Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
537228|NCT00093847|Drug|Placebo|Placebo to be taken daily for 6 weeks
537229|NCT00093834|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
537369|NCT00002524|Radiation|Radiation Therapy|
546602|NCT00028925|Radiation|WBRT|
537230|NCT00093834|Drug|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
537231|NCT00093834|Drug|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
537232|NCT00093821|Drug|tanespimycin|Given IV
537233|NCT00093821|Other|pharmacological study|Correlative studies
537234|NCT00093821|Other|laboratory biomarker analysis|Correlative studies
537235|NCT00093808|Biological|trastuzumab|
537236|NCT00093808|Drug|capecitabine|
537237|NCT00093808|Drug|vinorelbine tartrate|
537238|NCT00093795|Drug|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
537239|NCT00093795|Drug|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
537240|NCT00093795|Drug|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
537241|NCT00093795|Drug|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
537242|NCT00093795|Drug|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
537243|NCT00093782|Drug|temsirolimus|Given IV
537244|NCT00093782|Other|laboratory biomarker analysis|Correlative studies
537245|NCT00093769|Drug|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
537246|NCT00093756|Radiation|3-dimensional conformal radiation therapy|
537247|NCT00093756|Drug|bortezomib|Given IV
537248|NCT00093756|Drug|paclitaxel|Given IV
537249|NCT00093756|Drug|carboplatin|Given IV
537250|NCT00093743|Drug|fludarabine phosphate|Given IV
537251|NCT00093743|Drug|cyclosporine|Given IV or PO
537252|NCT00093743|Radiation|total-body irradiation|Undergo TBI
537253|NCT00093743|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
537254|NCT00093743|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
537255|NCT00093743|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
537256|NCT00093743|Drug|mycophenolate mofetil|Given PO or IV
537257|NCT00093730|Drug|BMS-59926|
537258|NCT00093704|Drug|bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
537259|NCT00093678|Drug|celecoxib|
537260|NCT00093678|Procedure|anticachectic therapy|
537261|NCT00093678|Procedure|nutritional support|
537262|NCT00093678|Procedure|pain therapy|
537263|NCT00093678|Procedure|supportive care/therapy|
537264|NCT00093665|Drug|cisplatin|
537265|NCT00093665|Drug|fluorouracil|
537266|NCT00093665|Radiation|radiation therapy|
537267|NCT00093652|Drug|gefitinib|
537268|NCT00093652|Drug|oxaliplatin|
537269|NCT00093652|Procedure|conventional surgery|
537270|NCT00093652|Procedure|neoadjuvant therapy|
537271|NCT00093652|Radiation|radiation therapy|
537272|NCT00093639|Drug|everolimus|
537273|NCT00093639|Drug|imatinib mesylate|
537274|NCT00093626|Other|Laboratory Biomarker Analysis|Correlative studies
537275|NCT00093626|Drug|Sorafenib Tosylate|Given orally
537276|NCT00093613|Drug|sorafenib tosylate|Given PO
537277|NCT00093613|Other|pharmacological study|Correlative studies
537278|NCT00093600|Drug|cytarabine|
537279|NCT00093600|Drug|daunorubicin hydrochloride|
537280|NCT00093600|Drug|midostaurin|
537281|NCT00093587|Biological|anti-thymocyte globulin|
537282|NCT00093587|Drug|busulfan|
537283|NCT00093587|Drug|cyclophosphamide|
537284|NCT00093587|Drug|cyclosporine|
537285|NCT00093587|Procedure|allogeneic bone marrow transplantation|
537286|NCT00093587|Procedure|peripheral blood stem cell transplantation|
537287|NCT00093587|Radiation|radiation therapy|
537288|NCT00093561|Dietary Supplement|lycopene|
537289|NCT00093548|Biological|alpha fetoprotein adenoviral vector vaccine|
537290|NCT00093548|Biological|alpha fetoprotein plasmid DNA vaccine|
537291|NCT00093548|Biological|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
537292|NCT00093522|Biological|autologous tumor cell vaccine|
537293|NCT00093522|Biological|keyhole limpet hemocyanin|
537294|NCT00093522|Biological|therapeutic autologous dendritic cells|
537295|NCT00093522|Drug|fludarabine phosphate|
537296|NCT00093522|Procedure|conventional surgery|
537297|NCT00093509|Drug|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
537298|NCT00093509|Drug|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
537452|NCT00092612|Drug|Comparator: ezetimibe, placebo|
537453|NCT00092599|Drug|MK0653, ezetimibe|
537454|NCT00092599|Drug|Comparator: ezetimibe, placebo|
546729|NCT00023868|Drug|mitomycin C|
537299|NCT00093509|Procedure|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
537300|NCT00093509|Radiation|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of > 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
537301|NCT00093496|Drug|gemcitabine hydrochloride|Given IV
537302|NCT00093496|Drug|tanespimycin|Given IV
537303|NCT00093483|Biological|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
537304|NCT00093483|Drug|arsenic trioxide|IV over 1 hour on day 1
537305|NCT00093483|Drug|cytarabine|IV over 1 hour every 12 hours on days 1-6
537306|NCT00093483|Drug|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
537307|NCT00093470|Procedure|Clinical Observation|Undergo observation
537308|NCT00093470|Drug|Tipifarnib|Given PO
537309|NCT00093457|Drug|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
537310|NCT00093444|Drug|lyso-thermosensitive liposomal doxorubicin|
537311|NCT00093444|Procedure|radiofrequency ablation|
537312|NCT00093418|Drug|tipifarnib|Given orally
537313|NCT00093405|Drug|tanespimycin|
537314|NCT00093379|Drug|Capecitabine|825 mg/m^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
537315|NCT00093379|Drug|Oxaliplatin|50 mg/m^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
537316|NCT00093379|Radiation|Radiation Therapy (XRT)|Undergo radiotherapy* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. *Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
537317|NCT00093366|Biological|etanercept|
537318|NCT00093366|Drug|arsenic trioxide|
537319|NCT00093353|Drug|cefixime|
537320|NCT00093353|Drug|irinotecan hydrochloride|
537321|NCT00093353|Drug|temozolomide|
537322|NCT00093327|Procedure|Acupuncture|
537323|NCT00093314|Drug|HuMax-CD20|
537324|NCT00093860|Drug|Propranolol|
537325|NCT00093301|Drug|Levosimendan|
537326|NCT00093301|Drug|Dobutamine|
537327|NCT00093288|Drug|bupropion XL|
537328|NCT00093275|Drug|HP184|
537329|NCT00093262|Drug|clevidipine|
537330|NCT00093262|Drug|placebo|
537331|NCT00093249|Drug|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
537332|NCT00093249|Drug|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
537333|NCT00093236|Procedure|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
537334|NCT00093236|Procedure|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
537335|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m^2 ABI-007, administered IV, administered after placement of denovo stent(s).
537336|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|
537337|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
537338|NCT00093210|Drug|rFIX|
537339|NCT00093210|Drug|rFIX-R|
537340|NCT00093197|Drug|KAI-9803 for Injection|0.05 mg
537341|NCT00093197|Drug|KAI-9803 for Injection|0.5 mg
537342|NCT00093197|Drug|KAI-9803 for Injection|1.25 mg
537343|NCT00093197|Drug|KAI-9803 for Injection|5 mg
537344|NCT00093197|Drug|Placebo|
537345|NCT00093184|Drug|Angiomax (bivalirudin) anticoagulant|
537346|NCT00093171|Drug|rFIX|
537347|NCT00093158|Drug|Angiomax (bivalirudin) anticoagulant|
537348|NCT00093145|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
537349|NCT00093145|Drug|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
537350|NCT00093145|Drug|Herceptin®|Administered by IV infusion
537351|NCT00002543|Drug|gallium nitrate|
537352|NCT00002524|Biological|Bleomycin Sulfate|
537353|NCT00002524|Biological|Filgrastim|
537354|NCT00002524|Drug|Cisplatin|
537355|NCT00002524|Drug|Cyclophosphamide|
537356|NCT00002524|Drug|Cytarabine|
537357|NCT00002524|Drug|Doxorubicin Hydrochloride (DOX)|
537358|NCT00002524|Drug|Etoposide|
537359|NCT00002524|Drug|Fluorouracil|
537360|NCT00002524|Drug|Ifosfamide|
537361|NCT00002524|Drug|Leucovorin calcium|
537362|NCT00002524|Drug|Methotrexate|
537363|NCT00002524|Drug|Methylprednisolone|
537364|NCT00002524|Drug|Pentamidine|
537365|NCT00002524|Drug|Prednisone|
537366|NCT00002524|Drug|Trimethoprim-Sulfamethoxazole|
537367|NCT00002524|Drug|Vincristine Sulfate|
537370|NCT00093132|Drug|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
537371|NCT00093119|Drug|ABI-007|
537372|NCT00093093|Drug|Viramidine|
537373|NCT00093093|Drug|Ribavirin|
537374|NCT00093093|Drug|pegylated interferon alfa-2a|
537375|NCT00093080|Drug|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
537376|NCT00093067|Drug|daptomycin|
537377|NCT00093054|Drug|Cranberry juice|TID dosage for UTI treatment
537378|NCT00093054|Dietary Supplement|Placebo cranberry juice|TID placebo dosage to match active comparator
537379|NCT00093041|Drug|Zalutumumab|Weekly infusion
537380|NCT00093028|Drug|CC-5013 (Revlimid™)|N/A Study Complete
537381|NCT00093028|Drug|bortezomib|N/A Study Complete
537382|NCT00091520|Drug|Nesiritide|
537383|NCT00093015|Drug|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
537384|NCT00093015|Drug|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
537385|NCT00093002|Drug|Fulvestrant|250 mg & 500 mg intramuscular injection
537386|NCT00092989|Drug|montelukast sodium|Duration of Treatment: 1 dose
537387|NCT00092989|Drug|placebo|Duration of Treatment: 1 dose
537388|NCT00092976|Drug|ReFacto|
537389|NCT00092963|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
537390|NCT00092963|Drug|Comparator: placebo / Duration of Treatment: 1 day|
537391|NCT00092924|Drug|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
537392|NCT00092911|Drug|DVS-233 SR|
537393|NCT00092898|Drug|MK0653, ezetimibe|
537394|NCT00092898|Drug|Comparator: placebo|
537395|NCT00092885|Drug|MK0476, montelukast sodium|
537396|NCT00092885|Drug|Comparator: placebo|
537397|NCT00092872|Drug|MK0557|
537398|NCT00092859|Drug|MK0557|
537399|NCT00092846|Drug|MK0803, lovastatin|
537400|NCT00092846|Behavioral|Self-Management System|
537401|NCT00092833|Drug|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
537402|NCT00092820|Drug|MK0653, ezetimibe|
537403|NCT00092820|Drug|Comparator: placebo|
537404|NCT00092807|Drug|MK0653, ezetimibe|
537405|NCT00092807|Drug|Comparator: placebo|
537406|NCT00092781|Drug|MK0663, etoricoxib|
537407|NCT00092781|Drug|Comparator: celecoxib|
537408|NCT00092768|Drug|MK0663, etoricoxib|
537409|NCT00092768|Drug|Comparator: celecoxib|
537410|NCT00092755|Drug|MK0663, etoricoxib|
537411|NCT00092755|Drug|Comparators: ibuprofen and placebo|
537412|NCT00092742|Drug|MK0663, etoricoxib|
537413|NCT00092742|Drug|Comparator: Diclofenac sodium|
537414|NCT00092729|Drug|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
537415|NCT00092729|Drug|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
537416|NCT00092729|Drug|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
537417|NCT00092716|Drug|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
537418|NCT00092716|Drug|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
537419|NCT00092703|Drug|MK0663, etoricoxib|
537420|NCT00092703|Drug|Comparator: Diclofenac sodium|
537421|NCT00092690|Drug|MK0653A, ezetimibe (+) simvastatin|
537422|NCT00092690|Drug|Comparator: atorvastatin|
537423|NCT00092677|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
537424|NCT00092677|Drug|Comparator: Placebo|matching Placebo
537425|NCT00092664|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
537426|NCT00092651|Drug|MK0653A, ezetimibe (+) simvastatin|
537427|NCT00092651|Drug|Comparators: simvastatin and ezetimibe|
537428|NCT00092586|Drug|MK0653, ezetimibe|
537429|NCT00092586|Drug|Comparator: statins|
537430|NCT00092573|Drug|MK0653, ezetimibe|
537431|NCT00092573|Drug|Comparator: fenofibrate monotherapy|
537432|NCT00092560|Drug|MK0653, ezetimibe|
537433|NCT00092560|Drug|Comparator: fenofibrate monotherapy|
537434|NCT00092547|Biological|V501|0.5 mL intramuscular injection of V501
537435|NCT00092547|Biological|Comparator: Placebo|0.5 mL intramuscular injection of placebo
537436|NCT00092534|Biological|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|Duration of Treatment: 6 months
537437|NCT00092534|Biological|Matching Placebo|Matching Placebo to Quadrivalent Human Papillomavirus Vaccine
537438|NCT00092521|Biological|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
537439|NCT00092521|Biological|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
537440|NCT00092521|Biological|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
537441|NCT00092508|Drug|OPC-6535|
537442|NCT00092508|Drug|Asacol®|
537443|NCT00092300|Drug|MK0966, rofecoxib|
537444|NCT00092300|Drug|Comparator: valdecoxib|
537445|NCT00092950|Behavioral|Physical activity|
537446|NCT00092937|Drug|Busulfan|
537447|NCT00092638|Drug|MK0653, ezetimibe|
537448|NCT00092638|Drug|Comparator: ezetimibe, placebo|
537449|NCT00092625|Drug|MK0653, ezetimibe|
537450|NCT00092625|Drug|Comparator: ezetimibe, placebo|
537451|NCT00092612|Drug|MK0653, ezetimibe|
537455|NCT00092495|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
537456|NCT00092482|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
537457|NCT00092469|Biological|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
537458|NCT00092456|Biological|rotavirus vaccine, live, oral, pentavalent|Three oral doses (~8.81 X 10^7 IU/Dose for Lot 1; ~8.01 X 10^7 IU/Dose for Lot 2; and ~6.91 X 10^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
537459|NCT00092456|Biological|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10~weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
537460|NCT00092443|Biological|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
537461|NCT00092443|Biological|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
537462|NCT00092430|Biological|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
537463|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (~207,000 plaque-forming units [PFU]/0.65-mL dose)
537464|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (~58,000 plaque-forming units [PFU]/0.65-mL dose)
537465|NCT00092404|Biological|measles, mumps, and rubella virus vaccine live|
537466|NCT00092404|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
537467|NCT00092391|Biological|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
537468|NCT00092391|Biological|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
537469|NCT00092378|Drug|MK0966, rofecoxib|
537470|NCT00092378|Drug|Comparator: diclofenac sodium, placebo|
537471|NCT00092365|Drug|MK0966, rofecoxib|
537472|NCT00092365|Drug|Comparator: celecoxib, placebo|
537473|NCT00092352|Drug|MK0966, rofecoxib|
537474|NCT00092352|Drug|Comparator: celecoxib, placebo|
537475|NCT00092339|Drug|MK0966, rofecoxib|
537476|NCT00092339|Drug|Comparator: valdecoxib, placebo|
537477|NCT00092326|Drug|MK0966, rofecoxib|
537478|NCT00092326|Drug|Comparator: oxycodone with acetaminophen, placebo|
537479|NCT00092313|Drug|MK0966, rofecoxib|
537480|NCT00092313|Drug|Comparator: oxycodone and acetaminophen|
537481|NCT00092287|Drug|lanreotide Autogel (somatostatin analogue)|
537482|NCT00092287|Drug|Sandostatin long acting release (LAR) Depot (somatostatin analogue)|
537483|NCT00092274|Drug|HuMax-CD20|
537484|NCT00092001|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
537485|NCT00091650|Drug|Olanzapine|
537486|NCT00091650|Drug|placebo|
537487|NCT00092209|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium|
537488|NCT00092209|Drug|Comparator: placebo, losartan, hydrochlorothiazide|
537489|NCT00092196|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
537490|NCT00092183|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
537491|NCT00092183|Drug|Comparator: ondansetron / Duration of Treatment: 3 days|
537492|NCT00092170|Drug|MK0826, ertapenem sodium|
537493|NCT00092170|Drug|Comparator: Ticarcillin/Clavulanate|
537494|NCT00092157|Drug|MK0733, simvastatin|
537495|NCT00092157|Drug|Comparator: simvastatin|
537496|NCT00092144|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
537497|NCT00092144|Drug|Comparator: placebo / Duration of Treatment: 4 weeks|
537498|NCT00092131|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
537499|NCT00092131|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
537500|NCT00092118|Drug|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
537501|NCT00092118|Drug|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
537502|NCT00092105|Drug|MK0476, montelukast sodium|
537503|NCT00092105|Drug|Comparator: placebo|
537504|NCT00092092|Drug|Montelukast chewable tablets|Montelukast sodium 5 mg chewable tablets
537505|NCT00092092|Drug|Budesonide inhaler|Budesonide 200 mcg inhalation powder
537506|NCT00092092|Drug|Placebo to montelukast chewable tablets|Placebo chewable tablets
537507|NCT00092092|Drug|Placebo to budesonide inhaler|Placebo inhalation powder
537508|NCT00092079|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
537509|NCT00092066|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
537510|NCT00092053|Drug|Placebo|tablets
537511|NCT00092053|Drug|ibandronate|50 mg tablets
537512|NCT00092040|Drug|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
537513|NCT00092040|Drug|Comparator: risedronate / Duration of Intervention: 12 mo|
537514|NCT00092027|Drug|MK0217, alendronate sodium/Duration of Treatment: 6 months|
537515|NCT00092027|Drug|Comparator: placebo / Duration of Treatment: 6 months|
537516|NCT00092014|Drug|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
537517|NCT00092014|Drug|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
537518|NCT00092014|Dietary Supplement|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
537736|NCT00091273|Biological|sargramostim|
537519|NCT00092014|Dietary Supplement|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
537520|NCT00092014|Drug|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
537521|NCT00092014|Drug|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
537522|NCT00091962|Behavioral|Psychoeducation; Treatment recommendations|Counseling program
537523|NCT00091962|Drug|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
537524|NCT00091962|Other|Usual Care|Physicians' Usual care
537525|NCT00092222|Drug|Etoposide|Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
537526|NCT00092222|Drug|Interferon-alpha|Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
537527|NCT00092222|Drug|Rituximab|Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
537528|NCT00092222|Drug|Zidovudine|Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
537529|NCT00092222|Drug|Liposomal Doxorubicin|21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
537530|NCT00092222|Drug|Bortezomib|1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
537531|NCT00092222|Drug|Valganciclovir|Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
537532|NCT00092222|Drug|Doxorubicin|10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
537533|NCT00092222|Drug|Vincristine|0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
537534|NCT00092222|Drug|Cyclophosphamide|Cyclophosphamide: if CD4 < 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 greater than or equal to 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
537535|NCT00092222|Drug|Filgrastim (G-CSF)|Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
537536|NCT00092222|Drug|Prednisone|Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
537537|NCT00092222|Drug|Sirolimus|Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
537538|NCT00092222|Other|Observation Only|Observation of symptoms
537539|NCT00091988|Behavioral|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
537540|NCT00091988|Behavioral|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
537541|NCT00091975|Drug|Zemplar Capsule|
537542|NCT00091949|Drug|pioglitazone|a thiazolidinedione drug
537543|NCT00091949|Drug|placebo|an inactive substance
537544|NCT00091923|Device|Eye patch|
537545|NCT00091923|Device|Spectacles|
537546|NCT00091936|Drug|Didanosine|
537547|NCT00091936|Drug|Efavirenz|
537548|NCT00091936|Drug|Lamivudine|
537549|NCT00091936|Drug|Standard TB treatment|
537550|NCT00091910|Drug|Epoetin alfa|
537551|NCT00091858|Drug|Darbepoetin Alfa|6.75 mcg/kg Q4W
537552|NCT00091858|Drug|Placebo|Placebo Q4W
537553|NCT00091845|Drug|AVI-4020 Injection|
537554|NCT00091832|Biological|Denosumab|Denosumab administered by subcutaneous injection
537555|NCT00091832|Drug|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
537556|NCT00091819|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
537557|NCT00091819|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
537558|NCT00091806|Drug|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
537559|NCT00091806|Drug|Panitumumab|9 mg/kg once every 3 weeks
537560|NCT00091793|Drug|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
537561|NCT00091793|Drug|Placebo|Placebo given at day 1, month 6, month 12 and month 18
537562|NCT00091897|Drug|Rituximab|
537563|NCT00091897|Drug|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
537564|NCT00091741|Drug|Etanercept (Enbrel)|
537565|NCT00091728|Drug|Depo Medroxyprogesterone acetate|
537566|NCT00091728|Drug|Combined oral contraceptives|
537567|NCT00091715|Drug|bosentan|65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
537568|NCT00091715|Drug|placebo|placebo for 6 months followed by an open-label period
537569|NCT00091702|Biological|Cold-adapted live attenuated influenza vaccine (FluMist)|
537570|NCT00091702|Biological|Inactivated influenza vaccine (IAIV)|
537571|NCT00091689|Drug|852A|
537572|NCT00091676|Biological|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
537573|NCT00091676|Biological|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
537574|NCT00091663|Drug|Tarceva (erlotinib HCl)|
537575|NCT00091637|Drug|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
537576|NCT00091637|Drug|Placebo infusion|bolus infusion over a 10 minute period once
537577|NCT00004905|Biological|filgrastim|
537578|NCT00004905|Biological|recombinant interferon alfa|
537579|NCT00004905|Drug|cyclophosphamide|
537580|NCT00004905|Drug|cytarabine|
537581|NCT00004905|Drug|etoposide|
537582|NCT00004905|Drug|idarubicin|
537583|NCT00004905|Procedure|peripheral blood stem cell transplantation|
537584|NCT00004905|Radiation|radiation therapy|
537585|NCT00004209|Drug|cisplatin|
537586|NCT00004209|Drug|mitomycin C|
537587|NCT00004209|Drug|vinblastine sulfate|
537588|NCT00004195|Drug|eniluracil|Will be given to either subject pre-operative and metastatic disease
537589|NCT00004195|Procedure|conventional colon surgery|Only if the subject is amenable to surgical resections
537590|NCT00004194|Drug|fludarabine phosphate|
537591|NCT00004184|Biological|monoclonal antibody 4B5 anti-idiotype vaccine|
537592|NCT00004184|Biological|sargramostim|
537593|NCT00004184|Drug|alum adjuvant|
537594|NCT00004172|Biological|filgrastim|
537595|NCT00004172|Drug|carboplatin|
537596|NCT00004172|Drug|cyclophosphamide|
537597|NCT00004172|Drug|ifosfamide|
537598|NCT00004172|Drug|thiotepa|
537599|NCT00004172|Procedure|peripheral blood stem cell transplantation|
537600|NCT00004172|Radiation|radiation therapy|
537601|NCT00091624|Drug|CC-5013|
537602|NCT00091598|Drug|Ambrisentan|
537603|NCT00091585|Drug|SNS-595|
537604|NCT00091572|Drug|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
537605|NCT00091572|Drug|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
537606|NCT00091559|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
537607|NCT00004089|Biological|filgrastim|
537608|NCT00004089|Drug|fluorouracil|
537609|NCT00004089|Drug|hydroxyurea|
537610|NCT00004089|Drug|paclitaxel|
537611|NCT00004089|Procedure|conventional surgery|
537612|NCT00004089|Radiation|radiation therapy|
537613|NCT00004083|Drug|cisplatin liposomal|
537614|NCT00004014|Drug|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
537615|NCT00003956|Drug|fluorouracil|
537616|NCT00003956|Drug|leucovorin calcium|
537617|NCT00003956|Drug|lonafarnib|
537618|NCT00003858|Drug|mitoxantrone hydrochloride|
537619|NCT00003842|Biological|interleukin-4 PE38KDEL cytotoxin|
537620|NCT00003842|Drug|isolated perfusion|
537621|NCT00003842|Procedure|surgical procedure|
537622|NCT00003780|Biological|tumor infiltrating lymphocyte therapy|
537623|NCT00003780|Drug|gemcitabine hydrochloride|
537624|NCT00003775|Drug|leflunomide|
537625|NCT00003714|Drug|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
537626|NCT00003711|Drug|irinotecan hydrochloride|
537627|NCT00003711|Drug|pemetrexed disodium|
537628|NCT00091611|Drug|IL-2 (interleukin-2)|
537629|NCT00091611|Drug|OKT3|
537630|NCT00091611|Drug|Cyclophosphamide|
537631|NCT00091611|Drug|Fludarabine|
537632|NCT00091611|Drug|Mesna|
537633|NCT00091507|Drug|GIK|Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
537634|NCT00091507|Drug|Placebo|Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
537635|NCT00091481|Drug|Zemplar|
537636|NCT00091442|Drug|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
537637|NCT00091442|Drug|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
537638|NCT00004057|Drug|L-778,123|
537639|NCT00004057|Drug|paclitaxel|
537640|NCT00004036|Biological|sargramostim|
537641|NCT00004036|Drug|amifostine trihydrate|
537642|NCT00004036|Drug|carboplatin|
537643|NCT00004036|Drug|cyclophosphamide|
537644|NCT00004022|Biological|aldesleukin|
537645|NCT00004022|Biological|autologous tumor cell vaccine|
537646|NCT00004022|Biological|muromonab-CD3|
537647|NCT00004022|Biological|therapeutic autologous lymphocytes|
537648|NCT00004022|Procedure|surgical procedure|
537649|NCT00003673|Drug|chemotherapy|
537650|NCT00003673|Drug|gemtuzumab ozogamicin|
537651|NCT00003671|Drug|asparaginase|
537652|NCT00003671|Drug|cyclophosphamide|
537653|NCT00003671|Drug|cytarabine|
537654|NCT00003671|Drug|daunorubicin hydrochloride|
537655|NCT00003671|Drug|dexamethasone|
537656|NCT00003671|Drug|leucovorin calcium|
537657|NCT00003671|Drug|mercaptopurine|
537658|NCT00003671|Drug|methotrexate|
537659|NCT00003671|Drug|thioguanine|
537660|NCT00003671|Drug|vincristine sulfate|
537661|NCT00003666|Drug|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
537662|NCT00003634|Biological|oregovomab|
537663|NCT00003625|Drug|cyclosporine|
537664|NCT00003625|Drug|etoposide|
537665|NCT00003625|Drug|vincristine sulfate|
537666|NCT00003625|Radiation|radiation therapy|
537667|NCT00003599|Dietary Supplement|Vitamin E (AT)|Orally daily
537668|NCT00003599|Drug|Isotretinoin|Orally daily
537669|NCT00003591|Drug|paclitaxel|
537670|NCT00003591|Radiation|radiation therapy|
537671|NCT00003587|Drug|carboplatin|AUC=5.5 day 1 every 21 days X 3
537672|NCT00003587|Drug|cisplatin|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3
537673|NCT00003587|Drug|docetaxel|IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
537674|NCT00003587|Drug|gemcitabine|IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3
537675|NCT00003587|Drug|paclitaxel|IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
537676|NCT00003587|Drug|vinorelbine|IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3
537677|NCT00003564|Drug|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
537678|NCT00003564|Drug|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.~Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
537679|NCT00003551|Drug|aminocamptothecin colloidal dispersion|
537680|NCT00003546|Drug|gemcitabine hydrochloride|given IV
537681|NCT00003546|Radiation|radiation therapy|1.8 Gy to tumor bed
537682|NCT00003451|Biological|recombinant interferon alfa|
537683|NCT00003451|Biological|recombinant interleukin-12|
537684|NCT00003441|Drug|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
537685|NCT00003430|Drug|L-778,123|
537686|NCT00003428|Drug|arzoxifene hydrochloride|
537687|NCT00003353|Biological|filgrastim|
537688|NCT00003353|Drug|melphalan|
537689|NCT00003353|Procedure|bone marrow ablation with stem cell support|
537690|NCT00003353|Procedure|peripheral blood stem cell transplantation|
537691|NCT00003344|Drug|irinotecan hydrochloride|
537692|NCT00003344|Radiation|radiation therapy|
537693|NCT00003339|Biological|gp100 antigen|
537694|NCT00003339|Biological|incomplete Freund's adjuvant|
537695|NCT00003339|Biological|recombinant interleukin-12|
537696|NCT00003339|Biological|tyrosinase peptide|
537697|NCT00003331|Drug|fluorouracil|
537698|NCT00003331|Drug|leucovorin calcium|
537699|NCT00003331|Drug|topotecan hydrochloride|
537700|NCT00003288|Biological|filgrastim|
537701|NCT00003288|Drug|cyclophosphamide|
537702|NCT00003288|Drug|tirapazamine|
537703|NCT00003263|Biological|recombinant interferon alfa|vaccine
537704|NCT00003263|Drug|cisplatin|
537705|NCT00003263|Procedure|surgical procedure|
537706|NCT00003263|Radiation|radiation therapy|
537707|NCT00091429|Drug|Ranolazine|
537708|NCT00003257|Biological|Ad5CMV-p53 gene|
537709|NCT00003252|Drug|amifostine trihydrate|
537710|NCT00003248|Biological|rituximab|
537711|NCT00003248|Drug|fludarabine phosphate|
537712|NCT00003241|Drug|phenylacetate|
537713|NCT00003223|Drug|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
537714|NCT00091416|Biological|VRC-HIVADV014-00-VP|
537715|NCT00091390|Radiation|HDR brachytherapy boost|Brachytherapy could be performed before or after the external beam radiotherapy. The overall treatment course (external beam radiotherapy and brachytherapy) was limited to no longer than 8 weeks. 19 Gy in two fractions was to be given only to the clinical target volume (CTV). The first HDR treatment was to be delivered on the day of the catheter placement. The second treatment was to be delivered within 24 hours after the first treatment, but no less than 6 hours between implants.
537716|NCT00091390|Radiation|radiation therapy|1.8 Gy given five times per week for a total dose of 45 Gy.
537717|NCT00091377|Drug|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
537718|NCT00091377|Drug|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
537719|NCT00091377|Drug|phenoxodiol|IV 3 mg/kg
537720|NCT00091351|Procedure|conventional surgery|
537721|NCT00091351|Radiation|radiation therapy|
537722|NCT00091338|Biological|MART-1 antigen|
537723|NCT00091338|Biological|gp100 antigen|
537724|NCT00091338|Biological|incomplete Freund's adjuvant|
537725|NCT00091338|Biological|recombinant interleukin-7|
537726|NCT00091325|Dietary Supplement|defined green tea catechin extract|
537727|NCT00091312|Drug|FOLFIRI regimen|
537728|NCT00091312|Drug|fluorouracil|
537729|NCT00091312|Drug|irinotecan hydrochloride|
537730|NCT00091312|Drug|leucovorin calcium|
537731|NCT00091312|Procedure|adjuvant therapy|
537732|NCT00091299|Drug|warfarin|
537733|NCT00091286|Biological|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
537734|NCT00091273|Biological|incomplete Freund's adjuvant|
537735|NCT00091273|Biological|ovarian cancer peptide vaccine|
537737|NCT00091273|Biological|tetanus toxoid helper peptide|
537738|NCT00091273|Procedure|adjuvant therapy|
537739|NCT00091260|Drug|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
537740|NCT00091260|Drug|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
537741|NCT00091247|Drug|tetracycline hydrochloride|
537742|NCT00091247|Other|placebo|
537743|NCT00091234|Drug|gemtuzumab ozogamicin|
537744|NCT00091195|Drug|romidepsin|
537745|NCT00091182|Drug|oxaliplatin|Given IV
537746|NCT00091169|Dietary Supplement|levocarnitine|Given orally
537747|NCT00091169|Other|placebo|Given orally
537748|NCT00091156|Drug|gefitinib|
537749|NCT00091156|Procedure|adjuvant therapy|
537750|NCT00091143|Biological|gp100 antigen|
537751|NCT00091143|Biological|incomplete Freund's adjuvant|
537752|NCT00091143|Biological|keyhole limpet hemocyanin|
537753|NCT00091143|Drug|fludarabine phosphate|
537754|NCT00091143|Procedure|peripheral blood stem cell transplantation|
537755|NCT00091130|Biological|HspE7|Given SC
537756|NCT00091130|Other|placebo|Given SC
537757|NCT00091130|Other|laboratory biomarker analysis|Correlative studies
537758|NCT00091117|Drug|bortezomib|Given IV
537759|NCT00091117|Other|pharmacological study|Correlative studies
537760|NCT00091104|Biological|MART-1:27-35 peptide vaccine|
537761|NCT00091104|Biological|aldesleukin|
537762|NCT00091104|Biological|filgrastim|
537763|NCT00091104|Biological|incomplete Freund's adjuvant|
537764|NCT00091104|Biological|therapeutic autologous lymphocytes|
537765|NCT00091104|Biological|therapeutic tumor infiltrating lymphocytes|
537766|NCT00091104|Drug|cyclophosphamide|
537767|NCT00091104|Drug|fludarabine phosphate|
537768|NCT00091104|Procedure|autologous hematopoietic stem cell transplantation|
537769|NCT00091104|Procedure|in vitro-treated peripheral blood stem cell transplantation|
537770|NCT00091104|Radiation|total-body irradiation|
537771|NCT00091091|Other|medical chart review|
537772|NCT00091091|Other|questionnaire administration|
537773|NCT00091091|Procedure|management of therapy complications|
537774|NCT00091078|Biological|oblimersen sodium|Given IV
537775|NCT00091078|Drug|imatinib mesylate|Given orally
537776|NCT00091078|Other|laboratory biomarker analysis|Correlative studies
537777|NCT00091052|Biological|sargramostim|
537778|NCT00091052|Radiation|radiation therapy|
537779|NCT00091039|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|
537780|NCT00091039|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
537781|NCT00091039|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
537782|NCT00091039|Drug|carboplatin|
537783|NCT00091039|Drug|paclitaxel|
537784|NCT00091039|Radiation|radiation therapy|
537785|NCT00091026|Biological|cetuximab|Given IV
537786|NCT00091026|Drug|gemcitabine hydrochloride|Given IV
537787|NCT00091026|Biological|bevacizumab|Given IV
537788|NCT00091026|Drug|erlotinib hydrochloride|Given orally
537789|NCT00090987|Drug|imatinib mesylate|400 mg orally once a day for up to 6 months.
537790|NCT00090974|Procedure|quality-of-life assessment|
537791|NCT00090961|Other|educational intervention|
537792|NCT00090961|Other|supervised exercise program|
537793|NCT00090909|Drug|cisplatin|
537794|NCT00090909|Drug|dexamethasone|
537795|NCT00090909|Drug|gemcitabine hydrochloride|
537796|NCT00090896|Biological|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
537797|NCT00090870|Biological|PEG-interferon alfa-2b|Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.
537798|NCT00090870|Biological|GM-CSF|GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle
537799|NCT00090870|Drug|thalidomide|200mg daily by mouth
537800|NCT00090857|Drug|Letrozole|
537801|NCT00090857|Other|Placebo|
537802|NCT00090844|Drug|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
537803|NCT00090779|Drug|Emtricitabine/ tenofovir disoproxil fumarate|once daily
537804|NCT00090779|Drug|Lopinavir/Ritonavir|twice daily
537805|NCT00090766|Drug|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
537806|NCT00090753|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
537807|NCT00090753|Drug|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
537808|NCT00090753|Drug|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
537809|NCT00090753|Drug|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
537810|NCT00090727|Drug|AQ4N|
537811|NCT00090714|Genetic|pVGI.1(VEGF2)|
537812|NCT00090701|Drug|AG2037|
537813|NCT00003217|Biological|filgrastim|
537814|NCT00003217|Drug|cyclophosphamide|
537815|NCT00003217|Drug|cytarabine|
537816|NCT00003217|Drug|dexamethasone|
537817|NCT00003217|Drug|doxorubicin hydrochloride|
537818|NCT00003217|Drug|methotrexate|
537819|NCT00003217|Drug|vincristine sulfate|
537820|NCT00003172|Biological|filgrastim|
537821|NCT00003172|Biological|recombinant interferon alfa|
537823|NCT00003172|Drug|doxorubicin hydrochloride|
537824|NCT00003172|Drug|fluorouracil|
537825|NCT00003172|Drug|hydroxyurea|
537826|NCT00003170|Dietary Supplement|glutamine|
537827|NCT00003170|Other|placebo|
537828|NCT00003139|Drug|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
537829|NCT00003139|Other|Placebo|
537830|NCT00003134|Drug|irinotecan hydrochloride|
537831|NCT00003100|Dietary Supplement|soy isoflavones|
537832|NCT00003088|Drug|cyclophosphamide|given IV
537833|NCT00003088|Drug|doxorubicin hydrochloride|given IV
537834|NCT00003088|Drug|paclitaxel|given IV
537835|NCT00003072|Drug|amifostine trihydrate|
537836|NCT00003072|Drug|carboplatin|
537837|NCT00003072|Drug|paclitaxel|
537838|NCT00003048|Drug|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
537839|NCT00003039|Drug|alvocidib|
537840|NCT00090688|Biological|meCS6 + LT(R192G)|
537841|NCT00090675|Drug|ZD1839|
537842|NCT00003005|Drug|Cordycepin|"Dose escalation study using the following doses:~6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
537843|NCT00003005|Drug|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
537844|NCT00002993|Drug|cisplatin|
537845|NCT00002993|Drug|doxorubicin hydrochloride|
537846|NCT00002993|Drug|mitomycin C|
537847|NCT00002980|Drug|decitabine|
537848|NCT00002967|Drug|cyclophosphamide|
537849|NCT00002967|Drug|doxorubicin hydrochloride|
537850|NCT00002967|Drug|octreotide pamoate|
537851|NCT00002967|Drug|tamoxifen citrate|
537852|NCT00002946|Drug|penclomedine|
537853|NCT00002942|Procedure|autologous bone marrow transplantation|
537854|NCT00002942|Procedure|peripheral blood stem cell transplantation|
537855|NCT00002937|Drug|paclitaxel|
537856|NCT00002937|Drug|valspodar|
537857|NCT00002932|Drug|cisplatin|
537858|NCT00002932|Radiation|radiation therapy|
537859|NCT00002904|Drug|trabectedin|
537860|NCT00002897|Drug|cisplatin|
537861|NCT00002897|Drug|fluorouracil|
537862|NCT00002897|Procedure|conventional surgery|
537863|NCT00002873|Radiation|brachytherapy|
537864|NCT00002872|Biological|bleomycin sulfate|
537865|NCT00002872|Drug|doxycycline|
537866|NCT00002872|Other|talc|
537867|NCT00002811|Drug|liposomal T4N5 lotion|
537868|NCT00002805|Biological|filgrastim|
537869|NCT00002805|Drug|cladribine|
537870|NCT00002805|Drug|cytarabine|
537871|NCT00002805|Drug|etoposide|
537872|NCT00002805|Drug|methotrexate|
537873|NCT00002805|Drug|mitoxantrone hydrochloride|
537874|NCT00002805|Drug|therapeutic hydrocortisone|
537875|NCT00002805|Procedure|allogeneic bone marrow transplantation|
537876|NCT00002805|Procedure|autologous bone marrow transplantation|
537877|NCT00002805|Procedure|peripheral blood stem cell transplantation|
537878|NCT00002805|Radiation|low-LET cobalt-60 gamma ray therapy|
537879|NCT00002805|Radiation|low-LET electron therapy|
537880|NCT00002805|Radiation|low-LET photon therapy|
537881|NCT00002793|Drug|fluorouracil|
537882|NCT00002793|Drug|leucovorin calcium|
537883|NCT00002791|Biological|filgrastim|
537884|NCT00002791|Drug|dacarbazine|
537885|NCT00002791|Drug|doxorubicin hydrochloride|
537886|NCT00002791|Drug|ifosfamide|
537887|NCT00002791|Drug|mesna|
537888|NCT00002791|Procedure|conventional surgery|
537889|NCT00002791|Radiation|brachytherapy|
537890|NCT00002791|Radiation|intraoperative radiation therapy|
537891|NCT00002791|Radiation|radioisotope therapy|
537892|NCT00002790|Drug|cyclosporine|
537893|NCT00002790|Drug|methotrexate|
537894|NCT00002790|Drug|sirolimus|
537895|NCT00002781|Drug|boronophenylalanine-fructose complex|
537896|NCT00002775|Drug|docetaxel|
537897|NCT00002775|Drug|estramustine phosphate sodium|
537898|NCT00002767|Biological|Detox-B adjuvant|
537899|NCT00002767|Biological|recombinant interferon alfa|
537900|NCT00090649|Drug|DVS-233 SR|
537901|NCT00090623|Drug|rhuFab V2 (ranibizumab)|
537902|NCT00002744|Drug|asparaginase|
537903|NCT00002744|Drug|cyclophosphamide|
537904|NCT00002744|Drug|cytarabine|
537905|NCT00002744|Drug|daunorubicin hydrochloride|
537906|NCT00002744|Drug|dexamethasone|
537907|NCT00002744|Drug|doxorubicin hydrochloride|
537908|NCT00002744|Drug|mercaptopurine|
537909|NCT00002744|Drug|methotrexate|
537910|NCT00002744|Drug|pegaspargase|
537911|NCT00002744|Drug|prednisone|
537912|NCT00002744|Drug|therapeutic hydrocortisone|
537913|NCT00002744|Drug|thioguanine|
537914|NCT00002744|Drug|vincristine sulfate|
537915|NCT00002744|Radiation|low-LET cobalt-60 gamma ray therapy|
537916|NCT00002744|Radiation|low-LET photon therapy|
537917|NCT00002735|Drug|Induction chemotherapy|Cisplatin and 5-Fluorouracil
537918|NCT00002735|Drug|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
537919|NCT00002735|Drug|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
537920|NCT00002735|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
537921|NCT00002730|Drug|buthionine sulfoximine|
537922|NCT00002730|Drug|melphalan|
537923|NCT00002703|Radiation|high-LET heavy ion therapy|
537924|NCT00002703|Radiation|low-LET photon therapy|
538008|NCT00002471|Drug|daunorubicin hydrochloride|
538009|NCT00002471|Drug|dexamethasone|
537925|NCT00090610|Drug|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
537926|NCT00090610|Drug|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
537927|NCT00090584|Drug|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
537928|NCT00090584|Behavioral|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
537929|NCT00090532|Drug|AG-013,958|
537930|NCT00090519|Drug|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
537931|NCT00090519|Drug|placebo|QD oral for up to 36 months
537932|NCT00090493|Biological|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
537933|NCT00090493|Biological|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
537934|NCT00090480|Biological|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
537935|NCT00002659|Drug|cisplatin-e therapeutic implant|
537936|NCT00002631|Drug|chemotherapy|
537937|NCT00002631|Drug|cisplatin|
537938|NCT00002631|Drug|fluorouracil|
537939|NCT00002631|Radiation|low-LET electron therapy|
537940|NCT00002631|Radiation|low-LET photon therapy|
537941|NCT00002628|Biological|filgrastim|
537942|NCT00002628|Drug|carboplatin|
537943|NCT00002628|Drug|cyclophosphamide|
537944|NCT00002628|Drug|mesna|
537945|NCT00002628|Drug|paclitaxel|
537946|NCT00002628|Procedure|peripheral blood stem cell transplantation|
537947|NCT00002622|Drug|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
537948|NCT00002622|Drug|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
537949|NCT00002616|Biological|aldesleukin|
537950|NCT00002616|Biological|filgrastim|
537951|NCT00002616|Drug|carboplatin|
537952|NCT00002616|Drug|cyclophosphamide|
537953|NCT00002616|Drug|thiotepa|
537954|NCT00002616|Procedure|peripheral blood stem cell transplantation|
537955|NCT00002593|Drug|fluorouracil|Given IV as described in Arm Description
537956|NCT00002593|Drug|leucovorin calcium|Given IV as described in Arm description.
537957|NCT00002593|Drug|levamisole hydrochloride|Given as described in arm description
537958|NCT00002570|Drug|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
537959|NCT00002570|Drug|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
537960|NCT00002554|Drug|busulfan|
537961|NCT00002554|Drug|cyclophosphamide|
537962|NCT00002554|Drug|methotrexate|
537963|NCT00002554|Procedure|allogeneic bone marrow transplantation|
537964|NCT00002554|Radiation|radioimmunotherapy|
537965|NCT00002527|Drug|aspirin|
537966|NCT00002527|Other|placebo|
537967|NCT00002509|Biological|filgrastim|
537968|NCT00002509|Drug|carboplatin|
537969|NCT00002509|Drug|cyclophosphamide|
537970|NCT00002509|Drug|etoposide|
537971|NCT00002509|Drug|mesna|
537972|NCT00002509|Procedure|autologous bone marrow transplantation|
537973|NCT00002509|Procedure|peripheral blood stem cell transplantation|
537974|NCT00090376|Drug|GPI 1485|
537975|NCT00090363|Drug|ZD4054 15 mg|15 mg oral tablet once daily
537976|NCT00090363|Drug|Placebo|
537977|NCT00090363|Drug|ZD4054 10 mg|10mg oral tablet once daily
537978|NCT00090324|Drug|quetiapine fumarate tablets|
537979|NCT00090311|Drug|quetiapine fumarate|
537980|NCT00090298|Drug|MK0653A, ezetimibe (+) simvastatin|
537981|NCT00090298|Drug|Comparator: Rosuvastatin|
537982|NCT00004915|Drug|raloxifene|
537983|NCT00004201|Drug|carboplatin|
537984|NCT00004201|Drug|cisplatin|
537985|NCT00004201|Drug|gemcitabine hydrochloride|
537986|NCT00004090|Drug|cisplatin|
537987|NCT00004090|Drug|gemcitabine hydrochloride|
537988|NCT00004029|Biological|recombinant viral vaccine therapy|
537989|NCT00004029|Biological|sargramostim|
537990|NCT00002489|Biological|dactinomycin|
537991|NCT00002489|Biological|filgrastim|
537992|NCT00002489|Drug|carboplatin|
537993|NCT00002489|Drug|cyclophosphamide|
537994|NCT00002489|Drug|doxorubicin hydrochloride|
537995|NCT00002489|Drug|etoposide|
537996|NCT00002489|Drug|leucovorin calcium|
537997|NCT00002489|Drug|methotrexate|
537998|NCT00002489|Drug|vincristine sulfate|
537999|NCT00002489|Procedure|conventional surgery|
538000|NCT00002488|Drug|cisplatin|
538001|NCT00002488|Drug|cyclophosphamide|
538002|NCT00002488|Drug|etoposide|
538003|NCT00002487|Drug|dipyridamole|
538004|NCT00002487|Drug|methotrexate|
538005|NCT00002471|Drug|asparaginase|
538006|NCT00002471|Drug|cyclophosphamide|
538007|NCT00002471|Drug|cytarabine|
538014|NCT00002471|Drug|therapeutic hydrocortisone|
538015|NCT00002471|Drug|thiotepa|
538016|NCT00002471|Drug|vincristine sulfate|
538017|NCT00002458|Biological|monoclonal antibody 3F8|
538018|NCT00090558|Drug|nitroglycerin|
538019|NCT00090545|Drug|BAY 43-9006|400 mg BAY 43-9006 orally twice daily in 28 day cycles.
538020|NCT00090506|Behavioral|Yoga|
538021|NCT00090428|Behavioral|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
538022|NCT00090428|Behavioral|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
538023|NCT00090415|Behavioral|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
538024|NCT00090285|Biological|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
538025|NCT00090285|Biological|Comparator: placebo (unspecified)|0.5 mL intramuscular injection in the deltoid muscle at Day 1, Month 2, and Month 6 in the Base Study
538026|NCT00090272|Drug|MK0826, ertapenem sodium|
538027|NCT00090272|Drug|Comparator: cefotetan|
538028|NCT00090259|Drug|Losartan 50 mg|50-mg losartan oral tablet
538029|NCT00090259|Drug|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
538030|NCT00090246|Drug|MK0869, aprepitant|
538031|NCT00090246|Drug|Comparator: ondansetron IV|
538032|NCT00090233|Biological|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
538033|NCT00090233|Biological|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
538034|NCT00090220|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
538035|NCT00090220|Biological|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
538036|NCT00090207|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
538037|NCT00090207|Drug|Comparator: ondansetron / Duration of Treatment: 4 days|
538038|NCT00090181|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
538039|NCT00090181|Drug|Comparator: diclofenac / Duration of Treatment: 4 weeks|
538040|NCT00090168|Drug|MK0653A , ezetimibe (+) simvastatin|
538041|NCT00090168|Drug|Comparator: atorvastatin|
538042|NCT00090168|Drug|Duration of Treatment: 6 weeks|
538043|NCT00090155|Drug|MK0869, aprepitant|
538044|NCT00090155|Drug|Comparator: ondansetron IV|
538045|NCT00004026|Drug|CT-2584|
538046|NCT00004026|Drug|chemotherapy|
538047|NCT00004009|Drug|tipifarnib|
538048|NCT00003989|Biological|ISIS 3521|
538049|NCT00003962|Biological|aldesleukin|
538050|NCT00003778|Drug|dolastatin 10|
538051|NCT00090402|Dietary Supplement|Fish Oil|Fish oil capsule
538052|NCT00090402|Dietary Supplement|Lipoic Acid|Lipoic acid capsule
538053|NCT00090402|Other|Fish Oil Placebo|Soybean oil placebo capsule
538054|NCT00090402|Other|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
538055|NCT00090389|Procedure|Chinese Acupuncture|
538056|NCT00090337|Procedure|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
538057|NCT00090337|Procedure|standard follow-up care|Patients undergo standard care
538058|NCT00090194|Biological|Immune Globulin Intravenous (Human), 10%|
538059|NCT00090142|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
538060|NCT00090142|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
538061|NCT00090129|Drug|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
538062|NCT00090129|Drug|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
538063|NCT00090116|Drug|Neramexane|
538064|NCT00090103|Drug|dutasteride 0.5mg once daily for 4 years|combination or single agent
538065|NCT00090103|Drug|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
538066|NCT00090077|Drug|GW695634|
538067|NCT00003654|Drug|patent blue V dye|
538068|NCT00003654|Procedure|lymphangiography|
538069|NCT00003654|Procedure|radionuclide imaging|
538070|NCT00003654|Procedure|sentinel lymph node biopsy|
538071|NCT00003654|Radiation|technetium Tc 99m sulfur colloid|
538072|NCT00003601|Drug|fenretinide|
538073|NCT00003601|Drug|tretinoin|
538074|NCT00003588|Biological|Ad5CMV-p53 gene|
538075|NCT00003588|Procedure|laparoscopic surgery|
538076|NCT00003519|Drug|cyclophosphamide|
538077|NCT00003519|Drug|docetaxel|
538078|NCT00003519|Drug|doxorubicin hydrochloride|
538082|NCT00003406|Procedure|autologous bone marrow transplantation|
538083|NCT00003406|Procedure|bone marrow ablation with stem cell support|
538084|NCT00003406|Procedure|peripheral blood stem cell transplantation|
538085|NCT00003390|Drug|irofulven|
538086|NCT00003378|Drug|carboplatin|
538087|NCT00003378|Drug|gemcitabine hydrochloride|
538088|NCT00003378|Drug|paclitaxel|
538089|NCT00003362|Biological|QS21|
538090|NCT00003362|Biological|gp100 antigen|
538091|NCT00003362|Biological|incomplete Freund's adjuvant|
538092|NCT00003362|Biological|sargramostim|
538093|NCT00003362|Biological|tyrosinase peptide|
538094|NCT00003315|Biological|sargramostim|
538095|NCT00003315|Drug|liposomal amphotericin B|
538096|NCT00003304|Drug|temozolomide|
538097|NCT00090090|Drug|Elsamitrucin|
538098|NCT00090064|Drug|3,4-methylenedioxymethamphetamine (MDMA)|125 mg and 62.5 mg MDMA
538099|NCT00090064|Drug|lactose (placebo|two capsules placebo matched in weight with MDMA capsules
538100|NCT00090064|Behavioral|Psychotherapy|Psychotherapy provided by a team of two co-therapists
538101|NCT00090051|Drug|Rituximab|Intravenous repeating dose
538102|NCT00090051|Drug|Fludarabine Phosphate|Intravenous repeating dose
538103|NCT00090051|Drug|Cyclophosphamide|Intravenous repeating dose
538104|NCT00003279|Biological|BCG vaccine|
538105|NCT00003279|Biological|monoclonal antibody BEC2|
538106|NCT00003260|Drug|FOLFIRI regimen|
538107|NCT00003260|Drug|FOLFOX regimen|
538108|NCT00003260|Drug|fluorouracil|
538109|NCT00003260|Drug|irinotecan hydrochloride|
538110|NCT00003260|Drug|leucovorin calcium|
538111|NCT00003260|Drug|oxaliplatin|
538112|NCT00003237|Drug|cisplatin|
538113|NCT00003237|Drug|paclitaxel|
538114|NCT00003237|Procedure|surgical procedure|
538115|NCT00003229|Biological|aldesleukin|
538116|NCT00003229|Biological|gp100 antigen|
538117|NCT00003229|Biological|tyrosinase peptide|
538118|NCT00003224|Biological|QS21|vaccine adjuvant
538119|NCT00003224|Biological|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
538120|NCT00003224|Biological|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
538121|NCT00003224|Biological|p946/tet-p|This peptide is a longer version of p946 (gp100 [280-288]) sythesized colinearly with the tetanus helper peptide (Tet-p)
538122|NCT00003224|Biological|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
538123|NCT00090038|Drug|rituximab|Dose, schedule,and duration specified in protocol
538124|NCT00003151|Dietary Supplement|bismuth subcitrate|
538125|NCT00003151|Drug|amoxicillin|
538126|NCT00003151|Drug|clarithromycin|
538127|NCT00003151|Drug|metronidazole hydrochloride|
538128|NCT00003151|Drug|omeprazole|
538129|NCT00003151|Drug|tetracycline hydrochloride|
538130|NCT00003147|Biological|Ad5CMV-p53 gene|
538131|NCT00003136|Biological|filgrastim|
538132|NCT00003136|Drug|amifostine trihydrate|
538133|NCT00003136|Drug|carboplatin|
538134|NCT00003136|Drug|cyclophosphamide|
538135|NCT00003136|Procedure|peripheral blood stem cell transplantation|
538136|NCT00003131|Drug|chemotherapy|
538137|NCT00003131|Drug|gemtuzumab ozogamicin|
538138|NCT00002969|Drug|paclitaxel|
538139|NCT00002960|Biological|recombinant adenovirus-p53 SCH-58500|
538140|NCT00002888|Drug|cisplatin|
538141|NCT00002888|Drug|fluorouracil|
538142|NCT00002888|Drug|paclitaxel|
538143|NCT00002881|Drug|flutamide|
538144|NCT00002881|Drug|goserelin acetate|
538145|NCT00002881|Drug|leuprolide acetate|
538146|NCT00002881|Drug|suramin|
538147|NCT00002881|Drug|therapeutic hydrocortisone|
538148|NCT00002881|Procedure|orchiectomy|
538149|NCT00002879|Drug|cladribine|
538150|NCT00002845|Biological|aldesleukin|
538151|NCT00002783|Drug|cisplatin|
538152|NCT00002783|Drug|floxuridine|
538153|NCT00002783|Drug|fluorouracil|
538154|NCT00002783|Drug|leucovorin calcium|
538155|NCT00002783|Procedure|conventional surgery|
538156|NCT00002755|Biological|filgrastim|
538157|NCT00002755|Drug|CMF regimen|
538158|NCT00002755|Drug|cyclophosphamide|
538159|NCT00002755|Drug|doxorubicin hydrochloride|
538160|NCT00002755|Drug|fluorouracil|
538161|NCT00002755|Drug|methotrexate|
538162|NCT00002755|Drug|tamoxifen citrate|
538163|NCT00002755|Drug|thiotepa|
538164|NCT00002755|Procedure|autologous bone marrow transplantation|
538165|NCT00002755|Procedure|peripheral blood stem cell transplantation|
538166|NCT00002755|Radiation|low-LET cobalt-60 gamma ray therapy|
538167|NCT00002755|Radiation|low-LET electron therapy|
538168|NCT00002755|Radiation|low-LET photon therapy|
538169|NCT00002742|Drug|amphotericin B deoxycholate|
538170|NCT00002742|Drug|nystatin|
538171|NCT00002711|Drug|chemotherapy|
538172|NCT00002711|Drug|cisplatin|
538173|NCT00002711|Drug|paclitaxel|
538174|NCT00002711|Radiation|low-LET electron therapy|
538175|NCT00002711|Radiation|low-LET photon therapy|
538176|NCT00090025|Drug|becatecarin|Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
538177|NCT00090025|Drug|5-Fluorouracil Plus Leucovorin|5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
538178|NCT00090012|Drug|Olanzapine|
538179|NCT00090012|Drug|Quetiapine|
538180|NCT00089999|Drug|Lapatinib|
538181|NCT00089986|Drug|Intravenous GR270773- Phospholipid Emulsion|
538182|NCT00089986|Other|Placebo|
538183|NCT00005024|Drug|carboplatin|
538184|NCT00005024|Drug|cyclophosphamide|
538185|NCT00005024|Drug|doxorubicin hydrochloride|
538186|NCT00005024|Drug|granisetron hydrochloride|
538187|NCT00004906|Biological|filgrastim|
538188|NCT00004906|Drug|anastrozole|
538189|NCT00004906|Drug|carboplatin|
538190|NCT00004906|Drug|cisplatin|
538191|NCT00004906|Drug|cyclophosphamide|
538192|NCT00004906|Drug|docetaxel|
538193|NCT00004906|Drug|doxorubicin hydrochloride|
538194|NCT00004906|Drug|etoposide|
538195|NCT00004906|Drug|pamidronate disodium|
538196|NCT00004906|Drug|thiotepa|
538197|NCT00004906|Procedure|peripheral blood stem cell transplantation|
538198|NCT00002674|Biological|filgrastim|
538199|NCT00002674|Drug|cytarabine|
538200|NCT00002674|Drug|etoposide|
538201|NCT00002674|Drug|hydroxyurea|
538202|NCT00002674|Drug|mitoxantrone hydrochloride|
538203|NCT00002674|Procedure|peripheral blood stem cell transplantation|
538204|NCT00002634|Biological|filgrastim|
538205|NCT00002634|Biological|monoclonal antibody 3F8|
538206|NCT00002634|Drug|cisplatin|
538207|NCT00002634|Drug|cyclophosphamide|
538208|NCT00002634|Drug|doxorubicin hydrochloride|
538209|NCT00002634|Drug|etoposide|
538210|NCT00002634|Drug|mesna|
538211|NCT00002634|Drug|perfosfamide|
538212|NCT00002634|Drug|vincristine sulfate|
538213|NCT00002634|Procedure|autologous bone marrow transplantation|
538214|NCT00002634|Procedure|in vitro-treated bone marrow transplantation|
538215|NCT00002634|Radiation|low-LET cobalt-60 gamma ray therapy|
538216|NCT00002634|Radiation|low-LET photon therapy|
538217|NCT00002634|Radiation|radioisotope therapy|
538218|NCT00002579|Drug|CMF regimen|
538219|NCT00002579|Drug|cyclophosphamide|
538220|NCT00002579|Drug|fluorouracil|
538221|NCT00002579|Drug|methotrexate|
538222|NCT00002579|Drug|tamoxifen citrate|
538223|NCT00002579|Procedure|conventional surgery|
538224|NCT00002579|Radiation|radiation therapy|
538225|NCT00002510|Biological|filgrastim|
538226|NCT00002510|Drug|cyclophosphamide|
538227|NCT00002510|Drug|etoposide|
538228|NCT00002510|Drug|mesna|
538229|NCT00002510|Procedure|peripheral blood stem cell transplantation|
538230|NCT00002510|Radiation|radiation therapy|
538231|NCT00002499|Drug|asparaginase|
538232|NCT00002499|Drug|cytarabine|
538233|NCT00002499|Drug|daunorubicin hydrochloride|
538234|NCT00002499|Drug|dexamethasone|
538235|NCT00002499|Drug|methotrexate|
538236|NCT00002499|Drug|prednisone|
538237|NCT00002499|Drug|vincristine sulfate|
538238|NCT00002499|Radiation|radiation therapy|
538239|NCT00002498|Drug|CMF regimen|
538240|NCT00002498|Drug|cyclophosphamide|
538241|NCT00002498|Drug|fluorouracil|
538242|NCT00002498|Drug|methotrexate|
538243|NCT00002498|Drug|mitoxantrone hydrochloride|
538244|NCT00002493|Drug|cisplatin|
538245|NCT00002493|Drug|doxorubicin hydrochloride|
538246|NCT00002493|Radiation|low-LET photon therapy|
538247|NCT00002479|Drug|tretinoin|
538248|NCT00089973|Drug|Ispinesib|Given intravenously at a dose of 18 milligram (mg)/ meter square (m^2).
538249|NCT00089960|Drug|AMG 706|AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
538250|NCT00089947|Drug|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
538251|NCT00089921|Drug|SCIO-469|60 mg capsule three times daily for 12 weeks
538252|NCT00089921|Drug|SCIO-469|30 mg capsule three times daily for 12 weeks
538253|NCT00089921|Drug|Placebo|2 capsules three times daily and one tablet daily
538254|NCT00089921|Drug|SCIO-469|100 mg tablet once daily for 12 weeks
538255|NCT00004900|Biological|filgrastim|
538256|NCT00004900|Drug|anastrozole|
538257|NCT00004900|Drug|carboplatin|
538258|NCT00004900|Drug|cisplatin|
538259|NCT00004900|Drug|cyclophosphamide|
538260|NCT00004900|Drug|etoposide|
538261|NCT00004900|Drug|thiotepa|
538262|NCT00004900|Procedure|peripheral blood stem cell transplantation|
538263|NCT00004900|Radiation|radiation therapy|
538264|NCT00004182|Drug|irinotecan hydrochloride|
538265|NCT00004136|Procedure|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
538266|NCT00004042|Biological|monoclonal antibody F19|
538267|NCT00004042|Radiation|iodine I 131 monoclonal antibody F19|
538268|NCT00003974|Biological|lung tumor associated antigen|
538269|NCT00003974|Drug|DetoxPC|
538270|NCT00003974|Drug|chemotherapy|
538271|NCT00003974|Drug|cyclophosphamide|
538272|NCT00089908|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
538273|NCT00089908|Biological|Placebo|Placebo for rDEN1delta30
538274|NCT00089895|Drug|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG [coronary artery bypass graft]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
538275|NCT00089895|Drug|Placebo|intravenous; delivery to match eptifibatide to maintain blind
538276|NCT00089882|Procedure|APOE Genetic susceptibility testing|
538277|NCT00089869|Drug|olanzapine|
538278|NCT00089869|Drug|atomoxetine|
538279|NCT00089869|Drug|placebo|
538280|NCT00089856|Biological|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
538281|NCT00089856|Drug|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
538282|NCT00003951|Drug|exatecan mesylate|
538283|NCT00003897|Biological|gp100 antigen|
538284|NCT00003897|Biological|sargramostim|
538285|NCT00003885|Drug|arsenic trioxide|
538286|NCT00003776|Biological|filgrastim|
538287|NCT00003776|Drug|cisplatin|
538288|NCT00003776|Drug|doxorubicin hydrochloride|
538289|NCT00003776|Drug|ifosfamide|
538290|NCT00003776|Drug|leucovorin calcium|
538291|NCT00003776|Drug|methotrexate|
538292|NCT00003776|Drug|trimetrexate glucuronate|
538293|NCT00003776|Procedure|surgical procedure|
538294|NCT00003751|Drug|penicillamine|
538295|NCT00003751|Radiation|radiation therapy|
538296|NCT00089843|Drug|Testosterone|Testosterone patch 150mcg daily
538297|NCT00089843|Drug|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
538298|NCT00089843|Drug|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
538299|NCT00089843|Drug|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
538300|NCT00089830|Drug|MSI-1256F (Squalamine Lactate)|
538301|NCT00089804|Drug|abetimus sodium (LJP 394) and/or placebo solution|300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
538302|NCT00089804|Drug|abetimus sodium (LJP 394)|900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
538303|NCT00089804|Drug|Phosphate-buffered saline|A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
538304|NCT00003709|Drug|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
538305|NCT00003686|Drug|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
538306|NCT00003686|Drug|Placebo|Placebo 5 mg po qid x 4 weeks
538307|NCT00003684|Drug|theophylline|
538308|NCT00003684|Procedure|quality-of-life assessment|
538309|NCT00003626|Drug|dolastatin 10|
538310|NCT00003556|Biological|ALVAC-hB7.1|
538311|NCT00003556|Biological|canarypox-hIL-12 melanoma vaccine|
538312|NCT00089791|Drug|placebo|Placebo administered by subcutaneous injection
538313|NCT00089791|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection
538314|NCT00089752|Device|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
538315|NCT00089752|Device|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
538316|NCT00003555|Drug|amifostine trihydrate|
538317|NCT00003555|Drug|paclitaxel|
538318|NCT00003543|Biological|monoclonal antibody A33|
538319|NCT00003543|Drug|carmustine|
538320|NCT00003543|Drug|fluorouracil|
538321|NCT00003543|Drug|streptozocin|
538322|NCT00003543|Drug|vincristine sulfate|
538323|NCT00003400|Biological|filgrastim|
538324|NCT00003400|Drug|carmustine|
538325|NCT00003400|Drug|cisplatin|
538326|NCT00003400|Drug|melphalan|
538327|NCT00003400|Drug|vinorelbine tartrate|
538328|NCT00003400|Procedure|peripheral blood stem cell transplantation|
538329|NCT00003395|Drug|arsenic trioxide|
538330|NCT00003380|Drug|etoposide|
538331|NCT00003380|Drug|pegylated liposomal doxorubicin hydrochloride|
538332|NCT00003360|Radiation|iodine I 131 monoclonal antibody A33|
538333|NCT00003357|Biological|GM2-KLH vaccine|
538334|NCT00003357|Biological|QS21|
538335|NCT00003348|Drug|O6-benzylguanine|
538336|NCT00003348|Drug|carmustine|
538337|NCT00003340|Drug|cyclophosphamide|
538338|NCT00003340|Drug|topotecan hydrochloride|
538339|NCT00003312|Radiation|iodine I 125|
538340|NCT00089778|Drug|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
538341|NCT00089778|Drug|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
538342|NCT00089778|Other|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
538343|NCT00089765|Drug|Ranibizumab|
538344|NCT00003294|Biological|filgrastim|
538345|NCT00003294|Drug|amifostine trihydrate|
538346|NCT00003294|Drug|carboplatin|
538347|NCT00003294|Drug|paclitaxel|
538348|NCT00003284|Biological|filgrastim|
538349|NCT00003284|Drug|carboplatin|
538350|NCT00003284|Drug|etoposide|
538351|NCT00003284|Drug|ifosfamide|
538352|NCT00003284|Drug|paclitaxel|
538353|NCT00003284|Procedure|peripheral blood stem cell transplantation|
538354|NCT00003284|Radiation|radiation therapy|
538355|NCT00003251|Drug|amifostine trihydrate|
538356|NCT00003251|Drug|cisplatin|
538357|NCT00003251|Drug|paclitaxel|
538358|NCT00003251|Radiation|radiation therapy|
538359|NCT00003220|Drug|bryostatin 1|
538360|NCT00003200|Drug|Taxotere|
538361|NCT00003200|Radiation|Radiation therapy|
538362|NCT00089726|Biological|CG8123|
538363|NCT00089726|Drug|Cyclophosphamide|
538364|NCT00089713|Drug|alagebrium chloride (ALT-711)|
538365|NCT00089700|Drug|TNX-355|
538366|NCT00003197|Dietary Supplement|green tea extract|
538367|NCT00003123|Drug|amifostine trihydrate|
538368|NCT00003115|Drug|hydromorphone hydrochloride|
538369|NCT00003102|Radiation|iodine I 131 chimeric monoclonal antibody G-250|
538370|NCT00003058|Drug|troglitazone|
538371|NCT00003044|Drug|cisplatin-e therapeutic implant|
538372|NCT00003025|Biological|vitespen|
538373|NCT00003003|Biological|sargramostim|
538374|NCT00003003|Drug|mitomycin C|
538375|NCT00003003|Drug|mitoxantrone hydrochloride|
538376|NCT00002955|Drug|fluorouracil|
538377|NCT00002955|Drug|leucovorin calcium|
538378|NCT00002955|Drug|trimetrexate glucuronate|
538379|NCT00002933|Drug|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
538380|NCT00089687|Drug|GBR 12909|
538381|NCT00089674|Drug|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
538382|NCT00089674|Drug|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
538383|NCT00089661|Drug|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
538384|NCT00089661|Drug|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
538385|NCT00089648|Drug|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
538386|NCT00089635|Drug|Panitumumab|Administered by intravenous infusion
538387|NCT00002914|Drug|piritrexim|
538388|NCT00002909|Drug|chemotherapy|
538389|NCT00002909|Drug|oral sodium phenylbutyrate|
538390|NCT00002890|Biological|lintuzumab|
538391|NCT00002865|Biological|filgrastim|
538392|NCT00002865|Drug|cyclophosphamide|
538393|NCT00002865|Drug|cytarabine|
538394|NCT00002865|Drug|dexamethasone|
538395|NCT00002865|Drug|doxorubicin hydrochloride|
538396|NCT00002865|Drug|etoposide|
538397|NCT00002865|Drug|ifosfamide|
538398|NCT00002865|Drug|leucovorin calcium|
538399|NCT00002865|Drug|mesna|
538400|NCT00002865|Drug|methotrexate|
538401|NCT00002865|Drug|therapeutic hydrocortisone|
538402|NCT00002865|Drug|vincristine sulfate|
538403|NCT00002865|Radiation|low-LET cobalt-60 gamma ray therapy|
538404|NCT00002865|Radiation|low-LET photon therapy|
538405|NCT00002749|Drug|carboplatin|
538406|NCT00002655|Procedure|cryosurgery|
538407|NCT00002635|Biological|filgrastim|
538408|NCT00002635|Drug|aminocamptothecin|
538409|NCT00002619|Biological|filgrastim|
538410|NCT00002619|Drug|carboplatin|
538411|NCT00002619|Drug|thiotepa|
538412|NCT00002619|Procedure|autologous bone marrow transplantation|
538413|NCT00002619|Procedure|peripheral blood stem cell transplantation|
538414|NCT00002609|Biological|lintuzumab|
538415|NCT00002609|Drug|cytarabine|
538416|NCT00002609|Drug|idarubicin|
538417|NCT00002585|Drug|pyrazoloacridine|
538418|NCT00089596|Procedure|Expansion of umbilical cord stem cells|
538419|NCT00089583|Drug|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
538420|NCT00089583|Drug|Ritonavir|Ritonavir solution bid
538421|NCT00005626|Drug|Irinotecan|Irinotecan as outlined in treatment arm
538422|NCT00005607|Drug|FOLFIRI regimen|
538423|NCT00005607|Drug|fluorouracil|
538424|NCT00005607|Drug|irinotecan hydrochloride|
538425|NCT00005607|Drug|leucovorin calcium|
538426|NCT00002574|Biological|recombinant interferon alfa|
538427|NCT00002574|Drug|omacetaxine mepesuccinate|
538428|NCT00002562|Drug|paclitaxel|
538429|NCT00002507|Drug|mitomycin C|
538430|NCT00002507|Drug|porfiromycin|
538431|NCT00002507|Radiation|brachytherapy|
538432|NCT00002507|Radiation|radiation therapy|
538433|NCT00089622|Drug|Intravenous Levodopa|
538434|NCT00089622|Drug|Lisuride Transdermal System|
538435|NCT00089609|Drug|Docetaxel|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
538436|NCT00089609|Drug|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
538437|NCT00089609|Drug|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
538438|NCT00089609|Biological|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
538439|NCT00089609|Genetic|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
538440|NCT00089609|Other|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
538441|NCT00089609|Other|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
538442|NCT00089609|Other|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
538443|NCT00089570|Drug|terlipressin|
538444|NCT00089570|Drug|Placebo|
538445|NCT00089557|Drug|Capsaicin Dermal Patch|
538446|NCT00089544|Drug|Dacarbazine|Given IV
538447|NCT00089544|Drug|Doxorubicin Hydrochloride|Given IV
538448|NCT00089544|Biological|Filgrastim|Given subcutaneously
538449|NCT00089544|Drug|Ifosfamide|Given IV
538450|NCT00089544|Other|Laboratory Biomarker Analysis|Correlative studies
538451|NCT00089544|Radiation|Radiation Therapy|Undergo radiotherapy
538452|NCT00089544|Drug|Thalidomide|Given orally
538453|NCT00089544|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
538454|NCT00005591|Biological|cetuximab|
538455|NCT00005591|Drug|gemcitabine hydrochloride|
538456|NCT00005076|Biological|cetuximab|
538457|NCT00005076|Drug|irinotecan hydrochloride|
538458|NCT00005070|Drug|irofulven|
538459|NCT00005057|Biological|adenovirus RSV-TK|
538460|NCT00005057|Drug|ganciclovir|
538461|NCT00005056|Drug|bryostatin 1|
538462|NCT00004937|Drug|acridine carboxamide|
538463|NCT00004219|Drug|granisetron hydrochloride|
538464|NCT00004219|Drug|lerisetron|
538465|NCT00004219|Radiation|radiation therapy|
538466|NCT00004215|Biological|filgrastim|
538467|NCT00004215|Biological|leridistim|
538468|NCT00004215|Drug|cytarabine|
538469|NCT00004215|Drug|daunorubicin hydrochloride|
538470|NCT00004207|Drug|liposomal daunorubicin citrate|
538471|NCT00089531|Drug|VRC-HIVDNA016-00-VP|
538472|NCT00089518|Drug|Valsartan|
538473|NCT00089505|Drug|Emtricitabine|200 mg taken orally
538474|NCT00089505|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
538475|NCT00089505|Drug|Lopinavir/Ritonavir|400/100 mg taken orally
538476|NCT00089505|Drug|Nevirapine|200 mg taken orally
538477|NCT00089505|Drug|Tenofovir disoproxil fumarate|300 mg taken orally
538478|NCT00089492|Drug|Optimized Background ARVs|As prescribed
538479|NCT00089492|Drug|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
538480|NCT00089492|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
538481|NCT00089479|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
538482|NCT00089479|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
538483|NCT00089479|Drug|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
538484|NCT00089466|Drug|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
538485|NCT00089453|Drug|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
538486|NCT00089453|Drug|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
538487|NCT00089453|Drug|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period <or= 20 minutes on day -1.
538488|NCT00089453|Drug|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
538489|NCT00089453|Drug|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
538490|NCT00089453|Procedure|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
538491|NCT00089453|Drug|Interleukin|2 at 3x10x6 IU on days +1 to 13.
538492|NCT00089453|Procedure|Infusion #1|Infusion of donor NK Cells #1 on day 0
538493|NCT00089453|Procedure|Leukapheresis #2|on day +2
538494|NCT00089453|Procedure|Infusion #2|on day +2
538495|NCT00089453|Procedure|Auto Graft|on day +14
538496|NCT00089440|Drug|Aripiprazole|
538497|NCT00089427|Drug|IL13-PE38QQR|
538498|NCT00089427|Procedure|Surgery for placement|
538499|NCT00089427|Procedure|Radiation therapy|
538500|NCT00089427|Drug|Temozolomide with radiation therapy|
538501|NCT00089414|Drug|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
538502|NCT00089414|Drug|Placebo|
538503|NCT00089414|Drug|CDB 2914|
538504|NCT00089401|Drug|isolated perfusion|
538505|NCT00089401|Drug|melphalan|
538506|NCT00089401|Procedure|conventional surgery|
538507|NCT00089388|Drug|cilengitide|Given IV
538508|NCT00089362|Drug|alvespimycin hydrochloride|Given IV
538509|NCT00089362|Other|laboratory biomarker analysis|Correlative studies
538510|NCT00089362|Other|pharmacological study|Correlative studies
538511|NCT00089349|Biological|alemtuzumab|Given IV
538512|NCT00089349|Drug|methotrexate|Given IV
538513|NCT00089349|Drug|mercaptopurine|Given PO
538514|NCT00089323|Procedure|Bone Marrow Aspiration|
538515|NCT00089310|Radiation|technetium-99|0.25 mCi in 4 equal doses
538516|NCT00089297|Biological|Cetuximab|"Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.~Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).~Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
538564|NCT00089063|Biological|gp100 antigen|Given SC
538565|NCT00089063|Biological|MART-1 antigen|Given SC
538566|NCT00089063|Biological|incomplete Freund's adjuvant|Given SC
538567|NCT00089063|Drug|Montanide ISA 51 VG|Given SC
538568|NCT00089063|Biological|sargramostim|Given SC
538517|NCT00089297|Drug|Carboplatin|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
538518|NCT00089297|Drug|Paclitaxel|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.~Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
538519|NCT00089297|Radiation|Radiation therapy|"Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).~If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).~Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
538520|NCT00089284|Drug|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
538521|NCT00089284|Drug|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
538522|NCT00089284|Drug|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
538523|NCT00089271|Drug|alvespimycin hydrochloride|Given IV
538524|NCT00089271|Other|laboratory biomarker analysis|Correlative studies
538525|NCT00089258|Biological|beta-glucan|
538526|NCT00089258|Biological|monoclonal antibody 3F8|
538527|NCT00089258|Biological|sargramostim|
538528|NCT00089258|Drug|isotretinoin|
538529|NCT00089245|Radiation|iodine I 131 monoclonal antibody 8H9|
538530|NCT00089219|Biological|IFA|vaccine adjuvant
538531|NCT00089219|Biological|6MHP|melanoma helper peptides
538532|NCT00089219|Biological|GM-CSF|vaccine adjuvant
538533|NCT00089206|Biological|incomplete Freund's adjuvant|
538534|NCT00089206|Biological|multi-epitope melanoma peptide vaccine|
538535|NCT00089206|Biological|sargramostim|
538536|NCT00089193|Biological|incomplete Freund's adjuvant|
538537|NCT00089193|Biological|multi-epitope melanoma peptide vaccine|
538538|NCT00089193|Biological|sargramostim|
538539|NCT00089180|Drug|liposomal T4N5 lotion|Given topically
538540|NCT00089180|Other|placebo|Given topically
538541|NCT00089180|Other|laboratory biomarker analysis|Correlative studies
538542|NCT00089167|Biological|filgrastim|
538543|NCT00089167|Drug|dexamethasone|
538544|NCT00089167|Drug|melphalan|
538545|NCT00089167|Drug|thalidomide|
538546|NCT00089154|Biological|apolizumab|Given IV
538547|NCT00089154|Other|laboratory biomarker analysis|Correlative studies
538548|NCT00089154|Other|pharmacological study|Correlative studies
538549|NCT00089141|Drug|mycophenolate mofetil|Given orally
538550|NCT00089141|Drug|placebo|Given orally
538551|NCT00089128|Drug|gemcitabine hydrochloride|
538552|NCT00089128|Drug|irinotecan hydrochloride|
538553|NCT00089115|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
538554|NCT00089115|Biological|rituximab|
538555|NCT00089115|Biological|sargramostim|
538556|NCT00089102|Drug|gemcitabine hydrochloride|1,000 mg/m2/dose in 250 cc of NS IV over 30 minutes on Days 1 and 8 of each 21 day cycle
538557|NCT00089102|Drug|irinotecan hydrochloride|100mg/m2/dose in 500 cc of D5W or NS IV over 90 minutes on days 1 and 8 of each 21 day cycle
538558|NCT00089089|Drug|decitabine|Given IV
538559|NCT00089089|Other|pharmacological study|Correlative studies
538560|NCT00089089|Other|laboratory biomarker analysis|Correlative studies
538561|NCT00089076|Biological|ipilimumab|Given IV
538562|NCT00089076|Other|laboratory biomarker analysis|Correlative studies
538563|NCT00089063|Biological|tyrosinase peptide|Given SC
538569|NCT00089063|Other|laboratory biomarker analysis|Correlative studies
538570|NCT00089050|Drug|cyclosporine|
538571|NCT00089050|Drug|gemtuzumab ozogamicin|
538572|NCT00089037|Drug|methotrexate|
538573|NCT00089037|Drug|sirolimus|
538574|NCT00089037|Drug|tacrolimus|
538575|NCT00089024|Drug|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 & 2; Repeat one 3-week cycle starting day 22
538576|NCT00089024|Drug|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 & 2; Repeat one 3-week cycle starting day 22
538577|NCT00089024|Drug|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
538578|NCT00089024|Drug|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
538579|NCT00089024|Procedure|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.~If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
538580|NCT00089024|Procedure|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 [negative margins] or R1 [positive microscopic margins]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
538581|NCT00089024|Procedure|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
538582|NCT00089024|Radiation|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
538583|NCT00089011|Drug|fludarabine phosphate|Given IV
538584|NCT00089011|Radiation|total-body irradiation|Undergo radiotherapy
538585|NCT00089011|Drug|mycophenolate mofetil|Given IV or PO
538586|NCT00089011|Drug|tacrolimus|Given IV or PO
538587|NCT00089011|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
538588|NCT00089011|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
538589|NCT00089011|Other|laboratory biomarker analysis|Correlative studies
538590|NCT00088998|Biological|bevacizumab|
538591|NCT00088998|Drug|capecitabine|
538592|NCT00088998|Drug|docetaxel|
538593|NCT00088985|Biological|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
538594|NCT00088985|Biological|trastuzumab|4 mg/kg intravenously, every 14 days
538595|NCT00088985|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
538596|NCT00088972|Drug|celecoxib|Given orally
538597|NCT00088972|Other|placebo|Given orally
538598|NCT00088959|Drug|erlotinib hydrochloride|Given orally
538599|NCT00088959|Drug|celecoxib|Given orally
538600|NCT00088959|Other|laboratory biomarker analysis|Correlative studies
538601|NCT00088946|Dietary Supplement|Polyphenon E|4-200mg capsules PO daily for 12 months
538602|NCT00088946|Drug|erlotinib hydrochloride|100 mg PO daily for 12 months
538603|NCT00088946|Other|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
538604|NCT00088946|Other|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
538605|NCT00088933|Drug|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
538606|NCT00088933|Drug|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
538607|NCT00088933|Drug|docetaxel|Given IV
538608|NCT00088933|Drug|sargramostim|Given subcutaneously
538609|NCT00088907|Drug|docetaxel|Given IV
538610|NCT00088907|Other|placebo|Given orally
538611|NCT00088907|Drug|gefitinib|Given orally
538612|NCT00088894|Drug|gemcitabine hydrochloride|Given IV
538613|NCT00088894|Biological|bevacizumab|Given IV
538614|NCT00088894|Other|placebo|Given IV
538615|NCT00088894|Other|laboratory biomarker analysis|Correlative studies
538616|NCT00088894|Other|pharmacogenomic studies|Correlative studies
538617|NCT00088894|Other|pharmacological study|Correlative studies
538618|NCT00088881|Biological|rituximab|Given IV
538619|NCT00088881|Drug|prednisone|Given orally
538620|NCT00088881|Drug|cyclophosphamide|Given IV
538621|NCT00088881|Drug|doxorubicin|Given IV
538622|NCT00088881|Drug|vincristine|Given IV
538623|NCT00088881|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
538714|NCT00003661|Drug|cyclosporine|
538624|NCT00088881|Radiation|radiation therapy|Undergo radiotherapy
538625|NCT00088881|Procedure|positron emission tomography|Undergo PET scans
538626|NCT00088868|Drug|alvespimycin hydrochloride|
538627|NCT00088855|Drug|Bortezomib|Given IV
538628|NCT00088855|Other|Laboratory Biomarker Analysis|Correlative studies
538629|NCT00088855|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
538630|NCT00088829|Drug|paclitaxel|subjects will receive paclitaxel neoadjuvantly
538631|NCT00088829|Genetic|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
538632|NCT00088829|Procedure|biopsy|All subjects will have a biopsy to collect tissue
538633|NCT00088829|Procedure|neoadjuvant therapy|paclitaxel is given neoadjuvantly
538634|NCT00088829|Drug|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
538635|NCT00088816|Drug|cisplatin|
538636|NCT00088816|Drug|tegafur-gimeracil-oteracil potassium|
538637|NCT00088816|Procedure|adjuvant therapy|
538638|NCT00088816|Procedure|conventional surgery|
538639|NCT00088816|Procedure|neoadjuvant therapy|
538640|NCT00088803|Genetic|molecular genetic technique|
538641|NCT00088803|Genetic|polymerase chain reaction|
538642|NCT00088803|Genetic|polymorphism analysis|
538643|NCT00088790|Drug|AZD5438|
538644|NCT00088777|Behavioral|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
538645|NCT00088777|Behavioral|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
538646|NCT00088764|Behavioral|Coping skills training|8 sessions of pain and stress coping skills training
538647|NCT00088764|Behavioral|Written emotional disclosure|4 sessions of writing about stress
538648|NCT00088764|Behavioral|Arthritis education|8 sessions of learning about rheumatoid arthritis
538649|NCT00088764|Behavioral|Health behavior writing|4 sessions of writing about various health behaviors
538650|NCT00004193|Drug|ISIS 2503|
538651|NCT00004187|Drug|capecitabine|
538652|NCT00004187|Drug|oxaliplatin|
538653|NCT00004186|Drug|carboplatin|
538654|NCT00004186|Drug|etoposide|
538655|NCT00004186|Drug|ifosfamide|
538656|NCT00004186|Drug|topotecan hydrochloride|
538657|NCT00004186|Radiation|radiation therapy|
538658|NCT00004162|Biological|sargramostim|
538659|NCT00004162|Drug|methotrexate|
538660|NCT00004162|Drug|pegylated liposomal doxorubicin hydrochloride|
538661|NCT00004162|Drug|vincristine sulfate|
538662|NCT00004096|Drug|carboplatin|
538663|NCT00004096|Drug|vinorelbine ditartrate|
538664|NCT00004080|Biological|recombinant adenovirus-p53 SCH-58500|
538665|NCT00004080|Procedure|conventional surgery|
538666|NCT00004064|Biological|oregovomab|
538667|NCT00004040|Biological|recombinant interferon alfa|
538668|NCT00004040|Biological|rituximab|
538669|NCT00004039|Biological|recombinant interferon alfa|
538670|NCT00004039|Biological|rituximab|
538671|NCT00004039|Drug|cyclophosphamide|
538672|NCT00004039|Drug|doxorubicin hydrochloride|
538673|NCT00004039|Drug|prednisone|
538674|NCT00004039|Drug|vincristine sulfate|
538675|NCT00003957|Biological|filgrastim|
538676|NCT00003957|Biological|recombinant human stem cell factor|
538677|NCT00003957|Drug|cyclophosphamide|
538678|NCT00003957|Drug|cytarabine|
538679|NCT00003957|Drug|etoposide|
538680|NCT00003957|Drug|melphalan|
538681|NCT00003957|Drug|mitoxantrone hydrochloride|
538682|NCT00003957|Drug|paclitaxel|
538683|NCT00003957|Procedure|peripheral blood stem cell transplantation|
538684|NCT00003892|Drug|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
538685|NCT00003828|Drug|vinorelbine|
538686|NCT00003821|Drug|aminopterin|
538687|NCT00003810|Drug|docetaxel|
538688|NCT00003810|Drug|gemcitabine hydrochloride|
538689|NCT00003798|Drug|motexafin gadolinium|
538690|NCT00003798|Radiation|radiation therapy|
538691|NCT00003786|Drug|irofulven|
538692|NCT00003784|Drug|CHOP regimen|
538693|NCT00003784|Drug|cyclophosphamide|
538694|NCT00003784|Drug|doxorubicin hydrochloride|
538695|NCT00003784|Drug|prednisone|
538696|NCT00003784|Drug|vincristine sulfate|
538697|NCT00003784|Radiation|tositumomab and iodine I 131 tositumomab|
538698|NCT00003760|Drug|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
538699|NCT00003708|Drug|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
538700|NCT00003681|Biological|epoetin alfa|
538701|NCT00003681|Drug|amifostine trihydrate|
538702|NCT00003663|Biological|rituximab|
538703|NCT00003663|Drug|dexamethasone|
538704|NCT00003662|Biological|anti-thymocyte globulin|
538705|NCT00003662|Drug|busulfan|
538706|NCT00003662|Drug|cyclophosphamide|
538707|NCT00003662|Drug|cyclosporine|
538708|NCT00003662|Drug|melphalan|
538709|NCT00003662|Drug|methylprednisolone|
538710|NCT00003662|Procedure|umbilical cord blood transplantation|
538711|NCT00003662|Radiation|radiation therapy|
538712|NCT00003661|Biological|anti-thymocyte globulin|
538713|NCT00003661|Drug|busulfan|
538717|NCT00003661|Procedure|umbilical cord blood transplantation|
538718|NCT00003661|Radiation|radiation therapy|
538719|NCT00003605|Biological|rituximab|
538720|NCT00003605|Drug|cyclophosphamide|
538721|NCT00003542|Biological|pegylated interferon alfa|
538722|NCT00003539|Biological|trastuzumab|
538723|NCT00003539|Drug|paclitaxel|
538724|NCT00003431|Biological|recombinant flt3 ligand|
538725|NCT00003424|Drug|tamoxifen citrate|
538726|NCT00088673|Drug|3APS|
538727|NCT00003416|Biological|filgrastim|
538728|NCT00003416|Biological|recombinant interferon alfa|
538729|NCT00003416|Drug|dexamethasone|
538730|NCT00003416|Drug|melphalan|
538731|NCT00003416|Procedure|peripheral blood stem cell transplantation|
538732|NCT00003415|Drug|amifostine trihydrate|
538733|NCT00003415|Drug|topotecan hydrochloride|
538734|NCT00003413|Biological|filgrastim|
538735|NCT00003413|Drug|carmustine|
538736|NCT00003413|Drug|cisplatin|
538737|NCT00003413|Drug|melphalan|
538738|NCT00003413|Drug|paclitaxel|
538739|NCT00003413|Procedure|peripheral blood stem cell transplantation|
538740|NCT00003413|Procedure|surgical procedure|
538741|NCT00088738|Drug|[18F] SPA-RQ|
538742|NCT00088699|Drug|Ketamine|
538743|NCT00088699|Drug|Placebo|
538744|NCT00088686|Drug|Capsaicin (Intramucosal Injection)|
538745|NCT00088660|Biological|PANVAC™-VF|
538746|NCT00088647|Drug|MST-997|
538747|NCT00088634|Drug|Lurasidone|80 mg AM dosing once daily
538748|NCT00088634|Drug|Placebo|Matching Placebo to 40mg lurasidone tablets
538749|NCT00088621|Drug|Lurasidone 80mg tablet|
538750|NCT00088608|Drug|SOM230 s.c.|
538751|NCT00088595|Drug|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
538752|NCT00088582|Drug|Pasireotide (SOM230), Octreotide (Sandostatin)|
538753|NCT00003358|Drug|chemotherapy|
538754|NCT00003358|Drug|cisplatin|
538755|NCT00003358|Drug|gemcitabine hydrochloride|
538756|NCT00003305|Drug|aminopterin|
538757|NCT00003305|Drug|leucovorin calcium|
538758|NCT00003259|Drug|vinorelbine tartrate|
538759|NCT00003256|Drug|alvocidib|
538760|NCT00003214|Drug|carboplatin|
538761|NCT00003214|Drug|cisplatin|
538762|NCT00003214|Drug|cyclophosphamide|
538763|NCT00003214|Drug|doxorubicin hydrochloride|
538764|NCT00003214|Drug|in vitro sensitivity-directed chemotherapy|
538765|NCT00003214|Drug|paclitaxel|
538766|NCT00003213|Drug|dexamethasone|4 mg Dexamethasone in the morning
538767|NCT00003213|Drug|granisetron hydrochloride|1 mg Granisetron in the morning
538768|NCT00003213|Drug|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
538769|NCT00003182|Drug|cisplatin|
538770|NCT00003182|Drug|gemcitabine hydrochloride|
538771|NCT00003158|Drug|carboplatin|
538772|NCT00003158|Drug|etoposide|
538773|NCT00003158|Drug|paclitaxel|
538774|NCT00003158|Radiation|radiation therapy|
538775|NCT00003152|Biological|filgrastim|
538776|NCT00003152|Biological|recombinant interferon alfa|
538777|NCT00003152|Drug|cyclophosphamide|
538778|NCT00003152|Drug|prednisone|
538779|NCT00003152|Drug|vincristine sulfate|
538780|NCT00003152|Procedure|autologous bone marrow transplantation|
538781|NCT00003152|Procedure|bone marrow ablation with stem cell support|
538782|NCT00003152|Procedure|peripheral blood stem cell transplantation|
538783|NCT00003152|Radiation|radiation therapy|
538784|NCT00003097|Other|preventative dietary intervention|
538785|NCT00003090|Biological|aldesleukin|
538786|NCT00003087|Drug|cisplatin|
538787|NCT00003087|Drug|paclitaxel|
538788|NCT00003087|Procedure|surgical procedure|
538789|NCT00003087|Radiation|radiation therapy|
538790|NCT00003068|Drug|amifostine trihydrate|
538791|NCT00003068|Drug|cyclophosphamide|
538792|NCT00003068|Drug|mitoxantrone hydrochloride|
538793|NCT00003068|Drug|thiotepa|
538794|NCT00003068|Procedure|peripheral blood stem cell transplantation|
538795|NCT00088569|Drug|0-15 Water|
538796|NCT00088556|Drug|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
538797|NCT00088556|Drug|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
538798|NCT00088556|Drug|paclitaxel|200 mg/m² Once every 3 weeks
538799|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
538800|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
538801|NCT00003055|Drug|cisplatin|
538802|NCT00003055|Drug|irinotecan hydrochloride|
538803|NCT00003050|Drug|cyclophosphamide|
538804|NCT00003050|Drug|doxorubicin hydrochloride|
538805|NCT00003050|Drug|paclitaxel|
538806|NCT00003050|Drug|tamoxifen citrate|
538807|NCT00003050|Procedure|surgical procedure|
538808|NCT00003050|Radiation|radiation therapy|
538809|NCT00003002|Biological|HER-2/neu peptide vaccine|
538810|NCT00003002|Biological|sargramostim|
538811|NCT00003000|Drug|fentanyl citrate|
538812|NCT00003000|Drug|morphine sulfate|
538813|NCT00002984|Drug|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
538864|NCT00002753|Radiation|iodine I 131 monoclonal antibody 81C6|
538865|NCT00002688|Drug|cyclosporine|
538814|NCT00002984|Drug|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
538815|NCT00002984|Drug|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
538816|NCT00002984|Procedure|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
538817|NCT00002984|Radiation|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
538818|NCT00002921|Drug|suramin|
538819|NCT00002921|Drug|therapeutic hydrocortisone|
538820|NCT00002833|Biological|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
538821|NCT00002833|Drug|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
538822|NCT00002833|Drug|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
538823|NCT00002833|Drug|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
538824|NCT00002833|Drug|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
538825|NCT00002833|Drug|Idarubicin|IV Days -6, -5 and -4.
538826|NCT00002833|Drug|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
538827|NCT00002833|Procedure|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
538828|NCT00088530|Drug|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
538829|NCT00088530|Drug|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
538830|NCT00002832|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
538831|NCT00002832|Drug|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
538832|NCT00002832|Drug|Decitabine|IV for 6 hours every 12 hr for 5 days.
538833|NCT00002832|Procedure|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
538834|NCT00002832|Procedure|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
538835|NCT00002831|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
538836|NCT00002831|Drug|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
538837|NCT00002831|Drug|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
538838|NCT00002831|Drug|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
538839|NCT00002831|Drug|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
538840|NCT00002831|Drug|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
538841|NCT00002831|Drug|Methylprednisolone|Given according to clinical grade of GVHD procedures.
538842|NCT00002831|Drug|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
538843|NCT00002831|Procedure|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
538844|NCT00002831|Procedure|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
538845|NCT00002824|Biological|gene therapy|
538846|NCT00002824|Drug|chemotherapy|
538847|NCT00002824|Drug|ganciclovir|
538848|NCT00002824|Procedure|conventional surgery|
538849|NCT00002784|Biological|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
538850|NCT00002784|Drug|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
538851|NCT00002784|Drug|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
538852|NCT00002784|Drug|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
538853|NCT00002784|Drug|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
538854|NCT00002784|Drug|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
538855|NCT00002784|Drug|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
538856|NCT00002784|Drug|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
538857|NCT00002784|Drug|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
538858|NCT00002784|Procedure|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
538859|NCT00002784|Radiation|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
538860|NCT00002784|Radiation|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
538861|NCT00002779|Drug|fludarabine phosphate|
538862|NCT00002779|Drug|octreotide acetate|
538863|NCT00002754|Biological|monoclonal antibody Me1-14 F(ab')2|
538867|NCT00002688|Drug|mitoxantrone hydrochloride|
538868|NCT00002675|Biological|filgrastim|
538869|NCT00002675|Drug|carboplatin|
538870|NCT00002675|Drug|cisplatin|
538871|NCT00002675|Drug|cyclophosphamide|
538872|NCT00002675|Drug|etoposide|
538873|NCT00002675|Drug|mesna|
538874|NCT00002675|Drug|vincristine sulfate|
538875|NCT00002665|Drug|asparaginase|10,000 units/d IV or IM 15 - 24
538876|NCT00002665|Drug|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
538877|NCT00002665|Drug|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
538878|NCT00002665|Drug|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
538879|NCT00002665|Drug|dexamethasone|main: 10 mg/m2/day PO 1 - 28
538880|NCT00002665|Drug|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
538881|NCT00002665|Drug|etoposide|60 mg/kg based on ideal body weight day -3
538882|NCT00002665|Drug|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC < 3,000 /μl
538883|NCT00002665|Drug|mercaptopurine|con: 60 mg/m2 PO 1 - 28
538884|NCT00002665|Drug|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
538885|NCT00002665|Drug|prednisone|"ind: 60 mg/m2/d PO 1 - 21*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.~ind2: 60 mg/m2/d PO through day 42"
538886|NCT00002665|Drug|thioguanine|main: 60 mg/m2/day PO 1 - 14
538887|NCT00002665|Drug|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
538888|NCT00002665|Procedure|allogeneic bone marrow transplantation|day 0
538889|NCT00002665|Radiation|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
538890|NCT00002630|Biological|filgrastim|
538891|NCT00002630|Drug|cyclophosphamide|
538892|NCT00002630|Drug|melphalan|
538893|NCT00002630|Procedure|peripheral blood stem cell transplantation|
538894|NCT00002630|Radiation|low-LET cobalt-60 gamma ray therapy|
538895|NCT00002630|Radiation|low-LET photon therapy|
538896|NCT00002627|Biological|filgrastim|
538897|NCT00002627|Drug|carboplatin|
538898|NCT00002627|Drug|cyclophosphamide|
538899|NCT00002627|Drug|mesna|
538900|NCT00002627|Drug|paclitaxel|
538901|NCT00002627|Procedure|peripheral blood stem cell transplantation|
538902|NCT00002618|Biological|filgrastim|
538903|NCT00002618|Drug|cytarabine|
538904|NCT00002618|Drug|doxorubicin hydrochloride|
538905|NCT00002618|Drug|leucovorin calcium|
538906|NCT00002618|Drug|mercaptopurine|
538907|NCT00002618|Drug|methotrexate|
538908|NCT00002618|Drug|prednisone|
538909|NCT00002618|Drug|vincristine sulfate|
538910|NCT00002618|Radiation|low-LET cobalt-60 gamma ray therapy|
538911|NCT00002618|Radiation|low-LET electron therapy|
538912|NCT00002618|Radiation|low-LET photon therapy|
538913|NCT00002604|Drug|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
538914|NCT00002604|Drug|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
538915|NCT00002604|Drug|chemosensitization/potentiation therapy|
538916|NCT00002588|Drug|etoposide|
538917|NCT00002588|Drug|topotecan hydrochloride|
538918|NCT00002572|Biological|aldesleukin|
538919|NCT00002572|Biological|muromonab-CD3|
538920|NCT00002572|Biological|therapeutic tumor infiltrating lymphocytes|
538921|NCT00002572|Procedure|conventional surgery|
538922|NCT00002542|Drug|CMF regimen|
538923|NCT00002542|Drug|cyclophosphamide|
538924|NCT00002542|Drug|doxorubicin hydrochloride|
538925|NCT00002542|Drug|epirubicin hydrochloride|
538926|NCT00002542|Drug|fluorouracil|
538927|NCT00002542|Drug|methotrexate|
538928|NCT00002542|Drug|tamoxifen citrate|
538929|NCT00002542|Radiation|radiation therapy|
538930|NCT00002535|Biological|aldesleukin|
538931|NCT00002535|Biological|lymphokine-activated killer cells|
538932|NCT00002535|Biological|therapeutic tumor infiltrating lymphocytes|
538933|NCT00002535|Drug|cyclophosphamide|
538934|NCT00002535|Drug|indomethacin|
538935|NCT00002529|Drug|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
538936|NCT00002529|Drug|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
538937|NCT00002529|Drug|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
538938|NCT00002529|Drug|tamoxifen citrate|Tamoxifen 20 mg daily.
538939|NCT00002529|Drug|toremifene|Toremifene 60 mg daily.
538940|NCT00088517|Drug|[11C]NNC-112|
538941|NCT00088504|Drug|Merimepodib|
538942|NCT00088504|Drug|PEG-Interferon-alpha 2a (Pegasys®)|
538943|NCT00088504|Drug|Ribavirin (Copegus®)|
538944|NCT00088491|Drug|Intramuscular Olanzapine Depot|
538945|NCT00088491|Drug|Oral Olanzapine|
538946|NCT00088478|Drug|Intramuscular Olanzapine Depot|
538947|NCT00088478|Drug|Placebo|
538948|NCT00088465|Drug|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
538949|NCT00088452|Drug|ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
538950|NCT00088452|Drug|lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
538951|NCT00088452|Drug|valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
538952|NCT00088413|Biological|PANVAC-V|Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.
539035|NCT00002462|Drug|vincristine sulfate|
546936|NCT00009932|Drug|cisplatin|
538953|NCT00088413|Biological|PANVAC-F|Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.
538954|NCT00088413|Drug|Sargramostim (GM-CSF, Leukine)|100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.
538955|NCT00088400|Drug|TransMID|
538956|NCT00088387|Drug|Divalproex|
538957|NCT00088387|Drug|Lithium|
538958|NCT00088374|Drug|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
538959|NCT00088374|Drug|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
538960|NCT00088374|Drug|[15-O] H2O|[15-0] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
538961|NCT00088374|Drug|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
538962|NCT00088309|Procedure|Eye exam|
538963|NCT00088309|Procedure|Oral exam|
538964|NCT00088309|Procedure|CT scan|
538965|NCT00088309|Procedure|Neuropsychological testing|
538966|NCT00088309|Procedure|Electrocardiogram|
538967|NCT00088309|Procedure|Echocardiogram|
538968|NCT00088296|Procedure|Blood Draw|
538969|NCT00088283|Drug|pegaptanib sodium|
538970|NCT00088270|Drug|OSI-7904L|
538971|NCT00088270|Drug|5-Fluorouracil/Leucovorin|
538972|NCT00005884|Drug|eflornithine|
538973|NCT00005852|Biological|anti-thymocyte globulin|
538974|NCT00005852|Biological|filgrastim|
538975|NCT00005852|Biological|muromonab-CD3|
538976|NCT00005852|Drug|cyclophosphamide|
538977|NCT00005852|Drug|cyclosporine|
538978|NCT00005852|Drug|methylprednisolone|
538979|NCT00005852|Procedure|allogeneic bone marrow transplantation|
538980|NCT00005805|Dietary Supplement|St. John's wort|
538981|NCT00005633|Biological|OVA BiP peptide|
538982|NCT00005633|Biological|gp209-2M antigen|
538983|NCT00005633|Biological|recombinant 70-kD heat-shock protein|
538984|NCT00005633|Biological|tyrosinase peptide|
538985|NCT00005624|Drug|CI-994|CI-994 as outlined in treatment arm.
538986|NCT00005614|Drug|Gemcitabine hydrochloride|Gemcitabine via IV
538987|NCT00005611|Drug|BMS-188797|
538988|NCT00004902|Drug|tocladesine|
538989|NCT00004901|Drug|ethynyluracil|
538990|NCT00004901|Drug|fluorouracil|
538991|NCT00004901|Drug|hydroxyurea|
538992|NCT00004901|Radiation|radiation therapy|
538993|NCT00004897|Biological|recombinant interferon alfa|
538994|NCT00004897|Drug|cisplatin|
538995|NCT00004897|Drug|fluorouracil|
538996|NCT00004897|Drug|hydroxyurea|
538997|NCT00004897|Drug|leucovorin calcium|
538998|NCT00004897|Procedure|conventional surgery|
538999|NCT00004897|Radiation|radiation therapy|
539000|NCT00004875|Drug|enoxaparin|
539001|NCT00004875|Drug|heparin|
539002|NCT00004265|Drug|paclitaxel|
539003|NCT00004264|Drug|amifostine trihydrate|
539004|NCT00004264|Drug|cisplatin|
539005|NCT00004264|Drug|docetaxel|
539006|NCT00004263|Drug|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
539007|NCT00004263|Drug|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
539008|NCT00004258|Drug|cilengitide|dose escalation of cilengitide
539009|NCT00004169|Drug|carboplatin|
539010|NCT00004169|Drug|cyclophosphamide|
539011|NCT00004169|Drug|etoposide|
539012|NCT00004169|Procedure|peripheral blood stem cell transplantation|
539013|NCT00004169|Radiation|radiation therapy|
539014|NCT00004159|Drug|gemcitabine hydrochloride|
539015|NCT00004159|Drug|paclitaxel|
539016|NCT00003942|Biological|RevM10 gene|
539017|NCT00003942|Biological|RevM10/polAS gene|
539018|NCT00003942|Procedure|in vitro-treated peripheral blood stem cell transplantation|
539019|NCT00003942|Procedure|peripheral blood stem cell transplantation|
539020|NCT00003936|Drug|bryostatin 1|
539021|NCT00003929|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
539022|NCT00003929|Drug|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
539023|NCT00003929|Drug|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
539024|NCT00003929|Radiation|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
539025|NCT00002506|Biological|recombinant interferon alfa|
539026|NCT00002506|Drug|isotretinoin|
539027|NCT00002504|Biological|aldesleukin|
539028|NCT00002504|Biological|recombinant interferon alfa|
539029|NCT00002462|Biological|bleomycin sulfate|
539030|NCT00002462|Drug|doxorubicin hydrochloride|
539031|NCT00002462|Drug|mechlorethamine hydrochloride|
539032|NCT00002462|Drug|prednisone|
539033|NCT00002462|Drug|procarbazine hydrochloride|
539034|NCT00002462|Drug|vinblastine sulfate|
539036|NCT00002462|Radiation|low-LET cobalt-60 gamma ray therapy|
539037|NCT00002462|Radiation|low-LET photon therapy|
539038|NCT00002462|Radiation|radiation therapy|
539039|NCT00088231|Drug|Imatinib Mesylate (Gleevec)|"600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.~400 mg by mouth every day (for AMM) for a 28 day cycle."
539040|NCT00088231|Drug|PTK 787 (vatalanib)|"For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.~Starting dose: 250 mg by mouth every day for a 28 day cycle."
539041|NCT00088218|Drug|Clofarabine|1-hour IV infusion 30 mg/m^2 daily times 5 days (Days 1-5)
539042|NCT00088218|Drug|Ara-C|20 mg/m^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
539043|NCT00088205|Drug|enzastaurin|500 mg, oral, daily, up to six 28 day cycles
539044|NCT00088179|Drug|pexelizumab in conjunction with CABG|
539045|NCT00087997|Drug|STA-4783|
539046|NCT00088192|Drug|pegaptanib sodium|
539047|NCT00088166|Drug|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
539048|NCT00088166|Drug|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
539049|NCT00003884|Drug|zoledronic acid|
539050|NCT00003884|Procedure|quality-of-life assessment|
539051|NCT00003812|Biological|filgrastim|
539052|NCT00003812|Drug|carboplatin|
539053|NCT00003812|Drug|etoposide|
539054|NCT00003812|Drug|paclitaxel|
539055|NCT00003812|Drug|topotecan hydrochloride|
539056|NCT00003812|Radiation|radiation therapy|
539057|NCT00003808|Drug|theophylline|
539058|NCT00003781|Drug|docetaxel|
539059|NCT00003781|Procedure|pain therapy|
539060|NCT00003781|Procedure|quality-of-life assessment|
539061|NCT00003763|Procedure|radionuclide imaging|
539062|NCT00003763|Radiation|indium In 111 folic acid|
539063|NCT00003748|Drug|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
539064|NCT00003725|Drug|valrubicin|
539065|NCT00003725|Procedure|conventional surgery|
539066|NCT00003677|Drug|Dolastatin 10|IV bolus once every 21 days.
539067|NCT00003675|Drug|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
539068|NCT00003610|Dietary Supplement|capsaicin|
539069|NCT00003610|Other|placebo|
539070|NCT00003610|Radiation|radiation therapy|
539071|NCT00003585|Biological|aldesleukin|
539072|NCT00003585|Biological|recombinant interferon alfa|
539073|NCT00003585|Drug|fluorouracil|
539074|NCT00003585|Drug|isotretinoin|
539075|NCT00003585|Procedure|surgical procedure|
539076|NCT00003557|Drug|dolastatin 10|
539077|NCT00003392|Biological|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
539078|NCT00003392|Drug|carboplatin|18 AUC IV, approximately days 21, 42
539079|NCT00003392|Drug|cyclophosphamide|4 gm/m2 IV, day 1
539080|NCT00003392|Drug|melphalan|140 mg/m2 IV , approximately day 63
539081|NCT00003392|Drug|paclitaxel|170 mg/m2 IV day 1
539082|NCT00003392|Procedure|bone marrow ablation with stem cell support|
539083|NCT00003392|Procedure|peripheral blood stem cell transplantation|
539084|NCT00003391|Biological|monoclonal antibody muJ591|
539085|NCT00003267|Procedure|infection prophylaxis and management|
539086|NCT00003267|Procedure|management of therapy complications|
539087|NCT00003267|Procedure|surgical procedure|
539088|NCT00088153|Drug|Physiologic Estrogen/progesterone|Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
539089|NCT00088153|Other|Placebo|Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
539090|NCT00088140|Drug|IDN-6556|
539091|NCT00088140|Drug|Placebo|
539092|NCT00088114|Drug|STA-4783/paclitaxel|
539093|NCT00088101|Drug|STA-5312|
539094|NCT00088088|Drug|Paclitaxel|
539095|NCT00088088|Drug|Carboplatin|
539096|NCT00088088|Drug|STA 4783|
539097|NCT00088075|Drug|Risperidone|
539098|NCT00088062|Drug|STA-5326|
539099|NCT00088049|Drug|Olanzapine|
539100|NCT00088049|Drug|Aripiprazole|
539101|NCT00088036|Drug|Olanzapine|
539102|NCT00003238|Drug|perillyl alcohol|
539103|NCT00003225|Drug|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
539104|NCT00003225|Drug|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.~Administered every 14 days for 3 cycles"
539105|NCT00088023|Drug|PT-523 for Injection|
539106|NCT00088010|Drug|Arzoxifene|20mg, oral, tablet, once a day for 36 months
539107|NCT00088010|Drug|Placebo|oral, tablet, once a day for 36 months
539108|NCT00087984|Biological|MB-002|Dendritic Cell Immunotherapy
539109|NCT00087958|Drug|XRP9881|
539110|NCT00087945|Drug|Abacavir sulfate|
539111|NCT00087945|Drug|Abacavir sulfate, lamivudine, and zidovudine|
539112|NCT00087880|Drug|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
539113|NCT00087867|Drug|SCIO-469|two 30-mg capsules three times daily
539210|NCT00002549|Procedure|peripheral blood stem cell transplantation|
539211|NCT00002549|Radiation|radiation therapy|
539212|NCT00002545|Drug|carmustine|
539114|NCT00087867|Drug|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
539115|NCT00005996|Drug|cisplatin|
539116|NCT00005996|Drug|gemcitabine hydrochloride|
539117|NCT00005996|Drug|semaxanib|
539118|NCT00005806|Drug|carboplatin|
539119|NCT00005806|Drug|gefitinib|
539120|NCT00005806|Drug|paclitaxel|
539121|NCT00005632|Biological|MUC1-KLH vaccine/QS21|
539122|NCT00005619|Genetic|polymerase chain reaction|
539123|NCT00005619|Other|flow cytometry|
539124|NCT00005619|Other|immunohistochemistry staining method|
539125|NCT00005042|Drug|semaxanib|
539126|NCT00005029|Drug|topotecan hydrochloride|
539127|NCT00004199|Drug|cisplatin|
539128|NCT00004199|Drug|gemcitabine hydrochloride|
539129|NCT00004199|Drug|prinomastat|
539130|NCT00004164|Biological|filgrastim|
539131|NCT00004164|Drug|cisplatin|
539132|NCT00004164|Drug|docetaxel|
539133|NCT00004164|Drug|fluorouracil|
539134|NCT00004164|Drug|leucovorin calcium|
539135|NCT00004164|Radiation|radiation therapy|
539136|NCT00004160|Drug|cisplatin|
539137|NCT00004160|Drug|gemcitabine hydrochloride|
539138|NCT00004160|Drug|paclitaxel|
539139|NCT00004160|Radiation|radiation therapy|
539140|NCT00004158|Drug|melphalan|
539141|NCT00004158|Procedure|peripheral blood stem cell transplantation|
539142|NCT00004158|Radiation|holmium Ho 166 DOTMP|
539143|NCT00004104|Biological|liposomal interleukin-2|
539144|NCT00004104|Biological|polyvalent melanoma vaccine|
539145|NCT00004104|Biological|recombinant interferon alfa|
539146|NCT00004060|Drug|exatecan mesylate|
539147|NCT00004047|Drug|exatecan mesylate|
539148|NCT00004041|Biological|Ad5CMV-p53 gene|
539149|NCT00004041|Procedure|conventional surgery|
539150|NCT00003881|Biological|trastuzumab|
539151|NCT00003881|Drug|carboplatin|
539152|NCT00003881|Drug|paclitaxel|
539153|NCT00003219|Drug|perillyl alcohol|
539154|NCT00003196|Drug|chemotherapy|Undergo cytoreductive chemotherapy
539155|NCT00003196|Radiation|total-body irradiation|Undergo TBI
539156|NCT00003196|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
539157|NCT00003196|Drug|cyclosporine|Given IV or PO
539158|NCT00003196|Drug|mycophenolate mofetil|Given PO
539159|NCT00003196|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
539160|NCT00003196|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
539161|NCT00003171|Drug|bryostatin 1|
539162|NCT00003082|Biological|monoclonal antibody A27.15|
539163|NCT00003082|Biological|monoclonal antibody E2.3|
539164|NCT00003057|Drug|loperamide hydrochloride|
539165|NCT00003057|Drug|octreotide acetate|
539166|NCT00002998|Drug|cisplatin|
539167|NCT00002998|Drug|gemcitabine hydrochloride|
539168|NCT00002994|Biological|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
539169|NCT00002994|Biological|rhuMAb|90 min IV infusion day 7 of each cycle
539170|NCT00002956|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
539171|NCT00002925|Drug|ara-C|
539172|NCT00002925|Drug|Daunorubicin|
539173|NCT00002925|Drug|Etoposide|
539174|NCT00002925|Drug|PSC-833|
539175|NCT00002925|Biological|Aldesleukin|
539176|NCT00002908|Drug|bryostatin 1|
539177|NCT00002908|Drug|vincristine sulfate|
539178|NCT00002907|Drug|bryostatin 1|
539179|NCT00002862|Drug|perillyl alcohol|
539180|NCT00002763|Biological|recombinant interferon alfa|
539181|NCT00002760|Drug|ketoconazole|400 mg PO tid for as long as treatment is effective
539182|NCT00002760|Drug|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
539183|NCT00002760|Other|Withdrawal of antiandrogen therapy|no drugs given
539184|NCT00002667|Other|cytology specimen collection procedure|
539185|NCT00002667|Other|immunoenzyme technique|
539186|NCT00002667|Procedure|study of high risk factors|
539187|NCT00002620|Drug|carmustine|
539188|NCT00002620|Drug|chemotherapy|
539189|NCT00002620|Drug|mitolactol|
539190|NCT00002620|Radiation|low-LET cobalt-60 gamma ray therapy|
539191|NCT00002620|Radiation|low-LET photon therapy|
539192|NCT00002563|Procedure|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
539193|NCT00002563|Procedure|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
539194|NCT00002557|Drug|CHOP regimen|
539195|NCT00002557|Drug|doxorubicin hydrochloride|
539196|NCT00002557|Drug|etoposide|
539197|NCT00002557|Drug|leucovorin calcium|
539198|NCT00002557|Drug|methotrexate|
539199|NCT00002549|Biological|filgrastim|
539200|NCT00002549|Drug|busulfan|
539201|NCT00002549|Drug|cyclophosphamide|
539202|NCT00002549|Drug|cytarabine|
539203|NCT00002549|Drug|daunorubicin hydrochloride|
539204|NCT00002549|Drug|etoposide|
539205|NCT00002549|Drug|idarubicin|
539206|NCT00002549|Drug|mesna|
539207|NCT00002549|Drug|mitoxantrone hydrochloride|
539208|NCT00002549|Procedure|allogeneic bone marrow transplantation|
539209|NCT00002549|Procedure|autologous bone marrow transplantation|
539213|NCT00002545|Radiation|low-LET photon therapy|
539214|NCT00002502|Drug|busulfan|
539215|NCT00002502|Drug|cyclophosphamide|
539216|NCT00002502|Drug|cytarabine|
539217|NCT00002502|Procedure|allogeneic bone marrow transplantation|
539218|NCT00002495|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15
539219|NCT00002495|Drug|vinblastine|6 mg/m^2 on days 1 and 15
539220|NCT00002495|Radiation|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
539221|NCT00002465|Drug|megestrol acetate|
539222|NCT00087854|Drug|Amonafide L-malate (drug)|
539223|NCT00087841|Behavioral|Self-hypnotic relaxation|
539224|NCT00087828|Drug|Cranberry juice cocktail|
539225|NCT00087815|Drug|dexamethasone|
539226|NCT00087815|Drug|hyperbaric oxygen|
539227|NCT00087815|Procedure|cognitive assessment|
539228|NCT00087815|Procedure|magnetic resonance imaging|
539229|NCT00087815|Procedure|positron emission tomography|
539230|NCT00087815|Procedure|quality-of-life assessment|
539231|NCT00087802|Drug|gemcitabine/Eloxatin (GEMOX)|GEMOX [gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days [3-week cycle]
539232|NCT00087802|Drug|carboplatin/paclitaxel (CP)|"CP [carboplatin/paclitaxel - 21 day cycle]~o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days [3-week cycle]"
539233|NCT00087789|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10^10 vg, CERE-110 1.0 x 10^11 vg, CERE-110 2.0 x 10^11 vg
539234|NCT00087776|Drug|Chemotherapy|
539235|NCT00087763|Drug|Macugen ™ (pegaptanib sodium injection)|
539236|NCT00087750|Drug|Quetiapine|
539237|NCT00087737|Drug|DVS-233 SR|
539238|NCT00087737|Drug|Venlafaxine ER|
539239|NCT00087711|Drug|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
539240|NCT00087711|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
539241|NCT00087711|Drug|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
539242|NCT00087698|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
539243|NCT00087698|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
539244|NCT00082511|Drug|Prasterone (GL701)|"There were 4 arms to the study:~During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
539245|NCT00003877|Biological|filgrastim|
539246|NCT00003877|Drug|carboplatin|
539247|NCT00003877|Drug|cyclophosphamide|
539248|NCT00003877|Drug|paclitaxel|
539249|NCT00003877|Drug|thiotepa|
539250|NCT00003877|Procedure|in vitro-treated bone marrow transplantation|
539251|NCT00003877|Procedure|in vitro-treated peripheral blood stem cell transplantation|
539252|NCT00003874|Biological|monoclonal antibody CD19|
539253|NCT00003874|Biological|monoclonal antibody CD20|
539254|NCT00003874|Procedure|in vitro-treated peripheral blood stem cell transplantation|
539255|NCT00003873|Drug|fluorouracil|Given IV or orally
539256|NCT00003873|Drug|eniluracil|Given orally
539257|NCT00003853|Drug|4'-iodo-4'-deoxydoxorubicin|
539258|NCT00003805|Drug|piperacillin sodium|
539259|NCT00003805|Drug|piperacillin-tazobactam|
539260|NCT00003805|Drug|tazobactam sodium|
539261|NCT00003805|Drug|vancomycin|
539262|NCT00003804|Biological|dactinomycin|
539263|NCT00003804|Drug|vincristine sulfate|
539264|NCT00003804|Procedure|conventional surgery|
539265|NCT00003792|Biological|MART-1 antigen|
539266|NCT00003792|Biological|filgrastim|
539267|NCT00003792|Biological|flu matrix peptide p58-66|
539268|NCT00003792|Biological|gp100 antigen|
539269|NCT00003792|Biological|recombinant MAGE-3.1 antigen|
539270|NCT00003792|Biological|tyrosinase peptide|
539271|NCT00003792|Procedure|in vitro-treated peripheral blood stem cell transplantation|
539272|NCT00003743|Biological|aldesleukin|
539273|NCT00003664|Biological|aldesleukin|
539274|NCT00003664|Biological|recombinant interferon alfa|
539275|NCT00003664|Drug|fluorouracil|
539276|NCT00003664|Drug|gemcitabine hydrochloride|
539277|NCT00003639|Biological|recombinant interferon alfa|
539278|NCT00003639|Drug|chlorambucil|
539279|NCT00003639|Drug|dexamethasone|
539280|NCT00003639|Drug|idarubicin|
539281|NCT00003604|Biological|aldesleukin|
539282|NCT00003359|Drug|batabulin sodium|
539283|NCT00003343|Drug|endocrine-modulating drug therapy|
539284|NCT00003343|Drug|mitoxantrone hydrochloride|
539285|NCT00003343|Drug|prednisone|
539286|NCT00003343|Drug|prinomastat|
539287|NCT00003328|Drug|porfiromycin|
539288|NCT00003328|Radiation|radiation therapy|
539289|NCT00087724|Drug|FK962|
539290|NCT00087685|Drug|RAD001|10 mg by mouth Daily
539291|NCT00087672|Drug|CC-5013|10 mg orally (2 capsules) daily
539292|NCT00087659|Drug|zoledronic acid|
539293|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 72 weeks
539294|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 48 weeks
539295|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
539296|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
539297|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
539298|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
539299|NCT00087633|Drug|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
539300|NCT00087633|Drug|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
539301|NCT00087620|Drug|XELODA [capecitabine]|
539302|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
539303|NCT00087607|Drug|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
539304|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
539305|NCT00087607|Drug|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
539306|NCT00087594|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
539307|NCT00087594|Drug|ribavirin|1000/1200mg (< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
539308|NCT00087581|Drug|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
539309|NCT00087581|Drug|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
539310|NCT00087581|Drug|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
539311|NCT00087568|Drug|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
539312|NCT00087568|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
539313|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
539314|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
539315|NCT00087555|Drug|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
539316|NCT00087542|Drug|ACP-103|
539317|NCT00087529|Drug|placebo|Intravenous repeating dose
539318|NCT00087529|Drug|rituximab|Intravenous repeating dose
539319|NCT00087516|Drug|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
539320|NCT00087516|Drug|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
539321|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
539322|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
539323|NCT00087516|Drug|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
539324|NCT00087503|Drug|Edotecarin|
539325|NCT00087490|Drug|linezolid|
539326|NCT00087490|Drug|vancomycin|
539327|NCT00087477|Drug|Pivanex|
539328|NCT00087464|Drug|Emtricitabine|
539329|NCT00087464|Drug|Nevirapine|
539330|NCT00087464|Drug|Tenofovir disoproxil fumarate|
539331|NCT00087451|Drug|AP23573|ridaforolimus
539332|NCT00086710|Drug|Fuzeon|
539333|NCT00086645|Drug|citalopram hydrobromide|10mg/5ml solution
539334|NCT00086645|Other|placebo|up to equivalent of 20 mg of active comparator daily
539335|NCT00003589|Drug|cisplatin|
539336|NCT00003589|Drug|gemcitabine hydrochloride|
539337|NCT00003589|Drug|paclitaxel|
539338|NCT00087438|Radiation|stereotactic body radiation therapy|
539339|NCT00087425|Biological|rituximab|
539340|NCT00087425|Drug|bryostatin 1|
539341|NCT00087412|Drug|erlotinib hydrochloride|Given orally
539342|NCT00087412|Other|laboratory biomarker analysis|Correlative studies
539343|NCT00087399|Drug|gabapentin|
539344|NCT00087399|Drug|antidepressant|
539345|NCT00087386|Drug|tanespimycin|Given IV
539346|NCT00087386|Other|laboratory biomarker analysis|Correlative studies
539347|NCT00087373|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
539348|NCT00087373|Other|laboratory biomarker analysis|Correlative studies
539349|NCT00087360|Other|counseling intervention|
539350|NCT00087360|Other|physiologic testing|
539351|NCT00087360|Procedure|evaluation of cancer risk factors|
539352|NCT00087347|Drug|ferumoxytol|
539353|NCT00087347|Procedure|magnetic resonance imaging|
539354|NCT00087334|Drug|capecitabine|
539355|NCT00087334|Drug|gefitinib|
539356|NCT00087334|Drug|oxaliplatin|
539357|NCT00087295|Drug|Depsipeptide|Depsipeptide wil be given 13 mg/m^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
539358|NCT00087282|Drug|alvocidib|
539359|NCT00087282|Drug|irinotecan hydrochloride|
539360|NCT00087269|Drug|erlotinib hydrochloride|Given orally
539361|NCT00087269|Procedure|therapeutic endoscopic surgery|Undergo surgical resection
539362|NCT00087269|Other|laboratory biomarker analysis|Correlative studies
539365|NCT00087217|Drug|tanespimycin|Given IV
539366|NCT00087217|Drug|paclitaxel|Given IV
539367|NCT00087217|Other|laboratory biomarker analysis|Correlative studies
539368|NCT00087217|Other|pharmacological study|Correlative studies
539369|NCT00087204|Drug|becatecarin|Given IV
539370|NCT00087204|Other|laboratory biomarker analysis|Correlative studies
539371|NCT00087191|Drug|EF5|Given IV
539372|NCT00087191|Drug|motexafin lutetium|Given IV
539373|NCT00087191|Other|pharmacological study|Correlative studies
539374|NCT00087178|Drug|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
539375|NCT00087178|Drug|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
539376|NCT00087178|Drug|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
539377|NCT00087178|Drug|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
539378|NCT00087165|Biological|GTI-2040|
539379|NCT00087165|Drug|docetaxel|
539380|NCT00087165|Drug|prednisone|
539381|NCT00087152|Drug|Capecitabine|1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle
539382|NCT00087152|Drug|Imatinib mesylate|400 mg by mouth daily
539383|NCT00087139|Drug|ixabepilone|Given IV
539384|NCT00087126|Drug|topotecan hydrochloride|
539385|NCT00087113|Drug|pemetrexed disodium|
539386|NCT00087100|Drug|pemetrexed disodium|
539387|NCT00087087|Drug|pemetrexed disodium|
539388|NCT00087074|Drug|temsirolimus|Given IV
539389|NCT00087074|Other|laboratory biomarker analysis|Optional correlative studies
539390|NCT00087061|Drug|gimatecan|
539391|NCT00087048|Drug|topotecan hydrochloride|
539392|NCT00087035|Drug|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
539393|NCT00087035|Drug|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
539394|NCT00087022|Biological|girentuximab|Given IV
539395|NCT00087022|Other|placebo|Given IV
539396|NCT00087009|Biological|beta-glucan|Given orally
539397|NCT00087009|Biological|rituximab|Given IV
539398|NCT00086996|Drug|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
539399|NCT00086996|Drug|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
539400|NCT00086996|Procedure|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
539401|NCT00086996|Radiation|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
539402|NCT00086983|Drug|becatecarin|Given IV
539403|NCT00086983|Drug|oxaliplatin|Given IV
539404|NCT00086983|Other|pharmacological study|Correlative studies
539405|NCT00086970|Drug|ifosfamide|Given IV
539406|NCT00086970|Drug|O6-benzylguanine|Given IV
539407|NCT00086957|Biological|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
539408|NCT00086957|Drug|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
539409|NCT00086957|Drug|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
539410|NCT00086944|Biological|oblimersen sodium|Given IV
539411|NCT00086944|Biological|rituximab|Given IV
539412|NCT00086944|Drug|ifosfamide|Given IV
539413|NCT00086944|Drug|carboplatin|Given IV
539414|NCT00086944|Drug|etoposide|Given IV
539415|NCT00086944|Biological|filgrastim|Given SC
539416|NCT00086944|Biological|pegfilgrastim|Given SC
539417|NCT00086944|Other|laboratory biomarker analysis|Correlative studies
539418|NCT00086931|Drug|capecitabine|oral dose escalating, twice daily.
539419|NCT00086931|Drug|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
539420|NCT00086931|Procedure|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
539421|NCT00086931|Procedure|neoadjuvant therapy|chemotherapy and radiation prior to surgery
539422|NCT00086931|Radiation|radiation therapy|once daily 5 days a week for 5.5 weeks
539423|NCT00086892|Biological|cetuximab|
539424|NCT00086892|Drug|carboplatin|
539425|NCT00086879|Drug|carmustine|
539426|NCT00086879|Drug|erlotinib hydrochloride|
539427|NCT00086879|Drug|temozolomide|
539428|NCT00086866|Biological|D1/3-MAGE-3-His fusion protein|
539429|NCT00086866|Biological|SB-AS02B adjuvant|
539430|NCT00086866|Biological|SB-AS15 adjuvant|
539431|NCT00086840|Drug|temsirolimus|Given IV
539432|NCT00086840|Other|laboratory biomarker analysis|Correlative studies
539433|NCT00086827|Drug|romidepsin|Given IV
539434|NCT00086827|Other|laboratory biomarker analysis|Correlative studies
539435|NCT00086801|Drug|doxorubicin hydrochloride|given IV
539436|NCT00086801|Drug|gemcitabine hydrochloride|given IV
539437|NCT00086801|Drug|vinblastine|given IV
539438|NCT00086801|Procedure|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
539439|NCT00086801|Procedure|CT scan|
539440|NCT00086775|Biological|alemtuzumab|
539441|NCT00086775|Biological|rituximab|
539442|NCT00086775|Drug|fludarabine phosphate|
539443|NCT00086762|Behavioral|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
539444|NCT00086762|Behavioral|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
539583|NCT00086216|Drug|Atiprimod|Oral, once a day, 14 days on 14 days off
539445|NCT00086762|Behavioral|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
539446|NCT00086762|Behavioral|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
539447|NCT00086736|Drug|bicalutamide|
539448|NCT00086736|Drug|eflornithine|
539449|NCT00086736|Drug|oral eflornithine placebo|
539450|NCT00086736|Drug|oral bicalutamide placebo|
539451|NCT00086723|Biological|recombinant tissue plasminogen activator|
539452|NCT00086723|Drug|captopril|
539453|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
539454|NCT00086684|Drug|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
539455|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
539456|NCT00086671|Drug|ABT-874/Human monoclonal antibody against IL-12|
539457|NCT00086671|Drug|Placebo|
539458|NCT00086658|Drug|mepolizumab|
539459|NCT00086632|Drug|oregovomab|
539460|NCT00086606|Drug|Xolair (omalizumab)|
539461|NCT00086619|Drug|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
539462|NCT00086593|Drug|lamotrigine|
539463|NCT00086580|Biological|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
539464|NCT00086580|Biological|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
539465|NCT00003297|Drug|mitoxantrone hydrochloride|
539466|NCT00003297|Drug|thiotepa|
539467|NCT00003297|Drug|topotecan hydrochloride|
539468|NCT00003297|Procedure|peripheral blood stem cell transplantation|
539469|NCT00003296|Biological|filgrastim|
539470|NCT00003296|Drug|pegylated liposomal doxorubicin hydrochloride|
539471|NCT00003230|Drug|paclitaxel|
539472|NCT00003198|Drug|ifosfamide|
539473|NCT00003198|Drug|topotecan hydrochloride|
539474|NCT00003109|Drug|irinotecan hydrochloride|
539475|NCT00003109|Drug|raltitrexed|
539476|NCT00086541|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
539477|NCT00086528|Drug|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
539478|NCT00086411|Drug|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
539479|NCT00086411|Drug|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
539480|NCT00086411|Behavioral|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
539481|NCT00086411|Behavioral|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
539482|NCT00086411|Drug|placebo patch|placebo patch containing no nicotine
539483|NCT00086411|Drug|placebo bupropion|placebo pills
539484|NCT00086398|Behavioral|Behavior Therapy|
539485|NCT00086385|Drug|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
539486|NCT00003091|Biological|aldesleukin|
539487|NCT00003091|Biological|recombinant interferon alfa|
539488|NCT00002953|Drug|cyclophosphamide|
539489|NCT00002953|Drug|epirubicin hydrochloride|
539490|NCT00002953|Drug|paclitaxel|
539491|NCT00002922|Drug|paclitaxel|
539492|NCT00002863|Drug|chemotherapy|
539493|NCT00002863|Procedure|conventional surgery|
539494|NCT00002863|Procedure|cryosurgery|
539495|NCT00086515|Drug|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
539496|NCT00086515|Drug|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
539497|NCT00086515|Drug|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
539498|NCT00086515|Drug|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period [Phase A], from Visit 5 (Week 6) to Visit 8 (Week 24)
539499|NCT00086502|Drug|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
539914|NCT00002785|Drug|dexamethasone|
539500|NCT00086502|Drug|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
539501|NCT00086502|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
539502|NCT00086502|Drug|Metformin|"Metformin rescue for patients meeting~pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
539503|NCT00086489|Drug|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
539504|NCT00086489|Drug|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
539505|NCT00086463|Drug|Iloprost or placebo|
539506|NCT00086450|Procedure|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
539507|NCT00086450|Device|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.~The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
539508|NCT00002999|Drug|cisplatin|
539509|NCT00002999|Drug|fluorouracil|
539510|NCT00002999|Radiation|radiation therapy|
539511|NCT00086346|Drug|Sirolimus (Rapamune)|
539512|NCT00086346|Drug|Cyclosporine or Tacrolimus|
539513|NCT00086333|Drug|SGN-15, Docetaxel|
539514|NCT00086359|Drug|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
539515|NCT00086359|Drug|Lamivudine/zidovudine|one pill twice daily
539516|NCT00086359|Drug|Lopinavir/ritonavir|four pills twice daily
539517|NCT00086320|Drug|Paliperidone ER|
539518|NCT00086281|Drug|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
539519|NCT00086281|Drug|Zolpidem (Z)|Zolpidem 10 mg oral tablets
539520|NCT00086281|Drug|Modafinil (M)|Modafinil Oral Tablets
539521|NCT00086281|Drug|Placebo (P)|Placebo Oral Solution
539522|NCT00086268|Drug|zoledronic acid|
539523|NCT00086268|Drug|Taxotere|
539524|NCT00086268|Drug|Carboplatin|
539525|NCT00002837|Biological|Filgrastim (G-CSF)|
539526|NCT00002837|Drug|Cyclophosphamide|
539527|NCT00002837|Drug|Doxorubicin Hydrochloride|
539528|NCT00002837|Drug|Paclitaxel|
539529|NCT00002837|Procedure|Peripheral Blood Stem Cell Transplantation|
539530|NCT00002804|Biological|filgrastim|
539531|NCT00002804|Drug|doxorubicin hydrochloride|
539532|NCT00002804|Drug|ifosfamide|
539533|NCT00002804|Drug|mesna|
539534|NCT00002804|Drug|vincristine sulfate|
539535|NCT00002804|Procedure|conventional surgery|
539536|NCT00002804|Radiation|brachytherapy|
539537|NCT00002804|Radiation|low-LET cobalt-60 gamma ray therapy|
539538|NCT00002804|Radiation|low-LET electron therapy|
539539|NCT00002804|Radiation|low-LET photon therapy|
539540|NCT00002751|Biological|monoclonal antibody Me1-14 F(ab')2|
539541|NCT00002733|Biological|aldesleukin|
539542|NCT00002733|Biological|recombinant interferon alfa|
539543|NCT00002733|Biological|therapeutic tumor infiltrating lymphocytes|
539544|NCT00002733|Drug|cimetidine|
539545|NCT00002705|Drug|topotecan hydrochloride|
539546|NCT00002704|Biological|filgrastim|
539547|NCT00002704|Drug|asparaginase|
539548|NCT00002704|Drug|cyclophosphamide|
539549|NCT00002704|Drug|daunorubicin hydrochloride|
539550|NCT00002704|Drug|dexamethasone|
539551|NCT00002704|Drug|etoposide|
539552|NCT00002704|Drug|leucovorin calcium|
539553|NCT00002704|Drug|liposomal cytarabine|
539554|NCT00002704|Drug|mercaptopurine|
539555|NCT00002704|Drug|mesna|
539556|NCT00002704|Drug|methotrexate|
539557|NCT00002704|Drug|therapeutic hydrocortisone|
539558|NCT00002704|Drug|thiotepa|
539559|NCT00002704|Drug|vincristine sulfate|
539560|NCT00002704|Radiation|low-LET electron therapy|
539561|NCT00002704|Radiation|low-LET photon therapy|
539562|NCT00002691|Biological|filgrastim|
539563|NCT00002691|Drug|asparaginase|
539564|NCT00002691|Drug|cyclophosphamide|
539565|NCT00002691|Drug|cytarabine|
539566|NCT00002691|Drug|daunorubicin hydrochloride|
539567|NCT00002691|Drug|dexamethasone|
539568|NCT00002691|Drug|etoposide|
539569|NCT00002691|Drug|leucovorin calcium|
539570|NCT00002691|Drug|mesna|
539571|NCT00002691|Drug|methotrexate|
539572|NCT00002691|Drug|vincristine sulfate|
539573|NCT00002654|Drug|chemotherapy|
539574|NCT00002654|Drug|cisplatin|
539575|NCT00002654|Radiation|low-LET cobalt-60 gamma ray therapy|
539576|NCT00002654|Radiation|low-LET electron therapy|
539577|NCT00002654|Radiation|low-LET photon therapy|
539578|NCT00086307|Drug|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
539579|NCT00086307|Drug|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
539580|NCT00086294|Drug|Intravenous Levodopa|
539584|NCT00002642|Drug|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
539585|NCT00002642|Drug|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
539586|NCT00002642|Procedure|conventional surgery|surgery some time between weeks 9 and 12
539587|NCT00002642|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
539588|NCT00002565|Biological|bleomycin sulfate|
539589|NCT00002565|Drug|CHOP regimen|
539590|NCT00002565|Drug|cisplatin|
539591|NCT00002565|Drug|cyclophosphamide|
539592|NCT00002565|Drug|cytarabine|
539593|NCT00002565|Drug|doxorubicin hydrochloride|
539594|NCT00002565|Drug|etoposide|
539595|NCT00002565|Drug|idarubicin|
539596|NCT00002565|Drug|ifosfamide|
539597|NCT00002565|Drug|mesna|
539598|NCT00002565|Drug|methylprednisolone|
539599|NCT00002565|Drug|mitoxantrone hydrochloride|
539600|NCT00002565|Drug|prednisone|
539601|NCT00002565|Drug|vincristine sulfate|
539602|NCT00086242|Behavioral|Psychosocial Telephone Counseling (PTC)|Eligible patients are randomized to receive psychosocial telephone counseling (PTC) or usual care.The PTC intervention was specifically designed to help women cope with the stressful events and feelings of distress associated with cervical cancer. The PTC arm of the study received six counseling sessions, ~45 to 50 min in length, in their preferred language, consisting of five consecutive weekly sessions and a 1-month booster session, delivered by a psychologist. A review letter, generated by the counselor after each session, recapitulated the session's contents and reinforced adaptive coping strategies.
539603|NCT00086229|Drug|Glucosamine|
539604|NCT00086229|Drug|Chondroitin|
539605|NCT00086203|Drug|Talabostat mesylate (PT-100) tablets|
539606|NCT00086203|Drug|Rituximab|
539607|NCT00086190|Drug|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
539608|NCT00086190|Drug|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
539609|NCT00086190|Other|placebo|an inactive substance
539610|NCT00086177|Drug|8% progesterone vaginal gel|Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
539611|NCT00086177|Drug|Placebo Vaginal Gel|Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
539612|NCT00086164|Drug|edifoligide (E2F Decoy)|
539613|NCT00086138|Drug|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
539614|NCT00086138|Drug|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
539615|NCT00086125|Drug|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
539616|NCT00086112|Drug|risperidone oral tablets|
539617|NCT00006041|Biological|MUC1-KLH conjugate vaccine|
539618|NCT00006041|Biological|MUC1-KLH vaccine/QS21|
539619|NCT00006041|Biological|QS21|
539620|NCT00005975|Drug|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
539621|NCT00005975|Drug|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
539622|NCT00005975|Drug|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
539623|NCT00005975|Drug|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
539624|NCT00005854|Drug|cyclophosphamide|
539625|NCT00005854|Drug|cyclosporine|
539626|NCT00005854|Drug|methotrexate|
539627|NCT00005854|Procedure|allogeneic bone marrow transplantation|
539628|NCT00005854|Procedure|in vitro-treated bone marrow transplantation|
539629|NCT00005854|Radiation|radiation therapy|
539630|NCT00002505|Biological|filgrastim|
539631|NCT00002505|Biological|recombinant interferon gamma|
539632|NCT00002505|Biological|tumor cell lysate vaccine therapy|
539633|NCT00002482|Biological|antibody therapy|
539634|NCT00002482|Biological|biological therapy|
539635|NCT00002482|Biological|muromonab-CD3|
539636|NCT00002482|Drug|cyclophosphamide|
539637|NCT00086099|Drug|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
539638|NCT00086099|Drug|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
539639|NCT00005613|Drug|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
539640|NCT00005613|Drug|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
539641|NCT00005613|Drug|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
539642|NCT00004202|Drug|carboplatin|
539643|NCT00004202|Drug|chemotherapy|
539644|NCT00004202|Drug|efaproxiral|
539645|NCT00004202|Drug|paclitaxel|
539646|NCT00004202|Radiation|radiation therapy|
539647|NCT00004197|Biological|keyhole limpet hemocyanin|
539648|NCT00004197|Biological|sargramostim|
539649|NCT00004197|Biological|tumor cell-based vaccine therapy|
539650|NCT00004197|Drug|cyclophosphamide|
539651|NCT00004197|Drug|doxorubicin hydrochloride|
539652|NCT00004197|Drug|mitoxantrone hydrochloride|
539653|NCT00004197|Drug|prednisone|
539654|NCT00004197|Drug|vincristine sulfate|
539655|NCT00004192|Biological|filgrastim|
539656|NCT00004192|Biological|pegfilgrastim|
539657|NCT00004192|Drug|cisplatin|
539658|NCT00004192|Drug|cytarabine|
539659|NCT00004192|Drug|etoposide|
539660|NCT00004192|Drug|methylprednisolone|
539661|NCT00003995|Biological|trastuzumab|
539662|NCT00003995|Drug|irinotecan hydrochloride|
539663|NCT00003946|Drug|danazol|
539664|NCT00086086|Drug|Darbepoetin Alfa|
539665|NCT00003762|Drug|docetaxel|
539666|NCT00003762|Drug|gemcitabine hydrochloride|
539667|NCT00003723|Drug|gemcitabine hydrochloride|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days)
539668|NCT00003691|Biological|filgrastim|
539669|NCT00003691|Drug|cisplatin|
539670|NCT00003691|Drug|doxorubicin hydrochloride|
539671|NCT00003691|Drug|paclitaxel|
539672|NCT00003667|Drug|cyclophosphamide|
539673|NCT00003667|Drug|dexrazoxane hydrochloride|
539674|NCT00003667|Drug|disaccharide tripeptide glycerol dipalmitoyl|
539675|NCT00003667|Drug|doxorubicin hydrochloride|
539676|NCT00003667|Drug|vincristine sulfate|
539677|NCT00003667|Procedure|surgical procedure|
539678|NCT00003667|Radiation|radiation therapy|
539679|NCT00003630|Drug|arsenic trioxide|
539680|NCT00003549|Drug|CMF regimen|
539681|NCT00003549|Drug|cyclophosphamide|
539682|NCT00003549|Drug|fluorouracil|
539683|NCT00003549|Drug|methotrexate|
539684|NCT00003369|Drug|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
539685|NCT00003369|Drug|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
539686|NCT00003317|Drug|carboplatin|
539687|NCT00003317|Drug|paclitaxel|
539688|NCT00003317|Radiation|radiation therapy|
539689|NCT00003317|Procedure|surgery|
539690|NCT00003127|Drug|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
539691|NCT00003127|Drug|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
539692|NCT00003127|Drug|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
539693|NCT00086060|Behavioral|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
539694|NCT00086060|Behavioral|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
539695|NCT00086060|Behavioral|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
539696|NCT00086047|Behavioral|Coping Skills Training|8 weekly sessions of behavioral treatment
539697|NCT00086047|Behavioral|Education|8 weekly sessions of fibromyalgia education
539698|NCT00086034|Drug|Motexafin gadolinium|
539699|NCT00003078|Drug|cisplatin|
539700|NCT00003078|Drug|fluorouracil|
539701|NCT00003078|Radiation|brachytherapy|
539702|NCT00003078|Radiation|radiation therapy|
539703|NCT00002844|Drug|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
539704|NCT00002844|Procedure|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
539705|NCT00002844|Procedure|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
539706|NCT00002844|Radiation|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
539707|NCT00002816|Drug|cytarabine|Given IV
539708|NCT00002816|Drug|dexamethasone|Given IV
539709|NCT00002816|Drug|etoposide|Given IV
539710|NCT00002816|Drug|idarubicin|Given IV
539711|NCT00002816|Drug|ifosfamide|Given IV
539712|NCT00002816|Drug|leucovorin calcium|
539713|NCT00002816|Drug|mesna|Given IV
539714|NCT00002816|Drug|pegaspargase|Given IV
539715|NCT00002816|Drug|therapeutic hydrocortisone|
539716|NCT00002816|Drug|thioguanine|
539717|NCT00002816|Drug|vincristine sulfate|Given IV
539718|NCT00002816|Radiation|low-LET cobalt-60 gamma ray therapy|
539719|NCT00002816|Radiation|low-LET electron therapy|
539720|NCT00002816|Radiation|low-LET photon therapy|
539721|NCT00002816|Drug|Methotrexate|Given IV
539722|NCT00002747|Drug|cisplatin|
539723|NCT00002747|Drug|fluorouracil|
539724|NCT00002747|Procedure|conventional surgery|
539725|NCT00002747|Radiation|low-LET cobalt-60 gamma ray therapy|
539726|NCT00002747|Radiation|low-LET photon therapy|
539727|NCT00002725|Drug|bryostatin 1|
539728|NCT00002725|Drug|chemotherapy|
539729|NCT00086021|Procedure|Acupuncture|
539730|NCT00085969|Drug|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
539731|NCT00085969|Drug|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
539732|NCT00085969|Drug|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
539733|NCT00085969|Drug|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
539734|NCT00085969|Drug|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
539735|NCT00085969|Drug|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
539736|NCT00085956|Drug|Arzoxifene|
539737|NCT00085956|Drug|Placebo|
539738|NCT00006241|Biological|filgrastim|
539739|NCT00006241|Drug|chemotherapy|
539740|NCT00006241|Procedure|in vitro-treated peripheral blood stem cell transplantation|
539741|NCT00006241|Procedure|peripheral blood stem cell transplantation|
539742|NCT00006241|Radiation|radiation therapy|
539743|NCT00006235|Drug|carboplatin|
539744|NCT00006235|Drug|pegylated liposomal doxorubicin hydrochloride|
539745|NCT00006214|Drug|flutamide|
539746|NCT00006214|Other|placebo|
539747|NCT00006117|Drug|gemcitabine hydrochloride|
539748|NCT00006117|Drug|oxaliplatin|
539749|NCT00006116|Drug|cisplatin|
539750|NCT00006116|Drug|gemcitabine hydrochloride|
539751|NCT00006088|Drug|vinorelbine tartrate|
539752|NCT00002717|Drug|cisplatin|
539753|NCT00002717|Drug|paclitaxel|
539754|NCT00002657|Biological|bleomycin sulfate|5 mg/m^2
539755|NCT00002657|Biological|recombinant interferon alfa|3.0 x 10^6 IU/m^2
539756|NCT00002657|Drug|cyclophosphamide|650 mg/m^2
539757|NCT00002657|Drug|cytarabine|300 mg/m^2
539758|NCT00002657|Drug|doxorubicin hydrochloride|25 mg/m^2
539759|NCT00002657|Drug|etoposide|120 mg/m^2
539760|NCT00002657|Drug|methotrexate|120 mg/m^2
539761|NCT00002657|Drug|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m^2.
539762|NCT00002657|Drug|vincristine sulfate|1.4 mg/m^2
539763|NCT00002657|Procedure|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
539764|NCT00002657|Radiation|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
539765|NCT00085982|Drug|Metreleptin|Administered SQ twice/day to achieve physiological concentrations that will be effective in improving the severe state of insulin resistance seen in patients with genetic defects on their insulin rece
539766|NCT00085943|Drug|LEXIVA (GW433908)|
539767|NCT00085943|Drug|Ritonavir|
539768|NCT00085943|Drug|KALETRA|
539769|NCT00085943|Drug|EPIVIR|
539770|NCT00085943|Drug|Ziagen|
539771|NCT00085943|Drug|Abacavir/Lamivudine|
539772|NCT00085943|Drug|Fosamprenavir|
539773|NCT00085930|Biological|EBV specific CTLs|CTLs: 2x10e7 cells/m2
539774|NCT00006035|Biological|bleomycin sulfate|
539775|NCT00006035|Drug|electroporation therapy|
539776|NCT00006033|Biological|gene therapy|
539777|NCT00006033|Biological|interleukin-2 gene|
539778|NCT00006033|Drug|methotrexate|
539779|NCT00005993|Drug|aldesleukin|
539780|NCT00005993|Drug|filgrastim|
539781|NCT00005993|Drug|recombinant human stem cell factor|
539782|NCT00005993|Procedure|peripheral blood stem cell transplantation|
539783|NCT00005968|Drug|irofulven|
539784|NCT00085904|Drug|SB-485232|
539785|NCT00085891|Drug|Quetiapine Fumarate|
539786|NCT00085878|Drug|SB-485232|
539787|NCT00083421|Drug|ONO-2506PO|
539788|NCT00005829|Drug|gemcitabine hydrochloride|
539789|NCT00005826|Drug|rubitecan|
539790|NCT00005616|Procedure|conventional surgery|
539791|NCT00005616|Procedure|neoadjuvant therapy|
539792|NCT00005616|Procedure|radionuclide imaging|
539793|NCT00005616|Radiation|iodine I 131 monoclonal antibody F19|
539794|NCT00005093|Drug|gemcitabine hydrochloride|
539795|NCT00005093|Drug|tacedinaline|
539796|NCT00005073|Drug|zoledronic acid|
539797|NCT00005048|Drug|estramustine phosphate sodium|
539798|NCT00005048|Drug|paclitaxel|
539799|NCT00005041|Drug|tipifarnib|
539800|NCT00004929|Biological|MUC-2-KLH vaccine|
539801|NCT00004929|Biological|QS21|
539802|NCT00004861|Drug|gemcitabine hydrochloride|
539803|NCT00004861|Drug|tacedinaline|
539804|NCT00004260|Biological|recombinant interleukin-12|
539805|NCT00004260|Biological|rituximab|
539806|NCT00004217|Biological|filgrastim|5 μg/kg/day IV or SC
539807|NCT00004217|Biological|sargramostim|5 μg/kg/day IV or SC starting d 15
539808|NCT00004217|Drug|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
539809|NCT00004217|Drug|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
539810|NCT00004217|Drug|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
539811|NCT00085917|Drug|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
539812|NCT00085917|Drug|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
539813|NCT00085852|Biological|BLVR|10 mL Hydrogel
539814|NCT00085839|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
539815|NCT00085839|Drug|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
539816|NCT00085826|Drug|Exisulind|
539817|NCT00085813|Drug|Ispinesib|
539818|NCT00085787|Drug|ARRY-142886, MEK inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
539819|NCT00085774|Drug|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
539820|NCT00085774|Drug|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
539821|NCT00085774|Drug|placebo aerosol by HFA|placebo HFA
539822|NCT00085761|Drug|Capsaicin Dermal Patch|
539823|NCT00004251|Drug|letrozole|2.5 mg of letrozole per day
539824|NCT00004076|Drug|mureletecan|
539825|NCT00004043|Dietary Supplement|calcitriol|
539826|NCT00003996|Drug|carmustine|
539827|NCT00003996|Drug|chemotherapy|
539828|NCT00003996|Drug|cisplatin|
539829|NCT00003996|Drug|etoposide|
539830|NCT00003996|Radiation|radiation therapy|
539831|NCT00003920|Biological|filgrastim|
539832|NCT00003920|Drug|cyclosporine|
539833|NCT00003920|Procedure|peripheral blood stem cell transplantation|
539834|NCT00003920|Radiation|indium In 111 monoclonal antibody m170|
539835|NCT00003920|Radiation|yttrium Y 90 monoclonal antibody m170|
539836|NCT00003898|Dietary Supplement|glutamine|Oral
539837|NCT00003894|Drug|thalidomide|
539838|NCT00003891|Drug|lurtotecan liposome|
539839|NCT00085748|Drug|paliperidone ER|
539840|NCT00085735|Drug|Cisplatin|Given IV
539841|NCT00085735|Radiation|Craniospinal Irradiation|Undergo craniospinal Irradiation
539842|NCT00085735|Drug|Cyclophosphamide|Given IV
539843|NCT00085735|Radiation|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
539844|NCT00085735|Other|Laboratory Biomarker Analysis|Correlative studies
539845|NCT00085735|Drug|Lomustine|Given orally
539846|NCT00085735|Other|Quality-of-Life Assessment|Ancillary studies
539847|NCT00085735|Radiation|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
539848|NCT00085735|Drug|Vincristine Sulfate|Given IV
539849|NCT00085722|Procedure|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
539850|NCT00085722|Procedure|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
539851|NCT00085722|Other|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
539852|NCT00085709|Drug|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses >/= 28 days apart
539853|NCT00085709|Other|observation|No treatment given
539854|NCT00085709|Drug|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
539855|NCT00085709|Drug|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
539856|NCT00085644|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
539857|NCT00085644|Biological|placebo|Placebo every other week, subcutaneous
539858|NCT00003871|Biological|fowlpox virus vaccine vector|
539859|NCT00003871|Biological|recombinant vaccinia prostate-specific antigen vaccine|
539860|NCT00003860|Biological|filgrastim|
539861|NCT00003860|Drug|carboplatin|
539862|NCT00003860|Drug|etoposide|
539863|NCT00003860|Drug|ifosfamide|
539864|NCT00003860|Procedure|in vitro-treated peripheral blood stem cell transplantation|
539865|NCT00003847|Drug|biricodar dicitrate|
539866|NCT00003847|Drug|doxorubicin hydrochloride|
539867|NCT00003847|Drug|vincristine sulfate|
539868|NCT00003829|Drug|cyclophosphamide|
539869|NCT00003829|Drug|fludarabine phosphate|
539870|NCT00003720|Drug|semaxanib|
539871|NCT00003624|Drug|amifostine trihydrate|
539872|NCT00003624|Drug|cisplatin|
539873|NCT00003624|Drug|paclitaxel|
539874|NCT00003592|Drug|methotrexate|
539875|NCT00003592|Drug|paclitaxel|
539876|NCT00003574|Procedure|surgical procedure|
539877|NCT00003574|Radiation|brachytherapy|
539878|NCT00003574|Radiation|intraoperative radiation therapy|
539879|NCT00003574|Radiation|iodine I 125|
539880|NCT00003254|Drug|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
539881|NCT00003254|Drug|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
539882|NCT00003242|Drug|bryostatin 1|
539883|NCT00003242|Drug|cisplatin|
539884|NCT00003242|Drug|paclitaxel|
539885|NCT00003206|Drug|carboplatin|
539886|NCT00003206|Drug|paclitaxel|
539887|NCT00003143|Drug|Amifostine|
539888|NCT00003143|Drug|DHAP|
539889|NCT00003099|Drug|Fenretinide|Daily for 14-28 days.
539890|NCT00003099|Drug|Tamoxifen Citrate|Daily for 14-28 days.
539891|NCT00003099|Other|Placebo|Daily for 14-28 days
539892|NCT00003085|Procedure|laparoscopy|
539893|NCT00003085|Procedure|ultrasound imaging|
539894|NCT00003028|Drug|sabarubicin|
539895|NCT00003009|Biological|aldesleukin|
539896|NCT00002973|Drug|melphalan|
539897|NCT00002973|Procedure|hyperthermia treatment|
539898|NCT00002949|Drug|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
539899|NCT00002949|Drug|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
539900|NCT00002949|Radiation|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
539901|NCT00002915|Drug|penclomedine|
539902|NCT00002864|Drug|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
539903|NCT00002864|Drug|tamoxifen citrate|20 mg PO for 5 years
539904|NCT00002838|Biological|Filgrastim (G-CSF)|
539905|NCT00002838|Drug|Cyclophosphamide|
539906|NCT00002838|Drug|Fludarabine Phosphate|
539907|NCT00002838|Procedure|Peripheral Blood Stem Cell Transplantation|
539908|NCT00002785|Biological|filgrastim|
539909|NCT00002785|Drug|asparaginase|
539910|NCT00002785|Drug|cyclophosphamide|
539911|NCT00002785|Drug|cyclosporine|
539912|NCT00002785|Drug|cytarabine|
539913|NCT00002785|Drug|daunorubicin hydrochloride|
539923|NCT00002785|Drug|therapeutic hydrocortisone|
539924|NCT00002785|Drug|vincristine sulfate|
539925|NCT00002785|Procedure|allogeneic bone marrow transplantation|
539926|NCT00002785|Radiation|low-LET cobalt-60 gamma ray therapy|
539927|NCT00002785|Radiation|low-LET photon therapy|
539928|NCT00002740|Biological|filgrastim|
539929|NCT00002740|Drug|carboplatin|
539930|NCT00002740|Drug|cyclophosphamide|
539931|NCT00002740|Drug|doxorubicin hydrochloride|
539932|NCT00002740|Drug|etoposide|
539933|NCT00002740|Drug|mesna|
539934|NCT00002740|Drug|vincristine sulfate|
539935|NCT00002740|Procedure|conventional surgery|
539936|NCT00002740|Procedure|peripheral blood stem cell transplantation|
539937|NCT00002740|Radiation|low-LET cobalt-60 gamma ray therapy|
539938|NCT00002740|Radiation|low-LET photon therapy|
539939|NCT00085696|Drug|VELCADE and rituximab|
539940|NCT00085631|Drug|cisplatin|Given IV
539941|NCT00085631|Procedure|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
539942|NCT00085631|Radiation|brachytherapy|Patients undergo brachytherapy for 2-3 days
539943|NCT00085631|Radiation|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
539944|NCT00085579|Biological|aldesleukin|
539945|NCT00085579|Biological|sargramostim|
539946|NCT00085579|Procedure|adjuvant therapy|
539947|NCT00085566|Drug|everolimus|
539948|NCT00085566|Drug|gefitinib|
539949|NCT00085553|Drug|Erlotinib Hydrochloride|Given PO
539950|NCT00085553|Other|Laboratory Biomarker Analysis|Correlative studies
539951|NCT00085553|Other|Pharmacological Study|Correlative studies
539952|NCT00085553|Drug|Tipifarnib|Given PO
539953|NCT00085540|Drug|depsipeptide|Given IV
539954|NCT00085527|Drug|depsipeptide|
539955|NCT00085501|Drug|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.~Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
539956|NCT00085501|Drug|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2~Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
539957|NCT00085501|Drug|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.~Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
539958|NCT00085488|Biological|autologous tumor cell vaccine|
539959|NCT00085488|Biological|therapeutic autologous dendritic cells|
539960|NCT00085475|Drug|imatinib mesylate|
539961|NCT00085475|Procedure|conventional surgery|
539962|NCT00085462|Biological|aldesleukin|
539963|NCT00085462|Biological|filgrastim|
539964|NCT00085462|Biological|gp100-fowlpox vaccine|
539965|NCT00085462|Biological|therapeutic autologous lymphocytes|
539966|NCT00085462|Biological|therapeutic tumor infiltrating lymphocytes|
539967|NCT00085462|Drug|cyclophosphamide|
539968|NCT00085462|Drug|fludarabine phosphate|
539969|NCT00085449|Biological|alemtuzumab|
539970|NCT00085449|Drug|cyclosporine|
539971|NCT00085449|Drug|fludarabine phosphate|
539972|NCT00085449|Drug|melphalan|
539973|NCT00085449|Drug|mycophenolate mofetil|
539974|NCT00085449|Procedure|peripheral blood stem cell transplantation|
539975|NCT00085449|Radiation|radiation therapy|
539976|NCT00085436|Biological|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
539977|NCT00085436|Biological|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
539978|NCT00085436|Biological|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
539979|NCT00085423|Biological|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
539980|NCT00085423|Biological|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
539981|NCT00085423|Drug|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
539982|NCT00085423|Drug|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
539983|NCT00085410|Drug|bortezomib|Given IV
539984|NCT00085397|Biological|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
539985|NCT00085397|Biological|gp100 antigen|Given IV
539986|NCT00085397|Biological|therapeutic autologous dendritic cells|Given IV
539987|NCT00085384|Biological|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
539988|NCT00085384|Drug|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously"
540081|NCT00084838|Drug|therapeutic hydrocortisone|
539989|NCT00085384|Biological|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron"
539990|NCT00085371|Drug|triapine|Given IV
539991|NCT00085358|Drug|carboplatin|Given intraperitoneally
539992|NCT00085358|Drug|paclitaxel|Given IV or intraperitoneally
539993|NCT00085358|Drug|docetaxel|Given IV
539994|NCT00085358|Biological|bevacizumab|Given IV
539995|NCT00085345|Drug|arsenic trioxide|
539996|NCT00085345|Drug|ascorbic acid|
539997|NCT00085345|Drug|melphalan|
539998|NCT00085345|Procedure|chemosensitization/potentiation|
539999|NCT00085345|Procedure|chemotherapy|
540000|NCT00085332|Drug|docetaxel|
540001|NCT00085306|Biological|recombinant interferon beta|recombinant interferon beta
540002|NCT00085293|Drug|Decitabine|Starting dose 6 mg/m^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
540003|NCT00085293|Radiation|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
540004|NCT00085293|Biological|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
540005|NCT00085293|Radiation|Fludeoxyglucose F 18|Optional correlative studies
540006|NCT00085293|Procedure|Positron emission tomography|Optional correlative studies
540007|NCT00085280|Drug|erlotinib hydrochloride|Given orally
540008|NCT00085280|Other|laboratory biomarker analysis|Correlative studies
540009|NCT00085254|Drug|cilengitide|Given IV
540010|NCT00085254|Drug|temozolomide|Given orally
540011|NCT00085254|Radiation|radiation therapy|Undergo radiotherapy
540012|NCT00085254|Other|laboratory biomarker analysis|Correlative studies
540013|NCT00085254|Other|pharmacological study|Correlative studies
540014|NCT00085228|Biological|oblimersen sodium|
540015|NCT00085228|Drug|docetaxel|
540016|NCT00085202|Biological|filgrastim|Given subcutaneously
540017|NCT00085202|Drug|cisplatin|Given IV
540018|NCT00085202|Drug|cyclophosphamide|Given IV
540019|NCT00085202|Drug|vincristine|Given IV
540020|NCT00085202|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
540021|NCT00085202|Radiation|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
540022|NCT00085189|Biological|gp100 antigen|Given SC
540023|NCT00085189|Biological|tyrosinase peptide|Given SC
540024|NCT00085189|Biological|recombinant MAGE-3.1 antigen|Given SC
540025|NCT00085189|Biological|multi-epitope melanoma peptide vaccine|Given SC
540026|NCT00085189|Biological|incomplete Freund's adjuvant|Given SC
540027|NCT00085189|Drug|Montanide ISA 51 VG|Given SC
540028|NCT00085189|Drug|agatolimod sodium|Given SC
540029|NCT00085189|Other|laboratory biomarker analysis|Correlative studies
540030|NCT00085176|Procedure|management of therapy complications|
540031|NCT00085176|Procedure|psychosocial assessment and care|
540032|NCT00085163|Drug|celecoxib|
540033|NCT00085163|Drug|fluorouracil|
540034|NCT00085163|Drug|leucovorin calcium|
540035|NCT00085163|Procedure|adjuvant therapy|
540036|NCT00085150|Biological|LMB-2 immunotoxin|
540037|NCT00085124|Biological|oblimersen sodium|Given IV
540038|NCT00085124|Drug|cytarabine|Given IV
540039|NCT00085124|Drug|daunorubicin hydrochloride|Given IV
540040|NCT00085124|Other|laboratory biomarker analysis|Correlative studies
540041|NCT00085111|Biological|bevacizumab|Given IV
540042|NCT00085098|Biological|filgrastim|Given by infusion or injection
540043|NCT00085098|Drug|carboplatin|Given IV over 1 hour
540044|NCT00085098|Drug|cisplatin|Given IV over 6 hours
540045|NCT00085098|Drug|cyclophosphamide|Given IV over 1 hour
540046|NCT00085098|Drug|etoposide|Given IV over 2 hours
540047|NCT00085098|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week
540048|NCT00085059|Drug|boronophenylalanine-fructose complex|
540049|NCT00085020|Biological|trastuzumab|
540050|NCT00085020|Drug|lapatinib ditosylate|
540051|NCT00084981|Drug|decitabine|Given IV
540052|NCT00084981|Drug|valproic acid|Given PO
540053|NCT00084981|Other|pharmacological study|Correlative studies
540054|NCT00084981|Other|laboratory biomarker analysis|Correlative studies
540055|NCT00084942|Drug|capecitabine|
540056|NCT00084942|Drug|gemcitabine hydrochloride|
540057|NCT00084929|Procedure|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
540058|NCT00084916|Drug|temsirolimus|Given IV
540059|NCT00084916|Other|laboratory biomarker analysis|Correlative studies
540060|NCT00084903|Procedure|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
540061|NCT00084903|Procedure|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
540062|NCT00084890|Drug|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
540063|NCT00084890|Drug|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
540064|NCT00084877|Drug|triapine|Given IV
540065|NCT00084877|Drug|irinotecan hydrochloride|Given IV
540066|NCT00084877|Other|laboratory biomarker analysis|Correlative studies
540067|NCT00084877|Other|pharmacological study|Correlative studies
540068|NCT00084864|Dietary Supplement|calcitriol|Given orally
540069|NCT00084864|Drug|dexamethasone|Given orally
540070|NCT00084864|Other|clinical observation|No intervention before surgery
540071|NCT00084838|Biological|filgrastim|
540072|NCT00084838|Drug|cisplatin|
540073|NCT00084838|Drug|cyclophosphamide|
540074|NCT00084838|Drug|cytarabine|
540075|NCT00084838|Drug|dexrazoxane hydrochloride|
540076|NCT00084838|Drug|doxorubicin hydrochloride|
540082|NCT00084838|Drug|vincristine sulfate|
540083|NCT00084838|Radiation|radiation therapy|
540084|NCT00084838|Drug|Dactinomycin|
540085|NCT00084825|Drug|Docetaxel|30 mg/m^2 IV on days 1, 8, 15, and 22 every 42 days
540086|NCT00084825|Drug|Imatinib mesylate|600 mg orally daily
540087|NCT00084812|Drug|cisplatin|
540088|NCT00084812|Drug|safingol|
540089|NCT00084799|Biological|monoclonal antibody Hu3S193|
540090|NCT00084786|Drug|docetaxel|
540091|NCT00084786|Drug|gefitinib|
540092|NCT00084773|Biological|cetuximab|
540093|NCT00084773|Drug|fluorouracil|
540094|NCT00084773|Procedure|neoadjuvant therapy|
540095|NCT00084773|Radiation|radiation therapy|
540096|NCT00084747|Drug|bortezomib|
540097|NCT00084734|Drug|capecitabine|Oral
540098|NCT00084734|Drug|cisplatin|IV
540099|NCT00084734|Drug|docetaxel|IV
540100|NCT00084721|Drug|celecoxib|
540101|NCT00084721|Drug|irinotecan hydrochloride|
540102|NCT00084708|Dietary Supplement|calcitriol|
540103|NCT00084708|Drug|dexamethasone|
540104|NCT00084708|Drug|gefitinib|
540105|NCT00084695|Biological|anti-thymocyte globulin|Given IV
540106|NCT00084695|Drug|busulfan|Given orally
540107|NCT00084695|Drug|cyclophosphamide|Given IV
540108|NCT00084695|Drug|fludarabine phosphate|Given IV
540109|NCT00084695|Drug|melphalan|Given IV
540110|NCT00084695|Drug|methylprednisolone|Given IV
540111|NCT00084695|Radiation|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
540112|NCT00084682|Drug|romidepsin|Given IV
540113|NCT00084669|Drug|venlafaxine|
540114|NCT00084669|Drug|zolpidem tartrate|
540115|NCT00084669|Procedure|management of therapy complications|
540116|NCT00084656|Biological|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
540117|NCT00084656|Biological|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
540118|NCT00084643|Biological|GTI-2040|Given IV
540119|NCT00084643|Drug|oxaliplatin|Given IV
540120|NCT00084643|Drug|capecitabine|Given orally
540121|NCT00084643|Other|pharmacological study|Correlative studies
540122|NCT00084643|Other|laboratory biomarker analysis|Correlative studies
540123|NCT00084630|Drug|imatinib mesylate|Given orally
540124|NCT00084630|Other|laboratory biomarker analysis|Correlative studies
540125|NCT00084617|Drug|oxaliplatin|Given IV
540126|NCT00084617|Drug|irinotecan hydrochloride|Given IV
540127|NCT00084617|Drug|capecitabine|Given orally
540128|NCT00084604|Drug|irinotecan hydrochloride|Given IV
540129|NCT00084604|Biological|bevacizumab|Given IV
540130|NCT00084604|Drug|cisplatin|Given IV
540131|NCT00084604|Procedure|computed tomography|Correlative studies
540132|NCT00084604|Other|laboratory biomarker analysis|Correlative studies
540133|NCT00084591|Drug|capecitabine|
540134|NCT00084591|Procedure|conventional surgery|
540135|NCT00084591|Procedure|neoadjuvant therapy|
540136|NCT00084591|Radiation|radiation therapy|
540137|NCT00084578|Drug|celecoxib|
540138|NCT00084578|Drug|rosiglitazone maleate|
540139|NCT00084578|Procedure|conventional surgery|
540140|NCT00084578|Procedure|neoadjuvant therapy|
540141|NCT00084565|Drug|estramustine phosphate sodium|
540142|NCT00084565|Drug|paclitaxel|
540143|NCT00084565|Drug|topotecan hydrochloride|
540144|NCT00084552|Radiation|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
540145|NCT00084539|Radiation|Radiation therapy|
540146|NCT00084526|Procedure|computed tomography|
540147|NCT00084526|Procedure|ultrasound imaging|
540148|NCT00084513|Biological|trastuzumab|
540149|NCT00084513|Drug|imatinib mesylate|
540150|NCT00084487|Drug|becatecarin|Given IV
540151|NCT00084461|Drug|romidepsin|Given IV
540152|NCT00084461|Other|laboratory biomarker analysis|Correlative studies
540153|NCT00084448|Drug|celecoxib|
540154|NCT00084448|Drug|paclitaxel|
540155|NCT00084435|Drug|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
540156|NCT00084435|Drug|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
540157|NCT00084435|Radiation|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
540158|NCT00084422|Drug|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
540159|NCT00084409|Drug|iloprost|Given orally
540160|NCT00084409|Other|placebo|Given orally
540161|NCT00084396|Drug|letrozole|
540162|NCT00084396|Procedure|conventional surgery|
540163|NCT00084383|Biological|GVAX pancreatic cancer vaccine|"Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination."
540164|NCT00084370|Drug|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
540165|NCT00084370|Procedure|oophorectomy|
540166|NCT00084344|Drug|4-hydroxytamoxifen|
540167|NCT00084344|Procedure|breast imaging study|
540168|NCT00084344|Procedure|radiomammography|
540450|NCT00003401|Procedure|bone marrow ablation with stem cell support|
540169|NCT00084318|Biological|cetuximab|400 mg/m^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m^2 intravenously over 60 minutes in weeks 2 through 7.
540170|NCT00084318|Drug|cisplatin|30 mg/m^2 intravenously infused over over 60 minutes in weeks 2 through 7.
540171|NCT00084318|Drug|docetaxel|15 mg/m^2 intravenously infused over 30 minutes in weeks 2 through 7.
540172|NCT00084318|Radiation|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
540173|NCT00084279|Drug|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
540174|NCT00084266|Drug|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
540175|NCT00084266|Drug|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
540176|NCT00084253|Drug|Atazanavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
540177|NCT00084253|Drug|Atazanavir-Ritonavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD*, Once daily, 96 weeks.
540178|NCT00084240|Drug|Azithromycin/Chloroquine|
540179|NCT00084240|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
540180|NCT00084227|Drug|Azithromycin/Chloroquine|
540181|NCT00084227|Drug|Atovaquone/Proguanil|
540182|NCT00084214|Drug|STA-4783|
540183|NCT00084214|Drug|Paclitaxel|
540184|NCT00002682|Drug|Amoxicillin|
540185|NCT00002682|Drug|Bismuth Subsalicylate|
540186|NCT00002682|Drug|Clarithromycin|
540187|NCT00002682|Drug|Metronidazole Hydrochloride|
540188|NCT00002682|Drug|Omeprazole|
540189|NCT00002682|Drug|Tetracycline Hydrochloride|
540190|NCT00002676|Drug|carmustine|
540191|NCT00002676|Drug|cyclophosphamide|
540192|NCT00002676|Drug|cytarabine|
540193|NCT00002676|Drug|dexamethasone|
540194|NCT00002676|Drug|doxorubicin hydrochloride|
540195|NCT00002676|Drug|methotrexate|
540196|NCT00002676|Drug|vincristine sulfate|
540197|NCT00002676|Radiation|low-LET cobalt-60 gamma ray therapy|
540198|NCT00002676|Radiation|low-LET photon therapy|
540199|NCT00002670|Drug|chemotherapy|
540200|NCT00002670|Drug|cisplatin|
540201|NCT00002670|Radiation|low-LET cobalt-60 gamma ray therapy|
540202|NCT00002670|Radiation|low-LET electron therapy|
540203|NCT00002670|Radiation|low-LET photon therapy|
540204|NCT00002656|Drug|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.~Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
540205|NCT00002646|Drug|fenretinide|
540206|NCT00002646|Drug|tamoxifen citrate|
540207|NCT00002637|Biological|aldesleukin|
540208|NCT00002637|Biological|gene-modified tumor cell vaccine therapy|
540209|NCT00002637|Biological|recombinant interferon gamma|
540210|NCT00002632|Drug|paclitaxel|
540211|NCT00002625|Drug|topotecan hydrochloride|
540212|NCT00002625|Radiation|low-LET electron therapy|
540213|NCT00002625|Radiation|low-LET photon therapy|
540214|NCT00002551|Drug|fluorouracil|See arm assignments.
540215|NCT00002551|Drug|leucovorin calcium|See arm assignments.
540216|NCT00002551|Drug|levamisole hydrochloride|See arm assignments.
540217|NCT00002551|Radiation|radiation therapy|See arm assignments.
540218|NCT00002538|Procedure|laparoscopic surgery|
540219|NCT00084201|Drug|Cranberry juice|
540220|NCT00084201|Drug|Amoxicillin|
540221|NCT00084188|Behavioral|Behavior Therapy|
540222|NCT00084175|Behavioral|Behavior Therapy|
540223|NCT00006451|Drug|anti-thymocyte globulin|
540224|NCT00006451|Drug|cyclophosphamide|
540225|NCT00006451|Drug|cyclosporine|
540226|NCT00006451|Drug|methotrexate|
540227|NCT00006451|Drug|methylprednisolone|
540228|NCT00006451|Procedure|allogeneic bone marrow transplantation|
540229|NCT00006451|Procedure|in vitro-treated bone marrow transplantation|
540230|NCT00006451|Procedure|radiation therapy|
540231|NCT00006387|Biological|QS21|
540232|NCT00006387|Biological|ras peptide cancer vaccine|
540233|NCT00006382|Procedure|bronchoscopic and lung imaging studies|
540234|NCT00006382|Procedure|comparison of screening methods|
540235|NCT00006382|Procedure|computed tomography|
540236|NCT00006382|Procedure|radiography|
540237|NCT00006382|Procedure|study of high risk factors|
540238|NCT00006380|Biological|monoclonal antibody muJ591|
540239|NCT00006380|Radiation|iodine I 131 monoclonal antibody muJ591|
540240|NCT00006378|Drug|carboplatin|
540241|NCT00006378|Drug|paclitaxel|
540242|NCT00006378|Radiation|radiation therapy|
540243|NCT00006374|Biological|filgrastim|
540244|NCT00006374|Drug|cisplatin|
540245|NCT00006374|Drug|etoposide|
540246|NCT00006374|Drug|paclitaxel|
540247|NCT00006374|Drug|topotecan hydrochloride|
540248|NCT00006251|Radiation|total-body irradiation|Undergo TBI
540249|NCT00006251|Drug|fludarabine phosphate|Given IV
540250|NCT00006251|Drug|cyclosporine|Given PO
540251|NCT00006251|Drug|mycophenolate mofetil|Given PO
540252|NCT00006251|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
540253|NCT00006251|Biological|donor lymphocytes|Undergo DLI
540254|NCT00006251|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
540255|NCT00006251|Other|laboratory biomarker analysis|Correlative studies
540256|NCT00005994|Drug|ondansetron|
540257|NCT00005790|Other|laboratory biomarker analysis|
540258|NCT00005790|Procedure|biopsy|
540259|NCT00005790|Procedure|magnetic resonance imaging|
540260|NCT00005790|Radiation|gadopentetate dimeglumine|
540261|NCT00005084|Procedure|conventional surgery|
540262|NCT00005084|Procedure|magnetic resonance spectroscopic imaging|
540263|NCT00005084|Radiation|radiation therapy|
540264|NCT00005045|Drug|carboxyamidotriazole|
540265|NCT00004236|Drug|pegylated liposomal doxorubicin hydrochloride|
540266|NCT00003992|Biological|trastuzumab|
540267|NCT00003992|Drug|cyclophosphamide|
540268|NCT00003992|Drug|doxorubicin hydrochloride|
540269|NCT00003992|Drug|paclitaxel|
540270|NCT00003992|Drug|tamoxifen citrate|
540271|NCT00003859|Drug|carboplatin|
540272|NCT00003859|Drug|cyclophosphamide|
540273|NCT00003859|Drug|etoposide|
540274|NCT00003859|Drug|vincristine sulfate|
540275|NCT00003859|Procedure|surgical procedure|
540276|NCT00003859|Radiation|radiation therapy|
540277|NCT00003733|Drug|carboplatin|
540278|NCT00003733|Drug|paclitaxel|
540279|NCT00003733|Drug|topotecan hydrochloride|
540280|NCT00003584|Drug|estramustine phosphate sodium|
540281|NCT00003584|Drug|prednisone|
540282|NCT00003584|Drug|vinorelbine tartrate|
540283|NCT00003435|Biological|anti-thymocyte globulin|
540284|NCT00003435|Drug|melphalan|
540285|NCT00003435|Procedure|antiviral therapy|
540286|NCT00003435|Procedure|bone marrow ablation with stem cell support|
540287|NCT00003435|Procedure|peripheral blood stem cell transplantation|
540288|NCT00003435|Procedure|umbilical cord blood transplantation|
540289|NCT00003435|Radiation|radiation therapy|
540290|NCT00003410|Drug|motexafin gadolinium|
540291|NCT00003410|Procedure|magnetic resonance imaging|
540292|NCT00003410|Procedure|surgical procedure|
540293|NCT00003372|Drug|topotecan hydrochloride|
540294|NCT00003236|Biological|ISIS 3521|
540295|NCT00003236|Drug|ISIS 5132|
540296|NCT00002905|Drug|cyclophosphamide|
540297|NCT00002905|Drug|didanosine|
540298|NCT00002905|Drug|doxorubicin hydrochloride|
540299|NCT00002905|Drug|etoposide|
540300|NCT00002905|Drug|mitoxantrone hydrochloride|
540301|NCT00002905|Drug|prednimustine|
540302|NCT00002905|Drug|zidovudine|
540303|NCT00002496|Drug|chemotherapy|
540304|NCT00002496|Drug|cisplatin|
540305|NCT00002496|Drug|fluorouracil|
540306|NCT00002496|Procedure|conventional surgery|
540307|NCT00002496|Radiation|low-LET cobalt-60 gamma ray therapy|
540308|NCT00002496|Radiation|low-LET electron therapy|
540309|NCT00002496|Radiation|low-LET photon therapy|
540310|NCT00002478|Drug|etoposide|
540311|NCT00002476|Biological|bleomycin sulfate|
540312|NCT00002476|Drug|fluorouracil|
540313|NCT00002476|Drug|leucovorin calcium|
540314|NCT00002476|Drug|methotrexate|
540315|NCT00002476|Drug|vincristine sulfate|
540316|NCT00002476|Radiation|low-LET cobalt-60 gamma ray therapy|
540317|NCT00002476|Radiation|low-LET photon therapy|
540318|NCT00002476|Radiation|radiation therapy|
540319|NCT00002460|Drug|goserelin acetate|
540320|NCT00002460|Drug|tamoxifen citrate|
540321|NCT00002460|Procedure|ablative endocrine surgery|
540322|NCT00002460|Procedure|oophorectomy|
540323|NCT00084149|Drug|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
540324|NCT00084149|Drug|Lopinavir/Ritonavir|antiretroviral therapy
540325|NCT00084136|Drug|Atazanavir|400 mg taken orally daily
540326|NCT00084136|Drug|Didanosine (enteric-coated)|400 mg taken orally daily
540327|NCT00084136|Drug|Efavirenz|600 mg taken orally daily
540328|NCT00084136|Drug|Emtricitabine|200 mg taken orally daily
540329|NCT00084136|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
540330|NCT00084136|Drug|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
540331|NCT00084123|Behavioral|Healing Touch Therapy|
540332|NCT00084123|Behavioral|Relaxation Therapy|
540333|NCT00084123|Behavioral|Standard Care|Standard Care
540334|NCT00084071|Drug|Tifacogin|
540335|NCT00083993|Drug|Temsirolimus (CCI-779) for 34 months|
540336|NCT00083993|Drug|Letrozole for 34 months|
540337|NCT00005960|Biological|filgrastim|
540338|NCT00005960|Drug|cyclophosphamide|
540339|NCT00005960|Drug|docetaxel|
540340|NCT00005960|Drug|doxorubicin hydrochloride|
540341|NCT00005960|Procedure|pain therapy|
540342|NCT00005641|Biological|anti-thymocyte globulin|
540343|NCT00005641|Drug|busulfan|
540344|NCT00005641|Drug|cyclophosphamide|
540345|NCT00005641|Drug|cyclosporine|
540346|NCT00005641|Drug|leucovorin calcium|
540347|NCT00005641|Drug|methotrexate|
540348|NCT00005641|Drug|methylprednisolone|
540349|NCT00005641|Procedure|allogeneic bone marrow transplantation|
540350|NCT00005641|Procedure|in vitro-treated bone marrow transplantation|
540351|NCT00005641|Radiation|radiation therapy|
540352|NCT00005091|Drug|exatecan mesylate|
540353|NCT00005054|Drug|temozolomide|
540354|NCT00005050|Drug|ethynyluracil|
540355|NCT00005050|Drug|fluorouracil|
540356|NCT00005050|Drug|oxaliplatin|
540357|NCT00084097|Drug|Omalizumab|
540451|NCT00003401|Procedure|peripheral blood stem cell transplantation|
540358|NCT00084084|Drug|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
540359|NCT00084058|Drug|Lopinavir/ritonavir|
540360|NCT00084058|Drug|Saquinavir|
540361|NCT00084045|Procedure|Intrapartum HIV counseling/testing|
540362|NCT00084045|Procedure|Postpartum HIV counseling/testing|
540363|NCT00084032|Behavioral|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
540364|NCT00084032|Drug|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
540365|NCT00084019|Drug|Atazanavir|
540366|NCT00084019|Drug|Ritonavir|
540367|NCT00083980|Drug|Venlafaxine ER|75 to 225 mg daily
540368|NCT00083980|Drug|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
540369|NCT00083980|Drug|Kava|140 to 280 mg per day
540370|NCT00083967|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
540371|NCT00083954|Drug|Quetiapine Fumarate|
540372|NCT00083941|Biological|TroVax in combination with IL-2|1ml intramuscular injection
540373|NCT00083928|Drug|Å6 subcutaneous injection|
540374|NCT00083915|Drug|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
540375|NCT00083915|Drug|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
540376|NCT00083915|Drug|Adriamycin|20mg/m2 continuous infusion -3 and -2.
540377|NCT00083915|Drug|Etoposide|80mg/m2 continuous infusion -3 and -2.
540378|NCT00083915|Drug|Melphalan|200 mg/m2 IV over <20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
540379|NCT00083915|Drug|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets >50 thousand (K).
540380|NCT00083915|Drug|Dexamethasone|40 mg po days 1 - 4 (4 days)
540381|NCT00083902|Drug|Thalidomide|
540382|NCT00083902|Drug|Dexamethasone|
540383|NCT00083889|Drug|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
540384|NCT00083889|Drug|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
540385|NCT00083876|Drug|Thalidomide|
540386|NCT00083824|Drug|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
540387|NCT00083824|Drug|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
540388|NCT00083824|Drug|Placebo|2 pills/day QID for 3 years
540389|NCT00005032|Biological|oblimersen sodium|
540390|NCT00005032|Drug|paclitaxel|
540391|NCT00005030|Drug|SCH 66336|
540392|NCT00005030|Procedure|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
540393|NCT00004979|Drug|paclitaxel|
540394|NCT00004979|Drug|topotecan hydrochloride|
540395|NCT00004927|Drug|ixabepilone|
540396|NCT00004877|Drug|BMS-214662|
540397|NCT00004161|Drug|fenretinide|
540398|NCT00004161|Drug|Placebo|
540399|NCT00004146|Radiation|radiation therapy|Undergo radiotherapy
540400|NCT00004146|Drug|carboxyamidotriazole|Given orally
540401|NCT00004146|Other|pharmacological study|Correlative studies
540402|NCT00004071|Drug|leflunomide|
540403|NCT00004071|Drug|mitoxantrone hydrochloride|
540404|NCT00004071|Drug|prednisone|
540405|NCT00004070|Biological|IL-12|
540406|NCT00004062|Drug|azacitidine|
540407|NCT00004062|Drug|liothyronine sodium|
540408|NCT00004062|Radiation|iodine I 131|
540409|NCT00083785|Drug|Talaporfin sodium (LS11)|
540410|NCT00083785|Device|LED-based light infusion device|
540411|NCT00083785|Device|Light emitting diodes (LED)|
540412|NCT00083785|Procedure|Photodynamic therapy|
540413|NCT00083785|Procedure|Phototherapy|
540414|NCT00083785|Procedure|Chemotherapy|
540415|NCT00083772|Drug|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
540416|NCT00083759|Drug|natalizumab|
540417|NCT00083759|Drug|placebo|
540418|NCT00004055|Biological|filgrastim|
540419|NCT00004055|Drug|paclitaxel|
540420|NCT00004055|Drug|topotecan hydrochloride|
540421|NCT00003998|Drug|carboplatin|
540422|NCT00003998|Drug|docetaxel|
540423|NCT00003998|Drug|paclitaxel|
540424|NCT00003998|Procedure|surgical procedure|
540425|NCT00003997|Drug|irofulven|
540426|NCT00003991|Biological|aldesleukin|
540427|NCT00003991|Drug|histamine dihydrochloride|
540428|NCT00003939|Drug|trabectedin|
540429|NCT00003856|Drug|temoporfin|
540430|NCT00003850|Drug|thalidomide|
540431|NCT00003787|Behavioral|educational/counseling intervention|
540432|NCT00003787|Behavioral|therapeutic dietary intervention|
540433|NCT00003773|Drug|oglufanide disodium|
540434|NCT00003758|Drug|cytarabine|
540435|NCT00003758|Drug|idarubicin|
540436|NCT00003758|Procedure|allogeneic bone marrow transplantation|
540437|NCT00003758|Procedure|autologous bone marrow transplantation|
540438|NCT00003758|Procedure|peripheral blood stem cell transplantation|
540439|NCT00003755|Drug|MKC-1|
540440|NCT00003740|Biological|trastuzumab|
540441|NCT00003443|Drug|bryostatin 1|
540442|NCT00003401|Drug|carmustine|
540443|NCT00003401|Drug|cisplatin|
540444|NCT00003401|Drug|cyclophosphamide|
540445|NCT00003401|Drug|dexamethasone|
540446|NCT00003401|Drug|etoposide|
540447|NCT00003401|Drug|gemcitabine hydrochloride|
540448|NCT00003401|Drug|melphalan|
540449|NCT00003401|Drug|paclitaxel|
540452|NCT00003399|Drug|carmustine|
540459|NCT00003399|Procedure|in vitro-treated peripheral blood stem cell transplantation|
540460|NCT00003396|Biological|anti-thymocyte globulin|
540461|NCT00003396|Biological|graft-versus-tumor induction therapy|
540462|NCT00003396|Drug|cyclophosphamide|
540463|NCT00003396|Drug|melphalan|
540464|NCT00003396|Procedure|peripheral blood stem cell transplantation|
540465|NCT00003396|Radiation|radiation therapy|
540466|NCT00003293|Drug|leflunomide|
540467|NCT00003293|Drug|procarbazine hydrochloride|
540468|NCT00003249|Drug|carboxyamidotriazole|
540469|NCT00003249|Drug|chemotherapy|
540470|NCT00003249|Drug|ketoconazole|
540471|NCT00003231|Drug|cisplatin|
540472|NCT00003231|Drug|docetaxel|
540473|NCT00003231|Procedure|surgical procedure|
540474|NCT00003231|Radiation|radiation therapy|
540475|NCT00083720|Biological|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
540476|NCT00083707|Drug|Thalidomide|
540477|NCT00083694|Drug|Thalidomide|
540478|NCT00083681|Drug|Thalidomide|
540479|NCT00083681|Drug|Dexamethasone|
540480|NCT00083681|Drug|Cytoxan|
540481|NCT00083681|Drug|Etoposide|
540482|NCT00083681|Drug|Cisplatin|
540483|NCT00083681|Drug|G-CSF|
540484|NCT00083668|Drug|Paliperidone ER|
540485|NCT00083616|Biological|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
540486|NCT00083564|Drug|STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)|
540487|NCT00083629|Procedure|PET|
540488|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^7 pfu /2mL administered in each deltoid
540489|NCT00083603|Biological|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
540490|NCT00083603|Biological|Empty TBC-FPV|Empty FPV 10^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
540491|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^8 pfu /2mL administered in each deltoid
540492|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^9 pfu /2mL administered in each deltoid
540493|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^7 pfu/2mL administered into each deltoid
540494|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^8 pfu/2mL administered into each deltoid
540495|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^9 pfu/2mL administered into each deltoid
540496|NCT00083590|Drug|Huperzine A|
540497|NCT00083577|Drug|Thalidomide|
540498|NCT00083551|Drug|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
540499|NCT00083551|Drug|Ara-C|"Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).~Start infusion 30 minutes after completion of BCNU on day -5."
540500|NCT00083551|Drug|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
540501|NCT00083551|Drug|Cisplatin|"Cisplatin* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)~*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) < 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) > 3.0 mg/dl"
540502|NCT00083551|Drug|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
540503|NCT00083551|Drug|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as < 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
540504|NCT00083551|Drug|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
540505|NCT00083551|Drug|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
540506|NCT00083551|Drug|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
540507|NCT00083551|Drug|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
540508|NCT00083551|Drug|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
540509|NCT00083551|Drug|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
540510|NCT00083551|Drug|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
540511|NCT00083538|Drug|Dexamethasone|
540512|NCT00083538|Drug|Thalidomide|
540513|NCT00083538|Drug|Cisplatinum|
540514|NCT00083538|Drug|Adriamycin|
540515|NCT00083538|Drug|Cyclophosphamide|
540516|NCT00083538|Drug|Etoposide|
540517|NCT00083486|Drug|epoetin alfa|
540518|NCT00003160|Drug|paclitaxel|
540519|NCT00003079|Drug|bryostatin 1|
540520|NCT00003079|Drug|cytarabine|
540521|NCT00003075|Drug|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
540522|NCT00003075|Other|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
540523|NCT00003031|Drug|amphotericin B deoxycholate|
540524|NCT00003031|Drug|voriconazole|
540525|NCT00003015|Drug|carboplatin|
540526|NCT00003015|Drug|vincristine sulfate|
540527|NCT00003015|Procedure|conventional surgery|
540528|NCT00003015|Radiation|radiation therapy|
540529|NCT00083525|Drug|WX-UK1 in combination with Capecitabine|
540530|NCT00083473|Drug|Pivanex|
540531|NCT00083460|Drug|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
540532|NCT00083460|Drug|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
540533|NCT00083460|Drug|Dexamethasone|A dose of 20mg for cylces 3-8.
540534|NCT00083447|Drug|TransMID™|
540535|NCT00083434|Drug|Epoetin alfa|
540536|NCT00006877|Drug|temozolomide|
540537|NCT00006358|Drug|temozolomide|
540538|NCT00006358|Drug|thalidomide|
540539|NCT00006343|Biological|recombinant interferon alfa|
540540|NCT00006343|Drug|cytarabine|
540541|NCT00006343|Drug|imatinib mesylate|
540542|NCT00006222|Drug|cilengitide|
540543|NCT00006212|Drug|cisplatin|
540544|NCT00006212|Drug|vinblastine sulfate|
540545|NCT00006212|Radiation|phosphorus P32|
540546|NCT00006212|Radiation|radiation therapy|
540547|NCT00006083|Drug|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
540548|NCT00006083|Other|placebo|placebo injected subcutaneously daily
540549|NCT00006079|Drug|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
540550|NCT00006079|Other|Placebo|Patients receive oral placebo daily for 28 days.
540551|NCT00006001|Drug|semaxanib|
540552|NCT00005942|Drug|liposomal daunorubicin citrate|Given IV
540553|NCT00005942|Drug|semaxanib|Given IV
540554|NCT00005942|Other|laboratory biomarker analysis|Correlative studies
540555|NCT00005939|Radiation|brachytherapy|
540556|NCT00005939|Radiation|phosphorus P32|
540557|NCT00005841|Biological|MART-1 antigen|
540558|NCT00005841|Biological|gp100 antigen|
540559|NCT00005841|Biological|incomplete Freund's adjuvant|
540560|NCT00005841|Biological|progenipoietin|
540561|NCT00005841|Biological|tyrosinase peptide|
540562|NCT00005645|Drug|ILX-295501|
540563|NCT00005640|Procedure|Preoperative Endoscopy|
540564|NCT00005640|Radiation|Technetium Tc 99m Sulfur Colloid|
540565|NCT00005640|Procedure|Gamma Probe|
540566|NCT00005640|Procedure|Biopsy of Sentinel Lymph Nodes|
540567|NCT00005636|Drug|cisplatin|
540568|NCT00005636|Drug|pemetrexed disodium|
540569|NCT00005578|Biological|bleomycin sulfate|
540570|NCT00005578|Biological|filgrastim|
540571|NCT00005578|Drug|cyclophosphamide|
540572|NCT00005578|Drug|dexrazoxane hydrochloride|
540573|NCT00005578|Drug|doxorubicin hydrochloride|
540574|NCT00005578|Drug|etoposide|
540575|NCT00005578|Drug|prednisone|
540576|NCT00005578|Drug|vincristine sulfate|
540577|NCT00005578|Radiation|radiation therapy|
540578|NCT00005088|Drug|cisplatin|
540579|NCT00005088|Radiation|radiation therapy|
540580|NCT00005069|Drug|arsenic trioxide|
540581|NCT00005059|Drug|carboplatin|
540582|NCT00005059|Drug|paclitaxel|
540583|NCT00002923|Drug|KRN5500|
540584|NCT00002917|Drug|paclitaxel|
540585|NCT00002911|Drug|marimastat|
540586|NCT00002829|Biological|Recombinant Interferon Alfa|Daily
540587|NCT00002829|Drug|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
540588|NCT00002829|Drug|Etoposide|Administered intravenously on Day -8
540589|NCT00002829|Drug|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
540590|NCT00002829|Procedure|Bone Marrow Transplantation|Infusion on Day 0.
540591|NCT00002829|Radiation|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
540592|NCT00002827|Biological|bleomycin sulfate|Given IV
540593|NCT00002827|Biological|filgrastim|Given IV
540594|NCT00002827|Drug|dexrazoxane hydrochloride|Given IV
540595|NCT00002827|Drug|doxorubicin hydrochloride|Given IV
540596|NCT00002827|Drug|etoposide|Given IV
540597|NCT00002827|Drug|vincristine sulfate|Given IV
540598|NCT00002827|Radiation|low-LET cobalt-60 gamma ray therapy|
540599|NCT00002827|Radiation|low-LET electron therapy|
540600|NCT00002827|Radiation|low-LET photon therapy|
540601|NCT00002819|Drug|carboplatin|
540602|NCT00002819|Drug|cyclophosphamide|
540603|NCT00002819|Drug|mitoxantrone hydrochloride|
540604|NCT00002819|Drug|paclitaxel|
540605|NCT00002819|Procedure|autologous bone marrow transplantation|
540606|NCT00002819|Procedure|peripheral blood stem cell transplantation|
540607|NCT00002806|Drug|lomustine|
540608|NCT00002806|Drug|procarbazine hydrochloride|
540609|NCT00002806|Drug|vincristine sulfate|
540610|NCT00002806|Radiation|low-LET photon therapy|
540611|NCT00002721|Drug|doxorubicin hydrochloride|
540612|NCT00002721|Drug|estramustine phosphate sodium|
540613|NCT00002721|Procedure|drug resistance inhibition treatment|
540614|NCT00002639|Drug|chemotherapy|
540615|NCT00002639|Drug|suramin|
540616|NCT00002602|Radiation|3D-CRT|3 dimensional conformal radiation therapy
540617|NCT00002555|Drug|cisplatin|
540618|NCT00002555|Radiation|low-LET cobalt-60 gamma ray therapy|
540619|NCT00002555|Radiation|low-LET electron therapy|
540620|NCT00002555|Radiation|low-LET photon therapy|
540621|NCT00002477|Drug|carboplatin|
540622|NCT00002477|Drug|cisplatin|
540623|NCT00002477|Drug|cyclophosphamide|
540624|NCT00002477|Drug|doxorubicin hydrochloride|
540625|NCT00083408|Drug|Pamidronate|
540626|NCT00083408|Drug|Thalidomide|
540627|NCT00004881|Biological|MVA-MUC1-IL2 vaccine|
540628|NCT00004200|Drug|prinomastat|
540629|NCT00004200|Drug|temozolomide|
540630|NCT00004190|Drug|gemcitabine hydrochloride|
540631|NCT00004190|Drug|oxaliplatin|
540632|NCT00004176|Drug|amifostine trihydrate|
540633|NCT00004176|Drug|cisplatin|
540634|NCT00004176|Drug|etoposide|
540635|NCT00004176|Radiation|radiation therapy|
540636|NCT00004139|Drug|docetaxel|
540637|NCT00004139|Drug|gemcitabine hydrochloride|
540638|NCT00004139|Drug|irinotecan hydrochloride|
540639|NCT00004112|Biological|rituximab|
540640|NCT00004112|Drug|CHOP regimen|
540641|NCT00004112|Drug|cyclophosphamide|
540642|NCT00004112|Drug|doxorubicin hydrochloride|
540643|NCT00004112|Drug|prednisone|
540644|NCT00004112|Drug|vincristine sulfate|
540645|NCT00004105|Drug|estramustine phosphate sodium|
540646|NCT00004105|Drug|paclitaxel|
540647|NCT00004105|Drug|vinorelbine ditartrate|
540648|NCT00004061|Biological|filgrastim|
540649|NCT00004061|Biological|palifermin|
540650|NCT00004061|Drug|cyclophosphamide|
540651|NCT00004061|Drug|etoposide|
540652|NCT00004061|Drug|ifosfamide|
540653|NCT00004061|Procedure|peripheral blood stem cell transplantation|
540654|NCT00004061|Procedure|quality-of-life assessment|
540655|NCT00004061|Radiation|radiation therapy|
540656|NCT00004030|Drug|VX-853|
540657|NCT00004030|Drug|pegylated liposomal doxorubicin hydrochloride|
540658|NCT00004012|Drug|capecitabine|
540659|NCT00003985|Drug|KRN7000|
540660|NCT00003984|Biological|lintuzumab|
540661|NCT00003982|Drug|sabarubicin|
540662|NCT00003980|Drug|BIBX 1382|
540663|NCT00003944|Biological|filgrastim|
540664|NCT00003944|Drug|carboplatin|
540665|NCT00003944|Drug|cyclophosphamide|
540666|NCT00003944|Drug|paclitaxel|
540667|NCT00003944|Drug|topotecan hydrochloride|
540668|NCT00003944|Procedure|peripheral blood stem cell transplantation|
540669|NCT00003846|Biological|filgrastim|
540670|NCT00003846|Drug|carboplatin|
540671|NCT00003846|Drug|cyclophosphamide|
540672|NCT00003846|Drug|thiotepa|
540673|NCT00003846|Drug|vincristine sulfate|
540674|NCT00003846|Procedure|bone marrow ablation with stem cell support|
540675|NCT00003846|Procedure|peripheral blood stem cell transplantation|
540676|NCT00003846|Radiation|radiation therapy|
540677|NCT00003752|Drug|bexarotene|
540678|NCT00003669|Drug|arzoxifene hydrochloride|
540679|NCT00003580|Drug|amifostine trihydrate|
540680|NCT00003580|Drug|cisplatin|
540681|NCT00003580|Radiation|radiation therapy|
540682|NCT00083382|Drug|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
540683|NCT00083382|Drug|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.~Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
540684|NCT00083382|Drug|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
540685|NCT00083343|Drug|MK0991, caspofungin acetate/Duration of Treatment: variable|
540686|NCT00008229|Biological|filgrastim|
540687|NCT00008229|Drug|melphalan|
540688|NCT00008229|Procedure|peripheral blood stem cell transplantation|
540689|NCT00008229|Radiation|holmium Ho 166 DOTMP|
540690|NCT00008073|Drug|doxorubicin hydrochloride|
540691|NCT00008073|Drug|octreotide acetate|
540692|NCT00006344|Radiation|radiation therapy|
540693|NCT00006269|Drug|irinotecan hydrochloride|
540694|NCT00006269|Drug|octreotide acetate|
540695|NCT00003614|Drug|estramustine phosphate sodium|
540696|NCT00003614|Drug|paclitaxel|
540697|NCT00003523|Drug|aminocamptothecin colloidal dispersion|
540698|NCT00003518|Drug|gemcitabine hydrochloride|
540699|NCT00003518|Drug|paclitaxel|
540700|NCT00003444|Biological|recombinant interferon alfa|
540701|NCT00003444|Radiation|radiation therapy|
540702|NCT00003405|Biological|recombinant interferon alfa|
540703|NCT00003405|Drug|amifostine trihydrate|
540704|NCT00003405|Drug|bromodeoxyuridine|
540705|NCT00003405|Drug|cytarabine|
540709|NCT00003405|Drug|mitoxantrone hydrochloride|
540710|NCT00003403|Drug|GPX-100|
540711|NCT00003269|Biological|sargramostim|
540712|NCT00003269|Drug|amifostine trihydrate|
540713|NCT00003269|Drug|cisplatin|
540714|NCT00003269|Drug|cyclophosphamide|
540715|NCT00003269|Drug|etoposide|
540716|NCT00003195|Biological|recombinant interferon alfa|
540717|NCT00003195|Drug|busulfan|
540718|NCT00003195|Procedure|allogeneic bone marrow transplantation|
540719|NCT00003195|Procedure|peripheral blood stem cell transplantation|
540720|NCT00003195|Radiation|radiation therapy|
540721|NCT00003187|Biological|filgrastim|
540722|NCT00003187|Drug|cyclophosphamide|
540723|NCT00003187|Drug|cyclosporine|
540724|NCT00003187|Drug|cytarabine|
540725|NCT00003187|Drug|methotrexate|
540726|NCT00003187|Drug|methylprednisolone|
540727|NCT00003187|Procedure|allogeneic bone marrow transplantation|
540728|NCT00003187|Procedure|in vitro-treated bone marrow transplantation|
540729|NCT00003187|Radiation|radiation therapy|
540730|NCT00003098|Other|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
540731|NCT00003098|Other|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
540732|NCT00003084|Drug|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
540733|NCT00003084|Drug|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.~Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
540734|NCT00003084|Drug|Etoposide|Oral etoposide twice daily on days 1-14.
540735|NCT00003084|Drug|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
540736|NCT00003084|Drug|Paclitaxel|IV over 1 hour on day 2.
540737|NCT00003084|Drug|Vinblastine|IV on days 8, 22, and 36.
540738|NCT00003056|Drug|cyclosporine|
540739|NCT00003056|Drug|cyclosporine and methotrexate|
540740|NCT00003004|Drug|alvocidib|
540741|NCT00003004|Drug|cisplatin|
540742|NCT00003004|Drug|paclitaxel|
540743|NCT00002924|Other|mutation analysis|
540744|NCT00002902|Drug|irinotecan hydrochloride|
540745|NCT00002902|Drug|raltitrexed|
540746|NCT00002875|Biological|filgrastim|
540747|NCT00002875|Drug|cisplatin|
540748|NCT00002875|Drug|cyclophosphamide|
540749|NCT00002875|Drug|lomustine|
540750|NCT00002875|Drug|mesna|
540751|NCT00002875|Drug|vincristine sulfate|
540752|NCT00002875|Radiation|low-LET electron therapy|
540753|NCT00002875|Radiation|low-LET photon therapy|
540754|NCT00002780|Biological|aldesleukin|
540755|NCT00002780|Biological|cytokine therapy|
540756|NCT00002780|Biological|sargramostim|
540757|NCT00002780|Drug|carboplatin|
540758|NCT00002780|Drug|cyclophosphamide|
540759|NCT00002780|Drug|thiotepa|
540760|NCT00002780|Procedure|peripheral blood stem cell transplantation|
540761|NCT00002750|Drug|melphalan|
540762|NCT00002734|Biological|recombinant interferon alfa|
540763|NCT00002734|Drug|chemotherapy|
540764|NCT00002734|Drug|paclitaxel|
540765|NCT00002734|Drug|topotecan hydrochloride|
540766|NCT00002734|Radiation|lutetium Lu 177 monoclonal antibody CC49|
540767|NCT00002734|Radiation|yttrium Y 90 monoclonal antibody CC49|
540768|NCT00002671|Drug|aminocamptothecin|
540769|NCT00002664|Biological|edrecolomab|
540770|NCT00002664|Biological|sargramostim|
540771|NCT00002576|Drug|cyclophosphamide|
540772|NCT00002576|Drug|doxorubicin hydrochloride|
540773|NCT00002576|Drug|mitoxantrone hydrochloride|
540774|NCT00002576|Drug|prednisolone|
540775|NCT00002576|Drug|vincristine sulfate|
540776|NCT00002571|Biological|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
540777|NCT00002571|Biological|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
540778|NCT00002571|Drug|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
540779|NCT00002571|Drug|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
540780|NCT00002571|Drug|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
540781|NCT00002571|Drug|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
540782|NCT00002571|Drug|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
540783|NCT00002571|Drug|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
540784|NCT00002571|Drug|prednisone|60 mg/m2 po QD x 14days for 6 cycles
540785|NCT00002571|Drug|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
540786|NCT00002571|Drug|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
546937|NCT00009932|Drug|fenretinide|
540787|NCT00002571|Radiation|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
540788|NCT00002571|Drug|Intrathecal cytarabine|"If initial bone marrow positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.~If initial CSF cytology positive:~Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.~If initial bone marrow and CSF negative:~Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy."
540789|NCT00002567|Biological|filgrastim|
540790|NCT00002567|Drug|etoposide|
540791|NCT00002567|Procedure|peripheral blood stem cell transplantation|
540792|NCT00002567|Radiation|low-LET electron therapy|
540793|NCT00002567|Radiation|low-LET photon therapy|
540794|NCT00002552|Biological|filgrastim|
540795|NCT00002552|Biological|sargramostim|
540796|NCT00002552|Drug|carmustine|
540797|NCT00002552|Drug|cyclophosphamide|
540798|NCT00002552|Drug|cytarabine|
540799|NCT00002552|Drug|etoposide|
540800|NCT00002552|Drug|leucovorin calcium|
540801|NCT00002552|Drug|methotrexate|
540802|NCT00002552|Drug|perfosfamide|
540803|NCT00002552|Drug|therapeutic hydrocortisone|
540804|NCT00002552|Procedure|allogeneic bone marrow transplantation|
540805|NCT00002552|Procedure|autologous bone marrow transplantation|
540806|NCT00002552|Procedure|in vitro-treated bone marrow transplantation|
540807|NCT00002552|Procedure|peripheral blood stem cell transplantation|
540808|NCT00002552|Procedure|syngeneic bone marrow transplantation|
540809|NCT00002552|Radiation|radiation therapy|
540810|NCT00002547|Drug|busulfan|
540811|NCT00002547|Drug|cyclophosphamide|
540812|NCT00002547|Drug|cyclosporine|
540813|NCT00002547|Drug|cytarabine|
540814|NCT00002547|Drug|methotrexate|
540815|NCT00002547|Procedure|allogeneic bone marrow transplantation|
540816|NCT00002547|Procedure|syngeneic bone marrow transplantation|
540817|NCT00083356|Procedure|Wisdom tooth extraction|
540818|NCT00005648|Drug|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
540819|NCT00005648|Drug|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
540820|NCT00004198|Biological|keyhole limpet hemocyanin|
540821|NCT00004198|Biological|sargramostim|
540822|NCT00004198|Biological|tumor cell-based vaccine therapy|
540823|NCT00004126|Drug|oxaliplatin|
540824|NCT00004126|Drug|paclitaxel|
540825|NCT00004122|Biological|BCG vaccine|
540826|NCT00004122|Biological|recombinant interferon alfa|
540827|NCT00004113|Drug|temozolomide|
540828|NCT00003976|Drug|indisulam|
540829|NCT00003908|Drug|carboplatin|
540830|NCT00003908|Drug|docetaxel|
540831|NCT00003822|Drug|apomine|
540832|NCT00003747|Drug|carboplatin|
540833|NCT00003747|Drug|temozolomide|
540834|NCT00003724|Procedure|surgical procedure|
540835|NCT00003670|Drug|arzoxifene hydrochloride|
540836|NCT00003606|Drug|cisplatin|
540837|NCT00003606|Drug|cyclophosphamide|
540838|NCT00003606|Drug|epirubicin hydrochloride|
540839|NCT00003606|Drug|etoposide|
540840|NCT00003606|Radiation|radiation therapy|
540841|NCT00003562|Drug|carboplatin|
540842|NCT00003562|Drug|docetaxel|
540843|NCT00003490|Biological|sargramostim|
540844|NCT00003490|Drug|cyclophosphamide|
540845|NCT00003490|Drug|prednisone|
540846|NCT00003490|Drug|vincristine sulfate|
540847|NCT00003447|Drug|gemcitabine hydrochloride|
540848|NCT00003447|Drug|vinorelbine tartrate|
540849|NCT00003365|Dietary Supplement|curcumin|
540850|NCT00003365|Dietary Supplement|rutin|
540851|NCT00003365|Drug|quercetin|
540852|NCT00003365|Drug|sulindac|
540853|NCT00003322|Drug|cisplatin|
540854|NCT00003322|Drug|paclitaxel|
540855|NCT00003322|Procedure|quality-of-life assessment|
540856|NCT00003289|Drug|7-hydroxystaurosporine|
540857|NCT00003250|Drug|fenretinide|
540858|NCT00003101|Biological|filgrastim|
540859|NCT00003101|Drug|busulfan|
540860|NCT00003101|Drug|lomustine|
540861|NCT00003101|Drug|procarbazine hydrochloride|
540862|NCT00003101|Drug|thiotepa|
540863|NCT00003101|Drug|vincristine sulfate|
540864|NCT00003101|Procedure|autologous bone marrow transplantation|
540865|NCT00003101|Procedure|peripheral blood stem cell transplantation|
540866|NCT00002880|Drug|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
540867|NCT00002876|Drug|cisplatin|
540868|NCT00002876|Drug|etoposide|
540869|NCT00002813|Drug|cisplatin|
540870|NCT00002813|Drug|vinorelbine tartrate|
540871|NCT00002787|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
540872|NCT00002787|Biological|sargramostim|Given SC
540873|NCT00002787|Biological|aldesleukin|Given SC
540874|NCT00002787|Other|laboratory biomarker analysis|Correlative studies
540875|NCT00002707|Drug|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
540876|NCT00002707|Drug|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
540877|NCT00002707|Drug|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
540878|NCT00002707|Drug|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
540879|NCT00002692|Drug|fluorouracil|
540880|NCT00002692|Drug|isolated perfusion|
540881|NCT00002692|Drug|leucovorin calcium|
540882|NCT00002673|Procedure|infection prophylaxis and management|
540883|NCT00002599|Biological|filgrastim|
540884|NCT00002599|Biological|recombinant interferon alfa|
540885|NCT00002599|Biological|sargramostim|
540886|NCT00002599|Drug|carmustine|
540887|NCT00002599|Drug|cyclophosphamide|
540888|NCT00002599|Drug|doxorubicin hydrochloride|
540889|NCT00002599|Drug|melphalan|
540890|NCT00002599|Drug|methylprednisolone|
540891|NCT00002599|Drug|prednisone|
540892|NCT00002599|Drug|vincristine sulfate|
540893|NCT00002599|Radiation|low-LET cobalt-60 gamma ray therapy|
540894|NCT00002599|Radiation|low-LET photon therapy|
540895|NCT00083330|Drug|VRC-HIVADV014-00-VP|
540896|NCT00083278|Drug|MDX-010|
540897|NCT00012350|Drug|FTI|
540898|NCT00010088|Drug|fluorouracil|
540899|NCT00010088|Drug|gemcitabine hydrochloride|
540900|NCT00010088|Drug|leucovorin calcium|
540901|NCT00010088|Procedure|conventional surgery|
540902|NCT00010088|Radiation|radiation therapy|
540903|NCT00006220|Drug|arsenic trioxide|
540904|NCT00006220|Drug|tretinoin|
540905|NCT00005814|Biological|cetuximab|
540906|NCT00005814|Drug|cisplatin|
540907|NCT00005814|Radiation|radiation therapy|
540908|NCT00005581|Drug|cyclophosphamide|
540909|NCT00005581|Drug|epirubicin hydrochloride|
540910|NCT00005581|Drug|fluorouracil|
540911|NCT00005581|Drug|paclitaxel|
540912|NCT00004880|Biological|dendritic cell vaccine therapy|
540913|NCT00004880|Procedure|conventional surgery|
540914|NCT00004211|Biological|PSA RNA-pulsed dendritic cell vaccine|
540915|NCT00004156|Biological|MUC1-KLH vaccine/QS21|
540916|NCT00004132|Biological|filgrastim|
540917|NCT00004132|Biological|palifermin|
540918|NCT00004132|Drug|cyclophosphamide|
540919|NCT00004132|Drug|etoposide|
540920|NCT00004132|Drug|ifosfamide|
540921|NCT00004132|Procedure|quality-of-life assessment|
540922|NCT00004132|Radiation|radiation therapy|
540923|NCT00004073|Drug|suramin|
540924|NCT00004073|Radiation|radiation therapy|
540925|NCT00004056|Biological|filgrastim|
540926|NCT00004056|Drug|asparaginase|
540927|NCT00004056|Drug|cytarabine|
540928|NCT00004056|Drug|daunorubicin hydrochloride|
540929|NCT00004056|Drug|melphalan|
540930|NCT00004056|Drug|thioguanine|
540931|NCT00004056|Procedure|peripheral blood stem cell transplantation|
540932|NCT00004051|Drug|irinotecan hydrochloride|
540933|NCT00004038|Biological|Ad5CMV-p53 gene|
540934|NCT00004038|Drug|chemotherapy|
540935|NCT00003924|Biological|recombinant interferon alfa|
540936|NCT00003876|Drug|polifeprosan 20 with carmustine implant|
540937|NCT00003876|Procedure|surgical procedure|
540938|NCT00003876|Radiation|iodine I 125|
540939|NCT00003801|Procedure|management of therapy complications|
540940|NCT00003801|Procedure|quality-of-life assessment|
540941|NCT00003731|Drug|temozolomide|
540942|NCT00003700|Biological|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC > 5,000 uL after nadir: 7 day minimum for Courses I & IV
540943|NCT00003700|Drug|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I & IV
540944|NCT00003700|Drug|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I & IV (pts < 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II & V
540945|NCT00003700|Drug|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, & 3: Courses II & V
540946|NCT00003700|Drug|daunorubicin hydrochloride|80mg/sq m (pts<60y/o)OR 60mg/sq m (pts =/>60y/o) IV infusion over 5-10 min Days 1,2,& 3: Courses I & IV
540947|NCT00003700|Drug|leucovorin calcium|"Courses III & VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX <0.05 uM after ea IV dose"
540948|NCT00003700|Drug|mercaptopurine|60mg/sq m/d PO every day Course VII
540949|NCT00003700|Drug|methotrexate|15mg intrathecal Day 1 Courses II & V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, & 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III & VI.
540950|NCT00003700|Drug|prednisone|60mg/sq m/day PO Days 1-21 (pts<60y/o) OR Days 1-7 (pts >/= 60y/o) Courses I & IV and Days 1-5 of ea 4 cycle in Course VII
540951|NCT00003700|Drug|vincristine sulfate|2 mg total IV infusion Days 1,8,15,& 22 Courses I & IV and Days 1, 8, & 15 Courses III & VI, and Day 1 of ea 4 wk cycle in Course VII
540952|NCT00003700|Drug|Allopurinol|300mg PO q day Days 1-14 Course I
540953|NCT00003698|Drug|fosbretabulin disodium|
540954|NCT00003697|Drug|vadimezan|
540955|NCT00003685|Procedure|fatigue assessment and management|
540956|NCT00003685|Procedure|nausea and vomiting therapy|
540957|NCT00003685|Procedure|pain therapy|
540958|NCT00003685|Procedure|quality-of-life assessment|
540959|NCT00003685|Radiation|radiation therapy|
540960|NCT00003640|Biological|filgrastim|
540961|NCT00003640|Drug|cisplatin|
540962|NCT00003640|Drug|doxorubicin hydrochloride|
540963|NCT00003640|Drug|methotrexate|
540964|NCT00003640|Drug|vinblastine sulfate|
540965|NCT00003640|Procedure|surgical procedure|
540966|NCT00003640|Radiation|radiation therapy|
540967|NCT00003575|Biological|filgrastim|
540968|NCT00003575|Biological|recombinant interleukin-12|
540969|NCT00003575|Drug|etoposide|
540970|NCT00003575|Drug|ifosfamide|
540971|NCT00003439|Biological|recombinant interleukin-12|
540972|NCT00003423|Drug|asparaginase|
540973|NCT00003423|Drug|cyclophosphamide|
540974|NCT00003423|Drug|cytarabine|
540975|NCT00003423|Drug|daunorubicin hydrochloride|
540976|NCT00003423|Drug|dexamethasone|
540977|NCT00003423|Drug|etoposide|
540978|NCT00003423|Drug|mercaptopurine|
540979|NCT00003423|Drug|methotrexate|
540980|NCT00003423|Drug|prednisolone|
540981|NCT00003423|Drug|thioguanine|
540982|NCT00003423|Drug|vincristine sulfate|
540983|NCT00003330|Biological|recombinant interleukin-12|
540984|NCT00003326|Drug|paclitaxel|
540985|NCT00003255|Drug|carboplatin|
540986|NCT00003255|Drug|topotecan hydrochloride|
540987|NCT00002578|Drug|cytarabine|
540988|NCT00002578|Drug|gallium nitrate|
540989|NCT00002578|Drug|leucovorin calcium|
540990|NCT00002578|Drug|methotrexate|
540991|NCT00002503|Radiation|strontium chloride Sr 89|
540992|NCT00083304|Drug|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
540993|NCT00083304|Radiation|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
540994|NCT00083304|Other|Supplemental Oxygen|"4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
540995|NCT00083213|Biological|ziv-aflibercept|
540996|NCT00082940|Biological|denileukin diftitox|
540997|NCT00082927|Drug|ibandronate sodium|
540998|NCT00082914|Biological|denileukin diftitox|
540999|NCT00082888|Other|Laboratory Biomarker Analysis|Correlative studies
541000|NCT00082888|Drug|Tipifarnib|Given PO
541001|NCT00082875|Drug|cilengitide|Given IV
541002|NCT00082875|Other|pharmacological study|Correlative studies
541003|NCT00082875|Other|laboratory biomarker analysis|Correlative studies
541004|NCT00082862|Biological|recombinant interferon alfa|
541005|NCT00082862|Drug|cisplatin|
541006|NCT00082862|Drug|gemcitabine hydrochloride|
541007|NCT00082862|Procedure|hyperthermia treatment|
541008|NCT00082836|Biological|rituximab|
541009|NCT00082836|Radiation|yttrium Y 90 ibritumomab tiuxetan|
541010|NCT00082823|Biological|ziv-aflibercept|
541011|NCT00082810|Drug|fulvestrant|Given intramuscularly
541012|NCT00082810|Drug|tipifarnib|Given IV
541013|NCT00082797|Drug|leucovorin calcium|
541014|NCT00082797|Drug|methotrexate|
541015|NCT00082784|Drug|Bortezomib|Given IV
541016|NCT00082784|Drug|Alvocidib Hydrochloride|Given IV
541017|NCT00082784|Other|Pharmacological Study|Correlative studies
541018|NCT00082758|Biological|hu14.18-Interleukin-2 fusion protein|Given IV
541019|NCT00082745|Other|Laboratory Biomarker Analysis|Correlative studies
541020|NCT00082745|Other|Questionnaire Administration|Ancillary studies
541021|NCT00082732|Behavioral|behavioral dietary intervention|
541022|NCT00082732|Dietary Supplement|dietary intervention|
541023|NCT00082732|Procedure|therapeutic dietary intervention|
541024|NCT00082719|Biological|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
541025|NCT00082706|Drug|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
541026|NCT00082706|Drug|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
541027|NCT00082706|Drug|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
541028|NCT00082706|Drug|Gemcitabine|Day: 1 & 5 Dose: 200 mg/m2 (Two doses only)
541029|NCT00082667|Drug|gefitinib|
541030|NCT00082667|Procedure|Surgery|
541031|NCT00082654|Procedure|psychosocial assessment and care|
541032|NCT00082641|Biological|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
541033|NCT00003186|Drug|isosulfan blue|
541034|NCT00003186|Procedure|lymphangiography|
541035|NCT00003186|Procedure|sentinel lymph node biopsy|
541036|NCT00003183|Biological|filgrastim|
541037|NCT00003183|Drug|mitoxantrone hydrochloride|
541038|NCT00003154|Drug|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
541039|NCT00003118|Drug|cisplatin|
541040|NCT00003118|Drug|fluorouracil|
541041|NCT00003118|Procedure|surgical procedure|
541042|NCT00003118|Radiation|radiation therapy|
541043|NCT00003117|Drug|carboplatin|
541044|NCT00003117|Drug|paclitaxel|
541045|NCT00003020|Biological|LMB-7 immunotoxin|
541046|NCT00002988|Drug|carmustine|
541047|NCT00002988|Drug|irinotecan hydrochloride|
541048|NCT00002985|Drug|daunorubicin hydrochloride|
541049|NCT00002985|Drug|pegylated liposomal doxorubicin hydrochloride|
541050|NCT00002961|Drug|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
541051|NCT00002961|Drug|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.~When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
541123|NCT00082576|Drug|Azithromycin/Chloroquine|
541052|NCT00002961|Drug|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
541053|NCT00002961|Drug|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.~Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is >2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
541054|NCT00002961|Procedure|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
541055|NCT00002961|Radiation|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) [200 cGy twice a day (BID)].
541056|NCT00002961|Drug|Busulfan|"Conditioning Regimen Arm B:~Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.~Patients </= 20kg to receive busulfan 1.0 mg/kg/dose IV**Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients >20kg and 1.25 mg/kg/dose by mouth (po) for patients </= 20 kg."
541057|NCT00002961|Drug|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
541058|NCT00002961|Radiation|Radiation|"Central Nervous System (CNS) therapy:~a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) >/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses >3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.~Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
541059|NCT00083252|Drug|talabostat (PT-100) tablets|
541060|NCT00083252|Drug|cisplatin|
541061|NCT00083239|Drug|talabostat (PT-100) tablets|
541062|NCT00083226|Drug|doxorubicin|Given IV
541063|NCT00083226|Drug|bortezomib|Given IV
541064|NCT00083187|Drug|hydroxyurea|
541065|NCT00083187|Drug|laromustine|
541066|NCT00083174|Drug|exemestane|one 25 mg tablet daily in am
541067|NCT00083161|Drug|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
541068|NCT00083161|Drug|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
541069|NCT00083161|Drug|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
541070|NCT00083148|Drug|capecitabine|
541071|NCT00083148|Drug|irinotecan hydrochloride|
541072|NCT00083135|Biological|filgrastim|
541073|NCT00083135|Procedure|autologous bone marrow transplantation|
541074|NCT00083135|Procedure|peripheral blood stem cell transplantation|
541075|NCT00083135|Radiation|iobenguane I 131|
541076|NCT00083122|Drug|cisplatin|Given IV
541077|NCT00083122|Drug|alvocidib|Given IV
541078|NCT00083122|Drug|cisplatin/flavopiridol|Given IV
541079|NCT00083109|Drug|Fluorouracil|Given IV
541080|NCT00083109|Other|Pharmacological Study|Correlative studies
541081|NCT00083109|Drug|Suramin|Given IV
541082|NCT00083096|Drug|lonafarnib|
541083|NCT00083096|Drug|temozolomide|
541084|NCT00083083|Drug|carboplatin|
541085|NCT00083083|Drug|cisplatin|
541086|NCT00083083|Drug|docetaxel|
541087|NCT00083083|Drug|etoposide|
541088|NCT00083083|Drug|paclitaxel|
541089|NCT00083083|Drug|vinblastine sulfate|
541090|NCT00083083|Drug|vinorelbine tartrate|
541091|NCT00083083|Genetic|gene expression analysis|
541092|NCT00083083|Procedure|positron emission tomography|
541093|NCT00083083|Radiation|fludeoxyglucose F 18|
541094|NCT00083083|Radiation|radiation therapy|
541095|NCT00083070|Drug|temozolomide|
541096|NCT00083057|Drug|gefitinib|
541097|NCT00083057|Drug|paclitaxel|
541098|NCT00083057|Radiation|radiation therapy|
541099|NCT00083031|Drug|bevacizumab|
541100|NCT00083031|Drug|cyclophosphamide|
541101|NCT00083031|Drug|methotrexate|
541102|NCT00083018|Genetic|cytogenetic analysis|
541103|NCT00083018|Genetic|proteomic profiling|
541104|NCT00083018|Other|cytology specimen collection procedure|
541105|NCT00083018|Other|immunohistochemistry staining method|
541106|NCT00083018|Other|laboratory biomarker analysis|
541107|NCT00083018|Procedure|breast duct lavage|
541108|NCT00083005|Drug|docetaxel|
541109|NCT00083005|Drug|estramustine phosphate sodium|
541110|NCT00083005|Drug|thalidomide|
541111|NCT00082979|Genetic|cytogenetic analysis|
541112|NCT00082979|Genetic|proteomic profiling|
541113|NCT00082979|Other|cytology specimen collection procedure|
541114|NCT00082979|Other|immunohistochemistry staining method|
541115|NCT00082979|Other|laboratory biomarker analysis|
541116|NCT00082979|Procedure|breast duct lavage|
541117|NCT00082966|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
541118|NCT00082628|Drug|Placebo|Placebo matched to serostim® as subcutaneous injection.
541119|NCT00082628|Drug|Serostim® 4 mg|Serostim® as subcutaneous injection at a maximum dose of 4 milligram (mg) per day based on body weight.
541120|NCT00082628|Drug|Serostim® 2 mg|Serostim® 2 mg as subcutaneous injection on alternate days.
541121|NCT00082602|Drug|galantamine ER|
541125|NCT00082563|Drug|Azithromycin/Chloroquine|
541126|NCT00082563|Drug|Chloroquine|
541127|NCT00082537|Drug|caspofungin acetate|Duration of Treatment: 28-90 days
541128|NCT00082537|Drug|Comparator: AmBisome|Duration of Treatment: 28-90 days
541129|NCT00082524|Drug|caspofungin acetate|Duration of Treatment - 7-90 days
541130|NCT00002936|Drug|altretamine|
541131|NCT00002936|Drug|etoposide|
541132|NCT00002903|Drug|docetaxel|
541133|NCT00002896|Drug|chemotherapy|
541134|NCT00002896|Drug|fluorouracil|
541135|NCT00002896|Drug|leucovorin calcium|
541136|NCT00002896|Procedure|conventional surgery|
541137|NCT00002896|Radiation|low-LET cobalt-60 gamma ray therapy|
541138|NCT00002896|Radiation|low-LET photon therapy|
541139|NCT00002893|Drug|fluorouracil|
541140|NCT00002893|Drug|leucovorin calcium|
541141|NCT00002893|Drug|raltitrexed|
541142|NCT00002892|Biological|recombinant interferon alfa|
541143|NCT00082498|Drug|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
541144|NCT00082498|Drug|Placebo|Patients in Group 1 will receive placebo.
541145|NCT00082485|Drug|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
541146|NCT00082485|Other|Placebo|Placebo
541147|NCT00082472|Drug|Doxorubicin HCl Inhalation Solution|
541148|NCT00082472|Drug|Docetaxel|
541149|NCT00082472|Drug|Cisplatin|
541150|NCT00082459|Biological|autologous human tumor-derived HSPPC-96|
541151|NCT00002870|Biological|filgrastim|
541152|NCT00002870|Drug|cyclophosphamide|
541153|NCT00002870|Drug|epirubicin hydrochloride|
541154|NCT00002870|Drug|fluorouracil|
541155|NCT00002870|Drug|thiotepa|
541156|NCT00002870|Procedure|peripheral blood stem cell transplantation|
541157|NCT00002826|Drug|paclitaxel|
541158|NCT00002826|Drug|valspodar|
541159|NCT00002803|Drug|cyclophosphamide|
541160|NCT00002803|Drug|doxorubicin hydrochloride|
541161|NCT00002803|Drug|vincristine sulfate|
541162|NCT00002803|Procedure|conventional surgery|
541163|NCT00002802|Drug|carboplatin|
541164|NCT00002802|Drug|cisplatin|
541165|NCT00002802|Drug|cyclophosphamide|
541166|NCT00002802|Drug|dacarbazine|
541167|NCT00002802|Drug|doxorubicin hydrochloride|
541168|NCT00002802|Drug|etoposide|
541169|NCT00002802|Drug|ifosfamide|
541170|NCT00002802|Drug|melphalan|
541171|NCT00002802|Drug|mesna|
541172|NCT00002802|Drug|vincristine sulfate|
541173|NCT00002802|Drug|vindesine|
541174|NCT00002802|Procedure|autologous bone marrow transplantation|
541175|NCT00002802|Procedure|conventional surgery|
541176|NCT00002802|Radiation|low-LET cobalt-60 gamma ray therapy|
541177|NCT00002802|Radiation|low-LET electron therapy|
541178|NCT00002802|Radiation|low-LET photon therapy|
541179|NCT00002802|Radiation|radioisotope therapy|
541180|NCT00082446|Biological|Live vaccinia virus vaccine|Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
541181|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN 1x10^8 will be administered intramuscularly to Group F on day 0 and day 28.
541182|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10^7, 5x10^7, 1x10^8, 1x10^8, respectively, on days 0 and day 28.
541183|NCT00082446|Other|Placebo|Group E will receive sterile saline placebo for injection via scarification on day 112.
541184|NCT00082446|Other|Placebo|Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
541185|NCT00082433|Drug|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
541186|NCT00082433|Drug|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
541187|NCT00082381|Drug|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
541188|NCT00082381|Drug|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
541189|NCT00002788|Biological|filgrastim|
541190|NCT00002788|Drug|cyclophosphamide|
541191|NCT00002788|Drug|dexamethasone|
541192|NCT00002788|Drug|etoposide|
541193|NCT00002788|Procedure|peripheral blood stem cell transplantation|
541194|NCT00002788|Radiation|radiation therapy|
541195|NCT00002737|Biological|recombinant interferon alfa|
541196|NCT00002737|Drug|chemotherapy|
541197|NCT00002737|Drug|isotretinoin|
541198|NCT00002677|Drug|chemotherapy|
541199|NCT00002677|Drug|tributyrin|
541200|NCT00002644|Drug|Tamoxifen Citrate 20Mg Tab|Tamoxifen Citrate 20Mg Tab
541201|NCT00002644|Other|Placebo|Placebo 20Mg Tab
541202|NCT00002587|Drug|paclitaxel|
541203|NCT00002587|Drug|topotecan hydrochloride|
541204|NCT00082407|Drug|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
541205|NCT00082407|Drug|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
541206|NCT00082394|Drug|Trizivir|
541207|NCT00082394|Drug|atazanavir|
541208|NCT00082394|Drug|Combivir|
541209|NCT00082316|Drug|Capsaicin Dermal Patch|
541301|NCT00005612|Drug|topotecan hydrochloride|
541210|NCT00082368|Drug|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
541211|NCT00082368|Drug|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
541212|NCT00082355|Drug|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
541213|NCT00082342|Device|Phoressor II (IOMED)|sham stimulation
541214|NCT00082342|Device|Phoressor II (IOMED)|real tDCS stimulation
541215|NCT00082329|Drug|AMD 3100 (Mozobil plerixafor)|Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis
541216|NCT00082303|Behavioral|Music Imagery|
541217|NCT00082290|Other|massage therapy|
541218|NCT00082290|Other|visit with a volunteer|
541219|NCT00082290|Other|period of quiet time|
541220|NCT00082290|Behavioral|questionaire about pain|
541221|NCT00082277|Drug|Anastrozole|1mg/Day Oral
541222|NCT00082277|Drug|Risedronate Sodium|35mg/week, oral
541223|NCT00082251|Drug|Niacin extended release and simvastatin tablets|
541224|NCT00082238|Other|Stable isotopes|Stable isotopes were used to quantify gluconeogenesis GNG, hepatic glucose production (HGP), and protein breakdown.
541225|NCT00082225|Biological|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
541226|NCT00082225|Biological|EBV specific T cells|"The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:~2 x 10e7 cells/m2 5 x 10e7 cells/m2~1 x 10e8 cells/m2"
541227|NCT00082212|Biological|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
541228|NCT00014651|Drug|vapreotide|
541229|NCT00014651|Procedure|conventional surgery|
541230|NCT00010322|Drug|atamestane|
541231|NCT00010322|Drug|toremifene|
541232|NCT00008255|Drug|INS316|
541233|NCT00008255|Other|sputum cytology|
541234|NCT00002568|Drug|cisplatin|
541235|NCT00002568|Drug|paclitaxel|
541236|NCT00002568|Procedure|conventional surgery|
541237|NCT00002516|Biological|dactinomycin|
541238|NCT00002516|Drug|cyclophosphamide|
541239|NCT00002516|Drug|doxorubicin hydrochloride|
541240|NCT00002516|Drug|etoposide|
541241|NCT00002516|Drug|ifosfamide|
541242|NCT00002516|Drug|mesna|
541243|NCT00002516|Drug|vincristine sulfate|
541244|NCT00002516|Procedure|conventional surgery|
541245|NCT00002516|Radiation|low-LET cobalt-60 gamma ray therapy|
541246|NCT00002516|Radiation|low-LET photon therapy|
541247|NCT00082199|Drug|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
541248|NCT00082199|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks.
541249|NCT00082186|Drug|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
541250|NCT00082173|Drug|Moxifloxacin|400mg daily for 8 weeks
541251|NCT00082160|Behavioral|Meditation|
541252|NCT00082160|Procedure|Functional Magnetic Resonance Imaging|
541253|NCT00082134|Drug|ILX651|
541254|NCT00082121|Drug|TP10|
541255|NCT00011934|Biological|recombinant interferon alfa|
541256|NCT00011934|Biological|sargramostim|
541257|NCT00011934|Procedure|autologous bone marrow transplantation|
541258|NCT00008242|Drug|dexamethasone|
541259|NCT00008242|Drug|doxorubicin hydrochloride|
541260|NCT00008242|Drug|thalidomide|
541261|NCT00008125|Biological|filgrastim|
541262|NCT00008125|Drug|carboplatin|
541263|NCT00008125|Drug|docetaxel|
541264|NCT00008125|Drug|gemcitabine hydrochloride|
541265|NCT00008099|Biological|MUC1 antigen/SB AS-2|
541266|NCT00006682|Drug|docetaxel|
541267|NCT00006682|Drug|vinorelbine ditartrate|
541268|NCT00006669|Biological|rituximab|
541269|NCT00006669|Biological|sargramostim|
541270|NCT00006669|Drug|EPOCH regimen|
541271|NCT00006669|Drug|cyclophosphamide|
541272|NCT00006669|Drug|doxorubicin hydrochloride|
541273|NCT00006669|Drug|etoposide|
541274|NCT00006669|Drug|prednisone|
541275|NCT00006669|Drug|vincristine sulfate|
541276|NCT00006342|Genetic|chromosomal translocation analysis|
541277|NCT00006342|Genetic|gene rearrangement analysis|
541278|NCT00006342|Genetic|mutation analysis|
541279|NCT00006112|Drug|chemotherapy|
541280|NCT00006112|Drug|fluorouracil|
541281|NCT00006112|Drug|leucovorin calcium|
541282|NCT00006112|Drug|mitomycin C|
541283|NCT00006097|Drug|CC-1088|
541284|NCT00006053|Drug|imatinib mesylate|
541285|NCT00006039|Biological|pegylated interferon alfa|
541286|NCT00005988|Drug|cyclophosphamide|
541287|NCT00005988|Drug|cyclosporine|
541288|NCT00005988|Drug|leucovorin calcium|
541289|NCT00005988|Drug|methotrexate|
541290|NCT00005988|Drug|methylprednisolone|
541291|NCT00005988|Procedure|in vitro-treated bone marrow transplantation|
541292|NCT00005988|Radiation|radiation therapy|
541293|NCT00005974|Drug|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
541294|NCT00005871|Drug|fluorouracil|
541295|NCT00005871|Drug|rubitecan|
541296|NCT00005612|Biological|filgrastim|
541297|NCT00005612|Drug|carboplatin|
541298|NCT00005612|Drug|cyclophosphamide|
541299|NCT00005612|Drug|etoposide|
541302|NCT00005612|Procedure|peripheral blood stem cell transplantation|
541303|NCT00005594|Drug|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
541304|NCT00005081|Drug|O6-benzylguanine|
541305|NCT00005081|Drug|carmustine|
541306|NCT00005055|Drug|glufosfamide|
541307|NCT00005053|Drug|glufosfamide|
541308|NCT00005021|Biological|filgrastim|
541309|NCT00005021|Drug|carboplatin|
541310|NCT00005021|Drug|paclitaxel|
541311|NCT00005021|Drug|topotecan hydrochloride|
541312|NCT00004893|Biological|recombinant interleukin-12|
541313|NCT00004892|Drug|O6-benzylguanine|
541314|NCT00004892|Drug|polifeprosan 20 with carmustine implant|
541315|NCT00004892|Procedure|conventional surgery|
541316|NCT00004884|Drug|cisplatin|
541317|NCT00004884|Drug|docetaxel|
541318|NCT00004884|Drug|gemcitabine hydrochloride|
541319|NCT00004246|Drug|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
541320|NCT00004246|Radiation|Radiation Therapy (RT)|Days 1-5 for 7 weeks
541321|NCT00004230|Drug|captopril|
541322|NCT00004230|Drug|cyclophosphamide|
541323|NCT00004230|Procedure|autologous bone marrow transplantation|
541324|NCT00004230|Procedure|peripheral blood stem cell transplantation|
541325|NCT00004230|Radiation|radiation therapy|
541326|NCT00004213|Drug|triapine|
541327|NCT00004101|Biological|apolizumab|
541328|NCT00004049|Drug|apomine|
541329|NCT00003972|Biological|filgrastim|
541330|NCT00003972|Biological|sargramostim|
541331|NCT00003972|Drug|busulfan|
541332|NCT00003972|Drug|carboplatin|
541333|NCT00003972|Drug|cyclophosphamide|
541334|NCT00003972|Drug|melphalan|
541335|NCT00003972|Drug|paclitaxel|
541336|NCT00003972|Drug|tamoxifen citrate|
541337|NCT00003972|Drug|thiotepa|
541338|NCT00003972|Procedure|peripheral blood stem cell transplantation|
541339|NCT00003972|Radiation|radiation therapy|
541340|NCT00003968|Drug|bryostatin 1|
541341|NCT00003943|Biological|filgrastim|5 ug/kg
541342|NCT00003943|Drug|carboplatin|AUC 5
541343|NCT00003943|Drug|cyclophosphamide|3 gm/m2
541344|NCT00003943|Drug|paclitaxel|250 mg/m2
541345|NCT00003943|Drug|topotecan hydrochloride|10 mg/m2
541346|NCT00003943|Procedure|peripheral blood stem cell transplantation|harvest via apheresis
541347|NCT00003900|Drug|docetaxel|
541348|NCT00003900|Drug|irinotecan hydrochloride|
541349|NCT00003849|Biological|rituximab|
541350|NCT00003825|Drug|pentosan polysulfate sodium|
541351|NCT00003825|Procedure|quality-of-life assessment|
541352|NCT00003768|Drug|fosbretabulin disodium|
541353|NCT00003726|Biological|lepirudin|lepirudin
541354|NCT00003713|Drug|intoplicine|
541355|NCT00003680|Drug|CMF regimen|
541356|NCT00003680|Drug|cyclophosphamide|
541357|NCT00003680|Drug|fluorouracil|
541358|NCT00003680|Drug|methotrexate|
541359|NCT00003680|Drug|tamoxifen citrate|
541360|NCT00003680|Drug|thiotepa|
541361|NCT00003680|Procedure|peripheral blood stem cell transplantation|
541362|NCT00003680|Radiation|radiation therapy|
541363|NCT00003646|Drug|allovectin-7|
541364|NCT00003638|Biological|Detox-B adjuvant|
541365|NCT00003638|Biological|THERATOPE STn-KLH vaccine|
541366|NCT00003638|Biological|keyhole limpet hemocyanin|
541367|NCT00003638|Drug|cyclophosphamide|
541368|NCT00003622|Drug|paclitaxel|
541369|NCT00003622|Drug|vinorelbine tartrate|
541370|NCT00082147|Procedure|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
541371|NCT00082095|Drug|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
541372|NCT00082095|Drug|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
541373|NCT00082082|Drug|Thymalfasin (thymosin alpha-1)|
541374|NCT00082082|Procedure|Trans arterial chemoembolization (TACE)|
541375|NCT00082069|Biological|Shigella flexneri 2a Invaplex 50|
541376|NCT00081978|Drug|TMC125|
541377|NCT00003583|Drug|amifostine trihydrate|
541378|NCT00003583|Drug|cisplatin|
541379|NCT00003583|Drug|etoposide|
541380|NCT00003583|Radiation|radiation therapy|
541381|NCT00003563|Radiation|WBRT|3 GY of WBRT daily for a total of 10 days
541382|NCT00003563|Drug|MGd|5.0 mg /kg MGd plus WBRT
541383|NCT00003554|Biological|rituximab|
541384|NCT00003554|Drug|melphalan|
541385|NCT00003554|Drug|prednisone|
541386|NCT00003397|Biological|filgrastim|
541387|NCT00003397|Biological|rituximab|
541388|NCT00003397|Biological|sargramostim|
541389|NCT00003397|Drug|carmustine|
541390|NCT00003397|Drug|cisplatin|
541391|NCT00003397|Drug|cyclophosphamide|
541392|NCT00003397|Drug|dexamethasone|
541393|NCT00003397|Drug|etoposide|
541394|NCT00003397|Drug|gemcitabine hydrochloride|
541395|NCT00003397|Drug|melphalan|
541396|NCT00003397|Drug|paclitaxel|
541397|NCT00003397|Procedure|bone marrow ablation with stem cell support|
541860|NCT00005989|Drug|tipifarnib|
541398|NCT00003397|Procedure|peripheral blood stem cell transplantation|
541399|NCT00003394|Drug|carboplatin|
541400|NCT00003394|Drug|endocrine-modulating drug therapy|
541401|NCT00003394|Drug|estramustine phosphate sodium|
541402|NCT00003394|Drug|goserelin acetate|
541403|NCT00003394|Drug|leuprolide acetate|
541404|NCT00003394|Drug|paclitaxel|
541405|NCT00003276|Drug|irinotecan hydrochloride|
541406|NCT00003239|Biological|Recombinant Interferon Alfa|Daily by subcutaneous injection.
541407|NCT00003239|Drug|Cytarabine|Daily by subcutaneous injection.
541408|NCT00003239|Drug|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
541409|NCT00003181|Biological|aldesleukin|
541410|NCT00003181|Biological|sargramostim|
541411|NCT00003181|Drug|vinblastine sulfate|
541412|NCT00003175|Drug|fluorouracil|
541413|NCT00003165|Drug|doxorubicin-HPMA conjugate|
541414|NCT00003133|Biological|filgrastim|
541415|NCT00003133|Drug|cisplatin|
541416|NCT00003133|Drug|doxorubicin hydrochloride|
541417|NCT00003133|Drug|gemcitabine hydrochloride|
541418|NCT00003133|Drug|paclitaxel|
541419|NCT00003038|Drug|doxorubicin hydrochloride|
541420|NCT00003038|Drug|suramin|
541421|NCT00003019|Drug|methotrexate|
541422|NCT00003019|Drug|vinblastine sulfate|
541423|NCT00081939|Drug|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m^2. Maintenance year one 1.0mg/m^2 1,4,8,11 q 28 days.
541424|NCT00081939|Drug|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
541425|NCT00081926|Drug|Gleevec|
541426|NCT00014365|Drug|MKC-1|
541427|NCT00006483|Biological|sargramostim|
541428|NCT00006261|Biological|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
541429|NCT00006261|Drug|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
541430|NCT00006261|Drug|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
541431|NCT00006261|Drug|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
541432|NCT00006261|Drug|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
541433|NCT00006261|Procedure|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
541434|NCT00006106|Drug|cisplatin|
541435|NCT00006106|Drug|fluorouracil|
541436|NCT00006106|Drug|ONYX-015|
541437|NCT00003001|Drug|fluorouracil|
541438|NCT00003001|Drug|gemcitabine hydrochloride|
541439|NCT00003001|Drug|leucovorin calcium|
541440|NCT00002977|Biological|filgrastim|
541441|NCT00002977|Drug|melphalan|
541442|NCT00002977|Drug|thiotepa|
541443|NCT00002977|Procedure|peripheral blood stem cell transplantation|
541444|NCT00002939|Drug|irinotecan hydrochloride|
541445|NCT00002939|Drug|paclitaxel|
541446|NCT00002912|Drug|etoposide|
541447|NCT00002912|Drug|mitoxantrone hydrochloride|
541448|NCT00002912|Drug|valspodar|
541449|NCT00002884|Drug|chemotherapy|
541450|NCT00002884|Drug|cisplatin|
541451|NCT00002884|Drug|fluorouracil|
541452|NCT00002884|Radiation|brachytherapy|
541453|NCT00002884|Radiation|radiation therapy|
541454|NCT00002773|Biological|allogeneic tumor cell vaccine|
541455|NCT00002773|Biological|recombinant interferon alfa|
541456|NCT00002773|Biological|sargramostim|
541457|NCT00002773|Drug|cyclophosphamide|
541458|NCT00002719|Biological|filgrastim|
541459|NCT00002719|Drug|amsacrine|
541460|NCT00002719|Drug|carmustine|
541461|NCT00002719|Drug|cytarabine|
541462|NCT00002719|Drug|etoposide|
541463|NCT00002719|Drug|idarubicin|
541464|NCT00002719|Drug|mitoxantrone hydrochloride|
541465|NCT00002719|Procedure|peripheral blood stem cell transplantation|
541466|NCT00002680|Biological|filgrastim|
541467|NCT00002680|Drug|cyclophosphamide|
541468|NCT00002680|Drug|megestrol acetate|
541469|NCT00002680|Drug|melphalan|
541470|NCT00002680|Drug|tamoxifen citrate|
541471|NCT00002680|Drug|thiotepa|
541472|NCT00002680|Procedure|conventional surgery|
541473|NCT00002680|Procedure|peripheral blood stem cell transplantation|
541474|NCT00002680|Radiation|radiation therapy|
541475|NCT00002590|Biological|filgrastim|
541476|NCT00002590|Drug|cyclophosphamide|
541477|NCT00002590|Drug|cytarabine|
541478|NCT00002590|Drug|daunorubicin hydrochloride|
541479|NCT00002590|Drug|doxorubicin hydrochloride|
541480|NCT00002590|Drug|etoposide|
541481|NCT00002590|Drug|leucovorin calcium|
541482|NCT00002590|Drug|methotrexate|
541483|NCT00002590|Drug|pegaspargase|
541484|NCT00002590|Drug|prednisone|
541485|NCT00002590|Drug|thioguanine|
541486|NCT00002590|Drug|vincristine sulfate|
541487|NCT00002590|Radiation|radiation therapy|
541488|NCT00002564|Other|educational intervention|
541489|NCT00002564|Procedure|therapeutic dietary intervention|
541490|NCT00002481|Drug|cisplatin|
541491|NCT00002481|Drug|cyclophosphamide|
541492|NCT00002481|Drug|cytarabine|
541493|NCT00002481|Drug|dexamethasone|
541494|NCT00002481|Drug|etoposide|
541495|NCT00002481|Procedure|autologous bone marrow transplantation|
541496|NCT00002481|Radiation|radiation therapy|
541497|NCT00082043|Drug|Dutasteride|
541498|NCT00082043|Drug|Placebo oral capsule|
541499|NCT00082017|Drug|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days.~UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
541500|NCT00081965|Procedure|acupuncture therapy|
541501|NCT00081965|Procedure|hot flashes attenuation|
541502|NCT00081965|Procedure|management of therapy complications|
541503|NCT00081952|Drug|L-norleucine|
541504|NCT00081913|Genetic|Cell Therapy - Autologous CD34 Positive Cells|
541505|NCT00081900|Drug|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m^2, then escalating to 120mg/m^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
541506|NCT00005969|Drug|Chemotherapy|
541507|NCT00005969|Drug|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
541508|NCT00005883|Drug|phenethyl isothiocyanate|
541509|NCT00005796|Procedure|filgrastim|GCSF is given after chemo administration
541510|NCT00005796|Biological|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
541511|NCT00005796|Drug|lomustine|chemotherapy is administered every 21 days
541512|NCT00005796|Drug|procarbazine hydrochloride|chemotherapy is administered every 21 days.
541513|NCT00005796|Drug|vincristine sulfate|chemotherapy is administered every 21 days
541514|NCT00005796|Procedure|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
541515|NCT00005649|Drug|capecitabine|
541516|NCT00005649|Drug|paclitaxel|
541517|NCT00004933|Drug|hydroxyurea|0.5 to 5 grams PO per day
541518|NCT00004933|Drug|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
541519|NCT00004923|Drug|docetaxel|
541520|NCT00004923|Drug|irinotecan hydrochloride|
541521|NCT00004903|Biological|filgrastim|
541522|NCT00004903|Biological|recombinant interferon alfa|
541523|NCT00004903|Drug|cisplatin|
541524|NCT00004903|Drug|cyclophosphamide|
541525|NCT00004903|Drug|cytarabine|
541526|NCT00004903|Drug|etoposide|
541527|NCT00004903|Drug|melphalan|
541528|NCT00004903|Procedure|peripheral blood stem cell transplantation|
541529|NCT00004878|Biological|therapeutic allogeneic lymphocytes|
541530|NCT00004878|Drug|cytarabine|
541531|NCT00004878|Drug|fludarabine phosphate|
541532|NCT00004878|Drug|idarubicin|
541533|NCT00004878|Drug|methotrexate|
541534|NCT00004878|Drug|tacrolimus|
541535|NCT00004878|Procedure|in vitro-treated peripheral blood stem cell transplantation|
541536|NCT00004878|Procedure|peripheral blood stem cell transplantation|
541537|NCT00004872|Biological|recombinant human endostatin|
541538|NCT00004858|Biological|B43-genistein immunoconjugate|
541539|NCT00004604|Biological|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
541540|NCT00004249|Biological|QS21|
541541|NCT00004249|Biological|keyhole limpet hemocyanin|
541542|NCT00004249|Drug|polysialic acid|
541543|NCT00004174|Biological|filgrastim|
541544|NCT00004174|Drug|cyclophosphamide|
541545|NCT00004174|Drug|paclitaxel|
541546|NCT00004174|Drug|thiotepa|
541547|NCT00004174|Procedure|peripheral blood stem cell transplantation|
541548|NCT00004174|Radiation|radiation therapy|
541549|NCT00003960|Drug|busulfan|
541550|NCT00003960|Drug|cyclophosphamide|
541551|NCT00003960|Drug|methylprednisolone|
541552|NCT00003960|Procedure|allogeneic bone marrow transplantation|
541553|NCT00003960|Procedure|in vitro-treated bone marrow transplantation|
541554|NCT00003953|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
541555|NCT00003953|Drug|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
541556|NCT00003953|Drug|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
541557|NCT00003953|Drug|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
541558|NCT00003953|Drug|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
541559|NCT00003953|Procedure|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
541560|NCT00003953|Procedure|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
541561|NCT00003953|Radiation|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
541562|NCT00081887|Drug|Clofarabine|Starting dose is 10 mg/m^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
541563|NCT00081874|Drug|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.~Phase II: Maximum Tolerated Dose (MTD) from Phase I."
541564|NCT00081861|Drug|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
541861|NCT00005958|Biological|filgrastim|
541565|NCT00081861|Drug|Rituximab|375 mg/m^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
541566|NCT00003950|Drug|cyclosporine|
541567|NCT00003950|Drug|CPT-11|
541568|NCT00003914|Drug|dolastatin 10|
541569|NCT00003887|Biological|peripheral blood lymphocyte therapy|
541570|NCT00003835|Drug|leucovorin calcium|Given IV
541571|NCT00003835|Drug|fluorouracil|Given IV
541572|NCT00003835|Drug|irinotecan hydrochloride|Given IV
541573|NCT00003835|Other|laboratory biomarker analysis|Correlative studies
541574|NCT00003819|Biological|QS21|
541575|NCT00003819|Biological|TF(c)-KLH conjugate vaccine|
541576|NCT00003819|Biological|Thomsen-Friedenreich antigen|
541577|NCT00003819|Biological|keyhole limpet hemocyanin|
541578|NCT00003783|Biological|filgrastim|
541579|NCT00003783|Drug|asparaginase|
541580|NCT00003783|Drug|cyclophosphamide|
541581|NCT00003783|Drug|cytarabine|
541582|NCT00003783|Drug|daunorubicin hydrochloride|
541583|NCT00003783|Drug|dexamethasone|
541584|NCT00003783|Drug|etoposide|
541585|NCT00003783|Drug|idarubicin|
541586|NCT00003783|Drug|leucovorin calcium|
541587|NCT00003783|Drug|mercaptopurine|
541588|NCT00003783|Drug|methotrexate|
541589|NCT00003783|Drug|prednisone|
541590|NCT00003783|Drug|vincristine sulfate|
541591|NCT00003783|Radiation|radiation therapy|
541592|NCT00003765|Drug|O6-benzylguanine|
541593|NCT00003765|Drug|carmustine|
541594|NCT00003619|Biological|filgrastim|
541595|NCT00003619|Dietary Supplement|vitamin E|
541596|NCT00003619|Drug|busulfan|
541597|NCT00003619|Drug|cytarabine|
541598|NCT00003619|Drug|etoposide|
541599|NCT00003619|Drug|fludarabine phosphate|
541600|NCT00003619|Drug|isotretinoin|
541601|NCT00003619|Drug|topotecan hydrochloride|
541602|NCT00003619|Procedure|bone marrow ablation with stem cell support|
541603|NCT00003619|Procedure|peripheral blood stem cell transplantation|
541604|NCT00003544|Drug|irinotecan hydrochloride|
541605|NCT00003544|Procedure|surgical procedure|
541606|NCT00003434|Biological|carcinoembryonic antigen peptide 1|
541607|NCT00003434|Biological|hepatitis B antigen peptide|
541608|NCT00003427|Drug|irinotecan hydrochloride|
541609|NCT00003427|Drug|oxaliplatin|
541610|NCT00003407|Drug|amifostine trihydrate|
541611|NCT00003407|Drug|cytarabine|
541612|NCT00003407|Drug|mitoxantrone hydrochloride|
541613|NCT00003398|Biological|anti-thymocyte globulin|
541614|NCT00003398|Biological|filgrastim|
541615|NCT00003398|Drug|cyclophosphamide|
541616|NCT00003398|Drug|thiotepa|
541617|NCT00003398|Procedure|allogeneic bone marrow transplantation|
541618|NCT00003398|Procedure|bone marrow ablation with stem cell support|
541619|NCT00003398|Radiation|radiation therapy|
541620|NCT00003270|Biological|anti-thymocyte globulin|IV
541621|NCT00003270|Biological|filgrastim|IV
541622|NCT00003270|Drug|busulfan|IV
541623|NCT00003270|Drug|cyclophosphamide|IV
541624|NCT00003270|Drug|cyclosporine|IV
541625|NCT00003270|Drug|methylprednisolone|IV
541626|NCT00003270|Procedure|bone marrow ablation with stem cell support|IV
541627|NCT00003270|Procedure|umbilical cord blood transplantation|IV
541628|NCT00003270|Radiation|radiation therapy|High energy X-rays
541629|NCT00003144|Drug|amifostine trihydrate|
541630|NCT00003144|Drug|cisplatin|
541631|NCT00003144|Drug|gemcitabine hydrochloride|
541632|NCT00003094|Other|preventative dietary intervention|
541633|NCT00003081|Biological|filgrastim|
541634|NCT00003081|Drug|busulfan|
541635|NCT00003081|Drug|melphalan|
541636|NCT00003081|Drug|thiotepa|
541637|NCT00003081|Procedure|peripheral blood stem cell transplantation|
541638|NCT00003081|Radiation|radiation therapy|
541639|NCT00002964|Drug|porfimer sodium|
541640|NCT00002964|Other|fluorophotometry|
541641|NCT00002866|Biological|filgrastim|
541642|NCT00002866|Drug|docetaxel|
541643|NCT00002866|Drug|epirubicin hydrochloride|
541644|NCT00006475|Drug|imatinib mesylate|
541645|NCT00006463|Drug|ECTEINASCIDIN 743|
541646|NCT00006357|Drug|imatinib mesylate|
541647|NCT00006216|Biological|PA-1-STK ovarian carcinoma vaccine|
541648|NCT00006216|Drug|ganciclovir|
541649|NCT00006049|Drug|carboplatin|
541650|NCT00006049|Drug|gefitinib|
541651|NCT00006049|Drug|paclitaxel|
541652|NCT00006048|Drug|cisplatin|
541653|NCT00006048|Drug|gefitinib|
541654|NCT00006048|Drug|gemcitabine hydrochloride|
541655|NCT00005870|Drug|fluorouracil|
541656|NCT00005870|Drug|gemcitabine hydrochloride|
541657|NCT00005870|Drug|mitomycin C|
541658|NCT00005870|Drug|rubitecan|
541659|NCT00005849|Drug|bryostatin 1|
541660|NCT00005849|Drug|paclitaxel|
541661|NCT00005842|Biological|trastuzumab|
541662|NCT00005842|Drug|tipifarnib|
541663|NCT00005832|Drug|R115777|300mg/dose BID, PO, Days 1-21, q 28days
541664|NCT00002794|Drug|carboplatin|
541665|NCT00002794|Drug|vincristine sulfate|
541666|NCT00002553|Drug|cyclophosphamide|
541667|NCT00002553|Procedure|allogeneic bone marrow transplantation|
541668|NCT00002553|Radiation|low-LET cobalt-60 gamma ray therapy|
541669|NCT00002485|Procedure|psychosocial assessment and care|
541670|NCT00002466|Drug|cyclophosphamide|
541671|NCT00002466|Drug|doxorubicin hydrochloride|
541672|NCT00002466|Drug|etoposide|
541673|NCT00002466|Drug|ifosfamide|
541862|NCT00005958|Drug|docetaxel|
541674|NCT00002466|Drug|vincristine sulfate|
541675|NCT00002466|Procedure|conventional surgery|
541676|NCT00002466|Radiation|radiation therapy|
541677|NCT00002456|Drug|cyclosporine|
541678|NCT00002456|Drug|methotrexate|
541679|NCT00002456|Procedure|allogeneic bone marrow transplantation|
541680|NCT00081822|Drug|clofarabine|Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
541681|NCT00081822|Drug|Ara-C|Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 & 3.
541682|NCT00081809|Drug|autologous human tumor-derived HSPPC-96|
541683|NCT00005092|Drug|Cyclophosphamide|IV over 2 hours on days 2 and 3
541684|NCT00005092|Drug|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
541685|NCT00005092|Drug|Thiotepa|IV over 2 hours on day 1
541686|NCT00005092|Procedure|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
541687|NCT00005092|Procedure|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
541688|NCT00005092|Radiation|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
541689|NCT00005082|Procedure|biopsy|
541690|NCT00005082|Procedure|magnetic resonance imaging|
541691|NCT00005023|Biological|HER-2/neu peptide vaccine|
541692|NCT00005023|Biological|sargramostim|
541693|NCT00004870|Biological|oblimersen sodium|
541694|NCT00004870|Drug|irinotecan hydrochloride|
541695|NCT00004254|Drug|raltitrexed|
541696|NCT00004013|Biological|trastuzumab|
541697|NCT00004013|Drug|paclitaxel|
541698|NCT00003899|Biological|filgrastim|
541699|NCT00003899|Drug|cyclophosphamide|
541700|NCT00003899|Drug|melphalan|
541701|NCT00003899|Drug|paclitaxel|
541702|NCT00003899|Drug|thiotepa|
541703|NCT00003899|Procedure|autologous bone marrow transplantation|
541704|NCT00003899|Procedure|peripheral blood stem cell transplantation|
541705|NCT00003880|Biological|recombinant adenovirus-p53 SCH-58500|
541706|NCT00003880|Drug|carboplatin|
541707|NCT00003880|Drug|paclitaxel|
541708|NCT00003790|Genetic|polymerase chain reaction|
541709|NCT00003790|Other|flow cytometry|
541710|NCT00003735|Drug|topotecan hydrochloride|given by mouth
541711|NCT00003715|Biological|BCG vaccine|
541712|NCT00003715|Biological|autologous tumor cell vaccine|
541713|NCT00003715|Biological|recombinant interferon alfa|
541714|NCT00003715|Drug|chemotherapy|
541715|NCT00003715|Drug|cyclophosphamide|
541716|NCT00003701|Drug|carboplatin|
541717|NCT00003701|Drug|cisplatin|
541718|NCT00003701|Drug|doxorubicin hydrochloride|
541719|NCT00003701|Drug|methotrexate|
541720|NCT00003701|Drug|paclitaxel|
541721|NCT00003701|Drug|vinblastine sulfate|
541722|NCT00003621|Drug|carmustine|
541723|NCT00003621|Drug|cisplatin|
541724|NCT00003621|Drug|etoposide|
541725|NCT00003621|Radiation|radiation therapy|
541726|NCT00003445|Drug|docetaxel|
541727|NCT00003386|Biological|BCG vaccine|
541728|NCT00003386|Biological|autologous tumor cell vaccine|
541729|NCT00003386|Drug|carboplatin|
541730|NCT00003386|Drug|cisplatin|
541731|NCT00003386|Drug|cyclophosphamide|
541732|NCT00003386|Drug|paclitaxel|
541733|NCT00003386|Other|dinitrophenyl|
541734|NCT00003386|Procedure|surgical procedure|
541735|NCT00003148|Biological|aldesleukin|
541736|NCT00003146|Drug|busulfan|
541737|NCT00003146|Drug|melphalan|
541738|NCT00003146|Drug|thiotepa|
541739|NCT00003146|Procedure|bone marrow transplantation|
541740|NCT00003146|Procedure|peripheral blood stem cell transplantation|
541741|NCT00003076|Drug|eflornithine|
541742|NCT00003041|Drug|pyrazoloacridine|
541743|NCT00081848|Drug|rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|
541744|NCT00081848|Drug|rF-CEA(6D)/TRICOM|
541745|NCT00081848|Drug|Recombinant Fowlpox-GM-CSF|
541746|NCT00081848|Drug|Celecoxib|
541747|NCT00081835|Drug|NP-016 Vaccine Immune Globulin (IV-VIG)|
541748|NCT00081796|Drug|larotaxel (RPR109881, XRP9881)|
541749|NCT00081796|Drug|capecitabine|
541750|NCT00081783|Drug|Xcellerated T Cells|
541751|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
541752|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
541753|NCT00081770|Drug|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
541754|NCT00081770|Biological|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
541755|NCT00081770|Drug|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
541756|NCT00081757|Drug|Thalidomide|
541757|NCT00021346|Drug|carboplatin|
541758|NCT00021346|Drug|gemcitabine hydrochloride|
541759|NCT00019357|Biological|aldesleukin|
541760|NCT00019357|Biological|therapeutic autologous lymphocytes|
541761|NCT00019357|Biological|therapeutic tumor infiltrating lymphocytes|
541762|NCT00003018|Drug|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
541763|NCT00003018|Drug|fluorouracil|200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle
541764|NCT00003018|Drug|leucovorin calcium|30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle
541863|NCT00005958|Drug|gemcitabine hydrochloride|
541765|NCT00003018|Drug|mitomycin C|10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
541766|NCT00003017|Biological|recombinant interleukin-12|
541767|NCT00002952|Biological|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
541768|NCT00002952|Biological|recombinant MAGE-3.1 antigen|
541769|NCT00002952|Biological|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
541770|NCT00002889|Drug|flutamide|
541771|NCT00002889|Drug|goserelin|
541772|NCT00002889|Drug|leuprolide acetate|
541773|NCT00002889|Radiation|low-LET photon therapy|
541774|NCT00002818|Drug|cytarabine|
541775|NCT00002818|Drug|deoxycytidine|
541776|NCT00002800|Biological|filgrastim|
541777|NCT00002800|Biological|lintuzumab|
541778|NCT00002800|Drug|cytarabine|
541779|NCT00002800|Drug|etoposide|
541780|NCT00002800|Drug|idarubicin|
541781|NCT00002772|Biological|filgrastim|
541782|NCT00002772|Drug|carboplatin|
541783|NCT00002772|Drug|carmustine|
541784|NCT00002772|Drug|cisplatin|
541785|NCT00002772|Drug|cyclophosphamide|
541786|NCT00002772|Drug|doxorubicin hydrochloride|
541787|NCT00002772|Drug|paclitaxel|
541788|NCT00002772|Drug|tamoxifen citrate|
541789|NCT00002772|Drug|thiotepa|
541790|NCT00002772|Procedure|autologous bone marrow transplantation|
541791|NCT00002772|Procedure|peripheral blood stem cell transplantation|
541792|NCT00002772|Radiation|radiation therapy|
541793|NCT00002768|Biological|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
541794|NCT00002768|Drug|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
541795|NCT00002768|Drug|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
541796|NCT00002768|Drug|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
541797|NCT00002768|Drug|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
541798|NCT00002768|Procedure|peripheral blood stem cell transplantation|Infusion on Day 0
541799|NCT00002764|Biological|filgrastim|
541800|NCT00002764|Drug|doxorubicin hydrochloride|
541801|NCT00002764|Drug|ifosfamide|
541802|NCT00002764|Procedure|conventional surgery|
541803|NCT00002745|Drug|aminocamptothecin|850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
541804|NCT00002722|Drug|cisplatin|
541805|NCT00002722|Drug|fluorouracil|
541806|NCT00002722|Drug|leucovorin calcium|
541807|NCT00002595|Drug|toremifene|
541808|NCT00002595|Procedure|conventional surgery|
541809|NCT00002583|Drug|cisplatin|50 mg/m2 IV
541810|NCT00002583|Drug|vinorelbine ditartrate|25 mg/m2 IV
541811|NCT00002534|Biological|anti-thymocyte globulin|
541812|NCT00002534|Drug|cyclophosphamide|
541813|NCT00002534|Drug|cytarabine|
541814|NCT00002534|Drug|methylprednisolone|
541815|NCT00002534|Drug|thiotepa|
541816|NCT00002534|Procedure|allogeneic bone marrow transplantation|
541817|NCT00002534|Procedure|in vitro-treated bone marrow transplantation|
541818|NCT00002534|Radiation|low-LET electron therapy|
541819|NCT00002534|Radiation|low-LET photon therapy|
541820|NCT00002519|Drug|chemotherapy|
541821|NCT00002519|Drug|paclitaxel|
541822|NCT00002519|Radiation|radiation therapy|
541823|NCT00002501|Biological|filgrastim|
541824|NCT00002501|Drug|cyclophosphamide|
541825|NCT00002492|Drug|cisplatin|
541826|NCT00002492|Drug|doxorubicin hydrochloride|
541827|NCT00002492|Drug|isolated limb perfusion|
541828|NCT00002492|Procedure|conventional surgery|
541829|NCT00002492|Radiation|brachytherapy|
541830|NCT00002492|Radiation|radiation therapy|
541831|NCT00002463|Drug|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
541832|NCT00002463|Drug|Leucovorin Calcium|
541833|NCT00002463|Drug|Mechlorethamine Hydrochloride|
541834|NCT00002463|Drug|Methotrexate|
541835|NCT00002463|Drug|Prednisone|
541836|NCT00002463|Drug|Procarbazine Hydrochloride|
541837|NCT00002463|Drug|Vincristine Sulfate|
541838|NCT00002463|Procedure|Conventional Surgery|
541839|NCT00081744|Drug|Tigecycline|
541840|NCT00081731|Drug|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
541841|NCT00081731|Procedure|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
541842|NCT00081653|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
541843|NCT00081653|Drug|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
541844|NCT00019344|Drug|alvocidib|
541845|NCT00019240|Drug|cidofovir|
541846|NCT00016900|Drug|liposomal paclitaxel|
541847|NCT00010010|Drug|exemestane|
541848|NCT00010010|Drug|goserelin acetate|
541849|NCT00009828|Drug|leucovorin calcium|
541850|NCT00009828|Drug|paclitaxel|
541851|NCT00009828|Drug|tegafur-uracil|
541852|NCT00081614|Drug|Avastin (bevacizumab)|
541853|NCT00081614|Drug|Tarceva (erlotinib HCl)|
541854|NCT00081549|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
541855|NCT00081536|Drug|Aroplatin (Liposomal NDDP) in combination with capecitabine|
541856|NCT00012129|Drug|liposomal annamycin|
541857|NCT00009815|Drug|etoposide|
541858|NCT00009815|Drug|leucovorin calcium|
541859|NCT00009815|Drug|tegafur-uracil|
541864|NCT00005950|Drug|nelarabine|Given IV
541865|NCT00005938|Drug|exatecan mesylate|
541866|NCT00005828|Dietary Supplement|green tea extract|
541867|NCT00005827|Dietary Supplement|genistein|
541868|NCT00081640|Drug|PRO 2000/5 Gel (P)|
541869|NCT00081601|Drug|CEP-701|
541870|NCT00081588|Drug|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
541871|NCT00081575|Drug|Tigecycline|
541872|NCT00081575|Drug|Levofloxacin|
541873|NCT00081380|Drug|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
541874|NCT00081380|Drug|lithium (mood stabilizer)|
541875|NCT00081380|Drug|divalproex (mood stabilizer)|
541876|NCT00005810|Biological|filgrastim|
541877|NCT00005810|Drug|carboplatin|
541878|NCT00005810|Drug|docetaxel|
541879|NCT00005810|Drug|estramustine phosphate sodium|
541880|NCT00005809|Procedure|computed tomography|
541881|NCT00005809|Procedure|diagnostic colonoscopy|
541882|NCT00005643|Drug|pegylated liposomal doxorubicin hydrochloride|
541883|NCT00005625|Drug|trabectedin|
541884|NCT00005608|Drug|leucovorin calcium|
541885|NCT00005608|Drug|tegafur-uracil|
541886|NCT00005080|Drug|nelarabine|Given IV
541887|NCT00005071|Procedure|biopsy|
541888|NCT00005071|Procedure|bronchoscopy|
541889|NCT00005071|Procedure|computed tomography|
541890|NCT00005071|Procedure|quality-of-life assessment|
541891|NCT00004252|Drug|fluorouracil|
541892|NCT00004252|Drug|leucovorin calcium|
541893|NCT00004252|Drug|semaxanib|
541894|NCT00004229|Biological|recombinant human endostatin|
541895|NCT00004178|Biological|therapeutic autologous lymphocytes|
541896|NCT00081510|Drug|Lonafarnib|
541897|NCT00081510|Drug|Placebo|
541898|NCT00081510|Drug|anastrozole|
541899|NCT00081497|Biological|agalsidase beta|1.0 mg/kg every 2 weeks
541900|NCT00081484|Drug|epoetin alfa or beta|iv or sc, as prescribed
541901|NCT00081484|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
541902|NCT00081471|Drug|darbepoetin alfa|0.45 micrograms/kg sc (starting dose) weekly
541903|NCT00081471|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg sc (starting dose) once every 2 weeks
541904|NCT00004177|Biological|filgrastim|as prescribed by physician
541905|NCT00004177|Procedure|peripheral blood stem cell transplantation|1-2 weeks from treatment
541906|NCT00004177|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
541907|NCT00004177|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
541908|NCT00004108|Drug|exatecan mesylate|
541909|NCT00004107|Biological|filgrastim|as prescribed by physician
541910|NCT00004107|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
541911|NCT00004107|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
541912|NCT00004107|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
541913|NCT00004107|Radiation|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
541914|NCT00004100|Drug|cisplatin|
541915|NCT00004100|Drug|gemcitabine hydrochloride|
541916|NCT00004100|Drug|vinorelbine tartrate|
541917|NCT00004087|Biological|filgrastim|as prescribed by physician
541918|NCT00004087|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
541919|NCT00004087|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
541920|NCT00004087|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
541921|NCT00004087|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
541922|NCT00004086|Biological|filgrastim|
541923|NCT00004086|Drug|cisplatin|
541924|NCT00004086|Drug|cytarabine|
541925|NCT00004086|Drug|etoposide|
541926|NCT00004086|Drug|ifosfamide|
541927|NCT00004086|Procedure|autologous bone marrow transplantation|
541928|NCT00004086|Procedure|peripheral blood stem cell transplantation|
541929|NCT00004086|Radiation|indium In 111 LL2 IgG|
541930|NCT00004086|Radiation|yttrium Y 90 epratuzumab|
541931|NCT00004085|Biological|filgrastim|as prescribed by physician
541932|NCT00004085|Procedure|autologous bone marrow transplantation|1-2 weeks prior to treatment
541933|NCT00004085|Procedure|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
541934|NCT00004085|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
541935|NCT00004084|Radiation|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
541936|NCT00004084|Radiation|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
541937|NCT00004048|Biological|filgrastim|
541938|NCT00004048|Drug|doxorubicin hydrochloride|
541939|NCT00004048|Procedure|autologous bone marrow transplantation|
541940|NCT00004048|Procedure|peripheral blood stem cell transplantation|
541941|NCT00004048|Radiation|indium In 111 monoclonal antibody MN-14|
541942|NCT00004048|Radiation|yttrium Y 90 monoclonal antibody MN-14|
541943|NCT00004046|Drug|exatecan mesylate|
541944|NCT00004045|Drug|exatecan mesylate|
541945|NCT00004033|Drug|liposomal NDDP|
541946|NCT00004033|Procedure|therapeutic thoracoscopy|
541947|NCT00004016|Biological|recombinant interferon gamma|
541948|NCT00004010|Biological|bleomycin sulfate|
541949|NCT00004010|Biological|filgrastim|
541950|NCT00004010|Drug|ABVD regimen|
541951|NCT00004010|Drug|cyclophosphamide|
541952|NCT00004010|Drug|dacarbazine|
541953|NCT00004010|Drug|doxorubicin hydrochloride|
541954|NCT00004010|Drug|etoposide|
541956|NCT00004010|Drug|procarbazine hydrochloride|
541957|NCT00004010|Drug|vinblastine sulfate|
541958|NCT00004010|Drug|vincristine sulfate|
541959|NCT00004010|Radiation|radiation therapy|
541960|NCT00003954|Drug|melphalan|Given IV
541961|NCT00003954|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
541962|NCT00003954|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
541963|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
541964|NCT00003954|Radiation|total-body irradiation|Undergo TBI
541965|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo donor PBSCT
541966|NCT00003954|Drug|cyclosporine|Given IV and PO
541967|NCT00003954|Drug|mycophenolate mofetil|Given PO
541968|NCT00003954|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
541969|NCT00081458|Drug|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
541970|NCT00081458|Drug|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
541971|NCT00081458|Drug|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
541972|NCT00003917|Drug|topotecan hydrochloride|
541973|NCT00003870|Drug|cyclophosphamide|
541974|NCT00003870|Drug|methotrexate|
541975|NCT00003870|Procedure|allogeneic bone marrow transplantation|
541976|NCT00003870|Radiation|iodine I 131 monoclonal antibody BC8|
541977|NCT00003870|Radiation|radiation therapy|
541978|NCT00003834|Drug|fluorouracil|
541979|NCT00003834|Drug|leucovorin calcium|
541980|NCT00003834|Drug|oxaliplatin|
541981|NCT00003824|Drug|cephalexin|500 mg oral bid for 3 days starting the night before resection
541982|NCT00003824|Procedure|surgical procedure|
541983|NCT00003824|Drug|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
541984|NCT00003809|Biological|cetuximab|
541985|NCT00003809|Drug|cisplatin|
541986|NCT00003719|Drug|irinotecan hydrochloride|
541987|NCT00003718|Drug|temozolomide|
541988|NCT00003717|Drug|estramustine phosphate sodium|
541989|NCT00003717|Drug|paclitaxel|
541990|NCT00003674|Drug|dalteparin|
541991|NCT00003674|Drug|standard therapy|
541992|NCT00003493|Drug|dexamethasone|
541993|NCT00003493|Drug|pegylated liposomal doxorubicin hydrochloride|
541994|NCT00003493|Drug|vincristine sulfate|
541995|NCT00003307|Drug|amifostine trihydrate|
541996|NCT00003307|Radiation|radiation therapy|
541997|NCT00003283|Drug|octreotide acetate|
541998|NCT00003283|Drug|prednisone|
541999|NCT00003235|Drug|carboplatin|
542000|NCT00003235|Drug|paclitaxel|
542001|NCT00003235|Radiation|radiation therapy|
542002|NCT00003209|Biological|bleomycin sulfate|
542003|NCT00003209|Drug|cisplatin|
542004|NCT00003209|Drug|fluorouracil|
542005|NCT00003209|Drug|ifosfamide|
542006|NCT00003209|Drug|methotrexate|
542007|NCT00003209|Drug|mitomycin C|
542008|NCT00003209|Drug|vinblastine sulfate|
542009|NCT00003209|Drug|vindesine|
542010|NCT00003209|Radiation|radiation therapy|
542011|NCT00003125|Biological|ALVAC-CEA vaccine|
542012|NCT00003125|Biological|aldesleukin|
542013|NCT00003125|Biological|sargramostim|
542014|NCT00003125|Biological|vaccinia-CEA vaccine|
542015|NCT00003080|Drug|endocrine-modulating drug therapy|
542016|NCT00003080|Drug|melphalan|
542017|NCT00003080|Drug|mitoxantrone hydrochloride|
542018|NCT00003080|Drug|tamoxifen citrate|
542019|NCT00003080|Drug|thiotepa|
542020|NCT00003080|Procedure|peripheral blood stem cell transplantation|
542021|NCT00003061|Drug|cytarabine|
542022|NCT00003061|Drug|methotrexate|
542023|NCT00003061|Radiation|radiation therapy|
542024|NCT00003032|Biological|filgrastim|
542025|NCT00003032|Drug|cisplatin|
542026|NCT00003032|Drug|cyclophosphamide|
542027|NCT00003032|Drug|mitoxantrone hydrochloride|
542028|NCT00003032|Drug|tamoxifen citrate|
542029|NCT00003010|Drug|marimastat|
542030|NCT00021398|Drug|fluorouracil|
542031|NCT00021398|Drug|leucovorin calcium|
542032|NCT00021398|Procedure|conventional surgery|
542033|NCT00021398|Radiation|radiation therapy|
542034|NCT00021281|Drug|FOLFIRI regimen|
542035|NCT00021281|Drug|fluorouracil|
542036|NCT00021281|Drug|irinotecan hydrochloride|
542037|NCT00021281|Drug|leucovorin calcium|
542038|NCT00021281|Drug|semaxanib|
542039|NCT00021151|Biological|alemtuzumab|
542040|NCT00021008|Drug|picoplatin|
542041|NCT00020774|Drug|gemcitabine hydrochloride|
542042|NCT00020774|Drug|lonafarnib|
542043|NCT00020774|Procedure|conventional surgery|
542044|NCT00019552|Drug|irofulven|
542045|NCT00019474|Biological|filgrastim|
542046|NCT00019474|Biological|recombinant interferon alfa|
542047|NCT00019474|Drug|fluorouracil|
542048|NCT00019474|Drug|hydroxyurea|
542049|NCT00019318|Drug|romidepsin|
542050|NCT00019123|Drug|thalidomide|
542051|NCT00014391|Biological|palivizumab|
542052|NCT00014391|Drug|ribavirin|
542053|NCT00012311|Biological|filgrastim|
542054|NCT00012311|Drug|CMF regimen|
542055|NCT00012311|Drug|carboplatin|
542056|NCT00012311|Drug|cyclophosphamide|
542057|NCT00012311|Drug|docetaxel|
542058|NCT00012311|Drug|doxorubicin hydrochloride|
542059|NCT00012311|Drug|etoposide|
542060|NCT00012311|Drug|fluorouracil|
542061|NCT00012311|Drug|ifosfamide|
542064|NCT00012311|Procedure|peripheral blood stem cell transplantation|
542065|NCT00010283|Drug|beclomethasone dipropionate|
542066|NCT00007943|Drug|gemcitabine hydrochloride|
542067|NCT00006045|Biological|lintuzumab|
542068|NCT00006045|Drug|cytarabine|
542069|NCT00006045|Drug|etoposide|
542070|NCT00006045|Drug|mitoxantrone hydrochloride|
542071|NCT00005875|Drug|rubitecan|
542072|NCT00005874|Drug|rubitecan|
542073|NCT00005873|Drug|rubitecan|
542074|NCT00002708|Procedure|surgical procedure|
542075|NCT00002708|Radiation|radiation therapy|
542076|NCT00002708|Radiation|stereotactic radiosurgery|
542077|NCT00081406|Behavioral|Individual Child CBT|
542078|NCT00081406|Behavioral|Family CBT|
542079|NCT00081406|Behavioral|Education/Support/Attention|
542080|NCT00081367|Behavioral|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
542081|NCT00081367|Behavioral|Standard care alone|Participants will receive standard care for suicide prevention.
542082|NCT00081328|Drug|Metformin|capsule, 1000 mg bid
542083|NCT00081328|Drug|Rosiglitazone|capsule, 4 mg bid
542084|NCT00081328|Behavioral|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
542085|NCT00005872|Drug|rubitecan|
542086|NCT00005833|Drug|R115777|300mg P.O. BID.
542087|NCT00005820|Drug|nitrocamptothecin|
542088|NCT00005801|Biological|therapeutic allogeneic lymphocytes|
542089|NCT00005801|Procedure|peripheral blood stem cell transplantation|
542090|NCT00005801|Radiation|radiation therapy|
542091|NCT00005077|Drug|oxaliplatin|
542092|NCT00005066|Drug|O6-benzylguanine|
542093|NCT00005066|Drug|carmustine|
542094|NCT00005061|Biological|bevacizumab|
542095|NCT00005058|Procedure|ultrasound imaging|
542096|NCT00005040|Drug|arsenic trioxide|
542097|NCT00004885|Drug|FOLFIRI regimen|
542098|NCT00004885|Drug|fluorouracil|
542099|NCT00004885|Drug|irinotecan hydrochloride|
542100|NCT00004885|Drug|leucovorin calcium|
542101|NCT00004860|Drug|leucovorin calcium|
542102|NCT00004860|Drug|tegafur-uracil|
542103|NCT00004238|Drug|pralatrexate|
542104|NCT00004166|Drug|amifostine trihydrate|
542105|NCT00004166|Procedure|quality-of-life assessment|
542106|NCT00004137|Biological|filgrastim|
542107|NCT00004137|Drug|carboplatin|
542108|NCT00004137|Drug|paclitaxel|
542109|NCT00004137|Drug|topotecan hydrochloride|
542110|NCT00004102|Drug|FOLFOX regimen|
542111|NCT00004102|Drug|fluorouracil|
542112|NCT00004102|Drug|leucovorin calcium|
542113|NCT00004102|Drug|oxaliplatin|
542114|NCT00004082|Drug|carboplatin|
542115|NCT00004082|Drug|docetaxel|
542116|NCT00004082|Drug|gemcitabine hydrochloride|
542117|NCT00004002|Drug|bortezomib|
542118|NCT00003911|Radiation|stereotactic radiosurgery|
542119|NCT00003840|Biological|DTGM fusion protein|
542120|NCT00081315|Drug|Amifostine|
542121|NCT00005943|Biological|aldesleukin|
542122|NCT00005943|Biological|staphylococcal enterotoxin B|
542123|NCT00003754|Drug|cyclophosphamide|
542124|NCT00003754|Drug|thalidomide|
542125|NCT00003710|Drug|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
542126|NCT00003710|Drug|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
542127|NCT00003692|Procedure|therapeutic thoracoscopy|
542128|NCT00003692|Procedure|video-assisted surgery|
542129|NCT00003642|Drug|cisplatin|
542130|NCT00003642|Drug|fluorouracil|
542131|NCT00003642|Radiation|radiation therapy|
542132|NCT00003446|Drug|fluorouracil|
542133|NCT00003446|Drug|leucovorin calcium|
542134|NCT00003446|Drug|trimetrexate glucuronate|
542135|NCT00003376|Drug|carboplatin|
542136|NCT00003376|Drug|cisplatin|
542137|NCT00003376|Drug|doxorubicin hydrochloride|
542138|NCT00003376|Drug|methotrexate|
542139|NCT00003376|Drug|paclitaxel|
542140|NCT00003376|Drug|vinblastine|
542141|NCT00003316|Drug|gemcitabine hydrochloride|
542142|NCT00003301|Drug|irinotecan hydrochloride|
542143|NCT00003232|Drug|clodronate disodium|
542144|NCT00003232|Drug|mitoxantrone hydrochloride|
542145|NCT00003232|Drug|prednisone|
542146|NCT00003232|Procedure|quality-of-life assessment|
542147|NCT00081302|Biological|cetuximab|
542148|NCT00081302|Drug|carboplatin|
542149|NCT00081302|Drug|paclitaxel|
542150|NCT00081302|Radiation|radiation therapy|
542238|NCT00080886|Procedure|autologous bone marrow transplantation|
546938|NCT00009932|Drug|paclitaxel|
542151|NCT00081289|Radiation|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
542152|NCT00081289|Drug|Capecitabine 1650 mg/m^2/day|825 mg/m^2 q12 hours (1650 mg/m^2/day) orally 5 days per week during radiotherapy.
542153|NCT00081289|Drug|Capecitabine 1200 mg/m^2/day|600 mg/m^2 q12 hours(1200 mg/m^2/day) orally 5 days per week during radiotherapy.
542154|NCT00081289|Drug|Irinotecan|50mg/m^2 IV over 1 hour on days 1, 8, 22, and 29
542155|NCT00081289|Drug|Oxaliplatin|50mg/m^2 IV over 2 hours on days 1, 8, 15, 22, and 29
542156|NCT00081289|Procedure|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
542157|NCT00081289|Drug|Folinic Acid|400 mg/m^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
542158|NCT00081289|Drug|Fluorouracil|"5-fluorouracil bolus 400 mg/m^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.~5-fluorouracil infusion 2400 mg/m^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles."
542159|NCT00081289|Drug|Oxaliplatin|85 mg/m^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
542160|NCT00081276|Drug|triapine|Given IV
542161|NCT00081276|Drug|cisplatin|Given IV
542162|NCT00081276|Other|laboratory biomarker analysis|Correlative studies
542163|NCT00081263|Drug|Celecoxib|Given orally
542164|NCT00081263|Other|Laboratory Biomarker Analysis|Correlative studies
542165|NCT00081263|Other|Placebo|Given orally
542166|NCT00081250|Dietary Supplement|creatine monohydrate|Given orally
542167|NCT00081250|Other|placebo|Given orally
542168|NCT00081237|Drug|OSI-7904L|
542169|NCT00081237|Drug|oxaliplatin|
542170|NCT00081224|Drug|capecitabine|
542171|NCT00081224|Drug|celecoxib|
542172|NCT00081224|Radiation|radiation therapy|
542173|NCT00081224|Procedure|surgery|
542174|NCT00081211|Biological|PV701|Given intratumorally
542175|NCT00081172|Radiation|lutetium Lu 177 monoclonal antibody J591|
542176|NCT00081159|Drug|Doxorubicin hydrochloride|Doxorubicin 20 mg/m^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
542177|NCT00081159|Drug|Goserelin acetate|
542178|NCT00081159|Drug|Leuprolide acetate|
542179|NCT00081159|Drug|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
542180|NCT00081159|Procedure|orchiectomy|
542181|NCT00081159|Radiation|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
542182|NCT00081133|Drug|arsenic trioxide|
542183|NCT00081133|Drug|imatinib mesylate|
542184|NCT00081107|Drug|epothilone D|
542185|NCT00081094|Procedure|18F-Fluorodeoxyglucose-PET (FDG-PET)|
542186|NCT00081094|Procedure|11Carbon-Acetate-PET|
542187|NCT00081068|Biological|alemtuzumab|
542188|NCT00081055|Biological|autologous expanded mesenchymal stem cells OTI-010|
542189|NCT00081055|Drug|busulfan|
542190|NCT00081055|Drug|cyclophosphamide|
542191|NCT00081055|Drug|cyclosporine|
542192|NCT00081055|Drug|methotrexate|
542193|NCT00081055|Procedure|peripheral blood stem cell transplantation|
542194|NCT00081055|Radiation|radiation therapy|
542195|NCT00081042|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
542196|NCT00081029|Procedure|management of therapy complications|
542197|NCT00081029|Radiation|radiation therapy|
542198|NCT00081003|Genetic|gene expression analysis|
542199|NCT00081003|Genetic|protein expression analysis|
542200|NCT00081003|Other|cytology specimen collection procedure|
542201|NCT00081003|Other|laboratory biomarker analysis|
542202|NCT00081003|Other|physiologic testing|
542203|NCT00081003|Procedure|breast duct lavage|
542204|NCT00081003|Procedure|endoscopic biopsy|
542205|NCT00081003|Procedure|study of high risk factors|
542206|NCT00080990|Drug|alvocidib|Given IV
542207|NCT00080990|Drug|fluorouracil|Given IV
542208|NCT00080990|Drug|oxaliplatin|Given IV
542209|NCT00080990|Drug|leucovorin calcium|Given IV
542210|NCT00080977|Biological|aldesleukin|
542211|NCT00080951|Drug|fluorouracil|
542212|NCT00080951|Drug|irinotecan hydrochloride|
542213|NCT00080951|Drug|leucovorin calcium|
542214|NCT00080951|Drug|oxaliplatin|
542215|NCT00080938|Drug|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
542216|NCT00080938|Radiation|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
542217|NCT00080925|Biological|filgrastim|
542218|NCT00080925|Biological|graft-versus-tumor induction therapy|
542219|NCT00080925|Biological|rituximab|
542220|NCT00080925|Biological|therapeutic allogeneic lymphocytes|
542221|NCT00080925|Drug|cyclophosphamide|
542222|NCT00080925|Drug|cyclosporine|
542223|NCT00080925|Drug|cytarabine|
542224|NCT00080925|Drug|doxorubicin hydrochloride|
542225|NCT00080925|Drug|etoposide|
542226|NCT00080925|Drug|fludarabine phosphate|
542227|NCT00080925|Drug|prednisone|
542228|NCT00080925|Drug|vincristine sulfate|
542229|NCT00080925|Procedure|peripheral blood stem cell transplantation|
542230|NCT00080912|Radiation|radiation therapy|Given in a single fraction or multiple fractions
542231|NCT00080899|Drug|fenretinide|Given orally
542232|NCT00080899|Other|laboratory biomarker analysis|Correlative studies
542239|NCT00080886|Procedure|peripheral blood stem cell transplantation|
542240|NCT00080873|Drug|Traumeel S|
542241|NCT00080873|Other|Placebo|
542242|NCT00080860|Genetic|microarray analysis|
542243|NCT00080860|Other|immunohistochemistry staining method|
542244|NCT00080860|Procedure|conventional surgery|
542245|NCT00080860|Procedure|lymphangiography|
542246|NCT00080860|Procedure|radionuclide imaging|
542247|NCT00080860|Procedure|sentinel lymph node biopsy|
542248|NCT00080860|Radiation|technetium Tc 99m sulfur colloid|
542249|NCT00080847|Biological|oblimersen sodium|Given IV
542250|NCT00080847|Biological|rituximab|Given IV
542251|NCT00080847|Drug|cyclophosphamide|Given IV
542252|NCT00080847|Drug|doxorubicin hydrochloride|Given IV
542253|NCT00080847|Drug|vincristine sulfate|Given IV
542254|NCT00080847|Drug|prednisone|Given orally
542255|NCT00080847|Other|laboratory biomarker analysis|Correlative studies
542256|NCT00080834|Drug|DJ-927|
542257|NCT00080808|Drug|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
542258|NCT00080808|Drug|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
542259|NCT00080808|Drug|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
542260|NCT00080808|Drug|Sildenafil citrate|Oral sildenafil as needed
542261|NCT00080808|Procedure|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
542262|NCT00080795|Biological|filgrastim|
542263|NCT00080795|Drug|cisplatin|
542264|NCT00080795|Drug|doxorubicin hydrochloride|
542265|NCT00080795|Drug|gemcitabine hydrochloride|
542266|NCT00080795|Drug|ifosfamide|
542267|NCT00080795|Procedure|conventional surgery|
542268|NCT00080795|Procedure|neoadjuvant therapy|
542269|NCT00080782|Drug|Celecoxib|Oral celecoxib twice daily in the absence of disease progression.
542270|NCT00080782|Drug|Doxorubicin Hydrochloride|By vein (IV) over 30 minutes on days 1, 8, 15, and 22
542271|NCT00080782|Radiation|Strontium chloride Sr 89|IV on day 1
542272|NCT00080756|Biological|therapeutic estradiol|0.35mg/100ul per day as a nasal spray
542273|NCT00080756|Drug|deslorelin|1mg/100ul per day as a nasal spray
542274|NCT00080756|Drug|therapeutic testosterone|0.275mg/100ul per day as a nasal spray
542275|NCT00080756|Procedure|therapeutic conventional surgery|Undergo risk reduction mastectomy
542276|NCT00080756|Other|active surveillance|Undergo continued surveillance
542277|NCT00080756|Procedure|quality-of-life assessment|Ancillary studies
542278|NCT00080756|Other|laboratory biomarker analysis|Correlative studies
542279|NCT00080743|Drug|gefitinib|250 mg po once daily
542280|NCT00080743|Drug|tamoxifen citrate|20 mg po once daily
542281|NCT00080743|Drug|Placebo|One pill po once daily
542282|NCT00080678|Drug|Docetaxel|
542283|NCT00080678|Drug|Imatinib Mesylate|
542284|NCT00080665|Drug|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
542285|NCT00080665|Drug|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
542286|NCT00080639|Other|physiologic testing|
542287|NCT00080639|Procedure|study of high risk factors|
542288|NCT00080626|Biological|pegfilgrastim|6 mg injection on day 1 of each cycle
542289|NCT00080626|Drug|docetaxel|100 mg per meter-squared, every 14 days for 4 cycles
542290|NCT00080626|Procedure|conventional surgery|lumpectomy or mastectomy at end of treatment
542291|NCT00080626|Procedure|neoadjuvant therapy|treatment prior to definitive breast surgery
542292|NCT00080613|Drug|exemestane|
542293|NCT00080613|Procedure|adjuvant therapy|
542294|NCT00080613|Procedure|aromatase inhibition|
542295|NCT00080613|Procedure|conventional surgery|
542296|NCT00080613|Procedure|endocrine therapy|
542297|NCT00080613|Procedure|hormone therapy|
542298|NCT00080613|Procedure|neoadjuvant therapy|
542299|NCT00080613|Procedure|surgery|
542300|NCT00080574|Procedure|Skin Biopsy|
542301|NCT00080535|Biological|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
542302|NCT00080522|Behavioral|Monitoring by HIV-trained primary care nurses|
542303|NCT00080522|Behavioral|Community-based directly observed therapy (DOT)|
542304|NCT00080522|Drug|stavudine|
542305|NCT00080522|Drug|lamivudine|
542306|NCT00080522|Drug|efavirenz|
542307|NCT00080522|Drug|zidovudine|
542308|NCT00080522|Drug|didanosine|
542309|NCT00080522|Drug|lopinavir/ritonavir|
542310|NCT00080509|Drug|KOS-862|
542311|NCT00080496|Drug|Tigecycline|
542312|NCT00080496|Drug|Imipenem|
542313|NCT00080496|Drug|Cilastatin|
542314|NCT00003176|Drug|carmustine|
542315|NCT00003176|Drug|temozolomide|
542316|NCT00003156|Drug|topotecan hydrochloride|
542317|NCT00003132|Drug|bryostatin 1|
542318|NCT00003132|Drug|cisplatin|
542319|NCT00003110|Biological|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
542320|NCT00002997|Procedure|cryosurgery|
542321|NCT00080483|Drug|Testosterone plus somatropin|AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
542322|NCT00080483|Drug|testosterone|AndroGel transdermally 5 g a day for two years
542323|NCT00024063|Drug|orantinib|
542324|NCT00003107|Biological|recombinant interleukin-12|
542325|NCT00003103|Biological|oblimersen sodium|
542329|NCT00003012|Drug|epirubicin hydrochloride|
542330|NCT00003012|Drug|fluorouracil|
542331|NCT00003012|Drug|methotrexate|
542332|NCT00002987|Biological|bleomycin sulfate|
542333|NCT00002987|Drug|cyclophosphamide|
542334|NCT00002987|Drug|doxorubicin hydrochloride|
542335|NCT00002987|Drug|etoposide|
542336|NCT00002987|Drug|prednisolone|
542337|NCT00002987|Drug|vincristine sulfate|
542338|NCT00002987|Radiation|radiation therapy|
542339|NCT00002814|Biological|filgrastim|
542340|NCT00002814|Drug|paclitaxel|
542341|NCT00002814|Drug|topotecan hydrochloride|
542342|NCT00002774|Drug|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.~Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.~Tirapazamine dose was as follows:~Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)~Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)~Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
542343|NCT00002774|Drug|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
542344|NCT00002774|Drug|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.~The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
542345|NCT00002774|Radiation|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.~After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).~Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
542346|NCT00002714|Biological|bleomycin sulfate|
542347|NCT00002714|Drug|Stanford V regimen|
542348|NCT00002714|Drug|doxorubicin hydrochloride|
542349|NCT00002714|Drug|etoposide|
542350|NCT00002714|Drug|mechlorethamine hydrochloride|
542351|NCT00002714|Drug|prednisone|
542352|NCT00002714|Drug|vinblastine sulfate|
542353|NCT00002714|Drug|vincristine sulfate|
542354|NCT00002714|Radiation|radiation therapy|
542355|NCT00002600|Biological|filgrastim|
542356|NCT00002600|Drug|carboplatin|
542357|NCT00002600|Drug|cyclophosphamide|
542358|NCT00002600|Procedure|autologous bone marrow transplantation|
542359|NCT00002600|Procedure|peripheral blood stem cell transplantation|
542360|NCT00002525|Drug|fluorouracil|"Perioperative 5-FU: 600 mg/m^2/d x 7 days continuous IV, beginning within 24 hours of surgery~After surgery, 5-FU was given 425 mg/m^2 IV push on days 1-5"
542361|NCT00002525|Drug|leucovorin calcium|given after surgery at dose of 20mg/m^2 IV push on days 1-5
542362|NCT00002494|Drug|cyclophosphamide|
542363|NCT00002494|Drug|cytarabine|
542364|NCT00002494|Drug|dexamethasone|
542365|NCT00002494|Drug|doxorubicin hydrochloride|
542366|NCT00002494|Drug|etoposide|
542367|NCT00002494|Drug|ifosfamide|
542368|NCT00002494|Drug|leucovorin calcium|
542369|NCT00002494|Drug|mesna|
542370|NCT00002494|Drug|methotrexate|
542371|NCT00002494|Drug|prednisone|
542372|NCT00002494|Drug|therapeutic hydrocortisone|
542373|NCT00002494|Drug|vincristine sulfate|
542374|NCT00002494|Radiation|low-LET cobalt-60 gamma ray therapy|
542375|NCT00002494|Radiation|low-LET photon therapy|
542376|NCT00080470|Device|bion|battery powered microstimulator
542377|NCT00080457|Drug|sitaxsentan sodium|
542378|NCT00023816|Drug|carbendazim|
542379|NCT00022386|Biological|epoetin alfa|
542380|NCT00022386|Procedure|quality-of-life assessment|
542381|NCT00022256|Drug|motexafin gadolinium|
542382|NCT00022256|Radiation|radiation therapy|
542383|NCT00020605|Drug|naloxone hydrochloride|
542384|NCT00020540|Biological|recombinant CD40-ligand|
542385|NCT00020540|Biological|recombinant flt3 ligand|
542386|NCT00019071|Drug|chemotherapy|
542387|NCT00019071|Drug|cladribine|
542388|NCT00019071|Radiation|radiation therapy|
542389|NCT00019058|Drug|chemotherapy|
542390|NCT00019058|Drug|hydroxyurea|
542391|NCT00019058|Drug|pentoxifylline|
542392|NCT00019058|Radiation|radiation therapy|
542393|NCT00016042|Biological|lymphokine-activated killer cells|
542394|NCT00016042|Biological|recombinant interferon alfa|
542395|NCT00016042|Biological|sargramostim|
542396|NCT00016042|Drug|fluorouracil|
542397|NCT00014573|Biological|aldesleukin|
542398|NCT00014573|Biological|autologous tumor cell vaccine|
542399|NCT00014573|Biological|filgrastim|
542400|NCT00014573|Biological|sargramostim|
542401|NCT00014573|Biological|therapeutic autologous lymphocytes|
542402|NCT00014573|Drug|carmustine|
542403|NCT00014573|Drug|cisplatin|
542404|NCT00014573|Drug|cyclophosphamide|
542405|NCT00014573|Drug|paclitaxel|
542406|NCT00014573|Procedure|autologous bone marrow transplantation|
542407|NCT00014573|Procedure|conventional surgery|
542408|NCT00014573|Procedure|peripheral blood stem cell transplantation|
542409|NCT00080444|Drug|aprepitant|aprepitant capsules
542410|NCT00080444|Drug|ondansetron|ondansetron IV preparation
542411|NCT00080444|Drug|dexamethasone|dexamethasone tablets
542412|NCT00080444|Drug|placebo to aprepitant|Matching placebo to aprepitant capsules
542413|NCT00080444|Drug|placebo to dexamethasone|Matching placebo to dexamethasone tablets
542414|NCT00080444|Drug|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
542415|NCT00080418|Drug|Liposome Entrapped Paclitaxel Easy to Use|
542416|NCT00080405|Drug|Bortezomib|
542417|NCT00009841|Biological|EGFR antisense DNA|
542418|NCT00009841|Biological|growth factor antagonist therapy|
542419|NCT00009841|Drug|DC-cholesterol liposome|
542420|NCT00007813|Biological|filgrastim|
542421|NCT00007813|Drug|carboplatin|
542422|NCT00007813|Drug|cyclophosphamide|
542423|NCT00007813|Drug|etoposide|
542424|NCT00007813|Procedure|autologous bone marrow transplantation|
542425|NCT00007813|Procedure|peripheral blood stem cell transplantation|
542426|NCT00006487|Drug|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
542427|NCT00006487|Drug|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion~During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
542428|NCT00006487|Drug|tirapazamine|"During induction:~Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion~Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion~During consolidation:~330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
542429|NCT00006487|Radiation|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
542430|NCT00006458|Radiation|indium In 111 monoclonal antibody MN-14|
542431|NCT00006458|Radiation|yttrium Y 90 monoclonal antibody MN-14|
542432|NCT00006376|Drug|chemotherapy|
542433|NCT00006376|Drug|tipifarnib|
542434|NCT00006371|Drug|aminoglutethimide|
542435|NCT00006371|Drug|ketoconazole|
542436|NCT00006371|Drug|therapeutic hydrocortisone|
542437|NCT00006370|Radiation|yttrium Y 90-edotreotide|
542438|NCT00006369|Drug|ERA-923|
542439|NCT00006368|Radiation|yttrium Y 90-edotreotide|
542440|NCT00006052|Drug|imatinib mesylate|
542441|NCT00006043|Drug|temozolomide|
542442|NCT00006032|Drug|etoposide|
542443|NCT00006032|Drug|ifosfamide|
542444|NCT00006032|Drug|topotecan hydrochloride|
542445|NCT00006032|Procedure|peripheral blood stem cell transplantation|
542446|NCT00006031|Procedure|Needle localized breast biopsy with specimen x-ray|
542447|NCT00006031|Procedure|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
542448|NCT00005948|Biological|aldesleukin|
542449|NCT00005948|Biological|recombinant interferon alfa|
542450|NCT00005948|Biological|sargramostim|
542451|NCT00005948|Drug|busulfan|
542452|NCT00005948|Procedure|peripheral blood stem cell transplantation|
542453|NCT00005860|Drug|floxuridine|
542454|NCT00005860|Drug|leucovorin calcium|
542455|NCT00005860|Drug|oxaliplatin|
542456|NCT00005799|Drug|fludarabine phosphate|Given IV
542457|NCT00005799|Radiation|total-body irradiation|Undergo low-dose TBI
542458|NCT00005799|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
542459|NCT00005799|Procedure|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
542460|NCT00005799|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
542461|NCT00005799|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
542462|NCT00005799|Drug|cyclosporine|Given PO
542463|NCT00005799|Drug|mycophenolate mofetil|Given PO
542464|NCT00005799|Other|pharmacological study|Correlative studies
542465|NCT00005799|Other|laboratory biomarker analysis|Correlative studies
542466|NCT00005798|Drug|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
542467|NCT00005798|Drug|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
542468|NCT00005798|Drug|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
542469|NCT00005628|Biological|vitespen|
542470|NCT00005618|Drug|arsenic trioxide|
542471|NCT00005615|Biological|Interferon alfa|Interferon alfa as outlined in treatment arm.
542472|NCT00005615|Radiation|Radiation therapy|Radiation therapy as outlined in treatment arm.
542473|NCT00005577|Drug|gemcitabine hydrochloride|
542569|NCT00002759|Drug|irinotecan hydrochloride|
542570|NCT00002759|Drug|phenobarbital|
542571|NCT00002592|Biological|c-myb antisense oligonucleotide G4460|
542572|NCT00002592|Biological|filgrastim|
542573|NCT00002592|Drug|busulfan|
542574|NCT00002592|Drug|cyclophosphamide|
547447|NCT00003436|Drug|asparaginase|
542474|NCT00005097|Drug|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
542475|NCT00005068|Drug|fluorouracil|
542476|NCT00005068|Drug|irinotecan hydrochloride|
542477|NCT00005068|Drug|leucovorin calcium|
542478|NCT00005068|Drug|oxaliplatin|
542479|NCT00003864|Drug|carboplatin|
542480|NCT00003864|Drug|docetaxel|
542481|NCT00080431|Drug|Daclizumab|
542482|NCT00005031|Drug|irofulven|
542483|NCT00004248|Biological|aldesleukin|
542484|NCT00004248|Drug|doxorubicin hydrochloride|
542485|NCT00004097|Drug|fluorouracil|
542486|NCT00004097|Drug|gemcitabine hydrochloride|
542487|NCT00004097|Drug|paclitaxel|
542488|NCT00004097|Radiation|radiation therapy|
542489|NCT00003967|Drug|etoposide|
542490|NCT00003967|Drug|topotecan hydrochloride|
542491|NCT00003883|Drug|fluconazole|
542492|NCT00003883|Drug|itraconazole|
542493|NCT00003769|Drug|perillyl alcohol|
542494|NCT00003769|Procedure|surgical procedure|
542495|NCT00003657|Biological|filgrastim|
542496|NCT00003657|Drug|Amifostine|
542497|NCT00003657|Drug|Carboplatin|
542498|NCT00003657|Drug|Etoposide|
542499|NCT00003657|Drug|Ifosfamide|
542500|NCT00003657|Procedure|peripheral blood stem cell transplantation|
542501|NCT00003635|Drug|nelarabine|
542502|NCT00003412|Biological|recombinant interleukin-12|
542503|NCT00003402|Drug|carmustine|
542504|NCT00003402|Drug|cisplatin|
542505|NCT00003402|Drug|cyclophosphamide|
542506|NCT00003402|Drug|dexamethasone|
542507|NCT00003402|Drug|etoposide|
542508|NCT00003402|Drug|melphalan|
542509|NCT00003402|Drug|paclitaxel|
542510|NCT00003402|Procedure|bone marrow ablation with stem cell support|
542511|NCT00003402|Procedure|peripheral blood stem cell transplantation|
542512|NCT00080392|Drug|DNA Plasmid Vector|
542513|NCT00080392|Drug|EW-A-401 DNA Plasmid Vector|
542514|NCT00080340|Drug|TLK286 (Telcyta) HCl for Injection|
542515|NCT00080340|Drug|gefitinib (Iressa)|
542516|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
542517|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
542518|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
542519|NCT00080327|Drug|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
542520|NCT00080314|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
542521|NCT00080314|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
542522|NCT00080301|Drug|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity~Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
542523|NCT00080301|Drug|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
542524|NCT00003345|Drug|cisplatin|
542525|NCT00003345|Drug|irinotecan hydrochloride|
542526|NCT00003192|Drug|aminocamptothecin|
542527|NCT00003157|Drug|cisplatin|
542528|NCT00003157|Drug|gemcitabine hydrochloride|
542529|NCT00003157|Radiation|radiation therapy|
542530|NCT00003149|Biological|recombinant interleukin-12|
542531|NCT00002974|Drug|carboplatin|
542532|NCT00002974|Drug|etoposide|
542533|NCT00002974|Drug|ifosfamide|
542534|NCT00002974|Procedure|hyperthermia treatment|
542535|NCT00080366|Drug|1-Octanol|
542536|NCT00080353|Drug|IL-2|
542537|NCT00080353|Drug|gp100:209-217|
542538|NCT00080353|Drug|OKT3|
542539|NCT00080353|Drug|rF-go 100P209|
542540|NCT00080353|Drug|Montanide ISA 51|
542541|NCT00080288|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
542542|NCT00080288|Drug|Placebo|Matching placebo tablets once daily
542543|NCT00080275|Drug|Niacin Extended-Release and simvastatin Tablets|
542544|NCT00080262|Drug|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
542545|NCT00080236|Drug|IDN-6556|
542546|NCT00080236|Drug|Placebo|
542547|NCT00080223|Drug|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
542548|NCT00080158|Drug|fluoxetine|
542549|NCT00080158|Drug|sertraline|
542550|NCT00080158|Drug|citalopram|
542551|NCT00080158|Drug|escitalopram|
542552|NCT00080158|Drug|bupropion|
542553|NCT00080158|Drug|mirtazapine|
542554|NCT00080158|Drug|venlafaxine|
542555|NCT00080158|Drug|lithium|
542556|NCT00080158|Behavioral|Cognitive Behavioral Therapy|
542557|NCT00012142|Drug|temsirolimus|
542558|NCT00002950|Biological|sargramostim|
542559|NCT00002950|Drug|topotecan hydrochloride|
542560|NCT00002947|Radiation|indium In 111 pentetreotide|
542561|NCT00002887|Drug|cisplatin|
542562|NCT00002887|Drug|etoposide|
542563|NCT00002887|Drug|hydroxyurea|
542564|NCT00002887|Drug|vinblastine sulfate|
542565|NCT00002887|Drug|vindesine|
542566|NCT00002887|Drug|vinorelbine tartrate|
542567|NCT00002887|Procedure|drug resistance inhibition treatment|
542568|NCT00002759|Drug|cyclosporine|
542575|NCT00002592|Procedure|autologous bone marrow transplantation|
542576|NCT00002592|Procedure|in vitro-treated bone marrow transplantation|
542577|NCT00002540|Other|Laboratory Biomarker Analysis|Correlative studies
542578|NCT00002540|Procedure|Medical Examination|Undergo DRE
542579|NCT00002540|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
542580|NCT00002536|Drug|cisplatin|
542581|NCT00002536|Drug|vincristine sulfate|
542582|NCT00002536|Procedure|surgical procedure|
542583|NCT00002536|Radiation|radiation therapy|
542584|NCT00002461|Biological|filgrastim|
542585|NCT00002461|Biological|sargramostim|
542586|NCT00002461|Drug|carmustine|
542587|NCT00002461|Drug|cisplatin|
542588|NCT00002461|Drug|cyclophosphamide|
542589|NCT00002461|Drug|etoposide|
542590|NCT00002461|Procedure|autologous bone marrow transplantation|
542591|NCT00002461|Procedure|in vitro-treated bone marrow transplantation|
542592|NCT00002461|Procedure|peripheral blood stem cell transplantation|
542593|NCT00002461|Radiation|radiation therapy|
542594|NCT00080210|Drug|Puricase|
542595|NCT00080197|Drug|E7070|
542596|NCT00080184|Procedure|Low Energy Neurofeedback System|
542597|NCT00080145|Drug|Risperidone|
542598|NCT00080145|Behavioral|Behavior Therapy|
542599|NCT00080132|Drug|implitapide|
542600|NCT00080119|Drug|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
542601|NCT00080119|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
542602|NCT00080119|Drug|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
542603|NCT00080106|Biological|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
542604|NCT00080106|Other|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
542605|NCT00010647|Procedure|Acupuncture|
542606|NCT00008320|Drug|ceramide|
542607|NCT00008151|Drug|cyclosporine|
542608|NCT00008151|Drug|fludarabine phosphate|
542609|NCT00008151|Drug|gemtuzumab ozogamicin|
542610|NCT00008151|Drug|methotrexate|
542611|NCT00008151|Drug|mycophenolate mofetil|
542612|NCT00008151|Procedure|allogeneic bone marrow transplantation|
542613|NCT00008151|Procedure|peripheral blood stem cell transplantation|
542614|NCT00008151|Radiation|radiation therapy|
542615|NCT00006348|Drug|ondansetron|
542616|NCT00006348|Other|placebo|
542617|NCT00006345|Biological|denileukin diftitox|
542618|NCT00006345|Drug|dexamethasone|
542619|NCT00006262|Drug|becatecarin|
542620|NCT00006090|Drug|arsenic trioxide|
542621|NCT00006084|Biological|lintuzumab|
542622|NCT00006051|Drug|cisplatin|
542623|NCT00006051|Drug|fluorouracil|
542624|NCT00006051|Radiation|radiation therapy|
542625|NCT00006036|Drug|cisplatin|
542626|NCT00006036|Drug|lurtotecan liposome|
542627|NCT00006030|Drug|tamoxifen citrate|
542628|NCT00006030|Procedure|conventional surgery|
542629|NCT00006030|Radiation|radiation therapy|
542630|NCT00080093|Behavioral|Individual feedback and specially-tailored manuals|Individual feedback and specially-tailored manuals
542631|NCT00080093|Behavioral|General HIV information feedback and the best-available information|General HIV information feedback and the best-available information
542632|NCT00080080|Drug|talabostat (PT-100) tablets|
542633|NCT00080080|Drug|Docetaxel|
542634|NCT00006023|Drug|capecitabine|
542635|NCT00005992|Biological|PSA prostate cancer vaccine|
542636|NCT00005992|Biological|therapeutic autologous dendritic cells|
542637|NCT00005972|Drug|gemcitabine hydrochloride|
542638|NCT00005972|Drug|irinotecan hydrochloride|
542639|NCT00005944|Drug|chemotherapy|
542640|NCT00005944|Drug|fluorouracil|
542641|NCT00005944|Drug|leucovorin calcium|
542642|NCT00005944|Drug|mitomycin C|
542643|NCT00005944|Procedure|conventional surgery|
542644|NCT00005944|Procedure|laparoscopic surgery|
542645|NCT00005865|Drug|vinorelbine tartrate|
542646|NCT00080054|Drug|Motexafin Gadolinium Injection|
542647|NCT00080041|Drug|Motexafin Gadolinium Injection|
542648|NCT00080028|Drug|Motexafin Gadolinium Injection|
542649|NCT00080015|Drug|Diflomotecan (BN80915)|
542650|NCT00080002|Drug|Pegamotecan|
542651|NCT00079989|Drug|tigecycline|
542652|NCT00005816|Biological|therapeutic autologous dendritic cells|
542653|NCT00005816|Procedure|conventional surgery|
542654|NCT00004123|Drug|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
542655|NCT00004123|Procedure|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
542656|NCT00004123|Radiation|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
542657|NCT00004123|Radiation|Radiation Therapy (RT)|5 days a week for 4 weeks
542658|NCT00003817|Drug|dolasetron mesylate|
542659|NCT00003817|Drug|granisetron hydrochloride|
542660|NCT00003817|Drug|ondansetron|
542661|NCT00003817|Drug|tropisetron|
542662|NCT00003817|Procedure|quality-of-life assessment|
542663|NCT00003693|Drug|Dolastatin 10|IV bolus once every 3 weeks.
542664|NCT00003647|Drug|allovectin-7|
542665|NCT00003647|Drug|allovectin-7/dacarbazine|
542666|NCT00003647|Drug|dacarbazine|
542667|NCT00079976|Drug|Tigecycline|
542668|NCT00079963|Dietary Supplement|Vitamin C|1000 mg/day
542669|NCT00079963|Dietary Supplement|Vitamin E|800 IU/day
542670|NCT00079963|Dietary Supplement|Placebo|
542671|NCT00079950|Drug|Pegamotecan|
542672|NCT00079937|Drug|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
542673|NCT00079937|Drug|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
542674|NCT00079937|Drug|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
542675|NCT00003561|Biological|recombinant interferon alfa|
542676|NCT00003561|Biological|sargramostim|
542677|NCT00003356|Biological|aldesleukin|
542678|NCT00003356|Biological|rituximab|
542679|NCT00003327|Drug|paclitaxel|
542680|NCT00003321|Procedure|psychosocial assessment and care|
542681|NCT00003321|Procedure|quality-of-life assessment|
542682|NCT00003274|Biological|gp100 antigen|
542683|NCT00003274|Biological|incomplete Freund's adjuvant|
542684|NCT00003274|Biological|sargramostim|
542685|NCT00003274|Biological|tyrosinase peptide|
542686|NCT00079924|Drug|teriparatide|
542687|NCT00079924|Drug|aldrenodate|
542688|NCT00079924|Drug|raloxifene|
542689|NCT00079911|Drug|valacyclovir hydrochloride|valacyclovir hydrochloride
542690|NCT00079898|Procedure|Acupuncture|
542691|NCT00079885|Drug|tigecycline|
542692|NCT00079872|Drug|Pemetrexed|
542693|NCT00022360|Drug|taurolidine|
542694|NCT00022165|Dietary Supplement|selenium|
542695|NCT00021138|Behavioral|smoking cessation intervention|
542696|NCT00021138|Drug|nicotine|
542697|NCT00003166|Drug|bryostatin 1|Given IV
542698|NCT00003166|Drug|vincristine sulfate|Given IV
542699|NCT00003166|Other|laboratory biomarker analysis|Correlative studies
542700|NCT00002789|Drug|busulfan|
542701|NCT00002789|Drug|cyclophosphamide|
542702|NCT00002789|Drug|cyclosporine|
542703|NCT00002789|Drug|methotrexate|
542704|NCT00002789|Procedure|allogeneic bone marrow transplantation|
542705|NCT00002789|Procedure|peripheral blood stem cell transplantation|
542706|NCT00079859|Drug|Implitapide|
542707|NCT00079846|Drug|Implitapide|
542708|NCT00079833|Drug|Esomeprazole magnesium (Nexium)|
542709|NCT00079820|Biological|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
542710|NCT00020930|Biological|cetuximab|
542711|NCT00020865|Drug|cefepime hydrochloride|
542712|NCT00020865|Drug|levofloxacin|
542713|NCT00014300|Drug|glufosfamide|
542714|NCT00012337|Drug|gefitinib|
542715|NCT00009737|Drug|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
542716|NCT00009737|Drug|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
542717|NCT00009737|Drug|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
542718|NCT00006812|Drug|capecitabine|
542719|NCT00006708|Biological|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
542720|NCT00006708|Biological|rituximab|
542721|NCT00006708|Drug|carboplatin|
542722|NCT00006708|Drug|etoposide|
542723|NCT00006708|Drug|ifosfamide|
542724|NCT00006218|Drug|triapine|
542725|NCT00006215|Biological|filgrastim|
542726|NCT00006215|Drug|docetaxel|
542727|NCT00006215|Drug|vinorelbine tartrate|
542728|NCT00006098|Drug|bortezomib|
542729|NCT00079807|Drug|Alpha-Lipoic Acid|
542730|NCT00079794|Drug|Iscar|
542731|NCT00079794|Drug|mistletoe|
542732|NCT00079781|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
542733|NCT00079781|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
542734|NCT00079755|Drug|SGN-30 (anti-CD30 mAb)|
542735|NCT00079742|Drug|Nutropin AQ [somatropin (DNA origin) injection]|
542736|NCT00079716|Drug|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
542737|NCT00006091|Drug|arsenic trioxide|
542738|NCT00006085|Drug|CP-609,754|
542739|NCT00006026|Drug|rubitecan|
542740|NCT00005866|Drug|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
542741|NCT00005866|Drug|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
542742|NCT00005866|Drug|cyclosporine|both arms per published schedule
542743|NCT00005866|Drug|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
542744|NCT00005866|Procedure|allogeneic bone marrow transplantation|day 0
542745|NCT00005866|Radiation|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
542746|NCT00005848|Drug|chemotherapy|
542748|NCT00005834|Biological|filgrastim|Arms 1 and 2: 300 mcg (pts </= 60 kg) or 480 mcg (pts > 60 kg), SC beginning day 5
542749|NCT00005834|Drug|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
542750|NCT00005834|Drug|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
542751|NCT00005834|Drug|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
542752|NCT00005834|Drug|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
542753|NCT00005834|Drug|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
542754|NCT00005635|Biological|trastuzumab|
542755|NCT00005635|Drug|paclitaxel|
542756|NCT00005085|Drug|becatecarin|
542757|NCT00005037|Drug|temozolomide|
542758|NCT00005037|Drug|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
542759|NCT00004926|Dietary Supplement|vitamin D3 analogue ILX23-7553|
542760|NCT00004913|Drug|cisplatin|
542761|NCT00004913|Drug|docetaxel|
542762|NCT00004913|Drug|fluorouracil|
542763|NCT00004913|Drug|leucovorin calcium|
542764|NCT00004865|Biological|cetuximab|
542765|NCT00004865|Drug|cisplatin|
542766|NCT00004865|Drug|fluorouracil|
542767|NCT00004865|Drug|paclitaxel|
542768|NCT00004864|Drug|GEM 231|
542769|NCT00004864|Drug|docetaxel|
542770|NCT00004863|Drug|GEM 231|
542771|NCT00004863|Drug|paclitaxel|
542772|NCT00004163|Drug|Trastuzumab|
542773|NCT00004151|Drug|acridine carboxamide|
542774|NCT00004142|Drug|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
542775|NCT00004142|Drug|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
542776|NCT00004142|Procedure|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
542777|NCT00004142|Procedure|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
542778|NCT00004109|Drug|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
542779|NCT00004109|Radiation|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
542780|NCT00003959|Biological|ras peptide cancer vaccine|
542781|NCT00003959|Biological|sargramostim|
542782|NCT00003779|Biological|Connaught|Compare two strains of BCG
542783|NCT00003779|Biological|Tice|Compare two strains of BCG
542784|NCT00003772|Procedure|quality-of-life assessment|
542785|NCT00003742|Drug|cisplatin|
542786|NCT00003742|Drug|irinotecan hydrochloride|
542787|NCT00003742|Drug|paclitaxel|
542788|NCT00003706|Drug|pemetrexed disodium|
542789|NCT00003705|Drug|BMS-184476|
542790|NCT00003704|Drug|capecitabine|
542791|NCT00003704|Radiation|radiation therapy|
542792|NCT00003703|Drug|SarCNU|
542793|NCT00003695|Drug|chemotherapy|
542794|NCT00003695|Procedure|surgical procedure|
542795|NCT00079768|Drug|Alemtuzumab (Campath)|
542796|NCT00079677|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
542797|NCT00079677|Drug|Placebo|Matching placebo tablets once daily
542798|NCT00079664|Behavioral|Tai Chi|
542799|NCT00079651|Behavioral|Montessori-based dementia programming|
542800|NCT00079638|Drug|Niacin|
542801|NCT00079638|Drug|Atorvastatin|
542802|NCT00079638|Drug|Simvastatin|
542803|NCT00079638|Drug|Ezetimibe|
542804|NCT00079638|Drug|Rosuvastatin|
542805|NCT00078039|Drug|Paliperidone ER|
542806|NCT00003617|Drug|chlorambucil|
542807|NCT00003617|Drug|clarithromycin|
542808|NCT00003617|Drug|omeprazole|
542809|NCT00003617|Drug|tinidazole|
542810|NCT00003465|Drug|temozolomide|
542811|NCT00003421|Biological|bleomycin sulfate|
542812|NCT00003421|Drug|ABVD regimen|
542813|NCT00003421|Drug|chlorambucil|
542814|NCT00003421|Drug|dacarbazine|
542815|NCT00003421|Drug|doxorubicin hydrochloride|
542816|NCT00003421|Drug|etoposide|
542817|NCT00003421|Drug|prednisolone|
542818|NCT00003421|Drug|procarbazine hydrochloride|
542819|NCT00003421|Drug|vinblastine sulfate|
542820|NCT00003421|Drug|vincristine sulfate|
542821|NCT00003421|Radiation|radiation therapy|
542822|NCT00003368|Drug|irinotecan hydrochloride|
542823|NCT00003361|Drug|decitabine|
542824|NCT00003338|Procedure|immunoscintigraphy|
542825|NCT00003338|Radiation|technetium Tc 99m epratuzumab|
542826|NCT00003337|Procedure|immunoscintigraphy|
542827|NCT00003337|Radiation|technetium Tc 99m epratuzumab|
542828|NCT00003212|Drug|doxorubicin hydrochloride|
542829|NCT00003212|Drug|ifosfamide|
542830|NCT00003021|Drug|bizelesin|
542831|NCT00003014|Drug|carboplatin|
542832|NCT00003014|Radiation|radiation therapy|
542833|NCT00002930|Procedure|positron emission tomography|
542834|NCT00002930|Radiation|fludeoxyglucose F 18|
542835|NCT00002928|Drug|paclitaxel|
542836|NCT00002919|Biological|filgrastim|
542837|NCT00002919|Drug|cisplatin|
542838|NCT00002919|Drug|doxorubicin hydrochloride|
542839|NCT00002919|Drug|methotrexate|
542840|NCT00002919|Drug|vinblastine sulfate|
542841|NCT00002919|Procedure|conventional surgery|
542842|NCT00002901|Drug|docetaxel|
542843|NCT00002858|Drug|cisplatin|
542844|NCT00002858|Drug|cyclophosphamide|
542845|NCT00002858|Drug|doxorubicin hydrochloride|
542846|NCT00002858|Drug|etoposide|
542847|NCT00002858|Radiation|radiation therapy|
542848|NCT00079612|Drug|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
542849|NCT00079612|Drug|Placebo|2x 400mg tabs daily
542850|NCT00079586|Drug|Heparin|Unfractionated Heparin per institutional practice
542851|NCT00079586|Drug|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
542852|NCT00079508|Drug|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
542853|NCT00021359|Drug|dexamethasone|
542854|NCT00021359|Drug|isotretinoin|
542855|NCT00017030|Drug|trabectedin|
542856|NCT00016978|Drug|FOLFOX regimen|
542857|NCT00016978|Drug|fluorouracil|
542858|NCT00016978|Drug|leucovorin calcium|
542859|NCT00016978|Drug|oxaliplatin|
542860|NCT00014547|Drug|BBR 3464|
542861|NCT00007969|Biological|Detox-B adjuvant|
542862|NCT00007969|Drug|verteporfin|
542863|NCT00002823|Drug|cisplatin|
542864|NCT00002823|Drug|etoposide|
542865|NCT00002823|Drug|vinblastine sulfate|
542866|NCT00002823|Drug|vindesine|
542867|NCT00002823|Drug|vinorelbine tartrate|
542868|NCT00002823|Radiation|radiation therapy|
542869|NCT00002650|Dietary Supplement|folic acid|
542870|NCT00002601|Biological|filgrastim|5 ug/kg daily following stem cell reinfusion
542871|NCT00002601|Drug|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
542872|NCT00002601|Drug|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
542873|NCT00002601|Drug|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
542874|NCT00002601|Drug|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
542875|NCT00002601|Procedure|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
542876|NCT00002581|Drug|cyclophosphamide|
542877|NCT00002581|Drug|fluorouracil|
542878|NCT00002581|Drug|methotrexate|
542879|NCT00002581|Drug|tamoxifen citrate|
542880|NCT00002581|Procedure|conventional surgery|
542881|NCT00002581|Radiation|radiation therapy|
542882|NCT00002580|Drug|cyclophosphamide|
542883|NCT00002580|Drug|fluorouracil|
542884|NCT00002580|Drug|goserelin acetate|
542885|NCT00002580|Drug|leuprolide acetate|
542886|NCT00002580|Drug|methotrexate|
542887|NCT00002580|Drug|tamoxifen citrate|
542888|NCT00002580|Procedure|conventional surgery|
542889|NCT00002580|Procedure|laparoscopic surgery|
542890|NCT00002580|Procedure|oophorectomy|
542891|NCT00002580|Radiation|radiation therapy|
542892|NCT00002537|Drug|topotecan hydrochloride|
542893|NCT00002537|Radiation|radiation therapy|
542894|NCT00002526|Biological|filgrastim|
542895|NCT00002526|Drug|doxorubicin hydrochloride|
542896|NCT00002526|Drug|ifosfamide|
542897|NCT00002508|Drug|carboplatin|
542898|NCT00002508|Drug|etoposide|
542899|NCT00002508|Procedure|autologous bone marrow transplantation|
542900|NCT00002508|Procedure|peripheral blood stem cell transplantation|
542901|NCT00002480|Radiation|radiation therapy|
542902|NCT00002459|Radiation|radiation therapy|
542903|NCT00079625|Drug|Th2/Tc2 Cells|
542904|NCT00079599|Drug|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
542905|NCT00079599|Other|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
542906|NCT00079573|Behavioral|Atkins diet (extremely low carbohydrate)|
542907|NCT00079573|Behavioral|Zone diet (low carbohydrate, high protein)|
542908|NCT00079573|Behavioral|Ornish diet (very low fat)|
542909|NCT00079560|Drug|dronabinol|dronabinol to prevent development of marijuana withdrawal
542910|NCT00079547|Behavioral|Low-calorie diet|low-calorie diet
542911|NCT00079547|Behavioral|low-carbohydrate diet|low-carbohydrate diet
542912|NCT00079534|Behavioral|Non-local/distant healing or prayer|
542913|NCT00079521|Procedure|Therapeutic Touch|
542914|NCT00079495|Drug|NBI-5788|
542915|NCT00079482|Drug|CEP-701|
542916|NCT00079482|Drug|high-dose cytarabine|Chemotherapy
542917|NCT00079482|Drug|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
542918|NCT00079469|Behavioral|smoking cessation intervention|
542919|NCT00079469|Drug|bupropion hydrochloride|
542920|NCT00079456|Drug|temsirolimus|Given IV
542921|NCT00079456|Other|pharmacological study|Correlative studies
542922|NCT00079456|Other|laboratory biomarker analysis|Correlative studies
542923|NCT00079443|Drug|romidepsin|Given IV
542924|NCT00079443|Biological|rituximab|Given IV
542925|NCT00079443|Drug|fludarabine phosphate|Given IV
542926|NCT00079443|Other|laboratory biomarker analysis|Correlative studies
542927|NCT00079430|Procedure|adjuvant therapy|
542928|NCT00079430|Drug|paclitaxel|Given IV
542929|NCT00079430|Drug|carboplatin|Given intraperitoneally
542930|NCT00079430|Biological|bevacizumab|Given IV
542931|NCT00079417|Procedure|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
542932|NCT00079417|Procedure|infrared laser therapy|"Laser therapy or photobiomodulation is the use of specific wavelength of light (red and near-infrared) to create therapeutic effects"
547448|NCT00003436|Drug|cytarabine|
542933|NCT00079417|Radiation|iodine I 125|Undergo radioactive therapy
542934|NCT00079417|Radiation|ruthenium Ru 106|Undergo radioactive therapy
542935|NCT00079417|Drug|carboplatin|Given IV
542936|NCT00079417|Drug|vincristine sulfate|Given IV
542937|NCT00079417|Radiation|radiation therapy|Undergo radioactive therapy
542938|NCT00079404|Drug|tanespimycin|Given IV
542939|NCT00079391|Device|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
542940|NCT00079378|Drug|decitabine|Given IV
542941|NCT00079378|Drug|valproic acid|Given orally
542942|NCT00079378|Other|pharmacological study|Correlative studies
542943|NCT00079378|Other|laboratory biomarker analysis|Correlative studies
542944|NCT00079365|Drug|fluorouracil|
542945|NCT00079365|Drug|gemcitabine hydrochloride|
542946|NCT00079365|Radiation|brachytherapy|
542947|NCT00079365|Radiation|phosphorus P32|
542948|NCT00079365|Radiation|radiation therapy|
542949|NCT00079352|Drug|alvocidib|Given IV
542950|NCT00079352|Drug|gemcitabine hydrochloride|Given IV
542951|NCT00079352|Drug|irinotecan hydrochloride|Given IV
542952|NCT00079339|Radiation|radiation therapy|Undergo radiotherapy
542953|NCT00079339|Drug|tipifarnib|Given orally
542954|NCT00079326|Biological|trastuzumab|Given IV
542955|NCT00079326|Drug|ixabepilone|Given IV
542956|NCT00079326|Other|laboratory biomarker analysis|Correlative studies
542957|NCT00079313|Drug|Imatinib|
542958|NCT00079300|Drug|imiquimod|
542959|NCT00079300|Procedure|conventional surgery|
542960|NCT00079287|Drug|carboplatin|
542961|NCT00079287|Drug|docetaxel|
542962|NCT00079287|Drug|gemcitabine hydrochloride|
542963|NCT00079287|Drug|paclitaxel|
542964|NCT00079287|Drug|vinorelbine tartrate|
542965|NCT00079274|Drug|irinotecan hydrochloride|Given IV
542966|NCT00079274|Drug|oxaliplatin|Given IV
542967|NCT00079274|Drug|leucovorin calcium|Given IV
542968|NCT00079274|Drug|fluorouracil|Given IV
542969|NCT00079274|Biological|cetuximab|Given IV
542970|NCT00079274|Drug|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
542971|NCT00079261|Drug|CHOP regimen|
542972|NCT00079261|Drug|cyclophosphamide|
542973|NCT00079261|Drug|doxorubicin hydrochloride|
542974|NCT00079261|Drug|gemcitabine hydrochloride|
542975|NCT00079261|Drug|prednisone|
542976|NCT00079261|Drug|vincristine sulfate|
542977|NCT00079248|Biological|therapeutic progesterone|
542978|NCT00079248|Drug|conjugated estrogens|
542979|NCT00079235|Drug|temsirolimus|Given IV
542980|NCT00079235|Other|laboratory biomarker analysis|Correlative studies
542981|NCT00079222|Drug|itraconazole|
542982|NCT00079222|Drug|voriconazole|
542983|NCT00079183|Drug|sirolimus|Given PO
542984|NCT00079170|Dietary Supplement|garlic|
542985|NCT00079170|Drug|docetaxel|
542986|NCT00079157|Biological|incomplete Freund's adjuvant|
542987|NCT00079157|Biological|sargramostim|
542988|NCT00079157|Biological|telomerase: 540-548 peptide vaccine|
542989|NCT00079144|Biological|NY-ESO-1 peptide vaccine|
542990|NCT00079144|Biological|aldesleukin|
542991|NCT00079144|Biological|filgrastim|
542992|NCT00079144|Biological|incomplete Freund's adjuvant|
542993|NCT00079144|Biological|therapeutic autologous lymphocytes|
542994|NCT00079144|Drug|cyclophosphamide|
542995|NCT00079144|Drug|fludarabine phosphate|
542996|NCT00079131|Biological|oblimersen sodium|Given IV
542997|NCT00079131|Other|pharmacological study|Correlative studies
542998|NCT00079131|Other|laboratory biomarker analysis|Correlative studies
542999|NCT00079118|Drug|docetaxel|
543000|NCT00079118|Drug|irinotecan hydrochloride|
543001|NCT00079105|Biological|bleomycin sulfate|Treatment
543002|NCT00079105|Drug|cyclophosphamide|Treatment
543003|NCT00079105|Drug|etoposide|Treatment
543004|NCT00079105|Drug|mitoxantrone hydrochloride|Treatment
543005|NCT00079105|Drug|prednisolone|Treatment
543006|NCT00079105|Drug|procarbazine hydrochloride|Treatment
543007|NCT00079105|Drug|vinblastine sulfate|Treatment
543008|NCT00079092|Drug|procarbazine hydrochloride|
543009|NCT00079092|Drug|thalidomide|
543010|NCT00079079|Drug|carboplatin|
543011|NCT00079079|Drug|cisplatin|
543012|NCT00079079|Drug|gemcitabine hydrochloride|
543013|NCT00079066|Biological|cetuximab|
543014|NCT00079066|Procedure|quality-of-life assessment|
543015|NCT00079053|Drug|erlotinib hydrochloride|
543016|NCT00079053|Procedure|adjuvant therapy|
543017|NCT00079040|Drug|cisplatin|Given IV
543018|NCT00079040|Drug|etoposide|Given IV
543019|NCT00079040|Biological|bevacizumab|Given IV
543020|NCT00079040|Other|laboratory biomarker analysis|Correlative studies
543021|NCT00079027|Drug|doxorubicin hydrochloride|
543022|NCT00079027|Procedure|hepatic artery embolization|
543023|NCT00079014|Drug|triapine|Given IV
543024|NCT00079014|Drug|doxorubicin hydrochloride|Given IV
543025|NCT00079014|Other|laboratory biomarker analysis|Correlative studies
543026|NCT00079014|Other|pharmacological study|Correlative studies
543027|NCT00079001|Drug|zoledronic acid|Given IV
543028|NCT00079001|Other|placebo|Given IV
543246|NCT00017303|Drug|oglufanide disodium|
543247|NCT00017303|Drug|paclitaxel|
543029|NCT00079001|Drug|androgen deprivation therapy|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
543030|NCT00079001|Drug|GnRH agonist|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
543031|NCT00079001|Dietary Supplement|Calcium supplement|Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
543032|NCT00079001|Dietary Supplement|Vitamin D|Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
543033|NCT00078988|Biological|filgrastim|Given IV
543034|NCT00078988|Drug|carboplatin|Given IV
543035|NCT00078988|Drug|etoposide|Given IV
543036|NCT00078988|Drug|isotretinoin|Given IV
543037|NCT00078988|Drug|thiotepa|Given IV
543038|NCT00078988|Procedure|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
543039|NCT00078988|Procedure|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
543040|NCT00078975|Drug|gemcitabine hydrochloride|
543041|NCT00078975|Drug|triapine|
543042|NCT00078962|Biological|GTI-2040|Given IV
543043|NCT00078962|Drug|gemcitabine hydrochloride|Given IV
543044|NCT00078962|Other|laboratory biomarker analysis|Correlative studies
543045|NCT00078962|Other|pharmacological study|Correlative studies
543046|NCT00078949|Biological|rituximab|Given IV
543047|NCT00078949|Drug|cisplatin|Given IV
543048|NCT00078949|Drug|cytarabine|Given IV
543049|NCT00078949|Drug|dexamethasone|Given IV
543050|NCT00078949|Drug|gemcitabine hydrochloride|Given IV
543051|NCT00078923|Dietary Supplement|soy isoflavones|
543052|NCT00078923|Procedure|neoadjuvant therapy|Prostatectomy or Brachytherapy
543053|NCT00078923|Other|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
543054|NCT00078910|Drug|exisulind|
543055|NCT00078910|Procedure|conventional surgery|
543056|NCT00078910|Procedure|neoadjuvant therapy|
543057|NCT00078897|Drug|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
543058|NCT00078858|Drug|fludarabine phosphate|Given IV
543059|NCT00078858|Radiation|total-body irradiation|Undergo TBI
543060|NCT00078858|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
543061|NCT00078858|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
543062|NCT00078858|Drug|cyclosporine|Given PO
543063|NCT00078858|Drug|mycophenolate mofetil|Given PO or IV
543064|NCT00078858|Other|laboratory biomarker analysis|Correlative studies
543065|NCT00078845|Drug|Amifostine|500 mg three times a week.
543066|NCT00078832|Drug|anastrozole|aromatase inhibitor
543067|NCT00078832|Drug|placebo|Arimidex placebo
543068|NCT00078819|Drug|Etanercept|Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week
543069|NCT00078819|Drug|Placebo|Placebo matching to etanercept administered by subcutaneous injection once a week
543070|NCT00078806|Drug|Etanercept|Administered by subcutaneous injection twice a week
543071|NCT00078806|Drug|Placebo|Administered by subcutaneous injection twice a week
543072|NCT00078793|Drug|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
543073|NCT00078767|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent
543074|NCT00078767|Drug|Sertraline Pill|12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
543075|NCT00078767|Drug|Placebo Oral Tablet|12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
543076|NCT00078754|Drug|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
543077|NCT00078754|Drug|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
543078|NCT00078754|Drug|Placebo|Placebo capsules by mouth, up to 8 capsules daily
543079|NCT00078741|Behavioral|Cognitive Behavioral Therapy (CBT)|
543080|NCT00078728|Behavioral|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
543081|NCT00078728|Behavioral|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
543082|NCT00078611|Drug|natalizumab|
543083|NCT00007007|Procedure|management of therapy complications|
543084|NCT00007007|Procedure|quality-of-life assessment|
543085|NCT00006890|Drug|prednisone|Prednisone 50mg on alternate days
543086|NCT00006890|Drug|thalidomide|THALIDOMIDE 200 mg qhs
543087|NCT00006467|Drug|ISIS 2503|
543088|NCT00006467|Drug|gemcitabine hydrochloride|
543089|NCT00006452|Drug|motexafin gadolinium|
543090|NCT00006452|Radiation|radiation therapy|
543091|NCT00006350|Biological|daclizumab|
543092|NCT00006350|Biological|therapeutic allogeneic lymphocytes|
543093|NCT00006350|Drug|mycophenolate mofetil|
543094|NCT00006350|Drug|tacrolimus|
543095|NCT00006350|Procedure|peripheral blood stem cell transplantation|
543248|NCT00017303|Procedure|conventional surgery|
543096|NCT00006259|Radiation|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
543097|NCT00006253|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
543098|NCT00006253|Behavioral|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
543099|NCT00006126|Drug|busulfan|
543100|NCT00006126|Drug|cyclophosphamide|
543101|NCT00006126|Drug|etoposide|
543102|NCT00006126|Drug|fludarabine phosphate|
543103|NCT00006126|Procedure|peripheral blood stem cell transplantation|
543104|NCT00006126|Radiation|radiation therapy|
543105|NCT00006115|Drug|FOLFIRI regimen|
543106|NCT00006115|Drug|FOLFOX regimen|
543107|NCT00006115|Drug|fluorouracil|
543108|NCT00006115|Drug|irinotecan hydrochloride|
543109|NCT00006115|Drug|leucovorin calcium|
543110|NCT00006115|Drug|oxaliplatin|
543111|NCT00006018|Drug|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
543112|NCT00006018|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
543113|NCT00078715|Drug|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
543114|NCT00078715|Drug|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
543115|NCT00078689|Drug|Daclizumab|
543116|NCT00078637|Drug|E7820|
543117|NCT00006000|Drug|cisplatin|
543118|NCT00006000|Drug|irinotecan hydrochloride|
543119|NCT00006000|Drug|semaxanib|
543120|NCT00005965|Drug|bryostatin 1|
543121|NCT00005965|Drug|cisplatin|
543122|NCT00005947|Biological|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
543123|NCT00005947|Biological|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
543124|NCT00005946|Biological|filgrastim|
543125|NCT00005946|Biological|therapeutic allogeneic lymphocytes|
543126|NCT00005946|Drug|cyclophosphamide|
543127|NCT00005946|Drug|etoposide|
543128|NCT00005843|Drug|tipifarnib|
543129|NCT00078663|Behavioral|Oral Care|
543130|NCT00078624|Other|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
543131|NCT00078624|Other|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
543132|NCT00005595|Drug|arsenic trioxide|
543133|NCT00005096|Drug|docetaxel|
543134|NCT00005035|Drug|oxaliplatin|
543135|NCT00004914|Biological|epoetin alfa|
543136|NCT00004914|Procedure|physical therapy|
543137|NCT00078598|Drug|Rituximab or Iodine I 131 Tositumomab Therapy|
543138|NCT00078585|Biological|PROSTVAC®-VF/TRICOM™|
543139|NCT00078572|Drug|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
543140|NCT00078572|Drug|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
543141|NCT00078507|Behavioral|Sensory Re-training|
543142|NCT00078507|Behavioral|Sensory Retraining|Facial Exercises
543143|NCT00078507|Behavioral|Opening Exercises|
543144|NCT00004912|Drug|megestrol acetate|
543145|NCT00004912|Procedure|physical therapy|
543146|NCT00004908|Drug|cyclophosphamide|
543147|NCT00004908|Procedure|peripheral blood stem cell transplantation|
543148|NCT00004908|Radiation|radiation therapy|
543149|NCT00004904|Biological|anti-thymocyte globulin|
543150|NCT00004904|Biological|filgrastim|
543151|NCT00004904|Drug|cladribine|
543152|NCT00004904|Drug|cyclophosphamide|
543153|NCT00004904|Drug|etoposide|
543154|NCT00004904|Drug|methylprednisolone|
543155|NCT00004904|Drug|tacrolimus|
543156|NCT00004904|Procedure|allogeneic bone marrow transplantation|
543157|NCT00004904|Procedure|in vitro-treated peripheral blood stem cell transplantation|
543158|NCT00004898|Biological|filgrastim|
543159|NCT00004898|Drug|cyclophosphamide|
543160|NCT00004898|Drug|etoposide|
543161|NCT00004898|Procedure|peripheral blood stem cell transplantation|
543162|NCT00004898|Radiation|radiation therapy|
543163|NCT00004235|Drug|docetaxel|
543164|NCT00004235|Drug|irinotecan hydrochloride|
543165|NCT00004175|Drug|cyclophosphamide|
543166|NCT00004175|Drug|docetaxel|
543167|NCT00004175|Drug|doxorubicin hydrochloride|
543168|NCT00004175|Procedure|conventional surgery|
543169|NCT00078559|Drug|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
543170|NCT00078559|Drug|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
543171|NCT00078559|Drug|Tacrolimus|2mg orally twice daily, on days 1-60
543172|NCT00078559|Procedure|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
543173|NCT00078559|Drug|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
543315|NCT00004223|Drug|gemcitabine hydrochloride|
543316|NCT00004216|Biological|salmonella VNP20009|
543174|NCT00078559|Drug|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
543175|NCT00078559|Drug|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
543176|NCT00078559|Drug|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
543177|NCT00078559|Drug|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
543178|NCT00078559|Drug|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
543179|NCT00078559|Drug|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
543180|NCT00078559|Drug|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
543181|NCT00078559|Drug|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
543182|NCT00078546|Biological|EBV specific CTL Infusion|"One injection at one of the following dose levels~Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"
543183|NCT00078546|Biological|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
543184|NCT00078533|Biological|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10^7cells/m2 and the highest will be 1x10^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
543185|NCT00078520|Biological|IL-2 AND HUMAN CD40 LIGAND PLASMID GENE MODIFIED AUTOLOGOUS TUMOR CELLS|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
543186|NCT00078468|Drug|PELITREXOL/AG-2037|
543187|NCT00078494|Drug|EBV-LMP-2|
543188|NCT00078481|Drug|Idebenone|
543189|NCT00078455|Drug|ILX651|
543190|NCT00078221|Device|Rheopheresis blood filtration|
543191|NCT00004171|Drug|busulfan|
543192|NCT00004171|Drug|cyclophosphamide|
543193|NCT00004171|Procedure|peripheral blood stem cell transplantation|
543194|NCT00004091|Other|Papanicolaou test|
543195|NCT00004091|Other|cytology specimen collection procedure|
543196|NCT00004091|Other|fluorescent antibody technique|
543197|NCT00004091|Procedure|colposcopic biopsy|
543198|NCT00004091|Procedure|study of high risk factors|
543199|NCT00003528|Drug|raltitrexed|Given IV
543200|NCT00003351|Drug|irinotecan hydrochloride|
543201|NCT00003302|Procedure|biopsy|
543202|NCT00003302|Diagnostic Test|magnetic resonance imaging|
543203|NCT00003302|Diagnostic Test|mammography|
543204|NCT00003264|Drug|cisplatin|
543205|NCT00003264|Drug|gemcitabine hydrochloride|
543206|NCT00003070|Drug|enalapril maleate|
543207|NCT00003070|Procedure|quality-of-life assessment|
543208|NCT00003040|Procedure|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
543209|NCT00003040|Radiation|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
543210|NCT00002825|Biological|filgrastim|
543211|NCT00002825|Drug|docetaxel|
543212|NCT00002652|Drug|suramin|
543213|NCT00026429|Biological|denileukin diftitox|
543214|NCT00025012|Drug|isotretinoin|
543215|NCT00024037|Procedure|management of therapy complications|
543216|NCT00022542|Drug|ixabepilone|Given IV
543217|NCT00022308|Drug|cisplatin|
543218|NCT00022308|Drug|irinotecan hydrochloride|
543219|NCT00022308|Radiation|radiation therapy|
543220|NCT00022217|Drug|carboplatin|
543221|NCT00022217|Drug|cisplatin-e therapeutic implant|
543222|NCT00022217|Drug|paclitaxel|
543223|NCT00022178|Drug|cisplatin|
543224|NCT00022178|Drug|cyclophosphamide|
543225|NCT00022178|Drug|doxorubicin hydrochloride|
543226|NCT00022178|Drug|epirubicin hydrochloride|
543227|NCT00022178|Drug|fluorouracil|
543228|NCT00022178|Drug|vincristine sulfate|
543229|NCT00021996|Drug|valdecoxib|
543230|NCT00021372|Drug|estramustine phosphate sodium|
543231|NCT00021372|Drug|paclitaxel|
543232|NCT00020618|Drug|morphine sulfate|
543233|NCT00020618|Procedure|quality-of-life assessment|
543234|NCT00020098|Procedure|evaluation of cancer risk factors|
543235|NCT00019409|Drug|asparaginase|
543236|NCT00019409|Drug|cyclophosphamide|
543237|NCT00019409|Drug|cytarabine|
543238|NCT00019409|Drug|daunorubicin hydrochloride|
543239|NCT00019409|Drug|mercaptopurine|
543240|NCT00019409|Drug|methotrexate|
543241|NCT00019409|Drug|prednisone|
543242|NCT00019409|Drug|therapeutic hydrocortisone|
543243|NCT00019409|Drug|vincristine sulfate|
543244|NCT00019409|Radiation|radiation therapy|
543245|NCT00017303|Drug|carboplatin|
543249|NCT00016367|Biological|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.~Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
543250|NCT00016367|Drug|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.~Regimen B: Cisplatin IV over 2 hours on day 1."
543251|NCT00016367|Drug|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.~Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
543252|NCT00015990|Drug|thalidomide|Given orally
543253|NCT00015990|Other|laboratory biomarker analysis|Correlative studies
543254|NCT00015964|Drug|ZD1839|
543255|NCT00002597|Drug|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
543256|NCT00002597|Drug|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
543257|NCT00002597|Drug|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
543258|NCT00002597|Radiation|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week [26 fx]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
543259|NCT00002577|Radiation|radiation therapy|
543260|NCT00002454|Biological|autologous tumor cell vaccine|
543261|NCT00078442|Drug|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
543262|NCT00078390|Drug|S-3304|S-3304 will be administered at the tolerable dose BID along with chemo-irradiation
543263|NCT00078390|Other|Chemo-irradiation|Standard of care chemo-irradiation
543264|NCT00078377|Drug|Armodafinil|Armodafinil 250 mg once daily in the morning
543265|NCT00078377|Drug|Armodafinil|Armodafinil 150 mg once daily in the morning
543266|NCT00078377|Drug|Placebo|Matching placebo tablets once daily
543267|NCT00078338|Drug|Rebif®|Subjects will be administered with Rebif® (Recombinant interferon beta-1a) as subcutaneous (SC) injection at a dose of 44 microgram (mcg) three times weekly (tiw).
543268|NCT00078338|Drug|Copaxone®|Subjects will be administered with Copaxone® (Glatiramer acetate) as subcutaneous (SC) injection at a dose of 20 milligram (mg) once daily (qd).
543269|NCT00076687|Biological|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
543270|NCT00076687|Biological|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
543271|NCT00076687|Drug|saline|Saline injection at Day 1, Week 12, Week 18
543272|NCT00014690|Drug|plevitrexed|
543273|NCT00014690|Drug|topotecan hydrochloride|
543274|NCT00014339|Drug|Wobe-Mugos E|
543275|NCT00014339|Drug|melphalan|
543276|NCT00014339|Drug|prednisone|
543277|NCT00014339|Procedure|quality-of-life assessment|
543278|NCT00012259|Drug|troxacitabine|
543279|NCT00010179|Drug|lurtotecan liposome|
543280|NCT00006472|Drug|carboplatin|
543281|NCT00006472|Drug|fluorouracil|
543282|NCT00006472|Drug|paclitaxel|
543283|NCT00006472|Procedure|conventional surgery|
543284|NCT00006472|Radiation|radiation therapy|
543285|NCT00006365|Radiation|brachytherapy|
543286|NCT00006365|Radiation|iodine I 125|
543287|NCT00006365|Radiation|radiation therapy|
543288|NCT00006108|Biological|trastuzumab|
543289|NCT00006108|Drug|capecitabine|
543290|NCT00006108|Drug|paclitaxel|
543291|NCT00006037|Drug|fluorouracil|
543292|NCT00006037|Drug|irinotecan hydrochloride|
543293|NCT00006037|Drug|oglufanide disodium|
543294|NCT00006014|Drug|semaxanib|
543295|NCT00078403|Drug|Peginterferon alfa-2a|180 mcg PEG-IFN subcutaneously
543296|NCT00078403|Drug|Ribavirin|One tablet or capsule containing ribavirin 200 mg
543297|NCT00078325|Drug|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
543298|NCT00078325|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
543299|NCT00078325|Drug|Placebo|Matching placebo tablets once daily in the morning
543300|NCT00078312|Drug|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
543301|NCT00005991|Drug|gemcitabine hydrochloride|
543302|NCT00005991|Drug|pegylated liposomal doxorubicin hydrochloride|
543303|NCT00005880|Drug|budesonide|
543304|NCT00005869|Drug|gemcitabine hydrochloride|
543305|NCT00005869|Drug|rubitecan|
543306|NCT00005864|Drug|chloroquinoxaline sulfonamide|
543307|NCT00005593|Drug|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
543308|NCT00005593|Drug|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
543309|NCT00005593|Drug|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
543310|NCT00005075|Procedure|high-intensity focused ultrasound ablation|
543311|NCT00005026|Drug|carboplatin|
543312|NCT00005026|Drug|paclitaxel|
543313|NCT00005026|Drug|topotecan hydrochloride|
543314|NCT00004223|Drug|docetaxel|
543320|NCT00004216|Drug|trimethoprim-sulfamethoxazole|
543321|NCT00004183|Drug|capecitabine|
543322|NCT00078364|Procedure|MRI|
543323|NCT00078351|Procedure|High molecular weight hylan (Synvisc) injection|
543324|NCT00078286|Drug|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
543325|NCT00078286|Drug|Placebo|Dosage ranging from 50 mg to 200 mg once a day
543326|NCT00078273|Behavioral|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
543327|NCT00078273|Behavioral|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
543328|NCT00078260|Drug|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression~B: 900 mg/m2, IV, q 21 days until disease progression"
543329|NCT00078247|Drug|Abacavir|300 mg tablet taken orally twice daily
543330|NCT00078247|Drug|Lamivudine|300 mg tablet taken orally daily
543331|NCT00078247|Drug|Zidovudine|300 mg tablet taken orally twice daily
543332|NCT00078247|Drug|Tuberculosis treatment|Tuberculosis treatment
543333|NCT00078234|Drug|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
543334|NCT00078169|Behavioral|Behavior Therapy|
543335|NCT00078156|Behavioral|Behavior Therapy|
543336|NCT00078143|Behavioral|Behavior Therapy|
543337|NCT00078195|Biological|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
543338|NCT00078195|Biological|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
543339|NCT00078195|Biological|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
543340|NCT00078195|Biological|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
543341|NCT00078195|Biological|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
543342|NCT00078195|Biological|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
543343|NCT00078182|Drug|Tenofovir DF|
543344|NCT00078130|Drug|Buprenorphine/naloxone|
543345|NCT00078117|Drug|Buprenorphine|
543346|NCT00078065|Drug|Xcellerated T Cells|
543347|NCT00004148|Biological|recombinant vaccinia-B7.1 vaccine|
543348|NCT00003935|Drug|etoposide|
543349|NCT00003935|Drug|vincristine sulfate|
543350|NCT00003935|Radiation|radiation therapy|
543351|NCT00003814|Drug|eflornithine|
543352|NCT00003766|Drug|O6-benzylguanine|
543353|NCT00003623|Dietary Supplement|multivitamin|
543354|NCT00003623|Other|Placebo|
543355|NCT00003615|Biological|denileukin diftitox|
543356|NCT00003600|Biological|epoetin alfa|
543357|NCT00003600|Other|placebo|
543358|NCT00003573|Biological|filgrastim|
543359|NCT00003573|Drug|cisplatin|
543360|NCT00003573|Drug|cyclophosphamide|
543361|NCT00003573|Drug|etoposide|
543362|NCT00003573|Drug|vincristine sulfate|
543363|NCT00003573|Radiation|radiation therapy|
543364|NCT00003572|Biological|peripheral blood lymphocyte therapy|
543365|NCT00003572|Drug|mycophenolate mofetil|
543366|NCT00003572|Drug|tacrolimus|
543367|NCT00003572|Procedure|allogeneic bone marrow transplantation|
543368|NCT00003572|Radiation|radiation therapy|
543369|NCT00003548|Drug|aminocamptothecin colloidal dispersion|
543370|NCT00003425|Biological|filgrastim|
543371|NCT00003425|Drug|amifostine trihydrate|
543372|NCT00003425|Drug|cyclophosphamide|
543373|NCT00003425|Drug|melphalan|
543374|NCT00003425|Procedure|peripheral blood stem cell transplantation|
543375|NCT00003411|Drug|motexafin gadolinium|
543376|NCT00003411|Radiation|radiation therapy|
543377|NCT00003299|Drug|cisplatin|
543378|NCT00003299|Drug|etoposide|
543379|NCT00003299|Drug|paclitaxel|
543380|NCT00003240|Drug|cisplatin|
543381|NCT00003240|Drug|ifosfamide|
543382|NCT00003240|Drug|mitomycin C|
543383|NCT00003240|Drug|vinblastine sulfate|
543384|NCT00003240|Drug|vindesine|
543385|NCT00003240|Drug|vinorelbine tartrate|
543386|NCT00003240|Procedure|conventional surgery|
543387|NCT00003240|Radiation|radiation therapy|
543388|NCT00003120|Drug|paclitaxel|135 mg/m2 IV every 28 days
543389|NCT00078104|Procedure|Extraction of wisdom teeth|
543390|NCT00078026|Drug|Apomine|
543391|NCT00030602|Biological|PSA prostate cancer vaccine|
543392|NCT00030602|Biological|incomplete Freund's adjuvant|
543393|NCT00003089|Drug|amifostine trihydrate|
543394|NCT00003089|Drug|carboplatin|
543395|NCT00003089|Drug|paclitaxel|
543396|NCT00003089|Radiation|radiation therapy|
543397|NCT00003046|Biological|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
543398|NCT00003035|Biological|filgrastim|
543399|NCT00003035|Drug|doxorubicin hydrochloride|
543400|NCT00003035|Drug|paclitaxel|
543401|NCT00003035|Drug|tamoxifen citrate|
543402|NCT00003035|Procedure|surgical procedure|
543403|NCT00003035|Radiation|radiation therapy|
543404|NCT00078013|Drug|MCC-135|
543405|NCT00078000|Drug|SU011248|
543406|NCT00077987|Drug|SU011248|
543407|NCT00077974|Drug|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
543408|NCT00077961|Drug|CAMPATH (alemtuzumab)|
543409|NCT00077948|Drug|Enoximone|Enoximone administered orally
543410|NCT00077948|Drug|Metoprolol succinate|Metoprolol succinate administered orally
543411|NCT00077948|Drug|Placebo to match enoximone|Placebo to match match enoximone administered orally
543412|NCT00077948|Drug|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
543413|NCT00077935|Drug|Civamide|Cream 0.075%, TID for 52 weeks
543414|NCT00077844|Drug|Enoxaparin sodium|
543415|NCT00077883|Drug|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
543416|NCT00077870|Drug|ocrelizumab|
543417|NCT00077857|Drug|capecitabine (Xeloda®)|825 mg/m^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
543418|NCT00077857|Drug|docetaxel (Taxotere®)|75 mg/m^2 intravenous on day 1 of each 3 week cycle
543419|NCT00077831|Behavioral|neurobehavioral development|observational study of infant and child development
543420|NCT00077818|Drug|Enoxaparin sodium|
543421|NCT00077805|Drug|Enoxaparin sodium|
543422|NCT00077792|Drug|Enoxaparin sodium (XRP4563)|
543423|NCT00077779|Drug|Adalimumab|
543424|NCT00077766|Drug|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
543425|NCT00077766|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
543426|NCT00077753|Drug|enoxaparin sodium|
543427|NCT00077727|Drug|Extended-release galantamine hydrobromide|
543428|NCT00077714|Drug|Paliperidone ER|
543429|NCT00077688|Drug|TOCOSOL Paclitaxel|
543430|NCT00076973|Drug|montelukast sodium|Duration of Treatment: 6 months
543431|NCT00076973|Drug|Comparator: placebo|Duration of Treatment: 6 months
543432|NCT00027924|Drug|busulfan|
543433|NCT00027924|Drug|cyclosporine|
543434|NCT00027924|Drug|fludarabine phosphate|
543435|NCT00027924|Drug|methotrexate|
543436|NCT00027924|Procedure|peripheral blood stem cell transplantation|
543437|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
543438|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
543439|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
543440|NCT00021294|Drug|eflornithine|
543441|NCT00021294|Drug|triamcinolone|
543442|NCT00021034|Drug|chemotherapy|
543443|NCT00021034|Drug|taurolidine|
543444|NCT00021021|Biological|anti-FLT-1 ribozyme|
543445|NCT00020917|Biological|cetuximab|
543446|NCT00020917|Drug|fluorouracil|
543447|NCT00020917|Drug|irinotecan hydrochloride|
543448|NCT00020917|Drug|leucovorin calcium|
543449|NCT00020553|Procedure|psychosocial assessment and care|
543450|NCT00017459|Drug|cisplatin|
543451|NCT00017459|Drug|tirapazamine|
543452|NCT00017459|Drug|vinorelbine tartrate|
543453|NCT00017199|Drug|bortezomib|
543454|NCT00017056|Drug|ixabepilone|
543455|NCT00016172|Drug|pegylated liposomal doxorubicin hydrochloride|
543456|NCT00016172|Drug|picoplatin|
543457|NCT00014625|Drug|indisulam|
543458|NCT00014430|Biological|trastuzumab|"Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.~The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably."
543459|NCT00014430|Drug|vinorelbine ditartrate|Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
543460|NCT00008281|Drug|FOLFOX regimen|
543461|NCT00008281|Drug|fluorouracil|
543462|NCT00008281|Drug|leucovorin calcium|
543463|NCT00008281|Drug|oxaliplatin|
543464|NCT00007878|Drug|bortezomib|Given IV
543465|NCT00007878|Drug|fluorouracil|Given IV
543466|NCT00007878|Drug|leucovorin calcium|Given IV
543467|NCT00007878|Other|pharmacological study|Correlative studies
543468|NCT00007878|Other|laboratory biomarker analysis|Correlative studies
543469|NCT00006122|Drug|cytarabine|
543471|NCT00006122|Drug|gemtuzumab ozogamicin|
543472|NCT00006122|Drug|idarubicin|
543473|NCT00006122|Drug|mitoxantrone hydrochloride|
543474|NCT00005795|Drug|arsenic trioxide|
543475|NCT00005791|Drug|cisplatin|
543476|NCT00005791|Drug|fluorouracil|
543477|NCT00005791|Drug|irinotecan hydrochloride|
543478|NCT00005631|Biological|filgrastim|
543479|NCT00005631|Biological|rituximab|
543480|NCT00005631|Drug|carboplatin|
543481|NCT00005631|Drug|etoposide|
543482|NCT00005631|Drug|ifosfamide|
543483|NCT00005609|Biological|rituximab|
543484|NCT00005089|Biological|rituximab|375 mg/m^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
543485|NCT00005089|Drug|cyclophosphamide|750 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
543486|NCT00005089|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
543487|NCT00005089|Drug|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
543488|NCT00005089|Drug|vincristine sulfate|1.4 mg/m^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
543489|NCT00005089|Radiation|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
543490|NCT00004152|Drug|iodinated contrast dye|
543491|NCT00004152|Procedure|computed tomography|
543492|NCT00004152|Procedure|positron emission tomography|
543493|NCT00004152|Radiation|fludeoxyglucose F 18|
543494|NCT00004145|Biological|anti-thymocyte globulin|
543495|NCT00004145|Drug|cyclophosphamide|
543496|NCT00004145|Drug|fludarabine phosphate|
543497|NCT00004145|Procedure|peripheral blood stem cell transplantation|
543498|NCT00004114|Biological|filgrastim|
543499|NCT00004114|Drug|cyclophosphamide|
543500|NCT00004114|Drug|cytarabine|
543501|NCT00004114|Drug|fludarabine phosphate|
543502|NCT00004114|Procedure|peripheral blood stem cell transplantation|
543503|NCT00003916|Radiation|radiation therapy|
543504|NCT00003916|Radiation|stereotactic radiosurgery|
543505|NCT00003867|Drug|capecitabine|
543506|NCT00003867|Drug|irinotecan hydrochloride|
543507|NCT00003632|Biological|filgrastim|
543508|NCT00003632|Drug|carmustine|
543509|NCT00003632|Drug|cytarabine|
543510|NCT00003632|Drug|etoposide|
543511|NCT00003632|Drug|melphalan|
543512|NCT00003632|Drug|methotrexate|
543513|NCT00003632|Procedure|peripheral blood stem cell transplantation|
543514|NCT00003582|Drug|amifostine trihydrate|
543515|NCT00003582|Drug|cisplatin|
543516|NCT00003582|Drug|fluorouracil|
543517|NCT00003582|Drug|paclitaxel|
543518|NCT00003582|Procedure|quality-of-life assessment|
543519|NCT00003582|Radiation|radiation therapy|
543520|NCT00003545|Drug|nelarabine|
543521|NCT00003207|Drug|pegylated liposomal doxorubicin hydrochloride|
543522|NCT00003207|Drug|PSC 833|
543523|NCT00003150|Biological|rituximab|
543524|NCT00003150|Drug|CHOP regimen|
543525|NCT00003150|Drug|cyclophosphamide|
543526|NCT00003150|Drug|doxorubicin hydrochloride|
543527|NCT00003150|Drug|prednisone|
543528|NCT00003150|Drug|vincristine sulfate|
543529|NCT00003066|Drug|docetaxel|
543530|NCT00003066|Drug|estramustine phosphate sodium|
543531|NCT00003062|Drug|temozolomide|
543532|NCT00003011|Drug|marimastat|10 mg PO BID
543533|NCT00003011|Drug|Placebo|10 mg PO BID
543534|NCT00002869|Biological|recombinant interferon alfa|
543535|NCT00002869|Drug|cytarabine|
543536|NCT00002869|Drug|hydroxyurea|
543537|NCT00002868|Biological|filgrastim|
543538|NCT00002868|Biological|recombinant interferon alfa|
543539|NCT00002868|Drug|busulfan|
543540|NCT00002868|Drug|cytarabine|
543541|NCT00002868|Drug|etoposide|
543542|NCT00002868|Drug|hydroxyurea|
543543|NCT00002868|Drug|idarubicin|
543544|NCT00002868|Procedure|peripheral blood stem cell transplantation|
543545|NCT00002532|Biological|filgrastim|
543546|NCT00002532|Drug|asparaginase|
543547|NCT00002532|Drug|cytarabine|
543548|NCT00002532|Drug|daunorubicin hydrochloride|
543549|NCT00002532|Drug|dexamethasone|
543550|NCT00002532|Drug|etoposide|
543551|NCT00002532|Drug|idarubicin|
543552|NCT00002532|Drug|ifosfamide|
543553|NCT00002532|Drug|leucovorin calcium|
543554|NCT00002532|Drug|methotrexate|
543555|NCT00002532|Drug|prednisolone|
543556|NCT00002532|Drug|vindesine|
543557|NCT00002531|Drug|asparaginase|
543558|NCT00002531|Drug|cyclophosphamide|
543559|NCT00002531|Drug|cytarabine|
543560|NCT00002531|Drug|daunorubicin hydrochloride|
543561|NCT00002531|Drug|dexamethasone|
543562|NCT00002531|Drug|doxorubicin hydrochloride|
543563|NCT00002531|Drug|etoposide|
543564|NCT00002531|Drug|ifosfamide|
543565|NCT00002531|Drug|leucovorin calcium|
543566|NCT00002531|Drug|mercaptopurine|
543567|NCT00002531|Drug|methotrexate|
543568|NCT00002531|Drug|mitoxantrone hydrochloride|
543569|NCT00002531|Drug|prednisolone|
543570|NCT00002531|Drug|teniposide|
543571|NCT00002531|Drug|thioguanine|
543572|NCT00002531|Drug|vincristine sulfate|
543573|NCT00002531|Drug|vindesine|
543574|NCT00002531|Procedure|allogeneic bone marrow transplantation|
543575|NCT00002531|Procedure|peripheral blood stem cell transplantation|
543576|NCT00002531|Radiation|radiation therapy|
543577|NCT00077922|Drug|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
543578|NCT00077896|Procedure|Direct Current Polarization|
543579|NCT00077675|Drug|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
543580|NCT00077675|Drug|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
543581|NCT00077649|Drug|ribavirin [Copegus]|600mg po bid for 48 weeks
543582|NCT00077649|Drug|ribavirin [Copegus]|800mg po bid for 48 weeks
543583|NCT00077649|Drug|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
543584|NCT00077649|Drug|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
543585|NCT00077636|Drug|Copegus|400mg po bid for 16 weeks
543586|NCT00077636|Drug|Copegus|400mg po bid for 24 weeks
543587|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
543588|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
543589|NCT00077623|Drug|epoetin alfa or beta|iv 3 times weekly, as prescribed
543590|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
543591|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
543592|NCT00077610|Drug|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
543593|NCT00077610|Drug|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
543594|NCT00077610|Drug|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
543595|NCT00077597|Drug|epoetin|3 times a week iv, as prescribed.
543596|NCT00077597|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
543597|NCT00077558|Drug|fludarabine phosphate|
543598|NCT00077558|Drug|triapine|
543599|NCT00077545|Drug|triapine|Given IV
543600|NCT00077545|Drug|cisplatin|Given IV
543601|NCT00077532|Biological|gp100 antigen|
543602|NCT00077532|Biological|incomplete Freund's adjuvant|
543603|NCT00077532|Biological|ipilimumab|
543604|NCT00077519|Drug|tipifarnib|
543605|NCT00077519|Radiation|radiation therapy|
543606|NCT00077493|Drug|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
543607|NCT00077493|Procedure|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
543608|NCT00077493|Procedure|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
543609|NCT00077493|Procedure|monoclonal antibody therapy|administered intravenously over 30 minutes.
543610|NCT00077467|Drug|bortezomib|Given IV
543611|NCT00077467|Other|pharmacological study|Correlative studies
543612|NCT00077467|Other|laboratory biomarker analysis|Correlative studies
543613|NCT00077454|Drug|erlotinib hydrochloride|Given orally (PO)
543614|NCT00077454|Drug|temozolomide|Given PO
543615|NCT00077454|Other|pharmacological study|Correlative studies
543616|NCT00077454|Other|laboratory biomarker analysis|Correlative studies
543617|NCT00077441|Drug|bortezomib|Given IV
543618|NCT00077441|Other|laboratory biomarker analysis|Correlative studies
543619|NCT00077428|Drug|bortezomib|Given IV
543620|NCT00077428|Drug|doxorubicin hydrochloride|Given IV
543621|NCT00077428|Other|laboratory biomarker analysis|Correlative studies
543622|NCT00077415|Drug|gemcitabine hydrochloride|
543623|NCT00077415|Drug|triapine|
543624|NCT00077402|Drug|fenretinide|
543625|NCT00077389|Drug|carboplatin|
543626|NCT00077389|Drug|cisplatin|
543627|NCT00077389|Drug|doxorubicin hydrochloride|
543628|NCT00077389|Procedure|adjuvant therapy|
543629|NCT00077389|Procedure|conventional surgery|
543630|NCT00077389|Procedure|neoadjuvant therapy|
543631|NCT00077376|Biological|trastuzumab|Given IV
543632|NCT00077376|Drug|ixabepilone|Given IV
543633|NCT00077376|Drug|carboplatin|Given IV
543634|NCT00077376|Other|laboratory biomarker analysis|Correlative studies
543635|NCT00077363|Drug|tipifarnib|Given PO
543636|NCT00077363|Drug|capecitabine|Given PO
543637|NCT00077350|Drug|triapine|Given IV
543638|NCT00077350|Drug|gemcitabine hydrochloride|Given IV
543639|NCT00077350|Other|laboratory biomarker analysis|Correlative studies
543640|NCT00077337|Drug|romidepsin|
543641|NCT00077324|Genetic|proteomic profiling|
543642|NCT00077324|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
543643|NCT00077324|Procedure|biopsy|
543644|NCT00077324|Procedure|surgery|
543645|NCT00077311|Biological|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB < or = 11 g/dL
543646|NCT00077311|Biological|pegfilgrastim|6 mg sub Q day 2 of each cycle
543647|NCT00077311|Drug|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
543648|NCT00077311|Drug|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
543649|NCT00077311|Drug|BNP7787|40 g IV over 30 min Day 1 of each cycle
543650|NCT00007852|Biological|rituximab|Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
543651|NCT00007852|Drug|carmustine|BCNU 300 mg/M2 IV day -6
548643|NCT00052494|Drug|cisplatin|
543652|NCT00007852|Drug|cytarabine|100 mg/m2 on days -5 through -2
543653|NCT00007852|Drug|etoposide|100mg/M2 BID on days -5 through -2
543654|NCT00007852|Drug|melphalan|140 mg/m2 IV on day -1
543655|NCT00007852|Procedure|autologous hematopoietic stem cell transplantation|Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
543656|NCT00006786|Biological|bevacizumab|
543657|NCT00006786|Drug|fluorouracil|
543658|NCT00006786|Drug|irinotecan hydrochloride|
543659|NCT00006786|Drug|leucovorin calcium|
543660|NCT00006459|Drug|gemcitabine hydrochloride|
543661|NCT00006459|Drug|paclitaxel|
543662|NCT00006388|Drug|tamoxifen citrate|
543663|NCT00006388|Radiation|radiation therapy|
543664|NCT00006375|Drug|LY293111|
543665|NCT00006123|Biological|trastuzumab|
543666|NCT00006123|Drug|carboplatin|
543667|NCT00006123|Drug|carmustine|
543668|NCT00006123|Drug|cisplatin|
543669|NCT00006123|Drug|cyclophosphamide|
543670|NCT00006123|Drug|thiotepa|
543671|NCT00006123|Procedure|peripheral blood stem cell transplantation|
543672|NCT00006047|Drug|Oral Etoposide|
543673|NCT00006047|Drug|Oral 9-Nitrocamptothecin|
543674|NCT00006038|Drug|cisplatin|
543675|NCT00006038|Drug|docetaxel|
543676|NCT00006038|Drug|floxuridine|
543677|NCT00006038|Drug|fluorouracil|
543678|NCT00006038|Drug|leucovorin calcium|
543679|NCT00006038|Procedure|conventional surgery|
543680|NCT00005995|Drug|shark cartilage extract AE-941|
543681|NCT00005986|Drug|busulfan|
543682|NCT00005986|Drug|cyclophosphamide|
543683|NCT00005986|Drug|filgrastim|
543684|NCT00005986|Drug|recombinant interferon alfa|
543685|NCT00005986|Procedure|in vitro-treated peripheral blood stem cell transplantation|
543686|NCT00005986|Procedure|peripheral blood stem cell transplantation|
543687|NCT00005986|Procedure|radiation therapy|
543688|NCT00005877|Drug|rubitecan|
543689|NCT00005862|Drug|semaxanib|
543690|NCT00005610|Biological|sargramostim|
543691|NCT00004919|Drug|cisplatin|Given IV
543692|NCT00004919|Drug|irinotecan hydrochloride|Given IV
543693|NCT00004919|Drug|amifostine trihydrate|Given IV
543694|NCT00004919|Other|pharmacological study|Correlative studies
543695|NCT00004889|Biological|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
543696|NCT00004203|Drug|oxaliplatin|
543697|NCT00004157|Biological|filgrastim|
543698|NCT00004157|Biological|recombinant interleukin-11|
543699|NCT00004003|Drug|cisplatin|
543700|NCT00004003|Drug|fluorouracil|
543701|NCT00004003|Drug|gemcitabine hydrochloride|
543702|NCT00077584|Drug|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
543703|NCT00077584|Drug|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
543704|NCT00077584|Drug|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
543705|NCT00077298|Biological|cetuximab|Given IV
543706|NCT00077298|Biological|bevacizumab|Given IV
543707|NCT00077298|Drug|irinotecan hydrochloride|Given IV
543708|NCT00077298|Other|laboratory biomarker analysis|Correlative studies
543709|NCT00077285|Biological|filgrastim|
543710|NCT00077285|Drug|carboplatin|
543711|NCT00077285|Drug|cyclophosphamide|
543712|NCT00077285|Drug|dexrazoxane hydrochloride|
543713|NCT00077285|Drug|doxorubicin hydrochloride|
543714|NCT00077285|Drug|etoposide|
543715|NCT00077285|Drug|ifosfamide|
543716|NCT00077285|Drug|irinotecan hydrochloride|
543717|NCT00077285|Drug|vincristine sulfate|
543718|NCT00077285|Procedure|conventional surgery|
543719|NCT00077285|Radiation|radiation therapy|
543720|NCT00077259|Drug|epothilone D|
543721|NCT00077246|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
543722|NCT00077233|Drug|cetuximab|IV
543723|NCT00077233|Drug|5-FU|IV
543724|NCT00077233|Drug|irinotecan|IV
543725|NCT00077233|Drug|leucovorin|IV
543726|NCT00077233|Drug|oxaliplatin|IV
543727|NCT00077220|Drug|carboplatin|
543728|NCT00077220|Drug|paclitaxel|
543729|NCT00077220|Procedure|adjuvant therapy|
543730|NCT00077220|Radiation|radiation therapy|
543731|NCT00077207|Drug|carboplatin|Given IV
543732|NCT00077207|Drug|temozolomide|Given orally
543733|NCT00077207|Drug|vincristine sulfate|Given IV
543734|NCT00077194|Drug|romidepsin|
543735|NCT00077181|Drug|cytarabine|Given IV
543736|NCT00077181|Drug|triapine|Given IV
543737|NCT00077181|Other|laboratory biomarker analysis|Correlative studies
543738|NCT00077168|Drug|anastrozole|
543739|NCT00077168|Drug|tamoxifen citrate|
543740|NCT00077168|Procedure|adjuvant therapy|
543741|NCT00077168|Radiation|radiation therapy|
543742|NCT00077155|Drug|cilengitide|
543743|NCT00077142|Drug|TAC-101|Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
543744|NCT00077129|Drug|carboplatin|
543745|NCT00077129|Drug|paclitaxel|
543746|NCT00077116|Drug|busulfan|
543747|NCT00077116|Drug|cyclophosphamide|
543748|NCT00077116|Drug|cytarabine|
543749|NCT00077116|Drug|gemtuzumab ozogamicin|
543750|NCT00077116|Drug|idarubicin|
543751|NCT00077116|Procedure|allogeneic bone marrow transplantation|
543752|NCT00077116|Procedure|peripheral blood stem cell transplantation|
543753|NCT00077116|Radiation|radiation therapy|
544075|NCT00076050|Dietary Supplement|Placebo|Placebo soy isoflavones
543754|NCT00077103|Biological|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
543755|NCT00077103|Biological|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
543756|NCT00077103|Drug|cisplatin|cisplatin IV over 30-60 minutes on day 1
543757|NCT00077103|Drug|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
543758|NCT00077103|Drug|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
543759|NCT00077103|Radiation|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
543760|NCT00077090|Drug|hyperbaric oxygen|
543761|NCT00077077|Drug|DJ-927|
543762|NCT00077077|Drug|capecitabine|
543763|NCT00077064|Drug|captopril|Captopril 12.5 mg t.i.d. for first two weeks, increased to 25 mg t.i.d. for the second two weeks of therapy. Thereafter, the dose will be increased to 50 mg t.i.d. for the remainder of the one-year of therapy (52 total weeks of drug administration).
543764|NCT00077051|Drug|cisplatin|
543765|NCT00077051|Drug|cytochlor|
543766|NCT00077051|Drug|tetrahydrouridine|
543767|NCT00077051|Radiation|radiation therapy|
543768|NCT00077025|Drug|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
543769|NCT00077025|Drug|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
543770|NCT00077012|Drug|QLT0074|
543771|NCT00077012|Drug|Photodynamic therapy|
543772|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
543773|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
543774|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
543775|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
543776|NCT00076986|Drug|IL13-PE38QQR|
543777|NCT00076986|Procedure|surgery and catheter placement (2 procedures)|
543778|NCT00076986|Drug|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
543779|NCT00076986|Procedure|surgery and wafer placement (1 procedure)|
543780|NCT00076960|Drug|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
543781|NCT00076947|Biological|EnvPro|
543782|NCT00076934|Drug|RG2077 (CTLA4-IgG4m)|RG2077
543783|NCT00003937|Drug|cisplatin|
543784|NCT00003937|Drug|dexrazoxane hydrochloride|
543785|NCT00003937|Drug|doxorubicin hydrochloride|
543786|NCT00003937|Drug|etoposide|
543787|NCT00003937|Drug|ifosfamide|
543788|NCT00003937|Drug|methotrexate|
543789|NCT00003937|Procedure|conventional surgery|
543790|NCT00003923|Drug|porfimer sodium|
543791|NCT00003721|Drug|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
543792|NCT00003665|Biological|dendritic cell-MART-1 peptide vaccine|
543793|NCT00003665|Biological|gp100 antigen|
543794|NCT00003665|Biological|therapeutic tumor infiltrating lymphocytes|
543795|NCT00003665|Biological|tyrosinase peptide|
543796|NCT00003616|Drug|irinotecan hydrochloride|
543797|NCT00003370|Drug|irofulven|
543798|NCT00003367|Dietary Supplement|green tea|
543799|NCT00003367|Dietary Supplement|soy protein isolate|
543800|NCT00003367|Dietary Supplement|vitamin E|
543801|NCT00003334|Drug|paclitaxel|
543802|NCT00003334|Drug|pegylated liposomal doxorubicin hydrochloride|
543803|NCT00003222|Biological|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
543804|NCT00003222|Biological|gp100 antigen|
543805|NCT00003222|Biological|incomplete Freund's adjuvant|
543806|NCT00003222|Biological|sargramostim|
543807|NCT00003222|Biological|tetanus peptide melanoma vaccine|
543808|NCT00003222|Biological|tyrosinase peptide|
543809|NCT00003185|Biological|autologous tumor cell vaccine|
543810|NCT00003185|Biological|sargramostim|
543811|NCT00003185|Biological|tumor-draining lymph node lymphocyte therapy|
543812|NCT00003185|Drug|cyclophosphamide|
543813|NCT00003185|Procedure|conventional surgery|
543814|NCT00003108|Drug|bryostatin 1|
543815|NCT00003108|Drug|cisplatin|
543816|NCT00003086|Biological|filgrastim|
543817|NCT00003086|Drug|CAF regimen|
543818|NCT00003086|Drug|carboplatin|
543819|NCT00003086|Drug|cisplatin|
543820|NCT00003086|Drug|cyclophosphamide|
543821|NCT00003086|Drug|doxorubicin hydrochloride|
543822|NCT00003086|Drug|fluorouracil|
543823|NCT00003086|Drug|ifosfamide|
543824|NCT00003086|Drug|melphalan|
543825|NCT00003086|Drug|paclitaxel|
543826|NCT00003086|Drug|thiotepa|
543827|NCT00003086|Procedure|peripheral blood stem cell transplantation|
543828|NCT00003086|Radiation|samarium Sm 153 lexidronam pentasodium|
543829|NCT00076869|Drug|MK0991, caspofungin acetate|
543830|NCT00076869|Drug|Comparator: amphotericin B|
543831|NCT00076869|Drug|Comparator: lipid formulation of amphotericin B and/or azole|
543832|NCT00076856|Drug|Temozolomide|
543833|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
543834|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
543835|NCT00076804|Behavioral|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
543836|NCT00076791|Drug|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
543837|NCT00076791|Drug|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
543838|NCT00033592|Other|placebo|
543839|NCT00033592|Drug|bupropion hydrochloride|
543840|NCT00033592|Drug|nicotine|
543841|NCT00026377|Drug|bicalutamide|50 mg daily for 1 month
543842|NCT00026377|Drug|flutamide|250 mg 3 times daily for 1 month
543843|NCT00026377|Drug|goserelin acetate|3.6 mg once a month for 4 months
543844|NCT00026377|Drug|leuprolide acetate|7.5 mg once a month for 4 months
543845|NCT00026377|Drug|SU5416|IV infusion at assigned dose
543846|NCT00026377|Radiation|radiation therapy|daily for 5 days each week
543847|NCT00024362|Drug|BBR 3464|
543848|NCT00024011|Drug|bortezomib|Given IV
543849|NCT00024011|Other|laboratory biomarker analysis|Correlative studies
543850|NCT00003320|Procedure|surgical procedure|
543851|NCT00003320|Radiation|radiation therapy|
543852|NCT00003320|Radiation|stereotactic radiosurgery|
543853|NCT00003073|Drug|liposomal cytarabine|
543854|NCT00002801|Drug|leucovorin calcium|
543855|NCT00002801|Drug|tegafur-uracil|
543856|NCT00002801|Radiation|radiation therapy|
543857|NCT00002679|Biological|filgrastim|
543858|NCT00002679|Drug|cyclophosphamide|
543859|NCT00002679|Drug|doxorubicin hydrochloride|
543860|NCT00002679|Drug|paclitaxel|
543861|NCT00002679|Drug|tamoxifen citrate|
543862|NCT00002679|Radiation|radiation therapy|
543863|NCT00076843|Drug|Hu MiK-Beta-1|
543864|NCT00076726|Drug|Infliximab|
543865|NCT00076544|Drug|Ziconotide|
543866|NCT00076518|Drug|Fenofibrate|
543867|NCT00076518|Drug|Fish Oil|
543868|NCT00022373|Drug|iseganan HCl oral solution|
543869|NCT00022373|Procedure|management of therapy complications|
543870|NCT00022243|Drug|batabulin sodium|
543871|NCT00022204|Dietary Supplement|vitamin E|
543872|NCT00022204|Drug|pentoxifylline|
543873|NCT00022204|Procedure|quality-of-life assessment|
543874|NCT00021385|Drug|carboplatin|
543875|NCT00021385|Drug|squalamine lactate|
543876|NCT00020696|Drug|cisplatin|
543877|NCT00020696|Drug|tirapazamine|
543878|NCT00017407|Biological|ISIS 3521|
543879|NCT00017407|Drug|carboplatin|
543880|NCT00017407|Drug|paclitaxel|
543881|NCT00014105|Drug|carboplatin|
543882|NCT00014105|Drug|temozolomide|
543883|NCT00014066|Drug|hematoporphyrin derivative|
543884|NCT00014066|Radiation|brachytherapy|
543885|NCT00010244|Radiation|radiation therapy|
543886|NCT00076752|Drug|fludarabine phosphate|Conditioning and transplant regimen: 30 mg/m^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
543887|NCT00076752|Drug|cyclophosphamide|Priming regimen: 2000 mg/m^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
543888|NCT00076752|Biological|Rituxan (rituximab)|Priming regimen: 375 mg/m^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m^2 intravenous infusion, day -7.
543889|NCT00076752|Biological|filgrastim|Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC >500 microliters.
543890|NCT00076752|Drug|methylprednisolone|Priming regimen:1000 mg intravenous over 30 minutes, day 1.
543891|NCT00076752|Other|immunologic technique|Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
543892|NCT00076752|Other|laboratory biomarker analysis|Standard human immunology research laboratory ex vivo studies.
543893|NCT00076752|Procedure|autologous hematopoietic stem cell transplantation|Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
543894|NCT00076752|Drug|Diphenhydramine|Conditioning and transplant regimen 25-50 mg orally or intravenously.
543895|NCT00076752|Drug|Mesna|Priming regimen: 600 mg/m^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
543896|NCT00009997|Biological|trastuzumab|
543897|NCT00009997|Drug|cyclophosphamide|
543898|NCT00009997|Drug|doxorubicin hydrochloride|
543899|NCT00009997|Drug|paclitaxel|
543900|NCT00009997|Drug|tamoxifen citrate|
543901|NCT00009997|Procedure|conventional surgery|
543902|NCT00009958|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
543903|NCT00009958|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
543904|NCT00009958|Biological|sargramostim|Given SC
543905|NCT00009958|Other|laboratory biomarker analysis|Correlative studies
543906|NCT00009906|Drug|Imatinib Mesylate|Given orally
543907|NCT00008333|Drug|vinorelbine tartrate|
543908|NCT00008034|Drug|capecitabine|
543909|NCT00008034|Drug|cyclophosphamide|
543910|NCT00008034|Drug|epirubicin hydrochloride|
543911|NCT00006460|Drug|hyperbaric oxygen|
543912|NCT00006460|Radiation|radiation therapy|
543913|NCT00006454|Drug|carboplatin|
543914|NCT00006454|Drug|paclitaxel|
543915|NCT00006454|Drug|topotecan hydrochloride|
543916|NCT00006111|Drug|cisplatin|
543917|NCT00006111|Drug|fluorouracil|
543918|NCT00006111|Procedure|conventional surgery|
543919|NCT00006111|Radiation|radiation therapy|
543920|NCT00006050|Drug|FOLFOX regimen|
543921|NCT00006050|Drug|fluorouracil|
543922|NCT00006050|Drug|isolated perfusion|
543923|NCT00006050|Drug|leucovorin calcium|
543924|NCT00006050|Drug|oxaliplatin|
544076|NCT00076037|Biological|HIV CTL MEP administered with RC529-SE adjuvant|
544077|NCT00076037|Drug|GM-CSF|
543925|NCT00005881|Other|Quality of Life Forms|Completion of the instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
543926|NCT00005792|Drug|etoposide phosphate|Etoposide phosphate 1363 mg/m^2/day IV over 4 hours (total dose 2726 mg/m^2, or 2400 mg/m^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
543927|NCT00005792|Drug|melphalan|Melphalan 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2), followed immediately by topotecan. Days -7, -6, -5
543928|NCT00005792|Drug|topotecan|Topotecan 3.3 mg/m^2/day (starting total dose = 10 mg/m^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
543929|NCT00005792|Procedure|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
543930|NCT00005064|Drug|bortezomib|Given IV
543931|NCT00076648|Drug|Poly SFH-P Injection|
543932|NCT00076635|Drug|Interferon gamma-1b|200 mcg, SQ, 3x per week
543933|NCT00076674|Drug|Intravenous Levodopa|
543934|NCT00076622|Drug|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
543935|NCT00076622|Drug|No antidepressant medication|Participants assigned to discontinue current medication (no antidepressant medication) will be monitored over a period of one year for recurrence of depression and related symptoms.
543936|NCT00005022|Drug|cisplatin|
543937|NCT00005022|Drug|etoposide|
543938|NCT00005022|Radiation|radiation therapy|
543939|NCT00004862|Biological|filgrastim|
543940|NCT00004862|Biological|oblimersen sodium|
543941|NCT00004862|Drug|cytarabine|
543942|NCT00004862|Drug|fludarabine phosphate|
543943|NCT00004239|Drug|Compound 506U78|
543944|NCT00003888|Drug|cisplatin|
543945|NCT00003888|Drug|docetaxel|
543946|NCT00003888|Drug|fluorouracil|
543947|NCT00003888|Radiation|radiation therapy|
543948|NCT00076609|Drug|PHY906|
543949|NCT00076609|Drug|capecitabine|
543950|NCT00076557|Genetic|Adeno-Associated Viral with Human Factor IX|
543951|NCT00076570|Drug|Sirolimus|
543952|NCT00076570|Drug|Tacrolimus|
543953|NCT00076531|Drug|Leuprolide Acetate for Injectable Suspension 22.5 mg|
543954|NCT00076492|Drug|CoQ10|
543955|NCT00076492|Drug|GPI 1485|
543956|NCT00003882|Drug|anhydrovinblastine|
543957|NCT00003852|Biological|filgrastim|
543958|NCT00003852|Drug|carboplatin|
543959|NCT00003852|Drug|cyclophosphamide|
543960|NCT00003852|Drug|epirubicin hydrochloride|
543961|NCT00003852|Drug|etoposide|
543962|NCT00003852|Drug|ifosfamide|
543963|NCT00003852|Drug|paclitaxel|
543964|NCT00003852|Drug|thiotepa|
543965|NCT00003852|Procedure|bone marrow ablation with stem cell support|
543966|NCT00003852|Procedure|peripheral blood stem cell transplantation|
543967|NCT00003683|Drug|doxorubicin hydrochloride|
543968|NCT00003683|Drug|ifosfamide|
543969|NCT00003682|Drug|doxorubicin hydrochloride|
543970|NCT00003682|Drug|methylprednisolone|
543971|NCT00003578|Drug|CHOP regimen|
543972|NCT00003578|Drug|carmustine|
543973|NCT00003578|Drug|cyclophosphamide|
543974|NCT00003578|Drug|cytarabine|
543975|NCT00003578|Drug|doxorubicin hydrochloride|
543976|NCT00003578|Drug|etoposide|
543977|NCT00003578|Drug|melphalan|
543978|NCT00003578|Drug|prednisone|
543979|NCT00003578|Drug|vincristine sulfate|
543980|NCT00003578|Procedure|autologous bone marrow transplantation|
543981|NCT00003578|Procedure|peripheral blood stem cell transplantation|
543982|NCT00076453|Device|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
543983|NCT00076453|Device|Standard orthotic shoe inserts|Neutral orthotic inserts
543984|NCT00076440|Drug|Leuprolide acetate|
543985|NCT00076401|Drug|Motexafin gadolinium|
543986|NCT00076388|Drug|Gefitinib|
543987|NCT00076388|Drug|Docetaxel|
543988|NCT00076375|Drug|Nanocrystalline silver cream (NPI)|
543989|NCT00076362|Drug|Sandostatin LAR|
543990|NCT00003541|Biological|filgrastim|
543991|NCT00003541|Drug|CHOP regimen|
543992|NCT00003541|Drug|carboplatin|
543993|NCT00003541|Drug|cyclophosphamide|
543994|NCT00003541|Drug|doxorubicin hydrochloride|
543995|NCT00003541|Drug|etoposide|
543996|NCT00003541|Drug|ifosfamide|
543997|NCT00003541|Drug|prednisone|
543998|NCT00003541|Drug|vincristine sulfate|
543999|NCT00003541|Procedure|peripheral blood stem cell transplantation|
544000|NCT00003541|Radiation|radiation therapy|
544001|NCT00003418|Drug|exemestane|
544002|NCT00003418|Drug|tamoxifen citrate|
544003|NCT00003364|Drug|cisplatin|
544004|NCT00003364|Drug|cyclophosphamide|
544005|NCT00003364|Drug|doxorubicin hydrochloride|
544006|NCT00003364|Drug|etoposide|
544007|NCT00003364|Drug|vincristine sulfate|
544008|NCT00003364|Radiation|radiation therapy|
544009|NCT00003298|Drug|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
544010|NCT00003298|Drug|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
544011|NCT00003298|Drug|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
544012|NCT00003298|Drug|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
544078|NCT00076024|Drug|Placebo|5 mg twice daily [bid] continuous dosing
544013|NCT00003298|Procedure|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.~A complete surgical resection was required"
544014|NCT00003298|Radiation|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
544015|NCT00003287|Drug|FOLFOX regimen|
544016|NCT00003287|Drug|fluorouracil|
544017|NCT00003287|Drug|leucovorin calcium|
544018|NCT00003287|Drug|oxaliplatin|
544019|NCT00076414|Drug|Acetylcholine|
544020|NCT00076414|Drug|L-NMMA|
544021|NCT00076349|Drug|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
544022|NCT00076336|Drug|Telbivudine|600mg/day oral tablet for 104 weeks
544023|NCT00076336|Drug|Lamivudine|100mg/day oral tablet for 104 weeks
544024|NCT00076336|Drug|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
544025|NCT00003137|Drug|irinotecan hydrochloride|
544026|NCT00003007|Biological|recombinant interferon alfa|
544027|NCT00003007|Biological|sargramostim|
544028|NCT00003007|Drug|cyclophosphamide|
544029|NCT00003007|Drug|dexamethasone|
544030|NCT00003007|Drug|melphalan|
544031|NCT00003007|Procedure|peripheral blood stem cell transplantation|
544032|NCT00002840|Drug|lomustine|
544033|NCT00002840|Drug|procarbazine hydrochloride|
544034|NCT00002840|Drug|vincristine sulfate|
544035|NCT00002840|Radiation|radiation therapy|
544036|NCT00002817|Biological|sargramostim|
544037|NCT00002817|Biological|vaccinia-GM-CSF vaccine|
544038|NCT00002748|Biological|gene-modified tumor cell vaccine therapy|
544039|NCT00002748|Biological|interleukin-2 gene|
544040|NCT00076323|Drug|Primaquine|
544041|NCT00076310|Drug|Docetaxel|60 mg/m^2 IV repeated every 21 days.
544042|NCT00076310|Drug|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
544043|NCT00076310|Drug|Cisplatin|75 mg/m^2 IV every 21 days.
544044|NCT00076284|Drug|GW873140|
544045|NCT00076258|Behavioral|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
544046|NCT00076258|Behavioral|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
544047|NCT00076245|Behavioral|Light Therapy|Light therapy will involve exposure to bright light twice a day.
544048|NCT00076245|Behavioral|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
544049|NCT00076219|Procedure|renal replacement therapy|renal replacement therapy
544050|NCT00076206|Drug|CCI-779|
544051|NCT00076206|Drug|Placebo|
544052|NCT00076232|Drug|Acyclovir|400 mg tablet taken orally twice daily
544053|NCT00076232|Drug|Acyclovir placebo|Oral tablet taken twice daily
544054|NCT00076115|Drug|Risperidone|
544055|NCT00076180|Biological|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
544056|NCT00076089|Drug|Roflumilast|
544057|NCT00076076|Drug|Roflumilast|
544058|NCT00033735|Drug|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
544059|NCT00033735|Drug|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
544060|NCT00027508|Drug|trabectedin|
544061|NCT00024401|Drug|DHA-paclitaxel|
544062|NCT00002566|Drug|carboplatin|
544063|NCT00002566|Drug|cisplatin|
544064|NCT00002566|Drug|cyclophosphamide|
544065|NCT00002566|Drug|etoposide|
544066|NCT00002566|Drug|ifosfamide|
544067|NCT00002566|Drug|vinblastine sulfate|
544068|NCT00002566|Procedure|autologous bone marrow transplantation|
544069|NCT00002566|Procedure|conventional surgery|
544070|NCT00002566|Procedure|peripheral blood stem cell transplantation|
544071|NCT00076102|Drug|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
544072|NCT00076063|Biological|ALVAC-HIV (vCP1452)|experimental vaccine
544073|NCT00076063|Biological|LIPO-5|experimental vaccine
544074|NCT00076050|Dietary Supplement|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
544079|NCT00076024|Drug|Docetaxel|Standard of care drug administration
544080|NCT00076024|Drug|AG-013736 (axitinib)|5mg twice daily [bid] continuous dosing
544081|NCT00076024|Drug|Docetaxel|Standard of care drug administration
544082|NCT00076011|Drug|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
544083|NCT00075998|Drug|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
544084|NCT00075972|Behavioral|Mood Tolearance|
544085|NCT00075972|Behavioral|Mood Management|
544086|NCT00075972|Drug|Nicotine Replacement therapy|
544087|NCT00075959|Drug|NXY-059|
544088|NCT00075946|Biological|rituximab|Given IV
544089|NCT00024388|Drug|DHA-paclitaxel|
544090|NCT00022347|Drug|canfosfamide hydrochloride|
544091|NCT00022321|Drug|gemtuzumab ozogamicin|
544092|NCT00021333|Biological|filgrastim|
544093|NCT00021333|Drug|cisplatin|
544094|NCT00021333|Drug|paclitaxel|
544095|NCT00021333|Radiation|radiation therapy|
544096|NCT00021307|Drug|carboplatin|
544097|NCT00021307|Drug|temozolomide|
544098|NCT00075933|Drug|ARQ 501|
544099|NCT00075907|Drug|Efavirenz + 2 NRTIs|
544100|NCT00075907|Drug|Lopinavir/Ritonavir + 2 NRTIs|
544101|NCT00075907|Procedure|Therapeutic Drug Monitoring|
544102|NCT00075894|Drug|L-alanosine|
544103|NCT00075881|Drug|bortezomib|Given IV
544104|NCT00075881|Other|laboratory biomarker analysis|Optional correlative studies
544105|NCT00075868|Drug|octreotide acetate|
544106|NCT00075868|Other|Placebo|
544107|NCT00075855|Drug|therapeutic testosterone|
544108|NCT00075855|Other|placebo|
544109|NCT00075842|Dietary Supplement|Valeriana officinalis extract|Given orally
544110|NCT00075842|Other|placebo|Given orally
544111|NCT00075829|Procedure|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive ~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) > 500/mm3 for two days.
544112|NCT00075829|Procedure|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
544113|NCT00075829|Procedure|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
544114|NCT00075829|Drug|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
544115|NCT00075829|Drug|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
544116|NCT00075829|Behavioral|Observation|One year of observation post-transplants.
544117|NCT00075816|Biological|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
544118|NCT00075816|Biological|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
544119|NCT00075803|Drug|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients > 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients < 12 years, intravenous doses will be prepared.
544120|NCT00075803|Drug|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients > 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients > 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age < 12 years.
544121|NCT00075777|Drug|valproic acid|250 mg by mouth twice a day
544122|NCT00075764|Drug|anastrozole|Given orally
544123|NCT00075764|Drug|fulvestrant|Given intramuscularly
544124|NCT00075751|Drug|gemcitabine hydrochloride|Given IV
544125|NCT00075751|Drug|carboplatin|Given IV
544126|NCT00075751|Drug|bortezomib|Given IV
544127|NCT00075738|Drug|cisplatin|
544128|NCT00075738|Drug|fluorouracil|
544129|NCT00075738|Drug|irinotecan hydrochloride|
544130|NCT00075738|Drug|leucovorin calcium|
544131|NCT00075725|Drug|cyclophosphamide|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544132|NCT00075725|Drug|cytarabine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544133|NCT00075725|Drug|daunorubicin hydrochloride|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544134|NCT00075725|Drug|dexamethasone|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544135|NCT00075725|Drug|doxorubicin hydrochloride|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544136|NCT00075725|Drug|leucovorin calcium|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544405|NCT00074438|Drug|rituximab|Intravenous repeating dose
544137|NCT00075725|Drug|mercaptopurine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544138|NCT00075725|Drug|methotrexate|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544139|NCT00075725|Drug|pegaspargase|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544140|NCT00075725|Drug|prednisone|Given IV or orally
544141|NCT00075725|Drug|thioguanine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544142|NCT00075725|Drug|vincristine sulfate|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
544143|NCT00075725|Radiation|radiation therapy|Patients undergo radiation therapy periodically during study treatment
544144|NCT00075712|Drug|carboplatin|
544145|NCT00075712|Drug|paclitaxel|
544146|NCT00075712|Procedure|adjuvant therapy|
544147|NCT00075712|Procedure|conventional surgery|
544148|NCT00075712|Procedure|neoadjuvant therapy|
544149|NCT00075699|Drug|cisplatin|
544150|NCT00075699|Drug|mitomycin C|
544151|NCT00075699|Drug|vincristine sulfate|
544152|NCT00075699|Drug|vinorelbine tartrate|
544153|NCT00075699|Procedure|pain therapy|
544154|NCT00075699|Procedure|psychosocial assessment and care|
544155|NCT00075699|Procedure|quality-of-life assessment|
544156|NCT00075686|Biological|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles
544157|NCT00075686|Drug|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
544158|NCT00075673|Drug|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
544159|NCT00075673|Drug|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
544160|NCT00075660|Drug|triapine|
544161|NCT00075647|Drug|temsirolimus|Given IV
544162|NCT00075647|Other|laboratory biomarker analysis|Correlative studies
544163|NCT00075634|Drug|decitabine|Given IV
544164|NCT00075634|Drug|doxorubicin hydrochloride|Given IV
544165|NCT00075634|Drug|cyclophosphamide|Given IV
544166|NCT00075634|Biological|filgrastim|Given SC
544167|NCT00075634|Biological|pegfilgrastim|Given SC
544168|NCT00075634|Other|laboratory biomarker analysis|Correlative studies
544169|NCT00075634|Other|pharmacological study|Correlative studies
544170|NCT00075621|Drug|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
544171|NCT00075621|Drug|melphalan|200 mg/kg over 2 days
544172|NCT00075621|Procedure|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
544173|NCT00075608|Biological|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
544174|NCT00075608|Drug|melphalan|140-200 mcg/kg IV over two days
544175|NCT00075608|Procedure|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
544176|NCT00075608|Procedure|stem cell infusion|infusion of previously collected stem cells on Day 0
544177|NCT00075595|Drug|FOLFIRI regimen|
544178|NCT00075595|Drug|fluorouracil|
544179|NCT00075595|Drug|irinotecan hydrochloride|
544180|NCT00075595|Drug|leucovorin calcium|
544181|NCT00075582|Procedure|conventional surgery|Some patients may undergo second-look surgery
544182|NCT00075582|Drug|dactinomycin|Given IV
544183|NCT00075582|Drug|cyclophosphamide|Given IV
544184|NCT00075582|Drug|vincristine sulfate|Given IV
544185|NCT00075582|Radiation|radiation therapy|Undergo radiotherapy
544186|NCT00075569|Biological|HspE7|500 micrograms of SGN-00101 (HspE7, Nventa, San Diego, CA) is a novel therapeutic vaccine consisting of a fusion protein containing an M. bovis BCG heat shock protein (Hsp65) covalently linked to the entire sequence of HPV 16 E7.
544187|NCT00075556|Drug|capecitabine|
544188|NCT00075556|Procedure|conventional surgery|
544189|NCT00075556|Procedure|neoadjuvant therapy|
544190|NCT00075556|Radiation|radiation therapy|
544191|NCT00075543|Drug|docetaxel|
544192|NCT00075543|Drug|oxaliplatin|
544193|NCT00075517|Drug|docetaxel|
544194|NCT00075517|Drug|gemcitabine hydrochloride|
544195|NCT00075504|Drug|triapine|Given IV
544196|NCT00075504|Drug|gemcitabine|Given IV
544197|NCT00075491|Drug|fenretinide|Given orally
544198|NCT00075491|Procedure|therapeutic conventional surgery|Undergo surgery
544199|NCT00075491|Other|pharmacological study|Correlative studies
544200|NCT00075491|Other|laboratory biomarker analysis|Correlative studies
544201|NCT00075478|Procedure|Total-Body Irradiation|Undergo TBI
544202|NCT00075478|Drug|Fludarabine Phosphate|Given IV
544203|NCT00075478|Drug|Mycophenolate Mofetil|Given PO
544204|NCT00075478|Drug|Cyclosporine|Given PO
544205|NCT00075478|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
544206|NCT00075465|Drug|docetaxel|
544207|NCT00075465|Drug|epirubicin hydrochloride|
544208|NCT00075452|Drug|gemcitabine hydrochloride|
544209|NCT00075452|Drug|oxaliplatin|
544210|NCT00075439|Drug|gefitinib|Given orally
544211|NCT00075439|Other|laboratory biomarker analysis|Correlative studies
544212|NCT00075426|Drug|arsenic trioxide|
544213|NCT00075413|Drug|arsenic trioxide|
544214|NCT00075400|Drug|imatinib mesylate|Given PO
544215|NCT00075400|Other|laboratory biomarker analysis|Correlative studies
544216|NCT00075387|Drug|Carboplatin|Given IA
544217|NCT00075387|Drug|Cyclophosphamide|Given IV
544218|NCT00075387|Drug|Etoposide Phosphate|Given IV
544219|NCT00075387|Other|Quality-of-Life Assessment|Ancillary studies
544220|NCT00075387|Drug|Sodium Thiosulfate|Given IV
544221|NCT00075374|Drug|docetaxel|"Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.~OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.~Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.~Patients are followed at 1 month and then every 2-3 months thereafter."
544222|NCT00075348|Genetic|mutation analysis|
544223|NCT00075335|Drug|AMD3100 (Mozobil plerixafor)|AMD 3100 (Mozobil plerixafor)mobilized peripheral blood hematopoietic progenitor cells from healthy volunteers will be characterized by cellular content and immunological properties.
544224|NCT00075283|Device|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
544225|NCT00075270|Drug|Paclitaxel|Active Comparator
544226|NCT00075270|Drug|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
544227|NCT00075257|Drug|DVS-233 SR|
544228|NCT00075231|Drug|Kaletra® (lopinavir/ritonavir)|
544229|NCT00075231|Drug|Combivir® (lamivudine, zidovudine)|
544230|NCT00075231|Drug|Sustiva® (efavirenz)|
544231|NCT00075218|Drug|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
544232|NCT00075218|Drug|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
544233|NCT00020787|Biological|G17DT Immunogen|Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
544234|NCT00020787|Drug|cisplatin|dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
544235|NCT00020787|Drug|fluorouracil|Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
544236|NCT00017576|Dietary Supplement|calcitriol|
544237|NCT00017576|Drug|carboplatin|
544238|NCT00017537|Biological|MVF-HER-2(628-647)-CRL 1005 vaccine|
544239|NCT00017433|Drug|arsenic trioxide|
544240|NCT00075244|Drug|Replagal|
544241|NCT00075192|Drug|CP-675,206 and leuprolide acetate and bicalutamide|
544242|NCT00075192|Drug|leuprolide acetate and bicalutamide|
544243|NCT00017082|Drug|oxaliplatin|
544244|NCT00016237|Biological|tucotuzumab celmoleukin|
544245|NCT00016198|Drug|FOLFOX regimen|
544246|NCT00016198|Drug|fluorouracil|
544247|NCT00016198|Drug|leucovorin calcium|
544248|NCT00016198|Drug|oxaliplatin|
544249|NCT00014404|Drug|celecoxib|
544250|NCT00014287|Drug|gemcitabine hydrochloride|
544251|NCT00075205|Drug|SR141716 (Rimonabant)|
544252|NCT00075179|Drug|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
544253|NCT00075179|Procedure|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
544254|NCT00075166|Procedure|Stereotactic surgery (SRS)|
544255|NCT00075166|Procedure|Craniotomy|
544256|NCT00075140|Genetic|Mutation in the gene|
544257|NCT00075114|Behavioral|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
544258|NCT00075101|Drug|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
544259|NCT00075088|Device|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
544260|NCT00075088|Other|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
544261|NCT00075075|Drug|Infliximab|
544262|NCT00075062|Procedure|Flexible Sigmoidoscopy|
544263|NCT00075062|Procedure|Rectal Biopsy|
544264|NCT00075049|Biological|RTS,S with AS02A/AS01B adjuvant|
544265|NCT00014183|Drug|gefitinib|
544266|NCT00012116|Drug|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
544267|NCT00009919|Drug|semaxanib|Given IV
544268|NCT00009893|Drug|fluorouracil|
544269|NCT00009893|Drug|gemcitabine hydrochloride|
544270|NCT00009893|Drug|leucovorin calcium|
544271|NCT00075023|Drug|Thalidomide Gel|
544272|NCT00075023|Drug|Placebo Gel|
544273|NCT00075010|Drug|Decitabine|15 mg/m^2 by vein over 1 hour times 10 days
544274|NCT00075010|Drug|Valproic acid|20 mg/kg given orally daily for 10 days
544275|NCT00074997|Other|Placebo|Single intravenous infusion of placebo.
544276|NCT00074997|Genetic|OZ1|Single intravenous infusion of OZ1.
544277|NCT00074997|Genetic|CD34+ cells|Autologous CD34+ cells.
544278|NCT00009867|Drug|arsenic trioxide|Given IV
544279|NCT00009698|Biological|aldesleukin|Given SQ and IV
544280|NCT00006481|Drug|Biafine cream|
544281|NCT00006481|Procedure|quality-of-life assessment|
544282|NCT00006481|Radiation|radiation therapy|
544283|NCT00006480|Biological|aldesleukin|
544284|NCT00006480|Biological|therapeutic autologous lymphocytes|
544285|NCT00006480|Drug|chemotherapy|
544286|NCT00006480|Drug|ganciclovir|
544287|NCT00074984|Biological|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
544288|NCT00074984|Biological|Placebo|1 mg/kg placebo intravenously every 2 weeks
544289|NCT00074971|Drug|Fabrazyme (agalsidase beta)|
544290|NCT00074958|Biological|Fabrazyme (agalsidase beta)|1 mg/kg every 2 weeks
544291|NCT00074932|Biological|Myozyme|20 mg/kg
544292|NCT00074919|Biological|alglucosidase alfa|20 mg/kg qow
544293|NCT00074906|Drug|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
544294|NCT00074893|Device|piezoelectric wrist brace|
544295|NCT00074867|Drug|CP-547,632|
544296|NCT00074854|Drug|CP-547,632|
544297|NCT00074841|Drug|Azithromycin/Chloroquine|
544298|NCT00074841|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
544299|NCT00006384|Biological|recombinant interferon alfa|
544300|NCT00006384|Drug|semaxanib|
544301|NCT00006353|Drug|temozolomide|
544302|NCT00006353|Radiation|radiation therapy|
544303|NCT00006247|Drug|semaxanib|
544304|NCT00006213|Drug|BMS-214662|Given IV
544305|NCT00006213|Other|pharmacological study|Correlative studies
544306|NCT00006213|Other|laboratory biomarker analysis|Correlative studies
544307|NCT00006104|Biological|trastuzumab|
544308|NCT00006104|Drug|docetaxel|
544309|NCT00074828|Drug|LY517717|
544310|NCT00074828|Drug|enoxaparin|
544311|NCT00074763|Biological|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
544312|NCT00074750|Drug|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
544313|NCT00074737|Drug|cenersen|cenersen with standard of care
544314|NCT00074737|Drug|Idarubicin|standard of care for AML
544315|NCT00074737|Drug|Cytarabine|standard of care Ara-C and High dose Ara-C
544316|NCT00074724|Procedure|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
544317|NCT00074724|Drug|Modern medical management|Therapies with evidence-based recommendations.
544318|NCT00074724|Device|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
544319|NCT00074724|Drug|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
544320|NCT00006099|Other|immunohistochemistry staining method|
544321|NCT00006099|Procedure|biopsy|
544322|NCT00006099|Procedure|immunoscintigraphy|
544323|NCT00006099|Radiation|indium In 111 monoclonal antibody Hu3S193|
544324|NCT00006087|Procedure|annual screening|
544325|NCT00006087|Procedure|bronchoscopic and lung imaging studies|
544326|NCT00006087|Procedure|comparison of screening methods|
544327|NCT00006087|Procedure|computed tomography|
544328|NCT00006087|Procedure|radiography|
544329|NCT00006087|Procedure|study of high risk factors|
544330|NCT00006080|Drug|fenretinide|
544331|NCT00005978|Biological|filgrastim|
544332|NCT00005978|Drug|carboplatin|
544333|NCT00005978|Drug|etoposide|
544334|NCT00005978|Drug|melphalan|
544335|NCT00005978|Procedure|autologous bone marrow transplantation|
544336|NCT00005978|Procedure|peripheral blood stem cell transplantation|
544337|NCT00005978|Radiation|iobenguane I 131|
544338|NCT00005978|Radiation|radiation therapy|
544339|NCT00005963|Drug|carboplatin|
544340|NCT00005963|Drug|docetaxel|
544341|NCT00074815|Drug|Serotonin reuptake inhibitors management|"Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI."
544342|NCT00074815|Behavioral|Cognitive behavioral therapy by a psychologist|CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
544343|NCT00074815|Behavioral|Instructional cognitive behavioral therapy by a psychiatrist|"The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy."
544344|NCT00074802|Drug|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
544345|NCT00074802|Behavioral|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
544346|NCT00074789|Behavioral|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
544347|NCT00074789|Behavioral|Attention control/usual care|Participants will receive the usual care for depression.
544348|NCT00074776|Drug|Lithium|Participants will receive lithium.
544349|NCT00074776|Drug|Lamotrigine|Participants will receive lamotrigine.
544350|NCT00074711|Drug|Calcium carbonate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
544351|NCT00074711|Drug|Calcium Phosphate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
544352|NCT00074698|Drug|FG-3019|
544353|NCT00074646|Drug|CC-8490|
544354|NCT00074633|Behavioral|Health at Every Size (HAES)|
544355|NCT00074633|Behavioral|Diet (Traditional, moderate energy restriction)|
544356|NCT00074620|Drug|PEG-hirudin|
544357|NCT00074607|Drug|Gemcitabine|"Schedule~Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).~In the absence of disease progression or DLT, patients may proceed to consolidation.~Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.~Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
544358|NCT00074581|Drug|Atazanavir|300 mg taken orally once daily
544359|NCT00074581|Drug|Didanosine|400 mg taken orally once daily
544360|NCT00074581|Drug|Efavirenz|600 mg taken orally once daily
544361|NCT00074581|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
544362|NCT00074581|Drug|Lamivudine|300 mg taken orally once daily
544363|NCT00074581|Drug|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
544364|NCT00074581|Drug|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
544365|NCT00074581|Drug|Stavudine|Dosage depends on weight
544366|NCT00074581|Drug|Tenofovir disoproxil fumarate|300 mg taken orally once daily
544367|NCT00074581|Drug|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
544368|NCT00005959|Biological|filgrastim|
544369|NCT00005959|Biological|rituximab|
544370|NCT00005959|Drug|cyclophosphamide|
544371|NCT00005959|Drug|doxorubicin hydrochloride|
544372|NCT00005959|Drug|prednisone|
544373|NCT00005959|Drug|vincristine sulfate|
544374|NCT00005876|Drug|rubitecan|
544375|NCT00005646|Drug|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
544376|NCT00005642|Drug|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
544377|NCT00005634|Drug|vorinostat|
544378|NCT00074542|Drug|Epanova™ (Omega-3 Free Fatty Acids)|
544379|NCT00074529|Drug|MK0677|
544380|NCT00005598|Drug|amifostine trihydrate|
544381|NCT00005598|Drug|azacitidine|
544382|NCT00005592|Biological|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
544383|NCT00005592|Biological|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
544384|NCT00005592|Radiation|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
544385|NCT00005083|Procedure|conventional surgery|
544386|NCT00005083|Procedure|magnetic resonance imaging|
544387|NCT00005083|Procedure|magnetic resonance spectroscopic imaging|
544388|NCT00004890|Biological|aldesleukin|
544389|NCT00004890|Drug|Biomed 101|
544390|NCT00004874|Radiation|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
544391|NCT00074490|Drug|Rituximab|Rituximab: 375 mg/m(2)/day intravenous (IV), day 1 (for cluster of differentiation 20 (CD20+) patients).
544392|NCT00074490|Drug|Fludarabine|Fludarabine: 30 mg/m(2)/day intravenous (IV), days -6 to -3.
544393|NCT00074490|Drug|Etoposide|Etoposide: 50 mg/m(2)/day continuous intravenous (CIV), days 1-4.
544394|NCT00074490|Drug|Doxorubicin|Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
544395|NCT00074490|Drug|Vincristine|Vincristine: 0.4 mg/m(2)/day continuous intravenous (CIV), days 1-4.
544396|NCT00074490|Drug|Cyclophosphamide|Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
544397|NCT00074490|Procedure|Peripheral blood stem cell (PBSC) transplantation|PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell.
544398|NCT00074490|Genetic|T cell donor lymphocyte infusion (DLI) with unmanipulated donor T cells|The dose of the T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) T cells/kg; minimum dose will be 1 x 10(7) T cells/kg).
544399|NCT00074490|Drug|Prednisone|Prednisone: 60 mg/m(2)/day by mouth (PO), days 1-5.
544400|NCT00074490|Procedure|Allogeneic hematopoietic stem cell transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant.
544401|NCT00074490|Drug|Filgrastim|Filgrastim: 5 mcg/kg/day subcutaneous (SC), day 6 (require absolute neutrophil count (ANC) > 1000, two values; or ANC > 5000 cells/ul on one occasion).
544402|NCT00074490|Genetic|T-Rapa cell Donor Lymphocyte Infusion (DLI)|The dose of T helper 2 (Th2) cells or unmanipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 10(7) Th2/kg; minimum dose will be 1 x 10(7) Th2/kg).
544403|NCT00074477|Drug|R092670|
544404|NCT00074438|Drug|methotrexate|Oral or parenteral repeating dose
544406|NCT00074438|Drug|corticosteroids|Intravenous repeating dose
544407|NCT00074438|Drug|placebo|Intravenous repeating dose
544408|NCT00074425|Drug|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
544409|NCT00074425|Drug|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
544410|NCT00074425|Drug|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
544411|NCT00074412|Drug|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
544412|NCT00074412|Drug|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
544413|NCT00074399|Drug|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
544414|NCT00074399|Drug|Nevirapine placebo|Placebo tablet taken orally daily
544415|NCT00074373|Other|No intervention; observational|
544416|NCT00021983|Biological|BL22 immunotoxin|
544417|NCT00008177|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
544418|NCT00008177|Radiation|total-body irradiation|Undergo total-body irradiation
544419|NCT00008177|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
544420|NCT00008177|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
544421|NCT00008177|Drug|fludarabine phosphate|Given IV
544422|NCT00008177|Drug|cyclosporine|Given orally or IV
544423|NCT00008177|Drug|mycophenolate mofetil|Given orally or IV
544424|NCT00008177|Other|laboratory biomarker analysis|Correlative studies
544425|NCT00074334|Biological|TGFa-PE38 immunotoxin|
544426|NCT00074334|Procedure|conventional surgery|
544427|NCT00074321|Drug|irinotecan hydrochloride|Given IV
544428|NCT00074321|Drug|oxaliplatin|Given IV
544429|NCT00074321|Drug|capecitabine|Given PO
544430|NCT00074321|Other|laboratory biomarker analysis|Correlative studies
544431|NCT00074321|Other|pharmacological study|Correlative studies
544432|NCT00074308|Drug|imatinib mesylate|Given orally
544433|NCT00074308|Biological|bevacizumab|Given IV
544434|NCT00074308|Other|pharmacological study|Correlative studies
544435|NCT00074308|Other|laboratory biomarker analysis|Correlative studies
544436|NCT00074295|Biological|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
544437|NCT00074282|Biological|rituximab|
544438|NCT00074282|Drug|cyclophosphamide|
544439|NCT00074282|Drug|pentostatin|
544440|NCT00074282|Drug|Alemtuzumab|
544441|NCT00074269|Biological|anti-thymocyte globulin|
544442|NCT00074269|Biological|filgrastim|
544443|NCT00074269|Biological|graft-versus-tumor induction therapy|
544444|NCT00074269|Biological|therapeutic allogeneic lymphocytes|
544445|NCT00074269|Drug|cyclosporine|
544446|NCT00074269|Drug|fludarabine phosphate|
544447|NCT00074269|Drug|melphalan|
544448|NCT00074269|Drug|methotrexate|
544449|NCT00074269|Procedure|peripheral blood stem cell transplantation|
544450|NCT00074243|Drug|CC-8490|
544451|NCT00074230|Biological|Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin|Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.
544452|NCT00074204|Drug|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
544453|NCT00074204|Drug|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.~Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.~In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
544454|NCT00074204|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
544455|NCT00074191|Drug|cytarabine|
544456|NCT00074191|Drug|dexamethasone|
544457|NCT00074191|Drug|lomustine|
544458|NCT00074191|Drug|methotrexate|
544459|NCT00074191|Drug|procarbazine hydrochloride|
544460|NCT00074178|Biological|filgrastim|
544461|NCT00074178|Biological|pegfilgrastim|
544462|NCT00074178|Drug|cyclophosphamide|
544463|NCT00074178|Drug|cytarabine|
544464|NCT00074178|Drug|dexamethasone|
544465|NCT00074178|Drug|etoposide phosphate|
544466|NCT00074178|Drug|methotrexate|
544467|NCT00074165|Drug|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
544468|NCT00074165|Drug|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
544469|NCT00074165|Drug|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
544470|NCT00074165|Drug|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
544471|NCT00074165|Drug|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
544472|NCT00074165|Drug|Sodium thiosulfate|"Dose: 4 hrs post carboplatin = 20gm/m2;~Dose: 8 hrs post carboplatin = 16gm/m2~Infused IV x 2 days"
544473|NCT00074165|Drug|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
548644|NCT00052494|Drug|imatinib mesylate|
544474|NCT00074165|Drug|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
544475|NCT00074165|Drug|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
544476|NCT00074152|Drug|chemotherapy|Given within 10 weeks after surgery.
544477|NCT00074152|Radiation|radiation therapy|Given within 6 months after surgery
544478|NCT00074139|Drug|cyclophosphamide|
544479|NCT00074139|Drug|docetaxel|
544480|NCT00074139|Drug|doxorubicin hydrochloride|
544481|NCT00074100|Drug|amonafide dihydrochloride|
544482|NCT00074087|Drug|pegylated liposomal doxorubicin hydrochloride|
544483|NCT00074074|Biological|infliximab|
544484|NCT00074048|Drug|BL22|Dosing via IV on Days 1,3, and 5.
544485|NCT00074035|Drug|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
544486|NCT00074022|Biological|GTI-2040|Given IV
544487|NCT00074022|Drug|docetaxel|Given IV
544488|NCT00074022|Other|laboratory biomarker analysis|Correlative studies
544489|NCT00074022|Other|pharmacological study|Correlative studies
544490|NCT00074009|Drug|bortezomib|
544491|NCT00073983|Biological|filgrastim|filgrastim
544492|NCT00073983|Biological|pegfilgrastim|pegfilgrastim
544493|NCT00073983|Drug|docetaxel|docetaxel
544494|NCT00073983|Drug|gemcitabine hydrochloride|gemcitabine hydrochloride
544495|NCT00073983|Genetic|microarray analysis|microarray analysis
544496|NCT00073983|Other|laboratory biomarker analysis|laboratory biomarker analysis
544497|NCT00073983|Other|pharmacokinetic study|pharmacokinetic study
544498|NCT00073970|Drug|celecoxib|400mg, given twice daily
544499|NCT00073957|Biological|rituximab|
544500|NCT00073957|Drug|cytarabine|to be used for CNS prophylaxis
544501|NCT00073957|Drug|liposomal cytarabine|to be used as CNS prophylaxis
544502|NCT00073957|Radiation|yttrium Y 90 ibritumomab tiuxetan|
544503|NCT00073944|Drug|forodesine hydrochloride|
544504|NCT00073931|Biological|filgrastim|5 µg/kg/day subcutaneously
544505|NCT00073931|Biological|sargramostim|250µg/m2/d subcutaneously
544506|NCT00073931|Procedure|autologous bone marrow transplantation|autologous stem cells given via central catheter
544507|NCT00073931|Procedure|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
544508|NCT00073931|Radiation|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with ~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
544509|NCT00073918|Drug|cyclophosphamide|Given IV
544510|NCT00073918|Drug|etoposide|Given IV
544511|NCT00073918|Radiation|iodine I 131 tositumomab|Given IV
544512|NCT00073918|Procedure|quality-of-life assessment|Ancillary study
544513|NCT00073918|Procedure|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
544514|NCT00073905|Drug|capecitabine plus gemcitabine|capecitabine plus gemcitabine
544515|NCT00073892|Drug|PI-88|250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
544516|NCT00073879|Biological|alemtuzumab|
544517|NCT00073879|Biological|graft-versus-tumor induction therapy|
544518|NCT00073879|Drug|cyclophosphamide|
544519|NCT00073879|Drug|fludarabine phosphate|
544520|NCT00073879|Procedure|allogeneic bone marrow transplantation|
544521|NCT00073879|Procedure|peripheral blood stem cell transplantation|
544522|NCT00073866|Drug|celecoxib|
544523|NCT00073866|Drug|docetaxel|
544524|NCT00073866|Drug|irinotecan hydrochloride|
544525|NCT00073853|Procedure|Autologous Incubated Macrophages (cell therapy)|
544526|NCT00073840|Drug|levalbuterol|"Levalbuterol 90 ųg QID (manufacturing sites A or B);~Racemic Albuterol 180 ųg QID;~Placebo QID"
544527|NCT00073827|Drug|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
544528|NCT00073827|Drug|racemic albuterol MDI|racemic albuterol 180 mcg QID
544529|NCT00073827|Drug|Placebo|Placebo MDI QID
544530|NCT00004857|Biological|alemtuzumab|30 mg subQ injection tiw for 6 weeks
544531|NCT00004857|Drug|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
544532|NCT00004261|Drug|EF5|
544533|NCT00004261|Other|flow cytometry|
544534|NCT00004261|Other|fluorescent antibody technique|
544535|NCT00004261|Other|immunohistochemistry staining method|
544536|NCT00004261|Procedure|biopsy|
544537|NCT00004242|Drug|fluorouracil|
544538|NCT00004242|Drug|gemcitabine hydrochloride|
544539|NCT00004242|Drug|oxaliplatin|
544540|NCT00003927|Biological|filgrastim|
544541|NCT00003927|Drug|amifostine trihydrate|
544542|NCT00003927|Drug|cyclophosphamide|
544543|NCT00003927|Drug|doxorubicin hydrochloride|
544544|NCT00003927|Drug|paclitaxel|
544545|NCT00003927|Procedure|peripheral blood stem cell transplantation|
544546|NCT00073814|Drug|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
544547|NCT00073814|Drug|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
544548|NCT00073814|Drug|Placebo|Placebo MDI QID
544549|NCT00073788|Procedure|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
544550|NCT00003811|Biological|bleomycin sulfate|
544551|NCT00003811|Drug|amifostine trihydrate|
544552|NCT00003811|Drug|cisplatin|
544553|NCT00003811|Drug|etoposide|
544554|NCT00003811|Procedure|conventional surgery|
544555|NCT00003777|Drug|amifostine trihydrate|
544556|NCT00003777|Drug|cisplatin|
544557|NCT00003777|Drug|fluorouracil|
544558|NCT00003777|Procedure|surgical procedure|
544559|NCT00003777|Radiation|radiation therapy|
544711|NCT00073333|Behavioral|Social Skills Training|Social skills training once per week
544560|NCT00003761|Biological|rV-DF3/MUC1|"- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.~-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination~Level 1 4.76 x 106 PFU~Level 2 4.76 x 107 PFU~Level 3 4.76 x 108 PFU"
544561|NCT00003729|Drug|cytarabine|
544562|NCT00003729|Drug|fludarabine phosphate|
544563|NCT00003729|Drug|idarubicin|
544564|NCT00003734|Drug|flutamide|
544565|NCT00003734|Drug|triptorelin|
544566|NCT00003734|Radiation|radiation therapy|
544567|NCT00073762|Drug|DVS-233 SR|
544568|NCT00073749|Drug|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
544569|NCT00073736|Drug|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
544570|NCT00073736|Drug|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
544571|NCT00073736|Drug|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
544572|NCT00073736|Drug|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
544573|NCT00073736|Drug|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
544574|NCT00073723|Drug|ABI-007|
544575|NCT00003716|Biological|rituximab|
544576|NCT00003694|Drug|omacetaxine mepesuccinate|Given IV
544577|NCT00003694|Drug|cytarabine|Given IV
544578|NCT00003694|Other|laboratory biomarker analysis|Correlative studies
544579|NCT00003679|Drug|cyclophosphamide|
544580|NCT00003679|Drug|docetaxel|
544581|NCT00003679|Drug|doxorubicin hydrochloride|
544582|NCT00003679|Drug|tamoxifen citrate|
544583|NCT00003679|Procedure|conventional surgery|
544584|NCT00003679|Radiation|radiation therapy|
544585|NCT00003598|Drug|tretinoin|
544586|NCT00003450|Biological|Ad5CMV-p53 gene|
544587|NCT00073710|Drug|Zemplar|
544588|NCT00073710|Procedure|42 Ca carbonate absorption via single tracer method|
544589|NCT00073710|Drug|Calcijex|
544590|NCT00073697|Drug|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
544591|NCT00073697|Behavioral|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
544592|NCT00073697|Other|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
544593|NCT00073684|Behavioral|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
544594|NCT00073684|Behavioral|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
544595|NCT00073684|Behavioral|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
544596|NCT00073684|Behavioral|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
544597|NCT00073684|Behavioral|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
544598|NCT00073671|Behavioral|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
544599|NCT00073671|Other|Usual care|Participants receive usual care
544600|NCT00073658|Drug|Citalopram|
544601|NCT00073658|Drug|Risperidone|
544602|NCT00073645|Behavioral|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
544603|NCT00073645|Behavioral|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
544604|NCT00073632|Behavioral|Acceptance Based Behavioral Therapy|
544605|NCT00073619|Behavioral|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
544606|NCT00003426|Drug|gemcitabine hydrochloride|
544607|NCT00003426|Radiation|radiation therapy|
544608|NCT00003414|Biological|aldesleukin|
544609|NCT00003414|Biological|recombinant interferon gamma|
544610|NCT00003414|Drug|busulfan|
544611|NCT00003414|Drug|cyclophosphamide|
544612|NCT00003414|Drug|cyclosporine|
544613|NCT00003414|Procedure|peripheral blood stem cell transplantation|
544614|NCT00003414|Radiation|radiation therapy|
544615|NCT00003409|Drug|motexafin gadolinium|
544616|NCT00003409|Radiation|radiation therapy|
544617|NCT00003388|Biological|filgrastim|
544618|NCT00003388|Drug|cyclophosphamide|
544619|NCT00003388|Drug|cytarabine|
544620|NCT00003388|Drug|methotrexate|
544621|NCT00003388|Drug|pegylated liposomal doxorubicin hydrochloride|
544622|NCT00003388|Drug|prednisone|
544623|NCT00003388|Drug|vincristine sulfate|
544624|NCT00003388|Radiation|radiation therapy|
544625|NCT00073593|Drug|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) >300 seconds (s).
544626|NCT00073593|Drug|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of >300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
544627|NCT00073593|Drug|Protamine|Per institutional practice. Batches from hospital stock.
544628|NCT00073580|Drug|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) >300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
544629|NCT00073554|Drug|Alfimeprase|
544630|NCT00073541|Drug|EMD 72000|
544631|NCT00073528|Drug|Lapatinib (GW572016)|1500 mg orally once a day
544632|NCT00073528|Drug|Letrozole|2.5 mg orally once a day
544633|NCT00003387|Drug|carboplatin|
544634|NCT00003387|Drug|chemotherapy|
544635|NCT00003387|Drug|paclitaxel|
544636|NCT00003387|Radiation|radiation therapy|
544637|NCT00003313|Biological|filgrastim|
544638|NCT00003313|Drug|amifostine trihydrate|
544639|NCT00003313|Drug|carboplatin|
544640|NCT00003313|Drug|paclitaxel|
544641|NCT00003313|Radiation|radiation therapy|
544642|NCT00003253|Drug|paclitaxel|
544643|NCT00003253|Other|antitumor drug screening assay|
544644|NCT00003202|Drug|cisplatin|
544645|NCT00003202|Drug|gemcitabine hydrochloride|
544646|NCT00003202|Radiation|radiation therapy|
544647|NCT00003191|Drug|fenretinide|
544648|NCT00073515|Drug|Alfimeprase|
544649|NCT00073502|Drug|OSI-7904L|
544650|NCT00073489|Drug|OSI-461|
544651|NCT00073463|Genetic|tgAAVCF|
544652|NCT00003167|Biological|Ad5CMV-p53 gene|Given intravesically
544653|NCT00003130|Drug|paclitaxel|
544654|NCT00003060|Biological|filgrastim|
544655|NCT00003060|Drug|busulfan|
544656|NCT00003060|Drug|cyclophosphamide|
544657|NCT00003060|Drug|cyclosporine|
544658|NCT00003060|Drug|methotrexate|
544659|NCT00003060|Procedure|allogeneic bone marrow transplantation|
544660|NCT00003037|Drug|cisplatin|
544661|NCT00003037|Drug|docetaxel|
544662|NCT00003037|Drug|gemcitabine hydrochloride|
544663|NCT00002989|Drug|busulfan|
544664|NCT00002989|Drug|cyclophosphamide|
544665|NCT00002989|Drug|idarubicin|
544666|NCT00002989|Drug|melphalan|
544667|NCT00002989|Radiation|radiation therapy|
544668|NCT00073476|Drug|traxiprodil (CP-101,606)|
544669|NCT00073450|Drug|Farnesyl Protein Transferase Inhibitor|
544670|NCT00073437|Drug|Infliximab|
544671|NCT00002940|Drug|hydroxyurea|
544672|NCT00002836|Biological|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
544673|NCT00002836|Drug|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
544674|NCT00002836|Drug|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
544675|NCT00002836|Drug|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
544676|NCT00002836|Drug|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
544677|NCT00002836|Drug|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
544678|NCT00002836|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
544679|NCT00002828|Drug|fluorouracil|
544680|NCT00002828|Drug|raltitrexed|
544681|NCT00002812|Drug|asparaginase|Given IV
544682|NCT00002812|Drug|cyclophosphamide|Given IV
544683|NCT00002812|Drug|cytarabine|Given IV
544684|NCT00002812|Drug|daunorubicin hydrochloride|Given IV
544685|NCT00002812|Drug|dexamethasone|Given IV
544686|NCT00002812|Drug|doxorubicin hydrochloride|Given IV
544687|NCT00002812|Drug|idarubicin|Given IV
544688|NCT00002812|Drug|mercaptopurine|Given IV
544689|NCT00002812|Drug|methotrexate|Given PO
544690|NCT00002812|Drug|pegaspargase|Given IV
544691|NCT00002812|Drug|prednisone|Given PO
544692|NCT00002812|Drug|thioguanine|Given IV
544693|NCT00002812|Drug|vincristine sulfate|Given IV
544694|NCT00002812|Radiation|radiation therapy|
544695|NCT00002761|Biological|filgrastim|
544696|NCT00002761|Biological|recombinant interferon gamma|
544697|NCT00002761|Drug|busulfan|
544698|NCT00002761|Drug|cyclophosphamide|
544699|NCT00002761|Drug|cyclosporine|
544700|NCT00002761|Drug|cytarabine|
544701|NCT00002761|Drug|idarubicin|
544702|NCT00002761|Procedure|peripheral blood stem cell transplantation|
544703|NCT00073411|Drug|duloxetine|
544704|NCT00073411|Drug|escitalopram|
544705|NCT00073411|Drug|placebo|
544706|NCT00073385|Drug|Pivanex|
544707|NCT00073385|Drug|Docetaxel|
544708|NCT00073372|Drug|Abciximab|
544709|NCT00073359|Behavioral|Cognitive Behavioral Therapy|
544710|NCT00073346|Behavioral|Cognitive Behavioral Treatment|
544793|NCT00072826|Drug|Acetylcholine|
544712|NCT00073333|Behavioral|Exposure Treatment|Exposure once per week
544713|NCT00073333|Behavioral|Placebo|Placebo
544714|NCT00073320|Drug|Paliperidone Palmitate|
544715|NCT00073307|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
544716|NCT00073307|Drug|Placebo|Placebo
544717|NCT00036920|Drug|canfosfamide hydrochloride|
544718|NCT00027521|Biological|bleomycin sulfate|
544719|NCT00027521|Drug|electroporation therapy|
544720|NCT00025532|Other|iodine I 131 monoclonal antibody CC49-deltaCH2|
544721|NCT00002561|Biological|bleomycin sulfate|10 units/m2
544722|NCT00002561|Drug|dacarbazine|375mg/m2
544723|NCT00002561|Drug|doxorubicin hydrochloride|25mg/m2
544724|NCT00002561|Drug|vinblastine|6mg/m2
544725|NCT00002561|Radiation|radiation therapy|35Gy in 20 fractions (daily)
544726|NCT00073398|Biological|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
544727|NCT00073294|Behavioral|diet|
544728|NCT00073281|Procedure|Islet transplantation|
544729|NCT00073255|Drug|hokt3g1 (ALA-ALA)|
544730|NCT00073268|Behavioral|Exercise|
544731|NCT00073242|Drug|Leptin|leptin administration
544732|NCT00073242|Behavioral|Dietary modification|Subjects lose 10% of body weight via dietary restriction
544733|NCT00073242|Drug|T3 repletion|administer T3
544734|NCT00073216|Biological|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
544735|NCT00073216|Biological|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
544736|NCT00073203|Drug|R228060|
544737|NCT00073203|Drug|Placebo and Paroxetine|
544738|NCT00073177|Drug|Roflumilast|
544739|NCT00073190|Behavioral|Osteoporosis Education|
544740|NCT00073164|Drug|Divalproex Sodium Extended-Release Tablets|
544741|NCT00073164|Drug|Olanzapine|
544742|NCT00073164|Drug|Risperidone|
544743|NCT00073151|Drug|ABT-751|
544744|NCT00073138|Drug|ABT-751|
544745|NCT00073125|Drug|ABT-510/Thrombospondin-1 mimetic|
544746|NCT00073112|Drug|ABT-751|
544747|NCT00073047|Drug|Daclizumab|
544748|NCT00073034|Drug|EAA-090|
544749|NCT00073073|Drug|Exemestane|exemestane 25 mg by mouth (PO) every day for two years
544750|NCT00073073|Dietary Supplement|Calcium carbonate|calcium carbonate 1200 mg PO every day x 2 years
544751|NCT00073073|Dietary Supplement|Vitamin D|Vitamin D 400 international units PO every day x 2 years
544752|NCT00073021|Drug|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
544753|NCT00073021|Drug|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
544754|NCT00073008|Drug|GW572016 (lapatinib)|tyrosine kinase inhibitor
544755|NCT00072995|Behavioral|Four Diets Differing in Macronutrient Composition|
544756|NCT00072995|Behavioral|Diets Low in Saturated Fat|
544757|NCT00072982|Drug|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
544758|NCT00072982|Drug|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
544759|NCT00072982|Drug|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
544760|NCT00072943|Drug|anti-Interferon-gamma monoclonal antibody|
544761|NCT00072930|Biological|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
544762|NCT00072930|Biological|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
544763|NCT00072904|Drug|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
544764|NCT00072904|Drug|Repaglinide|0.5mg tab with meals tid
544765|NCT00072891|Behavioral|telephone counseling|
544766|NCT00072969|Drug|Daclizumab|
544767|NCT00072865|Drug|Pemetrexed|
544768|NCT00072865|Drug|Carboplatin|
544769|NCT00072852|Drug|Irinotecan|
544770|NCT00072839|Drug|ALX-0600|teduglutide
544771|NCT00072839|Drug|placebo|placebo solution injected subcutaneously
544772|NCT00072839|Drug|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
544773|NCT00072839|Drug|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
544774|NCT00072839|Drug|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
544775|NCT00072839|Drug|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
544776|NCT00072787|Drug|S-1|
544777|NCT00072787|Drug|cisplatin|
544778|NCT00072774|Drug|DVS-233 SR|
544779|NCT00072761|Procedure|transfusion therapy|Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
544780|NCT00072748|Drug|EKB-569|
544781|NCT00072722|Drug|CC-4047|
544782|NCT00017017|Drug|paclitaxel poliglumex|
544783|NCT00014677|Biological|interleukin-4 PE38KDEL cytotoxin|
544784|NCT00014677|Procedure|conventional surgery|
544785|NCT00014638|Drug|letrozole|
544786|NCT00014352|Drug|docetaxel|
544787|NCT00014352|Drug|doxorubicin hydrochloride|
544788|NCT00014352|Drug|estramustine phosphate sodium|
544789|NCT00014352|Drug|ketoconazole|
544790|NCT00014352|Drug|warfarin|
544791|NCT00072826|Drug|Oxypurinol|
544792|NCT00072826|Drug|L-NMMA|
544796|NCT00072670|Drug|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m^2) weekly as 3-hour infusion or 1.5 mg/m^2 or 1.2 mg/m^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
544797|NCT00012090|Drug|bicalutamide|
544798|NCT00012090|Drug|goserelin acetate|
544799|NCT00010309|Biological|MART-1 antigen|
544800|NCT00010309|Biological|gp100 antigen|
544801|NCT00008372|Drug|chloroquinoxaline sulfonamide|
544802|NCT00006367|Biological|filgrastim|
544803|NCT00006367|Drug|busulfan|
544804|NCT00006367|Drug|cytarabine|
544805|NCT00006367|Drug|idarubicin|
544806|NCT00006367|Procedure|peripheral blood stem cell transplantation|
544807|NCT00006224|Drug|gemcitabine hydrochloride|
544808|NCT00072735|Procedure|Electrocardiogram|
544809|NCT00072657|Behavioral|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
544810|NCT00072657|Behavioral|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
544811|NCT00072657|Behavioral|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
544812|NCT00072631|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
544813|NCT00072618|Drug|Exisulind|
544814|NCT00072501|Procedure|breast imaging study|
544815|NCT00072501|Procedure|comparison of screening methods|
544816|NCT00072501|Procedure|magnetic resonance imaging|
544817|NCT00072501|Procedure|radiomammography|
544818|NCT00072501|Procedure|ultrasound imaging|
544819|NCT00072488|Procedure|computed tomography|
544820|NCT00072488|Procedure|magnetic resonance imaging|
544821|NCT00072488|Procedure|positron emission tomography|
544822|NCT00072475|Drug|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or > tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
544823|NCT00072462|Drug|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
544824|NCT00072462|Drug|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
544825|NCT00072449|Biological|rituximab|
544826|NCT00072436|Drug|gemcitabine hydrochloride|Given IV
544827|NCT00072436|Drug|alvocidib|Given IV
544828|NCT00072436|Other|pharmacological study|Correlative studies
544829|NCT00072410|Radiation|yttrium Y 90 monoclonal antibody Hu3S193|
544830|NCT00072384|Drug|liposomal vincristine sulfate|Given IV
544831|NCT00072384|Procedure|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
544832|NCT00072384|Procedure|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
544833|NCT00072384|Drug|carboplatin|Given IV
544834|NCT00072384|Drug|etoposide|Given IV
544835|NCT00072384|Biological|filgrastim|Given subcutaneously
544836|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
544837|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
544838|NCT00072345|Drug|lomustine|
544839|NCT00072345|Drug|temozolomide|
544840|NCT00072345|Drug|thalidomide|
544841|NCT00072332|Drug|cisplatin|
544842|NCT00072332|Drug|edotecarin|
544843|NCT00072319|Biological|filgrastim|
544844|NCT00072319|Drug|cyclophosphamide|
544845|NCT00072319|Drug|epirubicin hydrochloride|
544846|NCT00072319|Drug|paclitaxel|
544847|NCT00072319|Procedure|adjuvant therapy|
544848|NCT00072319|Procedure|neoadjuvant therapy|
544849|NCT00072293|Procedure|Axillary lymph node dissection|Axillary lymph node dissection
544850|NCT00072293|Procedure|No axillary lymph node dissection|Therapeutic conventional surgery
544851|NCT00072280|Biological|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose < 1yr 0.025 mg/kg > or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
544852|NCT00072280|Drug|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
544853|NCT00072280|Drug|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
544854|NCT00072280|Drug|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
549010|NCT00046826|Drug|docetaxel|
544855|NCT00072280|Drug|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
544856|NCT00072280|Procedure|Conventional Surgery|"Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections."
544857|NCT00072280|Biological|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
544858|NCT00072280|Biological|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
544859|NCT00072267|Drug|7-hydroxystaurosporine|
544860|NCT00072267|Drug|topotecan hydrochloride|
544861|NCT00072228|Drug|gemcitabine|
544862|NCT00072228|Drug|soblidotin|
544863|NCT00072228|Procedure|chemotherapy|
544864|NCT00072215|Drug|cisplatin|given IV
544865|NCT00072215|Drug|ifosfamide|given IV
544866|NCT00072215|Drug|paclitaxel|given IV
544867|NCT00072215|Drug|vinblastine|given IV
544868|NCT00072189|Drug|7-hydroxystaurosporine|Given IV
544869|NCT00072189|Other|laboratory biomarker analysis|Correlative studies
544870|NCT00072189|Other|pharmacological study|Correlative studies
544871|NCT00072176|Drug|temsirolimus|Given IV
544872|NCT00072176|Other|laboratory biomarker analysis|Correlative studies
544873|NCT00072163|Drug|temozolomide|Given orally
544874|NCT00072163|Drug|thalidomide|Given orally
544875|NCT00072150|Drug|bortezomib|Given IV
544876|NCT00072137|Biological|Recombinant Fowlpox-TRICOM Vaccine|Given intravesically
544877|NCT00072137|Biological|Recombinant Fowlpox GM-CSF Vaccine Adjuvant|Given intravesically
544878|NCT00072137|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy
544879|NCT00072137|Other|Pharmacological Study|Correlative studies
544880|NCT00072137|Other|Laboratory Biomarker Analysis|Correlative studies
544881|NCT00072124|Drug|cisplatin|
544882|NCT00072124|Drug|dacarbazine|
544883|NCT00072124|Procedure|conventional surgery|
544884|NCT00072111|Biological|anakinra|
544885|NCT00072098|Biological|adenovirus vector|
544886|NCT00072098|Biological|interleukin-12 gene|
544887|NCT00072085|Biological|aldesleukin|
544888|NCT00072085|Biological|gp100 antigen|
544889|NCT00072085|Biological|incomplete Freund's adjuvant|
544890|NCT00072072|Drug|celecoxib|
544891|NCT00072072|Drug|erlotinib hydrochloride|
544892|NCT00072059|Biological|methoxy polyethylene glycol epoetin beta|
544893|NCT00072046|Biological|bevacizumab|10mg/kg IV infusion on Days 1 & 15 of each cycle
544894|NCT00072046|Biological|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
544895|NCT00072033|Drug|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
544896|NCT00072020|Drug|zoledronic acid|
544897|NCT00072020|Procedure|adjuvant therapy|
544898|NCT00072020|Procedure|neoadjuvant therapy|
544899|NCT00072007|Biological|filgrastim|filgrastim
544900|NCT00072007|Biological|rituximab|rituximab
544901|NCT00072007|Drug|CHOP regimen|CHOP regimen
544902|NCT00072007|Drug|cladribine|cladribine
544903|NCT00072007|Drug|cyclophosphamide|cyclophosphamide
544904|NCT00072007|Drug|doxorubicin hydrochloride|doxorubicin hydrochloride
544905|NCT00072007|Drug|prednisone|prednisone
544906|NCT00072007|Drug|vincristine sulfate|vincristine sulfate
544907|NCT00071994|Drug|gefitinib|Given orally
544908|NCT00071994|Other|laboratory biomarker analysis|Correlative studies
544909|NCT00071981|Biological|incomplete Freund's adjuvant|Given by injection
544910|NCT00071981|Biological|melanoma helper peptide vaccine|Given by injection
544911|NCT00071981|Biological|multi-epitope melanoma peptide vaccine|Given by injection
544912|NCT00071981|Biological|sargramostim|Given by injection
544913|NCT00071981|Biological|tetanus peptide melanoma vaccine|Given by injection
544914|NCT00071968|Drug|temsirolimus|
544915|NCT00071968|Procedure|conventional surgery|
544916|NCT00071968|Procedure|neoadjuvant therapy|
544917|NCT00071955|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
544918|NCT00071955|Biological|sargramostim|
544919|NCT00071942|Biological|recombinant vaccinia-MUC1 vaccine|Given intradermally
544920|NCT00071942|Biological|recombinant vaccinia-TRICOM vaccine|Given intradermally
544921|NCT00071942|Other|laboratory biomarker analysis|Correlative studies
544922|NCT00071942|Procedure|quality-of-life assessment|Ancillary studies
544923|NCT00071929|Drug|oxaliplatin|
544924|NCT00003141|Biological|filgrastim|Given IV
544925|NCT00003141|Drug|carboplatin|Given IV
544926|NCT00003141|Drug|cisplatin|Given IV
544927|NCT00003141|Drug|cyclophosphamide|Given IV
544928|NCT00003141|Drug|etoposide|Given IV
544929|NCT00003141|Drug|thiotepa|Given IV
544930|NCT00003141|Drug|vincristine sulfate|Given IV
544931|NCT00003141|Procedure|conventional surgery|
544932|NCT00003141|Procedure|peripheral blood stem cell transplantation|
544933|NCT00072605|Drug|VRC-EBODNA012-00-VP|
544934|NCT00072592|Drug|Rituximab|
544935|NCT00072579|Biological|sargramostim|
544936|NCT00072566|Biological|Bevacizumab|Given IV
544937|NCT00072566|Drug|Cyclophosphamide|Given PO
544938|NCT00072566|Other|Laboratory Biomarker Analysis|Correlative studies
544939|NCT00072553|Drug|celecoxib|
544940|NCT00072553|Drug|fluorouracil|
544941|NCT00072553|Drug|leucovorin calcium|
544942|NCT00072553|Drug|oxaliplatin|
544943|NCT00072553|Procedure|adjuvant therapy|
549014|NCT00045747|Drug|fluorouracil|
544944|NCT00072553|Procedure|conventional surgery|
544945|NCT00072553|Procedure|neoadjuvant therapy|
544946|NCT00072540|Drug|celecoxib|
544947|NCT00072540|Procedure|anti-cytokine therapy|
544948|NCT00072540|Procedure|antiangiogenesis therapy|
544949|NCT00072540|Procedure|biological therapy|
544950|NCT00072540|Procedure|cancer prevention intervention|
544951|NCT00072540|Procedure|chemoprevention of cancer|
544952|NCT00072540|Procedure|enzyme inhibitor therapy|
544953|NCT00072540|Procedure|growth factor antagonist therapy|
544954|NCT00072527|Drug|carboplatin|IV
544955|NCT00072527|Drug|cisplatin|IV
544956|NCT00072527|Drug|etoposide|IV
544957|NCT00072527|Drug|irinotecan hydrochloride|IV
544958|NCT00072527|Radiation|radiation therapy|
544959|NCT00072514|Drug|gemcitabine hydrochloride|Given IV
544960|NCT00072514|Drug|carboplatin|Given IV
544961|NCT00072514|Drug|dexamethasone|Given PO
544962|NCT00072514|Biological|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
544963|NCT00071851|Biological|VRC-HIVDNA009-00-VP|
544964|NCT00071812|Drug|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
544965|NCT00071812|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
544966|NCT00071812|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
544967|NCT00071812|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
544968|NCT00071799|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
544969|NCT00071799|Other|Physician Choice|"Physician Choice was one of three options:~Best supportive care (BSC) alone,~Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or~Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).~All three options included best supportive care"
544970|NCT00006008|Drug|arsenic trioxide|
544971|NCT00005964|Biological|filgrastim|
544972|NCT00005964|Drug|cyclophosphamide|
544973|NCT00005964|Drug|doxorubicin hydrochloride|
544974|NCT00005964|Drug|etoposide|
544975|NCT00005964|Drug|prednisone|
544976|NCT00005964|Drug|vincristine sulfate|
544977|NCT00005962|Biological|sargramostim|
544978|NCT00005962|Drug|cyclophosphamide|
544979|NCT00005962|Drug|cytarabine|
544980|NCT00005962|Drug|gemtuzumab ozogamicin|
544981|NCT00005962|Drug|liposomal daunorubicin citrate|
544982|NCT00005962|Drug|topotecan hydrochloride|
544983|NCT00005576|Biological|monoclonal antibody Ch14.18|Given IV
544984|NCT00005576|Drug|isotretinoin|Given orally
544985|NCT00005576|Biological|aldesleukin|Given IV
544986|NCT00005576|Biological|sargramostim|Given IV
544987|NCT00005094|Drug|celecoxib|Given orally
544988|NCT00005094|Other|placebo|Given orally
544989|NCT00071890|Drug|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
544990|NCT00071890|Drug|HAART|HAART from week 0 to week 24
544991|NCT00071890|Drug|Treatment interruption|HAART is interrupted from week 24 in both arms
544992|NCT00071877|Drug|Replagal|
544993|NCT00005072|Biological|Leuvectin|1000 ug of Leuvectin injected intratumorally
544994|NCT00005046|Drug|chemotherapy|
544995|NCT00005046|Drug|paclitaxel|
544996|NCT00004206|Drug|FOLFOX regimen|
544997|NCT00004206|Drug|fluorouracil|
544998|NCT00004206|Drug|leucovorin calcium|
544999|NCT00004206|Drug|oxaliplatin|
545000|NCT00004093|Drug|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
545001|NCT00004093|Drug|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
545002|NCT00004093|Drug|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
545003|NCT00004093|Drug|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
545004|NCT00004093|Radiation|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
545005|NCT00004093|Drug|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
549108|NCT00045097|Drug|ixabepilone|
545006|NCT00004093|Drug|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
545007|NCT00071838|Drug|Daclizumab|
545008|NCT00071773|Procedure|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
545009|NCT00071773|Procedure|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
545010|NCT00071760|Drug|GW433908|Fosamprenavir suspension bid
545011|NCT00071760|Drug|ritonavir|Ritonavir solution bid
545012|NCT00071747|Drug|lamotrigine|
545013|NCT00071721|Drug|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
545014|NCT00071721|Drug|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
545015|NCT00071708|Drug|Duloxetine Hydrochloride|
545016|NCT00071695|Drug|Duloxetine Hydrochloride|
545017|NCT00071695|Drug|Venlafaxine Extended Release|
545018|NCT00071669|Procedure|Acupuncture|
545019|NCT00071656|Behavioral|Psychosocial (behavioral) Intervention|
545020|NCT00071643|Behavioral|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
545021|NCT00071643|Drug|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
545022|NCT00071643|Other|Placebo|Participants will receive a placebo pill.
545023|NCT00071630|Behavioral|Cognitive Behavioral Therapy|
545024|NCT00071617|Behavioral|Youth-Nominated Support Team|
545025|NCT00071604|Behavioral|Medication Adherence Therapy|
545026|NCT00071604|Behavioral|Friendly Support Group|
545027|NCT00071591|Behavioral|Functional Adaptation Skills Training (FAST)|
545028|NCT00071578|Behavioral|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
545029|NCT00071578|Behavioral|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
545030|NCT00071552|Drug|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
545031|NCT00071552|Drug|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
545032|NCT00071539|Drug|TP-38|Recombinant chimeric protein
545033|NCT00071539|Drug|TP38|recombinant chimeric protein
545034|NCT00004074|Biological|recombinant interleukin-12|Given IV
545035|NCT00004074|Biological|ABI-007/carboplatin/trastuzumab|Given IV
545036|NCT00004050|Biological|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
545037|NCT00004025|Biological|aldesleukin|
545038|NCT00004025|Biological|dendritic cell-gp100-MART-1 antigen vaccine|
545039|NCT00003794|Procedure|psychosocial assessment and care|
545040|NCT00003794|Procedure|quality-of-life assessment|
545041|NCT00003648|Genetic|DNA stability analysis|
545042|NCT00003648|Genetic|gene rearrangement analysis|
545043|NCT00071513|Behavioral|CAST-T/HSTS|Skills training small group.
545044|NCT00071513|Behavioral|Brief Intervention|Assessment of needs and referral to services as needed.
545045|NCT00071500|Device|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
545046|NCT00071487|Drug|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
545047|NCT00071487|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
545048|NCT00071487|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
545049|NCT00071487|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
545050|NCT00003595|Biological|filgrastim|
545051|NCT00003595|Biological|rituximab|
545052|NCT00003595|Drug|CHOP regimen|
545053|NCT00003595|Drug|cyclophosphamide|
545054|NCT00003595|Drug|doxorubicin hydrochloride|
545055|NCT00003595|Drug|prednisone|
545056|NCT00003595|Drug|vincristine sulfate|
545057|NCT00003266|Drug|methylphenidate hydrochloride|
545058|NCT00003266|Procedure|quality-of-life assessment|
545059|NCT00003234|Drug|vinorelbine tartrate|
545060|NCT00003190|Drug|cytarabine|Given IV
545061|NCT00003190|Drug|daunorubicin hydrochloride|Given IV
545062|NCT00003190|Drug|etoposide|Given IV
545063|NCT00003190|Drug|valspodar|Given IV
545064|NCT00003126|Drug|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
545065|NCT00071474|Procedure|shamanic healing|
545066|NCT00071461|Drug|bosentan|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
545067|NCT00071461|Drug|Placebo|"Initial dose: 62.5 mg b.i.d. for 4 weeks.~Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).~body weight < 40 kg (90 lb): 62.5 mg b.i.d."
545068|NCT00071448|Drug|insulin human|
545069|NCT00071448|Drug|insulin lispro|
545070|NCT00071448|Drug|insulin aspart|
545071|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
545072|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
545073|NCT00071422|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
545074|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
545075|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
545076|NCT00071409|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
545077|NCT00071396|Drug|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
545078|NCT00071396|Drug|Rituximab|375 mg/m^2 IV infusion on day 1, then 500 mg/m^2 on days 8, 15, and 22.
545079|NCT00033527|Drug|INS316|
545080|NCT00033527|Other|sputum cytology|
545081|NCT00025350|Drug|gefitinib|
545082|NCT00003077|Dietary Supplement|omega-3 fatty acid|
545083|NCT00002935|Drug|porfimer sodium|
545084|NCT00002723|Drug|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
545085|NCT00002723|Drug|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
545086|NCT00002723|Drug|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
545087|NCT00071331|Drug|Tolvaptan|
545088|NCT00071292|Behavioral|stress reduction program|
545089|NCT00071292|Behavioral|meditation|
545090|NCT00030420|Drug|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
545091|NCT00030420|Drug|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
545092|NCT00026260|Drug|semaxanib|
545093|NCT00024206|Drug|orantinib|Given orally
545094|NCT00024206|Other|laboratory biomarker analysis|Correlative studies
545095|NCT00024206|Other|pharmacological study|Correlative studies
545096|NCT00024128|Biological|anti-thymocyte globulin|
545097|NCT00024128|Biological|therapeutic allogeneic lymphocytes|
545098|NCT00024128|Drug|cyclophosphamide|
545099|NCT00024128|Drug|cyclosporine|
545100|NCT00024128|Procedure|peripheral blood stem cell transplantation|
545101|NCT00024128|Radiation|radiation therapy|
545102|NCT00023738|Biological|filgrastim|
545103|NCT00023738|Drug|dacarbazine|
545104|NCT00023738|Drug|doxorubicin hydrochloride|
545105|NCT00023738|Drug|ifosfamide|
545106|NCT00023738|Drug|semaxanib|
545107|NCT00023738|Procedure|conventional surgery|
545108|NCT00023738|Radiation|radiation therapy|
545109|NCT00071279|Drug|SR34006 (idraparinux sodium) Injection|
545110|NCT00071266|Drug|Niacin Extended Release and Lovastatin Tablets|
545111|NCT00071253|Drug|Divalproex Sodium (Delayed-Release Tablets)|
545112|NCT00071253|Drug|Divalproex Sodium (Extended-Release Tablets)|
545113|NCT00071253|Drug|Olanzapine|
545114|NCT00071240|Drug|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
545115|NCT00071214|Biological|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
545116|NCT00071201|Drug|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
545117|NCT00064428|Drug|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
545118|NCT00064428|Other|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
545119|NCT00064428|Drug|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
545120|NCT00064428|Drug|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
545121|NCT00071227|Drug|Triamcinolone Acetonide (TAC-PF)|
545122|NCT00071188|Drug|ZD6474|
545123|NCT00071188|Drug|Paclitaxel|
545124|NCT00071188|Drug|Carboplatin|
545125|NCT00071136|Drug|pemetrexed|
545126|NCT00071136|Drug|gemcitabine|
545127|NCT00071110|Procedure|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20—on the crown of the head and yin tang—on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
545128|NCT00071110|Procedure|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
545129|NCT00071097|Drug|TMC114/rtv|800mg TMC114/100mg rtv once daily
545130|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
545131|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv once daily
549297|NCT00041028|Other|flow cytometry|
545132|NCT00071097|Drug|TMC114/rtv|600mg TMC114/100mg rtv twice daily
545133|NCT00071084|Drug|HuMax-CD4|
545134|NCT00071071|Drug|HuMax-CD4|
545135|NCT00025467|Drug|thalidomide|Given orally
545136|NCT00025467|Other|laboratory biomarker analysis|Correlative studies
545137|NCT00023725|Drug|semaxanib|
545138|NCT00023725|Procedure|conventional surgery|
545139|NCT00023725|Radiation|radiation therapy|
545140|NCT00023699|Drug|gefitinib|
545141|NCT00022282|Drug|shark cartilage extract AE-941|
545142|NCT00016250|Drug|MKC-1|
545143|NCT00015912|Biological|recombinant interferon alfa|Given IV
545144|NCT00015912|Drug|thalidomide|Given orally
545145|NCT00015912|Other|laboratory biomarker analysis|Correlative studies
545146|NCT00015886|Drug|docetaxel|75 milligrams per meter squared intraveneously
545147|NCT00015886|Drug|fluorouracil|350 milligrams intraveneously
545148|NCT00014144|Drug|gefitinib|
545149|NCT00007917|Drug|alvocidib|
545150|NCT00007917|Drug|gemcitabine hydrochloride|
545151|NCT00071032|Biological|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
545152|NCT00071032|Biological|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
545153|NCT00071006|Drug|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
545154|NCT00070993|Drug|creatine monohydrate|
545155|NCT00070980|Procedure|Massage therapy|
545156|NCT00070967|Procedure|Acupuncture|
545157|NCT00070954|Drug|ginkgo biloba|EgB 761
545158|NCT00070954|Other|matched placebo|Inactive look-alike placebo
545159|NCT00070941|Drug|SAM-e|oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
545160|NCT00070941|Drug|oral escitalopram|20mg or 30mg daily in two divided doses, along with placebo SAM-e.
545161|NCT00070941|Drug|placebo|oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
545162|NCT00070928|Drug|valerian|
545163|NCT00070915|Behavioral|Tai chi|
545164|NCT00070915|Behavioral|Mindfulness-based Stress Reduction program|
545165|NCT00070915|Procedure|Therapeutic massage|
545166|NCT00070902|Procedure|Lumbar side-posture spinal adjusting|
545167|NCT00070837|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
545168|NCT00070824|Procedure|acupuncture|
545169|NCT00070811|Procedure|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
545170|NCT00070720|Behavioral|Opinion Leaders, Academic Detailing, Reminders, and Feedback|
545171|NCT00071058|Drug|XR9576 (Tariquidar)|
545172|NCT00070733|Drug|testosterone enanthate|
545173|NCT00070733|Drug|duastride|
545174|NCT00070707|Drug|Mometasone|Mometasone nasal spray 200 mcg/day administered as 2 sprays (50 mcg/spray) in each nostril.
545175|NCT00070707|Drug|Placebo|Matching placebo nasal spray, administered QD as 2 sprays in each nostril.
545176|NCT00070707|Drug|Albuterol/Salbutamol|Albuterol/salbutamol metered dose inhaler (90 mcg/puff) used as needed as asthma rescue medication.
545177|NCT00070876|Behavioral|Mental health communication skills training|
545178|NCT00070863|Behavioral|Individual Cognitive Behavioral Therapy|
545179|NCT00070681|Procedure|Polysomnography|
545180|NCT00070655|Drug|SR34006 (idraparinux sodium) Injection|
545181|NCT00070655|Drug|vitamin K antagonist (warfarin or acenocoumarol) tablets|
545182|NCT00069433|Procedure|Social skills and symptom management training|
545183|NCT00021099|Drug|ixabepilone|Given IV
545184|NCT00017368|Biological|filgrastim|
545185|NCT00017368|Biological|sargramostim|
545186|NCT00017368|Drug|carboplatin|
545187|NCT00017368|Drug|cisplatin|
545188|NCT00017368|Drug|cyclophosphamide|
545189|NCT00017368|Drug|doxorubicin hydrochloride|
545190|NCT00017368|Drug|etoposide|
545191|NCT00017368|Drug|etoposide phosphate|
545192|NCT00017368|Drug|ifosfamide|
545193|NCT00017368|Drug|isotretinoin|
545194|NCT00017368|Drug|melphalan|
545195|NCT00017368|Drug|thiotepa|
545196|NCT00017368|Drug|vincristine sulfate|
545197|NCT00017368|Procedure|conventional surgery|
545198|NCT00017368|Procedure|peripheral blood stem cell transplantation|
545199|NCT00017368|Radiation|radiation therapy|
545200|NCT00003907|Drug|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
545201|NCT00003907|Drug|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
545202|NCT00003907|Drug|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
545203|NCT00003907|Procedure|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
545204|NCT00070759|Drug|Daclizumab|
545205|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
545206|NCT00070642|Drug|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
545290|NCT00070317|Drug|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
545207|NCT00070642|Drug|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:~dacarbazine 850mg/m2"
545208|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
545209|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
545210|NCT00070629|Drug|CPG 7909|CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
545211|NCT00070629|Drug|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
545212|NCT00070629|Drug|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:~Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
545213|NCT00070616|Drug|Palifermin 6 x 60 μg/kg/day|
545214|NCT00070616|Drug|Palifermin 2 x 180 μg/kg/day|
545215|NCT00070616|Radiation|radiotherapy|
545216|NCT00070616|Drug|Chemotherapy|
545217|NCT00070590|Drug|Bosentan|
545218|NCT00007839|Drug|beta alethine|
545219|NCT00006482|Drug|cisplatin|
545220|NCT00006482|Drug|gemcitabine hydrochloride|
545221|NCT00006466|Drug|beta alethine|
545222|NCT00006257|Drug|paclitaxel|
545223|NCT00006257|Drug|semaxanib|
545224|NCT00006121|Drug|oxaliplatin|
545225|NCT00006012|Biological|filgrastim|
545226|NCT00006012|Drug|amifostine trihydrate|
545227|NCT00006012|Drug|cisplatin|
545228|NCT00006012|Drug|etoposide|
545229|NCT00006012|Drug|paclitaxel|
545230|NCT00006012|Drug|topotecan hydrochloride|
545231|NCT00006012|Radiation|radiation therapy|
545232|NCT00006009|Biological|visilizumab|
545233|NCT00005998|Drug|carmustine|
545234|NCT00005998|Drug|cyclophosphamide|
545235|NCT00005998|Drug|cytarabine|
545236|NCT00005998|Drug|dexamethasone|
545237|NCT00005998|Drug|etoposide|
545238|NCT00005998|Drug|filgrastim|
545239|NCT00005998|Drug|mitoxantrone hydrochloride|
545240|NCT00005998|Drug|retrovirus vector LN|
545241|NCT00005998|Procedure|in vitro-treated peripheral blood stem cell transplantation|
545242|NCT00005998|Procedure|peripheral blood stem cell transplantation|
545243|NCT00005998|Procedure|radiation therapy|
545244|NCT00005800|Biological|Filgrastim|
545245|NCT00005800|Drug|Docetaxel|
545246|NCT00005800|Drug|Doxorubicin|
545247|NCT00005800|Procedure|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
545248|NCT00005794|Drug|perifosine|
545249|NCT00070694|Drug|MDL100.907|
545250|NCT00070564|Biological|pegfilgrastim|Given IV
545251|NCT00070564|Drug|AC regimen|Given IV
545252|NCT00070564|Drug|cyclophosphamide|Given IV
545253|NCT00070564|Drug|doxorubicin hydrochloride|Given IV
545254|NCT00070564|Drug|paclitaxel|Given IV
545255|NCT00070551|Biological|GTI-2040|Given IV
545256|NCT00070551|Drug|cytarabine|Given IV
545257|NCT00070551|Other|pharmacological study|Optional correlative studies
545258|NCT00070551|Other|laboratory biomarker analysis|Optional correlative studies
545259|NCT00070538|Drug|cytarabine|
545260|NCT00070538|Drug|laromustine|
545261|NCT00070525|Drug|tipifarnib|Given orally
545262|NCT00070499|Drug|Dasatinib|Given PO
545263|NCT00070499|Drug|Imatinib Mesylate|Given PO
545264|NCT00070499|Other|Laboratory Biomarker Analysis|Correlative studies
545265|NCT00070486|Drug|carboplatin|given IV
545266|NCT00070486|Drug|celecoxib|given PO
545267|NCT00070486|Drug|gemcitabine hydrochloride|given IV
545268|NCT00070486|Drug|zileuton|given PO
545269|NCT00070473|Drug|pemetrexed disodium|
545270|NCT00070447|Biological|rituximab|
545271|NCT00070447|Drug|cyclophosphamide|
545272|NCT00070447|Drug|doxorubicin hydrochloride|
545273|NCT00070447|Drug|prednisone|
545274|NCT00070447|Drug|vincristine sulfate|
545275|NCT00070447|Radiation|yttrium Y 90 ibritumomab tiuxetan|
545276|NCT00070434|Drug|capecitabine|825mg/m2 BID, PO, daily
545277|NCT00070434|Drug|fluorouracil|Bolus + IV for 46 hrs on Day 1
545278|NCT00070434|Drug|irinotecan hydrochloride|IV infusion over 90 min on Day 1
545279|NCT00070434|Drug|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
545280|NCT00070434|Drug|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
545281|NCT00070434|Radiation|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
545282|NCT00070434|Drug|Pyridoxine|50mg TID, PO daily
545283|NCT00070421|Procedure|complementary or alternative medicine procedure|
545284|NCT00070421|Procedure|management of therapy complications|
545285|NCT00070421|Procedure|psychosocial assessment and care|
545286|NCT00070382|Drug|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
545287|NCT00070382|Drug|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
545288|NCT00070343|Biological|oblimersen sodium|
545289|NCT00070343|Drug|dacarbazine|
545291|NCT00070317|Procedure|Lymph Node Mapping|Undergo lymphatic mapping
545292|NCT00070317|Procedure|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
545293|NCT00070317|Drug|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
545294|NCT00070317|Procedure|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
545295|NCT00070317|Procedure|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
545296|NCT00070317|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
545297|NCT00070317|Procedure|Therapeutic Conventional Surgery|Undergo radical hysterectomy
545298|NCT00070304|Biological|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
545299|NCT00070304|Drug|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
545300|NCT00070304|Drug|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
545301|NCT00070291|Drug|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is > 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
545302|NCT00070278|Drug|cyclophosphamide|
545303|NCT00070278|Drug|epirubicin hydrochloride|
545304|NCT00070278|Drug|gemcitabine hydrochloride|
545305|NCT00070278|Drug|paclitaxel|
545306|NCT00070278|Genetic|comparative genomic hybridization|
545307|NCT00070278|Genetic|microarray analysis|
545308|NCT00070278|Genetic|mutation analysis|
545309|NCT00070278|Procedure|conventional surgery|
545310|NCT00070278|Procedure|neoadjuvant therapy|
545311|NCT00070265|Drug|oxaliplatin|Given IV
545312|NCT00070265|Drug|capecitabine|Given orally
545313|NCT00070265|Procedure|therapeutic conventional surgery|Undergo surgical resection
545314|NCT00070265|Other|laboratory biomarker analysis|Correlative studies
545315|NCT00070252|Drug|Capecitabine|Given PO
545316|NCT00070252|Drug|Docetaxel|Given IV
545317|NCT00070252|Other|Laboratory Biomarker Analysis|Correlative studies
545318|NCT00070252|Other|Pharmacological Study|Correlative studies
545319|NCT00070252|Drug|Tipifarnib|Given orally (PO)
545320|NCT00070239|Drug|alvocidib|Given IV
545321|NCT00070239|Other|pharmacological study|Correlative studies
545322|NCT00070239|Radiation|fludeoxyglucose F 18|Correlative studies
545323|NCT00070239|Other|fluorine F 18 fluorothymidine|Correlative studies
545324|NCT00070239|Procedure|positron emission tomography|Correlative studies
545325|NCT00070213|Drug|FOLFOX regimen|
545326|NCT00070213|Drug|capecitabine|
545327|NCT00070213|Drug|fluorouracil|
545328|NCT00070213|Drug|leucovorin calcium|
545329|NCT00070213|Drug|oxaliplatin|
545330|NCT00070213|Procedure|quality-of-life assessment|
545331|NCT00070200|Biological|filgrastim|
545332|NCT00070200|Drug|cisplatin|
545333|NCT00070200|Drug|cyclophosphamide|
545334|NCT00070200|Drug|doxorubicin hydrochloride|
545335|NCT00070200|Drug|etoposide|
545336|NCT00070200|Drug|isotretinoin|
545337|NCT00070200|Drug|melphalan|
545338|NCT00070200|Drug|topotecan hydrochloride|
545339|NCT00070200|Drug|vincristine sulfate|
545340|NCT00070200|Procedure|conventional surgery|
545341|NCT00070200|Procedure|peripheral blood stem cell transplantation|
545342|NCT00070200|Radiation|radiation therapy|
545343|NCT00070187|Biological|aldesleukin|Given IV
545344|NCT00070187|Biological|filgrastim|Given IV
545345|NCT00070187|Biological|recombinant interferon gamma|Given IV
545346|NCT00070187|Drug|carmustine|Given IV
545347|NCT00070187|Drug|cyclosporine|Given IV
545348|NCT00070187|Drug|cytarabine|Given IV
545349|NCT00070187|Drug|etoposide|Given IV
545350|NCT00070187|Drug|melphalan|Given IV
545351|NCT00070187|Procedure|autologous bone marrow transplantation|
545352|NCT00070187|Procedure|bone marrow ablation with stem cell support|
545353|NCT00070187|Procedure|peripheral blood stem cell transplantation|
545354|NCT00070174|Drug|asparaginase|
545355|NCT00070174|Drug|busulfan|
545356|NCT00070174|Drug|cyclophosphamide|
545357|NCT00070174|Drug|cyclosporine|
545358|NCT00070174|Drug|cytarabine|
545359|NCT00070174|Drug|daunorubicin hydrochloride|
545360|NCT00070174|Drug|etoposide|
545361|NCT00070174|Drug|gemtuzumab ozogamicin|
545362|NCT00070174|Drug|methotrexate|
545363|NCT00070174|Drug|mitoxantrone hydrochloride|
545364|NCT00070174|Procedure|allogeneic bone marrow transplantation|
545365|NCT00070161|Dietary Supplement|EGb761|
545366|NCT00070161|Drug|donepezil hydrochloride|
545367|NCT00070161|Procedure|cognitive assessment|
545368|NCT00070148|Drug|Megestrol Acetate|Megace by mouth for 12 weeks
545369|NCT00070148|Drug|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
545370|NCT00070135|Biological|filgrastim|Given SC
545371|NCT00070135|Biological|Anti-Thymocyte Globulin|Given IV
545372|NCT00070135|Drug|busulfan|Given IV
545373|NCT00070135|Drug|fludarabine phosphate|Given IV
545374|NCT00070135|Drug|methotrexate|Given IV
545375|NCT00070135|Drug|tacrolimus|Given PO or IV
545376|NCT00070135|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
545377|NCT00070122|Drug|oxaliplatin|Given IV
545378|NCT00070122|Drug|leucovorin calcium|Given IV
545379|NCT00070122|Drug|capecitabine|Given orally
545380|NCT00070122|Biological|bevacizumab|Given IV
545381|NCT00070122|Drug|fluorouracil|Given IV
545382|NCT00070122|Other|laboratory biomarker analysis|Correlative studies
545383|NCT00070109|Drug|trabectedin|Given IV
545384|NCT00070109|Other|pharmacological study|Correlative studies
545385|NCT00070096|Drug|ixabepilone|
545386|NCT00070083|Biological|oblimersen sodium|
545387|NCT00070083|Biological|rituximab|
545388|NCT00070083|Drug|cyclophosphamide|
545389|NCT00070083|Drug|doxorubicin hydrochloride|
545390|NCT00070083|Drug|prednisone|
545391|NCT00070083|Drug|vincristine sulfate|
545392|NCT00070070|Biological|BCG vaccine|
545393|NCT00070070|Biological|NY-ESO-1 peptide vaccine|
545394|NCT00070070|Biological|sargramostim|
545395|NCT00070057|Drug|celecoxib|Given orally
545396|NCT00070057|Procedure|therapeutic conventional surgery|Undergo surgery
545397|NCT00070057|Other|pharmacological study|Correlative studies
545398|NCT00070057|Other|laboratory biomarker analysis|Correlative studies
545399|NCT00070031|Drug|edotecarin|
545400|NCT00070018|Biological|rituximab|250 mg/m^2, as part of Zevalin regimen
545401|NCT00070018|Drug|Cyclophosphamide|750 mg/m^2
545402|NCT00070018|Drug|doxorubicin hydrochloride|50 mg/m^2
545403|NCT00070018|Drug|prednisone|100 mg
545404|NCT00070018|Drug|vincristine sulfate|1.4 mg/m^2
545405|NCT00070018|Radiation|radiation therapy|4000-5000 cGy total
545406|NCT00070018|Biological|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
545407|NCT00070018|Biological|Indium-111 ibritumomab tiuxetan|5 mCi
545408|NCT00070005|Procedure|conventional surgery|
545409|NCT00070005|Procedure|management of therapy complications|
545410|NCT00069992|Radiation|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
545411|NCT00069992|Drug|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
545412|NCT00069992|Drug|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
545413|NCT00069966|Biological|filgrastim|
545414|NCT00069966|Biological|rituximab|
545415|NCT00069966|Drug|cisplatin|
545416|NCT00069966|Drug|cytarabine|
545417|NCT00069966|Drug|methylprednisolone|
545418|NCT00069966|Drug|pixantrone dimaleate|
545419|NCT00069966|Procedure|autologous bone marrow transplantation|
545420|NCT00069966|Procedure|peripheral blood stem cell transplantation|
545421|NCT00069953|Biological|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients >70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
545422|NCT00069953|Biological|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
545423|NCT00069953|Drug|cisplatin|During induction therapy, patients receive 15 mg/m^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m^2/day by IV over 1 hour beginning on days 57-61.
545424|NCT00069953|Drug|fluorouracil|During induction therapy, patients receive 650 mg/m^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
545425|NCT00069953|Drug|paclitaxel|During induction therapy, patients receive 200 mg/m^2/day by IV over 2 hours on days 1 and 29.
545426|NCT00069953|Procedure|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
545427|NCT00069953|Radiation|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (> 6 MV) will be used to deliver multiple (> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
545428|NCT00069940|Biological|sargramostim|
545429|NCT00069940|Biological|telomerase: 540-548 peptide vaccine|
545430|NCT00069927|Drug|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
545431|NCT00069927|Drug|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
545432|NCT00006034|Biological|keyhole limpet hemocyanin|Given intradermally and IV
545433|NCT00006034|Drug|doxorubicin hydrochloride|Given IV
545434|NCT00003868|Drug|cyclophosphamide|
545435|NCT00003868|Drug|methotrexate|
545436|NCT00003868|Procedure|allogeneic bone marrow transplantation|
545437|NCT00003868|Procedure|peripheral blood stem cell transplantation|
545438|NCT00003868|Radiation|iodine I 131 monoclonal antibody BC8|
545439|NCT00003868|Radiation|radiation therapy|
545440|NCT00069901|Drug|CT-2103 (poly(L)glutamate-paclitaxel)|
545441|NCT00069901|Drug|carboplatin|
545442|NCT00069888|Drug|Docetaxel|
545443|NCT00069875|Drug|Gemcitabine|
545444|NCT00069875|Drug|LY293111|
545445|NCT00069875|Drug|cisplatin|
545446|NCT00069784|Drug|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
545447|NCT00069784|Drug|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
545448|NCT00069784|Drug|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
545449|NCT00069784|Device|reusable pen device for insulin injection|
545450|NCT00069745|Drug|Satraplatin|
545451|NCT00069745|Drug|Prednisone|
545452|NCT00069719|Drug|Glaucoma therapy|
545453|NCT00069706|Drug|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
545454|NCT00069706|Other|AL-12182 Ophthalmic Solution Vehicle|Placebo
545455|NCT00069706|Drug|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
545608|NCT00068861|Drug|metformin XR|
545456|NCT00069706|Drug|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
545457|NCT00069706|Drug|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
545458|NCT00069862|Drug|Deferitrin (GT56-252)|
545459|NCT00069862|Drug|desferoxamine (DFO)|
545460|NCT00069836|Drug|Rosiglitazone/metformin|
545461|NCT00069823|Drug|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
545462|NCT00069823|Drug|Placebo proton pump inhibitor|Placebo proton pump inhibitor
545463|NCT00069732|Behavioral|qigong|
545464|NCT00069732|Behavioral|acupressure-TAT|
545465|NCT00069849|Drug|ABT-089|
545466|NCT00069758|Drug|SDX-105|
545467|NCT00069641|Biological|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
545468|NCT00069641|Biological|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
545469|NCT00069641|Biological|Placebo|Patients will receive weekly infusions of placebo.
545470|NCT00069524|Drug|oyster mushroom|
545471|NCT00005630|Biological|ras peptide cancer vaccine|
545472|NCT00005630|Biological|sargramostim|
545473|NCT00005629|Biological|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.~Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
545474|NCT00004922|Drug|irinotecan hydrochloride|
545475|NCT00004886|Drug|docetaxel|
545476|NCT00004886|Drug|dofequidar fumarate|
545477|NCT00069654|Procedure|Forearm blood flow study|
545478|NCT00069654|Procedure|Brachial artery reactivity study|
545479|NCT00069654|Procedure|Treadmill exercise test|
545480|NCT00069628|Device|GlucoWatch® G2™ Biographer (GW2B)|
545481|NCT00069628|Device|Continuous Glucose Monitoring System (CGMS)|
545482|NCT00069615|Device|GlucoWatch® G2™ Biographer (GW2B)|
545483|NCT00069615|Device|Continuous Glucose Monitoring System™ (CGMS)|
545484|NCT00069602|Device|Continuous Glucose Monitoring System (CGMS)|
545485|NCT00069602|Device|GlucoWatch G2TM Biographer (GW2B)|
545486|NCT00069576|Behavioral|nutritional counseling|
545487|NCT00069576|Behavioral|self blood glucose monitoring|
545488|NCT00069563|Behavioral|Reaching Educators, Children, and Parents (RECAP)|
545489|NCT00069550|Drug|dextromethorphan|
545490|NCT00069550|Drug|donepezil hydrochloride|
545491|NCT00069537|Device|The GlucoWatch® G2™ Biographer (GW2B)|
545492|NCT00069537|Device|The Continuous Glucose Monitoring System (CGMS™)|
545493|NCT00069511|Drug|UT-231B|
545494|NCT00069498|Drug|5-aminosalicylic acid|
545495|NCT00004883|Biological|trastuzumab|Given IV
545496|NCT00004883|Other|laboratory biomarker analysis|Correlative studies
545497|NCT00004856|Biological|trastuzumab|Given IV
545498|NCT00003930|Drug|cisplatin|
545499|NCT00003930|Drug|gemcitabine hydrochloride|
545500|NCT00003930|Drug|paclitaxel|
545501|NCT00003930|Procedure|conventional surgery|
545502|NCT00003930|Radiation|radiation therapy|
545503|NCT00003832|Drug|bromodeoxyuridine|Given IV
545504|NCT00003832|Procedure|conventional surgery|Undergo surgery
545505|NCT00003832|Other|laboratory biomarker analysis|Correlative studies
545506|NCT00069459|Drug|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
545507|NCT00069446|Drug|rhuMAb VEGF (telbermin)|
545508|NCT00069420|Behavioral|Cognitive Motivational Behavior Therapy|
545509|NCT00069407|Procedure|Electroconvulsive Therapy|Electroconvulsive therapy
545510|NCT00069381|Behavioral|Psychotherapy treatment|
545511|NCT00003827|Drug|amifostine trihydrate|
545512|NCT00003827|Drug|cytarabine|
545513|NCT00003827|Drug|topotecan hydrochloride|
545514|NCT00003620|Drug|alvocidib|Given IV
545515|NCT00003620|Other|laboratory biomarker analysis|Correlative studies
545516|NCT00003594|Drug|irinotecan|
545517|NCT00003594|Drug|fluorouracil|
545518|NCT00003594|Drug|leucovorin calcium|
545519|NCT00003594|Drug|oxaliplatin|
545520|NCT00003540|Drug|gemcitabine hydrochloride|
545521|NCT00003463|Drug|carmustine|
545522|NCT00003463|Drug|irinotecan hydrochloride|
545523|NCT00003463|Drug|polifeprosan 20 with carmustine implant|
545524|NCT00003463|Procedure|surgical procedure|
545525|NCT00069355|Drug|Propranolol|
545526|NCT00069277|Drug|E7389|
545527|NCT00069264|Drug|E7389|E7389 Dose-escalation starting at 0.25 mg/m^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
545528|NCT00069251|Drug|Bupropion|
545529|NCT00003449|Drug|dexamethasone|
545530|NCT00003449|Drug|gemcitabine hydrochloride|
545531|NCT00003449|Drug|paclitaxel|
545532|NCT00003281|Drug|paclitaxel|
545533|NCT00003281|Drug|topotecan hydrochloride|
545534|NCT00003281|Radiation|radiation therapy|
545535|NCT00003280|Biological|rituximab|
545536|NCT00003245|Drug|irinotecan hydrochloride|
545537|NCT00003113|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
545538|NCT00003113|Drug|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
545539|NCT00003113|Drug|etoposide|Etoposide is given on days 1-3.
545540|NCT00003113|Drug|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
545609|NCT00068861|Drug|clomiphene citrate|
545541|NCT00003113|Drug|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
545542|NCT00003113|Radiation|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
545543|NCT00069329|Drug|anakinra|daily injection of subcutaneous injection
545544|NCT00069316|Drug|Omr-IgG-am|
545545|NCT00069186|Drug|Creatine Monohydrate|
545546|NCT00069238|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
545547|NCT00069238|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
545548|NCT00069121|Drug|capecitabine [Xeloda]|1000mg/m2 iv bid on days 1-15 of each 3 week cycle
545549|NCT00069121|Drug|Oxaliplatin|As prescribed, in 3 week cycles
545550|NCT00069121|Drug|Oxaliplatin|As prescribed, in 2 week cycles
545551|NCT00069121|Drug|Leucovorin|As prescribed, in 2 week cycles.
545552|NCT00069121|Drug|5 FU|As prescribed, in 2 week cycles
545553|NCT00069108|Drug|5 FU|As prescribed, in 2 week cycles
545554|NCT00069108|Drug|Leucovorin|As prescribed, in 2 week cycles
545555|NCT00069108|Drug|Oxaliplatin|As prescribed, in 3 week cycles
545556|NCT00069108|Drug|Oxaliplatin|As prescribed, in 2 week cycles
545557|NCT00069108|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
545558|NCT00069095|Drug|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
545559|NCT00069095|Drug|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
545560|NCT00069095|Drug|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
545561|NCT00069095|Drug|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
545562|NCT00069095|Drug|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m^2 was administered simultaneously with leucovorin in a 2 h infusion.
545563|NCT00069095|Drug|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m^2 in a 2 h infusion.
545564|NCT00069095|Drug|Fluorouracil 400 mg/m^2|
545565|NCT00069095|Drug|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
545566|NCT00069095|Drug|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
545567|NCT00002638|Biological|filgrastim|
545568|NCT00002638|Biological|sargramostim|
545569|NCT00002638|Drug|carmustine|
545570|NCT00002638|Drug|cyclophosphamide|
545571|NCT00002638|Drug|cytarabine|
545572|NCT00002638|Drug|etoposide|
545573|NCT00002638|Procedure|peripheral blood stem cell transplantation|
545574|NCT00002638|Radiation|radiation therapy|
545575|NCT00002559|Biological|filgrastim|
545576|NCT00002559|Drug|cisplatin|
545577|NCT00002559|Drug|ifosfamide|
545578|NCT00002559|Drug|paclitaxel|
545579|NCT00002533|Drug|fluconazole|
545580|NCT00002533|Radiation|radiation therapy|
545581|NCT00069173|Behavioral|Project FAB (Fitness and Bone)|
545582|NCT00069134|Dietary Supplement|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
545583|NCT00069017|Biological|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
545584|NCT00069017|Other|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D&C Yellow #10.
545585|NCT00030381|Drug|4'-iodo-4'-deoxydoxorubicin|Given IV
545586|NCT00030381|Other|pharmacological study|Correlative studies
545587|NCT00026286|Drug|conjugated estrogens|
545588|NCT00026286|Drug|medroxyprogesterone|
545589|NCT00025116|Drug|gefitinib|
545590|NCT00069160|Drug|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
545591|NCT00069160|Drug|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
545592|NCT00069160|Other|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
545593|NCT00069082|Drug|Civamide (Zucapsaicin)|Nasal Solution 0.01%
545594|NCT00069082|Drug|Sodium Chloride|Nasal Solution 10%
545595|NCT00069030|Biological|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
545596|NCT00068991|Behavioral|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
545597|NCT00068991|Behavioral|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
545598|NCT00068991|Behavioral|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
545599|NCT00068952|Drug|Edotecarin|
545600|NCT00068952|Drug|Temozolomide|
545601|NCT00068952|Drug|Carmustine (BCNU)|
545602|NCT00068952|Drug|Lomustine (CCNU)|
545603|NCT00069069|Drug|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
545604|NCT00069056|Procedure|Laser Treatment|
545605|NCT00068913|Drug|Dichloroacetate|
545606|NCT00068874|Behavioral|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
545607|NCT00068874|Behavioral|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
545610|NCT00068848|Behavioral|Quick start oral contraceptive initiation|
545611|NCT00068835|Behavioral|Lindamood-Bell training for dyslexia|
545612|NCT00068822|Device|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
545613|NCT00068822|Procedure|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
545614|NCT00068809|Procedure|Short Cycle Antiretroviral Therapy|
545615|NCT00068783|Drug|imatinib mesylate|Given orally
545616|NCT00068783|Other|laboratory biomarker analysis|Correlative studies
545617|NCT00068770|Radiation|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
545618|NCT00068770|Drug|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
545619|NCT00068757|Biological|trastuzumab|
545620|NCT00068757|Drug|lonafarnib|
545621|NCT00068757|Drug|paclitaxel|
545622|NCT00068757|Other|pharmacological study|
545623|NCT00068744|Drug|cisplatin|
545624|NCT00068744|Drug|fluorouracil|
545625|NCT00068744|Drug|mitomycin C|
545626|NCT00068744|Radiation|radiation therapy|
545627|NCT00068731|Dietary Supplement|lycopene|
545628|NCT00068718|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
545629|NCT00068692|Radiation|Radiotherapy|Undergo external beam radiation therapy
545630|NCT00068692|Drug|Fluorouracil|Given IV
545631|NCT00068692|Drug|Leucovorin Calcium|Given IV
545632|NCT00068692|Drug|Oxaliplatin|Given IV
545633|NCT00068692|Drug|Irinotecan|Given IV
545634|NCT00068666|Drug|temozolomide|
545635|NCT00068666|Radiation|radiation therapy|
545636|NCT00068653|Drug|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
545637|NCT00068653|Drug|ZD1839|ZD1839 250 mg po every day, taken with or without food.
545638|NCT00068614|Biological|HER-2/neu peptide vaccine|
545639|NCT00068601|Drug|cyclophosphamide|Part of planned chemotherapy regimen
545640|NCT00068601|Drug|goserelin acetate|Given subcutaneously
545641|NCT00068588|Biological|GTI-2040|Given IV
545642|NCT00068588|Drug|capecitabine|Given orally
545643|NCT00068575|Biological|Recombinant Interferon Alfa|3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
545644|NCT00068575|Drug|Cisplatin|30 mg/m^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
545645|NCT00068575|Drug|Fluorouracil|175 mg/m^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
545646|NCT00068575|Radiation|Radiation Therapy|External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
545647|NCT00068549|Drug|Gemcitabine Hydrochloride|Given IV
545648|NCT00068549|Drug|Cisplatin|Given IV
545649|NCT00068549|Radiation|Radiation Therapy|Undergo whole pelvis radiotherapy
545650|NCT00068549|Radiation|Internal Radiation Therapy|Undergo brachytherapy
545651|NCT00068523|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
545652|NCT00068523|Drug|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
545653|NCT00068523|Drug|cyclosporine|oral cyclosporine on days -1 to 100
545654|NCT00068523|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
545655|NCT00068523|Drug|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
545656|NCT00068523|Procedure|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
545657|NCT00068523|Procedure|allogeneic bone marrow transplantation|
545658|NCT00068523|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
545659|NCT00068510|Biological|therapeutic autologous dendritic cells|
545660|NCT00068497|Drug|gefitinib|Given orally
545661|NCT00068484|Drug|topotecan hydrochloride|Given IV
545662|NCT00068484|Drug|bortezomib|Given IV
545663|NCT00068484|Other|pharmacological study|Correlative studies
545664|NCT00068484|Other|laboratory biomarker analysis|Correlative studies
545665|NCT00068471|Drug|anidulafungin|
545666|NCT00068458|Dietary Supplement|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
545667|NCT00068458|Other|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
545668|NCT00068458|Other|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
545669|NCT00068445|Drug|lamotrigine|
545670|NCT00068445|Other|Placebo|
545671|NCT00068432|Drug|Celecoxib|Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
545672|NCT00068432|Drug|Gemcitabine Hydrochloride|Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
545673|NCT00068419|Drug|tamoxifen citrate|Given orally
545674|NCT00068419|Drug|sulindac|Given orally
545675|NCT00068419|Other|laboratory biomarker analysis|Correlative studies
545676|NCT00068406|Radiation|3-Dimensional Conformal Radiation Therapy|
545677|NCT00068406|Drug|Cisplatin|Given IV
545678|NCT00068406|Procedure|Conventional Surgery|
545679|NCT00068393|Drug|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
545745|NCT00068029|Drug|Pegvisomant|
545680|NCT00068393|Drug|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
545681|NCT00068393|Drug|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
545682|NCT00068393|Drug|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
545683|NCT00068380|Drug|imatinib mesylate|Given orally
545684|NCT00068380|Other|laboratory biomarker analysis|Correlative studies
545685|NCT00068367|Drug|erlotinib hydrochloride|150 mg per day, daily until disease progression
545686|NCT00068341|Biological|trastuzumab|Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
545687|NCT00068341|Drug|carboplatin|Cycle 1-8 Day 1 or 2 AUC = 6 IV
545688|NCT00068341|Drug|docetaxel|Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
545689|NCT00068341|Biological|trastuzumab|"Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV~Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV"
545690|NCT00068328|Procedure|psychosocial assessment and care|
545691|NCT00068328|Procedure|quality-of-life assessment|
545692|NCT00068315|Drug|bortezomib|Given IV
545693|NCT00068315|Drug|fludarabine phosphate|Given IV
545694|NCT00068315|Biological|rituximab|Given IV
545695|NCT00068302|Drug|sirolimus|3-6 subjects will be enrolled into each dose level
545696|NCT00068289|Drug|bortezomib|
545697|NCT00068276|Dietary Supplement|cholecalciferol|
545698|NCT00068263|Radiation|radiation therapy|
545699|NCT00068250|Drug|rituximab|375 mg/m2, intravenously three days prior to the first cycle of methotrexate
545700|NCT00068250|Drug|methotrexate|Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
545701|NCT00068250|Drug|temozolomide 100 mg/m^2|Temozolomide 100 mg/m^2 by mouth per day for five days on weeks 4 and 8.
545702|NCT00068250|Drug|temozolomide 150 mg/m^2|Temozolomide 150 mg/m^2 by mouth per day for five days on weeks 4 and 8.
545703|NCT00068250|Drug|temozolomide 200 mg/m^2|Temozolomide 200 mg/m^2 per day by mouth for five days on weeks 4 and 8.
545704|NCT00068250|Radiation|radiation therapy|Whole brain irradiation (WBRT) during weeks 11, 12, and 13, five days per week (excluding weekends). A daily dose of 2.4 Gy delivered in two fractions of 1.2 Gy each with a minimum inter-fraction interval of 6 hours, with a total dose to brain and meninges of 36 Gy.
545705|NCT00068250|Drug|post-radiation therapy temozolomide|Temozolomide (TMZ) 200 mg/m^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
545706|NCT00068237|Procedure|salivary gland transfer|Seikaly and Jha method of submandibular salivary gland transfer at the time of surgery for the primary tumor and neck nodes on Day 1
545707|NCT00068237|Radiation|Post-operative radiation therapy|Dose ranging from 54-70 Gy over 5.5-7 weeks, at 2.0 Gy/fraction. Starts within 4-6 weeks of surgery.
545708|NCT00068211|Drug|ILX651|
545709|NCT00068198|Biological|Dryvax|
545710|NCT00068185|Drug|Black cohosh|
545711|NCT00068172|Drug|PI-88|
545712|NCT00068133|Genetic|Plasmid based Gene Transfer product-VLTS-589|
545713|NCT00025207|Drug|gefitinib|Given orally
545714|NCT00025207|Other|laboratory biomarker analysis|Correlative studies
545715|NCT00021268|Drug|tocladesine|
545716|NCT00020904|Drug|ixabepilone|
545717|NCT00068094|Drug|Probiotic-containing powder|
545718|NCT00068081|Drug|Capsaicin Dermal Patch|
545719|NCT00017043|Drug|ixabepilone|
545720|NCT00016939|Drug|alvocidib|
545721|NCT00016874|Drug|cisplatin|
545722|NCT00016874|Drug|paclitaxel|
545723|NCT00016874|Drug|triapine|
545724|NCT00016341|Biological|filgrastim|
545725|NCT00016341|Drug|cisplatin|
545726|NCT00016341|Drug|doxorubicin hydrochloride|
545727|NCT00016341|Drug|megestrol acetate|
545728|NCT00016341|Drug|paclitaxel|
545729|NCT00016341|Drug|tamoxifen citrate|
545730|NCT00068107|Drug|Replagal|enzyme replacement therapy
545731|NCT00068068|Drug|Talaporfin sodium (LS11)|
545732|NCT00068068|Device|LED-based light infusion device|
545733|NCT00068068|Device|Light emitting diodes (LED)|
545734|NCT00068068|Procedure|Photodynamic therapy|
545735|NCT00068068|Procedure|Phototherapy|
545736|NCT00068068|Procedure|Chemotherapy|
545737|NCT00068055|Drug|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
545738|NCT00068055|Drug|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
545739|NCT00068055|Drug|Placebo|Normal Saline.
545740|NCT00068042|Drug|Pegvisomant|
545741|NCT00068042|Drug|Sandostatin LAR|
545742|NCT00067899|Drug|Vitamin E with and without Vitamin C|
545743|NCT00068029|Drug|Pegvisomant/ Sandostatin LAR|
545744|NCT00068029|Drug|Sandostatin LAR|
545746|NCT00067990|Drug|Losartan 100mg|To be started within three months of transplant and continued for five years.
545747|NCT00067990|Drug|Placebo|No treatment with continued follow-up for five years.
545748|NCT00067964|Behavioral|small changes in physical activity and diet|
545749|NCT00067951|Drug|rosiglitazone/metformin|
545750|NCT00067938|Drug|lamotrigine|Lamotrigine
545751|NCT00067925|Behavioral|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
545752|NCT00016276|Drug|dexrazoxane hydrochloride|Given IV
545753|NCT00016276|Drug|doxorubicin hydrochloride|Given IV
545754|NCT00016276|Drug|cyclophosphamide|Given IV
545755|NCT00016276|Drug|paclitaxel|Given IV
545756|NCT00016276|Biological|trastuzumab|Given IV
545757|NCT00016276|Procedure|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
545758|NCT00016276|Radiation|radiation therapy|Undergo radiation therapy
545759|NCT00016276|Drug|tamoxifen citrate|Given orally
545760|NCT00016276|Other|laboratory biomarker analysis|Correlative studies
545761|NCT00010036|Drug|carboplatin|
545762|NCT00010036|Drug|irinotecan hydrochloride|
545763|NCT00010036|Radiation|radiation therapy|
545764|NCT00008359|Drug|caspofungin acetate|
545765|NCT00008359|Drug|liposomal amphotericin B|
545766|NCT00008086|Dietary Supplement|calcitriol|
545767|NCT00008086|Drug|carboplatin|
545768|NCT00006346|Procedure|psychosocial assessment and care|
545769|NCT00006346|Procedure|quality-of-life assessment|
545770|NCT00067912|Drug|Duloxetine Hydrochloride|
545771|NCT00067912|Drug|Venlafaxine Extended Release|
545772|NCT00006265|Drug|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
545773|NCT00006265|Biological|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, & IV); & D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) & D 14 (Cohort II)
545774|NCT00006254|Biological|salmonella VNP20009|
545775|NCT00006223|Biological|recombinant flt3 ligand|
545776|NCT00006103|Drug|fluorouracil|
545777|NCT00006103|Drug|irinotecan hydrochloride|
545778|NCT00006103|Drug|leucovorin calcium|
545779|NCT00006096|Drug|cisplatin|
545780|NCT00006096|Radiation|radiation therapy|
545781|NCT00067873|Behavioral|Diet|
545782|NCT00067873|Behavioral|Aerobic exercise|
545783|NCT00067873|Behavioral|Resistance exercise|
545784|NCT00067860|Drug|recombinant human growth hormone|
545785|NCT00067860|Behavioral|diet modification|
545786|NCT00067847|Behavioral|State-directed nutrition policy change|
545787|NCT00067834|Device|Pulsing electromagnetic field (PEMF)|
545788|NCT00006019|Drug|azacitidine|
545789|NCT00006019|Drug|sodium phenylbutyrate|
545790|NCT00006002|Drug|dexamethasone|
545791|NCT00006002|Drug|semaxanib|
545792|NCT00005887|Drug|efaproxiral|
545793|NCT00005887|Radiation|radiation therapy|
545794|NCT00005886|Drug|arzoxifene hydrochloride|
545795|NCT00005886|Drug|tamoxifen citrate|
545796|NCT00005857|Biological|trastuzumab|
545797|NCT00005857|Drug|docetaxel|
545798|NCT00005845|Drug|tipifarnib|Given PO
545799|NCT00005845|Other|laboratory biomarker analysis|Correlative studies
545800|NCT00005845|Other|pharmacological study|Correlative studies
545801|NCT00067808|Drug|Decitabine|10 mg/m^2 by vein over 1 hour daily for 10 days
545802|NCT00067808|Drug|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
545803|NCT00067808|Drug|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
545804|NCT00067782|Drug|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
545805|NCT00067782|Drug|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
545806|NCT00067769|Behavioral|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
545807|NCT00067769|Behavioral|treatment as usual|Routine clinical care.
545808|NCT00005804|Drug|cyclophosphamide|
545809|NCT00005804|Procedure|allogeneic bone marrow transplantation|
545810|NCT00005804|Radiation|radiation therapy|
545811|NCT00005090|Biological|bleomycin sulfate|10 U/m^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
545812|NCT00005090|Drug|carmustine|150/m^2 on days -6 to -4 (4-6 days before transplant).
545813|NCT00005090|Drug|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
545814|NCT00005090|Drug|dacarbazine|375 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
545815|NCT00005090|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
545816|NCT00005090|Drug|etoposide|60 mg/kg on day -4 (4 days before transplant).
545817|NCT00005090|Drug|vinblastine|6 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
545818|NCT00005090|Procedure|peripheral blood stem cell transplantation|2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight
545819|NCT00067756|Drug|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
545820|NCT00067743|Drug|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
545821|NCT00067730|Drug|Drotrecogin Alfa (activated)|
545822|NCT00067717|Behavioral|Distance healing|
545823|NCT00067704|Behavioral|Trauma writing|
545824|NCT00067704|Behavioral|Writing about daily events|
545825|NCT00067691|Procedure|Acupuncture|
545826|NCT00067678|Drug|soy protein|
545827|NCT00067665|Other|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
545828|NCT00067652|Behavioral|Education and awareness about body image issues.|
545829|NCT00067639|Drug|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
545830|NCT00067639|Procedure|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
545831|NCT00067626|Dietary Supplement|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
545832|NCT00067613|Other|Benchmarking Management Practices|"The Benchmarking intervention included:~Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.~Training in Continuous Quality Improvement (CQI) Techniques~Review of best existing evidence~Site visits to the Centers with the Lowest Rates of BPD~Selection of Practices to change: Each site team selected practices for modification at their own center"
545833|NCT00067613|Other|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
545834|NCT00067600|Behavioral|Diet with increased fruits, vegetables, and calcium|
545835|NCT00067600|Behavioral|Increased high impact activity and resistance training|
545836|NCT00067574|Behavioral|Structured treatment interruption|
545837|NCT00067561|Drug|Alosetron|
545838|NCT00067548|Drug|EKB-569|
545839|NCT00067535|Drug|Cocaine-Related Disorders|
545840|NCT00067522|Behavioral|User-independent contraception program|
545841|NCT00067522|Behavioral|Future Planning Perspectives program|
545842|NCT00067509|Drug|emergency contraception (estrogen/progesterone)|
545843|NCT00067470|Drug|Placebo|
545844|NCT00067470|Drug|N-acetylgalactosamine 4-sulfatase|
545845|NCT00004256|Biological|sargramostim|
545846|NCT00004256|Procedure|quality-of-life assessment|
545847|NCT00004256|Radiation|radiation therapy|
545848|NCT00004233|Drug|fluorouracil|
545849|NCT00004233|Drug|leucovorin calcium|
545850|NCT00004233|Drug|triacetyluridine|
545851|NCT00004221|Drug|Carboplatin|Given IV
545852|NCT00004221|Drug|Cyclophosphamide|Given IV
545853|NCT00004221|Biological|Filgrastim|Given SQ
545854|NCT00004221|Drug|Paclitaxel|Given IV
545855|NCT00004221|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
545856|NCT00004221|Drug|Topotecan Hydrochloride|Given IV
545857|NCT00004125|Drug|cyclophosphamide|
545858|NCT00004125|Drug|docetaxel|
545859|NCT00004125|Drug|doxorubicin hydrochloride|
545860|NCT00004125|Drug|paclitaxel|
545861|NCT00004125|Drug|tamoxifen citrate|
545862|NCT00004125|Radiation|radiation therapy|
545863|NCT00004032|Biological|ALVAC-hB7.1|Given IP
545864|NCT00004032|Biological|recombinant interferon gamma|Given IP
545865|NCT00004032|Other|laboratory biomarker analysis|Correlative studies
545866|NCT00067496|Drug|Modafinil|
545867|NCT00067457|Drug|alosetron|
545868|NCT00067444|Drug|Paroxetine CR|
545869|NCT00067431|Drug|Divalproex Sodium (Depakote® Sprinkle Capsules)|
545870|NCT00067405|Drug|Intravenous micronutrient therapy|
545871|NCT00067392|Procedure|Dental Implant|Dental Implant 4 month time frame
545872|NCT00067340|Drug|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
545873|NCT00067340|Other|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
545874|NCT00004004|Drug|procarbazine hydrochloride|
545875|NCT00003931|Genetic|reverse transcriptase-polymerase chain reaction|
545876|NCT00003890|Drug|MG 98|
545877|NCT00003736|Drug|motexafin gadolinium|
545878|NCT00003736|Procedure|biopsy|
545879|NCT00003736|Procedure|breast imaging study|
545880|NCT00003736|Procedure|comparison of screening methods|
545881|NCT00003736|Procedure|magnetic resonance imaging|
545882|NCT00003736|Procedure|study of high risk factors|
545883|NCT00003464|Drug|temozolomide|
545884|NCT00003464|Radiation|radiation therapy|
545885|NCT00067379|Procedure|interceptive orthodontic treatments|orthodontic procedures
545886|NCT00067366|Behavioral|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
545887|NCT00067366|Behavioral|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
545888|NCT00067353|Drug|Fluoride varnish|
545889|NCT00067327|Drug|Inosine|
545890|NCT00067314|Drug|Edotecarin|
545891|NCT00067301|Drug|Polyunsaturated Fatty Acids (PUFA)|
545892|NCT00067301|Drug|Citalopram|
545893|NCT00067288|Behavioral|Meaning-Centered Group Psychotherapy|
545894|NCT00067288|Behavioral|Standard Supportive Group Psychotherapy|
545895|NCT00067262|Drug|Divalproex Sodium Extended-Release Tablets|
545896|NCT00067236|Drug|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
545897|NCT00067236|Drug|Placebo tablet|placebo tablet, twice a day for 90 days
545898|NCT00067210|Device|Head and Neck Cooling System|
545899|NCT00067184|Device|Toitu 320/325|Fetal monitor
545900|NCT00067171|Behavioral|Behavior Therapy|
545901|NCT00067158|Drug|nicotine transdermal system|
545902|NCT00067145|Behavioral|Face-to-face maintenance program|
545903|NCT00067145|Behavioral|Internet maintenance program|
545904|NCT00067132|Procedure|Juven (nutritional), HMB (nutritional)|
545905|NCT00067119|Drug|Aggrenox|
545906|NCT00067119|Drug|Placebo|
545907|NCT00067093|Drug|SanOrg34006|
545908|NCT00067093|Drug|LMW heparin|
545909|NCT00067093|Drug|Unfractionated heparin|
545910|NCT00067093|Drug|Vitamin K antagonist (VKA)|
545911|NCT00067080|Drug|ICL670, deferoxamine|
545912|NCT00067041|Drug|Remodulin (treprostinil sodium) Injection|
545913|NCT00067028|Drug|Clofarabine|30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.
545914|NCT00067028|Drug|Idarubicin|"Clofarabine + Idarubicin:~10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
545915|NCT00067028|Drug|Ara-C|Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
545916|NCT00003433|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
545917|NCT00003323|Drug|finasteride|5 mg/d PO
545918|NCT00003323|Drug|flutamide|250 mg PO tid
545919|NCT00003323|Other|quality-of-life assessment|Assessment survey administered at baseline, and 3 & 6 months post initiation of treatment
545920|NCT00003210|Biological|recombinant interleukin-12|Given subcutaneously
545921|NCT00003210|Other|laboratory biomarker analysis|Correlative studies
545922|NCT00003114|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
545923|NCT00003114|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
545924|NCT00003114|Drug|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
545925|NCT00003114|Drug|lomustine|Patients receive oral lomustine on day 1.
545926|NCT00003114|Drug|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
545927|NCT00003114|Radiation|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
545928|NCT00003006|Genetic|reverse transcriptase-polymerase chain reaction|
545929|NCT00003006|Other|immunohistochemistry staining method|
545930|NCT00067015|Drug|bicalutamide|
545931|NCT00067015|Drug|goserelin acetate|
545932|NCT00067015|Procedure|assessment of therapy complications|
545933|NCT00067015|Procedure|quality-of-life assessment|
545934|NCT00067015|Radiation|radiation therapy|
545935|NCT00067002|Procedure|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
545936|NCT00067002|Procedure|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
545937|NCT00067002|Drug|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
545938|NCT00067002|Drug|Melphalan|140 mg/m2 by vein on Day -8.
545939|NCT00067002|Drug|Thiotepa|5 mg/Kg by vein on Day -7.
545940|NCT00067002|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
545941|NCT00067002|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6.
545942|NCT00067002|Drug|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
545943|NCT00067002|Radiation|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
545944|NCT00066989|Drug|Staphylococcus aureus Immune Globulin (Human) 5%|
545945|NCT00046878|Drug|O6-benzylguanine|
545946|NCT00046878|Drug|carmustine|
545947|NCT00002970|Drug|nelarabine|Given IV
545948|NCT00002970|Drug|methotrexate|Given IT
545949|NCT00002970|Drug|cytarabine|Given IT
545950|NCT00002970|Drug|therapeutic hydrocortisone|Given IT
545951|NCT00002621|Biological|recombinant interferon alfa|
545952|NCT00002548|Biological|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday~-Friday (3 times a week)"
545953|NCT00002548|Drug|carmustine|20 mg/m2 I.V. day 1 q 35 days
545954|NCT00002548|Drug|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
545955|NCT00002548|Drug|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
545956|NCT00002548|Drug|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
545957|NCT00002548|Drug|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
545958|NCT00002548|Drug|prednisone|40 mg/m2 PO days 1-7 q 35 days
545959|NCT00002548|Drug|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
545960|NCT00002548|Procedure|allogeneic bone marrow transplantation|day 0
545961|NCT00002548|Procedure|autologous bone marrow transplantation|day 0
545962|NCT00002548|Procedure|peripheral blood stem cell transplantation|day 0
545963|NCT00002548|Radiation|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
545964|NCT00002520|Drug|nicotine|
545965|NCT00002520|Behavioral|Usual Care|
545966|NCT00066963|Device|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
545967|NCT00066950|Drug|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
545968|NCT00066950|Device|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
545969|NCT00066937|Drug|Nortriptyline Oral Capsule|Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
545970|NCT00066937|Drug|Benztropine Oral Product|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
545971|NCT00066937|Behavioral|CBT|Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
545972|NCT00066937|Behavioral|Disease MGT|Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
545973|NCT00066898|Drug|AGI-1067|
545974|NCT00066885|Drug|calcitriol + docetaxel|
545975|NCT00011973|Drug|fenretinide|
545976|NCT00005027|Drug|becatecarin|
545977|NCT00066872|Drug|imiquimod|
545978|NCT00066872|Procedure|conventional surgery|
545979|NCT00066859|Drug|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
545980|NCT00066859|Dietary Supplement|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
545981|NCT00066846|Biological|bevacizumab|
545982|NCT00066846|Drug|fluorouracil|
545983|NCT00066846|Drug|leucovorin calcium|
545984|NCT00066807|Drug|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
545985|NCT00066807|Drug|exemestane|Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
545986|NCT00066807|Drug|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
545987|NCT00066807|Drug|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
545988|NCT00066807|Procedure|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
545989|NCT00066807|Procedure|ovarian irradiation|Bilateral ovarian irradiation.
545990|NCT00066794|Biological|filgrastim|5 mcg/kg/d IV or SC starting apx day 15
545991|NCT00066794|Biological|sargramostim|250 mcg/kg/d IV or SC starting apx day 15
545992|NCT00066794|Drug|cyclosporine|ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
545993|NCT00066794|Drug|cytarabine|ind: 200 mg/m2/d cont IV days 2-74
545994|NCT00066794|Drug|daunorubicin hydrochloride|ind: 45 mg/m2/d cont IV days 2-74
545995|NCT00066781|Drug|gemcitabine hydrochloride|Given IV
545996|NCT00066781|Drug|irinotecan hydrochloride|Given IV
545997|NCT00066768|Drug|suramin|Given IV
545998|NCT00066768|Drug|docetaxel|Given IV
545999|NCT00066768|Drug|gemcitabine hydrochloride|Given IV
546000|NCT00066768|Other|laboratory biomarker analysis|Correlative studies
546001|NCT00066768|Other|pharmacological study|Correlative studies
546002|NCT00066742|Drug|tirapazamine|Given IV
546003|NCT00066742|Drug|cisplatin|Given IV
546004|NCT00066742|Drug|etoposide|Given IV
546005|NCT00066742|Radiation|radiation therapy|Undergo radiation therapy
546006|NCT00066742|Other|laboratory biomarker analysis|Correlative studies
546007|NCT00066729|Biological|NY-ESO-1 peptide vaccine|
546008|NCT00066729|Biological|incomplete Freund's adjuvant|
546009|NCT00066716|Drug|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
546010|NCT00066716|Drug|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
546011|NCT00066716|Drug|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
546012|NCT00066716|Procedure|adjuvant therapy|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~Operation will be performed within 6-12 hours from the last dose of celecoxib.~Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.~Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
546013|NCT00066716|Procedure|conventional surgery|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~Operation will be performed within 6-12 hours from the last dose of celecoxib.~Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
546014|NCT00066716|Procedure|neoadjuvant therapy|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.~Operation will be performed within 6-12 hours from the last dose of celecoxib.~Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
546015|NCT00066703|Drug|exemestane|
546016|NCT00066703|Drug|tamoxifen|
546017|NCT00066703|Drug|triptorelin|
546018|NCT00066690|Drug|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
546019|NCT00066690|Other|Laboratory Biomarker Analysis|Correlative studies
546020|NCT00066690|Procedure|Oophorectomy|Undergo bilateral surgical oophorectomy
546021|NCT00066690|Other|Quality-of-Life Assessment|Ancillary studies
546022|NCT00066690|Radiation|Radiation Therapy|Undergo ovarian irradiation
546023|NCT00066690|Drug|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
546024|NCT00066690|Drug|Triptorelin|3.75 mg by im injection q28 days for 5 years
546025|NCT00066677|Biological|bevacizumab|
546026|NCT00066677|Drug|docetaxel|
546027|NCT00066664|Genetic|proteomic profiling|
546028|NCT00066651|Biological|SS1(dsFv)-PE38 immunotoxin|
546029|NCT00066638|Drug|Romidepsin|Given IV
546030|NCT00066638|Other|Laboratory Biomarker Analysis|Correlative studies
546031|NCT00066625|Drug|oxaliplatin|Given IV
546032|NCT00066625|Drug|bortezomib|Given IV
546033|NCT00066625|Other|laboratory biomarker analysis|Correlative studies
546034|NCT00066625|Other|pharmacological study|Correlative studies
546035|NCT00066612|Drug|irinotecan hydrochloride|Irinotecan will be given 250 mg/m^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
546036|NCT00066599|Drug|voriconazole|
546037|NCT00066586|Drug|exemestane|exemestane 25 mg once daily x 1 year
546038|NCT00066586|Drug|Placebo|placebo once daily x 1 year
546039|NCT00066573|Drug|anastrozole|Given orally
546040|NCT00066573|Drug|exemestane|Given orally
546041|NCT00066547|Biological|monoclonal antibody HuHMFG1|
546042|NCT00066508|Drug|bortezomib|
546043|NCT00066482|Biological|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children < 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
546044|NCT00066482|Biological|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC > 5,000/uL
546045|NCT00066482|Drug|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children < 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
546046|NCT00066482|Drug|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children < 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
546047|NCT00066482|Drug|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children < 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
546048|NCT00066482|Procedure|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
546049|NCT00066482|Biological|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
546050|NCT00066469|Biological|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: < 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: < 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
546051|NCT00066469|Drug|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
546052|NCT00066469|Drug|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
546053|NCT00066469|Drug|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
546054|NCT00066456|Radiation|3-Dimensional Conformal Radiation Therapy|
546055|NCT00066456|Drug|Chemosensitization/Potentiation Therapy|
546056|NCT00066456|Drug|Docetaxel|Given IV
546057|NCT00066443|Biological|pegfilgrastim|Dose escalation schedule A&B = 6mg fixed dose once per cycle on day 2
546058|NCT00066443|Drug|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
546059|NCT00066443|Drug|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
546060|NCT00066430|Procedure|infrared photocoagulation therapy|
546061|NCT00066430|Device|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
546062|NCT00066417|Drug|cyclophosphamide|
546063|NCT00066417|Drug|cyclosporine|
546064|NCT00066417|Drug|fludarabine phosphate|
546065|NCT00066417|Drug|methylprednisolone|
546066|NCT00066417|Drug|therapeutic allogeneic lymphocytes|
546067|NCT00066417|Drug|thiotepa|
546068|NCT00066417|Procedure|allogeneic bone marrow transplantation|
546069|NCT00066417|Procedure|biological therapy|
546070|NCT00066417|Procedure|bone marrow ablation with stem cell support|
546071|NCT00066417|Procedure|bone marrow transplantation|
546072|NCT00066417|Procedure|chemotherapy|
546073|NCT00066417|Procedure|leukocyte therapy|
546074|NCT00066417|Procedure|non-specific immune-modulator therapy|
546075|NCT00066417|Procedure|peripheral blood lymphocyte therapy|
546076|NCT00066417|Procedure|peripheral blood stem cell transplantation|
546077|NCT00066417|Procedure|radiation therapy|
546078|NCT00066404|Biological|recombinant adenovirus-hIFN-beta|
546079|NCT00066391|Drug|cisplatin|
546080|NCT00066391|Drug|irinotecan hydrochloride|
546081|NCT00066391|Procedure|neoadjuvant therapy|
546082|NCT00066378|Drug|anastrozole|
546083|NCT00066378|Drug|gefitinib|
546084|NCT00066365|Biological|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
546085|NCT00066365|Procedure|conventional surgery|thoracotomy
546086|NCT00066352|Drug|bortezomib|
546087|NCT00066339|Drug|gefitinib|
546088|NCT00066326|Drug|imatinib mesylate|
546089|NCT00066326|Drug|tanespimycin|
546090|NCT00066313|Drug|vandetanib|
546091|NCT00066313|Procedure|adjuvant therapy|
546092|NCT00066274|Drug|FOLFIRI regimen|
546093|NCT00066274|Drug|FOLFOX regimen|
546094|NCT00066274|Drug|fluorouracil|
546095|NCT00066274|Drug|irinotecan hydrochloride|
546096|NCT00066274|Drug|leucovorin calcium|
546097|NCT00066274|Drug|oxaliplatin|
546098|NCT00066248|Drug|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
546099|NCT00066248|Drug|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
546100|NCT00066222|Drug|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
546101|NCT00066222|Drug|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
546102|NCT00066222|Radiation|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
546103|NCT00066196|Biological|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
546104|NCT00066196|Biological|Integrin + Dacarbazine|supplied in other formulations
546105|NCT00020462|Biological|aldesleukin|
546106|NCT00020462|Biological|autologous tumor cell vaccine|
546107|NCT00019721|Biological|MART-1 antigen|
546108|NCT00019721|Biological|aldesleukin|
546109|NCT00019721|Biological|gp100 antigen|
546110|NCT00019721|Biological|incomplete Freund's adjuvant|
546111|NCT00019383|Biological|aldesleukin|
546112|NCT00019383|Biological|incomplete Freund's adjuvant|
546113|NCT00019383|Biological|sargramostim|
546114|NCT00019383|Biological|tyrosinase peptide|
546115|NCT00019383|Biological|tyrosinase-related protein-1|
546116|NCT00066170|Drug|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
546117|NCT00066170|Drug|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
546118|NCT00066170|Drug|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
546119|NCT00066170|Drug|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
546120|NCT00033722|Dietary Supplement|folic acid|
546121|NCT00033722|Drug|lometrexol|
546122|NCT00033306|Drug|ixabepilone|
546123|NCT00033306|Drug|Fluoropyrimidine|
546124|NCT00033306|Drug|Irinotecan|
546125|NCT00031811|Drug|raloxifene|
546126|NCT00031811|Procedure|quality-of-life assessment|
546127|NCT00031785|Drug|megestrol acetate|
546128|NCT00031785|Radiation|radiation therapy|
546129|NCT00066157|Drug|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
546130|NCT00066157|Drug|Medroxyprogesterone|2.5mg tablet daily for 12 months
546131|NCT00066157|Drug|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
546132|NCT00066157|Drug|Placebo|Placebo tablet daily for 12 months
546133|NCT00066144|Drug|Cimicifuga racemosa|
546134|NCT00066144|Drug|Trifolium pratense|
546135|NCT00066144|Drug|Black cohosh|
546136|NCT00066144|Drug|Red clover|
546137|NCT00066131|Procedure|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
546138|NCT00066131|Procedure|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
546139|NCT00066118|Device|Dental amalgam restorations|
546140|NCT00066092|Drug|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
546141|NCT00066092|Drug|filgrastim|Filgrastim given daily for PBPC mobilization
546142|NCT00066092|Drug|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
546143|NCT00066079|Procedure|massage|
546144|NCT00066079|Behavioral|relaxation|
546145|NCT00066066|Procedure|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
546146|NCT00066066|Drug|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
546147|NCT00066066|Drug|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
546148|NCT00066066|Drug|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
546149|NCT00066053|Procedure|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
546150|NCT00066053|Procedure|Referral|
546151|NCT00066040|Drug|Cervitec chlorhexidine varnish|
546152|NCT00066040|Drug|Duraphat fluoride varnish|
546153|NCT00066040|Drug|xylitol gum from Fennobon, Finland|
546154|NCT00066027|Drug|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
546155|NCT00066027|Drug|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
546156|NCT00066014|Procedure|Implant Overdenture Treatment|All overdenture treatment modalities were provided to each subject using a crossover design.
546157|NCT00066001|Drug|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
546158|NCT00065988|Device|Dispersed phase amalgam restoration /composite restoration|
546159|NCT00065975|Procedure|massage therapy|
546160|NCT00065975|Procedure|chiropractic|
546161|NCT00065975|Procedure|acupuncture|
546162|NCT00065962|Drug|secretin, synthetic porcine|
546163|NCT00065962|Drug|secretin, biologically derived porcine|
546164|NCT00065949|Drug|magnesium sulfate|
546165|NCT00065936|Drug|Naltrexone hydrochloride|
546166|NCT00065936|Procedure|Transcutaneous sensory nerve stimulation|
546167|NCT00065923|Drug|Topiramate|
546168|NCT00065910|Behavioral|Caregiver joint attention intervention|
546169|NCT00065897|Procedure|Amniocentesis|
546170|NCT00065897|Procedure|Transabdominal chorionic villus sampling (TA CVS)|
546171|NCT00065884|Drug|Valproate|
546172|NCT00065871|Behavioral|Contraceptive Screening by Pharmacist|
546173|NCT00065871|Behavioral|Contraceptive Prescribing by Pharmacist|
546174|NCT00065858|Drug|BufferGel|
546175|NCT00065845|Procedure|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
546176|NCT00031707|Dietary Supplement|eicosapentaenoic acid|
546177|NCT00031707|Drug|megestrol acetate|
546178|NCT00031707|Other|placebo|
546179|NCT00026273|Drug|FOLFIRI regimen|
546180|NCT00026273|Drug|fluorouracil|
546181|NCT00026273|Drug|irinotecan hydrochloride|
546182|NCT00026273|Drug|leucovorin calcium|
546183|NCT00025688|Drug|carboplatin|
546184|NCT00025688|Drug|paclitaxel|
546185|NCT00024024|Drug|rebimastat|
546186|NCT00022477|Drug|BMS-247550|
546187|NCT00065832|Behavioral|Reading Instruction|
546188|NCT00065819|Behavioral|HIV Symptom Education Program|
546189|NCT00065806|Drug|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
546190|NCT00065806|Drug|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
546191|NCT00065767|Drug|Raloxifene|
546192|NCT00065754|Drug|placebo|
546193|NCT00065741|Drug|silymarin|
546194|NCT00065728|Drug|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
546195|NCT00065715|Dietary Supplement|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = < 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
546196|NCT00065715|Other|Blinded placebo|Blinded placebo - Coated tablet
546197|NCT00065702|Drug|Active liquid remedy|
546198|NCT00065689|Device|high-intensity light therapy|
546199|NCT00065676|Other|Quercetin|1 or 2 grams of quercetin or placebo will be given while patients undergo 6-hour OGTT
546200|NCT00065676|Other|Placebo|
546201|NCT00065663|Genetic|GAM501|
546202|NCT00065650|Drug|Vedic Medicine|
546203|NCT00065650|Behavioral|Vedic Medicine|
546204|NCT00065624|Drug|lipoic acid|
546205|NCT00065585|Procedure|Accupuncture|
546206|NCT00065572|Drug|ZD6126|
546207|NCT00065572|Drug|Placebo|
546208|NCT00065559|Drug|celecoxib|
546209|NCT00065546|Other|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
546210|NCT00065546|Other|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
546211|NCT00065546|Other|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
546212|NCT00065637|Drug|Teriparatide|Synthetic human parathyroid hormone
546213|NCT00065637|Drug|Placebo teriparatide|Placebo injections
546214|NCT00014560|Biological|bispecific antibody 4G7xH22|
546215|NCT00014560|Biological|sargramostim|
546216|NCT00014261|Biological|PEG-interferon alfa-2b|
546217|NCT00014261|Drug|temozolomide|
546218|NCT00014248|Drug|adenosine triphosphate|
546219|NCT00014248|Procedure|quality-of-life assessment|
546220|NCT00014209|Drug|cisplatin|
546221|NCT00014209|Drug|dexamethasone|
546222|NCT00014209|Drug|gemcitabine hydrochloride|
546223|NCT00010127|Biological|therapeutic autologous dendritic cells|
546297|NCT00065117|Drug|ZD6126|
546298|NCT00065117|Drug|Placebo|
546299|NCT00065117|Drug|5-fluorouracil|
546300|NCT00065117|Drug|leucovorin|
546301|NCT00065117|Drug|oxaliplatin|
546224|NCT00065611|Drug|Oral dexamethasone|"Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.~Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.~over 36 weeks."
546225|NCT00065533|Drug|pemetrexed|
546226|NCT00065507|Drug|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
546227|NCT00065507|Drug|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
546228|NCT00006799|Drug|megestrol acetate|
546229|NCT00006799|Procedure|quality-of-life assessment|
546230|NCT00006486|Drug|carboxyamidotriazole|Given orally
546231|NCT00006486|Other|placebo|Given orally
546232|NCT00006453|Drug|carboplatin|
546233|NCT00006453|Drug|gemcitabine hydrochloride|
546234|NCT00006352|Biological|BCG vaccine|
546235|NCT00006352|Biological|monoclonal antibody BEC2|
546236|NCT00006240|Biological|sargramostim|
546237|NCT00006240|Drug|dexamethasone|
546238|NCT00006240|Drug|oral sodium phenylbutyrate|
546239|NCT00065468|Drug|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
546240|NCT00065468|Drug|CCI-779|25 mg of CCI-779 given Intra Venously once per week
546241|NCT00065468|Drug|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
546242|NCT00006229|Drug|carboplatin|
546243|NCT00006229|Drug|paclitaxel|
546244|NCT00006229|Drug|rebimastat|
546245|NCT00006081|Drug|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
546246|NCT00006081|Drug|Paclitaxel (Taxol)|80 mg/m^2 one-hour infusion weekly x 3 every 4 weeks
546247|NCT00065455|Drug|Vitamin A|
546248|NCT00065442|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
546249|NCT00065442|Biological|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
546250|NCT00065429|Drug|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
546251|NCT00005604|Biological|recombinant interleukin-12|Given IV
546252|NCT00005604|Biological|aldesleukin|Given SC
546253|NCT00005604|Other|laboratory biomarker analysis|Correlative studies
546254|NCT00004887|Drug|carboplatin|
546255|NCT00004887|Drug|cisplatin|
546256|NCT00004887|Drug|ifosfamide|
546257|NCT00004887|Drug|mitomycin C|
546258|NCT00004887|Drug|paclitaxel|
546259|NCT00004887|Drug|vinblastine sulfate|
546260|NCT00065416|Procedure|massage|
546261|NCT00065403|Device|Acupuncture|
546262|NCT00065364|Behavioral|Newborn Individualized Developmental Care Assessment Program|
546263|NCT00065351|Drug|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
546264|NCT00065338|Behavioral|Exercise and behavior modification|Participants will undergo 1000 kcal/day caloric restriction (relative to experimentally determined weight-maintenance caloric needs) for 8 weeks during one phase of study. Additional 11 week period consists of 8 weeks of caloric restriction with an additional daily walking program.
546265|NCT00065325|Drug|Fulvestrant|intramuscular injection
546266|NCT00065325|Drug|Exemestane|oral capsule
546267|NCT00004253|Drug|carboplatin|
546268|NCT00004253|Drug|paclitaxel|
546269|NCT00004253|Radiation|radiation therapy|
546270|NCT00065390|Drug|Pyrimethamine|
546271|NCT00065377|Drug|Glucosamine Hydrochloride|
546272|NCT00065312|Drug|naveglitazar|
546273|NCT00065299|Behavioral|Restricted phenylalanine diet|
546274|NCT00065273|Drug|risperidone|
546275|NCT00065273|Drug|clozapine|
546276|NCT00065273|Drug|olanzapine|
546277|NCT00065247|Behavioral|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
546278|NCT00065234|Procedure|Acupuncture|
546279|NCT00065221|Drug|Ginger|
546280|NCT00065208|Behavioral|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
546281|NCT00065208|Behavioral|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
546282|NCT00065208|Behavioral|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
546283|NCT00065260|Drug|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
546284|NCT00065260|Drug|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
546285|NCT00065260|Drug|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
546286|NCT00065195|Procedure|Moving touch therapy|
546287|NCT00065195|Procedure|Nonmoving touch therapy|
546288|NCT00065182|Drug|Topotecan/Docetaxel combination|
546289|NCT00065182|Drug|Docetaxel|
546290|NCT00065169|Drug|Celecoxib|
546291|NCT00065156|Drug|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
546292|NCT00065143|Drug|clofarabine|
546293|NCT00065143|Drug|Ara-C|
546294|NCT00065130|Drug|human insulin|
546295|NCT00065130|Drug|insulin NPH|
546296|NCT00065130|Drug|insulin aspart|
546303|NCT00065078|Procedure|Home dispensing of contraception|
546304|NCT00065065|Drug|Rosiglitazone|4mg orally twice daily for 12 weeks
546305|NCT00065065|Drug|Placebo|pill that looks identical to rosiglitazone
546306|NCT00065052|Behavioral|Behavior modification|
546307|NCT00065039|Behavioral|Promotion of a healthy diet and physical activity|
546308|NCT00065039|Behavioral|Avoidance of Alcohol, Drugs, and Tobacco|
546309|NCT00065026|Behavioral|Physical activity opportunities for low-income women|
546310|NCT00065013|Behavioral|strength training|
546311|NCT00065000|Behavioral|Water, Cafeteria and Staff Health Promotion|
546312|NCT00004204|Drug|temozolomide|
546313|NCT00004006|Biological|filgrastim|
546314|NCT00004006|Drug|carboplatin|
546315|NCT00004006|Drug|cyclophosphamide|
546316|NCT00004006|Drug|doxorubicin hydrochloride|
546317|NCT00004006|Drug|etoposide|
546318|NCT00004006|Drug|topotecan hydrochloride|
546319|NCT00004006|Procedure|autologous bone marrow transplantation|
546320|NCT00004006|Radiation|radiation therapy|
546321|NCT00003895|Biological|HPV 16 E7:12-20|Given SC
546322|NCT00003895|Biological|gp100:209-217(210M)|Given SC
546323|NCT00003895|Other|laboratory biomarker analysis|Correlative studies
546324|NCT00003795|Procedure|quality-of-life assessment|
546325|NCT00003759|Biological|BCG vaccine|
546326|NCT00003759|Drug|valrubicin|
546327|NCT00003759|Procedure|conventional surgery|
546328|NCT00064987|Procedure|Testicular biopsy|Outpatient surgical procedure.
546329|NCT00064987|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
546330|NCT00064987|Drug|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
546331|NCT00064974|Drug|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
546332|NCT00064961|Behavioral|Individualized dietary-control and exercise program|
546333|NCT00064961|Behavioral|Weight-management and smoking cessation maintenance|
546334|NCT00064961|Behavioral|Smoking Cessation program|
546335|NCT00064935|Procedure|Endometrial biopsy|
546336|NCT00064922|Behavioral|Behavior Therapy|
546337|NCT00064857|Drug|Pycnogenol|
546338|NCT00064896|Procedure|MRI|
546339|NCT00064844|Behavioral|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
546340|NCT00064831|Drug|Black Cohosh Extract (BCE)|
546341|NCT00064805|Behavioral|Cognitive Therapy to Improve Reading|
546342|NCT00064779|Drug|IL13-PE38QQR|
546343|NCT00064779|Procedure|targeted fusion protein therapy|
546344|NCT00064779|Procedure|surgery|
546345|NCT00064766|Drug|doxycycline|
546346|NCT00064753|Drug|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
546347|NCT00064753|Device|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
546348|NCT00003712|Drug|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.~The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.~•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
546349|NCT00003707|Drug|gemcitabine hydrochloride|
546350|NCT00003707|Drug|tipifarnib|
546351|NCT00003645|Drug|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
546352|NCT00003645|Drug|Leuprolide Acetate|50 mg tablet orally daily for 12 months
546353|NCT00003571|Genetic|mutation analysis|
546354|NCT00003571|Genetic|tumor replication error analysis|
546355|NCT00003382|Biological|filgrastim|
546356|NCT00003382|Drug|gemcitabine hydrochloride|
546357|NCT00003382|Drug|topotecan hydrochloride|
546358|NCT00064792|Drug|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
546359|NCT00064792|Drug|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
546360|NCT00064740|Behavioral|relaxation response|
546361|NCT00064701|Drug|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
546362|NCT00064701|Drug|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
546363|NCT00064701|Drug|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
546364|NCT00064701|Drug|mycophenolate mofetil|Oral
546365|NCT00064727|Drug|Avandia (Rosiglitazone)|
546366|NCT00064727|Drug|Avanclia (Rosiqlitazone)|
546367|NCT00064714|Drug|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
546368|NCT00064714|Drug|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
546369|NCT00064662|Procedure|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
546370|NCT00064662|Procedure|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
546371|NCT00064649|Device|Transurethral Microwave Thermotherapy (TUMT)|type of minimally invasive surgical therapy for BPH
546372|NCT00064649|Device|Transurethral Needle Ablation (TUNA) Therapy|type of minimally invasive surgical therapy for BPH
546373|NCT00064649|Drug|Finasteride and Alfuzosin|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
546374|NCT00064636|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
546375|NCT00064623|Drug|Capsaicin Dermal Patch|
546376|NCT00064610|Drug|VELCADE TM (bortezomib) for Injection|
546377|NCT00063726|Drug|bortezomib|
546378|NCT00003350|Drug|paclitaxel|Given IV
546379|NCT00003350|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
546380|NCT00003350|Other|laboratory biomarker analysis|Correlative studies
546381|NCT00003350|Procedure|quality-of-life assessment|Ancillary studies
546382|NCT00003184|Biological|BCG vaccine|
546383|NCT00003184|Biological|CD80 breast cancer vaccine|
546384|NCT00003184|Biological|sargramostim|
546385|NCT00003045|Device|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
546386|NCT00003045|Radiation|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
546387|NCT00003008|Drug|indinavir sulfate|
546388|NCT00003008|Drug|nelfinavir mesylate|
546389|NCT00003008|Drug|paclitaxel|
546390|NCT00003008|Drug|ritonavir|
546391|NCT00003008|Drug|saquinavir mesylate|
546392|NCT00002965|Biological|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
546393|NCT00064584|Drug|CT53518|
546394|NCT00064571|Procedure|vocal fold medialization|
546395|NCT00064571|Procedure|vocal fold reinnervation|
546396|NCT00064467|Drug|Extended-release bupropion (HCl)|
546397|NCT00064454|Drug|OPC-6535 Tablets (drug)|
546398|NCT00064441|Drug|OPC-6535 Tablets (drug)|
546399|NCT00064415|Drug|arformoterol|Arformoterol inhalation solution, 50 mcg QD
546400|NCT00064415|Drug|Salmeterol|Salmeterol MDI, 42 mcg BID
546401|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
546402|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
546403|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
546404|NCT00064402|Drug|Salmeterol|Salmeterol MDI 42 mcg BID
546405|NCT00064402|Drug|Placebo|Placebo BID
546406|NCT00064389|Drug|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
546407|NCT00064389|Drug|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
546408|NCT00064376|Drug|paricalcitol|
546409|NCT00064363|Drug|talampanel|
546410|NCT00064350|Drug|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.~Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.~Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
546411|NCT00064350|Drug|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
546412|NCT00064337|Biological|filgrastim|
546413|NCT00064337|Drug|cyclophosphamide|
546414|NCT00064337|Drug|dexamethasone|
546415|NCT00064337|Drug|melphalan|
546416|NCT00064337|Drug|thalidomide|
546417|NCT00064337|Procedure|peripheral blood stem cell transplantation|
546418|NCT00064324|Drug|perifosine|Given orally
546419|NCT00064324|Other|laboratory biomarker analysis|Correlative studies
546420|NCT00064324|Other|pharmacological study|Correlative studies
546421|NCT00064311|Drug|ravuconazole|
546422|NCT00064298|Dietary Supplement|fruit and vegetable extracts|Given orally
546423|NCT00064298|Dietary Supplement|placebo|Given orally
546424|NCT00064285|Drug|alvocidib|
546425|NCT00064285|Drug|imatinib mesylate|
546426|NCT00064272|Drug|ginger extract|Given orally
546427|NCT00064272|Other|placebo|Given orally
546428|NCT00064259|Biological|oblimersen sodium|Given IV
546430|NCT00064259|Drug|fluorouracil|Given IV
546431|NCT00064246|Biological|rituximab|Given IV
546432|NCT00064246|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
546433|NCT00064246|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
546434|NCT00064233|Drug|dasatinib|
546435|NCT00064220|Drug|soblidotin|
546436|NCT00064207|Drug|gemcitabine hydrochloride|
546437|NCT00064207|Procedure|adjuvant therapy|
546438|NCT00064207|Radiation|radiation therapy|
546439|NCT00064194|Dietary Supplement|selenium|
546440|NCT00064194|Dietary Supplement|soy protein isolate|
546441|NCT00064194|Dietary Supplement|vitamin E|
546442|NCT00064181|Drug|FOLFIRI regimen|
546443|NCT00064181|Drug|capecitabine|
546444|NCT00064181|Drug|celecoxib|
546445|NCT00064181|Drug|fluorouracil|
546446|NCT00064181|Drug|irinotecan hydrochloride|
546447|NCT00064181|Drug|leucovorin calcium|
546448|NCT00064142|Drug|halofuginone hydrobromide|Applied topically
546449|NCT00064142|Other|placebo|Applied topically
546450|NCT00064142|Other|laboratory biomarker analysis|Correlative studies
546451|NCT00064142|Other|pharmacological study|Correlative studies
546452|NCT00064129|Biological|Ipilimumab|Given IV
546453|NCT00064129|Other|Laboratory Biomarker Analysis|Correlative studies
546454|NCT00064129|Other|Pharmacological Study|Correlative studies
546455|NCT00064129|Biological|Sargramostim|Given SC
546456|NCT00064116|Biological|rituximab|Rituximab 375 mg/m² i.v. day 1
546457|NCT00064116|Drug|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
546458|NCT00064103|Biological|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
546459|NCT00064103|Other|laboratory biomarker analysis|Correlative studies
546460|NCT00064090|Drug|cytarabine|
546461|NCT00064090|Drug|triapine|
546462|NCT00064077|Drug|Cisplatin|Given IV
546463|NCT00064077|Drug|Gemcitabine Hydrochloride|
546464|NCT00064077|Drug|Paclitaxel|Given IV
546465|NCT00064077|Other|Quality-of-Life Assessment|Ancillary studies
546466|NCT00064077|Drug|Topotecan Hydrochloride|Given IV
546467|NCT00064077|Drug|Vinorelbine Tartrate|Given IV
546468|NCT00064064|Drug|gemcitabine hydrochloride|
546469|NCT00064064|Drug|triapine|
546470|NCT00064051|Drug|gemcitabine hydrochloride|
546471|NCT00064051|Drug|triapine|
546472|NCT00064038|Drug|dexamethasone|Given orally
546473|NCT00064038|Drug|lenalidomide|Given orally
546474|NCT00064038|Other|placebo|Given orally
546475|NCT00064025|Other|Laboratory Biomarker Analysis|Correlative studies
546476|NCT00064025|Drug|Medroxyprogesterone|Given IM
546477|NCT00064025|Procedure|Therapeutic Conventional Surgery|Undergo surgical hysterectomy
546478|NCT00064012|Drug|bortezomib|
546479|NCT00064012|Drug|docetaxel|
546480|NCT00063999|Drug|Carboplatin|Given IV
546481|NCT00063999|Drug|Cisplatin|Given IV
546482|NCT00063999|Drug|Doxorubicin Hydrochloride|Given IV
546483|NCT00063999|Biological|Filgrastim|Given SC
546484|NCT00063999|Other|Laboratory Biomarker Analysis|Correlative studies
546485|NCT00063999|Drug|Paclitaxel|Given IV
546486|NCT00063999|Biological|Pegfilgrastim|Given SC
546487|NCT00063999|Other|Quality-of-Life Assessment|Ancillary studies
546488|NCT00063986|Procedure|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
546489|NCT00063973|Drug|cilengitide|Given IV
546490|NCT00063973|Other|laboratory biomarker analysis|Correlative studies
546491|NCT00063960|Drug|floxuridine|
546492|NCT00063960|Drug|irinotecan hydrochloride|
546493|NCT00063947|Drug|erlotinib hydrochloride|Given orally
546494|NCT00063947|Drug|gemcitabine hydrochloride|Given IV
546495|NCT00063947|Radiation|radiation therapy|Undergo radiotherapy
546496|NCT00063947|Other|laboratory biomarker analysis|Correlative studies
546497|NCT00063934|Biological|oblimersen sodium|Given IV
546498|NCT00063934|Drug|doxorubicin hydrochloride|Given IV
546499|NCT00063934|Drug|docetaxel|Given IV
546500|NCT00063934|Biological|filgrastim|Given SC
546501|NCT00063934|Biological|pegfilgrastim|Given SC
546502|NCT00063934|Procedure|therapeutic conventional surgery|Undergo surgical resection
546503|NCT00063934|Other|pharmacological study|Optional correlative studies
546504|NCT00063934|Other|laboratory biomarker analysis|Optional correlative studies
546505|NCT00063895|Drug|erlotinib hydrochloride|Given PO
546506|NCT00063895|Other|pharmacological study|Correlative studies
546507|NCT00063895|Other|pharmacogenomic studies|Correlative studies
546508|NCT00063895|Other|laboratory biomarker analysis|Correlative studies
546509|NCT00063882|Radiation|Brachytherapy (100/110)|100 Gy Palladium-103 (P-102) or 110 Gy Iodine-125 (I-125) seeds within 2-4 weeks of completion of external beam radiotherapy.
546510|NCT00063882|Radiation|Brachytherapy (125/145)|125 Gy Palladium-103 (P-103) or 145 Gy Iodine-125 (I-125) seeds within 4 weeks of study entry.
546511|NCT00063882|Radiation|External Beam Radiation Therapy|Total dose of 45 Gy to the prostate and seminal vesicles as a daily dose of 1.8 Gy given 5 times per week. The prescribed dose is defined at the International Commission of Radiation Units and Measurements (ICRU) reference point. Both 3D-conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) are permitted.
546512|NCT00063869|Drug|Etanercept|
546513|NCT00023907|Drug|paclitaxel|
546514|NCT00005940|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
546515|NCT00005940|Drug|busulfan|Given PO
546516|NCT00005940|Drug|cyclophosphamide|Given IV
546517|NCT00005940|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
546518|NCT00005940|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
546519|NCT00005940|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
546520|NCT00005940|Drug|cyclosporine|Given IV or PO
546521|NCT00005940|Drug|methotrexate|Given IV
546522|NCT00005940|Other|laboratory biomarker analysis|Correlative studies
546523|NCT00003211|Biological|filgrastim|
546524|NCT00003211|Drug|amifostine trihydrate|
546525|NCT00003211|Drug|cisplatin|
546526|NCT00003211|Drug|cyclophosphamide|
546527|NCT00003211|Drug|vincristine sulfate|
546528|NCT00003211|Procedure|peripheral blood stem cell transplantation|
546529|NCT00003211|Radiation|radiation therapy|
546530|NCT00002878|Drug|dexamethasone|
546531|NCT00002878|Drug|doxorubicin hydrochloride|
546532|NCT00002878|Drug|valspodar|
546533|NCT00002878|Drug|vincristine sulfate|
546534|NCT00063856|Biological|Wetvax (APSV)|
546535|NCT00063843|Biological|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
546536|NCT00063830|Drug|Alicaforsen|
546537|NCT00063817|Drug|Conditioning Regimen|Cyclophosphamide 60 mg per kilogram (kg) of body weight per day intravenously (IV) on days -5 and -4 with respect to transplantation; humanized anti-CD2 monoclonal antibody (MEDI-507) 0.6 mg per kg on days -1, 0, and 1 (after test dose of 0.1 mg per kg on day -2); and cyclosporine A 5 mg per kg IV and thymic irradiation (700 cGy) on day -1. Hemodialysis was performed before and 14 hours after each dose of cyclophosphamide.Kidney transplantation was followed by IV infusion of donor bone marrow. Oral cyclosporine A was administered postoperatively, 8 to 12 mg per kg per day, with target trough blood levels of 250 to 350 ng per milliliter; the dose was tapered and discontinued over a period of several months. Protocol amendment that applied to participant 4 and 5: rituximab, 375 mg per square meter of body-surface area days -7 and -2; and prednisone, 2 mg per kg per day starting on the day of transplantation with tapering over the next 10 days.
546538|NCT00063804|Drug|Ritonavir|
546539|NCT00063804|Drug|AMD070|
546540|NCT00063791|Drug|Bortezomib|
546541|NCT00063778|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
546542|NCT00063778|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
546543|NCT00063752|Drug|PI-0824|
546544|NCT00045357|Biological|therapeutic autologous lymphocytes|
546545|NCT00042900|Drug|pyroxamide|
546546|NCT00040820|Drug|oxaliplatin|
546547|NCT00039169|Drug|ortataxel|
546548|NCT00036660|Drug|SarCNU|
546549|NCT00033384|Drug|CI-1040|
546550|NCT00002752|Radiation|iodine I 131 monoclonal antibody 81C6|
546551|NCT00002582|Drug|CMF regimen|
546552|NCT00002582|Drug|cyclophosphamide|
546553|NCT00002582|Drug|doxorubicin hydrochloride|
546554|NCT00002582|Drug|fluorouracil|
546555|NCT00002582|Drug|goserelin acetate|
546556|NCT00002582|Drug|leuprolide acetate|
546557|NCT00002582|Drug|methotrexate|
546558|NCT00002582|Drug|tamoxifen citrate|
546559|NCT00002582|Procedure|oophorectomy|
546560|NCT00002582|Radiation|radiation therapy|
546561|NCT00063765|Drug|Ciliary Neurotrophic Factor Implant NT-501|
546562|NCT00063713|Drug|VELCADE TM (bortezomib) for Injection|
546563|NCT00063700|Procedure|reducing exposure to marketing pressures|
546564|NCT00063687|Drug|Oxypurinol|
546565|NCT00063674|Behavioral|Nutrition Education|
546566|NCT00063674|Behavioral|After-school dance class|
546567|NCT00063648|Biological|EBV-specific autologous CTL|
546568|NCT00063635|Drug|Metformin|500 mg, twice daily
546569|NCT00063635|Dietary Supplement|Vitamin E|400 IU, twice daily
546570|NCT00063635|Drug|Matching placebo|Twice daily
546571|NCT00063622|Drug|Pioglitazone|30 mg daily
546572|NCT00063622|Dietary Supplement|Vitamin E|800 IU daily
546573|NCT00063622|Drug|Matching placebo|Daily
546574|NCT00063609|Drug|zoledronic acid|
546575|NCT00063596|Drug|Vitamin A supplementation|
546576|NCT00063583|Drug|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
546577|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
546578|NCT00063570|Drug|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
546579|NCT00063570|Drug|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
546580|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
546581|NCT00063323|Drug|Bupropion|
546582|NCT00033319|Dietary Supplement|folic acid|
546583|NCT00033319|Drug|acetylsalicylic acid|
546584|NCT00031954|Drug|carboplatin|
546585|NCT00031954|Drug|gemcitabine hydrochloride|
546586|NCT00031954|Drug|paclitaxel|
546587|NCT00031889|Drug|Exemestane|Exemestane
546588|NCT00031889|Drug|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
546589|NCT00031668|Radiation|radiation therapy|
546590|NCT00028938|Biological|epoetin alfa|
546591|NCT00028938|Drug|carboplatin|
546592|NCT00028938|Drug|paclitaxel|
546593|NCT00028938|Radiation|radiation therapy|
546594|NCT00063479|Drug|Zoledronic Acid|
546595|NCT00063453|Dietary Supplement|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
546596|NCT00063453|Dietary Supplement|Selenium|selenium (200 μg/d L-selenomethionine)
546597|NCT00063453|Dietary Supplement|Vitamin E placebo|placebo
546598|NCT00063453|Dietary Supplement|Selenium placebo|placebo
546599|NCT00028925|Biological|filgrastim|
546600|NCT00028925|Drug|carboplatin|
546601|NCT00028925|Drug|topotecan hydrochloride|
546603|NCT00028613|Radiation|iodine I 131 monoclonal antibody Lym-1|
546604|NCT00063427|Drug|MAC-321|
546605|NCT00063414|Drug|Alicaforsen|
546606|NCT00063401|Biological|Cetuximab:|400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
546607|NCT00063401|Drug|Paclitaxel|175 mg/m2 Day 1, six 21-day cycles
546608|NCT00063401|Drug|Carboplatin|AUC = 6 Day1, six 21-day cycles
546609|NCT00063388|Biological|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
546610|NCT00063375|Behavioral|Computer Based Cognitive Behavioral Therapy|
546611|NCT00063362|Drug|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
546612|NCT00063362|Drug|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
546613|NCT00063362|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
546614|NCT00063362|Drug|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
546615|NCT00063336|Behavioral|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
546616|NCT00063336|Behavioral|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
546617|NCT00030446|Drug|carboplatin|
546618|NCT00030446|Drug|erlotinib hydrochloride|
546619|NCT00028483|Drug|cBR96-doxorubicin immunoconjugate|
546620|NCT00028483|Drug|docetaxel|
546621|NCT00006968|Biological|filgrastim|
546622|NCT00006968|Drug|cyclosporine|
546623|NCT00006968|Drug|pentostatin|
546624|NCT00006968|Procedure|allogeneic bone marrow transplantation|
546625|NCT00006968|Procedure|peripheral blood stem cell transplantation|
546626|NCT00003352|Drug|cyclophosphamide|600 mg/m2, IV, every 3 weeks
546627|NCT00003352|Drug|Taxotere|60 mg/m2, IV, every 3 weeks
546628|NCT00003352|Drug|Adriamycin|60 mg/m2, IV, every 3 weeks
546629|NCT00063310|Drug|Leuprolide acetate|
546630|NCT00063297|Drug|R209130|
546631|NCT00040729|Genetic|mutation analysis|
546632|NCT00063284|Device|Magstim Rapid Magnetic Stimulator|
546633|NCT00063258|Drug|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
546634|NCT00063258|Drug|Paclitaxel|Planned dose of 200 mg/m^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
546635|NCT00063258|Drug|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
546636|NCT00063219|Drug|MAC-321|
546637|NCT00063206|Drug|DVS-233 SR|
546638|NCT00063193|Drug|minocycline|
546639|NCT00063193|Drug|creatine|
546640|NCT00063154|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
546641|NCT00063141|Drug|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
546642|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
546643|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
546644|NCT00063128|Drug|insulin|"Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.~Inject into abdomen only."
546645|NCT00063128|Drug|human insulin inhalation powder (HIIP)|"Administer HIIP within 15 minutes before meals.~Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin"
546646|NCT00030797|Drug|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
546647|NCT00030797|Drug|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
546648|NCT00026520|Biological|recombinant interferon alfa|
546649|NCT00026520|Drug|thalidomide|
546650|NCT00026364|Drug|fluorouracil|
546651|NCT00026364|Drug|gefitinib|
546652|NCT00026364|Drug|irinotecan hydrochloride|
546653|NCT00026364|Drug|leucovorin calcium|
546654|NCT00026351|Biological|rituximab|
546655|NCT00026351|Drug|pentostatin|
546656|NCT00025571|Drug|HPPH|
546657|NCT00006013|Drug|semaxanib|
546658|NCT00004037|Drug|docetaxel|
546659|NCT00003054|Drug|paclitaxel|
546730|NCT00022594|Drug|liposomal lurtotecan|
546731|NCT00022529|Drug|BMS-214662|Given IV
546732|NCT00022529|Biological|trastuzumab|Given IV
546733|NCT00022529|Other|pharmacological study|Correlative studies
546734|NCT00062764|Drug|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
546735|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
546660|NCT00063232|Drug|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
546661|NCT00063102|Drug|ABT-751|
546662|NCT00063089|Drug|S. aureus Immune Globulin Intravenous (Human) 5%|
546663|NCT00063076|Drug|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
546664|NCT00063050|Behavioral|Physical activity and nutrition intervention|
546665|NCT00063037|Behavioral|Behavioral modification - nutrition education|
546666|NCT00063024|Behavioral|Increased calcium intake|
546667|NCT00063024|Behavioral|Weight-bearing physical activity|
546668|NCT00063011|Behavioral|Calcium rich diet|
546669|NCT00063011|Behavioral|Weight bearing exercise|
546670|NCT00025545|Drug|cyclophosphamide|
546671|NCT00025545|Drug|methotrexate|
546672|NCT00025545|Procedure|peripheral blood stem cell transplantation|
546673|NCT00025545|Radiation|radiation therapy|
546674|NCT00024323|Drug|cisplatin|
546675|NCT00024323|Drug|triapine|
546676|NCT00024310|Dietary Supplement|folic acid|
546677|NCT00024310|Drug|lometrexol|
546678|NCT00024310|Drug|paclitaxel|
546679|NCT00024141|Drug|fluorouracil|
546680|NCT00024141|Drug|irinotecan hydrochloride|
546681|NCT00023933|Drug|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
546682|NCT00062985|Behavioral|Mail-based weight loss intervention|
546683|NCT00062985|Behavioral|Phone-based weight loss intervention|
546684|NCT00062972|Drug|donepezil|
546685|NCT00062972|Drug|glucose|
546686|NCT00062959|Behavioral|Going Places: School program to prevent problem behavior|
546687|NCT00062907|Biological|Recombinant DNA- pVAX/L523S|
546688|NCT00062907|Biological|Recombinant adenovirus- Ad/L523S|
546689|NCT00062894|Drug|Iodine I 131 Tositumomab|
546690|NCT00062946|Drug|(18F)fallypride|
546691|NCT00062933|Procedure|Laparotomy|
546692|NCT00062881|Drug|Intrathecal Mafosfamide|
546693|NCT00062868|Biological|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2 x 10^7 cells/m2; Day 14: 2 x 10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
546694|NCT00062868|Biological|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
546695|NCT00062868|Biological|LMP1/2 CTLs (Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One~Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2~Dose Level Two~Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2~Dose Level Three~Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
546696|NCT00062855|Procedure|Skin Biopsy|
546697|NCT00062855|Genetic|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.~A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).~At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
546698|NCT00062842|Drug|Irinotecan|
546699|NCT00062829|Behavioral|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
546700|NCT00062816|Drug|ISIS 14803, peginterferon alfa, ribavirin|
546701|NCT00002643|Biological|filgrastim|
546702|NCT00002643|Drug|amifostine trihydrate|
546703|NCT00002643|Drug|cyclophosphamide|
546704|NCT00002643|Drug|doxorubicin hydrochloride|
546705|NCT00002643|Drug|etoposide|
546706|NCT00002643|Drug|ifosfamide|
546707|NCT00002643|Drug|topotecan hydrochloride|
546708|NCT00002643|Drug|vincristine sulfate|
546709|NCT00002643|Procedure|conventional surgery|
546710|NCT00002643|Radiation|low-LET cobalt-60 gamma ray therapy|
546711|NCT00002643|Radiation|low-LET electron therapy|
546712|NCT00002643|Radiation|low-LET photon therapy|
546713|NCT00062803|Drug|SR34006|
546714|NCT00062803|Drug|(LMW)heparin|
546715|NCT00062803|Drug|Warfarin VKA|
546716|NCT00062803|Drug|Acenocoumarol VKA|
546717|NCT00062790|Drug|Dutasteride|
546718|NCT00027612|Drug|carmustine|IV
546719|NCT00027612|Drug|irinotecan hydrochloride|IV
546720|NCT00027612|Radiation|radiation therapy|
546721|NCT00025376|Drug|PS-341|
546722|NCT00025376|Procedure|Tumor Biopsy|
546723|NCT00023868|Drug|FOLFIRI regimen|
546724|NCT00023868|Drug|cisplatin|
546725|NCT00023868|Drug|doxorubicin hydrochloride|
546726|NCT00023868|Drug|fluorouracil|
546727|NCT00023868|Drug|irinotecan hydrochloride|
546728|NCT00023868|Drug|leucovorin calcium|
546736|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
546737|NCT00062751|Drug|Letrozole|Letrozole 2.5 mg daily
546738|NCT00062738|Drug|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
546739|NCT00062738|Drug|Nortriptyline|nortriptyline 25 - 75 mg q hs
546740|NCT00062738|Other|placebo|matching placebo
546741|NCT00062699|Drug|Zemplar (paricalcitol injection)|
546742|NCT00062699|Drug|Calcijex|
546743|NCT00062712|Drug|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
546744|NCT00062686|Drug|GW572016|
546745|NCT00062673|Drug|Duloxetine|
546746|NCT00062673|Drug|Placebo|
546747|NCT00062660|Drug|Tipranavir|Tipranavir 250 mg soft elastic capsules
546748|NCT00062647|Drug|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
546749|NCT00062647|Drug|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
546750|NCT00062634|Behavioral|Female condom skills training|
546751|NCT00062621|Procedure|Combined bone marrow and kidney transplant|
546752|NCT00062608|Behavioral|Written self-disclosure|
546753|NCT00062595|Drug|phylloquinone (K1)|
546754|NCT00062595|Drug|menatetranone (MK4)|
546755|NCT00062569|Behavioral|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
546756|NCT00062569|Behavioral|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
546757|NCT00062556|Drug|Niacin Extended Release and Lovastatin Tablets|
546758|NCT00062543|Procedure|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
546759|NCT00062543|Device|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
546760|NCT00062530|Biological|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
546761|NCT00062504|Drug|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
546762|NCT00062491|Drug|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
546763|NCT00062478|Drug|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
546764|NCT00022009|Drug|gemcitabine hydrochloride|
546765|NCT00018954|Drug|asparaginase|
546766|NCT00018954|Drug|cyclophosphamide|
546767|NCT00018954|Drug|cytarabine|
546768|NCT00018954|Drug|daunorubicin hydrochloride|
546769|NCT00018954|Drug|doxorubicin hydrochloride|
546770|NCT00018954|Drug|etoposide|
546771|NCT00018954|Drug|ifosfamide|
546772|NCT00018954|Drug|mercaptopurine|
546773|NCT00018954|Drug|methotrexate|
546774|NCT00018954|Drug|prednisone|
546775|NCT00018954|Drug|vincristine sulfate|
546776|NCT00018954|Procedure|conventional surgery|
546777|NCT00018954|Radiation|radiation therapy|
546778|NCT00017446|Drug|CP4071|
546779|NCT00017394|Biological|bevacizumab|Given IV
546780|NCT00017394|Drug|vinorelbine tartrate|Given IV
546781|NCT00017394|Other|laboratory biomarker analysis|Correlative studies
546782|NCT00017316|Drug|semaxanib|
546783|NCT00017316|Drug|thalidomide|
546784|NCT00062582|Drug|Roflumilast|
546785|NCT00016107|Drug|estramustine phosphate sodium|Given orally
546786|NCT00016107|Drug|docetaxel|Given IV
546787|NCT00016107|Biological|bevacizumab|Given IV
546788|NCT00016107|Other|laboratory biomarker analysis|Correlative studies
546789|NCT00014664|Biological|apolizumab|
546790|NCT00014534|Biological|filgrastim|6 mg sub Q
546791|NCT00014534|Drug|cisplatin|60 mg/sq m IV
546792|NCT00014534|Drug|doxorubicin hydrochloride|50 mg/ sq m IV
546793|NCT00014534|Drug|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
546794|NCT00014170|Drug|gefitinib|Given orally
546795|NCT00014170|Other|pharmacological study|Correlative studies
546796|NCT00014170|Other|laboratory biomarker analysis|Correlative studies
546797|NCT00014170|Other|questionnaire administration|Ancillary studies
546798|NCT00014170|Procedure|quality-of-life assessment|Ancillary studies
546799|NCT00012155|Biological|NV1020|
546800|NCT00062465|Drug|TwHF|
546801|NCT00062439|Drug|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 & 36. In any appropriate vehicle over 60 minutes
546802|NCT00062439|Drug|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
546803|NCT00062439|Drug|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
546804|NCT00062439|Procedure|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
546890|NCT00061945|Drug|daunorubicin hydrochloride|Given IV
546805|NCT00062439|Radiation|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
546806|NCT00062426|Biological|bevacizumab|
546807|NCT00062426|Drug|capecitabine|
546808|NCT00062426|Drug|fluorouracil|
546809|NCT00062426|Drug|leucovorin calcium|
546810|NCT00062426|Drug|oxaliplatin|
546811|NCT00062400|Procedure|psychosocial assessment and care|
546812|NCT00062387|Drug|perifosine|
546813|NCT00062374|Drug|Cisplatin|Given IV
546814|NCT00062374|Procedure|Computed Tomography|Undergo FDG and FLT PET/CT
546815|NCT00062374|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
546816|NCT00062374|Other|Fluorothymidine F-18|Undergo FLT-PET/CT
546817|NCT00062374|Drug|Irinotecan Hydrochloride|Given IV
546818|NCT00062374|Procedure|Positron Emission Tomography|Undergo FDG and FLT PET/CT
546819|NCT00062374|Procedure|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
546820|NCT00062348|Drug|boronophenylalanine-fructose complex|
546821|NCT00062348|Drug|sodium borocaptate|
546822|NCT00062348|Procedure|conventional surgery|
546823|NCT00062335|Radiation|radiation therapy|
546824|NCT00062322|Drug|cisplatin|
546825|NCT00062322|Drug|irinotecan hydrochloride|
546826|NCT00062322|Procedure|conventional surgery|
546827|NCT00062322|Procedure|neoadjuvant therapy|
546828|NCT00062322|Radiation|radiation therapy|
546829|NCT00062309|Radiation|radiation therapy|
546830|NCT00062296|Biological|rituximab|
546831|NCT00062296|Drug|epirubicin hydrochloride|
546832|NCT00062283|Drug|L-alanosine|
546833|NCT00062270|Drug|cisplatin|
546834|NCT00062270|Drug|docetaxel|
546835|NCT00062270|Drug|gefitinib|
546836|NCT00062270|Drug|gemcitabine hydrochloride|
546837|NCT00062270|Procedure|conventional surgery|
546838|NCT00062270|Procedure|neoadjuvant therapy|
546839|NCT00062270|Radiation|radiation therapy|
546840|NCT00062257|Drug|irofulven|
546841|NCT00062244|Biological|oblimersen sodium|Given IV
546842|NCT00062231|Drug|amoxicillin-clavulanate potassium|
546843|NCT00062231|Drug|ciprofloxacin|
546844|NCT00062231|Drug|moxifloxacin hydrochloride|
546845|NCT00062231|Procedure|management of therapy complications|
546846|NCT00062205|Drug|imatinib mesylate|
546847|NCT00062179|Drug|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
546848|NCT00062179|Drug|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
546849|NCT00062179|Drug|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
546850|NCT00062179|Other|Placebo|placebo 3-7 days before first dose of chemotherapy
546851|NCT00062140|Drug|cyclophosphamide|
546852|NCT00062140|Procedure|allogeneic bone marrow transplantation|
546853|NCT00062140|Procedure|peripheral blood stem cell transplantation|
546854|NCT00062140|Radiation|radiation therapy|
546855|NCT00062127|Drug|irinotecan hydrochloride|Given IV
546856|NCT00062127|Drug|thalidomide|Given orally
546857|NCT00062127|Other|pharmacological study|Correlative studies
546858|NCT00062114|Biological|rituximab|
546859|NCT00062114|Radiation|yttrium Y 90 ibritumomab tiuxetan|
546860|NCT00062101|Drug|erlotinib hydrochloride|Given orally (PO)
546861|NCT00062101|Drug|celecoxib|Given PO
546862|NCT00062101|Other|laboratory biomarker analysis|Correlative studies
546863|NCT00062075|Drug|romidepsin|Given IV
546864|NCT00062062|Drug|carboplatin|
546865|NCT00062062|Drug|gefitinib|
546866|NCT00062062|Drug|paclitaxel|
546867|NCT00062049|Biological|recombinant interleukin-7|
546868|NCT00062036|Biological|aldesleukin|
546869|NCT00062036|Biological|filgrastim|
546870|NCT00062036|Biological|incomplete Freund's adjuvant|
546871|NCT00062036|Biological|interleukin-2 gene|
546872|NCT00062036|Biological|therapeutic tumor infiltrating lymphocytes|
546873|NCT00062036|Drug|cyclophosphamide|
546874|NCT00062036|Drug|fludarabine phosphate|
546875|NCT00062023|Drug|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
546876|NCT00062023|Drug|Sulindac|Patients receive oral sulindac twice daily for 12 months.
546877|NCT00062023|Drug|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
546878|NCT00062023|Other|Sulindac Placebo|Oral sulindac placebo twice daily.
546879|NCT00062010|Biological|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
546880|NCT00062010|Drug|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
546881|NCT00062010|Drug|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
546882|NCT00061997|Dietary Supplement|inositol|
546883|NCT00061984|Biological|pegfilgrastim|
546884|NCT00061984|Drug|doxorubicin hydrochloride|
546885|NCT00061984|Drug|ifosfamide|
546886|NCT00061984|Procedure|multimodality therapy|
546887|NCT00061958|Drug|arsenic trioxide|Given IV
546888|NCT00061945|Drug|allopurinol|Given PO
546889|NCT00061945|Drug|cyclophosphamide|Given IV
546891|NCT00061945|Drug|vincristine sulfate|Given IV
546892|NCT00061945|Drug|dexamethasone|Given PO and as eye drops
546893|NCT00061945|Drug|asparaginase|Given SC
546894|NCT00061945|Biological|filgrastim|Given SC
546895|NCT00061945|Drug|imatinib mesylate|Given PO
546896|NCT00061945|Drug|methotrexate|Given IT, IV, and PO
546897|NCT00061945|Drug|cytarabine|Given IV
546898|NCT00061945|Drug|trimethoprim-sulfamethoxazole|Given PO
546899|NCT00061945|Drug|mercaptopurine|Given PO
546900|NCT00061945|Drug|leucovorin calcium|Given IV and PO
546901|NCT00061945|Biological|alemtuzumab|Given SC
546902|NCT00061945|Drug|acyclovir|Given PO
546903|NCT00061945|Other|laboratory biomarker analysis|Correlative studies
546904|NCT00061945|Other|pharmacological study|Correlative studies
546905|NCT00061932|Drug|bortezomib|Given IV
546906|NCT00061932|Drug|irinotecan|Given IV
546907|NCT00061919|Drug|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
546908|NCT00061919|Drug|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
546909|NCT00061906|Drug|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
546910|NCT00061893|Drug|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. [Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.] .
546911|NCT00061893|Drug|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
546912|NCT00061893|Drug|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
546913|NCT00061893|Drug|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
546914|NCT00061893|Drug|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
546915|NCT00061893|Drug|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. [Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.]
546916|NCT00061893|Drug|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
546917|NCT00061893|Procedure|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
546918|NCT00061893|Radiation|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
546919|NCT00061893|Drug|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
546920|NCT00061893|Drug|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
546921|NCT00061880|Drug|forodesine hydrochloride|
546922|NCT00061867|Drug|pegylated liposomal doxorubicin hydrochloride|
546923|NCT00061867|Procedure|hyperthermia treatment|
546924|NCT00061854|Drug|soblidotin|
546925|NCT00061841|Behavioral|exercise|
546926|NCT00061815|Biological|cetuximab|400 mg/m2 IV
546927|NCT00061815|Drug|oxaliplatin|85 mg/m2 IV
546928|NCT00061815|Drug|leucovorin|200 mg/m2 IV
546929|NCT00061815|Drug|5-fluorouracil|400 mg/m2 IV
546930|NCT00061815|Drug|5-fluorouracil|600 mg/m2 IV
546931|NCT00061815|Biological|cetuximab|250 mg/m2 IV
546932|NCT00033462|Drug|erlotinib hydrochloride|Given orally
546933|NCT00033462|Other|laboratory biomarker analysis|Correlative studies
546934|NCT00010231|Dietary Supplement|calcitriol|
546935|NCT00010231|Drug|dexamethasone|
546939|NCT00009802|Dietary Supplement|calcitriol|
546940|NCT00009802|Drug|paclitaxel|
546941|NCT00061802|Drug|risperidone, quetiapine|
546942|NCT00009789|Radiation|accelerated conformational radiotherapy|
546943|NCT00008424|Drug|irinotecan hydrochloride|
546944|NCT00008398|Biological|sargramostim|
546945|NCT00008398|Procedure|quality-of-life assessment|
546946|NCT00008398|Radiation|radiation therapy|
546947|NCT00008203|Biological|aldesleukin|
546948|NCT00008203|Biological|recombinant interferon gamma|
546949|NCT00008203|Drug|carboplatin|
546950|NCT00008203|Drug|cyclophosphamide|
546951|NCT00008203|Drug|cyclosporine|
546952|NCT00008203|Drug|thiotepa|
546953|NCT00008203|Procedure|autologous bone marrow transplantation|
546954|NCT00008203|Procedure|peripheral blood stem cell transplantation|
546955|NCT00008112|Drug|cisplatin|
546956|NCT00008112|Procedure|hyperthermia treatment|
546957|NCT00008112|Radiation|brachytherapy|
546958|NCT00008112|Radiation|radiation therapy|
546959|NCT00061789|Drug|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
546960|NCT00061776|Drug|Capsaicin Dermal Patch|
546961|NCT00061763|Drug|Deferasirox|
546962|NCT00061750|Drug|ICL670|
546963|NCT00061750|Drug|deferoxamine|
546964|NCT00061711|Drug|Hormone Replacement Therapy|
546965|NCT00061711|Drug|Cimicifuga racemosa (Black Cohosh)|
546966|NCT00061711|Drug|Multibotanical phytoestrogen formula|
546967|NCT00061698|Behavioral|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
546968|NCT00061698|Behavioral|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
546969|NCT00061672|Drug|ABT-510 - Thrombospondin-1 Mimetic|
546970|NCT00061659|Drug|ABT-510 - Thrombospondin-1 mimetic|
546971|NCT00061646|Drug|ABT-510/Thrombospondin-1 mimetic|
546972|NCT00061646|Drug|Carboplatin/Taxol|
546973|NCT00051714|Behavioral|Family-Based Preventive Intervention|
546974|NCT00061633|Drug|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
546975|NCT00061633|Drug|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
546976|NCT00061620|Drug|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
546977|NCT00059462|Drug|Interleukin-2 SA|HAART and Bay 50-4798
546978|NCT00059462|Drug|HAART|HAART alone
546979|NCT00008021|Biological|filgrastim|
546980|NCT00008021|Biological|monoclonal antibody Lym-1|
546981|NCT00008021|Drug|cyclosporine|
546982|NCT00008021|Drug|paclitaxel|
546983|NCT00008021|Procedure|peripheral blood stem cell transplantation|
546984|NCT00008021|Radiation|indium In 111 monoclonal antibody Lym-1|
546985|NCT00008021|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
546986|NCT00006864|Biological|aldesleukin|
546987|NCT00006484|Drug|carboplatin|
546988|NCT00006484|Drug|paclitaxel|
546989|NCT00006484|Drug|tirapazamine|
546990|NCT00061594|Drug|rhuFab V2 (ranibizumab)|
546991|NCT00061542|Drug|BETOPTIC S (betaxolol HCl)|betaxolol HC)
546992|NCT00061542|Drug|Timolol Gel-forming Solution (TGFS)|timolol maleate 0.25% and 0.5%
546993|NCT00061529|Drug|Brimonidine Tartrate Ophthalmic Solution|
546994|NCT00061516|Drug|BETAXON (levobetaxolol HCl)|levobetaxolol suspension, 0.5%
546995|NCT00061516|Drug|AZOPT (brinzolamide)|brinzolamide suspension, 1%
546996|NCT00061503|Drug|Travoprost|
546997|NCT00006464|Drug|7-hydroxystaurosporine|
546998|NCT00006464|Drug|cisplatin|
546999|NCT00006457|Drug|oltipraz|
547000|NCT00006383|Drug|liposomal vincristine sulfate|
547001|NCT00006377|Drug|carboplatin|
547002|NCT00006377|Drug|doxorubicin hydrochloride|
547003|NCT00006377|Drug|paclitaxel|
547004|NCT00006361|Drug|semaxanib|
547005|NCT00061581|Device|Isolex 300i Stem Cell Selection|
547006|NCT00061568|Procedure|Peripheral blood hematopoietic progenitor cell (PBPC) transplant|Peripheral blood hematopoietic progenitor cell (PBPC) transplant
547007|NCT00061568|Drug|Alemtuzumab|Alemtuzumab
547008|NCT00061568|Procedure|Peripheral blood hematopoieticprogenitor cell Apherisis|Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis
547009|NCT00061568|Drug|Sirolimus|Sirolimus
547010|NCT00061490|Behavioral|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
547011|NCT00061477|Drug|Pemetrexed|
547012|NCT00061477|Drug|Gemcitabine|
547013|NCT00061464|Drug|pemetrexed|
547014|NCT00061464|Drug|gemcitabine|
547015|NCT00061451|Drug|Pemetrexed|
547016|NCT00061451|Drug|Gemcitabine|
547017|NCT00006349|Dietary Supplement|vitamin E|
547018|NCT00006349|Drug|donepezil hydrochloride|
547019|NCT00006349|Other|placebo|
547020|NCT00006341|Other|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
547021|NCT00061438|Drug|meropenem|
547022|NCT00061425|Drug|radiolabeled epratuzumab|
547023|NCT00061412|Behavioral|Comprehensive program to improve reading and writing skills|
547024|NCT00061386|Behavioral|Nutrition and physical activity program|
547025|NCT00061321|Drug|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
547026|NCT00061308|Drug|Topotecan|
547027|NCT00061308|Drug|Gemcitabine|
547028|NCT00061295|Procedure|Body weight support treadmill training|
547029|NCT00045149|Biological|aldesleukin|
547030|NCT00045149|Biological|therapeutic tumor infiltrating lymphocytes|
547031|NCT00019734|Biological|aldesleukin|
547032|NCT00019734|Biological|fowlpox virus vaccine vector|
547033|NCT00019734|Biological|vaccinia-tyrosinase vaccine|
547034|NCT00061373|Drug|Aspirin|A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
547035|NCT00061373|Drug|tinzaparin sodium|A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
547036|NCT00061373|Drug|eptifibatide|Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
547037|NCT00061360|Drug|ATG+Rapamune+cyclosporine|ATG+Rapamune+cyclosporine
547038|NCT00061360|Drug|ATG+cyclosporine|ATG+cyclosporine
547039|NCT00061347|Procedure|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
547040|NCT00061282|Drug|Clotrimazole|One retention enema, administered nightly
547041|NCT00041353|Other|cytology specimen collection procedure|
547042|NCT00041353|Procedure|comparison of screening methods|
547043|NCT00041353|Procedure|study of high risk factors|
547044|NCT00019175|Biological|aldesleukin|
547045|NCT00019175|Biological|fowlpox virus vaccine vector|
547046|NCT00019175|Biological|gp100 antigen|
547047|NCT00002786|Biological|aldesleukin|
547048|NCT00002786|Biological|therapeutic tumor infiltrating lymphocytes|
547049|NCT00061269|Procedure|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
547050|NCT00061256|Drug|Alendronate|
547051|NCT00061256|Drug|Calcium carbonate|
547052|NCT00061256|Drug|Vitamin D|
547053|NCT00061243|Biological|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
547054|NCT00061230|Behavioral|biofeedback-monitored relaxation training|
547055|NCT00061217|Device|Unrectified prosthetic socket|
547056|NCT00061217|Device|Rectified prosthetic socket|
547057|NCT00061178|Drug|rhuMAb VEGF (Bevacizumab)|
547058|NCT00061165|Behavioral|School + family changes promoting healthy eating + activity|
547059|NCT00019084|Biological|aldesleukin|
547060|NCT00019084|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
547061|NCT00019084|Biological|ras peptide cancer vaccine|
547062|NCT00019084|Biological|sargramostim|
547063|NCT00019084|Biological|therapeutic autologous lymphocytes|
547064|NCT00019084|Biological|therapeutic tumor infiltrating lymphocytes|
547065|NCT00015821|Drug|thalidomide|Given PO
547066|NCT00015821|Other|laboratory biomarker analysis|Correlative studies
547067|NCT00004868|Drug|semaxanib|
547068|NCT00003408|Biological|aldesleukin|
547069|NCT00003408|Biological|recombinant interferon alfa|
547070|NCT00003408|Biological|sargramostim|
547071|NCT00061152|Drug|Capsaicin Dermal Patch|
547072|NCT00061139|Behavioral|Pediatric Constraint-Induced Movement therapy|
547073|NCT00061139|Behavioral|Conventional pediatric motor rehabilitation therapy|
547074|NCT00061126|Drug|ABX-EGF|
547075|NCT00061113|Drug|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
547076|NCT00061113|Drug|fluoxetine|20mg, QD x 16 weeks
547077|NCT00061113|Drug|placebo + CBT|single fixed morning dose X 16 weeks
547078|NCT00061100|Behavioral|Behavior Therapy-RISE|manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter
547079|NCT00061100|Behavioral|Standard prevention Education|standard psychosocial Education for HIV/hepatitis prevention
547080|NCT00061087|Drug|Methylphenidate|Methylphenidate 80mg/day
547081|NCT00061087|Drug|Bupropion|Bupropion 400mg/day
547082|NCT00061087|Other|Placebo|Placebo
547083|NCT00061074|Drug|Nicotrol|
547084|NCT00061061|Behavioral|Behavior Therapy|
547085|NCT00061035|Biological|Transgenic Lymphocyte Immunization Vaccine (TLI)|
547086|NCT00006243|Biological|tyrosinase peptide|Given SC
547087|NCT00006243|Biological|MART-1:27-35 peptide vaccine|Given SC
547088|NCT00006243|Biological|gp100 antigen|Given SC
547089|NCT00006243|Biological|incomplete Freund's adjuvant|Given SC
547090|NCT00006243|Biological|sargramostim|Given SC
547091|NCT00006243|Other|laboratory biomarker analysis|Correlative studies
547092|NCT00006242|Drug|BMS-214662|Given IV
547093|NCT00006242|Other|laboratory biomarker analysis|Correlative studies
547094|NCT00006242|Other|pharmacological study|Correlative studies
547095|NCT00006095|Drug|irinotecan hydrochloride|
547096|NCT00006095|Drug|vincristine sulfate|
547097|NCT00006086|Drug|BMS-188797|
547098|NCT00006086|Drug|carboplatin|
547099|NCT00006082|Drug|rubitecan|
547187|NCT00060632|Drug|ridaforolimus|"Administered intravenously once weekly for 4 weeks (1 cycle).~In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."
547100|NCT00061048|Biological|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
547101|NCT00061022|Drug|NXY-059|
547102|NCT00006046|Biological|monoclonal antibody Hu3S193|
547103|NCT00005999|Drug|arsenic trioxide|
547104|NCT00005977|Biological|filgrastim|Given IV
547105|NCT00005977|Drug|cyclophosphamide|Given IV
547106|NCT00005977|Drug|cytarabine|Given IV
547107|NCT00005977|Drug|dexamethasone|Given IV
547108|NCT00005977|Drug|doxorubicin hydrochloride|Given IV
547109|NCT00005977|Drug|etoposide|Given IV
547110|NCT00005977|Drug|ifosfamide|Given IV
547111|NCT00005977|Drug|leucovorin calcium|Given IV
547112|NCT00005977|Drug|methotrexate|Given IV
547113|NCT00005977|Drug|vincristine sulfate|Given IV
547114|NCT00005971|Drug|alvocidib|
547115|NCT00005956|Biological|HER-2/neu intracellular domain protein|
547116|NCT00005956|Biological|therapeutic autologous dendritic cells|
547117|NCT00005868|Drug|cisplatin|
547118|NCT00005868|Drug|docetaxel|
547119|NCT00060996|Drug|Remodulin® (treprostinil sodium) Injection|
547120|NCT00005813|Biological|bispecific antibody MDX447|
547121|NCT00005813|Biological|lymphokine-activated killer cells|
547122|NCT00005813|Procedure|conventional surgery|
547123|NCT00060983|Procedure|Body weight supported locomotor training|
547124|NCT00060983|Procedure|Functional electrical stimulation|
547125|NCT00060970|Procedure|Physical Therapy|
547126|NCT00060957|Drug|Botulinum toxin type A|
547127|NCT00060944|Drug|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
547128|NCT00060944|Drug|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
547129|NCT00060944|Drug|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
547130|NCT00060944|Drug|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
547131|NCT00005861|Drug|pegylated liposomal doxorubicin hydrochloride|
547132|NCT00005588|Radiation|radiation therapy|
547133|NCT00005587|Radiation|radiation therapy|
547134|NCT00003203|Biological|filgrastim|Given IV
547135|NCT00003203|Drug|carboplatin|Given IV
547136|NCT00003203|Drug|cisplatin|Given IV
547137|NCT00003203|Drug|cyclophosphamide|Given IV
547138|NCT00003203|Drug|vincristine sulfate|Given IV
547139|NCT00003203|Procedure|adjuvant therapy|
547140|NCT00003203|Radiation|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT*
547141|NCT00060931|Drug|carvedilol|
547142|NCT00060931|Drug|metoprolol|
547143|NCT00060918|Drug|carvedilol|
547144|NCT00060918|Drug|metoprolol|
547145|NCT00060905|Drug|Divalproex Sodium (Depakote ER)|
547146|NCT00060892|Genetic|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
547147|NCT00005086|Drug|cisplatin|
547148|NCT00005086|Drug|docetaxel|
547149|NCT00005086|Drug|gemcitabine hydrochloride|
547150|NCT00005086|Drug|methotrexate|
547151|NCT00005078|Drug|carboplatin|
547152|NCT00005078|Drug|paclitaxel|
547153|NCT00005078|Drug|tirapazamine|
547154|NCT00060866|Drug|Propranolol|
547155|NCT00060840|Drug|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
547156|NCT00060840|Drug|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
547157|NCT00060827|Device|Head Impact Recording Technology (HIRT)|
547158|NCT00060814|Other|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
547159|NCT00060801|Drug|BIIL 283 BS (Amelubent)|
547160|NCT00004931|Drug|leucovorin calcium|Given IV
547161|NCT00004931|Drug|fluorouracil|Given IV
547162|NCT00004931|Drug|oxaliplatin|Given IV
547163|NCT00004931|Other|laboratory biomarker analysis|Correlative studies
547164|NCT00004928|Dietary Supplement|calcitriol|
547165|NCT00004928|Drug|zoledronic acid|
547166|NCT00004925|Biological|trastuzumab|
547167|NCT00004925|Drug|pegylated liposomal doxorubicin hydrochloride|
547168|NCT00004916|Drug|ifosfamide|
547169|NCT00004916|Drug|paclitaxel|
547170|NCT00004916|Drug|teniposide|
547171|NCT00004916|Procedure|peripheral blood stem cell transplantation|
547172|NCT00004911|Procedure|bowel obstruction management|
547173|NCT00004911|Procedure|quality-of-life assessment|
547174|NCT00060762|Behavioral|Interpersonal Therapy|20 sessions of interpersonal therapy were provided over a 6-month period
547175|NCT00060762|Behavioral|Behavioral Weight Loss Treatment|20 sessions of behavioral weight loss treatment were provided over a 6-month period
547176|NCT00060762|Behavioral|Guided Self Help|10 sessions of guided self help were provided over a 6-month period
547177|NCT00060710|Drug|CP-461|
547178|NCT00060749|Drug|Docosahexaenoic Acid (DHA) Dietary Supplement|
547179|NCT00060697|Behavioral|Adolescent sexual activity education for mothers|
547180|NCT00060684|Drug|Pixantrone (BBR 2778)|
547181|NCT00060684|Drug|fludarabine|
547182|NCT00060684|Drug|dexamethasone|
547183|NCT00060684|Drug|rituximab|
547184|NCT00060671|Drug|rituximab|
547185|NCT00060671|Drug|Pixantrone (BBR 2778)|
547186|NCT00060645|Drug|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
547188|NCT00060619|Behavioral|thermal biofeedback|
547189|NCT00060619|Behavioral|relaxation training|
547190|NCT00060619|Behavioral|cognitive coping skills|
547191|NCT00060619|Behavioral|parent education|
547192|NCT00060606|Procedure|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
547193|NCT00060606|Procedure|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
547194|NCT00060567|Drug|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
547195|NCT00060567|Drug|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
547196|NCT00060567|Drug|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
547197|NCT00004910|Procedure|bowel obstruction management|
547198|NCT00004910|Procedure|quality-of-life assessment|
547199|NCT00004895|Drug|octreotide acetate|
547200|NCT00004255|Biological|anti-thymocyte globulin|
547201|NCT00004255|Biological|filgrastim|
547202|NCT00004255|Drug|cyclophosphamide|
547203|NCT00004255|Drug|fludarabine phosphate|
547204|NCT00004255|Drug|methylprednisolone|
547205|NCT00004255|Drug|tacrolimus|
547206|NCT00004255|Procedure|allogeneic bone marrow transplantation|
547207|NCT00004255|Procedure|in vitro-treated bone marrow transplantation|
547208|NCT00004255|Radiation|radiation therapy|
547209|NCT00004232|Biological|filgrastim|
547210|NCT00004232|Drug|cyclosporine|
547211|NCT00004232|Drug|methylprednisolone|
547212|NCT00004232|Drug|prednisone|
547213|NCT00004232|Procedure|allogeneic bone marrow transplantation|
547214|NCT00004232|Procedure|peripheral blood stem cell transplantation|
547215|NCT00004180|Drug|rosiglitazone maleate|
547216|NCT00060580|Procedure|Raman scattering spectroscopy|
547217|NCT00060554|Drug|fondaparinux sodium|
547218|NCT00060554|Drug|heparin|
547219|NCT00060554|Procedure|percutaneous coronary intervention (PCI)|
547220|NCT00060515|Drug|RG2133 (2',3',5'-tri-O-acetyluridine)|
547221|NCT00060502|Drug|Infliximab; Gemcitabine|
547222|NCT00060489|Drug|SEROQUEL (quetiapine fumarate) Tablets|
547223|NCT00004094|Drug|carboplatin|
547224|NCT00004094|Drug|fluorouracil|
547225|NCT00004094|Drug|hydroxyurea|
547226|NCT00004094|Drug|paclitaxel|
547227|NCT00004094|Procedure|conventional surgery|
547228|NCT00004094|Radiation|radiation therapy|
547229|NCT00004068|Drug|irinotecan hydrochloride|
547230|NCT00004068|Drug|temozolomide|
547231|NCT00004068|Procedure|conventional surgery|
547232|NCT00004068|Radiation|radiation therapy|
547233|NCT00004059|Drug|7-hydroxystaurosporine|
547234|NCT00004059|Drug|fluorouracil|
547235|NCT00004052|Biological|QS21|
547236|NCT00004052|Biological|bcr-abl peptide vaccine|
547237|NCT00004008|Drug|bryostatin 1|
547238|NCT00060528|Drug|Recombinant Fowlpox-GM-CSF|
547239|NCT00060528|Drug|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
547240|NCT00060528|Drug|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
547241|NCT00060528|Drug|Recombinant Human GM-CSF|
547242|NCT00060476|Drug|rofecoxib|
547243|NCT00060476|Drug|Comparator: placebo (unspecified)|
547244|NCT00060463|Behavioral|Increased access to emergency contraceptive pills|
547245|NCT00060450|Drug|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
547246|NCT00060450|Drug|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
547247|NCT00060437|Drug|perifosine|
547248|NCT00060424|Drug|Cyclosporine|Given PO
547249|NCT00060424|Drug|Fludarabine Phosphate|Given IV
547250|NCT00060424|Procedure|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
547251|NCT00060424|Other|Laboratory Biomarker Analysis|Correlative studies
547252|NCT00060424|Drug|Mycophenolate Mofetil|Given PO
547253|NCT00060424|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
547254|NCT00060424|Radiation|Total-Body Irradiation|Undergo TBI
547255|NCT00060411|Drug|erlotinib hydrochloride|Given IV
547256|NCT00060411|Drug|fluorouracil|Given IV
547257|NCT00060411|Drug|leucovorin calcium|Given IV
547258|NCT00060411|Drug|oxaliplatin|Given IV
547259|NCT00060411|Biological|bevacizumab|Given IV
547260|NCT00060398|Biological|epoetin alfa|
547261|NCT00060398|Drug|dexamethasone|
547262|NCT00060385|Drug|CHOP regimen|
547263|NCT00060385|Drug|EPOCH regimen|
547264|NCT00060385|Drug|cyclophosphamide|
547265|NCT00060385|Drug|doxorubicin hydrochloride|
547266|NCT00060385|Drug|etoposide|
547267|NCT00060385|Drug|prednisone|
547268|NCT00060385|Drug|vincristine sulfate|
547269|NCT00060385|Radiation|radiation therapy|
547270|NCT00060372|Drug|ipilimumab|Given IV
547271|NCT00060372|Drug|therapeutic allogeneic lymphocytes|Given IV
547272|NCT00060359|Drug|Carboplatin|Given IV
547273|NCT00060359|Drug|Paclitaxel Poliglumex|Given IV
547274|NCT00060359|Other|Pharmacological Study|Correlative studies
547346|NCT00059826|Drug|cisplatin|IV
547347|NCT00059826|Drug|5-fluorouracil|IV
547348|NCT00059826|Radiation|radiation therapy|
547349|NCT00059813|Biological|recombinant interferon alfa|Given SC
547350|NCT00059813|Biological|oblimersen sodium|Given IV
547351|NCT00059813|Other|pharmacological study|Correlative studies
547352|NCT00059800|Radiation|boron neutron capture therapy|
547353|NCT00059787|Drug|paclitaxel|Given IV
549574|NCT00036712|Procedure|pain therapy|
547275|NCT00060346|Biological|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
547276|NCT00060346|Drug|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.~The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
547277|NCT00060346|Drug|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
547278|NCT00060346|Drug|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
547279|NCT00060346|Drug|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.~Given as IV push over 1 minute, using extravasation precautions."
547280|NCT00060333|Radiation|radiation therapy|
547281|NCT00060320|Dietary Supplement|black cohosh|
547282|NCT00060320|Other|placebo|
547283|NCT00060307|Drug|erlotinib hydrochloride|Given orally
547284|NCT00060307|Other|laboratory biomarker analysis|Correlative studies
547285|NCT00060294|Biological|rituximab|
547286|NCT00060294|Radiation|yttrium Y 90 ibritumomab tiuxetan|
547287|NCT00060268|Drug|HPPH|iv
547288|NCT00060255|Drug|busulfan|iv
547289|NCT00060255|Drug|carboplatin|iv
547290|NCT00060255|Drug|carmustine|iv
547291|NCT00060255|Drug|cyclophosphamide|iv
547292|NCT00060255|Drug|etoposide|iv
547293|NCT00060255|Drug|melphalan|oral
547294|NCT00060255|Drug|thiotepa|iv
547295|NCT00060255|Procedure|autologous bone marrow transplantation|iv
547296|NCT00060255|Procedure|bone marrow ablation with stem cell support|iv
547297|NCT00060255|Procedure|peripheral blood stem cell transplantation|iv
547298|NCT00060255|Radiation|radiation therapy|body x-ray
547299|NCT00060242|Drug|fosbretabulin disodium|Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
547300|NCT00060203|Drug|brostallicin|"Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity."
547301|NCT00060151|Drug|pazopanib hydrochloride|
547302|NCT00060138|Biological|monoclonal antibody CAL|
547303|NCT00060138|Drug|zoledronic acid|
547304|NCT00060125|Drug|tipifarnib|Given orally
547305|NCT00060125|Other|laboratory biomarker analysis|Correlative studies
547306|NCT00060112|Biological|oblimersen sodium|Given IV
547307|NCT00060112|Drug|gemcitabine hydrochloride|Given IV
547308|NCT00060112|Other|pharmacological study|Correlative studies
547309|NCT00060112|Other|laboratory biomarker analysis|Correlative studies
547310|NCT00060099|Biological|HspE7|
547311|NCT00060086|Dietary Supplement|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
547312|NCT00060021|Procedure|acupuncture therapy|
547313|NCT00060021|Procedure|management of therapy complications|
547314|NCT00060021|Procedure|pain therapy|
547315|NCT00060008|Radiation|fludeoxyglucose F 18|
547316|NCT00060008|Radiation|gadopentetate dimeglumine|
547317|NCT00059995|Biological|iratumumab|
547318|NCT00059982|Drug|perifosine|
547319|NCT00059943|Drug|docetaxel|
547320|NCT00059930|Drug|FOLFOX regimen|
547321|NCT00059930|Drug|dexamethasone|
547322|NCT00059930|Drug|floxuridine|
547323|NCT00059930|Drug|fluorouracil|
547324|NCT00059930|Drug|leucovorin calcium|
547325|NCT00059930|Drug|oxaliplatin|
547326|NCT00059930|Procedure|adjuvant therapy|
547327|NCT00059930|Procedure|conventional surgery|
547328|NCT00059917|Drug|polyglutamate camptothecin|
547329|NCT00059904|Biological|aldesleukin|
547330|NCT00059904|Biological|rituximab|
547331|NCT00059891|Procedure|conventional surgery|
547332|NCT00059891|Procedure|management of therapy complications|
547333|NCT00059878|Biological|recombinant interferon gamma|
547334|NCT00059878|Drug|voriconazole|
547335|NCT00059865|Drug|gemcitabine hydrochloride|
547336|NCT00059865|Drug|pemetrexed disodium|
547337|NCT00059852|Drug|erlotinib hydrochloride|
547338|NCT00059852|Drug|gemcitabine hydrochloride|
547339|NCT00059839|Drug|doxorubicin hydrochloride|Given IV
547340|NCT00059839|Drug|mercaptopurine|Given by mouth
547341|NCT00059839|Drug|methotrexate|Given IV and intrathecally
547342|NCT00059839|Drug|prednisone|Given by mouth
547343|NCT00059839|Drug|vinblastine sulfate|Given IV
547344|NCT00059839|Drug|vincristine sulfate|Given IV
547345|NCT00059826|Biological|interferon-alfa-2b|IV
547354|NCT00059787|Drug|carboplatin|Given IV
547355|NCT00059787|Drug|erlotinib|Given PO
547356|NCT00059761|Drug|cisplatin|
547357|NCT00059761|Drug|irinotecan hydrochloride|
547358|NCT00059761|Radiation|radiation therapy|
547359|NCT00059735|Drug|E7070|
547360|NCT00043108|Drug|carboplatin|
547361|NCT00043108|Drug|paclitaxel|
547362|NCT00043108|Procedure|conventional surgery|
547363|NCT00043108|Radiation|radiation therapy|
547364|NCT00030667|Drug|imatinib mesylate|Given orally
547365|NCT00030667|Other|laboratory biomarker analysis|Correlative studies
547366|NCT00030667|Other|pharmacological study|Correlative studies
547367|NCT00030524|Drug|gefitinib|
547368|NCT00027599|Biological|bevacizumab|
547369|NCT00027599|Biological|prostatic acid phosphatase-sargramostim fusion protein|
547370|NCT00027599|Biological|sipuleucel-T|
547371|NCT00027599|Biological|therapeutic autologous dendritic cells|
547372|NCT00027599|Procedure|in vitro-treated peripheral blood stem cell transplantation|
547373|NCT00017134|Drug|fenretinide|
547374|NCT00017134|Procedure|conventional surgery|
547375|NCT00016315|Drug|carboplatin|
547376|NCT00016315|Drug|gemcitabine hydrochloride|
547377|NCT00016315|Drug|paclitaxel|
547378|NCT00016315|Radiation|radiation therapy|
547379|NCT00006225|Biological|filgrastim|
547380|NCT00006225|Biological|recombinant flt3 ligand|
547381|NCT00006225|Biological|recombinant human thrombopoietin|
547382|NCT00006225|Biological|recombinant interleukin-3|
547383|NCT00006225|Procedure|in vitro-treated peripheral blood stem cell transplantation|
547384|NCT00005793|Drug|Cytarabine|
547385|NCT00005793|Drug|Daunorubicin|
547386|NCT00005793|Drug|Etoposide|
547387|NCT00005793|Drug|Topotecan|
547388|NCT00005065|Drug|paclitaxel|Given IV
547389|NCT00005065|Drug|carboplatin|Given IV
547390|NCT00005065|Drug|motexafin gadolinium|Given IV
547391|NCT00005065|Procedure|conventional surgery|Undergo complete surgical resection
547392|NCT00005065|Radiation|radiation therapy|Undergo radiation therapy
547393|NCT00004127|Drug|FOLFOX regimen|
547394|NCT00004127|Drug|fluorouracil|
547395|NCT00004127|Drug|leucovorin calcium|
547396|NCT00004127|Drug|oxaliplatin|
547397|NCT00004095|Drug|gemcitabine hydrochloride|
547398|NCT00004095|Drug|irinotecan hydrochloride|
547399|NCT00019435|Biological|LMB-9 immunotoxin|
547400|NCT00002765|Biological|LMB-2 immunotoxin|
547401|NCT00059722|Drug|ZD6474|
547402|NCT00059722|Drug|Placebo|
547403|NCT00059722|Drug|ZD1839|
547404|NCT00059709|Procedure|Mediated Negotiation Training|
547405|NCT00059696|Procedure|Constraint-Induced Movement Therapy|
547406|NCT00059683|Procedure|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
547407|NCT00018941|Biological|aldesleukin|
547408|NCT00005837|Drug|oxaliplatin|
547409|NCT00005818|Drug|irinotecan hydrochloride|Given IV
547410|NCT00005818|Drug|semaxanib|Given IV
547411|NCT00005818|Other|laboratory biomarker analysis|Correlative studies
547412|NCT00005025|Biological|herpes simplex thymidine kinase|
547413|NCT00005025|Drug|ganciclovir|
547414|NCT00002971|Drug|O6-benzylguanine|
547415|NCT00059670|Procedure|Shaker Exercise vs. Traditional Dysphagia Therapy Regime|
547416|NCT00059657|Drug|Ecraprost in lipid emulsion|
547417|NCT00059644|Drug|Ecraprost in lipid emulsion|
547418|NCT00003933|Other|laboratory biomarker analysis|
547419|NCT00003926|Drug|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.~Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
547420|NCT00003926|Drug|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
547421|NCT00003926|Drug|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
547422|NCT00003926|Drug|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
547423|NCT00003926|Drug|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
547424|NCT00003926|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
547425|NCT00003925|Drug|gemcitabine hydrochloride|
547426|NCT00003925|Drug|leucovorin calcium|
547427|NCT00003925|Drug|tegafur-uracil|
547428|NCT00003802|Drug|pyrazoloacridine|
547429|NCT00003797|Biological|trastuzumab|
547430|NCT00003797|Drug|gemcitabine hydrochloride|
547431|NCT00059631|Drug|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
547432|NCT00059631|Drug|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
547433|NCT00059618|Drug|PS-341 (Bortezomib)|Starting dose 0.8 mg/m^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
547434|NCT00059618|Drug|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
547435|NCT00059605|Genetic|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
547436|NCT00059592|Drug|Valacyclovir|
547437|NCT00003757|Biological|rituximab|
547438|NCT00003649|Biological|Ad5CMV-p53 gene|
547439|NCT00003627|Drug|cisplatin|
547440|NCT00003627|Drug|fluorouracil|
547441|NCT00003627|Radiation|radiation therapy|
547442|NCT00003484|Drug|carmustine|
547443|NCT00003484|Drug|irinotecan hydrochloride|
547444|NCT00003484|Procedure|surgical procedure|
547445|NCT00003484|Radiation|iodine I 131 monoclonal antibody 81C6|
547446|NCT00003436|Drug|amsacrine|
547449|NCT00003436|Drug|daunorubicin hydrochloride|
547450|NCT00003436|Drug|etoposide|
547451|NCT00003436|Drug|methotrexate|
547452|NCT00003436|Drug|mitoxantrone hydrochloride|
547453|NCT00003436|Drug|therapeutic hydrocortisone|
547454|NCT00003436|Procedure|allogeneic bone marrow transplantation|
547455|NCT00059553|Behavioral|Locomotor treadmill training with body weight support|
547456|NCT00059527|Behavioral|Healthy Youth Places: a behavior change model|
547457|NCT00059514|Behavioral|Modified Project Toward No Tobacco Use|
547458|NCT00005836|Drug|oxaliplatin|
547459|NCT00059475|Drug|Glycoprotein 100 (GP100): 209-217 (210M)|
547460|NCT00059475|Drug|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
547461|NCT00059475|Drug|Montanide ISA 51|
547462|NCT00059475|Drug|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
547463|NCT00059475|Drug|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
547464|NCT00059475|Drug|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
547465|NCT00059436|Behavioral|Mental effort in muscle strengthening|
547466|NCT00003432|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
547467|NCT00003346|Drug|acetaminophen|
547468|NCT00003346|Drug|acetylcysteine|
547469|NCT00003346|Drug|carmustine|
547470|NCT00003341|Biological|epoetin alfa|
547471|NCT00003341|Procedure|quality-of-life assessment|
547472|NCT00003324|Procedure|conventional surgery|
547473|NCT00003324|Radiation|radiation therapy|
547474|NCT00003311|Biological|filgrastim|
547475|NCT00003311|Drug|cyclophosphamide|
547476|NCT00003311|Drug|cytarabine|
547477|NCT00003311|Drug|dexamethasone|
547478|NCT00003311|Drug|doxorubicin hydrochloride|
547479|NCT00003311|Drug|methotrexate|
547480|NCT00003311|Drug|vincristine sulfate|
547481|NCT00059384|Behavioral|Concentration-controlled therapy|
547482|NCT00059371|Procedure|male circumcision|
547483|NCT00059358|Drug|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
547484|NCT00059358|Drug|Ribavirin|Oral tablet taken daily
547485|NCT00059358|Drug|Peginterferon alfa-2b|Subcutaneous injection
547486|NCT00059345|Procedure|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
547487|NCT00059345|Procedure|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
547488|NCT00059345|Other|Usual Care|Usual care for knee osteoarthritis
547489|NCT00059332|Drug|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
547490|NCT00059332|Drug|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
547491|NCT00059319|Procedure|single aorta clamp with retrograde cardioplegia|
547492|NCT00059319|Procedure|multiple aorta clamps with antegrade cardioplegia|
547493|NCT00059306|Drug|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
547494|NCT00059306|Drug|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
547495|NCT00059306|Other|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure—either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
547496|NCT00059306|Other|placebo|an inactive substance
547497|NCT00058981|Drug|DiaPep277|
547498|NCT00059280|Biological|Myozyme|20 mg/kg qow or 40mg/kg qow
547499|NCT00059267|Drug|HBIG, Epivir, Hepsera|
547500|NCT00059254|Dietary Supplement|Oleic acid (OA)|OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
547501|NCT00059254|Dietary Supplement|Palmitic Acid (PA)|PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
547502|NCT00059241|Behavioral|Parent-child communication education|
547503|NCT00059241|Behavioral|Service learning|
547504|NCT00059241|Behavioral|Classroom health curriculum|
547505|NCT00059215|Drug|Prasugrel (CS-747)|Administered orally
547506|NCT00059215|Drug|Clopidogrel|Administered orally
547507|NCT00003290|Biological|gonadotrophin releasing hormone|
547508|NCT00003290|Radiation|radiation therapy|
547509|NCT00003262|Biological|bleomycin sulfate|
547510|NCT00003262|Biological|filgrastim|
547511|NCT00003262|Drug|Stanford V regimen|
547512|NCT00003262|Drug|doxorubicin hydrochloride|
547513|NCT00003262|Drug|epirubicin hydrochloride|
547514|NCT00003262|Drug|etoposide|
547515|NCT00003262|Drug|mechlorethamine hydrochloride|
547516|NCT00003262|Drug|prednisone|
547517|NCT00003262|Drug|vinblastine sulfate|
547518|NCT00003262|Drug|vincristine sulfate|
547519|NCT00003205|Drug|bryostatin 1|
547520|NCT00003193|Drug|amifostine trihydrate|
547521|NCT00003193|Drug|paclitaxel|
547522|NCT00003193|Procedure|conventional surgery|
547523|NCT00003193|Radiation|radiation therapy|
547524|NCT00003173|Biological|filgrastim|
547525|NCT00003173|Drug|thiotepa|
547526|NCT00003173|Procedure|autologous bone marrow transplantation|
547527|NCT00003173|Procedure|peripheral blood stem cell transplantation|
547528|NCT00059228|Drug|17beta Estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
547529|NCT00059228|Drug|Placebos|Placebo skin patch for 6 weeks
547530|NCT00059202|Drug|Ursodeoxycholic Acid|
547531|NCT00059189|Device|Magstim Rapid Magnetic Stimulator|
547532|NCT00005839|Drug|capecitabine|
547533|NCT00005839|Drug|oxaliplatin|
547534|NCT00004220|Drug|gemcitabine hydrochloride|
547535|NCT00004220|Drug|oxaliplatin|
547536|NCT00004257|Drug|fluorouracil|
547537|NCT00004257|Drug|oxaliplatin|
547538|NCT00004257|Procedure|conventional surgery|
547539|NCT00004257|Radiation|radiation therapy|
547540|NCT00004243|Drug|docetaxel|
547541|NCT00004243|Drug|oxaliplatin|
547542|NCT00003597|Biological|recombinant human thrombopoietin|
547543|NCT00003597|Drug|carboplatin|
547544|NCT00003597|Drug|etoposide|
547545|NCT00003597|Drug|ifosfamide|
547546|NCT00003597|Biological|G-CSF|
547547|NCT00003163|Biological|filgrastim|
547548|NCT00003163|Biological|sargramostim|
547549|NCT00003163|Drug|cyclophosphamide|
547550|NCT00003163|Drug|melphalan|
547551|NCT00003163|Procedure|autologous bone marrow transplantation|
547552|NCT00003163|Procedure|peripheral blood stem cell transplantation|
547553|NCT00003163|Radiation|radiation therapy|
547554|NCT00003162|Procedure|pain therapy|
547555|NCT00003162|Radiation|radiation therapy|
547556|NCT00003129|Drug|valrubicin|
547557|NCT00003124|Drug|flutamide|
547558|NCT00003124|Drug|leuprolide acetate|
547559|NCT00003124|Radiation|radiation therapy|
547560|NCT00003064|Biological|filgrastim|
547561|NCT00003064|Drug|carboplatin|
547562|NCT00003064|Drug|etoposide phosphate|
547563|NCT00003064|Drug|paclitaxel|
547564|NCT00003064|Drug|thiotepa|
547565|NCT00003064|Drug|topotecan hydrochloride|
547566|NCT00003064|Procedure|peripheral blood stem cell transplantation|
547567|NCT00002972|Drug|paclitaxel|
547568|NCT00058994|Drug|anecortave acetate|
547569|NCT00058968|Drug|Duloxetine hydrochloride|
547570|NCT00058968|Drug|placebo|
547571|NCT00058955|Drug|sodium oxybate, triazolam and pentobarbital|sodium oxybate, triazolam and pentobarbital
547572|NCT00058942|Device|home drinking water treatment device|
547573|NCT00058929|Drug|treprostinil sodium|
547574|NCT00058903|Drug|sertraline|
547575|NCT00058890|Drug|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
547576|NCT00058890|Drug|Placebo|
547577|NCT00002945|Biological|aldesleukin|IV
547578|NCT00002945|Biological|filgrastim|IV
547579|NCT00002945|Drug|cyclophosphamide|IV
547580|NCT00002945|Drug|cytarabine|IV
547581|NCT00002945|Drug|etoposide|IV
547582|NCT00002945|Drug|idarubicin|IV
547583|NCT00002945|Drug|melphalan|IV
547584|NCT00002945|Procedure|peripheral blood stem cell transplantation|IV
547585|NCT00002945|Radiation|radiation therapy|delivered to the cancer cells
547586|NCT00002934|Procedure|long-term screening|
547587|NCT00002835|Biological|Bleomycin Sulfate (BLM)|
547588|NCT00002835|Biological|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
547589|NCT00002835|Biological|Recombinant Interferon Alfa|
547590|NCT00002835|Drug|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
547591|NCT00002835|Drug|Cisplatin (CDDP)|
547592|NCT00002835|Drug|Cyclophosphamide|
547593|NCT00002835|Drug|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
547594|NCT00002835|Drug|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
547595|NCT00002835|Drug|Idarubicin|
547596|NCT00002835|Drug|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
547597|NCT00002835|Drug|Leucovorin Calcium|
547598|NCT00002835|Drug|Melphalan|
547599|NCT00002835|Drug|Methotrexate|
547600|NCT00002835|Drug|Methylprednisolone|
547601|NCT00002835|Drug|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
547602|NCT00002835|Drug|Vincristine Sulfate|
547603|NCT00002835|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
547604|NCT00002835|Radiation|Radiation Therapy|
547605|NCT00002822|Drug|carboplatin|
547606|NCT00002822|Drug|cisplatin|
547607|NCT00002822|Drug|cyclophosphamide|
547608|NCT00002822|Drug|doxorubicin hydrochloride|
547609|NCT00002822|Drug|etoposide|
547610|NCT00002822|Drug|ifosfamide|
547611|NCT00002822|Drug|mesna|
547612|NCT00002822|Drug|vincristine sulfate|
547613|NCT00002822|Radiation|radiation therapy|
547614|NCT00058864|Device|Energy absorbing and distributing trochanteric pad|
547615|NCT00058851|Procedure|Manual lymph drainage|
547616|NCT00058851|Procedure|Combined physiotherapy|
547617|NCT00058851|Procedure|Compression bandaging|
547618|NCT00058838|Drug|sumanirole|
547619|NCT00058825|Biological|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
547620|NCT00058825|Drug|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
547621|NCT00058825|Procedure|Stem Cell Transplant|Day 0: Donor stem cells infused.
547622|NCT00058825|Radiation|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
547623|NCT00058825|Drug|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
547624|NCT00058812|Biological|EBV specific T cells|One injection of 2x10^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
547625|NCT00058799|Biological|Tumor Vaccine: CD40 LIGAND AND IL-2 GENE MODIFIED AUTOLOGOUS SKIN FIBROBLASTS AND TUMOR CELLS|"CD40L AND IL-2 GENE MODIFIED AUTOLOGOUS SKIN FIBROBLASTS AND TUMOR CELLS dosed at 3 different levels starting at:~Leukemic Blasts 2x10^7 IL-2 Fibroblasts 2x10^7 CD40L Fibroblasts 2x10^5 TOTAL CELLS 4.02x10^7 Each patient will receive 3 injections of their gene modified leukemia cells, each injection separated by 1-2 wks. If there is evidence of response without excessive toxicity and if more transduced cells are available, the pt may receive up to 3 additional SC injections (injections 4-6) separated by 2 weeks."
547626|NCT00058786|Biological|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
547627|NCT00058773|Drug|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.~Each patient will receive two injections, 14 days apart."
547628|NCT00058760|Behavioral|NIA intervention (after school health promotion didactic program)|
547629|NCT00058747|Drug|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
547630|NCT00058734|Biological|Dendritic Cells Pulsed with HIV antigens|
547631|NCT00058721|Drug|I-123-5-IA85380|
547632|NCT00058682|Drug|Anidulafungin|
547633|NCT00002777|Drug|exemestane|
547634|NCT00002777|Drug|tamoxifen citrate|
547635|NCT00002701|Drug|busulfan|
547636|NCT00002701|Drug|cyclophosphamide|
547637|NCT00002701|Drug|cytarabine|
547638|NCT00002701|Drug|etoposide|
547639|NCT00002701|Drug|idarubicin|
547640|NCT00002701|Drug|mercaptopurine|
547641|NCT00002701|Drug|methotrexate|
547642|NCT00002701|Drug|mitoxantrone hydrochloride|
547643|NCT00002701|Drug|thioguanine|
547644|NCT00002701|Drug|tretinoin|
547645|NCT00002701|Procedure|allogeneic bone marrow transplantation|
547646|NCT00002701|Procedure|autologous bone marrow transplantation|
547647|NCT00002701|Radiation|radiation therapy|
547648|NCT00002695|Genetic|DNA stability analysis|
547649|NCT00002695|Genetic|microsatellite instability analysis|
547650|NCT00002695|Genetic|mutation analysis|
547651|NCT00002695|Other|laboratory biomarker analysis|
547652|NCT00002693|Biological|filgrastim|
547653|NCT00002693|Drug|carboplatin|
547654|NCT00002693|Drug|topotecan hydrochloride|
547655|NCT00002669|Biological|aldesleukin|
547656|NCT00002669|Biological|recombinant interferon alfa|
547657|NCT00002669|Drug|cisplatin|
547658|NCT00002669|Drug|dacarbazine|
547659|NCT00058656|Procedure|Infusion of Activated & Expanded Autologous T Cells|
547660|NCT00002658|Biological|filgrastim|
547661|NCT00002658|Drug|amsacrine|
547662|NCT00002658|Drug|cyclophosphamide|
547663|NCT00002658|Drug|cytarabine|
547664|NCT00002658|Drug|daunorubicin hydrochloride|
547665|NCT00002658|Drug|etoposide|
547666|NCT00002658|Drug|idarubicin|
547667|NCT00002658|Drug|mitoxantrone hydrochloride|
547668|NCT00002658|Drug|thioguanine|
547669|NCT00002658|Drug|tretinoin|
547670|NCT00002658|Procedure|allogeneic bone marrow transplantation|
547671|NCT00002658|Procedure|autologous bone marrow transplantation|
547672|NCT00002658|Procedure|peripheral blood stem cell transplantation|
547673|NCT00002658|Radiation|radiation therapy|
547674|NCT00002653|Drug|carmustine|
547675|NCT00002653|Drug|cyclophosphamide|
547676|NCT00002653|Drug|doxorubicin hydrochloride|
547677|NCT00002653|Drug|melphalan|
547678|NCT00002653|Drug|prednisone|
547679|NCT00002653|Radiation|radiation therapy|
547680|NCT00002575|Procedure|conventional surgery|
547681|NCT00002575|Procedure|laparoscopic surgery|
547682|NCT00002550|Drug|cisplatin|
547683|NCT00002550|Drug|etoposide|
547684|NCT00002550|Procedure|conventional surgery|
547685|NCT00002550|Radiation|radiation therapy|
547686|NCT00002539|Biological|filgrastim|
547687|NCT00002539|Drug|cisplatin|
547688|NCT00002539|Drug|doxorubicin hydrochloride|
547689|NCT00002539|Procedure|conventional surgery|
547690|NCT00058617|Biological|Injection of EBV Specific CTLs|"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2~Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2~Group Three Day 0 1x10^8 cells/m2 Day 14 2x 10^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
547691|NCT00058604|Biological|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
547762|NCT00058201|Drug|fluorouracil|Given IV
547763|NCT00058201|Drug|gemcitabine hydrochloride|Given IV
547692|NCT00058591|Biological|Intravenous injection of EBV specific CTLS|"The dose levels for this study are as follows:~Level Dose~2 x 107 CTLs/m2~5 x 107 CTLs/m2~1 x 108 CTLs/m2~If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."
547693|NCT00058578|Drug|Cyclophosphamide|
547694|NCT00058578|Drug|Mesna|
547695|NCT00058578|Drug|G-CSF|
547696|NCT00058578|Procedure|Leukopheresis|
547697|NCT00058578|Procedure|Total Body Irradiation|
547698|NCT00058552|Drug|Pertuzumab (rhuMAb 2C4)|
547699|NCT00058539|Drug|rhuMAb 2C4 (pertuzumab)|
547700|NCT00058526|Biological|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
547701|NCT00058487|Drug|epirubicin hydrochloride|
547702|NCT00058487|Drug|thalidomide|
547703|NCT00058474|Drug|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
547704|NCT00058474|Drug|fluorouracil|225 mg/m2 IV daily continuous infusion
547705|NCT00058474|Drug|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
547706|NCT00058474|Radiation|radiation therapy|Given 5 days a week for 5-6 weeks
547707|NCT00058461|Drug|ifosfamide|Given IV
547708|NCT00058461|Drug|etoposide|Given IV
547709|NCT00058461|Biological|rituximab|Given IV
547710|NCT00058461|Drug|carboplatin|Given IV
547711|NCT00058461|Biological|filgrastim|Given SC
547712|NCT00058461|Drug|methotrexate|Given IT
547713|NCT00058461|Drug|cytarabine|Given IT
547714|NCT00058461|Other|laboratory biomarker analysis|Correlative studies
547715|NCT00058448|Drug|docetaxel|
547716|NCT00058435|Biological|abagovomab|
547717|NCT00058422|Biological|darbepoetin alfa|
547718|NCT00058422|Biological|filgrastim|
547719|NCT00058422|Biological|rituximab|
547720|NCT00058422|Drug|cyclophosphamide|
547721|NCT00058422|Drug|doxorubicin hydrochloride|
547722|NCT00058422|Drug|prednisone|
547723|NCT00058422|Drug|vincristine sulfate|
547724|NCT00058422|Radiation|indium In 111 ibritumomab tiuxetan|
547725|NCT00058422|Radiation|yttrium Y 90 ibritumomab tiuxetan|
547726|NCT00058396|Biological|lumiliximab|
547727|NCT00058370|Drug|cisplatin|
547728|NCT00058370|Drug|lomustine|
547729|NCT00058370|Drug|vincristine sulfate|
547730|NCT00058370|Procedure|adjuvant therapy|
547731|NCT00058370|Radiation|iodine I 131 monoclonal antibody 3F8|
547732|NCT00058370|Radiation|radiation therapy|
547733|NCT00058357|Drug|lidocaine|
547734|NCT00058357|Other|placebo|
547735|NCT00058331|Biological|epoetin alfa|
547736|NCT00058318|Drug|capecitabine|Capecitabine will be given 625 mg/m^2 (1250 mg/m^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
547737|NCT00058318|Drug|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
547738|NCT00058305|Drug|bryostatin 1|Given IV
547739|NCT00058305|Drug|vincristine sulfate|Given IV
547740|NCT00058305|Other|laboratory biomarker analysis|Correlative studies
547741|NCT00058292|Biological|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
547742|NCT00058292|Biological|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
547743|NCT00058292|Drug|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
547744|NCT00058292|Drug|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
547745|NCT00058292|Drug|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
547746|NCT00058292|Drug|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
547747|NCT00058292|Procedure|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
547748|NCT00058292|Radiation|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
547749|NCT00058279|Biological|aldesleukin|
547750|NCT00058279|Biological|ipilimumab|
547751|NCT00058266|Dietary Supplement|genistein|Given orally
547752|NCT00058266|Procedure|conventional surgery|Patients undergo surgery
547753|NCT00058253|Drug|tanespimycin|Given IV
547754|NCT00058253|Drug|docetaxel|Given IV
547755|NCT00058240|Drug|alvocidib|Given IV
547756|NCT00058227|Drug|alvocidib|Given IV
547757|NCT00058227|Drug|fludarabine phosphate|Given IV
547758|NCT00058227|Biological|rituximab|Given IV
547759|NCT00058227|Other|pharmacological study|Correlative studies
547760|NCT00058214|Drug|perifosine|Given orally
547761|NCT00058214|Other|laboratory biomarker analysis|Correlative studies
547764|NCT00058201|Drug|leucovorin calcium|Given IV
547765|NCT00058201|Other|clinical observation|No intervention
547766|NCT00058188|Dietary Supplement|cholecalciferol|Given orally
547767|NCT00058188|Drug|calcium gluconate|Given orally
547768|NCT00058188|Drug|zoledronic acid|Given IV
547769|NCT00058149|Drug|gemcitabine hydrochloride|
547770|NCT00058149|Drug|oxaliplatin|
547771|NCT00058123|Drug|poly ICLC|
547772|NCT00058097|Drug|tipifarnib|Given orally
547773|NCT00058097|Radiation|radiation therapy|Undergo radiation therapy
547774|NCT00058084|Drug|ixabepilone|Given IV
547775|NCT00058084|Drug|mitoxantrone hydrochloride|Given IV
547776|NCT00058084|Drug|prednisone|Given orally
547777|NCT00058071|Drug|amifostine trihydrate|
547778|NCT00058058|Procedure|MRI|Breast contralateral to the breast diagnosed with cancer was scanned prior to initiation of chemotherapy and within 90 days of a negative mammogram of the study breast. A recent (within 90 days) negative or benign mammogram (defined by final BI RADS category 1 or 2) and negative or benign clinical breast exam of the study breast were required for entry into the study.
547779|NCT00058045|Biological|aldesleukin|
547780|NCT00058045|Biological|recombinant human stem cell factor|
547781|NCT00058032|Other|screening questionnaire administration|
547782|NCT00058032|Procedure|annual screening|
547783|NCT00058019|Drug|ixabepilone|Given IV
547784|NCT00058006|Drug|celecoxib|
547785|NCT00058006|Procedure|adjuvant therapy|
547786|NCT00057993|Biological|trastuzumab|
547787|NCT00057993|Drug|exemestane|
547788|NCT00057980|Drug|celecoxib|
547789|NCT00057980|Drug|epirubicin hydrochloride|
547790|NCT00057967|Biological|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
547791|NCT00057954|Procedure|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
547792|NCT00057954|Drug|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
547793|NCT00057954|Radiation|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
547794|NCT00057954|Procedure|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10^6 CD34/kg
547795|NCT00057954|Drug|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
547796|NCT00057954|Drug|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
547797|NCT00057954|Drug|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with > 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
547798|NCT00057941|Drug|anastrozole|Given orally
547799|NCT00057941|Drug|gefitinib|Given orally
547800|NCT00057941|Drug|fulvestrant|Given intramuscularly
547801|NCT00057941|Other|laboratory biomarker analysis|Correlative studies
547802|NCT00057928|Drug|cisplatin|
547803|NCT00057928|Drug|gemcitabine hydrochloride|
547804|NCT00057928|Drug|paclitaxel|
547805|NCT00057915|Biological|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
547806|NCT00057889|Biological|ipilimumab|
547807|NCT00057876|Drug|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m^2 intravenously once per week for 6 weeks followed by 1 week rest.~Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
547808|NCT00057876|Radiation|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.~Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
547809|NCT00057863|Drug|Paclitaxel|Given IV
547810|NCT00057863|Drug|Oxaliplatin|Given IV
547811|NCT00057850|Drug|cisplatin|
547812|NCT00057850|Drug|ixabepilone|
547813|NCT00057837|Biological|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery > 10,000 dL.
547814|NCT00057837|Drug|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
547815|NCT00057837|Drug|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
547816|NCT00057837|Drug|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
547817|NCT00057837|Drug|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
547818|NCT00057811|Drug|doxorubicin hydrochloride|Given IV, IT, or orally
547819|NCT00057811|Drug|cyclophosphamide|Given IV
547820|NCT00057811|Drug|methotrexate|Given IV or IT
547821|NCT00057811|Drug|rasburicase|Given IV
547822|NCT00057811|Drug|leucovorin calcium|Given IV or orally
547823|NCT00057811|Drug|prednisone|Given IV or orally
547824|NCT00057811|Drug|methylprednisolone|Given IV or orally
547825|NCT00057811|Biological|filgrastim|Given subcutaneously
547826|NCT00057811|Biological|rituximab|Given IV
547827|NCT00057811|Drug|cytarabine|Given IT
547828|NCT00057811|Drug|etoposide|Given IV
547829|NCT00057811|Drug|vincristine sulfate|Given IV
547830|NCT00057811|Drug|hydrocortisone sodium succinate|Given IT
547831|NCT00057811|Other|laboratory biomarker analysis|Correlative studies
547832|NCT00057798|Drug|gemcitabine hydrochloride|
547833|NCT00057798|Drug|vinorelbine ditartrate|
547834|NCT00057798|Genetic|cytogenetic analysis|
547835|NCT00057798|Genetic|loss of heterozygosity analysis|
547836|NCT00057798|Genetic|microarray analysis|
547837|NCT00057798|Procedure|conventional surgery|
547838|NCT00057798|Procedure|neoadjuvant therapy|
547839|NCT00057785|Drug|cisplatin|100 mg/m^2 intravenously on days 1, 22, and 43 and 80 mg/m^2 intravenously on days 71, 99, and 127
547840|NCT00057785|Drug|fluorouracil|1000 mg/m^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
547841|NCT00057785|Radiation|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume [CTV] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
547842|NCT00057759|Drug|sildenafil citrate|
547843|NCT00057759|Other|Placebo|Placebo
547844|NCT00057746|Radiation|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
547845|NCT00057746|Radiation|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
547846|NCT00057746|Radiation|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
547847|NCT00057733|Procedure|psychosocial assessment and care|
547848|NCT00057733|Procedure|quality-of-life assessment|
547849|NCT00030368|Drug|bortezomib|Given IV
547850|NCT00030368|Drug|paclitaxel|Given IV
547851|NCT00030368|Other|laboratory biomarker analysis|Correlative studies
547852|NCT00023673|Drug|carboplatin|
547853|NCT00023673|Drug|paclitaxel|
547854|NCT00023673|Radiation|three-dimensional conformal radiation therapy|
547855|NCT00004079|Drug|SarCNU|Given PO
547856|NCT00004079|Other|pharmacological study|Correlative studies
547857|NCT00004079|Other|laboratory biomarker analysis|Correlative studies
547858|NCT00057720|Drug|TLK286 HCl for injection|
547859|NCT00057720|Drug|topotecan hydrochloride for injection|
547860|NCT00057720|Drug|doxorubicin HCl liposome injection|
547861|NCT00057707|Drug|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
547862|NCT00057707|Procedure|Functional MRI|
547863|NCT00057707|Procedure|Neuropsychological Testing|
547864|NCT00057681|Drug|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
547865|NCT00057681|Drug|Valproate|Titrated until blood level is 111 to 125 ug/mL
547866|NCT00057681|Drug|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
547867|NCT00057668|Behavioral|Multi-Setting Early Intervention|
547868|NCT00057668|Behavioral|Community Intervention|
547869|NCT00057642|Drug|Sertraline|
547870|NCT00057642|Drug|Venlafaxine Extended Release|
547871|NCT00057629|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
547872|NCT00057629|Behavioral|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
547873|NCT00057629|Behavioral|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
547874|NCT00057616|Drug|CC-5013|
547875|NCT00057603|Procedure|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
547876|NCT00057590|Behavioral|Care manager outreach and monitoring|
547877|NCT00057577|Behavioral|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
547953|NCT00056966|Procedure|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count >2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count >2 x 108/kg) will be substituted.
547954|NCT00056953|Behavioral|Peer mentoring program|
547878|NCT00057577|Drug|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
547879|NCT00057564|Drug|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
547880|NCT00057564|Drug|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
547881|NCT00057551|Behavioral|Brief Supportive Psychotherapy|brief supportive psychotherapy
547882|NCT00057551|Behavioral|CBASP|psychotherapy developed for chronic depression
547883|NCT00057551|Drug|Medication Only|antidepressant medication
547884|NCT00057538|Behavioral|Mantram Repetition|
547885|NCT00057525|Biological|Anthrax|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
547886|NCT00057525|Biological|Alhdryogel or PBS|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
547887|NCT00057512|Drug|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
547888|NCT00057499|Biological|IBC-VS01|IBC-VS01
547889|NCT00057499|Biological|IBC-VS01 placebo|IBC-VS01 placebo
547890|NCT00057486|Drug|IL-12|
547891|NCT00057473|Drug|carboplatin + irinotecan|Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.
547892|NCT00057473|Drug|irinotecan|Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.
547893|NCT00057447|Drug|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
547894|NCT00057447|Drug|Rituximab|375 mg per square meters, IV, 1x per week
547895|NCT00057434|Drug|multivitamin|
547896|NCT00057421|Drug|prednisolone|
547897|NCT00057460|Drug|Talampanel|
547898|NCT00057408|Drug|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
547899|NCT00057408|Drug|Placebo|Matching Placebo
547900|NCT00057395|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
547901|NCT00057382|Drug|T138067 intravenous|
547902|NCT00057382|Drug|doxorubicin intravenous|
547903|NCT00057369|Drug|dalbavancin|
547904|NCT00057356|Drug|conivaptan|IV
547905|NCT00057356|Drug|placebo|IV
547906|NCT00057343|Drug|Zevalin (ibritumomab tiuxetan)|
547907|NCT00057343|Drug|Rituxan (rituximab)|
547908|NCT00057330|Biological|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
547909|NCT00057330|Biological|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
547910|NCT00057317|Drug|Ro 205-2349|
547911|NCT00057304|Drug|Insulin sensitizer|
547912|NCT00057291|Behavioral|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
547913|NCT00057031|Drug|DN-101 (calcitriol)|
547914|NCT00057278|Drug|gabapentin|
547915|NCT00057265|Drug|telbivudine or lamivudine|
547916|NCT00057200|Procedure|Telephone, videophone care|
547917|NCT00057187|Behavioral|Contracting, Prompting and Reinforcing|
547918|NCT00057239|Drug|Radafaxine|
547919|NCT00057226|Drug|Radafaxine|
547920|NCT00057213|Drug|Radafaxine|
547921|NCT00057174|Drug|Disease management of gastroesophageal reflux disease|
547922|NCT00057161|Behavioral|Coordinated Representative Payeeship with Case Management|
547923|NCT00057148|Procedure|massage treatment|
547924|NCT00057135|Behavioral|Unit of use medication packaging|
547925|NCT00057135|Behavioral|Mailed reminders to patient when medication refills are due|
547926|NCT00057135|Behavioral|Note to Mental Health Provider when refill is overdue|
547927|NCT00057135|Procedure|Aligning all prescriptions to fall due on same date|
547928|NCT00057122|Drug|Isoniazid|300mg
547929|NCT00057122|Drug|Rifapentine|Rifapentine 900 mg
547930|NCT00057122|Drug|Rifampin|Rifampin 600 mg
547931|NCT00057096|Procedure|On-site vs. referral methods of care|
547932|NCT00057083|Other|Telemedicine Care|
547933|NCT00057070|Procedure|Smoking cessation information, collection, and dissemination|
547934|NCT00057057|Behavioral|Telephone Care|
547935|NCT00057044|Behavioral|education and reminder|
547936|NCT00057018|Procedure|Constraint-induced movement therapy|
547937|NCT00057005|Drug|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
547938|NCT00057005|Drug|Anti-CD45|Day-5 400 μg/kg
547939|NCT00057005|Drug|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
547940|NCT00057005|Drug|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
547941|NCT00057005|Drug|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
547942|NCT00057005|Radiation|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
547943|NCT00056992|Drug|ADI-PEG 20|
547944|NCT00056979|Drug|CAMPATH-1H|
547945|NCT00056979|Drug|Anti-CD45|
547946|NCT00056979|Drug|FK506|
547947|NCT00056979|Drug|Fludarabine|
547948|NCT00056966|Drug|ANTI-CD45|400ug/kg Day-5 through Day-2
547949|NCT00056966|Drug|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
547950|NCT00056966|Drug|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
547951|NCT00056966|Drug|Fludarabine|Day-8 through Day-5 30 mg/m2
547952|NCT00056966|Radiation|Total Body Irradiation|Day-1 single dose 450 cGy
547955|NCT00056940|Behavioral|Stages of Change|
547956|NCT00056940|Behavioral|Safety Check approach|
547957|NCT00056927|Behavioral|Anti-smoking Socialization Program|
547958|NCT00056875|Drug|recombinant human keratinocyte growth factor|
547959|NCT00056836|Drug|rhuFab V2 (ranibizumab)|
547960|NCT00056823|Drug|rhuFab V2 (ranibizumab)|
547961|NCT00056862|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
547962|NCT00056862|Drug|Peginterferon alfa-2a|180 mcg/week
547963|NCT00056862|Drug|Ribavirin|800 mg/day
547964|NCT00056810|Drug|4-aminopyridine (4-AP)|
547965|NCT00056797|Biological|ALVAC HIV vaccine (vCP1452)|
547966|NCT00056797|Drug|Interleukin-2|
547967|NCT00056758|Biological|Autologous Dendritic Cell HIV Vaccination|
547968|NCT00056745|Biological|TBC-3B|
547969|NCT00056693|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
547970|NCT00056680|Behavioral|Psychoeducational video|
547971|NCT00056680|Behavioral|Infant massage|
547972|NCT00056680|Behavioral|Brazelton Neonatal Behavioral Assessment Scale|
547973|NCT00056667|Behavioral|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
547974|NCT00056667|Behavioral|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
547975|NCT00056667|Other|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
547976|NCT00056654|Drug|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
547977|NCT00056641|Drug|tipranavir|
547978|NCT00056641|Drug|ritonavir|
547979|NCT00056641|Drug|saquinavir|
547980|NCT00056641|Drug|amprenavir|
547981|NCT00056641|Drug|lopinavir|
547982|NCT00056706|Procedure|Transient deafferentation|
547983|NCT00056628|Device|The COGNIShunt® System|
547984|NCT00056589|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
547985|NCT00056576|Drug|Zonisamide|
547986|NCT00056563|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
547987|NCT00056563|Other|best medical therapy|"Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months."
547988|NCT00056550|Biological|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
547989|NCT00056537|Drug|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
547990|NCT00056524|Drug|AVP-923|
547991|NCT00056511|Drug|Fresh garlic or garlic supplements|
547992|NCT00056498|Drug|Placebo|Placebo capsule daily for 16 weeks
547993|NCT00056498|Drug|Risperdal|Risperdal 4 mg per day for 16 weeks
547994|NCT00056485|Behavioral|Pleasant Events-Based Behavioral Intervention|
547995|NCT00056472|Drug|Olanzapine|10-20mg/day
547996|NCT00056472|Drug|Sertraline|150-200mg/day
547997|NCT00056472|Other|placebo|tablet that ressembles sertraline but contains no medication
547998|NCT00012454|Drug|E-Selectin nasal spray|
547999|NCT00056459|Drug|Vatalanib|
548000|NCT00056446|Drug|Vatalanib|
548001|NCT00056433|Drug|Hydroxyurea|
548002|NCT00056433|Drug|L-Arginine|
548003|NCT00056433|Drug|Sildenafil|
548004|NCT00056407|Drug|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
548005|NCT00056407|Drug|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
548006|NCT00056394|Behavioral|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
548007|NCT00056394|Behavioral|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
548008|NCT00056394|Behavioral|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
548009|NCT00056381|Drug|Anidulafungin|
548010|NCT00056368|Drug|Anidulafungin|
548011|NCT00056368|Drug|Fluconazole|
548012|NCT00056329|Drug|Vitamin E|1,000 international units twice daily for three years
548013|NCT00056329|Drug|multivitamin|once daily for three years
548014|NCT00056329|Drug|Placebo|Placebo twice daily for three years
548015|NCT00056355|Drug|UVADEX and UVAR XTS Photopheresis System|
548016|NCT00056316|Behavioral|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
548017|NCT00056316|Behavioral|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
548018|NCT00056303|Behavioral|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
548019|NCT00056303|Behavioral|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
548020|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
548021|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
548022|NCT00056277|Drug|lamotrigine|
548023|NCT00056264|Drug|Infliximab|
548024|NCT00056251|Procedure|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
548025|NCT00056238|Drug|NC-758 (Anti amyloidotic [Aß] agent)|
548026|NCT00056225|Drug|Folate|
548027|NCT00056225|Drug|Vitamin B6|
548028|NCT00056225|Drug|Vitamin B12|
548029|NCT00056212|Behavioral|Yoga|
548030|NCT00056212|Behavioral|Exercise|
548031|NCT00056173|Drug|GTI-2040|
548032|NCT00056199|Drug|EYE001|
548033|NCT00056160|Drug|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
548034|NCT00056160|Drug|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
548035|NCT00056147|Drug|denufosol tetrasodium (INS37217)|
548036|NCT00056134|Biological|Dendritic cell vaccine plus denileukin difitox|
548037|NCT00056095|Biological|therapeutic allogeneic lymphocytes|
548038|NCT00056095|Drug|cyclophosphamide|
548039|NCT00056095|Drug|cyclosporine|
548040|NCT00056095|Drug|fludarabine phosphate|
548041|NCT00056095|Procedure|allogeneic bone marrow transplantation|
548042|NCT00056095|Procedure|peripheral blood stem cell transplantation|
548043|NCT00056082|Drug|celecoxib|Celecoxib daily for 12 months
548044|NCT00056069|Other|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
548045|NCT00056056|Drug|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
548046|NCT00056056|Drug|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
548047|NCT00056056|Procedure|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
548048|NCT00056030|Biological|cetuximab|
548049|NCT00056030|Drug|fluorouracil|
548050|NCT00056030|Drug|leucovorin calcium|
548051|NCT00056030|Drug|oxaliplatin|
548052|NCT00056004|Drug|zileuton|
548053|NCT00055991|Drug|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
548054|NCT00055978|Drug|celecoxib|Given orally. 400mg twice daily for 6 months.
548055|NCT00055978|Other|placebo|Given orally
548056|NCT00055965|Drug|carboplatin|
548057|NCT00055965|Drug|cisplatin|
548058|NCT00055965|Drug|gemcitabine hydrochloride|
548059|NCT00055952|Drug|exatecan mesylate|
548060|NCT00055939|Drug|exatecan mesylate|
548061|NCT00055926|Drug|CP-724,714|
548062|NCT00055913|Biological|bevacizumab|Given IV
548063|NCT00055913|Drug|erlotinib hydrochloride|Given orally
548064|NCT00055913|Other|laboratory biomarker analysis|Correlative studies
548065|NCT00055887|Drug|carboplatin|
548066|NCT00055887|Drug|cisplatin|
548067|NCT00055887|Drug|efaproxiral|
548068|NCT00055887|Drug|gemcitabine hydrochloride|
548069|NCT00055887|Drug|paclitaxel|
548070|NCT00055887|Drug|vinorelbine ditartrate|
548071|NCT00055887|Procedure|radiation therapy|
548072|NCT00055874|Biological|recombinant interferon alfa|
548073|NCT00055874|Drug|cytarabine|
548074|NCT00055874|Drug|hydroxyurea|
548075|NCT00055874|Drug|imatinib mesylate|
548076|NCT00055874|Procedure|allogeneic bone marrow transplantation|
548077|NCT00055874|Procedure|autologous bone marrow transplantation|
548078|NCT00055874|Procedure|peripheral blood stem cell transplantation|
548079|NCT00055861|Biological|bevacizumab|Given IV
548080|NCT00055861|Drug|docetaxel|Given IV
548081|NCT00055861|Other|laboratory biomarker analysis|Correlative studies
548082|NCT00055848|Genetic|cytogenetic analysis|
548083|NCT00055848|Genetic|gene mapping|
548084|NCT00055848|Genetic|microarray analysis|
548085|NCT00055835|Drug|carboplatin|*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
548086|NCT00055835|Drug|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
548087|NCT00055835|Drug|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 & 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
548088|NCT00055835|Drug|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
548089|NCT00055835|Procedure|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
548090|NCT00055835|Radiation|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
548091|NCT00055822|Biological|oblimersen sodium|
548092|NCT00055822|Drug|fluorouracil|
548093|NCT00055822|Drug|leucovorin calcium|
548094|NCT00055822|Drug|oxaliplatin|
548095|NCT00055809|Biological|PEG-interferon alfa-2b|Given SC
548096|NCT00055809|Biological|bevacizumab|Given IV
548097|NCT00055809|Other|laboratory biomarker analysis|Optional correlative studies
548098|NCT00055783|Biological|apolizumab|
548099|NCT00055770|Drug|erlotinib hydrochloride|Given orally
548100|NCT00055770|Drug|docetaxel|Given IV
548101|NCT00055770|Other|laboratory biomarker analysis|Correlative studies
548102|NCT00055770|Other|pharmacological study|Correlative studies
548103|NCT00055757|Drug|tipifarnib|Given orally
548104|NCT00055757|Drug|cisplatin|Given IV
548105|NCT00055757|Drug|gemcitabine hydrochloride|Given IV
548106|NCT00055757|Other|laboratory biomarker analysis|Correlative studies
548107|NCT00055731|Drug|bicalutamide|
548108|NCT00055731|Drug|buserelin|
548109|NCT00055731|Drug|cyproterone acetate|
548110|NCT00055731|Drug|docetaxel|
548111|NCT00055731|Drug|estramustine phosphate sodium|
548112|NCT00055731|Drug|flutamide|
548113|NCT00055731|Drug|goserelin acetate|
548114|NCT00055731|Drug|leuprolide acetate|
548115|NCT00055731|Drug|nilutamide|
548116|NCT00055731|Drug|triptorelin|
548117|NCT00055731|Procedure|conventional surgery|
548118|NCT00055731|Procedure|neoadjuvant therapy|
548119|NCT00055731|Radiation|radiation therapy|
548120|NCT00055718|Dietary Supplement|silymarin|
548121|NCT00055705|Biological|PV701|
548122|NCT00055692|Biological|bevacizumab|Given orally
548123|NCT00055679|Drug|cyclophosphamide|
548124|NCT00055679|Drug|epirubicin hydrochloride|
548125|NCT00055679|Drug|fluorouracil|
548126|NCT00055666|Drug|beclomethasone dipropionate|
548127|NCT00055653|Biological|anti-thymocyte globulin|
548128|NCT00055653|Biological|filgrastim|
548129|NCT00055653|Drug|busulfan|
548130|NCT00055653|Drug|cyclophosphamide|
548131|NCT00055653|Drug|cyclosporine|
548132|NCT00055653|Drug|fludarabine phosphate|
548133|NCT00055653|Drug|melphalan|
548134|NCT00055653|Drug|methylprednisolone|
548135|NCT00055653|Procedure|umbilical cord blood transplantation|
548136|NCT00055653|Radiation|radiation therapy|
548137|NCT00055640|Biological|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
548138|NCT00055640|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
548139|NCT00055640|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
548140|NCT00055640|Drug|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
548141|NCT00055640|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
548142|NCT00055640|Genetic|microarray analysis|genetic testing
548143|NCT00055614|Drug|topotecan hydrochloride|
548144|NCT00055614|Procedure|adjuvant therapy|
548145|NCT00055601|Drug|cisplatin|Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
548146|NCT00055601|Drug|fluorouracil|Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
548147|NCT00055601|Drug|paclitaxel|Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
548298|NCT00054418|Drug|risedronate sodium|risedronate 35 mg weekly administered orally
548299|NCT00054418|Other|placebo|placebo tablet weekly administered orally for one year
548300|NCT00054405|Biological|recombinant interleukin-12|Given IV
548301|NCT00054405|Biological|aldesleukin|Given IV
548302|NCT00054392|Drug|carboplatin|
548303|NCT00054392|Drug|gemcitabine hydrochloride|
548304|NCT00054392|Drug|paclitaxel|
548148|NCT00055601|Radiation|radiation therapy|Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
548149|NCT00055601|Drug|Gemcitabine|Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
548150|NCT00055601|Procedure|Radical cystectomy|Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
548151|NCT00022139|Drug|carboplatin|
548152|NCT00022139|Drug|fluorouracil|
548153|NCT00022139|Drug|paclitaxel|
548154|NCT00022139|Procedure|conventional surgery|
548155|NCT00022139|Radiation|radiation therapy|
548156|NCT00005028|Drug|bryostatin 1|
548157|NCT00005028|Drug|paclitaxel|
548158|NCT00055588|Procedure|Locomotor training|
548159|NCT00055575|Drug|Transderm Scopolamine|
548160|NCT00055562|Drug|CC 5013|
548161|NCT00055536|Drug|natalizumab|
548162|NCT00055523|Drug|Adalimumab (D2E7)|
548163|NCT00055549|Drug|Dextromethorphan|
548164|NCT00055549|Drug|Lorazepam|
548165|NCT00055510|Drug|BO-653|
548166|NCT00055497|Biological|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
548167|NCT00055497|Biological|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
548168|NCT00055497|Biological|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
548169|NCT00055497|Biological|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
548170|NCT00055484|Drug|zonisamide|
548171|NCT00055471|Drug|ZD4054 10 mg|1 x 10 mg oral tablets once daily
548172|NCT00055471|Drug|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
548173|NCT00055471|Drug|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
548174|NCT00055445|Drug|IdB 1016|
548175|NCT00055432|Drug|Gemzar and Alimta|
548176|NCT00055419|Biological|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
548177|NCT00055393|Drug|Bupropion|18 subjects in this randomly controlled double blind study received bupropion.
548178|NCT00055393|Drug|Placebo|21 subjects received Placebo.
548179|NCT00055380|Procedure|Oral cytobrushing|
548180|NCT00055367|Drug|natalizumab|
548181|NCT00055354|Procedure|Acupuncture|
548182|NCT00055354|Behavioral|Cognitive Behavioral Therapy|
548183|NCT00055341|Drug|Peginterferon alfa-2a|
548184|NCT00055341|Drug|Ribavirin|
548185|NCT00055328|Behavioral|Problem-Solving Treatment for Primary Care|
548186|NCT00055315|Behavioral|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
548187|NCT00055315|Behavioral|Treatment As Usual (TAU)|
548188|NCT00055302|Drug|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
548189|NCT00055263|Drug|DN-101|
548190|NCT00055250|Drug|Gemcitabine|
548191|NCT00055250|Drug|LY293111|
548192|NCT00055250|Drug|placebo|
548193|NCT00055237|Biological|Bevacizumab|15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
548194|NCT00055198|Drug|daptomycin|
548195|NCT00055185|Drug|CD4-IgG2 (PRO 542)|
548196|NCT00055146|Drug|ONTAK|
548197|NCT00055133|Drug|Micellar Paclitaxel for Injection|
548198|NCT00055159|Procedure|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
548199|NCT00055120|Drug|Emtricitabine/tenofovir disoproxil fumarate|
548200|NCT00055120|Drug|Lopinavir/ritonavir|
548201|NCT00055120|Drug|Stavudine|
548202|NCT00055107|Drug|Nitazoxanide|
548203|NCT00055081|Behavioral|Critical Time Intervention|
548204|NCT00055068|Behavioral|Cognitive Behavioral Therapy (CBT)|
548205|NCT00055068|Behavioral|Relaxation Training|
548206|NCT00055042|Drug|Vitamin E|
548207|NCT00054977|Drug|GM-CT-01|IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
548208|NCT00054977|Drug|5-fluorouracil|IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
548209|NCT00054964|Drug|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
548210|NCT00054964|Drug|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
548211|NCT00054951|Drug|MTC-DOX for Injection|
548212|NCT00054938|Drug|pravastatin|
548213|NCT00054938|Drug|aspirin|
548214|NCT00054938|Drug|ramipril|
548215|NCT00054938|Drug|Vitamins: B6, B12, and folate|
548216|NCT00054938|Behavioral|heart health educational program|
548217|NCT00054925|Behavioral|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
548305|NCT00054353|Drug|fludarabine phosphate|Given IV
548306|NCT00054353|Drug|melphalan|Given IV
548307|NCT00054353|Radiation|total-body irradiation|Undergo TBI
548308|NCT00054353|Drug|mycophenolate mofetil|Given PO
548309|NCT00054353|Drug|cyclosporine|Given PO
548310|NCT00054353|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
548218|NCT00054925|Behavioral|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
548219|NCT00054912|Biological|EP2101|
548220|NCT00054899|Biological|EP2101|
548221|NCT00054886|Drug|SU-011,248|
548222|NCT00054873|Drug|tezacitabine|
548223|NCT00054873|Drug|5-fluorouracil|
548224|NCT00054860|Biological|EP HIV-1090|
548225|NCT00054847|Procedure|saphenous vein graft|Saphenous vein harvested from the arm is used as a conduit for CABG.
548226|NCT00054847|Procedure|radial artery graft|Radial artery harvested from the arm is used as a conduit for CABG.
548227|NCT00054834|Drug|hLL2 (epratuzumab)|
548228|NCT00054821|Procedure|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
548229|NCT00054821|Procedure|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
548230|NCT00054808|Drug|gallium nitrate|
548231|NCT00054795|Drug|Motexafin Gadolinium|
548232|NCT00054730|Drug|CX516 (Ampalex®)|
548233|NCT00054756|Drug|TRH (Thyrotropin Releasing Hormone)|
548234|NCT00054743|Procedure|Blood draw|
548235|NCT00054717|Drug|Tipranavir|
548236|NCT00054717|Drug|Ritonavir(r)|
548237|NCT00054717|Drug|Comparator Protease Inhibitor (CPI)|
548238|NCT00054704|Drug|Riluzole|Riluzole
548239|NCT00054704|Drug|Placebo|Placebo
548240|NCT00054691|Drug|Iressa|250 mg by mouth daily
548241|NCT00054678|Drug|MyoCell™|
548242|NCT00054678|Device|MyoCath™|
548243|NCT00050531|Drug|Gleevec|400 mg orally twice daily.
548244|NCT00050531|Drug|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
548245|NCT00050531|Drug|Sargramostim (GM-CSF)|125 mcg/m^2 three times per week subcutaneously.
548246|NCT00054665|Drug|PS-341|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
548247|NCT00054665|Drug|Etoposide|50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
548248|NCT00054665|Drug|Doxorubicin|10 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
548249|NCT00054665|Drug|Vincristine|0.4 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
548250|NCT00054665|Drug|Cyclophosphamide|750 mg/m^2 day IV day 5 bolus. Repeat cycle every 21 days.
548251|NCT00054665|Drug|Prednisone|60 mg/m^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
548252|NCT00054665|Drug|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycle every 21 days.
548253|NCT00054639|Biological|oblimersen sodium|Given IV
548254|NCT00054639|Biological|rituximab|Given IV
548255|NCT00054639|Other|laboratory biomarker analysis|Correlative studies
548256|NCT00054626|Drug|cisplatin|
548257|NCT00054626|Drug|gemcitabine hydrochloride|
548258|NCT00054626|Procedure|adjuvant therapy|
548259|NCT00054613|Drug|Methoxsalen|
548260|NCT00054613|Procedure|Extracorporeal Photopheresis|
548261|NCT00054600|Drug|Methoxsalen|
548262|NCT00054600|Procedure|Extracorporeal Photopheresis|
548263|NCT00054587|Biological|Trastuzumab|8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
548264|NCT00054587|Drug|Cyclophosphamide|500 mg/m², D1 and every 3 weeks
548265|NCT00054587|Drug|docetaxel|on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
548266|NCT00054587|Drug|Epirubicin|100 mg/m², D1 and every 3 weeks
548267|NCT00054587|Drug|Fluorouracil|500 mg/m², D1 and every 3 weeks
548268|NCT00054574|Biological|panitumumab|
548269|NCT00054561|Biological|recombinant interferon alfa|
548270|NCT00054561|Dietary Supplement|vitamin E|
548271|NCT00054561|Drug|isotretinoin|
548272|NCT00054561|Procedure|adjuvant therapy|
548273|NCT00054548|Biological|oblimersen sodium|Given IV
548274|NCT00054548|Drug|paclitaxel|Given IV
548275|NCT00054548|Other|laboratory biomarker analysis|Correlative studies
548276|NCT00054548|Other|pharmacological study|Correlative studies
548277|NCT00054535|Biological|aldesleukin|
548278|NCT00054535|Biological|recombinant fowlpox-tyrosinase vaccine|
548279|NCT00054535|Biological|vaccinia-tyrosinase vaccine|
548280|NCT00054522|Dietary Supplement|calcitriol|
548281|NCT00054522|Drug|dexamethasone|
548282|NCT00054496|Drug|erlotinib hydrochloride|
548283|NCT00054483|Drug|bortezomib|Given IV
548284|NCT00054483|Other|laboratory biomarker analysis|Correlative studies
548285|NCT00054483|Other|pharmacological study|Correlative studies
548286|NCT00054470|Biological|trastuzumab|
548287|NCT00054470|Drug|tipifarnib|
548288|NCT00054457|Drug|capecitabine|
548289|NCT00054457|Drug|docetaxel|
548290|NCT00054444|Drug|Topotecan Hydrochloride Liposomes|Given IV
548291|NCT00054444|Radiation|3-Dimensional Conformal Radiation Therapy|
548292|NCT00054444|Drug|Cisplatin|Given IV
548293|NCT00054431|Drug|imatinib mesylate|Given orally
548294|NCT00054431|Drug|decitabine|Given IV
548295|NCT00054431|Other|laboratory biomarker analysis|Correlative studies
548296|NCT00054418|Dietary Supplement|calcium carbonate|calcium 600 mg daily administered orally for one year
548297|NCT00054418|Dietary Supplement|vitamin D|vitamin D 400 U daily administered orally for one year
548311|NCT00054353|Procedure|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
548312|NCT00054353|Other|laboratory biomarker analysis|Correlative studies
548313|NCT00054340|Biological|anti-thymocyte globulin|
548314|NCT00054340|Drug|busulfan|
548315|NCT00054340|Drug|cyclophosphamide|
548316|NCT00054340|Drug|cyclosporine|
548317|NCT00054340|Drug|methotrexate|
548318|NCT00054340|Procedure|allogeneic bone marrow transplantation|
548319|NCT00054340|Procedure|peripheral blood stem cell transplantation|
548320|NCT00054327|Drug|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
548321|NCT00054327|Drug|cyclophosphamide|Given IV
548322|NCT00054327|Drug|cytarabine|Given IV
548323|NCT00054327|Radiation|radiation therapy|Patients undergo total body irradiation
548324|NCT00054327|Drug|Etoposide|infusion
548325|NCT00054327|Procedure|Stem Cell Transfusion|
548326|NCT00054314|Drug|ortataxel|
548327|NCT00054301|Procedure|adjuvant therapy|
548328|NCT00054301|Procedure|conventional surgery|Patients undergo excisional biopsy or surgery.
548329|NCT00054301|Radiation|intraoperative radiation therapy|Patients undergo excisional biopsy or surgery followed by an intraoperative dose of radiation to the tumor cavity.
548330|NCT00054288|Drug|gemcitabine hydrochloride|
548331|NCT00054288|Drug|irinotecan hydrochloride|
548332|NCT00054275|Drug|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
548333|NCT00054275|Drug|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
548334|NCT00054262|Drug|T900607|
548335|NCT00054249|Drug|T900607|
548336|NCT00054236|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
548337|NCT00054236|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
548338|NCT00054236|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
548339|NCT00054236|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
548340|NCT00054236|Procedure|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
548341|NCT00054236|Drug|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
548342|NCT00054223|Procedure|psychosocial assessment and care|
548343|NCT00054210|Drug|carboplatin|
548344|NCT00054210|Drug|paclitaxel|
548345|NCT00054210|Drug|paclitaxel poliglumex|
548346|NCT00054197|Drug|gemcitabine hydrochloride|
548347|NCT00054197|Drug|paclitaxel poliglumex|
548348|NCT00054197|Drug|vinorelbine tartrate|
548349|NCT00054184|Drug|docetaxel|
548350|NCT00054184|Drug|paclitaxel poliglumex|
548351|NCT00054171|Drug|aminolevulinic acid hydrochloride|
548352|NCT00054158|Drug|dexamethasone|
548353|NCT00054158|Drug|doxorubicin hydrochloride|
548354|NCT00054158|Drug|thalidomide|
548355|NCT00054158|Drug|vincristine sulfate|
548356|NCT00054145|Drug|perifosine|
548357|NCT00054132|Biological|Bevacizumab|Given IV
548358|NCT00054132|Drug|Erlotinib Hydrochloride|Given PO
548359|NCT00054132|Other|Laboratory Biomarker Analysis|Correlative studies
548360|NCT00054119|Drug|Cositecan|Given IV
548361|NCT00054119|Other|Pharmacological Study|Correlative studies
548362|NCT00054106|Drug|buserelin|
548363|NCT00054106|Drug|custirsen sodium|
548364|NCT00054106|Drug|flutamide|
548365|NCT00054106|Procedure|conventional surgery|
548366|NCT00054106|Procedure|neoadjuvant therapy|
548367|NCT00054067|Drug|cisplatin|
548368|NCT00054067|Procedure|adjuvant therapy|
548369|NCT00054067|Procedure|conventional surgery|
548370|NCT00054067|Radiation|brachytherapy|
548371|NCT00054067|Radiation|radiation therapy|
548372|NCT00054054|Drug|cisplatin|
548373|NCT00054054|Drug|docetaxel|
548374|NCT00054054|Drug|fluorouracil|
548375|NCT00054054|Radiation|radiation therapy|
548376|NCT00054041|Biological|HspE7|Given subcutaneously
548377|NCT00054041|Procedure|therapeutic conventional surgery|Undergo large loop excision
548378|NCT00054041|Other|laboratory biomarker analysis|Correlative studies
548379|NCT00054028|Drug|suramin|Given IV
548380|NCT00054028|Drug|paclitaxel|Given IV
548381|NCT00054028|Other|pharmacological study|Correlative studies
548382|NCT00054015|Drug|triapine|
548383|NCT00054002|Procedure|adjuvant therapy|Lung surgery
548384|NCT00054002|Procedure|conventional surgery|Lung surgery
548385|NCT00054002|Drug|porfimer sodium|iv
548386|NCT00053989|Biological|anti-thymocyte globulin|iv
548387|NCT00053989|Biological|graft-versus-tumor induction therapy|iv
548388|NCT00053989|Biological|sargramostim|iv
548389|NCT00053989|Biological|therapeutic allogeneic lymphocytes|iv
548390|NCT00053989|Drug|cyclophosphamide|injection
548391|NCT00053989|Drug|fludarabine phosphate|iv
548392|NCT00053989|Drug|methylprednisolone|oral
548393|NCT00053989|Drug|mycophenolate mofetil|oral
548394|NCT00053989|Drug|tacrolimus|oral
548395|NCT00053989|Procedure|allogeneic bone marrow transplantation|iv
548396|NCT00053989|Procedure|peripheral blood stem cell transplantation|iv
548397|NCT00053989|Procedure|umbilical cord blood transplantation|iv
548398|NCT00053976|Biological|Daclizumab|
548399|NCT00053976|Drug|methylprednisolone|
548400|NCT00053976|Drug|Placebo|
548401|NCT00053963|Drug|romidepsin|Given IV
548402|NCT00053950|Drug|pyrazoloacridine|Given IV
548403|NCT00053950|Biological|filgrastim|Given IV or SC
548404|NCT00053950|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
548405|NCT00053950|Procedure|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
548406|NCT00053950|Other|laboratory biomarker analysis|Correlative studies
548407|NCT00053950|Other|pharmacological study|Correlative studies
548408|NCT00053937|Drug|pirfenidone|
548409|NCT00053924|Drug|perifosine|
548410|NCT00053911|Drug|anastrozole|
548411|NCT00053911|Drug|cyclophosphamide|
548412|NCT00053911|Drug|docetaxel|
548413|NCT00053911|Drug|epirubicin hydrochloride|
548414|NCT00053911|Drug|fluorouracil|
548415|NCT00053911|Drug|goserelin acetate|
548416|NCT00053911|Drug|tamoxifen citrate|
548417|NCT00053911|Procedure|adjuvant therapy|
548418|NCT00053898|Drug|anastrozole|1 mg/day and placebo for 5 years
548419|NCT00053898|Drug|tamoxifen citrate|20 mg/day and placebo for 5 years
548420|NCT00053898|Radiation|Radiation Therapy|Adjuvant radiation therapy
548421|NCT00053885|Drug|PTK787/ZK 222584|oral
548422|NCT00053872|Drug|cisplatin|
548423|NCT00053872|Drug|lomustine|
548424|NCT00053872|Drug|vincristine sulfate|
548425|NCT00053872|Procedure|adjuvant therapy|
548426|NCT00053872|Radiation|radiation therapy|
548427|NCT00053846|Drug|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
548428|NCT00053846|Drug|Placebo|Placebo
548429|NCT00053833|Drug|irinotecan|
548430|NCT00053820|Biological|aldesleukin|
548431|NCT00053820|Biological|recombinant interferon alfa|
548432|NCT00053820|Drug|fluorouracil|
548433|NCT00053807|Biological|aldesleukin|
548434|NCT00053807|Biological|recombinant interferon alfa|
548435|NCT00053807|Drug|fluorouracil|
548436|NCT00053807|Procedure|adjuvant therapy|
548437|NCT00053794|Drug|perifosine|
548438|NCT00053781|Drug|perifosine|
548439|NCT00053768|Biological|filgrastim|
548440|NCT00053768|Drug|EPOCH regimen|
548441|NCT00053768|Drug|cyclophosphamide|
548442|NCT00053768|Drug|doxorubicin hydrochloride|
548443|NCT00053768|Drug|etoposide|
548444|NCT00053768|Drug|prednisone|
548445|NCT00053768|Drug|vincristine sulfate|
548446|NCT00053768|Radiation|radiation therapy|
548447|NCT00053716|Drug|Liprostin [liposomal Prostaglandin E1]|
548448|NCT00045123|Drug|tarenflurbil|
548449|NCT00045123|Procedure|adjuvant therapy|
548450|NCT00028678|Drug|dalteparin|
548451|NCT00028678|Radiation|radiation therapy|
548452|NCT00017342|Drug|bryostatin 1|
548453|NCT00017342|Drug|cytarabine|
548454|NCT00053742|Drug|Modified Vaccinia Virus Ankara TBC-MVA|
548455|NCT00053703|Drug|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
548456|NCT00053703|Drug|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
548457|NCT00053703|Drug|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
548458|NCT00053690|Behavioral|Cognitive Behavior Treatment|
548459|NCT00053677|Drug|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
548460|NCT00053677|Drug|Placebo|For subjects who were randomly assigned to placebo.
548461|NCT00053651|Behavioral|Survival Skills for Moms with New Babies|
548462|NCT00053638|Drug|efavirenz|
548463|NCT00053638|Drug|tenofovir|
548464|NCT00053638|Drug|abacavir/lamivudine|
548465|NCT00053625|Procedure|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
548466|NCT00053612|Drug|Vitamin A|
548467|NCT00053599|Drug|Simvastatin|
548468|NCT00053573|Biological|Myozyme|20 mg/kg to 40 mg/kg qow
548469|NCT00053560|Drug|Prasterone (GL701)|
548470|NCT00053547|Drug|paricalcitol injection|
548471|NCT00053508|Biological|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
548472|NCT00053508|Biological|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
548473|NCT00053495|Biological|Vaccinia virus: ACAM2000 smallpox vaccine|Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
548474|NCT00053495|Biological|vaccinia virus (calf lymph): Dryvax|Group 5 dose: 1.0x10-8th PFU/ml
548475|NCT00053482|Biological|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
548476|NCT00053482|Biological|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
548477|NCT00053443|Device|Medication Reminder System/Adherence Tracker|
548478|NCT00053430|Drug|Thalidomide|Tablet taken orally daily
548479|NCT00053430|Drug|Thalidomide placebo|Placebo tablet taken orally daily
548480|NCT00053417|Drug|Placebo|Placebo for 15 weeks
548481|NCT00053417|Drug|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)"
548482|NCT00053417|Drug|15 mg fampridine-SR (4-aminopyridine, 4-AP)|"10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)"
548641|NCT00052520|Other|staining method|Correlative studies
548483|NCT00053417|Drug|20 mg fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
548484|NCT00053391|Biological|recombinant CD40-ligand|
548485|NCT00053391|Biological|therapeutic autologous dendritic cells|
548486|NCT00053378|Drug|paricalcitol injection (Zemplar)|
548487|NCT00053378|Behavioral|Effects on calcium regulation|
548488|NCT00053378|Behavioral|Administration of elemental Ca during hypocalcemic ICU pts.|
548489|NCT00053365|Drug|irofulven|Given IV
548490|NCT00053352|Procedure|conventional surgery|
548491|NCT00053352|Drug|cisplatin|Given IV
548492|NCT00053352|Drug|etoposide|Given IV
548493|NCT00053352|Biological|bleomycin sulfate|Given IV
548494|NCT00053352|Other|laboratory biomarker analysis|Correlative studies
548495|NCT00053339|Drug|tamoxifen|
548496|NCT00053339|Drug|trastuzumab|
548497|NCT00053326|Drug|fenretinide|Given orally
548498|NCT00053326|Other|pharmacological study|Optional correlative studies
548499|NCT00053300|Drug|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
548500|NCT00053300|Procedure|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
548501|NCT00053287|Drug|carboplatin|Carboplatin IV over 24 hours on days 1-5
548502|NCT00053287|Drug|fludarabine phosphate|Fludarabine IV over 5-10 minutes on days 1-5.
548503|NCT00053287|Drug|thalidomide|Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
548504|NCT00053287|Drug|topotecan hydrochloride|Topotecan IV continuously over 72 hours.
548505|NCT00053261|Procedure|management of therapy complications|
548506|NCT00053248|Drug|arsenic trioxide|
548507|NCT00053248|Drug|imatinib mesylate|
548508|NCT00053235|Genetic|Comparative Genomic Hybridization|Correlative studies
548509|NCT00053235|Other|Laboratory Biomarker Analysis|Correlative studies
548510|NCT00053235|Genetic|Polymerase Chain Reaction|Correlative studies
548511|NCT00053222|Drug|arsenic trioxide|
548512|NCT00053209|Drug|gemcitabine hydrochloride|
548513|NCT00053209|Drug|pemetrexed disodium|
548514|NCT00053196|Biological|anti-thymocyte globulin|2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
548515|NCT00053196|Biological|G-CSF|5 ug/kg/day subQ injection Day 7 until ANC> 1000/uL for 3 consec days
548516|NCT00053196|Drug|busulfan|0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
548517|NCT00053196|Drug|fludarabine phosphate|30 mg/sq m/day IVBP over 30 min Days -7 thru -3
548518|NCT00053196|Drug|methotrexate|5 mg/sq m/day IV infusion Days 1, 3, & 6 for HLA-identical donor transplants and Days 1, 3, 6, & 11 for MUD & 9/10 related donor transplants
548519|NCT00053196|Drug|mycophenolate mofetil|15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
548520|NCT00053196|Drug|tacrolimus|target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
548521|NCT00053196|Procedure|allogeneic cell transplantation|2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
548522|NCT00053196|Drug|allopurinol|300 mg/day PO Days -8 thru -1
548523|NCT00053183|Procedure|conventional surgery|
548524|NCT00053183|Radiation|brachytherapy|
548525|NCT00053183|Radiation|radiation therapy|
548526|NCT00053157|Biological|sargramostim|
548527|NCT00053144|Drug|cytarabine|
548528|NCT00053144|Drug|irinotecan hydrochloride|
548529|NCT00053131|Biological|filgrastim|
548530|NCT00053131|Biological|sargramostim|
548531|NCT00053131|Drug|cytarabine|
548532|NCT00053131|Drug|mitoxantrone hydrochloride|
548533|NCT00053118|Biological|filgrastim|IV
548534|NCT00053118|Drug|carboplatin|IV
548535|NCT00053118|Drug|etoposide|IV
548536|NCT00053118|Procedure|bone marrow ablation with stem cell support|IV
548537|NCT00053118|Procedure|peripheral blood stem cell transplantation|IV
548538|NCT00053105|Drug|cisplatin|
548539|NCT00053105|Drug|cytarabine|
548540|NCT00053105|Drug|methylprednisolone|
548541|NCT00053105|Drug|pixantrone dimaleate|
548542|NCT00053092|Biological|rituximab|
548543|NCT00053092|Drug|cyclophosphamide|
548544|NCT00053092|Drug|fludarabine phosphate|
548545|NCT00053053|Dietary Supplement|Juven|
548546|NCT00053053|Dietary Supplement|Non-Juven Supplement|
548547|NCT00053040|Biological|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
548548|NCT00053040|Procedure|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
548549|NCT00053027|Biological|rituximab|
548550|NCT00053027|Drug|cladribine|
548551|NCT00053014|Biological|therapeutic allogeneic lymphocytes|
548552|NCT00053014|Drug|cyclosporine|
548553|NCT00053014|Drug|fludarabine|
548554|NCT00053014|Drug|mycophenolate mofetil|
548555|NCT00053014|Procedure|peripheral blood stem cell transplantation|
548556|NCT00053014|Radiation|radiation therapy|
548557|NCT00053001|Biological|epoetin alfa|
548558|NCT00053001|Drug|thalidomide|
548559|NCT00041275|Drug|megestrol acetate|
548560|NCT00004078|Drug|irinotecan hydrochloride|Given IV
548642|NCT00052507|Drug|bortezomib|
548561|NCT00003830|Procedure|conventional surgery|Sentinel node resection immediately followed by axillary dissection.
548562|NCT00003830|Procedure|Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
548563|NCT00052962|Procedure|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
548564|NCT00052962|Procedure|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.~Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m^2 and paclitaxel 125 mg/m^2.~Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
548565|NCT00052949|Drug|imatinib mesylate|Given orally
548566|NCT00052949|Other|laboratory biomarker analysis|Correlative studies
548567|NCT00052936|Biological|filgrastim|
548568|NCT00052936|Biological|rituximab|
548569|NCT00052936|Drug|CHOP regimen|
548570|NCT00052936|Drug|cyclophosphamide|
548571|NCT00052936|Drug|doxorubicin hydrochloride|
548572|NCT00052936|Drug|prednisone|
548573|NCT00052936|Drug|vincristine sulfate|
548574|NCT00052936|Radiation|radiation therapy|
548575|NCT00052923|Biological|filgrastim|
548576|NCT00052923|Biological|rituximab|
548577|NCT00052923|Drug|carmustine|
548578|NCT00052923|Drug|cyclophosphamide|
548579|NCT00052923|Drug|etoposide|
548580|NCT00052923|Procedure|peripheral blood stem cell transplantation|
548581|NCT00052923|Radiation|radiation therapy|
548582|NCT00052910|Drug|cisplatin|Given IV
548583|NCT00052910|Drug|epirubicin hydrochloride|Given IV
548584|NCT00052910|Drug|fluorouracil|Given IV
548585|NCT00052910|Drug|leucovorin calcium|Given IV
548586|NCT00052910|Radiation|radiation therapy|Given 5 days a week for 5 weeks
548587|NCT00052897|Biological|HspE7|
548588|NCT00052884|Biological|filgrastim|
548589|NCT00052884|Drug|amifostine trihydrate|
548590|NCT00052884|Drug|melphalan|
548591|NCT00052884|Procedure|bone marrow ablation with stem cell support|
548592|NCT00052884|Procedure|peripheral blood stem cell transplantation|
548593|NCT00052845|Drug|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
548594|NCT00052845|Drug|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
548595|NCT00052845|Drug|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
548596|NCT00052832|Dietary Supplement|doxercalciferol|
548597|NCT00052780|Drug|O6-benzylguanine|Given IV
548598|NCT00052780|Drug|temozolomide|Given PO
548599|NCT00052780|Biological|filgrastim|Given SC or IV
548600|NCT00052780|Other|pharmacological study|Correlative studies
548601|NCT00052780|Other|laboratory biomarker analysis|Correlative studies
548602|NCT00052754|Drug|gefitinib|
548603|NCT00052728|Drug|tamoxifen citrate|
548604|NCT00052728|Drug|tipifarnib|
548605|NCT00052715|Drug|poly ICLC|
548606|NCT00052689|Drug|bortezomib|Given IV
548607|NCT00052689|Drug|gemcitabine hydrochloride|Given IV
548608|NCT00052676|Drug|patent blue V dye|
548609|NCT00052676|Procedure|radionuclide imaging|
548610|NCT00052676|Procedure|sentinel lymph node biopsy|
548611|NCT00052676|Radiation|technetium Tc 99m sulfur colloid|
548612|NCT00052637|Drug|hexaminolevulinate|
548613|NCT00052637|Procedure|biopsy|
548614|NCT00052637|Procedure|cystoscopy|
548615|NCT00052624|Biological|transferrin-CRM107|
548616|NCT00052611|Drug|Celecoxib|
548617|NCT00052598|Biological|therapeutic allogeneic lymphocytes|Given IV
548618|NCT00052598|Biological|aldesleukin|Given SC
548619|NCT00052598|Other|laboratory biomarker analysis|Correlative studies
548620|NCT00052598|Other|flow cytometry|Correlative studies
548621|NCT00052585|Drug|irinotecan hydrochloride|Given IV
548622|NCT00052585|Drug|gefitinib|Given orally
548623|NCT00052585|Drug|leucovorin calcium|Given IV
548624|NCT00052585|Drug|fluorouracil|Given IV
548625|NCT00052572|Drug|ixabepilone|
548626|NCT00052559|Biological|bevacizumab|Given IV
548627|NCT00052559|Drug|fluorouracil|Given IV
548628|NCT00052559|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
548629|NCT00052559|Procedure|therapeutic conventional surgery|Undergo surgery
548630|NCT00052559|Other|laboratory biomarker analysis|Correlative studies
548631|NCT00052520|Biological|therapeutic allogeneic lymphocytes|Given IV
548632|NCT00052520|Biological|aldesleukin|Given SC
548633|NCT00052520|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
548634|NCT00052520|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
548635|NCT00052520|Other|laboratory biomarker analysis|Correlative studies
548636|NCT00052520|Genetic|gene expression analysis|Correlative studies
548637|NCT00052520|Other|immunologic technique|Correlative studies
548638|NCT00052520|Other|flow cytometry|Correlative studies
548639|NCT00052520|Genetic|polymerase chain reaction|Correlative studies
548640|NCT00052520|Genetic|cytogenetic analysis|Correlative studies
548645|NCT00052494|Drug|irinotecan hydrochloride|
548646|NCT00052481|Procedure|quality-of-life assessment|
548647|NCT00052468|Drug|TCG|
548648|NCT00052468|Drug|TC|
548649|NCT00052455|Drug|lomustine|
548650|NCT00052455|Drug|procarbazine hydrochloride|
548651|NCT00052455|Drug|temozolomide|
548652|NCT00052455|Drug|vincristine sulfate|
548653|NCT00052442|Drug|pralatrexate|
548654|NCT00052429|Drug|cisplatin|
548655|NCT00052429|Drug|fluorouracil|
548656|NCT00052429|Procedure|adjuvant therapy|
548657|NCT00052429|Radiation|radiation therapy|
548658|NCT00052416|Drug|thalidomide|
548659|NCT00052403|Drug|monoclonal antibody anti-anb3 integrin|
548660|NCT00052403|Procedure|anti-cytokine therapy|
548661|NCT00052403|Procedure|antiangiogenesis therapy|
548662|NCT00052403|Procedure|antibody therapy|
548663|NCT00052403|Procedure|biological response modifier therapy|
548664|NCT00052403|Procedure|growth factor antagonist therapy|
548665|NCT00052403|Procedure|monoclonal antibody therapy|
548666|NCT00052390|Biological|bevacizumab|
548667|NCT00052390|Drug|doxorubicin hydrochloride|
548668|NCT00052377|Biological|aldesleukin|Given SC
548669|NCT00052377|Biological|recombinant interleukin-12|Given SC
548670|NCT00052377|Other|laboratory biomarker analysis|Correlative studies
548671|NCT00052364|Drug|oxaliplatin|Given IV
548672|NCT00052364|Other|laboratory biomarker analysis|Correlative studies
548673|NCT00052351|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
548674|NCT00052351|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
548675|NCT00052351|Biological|sargramostim|
548676|NCT00052351|Drug|cyclophosphamide|
548677|NCT00052351|Drug|doxorubicin hydrochloride|
548678|NCT00052351|Drug|paclitaxel|
548679|NCT00052351|Radiation|radiation therapy|
548680|NCT00052338|Drug|gemcitabine hydrochloride|Given IV
548681|NCT00052338|Drug|carboplatin|Given IV
548682|NCT00052338|Drug|bortezomib|Given IV
548683|NCT00052338|Other|laboratory biomarker analysis|Correlative studies
548684|NCT00052325|Dietary Supplement|mistletoe extract|
548685|NCT00052312|Drug|cisplatin|
548686|NCT00052312|Drug|doxorubicin hydrochloride|
548687|NCT00052312|Drug|paclitaxel|
548688|NCT00052299|Drug|cytarabine|
548689|NCT00052299|Drug|etoposide|
548690|NCT00052299|Drug|gemtuzumab ozogamicin|
548691|NCT00052299|Drug|idarubicin|
548692|NCT00052299|Drug|mitoxantrone hydrochloride|
548693|NCT00052286|Drug|modafinil|
548694|NCT00052273|Drug|capecitabine|
548695|NCT00052273|Drug|enzastaurin hydrochloride|
548696|NCT00052221|Biological|Epoetin alfa|
548697|NCT00052221|Other|Placebo|
548698|NCT00052208|Drug|gefitinib|Given PO
548699|NCT00052208|Radiation|radiation therapy|Undergo radiation therapy
548700|NCT00052208|Other|laboratory biomarker analysis|Correlative studies
548701|NCT00052195|Biological|SRL-172|5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
548702|NCT00052182|Biological|EP HIV-1090|
548703|NCT00052169|Drug|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
548704|NCT00049712|Biological|etaracizumab|
548705|NCT00049699|Drug|laromustine|
548706|NCT00049686|Drug|laromustine|
548707|NCT00049673|Drug|prednisone|Given orally
548708|NCT00049673|Drug|thalidomide|Given orally
548709|NCT00049660|Drug|capecitabine|
548710|NCT00049660|Drug|vinorelbine tartrate|
548711|NCT00049634|Drug|busulfan|
548712|NCT00049634|Drug|cyclophosphamide|
548713|NCT00049634|Drug|cyclosporine|
548714|NCT00049634|Drug|methotrexate|
548715|NCT00049634|Procedure|in vitro-treated peripheral blood stem cell transplantation|
548716|NCT00049608|Dietary Supplement|mistletoe extract|
548717|NCT00049608|Drug|gemcitabine hydrochloride|
548718|NCT00049595|Biological|bleomycin sulfate|
548719|NCT00049595|Biological|filgrastim|
548720|NCT00049595|Biological|pegfilgrastim|
548721|NCT00049595|Drug|ABVD regimen|
548722|NCT00049595|Drug|BEACOPP regimen|
548723|NCT00049595|Drug|cyclophosphamide|
548724|NCT00049595|Drug|dacarbazine|
548725|NCT00049595|Drug|doxorubicin hydrochloride|
548726|NCT00049595|Drug|etoposide|
548727|NCT00049595|Drug|prednisone|
548728|NCT00049595|Drug|procarbazine hydrochloride|
548729|NCT00049595|Drug|vinblastine sulfate|
548730|NCT00049595|Drug|vincristine sulfate|
548731|NCT00049582|Drug|decitabine|Given IV
548732|NCT00049582|Other|laboratory biomarker analysis|Correlative studies
548733|NCT00049582|Other|pharmacological study|Correlative studies
548734|NCT00049569|Drug|cytarabine|Given IT
548735|NCT00049569|Drug|methotrexate|Given IT
548736|NCT00049569|Drug|vincristine sulfate|Given IV
548737|NCT00049569|Drug|prednisone|Given PO
548738|NCT00049569|Drug|pegaspargase|Given IM
548739|NCT00049569|Drug|doxorubicin hydrochloride|Given IV
548740|NCT00049569|Drug|imatinib mesylate|Given PO
548741|NCT00049569|Drug|cyclophosphamide|Given IV
548742|NCT00049569|Drug|etoposide|Given IV
548743|NCT00049569|Biological|filgrastim|Given SC
548744|NCT00049569|Drug|leucovorin calcium|Given IV
548745|NCT00049569|Drug|asparaginase|Given IM
548746|NCT00049569|Drug|therapeutic hydrocortisone|Given IT
548747|NCT00049556|Drug|gefitinib|
548748|NCT00049556|Other|immunohistochemistry staining method|
549808|NCT00030849|Drug|bexarotene|
548749|NCT00049556|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
548750|NCT00049556|Procedure|biopsy|
548751|NCT00049556|Procedure|sentinel lymph node biopsy|
548752|NCT00049543|Drug|gefitinib|Given PO
548753|NCT00049543|Other|placebo|Given PO
548754|NCT00049543|Other|laboratory biomarker analysis|Correlative studies
548755|NCT00049530|Biological|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
548756|NCT00049517|Biological|sargramostim|Given IV or as an injection
548757|NCT00049517|Drug|busulfan|Given IV
548758|NCT00049517|Drug|cyclophosphamide|Given IV
548759|NCT00049517|Drug|cytarabine|Given as a continuous infusion
548760|NCT00049517|Drug|gemtuzumab ozogamicin (GO)|Given IV
548761|NCT00049517|Drug|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
548762|NCT00049517|Procedure|Autologous HCT|Autologous hematopoietic cell transplantation
548763|NCT00049517|Procedure|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
548764|NCT00049504|Drug|cyclophosphamide|Given IV
548765|NCT00049504|Drug|fludarabine phosphate|Given IV
548766|NCT00049504|Drug|tacrolimus|Given IV or orally
548767|NCT00049504|Drug|mycophenolate mofetil|Given orally
548768|NCT00049504|Genetic|polymerase chain reaction|Correlative studies
548769|NCT00049504|Genetic|fluorescence in situ hybridization|Correlative studies
548770|NCT00049504|Genetic|polymorphism analysis|Correlative studies
548771|NCT00049504|Genetic|gene expression analysis|Correlative studies
548772|NCT00049504|Radiation|total-body irradiation|Undergo total-body irradiation
548773|NCT00049504|Procedure|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
548774|NCT00049504|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
548775|NCT00049465|Procedure|fatigue assessment and management|
548776|NCT00049465|Procedure|management of therapy complications|
548777|NCT00049465|Procedure|psychosocial assessment and care|
548778|NCT00049452|Drug|zoledronic acid|
548779|NCT00049439|Biological|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
548780|NCT00049439|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
548781|NCT00049439|Drug|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
548782|NCT00049439|Drug|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
548783|NCT00049439|Drug|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
548784|NCT00049413|Biological|rituximab|
548785|NCT00049413|Drug|cyclophosphamide|
548786|NCT00049413|Drug|pentostatin|
548787|NCT00049400|Drug|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
548788|NCT00049387|Drug|tipifarnib|Given PO
548789|NCT00049387|Drug|temozolomide|Given PO
548790|NCT00049387|Radiation|radiation therapy|Undergo partial brain radiation therapy
548791|NCT00049374|Biological|oblimersen sodium|
548792|NCT00049374|Drug|dexamethasone|
548793|NCT00049374|Drug|thalidomide|
548794|NCT00049361|Drug|temozolomide|
548795|NCT00049361|Drug|thalidomide|
548796|NCT00049361|Radiation|radiation therapy|
548797|NCT00049348|Biological|epoetin alfa|
548798|NCT00049348|Biological|filgrastim|
548799|NCT00049348|Drug|cisplatin|
548800|NCT00049348|Drug|fluorouracil|
548801|NCT00049348|Drug|gemcitabine hydrochloride|
548802|NCT00049348|Procedure|adjuvant therapy|
548803|NCT00049348|Procedure|conventional surgery|
548804|NCT00049348|Procedure|neoadjuvant therapy|
548805|NCT00049348|Radiation|radiation therapy|
548806|NCT00049335|Drug|capecitabine|1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, on Days 1-14 of 21 day cycle
548807|NCT00049322|Biological|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
548808|NCT00049309|Dietary Supplement|dietary intervention|
548809|NCT00049309|Dietary Supplement|flaxseed|
548810|NCT00049296|Drug|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
548811|NCT00049296|Drug|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
548812|NCT00049283|Drug|erlotinib hydrochloride|Given orally
548813|NCT00049283|Drug|docetaxel|Given IV
548814|NCT00049283|Radiation|radiation therapy|Undergo radiotherapy
548815|NCT00049283|Procedure|therapeutic conventional surgery|Undergo neck dissection
548816|NCT00049283|Other|laboratory biomarker analysis|Correlative studies
548817|NCT00049283|Other|pharmacological study|Correlative studies
548818|NCT00049257|Drug|carboplatin|Administered Day 1 of each cycle. AUC=6.
549810|NCT00030823|Biological|QS21|
548819|NCT00049257|Drug|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
548820|NCT00049244|Drug|capecitabine|
548821|NCT00049244|Drug|ixabepilone|
548822|NCT00049231|Drug|EF5|
548823|NCT00049231|Other|immunohistochemistry staining method|
548824|NCT00049231|Procedure|biopsy|
548825|NCT00049218|Biological|Autologous dendritic cell-adenovirus p53 vaccine|
548826|NCT00049218|Drug|Carboplatin|
548827|NCT00049218|Drug|Etoposide|
548828|NCT00049192|Biological|oblimersen sodium|Given IV
548829|NCT00049192|Drug|imatinib mesylate|Given PO
548830|NCT00049192|Other|laboratory biomarker analysis|Correlative studies
548831|NCT00049179|Drug|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
548832|NCT00049179|Drug|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
548833|NCT00049166|Drug|erlotinib hydrochloride|Given orally
548834|NCT00049166|Drug|cisplatin|Given IV
548835|NCT00049166|Radiation|intensity-modulated radiation therapy|Undergo intensity modulated radiation therapy
548836|NCT00049166|Other|laboratory biomarker analysis|Correlative studies
548837|NCT00049140|Drug|EF5|
548838|NCT00049140|Other|bioluminescence|
548839|NCT00049140|Other|flow cytometry|
548840|NCT00049140|Other|immunohistochemistry staining method|
548841|NCT00049140|Procedure|biopsy|
548842|NCT00049127|Drug|Imatinib Mesylate|Given PO
548843|NCT00049127|Other|Laboratory Biomarker Analysis|Optional correlative studies
548844|NCT00049127|Other|Pharmacological Study|Optional correlative studies
548845|NCT00049114|Drug|doxorubicin hydrochloride|
548846|NCT00049114|Drug|cyclophosphamide|Given IV
548847|NCT00049114|Drug|tipifarnib|Given orally
548848|NCT00049114|Biological|filgrastim|Given subcutaneously
548849|NCT00049114|Procedure|therapeutic conventional surgery|Undergo complete resection
548850|NCT00049114|Other|laboratory biomarker analysis|Correlative studies
548851|NCT00049101|Drug|erlotinib hydrochloride|
548852|NCT00049101|Drug|fluorouracil|
548853|NCT00049101|Drug|leucovorin calcium|
548854|NCT00049101|Drug|oxaliplatin|
548855|NCT00049088|Drug|docetaxel|Given IV
548856|NCT00049088|Biological|bevacizumab|Given IV
548857|NCT00049088|Other|laboratory biomarker analysis|Correlative studies
548858|NCT00049088|Other|pharmacological study|Correlative studies
548859|NCT00049075|Drug|fludarabine phosphate|
548860|NCT00049062|Drug|anastrozole|
548861|NCT00049062|Drug|gefitinib|
548862|NCT00049036|Biological|rituximab|Given IV
548863|NCT00049036|Drug|etoposide|Given IV
548864|NCT00049036|Drug|doxorubicin hydrochloride|Given IV
548865|NCT00049036|Drug|vincristine sulfate|Given IV
548866|NCT00049036|Drug|prednisone|Given orally
548867|NCT00049036|Drug|cyclophosphamide|Given IV
548868|NCT00049036|Other|laboratory biomarker analysis|Correlative studies
548869|NCT00049023|Radiation|90Y-DOTA-tyr3-OCTREOTIDE|
548870|NCT00049010|Genetic|comparative genomic hybridization|
548871|NCT00049010|Genetic|cytogenetic analysis|
548872|NCT00049010|Genetic|fluorescence in situ hybridization|
548873|NCT00049010|Other|immunohistochemistry staining method|
548874|NCT00048997|Radiation|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
548875|NCT00048997|Other|Observation|
548876|NCT00048984|Other|laboratory biomarker analysis|Correlative studies
548877|NCT00048971|Genetic|mutation analysis|
548878|NCT00048971|Genetic|polymorphic microsatellite marker analysis|
548879|NCT00048958|Genetic|cytogenetic analysis|
548880|NCT00047385|Device|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
548881|NCT00047385|Device|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
548882|NCT00047346|Drug|erlotinib hydrochloride|Given PO
548883|NCT00047346|Other|pharmacological study|Correlative studies
548884|NCT00047346|Other|laboratory biomarker analysis|Correlative studies
548885|NCT00047333|Drug|erlotinib hydrochloride|Given PO
548886|NCT00047333|Other|laboratory biomarker analysis|Correlative studies
548887|NCT00047333|Other|pharmacological study|Correlative studies
548888|NCT00047320|Drug|carboplatin|Given IV
548889|NCT00047320|Drug|etoposide|Given IV
548890|NCT00047320|Drug|ifosfamide|Given IV
548891|NCT00047320|Drug|thiotepa|Given IV
548892|NCT00047320|Procedure|adjuvant therapy|
548893|NCT00047320|Procedure|conventional surgery|
548894|NCT00047320|Procedure|neoadjuvant therapy|
548895|NCT00047320|Procedure|peripheral blood stem cell transplantation|
548896|NCT00047320|Radiation|radiation therapy|craniospinal irradiation
548897|NCT00047307|Drug|alvocidib|Given IV
548898|NCT00047307|Drug|gemcitabine hydrochloride|Given IV
548899|NCT00047307|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
548900|NCT00047307|Other|laboratory biomarker analysis|Correlative studies
548901|NCT00047294|Drug|celecoxib|
548902|NCT00047294|Drug|temozolomide|
548903|NCT00047294|Drug|thalidomide|
548904|NCT00047294|Procedure|adjuvant therapy|
548905|NCT00047281|Drug|celecoxib|
548906|NCT00047281|Drug|cyclophosphamide|
548907|NCT00047281|Drug|etoposide|
548908|NCT00047281|Drug|thalidomide|
548909|NCT00047268|Drug|cytarabine|
548910|NCT00047268|Drug|mercaptopurine|
548911|NCT00047268|Other|laboratory biomarker analysis|
549903|NCT00030095|Drug|2-methoxyestradiol|
548912|NCT00047268|Procedure|allogeneic bone marrow transplantation|
548913|NCT00047268|Procedure|biopsy|
548914|NCT00047268|Procedure|peripheral blood stem cell transplantation|
548915|NCT00047255|Biological|trastuzumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
548916|NCT00047255|Drug|carboplatin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
548917|NCT00047255|Drug|docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
548918|NCT00047255|Biological|trastuxumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.~Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.~Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
548919|NCT00047255|Drug|Docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.~Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.~Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
548920|NCT00047242|Drug|7-hydroxystaurosporine|
548921|NCT00047242|Drug|irinotecan hydrochloride|
548922|NCT00047229|Biological|oblimersen sodium|
548923|NCT00047229|Drug|doxorubicin hydrochloride|
548924|NCT00047216|Drug|tipifarnib|
548925|NCT00047203|Drug|alvocidib|Given IV
548926|NCT00047190|Drug|tipifarnib|Given PO
548927|NCT00047190|Other|laboratory biomarker analysis|Correlative studies
548928|NCT00047177|Drug|Oxaliplatin|
548929|NCT00047164|Biological|ipilimumab|
548930|NCT00047138|Biological|dactinomycin|
548931|NCT00047138|Drug|carboplatin|
548932|NCT00047138|Drug|cyclophosphamide|
548933|NCT00047138|Drug|doxorubicin hydrochloride|
548934|NCT00047138|Drug|etoposide|
548935|NCT00047138|Drug|vincristine sulfate|
548936|NCT00047138|Procedure|adjuvant therapy|
548937|NCT00047138|Procedure|conventional surgery|
548938|NCT00047138|Procedure|neoadjuvant therapy|
548939|NCT00047138|Radiation|radiation therapy|
548940|NCT00047125|Radiation|radiation therapy|
548941|NCT00047112|Drug|cisplatin|
548942|NCT00047112|Drug|fluorouracil|
548943|NCT00047112|Procedure|conventional surgery|
548944|NCT00047112|Procedure|neoadjuvant therapy|
548945|NCT00047112|Radiation|radiation therapy|
548946|NCT00047099|Drug|cyclophosphamide|
548947|NCT00047099|Drug|docetaxel|
548948|NCT00047099|Drug|epirubicin hydrochloride|
548949|NCT00047099|Drug|fluorouracil|
548950|NCT00047099|Drug|goserelin acetate|
548951|NCT00047099|Drug|tamoxifen citrate|
548952|NCT00047099|Procedure|adjuvant therapy|
548953|NCT00047099|Radiation|radiation therapy|
548954|NCT00047073|Drug|Rapamycin|"Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.~Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.~Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same."
548955|NCT00047073|Procedure|Surgery|Surgical resection.
549011|NCT00046826|Drug|estramustine phosphate sodium|
549012|NCT00046826|Drug|thalidomide|
549013|NCT00045747|Drug|7-hydroxystaurosporine|
548956|NCT00047073|Procedure|Supportive Care|"Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.~Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.~If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented."
548957|NCT00047060|Other|A matched peripheral donor stem cells|A matched peripheral donor stem cells
548958|NCT00047060|Drug|cyclosporine|cyclosporine
548959|NCT00047060|Drug|fludarabine|fludarabine
548960|NCT00047060|Drug|Campath|Campath
548961|NCT00047047|Drug|gemcitabine hydrochloride|Given IV
548962|NCT00047047|Drug|tanespimycin|Given IV
548963|NCT00047047|Drug|cisplatin|Given IV
548964|NCT00047047|Other|laboratory biomarker analysis|Correlative studies
548965|NCT00047034|Drug|eribulin mesylate|Given IV
548966|NCT00047034|Other|pharmacological study|Correlative studies
548967|NCT00047034|Other|laboratory biomarker analysis|Correlative studies
548968|NCT00047021|Biological|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
548969|NCT00047021|Drug|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
548970|NCT00047021|Drug|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
548971|NCT00047008|Drug|cisplatin|100 mg/m^2 intravenously on days 1, 22
548972|NCT00047008|Radiation|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
548973|NCT00047008|Radiation|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
548974|NCT00047008|Procedure|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.~A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
548975|NCT00046995|Drug|carboplatin|
548976|NCT00046995|Drug|fluorouracil|
548977|NCT00046995|Drug|leucovorin calcium|
548978|NCT00046995|Procedure|adjuvant therapy|
548979|NCT00046969|Biological|epoetin beta|
548980|NCT00046969|Drug|cisplatin|
548981|NCT00046969|Radiation|brachytherapy|
548982|NCT00046969|Radiation|radiation therapy|
548983|NCT00046943|Drug|atrasentan hydrochloride|
548984|NCT00046930|Biological|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
548985|NCT00046930|Biological|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
548986|NCT00046930|Drug|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
548987|NCT00046930|Drug|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
548988|NCT00046930|Drug|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
548989|NCT00046930|Drug|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.~The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
548990|NCT00046917|Drug|alvocidib|Given IV
548991|NCT00046917|Drug|irinotecan hydrochloride|Given IV
548992|NCT00046917|Drug|cisplatin|Given IV
548993|NCT00046904|Biological|etanercept|
548994|NCT00046891|Drug|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
548995|NCT00046891|Other|Placebo|Patients will take 1 tablet BID
548996|NCT00046865|Procedure|acupressure therapy|
548997|NCT00046865|Procedure|management of therapy complications|
548998|NCT00046865|Procedure|nausea and vomiting therapy|
548999|NCT00046852|Biological|filgrastim|
549000|NCT00046852|Biological|pneumococcal polyvalent vaccine|
549001|NCT00046852|Biological|therapeutic autologous lymphocytes|
549002|NCT00046852|Biological|therapeutic tumor infiltrating lymphocytes|
549003|NCT00046852|Drug|carmustine|
549004|NCT00046852|Drug|cyclophosphamide|
549005|NCT00046852|Drug|melphalan|
549006|NCT00046852|Procedure|bone marrow ablation with stem cell support|
549007|NCT00046852|Procedure|peripheral blood stem cell transplantation|
549008|NCT00046839|Drug|celecoxib|
549009|NCT00046839|Radiation|radiation therapy|
549015|NCT00045734|Drug|imatinib mesylate|Given orally
549016|NCT00045734|Other|laboratory biomarker analysis|Correlative studies
549017|NCT00045734|Other|pharmacological study|Correlative studies
549018|NCT00045721|Drug|O6-benzylguanine|
549019|NCT00045721|Drug|polifeprosan 20 with carmustine implant|
549020|NCT00045721|Procedure|adjuvant therapy|
549021|NCT00045721|Procedure|conventional surgery|
549022|NCT00045721|Procedure|neoadjuvant therapy|
549023|NCT00045708|Drug|ixabepilone|Given IV
549024|NCT00045708|Other|pharmacological study|Correlative studies
549025|NCT00045708|Drug|Anticonvulsant|Drugs that induce hepatic Metabolic enzymes
549026|NCT00045695|Drug|bortezomib|PS-341 bolus intravenous injection twice weekly* for 2 out of every 3 weeks
549027|NCT00045682|Drug|Paclitaxel Poliglumex|Given IV
549028|NCT00045669|Drug|imatinib mesylate|
549029|NCT00045630|Drug|carboplatin|
549030|NCT00045630|Drug|gemcitabine|
549031|NCT00045630|Drug|paclitaxel|
549032|NCT00045630|Procedure|surgery|
549033|NCT00045617|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
549034|NCT00045617|Biological|monoclonal antibody GD2 anti-idiotype vaccine|
549035|NCT00045617|Drug|cisplatin|
549036|NCT00045617|Drug|etoposide|
549037|NCT00045617|Radiation|radiation therapy|
549038|NCT00045604|Drug|cisplatin|
549039|NCT00045604|Drug|imatinib mesylate|
549040|NCT00045604|Drug|irinotecan hydrochloride|
549041|NCT00045591|Drug|celecoxib|100 mg PO bid
549042|NCT00045591|Drug|Celecoxib|400 mg PO bid
549043|NCT00045565|Drug|arsenic trioxide|Given IV
549044|NCT00045565|Radiation|radiation therapy|Undergo radiation therapy
549045|NCT00045539|Drug|leucovorin calcium|
549046|NCT00045539|Drug|methotrexate|
549047|NCT00045539|Drug|thiotepa|
549048|NCT00045526|Drug|erlotinib hydrochloride|Given PO
549049|NCT00045526|Other|laboratory biomarker analysis|Correlative studies
549050|NCT00045513|Drug|7-hydroxystaurosporine|
549051|NCT00045513|Drug|fludarabine phosphate|
549052|NCT00045500|Drug|7-hydroxystaurosporine|
549053|NCT00045500|Drug|prednisone|
549054|NCT00045487|Drug|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
549055|NCT00045474|Procedure|adjuvant therapy|
549056|NCT00045474|Radiation|iodine I 125|
549057|NCT00045461|Drug|carboplatin|
549058|NCT00045461|Drug|ifosfamide|
549059|NCT00045461|Procedure|hyperthermia treatment|
549060|NCT00045448|Drug|alvocidib|
549061|NCT00045448|Drug|docetaxel|
549062|NCT00045435|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
549063|NCT00045435|Drug|fludarabine phosphate|Given IV
549064|NCT00045435|Radiation|total-body irradiation|Undergo TBI
549065|NCT00045435|Drug|cyclosporine|Given PO
549066|NCT00045435|Drug|mycophenolate mofetil|Given PO
549067|NCT00045435|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
549068|NCT00045422|Biological|recombinant interferon alfa|
549069|NCT00045422|Drug|imatinib mesylate|
549070|NCT00045396|Drug|tipifarnib|Given orally
549071|NCT00045370|Biological|recombinant interferon alfa|
549072|NCT00045370|Drug|temsirolimus|
549073|NCT00045331|Genetic|proteomic profiling|
549074|NCT00045318|Drug|exatecan mesylate|
549075|NCT00045305|Drug|Cyclosporine|Immunosuppressant
549076|NCT00045305|Drug|Methotrexate|Antimetabolite
549077|NCT00045305|Drug|Photopheresis|Psoralens
549078|NCT00045305|Drug|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
549079|NCT00045305|Drug|Pentostatin|Purine analogue
549080|NCT00045305|Procedure|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
549081|NCT00045305|Procedure|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
549082|NCT00045305|Radiation|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
549083|NCT00045292|Drug|acyclovir|
549084|NCT00045292|Drug|acyclovir sodium|
549085|NCT00045292|Drug|valacyclovir|
549086|NCT00045279|Biological|PEG-interferon alfa-2b|
549087|NCT00045266|Biological|ziv-aflibercept|
549088|NCT00045227|Biological|recombinant fowlpox-prostate specific antigen vaccine|
549089|NCT00045227|Biological|recombinant vaccinia prostate-specific antigen vaccine|
549090|NCT00045227|Biological|recombinant vaccinia-B7.1 vaccine|
549091|NCT00045227|Biological|sargramostim|
549092|NCT00045227|Drug|docetaxel|
549093|NCT00045201|Drug|Erlotinib Hydrochloride|Given orally
549094|NCT00045201|Drug|Irinotecan Hydrochloride|Given IV
549095|NCT00045188|Drug|imatinib mesylate|Given PO
549096|NCT00045188|Other|laboratory biomarker analysis|Optional correlative studies
549097|NCT00045175|Drug|7-hydroxystaurosporine|
549098|NCT00045175|Drug|topotecan hydrochloride|
549099|NCT00045162|Drug|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles~Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
549100|NCT00045162|Drug|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 & 3. Q 3 weeks x 4 Cycles
549101|NCT00045162|Drug|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 & 15. Q 4 weeks x 4 Cycles
549102|NCT00045136|Drug|melphalan|
549103|NCT00045136|Procedure|peripheral blood stem cell transplantation|
549104|NCT00045136|Radiation|holmium Ho 166 DOTMP|
549105|NCT00045110|Drug|erlotinib hydrochloride|given orally
549106|NCT00045110|Other|laboratory biomarker analysis|correlative studies
549107|NCT00045110|Other|pharmacological study|correlative studies
549109|NCT00045045|Procedure|positron emission tomography|
549110|NCT00045045|Radiation|fludeoxyglucose F 18|
549111|NCT00045032|Drug|Herceptin|Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
549112|NCT00045032|Drug|Herceptin|Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
549113|NCT00045019|Other|quality-of-life assessment|QLQ-C30 SAT32
549114|NCT00045006|Drug|vorinostat|
549115|NCT00044993|Biological|Ad5CMV-p53 gene|
549116|NCT00044993|Drug|docetaxel|
549117|NCT00044993|Drug|doxorubicin hydrochloride|
549118|NCT00044993|Procedure|conventional surgery|
549119|NCT00044993|Procedure|neoadjuvant therapy|
549120|NCT00044980|Procedure|nutritional support|
549121|NCT00044980|Procedure|quality-of-life assessment|
549122|NCT00044967|Genetic|microsatellite instability analysis|
549123|NCT00044954|Biological|therapeutic allogeneic lymphocytes|
549124|NCT00044954|Drug|cyclosporine|
549125|NCT00044954|Drug|fludarabine phosphate|
549126|NCT00044954|Drug|mycophenolate mofetil|
549127|NCT00044954|Procedure|allogeneic bone marrow transplantation|
549128|NCT00044954|Procedure|peripheral blood stem cell transplantation|
549129|NCT00044954|Radiation|radiation therapy|
549130|NCT00043147|Drug|beclomethasone dipropionate|
549131|NCT00043147|Drug|methylprednisolone|
549132|NCT00043147|Drug|prednisone|
549133|NCT00043134|Drug|decitabine|
549134|NCT00043121|Drug|oxaliplatin|Given IV
549135|NCT00043121|Drug|leucovorin calcium|Given IV
549136|NCT00043121|Drug|fluorouracil|Given IV
549137|NCT00043121|Drug|capecitabine|Given orally
549138|NCT00043121|Other|pharmacological study|Correlative studies
549139|NCT00043095|Drug|gemcitabine hydrochloride|
549140|NCT00043095|Drug|ixabepilone|
549141|NCT00043082|Drug|carboplatin|intravenous q 4 weeks
549142|NCT00043082|Drug|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
549143|NCT00043069|Dietary Supplement|calcium carbonate|
549144|NCT00043069|Dietary Supplement|cholecalciferol|
549145|NCT00043069|Drug|Estrogen Antagonists|
549146|NCT00043069|Drug|risedronate sodium|
549147|NCT00043069|Other|placebo|
549148|NCT00043043|Drug|celecoxib|
549149|NCT00043030|Procedure|psychosocial assessment and care|
549150|NCT00043017|Procedure|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
549151|NCT00043017|Radiation|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
549152|NCT00043004|Biological|bevacizumab|
549153|NCT00043004|Drug|FOLFOX regimen|
549154|NCT00043004|Drug|fluorouracil|
549155|NCT00043004|Drug|leucovorin calcium|
549156|NCT00043004|Drug|oxaliplatin|
549157|NCT00043004|Procedure|conventional surgery|
549158|NCT00043004|Procedure|radiofrequency ablation|
549159|NCT00042991|Drug|gefitinib|Given orally
549160|NCT00042991|Radiation|radiation therapy|Undergo standard brain irradiation
549161|NCT00042991|Other|pharmacological study|Correlative studies
549162|NCT00042991|Other|laboratory biomarker analysis|Correlative studies
549163|NCT00042978|Biological|oblimersen sodium|Given IV
549164|NCT00042978|Drug|carboplatin|Given IV
549165|NCT00042978|Drug|etoposide|Given IV
549166|NCT00042965|Drug|capecitabine|
549167|NCT00042965|Drug|gemcitabine hydrochloride|
549168|NCT00042952|Drug|imatinib mesylate|Given orally
549169|NCT00042952|Procedure|therapeutic conventional surgery|Undergo surgical resection
549170|NCT00042952|Other|laboratory biomarker analysis|Correlative studies
549171|NCT00042939|Biological|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
549172|NCT00042939|Drug|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
549173|NCT00042939|Drug|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
549174|NCT00042926|Other|immunohistochemistry staining method|
549175|NCT00042926|Procedure|conventional surgery|
549176|NCT00042926|Procedure|lymphangiography|
549177|NCT00042926|Procedure|radionuclide imaging|
549178|NCT00042926|Procedure|sentinel lymph node biopsy|
549179|NCT00042926|Radiation|technetium Tc 99m sulfur colloid|
549180|NCT00042913|Biological|epratuzumab|
549181|NCT00042887|Drug|mitomycin C|
549182|NCT00042887|Procedure|conventional surgery|
549183|NCT00042874|Drug|alvocidib|Given IV
549184|NCT00042874|Drug|irinotecan hydrochloride|Given IV
549185|NCT00042874|Drug|fluorouracil|Given IV
549186|NCT00042874|Drug|leucovorin calcium|Given IV
549187|NCT00042874|Other|laboratory biomarker analysis|Correlative studies
549188|NCT00042861|Drug|7-hydroxystaurosporine|
549189|NCT00042861|Drug|fluorouracil|
549190|NCT00042861|Drug|leucovorin calcium|
549191|NCT00042848|Drug|modafinil|
549192|NCT00042835|Drug|cisplatin|Given IV
549193|NCT00042835|Drug|etoposide|Given IV
549194|NCT00042835|Drug|erlotinib hydrochloride|Given orally
549195|NCT00042835|Radiation|radiation therapy|Undergo radiotherapy
549196|NCT00042835|Drug|docetaxel|Given IV
549197|NCT00042835|Drug|paclitaxel|Given IV
549198|NCT00042835|Drug|carboplatin|Given IV
549199|NCT00042835|Other|laboratory biomarker analysis|Correlative studies
549200|NCT00042822|Drug|romidepsin|
549201|NCT00042809|Drug|paclitaxel|Given IV
549202|NCT00042809|Biological|trastuzumab|Given IV
549203|NCT00042809|Drug|erlotinib hydrochloride|Given orally
549204|NCT00042809|Other|laboratory biomarker analysis|Correlative studies
549205|NCT00042809|Other|pharmacological study|Correlative studies
549206|NCT00042796|Drug|decitabine|Given IV
549207|NCT00042796|Other|pharmacological study|Correlative studies
549208|NCT00042796|Other|laboratory biomarker analysis|Correlative studies
549209|NCT00042783|Biological|D1/3-MAGE-3-His fusion protein|
549210|NCT00042783|Biological|SB-AS02B adjuvant|
549211|NCT00042770|Other|talc|Given intrapleurally
549212|NCT00042770|Procedure|dyspnea management|No talc
549213|NCT00042731|Dietary Supplement|Lycopene|Daily administration as outlined in treatment arm(s)
549214|NCT00042731|Dietary Supplement|Multivitamin|Daily administration as outlined in treatment arm(s)
549215|NCT00042731|Dietary Supplement|Soy isoflavones|Daily administration as outlined in treatment arm(s)
549216|NCT00041379|Drug|beta alethine|
549217|NCT00041340|Drug|imatinib mesylate|Given orally
549218|NCT00041340|Other|laboratory biomarker analysis|Correlative studies
549219|NCT00041327|Biological|filgrastim|5 ug/kg/d
549220|NCT00041327|Biological|recombinant interferon alfa|9 mU subcutaneously per day for one year
549221|NCT00041327|Drug|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
549222|NCT00041327|Drug|cyclophosphamide|750 mg/m2 IV on day 5
549223|NCT00041327|Drug|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
549224|NCT00041327|Drug|lamivudine|150 mg bid
549225|NCT00041327|Drug|prednisone|60 mg/m2 given orally days 1-5
549226|NCT00041327|Drug|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
549227|NCT00041327|Drug|zidovudine|300 mg bid
549228|NCT00041314|Drug|carboplatin|
549229|NCT00041314|Drug|exisulind|
549230|NCT00041314|Drug|gemcitabine hydrochloride|
549231|NCT00041301|Other|QoL assessment|qol questionnaires
549232|NCT00041288|Biological|therapeutic allogeneic lymphocytes|
549233|NCT00041288|Drug|cyclophosphamide|
549234|NCT00041288|Drug|cyclosporine|
549235|NCT00041288|Drug|fludarabine phosphate|
549236|NCT00041288|Drug|methotrexate|
549237|NCT00041288|Drug|mycophenolate mofetil|
549238|NCT00041288|Drug|tacrolimus|
549239|NCT00041288|Procedure|peripheral blood stem cell transplantation|
549240|NCT00041288|Radiation|radiation therapy|
549241|NCT00041262|Drug|cisplatin|
549242|NCT00041262|Drug|epirubicin hydrochloride|
549243|NCT00041262|Drug|fluorouracil|
549244|NCT00041262|Procedure|conventional surgery|
549245|NCT00041262|Procedure|neoadjuvant therapy|
549246|NCT00041249|Drug|brostallicin|
549247|NCT00041236|Drug|exatecan mesylate|
549248|NCT00041223|Dietary Supplement|IH636 grape seed proanthocyanidin extract|
549249|NCT00041210|Biological|bleomycin sulfate|
549250|NCT00041210|Drug|ABVD regimen|
549251|NCT00041210|Drug|Stanford V regimen|
549252|NCT00041210|Drug|dacarbazine|
549253|NCT00041210|Drug|doxorubicin hydrochloride|
549254|NCT00041210|Drug|etoposide|
549255|NCT00041210|Drug|mechlorethamine hydrochloride|
549256|NCT00041210|Drug|prednisone|
549257|NCT00041210|Drug|vinblastine sulfate|
549258|NCT00041210|Drug|vincristine sulfate|
549259|NCT00041210|Radiation|radiation therapy|
549260|NCT00041197|Drug|imatinib mesylate|Given orally (PO)
549261|NCT00041197|Other|placebo|Given PO
549262|NCT00041197|Other|laboratory biomarker analysis|Correlative studies
549263|NCT00041171|Drug|Hypericum perforatum|
549264|NCT00041171|Drug|docetaxel|
549265|NCT00041171|Other|placebo|
549266|NCT00041132|Biological|filgrastim|5 ug/kg
549267|NCT00041132|Biological|rituximab|375 mg/m^2 on day 1 of cycles 1-6
549268|NCT00041132|Drug|cyclophosphamide|300 mg/m^2 on days 2-4 of cycles 1,3,5,7
549269|NCT00041132|Drug|cytarabine|12 g/m^2 over days 3-4 of cycles 2,4,6,8
549270|NCT00041132|Drug|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
549271|NCT00041132|Drug|doxorubicin|16.6 mg/m^2/day for days 5-7 of cycles 1,3,5,7
549272|NCT00041132|Drug|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
549273|NCT00041132|Drug|methotrexate|1000 mg/m^2 over days 2-3 of cycles 2,4,6,8
549274|NCT00041132|Drug|vincristine|1.4 mg/m^2 on days 5 and 12 of cycles 1,3,5,7
549275|NCT00041119|Drug|AC regimen|Given IV
549276|NCT00041119|Drug|cyclophosphamide|Given IV
549277|NCT00041119|Drug|doxorubicin hydrochloride|Given IV
549278|NCT00041119|Drug|paclitaxel|Given IV
549279|NCT00041106|Drug|gemcitabine hydrochloride|Given IV
549280|NCT00041106|Drug|cisplatin|Given IV
549281|NCT00041106|Drug|gefitinib|Given PO
549282|NCT00041106|Other|laboratory biomarker analysis|Correlative studies
549283|NCT00041093|Drug|Docetaxel|Given IV
549284|NCT00041080|Drug|tamoxifen citrate|Given orally
549285|NCT00041080|Drug|thalidomide|Given orally
549286|NCT00041080|Other|laboratory biomarker analysis|Correlative studies
549287|NCT00041067|Biological|filgrastim|
549288|NCT00041067|Biological|trastuzumab|
549289|NCT00041067|Drug|docetaxel|
549290|NCT00041067|Drug|vinorelbine|
549291|NCT00041054|Drug|carboplatin|
549292|NCT00041054|Drug|etoposide|
549293|NCT00041054|Drug|exisulind|
549294|NCT00041041|Drug|imatinib mesylate|Given PO
549295|NCT00041041|Other|laboratory biomarker analysis|Correlative studies
549296|NCT00041028|Drug|EF5|
549298|NCT00041028|Other|immunohistochemistry staining method|
549299|NCT00041015|Drug|cisplatin|
549300|NCT00041015|Drug|etoposide|
549301|NCT00041015|Drug|topotecan hydrochloride|
549302|NCT00040989|Drug|BAY 56-3722|
549303|NCT00040989|Procedure|enzyme inhibitor therapy|
549304|NCT00040950|Biological|rituximab|
549305|NCT00040950|Drug|agatolimod sodium|
549306|NCT00040937|Biological|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
549307|NCT00040937|Biological|sargramostim|"PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis~1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery"
549308|NCT00040937|Drug|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
549309|NCT00040937|Drug|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
549310|NCT00040937|Drug|melphalan|"st trans: 140 mg/m2 IV over 20 mins day -1~nd trans: 200mg/m2 IV over 20 mins day -1"
549311|NCT00040937|Drug|prednisone|maint: 50 mg/d PO every other day until progression
549312|NCT00040937|Drug|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
549313|NCT00040937|Procedure|peripheral blood stem cell transplantation|2-4 x 10^6/kg IV day 0
549314|NCT00040911|Procedure|electroacupuncture therapy|
549315|NCT00040911|Procedure|sham intervention|Undergo electroacupuncture therapy to sham points
549316|NCT00040911|Procedure|quality-of-life assessment|Ancillary studies
549317|NCT00040898|Dietary Supplement|Sho-saiko-to|
549318|NCT00040885|Biological|infliximab|
549319|NCT00040885|Drug|docetaxel|
549320|NCT00040885|Other|placebo|
549321|NCT00040872|Biological|filgrastim|
549322|NCT00040872|Biological|monoclonal antibody 3F8|
549323|NCT00040872|Biological|sargramostim|
549324|NCT00040872|Drug|carboplatin|
549325|NCT00040872|Drug|cisplatin|
549326|NCT00040872|Drug|cyclophosphamide|
549327|NCT00040872|Drug|doxorubicin hydrochloride|
549328|NCT00040872|Drug|etoposide|
549329|NCT00040872|Drug|isotretinoin|
549330|NCT00040872|Drug|thiotepa|
549331|NCT00040872|Drug|topotecan hydrochloride|
549332|NCT00040872|Drug|vincristine sulfate|
549333|NCT00040872|Procedure|autologous bone marrow transplantation|
549334|NCT00040872|Procedure|bone marrow ablation with stem cell support|
549335|NCT00040872|Procedure|conventional surgery|
549336|NCT00040872|Procedure|drug resistance inhibition treatment|
549337|NCT00040872|Procedure|peripheral blood stem cell transplantation|
549338|NCT00040872|Procedure|syngeneic bone marrow transplantation|
549339|NCT00040872|Radiation|radiation therapy|
549340|NCT00040859|Drug|capecitabine|
549341|NCT00040859|Drug|oxaliplatin|
549342|NCT00040846|Biological|alemtuzumab|Given IV
549343|NCT00040846|Drug|fludarabine phosphate|Given IV
549344|NCT00040846|Radiation|total-body irradiation|Undergo TBI
549345|NCT00040846|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
549346|NCT00040846|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
549347|NCT00040846|Drug|mycophenolate mofetil|Given PO
549348|NCT00040846|Drug|cyclosporine|Given IV or PO
549349|NCT00040833|Procedure|complementary or alternative medicine procedure|
549350|NCT00040833|Procedure|pain therapy|
549351|NCT00040807|Drug|docetaxel|
549352|NCT00040807|Drug|irinotecan hydrochloride|
549353|NCT00040794|Drug|paclitaxel|Given IV
549354|NCT00040794|Drug|carboplatin|Given IV
549355|NCT00040794|Drug|gefitinib|Given PO
549356|NCT00040794|Radiation|radiation therapy|Undergo radiotherapy
549357|NCT00040794|Other|laboratory biomarker analysis|Optional correlative studies
549358|NCT00040781|Drug|gefitinib|Given orally
549359|NCT00040781|Other|pharmacological study|Correlative studies
549360|NCT00040781|Other|laboratory biomarker analysis|Correlative studies
549361|NCT00040768|Drug|bortezomib|Given IV
549362|NCT00040755|Drug|rebimastat|Given orally
549363|NCT00040755|Other|laboratory biomarker analysis|Correlative studies
549364|NCT00040742|Dietary Supplement|ginger|Given orally
549365|NCT00040742|Other|placebo|Given orally
549366|NCT00040690|Biological|filgrastim|
549367|NCT00040690|Drug|cyclophosphamide|
549368|NCT00040690|Drug|cytarabine|
549369|NCT00040690|Drug|doxorubicin hydrochloride|
549370|NCT00040690|Drug|etoposide|
549371|NCT00040690|Drug|ifosfamide|
549372|NCT00040690|Drug|leucovorin calcium|
549373|NCT00040690|Drug|methotrexate|
549374|NCT00040690|Drug|vincristine sulfate|
549375|NCT00040690|Radiation|radiation therapy|
549376|NCT00039611|Drug|FOLFOX regimen|
549377|NCT00039611|Drug|fluorouracil|
549378|NCT00039611|Drug|leucovorin calcium|
549379|NCT00039611|Drug|oxaliplatin|
549380|NCT00039585|Drug|imatinib mesylate|
549381|NCT00039572|Drug|boronophenylalanine-fructose complex|
549382|NCT00039559|Other|Early detection|CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
549383|NCT00039546|Drug|cyclophosphamide|
549384|NCT00039546|Drug|epirubicin hydrochloride|
549385|NCT00039546|Drug|gemcitabine hydrochloride|
549386|NCT00039546|Drug|paclitaxel|
549387|NCT00039546|Procedure|adjuvant therapy|
549388|NCT00039520|Drug|docetaxel|
549389|NCT00039520|Drug|sulindac|
549390|NCT00039507|Procedure|conventional surgery|
549391|NCT00039507|Procedure|radiofrequency ablation|
549392|NCT00039494|Drug|erlotinib hydrochloride|Given orally
549393|NCT00039494|Radiation|3-dimensional conformal radiation therapy|
549394|NCT00039494|Drug|temozolomide|Given orally
549395|NCT00039481|Biological|oblimersen sodium|Given IV
549396|NCT00039481|Drug|dexrazoxane hydrochloride|Given IV
549397|NCT00039481|Drug|doxorubicin hydrochloride|Given IV
549398|NCT00039481|Drug|cyclophosphamide|Given IV
549399|NCT00039481|Biological|filgrastim|Given SC
549400|NCT00039481|Other|laboratory biomarker analysis|Correlative studies
549401|NCT00039481|Other|pharmacological study|Correlative studies
549402|NCT00039468|Drug|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
549403|NCT00039468|Drug|thalidomide|400mg/day oral
549404|NCT00039455|Biological|trastuzumab|Given IV
549405|NCT00039455|Drug|alvocidib|Given IV
549406|NCT00039455|Other|laboratory biomarker analysis|Correlative studies
549407|NCT00039455|Other|pharmacological study|Correlative studies
549408|NCT00039442|Drug|Capecitabine|Given orally
549409|NCT00039442|Other|Laboratory Biomarker Analysis|Correlative studies
549410|NCT00039429|Drug|atrasentan hydrochloride|
549411|NCT00039416|Drug|imatinib mesylate|Given orally
549412|NCT00039416|Other|laboratory biomarker analysis|Correlative studies
549413|NCT00039403|Drug|7-hydroxystaurosporine|Given IV
549414|NCT00039403|Drug|gemcitabine hydrochloride|Given IV
549415|NCT00039403|Other|pharmacological study|Correlative studies
549416|NCT00039403|Other|laboratory biomarker analysis|Correlative studies
549417|NCT00039390|Drug|capecitabine|Given orally (PO)
549418|NCT00039390|Drug|gefitinib|Given PO
549419|NCT00039390|Other|pharmacological study|Correlative studies
549420|NCT00039390|Other|laboratory biomarker analysis|Correlative studies
549421|NCT00039377|Drug|imatinib mesylate|Given PO
549422|NCT00039377|Drug|methotrexate|Given IT and IV
549423|NCT00039377|Drug|vincristine sulfate|Given IV
549424|NCT00039377|Drug|leucovorin calcium|Given IV and PO
549425|NCT00039377|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
549426|NCT00039377|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
549427|NCT00039377|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
549428|NCT00039377|Radiation|total-body irradiation|Undergo TBI
549429|NCT00039377|Drug|tacrolimus|Given IV or PO
549430|NCT00039377|Biological|filgrastim|Given SC
549431|NCT00039377|Drug|etoposide|Given IV
549432|NCT00039377|Drug|cyclophosphamide|Given IV
549433|NCT00039377|Drug|cytarabine|Given IV
549434|NCT00039377|Other|laboratory biomarker analysis|Correlative studies
549435|NCT00039364|Drug|imatinib mesylate|
549436|NCT00039351|Drug|cyclophosphamide|
549437|NCT00039351|Drug|prednisone|
549438|NCT00039351|Drug|vincristine sulfate|
549439|NCT00039351|Radiation|radiation therapy|
549440|NCT00039338|Procedure|conventional surgery|Radial hysterectomy
549441|NCT00039338|Procedure|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
549442|NCT00039338|Radiation|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
549443|NCT00039338|Radiation|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
549444|NCT00039338|Drug|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
549445|NCT00039325|Biological|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6 (for arm A) or 10^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
549446|NCT00039312|Other|Papanicolaou test|
549447|NCT00039312|Other|cytology specimen collection procedure|
549448|NCT00039312|Procedure|annual screening|
549449|NCT00039312|Procedure|colposcopic biopsy|
549450|NCT00039312|Procedure|comparison of screening methods|
549451|NCT00039299|Biological|therapeutic autologous lymphocytes|
549452|NCT00039286|Procedure|positron emission tomography|
549453|NCT00039286|Procedure|radionuclide imaging|
549454|NCT00039286|Radiation|fludeoxyglucose F 18|
549455|NCT00039273|Biological|panitumumab|
549456|NCT00039234|Biological|aldesleukin|
549457|NCT00039234|Drug|histamine dihydrochloride|
549458|NCT00039208|Drug|fluorouracil|
549459|NCT00039208|Drug|irinotecan hydrochloride|
549460|NCT00039208|Drug|leucovorin calcium|
549461|NCT00039208|Drug|oxaliplatin|
549462|NCT00039195|Biological|filgrastim|
549463|NCT00039195|Biological|rituximab|
549464|NCT00039195|Drug|carboplatin|
549465|NCT00039195|Drug|cyclophosphamide|
549466|NCT00039195|Drug|doxorubicin hydrochloride|
549467|NCT00039195|Drug|etoposide|
549468|NCT00039195|Drug|ifosfamide|
549469|NCT00039195|Drug|prednisone|
549470|NCT00039195|Drug|vincristine sulfate|
549471|NCT00039195|Procedure|peripheral blood stem cell transplantation|
549472|NCT00039195|Radiation|radiation therapy|
549473|NCT00039182|Drug|erlotinib hydrochloride|Given orally
549474|NCT00039182|Other|laboratory biomarker analysis|Correlative studies
549475|NCT00039156|Drug|ortataxel|
549476|NCT00039130|Biological|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC>5000/ul courses II-VII
549477|NCT00039130|Biological|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV & VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
549478|NCT00039130|Drug|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
549479|NCT00039130|Drug|cytarabine|1 g/sq m/day IV infusion Days 4 & 5, courses II, IV, VI
549480|NCT00039130|Drug|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
549481|NCT00039130|Drug|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 & 5 courses III,V, VII
549482|NCT00039130|Drug|etoposide|80 mg/sq m/day IV infusion Days 4 & 5 courses II, IV, VI
549483|NCT00039130|Drug|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
549484|NCT00039130|Drug|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX <10nM, courses II-VII
549485|NCT00039130|Drug|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
549486|NCT00039130|Drug|prednisone|60 mg/sq m PO/day Days 1-7 course I
549487|NCT00039130|Drug|vincristine sulfate|2 mg IV push Day 1 courses II-VII
549488|NCT00039130|Drug|Allopurinol|300 mg/day PO Days 1-14, course I
549489|NCT00039117|Biological|oblimersen sodium|Given IV
549490|NCT00039117|Drug|cytarabine|Given IV
549491|NCT00039117|Drug|daunorubicin hydrochloride|Given IV
549492|NCT00039117|Other|laboratory biomarker analysis|Correlative studies
549493|NCT00039117|Other|pharmacological study|Correlative studies
549494|NCT00039104|Drug|rebimastat|Given PO
549495|NCT00039104|Drug|zoledronic acid|Given IV
549496|NCT00039104|Other|laboratory biomarker analysis|Correlative studies
549497|NCT00039091|Biological|ipilimumab|Given IV
549498|NCT00039078|Radiation|yttrium Y 90 glass microspheres|
549499|NCT00039052|Biological|interleukin-4 PE38KDEL cytotoxin|
549500|NCT00039039|Drug|carboplatin|
549501|NCT00039039|Drug|chemotherapy|
549502|NCT00039039|Drug|cisplatin|
549503|NCT00039039|Drug|paclitaxel|
549504|NCT00039039|Radiation|radiation therapy|
549505|NCT00037037|Biological|MAGE-10.A2|
549506|NCT00037037|Biological|MART-1 antigen|
549507|NCT00037037|Biological|NY-ESO-1 peptide vaccine|
549508|NCT00037037|Biological|sargramostim|
549509|NCT00037037|Biological|tyrosinase peptide|
549510|NCT00037024|Procedure|fatigue assessment and management|
549511|NCT00037024|Procedure|nutritional support|
549512|NCT00037024|Procedure|physical therapy|
549513|NCT00037024|Procedure|psychosocial assessment and care|
549514|NCT00037024|Procedure|quality-of-life assessment|
549515|NCT00037011|Biological|beta-glucan|
549516|NCT00037011|Biological|monoclonal antibody 3F8|
549517|NCT00036998|Procedure|conventional surgery|
549518|NCT00036998|Procedure|neoadjuvant therapy|
549519|NCT00036998|Procedure|thermal ablation therapy|
549520|NCT00036985|Drug|cyclophosphamide|
549521|NCT00036985|Drug|doxorubicin hydrochloride|
549522|NCT00036985|Procedure|conventional surgery|
549523|NCT00036985|Procedure|neoadjuvant therapy|
549524|NCT00036985|Procedure|thermal ablation therapy|
549525|NCT00036972|Biological|cintredekin besudotox|
549526|NCT00036972|Procedure|adjuvant therapy|
549527|NCT00036972|Procedure|conventional surgery|
549528|NCT00036972|Procedure|neoadjuvant therapy|
549529|NCT00036959|Drug|ABT-751|
549530|NCT00036946|Biological|ziv-aflibercept|
549531|NCT00036933|Biological|MUC-2-Globo H-KLH conjugate vaccine|
549532|NCT00036933|Biological|QS21|
549533|NCT00036894|Drug|lenalidomide|
549534|NCT00036881|Dietary Supplement|zinc sulfate|
549535|NCT00036881|Other|placebo|
549536|NCT00036868|Biological|trastuzumab|
549537|NCT00036868|Drug|CMF regimen|
549538|NCT00036868|Drug|cyclophosphamide|
549539|NCT00036868|Drug|fluorouracil|
549540|NCT00036868|Drug|methotrexate|
549541|NCT00036855|Biological|rituximab|Given IV
549542|NCT00036855|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
549543|NCT00036855|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
549544|NCT00036855|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
549545|NCT00036855|Biological|filgrastim|Given subcutaneously
549546|NCT00036855|Other|laboratory biomarker analysis|Correlative studies
549547|NCT00036842|Drug|arsenic trioxide|
549548|NCT00036829|Procedure|pain therapy|
549549|NCT00036816|Biological|MART-1 antigen|
549550|NCT00036816|Biological|NA17-A antigen|
549551|NCT00036816|Biological|gp100 antigen|
549552|NCT00036816|Biological|tyrosinase peptide|
549553|NCT00036790|Drug|doxorubicin hydrochloride|
549554|NCT00036790|Drug|motexafin gadolinium|
549555|NCT00036777|Drug|carboplatin|Given IV
549556|NCT00036777|Drug|7-hydroxystaurosporine|Given IV
549557|NCT00036777|Other|pharmacological study|Correlative studies
549558|NCT00036764|Drug|ixabepilone|Given IV
549559|NCT00036764|Other|pharmacogenomic studies|Correlative studies
549560|NCT00036764|Other|laboratory biomarker analysis|Correlative studies
549561|NCT00036751|Drug|imatinib mesylate|Given orally
549562|NCT00036751|Other|laboratory biomarker analysis|Correlative studies
549563|NCT00036738|Drug|Cyclosporine|Given IV or PO
549564|NCT00036738|Drug|Dasatinib|Given PO
549565|NCT00036738|Drug|Fludarabine Phosphate|Given IV
549566|NCT00036738|Drug|Imatinib Mesylate|Given PO
549567|NCT00036738|Drug|Mycophenolate Mofetil|Given PO
549568|NCT00036738|Drug|Nilotinib|Given PO
549569|NCT00036738|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
549570|NCT00036738|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
549571|NCT00036738|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
549572|NCT00036738|Radiation|Total-Body Irradiation|Undergo TBI
549573|NCT00036712|Procedure|management of therapy complications|
549575|NCT00036686|Dietary Supplement|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
549576|NCT00036686|Other|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
549577|NCT00033748|Biological|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
549578|NCT00033748|Biological|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
549579|NCT00033709|Drug|temozolomide|
549580|NCT00033709|Drug|thalidomide|
549581|NCT00033696|Biological|filgrastim|
549582|NCT00033696|Drug|carboplatin|
549583|NCT00033696|Drug|etoposide|
549584|NCT00033696|Drug|paclitaxel|
549585|NCT00033696|Drug|topotecan hydrochloride|
549586|NCT00033696|Radiation|radiation therapy|
549587|NCT00033683|Drug|CMF regimen|
549588|NCT00033683|Drug|cyclophosphamide|
549589|NCT00033683|Drug|docetaxel|
549590|NCT00033683|Drug|epirubicin hydrochloride|
549591|NCT00033683|Drug|fluorouracil|
549592|NCT00033683|Drug|methotrexate|
549593|NCT00033683|Drug|tamoxifen citrate|
549594|NCT00033683|Procedure|adjuvant therapy|
549595|NCT00033683|Radiation|radiation therapy|
549596|NCT00033657|Drug|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29~Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
549597|NCT00033657|Drug|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29~Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
549598|NCT00033657|Drug|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29~Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
549599|NCT00033657|Procedure|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
549600|NCT00033657|Radiation|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
549601|NCT00033644|Biological|sargramostim|
549602|NCT00033644|Drug|cisplatin|
549603|NCT00033644|Drug|dacarbazine|
549604|NCT00033644|Drug|doxorubicin hydrochloride|
549605|NCT00033644|Drug|mitomycin C|
549606|NCT00033631|Radiation|70.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 Fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.
549607|NCT00033631|Radiation|79.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.
549608|NCT00033618|Drug|ixabepilone|Given IV
549609|NCT00033618|Other|laboratory biomarker analysis|Correlative studies
549610|NCT00033605|Drug|octreotide acetate|
549611|NCT00033605|Other|placebo|
549612|NCT00033605|Radiation|radiation|
549613|NCT00033566|Drug|S-3304|
549614|NCT00033553|Drug|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
549615|NCT00033553|Drug|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 & 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
549616|NCT00033553|Drug|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
549617|NCT00033553|Radiation|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
549618|NCT00033540|Drug|capecitabine|650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
549619|NCT00033540|Drug|gemcitabine hydrochloride|1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
549620|NCT00033514|Biological|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
549621|NCT00033514|Drug|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
549622|NCT00033488|Other|cytology specimen collection procedure|
549623|NCT00033488|Procedure|annual screening|
549624|NCT00033488|Procedure|comparison of screening methods|
549625|NCT00033475|Biological|therapeutic allogeneic lymphocytes|
549626|NCT00033449|Drug|gefitinib|Given orally
549627|NCT00033449|Radiation|radiation therapy|Undergo radiation therapy
549628|NCT00033449|Drug|cisplatin|Given IV
549629|NCT00033449|Other|laboratory biomarker analysis|Correlative studies
549630|NCT00033436|Dietary Supplement|niacinamide|
549631|NCT00033436|Drug|carbogen|
549632|NCT00033436|Radiation|radiation therapy|
549633|NCT00033423|Biological|rituximab|
549634|NCT00033423|Radiation|yttrium Y 90 ibritumomab tiuxetan|
549635|NCT00033410|Drug|carboplatin|
549636|NCT00033410|Drug|paclitaxel|
549637|NCT00033410|Drug|tirapazamine|
549638|NCT00033410|Radiation|radiation therapy|
549639|NCT00033397|Procedure|biopsy|
549640|NCT00033397|Procedure|magnetic resonance imaging|
549641|NCT00033397|Procedure|radiomammography|
549642|NCT00033397|Procedure|ultrasound imaging|
549643|NCT00033397|Radiation|gadopentetate dimeglumine|
549644|NCT00033397|Drug|chemotherapy|
549645|NCT00033371|Drug|Celecoxib|Given 400 mg PO twice a day
549646|NCT00033371|Other|Placebo|Given PO to match DFMO
549647|NCT00033371|Drug|eflornithine|Given PO at 0.5 gm/m^2/day rounded down to the nearest 250 mg dose (BSA of < 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of > 2.6 = 1,250 mg/day).
549648|NCT00033371|Other|Laboratory biomarker analysis|Correlative studies
549649|NCT00033371|Other|Questionnaire administration|Ancillary studies
549650|NCT00033358|Drug|medroxyprogesterone|Given intramuscularly
549651|NCT00033358|Drug|ethinyl estradiol|Given orally
549652|NCT00033358|Drug|norgestrel|Given orally
549653|NCT00033358|Other|laboratory biomarker analysis|Correlative studies
549654|NCT00033345|Drug|Indole-3-carbinol|400 mg pill taken daily
549655|NCT00033345|Drug|Indole-3-carbinol|800 mg pill taken daily
549656|NCT00033345|Other|Placebo|Placebo pill taken daily during run-in period
549657|NCT00033332|Drug|dexamethasone|
549658|NCT00033332|Drug|pamidronate disodium|
549659|NCT00033332|Drug|thalidomide|
549660|NCT00033332|Drug|zoledronic acid|
549661|NCT00033293|Biological|therapeutic immune globulin|Given IV
549662|NCT00033293|Other|clinical observation|Undergo observation
549663|NCT00033293|Drug|cyclophosphamide|Given IV
549664|NCT00033293|Drug|prednisone|Given orally
549665|NCT00033293|Procedure|magnetic resonance imaging|Correlative studies
549666|NCT00033293|Other|laboratory biomarker analysis|Correlative studies
549667|NCT00033293|Drug|Corticotropin-Releasing Hormone|administered subcutaneously
549668|NCT00033280|Drug|temozolomide|
549669|NCT00033280|Procedure|neoadjuvant therapy|
549670|NCT00033280|Radiation|radiation therapy|
549671|NCT00033267|Drug|temsirolimus|Given IV
549672|NCT00033254|Radiation|radiation therapy|Undergo conventional radiation therapy
549673|NCT00033254|Drug|thalidomide|Given orally
549674|NCT00033254|Procedure|quality-of-life assessment|Ancillary studies
549675|NCT00033241|Drug|erlotinib hydrochloride|
549676|NCT00033241|Drug|gemcitabine hydrochloride|
549677|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
549678|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
549679|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
549680|NCT00032188|Biological|aldesleukin|Given subcutaneously
549681|NCT00032188|Drug|bryostatin 1|Given IV
549682|NCT00032188|Other|laboratory biomarker analysis|Correlative studies
549683|NCT00032175|Drug|capecitabine|
549684|NCT00032175|Drug|gemcitabine hydrochloride|
549685|NCT00032162|Drug|carboplatin|AUC 6 q4w
549686|NCT00032162|Drug|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
549687|NCT00032149|Biological|bleomycin sulfate|
549688|NCT00032149|Biological|filgrastim|
549689|NCT00032149|Drug|cyclophosphamide|
549690|NCT00032149|Drug|etoposide|
549691|NCT00032149|Drug|mitoxantrone hydrochloride|
549692|NCT00032149|Drug|prednisolone|
549693|NCT00032149|Drug|vincristine sulfate|
549694|NCT00032136|Drug|exemestane|
549695|NCT00032136|Drug|tamoxifen citrate|
549696|NCT00032136|Procedure|adjuvant therapy|
549697|NCT00032123|Drug|erlotinib hydrochloride|
549698|NCT00032110|Drug|erlotinib hydrochloride|Given orally
549699|NCT00032110|Other|pharmacological study|Correlative studies
549700|NCT00032110|Other|laboratory biomarker analysis|Correlative studies
549701|NCT00032097|Drug|motexafin gadolinium|
549702|NCT00032097|Radiation|radiation therapy|
549703|NCT00032084|Behavioral|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
549704|NCT00032084|Drug|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
549705|NCT00032084|Drug|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
549706|NCT00032084|Procedure|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
549707|NCT00032058|Procedure|magnetic resonance imaging|
549708|NCT00032058|Procedure|magnetic resonance spectroscopic imaging|
549709|NCT00032045|Biological|gp100 antigen|
549710|NCT00032045|Biological|incomplete Freund's adjuvant|
549711|NCT00032045|Biological|ipilimumab|
549712|NCT00032032|Drug|carboplatin|
549713|NCT00032032|Drug|paclitaxel|
549714|NCT00032032|Radiation|radiation therapy|
549715|NCT00032019|Biological|filgrastim|Cycle 1: 300 ug (BW < = 70 kg) or 480ug (BW >70 kg) sub Q injection Day 6 until ANC > 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
549716|NCT00032019|Biological|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
549717|NCT00032019|Drug|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
549718|NCT00032019|Drug|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
549719|NCT00032019|Drug|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
549720|NCT00032019|Drug|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
549809|NCT00030823|Biological|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
549721|NCT00032019|Drug|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
549722|NCT00032006|Radiation|brachytherapy|
549723|NCT00032006|Radiation|radiation therapy|
549724|NCT00031993|Drug|erlotinib hydrochloride|Given PO
549725|NCT00031993|Other|laboratory biomarker analysis|Correlative studies
549726|NCT00031980|Drug|cyclosporine|
549727|NCT00031967|Drug|therapeutic melatonin|
549728|NCT00031967|Radiation|radiation therapy|
549729|NCT00031941|Drug|lenalidomide|
549730|NCT00031928|Drug|mafosfamide|
549731|NCT00031915|Drug|imatinib mesylate|
549732|NCT00031902|Biological|bleomycin sulfate|
549733|NCT00031902|Biological|rituximab|
549734|NCT00031902|Drug|prednisolone|
549735|NCT00031902|Drug|vincristine sulfate|
549736|NCT00031876|Drug|capecitabine|
549737|NCT00031876|Drug|paclitaxel|
549738|NCT00031863|Drug|rofecoxib|
549739|NCT00031863|Procedure|adjuvant therapy|
549740|NCT00031850|Drug|goserelin acetate|
549741|NCT00031850|Drug|raloxifene|
549742|NCT00031837|Drug|dalteparin|
549743|NCT00031837|Drug|gemcitabine hydrochloride|
549744|NCT00031837|Procedure|quality-of-life assessment|
549745|NCT00031824|Drug|cyclosporine|
549746|NCT00031824|Drug|hydroxychloroquine|
549747|NCT00031824|Drug|prednisone|
549748|NCT00031824|Drug|tacrolimus|
549749|NCT00031798|Drug|methylphenidate hydrochloride|
549750|NCT00031798|Procedure|quality-of-life assessment|
549751|NCT00031798|Radiation|radiation therapy|
549752|NCT00031772|Procedure|psychosocial assessment and care|Questionnaire and telephone intervention
549753|NCT00031759|Drug|imiquimod|
549754|NCT00031759|Procedure|Ablative or excisional therapy|
549755|NCT00031746|Dietary Supplement|soy protein isolate|25 mg daily
549756|NCT00031746|Dietary Supplement|casein proteins|25 mg daily
549757|NCT00031733|Biological|MART-1 antigen|
549758|NCT00031733|Biological|gp100 antigen|
549759|NCT00031733|Biological|incomplete Freund's adjuvant|
549760|NCT00031733|Biological|recombinant interleukin-12|
549761|NCT00031733|Biological|sargramostim|
549762|NCT00031733|Biological|tyrosinase peptide|
549763|NCT00031733|Drug|alum adjuvant|
549764|NCT00031733|Procedure|adjuvant therapy|
549765|NCT00031720|Dietary Supplement|soy protein|Given orally
549766|NCT00031720|Dietary Supplement|isoflavones|Given orally
549767|NCT00031720|Drug|Tamoxifen|
549768|NCT00031720|Other|Placebo|Oral
549769|NCT00031694|Drug|paclitaxel|Given IV
549770|NCT00031694|Drug|bryostatin 1|Given IV
549771|NCT00031681|Drug|7-hydroxystaurosporine|Given IV
549772|NCT00031681|Drug|irinotecan hydrochloride|Given IV
549773|NCT00031681|Other|diagnostic laboratory biomarker analysis|Correlative studies
549774|NCT00031655|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
549775|NCT00031655|Biological|donor lymphocytes|Given IV
549776|NCT00031655|Drug|cyclosporine|Given PO
549777|NCT00031655|Radiation|total-body irradiation|Undergo TBI
549778|NCT00031655|Drug|fludarabine phosphate|Given IV
549779|NCT00031655|Drug|mycophenolate mofetil|Given PO
549780|NCT00031655|Other|laboratory biomarker analysis|Correlative studies
549781|NCT00031655|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
549782|NCT00031642|Biological|rituximab|
549783|NCT00031642|Radiation|yttrium Y 90 ibritumomab tiuxetan|
549784|NCT00031629|Drug|Docetaxel|Given IV
549785|NCT00031629|Biological|Filgrastim|Given SC
549786|NCT00031629|Drug|Gemcitabine Hydrochloride|Given IV
549787|NCT00031629|Biological|Pegfilgrastim|Given IV
549788|NCT00031616|Drug|brivudine phosphoramidate|
549789|NCT00031590|Drug|Cisplatin|Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).
549790|NCT00031590|Drug|Cyclophosphamide|Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
549791|NCT00031590|Drug|Etoposide|Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).
549792|NCT00031590|Drug|Lomustine|Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).
549793|NCT00031590|Drug|Vincristine|Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).
549794|NCT00031590|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
549795|NCT00031577|Drug|paclitaxel|
549796|NCT00031577|Radiation|radiation therapy|
549797|NCT00031564|Biological|Interleukin-2|
549798|NCT00031564|Biological|B7-1|
549799|NCT00030914|Drug|medroxyprogesterone|
549800|NCT00030914|Drug|venlafaxine|
549801|NCT00030901|Drug|L-selenomethionine|Randomization between active L-selenomethionine and placebo
549802|NCT00030901|Drug|L-selenomethionine placebo|Randomization between active L-selenomethionine and placebo
549803|NCT00030888|Drug|7-hydroxystaurosporine|
549804|NCT00030875|Drug|bortezomib|
549805|NCT00030862|Drug|cisplatin|
549806|NCT00030862|Drug|irinotecan hydrochloride|
549807|NCT00030849|Biological|recombinant interferon alfa|
549811|NCT00030810|Radiation|Hyperfractionated|Hyperfractionated radiotherapy
549812|NCT00030810|Drug|Taxotere/Cisplatin|Taxotere/Cisplatin
549813|NCT00030810|Procedure|conventional surgery|conventional surgery
549814|NCT00030784|Drug|ifosfamide|
549815|NCT00030784|Drug|pegylated liposomal doxorubicin hydrochloride|
549816|NCT00030771|Drug|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
549817|NCT00030771|Radiation|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
549818|NCT00030771|Procedure|Surgery|3-4 weeks after termination of radiotherapy
549819|NCT00030758|Biological|filgrastim|
549820|NCT00030758|Biological|pegfilgrastim|
549821|NCT00030745|Drug|cisplatin|
549822|NCT00030745|Drug|gemcitabine hydrochloride|
549823|NCT00030745|Procedure|conventional surgery|
549824|NCT00030732|Drug|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
549825|NCT00030732|Drug|Gemcitabine alone|Gemcitabine alone
549826|NCT00030719|Biological|filgrastim|
549827|NCT00030719|Biological|monoclonal antibody Ch14.18|
549828|NCT00030719|Drug|busulfan|
549829|NCT00030719|Drug|carboplatin|
549830|NCT00030719|Drug|cyclophosphamide|
549831|NCT00030719|Drug|etoposide|
549832|NCT00030719|Drug|isotretinoin|
549833|NCT00030719|Drug|melphalan|
549834|NCT00030719|Drug|vincristine sulfate|
549835|NCT00030719|Procedure|bone marrow ablation with stem cell support|
549836|NCT00030719|Procedure|conventional surgery|
549837|NCT00030719|Procedure|peripheral blood stem cell transplantation|
549838|NCT00030719|Radiation|radiation therapy|
549839|NCT00030706|Drug|ixabepilone|
549840|NCT00030693|Biological|recombinant fowlpox-B7.1 vaccine|Given intratumorally
549841|NCT00030693|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
549842|NCT00030693|Other|laboratory biomarker analysis|Correlative studies
549843|NCT00030693|Procedure|quality-of-life assessment|Ancillary studies
549844|NCT00030680|Radiation|radiation therapy|
549845|NCT00030654|Drug|bicalutamide|
549846|NCT00030654|Drug|docetaxel|
549847|NCT00030654|Drug|doxorubicin hydrochloride|
549848|NCT00030654|Drug|estramustine phosphate sodium|
549849|NCT00030654|Drug|flutamide|
549850|NCT00030654|Drug|ketoconazole|
549851|NCT00030654|Drug|paclitaxel|
549852|NCT00030654|Drug|releasing hormone agonist therapy|
549853|NCT00030654|Drug|vinblastine sulfate|
549854|NCT00030641|Biological|oblimersen sodium|
549855|NCT00030641|Drug|docetaxel|
549856|NCT00030628|Radiation|radiation therapy|
549857|NCT00030628|Procedure|surgery|
549858|NCT00030628|Radiation|WBRT|
549859|NCT00030615|Drug|decitabine|Given IV
549860|NCT00030615|Other|pharmacological study|Correlative studies
549861|NCT00030615|Other|laboratory biomarker analysis|Correlative studies
549862|NCT00030589|Drug|bexarotene|
549863|NCT00030589|Drug|methoxsalen|
549864|NCT00030589|Procedure|UV light therapy|
549865|NCT00030576|Drug|cisplatin|
549866|NCT00030576|Drug|erlotinib hydrochloride|
549867|NCT00030563|Drug|irinotecan hydrochloride|
549868|NCT00030563|Procedure|adjuvant therapy|
549869|NCT00030563|Procedure|conventional surgery|
549870|NCT00030563|Procedure|radiofrequency ablation|
549871|NCT00030550|Drug|thalidomide|
549872|NCT00030537|Drug|erlotinib hydrochloride|
549873|NCT00030511|Drug|fluorouracil|
549874|NCT00030511|Procedure|conventional surgery|
549875|NCT00030511|Radiation|radiation therapy|
549876|NCT00030498|Drug|erlotinib hydrochloride|Given orally
549877|NCT00030498|Other|laboratory biomarker analysis|Correlative studies
549878|NCT00030485|Drug|erlotinib hydrochloride|
549879|NCT00030472|Drug|pegylated liposomal doxorubicin hydrochloride|
549880|NCT00030459|Drug|cisplatin|
549881|NCT00030459|Drug|mitomycin C|
549882|NCT00030459|Drug|vinblastine sulfate|
549883|NCT00030459|Drug|vinorelbine tartrate|
549884|NCT00030433|Drug|gemcitabine hydrochloride|
549885|NCT00030433|Drug|irinotecan hydrochloride|
549886|NCT00030407|Drug|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
549887|NCT00030407|Drug|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
549888|NCT00030394|Drug|imatinib mesylate|Given orally
549889|NCT00030394|Other|laboratory biomarker analysis|Correlative studies
549890|NCT00030394|Other|pharmacological study|Correlative studies
549891|NCT00030355|Drug|homoharringtonine|
549892|NCT00030355|Procedure|chemotherapy|
549893|NCT00030342|Biological|recombinant interferon alfa|
549894|NCT00030342|Biological|sargramostim|
549895|NCT00030342|Biological|therapeutic autologous lymphocytes|
549896|NCT00030342|Drug|fluorouracil|
549897|NCT00030303|Biological|recombinant 70-kD heat-shock protein|
549898|NCT00030290|Procedure|high-intensity focused ultrasound ablation|
549899|NCT00030277|Procedure|high-intensity focused ultrasound ablation|
549900|NCT00030264|Drug|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
549901|NCT00030264|Drug|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
549902|NCT00030108|Drug|ixabepilone|
549904|NCT00030082|Drug|isolated perfusion|
549905|NCT00030082|Drug|melphalan|
549906|NCT00029029|Procedure|pain therapy|
549907|NCT00029029|Procedure|radiofrequency ablation|
549908|NCT00029003|Drug|gefitinib|Given orally
549909|NCT00029003|Other|laboratory biomarker analysis|Correlative studies
549910|NCT00028990|Drug|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
549911|NCT00028990|Drug|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
549912|NCT00028977|Drug|herba scutellaria barbata|
549913|NCT00028977|Other|herba scutellaria Barbatae (HSB)|
549914|NCT00028964|Dietary Supplement|Chinese herbs|
549915|NCT00028964|Drug|cyclophosphamide|
549916|NCT00028964|Drug|doxorubicin hydrochloride|
549917|NCT00028964|Procedure|adjuvant therapy|
549918|NCT00028951|Drug|fibrin sealant|
549919|NCT00028951|Procedure|surgical wound closure|
549920|NCT00028912|Drug|bortezomib|
549921|NCT00028912|Drug|carboplatin|
549922|NCT00028899|Drug|asparaginase|
549923|NCT00028899|Drug|cytarabine|
549924|NCT00028899|Drug|gemtuzumab ozogamicin|
549925|NCT00028899|Drug|mitoxantrone hydrochloride|
549926|NCT00028886|Biological|filgrastim|
549927|NCT00028886|Biological|recombinant interferon alfa|
549928|NCT00028886|Drug|cyclophosphamide|
549929|NCT00028886|Drug|dexamethasone|
549930|NCT00028886|Drug|doxorubicin hydrochloride|
549931|NCT00028886|Drug|melphalan|
549932|NCT00028886|Drug|thalidomide|
549933|NCT00028886|Drug|vincristine sulfate|
549934|NCT00028886|Procedure|bone marrow ablation with stem cell support|
549935|NCT00028886|Procedure|peripheral blood stem cell transplantation|
549936|NCT00028873|Drug|docetaxel|
549937|NCT00028873|Drug|laniquidar|
549938|NCT00028873|Drug|paclitaxel|
549939|NCT00028860|Biological|filgrastim|
549940|NCT00028860|Drug|carboplatin|
549941|NCT00028860|Drug|gemcitabine hydrochloride|
549942|NCT00028860|Drug|ifosfamide|
549943|NCT00028860|Drug|paclitaxel|
549944|NCT00028860|Procedure|adjuvant therapy|
549945|NCT00028847|Drug|cytarabine|
549946|NCT00028847|Drug|imatinib mesylate|
549947|NCT00028834|Drug|gemcitabine hydrochloride|Given IV
549948|NCT00028834|Biological|bevacizumab|Given IV
549949|NCT00028834|Other|laboratory biomarker analysis|Correlative studies
549950|NCT00028821|Drug|2-methoxyestradiol|Given orally
549951|NCT00028821|Other|pharmacological study|Correlative studies
549952|NCT00028821|Other|laboratory biomarker analysis|Correlative studies
549953|NCT00028795|Drug|temozolomide|
549954|NCT00028795|Procedure|adjuvant therapy|
549955|NCT00028795|Radiation|radiation therapy|
549956|NCT00028782|Drug|etanidazole|Given IV
549957|NCT00028782|Procedure|therapeutic conventional surgery|Undergo surgery
549958|NCT00028782|Other|laboratory biomarker analysis|Correlative studies
549959|NCT00028769|Drug|bicalutamide|
549960|NCT00028769|Drug|estramustine|
549961|NCT00028769|Drug|etoposide|
549962|NCT00028769|Drug|flutamide|
549963|NCT00028769|Drug|goserelin|
549964|NCT00028769|Drug|leuprolide|
549965|NCT00028769|Drug|nilutamide|
549966|NCT00028769|Drug|paclitaxel|
549967|NCT00028756|Drug|doxorubicin hydrochloride|Given IV
549968|NCT00028756|Drug|gemcitabine hydrochloride|Given IV
549969|NCT00028756|Drug|vinblastine sulfate|Given IV
549970|NCT00028756|Drug|methotrexate|Given IV
549971|NCT00028756|Drug|cisplatin|Given IV
549972|NCT00028756|Biological|filgrastim|Given SC
549973|NCT00028743|Drug|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
549974|NCT00028743|Drug|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
549975|NCT00028743|Drug|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
549976|NCT00028743|Drug|topotecan hydrochloride|"4 cycles~.75mg/m2 (30 mins) days 1-5 of 21 day cycle"
549977|NCT00028730|Biological|anti-thymocyte globulin|
549978|NCT00028730|Biological|filgrastim|
549979|NCT00028730|Drug|cyclophosphamide|
549980|NCT00028730|Drug|fludarabine phosphate|
549981|NCT00028730|Drug|thiotepa|
549982|NCT00028730|Procedure|allogeneic bone marrow transplantation|
549983|NCT00028730|Radiation|radiation therapy|
549984|NCT00028717|Biological|filgrastim|
549985|NCT00028717|Biological|rituximab|
549986|NCT00028717|Drug|cyclophosphamide|
549987|NCT00028717|Drug|doxorubicin hydrochloride|
549988|NCT00028717|Drug|prednisone|
549989|NCT00028717|Drug|vincristine sulfate|
549990|NCT00028704|Procedure|conventional surgery|
549991|NCT00028704|Radiation|radiation therapy|
549992|NCT00028691|Drug|chlorambucil|
549993|NCT00028691|Radiation|radiation therapy|
549994|NCT00028665|Biological|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
549995|NCT00028665|Biological|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
549996|NCT00028665|Drug|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
549997|NCT00028665|Drug|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
549998|NCT00028665|Drug|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
549999|NCT00028665|Drug|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
550134|NCT00027547|Drug|cyclosporine|
550000|NCT00028665|Procedure|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
550001|NCT00028665|Procedure|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
550002|NCT00028665|Radiation|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
550003|NCT00028652|Biological|interleukin-12 gene|
550004|NCT00028639|Drug|bortezomib|
550005|NCT00028626|Drug|embolization therapy|
550006|NCT00028600|Biological|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC >= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC > 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
550007|NCT00028600|Biological|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
550008|NCT00028600|Drug|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
550009|NCT00028600|Drug|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
550010|NCT00028600|Drug|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
550011|NCT00028600|Drug|methotrexate|5mg/sq m/d IV infusion D 1,3,& 6: allo transpl
550012|NCT00028600|Drug|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
550013|NCT00028587|Drug|bortezomib|Given IV
550014|NCT00028587|Drug|paclitaxel|Given IV
550015|NCT00028587|Drug|carboplatin|Given IV
550016|NCT00028587|Other|laboratory biomarker analysis|Optional correlative studies
550017|NCT00028574|Drug|gabapentin|
550018|NCT00028574|Other|placebo|
550019|NCT00028561|Drug|ixabepilone|Given IV
550020|NCT00028561|Drug|carboplatin|Given IV
550021|NCT00028561|Other|laboratory biomarker analysis|Correlative studies
550022|NCT00028561|Other|pharmacological study|Correlative studies
550023|NCT00028548|Drug|R(+)XK469|
550024|NCT00028535|Biological|trastuzumab|Given IV
550025|NCT00028535|Drug|paclitaxel|Given IV
550026|NCT00028535|Biological|recombinant interleukin-12|Given SC
550027|NCT00028522|Drug|R(+)XK469|Given IV
550028|NCT00028509|Procedure|management of therapy complications|
550029|NCT00028496|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
550030|NCT00028496|Biological|sargramostim|Given subcutaneously
550031|NCT00028496|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
550032|NCT00028028|Drug|temsirolimus|Given IV
550033|NCT00028028|Other|pharmacological study|Correlative studies
550034|NCT00028028|Other|laboratory biomarker analysis|Correlative studies
550035|NCT00028015|Drug|SarCNU|
550036|NCT00028002|Procedure|Conventional Surgery|Undergo surgical resection
550037|NCT00028002|Drug|Imatinib Mesylate|Given orally
550038|NCT00027989|Drug|gemcitabine hydrochloride|
550039|NCT00027989|Drug|pegylated liposomal doxorubicin hydrochloride|
550040|NCT00027976|Drug|celecoxib|
550041|NCT00027976|Drug|Placebo|
550042|NCT00027963|Drug|gabapentin|
550043|NCT00027963|Other|placebo|
550044|NCT00027937|Biological|aldesleukin|
550045|NCT00027937|Biological|filgrastim|
550046|NCT00027937|Biological|sargramostim|
550047|NCT00027937|Drug|busulfan|
550048|NCT00027937|Drug|cyclophosphamide|
550049|NCT00027937|Drug|melphalan|
550050|NCT00027937|Drug|paclitaxel|
550051|NCT00027937|Drug|thiotepa|
550052|NCT00027937|Procedure|bone marrow ablation with stem cell support|
550053|NCT00027937|Procedure|in vitro-treated peripheral blood stem cell transplantation|
550054|NCT00027911|Biological|NY-ESO-1 peptide vaccine|
550055|NCT00027911|Biological|sargramostim|
550056|NCT00027898|Drug|bortezomib|Given IV
550057|NCT00027898|Drug|carboplatin|Given IV
550058|NCT00027898|Drug|etoposide|Given IV
550059|NCT00027898|Other|laboratory biomarker analysis|Correlative studies
550060|NCT00027898|Other|pharmacological study|Correlative studies
550061|NCT00027885|Biological|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
550062|NCT00027885|Drug|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
550063|NCT00027885|Drug|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
550064|NCT00027885|Drug|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
550065|NCT00027885|Procedure|adjuvant therapy|"After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.~Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
550066|NCT00027885|Procedure|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
550067|NCT00027885|Procedure|neoadjuvant therapy|"Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.~Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
550068|NCT00027885|Radiation|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
550069|NCT00027872|Drug|tipifarnib|Given orally
550070|NCT00027872|Other|laboratory biomarker analysis|Correlative studies
550071|NCT00027859|Drug|docetaxel|
550072|NCT00027859|Drug|estramustine phosphate sodium|
550073|NCT00027859|Drug|ketoconazole|
550074|NCT00027859|Drug|therapeutic hydrocortisone|
550075|NCT00027846|Biological|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC >1500/μl given subcutaneously or intravenously.
550076|NCT00027846|Drug|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA <0.45m2 the dose is 12.5 mg/kg/day.
550077|NCT00027846|Drug|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
550078|NCT00027846|Drug|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA < 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
550079|NCT00027846|Drug|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA<0.45m2 the dose is 0.05mg/kg.
550080|NCT00027846|Radiation|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
550081|NCT00027846|Drug|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
550082|NCT00027846|Procedure|therapeutic conventional surgery|
550083|NCT00027833|Biological|ALVAC-CEA-B7.1 vaccine|
550084|NCT00027833|Biological|tetanus toxoid|
550085|NCT00027833|Drug|FOLFIRI regimen|
550086|NCT00027833|Drug|fluorouracil|
550087|NCT00027833|Drug|irinotecan hydrochloride|
550088|NCT00027833|Drug|leucovorin calcium|
550089|NCT00027820|Drug|Fludarabine Phosphate|Given IV
550090|NCT00027820|Radiation|Total-Body Irradiation|Undergo TBI
550091|NCT00027820|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
550092|NCT00027820|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
550093|NCT00027820|Drug|Cyclosporine|Given PO
550094|NCT00027820|Drug|Mycophenolate Mofetil|Given PO
550095|NCT00027807|Biological|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
550096|NCT00027807|Biological|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
550097|NCT00027807|Biological|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
550098|NCT00027794|Procedure|conventional surgery|
550099|NCT00027781|Drug|sabarubicin|
550100|NCT00027768|Procedure|adjuvant therapy|
550101|NCT00027768|Radiation|iodine I 131 ethiodized oil|
550102|NCT00027742|Biological|pegylated interferon alfa|
550103|NCT00027742|Drug|temozolomide|
550104|NCT00027729|Biological|etaracizumab|
550105|NCT00027716|Drug|bortezomib|
550106|NCT00027703|Drug|gemcitabine hydrochloride|Given IV
550107|NCT00027703|Drug|cisplatin|Given IV
550108|NCT00027703|Biological|bevacizumab|Given IV
550109|NCT00027703|Other|placebo|Given IV
550110|NCT00027703|Other|laboratory biomarker analysis|Correlative studies
550111|NCT00027690|Drug|Gefitinib|Given orally
550112|NCT00027690|Other|Laboratory Biomarker Analysis|Correlative studies
550113|NCT00027677|Drug|halofuginone hydrobromide|
550114|NCT00027664|Biological|recombinant interferon alfa|
550115|NCT00027664|Drug|thalidomide|
550116|NCT00027638|Drug|thalidomide|
550117|NCT00027625|Drug|gefitinib|
550118|NCT00027625|Drug|temozolomide|
550119|NCT00027586|Drug|Imatinib mesylate (STI571)|400 mg twice a day orally
550120|NCT00027573|Biological|filgrastim|
550121|NCT00027573|Biological|therapeutic allogeneic lymphocytes|
550122|NCT00027573|Drug|cyclophosphamide|
550123|NCT00027573|Drug|fludarabine phosphate|
550124|NCT00027573|Drug|methotrexate|
550125|NCT00027573|Drug|tacrolimus|
550126|NCT00027573|Procedure|peripheral blood stem cell transplantation|
550127|NCT00027560|Biological|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.~Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
550128|NCT00027560|Drug|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
550129|NCT00027560|Drug|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
550130|NCT00027560|Drug|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
550131|NCT00027560|Procedure|allogeneic bone marrow transplantation|
550132|NCT00027560|Procedure|peripheral blood stem cell transplantation|
550133|NCT00027547|Biological|therapeutic allogeneic lymphocytes|
550135|NCT00027547|Drug|cytarabine|
550136|NCT00027547|Drug|fludarabine phosphate|
550137|NCT00027547|Drug|methotrexate|
550138|NCT00027547|Drug|mycophenolate mofetil|
550139|NCT00027547|Procedure|allogeneic bone marrow transplantation|
550140|NCT00027547|Procedure|peripheral blood stem cell transplantation|
550141|NCT00027547|Radiation|radiation therapy|
550142|NCT00027534|Biological|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
550143|NCT00027495|Dietary Supplement|curcumin|
550144|NCT00026533|Drug|thalidomide|
550145|NCT00026494|Drug|temozolomide|
550146|NCT00026494|Drug|vinorelbine tartrate|
550147|NCT00026468|Drug|exisulind|
550148|NCT00026442|Drug|capecitabine|
550149|NCT00026416|Biological|recombinant interferon alfa|
550150|NCT00026416|Drug|thalidomide|
550151|NCT00026416|Procedure|adjuvant therapy|
550152|NCT00026403|Drug|cisplatin|
550153|NCT00026403|Drug|gemcitabine hydrochloride|
550154|NCT00026403|Radiation|radiation therapy|
550155|NCT00026338|Drug|erlotinib hydrochloride|150 mg po daily
550156|NCT00026338|Drug|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
550157|NCT00026312|Biological|Aldesleukin|Given IV
550158|NCT00026312|Biological|Dinutuximab|Given IV
550159|NCT00026312|Drug|Isotretinoin|Given PO
550160|NCT00026312|Other|Laboratory Biomarker Analysis|Correlative studies
550161|NCT00026312|Other|Pharmacological Study|Correlative studies
550162|NCT00026312|Other|Quality-of-Life Assessment|Ancillary studies
550163|NCT00026312|Biological|Sargramostim|Given IV or SC
550164|NCT00026299|Drug|ZD1839|
550165|NCT00026299|Drug|oxaliplatin|
550166|NCT00026247|Procedure|pain therapy|
550167|NCT00026247|Procedure|radiofrequency ablation|
550168|NCT00026234|Drug|floxuridine|Given intra-arterially
550169|NCT00026234|Drug|dexamethasone|Given intra-arterially
550170|NCT00026234|Drug|oxaliplatin|Given IV
550171|NCT00026234|Drug|capecitabine|Given orally
550172|NCT00026221|Biological|Recombinant Interferon Alfa|Given SC
550173|NCT00026221|Biological|Bevacizumab|Given IV
550174|NCT00026208|Drug|Vincristine|1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
550175|NCT00026208|Drug|Cyclophosphamide|650 mg/m², on week 1 and 5
550176|NCT00026208|Drug|Doxorubicin|25 mg/m², on week 1, 3, 5, 7
550177|NCT00026208|Drug|Prednisone|40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy
550178|NCT00026208|Drug|Bleomycin|5 u/m² intravenously (IV) on week 2, 4, 6, 8
550179|NCT00026208|Drug|Etoposide|60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
550180|NCT00026208|Radiation|Low-dose radiotherapy (RT)|20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.
550181|NCT00026195|Drug|irinotecan hydrochloride|
550182|NCT00026182|Biological|rituximab|Given IV
550183|NCT00026182|Biological|recombinant interleukin-12|Given SC
550184|NCT00026182|Other|laboratory biomarker analysis|Correlative studies
550185|NCT00026182|Other|questionnaire administration|Ancillary studies
550186|NCT00026182|Procedure|quality-of-life assessment|Ancillary studies
550187|NCT00026169|Drug|imatinib mesylate|Given orally
550188|NCT00026169|Other|laboratory biomarker analysis|Correlative studies
550189|NCT00026169|Other|pharmacological study|Correlative studies
550190|NCT00026156|Drug|docetaxel|
550191|NCT00026156|Drug|vinorelbine tartrate|
550192|NCT00026143|Biological|recombinant interleukin-12|Given IV
550193|NCT00026143|Biological|recombinant interferon alfa|Given SC
550194|NCT00026143|Other|laboratory biomarker analysis|Correlative studies
550195|NCT00026130|Drug|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
550196|NCT00026130|Drug|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
550197|NCT00026130|Radiation|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
550198|NCT00026117|Drug|BenFin|
550199|NCT00026117|Other|placebo|
550200|NCT00026104|Drug|gemcitabine hydrochloride|Given IV
550201|NCT00026104|Drug|paclitaxel|Given IV
550202|NCT00026104|Drug|tipifarnib|Given orally
550203|NCT00026104|Radiation|radiation therapy|Undergo radiation therapy
550204|NCT00026091|Drug|fenretinide|Given orally
550205|NCT00026091|Other|laboratory biomarker analysis|Correlative studies
550206|NCT00026091|Other|pharmacological study|Correlative studies
550207|NCT00026078|Drug|docetaxel|
550208|NCT00026078|Drug|ifosfamide|
550209|NCT00025675|Drug|gefitinib|
550210|NCT00025662|Drug|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
550211|NCT00025662|Drug|Isolex system|CD34 selection/ T cell depletion used this system
550212|NCT00025649|Biological|filgrastim|
550213|NCT00025649|Drug|busulfan|
550214|NCT00025649|Drug|carboplatin|
550215|NCT00025649|Drug|cyclophosphamide|
550216|NCT00025649|Drug|doxorubicin hydrochloride|
550217|NCT00025649|Drug|etoposide|
550218|NCT00025649|Drug|melphalan|
550219|NCT00025649|Drug|vincristine sulfate|
550220|NCT00025649|Procedure|autologous bone marrow transplantation|
550221|NCT00025649|Procedure|conventional surgery|
550222|NCT00025649|Procedure|peripheral blood stem cell transplantation|
550223|NCT00025636|Biological|filgrastim|
550224|NCT00025636|Drug|carmustine|
550225|NCT00025636|Drug|cisplatin|
550226|NCT00025636|Drug|cyclophosphamide|
550227|NCT00025636|Drug|cytarabine|
550228|NCT00025636|Drug|dexamethasone|
550229|NCT00025636|Drug|etoposide|
550230|NCT00025636|Drug|melphalan|
550231|NCT00025636|Drug|methotrexate|
550232|NCT00025636|Drug|vincristine sulfate|
550233|NCT00025636|Procedure|bone marrow ablation with stem cell support|
550234|NCT00025636|Procedure|peripheral blood stem cell transplantation|
550235|NCT00025623|Drug|carboplatin|
550236|NCT00025623|Drug|cyclophosphamide|
550237|NCT00025623|Drug|doxorubicin hydrochloride|
550238|NCT00025623|Drug|etoposide|
550239|NCT00025623|Drug|vincristine sulfate|
550240|NCT00025623|Procedure|conventional surgery|
550241|NCT00025610|Drug|carboplatin|
550242|NCT00025610|Drug|cyclophosphamide|
550243|NCT00025610|Drug|doxorubicin hydrochloride|
550244|NCT00025610|Drug|etoposide|
550245|NCT00025610|Drug|vincristine sulfate|
550246|NCT00025597|Drug|carboplatin|
550247|NCT00025597|Drug|cyclophosphamide|
550248|NCT00025597|Drug|doxorubicin hydrochloride|
550249|NCT00025597|Drug|etoposide|
550250|NCT00025597|Drug|vincristine sulfate|
550251|NCT00025597|Procedure|conventional surgery|
550252|NCT00025584|Drug|bortezomib|Given IV
550253|NCT00025584|Other|laboratory biomarker analysis|Correlative studies
550254|NCT00025558|Biological|filgrastim|
550255|NCT00025558|Drug|carboplatin|
550256|NCT00025558|Drug|temozolomide|
550257|NCT00025558|Drug|thiotepa|
550258|NCT00025558|Procedure|autologous bone marrow transplantation|
550259|NCT00025558|Procedure|peripheral blood stem cell transplantation|
550260|NCT00025519|Biological|therapeutic allogeneic lymphocytes|
550261|NCT00025519|Drug|fludarabine phosphate|
550262|NCT00025519|Drug|mycophenolate mofetil|
550263|NCT00025519|Drug|tacrolimus|
550264|NCT00025519|Drug|thalidomide|
550265|NCT00025519|Procedure|peripheral blood stem cell transplantation|
550266|NCT00025519|Radiation|radiation therapy|
550267|NCT00025506|Other|Laboratory Biomarker Analysis|Correlative studies
550268|NCT00025506|Drug|Thalidomide|Given orally
550269|NCT00025493|Drug|docetaxel|
550270|NCT00025480|Drug|carboplatin|
550271|NCT00025480|Drug|paclitaxel|
550272|NCT00025480|Drug|tipifarnib|
550273|NCT00025480|Radiation|radiation therapy|
550274|NCT00025454|Drug|tipifarnib|
550275|NCT00025441|Biological|dactinomycin|
550276|NCT00025441|Biological|filgrastim|
550277|NCT00025441|Drug|carboplatin|
550278|NCT00025441|Drug|cyclophosphamide|
550279|NCT00025441|Drug|doxorubicin hydrochloride|
550280|NCT00025441|Drug|epirubicin hydrochloride|
550281|NCT00025441|Drug|etoposide|
550282|NCT00025441|Drug|ifosfamide|
550283|NCT00025441|Drug|vincristine sulfate|
550284|NCT00025441|Procedure|peripheral blood stem cell transplantation|
550285|NCT00025441|Radiation|radiation therapy|
550286|NCT00025428|Drug|carboplatin|
550287|NCT00025428|Drug|cyclophosphamide|
550288|NCT00025428|Drug|doxorubicin hydrochloride|
550289|NCT00025428|Drug|etoposide|
550290|NCT00025428|Drug|vincristine sulfate|
550291|NCT00025428|Procedure|adjuvant therapy|
550292|NCT00025428|Procedure|conventional surgery|
550293|NCT00025428|Procedure|neoadjuvant therapy|
550294|NCT00025415|Drug|imatinib mesylate|Given orally
550295|NCT00025415|Other|pharmacological study|Correlative studies
550296|NCT00025402|Biological|filgrastim|
550297|NCT00025402|Biological|recombinant interferon alfa|
550298|NCT00025402|Drug|busulfan|
550299|NCT00025402|Drug|cyclophosphamide|
550300|NCT00025402|Drug|cytarabine|
550301|NCT00025402|Drug|etoposide|
550302|NCT00025402|Drug|hydroxyurea|
550303|NCT00025402|Drug|idarubicin|
550304|NCT00025402|Procedure|allogeneic bone marrow transplantation|
550305|NCT00025402|Procedure|peripheral blood stem cell transplantation|
550306|NCT00025402|Radiation|radiation therapy|
550307|NCT00025389|Biological|bevacizumab|
550308|NCT00025389|Drug|carboplatin|
550309|NCT00025389|Drug|paclitaxel|
550310|NCT00025389|Procedure|conventional surgery|
550311|NCT00025389|Procedure|neoadjuvant therapy|
550312|NCT00025363|Drug|vincristine sulfate|Given IV
550313|NCT00025363|Drug|irinotecan hydrochloride|Given IV
550314|NCT00025363|Drug|cyclophosphamide|Given IV
550315|NCT00025363|Drug|doxorubicin hydrochloride|Given IV
550316|NCT00025363|Drug|ifosfamide|Given IV
550317|NCT00025363|Drug|etoposide|Given IV
550318|NCT00025363|Drug|tirapazamine|Given IV
550319|NCT00025363|Biological|filgrastim|Given SC
550320|NCT00025363|Biological|sargramostim|Given SC
550321|NCT00025363|Other|pharmacological study|Correlative studies
550322|NCT00025363|Other|pharmacogenomic studies|Correlative studies
550323|NCT00025363|Other|laboratory biomarker analysis|Correlative studies
550324|NCT00025337|Biological|bevacizumab|Given IV
550325|NCT00025337|Drug|oxaliplatin|Given IV
550326|NCT00025337|Drug|leucovorin calcium|Given IV
550327|NCT00025337|Drug|fluorouracil|Given IV
550328|NCT00025324|Biological|filgrastim|
550329|NCT00025324|Drug|carboplatin|
550330|NCT00025324|Drug|cyclophosphamide|
550331|NCT00025324|Drug|etoposide|
550332|NCT00025324|Drug|thiotepa|
550333|NCT00025324|Procedure|autologous bone marrow transplantation|
550334|NCT00025324|Procedure|bone marrow ablation with stem cell support|
550335|NCT00025324|Procedure|conventional surgery|
550336|NCT00025324|Procedure|peripheral blood stem cell transplantation|
550337|NCT00025324|Radiation|radiation therapy|
550338|NCT00025311|Drug|topotecan hydrochloride|
550339|NCT00025298|Drug|amifostine trihydrate|
550340|NCT00025298|Drug|carboplatin|
550341|NCT00025298|Drug|cisplatin|
550342|NCT00025298|Drug|paclitaxel|
550343|NCT00025298|Radiation|radiation therapy|
550344|NCT00025285|Drug|carboplatin|
550345|NCT00025285|Drug|irinotecan hydrochloride|
550346|NCT00025285|Drug|thalidomide|
550347|NCT00025272|Drug|carboplatin|
550348|NCT00025272|Drug|etoposide|
550349|NCT00025272|Drug|topotecan hydrochloride|
550350|NCT00025272|Radiation|radiation therapy|
550351|NCT00025259|Biological|Bleomycin Sulfate|Given IV or SC
550352|NCT00025259|Drug|Cisplatin|Given IV
550353|NCT00025259|Drug|Cyclophosphamide|Given IV
550354|NCT00025259|Drug|Cytarabine|Given IV
550355|NCT00025259|Drug|Dexamethasone|Given IV
550356|NCT00025259|Drug|Doxorubicin Hydrochloride|Given IV
550357|NCT00025259|Drug|Etoposide|Given IV
550358|NCT00025259|Biological|Filgrastim|Given SC
550359|NCT00025259|Radiation|Involved-Field Radiation Therapy|Undergo IFRT
550360|NCT00025259|Drug|Prednisone|Given orally
550361|NCT00025259|Drug|Vincristine Sulfate Liposome|Given IV
550362|NCT00025246|Drug|imatinib mesylate|Given orally
550363|NCT00025246|Other|laboratory biomarker analysis|Correlative studies
550364|NCT00025233|Biological|bevacizumab|Given IV
550365|NCT00025233|Other|laboratory biomarker analysis|Correlative studies
550366|NCT00025220|Drug|Thalidomide|Given PO
550367|NCT00025220|Other|Laboratory Biomarker Analysis|Correlative studies
550368|NCT00025194|Drug|estramustine phosphate sodium|
550369|NCT00025194|Drug|ixabepilone|
550370|NCT00025181|Biological|MART-1 antigen|
550371|NCT00025181|Biological|gp100 antigen|
550372|NCT00025181|Biological|incomplete Freund's adjuvant|
550373|NCT00025181|Biological|ipilimumab|
550374|NCT00025181|Biological|tyrosinase peptide|
550375|NCT00025181|Procedure|adjuvant therapy|
550376|NCT00025168|Drug|gemcitabine hydrochloride|
550377|NCT00025168|Drug|irinotecan hydrochloride|
550378|NCT00025168|Radiation|radiation therapy|
550379|NCT00025155|Drug|ixabepilone|Given IV
550380|NCT00025142|Drug|FOLFOX regimen|
550381|NCT00025142|Drug|fluorouracil|
550382|NCT00025142|Drug|gefitinib|
550383|NCT00025142|Drug|leucovorin calcium|
550384|NCT00025142|Drug|oxaliplatin|
550385|NCT00025129|Drug|laromustine|
550386|NCT00025103|Biological|dactinomycin|
550387|NCT00025103|Drug|carboplatin|
550388|NCT00025103|Drug|cyclophosphamide|
550389|NCT00025103|Drug|doxorubicin hydrochloride|
550390|NCT00025103|Drug|etoposide|
550391|NCT00025103|Drug|melphalan|
550392|NCT00025103|Drug|vincristine sulfate|
550393|NCT00025103|Procedure|autologous bone marrow transplantation|
550394|NCT00025103|Procedure|conventional surgery|
550395|NCT00025103|Procedure|peripheral blood stem cell transplantation|
550396|NCT00025103|Radiation|radiation therapy|
550397|NCT00025090|Drug|cisplatin|
550398|NCT00025090|Drug|fluorouracil|
550399|NCT00025090|Drug|mitomycin C|
550400|NCT00025090|Radiation|radiation therapy|
550401|NCT00025077|Biological|filgrastim|
550402|NCT00025077|Drug|carboplatin|
550403|NCT00025077|Drug|cyclophosphamide|
550404|NCT00025077|Drug|thiotepa|
550405|NCT00025077|Procedure|conventional surgery|
550406|NCT00025077|Procedure|peripheral blood stem cell transplantation|
550407|NCT00025077|Radiation|radiation therapy|
550408|NCT00025064|Biological|bleomycin sulfate|
550409|NCT00025064|Drug|chlorambucil|
550410|NCT00025064|Drug|cisplatin|
550411|NCT00025064|Drug|dacarbazine|
550412|NCT00025064|Drug|doxorubicin hydrochloride|
550413|NCT00025064|Drug|etoposide|
550414|NCT00025064|Drug|ifosfamide|
550415|NCT00025064|Drug|melphalan|
550416|NCT00025064|Drug|prednisolone|
550417|NCT00025064|Drug|procarbazine hydrochloride|
550418|NCT00025064|Drug|vinblastine sulfate|
550419|NCT00025064|Drug|vincristine sulfate|
550420|NCT00025064|Procedure|peripheral blood stem cell transplantation|
550421|NCT00025064|Radiation|radiation therapy|
550422|NCT00025051|Drug|celecoxib|
550423|NCT00025051|Procedure|anti-cytokine therapy|
550424|NCT00025051|Procedure|antiangiogenesis therapy|
550425|NCT00025051|Procedure|biological therapy|
550426|NCT00025051|Procedure|cancer prevention intervention|
550427|NCT00025051|Procedure|chemoprevention of cancer|
550428|NCT00025051|Procedure|growth factor antagonist therapy|
550429|NCT00025038|Drug|tipifarnib|Given orally
550430|NCT00025038|Drug|isotretinoin|Given orally
550431|NCT00025038|Drug|fludarabine phosphate|Given IV
550432|NCT00025038|Drug|cytarabine|Given IV
550433|NCT00025038|Radiation|radiation therapy|Undergo total body irradiation
550434|NCT00025038|Drug|cyclophosphamide|Given IV
550435|NCT00025038|Biological|anti-thymocyte globulin|Given IV
550436|NCT00025038|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
550437|NCT00025038|Procedure|double-unit umbilical cord blood transplantation|
550438|NCT00025038|Procedure|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
550439|NCT00025038|Other|laboratory biomarker analysis|Correlative studies
550440|NCT00025025|Other|sample testing|
550441|NCT00024466|Biological|GVAX|
550442|NCT00024466|Procedure|Autologous transplant|
550443|NCT00024453|Biological|teicoplanin|
550444|NCT00024440|Biological|filgrastim|
550445|NCT00024440|Biological|oblimersen sodium|
550446|NCT00024440|Drug|cyclophosphamide|
550447|NCT00024440|Drug|fludarabine phosphate|
550448|NCT00024427|Drug|fluorouracil|High dose 5-FU
550449|NCT00024427|Drug|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
550450|NCT00024427|Drug|triacetyluridine|6 grams (12 tablets)
550451|NCT00024414|Drug|DHA-paclitaxel|
550452|NCT00024375|Drug|DHA-paclitaxel|
550453|NCT00024349|Drug|fluorouracil|
550454|NCT00024349|Drug|mitomycin C|
550455|NCT00024349|Radiation|radiation therapy|
550456|NCT00024336|Drug|tamoxifen citrate|
550457|NCT00024336|Radiation|radiation therapy|
550458|NCT00024297|Drug|warfarin|
550459|NCT00024284|Drug|carboplatin|
550460|NCT00024284|Drug|irinotecan hydrochloride|
550461|NCT00024271|Biological|recombinant interferon gamma|
550462|NCT00024271|Drug|cisplatin|
550463|NCT00024271|Drug|doxorubicin hydrochloride|
550464|NCT00024271|Drug|gemcitabine hydrochloride|
550465|NCT00024271|Drug|mitomycin C|
550466|NCT00024271|Procedure|conventional surgery|
550467|NCT00024271|Procedure|hyperthermia treatment|
550468|NCT00024271|Radiation|radiation therapy|
550469|NCT00024258|Drug|arsenic trioxide|
550470|NCT00024245|Drug|pralatrexate|
550471|NCT00024245|Drug|probenecid|
550472|NCT00024232|Biological|monoclonal antibody huJ591|
550473|NCT00024193|Biological|filgrastim|
550474|NCT00024193|Drug|busulfan|
550475|NCT00024193|Drug|cisplatin|
550476|NCT00024193|Drug|cyclophosphamide|
550477|NCT00024193|Drug|doxorubicin hydrochloride|
550478|NCT00024193|Drug|etoposide|
550479|NCT00024193|Drug|melphalan|
550480|NCT00024193|Drug|vincristine sulfate|
550481|NCT00024193|Procedure|conventional surgery|
550482|NCT00024193|Procedure|peripheral blood stem cell transplantation|
550483|NCT00024180|Drug|romidepsin|
550484|NCT00024167|Drug|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
550485|NCT00024167|Drug|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
550486|NCT00024167|Drug|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
550487|NCT00024167|Drug|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
550488|NCT00024167|Drug|Prednisone|5 mg orally 2 x daily, weeks 1-14
550489|NCT00024167|Drug|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
550490|NCT00024167|Radiation|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
550491|NCT00024167|Drug|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
550492|NCT00024154|Biological|trastuzumab|Given IV
550493|NCT00024154|Drug|gefitinib|Given orally
550494|NCT00024154|Other|laboratory biomarker analysis|Correlative studies
550495|NCT00024115|Drug|BL22 immunotoxin|
550496|NCT00024115|Procedure|antibody therapy|
550497|NCT00024115|Procedure|biological response modifier therapy|
550498|NCT00024115|Procedure|immunotoxin therapy|
550499|NCT00024102|Drug|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 & 8 and 5-FU 600 mg/sq m IV push d 1 & 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
550500|NCT00024102|Drug|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
550501|NCT00024089|Drug|gefitinib|
550502|NCT00024076|Procedure|radiofrequency ablation|
550503|NCT00024050|Drug|busulfan|
550504|NCT00024050|Drug|cyclophosphamide|
550505|NCT00024050|Drug|cyclosporine|
550506|NCT00024050|Drug|methotrexate|
550507|NCT00024050|Procedure|allogeneic bone marrow transplantation|
550508|NCT00024050|Procedure|peripheral blood stem cell transplantation|
550509|NCT00023998|Drug|doxorubicin hydrochloride|Given IV
550510|NCT00023998|Drug|cisplatin|Given IV
550511|NCT00023998|Drug|methotrexate|Given IV
550512|NCT00023998|Drug|leucovorin calcium|Given IV or orally
550513|NCT00023998|Biological|filgrastim|Given IV
550514|NCT00023998|Procedure|therapeutic conventional surgery|Undergo resection
550515|NCT00023998|Radiation|radiation therapy|Undergo radiotherapy
550516|NCT00023998|Drug|etoposide|Given IV
550517|NCT00023998|Drug|ifosfamide|Given IV
550518|NCT00023998|Biological|trastuzumab|Given IV
550519|NCT00023998|Other|laboratory biomarker analysis|Correlative studies
550520|NCT00023985|Biological|autologous tumor cell vaccine|
550521|NCT00023985|Biological|therapeutic autologous dendritic cells|
550522|NCT00023985|Procedure|conventional surgery|
550523|NCT00023972|Drug|exatecan mesylate|
550524|NCT00023972|Drug|gemcitabine hydrochloride|
550525|NCT00023959|Drug|hydroxyurea|Given orally
550526|NCT00023959|Drug|fluorouracil|Given IV
550527|NCT00023959|Biological|bevacizumab|Given IV
550528|NCT00023959|Radiation|radiation therapy|Undergo radiotherapy
550529|NCT00023959|Biological|filgrastim|Given subcutaneously
550530|NCT00023959|Other|laboratory biomarker analysis|Correlative studies
550531|NCT00023946|Drug|ixabepilone|Given IV
550532|NCT00023946|Other|laboratory biomarker analysis|Correlative studies
550533|NCT00023920|Biological|bevacizumab|Given IV
550534|NCT00023920|Drug|idarubicin|Given IV
550535|NCT00023920|Drug|cytarabine|Given SC
550536|NCT00023894|Drug|alvocidib|
550537|NCT00023881|Drug|bortezomib|
550538|NCT00023855|Drug|bortezomib|
550539|NCT00023855|Drug|doxorubicin hydrochloride|
550540|NCT00023842|Biological|BCG vaccine|
550541|NCT00023842|Drug|mitomycin C|
550542|NCT00023842|Procedure|adjuvant therapy|
550543|NCT00023842|Procedure|conventional surgery|
550544|NCT00023829|Drug|bicalutamide|
550545|NCT00023829|Drug|flutamide|
550546|NCT00023829|Drug|releasing hormone agonist therapy|
550547|NCT00023829|Procedure|adjuvant therapy|
550548|NCT00023829|Radiation|radiation therapy|
550549|NCT00023790|Drug|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
550550|NCT00023777|Biological|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
550551|NCT00023777|Biological|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
550552|NCT00023777|Drug|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
550553|NCT00023777|Drug|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
550554|NCT00023764|Drug|bortezomib|Given IV
550555|NCT00023751|Drug|fluorouracil|
550556|NCT00023751|Drug|leucovorin calcium|
550557|NCT00023751|Procedure|conventional surgery|
550558|NCT00023751|Radiation|radiation therapy|
550559|NCT00023712|Drug|bortezomib|Given IV
550560|NCT00023712|Other|laboratory biomarker analysis|Correlative studies
550561|NCT00023712|Other|pharmacological study|Correlative studies
550562|NCT00023686|Procedure|surgery|
550563|NCT00023686|Radiation|radiation|
550564|NCT00023660|Drug|celecoxib|
550565|NCT00023660|Drug|cisplatin|
550566|NCT00023660|Drug|fluorouracil|
550567|NCT00023660|Radiation|brachytherapy|
550568|NCT00023660|Radiation|radiation therapy|
550569|NCT00023634|Biological|KLH|100 mcg w/EGFRvIII
550570|NCT00023634|Biological|GMCSF|arm 1: 100 mcg w/EGFRvIII
550571|NCT00023621|Drug|celecoxib|
550572|NCT00022737|Biological|filgrastim|Given SC
550573|NCT00022737|Drug|asparaginase|Given IM
550574|NCT00022737|Drug|cyclophosphamide|Given IV
550575|NCT00022737|Drug|cyclosporine|Given IV
550576|NCT00022737|Drug|cytarabine|Given IT and IV
550577|NCT00022737|Drug|daunorubicin hydrochloride|Given IV
550578|NCT00022737|Drug|dexamethasone|Given orally
550579|NCT00022737|Drug|etoposide|Given IV
550580|NCT00022737|Drug|ifosfamide|Given IV
550581|NCT00022737|Drug|imatinib mesylate|Given orally
550582|NCT00022737|Drug|leucovorin calcium|Given IV or orally
550583|NCT00022737|Drug|mercaptopurine tablet|Given orally
550584|NCT00022737|Drug|methotrexate|Given IT, IV, and orally
550585|NCT00022737|Drug|pegaspargase|Given IM
550586|NCT00022737|Drug|vincristine sulfate|Given IV
550587|NCT00022737|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
550588|NCT00022737|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
550589|NCT00022737|Procedure|umbilical cord blood transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
550590|NCT00022737|Radiation|radiation therapy|Undergo radiation therapy
550591|NCT00022724|Drug|temsirolimus|
550592|NCT00022711|Drug|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
550593|NCT00022698|Drug|Capecitabine|
550594|NCT00022698|Drug|Irinotecan|
550595|NCT00022685|Biological|epratuzumab|
550596|NCT00022672|Drug|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
550597|NCT00022672|Drug|anastrazole (Arimidex®)|1 mg tablet taken orally daily
550598|NCT00022659|Biological|bevacizumab|Given IV
550599|NCT00022659|Other|laboratory biomarker analysis|Correlative studies
550600|NCT00022646|Drug|gemcitabine hydrochloride|
550601|NCT00022646|Drug|pemetrexed disodium|
550602|NCT00022633|Drug|gemcitabine hydrochloride|
550603|NCT00022633|Drug|paclitaxel|
550604|NCT00022620|Drug|paclitaxel|
550605|NCT00022607|Biological|bevacizumab|
550606|NCT00022607|Drug|thalidomide|
550607|NCT00022581|Drug|thalidomide|Given orally
550608|NCT00022581|Other|laboratory biomarker analysis|Correlative studies
550609|NCT00022568|Biological|recombinant vaccinia-TRICOM vaccine|
550610|NCT00022555|Drug|bryostatin 1|Given IV
550611|NCT00022555|Drug|vincristine sulfate|Given IV
550612|NCT00022516|Drug|Cyclophosphamide|50 mg/day orally continuously for 1 year
550613|NCT00022516|Drug|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
550614|NCT00022490|Drug|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
550615|NCT00022490|Drug|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
550616|NCT00022464|Drug|temsirolimus|
550617|NCT00022451|Drug|tipifarnib|
550618|NCT00022438|Biological|aldesleukin|
550619|NCT00022438|Biological|incomplete Freund's adjuvant|
550620|NCT00022438|Biological|recombinant tyrosinase-related protein-2|
550621|NCT00022425|Drug|perillyl alcohol|
550622|NCT00022412|Dietary Supplement|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
550964|NCT00017225|Drug|vincristine sulfate|
550623|NCT00022412|Procedure|conventional surgery|Procedure: Prostatectomy for prostate cancer
550624|NCT00022399|Drug|celecoxib|400mg PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
550625|NCT00022399|Drug|Placebos|Placebo PO twice daily for 4-6 weeks up to 8 hours prior to prostatectomy.
550626|NCT00022334|Biological|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
550627|NCT00022295|Drug|idronoxil|
550628|NCT00022230|Biological|aldesleukin|
550629|NCT00022230|Biological|filgrastim|
550630|NCT00022230|Biological|sargramostim|
550631|NCT00022230|Biological|therapeutic autologous lymphocytes|
550632|NCT00022230|Drug|cyclophosphamide|
550633|NCT00022230|Drug|doxorubicin hydrochloride|
550634|NCT00022230|Drug|paclitaxel|
550635|NCT00022191|Drug|cisplatin|
550636|NCT00022191|Drug|gemcitabine hydrochloride|
550637|NCT00022191|Drug|paclitaxel|
550638|NCT00022152|Drug|vinorelbine tartrate|
550639|NCT00022126|Drug|asparaginase|
550640|NCT00022126|Drug|cyclophosphamide|
550641|NCT00022126|Drug|cyclosporine|
550642|NCT00022126|Drug|cytarabine|
550643|NCT00022126|Drug|daunorubicin hydrochloride|
550644|NCT00022126|Drug|dexamethasone|
550645|NCT00022126|Drug|doxorubicin hydrochloride|
550646|NCT00022126|Drug|mercaptopurine|
550647|NCT00022126|Drug|methotrexate|
550648|NCT00022126|Drug|methylprednisolone|
550649|NCT00022126|Drug|pegaspargase|
550650|NCT00022126|Drug|thioguanine|
550651|NCT00022126|Drug|vincristine sulfate|
550652|NCT00022126|Procedure|allogeneic bone marrow transplantation|
550653|NCT00022126|Radiation|radiation therapy|
550654|NCT00022113|Drug|cilengitide|Given IV
550655|NCT00022113|Other|pharmacological study|Correlative studies
550656|NCT00022113|Other|laboratory biomarker analysis|Correlative studies
550657|NCT00022087|Dietary Supplement|calcium salts|1000 mg PO per day
550658|NCT00022087|Dietary Supplement|cholecalciferol|400 IU PO per day
550659|NCT00022087|Drug|zoledronic acid|4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
550660|NCT00022074|Drug|gabapentin|
550661|NCT00022074|Procedure|quality-of-life assessment|
550662|NCT00022048|Biological|bevacizumab|
550663|NCT00022035|Biological|trivalent influenza vaccine|
550664|NCT00022022|Drug|docetaxel|
550665|NCT00022022|Procedure|quality-of-life assessment|
550666|NCT00021450|Drug|bicalutamide|
550667|NCT00021450|Drug|goserelin acetate|
550668|NCT00021450|Procedure|adjuvant therapy|
550669|NCT00021450|Radiation|radiation therapy|
550670|NCT00021424|Biological|recombinant fowlpox-TRICOM vaccine|
550671|NCT00021320|Drug|cisplatin|
550672|NCT00021320|Drug|fluorouracil|
550673|NCT00021320|Drug|paclitaxel|
550674|NCT00021320|Procedure|conventional surgery|
550675|NCT00021320|Procedure|neoadjuvant therapy|
550676|NCT00021320|Radiation|radiation therapy|
550677|NCT00021255|Drug|Doxorubicin|
550678|NCT00021255|Drug|Cyclophosphamide|
550679|NCT00021255|Drug|Docetaxel|
550680|NCT00021255|Drug|Herceptin|
550681|NCT00021255|Drug|Carboplatin|
550682|NCT00021242|Drug|docetaxel|Continuous IV infusion
550683|NCT00021229|Drug|imatinib mesylate|"Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
550684|NCT00021229|Radiation|local irradiation therapy|"Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
550685|NCT00021216|Drug|bortezomib|Given IV
550686|NCT00021216|Other|laboratory biomarker analysis|Correlative studies
550687|NCT00021216|Other|pharmacological study|Correlative studies
550688|NCT00021164|Biological|aldesleukin|
550689|NCT00021164|Biological|incomplete Freund's adjuvant|
550690|NCT00021164|Biological|telomerase: 540-548 peptide vaccine|
550691|NCT00021125|Procedure|adjuvant therapy|
550692|NCT00021125|Radiation|radiation therapy|
550693|NCT00021112|Drug|cisplatin|
550694|NCT00021112|Drug|etoposide|
550695|NCT00021112|Procedure|conventional surgery|
550696|NCT00021112|Radiation|radiation therapy|
550697|NCT00021073|Drug|alvocidib|Given IV
550698|NCT00021073|Drug|leucovorin calcium|Given IV
550699|NCT00021073|Drug|fluorouracil|Given IV
550700|NCT00021073|Drug|irinotecan hydrochloride|Given IV
550701|NCT00021060|Drug|paclitaxel|Given IV
550702|NCT00021060|Drug|carboplatin|Given IV
550703|NCT00021060|Biological|bevacizumab|Given IV
550704|NCT00021060|Other|laboratory biomarker analysis|Correlative studies
550705|NCT00021047|Drug|capecitabine|
550706|NCT00021047|Drug|carboplatin|
550707|NCT00021047|Drug|epirubicin hydrochloride|
550708|NCT00020995|Procedure|therapeutic dietary intervention|
550709|NCT00020969|Drug|arsenic trioxide|
550710|NCT00020943|Biological|filgrastim|5 ug/kg subQ daily day 4 until ANC >10,000 (or ANC> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
550965|NCT00017225|Drug|vindesine|
550711|NCT00020943|Biological|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 & 12 Tx 3, and weekly for 2 doses Tx 5
550712|NCT00020943|Drug|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
550713|NCT00020943|Drug|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 & 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
550714|NCT00020943|Drug|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
550715|NCT00020943|Drug|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1& 2
550716|NCT00020943|Drug|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
550717|NCT00020943|Drug|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels <0.05 uM, Tx 1 & 2
550718|NCT00020943|Drug|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 & 2
550719|NCT00020943|Drug|prednisone|100 mg/sq m PO Days 3-7, Tx 1 & 2
550720|NCT00020943|Drug|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 & 2
550721|NCT00020943|Procedure|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
550722|NCT00020891|Procedure|computed tomography|
550723|NCT00020891|Radiation|radiation therapy|
550724|NCT00020878|Drug|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
550725|NCT00020852|Procedure|conventional surgery|
550726|NCT00020852|Procedure|cryosurgery|
550727|NCT00020839|Drug|temozolomide|
550728|NCT00020839|Radiation|radiation therapy|
550729|NCT00020826|Other|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
550730|NCT00020800|Biological|rituximab|
550731|NCT00020800|Drug|fludarabine phosphate|
550732|NCT00020761|Drug|irinotecan hydrochloride|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."
550733|NCT00020761|Drug|paclitaxel|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.~Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
550734|NCT00020748|Drug|epirubicin hydrochloride|
550735|NCT00020748|Drug|irinotecan hydrochloride|
550736|NCT00020735|Drug|toremifene|
550737|NCT00020735|Procedure|conventional surgery|
550738|NCT00020735|Procedure|neoadjuvant therapy|
550739|NCT00020722|Biological|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.~The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
550740|NCT00020722|Drug|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.~Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.~Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.~VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
550741|NCT00020722|Drug|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).~Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.~Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.~Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
550742|NCT00020722|Procedure|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
550743|NCT00020722|Procedure|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
550744|NCT00020709|Drug|cisplatin|Given IV
550745|NCT00020709|Drug|docetaxel|Given IV
550746|NCT00020709|Drug|etoposide|Given IV
550747|NCT00020709|Drug|gefitinib|Given orally
550748|NCT00020709|Radiation|radiation therapy|Undergo radiation therapy
550749|NCT00020709|Other|placebo|Given orally
550750|NCT00020683|Drug|incyclinide|High dose given orally
550751|NCT00020683|Drug|incyclinide|Low dose given orally
550752|NCT00020683|Other|laboratory biomarker analysis|Correlative studies
550753|NCT00020670|Biological|CD 40|
550754|NCT00020657|Drug|dolasetron mesylate|
550755|NCT00020657|Drug|granisetron hydrochloride|
550756|NCT00020657|Drug|ondansetron|
550757|NCT00020657|Drug|prochlorperazine|
550758|NCT00020657|Procedure|quality-of-life assessment|
550759|NCT00020644|Drug|gemcitabine hydrochloride|
550760|NCT00020631|Drug|pirfenidone|
550761|NCT00020579|Drug|entinostat|
550762|NCT00020566|Biological|dactinomycin|Given IV
550763|NCT00020566|Drug|busulfan|Given orally and IV
550764|NCT00020566|Drug|doxorubicin hydrochloride|Given IV
550765|NCT00020566|Drug|etoposide|Given IV
550766|NCT00020566|Drug|ifosfamide|Given IV
550767|NCT00020566|Drug|melphalan|Given orally and IV
550768|NCT00020566|Drug|vincristine sulfate|Given IV
550769|NCT00020566|Procedure|autologous hematopoietic stem cell transplantation|Given IV
550770|NCT00020566|Procedure|conventional surgery|Given to patients deemed to require it
550771|NCT00020566|Radiation|radiation therapy|Given to patients deemed to require it
550772|NCT00020527|Drug|caspofungin acetate|
550773|NCT00020501|Drug|FOLFIRI regimen|
550774|NCT00020501|Drug|floxuridine|
550775|NCT00020501|Drug|fluorouracil|
550776|NCT00020501|Drug|irinotecan hydrochloride|
550777|NCT00020501|Drug|leucovorin calcium|
550778|NCT00020501|Drug|melphalan|
550779|NCT00020501|Procedure|hyperthermia treatment|
550780|NCT00020488|Drug|FOLFIRI regimen|
550781|NCT00020488|Drug|fluorouracil|
550782|NCT00020488|Drug|irinotecan hydrochloride|
550783|NCT00020488|Drug|leucovorin calcium|
550784|NCT00020449|Biological|recombinant interleukin-12|
550785|NCT00020449|Drug|paclitaxel|
550786|NCT00020449|Drug|pegylated liposomal doxorubicin hydrochloride|
550787|NCT00020410|Biological|filgrastim|
550788|NCT00020410|Procedure|peripheral blood stem cell transplantation|
550789|NCT00020410|Radiation|yttrium Y 90 monoclonal antibody B3|
550790|NCT00020397|Biological|NY-ESO-1 peptide vaccine|
550791|NCT00020397|Biological|aldesleukin|
550792|NCT00020358|Biological|aldesleukin|
550793|NCT00020358|Biological|gp100 antigen|
550794|NCT00020358|Biological|incomplete Freund's adjuvant|
550795|NCT00020358|Biological|tyrosinase peptide|
550796|NCT00020332|Drug|alvocidib|
550797|NCT00020332|Drug|docetaxel|
550798|NCT00020254|Biological|aldesleukin|
550799|NCT00020254|Biological|recombinant fowlpox-prostate specific antigen vaccine|
550800|NCT00020254|Biological|recombinant vaccinia prostate-specific antigen vaccine|
550801|NCT00020254|Biological|recombinant vaccinia-B7.1 vaccine|
550802|NCT00020254|Biological|sargramostim|
550803|NCT00020254|Drug|nilutamide|
550804|NCT00020189|Drug|acetylsalicylic acid|
550805|NCT00020189|Drug|alvocidib|
550806|NCT00020189|Drug|clopidogrel bisulfate|
550807|NCT00020176|Biological|filgrastim|
550808|NCT00020176|Biological|therapeutic allogeneic lymphocytes|
550809|NCT00020176|Drug|cyclophosphamide|
550810|NCT00020176|Drug|cyclosporine|
550811|NCT00020176|Drug|fludarabine phosphate|
550812|NCT00020176|Procedure|peripheral blood stem cell transplantation|
550813|NCT00020150|Drug|O6-benzylguanine|
550814|NCT00020150|Drug|temozolomide|
550815|NCT00020124|Drug|doxorubicin hydrochloride|
550816|NCT00020111|Drug|arsenic trioxide|
550817|NCT00020072|Other|laboratory biomarker analysis|
550818|NCT00020007|Drug|isolated perfusion|
550819|NCT00020007|Drug|paclitaxel|
550820|NCT00020007|Procedure|hyperthermia treatment|
550821|NCT00019994|Biological|MART-1 antigen|
550822|NCT00019994|Biological|aldesleukin|
550823|NCT00019994|Biological|gp100 antigen|
550824|NCT00019994|Biological|incomplete Freund's adjuvant|
550825|NCT00019955|Procedure|laparoscopic surgery|
550826|NCT00019955|Procedure|radiofrequency ablation|
550827|NCT00019955|Procedure|thermal ablation therapy|
550828|NCT00019929|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
550829|NCT00019929|Procedure|adjuvant therapy|
550830|NCT00019916|Biological|aldesleukin|
550831|NCT00019916|Biological|p53 peptide vaccine|
550832|NCT00019916|Procedure|in vitro-treated peripheral blood stem cell transplantation|
550833|NCT00019864|Biological|filgrastim|
550834|NCT00019864|Drug|cisplatin|
550835|NCT00019864|Drug|dexrazoxane hydrochloride|
550836|NCT00019864|Drug|doxorubicin hydrochloride|
550837|NCT00019864|Drug|leucovorin calcium|
550838|NCT00019864|Drug|methotrexate|
550839|NCT00019864|Procedure|adjuvant therapy|
550840|NCT00019864|Procedure|conventional surgery|
550841|NCT00019864|Procedure|neoadjuvant therapy|
550842|NCT00019838|Drug|7-hydroxystaurosporine|
550843|NCT00019838|Drug|fludarabine phosphate|
550844|NCT00019825|Drug|decitabine|
550845|NCT00019812|Biological|trastuzumab|
550846|NCT00019812|Drug|paclitaxel|
550847|NCT00019786|Drug|isolated perfusion|
550848|NCT00019786|Drug|melphalan|
550849|NCT00019786|Procedure|conventional surgery|
550850|NCT00019773|Drug|capecitabine|
550851|NCT00019773|Drug|oxaliplatin|
550852|NCT00019747|Drug|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
550853|NCT00019747|Procedure|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
550854|NCT00019747|Other|Placebo|oral placebo once daily
550855|NCT00019708|Drug|tanespimycin|Given IV
550856|NCT00019682|Biological|Aldesleukin|Given IV
550857|NCT00019682|Biological|gp100 Antigen|Given SC
550858|NCT00019682|Drug|Montanide ISA 51 VG|Given SC
550859|NCT00019682|Other|Quality-of-Life Assessment|Ancillary studies
550860|NCT00019682|Other|Questionnaire Administration|Ancillary studies
550861|NCT00019682|Other|Laboratory Biomarker Analysis|Correlative studies
550862|NCT00019669|Biological|aldesleukin|
550863|NCT00019669|Biological|fowlpox virus vaccine vector|
550864|NCT00019669|Biological|gp100 antigen|
550865|NCT00019656|Drug|perifosine|
550866|NCT00019604|Procedure|computed tomography|Scan to assess the effects of ablation.
550867|NCT00019604|Procedure|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
550868|NCT00019604|Procedure|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
550869|NCT00019604|Procedure|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
550870|NCT00019604|Procedure|radionuclide imaging|Imaging following injection of a radioactive material.
550871|NCT00019604|Procedure|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
550872|NCT00019604|Radiation|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
550873|NCT00019604|Radiation|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
550874|NCT00019591|Biological|aldesleukin|
550875|NCT00019591|Biological|ras peptide cancer vaccine|
550876|NCT00019591|Procedure|adjuvant therapy|
550877|NCT00019565|Procedure|magnetic resonance imaging|
550878|NCT00019565|Procedure|positron emission tomography|
550879|NCT00019565|Radiation|fludeoxyglucose F 18|
550880|NCT00019513|Drug|fluorouracil|
550881|NCT00019513|Drug|gemcitabine hydrochloride|
550882|NCT00019513|Drug|leucovorin calcium|
550883|NCT00019487|Biological|aldesleukin|
550884|NCT00019487|Biological|gp209-2M antigen|
550885|NCT00019487|Biological|incomplete Freund's adjuvant|
550886|NCT00019461|Drug|carboxyamidotriazole|
550887|NCT00019461|Drug|chemotherapy|
550888|NCT00019422|Drug|carboplatin|
550889|NCT00019422|Drug|lobradimil|
550890|NCT00019331|Biological|aldesleukin|
550891|NCT00019331|Biological|ras peptide cancer vaccine|
550892|NCT00019331|Biological|sargramostim|
550893|NCT00019331|Drug|DetoxPC|
550894|NCT00019227|Drug|pentetic acid calcium|
550895|NCT00019227|Radiation|yttrium Y 90 daclizumab|
550896|NCT00019214|Biological|MART-1 antigen|
550897|NCT00019214|Biological|aldesleukin|
550898|NCT00019214|Biological|gp100 antigen|
550899|NCT00019201|Other|cytology specimen collection procedure|
550900|NCT00019201|Other|immunohistochemistry staining method|
550901|NCT00019201|Other|sputum cytology|
550902|NCT00019201|Procedure|bronchoscopic and lung imaging studies|
550903|NCT00019201|Procedure|bronchoscopy|
550904|NCT00019201|Procedure|comparison of screening methods|
550905|NCT00019201|Procedure|endoscopic biopsy|
550906|NCT00019136|Biological|MOv-gamma chimeric receptor gene|
550907|NCT00019136|Biological|aldesleukin|
550908|NCT00019136|Biological|therapeutic allogeneic lymphocytes|
550909|NCT00019110|Biological|human papillomavirus 16 E7 peptide|
550910|NCT00019110|Biological|synthetic human papillomavirus 16 E6 peptide|
550911|NCT00019032|Biological|monoclonal antibody Mik-beta-1|
550912|NCT00019019|Drug|carboxyamidotriazole|
550913|NCT00019019|Drug|paclitaxel|
550914|NCT00018967|Drug|glucarpidase|
550915|NCT00017602|Biological|oblimersen sodium|
550916|NCT00017602|Drug|dexamethasone|
550917|NCT00017589|Biological|oblimersen sodium|
550918|NCT00017589|Drug|gemtuzumab ozogamicin|
550919|NCT00017563|Drug|docetaxel|35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
550920|NCT00017563|Drug|mitoxantrone hydrochloride|Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
550921|NCT00017563|Procedure|conventional surgery|Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
550922|NCT00017550|Biological|anti-thymocyte globulin|
550923|NCT00017524|Drug|pelitrexol|
550924|NCT00017511|Drug|cevimeline hydrochloride|
550925|NCT00017498|Drug|gemcitabine hydrochloride|
550926|NCT00017485|Drug|HPPH|
550927|NCT00017472|Biological|apolizumab|Given IV
550928|NCT00017472|Other|laboratory biomarker analysis|Correlative studies
550929|NCT00017472|Other|pharmacological study|Correlative studies
550930|NCT00017381|Biological|rituximab|Given IV
550931|NCT00017381|Drug|cyclophosphamide|Given IV
550932|NCT00017381|Biological|filgrastim|Given SC
550933|NCT00017381|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
550934|NCT00017381|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
550935|NCT00017355|Biological|filgrastim|
550936|NCT00017355|Biological|therapeutic autologous dendritic cells|
550937|NCT00017329|Drug|bortezomib|
550938|NCT00017290|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
550939|NCT00017290|Biological|keyhole limpet hemocyanin|
550940|NCT00017290|Biological|sargramostim|
550941|NCT00017290|Drug|cyclophosphamide|
550942|NCT00017290|Drug|prednisone|
550943|NCT00017290|Drug|vincristine sulfate|
550944|NCT00017277|Biological|epoetin alfa|
550945|NCT00017277|Radiation|radiation therapy|
550946|NCT00017264|Drug|atrasentan hydrochloride|
550947|NCT00017251|Biological|oblimersen sodium|Given IV
550948|NCT00017251|Drug|carboplatin|Given IV
550949|NCT00017251|Drug|etoposide|Given IV
550950|NCT00017251|Other|pharmacological study|Correlative studies
550951|NCT00017251|Other|laboratory biomarker analysis|Correlative studies
550952|NCT00017238|Drug|KRN5500|Given IV
550953|NCT00017238|Other|pharmacological study|Correlative studies
550954|NCT00017225|Biological|filgrastim|
550955|NCT00017225|Drug|carboplatin|
550956|NCT00017225|Drug|cisplatin|
550957|NCT00017225|Drug|cyclophosphamide|
550958|NCT00017225|Drug|dacarbazine|
550959|NCT00017225|Drug|doxorubicin hydrochloride|
550960|NCT00017225|Drug|etoposide|
550961|NCT00017225|Drug|ifosfamide|
550962|NCT00017225|Drug|melphalan|
550963|NCT00017225|Drug|tretinoin|
550966|NCT00017225|Procedure|autologous bone marrow transplantation|
550967|NCT00017225|Procedure|conventional surgery|
550968|NCT00017225|Procedure|peripheral blood stem cell transplantation|
550969|NCT00017225|Radiation|radiation therapy|
550970|NCT00017212|Drug|exatecan mesylate|
550971|NCT00017186|Drug|epirubicin hydrochloride|
550972|NCT00017186|Drug|gemcitabine hydrochloride|
550973|NCT00017173|Biological|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
550974|NCT00017173|Drug|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
550975|NCT00017173|Procedure|conventional surgery|conventional surgery
550976|NCT00017173|Radiation|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
550977|NCT00017160|Drug|doxorubicin|
550978|NCT00017160|Drug|filgrastim|
550979|NCT00017160|Drug|ifosfamide|
550980|NCT00017160|Procedure|biological response modifier therapy|
550981|NCT00017160|Procedure|brachytherapy|
550982|NCT00017160|Procedure|chemotherapy|
550983|NCT00017160|Procedure|colony-stimulating factor therapy|
550984|NCT00017160|Procedure|conventional surgery|
550985|NCT00017160|Procedure|cytokine therapy|
550986|NCT00017160|Procedure|intraoperative radiotherapy|
550987|NCT00017160|Procedure|radiation therapy|
550988|NCT00017160|Procedure|surgery|
550989|NCT00017147|Drug|carmustine|"40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.~200 mg/m^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
550990|NCT00017147|Radiation|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
550991|NCT00017147|Drug|O6-Benzylguanine|120 mg/m^2 IV over 1 hour on day 1 of each cycle
550992|NCT00017121|Biological|sargramostim|
550993|NCT00017108|Drug|chlorambucil|
550994|NCT00017108|Drug|cyclophosphamide|
550995|NCT00017108|Drug|fludarabine phosphate|
550996|NCT00017095|Biological|filgrastim|
550997|NCT00017095|Drug|cyclophosphamide|
550998|NCT00017095|Drug|docetaxel|
550999|NCT00017095|Drug|epirubicin hydrochloride|
551000|NCT00017095|Drug|fluorouracil|
551001|NCT00017095|Genetic|microarray analysis|
551002|NCT00017095|Other|immunohistochemistry staining method|
551003|NCT00017095|Other|laboratory biomarker analysis|
551004|NCT00017095|Procedure|biopsy|
551005|NCT00017095|Procedure|conventional surgery|
551006|NCT00017095|Procedure|neoadjuvant therapy|
551007|NCT00017095|Radiation|radiation therapy|
551008|NCT00017069|Drug|arsenic trioxide|
551009|NCT00017069|Drug|dexamethasone|
551010|NCT00017004|Radiation|External Beam Radiation Therapy|Undergo radiation
551011|NCT00017004|Drug|Cisplatin|Given IV
551012|NCT00017004|Radiation|Internal Radiation Therapy|Undergo radiation
551013|NCT00017004|Biological|Epoetin Alfa|Given SC
551014|NCT00016991|Drug|gefitinib|
551015|NCT00016965|Drug|ixabepilone|
551016|NCT00016952|Drug|fluorouracil|
551017|NCT00016952|Drug|irinotecan hydrochloride|
551018|NCT00016952|Drug|leucovorin calcium|
551019|NCT00016926|Drug|capecitabine|
551020|NCT00016913|Drug|carboplatin|AUC=6 week one of each 4 week cycle
551021|NCT00016913|Drug|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
551022|NCT00016913|Drug|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
551023|NCT00016913|Radiation|radiation therapy|77.4 Gy in 1.8 Gy fractions
551024|NCT00016913|Drug|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
551025|NCT00016887|Biological|filgrastim|
551026|NCT00016887|Biological|recombinant interferon alfa|
551027|NCT00016887|Drug|carmustine|
551028|NCT00016887|Drug|cyclophosphamide|
551029|NCT00016887|Drug|cytarabine|
551030|NCT00016887|Drug|dexamethasone|
551031|NCT00016887|Drug|etoposide|
551032|NCT00016887|Drug|melphalan|
551033|NCT00016887|Procedure|bone marrow ablation with stem cell support|
551034|NCT00016887|Procedure|peripheral blood stem cell transplantation|
551035|NCT00016887|Radiation|radiation therapy|
551036|NCT00016861|Drug|irinotecan hydrochloride|
551037|NCT00016432|Drug|exemestane|25 mg for 5 years
551038|NCT00016432|Drug|Placebo|Placebo
551039|NCT00016419|Biological|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
551040|NCT00016419|Drug|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
551041|NCT00016406|Biological|filgrastim|
551042|NCT00016406|Drug|cyclophosphamide|
551043|NCT00016406|Drug|doxorubicin|
551044|NCT00016406|Drug|paclitaxel|
551045|NCT00016406|Procedure|surgery|
551046|NCT00016393|Drug|ixabepilone|
551047|NCT00016380|Drug|dexamethasone|
551048|NCT00016380|Drug|ondansetron|
551049|NCT00016380|Procedure|quality-of-life assessment|
551050|NCT00016354|Drug|benzoylphenylurea|
551051|NCT00016328|Drug|temsirolimus|Given IV
551052|NCT00016328|Other|laboratory biomarker analysis|Correlative studies
551053|NCT00016328|Other|pharmacological study|Correlative studies
551054|NCT00016302|Drug|prednisone|Given orally
551055|NCT00016302|Drug|vincristine sulfate|Given IV
551056|NCT00016302|Drug|daunorubicin hydrochloride|Given IV
551057|NCT00016302|Drug|asparaginase|Given IM
551058|NCT00016302|Drug|methotrexate|Given IT and orally
551059|NCT00016302|Drug|cyclophosphamide|Given IV
551060|NCT00016302|Drug|cytarabine|Given IV or SC
551061|NCT00016302|Drug|mercaptopurine|Given orally
551166|NCT00014313|Drug|etoposide|
551062|NCT00016302|Drug|leucovorin calcium|Given IV or orally
551063|NCT00016302|Drug|dexamethasone|Given orally
551064|NCT00016302|Drug|doxorubicin hydrochloride|Given IV
551065|NCT00016302|Drug|thioguanine|Given orally
551066|NCT00016302|Radiation|radiation therapy|Undergo cranial irradiation
551067|NCT00016302|Drug|nelarabine|Given IV
551068|NCT00016302|Drug|pegaspargase|Given IM
551069|NCT00016302|Radiation|radiation therapy|Undergo craniocervical radiotherapy
551070|NCT00016302|Other|pharmacological study|Correlative studies
551071|NCT00016302|Other|laboratory biomarker analysis|Correlative studies
551072|NCT00016289|Biological|recombinant interleukin-12|Given intraperitoneally
551073|NCT00016263|Biological|oblimersen sodium|
551074|NCT00016263|Drug|dacarbazine|
551075|NCT00016224|Drug|thalidomide|
551076|NCT00016211|Radiation|radiation therapy|
551077|NCT00016185|Drug|alvocidib|
551078|NCT00016185|Drug|docetaxel|
551079|NCT00016159|Biological|filgrastim|
551080|NCT00016159|Biological|lintuzumab|
551081|NCT00016159|Drug|arsenic trioxide|
551082|NCT00016159|Drug|idarubicin|
551083|NCT00016159|Drug|tretinoin|
551084|NCT00016146|Biological|GPI-0100|
551085|NCT00016146|Biological|MUC-2-Globo H-KLH conjugate vaccine|
551086|NCT00016133|Biological|BCG vaccine|
551087|NCT00016133|Biological|autologous tumor cell vaccine|
551088|NCT00016133|Drug|fluorouracil|
551089|NCT00016133|Drug|leucovorin calcium|
551090|NCT00016133|Procedure|adjuvant therapy|
551091|NCT00016094|Biological|bevacizumab|Given IV
551092|NCT00016094|Other|laboratory biomarker analysis|Correlative studies
551093|NCT00016081|Drug|ribavirin|
551094|NCT00016068|Drug|ganciclovir|
551095|NCT00016068|Drug|valganciclovir|
551096|NCT00016055|Biological|lymphokine-activated killer cells|
551097|NCT00016055|Drug|temozolomide|
551098|NCT00016029|Other|screening questionnaire administration|
551099|NCT00016029|Procedure|barium enema injection|
551100|NCT00016029|Procedure|computed tomography|
551101|NCT00016029|Procedure|computed tomography colonography|
551102|NCT00016029|Procedure|diagnostic colonoscopy|
551103|NCT00016029|Procedure|screening colonoscopy|
551104|NCT00016016|Drug|cytarabine|Given IV
551105|NCT00016016|Drug|mitoxantrone hydrochloride|Given IV
551106|NCT00016016|Drug|alvocidib|Given IV
551107|NCT00016016|Other|pharmacological study|Correlative studies
551108|NCT00016016|Other|laboratory procedure|Correlative studies
551109|NCT00015977|Biological|PSA prostate cancer vaccine|
551110|NCT00015977|Biological|recombinant interleukin-12|
551111|NCT00015951|Biological|bevacizumab|
551112|NCT00015951|Drug|cytarabine|
551113|NCT00015951|Drug|mitoxantrone hydrochloride|
551114|NCT00015938|Biological|filgrastim|
551115|NCT00015938|Drug|docetaxel|
551116|NCT00015938|Drug|vinorelbine|
551117|NCT00015925|Drug|entinostat|
551118|NCT00015899|Drug|lonafarnib|
551119|NCT00015873|Drug|asparaginase|
551120|NCT00015873|Drug|cytarabine|
551121|NCT00015873|Drug|mercaptopurine|
551122|NCT00015873|Drug|methotrexate|
551123|NCT00015873|Drug|prednisolone|
551124|NCT00015873|Drug|vincristine sulfate|
551125|NCT00015860|Drug|daunorubicin hydrochloride|
551126|NCT00015860|Drug|imatinib mesylate|
551127|NCT00015860|Drug|prednisone|
551128|NCT00015860|Drug|vincristine sulfate|
551129|NCT00015847|Biological|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
551130|NCT00015847|Drug|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
551131|NCT00015834|Drug|imatinib mesylate|Given PO
551132|NCT00015834|Drug|cytarabine|Given IV
551133|NCT00014612|Procedure|axillary lymph node dissection|
551134|NCT00014612|Procedure|lymphoscintigraphy|
551135|NCT00014612|Procedure|therapeutic conventional surgery|
551136|NCT00014612|Radiation|radiation therapy|
551137|NCT00014599|Drug|paclitaxel|
551138|NCT00014586|Drug|bicalutamide|
551139|NCT00014586|Drug|goserelin acetate|
551140|NCT00014586|Procedure|orchiectomy|
551141|NCT00014521|Drug|karenitecin|
551142|NCT00014508|Biological|sargramostim|
551143|NCT00014508|Drug|cyclophosphamide|
551144|NCT00014508|Drug|cyclosporine|
551145|NCT00014508|Drug|fludarabine phosphate|
551146|NCT00014508|Drug|melphalan|
551147|NCT00014508|Procedure|peripheral blood stem cell transplantation|
551148|NCT00014495|Biological|filgrastim|
551149|NCT00014495|Drug|cytarabine|
551150|NCT00014495|Radiation|bismuth Bi213 monoclonal antibody M195|
551151|NCT00014482|Procedure|pain therapy|
551152|NCT00014482|Procedure|psychosocial assessment and care|
551153|NCT00014469|Drug|busulfan|
551154|NCT00014469|Drug|melphalan|
551155|NCT00014469|Drug|methotrexate|
551156|NCT00014469|Drug|tacrolimus|
551157|NCT00014469|Procedure|allogeneic bone marrow transplantation|
551158|NCT00014456|Biological|filgrastim|
551159|NCT00014456|Drug|docetaxel|
551160|NCT00014456|Drug|gemcitabine hydrochloride|
551161|NCT00014443|Drug|thalidomide|
551162|NCT00014443|Drug|topotecan hydrochloride|
551163|NCT00014378|Drug|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
551164|NCT00014326|Radiation|radiation therapy|
551165|NCT00014313|Drug|cisplatin|
551167|NCT00014274|Drug|carboplatin|
551168|NCT00014274|Drug|gemcitabine hydrochloride|
551169|NCT00014274|Drug|methotrexate|
551170|NCT00014274|Drug|vinblastine sulfate|
551171|NCT00014235|Drug|fludarabine phosphate|Given IV
551172|NCT00014235|Radiation|total-body irradiation|Undergo TBI
551173|NCT00014235|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
551174|NCT00014235|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
551175|NCT00014235|Drug|cyclosporine|Given PO or IV
551176|NCT00014235|Drug|mycophenolate mofetil|Given IV or PO
551177|NCT00014235|Other|laboratory biomarker analysis|Correlative studies
551178|NCT00014222|Biological|epoetin alfa|40,000 IU
551179|NCT00014222|Biological|filgrastim|5 mg/kg/d - days 2-13
551180|NCT00014222|Drug|cyclophosphamide|75, 600 and 830 mg/m2
551181|NCT00014222|Drug|doxorubicin hydrochloride|60 mg/m2
551182|NCT00014222|Drug|epirubicin hydrochloride|60 mg/m2
551183|NCT00014222|Drug|fluorouracil|500mg/m2
551184|NCT00014222|Drug|paclitaxel|175 mg/m2
551185|NCT00014196|Drug|cisplatin|
551186|NCT00014196|Drug|docetaxel|
551187|NCT00014196|Radiation|radiation therapy|
551188|NCT00014131|Biological|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
551189|NCT00014118|Drug|carboplatin|
551190|NCT00014118|Drug|paclitaxel|
551191|NCT00014118|Procedure|conventional surgery|
551192|NCT00014118|Radiation|radiation therapy|
551193|NCT00014092|Biological|aldesleukin|
551194|NCT00014092|Biological|recombinant interferon alfa|
551195|NCT00014092|Biological|sargramostim|
551196|NCT00014092|Drug|temozolomide|
551197|NCT00014079|Genetic|DNA stability analysis|
551198|NCT00014079|Genetic|loss of heterozygosity analysis|
551199|NCT00014079|Genetic|microsatellite instability analysis|
551200|NCT00012389|Drug|irinotecan hydrochloride|
551201|NCT00012389|Drug|oxaliplatin|
551202|NCT00012376|Drug|bryostatin 1|Given IV
551203|NCT00012376|Biological|sargramostim|Given subcutaneously
551204|NCT00012376|Other|laboratory biomarker analysis|Correlative studies
551205|NCT00012376|Other|pharmacological study|Correlative studies
551206|NCT00012363|Drug|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 & 8, q 21 days
551207|NCT00012363|Drug|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 & 8, q 21days
551208|NCT00012324|Drug|doxorubicin hydrochloride|
551209|NCT00012324|Drug|nolatrexed dihydrochloride|
551210|NCT00012298|Biological|rituximab|Given IV
551211|NCT00012298|Biological|yttrium Y 90 ibritumomab tiuxetan|Given IV
551212|NCT00012298|Biological|indium In 111 ibritumomab tiuxetan|Given IV
551213|NCT00012298|Biological|oprelvekin|Given subcutaneously
551214|NCT00012298|Biological|filgrastim|Given subcutaneously
551215|NCT00012246|Biological|carcinoembryonic antigen peptide 1-6D|
551216|NCT00012246|Biological|incomplete Freund's adjuvant|
551217|NCT00012246|Biological|sargramostim|
551218|NCT00012220|Drug|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 & 15 of ea cycle
551219|NCT00012220|Drug|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 & 8 of ea treatment cycle
551220|NCT00012220|Drug|gemcitabine hydrochloride|"Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, & 15 of ea cycle~cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 & 8 of ea cycle"
551221|NCT00012220|Drug|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 & 8 of ea cycle
551222|NCT00012207|Biological|aldesleukin|
551223|NCT00012207|Biological|therapeutic autologous lymphocytes|
551224|NCT00012207|Drug|cyclophosphamide|
551225|NCT00012207|Drug|prednisone|
551226|NCT00012207|Drug|vincristine sulfate|
551227|NCT00012207|Procedure|adjuvant therapy|
551228|NCT00012194|Drug|7-hydroxystaurosporine|Given IV
551229|NCT00012194|Drug|cisplatin|Given IV
551230|NCT00012194|Other|laboratory biomarker analysis|Correlative studies
551231|NCT00012181|Drug|alvocidib|Given IV
551232|NCT00012181|Other|pharmacological study|Correlative studies
551233|NCT00012168|Drug|isosulfan blue|
551234|NCT00012168|Genetic|polymerase chain reaction|
551235|NCT00012168|Other|immunohistochemistry staining method|
551236|NCT00012168|Procedure|lymphangiography|
551237|NCT00012168|Procedure|radionuclide imaging|
551238|NCT00012168|Procedure|sentinel lymph node biopsy|
551239|NCT00012168|Radiation|technetium Tc 99m sulfur colloid|
551240|NCT00012103|Other|bronchoalveolar lavage|
551241|NCT00012103|Other|screening questionnaire administration|
551242|NCT00012103|Other|sputum cytology|
551243|NCT00012103|Procedure|bronchoscopic and lung imaging studies|
551244|NCT00012103|Procedure|bronchoscopy|
551245|NCT00012103|Procedure|computed tomography|
551246|NCT00012103|Procedure|study of high risk factors|
551247|NCT00012064|Biological|therapeutic autologous dendritic cells|Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
551248|NCT00012051|Biological|filgrastim|
551249|NCT00012051|Biological|rituximab|
551250|NCT00012051|Drug|carmustine|
551251|NCT00012051|Drug|cisplatin|
551252|NCT00012051|Drug|cytarabine|
551253|NCT00012051|Drug|dexamethasone|
551254|NCT00012051|Drug|etoposide|
551255|NCT00012051|Drug|ifosfamide|
551256|NCT00012051|Drug|melphalan|
551257|NCT00012051|Drug|methotrexate|
551258|NCT00012051|Procedure|bone marrow ablation with stem cell support|
551259|NCT00012051|Procedure|peripheral blood stem cell transplantation|
551260|NCT00012051|Radiation|radiation therapy|
551261|NCT00012038|Drug|irofulven|
551262|NCT00012025|Drug|fulvestrant|
551263|NCT00012012|Drug|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
551264|NCT00012012|Drug|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
551265|NCT00012012|Radiation|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
551266|NCT00012012|Radiation|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
551267|NCT00011999|Drug|cisplatin|
551268|NCT00011999|Drug|paclitaxel|
551269|NCT00011999|Procedure|conventional surgery|
551270|NCT00011999|Radiation|radiation therapy|
551271|NCT00011986|Drug|Paclitaxel|Given IV
551272|NCT00011986|Drug|Carboplatin|Given IV
551273|NCT00011986|Drug|Gemcitabine Hydrochloride|Given IV
551274|NCT00011986|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|
551275|NCT00011986|Drug|Topotecan Hydrochloride|Given IV
551276|NCT00011986|Procedure|Therapeutic Conventional Surgery|Undergo surgery
551277|NCT00011960|Drug|cisplatin|
551278|NCT00011960|Drug|paclitaxel|
551279|NCT00011960|Procedure|adjuvant therapy|
551280|NCT00011960|Radiation|radiation therapy|
551281|NCT00011921|Biological|filgrastim|
551282|NCT00011921|Drug|carboplatin|
551283|NCT00011921|Drug|epirubicin hydrochloride|
551284|NCT00011921|Drug|etoposide|
551285|NCT00011921|Drug|etoposide phosphate|
551286|NCT00011921|Drug|ifosfamide|
551287|NCT00011921|Drug|paclitaxel|
551288|NCT00011921|Procedure|autologous bone marrow transplantation|
551289|NCT00011921|Procedure|bone marrow ablation with stem cell support|
551290|NCT00011921|Procedure|peripheral blood stem cell transplantation|
551291|NCT00011921|Radiation|radiation therapy|
551292|NCT00010270|Biological|LMB-9 immunotoxin|
551293|NCT00010257|Drug|carboplatin|Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
551294|NCT00010257|Drug|paclitaxel|225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
551295|NCT00010218|Drug|karenitecin|
551296|NCT00010205|Drug|benzoylphenylurea|Given orally
551297|NCT00010205|Other|pharmacological study|Correlative studies
551298|NCT00010192|Biological|rituximab|Given IV
551299|NCT00010192|Biological|aldesleukin|Given SC
551300|NCT00010192|Other|laboratory biomarker analysis|Correlative studies
551301|NCT00010192|Other|pharmacological study|Correlative studies
551302|NCT00010166|Drug|gemcitabine hydrochloride|
551303|NCT00010166|Procedure|adjuvant therapy|
551304|NCT00010166|Radiation|radiation therapy|
551305|NCT00010153|Drug|fulvestrant|
551306|NCT00010153|Procedure|conventional surgery|
551307|NCT00010140|Drug|docetaxel|
551308|NCT00010140|Drug|epirubicin hydrochloride|
551309|NCT00010140|Drug|tamoxifen citrate|
551310|NCT00010140|Procedure|adjuvant therapy|
551311|NCT00010075|Drug|fluorouracil|
551312|NCT00010075|Drug|leucovorin calcium|
551313|NCT00010075|Drug|mitoxantrone hydrochloride|
551314|NCT00010062|Drug|fluorouracil|
551315|NCT00010062|Radiation|radiation therapy|
551316|NCT00010049|Drug|imatinib mesylate|
551317|NCT00010023|Drug|capecitabine|
551318|NCT00010023|Drug|cisplatin|
551319|NCT00009984|Drug|fludarabine phosphate|Given IV
551320|NCT00009984|Drug|thalidomide|Given orally
551321|NCT00009971|Drug|fenretinide|
551322|NCT00009945|Drug|clodronate|1600 mg PO daily
551323|NCT00009945|Drug|placebo|2 pills PO daily
551324|NCT00009880|Biological|filgrastim|
551325|NCT00009880|Drug|cisplatin|
551326|NCT00009880|Drug|fluorouracil|
551327|NCT00009880|Drug|paclitaxel|
551328|NCT00009880|Radiation|radiation therapy|
551329|NCT00009854|Drug|carmustine in ethanol|
551330|NCT00009854|Procedure|conventional surgery|
551331|NCT00009776|Biological|monoclonal antibody Lym-1|
551332|NCT00009776|Drug|cyclosporine|
551333|NCT00009776|Drug|paclitaxel|
551334|NCT00009776|Radiation|indium In 111 monoclonal antibody Lym-1|
551335|NCT00009776|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
551336|NCT00009763|Biological|filgrastim|
551337|NCT00009763|Biological|monoclonal antibody m170|
551338|NCT00009763|Drug|cyclosporine|
551339|NCT00009763|Drug|paclitaxel|
551340|NCT00009763|Procedure|peripheral blood stem cell transplantation|
551341|NCT00009763|Radiation|yttrium Y 90 monoclonal antibody m170|
551342|NCT00009750|Biological|filgrastim|
551343|NCT00009750|Biological|monoclonal antibody m170|
551344|NCT00009750|Drug|cyclosporine|
551345|NCT00009750|Drug|paclitaxel|
551346|NCT00009750|Procedure|peripheral blood stem cell transplantation|
551347|NCT00009750|Radiation|indium In 111 monoclonal antibody m170|
551348|NCT00009750|Radiation|yttrium Y 90 monoclonal antibody m170|
551349|NCT00009711|Procedure|management of therapy complications|
551350|NCT00008697|Drug|arsenic trioxide|
551351|NCT00008437|Device|high-intensity focused ultrasound ablation|
551352|NCT00008411|Drug|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
551353|NCT00008411|Drug|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
551354|NCT00008385|Other|placebo|Given orally
551355|NCT00008385|Drug|selenium|Given orally
551356|NCT00008346|Diagnostic Test|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
551357|NCT00008346|Diagnostic Test|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
551358|NCT00008307|Biological|anti-thymocyte globulin|
551359|NCT00008307|Drug|cyclosporine|
551360|NCT00008307|Drug|fludarabine phosphate|
551361|NCT00008307|Drug|melphalan|
551362|NCT00008307|Drug|methylprednisolone|
551363|NCT00008307|Drug|mycophenolate mofetil|
551364|NCT00008307|Procedure|allogeneic bone marrow transplantation|
551365|NCT00008307|Procedure|peripheral blood stem cell transplantation|
551366|NCT00008307|Procedure|syngeneic bone marrow transplantation|
551367|NCT00008294|Drug|FOLFOX regimen|
551368|NCT00008294|Drug|dexamethasone|
551369|NCT00008294|Drug|floxuridine|
551370|NCT00008294|Drug|fluorouracil|
551371|NCT00008294|Drug|leucovorin calcium|
551372|NCT00008294|Drug|oxaliplatin|
551373|NCT00008268|Biological|filgrastim|
551374|NCT00008268|Drug|melphalan|
551375|NCT00008216|Procedure|Peripheral Blood Stem Cell Transplantation|
551376|NCT00008190|Biological|aldesleukin|
551377|NCT00008190|Biological|filgrastim|
551378|NCT00008190|Drug|busulfan|
551379|NCT00008190|Drug|cyclophosphamide|
551380|NCT00008190|Drug|etoposide|
551381|NCT00008190|Drug|melphalan|
551382|NCT00008190|Procedure|peripheral blood stem cell transplantation|
551383|NCT00008164|Procedure|umbilical cord blood transplantation|
551384|NCT00008138|Drug|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
551385|NCT00008138|Drug|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
551386|NCT00008138|Procedure|debulking surgery|exploratory laparotomy, interval cytoreduction (to < 1 cm residual)
551387|NCT00008060|Drug|FOLFIRI regimen|
551388|NCT00008060|Drug|FOLFOX regimen|
551389|NCT00008060|Drug|fluorouracil|
551390|NCT00008060|Drug|irinotecan hydrochloride|
551391|NCT00008060|Drug|leucovorin calcium|
551392|NCT00008060|Drug|oxaliplatin|
551393|NCT00008047|Drug|fluorouracil|
551394|NCT00008047|Drug|hydroxyurea|
551395|NCT00008047|Drug|paclitaxel|
551396|NCT00008047|Procedure|conventional surgery|
551397|NCT00008047|Radiation|radiation therapy|
551398|NCT00008008|Biological|filgrastim|
551399|NCT00008008|Biological|sargramostim|
551400|NCT00008008|Drug|cyclophosphamide|
551401|NCT00008008|Drug|thiotepa|
551402|NCT00008008|Procedure|autologous bone marrow transplantation|
551403|NCT00008008|Procedure|bone marrow ablation with stem cell support|
551404|NCT00008008|Procedure|peripheral blood stem cell transplantation|
551405|NCT00007995|Biological|filgrastim|
551406|NCT00007995|Biological|recombinant interferon alfa|
551407|NCT00007995|Biological|sargramostim|
551408|NCT00007995|Drug|busulfan|
551409|NCT00007995|Drug|cyclophosphamide|
551410|NCT00007995|Drug|melphalan|
551411|NCT00007995|Procedure|autologous bone marrow transplantation|
551412|NCT00007995|Procedure|bone marrow ablation with stem cell support|
551413|NCT00007995|Procedure|peripheral blood stem cell transplantation|
551414|NCT00007982|Biological|filgrastim|
551415|NCT00007982|Drug|carmustine|
551416|NCT00007982|Drug|cisplatin|
551417|NCT00007982|Drug|cyclophosphamide|
551418|NCT00007982|Drug|etoposide|
551419|NCT00007982|Drug|thiotepa|
551420|NCT00007982|Procedure|adjuvant therapy|
551421|NCT00007982|Procedure|autologous bone marrow transplantation|
551422|NCT00007982|Procedure|bone marrow ablation with stem cell support|
551423|NCT00007982|Procedure|peripheral blood stem cell transplantation|
551424|NCT00007956|Biological|monoclonal antibody mono-dgA-RFB4|
551425|NCT00007930|Procedure|conventional surgery|
551426|NCT00007930|Procedure|laparoscopic surgery|
551427|NCT00007904|Biological|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC > 10,000/uL x1 day after the nadir cycles 1-3.
551428|NCT00007904|Drug|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
551429|NCT00007904|Drug|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
551430|NCT00007904|Drug|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
551431|NCT00007904|Drug|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
551432|NCT00007904|Procedure|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
551433|NCT00007904|Radiation|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
551434|NCT00007891|Biological|filgrastim|
551435|NCT00007891|Procedure|autologous bone marrow transplantation|
551436|NCT00007891|Procedure|peripheral blood stem cell transplantation|
551437|NCT00007891|Radiation|indium In 111 monoclonal antibody BrE-3|
551438|NCT00007891|Radiation|yttrium Y 90 monoclonal antibody BrE-3|
551439|NCT00007865|Biological|rituximab|
551440|NCT00007865|Drug|carboplatin|
551441|NCT00007865|Drug|etoposide|
551442|NCT00007865|Drug|ifosfamide|
551443|NCT00007826|Biological|BCG vaccine|
551444|NCT00007826|Biological|monoclonal antibody 105AD7 anti-idiotype vaccine|
551445|NCT00007826|Drug|alum adjuvant|
551446|NCT00006994|Dietary Supplement|glutamine|20 cc three times daily for 60 days
551447|NCT00006994|Radiation|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
551448|NCT00006994|Drug|l-glutamine placebo|20 cc three times daily for 60 days
551449|NCT00006981|Biological|SS1(dsFv)-PE38 immunotoxin|
551450|NCT00006942|Drug|bryostatin 1|Given IV
551451|NCT00006942|Drug|cisplatin|Given IV
551452|NCT00006942|Other|laboratory biomarker analysis|Correlative studies
551453|NCT00006929|Drug|suramin|Given IV
551454|NCT00006929|Drug|carboplatin|Given IV
551455|NCT00006929|Drug|paclitaxel|Given IV
551456|NCT00006929|Other|pharmacological study|Correlative studies
551457|NCT00006929|Other|laboratory biomarker analysis|Correlative studies
551458|NCT00006916|Biological|bleomycin|
551459|NCT00006916|Device|Ommaya reservoir|
551460|NCT00006916|Radiation|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
551461|NCT00006903|Drug|Fulvestrant|Given intramuscularly
551462|NCT00006825|Biological|trastuzumab|
551463|NCT00006825|Drug|pegylated liposomal doxorubicin hydrochloride|
551464|NCT00006773|Drug|bortezomib|Given IV
551465|NCT00006760|Biological|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
551466|NCT00006760|Drug|ifosfamide|V over 24 hours on days 1-4
551467|NCT00006760|Drug|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
551468|NCT00006747|Drug|carmustine|IV
551469|NCT00006747|Drug|melphalan|IV
551470|NCT00006747|Drug|etoposide|IV
551471|NCT00006747|Drug|cytarabine|IV
551472|NCT00006747|Drug|tacrolimus|IV
551473|NCT00006747|Drug|methotrexate|IV
551474|NCT00006747|Drug|sargramostim|IV
551475|NCT00006747|Procedure|transplant|
551476|NCT00006734|Biological|filgrastim|Given IV
551477|NCT00006734|Drug|cyclophosphamide|Given IV
551478|NCT00006734|Drug|doxorubicin hydrochloride|Given IV
551479|NCT00006734|Drug|etoposide|Given IV
551480|NCT00006734|Drug|ifosfamide|Given IV
551481|NCT00006734|Drug|vincristine sulfate|Given IV
551482|NCT00006734|Procedure|adjuvant therapy|
551483|NCT00006734|Procedure|conventional surgery|
551484|NCT00006734|Procedure|neoadjuvant therapy|
551485|NCT00006734|Radiation|brachytherapy|
551486|NCT00006734|Radiation|radiation therapy|
551487|NCT00006721|Biological|rituximab|Given IV
551488|NCT00006721|Drug|cyclophosphamide|Given IV
551489|NCT00006721|Drug|doxorubicin|Given IV
551490|NCT00006721|Drug|prednisone|Given orally
551491|NCT00006721|Drug|vincristine|Given IV
551492|NCT00006721|Radiation|tositumomab|Given IV
551493|NCT00006695|Drug|carmustine|300 mg/m2 IV on Day -6
551494|NCT00006695|Drug|cytarabine|100 mg/m2 BID on Days -5 through -2
551495|NCT00006695|Drug|etoposide|100 mg/m2 BID on Days -5 through -2
551496|NCT00006695|Drug|melphalan|140 mg/m2 IV on Day -1
551497|NCT00006695|Procedure|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
551498|NCT00006695|Radiation|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
551499|NCT00006656|Drug|carmustine in ethanol|
551500|NCT00006656|Procedure|conventional surgery|
551501|NCT00006485|Drug|alvocidib|
551502|NCT00006485|Drug|irinotecan hydrochloride|
551503|NCT00006479|Drug|FOLFOX regimen|
551504|NCT00006479|Drug|fluorouracil|
551505|NCT00006479|Drug|leucovorin calcium|
551506|NCT00006479|Drug|oxaliplatin|
551507|NCT00006479|Procedure|adjuvant therapy|
551508|NCT00006479|Procedure|conventional surgery|
551509|NCT00006479|Procedure|neoadjuvant therapy|
551510|NCT00006478|Biological|autologous tumor cell vaccine|
551511|NCT00006478|Biological|keyhole limpet hemocyanin|
551512|NCT00006478|Biological|sargramostim|
551513|NCT00006478|Procedure|adjuvant therapy|
551514|NCT00006477|Dietary Supplement|mistletoe extract|
551515|NCT00006476|Drug|suramin|
551516|NCT00006476|Procedure|conventional surgery|
551517|NCT00006474|Drug|O6-benzylguanine|
551518|NCT00006474|Drug|temozolomide|
551519|NCT00006474|Procedure|conventional surgery|
551520|NCT00006473|Drug|oxaliplatin|Given IV
551521|NCT00006471|Drug|Fenretinide|1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
551522|NCT00006470|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
551523|NCT00006470|Biological|monoclonal antibody 3H1 anti-idiotype vaccine|
551524|NCT00006470|Radiation|radiation therapy|
551525|NCT00006469|Drug|carboplatin|
551526|NCT00006469|Drug|paclitaxel|
551527|NCT00006469|Procedure|conventional surgery|
551528|NCT00006469|Procedure|neoadjuvant therapy|
551529|NCT00006469|Radiation|radiation therapy|
551530|NCT00006468|Drug|FOLFOX regimen|
551531|NCT00006468|Drug|fluorouracil|
551532|NCT00006468|Drug|leucovorin calcium|
551533|NCT00006468|Drug|oxaliplatin|
551534|NCT00006465|Drug|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
551535|NCT00006465|Drug|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
551536|NCT00006465|Drug|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
551537|NCT00006462|Drug|gemcitabine hydrochloride|
551538|NCT00006461|Drug|cisplatin|Given IV
551539|NCT00006461|Drug|cyclophosphamide|Given IV
551540|NCT00006461|Drug|vincristine sulfate|Given IV
551541|NCT00006461|Drug|etoposide|Given PO
551542|NCT00006461|Procedure|therapeutic conventional surgery|Undergo surgery
551543|NCT00006461|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
551544|NCT00006456|Radiation|stereotactic radiosurgery|
551545|NCT00006455|Drug|cyclophosphamide|
551546|NCT00006455|Drug|cytarabine|
551547|NCT00006455|Drug|dexamethasone|
551548|NCT00006455|Drug|doxorubicin hydrochloride|
551549|NCT00006455|Drug|etoposide|
551550|NCT00006455|Drug|ifosfamide|
551551|NCT00006455|Drug|leucovorin calcium|
551552|NCT00006455|Drug|methotrexate|
551553|NCT00006455|Drug|therapeutic hydrocortisone|
551554|NCT00006455|Drug|vinblastine sulfate|
551555|NCT00006392|Drug|Vitamin E|400 IU daily by mouth for 7-12 years
551556|NCT00006392|Drug|Selenium|200 mcg daily for 7-12 years
551557|NCT00006392|Other|Vitamin E placebo|daily for 7-12 years
551558|NCT00006392|Other|selenium placebo|daily for 7-12 years
551559|NCT00006391|Drug|oxaliplatin|
551560|NCT00006391|Drug|topotecan hydrochloride|
551561|NCT00006390|Biological|alemtuzumab|
551562|NCT00006390|Biological|filgrastim|
551563|NCT00006390|Drug|cyclophosphamide|
551564|NCT00006390|Procedure|peripheral blood stem cell transplantation|
551565|NCT00006390|Radiation|radiation therapy|
551566|NCT00006389|Drug|bryostatin 1|Given IV
551567|NCT00006389|Drug|cisplatin|Given IV
551568|NCT00006389|Other|laboratory biomarker analysis|Correlative studies
551569|NCT00006386|Drug|carmustine|
551570|NCT00006386|Radiation|radiation therapy|
551571|NCT00006386|Radiation|stereotactic radiosurgery|
551572|NCT00006385|Biological|MART-1 antigen|
551573|NCT00006385|Biological|gp100 antigen|
551574|NCT00006385|Biological|incomplete Freund's adjuvant|
551575|NCT00006385|Biological|recombinant interferon alfa|
551576|NCT00006385|Biological|sargramostim|
551577|NCT00006385|Biological|tyrosinase peptide|
551578|NCT00006381|Biological|trastuzumab|
551579|NCT00006381|Drug|celecoxib|
551580|NCT00006379|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
551581|NCT00006379|Biological|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
551582|NCT00006379|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
551583|NCT00006379|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
551584|NCT00006379|Procedure|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
551585|NCT00006373|Drug|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
551586|NCT00006373|Drug|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
551587|NCT00006373|Drug|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
551588|NCT00006373|Procedure|autologous bone marrow transplantation|
551589|NCT00006373|Drug|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
551590|NCT00006372|Drug|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
551591|NCT00006372|Drug|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
551592|NCT00006372|Drug|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
551593|NCT00006366|Drug|fluorouracil|
551594|NCT00006366|Drug|irinotecan hydrochloride|
551595|NCT00006366|Procedure|conventional surgery|
551596|NCT00006366|Radiation|radiation therapy|
551597|NCT00006364|Drug|omacetaxine mepesuccinate|Given IV or SC
551598|NCT00006364|Other|pharmacological study|Correlative studies
551599|NCT00006364|Other|laboratory biomarker analysis|Correlative studies
551600|NCT00006363|Drug|cytarabine|Given IV
551601|NCT00006363|Drug|daunorubicin hydrochloride|Given IV
551602|NCT00006363|Drug|etoposide|Given IV
551603|NCT00006363|Drug|valspodar|Given IV
551604|NCT00006363|Biological|filgrastim|Given SC
551605|NCT00006363|Drug|busulfan|Given orally
551606|NCT00006363|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
551607|NCT00006363|Procedure|peripheral blood stem cell transplantation|Undergo autologous PBSCT
551608|NCT00006363|Biological|aldesleukin|Given SC
551609|NCT00006363|Other|clinical observation|Undergo clinical observation
551610|NCT00006363|Other|pharmacological study|Correlative studies
551611|NCT00006362|Drug|bortezomib|
551612|NCT00006360|Drug|radioprotection|
551613|NCT00006360|Radiation|radiation therapy|
551614|NCT00006359|Drug|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
551615|NCT00006359|Drug|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
551616|NCT00006359|Radiation|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
551617|NCT00006359|Radiation|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
551618|NCT00006356|Drug|carboplatin|
551619|NCT00006356|Drug|cisplatin|
551620|NCT00006356|Procedure|conventional surgery|
551621|NCT00006355|Drug|pyrazoloacridine|
551622|NCT00006355|Procedure|adjuvant therapy|
551623|NCT00006355|Radiation|radiation therapy|
551624|NCT00006354|Dietary Supplement|mistletoe extract|
551625|NCT00006351|Drug|gemcitabine hydrochloride|
551626|NCT00006351|Drug|lonafarnib|
551627|NCT00006347|Radiation|indium In 111 monoclonal antibody MN-14|
551628|NCT00006347|Radiation|yttrium Y 90 monoclonal antibody MN-14|
551629|NCT00006340|Drug|arginine butyrate|
551630|NCT00006340|Drug|ganciclovir|
551631|NCT00006268|Biological|cintredekin besudotox|
551632|NCT00006268|Drug|isolated perfusion|
551633|NCT00006268|Procedure|conventional surgery|
551634|NCT00006267|Drug|rubitecan|
551635|NCT00006264|Biological|aldesleukin|
551636|NCT00006264|Drug|ganciclovir|
551637|NCT00006264|Drug|zidovudine|
551638|NCT00006263|Biological|filgrastim|
551639|NCT00006263|Drug|carboplatin|
551640|NCT00006263|Drug|temozolomide|
551641|NCT00006260|Drug|cisplatin|cisplatin IV over 30 minutes on days 1-3.
551642|NCT00006260|Drug|etoposide|etoposide IV over 60-90 minutes on days 1-3.
551643|NCT00006260|Drug|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
551644|NCT00006260|Drug|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
551645|NCT00006258|Biological|filgrastim|
551646|NCT00006258|Drug|cisplatin|
551647|NCT00006258|Drug|cyclophosphamide|
551648|NCT00006258|Drug|etoposide|
551649|NCT00006258|Drug|methotrexate|
551650|NCT00006258|Drug|vincristine sulfate|
551651|NCT00006258|Procedure|adjuvant therapy|
551652|NCT00006258|Radiation|radiation therapy|
551653|NCT00006256|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
551654|NCT00006256|Procedure|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
551655|NCT00006256|Radiation|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
551656|NCT00006255|Procedure|radiofrequency ablation|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
551657|NCT00006255|Procedure|thermal ablation therapy|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
551658|NCT00006252|Drug|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
551659|NCT00006252|Drug|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
551660|NCT00006252|Biological|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
551661|NCT00006252|Drug|G-CSF|5 ug/kg/day subQ injection until ANC > 1000/uL for 3 days beginning Day 5
551662|NCT00006252|Biological|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
551663|NCT00006250|Drug|chlorambucil|
551664|NCT00006250|Drug|dexamethasone|
551665|NCT00006250|Drug|fludarabine phosphate|
551666|NCT00006250|Drug|mitoxantrone hydrochloride|
551667|NCT00006249|Biological|pegylated interferon alfa|
551668|NCT00006249|Procedure|adjuvant therapy|
551669|NCT00006248|Drug|cisplatin|
551670|NCT00006248|Drug|fluorouracil|
551671|NCT00006248|Drug|paclitaxel|
551672|NCT00006246|Drug|busulfan|
551673|NCT00006245|Drug|alvocidib|
551674|NCT00006245|Drug|paclitaxel|
551675|NCT00006244|Drug|melphalan|Given IV
551676|NCT00006244|Biological|recombinant interferon alfa|Given SC
551677|NCT00006244|Biological|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
551678|NCT00006244|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
551679|NCT00006239|Drug|sodium phenylbutyrate|
551680|NCT00006239|Drug|tretinoin|
551681|NCT00006237|Biological|interleukin-2|Given IV
551682|NCT00006237|Biological|filgrastim|Given subcutaneously
551683|NCT00006237|Biological|interferon alfa|Given IV and subcutaneously
551684|NCT00006237|Drug|cisplatin|Given IV
551685|NCT00006237|Drug|dacarbazine|Given IV
551686|NCT00006237|Drug|vinblastine|Given IV
551687|NCT00006234|Procedure|peripheral blood stem cell transplantation|
551688|NCT00006234|Radiation|holmium Ho 166 DOTMP|
551689|NCT00006233|Biological|therapeutic allogeneic lymphocytes|
551690|NCT00006233|Drug|cyclosporine|
551691|NCT00006233|Drug|fludarabine phosphate|
551692|NCT00006233|Drug|mycophenolate mofetil|
551693|NCT00006233|Procedure|peripheral blood stem cell transplantation|
551694|NCT00006233|Radiation|radiation therapy|
551695|NCT00006232|Drug|dexamethasone|
551696|NCT00006232|Drug|doxorubicin hydrochloride|
551697|NCT00006232|Drug|idarubicin|
551698|NCT00006232|Drug|vincristine sulfate|
551699|NCT00006231|Procedure|quality-of-life assessment|
551700|NCT00006231|Procedure|standard follow-up care|
551701|NCT00006231|Radiation|radiation therapy|
551702|NCT00006230|Drug|rubitecan|
551703|NCT00006228|Biological|trastuzumab|Given IV
551704|NCT00006228|Biological|aldesleukin|Given SC
551705|NCT00006228|Other|laboratory biomarker analysis|Correlative studies
551706|NCT00006228|Other|pharmacological study|Correlative studies
551707|NCT00006227|Drug|Paclitaxel|Given IV
551708|NCT00006226|Drug|thalidomide|Given PO
551709|NCT00006226|Other|laboratory biomarker analysis|Correlative studies
551710|NCT00006221|Drug|ixabepilone|
551711|NCT00006219|Drug|clarithromycin|
551712|NCT00006219|Drug|prasterone|
551713|NCT00006125|Drug|doxorubicin hydrochloride|
551714|NCT00006125|Drug|topotecan hydrochloride|
551715|NCT00006124|Drug|celecoxib|Given orally
551716|NCT00006124|Drug|placebo|Given orally
551717|NCT00006120|Drug|docetaxel|
551718|NCT00006120|Drug|paclitaxel|
551719|NCT00006119|Drug|hydroxyurea|
551720|NCT00006118|Drug|cisplatin|
551721|NCT00006118|Drug|gemcitabine hydrochloride|
551722|NCT00006118|Drug|paclitaxel|
551723|NCT00006114|Drug|mitoxantrone hydrochloride|
551724|NCT00006114|Drug|vinorelbine tartrate|
551725|NCT00006113|Biological|MART-1 antigen|
551726|NCT00006113|Biological|aldesleukin|
551727|NCT00006113|Biological|gp100 antigen|
551728|NCT00006113|Biological|recombinant CD40-ligand|
551729|NCT00006113|Biological|recombinant interferon gamma|
551730|NCT00006113|Biological|recombinant interleukin-4|
551731|NCT00006113|Biological|sargramostim|
551732|NCT00006113|Biological|therapeutic autologous dendritic cells|
551733|NCT00006113|Biological|therapeutic tumor infiltrating lymphocytes|
551734|NCT00006113|Biological|tyrosinase peptide|
551735|NCT00006113|Radiation|Candida albicans skin test reagent|
551736|NCT00006110|Biological|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
551737|NCT00006110|Drug|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
551738|NCT00006110|Drug|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
551739|NCT00006110|Drug|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
551740|NCT00006110|Procedure|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
551741|NCT00006107|Drug|Taxotere|
551742|NCT00006107|Procedure|Surgery|
551743|NCT00006107|Radiation|radiation therapy|
551744|NCT00006105|Drug|amifostine trihydrate|
551745|NCT00006105|Drug|cisplatin|
551746|NCT00006105|Drug|gemcitabine hydrochloride|
551747|NCT00006105|Procedure|adjuvant therapy|
551748|NCT00006102|Drug|becatecarin|
551749|NCT00006101|Drug|eflornithine|Take 500mg of DFMO per day for 12 months
551750|NCT00006101|Drug|Placebo|Take placebo per day for 12 months
551751|NCT00006100|Biological|aldesleukin|
551752|NCT00006100|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
551753|NCT00006100|Drug|fludarabine phosphate|
551754|NCT00006100|Procedure|peripheral blood stem cell transplantation|
551755|NCT00006094|Drug|oxaliplatin|Given IV
551756|NCT00006094|Drug|fluorouracil|Given IV
551757|NCT00006094|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
551758|NCT00006093|Drug|cilengitide|
551759|NCT00006092|Drug|Arsenic Trioxide|
551760|NCT00006089|Other|Laboratory Biomarker Analysis|Correlative studies
551761|NCT00006089|Biological|Trastuzumab|Given IV
551762|NCT00006078|Dietary Supplement|lycopene|
551763|NCT00006044|Drug|therapeutic testosterone|
551764|NCT00006042|Biological|filgrastim|
551765|NCT00006042|Drug|cyclophosphamide|
551766|NCT00006042|Drug|fludarabine phosphate|
551767|NCT00006042|Drug|mycophenolate mofetil|
551768|NCT00006042|Drug|tacrolimus|
551769|NCT00006042|Procedure|allogeneic bone marrow transplantation|
551770|NCT00006042|Radiation|radiation therapy|
551771|NCT00006040|Biological|filgrastim|
551772|NCT00006040|Drug|etoposide|
551773|NCT00006040|Procedure|autologous bone marrow transplantation|
551774|NCT00006040|Procedure|peripheral blood stem cell transplantation|
551775|NCT00006040|Radiation|yttrium Y 90 monoclonal antibody M195|
551776|NCT00006029|Drug|gemcitabine hydrochloride|
551777|NCT00006029|Drug|pegylated liposomal doxorubicin hydrochloride|
551778|NCT00006029|Drug|vinorelbine tartrate|
551779|NCT00006028|Drug|cisplatin|
551780|NCT00006028|Drug|gemcitabine hydrochloride|
551781|NCT00006027|Drug|cisplatin|
551782|NCT00006027|Drug|paclitaxel|
551783|NCT00006027|Procedure|adjuvant therapy|
551784|NCT00006027|Radiation|radiation therapy|
551785|NCT00006025|Drug|irinotecan hydrochloride|
551786|NCT00006025|Drug|temozolomide|
551787|NCT00006024|Drug|lomustine|
551788|NCT00006024|Drug|temozolomide|
551789|NCT00006022|Biological|aldesleukin|
551790|NCT00006022|Drug|bryostatin 1|
551791|NCT00006021|Dietary Supplement|ascorbic acid|
551792|NCT00006021|Drug|arsenic trioxide|
551793|NCT00006020|Drug|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
551794|NCT00006017|Drug|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
551795|NCT00006016|Drug|thalidomide|Given orally
551796|NCT00006016|Drug|doxorubicin hydrochloride|Given transarterially (chemoembolization)
551797|NCT00006016|Other|laboratory biomarker analysis|Correlative studies
551798|NCT00006015|Biological|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, & 22)
551799|NCT00006015|Drug|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
551800|NCT00006015|Drug|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
551801|NCT00006015|Drug|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 & 15 of each cycle
551802|NCT00006011|Drug|Doxorubicin Hydrochloride|Given IV
551803|NCT00006011|Drug|Cisplatin|Given IV
551804|NCT00006011|Biological|Filgrastim|Given SC
551805|NCT00006011|Biological|Pegfilgrastim|Given SC
551806|NCT00006011|Drug|Paclitaxel|Given IV
551807|NCT00006010|Drug|docetaxel|
551808|NCT00006010|Drug|gemcitabine hydrochloride|
551809|NCT00006007|Drug|gemcitabine hydrochloride|
551810|NCT00006007|Drug|pemetrexed disodium|
551811|NCT00006006|Biological|recombinant interferon alfa|
551812|NCT00006006|Drug|thalidomide|
551813|NCT00006005|Drug|thalidomide|
551814|NCT00006004|Drug|carboplatin|
551815|NCT00006004|Drug|cisplatin|
551816|NCT00006004|Drug|gemcitabine hydrochloride|
551817|NCT00006004|Drug|paclitaxel|
551818|NCT00006003|Drug|semaxanib|Given IV
551819|NCT00006003|Other|laboratory biomarker analysis|Correlative studies
551820|NCT00005997|Drug|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
551821|NCT00005990|Drug|tipifarnib|
551822|NCT00005990|Drug|topotecan hydrochloride|
551823|NCT00005987|Drug|carmustine|
551824|NCT00005987|Drug|cyclophosphamide|
551825|NCT00005987|Drug|dexamethasone|
551826|NCT00005987|Drug|etoposide|
551827|NCT00005987|Drug|filgrastim|
551828|NCT00005987|Drug|mitoxantrone hydrochloride|
551829|NCT00005987|Drug|recombinant interferon alfa|
551830|NCT00005987|Drug|sargramostim|
551831|NCT00005987|Procedure|bone marrow ablation with stem cell support|
551832|NCT00005987|Procedure|peripheral blood stem cell transplantation|
551833|NCT00005987|Procedure|radiation therapy|
551834|NCT00005985|Biological|filgrastim|
551835|NCT00005985|Drug|carmustine|
551836|NCT00005985|Drug|cyclophosphamide|
551837|NCT00005985|Drug|cytarabine|
551838|NCT00005985|Drug|dexamethasone|
551839|NCT00005985|Drug|etoposide|
551840|NCT00005985|Drug|mitoxantrone hydrochloride|
551841|NCT00005985|Procedure|peripheral blood stem cell transplantation|
551842|NCT00005985|Radiation|radiation therapy|
551843|NCT00005984|Drug|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
551844|NCT00005984|Drug|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
551845|NCT00005984|Drug|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
551846|NCT00005984|Procedure|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
551847|NCT00005984|Procedure|radiation therapy|total body irradiation twice a day on days -4 through -1
551848|NCT00005983|Radiation|radiation therapy|
551849|NCT00005983|Procedure|surgery|surgery
551850|NCT00005982|Drug|nelarabine|Given IV
551851|NCT00005982|Other|pharmacological study|Correlative studies
551852|NCT00005981|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
551853|NCT00005981|Drug|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
551854|NCT00005980|Drug|pegylated liposomal doxorubicin hydrochloride|
551855|NCT00005979|Drug|FOLFIRI regimen|
551856|NCT00005979|Drug|fluorouracil|
551857|NCT00005979|Drug|irinotecan hydrochloride|
551858|NCT00005979|Drug|leucovorin calcium|
551859|NCT00005976|Drug|carboplatin|
551860|NCT00005976|Drug|pyrazoloacridine|
551861|NCT00005973|Drug|BMS-214662|Given IV
551862|NCT00005973|Other|laboratory biomarker analysis|Correlative studies
551863|NCT00005970|Drug|Aromatase Inhibition Therapy|Given orally
551864|NCT00005970|Drug|Cyclophosphamide|Given IV
551865|NCT00005970|Drug|Doxorubicin Hydrochloride|Given IV
551866|NCT00005970|Other|Laboratory Biomarker Analysis|Correlative studies
551867|NCT00005970|Drug|Paclitaxel|Given IV
551868|NCT00005970|Drug|Tamoxifen Citrate|Given orally
551869|NCT00005970|Biological|Trastuzumab|Given IV
551870|NCT00005967|Drug|tipifarnib|
551871|NCT00005966|Biological|recombinant interferon alfa|
551872|NCT00005966|Drug|thalidomide|
551873|NCT00005961|Drug|O6-benzylguanine|
551874|NCT00005961|Drug|carmustine|
551875|NCT00005957|Radiation|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
551876|NCT00005957|Radiation|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
551877|NCT00005955|Drug|temozolomide|
551878|NCT00005954|Drug|temozolomide|
551879|NCT00005952|Biological|filgrastim|
551880|NCT00005952|Drug|temozolomide|
551881|NCT00005952|Procedure|peripheral blood stem cell transplantation|
551882|NCT00005951|Drug|irinotecan hydrochloride|
551883|NCT00005951|Drug|temozolomide|
551884|NCT00005949|Biological|aldesleukin|Given SC
551885|NCT00005949|Biological|gp100:209-217(210M) peptide vaccine|Given SC
551886|NCT00005949|Other|laboratory biomarker analysis|Correlative studies
551887|NCT00005945|Drug|cyclophosphamide|Given IV
551888|NCT00005945|Drug|cytarabine|Given IT
551889|NCT00005945|Drug|daunorubicin hydrochloride|Given IV
551890|NCT00005945|Drug|dexamethasone|Given PO
551891|NCT00005945|Drug|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
551892|NCT00005945|Drug|mercaptopurine|Given PO
551893|NCT00005945|Drug|methotrexate|Given PO and IT
551894|NCT00005945|Drug|pegaspargase|Given IM
551895|NCT00005945|Drug|thioguanine|Given PO
551896|NCT00005945|Drug|vincristine sulfate|Given IV
551897|NCT00005945|Radiation|radiation therapy|Undergo radiation therapy
551898|NCT00005941|Biological|therapeutic allogeneic lymphocytes|
551899|NCT00005941|Drug|cyclosporine|
551900|NCT00005941|Drug|fludarabine phosphate|
551901|NCT00005941|Drug|mycophenolate mofetil|
551902|NCT00005941|Procedure|peripheral blood stem cell transplantation|
551903|NCT00005941|Radiation|radiation therapy|
551904|NCT00005879|Drug|arzoxifene|one tablet daily
551905|NCT00005879|Drug|Placebo|matched tablet dialy
551906|NCT00005878|Drug|celecoxib|
551907|NCT00005867|Biological|bleomycin sulfate|
551908|NCT00005867|Drug|CHOP regimen|
551909|NCT00005867|Drug|cyclophosphamide|
551910|NCT00005867|Drug|doxorubicin hydrochloride|
551911|NCT00005867|Drug|etoposide|
551912|NCT00005867|Drug|mitoxantrone hydrochloride|
551913|NCT00005867|Drug|prednisolone|
551914|NCT00005867|Drug|vincristine sulfate|
551915|NCT00005863|Biological|filgrastim|
551916|NCT00005863|Drug|cytarabine|
551917|NCT00005863|Drug|daunorubicin hydrochloride|
551918|NCT00005863|Drug|etoposide|
551919|NCT00005863|Drug|fludarabine phosphate|
551920|NCT00005863|Drug|tretinoin|
551921|NCT00005859|Drug|tipifarnib|
551922|NCT00005858|Biological|LMB-9 immunotoxin|
551923|NCT00005856|Drug|oxaliplatin|Given IV
551924|NCT00005856|Other|pharmacological study|Correlative studies
551925|NCT00005855|Drug|carmustine|
551926|NCT00005855|Drug|efaproxiral|
551927|NCT00005853|Biological|anti-thymocyte globulin|
551928|NCT00005853|Biological|etanercept|
551929|NCT00005851|Drug|fludarabine phosphate|Given IV
551930|NCT00005851|Radiation|total-body irradiation|Undergo TBI
551931|NCT00005851|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
551932|NCT00005851|Drug|cyclosporine|Given PO or IV
551933|NCT00005851|Drug|mycophenolate mofetil|Given PO or IV
551934|NCT00005851|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
551935|NCT00005851|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
551936|NCT00005851|Other|laboratory biomarker analysis|Correlative studies
551937|NCT00005850|Drug|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
551938|NCT00005850|Drug|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
551939|NCT00005850|Drug|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
551940|NCT00005847|Biological|recombinant interferon alfa|
551941|NCT00005847|Drug|estramustine phosphate sodium|
551942|NCT00005847|Drug|isotretinoin|
551943|NCT00005847|Drug|mitoxantrone hydrochloride|
551944|NCT00005847|Drug|paclitaxel|
551945|NCT00005847|Drug|vinorelbine ditartrate|
551946|NCT00005844|Drug|oxaliplatin|
551947|NCT00005840|Drug|Paclitaxel|Given IV
551948|NCT00005840|Drug|Cisplatin|Given IV
551949|NCT00005840|Radiation|Radiation Therapy|Undergo whole abdominal radiation therapy
551950|NCT00005838|Drug|shark cartilage extract AE-941|Given orally
551951|NCT00005838|Other|placebo|Given orally
551952|NCT00005838|Drug|cisplatin|Given IV
551953|NCT00005838|Drug|vinorelbine tartrate|Given IV
551954|NCT00005838|Drug|carboplatin|Given IV
551955|NCT00005838|Drug|paclitaxel|Given IV
551956|NCT00005838|Radiation|radiation therapy|Undergo radiotherapy
551957|NCT00005835|Drug|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
551958|NCT00005835|Drug|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
551959|NCT00005835|Procedure|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
551960|NCT00005835|Other|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC >/= 1500 mm3 for three consecutive days.
551961|NCT00005831|Biological|trastuzumab|Given IV
551962|NCT00005831|Drug|paclitaxel|Given IV
551963|NCT00005831|Drug|carboplatin|Given IV
551964|NCT00005831|Drug|gemcitabine hydrochloride|Given IV
551965|NCT00005831|Other|laboratory biomarker analysis|Correlative studies
551966|NCT00005830|Drug|Doxorubicin Hydrochloride|Given IV
551967|NCT00005830|Drug|Cisplatin|Given IV
551968|NCT00005830|Radiation|Radiation Therapy|Undergo radiation therapy
551969|NCT00005825|Drug|cisplatin|
551970|NCT00005825|Drug|mitomycin C|
551971|NCT00005825|Drug|tretinoin|
551972|NCT00005825|Drug|vinorelbine tartrate|
551973|NCT00005824|Biological|filgrastim|
551974|NCT00005824|Drug|busulfan|
551975|NCT00005824|Drug|cyclophosphamide|
551976|NCT00005824|Procedure|peripheral blood stem cell transplantation|
551977|NCT00005823|Drug|cytarabine|
551978|NCT00005823|Drug|daunorubicin hydrochloride|
551979|NCT00005823|Drug|etoposide|
551980|NCT00005823|Drug|hydroxyurea|
551981|NCT00005823|Drug|idarubicin|
551982|NCT00005823|Drug|mitoxantrone hydrochloride|
551983|NCT00005823|Drug|thioguanine|
551984|NCT00005823|Drug|tretinoin|
551985|NCT00005823|Drug|valspodar|
551986|NCT00005822|Drug|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
551987|NCT00005822|Drug|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
551988|NCT00005822|Procedure|conventional surgery|Patients undergo a modified radical mastectomy.
551989|NCT00005822|Radiation|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
551990|NCT00005822|Drug|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
551991|NCT00005821|Drug|patent blue V dye|
551992|NCT00005821|Procedure|conventional surgery|
551993|NCT00005821|Procedure|lymphangiography|
551994|NCT00005821|Procedure|radionuclide imaging|
551995|NCT00005821|Procedure|sentinel lymph node biopsy|
551996|NCT00005821|Radiation|Technetium Tc 99m human serum albumin colloid|
551997|NCT00005819|Drug|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
551998|NCT00005819|Drug|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
551999|NCT00005819|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
552000|NCT00005817|Drug|becatecarin|Given IV
552001|NCT00005817|Other|laboratory biomarker analysis|Correlative studies
552002|NCT00005815|Drug|temozolomide|
552003|NCT00005815|Drug|thalidomide|
552004|NCT00005812|Drug|temozolomide|
552005|NCT00005811|Drug|topotecan hydrochloride|Given IT
552006|NCT00005811|Other|laboratory biomarker analysis|Correlative studies
552007|NCT00005808|Drug|motexafin lutetium|Given IV
552008|NCT00005808|Drug|photodynamic therapy|Undergo laser therapy
552009|NCT00005808|Procedure|loop electrosurgical excision procedure|Undergo LEEP
552010|NCT00005808|Other|laboratory biomarker analysis|Correlative studies
552011|NCT00005807|Drug|BMS-247550|anticancer agent for the treatment of patients with malignant tumors.
552012|NCT00005803|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
552013|NCT00005803|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
552014|NCT00005803|Drug|Carmustine|Given IV
552015|NCT00005803|Drug|Cyclophosphamide|Given IV
552016|NCT00005803|Drug|Cyclosporine|Given PO
552017|NCT00005803|Drug|Cytarabine|Given IV
552018|NCT00005803|Drug|Etoposide|Given IV
552019|NCT00005803|Drug|Fludarabine Phosphate|Given IV
552020|NCT00005803|Other|Laboratory Biomarker Analysis|Correlative studies
552021|NCT00005803|Drug|Melphalan|Given IV
552022|NCT00005803|Drug|Mycophenolate Mofetil|Given PO
552177|NCT00005039|Biological|recombinant fowlpox-prostate specific antigen vaccine|Given IM
552023|NCT00005803|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
552024|NCT00005803|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
552025|NCT00005803|Biological|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
552026|NCT00005803|Radiation|Total-Body Irradiation|Undergo radiotherapy
552027|NCT00005802|Biological|aldesleukin|
552028|NCT00005802|Biological|filgrastim|
552029|NCT00005802|Biological|therapeutic allogeneic lymphocytes|
552030|NCT00005802|Drug|cytarabine|
552031|NCT00005802|Drug|etoposide|
552032|NCT00005802|Drug|fludarabine phosphate|
552033|NCT00005802|Drug|methotrexate|
552034|NCT00005802|Drug|mitoxantrone hydrochloride|
552035|NCT00005802|Drug|therapeutic hydrocortisone|
552036|NCT00005802|Radiation|radiation therapy|
552037|NCT00005797|Drug|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
552038|NCT00005797|Drug|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
552039|NCT00005797|Drug|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
552040|NCT00005797|Radiation|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
552041|NCT00005788|Biological|aldesleukin|
552042|NCT00005787|Biological|epoetin alfa|
552043|NCT00005787|Biological|filgrastim|
552044|NCT00005787|Biological|recombinant flt3 ligand|
552045|NCT00005787|Biological|recombinant interleukin-3|
552046|NCT00005787|Biological|sargramostim|
552047|NCT00005787|Procedure|in vitro-treated peripheral blood stem cell transplantation|
552048|NCT00005786|Drug|arsenic trioxide|Given IV
552049|NCT00005786|Other|laboratory biomarker analysis|Correlative studies
552050|NCT00005647|Drug|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
552051|NCT00005647|Drug|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
552052|NCT00005644|Drug|gemcitabine hydrochloride|
552053|NCT00005644|Drug|paclitaxel|
552054|NCT00005639|Drug|Azacitidine Injection|subcutaneous injection (SC)
552055|NCT00005639|Drug|sodium phenylbutyrate|continuous intravenous (CIV)
552056|NCT00005638|Drug|cisplatin|
552057|NCT00005638|Drug|irinotecan hydrochloride|
552058|NCT00005638|Radiation|radiation therapy|
552059|NCT00005637|Drug|carmustine|
552060|NCT00005637|Drug|temozolomide|
552061|NCT00005627|Drug|carboplatin|
552062|NCT00005627|Drug|docetaxel|
552063|NCT00005627|Drug|estramustine phosphate sodium|
552064|NCT00005623|Drug|cyproterone acetate|
552065|NCT00005623|Procedure|quality-of-life assessment|
552066|NCT00005622|Drug|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
552067|NCT00005622|Radiation|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
552068|NCT00005617|Biological|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
552069|NCT00005617|Procedure|leukapheresis|Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
552070|NCT00005606|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
552071|NCT00005606|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
552072|NCT00005603|Drug|asparaginase|
552073|NCT00005603|Drug|cyclophosphamide|
552074|NCT00005603|Drug|cytarabine|
552075|NCT00005603|Drug|daunorubicin hydrochloride|
552076|NCT00005603|Drug|dexamethasone|
552077|NCT00005603|Drug|doxorubicin hydrochloride|
552078|NCT00005603|Drug|mercaptopurine|
552079|NCT00005603|Drug|methotrexate|
552080|NCT00005603|Drug|prednisone|
552081|NCT00005603|Drug|thioguanine|
552082|NCT00005603|Drug|vincristine sulfate|
552083|NCT00005602|Drug|carboplatin|
552084|NCT00005602|Drug|cereport|
552085|NCT00005602|Radiation|radiation therapy|
552086|NCT00005601|Biological|rituximab|
552087|NCT00005601|Drug|cisplatin|
552088|NCT00005601|Drug|cytarabine|
552089|NCT00005601|Drug|dexamethasone|
552090|NCT00005601|Drug|sargramostim|
552091|NCT00005600|Procedure|management of therapy complications|
552092|NCT00005599|Drug|bryostatin 1|
552093|NCT00005599|Drug|paclitaxel|
552094|NCT00005597|Drug|temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
552095|NCT00005596|Drug|cyclophosphamide|
552096|NCT00005596|Drug|cytarabine|
552097|NCT00005596|Drug|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
552098|NCT00005596|Drug|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
552099|NCT00005596|Drug|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
552178|NCT00005039|Biological|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
552179|NCT00005039|Other|laboratory biomarker analysis|Correlative studies
552100|NCT00005596|Drug|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC > 500/μL and platelets > 75,000/uL
552101|NCT00005596|Drug|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.~IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
552102|NCT00005596|Drug|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; > or = 1 day after the IT MTX
552103|NCT00005596|Drug|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC > or = 500/ul and platelets > or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
552104|NCT00005596|Drug|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
552105|NCT00005590|Drug|levofloxacin|
552106|NCT00005589|Biological|filgrastim|
552107|NCT00005589|Biological|rituximab|
552108|NCT00005589|Drug|carmustine|
552109|NCT00005589|Drug|cyclophosphamide|
552110|NCT00005589|Drug|cytarabine|
552111|NCT00005589|Drug|etoposide|
552112|NCT00005589|Drug|melphalan|
552113|NCT00005589|Procedure|bone marrow ablation with stem cell support|
552114|NCT00005589|Procedure|peripheral blood stem cell transplantation|
552115|NCT00005586|Drug|L-leucovorin|
552116|NCT00005586|Drug|fluorouracil|
552117|NCT00005586|Procedure|adjuvant therapy|
552118|NCT00005585|Drug|cyclophosphamide|Given IV
552119|NCT00005585|Drug|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
552120|NCT00005585|Drug|daunorubicin hydrochloride|Given IV
552121|NCT00005585|Drug|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
552122|NCT00005585|Drug|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
552123|NCT00005585|Drug|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
552124|NCT00005585|Drug|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
552125|NCT00005585|Drug|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
552126|NCT00005585|Drug|thioguanine|Given orally
552127|NCT00005585|Drug|vincristine sulfate|Given IV
552128|NCT00005584|Biological|bleomycin sulfate|
552129|NCT00005584|Drug|ABVD regimen|
552130|NCT00005584|Drug|BEACOPP regimen|
552131|NCT00005584|Drug|epirubicin hydrochloride|
552132|NCT00005584|Drug|prednisone|
552133|NCT00005584|Drug|vinblastine sulfate|
552134|NCT00005584|Radiation|radiation therapy|
552135|NCT00005583|Drug|cisplatin|
552136|NCT00005583|Drug|doxorubicin hydrochloride|
552137|NCT00005583|Drug|epirubicin hydrochloride|
552138|NCT00005583|Procedure|adjuvant therapy|
552139|NCT00005583|Procedure|conventional surgery|
552140|NCT00005583|Radiation|radiation therapy|
552141|NCT00005580|Drug|bryostatin 1|
552142|NCT00005580|Drug|fludarabine phosphate|
552143|NCT00005579|Drug|dolastatin 10|
552144|NCT00005095|Other|laboratory biomarker analysis|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
552145|NCT00005095|Other|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
552146|NCT00005095|Procedure|study of high risk factors|Subjects will be assessed for high risk factors.
552147|NCT00005087|Biological|filgrastim|
552148|NCT00005087|Drug|cisplatin|
552149|NCT00005087|Drug|paclitaxel|
552150|NCT00005087|Procedure|conventional surgery|
552151|NCT00005087|Radiation|radiation therapy|
552152|NCT00005079|Procedure|conventional surgery|
552153|NCT00005074|Drug|alvocidib|
552154|NCT00005067|Drug|motexafin lutetium|Given IV
552155|NCT00005067|Drug|photodynamic therapy|Undergo photodynamic therapy
552156|NCT00005062|Radiation|radiation therapy|
552157|NCT00005060|Drug|Taxotere-Cisplatin-5FU|Preoperatively
552158|NCT00005060|Drug|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
552159|NCT00005052|Biological|GM2-KLH vaccine|
552160|NCT00005052|Biological|QS21|
552161|NCT00005052|Procedure|adjuvant therapy|
552162|NCT00005051|Drug|carboplatin|
552163|NCT00005051|Drug|cisplatin|
552164|NCT00005051|Drug|paclitaxel|
552165|NCT00005051|Drug|topotecan hydrochloride|
552166|NCT00005049|Drug|carboplatin|
552167|NCT00005049|Drug|cisplatin|
552168|NCT00005049|Drug|floxuridine|
552169|NCT00005047|Drug|cisplatin|
552170|NCT00005047|Drug|doxorubicin hydrochloride|
552171|NCT00005047|Drug|methotrexate|
552172|NCT00005047|Drug|vinblastine|
552173|NCT00005044|Drug|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
552174|NCT00005044|Drug|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
552175|NCT00005044|Drug|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
552176|NCT00005044|Radiation|radiation therapy|[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)] OR [regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin]
552180|NCT00005038|Biological|aldesleukin|
552181|NCT00005038|Drug|histamine dihydrochloride|
552182|NCT00005036|Drug|irinotecan hydrochloride|Given IV
552183|NCT00005036|Drug|oxaliplatin|Given IV
552184|NCT00005036|Drug|leucovorin calcium|Given IV
552185|NCT00005036|Drug|fluorouracil|Given IV
552186|NCT00005036|Procedure|quality-of-life assessment|Ancillary studies
552187|NCT00005033|Biological|trastuzumab|
552188|NCT00005033|Procedure|conventional surgery|
552189|NCT00004936|Drug|iodinated contrast dye|
552190|NCT00004936|Procedure|computed tomography|
552191|NCT00004936|Procedure|magnetic resonance imaging|
552192|NCT00004936|Radiation|gadopentetate dimeglumine|
552193|NCT00004935|Drug|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
552194|NCT00004935|Drug|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
552195|NCT00004934|Drug|carboplatin|
552196|NCT00004934|Drug|epirubicin hydrochloride|
552197|NCT00004934|Drug|paclitaxel|
552198|NCT00004934|Procedure|conventional surgery|
552199|NCT00004932|Drug|imatinib mesylate|
552200|NCT00004930|Drug|doxorubicin hydrochloride|
552201|NCT00004924|Drug|irinotecan hydrochloride|
552202|NCT00004924|Drug|paclitaxel|
552203|NCT00004921|Biological|filgrastim|
552204|NCT00004921|Drug|carboplatin|
552205|NCT00004921|Drug|cyclophosphamide|
552206|NCT00004921|Drug|melphalan|
552207|NCT00004921|Drug|paclitaxel|
552208|NCT00004921|Procedure|adjuvant therapy|
552209|NCT00004921|Procedure|bone marrow ablation with stem cell support|
552210|NCT00004921|Procedure|peripheral blood stem cell transplantation|
552211|NCT00004920|Drug|cisplatin|
552212|NCT00004920|Drug|raltitrexed|
552213|NCT00004918|Biological|PR1 leukemia peptide vaccine|Given SC
552214|NCT00004918|Drug|Montanide ISA 51 VG|Given SC
552215|NCT00004918|Biological|sargramostim|Given SC
552216|NCT00004918|Other|laboratory biomarker analysis|Correlative studies
552217|NCT00004917|Biological|epoetin alfa|
552218|NCT00004917|Drug|cisplatin|
552219|NCT00004917|Radiation|radiation therapy|
552220|NCT00004907|Drug|busulfan|
552221|NCT00004907|Drug|cyclophosphamide|
552222|NCT00004907|Drug|etoposide|
552223|NCT00004907|Procedure|allogeneic bone marrow transplantation|
552224|NCT00004907|Procedure|bone marrow ablation with stem cell support|
552225|NCT00004907|Procedure|peripheral blood stem cell transplantation|
552226|NCT00004907|Radiation|radiation therapy|
552227|NCT00004899|Biological|filgrastim|
552228|NCT00004899|Drug|busulfan|
552229|NCT00004899|Drug|etoposide|
552230|NCT00004899|Procedure|autologous bone marrow transplantation|
552231|NCT00004896|Drug|busulfan|
552232|NCT00004896|Drug|cyclophosphamide|
552233|NCT00004896|Procedure|allogeneic bone marrow transplantation|
552234|NCT00004896|Procedure|bone marrow ablation with stem cell support|
552235|NCT00004896|Radiation|radiation therapy|
552236|NCT00004891|Drug|chemotherapy|
552237|NCT00004891|Procedure|computed tomography|
552238|NCT00004891|Procedure|conventional surgery|
552239|NCT00004891|Procedure|neoadjuvant therapy|
552240|NCT00004891|Procedure|positron emission tomography|
552241|NCT00004891|Procedure|radionuclide imaging|
552242|NCT00004891|Radiation|fludeoxyglucose F 18|
552243|NCT00004891|Radiation|radiation therapy|
552244|NCT00004888|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
552245|NCT00004888|Drug|docetaxel|Given IV
552246|NCT00004888|Biological|trastuzumab|Given IV
552247|NCT00004888|Other|laboratory biomarker analysis|Correlative studies
552248|NCT00004879|Biological|panitumumab|
552249|NCT00004876|Drug|carboplatin|
552250|NCT00004876|Drug|thalidomide|
552251|NCT00004873|Drug|cisplatin|
552252|NCT00004873|Drug|docetaxel|
552253|NCT00004873|Drug|epirubicin hydrochloride|
552254|NCT00004873|Drug|fluorouracil|
552255|NCT00004871|Drug|azacitidine|
552256|NCT00004871|Drug|sodium phenylbutyrate|
552257|NCT00004867|Procedure|conventional surgery|
552258|NCT00004867|Procedure|positron emission tomography|
552259|NCT00004867|Procedure|radionuclide imaging|
552260|NCT00004867|Radiation|fludeoxyglucose F 18|
552261|NCT00004867|Drug|chemotherapy|
552262|NCT00004867|Radiation|Radiotherapy|
552263|NCT00004866|Drug|exatecan mesylate|
552264|NCT00004859|Drug|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
552265|NCT00004859|Drug|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
552266|NCT00004859|Drug|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
552351|NCT00004208|Drug|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
552352|NCT00004208|Behavioral|Supportive care|Patients randomized to this arm will be treated as outpatients.
552353|NCT00004205|Drug|letrozole|Letrozole 2.5 mg daily oral administration.
552452|NCT00004088|Biological|filgrastim|
552267|NCT00004859|Radiation|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
552268|NCT00004262|Procedure|conventional surgery|
552269|NCT00004262|Radiation|3-dimensional conformal radiation therapy|
552270|NCT00004262|Radiation|stereotactic radiosurgery|
552271|NCT00004262|Drug|motexafin gadolinium|Given IV
552272|NCT00004262|Procedure|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
552273|NCT00004262|Procedure|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
552274|NCT00004259|Drug|BCNU 80mg/m2|BCNU 80 mg/m2 will be administered as an intravenous infusion on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58, then every eight weeks for four more cycles for a total of 6 cycles (maximum BCNU dose 1440 mg/m2).
552275|NCT00004259|Drug|TMZ 200mg/m2|200 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat every 28 days for a total of 12 cycles.
552276|NCT00004259|Radiation|radiation therapy|1.8 Gy fractions (to isocenter), 1 fraction per day, 5 days per week to a dose of 59.4 Gy in 33 fractions.
552277|NCT00004259|Drug|CCNU|CCNU at 130 mg/m2 orally every 8 weeks for a total of 6 cycles. Administered on day 1 of the first week of radiotherapy and on day 56, then administered every 8 weeks for four more cycles for a total of 6 cycles.
552278|NCT00004259|Drug|BCNU 150mg/m2|BCNU 150 mg/m2 will be administered as an intravenous infusion on day 5 of radiotherapy, and it will be repeated every eight weeks for a total of six cycles (maximum total BCNU dose 900 mg/m2).
552279|NCT00004259|Drug|BCNU 200mg/m2|BCNU 200 mg/m2 will be administered as an intravenous infusion on day 1 of radiotherapy and will be repeated every six weeks for a total of 6 cycles (maximum BCNU dose 1200 mg/m2).
552280|NCT00004259|Drug|TMZ 150mg/m2 six 6-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 6-week cycles
552281|NCT00004259|Drug|TMZ 150mg/m2 six 8-week cycles|150 mg/m2 orally on days 1-5 of the first week of radiotherapy. Repeat for a total of six 8-week cycles
552282|NCT00004250|Biological|dactinomycin|
552283|NCT00004250|Drug|isolated limb perfusion|
552284|NCT00004250|Drug|melphalan|
552285|NCT00004245|Drug|sodium salicylate|
552286|NCT00004244|Biological|recombinant interferon alfa|
552287|NCT00004244|Biological|recombinant interleukin-12|
552288|NCT00004241|Drug|tanespimycin|Given IV
552289|NCT00004241|Other|pharmacological study|Correlative studies
552290|NCT00004237|Drug|cyclophosphamide|
552291|NCT00004237|Drug|doxorubicin hydrochloride|
552292|NCT00004237|Drug|epirubicin hydrochloride|
552293|NCT00004237|Drug|mitoxantrone hydrochloride|
552294|NCT00004237|Drug|vinorelbine tartrate|
552295|NCT00004237|Procedure|conventional surgery|
552296|NCT00004237|Radiation|radiation therapy|
552297|NCT00004234|Procedure|management of therapy complications|
552298|NCT00004234|Radiation|radiation therapy|
552299|NCT00004231|Biological|aldesleukin|
552300|NCT00004231|Biological|filgrastim|
552301|NCT00004231|Biological|recombinant interferon alfa|
552302|NCT00004231|Drug|busulfan|
552303|NCT00004231|Drug|cyclophosphamide|
552304|NCT00004231|Drug|cytarabine|
552305|NCT00004231|Drug|doxorubicin hydrochloride|
552306|NCT00004231|Drug|leucovorin calcium|
552307|NCT00004231|Drug|methotrexate|
552308|NCT00004231|Drug|prednisone|
552309|NCT00004231|Drug|teniposide|
552310|NCT00004231|Drug|vincristine sulfate|
552311|NCT00004231|Procedure|allogeneic bone marrow transplantation|
552312|NCT00004231|Procedure|autologous bone marrow transplantation|
552313|NCT00004231|Procedure|peripheral blood stem cell transplantation|
552314|NCT00004228|Drug|asparaginase|Given IV
552315|NCT00004228|Drug|cyclophosphamide|Given IV
552316|NCT00004228|Drug|cytarabine|Given IV
552317|NCT00004228|Drug|daunorubicin hydrochloride|Given IV
552318|NCT00004228|Drug|dexamethasone|Given IV
552319|NCT00004228|Drug|doxorubicin hydrochloride|Given IV
552320|NCT00004228|Drug|leucovorin calcium|Given IV
552321|NCT00004228|Drug|mercaptopurine|Given IV
552322|NCT00004228|Drug|methotrexate|Given IV
552323|NCT00004228|Drug|prednisone|Given IV
552324|NCT00004228|Drug|thioguanine|Given PO
552325|NCT00004228|Drug|vincristine sulfate|Given IV
552326|NCT00004228|Radiation|radiation therapy|
552327|NCT00004227|Biological|cetuximab|
552328|NCT00004227|Procedure|conventional surgery|
552329|NCT00004227|Radiation|radiation therapy|
552330|NCT00004226|Radiation|radiation therapy|
552331|NCT00004225|Biological|Ad5CMV-p53 gene|
552332|NCT00004225|Radiation|radiation therapy|
552333|NCT00004224|Drug|cyclophosphamide|
552334|NCT00004224|Drug|etoposide|
552335|NCT00004224|Drug|vincristine sulfate|
552336|NCT00004224|Procedure|adjuvant therapy|
552337|NCT00004224|Procedure|conventional surgery|
552338|NCT00004224|Radiation|radiation therapy|
552339|NCT00004218|Drug|chlorambucil|
552340|NCT00004218|Drug|cyclophosphamide|
552341|NCT00004218|Drug|doxorubicin hydrochloride|
552342|NCT00004218|Drug|fludarabine phosphate|
552343|NCT00004218|Drug|prednisolone|
552344|NCT00004218|Drug|vincristine sulfate|
552345|NCT00004212|Biological|filgrastim|
552346|NCT00004212|Drug|exatecan mesylate|
552347|NCT00004210|Other|loss of heterozygosity analysis|
552348|NCT00004210|Other|microsatellite instability analysis|
552349|NCT00004210|Other|mutation analysis|
552350|NCT00004210|Other|counseling intervention|
552354|NCT00004205|Drug|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
552355|NCT00004196|Biological|recombinant interferon alfa|
552356|NCT00004196|Procedure|lymphangiography|
552357|NCT00004196|Drug|Observation|
552358|NCT00004189|Biological|filgrastim|
552359|NCT00004189|Drug|becatecarin|
552360|NCT00004189|Drug|cisplatin|
552361|NCT00004188|Biological|filgrastim|Given IV
552362|NCT00004188|Drug|carboplatin|Given IV
552363|NCT00004188|Drug|cisplatin|Given IV
552364|NCT00004188|Drug|cyclophosphamide|Given IV
552365|NCT00004188|Drug|doxorubicin hydrochloride|Given IV
552366|NCT00004188|Drug|etoposide|Given IV
552367|NCT00004188|Drug|isotretinoin|Given IV
552368|NCT00004188|Drug|melphalan|Given IV
552369|NCT00004188|Drug|topotecan hydrochloride|Given IV
552370|NCT00004188|Drug|vincristine sulfate|Given IV
552371|NCT00004188|Procedure|autologous bone marrow transplantation|
552372|NCT00004188|Procedure|bone marrow ablation with stem cell support|
552373|NCT00004188|Procedure|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
552374|NCT00004188|Procedure|peripheral blood stem cell transplantation|
552375|NCT00004188|Radiation|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
552376|NCT00004181|Drug|busulfan|
552377|NCT00004181|Drug|cyclophosphamide|
552378|NCT00004181|Procedure|allogeneic bone marrow transplantation|
552379|NCT00004181|Radiation|radiation therapy|
552380|NCT00004179|Biological|rituximab|
552381|NCT00004179|Drug|CHOP regimen|
552382|NCT00004179|Drug|cyclophosphamide|
552383|NCT00004179|Drug|doxorubicin hydrochloride|
552384|NCT00004179|Drug|prednisone|
552385|NCT00004179|Drug|vincristine sulfate|
552386|NCT00004173|Drug|oxaliplatin|
552387|NCT00004173|Drug|paclitaxel|
552388|NCT00004165|Biological|filgrastim|
552389|NCT00004165|Drug|melphalan|
552390|NCT00004165|Procedure|peripheral blood stem cell transplantation|
552391|NCT00004154|Drug|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
552392|NCT00004154|Other|Placebo|Two placebo capsules for 25 days of 28 day cycle.
552393|NCT00004153|Genetic|reverse transcriptase-polymerase chain reaction|
552394|NCT00004153|Procedure|sentinel lymph node biopsy|
552395|NCT00004150|Drug|fluorouracil|
552396|NCT00004150|Drug|leucovorin calcium|
552397|NCT00004150|Procedure|adjuvant therapy|
552398|NCT00004149|Drug|arsenic trioxide|
552399|NCT00004147|Drug|incyclinide|
552400|NCT00004144|Drug|bryostatin 1|
552401|NCT00004144|Drug|gemcitabine hydrochloride|
552402|NCT00004143|Drug|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
552403|NCT00004141|Drug|Cisplatin|
552404|NCT00004141|Drug|dacarbazine|
552405|NCT00004141|Drug|Granulocyte-macrophage colony-stimulating factor|
552406|NCT00004138|Procedure|positron emission tomography|
552407|NCT00004138|Procedure|radionuclide imaging|
552408|NCT00004138|Radiation|fludeoxyglucose F 18|
552409|NCT00004135|Biological|filgrastim|
552410|NCT00004135|Biological|therapeutic allogeneic lymphocytes|
552411|NCT00004135|Drug|cyclophosphamide|
552412|NCT00004135|Drug|fludarabine phosphate|
552413|NCT00004135|Procedure|peripheral blood stem cell transplantation|
552414|NCT00004129|Radiation|brachytherapy|
552415|NCT00004129|Radiation|phosphorus P32|
552416|NCT00004128|Biological|aldesleukin|
552417|NCT00004128|Biological|filgrastim|
552418|NCT00004128|Drug|busulfan|
552419|NCT00004128|Drug|cyclophosphamide|
552420|NCT00004128|Drug|cytarabine|
552421|NCT00004128|Drug|daunorubicin hydrochloride|
552422|NCT00004128|Drug|etoposide|
552423|NCT00004128|Procedure|autologous bone marrow transplantation|
552424|NCT00004128|Procedure|peripheral blood stem cell transplantation|
552425|NCT00004128|Radiation|radiation therapy|
552426|NCT00004124|Drug|bicalutamide|
552427|NCT00004124|Drug|goserelin|
552428|NCT00004124|Drug|mitoxantrone hydrochloride|
552429|NCT00004124|Drug|prednisone|
552430|NCT00004115|Radiation|yttrium Y 90 monoclonal antibody HMFG1|
552431|NCT00004110|Biological|monoclonal antibody 3F8|
552432|NCT00004110|Drug|etoposide|
552433|NCT00004110|Drug|isotretinoin|
552434|NCT00004106|Drug|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
552435|NCT00004103|Drug|cisplatin|
552436|NCT00004103|Drug|floxuridine|
552437|NCT00004103|Drug|irinotecan hydrochloride|
552438|NCT00004103|Procedure|adjuvant therapy|
552439|NCT00004103|Procedure|conventional surgery|
552440|NCT00004103|Procedure|neoadjuvant therapy|
552441|NCT00004099|Drug|cisplatin|
552442|NCT00004099|Drug|fluorouracil|
552443|NCT00004099|Drug|leucovorin calcium|
552444|NCT00004099|Procedure|neoadjuvant therapy|
552445|NCT00004092|Biological|filgrastim|Given IV or subcutaneously
552446|NCT00004092|Drug|carboplatin|Given IV
552447|NCT00004092|Drug|cyclophosphamide|Given IV
552448|NCT00004092|Drug|doxorubicin hydrochloride|Given IV
552449|NCT00004092|Drug|paclitaxel|Given IV
552450|NCT00004092|Drug|thiotepa|Given IV
552451|NCT00004092|Procedure|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
552453|NCT00004088|Biological|recombinant interferon alfa|
552454|NCT00004088|Drug|busulfan|
552455|NCT00004088|Drug|cyclophosphamide|
552456|NCT00004088|Drug|melphalan|
552457|NCT00004088|Drug|pamidronate disodium|
552458|NCT00004088|Drug|thalidomide|
552459|NCT00004088|Procedure|peripheral blood stem cell transplantation|
552460|NCT00004081|Drug|docetaxel|
552461|NCT00004077|Drug|cisplatin|
552462|NCT00004077|Drug|ifosfamide|
552463|NCT00004077|Drug|paclitaxel|
552464|NCT00004075|Drug|tanespimycin|
552465|NCT00004072|Drug|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
552466|NCT00004072|Drug|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
552467|NCT00004067|Biological|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
552468|NCT00004067|Drug|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
552469|NCT00004067|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
552470|NCT00004067|Drug|taxol|175 mg/m2 IV every 21 days for 4 cycles
552471|NCT00004066|Biological|filgrastim|
552472|NCT00004066|Drug|docetaxel|
552473|NCT00004066|Drug|gemcitabine hydrochloride|
552474|NCT00004065|Drug|tanespimycin|
552475|NCT00004063|Biological|recombinant interferon alfa|
552476|NCT00004063|Drug|cisplatin|
552477|NCT00004063|Drug|gemcitabine hydrochloride|
552478|NCT00004063|Procedure|hyperthermia treatment|
552479|NCT00004058|Drug|tetradecanoylphorbol acetate|
552480|NCT00004054|Drug|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
552481|NCT00004054|Drug|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
552482|NCT00004054|Drug|etoposide|50 mg/m^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
552483|NCT00004054|Drug|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
552484|NCT00004054|Drug|paclitaxel|135 mg/m^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
552485|NCT00004054|Drug|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
552486|NCT00004054|Radiation|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
552487|NCT00004054|Drug|warfarin|To keep international normalized ratio (INR) > 1.5 and < 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
552488|NCT00004031|Biological|rituximab|375 mg/m2 IV every 21 days
552489|NCT00004031|Drug|CHOP regimen|
552490|NCT00004031|Drug|carmustine|
552491|NCT00004031|Drug|cyclophosphamide|
552492|NCT00004031|Drug|doxorubicin hydrochloride|
552493|NCT00004031|Drug|etoposide|
552494|NCT00004031|Drug|prednisone|
552495|NCT00004031|Drug|vincristine sulfate|
552496|NCT00004031|Procedure|bone marrow ablation with stem cell support|
552497|NCT00004031|Procedure|peripheral blood stem cell transplantation|
552498|NCT00004031|Radiation|radiation therapy|
552499|NCT00004028|Drug|carmustine|
552500|NCT00004028|Procedure|conventional surgery|
552501|NCT00004024|Biological|aldesleukin|
552502|NCT00004024|Biological|autologous tumor cell vaccine|
552503|NCT00004024|Biological|muromonab-CD3|
552504|NCT00004024|Biological|sargramostim|
552505|NCT00004024|Biological|therapeutic autologous lymphocytes|
552506|NCT00004024|Procedure|surgical procedure|
552507|NCT00004024|Radiation|radiation therapy|
552508|NCT00004017|Procedure|conventional surgery|
552509|NCT00004017|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
552510|NCT00004015|Drug|sodium borocaptate|
552511|NCT00004015|Procedure|adjuvant therapy|
552512|NCT00004011|Drug|carboplatin|
552513|NCT00004011|Drug|paclitaxel|
552514|NCT00004011|Procedure|conventional surgery|
552515|NCT00004005|Drug|fluorouracil|
552516|NCT00004005|Drug|irinotecan hydrochloride|
552517|NCT00004005|Drug|leucovorin calcium|
552518|NCT00004005|Procedure|conventional surgery|
552519|NCT00004005|Radiation|radiation therapy|
552520|NCT00004001|Drug|docetaxel|
552521|NCT00004001|Drug|estramustine|
552522|NCT00004001|Drug|mitoxantrone|
552523|NCT00004001|Drug|prednisone|
552524|NCT00003994|Procedure|therapeutic conventional surgery|Undergo surgical resection
552525|NCT00003994|Drug|cisplatin|Given IV
552526|NCT00003994|Drug|vincristine sulfate|Given IV
552527|NCT00003994|Drug|fluorouracil|Given IV
552528|NCT00003994|Drug|amifostine trihydrate|Given IV
552529|NCT00003994|Drug|carboplatin|Given IV
552530|NCT00003993|Biological|aldesleukin|
552531|NCT00003993|Drug|bryostatin 1|
552532|NCT00003981|Drug|indisulam|
552533|NCT00003979|Drug|CHS 828|
552534|NCT00003977|Biological|human papillomavirus 16 E7 peptide|
552535|NCT00003977|Procedure|in vitro-treated peripheral blood stem cell transplantation|
552536|NCT00003970|Drug|irinotecan hydrochloride|Given IV
552537|NCT00003969|Drug|tanespimycin|
552538|NCT00003966|Drug|defibrotide|
552539|NCT00003963|Biological|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
552540|NCT00003963|Drug|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
552541|NCT00003961|Biological|sargramostim|
552542|NCT00003958|Biological|dactinomycin|Given IV
552543|NCT00003958|Drug|vincristine sulfate|Given IV
552544|NCT00003958|Drug|cyclophosphamide|Given IV
552545|NCT00003958|Procedure|therapeutic conventional surgery|Undergo surgery
552546|NCT00003958|Radiation|radiation therapy|Undergo radiotherapy
552547|NCT00003958|Drug|topotecan hydrochloride|Given IV
552548|NCT00003958|Biological|filgrastim|Given SC
552549|NCT00003958|Biological|sargramostim|Given SC
552550|NCT00003958|Other|laboratory biomarker analysis|Correlative studies
552551|NCT00003955|Biological|dactinomycin|
552552|NCT00003955|Biological|filgrastim|
552553|NCT00003955|Biological|pegfilgrastim|
552554|NCT00003955|Biological|sargramostim|
552555|NCT00003955|Drug|cyclophosphamide|
552556|NCT00003955|Drug|irinotecan hydrochloride|
552557|NCT00003955|Drug|vincristine sulfate|
552558|NCT00003955|Radiation|radiation therapy|
552559|NCT00003945|Drug|cisplatin|
552560|NCT00003945|Drug|topotecan hydrochloride|
552561|NCT00003941|Biological|bleomycin sulfate|
552562|NCT00003941|Biological|filgrastim|
552563|NCT00003941|Drug|cisplatin|
552564|NCT00003941|Drug|etoposide|
552565|NCT00003941|Drug|ifosfamide|
552566|NCT00003941|Procedure|bone marrow ablation with stem cell support|
552567|NCT00003941|Procedure|peripheral blood stem cell transplantation|
552568|NCT00003938|Drug|liposomal amphotericin B|
552569|NCT00003934|Drug|tretinoin|Given orally
552570|NCT00003934|Drug|daunorubicin hydrochloride|Given IV
552571|NCT00003934|Drug|cytarabine|Given IV
552572|NCT00003934|Drug|mercaptopurine|Given IV
552573|NCT00003934|Drug|methotrexate|Given IV
552574|NCT00003934|Drug|arsenic trioxide|Given IV
552575|NCT00003928|Drug|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
552576|NCT00003928|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
552577|NCT00003913|Biological|anti-thymocyte globulin|
552578|NCT00003913|Biological|filgrastim|
552579|NCT00003913|Drug|busulfan|
552580|NCT00003913|Drug|cyclophosphamide|
552581|NCT00003913|Drug|methylprednisolone|
552582|NCT00003913|Procedure|umbilical cord blood transplantation|
552583|NCT00003913|Radiation|radiation therapy|
552584|NCT00003912|Drug|carboplatin|
552585|NCT00003912|Drug|cisplatin|
552586|NCT00003912|Drug|doxorubicin hydrochloride|
552587|NCT00003912|Procedure|conventional surgery|
552588|NCT00003910|Drug|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
552589|NCT00003910|Drug|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
552590|NCT00003910|Drug|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
552591|NCT00003909|Drug|motexafin gadolinium|Given IV
552592|NCT00003909|Radiation|radiation therapy|Undergo radiation therapy
552593|NCT00003909|Other|pharmacological study|Correlatives studies
552594|NCT00003906|Drug|Raloxifene|60 mg/day plus placebo for 5 years
552595|NCT00003906|Drug|Tamoxifen|20 mg/day plus placebo for 5 years
552596|NCT00003903|Procedure|management of therapy complications|
552597|NCT00003902|Drug|capecitabine|
552598|NCT00003902|Drug|vinorelbine tartrate|
552599|NCT00003901|Other|immunohistochemistry staining method|
552600|NCT00003901|Procedure|biopsy|
552601|NCT00003901|Procedure|surgery|
552602|NCT00003896|Drug|cisplatin|
552603|NCT00003896|Drug|liposomal doxorubicin|
552604|NCT00003896|Drug|paclitaxel|
552605|NCT00003893|Drug|CMF regimen|
552606|NCT00003893|Drug|cyclophosphamide|
552607|NCT00003893|Drug|doxorubicin hydrochloride|
552608|NCT00003893|Drug|epirubicin hydrochloride|
552609|NCT00003893|Drug|fluorouracil|
552610|NCT00003893|Drug|methotrexate|
552611|NCT00003893|Drug|mitomycin C|
552612|NCT00003893|Drug|mitoxantrone hydrochloride|
552613|NCT00003893|Procedure|adjuvant therapy|
552614|NCT00003893|Radiation|radiation therapy|
552615|NCT00003878|Drug|polifeprosan 20 with carmustine implant|
552616|NCT00003878|Procedure|conventional surgery|
552617|NCT00003875|Drug|busulfan|Given PO or IV
552618|NCT00003875|Drug|etoposide|Given IV
552619|NCT00003875|Biological|aldesleukin|Given SC
552620|NCT00003875|Procedure|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
552621|NCT00003869|Drug|carboxyamidotriazole|Given PO
552622|NCT00003869|Other|placebo|Given PO
552623|NCT00003869|Procedure|quality-of-life assessment|Ancillary studies
552624|NCT00003869|Other|laboratory biomarker analysis|Correlative studies
552625|NCT00003865|Drug|toremifene|
552626|NCT00003863|Genetic|comparative genomic hybridization|
552627|NCT00003863|Genetic|cytogenetic analysis|
552628|NCT00003863|Genetic|fluorescence in situ hybridization|
552629|NCT00003863|Genetic|gene rearrangement analysis|
552630|NCT00003862|Drug|cisplatin|
552631|NCT00003862|Drug|fluorouracil|
552632|NCT00003862|Drug|leucovorin calcium|
552633|NCT00003862|Drug|paclitaxel|
552634|NCT00003862|Procedure|conventional surgery|
552635|NCT00003862|Procedure|neoadjuvant therapy|
552636|NCT00003862|Radiation|radiation therapy|
552637|NCT00003861|Other|laboratory biomarker analysis|
552638|NCT00003857|Drug|tamoxifen citrate|
552639|NCT00003857|Procedure|adjuvant therapy|
552640|NCT00003857|Radiation|radiation therapy|
552641|NCT00003855|Procedure|axillary lymph node dissection|
552642|NCT00003855|Radiation|whole breast irradiation|
552643|NCT00003854|Other|immunohistochemistry staining method|
552644|NCT00003854|Procedure|lymphangiography|
552645|NCT00003854|Procedure|sentinel lymph node biopsy|
552646|NCT00003854|Procedure|therapeutic conventional surgery|
552647|NCT00003854|Radiation|whole breast irradiation|
552648|NCT00003851|Biological|proteolytic enzymes|
552649|NCT00003851|Drug|gemcitabine hydrochloride|
552650|NCT00003851|Procedure|Gonzalez regimen|
552651|NCT00003843|Drug|irinotecan hydrochloride|
552652|NCT00003843|Genetic|mutation analysis|
552653|NCT00003843|Genetic|polymorphism analysis|
552654|NCT00003838|Other|T-cell replete PBPC allograft|Subjects will receive a non-myeloablative preparative regimen of cyclophosphamide 60mg/kg/d x 2 days, and fludarabine 25mg/m2 intravenously (IV) over 30 minutes daily x 5 days with or without ATG followed by a PBPC graft targeted to deliver >5x106 CD34+ cells /kg.
552655|NCT00003837|Drug|nelarabine|
552656|NCT00003833|Genetic|DNA stability analysis|
552657|NCT00003833|Genetic|gene mapping|
552658|NCT00003831|Procedure|conventional surgery|
552659|NCT00003820|Drug|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
552660|NCT00003816|Biological|anti-thymocyte globulin|Given IV
552661|NCT00003816|Drug|busulfan|Given IV
552662|NCT00003816|Drug|carboplatin|Given IV
552663|NCT00003816|Drug|cyclophosphamide|Given IV
552664|NCT00003816|Drug|etoposide|Given IV
552665|NCT00003816|Drug|fludarabine phosphate|Given IV
552666|NCT00003816|Drug|melphalan|Given IV
552667|NCT00003816|Drug|thiotepa|Given IV
552668|NCT00003816|Radiation|total-body irradiation|Given twice daily for 3 days
552669|NCT00003815|Biological|bleomycin sulfate|
552670|NCT00003815|Drug|carmustine|
552671|NCT00003815|Drug|cyclophosphamide|
552672|NCT00003815|Drug|cytarabine|
552673|NCT00003815|Drug|doxorubicin hydrochloride|
552674|NCT00003815|Drug|etoposide|
552675|NCT00003815|Drug|melphalan|
552676|NCT00003815|Drug|prednisolone|
552677|NCT00003815|Drug|vincristine sulfate|
552678|NCT00003815|Procedure|autologous bone marrow transplantation|
552679|NCT00003815|Radiation|radiation therapy|
552680|NCT00003803|Drug|cisplatin|
552681|NCT00003803|Drug|gemcitabine hydrochloride|
552682|NCT00003803|Radiation|radiation therapy|
552683|NCT00003800|Other|immunohistochemistry staining method|
552684|NCT00003800|Other|laboratory biomarker analysis|
552685|NCT00003800|Procedure|radionuclide imaging|
552686|NCT00003799|Drug|fluorouracil|Given IV
552687|NCT00003799|Drug|oxaliplatin|Given IV
552688|NCT00003799|Radiation|radiation therapy|Undergo radiotherapy
552689|NCT00003799|Drug|leucovorin calcium|Given IV
552690|NCT00003799|Procedure|therapeutic conventional surgery|Undergo surgery
552691|NCT00003796|Drug|irofulven|
552692|NCT00003793|Genetic|clonality analysis|
552693|NCT00003793|Genetic|microsatellite instability analysis|
552694|NCT00003793|Genetic|mutation analysis|
552695|NCT00003789|Drug|isolated limb perfusion|Undergo isolated limb perfusion
552696|NCT00003789|Drug|melphalan|Given via limb perfusion
552697|NCT00003789|Biological|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
552698|NCT00003789|Other|pharmacological study|Correlative studies
552699|NCT00003789|Other|laboratory biomarker analysis|Correlative studies
552700|NCT00003788|Drug|carmustine|
552701|NCT00003788|Drug|lomustine|
552702|NCT00003788|Drug|porfimer sodium|
552703|NCT00003788|Drug|procarbazine hydrochloride|
552704|NCT00003788|Procedure|neoadjuvant therapy|
552705|NCT00003788|Procedure|surgical procedure|
552706|NCT00003788|Radiation|radiation therapy|
552707|NCT00003782|Drug|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
552708|NCT00003782|Drug|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
552709|NCT00003782|Drug|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
552710|NCT00003771|Biological|therapeutic estradiol|
552711|NCT00003771|Drug|norethindrone acetate|
552712|NCT00003764|Drug|cyclophosphamide|
552713|NCT00003764|Drug|fludarabine phosphate|
552714|NCT00003753|Drug|dexamethasone|
552715|NCT00003753|Drug|floxuridine|
552716|NCT00003753|Drug|irinotecan hydrochloride|
552717|NCT00003753|Procedure|adjuvant therapy|
552718|NCT00003753|Procedure|conventional surgery|
552719|NCT00003750|Biological|hu14.18-IL2 fusion protein|
552720|NCT00003749|Procedure|adjuvant therapy|
552721|NCT00003749|Procedure|conventional surgery|
552722|NCT00003749|Radiation|brachytherapy|
552723|NCT00003749|Radiation|radiation therapy|
552724|NCT00003746|Drug|2-chlorodeoxyadenosine (CDA) daily|Daily administration
552725|NCT00003746|Drug|2-chlorodeoxyadenosine weekly|Weekly administration
552726|NCT00003745|Drug|topotecan hydrochloride|
552727|NCT00003744|Drug|gemcitabine|
552728|NCT00003741|Biological|monoclonal antibody HeFi-1|
552729|NCT00003739|Biological|filgrastim|
552730|NCT00003737|Drug|becatecarin|
552731|NCT00003732|Drug|carboplatin|
552732|NCT00003732|Drug|paclitaxel|
552733|NCT00003732|Drug|topotecan hydrochloride|
552734|NCT00003730|Drug|fluorouracil|
552735|NCT00003730|Drug|vinorelbine tartrate|
552736|NCT00003728|Drug|asparaginase|
552737|NCT00003728|Drug|cyclophosphamide|
552738|NCT00003728|Drug|cytarabine|
552739|NCT00003728|Drug|daunorubicin hydrochloride|
552740|NCT00003728|Drug|dexamethasone|
552741|NCT00003728|Drug|doxorubicin hydrochloride|
552742|NCT00003728|Drug|etoposide|
552743|NCT00003728|Drug|leucovorin calcium|
552744|NCT00003728|Drug|mercaptopurine|
552745|NCT00003728|Drug|methotrexate|
552746|NCT00003728|Drug|methylprednisolone|
552747|NCT00003728|Drug|mitoxantrone hydrochloride|
552748|NCT00003728|Drug|prednisolone|
552749|NCT00003728|Drug|therapeutic hydrocortisone|
552750|NCT00003728|Drug|thioguanine|
552751|NCT00003728|Drug|vincristine sulfate|
552752|NCT00003728|Drug|vindesine|
552753|NCT00003728|Procedure|allogeneic bone marrow transplantation|
552754|NCT00003728|Procedure|peripheral blood stem cell transplantation|
552755|NCT00003727|Biological|filgrastim|
552756|NCT00003727|Biological|recombinant interferon alfa|
552757|NCT00003727|Biological|sargramostim|
552758|NCT00003727|Biological|therapeutic autologous lymphocytes|
552759|NCT00003727|Drug|carmustine|
552760|NCT00003727|Drug|cyclophosphamide|
552761|NCT00003727|Drug|etoposide|
552762|NCT00003727|Drug|gemcitabine hydrochloride|
552763|NCT00003727|Drug|melphalan|
552764|NCT00003727|Procedure|bone marrow ablation with stem cell support|
552765|NCT00003727|Procedure|in vitro-treated peripheral blood stem cell transplantation|
552766|NCT00003702|Biological|Dactinomycin|Given IV
552767|NCT00003702|Drug|Methotrexate|Given intramuscularly
552768|NCT00003696|Drug|carboplatin|
552769|NCT00003696|Drug|cyclophosphamide|
552770|NCT00003696|Drug|doxorubicin hydrochloride|
552771|NCT00003696|Drug|etoposide|
552772|NCT00003696|Drug|paclitaxel|
552773|NCT00003690|Drug|alvocidib|
552774|NCT00003690|Drug|carboplatin|
552775|NCT00003690|Drug|cisplatin|
552776|NCT00003688|Biological|dactinomycin|
552777|NCT00003687|Drug|dextromethorphan hydrobromide|
552778|NCT00003687|Drug|morphine sulfate|
552779|NCT00003678|Drug|tamoxifen citrate|
552780|NCT00003678|Procedure|adjuvant therapy|
552781|NCT00003659|Biological|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients > 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
552782|NCT00003659|Biological|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
552783|NCT00003659|Drug|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
552784|NCT00003659|Drug|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
552785|NCT00003658|Biological|filgrastim|
552786|NCT00003658|Biological|rituximab|
552787|NCT00003658|Drug|cyclophosphamide|
552788|NCT00003658|Drug|pentostatin|
552789|NCT00003656|Biological|recombinant interferon alfa|
552790|NCT00003656|Drug|tretinoin liposome|
552791|NCT00003653|Drug|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
552792|NCT00003653|Drug|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
552847|NCT00003613|Drug|carmustine|Given topically
552848|NCT00003613|Other|laboratory biomarker analysis|Correlative studies
552849|NCT00003612|Biological|trastuzumab|
552850|NCT00003612|Drug|carboplatin|
552851|NCT00003612|Drug|paclitaxel|
552852|NCT00003611|Drug|acitretin|
552853|NCT00003611|Other|placebo|
552793|NCT00003653|Drug|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
552794|NCT00003653|Drug|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
552795|NCT00003653|Drug|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
552796|NCT00003653|Drug|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
552797|NCT00003653|Drug|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.~Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
552798|NCT00003652|Drug|cisplatin|
552799|NCT00003652|Drug|fluorouracil|
552800|NCT00003652|Procedure|neoadjuvant therapy|
552801|NCT00003652|Radiation|radiation therapy|
552802|NCT00003650|Drug|asparaginase|
552803|NCT00003650|Drug|cyclophosphamide|
552804|NCT00003650|Drug|cytarabine|
552805|NCT00003650|Drug|daunorubicin hydrochloride|
552806|NCT00003650|Drug|dexamethasone|
552807|NCT00003650|Drug|etoposide|
552808|NCT00003650|Drug|mercaptopurine|
552809|NCT00003650|Drug|methotrexate|
552810|NCT00003650|Drug|methylprednisolone|
552811|NCT00003650|Drug|mitoxantrone hydrochloride|
552812|NCT00003650|Drug|prednisone|
552813|NCT00003650|Drug|vincristine sulfate|
552814|NCT00003650|Radiation|radiation therapy|
552815|NCT00003644|Drug|carboplatin|
552816|NCT00003644|Drug|paclitaxel|
552817|NCT00003643|Biological|bleomycin sulfate|
552818|NCT00003643|Biological|filgrastim|
552819|NCT00003643|Drug|cisplatin|
552820|NCT00003643|Drug|etoposide|
552821|NCT00003643|Drug|paclitaxel|
552822|NCT00003641|Biological|interferon alfa-2b|Given IV
552823|NCT00003641|Other|observation|Patients undergo observation for 4 weeks.
552824|NCT00003637|Drug|cisplatin|
552825|NCT00003637|Drug|fluorouracil|
552826|NCT00003637|Radiation|radiation therapy|
552827|NCT00003636|Drug|carboplatin|
552828|NCT00003636|Drug|cisplatin|
552829|NCT00003636|Procedure|conventional surgery|
552830|NCT00003636|Procedure|neoadjuvant therapy|
552831|NCT00003633|Drug|docetaxel|
552832|NCT00003633|Drug|estramustine phosphate sodium|
552833|NCT00003633|Drug|mitoxantrone hydrochloride|
552834|NCT00003633|Drug|prednisone|
552835|NCT00003631|Biological|filgrastim|
552836|NCT00003631|Drug|carboplatin|
552837|NCT00003631|Drug|carmustine|
552838|NCT00003631|Drug|cyclophosphamide|
552839|NCT00003631|Drug|cytarabine|
552840|NCT00003631|Drug|etoposide|
552841|NCT00003631|Drug|ifosfamide|
552842|NCT00003631|Drug|melphalan|
552843|NCT00003631|Procedure|bone marrow ablation with stem cell support|
552844|NCT00003631|Procedure|peripheral blood stem cell transplantation|
552845|NCT00003631|Radiation|radiation therapy|
552846|NCT00003613|Drug|O6-benzylguanine|Given IV
552854|NCT00003607|Radiation|radiation therapy|
552855|NCT00003603|Drug|cyclophosphamide|
552856|NCT00003603|Drug|dexamethasone|
552857|NCT00003603|Drug|idarubicin|
552858|NCT00003603|Drug|lomustine|
552859|NCT00003603|Drug|melphalan|
552860|NCT00003603|Drug|prednisolone|
552861|NCT00003602|Drug|cytarabine|
552862|NCT00003602|Drug|etoposide|
552863|NCT00003602|Drug|idarubicin|
552864|NCT00003602|Drug|mitoxantrone hydrochloride|
552865|NCT00003596|Drug|cisplatin|
552866|NCT00003596|Drug|fluorouracil|
552867|NCT00003596|Drug|mitomycin C|
552868|NCT00003596|Radiation|radiation therapy|
552869|NCT00003593|Drug|asparaginase|Given IV
552870|NCT00003593|Drug|cytarabine|Given IT
552871|NCT00003593|Drug|daunorubicin hydrochloride|Given IV
552872|NCT00003593|Drug|methotrexate|Given IV
552873|NCT00003593|Drug|therapeutic hydrocortisone|Given IT
552874|NCT00003593|Drug|thioguanine|Given IV
552875|NCT00003590|Drug|hydroxyurea|20 mg/kg/day PO
552876|NCT00003577|Drug|CMF regimen|
552877|NCT00003577|Drug|cyclophosphamide|
552878|NCT00003577|Drug|epirubicin hydrochloride|
552879|NCT00003577|Drug|fluorouracil|
552880|NCT00003577|Drug|methotrexate|
552881|NCT00003577|Procedure|adjuvant therapy|
552882|NCT00003577|Radiation|radiation therapy|
552883|NCT00003576|Drug|cisplatin|
552884|NCT00003576|Drug|fluorouracil|
552885|NCT00003576|Procedure|surgical procedure|
552886|NCT00003576|Radiation|radiation therapy|
552887|NCT00003569|Drug|cisplatin|
552888|NCT00003569|Drug|dimesna|
552889|NCT00003569|Drug|paclitaxel|
552890|NCT00003568|Biological|aldesleukin|
552891|NCT00003568|Biological|gp100 antigen|
552892|NCT00003568|Biological|incomplete Freund's adjuvant|
552893|NCT00003567|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
552894|NCT00003567|Biological|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
552895|NCT00003567|Biological|therapeutic autologous lymphocytes|
552896|NCT00003567|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
552897|NCT00003567|Drug|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
552898|NCT00003567|Drug|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
552899|NCT00003567|Procedure|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
552900|NCT00003566|Procedure|videothoracoscopy|
552901|NCT00003565|Drug|docetaxel|
552902|NCT00003560|Drug|carboplatin|
552903|NCT00003560|Drug|docetaxel|
552904|NCT00003558|Drug|carboplatin|
552905|NCT00003558|Drug|etoposide|
552906|NCT00003558|Drug|fluorouracil|
552907|NCT00003558|Drug|leucovorin calcium|
552908|NCT00003558|Drug|paclitaxel|
552909|NCT00003553|Biological|anti-thymocyte globulin|Given IV
552910|NCT00003553|Drug|cyclophosphamide|Given IV
552911|NCT00003553|Drug|cyclosporine|Given IV
552912|NCT00003553|Drug|fludarabine phosphate|Given IV
552913|NCT00003553|Drug|methotrexate|Given as GVHD prophylaxis
552914|NCT00003553|Drug|mycophenolate mofetil|Given as GVHD prophylaxis
552915|NCT00003538|Biological|graft versus host disease prophylaxis/therapy|
552916|NCT00003538|Procedure|allogeneic bone marrow transplantation|
552917|NCT00003537|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
552918|NCT00003536|Drug|antineoplaston A10|
552919|NCT00003536|Drug|methotrexate|
552920|NCT00003536|Procedure|alternative product therapy|
552921|NCT00003536|Procedure|biological therapy|
552922|NCT00003536|Procedure|biologically based therapies|
552923|NCT00003536|Procedure|cancer prevention intervention|
552924|NCT00003536|Procedure|chemotherapy|
552925|NCT00003536|Procedure|complementary and alternative therapy|
552926|NCT00003536|Procedure|differentiation therapy|
552927|NCT00003535|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
552928|NCT00003534|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Refractory Stage IV Prostate Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552929|NCT00003533|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Metastatic Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552972|NCT00003505|Procedure|biological therapy|
552930|NCT00003532|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552931|NCT00003531|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552932|NCT00003530|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Primary Liver Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552933|NCT00003526|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of Unknown Primary Origin will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552934|NCT00003525|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552935|NCT00003524|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552936|NCT00003522|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552937|NCT00003521|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552938|NCT00003520|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552939|NCT00003517|Drug|antineoplaston A10|
552940|NCT00003517|Drug|antineoplaston AS2-1|
552941|NCT00003517|Drug|bicalutamide|
552942|NCT00003517|Drug|flutamide|
552943|NCT00003517|Drug|leuprolide acetate|
552944|NCT00003517|Procedure|alternative product therapy|
552945|NCT00003517|Procedure|antiandrogen therapy|
552946|NCT00003517|Procedure|biological therapy|
552947|NCT00003517|Procedure|biologically based therapies|
552948|NCT00003517|Procedure|cancer prevention intervention|
552949|NCT00003517|Procedure|complementary and alternative therapy|
552950|NCT00003517|Procedure|differentiation therapy|
552951|NCT00003517|Procedure|endocrine therapy|
552952|NCT00003517|Procedure|hormone therapy|
552953|NCT00003516|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
552954|NCT00003515|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552955|NCT00003514|Drug|antineoplaston A10|
552956|NCT00003514|Drug|antineoplaston AS2-1|
552957|NCT00003514|Procedure|alternative product therapy|
552958|NCT00003514|Procedure|biological therapy|
552959|NCT00003514|Procedure|biologically based therapies|
552960|NCT00003514|Procedure|cancer prevention intervention|
552961|NCT00003514|Procedure|complementary and alternative therapy|
552962|NCT00003514|Procedure|differentiation therapy|
552963|NCT00003513|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552964|NCT00003512|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552965|NCT00003511|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552966|NCT00003509|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Melanoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552967|NCT00003508|Drug|antineoplaston A10|
552968|NCT00003508|Drug|antineoplaston AS2-1|
552969|NCT00003505|Drug|antineoplaston A10|
552970|NCT00003505|Drug|antineoplaston AS2-1|
552971|NCT00003505|Procedure|alternative product therapy|
552973|NCT00003505|Procedure|biologically based therapies|
552974|NCT00003505|Procedure|cancer prevention intervention|
552975|NCT00003505|Procedure|complementary and alternative therapy|
552976|NCT00003505|Procedure|differentiation therapy|
552977|NCT00003502|Drug|antineoplaston A10|
552978|NCT00003502|Drug|antineoplaston AS2-1|
552979|NCT00003502|Procedure|alternative product therapy|
552980|NCT00003502|Procedure|biological therapy|
552981|NCT00003502|Procedure|biologically based therapies|
552982|NCT00003502|Procedure|cancer prevention intervention|
552983|NCT00003502|Procedure|complementary and alternative therapy|
552984|NCT00003502|Procedure|differentiation therapy|
552985|NCT00003501|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552986|NCT00003500|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552987|NCT00003499|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Low-grade non-Hodgkin's lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552988|NCT00003498|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552989|NCT00003497|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
552990|NCT00003496|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552991|NCT00003495|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552992|NCT00003494|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552993|NCT00003492|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552994|NCT00003491|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552995|NCT00003489|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
552996|NCT00003487|Drug|antineoplaston A10|
552997|NCT00003487|Drug|antineoplaston AS2-1|
552998|NCT00003486|Drug|antineoplaston A10|
552999|NCT00003486|Drug|antineoplaston AS2-1|
553000|NCT00003486|Procedure|alternative product therapy|
553001|NCT00003486|Procedure|biological therapy|
553002|NCT00003486|Procedure|biologically based therapies|
553003|NCT00003486|Procedure|cancer prevention intervention|
553004|NCT00003486|Procedure|complementary and alternative therapy|
553005|NCT00003486|Procedure|differentiation therapy|
553006|NCT00003485|Drug|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553007|NCT00003483|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
553008|NCT00003479|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
553009|NCT00003478|Procedure|conventional surgery|
553010|NCT00003478|Radiation|iodine I 131 monoclonal antibody 81C6|
553011|NCT00003478|Radiation|radiation therapy|
553012|NCT00003477|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
553013|NCT00003476|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
553070|NCT00003422|Procedure|conventional surgery|
553071|NCT00003422|Procedure|neoadjuvant therapy|
553072|NCT00003422|Radiation|radiation therapy|
553073|NCT00003420|Procedure|computed tomography|
553157|NCT00003273|Drug|leucovorin calcium|
553014|NCT00003475|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553015|NCT00003474|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553016|NCT00003473|Drug|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
553017|NCT00003473|Drug|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
553018|NCT00003472|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/progressive Oligodendroglioma will receive Antineoplaston therapy (Atengenal + Astugenal).
553019|NCT00003471|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a recurrent/progressive low grade astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553020|NCT00003470|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553021|NCT00003469|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
553022|NCT00003468|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
553023|NCT00003467|Drug|carmustine|
553024|NCT00003467|Drug|polifeprosan 20 with carmustine implant|
553025|NCT00003467|Procedure|surgical procedure|
553026|NCT00003466|Drug|temozolomide|
553027|NCT00003462|Drug|busulfan|
553028|NCT00003461|Procedure|surgical procedure|
553029|NCT00003461|Radiation|astatine At 211 monoclonal antibody 81C6|
553030|NCT00003460|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
553031|NCT00003459|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
553032|NCT00003458|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
553033|NCT00003457|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
553034|NCT00003456|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553035|NCT00003455|Drug|antineoplaston A10|
553036|NCT00003455|Drug|antineoplaston AS2-1|
553037|NCT00003455|Procedure|alternative product therapy|
553038|NCT00003455|Procedure|biological therapy|
553039|NCT00003455|Procedure|biologically based therapies|
553040|NCT00003455|Procedure|cancer prevention intervention|
553041|NCT00003455|Procedure|complementary and alternative therapy|
553042|NCT00003455|Procedure|differentiation therapy|
553043|NCT00003454|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553044|NCT00003453|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553045|NCT00003452|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
553046|NCT00003440|Drug|paclitaxel|Given IV over 1 hour or 3 hours
553047|NCT00003440|Biological|trastuzumab|Given IV
553048|NCT00003440|Procedure|quality-of-life assessment|Ancillary studies
553049|NCT00003440|Other|laboratory biomarker analysis|Correlative studies
553050|NCT00003437|Drug|asparaginase|
553051|NCT00003437|Drug|cyclophosphamide|
553052|NCT00003437|Drug|cytarabine|
553053|NCT00003437|Drug|daunorubicin hydrochloride|
553054|NCT00003437|Drug|dexamethasone|
553055|NCT00003437|Drug|doxorubicin hydrochloride|
553056|NCT00003437|Drug|mercaptopurine|
553057|NCT00003437|Drug|methotrexate|
553058|NCT00003437|Drug|pegaspargase|
553059|NCT00003437|Drug|prednisolone|
553060|NCT00003437|Drug|thioguanine|
553061|NCT00003437|Drug|vincristine sulfate|
553062|NCT00003437|Radiation|radiation therapy|
553063|NCT00003429|Procedure|biopsy|
553064|NCT00003429|Procedure|computed tomography|
553065|NCT00003429|Procedure|positron emission tomography|
553066|NCT00003429|Radiation|fludeoxyglucose F 18|
553067|NCT00003422|Drug|fluorouracil|
553068|NCT00003422|Drug|leucovorin calcium|
553069|NCT00003422|Procedure|adjuvant therapy|
553074|NCT00003419|Procedure|antiviral therapy|
553075|NCT00003417|Drug|carmustine|
553076|NCT00003417|Radiation|radiation therapy|
553077|NCT00003404|Radiation|Adjuvant Radiotherapy|Adjuvant radiation therapy
553078|NCT00003389|Drug|Doxorubicin|given IV
553079|NCT00003389|Drug|Bleomycin|given IV
553080|NCT00003389|Drug|Vinblastine|given IV
553081|NCT00003389|Drug|Dacarbazine|given IV
553082|NCT00003389|Drug|Vincristine|given IV
553083|NCT00003389|Drug|Mechlorethamine|given IV
553084|NCT00003389|Drug|Etoposide|given IV
553085|NCT00003389|Drug|Prednisone|taken orally
553086|NCT00003389|Drug|Cyclophosphamide|given IV
553087|NCT00003389|Radiation|Radiotherapy|
553088|NCT00003385|Drug|carboplatin|
553089|NCT00003385|Drug|paclitaxel|
553090|NCT00003385|Drug|pegylated liposomal doxorubicin hydrochloride|
553091|NCT00003384|Other|Cervical Papanicolaou Test|Undergo Pap smear
553092|NCT00003384|Procedure|Conization|Undergo cone biopsy
553093|NCT00003384|Other|Laboratory Biomarker Analysis|Correlative studies
553094|NCT00003379|Drug|cisplatin|
553095|NCT00003379|Drug|paclitaxel|
553096|NCT00003379|Radiation|brachytherapy|
553097|NCT00003379|Radiation|radiation therapy|
553098|NCT00003377|Drug|cisplatin|
553099|NCT00003377|Drug|paclitaxel|
553100|NCT00003377|Radiation|brachytherapy|
553101|NCT00003377|Radiation|radiation therapy|
553102|NCT00003375|Drug|lomustine|
553103|NCT00003375|Drug|procarbazine hydrochloride|
553104|NCT00003375|Drug|vincristine sulfate|
553105|NCT00003375|Radiation|radiation therapy|
553106|NCT00003354|Procedure|conventional surgery|
553107|NCT00003354|Procedure|laparoscopic surgery|
553108|NCT00003342|Biological|filgrastim|
553109|NCT00003342|Drug|carboplatin|
553110|NCT00003342|Drug|doxorubicin hydrochloride|
553111|NCT00003342|Drug|gemcitabine hydrochloride|
553112|NCT00003342|Drug|paclitaxel|
553113|NCT00003336|Biological|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
553114|NCT00003336|Drug|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
553115|NCT00003336|Drug|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
553116|NCT00003336|Drug|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
553117|NCT00003336|Drug|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
553118|NCT00003336|Procedure|bone marrow ablation with stem cell support|
553119|NCT00003336|Procedure|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
553120|NCT00003336|Radiation|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
553121|NCT00003335|Biological|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
553122|NCT00003335|Drug|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
553123|NCT00003335|Drug|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
553124|NCT00003335|Drug|melphalan|melphalan IV for three days on days -4 to -2
553125|NCT00003335|Drug|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
553126|NCT00003335|Procedure|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
553127|NCT00003335|Radiation|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
553128|NCT00003332|Drug|cisplatin|
553129|NCT00003332|Drug|gemcitabine hydrochloride|
553130|NCT00003332|Procedure|surgical procedure|
553131|NCT00003332|Radiation|radiation therapy|
553132|NCT00003329|Genetic|gene mapping|
553133|NCT00003325|Procedure|Sentinel lymph node mapping|Sentinel lymph node mapping
553134|NCT00003309|Biological|filgrastim|
553135|NCT00003309|Drug|cisplatin|
553136|NCT00003309|Drug|cyclophosphamide|
553137|NCT00003309|Drug|etoposide|
553138|NCT00003309|Drug|vincristine sulfate|
553139|NCT00003309|Procedure|adjuvant therapy|
553140|NCT00003309|Radiation|radiation therapy|
553141|NCT00003308|Radiation|stereotactic radiosurgery|
553142|NCT00003292|Drug|ifosfamide|
553143|NCT00003291|Genetic|cytogenetic analysis|
553144|NCT00003291|Genetic|mutation analysis|
553145|NCT00003291|Other|laboratory biomarker analysis|
553146|NCT00003282|Drug|EF5|Given IV
553147|NCT00003282|Procedure|therapeutic conventional surgery|Undergo resection
553148|NCT00003282|Procedure|biopsy|Undergo biopsy
553149|NCT00003282|Other|pharmacological study|Correlative studies
553150|NCT00003278|Drug|dexamethasone|
553151|NCT00003278|Radiation|radiation therapy|
553152|NCT00003273|Biological|filgrastim|
553153|NCT00003273|Drug|carboplatin|
553154|NCT00003273|Drug|cisplatin|
553155|NCT00003273|Drug|cyclophosphamide|
553156|NCT00003273|Drug|etoposide|
553158|NCT00003273|Drug|methotrexate|
553159|NCT00003273|Drug|temozolomide|
553160|NCT00003273|Drug|thiotepa|
553161|NCT00003273|Drug|vincristine sulfate|
553162|NCT00003273|Procedure|autologous bone marrow transplantation|
553163|NCT00003273|Procedure|peripheral blood stem cell transplantation|
553164|NCT00003273|Radiation|radiation therapy|
553165|NCT00003268|Drug|amifostine trihydrate|
553166|NCT00003268|Drug|cytarabine|
553167|NCT00003268|Drug|idarubicin|
553168|NCT00003261|Drug|methotrexate|
553169|NCT00003261|Drug|zidovudine|
553170|NCT00003261|Procedure|neoadjuvant therapy|
553171|NCT00003261|Radiation|radiation therapy|
553172|NCT00003243|Biological|aldesleukin|
553173|NCT00003243|Biological|filgrastim|
553174|NCT00003243|Biological|therapeutic allogeneic lymphocytes|
553175|NCT00003243|Drug|cyclophosphamide|
553176|NCT00003243|Drug|etoposide|
553177|NCT00003243|Drug|pegylated liposomal doxorubicin hydrochloride|
553178|NCT00003216|Drug|fluorouracil|
553179|NCT00003216|Drug|gemcitabine hydrochloride|
553180|NCT00003216|Radiation|radiation therapy|
553181|NCT00003215|Biological|filgrastim|
553182|NCT00003215|Drug|CHOP regimen|
553183|NCT00003215|Drug|cyclophosphamide|
553184|NCT00003215|Drug|cytarabine|
553185|NCT00003215|Drug|doxorubicin hydrochloride|
553186|NCT00003215|Drug|etoposide|
553187|NCT00003215|Drug|leucovorin calcium|
553188|NCT00003215|Drug|melphalan|
553189|NCT00003215|Drug|methotrexate|
553190|NCT00003215|Drug|methylprednisolone|
553191|NCT00003215|Drug|mitoxantrone hydrochloride|
553192|NCT00003215|Drug|prednisone|
553193|NCT00003215|Drug|therapeutic hydrocortisone|
553194|NCT00003215|Drug|vincristine sulfate|
553195|NCT00003215|Procedure|bone marrow ablation with stem cell support|
553196|NCT00003215|Procedure|peripheral blood stem cell transplantation|
553197|NCT00003215|Radiation|radiation therapy|
553198|NCT00003204|Drug|cyclophosphamide|Given IV
553199|NCT00003204|Drug|fludarabine phosphate|Given IV
553200|NCT00003204|Drug|vincristine sulfate|Given IV
553201|NCT00003204|Drug|prednisone|Given PO
553202|NCT00003204|Biological|rituximab|Given IV
553203|NCT00003204|Other|laboratory biomarker analysis|Correlative studies
553204|NCT00003199|Drug|tamoxifen citrate|Given orally
553205|NCT00003199|Drug|busulfan|Given orally
553206|NCT00003199|Drug|thiotepa|Given IV
553207|NCT00003199|Drug|melphalan|Given IV
553208|NCT00003199|Biological|aldesleukin|Given SC
553209|NCT00003199|Biological|sargramostim|Given SC
553210|NCT00003199|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
553211|NCT00003199|Radiation|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
553212|NCT00003194|Biological|filgrastim|
553213|NCT00003194|Drug|carboplatin|
553214|NCT00003194|Drug|cyclophosphamide|
553215|NCT00003194|Drug|etoposide|
553216|NCT00003194|Drug|thiotepa|
553217|NCT00003194|Drug|topotecan hydrochloride|
553218|NCT00003194|Procedure|peripheral blood stem cell transplantation|
553219|NCT00003179|Drug|medroxyprogesterone|
553220|NCT00003178|Biological|filgrastim|
553221|NCT00003178|Drug|cladribine|
553222|NCT00003178|Drug|idarubicin|
553223|NCT00003174|Drug|bryostatin 1|
553224|NCT00003174|Drug|cladribine|
553225|NCT00003159|Drug|carboplatin|
553226|NCT00003159|Drug|cisplatin|
553227|NCT00003159|Drug|docetaxel|
553228|NCT00003159|Drug|gemcitabine hydrochloride|
553229|NCT00003159|Drug|ifosfamide|
553230|NCT00003159|Drug|mitomycin C|
553231|NCT00003159|Drug|paclitaxel|
553232|NCT00003159|Drug|vinblastine sulfate|
553233|NCT00003159|Drug|vinorelbine tartrate|
553234|NCT00003159|Procedure|conventional surgery|
553235|NCT00003159|Procedure|neoadjuvant therapy|
553236|NCT00003153|Biological|therapeutic allogeneic lymphocytes|
553237|NCT00003145|Drug|Fludarabine Phosphate|Given IV
553238|NCT00003145|Radiation|Total-Body Irradiation|Undergo TBI
553239|NCT00003145|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
553240|NCT00003145|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
553241|NCT00003145|Drug|Cyclosporine|Given PO or IV
553242|NCT00003145|Drug|Mycophenolate Mofetil|Given PO or IV
553243|NCT00003145|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
553244|NCT00003145|Other|Laboratory Biomarker Analysis|Correlative studies
553245|NCT00003140|Drug|letrozole|Given orally
553246|NCT00003140|Other|placebo|Given orally
553247|NCT00003138|Biological|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
553248|NCT00003138|Biological|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
553249|NCT00003138|Procedure|Transfusion|Red cell and platelet transfusions
553250|NCT00003135|Drug|fluorouracil|
553251|NCT00003135|Drug|pegylated liposomal doxorubicin hydrochloride|
553252|NCT00003135|Procedure|hyperthermia treatment|
553253|NCT00003128|Biological|filgrastim|
553254|NCT00003128|Drug|ifosfamide|
553255|NCT00003128|Drug|paclitaxel|
553256|NCT00003122|Procedure|surgical procedure|
553257|NCT00003119|Biological|filgrastim|
553258|NCT00003119|Biological|sargramostim|
553259|NCT00003119|Drug|carboplatin|
553260|NCT00003119|Drug|cyclophosphamide|
553261|NCT00003119|Drug|doxorubicin hydrochloride|
553262|NCT00003119|Drug|etoposide|
553263|NCT00003119|Procedure|adjuvant therapy|
553264|NCT00003119|Procedure|conventional surgery|
553265|NCT00003119|Radiation|radiation therapy|
553266|NCT00003116|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
553267|NCT00003116|Drug|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
553268|NCT00003116|Drug|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
553269|NCT00003116|Drug|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
553270|NCT00003116|Procedure|bone marrow ablation with stem cell support|
553271|NCT00003116|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
553272|NCT00003111|Drug|carboplatin|
553273|NCT00003111|Drug|cisplatin|
553274|NCT00003111|Drug|irinotecan hydrochloride|
553275|NCT00003111|Drug|paclitaxel|
553276|NCT00003111|Procedure|neoadjuvant therapy|
553277|NCT00003111|Procedure|surgical procedure|
553278|NCT00003111|Radiation|radiation therapy|
553279|NCT00003105|Biological|filgrastim|
553280|NCT00003105|Drug|cisplatin|
553281|NCT00003105|Drug|doxorubicin hydrochloride|
553282|NCT00003105|Drug|gemcitabine hydrochloride|
553283|NCT00003105|Drug|ifosfamide|
553284|NCT00003105|Drug|paclitaxel|
553285|NCT00003104|Radiation|radiation therapy|
553286|NCT00003096|Genetic|DNA ploidy analysis|
553287|NCT00003096|Genetic|comparative genomic hybridization|
553288|NCT00003096|Genetic|cytogenetic analysis|
553289|NCT00003096|Genetic|fluorescence in situ hybridization|
553290|NCT00003093|Biological|filgrastim|
553291|NCT00003093|Biological|sargramostim|
553292|NCT00003093|Drug|carboplatin|
553293|NCT00003093|Drug|cyclophosphamide|
553294|NCT00003093|Drug|doxorubicin hydrochloride|
553295|NCT00003093|Drug|etoposide|
553296|NCT00003093|Procedure|conventional surgery|
553297|NCT00003093|Procedure|neoadjuvant therapy|
553298|NCT00003092|Drug|paclitaxel|
553299|NCT00003067|Biological|aldesleukin|
553300|NCT00003067|Biological|lymphokine-activated killer cells|
553301|NCT00003065|Biological|filgrastim|
553302|NCT00003065|Drug|paclitaxel|
553303|NCT00003065|Drug|topotecan hydrochloride|
553304|NCT00003063|Biological|recombinant interferon alfa|
553305|NCT00003063|Drug|fluorouracil|
553306|NCT00003063|Drug|leucovorin calcium|
553307|NCT00003063|Drug|levamisole hydrochloride|
553308|NCT00003053|Drug|cisplatin|
553309|NCT00003053|Drug|etoposide|
553310|NCT00003053|Procedure|adjuvant therapy|
553311|NCT00003052|Drug|doxorubicin hydrochloride|
553312|NCT00003052|Drug|etoposide|
553313|NCT00003052|Drug|ifosfamide|
553314|NCT00003052|Procedure|conventional surgery|
553315|NCT00003052|Procedure|hyperthermia treatment|
553316|NCT00003052|Radiation|radiation therapy|
553317|NCT00003049|Drug|fluorouracil|
553318|NCT00003049|Drug|leucovorin calcium|
553319|NCT00003049|Procedure|conventional surgery|
553320|NCT00003049|Radiation|radiation therapy|
553321|NCT00003042|Biological|filgrastim|
553322|NCT00003042|Drug|cisplatin|
553323|NCT00003042|Drug|cyclophosphamide|
553324|NCT00003042|Drug|doxorubicin hydrochloride|
553325|NCT00003042|Drug|melphalan|
553326|NCT00003042|Drug|mesna|
553327|NCT00003042|Drug|paclitaxel|
553328|NCT00003042|Drug|tamoxifen citrate|
553329|NCT00003042|Procedure|bone marrow ablation with stem cell support|
553330|NCT00003042|Procedure|conventional surgery|
553331|NCT00003042|Procedure|peripheral blood stem cell transplantation|
553332|NCT00003034|Drug|doxorubicin hydrochloride|Given IV
553333|NCT00003034|Drug|ranpirnase|Given IV
553334|NCT00003029|Drug|cisplatin|
553335|NCT00003029|Drug|fluorouracil|
553336|NCT00003027|Biological|aldesleukin|
553337|NCT00003027|Biological|filgrastim|
553338|NCT00003027|Biological|recombinant interferon alfa|
553339|NCT00003027|Drug|cisplatin|
553340|NCT00003027|Drug|dacarbazine|
553341|NCT00003027|Drug|vinblastine|
553342|NCT00003026|Drug|bicalutamide|
553343|NCT00003026|Drug|flutamide|
553344|NCT00003026|Drug|triptorelin|
553345|NCT00003026|Radiation|radiation therapy|
553346|NCT00003023|Biological|BCG vaccine|
553347|NCT00003023|Biological|monoclonal antibody A1G4 anti-idiotype vaccine|
553348|NCT00003022|Radiation|iodine I 131 monoclonal antibody 3F8|
553349|NCT00003016|Drug|tamoxifen citrate|
553350|NCT00003016|Procedure|adjuvant therapy|
553351|NCT00003013|Drug|CMF regimen|
553352|NCT00003013|Drug|cyclophosphamide|
553353|NCT00003013|Drug|doxorubicin hydrochloride|
553354|NCT00003013|Drug|fluorouracil|
553355|NCT00003013|Drug|methotrexate|
553356|NCT00003013|Drug|paclitaxel|
553357|NCT00003013|Drug|tamoxifen citrate|
553358|NCT00003013|Procedure|conventional surgery|
553359|NCT00003013|Radiation|radiation therapy|
553360|NCT00002996|Drug|flecainide acetate|
553361|NCT00002995|Biological|dactinomycin|
553362|NCT00002995|Biological|filgrastim|
553363|NCT00002995|Biological|sargramostim|
553364|NCT00002995|Drug|cyclophosphamide|
553365|NCT00002995|Drug|vincristine sulfate|
553366|NCT00002995|Radiation|radiation therapy|
553367|NCT00002990|Biological|BCG vaccine|
553368|NCT00002986|Drug|carmustine|
553369|NCT00002986|Drug|topotecan hydrochloride|
553370|NCT00002982|Biological|filgrastim|
553371|NCT00002982|Drug|carboplatin|
553372|NCT00002982|Drug|carmustine|
553373|NCT00002982|Drug|cytarabine|
553374|NCT00002982|Drug|etoposide|
553375|NCT00002982|Drug|ifosfamide|
553376|NCT00002982|Drug|melphalan|
553377|NCT00002982|Procedure|autologous bone marrow transplantation|
553378|NCT00002982|Procedure|peripheral blood stem cell transplantation|
553379|NCT00002982|Radiation|radiation therapy|
553380|NCT00002981|Procedure|positron emission tomography|
553381|NCT00002981|Radiation|fludeoxyglucose F 18|
553382|NCT00002981|Radiation|methionine C 11|
553383|NCT00002976|Drug|conjugated estrogens|
553384|NCT00002975|Drug|aminolevulinic acid|
553385|NCT00002968|Biological|edrecolomab|Given IV
553386|NCT00002968|Other|laboratory biomarker analysis|Correlative studies
553387|NCT00002963|Drug|aminolevulinic acid hydrochloride|
553388|NCT00002963|Procedure|conventional surgery|
553389|NCT00002951|Drug|fluorouracil|
553390|NCT00002951|Drug|hydroxyurea|
553391|NCT00002951|Procedure|surgical procedure|
553392|NCT00002951|Radiation|radiation therapy|
553393|NCT00002948|Biological|filgrastim|
553394|NCT00002948|Drug|topotecan hydrochloride|
553395|NCT00002948|Procedure|bone marrow ablation with stem cell support|
553396|NCT00002948|Procedure|peripheral blood stem cell transplantation|
553397|NCT00002944|Drug|carboplatin|Given IV
553398|NCT00002944|Drug|lomustine|Given IV
553399|NCT00002944|Drug|procarbazine hydrochloride|Given PO
553400|NCT00002944|Drug|thioguanine|Given PO
553401|NCT00002944|Drug|vincristine sulfate|Given PO and IV
553402|NCT00002943|Drug|carboplatin|
553403|NCT00002943|Drug|cyclophosphamide|
553404|NCT00002943|Drug|etoposide|
553405|NCT00002943|Procedure|autologous bone marrow transplantation|
553406|NCT00002941|Drug|carmustine|
553407|NCT00002941|Drug|cyclophosphamide|
553408|NCT00002941|Drug|etoposide|
553409|NCT00002941|Drug|mesna|
553410|NCT00002941|Procedure|peripheral blood stem cell transplantation|
553411|NCT00002938|Procedure|conventional surgery|Salvage prostatectomy
553412|NCT00002931|Biological|filgrastim|5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.
553413|NCT00002931|Drug|carboplatin|AUC=7, daily X 3
553414|NCT00002931|Drug|etoposide|20 mg/kg by 2 hours infusion daily X 3
553415|NCT00002931|Drug|ifosfamide|3 gm/m2 IV over 30 minutes X 3 days
553416|NCT00002931|Drug|paclitaxel|425 mg/m2 as 24 hour continuous infusion
553417|NCT00002931|Procedure|autologous bone marrow transplantation|Given in two divided infusions on day -2 and day 0
553418|NCT00002931|Procedure|bone marrow ablation with stem cell support|Two cycles of high dose chemotherapy followed by stem cell reinfusion
553419|NCT00002926|Drug|cytarabine|
553420|NCT00002926|Drug|etoposide|
553421|NCT00002926|Drug|idarubicin|
553422|NCT00002926|Procedure|allogeneic bone marrow transplantation|
553423|NCT00002926|Procedure|peripheral blood stem cell transplantation|
553424|NCT00002920|Drug|medroxyprogesterone|
553425|NCT00002920|Drug|tamoxifen citrate|
553426|NCT00002920|Procedure|adjuvant therapy|
553427|NCT00002916|Biological|human papillomavirus 16 E7 peptide|
553428|NCT00002916|Biological|synthetic human papillomavirus 16 E6 peptide|
553429|NCT00002916|Procedure|adjuvant therapy|
553430|NCT00002916|Procedure|surgical procedure|
553431|NCT00002916|Radiation|radiation therapy|
553432|NCT00002913|Drug|paclitaxel|Given IV
553433|NCT00002913|Drug|cisplatin|Given IV
553434|NCT00002913|Drug|topotecan hydrochloride|Given IV
553435|NCT00002913|Biological|filgrastim|Given SC
553436|NCT00002900|Procedure|management of therapy complications|
553437|NCT00002899|Procedure|adjuvant therapy|
553438|NCT00002899|Radiation|radiation therapy|
553439|NCT00002899|Radiation|stereotactic radiosurgery|
553440|NCT00002898|Biological|dactinomycin|
553441|NCT00002898|Drug|carboplatin|
553442|NCT00002898|Drug|cyclophosphamide|
553443|NCT00002898|Drug|epirubicin hydrochloride|
553444|NCT00002898|Drug|etoposide|
553445|NCT00002898|Drug|ifosfamide|
553446|NCT00002898|Drug|vincristine sulfate|
553447|NCT00002898|Procedure|adjuvant therapy|
553448|NCT00002898|Procedure|conventional surgery|
553449|NCT00002898|Procedure|neoadjuvant therapy|
553450|NCT00002898|Radiation|brachytherapy|
553451|NCT00002898|Radiation|radiation therapy|
553452|NCT00002895|Drug|chemotherapy|
553453|NCT00002894|Drug|carboplatin|
553454|NCT00002894|Drug|cisplatin|
553455|NCT00002894|Drug|paclitaxel|
553456|NCT00002883|Drug|cisplatin|
553457|NCT00002883|Drug|fluorouracil|
553458|NCT00002883|Procedure|adjuvant therapy|
553459|NCT00002883|Procedure|conventional surgery|
553460|NCT00002883|Procedure|neoadjuvant therapy|
553461|NCT00002882|Biological|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
553462|NCT00002882|Biological|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
553463|NCT00002882|Drug|Cisplatin|IV Days 1-4
553464|NCT00002882|Drug|Dacarbazine|IVPB on day 1
553465|NCT00002882|Drug|Vinblastine|IVPB on days 1-4
553466|NCT00002882|Procedure|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
553467|NCT00002874|Drug|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
553468|NCT00002874|Radiation|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
553469|NCT00002874|Drug|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
553470|NCT00002860|Procedure|Surgery|Complete surgical resection of metastatic melanoma
553471|NCT00002855|Drug|Bicalutamide|
553472|NCT00002855|Drug|Doxorubicin hydrochloride|
553473|NCT00002855|Drug|Estramustine Phosphate Sodium|
553474|NCT00002855|Drug|Flutamide|
553475|NCT00002855|Drug|Ketoconazole|
553476|NCT00002855|Drug|Nilutamide|
553477|NCT00002855|Drug|Therapeutic Hydrocortisone|
553478|NCT00002855|Drug|Vinblastine|
553479|NCT00002855|Procedure|Conventional Surgery|Surgical castration
553480|NCT00002854|Biological|filgrastim|
553481|NCT00002854|Drug|carboplatin|
553482|NCT00002854|Drug|cisplatin|
553483|NCT00002854|Drug|cyclophosphamide|
553484|NCT00002854|Drug|etoposide|
553485|NCT00002854|Drug|ifosfamide|
553486|NCT00002854|Drug|mesna|
553487|NCT00002854|Drug|paclitaxel|
553488|NCT00002854|Procedure|peripheral blood stem cell transplantation|
553489|NCT00002852|Drug|paclitaxel|Given IV
553490|NCT00002852|Drug|carboplatin|Given IV
553491|NCT00002852|Procedure|therapeutic conventional surgery|Undergo surgery
553492|NCT00002851|Procedure|adjuvant therapy|
553493|NCT00002851|Radiation|low-LET electron therapy|
553494|NCT00002851|Radiation|low-LET photon therapy|
553495|NCT00002850|Drug|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
553496|NCT00002850|Drug|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
553497|NCT00002850|Drug|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet [TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole] every 12 hours for two months..
553498|NCT00002849|Biological|recombinant interferon alfa|first 2 years
553499|NCT00002849|Drug|dexamethasone|40 mg*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles*
553500|NCT00002848|Procedure|psychosocial assessment and care|
553501|NCT00002848|Procedure|quality-of-life assessment|
553502|NCT00002847|Biological|aldesleukin|
553503|NCT00002847|Biological|recombinant interferon alfa|
553504|NCT00002847|Procedure|conventional surgery|
553505|NCT00002846|Biological|aldesleukin|
553506|NCT00002846|Procedure|conventional surgery|
553507|NCT00002842|Drug|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
553508|NCT00002842|Drug|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
553509|NCT00002842|Drug|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
553510|NCT00002842|Procedure|adjuvant therapy|Chemotherapy given after hepatic resection
553511|NCT00002842|Procedure|conventional surgery|Hepatic resection
553512|NCT00002839|Drug|cisplatin|
553513|NCT00002839|Drug|fluorouracil|
553514|NCT00002839|Procedure|conventional surgery|
553515|NCT00002839|Procedure|neoadjuvant therapy|
553516|NCT00002839|Radiation|radiation therapy|
553517|NCT00002810|Biological|filgrastim|
553518|NCT00002810|Drug|melphalan|
553519|NCT00002810|Procedure|bone marrow ablation with stem cell support|
553520|NCT00002810|Procedure|peripheral blood stem cell transplantation|
553521|NCT00002809|Biological|anti-thymocyte globulin|
553522|NCT00002809|Biological|filgrastim|
553523|NCT00002809|Biological|sargramostim|
553524|NCT00002809|Biological|therapeutic immune globulin|
553525|NCT00002809|Drug|cyclophosphamide|
553526|NCT00002809|Drug|methotrexate|
553527|NCT00002809|Drug|tacrolimus|
553528|NCT00002809|Procedure|allogeneic bone marrow transplantation|
553529|NCT00002809|Radiation|radiation therapy|
553530|NCT00002807|Radiation|radiation therapy|45 Gy in 25 fractions over 5 weeks
553531|NCT00002798|Drug|asparaginase|
553532|NCT00002798|Drug|daunorubicin hydrochloride|
553533|NCT00002798|Drug|fludarabine phosphate|
553534|NCT00002798|Drug|therapeutic hydrocortisone|
553535|NCT00002798|Procedure|allogeneic bone marrow transplantation|
553536|NCT00002798|Radiation|3-dimensional conformal radiation therapy|
553537|NCT00002798|Biological|filgrastim|Given SC
553538|NCT00002798|Drug|cytarabine|Given IV or IT
553539|NCT00002798|Drug|idarubicin|Given IV
553540|NCT00002798|Drug|dexamethasone|Given PO
553541|NCT00002798|Drug|thioguanine|Given PO
553542|NCT00002798|Drug|etoposide|Given IV
553543|NCT00002798|Drug|methotrexate|Given IT
553544|NCT00002798|Drug|cyclophosphamide|Given IV
553545|NCT00002798|Biological|aldesleukin|
553546|NCT00002798|Drug|busulfan|
553547|NCT00002796|Drug|fluorouracil|Given IV
553548|NCT00002796|Drug|sodium phenylbutyrate|Given IV
553549|NCT00002796|Drug|indomethacin|Given orally
553550|NCT00002796|Biological|recombinant interferon gamma|Given subcutaneously
553551|NCT00002792|Drug|busulfan|
553552|NCT00002792|Drug|cyclophosphamide|
553553|NCT00002792|Drug|cyclosporine|
553554|NCT00002792|Drug|methotrexate|
553555|NCT00002792|Drug|tacrolimus|
553556|NCT00002792|Procedure|allogeneic bone marrow transplantation|
553557|NCT00002792|Procedure|peripheral blood stem cell transplantation|
553558|NCT00002778|Biological|sargramostim|
553559|NCT00002778|Biological|therapeutic allogeneic lymphocytes|
553560|NCT00002778|Procedure|allogeneic bone marrow transplantation|
553561|NCT00002778|Procedure|in vitro-treated bone marrow transplantation|
553562|NCT00002771|Biological|recombinant interferon alfa|
553563|NCT00002771|Drug|busulfan|
553564|NCT00002771|Drug|cytarabine|
553565|NCT00002771|Drug|hydroxyurea|
553566|NCT00002771|Drug|idarubicin|
553567|NCT00002771|Procedure|allogeneic bone marrow transplantation|
553568|NCT00002771|Procedure|autologous bone marrow transplantation|
553569|NCT00002771|Procedure|peripheral blood stem cell transplantation|
553570|NCT00002771|Radiation|radiation therapy|
553571|NCT00002766|Biological|dactinomycin|
553572|NCT00002766|Biological|sargramostim|
553573|NCT00002766|Drug|carmustine|
553574|NCT00002766|Drug|cyclophosphamide|
553575|NCT00002766|Drug|cytarabine|
553576|NCT00002766|Drug|daunorubicin hydrochloride|
553577|NCT00002766|Drug|doxorubicin hydrochloride|
553578|NCT00002766|Drug|etoposide|
553579|NCT00002766|Drug|mercaptopurine|
553580|NCT00002766|Drug|methotrexate|
553581|NCT00002766|Drug|mitoxantrone hydrochloride|
553582|NCT00002766|Drug|pegaspargase|
553583|NCT00002766|Drug|prednisone|
553584|NCT00002766|Drug|vincristine sulfate|
553585|NCT00002766|Radiation|radiation therapy|
553586|NCT00002762|Behavioral|patient interviewing to obtain menstrual history|
553587|NCT00002762|Procedure|blood sampling|
553588|NCT00002757|Biological|filgrastim|
553589|NCT00002757|Drug|cyclophosphamide|
553590|NCT00002757|Drug|cytarabine|
553591|NCT00002757|Drug|doxorubicin hydrochloride|
553592|NCT00002757|Drug|etoposide|
553593|NCT00002757|Drug|methotrexate|
553594|NCT00002757|Drug|prednisolone|
553595|NCT00002757|Drug|prednisone|
553596|NCT00002757|Drug|therapeutic hydrocortisone|
553597|NCT00002757|Drug|vincristine sulfate|
553598|NCT00002756|Biological|filgrastim|
553599|NCT00002756|Drug|asparaginase|
553600|NCT00002756|Drug|cyclophosphamide|
553601|NCT00002756|Drug|cytarabine|
553602|NCT00002756|Drug|daunorubicin hydrochloride|
553603|NCT00002756|Drug|etoposide|
553604|NCT00002756|Drug|leucovorin calcium|
553605|NCT00002756|Drug|mercaptopurine|
553606|NCT00002756|Drug|methotrexate|
553607|NCT00002756|Drug|prednisone|
553608|NCT00002756|Drug|therapeutic hydrocortisone|
553609|NCT00002756|Drug|vincristine sulfate|
553610|NCT00002746|Biological|aldesleukin|
553611|NCT00002738|Drug|leucovorin calcium|
553612|NCT00002738|Drug|trimetrexate glucuronate|
553613|NCT00002727|Radiation|radiation therapy|
553614|NCT00002720|Drug|tamoxifen citrate|
553615|NCT00002720|Procedure|conventional surgery|
553616|NCT00002718|Biological|anti-thymocyte globulin|
553617|NCT00002718|Biological|filgrastim|
553618|NCT00002718|Drug|cyclophosphamide|
553619|NCT00002718|Drug|cytarabine|
553620|NCT00002718|Drug|methylprednisolone|
553621|NCT00002718|Drug|thiotepa|
553622|NCT00002718|Procedure|in vitro-treated bone marrow transplantation|
553623|NCT00002718|Procedure|in vitro-treated peripheral blood stem cell transplantation|
553624|NCT00002718|Radiation|radiation therapy|
553625|NCT00002716|Drug|dexamethasone|
553626|NCT00002716|Drug|floxuridine|
553627|NCT00002716|Drug|fluorouracil|
553628|NCT00002716|Drug|leucovorin calcium|
553629|NCT00002716|Procedure|laparotomy|
553630|NCT00002716|Procedure|conventional surgery|
553631|NCT00002715|Biological|bleomycin sulfate|
553632|NCT00002715|Drug|Stanford V regimen|
553633|NCT00002715|Drug|doxorubicin hydrochloride|
553634|NCT00002715|Drug|etoposide|
553635|NCT00002715|Drug|mechlorethamine hydrochloride|
553636|NCT00002715|Drug|prednisone|
553637|NCT00002715|Drug|vinblastine|
553638|NCT00002715|Drug|vincristine sulfate|
553639|NCT00002706|Procedure|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
553640|NCT00002706|Other|Quality-of-Life Assessment|Ancillary studies
553641|NCT00002706|Procedure|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
553642|NCT00002702|Biological|aldesleukin|
553643|NCT00002702|Procedure|adjuvant therapy|
553644|NCT00002702|Procedure|conventional surgery|
553645|NCT00002702|Procedure|neoadjuvant therapy|
553646|NCT00002702|Radiation|radiation therapy|
553647|NCT00002700|Drug|asparaginase|
553648|NCT00002700|Drug|cyclophosphamide|
553649|NCT00002700|Drug|cytarabine|
553650|NCT00002700|Drug|daunorubicin hydrochloride|
553651|NCT00002700|Drug|dexamethasone|
553652|NCT00002700|Drug|doxorubicin hydrochloride|
553653|NCT00002700|Drug|leucovorin calcium|
553654|NCT00002700|Drug|mercaptopurine|
553655|NCT00002700|Drug|methotrexate|
553656|NCT00002700|Drug|mitoxantrone hydrochloride|
553657|NCT00002700|Drug|prednisolone|
553658|NCT00002700|Drug|prednisone|
553659|NCT00002700|Drug|therapeutic hydrocortisone|
553660|NCT00002700|Drug|vincristine sulfate|
553661|NCT00002700|Procedure|allogeneic bone marrow transplantation|
553662|NCT00002700|Procedure|autologous bone marrow transplantation|
553663|NCT00002700|Radiation|radiation therapy|
553664|NCT00002697|Biological|filgrastim|
553665|NCT00002697|Biological|sargramostim|
553666|NCT00002697|Drug|carboplatin|
553667|NCT00002697|Drug|etoposide|
553668|NCT00002697|Drug|ifosfamide|
553669|NCT00002697|Procedure|autologous bone marrow transplantation|
553670|NCT00002697|Procedure|bone marrow ablation with stem cell support|
553671|NCT00002697|Procedure|peripheral blood stem cell transplantation|
553672|NCT00002697|Radiation|radiation therapy|
553673|NCT00002696|Drug|CAF regimen|
553674|NCT00002696|Drug|CMF regimen|
553675|NCT00002696|Drug|cyclophosphamide|
553676|NCT00002696|Drug|doxorubicin hydrochloride|
553677|NCT00002696|Drug|fluorouracil|
553678|NCT00002696|Drug|methotrexate|
553679|NCT00002696|Procedure|adjuvant therapy|
553680|NCT00002696|Procedure|conventional surgery|
553681|NCT00002696|Procedure|neoadjuvant therapy|
553682|NCT00002696|Radiation|radiation therapy|
553683|NCT00002689|Drug|dexamethasone|
553684|NCT00002689|Drug|fluorouracil|
553685|NCT00002689|Radiation|brachytherapy|
553686|NCT00002689|Radiation|phosphorus P32|
553687|NCT00002689|Radiation|radiation therapy|
553688|NCT00002687|Biological|aldesleukin|
553689|NCT00002684|Drug|cisplatin|
553690|NCT00002684|Drug|ifosfamide|
553691|NCT00002684|Drug|paclitaxel|
553692|NCT00002681|Biological|aldesleukin|
553693|NCT00002681|Biological|daclizumab|
553694|NCT00002678|Drug|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
553695|NCT00002678|Drug|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
553696|NCT00002678|Drug|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
553697|NCT00002668|Behavioral|Observation|
553698|NCT00002668|Behavioral|Educational Intervention and Behavioral Skills Training|
553699|NCT00002663|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
553700|NCT00002662|Drug|docetaxel|
553701|NCT00002662|Drug|paclitaxel|
553702|NCT00002651|Drug|bicalutamide|Given orally
553703|NCT00002651|Drug|goserelin acetate|Given subcutaneously
553704|NCT00002651|Other|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
553705|NCT00002649|Biological|aldesleukin|Given IV
553706|NCT00002649|Biological|filgrastim|Given SC or IV
553707|NCT00002649|Drug|cyclophosphamide|Given IV
553708|NCT00002649|Drug|etoposide|Given IV
553709|NCT00002649|Radiation|radiation therapy|Undergo radiation therapy
553710|NCT00002649|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
553711|NCT00002649|Procedure|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
553712|NCT00002647|Drug|verteporfin|
553713|NCT00002647|Procedure|conventional surgery|
553714|NCT00002641|Biological|filgrastim|
553715|NCT00002641|Drug|doxorubicin hydrochloride|
553716|NCT00002641|Drug|ifosfamide|
553717|NCT00002641|Drug|isolated perfusion|
553718|NCT00002641|Procedure|adjuvant therapy|
553719|NCT00002641|Procedure|conventional surgery|
553720|NCT00002641|Radiation|radiation therapy|
553721|NCT00002633|Drug|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
553722|NCT00002633|Drug|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
553723|NCT00002633|Drug|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
553724|NCT00002633|Drug|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
553813|NCT00002556|Biological|recombinant interferon alfa-2b|Given SC
553814|NCT00002556|Other|laboratory biomarker analysis|Correlative studies
553815|NCT00002546|Drug|cisplatin|
553816|NCT00002546|Drug|ifosfamide|
553817|NCT00002546|Procedure|adjuvant therapy|
553818|NCT00002546|Radiation|radiation therapy|
553725|NCT00002633|Drug|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
553726|NCT00002633|Drug|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
553727|NCT00002633|Procedure|orchiectomy|Optional orchiectomy
553728|NCT00002633|Radiation|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
553729|NCT00002624|Procedure|adjuvant therapy|
553730|NCT00002624|Procedure|diagnostic thoracoscopy|
553731|NCT00002624|Procedure|therapeutic thoracoscopy|
553732|NCT00002624|Procedure|video-assisted surgery|
553733|NCT00002624|Radiation|radiation therapy|
553734|NCT00002623|Drug|carboplatin|
553735|NCT00002623|Drug|cisplatin|
553736|NCT00002623|Procedure|conventional surgery|
553737|NCT00002623|Radiation|radiation therapy|
553738|NCT00002615|Drug|cisplatin|
553739|NCT00002615|Drug|epirubicin hydrochloride|
553740|NCT00002615|Drug|fluorouracil|
553741|NCT00002615|Procedure|conventional surgery|
553742|NCT00002611|Biological|dactinomycin|
553743|NCT00002611|Biological|filgrastim|
553744|NCT00002611|Drug|cyclophosphamide|
553745|NCT00002611|Drug|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; <5% in the urine. The drug has a very short initial t½ of <20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
553746|NCT00002611|Drug|etoposide|
553747|NCT00002611|Drug|vincristine sulfate|
553748|NCT00002611|Procedure|conventional surgery|
553749|NCT00002611|Radiation|radiation therapy|
553750|NCT00002610|Biological|dactinomycin|
553751|NCT00002610|Biological|filgrastim|
553752|NCT00002610|Drug|carboplatin|
553753|NCT00002610|Drug|cyclophosphamide|
553754|NCT00002610|Drug|doxorubicin hydrochloride|
553755|NCT00002610|Drug|etoposide|
553756|NCT00002610|Drug|vincristine sulfate|IV
553757|NCT00002610|Procedure|conventional surgery|
553758|NCT00002610|Radiation|radiation therapy|
553759|NCT00002608|Drug|cisplatin|
553760|NCT00002608|Drug|doxorubicin hydrochloride|
553761|NCT00002608|Drug|tamoxifen citrate|
553762|NCT00002608|Procedure|conventional surgery|
553763|NCT00002608|Radiation|radiation therapy|
553764|NCT00002598|Biological|recombinant interferon alfa|
553765|NCT00002598|Biological|sargramostim|
553766|NCT00002598|Drug|cyclophosphamide|
553767|NCT00002598|Drug|cytarabine|
553768|NCT00002598|Drug|etoposide|
553769|NCT00002598|Drug|methotrexate|
553770|NCT00002598|Drug|mitoxantrone hydrochloride|
553771|NCT00002598|Procedure|bone marrow ablation with stem cell support|
553772|NCT00002598|Radiation|radiation therapy|
553773|NCT00002596|Biological|bleomycin sulfate|
553774|NCT00002596|Biological|filgrastim|
553775|NCT00002596|Drug|carboplatin|
553776|NCT00002596|Drug|cisplatin|
553777|NCT00002596|Drug|cyclophosphamide|
553778|NCT00002596|Drug|etoposide|
553779|NCT00002596|Procedure|autologous bone marrow transplantation|
553780|NCT00002596|Procedure|bone marrow ablation with stem cell support|
553781|NCT00002596|Procedure|conventional surgery|
553782|NCT00002596|Procedure|peripheral blood stem cell transplantation|
553783|NCT00002596|Radiation|radiation therapy|
553784|NCT00002594|Biological|Sargramostim|Given IV
553785|NCT00002594|Drug|cyclophosphamide|Given IV
553786|NCT00002594|Drug|melphalan|Given IV
553787|NCT00002594|Procedure|autologous bone marrow transplantation|
553788|NCT00002594|Procedure|bone marrow ablation with stem cell support|
553789|NCT00002594|Procedure|peripheral blood stem cell transplantation|
553790|NCT00002589|Biological|aldesleukin|
553791|NCT00002589|Biological|muromonab-CD3|
553792|NCT00002589|Biological|therapeutic autologous lymphocytes|
553793|NCT00002589|Procedure|adjuvant therapy|
553794|NCT00002586|Drug|13-cis retinoic acid|
553795|NCT00002586|Dietary Supplement|Tocopherol|
553796|NCT00002569|Drug|lomustine|
553797|NCT00002569|Drug|procarbazine hydrochloride|
553798|NCT00002569|Drug|vincristine sulfate|
553799|NCT00002569|Radiation|radiation therapy|
553800|NCT00002560|Biological|monoclonal antibody 3F8|
553801|NCT00002560|Biological|sargramostim|
553802|NCT00002558|Biological|filgrastim|
553803|NCT00002558|Drug|carboplatin|
553804|NCT00002558|Drug|etoposide|
553805|NCT00002558|Drug|ifosfamide|
553806|NCT00002558|Drug|paclitaxel|
553807|NCT00002558|Procedure|peripheral blood stem cell transplantation|
553808|NCT00002556|Drug|vincristine sulfate|Given IV
553809|NCT00002556|Drug|carmustine|Given IV
553810|NCT00002556|Drug|melphalan|Given PO
553811|NCT00002556|Drug|cyclophosphamide|Given IV
553812|NCT00002556|Drug|prednisone|Given PO
553819|NCT00002544|Drug|docetaxel|
553820|NCT00002544|Drug|mitoxantrone hydrochloride|
553821|NCT00002528|Drug|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
553822|NCT00002528|Procedure|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
553823|NCT00002528|Radiation|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
553824|NCT00002528|Procedure|Axillary clearance|Axillary node dissection.
553825|NCT00002523|Drug|fluorouracil|
553826|NCT00002523|Drug|leucovorin calcium|
553827|NCT00002523|Procedure|conventional surgery|
553828|NCT00002523|Radiation|radiation therapy|
553829|NCT00002522|Drug|cisplatin|
553830|NCT00002522|Drug|cyclophosphamide|
553831|NCT00002522|Drug|etoposide|
553832|NCT00002522|Procedure|autologous bone marrow transplantation|
553833|NCT00002522|Procedure|bone marrow ablation with stem cell support|
553834|NCT00002522|Procedure|peripheral blood stem cell transplantation|
553835|NCT00002522|Procedure|syngeneic bone marrow transplantation|
553836|NCT00002522|Radiation|radiation therapy|
553837|NCT00002521|Drug|cisplatin|
553838|NCT00002521|Drug|cyclophosphamide|
553839|NCT00002521|Drug|etoposide|
553840|NCT00002521|Procedure|autologous bone marrow transplantation|
553841|NCT00002521|Procedure|bone marrow ablation with stem cell support|
553842|NCT00002521|Procedure|peripheral blood stem cell transplantation|
553843|NCT00002521|Procedure|syngeneic bone marrow transplantation|
553844|NCT00002521|Radiation|radiation therapy|
553845|NCT00002517|Drug|cytarabine|
553846|NCT00002517|Drug|daunorubicin hydrochloride|
553847|NCT00002517|Drug|dexamethasone|
553848|NCT00002517|Drug|etoposide|
553849|NCT00002517|Drug|idarubicin|
553850|NCT00002517|Drug|mitoxantrone hydrochloride|
553851|NCT00002517|Drug|thioguanine|
553852|NCT00002517|Procedure|allogeneic bone marrow transplantation|
553853|NCT00002517|Radiation|radiation therapy|
553854|NCT00002515|Biological|filgrastim|
553855|NCT00002515|Drug|carboplatin|
553856|NCT00002515|Drug|thiotepa|
553857|NCT00002515|Drug|topotecan hydrochloride|
553858|NCT00002515|Procedure|autologous bone marrow transplantation|
553859|NCT00002515|Procedure|bone marrow ablation with stem cell support|
553860|NCT00002515|Procedure|in vitro-treated bone marrow transplantation|
553861|NCT00002514|Biological|sargramostim|
553862|NCT00002514|Drug|asparaginase|
553863|NCT00002514|Drug|cyclophosphamide|
553864|NCT00002514|Drug|cytarabine|
553865|NCT00002514|Drug|daunorubicin hydrochloride|
553866|NCT00002514|Drug|dexamethasone|
553867|NCT00002514|Drug|etoposide|
553868|NCT00002514|Drug|imatinib mesylate|
553869|NCT00002514|Drug|leucovorin calcium|
553870|NCT00002514|Drug|mercaptopurine|
553871|NCT00002514|Drug|methotrexate|
553872|NCT00002514|Drug|prednisone|
553873|NCT00002514|Drug|thioguanine|
553874|NCT00002514|Drug|vincristine sulfate|
553875|NCT00002514|Procedure|allogeneic bone marrow transplantation|
553876|NCT00002514|Procedure|autologous bone marrow transplantation|
553877|NCT00002514|Procedure|peripheral blood stem cell transplantation|
553878|NCT00002514|Radiation|radiation therapy|
553879|NCT00002511|Radiation|low-LET photon therapy|
553880|NCT00002490|Biological|BCG vaccine|
553881|NCT00002490|Drug|mitomycin C|
553882|NCT00002490|Radiation|radiation therapy|
553883|NCT00002484|Radiation|radiation therapy|
553884|NCT00002475|Biological|allogeneic tumor cell vaccine|
553885|NCT00002475|Biological|autologous tumor cell vaccine|
553886|NCT00002475|Biological|recombinant interferon alfa|
553887|NCT00002475|Biological|recombinant interferon gamma|
553888|NCT00002475|Biological|sargramostim|
553889|NCT00002475|Drug|cyclophosphamide|
553890|NCT00002474|Drug|carboplatin|
553891|NCT00002474|Drug|cyclophosphamide|
553892|NCT00002474|Drug|mitoxantrone hydrochloride|
553893|NCT00002474|Procedure|autologous bone marrow transplantation|
553894|NCT00002474|Procedure|bone marrow ablation with stem cell support|
553895|NCT00002473|Procedure|conventional surgery|
553896|NCT00002472|Drug|cisplatin|
553897|NCT00002472|Drug|etoposide|
553898|NCT00002472|Procedure|conventional surgery|
553899|NCT00002472|Procedure|neoadjuvant therapy|
553900|NCT00002472|Radiation|radiation therapy|
553901|NCT00002470|Biological|recombinant interferon alfa|
553902|NCT00002470|Drug|fluorouracil|
553903|NCT00002455|Biological|Corynebacterium granulosum P40|
553904|NCT00002455|Procedure|adjuvant therapy|
553905|NCT00052156|Biological|CancerVax vaccine (CANVAXIN)|
553906|NCT00052130|Biological|CancerVax vaccine (CANVAXIN)|
553907|NCT00051818|Behavioral|Treatment interruption/reinitiation schedule|
553908|NCT00052117|Drug|capravirine|
553909|NCT00052117|Drug|Kaletra|
553910|NCT00052117|Drug|2 NRTIs|
553911|NCT00052104|Behavioral|Cognitive-Behavioral Family Systems Intervention|
553912|NCT00052091|Behavioral|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
553913|NCT00052091|Behavioral|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
553914|NCT00052078|Drug|Sertraline (SRT)|Participants were treated with sertraline.
553915|NCT00052078|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
553916|NCT00052078|Drug|Placebo|Participants were treated with a placebo pill.
553917|NCT00052065|Drug|TLK286|
553918|NCT00052052|Drug|interferon-gamma 1b|200 mcg, SQ, 3x per week
553919|NCT00052026|Drug|carvedilol|low-dose carvedilol administered twice daily for 8 months
553920|NCT00052026|Drug|placebo|administered twice daily for 8 months
553921|NCT00052026|Drug|carvedilol|high-dose carvedilol administered twice daily for 8 months
553922|NCT00052039|Drug|interferon-gamma 1b|This study was terminated prior to enrollment.
553923|NCT00052039|Drug|azathioprine|This study was terminated prior to enrollment.
553924|NCT00052013|Drug|PTK787/ZK 222584|
553925|NCT00052000|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
553926|NCT00051987|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
553927|NCT00051974|Drug|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
553928|NCT00051948|Drug|TLK286|
553929|NCT00051935|Drug|Alglucosidase alfa|20 mg/kg (qow); intravenous
553930|NCT00051922|Biological|PolyEnv1|Recombinant vaccinia virus vaccine
553931|NCT00051909|Drug|LY451395|
553932|NCT00051896|Drug|GBR 12909|
553933|NCT00051844|Drug|Capravirine|
553934|NCT00051831|Drug|Emtricitabine|Will be administered as one 200-mg capsule orally daily
553935|NCT00051831|Drug|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
553936|NCT00051831|Drug|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
553937|NCT00051831|Drug|Saquinavir|Will be administered as five hard gel capsules orally twice daily
553938|NCT00051831|Drug|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
553939|NCT00051870|Device|Magstim Rapid Magnetic Stimulator|
553940|NCT00051805|Behavioral|Promotion of adherence to ARV medications|
553941|NCT00051792|Behavioral|yoga|
553942|NCT00051779|Drug|CAL|
553943|NCT00051766|Behavioral|Computer-based Intervention|
553944|NCT00051753|Drug|levofloxacin; amoxicillin/clavulanate|
553945|NCT00051740|Behavioral|Cognitive Adaptation Therapy (CAT)|
553946|NCT00051740|Behavioral|Minimal Environmental Supports (MES)|
553947|NCT00051727|Behavioral|Bridges to High School Project|
553948|NCT00051701|Drug|alemtuzumab|
553949|NCT00051688|Drug|tezacitabine|
553950|NCT00051688|Drug|oxaliplatin|
553951|NCT00051675|Drug|ING-1(heMAb)|
553952|NCT00051662|Drug|efalizumab|
553953|NCT00051636|Drug|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
553954|NCT00051636|Drug|Risedronate|Oral risedronate 30 mg capsules.
553955|NCT00051636|Drug|Placebo to Risedronate|Oral placebo of risedronate capsules.
553956|NCT00051636|Drug|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
553957|NCT00051636|Dietary Supplement|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
553958|NCT00051623|Drug|Infliximab|
553959|NCT00051597|Drug|SGN-30 (monoclonal antibody)|
553960|NCT00051584|Drug|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
553961|NCT00051584|Drug|Gemzar (Gemcitabine)|
553962|NCT00051571|Drug|SGN-15|
553963|NCT00051571|Drug|Docetaxel|
553964|NCT00051428|Procedure|Reiki (distant and direct-contact)|
553965|NCT00051415|Behavioral|Flaxseed-supplemented diet|
553966|NCT00051402|Drug|Isoflavones|
553967|NCT00051558|Drug|Teriparatide|20 micrograms/day, injection, 36 months
553968|NCT00051558|Drug|Alendronate Sodium|10 mg/day, oral, 36 months
553969|NCT00051558|Drug|Placebo|Oral placebo, daily, 36 months
553970|NCT00051558|Drug|Placebo|Injection placebo, daily, 36 months
553971|NCT00051545|Drug|Seocalcitol|
553972|NCT00051532|Drug|Seocalcitol|
553973|NCT00051506|Drug|ALIMTA|
553974|NCT00051506|Drug|carboplatin|
553975|NCT00051506|Drug|cisplatin|
553976|NCT00051493|Drug|ALIMTA|
553977|NCT00051493|Drug|Carboplatin|
553978|NCT00051480|Genetic|TNFerade|
553979|NCT00051467|Genetic|TNFerade|
553980|NCT00051454|Biological|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
553981|NCT00051441|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|
553982|NCT00051389|Drug|Fosinopril|
553983|NCT00051376|Drug|L-Arginine|
553984|NCT00051363|Device|Active CPAP|Nightly nasal continuous positive airway pressure (CPAP)
553985|NCT00051363|Device|Sham CPAP|Sham CPAP machine will be used for participants in the placebo group.
553986|NCT00051350|Other|CARB|
553987|NCT00051298|Drug|Olanzapine|
553988|NCT00051298|Drug|Placebo|
553989|NCT00051285|Drug|Enoximone|Participants receive oral enoximone
553990|NCT00051285|Drug|Enoximone placebo|Participants receive placebo to match enoximone
553991|NCT00051311|Procedure|Stem cell transplantation|
553992|NCT00051272|Drug|Extended-release Bupropion Hydrochloride|
553993|NCT00051259|Drug|Extended-Release Bupropion Hydrochloride|
553994|NCT00051246|Behavioral|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
553995|NCT00051246|Behavioral|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
553996|NCT00051233|Procedure|World Wide Web-Based Psychoeducation|
553997|NCT00051220|Behavioral|One-Session Treatment for Specific Phobias|
553998|NCT00051207|Behavioral|Interpersonal Psychotherapy (IPT)|
553999|NCT00051207|Behavioral|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
554000|NCT00051194|Drug|Combination IOP Lowering Therapy|
554001|NCT00051181|Drug|Travoprost (0.004%)|
554002|NCT00051181|Drug|Latanoprost (0.005%)|
554003|NCT00051168|Drug|Travatan|Travoprost (0.004%) 1 drop each eye once daily
554004|NCT00051155|Drug|Travoprost (0.004%)|
554005|NCT00051155|Drug|Latanoprost (0.005%)/Timolol (0.5%)|
554006|NCT00051142|Drug|Travoprost|
554007|NCT00051142|Drug|Latanoprost|
554008|NCT00051129|Drug|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
554009|NCT00051129|Other|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
554010|NCT00051116|Drug|CC-5013|
554011|NCT00051103|Drug|Investigational Cancer Drug|
554012|NCT00051090|Drug|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
554013|NCT00051090|Drug|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
554014|NCT00051090|Drug|Efavirenz|Administered orally at a daily dose of 600 mg
554015|NCT00051090|Drug|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
554016|NCT00051090|Drug|Abacavir|Administered orally twice daily in doses of 300 mg
554017|NCT00051077|Drug|Adefovir dipivoxil|
554018|NCT00051077|Drug|Peginterferon-alfa-2A|
554019|NCT00051077|Drug|Ribavirin|
554020|NCT00051077|Procedure|Liver Biopsy|
554021|NCT00051051|Drug|CI-1033|
554022|NCT00051038|Drug|Entecavir|
554023|NCT00051025|Drug|ONTAK|
554024|NCT00051012|Drug|ONTAK|
554025|NCT00050999|Drug|ONTAK|
554026|NCT00050986|Drug|Temozolomide|Starting Dose Level: 100 mg/m^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
554027|NCT00050986|Drug|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
554028|NCT00050973|Drug|bexarotene|
554029|NCT00050960|Drug|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
554030|NCT00050960|Drug|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks.
554031|NCT00050947|Drug|oxcarbazepine|
554032|NCT00050934|Drug|oxcarbazepine|
554033|NCT00050921|Drug|somatropin|
554034|NCT00050921|Biological|Hepatitis A virus, inactivated|
554035|NCT00050921|Drug|Keyhole-Limpet Hemocyanin|
554036|NCT00050895|Drug|Lopinavir/ritonavir|
554037|NCT00050895|Drug|Efavirenz|
554038|NCT00050895|Drug|Stavudine|
554039|NCT00050895|Drug|Zidovudine|
554040|NCT00050895|Drug|Lamivudine|
554041|NCT00050895|Drug|Tenofovir disoproxil fumarate|
554042|NCT00050882|Drug|GM-611|
554043|NCT00050856|Drug|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
554044|NCT00050843|Drug|thalidomide|
554045|NCT00050830|Drug|CI 1033|
554046|NCT00050817|Drug|clopidogrel (SR25990)|
554047|NCT00050791|Drug|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
554048|NCT00050791|Behavioral|Very Low Calorie Diet|placebo injections
554049|NCT00050778|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
554050|NCT00050778|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ [CD4+] T-cell count was >=100*10^6 cells per liter).
554051|NCT00050778|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was >=100*10^6 cells per liter).
554052|NCT00050804|Drug|sertraline|
554053|NCT00050765|Drug|MyoCell™ Autologous Myoblasts|
554054|NCT00050687|Drug|Gallium maltolate|
554055|NCT00050726|Drug|Interleukin-2|
554056|NCT00050713|Drug|Sirolimus|
554057|NCT00050674|Drug|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
554058|NCT00050661|Drug|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
554059|NCT00050661|Device|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
554060|NCT00050648|Drug|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
554061|NCT00050648|Drug|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
554062|NCT00050648|Drug|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
554063|NCT00050635|Drug|Sandostatin LAR Depot|
554064|NCT00050609|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
554065|NCT00050609|Drug|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
554066|NCT00050609|Drug|placebo|Placebo tablet taken by mouth once a day for 8 weeks
554067|NCT00050427|Drug|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
554068|NCT00050427|Drug|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
554069|NCT00050622|Drug|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
554070|NCT00050622|Behavioral|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
554071|NCT00050622|Drug|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
554072|NCT00050622|Drug|Placebo|
554073|NCT00050622|Drug|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
554074|NCT00050622|Behavioral|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
554075|NCT00050596|Drug|MDX-010 / MDX-010 + Docetaxel|
554076|NCT00050583|Behavioral|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
554077|NCT00050583|Behavioral|CBT|Cognitive Behavioral Therapy
554078|NCT00050570|Behavioral|Web-based intervention to reduce eating disorder risk factors|
554079|NCT00050557|Behavioral|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
554080|NCT00050557|Behavioral|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
554081|NCT00050518|Biological|Aventis Pasteur Smallpox Vaccine|
554082|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
554083|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
554084|NCT00050479|Drug|Celecoxib (Celebrex)|
554085|NCT00050440|Drug|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
554086|NCT00050440|Drug|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
554087|NCT00050414|Drug|Trabectedin|Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
554088|NCT00050414|Drug|Dexamethasone|Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
554089|NCT00050401|Drug|MERREM I.V. 2g as a 3 hour infusion every 8 hours|
554090|NCT00050401|Drug|vancomycin I.V. 1 g every 12 hours|
554091|NCT00050401|Drug|tobramycin I.V. 5 mg/kg every 24 hours|
554092|NCT00050401|Drug|MERREM I.V. 1g as a 30 minute infusion every 8 hours|
554093|NCT00050401|Drug|MERREM I.V. 500 mg as a 3 hour infusion every 8 hours|
554094|NCT00011635|Drug|Silymarin (milk thistle)|
554095|NCT00011063|Drug|Ginkgo Biloba|
554096|NCT00009542|Drug|kava (Piper methysticum)|
554097|NCT00006395|Drug|St. John's Wort|
554098|NCT00006155|Drug|SU5416 and carboplatin|
554099|NCT00006062|Drug|oxaliplatin|
554100|NCT00005926|Drug|Gemcitabine|
554101|NCT00005926|Drug|Herceptin|
554102|NCT00005926|Procedure|Radiation therapy|
554103|NCT00005912|Drug|Voriconazole|
554104|NCT00005783|Drug|Recombinant-methionyl human stem cell factor|
554105|NCT00005574|Drug|Gentamicin|
554106|NCT00004576|Drug|LY300164|
554107|NCT00001986|Drug|1-Octanol|
554108|NCT00001968|Drug|Amprenavir|
554109|NCT00001968|Drug|Ritonavir|
554110|NCT00001968|Drug|Abacavir|
554111|NCT00001968|Drug|Lamivudine|
554112|NCT00001966|Drug|Mind-body therapy|
554113|NCT00001965|Drug|Cyclosporine A|
554114|NCT00001963|Procedure|hemoglobin-transported nitric oxide|
554115|NCT00001944|Drug|Vinorelbine|
554116|NCT00001944|Drug|XR9576|
554117|NCT00001940|Drug|Voriconazole|
554118|NCT00001937|Drug|FK463|
554119|NCT00001937|Drug|Fluconazole|
554120|NCT00001931|Drug|N-0923|
554121|NCT00001930|Drug|Amantadine|
554122|NCT00001929|Drug|Eliprodil|
554123|NCT00001909|Drug|Soluble recombinantly produced IL-4R|
554124|NCT00001906|Biological|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
554125|NCT00001903|Drug|RSV Polyclonal Immunoglobulin|
554126|NCT00001891|Procedure|Myocardial contrast echocardiography|
554127|NCT00001891|Procedure|Dobutamine echocardiography|
554128|NCT00001890|Drug|Estrogen therapy|
554129|NCT00001889|Procedure|Myocardial contrast echocardiography|
554130|NCT00001889|Procedure|Stress echocardiography with dobutamine|
554131|NCT00001886|Procedure|Real time 3-dimensional stress echocardiography|
554132|NCT00001857|Drug|BG9588|
554133|NCT00001839|Drug|Antithymocyte globulin|
554134|NCT00001839|Drug|Cyclosporine|
554135|NCT00001812|Drug|Nystatin|
554136|NCT00001810|Drug|Voriconazole|
554137|NCT00001805|Drug|Rituximab|
554138|NCT00001797|Drug|Recombinant human interleukin-10|
554139|NCT00001790|Drug|FK463|
554140|NCT00001789|Drug|BG9588|
554141|NCT00001777|Drug|Sertraline|
554142|NCT00001768|Drug|Intravenous immunoglobulin|
554143|NCT00001763|Drug|Interleukin-12|
554144|NCT00001761|Drug|Interleukin-10|
554145|NCT00001757|Drug|Voriconazole|
554146|NCT00001753|Procedure|Magnetic resonance imaging|
554147|NCT00001752|Drug|L-arginine|
554148|NCT00001752|Drug|Estrogen|
554149|NCT00001748|Procedure|Peripheral blood progenitor cell transplant|
554150|NCT00001736|Drug|Cysteamine|
554151|NCT00001735|Procedure|Gene therapy|
554152|NCT00001731|Drug|Cyclosporin A|
554153|NCT00001730|Drug|Thyrogen|
554154|NCT00001718|Device|Electropalatography|
554155|NCT00001705|Drug|GP100 peptide|
554156|NCT00001705|Drug|IL-2|
554157|NCT00001696|Drug|Genistein|
554158|NCT00001685|Biological|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
554159|NCT00001680|Drug|Thalidomide|
554160|NCT00001677|Drug|Methotrexate|
554161|NCT00001677|Drug|Fludarabine|
554162|NCT00001669|Drug|rhIGF-1 (CEP-151)|
554163|NCT00001658|Drug|Amoxicillin|
554164|NCT00001646|Drug|Voriconazole|
554165|NCT00001646|Drug|Amphotericin B|
554166|NCT00001633|Procedure|Coronary magnetic resonance angiography imaging|
554167|NCT00001629|Drug|Angiotensin II type 1 receptor antagonists|
554168|NCT00001628|Drug|Angiotensin II type 1 receptor antagonists|
554169|NCT00001624|Drug|Insulin|
554170|NCT00001622|Procedure|investigate the relationship between in vivo and in vitro vascular responses|
554171|NCT00001615|Drug|Corticosteroid|
554172|NCT00001614|Drug|Chicken type II collagen|
554173|NCT00001605|Biological|Nontypeable Haemophilus influenzae|
554174|NCT00001587|Procedure|Isolated hepatic portal and arterial perfusion|
554175|NCT00001587|Drug|Melphalan|
554176|NCT00001579|Drug|5-Fluorouracil|
554177|NCT00001579|Drug|Ethynyluracil|
554178|NCT00001579|Drug|Leucovorin|
554179|NCT00001577|Procedure|double isolated limb perfusion with melphalan alone|
554180|NCT00001573|Drug|SU101|
554181|NCT00001570|Drug|PSC 833|
554182|NCT00001570|Drug|vinblastine|
554183|NCT00001565|Drug|phenylbutyrate|
554184|NCT00001554|Device|intraoperative infrared (IR) neuroimaging|
554185|NCT00001538|Biological|APL 400-003|
554186|NCT00001533|Drug|cyclosporine|
554187|NCT00001520|Drug|neostigmine|
554188|NCT00001509|Drug|IFN-alpha with retinoic acid|
554189|NCT00001502|Drug|RMP-7 and carboplatin|
554190|NCT00001499|Drug|paclitaxel|
554191|NCT00001499|Drug|cisplatin|
554192|NCT00001499|Procedure|chest radiotherapy|
554193|NCT00001498|Drug|methotrexate|
554194|NCT00001498|Drug|leucovorin|
554195|NCT00001498|Drug|5-fluorouracil|
554196|NCT00001498|Drug|cyclophosphamide|
554197|NCT00001498|Procedure|peripheral blood progenitor cell|
554198|NCT00001498|Drug|paclitaxel|
554199|NCT00001498|Drug|doxorubicin|
554200|NCT00001495|Drug|irinotecan (CPT-11)|
554201|NCT00001493|Genetic|peripheral blood progenitor cells carrying MDR1|
554202|NCT00001482|Drug|Lamotrigine (Lamictal® (Registered Trademark)|
554203|NCT00001482|Drug|Gabapentin (Neurontin® (Registered Trademark))|
554204|NCT00001450|Drug|paclitaxel|
554205|NCT00001450|Drug|cisplatin|
554206|NCT00001449|Drug|gemcitabine|
554207|NCT00001449|Drug|fluorodeoxyuridine|
554208|NCT00001449|Drug|leucovorin|
554209|NCT00001446|Drug|thalidomide|
554210|NCT00001445|Biological|HIV-1 Immunogen|
554211|NCT00001443|Drug|indinavir (MK-0639)|
554212|NCT00001439|Biological|gp100 human melanoma peptide|
554213|NCT00001438|Drug|all-trans-retinoic acid with IFN-alpha2a|
554214|NCT00001437|Drug|pentoxifylline|
554215|NCT00001436|Drug|OncoLAR® (Registered Trademark)|
554216|NCT00001436|Drug|tamoxifen|
554217|NCT00001431|Drug|gemcitabine|
554218|NCT00001428|Drug|5-fluorouracil|
554219|NCT00001427|Drug|9-aminocamptothecin|
554220|NCT00001422|Drug|fludarabine|
554221|NCT00001421|Drug|methimazole|
554222|NCT00001416|Drug|CEREDASE™|
554223|NCT00001402|Device|PET scan|
554224|NCT00001387|Drug|paclitaxel|
554225|NCT00001384|Drug|Adriamycin|
554226|NCT00001384|Drug|cyclophosphamide|
554227|NCT00001384|Drug|G-CSF|
554228|NCT00001384|Drug|paclitaxel|
554229|NCT00001383|Drug|PSC 833|
554230|NCT00001383|Drug|paclitaxel|
554231|NCT00001382|Biological|PROSTVAC|
554232|NCT00001381|Drug|suramin|
554233|NCT00001378|Drug|fenretinide|
554234|NCT00001365|Drug|dextromethorphan|
554235|NCT00001344|Drug|dextromethorphan|
554236|NCT00001341|Drug|ZD1694 (TOMUDEX)|
554237|NCT00001338|Drug|FLAC chemotherapy with GM-CSF|
554238|NCT00001333|Drug|topotecan|
554239|NCT00001332|Procedure|CHPP with cisplatin|
554240|NCT00001318|Drug|interferon gamma|
554241|NCT00001317|Drug|interferon-gamma|
554242|NCT00001311|Device|heparin-surface modified intraocular lens|
554243|NCT00001300|Drug|doxorubicin|
554244|NCT00001300|Drug|ifosfamide|
554245|NCT00001300|Drug|mesna|
554246|NCT00001298|Drug|carboxypeptidase-G2|
554247|NCT00001296|Drug|melphalan|
554248|NCT00001296|Drug|tumor necrosis factor|
554249|NCT00001296|Drug|interferon-gamma|
554250|NCT00001296|Procedure|hyperthermic isolated limb perfusion|
554251|NCT00001287|Drug|intravenous immunoglobulin (IVIg)|
554252|NCT00001280|Drug|itraconazole|
554253|NCT00001272|Drug|taxol|
554254|NCT00001271|Drug|IgG-RFB4-SMPT-dgA|
554255|NCT00001270|Drug|interleukin-1|
554256|NCT00001269|Drug|IL-3|
554257|NCT00001267|Drug|zidovudine|
554258|NCT00001267|Drug|2',3'-dideoxyinosine|
554259|NCT00001249|Drug|Yttrium-90 radiolabeled anti-Tac antibody|
554260|NCT00001239|Drug|FLAC with GM-CSF|
554261|NCT00001237|Drug|granulocyte-macrophage colony stimulating factor (GM-CSF)|
554262|NCT00001217|Drug|pre-surgical chemotherapy|
554263|NCT00001209|Drug|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
554264|NCT00001193|Procedure|high dose melphalan and autologous bone marrow transplantation|
554265|NCT00001189|Procedure|radiotherapy|
554266|NCT00001188|Procedure|radiation therapy following surgery|
554267|NCT00050388|Genetic|Allovectin-7®|
554268|NCT00050375|Drug|oregovomab|
554269|NCT00050362|Drug|Rofecoxib and Bupivacaine|
554270|NCT00050349|Drug|EPO906 epothilone B|
554271|NCT00050336|Drug|Lonafarnib (SARASAR)|
554272|NCT00050323|Drug|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
554273|NCT00050297|Drug|YM598|
554274|NCT00050271|Drug|Acetyl-L-carnitine|
554275|NCT00050245|Drug|Rituximab|
554276|NCT00050232|Drug|AVP-923|
554277|NCT00050141|Drug|ZARNESTRA, tipifarnib, R115777|
554278|NCT00050206|Drug|Olanzapine|
554279|NCT00050206|Drug|Placebo|
554280|NCT00050167|Drug|Paclitaxel|80 mg/m^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
554281|NCT00050167|Drug|Docetaxel|75 mg/m^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
554282|NCT00050167|Drug|Capecitabine|1500 mg/m^2 by mouth Twice Daily x 2 Weeks
554283|NCT00050180|Drug|Midazolam|
554284|NCT00050180|Drug|Indinavir|
554285|NCT00050180|Drug|Saquinavir|
554286|NCT00050154|Drug|ZARNESTRA, tipifarnib, R115777|
554287|NCT00050128|Device|rTMS, Magstim|
554288|NCT00050102|Drug|MDX-010 (CTLA-4)|
554289|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
554290|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
554291|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
554292|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
554293|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
554294|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
554295|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
554296|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
554297|NCT00050076|Drug|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
554298|NCT00050076|Drug|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
554299|NCT00050076|Drug|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
554300|NCT00050076|Drug|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
554301|NCT00050063|Biological|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
554302|NCT00050050|Behavioral|Cognitive behavioral therapy|
554303|NCT00050050|Drug|Drug therapy|
554304|NCT00050037|Procedure|CBT|
554305|NCT00050011|Drug|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
554306|NCT00050011|Drug|Letrozole|Participants received Letrozole 2.5 mg daily.
554307|NCT00049998|Drug|topotecan|
554308|NCT00049985|Drug|Darbepoetin Alfa|
554309|NCT00049972|Drug|paroxetine CR|
554310|NCT00049959|Drug|verteporfin PDT|
554311|NCT00049946|Drug|talnetant|
554312|NCT00049946|Drug|risperidone|
554313|NCT00049842|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
554314|NCT00049829|Drug|Zoledronic Acid|
554315|NCT00049816|Behavioral|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
554316|NCT00049816|Behavioral|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
554317|NCT00049803|Drug|sodium oxybate|
554318|NCT00049790|Drug|recombinant human Angiostatin protein|
554319|NCT00049790|Drug|paclitaxel|
554320|NCT00049790|Drug|carboplatin|
554321|NCT00049777|Drug|Drotrecogin Alfa (Activated)|
554322|NCT00049777|Drug|Unfractionated heparin|
554323|NCT00049777|Drug|Low molecular weight heparin|
554324|NCT00049764|Drug|Drotrecogin alfa (activated)|
554325|NCT00049764|Drug|Placebo|
554326|NCT00049751|Drug|Adalimumab|
554327|NCT00048945|Drug|PEGASYS|
554328|NCT00049725|Drug|Daclizumab|
554329|NCT00048932|Drug|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Day 1, 15, and 29.
554330|NCT00048932|Drug|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
554331|NCT00048932|Drug|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Every 28 days.
554332|NCT00048854|Drug|Sertraline|Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
554333|NCT00048854|Other|Treatment as usual (TAU)|At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
554334|NCT00048841|Drug|alendronate|
554335|NCT00048828|Drug|Olanzapine|Participants will receive olanzapine for 12 weeks.
554336|NCT00048828|Drug|Clozapine|Participants will receive 12 weeks of clozapine.
554337|NCT00048815|Drug|Citalopram|Established Selective Serotonin Reuptake Inhibitor antidepressant
554338|NCT00048815|Drug|St. John's Wort|Natural extract from the St. John's Wort plant.
554339|NCT00048815|Drug|Placebos|Placebo pill
554340|NCT00048802|Drug|Lithium|
554341|NCT00048802|Drug|Olanzapine|
554342|NCT00048802|Drug|Divalproex|
554343|NCT00048802|Drug|Risperidone|
554344|NCT00048802|Drug|Quetiapine|
554345|NCT00048802|Drug|Ziprasidone|
554346|NCT00048802|Drug|Aripriprazole|
554347|NCT00048581|Drug|Abatacept|Vials, intravenous (IV), ~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
554348|NCT00048581|Drug|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
554349|NCT00048581|Drug|Abatacept|Vials, IV, ~10mg/kg abatacept, every 4 weeks, 5.5 years
554350|NCT00048568|Drug|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg < 60 kg); (750 mg 60-100 kg), )1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
554351|NCT00048568|Drug|Methotrexate|Tablets, Oral, >= 15 mg, weekly, 1 year
554352|NCT00048568|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
554353|NCT00048906|Drug|DRX005B|
554354|NCT00048893|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|4 x 10^8 pfu given monthly subcutaneously for three doses in the first series and three doses on each of the intermediate and late re-immunizations (total 9 doses).
554355|NCT00048893|Biological|recombinant vaccinia-CEA(6D)/TRICOM vaccine|rV-CEA (6D)/Tricom concomitantly with sargramostim (rGM-CSF). 1.2 x 10^8 pfu x 1 dose subcutaneously.
554356|NCT00048893|Biological|filgrastim|5 mcg/kg/day subcutaneously
554357|NCT00048893|Biological|sargramostim|100 mcg daily for 4 consecutive days at the same site as the rF-CEA (6D)/Tricom vaccine. The first dose will be given with the vaccine.
554358|NCT00048893|Drug|cyclophosphamide|"First induction chemotherapy: 2700 mg/m^2 per cycle (900 mg/m^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).~Second induction: 600 mg/m^2 per cycle (600 mg/m^2 intravenous over 1 hour day 1.~Immune depleting chemotherapy: 2400 mg/m^2 per cycle (600 mg/m^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4)."
554359|NCT00048893|Drug|doxorubicin hydrochloride|60 mg/m^2 per cycle (60 mg/m^2 slow intravenous push day 1).
554360|NCT00048893|Drug|fludarabine phosphate|120 mg/m^2 (30 mg/m^2 per day intravenous over 30 minutes for 4 consecutive days (days 1-4)).
554361|NCT00048893|Drug|paclitaxel|160 mg/m^2 per cycle (53.3 mg/m^2 per day by continuous intravenous infusion over 24 hours for 3 consecutive days 1-3).
554362|NCT00048893|Drug|Mesna|"Percent equals fraction of total daily cyclophosphamide dose. Initial: 20% of cyclophosphamide dose given intravenously (IV) mixed with cyclophosphamide.~3 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 6 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 9 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO)"
554363|NCT00048880|Drug|HeFi-1 Monoclonal Antibody|
554364|NCT00048776|Drug|Pletal|
554365|NCT00048763|Drug|Pletal|
554366|NCT00048789|Procedure|Extracorporeal Photopheresis|
554367|NCT00048750|Drug|Micafungin|IV
554368|NCT00048750|Drug|Placebo|IV
554369|NCT00048737|Drug|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
554370|NCT00048737|Drug|Rituximab|250 mg/m^2 on day 1 and day 8
554371|NCT00048737|Drug|Fludarabine|30 mg/m^2/day for 3 days
554372|NCT00048737|Drug|Cyclophosphamide|750 mg/m^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
554373|NCT00048737|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
554374|NCT00048724|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
554375|NCT00048711|Drug|N-acetylgalactosamine 4-sulfatase|
554376|NCT00048698|Procedure|TMS|
554377|NCT00048698|Procedure|EEG|
554378|NCT00048672|Drug|Gleevec|Starting dose of 400 mg orally daily.
554379|NCT00048659|Drug|YM598|
554380|NCT00048646|Drug|IV Progesterone|
554381|NCT00048633|Drug|Chemotherapy|
554382|NCT00048620|Drug|N-acetylgalactosamine 4-sulfatase|
554383|NCT00048607|Drug|aprepitant|
554384|NCT00048607|Drug|Comparator: paroxetine HCL|
554385|NCT00048607|Drug|Comparator: Placebo (Unspecified)|
554386|NCT00048594|Drug|aprepitant|
554387|NCT00048594|Drug|Comparator: placebo (unspecified)|
554388|NCT00048555|Drug|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions
554389|NCT00048542|Biological|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
554390|NCT00048542|Biological|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
554391|NCT00048542|Drug|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
554392|NCT00048542|Drug|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
554393|NCT00048529|Drug|T900607-sodium intravenous|
554394|NCT00048516|Drug|paricalcitol capsule|
554395|NCT00048503|Drug|ZARNESTRA, tipifarnib, R115777|
554396|NCT00048464|Procedure|Infusion of Activated & Expanded Autologous T Cells|
554397|NCT00048451|Drug|paricalcitol|
554398|NCT00048438|Drug|paricalcitol|
554399|NCT00048425|Drug|Levosimendan|
554400|NCT00048490|Device|transcranial magnetic stimulation (TMS)|
554401|NCT00048477|Drug|L-NMMA and Sodium Nitrite|
554402|NCT00048412|Drug|FLUDARABINE|
554403|NCT00048412|Drug|CAMPATH 1H|
554404|NCT00048412|Drug|FK50|
554405|NCT00048412|Procedure|Stem Cell Collection and Infusion|
554406|NCT00048399|Drug|Fludarabine|
554407|NCT00048399|Drug|CAMPATH 1H|
554408|NCT00048399|Drug|FK506|
554409|NCT00048399|Procedure|Stem Cell Transplantation|
554410|NCT00048386|Biological|autologous neuroblastoma vaccine|A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.
554411|NCT00048373|Drug|Etanercept|
554412|NCT00048360|Drug|Extended-release bupropion hydrochloride|
554413|NCT00048321|Drug|ISIS 104838|
554414|NCT00048308|Drug|pexelizumab|
554415|NCT00048347|Drug|AVONEX|30µg IM every week for 12 weeks
554416|NCT00048334|Drug|Depsipeptide, FR901228, FK228|
554417|NCT00048295|Drug|Alicaforsen|
554418|NCT00048230|Drug|bortezomib|
554419|NCT00048217|Drug|T-1249|
554420|NCT00048204|Drug|GW597599B|
554421|NCT00048204|Drug|paroxetine|
554422|NCT00048165|Drug|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
554423|NCT00048165|Drug|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
554424|NCT00048165|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
554425|NCT00048165|Drug|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
554426|NCT00048165|Drug|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
554427|NCT00048152|Drug|Corticosteroids|As prescribed
554428|NCT00048152|Drug|Neoral|Low dose (target trough level 50-100ng/mL)
554429|NCT00048152|Drug|Neoral|Standard dose (target trough level 150-300ng/mL)
554430|NCT00048152|Drug|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
554431|NCT00048152|Drug|mycophenolate mofetil [CellCept]|1g po bid
554432|NCT00048139|Drug|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
554433|NCT00048139|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
554434|NCT00048126|Drug|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
554435|NCT00048126|Drug|capecitabine [Xeloda]|1000mg po bid
554436|NCT00048113|Drug|Alicaforsen|
554437|NCT00048100|Procedure|Apheresis|Apheresis for T-Cell collection
554438|NCT00048100|Biological|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
554439|NCT00048087|Drug|ZD1839|250 mg by mouth daily each day for 4 weeks.
554440|NCT00048087|Drug|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
554441|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
554442|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2.5mg po daily
554443|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
554444|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|2.5mg po daily
554445|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
554446|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
554447|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|150mg po monthly
554448|NCT00048061|Dietary Supplement|Calcium|500 mg/day
554449|NCT00048061|Dietary Supplement|Vitamin D|400 IU/day
554450|NCT00048048|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
554451|NCT00048035|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
554452|NCT00048022|Drug|Dual Integrin Antagonist|
554453|NCT00048009|Drug|Dual Integrin Antagonist|
554454|NCT00047983|Dietary Supplement|Canola oil|
554455|NCT00047983|Dietary Supplement|Arginine|
554456|NCT00047983|Dietary Supplement|Fish oil emulsion|
554457|NCT00047840|Drug|ZD6474|
554458|NCT00047840|Drug|Placebo|
554459|NCT00047840|Drug|Docetaxel|
554460|NCT00047827|Drug|Micafungin|IV
554461|NCT00047827|Drug|Liposomal Amphotericin B|IV
554462|NCT00047814|Drug|FK788|
554463|NCT00047931|Drug|VRC-HIVDNA009-00-VP|
554464|NCT00047905|Behavioral|examine the process of prenatal genetic counseling|
554465|NCT00047879|Biological|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
554466|NCT00047879|Drug|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
554467|NCT00047801|Drug|TLK286 in combination with docetaxel|
554468|NCT00047788|Drug|ZD6474|
554469|NCT00047788|Drug|VEGF-receptor tyrosine kinase (KDR)|
554470|NCT00047775|Drug|BiDil|
554471|NCT00047762|Drug|Erlotinib (aka Tarceva or OSI-774)|
554472|NCT00047762|Drug|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
554473|NCT00047554|Drug|Travoprost, 0.004% ophthalmic solution|
554474|NCT00047541|Drug|Alcon Investigational Agent|
554475|NCT00047528|Drug|Alcon Investigational Agent|
554476|NCT00047515|Drug|Alcon Investigational Agent|
554477|NCT00047749|Drug|Prialt (ziconotide)|
554478|NCT00047736|Drug|Tarceva (erlotinib HCl)|
554479|NCT00047723|Drug|minocycline|
554480|NCT00047710|Drug|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
554481|NCT00047710|Drug|Capecitabine|650mg/m^2 taken by mouth twice a day 15-52 during the radiotherapy.
554482|NCT00047710|Radiation|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
554483|NCT00047697|Drug|Donepezil HCl|Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
554484|NCT00047697|Drug|Placebo|Placebo used in placed of Donepezil HCL
554485|NCT00047684|Behavioral|Brief Integrative Therapy|
554486|NCT00047671|Drug|Citalopram|PDA Approved antidepressant
554487|NCT00047658|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
554488|NCT00047645|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
554489|NCT00047632|Drug|Interferon gamma-1b|100 mcg, SQ, 3x per week
554490|NCT00047606|Drug|IOP Lowering Medications|
554491|NCT00047593|Drug|IOP Lowering Medications|
554492|NCT00047619|Procedure|Pulsatile Lavage|pulsatile lavage to wound bed
554493|NCT00047619|Other|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
554494|NCT00047580|Drug|tizanidine hydrochloride capsule|
554495|NCT00047567|Drug|zonisamide|
554496|NCT00046371|Drug|THERATOPE® vaccine|
554497|NCT00047502|Drug|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.~Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
554498|NCT00047502|Drug|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.~Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
554499|NCT00047489|Drug|ABT-751|
554500|NCT00047476|Drug|dexmethylphenidate(d-mph)|
554501|NCT00047463|Device|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
554502|NCT00047463|Device|Placebo-CPAP|Placebo-CPAP
554503|NCT00047450|Drug|Citalopram (Celexa)|Citalopram for 3 months
554504|NCT00047450|Drug|Placebo|Placebo for 3 months
554505|NCT00047437|Behavioral|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
554506|NCT00047424|Drug|simvastatin|
554507|NCT00047424|Drug|ACE inhibitors|
554508|NCT00047411|Other|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
554509|NCT00047411|Device|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
554510|NCT00046800|Drug|OSI-211 (Liposomal Lurtotecan)|
554511|NCT00046787|Drug|OSI-211 (Liposomal Lurtotecan)|
554512|NCT00046761|Drug|ONO-2506|
554513|NCT00046748|Drug|Omalizumab|
554514|NCT00046813|Drug|Nicotine patch|
554515|NCT00046774|Drug|MRA 003 US|
554516|NCT00046735|Drug|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
554517|NCT00046722|Drug|Smoked Marijuana|
554518|NCT00046527|Drug|ABI-007|
554519|NCT00046514|Drug|ABI-007|
554520|NCT00046423|Drug|ABI-007|
554521|NCT00046709|Drug|Smoked Marijuana|
554522|NCT00046696|Drug|NM-3|
554523|NCT00046683|Drug|alemtuzumab|
554524|NCT00046540|Drug|Liposome-encapsulated SN38|
554525|NCT00046501|Drug|Lantus (insulin glargine [rDNA origin] injection)|
554526|NCT00046501|Drug|Humulin N|
554527|NCT00046501|Drug|Humulin L|
554528|NCT00046501|Drug|Lispro|
554529|NCT00046488|Drug|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
554530|NCT00046475|Drug|Midodrine Hydrochloride|
554531|NCT00046462|Drug|Lantus (insulin glargine [rDNA origin] injection)|
554532|NCT00046462|Drug|Metformin|
554533|NCT00046462|Drug|Glyburide|
554534|NCT00046462|Drug|Thiazolidinedione|
554535|NCT00046449|Drug|Investigational Seasonal Affective Disorder (SAD) Drug|
554536|NCT00046566|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
554537|NCT00046566|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
554538|NCT00046566|Behavioral|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
554539|NCT00046553|Drug|RU-486 (Mifepristone)|
554540|NCT00046384|Drug|aripiprazole|
554541|NCT00046397|Drug|Modified Vaccinia Virus Ankara TBC-M|
554542|NCT00046345|Drug|Atazanavir (BMS-232632)|
554543|NCT00046332|Drug|GW810781|
554544|NCT00046319|Drug|BSF 208075|
554545|NCT00046306|Drug|Antioxidants|
554546|NCT00046358|Drug|Lovostatin|
554547|NCT00046358|Drug|Ibuprofen|
554548|NCT00046293|Drug|Reopro|
554549|NCT00046293|Drug|Retrovase|
554550|NCT00046267|Drug|Niacin|
554551|NCT00046254|Drug|Zoledronic Acid|
554552|NCT00046241|Drug|Extended-release bupropion hydrochloride|
554553|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
554554|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
554555|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
554556|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
554557|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
554558|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
554559|NCT00046176|Drug|abacavir/lamivudine|
554560|NCT00046176|Drug|abacavir|
554561|NCT00046176|Drug|lamivudine|
554562|NCT00046163|Drug|midodrine hydrochloride (ProAmatine®)|
554563|NCT00046150|Drug|Insulin glulisine (HMR1964)|
554564|NCT00046137|Drug|teriparatide|
554565|NCT00046137|Drug|raloxifene|
554566|NCT00046137|Drug|placebo|
554567|NCT00046111|Drug|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
554568|NCT00046085|Behavioral|Online Family Education|Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
554569|NCT00046085|Behavioral|Customary care|Participants received care as usual.
554570|NCT00046072|Drug|E5564|
554571|NCT00046033|Drug|Lopinavir/ritonavir|
554572|NCT00046033|Drug|Ritonavir|
554573|NCT00046033|Drug|Saquinavir|
554574|NCT00046033|Drug|Tenofovir disoproxil fumarate|
554575|NCT00046033|Drug|Amprenavir|
554576|NCT00046020|Drug|Venlafaxine ER|
554577|NCT00045994|Drug|ALT-711|
554578|NCT00045981|Drug|ALT-711|
554579|NCT00045968|Drug|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
554580|NCT00045955|Drug|Fexofenadine, Comparator = Montelukast|
554581|NCT00045942|Drug|Itraconazole|Itraconazole was commercially available.
554582|NCT00045942|Drug|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
554583|NCT00045916|Procedure|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
554584|NCT00045916|Drug|Nortriptyline|Participants will receive nortriptyline.
554585|NCT00045916|Drug|Venlafaxine|Participants will receive venlafaxine.
554586|NCT00045916|Drug|Lithium|Participants will receive lithium.
554587|NCT00045916|Procedure|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
554588|NCT00045903|Behavioral|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
554589|NCT00045903|Behavioral|Stress Management Therapy (Cognitive Behavior Therapy)|
554590|NCT00044824|Drug|Fexofenadine|
554591|NCT00044811|Drug|Fexofenadine|
554592|NCT00045877|Drug|Recombinant Human Interleukin-2 and Rituximab|
554593|NCT00045864|Drug|Recombinant Human Interleukin-2 and Rituximab|
554594|NCT00045838|Drug|VCR-HIVDNA006-00-VP|
554595|NCT00045812|Drug|SCH-58235|
554596|NCT00045799|Drug|Omeprazole sodium bicarbonate immediate release PWD/FS|
554597|NCT00045799|Drug|Cimetidine IV|
554598|NCT00045786|Drug|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
554599|NCT00045773|Drug|Sertraline|50 - 200mg, once per day for 12 weeks.
554600|NCT00045760|Drug|Drotrecogin alfa (activated)|
554601|NCT00044928|Drug|Piperacillin/Tazobactam|
554602|NCT00044915|Drug|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
554603|NCT00044915|Drug|Placebo|All patients receive 1.25 mg of placebo
554604|NCT00044902|Drug|epratuzumab|
554605|NCT00044889|Drug|clofarabine (IV formulation)|
554606|NCT00044863|Biological|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
554607|NCT00044837|Drug|Medroxyprogesterone acetate|
554608|NCT00044837|Drug|Estradiol|
554609|NCT00044876|Drug|CDB-2914|
554610|NCT00044798|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 treatments of rTMS over 3 weeks.
554611|NCT00044798|Drug|Citalopram|After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
554612|NCT00044798|Procedure|Sham rTMS|Participants will receive 15 treatments of sham rTMS over 3 weeks.
554613|NCT00044785|Drug|triacetyluridine|
554614|NCT00044785|Drug|fluorouracil|
554615|NCT00044785|Drug|leucovorin|
554616|NCT00044785|Drug|camptosar|
554617|NCT00044772|Drug|Venlafaxine ER|
554618|NCT00044759|Drug|Piperacillin/Tazobactam (Tazocin)|
554619|NCT00044746|Drug|Piperacillin/Tazobactam|
554620|NCT00044733|Drug|Mylotarg (gemtuzumab ozogamicin) Injection|
554621|NCT00044720|Drug|Rapamune|
554622|NCT00044707|Drug|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
554623|NCT00044694|Drug|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
554624|NCT00044694|Drug|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
554625|NCT00044694|Drug|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
554626|NCT00044694|Drug|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
554627|NCT00044694|Drug|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
554628|NCT00044694|Drug|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
554629|NCT00044694|Drug|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
554630|NCT00044694|Drug|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
554631|NCT00044681|Drug|risperidone|
554632|NCT00044668|Drug|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
554633|NCT00044655|Drug|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
555192|NCT00038272|Drug|Amdoxovir|
554634|NCT00044655|Drug|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
554635|NCT00044655|Drug|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
554636|NCT00044655|Drug|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
554637|NCT00044655|Drug|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
554638|NCT00044642|Drug|Lorazepam|
554639|NCT00044629|Behavioral|Cognitive-Behavioral Therapy for Insomnia|
554640|NCT00044629|Drug|zolpidem tartrate (Ambien)|
554641|NCT00044629|Drug|Placebo|
554642|NCT00044616|Drug|Fluoxetine|
554643|NCT00044616|Drug|Lithium|
554644|NCT00044577|Drug|abacavir/lamivudine|
554645|NCT00044577|Drug|abacavir|
554646|NCT00044577|Drug|lamivudine|
554647|NCT00044577|Drug|tenofovir|
554648|NCT00044564|Drug|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
554649|NCT00044551|Drug|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
554650|NCT00044538|Drug|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
554651|NCT00044525|Drug|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
554652|NCT00044512|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
554653|NCT00044486|Drug|Posaconazole oral suspension|
554654|NCT00044473|Drug|levofloxacin|
554655|NCT00044460|Drug|rosiglitazone|
554656|NCT00044447|Drug|Glimepiride|
554657|NCT00044434|Drug|bupropion (Wellbutrin)|
554658|NCT00044421|Drug|Ruboxistaurin mesylate|
554659|NCT00044408|Drug|Ruboxistaurin mesylate|
554660|NCT00044395|Drug|Ruboxistaurin mesylate|
554661|NCT00044382|Drug|CC-5013|
554662|NCT00044369|Procedure|Varicocele repair|
554663|NCT00044356|Genetic|Allovectin-7®|
554664|NCT00044343|Drug|lapatinib|
554665|NCT00044291|Drug|atamestane|
554666|NCT00044291|Drug|toremifene|
554667|NCT00044291|Drug|letrozole|
554668|NCT00044291|Drug|aromatase inhibition|
554669|NCT00044291|Procedure|hormone therapy|
554670|NCT00044291|Procedure|endocrine therapy|
554671|NCT00044291|Procedure|antiestrogen therapy|
554672|NCT00044304|Drug|Imatinib|The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC<1500/mm3, platelet counts < 75,000mm3 or abnormal liver function tests (ALT or AST > 2.5 or bilirubin > 3 times the upper limit of normal), the starting dose will be reduced to 300 mg poqD.
554673|NCT00044304|Drug|Ruxolitinib|The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts <100,000/mm3, moderate renal impairment (CrCl <60 ml/min) or abnormal liver function tests (AlT or AST > 2.5 or bilirubin > 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
554674|NCT00044278|Drug|lamotrigine|
554675|NCT00044265|Drug|ramipril|
554676|NCT00044226|Drug|ML-04A|
554677|NCT00044213|Drug|EDTA|Participants will receive 40 infusions of standard chelation solution.
554678|NCT00044213|Drug|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
554679|NCT00044213|Dietary Supplement|High Dose Vitamin|
554680|NCT00044213|Dietary Supplement|High Dose Vitamin Placebo|
554681|NCT00044187|Drug|Sibutramine|
554682|NCT00044148|Drug|LY333531|
554683|NCT00044135|Drug|clevudine (drug)|
554684|NCT00044070|Drug|YM872 (zonampanel)|
554685|NCT00044057|Drug|YM872 (zonampanel), t-PA (alteplase)|
554686|NCT00044044|Drug|Lurasidone 20 mg|Lurasidone 20mg/day tablets
554687|NCT00044044|Drug|Lurasidone 40mg|Lurasidone 40mg/day tablets
554688|NCT00044044|Drug|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
554689|NCT00044044|Drug|Haloperidol 10mg|Haloperidol 10mg/day tablets
554690|NCT00044044|Drug|Placebo|Matching Placebo to Lurasdione and Haloperidol
554691|NCT00044031|Biological|G17DT Immunogen|
554692|NCT00044018|Drug|CDC-501|
554693|NCT00044005|Drug|Lurasidone 20 mg|Lurasidone 20mg oral tablet taken once daily for 6-months
554694|NCT00044005|Drug|Lurasidone 40 mg|Lurasidone 40mg oral tablets taken once daily
554695|NCT00044005|Drug|Lurasidone 80mg|Lurasidone 80mg oral tablet taken once daily
554696|NCT00043329|Drug|Actimmune Registry|as administered by physician
554697|NCT00044109|Device|Magnets|
554698|NCT00044083|Other|Placebo|Placebo: One capsule 3 times a day from Day 1 to Day 7
554699|NCT00044083|Drug|Tolcapone|Tolcapone: One capsule 3 times a day from Day 1 to Day 7
554700|NCT00043966|Drug|Lopinavir/ritonavir|
554701|NCT00043966|Drug|Tenofovir DF|
554702|NCT00043966|Drug|Emtricitabine|
554703|NCT00043953|Drug|Lopinavir/ritonavir|
554704|NCT00043953|Drug|Saquinavir mesylate|
554705|NCT00043953|Drug|Lamivudine/zidovudine|
554706|NCT00043888|Drug|fosamprenavir|
554707|NCT00043888|Drug|COMBIVIR|
554708|NCT00043888|Drug|ritonavir|
554709|NCT00043888|Drug|TRIZIVIR|
554710|NCT00043979|Drug|F-18 Fluorodeoxyglucose|
554711|NCT00043979|Biological|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
554712|NCT00043979|Drug|cyclophosphamide|"Induction - 750 mg/m^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.~Transplant - 1200 mg/m^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3."
554713|NCT00043979|Drug|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
554714|NCT00043979|Drug|doxorubicin hydrochloride|Induction - 10 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
554715|NCT00043979|Drug|etoposide|50 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
554716|NCT00043979|Drug|fludarabine phosphate|"Induction - 25 mg/m^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.~Transplant - 30 mg/m^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3."
554717|NCT00043979|Drug|melphalan|Transplant - 100 mg/m^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
554718|NCT00043979|Drug|prednisone|Induction - 60 mg/m^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
554719|NCT00043979|Drug|sirolimus|Initiated on day +3. Patients >40kg, the initial dose will be 2 mg every 24 hours orally. Patients <40 kg, the initial dose will be 1 mg/m^2.
554720|NCT00043979|Drug|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
554721|NCT00043979|Drug|vincristine sulfate|Induction - 0.4 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
554722|NCT00043979|Procedure|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
554723|NCT00043979|Drug|Filgrastim|
554724|NCT00043979|Procedure|Peripheral Blood Stem Cell donation|
554725|NCT00043940|Drug|bivalirudin|Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.
554726|NCT00043927|Drug|topotecan/cisplatin|
554727|NCT00043927|Drug|etoposide/cisplatin|
554728|NCT00043914|Drug|lamotrigine|
554729|NCT00043901|Drug|lamotrigine|
554730|NCT00043875|Drug|lamotrigine|
554731|NCT00043862|Drug|topotecan|
554732|NCT00043849|Drug|Quetiapine|
554733|NCT00043836|Drug|ALT-711|
554734|NCT00043823|Drug|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
554735|NCT00043823|Drug|Tarceva|100 mg By Mouth Daily for 3 Weeks
554736|NCT00043810|Procedure|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
554737|NCT00043810|Drug|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
554738|NCT00043810|Drug|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
554739|NCT00043797|Drug|Lidorestat (IDD 676)|
554740|NCT00043784|Drug|enoxaparin|
554741|NCT00043693|Behavioral|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
554742|NCT00043693|Behavioral|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
554743|NCT00043771|Drug|Tolvaptan|
554744|NCT00043758|Drug|Tolvaptan|
554745|NCT00043745|Dietary Supplement|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
554746|NCT00043745|Dietary Supplement|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
554747|NCT00043732|Drug|SCIO-469|
554748|NCT00043719|Drug|Nitroglycerin ointment|
554749|NCT00043719|Drug|Calcium supplement with vitamin D|
554750|NCT00043706|Drug|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
554751|NCT00043602|Behavioral|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
554752|NCT00043602|Behavioral|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
554753|NCT00043589|Drug|donepezil|
554754|NCT00043589|Procedure|Memory-training class|
554755|NCT00043576|Drug|calcitriol|
554756|NCT00043576|Drug|docetaxel|
554757|NCT00043680|Drug|Celecoxib|
554758|NCT00043667|Drug|Daclizumab|
554759|NCT00043654|Drug|Mifepristone|
554760|NCT00043628|Procedure|Stem Cell Mobilization|
554761|NCT00043563|Behavioral|Cognitive-Behavior Therapy|
554762|NCT00043550|Behavioral|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
554763|NCT00043550|Drug|Sertraline|Participants will receive sertraline.
554764|NCT00043550|Drug|Pill Placebo|Participants will receive a pill placebo.
554765|NCT00043550|Drug|Venlafaxine|Participants will receive venlafaxine.
554766|NCT00043537|Behavioral|Social Effectiveness Therapy for Children (SET-C)|
554767|NCT00043537|Drug|Fluoxetine|
554768|NCT00043537|Drug|Pill Placebo|
554769|NCT00043511|Biological|pGA2/JS2 Plasmid DNA Vaccine|
554770|NCT00043459|Drug|intravenous T900607-sodium|
554771|NCT00043446|Drug|intravenous T900607-sodium|
554772|NCT00043433|Drug|intravenous T900607-sodium|
554773|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
554774|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
554775|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
554776|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
555193|NCT00038259|Drug|Aldesleukin|
554777|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
554778|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
554779|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
554780|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
554781|NCT00043407|Drug|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
554782|NCT00043394|Drug|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
554783|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
554784|NCT00043394|Drug|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
554785|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
554786|NCT00043394|Drug|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
554787|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
554788|NCT00043394|Drug|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
554789|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
554790|NCT00043381|Drug|decitabine (5-aza-2'deoxycytidine)|
554791|NCT00043368|Drug|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
554792|NCT00043355|Drug|interferon gamma-1b|500 mcg, oral, three times weekly
554793|NCT00043342|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
554794|NCT00043316|Drug|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
554795|NCT00043303|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
554796|NCT00043277|Drug|Angiomax (bivalirudin)|
554797|NCT00043264|Drug|Rifampin|
554798|NCT00043264|Drug|Azithromycin|
554799|NCT00043212|Drug|Dendritic cell immunotherapy|
554800|NCT00043199|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
554801|NCT00043186|Drug|Placebo|Placebo subcutaneous injection
554802|NCT00043186|Drug|Denosumab|Denosumab for subcutaneous injection
554803|NCT00043186|Drug|Alendronate|Alendronate 70 mg tablets
554804|NCT00042718|Drug|levofloxacin, azithromycin, amoxicillin/clavulanate|
554805|NCT00042679|Drug|Gemcitabine|
554806|NCT00042679|Drug|Carboplatin|
554807|NCT00042679|Drug|LY900003|
554808|NCT00042666|Drug|LY317615|500 mg, oral, daily, up to six 28 day cycles
554809|NCT00042653|Drug|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
554810|NCT00042653|Drug|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
554811|NCT00042601|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
554812|NCT00042601|Drug|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
554813|NCT00042588|Drug|Recombinant Chimeric Monoclonal Antibody|
554814|NCT00042575|Drug|Duloxetine|
554815|NCT00042562|Drug|duloxetine|
554816|NCT00042549|Device|Extracorporeal Shock Wave Lithotripsy|
554817|NCT00042549|Drug|ursodiol|
554818|NCT00042536|Drug|Naltrexone HCL/ Yohimbine HCL|
554819|NCT00042510|Biological|Treatment group|
554820|NCT00042497|Biological|autologous dexosomes loaded with tumor-specific peptides|
554821|NCT00042484|Procedure|Community-level intervention & policy change|
554822|NCT00042471|Drug|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
554823|NCT00042458|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
554824|NCT00042458|Drug|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
554825|NCT00042432|Drug|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
554826|NCT00042406|Drug|HuMax-CD4|
554827|NCT00042393|Drug|Adefovir Dipivoxil|
554851|NCT00042289|Drug|elvitegravir/cobicistat|Women will receive elvitegravir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
554852|NCT00042289|Drug|dolutegravir|Women will receive dolutegravir as prescribed by their clinicians. (Dosage will vary for each participant.)
554975|NCT00040027|Drug|placebo + PEGinterferon alfa-2a|
554976|NCT00040599|Drug|hMN14 (labetuzumab)|
554828|NCT00042367|Drug|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.~12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.~Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.~3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.~Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
554829|NCT00042367|Drug|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
554830|NCT00042367|Drug|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.~Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.~Monitor weekly CBC/diff/plt. If ANC < 500/mm3 or platelets (unsupported) < 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.~Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
554831|NCT00042367|Drug|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
554832|NCT00042367|Drug|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
554833|NCT00042367|Drug|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.~Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course~1."
554834|NCT00042367|Drug|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is < 1.012.~0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl~(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is > 2000 on two consecutive days, post ANC nadir."
554835|NCT00042367|Drug|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.~Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
554836|NCT00042367|Drug|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
554837|NCT00042367|Radiation|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.~8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
554838|NCT00042354|Drug|clofarabine (IV formulation)|
554839|NCT00042341|Drug|clofarabine (IV formulation)|
554840|NCT00042328|Drug|Valacyclovir|
554841|NCT00042315|Procedure|Chemotherapy|
554842|NCT00042315|Drug|tariquidar + vinorelbine|
554843|NCT00042315|Drug|placebo + vinorelbine|
554844|NCT00042302|Procedure|Chemotherapy|
554845|NCT00042302|Drug|tariquidar + paclitaxel/carboplatin|
554846|NCT00042302|Drug|placebo + paclitaxel/carboplatin|
554847|NCT00042289|Drug|atazanavir/cobicistat|Women will receive atazanavir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
554848|NCT00042289|Drug|darunavir/ritonavir|Women will receive darunavir/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
554849|NCT00042289|Drug|darunavir/cobicistat|Women will receive darunavir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
554850|NCT00042289|Drug|etravirine|Women will receive etravirine as prescribed by their clinicians. (Dosage will vary for each participant.)
554969|NCT00041392|Drug|Magnesium|100 mg/kg
554970|NCT00041392|Drug|0.9% saline|Placebo
554853|NCT00042289|Drug|tenofovir alafenamide fumarate (TAF)|Women will receive TAF as prescribed by their clinicians. (Dosage will vary for each participant.)
554854|NCT00042289|Drug|TAF/cobicistat|Women will receive TAF/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
554855|NCT00042289|Drug|TAF/ritonavir|Women will receive TAF/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
554856|NCT00042289|Drug|efavirenz|Women will receive efavirenz as prescribed by their clinicians. (Dosage will vary for each participant.)
554857|NCT00042289|Drug|lopinavir/ritonavir|Women will receive lopinavir/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
554858|NCT00042289|Drug|nevirapine|Women will receive nevirapine as prescribed by their clinicians. (Dosage will vary for each participant.)
554859|NCT00042289|Drug|rifampicin|Women will receive rifampicin as prescribed by their clinicians. (Dosage will vary for each participant.)
554860|NCT00042289|Drug|ethambutol|Women will receive ethambutol as prescribed by their clinicians. (Dosage will vary for each participant.)
554861|NCT00042289|Drug|isoniazid|Women will receive isoniazid as prescribed by their clinicians. (Dosage will vary for each participant.)
554862|NCT00042289|Drug|pyrazinamide|Women will receive pyrazinamide as prescribed by their clinicians. (Dosage will vary for each participant.)
554863|NCT00042289|Drug|rifampicin|Women will receive rifampicin as prescribed by their clinicians. (Dosage will vary for each participant.)
554864|NCT00042289|Drug|kanamycin|Women will receive kanamycin as prescribed by their clinicians. (Dosage will vary for each participant.)
554865|NCT00042289|Drug|amikacin|Women will receive amikacin as prescribed by their clinicians. (Dosage will vary for each participant.)
554866|NCT00042289|Drug|capreomycin|Women will receive capreomycin as prescribed by their clinicians. (Dosage will vary for each participant.)
554867|NCT00042289|Drug|moxifloxacin|Women will receive moxifloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
554868|NCT00042289|Drug|levofloxacin|Women will receive levofloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
554869|NCT00042289|Drug|ofloxacin|Women will receive ofloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
554870|NCT00042289|Drug|ethionamide/prothionamide|Women will receive ethionamide/prothionamide as prescribed by their clinicians. (Dosage will vary for each participant.)
554871|NCT00042289|Drug|terizidone/cycloserine|Women will receive terizidone/cycloserine as prescribed by their clinicians. (Dosage will vary for each participant.)
554872|NCT00042289|Drug|para-aminosalicylic acid (PAS)|Women will receive PAS as prescribed by their clinicians. (Dosage will vary for each participant.)
554873|NCT00042289|Drug|high dose isoniazid (INH)|Women will receive high dose INH as prescribed by their clinicians. (Dosage will vary for each participant.)
554874|NCT00042289|Drug|bedaquiline|Women will receive bedaquiline as prescribed by their clinicians. (Dosage will vary for each participant.)
554875|NCT00042289|Drug|clofazamine|Women will receive clofazamine as prescribed by their clinicians. (Dosage will vary for each participant.)
554876|NCT00042289|Drug|delamanid|Women will receive delamanid as prescribed by their clinicians. (Dosage will vary for each participant.)
554877|NCT00042289|Drug|linezolid|Women will receive linezolid as prescribed by their clinicians. (Dosage will vary for each participant.)
554878|NCT00042289|Drug|pretomanid|Women will receive pretomanid as prescribed by their clinicians. (Dosage will vary for each participant.)
554879|NCT00042289|Drug|atazanavir/ritonavir/tenofovir|Women will receive atazanavir/ritonavir/tenofovir as prescribed by their clinicians. (Dosage will vary for each participant.)
554880|NCT00042289|Drug|ethinyl estradiol oral contraceptive|Women will receive ethinyl estradiol oral contraceptive as prescribed by their clinicians. (Dosage will vary for each participant.)
554881|NCT00042289|Drug|etonogestrel implant|Women will receive etonogestrel implant as prescribed by their clinicians. (Dosage will vary for each participant.)
554882|NCT00041483|Drug|Anecortave Acetate 15 mg sterile suspension|
554883|NCT00041483|Other|Photodynamic Therapy (PDT)|
554884|NCT00042380|Drug|Novasoy|
554885|NCT00042250|Drug|Chemotherapy for hematologic malignancy|
554886|NCT00042237|Behavioral|Schema Therapy|
554887|NCT00042224|Procedure|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
554888|NCT00042224|Drug|Clozapine|Patients with psychotic symptoms will receive clozapine
554889|NCT00042211|Behavioral|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
554890|NCT00042211|Behavioral|Control|No treatment control
554891|NCT00042198|Behavioral|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
554892|NCT00042198|Behavioral|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
554893|NCT00042185|Behavioral|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
554894|NCT00042185|Behavioral|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
554971|NCT00040638|Drug|TLK286|
554972|NCT00040625|Drug|Pemetrexed|
554973|NCT00040625|Drug|Cisplatin|
554974|NCT00040027|Drug|thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|
554895|NCT00042185|Behavioral|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
554896|NCT00042172|Drug|Donepezil|
554897|NCT00042172|Drug|Ginkgo Biloba Extract|
554898|NCT00042159|Device|repetitive transcranial magnetic stimulation|1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
554899|NCT00042146|Behavioral|Cognitive-behavior therapy|
554900|NCT00042146|Drug|zolpidem|
554901|NCT00042094|Biological|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
554902|NCT00042081|Drug|CGT003 (E2F Duplex Decoy)|
554903|NCT00042068|Drug|Meloxicam|
554904|NCT00042055|Drug|CP-461|
554905|NCT00042042|Behavioral|Family based educational program|
554906|NCT00042029|Drug|MK0869, aprepitant|
554907|NCT00042029|Drug|Comparator: placebo|
554908|NCT00042016|Drug|decitabine (5-aza-2'deoxycytidine)|
554909|NCT00042003|Drug|decitabine (5-aza-2'deoxycytidine)|
554910|NCT00041990|Drug|decitabine (5-aza-2'deoxycytidine)|
554911|NCT00041977|Drug|doxycycline hyclate 20 mg twice daily|
554912|NCT00041938|Drug|aspirin|325 mg per day
554913|NCT00041938|Drug|Warfarin|INR 2.5-3.0; target INR 2.75
554914|NCT00041925|Drug|CGT003 (E2F Duplex Decoy)|
554915|NCT00041860|Procedure|Controlled Exposure to Environmental Contaminant|
554916|NCT00041821|Procedure|Nasal irritation thresholds and irritant provocation|
554917|NCT00041899|Drug|CDB-2914|
554918|NCT00041899|Drug|COB-2914|
554919|NCT00041808|Drug|MTC-DOX for Injection|
554920|NCT00041808|Procedure|Chemotherapy|
554921|NCT00041795|Drug|leteprinim potassium (Neotrofin)|
554922|NCT00041782|Drug|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
554923|NCT00041769|Procedure|Therapeutic Drug Monitoring (TDM)|
554924|NCT00041756|Drug|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
554925|NCT00041756|Drug|Placebo|One placebo tablet, twice daily for for one year
554926|NCT00041756|Drug|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
554927|NCT00041756|Drug|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
554928|NCT00041756|Drug|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
554929|NCT00041743|Behavioral|Group Cognitive Behavioral Therapy|
554930|NCT00041730|Biological|Id-KLH|
554931|NCT00041717|Drug|Fampridine-SR|25mg bid (twice daily)
554932|NCT00041717|Other|Placebo|Placebo
554933|NCT00041704|Drug|Anidulafungin, VER002|
554934|NCT00041691|Drug|hMN14 (labetuzumab)|
554935|NCT00041678|Drug|aripiprazole|
554936|NCT00041665|Drug|Recombinant Human Keratinocyte Growth Factor|
554937|NCT00041652|Drug|hMN14 (labetuzumab)|
554938|NCT00041639|Drug|hMN14 (labetuzumab)|
554939|NCT00041626|Genetic|INGN 201|
554940|NCT00041613|Genetic|INGN 201|
554941|NCT00041587|Drug|IL13-PE38QQR|
554942|NCT00041587|Procedure|targeted fusion protein therapy|
554943|NCT00041587|Procedure|surgery|
554944|NCT00041509|Drug|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
554945|NCT00041509|Drug|Placebo|matching placebo, oral, BID for 28 days
554946|NCT00041496|Drug|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
554947|NCT00041496|Other|Placebo|Placebo to match SB-207266
554948|NCT00041574|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
554949|NCT00041561|Drug|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
554950|NCT00041561|Drug|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
554951|NCT00041548|Drug|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
554952|NCT00041548|Drug|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
554953|NCT00041535|Drug|OGT 918|
554954|NCT00041470|Drug|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
554955|NCT00041470|Drug|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
554956|NCT00041470|Drug|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
554957|NCT00041470|Drug|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
554958|NCT00040677|Drug|Low Dose ICA-17043|Low dose arm
554959|NCT00040677|Drug|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
554960|NCT00040677|Drug|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
554961|NCT00040664|Drug|ritonavir|ritonavir oral capsules or oral solution
554962|NCT00040664|Drug|fosamprenavir|fosamprenavir oral suspension or tablet
554963|NCT00040651|Drug|Fludarabine|
554964|NCT00040651|Drug|Cyclophosphamide|
554965|NCT00040651|Drug|Thymoglobulin|
554966|NCT00040651|Procedure|Leukapheresis|
554967|NCT00040651|Procedure|Self bone marrow transplant|
554968|NCT00041431|Drug|Hormone Replacement Therapy|
554977|NCT00040586|Drug|Monoclonal Antibody J591|
554978|NCT00040586|Drug|Recombinant Interleukin-2|
554979|NCT00040573|Drug|131I-TM-601|
554980|NCT00040560|Drug|111In-DAC|
554981|NCT00040560|Procedure|Diagnostic|
554982|NCT00040547|Drug|Farnesyl Protein Transferase Inhibitor|
554983|NCT00040534|Drug|Farnesyl Protein Transferase Inhibitor|
554984|NCT00040521|Drug|Recombinant Human Interleukin-11 (rhIL-11)|
554985|NCT00040495|Drug|Pantoprazole|
554986|NCT00040482|Drug|Cyclophosphamide|
554987|NCT00040482|Drug|ATG|
554988|NCT00040482|Drug|MESNA|
554989|NCT00040482|Procedure|Radiation therapy|
554990|NCT00040469|Drug|Campath -1H|
554991|NCT00040469|Drug|Dilantin|
554992|NCT00040469|Drug|Busulfan|
554993|NCT00040469|Drug|Cyclophosphamide|
554994|NCT00040456|Drug|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
554995|NCT00040456|Drug|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
554996|NCT00040443|Drug|CX516|
554997|NCT00040443|Drug|Placebo|
554998|NCT00040430|Drug|111In-DAC|
554999|NCT00040430|Procedure|Diagnostic|
555000|NCT00040508|Drug|Sirolimus|
555001|NCT00040417|Drug|FLUDARABINE|
555002|NCT00040417|Drug|CAMPATH-IH|
555003|NCT00040417|Procedure|Total Body Irradiation|
555004|NCT00040417|Drug|FK506|
555005|NCT00040417|Drug|G-SCF (Granulocyte-colony stimulating factor)|
555006|NCT00040404|Drug|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
555007|NCT00040404|Drug|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
555008|NCT00040404|Drug|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
555009|NCT00040404|Other|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
555010|NCT00040391|Drug|Investigational drug|
555011|NCT00040391|Drug|Irinotecan|
555012|NCT00040391|Drug|5-fluorouracil|
555013|NCT00040391|Drug|Leucovorin|
555014|NCT00040378|Drug|alphatocopherol|400 IU daily
555015|NCT00040378|Drug|Selenium|200mcg daily
555016|NCT00040378|Drug|Placebo replacement for vitamin E|1 placebo pill daily
555017|NCT00040378|Drug|Placebo replacement for Selenium|1 placebo pill daily
555018|NCT00040365|Drug|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
555019|NCT00040365|Radiation|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
555020|NCT00040339|Procedure|hypothermia (body temperature lowered to 33°C or 91.4°F)|
555021|NCT00040326|Procedure|anteromesial temporal resection|surgical treatment for epilepsy
555022|NCT00040326|Drug|antiepileptic drugs|pharmacotherapy
555023|NCT00040313|Drug|pegaptanib sodium (Macugen)|
555024|NCT00040300|Drug|Racivir|
555025|NCT00040287|Behavioral|smoking cessation program|
555026|NCT00040287|Behavioral|weight control program|
555027|NCT00040274|Drug|DPC 817|
555028|NCT00040183|Drug|Tarceva (erlotinib HCl, OSI-774)|
555029|NCT00040170|Biological|MVA-MUC1-IL2|
555030|NCT00040157|Drug|ACH126-443 (Beta-L-Fd4C)|
555031|NCT00040144|Drug|ACH126, 433 (b-L-Fd4C)|
555032|NCT00040261|Drug|Memantine HCL|
555033|NCT00040248|Drug|Daclizumab|
555034|NCT00040235|Procedure|magnesium|
555035|NCT00040209|Drug|JP 1730|
555036|NCT00040209|Drug|IV Levodopa|
555037|NCT00040209|Drug|IV Apomorphine|
555038|NCT00040131|Drug|IL-10|
555039|NCT00040105|Drug|Zarnestra (R115777)|"Starting Dose:~300 mg by mouth (PO) Twice daily"
555040|NCT00040105|Drug|Gleevec (Imatinib mesylate)|"Starting Dose:~300 mg By Mouth (PO) daily"
555041|NCT00040092|Drug|Virulizin®|
555042|NCT00040014|Drug|exemestane|
555043|NCT00040001|Drug|DTI-0009|
555044|NCT00039988|Drug|Glatiramer acetate|20 mg administered subcutaneously daily
555045|NCT00039988|Drug|Albuterol|2 mg or 4 mg oral capsules taken daily
555046|NCT00039988|Drug|Albuterol placebo|Oral placebo capsules will be taken daily
555047|NCT00039975|Drug|Indinavir sulfate|
555048|NCT00039975|Drug|Ritonavir|
555049|NCT00039975|Drug|Amlodipine|
555050|NCT00039975|Drug|Diltiazem HCl|
555051|NCT00039962|Drug|thymalfasin (thymosin alpha 1)|
555052|NCT00039962|Drug|PEGinterferon alfa-2a|
555053|NCT00039936|Behavioral|Cognitive Behavior Treatment|
555054|NCT00039936|Behavioral|Self Help|
555055|NCT00039936|Behavioral|Partial Self Help|
555056|NCT00040066|Procedure|Cocaine (IV)|
555057|NCT00040053|Drug|Ondansetron|
555058|NCT00040040|Drug|Bupropion|
555059|NCT00039910|Drug|(PN-152,243)/ PN-196,444|
555060|NCT00039884|Drug|NESP - Novel Erythropoiesis Stimulating Protein|
555061|NCT00039871|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks
555062|NCT00039871|Drug|REBETOL (ribavirin; SCH 18908)|REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
555063|NCT00039858|Drug|Argatroban|
555064|NCT00039832|Drug|Abciximab (ReoPro) and Reteplase (Retavase)|
555065|NCT00039793|Procedure|Moderate-intensity and low-intensity bodywork therapy|
555066|NCT00039780|Drug|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
555067|NCT00039780|Drug|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
555068|NCT00039754|Drug|Holmium-166-DOTMP|
555069|NCT00039741|Drug|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
555070|NCT00039741|Drug|NNRTIs (EFV, NVP)|"Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)~Prescribed per participant's doctor"
555071|NCT00039741|Drug|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|"Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)~Prescribed per participant's doctor"
555072|NCT00039767|Drug|Lepirudin|
555073|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
555074|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
555075|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
555076|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
555077|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
555078|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
555079|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
555080|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
555081|NCT00039000|Drug|HSPPC-96 or Oncophage|
555082|NCT00038987|Biological|Wetvax (APSV)|
555083|NCT00038974|Drug|peginterferon alfa-2a|
555084|NCT00038974|Drug|Ribavirin|
555085|NCT00038961|Drug|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
555086|NCT00038961|Other|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
555087|NCT00039702|Drug|[123] 5-I-A-85380|
555088|NCT00039663|Drug|Pravastatin|
555089|NCT00039663|Drug|Gemfibrozil|
555090|NCT00039663|Drug|Rosiglitazone|
555091|NCT00039624|Radiation|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
555092|NCT00038948|Drug|Sirolimus|Sirolimus, Cyclosporine A & Tacrolimus are concentration controlled
555093|NCT00038948|Drug|tacrolimus|
555094|NCT00038948|Drug|Cyclosporine A|
555095|NCT00038935|Drug|ReFacto AF|
555096|NCT00038922|Drug|rhIL-11|
555097|NCT00038909|Drug|BDDrFVII|
555098|NCT00038896|Drug|Venlafaxine ER|
555099|NCT00038883|Drug|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
555100|NCT00038870|Biological|Dendritic Cell Activated Lymphocyte|
555101|NCT00038857|Procedure|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
555102|NCT00038857|Drug|Melphalan|140 mg/m^2 on day -8
555103|NCT00038857|Drug|Thiotepa|10 mg/kg on day -7
555104|NCT00038857|Drug|Fludarabine|160 mg/m^2 over 4 days on days -6, -5, -4, -3
555105|NCT00038857|Drug|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
555106|NCT00038844|Drug|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
555107|NCT00038844|Drug|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
555108|NCT00038844|Drug|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
555109|NCT00038844|Drug|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
555110|NCT00038831|Drug|Mylotarg|Starting dose 2 mg/m^2 over 2-hour intravenous infusion on day -12.
555111|NCT00038831|Drug|Fludarabine|30 mg/m^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
555112|NCT00038831|Drug|Melphalan|140 mg/m^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
555113|NCT00038831|Drug|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
555114|NCT00038831|Procedure|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
555115|NCT00038818|Biological|CD8 Depleted Donor Lymphocyte|
555116|NCT00038805|Drug|Mylotarg|
555117|NCT00038792|Drug|Recombinant Human Keratinocyte Growth Factor|
555118|NCT00038779|Procedure|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
555119|NCT00038766|Drug|semapimod|semapipmod 60 mg IV x 5 days
555120|NCT00038766|Drug|semapimod|IV 30 mg x 5 days
555121|NCT00038766|Drug|placebo|placebo IV
555122|NCT00038753|Procedure|Vision Screening|
555123|NCT00038727|Behavioral|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
555124|NCT00038727|Drug|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
555125|NCT00038727|Behavioral|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
555126|NCT00038727|Behavioral|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
555127|NCT00038714|Drug|SGN-00101|
555128|NCT00038701|Drug|TNP-470|
555129|NCT00038688|Behavioral|Peer HIV Education Program|
555130|NCT00038675|Drug|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
555131|NCT00038662|Drug|Atrasentan|
555132|NCT00038649|Drug|Gleevec|400 mg orally twice daily
555133|NCT00038636|Drug|Lopinavir/ritonavir|
555134|NCT00038636|Drug|Ritonavir|
555135|NCT00038623|Drug|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
555136|NCT00038623|Drug|Rituximab|250 mg/m^2 in the vein over 6 to 8 hours on Day 1.
555137|NCT00038610|Drug|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
555138|NCT00038610|Drug|Cyclophosphamide|300 mg/m^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m^2) for courses 1, 3, 5, 7.
555139|NCT00038610|Drug|Doxorubicin|50 mg/m^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
555140|NCT00038610|Drug|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
555141|NCT00038610|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
555142|NCT00038610|Drug|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.~200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
555143|NCT00038610|Drug|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.~3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
555144|NCT00038610|Drug|Mesna|600 mg/m^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
555145|NCT00038610|Drug|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
555146|NCT00038597|Drug|SCH66336|
555147|NCT00038584|Drug|SCH66336|
555148|NCT00038571|Drug|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
555149|NCT00038558|Drug|Filgrastim SD/01|
555150|NCT00038558|Drug|Adriamycin|
555151|NCT00038558|Drug|Bleomycin|
555152|NCT00038558|Drug|Vinblastine|
555153|NCT00038558|Drug|DTIC|
555154|NCT00038545|Drug|Filgrastim SD/01|
555155|NCT00038545|Drug|Paclitaxel|
555156|NCT00038545|Drug|Topotecan|
555157|NCT00038532|Drug|Amprenavir/ritonavir|
555158|NCT00038532|Drug|Saquinavir/ritonavir|
555159|NCT00038532|Drug|Efavirenz|
555160|NCT00038519|Drug|Amprenavir/ritonavir|
555161|NCT00038519|Drug|Saquinavir/ritonavir|
555162|NCT00038506|Drug|abacavir/lamivudine/zidovudine|
555163|NCT00038506|Drug|tenofovir|
555164|NCT00038493|Drug|Temozolomide and SCH66336|
555165|NCT00038480|Drug|Lopinavir/Ritonavir|
555166|NCT00038467|Drug|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
555167|NCT00038467|Drug|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
555168|NCT00038454|Drug|Hemolink (hemoglobin raffimer IV solution)|
555169|NCT00038441|Drug|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
555170|NCT00038428|Drug|TLK286|
555171|NCT00038415|Biological|CLL vaccine using DNA plasmid vector|
555172|NCT00038402|Drug|Herceptin|Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.
555173|NCT00038402|Drug|Taxol|225 mg/m^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.
555174|NCT00038402|Drug|Fluorouracil|500 mg/m^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
555175|NCT00038402|Drug|Cytoxan|500 mg/m^2 on Day 1 of each cycle for 4 cycles.
555176|NCT00038402|Drug|Epirubicin|75 mg/m^2 IV on Day 1 of each cycle for 4 cycles.
555177|NCT00038389|Drug|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
555178|NCT00038376|Drug|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
555179|NCT00038376|Drug|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
555180|NCT00038363|Procedure|Rehabilitation|
555181|NCT00038363|Procedure|Subacute care|
555182|NCT00038350|Behavioral|Lingual Strengthening|8 week lingual strengthening exercise protocol
555183|NCT00038337|Procedure|Health Literacy|
555184|NCT00038311|Drug|PN-152,243)/PN-196,444|
555185|NCT00038298|Drug|Placebo|Placebo given 3 times weekly
555186|NCT00038298|Drug|AMG 719|50 mg 3 times weekly
555187|NCT00038298|Drug|AGM 719|200 mg 3 times weekly
555188|NCT00038298|Drug|AMG 719|400 mg 3 times weekly
555189|NCT00038298|Drug|placebo to AMG 719|Placebo dose given 3 times weekly
555190|NCT00038285|Procedure|Amputation Prevention|
555191|NCT00038272|Drug|Mycophenolate mofetil|
555194|NCT00038246|Drug|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
555195|NCT00038246|Drug|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
555196|NCT00038246|Drug|Paclitaxel (Taxol)|100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10
555197|NCT00038233|Drug|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
555198|NCT00038220|Drug|Lopinavir/ritonavir|
555199|NCT00038220|Drug|Efavirenz|
555200|NCT00038220|Drug|Lamivudine|
555201|NCT00038220|Drug|Tenofovir DF|
555202|NCT00038207|Drug|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
555203|NCT00038194|Drug|imatinib mesylate|
555204|NCT00038194|Drug|docetaxel|
555205|NCT00038181|Drug|Thalidomide|
555206|NCT00038168|Drug|Estramustine|Intravenous dose
555207|NCT00038168|Drug|Taxol|Intravenous dose
555208|NCT00038155|Procedure|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
555209|NCT00038142|Drug|Vincristine|2.0 mg/m^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
555210|NCT00038142|Drug|Doxorubicin|90 mg/m^2 IV over 30 min x 1 repeated every 3 weeks X 6.
555211|NCT00038142|Drug|Cyclophosphamide|2.0 g/m^2 IV daily x 2 days repeated every 3 weeks X 6.
555212|NCT00038142|Drug|Dexrazoxane|900 mg/m^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
555213|NCT00038142|Biological|ImmTher|900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
555214|NCT00038129|Procedure|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
555215|NCT00038116|Procedure|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
555216|NCT00038116|Procedure|placebo|sham surgery
555217|NCT00038103|Drug|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
555218|NCT00038103|Drug|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
555219|NCT00038090|Drug|Thalidomide|100 mg capsules by mouth daily each evening
555220|NCT00038090|Drug|Dexamethasone|20 mg/m^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
555221|NCT00038077|Drug|Seloken ZOK/Toprol-XL|50 mg
555222|NCT00038077|Drug|Seloken ZOK/Toprol-XL|200 mg
555223|NCT00038077|Drug|Placebo|
555224|NCT00038064|Drug|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
555225|NCT00038064|Drug|rHuEPO|150 IU/kg TIW
555226|NCT00038051|Drug|Hum-195/rGel|Starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
555227|NCT00038038|Drug|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
555228|NCT00038038|Procedure|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
555229|NCT00038025|Drug|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
555230|NCT00038012|Drug|Thrombopoietin|
555231|NCT00038012|Procedure|Platelet-pheresis|
555232|NCT00038012|Drug|Carboplatin|
555233|NCT00037999|Procedure|Testosterone supplement|
555234|NCT00037986|Device|Hearing Aids|Hearing aid use
555235|NCT00037973|Behavioral|ventilation feedback|
555236|NCT00037973|Behavioral|exercise|
555237|NCT00037960|Procedure|Constrained Induced Therapy|
555238|NCT00037947|Procedure|Hearing in Multiple Sclerosis|
555239|NCT00037934|Device|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
555240|NCT00037934|Other|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
555241|NCT00037921|Procedure|Bacterial colonization|
555242|NCT00037908|Procedure|Strength training|
555243|NCT00037895|Procedure|Ambulation training|
555244|NCT00037882|Drug|PEG-Intron|Once weekly injection.
555245|NCT00037869|Drug|I-131 Metaiodobenzylguanidine|
555246|NCT00037843|Drug|I-131 Iodocholesterol|
555247|NCT00037830|Drug|GM1 ganglioside|100 mg twice per day by subcutaneous injection
555248|NCT00037830|Drug|Placebo|Twice per day subcutaneous injection, equal volume as active drug
555249|NCT00037817|Drug|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
555250|NCT00037817|Biological|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
555251|NCT00037817|Drug|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
555252|NCT00037804|Drug|Irinotecan|
555253|NCT00037791|Drug|(PN-152,243)/PN-196,444|
555254|NCT00004575|Drug|Miconazole, L-NMMA, Bradykinin|
555255|NCT00001866|Procedure|horizontal muscles of the eye will be cut and then reattached in the same position|
555256|NCT00001864|Drug|Atropine|
555257|NCT00001864|Device|Patch|
555258|NCT00001818|Drug|Hydroxyurea|
555259|NCT00001688|Drug|Ritonavir|
555260|NCT00001688|Drug|Nevirapine|
555261|NCT00001688|Drug|Stavudine|
555262|NCT00001542|Drug|fluconazole|
555263|NCT00001190|Drug|Deslorelin|
555358|NCT00036127|Drug|aripiprazole|
555359|NCT00036114|Drug|aripiprazole|
555360|NCT00036101|Drug|aripiprazole|
555361|NCT00036088|Drug|Olanzapine|
555362|NCT00036075|Drug|CP-461|
555264|NCT00037752|Drug|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
555265|NCT00037752|Behavioral|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
555266|NCT00037713|Biological|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 & 10.
555267|NCT00037700|Drug|anakinra|
555268|NCT00037700|Drug|pegsunercept|
555269|NCT00037687|Drug|rPAF-AH|
555270|NCT00037674|Drug|Topiramate|
555271|NCT00037661|Drug|INS365 Ophthalmic Solution|
555272|NCT00037648|Drug|Anakinra|anakinra
555273|NCT00037648|Drug|Placebo|placebo
555274|NCT00037635|Drug|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
555275|NCT00037635|Drug|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
555276|NCT00037622|Drug|ACH-126, 443 (beta-L-Fd4C)|
555277|NCT00037609|Drug|Capecitabine|1000 mg/m^2 taken by mouth twice daily.
555278|NCT00037609|Drug|Exisulind|125 mg taken by mouth twice daily.
555279|NCT00037596|Drug|Gemtuzumab Ozogamicin|
555280|NCT00037596|Drug|cytarabine.|
555281|NCT00037583|Drug|Gemtuzumab Ozogamicin|
555282|NCT00037570|Drug|Pantoprazole|
555283|NCT00037557|Drug|BeneFIX|
555284|NCT00037544|Drug|ReFacto AF|
555285|NCT00037531|Drug|Sirolimus (RAPAMUNE)|
555286|NCT00037518|Drug|AMG 073|
555287|NCT00037492|Procedure|home-based sessions/family meetings with trained clinician|
555288|NCT00037479|Drug|ceftriaxone|
555289|NCT00037440|Genetic|Polymorphisms measured|
555290|NCT00037219|Drug|Anidulafungin, VER002|
555291|NCT00037206|Drug|Anidulafungin, VER002|
555292|NCT00037180|Drug|Celecoxib|
555293|NCT00037180|Drug|Irinotecan|
555294|NCT00037180|Drug|5-fluorouracil|
555295|NCT00037180|Drug|Leucovorin|
555296|NCT00037167|Device|Exercise poles|
555297|NCT00037154|Drug|Saw Palmetto|
555298|NCT00037141|Drug|dehydrated alcohol|
555299|NCT00037128|Drug|GL701|
555300|NCT00037115|Drug|interferon beta 1a|
555301|NCT00037115|Drug|methotrexate|
555302|NCT00037115|Drug|methylprednisolone|
555303|NCT00037102|Drug|interferon beta 1a|
555304|NCT00037102|Drug|methotrexate|
555305|NCT00037089|Drug|UFT (Tegafur/Uracil)|
555306|NCT00037063|Drug|Thiamine hydrochloride|
555307|NCT00037063|Drug|Riboflavin|
555308|NCT00037063|Drug|Ascorbic acid|
555309|NCT00037063|Drug|Vitamin E|
555310|NCT00037050|Drug|Linezolid|
555311|NCT00037050|Drug|Vancomycin|
555312|NCT00037050|Drug|Oxacillin|
555313|NCT00037050|Drug|Dicloxacillin|
555314|NCT00036647|Drug|Tarceva (erlotinib HCl, OSI-774 )|
555315|NCT00036634|Drug|Tenofovir DF|Tenofovir DF tablet administered orally once daily
555316|NCT00036634|Drug|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
555317|NCT00036621|Drug|BMS-275291|
555318|NCT00036608|Drug|Entecavir|
555319|NCT00036582|Drug|Clozapine|
555320|NCT00036569|Procedure|adjuvant therapy|
555321|NCT00036569|Biological|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
555322|NCT00036556|Drug|Atrasentan|
555323|NCT00036543|Drug|Atrasentan|
555324|NCT00036517|Drug|PHY906|
555325|NCT00036504|Drug|Insulin Lispro low mixture|
555326|NCT00036491|Drug|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m^2
555327|NCT00036465|Behavioral|Treatment regimen change|
555328|NCT00036452|Drug|lopinavir/ritonavir|
555329|NCT00036452|Drug|emtricitabine|
555330|NCT00036452|Drug|stavudine|
555331|NCT00036452|Drug|tenofovir DF|
555332|NCT00036439|Drug|Infliximab|
555333|NCT00036426|Biological|FavId (Id-KLH) active immunotherapy|
555334|NCT00036413|Drug|TCH346|
555335|NCT00036400|Drug|epoetin alfa|
555336|NCT00036387|Drug|Infliximab|
555337|NCT00036374|Drug|Infliximab|
555338|NCT00036361|Drug|Aripiprazole|
555339|NCT00036348|Drug|Aripiprazole|
555340|NCT00036335|Drug|Duloxetine Hydrochloride|
555341|NCT00036309|Drug|Duloxetine Hydrochloride|
555342|NCT00036296|Drug|talampanel|75mg per day divided into 3 doses for 22 days
555343|NCT00036283|Drug|Celecoxib|
555344|NCT00036270|Drug|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
555345|NCT00036270|Drug|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
555346|NCT00036257|Drug|CP-461|
555347|NCT00036244|Drug|RG1068 (Synthetic Human Secretin)|
555348|NCT00036231|Drug|RG1068 (Synthetic Human Secretin)|
555349|NCT00036218|Drug|sumanirole|
555350|NCT00036218|Drug|ropinirole|
555351|NCT00036205|Drug|sumanirole|
555352|NCT00036192|Drug|FK614|
555353|NCT00036179|Drug|FK463|
555354|NCT00036166|Drug|FK463|
555355|NCT00036153|Drug|Tacrolimus (Prograf®)|
555356|NCT00036153|Drug|Methotrexate|
555357|NCT00036140|Drug|Investigational drug|
555363|NCT00036062|Drug|Sivelestat|
555364|NCT00036036|Drug|CP-461|
555365|NCT00036023|Drug|darbepoetin alfa|
555366|NCT00035997|Drug|Zometa|
555367|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
555368|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
555369|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
555370|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
555371|NCT00035971|Drug|raloxifene HCI and alendronate Na|
555372|NCT00035958|Drug|Prednisone|
555373|NCT00035958|Drug|Methotrexate|
555374|NCT00035958|Drug|Etanercept|
555375|NCT00035945|Drug|ISIS 14803|
555376|NCT00035932|Drug|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
555377|NCT00035932|Drug|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
555378|NCT00035932|Drug|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
555379|NCT00035919|Genetic|Mx-dnG1 Retroviral Vector|
555380|NCT00035906|Drug|DEX PS DDS®|
555381|NCT00035893|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
555382|NCT00035880|Drug|ABX-CBL|
555383|NCT00035867|Drug|TLK199 HCl Liposomes for Injection|
555384|NCT00035854|Drug|Zyvox® / Linezolid|
555385|NCT00035841|Drug|TLK286|
555386|NCT00035828|Drug|ABX-IL8|
555387|NCT00035815|Drug|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
555388|NCT00035815|Drug|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
555389|NCT00035802|Drug|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.~OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
555390|NCT00035802|Drug|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
555391|NCT00035789|Drug|Entecavir|
555392|NCT00035633|Drug|Entecavir|
555393|NCT00035620|Drug|pegfilgrastim|pegfilgrastim
555394|NCT00035620|Drug|filgrastim|filgrastim
555395|NCT00035607|Drug|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
555396|NCT00035607|Drug|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
555397|NCT00035594|Drug|pegfilgrastim|Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
555398|NCT00035581|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 24 weeks
555399|NCT00035568|Drug|Glucovance (metformin HCl/glyburide)|
555400|NCT00035568|Drug|or Metformin HCl alone|
555401|NCT00035568|Drug|or Glyburide alone.|
555402|NCT00035555|Drug|Belatacept|Solution, intravenous
555403|NCT00035555|Drug|Cyclosporine|Oral, capsule
555404|NCT00035555|Drug|Mycophenolate mofetil (MMF)|Oral, capsule
555405|NCT00035555|Drug|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
555406|NCT00035542|Drug|Glucovance (metformin HCl/glyburide)|
555407|NCT00035542|Drug|metformin HCl|
555408|NCT00035542|Drug|glyburide|
555409|NCT00035529|Drug|Placebo|Solution, i.v infusion, 0 mg, Days 1 & 15 then monthly, 10 months.
555410|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 & 15 then monthly, 10 months.
555411|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months.
555412|NCT00035516|Drug|Epothilone|
555413|NCT00035503|Drug|etiprednol dicloacetate|
555414|NCT00035490|Drug|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
555415|NCT00035490|Drug|placebo|placebo tablet, once daily for one year
555416|NCT00035490|Drug|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
555417|NCT00035477|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
555418|NCT00035477|Drug|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
555419|NCT00035464|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
555420|NCT00035464|Drug|Placebo|placebo tablets, twice a day for 6 months
555421|NCT00035451|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
555422|NCT00035451|Drug|Placebo|tablets, twice daily for 6 months
555423|NCT00035451|Drug|Sotalol|160 mg sot twice daily for 6 months
555424|NCT00035438|Drug|St. John’s Wort|
555425|NCT00035425|Drug|linezolid|600mg every 12 hours
555426|NCT00035425|Drug|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
555427|NCT00035412|Drug|St. John’s Wort|
555428|NCT00035399|Procedure|Acupuncture|
555429|NCT00035360|Drug|PEG-Intron|
555430|NCT00035347|Drug|IV azithromycin|500 mg once daily
555431|NCT00035347|Drug|ceftriaxone|1 gram once daily for 2 to 5 days
555432|NCT00035347|Drug|oral azithromycin|2 x 250 mg once daily
555433|NCT00035347|Drug|IV levofloxacin|500 mg once daily
555434|NCT00035347|Drug|oral levofloxacin|500 mg once daily
555435|NCT00035386|Procedure|trans-right ventricular alcohol septal ablation (TRVASA)|
555436|NCT00035334|Drug|NC-503 (Anti-amyloidotic (AA) Agent)|
555437|NCT00035321|Drug|Olanzapine|
555438|NCT00035321|Drug|Fluoxetine|
555439|NCT00035308|Drug|Abetimus sodium (LJP 394)|
555440|NCT00035295|Drug|MK0869, aprepitant|
555441|NCT00035295|Drug|Comparator: placebo|
555442|NCT00035282|Drug|aprepitant|
555443|NCT00035282|Drug|Comparator: placebo (unspecified)|
555444|NCT00035269|Drug|Antibiotic|
555445|NCT00035256|Drug|teriparatide|
555446|NCT00035256|Drug|raloxifene HCl|
555447|NCT00035256|Drug|placebo|
555448|NCT00035243|Drug|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
555449|NCT00035230|Drug|Topiramate|
555450|NCT00035204|Drug|galantamine|
555451|NCT00035191|Drug|galantamine|
555452|NCT00035178|Drug|Argatroban|
555453|NCT00035165|Drug|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
555454|NCT00035152|Drug|Paclitaxel and carboplatin|
555455|NCT00035139|Drug|methylphenidate|
555456|NCT00035126|Drug|epothilone b|
555457|NCT00035113|Drug|epothilone b|
555458|NCT00035100|Drug|epothilone b|
555459|NCT00035087|Drug|epothilone b|
555460|NCT00035074|Drug|Methotrexate|
555461|NCT00035061|Drug|pemetrexed|
555462|NCT00035048|Drug|aprepitant|
555463|NCT00035048|Drug|Comparator: placebo (unspecified)|
555464|NCT00035035|Drug|GEMZAR|
555465|NCT00035035|Drug|ALIMTA|
555466|NCT00035022|Drug|BCX-1777|
555467|NCT00035009|Drug|MK0869, aprepitant|
555468|NCT00035009|Drug|Comparator: paroxetine HCL|
555469|NCT00034983|Drug|aprepitant|
555470|NCT00034983|Drug|Comparator: paroxetine HCL|
555471|NCT00034970|Behavioral|Mindfulness-based at therapy|
555472|NCT00034957|Drug|Investigational drug|
555473|NCT00034944|Drug|MK0869, aprepitant|
555474|NCT00034944|Drug|Comparator: placebo|
555475|NCT00034918|Drug|ZD6474|
555476|NCT00034905|Drug|quetiapine fumarate vs risperidone|
555477|NCT00034892|Drug|Olanzapine, risperidone|
555478|NCT00034879|Drug|ZD1839 (Gefitinib)|
555479|NCT00034866|Drug|Protease inhibitor tipranavir|
555480|NCT00034853|Drug|meloxicam oral suspension|
555481|NCT00034853|Drug|naproxen oral suspension|
555482|NCT00034840|Drug|telmisartan, valsartan|
555483|NCT00034827|Drug|CI-1040|
555484|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 35mg TID
555485|NCT00034814|Drug|Placebo|Enzyme-inducing placebo TID
555486|NCT00034814|Drug|Talampanel|Enzyme-inducing Talampanel 35 mg TID
555487|NCT00034814|Drug|Talampanel|Enzyme-inducing TLP 50mg TID
555488|NCT00034814|Drug|Placebo|Non-enzyme-inducing placebo TID
555489|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 25mg TID
555490|NCT00034801|Drug|olanzapine|
555491|NCT00034801|Drug|ziprasidone|
555492|NCT00034788|Drug|Becaplermin|
555493|NCT00034775|Drug|risperidone|
555494|NCT00034762|Drug|risperidone|
555495|NCT00034749|Drug|Risperidone|
555496|NCT00034736|Drug|Levofloxacin|
555497|NCT00034710|Drug|Capsaicin Patch|
555498|NCT00034697|Drug|temozolomide|
555499|NCT00034684|Drug|Farnesyl Protein Transferase Inhibitor|
555500|NCT00034671|Drug|Posaconazole oral suspension|
555501|NCT00034658|Drug|Posaconazole|
555502|NCT00034645|Drug|Posaconazole oral suspension|
555503|NCT00034632|Drug|Posaconazole oral suspension|
555504|NCT00034619|Drug|ALIMTA|
555505|NCT00034619|Drug|Oxaliplatin|
555506|NCT00034606|Drug|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
555507|NCT00034593|Drug|ALIMTA|
555508|NCT00034593|Drug|gemcitabine|
555509|NCT00034580|Drug|olanzapine|
555510|NCT00034580|Drug|risperidone|
555511|NCT00034554|Biological|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5* patient safely completing the 2nd vaccination at the lower dose level.
555512|NCT00034541|Biological|cetuximab|400 mg/m2 i.v. over 120 minutes
555513|NCT00034541|Drug|paclitaxel|225 mg/m2, infusion
555514|NCT00034541|Drug|carboplatin|30-minute AUC = 6, infusion.
555515|NCT00034528|Drug|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
555516|NCT00034528|Drug|Fludarabine|30 mg/m^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
555517|NCT00034528|Drug|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
555518|NCT00034528|Drug|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
555689|NCT00031317|Drug|Clozapine|
555519|NCT00034515|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|
555520|NCT00034502|Drug|ALIMTA|
555521|NCT00034502|Drug|irinotecan|
555522|NCT00034489|Drug|pemetrexed|
555523|NCT00034489|Drug|gemcitabine|
555524|NCT00034476|Drug|sPLA2 Inhibitor|
555525|NCT00034463|Drug|ALIMTA|
555526|NCT00034463|Drug|folic acid|
555527|NCT00034463|Drug|multi-vitamins|
555528|NCT00034450|Drug|L-carnitine|
555529|NCT00034385|Drug|Valganciclovir|
555530|NCT00034372|Drug|oregovomab|
555531|NCT00034359|Drug|ACH-126, 443 (beta-L-Fd4C)|
555532|NCT00034359|Drug|Lamivudine|
555533|NCT00034359|Drug|Placebo|
555534|NCT00017862|Drug|SCH55700|
555535|NCT00034346|Drug|ABX-EGF|
555536|NCT00034346|Drug|paclitaxel|
555537|NCT00034346|Drug|carboplatin|
555538|NCT00034333|Drug|MTC-DOX for Injection|
555539|NCT00034307|Drug|sitaxsentan sodium|
555540|NCT00034294|Drug|GT160-246|
555541|NCT00034281|Drug|TAK-165|Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
555542|NCT00034268|Drug|LY900003|
555543|NCT00034255|Drug|INGAP Peptide|
555544|NCT00034203|Drug|efalizumab|
555545|NCT00034190|Drug|S-8184 Paclitaxel Injectable Emulsion|
555546|NCT00034177|Drug|S-8184 Paclitaxel Injectable Emulsion|
555547|NCT00034177|Drug|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
555548|NCT00034242|Drug|high-dose intravenous immunoglobulin (IVIG)|
555549|NCT00034229|Drug|Felbamate|
555550|NCT00034164|Drug|S-8184 Paclitaxel Injectable Emulsion|
555551|NCT00034151|Drug|S-8184 Paclitaxel Injectable Emulsion|
555552|NCT00034138|Drug|oregovomab|
555553|NCT00034125|Drug|LY353381|
555554|NCT00034125|Drug|tamoxifen|
555555|NCT00034112|Procedure|osteopathic manipulative treatment|
555556|NCT00034086|Drug|Lopinavir/Ritonavir|
555557|NCT00034086|Drug|Lamivudine/Zidovudine|
555558|NCT00034086|Drug|Tenofovir disoproxil fumarate|
555559|NCT00034086|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
555560|NCT00034086|Drug|Lamivudine|
555561|NCT00034086|Drug|Stavudine|
555562|NCT00034086|Drug|Zidovudine|
555563|NCT00034086|Drug|Didanosine|
555564|NCT00034086|Biological|Lyme Disease Vaccine Recombinant OspA|
555565|NCT00034086|Biological|Haemophilus B Conjugate Vaccine|
555566|NCT00034060|Drug|Etanercept|
555567|NCT00034047|Procedure|Acupuncture|
555568|NCT00034047|Drug|Chinese Products|
555569|NCT00034047|Drug|Nafarelin|
555570|NCT00034034|Procedure|Acupuncture|
555571|NCT00034021|Drug|Ginkgo Biloba|
555572|NCT00034021|Behavioral|Sex Therapy (genital focus)|
555573|NCT00034008|Behavioral|Healing Touch|
555574|NCT00033982|Drug|Posaconazole|
555575|NCT00033956|Drug|M40403|
555576|NCT00033943|Drug|deligoparin|
555577|NCT00033917|Drug|indomethacin|an anti-inflammatory drug
555578|NCT00033917|Drug|placebo|saline
555579|NCT00033904|Drug|autologous human tumor-derived HSPPC-96|
555580|NCT00033891|Drug|Infliximab|
555581|NCT00033878|Drug|Noni Extract|
555582|NCT00033865|Behavioral|Yoga, Relaxation Exercises, Sleep Hygiene|Sleep hygiene and relaxation exercises, with additional yoga
555583|NCT00033852|Procedure|Massage Therapy|
555584|NCT00033839|Drug|Civamide (Zucapsaicin)|
555585|NCT00033813|Drug|Oxatomide (tinset)|
555586|NCT00033215|Drug|S-3304|
555587|NCT00033202|Drug|Gimatecan® (ST-1481)|
555588|NCT00033189|Drug|Coenzyme Q10|
555589|NCT00033176|Drug|Alpha Lipoic Acid|
555590|NCT00033163|Drug|Adefovir dipivoxil|
555591|NCT00033163|Drug|Tenofovir disoproxil fumarate|
555592|NCT00033150|Behavioral|Fast ForWord|
555593|NCT00033150|Behavioral|Computer Assisted Language Intervention|
555594|NCT00033150|Behavioral|Individual Language Intervention|
555595|NCT00033150|Behavioral|Academic enrichment|
555596|NCT00033124|Behavioral|Behavior Therapy|
555597|NCT00033111|Drug|Cabergoline|
555598|NCT00033111|Drug|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
555599|NCT00033098|Drug|Metyrapone|
555600|NCT00033085|Drug|Ondansetron|
555601|NCT00033072|Drug|Selegiline|
555602|NCT00033059|Drug|Tolcapone|
555603|NCT00033046|Drug|Modafinil|
555604|NCT00033033|Drug|Reserpine|
555605|NCT00033020|Behavioral|Behavior Therapy|
555606|NCT00033007|Behavioral|Behavior Therapy|
555607|NCT00032994|Behavioral|Behavior Therapy|
555608|NCT00032981|Behavioral|Behavior Therapy|
555609|NCT00032968|Drug|Buprenorphine/naloxone|
555610|NCT00032955|Drug|Buprenorphine/naloxone|
555611|NCT00032942|Drug|Lofexidine|
555612|NCT00032929|Drug|Selegiline|
555613|NCT00032916|Drug|NS2359|
555614|NCT00032903|Drug|Gimatecan® (ST 1481)|
555615|NCT00032890|Drug|glucosamine|
555616|NCT00032890|Drug|chondroitin sulfate|
555617|NCT00032890|Drug|glucosamine and chondroitin sulfate combined|
555618|NCT00032890|Drug|celecoxib|
555619|NCT00032838|Drug|Yohimbine|
555620|NCT00032825|Drug|Ketaconazole|
555621|NCT00032825|Drug|Docetaxel|
555622|NCT00032799|Drug|natalizumab|
555623|NCT00032786|Drug|natalizumab|
555624|NCT00032773|Drug|pentostatin for injection|
555625|NCT00032812|Drug|Raclopride|
555626|NCT00032760|Behavioral|Meditation|
555627|NCT00032747|Drug|Vasopressin V2 Receptor Antagonist|
555628|NCT00032734|Drug|satavaptan (SR121463B)|
555629|NCT00032721|Procedure|Reiki; Subtle energy therapy|
555630|NCT00032708|Biological|Dryvax|
555631|NCT00032695|Drug|methionine|
555632|NCT00032669|Drug|HAART|
555633|NCT00032643|Drug|DITPA|
555634|NCT00032630|Procedure|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
555635|NCT00032630|Procedure|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
555636|NCT00032617|Procedure|Prolonged Exposure|trauma-focused exposure therapy
555637|NCT00032617|Procedure|Present Centered Therapy|therapy that focuses on current problems
555638|NCT00032591|Procedure|Weekly patient self-testing of prothrombin time|
555639|NCT00032591|Other|High quality anticoagulation management (HQACM) with conventional monthly testing|HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
555640|NCT00032526|Drug|Corticosteroids|
555641|NCT00032526|Behavioral|Classical conditioning to corticosteroid|
555642|NCT00032500|Drug|Echinacea|
555643|NCT00032487|Drug|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
555644|NCT00032487|Drug|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
555645|NCT00032487|Drug|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
555646|NCT00032487|Drug|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
555647|NCT00032474|Drug|Ginkgo biloba extract|
555648|NCT00032448|Procedure|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
555649|NCT00032435|Drug|PAL-40 Active|
555650|NCT00032435|Drug|PAL-40 Placebo|
555651|NCT00032422|Procedure|Acupuncture|
555652|NCT00032409|Behavioral|Music therapy-based relaxation/stress reduction|
555653|NCT00032396|Drug|Retisert Implant|
555654|NCT00032383|Behavioral|Tai Chi|
555655|NCT00032370|Procedure|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
555656|NCT00032370|Procedure|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
555657|NCT00032370|Procedure|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
555658|NCT00032357|Procedure|Ferritin reduction to 25 ng/ml by phlebotomy|
555659|NCT00032344|Procedure|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
555660|NCT00032331|Procedure|PET Imaging|
555661|NCT00032331|Procedure|CT scan|
555662|NCT00032305|Drug|Visilizumab|
555663|NCT00032292|Drug|Visilizumab|
555664|NCT00032279|Drug|Visilizumab|
555665|NCT00032240|Device|Shoe Insert|
555666|NCT00032227|Procedure|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
555667|NCT00032227|Other|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
555668|NCT00031551|Drug|Etanercept|
555669|NCT00031551|Drug|Placebo|
555670|NCT00031512|Drug|Placebo|Placebo.
555671|NCT00031512|Drug|Pleconaril (VP63843)|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
555672|NCT00031499|Drug|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
555673|NCT00031499|Drug|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
555674|NCT00031499|Drug|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
555675|NCT00031486|Drug|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
555676|NCT00031486|Drug|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
555677|NCT00031473|Drug|Virazole (Ribavirin) Inhalation Solution|
555678|NCT00031460|Drug|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
555679|NCT00031460|Drug|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
555680|NCT00031447|Drug|Acyclovir|Oral suspension 300 mg/m^2/dose, 3 times per day (TID), for 6 months.
555681|NCT00031447|Drug|Placebo|Placebo identical to oral acyclovir suspension in appearance and taste.
555682|NCT00031434|Drug|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
555683|NCT00031434|Drug|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
555684|NCT00031395|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
555685|NCT00031395|Drug|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
555686|NCT00031395|Other|placebo|an inactive substance
555687|NCT00031343|Drug|highly active antiretroviral therapy (HAART)|
555688|NCT00031317|Drug|Paroxetine|
555690|NCT00031291|Drug|Anthrax Immune Globulin|
555691|NCT00031278|Drug|CPG 7909|Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
555692|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
555693|NCT00031278|Drug|CPG 7909|Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
555694|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
555695|NCT00031278|Drug|CPG 7909|Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
555696|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
555697|NCT00031278|Drug|CPG 7909|Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
555698|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
555699|NCT00031265|Procedure|Family Intervention Telephone Tracking|
555700|NCT00031187|Drug|SGN-15 (cBR96-doxorubicin immunoconjugate)|
555701|NCT00031187|Drug|Taxotere (docetaxel)|
555702|NCT00031161|Drug|Nitisinone (NTBC)|
555703|NCT00031161|Drug|Dichloroacetate|
555704|NCT00031161|Behavioral|Low-tyrosin diet|
555705|NCT00031148|Drug|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
555706|NCT00031135|Drug|Choline Chloride|
555707|NCT00031122|Other|No Intervention|There is no intervention in this study
555708|NCT00031109|Biological|gp160 MN/LAI-2|
555709|NCT00031109|Biological|Aluminum hydroxide|
555710|NCT00031096|Drug|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
555711|NCT00031096|Drug|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
555712|NCT00031083|Genetic|Interferon-beta|
555713|NCT00031070|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
555714|NCT00031070|Drug|Cyclosporine|
555715|NCT00031070|Biological|Hepatitis A Vaccine (Inactivated)|
555716|NCT00031070|Drug|Efavirenz|
555717|NCT00031070|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
555718|NCT00031070|Biological|Rabies Vaccine|
555719|NCT00031057|Drug|Thiamine hydrochloride|
555720|NCT00031057|Drug|Riboflavin|
555721|NCT00031044|Drug|Enfuvirtide|
555722|NCT00031044|Drug|Amdoxovir|
555723|NCT00031031|Drug|Kanglaite Injection (KLT)|
555724|NCT00031018|Drug|Aricept|
555725|NCT00031018|Drug|IFN-alpha2A|
555726|NCT00031005|Procedure|modified stem cell transplant|
555727|NCT00030992|Drug|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
555728|NCT00030992|Drug|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
555729|NCT00030992|Drug|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
555730|NCT00030979|Drug|Donepezil|
555731|NCT00030966|Drug|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
555732|NCT00030966|Drug|Placebo|Placebo monthly infusion for up to 116 weeks.
555733|NCT00030238|Drug|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
555734|NCT00030238|Drug|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
555735|NCT00030225|Biological|ELAD|
555736|NCT00030225|Other|Standard of care (Control)|
555737|NCT00030186|Drug|CEP-701 60mg|60mg orally 2 times a day for 28 days
555738|NCT00030186|Drug|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
555739|NCT00030186|Drug|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
555740|NCT00030173|Drug|Epothilone D (KOS-862)|
555741|NCT00030160|Behavioral|Strength Training|
555742|NCT00030147|Drug|Raloxifene|60 mg a day orally administered
555743|NCT00030147|Drug|Rimostil|1000 mg twice a day administered orally
555744|NCT00030147|Drug|Transdermal Estradiol|100 microgram per day transdermal estradiol
555745|NCT00030147|Drug|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
555746|NCT00030121|Drug|recombinant human atrial natriuretic polypeptide|
555747|NCT00030069|Drug|Calcitriol|
555748|NCT00030069|Drug|Dexamethasone|
555749|NCT00030056|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
555750|NCT00030043|Device|Penetrating auditory brainstem implant|
555751|NCT00030030|Drug|Silymarin (milk thistle)|
555752|NCT00030004|Procedure|spinal manipulation|
555753|NCT00030004|Drug|midazolam|
555754|NCT00029991|Drug|Gingko Biloba (Herb)|
555755|NCT00029926|Drug|2-deoxy-2 [F-18] fluoro-2-d-glucose|
555756|NCT00029913|Other|Observation|Observation of participants who received HIV preventive vaccine and became infected.
555757|NCT00029900|Drug|ADI PEG|
555758|NCT00029874|Drug|Minocycline|
555759|NCT00029861|Drug|Rimonabant (SR141716)|
555760|NCT00029848|Drug|Rimonabant (SR141716)|
555761|NCT00029835|Drug|Rimonabant (SR141716)|
555762|NCT00029822|Drug|Alfuzosin (SL770499)|
555763|NCT00029809|Behavioral|Chinese exercise modalities|
555764|NCT00029796|Drug|soy isoflavones|
555765|NCT00029783|Procedure|Distant Healing|
555766|NCT00029770|Procedure|Chiropractic spinal manipulation|
555767|NCT00029770|Drug|Acetaminophen|
555768|NCT00029770|Behavioral|Self-care|
555769|NCT00029770|Drug|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
555770|NCT00029770|Drug|Tylenol with codeine|
555771|NCT00029757|Drug|Estrogen|
555772|NCT00029731|Drug|Arginine hydrochloride|
555773|NCT00029692|Drug|Ginseng|
555774|NCT00029692|Drug|Ginkgo|
555775|NCT00029679|Drug|Gingko biloba|
555776|NCT00029679|Drug|Borage oil|
555777|NCT00029666|Device|Neopulse Magnetic Stimulator|
555778|NCT00029627|Drug|Yohimbine|
555779|NCT00029614|Drug|Atomoxetine|
555780|NCT00029575|Device|Surgi-Vision Guidewire Coil|
555781|NCT00029536|Biological|Progesterone Lozenges|200mg Progesterone Lozenges
555782|NCT00029536|Other|Matched Placebo Lozenges|Matched Placebo Lozenges
555783|NCT00029523|Drug|Intrathecal (injected into the spinal fluid) DepoCyt|
555784|NCT00029523|Drug|Intrathecal methotrexate|
555785|NCT00029523|Drug|Intrathecal cytarabine (also known as ara-C)|
555786|NCT00029510|Drug|Magnesium|
555787|NCT00029497|Procedure|Acupuncture|
555788|NCT00029497|Drug|Amitriptyline|
555789|NCT00029484|Behavioral|Tai chi chih|
555790|NCT00029458|Drug|Clozapine|
555791|NCT00029393|Procedure|Hematopoietic Stem Cell Transplantation|
555792|NCT00029393|Drug|Immunosuppression|
555793|NCT00029380|Drug|Sangstat|
555794|NCT00029380|Drug|Cyclophosphamide|
555795|NCT00029380|Drug|Busulfan|
555796|NCT00029380|Drug|Mycophenolate Mofetil|
555797|NCT00029380|Drug|Cyclosporine|
555798|NCT00029380|Procedure|Cord Blood Transplantation|
555799|NCT00029341|Behavioral|Treatment Interruption|
555800|NCT00029328|Drug|etanercept|
555801|NCT00029315|Drug|Recombinant Tissue Plasminogen Activator (rt-PA)|
555802|NCT00029289|Drug|Lutein (10 or 30 mg/day) capsules|
555803|NCT00029276|Procedure|Prefrontal transcranial magnetic brain stimulation|
555804|NCT00029263|Drug|herbals|
555805|NCT00029250|Drug|Garlic powder standardized to allicin|
555806|NCT00029237|Behavioral|Cognitive-behavioral relaxation (Positively Living)|
555807|NCT00029237|Behavioral|Spiritual growth group|
555808|NCT00029237|Behavioral|Focused Tai Chi|
555809|NCT00029224|Drug|zoledronic acid|
555810|NCT00029211|Drug|Echinacea|
555811|NCT00029198|Procedure|massage|15 massage given tid
555812|NCT00029198|Procedure|Sham massage|non-massage touch
555813|NCT00029185|Drug|Dehydrex|
555814|NCT00029172|Other|case management|
555815|NCT00029159|Drug|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
555816|NCT00029159|Drug|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
555817|NCT00029159|Other|placebo|an inactive substance
555818|NCT00029146|Procedure|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
555819|NCT00029146|Drug|best medical therapy|best current practice medical therapy
555820|NCT00029133|Procedure|mild intraoperative hypothermia (33 degrees Celsius)|
555821|NCT00028431|Biological|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
555822|NCT00028418|Drug|Clofarabine|
555823|NCT00028405|Drug|LS 11(Taporfin Sodium)|
555824|NCT00028405|Device|Lumaflex Light Delivery Catheter|
555825|NCT00029107|Drug|Rituximab|anti-CD20 monoclonal antibody
555826|NCT00029042|Drug|Infliximab|
555827|NCT00028379|Procedure|Transcranial magnetic stimulation (TMS)|
555828|NCT00028366|Drug|Fosamprenavir|
555829|NCT00028366|Drug|Lopinavir/Ritonavir|
555830|NCT00028366|Drug|Ritonavir|
555831|NCT00028366|Drug|Tenofovir disoproxil fumarate|
555832|NCT00028353|Drug|GTX-006 (Acapodene)|
555833|NCT00028327|Drug|Lamivudine/Zidovudine|
555834|NCT00028327|Drug|Nelfinavir mesylate|
555835|NCT00028327|Drug|Efavirenz|
555836|NCT00028327|Drug|Lamivudine|
555837|NCT00028327|Drug|Zidovudine|
555838|NCT00028314|Drug|Abacavir sulfate|
555839|NCT00028314|Drug|Atazanavir/Ritonavir|
555840|NCT00028314|Drug|Lopinavir/Ritonavir|
555841|NCT00028314|Drug|Nevirapine|
555842|NCT00028301|Drug|Atazanavir|
555843|NCT00028301|Drug|Lopinavir/Ritonavir|
555844|NCT00028288|Drug|Daclizumab|
555845|NCT00028275|Drug|Gamma Interferon 1b|
555846|NCT00028262|Drug|Cystagon|
555847|NCT00028236|Drug|Gene-Transduced Autologous CD34+ Stem Cells|
555848|NCT00028171|Drug|Tacrolimus|
555849|NCT00028158|Drug|G207, an oncolytic virus|
555850|NCT00028145|Behavioral|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
555851|NCT00028132|Drug|Tenofovir|
555852|NCT00028106|Drug|[131]I-MIBG|
555853|NCT00028106|Drug|6-[18F]Fluorodopamine|
555854|NCT00028106|Drug|[123]I-MIBG|
555855|NCT00028093|Drug|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
555856|NCT00028093|Drug|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
555857|NCT00028067|Drug|Atazanavir|
555858|NCT00028067|Drug|Nelfinavir mesylate|
555859|NCT00027469|Procedure|MRI|
555860|NCT00027456|Drug|Leptin A-100|
555861|NCT00027443|Drug|Muromonab-CD3|
555862|NCT00027443|Drug|Cyclosporine|
555863|NCT00027430|Drug|TheraDerm|
555864|NCT00027417|Drug|Liothyronine sodium/triiodothyronine|
555865|NCT00027417|Procedure|Cardiopulmonary bypass and cardiac surgery|
555866|NCT00027404|Drug|Fluoxetine|
555867|NCT00027391|Drug|Albuterol|
555868|NCT00027391|Drug|Oxandrolone|
555869|NCT00027378|Drug|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
555870|NCT00027378|Drug|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
555871|NCT00027365|Biological|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
555872|NCT00027365|Biological|NefTat|
555873|NCT00027365|Drug|AS02A Adjuvant|
555874|NCT00027365|Biological|gp120W61D|
555875|NCT00027339|Drug|lopinavir/ritonavir|
555876|NCT00027339|Drug|indinavir sulfate|
555877|NCT00027339|Drug|tenofovir disoproxil fumarate|
555878|NCT00027339|Drug|ritonavir|
555879|NCT00027339|Drug|fosamprenavir|
555880|NCT00027300|Drug|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
555881|NCT00027300|Drug|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
555882|NCT00027287|Drug|Vitamin E|
555883|NCT00027261|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
555884|NCT00027248|Drug|MBI 226|
555885|NCT00027209|Drug|prempro|
555886|NCT00027170|Device|Siemens MRI scanner|Investigational or research MRI coils may be used in the protocol. The coils are noninvasive devices external to the body. The coils act as antennae to receive small radiofrequency signals out of the body. Coils of the type we use are used daily in clinical MRI practice.
555887|NCT00027144|Biological|Heat Shock Protein 70 HSP70|
555888|NCT00027131|Biological|Heat Shock Protein 70-peptide complexes (HSP70)|
555889|NCT00027079|Drug|ondansetron (Zofran)|
555890|NCT00027079|Drug|naltrexone (ReVia)|
555891|NCT00027079|Behavioral|Cognitive Behavioral Therapy|
555892|NCT00027066|Drug|Active Aspirin|325mg tablet daily
555893|NCT00027066|Drug|Active Warfarin|2mg scored tablet daily
555894|NCT00027066|Drug|Aspirin placebo|325mg aspirin placebo pill
555895|NCT00027066|Drug|Warfarin placebo|2mg scored placebo tablet
555896|NCT00027053|Drug|Trazodone|50 to 150 mg qhs
555897|NCT00027053|Drug|Placebo|
555898|NCT00027040|Drug|Selegiline hydrochloride|
555899|NCT00027027|Drug|rhuMAb 2C4|
555900|NCT00027014|Drug|St. John's Wort|
555901|NCT00027014|Drug|oxycodone|
555902|NCT00027014|Drug|fentanyl|
555903|NCT00027001|Behavioral|Aerobic and Resistance Exercises|
555904|NCT00027001|Behavioral|Qigong|
555905|NCT00026988|Drug|Creatine|
555906|NCT00026975|Procedure|Hyperbaric Oxygen|
555907|NCT00026962|Procedure|measuring estradiol and progesterone levels in saliva|
555908|NCT00026936|Procedure|Radiotherapy|
555909|NCT00026923|Procedure|Laparoscopic surgery|
555910|NCT00026897|Procedure|Gamma-camera imaging|
555911|NCT00026897|Procedure|Low-risk biopsy|
555912|NCT00026871|Procedure|Radiotherapy|
555913|NCT00026858|Behavioral|collaboration|
555914|NCT00026819|Drug|Rofecoxib|
555915|NCT00026637|Drug|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
555916|NCT00026637|Behavioral|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
555917|NCT00026624|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
555918|NCT00026624|Drug|Keyhole-Limpet Hemocyanin|
555919|NCT00026611|Biological|Dryvax vaccine|
555920|NCT00026585|Drug|Tamoxifen|
555921|NCT00026065|Behavioral|Biofeedback|
555922|NCT00026052|Drug|riluzole|
555923|NCT00026039|Drug|estrogen|
555924|NCT00026013|Drug|hypericum perforatum|
555925|NCT00025987|Device|Head and Neck Cooling System|
555926|NCT00025987|Device|Thermometer Pill|
555927|NCT00025909|Procedure|Leukapheresis|
555928|NCT00025896|Drug|recombinant human acid alpha-glucosidase (rhGAA)|
555929|NCT00027222|Procedure|retinal ablation|
555930|NCT00025883|Drug|Metreleptin|Drug treatment
555931|NCT00025818|Drug|Ophthalmic Emulsion|
555932|NCT00025805|Drug|G-CSF|
555933|NCT00025792|Drug|Pramipexole|
555934|NCT00025779|Drug|methylphenidate|
555935|NCT00025779|Drug|guanfacine|
555936|NCT00025766|Device|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
555937|NCT00025766|Behavioral|Optimal Medical Therapy|Participants will receive optimal medical therapy.
555938|NCT00025753|Drug|rosiglitazone (Avandia)|
555939|NCT00025753|Behavioral|Aerobic and weight lifting exercise training|
555940|NCT00025740|Drug|clonazepam and paroxetine|
555941|NCT00025727|Drug|Lopinavir/Ritonavir|
555942|NCT00025727|Drug|Ritonavir|
555943|NCT00025727|Drug|GW433908|
555944|NCT00024986|Drug|Tenofovir DF|
555945|NCT00024934|Drug|B-Lymphocyte Stimulator (BLyS)|
555946|NCT00024687|Drug|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
555947|NCT00024674|Drug|SS1(dsFv)-PE38|
555948|NCT00024661|Drug|LErafAON|
555949|NCT00024648|Drug|LErafAON|
555950|NCT00024570|Drug|IL13-PE38QQR|
555951|NCT00024570|Procedure|targeted fusion protein therapy|
555952|NCT00024570|Procedure|surgery|
555953|NCT00024557|Drug|IL13-PE38QQR|
555954|NCT00024557|Procedure|targeted fusion protein therapy|
555955|NCT00024557|Procedure|surgery|
555956|NCT00024544|Drug|anti-IL-4 monoclonal antibody (pascolizumab)|
555957|NCT00024531|Drug|Atorvastatin calcium|
555958|NCT00024518|Drug|30,000 units hrINF-alpha|
555959|NCT00024518|Drug|5,000 hrINF-alpha|
555960|NCT00024518|Other|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
555961|NCT00024492|Drug|Liposome Encapsulated Mitoxantrone (LEM)|
555962|NCT00023595|Procedure|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
555963|NCT00023595|Drug|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
555964|NCT00023595|Procedure|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
555965|NCT00023504|Biological|Pneumovax|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
555966|NCT00023504|Biological|Rabavert|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
555967|NCT00023504|Biological|Prevnar|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
555968|NCT00023504|Biological|Tetanus diphtheria toxoid|To determine the function of T and B cells in vivo using immunizations in patients with known or suspected immune disorders.
555969|NCT00023465|Procedure|FDG-PET|
555970|NCT00023465|Procedure|spirometry|
555971|NCT00023465|Procedure|bronchoscopy with BAL|
555972|NCT00023452|Drug|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons > 50.0 kg. For persons < 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.~PLUS~Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if > 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2—11 years old.~Therapy will be given by Directly Observed Therapy (DOT)."
555973|NCT00023452|Drug|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
555974|NCT00023439|Other|Nucleic Acid Amplification Methods for diagnosis|no intervention
555975|NCT00023426|Drug|rifapentine|
555976|NCT00023413|Drug|Rifabutin|
555977|NCT00023413|Drug|Efavirenz|
555978|NCT00023400|Drug|Nelfinavir|
555979|NCT00023400|Drug|Rifabutin|
555980|NCT00023387|Drug|Rifapentine|
555981|NCT00023387|Drug|25-desacetyl Rifapentine|
555982|NCT00023387|Drug|Isoniazid|
555983|NCT00023374|Drug|Rifampin|6mos REZ intermittent
555984|NCT00023374|Drug|Pyrazinamide|6mos REZ intermittent
555985|NCT00023374|Drug|Ethambutol|6mos REZ intermittent
555986|NCT00023374|Drug|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
555987|NCT00023361|Drug|Rifabutin|
555988|NCT00023348|Drug|Isoniazid|
555989|NCT00023348|Drug|Rifabutin|
555990|NCT00023335|Drug|Rifapentine|
555991|NCT00023335|Drug|Isoniazid|
555992|NCT00023543|Behavioral|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
555993|NCT00023543|Behavioral|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
555994|NCT00023530|Drug|fluconazole|
555995|NCT00023530|Drug|voriconazole|
555996|NCT00023530|Procedure|bone marrow transplant|
555997|NCT00023530|Drug|thalidomide|
555998|NCT00023530|Drug|dexamethasone|
555999|NCT00023322|Drug|Peginterferon Alpha-2a|Treatment
556000|NCT00023309|Drug|Lamivudine and adefovir|Lamivudine (100 mg/day) and adefovir (10 mg/day)
556001|NCT00023309|Drug|Adefovir alone|Adefovir (10 mg/day)
556002|NCT00023296|Drug|Nitric Oxide|
556003|NCT00023296|Device|INO Pulse - NO Delivery System|
556004|NCT00023283|Drug|Buprenorphine|"Experimental Standard Medical Management with once-weekly medication dispensing~Experimental Standard Medical Management with thrice-weekly medication dispensing~Experimental Enhanced Medical Management with thrice-weekly medication dispensing"
556005|NCT00023244|Drug|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
556006|NCT00023244|Drug|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
556007|NCT00023244|Drug|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
556008|NCT00023244|Drug|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
556009|NCT00023244|Drug|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
556010|NCT00023244|Drug|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
556011|NCT00023244|Drug|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
556012|NCT00023231|Drug|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
556013|NCT00023231|Drug|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
556014|NCT00023231|Drug|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
556015|NCT00023231|Drug|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
556016|NCT00023231|Drug|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
556017|NCT00023231|Drug|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
556018|NCT00023231|Drug|Lipitor|Oral tablet taken daily
556019|NCT00023218|Drug|Lopinavir/Ritonavir|
556020|NCT00023218|Drug|Efavirenz|
556021|NCT00023205|Behavioral|11th grade reading level arthritis materials|
556022|NCT00023205|Behavioral|Interactive in-person arthritis education|
556023|NCT00022763|Drug|Enfuvirtide|
556024|NCT00021762|Biological|HIV-1 Immunogen|
556025|NCT00021762|Procedure|Structured Treatment Interruption|
556026|NCT00021671|Drug|Erythromycin|
556027|NCT00021671|Drug|Nevirapine|
556028|NCT00021671|Drug|Ampicillin sodium|
556029|NCT00021671|Drug|Metronidazole|
556030|NCT00021554|Drug|Enfuvirtide|
556031|NCT00021489|Drug|Abacavir sulfate|
556032|NCT00021489|Drug|Mycophenolate mofetil|
556033|NCT00021463|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
556034|NCT00021463|Drug|Abacavir sulfate|
556035|NCT00021463|Drug|Efavirenz|
556036|NCT00021463|Drug|Nevirapine|
556037|NCT00017992|Drug|Lopinavir/Ritonavir|
556038|NCT00017992|Drug|Emtricitabine|
556039|NCT00017992|Drug|Stavudine|
556040|NCT00017784|Drug|Valganciclovir|
556041|NCT00017758|Drug|Pravastatin sodium|
556042|NCT00017758|Drug|Simvastatin|
556043|NCT00017758|Drug|Atorvastatin calcium|
556044|NCT00017758|Drug|Nelfinavir mesylate|
556045|NCT00017758|Drug|Efavirenz|
556046|NCT00017719|Drug|Lamivudine|
556047|NCT00017719|Drug|Lamivudine/Zidovudine|
556048|NCT00017719|Drug|Nelfinavir mesylate|
556049|NCT00017719|Drug|Nevirapine|
556050|NCT00017719|Drug|Zidovudine|
556051|NCT00017693|Biological|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
556052|NCT00017693|Biological|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
556053|NCT00016718|Drug|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m^2 up to a maximum of 400 mg once daily
556054|NCT00016718|Drug|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
556055|NCT00016718|Drug|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
556056|NCT00016692|Drug|Z-100|
556057|NCT00016601|Drug|Indinavir sulfate|
556058|NCT00016601|Drug|Ritonavir|
556059|NCT00016601|Drug|Nelfinavir mesylate|
556060|NCT00016601|Drug|Efavirenz|
556061|NCT00016601|Drug|Nevirapine|
556062|NCT00016601|Drug|Medroxyprogesterone acetate|
556063|NCT00016588|Drug|Tenofovir disoproxil fumarate|
556064|NCT00016536|Drug|Naphthalene 2-sulfonate polymer|
556065|NCT00016536|Drug|Carbopol polymer|
556066|NCT00015704|Drug|Aldesleukin|
556067|NCT00015691|Drug|Metformin hydrochloride|
556068|NCT00015691|Drug|Rosiglitazone maleate|
556069|NCT00015652|Drug|Ribavirin|
556070|NCT00015652|Drug|Aldesleukin|
556071|NCT00015652|Drug|Peginterferon alfa-2b|
556072|NCT00014937|Drug|lopinavir/ritonavir|
556073|NCT00014937|Drug|lamivudine/zidovudine|
556074|NCT00014937|Drug|efavirenz|
556075|NCT00014937|Drug|lamivudine|
556076|NCT00014937|Drug|stavudine|
556077|NCT00014937|Drug|zidovudine|
556078|NCT00014937|Drug|didanosine|
556079|NCT00014911|Procedure|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
556080|NCT00014911|Drug|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
556081|NCT00014911|Drug|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
556082|NCT00014911|Drug|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
556083|NCT00014911|Drug|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
556084|NCT00014911|Drug|Ganciclovir|An antiviral used to kill viruses and stop viral replication
556085|NCT00014911|Drug|Trimethoprim|An antibacterial used to prevent opportunistic infections
556086|NCT00014911|Drug|Pentamidine|An antiprotozoal used to prevent disease
556087|NCT00014014|Drug|Lamivudine/Zidovudine|
556088|NCT00013897|Drug|Atazanavir|
556089|NCT00013897|Drug|Lamivudine/Zidovudine|
556090|NCT00013897|Drug|Efavirenz|
556091|NCT00013871|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
556092|NCT00013871|Biological|Measles-Mumps-Rubella Vaccine (Live)|
556093|NCT00013871|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
556094|NCT00013871|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
556095|NCT00013871|Biological|Hepatitis B Vaccine (Recombinant)|
556096|NCT00013663|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
556097|NCT00013663|Drug|Aldesleukin|
556098|NCT00013585|Drug|Selegiline hydrochloride|
556099|NCT00013572|Biological|ALVAC-HIV MN120TMG (vCP205)|
556100|NCT00013520|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
556101|NCT00013520|Drug|Atazanavir|
556102|NCT00013520|Drug|Lamivudine/Zidovudine|
556103|NCT00013520|Drug|Abacavir sulfate|
556104|NCT00013520|Drug|Efavirenz|
556105|NCT00013520|Drug|Nevirapine|
556106|NCT00013520|Drug|Lamivudine|
556107|NCT00013520|Drug|Stavudine|
556108|NCT00013520|Drug|Zidovudine|
556109|NCT00013520|Drug|Didanosine|
556110|NCT00012519|Drug|indinavir sulfate|
556111|NCT00012519|Drug|ritonavir|
556112|NCT00012467|Drug|Itraconazole|
556113|NCT00012467|Drug|Flucytosine|
556114|NCT00012467|Drug|Fluconazole|
556115|NCT00012467|Drug|Amphotericin B|
556116|NCT00012467|Drug|Interferon gamma-1b|
556117|NCT00011895|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
556118|NCT00011895|Drug|Efavirenz|
556119|NCT00011479|Drug|Abacavir sulfate|
556120|NCT00011128|Behavioral|Antiretroviral Treatment Interruption|
556121|NCT00011089|Drug|Tenofovir disoproxil fumarate|
556122|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10^ 7 TCID50 administered intramuscularly
556123|NCT00011037|Biological|MN rgp120/HIV-1|0.6 mg administered intramuscularly
556124|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
556125|NCT00011037|Biological|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
556126|NCT00011011|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
556127|NCT00009555|Drug|Testosterone|
556128|NCT00009061|Drug|Ritonavir|
556129|NCT00009061|Drug|Abacavir sulfate|
556130|NCT00009061|Drug|Nelfinavir mesylate|
556131|NCT00009061|Drug|Lamivudine|
556132|NCT00009061|Drug|GW433908|
556133|NCT00008866|Biological|Tetanus Toxoid Vaccine|
556134|NCT00008866|Drug|Hydroxyurea|
556135|NCT00008866|Drug|Didanosine|
556136|NCT00008853|Biological|GBS III-TT-SSI|
556137|NCT00008853|Biological|GBS III-TT-MPHL|
556138|NCT00008554|Drug|Abacavir sulfate|
556139|NCT00008554|Drug|Nelfinavir mesylate|
556140|NCT00008554|Drug|Lamivudine|
556141|NCT00008554|Drug|GW433908|
556142|NCT00008528|Drug|Enfuvirtide|
556143|NCT00008489|Drug|Didanosine|
556144|NCT00008463|Drug|Ribavirin|
556145|NCT00008463|Drug|Interferon alfa-2a|
556146|NCT00008463|Drug|Peginterferon alfa-2a|
556147|NCT00007787|Biological|Cyclosporine|
556148|NCT00007787|Biological|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
556149|NCT00007787|Drug|Tacrolimus|
556150|NCT00007449|Drug|DPC 083|
556151|NCT00007436|Drug|Tenofovir disoproxil fumarate|
556152|NCT00007423|Biological|ALVAC-HIV MN120TMG (vCP205)|
556153|NCT00007423|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
556154|NCT00007332|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
556155|NCT00007332|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
556156|NCT00007202|Drug|Atazanavir|
556157|NCT00007202|Drug|Stavudine|
556158|NCT00007202|Drug|Didanosine|
556159|NCT00006630|Drug|Vaccinia Immune Globulin (Human)|
556160|NCT00006617|Drug|Abacavir sulfate|
556161|NCT00006617|Drug|Amprenavir|
556162|NCT00006617|Drug|Lamivudine|
556163|NCT00006617|Drug|Zidovudine|
556164|NCT00006604|Drug|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
556165|NCT00006604|Drug|Ritonavir|Administered as 100 mg capsules or oral solution.
556166|NCT00006591|Drug|Ritonavir|
556167|NCT00006591|Drug|Amprenavir|
556168|NCT00006578|Drug|Ritonavir|
556169|NCT00006578|Drug|Abacavir sulfate|
556170|NCT00006578|Drug|Amprenavir|
556171|NCT00006578|Drug|Lamivudine|
556172|NCT00006578|Drug|Filgrastim|
556173|NCT00006509|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
556174|NCT00006509|Biological|gp160 MN/LAI-2|
556175|NCT00006495|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
556176|NCT00006495|Biological|HIV-1 Immunogen|
556177|NCT00006443|Drug|Indinavir sulfate|
556178|NCT00006443|Drug|Nelfinavir mesylate|
556179|NCT00006443|Drug|Lamivudine|
556180|NCT00006443|Drug|Stavudine|
556181|NCT00006441|Drug|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
556182|NCT00006441|Drug|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
556183|NCT00006441|Drug|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
556184|NCT00006412|Drug|Pravastatin sodium|
556185|NCT00006412|Drug|Fenofibrate|
556186|NCT00006397|Drug|Indinavir sulfate|
556187|NCT00006397|Drug|Ritonavir|
556188|NCT00006397|Drug|Stavudine|
556189|NCT00006397|Drug|Didanosine|
556190|NCT00006396|Drug|Nevirapine|
556191|NCT00006396|Drug|Zidovudine|
556192|NCT00006339|Drug|Indinavir sulfate|
556193|NCT00006339|Drug|Ritonavir|
556194|NCT00006339|Drug|Hydroxyurea|
556195|NCT00006339|Drug|Stavudine|
556196|NCT00006339|Drug|Didanosine|
556197|NCT00006327|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
556198|NCT00006326|Drug|Indinavir sulfate|
556199|NCT00006326|Drug|Ritonavir|
556200|NCT00006326|Drug|Delavirdine mesylate|
556201|NCT00006325|Drug|Peginterferon alfa-2b|
556202|NCT00006324|Drug|Ethinyl estradiol/levonorgestrel|
556203|NCT00006324|Drug|Medroxyprogesterone acetate|
556204|NCT00006291|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
556205|NCT00006291|Drug|Aldesleukin|
556206|NCT00006279|Drug|Nevirapine|
556207|NCT00006211|Drug|Capravirine|
556208|NCT00006211|Drug|Nelfinavir mesylate|
556209|NCT00006209|Drug|Tucaresol|
556210|NCT00006208|Drug|Efavirenz|
556211|NCT00006208|Drug|Emtricitabine|
556212|NCT00006208|Drug|Stavudine|
556213|NCT00006208|Drug|Didanosine|
556214|NCT00006207|Drug|PRO 2000|
556215|NCT00006154|Drug|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
556216|NCT00006154|Drug|Ritonavir|100 mg liquid capsules equaling 400 mg daily
556217|NCT00006154|Drug|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
556218|NCT00006154|Drug|Efavirenz|200 mg capsules equaling 600 mg daily
556219|NCT00006154|Drug|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
556220|NCT00006154|Drug|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
556221|NCT00006154|Drug|Aldesleukin|Subcutaneous injection equaling 15 x 10^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
556222|NCT00006153|Biological|HIV-1 Immunogen|
556223|NCT00006152|Drug|Ritonavir|
556224|NCT00006152|Drug|Abacavir sulfate|
556225|NCT00006152|Drug|Amprenavir|
556226|NCT00006146|Biological|Approved influenza virus vaccine.|
556227|NCT00006145|Drug|Valganciclovir|
556228|NCT00006144|Drug|Lopinavir/Ritonavir|
556229|NCT00006144|Drug|Emtricitabine|
556230|NCT00006144|Drug|Stavudine|
556231|NCT00006143|Drug|Somatropin|
556232|NCT00006075|Drug|Chlorhexidine gluconate|
556233|NCT00006066|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
556234|NCT00006066|Biological|Diphtheria and Tetanus Toxoids Adsorbed|
556235|NCT00006066|Biological|Tetanus and Diphtheria Toxoids Adsorbed|
556236|NCT00006066|Drug|Bacteriophage phi X 174|
556237|NCT00006066|Drug|Aldesleukin|
556238|NCT00005931|Drug|SU5416|
556239|NCT00005921|Drug|L-743,872|
556240|NCT00005920|Drug|L-743,872|
556241|NCT00005918|Drug|Efavirenz|
556242|NCT00005918|Drug|Lamivudine|
556243|NCT00005918|Drug|Stavudine|
556244|NCT00005779|Drug|Interleukin-12|
556245|NCT00005779|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
556246|NCT00005764|Drug|Lamivudine/Zidovudine|
556247|NCT00005764|Drug|Abacavir sulfate|
556248|NCT00005764|Drug|Lamivudine|
556249|NCT00005762|Drug|Indinavir sulfate|
556250|NCT00005762|Drug|Ritonavir|
556251|NCT00005762|Drug|Amprenavir|
556252|NCT00005762|Drug|Nelfinavir mesylate|
556253|NCT00005762|Drug|Efavirenz|
556254|NCT00005762|Drug|Saquinavir|
556255|NCT00005758|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
556256|NCT00005758|Biological|HIV-1 Immunogen|
556257|NCT00005668|Drug|Itraconazole oral solution|
556258|NCT00005663|Drug|Valacyclovir hydrochloride|
556259|NCT00005120|Drug|Calanolide A|
556260|NCT00005118|Drug|Indinavir sulfate|
556261|NCT00005118|Drug|Ritonavir|
556262|NCT00005113|Drug|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
556263|NCT00005113|Drug|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
556264|NCT00005113|Drug|Tacrolimus|dosage is in oral form titrated to target trough level
556265|NCT00005106|Drug|Lamivudine/Zidovudine|
556266|NCT00005106|Drug|Abacavir sulfate|
556267|NCT00005106|Drug|Nelfinavir mesylate|
556268|NCT00005106|Drug|Lamivudine|
556269|NCT00005106|Drug|Stavudine|
556270|NCT00005018|Drug|Hydroxyurea|
556271|NCT00005018|Drug|Abacavir sulfate|
556272|NCT00005018|Drug|Efavirenz|
556273|NCT00005018|Drug|Didanosine|
556274|NCT00005017|Drug|Ritonavir|
556275|NCT00005017|Drug|Abacavir sulfate|
556276|NCT00005017|Drug|Amprenavir|
556277|NCT00005017|Drug|Efavirenz|
556278|NCT00005017|Drug|Lamivudine|
556279|NCT00005017|Drug|Stavudine|
556280|NCT00005012|Drug|Peginterferon alfa-2b|
556281|NCT00005010|Drug|Irbesartan|
556282|NCT00005010|Drug|Pravastatin|
556283|NCT00005009|Biological|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
556284|NCT00005002|Drug|Lamivudine/Zidovudine|
556285|NCT00005002|Biological|HIV-1 Immunogen|
556286|NCT00005002|Drug|Nelfinavir mesylate|
556287|NCT00005001|Biological|HIV-1 Immunogen|
556288|NCT00005000|Drug|Nelfinavir mesylate|
556289|NCT00005000|Drug|Efavirenz|
556290|NCT00005000|Drug|Lamivudine|
556291|NCT00005000|Drug|Keyhole-Limpet Hemocyanin|
556292|NCT00005000|Drug|Stavudine|
556293|NCT00005000|Drug|Zidovudine|
556294|NCT00005000|Drug|Didanosine|
556295|NCT00004999|Drug|Lamivudine/Zidovudine|
556296|NCT00004999|Drug|Capravirine|
556411|NCT00002424|Drug|Indinavir sulfate|
556297|NCT00004999|Drug|Nelfinavir mesylate|
556298|NCT00004998|Drug|Lamivudine/Zidovudine|
556299|NCT00004998|Drug|Capravirine|
556300|NCT00004998|Drug|Nelfinavir mesylate|
556301|NCT00004987|Drug|Dextrin 2-sulfate|
556302|NCT00004986|Drug|Nitazoxanide|
556303|NCT00004985|Drug|Capravirine|
556304|NCT00004985|Drug|Nelfinavir mesylate|
556305|NCT00004981|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
556306|NCT00004981|Drug|Lamivudine/Zidovudine|
556307|NCT00004981|Drug|Abacavir sulfate|
556308|NCT00004978|Drug|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
556309|NCT00004855|Drug|Lopinavir/Ritonavir|
556310|NCT00004855|Drug|Abacavir sulfate|
556311|NCT00004855|Drug|Nevirapine|
556312|NCT00004855|Drug|Lamivudine|
556313|NCT00004855|Drug|Stavudine|
556314|NCT00004852|Drug|Efavirenz|
556315|NCT00004852|Drug|Lamivudine|
556316|NCT00004852|Drug|Zidovudine|
556317|NCT00004736|Drug|Nelfinavir mesylate|
556318|NCT00004736|Drug|Ethambutol hydrochloride|
556319|NCT00004736|Drug|Isoniazid|
556320|NCT00004736|Drug|Pyrazinamide|
556321|NCT00004736|Drug|Lamivudine|
556322|NCT00004736|Drug|Rifabutin|
556323|NCT00004736|Drug|Stavudine|
556324|NCT00004736|Drug|Zidovudine|
556325|NCT00004735|Biological|Tetanus toxoid|
556326|NCT00004735|Biological|Hepatitis A Vaccine (Inactivated)|
556327|NCT00004585|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
556328|NCT00004585|Drug|Lamivudine/Zidovudine|
556329|NCT00004585|Drug|Abacavir sulfate|
556330|NCT00004585|Drug|Efavirenz|
556331|NCT00004584|Drug|Atazanavir|
556332|NCT00004584|Drug|Ritonavir|
556333|NCT00004584|Drug|Saquinavir|
556334|NCT00004583|Drug|Lopinavir/Ritonavir|
556335|NCT00004583|Drug|Nelfinavir mesylate|
556336|NCT00004583|Drug|Lamivudine|
556337|NCT00004583|Drug|Stavudine|
556338|NCT00004582|Drug|Lopinavir/Ritonavir|
556339|NCT00004582|Drug|Efavirenz|
556340|NCT00004581|Drug|Lopinavir/Ritonavir|
556341|NCT00004581|Drug|Nevirapine|
556342|NCT00004580|Drug|Lopinavir/Ritonavir|
556343|NCT00004580|Drug|Nevirapine|
556344|NCT00004579|Biological|gp160 MN/LAI-2|
556345|NCT00004579|Biological|ALVAC-HIV MN120TMG (vCP205)|
556346|NCT00004578|Drug|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
556347|NCT00004578|Drug|Lamivudine|150 mg, every 12 hours
556348|NCT00004578|Drug|Stavudine|40 mg every 12 hours
556349|NCT00002453|Drug|Tenofovir disoproxil fumarate|
556350|NCT00002452|Drug|L-756423|
556351|NCT00002452|Drug|Indinavir sulfate|
556352|NCT00002451|Drug|Indinavir sulfate|
556353|NCT00002451|Drug|Ritonavir|
556354|NCT00002451|Drug|Lamivudine|
556355|NCT00002451|Drug|Stavudine|
556356|NCT00002450|Drug|Tenofovir disoproxil fumarate|
556357|NCT00002449|Drug|Aldesleukin|
556358|NCT00002448|Drug|Ritonavir|
556359|NCT00002448|Drug|Efavirenz|
556360|NCT00002448|Drug|Saquinavir|
556361|NCT00002447|Drug|Ritonavir|
556362|NCT00002447|Drug|Efavirenz|
556363|NCT00002447|Drug|Saquinavir|
556364|NCT00002446|Drug|Posaconazole|
556365|NCT00002446|Drug|Fluconazole|
556366|NCT00002445|Drug|IM862|
556367|NCT00002444|Drug|Nitazoxanide|
556368|NCT00002443|Drug|Indinavir sulfate|
556369|NCT00002443|Drug|Zidovudine|
556370|NCT00002442|Drug|Indinavir sulfate|
556371|NCT00002442|Drug|Nelfinavir mesylate|
556372|NCT00002442|Drug|Lamivudine|
556373|NCT00002442|Drug|Stavudine|
556374|NCT00002441|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
556375|NCT00002440|Drug|Indinavir sulfate|
556376|NCT00002440|Drug|Ritonavir|
556377|NCT00002440|Drug|Abacavir sulfate|
556378|NCT00002440|Drug|Amprenavir|
556379|NCT00002440|Drug|Nelfinavir mesylate|
556380|NCT00002440|Drug|Saquinavir|
556381|NCT00002439|Drug|Alitretinoin|
556382|NCT00002438|Drug|Itraconazole|
556383|NCT00002437|Drug|Cidofovir|
556384|NCT00002437|Drug|Probenecid|
556385|NCT00002436|Drug|Lamivudine|
556386|NCT00002436|Drug|Zidovudine|
556387|NCT00002436|Drug|Zalcitabine|
556388|NCT00002435|Drug|Thymic Humoral Factor|
556389|NCT00002435|Drug|Zidovudine|
556390|NCT00002434|Drug|Trimetrexate glucuronate|
556391|NCT00002434|Drug|Leucovorin calcium|
556392|NCT00002433|Drug|Interferon gamma-1b|
556393|NCT00002432|Drug|Foscarnet sodium|
556394|NCT00002431|Drug|Chlorhexidine gluconate|
556395|NCT00002430|Drug|Indinavir sulfate|
556396|NCT00002430|Drug|Nelfinavir mesylate|
556397|NCT00002430|Drug|Lamivudine|
556398|NCT00002430|Drug|Stavudine|
556399|NCT00002429|Drug|Lamivudine/Zidovudine|
556400|NCT00002429|Drug|Nelfinavir mesylate|
556401|NCT00002429|Drug|Stavudine|
556402|NCT00002429|Drug|Didanosine|
556403|NCT00002428|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
556404|NCT00002428|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
556405|NCT00002427|Drug|Hydroxyurea|
556406|NCT00002427|Drug|Stavudine|
556407|NCT00002427|Drug|Didanosine|
556408|NCT00002426|Drug|Adefovir dipivoxil|
556409|NCT00002425|Drug|Saquinavir|
556410|NCT00002424|Drug|L-756423|
556412|NCT00002424|Drug|Lamivudine|
556413|NCT00002424|Drug|Stavudine|
556414|NCT00002423|Drug|Indinavir sulfate|
556415|NCT00002423|Drug|Abacavir sulfate|
556416|NCT00002423|Drug|Amprenavir|
556417|NCT00002423|Drug|Nelfinavir mesylate|
556418|NCT00002423|Drug|Lamivudine|
556419|NCT00002422|Drug|HE2000|
556420|NCT00002420|Drug|Emivirine|
556421|NCT00002420|Drug|Hydroxyurea|
556422|NCT00002420|Drug|Delavirdine mesylate|
556423|NCT00002420|Drug|Stavudine|
556424|NCT00002420|Drug|Didanosine|
556425|NCT00002419|Drug|Abacavir sulfate|
556426|NCT00002419|Drug|Amprenavir|
556427|NCT00002419|Drug|Efavirenz|
556428|NCT00002419|Drug|Adefovir dipivoxil|
556429|NCT00002418|Drug|Emivirine|
556430|NCT00002418|Drug|Hydroxyurea|
556431|NCT00002418|Drug|Nevirapine|
556432|NCT00002418|Drug|Stavudine|
556433|NCT00002418|Drug|Didanosine|
556434|NCT00002417|Drug|Amprenavir|
556435|NCT00002416|Drug|Emtricitabine|
556436|NCT00002416|Drug|Lamivudine|
556437|NCT00002415|Drug|Tenofovir disoproxil fumarate|
556438|NCT00002414|Drug|CPI-1189|
556439|NCT00002413|Drug|Emivirine|
556440|NCT00002412|Drug|Emivirine|
556441|NCT00002412|Drug|Hydroxyurea|
556442|NCT00002412|Drug|Stavudine|
556443|NCT00002412|Drug|Didanosine|
556444|NCT00002411|Drug|Nelfinavir mesylate|
556445|NCT00002411|Drug|Lamivudine|
556446|NCT00002411|Drug|Stavudine|
556447|NCT00002411|Drug|Zidovudine|
556448|NCT00002411|Drug|Didanosine|
556449|NCT00002410|Drug|Indinavir sulfate|
556450|NCT00002410|Drug|Lamivudine|
556451|NCT00002410|Drug|Zidovudine|
556452|NCT00002409|Drug|Lamivudine/Zidovudine|
556453|NCT00002409|Drug|Abacavir sulfate|
556454|NCT00002408|Drug|Crofelemer|
556455|NCT00002407|Drug|Indinavir sulfate|
556456|NCT00002407|Drug|Nevirapine|
556457|NCT00002407|Drug|Lamivudine|
556458|NCT00002407|Drug|Stavudine|
556459|NCT00002407|Drug|Didanosine|
556460|NCT00002406|Drug|Indinavir sulfate|
556461|NCT00002405|Drug|Amprenavir|
556462|NCT00002404|Drug|Valacyclovir hydrochloride|
556463|NCT00002403|Drug|Zintevir|
556464|NCT00002402|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
556465|NCT00002402|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
556466|NCT00002402|Biological|Aluminum hydroxide|
556467|NCT00002401|Drug|Indinavir sulfate|
556468|NCT00002401|Drug|Delavirdine mesylate|
556469|NCT00002401|Drug|Lamivudine|
556470|NCT00002401|Drug|Zidovudine|
556471|NCT00002400|Drug|Indinavir sulfate|
556472|NCT00002400|Drug|Delavirdine mesylate|
556473|NCT00002400|Drug|Lamivudine|
556474|NCT00002400|Drug|Zidovudine|
556475|NCT00002399|Drug|Posaconazole|
556476|NCT00002399|Drug|Fluconazole|
556477|NCT00002398|Drug|Levocarnitine|
556478|NCT00002398|Drug|Adefovir dipivoxil|
556479|NCT00002397|Drug|Nelfinavir mesylate|
556480|NCT00002397|Drug|Saquinavir|
556481|NCT00002397|Drug|Lamivudine|
556482|NCT00002397|Drug|Stavudine|
556483|NCT00002396|Drug|Tenofovir disoproxil fumarate|
556484|NCT00002395|Drug|Topotecan|
556485|NCT00002394|Drug|Terbinafine hydrochloride|
556486|NCT00002393|Drug|Indinavir sulfate|
556487|NCT00002393|Drug|Efavirenz|
556488|NCT00002392|Drug|Thalidomide|
556489|NCT00002391|Drug|Abacavir sulfate|
556490|NCT00002391|Drug|Lamivudine|
556491|NCT00002391|Drug|Zidovudine|
556492|NCT00002390|Drug|Abacavir sulfate|
556493|NCT00002389|Drug|Abacavir sulfate|
556494|NCT00002389|Drug|Lamivudine|
556495|NCT00002389|Drug|Zidovudine|
556496|NCT00002388|Drug|Abacavir sulfate|
556497|NCT00002387|Drug|Indinavir sulfate|
556498|NCT00002387|Drug|Efavirenz|
556499|NCT00002386|Drug|Indinavir sulfate|
556500|NCT00002386|Drug|Lamivudine|
556501|NCT00002386|Drug|Stavudine|
556502|NCT00002386|Drug|Zidovudine|
556503|NCT00002386|Drug|Zalcitabine|
556504|NCT00002386|Drug|Didanosine|
556505|NCT00002385|Drug|Fozivudine tidoxil|
556506|NCT00002384|Drug|Cidofovir|
556507|NCT00002383|Drug|Saquinavir|
556508|NCT00002382|Drug|Saquinavir|
556509|NCT00002381|Drug|Nelfinavir mesylate|
556510|NCT00002381|Drug|Nevirapine|
556511|NCT00002381|Drug|Stavudine|
556512|NCT00002380|Drug|Nelfinavir mesylate|
556513|NCT00002380|Drug|Saquinavir|
556514|NCT00002379|Drug|Indinavir sulfate|
556515|NCT00002379|Drug|Levocarnitine|
556516|NCT00002379|Drug|Adefovir dipivoxil|
556517|NCT00002379|Drug|Lamivudine|
556518|NCT00002379|Drug|Stavudine|
556519|NCT00002379|Drug|Zidovudine|
556520|NCT00002378|Drug|Ritonavir|
556521|NCT00002378|Drug|Nelfinavir mesylate|
556522|NCT00002378|Drug|Saquinavir|
556523|NCT00002378|Drug|Delavirdine mesylate|
556524|NCT00002378|Drug|Lamivudine|
556525|NCT00002378|Drug|Stavudine|
556526|NCT00002378|Drug|Zidovudine|
556527|NCT00002377|Drug|Valganciclovir|
556528|NCT00002377|Drug|Ganciclovir|
556529|NCT00002376|Drug|Indinavir sulfate|
556530|NCT00002376|Drug|Lamivudine|
556531|NCT00002376|Drug|Stavudine|
556532|NCT00002376|Drug|Zidovudine|
556533|NCT00002376|Drug|Didanosine|
556534|NCT00002375|Drug|Indinavir sulfate|
556535|NCT00002375|Drug|Nelfinavir mesylate|
556536|NCT00002374|Drug|Ritonavir|
556537|NCT00002374|Drug|Nelfinavir mesylate|
556538|NCT00002374|Drug|Saquinavir|
556539|NCT00002374|Drug|Stavudine|
556540|NCT00002373|Drug|Maribavir|
556541|NCT00002372|Drug|Indinavir sulfate|
556542|NCT00002372|Drug|Amprenavir|
556543|NCT00002372|Drug|Nelfinavir mesylate|
556544|NCT00002372|Drug|Saquinavir|
556545|NCT00002371|Drug|Indinavir sulfate|
556546|NCT00002371|Drug|Lamivudine|
556547|NCT00002371|Drug|Stavudine|
556548|NCT00002371|Drug|Zidovudine|
556549|NCT00002370|Drug|Itraconazole|
556550|NCT00002369|Drug|Indinavir sulfate|
556551|NCT00002369|Drug|Lamivudine|
556552|NCT00002369|Drug|Stavudine|
556553|NCT00002369|Drug|Zidovudine|
556554|NCT00002368|Drug|Nevirapine|
556555|NCT00002368|Drug|Lamivudine|
556556|NCT00002367|Drug|Saquinavir|
556557|NCT00002367|Drug|Lamivudine|
556558|NCT00002367|Drug|Zidovudine|
556559|NCT00002366|Drug|Ritonavir|
556560|NCT00002365|Drug|LXR015-1|
556561|NCT00002364|Drug|Abacavir sulfate|
556562|NCT00002363|Drug|Peptide Construction 3, Synthetic|
556563|NCT00002362|Drug|Abacavir sulfate|
556564|NCT00002362|Drug|Efavirenz|
556565|NCT00002362|Drug|Emtricitabine|
556566|NCT00002362|Drug|Stavudine|
556567|NCT00002361|Drug|Indinavir sulfate|
556568|NCT00002361|Drug|Ritonavir|
556569|NCT00002360|Drug|Didanosine|
556570|NCT00002359|Biological|HIV-1 Immunogen|
556571|NCT00002358|Drug|Sorivudine|
556572|NCT00002357|Drug|HBY 097|
556573|NCT00002357|Drug|Zidovudine|
556574|NCT00002356|Drug|Fomivirsen sodium|
556575|NCT00002355|Drug|Fomivirsen sodium|
556576|NCT00002354|Drug|Indinavir sulfate|
556577|NCT00002354|Drug|Stavudine|
556578|NCT00002353|Biological|P3C541b Lipopeptide|
556579|NCT00002352|Drug|Lobucavir|
556580|NCT00002351|Drug|Indinavir sulfate|
556581|NCT00002350|Biological|APL 400-003|
556582|NCT00002349|Drug|Stavudine|
556583|NCT00002348|Drug|Mitoguazone|
556584|NCT00002347|Drug|Saquinavir|
556585|NCT00002347|Drug|Nevirapine|
556586|NCT00002347|Drug|Zidovudine|
556587|NCT00002347|Drug|Zalcitabine|
556588|NCT00002346|Drug|Adefovir dipivoxil|
556589|NCT00002345|Drug|Megestrol acetate|
556590|NCT00002344|Drug|Azithromycin|
556591|NCT00002343|Drug|Ethambutol hydrochloride|
556592|NCT00002343|Drug|Rifabutin|
556593|NCT00002342|Drug|Tecogalan sodium|
556594|NCT00002341|Drug|Itraconazole|
556595|NCT00002340|Drug|Atovaquone|
556596|NCT00002340|Drug|Pentamidine isethionate|
556597|NCT00002339|Drug|Fluconazole|
556598|NCT00002338|Drug|Raluridine|
556599|NCT00002337|Drug|Vesnarinone|
556600|NCT00002336|Drug|Clarithromycin|
556601|NCT00002335|Drug|Emtricitabine|
556602|NCT00002334|Drug|Saquinavir|
556603|NCT00002334|Drug|Zidovudine|
556604|NCT00002334|Drug|Zalcitabine|
556605|NCT00002333|Drug|Saquinavir|
556606|NCT00002333|Drug|Zalcitabine|
556607|NCT00002332|Drug|Thymopentin|
556608|NCT00002331|Drug|Ethambutol hydrochloride|
556609|NCT00002331|Drug|Clarithromycin|
556610|NCT00002331|Drug|Clofazimine|
556611|NCT00002330|Drug|Ganciclovir|
556612|NCT00002329|Drug|Celgosivir hydrochloride|
556613|NCT00002328|Drug|Azithromycin|
556614|NCT00002327|Drug|Cidofovir|
556615|NCT00002326|Drug|Adefovir|
556616|NCT00002326|Drug|Zidovudine|
556617|NCT00002325|Drug|Fluconazole|
556618|NCT00002324|Drug|Nevirapine|
556619|NCT00002324|Drug|Zidovudine|
556620|NCT00002323|Drug|Nevirapine|
556621|NCT00002323|Drug|Zidovudine|
556622|NCT00002322|Drug|Atevirdine mesylate|
556623|NCT00002322|Drug|Zidovudine|
556624|NCT00002321|Drug|Aldesleukin|
556625|NCT00002320|Drug|Lamivudine|
556626|NCT00002320|Drug|Zidovudine|
556627|NCT00002319|Drug|Doxorubicin hydrochloride (liposomal)|
556628|NCT00002318|Drug|Doxorubicin hydrochloride (liposomal)|
556629|NCT00002318|Drug|Bleomycin sulfate|
556630|NCT00002318|Drug|Vincristine sulfate|
556631|NCT00002318|Drug|Doxorubicin hydrochloride|
556632|NCT00002317|Drug|Trimetrexate glucuronate|
556633|NCT00002317|Drug|Leucovorin calcium|
556634|NCT00002316|Drug|Lobradimil|
556635|NCT00002316|Drug|Amphotericin B|
556636|NCT00002315|Drug|Netivudine|
556637|NCT00002315|Drug|Acyclovir|
556638|NCT00002314|Drug|Ro 24-7429|
556639|NCT00002313|Drug|Nystatin|
556640|NCT00002313|Drug|Didanosine|
556641|NCT00002312|Drug|Delavirdine mesylate|
556642|NCT00002312|Drug|Zidovudine|
556643|NCT00002311|Drug|Wobenzym|
556644|NCT00002310|Drug|Crofelemer|
556645|NCT00002309|Drug|Azithromycin|
556646|NCT00002308|Drug|Stavudine|
556647|NCT00002307|Drug|Stavudine|
556648|NCT00002307|Drug|Zidovudine|
556649|NCT00002306|Drug|Fluconazole|
556650|NCT00002305|Drug|Flucytosine|
556651|NCT00002305|Drug|Fluconazole|
556652|NCT00002305|Drug|Amphotericin B|
556653|NCT00002304|Drug|Ketoconazole|
556654|NCT00002304|Drug|Fluconazole|
556655|NCT00002303|Drug|Epoetin alfa|
556656|NCT00002302|Drug|Epoetin alfa|
556657|NCT00002301|Drug|Foscarnet sodium|
556658|NCT00002300|Drug|Megestrol acetate|
556659|NCT00002299|Drug|Interferon beta-1b|
556660|NCT00002299|Drug|Ganciclovir|
556661|NCT00002298|Drug|Ribavirin|
556662|NCT00002297|Drug|Inosine pranobex|
556663|NCT00002296|Drug|Inosine pranobex|
556664|NCT00002295|Drug|Inosine pranobex|
556665|NCT00002294|Drug|Fluconazole|
556666|NCT00002293|Drug|Nystatin|
556667|NCT00002292|Drug|Pentamidine isethionate|
556668|NCT00002291|Drug|Pentamidine isethionate|
556669|NCT00002290|Drug|Zidovudine|
556670|NCT00002290|Drug|Acyclovir|
556671|NCT00002289|Drug|Thymopentin|
556672|NCT00002288|Drug|Zidovudine|
556673|NCT00002287|Drug|Zidovudine|
556674|NCT00002286|Drug|Zidovudine|
556675|NCT00002285|Drug|Zidovudine|
556676|NCT00002284|Drug|Zidovudine|
556677|NCT00002283|Drug|Trimethoprim|
556678|NCT00002283|Drug|Sulfamethoxazole|
556679|NCT00002283|Drug|Dapsone|
556680|NCT00002282|Drug|Clotrimazole|
556681|NCT00002282|Drug|Fluconazole|
556682|NCT00002281|Drug|Filgrastim|
556683|NCT00002281|Drug|Epoetin alfa|
556684|NCT00002281|Drug|Zidovudine|
556685|NCT00002280|Drug|Didanosine|
556686|NCT00002279|Drug|Zalcitabine|
556687|NCT00002278|Drug|Diclazuril|
556688|NCT00002277|Drug|Fluconazole|
556689|NCT00002277|Drug|Amphotericin B|
556690|NCT00002276|Drug|Ibuprofen|
556691|NCT00002276|Drug|Zidovudine|
556692|NCT00002275|Drug|Fat Emulsion 2%|
556693|NCT00002275|Drug|Fat Emulsion 20%|
556694|NCT00002274|Drug|Didanosine|
556695|NCT00002273|Drug|Ganciclovir|
556696|NCT00002272|Drug|Foscarnet sodium|
556697|NCT00002271|Drug|Alovudine|
556698|NCT00002270|Drug|Interferon alfa-2b|
556699|NCT00002270|Drug|Zidovudine|
556700|NCT00002269|Drug|Ampligen|
556701|NCT00002269|Drug|Zidovudine|
556702|NCT00002268|Drug|Sevirumab|
556703|NCT00002267|Drug|Rifabutin|
556704|NCT00002266|Drug|AS-101|
556705|NCT00002265|Drug|Zalcitabine|
556706|NCT00002264|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
556707|NCT00002263|Drug|Zidovudine|
556708|NCT00002263|Drug|Sargramostim|
556709|NCT00002262|Drug|Tumor Necrosis Factor|
556710|NCT00002261|Biological|Smallpox Vaccine|
556711|NCT00002261|Biological|HIVAC-1e|
556712|NCT00002261|Biological|gp160 Vaccine (MicroGeneSys)|
556713|NCT00002260|Drug|Alovudine|
556714|NCT00002259|Drug|Mitoxantrone hydrochloride|
556715|NCT00002258|Drug|Interleukin-3|
556716|NCT00002257|Drug|Ganciclovir|
556717|NCT00002256|Drug|Zalcitabine|
556718|NCT00002255|Drug|Filgrastim|
556719|NCT00002255|Drug|Epoetin alfa|
556720|NCT00002255|Drug|Zidovudine|
556721|NCT00002254|Drug|Alovudine|
556722|NCT00002253|Drug|Octreotide|
556723|NCT00002252|Drug|Octreotide|
556724|NCT00002251|Drug|Ganciclovir|
556725|NCT00002250|Drug|CD4-IgG|
556726|NCT00002249|Drug|Levofloxacin|
556727|NCT00002248|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
556728|NCT00002247|Drug|Ganciclovir|
556729|NCT00002246|Drug|Stavudine|
556730|NCT00002245|Drug|Abacavir sulfate|
556731|NCT00002245|Drug|Amprenavir|
556732|NCT00002245|Drug|Lamivudine|
556733|NCT00002244|Drug|WF10|
556734|NCT00002243|Drug|Calanolide A|
556735|NCT00002241|Drug|Indinavir sulfate|
556736|NCT00002241|Drug|Ritonavir|
556737|NCT00002241|Drug|Lamivudine|
556738|NCT00002241|Drug|Stavudine|
556739|NCT00002240|Drug|Atazanavir|
556740|NCT00002240|Drug|Nelfinavir mesylate|
556741|NCT00002240|Drug|Stavudine|
556742|NCT00002240|Drug|Didanosine|
556743|NCT00002239|Drug|Enfuvirtide|
556744|NCT00002239|Drug|Ritonavir|
556745|NCT00002239|Drug|Abacavir sulfate|
556746|NCT00002239|Drug|Amprenavir|
556747|NCT00002239|Drug|Efavirenz|
556748|NCT00002238|Drug|Interferon beta-1b|
556749|NCT00002238|Drug|Zidovudine|
556750|NCT00002237|Drug|Peldesine|
556751|NCT00002236|Drug|Indinavir sulfate|
556752|NCT00002236|Drug|Delavirdine mesylate|
556753|NCT00002236|Drug|Zidovudine|
556754|NCT00002235|Drug|Indinavir sulfate|
556755|NCT00002235|Drug|Nelfinavir mesylate|
556756|NCT00002235|Drug|Efavirenz|
556757|NCT00002234|Drug|Efavirenz|
556758|NCT00002234|Drug|Adefovir dipivoxil|
556759|NCT00002234|Drug|Lamivudine|
556760|NCT00002234|Drug|Didanosine|
556761|NCT00002233|Drug|Indinavir sulfate|
556762|NCT00002233|Drug|Abacavir sulfate|
556763|NCT00002233|Drug|Amprenavir|
556764|NCT00002233|Drug|Lamivudine|
556765|NCT00002232|Biological|APL 400-003|
556766|NCT00002231|Biological|APL 400-003|
556767|NCT00002230|Drug|Hydroxyurea|
556768|NCT00002230|Drug|Efavirenz|
556769|NCT00002230|Drug|Stavudine|
556770|NCT00002230|Drug|Didanosine|
556771|NCT00002229|Drug|Saquinavir|
556772|NCT00002228|Drug|Enfuvirtide|
556773|NCT00002227|Drug|Efavirenz|
556774|NCT00002227|Drug|Lamivudine|
556775|NCT00002227|Drug|Stavudine|
556776|NCT00002226|Drug|SU5416|
556777|NCT00002225|Drug|Efavirenz|
556778|NCT00002225|Drug|Stavudine|
556779|NCT00002225|Drug|Didanosine|
556780|NCT00002224|Drug|Nelfinavir mesylate|
556781|NCT00002224|Drug|Stavudine|
556782|NCT00002224|Drug|Didanosine|
556783|NCT00002223|Drug|Indinavir sulfate|
556784|NCT00002223|Drug|Ritonavir|
556785|NCT00002222|Drug|Valganciclovir|
556786|NCT00002221|Drug|Peripheral blood stem cells|
556787|NCT00002220|Drug|Indinavir sulfate|
556788|NCT00002220|Drug|Efavirenz|
556789|NCT00002220|Drug|Levocarnitine|
556790|NCT00002220|Drug|Adefovir dipivoxil|
556791|NCT00002219|Drug|Nelfinavir mesylate|
556792|NCT00002219|Drug|Levocarnitine|
556793|NCT00002219|Drug|Adefovir dipivoxil|
556794|NCT00002218|Drug|CI-1012|
556795|NCT00002217|Drug|Lamivudine/Zidovudine|
556796|NCT00002217|Drug|Abacavir sulfate|
556797|NCT00002217|Drug|Amprenavir|
556798|NCT00002216|Drug|Lamivudine/Zidovudine|
556799|NCT00002216|Drug|Abacavir sulfate|
556800|NCT00002216|Drug|Amprenavir|
556801|NCT00002216|Drug|Nelfinavir mesylate|
556802|NCT00002215|Drug|Emivirine|
556803|NCT00002215|Drug|Nelfinavir mesylate|
556804|NCT00002214|Drug|Capravirine|
556805|NCT00002213|Drug|Abacavir sulfate|
556806|NCT00002213|Drug|Amprenavir|
556807|NCT00002213|Drug|Efavirenz|
556808|NCT00002212|Drug|Bexarotene|
556809|NCT00002211|Drug|Nelfinavir mesylate|
556810|NCT00002211|Drug|Delavirdine mesylate|
556811|NCT00002211|Drug|Stavudine|
556812|NCT00002211|Drug|Didanosine|
556813|NCT00002210|Drug|Delavirdine mesylate|
556814|NCT00002209|Drug|CPI-1189|
556815|NCT00002208|Drug|Indinavir sulfate|
556816|NCT00002208|Drug|Lamivudine|
556817|NCT00002208|Drug|Stavudine|
556818|NCT00002208|Drug|Zidovudine|
556819|NCT00002207|Drug|Stavudine|
556820|NCT00002207|Drug|Didanosine|
556821|NCT00002206|Drug|Adefovir dipivoxil|
556822|NCT00002205|Drug|Abacavir sulfate|
556823|NCT00002205|Drug|Amprenavir|
556824|NCT00002204|Biological|HIV p24/MF59 Vaccine|
556825|NCT00002203|Drug|Lamivudine/Zidovudine|
556826|NCT00002203|Drug|Lamivudine|
556827|NCT00002203|Drug|Zidovudine|
556828|NCT00002202|Drug|Indinavir sulfate|
556829|NCT00002202|Drug|Amprenavir|
556830|NCT00002201|Drug|Ritonavir|
556831|NCT00002201|Drug|Nelfinavir mesylate|
556832|NCT00002200|Drug|Abacavir sulfate|
556833|NCT00002199|Drug|Indinavir sulfate|
556834|NCT00002199|Drug|Lamivudine/Zidovudine|
556835|NCT00002199|Drug|Abacavir sulfate|
556836|NCT00002198|Drug|Abacavir sulfate|
556837|NCT00002197|Drug|Abacavir sulfate|
556838|NCT00002196|Drug|CI-1012|
556839|NCT00002195|Drug|Amprenavir|
556840|NCT00002195|Drug|Lamivudine|
556841|NCT00002195|Drug|Zidovudine|
556842|NCT00002194|Drug|Erythromycin|
556843|NCT00002194|Drug|Nevirapine|
556844|NCT00002194|Drug|Clarithromycin|
556845|NCT00002193|Drug|Amprenavir|
556846|NCT00002192|Drug|Rifapentine|
556847|NCT00002192|Drug|Ethambutol hydrochloride|
556848|NCT00002192|Drug|Clarithromycin|
556849|NCT00002192|Drug|Azithromycin|
556850|NCT00002191|Drug|Albendazole|
556851|NCT00002190|Drug|Saquinavir|
556852|NCT00002190|Drug|Lamivudine|
556853|NCT00002190|Drug|Zidovudine|
556854|NCT00002189|Drug|Paclitaxel|
556855|NCT00002188|Drug|Alitretinoin|
556856|NCT00002187|Drug|Fomivirsen sodium|
556857|NCT00002186|Drug|Crofelemer|
556858|NCT00002186|Drug|Acyclovir|
556859|NCT00002185|Drug|Nelfinavir mesylate|
556860|NCT00002184|Drug|Nelfinavir mesylate|
556861|NCT00002184|Drug|Levocarnitine|
556862|NCT00002184|Drug|Adefovir dipivoxil|
556863|NCT00002184|Drug|Saquinavir|
556864|NCT00002184|Drug|Lamivudine|
556865|NCT00002184|Drug|Stavudine|
556866|NCT00002184|Drug|Zidovudine|
556867|NCT00002183|Drug|Abacavir sulfate|
556868|NCT00002183|Drug|Amprenavir|
556869|NCT00002183|Drug|Lamivudine|
556870|NCT00002183|Drug|Zidovudine|
556871|NCT00002182|Drug|Megestrol acetate|
556872|NCT00002181|Drug|Cidofovir|
556873|NCT00002180|Drug|Tenofovir|
556874|NCT00002179|Drug|Indinavir sulfate|
556875|NCT00002179|Drug|Lamivudine|
556876|NCT00002179|Drug|Zidovudine|
556877|NCT00002178|Drug|Ritonavir|
556878|NCT00002178|Drug|Nelfinavir mesylate|
556879|NCT00002178|Drug|Saquinavir|
556880|NCT00002178|Drug|Delavirdine mesylate|
556881|NCT00002177|Drug|Hydroxyurea|
556882|NCT00002177|Drug|Nelfinavir mesylate|
556883|NCT00002177|Drug|Stavudine|
556884|NCT00002177|Drug|Didanosine|
556885|NCT00002176|Drug|Hydroxyurea|
556886|NCT00002176|Drug|Nelfinavir mesylate|
556887|NCT00002176|Drug|Stavudine|
556888|NCT00002176|Drug|Didanosine|
556889|NCT00002175|Drug|Dinitrochlorobenzene|
556890|NCT00002174|Drug|Thalidomide|
556891|NCT00002173|Biological|HIV-1 Immunogen|
556892|NCT00002172|Biological|HIV-1 Immunogen|
556893|NCT00002171|Drug|Nelfinavir mesylate|
556894|NCT00002170|Drug|Nelfinavir mesylate|
556895|NCT00002169|Drug|Nelfinavir mesylate|
556896|NCT00002168|Drug|Indinavir sulfate|
556897|NCT00002168|Drug|Lamivudine|
556898|NCT00002168|Drug|Stavudine|
556899|NCT00002168|Drug|Zidovudine|
556900|NCT00002168|Drug|Didanosine|
556901|NCT00002167|Drug|Tin ethyl etiopurpurin|
556902|NCT00002166|Drug|Nevirapine|
556903|NCT00002165|Drug|Nelfinavir mesylate|
556904|NCT00002164|Drug|Nelfinavir mesylate|
556905|NCT00002163|Drug|Abacavir sulfate|
556906|NCT00002162|Drug|Saquinavir|
556907|NCT00002162|Drug|Lamivudine|
556908|NCT00002162|Drug|Stavudine|
556909|NCT00002162|Drug|Zidovudine|
556910|NCT00002162|Drug|Zalcitabine|
556911|NCT00002162|Drug|Didanosine|
556912|NCT00002161|Drug|Adefovir dipivoxil|
556913|NCT00002160|Drug|Ziconotide|
556914|NCT00002159|Drug|Itraconazole|
556915|NCT00002159|Drug|Amphotericin B|
556916|NCT00002158|Drug|Nitazoxanide|
556917|NCT00002157|Drug|Thalidomide|
556918|NCT00002156|Drug|Fomivirsen sodium|
556919|NCT00002156|Drug|Ganciclovir|
556920|NCT00002155|Drug|Indinavir sulfate|
556921|NCT00002155|Drug|Lamivudine|
556922|NCT00002155|Drug|Zidovudine|
556923|NCT00002154|Drug|Thioctic acid|
556924|NCT00002154|Drug|Selegiline hydrochloride|
556925|NCT00002153|Drug|A-007|
556926|NCT00002152|Drug|WF10|
556927|NCT00002151|Drug|Celgosivir hydrochloride|
556928|NCT00002150|Drug|Celgosivir hydrochloride|
556929|NCT00002149|Drug|Clavulanate potassium|
556930|NCT00002149|Drug|Pseudoephedrine hydrochloride|
556931|NCT00002149|Drug|Amoxicillin trihydrate|
556932|NCT00002148|Drug|OPC 14117|
556933|NCT00002147|Drug|Doxorubicin hydrochloride (liposomal)|
556934|NCT00002146|Drug|Magnesium sulfate|
556935|NCT00002146|Drug|Foscarnet sodium|
556936|NCT00002145|Drug|Foscarnet sodium|
556937|NCT00002144|Drug|Foscarnet sodium|
556938|NCT00002143|Drug|Acitretin|
556939|NCT00002142|Drug|Cidofovir|
556940|NCT00002142|Drug|Probenecid|
556941|NCT00002141|Drug|Abacavir sulfate|
556942|NCT00002140|Drug|Ethambutol hydrochloride|
556943|NCT00002140|Drug|Clarithromycin|
556944|NCT00002140|Drug|Azithromycin|
556945|NCT00002139|Drug|Azithromycin|
556946|NCT00002138|Drug|Tecogalan sodium|
556947|NCT00002137|Drug|Tecogalan sodium|
556948|NCT00002136|Drug|Tecogalan sodium|
556949|NCT00002135|Drug|Ganciclovir|
556950|NCT00002134|Drug|Ganciclovir|
556951|NCT00002133|Drug|Itraconazole|
556952|NCT00002132|Drug|Itraconazole|
556953|NCT00002132|Drug|Fluconazole|
556954|NCT00002131|Drug|Vesnarinone|
556955|NCT00002130|Drug|Vesnarinone|
556956|NCT00002129|Drug|Vesnarinone|
556957|NCT00002128|Drug|Adefovir dipivoxil|
556958|NCT00002127|Drug|Thalidomide|
556959|NCT00002126|Drug|Filgrastim|
556960|NCT00002125|Drug|Foscarnet sodium|
556961|NCT00002124|Drug|Delavirdine mesylate|
556962|NCT00002124|Drug|Lamivudine|
556963|NCT00002124|Drug|Zidovudine|
556964|NCT00002123|Drug|Delavirdine mesylate|
556965|NCT00002123|Drug|Didanosine|
556966|NCT00002122|Drug|Azithromycin|
556967|NCT00002122|Drug|Rifabutin|
556968|NCT00002122|Drug|Fluconazole|
556969|NCT00002121|Drug|Diethylhomospermine|
556970|NCT00002120|Drug|Trimetrexate glucuronate|
556971|NCT00002120|Drug|Trimethoprim|
556972|NCT00002120|Drug|Sulfamethoxazole|
556973|NCT00002120|Drug|Dapsone|
556974|NCT00002120|Drug|Leucovorin calcium|
556975|NCT00002119|Drug|WF10|
556976|NCT00002118|Drug|Zalcitabine|
556977|NCT00002117|Drug|Zidovudine|
556978|NCT00002117|Drug|Zalcitabine|
556979|NCT00002116|Drug|Cidofovir|
556980|NCT00002115|Drug|Adefovir|
556981|NCT00002114|Drug|Procysteine|
556982|NCT00002113|Drug|Flucytosine|
556983|NCT00002113|Drug|Fluconazole|
556984|NCT00002112|Drug|Nystatin|
556985|NCT00002112|Drug|Fluconazole|
556986|NCT00002111|Drug|Saquinavir|
556987|NCT00002110|Drug|Cysteamine|
556988|NCT00002110|Drug|Zidovudine|
556989|NCT00002109|Drug|Thymopentin|
556990|NCT00002109|Drug|Stavudine|
556991|NCT00002109|Drug|Zidovudine|
556992|NCT00002109|Drug|Zalcitabine|
556993|NCT00002109|Drug|Didanosine|
556994|NCT00002108|Drug|Lamivudine|
556995|NCT00002108|Drug|Zidovudine|
556996|NCT00002107|Drug|Aldesleukin|
556997|NCT00002106|Drug|Ranitidine hydrochloride|
556998|NCT00002105|Drug|Doxorubicin hydrochloride (liposomal)|
556999|NCT00002105|Drug|Bleomycin sulfate|
557000|NCT00002105|Drug|Vincristine sulfate|
557001|NCT00002104|Drug|Thalidomide|
557002|NCT00002103|Drug|Trimetrexate glucuronate|
557003|NCT00002103|Drug|Leucovorin calcium|
557004|NCT00002102|Drug|Trimetrexate glucuronate|
557005|NCT00002102|Drug|Leucovorin calcium|
557006|NCT00002101|Drug|Ethambutol hydrochloride|
557007|NCT00002101|Drug|Clarithromycin|
557008|NCT00002101|Drug|Rifabutin|
557009|NCT00002100|Drug|Curdlan sulfate|
557010|NCT00002099|Drug|Lentinan|
557011|NCT00002099|Drug|Didanosine|
557012|NCT00002098|Drug|Lentinan|
557013|NCT00002098|Drug|Didanosine|
557014|NCT00002097|Drug|Nystatin|
557015|NCT00002096|Drug|Zidovudine|
557016|NCT00002096|Drug|Didanosine|
557017|NCT00002096|Drug|Ganciclovir|
557018|NCT00002095|Drug|Ganciclovir|
557019|NCT00002094|Drug|Atevirdine mesylate|
557020|NCT00002093|Drug|Daunorubicin (liposomal)|
557021|NCT00002093|Drug|Bleomycin sulfate|
557022|NCT00002093|Drug|Vincristine sulfate|
557023|NCT00002093|Drug|Doxorubicin hydrochloride|
557024|NCT00002092|Drug|Cimetidine|
557025|NCT00002091|Drug|Pentoxifylline|
557026|NCT00002090|Drug|Azithromycin|
557027|NCT00002089|Drug|Azithromycin|
557028|NCT00002088|Drug|Saccharomyces boulardii|
557029|NCT00002087|Drug|Alvircept sudotox|
557030|NCT00002086|Drug|Zidovudine|
557031|NCT00002086|Drug|Zalcitabine|
557032|NCT00002086|Drug|Interferon alfa-n1|
557033|NCT00002085|Drug|Azithromycin|
557034|NCT00002084|Drug|Valacyclovir hydrochloride|
557035|NCT00002084|Drug|Acyclovir|
557036|NCT00002083|Drug|Peptide T|
557037|NCT00002082|Drug|Azithromycin|
557038|NCT00002081|Drug|Zidovudine|
557039|NCT00002081|Drug|Zalcitabine|
557040|NCT00002080|Drug|Rifabutin|
557041|NCT00002079|Drug|Butyldeoxynojirimycin|
557042|NCT00002079|Drug|Zidovudine|
557043|NCT00002078|Drug|Interferon alfa-n3|
557044|NCT00002077|Drug|Fluconazole|
557045|NCT00002076|Drug|Fluconazole|
557046|NCT00002075|Drug|Flucytosine|
557047|NCT00002075|Drug|Fluconazole|
557048|NCT00002075|Drug|Amphotericin B|
557049|NCT00002074|Drug|Fluconazole|
557050|NCT00002074|Drug|Amphotericin B|
557051|NCT00002073|Drug|Epoetin alfa|
557052|NCT00002072|Drug|Epoetin alfa|
557053|NCT00002071|Drug|Epoetin alfa|
557054|NCT00002070|Drug|Sargramostim|
557055|NCT00002070|Drug|Ganciclovir|
557056|NCT00002069|Drug|Ditiocarb sodium|
557057|NCT00002068|Drug|Fluconazole|
557058|NCT00002068|Drug|Amphotericin B|
557059|NCT00002067|Drug|Megestrol acetate|
557060|NCT00002066|Drug|Thymopentin|
557061|NCT00002065|Drug|Disulfiram|
557062|NCT00002064|Drug|Pyrimethamine|
557063|NCT00002064|Drug|Clindamycin|
557064|NCT00002063|Drug|Zidovudine|
557065|NCT00002062|Drug|Spiramycin|
557066|NCT00002061|Drug|Inosine pranobex|
557067|NCT00002060|Drug|Inosine pranobex|
557068|NCT00002059|Drug|Inosine pranobex|
557069|NCT00002058|Drug|Clofazimine|
557070|NCT00002057|Drug|Nystatin|
557071|NCT00002056|Drug|Pentamidine isethionate|
557072|NCT00002055|Drug|Pentamidine isethionate|
557073|NCT00002054|Drug|Pentamidine isethionate|
557074|NCT00002053|Drug|Pentamidine isethionate|
557075|NCT00002052|Drug|Ceftriaxone sodium|
557076|NCT00002052|Drug|Ampicillin sodium|
557077|NCT00002052|Drug|Amoxicillin trihydrate|
557078|NCT00002051|Drug|Thymopentin|
557079|NCT00002050|Drug|Thymopentin|
557080|NCT00002049|Drug|Thymopentin|
557081|NCT00002048|Drug|Zidovudine|
557082|NCT00002047|Drug|Zidovudine|
557083|NCT00002046|Drug|Zidovudine|
557084|NCT00002045|Drug|Zidovudine|
557085|NCT00002044|Drug|Zidovudine|
557086|NCT00002043|Drug|Dapsone|
557087|NCT00002042|Drug|Epoetin alfa|
557088|NCT00002041|Drug|Amphotericin B|
557089|NCT00002040|Drug|Fluconazole|
557090|NCT00002039|Drug|Foscarnet sodium|
557091|NCT00002038|Drug|Fluconazole|
557092|NCT00002037|Drug|Trifluridine|
557093|NCT00002036|Drug|Anti-HIV Immune Serum Globulin (Human)|
557094|NCT00002035|Drug|Zidovudine|
557095|NCT00002035|Drug|Didanosine|
557096|NCT00002034|Drug|Zidovudine|
557097|NCT00002034|Drug|Ganciclovir|
557098|NCT00002033|Drug|Zidovudine|
557099|NCT00002033|Drug|AS-101|
557100|NCT00002032|Drug|Rifabutin|
557101|NCT00002031|Drug|Dinitrochlorobenzene|
557102|NCT00002030|Drug|Pentamidine isethionate|
557103|NCT00002029|Drug|Fat Emulsion 2%|
557104|NCT00002029|Drug|Fat Emulsion 20%|
557105|NCT00002028|Drug|Didanosine|
557106|NCT00002027|Drug|Diclazuril|
557107|NCT00002026|Drug|Acyclovir|
557108|NCT00002025|Drug|Ganciclovir|
557109|NCT00002024|Drug|Ganciclovir|
557110|NCT00002023|Drug|Zidovudine|
557111|NCT00002022|Drug|Epoetin alfa|
557112|NCT00002021|Drug|Foscarnet sodium|
557113|NCT00002020|Drug|Zidovudine|
557114|NCT00002019|Drug|Amphotericin B, Lipid-based|
557115|NCT00002019|Drug|Amphotericin B|
557116|NCT00002018|Drug|Interferon alfa-n3|
557117|NCT00002017|Drug|Interleukin-2, Polyethylene Glycolated|
557118|NCT00002016|Drug|Sevirumab|
557119|NCT00002015|Drug|Ganciclovir|
557120|NCT00002014|Drug|Zidovudine|
557121|NCT00002014|Drug|Didanosine|
557122|NCT00002013|Drug|Zidovudine|
557123|NCT00002013|Drug|AS-101|
557124|NCT00002012|Drug|Interferon alfa-n3|
557125|NCT00002011|Drug|Methoxsalen|
557126|NCT00002010|Drug|Fluconazole|
557127|NCT00002009|Drug|Sargramostim|
557128|NCT00002008|Drug|Sargramostim|
557129|NCT00002007|Drug|Zidovudine|
557130|NCT00002007|Drug|Sargramostim|
557131|NCT00002006|Drug|Zidovudine|
557132|NCT00002006|Drug|Sargramostim|
557133|NCT00002005|Drug|CD4 Antigens|
557134|NCT00002004|Drug|CD4 Antigens|
557135|NCT00002003|Drug|Mitoxantrone hydrochloride|
557136|NCT00002003|Drug|Etoposide|
557137|NCT00002002|Drug|Trimethoprim|
557138|NCT00002002|Drug|Sulfamethoxazole|
557139|NCT00002002|Drug|Leucovorin calcium|
557140|NCT00002001|Drug|Zidovudine|
557141|NCT00002001|Drug|Zalcitabine|
557142|NCT00002001|Drug|Didanosine|
557143|NCT00002000|Drug|Valacyclovir hydrochloride|
557144|NCT00002000|Drug|Acyclovir|
557145|NCT00001999|Drug|Globulin, Immune|
557146|NCT00001999|Drug|Ganciclovir|
557147|NCT00001998|Drug|Nystatin|
557148|NCT00001997|Drug|Interleukin-2, Polyethylene Glycolated|
557149|NCT00001997|Drug|Zidovudine|
557150|NCT00001997|Drug|Didanosine|
557151|NCT00001996|Drug|Atovaquone|
557152|NCT00001996|Drug|Pentamidine isethionate|
557153|NCT00001995|Drug|Rifabutin|
557154|NCT00001994|Drug|Atovaquone|
557155|NCT00001993|Drug|Butyldeoxynojirimycin|
557156|NCT00001993|Drug|Zidovudine|
557157|NCT00001992|Biological|rgp120/HIV-1IIIB|
557158|NCT00001991|Drug|Atovaquone|
557159|NCT00001990|Drug|Atovaquone|
557160|NCT00001989|Drug|Trichosanthin|
557161|NCT00001989|Drug|Zidovudine|
557162|NCT00001136|Biological|ALVAC-HIV MN120TMG (vCP205)|
557163|NCT00001135|Drug|Nevirapine|
557164|NCT00001133|Drug|Indinavir sulfate|
557165|NCT00001133|Drug|Ritonavir|
557166|NCT00001132|Drug|Abacavir sulfate|
557167|NCT00001131|Drug|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10^6 mIU per day for the entire duration of therapy
557168|NCT00001131|Drug|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
557169|NCT00001129|Device|Electronic Medication Reminder System|
557170|NCT00001129|Behavioral|Medication Manager|
557171|NCT00001128|Drug|Interleukin-12|
557172|NCT00001128|Drug|Paromomycin sulfate|
557173|NCT00001128|Drug|Azithromycin|
557174|NCT00001127|Biological|Influenza virus vaccine (CAIV-T)|
557175|NCT00001126|Drug|Cidofovir|
557176|NCT00001125|Biological|Varicella Virus Vaccine (Live)|
557177|NCT00001123|Drug|Ribavirin|
557178|NCT00001122|Drug|Nelfinavir mesylate|
557179|NCT00001122|Drug|Efavirenz|
557180|NCT00001122|Drug|Stavudine|
557181|NCT00001122|Drug|Didanosine|
557182|NCT00001119|Biological|Tetanus Toxoid Vaccine|
557183|NCT00001119|Drug|Indinavir sulfate|
557184|NCT00001119|Drug|Lamivudine/Zidovudine|
557185|NCT00001119|Drug|Ritonavir|
557186|NCT00001119|Drug|Abacavir sulfate|
557187|NCT00001119|Drug|Amprenavir|
557188|NCT00001119|Drug|Efavirenz|
557189|NCT00001119|Biological|Hepatitis B Vaccine (Recombinant)|
557190|NCT00001119|Drug|Lamivudine|
557191|NCT00001119|Drug|Zidovudine|
557192|NCT00001118|Drug|Enfuvirtide|
557193|NCT00001116|Drug|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
557194|NCT00001115|Drug|Acyclovir|
557195|NCT00001114|Drug|Interferon alfa-2b|
557196|NCT00001114|Drug|Didanosine|
557197|NCT00001113|Drug|Interferon alfa-2a|
557198|NCT00001113|Drug|Zidovudine|
557199|NCT00001113|Drug|Interferon alfa-n1|
557200|NCT00001112|Drug|Zidovudine|
557201|NCT00001112|Drug|Interferon gamma-1b|
557202|NCT00001111|Drug|Nevirapine|
557203|NCT00001111|Drug|Zidovudine|
557204|NCT00001110|Procedure|Bronchoalveolar lavage|
557205|NCT00001108|Drug|Ritonavir|
557206|NCT00001108|Drug|Nelfinavir mesylate|
557207|NCT00001108|Drug|Saquinavir|
557208|NCT00001108|Drug|Nevirapine|
557209|NCT00001108|Drug|Lamivudine|
557210|NCT00001108|Drug|Stavudine|
557211|NCT00001108|Drug|Didanosine|
557212|NCT00001107|Drug|Fluconazole|
557213|NCT00001107|Drug|AmBisome|
557214|NCT00001106|Drug|Zidovudine|
557215|NCT00001105|Drug|F105 Monoclonal Antibody (Human)|
557216|NCT00001104|Drug|Zidovudine|
557217|NCT00001101|Drug|ceftriaxone|
557218|NCT00001101|Drug|doxycycline|
557219|NCT00001100|Drug|ganciclovir|
557220|NCT00001096|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
557221|NCT00001096|Biological|QS-21|
557222|NCT00001096|Biological|rgp120/HIV-1MN|
557223|NCT00001095|Drug|Indinavir sulfate|
557224|NCT00001095|Drug|Amprenavir|
557225|NCT00001095|Drug|Nevirapine|
557226|NCT00001095|Drug|Lamivudine|
557227|NCT00001095|Drug|Stavudine|
557228|NCT00001095|Drug|Zidovudine|
557229|NCT00001094|Drug|Lamivudine/Zidovudine|
557230|NCT00001094|Drug|Nelfinavir mesylate|
557231|NCT00001094|Drug|Saquinavir|
557232|NCT00001094|Drug|Delavirdine mesylate|
557233|NCT00001091|Drug|Ritonavir|
557234|NCT00001091|Drug|Nelfinavir mesylate|
557235|NCT00001091|Drug|Nevirapine|
557236|NCT00001091|Drug|Lamivudine|
557237|NCT00001091|Drug|Stavudine|
557238|NCT00001090|Biological|APL 400-047|
557239|NCT00001090|Biological|ALVAC-HIV MN120TMG (vCP205)|
557240|NCT00001090|Drug|Sargramostim|
557241|NCT00001088|Biological|APL 400-047|
557242|NCT00001088|Drug|Bupivacaine hydrochloride|
557243|NCT00001087|Drug|Ritonavir|
557244|NCT00001087|Drug|Nelfinavir mesylate|
557245|NCT00001087|Drug|Efavirenz|
557246|NCT00001087|Drug|Levocarnitine|
557247|NCT00001087|Drug|Adefovir dipivoxil|
557248|NCT00001087|Drug|Saquinavir|
557249|NCT00001087|Drug|Lamivudine|
557250|NCT00001087|Drug|Stavudine|
557251|NCT00001087|Drug|Zidovudine|
557252|NCT00001087|Drug|Zalcitabine|
557253|NCT00001087|Drug|Didanosine|
557254|NCT00001086|Drug|Indinavir sulfate|
557255|NCT00001086|Drug|Abacavir sulfate|
557256|NCT00001086|Drug|Efavirenz|
557257|NCT00001085|Drug|Amprenavir|
557258|NCT00001085|Drug|Lamivudine|
557259|NCT00001085|Drug|Zidovudine|
557260|NCT00001084|Drug|Indinavir sulfate|
557261|NCT00001084|Drug|Lamivudine|
557262|NCT00001084|Drug|Stavudine|
557263|NCT00001084|Drug|Zidovudine|
557264|NCT00001083|Drug|Indinavir sulfate|
557265|NCT00001083|Drug|Ritonavir|
557266|NCT00001083|Drug|Nevirapine|
557267|NCT00001083|Drug|Lamivudine|
557268|NCT00001083|Drug|Stavudine|
557269|NCT00001083|Drug|Zidovudine|
557270|NCT00001082|Drug|Levocarnitine|500 mg tablet taken orally daily
557271|NCT00001082|Drug|Adefovir dipivoxil|120 mg tablet taken orally daily
557272|NCT00001082|Drug|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
557273|NCT00001081|Drug|Nitazoxanide|
557274|NCT00001080|Biological|Influenza Virus Vaccine|
557275|NCT00001080|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
557276|NCT00001080|Drug|Lamivudine|
557277|NCT00001079|Drug|Testosterone enanthate|
557278|NCT00001079|Drug|Megestrol acetate|
557279|NCT00001078|Biological|Hepatitis A Vaccine (Inactivated)|
557280|NCT00001077|Dietary Supplement|Multivitamin and mineral supplements|Oral tablets taken daily
557281|NCT00001077|Dietary Supplement|Peptamen|Solution received daily
557282|NCT00001077|Dietary Supplement|NuBasics|Solution or dietary bar received daily
557283|NCT00001076|Biological|ALVAC-HIV MN120TMG (vCP205)|
557284|NCT00001076|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
557285|NCT00001076|Biological|rgp120/HIV-1 SF-2|
557286|NCT00001075|Drug|Ritonavir|
557287|NCT00001075|Drug|Lamivudine|
557288|NCT00001075|Drug|Zidovudine|
557289|NCT00001074|Drug|Hydroxyurea|
557290|NCT00001074|Drug|Didanosine|
557291|NCT00001073|Drug|Isotretinoin|
557292|NCT00001072|Biological|ALVAC-HIV MN120TMGNP (vCP300)|
557293|NCT00001072|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
557294|NCT00001072|Biological|rgp120/HIV-1 SF-2|
557295|NCT00001071|Drug|Filgrastim|
557296|NCT00001070|Drug|Oral Vitamin C|
557297|NCT00001068|Drug|Lamivudine|
557298|NCT00001067|Drug|Lamivudine|
557299|NCT00001067|Drug|Stavudine|
557300|NCT00001067|Drug|Zidovudine|
557301|NCT00001066|Drug|Lamivudine|
557302|NCT00001066|Drug|Zidovudine|
557303|NCT00001066|Drug|Didanosine|
557304|NCT00001065|Drug|Amphotericin B|
557305|NCT00001064|Drug|Allogenic Dendritic Cells|
557306|NCT00001063|Drug|Stavudine|
557307|NCT00001063|Drug|Zidovudine|
557308|NCT00001063|Drug|Didanosine|
557309|NCT00001062|Drug|Ganciclovir|
557310|NCT00001061|Drug|Sevirumab|
557311|NCT00001061|Drug|Foscarnet sodium|
557312|NCT00001061|Drug|Ganciclovir|
557313|NCT00001060|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
557314|NCT00001059|Drug|Doxorubicin hydrochloride (liposomal)|
557315|NCT00001059|Drug|Filgrastim|
557316|NCT00001059|Drug|Bleomycin sulfate|
557317|NCT00001059|Drug|Vincristine sulfate|
557318|NCT00001058|Drug|Indinavir sulfate|
557319|NCT00001058|Drug|Ritonavir|
557320|NCT00001058|Drug|Ethambutol hydrochloride|
557321|NCT00001058|Drug|Clarithromycin|
557322|NCT00001058|Drug|Rifabutin|
557323|NCT00001057|Drug|Zidovudine|
557324|NCT00001057|Drug|Didanosine|
557325|NCT00001056|Biological|gp160 Vaccine (Immuno-AG)|
557326|NCT00001055|Biological|ALVAC-HIV MN120TMG (vCP205)|
557327|NCT00001055|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
557328|NCT00001055|Biological|rgp120/HIV-1 SF-2|
557329|NCT00001054|Drug|Valacyclovir hydrochloride|
557330|NCT00001053|Biological|HIV p17/p24:Ty-VLP|
557331|NCT00001053|Biological|Aluminum hydroxide|
557332|NCT00001052|Biological|Aluminum hydroxide|
557333|NCT00001052|Biological|QS-21|
557334|NCT00001052|Biological|rgp120/HIV-1MN|
557335|NCT00001049|Drug|Zidovudine|
557336|NCT00001049|Drug|Didanosine|
557337|NCT00001048|Drug|Filgrastim|
557338|NCT00001048|Drug|Cytarabine|
557339|NCT00001048|Drug|Zidovudine|
557340|NCT00001048|Drug|Zalcitabine|
557341|NCT00001048|Drug|Didanosine|
557342|NCT00001047|Drug|Ethambutol hydrochloride|
557343|NCT00001047|Drug|Clarithromycin|
557344|NCT00001047|Drug|Clofazimine|
557345|NCT00001047|Drug|Rifabutin|
557346|NCT00001046|Biological|MF59|
557347|NCT00001046|Biological|rgp120/HIV-1 SF-2|
557348|NCT00001045|Drug|Nevirapine|
557349|NCT00001045|Drug|Zidovudine|
557350|NCT00001045|Drug|Didanosine|
557351|NCT00001044|Biological|Aluminum hydroxide|
557352|NCT00001044|Biological|QS-21|
557353|NCT00001044|Biological|rgp120/HIV-1MN|
557354|NCT00001043|Biological|gp160 Vaccine (Immuno-AG)|
557355|NCT00001042|Biological|Aluminum hydroxide|
557356|NCT00001042|Biological|Lipid A, Monophosphoryl|
557357|NCT00001042|Biological|Lipid A, Liposome-encapsulated monophosphoryl|
557358|NCT00001042|Biological|Syntex adjuvant formulation|
557359|NCT00001042|Biological|MF59|
557360|NCT00001042|Biological|Threonyl Muramyl Dipeptide|
557361|NCT00001042|Biological|rgp120/HIV-1 SF-2|
557362|NCT00001042|Biological|MTP-PE/MF59|
557363|NCT00001041|Biological|rgp120/HIV-1MN|
557364|NCT00001040|Drug|Saquinavir|
557365|NCT00001040|Drug|Zidovudine|
557366|NCT00001040|Drug|Zalcitabine|
557367|NCT00001039|Drug|Ethambutol hydrochloride|
557368|NCT00001039|Drug|Clarithromycin|
557369|NCT00001038|Drug|Valacyclovir hydrochloride|
557370|NCT00001038|Drug|Acyclovir|
557371|NCT00001037|Biological|gp160 Vaccine (Immuno-AG)|
557372|NCT00001036|Drug|Thymalfasin|
557373|NCT00001036|Drug|Interleukin-2, Polyethylene Glycolated|
557374|NCT00001036|Drug|Zidovudine|
557375|NCT00001035|Drug|Interferon alfa-2b|
557376|NCT00001035|Drug|Zidovudine|
557377|NCT00001035|Drug|Zalcitabine|
557378|NCT00001035|Drug|Didanosine|
557379|NCT00001034|Drug|Ganciclovir|
557380|NCT00001033|Drug|Ethambutol hydrochloride|
557381|NCT00001033|Drug|Isoniazid|
557382|NCT00001033|Drug|Pyrazinamide|
557383|NCT00001033|Drug|Pyridoxine hydrochloride|
557384|NCT00001033|Drug|Levofloxacin|
557385|NCT00001033|Drug|Rifampin|
557386|NCT00001032|Drug|Zidovudine|
557387|NCT00001032|Drug|Zalcitabine|
557388|NCT00001031|Biological|rgp120/HIV-1MN|
557389|NCT00001031|Biological|rgp120/HIV-1 SF-2|
557390|NCT00001030|Drug|Clarithromycin|
557391|NCT00001030|Drug|Rifabutin|
557392|NCT00001029|Drug|Zidovudine|
557393|NCT00001029|Drug|Zalcitabine|
557394|NCT00001029|Drug|Didanosine|
557395|NCT00001028|Drug|Pentamidine isethionate|
557396|NCT00001028|Drug|Dapsone|
557397|NCT00001027|Drug|Pentamidine isethionate|
557398|NCT00001026|Biological|gp160 Vaccine (Immuno-AG)|
557399|NCT00001026|Biological|rgp120/HIV-1IIIB|
557400|NCT00001026|Biological|rgp120/HIV-1MN|
557401|NCT00001026|Biological|rgp120/HIV-1 SF-2|
557402|NCT00001026|Biological|HIVAC-1e|
557403|NCT00001025|Drug|Zidovudine|
557404|NCT00001025|Drug|Didanosine|
557405|NCT00001024|Drug|Zidovudine|
557406|NCT00001024|Drug|Didanosine|
557407|NCT00001023|Drug|Clarithromycin|
557408|NCT00001023|Drug|Azithromycin|
557409|NCT00001023|Drug|Rifabutin|
557410|NCT00001022|Drug|Zidovudine|
557411|NCT00001022|Drug|Zalcitabine|
557412|NCT00001022|Drug|Didanosine|
557413|NCT00001021|Biological|rgp120/HIV-1IIIB|
557414|NCT00001021|Biological|rgp120/HIV-1MN|
557415|NCT00001020|Biological|rgp120/HIV-1IIIB|
557416|NCT00001020|Biological|rgp120/HIV-1MN|
557417|NCT00001019|Biological|rgp120/HIV-1 SF-2|
557418|NCT00001019|Biological|MTP-PE/MF59|
557419|NCT00001018|Drug|Letrazuril|
557420|NCT00001017|Drug|Fluconazole|
557421|NCT00001017|Drug|Amphotericin B|
557422|NCT00001016|Drug|Trimetrexate glucuronate|
557423|NCT00001016|Drug|Leucovorin calcium|
557424|NCT00001015|Drug|Ribavirin|
557425|NCT00001014|Drug|Trimetrexate glucuronate|
557426|NCT00001014|Drug|Sulfamethoxazole-Trimethoprim|
557427|NCT00001014|Drug|Leucovorin calcium|
557428|NCT00001013|Drug|Trimetrexate glucuronate|
557429|NCT00001013|Drug|Pentamidine isethionate|
557430|NCT00001013|Drug|Sulfamethoxazole-Trimethoprim|
557431|NCT00001013|Drug|Leucovorin calcium|
557432|NCT00001012|Drug|AL 721|
557433|NCT00001011|Drug|Zidovudine|
557434|NCT00001010|Drug|Zidovudine|
557435|NCT00001010|Drug|Acyclovir|
557436|NCT00001009|Drug|Dextran sulfate|
557437|NCT00001008|Drug|Methadone hydrochloride|
557438|NCT00001008|Drug|Zidovudine|
557439|NCT00001007|Drug|Zidovudine|
557440|NCT00001006|Drug|AS-101|
557441|NCT00001005|Drug|Zidovudine|
557442|NCT00001005|Drug|Aldesleukin|
557443|NCT00001004|Drug|Tumor Necrosis Factor|
557444|NCT00001004|Drug|Interferon gamma-1b|
557445|NCT00001003|Drug|Pentamidine isethionate|
557446|NCT00001003|Drug|Zidovudine|
557447|NCT00001002|Drug|Zidovudine|
557448|NCT00001002|Drug|Foscarnet sodium|
557449|NCT00001001|Drug|Zidovudine|
557450|NCT00001000|Drug|Ampligen|
557451|NCT00000999|Drug|Zidovudine|
557452|NCT00000998|Drug|Trimetrexate glucuronate|
557453|NCT00000998|Drug|Leucovorin calcium|
557454|NCT00000997|Drug|Zalcitabine|
557455|NCT00000996|Drug|Doxorubicin hydrochloride|
557456|NCT00000995|Drug|Zidovudine|
557457|NCT00000995|Drug|Ganciclovir|
557458|NCT00000994|Drug|Zidovudine|
557459|NCT00000993|Drug|Zidovudine|
557460|NCT00000992|Drug|Itraconazole|
557461|NCT00000991|Drug|Pentamidine isethionate|
557462|NCT00000991|Drug|Sulfamethoxazole-Trimethoprim|
557463|NCT00000991|Drug|Dapsone|
557464|NCT00000991|Drug|Zidovudine|
557465|NCT00000990|Drug|Zidovudine|
557466|NCT00000989|Drug|Zidovudine|
557467|NCT00000989|Drug|Sargramostim|
557468|NCT00000989|Drug|Ganciclovir|
557469|NCT00000988|Drug|Stavudine|
557470|NCT00000987|Drug|Bleomycin sulfate|
557471|NCT00000987|Drug|Vincristine sulfate|
557472|NCT00000987|Drug|Doxorubicin hydrochloride|
557473|NCT00000987|Drug|Zidovudine|
557474|NCT00000986|Drug|Zidovudine|
557475|NCT00000986|Drug|Aldesleukin|
557476|NCT00000985|Drug|Vidarabine|
557477|NCT00000985|Drug|Acyclovir|
557478|NCT00000985|Drug|Foscarnet sodium|
557479|NCT00000984|Drug|CD4 Antigens|
557480|NCT00000983|Drug|Zidovudine|
557481|NCT00000982|Drug|Zidovudine|
557482|NCT00000982|Drug|Didanosine|
557483|NCT00000981|Drug|Fiacitabine|
557484|NCT00000980|Drug|Spiramycin|
557485|NCT00000979|Drug|Zidovudine|
557486|NCT00000979|Drug|Didanosine|
557487|NCT00000978|Drug|Zidovudine|
557488|NCT00000978|Drug|Zalcitabine|
557489|NCT00000977|Biological|gp160 Vaccine (MicroGeneSys)|
557490|NCT00000976|Drug|CD4-IgG|
557491|NCT00000976|Drug|Zidovudine|
557492|NCT00000975|Drug|Itraconazole|
557493|NCT00000974|Drug|Pentamidine isethionate|
557494|NCT00000973|Drug|Pyrimethamine|
557495|NCT00000973|Drug|Leucovorin calcium|
557496|NCT00000973|Drug|Zidovudine|
557497|NCT00000972|Biological|MTP-PE/MF59|
557498|NCT00000972|Biological|Env 2-3|
557499|NCT00000971|Drug|Clarithromycin|
557500|NCT00000971|Drug|Zidovudine|
557501|NCT00000971|Drug|Didanosine|
557502|NCT00000970|Drug|Foscarnet sodium|
557503|NCT00000970|Drug|Ganciclovir|
557504|NCT00000969|Drug|Zalcitabine|
557505|NCT00000969|Drug|Didanosine|
557506|NCT00000968|Biological|gp160 Vaccine (Immuno-AG)|
557507|NCT00000967|Drug|Interferon alfa-2a|
557508|NCT00000967|Drug|Zidovudine|
557509|NCT00000966|Drug|Azithromycin|
557510|NCT00000966|Drug|Pyrimethamine|
557511|NCT00000966|Drug|Leucovorin calcium|
557512|NCT00000965|Drug|Zidovudine|
557513|NCT00000964|Drug|Ranitidine hydrochloride|
557514|NCT00000964|Drug|Foscarnet sodium|
557515|NCT00000963|Drug|Didanosine|
557516|NCT00000962|Drug|Nevirapine|
557517|NCT00000961|Drug|Anti-HIV Immune Serum Globulin (Human)|
557518|NCT00000961|Drug|Zidovudine|
557519|NCT00000960|Drug|Zidovudine|
557520|NCT00000959|Drug|Isoniazid|
557521|NCT00000959|Drug|Pyridoxine hydrochloride|
557522|NCT00000958|Biological|MTP-PE/MF59|
557523|NCT00000958|Biological|Env 2-3|
557524|NCT00000957|Biological|gp160 Vaccine (Immuno-AG)|
557525|NCT00000956|Biological|gp160 Vaccine (MicroGeneSys)|
557526|NCT00000955|Drug|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
557527|NCT00000954|Drug|Bleomycin sulfate|
557528|NCT00000954|Drug|Vincristine sulfate|
557529|NCT00000954|Drug|Doxorubicin hydrochloride|
557530|NCT00000954|Drug|Zalcitabine|
557531|NCT00000954|Drug|Didanosine|
557532|NCT00000953|Drug|Sorivudine|
557533|NCT00000953|Drug|Acyclovir|
557534|NCT00000952|Drug|Ritonavir|
557535|NCT00000952|Drug|Lamivudine|
557536|NCT00000952|Drug|Zidovudine|
557537|NCT00000951|Drug|Fluconazole|
557538|NCT00000950|Drug|Ethambutol hydrochloride|
557539|NCT00000950|Drug|Isoniazid|
557540|NCT00000950|Drug|Pyrazinamide|
557541|NCT00000950|Drug|Pyridoxine hydrochloride|
557542|NCT00000950|Drug|Rifampin|
557543|NCT00000949|Drug|Aldesleukin|
557544|NCT00000948|Drug|Aldesleukin|Il-2
557545|NCT00000948|Drug|ART|antiretroviral therapy for the treatment of HIV
557546|NCT00000947|Drug|Azithromycin|
557547|NCT00000946|Biological|HIV p24/MF59 Vaccine|
557548|NCT00000946|Biological|ALVAC-HIV MN120TMG (vCP205)|
557549|NCT00000946|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
557550|NCT00000946|Biological|rgp120/HIV-1 SF-2|
557551|NCT00000945|Drug|Cidofovir|
557552|NCT00000945|Drug|Probenecid|
557553|NCT00000944|Drug|Indinavir sulfate|
557554|NCT00000944|Drug|Lamivudine|
557555|NCT00000944|Drug|Zidovudine|
557556|NCT00000943|Biological|Tetanus Toxoid Vaccine|
557557|NCT00000943|Biological|Hepatitis A Vaccine (Inactivated)|
557558|NCT00000943|Biological|HIV-1 Immunogen|
557559|NCT00000943|Biological|Hepatitis B Vaccine (Recombinant)|
557560|NCT00000942|Drug|Nevirapine|
557561|NCT00000941|Drug|Pravastatin sodium|
557562|NCT00000941|Drug|Simvastatin|
557563|NCT00000941|Drug|Atorvastatin calcium|
557564|NCT00000941|Drug|Ritonavir|
557565|NCT00000941|Drug|Nelfinavir mesylate|
557566|NCT00000941|Drug|Saquinavir|
557567|NCT00000940|Drug|Ritonavir|
557568|NCT00000940|Drug|Abacavir sulfate|
557569|NCT00000940|Drug|Amprenavir|
557570|NCT00000940|Drug|Lamivudine|
557571|NCT00000940|Drug|Stavudine|
557572|NCT00000939|Drug|Hydroxyurea|
557573|NCT00000939|Drug|Efavirenz|
557574|NCT00000939|Drug|Stavudine|
557575|NCT00000939|Drug|Didanosine|
557576|NCT00000938|Drug|ceftriaxone|
557577|NCT00000938|Drug|doxycycline|
557578|NCT00000937|Drug|Antibiotics|
557579|NCT00000936|Drug|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
557580|NCT00000936|Drug|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
557581|NCT00000936|Drug|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
557582|NCT00000935|Biological|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
557583|NCT00000931|Behavioral|Behavioral intervention|
557584|NCT00000931|Behavioral|Risk-reduction counseling|
557585|NCT00000929|Drug|Nonoxynol-9|
557586|NCT00000928|Behavioral|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
557587|NCT00000927|Drug|BufferGel|
557588|NCT00000926|Drug|Nonoxynol-9|
557589|NCT00000925|Drug|Optimune oral nutritional supplement|
557590|NCT00000924|Drug|Ritonavir|
557591|NCT00000924|Drug|Nelfinavir mesylate|
557592|NCT00000924|Drug|Nevirapine|
557593|NCT00000924|Drug|Stavudine|
557594|NCT00000924|Drug|Didanosine|
557595|NCT00000923|Drug|Indinavir sulfate|
557596|NCT00000923|Drug|Lamivudine|
557597|NCT00000923|Drug|Stavudine|
557598|NCT00000923|Drug|Zidovudine|
557599|NCT00000923|Drug|Didanosine|
557600|NCT00000923|Drug|Aldesleukin|
557601|NCT00000922|Drug|Indinavir sulfate|
557602|NCT00000922|Drug|Abacavir sulfate|
557603|NCT00000922|Drug|Nelfinavir mesylate|
557604|NCT00000922|Drug|Efavirenz|
557605|NCT00000922|Drug|Nevirapine|
557606|NCT00000922|Drug|Lamivudine|
557607|NCT00000922|Drug|Stavudine|
557608|NCT00000922|Drug|Didanosine|
557609|NCT00000921|Drug|Prednisone|
557610|NCT00000920|Drug|Ritonavir|
557611|NCT00000920|Drug|Saquinavir|
557612|NCT00000920|Drug|Lamivudine|
557613|NCT00000920|Drug|Zidovudine|
557614|NCT00000919|Drug|Indinavir sulfate|
557615|NCT00000919|Drug|Lamivudine/Zidovudine|
557616|NCT00000919|Drug|Ritonavir|
557617|NCT00000919|Drug|Hydroxyurea|
557618|NCT00000919|Drug|Abacavir sulfate|
557619|NCT00000919|Drug|Amprenavir|
557620|NCT00000919|Drug|Nelfinavir mesylate|
557621|NCT00000919|Drug|Efavirenz|
557622|NCT00000919|Drug|Lamivudine|
557623|NCT00000919|Drug|Stavudine|
557624|NCT00000919|Drug|Zidovudine|
557625|NCT00000919|Drug|Didanosine|
557626|NCT00000918|Drug|Indinavir sulfate|
557627|NCT00000918|Drug|Lamivudine/Zidovudine|
557628|NCT00000918|Drug|Ritonavir|
557629|NCT00000918|Drug|Amprenavir|
557630|NCT00000918|Drug|Efavirenz|
557631|NCT00000918|Drug|Saquinavir|
557632|NCT00000918|Drug|Lamivudine|
557633|NCT00000918|Drug|Stavudine|
557634|NCT00000918|Drug|Zidovudine|
557635|NCT00000918|Drug|Didanosine|
557636|NCT00000916|Drug|Indinavir sulfate|
557637|NCT00000916|Drug|Lamivudine/Zidovudine|
557638|NCT00000916|Drug|Hydroxyurea|
557639|NCT00000916|Drug|Lamivudine|
557640|NCT00000916|Drug|Stavudine|
557641|NCT00000916|Drug|Zidovudine|
557642|NCT00000916|Drug|Didanosine|
557643|NCT00000915|Behavioral|Vaccine preparedness|
557644|NCT00000914|Drug|Indinavir sulfate|
557645|NCT00000914|Drug|Ritonavir|
557646|NCT00000914|Drug|Nelfinavir mesylate|
557647|NCT00000914|Drug|Efavirenz|
557648|NCT00000913|Drug|Ritonavir|
557649|NCT00000913|Drug|Nelfinavir mesylate|
557650|NCT00000913|Drug|Saquinavir|
557651|NCT00000912|Drug|Indinavir sulfate|
557652|NCT00000912|Drug|Abacavir sulfate|
557653|NCT00000912|Drug|Amprenavir|
557654|NCT00000912|Drug|Nelfinavir mesylate|
557655|NCT00000912|Drug|Efavirenz|
557656|NCT00000912|Drug|Levocarnitine|
557657|NCT00000912|Drug|Adefovir dipivoxil|
557658|NCT00000912|Drug|Saquinavir|
557659|NCT00000909|Drug|Aldesleukin|
557660|NCT00000906|Drug|Ritonavir|
557661|NCT00000906|Drug|Saquinavir|
557662|NCT00000906|Drug|Methadone hydrochloride|
557663|NCT00000904|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
557664|NCT00000904|Biological|gp160 MN/LAI-2|
557665|NCT00000904|Biological|ALVAC(1)120(B,MN)GNP (vCP1433)|
557666|NCT00000904|Biological|ALVAC-HIV MN120TMG (vCP205)|
557667|NCT00000904|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
557668|NCT00000903|Drug|Indinavir sulfate|
557669|NCT00000903|Drug|Lamivudine/Zidovudine|
557670|NCT00000903|Drug|Nelfinavir mesylate|
557671|NCT00000903|Drug|Efavirenz|
557672|NCT00000902|Drug|Ritonavir|
557673|NCT00000902|Drug|Nelfinavir mesylate|
557674|NCT00000902|Drug|Nevirapine|
557675|NCT00000902|Drug|Lamivudine|
557676|NCT00000902|Drug|Stavudine|
557677|NCT00000902|Drug|Zidovudine|
557678|NCT00000902|Drug|Zalcitabine|
557679|NCT00000902|Drug|Didanosine|
557680|NCT00000901|Drug|Indinavir sulfate|
557681|NCT00000901|Drug|Lamivudine|
557682|NCT00000901|Drug|Stavudine|
557683|NCT00000899|Drug|Nelfinavir mesylate|
557684|NCT00000899|Drug|Lamivudine|
557685|NCT00000899|Drug|Filgrastim|
557686|NCT00000899|Drug|Stavudine|
557687|NCT00000899|Drug|Cyclophosphamide|
557688|NCT00000898|Drug|Ritonavir|
557689|NCT00000898|Drug|Nelfinavir mesylate|
557690|NCT00000898|Drug|Saquinavir|
557691|NCT00000897|Drug|Zidovudine|
557692|NCT00000896|Drug|Indinavir sulfate|
557693|NCT00000896|Drug|Lamivudine/Zidovudine|
557694|NCT00000896|Biological|Hepatitis A Vaccine (Inactivated)|
557695|NCT00000896|Drug|Interleukin-12|
557696|NCT00000896|Drug|Nevirapine|
557697|NCT00000896|Drug|Stavudine|
557698|NCT00000896|Drug|Sargramostim|
557699|NCT00000895|Drug|Nelfinavir mesylate|
557700|NCT00000895|Drug|Nevirapine|
557701|NCT00000895|Drug|Azithromycin|
557702|NCT00000894|Drug|Cidofovir|
557703|NCT00000894|Drug|Probenecid|
557704|NCT00000894|Drug|Ganciclovir|
557705|NCT00000893|Drug|Nelfinavir mesylate|
557706|NCT00000893|Drug|Efavirenz|
557707|NCT00000892|Drug|Ritonavir|
557708|NCT00000892|Drug|Nelfinavir mesylate|
557709|NCT00000892|Drug|Levocarnitine|
557710|NCT00000892|Drug|Adefovir dipivoxil|
557711|NCT00000892|Drug|Saquinavir|
557712|NCT00000892|Drug|Delavirdine mesylate|
557713|NCT00000891|Drug|Ritonavir|
557714|NCT00000891|Drug|Saquinavir|
557715|NCT00000891|Drug|Delavirdine mesylate|
557716|NCT00000891|Drug|Lamivudine|
557717|NCT00000891|Drug|Stavudine|
557718|NCT00000891|Drug|Zidovudine|
557719|NCT00000891|Drug|Didanosine|
557720|NCT00000889|Drug|Aldesleukin|
557721|NCT00000888|Drug|Ritonavir|
557722|NCT00000888|Drug|Lamivudine|
557723|NCT00000888|Drug|Zidovudine|
557724|NCT00000887|Drug|Nelfinavir mesylate|
557725|NCT00000887|Drug|Lamivudine|
557726|NCT00000887|Drug|Zidovudine|
557727|NCT00000886|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
557728|NCT00000885|Drug|Indinavir sulfate|
557729|NCT00000885|Drug|Abacavir sulfate|
557730|NCT00000885|Drug|Nelfinavir mesylate|
557731|NCT00000885|Drug|Efavirenz|
557732|NCT00000885|Drug|Levocarnitine|
557733|NCT00000885|Drug|Adefovir dipivoxil|
557734|NCT00000885|Drug|Lamivudine|
557735|NCT00000885|Drug|Stavudine|
557736|NCT00000885|Drug|Zidovudine|
557737|NCT00000885|Drug|Didanosine|
557738|NCT00000884|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
557739|NCT00000884|Biological|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
557740|NCT00000884|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
557741|NCT00000883|Drug|Azithromycin|
557742|NCT00000882|Drug|Indinavir sulfate|
557743|NCT00000882|Drug|Delavirdine mesylate|
557744|NCT00000882|Drug|Lamivudine|
557745|NCT00000882|Drug|Stavudine|
557746|NCT00000882|Drug|Zidovudine|
557747|NCT00000881|Drug|Cidofovir|
557748|NCT00000881|Drug|Probenecid|
557749|NCT00000880|Drug|Cyclosporine|
557750|NCT00000879|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
557751|NCT00000879|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
557752|NCT00000879|Biological|ALVAC-HIV MN120TMG (vCP205)|
557753|NCT00000878|Drug|Lamivudine|
557754|NCT00000878|Drug|Stavudine|
557755|NCT00000878|Drug|Zidovudine|
557756|NCT00000877|Drug|Indinavir sulfate|
557757|NCT00000877|Drug|Rifabutin|
557758|NCT00000876|Drug|CD4-IgG2|
557759|NCT00000875|Drug|Indinavir sulfate|
557760|NCT00000875|Drug|Diphenhydramine hydrochloride|
557761|NCT00000875|Drug|Lymphocytes, Activated|
557762|NCT00000875|Drug|Lamivudine|
557763|NCT00000875|Drug|Zidovudine|
557764|NCT00000875|Drug|Acetaminophen|
557765|NCT00000875|Drug|Aldesleukin|
557766|NCT00000873|Drug|Infant Formula|
557767|NCT00000872|Drug|Abacavir sulfate|
557768|NCT00000872|Drug|Nelfinavir mesylate|
557769|NCT00000872|Drug|Nevirapine|
557770|NCT00000872|Drug|Lamivudine|
557771|NCT00000872|Drug|Stavudine|
557772|NCT00000872|Drug|Zidovudine|
557773|NCT00000871|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
557774|NCT00000871|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
557775|NCT00000871|Biological|ALVAC-HIV MN120TMG (vCP205)|
557776|NCT00000871|Biological|rgp120/HIV-1 SF-2|
557777|NCT00000870|Drug|Indinavir sulfate|
557778|NCT00000870|Drug|Lamivudine|
557779|NCT00000870|Drug|Stavudine|
557780|NCT00000870|Drug|Zidovudine|
557781|NCT00000870|Drug|Didanosine|
557782|NCT00000870|Drug|Aldesleukin|
557783|NCT00000869|Drug|Nevirapine|
557784|NCT00000868|Biological|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
557785|NCT00000868|Biological|Aluminum hydroxide|
557786|NCT00000868|Biological|MF59|
557787|NCT00000868|Biological|rgp120/HIV-1MN|
557788|NCT00000867|Drug|Memantine|
557789|NCT00000866|Biological|MN rgp120/HIV-1|
557790|NCT00000866|Biological|TBC-3B Vaccine|
557791|NCT00000865|Drug|Abacavir sulfate|
557792|NCT00000865|Drug|Lamivudine|
557793|NCT00000865|Drug|Stavudine|
557794|NCT00000865|Drug|Zidovudine|
557795|NCT00000865|Drug|Didanosine|
557796|NCT00000864|Drug|Abacavir sulfate|
557797|NCT00000864|Drug|Zidovudine|
557798|NCT00000863|Drug|Sitamaquine|
557799|NCT00000862|Drug|Zidovudine|
557800|NCT00000861|Drug|Indinavir sulfate|
557801|NCT00000859|Drug|Indinavir sulfate|
557802|NCT00000859|Drug|Ritonavir|
557803|NCT00000859|Drug|Nelfinavir mesylate|
557804|NCT00000857|Drug|Interleukin-12|
557805|NCT00000856|Drug|Foscarnet sodium|
557806|NCT00000856|Drug|Ganciclovir|
557807|NCT00000855|Drug|Zidovudine|
557808|NCT00000854|Drug|Nandrolone decanoate|
557809|NCT00000853|Biological|rgp120/HIV-1MN|
557810|NCT00000852|Procedure|Allogeneic lymphocyte transfer|
557811|NCT00000851|Drug|Stavudine|
557812|NCT00000851|Drug|Didanosine|
557813|NCT00000850|Drug|Indinavir sulfate|
557814|NCT00000850|Drug|Sargramostim|
557815|NCT00000849|Drug|Aldesleukin|
557816|NCT00000848|Drug|Indinavir sulfate|
557817|NCT00000848|Drug|Saquinavir|
557818|NCT00000847|Biological|ALVAC-HIV MN120TMG (vCP205)|
557819|NCT00000847|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
557820|NCT00000847|Biological|rgp120/HIV-1 SF-2|
557821|NCT00000846|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
557822|NCT00000846|Biological|HIV-1 Peptide Immunogen, Multivalent|
557823|NCT00000845|Biological|P3C541b Lipopeptide|
557824|NCT00000844|Drug|Interferon alfa-n3|
557825|NCT00000844|Drug|Interferon alfa-n1|
557826|NCT00000843|Drug|Adefovir dipivoxil|
557827|NCT00000842|Drug|Nerve Growth Factor, Recombinant Human|
557828|NCT00000841|Drug|Indinavir sulfate|
557829|NCT00000841|Drug|Lamivudine|
557830|NCT00000841|Drug|Stavudine|
557831|NCT00000841|Drug|Zidovudine|
557832|NCT00000839|Drug|Didanosine|
557833|NCT00000838|Drug|Lamivudine|
557834|NCT00000838|Drug|Stavudine|
557835|NCT00000838|Drug|Zidovudine|
557836|NCT00000838|Drug|Didanosine|
557837|NCT00000837|Biological|Varicella Virus Vaccine (Live)|
557838|NCT00000836|Drug|Sevirumab|
557839|NCT00000834|Drug|Lamivudine|
557840|NCT00000834|Drug|Methotrexate|
557841|NCT00000834|Drug|Zidovudine|
557842|NCT00000833|Drug|Ribavirin|
557843|NCT00000833|Drug|Didanosine|
557844|NCT00000832|Biological|MF59|
557845|NCT00000832|Biological|rgp120/HIV-1 SF-2|
557846|NCT00000831|Drug|Lamivudine|
557847|NCT00000831|Drug|Stavudine|
557848|NCT00000831|Drug|Zidovudine|
557849|NCT00000831|Drug|Didanosine|
557850|NCT00000829|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
557851|NCT00000829|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
557852|NCT00000829|Biological|Placebo|Administered at 0, 2, 4, and 15 months of age
557853|NCT00000827|Drug|Anti-HIV Immune Serum Globulin (Human)|
557854|NCT00000826|Drug|Clarithromycin|
557855|NCT00000826|Drug|Rifabutin|
557856|NCT00000826|Drug|Sulfamethoxazole-Trimethoprim|
557857|NCT00000826|Drug|Dapsone|
557858|NCT00000826|Drug|Fluconazole|
557859|NCT00000825|Drug|Aldesleukin|
557860|NCT00000824|Drug|Lymphocytes, Activated|
557861|NCT00000823|Drug|Zidovudine|
557862|NCT00000823|Drug|Didanosine|
557863|NCT00000822|Drug|Ritonavir|
557864|NCT00000822|Biological|gp160 Vaccine (Immuno-AG)|
557865|NCT00000822|Drug|Stavudine|
557866|NCT00000822|Drug|Didanosine|
557867|NCT00000821|Drug|Aldesleukin|
557868|NCT00000820|Drug|Aldesleukin|
557869|NCT00000819|Drug|Prednisone|
557870|NCT00000818|Drug|Zidovudine|
557871|NCT00000817|Drug|Amitriptyline hydrochloride|75 mg oral tablet taken daily
557872|NCT00000817|Drug|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
557873|NCT00000817|Procedure|Point acupuncture|Standardized or alternate acupuncture procedure
557874|NCT00000816|Drug|Sulfamethoxazole-Trimethoprim|
557875|NCT00000815|Biological|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
557876|NCT00000815|Biological|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
557877|NCT00000814|Drug|Nevirapine|
557878|NCT00000814|Drug|Zidovudine|
557879|NCT00000814|Drug|Didanosine|
557880|NCT00000813|Biological|ALVAC-HIV gp160MN (vCP125)|
557881|NCT00000813|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
557882|NCT00000813|Biological|rgp120/HIV-1 SF-2|
557883|NCT00000812|Drug|Thalidomide|
557884|NCT00000811|Drug|Azithromycin|
557885|NCT00000811|Drug|Atovaquone|
557886|NCT00000811|Drug|Sulfamethoxazole-Trimethoprim|
557887|NCT00000810|Drug|Delavirdine mesylate|
557888|NCT00000810|Drug|Zidovudine|
557889|NCT00000810|Drug|Didanosine|
557890|NCT00000809|Biological|Aluminum hydroxide|
557891|NCT00000809|Biological|QS-21|
557892|NCT00000809|Biological|MN rsgp120/HIV-1|
557893|NCT00000808|Drug|Nevirapine|
557894|NCT00000807|Drug|Etoposide|
557895|NCT00000806|Drug|Telinavir|
557896|NCT00000805|Drug|Ganciclovir|
557897|NCT00000804|Drug|Indinavir sulfate|
557898|NCT00000803|Drug|Delavirdine mesylate|
557899|NCT00000803|Drug|Zidovudine|
557900|NCT00000803|Drug|Didanosine|
557901|NCT00000802|Drug|Atovaquone|
557902|NCT00000802|Drug|Dapsone|
557903|NCT00000801|Drug|Filgrastim|
557904|NCT00000801|Drug|Vincristine sulfate|
557905|NCT00000801|Drug|Doxorubicin hydrochloride|
557906|NCT00000801|Drug|Cyclophosphamide|
557907|NCT00000801|Drug|Cytarabine|
557908|NCT00000801|Drug|Dexamethasone|
557909|NCT00000800|Drug|Methadone hydrochloride|
557910|NCT00000800|Drug|Zidovudine|
557911|NCT00000799|Drug|Cidofovir|
557912|NCT00000799|Drug|Probenecid|
557913|NCT00000798|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
557914|NCT00000796|Drug|Cycloserine|
557915|NCT00000796|Drug|Ethionamide|
557916|NCT00000796|Drug|Capreomycin sulfate|
557917|NCT00000796|Drug|Aminosalicylic acid|
557918|NCT00000796|Drug|Streptomycin sulfate|
557919|NCT00000796|Drug|Ethambutol hydrochloride|
557920|NCT00000796|Drug|Amikacin sulfate|
557921|NCT00000796|Drug|Isoniazid|
557922|NCT00000796|Drug|Pyrazinamide|
557923|NCT00000796|Drug|Pyridoxine hydrochloride|
557924|NCT00000796|Drug|Levofloxacin|
557925|NCT00000796|Drug|Rifampin|
557926|NCT00000796|Drug|Clofazimine|
557927|NCT00000795|Biological|HIV-1 Peptide Immunogen, Multivalent|
557928|NCT00000794|Drug|Sulfadiazine|
557929|NCT00000794|Drug|Clarithromycin|
557930|NCT00000794|Drug|Atovaquone|
557931|NCT00000794|Drug|Pyrimethamine|
557932|NCT00000794|Drug|Leucovorin calcium|
557933|NCT00000793|Drug|Mexiletine hydrochloride|
557934|NCT00000793|Drug|Benztropine mesylate|
557935|NCT00000793|Drug|Amitriptyline hydrochloride|
557936|NCT00000792|Drug|Hypericin|
557937|NCT00000791|Drug|Glycovir|
557938|NCT00000791|Drug|Zidovudine|
557939|NCT00000790|Drug|Thalidomide|
557940|NCT00000789|Drug|Stavudine|
557941|NCT00000789|Drug|Zidovudine|
557942|NCT00000788|Drug|Methadone hydrochloride|
557943|NCT00000788|Drug|Fluconazole|
557944|NCT00000787|Behavioral|Pre- and post-test counseling|
557945|NCT00000782|Biological|gp160 Vaccine (Immuno-AG)|
557946|NCT00000782|Biological|gp160 Vaccine (MicroGeneSys)|
557947|NCT00000781|Drug|Nevirapine|
557948|NCT00000781|Drug|Zidovudine|
557949|NCT00000781|Drug|Zalcitabine|
557950|NCT00000781|Drug|Didanosine|
557951|NCT00000779|Biological|Aluminum hydroxide|
557952|NCT00000779|Biological|MF59|
557953|NCT00000779|Biological|rgp120/HIV-1IIIB|
557954|NCT00000779|Biological|rgp120/HIV-1MN|
557955|NCT00000779|Biological|rgp120/HIV-1 SF-2|
557956|NCT00000779|Biological|Env 2-3|
557957|NCT00000778|Drug|Isoniazid|
557958|NCT00000778|Drug|Pyridoxine hydrochloride|
557959|NCT00000778|Drug|Levofloxacin|
557960|NCT00000777|Biological|gp160 Vaccine (MicroGeneSys)|
557961|NCT00000776|Drug|Flucytosine|
557962|NCT00000776|Drug|Fluconazole|
557963|NCT00000776|Drug|Amphotericin B|
557964|NCT00000776|Drug|Dexamethasone|
557965|NCT00000775|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
557966|NCT00000774|Biological|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
557967|NCT00000774|Biological|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
557968|NCT00000774|Biological|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
557969|NCT00000774|Biological|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
557970|NCT00000773|Drug|Atovaquone|
557971|NCT00000772|Drug|Ribavirin|
557972|NCT00000772|Drug|Didanosine|
557973|NCT00000771|Drug|Paromomycin sulfate|
557974|NCT00000770|Drug|Nevirapine|
557975|NCT00000770|Drug|Zidovudine|
557976|NCT00000770|Drug|Didanosine|
557977|NCT00000769|Drug|Interleukin-4|
557978|NCT00000768|Drug|Glutamic acid hydrochloride|
557979|NCT00000768|Drug|Ganciclovir|
557980|NCT00000767|Biological|TBC-3B Vaccine|
557981|NCT00000767|Biological|Smallpox Vaccine|
557982|NCT00000766|Drug|Foscarnet sodium|
557983|NCT00000766|Drug|Ganciclovir|
557984|NCT00000765|Drug|Zidovudine|
557985|NCT00000764|Drug|Isotretinoin|
557986|NCT00000764|Drug|Interferon alfa-2a|
557987|NCT00000763|Drug|TNP-470|
557988|NCT00000762|Biological|rgp120/HIV-1MN|
557989|NCT00000762|Biological|rgp120/HIV-1 SF-2|
557990|NCT00000762|Biological|gp160 Vaccine (MicroGeneSys)|
557991|NCT00000761|Drug|Interferon gamma-1b|
557992|NCT00000760|Drug|Ro 24-7429|
557993|NCT00000760|Drug|Zidovudine|
557994|NCT00000760|Drug|Didanosine|
557995|NCT00000758|Drug|Fluorouracil|
557996|NCT00000757|Biological|gp160 Vaccine (MicroGeneSys)|
557997|NCT00000756|Drug|Lymphocytes, Activated|
557998|NCT00000755|Biological|rgp120/HIV-1MN|
557999|NCT00000755|Drug|Zidovudine|
558000|NCT00000754|Drug|Interferon alfa-2a|
558001|NCT00000754|Drug|Zidovudine|
558002|NCT00000754|Drug|Zalcitabine|
558003|NCT00000753|Drug|Atevirdine mesylate|
558004|NCT00000753|Drug|Zidovudine|
558005|NCT00000753|Drug|Zalcitabine|
558006|NCT00000753|Drug|Didanosine|
558007|NCT00000752|Drug|Pseudoephedrine hydrochloride|
558008|NCT00000752|Drug|Guaifenesin|
558009|NCT00000752|Drug|Cefuroxime axetil|
558010|NCT00000752|Drug|Beclomethasone dipropionate|
558011|NCT00000751|Drug|Anti-HIV Immune Serum Globulin (Human)|
558012|NCT00000751|Drug|Globulin, Immune|
558013|NCT00000751|Drug|Zidovudine|
558014|NCT00000750|Drug|Zidovudine|
558015|NCT00000749|Biological|rgp120/HIV-1 SF-2|
558016|NCT00000748|Drug|Sulfamethoxazole-Trimethoprim|
558017|NCT00000747|Drug|Nevirapine|
558018|NCT00000746|Biological|rgp120/HIV-1 SF-2|
558019|NCT00000746|Biological|Env 2-3|
558020|NCT00000746|Biological|HIVAC-1e|
558021|NCT00000746|Biological|gp160 Vaccine (MicroGeneSys)|
558022|NCT00000745|Biological|Hepatitis B Vaccine (Recombinant)|
558023|NCT00000745|Biological|gp160 Vaccine (MicroGeneSys)|
558024|NCT00000744|Drug|Fluconazole|
558025|NCT00000743|Drug|Alvircept sudotox|
558026|NCT00000743|Drug|Zidovudine|
558027|NCT00000742|Drug|Atevirdine mesylate|
558028|NCT00000742|Drug|Zidovudine|
558029|NCT00000742|Drug|Didanosine|
558030|NCT00000741|Drug|Methylprednisolone|
558031|NCT00000740|Drug|Sitamaquine|
558032|NCT00000739|Drug|Dapsone|
558033|NCT00000738|Drug|Nimodipine|
558034|NCT00000738|Drug|Zidovudine|
558035|NCT00000737|Drug|Dronabinol|
558036|NCT00000737|Drug|Megestrol acetate|
558037|NCT00000736|Drug|Zidovudine|
558038|NCT00000735|Drug|Ampligen|
558039|NCT00000734|Drug|Sulfamethoxazole-Trimethoprim|
558040|NCT00000734|Drug|Zidovudine|
558041|NCT00000733|Drug|Ribavirin|
558042|NCT00000732|Drug|Sulfamethoxazole-Trimethoprim|
558043|NCT00000732|Drug|Zidovudine|
558044|NCT00000731|Drug|Zidovudine|
558045|NCT00000731|Drug|Acetaminophen|
558046|NCT00000730|Drug|Trimetrexate glucuronate|
558047|NCT00000730|Drug|Methylprednisolone|
558048|NCT00000730|Drug|Pentamidine isethionate|
558049|NCT00000730|Drug|Sulfamethoxazole-Trimethoprim|
558050|NCT00000730|Drug|Leucovorin calcium|
558051|NCT00000729|Drug|Foscarnet sodium|
558052|NCT00000728|Drug|Zidovudine|
558053|NCT00000728|Drug|Aldesleukin|
558054|NCT00000727|Drug|Pentamidine isethionate|
558055|NCT00000727|Drug|Pyrimethamine|
558056|NCT00000727|Drug|Sulfamethoxazole/Trimethoprim|
558057|NCT00000727|Drug|Sulfadoxine/Pyrimethamine|
558058|NCT00000727|Drug|Zidovudine|
558059|NCT00000726|Drug|Foscarnet sodium|
558060|NCT00000725|Drug|Interferon alfa-2a|
558061|NCT00000725|Drug|Zidovudine|
558062|NCT00000725|Drug|Interferon alfa-n1|
558063|NCT00000724|Drug|Trimetrexate glucuronate|
558064|NCT00000724|Drug|Leucovorin calcium|
558065|NCT00000723|Drug|Methotrexate|
558066|NCT00000723|Drug|Leucovorin calcium|
558067|NCT00000723|Drug|Zidovudine|
558068|NCT00000723|Drug|Dexamethasone|
558069|NCT00000722|Drug|Pentamidine isethionate|
558070|NCT00000721|Drug|CD4 Antigens|
558071|NCT00000720|Drug|Globulin, Immune|
558072|NCT00000720|Drug|Zidovudine|
558073|NCT00000719|Drug|Zidovudine|
558074|NCT00000719|Drug|Zalcitabine|
558075|NCT00000718|Drug|Zidovudine|
558076|NCT00000718|Drug|Zalcitabine|
558077|NCT00000717|Drug|Primaquine|
558078|NCT00000717|Drug|Clindamycin|
558079|NCT00000716|Drug|Zidovudine|
558080|NCT00000715|Drug|Pentamidine isethionate|
558081|NCT00000715|Drug|Sulfamethoxazole-Trimethoprim|
558082|NCT00000714|Drug|Trimetrexate glucuronate|
558083|NCT00000714|Drug|Leucovorin calcium|
558084|NCT00000713|Drug|Ampligen|
558085|NCT00000712|Drug|Zidovudine|
558086|NCT00000712|Drug|Acyclovir|
558087|NCT00000711|Drug|Zidovudine|
558088|NCT00000711|Drug|Sargramostim|
558089|NCT00000710|Drug|Didanosine|
558090|NCT00000709|Drug|Zidovudine|
558091|NCT00000708|Drug|Flucytosine|
558092|NCT00000708|Drug|Fluconazole|
558093|NCT00000708|Drug|Amphotericin B|
558094|NCT00000707|Drug|Pentamidine isethionate|
558095|NCT00000706|Drug|Quinine sulfate|
558096|NCT00000706|Drug|Probenecid|
558097|NCT00000706|Drug|Zidovudine|
558098|NCT00000705|Drug|Zidovudine|
558099|NCT00000704|Drug|Zalcitabine|
558100|NCT00000703|Drug|Bleomycin sulfate|
558101|NCT00000703|Drug|Vincristine sulfate|
558102|NCT00000703|Drug|Doxorubicin hydrochloride|
558103|NCT00000703|Drug|Cyclophosphamide|
558104|NCT00000703|Drug|Allopurinol|
558105|NCT00000703|Drug|Methotrexate|
558106|NCT00000703|Drug|Cytarabine|
558107|NCT00000703|Drug|Leucovorin calcium|
558108|NCT00000703|Drug|Zidovudine|
558109|NCT00000703|Drug|Dexamethasone|
558110|NCT00000702|Drug|Zidovudine|
558111|NCT00000701|Drug|Zidovudine|
558112|NCT00000700|Drug|Zidovudine|
558113|NCT00000699|Drug|Inosine pranobex|
558114|NCT00000699|Drug|Ribavirin|
558115|NCT00000698|Drug|Ganciclovir|
558116|NCT00000697|Drug|Foscarnet sodium|
558117|NCT00000696|Drug|Interferon alfa-2a|
558118|NCT00000696|Drug|Zidovudine|
558119|NCT00000695|Drug|Interferon beta-1b|
558120|NCT00000695|Drug|Zidovudine|
558121|NCT00000694|Drug|Interferon alfa-2b|
558122|NCT00000694|Drug|Zidovudine|
558123|NCT00000694|Drug|Sargramostim|
558124|NCT00000693|Drug|Zidovudine|
558125|NCT00000693|Drug|Acyclovir|
558126|NCT00000692|Drug|Butyldeoxynojirimycin|
558127|NCT00000691|Drug|Foscarnet sodium|
558128|NCT00000690|Drug|Dextran sulfate|
558129|NCT00000689|Drug|Bleomycin sulfate|
558130|NCT00000689|Drug|Vincristine sulfate|
558131|NCT00000689|Drug|Doxorubicin hydrochloride|
558132|NCT00000689|Drug|Cyclophosphamide|
558133|NCT00000689|Drug|Methotrexate|
558134|NCT00000689|Drug|Cytarabine|
558135|NCT00000689|Drug|Leucovorin calcium|
558136|NCT00000689|Drug|Sargramostim|
558137|NCT00000689|Drug|Dexamethasone|
558138|NCT00000688|Drug|Ganciclovir|
558139|NCT00000687|Drug|Interferon alfa-2a|
558140|NCT00000687|Drug|Zidovudine|
558141|NCT00000686|Drug|Stavudine|
558142|NCT00000685|Drug|Zidovudine|
558143|NCT00000684|Drug|Dextran sulfate|
558144|NCT00000683|Biological|HIVAC-1e|
558145|NCT00000683|Biological|gp160 Vaccine (MicroGeneSys)|
558146|NCT00000682|Drug|Zidovudine|
558147|NCT00000682|Drug|Zalcitabine|
558148|NCT00000681|Drug|Bleomycin sulfate|
558149|NCT00000681|Drug|Vincristine sulfate|
558150|NCT00000681|Drug|Doxorubicin hydrochloride|
558151|NCT00000681|Drug|Zidovudine|
558152|NCT00000681|Drug|Sargramostim|
558153|NCT00000680|Drug|Zidovudine|
558154|NCT00000680|Drug|Aldesleukin|
558155|NCT00000679|Drug|Zidovudine|
558156|NCT00000679|Drug|Zalcitabine|
558157|NCT00000678|Drug|Zidovudine|
558158|NCT00000678|Drug|Zalcitabine|
558159|NCT00000677|Drug|SCH 39304|
558160|NCT00000676|Drug|Clotrimazole|
558161|NCT00000676|Drug|Fluconazole|
558162|NCT00000675|Drug|CD4-IgG|
558163|NCT00000674|Drug|Pyrimethamine|
558164|NCT00000674|Drug|Leucovorin calcium|
558165|NCT00000674|Drug|Clindamycin|
558166|NCT00000673|Drug|Ganciclovir|
558167|NCT00000672|Drug|Didanosine|
558168|NCT00000671|Drug|Zidovudine|
558169|NCT00000671|Drug|Didanosine|
558170|NCT00000670|Drug|Probenecid|
558171|NCT00000670|Drug|Zidovudine|
558172|NCT00000669|Drug|Didanosine|
558173|NCT00000668|Drug|Ganciclovir|
558174|NCT00000667|Biological|gp160 Vaccine (MicroGeneSys)|
558175|NCT00000666|Drug|Pyrimethamine|
558176|NCT00000665|Drug|Foscarnet sodium|
558177|NCT00000665|Drug|Ganciclovir|
558178|NCT00000664|Drug|Interleukin-2, Polyethylene Glycolated|
558179|NCT00000664|Drug|Zidovudine|
558180|NCT00000663|Drug|CD4-IgG|
558181|NCT00000662|Drug|Zidovudine|
558182|NCT00000661|Drug|Oxazepam|
558183|NCT00000661|Drug|Zidovudine|
558184|NCT00000660|Drug|Etoposide|
558185|NCT00000659|Drug|CD4 Antigens|
558186|NCT00000659|Drug|Zidovudine|
558187|NCT00000658|Drug|Bleomycin sulfate|
558188|NCT00000658|Drug|Vincristine sulfate|
558189|NCT00000658|Drug|Doxorubicin hydrochloride|
558190|NCT00000658|Drug|Cyclophosphamide|
558191|NCT00000658|Drug|Allopurinol|
558192|NCT00000658|Drug|Methotrexate|
558193|NCT00000658|Drug|Cytarabine|
558194|NCT00000658|Drug|Leucovorin calcium|
558195|NCT00000658|Drug|Sargramostim|
558196|NCT00000658|Drug|Dexamethasone|
558197|NCT00000657|Drug|Zidovudine|
558198|NCT00000657|Drug|Didanosine|
558199|NCT00000656|Drug|Zidovudine|
558200|NCT00000656|Drug|Didanosine|
558201|NCT00000655|Drug|Atovaquone|
558202|NCT00000655|Drug|Sulfamethoxazole-Trimethoprim|
558203|NCT00000654|Drug|Fialuridine|
558204|NCT00000653|Drug|Zalcitabine|
558205|NCT00000652|Drug|Zidovudine|
558206|NCT00000652|Drug|Didanosine|
558207|NCT00000651|Drug|Zidovudine|
558208|NCT00000651|Drug|Zalcitabine|
558209|NCT00000650|Drug|Ditiocarb sodium|
558210|NCT00000649|Drug|Nevirapine|
558211|NCT00000649|Drug|Zidovudine|
558212|NCT00000648|Drug|Penicillin G potassium|
558213|NCT00000648|Drug|Ceftriaxone sodium|
558214|NCT00000647|Drug|CD4-IgG|
558215|NCT00000647|Drug|Zidovudine|
558216|NCT00000647|Drug|Interferon alfa-n1|
558217|NCT00000647|Procedure|Peripheral lymphocyte infusion|
558218|NCT00000647|Procedure|Bone marrow transplant|
558219|NCT00000646|Drug|Pentoxifylline|
558220|NCT00000645|Drug|Hypericin|
558221|NCT00000644|Drug|Clarithromycin|
558222|NCT00000643|Drug|Pyrimethamine|
558223|NCT00000643|Drug|Leucovorin calcium|
558224|NCT00000642|Drug|CD4-IgG|
558225|NCT00000641|Drug|Ciprofloxacin hydrochloride|
558226|NCT00000641|Drug|Ethambutol hydrochloride|
558227|NCT00000641|Drug|Amikacin sulfate|
558228|NCT00000641|Drug|Azithromycin|
558229|NCT00000641|Drug|Rifampin|
558230|NCT00000641|Drug|Clofazimine|
558231|NCT00000640|Drug|Primaquine|
558232|NCT00000640|Drug|Sulfamethoxazole-Trimethoprim|
558233|NCT00000640|Drug|Dapsone|
558234|NCT00000640|Drug|Clindamycin|
558235|NCT00000639|Drug|Itraconazole|
558236|NCT00000639|Drug|Flucytosine|
558237|NCT00000639|Drug|Fluconazole|
558238|NCT00000639|Drug|Amphotericin B|
558239|NCT00000638|Drug|Isoniazid|
558240|NCT00000638|Drug|Pyrazinamide|
558241|NCT00000638|Drug|Pyridoxine hydrochloride|
558242|NCT00000638|Drug|Rifampin|
558243|NCT00000637|Drug|Zidovudine|
558244|NCT00000637|Drug|Didanosine|
558245|NCT00000636|Drug|Isoniazid|
558246|NCT00000636|Drug|Pyrazinamide|
558247|NCT00000636|Drug|Pyridoxine hydrochloride|
558248|NCT00000636|Drug|Rifampin|
558249|NCT00000635|Drug|Trifluridine|
558250|NCT00000635|Drug|Bacitracin zinc/Polymyxin B sulfate|
558251|NCT00000634|Drug|Nevirapine|
558252|NCT00000633|Biological|gp160 Vaccine (Immuno-AG)|
558253|NCT00000633|Biological|Hepatitis B Vaccine (Recombinant)|
558254|NCT00000632|Biological|Env 2-3|
558255|NCT00000631|Biological|HIVAC-1e|
558256|NCT00000631|Biological|gp160 Vaccine (MicroGeneSys)|
558257|NCT00000630|Biological|HIVAC-1e|
558258|NCT00000630|Biological|gp160 Vaccine (MicroGeneSys)|
558259|NCT00000629|Drug|Valproic acid|
558260|NCT00000629|Drug|Zidovudine|
558261|NCT00000628|Drug|L-697,661|
558262|NCT00000628|Drug|Zidovudine|
558263|NCT00000627|Drug|Fluconazole|
558264|NCT00000626|Drug|Vinblastine sulfate|
558265|NCT00000626|Drug|Dacarbazine|
558266|NCT00000626|Drug|Filgrastim|
558267|NCT00000626|Drug|Bleomycin sulfate|
558268|NCT00000626|Drug|Doxorubicin hydrochloride|
558269|NCT00000625|Drug|Zidovudine|
558270|NCT00000625|Drug|Zalcitabine|
558271|NCT00000625|Drug|Didanosine|
558272|NCT00023192|Drug|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
558273|NCT00023166|Drug|PEG-paclitaxel|
558274|NCT00023153|Drug|Adefovir Dipivoxil|
558275|NCT00023127|Procedure|Integrated Pest Management|
558276|NCT00022971|Biological|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
558277|NCT00022971|Biological|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
558278|NCT00022958|Drug|Iodine-131 Anti-B1 Antibody|
558279|NCT00022945|Drug|Iodine-131 Anti-B1 Antibody|
558280|NCT00022945|Drug|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)|
558281|NCT00022932|Drug|Iodine-131 Anti-B1 Antibody|
558282|NCT00022906|Drug|Iodine-131 Anti-B1 Antibody|
558283|NCT00022893|Drug|Iodine-131 Anti-B1 Antibody|
558284|NCT00022880|Drug|Iodine-131 Anti-B1 Antibody|
558285|NCT00022867|Drug|Nondigestible oligosaccharide (NDO)|
558286|NCT00022854|Procedure|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
558287|NCT00022854|Procedure|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
558288|NCT00022854|Procedure|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
558289|NCT00022841|Drug|Pamidronate|
558290|NCT00022828|Device|3-D Laser Imaging Device|
558291|NCT00022815|Device|Tissue ultrafiltration|
558292|NCT00022802|Device|Image-guided surgical system|
558293|NCT00022776|Procedure|Surgical decompression|Simple decompression not requiring fusion.
558294|NCT00022776|Procedure|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
558295|NCT00022750|Behavioral|Nurse Case Manager and Community Health Worker Team|
558296|NCT00021866|Behavioral|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
558297|NCT00021866|Behavioral|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
558298|NCT00021853|Behavioral|constraint-induced movement therapy|
558299|NCT00021827|Drug|Parathyroid hormone-related protein or ''PTHrP''|
558300|NCT00021814|Drug|Doxazosin|
558301|NCT00021814|Drug|Finasteride|
558302|NCT00021814|Drug|Doxazosin placebo|
558303|NCT00021814|Drug|Finasteride placebo|
558304|NCT00021801|Procedure|Islet Cell Transplantation|
558305|NCT00021788|Procedure|islet cell transplantation|
558306|NCT00021749|Drug|Oblimerson sodium, G3139|
558307|NCT00021736|Drug|EYE001 anti-VEGF aptamer|
558308|NCT00021723|Biological|AN-1792 also known as AIP-001|
558309|NCT00021697|Drug|AVP-923|
558310|NCT00021658|Procedure|Pesticide application procedures|
558311|NCT00021645|Drug|Vitamin E|
558312|NCT00021580|Procedure|human cadaveric islet cell transplantation|
558313|NCT00021567|Drug|Interferon Gamma for Aerosol|
558314|NCT00021541|Drug|tipifarnib|Given orally, 200 mg/m^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
558315|NCT00021541|Other|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
558316|NCT00021528|Drug|citalopram|
558317|NCT00021528|Drug|BuproprionSR|
558318|NCT00021528|Drug|buspirone|
558319|NCT00021528|Drug|Lithium|
558320|NCT00021528|Drug|mirtazapine|
558321|NCT00021528|Drug|nortriptyline|
558322|NCT00021528|Drug|sertraline|
558323|NCT00021528|Drug|tranylcypromine|
558324|NCT00021528|Drug|VenlafaxineXR|
558325|NCT00021528|Behavioral|Cognitive Therapy|
558326|NCT00021528|Drug|T3 (Triiodothyronine)|
558327|NCT00021502|Drug|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
558328|NCT00021476|Behavioral|Behavioral treatments|
558329|NCT00021476|Behavioral|Physical therapy|
558330|NCT00018902|Drug|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
558331|NCT00018902|Drug|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
558332|NCT00018902|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
558333|NCT00018902|Drug|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
558334|NCT00018876|Procedure|Lumbar nerve root decompression|
558335|NCT00018876|Procedure|Preoperative low-dose external beam radiation|
558336|NCT00018863|Drug|Methylphenidate|
558337|NCT00018850|Drug|ondansetron|
558338|NCT00018850|Behavioral|neuropsychological testing|
558339|NCT00018850|Drug|nicotine|
558340|NCT00018850|Drug|haloperidol|
558341|NCT00018837|Behavioral|Community Re-Entry Program: What is Schizophrenia|
558342|NCT00018824|Drug|NALTREXONE|
558343|NCT00018824|Drug|Placebo|
558344|NCT00018811|Behavioral|Relaxation training & thermal biofeedback|
558345|NCT00018811|Behavioral|Surface EMG biofeedback|
558346|NCT00018785|Procedure|donor bone marrow infusion|
558347|NCT00018759|Drug|paroxetine|
558348|NCT00018759|Behavioral|ongoing psychological screening|
558349|NCT00018746|Device|repetitive transcranial magnetic stimulation|
558350|NCT00018733|Drug|paroxetine|
558351|NCT00018733|Drug|Desipramine|
558352|NCT00018694|Drug|Chenodeoxycholic Acid|
558353|NCT00018668|Drug|Risperidone|
558354|NCT00018668|Drug|Olanzapine|
558355|NCT00018668|Drug|Quetiapine|
558356|NCT00018655|Behavioral|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
558357|NCT00018655|Behavioral|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
558358|NCT00018642|Drug|quetiapine|
558359|NCT00018642|Drug|haloperidol decanoate|
558360|NCT00018616|Behavioral|MEMS caps|
558361|NCT00018603|Drug|guanfacine|
558362|NCT00018564|Drug|treatments for essential tremor|
558363|NCT00018551|Drug|Folic Acid|
558364|NCT00018538|Drug|calcifidiol|
558365|NCT00018525|Procedure|Lung Volume Reduction Surgery|
558366|NCT00018512|Procedure|Implant-supported denture|
558367|NCT00018460|Drug|Vitamin B|
558368|NCT00018447|Drug|PTH 1-34|
558369|NCT00018447|Drug|MFPSR-fluoride|
558370|NCT00018421|Procedure|Treadmill Exercise|
558371|NCT00018382|Drug|rosiglitazone|
558372|NCT00018356|Procedure|exercise|
558373|NCT00018356|Drug|testosterone|
558374|NCT00018343|Drug|estrogen|
558375|NCT00018330|Behavioral|Weight Loss|
558376|NCT00018317|Behavioral|low protein diet|
558377|NCT00018317|Behavioral|resistance training|
558378|NCT00018317|Behavioral|combination of diet control and exercise|
558379|NCT00018291|Drug|Risperidone|
558380|NCT00018291|Drug|Gabapentin|
558381|NCT00018278|Drug|Aricept|
558382|NCT00018278|Drug|Exelon|
558383|NCT00018278|Drug|Nicoderm Patch|
558384|NCT00018265|Behavioral|Task specific endurance training|
558385|NCT00018265|Behavioral|Tai Chi|
558386|NCT00018252|Behavioral|exercise|
558387|NCT00018239|Procedure|Exercise|
558388|NCT00018226|Behavioral|Case Management|
558389|NCT00018213|Drug|Naltrexone Hydrochloride|
558390|NCT00018213|Drug|Transdermal Nicotine|
558391|NCT00018200|Drug|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
558392|NCT00018200|Drug|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
558393|NCT00018200|Drug|Benztropine|Daily dose 0.125 to 0.5mg
558394|NCT00018187|Drug|Bupropion|
558395|NCT00018187|Drug|Mecamylamine|
558396|NCT00018187|Drug|Nicotine Patch|
558397|NCT00018174|Drug|Fluoxetine|
558398|NCT00018174|Behavioral|Behavioral group smoking cessation treatment|
558399|NCT00018174|Drug|Placebo|
558400|NCT00018161|Drug|Mecamylamine|
558401|NCT00018161|Drug|Nicotine Patch|
558402|NCT00018161|Behavioral|Cigarette brand switching|
558403|NCT00018148|Drug|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
558404|NCT00018148|Drug|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
558405|NCT00018135|Drug|calcium acetate|
558406|NCT00018135|Drug|aluminum hydroxide|
558407|NCT00018135|Drug|Sevelamer|
558408|NCT00018109|Drug|glutamine|
558409|NCT00018109|Drug|creatine monohydrate|
558410|NCT00018096|Biological|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
558411|NCT00018083|Drug|rifabutin|
558412|NCT00018083|Drug|isoniazid|
558413|NCT00018083|Drug|efavirenz|
558414|NCT00018070|Procedure|Angiography|
558415|NCT00018070|Procedure|Laser Treatment|
558416|NCT00018031|Drug|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
558417|NCT00018031|Drug|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
558418|NCT00018018|Drug|CD34+ cells transduced with ADA retrovir|
558419|NCT00018005|Behavioral|Self-Management|18 in-person group sessions providing self-management training.
558420|NCT00018005|Other|attention control|18 educational mailings follow by a a telephone call.
558421|NCT00017940|Genetic|Human Nerve Growth Factor|
558422|NCT00017953|Behavioral|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
558423|NCT00017953|Behavioral|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
558424|NCT00017927|Drug|Pegvisomant|
558425|NCT00017823|Procedure|Acupressure|
558426|NCT00017810|Behavioral|Dietary intervention|
558427|NCT00017706|Behavioral|physician-delivered weight control|
558428|NCT00016835|Procedure|Supra-gingival scaling and placebo|Included in arm/group description.
558429|NCT00016835|Procedure|Subgingival scaling and metronidazole|Included in arm/group description.
558430|NCT00016835|Procedure|Subgingival scaling and doxycycline|Included in arm/group description.
558431|NCT00017680|Drug|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
558432|NCT00017680|Procedure|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
558433|NCT00017654|Drug|anti-thymocyte globulin|
558434|NCT00017654|Drug|cyclophosphamide|
558435|NCT00017654|Drug|cyclosporine|
558436|NCT00017654|Drug|methylprednisolone|
558437|NCT00017654|Procedure|Allogeneic Bone Marrow Transplantation|
558438|NCT00017641|Drug|anti-thymocyte globulin|
558439|NCT00017641|Drug|cyclophosphamide|
558440|NCT00017641|Drug|filgrastim|
558441|NCT00017641|Procedure|CD34+ Peripheral Blood Stem Cell Reinfusion|
558442|NCT00017628|Drug|cyclophosphamide|
558443|NCT00017628|Drug|filgrastim|
558444|NCT00017628|Drug|methylprednisolone|
558445|NCT00017628|Procedure|Autologous Stem Cell Transplantation|
558446|NCT00016744|Drug|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
558447|NCT00016744|Drug|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
558448|NCT00016744|Drug|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
558449|NCT00016679|Drug|1-Octanol|
558450|NCT00016666|Drug|Propranolol|
558451|NCT00016653|Drug|Creatine Monohydrate|
558452|NCT00016653|Drug|Glutamine|
558453|NCT00016549|Biological|Bevacizumab|
558454|NCT00016523|Drug|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
558455|NCT00016523|Drug|Placebo|Started at 5 ppm and could be increased to 10 ppm
558456|NCT00016497|Procedure|bilateral myringotomy|
558457|NCT00016497|Procedure|bilateral myringotomy and tubes|
558458|NCT00016497|Procedure|adenoidectomy|
558459|NCT00016471|Procedure|Audiogram|
558460|NCT00016471|Procedure|Electroretinogram|
558461|NCT00016458|Drug|anti-thymocyte globulin|
558462|NCT00016458|Drug|cyclophosphamide|
558463|NCT00016445|Drug|growth hormone|
558464|NCT00015808|Drug|Idebenone|
558465|NCT00015795|Device|airway interruption test|
558466|NCT00015769|Drug|levetiracetam|
558467|NCT00015665|Drug|Voriconazole|
558468|NCT00015626|Drug|Metformin|
558469|NCT00015626|Procedure|skin biopsy|
558470|NCT00015626|Behavioral|diet and exercise|
558471|NCT00015626|Drug|pioglitazone|
558472|NCT00015626|Drug|rosiglitazone|
558473|NCT00015600|Behavioral|Behavior modification through social marketing|
558474|NCT00015548|Drug|Olanzapine|
558475|NCT00015548|Drug|Quetiapine|
558476|NCT00015548|Drug|Risperidone|
558477|NCT00015548|Drug|Citalopram|
558478|NCT00015457|Drug|Amlodipine plus Botulinum toxin|
558479|NCT00015015|Drug|Dichloroacetate|
558480|NCT00015340|Drug|Buprenorphine/naloxone|
558481|NCT00015301|Drug|Methylphenidate|
558482|NCT00015288|Drug|Buprenorphine/naloxone|
558483|NCT00015275|Behavioral|Cocaine-Related Disorders|
558484|NCT00015249|Drug|Amantadine|
558485|NCT00015236|Behavioral|Amantadine|
558486|NCT00015223|Drug|Methylphenidate|
558487|NCT00015210|Drug|Nefazodone|
558488|NCT00015210|Behavioral|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
558489|NCT00015171|Drug|Buprenorphine/naloxone|
558490|NCT00015132|Drug|Sertraline|
558491|NCT00015106|Drug|Lamotrigine|
558492|NCT00015080|Drug|Naltrexone|
558493|NCT00015067|Drug|Methylphenidate|
558494|NCT00015054|Drug|Methylphenidate|
558495|NCT00015041|Drug|Buprenorphine|
558496|NCT00015028|Drug|Buprenorphine/naloxone|
558497|NCT00015002|Drug|Betamethasone|"coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the Course). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first."
558498|NCT00014989|Drug|magnesium sulfate|
558499|NCT00014950|Procedure|CF newborn screening|
558500|NCT00014833|Other|No intervention|No intervention
558501|NCT00014807|Behavioral|Reducing Pesticide Exposure in Minority Families|
558502|NCT00014794|Drug|15-O labeled water|
558503|NCT00014768|Drug|glucose|
558504|NCT00014768|Drug|insulin|
558505|NCT00014768|Drug|leucine|
558506|NCT00014755|Drug|anti-thymocyte globulin|
558507|NCT00014755|Drug|cyclophosphamide|
558508|NCT00014755|Drug|filgrastim|
558509|NCT00014755|Drug|prednisone|
558510|NCT00014755|Procedure|peripheral blood stem cell transplantation|
558511|NCT00014755|Procedure|irradiation|
558512|NCT00014742|Drug|collagenase|
558513|NCT00014729|Drug|isotretinoin|
558514|NCT00014040|Drug|Nitric Oxide and INOpulse Delivery System|
558515|NCT00014027|Drug|Docosahexaenoic acid (DHA)|
558516|NCT00014027|Drug|Eicosapentaenoic acid|
558517|NCT00014001|Drug|perphenazine|
558518|NCT00014001|Drug|olanzapine|
558519|NCT00014001|Drug|quetiapine|
558520|NCT00014001|Drug|risperidone|
558521|NCT00014001|Drug|ziprasidone|
558522|NCT00014001|Drug|clozapine|
558523|NCT00014001|Drug|fluphenazine decanoate|
558524|NCT00013962|Drug|Vitamin D|
558525|NCT00013923|Drug|Nutritional Supplement|
558526|NCT00013910|Drug|NNC 90-1170|
558527|NCT00013884|Drug|T-20|
558528|NCT00013806|Drug|131I-MIBG|
558529|NCT00013793|Behavioral|Motivational enhancement and ultrasound|
558530|NCT00013767|Behavioral|Individual and Community education|
558531|NCT00013741|Behavioral|Tailored Education Messages|
558532|NCT00013702|Drug|Adefovir|
558533|NCT00013689|Drug|Fansidar (pyrimethamine and sulfadoxine)|
558534|NCT00013650|Drug|Cyclophosphamate|
558535|NCT00013624|Drug|IV Levodopa|
558536|NCT00013611|Drug|Proleukin|Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
558537|NCT00013598|Drug|Pioglitazone|
558538|NCT00013546|Drug|TMTDS|
558539|NCT00013533|Procedure|Stem cell transplantation|>3 x 106/kg CD34+ stem cells by IV infusion
558540|NCT00013507|Procedure|Falls|
558541|NCT00013494|Procedure|Stroke Rehabilitation|
558542|NCT00013481|Procedure|Stroke Rehabilitation|
558543|NCT00013468|Procedure|Tinnitus|
558544|NCT00013455|Device|Hearing|
558545|NCT00013442|Procedure|Auditory Evoked Response|
558546|NCT00013429|Procedure|Visual|
558547|NCT00013416|Procedure|Hearing|
558548|NCT00013403|Procedure|Blindness|
558549|NCT00013390|Procedure|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
558550|NCT00013390|Procedure|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
558551|NCT00013377|Procedure|Low vision|
558552|NCT00013364|Behavioral|Talker variability|
558553|NCT00013351|Procedure|Prevention of Falls|
558554|NCT00013338|Procedure|Ambulation Training|
558555|NCT00013325|Procedure|Cardiac Disease|
558643|NCT00011505|Procedure|Leukapheresis|
558556|NCT00013312|Procedure|Determine colonic tone|
558557|NCT00013299|Device|Prevention of Diabetic Ulcers|
558558|NCT00013286|Device|Prevention Diabetic Foot Ulcer|
558559|NCT00013273|Procedure|Physical Conditioning|
558560|NCT00013260|Procedure|Integrated model of primary care|
558561|NCT00013247|Behavioral|Prostate Cancer Screening Education|
558562|NCT00013234|Procedure|Teledermatology|
558563|NCT00013221|Behavioral|Exercise|
558564|NCT00013208|Behavioral|Case Management|
558565|NCT00013195|Behavioral|Telephone Care|
558566|NCT00013182|Behavioral|social activity|
558567|NCT00013169|Behavioral|Strong Patient Focus|
558568|NCT00013156|Procedure|Effectiveness of Lung Reduction Therapy|
558569|NCT00013143|Behavioral|Patient risk profiling (potential ADEs) w/provider feedback|
558570|NCT00013130|Behavioral|Provision of health status information to patients provider|
558571|NCT00013117|Behavioral|Telephone specialist consultation|
558572|NCT00013091|Behavioral|Self-management therapy; Psychoeducational group therapy|
558573|NCT00013078|Procedure|Physical restoration intervention|
558574|NCT00013052|Behavioral|Peer led classes. Led by trained veterans with a chronic disease.|
558575|NCT00013039|Behavioral|Computer reminders|
558576|NCT00013026|Behavioral|CHF Self-management Education (Web-based Education)|
558577|NCT00013013|Procedure|Systems Support|
558578|NCT00013000|Behavioral|Test strategy for implementation guideline|
558579|NCT00012987|Behavioral|Quality Improvement|
558580|NCT00012974|Behavioral|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
558581|NCT00012974|Procedure|Provider education, computer reminders, nurse case management|
558582|NCT00012948|Procedure|Telephone Care|
558583|NCT00012935|Behavioral|Help with decision making on prostate cancer treatment|
558584|NCT00012922|Behavioral|Low Literacy Intervention for Colorectal Cancer Screening|
558585|NCT00012909|Behavioral|Hormone Replacement Therapy Decision-Aid|
558586|NCT00012896|Behavioral|Telephone Care + Educational (AV Materials)|
558587|NCT00012883|Behavioral|Homewalking exercise program|
558588|NCT00012870|Behavioral|Behavioral Management|
558589|NCT00012857|Drug|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
558590|NCT00012844|Device|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
558591|NCT00012844|Procedure|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
558592|NCT00012818|Behavioral|relaxation technique|
558593|NCT00012818|Behavioral|educational program|
558594|NCT00012805|Procedure|Telephone Monitoring|
558595|NCT00012792|Behavioral|Exercise Training|
558596|NCT00012779|Behavioral|Health Education Program|
558597|NCT00012766|Behavioral|Integrated team care|
558598|NCT00012753|Procedure|Automated telephone health status assessments with nurse follow-up.|
558599|NCT00012740|Behavioral|Casefinding and Referral System|
558600|NCT00012727|Procedure|Matching Symptom Severity to Service Intensity|
558601|NCT00012714|Behavioral|Case management services|
558602|NCT00012688|Drug|Doxycycline HCI 10mg po for 2 weeks|
558603|NCT00012688|Procedure|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
558604|NCT00012662|Behavioral|Diabetes Self Management Education|
558605|NCT00012636|Procedure|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
558606|NCT00012610|Procedure|Telepsychiatry|
558607|NCT00012597|Procedure|Web-based telemedicine system for assessment of status of pressure ulcers|
558608|NCT00012584|Drug|methylphenidate|
558609|NCT00012584|Drug|fluvoxamine|
558610|NCT00012558|Drug|lithium|
558611|NCT00012558|Drug|valproate|
558612|NCT00012558|Drug|bupropion|
558613|NCT00012558|Drug|paroxetine|
558614|NCT00012558|Drug|lamotrigine|
558615|NCT00012558|Drug|risperidone|
558616|NCT00012558|Drug|inositol|
558617|NCT00012558|Drug|tranylcypromine|
558618|NCT00012558|Behavioral|Cognitive Behavioral Therapy|
558619|NCT00012558|Behavioral|Family-focused Therapy|
558620|NCT00012558|Behavioral|Interpersonal and Social Rhythms Therapy|
558621|NCT00012506|Drug|TNFR:Fc|
558622|NCT00012441|Procedure|hemodialysis|
558623|NCT00011908|Drug|hLL2 (Epratuzumab)|
558624|NCT00011830|Drug|G-CSF|
558625|NCT00011830|Procedure|Apheresis|
558626|NCT00011804|Drug|Topiramate|
558627|NCT00011778|Drug|bortezomib|
558628|NCT00011778|Radiation|radiation therapy|
558629|NCT00011765|Drug|Fluoxetine|
558630|NCT00011752|Drug|FCWAY|
558631|NCT00011713|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
558632|NCT00011661|Behavioral|Education on behaviors to reduce lead exposure|
558633|NCT00011622|Device|Continuous ambulatory subcutaneous glucose monitor|
558634|NCT00011609|Device|Robotic Arm|
558635|NCT00011596|Procedure|Gait Training|
558636|NCT00011583|Device|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
558637|NCT00011583|Device|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
558638|NCT00011570|Device|Bladder & Bowel Control|
558639|NCT00011557|Device|Assistance in Voiding|
558640|NCT00011544|Procedure|Performance Measure|
558641|NCT00011531|Procedure|Prevention of Pressure Ulcers|
558642|NCT00011505|Drug|G-CSF|
558644|NCT00011414|Drug|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
558645|NCT00011375|Drug|Rolipram|
558646|NCT00011362|Drug|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
558647|NCT00011362|Drug|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was >=2.4 on treatment day 14, or an additional two weeks of saline
558648|NCT00011297|Drug|gabapentin (Neurontin)|
558649|NCT00011297|Drug|lorazepam (Ativan)|
558650|NCT00011258|Drug|Paraoxonase|
558651|NCT00011141|Drug|Oral lactobacillus administration|
558652|NCT00011193|Behavioral|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
558653|NCT00011076|Drug|Pirfenidone|
558654|NCT00011115|Behavioral|Weight loss motivations|
558655|NCT00011102|Behavioral|Weight Gain Prevention for Women Project|
558656|NCT00011024|Procedure|Self Hypnosis|
558657|NCT00011024|Procedure|Acupuncture|
558658|NCT00011024|Procedure|Osteopathic Manipulation|
558659|NCT00010998|Procedure|Yoga|
558660|NCT00010985|Procedure|Acupuncture|
558661|NCT00010985|Procedure|Chiropractic|
558662|NCT00010985|Procedure|massage|
558663|NCT00010972|Procedure|Acupuncture|
558664|NCT00010959|Drug|Cimicifuga racemosa|
558665|NCT00010959|Drug|Trifolium pratense|
558666|NCT00010946|Procedure|Acupuncture|
558667|NCT00010933|Drug|chamomile tea|
558668|NCT00010933|Procedure|Relaxation/Guided Imagery|
558669|NCT00010920|Drug|Ginkgo Biloba Extract|
558670|NCT00010907|Drug|NPI-028|
558671|NCT00010881|Drug|antioxidants|
558672|NCT00010881|Behavioral|stress reduction|
558673|NCT00010868|Drug|Omega-3 Fatty Acids|
558674|NCT00010855|Behavioral|Self-hypnotic relaxation|
558675|NCT00010842|Drug|Ginkgo biloba|
558676|NCT00010842|Drug|Alpha-lipoic acid|
558677|NCT00010842|Drug|Vitamin E/Selenium|
558678|NCT00010842|Drug|Essential fatty acids|
558679|NCT00010829|Behavioral|American Heart Association Step 1 diet|
558680|NCT00010829|Behavioral|American Heart Association Step 2 diet + 10 g/day flax seed|
558681|NCT00010829|Behavioral|Macrobiotic dietary intervention|
558682|NCT00010816|Drug|Herbal remedies|
558683|NCT00010803|Drug|Ginkgo biloba|120mg twice a day
558684|NCT00010803|Drug|Placebo|One pill twice daily
558685|NCT00010777|Procedure|Multiple Component Mind/Body therapy|
558686|NCT00010764|Procedure|Acupuncture|
558687|NCT00010751|Procedure|Reiki|
558688|NCT00010738|Procedure|Meditation|
558689|NCT00010725|Drug|MAK|
558690|NCT00010725|Drug|Vitamin Supplements|
558691|NCT00010712|Drug|Black Cohosh|
558692|NCT00010699|Drug|Vitamin E|
558693|NCT00010686|Drug|Dietary Phytoestrogens|
558694|NCT00010634|Drug|Connective Tissue Nutrient Formula|
558695|NCT00010634|Drug|Adaptogenic herbs|
558696|NCT00010634|Drug|glutamine|
558697|NCT00010621|Procedure|Acupuncture|
558698|NCT00010621|Procedure|chiropractic therapy|
558699|NCT00010621|Procedure|bodywork therapy|
558700|NCT00010608|Behavioral|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
558701|NCT00010608|Behavioral|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
558702|NCT00010530|Procedure|Meditation|
558703|NCT00010517|Procedure|Acupuncture|
558704|NCT00010504|Procedure|Acupuncture|
558705|NCT00010491|Procedure|Acupuncture|
558706|NCT00010491|Procedure|Moxibustion|
558707|NCT00010478|Procedure|Acupuncture|
558708|NCT00010465|Procedure|Craniosacral Osteopathic Manipulative Treatment|
558709|NCT00010465|Drug|Botanicals|
558710|NCT00009685|Drug|VRC4302|
558711|NCT00009672|Drug|Nortriptyline|
558712|NCT00009672|Drug|Morphine|
558713|NCT00009659|Drug|CDB 2914|
558714|NCT00009646|Drug|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
558715|NCT00009646|Drug|Indomethacin|0.1 mg per kilogram of body weight
558716|NCT00009646|Drug|Placebo|0.1 mg per kilogram of body weight
558717|NCT00009620|Drug|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
558718|NCT00009620|Drug|Saline|Infusion of normal sal
558719|NCT00010452|Drug|picibanil|Up to .2 mg per injection, given intralesionally every 6-8 weeks
558720|NCT00010439|Drug|Alendronate|Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
558721|NCT00010426|Drug|cysteamine hydrochloride|
558722|NCT00010413|Drug|cyclophosphamide|
558723|NCT00010413|Drug|filgrastim|
558724|NCT00010400|Drug|Cyclophosphamide|
558725|NCT00010400|Drug|filgrastim|
558726|NCT00010387|Drug|cyclophosphamide|
558727|NCT00010387|Drug|filgrastim|
558728|NCT00010374|Device|intramuscular diaphragm electrodes|Conditioning of the diaphragm
558729|NCT00010374|Device|Intramuscular diaphragm electrodes|to test the safety, efficacy and clinical utility of diaphragm pacing using IM electrodes placed through a laparoscopic approach to achieve artificial ventilation in spinal cord injured patients who have an internal cardiac pacemaker and require full-time ventilator support.
558730|NCT00010361|Drug|cyclosporine|
558731|NCT00010361|Drug|fludarabine|
558732|NCT00010361|Drug|mycophenolate mofetil|
558733|NCT00010335|Procedure|Stem Cell Transplantation|Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
558734|NCT00010335|Device|CD34 selection|CD34+ cells are separated from the rest of the peripheral blood stem cells.
558735|NCT00009594|Procedure|Naturopathic Medicine|
558736|NCT00009594|Procedure|Traditional Chinese Medicine|
558737|NCT00009581|Drug|L-NMMA|
558738|NCT00009581|Drug|Acetylcholine|
558739|NCT00009230|Drug|Celecoxib|
558740|NCT00009217|Drug|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
558741|NCT00009217|Drug|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
558742|NCT00009204|Drug|Citalopram [Celexa]|
558743|NCT00009204|Drug|Perphenazine [Trilafon]|
558744|NCT00009191|Drug|Sertraline [Zoloft]|
558745|NCT00009048|Drug|EMD 128130|
558746|NCT00009048|Drug|IV Levodopa|
558747|NCT00009178|Drug|Fluoxetine|
558748|NCT00009178|Behavioral|Guided Self-Help|
558749|NCT00009009|Drug|immunosuppressive regimen designed to complement HAART|
558750|NCT00008801|Drug|hOKT3gamma1 (Ala-ala)|
558751|NCT00008775|Device|Pressure support ventilation|
558752|NCT00008736|Drug|metoclopramide|
558753|NCT00008827|Behavioral|Behavioral weight loss|
558754|NCT00008515|Drug|Fluocinolone|
558755|NCT00008476|Drug|Capsaicin|
558756|NCT00008450|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
558757|NCT00008450|Drug|Cyclosporine|Given PO or IV
558758|NCT00008450|Other|Laboratory Biomarker Analysis|Correlative studies
558759|NCT00008450|Drug|Mycophenolate Mofetil|Given PO or IV
558760|NCT00008450|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
558761|NCT00008450|Radiation|Total-Body Irradiation|Undergo TBI
558762|NCT00007800|Behavioral|Behavioral Group Weight Loss Intervention|
558763|NCT00007800|Behavioral|Motivational Interviewing|
558764|NCT00007670|Drug|Carbamazepine|
558765|NCT00007670|Drug|Gabapentin|
558766|NCT00007670|Drug|Lamotrigine|
558767|NCT00007657|Procedure|Intensive medical therapy|
558768|NCT00007657|Procedure|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
558769|NCT00007774|Drug|Haloperidol|
558770|NCT00007774|Drug|Olanzapine|
558771|NCT00007761|Behavioral|Bipolar Disorder Program|
558772|NCT00007761|Behavioral|Usual (psychiatric) Care|
558773|NCT00007748|Behavioral|Aerobic exercise|
558774|NCT00007748|Behavioral|Cognitive behavioral therapy|
558775|NCT00007735|Drug|Doxycycline (200mg/day) or Placebo|
558776|NCT00007683|Drug|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
558777|NCT00007683|Drug|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
558778|NCT00007683|Drug|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
558779|NCT00007644|Procedure|Radical prostatectomy|Surgical removal of the prostate
558780|NCT00007631|Drug|Tretinoin 0.1% cream or placebo|
558781|NCT00007631|Other|Placebo|Patients receive placebo for same amount of time
558782|NCT00007605|Drug|Amiodarone|Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
558783|NCT00007605|Drug|Sotalol|Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
558784|NCT00007592|Drug|Chlorthalidone|
558785|NCT00007592|Drug|Furosemide|
558786|NCT00007527|Drug|naloxone|
558787|NCT00007527|Drug|buprenorphine|
558788|NCT00007501|Biological|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
558789|NCT00007501|Biological|Placebo|Placebo vaccine
558790|NCT00007475|Procedure|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
558791|NCT00007475|Drug|Cyclophosphamide|For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
558792|NCT00007358|Drug|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
558793|NCT00007345|Drug|Romidepsin|
558794|NCT00007306|Drug|Parathyroid hormone ointment|
558795|NCT00007293|Device|UV-B Lightsource and Fiber Optic Comb|
558796|NCT00007280|Device|Bioengineered skin|
558797|NCT00007267|Behavioral|Cognitive behavioral therapy|
558798|NCT00007267|Behavioral|Disease/health education|
558799|NCT00007267|Behavioral|Self-help cognitive behavioral intervention facilitated by a psychologist|
558800|NCT00007254|Drug|Pain relief for pressure ulcers|
558801|NCT00007241|Device|Isometric exercise|
558802|NCT00007189|Drug|Naproxen Sodium (Aleve)|
558803|NCT00007189|Drug|Celecoxib (Celebrex)|
558804|NCT00007163|Drug|J695|
558805|NCT00007085|Device|Tomography, X-ray Computed|
558806|NCT00007059|Drug|mycophenolate mofetil|
558807|NCT00007033|Drug|magnesium gluconate|
558808|NCT00007033|Drug|magnesium sulfate|
558809|NCT00007020|Drug|Cholic Acids|10-15 mg/kg body weight/day taken orally.
558880|NCT00006305|Drug|Insulin, sulfonylurea|Insulin, sulfonylurea
558810|NCT00006565|Device|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
558811|NCT00006565|Device|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
558812|NCT00006519|Drug|Capravirine|
558813|NCT00006517|Device|bright light box|10,000 lux bright light therapy
558814|NCT00006517|Device|dawn simulator|gradual rise in bedroom illumination prior to wake-up
558815|NCT00006517|Device|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
558816|NCT00006517|Device|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
558817|NCT00006517|Device|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
558818|NCT00006516|Behavioral|Infant stimulation|
558819|NCT00006508|Procedure|Controlled hypoglycemia using insulin|
558820|NCT00006508|Procedure|formula meal|
558821|NCT00006505|Other|Islet Surgery|Islet cell transplantation. This study will test whether a new islet transplant procedure will enable patients with type 1 diabetes mellitus to stop insulin therapy
558822|NCT00006501|Procedure|ECG|A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
558823|NCT00006493|Drug|Rosiglitazone|
558824|NCT00006489|Behavioral|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
558825|NCT00006489|Drug|Naltrexone|Daily dosing 100 mg for 24 weeks
558826|NCT00006489|Drug|Placebo|Pill Placebo daily dosing 24 weeks
558827|NCT00006488|Drug|recombinant-methionyl human glial cell line-derived neurotrophic factor|
558828|NCT00006450|Drug|Phenylbutyrate|
558829|NCT00006449|Drug|naltrexone (Revia)|
558830|NCT00006449|Behavioral|broad spectrum treatment|
558831|NCT00006449|Behavioral|motivational enhancement therapy|
558832|NCT00006507|Behavioral|Occupational Therapy|
558833|NCT00006448|Behavioral|cognitive therapy|
558834|NCT00006448|Procedure|Physical Therapy|
558835|NCT00006448|Drug|Methadone|
558836|NCT00006447|Procedure|Social Support|
558837|NCT00006446|Procedure|Training in parenting skills and communication|
558838|NCT00006445|Procedure|Ultrasound|
558839|NCT00006445|Procedure|Serum screen|
558840|NCT00006439|Behavioral|Counseling in the home|
558841|NCT00006438|Device|Shoes with Rocker Soles|
558842|NCT00006436|Biological|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
558843|NCT00006436|Biological|filgrastim|Figrastim day 6 until ANC reaches 5000 after the nadir, every cycle
558844|NCT00006436|Drug|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
558845|NCT00006434|Biological|tumor-pulsed dendritic cells|
558846|NCT00006433|Drug|Doxil|
558847|NCT00006433|Procedure|heat treatment|
558848|NCT00006432|Procedure|very low fat diet|
558849|NCT00006431|Biological|DC RCC-RNA|
558850|NCT00006430|Biological|Autologous dendritic cells transfected with amplified tumor RNA|
558851|NCT00006429|Procedure|body weight-supported treadmill training|
558852|NCT00006428|Drug|Amitriptyline|
558853|NCT00006427|Drug|Amitriptyline|
558854|NCT00006426|Procedure|Achilles tendon-lengthening surgery|
558855|NCT00006422|Procedure|current standard of care treatments|
558856|NCT00006418|Procedure|DNA collection|
558857|NCT00006417|Procedure|Stem cell transplantation|
558858|NCT00006413|Procedure|Stem cell transplantation|
558859|NCT00006411|Other|corneas assigned by donor age group|A web-based computer program was used to select a cornea from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors >=66 and <66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
558860|NCT00006409|Behavioral|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
558861|NCT00006405|Behavioral|Exercise|
558862|NCT00006401|Drug|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
558863|NCT00006401|Other|Placebo|Inhaled Nitrogen
558864|NCT00006400|Drug|Hydroxyurea|Participants will receive hydroxyurea.
558865|NCT00006400|Drug|Placebo|Participants will receive placebo.
558866|NCT00006398|Drug|Timolol Maleate|
558867|NCT00006398|Drug|Placebo|
558868|NCT00006394|Drug|growth hormone|
558869|NCT00006337|Drug|KW-6002|
558870|NCT00006337|Drug|IV Levodopa|
558871|NCT00006332|Drug|Tetrathiomolybdate|
558872|NCT00006331|Procedure|renal transplant|
558873|NCT00006330|Drug|Digoxin|
558874|NCT00006330|Drug|Hawthorn|
558875|NCT00006329|Procedure|Minimally invasive radioguided parathyroidectomy|
558876|NCT00006320|Procedure|determine blood levels of anti-HIV drugs|
558877|NCT00006305|Procedure|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
558878|NCT00006305|Procedure|Coronary Artery Bypass|Coronary Artery Bypass
558879|NCT00006305|Drug|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
558881|NCT00006305|Drug|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
558882|NCT00006299|Drug|Celebrex|
558883|NCT00006294|Drug|Chlorthalidone|participant's drug dose will be titrated from 12.5mg to 25mg over the course of the study
558884|NCT00006294|Drug|Lisinopril|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
558885|NCT00006294|Drug|Amlodipine|participant's drug dose will be titrated from 10mg to 40mg over the course of the study
558886|NCT00006294|Drug|Doxazosin|participant's drug dose will be titrated from 2mg to 8mg over the course of the study
558887|NCT00006292|Drug|Infliximab|
558888|NCT00006289|Drug|Placebo|4 tabs b.i.d.
558889|NCT00006289|Drug|Neurotropin|4 tabs b.i.d.
558890|NCT00006286|Drug|Fluoxetine|
558891|NCT00006286|Behavioral|Psychotherapy|
558892|NCT00006276|Drug|Micellar Paclitaxel|
558893|NCT00006280|Drug|Tobramycin for Inhalation|
558894|NCT00006275|Drug|calcitriol|
558895|NCT00006270|Drug|cosyntropin|
558896|NCT00006270|Drug|metyrapone|
558897|NCT00006206|Drug|naltrexone (Revia)|
558898|NCT00006206|Drug|acamprosate (Campral)|
558899|NCT00006205|Drug|ondansetron + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d)
558900|NCT00006205|Drug|topiramate + cognitive behavioral therapy|topiramate (up to 300 mg/day)
558901|NCT00006205|Drug|Placebo + cognitive behavioral therapy|placebo
558902|NCT00006205|Drug|ondansetron + topiramate + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
558903|NCT00006204|Drug|naltrexone (Revia)|
558904|NCT00006204|Drug|fluoxetine (Prozac)|
558905|NCT00006203|Drug|naltrexone (Revia)|
558906|NCT00006202|Drug|Lutein|
558907|NCT00006200|Drug|thalidomide|
558908|NCT00006200|Drug|dacarbazine|
558909|NCT00006199|Drug|R115777 (farnesyl transferase inhibitor)|
558910|NCT00006199|Drug|Topotecan|
558911|NCT00006198|Drug|thalidomide|
558912|NCT00006198|Procedure|chemoembolization with doxorubicin/collagen|
558913|NCT00006196|Drug|Vitamin D|
558914|NCT00006195|Drug|risperidone|
558915|NCT00006195|Drug|olanzapine|
558916|NCT00006194|Behavioral|Exercise|
558917|NCT00006193|Behavioral|diet|
558918|NCT00006190|Drug|Nelfinavir mesylate|
558919|NCT00006190|Drug|Stavudine|
558920|NCT00006190|Drug|Lamivudine|
558921|NCT00006190|Drug|Efavirenz|
558922|NCT00006187|Drug|Investigational drug|
558923|NCT00006186|Procedure|Autologous fresh whole blood|
558924|NCT00006184|Drug|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
558925|NCT00006184|Drug|Bortezomib|Induction chemotherapy: 1.3 mg/m^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
558926|NCT00006184|Drug|Cyclophosphamide|Induction chemotherapy: 600 mg/m^2 day 4 Transplant: 1200 mg/m^2 intravenous x 4 days (days -6, -5, -4, -3)
558927|NCT00006184|Drug|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
558928|NCT00006184|Drug|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m^2 day continuous intravenous (CIV) days 1-3
558929|NCT00006184|Drug|Etoposide|Induction chemotherapy: 50 mg/m^2 day continuous intravenous days 1-3
558930|NCT00006184|Drug|Fludarabine phosphate|Induction chemotherapy: 25 mg/m^2 day intravenous days 1-3 Transplant: 30 mg/m^2 day x 4 days (days -6, -5, -4, -3 )
558931|NCT00006184|Drug|Prednisone|60 mg/m^2 day 1-4
558932|NCT00006184|Drug|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m^2 day continuous intravenous days 1-3
558933|NCT00006184|Drug|Methotrexate|Transplant: 5 mg/m^2 intravenous on days +1, +3, +6, +11
558934|NCT00006184|Biological|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m^2 subcutaneously every day, days 1-4
558935|NCT00006184|Biological|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) > 1000/ul x 2 days
558936|NCT00006185|Drug|Avandia administration for 6-12 weeks|
558937|NCT00006183|Procedure|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
558938|NCT00006183|Procedure|Thoracic Surgery|
558939|NCT00006182|Procedure|Blood Transfusion|
558940|NCT00006399|Drug|Donepezil|
558941|NCT00006399|Drug|Estrogen|
558942|NCT00006399|Drug|Progesterone|
558943|NCT00006181|Behavioral|Team-based intervention|
558944|NCT00006181|Behavioral|One-on-one intervention|
558945|NCT00006180|Drug|Alendronate|
558946|NCT00006178|Drug|Sirolimus|
558947|NCT00006178|Drug|Thymoglobulin|
558948|NCT00006174|Drug|Letrozole|
558949|NCT00006172|Device|Bright light box|60-min light therapy shortly after awakening
558950|NCT00006172|Device|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
558951|NCT00006172|Device|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
558952|NCT00006170|Drug|Bupropion|smoking cessation medication aid
558953|NCT00006170|Drug|Placebo|A matched placebo pill
558954|NCT00006170|Behavioral|weight concerns intervention|cognitive behavioral treatment to address weight concners
558955|NCT00006170|Behavioral|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
558956|NCT00006156|Other|Control|No injection of FSH
558957|NCT00006156|Drug|Drug: FSH|FSH Stimulation Test
558958|NCT00006169|Behavioral|Behavioral Treatment|
558959|NCT00006168|Drug|Methotrexate|
558960|NCT00006167|Drug|oxandrolone|
558961|NCT00006167|Behavioral|Progressive Resistance Training|
559199|NCT00004730|Drug|magnesium sulfate|
558962|NCT00006166|Procedure|Transjugular intrahepatic portasystemic shunts (TIPS)|
558963|NCT00006166|Procedure|Total paracentecis (TP)|
558964|NCT00006165|Behavioral|'Ohana (Family) Support Lifestyle Intervention|
558965|NCT00006164|Drug|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight <75 kg, >75 kg) daily in two divided doses for 24 weeks
558966|NCT00006164|Drug|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
558967|NCT00006163|Behavioral|Personalized Self-management|
558968|NCT00006163|Behavioral|Community Resources|
558969|NCT00006162|Behavioral|exercise and diet|
558970|NCT00006161|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
558971|NCT00006161|Procedure|Distal Splenorenal Shunt|
558972|NCT00006160|Behavioral|home based worker|
558973|NCT00006159|Behavioral|lifestyle (exercise, diet, and family and community support)|
558974|NCT00006158|Drug|Testosterone|
558975|NCT00006157|Drug|Desipramine|
558976|NCT00006157|Behavioral|Cognitive Behavioral Treatment|
558977|NCT00006151|Behavioral|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
558978|NCT00006077|Drug|NS2330|
558979|NCT00006077|Drug|Levodopa and Domperidone|
558980|NCT00006142|Behavioral|phenylalanine restricted diet|
558981|NCT00006137|Drug|enalapril|
558982|NCT00006136|Drug|arginine butyrate|
558983|NCT00006136|Drug|epoetin alfa|
558984|NCT00006135|Drug|acyclovir|
558985|NCT00006133|Drug|estradiol|
558986|NCT00006133|Drug|ethinyl estradiol|
558987|NCT00006133|Drug|medroxyprogesterone|
558988|NCT00006133|Drug|norethindrone|
558989|NCT00006132|Drug|acyclovir|
558990|NCT00006131|Drug|Valacyclovir|
558991|NCT00006130|Procedure|Core decompression|
558992|NCT00006129|Drug|testosterone|
558993|NCT00006127|Drug|amifostine|
558994|NCT00006072|Drug|Rituxan|
558995|NCT00006070|Drug|etanercept (Enbrel)|
558996|NCT00006068|Procedure|Pancreatic Islet Transplantation|
558997|NCT00005937|Drug|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
558998|NCT00005937|Drug|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
558999|NCT00005935|Drug|Mycophenolate mofetil|
559000|NCT00005935|Drug|Cyclosporine|
559001|NCT00005934|Drug|5-Azacytidine|
559002|NCT00006063|Drug|pancrelipase with bicarbonate|
559003|NCT00006061|Drug|phosphatidylcholine|
559004|NCT00006060|Drug|standard gadolinium contrast|
559005|NCT00006056|Drug|anti-thymocyte globulin|
559006|NCT00006056|Drug|busulfan|
559007|NCT00006056|Drug|cyclophosphamide|
559008|NCT00006056|Drug|cyclosporine|
559009|NCT00006056|Drug|etoposide|
559010|NCT00006056|Drug|filgrastim|
559011|NCT00006056|Drug|methotrexate|
559012|NCT00006056|Procedure|allogeneic hematopoietic stem cell transplantation|
559013|NCT00006055|Drug|anti-thymocyte globulin|
559014|NCT00006055|Drug|cyclophosphamide|
559015|NCT00006055|Drug|cyclosporine|
559016|NCT00006055|Drug|filgrastim|
559017|NCT00006055|Drug|methylprednisolone|
559018|NCT00006055|Drug|prednisone|
559019|NCT00006055|Procedure|Autologous Peripheral Blood Stem Cell Transplantation|
559020|NCT00006054|Drug|anti-thymocyte globulin|
559021|NCT00006054|Drug|busulfan|
559022|NCT00006054|Drug|cyclophosphamide|
559023|NCT00006054|Drug|cyclosporine|
559024|NCT00006054|Drug|etoposide|
559025|NCT00006054|Drug|methotrexate|
559026|NCT00006054|Drug|methylprednisolone|
559027|NCT00006054|Drug|prednisone|
559028|NCT00006054|Procedure|Allogeneic Bone Marrow Transplantation|
559029|NCT00005928|Drug|Ramipril|
559030|NCT00005925|Drug|Muscimol|
559031|NCT00005922|Behavioral|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
559032|NCT00005922|Drug|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
559033|NCT00005922|Other|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
559034|NCT00005916|Drug|rV-PSA|
559035|NCT00005916|Drug|rF-PSA|
559036|NCT00005916|Drug|rV-B7.1|
559037|NCT00005910|Procedure|Intraoperative ultrasound|
559038|NCT00005908|Drug|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m^2 intravenous day 1
559039|NCT00005908|Drug|Anastrozole|1 mg orally daily for five years
559040|NCT00005908|Drug|cyclophosphamide|600 mg/m^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
559041|NCT00005908|Drug|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m^2 intravenous day 1
559042|NCT00005908|Drug|Doxorubicin hydrochloride|60 mg/m^2 will be administered as a slow intravenous push on day 1
559043|NCT00005908|Drug|Tamoxifen Citrate|20 mg/day orally for five years
559044|NCT00005908|Drug|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m^2 orally twice daily day 2-15
559045|NCT00005908|Drug|Capecitabine - Dose A|capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
559046|NCT00005906|Drug|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
559047|NCT00005905|Drug|hu Leptin (A-100)|
559048|NCT00005903|Drug|GDNF & Synchro Med Infusion System|
559049|NCT00005901|Drug|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
559050|NCT00005898|Drug|anti-thymocyte globulin|
559051|NCT00005898|Drug|cyclophosphamide|
559052|NCT00005898|Drug|cyclosporine|
559053|NCT00005898|Drug|filgrastim|
559054|NCT00005898|Drug|fludarabine|
559055|NCT00005898|Drug|methylprednisolone|
559056|NCT00005896|Drug|filgrastim|
559057|NCT00005896|Genetic|Autologous stem cells transduced with FACC retroviral vector|
559058|NCT00005896|Procedure|Autologous Stem Cell Transplantation|
559059|NCT00005893|Drug|anti-thymocyte globulin|
559060|NCT00005893|Drug|busulfan|
559061|NCT00005893|Drug|cyclophosphamide|
559062|NCT00005893|Procedure|Bone marrow transplantation|
559063|NCT00005892|Drug|cyclophosphamide|
559064|NCT00005892|Procedure|Allogeneic Bone Marrow Transplantation|
559065|NCT00005891|Drug|cyclophosphamide|
559066|NCT00005891|Procedure|Allogeneic Bone Marrow Transplantation|
559067|NCT00005890|Drug|corticotropin|
559068|NCT00005889|Drug|alanine|
559069|NCT00005889|Drug|amino acids|
559070|NCT00005889|Drug|glucagon|
559071|NCT00005889|Drug|glucose|
559072|NCT00005889|Drug|glutamine|
559073|NCT00005889|Drug|glycerol|
559074|NCT00005889|Drug|insulin|
559075|NCT00005889|Drug|leucine|
559076|NCT00005889|Drug|lipids|
559077|NCT00005889|Drug|urea|
559078|NCT00005888|Behavioral|Fortified Pasteurized Donor Human Milk supplement|
559079|NCT00005888|Behavioral|Preterm Formula supplement|
559080|NCT00005785|Drug|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
559081|NCT00005782|Drug|Granulocyte colony-stimulating factor|
559082|NCT00005782|Procedure|Leukapheresis|
559083|NCT00005780|Drug|EPOCH-R|EPOCH-R for 6 cycles
559084|NCT00005780|Biological|GM-CSF|GM-CSF monthly with the vaccine for 5 doses
559085|NCT00005780|Biological|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
559086|NCT00005778|Drug|High-dose immunoablative therapy|"High dose cyclophosphamide for 4 days.~NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
559087|NCT00005777|Procedure|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (>52 mm Hg)
559088|NCT00005777|Procedure|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target <48 mm Hg)
559089|NCT00005777|Drug|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
559090|NCT00005777|Drug|Placebo|The infants in the placebo groups received equal volumes of saline.
559091|NCT00005776|Drug|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
559092|NCT00005776|Drug|Placebo|100% Oxygen
559093|NCT00005775|Drug|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
559094|NCT00005775|Drug|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
559095|NCT00005774|Drug|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
559096|NCT00005774|Drug|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
559097|NCT00005773|Drug|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had <=20 mm Hg increase in PaO2 (less than full response).
559098|NCT00005773|Drug|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
559099|NCT00005772|Device|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
559100|NCT00005772|Device|Control|Control group: standard care
559101|NCT00005771|Device|Visual utrasound feedback|
559102|NCT00005771|Procedure|Abdominal Hollowing Exercise|
559103|NCT00005770|Device|Acupuncture|
559104|NCT00005769|Drug|Hormone Replacement Therapy|
559105|NCT00005768|Drug|Estrogen|
559106|NCT00005766|Drug|Creatinine|
559107|NCT00005765|Drug|nicotine|
559108|NCT00005765|Drug|alcohol|
559109|NCT00005675|Drug|Oral bovine type I collagen|500 mcg of CI daily for 15 months
559110|NCT00005675|Drug|Placebo|CI placebo daily for 15 months
559111|NCT00005674|Drug|Creatine|
559112|NCT00005743|Behavioral|exercise|
559113|NCT00005743|Behavioral|weight loss|
559114|NCT00005739|Behavioral|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
559115|NCT00005739|Behavioral|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
559116|NCT00005727|Behavioral|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
559117|NCT00005724|Behavioral|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
559118|NCT00005724|Other|Minimal Intervention Group|Dietary Information pamphlets.
559119|NCT00005724|Behavioral|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
559200|NCT00004729|Behavioral|Ketogenic diet|
559201|NCT00004728|Drug|Warfarin|
559202|NCT00004728|Drug|Aspirin|
559203|NCT00004727|Drug|aspirin|
559120|NCT00005713|Behavioral|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
559121|NCT00005711|Behavioral|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
559122|NCT00005684|Drug|warfarin|
559123|NCT00005684|Drug|heparin|
559124|NCT00005555|Behavioral|Exercise|
559125|NCT00005553|Procedure|Catheter Ablation|
559126|NCT00005520|Drug|Hydrochlorothiazide|
559127|NCT00005520|Drug|Candesartan|
559128|NCT00005399|Other|No interventions|No interventions
559129|NCT00005398|Other|There is no intervention|No applicable
559130|NCT00005305|Other|No interventions - observational study|
559131|NCT00005195|Procedure|Catheter ablation|
559132|NCT00005137|Other|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
559133|NCT00005673|Drug|Capravirine|
559134|NCT00005669|Drug|Metformin HCL|Medication studied for ability to alter body weight and body composition.
559135|NCT00005669|Drug|Placebo|Control capsules for metformin
559136|NCT00005666|Procedure|PET scan use in radiotherapy planning|
559137|NCT00005665|Drug|interferon alpha|
559138|NCT00005658|Drug|Glycine|
559139|NCT00005655|Biological|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
559140|NCT00005655|Biological|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
559141|NCT00005654|Drug|clomiphene citrate|
559142|NCT00005654|Drug|metformin|
559143|NCT00005652|Drug|rituximab|
559144|NCT00005575|Drug|Imipramine|
559145|NCT00005575|Behavioral|Cognitive-behavior therapy|
559146|NCT00005571|Drug|h5G1.1-mAb|
559147|NCT00005569|Drug|SLPI (Secretory Leukocyte Protease Inhibitor)|
559148|NCT00005567|Behavioral|Parental knowledge and beliefs about infant sleep position|
559149|NCT00005566|Behavioral|Desperation Scale|
559150|NCT00005119|Procedure|Measures of calcium and bone turnover|
559151|NCT00005117|Drug|pravastatin|
559152|NCT00005112|Drug|Human recombinant growth hormone|
559153|NCT00005116|Behavioral|psychotherapy|
559154|NCT00005110|Drug|Salmeterol|
559155|NCT00005110|Drug|Albuterol|
559156|NCT00005108|Drug|Estradiol|
559157|NCT00005108|Drug|Progesterone|
559158|NCT00005107|Drug|N-monomethyl-L-arginine|
559159|NCT00005104|Drug|clomiphene citrate|
559160|NCT00005104|Drug|metformin|
559161|NCT00005015|Drug|Fluoxetine|
559162|NCT00005014|Drug|Risperidone|
559163|NCT00005013|Drug|Sertraline|
559164|NCT00005013|Drug|Hypericum perforatum (St. John's wort)|
559165|NCT00005007|Drug|Etanercept|
559166|NCT00005006|Drug|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
559167|NCT00005006|Drug|Alendronate|Alendronate 70mg/week
559168|NCT00005006|Drug|Teriparatide|Teriparatide 20mcg/day
559169|NCT00005005|Drug|PTH|
559170|NCT00005005|Drug|Alendronate|
559171|NCT00004997|Drug|Leucovorin|
559172|NCT00004993|Drug|Parathyroid hormone (hPTH 1-34)|
559173|NCT00004992|Behavioral|Intensive lifestyle|
559174|NCT00004992|Drug|Metformin|
559175|NCT00004992|Drug|Placebo|
559176|NCT00004990|Drug|Dexamethasone|
559177|NCT00004988|Drug|VNP20009|
559178|NCT00004984|Drug|Crystallized human recombinant insulin|
559179|NCT00004983|Behavioral|diabetes self-management education|
559180|NCT00004982|Drug|Combination Iron Chelation Therapy|
559181|NCT00004980|Device|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
559182|NCT00004980|Device|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
559183|NCT00004854|Drug|Carvedilol|
559184|NCT00004853|Biological|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC >=10,000/microliter
559185|NCT00004853|Biological|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
559186|NCT00004847|Drug|Fluorodopamine|
559187|NCT00004847|Drug|F-18 Fluorodopa|
559188|NCT00004846|Drug|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
559189|NCT00004739|Drug|Antiretroviral therapy|
559190|NCT00004845|Drug|Rofecoxib|
559191|NCT00004845|Drug|Naproxen|
559192|NCT00004734|Drug|pyridoxine|
559193|NCT00004734|Drug|cyanocobalamin|
559194|NCT00004734|Drug|folic acid multivitamin|
559195|NCT00004733|Drug|levodopa|
559196|NCT00004732|Procedure|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
559197|NCT00004732|Device|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
559198|NCT00004731|Drug|Coenzyme Q10|
559204|NCT00004727|Drug|ticlopidine|
559205|NCT00004941|Drug|monoclonal antibody cA2|
559206|NCT00004940|Drug|cysteine hydrochloride|
559207|NCT00004939|Drug|,4-diaminopyridine|
559208|NCT00004938|Drug|fluconazole|
559209|NCT00004844|Procedure|tissue implantation|
559210|NCT00004843|Procedure|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
559211|NCT00004843|Other|Observation|Usual care
559212|NCT00004842|Drug|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
559213|NCT00004840|Drug|thyrotropin-releasing hormone|
559214|NCT00004838|Drug|succimer|
559215|NCT00004834|Drug|imipramine|
559216|NCT00004834|Behavioral|cognitive-behavioral therapy|
559217|NCT00004833|Drug|Immune globulin|
559218|NCT00004832|Drug|3,4-diaminopyridine|
559219|NCT00004831|Drug|cysteine hydrochloride|
559220|NCT00004829|Drug|tobramycin|
559221|NCT00004828|Drug|liothyronine I 131|
559222|NCT00004827|Drug|docosahexaenoic acid|
559223|NCT00004826|Drug|clozapine|
559224|NCT00004825|Drug|recombinant human insulin-like growth factor I|
559225|NCT00004817|Drug|phenytoin|
559226|NCT00004817|Drug|valproate sodium|
559227|NCT00004816|Drug|monoclonal antibody M-T412|
559228|NCT00004815|Drug|growth hormone|
559229|NCT00004814|Drug|copolymer 1|
559230|NCT00004812|Behavioral|Exercise|
559231|NCT00004811|Drug|itraconazole|
559232|NCT00004810|Drug|-aminosalicylic acid|
559233|NCT00004809|Procedure|gene therapy|
559234|NCT00004808|Drug|fluconazole|
559235|NCT00004807|Drug|dextromethorphan|
559236|NCT00004807|Drug|topiramate|
559237|NCT00004807|Drug|Donepezil|
559238|NCT00004806|Genetic|Cystic fibrosis transmembrane conductance regulator|
559239|NCT00004805|Behavioral|CPR instruction|
559240|NCT00004804|Drug|interferon alfa|
559241|NCT00004802|Drug|dichlorphenamide|
559242|NCT00004801|Drug|monoclonal factor IX replacement therapy|
559243|NCT00004800|Biological|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
559244|NCT00004800|Biological|diphtheria-tetanus vaccine|
559245|NCT00004799|Biological|whole-cell pertussis vaccine|
559246|NCT00004799|Biological|diphtheria-tetanus vaccine|
559247|NCT00004797|Drug|fructose|
559248|NCT00004797|Drug|placebo|
559249|NCT00004796|Drug|lactulose|
559250|NCT00004795|Drug|dehydroepiandrosterone|
559251|NCT00004794|Drug|cidofovir|
559252|NCT00004789|Drug|heme arginate|
559253|NCT00004789|Drug|tin mesoporphyrin|
559254|NCT00004787|Drug|filgrastim|
559255|NCT00004786|Drug|iloprost|
559256|NCT00004785|Drug|dexamethasone|
559257|NCT00004785|Drug|methylprednisolone|
559258|NCT00004784|Drug|methotrexate|
559259|NCT00004784|Drug|ursodiol|
559260|NCT00004779|Genetic|Ad5-CB-CFTR|
559261|NCT00004778|Drug|betamethasone|
559262|NCT00004778|Drug|dexamethasone|
559263|NCT00004778|Drug|thyrotropin-releasing hormone|
559264|NCT00004776|Drug|topiramate|
559265|NCT00004772|Drug|Immune globulin|
559266|NCT00004771|Drug|leuprolide|
559267|NCT00004771|Drug|testosterone|
559268|NCT00004770|Drug|thioctic acid|
559269|NCT00004767|Drug|Sodium Benzoate|
559270|NCT00004767|Drug|Sodium Phenylacetate|
559271|NCT00004767|Drug|Sodium Phenylbutyrate|
559272|NCT00004767|Behavioral|Dietary Intervention|
559273|NCT00004763|Drug|leuprolide|
559274|NCT00004763|Drug|Ethinyl estradiol/norethindrone|
559275|NCT00004762|Drug|cladribine|
559276|NCT00004760|Behavioral|Exercise|
559277|NCT00004759|Drug|methylprednisolone|
559278|NCT00004759|Drug|tirilazad|
559279|NCT00004758|Drug|carbamazepine|
559280|NCT00004758|Drug|corticotropin|
559281|NCT00004758|Drug|nitrazepam|
559282|NCT00004758|Drug|pyridoxine|
559283|NCT00004758|Drug|valproic acid|
559284|NCT00004758|Procedure|Surgery|
559285|NCT00004757|Drug|acyclovir|
559286|NCT00004756|Procedure|Tailored educational program|
559287|NCT00004756|Procedure|Educational materials|
559288|NCT00004755|Drug|allopurinol|
559289|NCT00004755|Drug|glucantime|
559290|NCT00004754|Drug|epoprostenol|
559291|NCT00004751|Procedure|Surgery|
559292|NCT00004751|Procedure|Physical therapy|
559293|NCT00004748|Drug|colchicine|
559294|NCT00004748|Drug|methotrexate|
559295|NCT00004748|Drug|ursodiol|
559296|NCT00004747|Drug|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
559297|NCT00004744|Drug|immune globulin|
559298|NCT00004740|Drug|isoniazid|
559299|NCT00004705|Drug|amiloride|
559300|NCT00004705|Drug|uridine|
559301|NCT00004700|Drug|insulin-like growth factor I|
559302|NCT00004699|Drug|insulin-like growth factor I|
559303|NCT00004697|Drug|choline chloride|
559304|NCT00004696|Drug|morphine|
559305|NCT00004695|Drug|PEG-interleukin-2|
559306|NCT00004694|Drug|heparin|
559307|NCT00004690|Drug|monolaurin cream|
559308|NCT00004689|Drug|amithiozone|
559309|NCT00004689|Drug|clarithromycin|
559310|NCT00004689|Drug|ethambutol|
559311|NCT00004689|Drug|rifampin|
559312|NCT00004689|Drug|streptomycin|
559313|NCT00004688|Drug|carmustine|
559314|NCT00004688|Drug|mercaptopurine|
559315|NCT00004688|Drug|streptozocin|
559316|NCT00004686|Drug|methotrexate|
559317|NCT00004686|Drug|prednisone|
559318|NCT00004685|Drug|albuterol|
559319|NCT00004682|Drug|immune globulin|
559320|NCT00004670|Procedure|pallidotomy|
559321|NCT00004669|Drug|hydrocortisone|
559322|NCT00004667|Drug|von Willebrand factor|
559323|NCT00004665|Drug|dehydroepiandrosterone|
559324|NCT00004664|Drug|megestrol|
559325|NCT00004664|Behavioral|Exercise|
559326|NCT00004662|Drug|dehydroepiandrosterone|
559327|NCT00004660|Radiation|Radiotherapy|
559328|NCT00004660|Radiation|Sham treatment|
559329|NCT00004659|Procedure|irradiation|
559330|NCT00004659|Procedure|radiosurgery|
559331|NCT00004658|Drug|ribose|
559332|NCT00004658|Drug|thymidine|
559333|NCT00004658|Drug|uridine|
559334|NCT00004656|Procedure|Metabolic assessment with body composition evaluation|
559335|NCT00004654|Drug|soy protein isolate|
559336|NCT00004652|Drug|pimozide|
559337|NCT00004650|Drug|conjugated estrogens|
559338|NCT00004650|Drug|Medroxyprogesterone|
559339|NCT00004647|Drug|mexiletine|
559340|NCT00004646|Drug|prednisone|
559341|NCT00004645|Procedure|Plasma exchange|
559342|NCT00004644|Drug|acyclovir|
559343|NCT00004643|Drug|cytarabine|
559344|NCT00004642|Drug|SDZ MSL-109|
559345|NCT00004638|Procedure|pathogenesis study|
559346|NCT00004637|Drug|Vitamin E|
559347|NCT00004635|Drug|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
559348|NCT00004635|Drug|leuprolide acetate|Injections of leuprolide once a month for six months.
559349|NCT00004635|Drug|goserelin|Injections of Goserelin once a month for six months.
559350|NCT00004635|Other|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
559351|NCT00004573|Drug|ganciclovir|
559352|NCT00004572|Procedure|Sustacal challenge|
559353|NCT00004569|Procedure|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
559354|NCT00004567|Drug|Mycophenolate Mofetil|
559355|NCT00004564|Drug|Clopidogrel|
559356|NCT00004564|Drug|Atorvastatin|
559357|NCT00004563|Drug|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
559358|NCT00004563|Drug|Placebo|Matching gelcaps 25 mgs
559359|NCT00004562|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
559360|NCT00004562|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
559361|NCT00004562|Procedure|PTCA and stents|Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
559362|NCT00004562|Drug|ACE Inhibitors|Participants will receive ACE inhibitors.
559363|NCT00004561|Behavioral|exercise|
559364|NCT00004560|Device|defibrillator|
559365|NCT00004559|Behavioral|dietary polyunsaturated fatty acid|
559366|NCT00004558|Behavioral|dietary n-3 polyunsaturated fatty acids|
559367|NCT00004554|Drug|naltrexone (Revia)|100mg/day
559368|NCT00004554|Drug|sertraline (Zoloft)|200mg/day
559369|NCT00004554|Drug|Placebo|Placebo
559370|NCT00004553|Procedure|Electromyography|
559371|NCT00004552|Drug|acamprosate (Campral)|
559372|NCT00004551|Drug|nicotine replacement patch|
559373|NCT00004551|Behavioral|mood management|
559374|NCT00004549|Procedure|Magnetic resonance imaging|
559375|NCT00004547|Procedure|Surgery|Patients will undergo cytoreductive surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected.
559376|NCT00004547|Procedure|Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|
559377|NCT00004547|Drug|Postoperative dwell with paclitaxel and 5-FU|Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M^2) and 1 L of normal saline containing paclitaxel (125 mg/M^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
559378|NCT00004533|Drug|Adeno-associated virus-CFTR vector|
559379|NCT00000436|Behavioral|Self-efficacy and muscle strength training|
559380|NCT00000436|Procedure|High-intensity strength training|
559381|NCT00001984|Drug|Alemtuzumab and DSG|Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
559382|NCT00000435|Drug|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
559383|NCT00000435|Drug|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
559384|NCT00000434|Behavioral|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
559385|NCT00001972|Drug|15 O Water|
559386|NCT00001967|Drug|HAART|
559387|NCT00001964|Drug|Cyclosporine A|Cyclosporine A
559388|NCT00001964|Drug|ATG|ATG
559389|NCT00001964|Drug|MMF|MMF
559390|NCT00001962|Drug|Daclizumab|Daclizumab, 1mg/kg of body weight, every 2 weeks for a total of 5 infusions.
559391|NCT00001961|Procedure|MRI|
559392|NCT00001960|Device|Pacemaker therapy|
559393|NCT00001959|Drug|Pirfenidone|During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.
559394|NCT00001958|Drug|Hydroxyurea|
559395|NCT00001956|Procedure|Blood draw|
559396|NCT00001956|Procedure|Oral surgery|
559397|NCT00001956|Procedure|Tissue biopsy|
559398|NCT00001955|Drug|Etanercept|
559399|NCT00001955|Drug|Celecoxib|
559400|NCT00001954|Drug|Etanercept|
559401|NCT00001951|Drug|TMTDS|
559402|NCT00001946|Procedure|Magnetic resonance angiography|
559403|NCT00001941|Biological|daclizumab|
559404|NCT00000433|Drug|Anti-Tumor Necrosis Factor|
559405|NCT00000432|Behavioral|Education about disease prevention|
559406|NCT00000431|Drug|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
559407|NCT00000430|Drug|Alendronate|
559408|NCT00000430|Drug|Estrogen/progestin therapy|
559409|NCT00000429|Drug|Calcium carbonate|
559410|NCT00000428|Drug|Amitriptyline|Amitriptyline 25 mg po
559411|NCT00000428|Drug|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
559412|NCT00000427|Drug|Parathyroid hormone|
559413|NCT00000427|Drug|Alendronate|
559414|NCT00000111|Procedure|Oral mucosal graft|
559415|NCT00000110|Procedure|magnetic resonance spectroscopy|
559416|NCT00000110|Drug|dietary fat|
559417|NCT00000108|Behavioral|Exercise|
559418|NCT00000106|Device|Whole body hyperthermia unit|
559419|NCT00000393|Drug|Peptide T|
559420|NCT00000392|Drug|Peptide T|
559421|NCT00000392|Drug|Placebo|
559422|NCT00000391|Drug|Peptide T|
559423|NCT00000390|Drug|Imipramine hydrochloride|
559424|NCT00001934|Drug|Zenapax|
559425|NCT00001933|Drug|Nefiracetam|
559426|NCT00001926|Drug|O15|
559427|NCT00001926|Device|Cadwell rTMS|
559428|NCT00001925|Drug|Alcohol|
559429|NCT00001923|Procedure|Transcranial magnetic stimulation|
559430|NCT00001919|Drug|Hypericum (LI-160)|
559431|NCT00001917|Drug|O15|
559432|NCT00001917|Drug|[F-18] FP-TZTP|
559433|NCT00001911|Drug|Interleukin-12|
559434|NCT00001905|Drug|Interferon gamma|
559435|NCT00001901|Drug|Etanercept|
559436|NCT00001895|Drug|FDG|
559437|NCT00001895|Drug|NH(3)|
559438|NCT00001894|Procedure|pacemaker implantation|
559439|NCT00001894|Procedure|percutaneous transluminal septal ablation (PTSA)|
559440|NCT00001893|Drug|TNFR:Fc|
559441|NCT00001880|Drug|methotrexate|CSA beginning day -4 and intravenous MTX on days +1, +3, and +6 will be given
559442|NCT00001880|Drug|cyclosporin|CSA beginning day -4 and intravenous MTX on days +1, +3, and +6 will be given
559443|NCT00001877|Drug|Pentoxifylline|
559444|NCT00001873|Device|Isolex 300i plus MoAbs|
559445|NCT00001870|Drug|Acetylcholine|
559446|NCT00001865|Drug|Daclizumab|
559447|NCT00001863|Drug|Leflunomide|
559448|NCT00001862|Drug|Enbrel|
559449|NCT00001860|Drug|Sandostatin LAR Depot versus transsphenoidal surgery|
559450|NCT00001854|Drug|Ribavirin|
559451|NCT00001849|Drug|Pentetreotide|Binds primarily to the somatostatin receptors subtypes (sst) 2 and 5
559452|NCT00001849|Drug|18F-DOPA|F-DOPA is a radiolabeled amino acid used as a radiotracer in positron emission tomography.
559453|NCT00001848|Drug|Raloxifene|
559454|NCT00001842|Drug|Granulocyte colony-stimulating factor|
559455|NCT00001842|Drug|Dexamethasone|
559456|NCT00001835|Drug|Oxaliplatin|
559457|NCT00001832|Drug|gp100:209-217 (210M)|"gp100 = gp100:209‑217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209‑217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.~MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections."
559458|NCT00001832|Drug|Montanide ISA-51|MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
559459|NCT00001832|Drug|IL-2|"125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.~720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses."
559460|NCT00001832|Drug|MART-1:26-35(27L)|MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
559461|NCT00001832|Biological|Abl cells|Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10^9‑10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
559462|NCT00001832|Drug|Fludarabine|5x25 mg/m^2 intravenous
559463|NCT00001832|Drug|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
559464|NCT00001832|Biological|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count > 1.0 x10^9/L x 3 days or > 5.0 x10^9/L.
559465|NCT00001832|Procedure|Apheresis|
559466|NCT00001830|Drug|Th2 cells in allo HSCTT|
559467|NCT00001830|Drug|Th2 Cells|
559468|NCT00001827|Biological|aldesleukin|
559469|NCT00001827|Biological|incomplete Freund's adjuvant|
559470|NCT00001827|Biological|p53 peptide vaccine|
559471|NCT00001827|Biological|sargramostim|
559472|NCT00001827|Biological|therapeutic autologous dendritic cells|
559473|NCT00001827|Procedure|in vitro-treated peripheral blood stem cell transplantation|
559474|NCT00001806|Other|Genetic Education and Counseling|Group Education and Counseling
559475|NCT00001806|Other|Genetic Education and Counseling|Individual Education and Counlseing
559476|NCT00001785|Drug|Recombinant human interferon beta-1a|
559477|NCT00001784|Drug|Mexiletine|
559478|NCT00001783|Drug|0-15 Water|
559479|NCT00001781|Drug|CGP 77116|
559480|NCT00001776|Device|Cadwell Rapid Rate Magnetic Stimulator|
559481|NCT00001766|Drug|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
559482|NCT00001765|Device|Nexell Isolex with T-cell Depletion|
559483|NCT00001765|Device|Baxter isolex 300i|
559484|NCT00001764|Drug|Mycophenolate Mofetil|
559485|NCT00001758|Drug|Abacavir|
559486|NCT00001758|Drug|Amprenavir|
559487|NCT00001758|Drug|Efavirenz|
559488|NCT00001750|Drug|Stemgen|
559489|NCT00001749|Drug|Antithymocyte globulin|
559490|NCT00001749|Drug|Cyclosporine|
559491|NCT00001741|Drug|Losartan|
559492|NCT00001737|Drug|Cyclosporin A Implant|
559493|NCT00001729|Drug|Ribavirin|
559494|NCT00001728|Drug|Fosamax (Alendronate)|
559495|NCT00001725|Drug|Dextromethorphan|
559496|NCT00001724|Drug|Flurbiprofen|
559497|NCT00001723|Drug|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
559498|NCT00001723|Drug|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
559499|NCT00001720|Drug|Alendronate|
559500|NCT00001716|Drug|Nitric Oxide|
559501|NCT00001716|Drug|Nitroglycerin|
559502|NCT00001713|Drug|Recombinant Tissue Plasminogen Activator|
559503|NCT00001713|Drug|Heparin|
559504|NCT00001713|Drug|Warfarin|
559505|NCT00001703|Biological|incomplete Freund's adjuvant|0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
559506|NCT00001703|Biological|von Hippel-Lindau peptide vaccine|1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
559507|NCT00001698|Drug|Ketorolac Rinse|
559508|NCT00001693|Drug|Celecoxib (SC-58635)|
559509|NCT00001689|Drug|Vincristine|
559510|NCT00001683|Drug|COL-3|
559511|NCT00001676|Drug|SQ Fludarabine|
559512|NCT00001666|Device|Cadwell High-Speed Magnetoelectric Stimulator|
559513|NCT00001666|Device|Magpro High-Speed Magnetoelectric Stimulator|
559514|NCT00001663|Device|Magstim Super Rapid Stimulator|
559515|NCT00001662|Drug|CX516 (Ampalex)|
559516|NCT00001656|Drug|Olanzapine|tablet; 5-20mg/day; 8 weeks
559517|NCT00001656|Drug|Clozapine|tablet; 12.5-900mg/day; 8 weeks
559518|NCT00001651|Other|[6,6-2H2]-glucose|[6,6-2H2]-glucose will be administered as a continuous IV infusion for one to five days.
559519|NCT00001649|Drug|Valaciclovir|
559520|NCT00001647|Procedure|White blood cell infusion|
559521|NCT00001644|Drug|Indinavir|
559522|NCT00001644|Drug|Zidovudine|
559523|NCT00001644|Drug|Lamivudine|
559524|NCT00001644|Drug|Nevirapine|
559525|NCT00001644|Procedure|Blood testing|
559526|NCT00001644|Procedure|Lymph node biospy|
559527|NCT00001644|Procedure|Leukapheresis|
559528|NCT00001637|Procedure|Blood cell transplantation|
559529|NCT00001631|Procedure|Magnetic resonance imaging|
559530|NCT00001630|Device|Isolex 300i|
559531|NCT00001626|Drug|antithymocyte globulin|antithymocyte globulin
559532|NCT00001626|Drug|cyclophosphamide|cyclophosphamide
559533|NCT00001626|Drug|cyclosporine|cyclosporine
559534|NCT00001623|Procedure|Allogeneic Bone Marrow Transplant|
559535|NCT00001601|Procedure|Electrocardiogram|
559536|NCT00001601|Procedure|Biopsies|
559537|NCT00001601|Procedure|Diagnostic imaging|
559538|NCT00001599|Drug|Thalidomide|
559539|NCT00001598|Drug|Dehydroepiandrosterone|
559540|NCT00001596|Drug|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
559541|NCT00001596|Drug|Placebo|Placebo (3 pills), three times daily.
559542|NCT00001586|Biological|Rituximab|Rituxan
559543|NCT00001586|Drug|Fludarabine phosphate|Fludara
559544|NCT00001586|Other|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
559545|NCT00001576|Drug|Melphalan|
559546|NCT00001576|Drug|Floxuridine|
559547|NCT00001576|Drug|Leucovorin|
559548|NCT00001575|Biological|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
559549|NCT00001575|Drug|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
559550|NCT00001572|Drug|Id-KLH Vaccine|
559551|NCT00001572|Drug|QS-21 (Stimulation-QS-21) Drug|
559552|NCT00001569|Drug|Cisplatin|
559553|NCT00001569|Drug|Paclitaxel|
559554|NCT00001569|Drug|5-FU|
559555|NCT00001568|Drug|2-Fluoro-2-deoxyglucose|
559556|NCT00001567|Drug|Roferon-A|
559557|NCT00001566|Biological|therapeutic autologous dendritic cells|3 syringes containing 1 x 10^6peptide pulsed dendritic cells
559558|NCT00001566|Drug|indinavir sulfate|Oral dose, 350 mg/m^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
559559|NCT00001566|Procedure|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
559560|NCT00001564|Drug|EF-1 Peptide|
559561|NCT00001564|Drug|EF-2 Peptide|
559562|NCT00001564|Drug|PXFK Peptide|
559563|NCT00001564|Drug|E7 Peptide|
559564|NCT00001564|Drug|IL-2|
559565|NCT00001564|Drug|IL-4|
559566|NCT00001564|Drug|GM-CSF|
559567|NCT00001564|Drug|CD40 Ligand|
559568|NCT00001563|Biological|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
559569|NCT00001563|Biological|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
559570|NCT00001563|Drug|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
559571|NCT00001561|Drug|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
559572|NCT00001561|Drug|GM-CSF|
559573|NCT00001550|Drug|IVIg|
559574|NCT00001545|Device|Magstim Super Rapid Magnetic Stimulator|
559575|NCT00001545|Device|Cadwell MES-10|
559576|NCT00001535|Drug|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
559577|NCT00001534|Drug|Losartan|
559578|NCT00001532|Device|Toshibia Aquilion ONE CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
559579|NCT00001526|Drug|Daclizumab (Zenapax)|
559580|NCT00001524|Drug|Thalidomide|
559581|NCT00001521|Drug|Flutamide|Non steroidal antiandrogen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol
559582|NCT00001521|Drug|Letrozole|Armomatase inhibitor.
559583|NCT00001521|Drug|Hydrocortisone|
559584|NCT00001515|Device|virtual bronchoscopy|
559585|NCT00001512|Drug|Id-KLH Vaccine|
559586|NCT00001512|Drug|GM-CSF|
559587|NCT00001507|Drug|Monoclonal Antibody 3A1|
559588|NCT00001507|Drug|Monoclonal Antibody 95-5-49|
559589|NCT00001507|Drug|Monoclonal Antibody 95-6-22|
559590|NCT00001507|Device|Baxter Isolex 3001 Stem Cell Selection System|
559591|NCT00001507|Device|Ceprate SC|
559592|NCT00001504|Drug|9-cis-Retinoic Acid|
559593|NCT00001487|Drug|Dehydroepiandrosterone|
559594|NCT00001483|Drug|buproprion (Wellbutrin)|
559595|NCT00001483|Drug|sertraline (Zoloft)|
559596|NCT00001483|Drug|venlafaxine (Effexor)|
559597|NCT00001481|Drug|Estradiol, Progesterone, Placebo|To determine whether women who have had a previous episode of postpartum major affective episode will experience differential mood and behavioral effects compared with controls.
559598|NCT00001476|Drug|Gene Therapy Method for CGD|
559599|NCT00001476|Device|Isolex 300i Magnetic Cell Selector|
559600|NCT00001475|Drug|IL-2 plus Anti-TNF or Thalidomide|
559601|NCT00001474|Drug|Interleukin-2|
559602|NCT00001465|Device|Toshibia Aquilion One CT|The Toshiba Aquilion ONE CT system is currently being used for studies in both general CT radiology and CT cardiac imaging. One of the unique aspects of the Aquilion ONE CT system is its ability to acquire whole organ volume images in a single rotation by utilizing an x-ray detector that is configured as 320 detector rows with a 0.5 mm width, providing a z-axis coverage of 16 cm of anatomy. In line with the evolutionary changes to CT systems, the Aquilion ONE will be upgraded with new technology that will expand its capabilities. The changes being made to the Aquilion ONE will provide enhancements to image acquisition capabilities, reduce ionizing radiation dose, and improve subject access to the system. All of these features assist in enhancing the safety of the currently installed Aquilion ONE CT system.
559603|NCT00001460|Behavioral|inpatient evaluation and management|
559604|NCT00001457|Drug|Lamivudine|
559605|NCT00001444|Drug|7-hydroxystaurosporine (UCN-01)|
559606|NCT00001442|Drug|paclitaxel concurrent with radiation therapy|
559607|NCT00001440|Procedure|Autologous T cells|
559608|NCT00001440|Drug|Interleukin-2|
559609|NCT00001430|Procedure|PBSC|
559610|NCT00001430|Drug|IL-2|
559611|NCT00001430|Drug|EPOCH II|
559612|NCT00001426|Drug|Cyclophosphamide|
559613|NCT00001426|Drug|Paclitaxel|
559614|NCT00001426|Drug|Cisplatin|
559615|NCT00001426|Drug|G-CSF|
559616|NCT00001410|Drug|Lysodase|
559617|NCT00001409|Drug|Interleukin-2|
559618|NCT00001407|Drug|Interferon Gamma|
559619|NCT00001399|Drug|Transduced CD34+ Cells|
559620|NCT00001398|Drug|Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)|
559621|NCT00001396|Device|Paragon Pacemaker|
559622|NCT00001386|Drug|PCLUS 3-18 MN|
559623|NCT00001386|Drug|PCLUS 6.1 MN|
559710|NCT00000413|Behavioral|Psychoeducational program|
559711|NCT00000412|Drug|Alendronate|
559712|NCT00000412|Drug|Calcitriol|
559713|NCT00000412|Drug|Placebo Alendronate|
559624|NCT00001379|Biological|Interferon|For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.
559625|NCT00001379|Drug|Rituxan and EPOCH|For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
559626|NCT00001368|Procedure|cytokine and leukocyte activation profile|
559627|NCT00001359|Drug|Penicillin or Placebo|
559628|NCT00001357|Drug|Interleukin-2|
559629|NCT00001354|Drug|Interleukin-2/Zidovudine (AZT)|
559630|NCT00001353|Drug|Genetically Marked Syngeneic T Lymphocytes|
559631|NCT00001343|Drug|Humatrope|
559632|NCT00001343|Drug|Oxandrolone|
559633|NCT00001339|Drug|doxorubicin, vincristine, and etoposide with mitotane|
559634|NCT00001337|Drug|EPOCH|Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.
559635|NCT00001337|Biological|Rituximab|Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
559636|NCT00001335|Drug|ADR-529|
559637|NCT00001335|Drug|Topotecan|
559638|NCT00001335|Drug|G-CSF|
559639|NCT00001328|Drug|Cytovene (Ganciclovir Sodium)|
559640|NCT00001328|Device|G1TKSVNa.53 Producer Cell Line|
559641|NCT00001325|Drug|18 FDG|
559642|NCT00001307|Drug|Oxygen-15 Water|
559643|NCT00001307|Drug|Capsaicin|
559644|NCT00001305|Drug|Humatrope|Patients receive a subcutaneous injection.
559645|NCT00001304|Drug|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
559646|NCT00001304|Drug|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
559647|NCT00001303|Drug|Reference Endotoxin|
559648|NCT00001303|Drug|Inhaled Nitric Oxide|
559649|NCT00001302|Drug|PSC 833|
559650|NCT00001288|Drug|15 O Water|
559651|NCT00001288|Drug|FDG|
559652|NCT00001282|Drug|Zidovudine (AZT) & Interleukin-2 (IL2)|
559653|NCT00001266|Drug|Suramin|
559654|NCT00001262|Drug|Copper Histidine|
559655|NCT00001261|Drug|Gamma Globulin|
559656|NCT00001256|Drug|prednisone and methotrexate|
559657|NCT00001255|Drug|ADA PBSC|
559658|NCT00001255|Drug|ADA Umbilical Cord Blood Cells|
559659|NCT00001255|Drug|Transduced Lymphocytes|
559660|NCT00001253|Behavioral|cognitive tests and scales|
559661|NCT00001251|Drug|Mafosfamide|
559662|NCT00001250|Drug|preoperative dose intense chemotherapy (FLAC/G-CSF)|
559663|NCT00001248|Device|MRI|MRI evaluations of brain, spinal cord, or optic nerves may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk. Unless specifically designated below, MRI scans are performed on FDA- approved scanners with approved radiofrequency coils, and their use conforms to the corresponding FDA labels.
559664|NCT00001248|Device|Coils|MRI evaluations of brain, spinal cord, or optic nerves may be performed at field strengths of 1.5T, 3T, and/or 7T, under conditions designated by the FDA as constituting nonsignificant risk. Unless specifically designated below, MRI scans are performed on FDA- approved scanners with approved radiofrequency coils, and their use conforms to the corresponding FDA labels.
559665|NCT00001234|Genetic|human glucocerebrosidase cDNA|
559666|NCT00001228|Drug|Interferon|
559667|NCT00001221|Drug|Growth Hormone (Humatrope)|
559668|NCT00001213|Drug|Cysteamine|
559669|NCT00001212|Drug|prednisone|
559670|NCT00001212|Drug|cyclophosphamide|
559671|NCT00001212|Drug|cyclosporin A|
559672|NCT00001208|Other|Botulinum Toxin|
559673|NCT00001202|Drug|Spironolactone|
559674|NCT00001202|Drug|Testolactone|
559675|NCT00001202|Drug|Deslorelin|
559676|NCT00001197|Drug|Hydroxyurea|
559677|NCT00001191|Drug|Pantoprazole|
559678|NCT00001191|Drug|Omeprazole|
559679|NCT00001182|Procedure|current standard of care treatments|
559680|NCT00001181|Drug|Testolactone|
559681|NCT00001180|Drug|Ovine Corticotropin-Releasing Hormone (oCRH)|
559682|NCT00001165|Drug|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
559683|NCT00001155|Drug|cyclophosphamide|
559684|NCT00001151|Drug|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
559685|NCT00001146|Drug|Ethyl Eicosapentaenoic Acid|
559686|NCT00001146|Drug|OmegaBrite|
559687|NCT00001145|Drug|Bacteriophage|
559688|NCT00001145|Drug|rhuCD40L|
559689|NCT00001145|Drug|KLH|
559690|NCT00001144|Drug|Modified bone marrow stem cell transplantation|
559691|NCT00000426|Drug|Calcium supplement|
559692|NCT00000425|Drug|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
559693|NCT00000425|Drug|Acetaminophen|
559694|NCT00000424|Procedure|Tidal lavage vs. sham lavage of the knee|
559695|NCT00000423|Behavioral|Social support group|
559696|NCT00000423|Behavioral|Social support and education group|
559697|NCT00000422|Behavioral|Cognitive-behavioral psychotherapy and physical exercise|
559698|NCT00000421|Drug|Prednisone|
559699|NCT00000421|Drug|Placebo|
559700|NCT00000420|Drug|Ortho-Novum 777|
559701|NCT00000419|Drug|Premarin and Provera|
559702|NCT00000418|Procedure|Psychosocial intervention|
559703|NCT00000417|Procedure|Counseling intervention|
559704|NCT00000417|Device|Informational film|
559705|NCT00000416|Other|Rehabilitation counseling|Provided in 2 in-person meetings and in follow-up phone calls
559706|NCT00000415|Procedure|Physical activity|
559707|NCT00000415|Drug|Calcium supplement|
559708|NCT00000414|Behavioral|Arthritis Self-Management Program|
559709|NCT00000414|Behavioral|SMART Program|
559714|NCT00000412|Drug|Placebo Calcitriol|
559715|NCT00000411|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
559716|NCT00000411|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
559717|NCT00000410|Procedure|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
559718|NCT00000410|Procedure|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
559719|NCT00000409|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
559720|NCT00000409|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
559721|NCT00000409|Procedure|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
559722|NCT00000409|Procedure|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
559723|NCT00000408|Procedure|Patient education evaluation|
559724|NCT00000407|Behavioral|Vocational counseling intervention|
559725|NCT00000407|Behavioral|Reading materials for control participants|
559726|NCT00000407|Behavioral|Standard of care|No education or behavioral intervention
559727|NCT00000406|Procedure|Progressive resistance exercise|
559728|NCT00000405|Procedure|Exercise intervention|
559729|NCT00000404|Behavioral|Patient education in self-care of knee OA|
559730|NCT00000403|Drug|Doxycycline|
559731|NCT00000402|Drug|Calcium|
559732|NCT00000401|Drug|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
559733|NCT00000400|Drug|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
559734|NCT00000400|Drug|alendronate|70 mg/week by oral route
559735|NCT00000399|Drug|Hormone replacement therapy|
559736|NCT00000399|Procedure|Strength training|
559737|NCT00000398|Behavioral|Coping skills training|
559738|NCT00000398|Behavioral|Physical exercise training|
559739|NCT00000398|Behavioral|Coping skills training plus physical exercise training|
559740|NCT00000397|Behavioral|Behavioral insomnia therapy|
559741|NCT00000396|Behavioral|Patient self-care education|
559742|NCT00000395|Drug|Methotrexate|
559743|NCT00000395|Dietary Supplement|Folinic acid|
559744|NCT00000395|Dietary Supplement|Folic acid|
559745|NCT00000394|Procedure|Acupuncture therapy|
559746|NCT00000105|Biological|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
559747|NCT00000105|Biological|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
559748|NCT00000105|Drug|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
559749|NCT00000105|Biological|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
559750|NCT00000104|Procedure|ERP measures of attention and memory|
559751|NCT00000102|Drug|Nifedipine|
559752|NCT00000458|Drug|sertraline (Zoloft)|
559753|NCT00000458|Behavioral|cognitive behavior therapy|
559754|NCT00000457|Drug|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion~1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
559755|NCT00000457|Drug|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
559756|NCT00000456|Drug|naltrexone (Revia)|
559757|NCT00000456|Behavioral|cognitive behavior therapy|
559758|NCT00000456|Behavioral|motivational enhancement therapy|
559759|NCT00000455|Drug|naltrexone|
559760|NCT00000454|Drug|nicotine replacement patch|
559761|NCT00000452|Drug|naltrexone (Revia)|
559762|NCT00000452|Behavioral|Compliance Enhancement Tech.|
559763|NCT00000452|Behavioral|Cognitive Behavior Therapy|
559764|NCT00000451|Drug|sertraline|16 week outpatient study
559765|NCT00000451|Drug|naltrexone|16 week outpatient study
559766|NCT00000450|Drug|Naltrexone Tablet|
559767|NCT00000450|Drug|Matched Placebo Tablet|
559768|NCT00000449|Drug|naltrexone (Revia)|
559769|NCT00000449|Behavioral|cognitive behavioral therapy|
559770|NCT00000449|Behavioral|cue exposure treatment|
559859|NCT00000178|Drug|Prednisone|
559771|NCT00000448|Drug|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
559772|NCT00000448|Drug|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
559773|NCT00000447|Drug|naltrexone (Revia)|
559774|NCT00000447|Drug|nicotine replacement patch|
559775|NCT00000446|Drug|sertraline (Zoloft)|
559776|NCT00000445|Drug|naltrexone (Revia)|
559777|NCT00000444|Drug|nicotine replacement patch|
559778|NCT00000443|Drug|ondansetron (Zofran)|
559779|NCT00000442|Drug|naltrexone (Revia)|
559780|NCT00000441|Drug|lorazepam (Ativan)|
559781|NCT00000441|Drug|carbamazepine (Tegretol)|
559782|NCT00000440|Drug|naltrexone (Revia)|
559783|NCT00000440|Drug|sertraline (Zoloft)|
559784|NCT00000439|Drug|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
559785|NCT00000438|Drug|naltrexone (Revia)|
559786|NCT00000437|Drug|Naltrexone Tablet and Nicotine Patch|
559787|NCT00000437|Drug|Naltrexone Tablet and Placebo Patch|
559788|NCT00000437|Drug|Placebo Tablet and Nicotine Patch|
559789|NCT00000437|Drug|Placebo Tablet and Placebo Patch|
559790|NCT00000389|Drug|Fluvoxamine|
559791|NCT00000388|Behavioral|Psychosocial treatment|
559792|NCT00000388|Drug|Anti-ADHD medication|
559793|NCT00000388|Behavioral|Assessment-and-Referral|
559794|NCT00000387|Behavioral|Self-management therapy|Behavioral
559795|NCT00000387|Behavioral|Self-management therapy|
559796|NCT00000386|Behavioral|Exposure and Response Prevention|
559797|NCT00000386|Behavioral|Family Treatment Program|
559798|NCT00000386|Behavioral|Relaxation Training|
559799|NCT00000386|Behavioral|Behavior therapy|
559800|NCT00000386|Behavioral|Family Counseling|
559801|NCT00000385|Drug|Lithium|Lithium 600 mg to 2700 mg per day
559802|NCT00000385|Drug|Placebo|Matching placebo
559803|NCT00000384|Behavioral|Cognitive Behavior Therapy|
559804|NCT00000384|Behavioral|Educational Support|
559805|NCT00000384|Drug|Sertraline|
559806|NCT00000383|Behavioral|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
559807|NCT00000383|Behavioral|Child-Centered Therapy|Client-directed supportive interventions
559808|NCT00000382|Behavioral|Infant-Parent Psychotherapy|
559809|NCT00000382|Behavioral|Child Protective Services|
559810|NCT00000382|Behavioral|Psychoeducational Home Visitation|
559811|NCT00000382|Behavioral|Parent Education|
559812|NCT00000381|Drug|Fluoxetine|
559813|NCT00000380|Drug|GHRH|
559814|NCT00000379|Drug|Fluoxetine|
559815|NCT00000379|Behavioral|EMDR|
559816|NCT00000378|Drug|Sertraline|12 week trial dose up to 200mgs
559817|NCT00000378|Drug|Nortriptyline|12 week trial dose adjusted to therapeutic level
559818|NCT00000377|Drug|Nortriptyline|
559819|NCT00000376|Behavioral|Cognitive therapy|
559820|NCT00000376|Drug|Desipramine|
559821|NCT00000375|Drug|Nortriptyline-lithium (NOR-Li)|
559822|NCT00000375|Procedure|Bilateral electroconvulsive therapy (ECT)|
559823|NCT00000375|Drug|Continuation therapy|
559824|NCT00000375|Behavioral|Continuation ECT|
559825|NCT00000374|Drug|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
559826|NCT00000374|Drug|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
559827|NCT00000373|Drug|olanzapine + fluoxetine|
559828|NCT00000373|Drug|placebo + fluoxetine|
559829|NCT00000372|Drug|D-cycloserine|
559830|NCT00000372|Drug|Glycine|
559831|NCT00000372|Drug|Clozapine|
559832|NCT00000372|Drug|Placebo|
559833|NCT00000371|Drug|D-cycloserine|50 mg/daily by mouth
559834|NCT00000371|Drug|Placebo|50 mg/day of placebo by mouth
559835|NCT00000370|Behavioral|Cognitive behavior therapy|
559836|NCT00000370|Behavioral|Performance-based exposure therapy|
559837|NCT00000370|Behavioral|Psychosocial intervention|
559838|NCT00000369|Behavioral|Individual psychotherapy|
559839|NCT00000369|Drug|Lithium carbonate|
559840|NCT00000368|Behavioral|Cognitive behavior therapy|
559841|NCT00000368|Drug|Paroxetine or other medication - algorithm used|
559842|NCT00000367|Drug|Treatment of depression|
559843|NCT00000367|Behavioral|Suicide prevention intervention|
559844|NCT00000367|Drug|Suicide prevention treatment|
559845|NCT00000363|Drug|Antihistamine|
559846|NCT00000363|Drug|Corticosteroid|
559847|NCT00000362|Behavioral|Chin-down position|
559848|NCT00000362|Behavioral|Thickened liquid administration|
559849|NCT00000361|Drug|Corticosteroids|
559850|NCT00000361|Drug|Methotrexate|
559851|NCT00000359|Behavioral|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
559852|NCT00000359|Behavioral|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
559853|NCT00000359|Behavioral|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
559854|NCT00000359|Behavioral|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
559855|NCT00000359|Behavioral|ShamManeuver|Passive movement of the head
559856|NCT00000180|Drug|AIT-082|
559857|NCT00000179|Drug|Trazodone|
559858|NCT00000179|Drug|Haloperidol|
559860|NCT00000177|Drug|Estrogen|
559861|NCT00000176|Drug|Estrogen|
559862|NCT00000176|Drug|Estrogen and Progesterone|
559863|NCT00000175|Drug|Estrogen|
559864|NCT00000175|Drug|Testosterone|
559865|NCT00000174|Drug|Rivastigmine|
559866|NCT00000173|Drug|Donepezil|
559867|NCT00000173|Drug|Vitamin E|
559868|NCT00000172|Drug|Galantamine|
559869|NCT00000171|Drug|Melatonin|
559870|NCT00000623|Drug|Deferoxamine|
559871|NCT00000623|Drug|Deferiprone|
559872|NCT00000623|Drug|Arginine|
559873|NCT00000623|Drug|Sildenafil|
559874|NCT00000623|Drug|Decitabine|
559875|NCT00000621|Drug|all trans retinoic acid|
559876|NCT00000621|Drug|13 cis retinoic acid|
559877|NCT00000621|Drug|placebo|
559878|NCT00000620|Drug|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control <6%; standard control 7.0-7.9%).
559879|NCT00000620|Drug|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control <120 mm Hg; standard control <140 mm Hg).
559880|NCT00000620|Drug|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
559881|NCT00000619|Procedure|catheterization, Swan-Ganz|
559882|NCT00000617|Drug|azithromycin|
559883|NCT00000616|Behavioral|diet, sodium-restricted|
559884|NCT00000616|Behavioral|diet, fat-restricted|
559885|NCT00000616|Behavioral|exercise|
559886|NCT00000616|Behavioral|diet, reducing|
559887|NCT00000616|Behavioral|alcohol drinking|
559888|NCT00000615|Behavioral|diet, reducing|
559889|NCT00000614|Drug|warfarin|
559890|NCT00000613|Behavioral|dietary supplements|
559891|NCT00000613|Drug|genistein|
559892|NCT00000613|Behavioral|diet, soy proteins|
559893|NCT00000612|Drug|estrogens, conjugated|
559894|NCT00000612|Behavioral|diet, soy proteins|
559895|NCT00000612|Behavioral|dietary supplements|
559896|NCT00000611|Drug|hormone replacement therapy|
559897|NCT00000611|Drug|estrogens|
559898|NCT00000611|Drug|progestins|
559899|NCT00000611|Drug|estrogen replacement therapy|
559900|NCT00000611|Behavioral|diet, fat-restricted|
559901|NCT00000611|Drug|calcium|
559902|NCT00000611|Drug|vitamin D|
559903|NCT00000611|Behavioral|dietary supplements|
559904|NCT00000610|Drug|magnesium|
559905|NCT00000609|Drug|amiodarone|
559906|NCT00000609|Device|defibrillators, implantable|
559907|NCT00000608|Behavioral|diet, fat-restricted|
559908|NCT00000608|Behavioral|diet, sodium-restricted|
559909|NCT00000607|Device|Left ventricular assist device|A type of implantable heart pump
559910|NCT00000607|Device|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
559911|NCT00000606|Procedure|Lung volume reduction surgery|
559912|NCT00000605|Drug|hormone replacement therapy|
559913|NCT00000605|Drug|estrogens|
559914|NCT00000605|Drug|medroxyprogesterone|
559915|NCT00000604|Procedure|cardiopulmonary bypass|
559916|NCT00000604|Procedure|heart arrest, induced|
559917|NCT00000603|Procedure|stem cell transplantation|
559918|NCT00000602|Drug|hydroxyurea|
559919|NCT00000601|Drug|estrogen replacement therapy|
559920|NCT00000601|Drug|estrogens|
559921|NCT00000601|Drug|progesterone|
559922|NCT00000601|Drug|hormone replacement therapy|
559923|NCT00000600|Drug|Vitamin E|
559924|NCT00000600|Drug|Vitamin C|
559925|NCT00000599|Drug|colestipol|
559926|NCT00000599|Drug|niacin|
559927|NCT00000599|Behavioral|diet, fat-restricted|
559928|NCT00000598|Behavioral|diet, fat-restricted|
559929|NCT00000598|Behavioral|exercise|
559930|NCT00000597|Drug|antilymphocyte serum|
559931|NCT00000597|Drug|nandrolone|
559932|NCT00000596|Drug|prednisone|
559933|NCT00000596|Drug|cyclophosphamide|
559934|NCT00000596|Drug|dapsone|
559935|NCT00000595|Drug|deferoxamine|
559936|NCT00000594|Drug|cholestyramine|
559937|NCT00000593|Procedure|blood transfusion|
559938|NCT00000592|Procedure|blood transfusion|
559939|NCT00000591|Procedure|lymphocyte depletion|
559940|NCT00000590|Drug|immunoglobulins|
559941|NCT00000589|Procedure|platelet transfusion|
559942|NCT00000588|Drug|chelation therapy|
559943|NCT00000587|Procedure|erythropoietin, recombinant|
559944|NCT00000586|Drug|hydroxyurea|
559945|NCT00000585|Drug|penicillin|
559946|NCT00000584|Drug|immunoglobulins|
559947|NCT00000583|Biological|hepatitis B vaccines|
559948|NCT00000582|Drug|factor ix|
559949|NCT00000581|Procedure|leukocyte transfusions|
559950|NCT00000580|Drug|immunoglobulins, intravenous|
559951|NCT00000579|Procedure|Low Tidal Volume Ventilation|
559952|NCT00000579|Procedure|Positive End-Expiratory Pressure|
559953|NCT00000579|Drug|Lysofylline|
559954|NCT00000579|Drug|Methylprednisolone|
559955|NCT00000579|Drug|Ketoconazole|
559956|NCT00000579|Procedure|Fluid Management|
559957|NCT00000579|Procedure|Pulmonary Artery Catheter|
559958|NCT00000578|Drug|theophylline|
559959|NCT00000578|Drug|beclomethasone|
559960|NCT00000577|Drug|Albuterol|
559961|NCT00000577|Drug|Colchicine|
559962|NCT00000577|Drug|Adrenal Cortex Hormones|
559963|NCT00000577|Drug|Adrenergic-Beta Agonists|
559964|NCT00000576|Drug|beclomethasone|
559965|NCT00000575|Drug|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
559966|NCT00000575|Drug|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
559967|NCT00000575|Drug|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
559968|NCT00000574|Drug|ibuprofen|
559969|NCT00000573|Procedure|enteral nutrition|
559970|NCT00000572|Procedure|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
559971|NCT00000572|Procedure|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
559972|NCT00000571|Device|ventilators, negative pressure|
559973|NCT00000570|Drug|pulmonary surfactant|
559974|NCT00000569|Drug|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
559975|NCT00000569|Other|Placebo|Placebo
559976|NCT00000568|Behavioral|smoking cessation|
559977|NCT00000568|Drug|ipratropium|
559978|NCT00000567|Procedure|high-frequency ventilation|
559979|NCT00000566|Procedure|ventilation-perfusion ratio|
559980|NCT00000566|Procedure|angiography|
559981|NCT00000565|Procedure|intermittent positive-pressure breathing|
559982|NCT00000564|Procedure|oxygen inhalation therapy|
559983|NCT00000563|Drug|dexamethasone|
559984|NCT00000562|Procedure|extracorporeal membrane oxygenation|
559985|NCT00000561|Device|pacemaker, artificial|
559986|NCT00000560|Drug|adrenergic beta antagonists|
559987|NCT00000559|Drug|estrogen replacement therapy|
559988|NCT00000559|Drug|hormone replacement therapy|
559989|NCT00000559|Drug|estradiol|
559990|NCT00000559|Drug|medroxyprogesterone|
559991|NCT00000558|Drug|angiotensin-converting enzyme inhibitors|
559992|NCT00000557|Behavioral|social support|
559993|NCT00000556|Drug|amiodarone|
559994|NCT00000556|Drug|sotalol|
559995|NCT00000556|Drug|propafenone|
559996|NCT00000556|Drug|flecainide|
559997|NCT00000556|Drug|quinidine|
559998|NCT00000556|Drug|moricizine|
559999|NCT00000556|Drug|disopyramide|
560000|NCT00000556|Drug|procainamide|
560001|NCT00000556|Drug|adrenergic beta antagonists|
560002|NCT00000556|Drug|verapamil|
560003|NCT00000556|Drug|diltiazem|
560004|NCT00000556|Drug|digoxin|
560005|NCT00000556|Procedure|catheter ablation|
560006|NCT00000556|Device|pacemaker, artificial|
560007|NCT00000555|Drug|estrogen replacement therapy|
560008|NCT00000555|Drug|estrogens, conjugated|
560009|NCT00000555|Drug|progesterone|
560010|NCT00000555|Drug|hormone replacement therapy|
560011|NCT00000555|Drug|supplementation, food|
560012|NCT00000555|Drug|ascorbic acid|
560013|NCT00000555|Drug|vitamin e|
560014|NCT00000554|Procedure|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
560015|NCT00000554|Procedure|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
560016|NCT00000553|Drug|simvastatin|
560017|NCT00000553|Drug|niacin|
560018|NCT00000553|Drug|antioxidants|
560019|NCT00000552|Procedure|angioplasty, transluminal, percutaneous coronary|
560020|NCT00000552|Procedure|coronary artery bypass|
560021|NCT00000552|Drug|thrombolytic therapy|
560022|NCT00000551|Behavioral|health education|
560023|NCT00000550|Behavioral|health education|
560024|NCT00000549|Drug|estrogen replacement therapy|
560025|NCT00000549|Drug|hormone replacement therapy|
560026|NCT00000549|Drug|estrogens|
560027|NCT00000549|Drug|progestins|
560028|NCT00000548|Procedure|mechanical ventilation|
560029|NCT00000547|Drug|enalapril|
560030|NCT00000546|Behavioral|meditation|
560031|NCT00000545|Behavioral|exercise|
560032|NCT00000545|Behavioral|diet|
560033|NCT00000544|Behavioral|diet therapy|
560034|NCT00000543|Behavioral|dietary supplements|
560035|NCT00000543|Drug|calcium|
560036|NCT00000542|Drug|Inhibitors, ACE|
560037|NCT00000542|Drug|amlodipine|
560038|NCT00000542|Drug|lisinopril|
560039|NCT00000542|Drug|doxazosin|
560040|NCT00000542|Drug|chlorthalidone|
560041|NCT00000542|Drug|pravastatin|
560042|NCT00000542|Behavioral|diet, fat-restricted|
560043|NCT00000541|Behavioral|dietary supplements|
560044|NCT00000541|Drug|vitamin C|
560045|NCT00000541|Drug|vitamin E|
560046|NCT00000541|Drug|beta-carotene|
560047|NCT00000541|Drug|folic acid/Vitamin B6/Vitamin B12|
560048|NCT00000540|Device|defibrillators, implantable|
560049|NCT00000539|Drug|niacin|
560050|NCT00000539|Drug|pravastatin|
560051|NCT00000539|Drug|beta-carotene|
560052|NCT00000539|Drug|vitamin E|
560053|NCT00000539|Behavioral|dietary supplements|
560054|NCT00000539|Drug|vitamin C|
560055|NCT00000539|Drug|warfarin|
560056|NCT00000538|Behavioral|diet, fat-restricted|
560057|NCT00000537|Behavioral|meditation|
560058|NCT00000537|Behavioral|relaxation|
560059|NCT00000536|Behavioral|sodium, dietary|
560060|NCT00000535|Behavioral|diet, reducing|
560061|NCT00000535|Behavioral|diet, sodium-restricted|
560062|NCT00000534|Drug|calcium|
560063|NCT00000534|Behavioral|dietary supplements|
560064|NCT00000533|Behavioral|social support|
560065|NCT00000532|Behavioral|diet, fat-restricted|
560066|NCT00000531|Device|defibrillators, implantable|
560067|NCT00000531|Drug|amiodarone amiodarone|
560068|NCT00000531|Drug|sotalol|
560069|NCT00000530|Drug|nifedipine|
560070|NCT00000530|Behavioral|biofeedback (psychology)|
560071|NCT00000530|Procedure|electromyography|
560072|NCT00000529|Drug|tamoxifen|
560073|NCT00000528|Behavioral|diet, sodium-restricted (Phase III) diet, sodium-restricted|
560074|NCT00000528|Behavioral|diet, reducing (Phase III)|
560075|NCT00000527|Drug|aspirin|
560076|NCT00000527|Drug|dipyridamole|
560077|NCT00000526|Drug|encainide|
560078|NCT00000526|Drug|flecainide|
560079|NCT00000526|Drug|moricizine|
560080|NCT00000525|Drug|hydrochlorothiazide|
560081|NCT00000525|Behavioral|diet, potassium supplementation|
560082|NCT00000525|Behavioral|diet, magnesium supplementation|
560083|NCT00000525|Drug|triamterene|
560084|NCT00000525|Drug|chlorthalidone|
560085|NCT00000524|Drug|cyclosporine|
560086|NCT00000524|Drug|prednisone|
560087|NCT00000523|Behavioral|exercise|
560088|NCT00000522|Behavioral|diet, sodium-restricted|
560089|NCT00000522|Behavioral|diet, reducing|
560090|NCT00000522|Behavioral|exercise|
560091|NCT00000522|Behavioral|alcohol restriction|
560092|NCT00000522|Drug|chlorthalidone|
560093|NCT00000522|Drug|acebutolol|
560094|NCT00000522|Drug|doxazosin|
560095|NCT00000522|Drug|amlodipine|
560096|NCT00000522|Drug|enalapril|
560097|NCT00000521|Behavioral|diet, sodium-restricted|
560098|NCT00000521|Behavioral|diet, potassium-supplemented|
560099|NCT00000520|Drug|immunoglobulins, intravenous|
560100|NCT00000520|Drug|aspirin|
560101|NCT00000519|Behavioral|diet, reducing|
560102|NCT00000519|Behavioral|exercise|
560103|NCT00000519|Behavioral|diet, fat-restricted|
560104|NCT00000518|Procedure|electrophysiology|
560105|NCT00000518|Procedure|electrocardiography, ambulatory|
560106|NCT00000518|Drug|imipramine|
560107|NCT00000518|Drug|mexiletine|
560108|NCT00000518|Drug|procainamide|
560109|NCT00000518|Drug|quinidine|
560110|NCT00000518|Drug|sotalol|
560111|NCT00000517|Drug|warfarin|
560112|NCT00000516|Drug|enalapril|
560113|NCT00000515|Behavioral|diet, reducing|
560114|NCT00000514|Drug|chlorthalidone|
560115|NCT00000514|Drug|atenolol|
560116|NCT00000514|Drug|reserpine|
560117|NCT00000513|Behavioral|diet, reducing|
560118|NCT00000513|Behavioral|diet, sodium-restricted|
560119|NCT00000513|Drug|chlorthalidone|
560120|NCT00000513|Drug|atenolol|
560121|NCT00000512|Drug|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
560122|NCT00000512|Drug|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
560123|NCT00000512|Drug|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
560124|NCT00000512|Other|Placebo for colestipol|Placebo for colestipol.
560125|NCT00000512|Other|Placebo for lovastatin|Placebo for lovastatin
560126|NCT00000511|Dietary Supplement|mineral supplements|
560127|NCT00000511|Dietary Supplement|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
560128|NCT00000511|Behavioral|dietary supplements|
560129|NCT00000510|Drug|aspirin|
560130|NCT00000510|Drug|dipyridamole|
560131|NCT00000510|Procedure|angioplasty, transluminal, percutaneous coronary|
560132|NCT00000509|Behavioral|diet, sodium-restricted|
560133|NCT00000509|Behavioral|diet, potassium-supplementation|
560134|NCT00000508|Behavioral|smoking cessation|
560135|NCT00000508|Behavioral|diet, reducing|
560136|NCT00000508|Behavioral|exercise|
560137|NCT00000508|Behavioral|diet, fat-restricted|
560138|NCT00000507|Drug|streptokinase|
560139|NCT00000506|Drug|fenfluramine|
560140|NCT00000506|Drug|phentermine|
560141|NCT00000505|Drug|tissue plasminogen activator|
560142|NCT00000505|Procedure|angioplasty, transluminal, percutaneous coronary|
560143|NCT00000504|Drug|encainide|
560144|NCT00000504|Drug|moricizine|
560145|NCT00000504|Drug|flecainide|
560146|NCT00000504|Drug|imipramine|
560147|NCT00000503|Drug|nitroglycerin|
560148|NCT00000503|Drug|streptokinase|
560149|NCT00000503|Procedure|heart catheterization|
560150|NCT00000502|Procedure|cardiopulmonary resuscitation|
560151|NCT00000501|Behavioral|diet, sodium-restricted|
560152|NCT00000501|Behavioral|diet, reducing|
560153|NCT00000501|Drug|potassium|
560154|NCT00000500|Drug|aspirin|
560155|NCT00000500|Drug|carotene|
560156|NCT00000499|Drug|chlorthalidone|
560157|NCT00000499|Drug|reserpine|
560158|NCT00000499|Drug|hydralazine|
560159|NCT00000499|Drug|metoprolol|
560160|NCT00000498|Behavioral|diet, sodium-restricted|
560161|NCT00000498|Behavioral|diet, reducing|
560162|NCT00000498|Behavioral|alcohol restriction|
560163|NCT00000498|Drug|antihypertensive agents|
560164|NCT00000497|Behavioral|diet, sodium-restricted|
560165|NCT00000497|Behavioral|diet, reducing|
560166|NCT00000496|Drug|aspirin|
560167|NCT00000496|Drug|dipyridamole|
560168|NCT00000495|Behavioral|diet, reducing|
560169|NCT00000495|Behavioral|diet, sodium-restricted|
560170|NCT00000495|Behavioral|alcohol restriction|
560171|NCT00000495|Behavioral|exercise|
560172|NCT00000494|Drug|indomethacin|
560173|NCT00000494|Procedure|surgery, cardiovascular|
560174|NCT00000493|Drug|propranolol|
560175|NCT00000493|Drug|hyaluronidase|
560176|NCT00000492|Drug|propranolol|
560177|NCT00000491|Drug|aspirin|
560178|NCT00000490|Procedure|jejunoileal bypass|
560179|NCT00000490|Behavioral|diet, fat-restricted|
560180|NCT00000489|Procedure|coronary artery bypass|
560181|NCT00000488|Drug|cholestyramine|
560182|NCT00000488|Behavioral|diet, fat-restricted|
560183|NCT00000487|Drug|antihypertensive agents|
560184|NCT00000487|Behavioral|smoking cessation|
560185|NCT00000487|Behavioral|diet, fat-restricted|
560186|NCT00000487|Drug|diuretics|
560187|NCT00000486|Procedure|coronary artery bypass|
560188|NCT00000485|Drug|diuretics|
560189|NCT00000485|Drug|antihypertensive agents|
560190|NCT00000484|Drug|chlorothiazide|
560191|NCT00000484|Drug|Rauwolfia alkaloids|
560192|NCT00000483|Drug|estrogen|
560193|NCT00000483|Drug|clofibrate|
560194|NCT00000483|Drug|dextrothyroxine sodium|
560195|NCT00000483|Drug|niacin|
560196|NCT00000482|Drug|estrogen|
560197|NCT00000482|Drug|clofibrate clofibrate|
560198|NCT00000482|Drug|dextrothyroxine sodium|
560199|NCT00000482|Drug|niacin|
560200|NCT00000481|Behavioral|diet, fat-restricted|
560201|NCT00000480|Procedure|electrophysiology|
560202|NCT00000480|Drug|anti-arrhythmia agents|
560203|NCT00000480|Device|defibrillators, implantable|
560204|NCT00000479|Drug|Aspirin|Participants will receive 100 mg of aspirin every other day.
560205|NCT00000479|Drug|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
560206|NCT00000479|Behavioral|Placebo|Participants will receive placebo.
560207|NCT00000478|Drug|atenolol|
560208|NCT00000478|Drug|nifedipine|
560209|NCT00000478|Drug|diltiazem|
560210|NCT00000478|Drug|isosorbide dinitrate|
560211|NCT00000478|Procedure|coronary artery bypass coronary artery bypass|
560212|NCT00000478|Procedure|angioplasty, transluminal, percutaneous coronary|
560213|NCT00000477|Drug|lovastatin|
560214|NCT00000476|Drug|digitalis|
560215|NCT00000475|Behavioral|health education|
560216|NCT00000474|Behavioral|behavior therapy|
560217|NCT00000473|Behavioral|dietary supplements|
560218|NCT00000473|Drug|fatty acids, omega-3|
560219|NCT00000473|Behavioral|diet, fat-restricted|
560220|NCT00000472|Drug|tissue plasminogen activator|
560221|NCT00000472|Drug|heparin|
560222|NCT00000471|Behavioral|diet, vegetarianism|
560223|NCT00000471|Behavioral|diet, fat-restricted|
560224|NCT00000471|Behavioral|exercise|
560225|NCT00000471|Behavioral|smoking cessation|
560226|NCT00000470|Procedure|cardiac surgical procedures|
560227|NCT00000470|Procedure|cardiopulmonary bypass|
560228|NCT00000469|Drug|aspirin|
560229|NCT00000469|Drug|lovastatin|
560230|NCT00000468|Drug|tissue plasminogen activator|
560231|NCT00000467|Behavioral|diet|
560232|NCT00000467|Behavioral|exercise|
560233|NCT00000467|Behavioral|smoking cessation|
560234|NCT00000466|Drug|estrogens, conjugated|
560235|NCT00000466|Drug|medroxyprogesterone|
560236|NCT00000466|Drug|progesterone|
560237|NCT00000466|Drug|estrogen replacement therapy|
560238|NCT00000465|Procedure|angioplasty, transluminal, percutaneous coronary|
560239|NCT00000465|Procedure|coronary artery bypass|
560240|NCT00000464|Drug|amiodarone|
560241|NCT00000464|Drug|imipramine|
560242|NCT00000464|Drug|mexiletine|
560243|NCT00000464|Drug|procainamide|
560244|NCT00000464|Drug|propafenone|
560245|NCT00000464|Drug|quinidine|
560246|NCT00000464|Drug|sotalol|
560247|NCT00000463|Drug|lovastatin|
560248|NCT00000463|Drug|cholestyramine|
560249|NCT00000463|Drug|warfarin|
560250|NCT00000462|Procedure|angioplasty, transluminal, percutaneous coronary|
560251|NCT00000462|Procedure|coronary artery bypass|
560252|NCT00000461|Drug|pravastatin|
560253|NCT00000461|Drug|niacin|
560254|NCT00000461|Drug|cholestyramine|
560255|NCT00000461|Drug|gemfibrozil|
560256|NCT00000461|Drug|fatty acids, omega-3|
560257|NCT00000460|Behavioral|Low intensity exercise|
560258|NCT00000460|Behavioral|High intensity exercise|
560259|NCT00000459|Behavioral|diet, fat-restricted|
560260|NCT00004500|Drug|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
560261|NCT00004500|Other|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
560262|NCT00004498|Genetic|Adenoviral Vector-Mediated Gene Transfer|
560263|NCT00004497|Drug|UT-15|
560264|NCT00004496|Drug|alpha-melanocyte stimulating hormone|
560265|NCT00004495|Drug|cyanocobalamin|
560266|NCT00004495|Drug|folic acid|
560267|NCT00004495|Drug|pyridoxine|
560268|NCT00004494|Drug|vasoactive intestinal peptide|
560269|NCT00004493|Drug|sodium dichloroacetate|
560270|NCT00004492|Drug|clotrimazole|
560271|NCT00004492|Drug|hydroxyurea|
560272|NCT00004490|Drug|sodium dichloroacetate|
560273|NCT00004489|Drug|alendronate sodium|
560274|NCT00004489|Drug|calcium carbonate|
560275|NCT00004489|Drug|cholecalciferol|
560276|NCT00004488|Drug|alendronate sodium|
560277|NCT00004488|Drug|calcium carbonate|
560278|NCT00004488|Drug|cholecalciferol|
560279|NCT00004487|Drug|chondrocyte-alginate gel suspension|
560280|NCT00004486|Drug|fluoxetine|
560281|NCT00004485|Drug|cyclosporine|
560282|NCT00004485|Drug|fludarabine|
560283|NCT00004485|Drug|mycophenolate mofetil|
560284|NCT00004485|Procedure|Bone Marrow Transplantation|
560285|NCT00004482|Drug|Cyclosporine|
560286|NCT00004482|Drug|methylprednisolone|
560287|NCT00004482|Drug|Muromonab-CD3|
560288|NCT00004482|Drug|prednisone|
560289|NCT00004481|Procedure|genetic testing|
560290|NCT00004480|Drug|botulinum toxin type A|
560291|NCT00004479|Drug|midodrine|
560292|NCT00004478|Drug|droxidopa|
560293|NCT00004474|Drug|Anti-thymocyte globulin|Given via IV over 4 hours
560294|NCT00004474|Drug|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
560295|NCT00004474|Procedure|Bone marrow transplantation|Given on Day 0
560296|NCT00004471|Genetic|pGT-1 gene lipid complex|
560297|NCT00004468|Drug|calcitriol|
560298|NCT00004467|Drug|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
560299|NCT00004467|Drug|Placebo|Infusion of 5% dextrose
560300|NCT00004466|Drug|Atorvastatin|
560301|NCT00004466|Drug|Placebo|
560302|NCT00004465|Drug|SYNSORB Pk|
560303|NCT00004465|Drug|Placebo|
560304|NCT00004464|Drug|cyclophosphamide|
560305|NCT00004464|Drug|filgrastim|
560306|NCT00004454|Genetic|lymphocyte gene therapy|
560307|NCT00004451|Drug|Glucose|
560308|NCT00004450|Drug|glyceryl trierucate|
560309|NCT00004450|Drug|glyceryl trioleate|
560310|NCT00004450|Drug|interferon beta|
560311|NCT00004450|Drug|thalidomide|
560312|NCT00004449|Behavioral|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
560313|NCT00004449|Behavioral|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
560314|NCT00004448|Drug|omega-3 fatty acids|
560315|NCT00004448|Drug|prednisone|
560316|NCT00004446|Drug|fluoxetine|
560317|NCT00004445|Procedure|Surgery|
560318|NCT00004445|Device|IRS-8|
560319|NCT00004444|Drug|paromomycin|
560320|NCT00004444|Drug|streptomycin|
560321|NCT00004443|Drug|NTBC|
560322|NCT00004442|Drug|chenodeoxycholic acid|
560323|NCT00004442|Drug|cholic acid|
560324|NCT00004442|Drug|ursodiol|
560325|NCT00004441|Drug|tauroursodeoxycholic acid|
560326|NCT00004441|Drug|ursodiol|
560327|NCT00004440|Drug|ibuprofen|
560328|NCT00004438|Drug|leuprolide|
560329|NCT00004437|Device|Multichannel Auditory Brain Stem Implant|
560330|NCT00004436|Drug|leuprolide|
560331|NCT00004436|Drug|prednisone|
560332|NCT00004433|Drug|pergolide|
560333|NCT00004431|Drug|L-baclofen|
560334|NCT00004430|Drug|Dihematoporphyrin derivative|
560335|NCT00004430|Drug|prednisolone|
560336|NCT00004430|Procedure|Laser surgery|
560337|NCT00004429|Drug|growth hormone|
560338|NCT00004428|Drug|CPX|
560339|NCT00004426|Drug|gonadotropin releasing hormone|
560340|NCT00004426|Drug|leuprolide|
560341|NCT00004424|Drug|fentanyl|
560342|NCT00004424|Drug|Midazolam|
560343|NCT00004424|Drug|propofol|
560344|NCT00004423|Drug|-aminosalicylic acid|
560345|NCT00004422|Drug|immune globulin|
560346|NCT00004421|Device|implanted pulse generator|
560347|NCT00004420|Drug|gamma-Linolenic acid|
560348|NCT00004419|Drug|insulin-like growth factor I|
560349|NCT00004418|Drug|glyceryl trierucate|Glyceryl trierucate is an oil to reduce very long chain fatty acids
560350|NCT00004418|Drug|glyceryl trioleate|Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.
560351|NCT00004416|Drug|botulinum toxin type A|
560352|NCT00004415|Device|Medlink spinal cord electrode|
560353|NCT00004414|Drug|sincalide|
560354|NCT00004412|Drug|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
560355|NCT00004412|Other|Standard local care dressing|To heal leg ulcers.
560356|NCT00004410|Drug|tauroursodeoxycholic acid|
560357|NCT00004409|Drug|collagenase|
560358|NCT00004408|Drug|poloxamer 188|
560359|NCT00004407|Drug|immune globulin|
560360|NCT00004406|Drug|human parathyroid hormone|
560361|NCT00004404|Drug|clotrimazole|
560362|NCT00004404|Drug|hydroxyurea|
560363|NCT00004403|Drug|albendazole|
560364|NCT00004403|Drug|dexamethasone|
560365|NCT00004403|Drug|phenytoin|
560366|NCT00004402|Drug|calcitriol|
560367|NCT00004402|Drug|interferon gamma|
560368|NCT00004401|Drug|botulism immune globulin|
560369|NCT00004400|Drug|testosterone|
560370|NCT00004399|Drug|magnesium sulfate|
560371|NCT00004399|Drug|nimodipine|
560372|NCT00004398|Drug|heme arginate|
560373|NCT00004398|Drug|tin mesoporphyrin|
560374|NCT00004397|Drug|heme arginate|
560375|NCT00004397|Drug|tin mesoporphyrin|
560376|NCT00004396|Drug|heme arginate|
560377|NCT00004396|Drug|tin mesoporphyrin|
560378|NCT00004393|Drug|risperidone|
560379|NCT00004390|Drug|desipramine|
560380|NCT00004390|Drug|methadone|
560381|NCT00004390|Drug|morphine|
560382|NCT00004390|Drug|nortriptyline|
560383|NCT00004387|Procedure|fetal nigral transplantation|
560384|NCT00004386|Genetic|recombinant adenovirus containing the ornithine transcarbamylase gene|
560385|NCT00004382|Drug|tin mesoporphyrin|
560386|NCT00004382|Procedure|Phototherapy|
560387|NCT00004381|Drug|tin mesoporphyrin|
560388|NCT00004380|Drug|relaxin|
560389|NCT00004378|Procedure|Stem Cell Transplantation|
560390|NCT00004376|Drug|guanfacine|
560391|NCT00004375|Procedure|ultraviolet A-1 light treatment|
560392|NCT00004373|Drug|alprazolam|
560393|NCT00004368|Drug|colchicine|
560394|NCT00004367|Procedure|Clinical vestibular tests|
560395|NCT00004366|Procedure|Physical therapy|
560396|NCT00004364|Drug|desmopressin|
560397|NCT00004363|Drug|chlorpropamide|
560398|NCT00004363|Drug|desmopressin|
560399|NCT00004361|Drug|calcium gluconate|
560400|NCT00004361|Drug|sodium citrate|
560401|NCT00004360|Drug|chlorothiazide|
560402|NCT00004359|Drug|methoxsalen|
560403|NCT00004358|Drug|calcitonin|
560404|NCT00004357|Drug|Methylprednisolone|IV
560405|NCT00004357|Drug|Prednisolone|Oral
560406|NCT00004347|Behavioral|diet|
560407|NCT00004346|Drug|chenodeoxycholic acid|
560408|NCT00004346|Drug|lovastatin|
560409|NCT00004344|Drug|leuprolide|
560410|NCT00004344|Drug|testosterone|
560411|NCT00004340|Drug|calcitriol|
560412|NCT00004340|Drug|growth hormone|
560413|NCT00004339|Drug|tetrathiomolybdate|
560414|NCT00004339|Drug|trientine|
560415|NCT00004338|Drug|zinc acetate|
560416|NCT00004333|Drug|NTBC|
560417|NCT00004330|Drug|luteinizing hormone-releasing factor|
560418|NCT00004328|Drug|enalapril|
560419|NCT00004328|Drug|polystyrene sulfonate|
560420|NCT00004327|Drug|octreotide|
560421|NCT00004323|Drug|anti-thymocyte globulin|
560422|NCT00004323|Drug|cyclophosphamide|
560423|NCT00004323|Drug|cyclosporine|
560424|NCT00004323|Drug|mesna|
560425|NCT00004323|Drug|methotrexate|
560426|NCT00004323|Drug|methylprednisolone|
560427|NCT00004317|Drug|Leucovorin calcium|See arm descriptions
560428|NCT00004317|Drug|Pyrimethamine|See arm descriptions
560429|NCT00004317|Drug|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
560430|NCT00004317|Drug|Sulfadiazine|See arm descriptions
560431|NCT00004316|Drug|capsaicin|
560432|NCT00004315|Drug|ursodiol|
560433|NCT00004314|Drug|aminomidazole carboxamide riboside|
560434|NCT00004313|Drug|dehydroepiandrosterone|
560435|NCT00004311|Drug|leuprolide acetate|
560436|NCT00004311|Drug|spironolactone|
560437|NCT00004310|Drug|Clomipramine|
560438|NCT00004307|Behavioral|Protein and calorie controlled diet|
560439|NCT00004307|Genetic|Ornithine transcarbamylase vector|
560440|NCT00004300|Drug|bromocriptine|
560441|NCT00004300|Drug|sertraline hydrochloride|
560442|NCT00004297|Drug|diazepam|
560443|NCT00004297|Drug|lorazepam|
560444|NCT00004294|Genetic|human glucocerebrosidase gene into autologous peripheral blood stem cells|
560445|NCT00004293|Drug|glucocerebrosidase|
560446|NCT00004288|Drug|olsalazine|
560447|NCT00004287|Genetic|H5.001CBCFTR|
560448|NCT00004286|Drug|immune globulin|
560449|NCT00004285|Device|Standard dose, low flux hemodialysis|
560450|NCT00004285|Device|Standard dose, high flux hemodialysis|
560451|NCT00004285|Device|High dose, low flux hemodialysis|
560452|NCT00004285|Device|High dose, high flux hemodialysis|
560453|NCT00004284|Drug|potassium citrate|
560454|NCT00004284|Drug|potassium phosphate|
560455|NCT00004278|Drug|ganciclovir|
560456|NCT00004276|Drug|thalidomide|
560457|NCT00004275|Drug|growth hormone|
560458|NCT00004275|Drug|oxandrolone|
560459|NCT00004274|Drug|Estrogen|
560460|NCT00004268|Drug|midodrine|
560461|NCT00004266|Drug|Lisinopril|
560462|NCT00004266|Drug|Nifedipine|
560463|NCT00004266|Drug|Simvastatin|
560464|NCT00000170|Drug|Atropine|Atropine
560465|NCT00000170|Device|Eye Patch|Patching
560466|NCT00000167|Procedure|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
560467|NCT00000162|Procedure|Macular Argon Laser Photocoagulation|
560468|NCT00000162|Procedure|Peripheral Scatter Argon Laser Photocoagulation|
560469|NCT00000162|Procedure|Scatter Argon Laser Photocoagulation|
560470|NCT00000161|Drug|Aspirin|
560471|NCT00000161|Drug|Beta-Carotene|
560472|NCT00000161|Drug|Vitamin C|
560473|NCT00000161|Drug|Vitamin E|
560474|NCT00000160|Procedure|Xenon Photocoagulation|
560475|NCT00000160|Procedure|Argon Photocoagulation|
560476|NCT00000160|Procedure|Photocoagulation|
560477|NCT00000159|Drug|Sorbinil|
560478|NCT00000158|Procedure|Argon Blue-Green Laser Photocoagulation|
560479|NCT00000157|Drug|Aspirin|
560480|NCT00000156|Device|Goggles|
560481|NCT00000156|Procedure|Ambient Light Reduction|
560482|NCT00000154|Procedure|Vitrectomy|
560483|NCT00000153|Procedure|Blue-Green Argon Laser Treatment|
560484|NCT00000153|Procedure|Red Krypton Laser Treatment|
560485|NCT00000152|Drug|Aspirin|
560486|NCT00000152|Drug|Beta-Carotene|
560487|NCT00000151|Drug|Aspirin|
560488|NCT00000151|Procedure|Argon Laser Photocoagulation|
560489|NCT00000150|Procedure|Subfoveal Choroidal Neovascularization Removal|
560490|NCT00000149|Drug|Beta Blocker|
560491|NCT00000149|Procedure|Trabeculectomy|
560492|NCT00000149|Procedure|Argon Laser Trabeculoplasty|
560493|NCT00000148|Procedure|Argon Laser Trabeculoplasty|
560494|NCT00000148|Procedure|Trabeculectomy|
560495|NCT00000147|Drug|Methylprednisolone|
560496|NCT00000147|Drug|Prednisone|
560497|NCT00000146|Drug|Methylprednisolone|
560498|NCT00000146|Drug|Prednisone|
560499|NCT00000145|Dietary Supplement|Antioxidants|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
560500|NCT00000145|Dietary Supplement|Zinc|80 milligrams zinc oxide; 2 milligrams of cupric oxide
560501|NCT00000145|Dietary Supplement|Antioxidants and zinc|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
560502|NCT00000144|Procedure|Argon Laser Treatment|
560503|NCT00000143|Device|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
560504|NCT00000143|Drug|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
560505|NCT00000142|Drug|Cidofovir|"Three groups:~the deferral group, treatment deferred until retinitis progressed~Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.~High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
560506|NCT00000140|Drug|Perfluoropropane|
560507|NCT00000140|Drug|Sulfur Hexafluoride|
560508|NCT00000140|Drug|Silicone Oil|
560509|NCT00000139|Behavioral|Stress|
560510|NCT00000139|Drug|Acyclovir|
560511|NCT00000138|Drug|Prednisolone Phosphate|
560512|NCT00000138|Drug|Acyclovir|
560513|NCT00000137|Procedure|Histocompatibility Matching|
560514|NCT00000136|Drug|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
560515|NCT00000136|Drug|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
560516|NCT00000135|Drug|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
560517|NCT00000135|Other|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
560518|NCT00000134|Drug|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
560519|NCT00000134|Drug|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
560520|NCT00000133|Procedure|Trans-scleral Cryotherapy|
560521|NCT00000132|Drug|Betaxolol|
560522|NCT00000132|Procedure|Argon Laser Trabeculoplasty|
560523|NCT00000131|Procedure|Photocoagulation Therapy|
560524|NCT00000130|Drug|Intravitreal Antibiotics|
560525|NCT00000130|Procedure|Initial Pars Plana Vitrectomy|
560526|NCT00000129|Procedure|Radial Keratotomy|
560527|NCT00000128|Device|Bifocal Spectacle Lenses|
560528|NCT00000127|Procedure|Optic Nerve Sheath Decompression Surgery|
560529|NCT00000126|Procedure|Surgery|
560530|NCT00000125|Drug|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
560531|NCT00000124|Procedure|Brachytherapy|
560532|NCT00000124|Procedure|Eye Removal|
560533|NCT00000123|Device|Polymethyl Methacrylate-Silicone Contact Lenses|
560534|NCT00000123|Device|Polymethyl Methacrylate Contact Lenses|
560535|NCT00000122|Drug|5-Fluorouracil|
560536|NCT00000121|Device|Prisms in Eyeglasses|
560537|NCT00000120|Drug|Erythromycin Ointment|
560538|NCT00000120|Drug|Silver Nitrate Drops|
560539|NCT00000119|Device|Heparin Surface-Modified Intraocular Lens|
560540|NCT00000118|Device|Sustained-Release Intraocular Drug Delivery System|
560541|NCT00000117|Drug|Immunoglobulin|
560542|NCT00000116|Drug|Vitamin A|
560543|NCT00000116|Drug|Nutritional Supplement|
560544|NCT00000115|Drug|Acetazolamide|
560545|NCT00000114|Drug|Vitamin E|
560546|NCT00000114|Drug|Vitamin A|
560547|NCT00000113|Other|Progressive Addition Lenses|Varilux comfort with +2.00 addition
560548|NCT00000113|Other|single vision lenses|
560549|NCT00000358|Drug|Lofexidine|
560550|NCT00000357|Drug|Buprenorphine|
560551|NCT00000356|Drug|LAAM|
560552|NCT00000355|Drug|Buprenorphine|
560553|NCT00000354|Drug|Lofexidine|
560554|NCT00000353|Drug|Buprenorphine/naloxone|
560555|NCT00000352|Drug|Dextromethorphan|
560556|NCT00000350|Procedure|radioactive substance|
560557|NCT00000349|Drug|Flupenthixol|
560558|NCT00000348|Drug|Dihydrexidine|
560559|NCT00000347|Drug|Risperidone|
560560|NCT00000346|Behavioral|counseling|
560561|NCT00000345|Drug|Lofexidine|
560562|NCT00000344|Drug|Buprenorphine/naloxone|
560563|NCT00000343|Behavioral|counseling|
560564|NCT00000342|Drug|Risperidone|
560565|NCT00000341|Drug|Buprenorphine|
560566|NCT00000340|Drug|Pemoline|
560567|NCT00000339|Drug|Risperidone|
560568|NCT00000338|Drug|Lisuride|
560569|NCT00000337|Drug|Selegiline|
560570|NCT00000336|Drug|Selegiline|
560571|NCT00000335|Drug|Morphine|
560572|NCT00000334|Drug|Buprenorphine|
560573|NCT00000333|Drug|Benztropine|
560574|NCT00000332|Drug|Nimodipine|
560575|NCT00000331|Drug|Test Drug|
560576|NCT00000331|Drug|Placebo Drug|
560577|NCT00000330|Drug|Opioid-Related Disorders|
560578|NCT00000329|Drug|Opioid-Related Disorders|
560579|NCT00000328|Drug|Opioid-Related Disorders|
560580|NCT00000327|Drug|Heroin Dependence|
560581|NCT00000326|Drug|Heroin Dependence|
560582|NCT00000325|Behavioral|Gonadorelin|
560583|NCT00000324|Drug|Tryptophan|
560584|NCT00000322|Behavioral|Tyrosine|
560585|NCT00000321|Drug|Desipramine|
560586|NCT00000320|Drug|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
560587|NCT00000319|Drug|Buprenorphine|
560588|NCT00000318|Drug|Buprenorphine|"Experimental Maintenance treatment with daily medication~Experimental Maintenance treatment with thrice-weekly medication"
560589|NCT00000317|Drug|Risperidone|Risperidone (4mg/day)
560590|NCT00000317|Drug|Placebo|Placebo
560591|NCT00000317|Behavioral|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
560592|NCT00000316|Drug|Cocaine|
560593|NCT00000315|Drug|Cocaine|
560594|NCT00000314|Drug|M-CPP|
560595|NCT00000313|Drug|Fenfluramine|
560596|NCT00000312|Drug|M-CPP|
560597|NCT00000311|Drug|Buprenorphine|Medication and Behavioral
560598|NCT00000311|Drug|methadone|medication and behavioral
560599|NCT00000310|Drug|Risperidone|
560600|NCT00000309|Drug|Risperidone|
560601|NCT00000308|Drug|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
560602|NCT00000308|Drug|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
560603|NCT00000308|Drug|placebo|placebo
560604|NCT00000307|Drug|Naltrexone|
560605|NCT00000306|Drug|Dextroamphetamine|
560606|NCT00000305|Drug|Dextroamphetamine|
560607|NCT00000304|Drug|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
560608|NCT00000304|Drug|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
560609|NCT00000304|Drug|Placebo|Placebo
560610|NCT00000303|Drug|Baclofen|
560611|NCT00000302|Drug|Buprenorphine|
560612|NCT00000301|Drug|Amantadine|
560613|NCT00000300|Drug|LAAM|
560614|NCT00000299|Drug|Buprenorphine|
560615|NCT00000298|Drug|Buprenorphine/naloxone|
560616|NCT00000297|Drug|Labetalol|
560617|NCT00000296|Drug|Cotinine fumarate|
560618|NCT00000295|Drug|Micronized Progesterone|
560619|NCT00000294|Drug|Carvedilol|
560620|NCT00000293|Drug|Nefazodone|
560621|NCT00000292|Procedure|Cocaine|
560622|NCT00000291|Drug|Labetalol|
560623|NCT00000290|Drug|Cocaine|
560624|NCT00000289|Drug|Ondansetron|
560625|NCT00000288|Drug|Cotinine fumarate|
560626|NCT00000286|Drug|Nefazodone|
560627|NCT00000285|Drug|Phenytoin|
560628|NCT00000284|Drug|Cotinine fumarate|
560629|NCT00000282|Drug|Pemoline|
560630|NCT00000281|Behavioral|Amantadine|
560631|NCT00000280|Drug|Nimodipine|
560632|NCT00000279|Drug|Clonidine|
560633|NCT00000278|Drug|Disulfiram|
560634|NCT00000277|Drug|Mazindol|
560635|NCT00000276|Drug|Bupropion|
560636|NCT00000275|Drug|Flupenthixol|
560637|NCT00000274|Drug|Flupenthixol|
560638|NCT00000273|Drug|opiates|prescription opioids
560639|NCT00000271|Drug|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
560640|NCT00000271|Drug|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
560641|NCT00000270|Drug|Cocaine|
560642|NCT00000269|Drug|Pergolide|
560643|NCT00000268|Drug|Bupropion|
560644|NCT00000267|Drug|Risperidone|
560645|NCT00000266|Drug|Flupenthixol|
560646|NCT00000264|Drug|30% Nitrous oxide|
560647|NCT00000264|Other|0.35 g/Kg ethanol|
560648|NCT00000264|Other|0.7 g/Kg ethanol|
560649|NCT00000264|Other|0 g/Kg ethanol|
560650|NCT00000263|Drug|30% Nitrous oxide|
560651|NCT00000263|Other|0.25 g/Kg ethanol|
560652|NCT00000263|Other|0.5 g/KG ethanol|
560653|NCT00000263|Other|0 g/Kg ethanol|
560654|NCT00000262|Drug|30% Nitrous oxide|
560655|NCT00000262|Drug|0.4% Sevoflurane|
560656|NCT00000262|Drug|0.2% sevoflurane|
560657|NCT00000262|Other|Placebo|
560658|NCT00000261|Drug|30% Nitrous oxide|
560659|NCT00000261|Other|Placebo|No drug (100% oxygen)
560660|NCT00000261|Drug|0.2% sevoflurane|
560661|NCT00000261|Drug|0.4% sevoflurane|
560662|NCT00000261|Drug|0.6% sevoflurane|
560663|NCT00000260|Drug|Nitrous oxide|
560664|NCT00000259|Drug|15 % Nitrous oxide|
560665|NCT00000259|Drug|0.3 % Sevoflurane|
560666|NCT00000259|Drug|30% Nitrous oxide|
560667|NCT00000259|Drug|0.6% Sevoflurane|
560668|NCT00000259|Other|Placebo|
560669|NCT00000258|Drug|Nitrous oxide 10% & placebo|
560670|NCT00000258|Drug|Nitrous oxide 20% & placebo|
560671|NCT00000258|Drug|Nitrous oxide 30% & placebo|
560672|NCT00000258|Drug|Nitrous oxide 40% and placebo|
560673|NCT00000257|Drug|0% N2O and 10% N2O|
560674|NCT00000257|Drug|0% N2O and 20% N2O|
560675|NCT00000257|Drug|0% N2O and 30% N2O|
560676|NCT00000257|Drug|0% N2O and 40% N2O|
560677|NCT00000256|Drug|20% N2O|
560678|NCT00000256|Drug|40% N2O|
560679|NCT00000256|Drug|60% N2O|
560680|NCT00000256|Drug|80% N2O|
560681|NCT00000255|Drug|Nitrous oxide|
560682|NCT00000254|Drug|40% Nitrous oxide|Used as pain assay positive control
560683|NCT00000254|Other|Sham comparator|0% isoflurane in oxygen
560684|NCT00000254|Drug|0.2% isoflurane|
560685|NCT00000254|Drug|0.4% isoflurane|
560686|NCT00000254|Drug|0.6% isoflurane|
560687|NCT00000253|Drug|10% N2O|
560688|NCT00000253|Drug|20% N2O|
560689|NCT00000253|Drug|30% N2O|
560690|NCT00000253|Drug|40% N2O|
560691|NCT00000252|Drug|0% N2O|
560692|NCT00000252|Drug|10% N2O|
560693|NCT00000252|Drug|20% N2O|
560694|NCT00000252|Drug|30% N2O|
560695|NCT00000252|Drug|40% N2O|
560696|NCT00000251|Drug|30% N2O|
560697|NCT00000251|Drug|0.2% isoflurane|
560698|NCT00000251|Drug|0.4% isoflurane|
560699|NCT00000251|Other|100% oxygen|Placebo
560700|NCT00000250|Drug|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
560701|NCT00000250|Drug|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
560702|NCT00000249|Drug|20% N2O|20% inhaled N2O
560703|NCT00000249|Drug|30% N2O|30% inhaled N2O
560704|NCT00000249|Drug|40% N2O|40% inhaled N2O
560705|NCT00000248|Drug|Pergolide|
560706|NCT00000246|Drug|Flumazenil|
560707|NCT00000245|Drug|Desipramine|
560708|NCT00000244|Drug|Dynorphin 1 - 13|
560709|NCT00000243|Drug|Buprenorphine|
560710|NCT00000242|Drug|Carbamazepine|
560711|NCT00000241|Drug|Flupenthixol|
560712|NCT00000240|Drug|Buprenorphine|
560713|NCT00000239|Drug|Buprenorphine|
560714|NCT00000238|Drug|Buprenorphine|
560715|NCT00000237|Drug|Buprenorphine|
560716|NCT00000236|Drug|Buprenorphine/naloxone|
560717|NCT00000235|Drug|Buprenorphine|
560718|NCT00000234|Drug|Buprenorphine|
560719|NCT00000233|Drug|Buprenorphine|
560720|NCT00000232|Drug|Buprenorphine|
560721|NCT00000231|Drug|Buprenorphine|
560722|NCT00000230|Drug|Buprenorphine|
560723|NCT00000229|Drug|Buprenorphine|
560724|NCT00000228|Drug|Buprenorphine|
560725|NCT00000227|Drug|Buprenorphine|
560726|NCT00000226|Drug|Buprenorphine|
560727|NCT00000225|Drug|Buprenorphine|
560728|NCT00000224|Drug|Buprenorphine|
560729|NCT00000223|Drug|Buprenorphine|
560730|NCT00000222|Drug|Buprenorphine|
560731|NCT00000221|Drug|Buprenorphine|
560732|NCT00000220|Drug|Buprenorphine|
560733|NCT00000219|Drug|Buprenorphine|
560734|NCT00000218|Drug|Carbamazepine|
560735|NCT00000217|Drug|Carbamazepine|
560736|NCT00000216|Drug|Buprenorphine|
560737|NCT00000215|Drug|Pergolide|
560738|NCT00000214|Drug|Buprenorphine|
560739|NCT00000213|Drug|Fluoxetine|
560740|NCT00000212|Drug|Desipramine|
560741|NCT00000211|Drug|Buprenorphine|
560742|NCT00000210|Drug|Buprenorphine|
560743|NCT00000209|Drug|Buprenorphine|
560744|NCT00000208|Drug|Buprenorphine|
560745|NCT00000207|Drug|Buprenorphine|
560746|NCT00000206|Drug|Buprenorphine|
560747|NCT00000205|Drug|Buprenorphine|
560748|NCT00000204|Drug|Buprenorphine|
560749|NCT00000203|Drug|Buprenorphine|
560750|NCT00000202|Drug|Buprenorphine|
560751|NCT00000201|Drug|Selegiline|
560752|NCT00000200|Drug|Methadone|normal maintenance dose
560753|NCT00000199|Drug|Piracetam|
560754|NCT00000198|Drug|Piracetam|
560755|NCT00000197|Drug|Propranolol|
560756|NCT00000196|Drug|Naltrexone|
560757|NCT00000195|Drug|Naltrexone|
560758|NCT00000194|Drug|Cycloserine|
560759|NCT00000193|Drug|Gamma hydroxybutyric|
560760|NCT00000192|Drug|Lamotrigine|
560761|NCT00000191|Drug|Carbamazepine|
560762|NCT00000190|Procedure|Parotid Gland|
560763|NCT00000189|Drug|Gepirone|
560764|NCT00000188|Drug|Selegiline|
560765|NCT00000187|Drug|Ritanserin|
560766|NCT00004640|Drug|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
560767|NCT00004639|Procedure|Furlow double z-plasty palatoplasty palate repair|
560768|NCT00004639|Procedure|Von Langenbeck palatoplasty palate repair|
560769|NCT04181814|Device|Ultrasound|Use ultrasound to assess gastric contents in diabetic patients before anesthesia
560770|NCT04181801|Procedure|Subtotal cholecystectomy|a surgical procedure in which more than the top half of the gallbladder is removed
560771|NCT04181788|Drug|PF-06801591|A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.
560772|NCT04181775|Diagnostic Test|ADE-RED scoring tool|The ADE-RED scoring tool will reduce the incidence of future visits to the ED or future admissions by identifying patients who are at high risk for ADE-related readmissions.
560773|NCT04181762|Drug|secukinumab|STUDY DRUG
560774|NCT04181749|Drug|aspirin and atorvastatin|Patients will be randomized and prescribed either no treatment or aspirin 75mg and Atorvastatin 40mg
560775|NCT04181736|Drug|Guanfacine Pill|Guanfacine immediate release, sold under the brand name Tenex among others, is a medication used to treat high blood pressure and off-label to treat attention deficit hyperactivity disorder (ADHD). It is taken by mouth and will be compounded by a pharmacy to the required doses used in this study.
560776|NCT04181736|Drug|Placebo|Placebo masked to mirror the treatment drug dose regimen.
560777|NCT04181723|Drug|Trofinetide|Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
560817|NCT04181489|Drug|Prednisolone|Prednisolone 60mg/m2 d1-5
560778|NCT04181723|Other|Placebo|Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
560779|NCT04181710|Procedure|Kidney transplant|Organ preserved in preservation solution
560780|NCT04181697|Device|PA measurement with Fitbit Charge 3|Measurement of PA with Fitbit for all participants and controls.
560781|NCT04181697|Device|PA measurement with Fitbit and ActiGraph GT3X|Measurement of PA with ActiGraph for a subgroup of 20 participants.
560782|NCT04181684|Device|Procedure: LITT|This procedure is done under MRI guidance and employs low-powered thermal energy to achieve tumor ablation through coagulation.
560783|NCT04181684|Radiation|Hypo-Fractionated Radiation Therapy|Treatments will be delivered once daily on consecutive treatment days (typically 5 fractions per week). Radiation therapy simulation is to be performed within 10 days of the LITT procedure.
560784|NCT04181671|Other|Low Resistance training with venous blood flow restriction|"Total 20 males will participate in this group after warmup , Blood flow restriction will be provided through sphygmomanometer optimum pressure will be measured through following formula occlusion pressure (mmHg) = 0.514 (SBP) + 0.339 (DBP) + 1.461 (Arm circumference) + 17.236 then 30% of 1RM will be used for training . The standard protocol will be used which is four sets (1st set—30 repetitions, 2nd set—15 repetitions, 3rd set—15 repetitions, and 4th set—15 repetitions) with 30-60 s of interval between sets. ( the cuff must be deflated between sets of exercise) for 8 weeks (24) sessions on non-consecutive days. participants will be re-assessed for all baseline variables after 8 weeks of training biceps curls will be used for training.~Heart Rate and oxygen saturation will be measured during the session through Pulse oximeter"
560785|NCT04181671|Other|High Resistance training|Total 20 males will participate in this group after warm up. 80% of 1RM will be used for training, 3 sets of 8 repetitions will be used with 30-60 s of interval between sets. for 8 weeks (24) sessions on non-consecutive days.No blood flow restriction will be applied to this group Participants will be re-assessed for all baseline variables after 8 weeks of training. Bicep curls will be used for training.
560786|NCT04181658|Other|Real tDCS and Physical Therapy|The participant will receive 10, 20-minute sessions of real tDCS on the same day as one's physical therapy session (either before or after each physical therapy visit) over approximately 6 weeks.
560787|NCT04181658|Other|Sham stimulation and Physical Therapy|The participant will receive 10, 20-minute sessions of sham stimulation on the same day as one's physical therapy session (either before or after each physical therapy visit) over approximately 6 weeks.
560788|NCT04181645|Drug|Biological: SHR-1210 Drug: Gemcitabine Drug:Paclitaxel-albumin|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. Gemcitabine Other Name: Gemcitabine Hydrochloride for Injection Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection
560789|NCT04181632|Device|Buzzy Bee with Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used with an ice pack.
560790|NCT04181632|Device|Buzzy Bee without Ice pack|Buzzy uses natural pain relief to block needle pain for blood draws and shots. This intervention will be used without an ice pack.
560791|NCT04181632|Device|Shot Blocker|Shot Blocker is a device that instantly alleviates the pain and anxiety of needle injections when pressed firmly against the skin at the injection site.
560792|NCT04181619|Dietary Supplement|Coffeeberry beverage|One exposure of 300 mg coffeeberry extract in a 300 ml flavored still beverage
560793|NCT04181619|Other|Comparator beverage|One 300 ml still beverage, color and flavor matched to experimental beverage
560794|NCT04181606|Drug|Esmolol Hydrochloride or Saline|The Esmolol loading dose will be 0.4 mg/kg body mass/min administered over the first 3 minutes (loading dose), followed by a maintenance dose of 0.2 mg/kg body mass/min for the remainder of the protocol (maximum of 60 minutes). The total amount of Esmolol given over the course of this study visit for a 75 kg subject would be 990 mg (= 90 mg loading dose + 900 mg maintenance dose).
560795|NCT04181606|Other|Handgrip during infusion|Subjects will be asked to grip at 40% of their maximum and to maintain that grip until fatigue (i.e. inability to maintain required force despite verbal encouragement from a member of the research team who is blinded to the infusion order). At fatigue, the cuff around the upper arm will be inflated to suprasystolic pressure to stop blood flow into the arm for up to 3 minutes. The subject stops gripping as the cuff is inflated and keeps their arm relaxed during this 3 minute occlusion.
560796|NCT04181593|Drug|Omega 3 fatty acid|Omega 3 fatty acid Softgels
560797|NCT04181593|Drug|Placebos|Mineral oil Softgels
560798|NCT04181580|Device|Made-to-measure compression garment|Made-to-measure compression garment
560799|NCT04181567|Other|electroconvulsive therapy|electroconvulsive therapy 2 times weekly
560800|NCT04181567|Drug|agomelatine|agomelatine
560801|NCT04181567|Drug|Placebo|placebo
560802|NCT04181554|Other|Measurement of postural stability|The postural stability will assess by using Biodex balance system.
560803|NCT04181541|Procedure|Provider type: Physicians|In this cohort, women will receive second trimester medical abortion care from physicians
560804|NCT04181541|Procedure|Provider type: Midlevel Providers|In this cohort, women will receive second trimester medical abortion care from midlevel providers.
560805|NCT04181528|Device|Total knee arthroplasty implant|In patients undergoing unilateral TKA, decide the implant of TKA (anatomically aligned or conventional TKA implant) will be decided using ramdon number table
560806|NCT04181515|Drug|Placebo oral tablet|placebo stressor
560807|NCT04181515|Drug|Yohimbine + Hydrocortisone|Yohimbine 54mg + Hydrocortisone 20mg
560808|NCT04181515|Device|sham rTMS|sham rTMS (inactive coil)
560809|NCT04181515|Device|active rTMS|active rTMS (10 Hz dlPFC stimulation in group 1; 1 Hz mPFC stimulation in group 2)
560810|NCT04181502|Procedure|pneumatic tourniquet|a pneumatic tourniquet around 200 mmHg after venous chase of the lower limb, during 5 minutes then deflated. Repeated twice after general anaesthesia and prior to incision.
560811|NCT04181502|Other|No inflation|No inflation of the pneumatic tourniquet placed on the lower limb
560812|NCT04181489|Drug|Sintilimab|Sintilimab 200mg d0
560813|NCT04181489|Drug|Rituximab|Rituximab 375 mg/m2 d0
560814|NCT04181489|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 d1
560815|NCT04181489|Drug|Doxorubicin|Doxorubicin 50 mg/m2 d1
560816|NCT04181489|Drug|Vincristine|Vincristine 1.4mg/m2 (maximum 2mg) d1
562040|NCT03786783|Drug|Thiotepa|Given IV
560818|NCT04181476|Drug|Sunscreening Agents|Four different sunscreens
560819|NCT04181463|Drug|Isopropyl Alcohol|Given via nasal inhalation
560820|NCT04181463|Other|Placebo|Given via nasal inhalation
560821|NCT04181463|Other|Questionnaire Administration|Ancillary studies
560822|NCT04181450|Other|Determination of the Cut-off Scores of Biodex Balance System|Based on the findings of the Sherafat et al. (Sherafat, S., Salavati, M., Takamjani, I. E., Akhbari, B., Mohammadirad, S., Mazaheri, M., & Negahban, H. (2013). Intrasession and intersession reliability of postural control in participants with and without nonspecific low back pain using the Biodex Balance System. Journal of manipulative and physiological therapeutics, 36(2), 111-118.) related to intrasession and intersession reliability of BBS in patients with NSLBP12, in the present study, one stability level (Level 5; ICC ≥0.70) and two conditions (eyes-open and eyes-closed) will be selected as testing procedure. All postural assessments will be performed during bilateral stance for a period of 30 seconds.
560823|NCT04181437|Drug|NVP-1203-R1|1 tablet, Single oral dosing
560824|NCT04181437|Drug|NVP-1203-R2|1 tablet, Single oral dosing
560825|NCT04181437|Drug|NVP-1203-R1 and NVP-1203-R2|NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
560826|NCT04181424|Behavioral|Diabetes Education Plus Monthly Food Vouchers|Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer???s markets mailed to their home.
560827|NCT04181424|Behavioral|Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer???s markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.
560828|NCT04181424|Behavioral|Diabetes Education Only|Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.
560829|NCT04181424|Behavioral|Diabetes Education Plus Monthly Stock Boxes|Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
560830|NCT04181411|Drug|Durvalumab|Experimental arm: Durvalumab 1500 mg every 3 weeks for 4 to 6 cycles, followed by durvalumab 1500 mg every 4 weeks until disease progression or unacceptable toxicity.
560831|NCT04181411|Drug|Cisplatin|Experimental arm and active comparator arm: cisplatin 75 mg/m² every 3 weeks for 4 to 6 cycles
560832|NCT04181411|Drug|Pemetrexed|Experimental arm and active comparator arm: Pemetrexed 500 mg/m² every 3 weeks for 4 to 6 cycles
560833|NCT04181411|Drug|Carboplatin|Participants experiencing unacceptable toxicities due to cisplatin may be treated with carboplatin AUC 5 every 3 weeks for 4-6 cycles.
560834|NCT04181398|Diagnostic Test|Anthropometry|"Actual Height and weight~Calculated BMI from measured weight and height.~Pubertal development (Tanner stage)~Waist circumference~Skin fold measurement (Triceps and Subscapular)~Waist-to-height ratio will be calculated from measured height and waist circumference."
560835|NCT04181398|Diagnostic Test|Blood pressure|Blood pressure will be measured using an oscillometric, electronic device (Mindray). The blood pressure will be measured 3 times; the first measurement will not be taken into account and the mean of the second and third measurement will be considered as the real blood pressure.
560836|NCT04181398|Diagnostic Test|Peripheral arterial tonometry|The investigator will measure the pulse wave amplitude by using a finger plethysmograph (peripheral arterial tonometry). The investigator will use the EndoPAT device from Itamar Medical Ltd. At the end of the examination, the participants will be asked to give a VAS-score (Visual Analogue Pain scale).
560837|NCT04181398|Other|Questionnaire|General questionnaire on cardiovascular risk factors
560838|NCT04181398|Diagnostic Test|Blood sample|Blood sample for hs-CRP
560839|NCT04181385|Drug|Olanzapine 10 milligram|Oral olanzapine capsule
560840|NCT04181385|Drug|Bromocriptine 5 milligram|Oral bromocriptine capsule
560841|NCT04181385|Drug|Placebo oral tablet|oral placebo capsules
560842|NCT04181372|Drug|Anlotinib hydrochloride|Anlotinib hydrochloride was given 12mg once daily for two weeks, stop for one week, each 3-week cycle for 2 cycles.
560843|NCT04181372|Drug|platinum-based chemotherapy medicine|(1)Carboplatin was given dosed to an AUC of 6 i.v. injection on day 1, paclitaxel was given 150 mg/m^2 i.v. on day 1, every 21 days for 2 cycles.Or(2) Carboplatin was given dosed to an AUC 5 or Cisplatin was given 75 mg/m^2 ,i.v. on day 1, pemetrexed was given 500 mg/m^2 i.v. on day 1 for nonsquamous, every 21 days for 2 cycles.Or(3) Cisplatin was given 75 mg/m^2 i.v. on day 1; docetaxel was given 75 mg/m^2 i.v. on day 1 ,each 21-day cycle for 2 cycles.
560844|NCT04181359|Drug|Nitric Oxide|Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
560845|NCT04181359|Drug|Placebo|Inhaled placebo, which consists of breathing medical grade air (21% O2).
560846|NCT04181346|Drug|Pregabalin|antipsychotic
560847|NCT04181346|Drug|Placebo|Placebo
560848|NCT04181320|Device|Venous Leg Ulcer Standard of Care with Granulox|Granulox will be added as an adjunct therapy to defined standard of care in subjects with predominantly venous leg ulcers.
560849|NCT04181307|Behavioral|BE-EHR module|The BE-EHR module includes six components: 1) a tailored advisory for patients over 75 with diabetes, 2) medication refill protocol with information on Choosing Wisely guidelines, 3) pre-population of the medication preference list with metformin, 4) lab result protocol with information on Choosing Wisely guidelines, 5) peer comparisons regarding performance meeting guidelines, and 6) media campaign with information about Choosing Wisely guidelines. The set of nudges is referred to collectively as the BE-EHR module.
560850|NCT04181294|Behavioral|Family meetings using time limited trials as default ICU communication and care planning approach|Providers will be trained using didactics, focus groups, and simulations using actors as family members. A TLT protocol and checklist will be used to facilitate family meetings. A coordinator will schedule family meetings. Routine feedback sessions will be held with the local champions.
560851|NCT04181294|Behavioral|Usual practice|Baseline practice of ICU communication and care planning
560852|NCT04181281|Diagnostic Test|Contrast enhanced ultrasound|This is a regular ultrasound scanner used with an ultrasound contrast agent injected through veins to allow for kidney perfusion acquisition.
560890|NCT04180982|Drug|SHR4640 dose1 and Febuxostat dose2|Tablet,dose1, dose2 QD
560853|NCT04181281|Diagnostic Test|Arterial Spin Labelling -Magnetic Resonance Imaging|Arterial spin labelling is an MRI technique allow for measuring tissue perfusion. It uses magnetically labelled arterial blood water protons as a tracer.
560854|NCT04181268|Device|Percutaneous coronary Intervention|Calcified plaque modification during percutaneous coronary intervention
560855|NCT04181255|Drug|Curosurf|This arm will consist of a single dose of Curosurf (200 mg/kg) that will be given in the Pediatric Cardiothoracic Unit (PCTU) after surgery once the subject has reached a normalized body temperature.
560856|NCT04181255|Drug|Sham|This arm will consist of a single dose of sham (air) that will be given through the endotracheal tube in the Pediatric Cardiothoracic Intensive Care Unit after surgery once the subject has reached a normalized body temperature.
560857|NCT04181229|Procedure|Deep brain stimulation|Patients will receive surgical implantation of the Medtronic DBS device (Device # 37601). Two (2) electrodes will be implanted bilaterally in the centromedian nucleus.
560858|NCT04181216|Device|Anatomically aligned total knee arthroplasty implant|In same patient, one total knee arthroplasty using anatomically aligned total knee arthroplasty implant Other total knee arthroplasty using conventional total knee arthroplasty implant
560859|NCT04181203|Drug|Apalutamide|"240 mg PO daily should start the same day as the first LHRHa administration for 6 months.~months."
560860|NCT04181203|Radiation|Salvage radiotherapy (SRT)|"The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.~An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images."
560861|NCT04181203|Drug|Luteinising Hormone Releasing Hormone agonist (LHRHa)|Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.
560862|NCT04181190|Diagnostic Test|Total IgE|Levels of total IgE before biological treatments and at 4±2 months of treatments
560863|NCT04181190|Diagnostic Test|Blood cell counts|White Blood Cell Count and Differential (and in particular the levels of total leucocytes, lymphocytes, eosinophils and basophils)
560864|NCT04181190|Diagnostic Test|Asthma control assessment|Levels of asthma control assessed by asthma control questionnaire (ACT) before initiation of biological treatments and at 4± months of treatments
560865|NCT04181190|Diagnostic Test|lung function tests|Lung function tests performed before initiation of biological treatments and at 4± months of treatments
560866|NCT04181177|Other|Cosmetic product|"Cosmetic balm: application twice daily on the whole body in sufficient quantity to cover all the xerosis areas. It contains an I-modulia(r) complex which decreases the sensation of itching, CER-OMEGA which are lipids similar to those of the skin, help repair and nourish the skin, finally Avène Thermal Spring Water which have soothing and softening properties.~Targeted education action consist in advices and preventive measures (including hygiene) regarding xerosis and associated dermatological signs / symptoms. Emollient and application tips and other supportive care tips will be provided. The targeted educational action will be monitored by the medical and paramedical teams (specialized nurses)."
560867|NCT04181164|Other|Microindentation|Microindentation is a new technology directly measuring bone strength by a minimal invasive technique.
560868|NCT04181164|Other|High resolution peripheral quantitative computed tomography (HRpQCT)|HRpQCT scan can assess the cross-sectional geometry of the bone and is an appropriate investigation to evaluate bone quality.
560869|NCT04181164|Biological|Biochemical analysis of different bone markers.|Measurement of different bone markers by biochemical analysis of blood samples.
560870|NCT04181151|Other|Electromyographic device|An 8-channel surface EMG system (Noraxon Telemyo DTS system, Scottsdale, USA) will be used to measure signals from muscles during surface electromyography measurements.
560871|NCT04181125|Other|Biodex Balance System|For the computerized evaluation of postural control, Biodex Balance System will be used.
560872|NCT04181125|Other|Balance Error Scoring System (BESS)|For the clinical evaluation of postural control, the Modified Balance Error Scoring System (BESS) will be used.
560873|NCT04181112|Biological|Fecal Microbiota Transplantation (FMT)|FMT using retention enema
560874|NCT04181099|Other|Implant neck surface|The biofilm formation is tested on discs manufactured of zirconia with different surfaces in vivo using orthodontic devices that the participants carry over 24h
560875|NCT04181086|Procedure|surgical excision of intracranial cavernoma|microvascular excision of intracranial cavernoma
560876|NCT04181073|Device|Jet Nebuliser|Jet Nebuliser
560877|NCT04181073|Device|Vibrating Mesh Nebuliser|Aerogen Device
560878|NCT04181060|Biological|Bevacizumab|Given IV
560879|NCT04181060|Drug|Osimertinib|Given PO
560880|NCT04181047|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|Psychotherapy.
560881|NCT04181047|Other|Usual care|Access to usual care, including psychiatrist, medications, mental health therapist, general community mental health programs. Also, our hospital has a mindfulness program that inpatients have access to, upon referral from their psychiatrist. Patients can also attend this after discharge.
560882|NCT04181034|Behavioral|Adolescent Family Life Program Positive Youth Development (PYD) program|Home visiting program for pregnant and parenting teens with PYD component
560883|NCT04181034|Behavioral|Adolescent Family Life Program (AFLP)|Home visiting program for pregnant and parenting teens
560884|NCT04181021|Behavioral|Values Clarification and Attitudes Transformation (VCAT) Workshop|VCAT is a participatory workshop aimed to provide accurate information about abortion and family planning and space to engage in critical self-reflection, provoke dialogue on beliefs, values and professional ethics and responsibilities around providing abortion and contraceptive care, and provide a deeper understanding of the range of circumstances in which women seek abortion and contraception.
560885|NCT04181008|Drug|Amiloride|Amiloride Nasal Spray
560886|NCT04181008|Drug|Amiloride|Amiloride Nasal Spray
560887|NCT04181008|Drug|Amiloride|Amiloride Nasal Spray
560888|NCT04180995|Drug|TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)|TORIPALIMAB INJECTION(JS001 ) combined with chemotherapy, 3mg/kg, Q2W,up to 1 years of treatment.
560889|NCT04180982|Drug|SHR4640 dose1 and Febuxostat dose1|Tablet,dose1,QD
560891|NCT04180982|Drug|SHR4640 dose2 and Febuxostat dose3|Tablet,dose2, dose3 QD
560892|NCT04180969|Drug|yohimbine + hydrocortisone|yohimbine 54mg + hydrocortisone 20mg oral
560893|NCT04180969|Device|medial prefrontal cortex rTMS|1 Hz mPFC rTMS
560894|NCT04180969|Drug|Placebo oral tablet|placebo stressor
560895|NCT04180969|Device|sham rTMS|sham mPFC rTMS
560896|NCT04180956|Other|Bias-reduction Intervention|A training for doctors
560897|NCT04180943|Drug|interscalene nerve block|intra and post-operative analgesia
560898|NCT04180930|Diagnostic Test|CAPS-5|Clinician Administered PTSD Scale for DMS-5
560899|NCT04180930|Diagnostic Test|PSSI-5|PTSD Symptom Scale Interview for DSM-5
560900|NCT04180930|Diagnostic Test|CAPS-IV|Clinician Administered PTSD Scale for DSM-IV
560901|NCT04180917|Other|Survey|survey
560902|NCT04180904|Other|Diet M|Diet M will focus on which foods are eaten and the impact on disease outcomes.
560903|NCT04180904|Other|Diet L|This diet will limit the amount of food energy consumed each day and the impact on disease outcomes. This will be determined by factors including the subject's demographics (age, sex, weight, height).
560904|NCT04180878|Behavioral|Intervention|Participants received a interactive physical activity monitoring system that allowed study personnel to monitor their activity level.
560905|NCT04180878|Behavioral|Intervention 2|Participants received an interactive physical activity monitoring system, an electronic scale to report weekly body weight, weekly hour long conference calls with structured interactive educational lessons led by Health Educator, dietary recalls were completed at three different time points during their participation, and study personnel monitored physical activity levels weekly.
560906|NCT04180852|Other|Functional tests without clinical consequence for the patients therapy|Battery of tests, which measure the patients functional outcomes regarding their muscle mass, their muscle strength, fat mass, physical function, neuropsychological function and quality of life.
560907|NCT04180839|Behavioral|gaming-related retrieval-extinction|"During one training session,participants will first view a 5-min retrieval video containing gaming content and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole training includes 2 training sessions. Participants will receive one training session once a day for two consectutive days."
560908|NCT04180839|Behavioral|nongaming-related retrieval-extinction|"During one session,participants will first view a 5-min neutral video and then, 10 minutes later, receive 1-hour of extinction training in which they will be administered four sequences of video, picture and in vivo gaming cues.~The whole procedure includes 2 sessions. Participants will receive one session once a day for two consectutive days."
560909|NCT04180826|Other|Observational|"Initially, the patient will be placed in a strict supine position (at 0°) in his hospital bed, according to the usual care.~In a second step, the patient will be verticalized (from 0° to 90°). Intracranial hemodynamics parameters in supine position and during verticalization will be continuously recorded by attaching the ATYS TCD-X® transcranial Doppler helmet attached with glasses.~After 15 minutes of recording, the patient will be placed back in supine position. The end of the patient's participation in the study will correspond to the removal of the ATYS TCD-X® helmet."
560910|NCT04180813|Drug|Linagliptin|drug
560911|NCT04180813|Drug|Acarbose|drug
560912|NCT04180800|Other|Lubben Social Network Scale - 6|One short oral interview to complete the Lubben Social Network Scale in auto-survey, translated in French. It contains 6 questions on 30 points, higher scores are associated with more social engagement, lower scores, specifically under 12/30, are associated with social isolation.
560913|NCT04180787|Dietary Supplement|Beverage Consumption|Participants will consume either VPX Bang® Keto Coffee beverage or flavor-matched placebo beverage in each condition.
560914|NCT04180774|Biological|Tag-7 gene modified inactivated tumor cells|Patients received GMV once in three weeks subcutaneously in three points in the paravertebral region. One dose consisted of 10 million transfected and inactivated tumor cells. No dose reduction was allowed.
560915|NCT04180761|Drug|intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)|single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
560916|NCT04180748|Other|fluorescence imaging with 405nm light|Each group will have images taken with an Health Canada approved device to capture images under white light and 405nm fluorescence with an mCherry filter. These images will not be used for diagnostics and will be analyzed for features which correlate to identified microbes from 16S RNA analysis and traditional microbiological technique. Groups are self identified by participants in order to capture a diverse population.
560917|NCT04180735|Procedure|Liver transplantation|Liver transplantation
560918|NCT04180722|Device|aTouchAway™ platform|Participants will receive our multi-component Virtual Transition Intervention. The four components of the intervention comprise: (1) routine virtual clinic visits scheduled at the same frequency as usual care; (2) virtual care plan and action plan for respiratory infection/deterioration and management of ventilator issues; (3) remote, weekly and monthly monitoring of ventilator and cough assist metrics, VAI symptoms, and oxygen saturations; and (4) as needed clinical consultations triggered by identification of abnormal parameters or requested by the VAI or family caregiver.
560919|NCT04180709|Device|Sleepio|Sleepio is an online cognitive behavioural therapy (CBT) based intervention designed to treat insomnia, conducted is 6 sessions. The program is an automated media-rich web-based application that is driven dynamically by baseline, adherence, performance and progress data. At the beginning of each session The Prof conducts a progressive review with the participant exploring the diary data submitted the week prior that includes sleep status and pattern, as well as progress based on goals previously set by the participant. The information, support and advice are personally tailored based on underlying algorithms.
560920|NCT04180696|Device|aCRT ON|CRT device with AdaptivCRT enabled
560921|NCT04180696|Device|aCRT OFF|CRT device with AdaptivCRT disabled
560948|NCT04180449|Other|Screening for dysphagia along clinical routine|Screening for dysphagia using the water swallow test in intermediate care unit patients
560949|NCT04180436|Drug|rivaroxaban 20 mg once daily 8 days|Blood samples for the measurement of rivaroxaban PK parameters
561010|NCT04179851|Diagnostic Test|Thermal imaging of neck veins|Thermal imaging of neck veins
561011|NCT04179838|Behavioral|Sleep-deprived|Sleep for 4 hours at home
560922|NCT04180683|Other|Battery of screening tests with semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria and an ID will be assigned to the participants that meet the criteria. Posteriorly, a clinical psychologist will administer the GDS-30, GDS-15, GDS-10 and GDS-5, the BDI-II and a semi-structured interview about depressive disorders according to the DSM-5 criteria. Participants with even ID's from each institution will be answer the instruments according to the order GDS-30, GDS-10, BDI-II, GDS-5 e GDS-15 and participants with odd ID's will answer the battery in the reverse order. The assessment session will take place in a single moment in time. After the assessment, the clinical psychologist will answer a questionnaire about which version was more easily understandable by the participants and the participants' preference regarding the GDS versions.
560923|NCT04180683|Other|Battery of screening tests without semi-structured interview|First, participants will be administered the Mini-Mental State Examination to assess if they meet the inclusion criteria an ID will be assigned to the participants that meet the criteria. Posteriorly, a psychologist will administer the GDS-30, GDS-15 and the BDI-II. Participants with even ID's from each institution will answer the instruments according to the order GDS-30, BDI-II and GDS-15 and participants with odd ID's the administration order will answer the battery in the reverse order. The assessment session will take place in a single moment in time.
560924|NCT04180657|Genetic|Protein C deficiency|The effect of protein C deficiency on ghrelin levels are investigated.
560925|NCT04180644|Other|Skin tape strips|Skin tape strips will be collected from lesional and non-lesional skin. Adhesive skin sampling discs will be firmly pressed against the skin in a hairless location (not the face) followed by lifting it free of the skin. These discs will then be used to evaluate proteins and lipids in the upper layers of skin.
560926|NCT04180631|Diagnostic Test|Quantitative ultrasound imaging parameter (QUS)|Quantitative ultrasound imaging parameters (QUS) are analyzed to evaluate hepatic steatosis
560927|NCT04180618|Other|Personal health wallet service for emergency situation|Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
560928|NCT04180605|Other|Additional support for preoperative planning of LAA closure procedures|"The results of the computational simulations provided by FEops HEARTguideTM will be used in the computational simulation arm as an additional preoperative planning tool and their potential added value will be assessed by comparison to the standard of care arm."
560929|NCT04180605|Procedure|Left atrial appendage closure|Transcatheter device insertion to exclude the LAA from the cardiac circulation
560930|NCT04180592|Procedure|CT Fusion + Transrectal U/S Guided Prostate Biopsy|All patients will receive both a CT fusion biopsy and a standard TRUSP biopsy. They will be randomized to which is received first, followed by receipt of the alternative procedure.
560931|NCT04180579|Device|PAXMAN Scalp Cooler|Scalp cooling will occur with each dose of chemotherapy.
560932|NCT04180566|Other|Ultrasound Examination|Includes a regular growth ultrasound examination.
560933|NCT04180566|Other|Antenatal Testing (biophysical profile)|Includes weekly ultrasounds with a biophysical profile, which measures fetal tone, fetal movements, fetal breathing and amount of amniotic fluid (water around baby).
560934|NCT04180553|Diagnostic Test|Point of Care Ultrasound (POCUS)|The intervention group will receive a 4-view transthoracic echocardiogram including Parasternal long axis, parasternal short axis, apical 4-chamber, and supplemental subcostal short-axis/4-chamber views as needed. A standard 4-view thoracic lung ultrasound study will assess the left and right anterior chest wall, anterior axillary regions, as well as the costophrenic angle and posterolateral regions. At 5 discrete time intervals post-operatively, POCUS assessments will be used to adjust fluid resuscitation to fluid liberal (2cc/kg/hr) or fluid restrictive (0.8cc/kg/hr). Routine vital signs, biochemistry, and urine output as well as bedside physical exam will be assessed as usual. IV boluses of crystalloid will be permitted to treat hypotension with SBP <90mmHg with clinical signs of hypovolemia, but oliguria will not be used as a marker to titrate fluid infusion rates. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated.
560935|NCT04180553|Other|Usual Care|"The control group for usual care will undergo resuscitation guided by modalities used currently, which can include both static and dynamic measures. These will include review of vital signs, biochemistry, and urine output as well as bedside physical exam. In this arm, patients will not undergo POCUS during their admission. IV fluid infusion rates as well as targets for IV boluses will be left to the discretion of the attending physician and can include hypotension, hypovolemia, as well as oliguria. Blood transfusion may be used for post-operative bleeding or anemia as clinically indicated."
560936|NCT04180540|Device|Percutaneous Closure|The PerClose Proglide system will be used to deliver a suture to close the venous puncture following completion of ablation for treatment of atrial fibrillation.
560937|NCT04180540|Other|Manual Compression|"Manual compression is the standard method of attaining hemostasis following ablation for treatment of atrial fibrillation. Manual compression may be performed with or without figure of eight suture for hemostasis at the discretion of the treating physician)."
560938|NCT04180514|Diagnostic Test|intradialytic hypotension episode|Intradialytic hypotension episode under regular hemodialysis
560939|NCT04180501|Combination Product|SRS sequential sintilimab|The subjects first received a targeted radiotherapy of SRS, and started the treatment of sintilimab per 3 weeks within 35 days after SRS.
560940|NCT04180488|Drug|Dupilumab SAR231893|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
560941|NCT04180488|Drug|Placebo|Pharmaceutical form:Injection solution Route of administration: Subcutaneous
560942|NCT04180488|Drug|non sedating H1-antihistamine|Pharmaceutical form:Tablet Route of administration: oral administration
560943|NCT04180475|Device|MedRem application|Medication adherence smartwatch application
560944|NCT04180462|Other|Practice Facilitation|Practice facilitation to support quality improvement methods to effect practice change to develop a sustainable HPV vaccine delivery system.
560945|NCT04180462|Other|Education|An educational video to increase the provider's knowledge about guideline recommendations and patient and practice benefits of vaccination by age 13.
560946|NCT04180462|Other|Audit and Feedback|Audit and feedback of vaccine coverage to increase motivation to engage in practice change.
560947|NCT04180462|Other|Communication Strategy|A communication strategy to improve the provider's communication skills and their self-efficacy to address parental hesitation.
560950|NCT04180423|Device|Off-the-Shelf Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Off-the-Shelf implants use standard sizing.
560951|NCT04180423|Device|Customized Implant Total Knee Replacement|Total Knee Replacement, or knee arthroplasty, is a common surgical procedure performed to relieve the pain and disability resulting from osteoarthritis. In general, the surgery consists of replacing the diseased or damaged joint surfaces of the knee with metal and plastic components shaped to allow continued motion of the knee. Customized implants are customized individually made knee implants which are designed specific to each patient's unique anatomy.
560952|NCT04180410|Device|EIT|Electrical Impedance Tomography is performed before extubation, during follow-up visits of extubation and 48H after extubation. Follow-up visits are shortened in case of extubation failure.
560953|NCT04180397|Drug|Furosemide|Furosemide 10 mg/ml for injection/infusion
560954|NCT04180384|Drug|Oraxol|
560955|NCT04180371|Drug|BT5528|Participants will receive a 60-minute intravenous infusion of BT5528 once a week (Days 1, 8, 15, and 22) on a 4-week cycle at the selected dose.
560956|NCT04180371|Drug|Nivolumab|Participants will receive nivolumab at 480mg intravenous infusion every 4 weeks.
560957|NCT04180358|Behavioral|Native STAND|Native STAND is a comprehensive sexual health curriculum for Native high school students that focuses on sexually transmitted infections, HIV/AIDS, and teen pregnancy prevention, while also covering drug and alcohol use, suicide, and dating violence. Twenty-seven sessions support healthy decision-making through interactive discussions and activities that promote diversity, self-esteem, goals and values, team building, negotiation and refusal skills, and effective communication. Sessions will be conducted in regular Physical Education and/or Health Education classes during classroom/school hours.
560958|NCT04180358|Behavioral|Regular Health/Physical Education Curriculum|General health and physical education curriculum provided by New Mexico's Public Education Department.
560959|NCT04180345|Other|Psychometric validation of the questionnaire|"Delph Process : expert panel will include HCPs and patients. They will evaluate the relevance of items on a Likert scale (HCPs N = 25 ; Patients N = 25 ) Think aloud interviews (N = 10 patients) Psychometric validation ( N = 200 patients)"
560960|NCT04180332|Diagnostic Test|Blood sample|5ml of venous blood was taken from the ante cubital vein from each of the study subjects
560961|NCT04180306|Other|pediatric early warning scoring system and resuscitation curriculum|teaching resuscitation to medical providers and implementing a scoring tool to help identify patients at risk for clinical deterioration in an inpatient setting
560962|NCT04180293|Behavioral|Pilot psychoeducation program|Canadian Armed Forces veterans and their family members will be recruited to participate in this pilot psychoeducation program and its evaluation. Two six-week sessions will be implemented an OSI Clinic in Atlantic Canada - the first in January/February of 2020 and the second in the spring of 2020. A maximum of 10-15 participants (including both veterans and their family members) will be recruited for each group. Family members are defined as spouses/partners, siblings, parents, and adult children. Each of the weekly sessions will take place at the OSI clinic and will be led by at least two trained facilitators (one from the research team, and one member of the OSI clinical staff team). Each of these sessions will focus on providing education of different topics relevant to those accessing services at the clinic (e.g., types of treatments available, tools to support families, self care, etc.).
560963|NCT04180293|Other|Program evaluation|At the end of each six-week session, program outcomes will be assessed qualitatively by a member of the research team. Participants will take part in semi-structured interviews guided by questions informed by the ecological family systems theory.
560964|NCT04180280|Behavioral|Behavioral self-regulation Phone counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered using phone calls by a trained adherence and care engagement counselor.
560965|NCT04180280|Behavioral|Behavioral self-regulation Office counseling to improve HIV care|Participants receive 5 sessions of behavioral counseling to improve HIV care. Counseling is delivered in clinical care offices s by a trained adherence and care
560966|NCT04180267|Device|Low-magnitude High-frequency Vibration|35Hz, 0.3g, 20min/day, at least 3 times/week
560967|NCT04180254|Procedure|Effect of several processing on the auditory distance perception|The focus is a comparison of hearing instrument algorithms on the auditory distance perception
560968|NCT04180241|Procedure|POEM|Peroral endoscopic myotomy
560969|NCT04180228|Other|self-administred questionnaire|On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
560970|NCT04180215|Drug|HB-201 intravenous administration|Dose level to be assigned based on 3+3 dose escalation (3 to 6 patients per cohort).
560971|NCT04180215|Drug|HB-201 intratumoral administration on first cycle, followed by HB-201 intravenous administration on subsequent cycles|HB-201 dose level to be assigned based on 3+3 dose escalation (3 to 6 patients per cohort).
560972|NCT04180202|Device|Non-invasive central venous pressure|Non-invasive method to measure central venous pressure indicator
560973|NCT04180189|Other|Weighted fiber blanket|Using weighted blanket for four weeks
560974|NCT04180176|Other|Blood Draw|Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
560975|NCT04180163|Drug|Lanadelumab|Participants receive 300 mg of lanadelumab solution q2w (treatment period A) for 26 weeks and q2w or q4w (treatment period B) for 26 weeks, for overall 52 weeks of treatment period.
560976|NCT04180150|Drug|TQ-A3334|TQ-A3334 is a kind of TLR7 receptor agonist.
560977|NCT04180150|Drug|Placebo|Placebo is a treatment which is designed to have no therapeutic value.
560978|NCT04180150|Drug|Entecavir Tablet|Entecavir (ETV) tablet is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection.
560979|NCT04180137|Procedure|Endovenous laser ablation of great saphenous vein (GSV) and microphlebectomy of varicose veins|"Surgical treatment is performed as endovenous laser ablation of GSV and microphlebectomy of varicose branches according to a standard protocol:~The intervention includes treatment of the pathological upright reflux and varicose veins. Ultrasound-guided GSV puncture at the upper third of the leg under local anesthesia. The light guide is inserted into the vein lumen and pushed through to the saphenofemoral junction. Under ultrasound guidance the light guide is positioned at v. epigastrica superficialis junction. Under ultrasound guidance tumescent anesthesia is produced around the GSV from puncture site up to the saphenofemoral junction. Laser coagulation (with radial light guide), linear energy density — 75 J/cm, automatic traction of the light guide at the speed 0.7 mm/sec. Varicose veins are resected through skin punctures using Varady hook 1-2 mm."
560980|NCT04180137|Drug|Pharmacotherapy|After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
560981|NCT04180124|Other|Walking|"Patients walk over ground on a mat with sensors and on a treadmill with sensors (in different conditions) to compare their movement pattern.~Also the movement pattern will be compared between walking at comfortable walking speed en fast walking.~Finally, the correlation between upper extremity impairment and arm swing will be investigated."
560982|NCT04180111|Device|CATS Tonometer|CATS Tonometer Prism
560983|NCT04180098|Behavioral|C-mill intervention|A five week personalised rehabilitation program. Participants train gait adaptability via obstacle negotiation, precision stepping and unexpected accelerations and decelerations. The strategies are trained in a safe environment on the C-mill, a treadmill providing augmented reality via visual and acoustic cues. The treatment is implemented in a five week period via 10 biweekly sessions. Each treatment session lasts 60 minutes. In total, participants will receive C-mill training for a total of ten hours. The training will be carried out by a skilled physiotherapist.
560984|NCT04180098|Other|No intervention|Participants in the control group are placed on a waiting list.
560985|NCT04180085|Drug|Belatacept Injection|9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
560986|NCT04180072|Drug|Atezolizumab plus bevacizumab|Atezolizumab plus bevacizumab Day 1 of each 3 week cycle
560987|NCT04180059|Combination Product|CTL 19|Patients candidate for allogeneic transplantation who are both HLA-DPB1*04:01 and with a HLA-DPB1*04:01-expressing hematological malignancy (almost 100% of cases) with a donor HLA-DPB1*04:01 negative, will be proposed to receive one single infusion of the T cell clone at 4-5 months post-transplantation, once the immunosuppression by cyclosporine and/or mycophenolate mofetil has been discontinued.
560988|NCT04180033|Diagnostic Test|Colonoscopy surveillance|Participants will be asked to undergo a first colonoscopy surveillance.
560989|NCT04180020|Other|ID/LAB|ID/LAB is the new model in which OUD is managed by Infectious Disease (ID) specialists and/or Hospitalists concurrent with management of the infectious diseases, using long-acting injectable buprenorphine (LAB).
560990|NCT04180020|Other|TAU|TAU is designed to systematize what is the current practice at the participating hospitals and in most U.S. hospitals while offering a minimum standard of care. TAU will constitute recommendation for MOUD initiation and consultation for addiction medicine when available; in practice, it is typically detoxification from opioids and referral to community-based addiction treatment after hospital discharge.
560991|NCT04180007|Drug|Apatinib|500 mg Apatinib given orally once a day for 12 wk prior to RAI (131I) treatment.
560992|NCT04179994|Other|Miswak extract-containing toothpaste|Miswak extract-containing toothpaste will be applied to the tooth diagnosed with DH
560993|NCT04179994|Other|Potassium nitrates-containing toothpaste|Potassium nitrates-containing toothpaste will be applied to the tooth diagnosed with DH
560994|NCT04179994|Other|Placebo|A toothpaste containing the same ingredients of the test toothpaste except for the active ingredient
560995|NCT04179981|Device|Positive airway pressure|Positive airway pressure therapy. OVS patients randomized to PAP therapy arm will be titrated to optimal PAP therapy per standard protocol and assigned to use PAP therapy.
560996|NCT04179981|Other|Conservative care (control arm)|Eligible OVS patients will receive conservative care/usual care with education about sleep apnea and sleep hygiene via handouts and video instructions. This is the control arm.
560997|NCT04179968|Drug|68Ga PSMA-11 injection|Injection of 68Ga PSMA-11
560998|NCT04179968|Procedure|Positron Emission Tomography/Computed Tomography|PET/CT scan after 68Ga PSMA-11 injection
560999|NCT04179942|Diagnostic Test|Fractional exhaled nitric oxide and CRP levels|measurement of FeNO and Hs-CRP after 3months of CPAP
561000|NCT04179929|Drug|Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)|Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance)
561001|NCT04179929|Procedure|allogeneic HSCT|allogeneic HSCT
561002|NCT04179916|Diagnostic Test|stimulation in virtual reality|"HTC VIVE pro will be used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It is planned to submit 3 scenarios with a total stimulation time of up to 20 minutes."
561003|NCT04179903|Other|Physical activity|Physical Activity program is performed in a group in a gym and at home
561004|NCT04179890|Drug|Epidermal Growth Factor Tyrosine Kinase Inhibitor|Up to 30 months
561005|NCT04179890|Drug|Afatinib|Up to 30 months
561006|NCT04179877|Behavioral|IPS|Occupational rehabilitation and support Integrated with clinical treatment
561007|NCT04179864|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small-molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
561008|NCT04179864|Drug|Abiraterone/prednisone|1,000 mg (two 500 mg tablets or four 250 mg tablets) orally once daily in combination with prednisone 5 mg administered orally twice daily.
561009|NCT04179864|Drug|Enzalutamide|enzalutamide 160 mg (four 40 mg capsules) orally once daily
561012|NCT04179838|Behavioral|Not sleep-deprived|Sleep for 8 hours at home
561013|NCT04179799|Device|Diaphragm Pacing|"Intramuscular stimulation of the diaphragm, or diaphragm pacing' is achieved by laparoscopic placement of stimulation wires into each hemidiaphragm. Phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller."
561014|NCT04179786|Biological|Sci-B-Vac™|Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
561015|NCT04179773|Other|Current care study|"Observational study in two parts:~Cross-sectional study of patients with digestive or ENT cancer with indication for conventional chemotherapy treatment according to management guidelines, the objective of which is to determine the frequency of cirrhosis.~Exposed/non-exposed cohort study of patients receiving a first course of conventional chemotherapy initiated in outpatient oncology clinic. (safety population).~Exposed subjects will be patients with cirrhosis, included consecutively. Non-exposed subjects will be non-cirrhotic patients. They will be selected non-consecutively according to the following criteria, for matching to exposed subjects: age (±5 years), type of cancer (digestive vs. ENT), treatment stage (curative vs. palliative). Two unexposed subjects will be selected for 1 exposed subject."
561016|NCT04179760|Biological|SCM-AGH|SCM-AGH will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
561017|NCT04179760|Other|Placebo|Placebo will be administrated 3 times with 2-week intervals by IV infusion to subjects at Weeks 0, 2 and 4 (Visits 2, 3 and 4).
561018|NCT04179747|Behavioral|Cognitive Behavioral Psychotherapy|The Cognitive Behavior Psychotherapy was provided for a period of maximum 3 months.
561019|NCT04179747|Drug|Sildenafil Citrate 50Mg Tab|The participants in control group arm received Sildenafil Citrate 50mg tablet on demand for a period of maximum 3 months.
561020|NCT04179734|Drug|Bremelanotide|Melanocortin-4 receptor agonist subcutaneous injection.
561021|NCT04179734|Drug|Placebo|Placebo subcutaenous injection.
561022|NCT04179721|Behavioral|PES-4-BPSD Model|"I. Cohorting. Patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 10-bed medical unit. II. PES are mental health assistants with high school level education, who receive training in de-escalation and crisis prevention techniques and provide direct personal care to psychiatric patients. On the intervention unit, these PES purposefully engage patients with BPSD. III. Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to implement the program for the PES staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the PES staff will receive weekly 20 minute sessions. IV. Staff Support. Once recruitment begins, the PI will hold monthly 20 minute group sessions, to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of HCGs towards patients."
561023|NCT04179721|Behavioral|The attention control condition|"I. Cohorting. Patients with cognitive impairment AND past or present indication of BPSD, acutely admitted to the medicine or telemetry service, are cohorted on a 40-bed medical unit. II. Dementia Care Education and Training. The PI, with the support of the research team, will spend 12 weeks to implement the program for the NA staff. Based on the Try This: Best Practices in Nursing Care for Persons with Dementia, the NA staff will receive weekly 20 minute sessions. III. Staff Support. Once recruitment begins, the PI will hold monthly 20 minute group sessions, to reinforce training and discuss challenging patient behaviors; meant to improve the attitude and empathy of HCGs towards patients."
561024|NCT04179708|Other|Pain Neuroscience Education|"Intervention description Patients participate in a back school program including initial and final assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hours of educative initial assessment and ½ hour of educative final assessment.~The content of Pain Neuroscience Education (experimental group) focuses on deconstruction of patho-anatomical and biomechanical believes, and the explanation of pain from the biology. This framework allows the introduction of coping strategies (eg gradual exposure to exercise, activity and physical activity) and regulation strategy (eg fragmentation of activity, stress management, and so on)."
561025|NCT04179708|Other|Conventional education|"assessment, educational activities and therapeutic activities (eg. Physiotherapy, balneotherapy, physical activity, spine ergonomics, and so on) spread over 5 days. The therapeutic activities are the same in experimental and control group, only the educational activities differ.~The educational activities represent 4 hours of intervention, ½ hour of educative initial assessment and ½ hour of educative final assessment.~The content of conventional education (control grou) focuses on patho-anatomical and biomechanical notions. This framework allows the introduction of protection strategies (eg education on good posture, good handling techniques, physical activity and therapeutic exercise in stretch and strenghten the spine in order to protect it)."
561026|NCT04179695|Other|Consulting with PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
561027|NCT04179695|Other|Consulting without PARKINSUN as communication aid-tool|Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
561028|NCT04179682|Procedure|40-hour constraint-induced movement therapy|Participants were randomly allocated to 1 of 2 CIMT programs (40 hours): a 2-week 4-hours/day CIMT program and a 4-week 2-hours/day CIMT program. One CIMT program was performed 1 month after a BoNT-A injection, and then the second program was implemented with the next injection.
561029|NCT04179669|Drug|IBI306|Administered by subcutaneous injection
561030|NCT04179669|Drug|placebo|Administered by subcutaneous injection
561031|NCT04179656|Drug|Pyrotinib|400 mg administered orally, once daily, continuously in 21 day cycles
561032|NCT04179643|Biological|3 x 10e13vg NAN-101|There are 2 components to NAN-101. The first is an active I-1 transgene (AA 1-65 with T35D), and the second is the vector, BNP116, which delivers the gene selectively to the heart after intracoronary administration.
561033|NCT04179630|Biological|Aldafermin (NGM282)|Single 3 mg dose
561034|NCT04179617|Other|Flavored JUUL pod|JUUL pod in the participant's preferred flavor (not tobacco-flavored)
561035|NCT04179617|Other|Tobacco JUUL pod|Tobacco-flavored JUUL pod
561036|NCT04179604|Drug|Levosimendan|Levosimendan SIMDAX 2.5 mg / ml concentrate for solution for infusion. The concentrate is a clear solution, yellow or orange, for dilution before administration. A 5 ml vial contains 12.5 mg of levosimendan. The study drug infusion will start one day before surgery in an Intensive Care Unit with at least 8 hours of administration before surgery. A continuous infusion at 0.1 µg/kg/min will be administered to complete 24h duration.
561037|NCT04179604|Drug|Placebos|Patients in the placebo group will receive a water-soluble vitamin B2 concentrate with 0.4 mg / ml sodium riboflavin phosphate to obtain the same color as the preparation of levosimendan and ethanol anhydrous 100 mg / ml to resemble the levosimendan odor, which will be administered at the same levosimendan infusion rate.
561038|NCT04179591|Other|Exercise|Intrinsic foot muscles and tibialis posterior strengthening exercises
561039|NCT04179591|Other|Orthesis|Customized arch support insoles
561040|NCT04179578|Procedure|Crura plastic|Closure of hiatus with a running suture
561041|NCT04179565|Behavioral|Healthy Children Healthy Families|The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
561042|NCT04179552|Device|PAAG-OA|Intra-articular injection with PAAG-OA (polyacrylamide hydrogel)
561043|NCT04179539|Diagnostic Test|V/Q PET/CT|Ventilation images are acquired after inhalation of Galligas prepared using a Technegas generator (Cyclopharm, Sydney, Australia). The patients is placed in a supine position and inhaled Galligas using the standard ventilation technique. Ventilation images are then acquired. Without the patient moving, 68Ga-MAA are then injected. Perfusion PET images are then acquired
561044|NCT04179539|Diagnostic Test|CTPA|CTPA will be done according to the usual protocol in the radiology department of the investigator center
561045|NCT04179526|Behavioral|Transdiagnostic Internet-delivered REBT|The protocol is based on Rational Emotive and Behavioral Therapy (REBT; Ellis, 1962, 1994). The program will consist of 8 modules, delivered online over six weeks.
561046|NCT04179513|Biological|GB224 10mg|"10 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10~15 mg/week), oral administration, a total of 32 doses."
561047|NCT04179513|Biological|GB224 20mg|"20 mg, 12subjects, abdominal subcutaneous injection, the next dose group can be initiated only after the safety and tolerability are confirmed within 4 weeks after the second dosing is given.~Dosage and administration at enrollment are maintained (10~15 mg/week), oral administration, a total of 32 doses."
561048|NCT04179500|Drug|Pretomanid|200 mg pretomanid tablets will be taken once per day with a meal for 26 weeks
561049|NCT04179487|Diagnostic Test|OPTICA CTPA Protocol|Low dose CT pulmonary angiogram protocol
561050|NCT04179474|Drug|Ubrogepant|Single dose oral administration of ubrogepant
561051|NCT04179474|Drug|Erenumab|Single dose subcutaneous (SC) injection of erenumab
561052|NCT04179474|Drug|Galcanezumab|2 SC injections of galcanezumab
561053|NCT04179474|Drug|Ubrogepant|Repeated once daily oral doses of ubrogepant
561054|NCT04179461|Drug|Cholecalciferol|Oral administration
561055|NCT04179461|Drug|antihistamine|Oral administration
561056|NCT04179461|Drug|Azithromycin|Oral administration
561057|NCT04179461|Drug|emollient cream|Topical
561058|NCT04179461|Drug|Fluticasone Propionate|Nasal spray
561059|NCT04179461|Drug|Asthma Controller Medication|Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
561060|NCT04179448|Procedure|SAMRI|Side Access Mucosal Releasing Incision (SAMRI) will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
561061|NCT04179448|Procedure|STA|Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
561062|NCT04179435|Behavioral|Behavioral testing on cognitive computerized tasks|Testing on cognitive computerized tasks
561063|NCT04179435|Other|brain MRI|Brain MRI scans
561064|NCT04179435|Other|TMS|Measure of the cortical inhibitory capacity using TMS measures
561065|NCT04179422|Other|anthropometric measurement|weight, height, BMI
561066|NCT04179422|Other|nutritional questionnaire|24hs food recall, presence of feeding disorders
561067|NCT04179409|Drug|Casimersen|This drug is used to target skipping of exon 45 of the dystrophin gene.
561068|NCT04179409|Drug|Eteplirsen|This drug is used to target skipping of exon 51 of the dystrophin gene.
561069|NCT04179409|Drug|Golodirsen|This drug is used to target skipping of exon 53 of the dystrophin gene.
561070|NCT04179396|Drug|Rucaparib|Oral rucaparib will be administered twice daily
561071|NCT04179396|Drug|Enzalutamide|"Enzalutamide will be administered once daily.~Enrollment into Arm A will be prioritized over Arm B until the objectives for Arm A have been achieved."
561072|NCT04179396|Drug|Abiraterone|Abiraterone will be administered once daily with prednisone
561073|NCT04179383|Other|Constitution of a biobank|"We are collecting additional blood and CSF samples for patients with RCVS (only after their specific agreement) to constitute a biobank.~This is why this study is classified as 'interventional' rather than 'observational'."
561074|NCT04179370|Other|N/A - no intervention. Observational study.|N/A - no intervention. Observational study.
561075|NCT04179344|Other|Integrated e-healthcare services (IeHS) web-based app|Each participant is asked to complete study tasks using the IeHS web-based app as a part of IeHS simulation. This activity is followed by user experience survey, and an in-depth interview to explore user satisfaction on the IeHS web-based app
561076|NCT04179331|Other|Neurotensin|Neurotensin is an endogenous peptide released from the distal small intestine. It will be administered at three doses (2.5, 5.0 and 7.5pmol/kg/min), each for 1h, in sequence.
561077|NCT04179331|Other|Saline|Isotonic saline will serve as a placebo.
561180|NCT04172792|Dietary Supplement|high-caloric fatty diet|see arm/group description
561078|NCT04179318|Diagnostic Test|Geneswell BCT|Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.
561079|NCT04179305|Behavioral|Oncolo-GIST|"Behavioral: Oncolo-GIST Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~Principles of introducing prognosis in the setting of worsened scan results Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you) Addressing informational needs and psychological reactions Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
561080|NCT04179305|Behavioral|Usual Care Arm|Oncologists will provide care in non-specific manner.
561081|NCT04179292|Other|Hand Therapy by Physiotherapist|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
561082|NCT04179292|Other|Hand Therapy as home program|"stretching exercises; all finger joints, wrist and supination-pronation direction strengthening exercises; finger and wrist functional exercises retrograde massage; starting from the distal phalanx to the elbow sensory education; desentilation training (cotton…) breathing exercises 5 days / week, 8 weeks in total~3 days / week with physiotherapist~2 days / week as home program 30 minutes / day 12 repetitions"
561083|NCT04179279|Device|Gili Biosensor System (Gili Pro Biosensor)|Non-contact monitoring of heart and respiratory rates using an optical device
561084|NCT04179266|Drug|Ketamine|One Cluster headache attack is treated with intranasal ketamine
561085|NCT04179253|Diagnostic Test|office micro hysteroscopy|One hundred women with unexplained infertility recruited for office micro hysteroscopic sessions. A rigid fiberoptic 2-mm, 0 and 30 degrees angled hysteroscopy along with an operative channel for grasping forceps or scissors were used for both diagnostic and operative indications. The findings, complications, and patient tolerance were recorded.
561086|NCT04179240|Other|audio and animated cartoon questionnaire|participants were asked to complete a questionnaire audio and animated cartoon on a platform
561087|NCT04179227|Other|Questionnaire Administration|Ancillary studies
561088|NCT04179227|Other|Survey Administration|Ancillary studies
561089|NCT04179214|Other|Thoracic manipulation|Session will be performed twice a week for a three week period if a pop sound occurred then the therapist moved on next procedure ,if not subject will be repositioned and technique will performed again. This procedure will be performed for maximum of two attempts. Approximately 3 minutes of time is required to complete thrust manipulation subjects assigned to thrust manipulation also received general exercise program and manual pressure release technique as the control group. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
561090|NCT04179214|Other|conventional pt protocol|This group will receive manual pressure release technique along with general exercises program. General exercise group involve Stretching exercises for the pectoral muscles and resisted strengthening exercises for the scapular retractors and elevators and the glenohumeral abductors and external rotators were performed three times per week for 3 weeks.
561091|NCT04179188|Procedure|Bariatric surgery|Classical Bariatric surgery (ring, Sleeve gastrectomy or Bypass)
561092|NCT04179175|Drug|secukinumab|secukinumab 300mg every 2 or every 4 weeks
561093|NCT04179162|Drug|Bacillus Calmette-Guérin (BCG)|Patients will receive once-weekly intravesical BCG therapy (TICE strain, 50 mg) at weeks 2 (+/- 2 days), 3 (+/- 2 days), 5 (+/- 2 days), 6(+/- 2 days), 8 (+/- 2 days), and 9 (+/- 2 days).
561094|NCT04179162|Drug|Gemcitabine|Patients will receive gemcitabine at their specified dose level, given in a twice weekly fashion, with 72 to 96 h (+/- 1 day) between doses, at weeks 1, 4, 7, and 10.
561095|NCT04179149|Behavioral|Environmental enrichment|The experimental group will participate in six modules that mimic and integrate the three hallmarks of EE: social interaction (more animals per cage = support group meetings, online support), novelty (toys and activities = exposure to new hands-on activities), and larger enclosures (larger cages = meetings in open environments). There will be 2 interventions per month, for three months, and a follow up 3 months after the end of the intervention
561096|NCT04179136|Dietary Supplement|lignan capsules contain 300 mg flaxseed (SDG) extract|lignan capsules contain 300 mg flaxseed (SDG) extract
561097|NCT04179136|Dietary Supplement|Placebo treatment matching intervention|Placebo treatment matching intervention
561098|NCT04179123|Device|Customised PAP interfaces|Customised PAP interfaces
561099|NCT04179110|Drug|Pembrolizumab and Ramucirumab|Patients will receive Pembrolizumab 200 mg & Ramucirumab 10 mg/kg every 3 weeks.
561100|NCT04179019|Drug|Amlodipine|Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks
561101|NCT04179006|Dietary Supplement|LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressant(s)|3 pieces per day
561102|NCT04178980|Drug|Simvastatin in relapsing remitting multiple sclerosis|Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis
561103|NCT04178928|Drug|Levothyroxine|investigate the effect of replacement therapy with levothyroxine on cardiovascular risk factors in children with SCH.
561104|NCT04178798|Drug|Acalabrutinib 100 MG Oral Capsule|Patients in Arm A will receive acalabrutinib as one capsule of 100 mg orally twice daily on a continuos Schedule.
561105|NCT04178538|Procedure|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation|ACL reconstruction with bone marrow, demineralized bone marix, and internal brace augmentation with all inside technique
561106|NCT04178538|Procedure|Standard ACL reconstruction with all inside technique|Standard ACL reconstruction with all inside technique
561107|NCT04178512|Procedure|Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control|prevention of shivering after spinal anesthesia in patients undergoing transurethral prostatectomy
561108|NCT04178460|Drug|Niraparib combined with MGD013|"About 24 subjects will be enrolled during dose escalation phase, with fixed dose niraparib (200mg or 300mg) combined with MGD013 (120mg, 300mg or 600mg ) in different dose level.~About 35 subjects will be enrolled during dose expansion phase with fixed dose niraparib (200mg or 300mg) combined with fixe dose MGD013 (to be confirmed after dose escalation)"
561109|NCT04178408|Other|No intervention|No intervention
561110|NCT04178291|Device|Ultrasonic scaler and Gracey currettes|Full mouth subgingival debridement using ultrasonic scaler and Gracey currettes
561111|NCT04178291|Device|Air polishing with erythritol powder|Air flow PLUS
561112|NCT04178278|Diagnostic Test|Shuttle walking test|Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea
561113|NCT04178278|Diagnostic Test|Exercise stress test|Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.
561114|NCT04178278|Diagnostic Test|6 minutes walking test|When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
561115|NCT04178070|Biological|GB224 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
561116|NCT04178070|Biological|GB224 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
561117|NCT04178070|Biological|GB224 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
561118|NCT04178070|Biological|GB224 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
561119|NCT04178070|Biological|GB224 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
561120|NCT04178070|Biological|GB224 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
561121|NCT04178070|Other|Placebo, 2mg|2mg (100μL), single dose, abdominal subcutaneous injection
561122|NCT04178070|Other|Placebo, 5mg|5mg (250μL), single dose, abdominal subcutaneous injection
561123|NCT04178070|Other|Placebo, 10mg|10mg (500μL), single dose, abdominal subcutaneous injection
561124|NCT04178070|Other|Placebo, 15mg|15mg (750μL), single dose, abdominal subcutaneous injection
561125|NCT04178070|Other|Placebo, 20mg|20mg (1mL), single dose, abdominal subcutaneous injection
561126|NCT04178070|Other|Placebo, 30mg|30mg (1.5mL), single dose, abdominal subcutaneous injection
561127|NCT04178057|Biological|GB222 3mg/kg|Injection, strength 100mg/bottle, intravenous infusion, 3mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; low dose group.
561128|NCT04178057|Biological|GB222 5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 1.
561129|NCT04178057|Biological|GB222 7.5mg/kg|Injection, strength 100mg/bottle, intravenous infusion,7.5mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; intermediate dose group 2.
561130|NCT04178057|Biological|GB222 10mg/kg|Injection, strength 100mg/bottle, intravenous infusion,10mg/kg, dose escalation; After it is tolerated, 2 weeks/per time, combines use of chemotherapeutic agents is allowed after 3 months until disease progression, death, intolerable toxic reactions, withdrawal of informed consent form, loss to follow-up, death or study conclusion; high dose group.
561131|NCT04177862|Drug|Sublingual Sufentanil|30 mcg of sublingual sufentanil
561132|NCT04177862|Drug|IV Fentanyl|50 mcg of IV fentanyl
561133|NCT04177758|Drug|Vitamin D|Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
561134|NCT04177758|Drug|Control|Patients randomized to the control will receive a placebo
561135|NCT04177563|Other|whole body cryostimulation|Whole-body cryotherapy
561136|NCT04176965|Device|POD L IOL|Cataractous lens will be removed in the study eyes and the POD L IOL will be implanted in the capsular bag.
561137|NCT04176965|Device|AcrySof® IOL|Cataractous lens will be removed in the study eyes and the AcrySof® IOL will be implanted in the capsular bag.
561138|NCT04176952|Drug|FOLFOX-A|"nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)"
561139|NCT04176952|Drug|AG|"nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel)."
561140|NCT04176770|Procedure|ESP Block|ESP block: bilateral injection of 20 ml of isobaric Bupivacain 0,375% in the paraverebral space T5.
561141|NCT04176770|Procedure|TAP Block|TAP block: bilateral injection of 15 ml of Isobaric Bupivacain 0,5%
561142|NCT04176757|Drug|ZN-c5|ZN-c5 study drug to be administered orally daily
561143|NCT04176731|Device|Omnipod Horizon™ Automated Glucose Control System|The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
561144|NCT04176614|Other|cereal-legume snack|cereal-legume biscuit
561145|NCT04176614|Other|cereal snack|cereal biscuit
561146|NCT04176588|Drug|Etrasimod|Drug:Etrasimod Tablet other name:APD334
561147|NCT04176588|Drug|Placebo|Drug:placebo Tablet
561148|NCT04176484|Other|Survey|Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
561149|NCT04176237|Other|UV Dosimetry Laboratory|The UV Dosimetry Laboratory is a one hour lesson that incorporates science and health education - kids hypothesize what UV levels will be around the school yard, go and measure UV, review their results, and then come up with a SunSmart plan for playing in the school yard.
561150|NCT04175873|Other|music|Patients will listen to music with MP3 headphones for 1 hour preoperatively and throughout the operation.
561151|NCT04175808|Drug|Omecamtiv Mecarbil (OM)|In Part A treatment 1: 25-mg OM oral solution. In Part B treatment B: 50-mg OM oral solution
561152|NCT04175808|Drug|Placebo|Treatment A: Placebo oral solution
561153|NCT04175808|Drug|Moxifloxacin|Treatment C: 400-mg moxifloxacin oral tablet
561154|NCT04175756|Device|Caiman 5 articulating Maryland|Laparoscopic colorectal surgery
561155|NCT04175678|Other|Diet|Participants will receive delivered meals every 4 weeks for three months of a variety of foods for breakfast, lunch, dinner, two snacks, and an additional snack or dessert for each day.
561156|NCT04175678|Other|Exercise|Training will be supervised, individualized, and periodized, incorporating 3 sessions per week, 45-60 min per session for 36 sessions.
561157|NCT04175639|Behavioral|Mobile Health Pain Coping Skills Training (mPCST)|Participating in Mobile Health Pain Coping Skills Training will involve four 50-minute individual intervention sessions conducted over the course of 8 weeks with tele-video-conferencing at patient's community-based clinic. The therapist delivering the intervention will be at Duke University Medical Center, and patients will be at their community clinic.
561158|NCT04175587|Drug|Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid|Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
561159|NCT04175444|Diagnostic Test|VisuALL Field Analyzer|Each participant will conduct a visual field test with the visuaALL headset.
561160|NCT04175444|Diagnostic Test|Humphrey Field Analyzer|Each participant will conduct a standard of care Humphrey Visual Field.
561161|NCT04175379|Other|group 40|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 40 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
561162|NCT04175379|Other|group 50|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 50 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
561163|NCT04175379|Other|group 60|During surgery, the TV(tidal volume) should maintain 6ml/kg (ideal body weight). After position change and OLV(one lung ventilation) for operation, each patient adjusts RR(respiratory rate) to reach target PaCO2 60 ± 5mmHg. Hemodynamic records and arterial blood tests are performed at the following times: After tracheal intubation, 15 minutes after in two lung ventilatory state at the supine position (T0), after 30 minutes reaching to the target PaCO2 by adjusting RR at the lateral position starting one lung ventilation (T1), and after 60 minutes while maintaining target PaCO2 (T2).
561164|NCT04175366|Other|Shared Decision Making|Shared Decision Making including adapted decision aid.
561165|NCT04174911|Drug|BOL-DP-o-08|BOL-DP-o-08 sublingual drops
561166|NCT04174911|Drug|Placebo|sublingual drops
561167|NCT04174846|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|SAM children will receive approximately 190 kcal/kg/day of standard RUTF
561168|NCT04174846|Dietary Supplement|Ready-to-use-supplementary food (RUSF)|SAM children will receive approximately 190 kcal/kg/day of Acha Mum (AM-RUSF)
561169|NCT04174755|Drug|Semaglutide Injectable Product|Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.
561170|NCT04174755|Behavioral|Standard of care|Diet and exercise advice for 40 weeks
561171|NCT04173806|Other|Facebook intervention|"The intervention consists of the content of the course on telemedicine through a closed group of Facebook according to the established syllabus whose educational material is video classes, discussion forums and online questionnaires. The duration of the course will be 5 weeks, each week two classes will be uploaded to the Facebook platform in succession until the course is completed. So that the student can visualize the content progressively and continuously."
561172|NCT04173806|Other|Control Training:|In this group the participants are exposed to the same course content and perform similar activities as the intervention group on Facebook during the same period but on the Moodle educational platform. The Moodle platform was chosen because it has been widely used in several institutions, with a large user community worldwide, with approximately 50,000 registrations in more than 200 countries and due to the many easy-to-use educational tools it offers. So it is one of the educational platforms that has demonstrated its efficiency in the medical educational field.
561173|NCT04173689|Device|Threshold IMT|7 days a week, 2 times a day 15 min each
561174|NCT04173689|Other|breathing exercises combined with upper extremity and trunk|upper extremity and trunk exercises combined with breathing exercises for 7 days a week, 2 times a day for 15 minutes each
561175|NCT04173065|Drug|VK2809|Capsule
561176|NCT04173065|Drug|Placebos|Capsule
561177|NCT04172909|Other|LEGO Bricks MRI|LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) will be used by the child life specialist to prepare the child for MRI
561178|NCT04172909|Other|Mock MRI tube|Mock MRI tube will be used by the child life specialist to prepare the child for MRI
561179|NCT04172870|Diagnostic Test|Molecular analysis|RT- PCR
561181|NCT04172792|Dietary Supplement|ultra-high-caloric fatty diet|see arm/group description
561182|NCT04172792|Dietary Supplement|ultra-high-caloric carbohydrate-rich diet|see arm/group description
561183|NCT04172701|Drug|Long-acting Muscarinic Antagonists (LAMA)|drug
561184|NCT04172701|Drug|Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)|drug
561185|NCT04172597|Drug|Poziotinib Hydrochloride|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
561186|NCT04172246|Drug|Zanubrutinib|Zanubrutinib at 160 mg orally twice daily
561187|NCT04172129|Device|Total Hip Arthroplasty|
561188|NCT04171856|Device|REAplan(R)|motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
561189|NCT04171232|Other|Balance It|Each patient in group 1 i.e. Balance It group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to balance the objects falling from above on the imaginary bar (and an actual bar at later stages) held with their both hands, and not let those objects fall by opening their arms wide open and by staying or moving according to the target spot for the set time. This session would be repeated three times a week for two months (total 12 sessions/month).
561190|NCT04171232|Other|Bubble Pop|Each patient in group II i.e. Bubble Pop group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to reach for the balloons coming from random directions and pop them by moving their upper limbs and even their whole body if required. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
561191|NCT04171232|Other|Scoop'd|Each patient in group III i.e. Scoop'd group would be given a 15 minutes long session. Each session would start in standing position and the patient would play the game while they would be instructed to hold an imaginary ice cream cone (and an actual basket designed similar to an ice cream cone in later stages) with their both hands and move to catch the ice cream scoops falling at random spots from above, one spot at a time. They would also be instructed to avoid a specific object that would result in deduction of their overall game score. This session would be repeated three times a week for two months (total 12 sessions/month).
561192|NCT04170946|Other|Talazoparib in Combination with Low Dose Radiotherapy (RT)|Dose escalation model to determine the safety and MTD of talazoparib in combination with low dose RT.
561193|NCT04170738|Drug|Adderall|3 weeks of Adderall
561194|NCT04170595|Biological|GB221,2 mg/kg|Single dose 2mg/kg group: lyophilized powder for injection; strength 110mg/bottle; 2 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
561195|NCT04170595|Biological|GB221,6 mg/kg|Single dose 6mg/kg group: lyophilized powder for injection; strength 110mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
561196|NCT04170595|Biological|Herceptin,6 mg/kg|Single dose group: lyophilized powder for injection; strength 440 mg/bottle; 6 mg/kg for one dose, intravenous infusion, completed for over 90 minutes
561197|NCT04170595|Biological|GB221,8mg/kg|Single dose 8mg/kg group: lyophilized powder for injection; strength 110mg/bottle; 8mg/kg for one dose, intravenous infusion, completed for over 90 minutes
561198|NCT04170595|Biological|GB221:2mg/kg and Capecitabi:1000mg/kg|GB221:Lyophilized powder for injection; strength 110mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose group; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
561199|NCT04170595|Biological|Herceptin:2mg/kg and Capecitabin:1000mg/kg|Herceptin:Lyophilized powder for injection; strength 440 mg/bottle; 2mg/kg, the first infusion is completed over 90 minutes. If no serious adverse reaction is observed, the subsequent infusion can be completed over 30 minutes. The administration shall be continued until disease progression or intolerable toxic reactions or ICF withdrawal of subjects. Multiple dose groups; Capecitabine:1000mg/kg, orally twice daily (one dose each in the morning and evening; total daily dose of 2000 mg/m2), administration for 2 weeks followed by a 1-week rest period, as a 3-week cycle.
561200|NCT04169451|Drug|Letrozole|Women will be randomized to the group with ovarian stimulation with letrozole or the group without stimulation.
561201|NCT04169373|Drug|Upadacitinib|Upadacitinib is administered as oral tablet
561202|NCT04169373|Drug|Placebo|Placebo for upadacitinib is administered as oral tablet
561203|NCT04168840|Diagnostic Test|Compare clinical test with ultrasound parameters|Compare various clinical test with four ultrasound parameters to predict difficult intubation.
561204|NCT04168814|Other|Observational test|Nutritional risk (NutriScore), based on weight, weight loss, tumor location, and treatment, Nutritional status (VGS, Global Subjective Assessment Valoración Global Subjetiva, in Spanish), ECOG performance status; nutritional therapy (oral nutritional supplements, enteral nutrition, parenteral nutrition, dietary advice); type of treatment: chemo, type of chemo, adjuvant, neoadjuvant, palliative, curative endocrine therapy, targeted therapy +-immunotherapy vs QQT/RT therapy; cancer site.
561205|NCT04168710|Drug|ESP block with bupivacaine|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of 0.25% bupivacaine in the plane between the transverse process of the spine and the erector spinae muscle.
561206|NCT04168710|Other|Saline control/sham injection|Each participant randomized to the ESP block group will receive an ultrasound guided single shot injection of 20cc of normal saline in the plane between the transverse process of the spine and the erector spinae muscle.
561207|NCT04167943|Drug|Dual cured resin modified tricalcium silicate cement|A resin based, dual cured tricalcium silicate based cement
561208|NCT04167878|Device|3D printed biodegradable cervical fusion cage|ACDF with 3D printed biodegradable cervical interbody fusion cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
561209|NCT04167878|Device|PEEK cage|ACDF with PEEK cage for spinal fusion procedure at one level (C2 to T1) of the cervical spine.
561210|NCT04167696|Biological|CYAD-02|CYAD-02 is a Chimeric Antigen Receptor-T (CAR-T) administered after CYFLU.
561211|NCT04167696|Drug|ENDOXAN|administered as preconditioning chemotherapy
561212|NCT04167696|Drug|Fludara|administered as preconditioning chemotherapy
561213|NCT04167540|Biological|AAV2-GDNF|Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
561214|NCT04167306|Drug|Varenicline Tartrate 1 mg b.i.d|Capsules for oral use
561215|NCT04167306|Drug|Bupropion Hydrochloride 150 mg b.i.d|Capsules for oral use
561216|NCT04167306|Other|Placebo for varenicline|Capsules for oral use
561217|NCT04167306|Other|Placebo for bupropion|Capsules for oral use
561218|NCT04166747|Other|Virtual Reality experience|Participants will receive virtual reality based experience and will be assessed for its influence on happiness, functional fitness components and quality of life of older age groups.
561219|NCT04166383|Biological|VB-111|1E13 or 0.7E13 VP via IV infusion on Day 1 of cycle 1 and continue every 6 weeks
561220|NCT04166383|Drug|Nivolumab|240 mg of nivolumab via IV infusion on Day 1 of each cycle starting on cycle 2 and continue every 2 weeks
561221|NCT04166058|Drug|Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)|Participants whom are between the ages of 7-11 years old at their time of enrollment will be assigned a dose (72 μg or 145 μg) based on their weight. Randomized doses (145 μg or 290 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
561222|NCT04166058|Drug|Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers):|Participants whom are between the ages of 6-11 years old at their time of enrollment will be assigned a dose of 72 μg. Randomized doses (72 μg or 145 μg) will be assigned to participants whom are 12-17 years old at the time of enrollment.
561223|NCT04164823|Device|Medical taping|For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
561224|NCT04164823|Drug|Analgesic self-medication (OTC)|Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
561225|NCT04164108|Dietary Supplement|Intermittent Enteral Nutrition Protocol|Patients will receive total recommended nutrition divided into four equal meals, delivered at a rate of 400 cc/hr at 8:00, 12:00, 16:00, 20:00. Titration schedule will include administering 50% of volume for first two feeds, then 75%, and then 100%.
561226|NCT04163991|Drug|VIB4920|VIB4920 Dose 1 or 2 will be administered intravenously per dosing interval of 1 or 2 or 4.
561227|NCT04163991|Drug|Placebo|Placebo will be administered intravenously per dosing interval of 1 or 3 or 5.
561228|NCT04163458|Drug|MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL|Solution for injection in pre-filled pen, subcutaneous administration
561229|NCT04163458|Drug|MENOPUR powder and solvent for solution for injection, 75 IU|Solution for injection in vials (powder and diluent), subcutaneous administration
561230|NCT04163458|Other|Placebo (for MENOPUR solution for injection in pre-filled pen)|Solution for injection in pre-filled pen, subcutaneous administration
561231|NCT04163458|Other|Placebo (for MENOPUR powder and solvent for solution for injection)|Solution for injection in vials (powder and diluent); subcutaneous administration
561232|NCT04161391|Drug|TPX-0046|Oral TPX-0046 capsules
561233|NCT04160234|Other|web-based questionnaires|Patients will be asked to complete web-based questionnaires on a tablet-PC
561234|NCT04160195|Biological|Anti-CD19-CAR and Anti-CD20-CAR T cells|Dose-escalation trial starting dose: 0.66 x106 CAR+ T cells/kg (weight based dosing one time)(up to a maximum dose of 10x106 CAR+ T cells/kg based on cohort) infuse on day 0
561235|NCT04160195|Drug|Cyclophosphamide|500 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3
561236|NCT04160195|Drug|Fludarabine|30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
561237|NCT04160039|Device|Cycle ergometry|Lower extremity cycle ergometry, passive and/or active, up to 20 minutes per session, up to 5 sessions per week
561238|NCT04160013|Behavioral|Discipline education|Discipline education using the Play Nicely program.
561239|NCT04160013|Behavioral|Cavity Prevention|Cavity prevention using a 2 page handout.
561240|NCT04158908|Behavioral|Oncolo-GIST|"Oncolo-GIST is a brief, manualized communication intervention that guides oncologists in gist communication by itemizing 4 key steps in the process of imparting prognostic information.~Topic covered include:~Principles of introducing prognosis in the setting of worsened scan results~Coupling communicating realistic prognoses with psychological support (e.g., saying average life-expectancy is months… with emphasizing that the oncology team will always provide care for you)~Addressing informational needs and psychological reactions~Applying proven techniques for supporting patients who are reluctant to discuss prognosis.~The 4-step guide will include brief video-clips of demonstrating each talking point with a standardized patient, including ideal scenarios, common pitfalls to avoid, and how to respond to patient reactions that are particularly challenging, such as responding to optimism, death anxiety, and reliance on faith."
561241|NCT04157517|Drug|TAK-573|TAK-573 intravenous infusion.
561242|NCT04155931|Other|body temperature measurement|Postoperative analgesic and antiemetic requirements, nausea and vomiting were observed in the recovery room at 6, 12 and 24 hours
561243|NCT04153565|Drug|Pembrolizumab|Participants will receive PBZ at 200 mg/m2 IV every 3 weeks (Q3W) until disease progression, or until participant has received 35 administrations of PBZ (approximately 2 years)
561244|NCT04153565|Drug|Pemetrexed|Participants will receive PMX @ 500 mg/m2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
561245|NCT04153565|Drug|Cisplatin|Participants will receive CIS @ 75 mg/m2 IV on Day 1 of each cycle up to 4-6 cycles where each cycle = 3 weeks
561246|NCT04153149|Drug|Vutrisiran|Vutrisiran 25 mg will be administered by SC injection q3M.
561247|NCT04153149|Drug|Sterile Normal Saline (0.9% NaCl)|Sterile normal saline (0.9% NaCl) will be administered by SC injection q3M.
561248|NCT04152915|Drug|Semaglutide|Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 7 weeks
561249|NCT04152382|Drug|LY3462817 - IV|Administered IV
561250|NCT04152382|Drug|LY3462817 - SC|Administered SC
561251|NCT04152382|Drug|Placebo - IV|Administered IV
561252|NCT04152382|Drug|Placebo - SC|Administered SC
562041|NCT03786783|Drug|Topotecan|Given IV
561253|NCT04150562|Drug|rhIL-15|rhIL-15 will be administered by continuous intravenous infusion (CIV) at a starting dose of 2 mcg/kg/day for the first dose level followed by a second dose level of 4mcg/kg/day on days 1-5 of the 28-day cycle of each of four cycles.
561254|NCT04150562|Biological|Avelumab|avelumab (800mg by IV) will be administered on days 8 and 22 of the 28- day cycle for four cycles
561255|NCT04149028|Procedure|PRP injection inside the ovary by laparoscoy. The injection volume is 2 ml|intraovarian injection of 2 mml of PRP by laparoscopic guide
561256|NCT04147728|Drug|Anlotinib|Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret.
561257|NCT04147728|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery as the initial treatment of non small cell lung cancer patients with limited brain metastases
561258|NCT04147338|Drug|Guselkumab|Guselkumab will be administered subcutaneously.
561259|NCT04146506|Other|Muscle stretching exercises|Muscle stretching exercises consisting of static stretching exercises of the knee flexors
561260|NCT04146038|Drug|Azacitidine|Given IV
561261|NCT04146038|Drug|Decitabine|Given IV
561262|NCT04146038|Drug|Salsalate|Given PO
561263|NCT04146038|Drug|Venetoclax|Given PO
561264|NCT04144205|Other|Change of the fraction of inspired oxygen|"After the stabilization of cardiopulmonary bypass, in the first half of patients, fraction of inspired oxygen would be set at 0.5 and maintained for 5 minutes (T0), then it would be changed to 1.0 and maintained for 5 minutes (T1). Again, fraction of inspired oxygen would be resumed to be 0.5 and maintained for 5 minutes (T2).~In the other half of patients, the direction of change in fraction of inspired oxygen will be reversed as follows. It will be set at 1.0 and maintained for 5 minutes (T0), then changed to 0.5 and maintained for 5 minutes (T1), and finally to 1.0 and maintained for 5 minutes (T2)."
561265|NCT04144179|Biological|Quadrivalent RIV with H3 strain 1|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
561266|NCT04144179|Biological|Quadrivalent RIV with H3 strain 2|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
561267|NCT04144179|Biological|Quadrivalent RIV with H3 strain 3|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
561268|NCT04144179|Biological|Quadrivalent RIV with H3 strain 4|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
561269|NCT04144179|Biological|Quadrivalent RIV with 2018-2019 NH H3 strain|Pharmaceutical form: Pre-filled single-dose vial Route of administration: Intramuscular
561270|NCT04144023|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|Given intradermally
561271|NCT04144023|Biological|Multi-epitope HER2 Peptide Vaccine H2NVAC|Given intradermally
561272|NCT04144023|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
561273|NCT04143880|Drug|Progesterone|intramuscular injection intranasal administration
561274|NCT04143880|Other|saline|intramuscular injection intranasal administration
561275|NCT04143802|Drug|LY3437943|Administered SC
561276|NCT04143802|Drug|Dulaglutide|Administered SC
561277|NCT04143802|Drug|Placebo|Administered SC
561278|NCT04142619|Biological|UCARTCS1A|Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor
561279|NCT04142437|Drug|larotrectinib(Vitrakvi, BAY2757556)|In the study, patients treated under local standard of care clinical practice; all decisions in terms of diagnostic procedures, treatments, management of the disease, and resource utilization are fully dependent on mutual agreement between the patient and the attending physician, without interference by the study initiator or study protocol
561280|NCT04142112|Device|Ohana IVF Sperm Preparation Kit (OHB035)|The Ohana IVF Sperm Preparation Kit (OHB035) contains media for processing sperm through a series of timed steps prior to insemination with oocytes.
561281|NCT04142112|Device|Standard IVF Preparation Kit (OHB037)|The Standard IVF Sperm Preparation Kit (OHB037) contains media for processing sperm per the traditional steps prior to insemination with oocytes.
561282|NCT04141696|Drug|Ketamine|Given intravenously over 40 minutes
561283|NCT04141696|Drug|Midazolam|Given intravenously over 40 minutes
561284|NCT04140825|Device|Resmon PRO FULL|Measurement of lung impedance by the Forced Oscillation Technique
561285|NCT04139005|Behavioral|Awareness|The program foundation targets attention and awareness skills that are integral to many conceptions of mindfulness.
561286|NCT04139005|Behavioral|Connection|The Connection module targets skills underlying social connection, which refers to the sense of having close and positively experienced relationships with others in the social world.
561287|NCT04139005|Behavioral|Insight|The Insight module targets skills underlying dynamic self-inquiry and experiential self-knowledge.
561288|NCT04138758|Drug|Tiotropium bromide + Olodaterol|Tiotropium bromide + Olodaterol
561289|NCT04138758|Drug|LABA/ICS|Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
561290|NCT04138212|Drug|Paclitaxel, Cisplatin|Paclitaxel 175mg/m2 plus Cisplatin 75mg/m2, q21d, 2 cycles
561291|NCT04138212|Radiation|neoadjuvant chemoradiation therapy|Paclitaxel 50mg/m2 plus Carboplatin AUC=2, q1w, 5 cycles; 41.4Gy, 1.8Gy/d*23
561292|NCT04138121|Device|Ultrasound|Ultrasound scan of the cricothyroid membrane
561293|NCT04137458|Biological|Biological analysis|Blood and salivary samples will be taken at inclusion and a psychiatric assessment will be carried out
561294|NCT04136808|Drug|enfortumab vedotin (EV)|Participants will receive an intravenously (IV) administered dose once weekly for the first 3 weeks of every 4-week cycle (i.e., on days 1, 8, and 15)
561295|NCT04136093|Other|the MED|The MED diet will be composed of the basis food items traditional for the Mediterranean region i.e. olive oil, nuts, vegetables, fruits, and fish and this diet will be given an ad libitum approach. The MED diet will be giving a higher proportion of fat, at least 40% of the total energy, with 20% of the total energy from MUFAs, and less proportion of carbohydrates. To ensure the assumed supply of MUFAs and polyunsaturated fatty acids (PUFAs), the participants will be asked to daily intake 60 g (6 spoons) of extra virgin olive oil and 30 g (6 pieces) walnuts.
561328|NCT04129567|Other|Humidified oxygen|Delivering humidified oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
561329|NCT04129567|Other|Dry oxygen|Delivering dry oxygen at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
561296|NCT04136093|Other|the DASH|The DASH diet will be giving a higher proportion of carbohydrates, at least 60% of total energy and less fat. The DASH diet will be composed wholegrain cereal products, fruit, vegetables, low-fat dairy products, fish, seafood, poultry, beans, seeds and nuts and will be recommending eating of the traditional polish food items for example oatmeal, rye bread, barley groats, apples, plums, etc. and reducing the supply of salt, sweets, sugars, fats especially saturated fats and red meat. In our study, the DASH diet will be given an ad libitum approach. The sufficient supply of carbohydrates and β glucans in the DASH diet will be ensured by daily consumption at least 50g oatmeal and 50g of barley groats.
561297|NCT04136093|Other|Control diet|"The control group will only receive oral dietary recommendations based on the Harvard model Healthy Eating Plate, that recommend to eat a half of plate of vegetables and fruit, a quarter of plate of whole grains products, and a quarter of plate of protein products for one meal."
561298|NCT04135768|Procedure|Wrist joint haematoma washout|After plating of the distal radius is performed, a small incision is made on the wrist joint capsule. This is the portal for fluid efflux. An intravenous cannula is used to puncture the wrist joint capsule adjacent to the first incision and normal saline is infused through this cannula into the wrist joint. The infusion continues until the fluid efflux from the first portal is clear and no longer blood stained. This will be the point at which the washout is considered to be complete.
561299|NCT04135768|Procedure|Volar locking plate insertion of the distal radius|An anatomical locking plate is applied to the distal radius fracture using screws
561300|NCT04134260|Drug|Abiraterone Acetate|Given PO
561301|NCT04134260|Drug|Apalutamide|Given PO
561302|NCT04134260|Drug|Hormone Therapy|Receive hormone therapy
561303|NCT04134260|Drug|Prednisone|Given PO
561304|NCT04134260|Other|Quality-of-Life Assessment|Ancillary studies
561305|NCT04134260|Other|Questionnaire Administration|Ancillary studies
561306|NCT04134260|Radiation|Radiation Therapy|Undergo pelvis and prostate bed radiation therapy
561307|NCT04132765|Other|Drooling Impact Scale|A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
561308|NCT04132765|Other|Drooling Frequency and Severity Scale|In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
561309|NCT04132765|Other|The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)|A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
561310|NCT04132765|Other|Drooling Quotient (DQ)|DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
561311|NCT04132765|Other|Patient and caregiver visual analog scale (VAS) for drooling|Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
561312|NCT04132765|Other|Functional Oral Intake Scale (FOIS)|Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
561313|NCT04132765|Other|number of bibs daily used|Parents will be asked their children's number of bibs daily used.
561314|NCT04132765|Other|number of hospital admissions per year related to respiratory infections|Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
561315|NCT04132765|Other|Gross Motor Function Classification System (GMFCS)|The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
561316|NCT04132765|Other|Manual Ability Classification System (MACS)|The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
561317|NCT04132765|Other|Communication Function Classification System (CFCS)|The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
561318|NCT04132765|Other|Eating and Drinking Ability Classification System (EDACS)|EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
561319|NCT04132518|Device|Sculptra|Initial injection and optional 3 injections with Sculptra in Midface.
561320|NCT04131595|Biological|MVA-BN-WEV Dose 1|1 x 10^7 Inf.U MVA-BN-WEV vaccine
561321|NCT04131595|Biological|MVA-BN-WEV Dose 2|1 x 10^8 Inf.U MVA-BN-WEV vaccine
561322|NCT04131595|Biological|MVA-BN-WEV Dose 3|2 x 10^8 Inf.U MVA-BN-WEV vaccine.
561323|NCT04131556|Drug|Maribavir|Participants in both part 1 and part 2 of the study will receive maribavir tablet or suspension orally depending upon the treatment sequence allocation for a total of 7 and 10 days respectively.
561324|NCT04130854|Drug|Radiation Therapy 5Gy x 5 days|"APX005M 0.3 ug/m2 intravenously on day 3 of radiation and on day 3 of cycle 1 and 2 of FOLFOX chemotherapy~Short course radiation therapy 5 Gy x 5 days~Oxaliplatin 85mg/m2 intravenous day 1 of each cycle~Leucovorin 400mg/m2 IV Day 1 of each cycle~5-FU 2400 mg/m2 continuous infusion over 46 hours of each cycle"
561325|NCT04130646|Device|Transcranial Magnetic Stimulation|transcranial magnetic stimulation delivers magnetic pulses to the brain through the scalp/skull
561326|NCT04130646|Device|transcutaneous auricular vagus nerve stimulation (taVNS)|non-invasive vagus nerve stimulation delivers electricity to the ear
561327|NCT04130126|Behavioral|Taking cold showers|Showering behaviour
561417|NCT04093167|Drug|Pembrolizumab|200mg IV
561330|NCT04129567|Other|Humidified air|Delivering humidified air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
561331|NCT04129567|Other|Dry air|Delivering dry air at 15 liters per minute through the nose in a blinded fashion using a nasal cannula.
561332|NCT04129554|Drug|JNJ-73763989|JNJ-73763989 injection will be administered subcutaneously once per month up to 48 weeks.
561333|NCT04129554|Drug|JNJ-56136379|JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.
561334|NCT04129554|Drug|Placebo for JNJ-73763989|Matching placebo for JNJ-73763989 will be administered as subcutaneous injection up to 48 weeks.
561335|NCT04129554|Drug|Placebo for JNJ-56136379|Matching placebo for JNJ-56136379 tablets will be administered orally up to 48 weeks.
561336|NCT04129554|Drug|Entecavir (ETV) monohydrate|ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.
561337|NCT04129554|Drug|Tenofovir disoproxil fumarate (TDF)|TDF will be administered orally once daily up to 48 weeks as NA treatment.
561338|NCT04129554|Drug|Tenofovir alafenamide (TAF)|TAF will be administered orally once daily up to 48 weeks as NA treatment.
561339|NCT04129151|Drug|Palbociclib|Oral, per protocol pre determined dosage, once a day for 21 days
561340|NCT04129151|Drug|Ganitumab|-Intravenous, per protocol predetermined dosage, twice per cycle
561341|NCT04129112|Drug|We do not modify the normale general anesthesia delivery. We note the concentration of propofol at the effector site of body movementsand awakening|Propofol in our hospital is routinely delivered by Targeted Controlled Infusion (TCI) pumps. We note the concentration of propofol at the effector site of body movements and awakening
561342|NCT04128319|Drug|T-Guard|Patients will receive 4 doses of T-Guard treatment, administered intravenously as four 4-hour infusions at least two calendar days apart. Each dose consists of 4 mg/m2 Body Surface Area (BSA).
561343|NCT04126837|Other|Diagnosis and treatment|Monocentric, Prospective and Biomedical Research excluding Health Product
561344|NCT04124926|Drug|Vonoprazan|Over-encapsulated tablet administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
561345|NCT04124926|Drug|Lansoprazole|Over-encapsulated capsule administered orally with approximately 240 mL water, 30 minutes prior to the morning meal.
561346|NCT04124003|Drug|rosuvastatin|Specified dose on specified days
561347|NCT04124003|Drug|BMS-963272|Specified dose on specified days
561348|NCT04123626|Drug|QR-1123|unilateral IVT injection
561349|NCT04123626|Other|Sham procedure|Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
561350|NCT04123366|Drug|Olaparib|Oral tablet
561351|NCT04123366|Biological|Pembrolizumab|Intravenous infusion
561352|NCT04123314|Drug|Psilocybin|Dosing at the first session will be 15 mg/70 kg. For the second session participants will either remain at the initial dose, or increase to 25 mg/70 kg at the discretion of the study team.
561353|NCT04123197|Other|Stress Challenge|The stress challenge will assess how different parts of the body react to stress. Participants will be given no specific details about the contents of the test before administration.
561354|NCT04122625|Drug|Debio 1143|Debio 1143 will be administered capsule orally once daily for 10 consecutive days every 2 weeks and Days 15-24 q4w. The dose of Debio 150 mg can be escalated to 200 in Part A and it is to be decided in Part B.
561355|NCT04122625|Drug|Nivolumab|Nivolumab will be administered as 240 mg IV infusion on Days 1 and 15 of a 28-day cycle.
561356|NCT04122573|Diagnostic Test|Coronary angiography|Acute chest pain patients, suspected acute coronary syndrome, are diagnosed by coronary angiography.
561357|NCT04122573|Diagnostic Test|CT angiography of aorta|Acute chest pain patients, suspected acute aortic dissection, are diagnosed by gold standard of CTA.
561358|NCT04122573|Diagnostic Test|CT angiography of pulmonary arteries.|Acute chest pain patients, suspected acute pulmonary embolism, are diagnosed by gold standard of CTA.
561359|NCT04122573|Diagnostic Test|Electrocardiogram|All patients with acute chest pain will subject to ECG examination within 10 minutes of admission, which can quickly screen ST-segment elevation myocardial infarction.
561360|NCT04122573|Diagnostic Test|Cardiac Troponin|Dynamic changes of cardiac troponin I and/or T will be used in the diagnosis of acute myocardial infarction
561361|NCT04122235|Other|LETSGO follow-up|Nurse-led follow-up in 50% of the consultations Access to the LETSGO-app
561362|NCT04119271|Other|Breathe Easy at Home Kit Products|HEPA filtered upright vacuum cleaner, HEPA-filtered Air Purifier, Hypoallergenic latex free mattress cover, box spring cover, and two pillow covers, Healthier alternative to most household cleaners, Non- toxic glue type pest control devices for rodent control and a combination of safe products to locate and kill roaches.
561363|NCT04117347|Device|Light therapy A via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
561364|NCT04117347|Device|Light therapy B via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
561365|NCT04117347|Device|Light therapy C via the Re-Timer®|Subjects will conduct light treatment in the mornings at home.
561366|NCT04116008|Other|Standard Pain Followup and Monitorization|Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
561367|NCT04115865|Device|Endotracheal sonde or laryngeal mask|Healthy subjects ; requiring general anesthesia with endotracheal or endobuccal device
561368|NCT04114786|Device|3D-printed mask|After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
561418|NCT04093024|Drug|Nintedanib (Ofev®)|Capsule
561419|NCT04093024|Drug|Placebo|Capsule
561369|NCT04114786|Device|Thermoplastic mask|Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
561370|NCT04113668|Drug|BMS-986165|Specified Dose on Specified Days
561371|NCT04113668|Drug|diflunisal|Specified Dose on Specified Days
561372|NCT04113122|Diagnostic Test|Skin biopsy|A 4 mm skin biopsy will be performed at the upper leg of the patient. Before the skin biopsy local anesthesia is applied subcutaneously. In these skin biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels in the skin biopsies.
561373|NCT04113122|Diagnostic Test|Subcutaneous fat biopsy|"An abdominal subcutaneous fat biopsy will be performed 7-10 cm on the right side of the umbilicus. Before the fat biopsy local anesthesia is applied subcutaneously. An amount of 30 mg fat tissue will be collected using needle aspiration.~In these fat biopsies senescent cells will be detected by p16, p21 and yH2Ax staining. Furthermore, we will measure platinum levels (ICP-MS), adipocytokines (leptin, adiponectin, interleukin-6, PAI-1, TNF-α), p53 activation indirectly by measuring p21 or mdm2 expression using immunohistochemistry, microRNA regulation of insulin signaling in adipose tissue: miR-103, miR-107, miR-29."
561374|NCT04110028|Drug|Nicotinamide riboside|Nicotinamide riboside in different doses
561375|NCT04110028|Drug|Placebo|Placebo
561376|NCT04109066|Biological|nivolumab|Specified Dose on Specified days
561377|NCT04109066|Drug|paclitaxel (PTX)|Specified dose on Specified days
561378|NCT04109066|Other|nivolumab placebo|Specified dose on Specified days
561379|NCT04109066|Drug|anthracycline|Specified dose on Specified days
561380|NCT04109066|Drug|cyclophosphamide|Specified dose on Specified days
561381|NCT04109066|Drug|Endocrine Therapy|Variable endocrine therapy of investigators choice
561382|NCT04109066|Procedure|Surgery|Surgery for breast cancer
561383|NCT04108728|Diagnostic Test|BRIEF SCORE AT INCLUSION|BRIEF SCALE evaluation
561384|NCT04107246|Device|use of the KaliJAR box|"KaliJAR® : validated device for single-dose eye drops collection. the patient will be asked to discard each single dose of eye drops in the KaliJAR box. The patient returns with the KaliJAR box at each consultation as part of normal practice. The KaliJAR box will be emptied at each consultation by the doctor and then returned to the patient.~No further examination or visit."
561385|NCT04106583|Device|WAVE, as part of the SMART COIL System|WAVE, as part of the SMART COIL System
561386|NCT04102436|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
561387|NCT04102436|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
561388|NCT04102436|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) IV over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may be eligible to receive 72,000 IU/kg IV.
561389|NCT04102436|Biological|Sleeping Beauty Transposed PBL|Day 0: Cells are to be infused at a dose not to exceed 1.5e11 in 400 mL intravenously on the Patient Care Unit over 20-30 minutes or as clinically determined by an investigator for patient safety (between 2-4 days after the last dose of fludarabine).
561390|NCT04102189|Drug|Semaglutide|Participants will receive semaglutide s.c. once weekly for a dose escalation period of 16 weeks and a maintenance period of 52 weeks
561391|NCT04102189|Drug|Placebo|Participants will receive semaglutide placebo s.c. once weekly for a total of 68 weeks
561392|NCT04101045|Diagnostic Test|Oral Glucose Tolerance Test|Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
561393|NCT04099836|Drug|Atezolizumab|1200 mg IV
561394|NCT04099836|Drug|Bevacizumab|15 mg/kg IV
561395|NCT04099667|Drug|rimabotulinumtoxinB|IM injection on Day 1
561396|NCT04099667|Drug|Placebo|IM injection on Day 1
561397|NCT04099251|Biological|Nivolumab|specified dose on specified days
561398|NCT04099251|Other|Placebo|Matched placebo specified dose on specified days
561399|NCT04099238|Drug|Oral anticoagulant|Oral anticoagulants may comprise vitamin K antagonists (VKA) and non-vitamin K antagonist oral antagonists (NOAC).
561400|NCT04098744|Drug|Artesunate vaginal insert|Artesunate formulated as vaginal inserts, 200mg
561401|NCT04098744|Drug|Placebo vaginal insert|Placebo for artesunate vaginal inserts
561402|NCT04098575|Drug|Empagliflozin|drug
561403|NCT04097821|Drug|Ruxolitinib|5 mg tablets for oral use
561404|NCT04097821|Drug|Siremadlin|10 mg, 20 mg, or 40 mg capsules for oral use
561405|NCT04097821|Drug|Crizanlizumab|100 mg/mL concentrate for infusion for intravenous use
561406|NCT04097821|Drug|MBG453|100 mg/mL concentrate for infusion for intravenous use
561407|NCT04097561|Biological|Belimubab|Belimumab 10 mg/kg once every 2 weeks for 3 doses, and then once every 4 weeks for 5 doses, delivered via 1-hour intravenous (IV) infusion.
561408|NCT04096313|Diagnostic Test|HbA1c, Lipids, UACr|compare diagnostic tests to reference methods
561409|NCT04094519|Drug|enzalutamide|oral
561410|NCT04094519|Drug|enzalutamide Placebo|oral
561411|NCT04094519|Drug|digoxin|oral
561412|NCT04094519|Drug|rosuvastatin|oral
561413|NCT04093596|Genetic|ALLO-715|ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA
561414|NCT04093596|Biological|ALLO-647|ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen
561415|NCT04093596|Drug|Fludarabine|Chemotherapy for lymphodepletion
561416|NCT04093596|Drug|Cyclophosphamide|Chemotherapy for lymphodepletion
561420|NCT04091672|Device|Autografting with RECELL overspray|Autografting more widely meshed than the pre-specified grafting plan with RECELL overspray, along with Telfa™ Clear and Xeroform™ wound dressings
561421|NCT04091672|Procedure|Conventional Autografting|Autografting according to the pre-specified grafting plan, along with Telfa™ Clear and Xeroform™ wound dressings
561422|NCT04091607|Other|Music Therapy|Subject will listen to Music using provided ear buds or headphones.
561423|NCT04091269|Device|automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence|The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
561424|NCT04091217|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered intravenously every 3 weeks.
561425|NCT04091217|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg will be administered intravenously every 3 weeks.
561426|NCT04090736|Drug|Pevonedistat|Pevonedistat 20 mg/m2 intravenous on days 1, 3, and 5 (28-day cycles)
561427|NCT04090736|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneous on a 5-on/2-off [weekend]/2-on schedule (28-day cycle). Intravenous for patients who have non-tolerated local reactions
561428|NCT04090307|Behavioral|TLC Group Prenatal Care|TLC will start in the late first trimester or early second trimester and run for ~6-10 sessions. Groups of 2-10 consented women, with two or more GDM risk factors, will meet under the supervision of an obstetric provider (nurse practitioner or MD) and co-facilitator (health educator, nutritionist, or nurse) for two-hour sessions. A major focus of TLC will be education, and much of each visit will be spent on pregnancy, exercise/nutrition education, and behavioral health.
561429|NCT04089956|Other|No interventation|A retrospective cohort Observational study with no intervention
561430|NCT04088409|Drug|Baricitinib|Administered orally
561431|NCT04088409|Drug|Adalimumab|Administered SC
561432|NCT04087798|Behavioral|Control-EDI|Patients in the control group will receive Control-EDI from their primary care provider during clinic visit. Subsequent patient CKD education and follow-up will be provider dependent. Patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only).
561433|NCT04087798|Behavioral|Intervention-EDI and health coaching|"Patients in the intervention group will receive a personalized Intervention-EDI from their primary care provider during visit, which will include their most recent BP, their urine protein level and most recent eGFR. There is also a space for their provider to type in a sentence about specific goals for the patient.~Health coaches will conduct a baseline call and 4-6 coaching calls, based on patient's needs, over a 12-month period. There are 4 topic areas related to blood pressure and CKD that will be the focus of the calls. Coaches will also have pre-determined and vetted educational resources to provide patients if needed. Additionally, patients will be called and reminded of their study visits at 1, 6, 12 months to complete study measures, BP checks, and give urine and blood samples (baseline and 12-month visit only)."
561434|NCT04087174|Drug|Capivasertib|Patients will receive multiple oral dose of capivasertib.
561435|NCT04087174|Drug|Enzalutamide|Patients will receive 160 mg oral dose of enzalutamide.
561436|NCT04087174|Drug|Abiraterone|Patients will receive 1000 mg oral dose of abiraterone.
561437|NCT04086719|Drug|BMS-986165|Oral administration of tablet BMS- 986165
561438|NCT04086719|Drug|Pyrimethamine|Oral administration of Pyrimethamine in combination with BMS-986185
561439|NCT04086615|Device|NMES and exercise supplemented with high BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 80% of LOP, the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
561440|NCT04086615|Device|NMES and exercise supplemented with low BFR|"The BFR-NMES-Exercise training consists of 20-min sessions performed concurrently with NMES and exercise in the clinic 2x a week for a total of 18 in-clinic sessions. Using the Delfi PTS Personalized Tourniquet System for Blood Flow Restriction at 20mmHG venous pressure (no blood flow restricted), the participant performs 4 exercise sets of 60 repetitions (5 seconds ea) for 5 minutes, with a 1-minute BFR deflation between sets. The standard exercise rehabilitation protocol for PFPS combines open chain and closed chain quadriceps strengthening exercises: active straight leg raises, quadriceps straightening, step up, and squats. NMES training consists of 20-minute sessions: a 2-min warm-up, 15-min work-out, and a 3-min cool down using the KneeHAB® XP Multipath stimulation system which changes the current pathways between the electrodes for preset periods within each pulse, allowing for higher stimulation intensities that maximizes muscle fibre recruitment and minimizes muscle fatigue."
561441|NCT04086485|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE will be given by IV every 8 (+/-2) weeks for a total of 4 administrations
561442|NCT04086485|Drug|Olaparib|Olaparib is given as a pill taken orally and is to be taken twice a day, starting from 2 days before the first administration of Lu-177-DOTATATE until 4 weeks after the last administration
561443|NCT04086485|Diagnostic Test|Ga dotatate scanning|Ga68-DOTATATE PET /CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
561444|NCT04086485|Diagnostic Test|FDG-PET scanning|F18-FDG PET/CT scan will be done at baseline, at week 32, then every 24 weeks in followup period.
561445|NCT04086121|Drug|Spesolimab|Solution for SC injection
561446|NCT04085289|Drug|Galcanezumab|Administered SC
561447|NCT04085289|Drug|Placebo|Administered SC
561448|NCT04084392|Other|Bridge Clinic|Referral to the Bridge Clinic for temporary outpatient addiction treatment while the bridge clinic identifies an outpatient addiction treatment provider to accept the patient for long term treatment.
561449|NCT04084392|Other|Usual Care|Referral to an outpatient provider for addiction treatment.
561450|NCT04084366|Drug|OBI-999|For the dose-escalation phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
561451|NCT04084366|Drug|OBI-999|For the dose-expansion phase, OBI-999 will be administered on Day 1 of each 21-day cycle, for up to 35 cycles.
561452|NCT04083781|Drug|Concizumab|Concizumab 0.25 mg/kg administered daily subcutaneously (s.c., under the skin). Arms 1, 2 and 4 are starting with a loading dose of 1.0 mg/kg at the first day of dosing. In the extension part patients may increase the dose to 0.35 mg/kg, based on specific criteria.
561453|NCT04083716|Drug|ABI-H2158 Reference Formulation|ABI-H2158 tablets Reference Formulation
561454|NCT04083716|Drug|ABI-H2158 Test Formulation|ABI-H2158 tablets Test Formulation
561455|NCT04082975|Drug|NVP-1203|Oral dose for 7 days
561456|NCT04082975|Drug|NVP-1203-R|Oral dose for 7 days
561457|NCT04082975|Drug|NVP-1203 placebo|Oral dose for 7 days
561458|NCT04082975|Drug|NVP-1203-R placebo|Oral dose for 7 days
561459|NCT04082429|Drug|Concizumab|Concizumab 0.25 mg/kg administered daily subcutaneously (s.c., under the skin). Arms 1, 2 and 4 are starting with a loading dose of 1.0 mg/kg at the first day of dosing. In the extension part patients may increase the dose to 0.35 mg/kg, based on specific criteria.
561460|NCT04081597|Drug|Star-101|Administered orally
561461|NCT04081597|Drug|Placebo|Administered orally
561462|NCT04076020|Behavioral|Relational agent/AliveCor Kardia - Intervention Group|Use of the relational agent and Kardia daily for 120 days.
561463|NCT04076020|Behavioral|Usual Care|Use of the WebMD app daily for 120 days.
561464|NCT04075825|Biological|Darvadstrocel|Allogenic eASCs 5 million cells/ml - suspension for injection Cx601 received in previous ADMIRE-CD II study. No drug administration in this study.
561465|NCT04072835|Drug|Etripamil NS|Patients will be provided with an ambulatory Cardiac Monitoring System (CMS) to help document PSVT episodes. The CMS will be self-applied by the patient, when PSVT symptoms begin. Patients will self-administer etripamil NS if vagal maneuver is ineffective. After an episode of PSVT where drug is administered, the patient will return to the investigative site for a study visit and will be given the option to continue in NODE-303 and manage subsequent episodes of PSVT with etripamil NS.
561466|NCT04072393|Procedure|Cardiac rehabilitation|- Within 6 weeks of completion of standard of care radiation therapy patients, will be evaluated by the clinical team at The Heart Care Institute at Barnes-Jewish West County Hospital and begin a prescribed course of cardiac rehabilitation.
561467|NCT04072354|Drug|SEP-363856 50mg|SEP-363856 50mg tablet dosed once daily
561468|NCT04072354|Drug|SEP-363856 75mg|SEP-363856 75mg tablet dosed once daily
561469|NCT04072354|Drug|Placebo|Placebo tablet dosed once daily
561470|NCT04072211|Biological|Engerix-B|Hepatitis B vaccine administered through intramuscular injection at 0, 1, and 6 months
561471|NCT04071769|Drug|Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment|Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments
561472|NCT04071158|Biological|RSV Vaccine|RSV vaccine
561473|NCT04071158|Biological|Tdap|Tetanus, Diphtheria, and Acellular Pertussis Vaccine
561474|NCT04071158|Biological|Placebo|Normal saline solution for injection (0.9% sodium chloride injection)
561475|NCT04070495|Drug|KW-6356|A single oral dose will be administered at Day 1 and 15
561476|NCT04070495|Drug|Clarithromycin|400mg, oral tablet (2 x 200mg), twice daily (BID), Day 8-28
561477|NCT04070495|Drug|Rifampicin|600mg, oral tablet (4 x 150mg), once daily (QD), Day 8-21
561478|NCT04070456|Other|Tablet-based SDH tool|A tablet-based SDH tool, which integrates responses into the EpicCare electronic health record (EHR).
561479|NCT04067661|Behavioral|CHIP|The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.
561480|NCT04067661|Behavioral|Control|Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
561481|NCT04067453|Other|Fatiguing contractions|10 sustained external anal sphincter contractions with maximal voluntary contraction of 20 seconds followed by 10 seconds of resting.
561482|NCT04066712|Drug|LC350189 200 mg|Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7
561483|NCT04065334|Behavioral|High dose training|4 x 4 minutes of high intensity workload on treadmill and 4 repetitions x 4 sets of high intensity workload in hack squat
561484|NCT04065334|Behavioral|low dose training|1 x 4 minutes of high intensity workload on treadmill and 2 repetitions x 4 sets of high intensity workload in hack squat
561485|NCT04065269|Drug|AZD6738|ATR inhibitor
561486|NCT04065269|Drug|Olaparib|PARP inhibitor
561487|NCT04062448|Drug|Ibrutinib|Ibrutinib 420 mg will be administered orally.
561488|NCT04062448|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered intravenously.
561489|NCT04060888|Drug|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 milligram per kilogram via IV route based on body weight-range.
561490|NCT04060888|Drug|Ustekinumab 90 milligram (mg)|Participants will receive 90 mg ustekinumab via SC route.
561491|NCT04060888|Drug|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
561492|NCT04060680|Device|Defibrillation|VT/VF induction attempted for defibrillation testing, as well as requisite electrical testing.
561493|NCT04060199|Drug|Viltolarsen|IV infusion
561494|NCT04060199|Drug|Placebo|IV infusion
561495|NCT04060147|Drug|CILO|Tablets administered orally once daily
561496|NCT04059094|Drug|BI 1265162|Inhalation solution
561497|NCT04059094|Drug|Placebo|Inhalation solution
561498|NCT04058561|Device|MAGEC® Spinal Bracing And Distraction System|The magnetically controlled growth rod (MCGR) system is a remotely distractible, magnetically controlled growing rod. The remote capabilities allow for less invasive and less time-consuming outpatient distraction visits, which solves many of the problems facing current growing rod technologies. The MCGR system allows for more frequent lengthenings, and the implanted growing rods can be lengthened more often, which allows MCGR to better approximate normal spine growth compared to Traditional Growing Rods.
561499|NCT04058028|Drug|AMG 570|AMG 570 will be presented in 5 mL glass vial
561817|NCT03907488|Biological|Pegfilgrastim|Given SC
561500|NCT04058028|Drug|Placebo for AMG 570|Placebo for AMG 570 will be presented in 5 mL glass vial
561501|NCT04057222|Other|No intervention|Only propose water and wait for need to void
561502|NCT04056689|Drug|DNL151 low dose|DNL151 low dose
561503|NCT04056689|Drug|DNL151 high dose|DNL151 high dose
561504|NCT04056689|Drug|Placebo|Placebo
561505|NCT04055467|Drug|[F18]-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-[18F]fluorodibenzo[b,d]thiophene 5,5-dioxide)|Brain imaging of alpha-7 nicotinic acetylcholine receptors
561506|NCT04055467|Behavioral|Contingency Management|Incentive payments contingent upon provision of samples that meet criterion levels of exhaled carbon oxide and urinary cotinine at study visits
561507|NCT04055168|Drug|AZD6615|AZD6615 (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
561508|NCT04055168|Drug|Placebo|Placebo (dose 1, dose 2, or dose 3) will be administered as a single dose to the randomized subjects.
561509|NCT04054869|Other|Bio-mechanically correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments congruently to the direction of rotational loss.
561510|NCT04054869|Other|Bio-mechanically in-correct manual therapy at the cervical atlanto-axial joints|Participant is seated in a firm backed chair. The treating physical therapist mobilizes both the ipsi-lateral and contra-lateral atlanto-axial spinal segments in-congruently to the direction of rotational loss.
561511|NCT04054752|Biological|Recombinant human IL-7-hyFc (NT-I7)|NT-17 administered at escalating doses of 60, 120, 240 and 480 microgram/kg to determine MTD and OBD of NT-17
561512|NCT04054752|Biological|Vaccine sequence 1|"Day 1 1mmunization Pre-NT-17:Td, Polio, PCV13~Day 64, 1mmunization Post-NT-17: Hep A#1, Hep B#1~Day 106: Hep B#2 (Optional)~6 Month Post NT-17 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1"
561513|NCT04054752|Biological|Vaccine sequence 2|"Day 1 1mmunization Pre-NT-17: Hep A#1, Hep B#1~Day 64, 1mmunization Post-NT-17:Td, Polio, PCV13~Day 106: no Vaccine~6 Month Post NT-17 Vaccines (Optional): Polio, Hep A#2, Hep #3, PPSV23#1"
561514|NCT04053478|Drug|Ephedrine|Ephedrine in solution, 10 -10m to 10 -3M
561515|NCT04053478|Drug|Phenylephrine|Phenylephrine, 10 -10m to 10 -3M
561516|NCT04053478|Drug|Norepinephrine|Norepinephrine, 10 -10m to 10 -3M
561517|NCT04053283|Biological|NG-641|NG-641 is an oncolytic adenoviral vector which expresses a FAP-TAc antibody together with an immune enhancer module (CXCL9/CXCL10/IFNα).
561518|NCT04053283|Biological|NG-641|NG-641 is an oncolytic adenoviral vector which expresses a FAP-TAc antibody together with an immune enhancer module (CXCL9/CXCL10/IFNα).
561519|NCT04052997|Drug|Camidanlumab Tesirine|Intravenous Infusion
561520|NCT04052854|Drug|Zanubrutinib|Zanubrutinib (BGB-3111) will be orally administered in patients with treatment naive or R/R WM
561521|NCT04052516|Drug|Icosabutate|Icosabutate oral capsule once daily
561522|NCT04052516|Drug|Placebo|Matching placebo oral capsule
561523|NCT04051047|Drug|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
561524|NCT04051047|Procedure|Tumor biopsy and blood draw|As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
561525|NCT04049578|Drug|Balovaptan|Participants will receive an oral dose of balovaptan once a day (QD) for a 6-week treatment period, followed by an optional extension period of 48 weeks.
561526|NCT04044950|Biological|E7 TCR|The injection will be approximately 3x10^8 E7 TCR T cells, unless fewer cells are generated, at each site of organ involvement (i.e. primary tumor, palpable lymph node (s)) in approximately 1-2 ml of volume.
561527|NCT04044872|Diagnostic Test|[1-13C]pyruvate along with MRI imaging|[1-13C]pyruvate: 0.1 mmol/kg dose will be injected at the time of imaging performed at baseline (prior to radiation therapy), and within 3 months after completion of radiation therapy
561528|NCT04044053|Drug|PF-06865571 400 mg Immediate Release (IR) in Fed State|400 mg IR dose in fed state
561529|NCT04044053|Drug|PF-06865571 50 mg Modified Release (MR) in Fed State|50 mg MR in fed state
561530|NCT04044053|Drug|PF-06865571 400 mg MR in Fed State|400 mg MR in fed state
561531|NCT04044053|Drug|PF-06865571 400 mg MR in Fasted State|400 mg MR in fasted state
561532|NCT04042740|Drug|Glecaprevir/Pibrentasvir (G/P)|Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.
561533|NCT04042740|Drug|Ribavirin (RBV)|Tablets containing 200 mg of ribavirin. RBV dosed according to weight-based and renal dosing tables in study protocol.
561534|NCT04042506|Drug|Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]|480mg IV every 4 weeks
561535|NCT04042506|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT dose of 8-10 Gy x 3 fractions (at maximum 3 doses per week) delivered to 1 extracranial site between days 1-14 of Cycle 1.
561536|NCT04042480|Drug|SGN-CD228A|SGN-CD228A administered intravenously
561537|NCT04042441|Drug|Insulin Degludec/Insulin Aspart|Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
561538|NCT04040569|Radiation|Radiomics on MRI|"Through extracting and analyzing a large number of features from medical imaging, radiomics has shown promising results in treatment outcome prediction for many diseases including breast cancer (45-50). UTSW physics group has developed several new radiomic approaches and radiomic features, such as a multi-objective radiomics model(51) and a new radiomic Shell feature(52). As an exploratory end point for this trial, the investigators will explore the application radiomics using pre-treatment MRI, treatment parameters and clinical characteristics as input to predict pathological response of radiation therapy (XRT) based on pathology report of surgical tissues and local recurrence."
561539|NCT04039607|Drug|Nivolumab|Participants will receive nivolumab as intravenous (IV) infusion.
561540|NCT04039607|Drug|Ipilimumab|Participants will receive ipilimumab as IV infusion.
561541|NCT04039607|Drug|Sorafenib|Participants will receive sorafenib as oral tablets.
561542|NCT04039607|Drug|lenvatinib|Participants will receive lenvatinib as oral capsules.
561543|NCT04039373|Drug|BMS-986256|specified dose on specified days
561544|NCT04039373|Drug|Mycophenolate Mofetil|specified dose on specified days
561545|NCT04037215|Other|STUDY OF THE COGNITIVE TREATMENT OF DIETARY STIMULI AND BODY IMAGE|"Describe the cognitive treatment of patients with early onset anorexia nervosa in response to specific stimuli of the disorder (eating and body images), compared to age- and sex-matched control subjects:~children controls not achieved with normal BMI;~children with unbalanced insulin-dependent type 1 diabetes, therefore subject to a strict diet that requires good nutritional knowledge and no weight judgment disorders."
561546|NCT04034251|Drug|Paclitaxel|Paclitaxel (IP and IV), Day 1 of each 3-week cycle: Paclitaxel IP -Intraperitoneal paclitaxel (20 mg /m2) will be diluted in 500 mL of 0.9% NS, to be infused as rapidly as tolerated once per 3-week cycle on Day 1. Paclitaxel IV -Intravenous paclitaxel (80 mg/m2) will be administered concomitantly over 3 hours, diluted in 100 to 250 ml of 0.9% NS once per 3-week cycle on Day 1.
561547|NCT04034251|Drug|Capecitabine|Day 1-15 of each 3-week cycle: oral capecitabine (825 mg /m2) to be taken twice a day starting the evening of Day 1 of each cycle until the morning of Day 15, followed by a 7-day rest period during each 3-week cycle.
561548|NCT04034251|Device|BardPort Titanium Implanted Port withPeritoneal Catheter|After peritoneal chemo infusion port is placed (Days 1-3, as dictated by clinical status), patients will begin intraperitoneal paclitaxel and intravenous paclitaxel (Day 1) followed by oral capecitabine on the evening of Day 1 to the morning of Day 15.
561549|NCT04033913|Other|Self questionnaire|Patients who have successfully perform self-catheterization complete a self questionnaire on the importance of each criterion in choosing the catheter they have made.
561550|NCT04032626|Drug|Lenalidomide 10 mg|Lenalid
561551|NCT04032626|Drug|Placebos|Placebo
561552|NCT04032119|Procedure|Endoscopic submucosal dissection|Endoscopic submucosal dissection
561553|NCT04032119|Drug|Epinephrine|Epinephrine
561554|NCT04031898|Other|Non Interventional|This is a non interventional, observational, retrospective study including patients with EGFR-mutated advanced NSCLC, treated with 1st or 2nd generation EGFR TKI therapy in first line
561555|NCT04031131|Drug|Instillagel|Topical Anaesthetic Gel (Instillagel) licensed for rectal administration.
561556|NCT04031131|Other|KY Gel|Lubricant Gel
561557|NCT04030897|Behavioral|Parent-Directed Online Single-Session Program|Online, 15-minute self-administered program for parents
561558|NCT04030897|Behavioral|Youth-Directed Online Single-Session Program|Online, 30 minute self-administered program for youths
561559|NCT04030897|Behavioral|Information/Psychoeducation/Referral|Usual care at pediatric primary care clinics participating in this study
561560|NCT04030533|Drug|Guselkumab (SC): Dose 1|Participants will receive a single dose of guselkumab (dose 1) subcutaneously.
561561|NCT04030533|Drug|Guselkumab (SC): Dose 2|Participants will receive a single dose of guselkumab (dose 2) subcutaneously.
561562|NCT04030533|Drug|Guselkumab (IV): Dose 1|Participants will receive a single IV infusion of guselkumab (dose 1).
561563|NCT04030533|Drug|Guselkumab (IV): Dose 2|Participants will receive a single IV infusion of guselkumab (dose 2).
561564|NCT04030533|Drug|Ustekinumab 6 mg/mL|Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
561565|NCT04028973|Other|Single then dual task situation|Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
561566|NCT04028973|Other|Dual then single task situation|Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
561567|NCT04027426|Behavioral|FBT|FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.
561568|NCT04027426|Behavioral|FBT+Variety|This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
561569|NCT04027205|Other|Physiotherapist-led exercise|A programme of physiotherapist-led exercise over approximately 12 weeks.
561570|NCT04027205|Procedure|Surgical repair|Surgical repair of the rotator cuff plus usual post-operative rehabilitation
561571|NCT04026451|Device|Sedation guided by SEF95 (10-13 Hz) from SedLine® monitor|Dosage of propofol and fentanyl will be guided by SEF95 value between 10-13 Hz. If SEF95 is lower than 10 Hz, the infusion rate of propofol and fentanyl will be diminished; if SEF95 is higher than 13 Hz, the infusion rate of propofol and fentanyl will be increased; and if SEF95 is between 10-13 Hz, then the infusion rate will be kept.
561572|NCT04026451|Behavioral|Sedation guided by SAS scale (1-2)|Dosage of propofol and fentanyl will be guided by SAS to keep a value of 1-2. If SAS is higher than 1-2, then the infusion rate of propofol and fentanyl will be increased; and if SAS is 1-2, then the infusion rate of propofol and fentanyl will be maintained.
561573|NCT04026451|Drug|Deep sedation with propofol andfentanyl|Propofol and fentanyl will be infused to reach a score in the SAS of 1-2
561574|NCT04026451|Procedure|Mechanical Ventilation|Critically ill patients will be ventilated mechanically following the clinical indication.
561575|NCT04026412|Drug|Nivolumab|Specified dose on specified days
561576|NCT04026412|Drug|Ipilimumab|Q6W in maintenance period in Arm A
561577|NCT04026412|Drug|Durvalumab|Q2W in maintenance in Arm C
561578|NCT04025567|Drug|vancomycin|1,500 mg total daily dose, on days 1-21 of every 28 days cycle.
561579|NCT04025554|Drug|Anakinra|100 mg daily weeks 1-4, 200 mg daily weeks 5-8, 300 mg daily weeks 9-12.
561580|NCT04024761|Biological|CIML NK|CIML NK cells have enhanced ability to recognize and kill leukemia targets
561581|NCT04024761|Drug|Fludarabine|Fludarabine is a chemotherapy drug Chemotherapy is most effective at killing cells that are rapidly dividing.
561582|NCT04024761|Drug|Cyclophosphamide|Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system.
561583|NCT04018157|Drug|"Ketamine and dexmedetomidine and propofol and 0.9%saline"|patients will receive single intravenous bolus of combination from ketamine 0.5mg/kg and dexmedetomidine 1ug/kg in one syringe diluted in 10 ml 0.9% saline.
561584|NCT04018027|Drug|difelikefalin 0.25 mg|Oral difelikefalin 0.25 mg administered twice daily
561585|NCT04018027|Drug|difelikefalin 0.5 mg|Oral difelikefalin 0.5 mg administered twice daily
561586|NCT04018027|Drug|difelikefalin 1.0 mg|Oral difelikefalin 1.0 mg administered twice daily
561587|NCT04018027|Drug|Placebo|Oral Placebo administered twice daily
561588|NCT04017780|Device|Single-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
561589|NCT04017780|Device|Double-Limb Intensive Care Unit ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).
561590|NCT04017780|Device|Double-Limb Turbine-Driven Ventilator|Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 [ResMed]).
561591|NCT04017767|Procedure|Induced Acute Intermittent Hypoxia (AIH)|AIH will be administered on days 1-3. Each day entails 15 and 90 second hypoxic intervals (Fraction of Inspired Oxygen (FIO2) = 0.09) alternating with 60-second normoxic intervals (FIO2 = 0.21).
561592|NCT04017767|Device|AIH mask|Induced Intermitted hypoxia will be delivered via the AIH mask. The mask has two one-way valves restricting inspiration to the top valve and expiration to the bottom valve. Hypoxic and normoxic gas mixtures will be delivered through the top valve.
561593|NCT04016077|Drug|PF-06651600 30 mg|PF-06651600 in 10 mg oral tablets will be administered on days 1 to 10.
561594|NCT04014868|Device|Nasal high-flow|See arm description.
561595|NCT04014868|Other|Sham nasal high-flow|See arm description.
561596|NCT04014517|Other|Standard of Care|Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
561597|NCT04014517|Dietary Supplement|Immunonutrition|Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
561598|NCT04014309|Other|Supportive and survivorship care program|Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
561599|NCT04014309|Other|Usual care|Usual care
561600|NCT04012970|Other|Manual spinal mobilisations|
561601|NCT04012931|Drug|Rilpivirine|Rilpivirine 25 mg tablets or weight-based dose as tablets mixed in liquid will be administered orally once daily.
561602|NCT04012931|Drug|ARV Background Regimen|The investigator-selected ARVs, including but not limited to N(t)RTIs (example, azidothymidine [AZT], abacavir [ABC], tenofovir alafenamide [TAF], or tenofovir disoproxil fumarate [TDF] in combination with emtricitabine [FTC] or lamivudine [3TC]), whichever are approved and marketed or considered local standard of care for children in a particular country are to be administered. Integrase inhibitors (for example, dolutegravir [DTG] or raltegravir) can also be administered in combination with RPV, as appropriate.
561603|NCT04011735|Drug|Respimat|Soft Mist Inhaler product
561604|NCT04011670|Other|200 mg caffeine tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
561605|NCT04011670|Other|Non-active tablet|"Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) at 1 mA and passive vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and active vigilance condition~Transcranial alternating current stimulation (140 Hz tACS) sham and passive vigilance condition"
561606|NCT04010825|Other|Hypnosis intervention focused on the emotional dimension of the dyspnea|Individual hypnosis sessions will be for 1 hour. Each hypnosis session will be standardized and evaluated using a script and an observation grid ( Visual Analogic Scale comfort, patient's hypnotic state...) written in collaboration with experts from Institut Milton Hyland Erickson Toulouse France (IMHETO).
561607|NCT04009291|Combination Product|TransCon PTH|TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.
561608|NCT04009291|Combination Product|Placebo for TransCon PTH|Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.
561609|NCT04008030|Biological|Ipilimumab|Specified dose on specified days
561610|NCT04008030|Drug|Oxaliplatin|Specified dose on specified days
561611|NCT04008030|Drug|Leucovorin|Specified dose on specified days
561612|NCT04008030|Drug|Fluorouracil|Specified dose on specified days
561613|NCT04008030|Drug|Irinotecan|Specified dose on specified days
561614|NCT04008030|Drug|Bevacizumab|Specified dose on specified days
561615|NCT04008030|Drug|Cetuximab|Specified dose on specified days
561616|NCT04008030|Biological|Nivolumab|Specified dose on specified days
561653|NCT03989102|Other|Normal Saline|Sterile isotonic (0.9%) normal saline is a clear liquid, making it indistinguishable from the study product when drawn up into a syringe; and will be used as a placebo, rather than a comparator vaccine
561771|NCT03920293|Biological|Ravulizumab|Concentrated sterile, preservative-free aqueous solution (10 milligrams [mg]/milliliter [mL]) in single-use, 30-mL vial for intravenous (IV) infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
561617|NCT04007393|Behavioral|Lifestyle Modification Therapy (LSMT)|LSMT will consist of both in-person and by telephone sessions delivered throughout the entirety of the 48-week intervention phase. Each session will last 30-60 minutes. A trained study coordinator (a registered dietician or someone trained by our registered dietician) will delivery this therapy which consists of counseling using education, goal setting and barrier reduction. Topics covered will include calories, tracking, healthy food choices, reducing high fat, added sugar foods, setting goals and portions, changing the quality of your diet, volumetrics, purposeful activity, quick and easy meals, problem solving, food cues and eating patterns, emotional eating, accurate tracking, eating away from home, unhelpful thoughts, structured menus and the role of protein, social cues, managing stress, slips and relapse prevention, long-term physical activity and overcoming obstacles, high-risk situation and keys to success, motivation and looking to the future (long-term plans).
561618|NCT04007393|Drug|Phentermine Pill|Phentermine will be started only if a participant does not lose 5% of BMI after 12 or 24 weeks of LSMT depending on their random assignment. Subjects will take 15 mg of phentermine every morning for 12 weeks at which time there will be an assessment of weight loss. Subjects who achieve 5% or more BMI reduction after 12 weeks of phentermine will continue 15 mg every morning for the remainder of the study (through week 48) along with their LSMT.
561619|NCT04007393|Drug|Topiramate Pill|Participants who do no not achieve at least 5% BMI reduction after 12 weeks of phentermine+LSMT will be re-randomized 1:1 to either topiramate+phentermine+LSMT or topiramate+placebo+LSMT. Topiramate dosing will begin at 50 mg every morning for the first 7 days, and then increase to 100 mg every morning through week 48. At the end of week 48 the taper off will be 50 mg every morning for 7 days and then discontinue.
561620|NCT04006457|Drug|PF-06651600|50 mg oral tablets
561621|NCT04006431|Other|embolization|Retrospective, observational collection with division of patients into two groups according to unilateral or bilateral embolization of the porstatic arteries.
561622|NCT04005105|Behavioral|Intensive management|Management based on premorbid MAP and MPP
561623|NCT04003974|Drug|Losmapimod|This study includes a 24 week treatment period. Patients will receive Losmapimod 15 mg twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily. The study drug should be taken with food and the date and time of each dose taken recorded in the subject diary.
561624|NCT04003974|Drug|Placebo oral tablet|This study includes a 24 week treatment period. Patients will receive Placebo twice daily given as two 7.5 mg tablets per dose by mouth; for a total of 4 pills or 30 mg daily. The placebo tablets are identical to the Losmapimod tablets. Placebo should be taken with food and the date and time of each dose taken recorded in the subject diary.
561625|NCT04003389|Drug|fezolinetant|administered orally
561626|NCT04003389|Drug|placebo|administered orally
561627|NCT04003155|Drug|fezolinetant|administered orally
561628|NCT04003155|Drug|placebo|administered orally
561629|NCT04003142|Drug|fezolinetant|administered orally
561630|NCT04003142|Drug|placebo|administered orally
561631|NCT03998683|Drug|Guselkumab 100 mg|Guselkumab 100 mg will be administered as SC injection.
561632|NCT03998683|Drug|Placebo|Placebo will be administered as SC injection.
561633|NCT03997370|Procedure|Biospecimen Collection|Undergo collection of blood samples
561634|NCT03997370|Drug|Carboplatin|Given IV
561635|NCT03997370|Drug|Iohexol|Given IV
561636|NCT03995901|Biological|FCR001|FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
561637|NCT03995784|Biological|Coagulation Factor IX variant|Single intravenous injection of CB2679d
561638|NCT03995784|Biological|Coagulation Factor IX variant|Daily subcutaneous injections of CB2679d for 28 days
561639|NCT03995212|Drug|CR845 1.0 mg|Oral CR845 1.0 mg administered twice daily
561640|NCT03995212|Drug|Placebo|Oral Placebo administered twice daily
561641|NCT03993522|Other|Symptom limited cardiopulmonary exercise test & Sub-maximal cardiopulmonary exercise test|Exercise tests on cycle ergometer for the purpose of collecting expired breath gasses
561642|NCT03993379|Drug|CX-072|CX-072 in combination with anticancer therapy
561643|NCT03993132|Drug|Empagliflozin|new users (initiators) of Empagliflozin
561644|NCT03993132|Drug|Liraglutide|initiators of Liraglutide
561645|NCT03992729|Drug|Pregnant women exposed to tildrakizumab|Subjects exposure to tildrakizumab for the treatment of an approved indication, for any number of days, at any dose, and at any time from the first day of the last menstrual period (LMP) up to and including the end of pregnancy
561646|NCT03992729|Drug|Pregnant women not exposed to tildrakizumab|Subjects diagnosed with a tildrakizumab-approved indication; frequency matched to the exposed group by disease indication, with the indication validated by medical records when possible, and Subjects with no exposure to tildrakizumab at any time in the current pregnancy; may or may not have taken another medication for their disease in the current pregnancy
561647|NCT03992417|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: solution for injection~Route of administration: subcutaneous injection"
561648|NCT03990870|Other|dCBGT + WASABI|Participants in the experimental treatment group will complete daily Ecological Momentary Assessments (EMAs), 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week, and weekly cognitive biases assessments and self-reports for 16 weeks. Participants assigned to this intervention will also have daily access to 1:1 and group chat Instant Messaging (IM) and will have weekly electronic check-ins with study staff (as needed).
561649|NCT03990870|Other|dCBGT Only|Participants in the active comparator group will be asked to attend 1 hour of digitally delivered Cognitive Behavioral Group Therapy (dCBGT) per week for 16 weeks and weekly electronic check-ins with study staff (as needed).
561650|NCT03989232|Drug|Semaglutide|Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
561651|NCT03989232|Drug|Placebo (semaglutide)|Semaglutide placebo injected once-weekly from week 13 to week 40.
561652|NCT03989102|Biological|PfSPZ Vaccine|PfSPZ vaccine is comprised of aseptic, metabolically active, non-replicating, purified, cryopreserved P. falciparum sporozoites.
561815|NCT03907488|Biological|Filgrastim|Given SC or IV
561654|NCT03988400|Behavioral|Sensory Augmentation|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration delivered over the hip abductor musculature will scale with the mechanical state of the pelvis at the start of each step. For example, if the step begins with the pelvis far mediolaterally from the stance foot, the swing leg hip abductors will receive strong vibration. If instead the step begins with the pelvis close mediolaterally to the stance foot, the stance hip abductors will receive strong vibration.
561655|NCT03988400|Behavioral|Random Vibration|Participants will complete 8 training sessions over 4 weeks, in which they walk on a treadmill at their self-selected speed. During training sessions, the magnitude of the vibration applied to the hip abductors will vary randomly (following a normal distribution) on a step-by-step basis.
561656|NCT03988062|Device|TrelliX Embolic Coil System|Embolic coil with shape memory polymer
561657|NCT03987919|Drug|Tirzepatide|Administered SC
561658|NCT03987919|Drug|Semaglutide|Administered SC
561659|NCT03984448|Drug|Cyclophosphamide|Given IV
561660|NCT03984448|Drug|Doxorubicin|Given IV
561661|NCT03984448|Drug|Doxorubicin Hydrochloride|Given IV
561662|NCT03984448|Drug|Etoposide|Given IV
561663|NCT03984448|Drug|Prednisone|Given PO
561664|NCT03984448|Biological|Rituximab|Given IV
561665|NCT03984448|Drug|Venetoclax|Given PO
561666|NCT03984448|Drug|Vincristine|Given IV
561667|NCT03984448|Drug|Vincristine Sulfate|Given IV
561668|NCT03983837|Other|Neocate Splash|Neocate Splash is a hypoallergenic, amino acid based elemental liquid diet that is taken orally.
561669|NCT03982238|Drug|Insulin|Continuous subcutaneous insulin infusion therapy for 1 month
561670|NCT03982238|Drug|Metformin|Continuous subcutaneous insulin infusion plus metformin (at least1000mg/day) for 1 month
561671|NCT03982238|Drug|Dapagliflozin|Continuous subcutaneous insulin infusion plus metformin (10mg/day) for 1 month
561672|NCT03982199|Biological|RSV Vaccine|Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and Day 365.
561673|NCT03982199|Biological|Placebo|Participants will receive a single IM injection of placebo control on Day 1 and Day 365.
561674|NCT03981744|Drug|Ustekinumab 6 mg/kg|Participants will receive body weight-range based IV dosing of 6 mg/kg of ustekinumab at Week 0 in Group 1 and at Week 24 in Group 2.
561675|NCT03981744|Drug|Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg SC at Week 8 and every 8 Weeks (q8w) through Week 72 in Group 1 and q8w Week 32 through Week 72 in Group 2.
561676|NCT03981744|Drug|Placebo IV|Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
561677|NCT03981744|Drug|Placebo SC|Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
561678|NCT03981094|Drug|BMS-986278|suspension
561679|NCT03981094|Drug|Pirfenidone|capsule
561680|NCT03979274|Drug|Reference Eutirox®|Participants will receive single oral dose of Reference Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment period 1 or 2.
561681|NCT03979274|Drug|Test Eutirox®|Participants will receive single oral dose of Test Eutirox® 600 microgram (3 tablets of 200 microgram) either in treatment 1 or 2.
561682|NCT03979248|Drug|BMS-986165|Specified dose on specified days.
561683|NCT03979248|Drug|Rabeprazole|Specified dose on specified days.
561684|NCT03977610|Drug|Ga-68 PSMA ligand|For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
561685|NCT03976856|Drug|GB226|GB226 210mg，q2w，ivgtt.
561686|NCT03976856|Drug|Fruquintinib|Fruquintinib 3mg or 4mg or 5mg, qd.po. 3 weeks-on,1 week-off
561687|NCT03976843|Drug|18F-DCFPyL|18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
561688|NCT03974165|Other|Cereal-legume product 1|The intervention examines the effect of cereal based product fortified with legumes-1 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
561689|NCT03974165|Other|Cereal-legume product 2|The intervention examines the effect of cereal based product fortified with legumes-2 in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
561690|NCT03974165|Other|Cereal product|The intervention examines the effect of cereal product in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
561691|NCT03974165|Other|Reference food|The intervention examines the effect of reference food in appetite regulation in 1) subjects with normal body weight and 2) overweight subjects.
561692|NCT03973268|Drug|Ketamine|Arm 1,2, 3 Interventions
561693|NCT03973268|Drug|Perampanel|Arm 1 and 2 Interventions
561694|NCT03973268|Other|Placebo|Arm 2 and 3 Interventions
561695|NCT03971071|Drug|Erenumab 70 mg|Erenumab once every 4 weeks. Subcutaneous injection.
561696|NCT03971071|Drug|Erenumab 140mg|Erenumab once every 4 weeks. Subcutaneous injection.
561697|NCT03971071|Drug|Placebo|Placebo once every 4 weeks. Subcutaneous injection.
561698|NCT03970798|Drug|Midazolam|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
561699|NCT03970798|Drug|Caffeine|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
561700|NCT03970798|Drug|Rosuvastatin|In Period 1, Day 1 a single dose will be administered after fasting for at least 10 hours. In Period 2, Day 11 a single dose will be administered after fasting for at least 10 hours.
561701|NCT03970798|Drug|KW-6356|In Period 2, Day 4-13(except Day11) a single dose of KW-6356 will be administered after breakfast, Day 11 a single dose of KW-6356 will be administered after fasting for at least 10 hours.
561702|NCT03965793|Device|Automated management of hypotension|Fluid and vasopressor will be administered based on a novel automated clinical decision support system.
561703|NCT03965702|Device|Use of a decision support system on the EV1000 monitoring (AFM mode)|The way to administer fluid is based on the same monitoring device but will differ by the way fluid is given ( following a manual GDFT protocol versus following recommendation from an active clinical decision support system for fluid administration called AFM (assisted fluid management) Measurement of all microvascumlar parameters in blinded way.
561704|NCT03965702|Other|Manual application of the GDFT protocol (standard of care)|Manual application of a GDFT protocol to guide fluid administration. Measurement of all microvascumlar parameters in blinded way.
561705|NCT03960398|Drug|Iatrogenic disease impact on emergency consultations|Determination of the proportion of emergency consultations linked to iatrogenic diseases
561706|NCT03958799|Biological|Investigational Tdap vaccine Formulation B|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
561707|NCT03958799|Biological|Investigational Tdap vaccine Formulation C|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
561708|NCT03958799|Biological|Investigational Tdap vaccine Formulation A|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
561709|NCT03958799|Biological|Investigational Tdap vaccine Formulation D|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
561710|NCT03958799|Biological|Licensed Tdap vaccine|Pharmaceutical form:Suspension for injection Route of administration: Intramuscular
561711|NCT03957538|Behavioral|Virtual reality angiogram experience video|The VR video is watched via the VR headset, and describes the pre- procedural and procedural experience. Concurrent audio will be provided through earplugs to compete the patients' immersive experience. The video was written and directed by the team, and care has been taken to ensure that the same procedural information is contained within both the British Heart Foundation cardiac catheterisation video and of VR immersive video. Filming was performed within the cardiac catheterisation labs at our tertiary centre using the professional services of Orchard Media (Cardiff, UK). The investigators utilized real physicians and nurses to re-enact a typical day for a mock patient undergoing an uncomplicated procedure. There is also a short explanation of the procedure and animations explaining technical aspects of the procedure contained within the VR video.
561712|NCT03957096|Drug|SGN-CD47M|SGN-CD47M administered intravenously
561713|NCT03954041|Drug|BIIB093|Administered as specified in the treatment arm.
561714|NCT03954041|Drug|Placebo|Administered as specified in the treatment arm.
561715|NCT03953235|Biological|GRT-C903|a shared neoantigen cancer vaccine prime
561716|NCT03953235|Biological|GRT-R904|a shared neoantigen cancer vaccine boost
561717|NCT03953235|Biological|nivolumab|anti-PD-1 monoclonal antibody
561718|NCT03953235|Biological|ipilimumab|anti-CTLA-4 monoclonal antibody
561719|NCT03953196|Biological|Imvanex|Imvanex 0.5 milliliter (mL) suspension for injection will be administered as single subcutaneous (SC) injection.
561720|NCT03953196|Biological|Shingrix|Shingrix 0.5 mL suspension will be administered as single intramuscular (IM) injection.
561721|NCT03953196|Biological|LPS|LPS 1.0 nanogram per kilogram (ng/kg) endotoxin suspension will be administered as single IV injection.
561722|NCT03953196|Biological|Candin|Candin 0.1 mL solution for injection will be administered as one intradermal injection.
561723|NCT03953196|Other|Skin Biopsy|3 punch biopsies will be performed and lower abdomen tissue biopsy specimens will be collected on Day 1.
561724|NCT03953196|Other|Saline Control|Saline control solution for injection will be administered as one intradermal injection.
561725|NCT03952650|Drug|Chloroquine Phosphate|Chloroquine phosphate is approved for suppressive treatment (prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a blood-stage schizonticide, highly active against replicating forms of blood-stage drug- sensitive parasites. As such, it is routinely employed as first-line prophylaxis against development of patent parasitemia and clinical malaria in non-immune travelers to areas with chloroquine sensitive Pf. In the pilot, chloroquine administration will begin with a loading dose 2 days prior to PfSPZ Challenge and finishing with a maintenance dose 5 days after PfSPZ Challenge. In the main phase, chloroquine will be first administered as a loading dose 2 days prior to PfSPZ Challenge and continuing weekly using a maintenance dose for a total of 10 doses, finishing with a last dose 5 days after the third injection with PfSPZ Challenge.
561726|NCT03952650|Biological|PfSPZ Challenge|PfSPZ Challenge (NF54) acts as the immunogen in the PfSPZ-CVac approach to vaccinating against malaria. Participants will receive either one (in the pilot phase) or 3 (in the main phase) 400,000 or 300,000 aseptic, purified, cryopreserved, fully infectious PfSPZ injections by DVI (with concurrent administration of antimalarial drugs). Following immunization, participants in the main phase will be followed through the transmission season in order to assess vaccine efficacy.
561727|NCT03952650|Drug|Pyrimethamine|"Pyrimethamine has been FDA approved for acute treatment and chemoprophylaxis of malaria due to susceptible strains of plasmodia.~Pyrimethamine has been shown to possess both liver and blood stage activity. In this study, we plan to use a higher dose of pyrimethamine, 75 mg orally for either one or two days each month. The pilot arms will receive either a total of 1 daily dose or 2 daily doses. The main arms will receive a total of 3 daily doses or a total of 6 doses."
561728|NCT03952598|Device|3T MRI scanner|Research proton MRS (lH-MRS)followed by DW-MRI
561729|NCT03952585|Drug|Cisplatin|Given IV
561730|NCT03952585|Radiation|Image Guided Radiation Therapy|Undergo IGRT
561731|NCT03952585|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
561732|NCT03952585|Biological|Nivolumab|Given IV
561733|NCT03952585|Other|Quality-of-Life Assessment|Ancillary studies
561734|NCT03952585|Other|Questionnaire Administration|Ancillary studies
561735|NCT03952377|Drug|SX600|Transforaminal Epidural Injection
561736|NCT03952377|Drug|Placebo|Transforaminal Epidural Injection
561737|NCT03949166|Other|food during labor and delivery|The food that will be allowed during labor and delivery was approved by the anesthesia team. It includes - fruits, energy bars, yogurt,
561770|NCT03921515|Other|Skin Biopsies|The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
561816|NCT03907488|Biological|Nivolumab|Given IV
561738|NCT03948438|Procedure|Endoscopic septotomy|Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)
561739|NCT03947814|Drug|Pimodivir|Participants will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.
561740|NCT03945539|Drug|JNJ-56136379|Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2.
561741|NCT03945539|Drug|Itraconazole|Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34.
561742|NCT03942120|Drug|Ustekinumab|Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
561743|NCT03937830|Drug|durvalumab|1,150 mg flat dose every 21 days
561744|NCT03937830|Drug|Doxorubicin-Eluting Beads|used for TACE
561745|NCT03937830|Procedure|TACE|TACE with Doxorubicin-Eluting Beads
561746|NCT03937830|Drug|bevacizumab|7.5 mg/kg dose every 21 days
561747|NCT03935256|Drug|Carboplatin and Paclitaxel|Regimen I: Carboplatin AUC 6 & Paclitaxel 175mg/m2 given intravenously for 4 cycles during weeks 1, 10, 13, 16 Regimen II: Carboplatin AUC 2 & Paclitaxel 45mg/m2 given intravenously for 2 cycles during weeks 4 & 7 concurrent with radiotherapy
561748|NCT03935256|Radiation|Radiation Therapy|"An external beam radiation dose of 45 Gy in 25 fractions is routinely prescribed to the Planning Target Volume (PTV) for postoperative radiotherapy.~The Vaginal Brachytherapy (VBT) Boost will be delivered after the external beam radiation. Doses of 12-18 Gy in 2-3 fractions are often prescribed to the surface of the vagina to a treatment length of 3-5 cm. There is no standard dose or fractionation schedule, so this dose, fractionation, location of dose specification , and length of vagina treated will be individualized for the patient and will be at the discretion of the treating radiation oncologist."
561749|NCT03934216|Drug|BMS-986165|Participants will receive Dose 1 BMS-986165
561750|NCT03934216|Drug|Placebo|Participants will receive matching placebo to Dose 1 BMS-986165
561751|NCT03933202|Drug|Cladribine Tablets|No intervention will be administered as a part of this study. Participants will receive cladribine tablets as per investigator discretion and as per United States approved label: 3.5 milligram/kilogram (mg/kg) body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
561752|NCT03933098|Biological|Test Vaccine Vi-DT Typhoid conjugate|"Manufacturer: SK Bioscience Co., Ltd.~Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid~Dose: 25 µg of Vi polysaccharide/0.5 mL, presented in 3 mL multi-dose glass vial"
561753|NCT03933098|Biological|Control Vaccine Typbar TCV®|"Manufacturer: Bharat Biotech~Ingredient: Purified Vi capsular polysaccharide of Salmonella Ty2 conjugated to tetanus toxoid protein~Dose: 0.5 ml"
561754|NCT03932201|Drug|Damoctocog alfa pegol (Jivi, Bay94-9027)|Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
561755|NCT03929913|Device|Transmural Systems Transcatheter Mitral Cerclage Annuloplasty(TMCA)|The Transcatheter Mitral Cerclage Annuloplasty implant comprises two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and RVOT limbs. The procedure is performed from a transjugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein towards the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so that the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is then advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. Once the desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
561756|NCT03929120|Biological|Allogeneic Bone Marrow Derived Mesenchymal Stem Cells (BMD-MSCs)|Subjects will be treated with regular standard of care plus 0.5-1 million MSC/Kg intravenously.
561757|NCT03928951|Other|General practitioner reassessment of urinary infection antibiotherapy prescribed by emergency departments|Antibiotherapy will be prescribed by emergency physicians and general practitioners will be contacted 4 to 5 days later to know if antibiotherapy was modified
561758|NCT03926507|Procedure|Computed Tomography|Undergo PET/CT scan
561759|NCT03926507|Other|Fluciclovine F18|Given IV
561760|NCT03926507|Procedure|Positron Emission Tomography|Undergo PET/CT scan
561761|NCT03926195|Drug|Filgotinib|200-mg tablet administered orally once daily
561762|NCT03926195|Drug|Placebo|Placebo to match filgotinib tablet administered orally once daily
561763|NCT03926195|Drug|Standard of Care|Locally approved treatment, accepted by medical experts as a proper treatment for rheumatic conditions, prescribed according to best clinical practice, with no known testicular toxicity.
561764|NCT03926143|Drug|BAY94-9343 (Anetumab ravtansine)|BAY94-9343 (Anetumab ravtansine) will be administered as specified in the parent studies
561765|NCT03924349|Device|ICG-coated clip|Tumor localization using ICG-coated clip prior to surgery
561766|NCT03923478|Drug|ABI-M201|Active Treatment
561767|NCT03923478|Drug|Placebo|Control Treatment
561768|NCT03922438|Procedure|usage of cleft margin flap with anterior palatal closure during primary cleft lip repair.|Under general anesthesia, preparation of lip and palatal flaps will be done and then cleft margin flap which is designed to be inferiorly based will be used with anterior palatal closure in an attempt to decrease the incidence rate of naso-alveolar fistula (defect) that is usually occur and remain in those patients post-operatively.
561769|NCT03921515|Other|Blister induction|Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.
561772|NCT03920293|Drug|Placebo|Matching, sterile, preservative-free aqueous solution in single-use, 30-mL vial for IV infusion. Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
561773|NCT03920072|Drug|Burosumab|Burosumab is a sterile, clear, colourless and preservative free solution supplied in single-use 5ml vials containing 1mL of burosumab at a concentration of 30mg/mL
561774|NCT03920007|Drug|SAR439483|Pharmaceutical form:Solution for intraocular administration Route of administration: Subretinal injection
561775|NCT03920007|Drug|SAR439483 Diluent Solution|Pharmaceutical form:Solution for parenteral use Route of administration: Subretinal injection
561776|NCT03920007|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
561777|NCT03920007|Drug|Triamcinalone Acetonide|Pharmaceutical form:Suspension Route of administration: Peri-ocular injection
561778|NCT03920007|Drug|1% Prednisolone|Pharmaceutical form:Suspension Route of administration: Drops
561779|NCT03920007|Drug|Trimethoprim/polymyxin B|Pharmaceutical form:Solution Route of administration: Topical
561780|NCT03919071|Drug|Dabrafenib|Given PO
561781|NCT03919071|Drug|Dabrafenib Mesylate|Given PO
561782|NCT03919071|Radiation|Radiation Therapy|Undergo RT
561783|NCT03919071|Drug|Trametinib|Given PO
561784|NCT03919071|Drug|Trametinib Dimethyl Sulfoxide|Given PO
561785|NCT03918187|Drug|Bupivacaine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
561786|NCT03918187|Drug|Nalbuphine|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
561787|NCT03918187|Drug|Midazolam|compare between nalbuphine versus midazolam as an adjuvant to intrathecal bupivacain to evaluate postoperative analgesia .
561788|NCT03917654|Biological|Pfs230D1M-EPA/AS01|Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM phosphate-buffered saline (PBS) to a 2x dilution of the high dose (160 micrograms/mL in cGMP compliance at Walter Reed Bioproduction facility in April 2016 and will be provided as a single use vial. AS01B adjuvant was manufactured for use in the SHINGRIX vaccine by G
561789|NCT03917654|Biological|HAVRIX|HAVRIX (Hepatitis A Vaccine; HAV) is produced by GSK and is a sterile suspension of inactivated virus for IM administration. The virus (strain HM175) is propagated in MRC-5 human diploid cells. HAVRIX is FDA approved for active immunization against disease caused by HAV for persons 12 months of age and older.
561790|NCT03917654|Biological|TYPHIM Vi (Salmonelle typhi vaccine)|TYPHIM Vi (Typhoid Vi Polysaccharide Vaccine), produced by Sanofi Pasteur SA, for IM use, is a sterile solution containing the cell surface Vi polysaccharide extracted from serovar Typhi, S typhi Ty2 strain (inactivated, subunit vaccine). TYPHIM Vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by S typhi and is FDA approved for use in persons 2 years of age or older
561791|NCT03917654|Biological|Menactra|Menactra (Sanofi Pasteur) is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y, and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. No preservative or adjuvant is added during the manufacturing process. Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age.
561792|NCT03914300|Drug|Cabozantinib|Given PO
561793|NCT03914300|Drug|Cabozantinib S-malate|Given PO
561794|NCT03914300|Biological|Ipilimumab|Given IV
561795|NCT03914300|Biological|Nivolumab|Given IV
561796|NCT03912337|Drug|Placebo|Placebo once every 4 weeks. SC injection.
561797|NCT03912337|Drug|Erenumab|Erenumab once every 4 weeks. SC injection.
561798|NCT03911869|Drug|encorafenib|taken orally
561799|NCT03911869|Drug|binimetinib|taken orally
561800|NCT03910907|Drug|Comparison of two standard of care regimens|Treatment according to results of laboratory detection of resistance markers
561801|NCT03910205|Diagnostic Test|ELISA|Enzim linked immunoabsorbant assay
561802|NCT03910075|Behavioral|I-ACQUIRE - High Dosage|Children in this group will receive 6 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
561803|NCT03910075|Behavioral|I-ACQUIRE - Moderate Dosage|Children in this group will receive 3 hours of I-ACQUIRE therapy daily, 5 days a week for 4 consecutive weeks. Treatment is delivered in the home or homelike setting by a study trained I-ACQUIRE pediatric therapist.
561804|NCT03910075|Behavioral|Usual & Customary Treatment (U&CT)|Children in this group will receive the same U&CT that they had been receiving prior to the baseline assessment. The type and dosage of treatment(s) will be documented weekly.
561805|NCT03909893|Radiation|Adaptive Radiation Therapy|Cone-beam CT images as well as MRI scans will be used to make any changes to the radiation treatment plan, part of the way through the treatment. Adaptation of treatment plans may allow smaller target volumes to be treated with higher doses, while minimizing the side effects to surrounding organs.
561806|NCT03909854|Device|mode of mechanical ventilation|Adaptive Pressure Control mechanical ventilation is a dual controlled mode that is designed to auto-control flow and minimize inspiratory pressure while delivering a provider-determined tidal volume. Assist Volume Control mechanical ventilation is a mode in which the respiratory care provider determines patient tidal volume and flow.
561807|NCT03909464|Device|Neurosensory testing with Pressure-Specified Sensory Device|Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.
561808|NCT03909100|Device|CoolSculpting® System|A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
561809|NCT03908138|Drug|RDD|Lenalidomide: 25mg, po, d1-21， Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20-40mg, po, d1，d8，d15，d22
561810|NCT03908138|Drug|VDD|Bortezomib:1.3mg/m2，ih，d1，d4，d8，d11 Pegylated Liposomal Doxorubicin: 30-40mg/m2，ivgtt, d1 Dexamethasone: 20 mg, ivgtt, d1, 2, 4, 5, 8, 9, 11,12
561811|NCT03907488|Drug|Brentuximab Vedotin|Given IV
561812|NCT03907488|Drug|Dacarbazine|Given IV
561813|NCT03907488|Drug|Doxorubicin|Given IV
561814|NCT03907488|Drug|Doxorubicin Hydrochloride|Given IV
561818|NCT03907488|Other|Quality-of-Life Assessment|Ancillary studies
561819|NCT03907488|Other|Questionnaire Administration|Ancillary studies
561820|NCT03907488|Radiation|Radiation Therapy|Receive radiation therapy
561821|NCT03907488|Drug|Vinblastine|Given IV
561822|NCT03907488|Drug|Vinblastine Sulfate|Given IV
561823|NCT03905330|Drug|Maralixibat|Maralixibat oral solution (up to 600 mcg/kg) orally twice daily for 26 weeks.
561824|NCT03905330|Other|Placebo|Placebo matching to maralixibat orally twice daily for 26 weeks.
561825|NCT03903822|Drug|PF-06700841|PF-06700841 topical cream
561826|NCT03903822|Drug|Vehicle (Placebo)|Vehicle topical cream
561827|NCT03900962|Other|Home-based resistance training|"Patients completed two home-based resistance training sessions each week on non-consecutive days for 12 weeks. The programme was delivered online via individual playlists on Youtube (YouTube, San Bruno, California, USA), with each playlist involving an individually-prescribed series of pre-recorded exercise videos. Each session involved a dynamic warm-up followed by 11 resistance exercises using body weight and resistance bands, and finished with static stretching. Participants completed 1-2 sets of 5-12 repetitions at 4-7 on a modified 10-point rating of perceived exertion scale, which corresponded to qualitative descriptors of moderate to hard. Resistance training stimuli were progressed weekly by increasing the external load, modifying the exercise selection, increasing the number of repetitions, and/or increasing the number of sets."
561828|NCT03900962|Other|Walking intervention|After the initial baseline assessment, participants recorded the number of steps they walked daily for seven days using a waist-worn pedometer. Participants maintained their usual physical activity levels during this period. Participants were then encouraged to increase their total steps walked each day by 5% each week during the 12-week intervention.
561829|NCT03897972|Behavioral|Non-personalised diet advice delivered via the eNutri app (control)|Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).
561830|NCT03897972|Behavioral|Personalised diet advice delivered via the eNutri app (intervention)|Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
561831|NCT03896945|Drug|Placebo|oral capsules
561832|NCT03896945|Drug|AVP-786|oral capsules
561833|NCT03896789|Other|PEGASUS Program for Care|This Is in essence a checklist of pediatric guidelines to follow for participants who meet inclusion criteria. Site staff will receive training in how to implement this pathway into their usual care.
561834|NCT03896516|Drug|GLWL-01|Participants will take GLWL-01 450 mg b.i.d. or matched placebo for up to 16 days (Stage I). After a wash-out window, Stage II will take place during which the counterbalanced study drug will be administered for up to 16 days.
561835|NCT03896516|Other|Placebo|Participants will take GLWL-01 450 mg b.i.d. or matched placebo for up to 16 days
561836|NCT03896490|Behavioral|ACT|Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentation trigger motivating stimulations (cartoon animations with child-friendly sounds) every time the infant fulfils the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.
561837|NCT03896490|Behavioral|Control|The control procedure will involve presentation of cartoons on a screen, while infants' gaze direction will also be recorded using the same eye-tracker and camera. The crucial difference will be that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group will be matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group will see a replay of the session of the matched treated infant. Therefore, while the presentation will be exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation will not be interactive (i.e. not generated contingently on the infants' visual behaviour).
561838|NCT03895658|Device|Multichannel Stimulation Interface|Multichannel Stimulation Interface
561839|NCT03894540|Drug|IPN60090|Oral capsules given daily
561840|NCT03894540|Drug|pembrolizumab|An intravenous solution in single-use vial to be diluted for infusion.
561841|NCT03894540|Drug|paclitaxel|An intravenous solution in single-use vial to be diluted for infusion.
561842|NCT03894540|Drug|IPN60090 single administration|Oral capsules given once
561843|NCT03887533|Drug|VTS-270|Intravenous VTS-270 will be administered on a monthly dosing schedule for 12 months. Each participant will receive one of three doses (500, 1000 or 1500 mg/kg). Participants will have the option of receiving monthly 900 mg intrathecal VTS-270 therapy.
561844|NCT03883386|Drug|Loratadine|10 mg in a capsule
561845|NCT03883386|Drug|Placebo|Administered via capsule
561846|NCT03881696|Drug|Omalizumab|Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
561847|NCT03881696|Drug|Placebo for Omalizumab|Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms.
561848|NCT03881696|Drug|Multi-Allergen Oral Immunotherapy|"Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol."
561849|NCT03881696|Drug|Placebo for Multi-Allergen Oral Immunotherapy|Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol.
561958|NCT03828617|Biological|20vPnC|20vPnC
561850|NCT03881696|Other|Double-Blind Placebo-Controlled Food Challenge Based Treatment|"Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following:~Long-term follow-up with dietary consumption of a food; or~Long-term follow-up with avoidance of a food; or~Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time."
561851|NCT03880656|Biological|Intramuscular administration of autologous BM-MNCs|Intramuscular administration of autologous BM-MNCs at either a low or high cell dose.
561852|NCT03879954|Device|Catetherization approach|Out of plane inetrnal jugular vein Vs in plane supraclavicular subclavian vein catetherization
561853|NCT03877224|Drug|Dapagliflozin|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
561854|NCT03877224|Other|Placebo|Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.
561855|NCT03876769|Biological|CTL019|"Based on the subject's weight, one of two possible dose ranges will be prepared for the subject:~Subjects ≤ 50 kg: 0.2 to 5.0 x 10(6) CAR-positive viable T cells per kg body weight~OR~Subjects > 50 kg: 0.1 to 2.5 x 10(8) CAR-positive viable T cells"
561856|NCT03875482|Drug|Risankizumab|Risankizumab is administered as subcutaneous (SC) injection
561857|NCT03875482|Drug|Placebo|Placebo for risankizumab is administered as subcutaneous (SC) injection
561858|NCT03875469|Device|Centargo injector (BPI 1000045)|Contrast-enhanced computer tomography conducted with Centargo injector
561859|NCT03875469|Device|Stellant MP injector|Contrast-enhanced computer tomography conducted with Stellant MP injector
561860|NCT03873402|Biological|Nivolumab|Specified dose on specified days
561861|NCT03873402|Biological|Ipilimumab|Specified dose on specified days
561862|NCT03873402|Other|Ipilimumab placebo|Specified dose on specified days
561863|NCT03867812|Other|SOBAR|SOBAR is a high protein nutrition bar optimized to delay gastric emptying
561864|NCT03867812|Other|Control food|Chexmix (General Mills Inc.), Honey Nut Flavor
561865|NCT03867812|Other|Full meal|Stouffer's Bistro Crostini 5 cheeses, Oikos Strawberry yogurt, Tropicana Orange juice, Dad's oatmeal cookie
561866|NCT03867682|Biological|Lintuzumab-Ac225|In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 μCi/kg, 1.0 μCi/kg, and 1.5 μCi/kg. If the 0.50 μCi/kg dose is determined to exceed the MTD, a 0.25 μCi/kg dose will be explored.
561867|NCT03867682|Drug|Venetoclax|400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
561868|NCT03867682|Drug|Spironolactone|25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.
561869|NCT03867344|Other|Hypoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute hypoglycemic hyperinsulinemic clamp procedure.
561870|NCT03867344|Other|Normoglycemic Hyperinsulinemic Clamp|Participants undergo a 120-minute normoglycemic hyperinsulinemic clamp procedure.
561871|NCT03866798|Biological|Panzyga|Immune Globulin, intravenous, human-ifas
561872|NCT03866239|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous (IV) infusion as either a split or single dose approximately 2 weeks before Cycle 1, Day 1 (cycle = 21 days).
561873|NCT03866239|Drug|Atezolizumab|Atezolizumab will be administered at a fixed of 1200 mg dose by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
561874|NCT03866239|Drug|Cibisatamab|Cibisatamab will be administered at a fixed dose of 100 mg by IV infusion on Day 1 of each 21-day cycle until radiographic progression, unacceptable toxicity, or loss of clinical benefit.
561875|NCT03866239|Drug|Tocilizumab|Tocilizumab will be administered by IV infusion as necessary to manage adverse events (AEs)
561876|NCT03866174|Drug|Psilocybin|The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
561877|NCT03866174|Drug|Niacin|The active placebo is encapsulated using a HPMC capsule and contains 100 mg of pharmaceutical grade niacin.
561878|NCT03865732|Drug|Ganaxolone|active drug
561879|NCT03865732|Drug|Placebo|inactive
561880|NCT03864835|Behavioral|Moderate intensity aerobic exercise|Subjects that meet requirements for the exercise arm (12 total) will be required to exercise 30 minutes, five days per week at a moderate intensity (HR target corresponding to 45-55% of their relative VO2max). Each session will be supervised in-person at the Penn State University Fitness Center with an ACSM certified exercise physiologist. This is feasible as Zhang et al.(87) found 66 out of 70 subjects (95%) completed the twelve-month supervised in-person moderate-intensity exercise protocol five-days a week.
561881|NCT03861923|Other|Dry needling|Trigger point dry needling to trigger points in the shoulder or parascapular muscles using monofilament needle (i.e., acupuncture needle). Clean needle approach using sterile needles.
561882|NCT03861923|Other|Sham Dry Needling|Sham needle approach using a finishing nail in a tube sheath. The finishing nail will be placed over the trigger point so that the patient perceives a sharp sensation. The tube (not the nail) will be moved up and down to mimic the action of needling.
561883|NCT03861923|Other|Therapeutic Exercise|Exercise including flexibility, range of motion, strengthening will be provided by the treating physical therapist based on the impairments identified.
561884|NCT03861676|Radiation|Focal brachytherapy with PSMA PET imaging|Focal brachytherapy with PSMA PET imaging. Focal (partial prostate gland) brachytherapy following 18F-DCFPyl PET/CT radiotracer imaging. Patients will also undergo pre-treatment transperineal mapping biopsy.
561885|NCT03861676|Drug|(18F)DCFPyL|18F-DCFPyl PET/CT scan
561886|NCT03859648|Device|BONEBRIDGE|Bone Conduction Implant
561887|NCT03857165|Drug|SAP-001|SAP-001 or placebo treatment in a 3:1 randomization ratio.
561888|NCT03854474|Biological|Pembrolizumab|Given IV
561889|NCT03854474|Drug|Tazemetostat|Given PO
561890|NCT03854149|Drug|Apixaban|Apixaban 5mg or an adjusted dose of 2.5mg twice daily use
561891|NCT03853915|Diagnostic Test|[18-F]- FDG - PET|[F-18]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, [F-18]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.
561892|NCT03853694|Drug|50 mcg Duramorph+ EXPAREL + multi-modal pain regimen|Intrathecal injection of 50 mcg Duramorph + EXPAREL administered via TAP infiltration + multi-modal pain regimen.
561893|NCT03853694|Drug|150 mcg Duramorph + multi-modal pain regimen|Intrathecal injection of 150 mcg Duramorph + multi-modal pain regimen.
561894|NCT03853694|Drug|Exparel TAP + multi-modal pain regimen|EXPAREL administered via TAP infiltration + multi-modal pain regimen.
561895|NCT03852602|Drug|Preemptive Analgesics|Analgesic application15 minutes before the treatment
561896|NCT03852602|Drug|Control|Analgesic application15 minutes before the end of the treatment
561897|NCT03852316|Device|Click Device|A single-use device containing a polymerase chain reaction (PCR)-based nucleic acid amplification test (NAAT) for detection of deoxyribonucleic acid (DNA) from Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) in self-collected vaginal specimens.
561898|NCT03851913|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
561899|NCT03847896|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
561900|NCT03847896|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
561901|NCT03847896|Combination Product|Budesonide metered-dose inhaler 160 µg|Budesonide inhalation aerosol
561902|NCT03847896|Combination Product|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
561903|NCT03847896|Combination Product|Placebo metered-dose inhaler|Placebo inhalation aerosol administered 4 times daily
561904|NCT03847181|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban at a dose of 15 or 20 mg once daily
561905|NCT03847181|Drug|Apixaban (Eliquis)|Apixaban at a dose of 2.5 or 5 mg twice daily
561906|NCT03847181|Drug|Warfarin|Warfarin dose as prescribed by medical practitioner
561907|NCT03844022|Diagnostic Test|MRI|magnetic resonance imaging
561908|NCT03842163|Diagnostic Test|Diagnosis of TTR amyloidosis cardiomyopathy|Diagnosis of TTR amyloidosis cardiomyopathy with scintigraphy
561909|NCT03840382|Behavioral|Tele-PrEP Intervention|Telemedicine conferences with PrEP-specialists
561910|NCT03838159|Drug|Paclitaxel|"Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.~The infusions must be mixed as soon as possible before the start of each infusion since the stability of paclitaxel beyond 24 hours is not known.~In-line filtration is obligatory since a small number of fibers within the acceptable limits of the USP Particulate Matter Test for LVP have been reported. Cellulose acetate filters of 0.22-micron pore size (such as IVEX II) can be used. The solution that shows excessive particulate matter must be rejected."
561911|NCT03838159|Drug|Carboplatin|Carboplatin must be administered at the end of the Paclitaxel infusion
561912|NCT03838159|Drug|Nivolumab|"Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains and 2 identical light chains.~The administration of nivolumab infusion must be completed within 24 hours of preparation."
561913|NCT03836040|Drug|Erenumab Dose 1|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 2.
561914|NCT03836040|Drug|Erenumab Dose 2|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 2.~Subjects weighing threshold or more at Day 1 will be randomized to either Dose 2 or Dose 3."
561915|NCT03836040|Drug|Erenumab Dose 3|Subjects weighing threshold or more at Day 1 will be randomized to either Dose 2 or Dose 3.
561916|NCT03836040|Other|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
561917|NCT03836014|Combination Product|Daratumumab/Lenalidomide/Dexamethasone for 24 months|"Conditioning regimen: 16 mg/kg IV :~Weekly (Cycles 1 and C2)~Every two weeks (C3 to C6)~Monthly from C7 up to 24 months in total (Arm 1)~Infusion reaction prophylaxis :~Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle up to 24 months in total (Arm 1)~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle up to 24 months in total (Arm 1)"
561918|NCT03836014|Combination Product|Daratumumab/Lenalidomide/Dexamethasone until progression|"Conditioning regimen: 16 mg/kg IV :~Weekly (Cycles 1 and C2)~Every two weeks (C3 to C6)~Monthly from C7 until disease progression (Arm 2).~Infusion reaction prophylaxis :~Acetaminophen (paracetamol) 650-1000 mg IV or orally (PO) approximately 1 hour or less prior to infusion~An antihistamine (diphenhydramine 25-50 mg IV or PO, or equivalent but avoid IV use of promethazine) approximately 1hour prior to infusion; after Cycle 6, if a subject has not developed an infusion-related reaction and is intolerant to antihistamines, modifications are acceptable as per investigator discretion~Dexamethasone 40 mg IV (preferred) or PO, approximately 1 hour or less prior infusion.~Lenalidomide:~Conditioning regimen: 25 mg per os. From day 1 to day 21 of each cycle until disease progression (Arm 2).~Dexamethasone:~Conditioning regimen: 40 mg at day 1 (preinfusion medication IV preferred), day 8, day 15 and day 22 per os of each cycle until disease progression (Arm 2)."
561919|NCT03835754|Device|OCS Heart System|The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
561920|NCT03834740|Drug|Ribociclib|Ribociclib administered orally in 5 daily doses prior to resection
561921|NCT03834740|Drug|Everolimus|Everolimus administered orally in 5 daily doses prior to resection
561959|NCT03828617|Biological|13vPnC|Pneumococcal conjugate vaccine
562037|NCT03786783|Drug|Isotretinoin|Given PO
562038|NCT03786783|Drug|Melphalan|Given IV
562039|NCT03786783|Biological|Sargramostim|Given SC
561922|NCT03834714|Other|Active treatment|Only subjects in the experimental group will receive exposure to NIR light therapy. . NIR light-therapy exposures are administered to each ear individually, for a duration of 180 seconds per ear. The 180 second NIR light-therapy exposures occur in each of the 4 sessions. To allow for maximum effectiveness, NIR light exposures will be administered on a schedule that provides adequate, but not excessive, separation between sessions.
561923|NCT03834714|Other|Control|The control group will have a powered-down device placed in the ears for a duration of 180 seconds. NIR light-therapy exposures are administered to each ear individually, for a duration of 180 seconds per ear. The 180 second NIR light-therapy exposures occur in each of the 4 sessions. To allow for maximum effectiveness, NIR light exposures will be administered on a schedule that provides adequate, but not excessive, separation between sessions.
561924|NCT03834220|Drug|Debio 1347|80 milligrams (mg) dose of Debio 1347 orally once daily from Day 1 to Day 28 in 28-Day cycle.
561925|NCT03834194|Behavioral|Lottery + Monthly Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
561926|NCT03834194|Behavioral|Lottery + Overall Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
561927|NCT03834194|Behavioral|Lottery + Overall Weight|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
561928|NCT03834194|Behavioral|Loss + Overall Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study."
561929|NCT03834194|Behavioral|Loss + Overall Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) by the end of the study.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
561930|NCT03834194|Behavioral|Lottery + Monthly Weight + Exercise|"Lottery for daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
561931|NCT03834194|Behavioral|Loss + Monthly Weight|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis."
561932|NCT03834194|Behavioral|Loss + Monthly Weight + Exercise|"Certain loss for not engaging in daily self-weighing.~Incentives for gaining weight within a recommended (by Institute of Medicine) on a monthly basis.~Incentives for meeting an exercise goal of 150 minutes of moderate physical activity per week, as recommended by the American College of Obstetricians and Gynecologists."
561933|NCT03833999|Drug|Ondansetron 8mg|ondansetron, a 5HT3 receptor antagonist used clinically in nausea and vomiting
561934|NCT03833999|Diagnostic Test|abdominal MRI|serial MRIs on day 1 and day 3 of the study, at baseline and 2 hours apart 0-6 hours after meal ingestion on day 1 and 0-4 hours after the meal on day 3
561935|NCT03833999|Drug|Lactulose|Participants will receive 20mls lactulose twice daily for 48 hours prior to the third study day
561936|NCT03833999|Drug|Placebo oral capsule|overcoated placebo tablet, identical to the ondansetron
561937|NCT03832998|Drug|Erenumab Dose 1|Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 2.
561938|NCT03832998|Drug|Erenumab Dose 2|"Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 2.~Subjects weighing threshold or more at Day 1 will be randomized to either Dose 2 or Dose 3."
561939|NCT03832998|Drug|Erenumab Dose 3|Subjects weighing threshold or more at Day 1 will be randomized to either Dose 2 or Dose 3.
561940|NCT03832998|Other|Placebo|Placebo matching dose for erenumab dose 1, 2 and 3.
561941|NCT03830827|Drug|Vortioxetine|8-week 10-20mg/day vortioxetine; 2-hour MBRP intervention per week in 8 weeks
561942|NCT03830528|Drug|KW-6356 Low Dose|KW-6356 will be administered as single doses.
561943|NCT03830528|Drug|KW-6356 Middle Dose|KW-6356 will be administered as single doses.
561944|NCT03830528|Drug|KW-6356 High Dose|KW-6356 will be administered as single doses.
561945|NCT03830528|Drug|KW-6356 X Dose|KW-6356 will be administered as multiple doses.
561946|NCT03830528|Drug|KW-6356 Y Dose|KW-6356 will be administered for Japanese healthy men as multiple doses.
561947|NCT03830528|Drug|Placebo|All study cohorts (except Part C) are placebo controlled.
561948|NCT03829436|Drug|Part 1 TPST-1120|Subjects will receive escalating doses of TPST-1120 administered orally twice daily continuously until MTD is reached or until disease progression
561949|NCT03829436|Drug|Part 2a TPST-1120 + nivolumab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily
561950|NCT03829436|Drug|Part 2b TPST-1120 + docetaxel|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with docetaxel administered intravenously every 21 days until MTD is reached for TPST-1120 or until disease progression
561951|NCT03829436|Drug|Part 2c TPST-1120 + cetuximab|Subjects will receive escalating doses of TPST-1120 administered orally twice daily in combination with cetuximab administered intravenously every 7 days until MTD is reached for TPST-1120 or until disease progression
561952|NCT03829436|Drug|Part 3 TPST-1120|Selected dose of TPST-1120 administered orally twice daily until disease progression
561953|NCT03829436|Drug|Part 4a TPST-1120 + nivolumab|Selected dose of TPST-1120 administered orally twice daily in combination with nivolumab administered intravenously every 28 days until MTD is reached for TPST-1120 or until disease progression
561954|NCT03829436|Drug|Part 4b TPST-1120 + docetaxel|Selected dose of TPST-1120 administered orally twice daily in combination with docetaxel administered intravenously every 21 days until MTD is reached for TPST-1120 or until disease progression
561955|NCT03829436|Drug|Part 4c TPST-1120 + cetuximab|Selected dose of TPST-1120 administered orally twice daily in combination with cetuximab administered intravenously every 7 days until MTD is reached for TPST-1120 or until disease progression
561956|NCT03828617|Biological|20vPnC|20vPnC
561957|NCT03828617|Biological|20vPnC|20vPnC
561960|NCT03827954|Other|HeartMapp+CT|HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
561961|NCT03826030|Device|Sham|sham group receives no active current stimulation except 15 seconds of current ramp up in the beginning and 15 seconds of current ramp up in the end of the 30-minute session to create a scalp perception to blind the subject.
561962|NCT03826030|Device|Low dose tDCS|The low dose tDCS group receives direct current stimulation at 2 mA for 30 minutes per session
561963|NCT03826030|Device|High dose tDCS|The high dose tDCS group receives direct current stimulation at 4 mA for 30 minutes per session
561964|NCT03826030|Behavioral|mCIMT|All three tDCS groups receive constraint-induced movement therapy as the adjunctive behavioral therapy for 2 hours per session
561965|NCT03823300|Drug|Faricimab|Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
561966|NCT03823300|Drug|Aflibercept|Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
561967|NCT03823300|Drug|Sham Procedure|The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatment arms at applicable visits to maintain masking.
561968|NCT03820830|Drug|Palbociclib 125mg|Palbociclib 125 mg oral tablet taken daily for 3 years from randomization
561969|NCT03820830|Drug|Standard endocrine therapy|Aromatase inhibitor (anastrozole or exemestane or letrozole) oral daily tablet, or Selective Estrogen Receptor Modulator (SERM) such as tamoxifen oral daily tablet or fulvestrant (Faslodex) injection once every 2 weeks for 3 doses then every month. Premenopausal women and men may also receive an LHRH (luteinizing hormone-releasing hormone) agonist by injection. Standard endocrine therapy will be given for at least 3 years from randomization.
561970|NCT03820687|Other|Clinical Trial Educational Video|Culturally tailored educational video, brochure, and support from a patient navigator to empower new cancer patients to make informed decisions about cancer clinical trials.
561971|NCT03820687|Other|Clinical Trial Fact Sheet|General Clinical Trial fact sheet with usual care information regarding Clinical Trials.
561972|NCT03820687|Other|Brochure|A brochure with educational material about clinical trials and services offered by Mays Cancer Center.
561973|NCT03820687|Other|Navigator|Support that will be provided by a patient navigator to empower new cancer patients to make an informed decision about cancer clinical trials by increasing awareness of clinical trials and MCC services, positive attitudes and intentions to consider clinical trials as an appropriate treatment option.
561974|NCT03819153|Drug|Semaglutide|Participants are to inject semaglutide with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject semaglutide under their skin. Participants will inject semaglutide 1 time a week on the same day of the week. Participants' dose of semaglutide will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
561975|NCT03819153|Drug|Placebo (semaglutide)|Participants are to inject placebo (semaglutide) with a needle in the stomach, thigh or upper arm. Participants will use a pen to inject placebo (semaglutide) under their skin. Participants will inject placebo (semaglutide) 1 time a week on the same day of the week. Participants' dose of placebo (semaglutide) will be changed over time. Participants start by taking a smaller amount (0.25 mg). After 4 weeks the dose will be increased to 0.5 mg. It will be increased more (to 1 mg) at 8 weeks. Participants will then stay on the same dose for the rest of the study.
561976|NCT03818607|Drug|ABP 959|intravenous infusion
561977|NCT03818607|Drug|Eculizumab|intravenous infusion
561978|NCT03818308|Drug|Sofosbuvir and Velpatasvir|All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
561979|NCT03818035|Drug|Guselkumab|Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a, 2c, 2d and 3c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.
561980|NCT03818035|Drug|Placebo Injection|Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.
561981|NCT03817463|Drug|Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor|Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor
561982|NCT03817463|Drug|Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor|Dipeptidyl peptidase-4 (DPP-4) inhibitor
561983|NCT03816163|Drug|zolbetuximab|Administered as an intravenous infusion.
561984|NCT03816163|Drug|nab-paclitaxel|Administered as an intravenous infusion
561985|NCT03816163|Drug|gemcitabine|Administered as an intravenous infusion
561986|NCT03815695|Drug|FT-4202/Placebo|Healthy volunteer subjects will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
561987|NCT03815695|Drug|FT-4202|Healthy volunteer subjects will receive FT-4202 with or without food and undergo pharmacokinetic studies
561988|NCT03815695|Drug|FT-4202/Placebo|SCD subjects will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
561989|NCT03811535|Drug|Somapacitan|Somapacitan will be administered subcutaneously (s.c.; under the skin) once weekly by PDS290 pen-injector. Somapacitan can be injected any time during the once weekly dosing day. The dose will be calculated based on the subject's current body weight.
561990|NCT03811535|Drug|Norditropin®|Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
561991|NCT03809416|Device|Lasers|Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
562034|NCT03786783|Drug|Doxorubicin|Given IV
562035|NCT03786783|Drug|Etoposide|Given IV
562036|NCT03786783|Radiation|External Beam Radiation Therapy|Undergo EBRT
561992|NCT03809416|Other|Platelets Rich Plasma|Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
561993|NCT03809416|Combination Product|Lasers plus Normal Saline Solution|Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
561994|NCT03807440|Drug|Empagliflozin|Empagliflozin
561995|NCT03807440|Drug|Sodium Glucose Transporter 2 inhibitor|Sodium Glucose Transporter 2 inhibitor
561996|NCT03807440|Drug|Dipeptidyl-peptidase 4 inhibitor|Dipeptidyl-peptidase 4 inhibitor
561997|NCT03807440|Drug|Glucagon-like peptide 1 agonist|Glucagon-like peptide 1 agonist
561998|NCT03806530|Drug|Gabapentin|100 mg capsule
561999|NCT03806530|Drug|Ropinirole|0.50 mg capsule
562000|NCT03806530|Drug|Placebo Gabapentin|Placebo capsule
562001|NCT03806530|Drug|Placebo Ropinirole|Placebo capsule
562002|NCT03806491|Behavioral|Cognitive Behavioral Therapy for Insomnia|Study therapists will follow the 2014 CBT-I in Veterans manual developed by leading researchers in the behavioral sleep medicine field (see Table 3).23 Intervention components include (1) sleep hygiene: limiting naps; avoiding caffeine, tobacco, alcohol, and rich/heavy foods before bedtime; exercising; establishing a bedtime routine; and creating a comfortable sleep environment; (2) sleep restriction: limiting time in bed in order to improve sleep efficiency, or the percentage of time in bed that is actually spent sleeping; time in bed will be titrated each week based on sleep efficiency; (3) stimulus control: strengthening association between bedroom and sleep to decrease conditioned arousal; (4) relaxation: diaphragmatic breathing, progressive muscle relaxation, and visual imagery to reduce arousal; and (5) cognitive therapy: identifying and challenging thoughts that interfere with sleep.
562003|NCT03806491|Behavioral|Sleep Hygiene Education|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the EDU condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
562004|NCT03806491|Behavioral|Cognitive Behavioral Therapy for Alcohol Use Disorders|CBT-based groups for Alcohol Use Disorder will focus on the acquisition of skills needed to cope effectively with urges and cravings to drink and manage high-risk situations.
562005|NCT03805217|Device|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software|EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
562006|NCT03805152|Drug|Neuronox(R)|Injection botulinum toxin intramuscular for affected neck muscle
562007|NCT03805152|Drug|Dysport (R)|Intramuscular injection
562008|NCT03804788|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia (CBT-I). Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. A sixth week of treatment will be included - and scheduled for the same date as the post-treatment assessment - if the participant and research team agree that it would be beneficial (e.g., if a participant has difficulty grasping cognitive therapy concepts). Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
562009|NCT03804788|Behavioral|Sleep Hygeine|All participants will receive a one-page handout on sleep hygiene that includes personalized normative feedback on their alcohol use. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
562010|NCT03803384|Other|Oxygen therapy|Oxygen supply during ESWT, once with the prescribed constant oxygen flow and once using an auto-regulated oxygen flow system setting the SpO2 target at 92%.
562011|NCT03802526|Drug|NVP-1805-R1|1 tablet, multiple oral dosing
562012|NCT03802526|Drug|NVP-1805-R2|1 tablet, multiple oral dosing
562013|NCT03802526|Drug|NVP-1805-R1 and NVP-1805-R2|NVP-1805-R1,1 tablet and NVP-1805-R2, 1 tablet, co-administration, multiple oral dosing
562014|NCT03799523|Other|Temporary skin markings|To use temporary markings in lieu of localization tattoos.
562015|NCT03799523|Other|Surface imaging|To use light-based surface imaging for patient positioning during radiation treatment.
562016|NCT03794726|Procedure|Orthodontic Molar Protraction and PAOO|Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
562017|NCT03794726|Procedure|Orthodontic Molar Protraction|Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
562018|NCT03793179|Drug|Carboplatin|Given IV
562019|NCT03793179|Biological|Pembrolizumab|Given IV
562020|NCT03793179|Drug|Pemetrexed|Given IV
562021|NCT03793166|Drug|Cabozantinib|Given PO
562022|NCT03793166|Biological|Ipilimumab|Given IV
562023|NCT03793166|Biological|Nivolumab|Given IV
562024|NCT03793166|Other|Quality-of-Life Assessment|Ancillary studies
562025|NCT03793166|Other|Questionnaire Administration|Ancillary studies
562026|NCT03787732|Drug|Fluid Bolus|500 milliliters of an intravenous crystalloid solution of the operator's choosing
562027|NCT03787732|Other|No Fluid Bolus|No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation
562028|NCT03786783|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
562029|NCT03786783|Drug|Carboplatin|Given IV
562030|NCT03786783|Drug|Cisplatin|Given IV
562031|NCT03786783|Drug|Cyclophosphamide|Given IV
562032|NCT03786783|Drug|Dexrazoxane|Given IV
562033|NCT03786783|Biological|Dinutuximab|Given IV
562042|NCT03786783|Drug|Vincristine|Given IV
562043|NCT03786094|Drug|Eribulin|Eribulin alone
562044|NCT03786094|Drug|Balixafortide|balixafortide + eribulin
562045|NCT03785925|Biological|Bempegaldesleukin|Specified dose on specified days
562046|NCT03785925|Biological|Nivolumab|Specified dose on specified days
562047|NCT03785522|Drug|Insulin degludec|Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
562048|NCT03783325|Behavioral|UV Counseling|This is a sub-study that involves a behavioral intervention. Participants will wear a UV dosimetry for 3 weeks, return the device and receive feedback. After the feedback, they will re-wear the device for an additional 3 weeks.
562049|NCT03783325|Other|UV Photo|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
562050|NCT03783325|Other|Biological Sample|Technically, this arm is a sub-study that does not involve an intervention. Patients are not receiving an intervention; they are simply providing data to the study team.
562051|NCT03782376|Drug|Ustekinumab approximately 6 mg/kg (IV)|Participants will receive ustekinumab approximately 6mg/kg intravenously at Week 0.
562052|NCT03782376|Drug|Placebo (SC)|Participants will receive SC injection of placebo at Week 0.
562053|NCT03782376|Drug|Placebo (IV)|Participants will receive IV infusion of placebo at Week 0.
562054|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 1|Participants will receive SC injection of ustekinumab 90 mg at Weeks 8 and 16.
562055|NCT03782376|Drug|Ustekinumab 90 mg (SC) Group 2|Participants will receive SC injection of ustekinumab 90 mg at Weeks 0, 8 and 16.
562056|NCT03780725|Drug|BI 754111|Solution for infusion
562057|NCT03780725|Drug|[89Zr]Zr-BI 754111|Solution for infusion
562058|NCT03780725|Drug|BI 754091|Solution for infusion
562059|NCT03778229|Drug|osimertinib|osimertinib (80 mg oral od).
562060|NCT03778229|Drug|savolitinib|savolitinib (300 mg oral OD or 600 mg oral OD)
562061|NCT03777176|Drug|dasiglucagon|Glucagon analog
562062|NCT03777176|Other|Standard of Care|Standard of care according to site and/or country
562063|NCT03777059|Drug|Atogepant 30 mg|Tablets containing atogepant 30 mg
562064|NCT03777059|Drug|Atogepant 60 mg|Tablets containing atogepant 60 mg
562065|NCT03777059|Drug|Placebo|10 mg, 30 mg and 60 mg tablets containing atogepant-matching placebo
562066|NCT03777059|Drug|Atogepant 10 mg|Tablets containing atogepant 10 mg
562067|NCT03775421|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
562068|NCT03775265|Drug|Atezolizumab|Given IV
562069|NCT03775265|Drug|Cisplatin|Given IV
562070|NCT03775265|Drug|Fluorouracil|Given IV
562071|NCT03775265|Drug|Gemcitabine|Given IV
562072|NCT03775265|Drug|Mitomycin|Given IV
562073|NCT03775265|Other|Quality-of-Life Assessment|Ancillary studies
562074|NCT03775265|Radiation|Radiation Therapy|Undergo 3DCRT or IMRT
562075|NCT03775265|Other|Survey Administration|Ancillary studies
562076|NCT03774446|Drug|Seliciclib|Drug: Seliciclib
562077|NCT03773133|Drug|Satoreotide tetraxetan|Radioactivity delivered in 2 administrations (cycles): one loading dose followed by a lower maintenance dose, 6 weeks apart until progression or unacceptable toxicity (up to 4 additional cycles could be administered depending on efficacy and tolerability).
562078|NCT03773133|Drug|Satoreotide trizoxetan|Imaging companion: 1 administration at screening and one administration at End of core Trial cycle.
562079|NCT03770000|Drug|Tenalisib|Tenalisib, BID orally daily
562080|NCT03770000|Drug|Romidepsin|Romidepsin IV
562081|NCT03769506|Combination Product|ASP-1929|Use of ASP-1929 PIT therapy
562082|NCT03769506|Drug|Physician's Choice SOC|docetaxel, cetuximab, methotrexate, or paclitaxel
562083|NCT03769090|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
562084|NCT03769090|Combination Product|Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg|Budesonide/albuterol sulfate combination inhalation aerosol
562085|NCT03769090|Combination Product|Albuterol sulfate metered-dose inhaler 180 μg|Albuterol sulfate inhalation aerosol
562086|NCT03767933|Drug|Ibuprofen|10mg/kg, maximum 600mg; Oral liquid
562087|NCT03767933|Drug|Acetaminophen|15mg/kg, maximum 1000mg; Oral liquid
562088|NCT03767933|Drug|Hydromorphone|0.05mg/kg, maximum 5 mg; Oral liquid
562089|NCT03767933|Drug|Acetaminophen placebo|Oral liquid
562090|NCT03767933|Drug|Hydromorphone placebo|Oral liquid
562091|NCT03767621|Other|Indication of revascularization|Device: iFR/FFR
562092|NCT03766399|Drug|AZD0449|Participants will receive single inhaled AZD0449 nebulizer suspension and single IV dose of AZD0449 solution.
562093|NCT03766399|Drug|Placebo|Participants will receive single dose of placebo for AZD0449 (nebulizer suspension).
562094|NCT03765541|Drug|Dexamethasone|"In combination with intensive chemotherapy amsacrine-cytarabine:~Induction (1 cycle): 10 mg/12h from Day 1 to Day 3 of cycle (2 infusions/24h, slow IV [10 minutes])~Consolidation (3 cycles): 10 mg/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV [10 minutes])~In combination with azacitidine:~Cycle 1: 20 mg/24h from Day 1 to Day 3 of cycle (1 infusion/24h, slow IV [10 minutes]).~Subsequent cycles: 20 mg/24h on Day 1 of each cycle (1 infusion/24h, slow IV [10minutes])."
562095|NCT03765541|Drug|Amsacrine|"Induction (1 cycle): 200 mg/m2/24h from Day 1 to Day 3 of cycle (slow IV [3 hours])~Consolidation (3 cycles): 200 mg/m2/24h on Day 1 of each cycle (slow IV [3 hours])"
562096|NCT03765541|Drug|Cytarabine|"Patients < 60 years of age:~Induction (1 cycle): 3 g/m2/12h from Day 1 to Day 4 of cycle (2 infusions/24h, slow IV [2 hours])~Consolidation (3 cycles): 3 g/m2/12h from Day 1 to Day 3 of each cycle (2 infusions/24h, slow IV [2 hours]) Note: If the investigators believe that there is an undue risk for the safety of a patient under 60 years of age with comorbidity in receiving a dose level of 3 g/m2/12h, the dose may be reduced to 1 g/m2/12h"
562097|NCT03765541|Drug|Azacitidine|75 mg/m2/24h from Day 1 to Day 7 of each cycle [or from Day 1 to Day 5 and from Day 8 to Day 9 of each cycle] (SC)
562098|NCT03765294|Drug|ACT-541468|Film-coated tablet for oral use
562099|NCT03765294|Drug|Placebo|Film-coated tablet for oral use
562100|NCT03763838|Other|Acupressure|Six weeks of daily self-administered relaxing acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. These are points that are recognized as effective in Traditional Chinese Medicine (TCM).
562101|NCT03763838|Other|Sham acupressure|Six weeks of daily self-administered sham acupressure. Instructions will be provided for how to perform acupressure on self. A tool (AcuWand) will be provided to help participants apply the right amount of pressure; however, the points that participants are instructed to use are not known to have any effect on the body.
562102|NCT03763838|Other|Standard of Care|Fatigue management provided by participants' health care providers.
562103|NCT03762018|Drug|Carboplatin|Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.
562104|NCT03762018|Drug|Pemetrexed|Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.
562105|NCT03762018|Drug|Bevacizumab|Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.
562106|NCT03762018|Drug|Atezolizumab|Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.
562107|NCT03761095|Drug|PTC596|PTC596 will be administered as per the dose and schedule specified in the arm.
562108|NCT03761095|Drug|Dacarbazine|Dacarbazine will be administered as per the dose and schedule specified in the arm.
562109|NCT03756792|Behavioral|Normal Education Material|Patients will receive standard educational material about Mohs micrographic surgery.
562110|NCT03756792|Behavioral|Vignette|Patients will receive standard educational material about Mohs micrographic surgery and read a vignette detailing the typical experience of a Mohs patient.
562111|NCT03754582|Drug|Perampanel|Perampanel intravenous infusion.
562112|NCT03752216|Drug|Niraparib|"Two different doses of Niraparib can be administrated:~For patient who had at baseline (T0) a body weight ≥ 77 kg and a platelet count ≥ 150 000/µL, Niraparib will be administrated at a dose of 300 mg daily. The planned dose of 300 mg daily will be made up of three 100 mg capsules.~For patient who had at baseline (T0) a body weight < 77 kg or a platelet count <150 000/µL, Niraparib will be administrated at a dose of 200 mg daily. The planned dose of 200 mg daily will be made up of two 100 mg capsules.~Patient should continue to receive study treatment until disease progression as per RECIST as assessed by the investigator or they do not meet any other discontinuation criteria."
562113|NCT03751657|Drug|Insulin 287|Insulin 287 once weekly subcutaneous (s.c.) injections at the starting dose of 70 units. Dose adjustment was done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL)
562114|NCT03751657|Drug|Placebo (insulin 287)|Participants will receive once weekly s.c. injections of placebo equivalent to insulin 287.
562115|NCT03751657|Drug|Metformin|Metformin is considered as non investigational medicinal product. Subject will continue metformin at stable pre-trial dose.
562116|NCT03751657|Drug|Dipeptidyl peptidase-4 inhibitors|Dipeptidyl peptidase-4 inhibitors are considered as non investigational medicinal products. Subject will continue dipeptidyl peptidase-4 inhibitor at stable pre-trial dose.
562117|NCT03751657|Drug|Insulin glargine|Insulin glargine (100 U/mL) once daily s.c. injections at the starting dose of 10 units. Dose adjustment will be done for the individual patient based on the three pre-breakfast self-measured plasma glucose values measured on two days prior to titration and on the day of the contact. The insulin dose adjustment should aim to reach an SMPG of 3.9-6.0 mmol/L (70-108 mg/dL).
562118|NCT03751657|Drug|Placebo (insulin glargine)|Participants will receive once daily s.c. injections of placebo equivalent to insulin glargine.
562119|NCT03748641|Drug|Niraparib|Participants will receive niraparib 200 mg (2 capsules of 100 mg each) capsules once daily.
562120|NCT03748641|Drug|Abiraterone Acetate|Participants will receive abiraterone acetate 1000 mg (4 tablets of 250 mg each) tablets once daily.
562121|NCT03748641|Drug|Prednisone|Participants will receive prednisone 10 mg (2 tablets of 5 mg each) tablets daily.
562122|NCT03748641|Drug|Placebo|Participants will receive matching placebo capsules once daily.
562123|NCT03748459|Other|Closure with Permanent Suture|Skin closure with permanent suture (prolene) (6-0 polypropylene) in open rhinoplasty.
562124|NCT03748459|Other|Closure with Resorbable Suture|Skin closure with Resorbable Suture (5-0 fast absorbing plain gut) in open rhinoplasty.
562125|NCT03747133|Radiation|Stereotactic Ablative Radiotherapy|Stereotactic Ablative Radiotherapy to renal tumors with a dose of 27.5-40 Gy in 5 fractions.
562126|NCT03745859|Device|Fraxinus VBN system|Open source planning tool for bronchoscopy
562127|NCT03743844|Behavioral|Compassion-focused psychoeducation group|Attending six 2-hour weekly group-based psychoeducation sessions and participating in mindfulness, meditation, and acceptance-based experiential exercises
562128|NCT03743012|Other|Integrated cardiac rehabilitation|Participants enrolled to the integrated cardiac rehabilitation arm will participate in individually tailored rehabilitation sessions that will involve aerobic activity focused on exertion at the participant's aerobic threshold (AT) over a duration of three months.
562129|NCT03743012|Other|Usual Care|Participants randomized to the usual care arm will be instructed on the benefits of exercise and continue with usual care. Participant activity will be tracked monthly using pedometers for three months of follow up.
562130|NCT03741881|Other|No treatment given|Participants are treated with their usual prescribed treatment, either given regularly as a prevention (prophylaxis) or when needed (on-demand).
562131|NCT03739866|Drug|GS-6207|Administered subcutaneously in the abdomen
562132|NCT03739866|Drug|Placebo|Administered subcutaneously in the abdomen
562133|NCT03739866|Drug|B/F/TAF|50/200/25 mg tablets administered orally once daily
562134|NCT03739866|Drug|TAF|Tablets administered orally
562135|NCT03738241|Biological|A/H7N9|Monovalent split 2017 A/H7N9 Inactivated Influenza Virus Vaccine containing the Hemagglutinin (HA) and Neuraminidase (NA) from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1). The HA content of the 2017 A/H7N9 vaccine formulations were determined by Single Radial Immunodiffusion (SRID) assay to be approximately two times higher (14.45 mcg of HA per 0.5 mL dose) than the targeted HA content on the label (7.5 mcg of HA per 0.5 mL dose).
562136|NCT03738241|Drug|AS03|AS03 oil-in-water emulsion-based adjuvant system containing DL-alpha-tocopherol, squalene, polysorbate 80, and a buffer.
562137|NCT03738241|Other|Phosphate Buffered Saline (PBS) diluent|0.006M PBS diluent for Influenza Virus Vaccine.
562138|NCT03737981|Drug|Ibrutinib|Given PO
562139|NCT03737981|Biological|Obinutuzumab|Given IV
562140|NCT03737981|Other|Observation|Undergo observation
562141|NCT03737981|Drug|Venetoclax|Given PO
562142|NCT03735732|Behavioral|prime|groups be confronted with health or palatability aspects of food items
562143|NCT03735667|Device|ACURATE neo2™ Transfemoral TAVR System|Symetis ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
562144|NCT03735667|Device|Medtronic CoreValve TAVR System|Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
562145|NCT03735667|Device|Edwards SAPIEN 3 TAVR System|Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)
562146|NCT03735628|Drug|Copanlisib|Copanlisib: lyophilisate for reconstitution and further dilution for infusion
562147|NCT03735628|Drug|Nivolumab|Nivolumab: concentrate for solution for infusion
562148|NCT03735290|Biological|ilixadencel|Intra-tumoral injection
562149|NCT03735290|Drug|Pembrolizumab|Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
562150|NCT03734289|Behavioral|Caregiver Coaching|Online coaching sessions will occur weekly for 6 weeks. Web-based courses containing instructional materials that deal with preventing and reducing care resistant behavior (CRB) within intimate care (dressing, bathing, toileting) and treatment regimens (medication, therapeutic activities) after the initial study visit. The NeuroNS-Care intervention is an innovative distance-learning , internet based, family caregiver coaching program; one for the caregivers of persons with dementia and one for the caregivers of persons recovering from TBI. It will be delivered using Instructure's Canvas™ web-based platform.
562151|NCT03733067|Drug|Orencia (abatacept)|Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.
562152|NCT03733067|Other|Placebo|Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
562153|NCT03730714|Drug|"Local Anesthetic, Epinephrine and Morphine"|local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
562154|NCT03730714|Drug|"Local Anesthetic, Epinephrine, Morphine and Gelfoam"|Gelfoam soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)
562155|NCT03730714|Drug|"Normal Saline"|normal saline 0.9% to soak the gelfoam according to the planned technique
562156|NCT03729310|Device|Propel 'implant'|The Propel 'implant' is composed of small, flexible tubes which dissolve while releasing Mometasone which is one type of steroid. This application has been approved for use by the FDA.
562157|NCT03729310|Drug|Triamcinolone|Triamcinolone has been approved for use topically elsewhere on the body, although the specific use of Triamcinolone in the sinuses has not been approved by the FDA.
562158|NCT03729310|Device|Nasopore|"This packing' is a sponge-like material which dissolves while releasing triamcinolone."
562159|NCT03728777|Dietary Supplement|Resveratrol|Resveratrol supplementation 1000 mg /day or placebo
562160|NCT03727841|Drug|Marizomib|0.8mg/m2 IV on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
562161|NCT03726437|Behavioral|RealConsent|"This 3-hour web-based program consists of four 45-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama (Squad), which allow for the modeling of positive behaviors and illustrate both positive and negative outcome expectations. Behaviors modeled include drinking safely (e.g., eating before drinking, pacing, and drinking water), having a game plan before going out, communicating with male sex partners, engaging in protective dating behaviors, use of resistance strategies, self-defense strategies and bystander intervention with the goal of reducing risk of being sexually assaulted."
562162|NCT03726437|Behavioral|Stress and Mood Management|"This 3-hour general health promotion web-based program consists of four 45-minute modules (Stress Management, Managing Depression, Managing Anxiety, and Treatments that work) that provide a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise."
562163|NCT03725033|Drug|Subetta|For oral use. 2 tablets 2 times a day 15 minutes before meals. Keep the tablets in your mouth, not swallowing, until completely they are dissolved.
562164|NCT03725033|Drug|Placebo|For oral use. 2 tablets 2 times a day 15 minutes before meals. Keep the tablets in your mouth, not swallowing, until completely they are dissolved.
562165|NCT03724890|Drug|M3814|Participants will receive M3814 twice daily (BID) continuously starting from Day 1 until progressive disease (PD) or unacceptable toxicity.
562166|NCT03724890|Drug|M3814|Participants will receive M3814 concomitantly with RT once (QD) daily starting Day 1 for 5 days per week for 2 weeks in total.
562167|NCT03724890|Drug|Avelumab|Participants will receive avelumab once every 2 weeks (Q2W) starting from Day 1 until PD or unacceptable toxicity.
562168|NCT03724890|Radiation|Radiotherapy|Participants will receive radiotherapy at the dose of 3 grays (Gy) per day starting Day 1 for 5 days per week for 2 weeks.
562169|NCT03723551|Drug|Afabicin|Afabicin will be given IV at a dose 160 mg BID for a minimum of 1 day (2 doses) and up to a maximum of 14 days (2 weeks), followed by a switch to oral Afabicin at a dose of 240 mg BID for the remaining treatment duration.
562170|NCT03723551|Drug|SOC|For oxacillin-/ methicillin-susceptible staphylococci, the recommended SOC for the comparator arm are: IV - cefazolin or vancomycin or linezolid or clindamycin and oral - linezolid or clindamycin. For oxacillin-/ methicillin-resistant staphylococci, the recommended SOC for the comparator arm are: IV - vancomycin or clindamycin or linezolid and oral - linezolid or clindamycin.
562171|NCT03723070|Device|The Cryterion Cardiac Cryoablation System|Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
562172|NCT03722446|Device|Arrow Catheter Kit.|The group will be randomized to receive this labor analgesia kit.
562173|NCT03722446|Device|B.Braun Catheter Kit|The group will be randomized to receive this labor analgesia kit.
562174|NCT03721952|Behavioral|Facilitator-Based Intervention|Facilitators interact in person with patients, family, and clinicians both during and following the patient's ICU stay for 3 months. In-person contacts include visits to patients' homes and/or care facilities; phone contacts include calls to patients, families and clinicians. Patients and families have access to facilitators through phone and email 5 days per week. Facilitators may attend clinic visits with patients. In addition to checking directly with patients/families during regular contacts, facilitators also access the electronic health record to ensure they have accurate information about appointments and treatment plans and to document key points for the clinical team. Facilitators encourage referral to inpatient or outpatient palliative care services when needs are identified.
562175|NCT03721276|Behavioral|ESTEEM (Effective Skills to Empower Effective Men) for Women|Individuals assigned to therapy will receive 10 weekly individually-delivered sessions, directly after baseline assessment, that address minority stress mechanisms underlying SMW's depression, anxiety, and alcohol abuse.
562176|NCT03720665|Combination Product|Caffeine_TMS|Caffeine group: participants will receive a caffeine tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)] Placebo tablet: participants will receive a placebo tablet and all electrical stimulations in a random order [transcranial electrical stimulation (tACS 140 Hz at 1 mA, 0.4 mA, sham) and paired associative stimulation (PAS 25)]
562177|NCT03719313|Drug|Lonafarnib|Lonafarnib (LNF) 50 mg BID
562178|NCT03719313|Drug|Ritonavir|Ritonavir (RTV) 100 mg BID
562179|NCT03719313|Drug|PEG IFN-alfa-2a|PEG IFN alfa-2a 180 mcg QW
562180|NCT03719313|Drug|Placebo Lonafarnib|Placebo
562181|NCT03719313|Drug|Placebo Ritonavir|Placebo
562182|NCT03718767|Drug|Nivolumab|Nivolumab is given IV as flat dose of 240 mg for Cycles 1-4 and 480 mg for Cycles 5-16.
562183|NCT03718650|Drug|Pimonidazole|Patients will take a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral pimonidazole HCI 16 to 24 hours prior to surgery.
562184|NCT03718650|Procedure|Surgical Resection|Patients will undergo Pancreaticoduodenectomy or Whipple procedure, which involves the resection of the pancreatic head, duodenum, gallbladder, and a portion of the stomach, 16 to 24 hours after consuming oral pimonidazole.
562185|NCT03717155|Drug|Avelumab|Participants will receive avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, it will be given every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
562186|NCT03717155|Drug|Cetuximab|Participants will receive cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m^2) body surface area on Day 1 and 500 mg/m^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, it will be given at a dose of 500 mg/m^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
562187|NCT03717155|Drug|Gemcitabine|Participants will receive gemcitabine intravenous infusions at a dose of 1250 mg/m^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles.
562188|NCT03717155|Drug|Cisplatin|Participants will receive cisplatin intravenous infusions at a dose of 75 mg/m^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles.
562189|NCT03717051|Drug|Nicotine replacement therapy (NRT) sampling|1-week free NRT samples (patch or gum)
562190|NCT03717051|Behavioral|Medication counseling|Medication counseling
562191|NCT03716726|Behavioral|WE CARE SDoH Screening Survey|The survey will be given at all visits by the front desk staff to all parents of SCA patients. It consists of 12 questions designed to: (1) briefly identify 6 unmet material needs (e.g., childcare, employment, food security, household heat, housing inadequate education) by self-report and (2) using a family-centered approach, determine whether parents would like assistance with each problem Parents wanting help will receive a resource referral. Clinical team members will be trained to review the WE CARE SDoH survey at visits and to provide community resource information sheets to parents with needs. Completed surveys will be scanned into the EHR
562192|NCT03716726|Behavioral|Family Resource Book|The Family Resource book will contain one-page information sheets listing community resources (e.g., food pantries) and their contact information (i.e. telephone number) for each specific material need (e.g., food insecurity). Information sheets will be specific to each site and written at, or below, the 8th grade level. For parents with an identified need, providers will be instructed to give an information sheet. The book will contain six separate tabs, one for each unmet need, and will contain multiple copies of the information sheets. The Family Resource Book will be made available in each exam room. The investigators will work with each practice to create a Family Resource Book prior to study initiation.
562193|NCT03716726|Other|Standard of care|Usual outpatient care for pediatric patients with sickle cell anemia will be provided.
562194|NCT03716518|Drug|Tonifying Spleen and Kidney Sequential Regimen|TSKSR will be given to the participants as follows:Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and Qi-tu-er-zhi Granule,1 pack each time,twice a day,PO,from 7th to 20th day of chemotherapy.
562195|NCT03716518|Drug|Placebo of 'Tonifying Spleen and Kidney Sequential Regimen|Placebo of TCM-TSKSR will be given to the participants as follows:placebo of Liu-jun-an-wei Granule,1 pack each time,twice a day,PO,from 0 to 6th day of chemotherapy and placebo of Qi-tu-er-zhi Granule,1 pack each time,twice a day,from 7th to 20th day of chemotherapy.
562196|NCT03716505|Device|gammaCore Sapphire active|GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
562197|NCT03716505|Device|gammaCore Sapphire Sham|The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
562198|NCT03716453|Procedure|Standard protocol|Give narcotic according to vital signs
562199|NCT03716453|Procedure|ANI protocol|"ANI score 50-70 indicates optimal narcotic effect. ANI score > 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score < 50 indicates inadequate narcotic and narcotic should be given."
562200|NCT03715829|Drug|PF-06651600|Induction dose 1. Oral tablet taken QD
562201|NCT03715829|Drug|PF-06651600|Induction dose 2. Oral tablet taken QD
562202|NCT03715829|Drug|PF-06651600|Maintenance dose A. Oral tablet taken QD
562203|NCT03715829|Drug|PF-06651600|Maintenance Dose B. Oral tablet taken QD
562204|NCT03715829|Drug|PF-06651600|Maintenance Dose C. Oral tablet taken QD
562205|NCT03715829|Drug|placebo|placebo
562206|NCT03715829|Drug|PF06700841|Oral tablet taken QD
562207|NCT03715829|Device|narrow-band UVB phototherapy|Phototherapy will be combined with PF-06651600
562208|NCT03714815|Drug|macitentan 10 mg|macitentan 10 mg, film-coated tablet, oral use
562209|NCT03714308|Drug|Ivt. Aflibercept (Eylea, BAY86-5321)|Treatment is applied according to routine clinical practice and independent of the study setting.
562210|NCT03707600|Device|TMS|MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil.
562211|NCT03707444|Device|Scrambler Therapy Device|Superficial neuromodulation using EKG type electrodes [Scrambler (MC5-A Calmare) Therapy]
562212|NCT03705910|Other|Perceptive Rehabilitation|"In each session, over one hundred cones will be placed on a rigid wooden base using elastic strips. The patient will be asked to lie down supine on the material. Patients weigh will create pressure and reaction force to his/her body. Treatments will be 2 times a week till 8 weeks.~The therapist will ask the patient firstly to breathe normally and feel the pressure. The patient will then perform breathing exercises and active exercises (including stretching, warming up, and cooling down) under supervision. During the session, the therapist will ask about the pressure of the cones and will correct the patient's posture. At the end of each session, the therapist will photograph the patient's back with the aim of documenting the pressure and hyperaemic areas."
562213|NCT03705910|Other|Mobilisation Techniques|"A certified physiotherapist will perform mobilisation techniques. All participants in this group will receive treatment protocol according to the list on below. Treatments will be 2 times a week till 8 weeks.~For this treatment, the participant should lie on a bed and change their position according to the technique (supine, position or side-lying). Also, the therapist will be changing her position according to the technique. All technique will be on the range of motion limit. For releasing techniques the therapist will apply three-dimensional pressures till 3-5 minutes, with the feeling of relaxing therapist will change the limit for the next point."
562214|NCT03705819|Drug|[11C]-NOP46|Subjects will receive a microdose (≤10 µg) of [11C]-NOP46.
562215|NCT03705819|Radiation|PET/CT scan|After subjects receive a microdose of [11C]-NOP46, whole body PET/CT scan(s) will be performed to determine dosimetry and perform an initial safety evaluation of the radiotracer in Stage 1 and region of interests in Stage 2.
562216|NCT03705806|Radiation|Radiation combined with immunotherapy|The trial is designed as a prospective observational single arm study investigating stage IV non-small cell lung cancer patients who are routinely treated with a PD-1 inhibitor for indications approved by Health Canada. All patients who are selected will be referred for palliative thoracic radiotherapy and treated with a standard dose prescription of 30 Gy in 10 fractions.
562217|NCT03705351|Device|Tumor Treating Fields|Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Treatment will begin approximately 1 week prior to start of radiation and temozolomide treatment and continue concurrently throughout the duration of the study.
562218|NCT03705351|Drug|Temozolomide|Patients will be given temozolomide according to routine treatment dosing and schedule.
562219|NCT03705351|Radiation|Radiation Therapy|Patients will be given radiation therapy according to routine treatment dosing and schedule.
562220|NCT03705234|Drug|Inclisiran|Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
562221|NCT03705234|Drug|Placebo|Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
562222|NCT03703570|Drug|KW-6356|Oral administration
562223|NCT03703570|Drug|Placebo|Oral administration
562224|NCT03701594|Other|Yoga-based physical therapy group|All yoga-based sessions will be led by the same therapist to maximize between-session consistency. A trained researcher will also be present to provide additional cueing to subjects when required. The basic elements of the postures are similar to that of traditional physical therapy balance exercises. Cues will be provided throughout to pair appropriate breath cycles with appropriate postures consistent with a standard, able-bodied yoga program. The session will close with a 4-5 minute savasana performed in a supine or seated position pending patient physical abilities, which consists of progressive relaxation, guided meditation, and guided motor imagery.
562310|NCT03656510|Drug|JNJ-53718678|Participants will receive of JNJ-53718678 (high dose or low dose) orally once daily for 7 days.
562225|NCT03701594|Other|Seated Rest|Subjects will engage in 1 hour of seated rest in a relaxing environment in a group of approximately 2-5 individuals. This session will occur in the same enclosed, quiet space as condition A to minimize outside noise or distraction and to reproduce environment of condition A. The lights will be dimmed, and the same light, instrumental, calming music will be played throughout to contribute to a relaxing ambiance. Subjects will be instructed to rest quietly.
562226|NCT03701594|Other|Conventional Physical Therapy|"Subjects will engage in 1 hour of a conventional PT session (or treatment as usual) led by a different physical therapist than who is leading the yoga-based session to minimize bias. There will be no restrictions on what can and cannot occur during conventional PT sessions in order to accurately represent and preserve the wide range of treatments that may occur during a physical therapy session in the inpatient setting. Examples of what may occur include, but are not limited to: gait, standing balance, functional mobility, or therapeutic exercise."
562227|NCT03701334|Drug|Ribociclib|Ribociclib + ET
562228|NCT03701334|Other|Endocrine Therapy|Endocrine Therapy (ET)
562229|NCT03701282|Drug|Ibrutinib|Given PO
562230|NCT03701282|Biological|Obinutuzumab|Given IV
562231|NCT03701282|Other|Quality-of-Life Assessment|Ancillary studies
562232|NCT03701282|Drug|Venetoclax|Given PO
562233|NCT03700359|Drug|Anlotinib Hydrochloride|Anlotinib: Maintenance therapy 12mg/day P.O., day 1-15 every 21 days (2 weeks on, 1 week off) until progressive disease or treatment discontinuation
562234|NCT03700359|Drug|Lobaplatin|Lobaplatin:30 mg/m2 IV every 21 days for up to 4 cycles of 21 days
562235|NCT03700359|Drug|Etoposide|Etoposide: 60 mg/m2 IV every 21 days for up to 4 cycles of 21 days
562236|NCT03699202|Drug|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The capsule containing enteric coated AK0529 pellets will be orally administered to patients at one of a 100mg, 200mg or 300mg dose level.
562237|NCT03699202|Drug|Placebo|The placebo is made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed of microcrystaline cellulose pellet.
562238|NCT03699124|Biological|FD MVA-BN|Vaccinations with a 0.5 mL dose of vaccine containing at least 0.5 x 10E8 Infectious Units (Inf.U)
562239|NCT03695380|Drug|Cobimetinib|Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).
562240|NCT03695380|Drug|Niraparib|Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).
562241|NCT03695380|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
562242|NCT03692403|Drug|Quinagolide 360 µg|Vaginal ring containing quinagolide 360 µg for daily releases
562243|NCT03692403|Drug|Quinagolide 720 µg|Vaginal ring containing quinagolide 720 µg for daily releases
562244|NCT03692403|Drug|Quinagolide 1080 µg|Vaginal ring containing quinagolide 1080 µg for daily releases
562245|NCT03692403|Drug|Placebo|Matching placebo
562246|NCT03691974|Drug|Fasinumab|Subcutaneous (SC) every four weeks (Q4W)
562247|NCT03691974|Other|Placebo|Subcutaneous (SC) every four weeks (Q4W)
562248|NCT03691948|Other|Responsible Opioid Prescriber Education (ROPES)|The ROPEs intervention is a self-guided, web-based continuing dental education intervention. Consistent with ADA recommendations, ROPEs consists of seven modules of active content: (1) Overview; (2) Background on the Opioid Epidemic; (3) Dental Pain Management and the Role of Opioids; (4) Universal Precautions Approach; (5) Screening, Monitoring, and PDMP use; (6) Providing Patient Education; and, (7) Case Vignettes. All key intervention content is delivered via video-based platform and includes downloadable practice aides and resources.
562249|NCT03691948|Other|Active Comparator Control|An online PDF version of the Center for Disease Control Guideline for Prescribing Opioids for Chronic Pain.
562250|NCT03689244|Drug|Selexipag|oral tablets containing 200 µg of selexipag. Depending on the iMTD, subjects will receive 1 to 8 tablets at each administration
562251|NCT03689244|Drug|Placebo|Oral tablets without active compound
562252|NCT03687827|Drug|Insulin degludec|Participants will receive insulin degludec U100 subcutaneous (s.c.) injection once daily for 36 weeks. Doses will be adjusted according to the fasting self-measured plasma glucose (SMPG) values. Participants earlier treated with one or more allowed oral antidiabetic drug(s) (OAD(s)), should continue their pre-trial OAD(s) treatment throughout the trial.
562253|NCT03687827|Drug|Insulin glargine|Participants will receive insulin glargine U100 s.c. injection once daily for 36 weeks. Doses will be adjusted according to the fasting SMPG values. Participants earlier treated with one or more allowed OAD(s), should continue their pre-trial OAD(s) treatment throughout the trial.
562254|NCT03686215|Combination Product|Study Device Arm|LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
562255|NCT03682120|Biological|A/H7N9|"Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1)."
562256|NCT03682120|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
562257|NCT03682120|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
562258|NCT03682068|Drug|Durvalumab|Durvalumab IV (intravenous infusion)
562259|NCT03682068|Drug|Tremelimumab|Tremelimumab IV (intravenous infusion)
562260|NCT03682068|Drug|Cisplatin + Gemcitabine|Cisplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
562261|NCT03682068|Drug|Carboplatin + Gemcitabine|Carboplatin IV (intravenous)+ Gemcitabine IV(intravenous), as standard of care.
562262|NCT03681210|Device|HeartWare Ventricular Assist Device|The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
562263|NCT03680547|Other|patient with sickle cell disease|assess degree of renal affection in patientswith sickle cell disease attending Assuit university Children hospital by estimating some predictors of glomerular and tubular dysfunction.
562264|NCT03677934|Drug|PDS Implant filled with 100 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
562265|NCT03677934|Drug|Intravitreal Injections of 10 mg/mL Ranibizumab|Will be administered as per the schedule described in individual arm.
562266|NCT03677401|Drug|5mg Serlopitant Tablets|Serlopitant Tablets
562267|NCT03677401|Drug|Placebo Tablets|Placebo Tablets
562268|NCT03677154|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
562269|NCT03677154|Drug|Tocilizumab|Participants will receive tocilizumab via IV.
562270|NCT03675477|Drug|SHR0302|The study drug, SHR0302, is designed to block the activity of an enzyme protein called JAK (known as a JAK inhibitor).
562271|NCT03675477|Drug|Placebos|Placebo Oral Tablet
562272|NCT03674970|Drug|Nicotine Film|"Three doses of nicotine films will be used in this project: 0 mg, 2 mg, and 4 mg.~The active pharmaceutical ingredient in the nicotine film product is nicotine polacrilex (20%, USP). The film has a muco-adhesive property and allows nicotine to be absorbed through the oral mucosa. After placement in the oral cavity, the nicotine film dissolves in less than five minutes. The film is in the form of 1 inch x 1 inch square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting."
562273|NCT03674567|Drug|FLX475|tablet
562274|NCT03674567|Drug|Pembrolizumab|IV infusion
562275|NCT03672864|Behavioral|Intensive exercise|Intensive, child-initiated movement of the lower extremity: 1 hour/day, 4 days/week, 2 sessions delivered by a physical therapist, 2 delivered by a parent. All activities are play based, and exercise intensity is enhanced by small weights placed on the dorsum of the foot and the ankle of the affected limb. Intervention is delivered over 12 weeks for a target of 48 hours of training.
562276|NCT03671499|Behavioral|Social Cognitive Theory based text messages|Participants receive daily text messages and bi-weekly newsletters with information about reducing sitting behavior and increasing physical activity.
562277|NCT03671018|Drug|Mosunetuzumab|Participants will receive intravenous (IV) mosunetuzumab.
562278|NCT03671018|Drug|Polatuzumab vedotin|Participants will receive IV polatuzumab vedotin.
562279|NCT03671018|Drug|Rituximab|Participants will receive IV rituxumab.
562280|NCT03671018|Drug|Bendamustine|Participants will receive IV bendamustine.
562281|NCT03671018|Drug|Tocilizumab|Participants will receive IV tocilizumab as needed.
562282|NCT03667690|Drug|Rezafungin for Injection|Intravenous antifungal therapy
562283|NCT03667690|Drug|Caspofungin|Intravenous antifungal therapy
562284|NCT03667690|Drug|Fluconazole|Oral antifungal therapy
562285|NCT03667690|Drug|intravenous placebo|Normal saline
562286|NCT03667690|Drug|oral placebo|Microcrystalline cellulose
562287|NCT03666273|Drug|BAY1905254|Intravenous administration of escalating doses of BAY1905254 (dose escalation) or of maximum tolerated dose (expansion)
562288|NCT03666273|Drug|BAY1905254 + Pembrolizumab|Intravenous administration of escalating doses of BAY1905254 (dose escalation) or of maximum tolerated dose (expansion), and of a fixed dose of pembrolizumab
562289|NCT03663101|Drug|Lidocaine|0.5 mL (2.5 mg) of lidocaine per injection point will be injected subcutaneously (maximum 10 injection points).
562290|NCT03663101|Biological|Botulinum toxin type A|0.2 mL of one of three different doses of Dysport per injection point will be injected intradermally (maximum 10 injection points).
562291|NCT03663101|Drug|Placebo|Part A - 0.5 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected subcutaneously (maximum 10 injection points).
562292|NCT03663101|Drug|Placebo|Part B - 0.2 mL of sodium chloride solution 0.9% (saline solution) per injection point will be injected intradermally (maximum 10 injection points, 2,0 mL maximum).
562293|NCT03662542|Drug|Guselkumab Dose 1|Guselkumab Dose 1 will be administered as IV infusion.
562294|NCT03662542|Drug|Guselkumab Dose 2|Guselkumab Dose 2 will be administered as SC injection.
562295|NCT03662542|Drug|Golimumab Dose 1|Golimumab Dose 1 will be administered as SC injection.
562296|NCT03662542|Drug|Golimumab Dose 2|Golimumab Dose 2 will be administered as SC injection.
562297|NCT03662542|Drug|Placebo|Placebo will be administered.
562298|NCT03662308|Device|Heated Vest|Heated vest that regulates its heat output based on the user's skin, the user's core temperature, and the ambient temperature
562299|NCT03662308|Device|Non-Heated Vest|A similarly insulated (compared to the experimental vest), but non-heated vest
562300|NCT03661840|Behavioral|Acceptance and Commitment Therapy|Intervention group participants will attend eight weekly, 90-minute, in person, group-based ACT sessions. Groups will be initiated with no more than 10 participants and no fewer than 6 participants. Sessions will include key theoretical ACT constructs and strategies as they relate to chronic pain. A licensed clinical psychologist or licensed clinical social worker trained in ACT will facilitate all sessions. Participants in the ACT intervention group will also continue to receive medication management and other behavioral management interventions that they would get as usual treatment.
562301|NCT03661840|Other|Treatment as Usual|Treatment as usual will include ongoing provision of usual treatment options for pain management. This includes continued medication management for cancer related chronic pain by prescribing providers, and access to supportive oncology services. It may also include other behavioral pain management such as physical therapy, acupuncture, or massage.
562302|NCT03661320|Biological|Nivolumab|Specified dose on specified day
562303|NCT03661320|Drug|BMS-986205|Specified dose on specified day
562304|NCT03661320|Drug|Gemcitabine|Specified dose on specified day
562305|NCT03661320|Drug|Cisplatin|Specified dose on specified day
562306|NCT03661320|Drug|BMS-986205 Placebo|Specified dose on specified day
562307|NCT03660072|Other|Non-Interventional|Non-Interventional
562308|NCT03656848|Diagnostic Test|QFR|QFR is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on two angiographic projections.
562309|NCT03656848|Diagnostic Test|Angiography|Coronary angiography is a procedure that uses contrast under x-ray pictures to detect stenosis in the coronary arteries
562311|NCT03656510|Drug|Placebo|Participants will receive of matching placebo (high volume or low volume) orally once daily for 7 days.
562312|NCT03653507|Drug|zolbetuximab|Zolbetuximab will be administered as a minimum 2-hour IV infusion.
562313|NCT03653507|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
562314|NCT03653507|Drug|capecitabine|Capecitabine will be administered orally twice daily (bid).
562315|NCT03653507|Drug|placebo|Placebo will be administered as a minimum 2-hour IV infusion.
562316|NCT03650413|Drug|UTTR1147A|UTTR1147A will be administered based on disease status, as described in the protocol.
562317|NCT03648541|Drug|Spesolimab IV infusion|Solution for infusion
562318|NCT03648541|Drug|Spesolimab SC solution for injection|Solution for injection
562319|NCT03647228|Drug|IONIS-ENaCRx|Ascending single and multiple doses of IONIS-ENaCRx inhaled or nebulized.
562320|NCT03647228|Drug|Placebo|Placebo comparator calculated volume to match active comparator inhaled or nebulized.
562321|NCT03645824|Drug|Pacritinib|Patients receive up to 4 cycles of pacritinib before allo-SCT
562322|NCT03644186|Drug|Paclitaxel|Chemotherapy plus HER2 Blockade
562323|NCT03644186|Drug|Trastuzumab|Chemotherapy plus HER2 Blockade
562324|NCT03644186|Drug|Pertuzumab|Chemotherapy plus HER2 Blockade
562325|NCT03644186|Drug|Palbociclib|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
562326|NCT03644186|Drug|Letrozole|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
562327|NCT03644186|Drug|Trastuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
562328|NCT03644186|Drug|Pertuzumab|CDK Inhibition plus Hormonal Therapy plus HER2 Blockade
562329|NCT03638999|Drug|Ketorolac Trometamol 30Mg/1mL Injection|Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
562330|NCT03638999|Drug|Normal saline|Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
562331|NCT03638128|Drug|Denosumab|clear, colorless to slightly yellow, preservative free liquid, in single-use 3.0 mL glass vials containing a deliverable dose of 120mg/1.7 mL (70 mg/mL).
562332|NCT03637478|Behavioral|Enhanced Systems of Care Team|E-SOC team will be increasing connections between clinical care and community partners, such as schools, juvenile justice and child-serving state agencies, to reduce disparities in access to mental health/substance use evaluation and treatment. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning. Overall goals are: earlier identification of mental health needs including child trauma; increased treatment access and adherence; care delivered in least restrictive settings; care experience reflecting active youth and family engagement; program sustainability and replicability.
562333|NCT03635983|Biological|NKTR-214|Specified dose on specified days
562334|NCT03635983|Biological|Nivolumab|Specified dose on specified days
562335|NCT03635957|Biological|Pegloticase with MTX|Participants will receive MTX during the run-in period and then pegloticase with MTX for 52 weeks
562336|NCT03635112|Drug|Placebo|Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
562337|NCT03635112|Drug|TD-1473|TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
562338|NCT03634995|Drug|BMS-986256|Specified dose on specified days
562339|NCT03634995|Other|Placebo|Specified dose on specified days
562340|NCT03634969|Drug|BMS-986224|Specified dose on specified days
562341|NCT03631199|Drug|canakinumab|canakinumab every 3 weeks (squamous and non-squamous)
562342|NCT03631199|Drug|canakinumab matching placebo|canakinumab placebo every 3 weeks (squamous and non-squamous)
562343|NCT03631199|Drug|pembrolizumab|200 mg every 3 weeks (squamous and non-squamous)
562344|NCT03631199|Drug|carboplatin|AUC 5 mg/mL*min every 3 weeks (non-squamous) or AUC 6 mg/mL*min (squamous)
562345|NCT03631199|Drug|cisplatin|75 mg/m2 every 3 weeks (non-squamous)
562346|NCT03631199|Drug|paclitaxel|200 mg/m2 every 3 weeks (squamous)
562347|NCT03631199|Drug|nab-paclitaxel|100 mg/m2 every 3 weeks (squamous)
562348|NCT03631199|Drug|pemetrexed|500 mg/m2 every 3 weeks (non-squamous)
562349|NCT03628924|Drug|Guselkumab dose 1|Participants will receive guselkumab dose 1 IV.
562350|NCT03628924|Drug|Guselkumab dose 2|Participants will receive guselkumab dose 2 SC in Group 1, 2 and Group 3.
562351|NCT03628924|Drug|Guselkumab dose 3|Participants will receive guselkumab dose 3 SC in Group 3.
562352|NCT03628924|Drug|Placebo|Participants will receive matched placebo SC and IV in group 1, 2 and 3 with an additional placebo SC dose in Group 3.
562353|NCT03628612|Biological|AUTO CAR T cell therapy|No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
562354|NCT03627832|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Participants assigned to the CBT-I condition will attend 1-hour individual sessions of CBT-I once a week for five weeks. Consistent with clinical guidelines (Schutte-Rodin, Broch, Buysse, Dorsey, & Sateia, 2008), treatment will include stimulus control (e.g., limit use of bed to sleep or sexual activity, get out of bed if lying awake for more than 20 minutes), sleep restriction (limit time in bed to amount of time spent sleeping on a typical night), sleep hygiene (e.g., avoid exercise within 2 hours of bedtime, create cool and dark sleep environment), relaxation training, and cognitive restructuring.
562355|NCT03627832|Behavioral|Sleep Hygiene|All participants will receive a one-page handout on sleep hygiene. This is the only intervention that participants assigned to the Sleep Hygiene condition will receive and is consistent with what may be expected as standard care in a doctor's visit with a primary care physician.
562356|NCT03626506|Drug|Spironolactone|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take spironolactone 20mg once daily on top of amlodipine for 12 months. During the first two months after randomization, spironolactone can be titrated to 40mg if office SBP remains ≥ 140mmHg.
562466|NCT03538652|Other|JITAI|Just-In-Time Adaptive Intervention delivered via smartphone app
562357|NCT03626506|Drug|Indapamide|After a 2-week run-in period on amlodipine, patients who still have SBP ≥ 140mmHg will take extended-release indapamide 1.5mg once daily on top of amlodipine for 12 months. During the first two months after randomization, indapamide can be titrated to 3mg if office SBP remains ≥ 140mmHg.
562358|NCT03626506|Drug|Amlodipine|After a 2-week run-in period on amlodipine 5mg once daily, patients who still have SBP ≥ 140mmHg will be randomized to add spironolactone 20mg once daily or extended-release indapamide 1.5mg once daily to amlodipine for 12 months. During the first two months after randomization, amlodipine can be titrated to 10mg if office SBP remains ≥ 140mmHg.
562359|NCT03625141|Drug|Cobimetinib|60 mg (three tablets of 20 mg each) orally (PO) once a day (QD) on Days 1−21 of each 28-day cycle.
562360|NCT03625141|Drug|Atezolizumab|"Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.~Only for cohort 2, no dose of atezolizumab will be given during the run-in period (cycle 1)."
562361|NCT03625141|Drug|Vemurafenib|Participants will receive vemurafenib 960 mg (four 240 mg tablets) orally (PO) twice daily (BID) on days 1-21 of the run-in period (cycle 1); thereafter, they will receive vemurafenib 720 mg dose (three 240 mg tablets) PO BID on days 22-28 of cycle 1 and on days 1-28 of all subsequent cycles.
562362|NCT03623386|Other|PD neurofeedback|PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
562363|NCT03623386|Other|PD control|PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
562364|NCT03621397|Device|brainHQ by Posit Science|This is an online cognitive training program. It consists of 29 online exercises that work out attention, brain speed, memory, people skills, navigation, and intelligence. The current study will focus on the following exercises: attention, brain speed (e.g., processing speed), executive function, and memory.
562365|NCT03618095|Device|LOTUS Edge Valve System|TAVR with the LOTUS Edge Valve System
562366|NCT03615495|Device|Flourish Pediatric Esphogeal Atresia device|The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
562367|NCT03611751|Drug|BMS-986165|Specified dose on specified days
562368|NCT03611751|Other|Placebo|Specified dose on specified days
562369|NCT03611751|Drug|Apremilast|Specified dose on specified days
562370|NCT03610620|Procedure|Vivascope 2500 ex-vivo fluorescent confocal microscope|scanned with the Vivascope 2500
562371|NCT03610581|Biological|Ad26.HPV16|Participants will receive Ad26.HPV16 as a solution for intramuscular injection.
562372|NCT03610581|Biological|Ad26.HPV18|Participants will receive Ad26.HPV18 as a solution for intramuscular injection.
562373|NCT03610581|Biological|MVA.HPV16/18|Participants will receive MVA.HPV16/18 as a solution for intramuscular injection.
562374|NCT03610581|Biological|Placebo|Participants will receive matched placebo as a solution for intramuscular injection.
562375|NCT03607695|Other|Gait training|Walking on a treadmill and receiving audio cues to improve gait
562376|NCT03607422|Drug|Upadacitinib|It is administered orally.
562377|NCT03607422|Drug|Placebo for Upadacitinib|It is administered orally.
562378|NCT03606642|Drug|Dual Antiplatelet (DAPT) Therapy|"DAPT - one of three (3) antiplatelet medications: ticagrelor (Brilinta), clopidogrel (Plavix) or prasugrel (Effient) with Aspirin.~Aspirin loading dose (LD) = 325 mg. Aspirin maintenance dose (MD) = 81 mg.~P2Y12 Inhibitor Loading Dose (investigator preference):~Clopidogrel 600 mg PO x 1 or 75 mg PO daily x 4; Prasugrel 60 mg PO x 1; Ticagrelor 180 mg PO x 1.~P2Y12 Inhibitor Maintenance Dose (investigator preference):~Clopidogrel 75 mg PO daily; Prasugrel 10 mg PO daily; Ticagrelor 90 mg PO BID."
562379|NCT03606642|Device|The Synergy® stent|IVUS guided stent
562380|NCT03606512|Biological|Ad26.RSV.preF|Ad26.RSV.preF will be administered as IM injection at a dose of 2.5*10^10 vp.
562381|NCT03606512|Biological|Placebo|Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.
562382|NCT03606512|Biological|Nimenrix|Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
562383|NCT03606421|Radiation|SRS and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
562384|NCT03606421|Radiation|WBRT and neurocognitive assessments|Patients will be assessed for cerebral blood flow and their neurocognitive function based on a series of neurocognitive tests and questionnaires.
562385|NCT03603366|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
562386|NCT03599323|Drug|Clotrimazole 1% (Empecid L Cream, BAYB5097)|Consumers who self-select and are then deemed appropriate users of the product by the pharmacist for treatment of Vulvar itching with rash due to recurrent vaginal candida (only in patients previously diagnosed and treated by a doctor).
562387|NCT03599141|Behavioral|Trust-building Self-management Together|Trust building plus depression self-management
562388|NCT03599141|Behavioral|Depression Management|Traditional depression self-management
562389|NCT03598777|Biological|Botulinum toxin type A|Botulinum Toxin Type A (Dysport) using a vial of 500 U will be injected intramuscularly across pelvic floor muscles.
562390|NCT03598777|Drug|Placebo|The reconstituted solution will be injected intramuscularly across pelvic floor muscles.
562391|NCT03597282|Biological|NEO-PV-01|Personal Cancer Vaccine
562392|NCT03597282|Biological|Nivolumab|monoclonal antibody against PD-1
562393|NCT03597282|Other|Adjuvant|immune adjuvant
562394|NCT03597282|Biological|APX005M|monoclonal agonist antibody against CD40
562395|NCT03597282|Biological|ipilimumab|monoclonal antibody against CTLA4
562467|NCT03538652|Other|Placebo|Placebo
562396|NCT03596645|Drug|Golimumab|Participants receive subcutaneous (SC) golimumab through Week 50, where doses will be based on body surface area. After the Week 54 evaluations, at the discretion of investigator, participants benefiting from continued SC golimumab will continue to receive SC golimumab in the extension until end of study.
562397|NCT03596645|Drug|Infliximab|Participants will receive infliximab intravenous (IV) through Week 46. Doses will be based on body weight. After the Week 54 evaluations, participants receiving infliximab will be withdrawn from study participation and transition to local standard of care which may include continued commercially available infliximab at the discretion of their physician.
562398|NCT03596242|Other|SMS System|Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence
562399|NCT03594110|Drug|Empagliflozin|Taken daily with or without food
562400|NCT03594110|Drug|Matching placebo|Taken daily with or without food
562401|NCT03592641|Drug|Savolitinib|Given PO
562402|NCT03592368|Device|IBT|Interpretation bias training
562403|NCT03589807|Biological|A/H7N9|Monovalent split 2017 A/H7N9 Inictivated Influenza Virus vaccine containing the HA and NA from low pathogenic avian influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
562404|NCT03589807|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
562405|NCT03589807|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent split 2013 A/H7N9 Inavtivated Influenza Virus vaccine containing the HA and NA from avian influenza A/Shanghai/2/2013 (H7N9) and the PB2, PB1, PA, NP, M and NS from A/Puerto Rico/8/1934 (H1N1).
562406|NCT03589807|Other|Phosphate Buffered Saline (PBS) diluent|Diluent for Influenza Virus Vaccine.
562407|NCT03589768|Biological|Tetanus and Diphtheria Toxoids Adsorbed|Used for active immunization of adults and children 7 years of age and older against diphtheria and tetanus.
562408|NCT03589768|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide|A sterile isotonic suspension of tetanus and diphtheria toxoids and pertussis antigens adsorbed on Aluminum hydroxide.
562409|NCT03587740|Drug|T-DM1|T-DM1 is an antibody-drug conjugate; it is made up of an antibody (trastuzumab) linked to a cytotoxic drug, DM1 (chemotherapy). T-DM1 functions as a targeted cancer therapy because it targets HER2-positive breast cancer cells directly, limiting exposure of the rest of the body to chemotherapy.
562410|NCT03583944|Drug|Eribulin Mesylate|Eribulin mesylate IV infusion.
562411|NCT03583606|Biological|ChAd3-EBO-Z|Zaire ebolavirus vaccine administered by an IM injection into the deltoid as a single dose of 2 x 10^11 virus particles (vp)).
562412|NCT03583606|Biological|MVA Multi-Filo Ebola Vaccine|A booster vaccination of replication defective MVA-BN-Filo administered by an IM injection into the deltoid as a single dose of 1 x 10^8 Infectious Units (IU).
562413|NCT03583606|Other|Placebo|0.5 mL normal saline administered via IM injection into the deltoid.
562414|NCT03582891|Device|Summit RC+S|Using the RC+S pulse generator, investigators will measure cortical biomarkers of hyper and hypokinesia in Parkinson's and dystonia patients to develop an adaptive algorithm which adjusts the level of deep brain stimulation needed based upon the patient's physiology.
562415|NCT03582891|Diagnostic Test|1-month pilot trial of Closed-loop vs. Open-loop Stimulation|These patients will have a blinded trial of closed-loop stimulation or open-loop stimulation for 1 month at either 11 or 12 months into the study. This trial will take place at either 11 or 12 months into the study, a participants will be randomly assigned to receive closed or open-loop stimulation first.
562416|NCT03581292|Radiation|Radiation Therapy|Undergo radiation therapy
562417|NCT03581292|Drug|Temozolomide|Given PO
562418|NCT03581292|Drug|Veliparib|Given PO
562419|NCT03579940|Drug|Lasmiditan|Administered orally.
562420|NCT03579940|Drug|Placebo|Administered orally.
562421|NCT03578939|Procedure|Biopsy EUS guided|NGS Sequencing on Biopsy samples
562422|NCT03575403|Drug|Alcohol|In each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
562423|NCT03575403|Drug|Placebos|Subjects will receive placebo capsules.
562424|NCT03575403|Drug|Duloxetine|Subjects will receive duloxetine capsules.
562425|NCT03575403|Drug|Methylphenidate|Subjects will receive methylphenidate capsules.
562426|NCT03575364|Device|ClotTriever|Thrombectomy
562427|NCT03574597|Drug|Semaglutide|Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.24 mg; dose will gradually be increased every 4 weeks up to 2.4 mg.
562428|NCT03574597|Drug|Placebo (semaglutide)|Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
562429|NCT03571256|Drug|deutetrabenazine Low|6-, 9-, 12-, 15-, and 18-mg tablets
562430|NCT03571256|Drug|deutetrabenazine High|6-, 9-, 12-, 15-, and 18-mg tablets
562431|NCT03571256|Drug|Placebo|Matching Placebo
562432|NCT03569020|Other|Subsidy for food purchases and dietitian education|$105/wk of DASH-like foods over 4 weeks purchased with the help of a dietitian in a proportion that reflects the DASH diet.
562433|NCT03567733|Device|XIENCE Sierra|Percutaneous coronary intervention
562434|NCT03567018|Device|MRI Scan|Study participants will be scanned with a 3.0 Tesla Phillips Ingenia CX whole body clinical MRI system located at the Wright Center of Innovation at The Ohio State University Medical Center. Anatomical and angiographic MR images will be acquired for one of the most commonly used flap surgery donor perforators including but not limited to: the deep inferior epigastric perforators (DIEP); the superior gluteal arter perforators (SGAP); the inferior gluteal artery perforators (IGAP); the thoracodorsal artery perforators (TDAP); the anterolateral thigh perforators (ATL).
562435|NCT03565445|Drug|ASP1948|Intravenously (IV)
562436|NCT03565445|Drug|nivolumab|Intravenously (IV)
562437|NCT03562871|Biological|IO102|test immunotherapy
562438|NCT03562871|Biological|pembrolizumab (Keytruda)|anti-PD-1 immunotherapy
562439|NCT03562871|Drug|Carboplatin (Carboplatin Kabi)|chemotherapy
562440|NCT03562871|Drug|Pemetrexed (Pemetrexed Alvogen)|chemotherapy
562441|NCT03560960|Drug|Pramlintide challenge test|Enrolled subjects will have a pre-trial blood draw (3 ml) and will be placed with an IV needle for future blood draws. Pramlintide will be subcutaneously injected in the abdominal area. For each arm the participants will be randomized so that half will be given a dose of 0.8 mcg/kg and the other half of the arm a dose of 1.6 mcg/kg. Blood will be drawn before and at 5, 30, 60, and 180 min after injection. Vital signs and blood glucose will also be checked at these time points. Thirty minutes after the injection, subjects will be offered a standard meal. Subjects will have a final check of vital signs and blood glucose approximately 15 min before discharge.
562442|NCT03560622|Device|multi-modality neuroimaging|multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
562443|NCT03556930|Device|AlignRT system (VisionRT LTD, UK)|Pediatric patient will watch age-proper movie during radiation treatment. The motion of pediatric patient will continually be monitored by an AlignRT system (VisionRT LTD, UK). Both movie and radiation beam will be paused if the motion of pediatric patient is beyond positioning accuracy threshold. Movie and beam will be resumed if pediatric patient is positioning with in tolerance.
562444|NCT03556774|Behavioral|'WeChat WeQuit' smoking cessation training program|Providing 'WeChat WeQuit' smoking cessation training program for healthcare service providers (HSPs) and assessing their utilization of behavioral and pharmacotherapy interventions for cigarette smoking cessation.
562445|NCT03554564|Behavioral|VOICE/Fitbit|During the VOICE (intervention) phase, participants will use the digital health platform plus Fitbit walking activity tracking for a total of five weeks (one week run-in phase plus four week study phase)
562446|NCT03554564|Other|Daily self-reported exercise adherence|During usual care, patients will self-report on a daily basis if they met the walking exercise goal consistent with instructions from their clinician. Self-report will be recorded as a daily categorical (yes/no) variable.
562447|NCT03554473|Drug|M7824|Arm A &amp; B: 2400mg IV over up to 120 minutes every 3weeks on a 3-week cycle. Arm C: 1200 mg IV over 1 hour every 2 weeks on a 4-week cycle.
562448|NCT03554473|Drug|Topotecan|Arm B: 1 mg/m2 IV over 30 minutes days 1-5 on a 3-week cycle.
562449|NCT03554473|Drug|Temozolomide|Arm C and progressive disease patients on Arm A: 200 mg/m2 PO days 1-5 on a 4-week cycle
562450|NCT03553940|Biological|Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine|Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.
562451|NCT03553940|Other|Placebo|H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.
562452|NCT03553940|Biological|Quadrivalent MDCK Inactivated Influenza Vaccine|A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.
562453|NCT03552692|Drug|Venetoclax|"Venetoclax (ABT-199) will be administered orally (800 mg daily). Patients will receive ABT-199 until disease progression, unacceptable toxicity, withdrawal of consent and/or the investigator determines that further therapy is not in the patient's best interest.~Tumor Lysis Syndrome (TLS) is an important identified risk for Venetoclax in oncology studies. Since there are no available data on the risk of TLS in PTCL, the risk of TLS development should be closely monitored during the study.~to avoid TLS ABT-199 will be administered according the following ramp up: W eek 1 day 1: 20 mg W 1 day 2-3: 50 mg W 1 day 4-7: 100 mg W 2: 200 mg W 3: 400 mg W 4 and following: 800 mg"
562454|NCT03549624|Other|Standardised protocol for the perioperative management in patients in need of an acute laparotomy|A standardised protocol for the perioperative management of patients including early start of antibiotics and swift surgical intervention as well as an emphasis on repeated monitoring of physiological parameters pre- and post-operatively.
562455|NCT03545113|Procedure|Upper arm arteriovenous graft surgery|Creation of arteriovenous graft vascular access for hemodialysis
562456|NCT03545113|Procedure|Upper arm arteriovenous fistula surgery|Creation of arteriovenous fistula vascular access for hemodialysis
562457|NCT03543878|Device|Flicker|The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
562458|NCT03542604|Behavioral|Cognitive Behavioral Therapy for Insomnia|CBT-I involves identifying and replacing thoughts and behaviors that cause or worsen sleep problems with habits that promote sound sleep. There will be 6 intervention sessions over an 8-week period. The first two sessions are consecutive weekly in-person sessions followed by a rest week. The third session is conducted remotely by phone, followed by another rest week. The three remaining sessions are weekly and conducted remotely.
562459|NCT03542604|Behavioral|Sleep Education|EDU involves learning behavioral treatment information about sleep that is widely available to patients and practitioners. The program will parallel the CBT-I intervention in schedule, number, and length of sessions.
562460|NCT03541499|Biological|BPZE1|Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10^7 colony forming units (CFU) or 10^9 CFU.
562461|NCT03541499|Other|Placebo|The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
562462|NCT03541369|Drug|AMG 427|AMG 427 will be administered as an intravenous (IV) infusion in adult subjects with relapsed/refractory AML.
562463|NCT03539848|Device|I-PAS Goggles|Portable, head-mounted display goggle system with integrated eye capture technology
562464|NCT03539575|Other|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
562465|NCT03539536|Drug|Telisotuzumab vedotin|intravenous
562468|NCT03537495|Drug|Linezolid|"Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen."
562469|NCT03535870|Drug|Fluticasone propionate/salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the LOMI inhaler device
562470|NCT03535870|Drug|Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder|Advair (Fixed dose combination of fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
562471|NCT03535870|Drug|Placebo|placebo dry powder administered via the LOMI inhaler device
562472|NCT03535831|Diagnostic Test|18F-DCFPyL|The purpose of this study is to determine if use of 18F-DCFPyL would increase the detection of lesions and to better inform your oncologist on the best method of treatment for your disease.
562473|NCT03531086|Drug|Ioflupane I 123|Ioflupane I 123 will be administered IV push prior to SPECT imaging
562474|NCT03527589|Device|Prostate embolization with Embosphere Microspheres|Patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) will be treated with Embosphere Microspheres via prostate artery embolization.
562475|NCT03526250|Other|Laboratory Biomarker Analysis|Correlative studies
562476|NCT03526250|Drug|Palbociclib|Given PO
562477|NCT03526250|Other|Pharmacological Study|Correlative studies
562478|NCT03524404|Behavioral|6 Week Intervention|Weekly interactive webinars based on the DPP curriculum at senior center.
562479|NCT03522168|Drug|Risperidone|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
562480|NCT03522168|Drug|Aripiprazole|Medications prescribed as standard of care for Schizophrenia, Bipolar mania/acute treatment of manic and mixed episodes associated with Bipolar I disorder, Tourette's disorder, persistent (chronic) motor or vocal tic disorder and Irritability associated with autistic disorder
562481|NCT03521635|Drug|Pramipexole SR|Tablets
562482|NCT03521635|Drug|Pramipexole IR|Tablets
562483|NCT03519659|Diagnostic Test|PET/CT scan with 13 mCi radiation dose|13 mCi 18F-FDG dose
562484|NCT03519659|Diagnostic Test|PET/CT scan with 5 mCi radiation dose|5 mCi 18F-FDG dose
562485|NCT03519659|Diagnostic Test|PET/CT scan with 2.5 mCi radiation dose|2.5 mCi 18F-FDG dose
562486|NCT03519659|Diagnostic Test|PET/CT Scan with 6.5 mCi radiation dose|6.5 mCi 18F-FDG dose
562487|NCT03519659|Diagnostic Test|PET/CT Scan with not yet determined radiation dose|We plan for the possibility that one of the three-Sub-Studies (A-B) would not demonstrate equivalency, and we would then perform a modified protocol in which the SOC dosing is compared to a lower and higher dose than originally tested.
562488|NCT03518034|Drug|Testosterone|It will be administered topically.
562489|NCT03518034|Drug|Placebo|A matching placebo to testosterone will be administered topically.
562490|NCT03517722|Drug|Placebo|Participants will receive placebo matching to ustekinumab IV or SC.
562491|NCT03517722|Drug|Ustekinumab (approximately 6 mg/kg)|Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
562492|NCT03517722|Drug|Ustekinumab 90 mg|Participants will receive 90 mg ustekinumab via SC route.
562493|NCT03514433|Other|TRIP Patient Navigation Intervention|The TRIP intervention will replace the current standard of care at the 6 participating hospitals once it is rolled out on-site. Any TRIP eligible patients receiving patient navigation services over the course of the study will receive the enhanced services.
562494|NCT03512964|Drug|dolutegravir and descovy|Patients newly diagnosed with HIV or previously diagnosed with HIV and not on treatment or in care for at least six months will be given antiretroviral therapy starter packs containing dolutegravir (tivicay) 50 mg 1 tablet by mouth daily and emtricitabine 200 mg/tenofovir alafenamide 25 mg (descovy). Number of doses dispensed will be determined by the prescribing provider. Pill boxes will be given with each starter pack. At each clinic, patients are provided with 24/7 clinic contact information should he/she experience adverse side effects to medication and/or experience a medical emergency.
562495|NCT03507439|Device|VitalPatch Biosensor|Patients will receive the VitalPatch Biosensor system at 5 monitoring periods
562496|NCT03507439|Device|DynaPort Move Monitor|Patients will receive the DynaPort Move Monitor (belt) at 2 monitoring periods
562497|NCT03505736|Biological|Adenosine|Given IV
562498|NCT03505736|Procedure|Magnetic Resonance Imaging|Undergo CMR imaging
562499|NCT03505736|Drug|Regadenoson|Given IV
562500|NCT03505736|Procedure|Stress Management Therapy|Undergo stress test
562501|NCT03505320|Drug|zolbetuximab|Zolbetuximab will be administered as a 2-hour IV infusion.
562502|NCT03505320|Drug|oxaliplatin|Oxaliplatin will be administered as a 2-hour IV infusion.
562503|NCT03505320|Drug|leucovorin|Leucovorin will be administered as a 2-hour IV infusion.
562504|NCT03505320|Drug|fluorouracil|Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
562505|NCT03501381|Drug|Entinostat|Entinostat should be taken 1-2 hours prior to the HD IL-2 infusion. Dose reductions for entinostat should be followed. Entinostat will continue after high dose IL-2 every 2 weeks
562506|NCT03501381|Drug|Interleukin-2|In the event of clinical benefit around Day 84 (stable disease or tumor shrinkage) patients will receive a second treatment course of HD IL-2 therapy. Patients with evidence of tumor shrinkage after the 2nd HD IL-2 treatment course may receive a 3rd treatment course of HD IL-2.
562507|NCT03501030|Behavioral|Activity restriction|Women in the intervention group will be recommended activity restriction. Activity restriction is defined as the following forms of activity restriction: pelvic rest and prohibition of sexual activity, reduction of work and/or non work activity. Bed rest will not recommended.
562667|NCT03358706|Drug|Caffeine 100 mg|Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
562668|NCT03358329|Combination Product|S8 Sinus Implant|In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
562508|NCT03500484|Drug|Liraglutide|Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.
562509|NCT03499899|Drug|LAG525|LAG525, a concentrate for solution for intravenous infusion, comes in 100mg vials as a liquid formulation for infusion and is dosed at 400mg every 21 days.
562510|NCT03499899|Drug|spartalizumab|Spartalizumab is a concentrate for solution for intravenous infusion, comes in 100mg vials as a liquid formulation for infusion and is dosed at 300mg every 21 days.
562511|NCT03499899|Drug|carboplatin|Carboplatin is a concentrate for solution for intravenous infusion, comes in 100mg/mL and is dosed per AUC 6 every 21 days.
562512|NCT03499249|Drug|N-Acetyl cysteine|Intravenous NAC therapy (6.25 mg/kg/hour of 10 mg/ml solution, or 0.625 ml/kg/hour, to give 150 mg/kg/day), starting within 24 hours of completion of KP and lasting for a total of 7 days
562513|NCT03496077|Other|Flavored and unflavored little cigars/cigarillos (LCCs)|Flavored and unflavored LCCs that are currently available for purchase
562514|NCT03491059|Drug|C-11 labeled nicotine|Participants will vape with e-cigarettes radio-labeled with C-11 nicotine.
562515|NCT03491059|Radiation|PET/CT imaging|After vaping with radio-labeled e-cigarettes, participants will be PET/CT imaged.
562516|NCT03491046|Device|PET scan|low dose fluorodeoxyglucose (FDG) PET research scan with CEST sequence
562517|NCT03491046|Device|MRI scan|standard of care MRI
562518|NCT03490812|Diagnostic Test|PET scan|Investigational PET scan as add-on to standard-of-care scan
562519|NCT03490812|Other|Retrospective data analysis|Review of pre-existing data from January 1, 2001 through December 5, 2017
562520|NCT03490656|Diagnostic Test|MRI Scan - in addition to standard of care|Up to 3 Tesla (T) MRI
562521|NCT03490656|Diagnostic Test|MRI Scan - not in addition to standard of care|Up to 3 Tesla (T) MRI
562522|NCT03488875|Behavioral|mMBRT|Madison Mindfulness-Based Resilience Training (mMBRT) is an 8-week mindfulness-based intervention developed specifically for police officers, which is similar to and inspired by a program developed by researchers at Pacific (OR) University (Christopher, Goerling et al., 2016). mMBRT includes 8 weekly 2-hour classes involving guided meditation practice, gentle movement, and group-based discussion (the 7th class is a longer, 4-hour class). The total class time is about 18 hours over 8 weeks, and participants are asked to engage in home practice for up to 30 minutes/day, 6 days/week throughout the intervention.
562523|NCT03486444|Diagnostic Test|Phillips Lumify Diagnostic Ultrasound System|portable ultrasound device
562524|NCT03486444|Other|Surveys|surveys assessing perception of ultrasound
562525|NCT03484975|Device|Observation group|Collect coronary images with a hybrid IVUS OCT system.
562526|NCT03482635|Drug|Spesolimab|Solution for infusion
562527|NCT03482635|Drug|Placebo|Solution for infusion
562528|NCT03480776|Drug|Acetylsalicylic acid|81 mg PO daily or 325 mg PO daily
562529|NCT03480776|Other|Placebo|One tablet PO daily
562530|NCT03478904|Drug|Enzalutamide Liquid|Enzalutamide liquid formulation given orally (160mg)
562531|NCT03478904|Drug|Enzalutamide Capsule|Enzalutamide gel capsule (4X 40mg)
562532|NCT03475563|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty with BiOSS LIM C stent implantation
562533|NCT03474718|Biological|Platelet-rich Plasma Left Side|Group A will receive PRP on left side of scalp and placebo (saline solution) on right side of scalp.
562534|NCT03474718|Biological|Platelet-rich Plasma Right Side|Group B will receive PRP on right side of scalp and placebo (saline solution) on left side of scalp.
562535|NCT03474107|Drug|enfortumab vedotin|Intravenously (IV)
562536|NCT03474107|Drug|docetaxel|Intravenously (IV)
562537|NCT03474107|Drug|vinflunine|Intravenously (IV)
562538|NCT03474107|Drug|paclitaxel|IV infusion
562539|NCT03465722|Drug|avapritinib|Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.
562540|NCT03465722|Drug|regorafenib|Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).
562541|NCT03464136|Biological|Placebo for Ustekinumab|Participants will receive placebo as SC injection to blind adalimumab.
562542|NCT03464136|Biological|Placebo for Adalimumab|Participants will receive placebo as IV infusion to blind ustekinumab.
562543|NCT03464136|Biological|Ustekinumab (6 mg/kg)|Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.
562544|NCT03464136|Biological|Ustekinumab (90 mg)|Participants will self-administer SC injection of ustekinumab 90 mg.
562545|NCT03464136|Biological|Adalimumab (40 mg)|Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
562546|NCT03463616|Radiation|CT abdomen|CT scan of abdomen for metastasis staging of rectal cancer
562547|NCT03463616|Radiation|MRI abdomen|MRI of abdomen for metastasis staging of rectal cancer
562548|NCT03463369|Biological|JNJ-64300535|Participants will receive JNJ-64300535 vaccine by electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
562549|NCT03463369|Biological|Placebo|Participants will receive 1 mL (0.9 percent [%] sodium chloride [NaCl]) of placebo solution matching to JNJ-64300535 electroporation-mediated IM injection on Day 1, Week 4, and Week 12.
562550|NCT03463369|Drug|Nucleos(t)ide Analogs (NA)|Participants will receive NA as a standard of care treatment.
562551|NCT03462004|Biological|HPIV3/ΔHNF/EbovZ GP vaccine|Administered intranasally
562552|NCT03462004|Biological|Placebo|Administered intranasally
562553|NCT03459482|Other|Food Elimination Diet|Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
562554|NCT03458039|Other|Train the trainer|Training the trainer involves taking an experienced counselor and teaching them how to train additional counselors in a specific therapy. A technology-based train the trainer strategy will be developed and tested. The hypothesis is that the technology strategy will have similar effectiveness to the standard live strategy. Therefore, all experienced-counselors will receive a train-the-trainer intervention.
562555|NCT03456895|Other|Light perception|We will be using Wi-Fi/IP programmable LED lighting systems that will replace conventional lighting systems and may be in canned lights, spot lights, light chains or table lights. These lighting systems can be fully controlled by web based applications on smart phones tablets and computer systems and can be combined with input systems such as switches, motion detection or voice activated. Differences in lighting perception will be explored by varying lighting color and brightness.
562556|NCT03456895|Other|Sound perception|We will be using Wi-Fi/Bluetooth addressable sound systems that will be linked with sound sources such as media players on smart devices or computer systems. Differences in sound perception will be explored by varying sound types (i.e. different music types, ambient noise, etc.).
562557|NCT03456895|Other|Smell perception|We will explore the use of consumer grade ventilation systems that can be equipped to distribute packaged scents. Differences in smell perception will be explored by varying the types of scents.
562558|NCT03456895|Other|Vibration perception|We will explore the use of chairs or blankets that enable subjects to perceive vibrations. An initial implementation will be the use of on relaxing/massage chair that enables the experience of vibration sensation in the back or leg area. We may use also potentially vibration blankets in the arm or neck area. Differences in vibration perception will be explored by varying the location, frequency, etc. of vibrations with the subject being placed in a chair on an imaging table/bed.
562559|NCT03456895|Other|Voice activation|We will explore the use and linkage of voice activation system such as Amazon Echo, Google home or similar devices. Some participants may be asked to use voice activations to verbally select and/or change the environmental settings according to their preferences. We are evaluating the feasibility of voice activation with the imaging environment.
562560|NCT03451851|Drug|Guselkumab|Participants will receive a weight-based dose of guselkumab subcutaneously.
562561|NCT03451851|Drug|Placebo for guselkumab|Participants will receive a weight-based dose of placebo for guselkumab subcutaneously.
562562|NCT03451851|Drug|Etanercept|Participants will receive a weight-based dose of etanercept (up to 50 mg) subcutaneously.
562563|NCT03448692|Drug|PF-06730512|Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV.
562564|NCT03448224|Other|Questionnaire Administration|Questionnaire
562565|NCT03448224|Other|Internet-Based Intervention|Intervention
562566|NCT03445663|Drug|AMG 424|Subjects will receive IV infusions of AMG 424
562567|NCT03445533|Drug|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 1, 4, 7, and 10.
562568|NCT03445533|Drug|IMO-2125|IMO-2125 intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 16, 20, and 24.
562569|NCT03445533|Drug|Ipilimumab|Ipilimumab administered as 4 doses on Weeks 2, 5, 8, and 11.
562570|NCT03439514|Drug|ARRY-371797|400 mg twice daily (BID)
562571|NCT03439514|Other|Placebo|BID
562572|NCT03434353|Drug|Inarigivir|Administered orally once daily one hour before or one hour after a meal
562573|NCT03434353|Drug|TAF|25 mg tablet administered orally once daily with food
562574|NCT03433898|Drug|BI 754091|Solution for infusion
562575|NCT03433898|Drug|BI 754111|Solution for infusion
562576|NCT03432572|Drug|Pyridium|a urine discoloration agent
562577|NCT03432572|Drug|Riboflavin|a urine discoloration agent
562578|NCT03432572|Drug|Thiamine|active placebo not known to cause urine discoloration
562579|NCT03430011|Biological|JCARH125|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).
562580|NCT03429712|Device|Dual-source multi-detector computed tomography (DSSE)|Dose split technique in a cohort of pediatric patients to determine, without increase in patient radiation dose, the optimal patient-specific and task-specific radiation dose levels for pediatric cardiothoracic and abdominal CT applications.
562581|NCT03427736|Drug|Ketorolac Tromethamine|IV ketorolac will be given per standard of care, not prescribed for this study
562582|NCT03427736|Drug|Hydromorphone|IV Hydromorphone will be given per standard of care, not prescribed for this study
562583|NCT03427164|Procedure|Transjugular Intrahepatic Portosystemic Shunt|The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
562584|NCT03425253|Drug|BELKYRA®|BELKYRA® is injected into preplaytsmal fat tissue in the submental area. When the Investigator and subject agree that no further intervention is required to achieve the desired result, subjects will be eligible to receive VOLUMA™ treatment.
562585|NCT03425253|Device|Juvéderm® VOLUMA™ with Lidocaine|VOLUMA™ is injected along the mandibular border.
562586|NCT03424941|Device|FFR-guided PCI and TAVI|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for FFR-guided PCI and TAVI (Medtronic CoreValve Evolut R or Medtronic CoreValve Evolut R PRO)
562587|NCT03424941|Device|CABG and SAVR|Treatment of subjects with multivessel coronary artery disease and aortic stenosis for CABG and SAVR
562588|NCT03422627|Drug|AMG 592|"Phase 1b Each dosing cohort will receive either weekly or biweekly AMG 592 for up to 52 weeks.~Phase 2 All subjects will receive the recommended phase 2 dose of AMG 592 for up to 52 weeks."
562589|NCT03421210|Drug|Nicotine patch|Participants will wear nicotine patches for 10 weeks after their quit date. 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment.
562590|NCT03420768|Drug|BMS-986263|Administered by intravenous (IV) infusion
562591|NCT03420768|Other|Placebo|Administered by intravenous (IV) infusion
562592|NCT03419572|Other|Data collection|Only available evaluations as decided by the investigator based on local clinical practice will be collected.
562593|NCT03416153|Drug|Carboplatin|AUC=1 weekly during radiation therapy. Carboplatin will be given once a week in combination with paclitaxel (standard treatment), concurrent with radiation therapy. Given IV.
562669|NCT03353506|Biological|LFMT|Lyophilized fecal microbiota transplant
562670|NCT03353506|Biological|LSFF|Lyophilized sterile fecal filtrate
562594|NCT03416153|Radiation|Radiation Therapy|Patients will initially receive a single prescription of 70 Gy to PTV1 in 35 fractions with RT given once daily, 5 days a week along with weekly carboplatin and paclitaxel (standard therapy). Dose will be reduced to 54Gy to high risk PTV and 43.2Gy to low risk PTV all in 27 fractions for patients who meet pPET-CT and iPET-CT parameters.
562595|NCT03416153|Drug|Paclitaxel|30 mg/m2 weekly during radiation therapy. Paclitaxel will be given once a week in combination with carboplatin (standard treatment), concurrent with radiation therapy. Given IV.
562596|NCT03416036|Biological|TetraVax-DV-TV003 (TV003)|TV003 contains 10^3.3 plaque-forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN2/4Δ30(ME), 10^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10^3.3 PFU/mL of rDEN4Δ30. Administered by subcutaneous injection in the deltoid region of the upper arm
562597|NCT03416036|Biological|rDEN2Δ30-7169 (DENV-2)|Administered at a dose of 10^3 PFU by subcutaneous injection in the deltoid region of the upper arm
562598|NCT03416036|Biological|rDEN3Δ30 (DENV-3)|Administered at a dose of 10^3 PFU by subcutaneous injection in the deltoid region of the upper arm
562599|NCT03416036|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
562600|NCT03414008|Drug|BI 1291583|Single dose
562601|NCT03414008|Drug|Matching placebo: Tartaric acid|Single dose
562602|NCT03410693|Drug|Rogaratinib (BAY1163877)|Rogaratinib administered as oral (p.o.) tablets twice daily (b.i.d.) continuously
562603|NCT03410693|Drug|Chemotherapy|Chemotherapy as taxane (docetaxel or paclitaxel) or vinflunine administered through intravenous (i.v.) infusion every 3 weeks (on day 1 of a 21-day cycle) The choice of the chemotherapy is at the discretion of the investigator, taking into consideration the status of the authorization in the given Country (i.e. the drug has to be approved at least for one indication in the given country).
562604|NCT03410615|Radiation|Radiation|70 Gy in 35 fractions over 7 weeks (i.e. 2 Gy per fraction)
562605|NCT03410615|Drug|Cisplatin|100 mg/m2 days 1, 22, 43 concurrently with RT
562606|NCT03410615|Drug|Durvalumab|Given in concurrent and adjuvant phase
562607|NCT03410615|Drug|Tremelimumab|ARM CLOSED TO ACCRUAL - 2019
562608|NCT03410446|Drug|Ketamine Hydrochloride|Ketamine is a N-methyl-D-aspartate (NMDA) antagonist.
562609|NCT03410238|Behavioral|Saferteens Brief Intervention|A 30 minute private one-on-one brief motivational interviewing intervention administered by clinic staff. The goal of the intervention is to reduce and prevent youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on-one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior. In the 2 months following the intervention, participants will receive booster text messages tailored to their responses during the intervention.
562610|NCT03409900|Other|LPB|The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
562611|NCT03409900|Other|QLB|The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
562612|NCT03406884|Biological|c-kit+ cells|The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
562613|NCT03401398|Drug|Hydrocortisone, sodium succinate|Patients randomized to the hydrocortisone treatment arm will receive an initial bolus of 2 mg/kg IV hydrocortisone, followed by 1 mg/kg (maximum 50 mg) of hydrocortisone dosed every six hours for a maximum of seven days or until all vasoactive infusions have been discontinued for at least 12 hours, whichever comes first. When the hydrocortisone course is completed, the medication will be discontinued.
562614|NCT03401398|Drug|Normal saline|Patients randomized to the placebo treatment arm will receive an equivalent volume of normal saline, with the identical dosing schedule to the intervention (hydrocortisone) arm.
562615|NCT03395886|Drug|Remifentanil|The noninvasive ventilation intolerated patients was sedated by remifentanil.
562616|NCT03395886|Drug|Dexmedetomidine|The noninvasive ventilation intolerated patients was sedated by dexmeditomidine.
562617|NCT03395405|Drug|Nitazoxanide|One 500 mg tablet twice daily with food for 56 consecutive doses
562618|NCT03395405|Other|Placebo|One tablet twice daily with food for 56 consecutive doses
562619|NCT03395314|Drug|Ketamine|1 single dose of IV ketamine
562620|NCT03395314|Drug|Midazolam|1 single dose of IV midazolam
562621|NCT03393520|Drug|Placebo|oral capsules
562622|NCT03393520|Drug|AVP-786|oral capsules
562623|NCT03392324|Device|PRIMA|Implantation of PRIMA device
562624|NCT03387618|Diagnostic Test|Digital PET/CT imaging|Next generation PET/CT imaging
562625|NCT03384875|Device|CytoSorb|To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)
562626|NCT03384641|Drug|Bedaquiline 200 mg|Participants will receive bedaquiline 200 mg (2*100 mg tablets) once daily for 2 weeks followed by 100 mg tablet tiw for 6 weeks with at least 48 hours between doses.
562627|NCT03383458|Biological|Nivolumab|Specified dose on specified days
562628|NCT03383458|Other|Placebo|specified dose on specified days
562629|NCT03381573|Drug|Roflumilast|Roflumilast
562630|NCT03381196|Drug|Pimodivir 600 mg|Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6).
562631|NCT03381196|Drug|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6).
562632|NCT03381196|Other|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
562633|NCT03380871|Biological|NEO-PV-01|Personal Cancer Vaccine
562634|NCT03380871|Biological|Pembrolizumab|monoclonal antibody against PDL1
562635|NCT03380871|Other|Adjuvant|immune adjuvant
562636|NCT03380871|Drug|Carboplatin|chemotherapy
562637|NCT03380871|Drug|Pemetrexed|chemotherapy
562638|NCT03379675|Drug|JNJ-53718678 500 mg|Participants will receive 500 mg dose of JNJ-53718678 oral solution once daily for 7 days.
562639|NCT03379675|Drug|JNJ-53718678 80 mg|Participants will receive 80 mg dose of JNJ-53718678 oral solution along with the matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
562640|NCT03379675|Drug|Placebo|In treatment B, participants will receive matching placebo along with JNJ-53718678 to maintain the same total volume as for the 500 mg dose once daily for 7 days. In treatment C, participants will receive matching placebo to the same total volume as for the 500 mg dose once daily for 7 days.
562641|NCT03376321|Drug|Pimodivir 600 mg|Participants will receive pimodivir 600 mg orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
562642|NCT03376321|Drug|Placebo|Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 [evening], dosing will continue until the morning of Day 6). Participants who meet treatment extension criteria may receive an additional 5 day course of the same treatment as received at study start (on Days 6 through 10).
562643|NCT03376321|Other|SOC Treatment|Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be started no later than the day when participants initially receive pimodivir. An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during either the treatment period or extension phase, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.
562644|NCT03375320|Drug|Cabozantinib S-malate|Given PO
562645|NCT03375320|Other|Laboratory Biomarker Analysis|Correlative studies
562646|NCT03375320|Other|Placebo|Given PO
562647|NCT03375320|Other|Quality-of-Life Assessment|Ancillary studies
562648|NCT03374007|Biological|GB226|single-dose:1mg/kg, 3mg/kg, 10mg/kg; multiple dosing: 1mg/kg, 3mg/kg, 10mg/kg, treat every 2 weeks; multiple dosing: 280mg,treat every 3 weeks, 3mg/kg, treat every 2 weeks
562649|NCT03372148|Diagnostic Test|pHRMi|Pharyngeal High Resolution Manometry and Impedance swallowing function evaluation
562650|NCT03369223|Biological|BMS-986249|specified dose on specified day
562651|NCT03369223|Biological|Nivolumab|Specified dose on specified days
562652|NCT03369223|Biological|Ipilimumab|Specified dose on specified days
562653|NCT03368963|Drug|Nanoliposomal Irinotecan|Given IV
562654|NCT03368963|Drug|Trifluridine and Tipiracil Hydrochloride|Given PO
562655|NCT03367247|Behavioral|BOLSTER|BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.
562656|NCT03367247|Other|Enhanced Discharge Planning (EDP)|EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.
562657|NCT03364673|Other|Fitness Tracker|Fitness trackers (e.g. Fitbit) are accelerometers that are worn on the wrist and tracks users' heart rate continuously in addition to steps, distance, calories, and active minutes
562658|NCT03364673|Other|Social Incentive (Way to Health)|The Way to Health platform is an automated information technology platform that integrates wireless devices, clinical trial randomization and enrollment processes, messaging (text, e-mail or voice), self-administered surveys, automatic transfers of financial incentives, and secure data capture for research purposes.
562659|NCT03362736|Drug|Ustekinumab|All participants will receive a single intravenous (IV) tiered dose of ustekinumab based on body weight at Week 0 (participants less than or equal to [<=] 55 kilogram [kg] will receive 260 milligram [mg] ustekinumab; > 55 kg to <= 85 kg will receive 390 mg ustekinumab; and > 85 kg will receive 520 mg ustekinumab infusion) during induction period. After the IV induction dose, all participants will receive the first maintenance dose of 90 mg ustekinumab subcutaneous (SC) injection 8 weeks later (Week 8). The participants with adequate response based on the physician's judgement will be subsequently treated with 90 mg ustekinumab SC injection with every 12 weeks through Week 80 and participants with an inadequate response to ustekinumab dosing every 12 weeks based on the physician's judgement will be subsequently treated with 90 mg of ustekinumab every 8 weeks through Week 80.
562660|NCT03358706|Drug|Ustekinumab IV Infusion|Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.
562661|NCT03358706|Drug|Ustekinumab SC Injection|Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.
562662|NCT03358706|Drug|Midazolam 2 mg|Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.
562663|NCT03358706|Drug|Warfarin 10 mg|Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.
562664|NCT03358706|Drug|Vitamin K 10 mg|Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
562665|NCT03358706|Drug|Omeprazole 20 mg|Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.
562666|NCT03358706|Drug|Dextromethorphan 30 mg|Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.
562671|NCT03351608|Drug|Sugammadex 2 mg/kg|For moderate NMB reversal, a single i.v. bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
562672|NCT03351608|Drug|Sugammadex 4 mg/kg|For deep NMB reversal, a single i.v. bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).
562673|NCT03351608|Drug|Neostigmine + Glycopyrrolate|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
562674|NCT03351608|Drug|Neostigmine + Atropine|For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to TOF stimulations.
562675|NCT03349710|Biological|Nivolumab|Specified dose on specified day
562676|NCT03349710|Drug|Cetuximab|Specified dose on specified day
562677|NCT03349710|Drug|Cisplatin|Specified dose on specified day
562678|NCT03349710|Radiation|Radiotherapy|Specified dose on specified day
562679|NCT03349268|Device|Pulsed UV Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
562680|NCT03349268|Device|Sham Device|"Two Detroit Medical Center (DMC) acute-care hospitals are being proposed for this project, Sinai-Grace Hospital (SGH) and Detroit Receiving Hospital (DRH). SGH is a 383-bed hospital, and DRH is a 248-bed hospital. The study will be conducted in eight hospital units in SGH and eight hospital units in DRH, including two medical intensive care units (ICUs), two surgical ICUs and 12 non-ICU medical-surgical wards. The 16 study units include a total of 379 beds.~Devices will be deployed on these study units with the sham and intervention devices split evenly between SGH and DRH. Within each study site, the types of devices (PX-UV vs sham) will be assigned randomly to the units in Phase 1 and then switched in Phase 2."
562681|NCT03347422|Drug|Sutimlimab|Sutimlimab will be administered by IV.
562682|NCT03347422|Drug|Placebo|Placebo will be administered by IV.
562683|NCT03347396|Drug|Sutimlimab|Sutimlimab will be administered as IV infusion.
562684|NCT03347058|Other|Supportive programming|Access to a suite of resources, including digital tools, person-to-person support, and educational resources
562685|NCT03345836|Other|Matching placebo for upadacitinib|Tablet
562686|NCT03345836|Drug|upadacitinib|Tablet
562687|NCT03345433|Behavioral|interactive group drumming sessions|interactive group drumming sessions
562688|NCT03343067|Drug|elagolix|Tablets
562689|NCT03343067|Drug|estradiol/norethindrone acetate (E2/NETA)|Capsules
